ISSN: 0090-1423

National Library of Medicine

CUMULATED INDEX MEDICUS

Volume 37, 1996

Subject Index Os-Psi

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, Maryland 20894

NIH Publication No. 97-259

Book 9

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated Index medicus.
Vol. 1 (Jan.-Dec. 1960)-
–Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1961-
v.

Vols. for 1971-1978 issued as DHEW publication ; no. (NIH) 72-259, etc.; for 1979- as NIH publication ; no. 80-259, etc.
Annual cumulation of the monthly issues of Index medicus.
Continues: Quarterly cumulative Index medicus.
Issues for 1967- include Bibliography of medical reviews.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.). III. Bibliography of medical reviews IV. Index medicus V. Series: DHEW publication ; no. (NIH) 72-259, etc. VI. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated Index medicus.

ZW 1 I384



This book is printed on acid-free paper for permanence.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1997.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-048940-7

CUMULATED INDEX MEDICUS 1996

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xv

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1393
Full Title Listing 1489

BOOK 2 Subject Index **A** 1565

BOOK 3 Subject Index **B-Chi** 2972

BOOK 4 Subject Index **Chl-Do** 4295

BOOK 5 Subject Index **Dr-Geo** 5591

BOOK 6 Subject Index **Ger-Ino** 6929

BOOK 7 Subject Index **Inp-Mei** 8260

BOOK 8 Subject Index **Mel-Or** 9583

BOOK 9 Subject Index **Os-Psi** 10915

BOOK 10 Subject Index **Pso-Sr** 12241

BOOK 11 Subject Index **St-Z** 13570

BOOK 12 Author Index **A-Dh** 14907

BOOK 13 Author Index **Di-Jd** 16222

BOOK 14 Author Index **Je-Mor** 17550

BOOK 15 Author Index **Mos-She** 18896

BOOK 16 Author Index **Shi-Z** 20223

BOOK 17 Bibliography of Medical Reviews 21539

ORYZIAS

EMBRYOLOGY

Temporal and spatial patterns of gene expression for the hatching enzyme in the teleost embryo, Oryzias latipes. Inohaya K, et al. **Dev Biol** 1995 Oct;171(2):374–85

GENETICS

Insertion of a novel transposable element in the tyrosinase gene is responsible for an albino mutation in the medaka fish, Oryzias latipes. Koga A, et al. **Mol Gen Genet** 1995 Dec 10;249(4):400–5

Transposable element in fish [letter] Koga A, et al. **Nature** 1996 Sep 5;383(6595):30

METABOLISM

Molecular cloning and functional expression of the alpha1A-adrenoceptor of Medaka fish, Oryzias latipes. Yasuoka A, et al. **Eur J Biochem** 1996 Feb 1;235(3):501–7

PHYSIOLOGY

Evaluation of solubilizing methods of the egg envelope of the fish, Oryzias latipes, and partial determination of amino acid sequence of its subunit protein, ZI-3. Sugiyama H, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May;114(1):27–33

Structure and promoter analysis of the cytochrome P-450 aromatase gene of the teleost fish, medaka (Oryzias latipes). Tanaka M, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):719–25

A recessive lethal mutation, tb, that bends the midbrain region of the neural tube in the early embryo of the medaka. Ishikawa Y. **Neurosci Res** 1996 Feb;24(3):313–7

Reactivity of tissue-specific antigens in N-methyl-N'-nitro-N-nitrosoguanidine-induced neoplasms and normal tissues from medaka (Oryzias latipes). Bunton TE, et al. **Toxicol Pathol** 1996 May-Jun; 24(3):331–8

N-methyl-N'-nitro-N-nitrosoguanidine-induced neoplasms in medaka (Oryzias latipes). Bunton TE, et al. **Toxicol Pathol** 1996 May-Jun;24(3):323–30

ORYZOMYS see HESPEROMYINAE

OS TRIGONUM see TALUS

OSCILLATORS, ENDOGENOUS see BIOLOGICAL CLOCKS

OSCILLOMETRY

Noninvasive blood pressure monitoring from the supraorbital artery using an artificial neural network oscillometric algorithm. Narus S, et al. **J Clin Monit** 1995 Sep; 11(5):289–97

INSTRUMENTATION

[Comparison of invasive blood pressure measurement in the aorta with indirect oscillometric blood pressure measurement at the wrist and forearm] Saul F, et al. **Z Kardiol** 1995 Sep;84(9):675–85 (Eng. Abstr.) **(Ger)**

METHODS

Optimal sites for forehead oscillometric blood pressure monitoring. Lee TK, et al. **J Clin Monit** 1995 Sep; 11(5):298–304

STANDARDS

Accuracy of oscillometric blood pressure measurement in critically ill neonates with reference to the arterial pressure wave shape. Gevers M, et al. **Intensive Care Med** 1996 Mar;22(3):242–8

OSGOOD-SCHLATTER DISEASE see OSTEOCHONDRITIS

OSLER-RENDU DISEASE see TELANGIECTASIA, HEREDITARY HEMORRHAGIC

OSLER-VAQUEZ DISEASE see POLYCYTHEMIA VERA

OSMIC ACID see OSMIUM TETROXIDE

OSMIUM

Scanning tunneling microscopic study of osmium-impregnated collagen. Kure M, et al. **J Electron Microsc (Tokyo)** 1995 Aug;44(4):207–11

CHEMISTRY

An improved 191Os/191mIr generator using a hybrid anion exchanger. Packard AB, et al. **Nucl Med Biol** 1995 Oct; 22(7):887–91

OSMIUM COMPOUNDS

Activation of osmium ammine by SO2-generating chemicals for EM Feulgen-type staining of DNA. Vázquez-Nin GH, et al. **Eur J Histochem** 1995;39(2):101–6

OSMIUM TETROXIDE

Lipiodol accumulation in hepatic hemangioma. Detection with osmium postfixation. Wanless IR, et al. **Am J Surg Pathol** 1996 Apr;20(4):480–2

Osmium tetroxide-potassium ferrocyanide intensification of a diaminobenzidine product obtained by photoconversion of a fluorescent label: a study of human neutrophil granules. Mutasa HC. **Biotech Histochem** 1995 Jul;70(4):194–201

A simple technique for flat osmicating and flat embedding of immunolabelled vibratome sections of the rat spinal cord for light and electron microscopy. Nguyen KB, et al. **J Neurosci Methods** 1996 Mar;65(1):51–4

ADMINISTRATION & DOSAGE

Comparison of the efficacy of nonsurgical synovectomy (synoviorthesis) and joint lavage in knee osteoarthritis with effusions. Hilliquin P, et al. **Rev Rhum Engl Ed** 1996 Feb; 63(2):93–102

[Intradiscal injection of hypertonic saline, phenol-glycerin and osmic acid for the treatment of lumbar disc herniation: an experimental study] Shioda M. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct;69(10):964–76 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Specificity of the zinc-iodide-osmium (ZIO) reagent in the nervous tissue: evaluation of the Ca++ binding sites hypothesis. Casoli T, et al. **Boll Soc Ital Biol Sper** 1995 Jul-Aug;71(7–8):197–204

OSMOLALITY see OSMOLAR CONCENTRATION

OSMOLAR CONCENTRATION

Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion [see comments] Glaser DS. **Ann Emerg Med** 1996 Mar;27(3):343–6. Comment in: Ann Emerg Med 1996 Mar;27(3):363–4.

Ion selectivity of volume regulatory mechanisms present during a hypoosmotic challenge in vestibular dark cells. Shiga N, et al. **Biochim Biophys Acta** 1995 Nov 22; 1240(1):48–54

Advances in diabetic ketoacidosis and hyperosmolar syndrome pathogenesis and management. Gowrishankar M, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2–3):95–9

The effect of graded hypertonia on interstitial volume, tissue resistance and synaptic transmission in rat hippocampal tissue slices. Huang R, et al. **Brain Res** 1995 Dec 8; 702(1–2):181–7

Challenging consults: application of principles of physiology and biochemistry to the bedside. Osmotic diuresis: the importance of counting the number of osmoles excreted. Levin A, et al. **Clin Invest Med** 1995 Oct;18(5):401–5

The role of relaxin in the pregnancy associated reduction in plasma osmolality. Johnson MR, et al. **Hum Reprod** 1996 May;11(5):1105–8

Immobilized and hypo-osmotic swollen spermatozoa on intracytoplasmic sperm injection. Chida S. **J Assist Reprod Genet** 1995 Aug;12(7):453–5

Regulatory volume decrease in cultured kidney cells (A6): role of amino acids. De Smet P, et al. **J Gen Physiol** 1995 Sep;106(3):525–42

The use of low-osmolar contrast agents: technological change and defensive medicine [see comments] Jacobson PD, et al. **J Health Polit Policy Law** 1996 Summer; 21(2):243–66. Comment in: J Health Polit Policy Law 1996 Summer;21(2):267–88.

Osmo- and mechanosensitivity of the transient outward K+ current in a mammalian neuronal cell line. Schoenmakers TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):419–30

hns, rpoS and lrp mutations affect stationary-phase survival at high osmolarity. Levinthal M, et al. **Res Microbiol** 1996 Jun;147(5):333–42

[Osmolality] Shimizu K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:776–81 (13 ref.) **(Jpn)**

OSMOLARITY see OSMOLAR CONCENTRATION

OSMOREGULATION see WATER-ELECTROLYTE BALANCE

OSMOSIS

Micro-osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165–72 (54 ref.)

Outer hair cell length changes in an external electric field. I. The role of intracellular electro-osmotically generated pressure gradients. Jerry RA, et al. **J Acoust Soc Am** 1995 Oct;98(4):2000–10

Sugars act as signal molecules and osmotica to regulate the expression of alpha-amylase genes and metabolic activities in germinating cereal grains. Yu SM, et al. **Plant Mol Biol** 1996 Mar;30(6):1277–89

PHYSIOLOGY

Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Muldoon LL, et al. **Am J Pathol** 1995 Dec;147(6):1840–51

Role of hepatic receptors in controlling body fluid homeostasis. Morita H, et al. **Jpn J Physiol** 1995; 45(3):355–68 (47 ref.)

Photometric determination of phenomenological correlation between osmotic behavior and hemolysis of red blood cells. Yang XS, et al. **Jpn J Physiol** 1995;45(5):723–41

NPY mRNA and peptide immunoreactivity in the arcuate nucleus are increased by osmotic stimuli: correlation with dehydration anorexia. O'Shea RD, et al. **Peptides** 1995; 16(6):1117–25

OSMOTIC DIURETICS see DIURETICS, OSMOTIC

OSMOTIC FRAGILITY

Spurious automated white cell count with Coulter STKS in the myelodysplastic syndromes suggests the presence of a red cell membrane defect [letter] Elghetany MT, et al. **Am J Hematol** 1996 May;52(1):69

Mathematical modeling of the osmotic fragility of rabbit red blood cells. Orcutt RH, et al. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):169–74

DRUG EFFECTS

Protective effects of some neutral amino acids against hypotonic hemolysis. Morimoto Y, et al. **Biol Pharm Bull** 1995 Oct;18(10):1417–22

Effect of lactic acid on water content and osmotic fragility of erythrocytes in vitro. Kogawa H, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Sep;41(6):809–12

Murine red blood cell fragility is not affected by either vitamin E depletion or supplementation. Bei RA, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):280–3

PHYSIOLOGY

Hypertonic hemolysis in patients with a mood disorder. Hoeksema T, et al. **Biol Psychiatry** 1996 Jan 1;39(1):11–5

OSMOTIC PRESSURE

Effect of osmotic stress on sarcolemmal integrity of isolated cardiomyocytes following transient metabolic inhibition. Ruiz-Meana M, et al. **Cardiovasc Res** 1995 Jul;30(1):64–9

Mutants of Saccharomyces cerevisiae sensitive to oxidative and osmotic stress. Krems B, et al. **Curr Genet** 1995 Apr; 27(5):427–34

Physiology of the osmotic stress response in microorganisms. Gutierrez C, et al. **Int J Food Microbiol** 1995 Dec; 28(2):233–44

The ratio of elastic moduli of cochlear outer hair cells derived from osmotic experiments. Ratnanather JT, et al. **J Acoust Soc Am** 1996 Feb;99(2):1025–8

Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. Matthews CC, et al. **J Cell Physiol** 1996 Feb;166(2):323–31

Water compartmentalization and extracellular tortuosity after osmotic changes in cerebellum of Trachemys scripta. Krizaj D, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):887–96

Blood volume, colloid osmotic pressure and F-cell ratio in children with the nephrotic syndrome. Vande Walle J, et al. **Kidney Int** 1996 May;49(5):1471–7

Macromolecules and water: probing with osmotic stress. Parsegian VA, et al. **Methods Enzymol** 1995;259:43–94

Hydrostatic and osmotic pressure as tools to study macromolecular recognition. Robinson CR, et al. **Methods Enzymol** 1995;259:395–427

Characterization of the osmotically inducible gene osmE of Escherichia coli K-12. Gutierrez C, et al. **Mol Microbiol** 1995 May;16(3):553–63

Characterization of the osmotic response element of the human aldose reductase gene promoter. Ruepp B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8624–9

Effects of changes in colloid osmotic pressure on excretion of sodium by the ovine fetal kidney. Lumbers ER, et al. **Reprod Fertil Dev** 1995;7(5):1321–7

Tolerance to osmotic shocks in rats kidney cortex and medulla. Gilles R, et al. **Tissue Cell** 1995 Dec;27(6):667–77

DRUG EFFECTS

Effect of a dynein inhibitor on vasopressin action in toad urinary bladder. Marples D, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):767–74

OSSEOINTEGRATED DENTAL IMPLANTATION see DENTAL IMPLANTATION, ENDOSSEOUS

OSSEOINTEGRATION

see related
ARTHROPLASTY
BONE SUBSTITUTES
DENTAL IMPLANTATION, ENDOSSEOUS
HIP PROSTHESIS

Bone formation in hydroxyapatite orbital implants. Green JP, et al. **Am J Ophthalmol** 1995 Nov;120(5):681–2

Osteoinductive agents. Basic science and clinical applications. Kale AA, et al. **Am J Orthop** 1995 Oct;24(10):752–61 (92 ref.)

Onlay bone augmentation with an osteoinductive implant. Hetherington HE, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):568–73

Implant-retained prosthetic rehabilitation of orbital defects. Moran WJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):46–50

Significance of interstitial bone ingrowth under load-bearing conditions: a comparison between solid and porous implant materials. Chang YS, et al. **Biomaterials** 1996 Jun; 17(11):1141–8

Periosteal and endosteal reaction to reaming and nailing: the possible role of revascularization on the endosteal anchorage of cementless stems. Pazzaglia UE. **Biomaterials** 1996 May;17(10):1009–14

Direct bone formation on sand-blasted titanium implants: an experimental study. Piattelli A, et al. **Biomaterials** 1996 May;17(10):1015–8

Fixture stability and nerve function after transposition and lateralization of the inferior alveolar nerve and fixture installation. Hirsch JM, et al. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):276–81

Quantitative measurement of vascularization and vascular ingrowth rate of coralline hydroxyapatite ocular implant by Tc-99m MDP bone imaging. Civelek AC, et al. **Clin Nucl Med** 1995 Sep;20(9):779–87

Biology of grit-blasted titanium alloy implants. Goldberg VM, et al. **Clin Orthop** 1995 Oct;(319):122–9

Proximal femoral allografts for reconstruction of bone stock in revision arthroplasty of the hip. Gross AE, et al. **Clin Orthop** 1995 Oct;(319):151–8

Morselized allograft in acetabular reconstruction. A postmortem retrieval analysis. Heekin RD, et al. **Clin Orthop** 1995 Oct;(319):184–90

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)

Long term bone remodeling around the Charnley femoral prostheses. Kobayashi S, et al. **Clin Orthop** 1996 May; (326):162–73

Femoral revision hip arthroplasty with uncemented, porous-coated stems. Moreland JR, et al. **Clin Orthop** 1995 Oct;(319):141–50

Bone repair by regeneration. Habal MB. **Clin Plast Surg** 1996 Jan;23(1):93–101

A multidisciplinary approach to oral rehabilitation with osseointegrated implants in children and adolescents with multiple aplasia. Bergendal B, et al. **Eur J Orthod** 1996 Apr;18(2):119–29

Osseointegrated implants: a review of the literature. Shearer BH. **Int Dent J** 1995 Aug;45(4):261–6 (25 ref.)

Mechanical properties of bone–implant interface: an in vitro comparison of the parameters at placement and at 3 months. Brosh T, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):729–35

Osseointegration of titanium implants in bone regenerated in membrane-protected defects: a histologic study in the canine mandible. Buser D, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):666–81

A 5-year prospective multicenter follow-up report on overdentures supported by osseointegrated implants. Jemt T, et al. **Int J Oral Maxillofac Implants** 1996 May–Jun; 11(3):291–8

Mandibular lengthening by intraoral distraction using osseointegrated implants. Sawaki Y, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr;11(2):186–93

The reverse-torque test: a clinical report. Sullivan DY, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):179–85 (15 ref.)

The fixation of porous-coated femoral stems. A radiographic study of 113 cases with a 4 to 8 year follow up. Munuera L, et al. **Int Orthop** 1995;19(4):212–6

Consolidation of massive bone allografts in limb-preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)

Spinal fusion induced by porous hydroxyapatite blocks (HA). Experimental comparative study with HA, demineralized bone matrix and autogenous bone marrow. Ragni P, et al. **Ital J Orthop Traumatol** 1993;19(1):133–44

Interface mechanics and histomorphometric analysis of hydroxyapatite-coated and porous glass-ceramic implants in canine bone. Nimb L, et al. **J Biomed Mater Res** 1995 Dec;29(12):1477–82

Effect of surface topology on the osseointegration of implant materials in trabecular bone. Wong M, et al. **J Biomed Mater Res** 1995 Dec;29(12):1567–75

Mechanical consequences of bone ingrowth in a hip prosthesis inserted without cement [letter; comment] Engh CA. **J Bone Joint Surg Am** 1996 Feb;78(2):312–3. Comment on: J Bone Joint Surg Am 1995 Jun;77(6):911–23.

One-stage procedure to establish osseointegration: a zero to five years follow-up report. Tjellström A, et al. **J Laryngol Otol** 1995 Jul;109(7):593–8

Mandibular lengthening by distraction osteogenesis using osseointegrated implants and an intraoral device: a preliminary report. Sawaki Y, et al. **J Oral Maxillofac Surg** 1996 May;54(5):594–600

In vitro investigation of various attachments for overdentures on osseointegrated implants. Besimo C, et al. **J Oral Rehabil** 1995 Sep;22(9):691–8

Bone regeneration with resorbable polymeric membranes: treatment of diaphyseal bone defects in the rabbit radius with poly(L-lactide) membrane. A pilot study. Meinig RP, et al. **J Orthop Trauma** 1996;10(3):178–90

The three-dimensional bone interface of an osseointegrated implant. II: A morphometric evaluation after three months of loading. Sahin S, et al. **J Prosthet Dent** 1996 Aug; 76(2):176–80

The three-dimensional bone interface of an osseointegrated implant. I: A morphometric evaluation in initial healing. Wadamoto M, et al. **J Prosthet Dent** 1996 Aug;76(2):170–5

Utilizing the osseointegration principle for fixation of nail prostheses. Baruchin AM, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1665–71

Autogenous soft-tissue procedures and osseointegrated alloplastic reconstruction: their role in the treatment of complex craniofacial defects. Harris L, et al. **Plast Reconstr Surg** 1996 Sep;98(3):387–92

[Ear prosthesis anchored on osseointegrated implants. Experience with 9 cases] Charles X, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):145–9 (Eng. Abstr.) **(Fre)**

[Filling of bone defects using biphasic macroporous calcium phosphate ceramic. Apropos of 23 cases] Gouin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):59–65 (Eng. Abstr.) **(Fre)**

[Radiographic and histologic observations of autoclaved and non autoclaved allografts in the distal femoral metaphysis in dogs] Massin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(3):189–97 (Eng. Abstr.) **(Fre)**

[Additional supra-malleolar osteotomy] Vichard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):63–69 (Eng. Abstr.) **(Fre)**

[Dental rehabilitation using osseointegrated implants: treatment of oro-maxillo-facial cancer. A preliminary study of 7 cases] Aldegheri A, et al. **Rev Stomatol Chir Maxillofac** 1996;97(2):108–16 (Eng. Abstr.) **(Fre)**

[Endoprosthesis and bone reaction] Kohn D, et al. **Orthopade** 1995 Sep;24(5):409–15 (52 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical reaction of the bones to intra- and extramedullary load bearers: the significance of implant contact] Perren SM. **Orthopade** 1995 Sep;24(5):402–8 (Eng. Abstr.) **(Ger)**

[Allograft transplantation in pelvic instability following prosthesis exchange] Bettin D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):380–6 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

BMP-2 for intramuscular bone induction: effect in squirrel monkeys is dependent on implantation site. Aspenberg P, et al. **Acta Orthop Scand** 1996 Feb;67(1):3–6

Basic fibroblast growth factor infused at different times during bone graft incorporation. Titanium chamber study in rats. Wang JS, et al. **Acta Orthop Scand** 1996 Jun; 67(3):229–36

Transforming growth factor-beta 1 stimulates bone ongrowth to weight-loaded tricalcium phosphate coated implants: an experimental study in dogs. Lind M, et al. **J Bone Joint Surg Br** 1996 May;78(3):377–82

Transforming growth factor-beta 1 enhances bone healing to unloaded tricalcium phosphate coated implants: an experimental study in dogs. Lind M, et al. **J Orthop Res** 1996 May;14(3):343–50

[Implant fixation strength and osseointegration following systemic administration of recombinant factor XIII and factor XIII concentrate. Animal experiment with implant fixation strength and osseointegration of porous surface implants] Kienapfel H, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):394–400 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The interface between ionomer cement and bone in the porcine cervical spine. Langmayr JJ, et al. **Acta Neurochir (Wien)** 1996;138(2):154–61

In vitro modeling of the bone/implant interface. Davies JE. **Anat Rec** 1996 Jun;245(2):426–45 (94 ref.)

Relationships between endothelial cells, pericytes, and osteoblasts during bone formation in the sheep femur following implantation of tricalciumphosphate-ceramic. Decker B, et al. **Anat Rec** 1995 Jul;242(3):310–20

Soft and hard tissue response to endosseous dental implants. Listgarten MA. **Anat Rec** 1996 Jun;245(2):410–25 (154 ref.)

Influence of callus deformation time. Bone chamber study in rabbits. Aspenberg P, et al. **Clin Orthop** 1996 Jan; (322):253–61

Effects of hydroxyapatite tricalcium phosphate coating and intracancellous placement on bone ingrowth in titanium fibermetal implants. Dean JC, et al. **J Arthroplasty** 1995 Dec;10(6):830–8

Fixation of the acetabular component: the case for cementless bone ingrowth modular sockets. Dorr LD. **J Arthroplasty** 1996 Jan;11(1):3–5; discussion 5–6

Influence of intraoperative femoral fractures and cerclage wiring on bone ingrowth into canine porous-coated femoral components. Schutzer SF, et al. **J Arthroplasty** 1995 Dec;10(6):823–9

Osseointegrated thumb prostheses: a concept for fixation of digit prosthetic devices. Lundborg G, et al. **J Hand Surg [Am]** 1996 Mar;21(2):216–21

Influence of biomaterial surface texture on bone ingrowth in the rabbit femur. Friedman RJ, et al. **J Orthop Res** 1996 May;14(3):455–64

Bone formation and bone resorption in failed total joint arthroplasties: histomorphometric analysis with histochemical and immunohistochemical technique. Kadoya Y, et al. **J Orthop Res** 1996 May;14(3):473–82

The "bottle brush": a new concept for uncemented anchorage of bone implants. Preliminary mechanical and biomechanical studies. Berggren M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):221–6

[Bone reaction to contact with a granulated titanium surface. Apropos of 101 total hip prostheses with six years follow-up] Nègre J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):106–13 (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

In vitro backscattering from implant materials during radiotherapy. Wang RR, et al. **J Prosthet Dent** 1996 Jun; 75(6):626–32

OSSICULAR REPLACEMENT PROSTHESIS

Myringochorda-vestibulopexy: a new method for total replacement of the ossicular chain. Cremers WR. **Am J Otol** 1994 May;15(3):445–7

Ossiculoplasty using the black hydroxylapatite hybrid ossicular replacement prostheses. Macias JD, et al. **Am J Otol** 1995 Nov;16(6):718–21

Bone pate repair of the eroded incus—five years on. Snow DG, et al. **J Laryngol Otol** 1995 Nov;109(11):1048–50

The lessons of middle-ear function in non-mammals: improving columellar prostheses [editorial] Manley GA. **J R Soc Med** 1995 Jul;88(7):367–8 (8 ref.)

Ossiculoplasty with polymaleinate ionomeric prosthesis. McElveen JT Jr, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):420–6

Experimental results concerning the reconstruction of the stapes superstructure with bioactive ceramics. Dost P, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(2):133–6

The ABC (anchored bone conduction) system [letter] Janeke JB. **S Afr Med J** 1995 Nov;85(11):1199–200

[Stapes-plasty and diving sports. Is diving after stapes-plasty really indicated? (letter)] Strutz J. **HNO** 1995 Aug; 43(8):465, discussion 466 **(Ger)**

[Stapes-plasty and diving sports. Condition of the ear and diving capacity (letter)] Zeller T. **HNO** 1995 Aug; 43(8):465–6 **(Ger)**

[The use of a combined prosthesis for the auditory ossicle chain of the author's own design in tympanoplasty] Semenov FV. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):44 **(Rus)**

OSSIFICATION, HETEROTOPIC

see related

SYNOSTOSIS

Diaphragmatic defects, limb deficiencies, and ossification defects of the skull: a distinctive malformation syndrome. Froster UG, et al. **Am J Med Genet** 1996 Mar 1;62(1):48–53

Skin and bones [editorial; comment] Kaplan FS. **Arch Dermatol** 1996 Jul;132(7):815–8. Comment on: Arch Dermatol 1996 Jul;132(7):787–91.

Operative treatment of bone overgrowth in children who have an aquired or congenital amputation [letter] Abraham E. **J Bone Joint Surg Am** 1996 Aug;78(8):1287–8

[Traumatic myositis ossificans. Posttraumatic non-neoplastic heterotopic ossification] Jacobsen S. **Ugeskr Laeger** 1995 Sep 25;157(39):5385–8 (35 ref.) (Eng. Abstr.) **(Dan)**

[Heterotopic bone formation] Kiyomatsu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):462–3 (9 ref.) **(Jpn)**

CHEMICALLY INDUCED

Periarticular heterotopic ossification following pharmacologically induced paralysis. Ray TD, et al. **Skeletal Radiol** 1995 Nov;24(8):609–12

COMPLICATIONS

Paraplegia following post-traumatic thoracic spinal stenosis: a case report. Farooq MT, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):84–5

CT-guided aspiration in potentially infected total hip replacements complicated by heterotopic bone. Chew FS, et al. **Eur J Radiol** 1995 May;20(1):72–4

An unusual cause of otalgia—an ossified stylohyoid ligament. Riley N. **Ir J Med Sci** 1996 Apr–Jun;165(2):139

Patellar tendinitis—a case report of elongation and ossification of the inferior pole of the patella. Grossfeld SL, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):308–10

Spinal intermittent claudication due to cervical and thoracic degenerative spine disease. Kikuchi S, et al. **Spine** 1996 Feb 1;21(3):313–8

[Fracture of an ossified Achilles tendon] Krause K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):171–2 (9 ref.) **(Ger)**

DIAGNOSIS

Heterotopic ossification of midline abdominal incisions: CT and MR imaging findings. Jacobs JE, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):579–84

Ossification of the penis: report of two cases. Fahal AH, et al. **East Afr Med J** 1996 Apr;73(4):276–7
Stylohyoid ligament ossification mimicking submandibular sialadenopathy. Mandel L, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):366–8
Intramuscular ossified hemangioma. Jiang TT, et al. **Skeletal Radiol** 1995 Oct;24(7):538–40
Melorheostosis with an ossified soft tissue mass: MR features. Yu JS, et al. **Skeletal Radiol** 1995 Jul;24(5):367–70
Postsurgical ossified extradural cyst of the lumbar spine: a case report. Saito H, et al. **Spine** 1996 Feb 1;21(3):386–8
[Two cases of skeletal fluorosis in the hand] Sy MH, et al. **Ann Chir Main Memb Super** 1996;15(2):109–14 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Ectopic bone formation due to a distal venting hole in intramedullary nailing. Verfaillie S, et al. **Acta Orthop Belg** 1996 Mar;62(1):49–51
Radiological case of the month. Ectopic ossification and calcification in pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Zung A, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):643–4
Periarticular heterotopic ossification: a complication of arthroscopic anterior cruciate ligament reconstruction using a two-incision technique. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Dec;11(6):676–9
Pregnancy achieved after treatment in a case of endometrial ossification. A case report and literature review. Liu Q, et al. **Chin Med J (Engl)** 1995 Oct;108(10):793–5
Heterotopic ossification following primary total knee arthroplasty [see comments] Furia JP, et al. **J Arthroplasty** 1995 Aug;10(4):413–9. Comment in: J Arthroplasty 1996 Feb;11(2):223–4.
Heterotopic ossification. Incidence in cemented versus cementless total hip arthroplasty. Purtill JJ, et al. **J Arthroplasty** 1996 Jan;11(1):58–63
Elbow anchylosis due to postburn heterotopic ossification. Holguin PH, et al. **J Burn Care Rehabil** 1996 Mar-Apr; 17(2):150–4
Osseous overgrowth after amputation in adolescents and children. O'Neal ML, et al. **J Pediatr Orthop** 1996 Jan-Feb; 16(1):78–84
Heterotopic ossification after acromioplasty and distal clavicle resection. Berg EE, et al. **J Shoulder Elbow Surg** 1995 May-Jun;4(3):188–93
Association between muscle trauma and heterotopic ossification in spinal cord injured patients: reflections on their causal relationship and the diagnostic value of ultrasonography. Snoecx M, et al. **Paraplegia** 1995 Aug; 33(8):464–8
Is heterotopic bone formation, occurring near a cut ureter, a sign of osteoinductive potency of human urothelium? Włodarski K, et al. **Urol Int** 1995;55(2):115–7

METABOLISM

Biochemical analysis of heterotopic ossification in spinal cord injury patients. Chantraine A, et al. **Paraplegia** 1995 Jul; 33(7):398–401

PATHOLOGY

Progressive osseous heteroplasia [see comments] Miller ES, et al. **Arch Dermatol** 1996 Jul;132(7):787–91. Comment in: Arch Dermatol 1996 Jul;132(7):815–8.
Interleukin-1 immunoreactive nerves in heterotopic bone induced by DBM. Kreicbergs A, et al. **Bone** 1995 Oct; 17(4):341–5
Styloid chain ossification: report of a case with articulations. Kiely ML, et al. **Clin Anat** 1995;8(5):359–62
Prolonged retention of fetal bones with osseous metaplasia of the endometrium [letter] Bolaji II, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):65–6
A necropsy and histomorphometric study of abnormalities in the course of the vertebral artery associated with ossified stylohyoid ligaments. Johnson CP, et al. **J Clin Pathol** 1995 Jul;48(7):637–40
Osseous choristoma of the tongue. Wei Cheong Ngeow, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):49–51 (3 ref.)
Congenital constriction band syndrome. Perdue PS, et al. **J South Orthop Assoc** 1996 Spring;5(1):71–5 (12 ref.)
Adult idiopathic chondrolysis of the hip—report of two cases. Wada Y, et al. **Kurume Med J** 1995;42(2):121–8
Ossification of the lumbosacral dura and arachnoid following spinal cord trauma. Case report. Bell RB, et al. **Paraplegia** 1995 Sep;33(9):543–6
Progressive osseous heteroplasia, uncommon cause of soft tissue ossification: a case report and review of the literature. Rodriguez-Jurado R, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct;15(5):813–27 (15 ref.)
Ossifying renal tumor of infancy: a clinicopathologic study of nine cases. Sotelo-Avila C, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct;15(5):745–62 (9 ref.)
[The nucleus of ossification in kidney calculus] Alcover J, et al. **Ann Urol (Paris)** 1995;29(6-7):333–6 (Eng. Abstr.) **(Fre)**
[Renal cell carcinoma accompanied with ossification: a case report] Urushibara M, et al. **Hinyokika Kiyo** 1996 Feb; 42(2):127–9 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Bone morphogenetic protein-induced heterotopic bone in osteopetrosis. Miyazawa K, et al. **Clin Orthop** 1996 Mar; (324):259–68

PREVENTION & CONTROL

Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Burssens A, et al. **Acta Orthop Belg** 1995;61(3):205–11
Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips. Gebuhr P, et al. **Acta Orthop Scand** 1996 Feb;67(1):29–32
Heterotopic bone formation affecting the hip joint is preventable in high risk patients by post-operative radiation. Spry NA, et al. **Australas Radiol** 1995 Nov; 39(4):379–83
Case report: radiation prevention of heterotopic ossification after bone and joint surgery in sites other than hips. Lo TC, et al. **Br J Radiol** 1996 Jul;69(823):673–7
Calcitonin inhibits heterotopic bone formation in rats. Günal I, et al. **Int J Tissue React** 1995;17(2):87–91
The effect of low dose diclofenac sodium administered locally on heterotopic bone formation in rats. Risto O, et al. **Int Orthop** 1995;19(6):392–5
Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. Pellegrini VD Jr, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):870–81
Prevention of heterotopic bone formation after acetabular fracture fixation by single-dose radiation therapy: a preliminary report. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):258–63
Clinical effect of etidronate disodium (EHDP) on heterotopic ossification following total hip arthroplasty. Yutani Y, et al. **Osaka City Med J** 1995 Dec;41(2):63–73
[Eight days of naproxen therapy can prevent heterotopic ossification after total hip alloplasty] Gebuhr PH, et al. **Ugeskr Laeger** 1996 Feb 19;158(8):1076–8 (Eng. Abstr.) **(Dan)**

RADIOGRAPHY

Stylohyoid chain ossification: choice of the surgical approach. Chouvel P, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):57–61
An ossifying carcinosarcoma of the gallbladder: radiologic findings [letter] Nakagawa T, et al. **AJR Am J Roentgenol** 1996 May;166(5):1233–4
Heterotopic ossification following primary total knee arthroplasty [letter; comment] Harwin SF. **J Arthroplasty** 1996 Feb;11(2):223–4. Comment on: J Arthroplasty 1995 Aug;10(4):413–9.
An unusual location for heterotopic ossification: lumbar anterior longitudinal ligament. Czyrny JJ, et al. **J Spinal Cord Med** 1995 Jul;18(3):194–9 (32 ref.)

RADIONUCLIDE IMAGING

Heterotopic ossification mimicking infection. Scintigraphic evaluation. Nagaraj N, et al. **Clin Nucl Med** 1995 Sep; 20(9):763–6
Colonic adenocarcinoma metastatic to bone with gross heterotopic bone formation. Bone scan appearance with correlative imaging. Stuckey SL. **Clin Nucl Med** 1996 May; 21(5):396–7
Case report: ossifying metastases from carcinoma of the large bowel demonstrated by bone scintigraphy. Stabler J. **Clin Radiol** 1995 Oct;50(10):730–1
Thallium-201 accumulation in myositis ossificans and in juxta-articular ossification. Osmanagaoglu K, et al. **J Nucl Med** 1995 Dec;36(12):2239–42

RADIOTHERAPY

[Postoperative, conventional fractionated radiotherapy for prevention of heterotopic ossification after total endoprosthesis of the hip joint] Heyd R, et al. **Rontgenpraxis** 1995 Aug;48(8):233–7 (Eng. Abstr.) **(Ger)**
[Suppression of heterotopic ossification: single-dose versus fractionated irradiation—animal study] Sell S, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov-Dec;133(6):514–9 (Eng. Abstr.) **(Ger)**

SURGERY

Ineraid cochlear implant in the ossified cochlea: surgical techniques and results. Montandon PB, et al. **Am J Otol** 1994 Nov;15(6):748–51
A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May-Jun;34(3):305–11 (41 ref.)
Anterior decompression and fusion for ossification of posterior longitudinal ligament in the thoracic spine. Ido K, et al. **J Spinal Disord** 1995 Aug;8(4):317–23
Systematic approach to electrode insertion in the ossified cochlea. Balkany T, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):4–11
Long-term follow-up evaluation of surgery for ossification of the posterior longitudinal ligament. Goto S, et al. **Spine** 1995 Oct 15;20(20):2247–56

ULTRASONOGRAPHY

Supernumerary ovary with an endometrioma and osseous metaplasia: a case report. Badawy SZ, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1623–4
Association between muscle trauma and heterotopic ossification in spinal cord injured patients: reflections on their causal relationship and the diagnostic value of ultrasonography. Snoecx M, et al. **Paraplegia** 1995 Aug; 33(8):464–8
[Use of ultrasonography methods in the diagnosis of neurogenic paraosteoarthropathy in spinal cord injury] Pistarini C, et al. **Recenti Prog Med** 1995 Dec;86(12):483–8 (Eng. Abstr.) **(Ita)**

VETERINARY

Mineralized paraprostatic cyst in a dog. Girard C, et al. **Can Vet J** 1995 Sep;36(9):573–4

OSSIFICATION OF POSTERIOR LONGITUDINAL LIGAMENT

COMPLICATIONS

IgA nephropathy associated with hyper IgAnemia, psoriasis or pustulosis and ossification. Imai H, et al. **Clin Nephrol** 1995 Jul;44(1):64–8
Ossification of the posterior longitudinal ligament, diffuse, idiopathic skeletal hyperostosis, abnormal retinol and retinol binding protein: a familial observation. De Bandt M, et al. **J Rheumatol** 1995 Jul;22(7):1395–8
[Cervical spinal cord compression caused by ossification of the posterior vertebral ligament. Apropos of a case] Klisnick A, et al. **Neurochirurgie** 1995;41(5):359–62 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Electrophysiological and MRI study on poor outcome after surgery for cervical myelopathy] Kameyama O, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov; 69(11):1095–101 (Eng. Abstr.) **(Jpn)**

GENETICS

Restriction fragment length polymorphism of genes of the alpha 2(XI) collagen, bone morphogenetic protein-2, alkaline phosphatase, and tumor necrosis factor-alpha among patients with ossification of posterior longitudinal ligament and controls from the Japanese population. Koga H, et al. **Spine** 1996 Feb 15;21(4):469–73

METABOLISM

[Affinity of estrogen binding in the cultured spinal ligament cells: an in vitro study using cells from spinal ligament ossification patients] Wada A. **Nippon Seikeigeka Gakkai Zasshi** 1995 Jul;69(7):440–9 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Histochemical and immunohistochemical study on the skin of patients with ossification of the posterior longitudinal ligament in the cervical spine. Imamura T, et al. **In Vivo** 1995 May-Jun;9(3):167–71

PHYSIOPATHOLOGY

[Electrophysiological and MRI study on poor outcome after surgery for cervical myelopathy] Kameyama O, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov; 69(11):1095–101 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Bone mineral density of the lumbar spine in patients with ossification of the posterior longitudinal ligament of the cervical spine. Hirai N, et al. **J Spinal Disord** 1995 Oct; 8(5):337–41

SURGERY

Spinal cord expansion after decompression in cervical myelopathy. Investigation by computed tomography myelography and ultrasonography. Matsuyama Y, et al. **Spine** 1995 Aug 1;20(15):1657–63

OSSIFICATION, PATHOLOGIC see **OSSIFICATION, HETEROTOPIC**

OSSIFICATION, PHYSIOLOGIC see **OSTEOGENESIS**

OSTEITIS

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017–9 (20 ref.)
SAPHO syndrome: a followup study of 19 cases with special emphasis on enthesis involvement. Maugars Y, et al. **J Rheumatol** 1995 Nov;22(11):2135–41
SAPHO syndrome. Cotten A, et al. **Radiographics** 1995 Sep; 15(5):1147–54
Sapho syndrome associated with acne fulminans and prominent acromioclavicular joint involvement. Bölükbaş N, et al. **Scand J Rheumatol** 1996;25(3):180–2

OSTEITIS

COMPLICATIONS

SAPHO syndrome: a new pulmonary manifestation? [letter] Vaile JH, et al. **J Rheumatol** 1995 Nov;22(11):2190–1

[Sapho syndrome] Cotten A, et al. **Rev Med Interne** 1996; 17(4):341–3 **(Fre)**

[Multifocal periostitis in SAPHO syndrome] Steinborn M, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jun;164(6):514–6 **(Ger)**

DIAGNOSIS

Suppurative petrous apicitis: osteitis or osteomyelitis? an imaging case report. Horn KL, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):54–7

Cat scratch disease presenting as multifocal osteitis. Gallemore G, et al. **Tenn Med** 1996 Aug;89(8):289–90

[Current aspects of SAPHO syndrome] Kaiser H.
Z Rheumatol 1995 Jul–Aug;54(4):254 **(Ger)**

DRUG THERAPY

Osteitis pubis. A case of successful treatment with anticoagulants. Watkin NA, et al. **Acta Orthop Scand** 1995 Dec;66(6):569–70

EPIDEMIOLOGY

[Tuberculous osteitis in infants] Mushkin AIu, et al.
Probl Tuberk 1995;(5):8–11 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Osteitis pubis as a complication of prostate cryotherapy. Seigne JD, et al. **J Urol** 1996 Jul;156(1):182

[Osteitis secondary to toxic dermatitis caused by hydroxyurea. Apropos ofa case, review of the literature (letter)] Mounier N, et al. **Ann Med Interne (Paris)** 1995; 146(8):590–1 (14 ref.) **(Fre)**

[Inguinal hernia under laparoscopy. Pubic osteitis (letter)] Giuly J, et al. **J Chir (Paris)** 1996 Apr;133(2):93–6 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Osteitis condensans ilii [letter; comment] Olivieri I, et al. **Br J Rheumatol** 1996 Mar;35(3):295–7. Comment on: Br J Rheumatol 1994 Jun;33(6):599–600.

Osteitis condensans of the clavicle: does fibrocartilage play a role? A report of two cases with spontaneous clinical and roentgenographic resolution. Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):501–6 (54 ref.)

[Pubalgia in sportsmen] Zeitoun F, et al.
Ann Radiol (Paris) 1995;38(5):244–54 (31 ref.) (Eng. Abstr.) **(Fre)**

[Sarcoidosic dactylitis] Flipo RM, et al. **Rev Med Interne** 1995;16(9):724–5 **(Fre)**

[A young woman with dermopathy and thoracic pain] Fernández Sánchez JA, et al. **Rev Clin Esp** 1996 Apr; 196(4):259–60 **(Spa)**

SURGERY

Total hip replacement in irradiated hips. A retrospective study of 71 cases. Massin P, et al.
J Bone Joint Surg Br 1995 Nov;77(6):847–52

THERAPY

Treatment of osteitis pubis in athletes. Results of corticosteroid injections. Holt MA, et al.
Am J Sports Med 1995 Sep–Oct;23(5):601–6

OSTEITIS DEFORMANS

Paget's disease of bone: diagnosis and management [see comments] Hosking D, et al. **BMJ** 1996 Feb 24; 312(7029):491–4 (33 ref.). Comment in: BMJ 1996 Jun 8;312(7044):1476–7.

BLOOD

Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone [letter] Sharp CA, et al. **Clin Chem** 1996 Jul;42(7):1121–2

Clinical utility of a wheat–germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases. Braga V, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):433–9

COMPLICATIONS

Hearing loss in Paget's disease of bone: evidence of auditory nerve integrity. Monsell EM, et al. **Am J Otol** 1995 Jan; 16(1):27–33

Pulsed saline lavage causing venous air embolism in a patient with Paget's disease. Sides CA. **Br J Anaesth** 1996 Feb; 76(2):330–1

Osteoarthritis and Paget's disease. Helliwell PS.
Br J Rheumatol 1995 Nov;34(11):1061–3

The Ilizarov external fixator for treatment of deformities in Paget's disease. Louette L, et al. **Clin Orthop** 1996 Feb; (323):298–303

Scapular pain and swelling in a 60–year–old man with Paget's disease [clinical conference] Ueda T, et al. **Clin Orthop** 1996 May;(326):284–6, 310–2

Reconstruction nailing for subtrochanteric fractures in the Pagetic femur [letter; comment] Kerr PS, et al. **Injury** 1995 Jul;26(6):427. Comment on: Injury 1994 Sep;25(7):426–8.

Dental, visual, auditory and olfactory complications in Paget's disease of bone. Wheeler TT, et al.
J Am Geriatr Soc 1995 Dec;43(12):1384–91

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

Epilepsy and Paget's disease [letter] Javier RM, et al.
Rev Rhum Engl Ed 1995 Oct;62(9):606

[A case of Paget's disease with progressive sensorineural hearing loss involved in the bilateral bony labyrinths] Kokai H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun; 99(6):910–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Unusual endocrine presentations of nasopharyngeal carcinoma. Tan KC, et al. **Cancer** 1996 May 15; 77(10):1967–72

Paget's disease of bone presenting as chronic ankle pain. Neylon TA. **J Am Podiatr Med Assoc** 1995 Oct; 85(10):556–9

Appendicular metastatic prostate cancer simulating osteosarcoma, Paget's disease, and Paget's sarcoma. Igou D, et al. **Skeletal Radiol** 1995 Aug;24(6):447–9

[Vertebral localizations of Paget disease] Chrétien J.
Ann Radiol (Paris) 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Alendronate reaches U.S. market for osteoporosis, Paget's disease [news] **Am J Health Syst Pharm** 1995 Nov 15; 52(22):2513–4

Treatment response in Paget's disease. Patel S.
Ann Rheum Dis 1995 Oct;54(10):783–4

Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Patel S, et al.
Arthritis Rheum 1995 Oct;38(10):1506–12

Disodium pamidronate has beneficial effect in Paget's disease of bone [letter; comment] Chakravarty K, et al. **BMJ** 1996 Jun 8;312(7044):1476–7. Comment on: BMJ 1996 Feb 24;312(7029):491–4.

Tiludronate for Bone Diseases. Proceedings of a satellite symposium of the XIIth International Conference on Calcium Regulating Hormones (ICCRH). Melbourne, Australia, 14 February 1995. **Bone** 1995 Nov;17(5 Suppl):471S–519S

Tiludronate therapy for Paget's disease of bone. McClung MR, et al. **Bone** 1995 Nov;17(5 Suppl):493S–496S

Therapeutic strategy in Paget's disease of bone. Meunier PJ, et al. **Bone** 1995 Nov;17(5 Suppl):489S–491S

Skeletal safety of tiludronate. Neer RM. **Bone** 1995 Nov;17(5 Suppl):501S–503S (27 ref.)

Efficacy and safety of drugs for Paget's disease of bone. Reginster JY, et al. **Bone** 1995 Nov;17(5 Suppl):485S–488S (49 ref.)

The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Roux C. **Bone** 1995 Nov;17(5 Suppl):497S–499S

Paget's disease: ocular complications of disodium pamidronate treatment. O'Donnell NP, et al.
Br J Clin Pract 1995 Sep–Oct;49(5):272–3

Lymphocyte subsets in pamidronate–induced lymphopenia [letter] Lioté F, et al. **Br J Rheumatol** 1995 Oct; 34(10):993–5

Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. de la Piedra C, et al.
Calcif Tissue Int 1996 Aug;59(2):95–9

Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Blumsohn A, et al. **Clin Chem** 1995 Nov;41(11):1592–8

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)

Paget's disease of bone [editorial] Smith R.
J Bone Joint Surg Br 1995 Sep;77(5):673–4

The effects of intravenous alendronate in Paget's disease of bone. O'Doherty DP, et al. **J Bone Miner Res** 1995 Jul; 10(7):1094–100

Interleukin–6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen–containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. Schweitzer DH, et al. **J Bone Miner Res** 1995 Jun; 10(6):956–62

Effects of calcitriol administration in a pagetic uremic patient unresponsive to conventional therapy [letter] Rolla D, et al. **Nephron** 1995;71(4):479

EPIDEMIOLOGY

Low rates of Paget's disease of bone and osteosarcoma in elderly Japanese [letter] Ishikawa Y, et al. **Lancet** 1996 Jun 1;347(9014):1559

Current prevalence of Paget's disease of bone in a region of France (Anjou). Rénier JC, et al.
Rev Rhum Engl Ed 1995 Oct;62(9):571–5

ETHNOLOGY

Paget's disease of bone in Negev Bedouin: report of two cases. Lowenthal MN, et al. **Isr J Med Sci** 1995 Oct; 31(10):628–9

HISTORY

Geriatrics photo quiz. Paget's disease: skeletal deformity with or without pain. Gross JS, et al. **Geriatrics** 1996 Jun; 51(6):19, 50

METABOLISM

Paget's disease is associated with changes in the immunohistochemical distribution of noncollagenous matrix proteins in bone. Ingram RT, et al.
J Clin Endocrinol Metab 1996 May;81(5):1810–20

Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Constantin A, et al.
Rev Rhum Engl Ed 1995 Jul–Sep;62(7–8):493–500

[What do we know about the significance of vitamin D in Paget's disease of the bone?] Wilczek H, et al.
Cas Lek Cesk 1995 Dec 13;134(24):785–7 (Eng. Abstr.) **(Cze)**

PATHOLOGY

Canine bone marrow cell cultures infected with canine distemper virus: an in vitro model of Paget's disease. Mee AP, et al. **Bone** 1995 Oct;17(4 Suppl):461S–466S

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S–61S (30 ref.)

Skeletal response to immobilization in Paget's disease of bone: a case report. Wallace K, et al. **Clin Orthop** 1996 Jul; (328):236–40

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

[A case of Paget's disease with progressive sensorineural hearing loss involved in the bilateral bony labyrinths] Kokai H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun; 99(6):910–7 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Paget's disease of bone: why not use less expensive skull films? [letter] Cowley DM. **Geriatrics** 1996 Aug;51(8):11

Images in clinical medicine. Paget's disease of bone. Simcic KJ, et al. **N Engl J Med** 1996 Jan 18;334(3):161

RADIONUCLIDE IMAGING

Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Patel S, et al.
Arthritis Rheum 1995 Oct;38(10):1506–12

An anatomy lesson by Sir James Paget. de Geeter F.
Clin Nucl Med 1995 Sep;20(9):843

Paget's disease of the mandible. Lincoln sign on bone scintigraphy. Nahum E, et al. **Clin Nucl Med** 1996 Mar; 21(3):246–7

Images in clinical medicine. Paget's disease of bone. Thomas P, et al. **N Engl J Med** 1996 Jan 18;334(3):160

SURGERY

[Anesthetic management of a Paget's disease patient complicated with Parkinson disease] Tomioka T, et al.
Masui 1995 Oct;44(10):1384–7 (Eng. Abstr.) **(Jpn)**

VIROLOGY

Viral behavior of paracrystalline inclusions in osteoclasts of Paget's disease of bone. Abe S, et al. **Ultrastruct Pathol** 1995 Nov–Dec;19(6):455–61

[Viral origin of Paget's disease of bone?] Basle MF, et al.
Presse Med 1996 Jan 27;25(3):113–8 (25 ref.) (Eng. Abstr.) **(Fre)**

OSTEITIS FIBROSA CYSTICA

COMPLICATIONS

[Spontaneous pulmonary hernia and Recklinghausen disease] Bouttier E, et al. **J Radiol** 1996 Feb;77(2):137–9 (Eng. Abstr.) **(Fre)**

CONGENITAL

[Contribution of Ilizarov's equipment in the treatment of congenital pseudarthrosis of the lower limb] Damsin JP, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(1):34–41 (Eng. Abstr.) **(Fre)**

HISTORY

[Friedrich Daniel von Recklinghausen. Biography and significance of his osteopathologic work after more than 100 years] Kummerfeldt K, et al. **Pathologe** 1996 Jan; 17(1):78–82 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Tc–99m sestamibi imaging of brown tumors of primary hyperparathyroidism. Dinauer PA, et al. **Clin Nucl Med** 1996 Mar;21(3):192–6

VETERINARY

[Skeletal findings in an adult dog recovering from

osteodystrophia fibrosa] Weiler H.
Berl Munch Tierarztl Wochenschr 1995 Oct;108(10):361–6 (Eng. Abstr.) **(Ger)**

OSTEITIS FIBROSA DISSEMINATA see **FIBROUS DYSPLASIA OF BONE**

OSTEO–ONYCHODYSPLASIA, HEREDITARY see **NAIL–PATELLA SYNDROME**

OSTEOARTHRITIS

Osteoarthrosis—the orthopedic surgeon's perspective. Radin EL. **Acta Orthop Scand Suppl** 1995 Oct;266:6–9 (18 ref.)
Weight and osteoarthritis. Felson DT. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):430S–432S (10 ref.)
New perspectives on osteoarthritis. Oddis CV.
Am J Med 1996 Feb 26;100(2A):10S–15S (39 ref.)
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Belcher C, et al. **Ann Rheum Dis** 1996 Apr;55(4):230–6
Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Takahashi M, et al. **Ann Rheum Dis** 1996 May; 55(5):324–7
Activation of the transcription factor nuclear factor–kappaB in human inflamed synovial tissue. Marok R, et al.
Arthritis Rheum 1996 Apr;39(4):583–91
Relationship between osteoarthrosis and osteoporosis. An experimental and clinical study. Moreschini O, et al.
Chir Organi Mov 1995 Apr–Jun;80(2):237–43 **(Eng, Ita)**
Degenerative joint disease. Buckwalter JA, et al.
Clin Symp 1995;47(2):1–32
Osteoarthritis and crystal deposition diseases.
Curr Opin Rheumatol 1995 Jul;7(4):B73–9
Osteoarthritis in old age. Erhardt K. **J R Soc Med** 1995 Sep; 88(9):539P–542P
New insights into osteoarthritis. Brooks PM, et al.
Med J Aust 1995 Oct 2;163(7):367–9 (33 ref.)
Quantitative photometrical assessment of iron deposits in synovial membranes in different joint diseases. Fritz P, et al. **Rheumatol Int** 1996;15(5):211–6
Osteoarthritis. A continuing challenge. Sack KE.
West J Med 1995 Dec;163(6):579–86 (149 ref.)

BLOOD

Mud pack treatment increases serum antioxidant defenses in osteoarthrosic patients [letter] Bellometti S, et al.
Biomed Pharmacother 1996;50(1):37
Elevated levels of corticotrophin–releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid. Woods RJ, et al. **Br J Rheumatol** 1996 Feb; 35(2):120–4
Microheterogeneity of acute phase proteins in patients with clinically active and clinically nonactive osteoarthritis. Hrycaj P, et al. **Clin Rheumatol** 1995 Jul;14(4):434–40
Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25–hydroxyvitamin D3 in patients with systemic lupus erythematosus. Müller K, et al.
Clin Rheumatol 1995 Jul;14(4):397–400
Serial changes in serum vitamin K1, triglyceride, cholesterol, osteocalcin and 25–hydroxyvitamin D3 in patients after hip replacement for fractured neck of femur or osteoarthritis. Roberts NB, et al. **Eur J Clin Invest** 1996 Jan;26(1):24–9
[Changes in the biophysical indices of the erythrocytes in osteoarthrosis patients being treated with Tskhaltubo mineral baths] Shavianidze GO, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1996 Jan–Feb; (1):39–40 **(Rus)**

CHEMICALLY INDUCED

Indomethacin hastens large joint osteoarthritis in humans—how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)
[Polyarticular pain syndrome during treatment with cyclosporine for severe acute colitis (letter)] Andant C, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):219–20 **(Fre)**

CLASSIFICATION

Assessing performance–related disability in patients with knee osteoarthritis. Rejeski WJ, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):157–67

COMPLICATIONS

Stress fracture of the proximal tibia associated with severe osteoarthritis. Nabors ED, et al. **Am J Knee Surg** 1995 Fall; 8(4):141–3
Asymmetrical nodular osteoarthritis in a patient with a hemiparesis [letter] Etherington J, et al.
Ann Rheum Dis 1995 Nov;54(11):936–7
Analysis of the association between chondrocalcinosis and osteoarthritis: a community based study. Sanmarti R, et al. **Ann Rheum Dis** 1996 Jan;55(1):30–3
Unilateral osteoarthritis and neurological deficit [letter] Kavanagh RT, et al. **Clin Exp Rheumatol** 1995 Sep–Oct; 13(5):679–80
Treatment of diaphyseal tibial stress fractures associated with knee osteoarthrosis. Templeton PA, et al. **Injury** 1995 Jul; 26(6):419–20
The relation between osteoporosis of the spine and osteoarthritis of the knee. A study using dual energy X–ray absorptiometry and radiographs. Yokozeki H, et al.
Int Orthop 1995;19(5):282–4
Self–efficacy and pain in disability with osteoarthritis of the knee. Rejeski WJ, et al.
J Gerontol B Psychol Sci Soc Sci 1996 Jan;51(1):P24–9
Bilateral scaphoid exostoses. Harris NJ, et al.
J Hand Surg [Br] 1995 Dec;20(6):745
Scaphoid exostosis and radio–carpal osteoarthrosis. Rimmer SG, et al. **J Hand Surg [Br]** 1995 Dec;20(6):741–4
Lack of association between thyroid status and chondrocalcinosis or osteoarthritis: the Framingham Osteoarthritis Study. Chaisson CE, et al. **J Rheumatol** 1996 Apr;23(4):711–5
Gouty arthritis in nodal osteoarthritis. Fam AG, et al.
J Rheumatol 1996 Apr;23(4):684–9
The effect of noninsulin dependent diabetes mellitus on the prevalence of clinical osteoarthritis. A population based study. Frey MI, et al. **J Rheumatol** 1996 Apr;23(4):716–22
Osteoarthritis, bone density, postural stability, and osteoporotic fractures: a population based study. Jones G, et al. **J Rheumatol** 1995 May;22(5):921–5
Combined arthroscopic management of impingement syndrome and acromioclavicular joint arthritis. Lozman PR, et al. **J South Orthop Assoc** 1995 Fall;4(3):177–81
Treatment of a knee contracture using a knee orthosis incorporating stress–relaxation techniques. Jansen CM, et al. **Phys Ther** 1996 Feb;76(2):182–6
[Tetraplegia after benign neck injury in cervical arthrosis. Value of high–dose corticoid treatment (letter)] Seror P.
Presse Med 1996 Jun 29;25(23):1085 **(Fre)**
[A new case of tibial stress fracture as a complication of knee osteoarthritis] Sy MH, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(5):445–8 (Eng. Abstr.) **(Fre)**
[Atlanto–axial osteoarthritis (letter)] Desbonnets A, et al.
Rev Med Interne 1996;17(3):267–9 **(Fre)**

DIAGNOSIS

Validating markers in osteoarthritis. Felson DT.
Acta Orthop Scand Suppl 1995 Oct;266:205–7 (1 ref.)
The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis. Lohmander LS, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:84–7 (32 ref.)
High levels of aggrecan aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis. Ratcliffe A, et al.
Acta Orthop Scand Suppl 1995 Oct;266:111–5
Detection and monitoring of progressive degeneration of osteoarthritic cartilage by MRI. Tyler JA, et al.
Acta Orthop Scand Suppl 1995 Oct;266:130–8
Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)
Osteoarthritis: what to look for, and when to treat it [interview by Peter Pompei] Clyman BB. **Geriatrics** 1996 Aug;51(8):36–8, 41
Joint failure in erosive osteoarthritis of the hands. Rovetta G, et al. **Int J Tissue React** 1995;17(1):33–42 (36 ref.)
A mathematical model that improves the validity of osteoarthritis diagnoses obtained from a computerized diagnostic database. Gabriel SE, et al. **J Clin Epidemiol** 1996 Sep;49(9):1025–9
Intertester reliability of the cyriax evaluation in assessing patients with shoulder pain. Pellecchia GL, et al.
J Orthop Sports Phys Ther 1996 Jan;23(1):34–8
The case for a simple method of grading osteoarthritis severity at arthroscopy [editorial; comment] Marshall KW.
J Rheumatol 1996 Apr;23(4):582–5 (24 ref.). Comment on: J Rheumatol 1996 Apr;23(4):698–706.
Polymyalgia rheumatica [letter] Sweetman BJ. **Lancet** 1996 Aug 24;348(9026):550
Imaging of osteoarthritis. Preidler KW, et al.
Radiol Clin North Am 1996 Mar;34(2):259–71, x (63 ref.)
Rapidly destructive hip disease. Lawrance JA, et al.
Skeletal Radiol 1995 Nov;24(8):639–41
[Peripheral arthritis in family practice] de Bock GH.
Tijdschr Gerontol Geriatr 1996 Apr;27(2):67–72 (Eng. Abstr.) **(Dut)**
[Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association] Protzer U, et al. **Med Klin** 1996 Jun 15; 91(6):330–5 (Eng. Abstr.) **(Ger)**
[The MRT of osteophytosis in experimental gonarthrosis] Nolte–Ernsting CC, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Nov;163(5):430–6 (Eng. Abstr.) **(Ger)**
[Orthopedic examination of the foot: refresher course] Dvořák J, et al. **Sportverletz Sportschaden** 1995 Sep; 9(3):A19–29 **(Ger)**
[Value of anamnesis and clinical examination in degenerative impingement syndrome in comparison with surgical findings—a prospective study] Hermann B, et al.
Z Orthop Ihre Grenzgeb 1996 Mar–Apr;134(2):166–70 (Eng. Abstr.) **(Ger)**
[Clinical relevance of the early detection of arthrosis] Willauschus W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):507–13 (49 ref.) (Eng. Abstr.) **(Ger)**
[Arthrosis of the hand: epidemiologic and clinical characteristics] Jelčić A, et al. **Reumatizam** 1995;42(1):1–5 (Eng. Abstr.) **(Scr)**
[Immunoglobulin E and beta 2–microglobulin in the blood serum and synovial fluid of patients with rheumatoid arthritis, arthrosis deformans and traumatic arthritis] Neĭko IeM, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):127–9 **(Ukr)**

DRUG THERAPY

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S–30S (47 ref.)
Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section.
Ann Rheum Dis 1996 Aug;55(8):552–7
Intra–articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Lohmander LS, et al.
Ann Rheum Dis 1996 Jul;55(7):424–31
Clinical trials in osteoarthritis [editorial] March LM, et al.
Ann Rheum Dis 1996 Aug;55(8):491–3 (27 ref.)
Practical management of osteoarthritis. Integration of pharmacologic and nonpharmacologic measures. Griffin MR, et al. **Arch Fam Med** 1995 Dec;4(12):1049–55 (102 ref.)
Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Fernandes JC, et al. **Arthritis Rheum** 1995 Sep;38(9):1290–303
An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Bevis PJ, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:56–60
Safety of meloxicam: a global analysis of clinical trials. Distel M, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:68–77
Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Ghozlan PR, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:51–5
Meloxicam in osteoarthritis: a 6–month, double–blind comparison with diclofenac sodium. Hosie J, et al.
Br J Rheumatol 1996 Apr;35 Suppl 1:39–43
Clinical implications of patients' knowledge. Mahmud T, et al. **Clin Rheumatol** 1995 Nov;14(6):627–30
Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Ward DE, et al. **Clin Rheumatol** 1995 Nov; 14(6):656–62
Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Atkinson MH, et al.
Clin Ther 1995 Sep–Oct;17(5):827–37
Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double–blind, placebo–controlled study. Dore R, et al. **Clin Ther** 1995 Jul–Aug;17(4):656–66
Double–blind, placebo–controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Schnitzer TJ, et al. **Clin Ther** 1995 Jul–Aug; 17(4):602–12
Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Weaver A, et al. **Clin Ther** 1995 Jul–Aug; 17(4):735–45
A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single–blind, randomized, multicentre study. Carrabba M, et al. **Curr Med Res Opin** 1995; 13(6):343–55
Assessment outcomes of clinical drug trials in osteoarthritis. Sangha O, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):352–5 (24 ref.)
Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post–herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al.
Drugs Aging 1995 Oct;7(4):317–28 (52 ref.)
Radiological assessment of relaxin–induced pubic symphyseal changes in guinea pigs: a model for screening disease modifying agents for osteoarthritis. Jimenez PA, et al.
Inflamm Res 1995 Aug;44 Suppl 2:S164–5
Biological evaluation of matrix metalloproteinase inhibitors, 18 May 1995, New York. Pratta MA. **Inflamm Res** 1995 Nov;44(11):458–60
Protein kinase C activator inhibits progression of osteoarthritis induced in rabbit knee joints [see comments] Hamanishi C, et al. **J Lab Clin Med** 1996 Jun;127(6):540–4 . Comment in: J Lab Clin Med 1996 Jun;127(6):520–1.
A model of osteoarthritis and a potential new therapy [editorial; comment] Oegema TR Jr. **J Lab Clin Med** 1996 Jun;127(6):520–1. Comment on: J Lab Clin Med 1996 Jun;127(6):540–4.
Acute local reactions after intraarticular hylan for osteoarthritis of the knee [letter] Adams ME.
J Rheumatol 1996 May;23(5):944–5; discussion 946
A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. Bellamy N, et al.
J Rheumatol 1995 May;22(5):915–20
Hydroxychloroquine in the treatment of erosive osteoarthritis. Bryant LR, et al. **J Rheumatol** 1995 Aug; 22(8):1527–31
Guidelines for testing slow acting drugs in arthritis—addendum [letter] Lequesne M, et al.
J Rheumatol 1995 Jul;22(7):1442
Neurogenic influences in arthritis: potential modification by

capsaicin [editorial] Matucci Cerinic M, et al. **J Rheumatol** 1995 Aug;22(8):1447–9 (27 ref.)

Acute local reactions after intraarticular hylan for osteoarthritis of the knee [letter] O'Hanlon D. **J Rheumatol** 1996 May;23(5):945–6

Acute local reactions after intraarticular hylan for osteoarthritis of the knee. Puttick MP, et al. **J Rheumatol** 1995 Jul;22(7):1311–4

When Goody's Powder is not so good. Hamdy RC, et al. **J Tenn Med Assoc** 1996 Feb;89(2):43–4

MRI evaluation of dexamethasone acetate therapy for osteoarthritis in the hand. Tankhiwale A, et al. **Magn Reson Imaging** 1995;13(6):911–4

The role of viscosupplementation with hylan G–F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G–F 20 alone, hylan G–F 20 with non–steroidal anti–inflammatory drugs (NSAIDs) and NSAIDs alone. Adams ME, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):213–25

Intra–articular hyaluronic acid compared to intra–articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Jones AC, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):269–73

Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S–62S (22 ref.)

Therapeutic trials in digital osteoarthritis. A critical review. Trêves R, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):33S–41S

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

Clinical implications of selective cyclooxygenase–2 inhibition. Emery P. **Scand J Rheumatol Suppl** 1996; 102:23–8

Assessment and follow–up of osteoarthritis of the limbs—outcome measures. Lequesne M. **Schweiz Med Wochenschr Suppl** 1996;80:8S–9S

[Peripheral arthritis in family practice] de Bock GH. **Tijdschr Gerontol Geriatr** 1996 Apr;27(2):67–72 (Eng. Abstr.) **(Dut)**

[DMSO in patients with active gonarthrosis. A double–blind placebo controlled phase III study] Eberhardt R, et al. **Fortschr Med** 1995 Nov 10;113(31):446–50 (Eng. Abstr.) **(Ger)**

[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases] Delfino M, et al. **Clin Ter** 1996 Mar; 147(3):113–6 (Eng. Abstr.) **(Ita)**

[The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis] Giordano N, et al. **Clin Ter** 1996 Mar;147(3):99–105 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double–blind controlled study] Bestetti F. **Minerva Med** 1996 Mar;87(3):117–22 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial] Peretti G. **Minerva Med** 1996 Apr;87(4):155–60 (Eng. Abstr.) **(Ita)**

[Establish the optimal dosage of TSA–234 (rhSOD) in the treatment of osteoarthritis] **Ryumachi** 1995 Jun;35(3):621–35 **(Jpn)**

[Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS)] Badurski J, et al. **Pol Tyg Lek** 1995 Nov; 50(44–47):37–40 (Eng. Abstr.) **(Pol)**

ECONOMICS

Average charges for a total knee replacement: United States, 1994. Mushinski M. **Stat Bull Metrop Insur Co** 1996 Apr–Jun;77(2):24–30

ENZYMOLOGY

Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Ronday HK, et al. **Br J Rheumatol** 1996 May; 35(5):416–23

Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase–13 from human osteoarthritic cartilage. Mitchell PG, et al. **J Clin Invest** 1996 Feb 1; 97(3):761–8

The new collagenase, collagenase–3, is expressed and synthesized by human chondrocytes, but not by synoviocytes. A role in osteoarthritis. Reboul P, et al. **J Clin Invest** 1996 May 1;97(9):2011–9

The expression and regulation of nitric oxide synthase in human osteoarthritis–affected chondrocytes: evidence for up–regulated neuronal nitric oxide synthase. Amin AR, et al. **J Exp Med** 1995 Dec 1;182(6):2097–102

Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. Wernicke D, et al. **J Rheumatol** 1996 Apr;23(4):590–5

EPIDEMIOLOGY

Association of bone mineral density and sex hormone levels with osteoarthritis of the hand and knee in premenopausal women. Sowers MF, et al. **Am J Epidemiol** 1996 Jan 1; 143(1):38–47

The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Felson DT, et al. **Arthritis Rheum** 1995 Oct;38(10):1500–5

Risk of osteoarthritis associated with long–term weight–bearing sports: a radiologic survey of the hips and knees in female ex–athletes and population controls. Spector TD, et al. **Arthritis Rheum** 1996 Jun;39(6):988–95

Knee pain amongst the poor and affluent in Pakistan. Gibson T, et al. **Br J Rheumatol** 1996 Feb;35(2):146–9

The evolutionary origins of osteoarthritis: a comparative skeletal study of hand disease in 2 primates. Lim KK, et al. **J Rheumatol** 1995 Nov;22(11):2132–4

Patient self–assessment of health status and function in glenohumeral degenerative joint disease. Matsen FA 3rd, et al. **J Shoulder Elbow Surg** 1995 Sep–Oct;4(5):345–51

Increased rate of hysterectomy in women undergoing surgery for osteoarthritis of the knee. Inoue K, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):205–9

Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age. Roos H, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):261–7

The epidemiology of osteoarthritis of the hand [see comments] Cicuttini FM, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):3S–8S (45 ref.). Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

["State of the art" in epidemiology of arthroses. An overview of important studies of etiology and sequelae] Kriegel W, et al. **Z Rheumatol** 1995 Jul–Aug;54(4):223–40 (90 ref.) (Eng. Abstr.) **(Ger)**

[Osteoarticular disorders in the elderly: an approach to their population impact (see comments)] Espallargues M, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):601–6 (Eng. Abstr.) . Comment in: Med Clin (Barc) 1996 Apr; 27;106(16):617–8. **(Spa)**

[Why I do not grease up my axles... (editorial; comment)] Tena Marsà X. **Med Clin (Barc)** 1996 Apr 27;106(16):617–8 (21 ref.). Comment on: Med Clin (Barc) 1996 Apr 27;106(16):601–6. **(Spa)**

ETIOLOGY

Osteoarthritis of the elbow following an extensive Darrach procedure. Stuer P, et al. **Acta Orthop Belg** 1996 Mar; 62(1):62–5

Osteoarthritis and molecular markers. A rheumatologist's perspective. Dieppe P. **Acta Orthop Scand Suppl** 1995 Oct; 266:1–5 (25 ref.)

Long–term followup of Bankart reconstruction. Incidence of late degenerative glenohumeral arthrosis. Rosenberg BN, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):538–44

Hypermobility associated with osteoarthritis of the thumb base: a clinical and radiological subset of hand osteoarthritis. Jónsson H, et al. **Ann Rheum Dis** 1996 Aug; 55(8):540–3

Osteoarthritis and Paget's disease. Helliwell PS. **Br J Rheumatol** 1995 Nov;34(11):1061–3

Pathogenesis of degenerative joint disease in the human temporomandibular joint. Haskin CL, et al. **Crit Rev Oral Biol Med** 1995;6(3):248–77 (359 ref.)

Overweight, gender and knee osteoarthritis. Manninen P, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):595–7

Duplication of medial erosion in unicompartmental knee arthroplasties. McCallum JD 3rd, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):726–8

Effects of valgus tibial angulation on cartilage degeneration in the rabbit knee. Lovász G, et al. **J Orthop Res** 1995 Nov;13(6):846–53

Degenerative arthritis after tibial plateau fractures. Honkonen SE. **J Orthop Trauma** 1995;9(4):273–7

Patellectomy and osteoarthritis: arthroscopic findings following previous patellectomy. Feller JA, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):159–61

Experimental osteoarthritis in dogs: a comparison of the Pond–Nuki and medial arthrotomy methods. Visco DM, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):9–22

Etiologic factors in finger osteoarthritis [see comments] Verrouil E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):9S–13S (39 ref.). Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

An aseptic inflammation of the clavicle in a patient with Crohn's disease. A potential manifestation of the SAPHO syndrome. Kotilainen PM, et al. **Scand J Rheumatol** 1996; 25(2):112–4

[Arthroses of the finger joints and thumb saddle joint and occupationally related factors] Elsner G, et al. **Gesundheitswesen** 1995 Dec;57(12):786–91 (Eng. Abstr.) **(Ger)**

[Knee joint arthroses and work–related factors] Elsner G, et al. **Soz Praventivmed** 1996;41(2):98–106 (Eng. Abstr.) **(Ger)**

[Orthopaedic disorders and problems related to obesity] Koshino T. **Nippon Rinsho** 1995 Jun;53 Suppl:382–7 (20 ref.) **(Jpn)**

[Diagnostic methods of detection of early degenerative changes in the lumbo–coccygeal triangle in relation to the use of prostheses] MatanovićB, et al. **Reumatizam** 1993; 40(1):11–4 (Eng. Abstr.) **(Ser)**

GENETICS

Association of two loci on chromosome 2q with nodal osteoarthritis. Wright GD, et al. **Ann Rheum Dis** 1996 May; 55(5):317–9

Commentary: genes for osteoarthritis: interpreting twin data [comment] Hopper J. **BMJ** 1996 Apr 13;312(7036):943–4 . Comment on: BMJ 1996 Apr 13;312(7036):940–3.

Genetic liability to osteoarthritis may be greater in women than men [letter] Kaprio J, et al. **BMJ** 1996 Jul 27; 313(7051):232

Genetic influences on osteoarthritis in women: a twin study [see comments] Spector TD, et al. **BMJ** 1996 Apr 13; 312(7036):940–3. Comment in: BMJ 1996 Apr 13;312(7036):943–4.

Differential expression of the protooncogene bcl–2 in normal and osteoarthritic human articular cartilage. Erlacher L, et al. **J Rheumatol** 1995 May;22(5):926–31

Expression of a multidrug resistance gene in human rheumatoid synovium. Jorgensen C, et al. **Rheumatol Int** 1995;15(2):83–6

Genetics of osteoarthritis (OA). Doherty M. **Schweiz Med Wochenschr Suppl** 1996;80:6S–7S

[Arthropathy as a diagnostic early symptom of hereditary systemic disease] Vogtherr B, et al. **Internist (Berl)** 1996 Jul;37(7):731–4 **(Ger)**

IMMUNOLOGY

Fas antigen expression on synovial cells was down–regulated by interleukin 1 beta. Tsuboi M, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):280–5

Monocyte–macrophage antigen expression on chondrocytes. Summers KL, et al. **J Rheumatol** 1995 Jul;22(7):1326–34

METABOLISM

Localization of the glycosaminoglycans in the synovial tissues from osteoarthritic knees. Nishida K, et al. **Acta Med Okayama** 1995 Dec;49(6):287–94

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:121–4 (32 ref.)

MMP–8 (neutrophil collagenase) mRNA and aggrecanase cleavage products are present in normal and osteoarthritic human articular cartilage. Cole AA, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:98–102

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92–7 (31 ref.)

Association between synovial fluid levels of inorganic pyrophosphate and short term radiographic outcome of knee osteoarthritis. Doherty M, et al. **Ann Rheum Dis** 1996 Jul;55(7):432–6

Differential distribution of annexins–I, –II, –IV, and –VI in synovium. Goulding NJ, et al. **Ann Rheum Dis** 1995 Oct; 54(10):841–5

Concentration and size distribution of insulin–like growth factor–I in human normal and osteoarthritic synovial fluid and cartilage. Schneiderman R, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):173–88

Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage. Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Nakamura S, et al. **Arthritis Rheum** 1996 Apr;39(4):539–51

Normal expression of type 1 insulin–like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin–like growth factor binding proteins. Tardif G, et al. **Arthritis Rheum** 1996 Jun;39(6):968–78

High DNA–binding activity of transcription factor NF–kappa B in synovial membranes of patients with rheumatoid arthritis. Asahara H, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):827–32

The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Caldwell JR, et al. **Br J Clin Pharmacol** 1995; 39 Suppl 1:3S–9S

Increased expression of the Ed–B–containing fibronectin (an embryonic isoform of fibronectin) in human osteoarthritic cartilage. Chevalier X, et al. **Br J Rheumatol** 1996 May; 35(5):407–15

Proteoglycan–degrading activity associated with the 40 kDa collagen–binding fragment of fibronectin. Chevalier X, et al. **Br J Rheumatol** 1996 Jun;35(6):506–14

Production of binding proteins and role of the insulin–like growth factor I binding protein 3 in human articular cartilage explants. Chevalier X, et al. **Br J Rheumatol** 1996 Jun;35(6):515–22

Increased expression of interferon (IFN)–gamma together with IFN–gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Dolhain RJ, et al. **Br J Rheumatol** 1996 Jan; 35(1):24–32

The levels of collagenase, tissue inhibitor of metalloproteinases–1 (TIMP–1), collagenase approximately TIMP–1 complexes and glycosaminoglycan (GAG) in sequential samples of synovial fluid aspirated from patients with osteoarthritis. Cawston TE, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):431–7

Macrophage inflammatory protein–1 beta: a C–C chemokine in osteoarthritis. Koch AE, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):307–14

Biochemical markers in synovial fluid identify early osteoarthritis of the glenohumeral joint. Ratcliffe A, et al. **Clin Orthop** 1996 Sep;(330):45–53

Overexpression of the NC4 domain of type IX collagen induces osteoarthritis in mice. Haimes HB, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S127–8

Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. Zhao M, et al. **J Biol Chem** 1995 Nov 3;270(44):26657–63

Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes. Zafarullah M, et al. **J Cell Biochem** 1996 Feb;60(2):211–7

Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. Hollander AP, et al. **J Clin Invest** 1995 Dec; 96(6):2859–69

Insulin-like growth factor (IGF) receptor, IGF-I, interleukin-1 beta (IL-1 beta), and IL-6 mRNA expression in osteoarthritic and normal human cartilage. Middleton J, et al. **J Histochem Cytochem** 1996 Feb;44(2):133–41

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep. Little CB, et al. **J Orthop Res** 1996 May;14(3):433–44

Expression of interleukin-6 in osteoarthritic chondrocytes and effects of fluid-induced shear on this expression in normal human chondrocytes in vitro. Mohtai M, et al. **J Orthop Res** 1996 Jan;14(1):67–73

Effects of basic fibroblast growth factor, transforming growth factor-beta 1, insulin-like growth factor-1, and insulin on human osteoarthritic articular cartilage explants. Posever J, et al. **J Orthop Res** 1995 Nov;13(6):832–7

Inorganic pyrophosphate generation from adenosine triphosphate by cell-free human synovial fluid. Park W, et al. **J Rheumatol** 1996 Apr;23(4):665–71

Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. Pruzanski W, et al. **J Rheumatol** 1995 Nov;22(11):2114–9

Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Qu Z, et al. **Lab Invest** 1995 Sep;73(3):339–46

Expression of extracellular matrix in human mandibular condyle. Ishibashi H, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):402–14

Articular cartilage proteoglycans in osteoarthritic STR/Ort mice. Gaffen JD, et al. **Osteoarthritis Cartilage** 1995 Jun; 3(2):95–104

Tumor necrosis factor-alpha (TNF-alpha) in canine osteoarthritis: Immunolocalization of TNF-alpha, stromelysin and TNF receptors in canine osteoarthritic cartilage. Kammermann JR, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):23–34

Cyclic loading is harmful to articular cartilage from which proteoglycans have been partially depleted by retinoic acid. Ostendorf RH, et al. **Osteoarthritis Cartilage** 1995 Dec; 3(4):275–84

The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Pelletier JP, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):77–84

Acute-phase proteins in osteoarthritis. Sipe JD. **Semin Arthritis Rheum** 1995 Oct;25(2):75–86 (115 ref.)

PATHOLOGY

Comparative pathoanatomy of the Asian and Caucasian trapeziometacarpal joint. Pellegrini VD Jr. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):21–5

Association of hand and knee osteoarthritis: evidence for a polyarticular disease subset. Hirsch R, et al. **Ann Rheum Dis** 1996 Jan;55(1):25–9

Ultrastructural changes in primary guinea pig osteoarthritis with special reference to collagen. Hedlund H, et al. **APMIS** 1996 May;104(5):374–82

Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Fernandes JC, et al. **Arthritis Rheum** 1995 Sep;38(9):1290–303

Trabecular microstructure in the medial condyle of the proximal tibia of patients with knee osteoarthritis. Kamibayashi L, et al. **Bone** 1995 Jul;17(1):27–35

Radiological medical joint space narrowing and meniscal lesions. Steering Committee of French Society of Arthroscopy [letter] Ayral X, et al. **Br J Rheumatol** 1995 Oct;34(10):991

Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Johansen JS, et al. **Br J Rheumatol** 1996 Jun; 35(6):553–9

Induction of osteoarthritis in guinea pigs by transection of the anterior cruciate ligament: radiographic and histopathological changes. Jimenez PA, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S129–30

Patterns of degenerative change in the acromioclavicular joint. Edelson JG. **J Bone Joint Surg Br** 1996 Mar; 78(2):242–3

Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. Baragi VM, et al. **J Clin Invest** 1995 Nov;96(5):2454–60

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

Primary osteoarthrosis in guinea pigs: a stereological study. de Bri E, et al. **J Orthop Res** 1995 Sep;13(5):769–76

Arthroscopic evaluation of chondropathy in osteoarthritis of the knee [see comments] Ayral X, et al. **J Rheumatol** 1996 Apr;23(4):698–706. Comment in: J Rheumatol 1996 Apr;23(4):582–5.

Mononuclear cell (MNC) subtypes in osteoarthritis synovial fluid. Comparison with MNC subtypes in rheumatoid arthritis synovial fluid. Fort JG, et al. **J Rheumatol** 1995 Jul;22(7):1335–7

Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Sadouk MB, et al. **Lab Invest** 1995 Sep;73(3):347–55

MRI evaluation of dexamethasone acetate therapy for osteoarthritis in the hand. Tankhiwale A, et al. **Magn Reson Imaging** 1995;13(6):911–4

Osteoarthritis staging: comparison between magnetic resonance imaging, gross pathology and histopathology in the rhesus macaque. Gahunia HK, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):169–80

Osteoarthritis of the hand. New methods. New data [editorial; comment] Lequesne M, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6 Suppl 1):1S–2S. Comment on: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):3S–8S. Comment on: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):9S–13S. Comment on: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):14S–26S. Comment on: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):27S–32S. Comment on: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):43S–53S.

Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S–62S (22 ref.)

Numerical scoring systems for the progression of osteoarthritis of the finger joints [see comments] Verbruggen G, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):27S–32S. Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

Etiologic factors in finger osteoarthritis [see comments] Verrouil E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):9S–13S (39 ref.). Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

Quantification of morphometric changes in murine experimental osteoarthritis using image analysis. van Valburg AA, et al. **Rheumatol Int** 1996;15(5):181–7

Pathogenesis aspects of arthrosis in histopathological and electronmicroscopical studies of articular cartilage, correlated to some immunological parameters. Ciobanu A, et al. **Rom J Morphol Embryol** 1994 Jul–Dec; 40(3–4):109–17

Histopathological and ultrastructural modifications of the arthrosis articular cartilage. Ciobanu A, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):119–23

[Advances in pathology of 5 endemic diseases in China] Wang F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):252–4 (20 ref.) **(Chi)**

[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21–9 (37 ref.) (Eng. Abstr.) **(Ger)**

[Comparative histomorphometry of subchondral bone density and articular cartilage thickness in the tibial head in early human arthritis] Böhringer ME, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):291–302 (61 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical and morphological studies on soft tissues in hip osteoarthrosis] Tsuchimochi T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1248–58 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Differential release of molecular markers in joint disease. Saxne T. **Acta Orthop Scand Suppl** 1995 Oct;266:80–3 (29 ref.)

Upregulation of type X collagen expression in osteoarthritic cartilage. von der Mark K, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:125–9

Isokinetic and isometric strength in osteoarthrosis of the knee. A comparative study with healthy women. Tan J, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):364–9

Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. McAlindon TE, et al. **Ann Intern Med** 1996 Sep 1;125(5):353–9

Interobserver reliability in measuring flexion, internal rotation, and external rotation of the hip using a plurimeter. Croft PR, et al. **Ann Rheum Dis** 1996 May;55(5):320–3

Bone mineral density and bone turnover in spinal osteoarthritis [letter; comment] Dequeker J, et al. **Ann Rheum Dis** 1996 May;55(5):331. Comment on: Ann Rheum Dis 1995 Nov;54(11):867–71.

Lateral bone density measurements in osteoarthritis of the lumbar spine. Peacock DJ, et al. **Ann Rheum Dis** 1996 Mar; 55(3):196–9

Bone mineral density and bone turnover in spinal osteoarthrosis [see comments] Peel NF, et al. **Ann Rheum Dis** 1995 Nov;54(11):867–71. Comment in: Ann Rheum Dis 1996 May;55(5):331.

Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam Study. Burger H, et al. **Arthritis Rheum** 1996 Jan;39(1):81–6

Knee laxity in patients with osteoarthritis and rheumatoid arthritis. Wada M, et al. **Br J Rheumatol** 1996 Jun; 35(6):560–3

Physiological patellofemoral crepitus in knee joint disorders. Jiang CC, et al. **Bull Hosp Jt Dis** 1993–95;53(4):22–6

Assessment of extensor and flexor strength in the individual gonarthrotic patient: interpretation of performance changes. Madsen OR, et al. **Clin Rheumatol** 1996 Mar; 15(2):154–60

Levels of lactate dehydrogenase in osteoarthritic and failed total knee joints. Messieh M. **J Arthroplasty** 1996 Apr; 11(3):354–5

The role of synovial fluid filtration by cartilage in lubrication of synovial joints--IV. Squeeze-film lubrication: the central film thickness for normal and inflammatory synovial fluids for axial symmetry under high loading conditions. Hlaváček M. **J Biomech** 1995 Oct;28(10):1199–205

Mechanical responses of the rabbit patello-femoral joint to blunt impact. Haut RC, et al. **J Biomech Eng** 1995 Nov; 117(4):402–8

An analytical model to study blunt impact response of the rabbit P-F joint. Li X, et al. **J Biomech Eng** 1995 Nov; 117(4):485–91

Displaced intra-articular fractures of the distal radius: the effect of fracture displacement on contact stresses in a cadaver model. Baratz ME, et al. **J Hand Surg [Am]** 1996 Mar;21(2):183–8

Osteoarthritis in rhesus macaque knee joint: quantitative magnetic resonance imaging tissue characterization of articular cartilage. Gahunia HK, et al. **J Rheumatol** 1995 Sep;22(9):1747–56

A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. Jones G, et al. **J Rheumatol** 1995 May;22(5):932–6

Changing perceptions of osteoarthritis [editorial] Bellamy N. **Med J Aust** 1996 Sep 2;165(5):247–8

Effects of muscle-strength training on the functional status of patients with osteoarthritis of the knee joint. Schilke JM, et al. **Nurs Res** 1996 Mar–Apr;45(2):68–72

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

Parametric and non-parametric measures in the assessment of knee and hip osteoarthritis: interobserver reliability and correlation with radiology. Theiler R, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):35–42

The relationship between osteoarthritis of the hands, bone mineral density, and osteoporotic fractures in elderly women. Marcelli C, et al. **Osteoporos Int** 1995;5(5):382–8

Treatment of a knee contracture using a knee orthosis incorporating stress-relaxation techniques. Jansen CM, et al. **Phys Ther** 1996 Feb;76(2):182–6

Validation of an algofunctional index for osteoarthritis of the hand [see comments] Dreiser RL, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):43S–53S. Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

The reliability and validity of pain threshold measurements in osteoarthritis of the knee. Wessel J. **Scand J Rheumatol** 1995;24(4):238–42

[Synovial volume of healthy and arthrotic human knee joints] Heilmann HH, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr;134(2):144–8 (Eng. Abstr.) **(Ger)**

[Idiopathic varus gonarthrosis: diminished nociceptive vs. unchanged somatosensory sensitivity] Krause K, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):352–6 (Eng. Abstr.) **(Ger)**

[Electromyographic findings in muscles around the osteoarthritic knee: integrated electromyography and frequency analysis] Hiranaka T, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):675–84 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? McAlindon TE, et al. **Arthritis Rheum** 1996 Apr; 39(4):648–56

Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. O'Byrne EM, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S117–8

[Contralateral preventive screwing in proximal femoral epiphysiolysis] Ghanem I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):130–6 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Personality and stress: an exploratory comparison of rheumatoid arthritis and osteoarthritis. Latman NS, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):796–800

Mechanisms related to psychological well-being in older women with chronic illnesses: age and disease comparisons. Heidrich SM. **Res Nurs Health** 1996 Jun;19(3):225–35 (47 ref.)

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Buckland-Wright JC, et al. **Ann Rheum Dis** 1995 Nov; 54(11):872–80

Choosing the best method for radiological assessment of patellofemoral osteoarthritis. Cicuttini FM, et al. **Ann Rheum Dis** 1996 Feb;55(2):134–6

Spiking of the tibial tubercles--a radiological feature of osteoarthritis? Donnelly S, et al. **Ann Rheum Dis** 1996 Feb; 55(2):105–8

Clinical image: silicone synovitis. Kenik J. **Arthritis Rheum** 1995 Oct;38(10):1523

Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Verbruggen G, et al. **Arthritis Rheum** 1996 Feb;39(2):308–20

Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Yu W, et al. **Calcif Tissue Int** 1995 Sep;57(3):169–74

Atlantoodontoid osteoarthritis: comparison of lateral cervical projection and CT. Zapletal J, et al. **Eur Spine J** 1995; 4(4):238–41

The posteroanterior 45 degrees flexion weight-bearing radiograph of the knee. Mason RB, et al. **J Arthroplasty** 1995 Dec;10(6):790–2

Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy [see comments] Buckland-Wright JC, et al. **J Rheumatol** 1995 May;22(5):937–43. Comment in: J Rheumatol 1995 May;22(5):807–8.

Patterns of joint involvement in osteoarthritis of the hand: the Chingford Study. Egger P, et al. **J Rheumatol** 1995 Aug;22(8):1509–13

Measuring joint space in knee osteoarthritis: position or precision? [comment] Spector T. **J Rheumatol** 1995 May; 22(5):807–8. Comment on: J Rheumatol 1995 May;22(5):937–43.

Relationship between atlanto-odontoid osteoarthritis and idiopathic suboccipital neck pain. Zapletal J, et al. **Neuroradiology** 1996 Jan;38(1):62–5

Association of transverse ligament calcification with anterior atlanto-odontoid osteoarthritis: CT findings. Zapletal J, et al. **Neuroradiology** 1995 Nov;37(8):667–9

Radiographic changes in the temporomandibular joint in patients with generalized osteoarthritis and rheumatoid arthritis. Gynther GW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):613–8

Atlas of individual radiographic features in osteoarthritis. Altman RD, et al. **Osteoarthritis Cartilage** 1995 Sep;3 Suppl A:3–70

Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Buckland-Wright C. **Osteoarthritis Cartilage** 1995 Sep;3 Suppl A:71–80

Radiographic atlases for the assessment of osteoarthritis. Cooper C. **Osteoarthritis Cartilage** 1995 Sep;3 Suppl A:1–2

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

Quantitative serial assessment of patellofemoral joint osteoarthritis from lateral knee radiographs. Speake SC, et al. **Osteoarthritis Cartilage** 1995 Sep;3 Suppl A:89–96

Enlargement of the third intercondylar tubercle of Parsons as a sign of osteoarthritis of the knee: a paleopathologic and radiographic study. Brossmann J, et al. **Radiology** 1996 Mar;198(3):845–9

Arthrography and computed arthrotomography study of seventy patients with primary glenohumeral osteoarthritis. Badet R, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):555–62

Sensitivity of radiographic features and specificity of scintigraphic imaging in hand osteoarthritis [see comments] Buckland-Wright JC, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6 Suppl 1):14S–26S. Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

Degenerative changes of the trapeziometacarpal joint: radiologic assessment. Cooke KS, et al. **Skeletal Radiol** 1995 Oct;24(7):523–7

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**

[Pubalgia in sportsmen] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):244–54 (31 ref.) (Eng. Abstr.) **(Fre)**

[Climacteric arthralgia and hand arthrosis] Holzer G, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):653–6 (Eng. Abstr.) **(Ger)**

[Injuries of the medial collateral ligament and anterior cruciate ligament of the knee joint and Lemaire surgical functional treatment. Long-term outcome] Schmid F. **Unfallchirurgie** 1996 Jun;22(3):124–9 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Avid In-111 labeled WBC accumulation in a patient with active osteoarthritis of both knees. Thomas PA, et al. **Clin Nucl Med** 1995 Nov;20(11):973–5

Progression of digital osteoarthritis: a sequential scintigraphic and radiographic study. Balblanc JC, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):181–6

Sensitivity of radiographic features and specificity of scintigraphic imaging in hand osteoarthritis [see comments] Buckland-Wright JC, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6 Suppl 1):14S–26S. Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

RADIOTHERAPY

Our experience in brachytherapy of certain non-cancerous diseases. Navrátil L, et al. **Sb Lek** 1996;97(1):103–13

[Radiotherapy of degenerative inflammatory joint diseases in the elderly. A worthwhile therapeutic measure] Merte H, et al. **Fortschr Med** 1995 Aug 20;113(22–23):323–4 **(Ger)**

[The effect of x-rays on experimental arthritis in the rat] Trott KR, et al. **Strahlenther Onkol** 1995 Sep;171(9):534–8 (Eng. Abstr.) **(Ger)**

REHABILITATION

Effects of muscle-strength training on the functional status of patients with osteoarthritis of the knee joint. Schilke JM, et al. **Nurs Res** 1996 Mar-Apr;45(2):68–72

Mechanical unweighting effects on treadmill exercise and pain in elderly people with osteoarthritis of the knee. Mangione KK, et al. **Phys Ther** 1996 Apr;76(4):387–94

[The combined use of cryogenic exposure and ultrasound in patients with arthrosis of the joints of the legs] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan-Feb; (1):18–21 (Eng. Abstr.) **(Rus)**

[Traction of the lower extremities in treating and rehabilitating osteoarthrosis patients] Shavianidze GO, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep-Oct; (5):19–21 (Eng. Abstr.) **(Rus)**

[Physical factors in the treatment of patients with osteoarthrosis and venous insufficiency] Tereshina LG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul-Aug; (4):20–2 (Eng. Abstr.) **(Rus)**

SURGERY

A severely overcorrected high tibial osteotomy: revision by osteotomy and a long stem component. Uchinou S, et al. **Acta Orthop Scand** 1996 Apr;67(2):193–4

Medial compartment arthrosis of the knee. Dearborn JT, et al. **Am J Orthop** 1996 Jan;25(1):18–26 (64 ref.)

Surgical treatment for osteoarthritis at the base of the thumb. Kuschner SH, et al. **Am J Orthop** 1996 Feb;25(2):91–100 (73 ref.)

Arthroscopic treatment of osteoarthritis of the knee: a prospective, randomized, placebo-controlled trial. Results of a pilot study. Moseley JB Jr, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):28–34

Autotransfusion of drained blood after total knee arthroplasty. Veikkolin T, et al. **Ann Chir Gynaecol** 1995; 84(3):281–4

Outcome analysis of total knee-replacements in patients with rheumatoid arthritis versus osteoarthritis. Elke R, et al. **Arch Orthop Trauma Surg** 1995;114(6):330–4

Complications in hip arthroscopy. Funke EL, et al. **Arthroscopy** 1996 Apr;12(2):156–9

Arthroscopic debridement for the osteoarthritic ankle. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Aug;11(4):433–6

Arthroscopic treatment for posterior impingement in degenerative arthritis of the elbow. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Aug;11(4):437–43

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul-Aug; 80(3):323–8 (30 ref.)

Resurfacing versus not resurfacing the patella during total knee replacement. Bourne RB, et al. **Clin Orthop** 1995 Dec; (321):156–61

Patellofemoral arthroplasty. A 2- to 18-year followup study. Krajca-Radcliffe JB, et al. **Clin Orthop** 1996 Sep; (330):143–51

History of the contralateral knee after primary knee arthroplasty for osteoarthritis. Mont MA, et al. **Clin Orthop** 1995 Dec;(321):145–50

Flat-on-flat, nonconstrained, compression molded polyethylene total knee replacement. Ritter MA, et al. **Clin Orthop** 1995 Dec;(321):79–85

Catastrophic osteolysis in total knee replacement. A report of 17 cases. Robinson EJ, et al. **Clin Orthop** 1995 Dec; (321):98–105

Location of the femoral sulcus in the osteoarthritic knee. Eckhoff DG, et al. **J Arthroplasty** 1996 Feb;11(2):163–5

Tibial polyethylene failure after primary porous-coated anatomic total knee arthroplasty. Aids to diagnosis and revision. Knight JL, et al. **J Arthroplasty** 1995 Dec; 10(6):748–57

Oxford meniscal bearing knee versus the Marmor knee in unicompartmental arthroplasty for arthrosis. A Swedish multicenter survival study. Lewold S, et al. **J Arthroplasty** 1995 Dec;10(6):722–31

Open-knee Magnuson debridement as conservative treatment for degenerative osteoarthritis of the knee. McEldowney AJ, et al. **J Arthroplasty** 1995 Dec;10(6):805–9

Predicting quality-of-life outcomes following total joint arthroplasty. Limitations of the SF-36 Health Status Questionnaire. McGuigan FX, et al. **J Arthroplasty** 1995 Dec;10(6):742–7

Management of patellar clunk under local anesthesia. Messieh M. **J Arthroplasty** 1996 Feb;11(2):202–3

Anterior cruciate-retaining total knee arthroplasty. Pritchett JW. **J Arthroplasty** 1996 Feb;11(2):194–7

Comparative outcomes of total joint arthroplasty. Ritter MA, et al. **J Arthroplasty** 1995 Dec;10(6):737–41

The Porous-Coated Anatomic total knee experience. Special emphasis on complications and wear. Toksvig-Larsen S, et al. **J Arthroplasty** 1996 Jan;11(1):11–7

Miller-Galante unicompartmental knee arthroplasty at 2- to 5-year follow-up evaluations. Voss F, et al. **J Arthroplasty** 1995 Dec;10(6):764–71

Varus osteotomy of the distal part of the femur. A survivorship analysis. Finkelstein JA, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1348–52

Osteoarthrosis of the atlanto-axial joints. Long-term follow-up after treatment with arthrodesis. Ghanayem AJ, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1300–7

Mid-tarsal and tarsometatarsal arthrodesis for primary degenerative osteoarthrosis or osteoarthrosis after trauma. Mann RA, et al. **J Bone Joint Surg Am** 1996 Sep; 78(9):1376–85

Proximal tibial osteotomy. A subjective outcome study. Nagel A, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1353–8

Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. Westrich GH, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):826–34

Extensile posterior approach to the ankle. Hayes AG, et al. **J Bone Joint Surg Br** 1996 May;78(3):468–70

Articular debridement versus washout for degeneration of the medial femoral condyle. A five-year study. Hubbard MJ. **J Bone Joint Surg Br** 1996 Mar;78(2):217–9

Can Ilizarov joint distraction delay the need for an arthrodesis of the ankle? A preliminary report. van Valburg AA, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):720–5

Cheilectomy, chondroplasty, and sagittal "Z" osteotomy: a preliminary report on an alternative joint preservation approach to hallux limitus. Kissel CG, et al. **J Foot Ankle Surg** 1995 May-Jun;34(3):312–8

Stabilized resection arthroplasty by an anterior approach in trapeziometacarpal arthritis: results and surgical technique. Le Viet D, et al. **J Hand Surg [Am]** 1996 Mar;21(2):194–201

Basal joint arthritis: trapeziectomy with ligament reconstruction and tendon interposition arthroplasty. Lins RE, et al. **J Hand Surg [Am]** 1996 Mar;21(2):202–9

The Sauvé-Kapandji procedure for osteoarthritis of the distal radioulnar joint. Minami A, et al. **J Hand Surg [Am]** 1995 Jul;20(4):602–8

Dynamic scapholunate instability: results of operative treatment with dorsal capsulodesis. Wintman BI, et al. **J Hand Surg [Am]** 1995 Nov;20(6):971–9

Motion-preserving procedures in the treatment of scapholunate advanced collapse wrist: proximal row carpectomy versus four-corner arthrodesis. Wyrick JD, et al. **J Hand Surg [Am]** 1995 Nov;20(6):965–70

The carpal boss. A 20-year review of operative management. Fusi S, et al. **J Hand Surg [Br]** 1995 Jun;20(3):405–8

Scapho-trapezoid arthritis. A cause of residual pain after arthroplasty of the trapezio-metacarpal joint. Irwin AS, et al. **J Hand Surg [Br]** 1995 Jun;20(3):346–52

Partial trapeziectomy and interpositional arthroplasty for trapeziometacarpal osteoarthritis of the thumb. Menon J. **J Hand Surg [Br]** 1995 Oct;20(5):700–6

Early active mobilization after tendon transfers using mesh reinforced suture techniques. Silfverskiöld KL, et al. **J Hand Surg [Br]** 1995 Jun;20(3):291–300

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):3–11 (20 ref.)

Variation in rheumatologists' and family physicians' perceptions of the indications for and outcomes of knee replacement surgery [see comments] Coyte PC, et al. **J Rheumatol** 1996 Apr;23(4):730–8. Comment in: J Rheumatol 1996 Apr;23(4):586–9.

Proximal clavicle excision: an analysis of results. Acus RW 3rd, et al. **J Shoulder Elbow Surg** 1995 May-Jun;4(3):182–7

Combined arthroscopic management of impingement syndrome and acromioclavicular joint arthritis. Lozman PR, et al. **J South Orthop Assoc** 1995 Fall;4(3):177–81

Arthroscopic debridement for osteoarthritis of the knee: a seven years follow-up study. Su JY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):667–72

Which factors influence the progression of degenerative osteoarthritis after ACL surgery? Küllmer K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):80–4

Arthroscopic treatment for osteoarthritis of the elbow. O'Driscoll SW. **Orthop Clin North Am** 1995 Oct; 26(4):691–706

Isolated patellofemoral arthritis. Dennis DA. **Orthopedics** 1995 Sep;18(9):893–5 (33 ref.)

Unicompartmental disease: solution options. Kennedy WR. **Orthopedics** 1995 Sep;18(9):896–7, 901

Controversial issues in knee arthroplasty. Rorabeck CH, et al. **Orthopedics** 1995 Sep;18(9):905–14

Bi/tri-compartmental degenerative knee disease in the young patient. Stulberg SD. **Orthopedics** 1995 Sep;18(9):899–901

Osteotomy of the first metacarpal for osteoarthrosis of the basal joints of the thumb. Holmberg J, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar; 30(1):67–70

[Shoulder prosthesis]
Rev Chir Orthop Reparatrice Appar Mot 1995;81 Suppl 2:73–133 **(Fre)**
[Surgical treatment of articular arthritis of the thumb] Egloff DV, et al. **Rev Med Suisse Romande** 1996 Mar;116(3):181–5 **(Fre)**
[Arthrodesis of the wrist in arthritis] Knopp W, et al. **Orthopade** 1996 Apr;25(2):121–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Post-traumatic shoulder arthrodeses—indications, technique, results] Dávid A, et al. **Unfallchirurg** 1995 Nov; 98(11):566–9 (Eng. Abstr.) **(Ger)**
[Biomechanical study of the initial stability of various arthrodesis methods for the upper ankle joint] Pommer A, et al. **Unfallchirurg** 1995 Oct;98(10):535–9 (Eng. Abstr.) **(Ger)**
[Progression of arthrosis after alloplasty—what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**
[Sliding axis endoprosthesis in severe unstable gonarthrosis and as revision prosthesis] Buchelt M, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):246–53 (Eng. Abstr.) **(Ger)**
[Endoprosthetic joint replacement in Morquio–Brailsford syndrome] Heisel J, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr;134(2):189–94 (Eng. Abstr.) **(Ger)**
[Outcome of treating osteoarthritic degenerative changes in the knee with high tibial osteotomy] Witoński D, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(1):39–43 (Eng. Abstr.) **(Pol)**
[Treatment of gonarthrosis with arthroscopic abrasion] Hašpl M, et al. **Lijec Vjesn** 1995 Sep–Oct;117(9–10):236–40 (Eng. Abstr.) **(Scr)**

THERAPY

Instruments to assess osteoarthritis—current status and future needs [editorial] Bellamy N. **Ann Rheum Dis** 1995 Sep; 54(9):692–3
Nonsurgical management of osteoarthritis, with an emphasis on nonpharmacologic measures. Brandt KD. **Arch Fam Med** 1995 Dec;4(12):1057–64 (73 ref.)
Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Bellamy N, et al. **Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee.American College of Rheumatology [see comments] Hochberg MC, et al. **Arthritis Rheum** 1995 Nov;38(11):1541–6. Comment in: Arthritis Rheum 1995 Nov;38(11):1533–4.
Health outcomes of two telephone interventions for patients with rheumatoid arthritis or osteoarthritis. Maisiak R, et al. **Arthritis Rheum** 1996 Aug;39(8):1391–9
Case management study: osteoarthritis of the knee. Arnold WJ. **Bull Rheum Dis** 1995 Oct;44(6):1–2
What can be done about osteoarthritis? **Drug Ther Bull** 1996 May;34(5):33–5 (21 ref.)
Osteoarthritis in older patients. Optimum treatment. Bagge E, et al. **Drugs Aging** 1995 Sep;7(3):176–83 (47 ref.)
Rheumatological audit—a general practice perspective. Bird W. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):3–4
Osteoarthritis: what to look for, and when to treat it [interview by Peter Pompei] Clyman BB. **Geriatrics** 1996 Aug;51(8):36–8, 41
Osteoarthritis, the hazard of living longer: arthroscopy vs. conservative treatment. Israeli A, et al. **Isr J Med Sci** 1996 Feb;32(2):121–2
Restoration of the osteoarthrotic joint [editorial] Mankin HJ, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):1–2
Articular debridement versus washout for degeneration of the medial femoral condyle. A five-year study. Hubbard MJ. **J Bone Joint Surg Br** 1996 Mar;78(2):217–9
Clinical assessment of the pumping technique in treating TMJ arthrosis with closed lock. Ozawa M, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):1–10
Challenges for clinical decision making in the management of osteoarthritis of the knee [editorial; comment] Williams MH. **J Rheumatol** 1996 Apr;23(4):586–9 (63 ref.). Comment on: J Rheumatol 1996 Apr;23(4):730–8.
The treatment of osteoarthritis of the knee with pulsed electrical stimulation. Zizic TM, et al. **J Rheumatol** 1995 Sep;22(9):1757–61
Joint distraction for osteoarthritis. Buckwalter JA. **Lancet** 1996 Feb 3;347(8997):279–80
Efficacy of traditional Chinese acupuncture in the treatment of symptomatic knee osteoarthritis: a pilot study. Berman BM, et al. **Osteoarthritis Cartilage** 1995 Jun;3(2):139–42
Comparison of the efficacy of nonsurgical synovectomy (synoviorthesis) and joint lavage in knee osteoarthritis with effusions. Hilliquin P, et al. **Rev Rhum Engl Ed** 1996 Feb; 63(2):93–102
Spa therapy for gonarthrosis: a prospective study. Wigler I, et al. **Rheumatol Int** 1995;15(2):65–8
New treatments in osteoarthritis (OA). Doherty M. **Schweiz Med Wochenschr Suppl** 1996;80:10S–11S
[Medical treatment of osteoarthritis (news)] Bertin P, et al. **Presse Med** 1996 Apr 20;25(14):653–6 (Eng. Abstr.) **(Fre)**
[Dead sea bath salts for osteoarthritis of the knee] Sukenik S, et al. **Harefuah** 1995 Aug;129(3–4):100–3, 159, 158 (Eng. Abstr.) **(Heb)**
[Measurement of motor strength of the hand using the Martin Vigorometer in evaluating the success of physical therapy in arthritis of the thumb (see comments)] Culjak M, et al. **Reumatizam** 1993;40(1):21–3 (Eng. Abstr.). Comment in: Reumatizam 1993;40(1):25–8. **(Scr)**

URINE

Receiver operating characteristic analysis of urinary pyridinium cross-links in arthritis [letter] Takahashi M, et al. **Br J Rheumatol** 1995 Aug;34(8):792–3

VETERINARY

A remembrance of Fred, the lowland gorilla. Atkinson JP. **Arthritis Rheum** 1996 Jun;39(6):891–3
Inflammatory mediators in equine synovial fluid. Gibson KT, et al. **Aust Vet J** 1996 Apr;73(4):148–51
Use of sodium monoiodoacetate to fuse the distal hock joints in horses. Sammut EB, et al. **Aust Vet J** 1995 Jan;72(1):25–8
Treatment of canine hip dysplasia: a review. Remedios AM, et al. **Can Vet J** 1995 Aug;36(8):503–9 (73 ref.)
In favor of shelf arthroplasty in some dogs [letter] Whittick WG. **J Am Vet Med Assoc** 1996 Aug 1;209(3):542–3
Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation–induced X-ray emission (SRIXE) study. Rizzo R, et al. **J Exp Zool** 1995 Sep 1;273(1):82–6
Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)
Systemic use of pentosan polysulphate in the treatment of osteoarthritis. Read RA, et al. **J Small Anim Pract** 1996 Mar;37(3):108–14
Knee joint function, meniscal disease, and osteoarthritis. Bellenger CR. **Vet Q** 1995 Apr;17 Suppl 1:S5–6 (6 ref.)

OSTEOARTHRITIS, HIP

Relationship between osteoarthrosis and osteoporosis. An experimental and clinical study. Moreschini O, et al. **Chir Organi Mov** 1995 Apr–Jun;80(2):237–43 **(Eng, Ita)**

BLOOD

[The role of shifts in blood rheology in the genesis of thrombosis in patients with arthrosis deformans of the hip joint] Puchin'ian DM, et al. **Gematol Transfuziol** 1995 Nov–Dec;40(6):21–3 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Septic arthritis in osteoarthritic hips. Knight DJ, et al. **BMJ** 1996 Jul 6;313(7048):40–1
The influence of osteoarthritis on the pattern of proximal femoral fractures. Middleton R, et al. **Clin Orthop** 1996 Mar;(324):214–16
[Treatment for complications of hip septic arthritis in newborns] Zwierzchowski H, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):287–93 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Cause of pain in early dysplasia coxarthrosis. A case report] Mau H, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug; 133(4):364–6 (Eng. Abstr.) **(Ger)**
[Clinical relevance of the early detection of arthrosis] Willauschus W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):507–13 (49 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Drug-related segmental colitis: angiographic findings. Morin B, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):529–30
A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Lindén B, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:35–8
When Goody's Powder is not so good. Hamdy RC, et al. **J Tenn Med Assoc** 1996 Feb;89(2):43–4

ENZYMOLOGY

Neuropeptide-converting enzymes in cerebrospinal fluid: activities increased in pain from herniated lumbar dis, but not from coxarthrosis. Lindh C, et al. **Acta Orthop Scand** 1996 Apr;67(2):189–92

EPIDEMIOLOGY

Hip osteoarthritis and dysplasia in Chinese men. Lau EM, et al. **Ann Rheum Dis** 1995 Dec;54(12):965–9
The epidemiology of hip osteoarthritis and rheumatoid arthritis in the Orient. Lau EM, et al. **Clin Orthop** 1996 Feb;(323):81–90 (67 ref.)

ETIOLOGY

Reactivation of a tuberculous coxitis due to loosening of a total hip endoprosthesis. Fink B, et al. **Arch Orthop Trauma Surg** 1995;114(5):298–301
Ochronotic arthropathy: rapid destructive hip osteoarthritis associated with metabolic disease. Corrà T, et al. **Clin Rheumatol** 1995 Jul;14(4):474–7
[Destructive arthritis of the hip in Crohn disease. 10 cases] Beauvais C, et al. **Presse Med** 1995 Nov 4;24(33):1555–8 (Eng. Abstr.) **(Fre)**

METABOLISM

Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis. Ghosh P, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):43–53

PATHOLOGY

Scanning electron microscopy study of articular cartilage in the evolution of hip arthritis. De Santis E, et al. **Ital J Orthop Traumatol** 1993;19(1):87–93
Fractal dimension and architecture of trabecular bone. Fazzalari NL, et al. **J Pathol** 1996 Jan;178(1):100–5
Study of the intraosseous vessels of the femoral head in patients with fractures of the femoral neck or osteoarthritis of the hip. Laroche M, et al. **Osteoporos Int** 1995;5(4):213–7

PHYSIOPATHOLOGY

Parametric and non-parametric measures in the assessment of knee and hip osteoarthritis: interobserver reliability and correlation with radiology. Theiler R, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):35–42

PREVENTION & CONTROL

Osteotomies about the hip for the prevention and treatment of osteoarthrosis. Millis MB, et al. **Instr Course Lect** 1996; 45:209–26 (86 ref.)

RADIOGRAPHY

Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status. Dougados M, et al. **Ann Rheum Dis** 1996 Jun;55(6):356–62
Severity of radiographic findings in hip osteoarthritis associated with total hip arthroplasty. Fox KM, et al. **J Rheumatol** 1996 Apr;23(4):693–7
Quantitative assessment of radiographic normal and osteoarthritic hip joint space. Conrozier T, et al. **Osteoarthritis Cartilage** 1995 Sep;3 Suppl A:81–7
[Radiologic analysis of osseous changes in coxarthrosis] Jovanić s, et al. **Reumatizam** 1993;40(1):5–9 (Eng. Abstr.) **(Scr)**

RADIONUCLIDE IMAGING

Grafted bone used in acetabular reconstruction: assessment by SPECT scintigraphy. Fujikawa Y, et al. **Skeletal Radiol** 1995 Aug;24(6):441–5

SURGERY

Revision arthroplasty of the hip with extensive bone loss. Preliminary study. Lakatos J, et al. **Acta Chir Hung** 1995–96;35(1–2):103–11
Long-term results of intertrochanteric varus osteotomy for arthrosis of the dysplastic hip (over 10 years' follow-up). Iwase T, et al. **Arch Orthop Trauma Surg** 1995;114(5):243–7
Uncemented porous-coated anatomic total hip replacement in Chinese patients. Chiu KH, et al. **Int Orthop** 1995; 19(5):304–8
Chiari osteotomy in association with intertrochanteric osteotomy in adults. Racalbuto S, et al. **Ital J Orthop Traumatol** 1993;19(1):51–6
Fracture of the femoral head after ceramic-on-polyethylene total hip arthroplasty. Callaway GH, et al. **J Arthroplasty** 1995 Dec;10(6):855–9
Fracture of an alumina ceramic head in total hip arthroplasty. Higuchi F, et al. **J Arthroplasty** 1995 Dec;10(6):851–4
Total hip arthroplasty using the Zweymuller stem implanted without cement. A prospective study of consecutive patients with minimum 3-year follow-up period. Huo MH, et al. **J Arthroplasty** 1995 Dec;10(6):793–9
Total hip arthroplasty in patients who have chronic lymphocytic leukemia. McGrory BJ, et al. **J Arthroplasty** 1995 Dec;10(6):758–63
Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)
Osteolysis in cemented versus cementless acetabular components. Nayak NK, et al. **J Arthroplasty** 1996 Feb; 11(2):135–40
Significance of the Trendelenburg test in total hip arthroplasty. Influence of lateral approaches. Pai VS. **J Arthroplasty** 1996 Feb;11(2):174–9
Comparative outcomes of total joint arthroplasty. Ritter MA, et al. **J Arthroplasty** 1995 Dec;10(6):737–41
Outcome of the contralateral hip following total hip arthroplasty for osteoarthritis. Ritter MA, et al. **J Arthroplasty** 1996 Apr;11(3):242–6
Radiographic appearance and structural properties of proximal femoral bone in total hip arthroplasty patients. Rosson JW, et al. **J Arthroplasty** 1996 Feb;11(2):180–3
Role of inflammatory mediators and adhesion molecules in the pathogenesis of aseptic loosening in total hip arthroplasties. Sabokbar A, et al. **J Arthroplasty** 1995 Dec; 10(6):810–6
Total hip replacement for coxarthrosis secondary to congenital dysplasia and dislocation of the hip. Long-term results. MacKenzie JR, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):55–61
Early migration predicts late aseptic failure of hip sockets. Krismer M, et al. **J Bone Joint Surg Br** 1996 May; 78(3):422–6

A 76- year-old woman considering total hip replacement. Callaghan JJ. **JAMA** 1996 Aug 14;276(6):486-91

A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. Chang RW, et al. **JAMA** 1996 Mar 20;275(11):858-65

The role of osteotomies in the 90's. Böhler N, et al. **Orthopedics** 1995 Sep;18(9):819-21

Predictors of the need for total hip replacement in patients with osteoarthritis of the hip. Vinciguerra C, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):563-70

Patch-grafting for regional femoral bone loss in cementless revision hip arthroplasty. Hussell JG, et al. **S Afr J Surg** 1995 Dec;33(4):179-83

Grafted bone used in acetabular reconstruction: assessment by SPECT scintigraphy. Fujikawa Y, et al. **Skeletal Radiol** 1995 Aug;24(6):441-5

[Outcome of hip shelf arthroplasty in adults after a minimum of 15 years of follow-up. Long term results and analysis of failures of 56 dysplastic hips] Migaud H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):716-23 (Eng. Abstr.) **(Fre)**

[Inlay dislocations after primary, cement-free hip joint replacement] Kleihues H, et al. **Unfallchirurgie** 1995 Aug; 21(4):202-3 (Eng. Abstr.) **(Ger)**

[Long-term results of cemented total endoprostheses of the hip joint] Möllenhoff G, et al. **Zentralbl Chir** 1995; 120(9):716-20 (Eng. Abstr.) **(Ger)**

[Triple osteotomy (modified Tönnis method) for advanced coxarthrosis] Ohmura T, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1226-36 (Eng. Abstr.) **(Jpn)**

THERAPY

Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip.American College of Rheumatology [see comments] Hochberg MC, et al. **Arthritis Rheum** 1995 Nov;38(11):1535-40. Comment in: Arthritis Rheum 1995 Nov;38(11):1533-4.

Management of hip osteoarthritis. Dieppe P. **BMJ** 1995 Sep 30;311(7009):853-7 (23 ref.)

VETERINARY

[Pectineus myectomy, tenotomy of the iliopsoas and neurectomy of the joint capsule as symptomatic therapy for coxarthrosis of the dog] Ballinari U, et al. **Schweiz Arch Tierheilkd** 1995;137(6):251-7 (Eng. Abstr.) **(Ger)**

OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC

Pachydermoperiostosis: dermatological, neurological and radiological observations. Cantatore FP, et al. **Clin Rheumatol** 1995 Nov;14(6):705-7

DIAGNOSIS

Pachydermoperiostosis in a 13 year-old boy presenting as an acromegaly-like syndrome. Singh GR, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar;8(1):51-4

ETIOLOGY

Psoriatic onycho-pachydermo-periostitis. A variant of psoriatic distal interphalangeal arthritis? Boisseau-Garsaud AM, et al. **Arch Dermatol** 1996 Feb;132(2):176-80 (22 ref.)

METABOLISM

Alteration of matrix macromolecule synthesis by fibroblasts from a patient with pachydermoperiostosis. Wegrowski Y, et al. **J Invest Dermatol** 1996 Jan;106(1):70-4

PATHOLOGY

[Involvement of the connective tissue of the eyelids in pachydermoperiostosis] Offret H, et al. **J Fr Ophtalmol** 1996;19(1):64-8 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Primary hypertrophic osteoarthropathy] Eckardt A, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul-Aug;133(4):303-5 (Eng. Abstr.) **(Ger)**

OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC

Long-term follow-up of cutaneous changes in siblings with mandibuloacral dysplasia who were originally considered to have hereditary sclerosing poikiloderma. Fryburg JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):900-2

COMPLICATIONS

Probable right ventricular dysplasia and patent foramen ovale presenting with cyanosis and clubbing in a patient with characteristics of Noonan syndrome. Wilmshurst P, et al. **Br Heart J** 1995 Oct;74(4):471-5

Hypertrophic osteoarthropathy in Hodgkin's disease. Babu KG, et al. **J Assoc Physicians India** 1995 Oct;43(10):704-5

Plasma cell granuloma of the lung in childhood: atypical radiologic findings and association with hypertrophic osteoarthropathy. Más Estellés F, et al. **Pediatr Radiol** 1995; 25(5):369-72

A case of small cell carcinoma of the lung associated with hypertrophic pulmonary osteoarthropathy. Fujishita T, et al. **Tumori** 1996 May-Jun;82(3):259-61

ETIOLOGY

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101-3 (16 ref.)

Clubbing in human immunodeficiency virus infection. Boonen A, et al. **Br J Rheumatol** 1996 Mar;35(3):292-4

Digital clubbing associated with polymyositis and interstitial lung disease. Grathwohl KW, et al. **Chest** 1995 Dec; 108(6):1751-2

Digital clubbing associated with pulmonary artery sarcoma. Loredo JS, et al. **Chest** 1996 Jun;109(6):1651-3

Fibrosarcoma of the lung with extrapulmonary manifestations: case report. McLigeyo SO, et al. **East Afr Med J** 1995 Jul;72(7):465-7

The relationship between digital clubbing and serum growth hormone level in patients with lung cancer. Yorgancioğlu A, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):185-7

Hypertrophic osteoarthropathy caused by lipoid pneumonia. Hugosson C, et al. **Pediatr Radiol** 1995;25(6):482-3

Pulmonary cancer and hypertrophic osteoarthropathy. Brief recurrence of the osteoarticular symptoms after surgical resection. Pereira JR, et al. **Rev Paul Med** 1995 Jan-Feb; 113(1):726-8

[Pulmonary hypertrophic osteoarthropathy and clubbing of fingers in patients with lung cancer] Hirakata Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1080-5 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Hypertrophic osteoarthropathy of cystic fibrosis] Gutowska-Grzegorczyk G, et al. **Pediatr Pol** 1995 Mar; 70(3):263-7 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Hypertrophic pulmonary osteoarthropathy in nasopharyngeal carcinoma: an early sign of pulmonary metastasis. Liu RS, et al. **Nucl Med Commun** 1995 Sep; 16(9):785-9

RADIOTHERAPY

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101-3 (16 ref.)

OSTEOARTHROSIS see **OSTEOARTHRITIS**

OSTEOARTHROSIS DEFORMANS see **OSTEOARTHRITIS**

OSTEOBLASTOMA

COMPLICATIONS

Low back pain in a 23-year-old man [clinical conference] Johnston JO, et al. **Clin Orthop** 1995 Dec;(321):270-3, 280-1

DIAGNOSIS

CT and MR imaging of vertebral osteoblastoma. A report of two cases. Ozkal E, et al. **Clin Imaging** 1996 Jan-Mar; 20(1):37-41 (13 ref.)

Osteoid osteoma and osteoblastoma: MRI appearances and the significance of ring enhancement. Youssef BA, et al. **Eur Radiol** 1996;6(3):291-6

CT and MRI of aggressive osteoblastoma of thyroid cartilage. Agarwala R, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):116-8

Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Frassica FJ, et al. **Orthop Clin North Am** 1996 Jul;27(3):559-74 (66 ref.)

ENZYMOLOGY

The ubiquitous VA68 isoform of subunit A of the vacuolar H(+)-ATPase is highly expressed in human osteoclasts. van Hille B, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1108-13

EPIDEMIOLOGY

[Tumors and tumor-like diseases of the bones in children] Litovka VK, et al. **Klin Khir** 1995;(5):34-6 **(Rus)**

PATHOLOGY

Osteoblastoma: varied histological presentations with a benign clinical course. An analysis of 55 cases. Della Rocca C, et al. **Am J Surg Pathol** 1996 Jul;20(7):841-50

RADIOGRAPHY

Unusual imaging findings in association with spinal osteoblastoma. Sherazi Z, et al. **Clin Radiol** 1996 Sep; 51(9):644-8

CT and MRI of aggressive osteoblastoma of thyroid cartilage. Agarwala R, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):116-8

SURGERY

Bone tumours in childhood. Vizkelety T. **Acta Med Hung** 1994;50(3-4):229-35

OSTEOBLASTS

CHEMISTRY

Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Suda M, et al. **Endocrinology** 1996 May; 137(5):1698-705

CD44 expression in fetal rat bone: in vivo and in vitro analysis. Jamal HH, et al. **Exp Cell Res** 1996 Mar 15; 223(2):467-77

Discordant expression of osteoblast markers in MC3T3-E1 cells that synthesize a high turnover matrix. Wenstrup RJ, et al. **J Biol Chem** 1996 Apr 26;271(17):10271-6

Ultrastructural characterization and immunolocalization of osteopontin in rat calvarial osteoblast primary cultures. Nanci A, et al. **Microsc Res Tech** 1996 Feb 1;33(2):214-31

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342-60 (69 ref.)

Relationships between endothelial cells, pericytes, and osteoblasts during bone formation in the sheep femur following implantation of tricalciumphosphate-ceramic. Decker B, et al. **Anat Rec** 1995 Jul;242(3):310-20

Changes in bone morphogenetic protein sensitivity relative to differentiation in fetal rat bone cell cultures. Centrella M, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:224-6

Bone morphogenetic protein-12 and -13 inhibit terminal differentiation of myoblasts, but do not induce their differentiation into osteoblasts. Inada M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):317-22

Reciprocal regulation by cyclic nucleotides of the differentiation of rat osteoblast-like cells and mineralization of nodules. Inoue A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1104-10

Whey protein stimulated the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Takada Y, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):445-9

Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Yamaguchi A, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):366-71

Regulation of cell volume and intracellular pH in hyposmotically swollen rat osteosarcoma cells. Lo C, et al. **Biochem Cell Biol** 1995 Jul-Aug;73(7-8):535-44

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137-46 (94 ref.)

Osteoblast and chondroblast differentiation. Aubin JE, et al. **Bone** 1995 Aug;17(2 Suppl):77S-83S (56 ref.)

Human osteoblasts survive and deposit new bone when human bone is implanted in SCID mouse. Boynton E, et al. **Bone** 1996 Apr;18(4):321-6

Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S-91S (30 ref.)

Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPs. Thrailkill KM, et al. **Bone** 1995 Sep;17(3):307-13

Trabecular bone cell proliferation ex vivo increases with donor age in the rat: it is correlated with the extent of bone loss and not with histomorphometric indices of bone formation. Egrise D, et al. **Calcif Tissue Int** 1996 Jul; 59(1):45-50

Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Izbicka E, et al. **Cancer Res** 1996 Feb 1; 56(3):633-6

Expression of cell cycle regulatory factors in differentiating osteoblasts: postproliferative up-regulation of cyclins B and E. Smith E, et al. **Cancer Res** 1995 Nov 1;55(21):5019-24

Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells. Gitelman SE, et al. **Cell Growth Differ** 1995 Jul;6(7):827-36

Shape changes of osteoblastic cells under gravitational variations during parabolic flight--relationship with PGE2 synthesis. Guignandon A, et al. **Cell Struct Funct** 1995 Oct; 20(5):369-75

Glucocorticoids induce mineralization coupled with bone protein expression without influence on growth of a human osteoblastic cell line. Iba K, et al. **Cell Struct Funct** 1995 Oct;20(5):319-30

Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Ghosh-Choudhury N, et al. **Endocrinology** 1996 Jan; 137(1):331-9

An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats. Yokose S, et al. **Endocrinology** 1996 Feb;137(2):469-78

Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human

osteoblast-like cell proliferation. Chevalley T, et al. **Eur J Endocrinol** 1996 May;134(5):591–601

Physiological concentrations of retinoic acid suppress the osteoblastic differentiation of fetal rat calvaria cells in vitro. Ohishi K, et al. **Eur J Endocrinol** 1995 Sep;133(3):335–41

Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Asahina I, et al. **Exp Cell Res** 1996 Jan 10;222(1):38–47

Effect of retinoic acid on the proliferation and alkaline phosphatase activity of osteoblastic MC3T3-E1 cells by modulating the release of local regulators from monocytes. Kaji H, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):297–302

Human osteosarcoma cell lines MG-63 and SaOS-2 produce G-CSF and GM-CSF: identification and partial characterization of cell-associated isoforms. Taichman RS, et al. **Exp Hematol** 1996 Mar;24(4):509–17

Implication of TGF beta 1 in co-culture of chondrocytes-osteoblasts [letter] Lacombe-Gleize S, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):649–52

Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha. Panagakos FS, et al. **Inflammation** 1995 Aug;19(4):423–43

Correlative microscopic investigation of the interface between titanium alloy and the osteoblast–osteoblast matrix using mineralizing cultures of primary fetal bovine mandibular osteoblasts. Yliheikkilä PK, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):655–65

Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. Takeuchi Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3938–44

Comparison of the release of growth hormone from hydroxyapatite, heat-treated hydroxyapatite, and fluoroapatite coatings on titanium. Downes S, et al. **J Biomed Mater Res** 1995 Sep;29(9):1053–60

Polysulphone inhibits final differentiation steps of osteogenesis in vitro. van Loon JJ, et al. **J Biomed Mater Res** 1995 Sep;29(9):1155–63

Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function. Donahue HJ, et al. **J Bone Miner Res** 1995 Jun; 10(6):881–9

Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age. Fedarko NS, et al. **J Bone Miner Res** 1995 Nov;10(11):1705–12

Extracellular matrix synthesized by clonal osteogenic cells is osteoinductive in vivo and in vitro: role of transforming growth factor-beta 1 in osteoblast cell-matrix interaction. Kirk MD, et al. **J Bone Miner Res** 1995 Aug;10(8):1203–8

Fibronectin gene expression, synthesis and accumulation during in vitro differentiation of chicken osteoblasts. Winnard RG, et al. **J Bone Miner Res** 1995 Dec; 10(12):1969–77

Regulation of gap junction intercellular communication by pH in MC3T3-E1 osteoblastic cells. Yamaguchi DT, et al. **J Bone Miner Res** 1995 Dec;10(12):1891–9

Osteogenic differentiation of hypertrophic chondrocytes involves asymmetric cell divisions and apoptosis. Roach HI, et al. **J Cell Biol** 1995 Oct;131(2):483–94

Thrombin induces proliferation of osteoblast-like cells through phosphatidylcholine hydrolysis. Suzuki A, et al. **J Cell Physiol** 1996 Jul;168(1):209–16

Osteogenic potential of murine osteosarcoma cells: comparison of bone-specific gene expression in in vitro and in vivo conditions. Gerstenfeld LC, et al. **Lab Invest** 1996 May;74(5):895–906

Time-lapse microcinematography of osteocytes. Tanaka K, et al. **Miner Electrolyte Metab** 1995;21(1–3):189–92

Transcriptional control of osteoblast growth and differentiation. Stein GS, et al. **Physiol Rev** 1996 Apr; 76(2):593–629 (461 ref.)

[Osteoblast-like cells cultured in vitro] Rao H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):301–4 (Eng. Abstr.) **(Chi)**

DRUG EFFECTS

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García-Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70

Osteogenic protein-1 enhances phenotypic expression in ROS 17/2.8 cells. Kitten AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E918–26

Calcemic hormones regulate the level of sodium-calcium exchange protein in osteoblastic cells. Krieger NS. **Ann N Y Acad Sci** 1996 Apr 15;779:293–4

Posttranscriptional regulation of osteocalcin mRNA in clonal osteoblast cells by 1,25-dihydroxyvitamin D3. Mosavin R, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):142–52

The effects of smokeless tobacco extract on bone nodule formation and mineralization by chick osteoblasts in vitro. Henderson JS, et al. **Arch Oral Biol** 1995 Jul;40(7):615–21

The effect of methotrexate on mouse bone cells in culture. May KP, et al. **Arthritis Rheum** 1996 Mar;39(3):489–94

Stimulation by C-type natriuretic peptide of the differentiation of clonal osteoblastic MC3T3-E1 cells. Inoue A, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):703–7

Okadaic acid inhibits alkaline phosphatase activity in MC3T3-E1 cells. Choi JY, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):943–7

Effect of KCA-098 on the function of osteoblast-like cells and the formation of TRAP-positive multinucleated cells in a mouse bone marrow cell population. Kawashima K, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):133–9

Neurotrophin-3 increases the DNA-binding activities of several transcription factors in a mouse osteoblastic cell line. Iwata E, et al. **Biochim Biophys Acta** 1996 Apr 24; 1311(2):85–92

Evidence for coordinated regulation of osteoblast function by 1,25-dihydroxyvitamin D3 and parathyroid hormone. van Leeuwen JP, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):54–62

Conditions which promote mineralization at the bone-implant interface: a model in vitro study. Dee KC, et al. **Biomaterials** 1996 Jan;17(2):209–15

In vitro effects of bone cements on the cell cycle of osteoblast-like cells. Granchi D, et al. **Biomaterials** 1995 Oct;16(15):1187–92

In vitro biocompatibility testing of polymers for orthopaedic implants using cultured fibroblasts and osteoblasts. Morrison C, et al. **Biomaterials** 1995 Sep;16(13):987–92

Effect of Ti, Al, and V ions on the relative growth rate of fibroblasts (L929) and osteoblasts (MC3T3-E1) cells. Rao S, et al. **Biomed Mater Eng** 1996;6(2):79–86

Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. Lind M, et al. **Bone** 1996 Jan;18(1):53–7

Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Nishikawa M, et al. **Bone** 1996 Jan;18(1):9–14

In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Onyia JE, et al. **Bone** 1995 Nov;17(5):479–84

Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Sabatini M, et al. **Bone** 1996 Jan;18(1):59–65

In vitro effects of methotrexate on human articular cartilage and bone-derived osteoblasts. van der Veen MJ, et al. **Br J Rheumatol** 1996 Apr;35(4):342–9

Taxol inhibits osteoclastic bone resorption. Hall TJ, et al. **Calcif Tissue Int** 1995 Dec;57(6):463–5

17 beta-estradiol increases the receptor number and modulates the action of 1,25-dihydroxyvitamin D3 in human osteosarcoma-derived osteoblast-like cells. Ishibe M, et al. **Calcif Tissue Int** 1995 Dec;57(6):430–5

Effects of androgens on subpopulations of the human osteosarcoma cell line SaOS2. Kasperk CH, et al. **Calcif Tissue Int** 1996 May;58(5):376–82

The role of glucocorticoids and prostaglandin E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: positive and negative effects. Scutt A, et al. **Calcif Tissue Int** 1996 Sep;59(3):154–62

The effects of orthopaedic cements on osteoblastic cells cultured in vitro. Ciapetti G, et al. **Chir Organi Mov** 1995 Oct-Dec;80(4):409–15 **(Eng, Ita)**

Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption [see comments] Jay PR, et al. **Endocrinology** 1996 Apr;137(4):1151–8. Comment in: Endocrinology 1996 Apr;137(4):1149–50.

Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Schmidt IU, et al. **Endocrinology** 1995 Nov;136(11):5127–34

Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Elomaa I, et al. **Eur J Cancer** 1996 Jun;32A(7):1166–70

1 alpha,25-dihydroxyvitamin D3 increases IGF binding protein-5 expression in cultured osteoblasts. Schmid C, et al. **FEBS Lett** 1996 Aug 19;392(1):21–4

Decreased mitogenic and osteogenic responsiveness of calvarial osteoblasts isolated from aged rats to basic fibroblast growth factor. Kato H, et al. **Gerontology** 1995; 41 Suppl 1:20–7

The effect of recombinant human basic fibroblast growth factor rhFGF-2 on human osteoblast in growth and phenotype expression. Berrada S, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):698–702

Pasteurella multocida toxin is a mitogen for bone cells in primary culture. Mullan PB, et al. **Infect Immun** 1996 Mar; 64(3):959–65

Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. Greenfield EM, et al. **J Biol Chem** 1996 May 3;271(18):10984–9

Domain-specific gene activation by parathyroid hormone in osteoblastic ROS17/2.8 cells. Hollnagel A, et al. **J Biol Chem** 1996 Sep 6;271(36):21870–7

Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. McCarthy TL, et al. **J Biol Chem** 1996 Mar 22; 271(12):6666–71

Effects of gamma-alumina and hydroxyapatite coatings on the growth and metabolism of human osteoblasts. Labat B, et al. **J Biomed Mater Res** 1995 Nov;29(11):1397–401

Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. Brixen K, et al. **J Bone Miner Res** 1995 Dec;10(12):1865–74

Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. Inaba M, et al. **J Bone Miner Res** 1995 Jul;10(7):1050–6

EndothelinB receptor activation enhances parathyroid hormone-induced calcium signals in UMR-106 cells. Lee SK, et al. **J Bone Miner Res** 1995 Sep;10(9):1343–51

Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts. Lowe C, et al. **J Bone Miner Res** 1995 Nov;10(11):1644–50

Effects of differentiation and transforming growth factor beta 1 on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. McCauley LK, et al. **J Bone Miner Res** 1995 Aug; 10(8):1243–55

Effect of prostaglandin E2 on phospholipase D activity in osteoblast-like MC3T3-E1 cells. Oiso Y, et al. **J Bone Miner Res** 1995 Aug;10(8):1185–90

Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3. Scheven BA, et al. **J Bone Miner Res** 1995 Jun;10(6):874–80

Estrogen pretreatment increases arachidonic acid release by bradykinin stimulated normal human osteoblast-like cells. Cissel DS, et al. **J Cell Biochem** 1996 Feb;60(2):260–70

Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes. Tang KT, et al. **J Cell Biochem** 1996 Apr;61(1):152–66

17 beta-oestradiol enhances the stimulatory effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity in human osteosarcoma SaOS-2 cells in a differentiation-dependent manner. Rao LG, et al. **J Endocrinol** 1996 Jan;148(1):181–7

IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. Onoe Y, et al. **J Immunol** 1996 Jan 15; 156(2):758–64

NaF potentiates a K(+)-selective ion channel in G292 osteoblastic cells. Gofa A, et al. **J Membr Biol** 1996 Feb; 149(3):211–9

Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts. Kaysinger KK, et al. **J Orthop Trauma** 1995;9(4):303–11

Bone toxicity of locally applied aminoglycosides. Miclau T, et al. **J Orthop Trauma** 1995;9(5):401–6

Variation in 1,25-dihydroxyvitamin D3 regulation of proliferation and alkaline phosphatase activity in late-passage rat osteoblastic cell lines. Murray S, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):227–33

Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells. Sömjen D, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):211–7

Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. van den Bemd GJ, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):337–46

Effects of medroxyprogesterone acetate and beta-estradiol on interleukin-6 production from osteoblasts and bone marrow macrophages of Wistar rats of different ages. Futamura Y. **J Toxicol Sci** 1995 May;20(2):155–60

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

Activation of the Ca2+ message system by parathyroid hormone is dependent on the cell cycle. Avioli LV, et al. **Miner Electrolyte Metab** 1995;21(1–3):29–34

PTH-mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al. **Miner Electrolyte Metab** 1995;21(1–3):184–8 (20 ref.)

Effects of C-terminal parathyroid hormone-related peptide on osteoblasts. Seitz PK, et al. **Miner Electrolyte Metab** 1995;21(1–3):180–3

Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Yoshida O, et al. **Miner Electrolyte Metab** 1995;21(1–3):201–4

Induction of early growth response-1 gene by interleukin-1 beta and tumor necrosis factor-alpha in normal human bone marrow stromal an osteoblastic cells: regulation by a protein kinase C inhibitor. Chaudhary LR, et al. **Mol Cell Biochem** 1996 Mar 9;156(1):69–77

Calcium-induced relocation of annexins IV and V in the human osteosarcoma cell line MG-63. Mohiti J, et al. **Mol Membr Biol** 1995 Oct-Dec;12(4):321–9

Zinc modulation of insulin-like growth factor's effect in osteoblastic MC3T3-E1 cells. Matsui T, et al. **Peptides** 1995;16(6):1063–8

Prostaglandin E2 induces Egr-1 mRNA in MC3T3-E1 osteoblastic cells by a protein kinase C-dependent pathway. Fang MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):109–14

[Effects of an hydrosoluble fraction from bovine bone (Ossopan) on murine osteoblasts in culture] Cuq P, et al. **C R Seances Soc Biol Fil** 1995;189(2):303–12 (Eng. Abstr.) **(Fre)**

OSTEOBLASTS

ENZYMOLOGY

Phosphotyrosyl protein phosphatase-like activity of a clonal osteoblastic cell line (MC3T3-E1 cell). Suzuki K, et al. **Arch Oral Biol** 1995 Sep;40(9):825-30

Pretreatment with 17 beta-estradiol attenuates basal- and PTH-stimulated membrane adenylyl cyclase activity in human osteoblast-like SAOS-2 cells. Monroe JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):320-5

Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63): regulation by interleukin-1 beta and parathyroid hormone. Aisa MC, et al. **Biochim Biophys Acta** 1996 May 21; 1290(1):29-36

Microsomal casein kinase II in endoplasmic reticulum- and Golgi apparatus-rich fractions of ROS 17/2.8 osteoblast-like cells: an enzyme that modifies osteopontin. Wu CB, et al. **Calcif Tissue Int** 1995 Oct;57(4):285-92

1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Tanaka S, et al. **Endocrinology** 1996 May;137(5):1860-9

Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. Delany AM, et al. **J Biol Chem** 1995 Nov 3;270(44):26607-12

Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. Allan EH, et al. **J Cell Physiol** 1995 Dec; 165(3):521-9

Peptide bond cleavage site determination of novel proteolytic enzymes found in ROS 17/2.8 cell lysates. Guidon PT Jr, et al. **J Cell Physiol** 1996 Feb;166(2):407-12

IMMUNOLOGY

Monoclonal antibodies recognize antigen expressed by osteoblasts. Benayahu D, et al. **J Bone Miner Res** 1995 Oct;10(10):1496-503

The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. Romas E, et al. **J Exp Med** 1996 Jun 1; 183(6):2581-91

Monoclonal antibodies as tools for studying the osteoblast lineage. Aubin JE, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):128-40 (119 ref.)

METABOLISM

Actions of palytoxin on Na+ and Ca2+ homeostasis in human osteoblast-like Saos-2 cells. Monroe JJ, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C582-9

Thromboxane A2-stimulated phospholipase D in osteoblast-like cells: possible involvement of PKC. Shinoda J, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E524-9

Calcium waves in fluid flow stimulated osteoblasts are G protein mediated. McDonald F, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):31-8

Posttranscriptional regulation of osteocalcin mRNA in clonal osteoblast cells by 1,25-dihydroxyvitamin D3. Mosavin R, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):142-52

C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Suda M, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):1-6

Functional activation of the egr-1 (early growth response-1) gene by hydrogen peroxide. Nose K, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):381-3

Production of interleukin-6 by osteoblastic cells is independent of medium inorganic phosphate. Tran JM, et al. **Biochem Mol Med** 1995 Aug;55(2):90-5

Identification of an osteoblastic silencer element in the first intron of the rat osteocalcin gene. Goto K, et al. **Biochemistry** 1996 Aug 20;35(33):11005-11

Changes in chromatin structure support constitutive and developmentally regulated transcription of the bone-specific osteocalcin gene in osteoblastic cells. Montecino M, et al. **Biochemistry** 1996 Apr 16; 35(15):5093-102

Effects of estrogen and parathyroid hormone on osteoblastic activity via regulating the binding activity of insulin-like growth factor binding protein-4 in SaOS-2 cells: implications for the pathogenesis of postmenopausal osteoporosis. Kudo Y, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):402-6

Analysis of osteoblast mineral deposits on orthopaedic/dental implant metals. Squire MW, et al. **Biomaterials** 1996 Apr; 17(7):725-33

Modulation of the resorptive activity of rat osteoclasts by small changes in extracellular pH near the physiological range. Arnett TR, et al. **Bone** 1996 Mar;18(3):277-9

Expression of prostaglandin E receptor subtypes in bone: expression of EP2 in bone development. Kasugai S, et al. **Bone** 1995 Jul;17(1):1-4

The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone. Meikle MC, et al. **Bone** 1995 Sep;17(3):255-60

The iron-binding protein ferritin is expressed in cells of the osteoblastic lineage in vitro and in vivo. Spanner M, et al. **Bone** 1995 Aug;17(2):161-5

Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells: association of receptor levels with alkaline phosphatase activity. Sutherland MK, et al. **Bone** 1996 Apr;18(4):361-9

Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPs. Thrailkill KM, et al. **Bone** 1995 Sep;17(3):307-13

The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts. Vignery A, et al. **Bone** 1996 Apr;18(4):331-5

Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture. Santibáñez JF, et al. **Br J Cancer** 1996 Aug;74(3):418-22

Epidermal growth factor induces Egr-1 messenger RNA and protein in mouse osteoblastic cells. Fang MA, et al. **Calcif Tissue Int** 1995 Dec;57(6):450-5

Retinoids modulate the effect of PTH and calcitriol on EGF receptor expression in UMR 106-01 cells. González EA, et al. **Calcif Tissue Int** 1996 Jun;58(6):429-34

Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Horowitz SM, et al. **Calcif Tissue Int** 1995 Oct;57(4):301-5

Demonstration of isoforms of the estrogen receptor in the bone tissues and in osteoblastic cells. Hoshino S, et al. **Calcif Tissue Int** 1995 Dec;57(6):466-8

Differential effects of glucocorticoids on human osteoblastic cell metabolism in vitro. Kasperk C, et al. **Calcif Tissue Int** 1995 Aug;57(2):120-6

Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. MacNamara P, et al. **Calcif Tissue Int** 1995 Dec; 57(6):436-41

Bone chondroadherin promotes attachment of osteoblastic cells to solid-state substrates and shows affinity to collagen. Mizuno M, et al. **Calcif Tissue Int** 1996 Sep;59(3):163-7

Expression of cell cycle regulatory factors in differentiating osteoblasts: postproliferative up-regulation of cyclins B and E. Smith E, et al. **Cancer Res** 1995 Nov 1;55(21):5019-24

24,25(OH)2 vitamin D3 modulates the L-type Ca2+ channel current in UMR 106 cells: involvement of protein kinase A and protein kinase C. Li B, et al. **Cell Calcium** 1996 Mar;19(3):193-200

Down-regulation and differential restoration of cAMP responses upon transient phorbol ester treatment of primary osteoblastic cells. Bos MP, et al. **Cell Signal** 1995 Aug; 7(6):617-26

Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage. Franchimont N, et al. **Endocrinology** 1995 Dec;136(12):5469-75

Cortisol enhances the transcription of insulin-like growth factor-binding protein-6 in cultured osteoblasts. Gabbitas B, et al. **Endocrinology** 1996 May;137(5):1687-92

Thyroid hormone and retinoic acid induce the synthesis of insulin-like growth factor-binding protein-4 in mouse osteoblastic cells. Glantschnig H, et al. **Endocrinology** 1996 Jan;137(1):281-6

Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Goad DL, et al. **Endocrinology** 1996 Jun;137(6):2262-8

Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-like cells and its functional role in osteoblast metabolic activity. Hukkanen M, et al. **Endocrinology** 1995 Dec; 136(12):5445-53

Calcitonin gene-related peptide rapidly inhibits calcium uptake in osteoblastic cell lines via activation of adenosine triphosphate-sensitive potassium channels. Kawase T, et al. **Endocrinology** 1996 Mar;137(3):984-90

Insulin-like growth factor I and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts: evidence for a peripheral feedback loop regulating GH action. Leung K, et al. **Endocrinology** 1996 Jul; 137(7):2694-702

Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST-PTP, in rat osteoblast-like cells. Mauro LJ, et al. **Endocrinology** 1996 Mar;137(3):925-33

Transcriptional regulation of insulin-like growth factor-binding protein-5 by prostaglandin E2 in osteoblast cells. Pash JM, et al. **Endocrinology** 1996 Jun; 137(6):2375-82

Forskolin inhibits protein kinase C-induced mitogen activated protein kinase activity in MC3T3-E1 osteoblasts. Siddhanti SR, et al. **Endocrinology** 1995 Nov; 136(11):4834-41

Osteogenic protein-1-mediated insulin-like growth factor gene expression in primary cultures of rat osteoblastic cells. Yeh LC, et al. **Endocrinology** 1996 May;137(5):1921-31

Retinoic acid regulates insulin-like growth factor-binding protein expression in human osteoblast cells. Zhou Y, et al. **Endocrinology** 1996 Mar;137(3):975-83

Transforming growth factor beta 1 influences lysyl hydroxylation of collagen I and reduces steady-state levels of lysyl hydroxylase mRNA in human osteoblast-like cells. Seitzer U, et al. **Eur J Clin Invest** 1995 Dec;25(12):959-66

Regulation of osteoblast gene expression in intratypic osteosarcoma hybrid cells. Johnson-Pais TL, et al. **Exp Cell Res** 1995 Dec;221(2):370-6

Effect of retinoic acid on the proliferation and alkaline phosphatase activity of osteoblastic MC3T3-E1 cells by modulating the release of local regulators from monocytes. Kaji H, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):297-302

Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling? Pitsillides AA, et al. **FASEB J** 1995 Dec;9(15):1614-22

Isolation of a novel ras-recision gene that is induced by hydrogen peroxide from a mouse osteoblastic cell line, MC3T3-E1. Egawa K, et al. **FEBS Lett** 1995 Sep 18; 372(1):74-7

Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Shenker A, et al. **Hum Mol Genet** 1995 Sep; 4(9):1675-6

Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. Andress DL. **J Biol Chem** 1995 Nov 24; 270(47):28289-96

Identification of a TAAT-containing motif required for high level expression of the COL1A1 promoter in differentiated osteoblasts of transgenic mice. Dodig M, et al. **J Biol Chem** 1996 Jul 5;271(27):16422-9

The mouse bone morphogenetic protein-4 gene. Analysis of promoter utilization in fetal rat calvarial osteoblasts and regulation by COUP-TFI orphan receptor. Feng JQ, et al. **J Biol Chem** 1995 Nov 24;270(47):28364-73

A PEBP2 alpha/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. Geoffroy V, et al. **J Biol Chem** 1995 Dec 29;270(52):30973-9

Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. Takeuchi Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3938-44

Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E2 in osteoblasts. Thomas MJ, et al. **J Biol Chem** 1996 Sep 6;271(36):21835-41

Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks. Vander Molen MA, et al. **J Biol Chem** 1996 May 24; 271(21):12165-71

Identification and cloning of human P2U purinoceptor present in osteoclastoma, bone, and osteoblasts. Bowler WB, et al. **J Bone Miner Res** 1995 Jul;10(7):1137-45

Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. Fedarko NS, et al. **J Bone Miner Res** 1995 Jul;10(7):1122-9

PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. Fermor B, et al. **J Bone Miner Res** 1995 Dec;10(12):1935-43

rHox: a homeobox gene expressed in osteoblastic cells. Hu Y, et al. **J Cell Biochem** 1995 Dec;59(4):486-97

Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes. Tang KT, et al. **J Cell Biochem** 1996 Apr;61(1):152-66

Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. Erlebacher A, et al. **J Cell Biol** 1996 Jan;132(1-2):195-210

Synthesis of membrane- and matrix-bound colony-stimulating factor-1 by cultured osteoblasts. Felix R, et al. **J Cell Physiol** 1996 Feb;166(2):311-22

Regulation of parathyroid hormone/parathyroid hormone-related protein receptor expression by osteoblast-deposited extracellular matrix in a human osteoblast-like cell line. Hausmann S, et al. **J Cell Physiol** 1995 Oct;165(1):164-71

Tumor necrosis factor-alpha induces transcription of the colony-stimulating factor-1 gene in murine osteoblasts. Kaplan DL, et al. **J Cell Physiol** 1996 Jul;168(1):199-208

Prostaglandin mediated modulation of transforming growth factor-beta metabolism in primary mouse osteoblastic cells in vitro. Klein-Nulend J, et al. **J Cell Physiol** 1996 Jul; 168(1):1-7

Expression of parathyroid hormone-related protein in cells of osteoblast lineage. Suda N, et al. **J Cell Physiol** 1996 Jan;166(1):94-104

Expression of functional growth hormone receptors in cultured human osteoblast-like cells. Nilsson A, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3483-8

Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. Bellido T, et al. **J Clin Invest** 1996 Jan 15;97(2):431-7

Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. Kovacs CS, et al. **J Endocrinol** 1996 May; 149(2):287-95

Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. Swolin D, et al. **J Endocrinol** 1996 Jun;149(3):397-403

Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Udagawa N, et al. **J Exp Med** 1995 Nov 1;182(5):1461-8

Activation of maxi-K channels by parathyroid hormone and prostaglandin E2 in human osteoblast bone cells. Moreau R, et al. **J Membr Biol** 1996 Mar;150(2):175-84

Comparison of the type-2 insulin-like growth factor receptor in normal osteoblasts and osteosarcoma-derived osteoblast-like cells. Ishibe M, et al. **J Orthop Res** 1995

Sep;13(5):643–8
De novo synthesis of type–I collagen in bone biopsy material. Röcher W, et al. **J Orthop Res** 1995 Sep;13(5):649–54
Involvement of platelets in stimulating osteogenic activity. Slater M, et al. **J Orthop Res** 1995 Sep;13(5):655–63
Hyperosmotic modulation of the cytosolic calcium concentration in a rat osteoblast–like cell line. Dascalu A, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):97–104
Characterization of a volume–sensitive chloride current in rat osteoblast–like (ROS 17/2.8) cells. Gosling M, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):671–82
Differential effects of 1,25–dihydroxyvitamin D3–analogs on osteoblast–like cells and on in vitro bone resorption. van den Bemd GJ, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):337–46
Prostate specific antigen cleaves parathyroid hormone–related protein in the PTH–like domain: inactivation of PTHrP–stimulated cAMP accumulation in mouse osteoblasts. Cramer SD, et al. **J Urol** 1996 Aug;156(2 Pt 1):526–31
Differential expression of plasma membrane calcium pump mRNA isoforms in rat osteoblast–like cells. Abramowitz J, et al. **Miner Electrolyte Metab** 1995;21(6):367–74
A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF–1 family of transcription factors mediates the vitamin D responsiveness of the c–fos promoter. Candeliere GA, et al. **Mol Cell Biol** 1996 Feb;16(2):584–92
Developmental regulation of proenkephalin gene expression in osteoblasts. Rosen H, et al. **Mol Endocrinol** 1995 Nov; 9(11):1621–31
The mechanism of uptake of ascorbic acid into osteoblasts and leukocytes. Wolf G. **Nutr Rev** 1996 May;54(5):150–2 (12 ref.)
Positive interaction between 17 beta–Estradiol and parathyroid hormone in normal human osteoblasts cultured long term in the presence of dexamethasone. Rao LG, et al. **Osteoporos Int** 1996;6(2):111–9
Age–dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long–term in the presence of dexamethasone. Sutherland MS, et al. **Osteoporos Int** 1995;5(5):335–43
The regulation of L–proline transport by insulin–like growth factor–I in human osteoblast–like SaOS–2 cells. Kudo Y, et al. **Pflugers Arch** 1996 Jul;432(3):419–25
Identification of a minimal sequence of the mouse pro–alpha 1(I) collagen promoter that confers high–level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Rossert JA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1027–31
Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. Szentirmai M, et al. **West J Med** 1995 Dec;163(6):577–8
[Effect of estradiol on 5 alpha–reductase activity in osteoblast–like cell (UMR106–01)] Suwa H, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Jul 20;71(5):651–8 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Bushinsky DA. **Am J Physiol** 1996 Jul;271(1 Pt 2):F216–22
Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. Reed BY, et al. **J Bone Miner Res** 1995 Aug;10(8):1218–24
Prostate–derived soluble factors block osteoblast differentiation in culture. Martínez J, et al. **J Cell Biochem** 1996 Apr;61(1):18–25
Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. Jilka RL, et al. **J Clin Invest** 1996 Apr 1; 97(7):1732–40

PHYSIOLOGY

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García–Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53
Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70
Osteogenic protein–1 enhances phenotypic expression in ROS 17/2.8 cells. Kitten AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E918–26
Reciprocal regulation by cyclic nucleotides of the differentiation of rat osteoblast–like cells and mineralization of nodules. Inoue A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1104–10
1 alpha,25(OH)2 vitamin D3–mediated stimulation of outward anionic currents in osteoblast–like ROS 17/2.8 cells. Zanello LP, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):551–6
Mechano–reception in osteoblast–like cells. Jones D, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):525–34 (80 ref.)
Evidence for coordinated regulation of osteoblast function by 1,25–dihydroxyvitamin D3 and parathyroid hormone. van Leeuwen JP, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):54–62
Osteoblast adherence and resorption activity of isolated osteoclasts on calcium sulphate hemihydrate. Sidqui M, et al. **Biomaterials** 1995 Nov;16(17):1327–32
Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Taichman RS, et al. **Blood** 1996 Jan 15;87(2):518–24
The insulin–like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S–98S (32 ref.)
The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)
Effect of osteoblast supernatants on cancer cell migration and invasion. Giunciuglio D, et al. **Cancer Lett** 1995 Oct 20;97(1):69–74
In vitro studies on the role of titanium in aseptic loosening. Gonzales JB, et al. **Clin Orthop** 1996 Sep;(330):244–50
Involvement of interleukin 1 and tumour necrosis factor alpha as endogenous growth factors in human osteoblastic cells. Modrowski D, et al. **Cytokine** 1995 Oct;7(7):720–6
Immortalized murine osteoblasts derived from BMP 2–T–antigen expressing transgenic mice. Ghosh–Choudhury N, et al. **Endocrinology** 1996 Jan; 137(1):331–9
Osteoclast function is activated by osteoblastic cells through a mechanism involving cell–to–cell contact. Jimi E, et al. **Endocrinology** 1996 May;137(5):2187–90
Activation of the JAK–STAT signal transduction pathway by oncostatin–M cultured human and mouse osteoblastic cells. Levy JB, et al. **Endocrinology** 1996 Apr; 137(4):1159–65
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast–mediated resorption. Vitté C, et al. **Endocrinology** 1996 Jun;137(6):2324–33
Intercellular chatter: osteoblasts, osteoclasts and interleukin 6. Hofbauer LC, et al. **Eur J Endocrinol** 1996 Apr; 134(4):425–6
Effects of microgravity on osteoblast growth activation. Hughes–Fulford M, et al. **Exp Cell Res** 1996 Apr 10; 224(1):103–9
Induction of osteoclast characteristics in cultured avian blood monocytes; modulation by osteoblasts and 1,25–(OH)2 vitamin D3. van't Hof RJ, et al. **Int J Exp Pathol** 1995 Jun;76(3):205–14
Human osteoblasts from younger normal and osteoporotic donors show differences in proliferation and TGF beta–release in response to cyclic strain. Neidlinger–Wilke C, et al. **J Biomech** 1995 Dec;28(12):1411–8
Cellular deformation reversibly depresses RT–PCR detectable levels of bone–related mRNA. Stanford CM, et al. **J Biomech** 1995 Dec;28(12):1419–27
Immunofluorescence and confocal laser scanning microscopy studies of osteoblast growth and phenotypic expression in three–dimensional degradable synthetic matrices. Attawia MA, et al. **J Biomed Mater Res** 1995 Jul;29(7):843–8
Biological evaluation of the effect of magnetron sputtered Ca/P coatings on osteoblast–like cells in vitro. Hulshoff JE, et al. **J Biomed Mater Res** 1995 Aug;29(8):967–75
Analysis of osteoblast activity at biomaterial–bone interfaces by in situ hybridization. Neo M, et al. **J Biomed Mater Res** 1996 Apr;30(4):485–92
Regulation of plasminogen activation, matrix metalloproteinases and urokinase–type plasminogen activator–mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin–1 alpha. de Bart AC, et al. **J Bone Miner Res** 1995 Sep;10(9):1374–84
Mineralization of bone–like extracellular matrix in the absence of functional osteoblasts. Marsh ME, et al. **J Bone Miner Res** 1995 Nov;10(11):1635–43
Structural and chemical characteristics and maturation of the calcium–phosphate crystals formed during the calcification of the organic matrix synthesized by chicken osteoblasts in cell culture. Rey C, et al. **J Bone Miner Res** 1995 Oct; 10(10):1577–88
Osteoblasts are regulated by the cellular adhesion through ICAM–1 and VCAM–1. Tanaka Y, et al. **J Bone Miner Res** 1995 Oct;10(10):1462–9
Constitutive expression of calreticulin in osteoblasts inhibits mineralization. St–Arnaud R, et al. **J Cell Biol** 1995 Dec; 131(5):1351–9
Pro–inflammatory cytokines downregulate platelet derived growth factor–alpha receptor gene expression in human osteoblastic cells. Kose KN, et al. **J Cell Physiol** 1996 Jan; 166(1):188–97
Proliferative and phenotypic responses of bone–like cells to mechanical deformation. Stanford CM, et al. **J Orthop Res** 1995 Sep;13(5):664–70
Regulation of bone cells by 1,25(OH)2D3. Ljunghall S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:11–3; discussion 37–43 (17 ref.)
Potential mechanism of estrogen–mediated decrease in bone formation: estrogen increases production of inhibitory insulin–like growth factor–binding protein–4. Kassem M, et al. **Proc Assoc Am Physicians** 1996 Mar;108(2):155–64
Antisense oligodeoxynucleotide inhibition of a swelling–activated cation channel in osteoblast–like osteosarcoma cells. Duncan RL, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1864–9
Stimulation of human prostate cancer cell lines by factors present in human osteoblast–like cells but not in bone marrow. Lang SH, et al. **Prostate** 1995 Nov;27(5):287–93
Osteoblasts from the toothless (osteopetrotic) mutation in the rat are unable to direct bone resorption by normal osteoclasts in response to 1,25–dihydroxyvitamin D. Sundquist KT, et al. **Tissue Cell** 1995 Oct;27(5):569–74

SECRETION

Myeloma cells upregulate interleukin–6 secretion in osteoblastic cells through cell–to–cell contact but downregulate osteocalcin. Barillé S, et al. **Blood** 1995 Oct 15;86(8):3151–9

TRANSPLANTATION

Bone tissue engineering. Crane GM, et al. **Nat Med** 1995 Dec;1(12):1322–4

ULTRASTRUCTURE

Junctions between early developing osteoblasts of rat calvaria as revealed by freeze–fracture and ultrathin section electron microscopy. Arana–Chavez VE, et al. **Arch Histol Cytol** 1995 Aug;58(3):285–92
A transmission electron microscopy examination of the interface between osteoblasts and metal biomaterials. Garvey BT, et al. **J Biomed Mater Res** 1995 Aug; 29(8):987–92

OSTEOCALCIN

ANALYSIS

Osteocalcin in canine joint diseases [see comments] Arican M, et al. **Br Vet J** 1996 Jul;152(4):411–23. Comment in: Br Vet J 1996 Jul;152(4):373–5.
Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. McKee MD, et al. **J Bone Miner Res** 1995 Dec; 10(12):1913–29
Crevicular fluid osteocalcin and pyridinoline cross–linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. Giannobile WV, et al. **J Clin Periodontol** 1995 Dec;22(12):903–10
Osteocalcin expression in primary bone tumors––in situ hybridization and immunohistochemical study. Park YK, et al. **J Korean Med Sci** 1995 Aug;10(4):263–8

BIOSYNTHESIS

Myeloma cells upregulate interleukin–6 secretion in osteoblastic cells through cell–to–cell contact but downregulate osteocalcin. Barillé S, et al. **Blood** 1995 Oct 15;86(8):3151–9
Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. Boudreaux JM, et al. **J Biol Chem** 1996 Mar 29;271(13):7508–15
G/C element contributes to the cell line–specific expression of the proximal osteocalcin promoter. Goldberg D, et al. **J Cell Biochem** 1995 Aug;58(4):499–508

BLOOD

Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels [letter; comment] Teramoto S, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):879–80. Comment on: Am J Respir Crit Care Med 1995 Feb;151(2 Pt 1):333–6.
Effect of glucocorticoids on serum osteocalcin concentration in horses. Geor R, et al. **Am J Vet Res** 1995 Sep; 56(9):1201–5
Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Durham BH, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):422–3
Osteocalcin, growth, and inhaled corticosteroids: a prospective study. Doull I, et al. **Arch Dis Child** 1996 Jun; 74(6):497–501
Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure. Lin YF, et al. **ASAIO J** 1994 Jul–Sep;40(3):M440–4
Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population–based study. Jie KS, et al. **Atherosclerosis** 1995 Jul;116(1):117–23
Umbilical cord osteocalcin in normal pregnancies and pregnancies complicated by fetal growth retardation or diabetes mellitus. Verhaeghe J, et al. **Biol Neonate** 1995; 68(6):377–83
Regulation of plasma osteocalcin by corticosterone and norepinephrine during restraint stress. Patterson–Buckendahl P, et al. **Bone** 1995 Nov;17(5):467–72
Joint disease––a role for serum markers in diagnosis, control and prevention [editorial; comment] Thorp B. **Br Vet J** 1996 Jul;152(4):373–5. Comment on: Br Vet J 1996 Jul;152(4):411–23.
Diet, bone mass, and osteocalcin: a cross–sectional study. Michaëlsson K, et al. **Calcif Tissue Int** 1995 Aug; 57(2):86–93
Changes in serum carboxyterminal telopeptide of type I collagen in an experimental model of canine osteomyelitis. Philipov JP, et al. **Calcif Tissue Int** 1995 Aug;57(2):152–4
Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Reeve J, et al. **Calcif Tissue Int** 1995 Aug;57(2):105–10
Increasing serum osteocalcin after glycemic control in diabetic men. Sayinalp S, et al. **Calcif Tissue Int** 1995 Dec; 57(6):422–5
Serum levels of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen (ICTP) and osteocalcin in

rachitic children in Nigeria. Scariano JK, et al. **Clin Biochem** 1995 Oct;28(5):541–5

Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Rosenquist C, et al. **Clin Chem** 1995 Oct;41(10):1439–45

Serum concentrations of osteocalcin in pregnant women with multinodular thyroid goiter undergoing treatment with levothyroxine. Letizia C, et al. **Endocr Res** 1995 Aug; 21(3):645–52

Serial changes in serum vitamin K1, triglyceride, cholesterol, osteocalcin and 25–hydroxyvitamin D3 in patients after hip replacement for fractured neck of femur or osteoarthritis. Roberts NB, et al. **Eur J Clin Invest** 1996 Jan;26(1):24–9

Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM). Mejjad O, et al. **Eur J Haematol** 1996 Jan–Feb; 56(1–2):30–4

Increased degradation of type I collagen in patients with inflammatory bowel disease. Silvennoinen J, et al. **Gut** 1996 Feb;38(2):223–8

A comparison of the effects of parathyroid hormone and parathyroid hormone–related protein on osteocalcin in the rat. Gundberg CM, et al. **J Bone Miner Res** 1995 Jun; 10(6):903–9

Serum sex hormone–binding globulin and osteocalcin in systemic nonthyroidal illness associated with low thyroid hormone concentrations. Seppel T, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1663–5

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. Conti A, et al. **J Endocrinol Invest** 1996 Feb;19(2):127–30

Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. Joffe P, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1912–7

Release of osteocalcin fragments in the serum of dialyzed patients during desferrioxamine treatment [letter] Gerakis A, et al. **Nephron** 1995;71(1):124

Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Magnusson P, et al. **Pediatr Res** 1995 Dec;38(6):955–61

Biological variation in bone–derived biochemical markers in serum. Panteghini M, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):609–16

Serum osteocalcin levels in type I diabetes mellitus. Paşaoğlu H, et al. **Turk J Pediatr** 1995 Oct–Dec;37(4):323–9

[Study of variations of osteocalcin concentrations in function of collection, assay method and its nyctohemeral rhythm] Caillot–Augusseau A, et al. **Ann Endocrinol (Paris)** 1995; 56(6):591–8 (Eng. Abstr.) **(Fre)**

[Effect of GH/IGF–I deficiency on bone and collagen turnover in children and adults with GH deficiency] Sartorio A, et al. **Minerva Endocrinol** 1995 Jun;20(2):135–40 (Eng. Abstr.) **(Ita)**

[Osteocalcin] Hino F, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:745–8 (10 ref.) **(Jpn)**

[Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure] Węglarska J, et al. **Pediatr Pol** 1995 Dec;70(12):1011–5 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Conformational studies of osteocalcin in solution. Atkinson RA, et al. **Eur J Biochem** 1995 Sep 1;232(2):515–21

Identification of osteocalcin as a permanent aging constituent of the bone matrix: basis for an accurate age at death determination. Ritz S, et al. **Forensic Sci Int** 1996 Jan 12; 77(1–2):13–26

Amino–acid sequence of bone Gla protein from the African clawed toad Xenopus laevis and the fish Sparus aurata. Cancela ML, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):419–23

GENETICS

Posttranscriptional regulation of osteocalcin mRNA in clonal osteoblast cells by 1,25–dihydroxyvitamin D3. Mosavin R, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):142–52

Preferential expression of osteocalcin–related protein mRNA in gonadal tissues of male mice. Sato M, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):412–21

Identification of an osteoblastic silencer element in the first intron of the rat osteocalcin gene. Goto K, et al. **Biochemistry** 1996 Aug 20;35(33):11005–11

The tissue–specific nuclear matrix protein, NMP–2, is a member of the AML/CBF/PEBP2/runt domain transcription factor family: interactions with the osteocalcin gene promoter. Merriman HL, et al. **Biochemistry** 1995 Oct 10;34(40):13125–32

Changes in chromatin structure support constitutive and developmentally regulated transcription of the bone–specific osteocalcin gene in osteoblastic cells. Montecino M, et al. **Biochemistry** 1996 Apr 16; 35(15):5093–102

Transforming growth factor–beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein–1 binding site. Banerjee C, et al. **Endocrinology** 1996 May; 137(5):1991–2000

Control of 1,25–dihydroxyvitamin D3 receptor–mediated enhancement of osteocalcin gene transcription: effects of perturbing phosphorylation pathways by okadaic acid and staurosporine. Desai RK, et al. **Endocrinology** 1995 Dec; 136(12):5685–93

Antagonistic effects of transforming growth factor–beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Staal A, et al. **Endocrinology** 1996 May; 137(5):2001–11

Synthetic 20–epi analogs of calcitriol are potent inducers of target–gene activation in osteoblastic cells. Ryhänen S, et al. **Eur J Biochem** 1996 May 15;238(1):97–103

A PEBP2 alpha/AML–1–related factor increases osteocalcin promoter activity through its binding to an osteoblast–specific cis–acting element. Geoffroy V, et al. **J Biol Chem** 1995 Dec 29;270(52):30973–9

Cellular deformation reversibly depresses RT–PCR detectable levels of bone–related mRNA. Stanford CM, et al. **J Biomech** 1995 Dec;28(12):1419–27

Effects of differentiation and transforming growth factor beta 1 on PTH/PTHrP receptor mRNA levels in MC3T3–E1 cells. McCauley LK, et al. **J Bone Miner Res** 1995 Aug; 10(8):1243–55

G/C element contributes to the cell line–specific expression of the proximal osteocalcin promoter. Goldberg D, et al. **J Cell Biochem** 1995 Aug;58(4):499–508

Identification of an osteocalcin gene promoter sequence that binds AP1. Goldberg D, et al. **J Cell Biochem** 1996 Mar 15;60(4):447–57

Contributions of distal and proximal promoter elements to glucocorticoid regulation of osteocalcin gene transcription. Aslam F, et al. **Mol Endocrinol** 1995 Jun;9(6):679–90

Characterization of a silencer element in the first exon of the human osteocalcin gene. Li YP, et al. **Nucleic Acids Res** 1995 Dec 25;23(24):5064–72

An AML–1 consensus sequence binds an osteoblast–specific complex and transcriptionally activates the osteocalcin gene. Banerjee C, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4968–73

METABOLISM

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García–Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

Carboxylation of osteocalcin in post–menopausal osteoporotic women following vitamin K and D supplementation. Douglas AS, et al. **Bone** 1995 Jul; 17(1):15–20

Effect of protein restriction on the messenger RNA contents of bone–matrix proteins, insulin–like growth factors and insulin–like growth factor binding proteins in femur of ovariectomized rats. Higashi Y, et al. **Br J Nutr** 1996 Jun; 75(6):811–23

Osteocalcin metabolism in late fetal life: fetal and maternal osteocalcin levels. Alataş O, et al. **Clin Chim Acta** 1995 Aug 14;239(2):179–83

Effects of short–term, high dose, heparin therapy on biochemical markers of bone metabolism. Cantini F, et al. **Clin Rheumatol** 1995 Nov;14(6):663–6

Basal and vitamin D–responsive activity of the rat osteocalcin promoter in stably transfected osteosarcoma cells: requirement of upstream sequences for control by the proximal regulatory domain. Frenkel B, et al. **Endocrinology** 1996 Mar;137(3):1080–88

Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Schmidt IU, et al. **Endocrinology** 1995 Nov;136(11):5127–34

PHARMACOKINETICS

Bioavailability and distribution of 125J osteocalcin in rats with experimental osteoporosis. Ryszka F, et al. **Pharmazie** 1995 Dec;50(12):831–2

PHYSIOLOGY

Increased bone formation in osteocalcin–deficient mice. Ducy P, et al. **Nature** 1996 Aug 1;382(6590):448–52

SECRETION

Influence of high glucose on 1,25–dihydroxyvitamin D3–induced effect on human osteoblast–like MG–63 cells. Inaba M, et al. **J Bone Miner Res** 1995 Jul;10(7):1050–6

OSTEOCHONDRITIS

COMPLICATIONS

Lesions of the lumbar posterior end plate in children and adolescents. An MRI study. Ikata T, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):951–5

Pseudoarthrosis between a patellar tendon ossicle and the tibial tuberosity in Osgood–Schlatter's disease. Robertsen K, et al. **Scand J Med Sci Sports** 1996 Feb;6(1):57–9

[Management of claudication in children] Silberman B. **Ann Radiol (Paris)** 1995;38(5):293–6 **(Fre)**

DIAGNOSIS

More on Kienbock's disease and avascular necrosis [letter; comment] Miller LC. **Clin Pediatr (Phila)** 1995 Jul;34(7):395 . Comment on: Clin Pediatr (Phila) 1994 Dec;33(12):752–4.

Lesions of the lumbar posterior end plate in children and adolescents. An MRI study. Ikata T, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):951–5

Avascular necrosis of carpal bones. Golimbu CN, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):281–303 (74 ref.)

[Van Neck disease or a variation of ischio–pubic synchondrosis development?] Rajewski F. **Chir Narzadow Ruchu Ortop Pol** 1992;57(4–6):346–8 (Eng. Abstr.) **(Pol)**

GENETICS

[Fluctuating asymmetry as a marker of phenotypic adaptiveness (modelled on the neurological manifestations of lumbar osteochondrosis] Verenich SV. **Ontogenez** 1996 Mar–Apr;27(2):137–40 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Histopathology of Kienböck's disease. Correlation with magnetic resonance and other imaging techniques. Hashizume H, et al. **J Hand Surg [Br]** 1996 Feb;21(1):89–93

Adult idiopathic chondrolysis of the hip--report of two cases. Wada Y, et al. **Kurume Med J** 1995;42(2):121–8

PHYSIOPATHOLOGY

[Intraosseous pressure measurement in Kienboeck's disease--initial findings] Martini AK, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):311–6 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiographic staging of Kienböck's disease. Poor reproducibility of Ståhl's and Lichtman's staging systems. Jensen CH, et al. **Acta Orthop Scand** 1996 Jun;67(3):274–6

SURGERY

Long–term results of radial shortening for Kienböck's disease. De Smet L, et al. **Acta Orthop Belg** 1995; 61(3):212–7

Autoarthroplasty of knee cartilage defects by osteoperiosteal grafts. Korkala OL, et al. **Arch Orthop Trauma Surg** 1995; 114(5):253–6

Allogeneic deep frozen meniscal graft for repair of osteochondral defects in the knee joint. Ochi M, et al. **Arch Orthop Trauma Surg** 1995;114(5):260–6

Biodegradable pin fixation of osteochondral fragments of the knee. Matsusue Y, et al. **Clin Orthop** 1996 Jan;(322):166–73

Ulnar lengthening and radial recession procedures for Kienböck's disease. Long–term clinical and radiographic follow–up. Trail IA, et al. **J Hand Surg [Br]** 1996 Apr; 21(2):169–76

[Transplantation of pedicled pisiform bone to replace lunate bone with aseptic necrosis] Zhong G, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):17–9 (Eng. Abstr.) **(Chi)**

[Differential indications for so–called "lateral release" in treatment of chondropathia patellae] Schultz W, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):13–8 (Eng. Abstr.) **(Ger)**

THERAPY

Healing of chondral and osteochondral defects in a canine model: the role of cultured chondrocytes in regeneration of articular cartilage. Shortkroff S, et al. **Biomaterials** 1996 Jan;17(2):147–54

Köhler's bone disease of the tarsal navicular. Borges JL, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):596–8

[Combined treatment using electrostimulation of the radicular–vascular syndromes in lumbar osteochondrosis] Zachatko TM. **Lik Sprava** 1995 Jul–Aug;(7–8):106–9 (Eng. Abstr.) **(Ukr)**

VETERINARY

Osteochondrosis in wild boar–Swedish Yorkshire crossbred pigs (F2 generation). Uhlhorn H, et al. **Acta Vet Scand** 1995;36(1):41–53

Unexpected death in a horse with arytenoid chondritis and perilaryngeal lesions. France MP, et al. **Aust Vet J** 1995 Sep;72(9):351–2

Osteochondrosis of the elbow: a review of the pathogenesis and a new approach to treatment. Thomson MJ, et al. **Aust Vet J** 1995 Oct;72(10):375–8

Critical thinking: how the characteristic coronoid lesion evolves. Farrow CS. **Can Vet J** 1996 May;37(5):310–1

Histologic appearance of axial osteochondral fragments from the proximoplantar/proximopalmar aspect of the proximal phalanx in horses [published erratum appears in J Am Vet Med Assoc 1995 Dec 15;207(12):1634] Nixon AJ, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1076–80

Arthroscopy in food animal practice. Gaughan EM. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):233–47 (11 ref.)

Osteochondrosis of the articular–epiphyseal cartilage complex in young horses: evidence for a defect in cartilage canal blood supply. Carlson CS, et al. **Vet Pathol** 1995 Nov; 32(6):641–7

Osteochondrosis in a pedigree Suffolk ram. Doherty ML, et al. **Vet Rec** 1996 Feb 10;138(6):137–8

Comparison of arthroscopy and arthrotomy for the treatment of osteochondritic lesions in the femoropatellar joint of

horses. Vatistas NJ, et al. **Vet Rec** 1995 Dec 16; 137(25):629–32

Pathological and radiological investigations on osteochondrosis in pigs, associated with leg weakness. Jørgensen B, et al. **Zentralbl Veterinarmed A** 1995 Oct; 42(8):489–504

OSTEOCHONDRITIS DISSECANS

Osteochondritis dissecans. Schenck RC Jr, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):439–56 (163 ref.)

COMPLICATIONS

[Intra-osseous and intra-articular cyst of the knee. Apropos of a case associated with osteochondritis dissecans] Lootvoet L, et al. **Acta Orthop Belg** 1995;61(4):308–11 (Eng. Abstr.) **(Fre)**

[Growth plate in primary osteochondritis dissecans of the hip: a prospective study with MRI] Lahdes-Vasama TT, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(5):395–403 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Current treatment modalities of osteochondritis dissecans of the knee joint: results of a nation-wide German survey. Jerosch J, et al. **Acta Orthop Belg** 1996 Jun;62(2):83–9

Bilateral osteochondritis dissecans of the medial trochlea femoris: an unusual case of patellofemoral pain. Luessenhop S, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3–4):187–8

Osteochondritis dissecans of the patellofemoral groove in athletes: unusual cases of patellofemoral pain. Mori Y, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):242–4

Reassessment of the MR criteria for stability of osteochondritis dissecans in the knee and ankle. De Smet AA, et al. **Skeletal Radiol** 1996 Feb;25(2):159–63

[Osteochondrosis dissecans of the humeral head] Ganter M, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb;134(1):73–5 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Biomechanical topography of human ankle cartilage. Athanasiou KA, et al. **Ann Biomed Eng** 1995 Sep–Oct; 23(5):697–704

Experimental osteochondritis dissecans—the role of cartilage canals in chondral fractures of young rabbits. Bravo C, et al. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):133–41

PHYSIOPATHOLOGY

The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes. Messner K, et al. **Acta Orthop Scand** 1996 Apr;67(2):165–8

RADIOGRAPHY

Case 9. Presentation. Osteochondritis dissecans. Hodge JC, et al. **Can J Surg** 1996 Jun;39(3):185, 204

SURGERY

Current treatment modalities of osteochondritis dissecans of the knee joint: results of a nation-wide German survey. Jerosch J, et al. **Acta Orthop Belg** 1996 Jun;62(2):83–9

Polylactic acid pins [letter; comment] Mainil-Varlet P. **Acta Orthop Scand** 1995 Dec;66(6):573–4. Comment on: Acta Orthop Scand 1994 Aug;65(4):472–5.

The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes. Messner K, et al. **Acta Orthop Scand** 1996 Apr;67(2):165–8

Arthroscopic osteochondral autograft transplantation in anterior cruciate ligament reconstruction: a preliminary clinical study. Bobić V. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):262–4

Bilateral osteochondritis dissecans of the medial trochlea femoris: an unusual case of patellofemoral pain. Luessenhop S, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3–4):187–8

[Patellar osteochondrosis dissecans—results of surgical therapy] Bruns J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb;134(1):7–10 (Eng. Abstr.) **(Ger)**

VETERINARY

The inheritance of osteochondritis dissecans and fragmented coronoid process of the elbow joint in labrador retrievers. Padgett GA, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug; 31(4):327–30

OSTEOCHONDRODYSPLASIAS

Syndrome of multiple epiphyseal dysplasia (ribbing type) with rhizomelic shortness, cleft palate, and micrognathia in two unrelated patients. Lowry RB, et al. **Am J Med Genet** 1996 May 3;63(1):55–61

Dysplasia epiphysealis hemimelica of the radius. Poli G, et al. **Chir Organi Mov** 1995 Jul–Aug;80(3):341–4

A new case of fibrochondrogenesis from Spain. Martínez-Frías ML, et al. **J Med Genet** 1996 May; 33(5):429–31

[Dyggve-Melchior-Clausen syndrome: description of 2 further cases] Galasso C, et al. **Pediatr Med Chir** 1995 Nov–Dec;17(6):573–6 (Eng. Abstr.) **(Ita)**

[The "Fantasy Island" syndrome. Identification of a new osteochondrodysplasia probably of autosomal dominant type] Cantú JM. **Gac Med Mex** 1995 Jan–Feb;131(1):23–6; discussion 27 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Evolution of the bone dysplasia family [editorial] Horton WA. **Am J Med Genet** 1996 May 3;63(1):4–6 (22 ref.)

COMPLICATIONS

Double patella syndrome with a form of multiple epiphyseal dysplasia. Yochum TR, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):407–10 (11 ref.)

Oral manifestations of severe short-limb dwarfism resembling Grebe chondrodysplasia: report of a case. Hattab FN, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):550–5

CONGENITAL

Spondyloepiphyseal dysplasia congenita syndrome: anesthetic implications [letter] Mogera C, et al. **Anesth Analg** 1996 Aug;83(2):433–4

DIAGNOSIS

Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL): clinical and radiological findings in a Guatemalan patient. Bradburn JM, et al. **Am J Med Genet** 1995 Nov 6;59(2):234–7

Micromelic dwarfism with cone epiphyses, metaphyseal dysplasia, and vertebral segmentation defects. Fryns JP, et al. **Am J Med Genet** 1996 Jan 11;61(2):164–7

Sponastrime dysplasia: five new cases and review of nine previously published cases. Langer LO Jr, et al. **Am J Med Genet** 1996 May 3;63(1):20–7 (6 ref.)

Dyssegmental dysplasia with glaucoma. Maroteaux P, et al. **Am J Med Genet** 1996 May 3;63(1):46–9

Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL): a Brazilian case. Pina-Neto JM, et al. **Am J Med Genet** 1996 Jan 11;61(2):131–3

Melnick Needles syndrome. Kothari V, et al. **Indian Pediatr** 1995 Apr;32(4):471–5 (8 ref.)

MRI findings of dysplasia epiphysealis hemimelica. Iwasawa T, et al. **Pediatr Radiol** 1996;26(1):65–7

Tracheobronchopathia osteochondroplastica. Report of a young man with severe disease and retrospective review of 18 cases. Vilkman S, et al. **Respiration** 1995;62(3):151–4 (13 ref.)

Genetic skeletal dysplasia in Thailand: the Siriraj experience. Wasant P, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:59–67

[Metaphyseal chondrodysplasia as differential diagnosis to rickets] Dahl M, et al. **Ugeskr Laeger** 1996 Mar 18; 158(12):1683–4 (Eng. Abstr.) **(Dan)**

[Spondylo-metaphyseal dysplasia type I (Kozłowski)] Bragoszewska H, et al. **Pediatr Pol** 1995 Oct;70(10):879–83 (Eng. Abstr.) **(Pol)**

EMBRYOLOGY

Achondrogenesis type I diagnosed by transvaginal ultrasonography at 13 weeks' gestation. Meizner I, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1620–2

Aetiology of the skeletal dysmorphology syndrome campomelic dysplasia: expression of the Sox9 gene during chondrogenesis in mouse embryos. Wheatley S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:350–2

EPIDEMIOLOGY

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)

Epidemiology of osteochondrodysplasias: changing trends due to advances in prenatal diagnosis. Rasmussen SA, et al. **Am J Med Genet** 1996 Jan 2;61(1):49–58

GENETICS

Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate-transporter gene (DTDST): evidence for a phenotypic series involving three chondrodysplasias. Hästbacka J, et al. **Am J Hum Genet** 1996 Feb;58(2):255–62

Mutations in SOX9, the gene responsible for Campomelic dysplasia and autosomal sex reversal [see comments] Kwok C, et al. **Am J Hum Genet** 1995 Nov;57(5):1028–36. Comment in: Am J Hum Genet 1995 Nov;57(5):998–1001.

Localization of a gene for autosomal dominant Larsen syndrome to chromosome region 3p21.1–14.1 in the proximity of, but distinct from, the COL7A1 locus. Vujic M, et al. **Am J Hum Genet** 1995 Nov;57(5):1104–13

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)

Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Bonaventure J, et al. **Am J Med Genet** 1996 May 3; 63(1):148–54

Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL): clinical and radiological findings in a Guatemalan patient. Bradburn JM, et al. **Am J Med Genet** 1995 Nov 6;59(2):234–7

Diastrophic dysplasia: extreme variability within a sibship. Hall BD. **Am J Med Genet** 1996 May 3;63(1):28–33

Evolution of the bone dysplasia family [editorial] Horton WA. **Am J Med Genet** 1996 May 3;63(1):4–6 (22 ref.)

Phenotypic expressions of a Gly 154Arg mutation in type II collagen in two unrelated patients with spondyloepimetaphyseal dysplasia (SEMD). Kaitila I, et al. **Am J Med Genet** 1996 May 3;63(1):111–22

Blomstrand lethal osteochondrodysplasia. Leroy JG, et al. **Am J Med Genet** 1996 May 3;63(1):84–9

Progress in medical genetics: map-based gene discovery and the molecular pathology of skeletal dysplasias. McKusick VA, et al. **Am J Med Genet** 1996 May 3;63(1):98–105

An unknown spondylo-meta-epiphyseal dysplasia in sibs with extreme short stature. Menger H, et al. **Am J Med Genet** 1996 May 3;63(1):80–3

An alpha 1(II) Gly913 to Cys substitution prevents the matrix incorporation of type II collagen which is replaced with type I and III collagens in cartilage from a patient with hypochondrogenesis. Mundlos S, et al. **Am J Med Genet** 1996 May 3;63(1):129–36

Clinical and ultrastructural findings in three patients with geleophysic dysplasia. Pontz BF, et al. **Am J Med Genet** 1996 May 3;63(1):50–4

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. **Am J Med Genet** 1995 Nov 20;59(3):295–9 (17 ref.)

Molecular defects in the chondrodysplasias. Rimoin DL. **Am J Med Genet** 1996 May 3;63(1):106–10 (35 ref.)

Spondyloperipheral dysplasia. Sorge G, et al. **Am J Med Genet** 1995 Nov 6;59(2):139–42

A chondrodysplasia family produced by mutations in the diastrophic dysplasia sulfate transporter gene: genotype/phenotype correlations. Superti-Furga A, et al. **Am J Med Genet** 1996 May 3;63(1):144–7 (28 ref.)

Stüve-Wiedemann syndrome: update and historical footnote. Wiedemann HR, et al. **Am J Med Genet** 1996 May 3; 63(1):12–6

A specific collagen type II gene (COL2A1) mutation presenting as spondyloperipheral dysplasia. Zabel B, et al. **Am J Med Genet** 1996 May 3;63(1):123–8

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)

Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Bellus GA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:182–7 (25 ref.)

Recurrent transition at a CG dinucleotide in exon 12 of COL2A1 produces kniest dysplasia with abnormal RNA splicing by chondrocytes and lymphoblasts and interruption of the triple helix of type II collagen. Chen L, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:234–7

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Mutations affecting multiple functional domains of FGFR3 cause different skeletal dysplasias: a personal retrospective in honor of John Wasmuth. Cohn DH. **Ann N Y Acad Sci** 1996 Jun 8;785:160–3

Sulfate transport in chondrodysplasia. Hästbacka J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:131–6 (29 ref.)

Progress in human chondrodysplasias: molecular genetics. Horton WA. **Ann N Y Acad Sci** 1996 Jun 8;785:150–9 (44 ref.)

A mutation in COL9A2 causes multiple epiphyseal dysplasia (EDM2). Muragaki Y, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:303–6

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137–49 (46 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti-Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195–201 (26 ref.)

Aetiology of the skeletal dysmorphology syndrome campomelic dysplasia: expression of the Sox9 gene during chondrogenesis in mouse embryos. Wheatley S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:350–2

Dutch variant of Bellini metaphyseal dysplasia: report of two siblings. Kozlowski K, et al. **Australas Radiol** 1995 Aug; 39(3):282–6 (6 ref.)

Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias. Olsen BR. **Bone** 1995 Aug;17(2 Suppl):45S–49S (30 ref.)

Lung hypoplasia and severe pulmonary hypertension in an infant with double heterozygosity for spondyloepiphyseal dysplasia congenita and achondroplasia. Günthard J, et al. **Clin Genet** 1995 Jul;48(1):35–40

High-resolution genetic and physical mapping of multiple epiphyseal dysplasia and pseudoachondroplasia mutations at chromosome 19p13.1–p12. Knowlton RG, et al. **Genomics** 1995 Aug 10;28(3):513–9

Recessive Schwartz-Jampel syndrome (SJS): confirmation of linkage to chromosome 1p, evidence of genetic homogeneity and reduction of the SJS locus to a 3-cM interval. Fontaine B, et al. **Hum Genet** 1996 Sep;98(3):380–5

Genetic mapping of Xp22.12–p22.31, with a refined

localization for spondyloepiphyseal dysplasia (SEDL). Heuertz S, et al. **Hum Genet** 1995 Oct;96(4):407–10

Translocation breakpoints in three patients with campomelic dysplasia and autosomal sex reversal map more than 130 kb from SOX9. Wirth J, et al. **Hum Genet** 1996 Feb; 97(2):186–93

Localization of the Schwartz–Jampel syndrome (SJS) locus to chromosome 1p34–p36.1 by homozygosity mapping. Nicole S, et al. **Hum Mol Genet** 1995 Sep;4(9):1633–6

Isolation of a testis-specific cDNA on chromosome 17q from a region adjacent to the breakpoint of t(12;17) observed in a patient with acampomelic campomelic dysplasia and sex reversal. Ninomiya S, et al. **Hum Mol Genet** 1996 Jan; 5(1):69–72

A common FGFR3 gene mutation in hypochondroplasia. Prinos P, et al. **Hum Mol Genet** 1995 Nov;4(11):2097–101

Linkage analysis of two Canadian families segregating for X linked spondyloepiphyseal dysplasia. Bernard LE, et al. **J Med Genet** 1996 May;33(5):432–4

Neonatal Schwartz–Jampel syndrome: a common autosomal recessive syndrome in the United Arab Emirates. Al-Gazali LI, et al. **J Med Genet** 1996 Mar;33(3):203–11

Actions of parathyroid hormone-related peptide and its receptors [editorial; comment] Martin TJ.
N Engl J Med 1996 Sep 5;335(10):736–8. Comment on: N Engl J Med 1996 Sep 5;335(10):708–14.

Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia [see comments] Schipani E, et al. **N Engl J Med** 1996 Sep 5;335(10):708–14. Comment in: N Engl J Med 1996 Sep 5;335(10):736–8.

A mutation in the gene encoding the alpha 2 chain of the fibril-associated collagen IX, COL9A2, causes multiple epiphyseal dysplasia (EDM2). Muragaki Y, et al.
Nat Genet 1996 Jan;12(1):103–5

A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Thomas JT, et al. **Nat Genet** 1996 Mar;12(3):315–7

Dominant mutations in the type II collagen gene, COL2A1, produce spondyloepimetaphyseal dysplasia, Strudwick type. Tiller GE, et al. **Nat Genet** 1995 Sep;11(1):87–9

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Gelb BD, et al. **Science** 1996 Aug 30; 273(5279):1236–8

[A case of type II achondrogenesis] Micheli E, et al.
Pediatr Med Chir 1996 Jan–Feb;18(1):105–7 (Eng. Abstr.) **(Ita)**

METABOLISM

Sulfate transport in chondrodysplasia. Hästbacka J, et al.
Ann N Y Acad Sci 1996 Jun 8;785:131–6 (29 ref.)

PATHOLOGY

Kniest dysplasia: radiologic, histopathological, and scanning electronmicroscopic findings. Gilbert-Barnes E, et al.
Am J Med Genet 1996 May 3;63(1):34–45

Clinical and ultrastructural findings in three patients with geleophysic dysplasia. Pontz BF, et al.
Am J Med Genet 1996 May 3;63(1):50–4

Regulators of chondrocyte differentiation in tibial dyschondroplasia: an in vivo and in vitro study. Farquharson C, et al. **Bone** 1995 Sep;17(3):279–86

Microcephalic osteodysplastic primordial dwarfism type II. al Gazali LI, et al. **Clin Dysmorphol** 1995 Jul;4(3):234–8

Wolcott–Rallison syndrome. al-Gazali LI, et al.
Clin Dysmorphol 1995 Jul;4(3):227–33

Opsismodysplasia: another case and literature review. Santos HG, et al. **Clin Dysmorphol** 1995 Jul;4(3):222–6 (7 ref.)

Patterson–Lowry rhizomelic dysplasia: a possible second example. Williams MS, et al. **Clin Dysmorphol** 1995 Jul; 4(3):216–21

Madelung deformity--the hallmark of dyschondrosteosis. Bhat M, et al. **Indian Pediatr** 1995 Dec;32(12):1314–6

PHYSIOPATHOLOGY

A new form of skeletal dysplasia with amelogenesis imperfecta and platyspondyly. Verloes A, et al.
Clin Genet 1996 Jan;49(1):2–5

Defect in formation of functional matrix vesicles by growth plate chondrocytes in avian tibial dyschondroplasia: evidence of defective tissue vascularization. Nie D, et al.
J Bone Miner Res 1995 Nov;10(11):1625–34

RADIOGRAPHY

Metaphyseal peg in geroderma osteodysplasticum: a new genetic bone marker and a specific finding? Eich GF, et al. **Am J Med Genet** 1996 May 3;63(1):62–7

Kniest dysplasia: radiologic, histopathological, and scanning electronmicroscopic findings. Gilbert-Barnes E, et al.
Am J Med Genet 1996 May 3;63(1):34–45

Stüve-Wiedemann dysplasia in a 3 1/2-year-old boy. Kozlowski K, et al. **Am J Med Genet** 1996 May 3;63(1):17–9

A new form of rhizo-mesomelic bone dysplasia. Baxova A, et al. **Pediatr Radiol** 1995;25(4):300–2

Shwachman–Diamond syndrome: clinical, radiological and sonographic findings. Berrocal T, et al. **Pediatr Radiol** 1995; 25(5):356–9

THERAPY

Bone marrow transplantation in cartilage-hair hypoplasia: correction of the immunodeficiency but not of the chondrodysplasia. Berthet F, et al. **Eur J Pediatr** 1996 Apr; 155(4):286–90

ULTRASONOGRAPHY

Prenatal diagnosis of osteochondrodysplasias in high risk pregnancy. Gordienko IYu, et al. **Am J Med Genet** 1996 May 3;63(1):90–7

Achondrogenesis type I diagnosed by transvaginal ultrasonography at 13 weeks' gestation. Meizner I, et al.
Am J Obstet Gynecol 1995 Nov;173(5):1620–2

VETERINARY

Immunohistochemical study of a chondroitin-6-sulfate in growth plates of broiler chickens with high and low genetic predispositions to tibial dyschondroplasia. Ling J, et al.
Avian Dis 1996 Jan–Mar;40(1):88–98

Distribution and quantification of pyridinium cross-links of collagen within the different maturational zones of the chick growth plate. Farquharson C, et al.
Biochim Biophys Acta 1996 Aug 13;1290(3):250–6

Interaction between dietary 1,25-dihydroxycholecalciferol and calcium and effects of management on the occurrence of tibial dyschondroplasia, leg abnormalities and performance in broiler chickens. Rennie JS, et al.
Br Poult Sci 1995 Jul;36(3):465–77

Effects of dietary calcium and 1,25-dihydroxycholecalciferol on the development of tibial dyschondroplasia in broilers during the starter and grower periods. Elliot MA, et al.
Poult Sci 1995 Sep;74(9):1495–505

Effect of dietary 1,25-dihydroxycholecalciferol level on broiler performance. Roberson KD, et al. **Poult Sci** 1996 Jan;75(1):90–4

Immunolocalization of basic fibroblastic growth factor in avian tibial dyschondroplastic cartilage. Twal WO, et al.
Poult Sci 1996 Jan;75(1):130–4

Effect of selection for high or low incidence of tibial dyschondroplasia for seven generations on live performance. Yalcin S, et al. **Poult Sci** 1995 Sep; 74(9):1411–7

Random amplified polymorphic DNA comparisons among broiler lines selected for incidence of tibial dyschondroplasia. Zhang X, et al. **Poult Sci** 1995 Aug; 74(8):1253–8

Sequential studies of endochondral ossification and serum 1,25-dihydroxycholecalciferol in broiler chickens between one and 21 days of age. Parkinson G, et al.
Res Vet Sci 1996 Mar;60(2):173–8

OSTEOCHONDROMA

First-rib exostosis bursa. Gupta NK, et al.
Ann Thorac Surg 1996 Jan;61(1):219–20

Dysplasia epiphysealis hemimelica of the radius. Poli G, et al. **Chir Organi Mov** 1995 Jul–Aug;80(3):341–4

COMPLICATIONS

Thoracic spine osteochondroma causing spinal cord compression. An unusual cause of paraparesis. de Jesús O, et al. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):57–9

Femoral osteochondroma [letter; comment] Khaira HS.
Eur J Vasc Endovasc Surg 1996 Feb;11(2):249–50. Comment on: Eur J Vasc Endovasc Surg 1995 May;9(4):501–2.

Fracture through an osteochondroma. Prakash U, et al.
Injury 1996 Jun;27(5):357–8

Pseudoaneurysm of the brachial artery caused by an osteochondroma. A report of two cases. Villanueva-Garcia E, et al. **Int Orthop** 1995;19(4):248–50

Proximal fibular osteochondroma with associated peroneal nerve palsy: a review of six cases. Cardelia JM, et al.
J Pediatr Orthop 1995 Sep–Oct;15(5):574–7

Pes anserinus syndrome due to solitary tibial spurs and osteochondromas. Fraser RK, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):247–8

Osteochondroma: an unusual cause of vascular disease in young adults. Eschelman DJ, et al.
J Vasc Interv Radiol 1995 Jul–Aug;6(4):605–13 (54 ref.)

Popliteal vein thrombosis associated with femoral osteochondroma and popliteal artery pseudoaneurysm. Scott EM, et al. **Postgrad Med J** 1995 Jul;71(837):441–2

[Pericardial perforation caused by an osteogenic exostosis (letter)] Etienne G, et al. **Presse Med** 1995 Dec 2; 24(37):1753 **(Fre)**

DIAGNOSIS

Osteochondroma of the cervical spine. MR findings. Morikawa M, et al. **Clin Imaging** 1995 Oct–Dec;19(4):275–8

Osteochondroma of the distal tibia. A case study. Southerland JT. **J Am Podiatr Med Assoc** 1995 Oct;85(10):542–5

Osteochondroma of the skull base: MR1 and histological correlation. Sato K, et al. **Neuroradiology** 1996 Jan; 38(1):41–3

Magnetic resonance imaging of cartilaginous tumors: is it useful or necessary? De Beuckeleer LH, et al.
Skeletal Radiol 1996 Feb;25(2):137–41

EPIDEMIOLOGY

[Tumors and tumor-like diseases of the bones in children] Litovka VK, et al. **Klin Khir** 1995;(5):34–6 **(Rus)**

ETIOLOGY

Simultaneous occurrence of osteosarcoma and osteochondroma following treatment of neuroblastoma with chemotherapy, radiotherapy, and bone marrow transplantation. Poustchi-Amin M, et al. **Pediatr Radiol** 1996;26(2):155–7

General case of the day. Radiation-induced osteochondroma. Rajah R, et al. **Radiographics** 1995 Nov;15(6):1510–2

PATHOLOGY

Case report: periosteal neurofibroma mimicking osteochondroma. Suvarna SK, et al. **Clin Radiol** 1995 Nov; 50(11):800–2

Oral presentation of secondary chondrosarcoma arising in osteochondroma of the nasal septum. Barrett AW, et al.
Int J Oral Maxillofac Surg 1996 Apr;25(2):119–21

Osteochondroma of the mandibular condyle: report of a case. Iizuka T, et al. **J Oral Maxillofac Surg** 1996 Apr; 54(4):495–501

Osteochondroma of the mandibular angle: report of a case. Koga K, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):510–3

Subungual (Dupuytren's) exostosis. Multhopp-Stephens H, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):582–4

Dedifferentiated chondrosarcoma arising in an osteochondroma. Park YK, et al. **Skeletal Radiol** 1995 Nov; 24(8):617–9

RADIOGRAPHY

Bizarre parosteal osteochondromatous proliferation of the hands and feet. Breidahl WH, et al. **Australas Radiol** 1995 Nov;39(4):401–4

Osteochondroma of the peroneal tubercle. A report of two cases. Martin MA, et al. **Int Orthop** 1995;19(6):405–7

Spontaneous regression of exostoses: two case reports. Castriota-Scanderbeg A, et al. **Pediatr Radiol** 1995; 25(7):544–8

Osteochondroma of the upper cervical spine. A case report. Arasil E, et al. **Spine** 1996 Feb 15;21(4):516–8

[Radiological case of the month. A case with osteocartilaginous exostosis of the distal end of the femur] Mayor B, et al. **Arch Pediatr** 1995 Oct;2(10):1013–5 **(Fre)**

SURGERY

Osteochondroma of the tibial sesamoid [letter] Mowad SC Sr, et al. **J Am Podiatr Med Assoc** 1995 Dec;85(12):765–6

Turret exostosis of the metacarpal: a case report. Rubin JA, et al. **J Hand Surg [Am]** 1996 Mar;21(2):296–8

Subungual (Dupuytren's) exostosis. Multhopp-Stephens H, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):582–4

[The scapula: rare localization of osteochondroma] Than P, et al. **Orv Hetil** 1995 Sep 17;136(38):2047–9 (Eng. Abstr.) **(Hun)**

OSTEOCHONDROMAS, MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

OSTEOCHONDROMATOSIS

COMPLICATIONS

Osteochondroma of the thoracic spine: an unusual cause of spinal cord compression. Quirini GE, et al.
AJNR Am J Neuroradiol 1996 May;17(5):961–4

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

DIAGNOSIS

[Osteoplastic bronchopathy (letter)] Bobichon I, et al.
Rev Pneumol Clin 1996;52(1):45–6 **(Fre)**

GENETICS

Hereditary spinal osteochondromas in diaphyseal aclasia. Robbins SE, et al. **Neuroradiology** 1996 Jan;38(1):59–61

PATHOLOGY

[Severe tracheopathia osteochondroplastica in a young male] Vilkman S, et al. **Duodecim** 1994;110(11):1079–83 **(Fin)**

SURGERY

[Osteochondromatosis in shoulder joint arthrosis--a case report] Schwarz G, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):330–2 (Eng. Abstr.) **(Ger)**

VETERINARY

Osteochondromatosis of the cervical spine causing compressive myelopathy in a dog. Caporn TM, et al.
J Small Anim Pract 1996 Mar;37(3):133–7

A case of multiple osteochondroma in the rat. Iwata H, et al. **J Vet Med Sci** 1995 Apr;57(2):339–40

OSTEOCHONDROMATOSIS, SYNOVIAL see **CHONDROMATOSIS, SYNOVIAL**

OSTEOCHONDROSIS see **OSTEOCHONDRITIS**

OSTEOCLASTIC BONE LOSS see BONE RESORPTION

OSTEOCLASTS

Cellular biology of bone-resorbing cells. Athanasou NA. **J Bone Joint Surg Am** 1996 Jul;78(7):1096–112 (170 ref.)
[Recent progress of the investigation of osteoclast] Nakamura T. **Nippon Geka Hokan** 1995 Jan 1;64(1):1–2 (9 ref.) **(Jpn)**

CHEMISTRY

Detection of transcripts and binding sites for colony-stimulating factor-1 during bone development. Hofstetter W, et al. **Bone** 1995 Aug;17(2):145–51
Toward a more complete molecular description of the osteoclast. Horne WC. **Bone** 1995 Aug;17(2):107–9 (14 ref.)
Osteoclast molecular phenotyping by random cDNA sequencing. Sakai D, et al. **Bone** 1995 Aug;17(2):111–9

CYTOLOGY

Local concentrations of macrophage colony-stimulating factor mediate osteoclastic differentiation. Perkins SL, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1024–30
Peripheral blood mononuclear cells develop into multinucleated osteoclasts in tissue culture. Shih C, et al. **Anat Rec** 1996 May;245(1):41–5
Bone cells required for osteoclastic resorption but not for osteoclastic differentiation. Owens JM, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):225–9
Normal human peripheral blood mononuclear cells mobilized with granulocyte colony-stimulating factor have increased osteoclastogenic potential compared to nonmobilized blood. Purton LE, et al. **Blood** 1996 Mar 1;87(5):1802–8
Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Mee AP, et al. **Bone** 1996 Apr;18(4):295–9
Generation of multinucleated osteoclast-like cells from canine bone marrow: effects of canine distemper virus. Mee AP, et al. **Bone** 1995 Jul;17(1):47–55
Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S–91S (30 ref.)
Effects of experimental conditions on the release of 45calcium from prelabeled fetal mouse long bones. van Beek E, et al. **Bone** 1995 Jul;17(1):63–9
Inhibition of prostaglandin synthesis leads to a change in adherence of mouse osteoclasts from bone to periosteum. Marshall MJ, et al. **Calcif Tissue Int** 1996 Sep;59(3):207–13
Interleukin-1 alpha stimulates osteoclast formation from peripheral blood monocytes and increases osteoclastic activity. Shih C, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb;57(2):85–92
A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. John V, et al. **Endocrinology** 1996 Jun; 137(6):2457–63
Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Nishiyama K, et al. **Endocrinology** 1996 Jan;137(1):35–41
Effects of 22-oxacalcitriol on bone metabolism in vitro: comparison with calcitriol—effects of 22-oxacalcitriol on osteoclast-like cell formation and bone-resorbing activity. Kanatani M, et al. **Eur J Endocrinol** 1995 Nov; 133(5):618–25
Osteoclast demise in the rat: physiological versus degenerative cell death. Lutton JD, et al. **Exp Physiol** 1996 Mar;81(2):251–60
Induction of osteoclast characteristics in cultured avian blood monocytes; modulation by osteoblasts and 1,25-(OH)2 vitamin D3. van't Hof RJ, et al. **Int J Exp Pathol** 1995 Jun;76(3):205–14
Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age. Fedarko NS, et al. **J Bone Miner Res** 1995 Nov;10(11):1705–12
Basic fibroblast growth factor inhibits osteoclast-like cell formation. Jimi E, et al. **J Cell Physiol** 1996 Aug; 168(2):395–402
Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone. Roux S, et al. **J Cell Physiol** 1996 Sep;168(3):489–98
Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. Xu LX, et al. **J Cell Physiol** 1995 Dec;165(3):624–9
Multinucleated cells can continuously generate mononucleated cells in the absence of mitosis: a study of cells of the avian osteoclast lineage. Solari F, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3233–41
The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. Väänänen HK, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2729–32 (39 ref.)
Human osteoclast and giant cell differentiation: the apparent switch from nonspecific esterase to tartrate resistant acid phosphatase activity coincides with the in situ expression of osteopontin mRNA. Connor JR, et al. **J Histochem Cytochem** 1995 Dec;43(12):1193–201
Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. Clohisy DR, et al. **J Orthop Res** 1996 May; 14(3):396–402
Formation of osteoclast-like cells is suppressed by low frequency, low intensity electric fields. Rubin J, et al. **J Orthop Res** 1996 Jan;14(1):7–15
Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells. Quinn JM, et al. **J Pathol** 1996 May;179(1):106–11
Cytoskeletal changes in osteoclasts during the resorption cycle. Lakkakorpi PT, et al. **Microsc Res Tech** 1996 Feb 1;33(2):171–81 (90 ref.)
Time-lapse microcinematography of osteocytes. Tanaka K, et al. **Miner Electrolyte Metab** 1995;21(1-3):189–92
Differential effects of transforming growth factor-beta on osteoclast-like cell formation in mouse marrow culture: relation to the effect of zinc-chelating dipeptides. Yamaguchi M, et al. **Peptides** 1995;16(8):1483–8

DRUG EFFECTS

Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70
The effects of high dose of parathyroid hormone on fetal osteoclasts and their precursors in vivo: an ultrastructural-cytochemical study. Isaki H, et al. **Anat Rec** 1995 Dec;243(4):421–9
The effect of methotrexate on mouse bone cells in culture. May KP, et al. **Arthritis Rheum** 1996 Mar;39(3):489–94
Toxicity of particulate silicon carbide for macrophages, fibroblasts and osteoblast-like cells in vitro. Allen M, et al. **Biomed Mater Eng** 1995;5(3):151–9
The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. Franchi-Miller C, et al. **Bone** 1995 Aug;17(2):185–91
A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Murakami H, et al. **Bone** 1995 Aug;17(2):137–44
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Nishikawa M, et al. **Bone** 1996 Jan;18(1):9–14
Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Rakopoulos M, et al. **Bone** 1995 Nov; 17(5):447–53
Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro. Wiberg K, et al. **Bone** 1995 Oct;17(4):391–5
Dose response effects of fluoride on resorption of deciduous teeth in young rabbits. Chen HS, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):709–15
Human calcitonin has the same inhibitory effect on osteoclastic bone resorption by human giant cell tumor cells as salmon calcitonin. Iida S, et al. **Calcif Tissue Int** 1996 Aug;59(2):10?–4
Effect of diacylglycerols on osteoclastic bone resorption. Moonga BS, et al. **Calcif Tissue Int** 1996 Aug;59(2):105–8
Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Kaji H, et al. **Endocrinology** 1996 Jun; 137(6):2217–24
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Vitté C, et al. **Endocrinology** 1996 Jun;137(6):2324–33
Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Elomaa I, et al. **Eur J Cancer** 1996 Jun;32A(7):1166–70
Short-term local injections of transforming growth factor-beta 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats. Beaudreuil J, et al. **J Bone Miner Res** 1995 Jun;10(6):971–7
Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. Biskobing DM, et al. **J Bone Miner Res** 1995 Jul; 10(7):1025–32
Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. Brixen K, et al. **J Bone Miner Res** 1995 Dec;10(12):1865–74
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Hughes DE, et al. **J Bone Miner Res** 1995 Oct;10(10):1478–87
Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. Kanatani M, et al. **J Bone Miner Res** 1995 Nov; 10(11):1681–90
In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. Most W, et al. **J Bone Miner Res** 1995 Oct;10(10):1523–30
Nitric oxide: a cytokine-induced regulator of bone resorption. Ralston SH, et al. **J Bone Miner Res** 1995 Jul; 10(7):1040–9
Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells. Sunyer T, et al. **J Cell Biochem** 1996 Mar 15;60(4):469–83
Basic fibroblast growth factor inhibits osteoclast-like cell formation. Jimi E, et al. **J Cell Physiol** 1996 Aug; 168(2):395–402
Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat. Klapisz-Wolikow M, et al. **J Cell Physiol** 1996 May;167(2):359–68
Osteoclast ATP receptor activation leads to a transient decrease in intracellular pH. Yu H, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3051–8
Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. Arnett TR, et al. **J Endocrinol** 1996 Jun;149(3):503–8
Parathyroid hormone induces superoxide anion burst in the osteoclast: evidence for the direct instantaneous activation of the osteoclast by the hormone. Datta HK, et al. **J Endocrinol** 1996 May;149(2):269–75
Prostaglandin E2 stimulates osteoclast formation via endogenous IL-1 beta expressed through protein kinase A. Amano S, et al. **J Immunol** 1996 Mar 1;156(5):1931–6
Osteoclast inhibition by factors from cells associated with regenerative tissue. Rowe DJ, et al. **J Periodontol** 1996 Apr;67(4):414–21
Parathyroid hormone induces a rapid increase in the number of active osteoclasts by releasing histamine from mast cells. Nakamura M, et al. **Life Sci** 1996;58(21):1861–8
Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)
Signal transduction mechanisms of parathyroid hormone- and parathyroid hormone-related-peptide-stimulated osteoclast-like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1-3):161–5 (22 ref.)
Catecholamines modulate growth and differentiation of human preosteoclastic cells. Frediani U, et al. **Osteoporos Int** 1996;6(1):14–21
Differential effects of transforming growth factor-beta on osteoclast-like cell formation in mouse marrow culture: relation to the effect of zinc-chelating dipeptides. Yamaguchi M, et al. **Peptides** 1995;16(8):1483–8
Inhibitory effect of zinc-chelating dipeptide on parathyroid hormone-stimulated osteoclast-like cell formation in mouse marrow cultures: involvement of calcium signaling. Yamaguchi M, et al. **Peptides** 1995;16(4):629–33

ENZYMOLOGY

The tartrate-resistant purple acid phosphatase of bone osteoclasts—a protein phosphatase with multivalent substrate specificity and regulation. Andersson G, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:189–94 (28 ref.)
Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Li YP, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):813–21
The ubiquitous VA68 isoform of subunit A of the vacuolar H(+)-ATPase is highly expressed in human osteoclasts. van Hille B, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1108–13
Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. Wu LW, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):515–23
[3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase. Mattsson JP, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):98–106
Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. Bossard MJ, et al. **J Biol Chem** 1996 May 24;271(21):12517–24
Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. Brömme D, et al. **J Biol Chem** 1996 Jan 26;271(4):2126–32
Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. Li YP, et al. **J Bone Miner Res** 1995 Aug;10(8):1197–202
Prostaglandin E2 stimulates osteoclast formation via endogenous IL-1 beta expressed through protein kinase A. Amano S, et al. **J Immunol** 1996 Mar 1;156(5):1931–6
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Gelb BD, et al. **Science** 1996 Aug 30; 273(5279):1236–8

IMMUNOLOGY

Segregated localization of immunocompetent cells and osteoclasts in the periodontal ligament of the rat molar. Kawahara I, et al. **Arch Histol Cytol** 1995 Aug;58(3):345–55

METABOLISM

Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Brömme D, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):379–84
Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Fiorelli G, et al. **Bone** 1996 Mar;18(3):269–76
Osteoclasts are not the major source of interleukin-6 in mouse parietal bones. Holt I, et al. **Bone** 1996 Mar;18(3):221–6
Functions of the M-CSF receptor on osteoclasts. Yang S, et al. **Bone** 1996 Apr;18(4):355–60
Downregulation of colony-stimulating factor-1 (CSF-1) binding by CSF-1 in isolated osteoclasts. Amano H, et al. **Calcif Tissue Int** 1995 Nov;57(5):367–70
Immunocytochemical localization of vacuolar H+-ATPase and Cl—HCO3- anion exchanger (erythrocyte band-3 protein) in avian osteoclasts: effect of calcium-deficient diet on polar expression of the H+-ATPase pump. Bastani B,

et al. **Calcif Tissue Int** 1996 May;58(5):332–6

Osteoclasts and transforming growth factor–beta: estrogen–mediated isoform–specific regulation of production. Robinson JA, et al. **Endocrinology** 1996 Feb; 137(2):615–21

Osteoclast radical interactions: NADPH causes pulsatile release of NO and stimulates superoxide production. Silverton SF, et al. **Endocrinology** 1995 Nov;136(11):5244–7

Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase Alpha–mediated mechanism. Wada S, et al. **Endocrinology** 1996 Jan;137(1):312–20

Calcitonin receptor down–regulation relates to calcitonin resistance in mature mouse osteoclasts. Wada S, et al. **Endocrinology** 1996 Mar;137(3):1042–8

Effect of calcitonin, elevated calcium and extracellular matrices on superoxide anion production by rat osteoclasts. Datta HK, et al. **Exp Physiol** 1995 Sep;80(5):713–9

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. Drake FH, et al. **J Biol Chem** 1996 May 24;271(21):12511–6

Interleukin–1 alpha activates an NF–kappaB–like factor in osteoclast–like cells. Jimi E, et al. **J Biol Chem** 1996 Mar 1;271(9):4605–8

Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. Dodds RA, et al. **J Bone Miner Res** 1995 Nov;10(11):1666–80

Localized calcium signaling in multinucleated osteoclasts. Xia SL, et al. **J Cell Physiol** 1996 Apr;167(1):148–55

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. Zimolo Z, et al. **J Clin Invest** 1995 Nov;96(5):2277–83

Human osteoclast and giant cell differentiation: the apparent switch from nonspecific esterase to tartrate resistant acid phosphatase activity coincides with the in situ expression of osteopontin mRNA. Connor JR, et al. **J Histochem Cytochem** 1995 Dec;43(12):1193–201

Phosphate transport in osteoclasts: a functional and immunochemical characterization. Gupta A, et al. **Kidney Int** 1996 Apr;49(4):968–74

Role of microscopy in elucidating the mechanism and regulation of the osteoclast resorptive apparatus. Gay CV. **Microsc Res Tech** 1996 Feb 1;33(2):165–70 (74 ref.)

Recent advances in the ultrastructural assessment of osteoclastic resorptive functions. Sasaki T. **Microsc Res Tech** 1996 Feb 1;33(2):182–91

Resorption–cycle–dependent polarization of mRNAs for different subunits of V–ATPase in bone–resorbing osteoclasts. Laitala–Leinonen T, et al. **Mol Biol Cell** 1996 Jan;7(1):129–42

Estrogen enhances alpha v beta 3 integrin expression by avian osteoclast precursors via stabilization of beta 3 integrin mRNA. Li CF, et al. **Mol Endocrinol** 1995 Jul;9(7):805–13

Tetrodotoxin–sensitive fast Na+ current in embryonic chicken osteoclasts. Gáspár R Jr, et al. **Pflugers Arch** 1995 Aug;430(4):596–8

PATHOLOGY

Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Bushinsky DA. **Am J Physiol** 1996 Jul;271(1 Pt 2):F216–22

Osteoclastic giant cell tumor of the pancreas: an immunohistochemical study. Dizon MA, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):306–9

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S–61S (30 ref.)

Automatic–interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Roux JP, et al. **Bone** 1995 Aug; 17(2):153–6

Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Boyce BF, et al. **Endocrinology** 1995 Dec;136(12):5751–9

Antibody to beta3 integrin inhibits osteoclast–mediated bone resorption in the thyroparathyroidectomized rat. Crippes BA, et al. **Endocrinology** 1996 Mar;137(3):918–24

Mixed pleomorphic–osteoclast–like tumor of the pancreas. Light microscopical, immunohistochemical, and molecular biological studies. Gatteschi B, et al. **Int J Pancreatol** 1995 Oct;18(2):169–75

Cellular and molecular mechanisms of bone resorption. Teitelbaum SL, et al. **Miner Electrolyte Metab** 1995; 21(1–3):193–6 (18 ref.)

Proliferation of osteoclast–like giant cells in a metastatic bone tumor from stomach cancer: report of a case and analysis of the autopsy findings. Saeki T, et al. **Surg Today** 1996; 26(4):276–80

[Transitional–cell sarcomatoid carcinoma of the renal pelvis with osteoclast–type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70

Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats. Gallagher AC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E407–12

The bone–specific estrogen centchroman inhibits osteoclastic bone resorption in vitro. Hall TJ, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):662–8

Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Kameda T, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):515–9

Mammalian mature osteoclasts as estrogen target cells. Mano H, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):637–42

Macrophage–stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast–like cells. Kurihara N, et al. **Blood** 1996 May 1;87(9):3704–10

Ontogenesis of chondro/osteoclasts and their precursors in the mandibular condyle of the mouse. Lewinson D, et al. **Bone** 1995 Sep;17(3):293–9

Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Horowitz SM, et al. **Calcif Tissue Int** 1995 Oct;57(4):301–5

Tartrate resistant acid phosphatase in the serum of patients with larynx carcinoma—a marker of osteoclast activation. Jarkowska–Kozłowska J, et al. **Clin Chim Acta** 1995 Sep 15;240(2):213–9

Membrane–associated interleukin–1 on macrophages stimulated with Actinobacillus actinomycetemcomitans lipopolysaccharide induces osteoclastic bone resorption in vivo. Nishihara T, et al. **Cytobios** 1995;81(327):229–37

Osteoclast function is activated by osteoblastic cells through a mechanism involving cell–to–cell contact. Jimi E, et al. **Endocrinology** 1996 May;137(5):2187–90

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast–mediated resorption. Vitté C, et al. **Endocrinology** 1996 Jun;137(6):2324–33

Intercellular chatter: osteoblasts, osteoclasts and interleukin 6. Hofbauer LC, et al. **Eur J Endocrinol** 1996 Apr; 134(4):425–6

Modulation of osteoclast–activating factor activity of multiple myeloma bone marrow cells by different interleukin–1 inhibitors. Torcia M, et al. **Exp Hematol** 1996 Jul;24(8):868–74

Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption. Tanaka S, et al. **J Cell Biochem** 1995 Aug;58(4):424–35

Different calcium sensitivity in osteoclasts on glass and on bone and maintenance of cytoskeletal structures on bone in the presence of high extracellular calcium. Lakkakorpi PT, et al. **J Cell Physiol** 1996 Sep;168(3):668–77

The osteoclast clear zone is a specialized cell–extracellular matrix adhesion structure. Väänänen HK, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2729–32 (39 ref.)

Localized, tumor–associated osteolysis involves the recruitment and activation of osteoclasts. Clohisy DR, et al. **J Orthop Res** 1996 Jan;14(1):2–6

Regulation of bone cells by 1,25(OH)2D3. Ljunghall S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:11–3; discussion 37–43 (17 ref.)

A mechanism for sympathectomy–induced bone resorption in the middle ear. Sherman BE, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):569–81

Identification of an inducible surface molecule specific to fusing macrophages. Saginario C, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12210–4

Protein–tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Schmidt A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3068–73

Osteoblasts from the toothless (osteopetrotic) mutation in the rat are unable to direct bone resorption by normal osteoclasts in response to 1,25–dihydroxyvitamin D. Sundquist KT, et al. **Tissue Cell** 1995 Oct;27(5):569–74

[Osteoclast activating factor (OAF)] Kamihagi K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:756–8 (14 ref.) **(Jpn)**

RADIATION EFFECTS

The effect of cobalt–60 irradiation on bone marrow cellularity and alveolar osteoclasts. Tsay TP, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):185–95

ULTRASTRUCTURE

Cytoskeletal architecture of rat calvarial osteoclasts: microfilaments, and intermediate filaments, and nuclear matrix as demonstrated by detergent perfusion. Watanabe H, et al. **Anat Rec** 1995 Oct;243(2):165–74

VIROLOGY

Viral behavior of paracrystalline inclusions in osteoclasts of Paget's disease of bone. Abe S, et al. **Ultrastruct Pathol** 1995 Nov–Dec;19(6):455–61

OSTEOCYTES

CHEMISTRY

Spatial distribution of CD44 and hyaluronan in the proximal tibia of the growing rat. Noonan KJ, et al. **J Orthop Res** 1996 Jul;14(4):573–81

CYTOLOGY

Mouse Meckel's cartilage chondrocytes evoke bone–like matrix and further transform into osteocyte–like cells in culture. Ishizeki K, et al. **Anat Rec** 1996 May;245(1):25–35

Adhesive properties of isolated chick osteocytes in vitro. Aarden EM, et al. **Bone** 1996 Apr;18(4):305–13

Immunogold localization of beta 1–integrin in bone: effect of glucocorticoids and insulin–like growth factor I on integrins and osteocyte formation. Gohel AR, et al. **J Histochem Cytochem** 1995 Nov;43(11):1085–96

METABOLISM

Osteocytic expression of mRNA for c–fos and IGF–I: an immediate early gene response to an osteogenic stimulus. Lean JM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E937–45

Sequential analysis of gene expression after an osteogenic stimulus: c–fos expression is induced in osteocytes. Inaoka T, et al. **Biochem Biophys Res Commun** 1995 Dec 5; 217(1):264–70

Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts—correlation with prostaglandin upregulation. Klein–Nulend J, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):640–8

An ultrastructural and immunogold localization study of proteoglycans associated with the osteocytes of fetal bone in osteogenesis imperfecta. Sarathchandra P, et al. **Calcif Tissue Int** 1996 Jun;58(6):435–42

Mechanically induced periosteal bone formation is paralleled by the upregulation of collagen type one mRNA in osteocytes as measured by in situ reverse transcript–polymerase chain reaction. Sun YQ, et al. **Calcif Tissue Int** 1995 Dec;57(6):456–62

PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. Fermor B, et al. **J Bone Miner Res** 1995 Dec;10(12):1935–43

PATHOLOGY

Bone metaplasia of urothelial mucosa: an unusual biological phenomenon causing kidney stones. Fernandez–Conde M, et al. **Bone** 1996 Mar;18(3):289–91

Microdamage and osteocyte–lacuna strain in bone: a microstructural finite element analysis. Prendergast PJ, et al. **J Biomech Eng** 1996 May;118(2):240–6

PHYSIOLOGY

Pulsating fluid flow increases prostaglandin production by cultured chicken osteocytes—a cytoskeleton–dependent process. Ajubi NE, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):62–8

A case for bone canaliculi as the anatomical site of strain generated potentials. Cowin SC, et al. **J Biomech** 1995 Nov; 28(11):1281–97

Loading of cells and a possible upper limit of load response with respect to strain energy density. McDonald F, et al. **J Biomed Mater Res** 1995 Dec;29(12):1577–85

ULTRASTRUCTURE

Histochemical demonstration of DNA in osteocytes from dinosaur bones. Pawlicki R. **Folia Histochem Cytobiol** 1995; 33(3):183–6

A case for bone canaliculi as the anatomical site of strain generated potentials. Cowin SC, et al. **J Biomech** 1995 Nov; 28(11):1281–97

OSTEOGENESIS

Bone formation in rabbit cancellous bone defects filled with bioactive glass granules. Heikkilä JT, et al. **Acta Orthop Scand** 1995 Oct;66(5):463–7

Osteoinductive substances in middle ear surgery. Heumann H, et al. **Am J Otol** 1995 Mar;16(2):226–30

Successful revision of failed cochlear implants in severe labyrinthitis ossificans. Telian SA, et al. **Am J Otol** 1996 Jan;17(1):53–60

Accessory ossifications in the ulno–carpal wrist region. Bade H, et al. **Anat Anz** 1996 Jun;178(3):263–8

The urokinase plasminogen activator (u–PA) and its inhibitor (PAI–1) in embryo–fetal bone formation in the human: an immunohistochemical study. Häckel C, et al. **Anat Embryol (Berl)** 1995 Oct;192(4):363–8

Transient local presence of nerve fibers at onset of secondary ossification in the rat knee joint. Hedberg A, et al. **Anat Embryol (Berl)** 1995 Sep;192(3):247–55

Localization of gene expression during endochondral ossification. Hillarby MC, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:263–6

Role of Krox–20 in endochondral bone formation. Levi G, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:288–91

Comparative study of the osteoinductive properties of bioceramic, coral and processed bone graft substitutes. Begley CT, et al. **Biomaterials** 1995 Oct;16(15):1181–5

Effects of different osteopromotive membrane porosities on experimental bone neogenesis in rats. Zellin G, et al. **Biomaterials** 1996 Apr;17(7):695–702

Osteoneogenesis and its influencing factors during treatment with the Ilizarov method. Fink B, et al. **Clin Orthop** 1996 Feb;(323):261–72

Bone morphogenetic protein–induced heterotopic bone in osteopetrosis. Miyazawa K, et al. **Clin Orthop** 1996 Mar; (324):259–68

A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone

formation. Alini M, et al. **Dev Biol** 1996 May 25; 176(1):124–32

Chondrocyte apoptosis in endochondral ossification of chick sterna. Gibson GJ, et al. **Dev Dyn** 1995 Aug;203(4):468–76

Mandibular distraction osteogenesis as first step in the early treatment of severe dysgnathia in childhood. Klein C, et al. **Fortschr Kieferorthop** 1996 Feb;57(1):46–54 **(Eng, Ger)**

Decreased mitogenic and osteogenic responsiveness of calvarial osteoblasts isolated from aged rats to basic fibroblast growth factor. Kato H, et al. **Gerontology** 1995; 41 Suppl 1:20–7

Effect of particulate porous hydroxyapatite on osteoinduction of demineralized bone autografts in experimental reconstruction of the rat mandible. Redondo LM, et al. **Int J Oral Maxillofac Surg** 1995 Dec;24(6):445–8

Differentiation potential of conditionally immortalized mesenchymal progenitor cells from adult marrow of a H-2Kb–tsA58 transgenic mouse. Dennis JE, et al. **J Cell Physiol** 1996 Jun;167(3):523–38

Cartilage–bone replacement in endochondral ossification of mandibular condylar heads in young beagle dogs. Sasaki T, et al. **J Electron Microsc (Tokyo)** 1996 Jun;45(3):213–22

Osteoplastic changes in attic cholesteatoma. Hoshino T, et al. **J Laryngol Otol** 1995 Aug;109(8):703–6

Mandibular alveolar ridge augmentation in the dog using distraction osteogenesis. Block MS, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):309–14

Mandibular lengthening by distraction osteogenesis using osseointegrated implants and an intraoral device: a preliminary report. Sawaki Y, et al. **J Oral Maxillofac Surg** 1996 May;54(5):594–600

Induction of bone by a demineralized bone matrix gel: a study in a rat femoral defect model. Feighan JE, et al. **J Orthop Res** 1995 Nov;13(6):881–91

Effect of Er:YAG laser holes on osteoinduction in demineralized rat calvarial allografts. O'Donnell RJ, et al. **J Orthop Res** 1996 Jan;14(1):108–13

Involvement of platelets in stimulating osteogenic activity. Slater M, et al. **J Orthop Res** 1995 Sep;13(5):655–63

Recorticalization after bifocal internal bone transport in the double-plated sheep femur. Windhager R, et al. **J Orthop Res** 1996 Jan;14(1):94–101

The histopathology of injury to the accessory malleolar ossification center. Ogden JA, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):61–2

Human demineralized freeze-dried bone: inadequate induced bone formation in athymic mice. A preliminary report. Becker W, et al. **J Periodontol** 1995 Sep;66(9):822–8

In vitro comparison of aged and young osteogenic and hemopoietic bone marrow stem cells and their derivative colonies. Dodson SA, et al. **J Periodontol** 1996 Mar; 67(3):184–96

Sterilization of partially demineralized bone matrix: the effects of different sterilization techniques on osteogenetic properties. Hallfeldt KK, et al. **J Surg Res** 1995 Nov; 59(5):614–20

Osteogenic potential of murine osteosarcoma cells: comparison of bone-specific gene expression in in vitro and in vivo conditions. Gerstenfeld LC, et al. **Lab Invest** 1996 May;74(5):895–906

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141–64 (112 ref.)

Bone tissue engineering. Crane GM, et al. **Nat Med** 1995 Dec;1(12):1322–4

Repair of calvarial defects with flap tissue: role of bone morphogenetic proteins and competent responding tissues. Khouri RK, et al. **Plast Reconstr Surg** 1996 Jul;98(1):103–9

Cortical defect of the distal fibula: variant of ossification. Ehara S, et al. **Radiology** 1995 Nov;197(2):447–9

PTH/PTHrP receptor in early development and Indian hedgehog–regulated bone growth [see comments] Lanske B, et al. **Science** 1996 Aug 2;273(5275):663–6. Comment in: Science 1996 Aug 2;273(5275):579.

Putting the brakes on bone growth [news; comment] Roush W. **Science** 1996 Aug 2;273(5275):579. Comment on: Science 1996 Aug 2;273(5275):613–22. Comment on: Science 1996 Aug 2;273(5275):663–6.

Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein [see comments] Vortkamp A, et al. **Science** 1996 Aug 2;273(5275):613–22. Comment in: Science 1996 Aug 2;273(5275):579.

Interactive effects of alcohol and diabetes during pregnancy on the rat fetus. Lin Y, et al. **Teratog Carcinog Mutagen** 1995;15(3):147–53

Orthotopic fetal bone allografts in primates: histologic outcome in three recipient baboons (Papio ursinus). Ripamonti U, et al. **Transplant Proc** 1996 Jun;28(3):1968–70

Effect of hyperbaric oxygenation on bone in HEBP-induced rachitic rats. Makihara N, et al. **Undersea Hyperb Med** 1996 Mar;23(1):1–4

[Osteoblast-like cells cultured in vitro] Rao H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):301–4 **(Eng, Chi)** (Abstr.)

[Advances in the understanding of the etiopathogenesis of non syndromic craniostenoses and therapeutic approaches] Czorny A, et al. **Ann Chir Plast Esthet** 1995 Dec; 40(6):657–65 (22 ref.) (Eng. Abstr.) **(Fre)**

[Basics of Pauwels' theory of the functional adaptation of bones] Kummer B. **Orthopade** 1995 Sep;24(5):387–93 (Eng. Abstr.) **(Ger)**

[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):205–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Osteoneogenesis in callus and epiphyseal distraction] Fink B, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec; 133(6):501–6 (Eng. Abstr.) **(Ger)**

[Bone formation and mechanical properties of the cancellous bone defect site filled with hydroxyapatite granules] Kuroda T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct; 69(10):1037–49 (Eng. Abstr.) **(Jpn)**

[Biochemical markers of bone formation in osteoporosis] Miki T, et al. **Rinsho Byori** 1996 May;44(5):410–4 (Eng. Abstr.) **(Jpn)**

[Energy metabolism of lymphocytes during bone tissue regeneration] Osipenko AV, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):310–2 **(Rus)**

[Reparative osteogenesis during the treatment of mandibular fractures under different medical geographic conditions] Ruzin GP. **Stomatologiia (Mosk)** 1995;74(4):19–22 (Eng. Abstr.) **(Rus)**

[The effect of the ossification processes of the hyoid bone and laryngeal cartilages on the formation of injuries to the organs of the neck] Khokhlov VD. **Sud Med Ekspert** 1996 Jan–Mar;39(1):9–12 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Bone graft proteins influence osteoconduction. A titanium chamber study in rats. Aspenberg P, et al. **Acta Orthop Scand** 1996 Aug;67(4):377–82

Growth factors: possible new clinical tools. A review. Lind M. **Acta Orthop Scand** 1996 Aug;67(4):407–17 (111 ref.)

The effects of smokeless tobacco extract on bone nodule formation and mineralization by chick osteoblasts in vitro. Henderson JS, et al. **Arch Oral Biol** 1995 Jul;40(7):615–21

The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Emkey RD, et al. **Arthritis Rheum** 1996 Feb;39(2):277–82

Effect of recombinant human granulocyte colony-stimulating factor (rh G-CSF) on rat bone: inhibition of bone formation at the endosteal surface of vertebra and tibia. Soshi S, et al. **Calcif Tissue Int** 1996 May;58(5):337–40

Dexamethasone enhances the osteogenic effects of fluoride in human TE85 osteosarcoma cells in vitro. Takada J, et al. **Calcif Tissue Int** 1996 May;58(5):355–61

Induction of osteogenesis by bovine platelet transforming growth factor-beta (TGF-beta) in adult mouse femur. Sun Y, et al. **Chin Med J (Engl)** 1995 Dec;108(12):914–8

Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Bostrom M, et al. **Clin Orthop** 1996 Jun; (327):272–82

Two distinctive BMP-carriers induce zonal chondrogenesis and membranous ossification, respectively; geometrical factors of matrices for cell-differentiation. Kuboki Y, et al. **Connect Tissue Res** 1995;32(1–4):219–26

Stimulation of bone formation in the expanding mid-palatal suture by transforming growth factor-beta 1 in the rat. Sawada M, et al. **Eur J Orthod** 1996 Apr;18(2):169–79

The influence of transforming growth factor beta 1 on the development of embryonic mouse long bones. Scheijmans CM, et al. **Eur J Orthod** 1996 Jun;18(3):237–43

Influence of lead on mineralization during bone growth. Hamilton JD, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):265–71

Effects of sublethal metal ion concentrations on osteogenic cells derived from bone marrow stromal cells. Thompson GJ, et al. **J Appl Biomater** 1995 Winter;6(4):249–58

Local delivery of indomethacin by a polyorthoester inhibits reossification of experimental bone defects. Solheim E, et al. **J Biomed Mater Res** 1995 Sep;29(9):1141–6

Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells. Takada J, et al. **J Bone Miner Res** 1995 Oct; 10(10):1512–22

The short term effects of tamoxifen on bone turnover in older women. Kenny AM, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3287–91

Transforming growth factor-beta 1 in a guanidine-extracted demineralized bone matrix carrier rapidly closes a rabbit critical calvarial defect. Moxham JP, et al. **J Otolaryngol** 1996 Apr;25(2):82–7

Evaluation of a novel osteogenic factor, bone cell stimulating substance, in a rabbit cranial defect model. Ashby ER, et al. **Plast Reconstr Surg** 1996 Sep;98(3):420–6

[Characteristics and osteoinductive activity of bone morphogenetic protein (BMP) encapsulated with poly (DL-lactide-co-glycolide)] Isobe M. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):506–12 (Eng. Abstr.) **(Jpn)**

[Effect of panangin on regenerative processes in tissues during lengthening of the extremities] Bazarnyĭ VV, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):308–9 **(Rus)**

[Osteogenesis during the correction of burns with alpha-tocopherol] Koveshnikov VG, et al. **Morfologiia** 1994 Jul–Dec;107(7–12):67–75 (Eng. Abstr.) **(Rus)**

[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology] Moiseenko VM, et al. **Vopr Onkol** 1996;42(2):17–30 (93 ref.) **(Rus)**

GENETICS

Sequential analysis of gene expression after an osteogenic stimulus: c-fos expression is induced in osteocytes. Inaoka T, et al. **Biochem Biophys Res Commun** 1995 Dec 5; 217(1):264–70

Thrombospondin-4 is expressed by early osteogenic tissues in the chick embryo. Tucker RP, et al. **Dev Dyn** 1995 Aug; 203(4):477–90

Mechanical stimulation by intermittent hydrostatic compression promotes bone-specific gene expression in vitro. Roelofsen J, et al. **J Biomech** 1995 Dec; 28(12):1493–503

Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Fang J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5753–8

IMMUNOLOGY

Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. Fukunaga T, et al. **Acta Orthop Scand** 1995 Dec;66(6):557–60

PHYSIOLOGY

Periosteal insulin-like growth factor I and bone formation. Changes during tibial lengthening in rabbits. Schumacher B, et al. **Acta Orthop Scand** 1996 Jun;67(3):237–41

High-resolution CT findings in the development of the sphenooccipital synchondrosis. Okamoto K, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):117–20

Nitric oxide is an early mediator of the increase in bone formation by mechanical stimulation. Fox SW, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E955–60

Osteocytic expression of mRNA for c-fos and IGF-I: an immediate early gene response to an osteogenic stimulus. Lean JM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E937–45

The effect of drilling and soft tissue grafting across open growth plates. A histologic study. Stadelmaier DM, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):431–5

Homeobox gene expression during bone formation induced by BMP. Iimura T, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:274–7

Theory of osteogenesis behavior based on calcium diffusion theory. Yokobori AT Jr, et al. **Biomed Mater Eng** 1995; 5(4):209–17

The insulin-like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S–98S (32 ref.)

Intermittent compression stimulates cartilage mineralization. van't Veen SJ, et al. **Bone** 1995 Nov;17(5):461–5

Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro. Wildburger R, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):693–8

Morphological aspects of periostal osteogenesis. Baltadjiev G. **Folia Med (Plovdiv)** 1995;37(4A Suppl):20

Transgenic mice with targeted inactivation of the Col2 alpha 1 gene for collagen II develop a skeleton with membranous and periosteal bone but no endochondral bone. Li SW, et al. **Genes Dev** 1995 Nov 15;9(22):2821–30

Localization of collagens and alkaline phosphatase activity during mineralization and ossification of human first rib cartilage. Claassen H, et al. **Histochem Cell Biol** 1996 Mar; 105(3):213–9

Differential expression of neural cell adhesion molecule (NCAM) during osteogenesis and secondary chondrogenesis in the embryonic chick. Fang J, et al. **Int J Dev Biol** 1995 Jun;39(3):519–28

Time-dependent expression of bone sialoprotein fragments in osteogenesis induced by bone morphogenetic protein. Kobayashi D, et al. **J Biochem (Tokyo)** 1996 Mar; 119(3):475–81

Polysulphone inhibits final differentiation steps of osteogenesis in vitro. van Loon JJ, et al. **J Biomed Mater Res** 1995 Sep;29(9):1155–63

The vascular supply to bone in distraction osteoneogenesis: an experimental study. Mosheiff R, et al. **J Bone Joint Surg Br** 1996 May;78(3):497–8

Decreased bone formation and increased mineral dissolution during acute fasting in young women. Grinspoon SK, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3628–33

Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. Jilka RL, et al. **J Clin Invest** 1996 Apr 1; 97(7):1732–40

Ovariectomy decreases osteogenetic activity in rat bone. Goseki MS, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb; 42(1):55–67

Acceleration of experimental endochondral ossification by biophysical stimulation of the progenitor cell pool. Aaron RK, et al. **J Orthop Res** 1996 Jul;14(4):582–9

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975–80 (24 ref.)

Distribution and expression of cartilage oligomeric matrix protein and bone sialoprotein show marked changes during rat femoral head development. Shen Z, et al. **Matrix Biol** 1995 Dec;14(9):773–81

Characterization of the phosphatidylinositol-specific phospholipase C-released form of rat osseous plate alkaline phosphatase and its possible significance on endochondral

ossification. Pizzuro JM, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):121–9

Histologic and biochemical analysis of osteogenic capacity of vascularized periosteum. Ishida H, et al. **Plast Reconstr Surg** 1996 Mar;97(3):512–8

Potential mechanism of estrogen–mediated decrease in bone formation: estrogen increases production of inhibitory insulin–like growth factor–binding protein–4. Kassem M, et al. **Proc Assoc Am Physicians** 1996 Mar;108(2):155–64

[Morphologic studies of the beginning of vascularization and ossification in human thyroid cartilage] Claassen H. **HNO** 1995 Sep;43(9):532–6 (Eng. Abstr.) **(Ger)**

[Relationship between time of ossification center appearance and hip joint development stage using Graf's method] Pyka P, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(2):157–61 (Eng. Abstr.) **(Pol)**

[Osteogenesis and angiogenesis in distraction osteosynthesis] Shevtsov VI, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):95–8 **(Rus)**

OSTEOGENESIS IMPERFECTA

see related
DENTINOGENESIS IMPERFECTA

Total intravenous anaesthesia for patients with osteogenesis imperfecta [letter] Baines D. **Paediatr Anaesth** 1995;5(2):144

CLASSIFICATION

A judicial comment on temporary brittle bone disease [letter; comment] Lynch MA. **Arch Dis Child** 1995 Oct;73(4):379 . Comment on: Arch Dis Child 1995 Feb;72(2):169–71; discussion 171–6.

The prognosis for walking in osteogenesis imperfecta. Daly K, et al. **J Bone Joint Surg Br** 1996 May;78(3):477–80

COMPLICATIONS

Osteogenesis imperfecta and hearing loss. Verstreken M, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):91–8 (47 ref.)

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Repeat cardiac operation in a patient with osteogenesis imperfecta [letter; comment] Cusimano RJ. **Ann Thorac Surg** 1996 Apr;61(4):1294. Comment on: Ann Thorac Surg 1995 Nov;60(5):1395–7. Comment on: Ann Thorac Surg 1995 Nov;60(5):1397–9. Comment on: Ann Thorac Surg 1995 Nov;60(5):1439–43.

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439–43 (36 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Algodystrophy in conjunction with van der Hoeve's syndrome. Chérié–Lignière G, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):361–5

Multiple flexion–stress vertebral end–plate fractures. An osteogenesis imperfecta presentation. Frater CJ, et al. **Clin Nucl Med** 1995 Dec;20(12):1055–7

Severe 5–fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta [letter] Beuzeboc P, et al. **Eur J Cancer** 1996 Feb;32A(2):369–70

The prognosis for walking in osteogenesis imperfecta. Daly K, et al. **J Bone Joint Surg Br** 1996 May;78(3):477–80

Orthognathic surgery in osteogenesis imperfecta: a case report with management considerations. Ormiston IW, et al. **J Craniomaxillofac Surg** 1995 Aug;23(4):261–5

Large cementifying fibroma in a patient with osteogenesis imperfecta. Shibahara T, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):1016–9; discussion 1019–20

Scanning electron microscopy of teeth in osteogenesis imperfecta type I. Lygidakis NA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):567–72

Malignant hyperthermia susceptibility in patients with osteogenesis imperfecta [letter] Peluso A, et al. **Paediatr Anaesth** 1995;5(6):398–9

Hyperplastic callus formation in both femurs in osteogenesis imperfecta. Kutsumi K, et al. **Skeletal Radiol** 1996 May; 25(4):384–7

[Severe 5–fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Osteogenesis imperfecta, non–accidental injury, and temporary brittle bone disease [letter; comment] Blumenthal I. **Arch Dis Child** 1996 Jan;74(1):91. Comment on: Arch Dis Child 1995 Feb;72(2):169–71; discussion 171–6.

Studies of collagen synthesis and structure in the differentiation of child abuse from osteogenesis imperfecta. Steiner RD, et al. **J Pediatr** 1996 Apr;128(4):542–7

Osteogenesis Imperfecta and non–accidental injury: problems in diagnosis and management. Kasim MS, et al. **Med J Malaysia** 1995 Jun;50(2):170–5

GENETICS

Tracing the pathway between mutation and phenotype in osteogenesis imperfecta: isolation of mineralization–specific genes. Culbert AA, et al. **Am J Med Genet** 1996 May 3; 63(1):167–74

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161–6 (34 ref.)

Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. Orioli IM, et al. **Am J Med Genet** 1995 Nov 6;59(2):209–17

Substitution of arginine for glycine at position 154 of the alpha 1 chain of type I collagen in a variant of osteogenesis imperfecta: comparison to previous cases with the same mutation. Zhuang J, et al. **Am J Med Genet** 1996 Jan 11; 61(2):111–16

Substitutions of aspartic acid for glycine–220 and of arginine for glycine–664 in the triple helix of the pro alpha 1(I) chain of type I procollagen produce lethal osteogenesis imperfecta and disrupt the ability of collagen fibrils to incorporate crystalline hydroxyapatite. Culbert AA, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):815–20

Gly802Asp substitution in the pro alpha 2(I) collagen chain in a family with recurrent osteogenesis imperfecta due to paternal mosaicism. Lund AM, et al. **Eur J Hum Genet** 1996;4(1):39–45

Clinical signs of mosaicism [letter; comment] Méhes K, et al. **Eur J Pediatr** 1995 Aug;154(8):690. Comment on: Eur J Pediatr 1995 Feb;154(2):123–9.

Deletion of a Gly–Pro–Pro repeat in the pro alpha2(I) chain of procollagen I in a family with dominant osteogenesis imperfecta type IV. Lund AM, et al. **Hum Genet** 1996 Mar; 97(3):287–90

Splice site mutation causing deletion of exon 21 sequences from the pro alpha 2(I) chain of type I collagen in a patient with severe dentinogenesis imperfecta but very mild osteogenesis imperfecta. Nicholls AC, et al. **Hum Mutat** 1996;7(3):219–27

Mutation in the carboxy–terminal propeptide of the Pro alpha 1(I) chain of type I collagen in a child with severe osteogenesis imperfecta (OI type III): possible implications for protein folding. Oliver JE, et al. **Hum Mutat** 1996; 7(4):318–26

Direct sequencing of PCR products derived from cDNAs for the pro alpha 1 and pro alpha 2 chains of type I procollagen as a screening method to detect mutations in patients with osteogenesis imperfecta. Zhuang J, et al. **Hum Mutat** 1996;7(2):89–99

A 931 + 2T−>C transition in one COL1A2 allele causes exon 16 skipping in PRO alpha 2(I) mRNA and produces moderately severe OI. Zolezzi F, et al. **Hum Mutat** 1995; 6(3):268–71

Finding relevant biomolecular features. Hunter L, et al. **Ismb** 1993;1:190–7

Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IB. Molecules containing the shortened alpha2(I) chains show differential incorporation into the bone and skin extracellular matrix. Mundlos S, et al. **J Biol Chem** 1996 Aug 30; 271(35):21068–74

Bone fragility in transgenic mice expressing a mutated gene for type I procollagen (COL1A1) parallels the age–dependent phenotype of human osteogenesis imperfecta. Pereira RF, et al. **J Bone Miner Res** 1995 Dec; 10(12):1837–43

Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. Redford–Badwal DA, et al. **J Clin Invest** 1996 Feb 15; 97(4):1035–40

Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen. Cole WG, et al. **J Med Genet** 1996 Mar;33(3):193–6

Absence of mutations in the promoter of the COL1A1 gene of type I collagen in patients with osteogenesis imperfecta type I. Willing MC, et al. **J Med Genet** 1995 Sep; 32(9):697–700

Intrafamilial variable expressivity of osteogenesis imperfecta due to mosaicism for a lethal G382R substitution in the COL1A1 gene. Cohen–Solal L, et al. **Mol Cell Probes** 1996 Jun;10(3):219–25

METABOLISM

Substitutions of aspartic acid for glycine–220 and of arginine for glycine–664 in the triple helix of the pro alpha 1(I) chain of type I procollagen produce lethal osteogenesis imperfecta and disrupt the ability of collagen fibrils to incorporate crystalline hydroxyapatite. Culbert AA, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):815–20

Mineral changes in a transgenic mouse model for osteogenesis imperfecta. Cassella JP, et al. **Br J Biomed Sci** 1996 Jun; 53(2):108–15

An ultrastructural and immunogold localization study of proteoglycans associated with the osteocytes of fetal bone in osteogenesis imperfecta. Sarathchandra P, et al. **Calcif Tissue Int** 1996 Jun;58(6):435–42

Type I collagen synthesis by skin fibroblasts from 17 patients with osteogenesis imperfecta type III. Pocock AE, et al. **Clin Chim Acta** 1995 Dec 15;243(1):53–72

MORTALITY

Life expectancy in osteogenesis imperfecta. Paterson CR, et al. **BMJ** 1996 Feb 10;312(7027):351

PATHOLOGY

Vertebral body shape as a predictor of spinal deformity in osteogenesis imperfecta. Ishikawa S, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):212–9

Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age. Fedarko NS, et al. **J Bone Miner Res** 1995 Nov;10(11):1705–12

Bone mineralization in an osteogenesis imperfecta mouse model studied by small–angle x–ray scattering. Fratzl P, et al. **J Clin Invest** 1996 Jan 15;97(2):396–402

Immunoreactivity of tenascin–C in dentin matrix in dentinogenesis imperfecta associated with osteogenesis imperfecta. Lukinmaa PL, et al. **J Dent Res** 1996 Jan; 75(1):581–7

[The establishment of osteogenesis imperfecta for personal identification] Osipenkova TK, et al. **Sud Med Ekspert** 1996 Apr–Jun;39(2):21–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. Fedarko NS, et al. **J Bone Miner Res** 1995 Jul;10(7):1122–9

[Evaluation of bone mineral density in selected regions of the skeleton in children with osteogenesis imperfecta and hypophosphatemic rickets] Olszaniecka M, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):32–4 **(Pol)**

SURGERY

Problems caused by osteogenesis imperfecta. Walker RW, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):182

Treatment of deformity of the lower limb in adults who have osteogenesis imperfecta. Ring D, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):220–5

Caudal block in a child with osteogenesis imperfecta, type II [letter] Barros F. **Paediatr Anaesth** 1995;5(3):202–3

[Combined total endoprosthesis implantation in bilateral femoral neck fracture with osteogenesis imperfecta tarda] Templin F, et al. **Unfallchirurg** 1996 Jun;99(6):454–6 (Eng. Abstr.) **(Ger)**

THERAPY

Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. Wang Q, et al. **J Clin Invest** 1996 Jan 15;97(2):448–54

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. Antoniazzi F, et al. **J Pediatr** 1996 Sep;129(3):432–9

ULTRASONOGRAPHY

Prenatal diagnosis of osteogenesis imperfecta congenita by ultrasonography. Chen FP, et al. **J Formos Med Assoc** 1996 May;95(5):386–9

[Significance of the length of the fetal femur] Pál A, et al. **Orv Hetil** 1995 Oct 29;136(44):2399–400 (Eng. Abstr.) **(Hun)**

OSTEOLYSIS

Foreign–body reaction and the course of osteolysis after polyglycolide implants for fracture fixation: experimental study in sheep. Weiler A, et al. **J Bone Joint Surg Br** 1996 May;78(3):369–76

Localized, tumor–associated osteolysis involves the recruitment and activation of osteoclasts. Clohisy DR, et al. **J Orthop Res** 1996 Jan;14(1):2–6

CLASSIFICATION

Classification of bone loss in total hip arthroplasty. Masri BA, et al. **Instr Course Lect** 1996;45:199–208

COMPLICATIONS

[Tooth mobility disclosing an osteolytic process] Gharbi–Guesguez L, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):368–71 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Acute radiocarpal collapse of unknown aetiology. ten Broeke RH, et al. **J Hand Surg [Br]** 1996 Jun;21(3):388–90

DRUG THERAPY

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629–36 (81 ref.)

Intravenous pamidronate in patients with tumor–induced osteolysis: a biochemical dose–response study. Body JJ,

et al. **J Bone Miner Res** 1995 Aug;10(8):1191–6

Management of myeloma with bisphosphonates [editorial; comment] Bataille R. **N Engl J Med** 1996 Feb 22; 334(8):529–30. Comment on: N Engl J Med 1996 Feb 22;334(8):488–93.

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments] Berenson JR, et al. **N Engl J Med** 1996 Feb 22;334(8):488–93. Comment in: N Engl J Med 1996 Feb 22;334(8):529–30.

[Role of bisphosphonates in the treatment of tumoral osteolysis] Claudepierre P, et al. **Ann Med Interne (Paris)** 1995;146(5):325–7 (38 ref.) **(Fre)**

ETIOLOGY

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629–36 (81 ref.)

Unpredictable progression of osteolysis following cementless hip arthroplasty. 24 femoral components followed for 6–10 years. Learmonth ID, et al. **Acta Orthop Scand** 1996 Jun; 67(3):245–8

Bisphosphonate inhibition of bone resorption induced by particulate biomaterial–associated macrophages. Pandey R, et al. **Acta Orthop Scand** 1996 Jun;67(3):221–8

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Production of parathyroid hormone–related peptide in a patient with acute lymphocytic leukemia with extensive osteolytic lesions and hypercalcemia [letter] Miyamura T, et al. **Am J Hematol** 1995 Oct;50(2):150–1

A 69–year–old woman with thigh pain 21 years after total hip arthroplasty. McGrory BJ, et al. **Am J Orthop** 1995 Oct;24(10):785–9

Osteolysis, wear and failure of a migrating acetabular component. A roentgen stereophotogram case report. Onsten I, et al. **Arch Orthop Trauma Surg** 1995;114(5):267–8

Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Samlaska CP, et al. **Br J Dermatol** 1995 Dec;133(6):972–7 (61 ref.)

Effect of porous–coating configuration on tibial osteolysis after total knee arthroplasty. Whiteside LA. **Clin Orthop** 1995 Dec;(321):92–7

The role of polyethylene properties in osteolysis after total hip replacement. Gómez–Barrena E, et al. **Instr Course Lect** 1996;45:187–97 (80 ref.)

Increasing prevalence of femoral lysis in cementless total hip arthroplasty. Smith E, et al. **J Arthroplasty** 1995 Aug; 10(4):407–12

Osteolysis of the acetabulum associated with a bipolar hemiarthroplasty. A late complication. Bose WJ, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1733–5

The posterior stabilized total knee prothesis. Assessment of polyethylene damage and osteolysis after a ten–year–minimum follow–up [letter] Schmalzried TP. **J Bone Joint Surg Am** 1996 Sep;78(9):1446–7

Osteolytic bone lesions in a patient with idiopathic myelofibrosis and bronchial carcinoma. Clutterbuck DJ, et al. **J Clin Pathol** 1995 Sep;48(9):867–8

Tumor osteolysis in osteopetrotic mice. Clohisy DR, et al. **J Orthop Res** 1995 Nov;13(6):892–7

Multifocal osteolysis following limb–sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)

[The assessment of solitary osteolytic bone lesions in breast carcinoma. A special case report] Mose S, et al. **Strahlenther Onkol** 1996 Jan;172(1):43–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Bone lesions in patients with multiple myeloma] Umeda M, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1070–4 (5 ref.) **(Jpn)**

[Effect of implantation errors on increased osteolysis in cemented hip arthroplasty] Paściak M, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):301–5 (Eng. Abstr.) **(Pol)**

GENETICS

Conductive hearing loss caused by hereditary incus necrosis: a study of familial expansile osteolysis. Esselman GH, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):639–41

METABOLISM

E–cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Mbalaviele G, et al. **Cancer Res** 1996 Sep 1;56(17):4063–70

PATHOLOGY

E–cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Mbalaviele G, et al. **Cancer Res** 1996 Sep 1;56(17):4063–70

The potential role of fibroblasts in periprosthetic osteolysis: fibroblast response to titanium particles. Yao J, et al. **J Bone Miner Res** 1995 Sep;10(9):1417–27

Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. Clohisy DR, et al. **J Orthop Res** 1996 May; 14(3):396–402

Osteolysis: a generic problem. Bauer TW, et al. **Orthopedics** 1995 Sep;18(9):791–4

Conductive hearing loss caused by hereditary incus necrosis: a study of familial expansile osteolysis. Esselman GH, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):639–41

PHYSIOPATHOLOGY

Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Maloney WJ, et al. **Instr Course Lect** 1996;45:171–82 (85 ref.)

PREVENTION & CONTROL

Bone cement as a seal protecting the femur from the ingress of particulate debris and femoral osteolysis. Harris WH, et al. **Instr Course Lect** 1996;45:183–5 (23 ref.)

RADIOGRAPHY

A 69–year–old woman with thigh pain 21 years after total hip arthroplasty. McGrory BJ, et al. **Am J Orthop** 1995 Oct;24(10):785–9

Effect of component fixation method on osteolysis in total knee arthroplasty. Ezzet KA, et al. **Clin Orthop** 1995 Dec; (321):86–91

Screw osteolysis after cementless total knee replacement. Lewis PL, et al. **Clin Orthop** 1995 Dec;(321):173–7

Catastrophic osteolysis in total knee replacement. A report of 17 cases. Robinson EJ, et al. **Clin Orthop** 1995 Dec; (321):98–105

Increasing incidence of femoral osteolysis in association with uncemented Harris–Galante total hip arthroplasty. A follow–up report. Maloney WJ, et al. **J Arthroplasty** 1996 Feb;11(2):130–4

Osteolysis in cemented versus cementless acetabular components. Nayak NK, et al. **J Arthroplasty** 1996 Feb; 11(2):135–40

Transient phalangeal osteolysis (microgeodic disease). Report of a case involving the foot. Sato K, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1888–90

Giant cell tumor of tendon sheath with intraosseous invasion: a case report. Booth KC, et al. **J Hand Surg [Am]** 1995 Nov;20(6):1000–2

[Rapid osteolysis of the hip and chondrocalcinosis] Hunkeler M, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16; 85(16):513–6 (Eng. Abstr.) **(Fre)**

SURGERY

Revision arthroplasty of the hip with extensive bone loss. Preliminary study. Lakatos J, et al. **Acta Chir Hung** 1995–96;35(1–2):103–11

Management of the structurally deficient femur in revision total hip replacement. Head WC, et al. **Orthopedics** 1995 Sep;18(9):865–8

Bone loss: prosthetic and augmentation method. Scott RD. **Orthopedics** 1995 Sep;18(9):923–6

Revision TKA: is cement really necessary? Whiteside LA. **Orthopedics** 1995 Sep;18(9):930–1

Patch–grafting for regional femoral bone loss in cementless revision hip arthroplasty. Hussell JG, et al. **S Afr J Surg** 1995 Dec;33(4):179–83

Massive osteolysis of the cervical spine. A case report. Foult H, et al. **Spine** 1995 Jul 15;20(14):1636–9

[Percutaneous cementoplasty for malignant osteolysis of the acetabulum] Cotten A, et al. **Presse Med** 1995 Sep 30; 24(28):1308–10 (Eng. Abstr.) **(Fre)**

THERAPY

Reversible osteolysis. Steinberg GG. **J Arthroplasty** 1995 Aug;10(4):556–9

Malignant acetabular osteolyses: percutaneous injection of acrylic bone cement. Cotten A, et al. **Radiology** 1995 Oct; 197(1):307–10

OSTEOLYSIS, ESSENTIAL

Gorham's disease: a literature review and case reports. Green HD, et al. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):435–41 (17 ref.)

COMPLICATIONS

A patient with carpotarsal osteolysis and nephropathy treated with long–term hemodialysis. Borra SI, et al. **Am J Kidney Dis** 1995 Nov;26(5):788–91

Massive osteolysis of the mandible with subsequent obstructive sleep apnea syndrome: a case report. Kayada Y, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1463–5 (14 ref.)

Acro–osteolysis (Hajdu–Cheney) syndrome: report of a case with abnormal tooth structure. Grant S, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):666–8

Abnormal glomerular basement membrane in idiopathic multicentric osteolysis. Bakker SJ, et al. **Pediatr Nephrol** 1996 Apr;10(2):200–2

DIAGNOSIS

Syringohydromyelia in Hajdu–Cheney syndrome. Nishimura G, et al. **Pediatr Radiol** 1996;26(1):59–61

Gorham's syndrome with pleural effusion and colonic carcinoma. Ng SE, et al. **Singapore Med J** 1995 Feb; 36(1):102–4

Idiopathic progressive osteolysis of craniofacial bones. Diaz–Ramon C, et al. **Skeletal Radiol** 1996 Apr;25(3):294–7

Gorham's disease of the spine. Livesley PJ, et al. **Skeletal Radiol** 1996 May;25(4):403–5

PHYSIOPATHOLOGY

Interleukin–6: a potential mediator of the massive osteolysis in patients with Gorham–Stout disease. Devlin RD, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1893–7

RADIOGRAPHY

Idiopathic osteolysis of the acetabulum: a case report. Nemec B, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):666–7 (8 ref.)

SURGERY

Successful treatment of chylothorax by bleomycin for Gorham's disease. Aoki M, et al. **Clin Orthop** 1996 Sep; (330):193–7

OSTEOLYSIS, IDIOPATHIC MULTICENTRIC see **OSTEOLYSIS, ESSENTIAL**

OSTEOLYSIS, MASSIVE see **OSTEOLYSIS, ESSENTIAL**

OSTEOMA

Osteoma of the maxillary antrum [letter] Ziccardi VB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):378–9

[Large osteoma of the frontal sinus] Kudrin AI. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):52–3 **(Rus)**

COMPLICATIONS

Bilateral choroidal osteomas associated with histiocytosis X. Okada K, et al. **Jpn J Ophthalmol** 1996;40(1):111–5

[Unilateral amaurosis caused by osteoma of the sphenoid sinus associated with mucocele. Apropos of a case] Noterman J, et al. **Neurochirurgie** 1995;41(6):419–23 (Eng. Abstr.) **(Fre)**

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Perforating plate–like osteoma cutis in a man with solitary morphoea profunda. Ahn SK, et al. **Br J Dermatol** 1996 May;134(5):949–52

PATHOLOGY

Osteoma of the malleus. Ramadan HH. **Am J Otol** 1994 Nov; 15(6):807–9

A histopathologic review of temporal bone exostoses and osteomata. Fenton JE, et al. **Laryngoscope** 1996 May;106(5 Pt 1):624–8

[Osteomas of frontal sinus] Dobroś W, et al. **Otolaryngol Pol** 1995;49(4):352–5 (Eng. Abstr.) **(Pol)**

[Gigantic osteoma of the maxillary sinus coexisting with retained tooth] Namysłowski G, et al. **Otolaryngol Pol** 1995; 49(4):346–51 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Osteoma of the mandible. A case report. Piattelli A, et al. **Acta Stomatol Belg** 1995 Mar;92(1):13–6 (18 ref.)

Imaging quiz case 2. Bilateral osteomas of the petrous temporal bones. Hamilton MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):793, 795 (9 ref.)

Osteoma of the internal auditory canal: case report. Coakley DJ, et al. **J Laryngol Otol** 1996 Feb;110(2):158–60 (10 ref.)

Osteoma of the innominate bone with intraosseous and parosteal involvement. Houghton MJ, et al. **Skeletal Radiol** 1995 Aug;24(6):455–7

SURGERY

Solitary intradural intracranial osteoma. Choudhury AR, et al. **Br J Neurosurg** 1995;9(4):557–9

Drilling in ear surgery. A comparison of pre– and postoperative bone–conduction thresholds in both the conventional and extended high–frequency ranges. Hallmo P, et al. **Scand Audiol** 1996;25(1):35–8

[Osteoma of the frontal sinus. Apropos of 10 cases] Detsouli M, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(6):293–7 (Eng. Abstr.) **(Fre)**

[Current aspects of frontal sinus surgery. IV: On therapy of frontal sinus osteoma] Weber R, et al. **HNO** 1995 Aug; 43(8):482–6 (Eng. Abstr.) **(Ger)**

OSTEOMA, GIANT OSTEOID see **OSTEOBLASTOMA**

OSTEOMA, OSTEOID

COMPLICATIONS

Osteoid osteoma in the differential diagnosis of persistent joint pain. Georgoulis AD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):125–8

DIAGNOSIS

Osteoid osteoma of the third lumbar vertebra: sequential observations with MRI—a case report. Koh S, et al. **Acta Orthop Scand** 1996 Feb;67(1):79–80

Misleading magnetic resonance imaging in spinal osteoid osteomata: a report of 3 children. van Rhijn LW, et al. **Acta Orthop Scand** 1996 Feb;67(1):81–3

Osteoid osteoma of the clavicle. Lepore L, et al. **Bull Hosp Jt Dis** 1995;54(1):43–5

A technique for preoperative localization of osteoid osteoma. Logan PM, et al. **Can Assoc Radiol J** 1995 Dec;46(6):471–4

Unusually located osteoid osteomas. Pikoulas C, et al. **Eur J Radiol** 1995 Jul;20(2):120–5

Osteoid osteoma and osteoblastoma: MRI appearances and the significance of ring enhancement. Youssef BA, et al. **Eur Radiol** 1996;6(3):291–6

Osteoid osteoma in the differential diagnosis of persistent joint pain. Georgoulis AD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):125–8

Intra-articular osteoid osteoma of the humerus with synovitis simulating chronic monoarthritis of the elbow in a recreational tennis player. Sanchis-Alfonso V, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):45–6

Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Frassica FJ, et al. **Orthop Clin North Am** 1996 Jul;27(3):559–74 (66 ref.)

Osteoid osteoma of the mastoid tip. Wilder WM, et al. **Skeletal Radiol** 1995 Oct;24(7):551–2

[Spinal osteoid osteoma, neuralgia and MRI] Ben Abdallah N, et al. **J Radiol** 1996 Feb;77(2):133–6 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Tumors and tumor-like diseases of the bones in children] Litovka VK, et al. **Klin Khir** 1995;(5):34–6 **(Rus)**

ETIOLOGY

Osteoid osteoma after a fracture of the distal radius. Adil A, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):145–6

PATHOLOGY

Painless osteoid osteoma of the rib in an adult. A case report and a review of the literature. McDermott MB, et al. **Cancer** 1996 Apr 15;77(8):1442–9 (62 ref.)

RADIOGRAPHY

Osteoid osteoma of the pubic bone. Report of a case. Sağlik Y, et al. **Acta Chir Belg** 1996 Jun;96(3):133–4

Evaluation of suspected osteoid osteoma. McGrath BE, et al. **Clin Orthop** 1996 Jun;(327):247–52

Preoperative CT localization and marking of osteoid osteoma: description of a new technique. Magre GR, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):526–9

RADIONUCLIDE IMAGING

Didactic review of 175 radionuclide-guided excisions of osteoid osteomas. Wioland M, et al. **Eur J Nucl Med** 1996 Aug;23(8):1003–11

Osteoid osteoma: comparative utility of high-resolution planar and pinhole magnification scintigraphy. Roach PJ, et al. **Pediatr Radiol** 1996;26(3):222–5

SURGERY

Localization of osteoid osteoma [letter] Hoeffel C, et al. **Can Assoc Radiol J** 1996 Aug;47(4):300

Didactic review of 175 radionuclide-guided excisions of osteoid osteomas. Wioland M, et al. **Eur J Nucl Med** 1996 Aug;23(8):1003–11

Apical hemifacetectomy of the first sacral vertebra in the treatment of an osteoid osteoma. Villas C, et al. **Eur Spine J** 1996;5(2):143–4

Osteoid osteoma: percutaneous radio-frequency ablation. Rosenthal DI, et al. **Radiology** 1995 Nov;197(2):451–4

[Percutaneous resection of osteoid osteoma] Galloy MA, et al. **J Chir (Paris)** 1996 Jan;133(1):37–42 (Eng. Abstr.) **(Fre)**

[Treatment of osteoid osteoma by CT-controlled percutaneous drill resection. Apropos of 27 cases] Kohler R, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(4):317–25 (Eng. Abstr.) **(Fre)**

[CT-guided percutaneous treatment of osteoid osteoma] D'Erme M, et al. **Radiol Med (Torino)** 1995 Jul–Aug; 90(1–2):84–7 (Eng. Abstr.) **(Ita)**

THERAPY

Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. Peyser AB, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1172–80 (20 ref.)

[A new treatment of osteoid osteoma: percutaneous sclerosis with ethanol under scanner guidance] Sanhaji L, et al. **J Radiol** 1996 Jan;77(1):37–40 (Eng. Abstr.) **(Fre)**

OSTEOMALACIA

[Osteomalacia] Kocián J. **Vnitr Lek** 1996 Feb;42(2):130–2 (Eng. Abstr.) **(Cze)**

CHEMICALLY INDUCED

Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. Thomas T, et al. **J Rheumatol** 1995 Nov;22(11):2183–5

COMPLICATIONS

Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clarke BL, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):479–90 (62 ref.)

Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Crouzet J, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):463–6 (34 ref.)

DIAGNOSIS

Musculoskeletal case of the day. Oncogenic osteomalacia. Kaplan PA, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):253, 256–7

Battered granny or spontaneous fractures? A legal dilemma. Connolly V, et al. **Postgrad Med J** 1995 Oct;71(840):630–2

DRUG THERAPY

Tertiary hyperparathyroidism after long-term phosphate supplementation in adult-onset hypophosphataemic osteomalacia. Narvácez J, et al. **Br J Rheumatol** 1996 Jun; 35(6):598–600

ETIOLOGY

Oncogenic osteomalacia: lesion detection by MR skeletal survey. Avila NA, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):343–5

Musculoskeletal case of the day. Oncogenic osteomalacia. Kaplan PA, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):253, 256–7

Oncogenic osteomalacia associated with a meningeal phosphaturic mesenchymal tumor. Case report. David K, et al. **J Neurosurg** 1996 Feb;84(2):288–92

Osteomalacia as a presenting manifestation of Sjögren's syndrome. Hajjaj-Hassouni N, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):529–32 (30 ref.)

Tumor-induced osteomalacia. Schapira D, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):35–46 (79 ref.)

Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Nakahama H, et al. **Urol Int** 1995;55(1):38–40

[Gluten-sensitive enteropathy with intestinal T-cell lymphoma: an unusual cause of in disabling osteomalacia] Rösler D, et al. **Schweiz Med Wochenschr** 1995 Oct 7; 125(40):1864–9 (Eng. Abstr.) **(Ger)**

[Hypophosphatemic osteomalacia acquired after renal transplantation: a a cause of severe osteoporosis] González F, et al. **Rev Med Chil** 1995 Jan;123(1):85–9 (Eng. Abstr.) **(Spa)**

METABOLISM

Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia. Kumar R, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):296–305

PREVENTION & CONTROL

Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Vogelsang H, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):609–14

OSTEOMYELITIS

Primary sternal osteomyelitis. Lin JC, et al. **Ann Thorac Surg** 1996 Jan;61(1):225–7

Opportunistic osteomyelitis in the jaws of children on immunosuppressive chemotherapy. Hovi L, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):90–4

BLOOD

Erythrocyte sedimentation rate and C reactive protein in the assessment of suspected bone infection—are they reliable indices? Perry M. **J R Coll Surg Edinb** 1996 Apr; 41(2):116–8

Local and systemic inflammatory mediator release in patients with acute and chronic posttraumatic osteomyelitis. Klosterhalfen B, et al. **J Trauma** 1996 Mar;40(3):372–8

CLASSIFICATION

Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis. One entity or two. Suei Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):401–8 (41 ref.)

[Differential diagnosis of childhood osteomyelitis—classification according to scintigraphic, radiologic and magnetic resonance tomographic characteristics] Reuland P, et al. **Nuklearmedizin** 1996 Jun; 35(3):68–77 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

First case of osteomyelitis due to Phialophora richardsiae in a patient with HIV infection [letter] Uberti-Foppa C, et al. **AIDS** 1995 Aug;9(8):975–6

Vertebral osteomyelitis as a cause of back pain after epidural anesthesia. Pinczower GR, et al. **Anesthesiology** 1996 Jan; 84(1):215–7

Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis [letter] Behbahani R, et al. **Ann Pharmacother** 1995 Sep; 29(9):936–7

Pustulosis palmoplantaris associated with chronic recurrent multifocal osteomyelitis of the mandible [letter] Brand CU, et al. **Br J Dermatol** 1996 May;134(5):977–9

Suppurative knee arthritis following acute osteomyelitis of the femur detected by magnetic resonance. Itokazu M, et al. **Chin Med J (Engl)** 1995 Sep;108(9):704–7

Clivus and cervical spinal osteomyelitis with epidural abscess presenting with multiple cranial neuropathies. Azizi SA, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):239–44

Cauda equina syndrome secondary to lumbar spondylodiscitis caused by Streptococcus milleri. Faraj A, et al. **Eur Spine J** 1996;5(2):134–6

Lancefield group C streptococcal arthritis and osteomyelitis [letter] Yoho RM, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):561–4

Mycotic aortic aneurysm in patients who have lumbar vertebral osteomyelitis. A report of two cases. Rubery PT, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1729–32

Bone metastasis with superimposed osteomyelitis in prostate cancer. Pruckmayer M, et al. **J Nucl Med** 1996 Jun; 37(6):999–1001

Osteomyelitis of the calcaneus in children. Puffinbarger WR, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):224–30

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

[Primary acute osteomyelitis of the sternum associated with anterior mediastinitis] Tabib W, et al. **J Chir (Paris)** 1996 Jan;133(1):20–2 (10 ref.) (Eng. Abstr.) **(Fre)**

[Pleural effusion associated with vertebral osteomyelitis (letter)] Mateos-Colino A, et al. **Arch Bronconeumol** 1995 Oct;31(8):430–1 **(Spa)**

DIAGNOSIS

Primary Aspergillus osteomyelitis in the tibia of an immunosuppressed man. Sonin AH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1277–9

Osteomyelitis and septic arthritis in children: guidelines for the use of imaging [letter; comment] Wysoki M, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):725. Comment on: AJR Am J Roentgenol 1995 Aug;165(2):399–403.

Suppurative petrous apicitis: osteitis or osteomyelitis? an imaging case report. Horn KL, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):54–7

A case of chronic Escherichia coli osteomyelitis of the clavicle [letter; comment] De Lord DA, et al. **Br J Rheumatol** 1996 Feb;35(2):192–4. Comment on: Br J Rheumatol 1994 Oct;33(10):985–7.

Acute abdomen: an atypical presentation of pubic osteomyelitis. Pang KW, et al. **Bull Hosp Jt Dis** 1995; 54(2):106–8

MRI appearance of spinal lesions: metastatic tumors or infections? Thajeb P, et al. **Chin Med J (Engl)** 1995 Nov; 108(11):839–43

Salmonella osteomyelitis presenting as fibrous dysplasia. A case report. Sanchez AA, et al. **Clin Orthop** 1996 Sep; (330):185–9

Osteomyelitis. Laughlin RT, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):315–21 (44 ref.)

A case of non-insulin-dependent diabetes mellitus with vertebral osteomyelitits: usefulness of imaging diagnosis. Yoshioka K. **Diabetes Res Clin Pract** 1995 Sep;29(3):211–4

Vertebral osteomyelitis mimicking chronic pancreatitis. Kortas DY, et al. **Dig Dis Sci** 1996 Jul;41(7):1527–9

Multimodality imaging of osteomyelitis. Elgazzar AH, et al. **Eur J Nucl Med** 1995 Sep;22(9):1043–63 (142 ref.)

Chronic recurrent multifocal osteomyelitis (CRMO). Schuster T, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):45–51 (32 ref.)

Differentiation of vertebral osteomyelitis and tuberculous spondylitis by magnetic resonance imaging. Arizono T, et al. **Int Orthop** 1995;19(5):319–22

Niemann Pick disease presenting as recurrent episodes of osteomyelitis. Thomas RV, et al. **J Assoc Physicians India** 1995 Apr;43(4):302

Osteomyelitis or abscess? [letter; comment] Baurmash H. **J Oral Maxillofac Surg** 1996 Jun;54(6):803–4. Comment on: J Oral Maxillofac Surg 1996 Feb;54(2):203–9.

Vertebral osteomyelitis presenting as lumbar dysfunction: a case study. Boeglin ER Jr. **J Orthop Sports Phys Ther** 1995 Dec;22(6):267–71

Role of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. Croll SD, et al. **J Vasc Surg** 1996 Aug;24(2):266–70

Pediatric osteomyelitis masquerading as skeletal neoplasia. Willis RB, et al. **Orthop Clin North Am** 1996 Jul; 27(3):625–34

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)

Progressive vertebral blastomycosis mimicking tuberculosis. Güler N, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):816–8

Primary sternal osteomyelitis. Heaton PA, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):722–3 (6 ref.)

Clinical and diagnostic features of osteomyelitis occurring in the first three months of life. Wong M, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1047–53

Osteomyelitis. Roy DR. **Pediatr Rev** 1995 Oct;16(10):380–4; quiz 385 (17 ref.)
Neonatal group B streptococcal vertebral osteomyelitis. Barton LL, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):459–61 (9 ref.)
Idiopathic osteomyelitis of the zygoma [letter] Kosaka Y, et al. **Plast Reconstr Surg** 1996 May;97(6):1305–6
Gadolinium–DTPA–enhanced magnetic resonance imaging of musculoskeletal infectious processes. Hopkins KL, et al. **Skeletal Radiol** 1995 Jul;24(5):325–30
Chronic recurrent multifocal osteomyelitis: an evolving clinical and radiological spectrum. Sundaram M, et al. **Skeletal Radiol** 1996 May;25(4):333–6
[Brodie abscess. Primarily misinterpreted as traumatic lesion] Nicolajsen K, et al. **Ugeskr Laeger** 1996 Jan 8;158(2):171–2 (Eng. Abstr.) **(Dan)**
[Neonatal osteomyelitis: a separate category as far as clinical picture and course are concerned] Joekes EC, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1105–9 **(Dut)**
[Osteomyelitis of the ischium with ipsilateral hip dislocation in an infant] Günther KP, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):350–3 (Eng. Abstr.) **(Ger)**
[Differential diagnosis of childhood osteomyelitis—classification according to scintigraphic, radiologic and magnetic resonance tomographic characteristics] Reuland P, et al. **Nuklearmedizin** 1996 Jun; 35(3):68–77 (Eng. Abstr.) **(Ger)**
[Tumorous space–occupying lesion of the ilium] Marx C, et al. **Radiologe** 1995 Sep;35(9):617–9 **(Ger)**
[Nonspecific osteomyelitis in childhood and adolescence. The contribution of imaging diagnosis] Urso S, et al. **Radiol Med (Torino)** 1995 Sep;90(3):212–8 (Eng. Abstr.) **(Ita)**
[Diffuse sclerosing chronic osteomyelitis of the mandible] García Marín F, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):249–59 (32 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Recurrent methicillin–resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers. Aspinall SL, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):694–7
Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)
Candida albicans osteomyelitis of the zygomatic bone. A distinctive case with a possible peculiar mechanism of infection and therapeutic failure with fluconazole. Arranz–Caso JA, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):161–4
Quinolones and osteomyelitis: state–of–the–art. Lew DP, et al. **Drugs** 1995;49 Suppl 2:100–11 (48 ref.)
Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Graninger W, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):643–7
Acute haematogenous osteomyelitis—evaluation of management in the 1990s. Lane–O'Kelly A, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):285–8
A novel drug delivery system for osteomyelitis using porous hydroxyapatite blocks loaded by centrifugation. Itokazu M, et al. **J Appl Biomater** 1995 Fall;6(3):167–9
Methicillin–resistant coagulase–negative staphylococcal osteomyelitis and its relationship to broad–spectrum oral antibiosis in a predominantly diabetic population. Armstrong DG, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):563–6
Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)
Methicillin–resistant coagulase–negative Staphylococcal osteomyelitis and its relationship to broad–spectrum oral antibiosis in a predominantly diabetic population [letter] Roberts KD. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):181–2
Effective treatment with interferon–alpha in chronic recurrent multifocal osteomyelitis. Andersson R. **J Interferon Cytokine Res** 1995 Oct;15(10):837–8
Subacute hematogenous osteomyelitis: are biopsy and surgery always indicated? Hamdy RC, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):220–3
Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)
Organism isolation and serum bactericidal titers in oral antibiotic therapy for pediatric osteomyelitis. Marshall GS, et al. **South Med J** 1996 Jan;89(1):68–70
[Treatment of osteomyelitis with oral bactericidal antibiotics— description of 9 cases] Major S, et al. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):124–7 (Eng. Abstr.) **(Ger)**
[Chronic recurrent multifocal osteomyelitis—personal experience] Radło W, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(5):415–8 (Eng. Abstr.) **(Pol)**
[Gentamycin–polymethylmethacrylate in the treatment of osteoarticular panaritium] Mladenović D, et al. **Acta Chir Iugosl** 1991;38(1):113–9 (Eng. Abstr.) **(Scc)**

ECONOMICS

Cost–effectiveness of noninvasive testing for osteomyelitis [letter; comment] Makler PT Jr. **JAMA** 1995 Oct 4; 274(13):1013–4. Comment on: JAMA 1995 Mar 1;273(9):712–20.

EPIDEMIOLOGY

[Osteoarticular infections by Salmonella non–typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette–Guérin therapy. Rozenblit A, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):711–3
Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)
Infectious complications after epidural anesthesia [letter] Kindler CH, et al. **Anesthesiology** 1996 Aug;85(2):444–5
Vertebral osteomyelitis as a cause of back pain after epidural anesthesia. Pinczower GR, et al. **Anesthesiology** 1996 Jan; 84(1):215–7
Atlanto–axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)
Osteomyelitis of the symphysis pubis after inguinal hernia repair. Baxandall RC, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):65–6
Localized chronic suppurative bone infection as a sequel of peri–implantitis in a hydroxyapatite–coated dental implant. Piattelli A, et al. **Biomaterials** 1995 Aug;16(12):917–20
Osteomyelitis complicating Burch colposuspension. Hall J, et al. **Br J Urol** 1996 Mar;77(3):470–1
Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694–5 (10 ref.)
Vertebral osteomyelitis due to Shigella boydii. Patel R, et al. **Clin Infect Dis** 1996 May;22(5):863–4
Bone and joint infections in patients with infective endocarditis: review of a 4–year experience. Sapico FL, et al. **Clin Infect Dis** 1996 May;22(5):783–7
Chronic septic arthritis and osteomyelitis in a prosthetic knee joint due to Clostridium difficile. Pron B, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):599–601
Streptococcus bovis endocarditis and vertebral osteomyelitis. Spadafora PF, et al. **Heart Lung** 1996 Mar–Apr;25(2):165–8
Mycobacterium haemophilum cellulitis and osteomyelitis in a man with AIDS. Holladay KL, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):122–4
Vertebral osteomyelitis due to Staphylococcus lugdunensis. Murdoch DR, et al. **J Clin Microbiol** 1996 Apr;34(4):993–4
Effective management of osteomyelitis after grade III open fractures. Monsivais JJ. **J South Orthop Assoc** 1996 Spring; 5(1):30–6
Spinal osteomyelitis after TPN catheter–induced septicemia. Corso FA, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):291–5
Sternotomy infection with Mycoplasma hominis in a neonate. Lequier L, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1010–2
Sternal mass and fever. Mineo TC, et al. **Postgrad Med J** 1995 Sep;71(839):569–71
Disseminated Mycobacterium avium complex presenting with osteomyelitis of the distal femur and proximal tibia. Weingardt JP, et al. **Skeletal Radiol** 1996 Feb;25(2):193–6
Osteomyelitis secondary to an osteoenteric fistula. Petrou SP, et al. **Urology** 1996 Jan;47(1):143–5
Orthopedic implications of tuberculosis. Cesario TC. **West J Med** 1995 Dec;163(6):565
[Osteomyelitis as complication of BCG vaccination (letter; comment)] Meijer PJ. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2759. Comment on: Ned Tijdschr Geneeskd 1995 Oct 7;139(40):2047–50. **(Dut)**
[Osteomyelitis as a complication following BCG vaccination] Withagen MI, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7; 139(40):2047–50 (Eng. Abstr.) **(Dut)**
[Risk of infection in centro–medullary locking nailing of open fractures of the femur and tibia] Jenny JY, et al. **Acta Orthop Belg** 1995;61 Suppl 1:212–5 (Eng. Abstr.) **(Fre)**
[Multiple bone lesions of a type of disseminated African histoplasmosis in a Togolese immunocompetent child] Pitche P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):745–48 (Eng. Abstr.) **(Fre)**
[Systemic lupus erythematosus and Salmonella enteritidis osteomyelitis] Benamour S, et al. **Rev Med Interne** 1995; 16(9):684–6 (Eng. Abstr.) **(Fre)**
[The duration of surgical procedures as a factor in the development of postoperative osteomyelitis] Golubović Z, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):557–61 (Eng. Abstr.) **(Scr)**

HISTORY

The origins of the concept of muscle flaps. Noszczyk BH. **Br J Plast Surg** 1996 Mar;49(2):107–10

IMMUNOLOGY

Alteration in the pattern of macrophage subtypes in chronic osteomyelitis compared with acute joint infection. Peters KM, et al. **Int Orthop** 1995;19(3):162–6

MICROBIOLOGY

Agranulocytosis in rheumatoid arthritis associated with long–term flucloxacillin for staphylococcal osteomyelitis. Burton IE, et al. **Acta Haematol** 1995;94(4):196–8
Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of Bacille Calmette–Guérin. Morgan MB, et al. **Am J Med** 1996 Mar; 100(3):372–3
Osteomyelitis of sacral spine caused by aspergillus versicolor with neurologic deficits. Liu Z, et al. **Chin Med J (Engl)** 1995 Jun;108(6):472–5
Spinal cord compression due to anaerobic vertebral osteomyelitis in a patient with metastatic prostate cancer [letter] Bilgrami S, et al. **Clin Infect Dis** 1995 Aug; 21(2):457–8
Skull osteomyelitis due to Salmonella species: two case reports and review. Kamarulzaman A, et al. **Clin Infect Dis** 1996 Apr;22(4):638–41 (27 ref.)
Paraparesis in an 83–year–old woman. Magid D, et al. **Clin Orthop** 1995 Nov;(320):279–82, 284–5
Salmonella osteomyelitis presenting as fibrous dysplasia. A case report. Sanchez AA, et al. **Clin Orthop** 1996 Sep; (330):185–9
Salmonella panama osteomyelitis in an otherwise healthy patient. A case report. van Cappelle HG, et al. **Clin Orthop** 1995 Dec;(321):235–8 (19 ref.)
Case report: Brucella osteomyelitis of the pubic bone. Hoffman C, et al. **Clin Radiol** 1996 May;51(5):368–70
Candida albicans osteomyelitis of the zygomatic bone. A distinctive case with a possible peculiar mechanism of infection and therapeutic failure with fluconazole. Arranz–Caso JA, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):161–4
Staphylococcal vertebral osteomyelitis: case report. Longe AC, et al. **East Afr Med J** 1995 Sep;72(9):609–10
Probable BCG osteomyelitis of the hard palate: a case report. Fujimoto T, et al. **Int J Oral Maxillofac Surg** 1996 Apr; 25(2):145–6
Radiological case of the month. Blastomycosis osteomyelitis with epidural and retropharyngeal abscess. Nokes SR, et al. **J Ark Med Soc** 1995 Oct;92(5):253–4
Methicillin–resistant coagulase–negative staphylococcal osteomyelitis and its relationship to broad–spectrum oral antibiosis in a predominantly diabetic population. Armstrong DG, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):563–6
Case report: brucella osteomyelitis—a difficult diagnosis. Howell GE. **J R Nav Med Serv** 1995 Winter;80(3):136–9
Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)
Septic arthritis and osteomyelitis caused by penicillin and cephalosporin–resistant Streptococcus pneumoniae in a children's hospital. Abbasi S, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):78–83
Eikenella corrodens thumb osteomyelitis [letter] Cuenca–Estrella M, et al. **Postgrad Med J** 1996 Mar; 72(845):188
Study of osteomyelitis: utility of combined histologic and microbiologic evaluation of percutaneous biopsy samples. White LM, et al. **Radiology** 1995 Dec;197(3):840–2
Haemophilus aphrophilus discitis and vertebral osteomyelitis. O'Driscoll JC, et al. **Scand J Infect Dis** 1995;27(3):291–3
Human immunodeficiency virus–associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)
Organism isolation and serum bactericidal titers in oral antibiotic therapy for pediatric osteomyelitis. Marshall GS, et al. **South Med J** 1996 Jan;89(1):68–70
Torulopsis glabrata spinal osteomyelitis involving two contiguous vertebrae. A case report. Curran MP, et al. **Spine** 1996 Apr 1;21(7):866–70 (8 ref.)
Bacterial causes of acute osteomyelitis in sickle cell anaemia: changing infection profile. Aken'Ova YA, et al. **West Afr J Med** 1995 Oct–Dec;14(4):255–8
[Chronic osteomyelitis caused by Klebsiella pneumoniae with a 50 year course. Medicosurgical management] Sarfati F, et al. **J Chir (Paris)** 1995 Aug–Sep;132(8–9):342–5 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Atypical osteomyelitis of the temporal bone. Ohashi T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:99–103
The destruction of bone by neutrophils. Allardyce RA, et al. **Chin Med J (Engl)** 1995 Sep;108(9):708–9
Incorporation of diaphyseal sequestra in chronic haematogenous osteomyelitis. Jain AK, et al. **Int Orthop** 1995;19(4):238–41
An expansile bony lesion of the posterior mandible in a 12–year–old girl [clinical conference] [see comments] Betts NJ, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):203–9. Comment in: J Oral Maxillofac Surg 1996 Jun;54(6):803–4.
Diffuse sclerosing osteomyelitis and florid osseous dysplasia. Groot RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):333–42
Tuberculous osteomyelitis: an unusual case of tuberculous infection in a child undergoing continuous ambulatory

peritoneal dialysis. Yalçinkaya F, et al. **Pediatr Nephrol** 1995 Aug;9(4):485–6

Study of osteomyelitis: utility of combined histologic and microbiologic evaluation of percutaneous biopsy samples. White LM, et al. **Radiology** 1995 Dec;197(3):840–2

[Peculiar cemental lesion of the jaws—its pathological entity and natural history] Miyamoto I. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):354–74 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Mathematical model of hydrodynamic flow in irrigation–suction drainage] Turčić J, et al. **Unfallchirurg** 1996 Jun;99(6):435–9 (Eng. Abstr.) **(Ger)**

[Diffuse sclerosing chronic osteomyelitis of the mandible] García Marín F, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):249–59 (32 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Primary subacute osteomyelitis of the wrist in children. De Smet L, et al. **Acta Orthop Belg** 1995;61(4):282–5 (16 ref.)

Swollen ischiopubic synchondrosis: a dilemma for the radiologist. Kozlowski K, et al. **Australas Radiol** 1995 Aug; 39(3):224–7

A 25-year-old man with back pain and an abnormal chest radiograph. Cordova F, et al. **Chest** 1996 Feb;109(2):559–61

Radiological case of the month. Blastomycosis osteomyelitis with epidural and retropharyngeal abscess. Nokes SR, et al. **J Ark Med Soc** 1995 Oct;92(5):253–4

Tuberculous osteomyelitis of skull in a sixty year old female. Dharwal M, et al. **J Assoc Physicians India** 1995 Aug; 43(8):575–7

Pott's puffy tumor: the forgotten entity. Case report. Babu RP, et al. **J Neurosurg** 1996 Jan;84(1):110–2

Results of three-phase bone scintigraphy and radiography in 20 cases of neonatal osteomyelitis. Aigner RM, et al. **Nucl Med Commun** 1996 Jan;17(1):20–8

Radiographic differentiation of osteogenic sarcoma, osteomyelitis, and fibrous dysplasia of the jaws. Petrikowski CG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):744–50

RADIONUCLIDE IMAGING

The value of Tc-99m citrate scintigraphy in chronic osteomyelitis. An indicator of the involved bone. Cağlar M, et al. **Clin Nucl Med** 1995 Aug;20(8):712–6

In-111 WBC imaging of osteomyelitis in patients with underlying bone scan abnormalities. Kolindou A, et al. **Clin Nucl Med** 1996 Mar;21(3):183–91

MAI osteomyelitis. 18-year scintigraphic follow-up. Mahan S, et al. **Clin Nucl Med** 1995 Jul;20(7):594–8

Tc-99m nanocolloid and Tc-99m MDP three-phase bone imaging in osteomyelitis and septic arthritis. A comparative study. Mudun A, et al. **Clin Nucl Med** 1995 Sep;20(9):772–8

Three-phase bone and Ga-67 scintigraphy in disseminated sporotrichosis. Patange V, et al. **Clin Nucl Med** 1995 Oct; 20(10):909–12

Scintigraphic findings in a Brodie's abscess. Silva F, et al. **Clin Nucl Med** 1995 Oct;20(10):913–5

Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Becker W, et al. **Clin Orthop** 1996 Aug;(329):263–72

Chronic osteomyelitis: diagnosis with technetium-99m-d, l-hexamethylpropylene amine oxime labelled leucocytes. Krznaric E, et al. **Eur J Nucl Med** 1996 Jul;23(7):792–7

Differentiation of infected from noninfected rapidly progressive neuropathic osteoarthropathy [letter; comment] Miles K. **J Nucl Med** 1996 Apr;37(4):706. Comment on: J Nucl Med 1995 Aug;36(8):1427–8.

Results of three-phase bone scintigraphy and radiography in 20 cases of neonatal osteomyelitis. Aigner RM, et al. **Nucl Med Commun** 1996 Jan;17(1):20–8

Neuroblastoma presenting clinically as hip osteomyelitis: a "signature" diagnosis on skeletal scintigraphy. Applegate K, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S93–6

SURGERY

Infected tibial nonunion. Good results after open cancellous bone grafting in 37 cases. Emami A, et al. **Acta Orthop Scand** 1995 Oct;66(5):447–51

Local muscle flaps of the second and third interosseus space for the treatment of osteomyelitis in the central metacarpal region. Hierner R, et al. **Ann Chir Main Memb Super** 1996; 15(2):61–9

Subtotal calcanectomy for osteomyelitis of the os calcis: a reasonable alternative to free tissue transfer. Isenberg JS, et al. **Ann Plast Surg** 1995 Dec;35(6):660–3

Free latissimus dorsi flap for chest wall repair after complete resection of infected sternum. Banic A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1028–32

Osteomyelitis. Laughlin RT, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):315–21 (44 ref.)

Sequestrectomy and local muscle flap implantation for chronic osteomyelitis in children and adolescents. Bassey LO, et al. **East Afr Med J** 1995 Dec;72(12):787–90

Update on management of chronic osteomyelitis: report of four cases. Fasika OM, et al. **East Afr Med J** 1995 Sep; 72(9):611–2 (9 ref.)

Incorporation of diaphyseal sequestra in chronic haematogenous osteomyelitis. Jain AK, et al. **Int Orthop** 1995;19(4):238–41

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

Surgical considerations for hematogenous osteomyelitis. Loder BG, et al. **J Foot Ankle Surg** 1995 Jul–Aug; 34(4):347–53 (58 ref.)

Pott's puffy tumor: the forgotten entity. Case report. Babu RP, et al. **J Neurosurg** 1996 Jan;84(1):110–2

Mandibular reconstruction in a patient with pyknodysostosis. Schmitz JP, et al. **J Oral Maxillofac Surg** 1996 Apr; 54(4):513–7

Subacute hematogenous osteomyelitis: are biopsy and surgery always indicated? Hamdy RC, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):220–3

Ilizarov bone transport for the treatment of chronic osteomyelitis: a rare complication. Gateley DR, et al. **J R Soc Med** 1996 Jun;89(6):348P–50P

Proximal clavicle excision: an analysis of results. Acus RW 3rd, et al. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):182–7

Effective management of osteomyelitis after grade III open fractures. Monsivais JJ. **J South Orthop Assoc** 1996 Spring; 5(1):30–6

Management of large infected tibial defects with radical debridement and staged double-rib composite free transfer. Ueng SW, et al. **J Trauma** 1996 Mar;40(3):345–50

One-stage treatment of infected bone defects of the tibia with skin loss by free vascularized osteocutaneous grafts. Doi K, et al. **Microsurgery** 1995;16(10):704–12

Refinements in the one-stage procedure for management of chronic osteomyelitis. Guelinckx PJ, et al. **Microsurgery** 1995;16(9):606–11

Anterior thoracic corpectomy for spinal cord decompression performed endoscopically. McAfee PC, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):339–48

[INfection of the orbits from the oromandibular surgery viewpoint] Schwenzer N, et al. **Fortschr Kiefer Gesichtschir** 1996;41:38–43 **(Ger)**

[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III-flap-plasty. Anatomic principles and case report] Giunta R, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):64–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[A case report of chronic sternal osteomyelitis after thoracic aortic aneurysmectomy] Ihaya A, et al. **Kyobu Geka** 1995 Nov;48(12):1065–7 (Eng. Abstr.) **(Jpn)**

[Use of the omentum for infected sternal dehiscence after aortic valve replacement—a case report] Toda R, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):54–7 (Eng. Abstr.) **(Jpn)**

THERAPY

Osteomyelitis of the calcaneus in children. Puffinbarger WR, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):224–30

Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Ozuna RM, et al. **Orthop Clin North Am** 1996 Jan;27(1):87–94 (59 ref.)

ULTRASONOGRAPHY

Radiological case of the month. Neonatal osteomyelitis diagnosed by ultrasound. Rubin LP, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):217–8

Ultrasound in children with osteomyelitis. Wright NB, et al. **Clin Radiol** 1995 Sep;50(9):623–7

The value of sonography in the detection of osteomyelitis. Riebel TW, et al. **Pediatr Radiol** 1996;26(4):291–7

VETERINARY

Surgical management of osteomyelitis of the sustentaculum tali in a horse. Dart AJ, et al. **Aust Vet J** 1996 Feb; 73(2):73–4

Changes in serum carboxyterminal telopeptide of type I collagen in an experimental model of canine osteomyelitis. Philipov JP, et al. **Calcif Tissue Int** 1995 Aug;57(2):152–4

Exophthalmos associated with frontal sinus osteomyelitis in a puppy. Grahn BH, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):397–401

What is your diagnosis? Osteomyelitis of the right tuber coxa. Hogan PM, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):415–6

What is your diagnosis? Irregular periosteal response, with a radiolucent defect within the distomedial aspect of the patella. Perris EE, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):665–6

Use of antimicrobial-impregnated polymethyl methacrylate beads for treatment of chronic, refractory septic arthritis and osteomyelitis of the digit in a bull. Trostle SS, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):404–7

What is your diagnosis?. Infected fracture with secondary osteomyelitis. Ferguson JF. **J Small Anim Pract** 1995 Aug; 36(8):348, 373–4

Mycotic osteomyelitis in a dog following nasal aspergillosis. Moore AH, et al. **Vet Rec** 1995 Sep 30;137(14):349–50

VIROLOGY

Childhood neoplasia and Haemophilus influenzae type b vaccine failure [letter] Jenkins DR, et al. **Lancet** 1996 Jul 13;348(9020):131

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)

OSTEON see **HAVERSIAN SYSTEM**

OSTEONECROSIS

Idiopathic osteonecrosis of the humeral head. Čičak N, et al. **Acta Med Croatica** 1995;49(2):93–8

The issue of vascularity in fractures and non-union of the scaphoid. Büchler U, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):726–35 (86 ref.)

Idiopathic avascular necrosis of the scaphoid in a child. Jensen CH, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):359–60 (6 ref.)

CHEMICALLY INDUCED

[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis] Tsurko VV, et al. **Ter Arkh** 1995; 67(7):71–4 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

Outcomes in surgical treatment of femoral neck fracture: analysis of failures secondary to osteonecrosis. Vail TP, et al. **J South Orthop Assoc** 1995 Summer;4(2):83–90

DIAGNOSIS

Idiopathic avascular necrosis of the scaphoid—a case of early diagnosis by MRI. Zadeh HG, et al. **Acta Orthop Scand** 1996 Jun;67(3):298–300

Multiple lesions of osteonecrosis depicted by magnetic resonance imaging. Nishii T, et al. **Am J Knee Surg** 1995 Fall;8(4):137–40

Avascular necrosis of the talus. Wright DG, et al. **Foot Ankle Int** 1995 Nov;16(11):743–4

Idiopathic avascular necrosis of the capitate. Kutty S, et al. **J Hand Surg [Br]** 1995 Jun;20(3):402–4

Avascular necrosis of carpal bones. Golimbu CN, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):281–303 (74 ref.)

Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Froberg PK, et al. **Radiol Clin North Am** 1996 Mar;34(2):273–91, x (63 ref.)

[The MR tomography of avascular necrosis of bone: the primary findings and the follow-up observations after core decompression] Adam G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):330–4 (Eng. Abstr.) **(Ger)**

[Multiple osseous avascular necrosis in a patient with systemic lupus erythematosus with antiphospholipid antibody positivity] Biasi D, et al. **Recenti Prog Med** 1995 Nov;86(11):449–50 **(Ita)**

EPIDEMIOLOGY

High incidence of osteonecrosis of femoral head in patients receiving more than 2 g of intravenous methylprednisolone after renal transplantation. Saisu T, et al. **Transplant Proc** 1996 Jun;28(3):1559–60

ETIOLOGY

Osteonecrosis of the knee following laser-assisted arthroscopic surgery: a report of six cases. Garino JP, et al. **Arthroscopy** 1995 Aug;11(4):467–74

Osteonecrosis of the knee following arthroscopic laser meniscectomy. Rozbruch SR, et al. **Arthroscopy** 1996 Apr; 12(2):245–50

Results of congenital dislocation of the hip joint with open reduction followed up to an age of fifteen years or more. Sugimoto N, et al. **Bull Hosp Jt Dis** 1993–95;53(4):30–6

Osteonecrosis and resorption of the patella after total knee replacement: a case report. Holtby RM, et al. **Clin Orthop** 1996 Jul;(328):155–8

Avascular necrosis of the proximal scaphoid after fracture union. Filan SL, et al. **J Hand Surg [Br]** 1995 Aug; 20(4):551–6

The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Gruppo R, et al. **J Lab Clin Med** 1996 May;127(5):481–8

Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws. Glueck CJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):557–66

Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. Glanzmann C, et al. **Radiother Oncol** 1995 Aug;36(2):94–100

Osteonecrosis of the femoral condyles following traumatic dislocation of the knee. Hunter JC, et al. **Skeletal Radiol** 1996 Apr;25(3):276–8

The immune reaction to heterologous serum causes osteonecrosis in rabbits. Matsui M, et al. **Virchows Arch** 1995;427(2):205–11

PATHOLOGY

Complete palmar dislocation of the lunate in rheumatoid

arthritis. Avascularity without avascular changes. Arner M, et al. **J Hand Surg [Br]** 1996 Jun;21(3):384–7
Femoral head perfusion and composition: MR imaging and spectroscopic evaluation of patients with systemic lupus erythematosus and at risk for avascular necrosis. Bluemke DA, et al. **Radiology** 1995 Nov;197(2):433–8

RADIOGRAPHY

Idiopathic necrosis of the capitate. Arcalis Arce A, et al. **Acta Orthop Belg** 1996 Mar;62(1):46–8

SURGERY

Core decompression in avascular necrosis of the hip in sickle-cell disease. Styles LA, et al. **Am J Hematol** 1996 Jun;52(2):103–7
A case report on bilateral avascular necrosis of the medical cuneiforms. Chew JT, et al. **Ann Acad Med Singapore** 1995 May;24(3):453–4
Osteonecrosis of the talus: treatment by hindfoot fusion. Urquhart MW, et al. **Foot Ankle Int** 1996 May;17(5):275–82
Miller-Galante unicompartmental knee arthroplasty at 2- to 5-year follow-up evaluations. Voss F, et al. **J Arthroplasty** 1995 Dec;10(6):764–71
Avascular necrosis of the hallucial sesamoids. Fleischli J, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):358–65 (34 ref.)
Ankle and subtalar fusion utilizing a tricortical bone graft, bone stimulator, and external fixator after avascular necrosis of the talus. Janis L, et al. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):120–6; discussion 188–9
Iliac crest bone grafting and Herbert screw fixation of nonunions of the scaphoid with avascular proximal poles. Robbins RR, et al. **J Hand Surg [Am]** 1995 Sep;20(5):818–31
Avascular necrosis of the scaphoid treated by total excision and radial advancement osteotomy. Günal I, et al. **J Hand Surg [Br]** 1995 Dec;20(6):736–40
[Articular necroses of the proximal interphalangeal joint. Treatment by resection-distraction using a multicentric MS3 fixator] Sokolow C. **Ann Chir Main Memb Super** 1995; 14(4–5):202–6 (Eng. Abstr.) **(Fre)**

OSTEONECTIN

ANALYSIS

Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Kuhn C, et al. **Am J Pathol** 1995 Dec;147(6):1759–69

BIOSYNTHESIS

SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Pichler RH, et al. **Am J Pathol** 1996 Apr;148(4):1153–67
Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage. Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Nakamura S, et al. **Arthritis Rheum** 1996 Apr;39(4):539–51
Enhanced osteonectin expression in the chondroid matrix of the unloaded mandibular condyle. Haas DW, et al. **Calcif Tissue Int** 1996 Sep;59(3):200–6

CHEMISTRY

Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals. Fujisawa R, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):53–60
Elements within the first 17 amino acids of human osteonectin are responsible for binding to type V collagen. Xie RL, et al. **J Biol Chem** 1996 Apr 5;271(14):8121–5
The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. Maurer P, et al. **J Mol Biol** 1995 Oct 20;253(2):347–57

GENETICS

Expression of biologically active human SPARC in Escherichia coli. Bassuk JA, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):8–19
Regional differences in expression of osteonectin mRNA after administration of cadmium to rats. Lee MJ, et al. **Arch Toxicol** 1995;69(9):590–5
Differential gene expression within the ovine corpus luteum: identification of secreted protein acidic and rich in cysteine as a major secretory product of small but not large luteal cells. Smith GW, et al. **Endocrinology** 1996 Feb; 137(2):755–62
A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Hafner M, et al. **Matrix Biol** 1995 Dec;14(9):733–41
EF-hands reach out [news] Kretsinger RH. **Nat Struct Biol** 1996 Jan;3(1):12–5

METABOLISM

Identification of SPARC in the anterior lens capsule and its expression by lens epithelial cells [letter] Sawhney RS. **Exp Eye Res** 1995 Nov;61(5):645–48
Two adjacent N-terminal glutamines of BM-40 (osteonectin, SPARC) act as amine acceptor sites in transglutaminaseC-catalyzed modification. Hohenadl C, et al. **J Biol Chem** 1995 Oct 6;270(40):23415–20
Role of N-linked glycosylation in human osteonectin. Effect of carbohydrate removal by N-glycanase and site-directed mutagenesis on structure and binding of type V collagen. Xie RL, et al. **J Biol Chem** 1995 Sep 29;270(39):23212–7
The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. Maurer P, et al. **J Mol Biol** 1995 Oct 20;253(2):347–57
Structure of a novel extracellular Ca(2+)-binding module in BM-40. Hohenester E, et al. **Nat Struct Biol** 1996 Jan; 3(1):67–73
SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Mok SC, et al. **Oncogene** 1996 May 2;12(9):1895–901

PHYSIOLOGY

SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Pichler RH, et al. **Am J Pathol** 1996 Apr;148(4):1153–67
SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81–94 (66 ref.)

SECRETION

Differential gene expression within the ovine corpus luteum: identification of secreted protein acidic and rich in cysteine as a major secretory product of small but not large luteal cells. Smith GW, et al. **Endocrinology** 1996 Feb; 137(2):755–62

OSTEOPATHIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

OSTEOPATHIC MEDICINE

Why do patients turn to complementary medicine? An empirical study. Vincent C, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):37–48
Fighting the odds in the UK. Richmond C. **Can Med Assoc J** 1996 May 15;154(10):1547–8
JAOA new members. **J Am Osteopath Assoc** 1995 Oct; 95(10):571
Osteopathic graduate medical education programs must be maintained [letter; comment] Burchett GD. **J Am Osteopath Assoc** 1995 Sep;95(9):508. Comment on: J Am Osteopath Assoc 1995 Mar;95(3):155.
Osteopathic graduate medical education programs must be maintained [letter; comment] Opipari MI. **J Am Osteopath Assoc** 1995 Sep;95(9):508, 510. Comment on: J Am Osteopath Assoc 1995 Mar;95(3):155.
Osteopathic medicine: an inherently natural approach to cholesterol reduction [editorial] Rogers FJ. **J Am Osteopath Assoc** 1996 Jan;96(1):28–9
Late-life depression in primary care. How well are we doing? Banazak DA. **J Gen Intern Med** 1996 Mar;11(3):163–7
Medical licensure for osteopathic physicians in Louisiana: why the State Board of Medical Examiners should accept the NBOME. Bellemare NA. **J La State Med Soc** 1995 Oct;147(10):431–4
Be not content to "sleep and feed" [letter] Holmes JA. **Phys Ther** 1996 Jun;76(6):664–6

EDUCATION

Osteopathic GME consortia [letter; comment] Meyer CT, et al. **Acad Med** 1995 Nov;70(11):950–1. Comment on: Acad Med 1994 Dec;69(12):931–43.
Retraining osteopaths for general practice [letter] Brumberg MA. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):35
Synergism strengthens osteopathic medical education programs [editorial] Allen TW. **J Am Osteopath Assoc** 1995 Oct;95(10):586
Osteopathic postdoctoral training institution: the osteopathic 'road map' to graduate medical education viability. Opipari MI. **J Am Osteopath Assoc** 1995 Nov;95(11):666–7
Marketing key to increased women applicants to COMs [letter] Payson SM. **J Am Osteopath Assoc** 1996 Jan; 96(1):26

MANPOWER

Female enrollment in colleges of osteopathic medicine: five years and five percentage points behind. Baker HH. **J Am Osteopath Assoc** 1995 Oct;95(10):604–6

TRENDS

Proposed matrix could yield bountiful 'harvest' [editorial; comment] Stiles EG. **J Am Osteopath Assoc** 1995 Sep; 95(9):522, 524. Comment on: J Am Osteopath Assoc 1995 Sep;95(9):528–32.

OSTEOPATHY see **OSTEOPATHIC MEDICINE**

OSTEOPENIA see **BONE DISEASES, METABOLIC**

OSTEOPETROSIS

COMPLICATIONS

Congenital stationary nightblindness in a patient with osteopetrosis [letter] Matsui Y, et al. **Br J Ophthalmol** 1995 Dec;79(12):1142–3
Benign osteopetrosis, in a patient with sickle-cell beta+ (beta+) thalassaemia. Kassimos D, et al. **Clin Rheumatol** 1995 Jul;14(4):471–3
Mandibular reconstruction in a patient with pyknodysostosis. Schmitz JP, et al. **J Oral Maxillofac Surg** 1996 Apr; 54(4):513–7
Petrous carotid canal stenosis in malignant osteopetrosis: CT documentation with MR angiographic correlation. Curé JK, et al. **Radiology** 1996 May;199(2):415–21

DIAGNOSIS

Bone scintigraphy and densitometry in children with osteopetrosis. el-Desouki M, et al. **Clin Nucl Med** 1995 Dec;20(12):1061–4
Clinical quiz. Osteopetrosis with carbonic anhydrase II deficiency. Flynn MT, et al. **Pediatr Nephrol** 1996 Feb; 10(1):125–6

DRUG THERAPY

Thrombocytopenia in the toothless (osteopetrotic) rat and its rescue by treatment with colony-stimulating factor-1. Thiede MA, et al. **Exp Hematol** 1996 May;24(6):722–7

ENZYMOLOGY

Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis. Yamamoto N, et al. **Blood** 1996 Aug 15;88(4):1473–8

ETIOLOGY

Osteopetrosis, anemia, thrombocytopenia, and marrow necrosis in beef calves naturally infected with bovine virus diarrhea virus. Scruggs DW, et al. **J Vet Diagn Invest** 1995 Oct;7(4):555–9

GENETICS

Follicular development and ovulation in macrophage colony-stimulating factor-deficient mice homozygous for the osteopetrosis (op) mutation. Araki M, et al. **Biol Reprod** 1996 Feb;54(2):478–84
Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Lowell CA, et al. **Blood** 1996 Mar 1;87(5):1780–92
Cortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypes. Brockstedt H, et al. **Bone** 1996 Jan;18(1):67–72
Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Bollerslev J, et al. **Eur J Endocrinol** 1995 Nov; 133(5):557–63
Heterogeneity of colony stimulating factor-1 gene expression in the skeleton of four osteopetrotic mutations in rats and mice. Shalhoub V, et al. **J Cell Physiol** 1996 Feb; 166(2):340–50
Non-phenotypic detection of osteopetrotic (op/op) mutation by using PCR-SSCP analysis. Kaneko H, et al. **Lab Anim** 1995 Oct;29(4):442–6
Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321–7 (36 ref.)

METABOLISM

Mild osteopetrosis in the microphthalmia-oak ridge mouse. A model for intermediate autosomal recessive osteopetrosis in humans. Nii A, et al. **Am J Pathol** 1995 Dec; 147(6):1871–82
Cytokine production by calvariae of osteopetrotic mice. Felix R, et al. **Bone** 1995 Jul;17(1):5–9
Osteopetrotic (op/op) mice are unable to maintain serum calcium levels despite hyperabsorption of calcium. McCary LC, et al. **Endocrinology** 1996 Mar;137(3):1049–56
Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Bollerslev J, et al. **Eur J Endocrinol** 1995 Nov; 133(5):557–63
Heterogeneity of colony stimulating factor-1 gene expression in the skeleton of four osteopetrotic mutations in rats and mice. Shalhoub V, et al. **J Cell Physiol** 1996 Feb; 166(2):340–50

PATHOLOGY

Mild osteopetrosis in the microphthalmia-oak ridge mouse. A model for intermediate autosomal recessive osteopetrosis in humans. Nii A, et al. **Am J Pathol** 1995 Dec; 147(6):1871–82
Use of bone cell cultures to study skeletal pathology. Jackson ME, et al. **Microsc Res Tech** 1996 Feb 1;33(2):232–9
Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Chackalaparampil I, et al. **Oncogene** 1996 Apr 4;12(7):1457–67
Histopathology and ultrastructure of the thymus in OP/OP

rats with special focus on thymic macrophages. Effect of bone marrow transplantation. Philippart C, et al. **Pathol Res Pract** 1995 Jul;191(6):499–505

Osteoblasts from the toothless (osteopetrotic) mutation in the rat are unable to direct bone resorption by normal osteoclasts in response to 1,25-dihydroxyvitamin D. Sundquist KT, et al. **Tissue Cell** 1995 Oct;27(5):569–74

[Morphology of the mandibular condyle in osteopetrotic (op/op) mouse] Kawata T, et al. **Exp Anim** 1995 Oct; 43(5):687–92 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Effects of macrophage colony-stimulating factor on macrophages and their related cell populations in the osteopetrosis mouse defective in production of functional macrophage colony-stimulating factor protein. Umeda S, et al. **Am J Pathol** 1996 Aug;149(2):559–74

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)

Bone morphogenetic protein-induced heterotopic bone in osteopetrosis. Miyazawa K, et al. **Clin Orthop** 1996 Mar; (324):259–68

Recent developments in the understanding of the pathophysiology of osteopetrosis. Felix R, et al. **Eur J Endocrinol** 1996 Feb;134(2):143–56 (142 ref.)

Managing osteopetrosis in children: a nutrition challenge. Williams R, et al. **J Am Diet Assoc** 1996 Feb;96(2):172–5

Tumor osteolysis in osteopetrotic mice. Clohisy DR, et al. **J Orthop Res** 1995 Nov;13(6):892–7

RADIOGRAPHY

Radiologic manifestations of osteopetrosis. Xu Y, et al. **Chin Med J (Engl)** 1995 Sep;108(9):692–8

Evaluation of jawbone calcification in osteopetrotic (op/op) mice using computed tomography. Kaneda T, et al. **J Nihon Univ Sch Dent** 1995 Sep;37(3):152–5

SURGERY

Infantile osteopetrosis; bone marrow transplantation from a cousin donor. Taylor GM, et al. **Arch Dis Child** 1995 Nov; 73(5):453–5

THERAPY

Normalization of mineral homeostasis after reversal of osteopetrosis. Nesbitt T, et al. **J Bone Miner Res** 1995 Jul; 10(7):1116–21

Bone marrow transplantation for infantile malignant osteopetrosis. Solh H, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):350–5

[Bone marrow transplantation in primary immunodeficiency syndrome and in osteopetrosis] Fasth A. **Nord Med** 1995; 110(12):316–7 (15 ref.) (Eng. Abstr.) **(Swe)**

VIROLOGY

Retroviruses and bone diseases. Labat ML. **Clin Orthop** 1996 May;(326):287–309 (109 ref.)

OSTEOPHYTOSIS, SPINAL see **SPINAL OSTEOPHYTOSIS**

OSTEOPOIKILOSIS

GENETICS

[Osteopoikilosis—case report] Zalewski W, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):523–6 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Osteopoikilosis—report of four cases. Chakravarty SK, et al. **J Assoc Physicians India** 1995 Oct;43(10):716–7

Radiologic case study. Osteopoikilosis. Rucker PT, et al. **Orthopedics** 1996 Apr;19(4):357–8

[A pea-shaped bone!] Godeau B, et al. **Rev Med Interne** 1995; 16(7):553–4 **(Fre)**

[Osteopoikilosis. A clinical case] Guerra M, et al. **Rev Med Chil** 1995 Jul;123(7):880–3 (Eng. Abstr.) **(Spa)**

OSTEOPOROSIS

Putting body weight and osteoporosis into perspective. Wardlaw GM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):433S–436S (43 ref.)

Osteoporosis. Cooper C, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):555–64 (40 ref.)

Department of Health shoots itself in the hip. Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing [see comments] Sheldon TA, et al. **BMJ** 1996 Feb 3;312(7026):296–7. Comment in: BMJ 1996 Feb 3;312(7026):297–8. Comment in: BMJ 1996 May 11;312(7040):1225. Comment in: BMJ 1996 May 11;312(7040):1225–6. Comment in: BMJ 1996 May 18;312(7041):1300–1.

Proceedings of the 3rd International Conference on Osteoporosis. Paris, France, October 20, 1995. **Bone** 1996 Mar;18(3 Suppl):119S–213S

Perspectives on osteoporosis research: its focus and some insights from a new paradigm [editorial] Ferretti JL, et al. **Calcif Tissue Int** 1995 Dec;57(6):399–404 (75 ref.)

Relationship between osteoarthrosis and osteoporosis. An experimental and clinical study. Moreschini O, et al. **Chir Organi Mov** 1995 Apr–Jun;80(2):237–43 **(Eng, Ita)**

Generalized osteoporosis in a patient with oculocutaneous hypopigmentation syndrome (OOCHS), without cerebral defects. A new syndrome? Hernández A, et al. **Clin Genet** 1996 Jan;49(1):46–8

Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality. Johnell O. **J Intern Med** 1996 Apr;239(4):299–304 (24 ref.)

Pregnancy-associated osteoporosis. Rizzoli R, et al. **Lancet** 1996 May 11;347(9011):1274–6

Pregnancy-associated osteoporosis [letter] Smith R, et al. **Lancet** 1996 Aug 10;348(9024):402–3

Osteoporotic fractures: background and prevention strategies. Wark JD. **Maturitas** 1996 Mar;23(2):193–207 (140 ref.)

[Osteoporosis] Stěpán J. **Sb Lek** 1995;96(4):359–63 **(Cze)**

[Osteoporosis. 1] Fojtík Z, et al. **Vnitr Lek** 1995 Nov; 41(11):796–801 (20 ref.) (Eng. Abstr.) **(Cze)**

[Male osteoporosis] Dolev E, et al. **Harefuah** 1995 Dec 15; 129(12):573–5 (25 ref.) **(Heb)**

BLOOD

Postparturient hypocalcemia of dairy cows: a model for the study of the interdependence of Ca, Pi, and Mg homeostasis. Riond JL, et al. **Bone** 1995 Oct;17(4 Suppl):429S–434S

Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases. Braga V, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):433–9

Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. Reed BY, et al. **J Bone Miner Res** 1995 Aug;10(8):1218–24

[Biochemical markers of bone formation in osteoporosis] Miki T, et al. **Rinsho Byori** 1996 May;44(5):410–4 (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Marystone JF, et al. **Am J Public Health** 1995 Dec;85(12):1693–5

Osteoporosis in steroid-dependent asthma. Villareal MS, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):369–72

Osteoporosis is a toxic effect of long-term etretinate therapy [see comments] DiGiovanna JJ, et al. **Arch Dermatol** 1995 Nov;131(11):1263–7. Comment in: Arch Dermatol 1995 Nov;131(11):1321–2. Comment in: Arch Dermatol 1996 Jun;132(6):713; discussion 714. Comment in: Arch Dermatol 1996 Jun;132(6):713–4.

Osteoporosis and long-term etretinate therapy [letter; comment] Margolis DJ. **Arch Dermatol** 1996 Jun; 132(6):713–4. Comment on: Arch Dermatol 1995 Nov;131(11):1263–7.

Iatrogenic osteoporosis [editorial; comment] Sewell KL. **Arch Dermatol** 1995 Nov;131(11):1321–2. Comment on: Arch Dermatol 1995 Nov;131(11):1263–7.

Osteoporosis and long-term etretinate therapy [letter; comment] Whitmore SE. **Arch Dermatol** 1996 Jun; 132(6):713; discussion 714. Comment on: Arch Dermatol 1995 Nov;131(11):1263–7.

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Muir JM, et al. **Blood** 1996 Aug 15;88(4):1314–20

Prevention and management of glucocorticoid-induced osteoporosis. Lane NE, et al. **Bull Rheum Dis** 1995 Aug; 44(5):1–4 (23 ref.)

Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Paoletti AM, et al. **Fertil Steril** 1996 Apr;65(4):707–10

Osteoporosis and hypercalciuria secondary to excessive salt ingestion [letter] Palmieri MA, et al. **J Lab Clin Med** 1995 Nov;126(5):503

Steroid-induced osteoporosis [letter; comment] Hough FS. **S Afr Med J** 1994 Dec;84(12):873–5. Comment on: S Afr Med J 1994 Jul;84(7):404–9.

The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Douketis JD, et al. **Thromb Haemost** 1996 Feb;75(2):254–7

[Long-term observations of the extent and reversibility of bone demineralization after leuprorelin acetate depot therapy] Spitz J, et al. **Zentralbl Gynakol** 1996; 118(4):198–205 (Eng. Abstr.) **(Ger)**

[Long-term corticosteroid therapy as a risk factor of osteoporosis in patients with asthma and chronic bronchitis] Kołaczkowska M, et al. **Pneumonol Alergol Pol** 1996; 64(3–4):196–203 (Eng. Abstr.) **(Pol)**

[Osteoporosis is a suspected adverse effect of amiodarone] Linde C, et al. **Lakartidningen** 1996 Sep 4;93(36):3050–2 **(Swe)**

CLASSIFICATION

Classification of osteoporosis in the elderly is dependent on site-specific analysis. Greenspan SL, et al. **Calcif Tissue Int** 1996 Jun;58(6):409–14

COMPLICATIONS

Senile (type II) osteoporosis: pathogenesis and prevention of estrogen deficiency-related bone loss at the proximal femur. Boonen S. **Acta Clin Belg** 1995;50(4):214–21 (54 ref.)

Transient osteoporosis of the hip in pregnancy complicated by femoral neck fracture: a case report. Junk S, et al. **Acta Orthop Scand** 1996 Feb;67(1):69–70

Late consequences of a low peak bone mass. Ribot C, et al. **Acta Paediatr Suppl** 1995 Sep;411:31–5; discussion 36 (39 ref.)

Refractory pelvic stress fracture in a female long-distance runner. O'Brien T, et al. **Am J Orthop** 1995 Sep;24(9):710–3

Quantitation of incident spinal fractures: comparison of visual detection with quantitative morphometry. Pak CY, et al. **Bone** 1996 Apr;18(4):349–53

Secular trends in osteoporotic pelvic fractures in Finland: number and incidence of fractures in 1970–1991 and prediction for the future. Parkkari J, et al. **Calcif Tissue Int** 1996 Aug;59(2):79–83

The osteoporotic spine. Lee YL, et al. **Clin Orthop** 1996 Feb; (323):91–7 (37 ref.)

The relationship between degenerative changes and osteoporosis in the lumbar spine. Margulies JY, et al. **Clin Orthop** 1996 Mar;(324):145–52

Femoral stiffness after osteosynthesis of a subcapital osteotomy in osteoporotic bone: an in-vitro comparison of nine fixation methods. Hernefalk L, et al. **J Orthop Trauma** 1995;9(6):464–9

Osteoarthritis, bone density, postural stability, and osteoporotic fractures: a population based study. Jones G, et al. **J Rheumatol** 1995 May;22(5):921–5

Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images. Cuénod CA, et al. **Radiology** 1996 May; 199(2):541–9

Magnetic resonance imaging differentiation of compression spine fractures or vertebral lesions caused by osteoporosis or tumor. Rupp RE, et al. **Spine** 1995 Dec 1; 20(23):2499–503; discussion 2504

[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control] de Laet CE, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1684–8 (Eng. Abstr.) **(Dut)**

[Osteoporotic vertebral crush fractures with severe neurologic manifestations. Apropos of 6 cases] Cortet B, et al. **Rev Med Interne** 1995;16(12):891–6 (Eng. Abstr.) **(Fre)**

[A case from practice (340). Transient regional osteoporosis of the right knee] Festini V. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):68–9 **(Ger)**

[The extremely low incidence of proximal femoral fractures due to osteoporosis in the population on the island of Ischia] Oriente P, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):159–62 (Eng. Abstr.) **(Ita)**

[Recurrent rheumatism and idiopathic osteoporosis in young adults. Coincidence or association?] Giordano N, et al. **Clin Ter** 1995 Dec;146(12):811–7 (16 ref.) (Eng. Abstr.) **(Ita)**

[Osteoporosis and fractures in Parkinson's disease] Yamada T, et al. **Nippon Ronen Igakkai Zasshi** 1995 Oct; 32(10):637–40 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Role of biochemical markers in assessment of osteoporosis. Riggs BL, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:14–8 (24 ref.)

The different faces of disease. FACE diagnosis of disease. Klock JC, et al. **Adv Exp Med Biol** 1995;376:13–25

Idiopathic juvenile osteoporosis. An unusual cause of back pain in an adolescent. Dimar JR 2nd, et al. **Am J Orthop** 1995 Nov;24(11):865–9

Clinical usefulness of risk factors for osteoporosis. Earnshaw SA, et al. **Ann Rheum Dis** 1996 Jun;55(6):338–9

Developing a policy on osteoporosis. Dual energy x ray absorptiometry may not be the gold standard [letter; comment] Paterson CR. **BMJ** 1996 May 11;312(7040):1225. Comment on: BMJ 1996 Feb 3;312(7026):296–7.

Developing a policy on osteoporosis. Clinical risk factors alone are insufficient in decision making [letter; comment] Selby P, et al. **BMJ** 1996 May 11;312(7040):1225. Comment on: BMJ 1996 Feb 3;312(7026):296–7.

Bone densitometry in clinical practice. Clinical uses of densitometry are not yet proved [letter; comment] Sheldon TA. **BMJ** 1995 Sep 9;311(7006):686–7. Comment on: BMJ 1995 Jun 10;310(6993):1507–10.

Developing a policy on osteoporosis. Bone densitometry is worth while [letter; comment] Torgerson DJ. **BMJ** 1996 May 11;312(7040):1225–6. Comment on: BMJ 1996 Feb 3;312(7026):296–7.

Osteoporosis: diagnosis and management today and tomorrow. Christiansen C. **Bone** 1995 Nov;17(5 Suppl):513S–516S (17 ref.)

Predictions on future diagnosis and treatment of osteoporosis: results and discussion of a recent opinion poll [editorial] Gruber HE, et al. **Calcif Tissue Int** 1995 Aug;57(2):83–5

Guidelines for the clinical utilization of bone mass measurement in the adult population. Society for Clinical Densitometry. Miller PD, et al. **Calcif Tissue Int** 1995 Oct; 57(4):251–2

Ultrasound, densitometry, and extraskeletal appendicular fracture risk factors: a cross-sectional report on the Saunders County Bone Quality Study. Travers-Gustafson D, et al. **Calcif Tissue Int** 1995 Oct;57(4):267–71

Investigation of osteoporosis. Smith R.

Clin Endocrinol (Oxf) 1996 Apr;44(4):371–4 (9 ref.)
Magnetic resonance imaging of the wrist in rheumatoid arthritis: comparison with other inflammatory joint diseases and control subjects. Tonolli-Serabian I, et al. **Clin Rheumatol** 1996 Mar;15(2):137–42
Current assessment of osteoporosis: proceedings of an international symposium convened during ECR '95 in Vienna, Austria [editorial] Genant HK. **Eur J Radiol** 1995 Sep;20(3):163–4
Quantitative computed tomography (QCT) and dual X-ray absorptiometry (DXA) in the diagnosis of osteoporosis. Guglielmi G. **Eur J Radiol** 1995 Sep;20(3):185–7
Magnetic resonance imaging in osteoporosis. Majumdar S, et al. **Eur J Radiol** 1995 Sep;20(3):193–7 (26 ref.)
Standardization of bone mineral density measurements and the European multicentre studies. Osteaux M, et al. **Eur J Radiol** 1995 Sep;20(3):170–2
Osteoporosis: using 'bone markers' for diagnosis and monitoring. Arnaud CD. **Geriatrics** 1996 Apr;51(4):24–30 (25 ref.)
Osteoporosis: diagnosis and treatment. Lane JM, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):618–32 (141 ref.)
Screening for osteoporosis: what is the role of heel ultrasound? [letter] Gilfillan CP, et al. **Med J Aust** 1996 Aug 5;165(3):175
The effect of fat on the coherent-to-Compton scattering ratio in the calcaneus: a computational analysis. Guttmann GD, et al. **Med Phys** 1995 Aug;22(8):1229–34
Screening for osteopenia and osteoporosis: selection by body composition. Michaëlsson K, et al. **Osteoporos Int** 1996; 6(2):120–6
The European spine phantom: reply to Dr Peter Tothill's letter [letter] Reeve J, et al. **Osteoporos Int** 1996;6(2):183–4
Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Froberg PK, et al. **Radiol Clin North Am** 1996 Mar;34(2):273–91, x (63 ref.)
[Bone density measurement for the prediction of risk of fracture in osteoporosis (editorial)] Meng X. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):579–80 **(Chi)**
[Transient osteoporosis of the hip. Presentation of a case and literature review] Leyes Vence M, et al. **Acta Orthop Belg** 1996 Mar;62(1):56–9 (6 ref.) (Eng. Abstr.) **(Fre)**
[Hip diseases in pregnancy] Hettfleisch J, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):657–60 (Eng. Abstr.) **(Ger)**
[Osteoporosis and densitometry screening: preliminary results] Sadun R, et al. **Minerva Med** 1995 Jun;86(6):245–9 (Eng. Abstr.) **(Ita)**
[Transient osteoporosis of the hip in magnetic resonance imaging] Tamburrini O, et al. **Radiol Med (Torino)** 1995 Sep;90(3):187–93 (Eng. Abstr.) **(Ita)**
[Role of densitometric examination in diagnosis of osteoporosis] Lorenc RS. **Pol Tyg Lek** 1995 Nov; 50(44–47):62–5 (Eng. Abstr.) **(Pol)**
[Regional transient osteoporosis and reflex sympathetic dystrophy. Are they different entities or clinical variants of the same disease?] Cuchacovich M, et al. **Rev Med Chil** 1995 Apr;123(4):485–92 (Eng. Abstr.) **(Spa)**

DIET THERAPY

[Osteoporosis and nutrition] Allolio B. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):19–24 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Osteoporosis prevention and treatment. Bellantoni MF. **Am Fam Physician** 1996 Sep 1;54(3):986–92, 995–6 (31 ref.)
Case report: reversal of decreased bone mass by antibiotic treatment in a patient with Whipple's disease. Carnevale V, et al. **Am J Med Sci** 1996 Mar;311(3):145–7
Use of bone densitometry results for decisions about therapy for osteoporosis [letter] Ettnger B, et al. **Ann Intern Med** 1996 Oct 1;125(7):623
Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Schwid SR, et al. **Arch Neurol** 1996 Aug; 53(8):753–7
Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade. Chorev M, et al. **Biopolymers** 1995;37(6):367–75 (44 ref.)
Tiludronate for Bone Diseases. Proceedings of a satellite symposium of the XIIth International Conference on Calcium Regulating Hormones (ICCRH). Melbourne, Australia, 14 February 1995. **Bone** 1995 Nov;17(5 Suppl):471S–519S
Skeletal changes in the ovariectomised ewe and subsequent response to treatment with 17 beta oestradiol. Hornby SB, et al. **Bone** 1995 Oct;17(4 Suppl):389S–394S
Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia. Jee WS, et al. **Bone** 1995 Oct;17(4 Suppl):309S–319S (49 ref.)
Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S–163S (46 ref.)
Assessing bone quality—animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S–352S (35 ref.)
Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Turner AS, et al. **Bone** 1995 Oct;17(4 Suppl):395S–402S
Osteoporosis into the year 2010. Mundy GR. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:32–7; discussion 37–8 (46 ref.)
The role of vitamin D metabolites in the treatment of osteoporosis [editorial] Civitelli R. **Calcif Tissue Int** 1995 Dec;57(6):409–14
Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis [editorial] Reginster JY, et al. **Calcif Tissue Int** 1995 Oct; 57(4):247–50
Transient osteoporosis of the hip: successful response to deflazacort. Carmona-Ortells L, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):653–5
Treatment of osteoporosis of rheumatoid arthritis [letter] Cantatore FP, et al. **Clin Rheumatol** 1995 Sep;14(5):594–5
Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. **Clin Rheumatol** 1995 Sep;14 Suppl 3:32–9 (52 ref.)
Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319–36 (137 ref.)
The lack of influence of long-term potassium citrate and calcium citrate treatment in total body aluminum burden in patients with functioning kidneys. Sakhaee K, et al. **J Am Coll Nutr** 1996 Feb;15(1):102–6
Osteoporosis: diagnosis and treatment. Lane JM, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):618–32 (141 ref.)
Calcium deficiency in fluoride-treated osteoporotic patients despite calcium supplementation. Dure-Smith BA, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):269–75
Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. Johansson AG, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):44–8
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. Landman JO, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3465–8
Corticosteroid-induced bone loss. Millard PS. **J Fam Pract** 1996 Apr;42(4):347
Distribution of menaquinone-4, a therapeutic agent for osteoporosis, in bone and other tissues of rats. Sano Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):499–514
Estrogen and diclofenac sodium therapy in a prepubertal female with idiopathic juvenile osteoporosis. Wright NM, et al. **J Pediatr Endocrinol Metab** 1995 Apr-Jun;8(2):135–9
New drugs for osteoporosis. **Med Lett Drugs Ther** 1996 Jan 5;38(965):1–3
Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1–3):87–90 (25 ref.)
A small dose of human parathyroid hormone(1–34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Sone T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):232–5
No bones about fluoride. Mundy GR. **Nat Med** 1995 Nov; 1(11):1130–1
Trends in submitting abstracts to the Italian society of osteoporosis: do they reflect a changing attitude of medical doctors? [letter] Mazzuoli G, et al. **Osteoporos Int** 1995; 5(6):484
Vitamin D in the treatment of osteoporosis revisited. Fujita T. **Proc Soc Exp Biol Med** 1996 Jun;212(2):110–5 (76 ref.)
Recent developments in the chemotherapy of osteoporosis. Dwivedy I, et al. **Prog Drug Res** 1995;45:289–338 (326 ref.)
Endometriosis and osteoporosis in practice [letter; comment] Maartens R. **S Afr Med J** 1995 Nov;85(11):1201. Comment on: S Afr Med J 1995 Feb;85(2):117.
[Studies of drugs for osteoporosis (3): synthesis of quinolinone derivatives and their treatment of osteoporosis] Xu MX, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):792–5 (Eng. Abstr.) **(Chi)**
[Administration of vitamin D3 and its active metabolites in the prevention and treatment of osteoporosis] Lips P. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):65–8 (34 ref.) **(Dut)**
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis] Lips P, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1215–7 (31 ref.) **(Dut)**
[Basic therapy of osteoporosis in the elderly (interview by Dr. rer. nat. Till Uwe Keil)] Minne W. **Fortschr Med** 1995 Sep 10;113(25):48 **(Ger)**
[Place of ipriflavone in the therapy of osteoporosis] Zsuzsanna B. **Acta Pharm Hung** 1995 Nov;65(6):229–32 (32 ref.) (Eng. Abstr.) **(Hun)**
[Rational bases for the treatment of osteoporosis] Adami S, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:18S–21S (29 ref.) (Eng. Abstr.) **(Ita)**
[Effect of phosphodiesterase IV inhibitors on bone tissue: a possibility for its use as a new agent to treat osteoporosis] Kasugai S, et al. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):432 **(Jpn)**
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44–47):41–2 (16 ref.) (Eng. Abstr.) **(Pol)**
[Use of bisphosphates in treatment of primary and secondary osteoporosis] Olszyński WP. **Pol Tyg Lek** 1995 Nov; 50(44–47):56–8 (6 ref.) (Eng. Abstr.) **(Pol)**
[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis] Rodionova SS. **Ter Arkh** 1995;67(10):43–5 (Eng. Abstr.) **(Rus)**
[Transient regional osteoporosis: an enigmatic disease with a good response to calcitonin] Nos C Fernández JM, et al. **Rev Neurol** 1995 Jan-Feb;23(119):183–4 **(Spa)**

ECONOMICS

Social and economic impact of osteoporosis. A review of the literature. Schütte HE. **Eur J Radiol** 1995 Sep; 20(3):165–9 (18 ref.)
Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Randell A, et al. **Osteoporos Int** 1995;5(6):427–32
[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control] de Laet CE, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1684–8 (Eng. Abstr.) **(Dut)**

EPIDEMIOLOGY

Risk factors for osteoporotic fractures in elderly men. Nguyen TV, et al. **Am J Epidemiol** 1996 Aug 1; 144(3):255–63
Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Pichette V, et al. **Am J Kidney Dis** 1996 Jul;28(1):105–14
Osteoporosis. Frequency, consequences, and risk factors. Ross PD. **Arch Intern Med** 1996 Jul 8;156(13):1399–411 (214 ref.)
Bone mineral densitometry in clinical practice. Different guidelines will yield different estimates of prevalence [letter; comment] Yeap SS, et al. **BMJ** 1995 Nov 11; 311(7015):1301. Comment on: BMJ 1995 Jun 10;310(6993):1507–10.
Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S–125S (53 ref.)
The worldwide problem of osteoporosis: insights afforded by epidemiology. Riggs BL, et al. **Bone** 1995 Nov;17(5 Suppl):505S–511S (47 ref.)
The epidemiology of osteoporosis. Dennison E, et al. **Br J Clin Pract** 1996 Jan-Feb;50(1):33–6 (24 ref.)
The epidemiology of osteoporosis. The oriental perspective in a world context. Lau EM, et al. **Clin Orthop** 1996 Feb; (323):65–74 (76 ref.)
Bone density profiles and osteoporosis incidence in Irish females. Donne B, et al. **Ir Med J** 1996 May-Jun;89(3):92–4
Osteoporosis: the emerging epidemic [editorial] Wark JD. **Med J Aust** 1996 Mar 18;164(6):327–8
Differences in the characteristics of responders and non-responders in a prevalence survey of vertebral osteoporosis. European Vertebral Osteoporosis Study Group. O Neill TW, et al. **Osteoporos Int** 1995;5(5):327–34
[Cost and effectiveness of different strategies in diagnosis of osteoporosis] Glüer CC, et al. **Radiologe** 1996 Apr; 36(4):315–26 (Eng. Abstr.) **(Ger)**
[Risk of osteoporosis in women in 4 different occupational groups] Rásky E, et al. **Wien Klin Wochenschr** 1996; 108(6):163–8 (Eng. Abstr.) **(Ger)**
[The epidemiology of osteoporotic fractures] Sartori L, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:5S–8S (Eng. Abstr.) **(Ita)**
[Epidemiological study of osteoporosis] Sudo A, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1217–25 (Eng. Abstr.) **(Jpn)**
[Evaluation of osteoporosis risk using densitometric examinations of the forearm in randomized probes of the provincial population of Warsaw] Matusik H, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):16–9 **(Pol)**
[Epidemiology of hip fractures in age groups at high risk for osteoporosis] Mikhailov EE, et al. **Ter Arkh** 1995; 67(10):39–42 (Eng. Abstr.) **(Rus)**
[Prevalence study of symptoms and risk factors associated with climacteric] Rollán Landeras M, et al. **Aten Primaria** 1995 Oct 15;16(6):352–5 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Cultural differences in attitudes, values, and beliefs about osteoporosis in first and second generation Japanese-American women. Matsumoto D, et al. **Women Health** 1995;23(4):39–56

ETIOLOGY

Osteoporosis in severe congenital neutropenia: inherent to the disease or a sequela of G-CSF treatment? [letter] Simon M, et al. **Am J Hematol** 1996 Jun;52(2):127
Treatable risk factor for osteoporosis? [letter; comment] Hay P. **Am J Psychiatry** 1996 Jan;153(1):140–1. Comment on: Am J Psychiatry 1994 Nov;151(11):1691–3.
Post-traumatic differential osteoporosis of the patella. Satku K, et al. **Ann Acad Med Singapore** 1995 May;24(3):479–81
Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S–22S (30 ref.)
Bone density loss during treatment of chronic GVHD. Stern JM, et al. **Bone Marrow Transplant** 1996 Mar;17(3):395–400
Aetiology and presenting symptoms in male osteoporosis. Peris P, et al. **Br J Rheumatol** 1995 Oct;34(10):936–41
High-turnover osteoporosis and diffuse idiopathic skeletal hyperostosis induced by retinoid therapy in a patient with superficial bladder cancer. Theiler R, et al. **Br J Urol** 1995 Sep;76(3):400–1
Severe osteoporosis before and after lung transplantation. Aris RM, et al. **Chest** 1996 May;109(5):1176–83

Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. Davies MC, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):741–6

Osteoporosis in rheumatoid arthritis. Dequeker J, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S21–6 (60 ref.)

Treatment of osteoporosis of rheumatoid arthritis [letter] Cantatore FP, et al. **Clin Rheumatol** 1995 Sep;14(5):594–5

Osteoporosis in rheumatoid arthritis: effect of disease activity. Celiker R, et al. **Clin Rheumatol** 1995 Jul;14(4):429–33

Biophysical parameters affecting osteoporosis. Behari J. **Crit Rev Biomed Eng** 1994;22(2):69–137 (637 ref.)

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11–5 (26 ref.)

A rotator cuff rupture produces permanent osteoporosis in the affected extremity, but not in those with whom shoulder function has returned to normal. Kannus P, et al. **J Bone Miner Res** 1995 Aug;10(8):1263–71

Clinical review 76: The nature of osteoporosis. Marcus R. **J Clin Endocrinol Metab** 1996 Jan;81(1):1–5 (36 ref.)

The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. Falcini F, et al. **J Endocrinol Invest** 1996 Mar;19(3):165–9

Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. Dobnig H, et al. **J Intern Med** 1996 Apr;239(4):365–9

Arthritis not immobilization causes bone loss in the carrageenan injection model of inflammatory arthritis. Bogoch ER, et al. **J Orthop Res** 1995 Sep;13(5):777–82

Cortical bone perfusion in plated fractured sheep tibiae. Kregor PJ, et al. **J Orthop Res** 1995 Sep;13(5):715–24

Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer [letter; comment] Horan AH. **J Urol** 1996 Apr;155(4):1395. Comment on: J Urol 1995 Aug;154(2 Pt 1):535–6.

Bone loss and oral state in patients on home parenteral nutrition. von Wowern N, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):105–9

Overexpression of the granulocyte colony–stimulating factor gene leads to osteoporosis in mice. Takahashi T, et al. **Lab Invest** 1996 Apr;74(4):827–34

Fracturing osteoporosis after kidney transplantation—what are the options? Coen G. **Nephrol Dial Transplant** 1996 Apr;11(4):567–9 (17 ref.)

Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Grotz WH, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2096–100

Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord section. Wilmet E, et al. **Paraplegia** 1995 Nov;33(11):674–7

Pregnancy–associated osteoporosis. Smith R, et al. **QJM** 1995 Dec;88(12):865–78

Alcohol dependence, smoking status, reproductive characteristics, and bone mineral density in premenopausal women. Clark K, et al. **Res Nurs Health** 1996 Oct; 19(5):399–408

Cytokines and osteoporosis [editorial] Cohen–Solal M, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):83–6 (19 ref.)

Osteoporosis and former athletes. Kučera M. **Sb Lek** 1994; 95(2):105–9

Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Silvennoinen JA, et al. **Scand J Gastroenterol** 1996 Apr;31(4):367–71

[Experimental studies of the effects of prestress on intact canine bone structure] Liu B, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):374–7 (Eng. Abstr.) **(Chi)**

[Systemic mastocytosis as a cause of osteoporosis] Kemink SA, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1277–9 (Eng. Abstr.) **(Dut)**

[Osteoporosis, and then?] van Guldener C, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):57–60 **(Dut)**

[Vertebral compression revealing acute lymphoblastic leukemia] Mandel R, et al. **Arch Pediatr** 1996 May; 3(5):466–9 (Eng. Abstr.) **(Fre)**

[Bone disorders in intestinal cryptogenetic inflammatory diseases] Abitbol V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):826–32 (54 ref.) **(Fre)**

[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Osteoporosis in ankylosing spondylitis] Toussirot E, et al. **Presse Med** 1996 Apr 27;25(15):720–4 (32 ref.) (Eng. Abstr.) **(Fre)**

[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):953–7 (45 ref.) **(Ger)**

[Osteoporosis following heart transplantation. Pathogenesis and therapy] Stempfle HU. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1103–7 (44 ref.) **(Ger)**

[The bones and their diseases. VI. The origin of "secondary" osteoporosis] Ziegler R. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1445–6 (0 ref.) **(Ger)**

[Generalized osteoporosis in chronic polyarthritis—pathomechanisms and treatment approaches] Ringe JD. **Z Rheumatol** 1996 May–Jun;55(3):149–57 (49 ref.) (Eng. Abstr.) **(Ger)**

[Effects of essential trace elements on bone turnover—in relation to the osteoporosis] Okano T. **Nippon Rinsho** 1996 Jan;54(1):148–54 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Symptoms of menopause and osteoporosis risk factors (letter)] Morera Montes J. **Aten Primaria** 1996 Mar 15; 17(4):303–5 **(Spa)**

[Renal acidification mechanism disorders in patients with osteoporosis] Sánchez A, et al. **Medicina (B Aires)** 1995; 55(3):197–202 (Eng. Abstr.) **(Spa)**

[Sinking of the cranial vault and headache] del Real Francia MA, et al. **Rev Clin Esp** 1995 Oct;195(10):715 **(Spa)**

[Hypophosphatemic osteomalacia acquired after renal transplantation: a a cause of severe osteoporosis] González F, et al. **Rev Med Chil** 1995 Jan;123(1):85–9 (Eng. Abstr.) **(Spa)**

GENETICS

Osteoporosis–pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12–13. Gong Y, et al. **Am J Hum Genet** 1996 Jul;59(1):146–51

Low spinal and pelvic bone mineral density among individuals with Down syndrome. Sepúlveda D, et al. **Am J Ment Retard** 1995 Sep;100(2):109–14

Evolution of osteoporosis. Purdie DW. **Ann Rheum Dis** 1996 Jun;55(6):335–7

Is osteoporosis a genetically determined disease? Kelly PJ. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:20–6; discussion 26–7 (50 ref.)

Effects of heredity, age, weight, puberty, activity, and calcium intake on bone mineral density in children. Lonzer MD, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):185–9

Population biology of human aging: segregation analysis of bone age characteristics. Livshits G, et al. **Hum Biol** 1996 Aug;68(4):540–54

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289–93 (43 ref.)

Vitamin D receptor gene alleles and osteoporosis: a contrasting view [editorial] Peacock M. **J Bone Miner Res** 1995 Sep;10(9):1294–7

Increased expression of TGF–beta 2 in osteoblasts results in an osteoporosis–like phenotype. Erlebacher A, et al. **J Cell Biol** 1996 Jan;132(1–2):195–210

Lack of association between vitamin D receptor genotypes and osteoporosis in Koreans. Lim SK, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3677–81

Vitamin D receptor gene and osteoporosis [letter] Nguyen TV, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1674–5

Differences in vitamin D receptor genotype and geographical variation in osteoporosis [letter] Beaven S, et al. **Lancet** 1996 Jul 13;348(9020):136–7

[Genetic determination of bone density] Baltzer A, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):198, 199–200 (Eng. Abstr.) **(Ger)**

HISTORY

Osteoporosis 4000 years ago [letter; comment] Foldes AJ, et al. **N Engl J Med** 1996 Mar 14;334(11):735. Comment on: N Engl J Med 1995 Nov 30;333(22):1468.

Images in clinical medicine. Osteoporosis in a woman of the early Bronze Age [see comments] Frigo P, et al. **N Engl J Med** 1995 Nov 30;333(22):1468. Comment in: N Engl J Med 1996 Mar 14;334(11):735.

[Age and sex specific differences in bone density of 4,000–year–old individuals. Bone density measurement of early Bronze Age femurs from excavations in Unterhautzenthal, Lower Austria] Frigo P, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):159–63 (Eng. Abstr.) **(Ger)**

METABOLISM

The effect of ovariectomy on bone metabolism in rats. Omi N, et al. **Bone** 1995 Oct;17(4 Suppl):163S–168S

Intestinal calcium absorption and response of calcium regulating hormones in the stroke–prone spontaneously hypertensive rat as a model of osteoporosis. Fukuda S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S240–1

The skeleton as an ion exchange system: implications for the role of acid–base imbalance in the genesis of osteoporosis. Barzel US. **J Bone Miner Res** 1995 Oct;10(10):1431–6 (31 ref.)

Skeletal metabolism in patients with osteoporosis after discontinuation of long–term treatment with oral pamidronate. Landman JO, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3465–8

Bioavailability and distribution of 125J osteocalcin in rats with experimental osteoporosis. Ryszka F, et al. **Pharmazie** 1995 Dec;50(12):831–2

Pharmacokinetics of calcitonin in rats with experimental osteoporosis. Ryszka F, et al. **Pharmazie** 1995 Oct; 50(10):704–5

Biological accessibility and distribution of calcitonin in rats with experimental osteoporosis. Ryszka F, et al. **Pharmazie** 1995 Sep;50(9):636–7

[Detection of estrogen receptor messenger ribonucleic acid in normal and ovariectomized rat bone] Li W, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct;24(5):312–4 (Eng. Abstr.) **(Chi)**

[Vitamin D and osteoporosis] Ljunghall S, et al. **Nord Med** 1995;110(10):253–7 (11 ref.) (Eng. Abstr.) **(Swe)**

NURSING

Patient care of osteoporosis. Recker RR, et al. **Clin Geriatr Med** 1995 Nov;11(4):625–40 (29 ref.)

PATHOLOGY

Measurement of bone density in osteoporosis [letter; comment] Perry W. **BMJ** 1995 Oct 7;311(7010):952. Comment on: BMJ 1995 Jul 22;311(6999):263–4.

Human osteoblasts from younger normal and osteoporotic donors show differences in proliferation and TGF beta–release in response to cyclic strain. Neidlinger–Wilke C, et al. **J Biomech** 1995 Dec;28(12):1411–8

[Spongiosa structure and polyostotic heterogeneity in osteoporosis. Mechanism of bone transformation, morphology, clinical significance] Ritzel H, et al. **Pathologe** 1996 Jan;17(1):68–77 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam Study. Burger H, et al. **Arthritis Rheum** 1996 Jan;39(1):81–6

Ability of bone mineral density to predict osteoporotic fractures. Conclusion of meta–analysis was unjustified [letter] Brooks K, et al. **BMJ** 1996 Aug 31;313(7056):561

Ability of bone mineral density to predict osteoporotic fractures. Case for screening exists [letter] Perry W. **BMJ** 1996 Aug 31;313(7056):561–2

The epidemiology of peripheral fractures. Baron JA, et al. **Bone** 1996 Mar;18(3 Suppl):209S–213S (29 ref.)

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S–144S (87 ref.)

Forearm fracture. Eastell R. **Bone** 1996 Mar;18(3 Suppl):203S–207S

Physical loading, exercise, and bone [editorial] Kannus P, et al. **Bone** 1996 Jan;18(1 Suppl):1S–3S

Femoral neck geometry and radiographic signs of osteoporosis as predictors of hip fracture. Karlsson KM, et al. **Bone** 1996 Apr;18(4):327–30

In vivo assessment of bone mechanical properties by vibration and ultrasonic wave propagation analysis. Van Der Perre G, et al. **Bone** 1996 Jan;18(1 Suppl):29S–35S

The natural history of osteoporosis. Ballard PA, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):503–7 (24 ref.)

Changes in bone density and biochemical markers of bone turnover in pregnancy–associated osteoporosis. Khastgir G, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):716–8

Trabecular bone cell proliferation ex vivo increases with donor age in the rat: it is correlated with the extent of bone loss and not with histomorphometric indices of bone formation. Egrise D, et al. **Calcif Tissue Int** 1996 Jul; 59(1):45–50

Aromatization of androgens is important for skeletal maintenance of aged male rats. Vanderschueren D, et al. **Calcif Tissue Int** 1996 Sep;59(3):179–83

Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187–96; discussion 197–202 (45 ref.)

Transient osteoporosis of the hip in pregnancy: natural history of changes in bone mineral density. Funk JL, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):373–82

Effects of calcium and exercise on bone mineral density in premenopausal women with osteoporosis. Holmes–Walker J, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):323–6

Notes on a "silent disease'. Slavkin HC. **J Am Dent Assoc** 1996 Jun;127(6):801–3

Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. Ensrud KE, et al. **J Bone Miner Res** 1995 Nov; 10(11):1778–87

Determinants of bone mineral density in older men. Glynn NW, et al. **J Bone Miner Res** 1995 Nov;10(11):1769–77

Choosing between predictors of fractures. Hui SL, et al. **J Bone Miner Res** 1995 Nov;10(11):1816–22

Vitamin D receptor gene and osteoporosis [letter] Nguyen TV, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1674–5

SLE and osteoporosis: dependence and/or independence on glucocorticoids. Sels F, et al. **Lupus** 1996 Apr;5(2):89–92 (23 ref.)

Effect of back supports on back strength in patients with osteoporosis: a pilot study. Kaplan RS, et al. **Mayo Clin Proc** 1996 Mar;71(3):235–41

Should we define osteoporosis based on bone mineral density criteria? [editorial] Ribot C, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):546–8

Lead intoxication caused by skeletal disease. Berlin K, et al. **Scand J Work Environ Health** 1995 Aug;21(4):296–300

The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)

[Bone structure and mechanical resistance of the bone tissue] Benhamou CL, et al. **Presse Med** 1996 Feb 17;25(6):249–54 (43 ref.) (Eng. Abstr.) **(Fre)**

[Arteriosclerosis and osteoporosis (editorial)] Laroche M. **Presse Med** 1996 Jan 20;25(2):52–4 (Eng. Abstr.) **(Fre)**

[Bones and bone diseases. Part V: Pathogenesis of type–II osteoporosis] Ziegler R. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1367–8 (00 ref.) **(Ger)**

[Pregnancy–associated osteoporosis] Ohana N, et al.

Harefuah 1996 Mar 1;130(5):344–6 (32 ref.) **(Heb)**
[Role of the family doctor in the complex treatment of early and late consequences of postmenopause. Effect of estrogen–progestogen on osteoporosis] Farkas M.
Acta Pharm Hung 1995 May;65(3):77–89 (Eng. Abstr.) **(Hun)**
[The physiopathology of osteoporosis: the role of local factors] Girasole G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:9S–17S (70 ref.) (Eng. Abstr.) **(Ita)**
[Vitamin D and osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44–47):53–5 (29 ref.) (Eng. Abstr.) **(Pol)**
[Physiologic principles of osteoporosis] Otfinowski J, et al. **Przegl Lek** 1996;53(1):26–8 (17 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Ipriflavone, an antiostheophorotic agent. Böcskei Z, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):1022–4
Training increases the in vivo fracture strength in osteoporotic bone. Protection by muscle contraction examined in rat tibiae. Kaastad TS, et al. **Acta Orthop Scand** 1996 Aug;67(4):371–6
Osteoporosis prevention and treatment. Bellantoni MF. **Am Fam Physician** 1996 Sep 1;54(3):986–92, 995–6 (31 ref.)
Dietary prevention of osteoporosis: are we ignoring the evidence? [letter; comment] Cappuccio FP. **Am J Clin Nutr** 1996 May;63(5):787–8. Comment on: Am J Clin Nutr 1995 Aug;62(2):417–25. Comment on: Am J Clin Nutr 1995 Oct;62(4):740–5.
Exercise in primary prevention of osteoporosis in women. Bassey EJ. **Ann Rheum Dis** 1995 Nov;54(11):861–2
Testosterone treatment of men treated with glucocorticoids [editorial; comment] Odell WD. **Arch Intern Med** 1996 Jun 10;156(11):1133–4. Comment on: Arch Intern Med 1996 Jun 10;156(11):1173–7.
Osteoporosis and schizophrenia: can we limit known risk factors? [letter] Abraham G, et al. **Biol Psychiatry** 1995 Jul 15;38(2):131–2
Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Walsh LJ, et al. **BMJ** 1996 Aug 10;313(7053):344–6
Osteoporosis and exercise. Mosekilde L. **Bone** 1995 Sep; 17(3):193–5 (42 ref.)
Ineffectiveness of calcitonin on a local–disuse osteoporosis in the sheep: a histomorphometric study. Thomas T, et al. **Calcif Tissue Int** 1995 Sep;57(3):224–8
The role of bisphosphonates in the prevention and treatment of osteoporosis. Reginster JY. **Clin Rheumatol** 1995 Sep;14 Suppl 3:22–5 (25 ref.)
Prevention of bone mineral loss in patients with Crohn's disease by long–term oral vitamin D supplementation. Vogelsang H, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):609–14
Bone density studies in pregnant women receiving heparin. Shefras J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):171–4
Current and future nonhormonal approaches to the treatment of osteoporosis. Bilezikian JP. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):148–55 (45 ref.)
Report from the Health Technology Assessment Unit of the Basque country (Osteba). **Int J Technol Assess Health Care** 1995 Summer;11(3):631–2
The relation of exercise habits to health beliefs and knowledge about osteoporosis. Taggart HM, et al. **J Am Coll Health** 1995 Nov;44(3):127–30
Should older women use estrogen replacement? [editorial; comment] Johnson SR. **J Am Geriatr Soc** 1996 Jan; 44(1):89–90. Comment on: J Am Geriatr Soc 1996 Jan;44(1):1–6.
Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats. Yamamura K, et al. **J Biomed Mater Res** 1995 Oct;29(10):1249–53
Lipid clearing agents in steroid–induced osteoporosis. Wang GJ, et al. **J Formos Med Assoc** 1995 Oct;94(10):589–92
Strategies for the prevention of senile (type II) osteoporosis: an update. Boonen S, et al. **J Intern Med** 1996 May; 239(5):383–91 (107 ref.)
Intraosseous infusion of prostaglandin E2 prevents disuse–induced bone loss in the tibia. Welch RD, et al. **J Orthop Res** 1996 Mar;14(2):303–10
Screening for osteoporosis: what is the role of heel ultrasound? Pocock NA, et al. **Med J Aust** 1996 Mar 18; 164(6):367–70
Calcium, why and how much? Palmieri GM. **Miner Electrolyte Metab** 1995;21(1–3):236–41 (44 ref.)
What do Norwegian women and men know about osteoporosis? Magnus JH, et al. **Osteoporos Int** 1996; 6(1):32–6
Successful strategies for preventing osteoporosis. Woolf A. **Practitioner** 1995 Nov;239(1556):642–4, 646–7, 650
Clinical implication of hormone treatment in postmenopausal kidney transplants. Hung CJ, et al. **Transplant Proc** 1996 Jun;28(3):1548–50
Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Van Cleemput J, et al. **Transplantation** 1996 May 27; 61(10):1495–9
Osteoporosis—new techniques for screening, diagnosis, and clinical monitoring. Arnaud CD. **West J Med** 1996 May; 164(5):441–2
Primary prevention of osteoporosis: pediatric approach to disease of the elderly. Ilich JZ, et al. **Womens Health Issues** 1996 Jul–Aug;6(4):194–203
[Physical activities and bone mass in women] Commandre F, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1483–91; discussion 1491–2 (Eng. Abstr.) **(Fre)**
[Calcium and vitamin D protect against osteoporosis fractures (letter)] Lüllmann H. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):356–7 **(Ger)**
[Prevention of osteoporosis—why? Who? How?] Siggelkow H, et al. **Med Klin** 1995 Nov 15;90(11):639–44 (43 ref.) **(Ger)**
[Overview of clinical studies with ipriflavone] Attila BK. **Acta Pharm Hung** 1995 Nov;65(6):223–8 (20 ref.) (Eng. Abstr.) **(Hun)**
[The ipriflavone story] György L, et al. **Acta Pharm Hung** 1995 Nov;65(6):191–4 (20 ref.) (Eng. Abstr.) **(Hun)**
[Place of ipriflavone in the therapy of osteoporosis] Zsuzsanna B. **Acta Pharm Hung** 1995 Nov;65(6):229–32 (32 ref.) (Eng. Abstr.) **(Hun)**
[Progress of osteoporosis examinations in Shimura public health center] Nishibori M, et al. **Nippon Koshu Eisei Zasshi** 1995 Jul;42(7):491–9 **(Jpn)**
[Mass screening for osteoporosis in Nansei—the Nansei Study (the second report)] Tsuneoka K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Nov;32(11):715–21 (Eng. Abstr.) **(Jpn)**
[Osteoporosis. Knowledge and attitudes of the Norwegian population] Joakimsen RM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2013–6 (Eng. Abstr.) **(Nor)**
[Prescription drugs against osteoporosis (letter)] Medical JB. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3661–2 **(Nor)**

PSYCHOLOGY

Social and economic impact of osteoporosis. A review of the literature. Schütte HE. **Eur J Radiol** 1995 Sep; 20(3):165–9 (18 ref.)

RADIOGRAPHY

Transient osteoporosis of the hip: a densitometric study. Varenna M, et al. **Clin Rheumatol** 1996 Mar;15(2):169–73
Bone densitometry: patients with end–stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)
Detection of simulated osteoporosis in maxillae using radiographic texture analysis. Southard TE, et al. **IEEE Trans Biomed Eng** 1996 Feb;43(2):123–32
A survey of dual–energy X–ray absorptiometry (DEXA) normal reference ranges used within the UK and their effect on patient classification. Simmons A, et al. **Nucl Med Commun** 1995 Dec;16(12):1041–53
Should we define osteoporosis based on bone mineral density criteria? [editorial] Ribot C, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):546–8
[Dual–energy X–ray absorptiometry: value in orthopedics] Maugars Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(4):326–32 (Eng. Abstr.) **(Fre)**
[Osteoporosis diagnosis—a radiological problem? (editorial)] Glüer CC. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):1–3 **(Ger)**
[A digital radiology method for assessing vertebral osteoporosis] Diacinti D, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):13–7 (Eng. Abstr.) **(Ita)**

REHABILITATION

Effects of functional electrical stimulation–induced lower extremity cycling on bone density of spinal cord–injured patients. BeDell KK, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):29–34
[Rehabilitation tactics in osteoporosis] Lesiak A, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):66–7 (12 ref.) **(Pol)**

SURGERY

Osteoporosis—a modifying factor of surgical treatment. Perlaky G, et al. **Acta Med Hung** 1994;50(3–4):245–56 (8 ref.)

THERAPY

Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha–2b. Weide R, et al. **Ann Hematol** 1996 Jan;72(1):41–3
Department of Health is fair to patients with osteoporosis [comment] Barlow D, et al. **BMJ** 1996 Feb 3; 312(7026):297–8. Comment on: BMJ 1996 Feb 3;312(7026):296–7.
Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)
Predictions on future diagnosis and treatment of osteoporosis: results and discussion of a recent opinion poll [editorial] Gruber HE, et al. **Calcif Tissue Int** 1995 Aug;57(2):83–5
Patient care of osteoporosis. Recker RR, et al. **Clin Geriatr Med** 1995 Nov;11(4):625–40 (29 ref.)
Office management of osteoporosis: a guide for the primary care provider. Daly PA. **Compr Ther** 1995 Oct; 21(10):565–74 (57 ref.)
Biophysical parameters affecting osteoporosis. Behari J. **Crit Rev Biomed Eng** 1994;22(2):69–137 (637 ref.)
Managing osteoporosis. **Drug Ther Bull** 1996 Jun;34(6):45–8 (34 ref.)
Effect of back supports on back strength in patients with osteoporosis: a pilot study. Kaplan RS, et al. **Mayo Clin Proc** 1996 Mar;71(3):235–41
[Experimental osteoporosis caused by estrogen deficiency in rats. Role of a lactose, L–arginine and L–lysine combination in the prevention and therapy] Fini M, et al. **Minerva Med** 1996 Mar;87(3):81–8 (Eng. Abstr.) **(Ita)**
[Recent progress in treatment of osteoporosis] Hosoi T. **Nippon Ronen Igakkai Zasshi** 1996 Apr;33(4):240–4 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Can parathormone be used to treat osteoporosis?] Hoppe A. **Pol Tyg Lek** 1995 Nov;50(44–47):59–61 (36 ref.) **(Pol)**

ULTRASONOGRAPHY

Ultrasound measurement of bone. van Daele PL, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):363–9 (52 ref.)
Screening for osteoporosis: what is the role of heel ultrasound? [letter] Mazess RB. **Med J Aust** 1996 Aug 5; 165(3):174–5
Screening for osteoporosis: what is the role of heel ultrasound? Pocock NA, et al. **Med J Aust** 1996 Mar 18; 164(6):367–70
On measuring bone to predict osteoporotic fracture: moving beyond statistical inference [editorial; comment] Beck TJ. **Radiology** 1996 Jun;199(3):612–4 (25 ref.). Comment on: Radiology 1996 Jun;199(3):725–32.
Skin thickness in patients with osteoporosis and controls quantified by ultrasound A scan. Pedersen H, et al. **Skin Pharmacol** 1995;8(4):207–10
[Evaluation of bones using quantitative ultrasonography] Krieg MA, et al. **Schweiz Med Wochenschr** 1996 Feb 3; 126(5):159–63 (Eng. Abstr.) **(Fre)**
[Evaluation of bone loss in postmenopausal women during the first 5 years after menopause] Pluskiewicz W, et al. **Ginekol Pol** 1995 Nov;66(11):640–5 (Eng. Abstr.) **(Pol)**
[Evaluation of bone mass in insulin dependent diabetes during ultrasonic examination] Sieradzki J, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):10–3 (Eng. Abstr.) **(Pol)**

VETERINARY

Biochemical changes in the collagenous matrix of osteoporotic avian bone. Knott L, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):1045–51
What is your diagnosis? Generalized loss of cortical bone density and a displaced compression fracture of 10th thoracic vertebra. Cook JL, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1019–20
Osteoporotic skull lesions in moose at Isle Royale National Park. Hindelang M, et al. **J Wildl Dis** 1996 Jan;32(1):105–8
Density and breaking strength of bones of mortalities among caged layers. McCoy MA, et al. **Res Vet Sci** 1996 Mar; 60(2):185–6

OSTEOPOROSIS, AGE–RELATED see **OSTEOPOROSIS**

OSTEOPOROSIS, POST–TRAUMATIC see **REFLEX SYMPATHETIC DYSTROPHY**

OSTEOPOROSIS, POSTMENOPAUSAL

Osteoporosis. It steals more than bone. Galsworthy TD, et al. **Am J Nurs** 1996 Jun;96(6):26–33; quiz 34 (10 ref.)
Osteoporosis: taking a fresh look. Barzel US. **Hosp Pract (Off Ed)** 1996 May 15;31(5):59–64, 67–8 (6 ref.)
Osteoporosis as a model for the long–term clinical consequences of the menopause. Kleerekoper M, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):181–8 (36 ref.)
[Medical evaluation of the climacteric patient] Forsbach G, et al. **Ginecol Obstet Mex** 1995 Oct;63:414–6 (Eng. Abstr.) **(Spa)**

BLOOD

Thyroid hormones and osteoporosis [letter; comment] Liel Y. **Arch Intern Med** 1996 Feb 12;156(3):341. Comment on: Arch Intern Med 1995 Jun 12;155(11):1130–1.
Creatinine clearance at menopause is not related to bone mass in later life. Hassager C, et al. **Maturitas** 1995 Sep; 22(2):131–6
[The periodontal status of patients with hypoestrogenemia in relation to the severity of systemic osteoporosis] Khokhlova EIu, et al. **Stomatologiia (Mosk)** 1995;74(2):31–3 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Thyroid hormone use and fractures [letter; comment] Bauer DC. **Arch Intern Med** 1996 Feb 12;156(3):341–2, 344. Comment on: Arch Intern Med 1995 Jun 12;155(11):1130–1.

COMPLICATIONS

Femoral neck fractures in the elderly patient: a preventable injury. Nguyen ND, et al. **Am J Emerg Med** 1996 May; 14(3):288–90
Not all stoops are due to osteoporosis. Ehrenstein MR, et al. **Ann Rheum Dis** 1996 Jan;55(1):21–3
Specter of the crone: the experience of vertebral fracture. Paier GS. **ANS Adv Nurs Sci** 1996 Mar;18(3):27–36

Mortality following fractures in older women. The study of osteoporotic fractures. Browner WS, et al. **Arch Intern Med** 1996 Jul 22;156(14):1521–5

Quantitation of incident spinal fractures: comparison of visual detection with quantitative morphometry. Pak CY, et al. **Bone** 1996 Apr;18(4):349–53

Insufficiency fractures of the sacrum and os pubis. Peh WC, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):15–9 (20 ref.)

Secular trends in osteoporotic pelvic fractures in Finland: number and incidence of fractures in 1970–1991 and prediction for the future. Parkkari J, et al. **Calcif Tissue Int** 1996 Aug;59(2):79–83

Spontaneous fracture of the sternum simulating myocardial infarction. Schapira D, et al. **Clin Rheumatol** 1995 Jul; 14(4):478–80

The relation between osteoporosis of the spine and osteoarthritis of the knee. A study using dual energy X-ray absorptiometry and radiographs. Yokozeki H, et al. **Int Orthop** 1995;19(5):282–4

Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. Black DM, et al. **J Bone Miner Res** 1995 Jun;10(6):890–902

DIAGNOSIS

Dehydroepiandrosterone sulphate in the diagnosis of osteoporosis. Miklós S. **Acta Biomed Ateneo Parmense** 1995; 66(3–4):139–46

Cut off values of bone mineral density defining postmenopausal women with bone fractures. Riario-Sforza GG, et al. **Ann Rheum Dis** 1995 Oct;54(10):807–10

Appendicular measurements in screening women for low axial bone mineral density. Martin JC, et al. **Br J Radiol** 1996 Mar;69(819):234–40

Reference ranges of bone mineral density for women in southern England: the impact of local data on the diagnosis of osteoporosis. Petley GW, et al. **Br J Radiol** 1996 Jul; 69(823):655–60

Reproducibility of DXA absorptiometry: a model for bone loss estimates. Fuleihan GE, et al. **J Bone Miner Res** 1995 Jul;10(7):1004–14

Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. Bettica P, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):542–6

Bone mineral density measurements: are they worth while? Torgerson DJ, et al. **J R Soc Med** 1996 Aug;89(8):457–61

Oral signs as indicators of possible osteoporosis in elderly women. Taguchi A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):612–6

Help obtained. Osteoporosis. Gómez Rodríguez N, et al. **Skeletal Radiol** 1996 May;25(4):344

Recurrent bilateral insufficiency fracture of the talus. A diagnostic pitfall for ankle pain. van Linthoudt D, et al. **Z Rheumatol** 1995 Jul-Aug;54(4):250–3

[Importance of the clinical profile in the postmenopausal osteoporosis screening by densitometry] Bigler JM, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31–32):1347–51 (Eng. Abstr.) **(Fre)**

[The diagnosis and prevention of osteoporosis in a sample of the female population of the city of Bologna] Scandellari G, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2–3):138–9 **(Ita)**

DRUG THERAPY

Prevention and treatment of osteoporosis [see comments] Chapuy MC, et al. **Aging (Milano)** 1995 Aug;7(4):164–73 (93 ref.). Comment in: Aging (Milano) 1995 Aug;7(4):161–3.

Safe play for osteoporosis? [editorial; comment] Sartori L. **Aging (Milano)** 1995 Aug;7(4):161–3 (15 ref.). Comment on: Aging (Milano) 1995 Aug;7(4):164–73.

Alendronate reaches U.S. market for osteoporosis, Paget's disease [news] **Am J Health Syst Pharm** 1995 Nov 15; 52(22):2513–4

Three-year follow-up on effects of transdermal estrogen [letter] Lufkin EG, et al. **Ann Intern Med** 1996 Jul 1; 125(1):77

An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women. Hirsch LJ, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:22S–28S (41 ref.)

New drugs—reports of new drugs recently approved by the FDA. Alendronate. Shinkai I, et al. **Bioorg Med Chem** 1996 Jan;4(1):3–4

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Adami S, et al. **Bone** 1995 Oct;17(4):383–90

Tiludronate: development as an osteoporosis therapy. Chesnut CH 3rd. **Bone** 1995 Nov;17(5 Suppl):517S–519S (16 ref.)

Treatable and untreatable risk factors for hip fracture. Cummings SR. **Bone** 1996 Mar;18(3 Suppl):165S–167S (20 ref.)

Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Davis JW, et al. **Bone** 1995 Oct;17(4):369–73

Carboxylation of osteocalcin in post-menopausal osteoporotic women following vitamin K and D supplementation. Douglas AS, et al. **Bone** 1995 Jul; 17(1):15–20

A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized rats. Li M, et al. **Bone** 1996 Apr;18(4):375–80

Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S–163S (46 ref.)

FDA Guidelines and animal models for osteoporosis. Thompson DD, et al. **Bone** 1995 Oct;17(4 Suppl):125S–133S

Nitric oxide donor alleviates ovariectomy-induced bone loss. Wimalawansa SJ, et al. **Bone** 1996 Apr;18(4):301–4

Alendronate: a new bisphosphonate for the treatment of osteoporosis. Keen RW, et al. **Br J Clin Pract** 1996 Jun; 50(4):211–7

Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis. Miller PD. **Br J Clin Pract** 1996 Jan-Feb;50(1):23–31 (71 ref.)

Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Ellerington MC, et al. **Calcif Tissue Int** 1996 Jul;59(1):6–11

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis [editorial] Reginster JY, et al. **Calcif Tissue Int** 1995 Oct; 57(4):247–50

Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance. Zanchetta JR, et al. **Calcif Tissue Int** 1996 Jul;59(1):70–2

Hormone replacement therapy and diabetes mellitus. Dunne FP, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):615–20 (48 ref.)

Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Erdtsieck RJ, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):557–65

Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women [see comments] Grey A, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):293–6. Comment in: Clin Endocrinol (Oxf) 1996 Mar;44(3):297–8.

Medroxyprogesterone and bone mineral density response to oestrogen [comment] Kanis JA. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):297–8. Comment on: Clin Endocrinol (Oxf) 1996 Mar;44(3):293–6.

Fluoride therapy of type I osteoporosis. Devogelaer JP, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:26–31 (57 ref.)

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)

Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. Brixen K, et al. **J Bone Miner Res** 1995 Dec;10(12):1865–74

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. Ghiron LJ, et al. **J Bone Miner Res** 1995 Dec; 10(12):1844–52

Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. Shen V, et al. **J Clin Invest** 1995 Nov;96(5):2331–8

Bone changes in postmenopausal Thai women with or without hormonal replacement therapy. Limpaphayom K, et al. **J Med Assoc Thai** 1995 Nov;78(11):573–7

Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. Thomas T, et al. **J Rheumatol** 1995 Nov;22(11):2183–5

Short- and long-term effects of calcitonin and calcium administration on blood calcium, magnesium and inorganic phosphorus in post menopausal osteoporosis. Casao E, et al. **J Trace Elem Med Biol** 1995 Oct;9(3):181–4

Postmenopausal osteoporosis: patient choices and outcomes. Cosman F, et al. **Maturitas** 1995 Sep;22(2):137–43

Treatment options for osteoporosis. Khosla S, et al. **Mayo Clin Proc** 1995 Oct;70(10):978–82 (17 ref.)

A small dose of human parathyroid hormone(1–34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Sone T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):232–5

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group [see comments] Liberman UA, et al. **N Engl J Med** 1995 Nov 30;333(22):1437–43. Comment in: N Engl J Med 1995 Nov 30;333(22):1495–6. Comment in: N Engl J Med 1996 Mar 14;334(11):733–4; discussion 734–5. Comment in: N Engl J Med 1996 Mar 14;334(11):734; discussion 734–5.

The treatment of postmenopausal osteoporosis [editorial; comment] Sambrook PN. **N Engl J Med** 1995 Nov 30; 333(22):1495–6. Comment on: N Engl J Med 1995 Nov 30;333(22):1437–43.

Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Giannini S, et al. **Obstet Gynecol** 1996 Sep;88(3):431–6

Cyclical etidronate and calcium carbonate (with citrate) supplementation for osteoporosis unmasking primary hyperparathyroidism. Forbes RB, et al. **Scott Med J** 1995 Dec;40(6):177–8

A decreasing CD4+/CD8+ ratio after one month of treatment with stanazolol in postmenopausal women. Zofková I, et al. **Steroids** 1995 Jul;60(7):430–3

Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382–6 (47 ref.)

[Clinical study on effect of bushen jiangu capsule on postmenopausal osteoporosis] Ding GZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):392–4 (Eng. Abstr.) **(Chi)**

[Postmenopausal osteoporosis. Treatment with calcitonin and a diet rich in collagen proteins] Adam M, et al. **Cas Lek Cesk** 1996 Jan 31;135(3):74–8 (Eng. Abstr.) **(Cze)**

[Significance of gestagens in the prevention and therapy of postmenopausal osteoporosis] Štěpán J. **Ceska Gynekol** 1995 Oct;60(5):237–9 **(Cze)**

[Progestins and osteoporosis. Does progestin contribute to the effectiveness of estrogen replacement therapy in menopause?] Lopes P. **Rev Fr Gynecol Obstet** 1995 May-Jun;90(5–6):307–8 (17 ref.) **(Fre)**

[Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis] Busi S, et al. **Clin Ter** 1995 Dec;146(12):857–9 (Eng. Abstr.) **(Ita)**

[Osteoporosis drugs prescribed on blue forms!] Halse J, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3050–1 (Eng. Abstr.) **(Nor)**

[Comparison of calcitonin tolerance after intramuscular or intranasal administration in treatment for postmenopausal osteoporosis] Horst-Sikorska W, et al. **Przegl Lek** 1996; 53(1):9–11 (Eng. Abstr.) **(Pol)**

[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis] Rodionova SS. **Ter Arkh** 1995;67(10):43–5 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Osteoporosis. Frequency, consequences, and risk factors. Ross PD. **Arch Intern Med** 1996 Jul 8;156(13):1399–411 (214 ref.)

The worldwide problem of osteoporosis: insights afforded by epidemiology. Riggs BL, et al. **Bone** 1995 Nov;17(5 Suppl):505S–511S (47 ref.)

Exercise and reproductive factors as predictors of bone density among osteoporotic women in Mexico City. Parra-Cabrera S, et al. **Calcif Tissue Int** 1996 Aug; 59(2):89–94

Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Epidémiologie de l'ostéoporose. Dargent-Molina P, et al. **Lancet** 1996 Jul 20; 348(9021):145–9

[Cost and effectiveness of different strategies in diagnosis of osteoporosis] Glüer CC, et al. **Radiologe** 1996 Apr; 36(4):315–26 (Eng. Abstr.) **(Ger)**

[Risk of osteoporosis in women in 4 different occupational groups] Rásky E, et al. **Wien Klin Wochenschr** 1996; 108(6):163–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Interleukin-6: a pathogenetic role in the postmenopausal osteoporosis? Girasole G, et al. **Acta Biomed Ateneo Parmense** 1995;66(3–4):125–38

Thyroid hormones and osteoporosis [letter; comment] Liel Y. **Arch Intern Med** 1996 Feb 12;156(3):341. Comment on: Arch Intern Med 1995 Jun 12;155(11):1130–1.

Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S–22S (30 ref.)

Evolution of the pathogenesis of postmenopausal bone loss. Kalu DN. **Bone** 1995 Oct;17(4 Suppl):135S–144S (60 ref.)

Natural versus surgical menopause: implications for the pathogenesis of osteoporosis. Kudo Y, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1002–4

Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Grant DJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):339–45

Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Grey AB, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):697–702

Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. Kipen E, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1088–91

Preferential bone mineral loss in postmenopausal dialysed women? [letter] Kiss E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):748–9

Oestrogen deficiency—does it have a role in the genesis of skeletal problems in dialysed women? [editorial] Silver J, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):565–6

[Studies on the bone metabolisms in either after natural menopause or surgical menopause: implications of IGF-IGFBP system for postmenopausal osteoporosis] Itatsu S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec;47(12):1329–36 (Eng. Abstr.) **(Jpn)**

GENETICS

Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Sano M, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):378–83

Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: cross sectional and longitudinal population study. Jørgensen HL, et al. **BMJ** 1996 Sep 7;313(7057):586–90

Vitamin D receptor polymorphism, bone mineral density, and osteoporotic vertebral fracture: studies in a UK population.

Houston LA, et al. **Bone** 1996 Mar;18(3):249–52

Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake. Krall EA, et al. **J Bone Miner Res** 1995 Jun;10(6):978–84

The contribution of vitamin D receptor gene alleles to the determination of bone mineral density in normal and osteoporotic women. Riggs BL, et al. **J Bone Miner Res** 1995 Jun;10(6):991–6

[vdr gene study in assessing the genetic risk of osteoporosis: from experimental research on the dialysis patient to its routine use in the diagnosis, prognosis and therapy of postmenopausal osteoporosis] Ruggiero M, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):140–1 **(Ita)**

IMMUNOLOGY

A decreasing CD4+/CD8+ ratio after one month of treatment with stanazolol in postmenopausal women. Zofková I, et al. **Steroids** 1995 Jul;60(7):430–3

METABOLISM

Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Sano M, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):378–83

Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. Cecchettin M, et al. **Biomed Pharmacother** 1995; 49(10):465–8

The role of bone turnover in the pathophysiology of osteoporosis. Riis BJ. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:9–14; discussion 14–5 (18 ref.)

PATHOLOGY

Measurement of femoral geometry in type I and type II osteoporosis: differences in hip axis length consistent with heterogeneity in the pathogenesis of osteoporotic fractures. Boonen S, et al. **J Bone Miner Res** 1995 Dec;10(12):1908–12

Microcallus formations of the cancellous bone: a quantitative analysis of the human spine. Hahn M, et al. **J Bone Miner Res** 1995 Sep;10(9):1410–6

Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. Parisien M, et al. **J Bone Miner Res** 1995 Sep;10(9):1393–9

[Bone histomorphometry study in post–menopausal women with osteopenia] Zhu J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):402–5 (Eng. Abstr.) **(Chi)**

[Osteoclastic resorption of Haversian system of femoral neck cortex in aged women] Chai B, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):313–5 (Eng. Abstr.) **(Chi)**

[Spongiosa structure and polyostotic heterogeneity in osteoporosis. Mechanism of bone transformation, morphology, clinical significance] Ritzel H, et al. **Pathologe** 1996 Jan;17(1):68–77 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. Cecchettin M, et al. **Biomed Pharmacother** 1995; 49(10):465–8

Meta–analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Marshall D, et al. **BMJ** 1996 May 18;312(7041):1254–9

Rate of bone loss from lumbar spine in women with distal forearm fracture. Peel NF, et al. **BMJ** 1996 Jun 8; 312(7044):1457

Progesterone antagonist RU 486 has bone–sparing effects in ovariectomized rats. Barengolts EI, et al. **Bone** 1995 Jul; 17(1):21–5

Forearm fracture. Eastell R. **Bone** 1996 Mar;18(3 Suppl):203S–207S

Development of osteopenia in ovariectomized cynomolgus monkeys (Macaca fascicularis). Jerome CP, et al. **Bone** 1995 Oct;17(4 Suppl):403S–408S

Femoral neck geometry and radiographic signs of osteoporosis as predictors of hip fracture. Karlsson KM, et al. **Bone** 1996 Apr;18(4):327–30

The ferret as a small animal model with BMU–based remodeling for skeletal research. Mackey MS, et al. **Bone** 1995 Oct;17(4 Suppl):191S–196S

The effect of oophorectomy on calcium homeostasis. Morris HA, et al. **Bone** 1995 Oct;17(4 Suppl):169S–174S

Decreased bone mineral density associated with early menopause progresses for at least ten years: cross–sectional comparisons between early and normal menopausal women. Ohta H, et al. **Bone** 1996 Mar;18(3):227–31

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Riggs BL, et al. **Bone** 1996 Mar;18(3 Suppl):197S–201S (26 ref.)

Vertebral fracture epidemiology. Wasnich RD. **Bone** 1996 Mar;18(3 Suppl):179S–183S (24 ref.)

The effect of estrogen deficiency on bone mineral density, renal calcium and phosphorus handling and calcitropic hormones in the rat. Dick IM, et al. **Calcif Tissue Int** 1996 Sep;59(3):174–8

Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Reeve J, et al. **Calcif Tissue Int** 1995 Aug;57(2):105–10

Increased bone resorption precedes increased bone formation in the ovariectomized rat. Sims NA, et al. **Calcif Tissue Int** 1996 Aug;59(2):121–7

Postmenopausal bone loss in Japanese women. Mizuno K, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):33–9

Maxillary molar extraction causes increased bone loss in the mandible of ovariectomized rats. Elovic RP, et al. **J Bone Miner Res** 1995 Jul;10(7):1087–93

Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. Ensrud KE, et al. **J Bone Miner Res** 1995 Nov; 10(11):1778–87

Choosing between predictors of fractures. Hui SL, et al. **J Bone Miner Res** 1995 Nov;10(11):1816–22

Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X–ray absorptiometry. Jergas M, et al. **J Bone Miner Res** 1995 Jul;10(7):1101–10

Effect of menopause on femoral and vertebral bone loss. Pouilles JM, et al. **J Bone Miner Res** 1995 Oct; 10(10):1531–6

The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women. Prince R, et al. **J Bone Miner Res** 1995 Jul; 10(7):1068–75

The effects of menopause and age on calcitropic hormones: a cross–sectional study of 655 healthy women aged 35 to 90. Prince RL, et al. **J Bone Miner Res** 1995 Jun; 10(6):835–42

Equivalent deficits in bone mass of the vertebral body and posterior processes in women with vertebral fractures: implications regarding the pathogenesis of spinal osteoporosis. Seeman E, et al. **J Bone Miner Res** 1995 Dec; 10(12):2005–10

Assessment of spine bone mineral density in ovariectomized rats using DXA. Yamauchi H, et al. **J Bone Miner Res** 1995 Jul;10(7):1033–9

Sex steroids, bone mass, and bone loss. A prospective study of pre–, peri–, and postmenopausal women. Slemenda C, et al. **J Clin Invest** 1996 Jan 1;97(1):14–21

Seasonal differences in biochemical parameters of bone remodelling. Douglas AS, et al. **J Clin Pathol** 1996 Apr; 49(4):284–9

Temporal relationship between bone loss and increased bone turnover: a longitudinal study following natural menopause. Rosso R, et al. **J Endocrinol Invest** 1995 Oct; 18(9):723–8

Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Adami S, et al. **Osteoporos Int** 1996;6(1):8–13

The relationship between osteoarthritis of the hands, bone mineral density, and osteoporotic fractures in elderly women. Marcelli C, et al. **Osteoporos Int** 1995;5(5):382–8

Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Riis BJ, et al. **Osteoporos Int** 1995;5(4):276–80

[Influence of body weight variations on the rate of bone loss at the beginning of menopause] Pouillès JM, et al. **Ann Endocrinol (Paris)** 1995;56(6):585–9 (Eng. Abstr.) **(Fre)**

[Arteriosclerosis and osteoporosis (editorial)] Laroche M. **Presse Med** 1996 Jan 20;25(2):52–4 (Eng. Abstr.) **(Fre)**

[Vertebral bone loss in perimenopause. Results of a 7–year longitudinal study] Pouillès JM, et al. **Presse Med** 1996 Feb 24;25(7):277–80 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention and treatment of osteoporosis [see comments] Chapuy MC, et al. **Aging (Milano)** 1995 Aug;7(4):164–73 (93 ref.). Comment in: Aging (Milano) 1995 Aug;7(4):161–3.

Safe play for osteoporosis? [editorial; comment] Sartori L. **Aging (Milano)** 1995 Aug;7(4):161–3 (15 ref.). Comment on: Aging (Milano) 1995 Aug;7(4):164–73.

Bone–sparing properties of oral contraceptives. DeCherney A. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):15–20 (25 ref.)

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Ke HZ, et al. **Bone** 1995 Nov; 17(5):491–6

Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)

HRT, a general practice approach: how to reach the most vulnerable. Coope JK, et al. **Br J Clin Pract** 1996 Jan–Feb; 50(1):38–43 (67 ref.)

What factors influence general practitioners' commencement of hormone replacement in perimenopausal women? Larcos G. **Br J Clin Pract** 1996 Jan–Feb;50(1):6–8

Comment: preventive strategies: is current clinical practice effective for bones? Rowe R. **Br J Clin Pract** 1996 Jan–Feb; 50(1):47–9 (8 ref.)

HRT use: where do we stand today? [editorial] Stevenson JC. **Br J Clin Pract** 1996 Jan–Feb;50(1):4–5

Prevention of both osteoporosis and coronary heart disease in primary care. Waine C. **Br J Clin Pract** 1996 Jan–Feb; 50(1):44–6 (12 ref.)

Postmenopausal women: HRT today and into the future. Proceedings of the 6th Novo Nordisk International Symposium. Copenhagen, Denmark, 20–30 September 1995. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:1–108

Screening and treatment in the elderly to reduce osteoporotic fracture risk. Black DM. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:2–7; discussion 7–8 (49 ref.)

The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)

Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post–menopausal ages. Evans SF, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):79–84

Prevention and treatment of postmenopausal osteoporosis. National consensus of the "Belgian Bone Club"—September 1993. **Clin Rheumatol** 1995 Sep;14 Suppl 3:7–8

Calcitonin for prevention and treatment of postmenopausal osteoporosis. Body JJ. **Clin Rheumatol** 1995 Sep;14 Suppl 3:18–21 (22 ref.)

Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. Kaufman JM. **Clin Rheumatol** 1995 Sep;14 Suppl 3:9–13 (46 ref.)

Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2–year study. Overgaard K, et al. **Clin Ther** 1995 Jul–Aug;17(4):680–5

Osteoporosis prevention clinical study program. Delmas P, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S39–45

Osteoporosis prevention in premenopausal women: using a stage model approach to examine the predictors of behavior. Blalock SJ, et al. **Health Psychol** 1996 Mar; 15(2):84–93

The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)

Sodium fluoride makes headway in osteoporosis study [news] **J Am Dent Assoc** 1995 Dec;126(12):1602, 1604

Droloxifene prevents ovariectomy–induced bone loss in tibiae and femora of aged female rats: a dual–energy X–ray absorptiometric and histomorphometric study. Chen HK, et al. **J Bone Miner Res** 1995 Aug;10(8):1256–62

Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study. Lohman T, et al. **J Bone Miner Res** 1995 Jul;10(7):1015–24

Tibolone: prevention of bone loss in late postmenopausal women [see comments] Bjarnason NH, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2419–22. Comment in: J Clin Endocrinol Metab 1996 Jul;81(7):2417–8.

Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women [editorial; comment] Riggs BL. **J Clin Endocrinol Metab** 1996 Jul;81(7):2417–8. Comment on: J Clin Endocrinol Metab 1996 Jul;81(7):2419–22.

Effect of tamoxifen on bone mineral density measured by dual–energy x–ray absorptiometry in healthy premenopausal and postmenopausal women. Powles TJ, et al. **J Clin Oncol** 1996 Jan;14(1):78–84

Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. Sagraves R. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):2S–10S (46 ref.)

Effects of estrogen on screening mammography: another complexity [editorial; comment] Black WC, et al. **J Natl Cancer Inst** 1996 May 15;88(10):627–8. Comment on: J Natl Cancer Inst 1996 May 15;88(10):643–9.

Hormone replacement grows; some experts worried [news] Blume E. **J Natl Cancer Inst** 1996 May 15;88(10):637–9

Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. Arjmandi BH, et al. **J Nutr** 1996 Jan;126(1):161–7

Calcium and vitamin D nutritional needs of elderly women Dawson–Hughes B. **J Nutr** 1996 Apr;126(4 Suppl):1165S–7S

Dietary casein phosphopeptides prevent bone loss in aged ovariectomized rats. Tsuchita H, et al. **J Nutr** 1996 Jan; 126(1):86–93

Phytoestrogens—a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167–75 (89 ref.)

Prevention of post–oophorectomy bone loss with Tibolone. Lyritis GP, et al. **Maturitas** 1995 Nov;22(3):247–53

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

The menopause and osteoporosis. Lindsay R. **Obstet Gynecol** 1996 Feb;87(2 Suppl):16S–19S

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non–hormonal, bone–active drug ipriflavone. Agnusdei D, et al. **Osteoporos Int** 1995;5(6):462–6

A randomized, double–masked, placebo–controlled trial of chlorthalidone and bone loss in elderly women. Wasnich RD, et al. **Osteoporos Int** 1995;5(4):247–51

Preventing and treating osteoporosis. Woolf A. **Practitioner** 1996 Apr;240(1561):244–6 (6 ref.)

Health promotion and osteoporosis prevention among postmenopausal women. Ali NS, et al. **Prev Med** 1995 Sep; 24(5):528–34

Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):243–54 (83 ref.)

Postmenopausal estrogen replacement therapy in the patient with breast carcinoma. Cyr MG. **R I Med** 1995 Sep; 78(9):261–3 (23 ref.)

Primary prevention of osteoporosis: pediatric approach to

disease of the elderly. Ilich JZ, et al. **Womens Health Issues** 1996 Jul–Aug;6(4):194–203

Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)

[Significance of gestagens in the prevention and therapy of postmenopausal osteoporosis] Štěpán J. **Ceska Gynekol** 1995 Oct;60(5):237–9 **(Cze)**

[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Estrogen–gestagen substitution in geriatric gynecology. Long–term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**

[Gerontologic aspects of postmenopausal measurement of bone density and prevention of osteoporosis] Wenderlein JM, et al. **Geburtshilfe Frauenheilkd** 1995 Nov; 55(11):647–52 (Eng. Abstr.) **(Ger)**

[Estrogens in menopause—therapy and prevention. II. Estrogens and osteoporosis] Hüfner M. **Internist (Berl)** 1996 Apr;37(4):405–9 (50 ref.) **(Ger)**

[Prevention of osteoporosis—why? Who? How?] Siggelkow H, et al. **Med Klin** 1995 Nov 15;90(11):639–44 (43 ref.) **(Ger)**

[Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution? (Continuous estradiol plus sequential oral norethisterone acetate)] Gass R, et al. **Schweiz Med Wochenschr** 1995 Aug 26;125(34):1583–91 (Eng. Abstr.) **(Ger)**

[Value of transdermal hormone substitution for postmenopausal osteoporosis] Felsenberg D. **Zentralbl Gynakol** 1995;117(10):516–23 (47 ref.) (Eng. Abstr.) **(Ger)**

[Practical questions about organizing a gynecologic outpatient clinic for climacteric–osteoporosis patients] Berkő P. **Orv Hetil** 1995 Nov 26;136(48):2619–22 (Eng. Abstr.) **(Hun)**

PSYCHOLOGY

The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Gold DT. **Bone** 1996 Mar;18(3 Suppl):185S–189S (29 ref.)

RADIOGRAPHY

Quantitative CT assessment of the lumbar spine and radius in patients with osteoporosis. Grampp S, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):133–40

Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Yu W, et al. **Calcif Tissue Int** 1995 Sep;57(3):169–74

Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Adami S, et al. **Osteoporos Int** 1996;6(1):8–13

[Quantitative ultrasonography in the evaluation of postmenopausal osteoporosis. Comparison with dual energy x–ray absorptiometry] Magarò M, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):218–21 (Eng. Abstr.) **(Ita)**

REHABILITATION

Systematic strength training as a model of therapeutic intervention. A controlled trial in postmenopausal women with osteopenia. Hartard M, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):21–8

THERAPY

Osteoporosis prevention and treatment with sex hormone replacement therapy. Rozenberg S, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:14–7 (28 ref.)

Office management of osteoporosis: a guide for the primary care provider. Daly PA. **Compr Ther** 1995 Oct; 21(10):565–74 (57 ref.)

Impact of a 12–month exercise program on the physical and psychological health of osteopenic women. Bravo G, et al. **J Am Geriatr Soc** 1996 Jul;44(7):756–62

[Osteoporosis. 2] Fojtík Z, et al. **Vnitr Lek** 1995 Dec; 41(12):851–7 (43 ref.) (Eng. Abstr.) **(Cze)**

[Contemporary views on use of estrogen replacement therapy in postmenopausal women. I. Hormone therapy in women with menopausal osteoporosis] Krasomski G. **Ginekol Pol** 1995 Jan;66(1):28–31 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Quantitative ultrasound of the tibia: a novel approach for assessment of bone status. Foldes AJ, et al. **Bone** 1995 Oct; 17(4):363–7

A precise method for the assessment of tibial ultrasound velocity. Orgee JM, et al. **Osteoporos Int** 1996;6(1):1–7

Osteoporosis: association of recent fractures with quantitative US findings [see comments] Glüer CC, et al. **Radiology** 1996 Jun;199(3):725–32. Comment in: Radiology 1996 Jun;199(3):612–4.

[Quantitative ultrasonography in the evaluation of postmenopausal osteoporosis. Comparison with dual energy x–ray absorptiometry] Magarò M, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):218–21 (Eng. Abstr.) **(Ita)**

URINE

Zinc, biochemical markers of nutrition, and type I osteoporosis. Relea P, et al. **Age Ageing** 1995 Jul; 24(4):303–7

OSTEOPOROSIS, SENILE see **OSTEOPOROSIS**

OSTEORADIONECROSIS

[Osteoradionecrosis of the jaws] Nagler R, et al. **Harefuah** 1995 Oct;129(7–8):254–6, 294 (Eng. Abstr.) **(Heb)**

COMPLICATIONS

Non–union of mandibulotomy sites following irradiation for squamous cell carcinoma of the oral cavity. Altman K, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):62–5

EPIDEMIOLOGY

An analysis of mandibular bone complications in radiotherapy for T1 and T2 carcinoma of the oral tongue. Fujita M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):333–9

Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology [see comments] Withers HR, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):563–8. Comment in: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):759–60.

ETIOLOGY

Incidence and possible aetiological factors in the development of pelvic insufficiency fractures following radical radiotherapy. Bliss P, et al. **Br J Radiol** 1996 Jun; 69(822):548–54

Osteoradionecrosis of the hyoid induced by combined modality therapy for laryngeal carcinoma. Robertson JS, et al. **Ear Nose Throat J** 1995 Aug;74(8):578–81

Refracture of a healed tibial shaft fracture after irradiation for post–traumatic squamous–cell carcinoma. Korovessis P, et al. **Injury** 1995 Oct;26(8):559–61

Late normal tissue complications: new insights [editorial; comment] Fowler JF. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):759–60. Comment on: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):563–8.

Early failure of acetabular components inserted without cement after previous pelvic irradiation. Jacobs JJ, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1829–35

[Late radiation–induced injuries: breast carcinoma in post–actinic ulceration of the thoracic–breast region with infected osteoradionecrosis. A case report] Sironi I, et al. **G Chir** 1996 Jan–Feb;17(1–2):37–42 (Eng. Abstr.) **(Ita)**

SURGERY

Radial forearm flap in maxillo–facial surgery. Kovács A, et al. **Acta Chir Hung** 1995–96;35(1–2):149–58

Total hip replacement in irradiated hips. A retrospective study of 71 cases. Massin P, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):847–52

Mandibular reconstruction using the double barrel fibular graft. Horiuchi K, et al. **Microsurgery** 1995;16(7):450–4

[Surgical tooth reconstruction in conjunction with irradiation of malignant tumors] Henrich GM, et al. **Fortschr Kiefer Gesichtschir** 1995;40:166–9 (Eng. Abstr.) **(Ger)**

[Dento–alveolar surgery of the irradiated jaw: is infected osteoradionecrosis a preventable complication?] Konter U, et al. **Fortschr Kiefer Gesichtschir** 1995;40:160–2 (Eng. Abstr.) **(Ger)**

[3–years results of endoprosthetic management of radiation–induced hip joint necrosis] Aigner C, et al. **Wien Klin Wochenschr** 1995;107(23):726–30 (Eng. Abstr.) **(Ger)**

[Osteoradionecrosis of the hip joint] Aigner C, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):467–73 (Eng. Abstr.) **(Ger)**

THERAPY

Hyperbaric oxygen in the management of osteoradionecrosis [clinical conference] Ashamalla HL, et al. **Med Pediatr Oncol** 1996 Jul;27(1):48–53

Hyperbaric oxygen therapy [letter; comment] Epstein J, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):265–6. Comment on: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Jul;80(1):12–6.

Hyperbaric oxygen treatment of osteoradionecrosis of the mandible. Experience in 29 patients [see comments] van Merkesteyn JP, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):12–6. Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):265–6.

Irradiated bone and its management. Costantino PD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1021–38 (29 ref.)

OSTEOSARCOMA

Extraskeletal osteosarcoma of the mediastinum associated with long–term patient survival. A case report. De Nictolis M, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2785–9

Primary osteosarcoma of the breast. Farrugia DC, et al. **Eur J Surg Oncol** 1995 Dec;21(6):686–8

Mediastinal mass following chemotherapy in patients with Ewing sarcoma and osteosarcoma. Panadero MA, et al. **J Intern Med** 1996 May;239(5):457–60

Osteosarcoma and its variants. Vander Griend RA. **Orthop Clin North Am** 1996 Jul;27(3):575–81 (30 ref.)

Cancer of bone in children. Jaffe N. **Pediatr Dent** 1995 Jul–Aug;17(4):263–7 (56 ref.)

Primary osteosarcoma presenting in axial bones in childhood. Akyüz C, et al. **Turk J Pediatr** 1995 Oct–Dec;37(4):375–81

Primary renal osteosarcoma. Case report and review of the literature. Messen S, et al. **Urol Int** 1995;55(3):158–61 (17 ref.)

[Osteosarcoma of the liver] Itoh A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):360–2 (19 ref.) **(Jpn)**

BLOOD

Bone–specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Liu PP, et al. **Oncology** 1996 Jul–Aug;53(4):275–80

CHEMICALLY INDUCED

Fluoride exposure and childhood osteosarcoma: a case–control study. Gelberg KH, et al. **Am J Public Health** 1995 Dec;85(12):1678–83

CHEMISTRY

Expression of p53 protein, PCNA, and Ki–67 in osteosarcomas of bone. Park HR, et al. **J Korean Med Sci** 1995 Oct;10(5):360–7

Osteocalcin expression in primary bone tumors—in situ hybridization and immunohistochemical study. Park YK, et al. **J Korean Med Sci** 1995 Aug;10(4):263–8

Expression of P–glycoprotein in high–grade osteosarcomas in relation to clinical outcome [see comments] Baldini N, et al. **N Engl J Med** 1995 Nov 23;333(21):1380–5. Comment in: N Engl J Med 1995 Nov 23;333(21):1417–9. Comment in: N Engl J Med 1996 May 16;334(20):1335–6; discussion 1336–7. Comment in: N Engl J Med 1996 May 16;334(20):1336; discussion 1336–7.

P–glycoprotein and multidrug resistance [letter; comment] Johnston JM. **N Engl J Med** 1996 May 16;334(20):1336; discussion 1336–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

P–glycoprotein and multidrug resistance [letter; comment] Mesa–Tejada R. **N Engl J Med** 1996 May 16; 334(20):1335–6; discussion 1336–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

New aspects of cell biology in osteosarcoma. Grundmann E, et al. **Pathol Res Pract** 1995 Jul;191(6):563–70

COMPLICATIONS

Sweet syndrome in a patient with osteosarcoma. Sandlund JT, et al. **Am J Clin Oncol** 1996 Aug;19(4):349–50

The surgical treatment of patients with osteosarcoma who sustain a pathologic fracture. Scully SP, et al. **Clin Orthop** 1996 Mar;(324):227–32

Extraskeletal osteosarcoma: an unusual presentation as tarsal tunnel syndrome. Jaffe KA, et al. **Foot Ankle Int** 1995 Dec; 16(12):796–9

Osteogenic sarcoma in a child with transfusion–dependent Diamond–Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)

Rothmund–Thomson syndrome and osteosarcoma. Cumin I, et al. **Med Pediatr Oncol** 1996 Jun;26(6):414–6

Osteogenic sarcoma in the Rothmund–Thomson syndrome. Leonard A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):249–53 (22 ref.)

Sonographic diagnosis and follow–up of diffuse neutropenic colitis: case report of a child treated for osteogenic sarcoma. Suarez B, et al. **Pediatr Radiol** 1995;25(5):373–4

[Rothmund–Thomson syndrome and osteosarcoma] Molina MI, et al. **Arch Pediatr** 1995 Sep;2(9):865–70 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

DentaCT for evaluating mandibular and maxillary invasion in cancer of the oral cavity. Talmi YP, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):431–7

Haematopoietic marrow hyperplasia simulating transarticular skip metastasis in osteosarcoma. Pui MH, et al. **Australas Radiol** 1995 Aug;39(3):303–5

Osteosarcoma in a 19–month–old girl. Graham NJ, et al. **Can Assoc Radiol J** 1996 Feb;47(1):33–5

Magnetic resonance imaging of primary osteosarcoma of the lumbar vertebra with metastasis to the perirenal fat. Tehranzadeh J, et al. **Can Assoc Radiol J** 1996 Aug; 47(4):275–8

Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma–like osteosarcoma. Naka T, et al. **Cancer** 1995 Sep 15;76(6):972–84

Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. Lin J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):200–1 (10 ref.)

Low grade central osteogenic sarcoma. A long–term followup of 20 patients. Choong PF, et al. **Clin Orthop** 1996 Jan;(322):198–206

Posterior thigh pain in a 42-year-old woman [clinical conference] Johnston JO, et al. **Clin Orthop** 1996 Jun; (327):305-7, 311-2

Knee pain and swelling in a 30-year-old woman. Makley JT, et al. **Clin Orthop** 1996 Sep;(330):304-7, 310-2

Intracortical low grade osteosarcoma. A unique case and review of the literature on intracortical osteosarcoma. Blasius S, et al. **Gen Diagn Pathol** 1996 Mar;141(3-4):273-8 (22 ref.)

Extraskeletal osteosarcoma with a highly malignant course. A case report. Simank HG, et al. **Int Orthop** 1995; 19(4):251-4

Vertebra plana: benign or malignant lesion? Baghaie M, et al. **Pediatr Radiol** 1996;26(6):431-3

Giant bone island of femur. Case report, literature review, and its distinction from low grade osteosarcoma. Brien EW, et al. **Skeletal Radiol** 1995 Oct;24(7):546-50 (15 ref.)

Appendicular metastatic prostate cancer simulating osteosarcoma, Paget's disease, and Paget's sarcoma. Igou D, et al. **Skeletal Radiol** 1995 Aug;24(6):447-9

High-grade surface osteosarcoma of the humerus. Okada K, et al. **Skeletal Radiol** 1995 Oct;24(7):531-4 (15 ref.)

Small cell osteosarcoma of the soft tissue. Robinson LH, et al. **Skeletal Radiol** 1995 Aug;24(6):462-5

Epithelioid sarcoma presenting as chronic synovitis and mistaken for osteosarcoma. von Hochstetter AR, et al. **Skeletal Radiol** 1995 Nov;24(8):636-8

[Vertebral osteosarcoma. Review of the literature apropos of a case] Peyrade F, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):551-6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Epitheloid osteosarcoma. Differential diagnostic problems] Richter D, et al. **Langenbecks Arch Chir** 1995;380(6):354-8 (Eng. Abstr.) **(Ger)**

[Chondroblastic osteosarcoma of the distal femur] Aschoff AJ, et al. **Rontgenpraxis** 1996 Jun;49(6):149-51 **(Ger)**

[Transitional-cell sarcomatoid carcinoma of the renal pelvis with osteoclast-type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63-7 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Mader RM, et al. **Arch Environ Health** 1996 Jul-Aug;51(4):310-4

Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres [letter] Craft AW, et al. **Aust N Z J Med** 1996 Apr;26(2):230

Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres. Jameson MB, et al. **Aust N Z J Med** 1995 Jun;25(3):224-9

Anaphylactoid reactions to methotrexate. Alkins SA, et al. **Cancer** 1996 May 15;77(10):2123-6 (13 ref.)

Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Patel SR, et al. **Cancer** 1996 Aug 15;78(4):741-4

Musculoskeletal tumour disorders [editorial] Marcove RC. **Compr Ther** 1996 Jan;22(1):7

The role of chemotherapy in osteogenic sarcoma. Bramwell VH. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):61-85 (187 ref.)

Synthetic 20-epi analogs of calcitriol are potent inducers of target-gene activation in osteoblastic cells. Ryhänen S, et al. **Eur J Biochem** 1996 May 15;238(1):97-103

Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Lin J, et al. **Eur J Nucl Med** 1995 Jun;22(6):553-5

Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Jaffe N, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):825-40 (79 ref.)

Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Pinski J, et al. **Int J Cancer** 1996 Mar 15;65(6):870-4

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374-6 (10 ref.)

Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. Takeshita H, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):366-75

Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells. Takada J, et al. **J Bone Miner Res** 1995 Oct; 10(10):1512-22

Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. Bacci G, et al. **J Chemother** 1995 Jun; 7(3):230-9

Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848-58 (38 ref.)

Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. Reddick WE, et al. **J Magn Reson Imaging** 1995 Nov-Dec; 5(6):689-94

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. Pinski J, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1787-94

Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. Hosain F, et al. **J Nucl Med** 1996 Jan;37(1):105-7

Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. Ohtomo K, et al. **J Nucl Med** 1996 Sep; 37(9):1444-8

P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Ballinger JR, et al. **Magn Reson Imaging** 1995;13(6):877-83

Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. Canpolat C, et al. **Med Pediatr Oncol** 1996 Jan;26(1):36-47

Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors. Kharasch VS, et al. **Med Pediatr Oncol** 1996 Aug;27(2):85-91

Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Lang P, et al. **Med Pediatr Oncol** 1996 May;26(5):329-33

A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Wada T, et al. **Oncology** 1996 May-Jun;53(3):221-7

[Chemotherapy of osteogenic sarcomas] Brain E, et al. **Chirurgie** 1994-95;120(13):193-8 (70 ref.) **(Fre)**

[Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up] Werner M, et al. **Pathologe** 1996 Jan;17(1):35-43 (Eng. Abstr.) **(Ger)**

[Preliminary evaluation of individualized use of large doses of methotrexate for treatment of osteosarcoma in children and adolescents] Perek D, et al. **Pediatr Pol** 1995 Nov; 70(11):929-37 (Eng. Abstr.) **(Pol)**

[Role of chemotherapy in treatment of osteosarcoma] Perek D, et al. **Pediatr Pol** 1995 Nov;70(11):939-47 (39 ref.) (Eng. Abstr.) **(Pol)**

[Current aspects of the treatment of osteogenic sarcoma] Glukhovskaia IIu, et al. **Klin Khir** 1995;(5):32-3 **(Rus)**

ENZYMOLOGY

Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63): regulation by interleukin-1 beta and parathyroid hormone. Aisa MC, et al. **Biochim Biophys Acta** 1996 May 21; 1290(1):29-36

Phosphate regulates the stability of skeletal alkaline phosphatase activity in human osteosarcoma (SaOS-2) cells without equivalent effects on the level of skeletal alkaline phosphatase immunoreactive protein. Farley JR. **Calcif Tissue Int** 1995 Nov;57(5):371-8

Stimulation of gelatinase B and tissue inhibitors of metalloproteinase (TIMP) production in co-culture of human osteosarcoma cells and human fibroblasts: gelatinase B production was stimulated via up-regulation of fibroblast growth factor (FGF) receptor. Kurogi T, et al. **Int J Cancer** 1996 Mar 28;66(1):82-90

17 beta-oestradiol enhances the stimulatory effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity in human osteosarcoma SaOS-2 cells in a differentiation-dependent manner. Rao LG, et al. **J Endocrinol** 1996 Jan;148(1):181-7

Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line. Morris AJ, et al. **Mol Pharmacol** 1995 Sep;48(3):532-9

EPIDEMIOLOGY

A review of 40 patients with extraskeletal osteosarcoma. Lee JS, et al. **Cancer** 1995 Dec 1;76(11):2253-9

Low rates of Paget's disease of bone and osteosarcoma in elderly Japanese [letter] Ishikawa Y, et al. **Lancet** 1996 Jun 1;347(9014):1559

Osteosarcoma in New Zealand 1981-7: an overview. Mills HJ, et al. **N Z Med J** 1995 Nov 10;108(1011):458-9

[Non-metastatic osteosarcoma of the extremities: the pattern of relapse as a function of the type of treatment and of the modulation of the radiological follow-up of the thorax] Rimondi E, et al. **Minerva Med** 1996 Jan-Feb;87(1-2):9-15 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885-9 (27 ref.)

Simultaneous occurrence of osteosarcoma and osteochondroma following treatment of neuroblastoma with chemotherapy, radiotherapy, and bone marrow transplantation. Poustchi-Amin M, et al. **Pediatr Radiol** 1996;26(2):155-7

GENETICS

Multidrug-resistance (MDR) phenotype of human osteosarcoma cells evaluated by quantitative morphological and electron microscopy analyses. Zini N, et al. **Biol Cell** 1995;84(3):195-204

ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Onda M, et al. **Cancer** 1996 Jan 1;77(1):71-8

Presence of double minutes and monosomy 17p in xenografted human osteosarcomas. López-Ginés C, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):57-62

Alterations of the p15, p16,and p18 genes in osteosarcoma. Miller CW, et al. **Cancer Genet Cytogenet** 1996 Feb; 86(2):136-42

c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Wang ZQ, et al. **Cancer Res** 1995 Dec 15;55(24):6244-51

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349-54 (40 ref.)

Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Forus A, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):15-21

Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Miller CW, et al. **J Cancer Res Clin Oncol** 1996; 122(9):559-65

Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. Feugeas O, et al. **J Clin Oncol** 1996 Feb;14(2):467-72

Progression of canine mammary tumours as reflected by DNA ploidy in primary tumours and their metastases. Hellmén E, et al. **J Comp Pathol** 1995 Nov;113(4):327-42

Deletion of Rb1 gene in late osteosarcoma from survivor of unilateral retinoblastoma--a case report. Lee SY, et al. **J Korean Med Sci** 1996 Feb;11(1):94-8

Osteosarcoma oncogene expression detected by in situ hybridization. Wang H, et al. **J Orthop Res** 1995 Sep; 13(5):671-8

Changes in radiation sensitivity of human osteosarcoma cells after p53 introduction. Miyakoshi J, et al. **Jpn J Cancer Res** 1995 Aug;86(8):711-3

Analysis of oncogenes, tumor suppressor genes, autocrine growth-factor production, and differentiation state of human osteosarcoma cell lines. Isfort RJ, et al. **Mol Carcinog** 1995 Nov;14(3):170-8

A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells. Kato MV, et al. **Oncogene** 1996 Mar 21;12(6):1361-4

New aspects of cell biology in osteosarcoma. Grundmann E, et al. **Pathol Res Pract** 1995 Jul;191(6):563-70

Multiple calcium channel transcripts in rat osteosarcoma cells: selective activation of alpha 1D isoform by parathyroid hormone. Barry EL, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10914-8

[Cytogenetics of bone sarcomas] Vagner-Capodano AM, et al. **Chirurgie** 1994-95;120(13):188-92 (Eng. Abstr.) **(Fre)**

[Osteosarcoma in 2 siblings. A case report] Danckwerth F, et al. **Klin Padiatr** 1995 Sep-Oct;207(5):298-301 (41 ref.) (Eng. Abstr.) **(Ger)**

[P-glycoprotein expression in osteosarcoma] Pösl M, et al. **Pathologe** 1996 Jan;17(1):50-5 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. Olafsen T, et al. **Acta Oncol** 1996;35(3):297-301

In vitro cytolytic activity of human NK cells against osteosarcoma cell lines. Tarozzi A, et al. **Boll Soc Ital Biol Sper** 1995 Jul-Aug;71(7-8):221-6

Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. Olafsen T, et al. **Nucl Med Biol** 1995 Aug;22(6):765-71

METABOLISM

Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography. Hjelstuen MH, et al. **Acta Oncol** 1996;35(3):273-9

Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Bodey B, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2461-8

Facs analysis of osteosarcoma cell line (MG-63) integrin subfamilies. Lisignoli G, et al. **Boll Soc Ital Biol Sper** 1995 Nov-Dec;71(11-12):309-15

Type I and type III collagen metabolites in adult osteosarcoma patients. Wiklund T, et al. **Br J Cancer** 1996 Jan;73(1):106-9

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Kostenuik PJ, et al. **Clin Exp Metastasis** 1996 Jan;14(1):19-26

Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Kobayashi H, et al. **Eur J Cancer** 1995 Sep; 31A(10):1689-96

Analysis of P-glycoprotein expression in osteosarcoma. Serra M, et al. **Eur J Cancer** 1995 Nov;31A(12):1998-2002

Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Oda Y, et al. **Gen Diagn Pathol** 1995 Oct;141(2):97-103

Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription

factors. Liang Y, et al. **J Biol Chem** 1996 May 17; 271(20):11792–7

In vitro metabolism of the vitamin D analog, 22–oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines. Masuda S, et al. **J Biol Chem** 1996 Apr 12; 271(15):8700–8

Growth patterns and cell kinetics of human osteosarcoma xenografts in serial passages in nude mice analyzed by in vivo labelling with iododeoxyuridine. Broström LA, et al. **J Cancer Res Clin Oncol** 1996;122(3):141–46

Comparison of the type–2 insulin–like growth factor receptor in normal osteoblasts and osteosarcoma–derived osteoblast–like cells. Ishibe M, et al. **J Orthop Res** 1995 Sep;13(5):643–8

Differential effects of 1,25–dihydroxyvitamin D3–analogs on osteoblast–like cells and on in vitro bone resorption. van den Bemd GJ, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):337–46

Osteogenic potential of murine osteosarcoma cells: comparison of bone–specific gene expression in in vitro and in vivo conditions. Gerstenfeld LC, et al. **Lab Invest** 1996 May;74(5):895–906

P–31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Ballinger JR, et al. **Magn Reson Imaging** 1995;13(6):877–83

Analysis of oncogenes, tumor suppressor genes, autocrine growth–factor production, and differentiation state of human osteosarcoma cell lines. Isfort RJ, et al. **Mol Carcinog** 1995 Nov;14(3):170–8

Regulation of NGF, BDNF and LNGFR gene expression in ROS 17/2.8 cells. Jehan F, et al. **Mol Cell Endocrinol** 1996 Feb 5;116(2):149–56

Mandibular osteosarcoma with unusual expression of alpha–actin smooth muscle antibody. Remadi S, et al. **Pathol Res Pract** 1996 Feb;192(2):148–53

Relationship between the induction of heat shock proteins and the decrease in glucocorticoid receptor during heat shock response in human osteosarcoma cells. Song L. **Sci China B** 1995 Dec;38(12):1473–81

MORTALITY

Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. Feugeas O, et al. **J Clin Oncol** 1996 Feb;14(2):467–72

PATHOLOGY

DentaCT for evaluating mandibular and maxillary invasion in cancer of the oral cavity. Talmi YP, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):431–7

BK virus–induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1835–42 (40 ref.)

A rare case of orbital osteogenic sarcoma [letter] Trevisani MG, et al. **Arch Ophthalmol** 1996 Apr;114(4):494–5

Sarcoma in association with bone infarcts. Report of five cases. Desai P, et al. **Arch Pathol Lab Med** 1996 May; 120(5):482–9

Multidrug–resistance (MDR) phenotype of human osteosarcoma cells evaluated by quantitative morphological and electron microscopy analyses. Zini N, et al. **Biol Cell** 1995;84(3):195–204

Myeloma cells upregulate interleukin–6 secretion in osteoblastic cells through cell–to–cell contact but downregulate osteocalcin. Barillé S, et al. **Blood** 1995 Oct 15;86(8):3151–9

Multidrug resistance and malignancy in human osteosarcoma. Scotlandi K, et al. **Cancer Res** 1996 May 15;56(10):2434–9

Osteosarcoma of jaw: the experience of Chang Gung Memorial Hospital. Chen JS, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):260–5

Human osteosarcoma cell lines MG–63 and SaOS–2 produce G–CSF and GM–CSF: identification and partial characterization of cell–associated isoforms. Taichman RS, et al. **Exp Hematol** 1996 Mar;24(4):509–17

Paget's sarcoma of the mandible. Gleich LL, et al. **Head Neck** 1995 Sep–Oct;17(5):425–30 (20 ref.)

Osteosarcoma. Specimen management following primary chemotherapy. Raymond AK, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):841–67 (70 ref.)

Osteogenic sarcoma of the scalp. Kircik L, et al. **Int J Dermatol** 1995 Dec;34(12):861–2

Growth patterns and cell kinetics of human osteosarcoma xenografts in serial passages in nude mice analyzed by in vivo labelling with iododeoxyuridine. Broström LA, et al. **J Cancer Res Clin Oncol** 1996;122(3):141–46

1 alpha, 25–dihydroxy–16–ene–23–yne–26,27–hexafluorocholecalciferol (Ro24–5531) modulation of insulin–like growth factor–binding protein–3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. Velez–Yanguas MC, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):93–9

Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)

Tumor size and prognosis in aggressively treated osteosarcoma [letter] Jaffe N, et al. **J Clin Oncol** 1996 Aug; 14(8):2399–400

A small cell osteosarcoma on the calcaneus—a case report. Park YK, et al. **J Korean Med Sci** 1995 Apr;10(2):147–51

Chondroblastic osteosarcoma of the mandible: report of a case. Kawasaki T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1123–7 (11 ref.)

Differential effects of 1,25–dihydroxyvitamin D3–analogs on osteoblast–like cells and on in vitro bone resorption. van den Bemd GJ, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):337–46

Changes in radiation sensitivity of human osteosarcoma cells after p53 introduction. Miyakoshi J, et al. **Jpn J Cancer Res** 1995 Aug;86(8):711–3

A follistatin–like gene, mac25, may act as a growth suppressor of osteosarcoma cells. Kato MV, et al. **Oncogene** 1996 Mar 21;12(6):1361–4

Primary osteosarcoma arising from cirrhotic liver. Kitayama Y, et al. **Pathol Int** 1995 Apr;45(4):320–5

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

Osteogenic sarcoma of the tongue. Case report and review of the literature. Loyzaga JM, et al. **Pathol Res Pract** 1996 Jan;192(1):75–8; discussion 79–80 (9 ref.)

Establishment of two rat osteosarcoma cell lines (YROS–1 and YROS–2) induced by radioactive phosphorus. Machida J, et al. **Pathol Res Pract** 1995 Jun;191(5):478–85

Primary osteosarcoma of the breast. Remadi S, et al. **Pathol Res Pract** 1995 Jun;191(5):471–4; discussion 475–7

Malignant bone tumors of childhood. Himelstein BP, et al. **Pediatr Clin North Am** 1996 Aug;43(4):967–84 (38 ref.)

Magnetic resonance imaging of massive bone allografts with histologic correlation. Hoeffner EG, et al. **Skeletal Radiol** 1996 Feb;25(2):165–70

Osteosarcoma after chemotherapy for neuroblastoma. Kriss VM, et al. **Skeletal Radiol** 1995 Nov;24(8):633–5

Well–differentiated, low–grade osteosarcoma of the clivus. Park YK, et al. **Skeletal Radiol** 1995 Jul;24(5):386–8

[A case of osteogenic sarcoma of the breast] Deliiski T, et al. **Khirurgiia (Sofiia)** 1995;48(6):50–1 **(Bul)**

[Can magnetic resonance imaging differentiate between benign and malignant conditions in patients with skeletal or soft tissue tumors?] Lundorf E, et al. **Ugeskr Laeger** 1996 Mar 11;158(11):1518–20 (Eng. Abstr.) **(Dan)**

[Osteogenic sarcomas. Easy and less easy anatomopathological diagnoses] Forest M. **Chirurgie** 1994–95;120(13):186–7 **(Fre)**

[Results given by x–ray computed tomography and MRI in the staging of bone sarcomas] Panuel M, et al. **Chirurgie** 1994–95;120(13):199–200 **(Fre)**

[MRI and cell necrosis after chemotherapy] Panuel M. **Chirurgie** 1994–95;120(13):201 **(Fre)**

[Cell proliferation in bone tumors. Immunohistologic study of Ki–67 protein expression] Stenzel I, et al. **Pathologe** 1996 Jan;17(1):56–62 (Eng. Abstr.) **(Ger)**

[DNA cytometry of solitary and aneurysmal bone cysts and low malignancy and high malignancy central osteosarcomas. Current significance within the scope of morphologic diagnosis of intraosseous cystic and osteoblastic lesions] Werner M, et al. **Pathologe** 1996 Jan; 17(1):44–9 (Eng. Abstr.) **(Ger)**

[Prostaglandins of series E in morphologic variants of osteogenic sarcoma and evaluation of the degree of therapeutic pathomorphism of the tumor] Kushlinskiĭ NE, et al. **Arkh Patol** 1995 Sep–Oct;57(5):25–30 (Eng. Abstr.) **(Rus)**

[Cardiac osteogenic sarcoma with chondroblastic differentiation] López–Pérez JM, et al. **An Med Interna** 1996 Apr;13(4):178–80 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Healing of a segmental defect in the rat femur with use of an extract from a cultured human osteosarcoma cell–line (Saos–2). A preliminary report. Hunt TR, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):41–8

RADIOGRAPHY

CT findings of primary osteosarcoma of the bladder [letter] Abbas AM, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):535–6

Osteosarcoma: subtle, rare, and misleading plain film features. Rosenberg ZS, et al. **AJR Am J Roentgenol** 1995 Nov; 165(5):1209–14

Pictorial review: Imaging of primary osteosarcoma of the spine. Green R, et al. **Clin Radiol** 1996 May;51(5):325–9 (22 ref.)

Multifocal synchronous osteosarcoma. Taccone A, et al. **Eur J Radiol** 1995 May;20(1):43–5

Primary osteosarcoma of the kidney. Case report and review of literature. Weingärtner K, et al. **Eur Urol** 1995;28(1):81–4

Calcification as a sign of sarcomatous degeneration of malignant pleural mesotheliomas: a new CT finding. Raizon A, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):42–4

Radiographic differentiation of osteogenic sarcoma, osteomyelitis, and fibrous dysplasia of the jaws. Petrikowski CG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):744–50

Osteosarcoma of the hard palate. Eustace S, et al. **Skeletal Radiol** 1995 Jul;24(5):392–4

[Osteosarcoma of the skull cap. Differential diagnosis and clinical considerations] Rademaker J. **Aktuelle Radiol** 1996 May;6(3):159–60 (Eng. Abstr.) **(Ger)**

[Invasion of the growth plate by bone tumors and osteomyelitis in childhood (letter)] Willich E. **Radiologe** 1995 Nov;35(11):878 (Eng. Abstr.) **(Ger)**

[Delayed diagnosis. Press campaign in Austria (news)] Engelhardt R. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr; 134(2):Oa23 **(Ger)**

RADIONUCLIDE IMAGING

Detection of adrenal metastasis from osteosarcoma by Tc–99m MDP scintigraphy. Kauffman WM, et al. **Clin Nucl Med** 1995 Aug;20(8):741

The role of bone scintigraphy in the follow–up of osteogenic sarcoma. Körholz D, et al. **Eur J Cancer** 1996 Mar; 32A(3):461–4

Quantitative evaluation of thallium–201 uptake in predicting chemotherapeutic response of osteosarcoma. Lin J, et al. **Eur J Nucl Med** 1995 Jun;22(6):553–5

Thallium–201 scintigraphy to assess effect of chemotherapy in osteosarcoma. Ohtomo K, et al. **J Nucl Med** 1996 Sep; 37(9):1444–8

Cloning and sequencing of V genes from anti–osteosarcoma monoclonal antibodies TP–1 and TP–3: location of lysine residues and implications for radiolabeling. Olafsen T, et al. **Nucl Med Biol** 1995 Aug;22(6):765–71

RADIOTHERAPY

Targeted radiotherapy of osteosarcoma using 153 Sm–EDTMP. A new promising approach. Bruland OS, et al. **Acta Oncol** 1996;35(3):381–4

REHABILITATION

[Gait analysis in patients with tumor endoprostheses of the HMRS type] Bach CM. **Wien Klin Wochenschr** 1996; 108(6):184–6 **(Ger)**

SECONDARY

Risk of tumor recurrence and growth hormone therapy [letter] Rivas–Crespo MF, et al. **Acta Paediatr** 1995 Oct; 84(10):1102

Video–assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed? Yim AP, et al. **Aust N Z J Surg** 1995 Oct;65(10):737–9

Haematopoietic marrow hyperplasia simulating transarticular skip metastasis in osteosarcoma. Pui MH, et al. **Australas Radiol** 1995 Aug;39(3):303–5

Osteosarcoma metastatic to the pancreas in young patients. Glass RJ, et al. **Clin Radiol** 1996 Apr;51(4):293–4

Biologic therapy for osteosarcoma using liposome–encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

Metastatic osteosarcoma of the ethmoid: an unusual cause of recurrent epistaxis and proptosis. Sharma HS, et al. **J Laryngol Otol** 1996 Jul;110(7):676–8

Metastatic osteosarcoma of the kidney presenting as renal hemorrhage. Raby WN, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):321–2

Solitary, thin–walled cavitary lung metastasis of osteogenic sarcoma. Nomori H, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):95–6

[Total spondylectomy in metastasizing osteosarcoma of the spine—case report] Krepler P, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):269–72 (Eng. Abstr.) **(Ger)**

SURGERY

Bone tumours in childhood. Vizkelety T. **Acta Med Hung** 1994;50(3–4):229–35

Rotationplasty for patients with osteosarcoma around the knee joint. Kawai A, et al. **Acta Med Okayama** 1995 Aug; 49(4):221–6

Replacement of the proximal humerus in primary bone tumours. Huckstep RL, et al. **Aust N Z J Surg** 1996 Feb; 66(2):97–100

Video–assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed? Yim AP, et al. **Aust N Z J Surg** 1995 Oct;65(10):737–9

The surgical treatment of patients with osteosarcoma who sustain a pathologic fracture. Scully SP, et al. **Clin Orthop** 1996 Mar;(324):227–32

Intraoperative clotting factor dilution and activated hemostasis in children with Ewing's sarcoma or osteosarcoma: a prospective longitudinal study. Nowak–Göttl U, et al. **Haematologica** 1995 Jul–Aug; 80(4):311–7

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)

Consolidation of massive bone allografts in limb–preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)

Osteogenic sarcoma of sphenoid bone: an extended lateral skull base approach. Hazarika P, et al. **J Laryngol Otol** 1995 Nov;109(11):1101–4

Spontaneous regeneration of a resected mandible in a preadolescent: a clinical report. Whitmyer CC, et al. **J Prosthet Dent** 1996 Apr;75(4):356–9

Malignant humeral bone tumors in children: excision and reconstruction with the use of rotated clavicle. Woźniak W, et al. **J Surg Oncol** 1996 Jul;62(3):183–5

A preliminary report of neoadjuvant chemotherapy NSH–7

study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Wada T, et al. **Oncology** 1996 May-Jun;53(3):221-7

Multifocal osteolysis following limb-sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158-61 (17 ref.)

Limb salvage procedures in osteosarcomas around the knee joint. Rodriguez Merchán EC, et al. **Rev Paul Med** 1994 Oct-Dec;112(4):661-7 (42 ref.)

Magnetic resonance imaging of massive bone allografts with histologic correlation. Hoeffner EG, et al. **Skeletal Radiol** 1996 Feb;25(2):165-70

[Diagnosis and treatment of osteogenic sarcomas, techniques of reconstructions. Future prospects] Poitout D, et al. **Chirurgie** 1994-95;120(13):204-15 (Eng. Abstr.) **(Fre)**

[Resection of osteosarcomas. Principles and methods] Tomeno B. **Chirurgie** 1994-95;120(13):202-3 **(Fre)**

[Osteosarcoma and Ewing's sarcoma. Improved recovery chances in the past 25 years according to the experience of Balgrist Hospital] Exner GU, et al. **Schweiz Rundsch Med Prax** 1996 May 28;85(22):706-13 (Eng. Abstr.) **(Ger)**

[Total spondylectomy in metastasizing osteosarcoma of the spine--case report] Krepler P, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):269-72 (Eng. Abstr.) **(Ger)**

[37-year survival of a patient with osteosarcoma of the proximal tibia after biological resection according to Grucy] Grabski RS. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(2):165-8 (Eng. Abstr.) **(Pol)**

[Modern therapy of osteogenic sarcoma in children. Our experience in limb salvage surgery] Woźniak W. **Pediatr Pol** 1995 Nov;70(11):959-63 (Eng. Abstr.) **(Pol)**

THERAPY

New aspects in the treatment of bone sarcomas. Szendröi M. **Acta Med Hung** 1994;50(3-4):237-44 (14 ref.)

Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Strander H, et al. **Acta Oncol** 1995;34(6):877-80

Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Skotzko M, et al. **Cancer Res** 1995 Dec 1; 55(23):5493-8

Osteosarcoma in Hong Kong. Yip KM, et al. **Clin Orthop** 1996 Feb;(323):49-59

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349-54 (40 ref.)

Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Manusama ER, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):152-7

Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. Peyser AB, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1172-80 (20 ref.)

Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence [letter; comment] Bielack SS, et al. **J Clin Oncol** 1996 Feb; 14(2):683-4. Comment on: J Clin Oncol 1994 Dec;12(12):2699-705.

The management of limb-length discrepancies in children after treatment of osteosarcoma and Ewing's sarcoma. González-Herranz P, et al. **J Pediatr Orthop** 1995 Sep-Oct; 15(5):561-5

Current combined treatment of high-grade osteosarcomas. Damron TA, et al. **Oncology (Huntingt)** 1995 Apr; 9(4):327-43; discussion 343-4, 347-50 (54 ref.)

[High grade osteosarcoma of the lower limb. Complications and results of the treatment of 20 patients] Babin SR, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(1):14-21 (Eng. Abstr.) **(Fre)**

[Bone sarcomas in children] Pashkov IuV, et al. **Vopr Onkol** 1995;41(2):75-8 **(Rus)**

ULTRASONOGRAPHY

Ultrasonographic monitoring of the effects of preoperative chemotherapy in osteosarcoma and Ewing's sarcoma. Kinoshita T, et al. **Int Orthop** 1995;19(5):312-4

ULTRASTRUCTURE

Nucleolar organizer regions in parosteal and central osteosarcomas. Schwint AE, et al. **Clin Orthop** 1996 Jun; (327):253-8

VETERINARY

Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. Hammer AS, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug;31(4):321-6

Canine mandibular osteosarcoma: 51 cases (1980-1992). Straw RC, et al. **J Am Anim Hosp Assoc** 1996 May-Jun; 32(3):257-62

What is your diagnosis? Osteogenic sarcoma causing lameness and lethargy in a dog. Farber M, et al. **J Am Vet Med Assoc** 1996 Feb 15;208(4):481-2

Intramedullary cisplatin chemotherapy: experience in four dogs with osteosarcoma. Hahn KA, et al. **J Small Anim Pract** 1996 Apr;37(4):187-92

Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. Moe L, et al. **J Small Anim Pract** 1996 May;37(5):241-6

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). Bergman PJ, et al. **J Vet Intern Med** 1996 Mar-Apr;10(2):76-81

p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Sagartz JE, et al. **Vet Pathol** 1996 Mar; 33(2):213-21

[A case of osteosarcoma in a white polar bear] Ponomarkov VI, et al. **Arkh Patol** 1995 Sep-Oct;57(5):81-3 (Eng. Abstr.) **(Rus)**

OSTEOSARCOMA, JUXTACORTICAL

PATHOLOGY

Giant cell rich parosteal osteosarcoma. Sciot R, et al. **Histopathology** 1995 Jul;27(1):51-5

Periosteal osteosarcoma of the mandible. Minić AJ. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):226-8

Juxtacortical dedifferentiated chondrosarcoma from a primary periosteal chondrosarcoma. Mitchell A, et al. **Mod Pathol** 1996 Mar;9(3):279-83

[Periosteal osteosarcoma. Histologic characteristics, preparation technique, growth pattern and differential diagnosis] Delling G, et al. **Pathologe** 1996 Jan;17(1):86-91 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Nucleolar organizer regions in parosteal and central osteosarcomas. Schwint AE, et al. **Clin Orthop** 1996 Jun; (327):253-8

VETERINARY

Periosteal osteosarcoma in the long head of the triceps in a dog. Cook JL, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug;31(4):317-20

OSTEOSCLEROSIS

CHEMICALLY INDUCED

[Generalized osteopathy with pathological fractures in a patient with long-term exposure to fluorine-containing plastics] Rhomberg W, et al. **Schweiz Med Wochenschr** 1995 Dec 2;125(48):2330-7 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy. Kuo MC, et al. **Ann Hematol** 1995 Sep; 71(3):147-51

Maternal high calcium diet fails to reverse rickets in the osteosclerotic mouse. Lester DR Jr, et al. **Clin Orthop** 1996 Sep;(330):271-80

Decreased cortical and increased cancellous bone in two children with primary hyperparathyroidism. Boechat MI, et al. **Metabolism** 1996 Jan;45(1):76-81

Hyperostotic and osteosclerotic changes of the tarsal navicular, associated with pustulosis palmaris and plantaris. Suh JS, et al. **Skeletal Radiol** 1996 May;25(4):377-80

[Schnitzler syndrome with stable course over a 18-year period. Report of a case (letter)] Dupuy O, et al. **Presse Med** 1995 Oct 14;24(30):1402 **(Fre)**

DIAGNOSIS

Ribbing disease (multiple diaphyseal sclerosis): imaging and differential diagnosis. Seeger LL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):689-94

Multiple lateral meningoceles, distinctive facies and skeletal anomalies: a new case of Lehman syndrome. Philip N, et al. **Clin Dysmorphol** 1995 Oct;4(4):347-51

Melorheostosis of the hand. Sharma R, et al. **J Hand Surg [Br]** 1996 Jun;21(3):413-5

Intracranial calcification in Raine syndrome. Al Mane KA, et al. **Pediatr Radiol** 1996;26(1):55-8

[Osteosclerotic myeloma. Report of a case] Ferrozzi F, et al. **Radiol Med (Torino)** 1996 May;91(5):643-5 **(Ita)**

DRUG THERAPY

Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy. Kuo MC, et al. **Ann Hematol** 1995 Sep; 71(3):147-51

ETIOLOGY

Sclerotic IgA myeloma and polyneuropathy: the POEMS syndrome. Case report [letter] Mertens I, et al. **Ann Oncol** 1995 Sep;6(7):731-2

[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350-2 (10 ref.) **(Ger)**

GENETICS

Autosomal dominant osteosclerosis type Stanescu: the third family. Horovitz DD, et al. **Am J Med Genet** 1995 Jul 17;57(4):605-9

Osteopathia striata with cranial sclerosis: variable expressivity in a four generation pedigree. König R, et al. **Am J Med Genet** 1996 May 3;63(1):68-73

A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Yan XQ, et al. **Blood** 1996 Jul 15;88(2):402-9

PATHOLOGY

Case report: dysosteosclerosis: a unique entity. Maheshwari A, et al. **Clin Radiol** 1996 Mar;51(3):224-8

RADIOGRAPHY

The incidence and relevance of bone sclerosis in orbital pseudotumour. Quaghebeur G, et al. **Clin Radiol** 1996 Feb; 51(2):123-6

[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561-72 (61 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Craniodiaphyseal dysplasia; another cause of difficult intubation. Appleby JN, et al. **Paediatr Anaesth** 1996; 6(3):225-9

THERAPY

A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Yan XQ, et al. **Blood** 1996 Jul 15;88(2):402-9

OSTEOSCLEROSIS FRAGILIS see **OSTEOPETROSIS**

OSTEOSYNTHESIS, FRACTURE see **FRACTURE FIXATION, INTERNAL**

OSTEOSYNTHESIS, FRACTURE, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

OSTEOTOMY

Possible complications of sagittal osteotomy of the mandibular ramus. Neméth T. **Acta Chir Plast** 1995; 37(2):45-6

Glenoplasty for recurrent posterior shoulder instability. Good results in 13 cases followed for 1-16 years. Bessems JH, et al. **Acta Orthop Scand** 1995 Dec;66(6):535-7

Bone scintigraphy as an indicator for dome osteotomy of the pelvis: comparison between scintigraphy, radiography and outcome in 57 hips. Nakamura N, et al. **Acta Orthop Scand** 1996 Apr;67(2):138-42

Treatment of painful basal joint arthritis of the thumb [letter] Hough G 3rd. **Am J Orthop** 1995 Oct;24(10):790

Long-term results of intertrochanteric varus osteotomy for arthrosis of the dysplastic hip (over 10 years' follow-up). Iwase T, et al. **Arch Orthop Trauma Surg** 1995;114(5):243-7

Inferior sagittal osteotomy with hyoid bone suspension for obese patients with sleep apnea. Ramirez SG, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):953-7

Tc-99m pertechnetate accumulation in osteotomy site. Hirano T, et al. **Clin Nucl Med** 1995 Nov;20(11):1025-6

Tendon transfer combined with calcaneal osteotomy for treatment of posterior tibial tendon insufficiency: a radiological investigation. Myerson MS, et al. **Foot Ankle Int** 1995 Nov;16(11):712-8

Evaluation of joint thickness in the hip before and after osteotomy using three-dimensional modelling. Yoshida K, et al. **Int Orthop** 1995;19(4):234-7

Surgical treatment of arthritic valgus knee: femoral supracondylar osteotomy or knee replacement? Berruto M, et al. **Ital J Orthop Traumatol** 1993;19(1):33-41

Review of the effect of fixation on complication rate in the base wedge osteotomy. Higgins KR, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):327-30

1995 William J. Stickel Silver Award. Structural analysis of absorbable pin and screw fixation in first metatarsal osteotomies. Higgins KR, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):528-32

Shortening Z-osteotomy [letter; comment] Kissel CG. **J Am Podiatr Med Assoc** 1995 Sep;85(9):512. Comment on: J Am Podiatr Med Assoc 1995 May;85(5):249-54.

Shortening Z-osteotomy [letter; comment] Singleton E. **J Am Podiatr Med Assoc** 1995 Sep;85(9):512. Comment on: J Am Podiatr Med Assoc 1995 May;85(5):249-54.

Intraosseous plating with absorbable self-reinforced poly-L-lactide plates in the fixation of distal femoral osteotomies on rabbits. Koskikare K, et al. **J Biomed Mater Res** 1996 Apr;30(4):417-21

Varus osteotomy of the distal part of the femur. A survivorship analysis. Finkelstein JA, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1348-52

Evaluation of the biomechanics of the hip following a triple osteotomy of the innominate bone. Hsin J, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):855-62

Corrective osteotomy for osteonecrosis of the femoral head. Mont MA, et al. **J Bone Joint Surg Am** 1996 Jul; 78(7):1032-8

Proximal tibial osteotomy. A subjective outcome study. Nagel A, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1353-8

Computer-assisted mandibular condyle positioning in orthognathic surgery. Bettega G, et al. **J Oral Maxillofac Surg** 1996 May;54(5):553-8

Autologous pericranial graft resurfacing after high condylectomy and discectomy of the temporomandibular joint in rabbits. Wong TY, et al.
J Oral Maxillofac Surg 1996 Jun;54(6):747–52

Femoral stiffness after osteosynthesis of a subcapital osteotomy in osteoporotic bone: an in–vitro comparison of nine fixation methods. Hernefalk L, et al.
J Orthop Trauma 1995;9(6):464–9

Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al.
J Orthop Trauma 1996;10(3):213–5 (12 ref.)

Treatment of avascular necrosis in the young patient. Hungerford DS. **Orthopedics** 1995 Sep;18(9):822–3

Stability of fronto–orbital advancement in nonsyndromic bilateral coronal synostosis: a quantitative three–dimensional computed tomographic study. Lo LJ, et al. **Plast Reconstr Surg** 1996 Sep;98(3):393–405; discussion 406–9

Osteotomy of the first metacarpal for osteoarthrosis of the basal joints of the thumb. Holmberg J, et al.
Scand J Plast Reconstr Surg Hand Surg 1996 Mar; 30(1):67–70

[Compression of the ulnar nerve at the elbow. Results of a series of 51 medial epicondyle osteotomies associated with decompression] Braun FM, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(3):240–7 (Eng. Abstr.) **(Fre)**

[Cephalometric study of changes in the upper airways after orthognathic surgery. Significance in the management of obstructive sleep apnea syndromes. Apropos of 43 cases] Paoli JR, et al. **Rev Stomatol Chir Maxillofac** 1996; 97(1):38–46 (Eng. Abstr.) **(Fre)**

[Wound management after wisdom tooth osteotomy] Hellner D, et al. **Fortschr Kiefer Gesichtschir** 1995;40:136–9 (Eng. Abstr.) **(Ger)**

[Proximal humerus shaft fracture as a complication after keyhole–plasty. A case report] Friedel R, et al.
Unfallchirurgie 1995 Aug;21(4):198–201 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Aneurysm complicating high tibial osteotomy: a case report. Tandon SC, et al. **Acta Orthop Scand** 1996 Feb;67(1):73–4

The risk of nasal osteotomies after ethmoid sinus surgery. Gliklich RE, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov;121(11):1315–8

Sub total unilateral oculomotor nerve palsy in a Le Fort I osteotomy. Herold J, et al.
Br J Oral Maxillofac Surg 1996 Feb;34(1):104–6

The mental nerve blink reflex in the diagnosis of lesions of the inferior alveolar nerve following orthognathic surgery of the mandible. Jääskeläinen SK, et al.
Br J Oral Maxillofac Surg 1996 Feb;34(1):87–95

Labial sensory function following sagittal split osteotomy. Pratt CA, et al. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):75–81

The re–establishment of molar occlusion following orthognathic surgery. Jones AG, et al. **Br J Orthod** 1996 Feb;23(1):61–4

Complications of varus derotation osteotomy in the treatment of CHD during growth. Valdiserri L, et al.
Chir Organi Mov 1995 Jul–Aug;80(3):273–8

Iatrogenic hallux varus surgical procedure: a study of 14 cases. Tourné Y, et al. **Foot Ankle Int** 1995 Aug; 16(8):457–63

Conversion disorder after maxillofacial trauma and surgery. Blinder D, et al. **Int J Oral Maxillofac Surg** 1996 Apr; 25(2):116–8

Tibial shaft fracture following tibial tubercle osteotomy. Ritter MA, et al. **J Arthroplasty** 1996 Jan;11(1):117–9

Arteriovenous fistula after fibular osteotomy leading to recurrent haemarthroses in a total knee replacement. Haddad FS, et al. **J Bone Joint Surg Br** 1996 May; 78(3):458–60

Dynamic radio–ulnar convergence after the Darrach procedure. McKee MD, et al. **J Bone Joint Surg Br** 1996 May;78(3):413–8

Pulpal and apical changes secondary to segmental osteotomy in the mandible—an experimental study. Duran S, et al. **J Craniomaxillofac Surg** 1995 Aug;23(4):256–60

Complications of distal first metatarsal osteotomies. Laughlin TJ. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):524–31; discussion 593–4 (46 ref.)

The Valenti procedure for hallux limitus/rigidus [letter] Oloff L. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):178–9; discussion 180–1

The use of a fibrin sealant to control intraoperative bleeding during a Le Fort I osteotomy: report of a case. Colm SJ. **J Oral Maxillofac Surg** 1996 Aug;54(8):1014–6

A comparison of questionnaire versus monofilament assessment of neurosensory deficit. Cunningham LL, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):454–9; discussion 459–60

Neurosensory recovery following the mandibular bilateral sagittal split osteotomy. Fridrich KL, et al.
J Oral Maxillofac Surg 1995 Nov;53(11):1300–6; discussion 1306–7

Osteomeatal complex obstruction and sinusitis following Le Fort I osteotomy. Menendez LF, et al.
J Oral Maxillofac Surg 1996 Jan;54(1):103–4

Blood loss and transfusion requirements in orthognatic surgery. Samman N, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):21–4; discussion 25–6

Horner's syndrome after vertical ramus osteotomy: report of a case. Weisagold DJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):913–4

Unusual complications of the Le Fort I osteotomy. Bendor–Samuel R, et al. **Plast Reconstr Surg** 1995 Nov; 96(6):1289–96; discussion 1297

INSTRUMENTATION

A new osteotome for performing chevron trochanteric osteotomy. Sochart DH, et al. **Acta Orthop Scand** 1995 Oct;66(5):445–6

Fixation of the Chevron osteotomy utilizing absorbable polydioxanon pins. Small HN, et al. **Foot Ankle Int** 1995 Jun;16(6):346–50

Titanium miniplate fixation for osteotomies in facial fibrous dysplasia—a histologic study of the screw/bone interface. Cheung LK, et al. **Int J Oral Maxillofac Surg** 1995 Dec; 24(6):401–5

A new appliance for condylar positioning (clamp system). Harada K, et al. **Int J Oral Maxillofac Surg** 1995 Oct; 24(5):342–3

Palatal surgical splint for transverse stability of Le Fort I osteotomies: a technical note. Reinkingh MR, et al.
Int J Oral Maxillofac Surg 1996 Apr;25(2):105–6

Hook method of retrieving wire for fixation of osteotomies. Folio L, et al. **J Am Podiatr Med Assoc** 1995 Dec; 85(12):741–3

Chevron bunionectomy fixation: in vitro stability assessment of plate–and–screw system compared with Kirschner wire. Buckenberger RK, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):266–72

Biofix fixation techniques and results in foot surgery. Burns AE. **J Foot Ankle Surg** 1995 May–Jun;34(3):276–82

Orthosorb: a case of foreign–body reaction. Kalla TP, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):366–70

The Osteomed M3–X Fixation System: a new bone screw with applications in foot surgery. Kissel CG, et al.
J Foot Ankle Surg 1995 Sep–Oct;34(5):458–64

Ulnar shortening using the AO small distractor. Wehbé MA, et al. **J Hand Surg [Am]** 1995 Nov;20(6):959–64

Measurements of shaft speed while drilling through bone [see comments] Abouzgia MB, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1308–15; discussion 1315–6. Comment in: J Oral Maxillofac Surg 1996 Mar;54(3):379.

Measurements of shaft speed while drilling through bone [letter; comment] Abouzgia MB, et al.
J Oral Maxillofac Surg 1996 Mar;54(3):379. Comment on: J Oral Maxillofac Surg 1995 Nov;53(11):1308–15; discussion 1315–6.

Mandibular alveolar ridge augmentation in the dog using distraction osteogenesis. Block MS, et al.
J Oral Maxillofac Surg 1996 Mar;54(3):309–14

Distraction osteogenesis in maxillofacial surgery using internal devices: review of five cases. Chin M, et al.
J Oral Maxillofac Surg 1996 Jan;54(1):45–53; discussion 54

Rigid fixation of the modified mandibular condylotomy. Gerard N. **J Oral Maxillofac Surg** 1996 Mar;54(3):371–2

A modified technique to determine the desired length of bicortical screws in sagittal split osteotomies. Jovanovic A, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):528–9

Postoperative computed tomography scan study of the pterygomaxillary separation during the Le Fort I osteotomy using a micro–oscillating saw. Lanigan DT, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1161–6

Mobility of the osteotomy site following Le Fort I osteotomy stabilized by titanium plate osteosynthesis. Rosenquist B, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1276–82

A new condylar positioning appliance for two–jaw osteotomies (Le Fort I and sagittal split ramus osteotomy). Harada K, et al. **Plast Reconstr Surg** 1996 Aug;98(2):363–5

[Universal 3–dimensional correction and reposition with the ring fixator using the hexapod configuration] Seide K, et al. **Unfallchirurg** 1996 Jun;99(6):422–4 (Eng. Abstr.) **(Ger)**

METHODS

Malunited fractures of the distal radius with volar angulation: corrective osteotomy in 6 cases using the volar approach. Linder L, et al. **Acta Orthop Scand** 1996 Apr;67(2):179–81

Osteotomy for cubitus varus: a simple technique in 10 children. Mahaisavariya B, et al. **Acta Orthop Scand** 1996 Feb;67(1):60–2

Resection of a recurrent nasal tumor via Le Fort I osteotomy approach. Alvi A, et al. **Am J Otolaryngol** 1995 Nov–Dec; 16(6):418–21

Congenital radioulnar synostosis. Surgical correction by derotational osteotomy. Castelló JR, et al.
Ann Chir Main Memb Super 1996;15(1):11–7 (8 ref.)

Failure of trochanteric osteotomy in total hip replacement: a comparison of two methods of reattachment. Teanby DN, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):43–4

The stability of facial osteotomies. 2. Mandibular advancement with bicortical screw fixation. Hoffman GR, et al. **Aust Dent J** 1995 Aug;40(4):213–9

The stability of facial osteotomies. 3. Chin advancement. Hoffman GR, et al. **Aust Dent J** 1995 Oct;40(5):289–95 (28 ref.)

The stability of facial osteotomies. Part 6. Chin setback. Hoffman GR, et al. **Aust Dent J** 1996 Jun;41(3):178–83 (21 ref.)

The stability of facial osteotomies. Part 5. Maxillary advancement with miniplate and screw fixation. Hoffman GR, et al. **Aust Dent J** 1996 Feb;41(1):21–7

The stability of facial osteotomies. 4. Maxillary and mandibular (with or without chin) advancement with rigid internal fixation. Hoffman GR, et al. **Aust Dent J** 1995 Dec;40(6):365–71

Changes in growth of the ilium after sopraacetabular osteotomy. Long–term evaluation. Capelli A, et al.
Chir Organi Mov 1995 Oct–Dec;80(4):369–76 **(Eng, Ita)**

Total knee arthroplasty after proximal tibial osteotomy. Marcacci M, et al. **Chir Organi Mov** 1995 Oct–Dec; 80(4):353–9 **(Eng, Ita)**

Cuneiform osteotomy of the femoral neck in severe slipped capital femoral epiphysis. DeRosa GP, et al.
Clin Orthop 1996 Jan;(322):48–60

Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al.
Clin Orthop 1996 Feb;(323):215–25 (52 ref.)

Revision total knee arthroplasty after failed unicompartmental knee arthroplasty or high tibial osteotomy. Gill T, et al. **Clin Orthop** 1995 Dec;(321):10–8

Reconstructive osteotomy for malunion of the distal radius. Ladd AL, et al. **Clin Orthop** 1996 Jun;(327):158–71

Oblique proximal tibial osteotomy for the correction of tibia vara in the young. Laurencin CT, et al. **Clin Orthop** 1996 Jun;(327):218–24

Femoral head reconstruction and revascularization. Treatment for ischemic necrosis. Leung PC.
Clin Orthop 1996 Feb;(323):139–45

Secure fixation of lumbar osteotomy. Surgical experience with 50 patients. Weale AE, et al. **Clin Orthop** 1995 Dec; (321):216–22

Exposure in difficult total knee arthroplasty using tibial tubercle osteotomy. Whiteside LA. **Clin Orthop** 1995 Dec; (321):32–5

A method to facilitate translation of the chevron osteotomy. Miller RA. **Foot Ankle Int** 1995 Oct;16(10):661–2

Potential for recurrence of hallux valgus after a modified Hohmann osteotomy: a biomechanical analysis. Sanders AP, et al. **Foot Ankle Int** 1995 Jun;16(6):351–6

Comparison of two fixation methods of oblique lesser metatarsal osteotomies: a biomechanical study. Slovenkai MP, et al. **Foot Ankle Int** 1995 Jul;16(7):437–9

Mandibular distraction osteogenesis as first step in the early treatment of severe dysgnathia in childhood. Klein C, et al. **Fortschr Kieferorthop** 1996 Feb;57(1):46–54 **(Eng, Ger)**

Cubital tunnel syndrome. Treatment by medial epicondylectomy. Kuschner SH. **Hand Clin** 1996 May; 12(2):411–9

Osteotomies about the hip for the prevention and treatment of osteoarthrosis. Millis MB, et al. **Instr Course Lect** 1996; 45:209–26 (86 ref.)

Stability of the Le Fort I osteotomy in patients with cleft lip and palate. Ayliffe PR, et al.
Int J Oral Maxillofac Surg 1995 Jun;24(3):201–7

Evaluation and prediction of the facial appearance after surgical correction of mandibular hyperplasia. Chen LH, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):322–6

Long–term effects of orthognathic surgery on the temporomandibular joint: comparison of rigid and nonrigid fixation methods. Feinerman DM, et al.
Int J Oral Maxillofac Surg 1995 Aug;24(4):268–72

Effects of Le Fort I osteotomy on human gingival and pulpal circulation. Geylikman YB, et al.
Int J Oral Maxillofac Surg 1995 Aug;24(4):255–60

Image–guided surgery. Wagner A, et al.
Int J Oral Maxillofac Surg 1996 Apr;25(2):147–51

Prevention of mandibular fractures by using constructional design principles. II. A tension strength test on beagle mandibles with two different types of segmental resections. Wittkampf AR, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):311–2

Fractioned drilling—a technique for wedge osteotomy of the knee. Sabo D, et al. **Int Orthop** 1995;19(6):352–4

Chiari osteotomy in association with intertrochanteric osteotomy in adults. Racalbuto S, et al.
Ital J Orthop Traumatol 1993;19(1):51–6

Tallor's bunion [letter] DeLauro TM.
J Am Podiatr Med Assoc 1996 Jun;86(6):295–6

Ultrasonically driven tools. de Steiger RN, et al.
J Arthroplasty 1996 Jan;11(1):120–1

Oblique osteotomy for the correction of tibial malunion [letter; comment] Marsh JL. **J Bone Joint Surg Am** 1996 Jan;78(1):151–2. Comment on: J Bone Joint Surg Am 1995 Feb;77(2):240–6.

Simultaneous open reduction and Salter innominate osteotomy for developmental dysplasia of the hip. Haidar RK, et al. **J Bone Joint Surg Br** 1996 May;78(3):471–6

Rotation osteotomy of the proximal humerus to stabilise the shoulder. Five years' experience. Kronberg M, et al.
J Bone Joint Surg Br 1995 Nov;77(6):924–7

Varus derotation osteotomy for persistent dysplasia in congenital dislocation of the hip. Proximal femoral growth and alignment changes in the leg. Suda H, et al.
J Bone Joint Surg Br 1995 Sep;77(5):756–61

Le Fort 1 downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al.
J Can Dent Assoc 1995 Dec;61(12):1048–52 (24 ref.)

Inferior positioning of the maxilla by a Le Fort I osteotomy:

a review of 25 patients with vertical maxillary deficiency. de Mol van Otterloo JJ, et al. **J Craniomaxillofac Surg** 1996 Apr;24(2):69–77

Long-term results of segmental repositioning of the maxilla in cleft palate patients without previously grafted alveolo-palatal clefts. Erbe M, et al. **J Craniomaxillofac Surg** 1996 Apr;24(2):109–17

Stabilization of the short sagittal split osteotomy: in vitro testing of different plate and screw configurations. Hammer B, et al. **J Craniomaxillofac Surg** 1995 Oct;23(5):321–4

Stability of simultaneous modified LeFort III/LeFort I osteotomies. Schmitz JP, et al. **J Craniomaxillofac Surg** 1995 Oct;23(5):287–95

The sandwich zygomatic osteotomy [letter] Walji S. **J Craniomaxillofac Surg** 1996 Apr;24(2):131

Cuneiform and cuboid wedge osteotomies for correction of residual metatarsus adductus: a surgical review. Brink DS, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):371–8 (26 ref.)

The Cosentino modification for tendon interpositional arthroplasty. Cosentino GL. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):501–8

Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)

Double calcaneal osteotomy in the treatment of posterior tibial tendon dysfunction. Frankel JP, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):254–61

Wagdy's technique for treatment of hallux valgus by double-V osteotomy [letter; comment] Gerbert J. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):597. Comment on: J Foot Ankle Surg 1995 Jan–Feb;34(1):65–73.

Cheilectomy, chondroplasty, and sagittal "Z" osteotomy: a preliminary report on an alternative joint preservation approach to hallux limitus. Kissel CG, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):312–8

The Valenti procedure for hallux limitus/rigidus [letter] Kravitz SR. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):178; discussion 180–1

The Valenti procedure for hallux limitus/rigidus. Saxena A. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):485–8; discussion 511

A variable first metatarsal distal "L" osteotomy with adductor tendon transfer. Vega MR, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):384–8

The Valenti procedure for hallux limitus/rigidus [letter] Weil LS. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):179–80; discussion 180–1

Rotation-angulation osteotomy in the hand. Evans DM, et al. **J Hand Surg [Br]** 1996 Feb;21(1):43–6

Avascular necrosis of the scaphoid treated by total excision and radial advancement osteotomy. Günal I, et al. **J Hand Surg [Br]** 1995 Dec;20(6):736–40

Wound healing after multisegmental Le Fort I osteotomy and transection of the descending palatine vessels. Bell WH, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1425–33; discussion 1433–4

The stability of segmentalized Le Fort I osteotomies with miniplate fixation in patients with maxillary hypoplasia. Chow J, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1407–12; discussion 1412–3

The effect of local anesthesia with vasoconstrictor on gingival blood flow during Le Fort I osteotomy. Dodson TB, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):810–4; discussion 815

Modification of the modified condylotomy. Hall HD. **J Oral Maxillofac Surg** 1996 May;54(5):548–51; discussion 551–2

A technique for ensuring accurate bone cuts in the intraoral vertical ramus osteotomy. Hibi H, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1480–1

In vitro comparison of parameters affecting the fixation strength of sagittal split osteotomies. Kohn DH, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1374–83; discussion 1383–5

Postoperative computed tomography scan study of the pterygomaxillary separation during the Le Fort I osteotomy using a micro-oscillating saw. Lanigan DT, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1161–6

Location of the descending palatine artery in relation to the Le Fort I osteotomy. Li KK, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):822–5; discussion 826–7

Reconstruction of the severely atrophic edentulous maxilla using Le Fort I osteotomy with simultaneous bone graft and implant placement. Li KK, et al. **J Oral Maxillofac Surg** 1996 May;54(5):542–6; discussion 547

Technique for vertical positioning of the maxilla after Le Fort osteotomy. Manna LM, et al. **J Oral Maxillofac Surg** 1996 May;54(5):652

A modified geniotomy technique for obstructive sleep apnea syndrome. Mintz SM, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1226–8

Induced hypotensive anesthesia for adolescent orthognathic surgery patients. Precious DS, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):680–3; discussion 683–4

Hemi-genioplasty: a technique to correct chin asymmetry. Raffaini M, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1362–4

Bicortical-monocortical fixation of the sagittal mandibular osteotomy. Schwartz HC, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):234–5

Functional stability of sagittal split ramus osteotomies: effects of positional screw size and placement configuration. Shetty V, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):601–9: discussion 609–10

Improvement of maximum occlusal forces after orthognathic surgery. Throckmorton GS, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1080–6

Distal femoral extension osteotomy for knee flexion contracture in patients with arthrogryposis. DelBello DA, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):122–6

Combination trochanteric arrest and intertrochanteric osteotomy for Perthes' disease. Matan AJ, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):10–4

Bilateral anterior pubic osteotomy in bladder exstrophy closure. Frey P. **J Urol** 1996 Aug;156(2 Pt 2):812–5

A combined vertical and horizontal pelvic osteotomy approach for primary and secondary repair of bladder exstrophy. Gearhart JP, et al. **J Urol** 1996 Feb; 155(2):689–93

Midline osteotomy with lag screw stabilization for mandibular swing. Lowlicht RA, et al. **Laryngoscope** 1995 Feb;105(2):210–3

Adolescent and young adult hip dysplasia. The role of Bernese periacetabular osteotomy. McClellan JW 3rd, et al. **Nebr Med J** 1995 Aug;80(8):271–5; discussion 275–6

Helal metatarsal osteotomy for the treatment of metatarsalgia: a critical analysis of results. Trnka HJ, et al. **Orthopedics** 1996 May;19(5):457–61

Craniofacial growth in rabbits after rigid or semi-rigid fixation of the frontonasal suture. Canady JW, et al. **Plast Reconstr Surg** 1996 Sep;98(3):410–7; discussion 418–9

Endonasal premaxillary osteotomy. Mixter RC, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1494–6

Monobloc and facial bipartition osteotomies for reconstruction of craniofacial malformations: a study of extradural dead space and morbidity. Posnick JC, et al. **Plast Reconstr Surg** 1996 May;97(6):1118–28

Alteration in facial sensibility in adolescents following sagittal split and chin osteotomies of the mandible. Posnick JC, et al. **Plast Reconstr Surg** 1996 Apr;97(5):920–7

Surgical refinement of the operative procedure for a minor degree of mandibular prognathism. Satoh K, et al. **Plast Reconstr Surg** 1996 Sep;98(4):740–6

[Modified distal osteotomy of shortening the first metatarsal for treatment of hallux valgus] Tang R, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):490–3 (Eng. Abstr.) **(Chi)**

[Restoration of the mandible after trans-mandibular approach of invasive tumors of the oropharynx (43 cases)] Beauvillain C, et al. **Bull Cancer Radiother** 1996;83(1):31–3 (Eng. Abstr.) **(Fre)**

[Hip dysplasia in adolescence] Barthès X, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(4):302–9 (Eng. Abstr.) **(Fre)**

[Value of pelvic osteotomy in the management of the hip in children with cerebral palsy] Cesari B, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(4):310–6 (Eng. Abstr.) **(Fre)**

[Total arthroplasty, using Hardinge's approach, combined with trochanterotomy: comparative results of 200 cases] Connault P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):44–50 (Eng. Abstr.) **(Fre)**

[Congenital convex talus. Methods and results of a single-stage surgical correction] Daumas L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):527–37 (Eng. Abstr.) **(Fre)**

[Progressive fragmentation of a bipartite patella: apropos of a case] Eberhard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):78–80 (Eng. Abstr.) **(Fre)**

[Distal intra-articular resection of the calcaneus in the treatment of severe or recurrent congenital clubfoot] Ghanem I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):709–15 (Eng. Abstr.) **(Fre)**

[The foot in hereditary motor and sensory neuropathies in children] Ghanem I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):152–60 (Eng. Abstr.) **(Fre)**

[Femoral lengthening by callotasis. A study of a series of 79 cases in children and adolescents] Glorion C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):147–56 (Eng. Abstr.) **(Fre)**

[Hallux valgus treated by shortening of the first phalanx with trans-epiphyseal impaction and adductor plasty. Apropos of 49 cases with 5-years follow-up] Jarde O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):136–41 (Eng. Abstr.) **(Fre)**

[Femoral loosening of total hip prosthesis caused by pseudarthrosis resulting from trochanterotomy] Langlais F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(2):95–105 (Eng. Abstr.) **(Fre)**

[Outcome of hip shelf arthroplasty in adults after a minimum of 15 years of follow-up. Long term results and analysis of failures of 56 dysplastic hips] Migaud H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):716–23 (Eng. Abstr.) **(Fre)**

[Surgery of congenital radio-ulnar synostosis. Technical error and therapeutic strategy] Poureyron Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):80–84 (Eng. Abstr.) **(Fre)**

[Additional supra-malleolar osteotomy] Vichard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):63–69 (Eng. Abstr.) **(Fre)**

[Mandibular reconstruction in benign tumors of the mandible] Kadiri F, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(1):65–70 (Eng. Abstr.) **(Fre)**

[Corrective osteotomies of the foot after compartment syndromes of the tibia] Dávid A, et al. **Chirurg** 1995 Nov; 66(11):1134–40 (Eng. Abstr.) **(Ger)**

[Indications for transposition osteotomy in coxa valga] Holz U. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):113 **(Ger)**

[Bimaxillary segmental osteotomies] Gattinger B, et al. **Fortschr Kiefer Gesichtschir** 1995;40:32–41 (39 ref.) **(Ger)**

[Surgical treatment of obstructive sleep apnea by maxillary and mandibular osteotomy] Hochban W, et al. **Fortschr Kiefer Gesichtschir** 1995;40:65–72 (28 ref.) **(Ger)**

[Bone stability after bimaxillary surgery] Hoffmeister B, et al. **Fortschr Kiefer Gesichtschir** 1995;40:57–65 **(Ger)**

[Lingual osteotomy--a little regarded technique for removal of the displaced mandibular wisdom tooth] Pape HD, et al. **Fortschr Kiefer Gesichtschir** 1995;40:120–3 (Eng. Abstr.) **(Ger)**

[Complications in bimaxillary surgical interventions] Sailer HF, et al. **Fortschr Kiefer Gesichtschir** 1995;40:41–9 (65 ref.) **(Ger)**

[Predictive soft tissue factors in bimaxillary operations] Steinhäuser EW, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:50–7 (31 ref.) **(Ger)**

[Wedge osteotomy of the tibial head using fractionated drilling. A complication-reducing surgical modification] Sabo D, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb; 134(1):11–5 (Eng. Abstr.) **(Ger)**

[Stabilization of interligamentous valgus procedure in tibial head osteotomy using staples] Zügel N, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):437–41 (31 ref.) (Eng. Abstr.) **(Ger)**

[Changes in the acetabular roof produced by Chiari pelvic osteotomy] Hayashi J. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1126–35 (Eng. Abstr.) **(Jpn)**

[Triple osteotomy (modified Tönnis method) for advanced coxarthrosis] Ohmura T, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1226–36 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for hallux valgus by metatarsal I osteotomy and soft tissue reconstruction in the area of the forefoot] Kuźma K, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):73–8 (Eng. Abstr.) **(Pol)**

[Early results of surgical treatment for congenital hip dislocation in children using Degi's method in children under 18 months of age] Pucher A, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(2):135–42 (Eng. Abstr.) **(Pol)**

[Treatment outcome of juvenile slipped capital femoral epiphysis with Imhauser osteotomy] Tokarowski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):307–12 (Eng. Abstr.) **(Pol)**

[Outcome of treating osteoarthritic degenerative changes in the knee with high tibial osteotomy] Witoński D, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(1):39–43 (Eng. Abstr.) **(Pol)**

STATISTICS & NUMERICAL DATA

Rates of tibial osteotomies in Canada and the United States. Wright J, et al. **Clin Orthop** 1995 Oct;(319):266–75

TRENDS

The role of osteotomies in the 90's. Böhler N, et al. **Orthopedics** 1995 Sep;18(9):819–21

[Bimaxillary osteotomy in osseous malocclusion. Dentoalveolar surgery. Opening address of the congress president] Härle F. **Fortschr Kiefer Gesichtschir** 1995;40:1–2 **(Ger)**

VETERINARY

Angular limb deformity in a calf treated by periosteotomy and wedge osteotomy. Edinger H, et al. **Vet Rec** 1995 Sep 2;137(10):245–6

[The use of bone morphogenetic proteins in delayed fracture healing, pseudoarthrosis and in ulna osteotomy carried out because of elbow joint diseases] Paatsama S, et al. **Tierarztl Prax** 1996 Apr;24(2):164–8 (Eng. Abstr.) **(Ger)**

OSTERREICHER SYNDROME see **NAIL-PATELLA SYNDROME**

OSTERTAGIA

Influence of early season moxidectin treatments on acquisition of immunity to Ostertagia ostertagi in calves. Satrija F, et al. **Acta Vet Scand** 1995;36(3):383–6

Different patterns of faecal egg output following infection of Scottish blackface lambs with Ostertagia circumcincta. Stear MJ, et al. **Vet Parasitol** 1995 Aug;59(1):29–38

DRUG EFFECTS

Ivermectin-moxidectin side resistance by Ostertagia species

isolated from goats and passaged to sheep. Watson TG, et al. **Vet Rec** 1996 May 11;138(19):472–3

GENETICS

Cloning and sequencing of an excretory/secretory antigen from Ostertagia ostertagi fourth-stage larvae containing multiple tandem repeats. de Graaf DC, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):239–41

IMMUNOLOGY

Antibody responses of grazing alpacas (Lama pacos) in New Zealand to intestinal nematodes. Green RS, et al. **Int J Parasitol** 1996 Apr;26(4):429–35

An ovine lymphocyte antigen is associated with reduced faecal egg counts in four-month-old lambs following natural, predominantly Ostertagia circumcincta infection. Stear MJ, et al. **Int J Parasitol** 1996 Apr;26(4):423–8

Immune response of lambs to vaccination with Ostertagia circumcincta surface antigens eliciting bile antibody responses. Wedrychowicz H, et al. **Int J Parasitol** 1995 Sep;25(9):1111–21

Isolation, characterization and immunolocalization of a globin-like antigen from Ostertagia ostertagi adults. de Graaf DC, et al. **Parasitology** 1996 Jul;113 (Pt 1):63–9

Local and plasma antibody responses to the parasitic larval stages of the abomasal nematode Ostertagia circumcincta. Sinski E, et al. **Vet Parasitol** 1995 Sep;59(2):107–18

ISOLATION & PURIFICATION

Efficacy of a spring strategic fenbendazole treatment program to reduce numbers of Ostertagia ostertagi inhibited larvae in beef stocker cattle. Williams JC, et al. **Vet Parasitol** 1995 Sep;59(2):127–37

PHYSIOLOGY

Viability of infective larvae of Haemonchus contortus, Ostertagia ostertagi, and Trichostrongylus colubriformis following exsheathment by various techniques. Conder GA, et al. **J Parasitol** 1996 Feb;82(1):100–2

OSTERTAGIA OSTERTAGI see **OSTERTAGIA**

OSTERTAGIASIS

PARASITOLOGY

Viability of infective larvae of Haemonchus contortus, Ostertagia ostertagi, and Trichostrongylus colubriformis following exsheathment by various techniques. Conder GA, et al. **J Parasitol** 1996 Feb;82(1):100–2

PHYSIOPATHOLOGY

Different patterns of faecal egg output following infection of Scottish blackface lambs with Ostertagia circumcincta. Stear MJ, et al. **Vet Parasitol** 1995 Aug;59(1):29–38

PREVENTION & CONTROL

Immune response of lambs to vaccination with Ostertagia circumcincta surface antigens eliciting bile antibody responses. Wedrychowicz H, et al. **Int J Parasitol** 1995 Sep;25(9):1111–21

VETERINARY

Influence of early season moxidectin treatments on acquisition of immunity to Ostertagia ostertagi in calves. Satrija F, et al. **Acta Vet Scand** 1995;36(3):383–6

The effect of ivermectin treatment of late pregnant dairy cows in south-west Victoria on subsequent milk production and reproductive performance [published erratum appears in Aust Vet J 1995 Sep;72(9):360] Walsh A, et al. **Aust Vet J** 1995 Jun;72(6):201–7

An ovine major histocompatibility complex DRB1 allele is associated with low faecal egg counts following natural, predominantly Ostertagia circumcincta infection. Schwaiger FW, et al. **Int J Parasitol** 1995 Jul;25(7):815–22

An ovine lymphocyte antigen is associated with reduced faecal egg counts in four-month-old lambs following natural, predominantly Ostertagia circumcincta infection. Stear MJ, et al. **Int J Parasitol** 1996 Apr;26(4):423–8

Efficacy of ivermectin pour-on against Ostertagia ostertagi infection and residues in the American bison, Bison bison. Marley SE, et al. **J Wildl Dis** 1995 Jan;31(1):62–5

Effect of dietary protein supplementation on the development of immunity to Ostertagia circumcincta in growing lambs. Coop RL, et al. **Res Vet Sci** 1995 Jul;59(1):24–9

Biological control of trichostrongyles in calves by the fungus Duddingtonia flagrans fed to animals under natural grazing conditions. Larsen M, et al. **Vet Parasitol** 1995 Dec; 60(3–4):321–30

Local and plasma antibody responses to the parasitic larval stages of the abomasal nematode Ostertagia circumcincta. Sinski E, et al. **Vet Parasitol** 1995 Sep;59(2):107–18

Efficacy of a spring strategic fenbendazole treatment program to reduce numbers of Ostertagia ostertagi inhibited larvae in beef stocker cattle. Williams JC, et al. **Vet Parasitol** 1995 Sep;59(2):127–37

Use of moxidectin in goats in New Zealand [letter; comment] Cobb RM, et al. **Vet Rec** 1995 Nov 4;137(19):496. Comment on: Vet Rec 1995 Apr 29;136(17):443–4.

Evaluation of doramectin in a programme for season-long control of parasitic gastroenteritis in calves. Fisher MA, et al. **Vet Rec** 1995 Sep 16;137(12):281–4

Persistent activity of ivermectin topical and moxidectin injection against Ostertagia ostertagi and Dictyocaulus viviparus in calves. Hong C, et al. **Vet Rec** 1995 Dec 16; 137(25):640–1

Ivermectin-moxidectin side resistance by Ostertagia species isolated from goats and passaged to sheep. Watson TG, et al. **Vet Rec** 1996 May 11;138(19):472–3

[Ostertagiasis in bulls used for bullfights] Méndez A, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):551–6 (Eng. Abstr.) **(Spa)**

OSTOMY

Simultaneous silicone intubation through the osteotomy and the nasolacrimal duct during dacryocystorhinostomy. Bartley GB. **Am J Ophthalmol** 1996 May;121(5):586–7

Marked intraocular pressure rise complicating intrableb autologous blood injection [letter] Siegfried CJ, et al. **Arch Ophthalmol** 1996 Apr;114(4):492–3

Thoracoscopic staging of stomal recurrence. Wax MK, et al. **Head Neck** 1995 Sep–Oct;17(5):409–13

[Toward the ideal bag: a clinical evaluation of a new aid for ostomized patients] Rubbini M, et al. **Minerva Chir** 1996 Mar;51(3):171–5 (Eng. Abstr.) **(Ita)**

OTALGIA see **EARACHE**

OTA'S NEVUS see **NEVUS OF OTA**

OTC DRUGS see **DRUGS, NON-PRESCRIPTION**

OTITIS

DRUG THERAPY

Safety of ototopical antibiotics [letter; comment] Masaki M. **Laryngoscope** 1996 Mar;106(3 Pt 1):370. Comment on: Laryngoscope 1995 May;105(5 Pt 1):472–4.

SURGERY

[Goode's transtympanic drains. Indications and complications] Dachy JP, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):183–6 (Eng. Abstr.) **(Fre)**

OTITIS EXTERNA

Otitis externa. Presentation and management. Briggs RJ. **Aust Fam Physician** 1995 Oct;24(10):1859–64

Otitis externa. Management in the primary care office. Mirza N. **Postgrad Med** 1996 May;99(5):153–4, 157–8 (9 ref.)

BLOOD

Blood group phenotype determines lectin-mediated adhesion of Pseudomonas aeruginosa to human outer ear canal epithelium. Steuer MK, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):287–95

COMPLICATIONS

Multiple cranial nerve palsy after otitis externa: a case report. Boringa JB, et al. **Clin Neurol Neurosurg** 1995 Nov; 97(4):332–5

[Otitis externa and cerumen obturans] Pieren C. **Ther Umsch** 1995 Nov;52(11):713–7 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

A painful ear. Golledge CL. **Aust Fam Physician** 1996 Aug; 25(8):1327

Bruton's agammaglobulinaemia in a child presenting with cryptococcal empyema thoracis and periauricular pyogenic abscess. Wahab JA, et al. **Singapore Med J** 1995 Dec; 36(6):686–9

[Dermatomycoses. 10: Mycoses of the mouth cavity and ear canals—clinical picture and differential diagnosis] Meinhof W. **Fortschr Med** 1995 Oct 10;113(28):399–400 **(Ger)**

[Dermatomycoses. 11: Mycoses of the mouth cavity and ear canals—epidemiology and therapy] Meinhof W. **Fortschr Med** 1995 Oct 20;113(29):423–4 **(Ger)**

DRUG THERAPY

Otitis externa: management of the recalcitrant case. Selesnick SH. **Am J Otol** 1994 May;15(3):408–12

Pseudomonas ear infections [letter] Pien FD. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):898–9

Antimicrobial activity of glycerine-ichthammol in otitis externa. Ahmed K, et al. **Clin Otolaryngol** 1995 Jun; 20(3):201–3

Glycerol and ichthammol: medicinal solution or mythical potion? Nilssen E, et al. **J Laryngol Otol** 1996 Apr; 110(4):319–21

Ofloxacin otic solution as treatment of chronic suppurative otitis media and diffuse bacterial otitis externa. Sumitsawan Y, et al. **J Med Assoc Thai** 1995 Sep;78(9):455–9

[Cyclosporin A therapy of chronic recurrent polychondritis] Diercks K, et al. **Hautarzt** 1996 May;47(5):376–7 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Non-osteitic complications of therapeutic radiation to the temporal bone. Smouha EE, et al. **Am J Otol** 1995 Jan; 16(1):83–7

Diabetes mellitus and malignant external otitis: a case study. Manfrini S, et al. **J Diabetes Complications** 1996 Jan–Feb; 10(1):2–5

[Malignant otitis externa: apropos of 19 cases] Rachidi-Alaoui F, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):315–9 (Eng. Abstr.) **(Fre)**

HISTORY

James R. Chandler: "Malignant external otitis." (Laryngoscope. 1968;78:1257–1294). Lucente FE, et al. **Laryngoscope** 1996 Jul;106(7):805–7

MICROBIOLOGY

Pseudomonas aeruginosa in otitis externa. A particular variety of the bacteria? Sundström J, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):833–6

Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. van Asperen IA, et al. **BMJ** 1995 Nov 25;311(7017):1407–10

Foot and ear disease—the dermatophytid reaction in otology. Derebery J, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):181–6

PREVENTION & CONTROL

[A headband—dry and wet (letter)] Hagström B. **Lakartidningen** 1996 May 8;93(19):1816 **(Swe)**

RADIONUCLIDE IMAGING

Scintigraphic findings of epidermoid carcinoma mimicking findings of malignant otitis externa. Lin WY, et al. **Clin Nucl Med** 1996 Jan;21(1):75

SPECT gallium scintigraphy in malignant external otitis: initial staging and follow-up. Case reports. Stokkel MP, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):338–40

VETERINARY

Antimicrobial susceptibility and rRNA gene restriction patterns among Staphylococcus intermedius from healthy dogs and from dogs suffering from pyoderma or otitis externa. Pedersen K, et al. **Acta Vet Scand** 1995; 36(3):335–42

Yeast infection in ferrets [letter] Dinsdale JR, et al. **Vet Rec** 1995 Dec 16;137(25):647–8

OTITIS INTERNA see **LABYRINTHITIS**

OTITIS MEDIA

Evaluation of self-report by adults of childhood otitis media histories. Stephenson H. **Audiology** 1995 May–Jun; 34(3):124–34

Acute otitis media. Forer M, et al. **Aust Fam Physician** 1995 Nov;24(11):2093, 2097

COMPLICATIONS

Neurotologic treatment of acquired cholesteatoma. Burggraaff B, et al. **Am J Otol** 1995 Jul;16(4):480–5

Cochlear fistula in chronic otitis media with cholesteatoma. Chao YH, et al. **Am J Otol** 1996 Jan;17(1):15–8

Chronic otitis media and sensorineural hearing loss: is there a clinically significant relation? Noordzij JP, et al. **Am J Otol** 1995 Jul;16(4):420–3

The ear in the acquired immunodeficiency syndrome: II. Clinical and audiologic investigation. Soucek S, et al. **Am J Otol** 1996 Jan;17(1):35–9

Acute otitis media and facial paralysis in children. Elliott CA, et al. **Ann Otol Rhinol Laryngol** 1996 Jan;105(1):58–62

Binaural hearing in adults with histories of otitis media in childhood. Stephenson H, et al. **Audiology** 1995 May–Jun; 34(3):113–23

A case of acquired petrous cholesteatoma associated with insidious middle ear infection treated by staging the surgical procedures. Gyo K, et al. **Auris Nasus Larynx** 1995; 22(3):192–6

Two cases of severe head-banging parasomnias in peripubertal males resulting from otitis media in toddlerhood. Bramble D. **Child Care Health Dev** 1995 Jul; 21(4):247–53

Pneumatization and otitis media in Greenlandic Inuit before European colonization. Homøe P, et al. **J Otolaryngol** 1995 Dec;24(6):330–5

Age and hearing function in patients with chronic otitis media. Vartiainen E, et al. **J Otolaryngol** 1995 Dec; 24(6):336–9

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):617–23 (35 ref.)

[Neuro-otological complications of middle ear infections; the importance of early diagnosis] Albers FW. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1726–9 (Eng. Abstr.) **(Dut)**

[A case of coexisting tuberculous otitis media and pulmonary tuberculosis] Spiewak W. **Pneumonol Alergol Pol** 1995; 63(7–8):436–9 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Otitis media: a personal perspective from a son [letter] Quinn MK. **Am Fam Physician** 1996 Sep 15;54(4):1212, 1216

Acute otitis media: making an accurate diagnosis. Weiss JC, et al. **Am Fam Physician** 1996 Mar;53(4):1200–6 (24 ref.)

Aural tuberculosis. Greenfield BJ, et al. **Am J Otol** 1995 Mar; 16(2):175–82

Magnetic resonance imaging features of Gradenigo's syndrome. Hardjasudarma M, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):247–50

Signs and symptoms predicting acute otitis media [letter; comment] Hick JF. **Arch Pediatr Adolesc Med** 1995 Nov; 149(11):1285. Comment on: Arch Pediatr Adolesc Med 1995 Jan;149(1):26–9.

Otitis media, communication style of primary caregivers, and language skills of 2 year olds: a preliminary report. Wallace IF, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):27–35

Eosinophilic granuloma presenting as chronic otitis media: pitfalls in the diagnosis of aural polyps in children. DeRowe A, et al. **J Otolaryngol** 1995 Aug;24(4):258–60

Concise review for primary–care physicians. Swanson JA, et al. **Mayo Clin Proc** 1996 Feb;71(2):179–83 (12 ref.)

Acute otitis media in children. Hanson MJ. **Nurse Pract** 1996 May;21(5):72–4, 80

Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. Hurst DS, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):531–44

An unusual differential diagnosis of myringitis bullosa haemorrhagica. Indudharan R, et al. **Trop Geogr Med** 1995; 47(5):227–8

[Diagnostic imaging and physiological function tests—cholesteatomatous otitis media] Kubo T. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Apr;99(4):612–5 **(Jpn)**

[Tuberculous otitis media: a case report] Crovetto de la Torre MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb; 47(1):63–6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antimicrobials in children and the problem of drug resistance [editorial] Aronoff SC. **Am Fam Physician** 1996 Jul; 54(1):44–6, 54, 56

Penicillin reduces secretory capacity in rat middle ear mucosa in acute otitis media. Cayé–Thomasen P, et al. **Am J Otol** 1996 Mar;17(2):354–9

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

Timing of penicillin treatment influences the course of Streptococcus pneumoniae–induced middle ear inflammation. Sato K, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1896–8

Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Bauchner H, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):396–9

Effect of ibuprofen treatment during experimental acute otitis media. Diven WF, et al. **Auris Nasus Larynx** 1995; 22(2):73–9

Development of beta–lactamase–mediated resistance to penicillin in middle–ear isolates of Moraxella catarrhalis in Finnish children, 1978–1993. Nissinen A, et al. **Clin Infect Dis** 1995 Nov;21(5):1193–6

Treatment of otitis media [letter; comment] van der Meer JW, et al. **Clin Infect Dis** 1995 Oct;21(4):1069. Comment on: Clin Infect Dis 1994 Nov;19(5):823–33.

Allergy due to topical medications in chronic otitis externa and chronic otitis media. Van Ginkel CJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):326–8

Management of otitis media. A review. Liston TE. **Clin Pediatr (Phila)** 1995 Oct;34(10):542–8 (53 ref.)

Management of acute otitis media and glue ear. **Drug Ther Bull** 1995 Feb;33(2):12–5 (52 ref.)

Outcome–oriented managed care comparing efficacies of cefaclor and amoxicillin in acute and recurrent acute otitis media. Perry BP, et al. **Ear Nose Throat J** 1995 Dec; 74(12):840–4

Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Principi N. **Eur J Clin Microbiol Infect Dis** 1995 Aug; 14(8):669–76

Acute otitis media in children: a study of nasopharyngeal carriage of potential pathogens and therapeutic efficacy of cefixime and amoxicillin–clavulanate. Boulesteix J, et al. **Infection** 1995;23 Suppl 2:S79–82

Acute otitis media in childhood: a study of 20,532 cases. Del Castillo F, et al. **Infection** 1995;23 Suppl 2:S70–3

Treatment of experimental acute otitis media with ibuprofen and ampicillin. Diven WF, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):127–39

Reduction of endotoxin–induced inflammation of the middle ear by polymyxin B. Darrow DH, et al. **Laryngoscope** 1996 Aug;106(8):1028–33

Concise review for primary–care physicians. Swanson JA, et al. **Mayo Clin Proc** 1996 Feb;71(2):179–83 (12 ref.)

Otitis media in children [letter] Mokry C. **N Engl J Med** 1995 Oct 26;333(17):1151; discussion 1152

Penicillin–resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Block SL, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):751–9

Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Bradley JS, et al. **Pediatr Infect Dis J** 1995 Dec; 14(12):1037–41

Treatment of persistent otitis media [letter; comment] Giebink GS. **Pediatr Infect Dis J** 1995 Oct;14(10):922–3. Comment on: Pediatr Infect Dis J 1995 Mar;14(3):183–8.

Pneumococcal meningitis during therapy of otitis media with clarithromycin. Reid R Jr, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1104–5

Managing otitis media: a time for change. Paradise JL. **Pediatrics** 1995 Oct;96(4 Pt 1):712–5

[Antibiotic prophylaxis in surgery of uncomplicated cholesteatoma: review of 150 patients] López Amado M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):421–6 (Eng. Abstr.) **(Spa)**

[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non–cholesteatomaous chronic otitis media in the suppurative phase] Lorente J, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):521–33 (Eng. Abstr.) **(Spa)**

[Amoxicillin: choice in the treatment of acute otitis media (letter)] Raigal Martín MY, et al. **Aten Primaria** 1995 Sep 30;16(5):293–4 **(Spa)**

[Restrictive prescription of antibiotics requires early follow–up] **Lakartidningen** 1996 Jul 10;93(28–29):2600 **(Swe)**

EPIDEMIOLOGY

Influenza A vaccine and the incidence of otitis media [letter; comment] Aligne CA. **Arch Pediatr Adolesc Med** 1996 Jun; 150(6):652–3. Comment on: Arch Pediatr Adolesc Med 1995 Oct;149(10):1113–7.

Ear disease in developing countries: a proposal. Kapur YP, et al. **Folia Phoniatr Logop** 1996;48(3):150–5

Otitis media: relationship to tonsillitis, sinusitis and atopic diseases. Kvaerner KJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):127–41

How should relative risk estimates for acute otitis media in children aged less than 2 years be perceived? Alho OP, et al. **J Clin Epidemiol** 1996 Jan;49(1):9–14

The follow up of acute otitis media in general practice. Newton AP. **J R Nav Med Serv** 1995 Summer;81(2):127–34

Prevalence of bacterial otitis media in primary school children in Enugu Surburb, Enugu state, Nigeria. Oyeka CA, et al. **West Afr J Med** 1995 Apr–Jun;14(2):78–81

ETHNOLOGY

Otitis media in a population of black American and white American infants, 0–2 years of age. Casselbrant ML, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug;33(1):1–16

ETIOLOGY

Public health impact of various risk factors for acute otitis media in northern Finland. Alho OP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1149–56

Healing of tympanic membrane after myringotomy during Streptococcus pneumoniae otitis media. An otomicroscopic and histologic study in the rat. Magnuson K, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):397–404

Early inflammatory changes of the Haemophilus influenzae–induced experimental otitis media. Kawana M. **Auris Nasus Larynx** 1995;22(2):80–5

Parental smoking and risk of otitis media in pre–school children. Collet JP, et al. **Can J Public Health** 1995 Jul–Aug;86(4):269–73

Adenovirus serotype 1 does not act synergistically with Moraxella (Branhamella) catarrhalis to induce otitis media in the chinchilla. Bakaletz LO, et al. **Infect Immun** 1995 Oct;63(10):4188–90

Roles of autolysin and pneumolysin in middle ear inflammation caused by a type 3 Streptococcus pneumoniae strain in the chinchilla otitis media model. Sato K, et al. **Infect Immun** 1996 Apr;64(4):1140–5

A virulent nonencapsulated Haemophilus influenzae. Nizet V, et al. **J Infect Dis** 1996 Jan;173(1):180–6

Barotitis in children after aviation; prevalence and treatment with Otovent. Stangerup SE, et al. **J Laryngol Otol** 1996 Jul;110(7):625–8

Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. Zenni MK, et al. **J Pediatr** 1995 Oct;127(4):533–7

Otitis media following tympanostomy tube placement in children with IgG2 deficiency. Masin JS, et al. **Laryngoscope** 1995 Nov;105(11):1188–90

Otitis media in children [letter] Bernstein JA. **N Engl J Med** 1995 Oct 26;333(17):1151–2

Smoking and middle ear disease [letter; comment] Adair–Bischoff CE, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):837–40. Comment on: Otolaryngol Head Neck Surg 1995 Mar;112(3):441–6.

A pacifier increases the risk of recurrent acute otitis media in children in day care centers. Niemelä M, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):884–8

[Persistent ear infection, impaired hearing and fever] Jantunen E, et al. **Duodecim** 1994;110(19):1797–9 **(Fin)**

HISTORY

[Fatal complications of otitis 60 years ago] Bergmann K. HNO 1995 Aug;43(8):478–81 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Comparison of the local immune response to nontypable Haemophilus influenzae (nHI) and Moraxella catarrhalis (MC) during otitis media. Faden H. **Adv Exp Med Biol** 1995;371B:733–6

Experimental recurrent otitis media induced by Haemophilus influenzae: protection and serum antibodies. Melhus A, et al. **Am J Otolaryngol** 1995 Nov–Dec;16(6):383–90

Nasopharyngeal antibodies to pneumococcal pneumolysin in children with acute otitis media. Virolainen A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):704–7

Nasopharyngeal antibodies to pneumococcal capsular polysaccharides in children with acute otitis media. Virolainen A, et al. **J Infect Dis** 1995 Oct;172(4):1115–8

Antibody response to measles–mumps–rubella vaccine of children with mild illness at the time of vaccination. King GE, et al. **JAMA** 1996 Mar 6;275(9):704–7

METABOLISM

Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Nahata MC, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1875–7

MICROBIOLOGY

Experimental recurrent otitis media induced by Haemophilus influenzae: protection and serum antibodies. Melhus A, et al. **Am J Otolaryngol** 1995 Nov–Dec;16(6):383–90

Adherence of nontypeable Haemophilus influenzae to respiratory epithelium of otitis–prone and normal children. Faden H, et al. **Ann Otol Rhinol Laryngol** 1996 May; 105(5):367–70

Experimental otitis media with Moraxella (Branhamella) catarrhalis. Fulghum RS, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):234–41

Influenza A vaccine decreases the incidence of otitis media in 6– to 30–month–old children in day care [see comments] Clements DA, et al. **Arch Pediatr Adolesc Med** 1995 Oct; 149(10):1113–7. Comment in: Arch Pediatr Adolesc Med 1996 Jun;150(6):652–3.

A case of acquired petrous cholesteatoma associated with insidious middle ear infection treated by staging the surgical procedures. Gyo K, et al. **Auris Nasus Larynx** 1995; 22(3):192–6

Bacteriology of chronic otitis media, chronic sinusitis, and paranasal mucopyocele in Japan. Ito K, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S214–9

Development of beta–lactamase–mediated resistance to penicillin in middle–ear isolates of Moraxella catarrhalis in Finnish children, 1978–1993. Nissinen A, et al. **Clin Infect Dis** 1995 Nov;21(5):1193–6

In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis. Gaillot O, et al. **Drugs** 1995;49 Suppl 2:200–2

Carriage of multiple ribotypes of non–encapsulated Haemophilus influenzae in aboriginal infants with otitis media. Smith–Vaughan HC, et al. **Epidemiol Infect** 1996 Apr;116(2):177–83

Isolation of a Bordetella avium–like organism from a human specimen. Dorittke C, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):451–4

Characterization of ear fluid isolates of Alloiococcus otitidis from patients with recurrent otitis media. Bosley GS, et al. **J Clin Microbiol** 1995 Nov;33(11):2876–80

Turnover of nonencapsulated Haemophilus influenzae in the nasopharynges of otitis–prone children. Samuelson A, et al. **J Clin Microbiol** 1995 Aug;33(8):2027–31

Atypical mycobacterial otomastoiditis. TerKonda RP, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1275–8

Etiology of acute otitis media in human immunodeficiency virus–infected children. Marchisio P, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):58–61

Prevalence of bacterial otitis media in primary school children in Enugu Surburb, Enugu state, Nigeria. Oyeka CA, et al. **West Afr J Med** 1995 Apr–Jun;14(2):78–81

[Etiology and rational therapy of acute otitis media in adults] Serra A, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec; 86(1–12):121–5 (Eng. Abstr.) **(Ita)**

PATHOLOGY

The ear in the acquired immunodeficiency syndrome: I. Temporal bone histopathologic study. Michaels L, et al. **Am J Otol** 1994 Jul;15(4):515–22

Hypohidrotic ectodermal dysplasia with recurrent otitis and sebaceous gland hypertrophy of the face. Piletta PA, et al. **Dermatology** 1995;191(4):355–8

Residual mesenchyme in temporal bones of children. Kasemsuwan L, et al. **Laryngoscope** 1996 Aug; 106(8):1040–3

PHYSIOPATHOLOGY

Medial canal stenosis—chronic stenosing external otitis. Birman CS, et al. **Am J Otol** 1996 Jan;17(1):2–6

Cochlear fistula in chronic otitis media with cholesteatoma. Chao YH, et al. **Am J Otol** 1996 Jan;17(1):15–8

Magnetic resonance imaging features of Gradenigo's syndrome. Hardjasudarma M, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):247–50

Effect of SC–41930, a potent selective leukotriene B4

receptor antagonist, in the guinea pig model of middle ear inflammation. Sutbeyaz Y, et al.
Ann Otol Rhinol Laryngol 1996 Jun;105(6):476–80

Early inflammatory changes of the Haemophilus influenzae–induced experimental otitis media. Kawana M. **Auris Nasus Larynx** 1995;22(2):80–5

Age and hearing function in patients with chronic otitis media. Vartiainen E, et al. **J Otolaryngol** 1995 Dec; 24(6):336–9

Early otitis media and phonological development at age 2 years. Abraham SS, et al. **Laryngoscope** 1996 Jun; 106(6):727–32

[The mucosal subepithelial space in the middle ear in prolonged tubal dysfunction] Soteras Olle J, et al.
Acta Otorrinolaringol Esp 1995 Nov–Dec;46(6):405–8 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Influenza A vaccine decreases the incidence of otitis media in 6– to 30–month–old children in day care [see comments] Clements DA, et al. **Arch Pediatr Adolesc Med** 1995 Oct; 149(10):1113–7. Comment in: Arch Pediatr Adolesc Med 1996 Jun;150(6):652–3.

Immunization with high–molecular–weight adhesion proteins of nontypeable Haemophilus influenzae modifies experimental otitis media in chinchillas. Barenkamp SJ. **Infect Immun** 1996 Apr;64(4):1246–51

Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide–protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. Giebink GS, et al. **J Infect Dis** 1996 Jan;173(1):119–27

The other effect of intravenously administered respiratory syncytial virus–enriched immune globulin for prophylaxis: less acute otitis media [editorial; comment] Harrison CJ. **J Pediatr** 1996 Aug;129(2):193–6. Comment on: J Pediatr 1996 Aug;129(2):214–9.

Respiratory syncytial virus–enriched globulin for the prevention of acute otitis media in high risk children [see comments] Simoes EA, et al. **J Pediatr** 1996 Aug; 129(2):214–9. Comment in: J Pediatr 1996 Aug;129(2):193–6.

RADIOGRAPHY

[Contribution and role of the scanner in the preoperative evaluation of chronic otitis. Radiosurgical correlation apropos of 85 cases] Rocher P, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(7):317–23 (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

[Curietherapy of the Eustachian tube using Ir–192 in chronic otitis of tubal origin] Mazeron JJ, et al.
Bull Cancer Radiother 1990;77(2):119–24 (Eng. Abstr.) **(Fre)**

SURGERY

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)

Middle ear mechanics of type IV and type V tympanoplasty: II. Clinical analysis and surgical implications. Merchant SN, et al. **Am J Otol** 1995 Sep;16(5):565–75

Evaluation of mastoid obliteration surgery. Minatogawa T, et al. **Am J Otol** 1995 Jan;16(1):99–103

Epitympanic compartment surgical considerations: reevaluation. Palva T, et al. **Am J Otol** 1995 Jul; 16(4):505–13 (24 ref.)

Ossiculoplasty by interposition of a minor columella between the tympanic membrane and stapes head. Zheng C, et al. **Am J Otol** 1996 Mar;17(2):200–2

Healing of tympanic membrane after myringotomy during Streptococcus pneumoniae otitis media. An otomicroscopic and histologic study in the rat. Magnuson K, et al.
Ann Otol Rhinol Laryngol 1996 May;105(5):397–404

Long–term post–operative follow–up of patients with chronic otitis media. Does it make sense? Vartiainen E, et al.
Clin Otolaryngol 1995 Aug;20(4):352–4

The role of the Davis graft technique in the treatment of chronic post–mastoidectomy otorrhoea. Walsh RM, et al.
Clin Otolaryngol 1996 Apr;21(2):162–7

Modified canal wall–up mastoidectomy with mastoid obliteration for severe chronic otitis media. Montandon P, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Jul–Aug; 57(4):198–201

Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)

Results of surgery for chronic otitis media: a 5–year study. Podoshin L, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995; 116(2):109–13

[Audiometric results of 81 ossiculoplasties after tympanoplasty with closed technique in chronic cholesteatomatous otitis] Caprio D, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(3):107–17 (16 ref.) (Eng. Abstr.) **(Fre)**

[Predictive factors of residual cholesteatoma in children] Roger G, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(6):262–74 (Eng. Abstr.) **(Fre)**

[Prevention of adhesions in the middle ear] von Scheel J. **Laryngorhinootologie** 1996 Apr;75(4):254 (Eng. Abstr.) **(Ger)**

[Chronic otitis media] Podoshin L, et al. **Harefuah** 1995 Oct; 129(7–8):238–42, 295 (Eng. Abstr.) **(Heb)**

[Reconstruction of the ossicle–tympanic system with a variable configuration prosthesis] Ostrovskiĭ AI.
Vestn Otorinolaringol 1995 Sep–Oct;(5):37–9 (Eng. Abstr.) **(Rus)**

[Antibiotic prophylaxis in surgery of uncomplicated cholesteatoma: review of 150 patients] López Amado M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):421–6 (Eng. Abstr.) **(Spa)**

THERAPY

Otitis media [letter; comment] Morris MS.
Arch Otolaryngol Head Neck Surg 1995 Dec;121(12):1434–6 . Comment on: Arch Otolaryngol Head Neck Surg 1994 Oct;120(10):1049–50. Comment on: Arch Otolaryngol Head Neck Surg 1994 Oct;120(10):1051–3.

Management of acute and chronic otitis media in pediatric practice. Berman S. **Curr Opin Pediatr** 1995 Oct; 7(5):513–22 (62 ref.)

Ear infection: a retrospective study examining improvement from chiropractic care and analyzing for influencing factors. Froehle RM. **J Manipulative Physiol Ther** 1996 Mar–Apr;19(3):169–77

Otitis media in children [letter] van Buchem FL, et al.
N Engl J Med 1995 Oct 26;333(17):1151; discussion 1152

What to expect from medical treatment of otitis media. Rosenfeld RM. **Pediatr Infect Dis J** 1995 Sep;14(9):731–7; quiz 738 (27 ref.)

Quality improvement: an ACQIP exercise on the management of otitis media. Sebring RH. **Pediatr Rev** 1996 Jul;17(7):251–6

Options for treating otitis media. McLay K. **Practitioner** 1996 Jan;240(1558):42–7 (10 ref.)

VETERINARY

Traumatic ear canal separations and para–aural abscessation in three dogs. McCarthy PE, et al.
J Am Anim Hosp Assoc 1995 Sep–Oct;31(5):419–24

Endoscopy of the auditory tube diverticula in four horses with otitis media/interna. Hassel DM, et al.
J Am Vet Med Assoc 1995 Oct 15;207(8):1081–4

VIROLOGY

Influenza A virus–-induced acute otitis media. Buchman CA, et al. **J Infect Dis** 1995 Nov;172(5):1348–51

OTITIS MEDIA, PURULENT see **OTITIS MEDIA, SUPPURATIVE**

OTITIS MEDIA, SECRETORY see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SEROUS see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SUPPURATIVE

COMPLICATIONS

Suppurative petrous apicitis: osteitis or osteomyelitis? an imaging case report. Horn KL, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):54–7

Burkholderia (Pseudomonas) cepacia as a cause of brain abscesses secondary to chronic suppurative otitis media. Hobson R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct; 14(10):908–11

Alcaligenes xylosoxidans–associated infection in an infant with cholesteatoma [letter] Bénaoudia F, et al.
Pediatr Infect Dis J 1995 Jul;14(7):637–8

CONGENITAL

Isolated congenital tuberculosis otitis in a preterm infant. Ng PC, et al. **Acta Paediatr** 1995 Aug;84(8):955–6

DIAGNOSIS

Histiocytosis X presenting as chronic discharging ears [letter] Paul AK, et al. **Indian Pediatr** 1995 Apr;32(4):501

[A combination of exacerbated chronic suppurative epitympanitis and tick–borne encephalitis] Bobrov VM.
Vestn Otorinolaringol 1996 Jan–Feb;(1):51–2 **(Rus)**

[A case of tuberculous meningitis erroneously interpreted as otogenous] Chumakov FI, et al. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):52–3 **(Rus)**

[Characteristics of the course of temporal lobe abscesses in patients with multiple otogenous intracranial complications] Gadzhimirzaev GA.
Vestn Otorinolaringol 1996 Jan–Feb;(1):47–9 **(Rus)**

DRUG THERAPY

Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Yuen PW, et al. **Am J Otol** 1994 Sep;15(5):670–3

Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin. Tutkun A, et al.
Arch Otolaryngol Head Neck Surg 1995 Dec;121(12):1414–6

Etiology and therapy of chronic suppurative otitis. Campos MA, et al. **J Chemother** 1995 Oct;7(5):427–31

A double–blind comparative study of ofloxacin otic drops versus neomycin–polymyxin B–hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. Tong MC, et al. **J Laryngol Otol** 1996 Apr; 110(4):309–14

Ofloxacin otic solution as treatment of chronic suppurative otitis media and diffuse bacterial otitis externa. Sumitsawan Y, et al. **J Med Assoc Thai** 1995 Sep;78(9):455–9

[Efficacy of cefditoren pivoxil in the treatment of acute otitis media due to benzylpenicillin–insensitive Streptococcus pneumoniae] Sugita R, et al. **Jpn J Antibiot** 1996 Apr; 49(4):386–98 (Eng. Abstr.) **(Jpn)**

[The use of pilastin for treating patients with chronic suppurative otitis media] Popova AE, et al.
Vestn Otorinolaringol 1996 Jan–Feb;(1):42–3 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Pathogenesis of middle ear adhesions. Cayé–Thomasen P, et al. **Laryngoscope** 1996 Apr;106(4):463–9

IMMUNOLOGY

Antibody–secreting cells and their relation to humoral antibodies in serum and in nasopharyngeal aspirates in children with pneumococcal acute otitis media. Nieminen T, et al. **J Infect Dis** 1996 Jan;173(1):136–41

Non–cholesteatomatous suppurative otitis media: facial nerve palsy in an immunocompromised patient. Hartley C, et al.
J Laryngol Otol 1995 Aug;109(8):755–8

MICROBIOLOGY

Bacterial agents causing chronic suppurative otitis media. Obi CL, et al. **East Afr Med J** 1995 Jun;72(6):370–2

Etiology and therapy of chronic suppurative otitis. Campos MA, et al. **J Chemother** 1995 Oct;7(5):427–31

Two cases of otolaryngeal tuberculosis in a Danish married couple. Holm E, et al. **J Laryngol Otol** 1995 Nov; 109(11):1080–1

Complicated suppurative otitis media in a Greek diver due to a marine halophilic Vibrio sp. Tsakris A, et al.
J Laryngol Otol 1995 Nov;109(11):1082–4

Effect of aerobic bacteriology on the clinical presentation and treatment results of chronic suppurative otitis media. Vartiainen E, et al. **J Laryngol Otol** 1996 Apr;110(4):315–8

Chronic bilateral suppurative otitis media caused by Aspergillus terreus. Tiwari S, et al. **Mycoses** 1995 Jul–Aug; 38(7–8):297–300

Alcaligenes xylosoxidans subsp xylosoxidans in children with chronic otorrhea. Wintermeyer SM, et al.
Otolaryngol Head Neck Surg 1996 Feb;114(2):332–4 (15 ref.)

Necrobacillosis: an unusual cause of purulent otitis media and sepsis. Cron RQ, et al. **Pediatr Emerg Care** 1995 Dec; 11(6):379–80

[Molecular epidemiology of pneumococci with decreased susceptibility to penicillin isolated in a Parisian pediatric hospital] Moissenet D, et al. **Pathol Biol (Paris)** 1996 May; 44(5):423–9 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Tympanic membrane changes in experimental otitis media with effusion. von Unge M, et al. **Am J Otol** 1994 Sep; 15(5):663–9

PHYSIOPATHOLOGY

Nasal and middle ear ciliary beat frequency in chronic suppurative otitis media. Agius AM, et al.
Clin Otolaryngol 1995 Oct;20(5):470–4

Audiometric findings in children with chronic suppurative otitis media without cholesteatoma. Kaplan DM, et al.
Int J Pediatr Otorhinolaryngol 1996 Apr;35(2):89–96

SURGERY

Cochlear implants in chronic suppurative otitis media. Gray RF, et al. **Am J Otol** 1995 Sep;16(5):682–6

Factors associated with recurrence of cholesteatoma. Vartiainen E. **J Laryngol Otol** 1995 Jul;109(7):590–2

Mastoid surgery in the only hearing ear. Perez de Tagle JR, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):67–70

[Acoustic characteristics of external auditory meatus after tympanoplasty with open mastoid reconstruction] Pan S, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995; 30(4):239–42 (Eng. Abstr.) **(Chi)**

[Long–term outcome of tympanoplasty in chronic suppurative middle ear infection in childhood] Feilen SE, et al. **HNO** 1996 Mar;44(3):143–7 (Eng. Abstr.) **(Ger)**

[Use of benzofurocaine in stimulation of regenerative processes in the surgical treatment of patients with chronic suppurative otitis media] Semenov FV, et al.
Vestn Otorinolaringol 1996 Mar–Apr;(2):45–8 (Eng. Abstr.) **(Rus)**

[Use of YAG–ND laser in the treatment of not healing trepanation cavities after cleansing surgery of the middle ear] Semenov FV, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):14–7 (Eng. Abstr.) **(Rus)**

OTITIS MEDIA WITH EFFUSION

Middle ear effusion. Bassila MK. **J Med Liban** 1994;

42(4):227–9 (22 ref.)
[Why not wait and see in spontaneously perforated otitis? (letter)] Reimer M. **Lakartidningen** 1996 Aug 28; 93(35):2923–4 **(Swe)**
[The Riskronden answers (letter)] Wadman B. **Lakartidningen** 1996 Aug 28;93(35):2924 **(Swe)**

CLASSIFICATION

[Experts' opinion on pathogenesis and classification of otitis media with effusion] Bellussi L, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):467–74 **(Ita)**

COMPLICATIONS

Intracranial complications of suppurative otitis media: 13 years' experience. Kangsanarak J, et al. **Am J Otol** 1995 Jan;16(1):104–9
Comparison of the hearing histories of children with and without cleft palate. Broen PA, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):127–33
The role of middle ear effusions and epidermal growth factor in cholesteatoma formation in the gerbilline temporal bone. Omura F, et al. **Eur Arch Otorhinolaryngol** 1995; 252(7):428–32
A prevalence study of ear problems in school children in Kiambu district, Kenya, May 1992. Hatcher J, et al. **Int J Pediatr Otorhinolaryngol** 1995 Nov;33(3):197–205
Acoustic-immittance characteristics of children with middle-ear effusion: longitudinal investigation. Silverman CA, et al. **J Am Acad Audiol** 1995 Jul;6(4):339–45
Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627–8 (10 ref.)
[Serous otitis media and allergy in children (editorial)] Pérez Martín J. **Rev Alerg Mex** 1995 Sep–Oct;42(5):79–80 **(Spa)**

DIAGNOSIS

The accuracy of tympanometry assessed by its sensitivity and specificity. Szucs E, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):287–92
Neuroma of the facial nerve masked by chronic otitis media. Sellari-Franceschini S, et al. **Am J Otol** 1994 May; 15(3):441–4
Microbial dynamics of persistent purulent otitis media in children. Brook I, et al. **J Pediatr** 1996 Feb;128(2):237–40
Prospective surveillance for otitis media with effusion among black infants in group child care. Zeisel SA, et al. **J Pediatr** 1995 Dec;127(6):875–80
The length of the referral chain after failing preschool tympanometry. Claridge O, et al. **N Z Med J** 1995 Nov 24;108(1012):479–81
Allergic otitis media with gelatinous mucoid fluid containing eosinophils. Morinaka S. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):665–8
[Imaging diagnosis and function tests—exudative otitis media (CT, MRI, ear canal function tests, and tympanography)] Honjo I. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun; 99(6):954–7 **(Jpn)**
[Clinical and microbiological study of otitis media in infants] Domínguez Rovira S, et al. **An Esp Pediatr** 1996 Apr; 44(4):341–4 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effect of oxatomide on otitis media with effusion—an experimental study. Tanaka T, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):532–8
The management of chronic suppurative otitis media with acid media solution. Aminifarshidmehr N. **Am J Otol** 1996 Jan;17(1):24–5
Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Gooch WM 3rd, et al. **Clin Ther** 1995 Sep–Oct;17(5):838–51
Nonsurgical management of surgical otitis media with effusion. Rosenfeld RM. **J Laryngol Otol** 1995 Sep; 109(9):811–6
Microbial dynamics of persistent purulent otitis media in children. Brook I, et al. **J Pediatr** 1996 Feb;128(2):237–40
Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. van Balen FA, et al. **Lancet** 1996 Sep 14; 348(9029):713–6
Nitric oxide: a mediator of endotoxin-induced middle ear effusions. Ball SS, et al. **Laryngoscope** 1996 Aug; 106(8):1021–7
Otitis media with effusion [letter; comment] Roydhouse N. **N Z Med J** 1996 Jul 12;109(1025):263. Comment on: N Z Med J 1996 May 24;109(1022):182–4.
Cost-effectiveness considerations in otitis media treatment. Gates GA. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):525–30
Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Members of the Ceftibuten Otitis Media International Study Group. Blumer JL, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S115–20
Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy. Brook I, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):805–8
Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)
Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Members of the Ceftibuten Otitis Media United States Study Group. Mclinn SE, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S108–14
[Medical treatment of seromucous otitis] Renou G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):327–8 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Changes in goblet cell density in rat middle ear mucosa in acute otitis media. Cayé-Thomasen P, et al. **Am J Otol** 1995 Jan;16(1):75–82
The habit of sniffing in nasal diseases as a cause of secretory otitis media. Yaginuma Y, et al. **Am J Otol** 1996 Jan; 17(1):108–10
Recurrent otitis media in children and obstructed nasal patency in endoscopic-radiographic examination. Złomaniec J, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:67–70
Middle ear effusion—allergy relationships [see comments] Mattucci KF, et al. **Ear Nose Throat J** 1995 Nov; 74(11):752–6, 758 (18 ref.). Comment in: Ear Nose Throat J 1995 Nov;74(11):739.
Allergy: a commonly neglected etiology of serous otitis media [editorial; comment] Pulec JL. **Ear Nose Throat J** 1995 Nov;74(11):739. Comment on: Ear Nose Throat J 1995 Nov;74(11):752–6, 758.
Middle ear pressures in patients with nasopharyngeal carcinoma and their clinical significance [letter] Anteunis LJ. **J Laryngol Otol** 1996 Jan;110(1):107
Should nasopharyngeal biopsy be mandatory in adult unilateral glue ear? Lee WC, et al. **J Laryngol Otol** 1996 Jan;110(1):62–4
Role of allergy in eustachian tube blockage and otitis media with effusion: a review. Bernstein JM. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):562–8 (28 ref.)
[Otologic manifestations presenting and predominating in necrotizing angiitis] Depondt J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):249–52 (Eng. Abstr.) **(Fre)**
[Experts' opinion on pathogenesis and classification of otitis media with effusion] Bellussi L, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):467–74 **(Ita)**

HISTORY

Bluestone et al.: Audiometry and tympanometry in relation to middle ear effusions in children. (Laryngoscope. 1973;83;594–604). Meyerhoff WL. **Laryngoscope** 1996 Jun; 106(6):684–7

IMMUNOLOGY

Analysis of T cell receptor beta chain repertoire in middle ear effusions. Takeuchi K, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):213–7
Spontaneous immunoglobulin production by adenoidal and tonsillar lymphocytes in relation to age and otitis media with effusion. Harabuchi Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):117–25
Interferon production by leukocytes in children with otitis media with effusion. Pitkäranta A, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):25–33

METABOLISM

Comparison of the proteins of middle ear effusion with human mast cell proteins. Rakover Y, et al. **J Laryngol Otol** 1995 Dec;109(12):1146–50

MICROBIOLOGY

Factors associated with positive bacteriological cultures of chronic middle ear effusions. Heaton JM, et al. **Clin Otolaryngol** 1995 Jun;20(3):262–5
The incidence of bacteria in middle ear effusions. Hinton A, et al. **Clin Otolaryngol** 1996 Apr;21(2):158–61
Bacterial DNA fragments in otitis media with effusion [letter; comment] Cantekin EI. **JAMA** 1996 Jan 17;275(3):186. Comment on: JAMA 1995 May 24–31;273(20):1598–604.
The microbiology of chronic otitis media with effusion in a group of Auckland children [see comments] Watson P, et al. **N Z Med J** 1996 May 24;109(1022):182–4. Comment in: N Z Med J 1996 Jul 12;109(1025):263.
Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy. Brook I, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):805–8
Failure to detect Chlamydia pneumoniae in ear fluids from children with otitis media. Goo YA, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1000–1
Increasing incidence of penicillin- and ampicillin-resistant middle ear pathogens. Rodriguez WJ, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1075–8
[Nature and antibiotic sensitivity of bacterial species isolated in secretory otitis in a cohort of children] Rivier A, et al. **Rev Med Suisse Romande** 1996 Feb;116(2):121–3 **(Fre)**
[Participation in causing O.M.E. with nasopharyngeal alpha-Streptococcus] Fujimori I, et al. **Kansenshogaku Zasshi** 1995 Sep;69(9):982–6 (Eng. Abstr.) **(Jpn)**
[The microbiology of secretory otitis] Lacosta JL, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):439–48 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Tympanic membrane changes in experimental otitis media with effusion. von Unge M, et al. **Am J Otol** 1994 Sep; 15(5):663–9
Biochemical evidence of platelet-activating factor (PAF) in human middle ear effusions. Furukawa M, et al. **Laryngoscope** 1995 Feb;105(2):188–91
[Two patients with acute promyelocytic leukemia whose relapse was noted by cytodiagnosis of middle ear discharge] Kikuno K, et al. **Rinsho Ketsueki** 1996 Apr;37(4):323–8 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Long-term effects of otitis media with effusion: otomicroscopic findings. Schilder AG, et al. **Am J Otol** 1995 May;16(3):365–72
The contralateral ear in patients with chronic otitis media. Vartiainen E, et al. **Am J Otol** 1996 Mar;17(2):190–2
Histopathologic changes of the tympanic membrane in acute and secretory otitis media. Berger G, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):458–62
Secretory otitis media in adults: I. The role of mastoid pneumatizationas a risk factor. Sadé J, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):643–7
Cause of eustachian tube constriction during swallowing in patients with otitis media with effusion. Takahashi H, et al. **Ann Otol Rhinol Laryngol** 1996 Sep;105(9):724–8
Neutrophil elastase-alpha 1-antitrypsin in middle ear fluid in chronic otitis media with effusion. Tierney P, et al. **Clin Otolaryngol** 1995 Jun;20(3):230–3
Classification of chronic suppurative otitis media: type I. Pulec JL, et al. **Ear Nose Throat J** 1996 Jul;75(7):400
Monitoring pH of otitis media effusion in chinchillas using fluorescence spectroscopy. Magin RL, et al. **IEEE Trans Biomed Eng** 1995 Oct;42(10):1027–32
Nitric oxide: a mediator of endotoxin-induced middle ear effusions. Ball SS, et al. **Laryngoscope** 1996 Aug; 106(8):1021–7
[Otitis media with effusion in children] Zielnik B. **Otolaryngol Pol** 1995;49(3):214–9 (53 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Water precautions in children with tympanostomy tubes. Salata JA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):276–80
Water precautions in children with tympanostomy tubes. Adelman A. **J Fam Pract** 1996 Jun;42(6):567–8
A cost-benefit analysis of the post-operative use of antibiotic ear drops following grommet insertion. Pearson CR, et al. **J Laryngol Otol** 1996 Jun;110(6):527–30
Per-operative antibiotic/steroid prophylaxis of tympanostomy tube otorrhoea: chemical or mechanical effect? Shinkwin CA, et al. **J Laryngol Otol** 1996 Jun; 110(6):531–3

PSYCHOLOGY

Otitis media in early childhood and cognitive, academic, and behavior outcomes at 12 years of age. Roberts JE, et al. **J Pediatr Psychol** 1995 Oct;20(5):645–60

SURGERY

Hearing results following modified radical versus canal-up mastoidectomy. Cook JA, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):379–83
Implications of middle ear hyperoxia induced by ventilation tubes in otitis media with effusion. Ovesen T. **APMIS Suppl** 1995;54:1–36 (233 ref.)
Parental knowledge and experiences after surgery for chronic otitis media. Marais J, et al. **Br J Clin Pract** 1996 Jun; 50(4):187–9
Findings at initial surgery for childhood otitis media with effusion and subsequent outcome. Mills RP, et al. **Clin Otolaryngol** 1995 Oct;20(5):461–4
Tympanosclerosis and mini grommets: the relevance of grommet design. Dingle AF, et al. **J Laryngol Otol** 1995 Oct;109(10):922–5
Long-term ventilation of the middle ear using a tympanotomy technique. Martin-Hirsch DP, et al. **J Laryngol Otol** 1995 Dec;109(12):1151–4
Raised ABR threshold after suction aspiration of glue from the middle ear: three case studies. Mason JD, et al. **J Laryngol Otol** 1995 Aug;109(8):726–8
The management of childhood otitis media with effusion. Mills R. **J R Soc Med** 1996 Mar;89(3):132–4 (36 ref.)
General anesthesia with and without nitrous oxide (N2O) and the weight of middle ear effusion in children undergoing adenoidectomy and tympanostomy. Koivunen P, et al. **Laryngoscope** 1996 Jun;106(6):724–6
Cost-effectiveness considerations in otitis media treatment. Gates GA. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):525–30
Grommets: what GPs need to know. Maw AR. **Practitioner** 1996 Jul;240(1564):450–3
[More stringent guidelines for tympanostomy tubes in

secretory otitis media in the USA] Lous J. **Ugeskr Laeger** 1996 Jun 24;158(26):3793–4 **(Dan)**
[Clinical analysis of indications to ventilation tube removal in otitis media with effusion] Namysłowski G, et al. **Otolaryngol Pol** 1995;49(3):209–13 (Eng. Abstr.) **(Pol)**
[Use of tarflen ventilation tubes in treatment of secretory otitis media in children] Namysłowski G, et al. **Pediatr Pol** 1995 Aug;70(8):657–60 (Eng. Abstr.) **(Pol)**

THERAPY

Management of acute otitis media and glue ear. **Drug Ther Bull** 1995 Feb;33(2):12–5 (52 ref.)
Otitis media with effusion in young children: treatment in search of a problem? Agency for Health Care and Policy Research. Culpepper L, et al. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):305–16
Raised ABR threshold after suction aspiration of glue from the middle ear: three case studies [letter] Mair IW. **J Laryngol Otol** 1996 Jan;110(1):106
Bacterial DNA fragments in otitis media with effusion [letter; comment] Cantekin EI. **JAMA** 1996 Jan 17;275(3):186. Comment on: JAMA 1995 May 24–31;273(20):1598–604.
Impact of clinical practice guidelines [letter] Froehlich P, et al. **Lancet** 1995 Oct 14;346(8981):1039–40
Randomized trial of the efficacy of trimethoprim–sulfamethoxazole and prednisone in preventing post–tympanostomy tube morbidity. Daly KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1068–74
Guidelines for managing chronic otitis media with effusion. Magit AE. **West J Med** 1995 Aug;163(2):153
[Clinical analysis of indications to ventilation tube removal in otitis media with effusion] Namysłowski G, et al. **Otolaryngol Pol** 1995;49(3):209–13 (Eng. Abstr.) **(Pol)**

OTOACOUSTIC EMISSIONS, SPONTANEOUS

Use of distortion product otoacoustic emissions to assess middle ear transducers in rhesus monkeys. Park JY, et al. **Am J Otol** 1995 Sep;16(5):576–90
Monitoring cochlear function intraoperatively using distortion product otoacoustic emissions. Telischi FF, et al. **Am J Otol** 1995 Sep;16(5):597–608
Bilateral evoked otoacoustic emissions in a child with bilateral profound hearing loss. Laccourreye L, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):286–8 (15 ref.)
Neonatal otoacoustic emission screening and the identification of deafness. Watkin PM. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F16–25
Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192–200 (89 ref.)
The contribution of spontaneous otoacoustic emissions to the click evoked otoacoustic emissions. Kulawiec JT, et al. **Ear Hear** 1995 Oct;16(5):515–20
Frequency variation of spontaneous otoacoustic emissions during a naturally occurring menstrual cycle, amenorrhea, and oral contraception: a brief report. Penner MJ. **Ear Hear** 1995 Aug;16(4):428–32
COAEs and SSOAEs in adults with increased age. Prieve BA, et al. **Ear Hear** 1995 Oct;16(5):521–8
Influence of hyperthermia on cochlear micromechanical properties in humans. Ferber–Viart C, et al. **Hear Res** 1995 Nov;91(1–2):202–7
Auditory phenotyping of heterozygous sound–responsive (+/dn) and deafness (dn/dn) mice. Huang JM, et al. **Hear Res** 1995 Aug;88(1–2):61–4
Time–varying alterations in the f2–f1 DPOAE response to continuous primary stimulation. I: Response characterization and contribution of the olivocochlear efferents. Kujawa SG, et al. **Hear Res** 1995 May; 85(1–2):142–54
Phase effects in forward masking of the compound action potential: a comparison of responses to stimulus and distortion frequencies. McAnally KI, et al. **Hear Res** 1995 Nov;91(1–2):110–8
Electromotile hearing: evidence from basilar membrane motion and otoacoustic emissions. Nuttall AL, et al. **Hear Res** 1995 Dec;92(1–2):170–7
Extracochlear electrically evoked otoacoustic emissions: a model for in vivo assessment of outer hair cell electromotility. Ren T, et al. **Hear Res** 1995 Dec; 92(1–2):178–83
Suppression of stimulus frequency otoacoustic emissions by contralateral noise. Souter M. **Hear Res** 1995 Nov; 91(1–2):167–77
Filtering of distortion–product otoacdustic emissions in the inner ear of birds and lizards. Taschenberger G, et al. **Hear Res** 1995 Nov;91(1–2):87–92
Acoustic enhancement of electrically evoked otoacoustic emissions reflects basilar membrane tuning: a model. Xue S, et al. **Hear Res** 1995 Nov;91(1–2):93–100
Spontaneous and evoked otoacoustic emissions in pre–term and full–term neonates: is there a clinical application? Morlet T, et al. **Int J Pediatr Otorhinolaryngol** 1995 Nov; 33(3):207–11
Transient evoked otoacoustic emission–based screening in typical nurseries: a responsc to Jacobson and Jacobson. White KR, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):17–21
[Definition of normal criteria of provoked otoacoustic emission in the newborn infant] Aidan D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):305–8 (Eng. Abstr.) **(Fre)**
[Evaluation of hearing loss by means of inner ear acoustic emission in neonates treated with aminoglycoside] Révai K, et al. **Orv Hetil** 1995 Nov 26;136(48):2615–8 (Eng. Abstr.) **(Hun)**

DRUG EFFECTS

[Monitoring ototoxic side effects in streptomycin therapy of tuberculosis patients with transitory evoked otoacoustic emissions TEOAE] Fürst G, et al. **Pneumologie** 1995 Nov; 49(11):590–5 (Eng. Abstr.) **(Ger)**

GENETICS

On the heritability of spontaneous otoacoustic emissions: A twins study. McFadden D, et al. **Hear Res** 1995 May; 85(1–2):181–98

PHYSIOLOGY

Distortion product otoacoustic emissions in the elderly. Karzon RK, et al. **Am J Otol** 1994 Sep;15(5):596–605
Otoacoustic emissions. Richardson M. **Arch Dis Child** 1995 Oct;73(4):284–6 (34 ref.)
An optimal filtering technique to reduce the influence of low–frequency noise on click–evoked otoacoustic emissions. Tognola G, et al. **Br J Audiol** 1995 Jun; 29(3):153–60
The emergence and disappearance of one subject's spontaneous otoacoustic emissions. Penner MJ. **Ear Hear** 1996 Apr;17(2):116–9
Binaural noise suppresses linear click–evoked otoacoustic emissions more than ipsilateral or contralateral noise. Berlin CI, et al. **Hear Res** 1995 Jul;87(1–2):96–103
Distortion–product otoacoustic emissions and their anaesthesia sensitivity in the European starling and the chicken. Kettembeil S, et al. **Hear Res** 1995 Jun; 86(1–2):47–62
Distortion product otoacoustic emissions in Macaca mulatta and humans. Lasky RE, et al. **Hear Res** 1995 Sep; 89(1–2):35–51
Effect of interstimulus interval on evoked otoacoustic emissions. Lina–Granade G, et al. **Hear Res** 1995 Jul; 87(1–2):55–61
Distortion product otoacoustic emissions in rhesus (Macaca mulatta) monkey ears: normative findings. Park JY, et al. **Hear Res** 1995 Jun;86(1–2):147–62
Distortion product otoacoustic emissions created through the interaction of spontaneous otoacoustic emissions and externally generated tones. Norrix LW, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):945–55
Click– and tone–burst–evoked otoacoustic emissions in normal–hearing and hearing–impaired ears. Prieve BA, et al. **J Acoust Soc Am** 1996 May;99(5):3077–86
Effect of otoacoustic emissions on just–noticeable differences for intensity in normally hearing subjects. Probst R, et al. **J Acoust Soc Am** 1996 Jul;100(1):504–10
Spatial periodicity in the cochlea: the result of interaction of spontaneous emissions? van Hengel PW, et al. **J Acoust Soc Am** 1996 Jun;99(6):3566–71
Mystery hum [letter] Burke PJ. **Vet Rec** 1996 Jan 20;138(3):72
[Mass screening of deafness in neonates using otoacoustic emissions (editorial)] François M. **Presse Med** 1996 Jan 6–13;25(1):9–11 (Eng. Abstr.) **(Fre)**
[Detection of hearing loss in patrons of a discoteque using TEOAE and DPOAE] Liebel J, et al. **Laryngorhinootologie** 1996 May;75(5):259–64 (Eng. Abstr.) **(Ger)**
[Clinical application of distortion products of otoacoustic emissions in presbycusis] Nieschalk M, et al. **Laryngorhinootologie** 1996 Mar;75(3):129–34 (Eng. Abstr.) **(Ger)**
[Diagnosis of endolymphatic hydrops with low tone masked otoacoustic emissions] Nubel K, et al. **Laryngorhinootologie** 1995 Nov;74(11):651–6 (Eng. Abstr.) **(Ger)**
[Distortion product otoacoustic emissions (DPOAE) in chronic noise–induced hearing loss—recommendations for expert assessment] Oeken I, et al. **Laryngorhinootologie** 1995 Aug;74(8):473–80 (Eng. Abstr.) **(Ger)**
[Amplitude changes in distortion products of otoacoustic emissions after acute noise exposure] Oeken J, et al. **Laryngorhinootologie** 1996 May;75(5):265–9 (Eng. Abstr.) **(Ger)**
[Specificity and sensitivity of transient click–evoked otoacoustic emissions (TEOAE)] Pröschel U, et al. **Laryngorhinootologie** 1995 Aug;74(8):481–8 (Eng. Abstr.) **(Ger)**

OTOCONIA see **OTOLITHIC MEMBRANE**

OTOLARYNGOLOGY

see related
OTORHINOLARYNGOLOGIC DISEASES

What is neurotology? [editorial] Corvera J. **Am J Otol** 1994 Jul;15(4):455
Indications for cranial nerve monitoring during otologic and neurotologic surgery. Jackler RK, et al. **Am J Otol** 1994 Sep;15(5):611–3
Anecdotal evidence [letter; comment] Katsarkas A. **Am J Otol** 1994 Sep;15(5):696. Comment on: Am J Otol 1994 Jan;15(1):4–7.
Proposal of a guideline in reporting hearing results in middle ear and mastoid surgery [editorial] Sakai M. **Am J Otol** 1994 May;15(3):291–3
Malignant hyperthermia in the otology patient: the UCLA experience. Wackym PA, et al. **Am J Otol** 1994 May; 15(3):371–5
Otoneurological expert system. Kentala E, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):654–8
The otolaryngology lane on the information superhighway [editorial] Burton MJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):115
Otolaryngology lane update [editorial; comment] Johns ME. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):925–6 . Comment on: Arch Otolaryngol Head Neck Surg 1996 Sep;122(9):921–2.
What's in a name? A lot [editorial] Johns ME, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):595
Prior authorship [letter; comment] Komisar A. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):207. Comment on: Arch Otolaryngol Head Neck Surg 1994 Jun;120(6):676.
The use of E–mail by otolaryngologists [see comments] Kuppersmith RB, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):921–2 . Comment in: Arch Otolaryngol Head Neck Surg 1996 Sep;122(9):925–6.
Injury prevention counseling opportunities in pediatric otolaryngology. Rosenfeld RM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):609–11
Critical periods, critical time: the centrality of pediatric otolaryngology. Ruben RJ. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):234–6
Maintaining quality in a discount store arena [news] Schechter GL. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):90–1
Angiotensin converting enzyme inhibitors and the otolaryngologist [editorial] Cruickshank HE. **Clin Otolaryngol** 1995 Jun;20(3):189–91
Should ENT out–patients be seen in hospital or General Practitioners' surgeries? Johnson IJ, et al. **Clin Otolaryngol** 1995 Dec;20(6):524–6
Allergy in otolaryngology—the experience of an expert [editorial] Shambaugh GE Jr. **Ear Nose Throat J** 1995 Dec; 74(12):798–9
Temporal bones for dissection. A diminishing asset? Jeannon JP. **J Laryngol Otol** 1996 Mar;110(3):219–20
Directory of otolaryngological societies. **Laryngoscope** 1996 Apr;106(4):524–6
Directory of Otolaryngological Societies. **Laryngoscope** 1996 Mar;106(3 Pt 1):371–3
Directory of otolaryngological societies. **Laryngoscope** 1995 Nov;105(11):1259–61
Directory of otolaryngological societies. **Laryngoscope** 1996 Feb;106(2 Pt 1):243–5
Directory of otolaryngological societies. **Laryngoscope** 1995 Dec;105(12 Pt 1):1402–4
Directory of otolaryngological societies. **Laryngoscope** 1996 May;106(5 Pt 1):670–1
Directory of otolaryngological societies. **Laryngoscope** 1995 Oct;105(10):1144–6
Examination room design for the pediatric otolaryngology practice. Cook SP. **Laryngoscope** 1996 Aug;106(8):1049–50
Safety awareness for the otolaryngologist caring for the HIV–positive patient. Kantu S, et al. **Laryngoscope** 1996 Aug;106(8):982–6
Annual meeting of the American Academy of Otolaryngology Head and Neck Surgery Foundation, Inc. Washington, D.C., September 29–October 2, 1996. Instructional course program. **Otolaryngol Head Neck Surg** 1996 May;114(5 Spec No):P15–196
100th Annual meeting of the American Academy of Otolaryngology–Head and Neck Surgery Foundation, Inc. Washington, D.C. September 29–October 2, 1996. Abstracts. **Otolaryngol Head Neck Surg** 1996 Aug;115(2 Spec No):P49–236
Management guidelines for improvement of otolaryngology referrals from primary care physicians. Benninger MS, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):446–52
Universal newborn screening for hearing loss: ideal vs. reality and the role of otolaryngologists. Bluestone CD. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):89–93
Academy Foundation Distinguished Award for Contributions in Clinical Otology. Forty years of ear after ear, year after year. House WF. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):717–9
Attitudes, knowledge, and practices of otolaryngologists treating patients infected with HIV. Hwang PH, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):733–9
Evolution of otolaryngic allergy and the American Academy of Otolaryngic Allergy. Osguthorpe JD. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):515–24
Otolaryngology and the Internet. Rothschild M. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):123–31
Proceedings of the 1994 Bari Ear Care Workshop. Bari, Italy. **Scand Audiol Suppl** 1996;42:1–56
The Bari Center: an audiology and otology pilot center for Mediterranean countries. Quaranta A. **Scand Audiol Suppl** 1996;42:5–7
A major Italian force in the ENT diagnostic field and in hearing rehabilitation. Rollier GM. **Scand Audiol Suppl**

1996;42:45–6
[Reports from the German ORL congress in Karlsruhe] **HNO** 1995 Aug;43(8):467–76 **(Ger)**
[1995 ENT Congress in Karlsruhe. The cranial base] Brunner FX. **HNO** 1995 Oct;43(10):582–3 **(Ger)**
[Where is Italian otorhinolaryngology going? (letter)] de Vincentiis I. **Acta Otorhinolaryngol Ital** 1995 Dec; 15(6):482–3 **(Ita)**
[Comments on organization and activity of ENT day hospital department: three years of experience] Marcotullio D, et al. **Acta Otorhinolaryngol Ital** 1995 Oct;15(5):395–9 (Eng. Abstr.) **(Ita)**
[The history corner: economic sanctions of 1935 and relations between Italian and French otolaryngologists] Sperati G. **Acta Otorhinolaryngol Ital** 1995 Oct;15(5):393–4 **(Ita)**
[The 96th Congress of the Japanese Society of Otolaryngology. May 11–13, 1995. Chiba, Japan. Abstracts] **Nippon Jibiinkoka Gakkai Kaiho** 1995 Oct;98(10):1501–780 **(Jpn)**
["Vertigo" the fact analysis of clinical practice by ENT physicians of Chiba Prefecture by "send–out" questionnaires] Yamamoto M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun;99(6):875–83 (Eng. Abstr.) **(Jpn)**
[Problems of organization and prospects of outpatient and inpatient ENT services in Moscow] Nikolaev MP. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):56–8 **(Rus)**
[The descriptive study of primary care in otorhinolaryngology] Benito JI, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):55–62 (Eng. Abstr.) **(Spa)**
[An outpatient study in ENT (otorhinolaryngology) emergencies at a general hospital] Pérez Obón J, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug;46(4):298–304 (Eng. Abstr.) **(Spa)**

EDUCATION

Learning fibreoptic skills in ear, nose and throat clinics. Burke LP, et al. **Anaesthesia** 1996 Jan;51(1):81–3
Balancing pediatric otolaryngology training for fellows and residents at a children's hospital. Grundfast KM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):714–8
Myringoplasty and tympanoplasty—results related to training and experience. Palva T, et al. **Clin Otolaryngol** 1995 Aug; 20(4):329–35
Clinical photographs as teaching aids: how reliable are they? McCombe A, et al. **J Laryngol Otol** 1995 Aug;109(8):741–3
The age of the medical education revolution. Alford BR. **Laryngoscope** 1996 Jul;106(7):801–4
Potential schemes for residency manpower reductions. Cummings CW. **Laryngoscope** 1995 Dec;105(12 Pt 1):1273–4
Complications of endoscopic sinus surgery in a residency training program. Kinsella JB, et al. **Laryngoscope** 1995 Oct;105(10):1029–32
Methodologies of teaching. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):258–61
[Methods of active teaching (practical game, discussion) at the Otorhinolaryngology Department] Beliakova LV, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):53–5 (Eng. Abstr.) **(Rus)**
[The rating evaluation of student knowledge in a department of otorhinolaryngology] Georgiadi GA. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):55–6 **(Rus)**
[Test control in the evaluation of knowledge in otorhinolaryngology] Luchikhin LA, et al. **Vestn Otorinolaringol** 1995 Nov–Dec;(6):53–5 **(Rus)**
[Systematization of otorhinolaryngology training] Alemán López O, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr; 47(2):89–92 (Eng. Abstr.) **(Spa)**

HISTORY

C. S. Hallpike and C. O. Nylén—some recollections of the founders of The Bárány Society. Stahle J. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:455–62
Chronic ear surgery: a historical review. Briggs RJ, et al. **Am J Otol** 1994 Jul;15(4):558–67
Review of the formative years—a guide for the future. Kohut RI. **Am J Otol** 1995 Jan;16(1):4–5
George E. Shambaugh, Jr, MD. A pioneer of American otomicrosurgery. Derlacki EL, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):596–9
Mightier than the sword. Martinez SA. **Ear Nose Throat J** 1996 Jan;75(1):25, 29–31
Twenty–five years old! [editorial] Alberti PW. **J Otolaryngol** 1996 Feb;25(1):1–4 **(Eng, Fre)**
History of otolaryngology in Canada, McGill University: Part 1. Baxter JD. **J Otolaryngol** 1996 Feb;25(1):49–58
History of otolaryngology in Canada, McGill University: Part 2. Baxter JD. **J Otolaryngol** 1996 Apr;25(2):130–5
The bloody angle: 100 years of acoustic neuroma surgery. Ramsden RT. **J R Soc Med** 1995 Aug;88(8):464P–468P
Advertisements in The Laryngoscope. Arsenauro, 1901–1904. **Laryngoscope** 1996 Aug;106(8):928
The age of the medical education revolution. Alford BR. **Laryngoscope** 1996 Jul;106(7):801–4
Laryngoscopy and laryngoscopes—who's first?: the forefathers/four fathers of laryngology. Bailey B. **Laryngoscope** 1996 Aug;106(8):939–43
What's all the fuss about?: The Laryngoscope pages cause an international incident. Bailey BJ. **Laryngoscope** 1996 Aug;106(8):925–7
Laryngology education at the turn of the century. Bailey BJ. **Laryngoscope** 1996 Jul;106(7):797–800
A tribute to Max Goldstein, MD, founder and editor of The Laryngoscope. Bailey BJ. **Laryngoscope** 1996 May;106(5 Pt 1):535–44
The evolution of head and neck surgery. Myers EN. **Laryngoscope** 1996 Aug;106(8):929–34
Lorente de No's "Anatomy of the eighth nerve. I. The central projection of the nerve endings of the internal ear; III. General plan of structure of the primary cochlear nuclei." (Laryngoscope. 1933;43:1–38 & 327–350). Pillsbury HC 3rd. **Laryngoscope** 1996 May;106(5 Pt 1):533–4
Jako: "Laser surgery of the vocal cords; an experimental study with carbon dioxide lasers on dogs." (Laryngoscope, 1972; 82:2204–2216) [classical article] Shapshay SM. **Laryngoscope** 1996 Aug;106(8):935–8
Evolution of research otolaryngology—head and neck surgery over the past century. Snow JB Jr. **Laryngoscope** 1996 May;106(5 Pt 1):529–31
The history of laryngology in the United States. Woodson GE. **Laryngoscope** 1996 Jun;106(6):677–9
The history of laryngology: a centennial celebration. Alberti PW. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):345–54
Centennial celebration of otolaryngology–head and neck surgery in the United States: history of the American Academy of Otolaryngology–Head and Neck Surgery. Papel ID, et al. **Otolaryngol Head Neck Surg** 1996 Jan; 114(1):1–3
Otology through the ages. Pappas DG. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):173–96
Facial plastic surgery: subspecialty helps otolaryngology define its boundaries. Simons RL, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):1–14
[100 years of radiotherapy in otorhinolaryngology] Bohndorf W. **HNO** 1995 Oct;43(10):579–81 **(Ger)**
[History of the ear speculum. Images from the history of otorhinolaryngology, highlighted by instruments from the collection of the German Medical History Museum in Ingolstadt] Feldmann H. **Laryngorhinootologie** 1996 May; 75(5):311–8 (Eng. Abstr.) **(Ger)**
[From otoscope to ophthalmoscope and back. The interwoven history of their invention and introduction into medical practice. Pictures from the history of otorhinolaryngology, illustrated by instruments from the collection of the Ingolstadt German Medical History Museum] Feldmann H. **Laryngorhinootologie** 1995 Nov; 74(11):707–17 (Eng. Abstr.) **(Ger)**
[The monochord, its path from Pythagorean musicology to testing the upper auditory tone limit. Pictures from the history of otorhinolaryngology, represented by instruments of the Ingolstadt German Medical History Museum] Feldmann H. **Laryngorhinootologie** 1995 Aug;74(8):519–23 (Eng. Abstr.) **(Ger)**
[A clinic in rapidly changing times. Recollections of the Cologne University Otorhinolaryngologic Clinic 1933–1953] Meyer zum Gottesberge A. **Laryngorhinootologie** 1995 Oct;74(10):645–9 **(Ger)**
[History corner. Pioneers of laryngology: Manuel Garcia (1805–1906)] Sperati G. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):465–6 **(Ita)**
[Diaphanoscopy (transillumination) of maxillary sinuses: a method too early forgotten?] Kierzek A. **Otolaryngol Pol** 1995;49(4):371–9 (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

Intra–operative image guidance in otolaryngology—the use of the ISG viewing wand. Carney AS, et al. **J Laryngol Otol** 1996 Apr;110(4):322–7
Re: otological drills [letter] Duque CS. **J Laryngol Otol** 1996 May;110(5):512
How I do it: an improved temporal bone holder. Gendeh BS, et al. **J Laryngol Otol** 1995 Jul;109(7):644–5
Measurement of small tissue volumes using Holden's apparatus. Mason JD, et al. **J Laryngol Otol** 1995 Dec; 109(12):1181–3
Evaluation of acoustic rhinometry and posterior rhinomanometry as tools for inhalation challenge studies. Kesavanathan J, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):295–307
Snare dissection uvulopalatoplasty [letter; comment] Harris NJ. **Laryngoscope** 1996 Mar;106(3 Pt 1):370. Comment on: Laryngoscope 1995 Oct;105(10):1033–6.
Advances in the development of the interferometric otoscope. Parnes SM, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):263–7
[Possibilities of the use of the sinus catheter IaMIK in rhinology] Markov GI. **Vestn Otorinolaringol** 1995 Nov–Dec;(6):41–3 (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

[Allografts in otology. Potential risk of prion contamination. Current status of knowledge and legislation] Martin CH, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):241–3 (Eng. Abstr.) **(Fre)**

MANPOWER

Time to think about nurses in ENT [editorial] Prinsley P. **J Laryngol Otol** 1995 Dec;109(12):1140
Restructuring the workforce in otolaryngology–head and neck surgery: it's time to play "what if"? Bailey BJ. **Laryngoscope** 1995 Nov;105(11):1149–51
Head and neck surgery workforce in the year 2014. Close LG, et al. **Laryngoscope** 1995 Oct;105(10):1081–5
Relationship between ENT specialists and deaf community. Filipo R, et al. **Scand Audiol Suppl** 1996;42:41–3

METHODS

Modified retrosigmoid approach: use for selected acoustic tumor removal. Shelton C, et al. **Am J Otol** 1995 Sep; 16(5):664–8
Orotracheal intubation with a nasal Ring–Adair–Elwyn tube provides an unobstructed view in otolaryngologic procedures [letter] Chee WK. **Anesthesiology** 1995 Dec; 83(6):1369
Percutaneous endoscopic gastrostomy. A useful tool for the otolaryngologist–head and neck surgeon. Selz PA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1249–52
Modifications of the Caldwell–Luc procedure for the prevention of post–operative sensitivity disorders. Ferekidis E, et al. **J Laryngol Otol** 1996 Mar;110(3):228–31
A new incision for placement of cochlear implants. Gibson WP, et al. **J Laryngol Otol** 1995 Sep;109(9):821–5
Excision of adenoid cystic carcinoma of the cervical trachea via an anterior castellated approach. Hartley BE, et al. **J Laryngol Otol** 1995 Aug;109(8):774–6
The reliability of acoustic rhinometry [letter; comment] Tomkinson A. **J Laryngol Otol** 1995 Dec;109(12):1234. Comment on: J Laryngol Otol 1995 Jun;109(6):536–7.
Airway control during percutaneous tracheotomy [letter; comment] DeWitt WS. **Laryngoscope** 1995 Feb;105(2):226 . Comment on: Laryngoscope 1994 Sep;104(9):1178–80.

ORGANIZATION & ADMINISTRATION

A nurse–led preadmission clinic for elective ENT surgery: the first 8 months. Koay CB, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):15–9

STANDARDS

Preoperative HIV testing [letter; comment] Pincus RL. **Ear Nose Throat J** 1995 Sep;74(9):657. Comment on: Ear Nose Throat J 1995 May;74(5):313.
Collegiality. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):206–12
The impaired physician. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):213–9
Commercial relationships. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):220–3
Compensation. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):224–7
Advertising. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):228–34
Resource selection. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):235–40
Obligations to patient, profession, society, family, and self—an integrating resolution. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):241–9
Informed consent. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):179–85
Patient rights and surrogacy. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):186–90
Delegation of authority. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):191–4
Research. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):195–9
Medical legal ethics. Casler J. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):250–7

TRENDS

Otology and neurotology in America: state of the specialty [editorial] Hughes GB, et al. **Am J Otol** 1994 Nov; 15(6):699–701
Trends in voice rehabilitation in the United Kingdom. Parker AJ, et al. **Folia Phoniatr Logop** 1995;47(5):286–90
What's new in otorhinolaryngology. Miller RH. **J Am Coll Surg** 1996 Feb;182(2):139–44 (23 ref.)
Otolaryngology–head and neck surgery. Richtsmeier WJ, et al. **JAMA** 1996 Jun 19;275(23):1838–9
Balancing community and academic health center needs while preserving educational quality. Krause C. **Laryngoscope** 1995 Oct;105(10):1021–3
New technology. Lanza DC.

Otolaryngol Head Neck Surg 1996 Sep;115(3):200–5

OTOLITHIC MEMBRANE

CYTOLOGY

Properties of otolith–related vestibular nuclear neurons in response to bidirectional off–vertical axis rotation of the rat. Lai CH, et al. **Brain Res** 1995 Sep 25;693(1–2):39–50

DRUG EFFECTS

Damage and recovery of otolithic function following streptomycin treatment in the rat. Meza G, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:666–9

EMBRYOLOGY

Non–invasive assessment of otolith formation during development of the Japanese red–bellied newt, Cynops pyrrhogaster. Koike H, et al. **Hear Res** 1995 Aug; 88(1–2):206–14

GROWTH & DEVELOPMENT

Altered gravitational conditions affect the early development of the static vestibulo–ocular reflex in lower vertebrates. Horn ER, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:635–8

INJURIES

Otolith disorder [letter] Philip N. **N Z Med J** 1996 Aug 23; 109(1028):324–5

Otolith disorder from diving [letter] Roydhouse N. **N Z Med J** 1996 Jun 28;109(1024):241–2

INNERVATION

New representations of otolithic primary afferent spatial tuning—a re–processing of the Fernández & Goldberg (1976) data. Curthoys IS, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:427–9

PHYSIOLOGY

Otolithic thresholds influence the perception of passive linear displacement. Glasauer S, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:41–4

The interaction of the human linear otolith–ocular and angular horizontal vestibulo–ocular reflexes in darkness. Anastasopoulos D, et al. **Ann N Y Acad Sci** 1996 Jun 19; 781:580–2

Organizational principles of otolith– and semicircular canal–ocular reflexes in rhesus monkeys. Angelaki DE, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:332–47

GABAergic pathways convey vestibular information to the beta nucleus and dorsomedial cell column of the inferior olive. Barmack NH. **Ann N Y Acad Sci** 1996 Jun 19; 781:541–52

Otolith directional sensitivity and ocular torsion. Bos JE, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:583–4

Changes in otolith VOR to off vertical axis rotation in infants learning to walk. Preliminary results of a longitudinal study. Wiener–Vacher SR, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:709–12

Otolith–semicircular canal interaction during postrotatory nystagmus in humans. Fetter M, et al. **Exp Brain Res** 1996 Mar;108(3):463–72

Vestibularly evoked potentials (VESTEPs) of the horizontal semicircular canals under different body positions in space. Probst T, et al. **J Vestib Res** 1995 Jul–Aug;5(4):253–63

Off–axis rotation as a test of otolith function. Blakely BW. **Laryngoscope** 1995 Dec;105(12 Pt 1):1342–6

Computer–controlled vibrations of a biological subject in the nm range. Goossens JH, et al. **Med Biol Eng Comput** 1995 Sep;33(5):732–5

ULTRASTRUCTURE

Atomic force microscope observations of otoconia in the newt. Hallworth R, et al. **Hear Res** 1995 May; 85(1–2):115–21

Visualization of newt aragonitic otoconial matrices using transmission electron microscopy. Steyger PS, et al. **Hear Res** 1995 Dec;92(1–2):184–91

OTOLITHS see **OTOLITHIC MEMBRANE**

OTOLOGY see **OTOLARYNGOLOGY**

OTORHINOLARYNGOLOGIC DISEASES

see related
EAR DISEASES
LARYNGEAL DISEASES
NOSE DISEASES
PHARYNGEAL DISEASES

Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):101–16 (55 ref.)

[The 96th Congress of the Japanese Society of Otolaryngology. May 11–13, 1995. Chiba, Japan. Abstracts] **Nippon Jibiinkoka Gakkai Kaiho** 1995 Oct;98(10):1501–780 **(Jpn)**

[ENT practice for the aged] Shitara T. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):72–7 **(Jpn)**

[The physician and the computer: no time–saving at a department of otorhinolaryngology] Lychou C. **Lakartidningen** 1996 Sep 4;93(36):3011–2 **(Swe)**

COMPLICATIONS

[ORL manifestations observed in AIDS. Apropos of 65 cases] Sacko HB, et al. **Bull Soc Pathol Exot** 1995 Apr;88(5):234–5 (Eng. Abstr.) **(Fre)**

[Rectal localization of Wegener's disease (letter)] Herody M, et al. **Gastroenterol Clin Biol** 1996;20(4):408–10 **(Fre)**

DIAGNOSIS

Screening—a unique way of better health care delivery for ENT patients. Datta PG, et al. **Bangladesh Med Res Counc Bull** 1995 Dec;21(3):99–103

Incidence of previously undetected disease in routine paediatric otolaryngology admissions. Zeitoun H, et al. **J Laryngol Otol** 1996 Jun;110(6):557–8

An application of telemedicine technology for otorhinolaryngology diagnosis. Crump WJ, et al. **Laryngoscope** 1996 May;106(5 Pt 1):595–8

[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Medical ENT diagnosis and therapy of sleep–associated respiratory disorders with obstruction of the upper airways] Riechelmann H, et al. **Pneumologie** 1995 Oct;49(10):523–7 (33 ref.) **(Ger)**

[Patients with ENT problems (editorial)] Probst R. **Ther Umsch** 1995 Nov;52(11):712 **(Ger)**

[State of the art and ways of progress in radiology of the head and neck] Chiesa A. **Radiol Med (Torino)** 1995 Nov; 90(5):626–8 **(Ita)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

[Features of the status of otorhinolaryngologic organs of subway train mechanics] Pankova VB, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):17–21 (Eng. Abstr.) **(Rus)**

[Features of changes in otorhinolaryngologic organs of operators of automatic plasma tube cutting] Sineva EL. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):21–3 **(Rus)**

DRUG THERAPY

Pharmacokinetic and clinical studies of T–3761 in otorhinolaryngeal infections. Shinkawa A, et al. **Drugs** 1995;49 Suppl 2:401–2

In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections. Speciale A, et al. **Drugs** 1995; 49 Suppl 2:403–5

[Use of rovamycin and amox–clav in patients with infectious–inflammatory pathology of the ORL organs] Kriukov AI, et al. **Vestn Otorinolaringol** 1996 Mar–Apr; (2):42–5 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Snoring, apnoea and ENT symptoms in the paediatric community. Owen GO, et al. **Clin Otolaryngol** 1996 Apr; 21(2):130–4

ETIOLOGY

Otolaryngologic manifestations of multiple pterygium syndrome. MacArthur CJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):135–40

Passive smoking. Lejeune HB, et al. **J La State Med Soc** 1995 Oct;147(10):444–7 (17 ref.)

Effects of air pollution on the upper aerodigestive tract. Holt GR. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):201–4

[Hemorrhage from the ORL area] Baerthold W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):703–6 (0 ref.) (Eng. Abstr.) **(Ger)**

[Problems in the pathogenesis, clinical picture and timely diagnosis of a diphtheritic lesion of the ENT organs] Grinchuk VI. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):5–13 **(Rus)**

GENETICS

[Manifestation of tuberous sclerosis in the ENT area] Helling K, et al. **HNO** 1996 May;44(5):264–6 (Eng. Abstr.) **(Ger)**

HISTORY

[History of diagnostic imaging in the area of the head–neck] Reisner K. **Radiologe** 1996 Mar;36(3):175–80 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

[Evolution of the susceptibility to penicillin G of Streptococcus pneumoniae at the Limoge University Hospital Center] Ploy MC, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):241–4 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neonatal cervical choristoma—a case report. Nayak S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S1

RADIOGRAPHY

Three–dimensional imaging of ENT diseases with helical computed tomography. Muraoka H, et al. **J Laryngol Otol** 1996 Jun;110(6):604–8

[Radiologic assessment of globus pharyngis. Comparison of the diagnostic value of conventional roentgen with videocinematography] Schober E, et al. **Radiologe** 1995 Oct;35(10):724–32 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[Low–intensity laser irradiation in otorhinolaryngology] Pluzhnikov MS, et al. **Vestn Otorinolaringol** 1996 Mar–Apr; (2):5–14 (Eng. Abstr.) **(Rus)**

SURGERY

CT and MR appearance of otolaryngologic packing materials. Hartley C, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1697–702

Review of uses of the laryngeal mask in ENT anaesthesia [see comments] Nair I, et al. **Anaesthesia** 1995 Oct; 50(10):898–900 (27 ref.). Comment in: Anaesthesia 1996 Apr;51(4):409.

Measuring patient benefit from otorhinolaryngological surgery and therapy. Robinson K, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):415–22

Is pre–operative patient assessment effective? A prospective trial of 100 patients. Banerjee AR, et al. **Ann R Coll Surg Engl** 1996 May;78(3 Suppl):119–21

A nurse–led preadmission clinic for elective ENT surgery: the first 8 months. Koay CB, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):15–9

The holmium:YAG laser–assisted otolaryngologic procedures. Gleich LL, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1162–6

Lasers in otorhinolaryngology–head and neck surgery. Rebeiz EE. **J Med Liban** 1994;42(4):242–9 (21 ref.)

Image– and model–based surgical planning in otolaryngology. Korves B, et al. **J Otolaryngol** 1995 Oct; 24(5):265–70

Laryngeal mask airway in paediatric otolaryngologic surgery. Ruby RR, et al. **J Otolaryngol** 1995 Oct; 24(5):288–91

The evolution of head and neck surgery. Myers EN. **Laryngoscope** 1996 Aug;106(8):929–34

Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081–91 (52 ref.)

Respiratory mucosa wound healing and its management. An overview. Dohar JE, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):897–912 (28 ref.)

Wound healing after laser surgery. Hendrick DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):969–86 (89 ref.)

Cutaneous wound healing. An overview. Koopmann CF Jr. **Otolaryngol Clin North Am** 1995 Oct;28(5):835–45 (14 ref.)

Methods and materials for wound closure. Reiter D. **Otolaryngol Clin North Am** 1995 Oct;28(5):1069–80 (64 ref.)

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

Cartilage wound healing. An overview. Silver FH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):847–64 (81 ref.)

Facial bone wound healing. An overview. Szachowicz EH. **Otolaryngol Clin North Am** 1995 Oct;28(5):865–80 (35 ref.)

100th Annual meeting of the American Academy of Otolaryngology–Head and Neck Surgery Foundation, Inc. Washington, D.C. September 29–October 2, 1996. Abstracts. **Otolaryngol Head Neck Surg** 1996 Aug;115(2 Spec No):P49–236

Annual meeting of the American Academy of Otolaryngology Head and Neck Surgery Foundation, Inc. Washington, D.C., September 29–October 2, 1996. Instructional course program. **Otolaryngol Head Neck Surg** 1996 May;114(5 Spec No):P15–196

[Patient assessment in ambulatory surgery. A questionnaire study] Nielsen TR, et al. **Ugeskr Laeger** 1996 Mar 25; 158(13):1823–6 (Eng. Abstr.) **(Dan)**

[Hemorrhagic complications of ORL surgery] Boisson–Bertrand D, et al. **Cah Anesthesiol** 1995; 43(5):489–95 (48 ref.) **(Fre)**

[ENT anesthesia: the German Society of Anesthesia and Intensive Care Medicine on the use of succinylcholine (comment)] **HNO** 1995 Nov;43(11):640–1. Comment on: HNO 1995 Nov;43(11):676–9. **(Ger)**

[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte–Sasse U. **HNO** 1995 Nov;43(11):676–9 (29 ref.) (Eng. Abstr.). Comment in: Hosp Formul 1995 Nov;43(11):640–1. **(Ger)**

THERAPY

[Manual medicine in otorhinolaryngology. Theoretical principles— clinical practice—principles of therapy and prevention] Seifert K. **Laryngorhinootologie** 1995 Oct; 74(10):583–90 (38 ref.) (Eng. Abstr.) **(Ger)**

[Patients with ENT problems (editorial)] Probst R.

Ther Umsch 1995 Nov;52(11):712 (Ger)

OTORHINOLARYNGOLOGIC NEOPLASMS

[ORL cancer and suspected bronchial lesion] Vaylet F, et al. **Rev Pneumol Clin** 1995;51(4):257–9 (Fre)

DIAGNOSIS

[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) (Ger)

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) (Ger)

[Value of fat signal suppression MRI pulse sequences for diagnosis of malignant tumors in the area of the head–neck] Müller–Lisse GU, et al. **Radiologe** 1996 Mar;36(3):199–206 (Eng. Abstr.) (Ger)

[Tumors in otorhinolaryngological surgery] Delank KW. **Ther Umsch** 1995 Nov;52(11):768–73 (Eng. Abstr.) (Ger)

DRUG THERAPY

[Concomitant radiochemotherapy in locally advanced ORL cancers: a prospective study of 68 cases] Maylin C, et al. **Bull Cancer Radiother** 1996;83(2):108–10 (Eng. Abstr.) (Fre)

[Implantable sites in cancerology. The percutaneous technique. Results of a homogeneous series of 141 cases] Maillart P, et al. **J Chir (Paris)** 1995 Dec;132(12):495–8 (Eng. Abstr.) (Fre)

GENETICS

[Manifestation of tuberous sclerosis in the ENT area] Helling K, et al. **HNO** 1996 May;44(5):264–6 (Eng. Abstr.) (Ger)

[Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation] Gottschlich S, et al. **Laryngorhinootologie** 1996 May;75(5):301–5 (Eng. Abstr.) (Ger)

HISTORY

[100 years of radiotherapy in otorhinolaryngology] Bohndorf W. **HNO** 1995 Oct;43(10):579–81 (Ger)

[History of diagnostic imaging in the area of the head–neck] Reisner K. **Radiologe** 1996 Mar;36(3):175–80 (Eng. Abstr.) (Ger)

IMMUNOLOGY

[Serum soluble interleukin 2 receptor in patients with squamous epithelial carcinomas of the upper aerodigestive tract] Gottschlich S, et al. **Laryngorhinootologie** 1995 Aug; 74(8):508–11 (Eng. Abstr.) (Ger)

[Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation] Gottschlich S, et al. **Laryngorhinootologie** 1996 May;75(5):301–5 (Eng. Abstr.) (Ger)

PATHOLOGY

[Ultrasound diagnosis in primary staging of head–neck tumors] Mende U, et al. **Radiologe** 1996 Mar;36(3):207–16 (Eng. Abstr.) (Ger)

RADIONUCLIDE IMAGING

[Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor] Schipper JH, et al. **HNO** 1996 May;44(5):254–7 (Eng. Abstr.) (Ger)

RADIOTHERAPY

[Intraoperative radiotherapy of ORL cancers. Review of the literature] Demange L. **Bull Cancer Radiother** 1996; 83(2):75–8 (25 ref.) (Eng. Abstr.) (Fre)

[Concomitant radiochemotherapy in locally advanced ORL cancers: a prospective study of 68 cases] Maylin C, et al. **Bull Cancer Radiother** 1996;83(2):108–10 (Eng. Abstr.) (Fre)

[Focus on the activity of the European group of radiobiology. NCI TPOT study T92–0045. 9 June 1995, Lyon] Mornex F, et al. **Bull Cancer Radiother** 1995;82(4):402–3 (Fre)

[Contribution of curietherapy in the treatment of ENT tumors] Beauvois S. **Rev Med Brux** 1996 Apr;17(2):86–90 (23 ref.) (Eng. Abstr.) (Fre)

[Possible applications of brachytherapy from the viewpoint of the ENT physician] Büntzel J, et al. **Laryngorhinootologie** 1995 Nov;74(11):673–7 (Eng. Abstr.) (Ger)

[Radiotherapy of ENT tumors and risk of lymphedema] Ewald H. **Z Lymphol** 1996 Jun;20(1):21–6 (10 ref.) (Eng. Abstr.) (Ger)

SURGERY

Beta–carbolines in chronic alcoholics undergoing elective tumor resection. Spies CD, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):969–76

Emergency balloon embolization for carotid artery rupture secondary to postoperative infection. Hirai T, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):50–2

Experience with percutaneous endoscopic gastrostomy on an otolaryngology service. Wilson WR, et al. **Ear Nose Throat J** 1995 Nov;74(11):760–2

The infected wound and its management. Bumpous JM, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):987–1001 (44 ref.)

The combined flap based on a single vascular source: a clinical experience with 32 cases. Yamamoto Y, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1385–90

[Tumors in otorhinolaryngological surgery] Delank KW. **Ther Umsch** 1995 Nov;52(11):768–73 (Eng. Abstr.) (Ger)

THERAPY

[Adoptive immunotherapy methods in ENT oncology] Daikhes NA, et al. **Vestn Otorinolaringol** 1996 Jan–Feb; (1):35–8 (Eng. Abstr.) (Rus)

OTORHINOLARYNGOLOGY see **OTOLARYNGOLOGY**

OTOSCLEROSIS

see related
FENESTRATION
STAPES MOBILIZATION

High–resolution computed tomographic evaluation of the cochlear capsule in otosclerosis: relationship between densitometry and sensorineural hearing loss. Güneri EA, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):659–64

COMPLICATIONS

Poor vibration of inner ear fluids as a cause of low tone tinnitus. Causse JB, et al. **Am J Otol** 1995 Sep;16(5):701–2

Simultaneous presentation of facial nerve neuroma and otosclerosis. Rizer FM, et al. **Am J Otol** 1994 May; 15(3):427–30

DIAGNOSIS

Magnetic resonance imaging of cochlear otosclerosis. Saunders JE, et al. **Ann Otol Rhinol Laryngol** 1995 Oct; 104(10 Pt 1):826–9

Quantifying the Carhart effect in otosclerosis. Cook JA, et al. **Clin Otolaryngol** 1995 Jun;20(3):258–61

DRUG THERAPY

Menière's syndrome: an approach to therapy. Brookler KH, et al. **Ear Nose Throat J** 1995 Aug;74(8):534–8, 540, 542

EPIDEMIOLOGY

Endolymphatic hydrops associated with otosclerosis. Shea JJ Jr, et al. **Am J Otol** 1994 May;15(3):348–57

GENETICS

The genetic background of anticipation [letter; comment] Morrison AW. **J R Soc Med** 1995 Aug;88(8):483. Comment on: J R Soc Med 1995 Apr;88(4):185–7.

[Human leukocyte antigen and otosclerosis] Gamir MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):26–8 (Eng. Abstr.) (Spa)

PATHOLOGY

Glycosaminoglycan metabolism in otosclerotic bone cells. Locci P, et al. **Biol Cell** 1996;86(1):73–8

[Pathogenesis of otosclerosis. "State of the art"] Arnold W, et al. **HNO** 1996 Mar;44(3):121–9 (61 ref.) (Eng. Abstr.) (Ger)

PHYSIOPATHOLOGY

Facial nerve stimulation produced by cochlear implants in patients with cochlear otosclerosis. Muckle RP, et al. **Am J Otol** 1994 May;15(3):394–8

Simultaneous presentation of facial nerve neuroma and otosclerosis. Rizer FM, et al. **Am J Otol** 1994 May; 15(3):427–30

Vestibular symptoms in otosclerosis—correlation of otosclerotic involvement of vestibular apparatus and Scarpa's ganglion cell count. Saim L, et al. **Am J Otol** 1996 Mar;17(2):263–70

Effect of drinking water fluoridation on hearing of patients with otosclerosis in a low fluoride area: a follow–up study. Vartiainen E, et al. **Am J Otol** 1994 Jul;15(4):545–8

Magnetic resonance imaging of cochlear otosclerosis. Saunders JE, et al. **Ann Otol Rhinol Laryngol** 1995 Oct; 104(10 Pt 1):826–9

RADIONUCLIDE IMAGING

Localization of active otosclerotic foci by tympano–cochlear scintigraphy (TCS) using correlative imaging. Ross UH, et al. **J Laryngol Otol** 1995 Nov;109(11):1051–6

SURGERY

Long–term hearing results following stapedotomy. Dornhoffer JL, et al. **Am J Otol** 1994 Sep;15(5):674–8 (14 ref.)

Long–term results after stapedectomy versus stapedotomy. Kürsten R, et al. **Am J Otol** 1994 Nov;15(6):804–6

Mixed hearing loss in otosclerosis: indication for long–term follow–up. Ramsay HA, et al. **Am J Otol** 1994 Jul; 15(4):536–9

Surgery in elderly patients with otosclerosis. Vartiainen E. **Am J Otol** 1995 Jul;16(4):536–8

Value of computed tomography in patients with persistent vertigo after stapes surgery. Kösling S, et al. **Invest Radiol** 1995 Dec;30(12):712–5

Intraoperative audiometry. Lippy WH, et al. **Laryngoscope** 1995 Feb;105(2):214–6

Ambulatory vs. in–patient stapedectomy: a randomized twenty–patient pilot study. Corvera G, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):355–9

[Stapedectomy and micro–stapedotomy in the treatment of otospongiosis. A comparative study] Portmann D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):317–22 (Eng. Abstr.) (Fre)

[Mastoid pneumatization in otosclerosis] Pyd M, et al. **Otolaryngol Pol** 1995;49(4):319–23 (Eng. Abstr.) (Pol)

[Cytogenetic study in otosclerosis] Gamir MA, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):119–20 (Eng. Abstr.) (Spa)

[Our experience in the surgery of otosclerosis] Hurtado Garcia JF, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug; 46(4):268–72 (Eng. Abstr.) (Spa)

OTOSPONGIOSIS see **OTOSCLEROSIS**

OTTERS

Light and scanning electron microscopic study on the lingual papillae in the newborn sea otter Enhydra lutris. Shimoda T, et al. **Okajimas Folia Anat Jpn** 1996 May;73(1):65–74

Clinical and clinical laboratory correlates in sea otters dying unexpectedly in rehabilitation centers following the Exxon Valdez oil spill. Rebar AH, et al. **Vet Pathol** 1995 Jul; 32(4):346–50

BLOOD

Forensics on wild animals: differentiation between otter and pheasant blood using electrophoretic methods. Miller I, et al. **Electrophoresis** 1995 May;16(5):865–8

Two–dimensional electrophoresis for the study of blood/serum proteins of the otter, an endangered species. Miller I, et al. **Electrophoresis** 1995 Jul;16(7):1193–8

GENETICS

Molecular cloning and sequencing of interleukin 6 cDNA fragments from the harbor seal (Phoca vitulina), killer whale (Orcinus orca), and Southern sea otter (Enhydra lutris nereis). King DP, et al. **Immunogenetics** 1996; 43(4):190–5

METABOLISM

Organochlorine residue levels and bioconcentration factors in otters (Lutra lutra L.) from northeast Spain. López–Martín JM, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):532–5

PHYSIOLOGY

Chemical restraint and anesthesia of sea otters affected by the oil spill in Prince William Sound, Alaska. Sawyer DC, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1831–4

OUABAIN

Ouabain: a new steroid hormone? Nicholls MG, et al. **Lancet** 1995 Nov 25;346(8987):1381–2

[Receptor function stability of cerebral Na+,K+–ATPase under conditions of modification of their enzymatic activity] Kaplia AA, et al. **Ukr Biokhim Zh** 1995 Sep–Oct; 67(5):43–8 (Eng. Abstr.) (Rus)

ANALOGS & DERIVATIVES

Different effects of isoproterenol and dihydroouabain on cardiac Ca2+ transients. Hotta Y, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):121–30

ANALYSIS

Solubilization of a complex of tryptic fragments of Na,K–ATPase containing occluded Rb ions and bound ouabain. Or E, et al. **Biochemistry** 1996 May 28; 35(21):6853–64

Stress–induced elevation of ouabainlike compound in rat plasma and adrenal. Goto A, et al. **Hypertension** 1995 Dec; 26(6 Pt 2):1173–6

Effects of intracerebroventricular administration of 6–hydroxydopamine on ouabain–like immunoreactivity in plasma and the hypothalamo–pituitary axis in rats. Komiyama Y, et al. **J Hypertens** 1996 Apr;14(4):447–52

ANTAGONISTS & INHIBITORS

Blockade of brain "ouabain" prevents sympathoexcitatory and pressor responses to high sodium in SHR. Huang BS, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H103–8

BLOOD

Commercial enzyme immunoassay reagent pack for ouabain compared with human placenta radioreceptor assay. Paci

A, et al. **Clin Chem** 1996 Apr;42(4):648–50

Insulin resistance is associated with high plasma ouabain–like immunoreactivity concentration in NIDDM. Wasada T, et al. **Diabetologia** 1995 Jul;38(7):792–7

Changes of erythrocyte ouabain maximum binding after birth in neonates—in relation to erythrocyte sodium and potassium concentrations. Matsuo Y, et al. **Early Hum Dev** 1995 Aug 30;43(1):59–69

Stress–induced elevation of ouabainlike compound in rat plasma and adrenal. Goto A, et al. **Hypertension** 1995 Dec; 26(6 Pt 2):1173–6

Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151–67 (136 ref.). Comment in: J Hypertens 1996 Feb;14(2):169–71.

Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169–71 (28 ref.). Comment on: J Hypertens 1996 Feb;14(2):151–67.

Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. Rossi G, et al. **J Hypertens** 1995 Oct;13(10):1181–91

CHEMISTRY

Simultaneous isolation of endogenous digoxin–like immunoreactive factor, ouabain–like factor, and deglycosylated congeners from mammalian tissues. Qazzaz HM, et al. **Arch Biochem Biophys** 1996 Apr 1; 328(1):193–200

METABOLISM

Quantification of the Na+/K(+)-pump in solubilized tissue by the ouabain binding method coupled with high–performance gel chromatography. Asami M, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):55–64

Brain 'ouabain' mediates sympathetic hyperactivity in congestive heart failure. Leenen FH, et al. **Circ Res** 1995 Nov;77(5):993–1000

Ouabain production by cultured adrenal cells. Doris PA, et al. **Endocrinology** 1996 Feb;137(2):533–9

Ouabain interactions with the H5–H6 hairpin of the Na,K–ATPase reveal a possible inhibition mechanism via the cation binding domain. Palasis M, et al. **J Biol Chem** 1996 Jun 14;271(24):14176–82

Why we should give a qualified welcome to ouabain: a whole new family of adrenal steroid hormones? Hinson JP, et al. **J Endocrinol** 1995 Sep;146(3):369–72

Ouabain resistance of the epithelial cell line (Ma104) is not due to lack of affinity of its pumps for the drug. Contreras RG, et al. **J Membr Biol** 1995 Jun;145(3):295–300

Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. Bossuyt X, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):891–6

Role of ouabain–like compound in the regulation of plasma aldosterone concentration in rats. Yamada K, et al. **Life Sci** 1996;58(21):1833–7

PHARMACOKINETICS

Human ATP1AL1 gene encodes a ouabain–sensitive H–K–ATPase. Modyanov NN, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C992–7

PHARMACOLOGY

The effect of hypoxia and ouabain on the muscle resting potential of Periplaneta americana L. Grajpel B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):103–6

Chronic ouabain infusion does not cause hypertension in sheep. Pidgeon GB, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E386–92

Modulation of the Ca2+,Mg(2+)-ATPase of sarcoplasmic reticulum by the hypothalamic hypophyseal inhibitory factor. Ricote M, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):217–24

The effect of furosemide on calcium ion concentration in myocardial cells. Rubin Y, et al. **Cell Calcium** 1995 Aug; 18(2):135–9

Long–term ouabain administration does not alter blood pressure in conscious Sprague–Dawley rats. Li M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):919–23

Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis. Peckham DG, et al. **Clin Sci (Colch)** 1995 Sep;89(3):277–84

Low concentrations of ouabain increase cytosolic free calcium concentration in rat vascular smooth muscle cells. Zhu Z, et al. **Clin Sci (Colch)** 1996 Jan;90(1):9–12

Altered [Ca2+]i mobilization in diabetic cardiomyocytes: responses to caffeine, KCl, ouabain, and ATP. Yu JZ, et al. **Diabetes Res Clin Pract** 1995 Oct;30(1):9–20

A comparison of the effect of cochlear perfusion with ouabain on summating potentials and distortion product otoacoustic emissions in the guinea pig. Klis SF, et al. **Eur Arch Otorhinolaryngol** 1995;252(7):405–8

Ultracytochemical localization of ouabain–sensitive K(+)-dependent paranitrophenylphosphatase in rat sciatic nerve fibers. Dolapchieva S. **Eur J Morphol** 1995 Jul; 33(3):247–55

Possible neuronal origin of ATP release evoked by forskolin and ouabain from guinea–pig atrial segments. Katsuragi T, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):213–7

Stimulatory effect of ouabain on VCAM–1 and iNOS expression in murine endothelial cells: involvement of NF–kappa B. Bereta J, et al. **FEBS Lett** 1995 Dec 11; 377(1):21–5

Alteration by ouabain of rat submandibular glands function. Dehpour AR, et al. **Gen Pharmacol** 1995 Sep;26(5):1009–13

Effect of hypothalamic–hypophysary inhibitory factor on mesangial cell activation. Rodríguez–Barbero A, et al. **Hypertension** 1995 Dec;26(6 Pt 1):905–11

Angiotensin II and angiotensin–(1–7) effects on free cytosolic sodium, intracellular pH, and the Na(+)–H+ antiporter in vascular smooth muscle. Ye M, et al. **Hypertension** 1996 Jan;27(1):72–8

Ouabain–insensitive 86Rb+ transport in peritoneal mast cells: role in histamine release. Németh A, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S32–3

In vitro ouabain–sensitive respiration and protein synthesis in rumen epithelial papillae of Hereford steers fed either timothy hay or timothy hay supplemented with cracked corn once daily. Kelly JM, et al. **J Anim Sci** 1995 Dec; 73(12):3775–84

Random mutagenesis of the sheep Na,K–ATPase alpha1 subunit generating the ouabain–resistant mutant L793P. Burns EL, et al. **J Biol Chem** 1996 Jul 5;271(27):15879–83

Partial inhibition of Na+/K+–ATPase by ouabain induces the Ca2+–dependent expressions of early–response genes in cardiac myocytes. Peng M, et al. **J Biol Chem** 1996 Apr 26;271(17):10372–8

Ouabain induces inhibition of the progression phase in human T–cell proliferation. Brodie C, et al. **J Cell Physiol** 1995 Nov;165(2):246–53

Long–term production of human monoclonal antibodies by human–mouse heterohybridomas. Yoshinari K, et al. **J Immunol Methods** 1995 Oct 12;186(1):17–25

Ouabain resistance of the epithelial cell line (Ma104) is not due to lack of affinity of its pumps for the drug. Contreras RG, et al. **J Membr Biol** 1995 Jun;145(3):295–300

Inhibition of Na+,K+–ATPase by ouabain opens calcium channels coupled to acetylcholine release in guinea pig myenteric plexus. Gomez RS, et al. **J Neurochem** 1996 Apr; 66(4):1440–7

Ouabain sensitive Na+/K(+)-ATPase content is elevated in mdx mice: implications for the regulation of ions in dystrophic muscle. Dunn JF, et al. **J Neurol Sci** 1995 Nov; 133(1–2):11–5

Use of digitalis glycosides to identify the mechanisms of amantadine transport by renal tubules. Escobar MR, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1189–94

Mechanisms of intracellular Mg2+ regulation affected by amiloride and ouabain in the guinea–pig taenia caeci. Nakayama S, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):1–12

Endothelial modulation of ouabain–induced contraction and sodium pump activity in aortas of normotensive Wistar–Kyoto and spontaneously hypertensive rats. Ponte A, et al. **J Vasc Res** 1996 Mar–Apr;33(2):164–74

Chemical modification by maleimide of toxic and nontoxic ouabain actions on neuromuscular transmission in the frog. Maeno T, et al. **Jpn J Physiol** 1995;45(5):811–21

Potentiation by ouabain of bradykinin–induced catecholamine secretion and calcium influx into cultured bovine adrenal chromaffin cells: evidence for involvement of Na+ influx associated with the bradykinin B2–receptor. Murakumo Y, et al. **Life Sci** 1995;57(17):PL259–64

Erythropoietin modified the cardiac action of ouabain in chronically anaemic–uraemic rats. Wald M, et al. **Nephron** 1995;71(2):190–6

Differential effects of calcium channel antagonists on tityustoxin and ouabain–induced release of [3H]acetylcholine from brain cortical slices. Casali TA, et al. **Neuropharmacology** 1995 Jun;34(6):599–603

Effect of chronic ouabain infusion on food, water, and NaCl intake, body composition, and plasma hormones of Sprague–Dawley rats. Tordoff MG. **Physiol Behav** 1996 Jan;59(1):87–92

An animal model for mania: preliminary results. el–Mallakh RS, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep;19(5):955–62

Effect of volume expansion on the natriuretic response to ouabain infusion. Yates NA, et al. **Ren Physiol Biochem** 1995 Nov–Dec;18(6):311–20

TOXICITY

Endocytosis inhibition protects the isolated guinea pig heart against ouabain toxicity. Núñez–Durán H, et al. **Life Sci** 1996;58(10):PL193–8

A galanin–mastoparan chimeric peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain. Langel U, et al. **Regul Pept** 1996 Apr 9;62(1):47–52

URINE

Characterization of ouabain–like immunoreactivity in human urine. Worgall S, et al. **J Hypertens** 1996 May;14(5):623–8

OUTBREAKS see **DISEASE OUTBREAKS**

OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)

Problems of process–efficiency studies in psychotherapy. Meyer AE. **Acta Psychiatr Belg** 1996 May–Aug; 96(3–4):117–34

How to have a high success rate in treatment: advice for evaluators of alcoholism programs. Miller WR, et al. **Addiction** 1996 Jun;91(6):779–85

Explaining abstinence rates following treatment for alcohol abuse: a quantitative synthesis of patient, research design and treatment effects. Monahan SC, et al. **Addiction** 1996 Jun;91(6):787–805

Influence of social desirability response set on self–report for assessing the outcome of treated alcoholics. Yoshino A, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1517–9

Physical characteristics of residential psychiatric and substance abuse programs: organizational determinants and patients outcomes. Timko C. **Am J Community Psychol** 1996 Feb;24(1):173–92

Assessing health status in a dialysis clinic. Chapman MM, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S31–2

Assessing the health status of adult patients with epilepsy. Wagner AK, et al. **Am J Health Syst Pharm** 1995 Jul 15; 52(14 Suppl 3):S29–31

The effectiveness of psychotherapy. The Consumer Reports study. Seligman ME. **Am Psychol** 1995 Dec;50(12):965–74 (11 ref.)

Review of efficiencies and patient satisfaction in Australian and New Zealand day surgery units: a pilot study. Rudkin GE, et al. **Anaesth Intensive Care** 1996 Feb;24(1):74–8

Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Friedmann PD, et al. **Ann Intern Med** 1996 Feb 15;124(4):414–21

Identifying adverse events caused by medical care: degree of physician agreement in a retrospective chart review. Localio AR, et al. **Ann Intern Med** 1996 Sep 15; 125(6):457–64

Psychiatric nursing outcome research: the state of the science. Merwin E, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):311–31 (101 ref.)

Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction [see comments] Mant J, et al. **BMJ** 1995 Sep 23;311(7008):793–6. Comment in: BMJ 1995 Sep 23;311(7008):766.

The California Adult Performance Outcome Survey: preliminary evidence on reliability and validity. Cuffel BJ, et al. **Community Ment Health J** 1995 Oct;31(5):425–36

Variations in the screening history and appropriateness of management of cervical cancer in South East England. Wolfe CD, et al. **Eur J Cancer** 1996 Jun;32A(7):1198–204

Quality of care in adult heart surgery: proposal for a self–assessment approach based on a French multicenter study. Roques F, et al. **Eur J Cardiothorac Surg** 1995; 9(8):433–9; discussion 439–40

Research and resources. Show and tell. Montague J. **Hosp Health Netw** 1996 Sep 5;70(17):70

A process evaluation of pulse polio immunization. Sokhey J, et al. **Indian Pediatr** 1996 Mar;33(3):257–61

Judging hospitals by severity–adjusted mortality rates: the case of CABG surgery. Landon B, et al. **Inquiry** 1996 Summer;33(2):155–66

The relationship of hospital process variables to patient outcome post–myocardial infarction. Proctor TF, et al. **Int J Nurs Stud** 1996 Apr;33(2):121–30

Two–dimensional outcome analysis as a guide for quality assurance of prostatectomy. Cohen YC, et al. **Int J Qual Health Care** 1996 Feb;8(1):67–73

Outcomes management in neonatal nursing clinical practice. Petryshen P, et al. **J Adv Nurs** 1995 Dec;22(6):1043–9

Current status of family–based outcome and process research. Diamond GS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):6–16 (120 ref.)

Care of acute myocardial infarction by noninvasive and invasive cardiologists: procedure use, cost and outcome. Di Salvo TT, et al. **J Am Coll Cardiol** 1996 Feb;27(2):262–9

The effectiveness and efficiency of outpatient geriatric evaluation and management. Engelhardt JB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):847–56

The Columbia Registry of Information and Utilization Management Trials. Balas EA, et al. **J Am Med Inform Assoc** 1995 Sep–Oct;2(5):307–15

Outcome of assisted reproduction technology in infertile couples of consanguineous marriage. Egbase PE, et al. **J Assist Reprod Genet** 1996 Apr;13(4):279–81

Outcome for families created by assisted conception programmes. McWhinnie A. **J Assist Reprod Genet** 1996 Apr;13(4):363–5

Physician coverage of therapeutic apheresis. Woll JE. **J Clin Apheresis** 1995;10(4):183–7

Generalizability of clinical studies conducted at tertiary care medical centers: a population–based analysis. Layde PM, et al. **J Clin Epidemiol** 1996 Aug;49(8):835–41

Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. Barber JP, et al. **J Consult Clin Psychol** 1996 Jun;64(3):619–22

Long–term outcome in cognitive–behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Brown TA, et al. **J Consult Clin Psychol** 1995 Oct;63(5):754–65

An approach to psychotherapy change process research: introduction to the special section. Greenberg LS, et al.

J Consult Clin Psychol 1996 Jun;64(3):435–8 (27 ref.)

The interaction of the alliance and therapy microprocess: a sequential analysis. Sexton HC, et al. **J Consult Clin Psychol** 1996 Jun;64(3):471–80

Determinants of research follow-up participation in an alcohol treatment outcome trial. Stout RL, et al. **J Consult Clin Psychol** 1996 Jun;64(3):614–8

Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Weisz JR, et al. **J Consult Clin Psychol** 1995 Oct;63(5):688–701 (70 ref.)

How to evaluate intraexaminer reliability using an interexaminer reliability study design [letter; comment] Lantz CA. **J Manipulative Physiol Ther** 1995 Sep; 18(7):486–8. Comment on: J Manipulative Physiol Ther 1995 Jan;18(1):10–5.

How to evaluate intraexaminer reliability using an interexaminer reliability study design [letter; comment] Norman GR, et al. **J Manipulative Physiol Ther** 1995 Sep; 18(7):484–6. Comment on: J Manipulative Physiol Ther 1995 Jan;18(1):10–5.

The Practice Environment Project. A process for outcome evaluation. Grindel CG, et al. **J Nurs Adm** 1996 May; 26(5):43–51

Benchmarking: a data-oriented look at improving health care performance. Czarnecki MT. **J Nurs Care Qual** 1996 Apr; 10(3):1–6

Stressful nurses: the effect on patient outcomes. Dugan J, et al. **J Nurs Care Qual** 1996 Apr;10(3):46–58

Tracking skin integrity: a template for hospital and vendor collaboration. Kilpack V, et al. **J Nurs Care Qual** 1996 Apr;10(3):18–27

Benchmarking: improving outcomes for the congestive heart failure population. Lauver LS. **J Nurs Care Qual** 1996 Apr; 10(3):7–11

Benchmarks and performance indicators: two tools for evaluating organizational results and continuous quality improvement efforts. McKeon T. **J Nurs Care Qual** 1996 Apr;10(3):12–7

Evaluating a nursing care delivery model using a quality improvement design. Nardone PL, et al. **J Nurs Care Qual** 1995 Oct;10(1):70–84

Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)

Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC. **J Prof Nurs** 1996 Jul–Aug;12(4):207–16 (47 ref.)

Outcome following fractured neck of femur—variation in acute hospital care or case mix? Withey C, et al. **J Public Health Med** 1995 Dec;17(4):429–37

Clinical economics and nonconorary vascular disease. Schwartz JS. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):116S–124S (16 ref.)

Some considerations in outcomes research. Wennberg J. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):102S–103S

Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats. Carson SS, et al. **JAMA** 1996 Jul 24–31; 276(4):322–8

Evidence-based medicine meets cost-effectiveness analysis [editorial; comment] Clancy CM, et al. **JAMA** 1996 Jul 24–31;276(4):329–30. Comment on: JAMA 1996 Jul 24–31;276(4):285–92.

The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators [see comments] Connors AF Jr, et al. **JAMA** 1996 Sep 18; 276(11):889–97. Comment in: JAMA 1996 Sep 18;276(11):916–8.

Is it time to pull the pulmonary artery catheter? [editorial; comment] Dalen JE, et al. **JAMA** 1996 Sep 18; 276(11):916–8. Comment on: JAMA 1996 Sep 18;276(11):889–97.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Godec MS. **JAMA** 1996 Apr 24;275(16):1230–1. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership [see comments] Goldmann DA, et al. **JAMA** 1996 Jan 17;275(3):234–40 (81 ref.). Comment in: JAMA 1996 May 22–29;275(20):1544.

Predicting short-term mortality from myocardial infarction [letter] Kahn KL, et al. **JAMA** 1996 Oct 2;276(13):1033

The medical outcomes study [letter; comment] Kastner T. **JAMA** 1996 Apr 10;275(14):1084–5. Comment on: JAMA 1995 Nov 8;274(18):1436–44.

The relationship between coronary angioplasty procedure volume and major complications [see comments] Kimmel SE, et al. **JAMA** 1995 Oct 11;274(14):1137–42. Comment in: JAMA 1995 Oct 11;274(14):1169–70. Comment in: JAMA 1996 Feb 28;275(8):595; discussion 596. Comment in: JAMA 1996 Feb 28;275(8):595–6.

From the Joint Commission on Accreditation of Healthcare Organizations. Loeb JM, et al. **JAMA** 1996 Feb 21; 275(7):508

Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. Mathew JP, et al. **JAMA** 1996 Jul 24–31; 276(4):300–6

The medical outcomes study [letter; comment] Matz R. **JAMA** 1996 Apr 10;275(14):1083–5; discussion 1084–5. Comment on: JAMA 1995 Nov 8;274(18):1436–44.

Users guides to the medical literature. X. How to use an article reporting variations in the outcomes of health services. The Evidence-Based Medicine Working Group. Naylor CD, et al. **JAMA** 1996 Feb 21;275(7):554–8

Coronary angioplasty procedure volume and major complications [letter; comment] Phillips KA, et al. **JAMA** 1996 Feb 28;275(8):595; discussion 596. Comment on: JAMA 1995 Oct 11;274(14):1137–42.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Prendergast TJ. **JAMA** 1996 Apr 24;275(16):1227; discussion 1230–1. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

Coronary angioplasty procedure volume and major complications [letter; comment] Reis GJ. **JAMA** 1996 Feb 28;275(8):595–6. Comment on: JAMA 1995 Oct 11;274(14):1137–42.

The critical question of procedure volume minimums for coronary angioplasty [editorial; comment] Ryan TJ. **JAMA** 1995 Oct 11;274(14):1169–70. Comment on: JAMA 1995 Oct 11;274(14):1137–42.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Sachs GA. **JAMA** 1996 Apr 24;275(16):1229; discussion 1230–1. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

From the Joint Commission on Accreditation of Healthcare Organizations. Schyve PM, et al. **JAMA** 1995 Nov 15; 274(19):1497

What do we learn from disciplined practice learning? [letter] Sheikh K. **JAMA** 1996 Aug 14;276(6):447–8

The medical outcomes study [letter; comment] Smith SA. **JAMA** 1996 Apr 10;275(14):1084–5. Comment on: JAMA 1995 Nov 8;274(18):1436–44.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Solomon MZ, et al. **JAMA** 1996 Apr 24;275(16):1229–31. Comment on: JAMA 1995 Nov 22–39;274(20):1591–8.

Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. Stone PH, et al. **JAMA** 1996 Apr 10; 275(14):1104–12

The medical outcomes study [letter; comment] Testa MA. **JAMA** 1996 Apr 10;275(14):1083; discussion 1084–5. Comment on: JAMA 1995 Nov 8;274(18):1436–44.

Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. Ware JE Jr, et al. **JAMA** 1996 Oct 2;276(13):1039–47

Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. Yelin EH, et al. **JAMA** 1996 Oct 2; 276(13):1048–53

Using continuous quality improvement tools to improve pediatric immunization rates. Carlin E, et al. **Jt Comm J Qual Improv** 1996 Apr;22(4):277–88

Phase II of the AHCPR-sponsored heart failure guideline: translating practice recommendations into review criteria. Hadorn DC, et al. **Jt Comm J Qual Improv** 1996 Apr; 22(4):265–76

Improving health care, Part 1: The clinical value compass. Nelson EC, et al. **Jt Comm J Qual Improv** 1996 Apr; 22(4):243–58

The Processes, Structures, and Outcomes of Care in Cardiac Surgery. Department of Veterans Affairs Cooperative Study in Health Services No. 5. **Med Care** 1995 Oct;33(10 Suppl):OS1–108

Quality and effectiveness issues related to oral health. Antczak-Bouckoms A. **Med Care** 1995 Nov;33(11 Suppl):NS123–42 (60 ref.)

An analysis of interobserver reliability and representativeness of data from the Veterans Affairs Cooperative Study on Processes, Structures, and Outcomes in Cardiac Surgery. Henderson WG, et al. **Med Care** 1995 Oct;33(10 Suppl):OS86–101

Evaluating anesthesia health care delivery for cardiac surgery. The role of process and structure variables. London MJ, et al. **Med Care** 1995 Oct;33(10 Suppl):OS66–75

The Processes, Structures, and Outcomes of Care in Cardiac Surgery study protocol. Shroyer AL, et al. **Med Care** 1995 Oct;33(10 Suppl):OS17–25

Relationships between patient-related risk factors, processes, structures, and outcomes of cardiac surgical care. Conceptual models. Shroyer AL, et al. **Med Care** 1995 Oct; 33(10 Suppl):OS26–34

Variations in processes and structures of cardiac surgery practice. Tobler HG, et al. **Med Care** 1995 Oct;33(10 Suppl):OS43–58

Variations in the processes and structures of cardiac surgery nursing care. VillaNueva CB, et al. **Med Care** 1995 Oct; 33(10 Suppl):OS59–65

Effects measured in the evaluation of automated information systems. van der Loo RP, et al. **Medinfo** 1995;8 Pt 2:1081–5

Quality of health care. Part 2: measuring quality of care [editorial] Brook RH, et al. **N Engl J Med** 1996 Sep 26; 335(13):966–70

Archie Cochrane and clinical outcomes [news] Kohli HS. **Natl Med J India** 1995 Sep–Oct;8(5):236–7

Outcomes and survival [editorial] Rothstein JM. **Phys Ther** 1996 Feb;76(2):126–7

Outcome for psychiatric emergency patients seen by an outreach police-mental health team. Lamb HR, et al. **Psychiatr Serv** 1995 Dec;46(12):1267–71

Measuring therapeutic interactions: research and clinical applications. Weissmark MS, et al. **Psychiatry** 1995 May; 58(2):173–88

Age and sex differences in the management of ischaemic heart disease. Majeed FA, et al. **Public Health** 1996 Jan; 110(1):7–12

Process and outcomes in general practice consultations: problems in defining high quality care. Winefield HR, et al. **Soc Sci Med** 1995 Oct;41(7):969–75

Pediatric discharge planning: complications, efficiency, and adequacy. Proctor EK, et al. **Soc Work Health Care** 1995; 22(1):1–18

Clinical indicators to assess the quality of social work services in nursing homes. Vourlekis BS, et al. **Soc Work Health Care** 1995;22(1):81–93

Classics in Spine. Surgery literature revisited. Bessette L, et al. **Spine** 1996 Feb 1;21(3):259–63 (13 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

Clinical audit in a developing country. Maher D. **Trop Med Int Health** 1996 Aug;1(4):409–13

Performance measurement in prostate cancer care: beyond report cards. Ullman M, et al. **Urology** 1996 Mar; 47(3):356–65 (80 ref.)

[Evaluation of technologies: stakes, methods, limits and suggestions] Grenier P. **J Radiol** 1995 Nov;76(11):999–1003 **(Fre)**

[Formal uniform organization of quality parameters in public health—a methodological suggestion] Harych H. **Gesundheitswesen** 1995 Jul;57(7):387–90 (Eng. Abstr.) **(Ger)**

[Aspects of process quality in quality assurance regarding inpatient psychosomatic rehabilitation] Mans EJ. **Gesundheitswesen** 1995 Jul;57(7):380–6 (Eng. Abstr.) **(Ger)**

[Goal attaining scale. Reliability and practical experiences in 397 psychiatric treatment courses. 2: Practical experiences with a simplified version of Goal Attainment Scaling in clinical practice and intermediate length rehabilitational treatment] Bolm W. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):75–88 (Eng. Abstr.) **(Ger)**

[Emotion-focused couples therapy—treatment approach—evaluating effectiveness and process research] Heekerens HP. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):308–24 (50 ref.) (Eng. Abstr.) **(Ger)**

[Individual therapy goals: on outcome documentation of inpatient psychotherapy from the patient and therapist viewpoint] Heuft G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):186–99 (Eng. Abstr.) **(Ger)**

[Methodologic decisions in evaluation of psychotherapy] Langenmayr A, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):273–90 (60 ref.) (Eng. Abstr.) **(Ger)**

[Outcome research (editorial)] Debrunner AM. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr;134(2):Oa1–2 **(Ger)**

ECONOMICS

Assessing the effectiveness of disease and injury prevention programs: costs and consequences. **MMWR Morb Mortal Wkly Rep** 1995 Aug 18; 44(RR-10):1–10

ORGANIZATION & ADMINISTRATION

Quality in residency training: toward a broader, multidimensional definition. Elliott RL, et al. **Acad Med** 1996 Mar;71(3):243–7 (15 ref.)

The evolving role of the Joint Commission for the Accreditation of Healthcare Organizations. Schyve PM. **Am J Med Qual** 1996 Spring;11(1):S54–7

Quality forum: benchmarking and congestive heart failure—a study in improvement of health care processes. Czarnecki M. **J Nurs Care Qual** 1996 Jul;10(4):78–81

Process improvement plan for the reduction of nosocomial pneumonia in patients on ventilators. Nicotra D, et al. **J Nurs Care Qual** 1996 Jul;10(4):18–23

Quality field [editorial] Schroeder P. **J Nurs Care Qual** 1996 Jul;10(4):viii

A regional collaborative effort for CQI in cardiovascular disease. Northern New England Cardiovascular Study Group. Malenka DJ, et al. **Jt Comm J Qual Improv** 1995 Nov;21(11):627–33

Establishing a meaningful relationship: case costing and clinical practice. Petryshen P, et al. **Medinfo** 1995;8 Pt 2:1331–4

Quality assurance and medical outcomes in the era of cost containment. Campion FX, et al. **Surg Clin North Am** 1996 Feb;76(1):139–59 (35 ref.)

Use of indicators in health care management [letter] Blecher M. **World Health Forum** 1996;17(3):287

STANDARDS

International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Sprung CL, et al. **Crit Care Med** 1996 Sep;24(9):1441–7

Quality watch ... the Foundation for Accountability [news]

Hosp Health Netw 1996 Aug 5;70(15):11

Using clinical practice improvement: an interview with Susan Horn [interview by Steven Berman] Horn SD.
Jt Comm J Qual Improv 1995 Jun;21(6):301–8

Quality and the medical marketplace—following elephants [editorial; comment] Angell M, et al. **N Engl J Med** 1996 Sep 19;335(12):883–5. Comment on: N Engl J Med 1996 Sep 19;335(12):891–4.

STATISTICS & NUMERICAL DATA

Randomised controlled trial of general practitioner versus usual medical care in an urban accident and emergency department: process, outcome, and comparative cost. Murphy AW, et al. **BMJ** 1996 May 4;312(7039):1135–42

Report card daze. Montague J. **Hosp Health Netw** 1996 Jan 5;70(1):33–6

A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators [see comments] **JAMA** 1995 Nov 22–29;274(20):1591–8. Comment in: JAMA 1995 Nov 22–29;274(20):1634–6. Comment in: JAMA 1996 Apr 24;275(16):1227; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1227–8; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228–9; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229–30; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1230–1. Comment in: JAMA 1996 Apr 24;275(16):1231–2.

Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. Results from the medical outcomes study [see comments] Greenfield S, et al. **JAMA** 1995 Nov 8;274(18):1436–44. Comment in: JAMA 1995 Nov 8;274(18):1473–4. Comment in: JAMA 1996 Apr 10;275(14):1083; discussion 1084–5. Comment in: JAMA 1996 Apr 10;275(14):1083–4; discussion 1084–5. Comment in: JAMA 1996 Apr 10;275(14):1084; discussion 1084–5. Comment in: JAMA 1996 Apr 10;275(14):1084–5.

Regionalization of cardiac surgery in the United States and Canada. Geographic access, choice, and outcomes [see comments] Grumbach K, et al. **JAMA** 1995 Oct 25;274(16):1282–8. Comment in: JAMA 1996 Mar 13;275(10):758–9.

Equation and nomogram for calculation of testing and treatment thresholds [letter] Djulbegovic B, et al.
Med Decis Making 1996 Apr–Jun;16(2):198–9

On the equivalence of collectively and individually collected responses: standard–gamble and time–tradeoff judgments of health states. Krabbe PF, et al. **Med Decis Making** 1996 Apr–Jun;16(2):120–32

A prospective audit of total parenteral nutrition at a major teaching hospital [see comments] Ioannides–Demos LL, et al. **Med J Aust** 1995 Sep 4;163(5):233, 235–7. Comment in: Med J Aust 1995 Sep;4;163(5):228.

The evolution of quality measurement in surgery: from standards to indicators. Jessee WF. **Swiss Surg** 1995;(1):24–8

[Baden–Württemberg quality assurance in surgery] Laas HD, et al. **Swiss Surg** 1995;(1):35–9 (Eng. Abstr.) **(Ger)**

TRENDS

What will be the outcome of the outcomes movement? Braithwaite J, et al. **Aust N Z J Med** 1995 Dec;25(6):731–5 (49 ref.)

Best practice in the health sector. Duckett S.
J Qual Clin Pract 1995 Sep;15(3):133–7

Evidence–based medical education: the missing variable in the quality improvement equation. Chessare JB.
Jt Comm J Qual Improv 1996 Apr;22(4):289–91

Why it is important to demonstrate linkages between outcomes of care and processes and structures of care. Hammermeister KE, et al. **Med Care** 1995 Oct;33(10 Suppl):OS5–16 (58 ref.)

OUTCOME ASSESSMENT (HEALTH CARE)

Costs and benefits of psychotherapy. Howard K, et al.
Acta Psychiatr Belg 1996 May–Aug;96(3–4):154–70

Two HIV/AIDS community support teams: patient characteristics, problems at referral and during the last 6 weeks of life. Butters E, et al. **AIDS Care** 1995;7(5):593–603

Mammography outcomes analysis: potential panacea or Pandora's box? [comment] Linver MN, et al.
AJR Am J Roentgenol 1996 Aug;167(2):373–5. Comment on: AJR Am J Roentgenol 1996 Aug;167(2):367–72.

Value of visual versus central quantitative measurements of angiographic success after percutaneous transluminal coronary angioplasty. NHLBI PTCA Registry Investigators. Faxon DP, et al. **Am J Cardiol** 1996 May 15;77(12):1067–72

Comparison of percutaneous transluminal coronary angioplasty outcome and hospital costs for low–volume and high–volume operators. Shook TL, et al.
Am J Cardiol 1996 Feb 15;77(5):331–6

Outcomes, endpoints, and expectations [editorial] Bryan–Brown CW, et al. **Am J Crit Care** 1996 Mar;5(2):87–9

Measuring heart attack care performance: new indices and understanding [editorial] Bahr RD, et al.
Am J Emerg Med 1996 Jan;14(1):89–90

Workshop synopses. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S32–5

Applying patient outcomes and pharmacoeconomics in patient care. Proceedings of a conference. Boston, Massachusetts, September 1994.
Am J Health Syst Pharm 1995 Jul 15;52(14 Suppl 3):S1–5

Pharmacoeconomics and outcomes research. Bootman JL.
Am J Health Syst Pharm 1995 Jul 15;52(14 Suppl 3):S16–9

Introduction to pharmacist participation in measuring and monitoring patients' health–related quality of life. Bungay KM, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S19–23

Caveats in interpreting and applying pharmacoeconomic data. Cahill NE. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S24–6

Relationship between medication compliance and medical outcomes. Cramer JA. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S27–9

The outcomes movement and health care reform. Grossman JH. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S6–11

Health care outcomes case study: Febrile neutropenia. Holdsworth MT, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S15–8

Communicating pharmaceutical outcomes to hospital administration. Mountzuris J. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S9–11

Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Reeder CE.
Am J Health Syst Pharm 1995 Oct 1;52(19 Suppl 4):S5–8 (4 ref.)

Health care outcomes case study: anemia in end–stage renal disease. Turco TF. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S19–23

Approaches for assessing the efficacy of occupational health and safety standards. Stayner L, et al. **Am J Ind Med** 1996 Apr;29(4):353–7 (12 ref.)

Combining multiple data bases for outcomes assessment. Patterson L, et al. **Am J Med Qual** 1996 Spring;11(1):S73–7

Measuring hospital outcomes from a buyer's perspective. Pauly MV, et al. **Am J Med Qual** 1996 Fall;11(3):112–22

Public reporting of clinical outcomes—the data needs of health care stakeholders. Sirio CA, et al.
Am J Med Qual 1996 Spring;11(1):S78–81

Designing the Optimal Health Assessment System: the Cleveland Quality Choice (CHQC) example. Sirio CA, et al. **Am J Med Qual** 1996 Spring;11(1):S66–9

Evaluating outcomes in cardiac care and developing consensus for action: the Pennsylvania Health Care Cost Containment Council experience. Sirio CA, et al.
Am J Med Qual 1996 Spring;11(1):S30–4

Assessment tools in psychiatry. Smith GR, et al.
Am J Med Qual 1996 Spring;11(1):S46–9

Evolution of analytical tools by MediQual Systems, Inc. Steen P, et al. **Am J Med Qual** 1996 Spring;11(1):S15–7

Assessment tools: functional health status and patient satisfaction. Ware JE Jr, et al. **Am J Med Qual** 1996 Spring;11(1):S50–3

Effect of cognitive impairment on rehabilitation outcome. Diamond PT, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):40–3

Reliability of a brief outpatient functional outcome assessment measure. Granger CV, et al. **Am J Phys Med Rehabil** 1995 Nov–Dec;74(6):469–75

Strong quasi–experimental designs for research on the effectiveness of rehabilitation. Johnston MV, et al.
Am J Phys Med Rehabil 1995 Sep–Oct;74(5):383–92 (50 ref.)

Functional gain and length of stay for major rehabilitation impairment categories. Patterns revealed by function related groups. Stineman MG, et al.
Am J Phys Med Rehabil 1996 Jan–Feb;75(1):68–78

The effectiveness of alternative planned durations of residential drug abuse treatment. McCusker J, et al.
Am J Public Health 1995 Oct;85(10):1426–9

Demystifying outcomes for the pharmacist. Cinque MP.
Am Pharm 1995 Oct;NS35(10):38–9

The need to disseminate outcomes research. Maine LL.
Am Pharm 1995 Oct;NS35(10):37–8

An introduction to patient care outcomes: linking science with practice. Pathak DS, et al. **Am Pharm** 1995 Oct;NS35(10):36–7

From outcomes research to disease management: a guide for the perplexed [see comments] Epstein RS, et al.
Ann Intern Med 1996 May 1;124(9):832–7. Comment in: Ann Intern Med 1996 May 1;124(9):838–42.

Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes [see comments] Iezzoni LI, et al. **Ann Intern Med** 1995 Nov 15;123(10):763–70. Comment in: Ann Intern Med 1995 Nov 15;123(10):802–3.

A report card for report cards [editorial; comment] Localio AR, et al. **Ann Intern Med** 1995 Nov 15;123(10):802–3. Comment on: Ann Intern Med 1995 Nov 15;123(10):763–70.

Measuring patient benefit from otorhinolaryngological surgery and therapy. Robinson K, et al.
Ann Otol Rhinol Laryngol 1996 Jun;105(6):415–22

Current challenges for outcome measurement in surgical practice. Williams MH, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):401–3

Instruments to assess osteoarthritis—current status and future needs [editorial] Bellamy N. **Ann Rheum Dis** 1995 Sep;54(9):692–3

The need for accurate risk–adjusted measures of outcome in surgery. Lessons learned through coronary artery bypass. Griffith BP, et al. **Ann Surg** 1995 Oct;222(4):593–8; discussion 598–9

Outcome as a function of annual coronary artery bypass graft volume. The Ad Hoc Committee on Cardiac Surgery Credentialing of The Society of Thoracic Surgeons [see comments] Clark RE. **Ann Thorac Surg** 1996 Jan;61(1):21–6 . Comment in: Ann Thorac Surg 1996 Jun;61(6):1879–80.

A randomized study would answer the question [editorial; comment] Jollis JG, et al. **Ann Thorac Surg** 1996 Feb;61(2):513–4. Comment on: Ann Thorac Surg 1996 Feb;61(2):552–7.

Clinical usefulness of risk–stratified outcome analysis in cardiac surgery in New Jersey. Parsonnet V, et al.
Ann Thorac Surg 1996 Feb;61(2 Suppl):S8–11; discussion S33–4

Organizational redesign: effect on institutional and consumer outcomes. Ingersoll GL. **Annu Rev Nurs Res** 1996;14:121–43 (52 ref.)

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Outcomes research on one continuing education activity. Brazen L. **AORN J** 1995 Jul;62(1):92–100

Whose data are these, anyway? [editorial; comment] Nowels D. **Arch Fam Med** 1995 Nov;4(11):935–6. Comment on: Arch Fam Med 1995 Nov;4(11):976–80.

Impact of marital status on outcomes in hospitalized patients. Evidence from an academic medical center. Gordon HS, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2465–71

Indications and immediate patient outcomes of pathology intraoperative consultations. College of American Pathologists/Centers for Disease Control and Prevention Outcomes Working Group Study. Zarbo RJ, et al.
Arch Pathol Lab Med 1996 Jan;120(1):19–25

Measuring outcomes in the postacute continuum. Kilgore KM. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC21–6

Translation and validation of arthritis outcome measures into Spanish. González VM, et al. **Arthritis Rheum** 1995 Oct;38(10):1429–46

Costs analysis of successful rotator cuff repair surgery: an outcome study. Comparison of gatekeeper system in surgical patients. Savoie FH 3rd, et al. **Arthroscopy** 1995 Dec;11(6):672–6

Health outcomes, health promotion and improved public health in Australia [editorial] Nutbeam D.
Aust J Public Health 1995 Aug;19(4):326–8

Readmissions to hospital: the contribution of morbidity data to the evaluation of asthma management. Rushworth RL, et al. **Aust J Public Health** 1995 Aug;19(4):363–7

An evidence based approach to individualising treatment. Glasziou PP, et al. **BMJ** 1995 Nov 18;311(7016):1356–9

Promoting clinical effectiveness [editorial] Hayward J.
BMJ 1996 Jun 15;312(7045):1491–2

MYMOP, a patient generated measure of outcomes. Research into outcomes has moved away from symptom based assessments [letter] Jenkinson C. **BMJ** 1996 Sep 7;313(7057):626; discussion 627

Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF–36 health survey. Paterson C. **BMJ** 1996 Apr 20;312(7037):1016–20

MYMOP, a patient generated measure of outcomes. Rate of completion of forms should have been analysed by age [letter] Primrose WR, et al. **BMJ** 1996 Sep 7;313(7057):626; discussion 627

MYMOP, a patient generated measure of outcomes. Reliability of such instruments needs to be proved [letter] Ruta D, et al. **BMJ** 1996 Sep 7;313(7057):626–7

Routine monitoring of all postoperative outcomes at one year: longitudinal study at the Royal National Throat, Nose and Ear Hospital. Ryan RM, et al. **BMJ** 1996 Aug 17;313(7054):403

Measuring outcome in rheumatoid arthritis—which measures are suitable for routine clinical use? [letter; comment] Blake DR. **Br J Rheumatol** 1996 Mar;35(3):301. Comment on: Br J Rheumatol 1995 Sep;34(9):802–4.

Quality of life measures. Carr AJ, et al. **Br J Rheumatol** 1996 Mar;35(3):275–81 (63 ref.)

Disease outcomes in rheumatology [editorial] Scott DL, et al. **Br J Rheumatol** 1995 Aug;34(8):704–6

Review of outcome instruments for evaluation of anterior cruciate ligament reconstruction. Vangsness CT Jr, et al.
Bull Hosp Jt Dis 1995;54(1):25–9 (29 ref.)

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15;154(12):1837–43 (61 ref.)

Outcome of patients discharged from a coronary care unit with a diagnosis of "chest pain not yet diagnosed" [see comments] Panju A, et al. **Can Med Assoc J** 1996 Sep 1;155(5):541–6. Comment in: Can Med Assoc J 1996 Sep 1;155(5):552–3.

Operator–specific outcomes. A call to professional responsibility [editorial] Califf RM, et al. **Circulation** 1996 Feb 1;93(3):403–6

Analysis and comparison of operator–specific outcomes in

interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. Ellis SG, et al. **Circulation** 1996 Feb 1;93(3):431-9

Use of standardized video recordings to assess cleft surgery outcome. Morrant DG, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):134-42

Flat-on-flat, nonconstrained, compression molded polyethylene total knee replacement. Ritter MA, et al. **Clin Orthop** 1995 Dec;(321):79-85

Clinical outcomes of two early postpartum IUD insertion programs in Africa. Morrison C, et al. **Contraception** 1996 Jan;53(1):17-21

Comparative assessment of pediatric intensive care in Moscow, the Russian Federation: a prospective, multicenter study. DiCarlo JV, et al. **Crit Care Med** 1996 Aug;24(8):1403-7

Prospective, controlled study of the outcome of human immunodeficiency virus-1 antibody-positive children admitted to an intensive care unit [see comments] Jeena PM, et al. **Crit Care Med** 1996 Jun;24(6):963-7. Comment in: Crit Care Med 1996 Jun;24(6):907-9.

Quality of life measures before and one year after admission to an intensive care unit [see comments] Konopad E, et al. **Crit Care Med** 1995 Oct;23(10):1653-9. Comment in: Crit Care Med 1995 Oct;23(10):1620-1.

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome [see comments] Marshall JC, et al. **Crit Care Med** 1995 Oct;23(10):1638-52 (40 ref.). Comment in: Crit Care Med 1995 Oct;23(10):1619-20. Comment in: Crit Care Med 1996 Jul;24(7):1272-3.

Prediction of three outcome states from pediatric intensive care. Ruttimann UE, et al. **Crit Care Med** 1996 Jan; 24(1):78-85

High-risk intrahospital transport of critically ill patients: safety and outcome of the necessary "road trip". Szem JW, et al. **Crit Care Med** 1995 Oct;23(10):1660-6

Difficulties in predicting outcome in cardiac surgery patients. Turner JS, et al. **Crit Care Med** 1995 Nov;23(11):1843-50

Life measures before and one year after admission to an intensive care unit [editorial; comment] Weil MH. **Crit Care Med** 1995 Oct;23(10):1620-1. Comment on: Crit Care Med 1995 Oct;23(10):1653-9.

Factors affecting the performance of the models in the Mortality Probability Model II system and strategies of customization: a simulation study. Zhu BP, et al. **Crit Care Med** 1996 Jan;24(1):57-63

Update on measurement of relevant outcomes in rheumatology. Pioro MH, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):101-5 (35 ref.)

Outcomes that matter [editorial] Butler C. **Dev Med Child Neurol** 1995 Sep;37(9):753-4

An empirical investigation of the Biopsychosocial Disease Consequence model: psychological impairment, disability and handicap in chronic pain patients. Talo S, et al. **Disabil Rehabil** 1995 Aug-Sep;17(6):281-92

The importance of socioeconomic issues in surgical outcomes: what is a relevant end point? [editorial] Rutkow IM. **Eur J Surg** 1995 Aug;161(8):545-8

The importance of volume for outcome in cancer surgery--an overview. Järhult J. **Eur J Surg Oncol** 1996 Jun;22(3):205-10

The influence of surgeon case volume on outcome in site-specific cancer surgery. Steele RJ. **Eur J Surg Oncol** 1996 Jun;22(3):211-3

The effect of managed care on the treatment outcome of substance use disorders. Renz EA, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):287-92

Outcomes research and practice guidelines. Upstream issues for downstream users. Gifford F. **Hastings Cent Rep** 1996 Mar-Apr;26(2):38-44

Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia. Bauer T, et al. **Infection** 1995 Sep-Oct;23(5):272-7

Health outcomes of oral disorders. Locker D. **Int J Epidemiol** 1995;24 Suppl 1:S85-9

The effects of a discharge information intervention on recovery outcomes following coronary artery bypass surgery. Moore SM. **Int J Nurs Stud** 1996 Apr;33(2):181-9

Assessing health benefit from hospitalization. Agreement between expert panels. Eriksen BO, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):126-35

Outcomes measurement. The key to the appropriate use of pharmaceuticals. Grey RR, et al. **Int J Technol Assess Health Care** 1995 Summer; 11(3):472-84

Is there a relationship between the volume of work carried out in intensive care and its outcome? Jones J, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):762-9

Outcome prediction for individual intensive care patients: useful, misused, or abused? Lemeshow S, et al. **Intensive Care Med** 1995 Sep;21(9):770-6

Epidemiologic aspects and results of applying the TRISS methodology in a Spanish trauma intensive care unit (TICU). Suárez-Alvarez JR, et al. **Intensive Care Med** 1995 Sep;21(9):729-36

Interhospital transfer of the critically ill trauma patient: the potential role of a specialist transport team in a trauma system. McGinn GH, et al. **J Accid Emerg Med** 1996 Mar; 13(2):90-2

Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience. Bramwell EC, et al. **J Adv Nurs** 1995 Dec;22(6):1063-7

The community psychiatric nurse in primary care: an economic analysis. Gournay K, et al. **J Adv Nurs** 1995 Oct;22(4):769-78

Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. Harvey RP, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1233-41

The outcomes movement and new measures of the severity of psoriasis. Mckenna KE, et al. **J Am Acad Dermatol** 1996 Mar;34(3):534-8 (47 ref.)

Changing outcome of angioplasty in the elderly. Thompson RC, et al. **J Am Coll Cardiol** 1996 Jan;27(1):8-14

Nutritional status outcomes for children: ethnic, cultural, and environmental contexts. Bronner YL. **J Am Diet Assoc** 1996 Sep;96(9):891-903 (88 ref.)

Change in eating attitudes: an outcome measure of patients with eating disorders. Eiger MR, et al. **J Am Diet Assoc** 1996 Jan;96(1):62-4

An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations. Ciol MA, et al. **J Am Geriatr Soc** 1996 Mar;44(3):285-90

Do rehabilitative nursing homes improve the outcomes of care? Kane RL, et al. **J Am Geriatr Soc** 1996 May; 44(5):545-54

Risk stratification in cardiac surgery: is it worthwhile? Parsonnet V. **J Card Surg** 1995 Nov;10(6):690-8

Health-related quality of life as an outcome for patients with heart failure. Shively M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):89-96 (14 ref.)

Universal access and insurance coverage: missing pieces [editorial] Oldridge NB. **J Cardpulm Rehabil** 1995 Jan-Feb; 15(1):9-13

Outcome measurement in cardiac and pulmonary rehabilitation. AACVPR Outcomes Committee. American Association of Cardiovascular and Pulmonary Rehabilitation. Pashkow P, et al. **J Cardpulm Rehabil** 1995 Nov-Dec;15(6):394-405

Method for separating patient and procedural factors while analyzing interdepartmental differences in rates of surgical infections: the Israeli Study of Surgical Infection in Abdominal Operations. Simchen E, et al. **J Clin Epidemiol** 1996 Sep;49(9):1003-7

Associations among different assessments of oral health outcomes. Kressin NR. **J Dent Educ** 1996 Jun;60(6):501-7

Symposium on self-reported assessments of oral health outcomes. Introduction. Kressin NR. **J Dent Educ** 1996 Jun;60(6):485-7

Applications of self-reported assessments of oral health outcomes. Locker D. **J Dent Educ** 1996 Jun;60(6):494-500

Demands and opportunities for development of self-reported assessments of oral health outcomes. Maas WR. **J Dent Educ** 1996 Jun;60(6):508-13

An overview of self-reported outcome assessment in dental research. Reisine S. **J Dent Educ** 1996 Jun;60(6):488-93 (25 ref.)

Reactor paper. Slade GD. **J Dent Educ** 1996 Jun;60(6):514-9

Is the short form 36 (SF-36) suitable for routine health outcomes assessment in health care for older people? Evidence from preliminary work in community based health services in England. Hill S, et al. **J Epidemiol Community Health** 1996 Feb;50(1):94-8

Informed decisions about protecting and promoting public health: rationale for a National Human Exposure Assessment Survey. Sexton K, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):233-56 (52 ref.)

Effectiveness of pharmacist consultations [comment] Flynn CA, et al. **J Fam Pract** 1996 Jan;42(1):22-3. Comment on: J Fam Pract 1995 Nov;41(5):469-72.

The impact of a pharmacotherapy consultation on the cost and outcome of medical therapy [see comments] Jameson J, et al. **J Fam Pract** 1995 Nov;41(5):469-72. Comment in: J Fam Pract 1996 Jan;42(1):22-3.

Outcomes of "inadequate" antidepressant treatment [see comments] Simon GE, et al. **J Gen Intern Med** 1995 Dec; 10(12):663-70. Comment in: J Gen Intern Med 1996 Dec;10(12):699-700.

Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Teri L, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S8-17 (63 ref.)

Baseline assessments in amyotrophic lateral sclerosis trials. Bossuyt PM, et al. **J Neurol Sci** 1995 May;129 Suppl:28

Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. Coffey CE, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):287-9

Using elements of the nursing minimum data set for determining outcomes. Blewitt DK, et al. **J Nurs Adm** 1996 Jun;26(6):48-56

Geriatric patients with depression. Improving outcomes using a multidisciplinary clinical path model. Bultema JK, et al. **J Nurs Adm** 1996 Jan;26(1):31-8

Outcomes: the mainstay of a framework for quality care. Peters DA. **J Nurs Care Qual** 1995 Oct;10(1):61-9

Understanding the new era in health care accountability: report cards. Ribnick PG, et al. **J Nurs Care Qual** 1995 Oct;10(1):1-8

Musculoskeletal Function Assessment instrument: criterion and construct validity. Engelberg R, et al. **J Orthop Res** 1996 Mar;14(2):182-92

Measuring outcomes [editorial] Keller RB. **J Orthop Res** 1996 Mar;14(2):171-2

Development of a musculoskeletal extremity health status instrument: the Musculoskeletal Function Assessment instrument. Martin DP, et al. **J Orthop Res** 1996 Mar; 14(2):173-81

The outcome for children with blunt trauma is best at a pediatric trauma center. Hall JR, et al. **J Pediatr Surg** 1996 Jan;31(1):72-6; discussion 76-7

A conceptual framework for understanding outcomes of oral implant therapy. Guckes AD, et al. **J Prosthet Dent** 1996 Jun;75(6):633-9 (76 ref.)

Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke. Pharoah PD, et al. **J Public Health Med** 1995 Jun;17(2):150-6

Patient utilities in fibromyalgia and the association with other outcome measures. Bakker C, et al. **J Rheumatol** 1995 Aug; 22(8):1536-43

Prediction of rib fracture injury outcome by an artificial neural network. Dombi GW, et al. **J Trauma** 1995 Nov; 39(5):915-21

Serious traumatic brain injury: an evaluation of functional outcomes. Hawkins ML, et al. **J Trauma** 1996 Aug; 41(2):257-63; discussion 263-4

Evaluation of the medical management and preventability of death in 137 road traffic fatalities in Victoria, Australia: an overview. Consultative Committee on Road Traffic Fatalities in Victoria. McDermott FT, et al. **J Trauma** 1996 Apr;40(4):520-33; discussion 533-5

Outcome assessment in vascular surgery--the Swedish experience. The Steering Committee of Swedvasc [letter; comment] Tröeng T, et al. **J Vasc Surg** 1995 Dec; 22(6):810-1. Comment on: J Vasc Surg 1995 Jan;21(1):6-15.

Potentially ineffective care. A new outcome to assess the limits of critical care. Esserman L, et al. **JAMA** 1995 Nov 15;274(19):1544-51

Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. Guyatt GH, et al. **JAMA** 1995 Dec 13;274(22):1800-4

Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. Normand ST, et al. **JAMA** 1996 May 1;275(17):1322-8

The effects of patient volume and level of care at the hospital of birth on neonatal mortality. Phibbs CS, et al. **JAMA** 1996 Oct 2;276(13):1054-9

Predicting short-term mortality from myocardial infarction [letter] Reyes-Ortiz CA. **JAMA** 1996 Oct 2;276(13):1033-4

Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. Wen SW, et al. **JAMA** 1995 Dec 6;274(21):1687-91

Measuring outcomes in psychiatry: an inpatient model. Davis DE, et al. **Jt Comm J Qual Improv** 1996 Feb;22(2):125-33

What would Archie Cochrane have said? [letter; comment] Chalmers I. **Lancet** 1995 Nov 11;346(8985):1300. Comment on: Lancet 1995 Oct 28;346(8983):1172.

Outcome assessments and air ambulance services [letter] Glaser A, et al. **Lancet** 1996 Jun 29;347(9018):1843

Which groups of patients benefit from helicopter evacuation? [see comments] Hotvedt R, et al. **Lancet** 1996 May 18; 347(9012):1362-6. Comment in: Lancet 1996 May 18;347(9012):1348-9.

Confusion of levels in monitoring outcomes and/or process. Long AF, et al. **Lancet** 1996 Jun 8;347(9015):1572

Air ambulances: missions of mercy or flights of futility? [comment] Naylor CD, et al. **Lancet** 1996 May 18; 347(9012):1348-9. Comment on: Lancet 1996 May 18;347(9012):1362-6.

Using case management to improve care delivery in the NICU. Thompson DG, et al. **MCN Am J Matern Child Nurs** 1995 Sep-Oct;20(5):257-60

Research issues related to optimal oral health outcomes. Dolan TA. **Med Care** 1995 Nov;33(11 Suppl):NS106-22

Impact of interhospital transfers on outcomes in an academic medical center. Implications for profiling hospital quality. Gordon HS, et al. **Med Care** 1996 Apr;34(4):295-309

Changes in health after elective percutaneous coronary revascularization. A comparison of generic and specific measures. Krumholz HM, et al. **Med Care** 1996 Aug; 34(8):754-9

Does this treatment work? Validation of an outcomes module for alcohol dependence. Rost KM, et al. **Med Care** 1996 Apr;34(4):283-94

Limited adverse occurrence screening: using medical record review to reduce hospital adverse patient events. Wolff AM. **Med J Aust** 1996 Apr 15;164(8):458-61

Capturing patients' perceptions in the computer-based patient record: essential prerequisites to the measurement of health-related outcomes. Holzemer WL, et al. **Medinfo** 1995;8 Pt 1:266-70

Dynamic patient data bases: the foundation of an integrated approach to outcome measures for the healthcare professionals. Kwok HK, et al. **Medinfo** 1995;8 Pt 1:483

Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51-85 (69 ref.)

Quality of health care. Part 4: The origins of the quality-of-care debate. Blumenthal D. **N Engl J Med** 1996 Oct 10;335(15):1146-9

Assessment of quality of life [letter; comment] Bradlyn AS, et al. **N Engl J Med** 1996 Aug 15;335(7):521; discussion 521-2. Comment on: N Engl J Med 1996 Mar 28;334(13):835-40.

Assessment of quality of life [letter; comment] Buchholz WM. **N Engl J Med** 1996 Aug 15;335(7):520–1; discussion 521–2 . Comment on: N Engl J Med 1996 Mar 28;334(13):835–40.
Quality of health care. Part 3: improving the quality of care. Chassin MR. **N Engl J Med** 1996 Oct 3;335(14):1060–3
Benefits and hazards of reporting medical outcomes publicly. Chassin MR, et al. **N Engl J Med** 1996 Feb 8;334(6):394–8
Viral load and response to treatment of HIV [letter; comment] De Gruttola V, et al. **N Engl J Med** 1996 Jun 20;334(25):1671–2; discussion 1672–3. Comment on: N Engl J Med 1996 Feb 15;334(7):426–31.
Viral load and response to treatment of HIV [letter; comment] Fessel WJ. **N Engl J Med** 1996 Jun 20; 334(25):1672; discussion 1672–3. Comment on: N Engl J Med 1996 Feb 15;334(7):426–31.
Outcomes and costs of care for acute low back pain [letter; comment] Goldstone RA. **N Engl J Med** 1996 Feb 1; 334(5):329–30; discussion 330. Comment on: N Engl J Med 1995 Oct 5;333(14):913–7.
Coronary-artery stenting [letter; comment] Holubkov R, et al. **N Engl J Med** 1996 Jul 4;335(1):61. Comment on: N Engl J Med 1996 Feb 29;334(9):561–6.
Three-year follow-up after implantation of metallic coronary-artery stents [see comments] Kimura T, et al. **N Engl J Med** 1996 Feb 29;334(9):561–6. Comment in: N Engl J Med 1996 Jul 4;335(1):61.
Assessment of quality of life [letter; comment] Meran JG. **N Engl J Med** 1996 Aug 15;335(7):521; discussion 521–2 . Comment on: N Engl J Med 1996 Mar 28;334(13):835–40.
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS [see comments] O'Brien WA, et al. **N Engl J Med** 1996 Feb 15; 334(7):426–31. Comment in: N Engl J Med 1996 Jun 20;334(25):1671; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1671–2; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1672; discussion 1672–3.
Influence of cardiac-surgery performance reports on referral practices and access to care. A survey of cardiovascular specialists. Schneider EC, et al. **N Engl J Med** 1996 Jul 25;335(4):251–6
Assesment of quality-of-life outcomes [see comments] Testa MA, et al. **N Engl J Med** 1996 Mar 28;334(13):835–40. Comment in: N Engl J Med 1996 Aug 15;335(7):520–1; discussion 521–2. Comment in: N Engl J Med 1996 Aug 15;335(7):521; discussion 521–2. Comment in: N Engl J Med 1996 Aug 15;335(7):521–2.
HCFA's Medicare mortality statistics. Jayaram S, et al. **N J Med** 1996 Apr;93(4):25–8
Audit of the outcome of patients with renal failure presenting to a regional nephrology service. Lynn KL, et al. **N Z Med J** 1996 Aug 9;109(1027):295–7
An analysis of posthospitalization telephone survey data. Minnick A, et al. **Nurs Res** 1995 Nov-Dec;44(6):371–5
Changing the mind-set of nurses [letter] Pittroff G. **Nurse Pract** 1996 Jan;21(1):6, 9
Impact of quality of life outcomes on clinical practice. Ganz PA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):61–5 (37 ref.)
Including oncology outcomes of care in the computer-based patient record. McCormick KA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):161–7 (44 ref.)
Historical and methodological perspectives on cancer outcomes research. Mandelblatt JS, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):23–32
The importance of "quality of care" [editorial] Lee P, et al. **Ophthalmology** 1996 Apr;103(4):549–50
Outcome assessment in spinal infections. Calderone RR, et al. **Orthop Clin North Am** 1996 Jan;27(1):201–5
Normal birth weight intensive care unit survivors: outcome assessment. Gray JE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):832–8
Changes in intubation rates and outcome of very low birth weight infants: a population-based study [see comments] Poets CF, et al. **Pediatrics** 1996 Jul;98(1):24–7. Comment in: Pediatrics 1996 Jul;98(1):125–7.
Quality of life: an overview of the concept and measures. Dedhiya S, et al. **Pharm World Sci** 1995 Sep 22;17(5):141–8 (48 ref.)
Overview of cost-consequence modeling in outcomes research. Stergachis A. **Pharmacotherapy** 1995 Sep-Oct; 15(5 Pt 2):40S–42S
Outcome analysis of a pharmacist-managed anticoagulation service. Wilt VM, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):732–9
Outcomes research: shifting the dominant research paradigm in physical therapy [see comments] Jette AM. **Phys Ther** 1995 Nov;75(11):965–70. Comment in: Phys Ther 1996 Feb;76(2):194–6.
Outcomes research [letter; comment] Michels E. **Phys Ther** 1996 Feb;76(2):194–6. Comment on: Phys Ther 1995 Nov;75(11):965–70.
Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)
The Plastic Surgery Educational Foundation, breast implants, and outcome studies [editorial] Luce EA. **Plast Reconstr Surg** 1995 Nov;96(6):1421–2
Outcomes research using the electronic patient record: Beth Israel Hospital's experience with anticoagulation. Einbinder JS, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :819–23
Developing an outcomes infrastructure for nursing. The Outcomes Taskforce. Lush MT, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:625–9
A randomized evaluation of a computer-based physician's workstation: design considerations and baseline results. Rotman BL, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:693–7
Promises and limitations of the Patient Outcome Research Teams: the low-back pain example. Deyo RA. **Proc Assoc Am Physicians** 1995 Oct;107(3):324–8 (22 ref.)
Using prediction models and cost-effectiveness analysis to improve clinical decisions: emergency department patients with acute chest pain. Goldman L. **Proc Assoc Am Physicians** 1995 Oct;107(3):329–33 (22 ref.)
Individual-patient monitoring in clinical practice: are available health status surveys adequate? McHorney CA, et al. **Qual Life Res** 1995 Aug;4(4):293–307
Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605–18 (52 ref.)
Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Pincus T. **Rheum Dis Clin North Am** 1995 Aug;21(3):619–54 (112 ref.)
Outcomes of referrals from general practice. Haikio JP, et al. **Scand J Prim Health Care** 1995 Dec;13(4):287–93
Outcome measures in rheumatoid arthritis. Stucki G, et al. **Schweiz Med Wochenschr Suppl** 1996;80:14S–17S
Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S. **Soc Sci Med** 1995 Nov;41(10):1383–94 (68 ref.)
Evaluating the efficacy of medical treatment: possibilities and limitations. Jenkinson C. **Soc Sci Med** 1995 Nov; 41(10):1395–401 (49 ref.)
Developing outcome measures for ambulatory care—an application to asthma and diabetes. McColl E, et al. **Soc Sci Med** 1995 Nov;41(10):1339–48
What happens to patients after nursing home placement? Bartlett MC, et al. **Soc Work Health Care** 1995;22(1):69–79
Outcomes in medical care—what are they? MacFadyen BV. **Surg Endosc** 1995 Nov;9(11):1213–4
The use of time study results in a system model for presenting dental care outcome. Swedberg Y. **Swed Dent J** 1995; 19(4):161–71
[QALYS or not QALYS: that is the question?] Moatti JP, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):573–83 (27 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of disease course in chronic rheumatoid arthritis: new quantitative dimensions for clinical practice] Stucki G, et al. **Schweiz Med Wochenschr** 1995 Oct 21; 125(42):2003–14 (39 ref.) (Eng. Abstr.) **(Ger)**
[The measurement of outcomes in chronic pathology. Its application to arthritis] Zeni L. **Minerva Med** 1995 May; 86(5):215–22 (35 ref.) **(Ita)**
[QOL assessment in the treatment of prostate cancer] Isaka S. **Gan To Kagaku Ryoho** 1996 Mar;23(4):427–31 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

In search of perioperative nursing data elements. Kleinbeck SV. **AORN J** 1996 May;63(5):926–31
Rasch analysis for outcomes measures: some methodological considerations. Chang WC, et al. **Arch Phys Med Rehabil** 1995 Oct;76(10):934–9
Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Torrance GW, et al. **Med Care** 1996 Jul;34(7):702–22

ECONOMICS

Drug-related morbidity and mortality. A cost-of-illness model. Johnson JA, et al. **Arch Intern Med** 1995 Oct 9; 155(18):1949–56
The use of condition specific outcome measures in economic appraisal. Brazier J, et al. **Health Econ** 1995 Jul-Aug; 4(4):255–64 (35 ref.)
The Multifund and outcome research. D'Souza MF. **Int J Epidemiol** 1995;24 Suppl 1:S113–8
Economic analysis alongside clinical trials: practical considerations. The Economics Workgroup. Drummond M, et al. **J Rheumatol** 1995 Jul;22(7):1418–9 (4 ref.)
Economic analysis alongside clinical trials: problems and potential. Drummond M. **J Rheumatol** 1995 Jul; 22(7):1403–7 (15 ref.)
Economic evaluation using mathematical models: the case of misoprostol prophylaxis. Gabriel SE. **J Rheumatol** 1995 Jul;22(7):1412–4
OMERACT II: the biologics perspective. Strand V. **J Rheumatol** 1995 Jul;22(7):1415–7 (24 ref.)
Laparoscopic cholecystectomy in Australia—outcomes and costs. Fletcher DR. **Surg Endosc** 1995 Nov;9(11):1230–5
CBD stones—outcomes and costs. Laparoscopic transcystic techniques other than choledochoscopy. Traverso LW, et al. **Surg Endosc** 1995 Nov;9(11):1242–4
Surgical endoscopy—outcomes and costs. Introduction. Traverso LW. **Surg Endosc** 1995 Nov;9(11):1211–2
Laparoscopic cholecystectomy. The Mississippi experience. Voyles CR. **Surg Endosc** 1995 Nov;9(11):1225–30

HISTORY

Research in psychodynamic psychotherapy. Wallerstein RS. **Mt Sinai J Med** 1996 May-Sep;63(3–4):167–77

ORGANIZATION & ADMINISTRATION

Strategic service quality management for health care. Anderson EA, et al. **Am J Med Qual** 1996 Spring; 11(1):3–10 (48 ref.)
Developing an outcomes measurement system: the value of testing. Braun BI, et al. **Am J Med Qual** 1996 Summer; 11(2):57–67
Assessment of delivery of preventive health services. Hershey CO, et al. **Am J Med Qual** 1996 Summer;11(2):81–6
The imperative of outcome assessment in psychiatry. Sederer LI, et al. **Am J Med Qual** 1995 Fall;10(3):127–32 (32 ref.)
A department of surgery looks at outcomes. Vogel TT. **Am J Med Qual** 1996 Fall;11(3):142–5
Assessment of health status in peritoneal dialysis patients: a potential outcome measure. Morton AR, et al. **Clin Nephrol** 1996 Mar;45(3):199–204
Efficiency measurement and the operationalization of hospital production. Magnussen J. **Health Serv Res** 1996 Apr; 31(1):21–37
Using operational research modelling to improve the provision of health services: the case of DNA technology. Beech R. **Int J Epidemiol** 1995;24 Suppl 1:S90–5
Patient-centred evaluation and rehabilitative care. Grenville J, et al. **J Adv Nurs** 1995 Nov;22(5):965–72
The imperative of outcomes analysis: an integration of traditional and nontraditional outcomes measures. Crawford BL, et al. **J Nurs Care Qual** 1996 Jan;10(2):33–40
Proving that less is more: linking resources to outcomes. Ebener MK, et al. **J Nurs Care Qual** 1996 Jan;10(2):1–9
Data-driven interventions to improve patient satisfaction. Luther KM. **J Nurs Care Qual** 1996 Jul;10(4):33–9
Assessing quality of nursing home care: the foundation for improving resident outcomes. Rantz MJ, et al. **J Nurs Care Qual** 1996 Jul;10(4):1–9
Multidimensional outcomes in intravenous access device maintenance: a pilot study. Reineck C, et al. **J Nurs Care Qual** 1996 Jul;10(4):10–7
The challenge of health outcomes. Hall J. **J Qual Clin Pract** 1996 Mar;16(1):5–15; discussion 17–8 (43 ref.)
Partnering with physicians to achieve quality improvement. Conway AC, et al. **Jt Comm J Qual Improv** 1995 Nov; 21(11):619–26
The future of outcomes research may benefit from the evolution of medical critical thinking. Kazandjian VA. **Jt Comm J Qual Improv** 1995 Oct;21(10):553–7
The California Hospital Outcomes Project: using administrative data to compare hospital performance. Romano PS, et al. **Jt Comm J Qual Improv** 1995 Dec; 21(12):668–82
Stroke units [see comments] Wilkinson TJ. **N Z Med J** 1995 Sep 8;108(1007):351–3. Comment in: N Z Med J 1995 Oct 13;108(1009):416.
Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec; 30(4):683–95 (53 ref.)
Health-care outcomes research. Texas Medical Association Council on Scientific Affairs. Burnside JW. **Tex Med** 1996 Jul;92(7):61–71

STANDARDS

Roles of the federal and state governments in outcomes assessment. Epstein MH, et al. **Am J Med Qual** 1996 Spring; 11(1):S18–21
Efficiency pattern analysis for medical rehabilitation. Stineman MG, et al. **Am J Med Qual** 1995 Winter; 10(4):190–8
Health care report cards. Validity of case definitions [see comments] Golden WE, et al. **Arch Fam Med** 1995 Nov; 4(11):976–80. Comment in: Arch Fam Med 1995 Nov;4(11):935–6.
Manipulative physiotherapy for spinal problems in primary care: outcomes of care. Bradshaw C, et al. **Br J Rheumatol** 1995 Nov;34(11):1070–3

STATISTICS & NUMERICAL DATA

Multivariate statistical analysis for pathologist. Part I, The logistic model. Vollmer RT. **Am J Clin Pathol** 1996 Jan; 105(1):115–26 (16 ref.)
Laparoscopic and open cholecystectomy outcomes in Medicare beneficiaries in member states of the Large State PRO Consortium. Samkoff JS, et al. **Am J Med Qual** 1995 Winter;10(4):183–9
Using physician claims to identify postoperative complications of carotid endarterectomy. Mitchell JB, et al. **Health Serv Res** 1996 Jun;31(2):141–52
Predicting nursing home length of stay and outcome with a resource-based classification system. Ljunggren G, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):72–9
Outcomes monitoring: adjusting for risk factors, severity of illness, and complexity of care. Petryshen P, et al. **J Am Med Inform Assoc** 1995 Jul-Aug;2(4):243–9 (40 ref.)
The inability of physicians to predict the outcome of in-hospital resuscitation. Ebell MH, et al. **J Gen Intern Med** 1996 Jan;11(1):16–22
Validation of a 28 day interval between discharge and readmission for emergency readmission rates. Sibbritt DW. **J Qual Clin Pract** 1995 Dec;15(4):211–20
Statistical methods and strategies for working with large data bases. Marshall G, et al. **Med Care** 1995 Oct;33(10 Suppl):OS35–42 (20 ref.)

Short-term mortality after repair of hip fracture. Do Manitoba elderly do worse? Roos LL, et al. **Med Care** 1996 Apr;34(4):310-26

Use of risk-adjusted outcome data for quality improvement by public hospitals. Luce JM, et al. **West J Med** 1996 May; 164(5):410-4

[Analysis of outcome quality control in intensive care medicine using the Simplified Acute Physiology Score II] Schuster HP, et al. **Med Klin** 1996 Jun 15;91(6):343-8 (Eng. Abstr.) (Ger)

TRENDS

The outcomes of patient care. Gouveia WA, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S11-5

OUTCOME MEASUREMENT ERRORS see **BIAS (EPIDEMIOLOGY)**

OUTCOMES RESEARCH see **OUTCOME ASSESSMENT (HEALTH CARE)**

OUTER MEMBRANE PROTEINS, BACTERIAL see **BACTERIAL OUTER MEMBRANE PROTEINS**

OUTPATIENT CARE see **AMBULATORY CARE**

OUTPATIENT CLINICS see **AMBULATORY CARE FACILITIES**

OUTPATIENT CLINICS, HOSPITAL

see related
AMBULATORY CARE

Consequences of shifting medical-student education to the outpatient setting: effects on performance and experiences. Grum CM, et al. **Acad Med** 1996 Jan;71(1 Suppl):S99-101

Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. Couldwell DL, et al. **AIDS** 1996 May; 10(5):521-5

Self-delivery of hemodialysis care: a therapy in itself. Meers C, et al. **Am J Kidney Dis** 1996 Jun;27(6):844-7

SHO surgical training, is the one-day case unit a suitable environment? Benson EA. **Ann R Coll Surg Engl** 1995 Jul; 77(4 Suppl):195-6

Who should see orthopaedic outpatients--physiotherapists or surgeons? Weale AE, et al. **Ann R Coll Surg Engl** 1995 Mar;77(2 Suppl):71-3

Medical audit: the role of an orthopaedic preoperative clinic. West R, et al. **Ann R Coll Surg Engl** 1995 May;77(3 Suppl):134-5

Who needs an immunization in a pediatric subspecialty clinic? Basco WT Jr, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):508-11

Diagnostic accuracy and appropriateness of general practitioner referrals to a dermatology out-patient clinic. Basarab T, et al. **Br J Dermatol** 1996 Jul;135(1):70-3

Comparison of a community clinic with a hospital out-patient clinic in rheumatology. Helliwell PS. **Br J Rheumatol** 1996 Apr;35(4):385-8

Family-friendly HIV and AIDS care the goal at Vancouver's Oak Tree Clinic. Kent H. **Can Med Assoc J** 1996 May 1;154(9):1407-9

Prescription writing in Gondar outpatient teaching hospital, Ethiopia. Desta Z, et al. **East Afr Med J** 1996 Feb; 73(2):115-9

Patients attending a vulval clinic in a genitourinary medicine department [letter] Wolpert KA, et al. **Genitourin Med** 1996 Apr;72(2):146

An audit of hepatitis B vaccination compliance rates in two genitourinary medicine clinics. Stevenson M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):364-5

Follow-up of pregnant teens at a hospital-based clinic. Forman SF, et al. **J Adolesc Health** 1995 Sep;17(3):193-7

Risk factors for appointment failures in a geriatric outpatient clinic [letter] Martin AI. **J Am Geriatr Soc** 1995 Dec; 43(12):1446-7

The first multi-disciplinary obstetrical brachial plexus clinic in Saudi Arabia. al-Qattan MM. **J Hand Surg [Br]** 1996 Feb;21(1):124-5

Telephone access to a university HIV/AIDS clinic. Dorko CS, et al. **J Tenn Med Assoc** 1995 Oct;88(10):386-8

Outcomes of patient disengagement policies: implications for managed care. Riegler JL, et al. **Mil Med** 1996 Aug; 161(8):479-82

Referrals to a comprehensive eating disorders service. Surgenor LJ, et al. **N Z Med J** 1996 Mar 8;109(1017):74-6

Pediatric residents' continuity clinics: how are we really doing? Dumont-Driscoll MC, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):616-21

Patient satisfaction with information provided at an outpatient clinic for respiratory diseases. Papagiannis A, et al. **Respir Med** 1995 Nov;89(10):673-6

Clinical coagulation laboratory and oral anticoagulant therapy treatment. Instrumentation and methodology. Barbui T, et al. **Thromb Haemost** 1995 Jul;74(1):511-4

[Familial hypercholesterolemia in eastern Quebec: a public health problem? The experience of the hyperlipidemia clinic of Chicoutimi] Gaudet D, et al. **Union Med Can** 1995 Sep;124(2):54-60 (Fre)

[The role of outpatient service for postmenopausal women and its use in the screening for hypertension and its risk factors] Szántó F, et al. **Orv Hetil** 1995 Oct 15; 136(42):2283-6 (Eng. Abstr.) (Hun)

[The use of serological tests for detecting HIV infection in general clinical consultations and hospital consultations] Maria VA, et al. **Acta Med Port** 1995 Oct;8(10):543-52 (Eng. Abstr.) (Por)

[The polyclinic--the central stage in rehabilitative treatment] Alekseev GK, et al. **Voen Med Zh** 1995 Aug;(8):9-13 (Rus)

ECONOMICS

Cost comparison of psychiatric outpatient clinics based in hospitals and in primary care (general practice health center). Shah A. **Acta Psychiatr Scand** 1995 Jul;92(1):30-4

HISTORY

[Twenty-five years at the Allergy Clinic AM in Bialymstok] Chyrek-Borowska S, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:9-11 (Pol)

[P. I. Iakobil and the creation of outpatient psychiatric care in Russia (on the 150th anniversary of his birth)] Shchigolev II. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):84-6 (Rus)

MANPOWER

Diabetes in urban African Americans. III. Management of type II diabetes in a municipal hospital setting. Ziemer DC, et al. **Am J Med** 1996 Jul;101(1):25-33

Measuring attending physician performance in a general medicine outpatient clinic. Hayward RA, et al. **J Gen Intern Med** 1995 Sep;10(9):504-10

Obstetric physicians: are they needed? The workload of a medical complications in pregnancy clinic. Nelson-Piercy C, et al. **J R Coll Physicians Lond** 1996 Mar-Apr; 30(2):150-4

ORGANIZATION & ADMINISTRATION

New models for emergency and ambulatory care at academic health centers--Part I: New York city. Ling LJ, et al. **Acad Emerg Med** 1995 Sep;2(9):836-43

Reporting adverse drug reactions in an ambulatory care setting. Finn B, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2704-6

Comprehensive services in an ambulatory care pharmacy. Lewis RK, et al. **Am J Health Syst Pharm** 1995 Aug 15; 52(16):1793-7

A nurse-led preadmission clinic for elective ENT surgery: the first 8 months. Koay CB, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):15-9

Accuracy of general practitioner referrals to a breast clinic. Marsh SK, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):203-5

Training in surgical outpatients. Raine C, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2 Suppl):59-61

Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care [see comments] Shaffer J, et al. **Arch Intern Med** 1995 Nov 27;155(21):2330-5. Comment in: Arch Intern Med 1996 Jul 8;156(13):1476, 1479.

Haemophilia care in Zimbabwe. Adewuyi JO, et al. **Cent Afr J Med** 1996 May;42(5):153-6 (15 ref.)

Cancer genetics clinics: target population and consultees' expectations [see comments] Julian-Reynier C, et al. **Eur J Cancer** 1996 Mar;32A(3):398-403. Comment in: Eur J Cancer 1996 Mar;32A(3):391-2.

Family planning in genitourinary medicine [letter; comment] Desmond NM, et al. **Genitourin Med** 1995 Oct;71(5):334-5 . Comment on: Genitourin Med 1995 Apr;71(2):103-5. Comment on: Genitourin Med 1995 Apr;71(2):106-8.

Screening for social and environmental problems in a VA primary care setting. Cook CA, et al. **Health Soc Work** 1996 Feb;21(1):41-7

An audit of nurse treatment sessions for female patients with genital warts. Frayne J, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):363

The CARE Program: a nurse-managed collaborative outpatient program to improve function of frail older people. Collaborative Assessment and Rehabilitation for Elders. Evans LK, et al. **J Am Geriatr Soc** 1995 Oct; 43(10):1155-60

Decreased utilization of healthcare resources after initiating a model geriatrics primary managed care practice [letter] McDowell JG, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1134

Outpatients revisited: subjective views and clinical decisions in the management of general surgical outpatients in south west England. Faulkner A, et al. **J Epidemiol Community Health** 1995 Dec;49(6):599-605

Improving outpatient clinic staffing and scheduling with computer simulation. Hashimoto F, et al. **J Gen Intern Med** 1996 Mar;11(3):182-4

Outpatient geriatric evaluation and management. Results of a randomized trial. Toseland RW, et al. **Med Care** 1996 Jun;34(6):624-40

Critical pathway for administering high-dose chemotherapy followed by peripheral blood stem cell rescue in the outpatient setting. Burns JM, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1219-24

[The medical angiology outpatient clinic today. The authors' personal experience and operational proposals] Ponte E, et al. **Minerva Cardioangiol** 1996 Apr;44(4):147-53 (Eng. Abstr.) (Ita)

[Management of hospital outpatient clinics (letter)] Aarseth HP. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):784 (Nor)

[Management of hospital outpatient clinics (letter)] Thrana FS. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):537-8 (Nor)

[Experience in organizing consultative and diagnostic work in a central polyclinic] Bredikhin VV, et al. **Voen Med Zh** 1995 Feb;(2):20-4 (Rus)

STANDARDS

Assessment of delivery of preventive health services. Hershey CO, et al. **Am J Med Qual** 1996 Summer;11(2):81-6

Efficiency in the outpatient department: the lessons from urology. O'Brien TS, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):287-9

Oral anticoagulant treatment in a medical care district--a descriptive study. Jansson JH, et al. **Scand J Prim Health Care** 1995 Dec;13(4):268-74

STATISTICS & NUMERICAL DATA

Patients dropping out of treatment in Italy. Morlino M, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):1-6

Clinical trials in cognitively impaired older adults: home versus clinic assessments. Bédard M, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1127-30

UTILIZATION

Clinic follow-up from the emergency department: do patients show up? Murray MJ, et al. **Ann Emerg Med** 1996 Jan; 27(1):56-8

Patient characteristics affecting attendance at general outpatient clinics. McClure RJ, et al. **Arch Dis Child** 1996 Feb;74(2):121-5

An interview based approach to seeking user views in genitourinary medicine. Evans D, et al. **Genitourin Med** 1996 Jun;72(3):223-6

Who goes to sexually transmitted disease clinics? Results from a national population survey. Johnson AM, et al. **Genitourin Med** 1996 Jun;72(3):197-202

Effects of a postdischarge clinic on housestaff satisfaction and utilization of hospital services. Diem SJ, et al. **J Gen Intern Med** 1996 Mar;11(3):179-81

Predicting daily visits to a walk-in clinic and emergency department using calendar and weather data. Holleman DR Jr, et al. **J Gen Intern Med** 1996 Apr;11(4):237-9

Most common diseases treated in primary health care facilities in Lebanon. Adib SM, et al. **J Med Liban** 1995; 43(1):17-22

Patient's choice of hospital or office for Medicaid ambulatory care in Alabama. Bronstein JM, et al. **Med Care** 1996 Apr; 34(4):348-60

The effects of California Proposition 187 on ophthalmology clinic utilization at an inner-city urban hospital. Marx JL, et al. **Ophthalmology** 1996 May;103(5):847-51

Patterns of decline among inpatient procedures [see comments] Duffy SQ, et al. **Public Health Rep** 1995 Nov-Dec;110(6):674-81. Comment in: Public Health Rep 1995 Nov-Dec;110(6):682-3.

Psychiatric disorder among adolescents attending a psychiatric out-patient clinic in Accra, Ghana: a seven year review study (1987-1994). Turkson SN. **West Afr J Med** 1996 Jan-Mar;15(1):31-5

OUTPATIENT HEALTH SERVICES see **AMBULATORY CARE**

OUTPATIENT INFUSION THERAPY see **HOME INFUSION THERAPY**

OUTPATIENT MONITORING see **MONITORING, AMBULATORY**

OUTPATIENT SURGERY see **AMBULATORY SURGERY**

OUTPATIENTS

Effects of a geriatric inpatient unit on elderly home care patients: a controlled trial. Karppi P. **Aging (Milano)** 1995 Jun;7(3):207-11

Oral terbutaline in the outpatient management of preterm labor. How HY, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1518-22

What influences physician practice behavior? [editorial; comment] Jogerst GJ, et al. **Arch Fam Med** 1996 Sep; 5(9):455-6. Comment on: Arch Fam Med 1996 Sep;5(9):448-54.

Should ENT out-patients be seen in hospital or General Practitioners' surgeries? Johnson IJ, et al. **Clin Otolaryngol** 1995 Dec;20(6):524-6

Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser Permanente/USC patient consultation study. McCombs JS, et al. **Clin Ther** 1995 Nov-Dec;17(6):1188-206

Patterns of in and out-patient activity for diabetes: a district survey. Currie CJ, et al. **Diabet Med** 1996 Mar;13(3):273-80

Evaluation of a structured outpatient group education program for intensive insulin therapy. Pieber TR, et al. **Diabetes Care** 1995 May;18(5):625-30

Clinical-anamnestic and instrumental data in outpatients

suffering from venous disease. Pinto A, et al. **Int Angiol** 1995 Dec;14(4):400–3

Incidence of Toxoplasma and Toxocara antibodies among out–patients in the Ophthalmic Research Institute, Egypt. Safar EH, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):839–52

Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests. Fortin PR, et al. **J Rheumatol** 1995 Nov;22(11):2078–83

Inadequate functional health literacy among patients at two public hospitals [see comments] Williams MV, et al. **JAMA** 1995 Dec 6;274(21):1677–82. Comment in: JAMA 1995 Dec 6;274(21):1719–20. Comment in: JAMA 1996 Mar 20;275(11):840.

Community–acquired pneumonia: is there difference in etiology between hospitalized and out–patients? Michetti G, et al. **Minerva Med** 1995 Sep;86(9):341–51

[Experiences with an ambulance for environmental medicine at the Hygiene Institute of the Heidelberg Universy Hospital] Eis D, et al. **Zentralbl Hyg Umweltmed** 1995 Apr; 197(1–3):212–21 (Eng. Abstr.) **(Ger)**

[Ambulatory liver biopsy] Gasper N, et al. **Harefuah** 1996 Apr 1;130(7):451–2, 504 (Eng. Abstr.) **(Heb)**

[The methods of using the echocardiogram in outpatients. The role of the cardiologist for more appropriate use of the procedure. The Ligurian Group of the Italian Society of Cardiovascular Echocardiography] Bertoli D, et al. **Cardiologia** 1996 Mar;41(3):267–73 (Eng. Abstr.) **(Ita)**

[Mitral valve prolapse: the clinical and echocardiographic characteristics in a hospital outpatient population] Zuppiroli A, et al. **G Ital Cardiol** 1995 Sep;25(9):1153–9 (Eng. Abstr.) **(Ita)**

[A nationwide investigation needs for rehabilitation of schizophrenic outpatients—the patients' attribute and actual conditions of living] Yamashita T, et al. **Seishin Shinkeigaku Zasshi** 1996;98(3):176–94 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Comparison of clinical and self reported diagnosis for rheumatology outpatients. Rasooly I, et al. **Ann Rheum Dis** 1995 Oct;54(10):850–2

The attribution of somatic symptoms in psychiatric outpatients. Wise TN, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):407–10

Suicidal ideation among urban medical outpatients. Zimmerman M, et al. **J Gen Intern Med** 1995 Oct; 10(10):573–6

STATISTICS & NUMERICAL DATA

Prevalence of comorbid anxiety disorders in primary care outpatients. Sherbourne CD, et al. **Arch Fam Med** 1996 Jan;5(1):27–34; discussion 35

Outpatients revisited: subjective views and clinical decisions in the management of general surgical outpatients in south west England. Faulkner A, et al. **J Epidemiol Community Health** 1995 Dec;49(6):599–605

[The epidemiologic role of patients with "atypical" diarrheal diseases as outpatients in maintaining and spreading enteric infections] Deac L, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):197–8 **(Rum)**

OVAL WINDOW

Validity of spontaneous perilymphatic fistula. Cole GG. **Am J Otol** 1995 Nov;16(6):815–9

ABNORMALITIES

CT cisternography in congenital perilymphatic fistula of the inner ear. Lövblad KO, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):797–9

RADIOGRAPHY

CT cisternography in congenital perilymphatic fistula of the inner ear. Lövblad KO, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):797–9

SURGERY

Comparison of endoscopic and surgical explorations for perilymphatic fistulas. Poe DS, et al. **Am J Otol** 1994 Nov; 15(6):735–8

OVALBUMIN

Development of a model system for investigating cell/surface affinity interactions. Usman J, et al. **Biochem Soc Trans** 1996 Feb;24(1):148S

ADMINISTRATION & DOSAGE

Cholera toxin–mediated cellular immune responses against ovalbumin administered orally. Bowen JC, et al. **Adv Exp Med Biol** 1995;371B:1531–3

Mucosal suppression by oral pre–treatment with ovalbumin and its conversion into stimulation when ovalbumin was conjugated to cholera toxin or its B subunit. van der Heijden PJ, et al. **Adv Exp Med Biol** 1995;371B:1251–5

Formaldehyde exposure enhances inhalative allergic sensitization in the guinea pig. Riedel F, et al. **Allergy** 1996 Feb;51(2):94–9

Multiple emulsions oral vaccine vehicles for inducing immunity or tolerance. Hearn TL, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:388–9

Effects of oral antigen in T–cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163–73 (20 ref.)

Anti–gamma delta T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Mengel J, et al. **Immunol Lett** 1995 Dec;48(2):97–102

Effect of antigen provocation of IL–5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness. Lefort J, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):788–99

Effect of temperature reduction on the vas deferens hyperresponsiveness of sensitized mice. Bidon JC, et al. **J Auton Pharmacol** 1995 Aug;15(4):227–38

Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. Ke Y, et al. **J Immunol** 1996 Feb 1;156(3):916–21

ANTAGONISTS & INHIBITORS

Role of lipoxygenase metabolites in platelet–activating factor– and antigen–induced bronchial hyperresponsiveness and eosinophil infiltration. Seeds EA, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):369–76

BIOSYNTHESIS

A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen–induced transcriptional, but not post–transcriptional, regulation of gene expression. Arao Y, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):269–74

Modulation of transcriptional activity of the chicken ovalbumin gene promoter in primary cultures of chicken oviduct cells: effects of putative regulatory elements in the 5'–flanking region. Park HM, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):811–6

Cloning sequencing and expression of the serpin ovalbumin gene Y. McCarthy BJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):111S

Induction of ovalbumin mRNA by ascorbic acid in primary cultures of tubular gland cells of the chicken oviduct. Muramatsu T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):209–16

Molecular cloning, expression, and partial characterization of two novel members of the ovalbumin family of serine proteinase inhibitors. Sprecher CA, et al. **J Biol Chem** 1995 Dec 15;270(50):29854–61

Regulation of the chicken ovalbumin gene by estrogen and corticosterone requires a novel DNA element that binds a labile protein, Chirp–1. Dean DM, et al. **Mol Cell Biol** 1996 May;16(5):2015–24

CHEMISTRY

Analysis of high–mass biomolecules using electrostatic fields and matrix–assisted laser desorption/ionization in a Fourier transform mass spectrometer. Yao J, et al. **Anal Chem** 1995 Oct 15;67(20):3638–42

A comparison of the immunogenicity of the native and denatured forms of a protein. Koch C, et al. **APMIS** 1996 Feb;104(2):115–25

Semi–synthesis of polymyxin–B conjugated ovalbumin: evaluation of lipopolysaccharide binding avidity and neutralization of induced tnf–alpha synthesis. Coyne CP, et al. **Biotherapy** 1994;8(1):69–83

Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Uchida T, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1569–73

Particle size studies for subcutaneous delivery of poly(lactide–co–glycolide) microspheres containing ovalbumin as vaccine formulation. Uchida T, et al. **J Pharm Pharmacol** 1995 Jul;47(7):556–60

Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Fujita H, et al. **Peptides** 1995;16(5):785–90

Conformational changes involved in the switch from ovalbumin to S–ovalbumin. Castellano AC, et al. **Z Naturforsch [C]** 1996 May–Jun;51(5–6):379–85

GENETICS

Age–related changes in the ovalbumin gene of the Japanese quail. Upadhyay R, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):356–61

Modulation of transcriptional activity of the chicken ovalbumin gene promoter in primary cultures of chicken oviduct cells: effects of putative regulatory elements in the 5'–flanking region. Park HM, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):811–6

Chicken ovalbumin upstream promoter–transcription factors and their regulation. Qiu Y, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):81–5 (30 ref.)

Repression of the ovalbumin gene involves multiple negative elements including a ubiquitous transcriptional silencer. Haecker SA, et al. **Mol Endocrinol** 1995 Sep;9(9):1113–26

IMMUNOLOGY

Cholera toxin–mediated cellular immune responses against ovalbumin administered orally. Bowen JC, et al. **Adv Exp Med Biol** 1995;371B:1531–3

Development of IgE antibodies and T cell reactivity against intestinal bacterial antigens in rats and the influence of feeding. Dahlman A, et al. **Adv Exp Med Biol** 1995; 371A:497–500

The absence of gut flora has no effect on the induction of oral tolerance to ovalbumin. Furrie E, et al. **Adv Exp Med Biol** 1995;371B:1239–41

Oral tolerance to ovalbumin in mice: effect of some parameters on the induction and persistence of the suppression of systemic IgE and IgG antibody responses. Moreau MC, et al. **Adv Exp Med Biol** 1995;371B:1229–34

Dietary antigen handling by mother and offspring in a two generation study. Telemo E, et al. **Adv Exp Med Biol** 1995; 371A:517–9

Mucosal suppression by oral pre–treatment with ovalbumin and its conversion into stimulation when ovalbumin was conjugated to cholera toxin or its B subunit. van der Heijden PJ, et al. **Adv Exp Med Biol** 1995;371B:1251–5

Immunological properties of allergen chemically modified with synthetic copolymer of N–vinylpyrrolidone and maleic anhydride. Babakhin AA, et al. **Allergy Proc** 1995 Sep–Oct;16(5):261–8

Parenteral and oral administration of tolerogens: protein–IgG conjugates. Borel Y, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:80–7

Breaking of oral tolerance by an encapsulated antigen. Flanagan M, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:373–5

Inactivation of Th1 and Th2 cells by feeding ovalbumin. Mowat AM, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:122–32

A comparison of the immunogenicity of the native and denatured forms of a protein. Koch C, et al. **APMIS** 1996 Feb;104(2):115–25

Oral tolerance to ovalbumin in mice as a model for detecting modulators of the immunologic tolerance to a specific antigen. Kim JH, et al. **Biol Pharm Bull** 1995 Jun; 18(6):854–8

Inhibition of interferon–gamma and interleukin–2 production from lymphocytes stimulated with food antigens by an anti–allergic drug, Tranilast, in patients with food–sensitive atopic dermatitis. Kondo N, et al. **Biotherapy** 1994; 8(1):19–22

Airway hyper– or hyporeactivity to inhaled spasmogens 24 h after ovalbumin challenge of sensitized guinea–pigs. Lewis CA, et al. **Br J Pharmacol** 1995 Nov;116(5):2351–8

Effect of supplemental chromium on antibody responses of newly arrived feeder calves to vaccines and ovalbumin. Chang GX, et al. **Can J Vet Res** 1996 Apr;60(2):140–4

Surfactant dysfunction develops when the immunized guinea–pig is challenged with ovalbumin aerosol. Liu M, et al. **Clin Exp Allergy** 1995 Nov;25(11):1053–60

Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Hessel EM, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):401–12

T cell proliferation restricted by HLA class II molecules in patients with hen's egg allergy. Shinbara M, et al. **Exp Clin Immunogenet** 1995;12(2):103–10

Brown Norway rat model of food allergy: effect of plant components on the development of oral sensitization. Atkinson HA, et al. **Food Chem Toxicol** 1996 Jan; 34(1):27–32

Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Norbury CC, et al. **Immunity** 1995 Dec;3(6):783–91

Anti–gamma delta T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Mengel J, et al. **Immunol Lett** 1995 Dec;48(2):97–102

Bystander suppression of the immune response to human serum albumin in rats fed ovalbumin. Dahlman–Höglund A, et al. **Immunology** 1995 Sep;86(1):128–33

Partial characterization of a circulating tolerogenic moiety which, after a feed of ovalbumin, suppresses delayed–type hypersensitivity in recipient mice. Furrie E, et al. **Immunology** 1995 Nov;86(3):480–6

Limiting dilution analysis of CD4 T–cell cytokine production in mice administered native versus polymerized ovalbumin: directed induction of T–helper type–1–like activation. Gieni RS, et al. **Immunology** 1996 Jan;87(1):119–26

Sensitization of MHC class I–restricted T cells to exogenous proteins: evidence for an alternative class I–restricted antigen presentation pathway. Martinez–Kinader B, et al. **Immunology** 1995 Oct;86(2):287–95

Airway responses following intradermal sensitization to different types of allergens: ovalbumin, trimellitic anhydride and Dermatophagoides farinae. Arakawa H, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):274–80

Establishment and characterization of ovalbumin–specific T cell lines from patients with egg allergy. Katsuki T, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):344–51

Decrease in systemic tolerance to fed ovalbumin in indomethacin–treated mice. Louis E, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):21–6

Ovalbumin–liposome conjugate induces IgG but not IgE antibody production. Naito S, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):223–8

Catecholamine and beta–adrenoceptor influences on airway reactivity to antigen in guinea pigs. Underwood DC, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):286–94

Expression of an ovalbumin–specific V beta 8.2 TCR transgene inhibits collagen arthritis in B10.Q mice. Nabozny GH, et al. **Int Immunol** 1995 Aug;7(8):1279–86

Effect of antigen provocation of IL–5 transgenic mice on

eosinophil mobilization and bronchial hyperresponsiveness. Lefort J, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):788–99

Tachykinins mediate the potentiation of antigen–induced bronchoconstriction by cold air in guinea pigs. Yoshihara S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):756–60

Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. Ke Y, et al. **J Immunol** 1996 Feb 1;156(3):916–21

Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen–MHC class I presentation pathway. Rock KL, et al. **J Immunol** 1996 May 15;156(10):3721–6

Effects of diphenyl dimethyl dicarboxylate on oral tolerance to ovalbumin in mice. Kim JH, et al. **J Toxicol Sci** 1995 Sep;20(4):375–82

Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat–labile enterotoxin. Gaboriau–Routhiau V, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):625–9

Food antigen activates intraepithelial and lamina propria lymphocytes in food–sensitive enteropathy in mice. Ohtsuka Y, et al. **Pediatr Res** 1996 May;39(5):862–6

Indirect effects are independent of the way of tolerance induction. Carvalho CR, et al. **Scand J Immunol** 1996 Jun; 43(6):613–8

Oral tolerization leads to active suppression and bystander tolerance in adult rats while anergy dominates in young rats. Lundin BS, et al. **Scand J Immunol** 1996 Jan; 43(1):56–63

Transfer of IgA from albumen into the yolk sac during embryonic development in the chicken. Kaspers B, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):225–31

ISOLATION & PURIFICATION

Effect of polyamines on the separation of ovalbumin glycoforms by capillary electrophoresis. Legaz ME, et al. **J Chromatogr A** 1996 Jan 5;719(1):159–70

On hen egg fractionation: applications of liquid chromatography to the isolation and the purification of hen egg white and egg yolk proteins. Awade AC. **Z Lebensm Unters Forsch** 1996 Jan;202(1):1–14 (108 ref.)

METABOLISM

Overlapping, but not identical, sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive ligands by the alphaMbeta2 integrin. Zhang L, et al. **J Biol Chem** 1996 Jul 26;271(30):18211–6

PHARMACOKINETICS

Effect of cholera toxin and its B subunit on intestinal permeability for ovalbumin. Pierre PG, et al. **Adv Exp Med Biol** 1995;371B:1519–21

PHARMACOLOGY

Interferon–gamma and interleukin–4 production of ovalbumin–stimulated lymphocytes in egg–sensitive children. Shinbara M, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):60–6

Proliferative responses towards native, heat–denatured and pepsin–treated ovalbumin by peripheral blood mononuclear cells from patients with hen's egg–sensitive atopic dermatitis. Nishida T, et al. **Biotherapy** 1994;8(1):33–40

Potentiation by viral respiratory infection of ovalbumin–induced guinea–pig tracheal hyperresponsiveness: role for tachykinins. Ladenius AR, et al. **Br J Pharmacol** 1995 Jul;115(6):1048–52

Induction of calcium–independent nitric oxide synthase by allergen challenge in sensitized rat lung in vivo. Yeadon M, et al. **Br J Pharmacol** 1995 Nov;116(6):2545–6

Allergenic epitopes of ovalbumin (OVA) in patients with hen's egg allergy: inhibition of basophil histamine release by haptenic ovalbumin peptide. Honma K, et al. **Clin Exp Immunol** 1996 Mar;103(3):446–53

A similarity and a difference between two models of late eosinophil accumulation into the airway induced by antigen exposure in actively sensitized brown Norway (BN) rats. Tominaga T, et al. **Gen Pharmacol** 1995 Mar;26(2):353–6

Expression of Th–2 cytokines interleukin–4 and –5 and of Th–1 cytokine interferon–gamma in ovalbumin–exposed sensitized Brown–Norway rats. Haczku A, et al. **Immunology** 1996 Jun;88(2):247–51

Ovalbumin–liposome conjugate induces IgG but not IgE antibody production. Naito S, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):223–8

Effects of KW–4679, a new orally active antiallergic drug, on antigen–induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Ohmori K, et al. **Int Arch Allergy Immunol** 1996 May;110(1):64–72

Tachykinins mediate the potentiation of antigen–induced bronchoconstriction by cold air in guinea pigs. Yoshihara S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):756–60

Influence of spasmogen inhalation by guinea pigs upon subsequent demonstration of ovalbumin–induced hyperreactivity in isolated airways tissues. Lewis CA, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):187–98

TOXICITY

Pharmacological studies of allergic cough in the guinea pig. Bolser DC, et al. **Eur J Pharmacol** 1995 Apr 24; 277(2–3):159–64

OVALOCYTOSIS, HEREDITARY see **ELLIPTOCYTOSIS, HEREDITARY**

OVARIAN CYCLE see **MENSTRUAL CYCLE**

OVARIAN CYSTS

see related
OVARIAN HYPERSTIMULATION SYNDROME

Hyperreactio luteinalis associated with pregnancy: a case report and review of the literature. Schnorr JA Jr, et al. **Am J Perinatol** 1996 Feb;13(2):95–7 (6 ref.)

Ovarian cysts. Minelli L. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):81–9 (106 ref.)

[Spontaneous rupture of an endometriotic cyst in pregnancy near term] Bieńkiewicz A, et al. **Ginekol Pol** 1996 Mar; 67(3):160–2 (Eng. Abstr.) **(Pol)**

[Current approaches to the diagnosis and management of patients with tumors and tumor–like formations of the ovaries] Strizhakov AN, et al. **Akush Ginekol (Mosk)** 1995; (4):15–8 (82 ref.) **(Rus)**

BLOOD

Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Norman RJ, et al. **Hum Reprod** 1995 Sep;10(9):2258–61

CHEMICALLY INDUCED

Ovarian cysts in premenopausal and postmenopausal tamoxifen–treated women with breast cancer. Shushan A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):141–4

[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):439–41 (11 ref.) **(Fre)**

[Environmental pollutants in ovarian cysts] Rixner–Koschade R. **Arch Gynecol Obstet** 1995;257(1–4):117–21 (11 ref.) **(Ger)**

CHEMISTRY

Binding properties of a blood group Le(a+) active sialoglycoprotein, purified from human ovarian cyst, with applied lectins. Wu AM, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):139–44

p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Hutson R, et al. **Histopathology** 1995 Oct;27(4):367–71

COMPLICATIONS

Ovarian hyperstimulation syndrome (OHSS) in pregnancy not associated with ovulation induction. Regi A, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):599–600

Management of an acute hemorrhagic ovarian cyst in a female patient with hemophilia A. O'Brien PM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):233–6

Ovaries in systemic lupus erythematosus [letter; comment] Praprotnik S, et al. **Lupus** 1995 Oct;4(5):418. Comment on: Lupus 1995 Feb;4(1):39–45.

Massive haemoperitoneum due to spontaneous rupture of ovarian cyst in children. A report of 2 cases. Sarihan H, et al. **S Afr J Surg** 1996 Feb;34(1):44–6

[Rupture of follicular and corpus luteum ovarian cysts—the cause of acute gynecological abdomen] Goranov M, et al. **Akush Ginekol (Sofiia)** 1995;34(3):66–7 (Eng. Abstr.) **(Bul)**

[Acute pancreatitis in the post–partum period. Apropos of 3 cases] El Mansari O, et al. **J Chir (Paris)** 1996 May; 133(3):127–31 (Eng. Abstr.) **(Fre)**

[The rupture of a cyst of the right ovary in a patient with angiohemophilia] Filippova NP, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):179–80 **(Rus)**

DIAGNOSIS

Neoplastic or nonneoplastic ovarian cyst? The role of cytology. Kreuzer GF, et al. **Acta Cytol** 1995 Sep–Oct; 39(5):882–6

Hyperreactio luteinalis masquerading as an ovarian neoplasm in a triplet pregnancy. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):177–80

Aspiration cytology of neoplastic and non–neoplastic ovarian cysts: is it accurate? Ganjei P, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):94–101

Normal ovaries and functional cysts: MR appearance. Outwater EK, et al. **Radiology** 1996 Feb;198(2):397–402

DRUG THERAPY

[Regression of functional cysts: high dosage ovulation inhibitor and gestagen therapy has no added effect] Graf M, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):387–92 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Cyst formation [letter] Jenkins JM. **Hum Reprod** 1995 Nov; 10(11):3079–80

Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. Gordon JD, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):353–9

IMMUNOLOGY

Follow–up of small, postmenopausal ovarian cysts using vaginal ultrasound and CA–125 antigen. Auslender R, et al. **J Clin Ultrasound** 1996 May;24(4):175–8

METABOLISM

A high–affinity soluble folate receptor in fluids of non–neoplastic ovarian cysts: radioligand binding, molecular size, hydrophobic residue, and immunological properties. Holm J, et al. **APMIS** 1995 Dec;103(12):862–8

Increased insulin–like growth factor binding protein–2 (IGFBP–2) gene expression and protein production lead to high IGFBP–2 content in malignant ovarian cyst fluid. Kanety H, et al. **Br J Cancer** 1996 May;73(9):1069–73

Testosterone–producing solitary ovarian cyst with luteinized stromal–cell hyperplasia. Goudas VT, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):870–2

PATHOLOGY

Choroidal cells in ovarian cyst fluid: a case report. Mulvany NJ, et al. **Acta Cytol** 1996 Mar–Apr;40(2):302–6

Fine–needle aspiration cytology of the ovary. Ganjei P. **Clin Lab Med** 1995 Sep;15(3):705–26 (19 ref.)

Endometriosis with myxoid change simulating mucinous adenocarcinoma and pseudomyxoma peritonei. Hameed A, et al. **Gynecol Oncol** 1996 Aug;62(2):317–9

Primary lymphatic dissemination of malignant elements in a mature cystic ovarian teratoma [letter; comment] Shetty MR. **Gynecol Oncol** 1996 Apr;61(1):156. Comment on: Gynecol Oncol 1995 May;57(2):250–3.

The value of cyst puncture in the differential diagnosis of benign ovarian tumours. Vercellini P, et al. **Hum Reprod** 1995 Jun;10(6):1465–9

Pathology of ovarian cancer precursors. Scully RE. **J Cell Biochem Suppl** 1995;23:208–18 (23 ref.)

Autoamputation of ovarian cyst in an infant. Aslam A, et al. **J Pediatr Surg** 1995 Nov;30(11):1609–10

Testosterone–producing solitary ovarian cyst with luteinized stromal–cell hyperplasia. Goudas VT, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):870–2

[Histology and cytology of laparoscopically operated "simple ovarian cysts"] Gerber B, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):369–73 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. Aston K, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):835–7

A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin–releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Ditkoff EC, et al. **Hum Reprod** 1996 May;11(5):1035–7

RADIOGRAPHY

Dermoid cyst of the ovary: computed tomography diagnosis of an unusual case. Garant M, et al. **Can Assoc Radiol J** 1996 Apr;47(2):107–10 (9 ref.)

SURGERY

Laparoscopic treatment of ovarian dermoid cysts [letter; comment] Chapron C, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):234–5. Comment on: Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):769–71.

Minilaparotomy for the ambulatory management of ovarian cysts. Flynn M, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1727–9; discussion 1729–30

Excision of ovarian dermoid cyst by laparoscopy and by laparotomy [see comments] Lin P, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):769–71. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):234–5.

Anaesthetic considerations for a possible malignant hyperthermia susceptible fetus [letter] Hersch PE, et al. **Anaesthesia** 1996 Jan;51(1):99

Anaesthetic dilemma: half a spinal is better than none. Smith AF, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12; 54(10):513–4

The case for laparoscopic management of the adnexal mass. Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):362–9 (32 ref.)

Laparoscopic oophorectomy. Russell JB. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):295–8 (20 ref.)

Laparoscopic management of malignant ovarian cysts: a 78–case national survey. Part 2: Follow–up and final treatment. Blanc B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):147–50

The impact of preoperative gonadotropin–releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Muzii L, et al. **Fertil Steril** 1996 Jun;

65(6):1235–7
Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. Keckstein J, et al. **Hum Reprod** 1996 Mar;11(3):579–82
The impact of ovarian cystectomy on ovarian response to stimulation during in-vitro fertilization cycles. Nargund G, et al. **Hum Reprod** 1996 Jan;11(1):81–3
Cost–benefit analysis of laparoscopic adnexectomy. Tintara H, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):21–5
A comparative study of outcome of laparoscopic salpingo–oophorectomy versus open salpingo–oophorectomy. Leetanaporn R, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):79–83
Sonographically guided aspiration of ovarian cyst with simple appearance. Caspi B, et al. **J Ultrasound Med** 1996 Apr;15(4):297–300
Treatment of nonendometriotic benign adnexal cysts: a randomized comparison of laparoscopy and laparotomy. Mais V, et al. **Obstet Gynecol** 1995 Nov;86(5):770–4
A comparative study of laparoscopy and colpotomy for the removal of ovarian dermoid cysts. Teng FY, et al. **Obstet Gynecol** 1996 Jun;87(6):1009–13
[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**
[Break and loss of the parietal wall suture needle. A rare complication of laparoscopic surgery (letter)] van den Brûle F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):216 **(Fre)**
[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**
[Borderline tumors and cancers of the ovary. Laparoscopic-surgical evaluation] Nicoloso E, et al. **Presse Med** 1995 Oct 21;24(31):1421–4 (Eng. Abstr.) **(Fre)**
[Contra endoscopic ovarian surgery] Kindermann G. **Arch Gynecol Obstet** 1995;257(1–4):107–15 **(Ger)**
[Pro endoscopic ovarian surgery] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):97–106 **(Ger)**
[Preoperative diagnosis of malignancy of ovarian space-occupying lesions with special reference to new, laparoscopic surgical techniques] Roch G. **Wien Klin Wochenschr** 1995;107(17):529–31 **(Ger)**
[Surgical treatment of ovarian cysts: economic analysis as a means for the evaluation of alternative technics. Results of a biennial study] Garcea N, et al. **Minerva Ginecol** 1996 Mar;48(3):77–83 (Eng. Abstr.) **(Ita)**
[One-stage surgical treatment of cholelithiasis and urolithiasis, renal cysts and ovarian cysts] Tomusiak TL. **Klin Khir** 1995;(4):53 **(Rus)**
[Ovarian cysts in childhood] Jiménez Alvarez C, et al. **Cir Pediatr** 1995 Jul;8(3):102–4 (Eng. Abstr.) **(Spa)**

THERAPY

Aspiration and tetracycline sclerotherapy for management of simple ovarian cysts. AbdRabbo S, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):171–4
[Acute alcoholism after ethanol fixation for ovarian chocolate cyst] Tei A, et al. **Masui** 1996 Apr;45(4):496–9 (Eng. Abstr.) **(Jpn)**
[Ovarian endometrial cysts—management and treatment] Pisarek-Miedzińska D, et al. **Ginekol Pol** 1996 Feb; 67(2):88–90 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Follow-up of small, postmenopausal ovarian cysts using vaginal ultrasound and CA-125 antigen. Auslender R, et al. **J Clin Ultrasound** 1996 May;24(4):175–8
Sonographically guided aspiration of ovarian cyst with simple appearance. Caspi B, et al. **J Ultrasound Med** 1996 Apr;15(4):297–300

VETERINARY

Characterization of ovarian follicular cysts and associated endocrine profiles in dairy cows. Hamilton SA, et al. **Biol Reprod** 1995 Oct;53(4):890–8
Serum biochemical changes associated with cystic ovarian degeneration in pigs after atrazine treatment. Gojmerac T, et al. **Toxicol Lett** 1996 Apr;85(1):9–15

OVARIAN DISEASES

Ceroid granulomas in the female genital system. Ooi K, et al. **J Clin Pathol** 1995 Nov;48(11):1057–9

BLOOD

Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters-Engl C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2727–30
Relationship between abnormally high levels of plasma CA 125 and resolution of acute pelvic pain in two women with endometrioma. Guerriero S, et al. **Gynecol Obstet Invest** 1995;40(1):61–3
Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gadducci A, et al. **Gynecol Oncol** 1996 Feb;60(2):197–202

CLASSIFICATION

[Classification of US findings of ovarian masses in children] Kidoura E, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):97–101 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Chronic pelvic pain caused by residual ovaries and other ovarian remnants [letter; comment] Sinha R. **Br J Obstet Gynaecol** 1995 Nov;102(11):935–6. Comment on: Br J Obstet Gynaecol 1994 Nov;101(11):979–85.
Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309–13
Prostatic tissue in benign cystic ovarian teratomas. Vadmal M, et al. **Hum Pathol** 1996 Apr;27(4):428–9
Use of a gonadotropin-releasing hormone agonist in the evaluation of postmenopausal virilization due to ovarian hyperthecosis. A case report. Koroscil TM, et al. **J Reprod Med** 1996 Apr;41(4):259–62
Massive edema of the ovary associated with androgenic manifestations. Siller BS, et al. **South Med J** 1995 Nov; 88(11):1153–5 (45 ref.)

DIAGNOSIS

Tuboovarian abscess caused by Edwardsiella tarda. Pien FD, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):964–5
Malacoplakia. Two case reports and a comparison of treatment modalities based on a literature review. van der Voort HJ, et al. **Arch Intern Med** 1996 Mar 11; 156(5):577–83 (118 ref.)
Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Deligdisch L, et al. **Cancer** 1995 Sep 15;76(6):1027–34
Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gadducci A, et al. **Gynecol Oncol** 1996 Feb;60(2):197–202
Ovarian torsion: clinical and imaging presentation in children. Meyer JS, et al. **J Pediatr Surg** 1995 Oct;30(10):1433–6
An unusual case of cyclical abdominal pain. Livingstone M, et al. **Med J Aust** 1995 Dec 4–18;163(11–12):584–5
Tumor markers and transvaginal ultrasonography in the diagnosis of endometrioma. Guerriero S, et al. **Obstet Gynecol** 1996 Sep;88(3):403–7
[Diagnostic methods in endometriosis] Tsenov D, et al. **Akush Ginekol (Sofiia)** 1995;34(3):40–2 (Eng. Abstr.) **(Bul)**

DRUG THERAPY

Large ovarian endometriomas. Donnez J, et al. **Hum Reprod** 1996 Mar;11(3):641–6
MRI in predicting the response of ovarian endometriomas to hormone therapy. Sugimura K, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):145–50

EPIDEMIOLOGY

Neoplastic and non-neoplastic ovarian disease in Zimbabwean women. Stanczuk G. **Cent Afr J Med** 1995 Sep;41(9):274–8
[Tubo-ovarian abscess. An analysis of 20 cases] Varela R, et al. **Acta Med Port** 1995 Oct;8(10):537–42 (Eng. Abstr.) **(Por)**

ETIOLOGY

Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993. Lafferty HW, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):641–5 (23 ref.)
A comparison of bladder and ovarian function two years following hysterectomy or endometrial ablation. Bhattacharya S, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):898–903
Tuboovarian abscess following transvaginal oocyte retrieval for in vitro fertilization: imaging appearance. Marlowe SD, et al. **Clin Imaging** 1995 Jul–Sep;19(3):180–1
Ruptured tubo-ovarian abscess complicating transcervical cryopreserved embryo transfer. Friedler S, et al. **Fertil Steril** 1996 May;65(5):1065–6
Preovulatory overripeness of the oocyte as a cause of ovarian dysfunction in the human female. Smits LJ, et al. **Med Hypotheses** 1995 Nov;45(5):441–8 (116 ref.)
[Aplastic anemia associated with ovarian bleeding] Nehashi Y, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1329–31 (Eng. Abstr.) **(Jpn)**

GENETICS

Gonads in trouble: follicle-stimulating hormone receptor gene mutation as a cause of inherited streak ovaries. Heufelder AE. **Eur J Endocrinol** 1996 Mar;134(3):296–7
Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, co-localizes with Il2, Fgfb, and Idd3. Teuscher C, et al. **J Exp Med** 1996 Feb 1;183(2):631–7

MICROBIOLOGY

Pasteurella multocida isolation from a tuboovarian abscess. A case report. Lukban JC, et al. **J Reprod Med** 1995 Aug; 40(8):603–5
Pasteurella multocida tubo-ovarian abscess in a virgin. Teng FY, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):883

PATHOLOGY

Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Sainz de la Cuesta R, et al. **Gynecol Oncol** 1996 Feb;60(2):238–44
Massive oedema and fibromatosis ovary—a report of three cases. Kanhere S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S29–30
Massive oedema of the ovary. Pai MR, et al. **J Indian Med Assoc** 1995 Sep;93(9):361, 330

PHYSIOPATHOLOGY

GnRH analogue in assessing chronic pelvic pain in women with residual ovaries. Carey MP, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):150–3
Recovery of ovarian function after laparoscopic detorsion. Shalev E, et al. **Hum Reprod** 1995 Nov;10(11):2965–6
Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. Paoletti AM, et al. **J Assist Reprod Genet** 1995 Apr;12(4):263–8
The corpus luteum insufficiency: a multifactorial disease. Hinney B, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):565–70

PREVENTION & CONTROL

Use of fibrin sealant for reproductive surgery: a randomized study in the rabbit model. Marana R, et al. **Gynecol Obstet Invest** 1996;41(3):199–202
Expanded polytetrafluoroethylene surgical membrane in ovarian surgery on the rabbit. Biocompatibility, adhesion prevention properties and ability to preserve reproductive capacity. Magro B, et al. **J Reprod Med** 1996 Feb;41(2):73–8

RADIOGRAPHY

Pulmonary and ovarian manifestations of systemic mastocytosis. Avila NA, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):969–70
Unusual presentation of ovarian pathology on CT. Biltjes IG, et al. **J Belge Radiol** 1996 Feb;79(1):9–11
Intravascular gas within an ovarian tumor: a CT sign of ovarian torsion. Kawahara Y, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):154–6

RADIONUCLIDE IMAGING

Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. Lapela M, et al. **J Nucl Med** 1995 Dec;36(12):2196–200

SURGERY

Laparoscopic removal of the adnexal mass: the case for caution. Maiman M. **Clin Obstet Gynecol** 1995 Jun; 38(2):370–9
Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299–306 (55 ref.)
Reconstruction of the ovary containing large endometriomas by an extraovarian endosurgical technique. Brosens IA, et al. **Fertil Steril** 1996 Oct;66(4):517–21
Large ovarian endometriomas. Donnez J, et al. **Hum Reprod** 1996 Mar;11(3):641–6
Laparoscopic findings after transvaginal ultrasound-guided aspiration of ovarian endometriomas. Muzii L, et al. **Hum Reprod** 1995 Nov;10(11):2902–3
Recovery of ovarian function after laparoscopic detorsion. Shalev E, et al. **Hum Reprod** 1995 Nov;10(11):2965–6
Expanded polytetrafluoroethylene surgical membrane in ovarian surgery on the rabbit. Biocompatibility, adhesion prevention properties and ability to preserve reproductive capacity. Magro B, et al. **J Reprod Med** 1996 Feb;41(2):73–8
[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**
–Chronic tubo-ovarian abscess with vaginal fistula after vaginal hysterectomy: combined laparoscopic-vaginal therapy– Rempen A. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):226–8 (Eng. Abstr.) **(Ger)**
[Neonatal ovarian endometriosis. Its conservative treatment] Diez García R, et al. **An Esp Pediatr** 1996 Apr;44(4):397–8 (16 ref.) **(Spa)**

THERAPY

The use of GnRH agonists in the treatment of endometriomas with or without drainage. Batioglu S, et al. **JPMA J Pak Med Assoc** 1996 Feb;46(2):30–2

ULTRASONOGRAPHY

Genitourinary case of the day. Endometrioma. Moran RE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):246, 248–9
Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Antonić J, et al. **Eur J Gynaecol Oncol** 1996;17(1):29–35
Ultrasound and Doppler in the diagnosis of ovarian torsion. Davis LG, et al. **Eur J Radiol** 1995 Jul;20(2):133–6

Three-dimensional ultrasound evaluation of ovarian masses. Bonilla-Musoles F, et al. **Gynecol Oncol** 1995 Oct; 59(1):129-35

Color Doppler sonography of adnexal torsion. Fleischer AC, et al. **J Ultrasound Med** 1995 Jul;14(7):523-8

Use of laparoscopic ultrasonography to detect ovarian remnants. Nezhat F, et al. **J Ultrasound Med** 1996 Jun; 15(6):487-8

Focal calcifications in otherwise ultrasonographically normal ovaries. Brandt KR, et al. **Radiology** 1996 Feb;198(2):415-7

[Classification of US findings of ovarian masses in children] Kidoura E, et al.
Nippon Igaku Hoshasen Gakkai Zasshi 1996 Feb; 56(3):97-101 (Eng. Abstr.) **(Jpn)**

VETERINARY

Gonadotrophin secretion in ewes with bilateral gonadal hypoplasia. Wright PJ, et al. **Aust Vet J** 1996 Apr; 73(4):157-8

OVARIAN FAILURE, PREMATURE

Spontaneous pregnancy after previous pregnancy by oocyte donation due to premature ovarian failure [letter] Sheu BC, et al. **Hum Reprod** 1996 Jun;11(6):1359-60

BLOOD

Application of Chinese hamster ovary cells transfected with the recombinant human follicle-stimulating hormone (FSH) receptor for measurement of serum FSH. Tano M, et al. **Fertil Steril** 1995 Dec;64(6):1120-4

Pregnancy in women under 35 with elevated early follicular phase follicle-stimulating hormone levels. A report of five cases. Rose BI. **J Reprod Med** 1996 Mar;41(3):201-4

CHEMICALLY INDUCED

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. McDermott EM, et al. **Ann Rheum Dis** 1996 Apr;55(4):224-9

DIAGNOSIS

Characterization of idiopathic premature ovarian failure. Conway GS, et al. **Fertil Steril** 1996 Feb;65(2):337-41

[Symptoms of ovarian failure after hysterectomy in premenopausal women. A retrospective study based on postoperative perception of 245 women] Habelt K, et al. **Zentralbl Gynakol** 1996;118(4):206-12 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Relationship between serum estradiol concentration and IGF-I, IGF-II and IGF-binding proteins in patients with premature ovarian failure on short-term estradiol therapy. Elias AN, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug; 40(4):196-201

Spontaneous pregnancies despite failed attempts at ovulation induction in a woman with latrogenic premature ovarian failure. Menashe Y, et al. **J Reprod Med** 1996 Mar; 41(3):207-10

EPIDEMIOLOGY

A study of premature ovarian failure in Turkish women. Gökmen O, et al. **Gynecol Endocrinol** 1995 Dec;9(4):283-7

ETIOLOGY

Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Aittomäki K, et al. **Cell** 1995 Sep 22;82(6):959-68

Successful pregnancy following oocyte donation in a patient with Diamond-Blackfan syndrome and premature ovarian failure. Aird IA, et al. **Hum Reprod** 1996 May;11(5):1123-5

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105-10 (27 ref.) **(Fre)**

GENETICS

A gene for premature ovarian failure associated with eyelid malformation maps to chromosome 3q22-q23 [letter] Amati P, et al. **Am J Hum Genet** 1996 May;58(5):1089-92

Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Aittomäki K, et al. **Cell** 1995 Sep 22;82(6):959-68

IMMUNOLOGY

Analysis of peripheral blood lymphocyte subsets, NK cells, and delayed type hypersensitivity skin test in patients with premature ovarian failure. Hoek A, et al.
Am J Reprod Immunol 1995 Jun;33(6):495-502

Circulating tumor necrosis factor (TNF)-alpha in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Naz RK, et al.
Am J Reprod Immunol 1995 Sep;34(3):170-5

Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. Chen S, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1871-6

Autoimmune premature ovarian failure. Kim JG, et al.
J Obstet Gynaecol 1995 Feb;21(1):59-66 (53 ref.)

PHYSIOPATHOLOGY

Success of donor oocyte in in vitro fertilization-embryo transfer in recipients with and without premature ovarian failure. Lydic ML, et al. **Fertil Steril** 1996 Jan;65(1):98-102

Patients with Turner's syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Yaron Y, et al. **Fertil Steril** 1996 Jun; 65(6):1249-52

The resistant ovary syndrome in a patient with galactosemia: a clue to the natural history of ovarian failure. Twigg S, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1329-31

Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Leslie WD, et al.
Nucl Med Commun 1995 Aug;16(8):698-702

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105-10 (27 ref.) **(Fre)**

PREVENTION & CONTROL

Laparoscopic lateral ovarian transposition. Treissman MJ, et al. **Fertil Steril** 1996 Jun;65(6):1229-31

OVARIAN FUNCTION TESTS

[Tests of adrenal gland and ovarian function in the hyperandrogenemia syndrome] Giljević Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:53-6 (Eng. Abstr.) **(Ser)**

METHODS

[Evaluation of ovarian sensitivity to gonadotrophins: role of ovarian reserve tests] Hugues JN, et al.
Contracept Fertil Sex 1996 Apr;24(4):303-6 (23 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Not all assays are equal [letter] Smith S. **Fertil Steril** 1996 Apr;65(4):892-3

OVARIAN HYPERSTIMULATION SYNDROME

Ovarian hyperstimulation syndrome (OHSS) in pregnancy not associated with ovulation induction. Regi A, et al.
Acta Obstet Gynecol Scand 1996 Jul;75(6):599-600

Diagnosis, prevention and management of ovarian hyperstimulation syndrome [see comments] Brinsden PR, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):767-72 (48 ref.). Comment in: Br J Obstet Gynaecol 1996 May;103(5):490.

Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome. Awonuga AO, et al. **J Assist Reprod Genet** 1996 Apr; 13(4):293-7

The influence of supraphysiologic estradiol levels on human nidation. Gelety TJ, et al. **J Assist Reprod Genet** 1995 Aug; 12(7):406-12

BLOOD

Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Balasch J, et al. **Fertil Steril** 1996 Oct; 66(4):608-13

Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Kodama H, et al.
Fertil Steril 1996 Sep;66(3):417-24

CHEMICALLY INDUCED

[Update on ovarian hyperstimulation syndrome] Delbaere A, et al. **Rev Med Brux** 1995 Nov;16(5):354-60 (39 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Spontaneous ovarian hyperstimulation syndrome and hyperprolactinemia in primary hypothyroidism. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):70-1

Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Kodama H, et al.
Fertil Steril 1995 Dec;64(6):1207-9

Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Zalel Y, et al.
Gynecol Endocrinol 1995 Dec;9(4):313-5

Ovarian hyperstimulation syndrome manifests as acute unilateral hydrothorax. Daniel Y, et al. **Hum Reprod** 1995 Jul;10(7):1684-5

Aorto-subclavian thromboembolism: a rare complication associated with moderate ovarian hyperstimulation syndrome. Germond M, et al. **Hum Reprod** 1996 Jun; 11(6):1173-6

Internal jugular vein thrombosis: a late complication of ovarian hyperstimulation syndrome [letter] Horstkamp B. **Hum Reprod** 1996 Jun;11(6):1358-9

Continuous ascitic recirculation in severe ovarian hyperstimulation syndrome. Beck DH, et al.
Intensive Care Med 1995 Jul;21(7):590-3

Acute arterial thrombosis after gamete intrafallopian transfer: a case report. Choktanasiri W, et al.
J Assist Reprod Genet 1995 May;12(5):335-7

Ovarian hyperstimulation syndrome complicated by uterine prolapse. Copperman AB, et al. **J Assist Reprod Genet** 1995 May;12(5):343-5

Massive vulvar edema in ovarian hyperstimulation syndrome. A case report. Coccia ME, et al. **J Reprod Med** 1995 Sep; 40(9):659-60

[Adnexial torsion caused by ovarian hyperstimulation syndrome] Grønlund LA, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6881-2 (Eng. Abstr.) **(Dan)**

[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691-6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Acute pleurisy secondary to ovarian hyperstimulation after in vitro fertilization] Caliandro R, et al.
Rev Mal Respir 1996;13(1):68-70 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The management of severe ovarian hyperstimulation syndrome [letter; comment] Jenkins JM, et al.
Br J Obstet Gynaecol 1995 Nov;102(11):935. Comment on: Br J Obstet Gynaecol 1995 Jul;102(7):585.

Conservative management of ovarian hyperstimulation syndrome. Morris RS, et al. **J Reprod Med** 1995 Oct; 40(10):711-4

EPIDEMIOLOGY

[Incidence of ovarian hyperstimulation syndrome in in-vitro-fertilization treatment over a period of 11 years] Niederberger V, et al. **Wien Med Wochenschr** 1995; 145(23):642-5 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Mathur RS, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3-4):233-5 (15 ref.)

Intrafollicular hemodynamics before the administration of human chorionic gonadotropin in women at risk of the ovarian hyperstimulation syndrome. Oyesanya OA, et al.
Fertil Steril 1996 Apr;65(4):874-6

Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Levy T, et al. **Hum Reprod** 1996 Jun; 11(6):1177-9

Severe ovarian hyperstimulation syndrome and combined intrauterine and tubal pregnancy after in-vitro fertilization and embryo transfer. Moosburger D, et al.
Hum Reprod 1996 Jan;11(1):68-9

A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Cluroe AD, et al. **Pathology** 1995 Oct; 27(4):344-6

IMMUNOLOGY

The role of the immune system in severe ovarian hyperstimulation syndrome. Orvieto R, et al.
Med Hypotheses 1995 Sep;45(3):231-4

PHYSIOPATHOLOGY

The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al.
Adv Exp Med Biol 1995;377:391-8 (37 ref.)

Elevated liver function tests in a case of moderate ovarian hyperstimulation syndrome. Wakim AN, et al.
Hum Reprod 1996 Mar;11(3):588-9

Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: ovarian immunohistochemical localization of interleukin-6 signal. Loret de Mola JR, et al.
Obstet Gynecol 1996 Apr;87(4):581-7

Doppler parameters of the ovarian and uterine blood circulation in ovarian hyperstimulation syndrome. Tekay A, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):50-3

[Syndrome of ovarian hyperstimulation. Report of a severe iatrogenic complication] Pham J, et al. **Presse Med** 1995 Nov 11;24(34):1603-4 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Albumin prophylaxis of ovarian hyperstimulation syndrome. DiPiro CV, et al. **Ann Pharmacother** 1996 Apr;30(4):402-4

The prevention of ovarian hyperstimulation syndrome. Mathur RS, et al. **Br J Obstet Gynaecol** 1996 Aug; 103(8):740-6 (64 ref.)

does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Lewit N, et al. **Fertil Steril** 1996 Oct;66(4):654-6

Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Shaker AG, et al.
Fertil Steril 1996 May;65(5):992-6

Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Kulikowski M, et al.
Gynecol Endocrinol 1995 Jun;9(2):97-102

Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A, et al. **Hum Reprod** 1996 Jun;

11(6):1146–8 (31 ref.)
Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome [letter; comment] Ben-Rafael Z, et al. **Hum Reprod** 1995 Oct;10(10):2750–2. Comment on: Hum Reprod 1993 Jul;8(7):1015–20.
Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin–releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF. **Hum Reprod** 1996 Jun;11(6):1144–6 (12 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin–releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S, et al. **Hum Reprod** 1996 Jun;11(6):1143–4 (15 ref.)
Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Morris RS, et al. **Hum Reprod** 1995 Jun;10(6):1355–8
Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in–vitro fertilization patients receiving intravenous albumin: a prospective study. Shalev E, et al. **Hum Reprod** 1995 Jun;10(6):1373–6
Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. Tomažević T, et al. **J Assist Reprod Genet** 1996 Apr;13(4):282–6
Use of buserelin and low–dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome. Wada I, et al. **J Assist Reprod Genet** 1995 Apr;12(4):252–7
In vitro fertilization of in vitro matured oocytes obtained from the follicles without hCG exposure for prevention of severe ovarian hyperstimulation syndrome: a case report. Kodama H, et al. **J Obstet Gynaecol Res** 1996 Feb; 22(1):61–5
[Evaluation of prophylactic approach to reduce incidence of ovarian hyperstimulation syndrome in in vitro fertilization] Fukuda J, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1071–4 **(Jpn)**

RADIOGRAPHY

Brain water intoxication and CT hypolucencies in ovarian hyperstimulation syndrome complicating gametes intrafallopian transfer (GIFT) and tubal pregnancy [letter] Onofrj M, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):233–4

SURGERY

A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on–going IVF–ET twin pregnancy. Bar–Hava I, et al. **Gynecol Endocrinol** 1995 Dec;9(4):295–8
Laparoscopic unwinding of hyperstimulated ischaemic ovaries during the second trimester of pregnancy. Levy T, et al. **Hum Reprod** 1995 Jun;10(6):1478–80

THERAPY

Ovarian hyperstimulation syndrome [letter; comment] Beck DH, et al. **Br J Anaesth** 1995 Sep;75(3):371–2. Comment on: Br J Anaesth 1994 Dec;73(6):731–3.
Diagnosis, prevention and management of ovarian hyperstimulation syndrome [letter; comment] Beck DH, et al. **Br J Obstet Gynaecol** 1996 May;103(5):490. Comment on: Br J Obstet Gynaecol 1995 Oct;102(10):767–72.
Management of ascites and pleural effusions in ovarian hyperstimulation syndrome [letter; comment] Aboulghar M, et al. **Fertil Steril** 1995 Dec;64(6):1228–9. Comment on: Fertil Steril 1995 May;63(5):1114–7.
Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis. Grochowski D, et al. **J Assist Reprod Genet** 1995 Jul;12(6):394–6

OVARIAN INTERSTITIAL CELLS see **THECA CELLS**

OVARIAN NEOPLASMS

see related
KRUKENBERG TUMOR
PSEUDOMYXOMA PERITONEI

Borderline ovarian tumors. Link CJ Jr, et al. **Am J Med** 1996 Aug;101(2):217–25 (70 ref.)
Pelvic endometriosis mimicking advanced ovarian cancer: presentation with pleural effusion, ascites, and elevated serum CA 125 level. Myers TJ, et al. **Am J Obstet Gynaecol** 1995 Sep;173(3 Pt 1):966–7
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Chang J, et al. **Ann Oncol** 1995 Oct;6(8):755–8
Ovarian cancer. Westhoff C. **Annu Rev Public Health** 1996; 17:85–96 (78 ref.)
The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Averette HE, et al. **Cancer** 1995 Sep 15;76(6):1096–103
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Boente MP, et al. **Curr Probl Cancer** 1996 Mar–Apr;20(2):83–137 (156 ref.)
Pregnancy following treatment of an adolescent with Yolk sac tumour. Tesic M, et al. **Eur J Gynaecol Oncol** 1996; 17(1):55–8
Krukenberg tumor complicated by pregnancy. Mackey JR, et al. **Gynecol Oncol** 1996 Apr;61(1):153–5
Serous cystadenocarcinoma and ovarian teratoma during pregnancy [letter] Angel–Müller E, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):55–6
An 81–year–old woman with an abdominal mass. Simmons B, et al. **J La State Med Soc** 1995 Nov;147(11):512–5
Squamous cell carcinoma in the ovary of a 14–year–old girl. Khanfar NM, et al. **Mayo Clin Proc** 1996 Apr;71(4):380–3 (22 ref.)
Multivariate analysis of DNA ploidy, steroid hormone receptors, and CA 125 as prognostic factors in ovarian carcinoma: a prospective study. Eissa S, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):622–6
Malignant mixed mesodermal tumors of the ovary. DiSilvestro PA, et al. **Obstet Gynecol** 1995 Nov;86(5):780–2
The management of early ovarian cancer. Schilder RJ, et al. **Oncology (Huntingt)** 1995 Feb;9(2):171–82; discussion 185–7 (63 ref.)
[Ovarian teratoma (case report)] Sváb J, et al. **Rozhl Chir** 1995 Sep;74(6):280–1 (Eng. Abstr.) **(Cze)**
[Ovarian cancer and pregnancy] Ayoubi J, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):335–41 (Eng. Abstr.) **(Fre)**
[Molecular biology of epithelial ovarian carcinoma] Piura B, et al. **Harefuah** 1995 Nov 1;129(9):351–7 (42 ref.) **(Heb)**
[Ovarian tumors in children] Fabbro MA, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):151–4 (Eng. Abstr.) **(Ita)**
[Current approaches to the diagnosis and management of patients with tumors and tumor–like formations of the ovaries] Strizhakov AN, et al. **Akush Ginekol (Mosk)** 1995; (4):15–8 (82 ref.) **(Rus)**
[Extrauterine choriocarcinoma—a rare form of gestational trophoblastic disease] Danihel L, et al. **Bratisl Lek Listy** 1996 May;97(5):279–83 (Eng. Abstr.) **(Slo)**
[Malignant Brenner tumor of the ovary] León M, et al. **Rev Chil Obstet Ginecol** 1994;59(5):393–5 (Eng. Abstr.) **(Spa)**

BLOOD

Preoperative serum intercellular adhesion molecule–1 (ICAM–1) and E–selectin (endothelial cell leukocyte adhesion molecule, ELAM–1) in patients with epithelial ovarian cancer. Ferdeghini M, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2255–60
The measurement of plasma D–dimer (DD) levels in the follow–up of patients with ovarian cancer. Gadducci A, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2683–6
Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125. Garzetti GG, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2123–7
Tumor–associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters–Engl C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2727–30
Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Sliutz G, et al. **Br J Cancer** 1995 Dec;72(6):1494–7
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Davelaar EM, et al. **Cancer** 1996 Jul 1; 78(1):118–27
Decreased branching, increased fucosylation and changed sialylation of alpha–1–proteinase inhibitor in breast and ovarian cancer. Goodarzi MT, et al. **Clin Chim Acta** 1995 May 15;236(2):161–71
Characterization of inhibin immunoreactivity in post–menopausal women with ovarian tumours. Burger HG, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):413–8
Measurements of haptoglobin by the reaction with concanavalin A in sera of patients with ovarian tumours. Kątnik I, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct; 33(10):727–32
An ovarian tumor of probable Wolffian origin with hormonal function. Inoue H, et al. **Gynecol Oncol** 1995 Nov; 59(2):304–8 (11 ref.)
Predictive and prognostic values of cancer–associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second–look laparotomy for ovarian cancer. Kierkegaard O, et al. **Gynecol Oncol** 1995 Nov;59(2):251–4
Clinical value of CA125, CA19–9, CEA, CA72–4, and TPA in borderline ovarian tumor. Tamakoshi K, et al. **Gynecol Oncol** 1996 Jul;62(1):67–72
Clinical evaluations of a new ovarian cancer marker, COX–1. Lee G, et al. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S27–32
Serum neopterin levels in ovarian tumors. Park IS, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):229–34
CA–125: an evolving role in the management of ovarian cancer [editorial] Markman M. **J Clin Oncol** 1996 May; 14(5):1411–2
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. Rustin GJ, et al. **J Clin Oncol** 1996 May;14(5):1545–51
Prospective study of serum micronutrients and ovarian cancer. Helzlsouer KJ, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):32–7
Re: Prospective study of serum micronutrients and ovarian cancer [letter] Knekt P, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1408
Cremophor pharmacokinetics in patients receiving 3–, 6–, and 24–hour infusions of paclitaxel. Rischin D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1297–301
Pelvic tuberculosis presenting as an asymptomatic pelvic mass with rising serum CA–125 levels. A case report. Miranda P, et al. **J Reprod Med** 1996 Apr;41(4):273–5
Serum gonadotropins and steroid hormones and the development of ovarian cancer. Helzlsouer KJ, et al. **JAMA** 1995 Dec 27;274(24):1926–30
Tumour marker levels during marimastat therapy [letter; comment] Gore M, et al. **Lancet** 1996 Jul 27; 348(9022):263–4. Comment on: Lancet 1996 Jun 1;347(9014):1497.
Use of CA 125 in follow–up of ovarian cancer [letter] Rustin G, et al. **Lancet** 1996 Jul 20;348(9021):191–2
IMx CA 125, an automated microparticle enzyme immunoassay: technical characteristics and clinical usefulness after recalibration. Mogensen O, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):289–94
Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Onsrud M, et al. **Tumour Biol** 1996;17(2):90–6
[Value of inhibin as a tumor marker in granulosa cell tumors. Apropos of 6 new cases treated at the Gustave–Roussy Institute] Pautier P, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):557–60 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Microvessel density, expression of proto–oncogenes, resistance–related proteins and incidence of metastases in primary ovarian carcinomas. Volm M, et al. **Clin Exp Metastasis** 1996 May;14(3):209–14
Conflicting Doppler data on the assessment of pelvic tumors vascularity [editorial] Kurjak A. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):1–2
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Gasparini G, et al. **Int J Cancer** 1996 Jun 21;69(3):205–11
Detection of ovarian malignancy [letter; comment] [see comments] Schoenfeld A. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):422. Comment on: Ultrasound Obstet Gynecol 1995 Mar;5(3):209–10. Comment in: Ultrasound Obstet Gynecol 1995 Sep;6(3):230.
[The evaluation of ovarian tumor vascularization using color Doppler transvaginal ultrasonography] Szpurek D, et al. **Ginekol Pol** 1995 Jan;66(1):32–5 (Eng. Abstr.) **(Pol)**
[Prognostic value of vaginal ultrasound with color Doppler in differentiating the malignancy of ovarian tumors] Szpurek D, et al. **Ginekol Pol** 1995 Feb;66(2):97–102 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

The risk of ovarian cancer after treatment for infertility. Bristow RE, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):32–7 (35 ref.)
Synchronous endometrial and ovarian cancer in young woman taking oral contraception. Fishman A, et al. **Eur J Gynaecol Oncol** 1995;16(5):346–8
Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Shushan A, et al. **Fertil Steril** 1996 Jan; 65(1):13–8
Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen [see comments] Cohen I, et al. **Gynecol Oncol** 1996 Jan;60(1):54–8. Comment in: Gynecol Oncol 1996 Apr;61(1):158–60.
Re: Population–based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers [letter; comment] Laderoute MP. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):210–1. Comment on: J Natl Cancer Inst 1995 Sep 20;87(18):1359–64.
Fertility drugs and breast and ovarian cancer [letter; comment] La Vecchia C, et al. **Lancet** 1995 Dec 16; 346(8990):1628. Comment on: Lancet 1995 Oct 14;346(8981):995–1000.
Fertility drugs and breast and ovarian cancer [letter; comment] Rossing MA, et al. **Lancet** 1995 Dec 16; 346(8990):1627–8. Comment on: Lancet 1995 Oct 14;346(8981):995–1000.
Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al. **Maturitas** 1996 Mar;23(2):235–9 (43 ref.)

CHEMISTRY

Aromatase in human common epithelial ovarian neoplasms. Kaga K, et al. **Am J Pathol** 1996 Jul;149(1):45–51
Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Kämäräinen M, et al. **Am J Pathol** 1996 May; 148(5):1435–43
Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Skubitz AP, et al. **Am J Pathol** 1996 May;148(5):1445–61
Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well–differentiated epithelial carcinomas of the human ovary. Kuwashima Y, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2847–50
Folate receptor in malignant effusions of ovarian carcinoma. Holm J, et al. **APMIS** 1995 Sep;103(9):663–70
Characterisation of seven human ovarian tumour cell lines. Wilson AP, et al. **Br J Cancer** 1996 Sep;74(5):722–7

p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Klemi PJ, et al. **Cancer** 1995 Oct 1;76(7):1201–8

A novel tumor–associated antigen expressed in human uterine and ovarian carcinomas. Sonoda K, et al. **Cancer** 1996 Apr 15;77(8):1501–9

Expression of cell regulatory proteins in ovarian borderline tumors. van Haaften–Day C, et al. **Cancer** 1996 May 15; 77(10):2092–8

The differential expression of cytokeratin 18 in cisplatin–sensitive and –resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Parekh HK, et al. **Cancer Res** 1995 Nov 15; 55(22):5203–6

Quantitative measurement of c–erbB–2 p185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay. Mabrouk GM, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):981–2

Mutant p53 protein as a predictor of survival in endometrial carcinoma. Strang P, et al. **Eur J Cancer** 1996 Apr; 32A(4):598–602

Glycosylation of alpha–1–proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Turner GA, et al. **Glycoconj J** 1995 Jun; 12(3):211–8 (62 ref.)

Estrogen receptor expression is a common feature of ovarian borderline tumors. Abu–Jawdeh GM, et al. **Gynecol Oncol** 1996 Feb;60(2):301–7

Elevated concentrations of antiestrogen binding sites in membrane fractions of human ovarian tumors. Batra S, et al. **Gynecol Oncol** 1996 Feb;60(2):228–32

Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Carreiras F, et al. **Gynecol Oncol** 1996 Aug;62(2):260–7

Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer. Guidozzi F, et al. **Gynecol Oncol** 1996 May;61(2):204–9

Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309–13

Prognostic significance of c–erB–2 mRNA in ovarian carcinoma. Tanner B, et al. **Gynecol Oncol** 1996 Aug; 62(2):268–77

p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Hutson R, et al. **Histopathology** 1995 Oct;27(4):367–71

Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Loo KT, et al. **Histopathology** 1995 Oct;27(4):388–90

Adrenal 4–binding protein in common epithelial and metastatic tumors of the ovary. Sasano H, et al. **Hum Pathol** 1996 Jun;27(6):595–8

Lipid cell (steroid cell) tumor of the ovary: immunophenotype with analysis of potential pitfall due to endogenous biotin–like activity. Seidman JD, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):331–8

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. Reles A, et al. **J Cancer Res Clin Oncol** 1996; 122(8):489–94

Biomarkers in the ovary. Berchuck A. **J Cell Biochem Suppl** 1995;23:223–6 (20 ref.)

Drug resistance–associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Izquierdo MA, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1230–7

Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. Li PY, et al. **J Nucl Med** 1996 Apr;37(4):665–72

Mucin histochemistry of ovarian mucinous cystadenomas expressing gastrointestinal characteristics. Nomura K. **Pathol Int** 1995 Jun;45(6):430–5

Location of BRCA1 in human breast and ovarian cancer cells [letter; comment] Sully R, et al. **Science** 1996 Apr 5;272(5258):123–6. Comment on: Science 1995 Nov 3;270(5237):789–91.

[Expression of epidermal growth factor receptor (EGFR) in endometrioid carcinoma of the ovary] Leng J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):281–3 (Eng. Abstr.) **(Chi)**

CLASSIFICATION

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126–39 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

The laparoscopic approach of a torsion of a benign mature ovarian teratoma: a case report and review of the literature. Van de Walle P, et al. **Acta Chir Belg** 1996 Apr;96(2):95–8

Sclerosing peritonitis associated with luteinized thecomas. Reginella RF, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):512–3

Ovarian dermoid cyst–associated autoimmune hemolytic anemia: a case report with emphasis on pathogenic mechanisms. Cobo F, et al. **Am J Clin Pathol** 1996 May; 105(5):567–71

Burning mouth syndrome [letter] Graham RM, et al. **Br Dent J** 1996 Jun 8;180(11):407

Pseudomyxoma peritonei. Fox H. **Br J Obstet Gynaecol** 1996 Mar;103(3):197–8

Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Jong P, et al. **Can J Surg** 1995 Oct;38(5):454–7

Trousseau's syndrome in association with ovarian carcinoma. Evans TR, et al. **Cancer** 1996 ..n 15;77(12):2544–9

Second malignant neoplasms among long–term survivors of ovarian cancer. Travis LB, et al. **Cancer Res** 1996 Apr 1;56(7):1564–70

A gonadotrophin dependent stromal luteoma: a rare cause of post–menopausal virilization. Chico A, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):645–9

An ovarian lipid cell tumour causing virilization and Cushing's syndrome. Elhadd TA, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):723–5

Mayer–Rokitansky–Küster–Hauser syndrome and ovarian cancer. Report of a case. Ghirardini G, et al. **Clin Exp Obstet Gynecol** 1995;22(3):247–8

Sertoli–Leydig cell tumor of the ovary: a clinicopathologic study of 10 cases. Ayhan A, et al. **Eur J Gynaecol Oncol** 1996;17(1):75–8

Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852–9

The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gogas H, et al. **Gynecol Oncol** 1996 Apr;61(1):22–6

Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. McMeekin DS, et al. **Gynecol Oncol** 1995 Oct;59(1):81–6

Octreotide in the management of bowel obstruction in terminal ovarian cancer. Mangili G, et al. **Gynecol Oncol** 1996 Jun;61(3):345–8

The prognostic implication of ascites in advanced–stage ovarian cancer. Puls LE, et al. **Gynecol Oncol** 1996 Apr; 61(1):109–12

Luteinized thecoma with sclerosing peritonitis presenting as an acute abdomen. Spiegel GW, et al. **Gynecol Oncol** 1996 May;61(2):275–81

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438–41 (13 ref.)

Central precocious puberty following feminizing right ovarian granulosa cell tumor. Kukuvitis A, et al. **Horm Res** 1995;44(6):268–70

Prostatic tissue in benign cystic ovarian teratomas. Vadmal M, et al. **Hum Pathol** 1996 Apr;27(4):428–9

Association of herpesvirus infection with the development of genital cancer. Koffa M, et al. **Int J Cancer** 1995 Sep 27;63(1):58–62

Dysgerminoma of the ovary in a patient with triple–X syndrome. Kemp B, et al. **Int J Gynaecol Obstet** 1995 Jul; 50(1):51–3

Vesicle formation in dermatomyositis associated with gynecologic malignancies. Kubo M, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):391–4 (27 ref.)

Dermatomyositis with malignancy. Balakrishnan C, et al. **J Assoc Physicians India** 1995 Apr;43(4):287–8

Langerhans' cell histiocytosis: possible association with malignant germ cell tumour. Ng WK, et al. **J Clin Pathol** 1995 Oct;48(10):963–5

Tripe palms: a cutaneous marker of internal malignancy. Requena L, et al. **J Dermatol** 1995 Jul;22(7):492–5

Gonadoblastoma in patient with Turner's syndrome. Lo KW, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):35–41

Mixed gonadal dysgenesis with gonadoblastoma in a female with Y chromosome: case report. Sadi AM, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):25–30

Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. Kohli M, et al. **J Rheumatol** 1995 Jul; 22(7):1393–4

Ovarian cancer and gangrene of the digits: case report and review of the literature. Chow SF, et al. **Mayo Clin Proc** 1996 Mar;71(3):253–8 (45 ref.)

Giant ovarian leiomyoma as a rare cause of acute abdomen and hydronephrosis. Khaffaf N, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):872–3

Case records of the Medical College of Virginia: a 10–year–old girl presenting with an acute onset of abdominal pain [clinical conference] Cunnion KM, et al. **Pediatr Emerg Care** 1996 Feb;12(1):52–5

Coexistence of struma ovarii and Graves' disease. Bayot MR, et al. **Thyroid** 1995 Dec;5(6):469–71

Diabetes mellitus induced by thecoma–fibroma tumour of the ovary: case report. Ghosh TS, et al. **West Afr J Med** 1995 Apr–Jun;14(2):121–3

[Subacute paraneoplastic cerebellar degeneration with anti–neuronal antibodies and gynecological cancers. A case report of a bilateral ovarian cancer where the classic "anti–YO" antibody is associated with another antineuronal antibody] Tremouilhac C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):253–6 (Eng. Abstr.) **(Fre)**

[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Granulocytic sarcoma (chloroma): a report of two cases. Colle I, et al. **Acta Clin Belg** 1996;51(2):106–10

Neoplastic or nonneoplastic ovarian cyst? The role of cytology. Kreuzer GF, et al. **Acta Cytol** 1995 Sep–Oct; 39(5):882–6

Endodermal sinus tumor of the ovary: imaging evaluation. Levitin A, et al. **AJR Am J Roentgenol** 1996 Sep; 167(3):791–3

Application of clonal analysis. Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Fujita M, et al. **Am J Clin Pathol** 1996 Mar;105(3):350–9

Pelvic–peritoneal tuberculosis simulating ovarian carcinoma: report of three cases with elevation of the CA 125. Nistal de Paz F, et al. **Am J Gastroenterol** 1996 Aug;91(8):1660–1

Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha–inhibin and estradiol. Rey RA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):958–65

Is early detection of ovarian cancer possible? Schwartz PE, et al. **Ann Med** 1995 Oct;27(5):519–28 (46 ref.)

Parovarian borderline malignancy in pregnancy. Fine BA, et al. **Arch Gynecol Obstet** 1996;258(2):105–8

The future of breast and ovarian cancer clinics [editorial] [see comments] Campbell H, et al. **BMJ** 1995 Dec 16; 311(7020):1584–5. Comment in: BMJ 1996 Apr 6;312(7035):913.

Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre–operative diagnosis of pelvic masses. Tingulstad S, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):826–31

The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)

Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2092–6 (25 ref.)

Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Deligdisch L, et al. **Cancer** 1995 Sep 15;76(6):1027–34

A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second–look laparotomy redundant. Frasci G, et al. **Cancer** 1996 Mar 15; 77(6):1122–30

Soluble interleukin–2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Hurteau JA, et al. **Cancer** 1995 Nov 1; 76(9):1615–20

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Skates SJ, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2004–10

Ovarian cancer screening. van Nagell JR Jr, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2086–91 (27 ref.)

Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. Lorigan PC, et al. **Cancer Lett** 1996 Jun 24;104(1):27–30

Burkitt's lymphoma presenting with obstructive jaundice [letter] Lucas GN, et al. **Ceylon Med J** 1995 Dec;40(4):169

Leiomyoma of the ovary. Case report. Morgante G, et al. **Clin Exp Obstet Gynecol** 1995;22(4):312–4

Case report: benign neural tumour of small bowel presenting as a pelvic mass. Nargund G. **Clin Exp Obstet Gynecol** 1995;22(3):202–3

Recurrent ovarian endodermal sinus tumor: demonstration by computed tomography, magnetic resonance imaging, and positron emission tomography. Romero JA, et al. **Eur J Nucl Med** 1995 Oct;22(10):1214–7

A combined approach for the early detection of ovarian cancer in asymptomatic women. Adonakis GL, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):221–5

Ovarian malignancies in childhood and adolescence. Major T, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov; 63(1):65–8

Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)

Hyperreactio luteinalis masquerading as an ovarian neoplasm in a triplet pregnancy. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):177–80

Mature cystic teratomas of the ovary: CT and MR findings. Guinet C, et al. **Eur J Radiol** 1995 Jul;20(2):137–43

Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays. Filella X, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):40–5

Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Nicholson S, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):46–9

Aspiration cytology of neoplastic and non–neoplastic ovarian cysts: is it accurate? Ganjei P, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):94–101

Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? Karlan BY. **J Cell Biochem Suppl** 1995;23:227–32 (40 ref.)

Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD. **J Cell Biochem Suppl** 1995;23:238–42 (12 ref.)

Early detection and screening for ovarian cancer. Schwartz PE, et al. **J Cell Biochem Suppl** 1995;23:233–7 (20 ref.)

Factoring outcomes in ovarian cancer [editorial] Bookman MA, et al. **J Clin Oncol** 1996 Feb;14(2):325–7

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second–look laparotomy. Pujade–Lauraine E, et al. **J Clin Oncol** 1996 Feb;14(2):343–50

Aunt Minnie's corner. Ovarian teratoma. Ford KL 3rd. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):336

CT and MR findings of Krukenberg tumors: comparison with primary ovarian tumors. Kim SH, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):393–8

Imaging of ovarian cancer. Forstner R, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):606–13 (82 ref.)

Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized tomography or magnetic resonance imaging. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Dec;21(6):551–6

Pelvic tuberculosis presenting as an asymptomatic pelvic mass with rising serum CA–125 levels. A case report. Miranda P, et al. **J Reprod Med** 1996 Apr;41(4):273–5

Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma [letter] Paira SO. **J Rheumatol** 1996 Apr; 23(4):792

Lipomatous uterine masses: potential to mimic ovarian dermoids on endovaginal sonography. Hertzberg BS, et al. **J Ultrasound Med** 1995 Sep;14(9):689–92; quiz 693–4

Magnetic resonance imaging of the ovary. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):245–74 (104 ref.)

Clinical problem–solving: hypereosinophilic syndrome [letter; comment] Hassell LA. **N Engl J Med** 1996 Feb 22;334(8):539; discussion 540. Comment on: N Engl J Med 1995 Nov 2;333(18):1208–11.

Ovarian fibroma in a prepubertal girl. Laufer L, et al. **Pediatr Radiol** 1996;26(1):40–2

Cystic teratoma of the ovary mimicking a bladder stone. Konety BR, et al. **Urology** 1996 Sep;48(3):466–7

[Ovarian carcinoma in the elderly; a diagnostic and therapeutic dilemma] Wymenga AN, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):650–3 (42 ref.) **(Dut)**

[Müllerian adenosarcoma] Bettini–Papon V, et al. **J Radiol** 1996 Jul;77(7):512–4 **(Fre)**

–Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma– Radke J, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):83–7 (Eng. Abstr.) **(Ger)**

[Preoperative differential diagnosis of cystic adnexal tumors: double–contrast MRT] Reuter M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):394–400 (Eng. Abstr.) **(Ger)**

[Study on the pretherapeutic differential diagnosis of adnexal tumors] Kunz J, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1342–8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Hemoperitoneum from post–traumatic ovarian cystoma. Videolaparoscopic treatment] Saccia A. **Minerva Chir** 1995 Nov;50(11):1005–7 (Eng. Abstr.) **(Ita)**

[MR appearance of fat distribution in ovarian teratoma: pathologic correlation] Hatanaka Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun; 56(7):477–81 (Eng. Abstr.) **(Jpn)**

[Applications of tumor markers to the screening of endometrial and ovarian cancers] Nozawa S, et al. **Nippon Rinsho** 1996 Jun;54(6):1665–73 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer] Sugiyama Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar;48(3):213–9 (Eng. Abstr.) **(Jpn)**

[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Andersson H, et al. **Acta Oncol** 1995;34(6):821–7

Experience with hormonal therapy in advanced epithelial ovarian cancer. van der Vange N, et al. **Acta Oncol** 1995; 34(6):813–20

A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Look KY, et al. **Am J Clin Oncol** 1996 Feb;19(1):7–9

Study affirms primacy of paclitaxel–cisplatin in advanced ovarian cancer [news] **Am J Health Syst Pharm** 1996 Mar 1;53(5):498

CA 125 kinetics: a cost–effective clinical tool to evaluate clinical trial outcomes in the 1990s. Buller RE, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1241–53; discussion 1253–4

Phase II study of high–dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Cain JM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1688–94; discussion 1694

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. Runowicz CD, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1151–9; discussion 1159–60

Capillary electrophoretic separation and laser–induced fluorescence detection of the major DNA adducts of cisplatin and carboplatin [published erratum appears in Anal Biochem 1995 Sep 1;230(1):197] Sharma M, et al. **Anal Biochem** 1995 Jul 1;228(2):307–11

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica [see comments] Bolis G, et al. **Ann Oncol** 1995 Nov;6(9):887–93. Comment in: Ann Oncol 1995 Nov;6(9):865–6.

A phase II study of Tomudex in relapsed epithelial ovarian cancer. Gore ME, et al. **Ann Oncol** 1995 Sep;6(7):724–5

Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild–type, mutated or no p53. Graniela Sirè EA, et al. **Ann Oncol** 1995 Jul;6(6):589–93

Activity of N–benzyl–adriamycin–14–valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Harstrick A, et al. **Anticancer Drugs** 1995 Oct;6(5):681–5

In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay. Kurbacher CM, et al. **Anticancer Drugs** 1995 Oct;6(5):697–704

Phase II study of gemcitabine in previously platinum–treated ovarian cancer patients. Lund B, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:61–2

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)

The activity of N–(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts. Coley HM, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1851–5

Energetic characteristics of cisplatin resistant ovarian carcinoma cells. Dorward AM, et al. **Anticancer Res** 1996 Jan–Feb;16(1):443–7

Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line. Griffon G, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):177–87

A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Jager W, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2639–42

Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Phillips KA, et al. **Aust N Z J Med** 1995 Aug;25(4):337–43

Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. De Pooter CM, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):629–34

Characterization of novel anthracycline prodrugs activated by human beta–glucuronidase for use in antibody–directed enzyme prodrug therapy. Houba PH, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):455–63

Site–specific prodrug activation by antibody–beta–lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Meyer DL, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):440–6

The relationship between tumour glutathione concentration, glutathione S–transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Ghazal–Aswad S, et al. **Br J Cancer** 1996 Aug;74(3):468–73

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Gore ME, et al. **Br J Cancer** 1995 Oct;72(4):1016–9

Schedule–dependent interaction between paclitaxel and 5–fluorouracil in human carcinoma cell lines in vitro. Kano Y, et al. **Br J Cancer** 1996 Sep;74(5):704–10

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Kerr DJ, et al. **Br J Cancer** 1995 Nov; 72(5):1267–9

Activity– and schedule–dependent interactions of paclitaxel, etoposide and hydroperoxy–ifosfamide in cisplatin–sensitive and –refractory human ovarian carcinoma cell lines. Klaassen U, et al. **Br J Cancer** 1996 Jul;74(2):224–8

Activation of methotrexate–phenylalanine by monoclonal antibody––carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281–7

A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Pronzato P, et al. **Br J Cancer** 1996 Jun;73(11):1425–7

Successful pregnancy after treatment of stage III bilateral ovarian dysgerminoma. Hudson CN, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1015–6

Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation–embryo transfer. Lawal AH, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):931–2

Is paclitaxel and cisplatin a cost–effective first–line therapy for advance ovarian carcinoma? Covens A, et al. **Cancer** 1996 May 15;77(10):2086–91

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Davelaar EM, et al. **Cancer** 1996 Jul 1; 78(1):118–27

Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Davol P, et al. **Cancer** 1995 Jul 1; 76(1):79–85

Promising new therapies in the treatment of advanced ovarian cancer. Runowicz CD, et al. **Cancer** 1995 Nov 15; 76(10 Suppl):2028–33 (37 ref.)

Radiotherapy as a cisplatin–sensitizer in a resistant ovarian carcinoma cell line. Siler DF, et al. **Cancer** 1996 May 1; 77(9):1850–3

Randomized trial of initial therapy with melphalan versus cisplatin–based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results––Eastern Cooperative Oncology Group Study E2878. Wadler S, et al. **Cancer** 1996 Feb 15;77(4):733–42

High–dose 5–fluorouracil and leucovorin as second–line chemotherapy in patients with platinum–resistant epithelial ovarian cancer. Kamphuis JT, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):190–2

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Nardi M, et al. **Cancer Chemother Pharmacol** 1996;38(3):298–301

Cross–resistance and collateral sensitivity to natural product drugs in cisplatin–sensitive and –resistant rat lymphoma and human ovarian carcinoma cells. Parekh H, et al. **Cancer Chemother Pharmacol** 1996;37(5):457–62

Hypertensive reactions associated with paclitaxel. Solimando DA, et al. **Cancer Invest** 1996;14(4):340–2

Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S, et al. **Cancer Res** 1996 Jul 1; 56(13):3087–90

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Andreotti PE, et al. **Cancer Res** 1995 Nov 15; 55(22):5276–82

Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Molpus KL, et al. **Cancer Res** 1996 Mar 1;56(5):1075–82

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P, et al. **Cancer Res** 1996 Feb 1; 56(3):556–62

Combination chemotherapy and photodynamic therapy with N–(2–hydroxypropyl) methacrylamide copolymer–bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Peterson CM, et al. **Cancer Res** 1996 Sep 1;56(17):3980–5

Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Pizer ES, et al. **Cancer Res** 1996 Mar 15;56(6):1189–93

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin–based chemotherapy in advanced ovarian carcinoma. Righetti SC, et al. **Cancer Res** 1996 Feb 15;56(4):689–93

Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Chen G, et al. **Cell Biol Toxicol** 1995 Oct;11(5):273–81

Contrast media induced irreversible acute renal failure in a patient treated with intraperitoneal cisplatin [letter] Oymak O. **Clin Nephrol** 1995 Aug;44(2):135–6

The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)

Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)

Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)

Very high–dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Benedetti–Panici P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1987–92

Chemotherapy for ovarian germ cell tumours [see comments] Bower M, et al. **Eur J Cancer** 1996 Apr;32A(4):593–7. Comment in: Eur J Cancer 1996 Apr;32A(4):572–3.

Salvage chemotherapy in non–dysgerminomatous germ cell tumours of the ovary [letter] Culine S, et al. **Eur J Cancer** 1995 Oct;31A(11):1890–1

An I.T.M.O. group study on second–line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Di Leo A, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2248–54

Chemotherapy for ovarian germ cell tumours [editorial; comment] Kaufmann M, et al. **Eur J Cancer** 1996 Apr; 32A(4):572–3. Comment on: Eur J Cancer 1996 Apr;32A(4):593–7.

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Kaye SB, et al. **Eur J Cancer** 1995;31A Suppl 4:S14–7

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Klaassen U, et al. **Eur J Cancer** 1996 Mar; 32A(3):547–9

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Kristensen GB, et al. **Eur J Cancer** 1995 Oct; 31A(11):1778–80

A randomised double–blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an

adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer [letter] Parnis FX, et al. **Eur J Cancer** 1995 Sep;31A(10):1721

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Skarlos DV, et al. **Eur J Cancer** 1996 Mar; 32A(3):421–8

Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment [letter] Zanetta G, et al. **Eur J Cancer** 1996 Jan;32A(1):178–9

A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Balat O, et al. **Eur J Gynaecol Oncol** 1996; 17(3):232–3

Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy—response to paclitaxel treatment. Case report. Hornreich G, et al. **Eur J Gynaecol Oncol** 1995;16(4):263–7

Absence of an association between G-CSF support and clinical response in heavily pre-treated ovarian cancer patients receiving salvage chemotherapy with paclitaxel (Taxol). Johnston CM, et al. **Eur J Gynaecol Oncol** 1995; 16(4):251–7

Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel. Johnston CM, et al. **Eur J Gynaecol Oncol** 1995; 16(6):439–47

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Lee CR, et al. **Eur J Gynaecol Oncol** 1996;17(2):99–103

Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Meden H, et al. **Eur J Gynaecol Oncol** 1996;17(2):114–22

Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Tresukosol D, et al. **Eur J Gynaecol Oncol** 1996;17(3):188–91

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Vermorken JB, et al. **Eur J Gynaecol Oncol** 1995; 16(6):433–8

Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Barakat RR, et al. **Gynecol Oncol** 1995 Dec;59(3):390–3

Meta-analysis comparing cisplatin total dose intensity and survival. Ben-David Y, et al. **Gynecol Oncol** 1995 Oct; 59(1):93–101

Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa. Cass I, et al. **Gynecol Oncol** 1996 Jun;61(3):309–14

Whither tamoxifen [editorial; comment] Edmonson JH. **Gynecol Oncol** 1996 Jul;62(1):1–3. Comment on: Gynecol Oncol 1996 Jul;62(1):4–6.

Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Emoto M, et al. **Gynecol Oncol** 1996 Jun;61(3):369–72

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Kohn EC, et al. **Gynecol Oncol** 1996 Aug;62(2):181–91

Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A, et al. **Gynecol Oncol** 1996 Feb;60(2):203–12

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report [see comments] Markman M, et al. **Gynecol Oncol** 1996 Jul; 62(1):4–6. Comment in: Gynecol Oncol 1996 Jul 62(1):1–3.

Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy—a randomized phase II study by theSouthwest Oncology Group. Muggia FM, et al. **Gynecol Oncol** 1996 Jun; 61(3):395–402

Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. Niwa K, et al. **Gynecol Oncol** 1995 Dec;59(3):398–400

Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Préfontaine M, et al. **Gynecol Oncol** 1996 May;61(2):249–52

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Reed E, et al. **Gynecol Oncol** 1996 Jun;61(3):349–53

Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC). Sweeten KM, et al. **Gynecol Oncol** 1995 Nov;59(2):211–5

Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Uslu R, et al. **Gynecol Oncol** 1996 Aug; 62(2):282–91

Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. Cornélissen G, et al. **In Vivo** 1995 Jul-Aug; 9(4):375–8

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cornarotti M, et al. **Int J Cancer** 1996 Aug 7;67(4):479–84

c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Wiechen K, et al. **Int J Cancer** 1995 Nov 15;63(4):604–8

Cutaneous manifestations of Taxol therapy. Link CJ Jr, et al. **Invest New Drugs** 1995;13(3):261–3

Successful parenteral desensitization to paclitaxel. Essayan DM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):42–6

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer? [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(8):443–4

Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(2):71–3

A comparison of two quality-of-life questionnaires for cancer clinical trials: the functional living index—cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30). King MT, et al. **J Clin Epidemiol** 1996 Jan; 49(1):21–9

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. Bookman MA, et al. **J Clin Oncol** 1996 Jun;14(6):1895–902

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. Conte PF, et al. **J Clin Oncol** 1996 Feb;14(2):351–6

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961–7

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. Kaye SB, et al. **J Clin Oncol** 1996 Jul;14(7):2113–9

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Kemp G, et al. **J Clin Oncol** 1996 Jul;14(7):2101–12

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Kudelka AP, et al. **J Clin Oncol** 1996 May;14(5):1552–7

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. Lind MJ, et al. **J Clin Oncol** 1996 Mar;14(3):800–5

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Markman M, et al. **J Clin Oncol** 1996 Mar; 14(3):796–9

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. Rustin GJ, et al. **J Clin Oncol** 1996 May;14(5):1545–51

Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. Fu KK, et al. **J Clin Pharm Ther** 1995 Jun; 20(3):167–72

Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. Dorval T, et al. **J Infus Chemother** 1996 Winter;6(1):47–9

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240–5 (26 ref.)

Paclitaxel premedication regimens [letter] Boehm DK, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):463–5

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Izquierdo MA, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1230–7

Immunohistochemical expression of glutathione S-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors. Hirazono K, et al. **J Obstet Gynaecol** 1995 Jun;21(3):305–12

Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Oct;21(5):521–7

Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. Yasumizu T, et al. **J Obstet Gynaecol** 1995 Dec; 21(6):569–76

Pediatric germ cell tumor. An experience with BEP. Kapoor G, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):318–24

Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. Sharma A, et al. **J Pharm Sci** 1995 Dec;84(12):1400–4

Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres. Kumagai S, et al. **Jpn J Cancer Res** 1996 Apr;87(4):412–7

Experimental intraperitoneal administration of cisplatin-activated carbon for rat ovarian adenocarcinomas. Sugiyama T, et al. **Kurume Med J** 1996;43(1):33–9

FDA approve bark-derived drug [news] Barnett AA. **Lancet** 1996 Jun 8;347(9015):1613

Chemotherapy for ovarian cancer [letter; comment] Cvitkovic E, et al. **N Engl J Med** 1996 May 9;334(19):1269; discussion 1270. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Chemotherapy for ovarian cancer [letter] Lacave AJ, et al. **N Engl J Med** 1996 May 9;334(19):1269–70

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments] McGuire WP, et al. **N Engl J Med** 1996 Jan 4;334(1):1–6. Comment in: N Engl J Med 1996 Jan 4;334(1):50–1. Comment in: N Engl J Med 1996 May 9;334(19):1268–9; discussion 1270. Comment in: N Engl J Med 1996 May 9;334(19):1269; discussion 1270.

New therapy for ovarian cancer [editorial; comment] Neijt JP. **N Engl J Med** 1996 Jan 4;334(1):50–1. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Chemotherapy for ovarian cancer [letter; comment] Parmar MK, et al. **N Engl J Med** 1996 May 9;334(19):1268–9; discussion 1270. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Gershenson DM, et al. **Obstet Gynecol** 1996 Apr; 87(4):527–31

Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Rose FV, et al. **Oncogene** 1996 Mar 7;12(5):999–1003

The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Cameron MR, et al. **Oncol Res** 1995;7(3–4):145–56

P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Yang X, et al. **Oncol Res** 1995;7(12):619–24

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Bruzzone M, et al. **Oncology** 1996 Sep-Oct;53(5):349–53

Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Falkson CI, et al. **Oncology** 1996 Jul-Aug;53(4):313–7

Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Fennelly D, et al. **Oncology (Huntingt)** 1995 Oct;9(10):911–21; discussion 922, 924, 926 (59 ref.)

Carboplatin versus cisplatin in ovarian cancer. Alberts DS. **Semin Oncol** 1995 Oct;22(5 Suppl 12):88–90 (6 ref.)

Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Bolis G. **Semin Oncol** 1995 Dec;22(6 Suppl 14):32–4

Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Braakhuis BJ, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):42–6

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Calvert AH, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):91–8; discussion 99–100

Intraperitoneal paclitaxel in the management of ovarian cancer. Markman M. **Semin Oncol** 1995 Oct;22(5 Suppl 12):86–7

Ifosfamide in the treatment of ovarian cancer. Markman M. **Semin Oncol** 1996 Jun;23(3 Suppl 6):47–9 (22 ref.)

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Meerpohl HG, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):7–12

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)

Current status of chemotherapy for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Oct;22(5 Suppl 12):61–6 (33 ref.)

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Paine GD, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):35–9

Interaction between cisplatin and gemcitabine in vitro and in vivo. Peters GJ, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):72–9

Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Rose PG. **Semin Oncol** 1996 Aug;23(4 Suppl 8):83–9

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Ruiz van Haperen VW, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):35–41

The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23–31 (30 ref.)

Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. Locatelli MC, et al. **Support Care Cancer** 1996 May;4(3):218–9

[Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer] Deng C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar; 31(3):159–62 (Eng. Abstr.) **(Chi)**

[Multidrug resistance—genes and chemotherapy of ovarian cancer] Leng J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep;75(9):567–9 (7 ref.) **(Chi)**

[Was chemotherapy beneficial for the patients with advanced ovarian cancer? A comparison of survival and resource use in two different time periods] Bertelsen K, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4767–70 (Eng. Abstr.) **(Dan)**

[Taxans in the treatment of ovarian cancer] Tuxen MK, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3951–2 **(Dan)**

[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**

[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer] Chauvergne J, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):315–23 (52 ref.) (Eng. Abstr.) **(Fre)**

[Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over] Delva R, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):63–69 (36 ref.) (Eng. Abstr.) **(Fre)**

[Implantable sites in cancerology. The percutaneous technique. Results of a homogeneous series of 141 cases] Maillart P, et al. **J Chir (Paris)** 1995 Dec;132(12):495–8 (Eng. Abstr.) **(Fre)**

[Convulsions in a patient treated for ovarian adenocarcinoma] Le Moing V, et al. **Rev Med Interne** 1996;17 Suppl 2:234s–236s **(Fre)**

–Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study– Kuhn W, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):105–10 (Eng. Abstr.) **(Ger)**

[Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma] Lahousen M. **Wien Med Wochenschr** 1995;145(24):663–8 (Eng. Abstr.) **(Ger)**

[Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb–IV ovarian carcinoma: cisplatin–paclitaxel vs. carboplatin–paclitaxel. AGO Protocol Ovar–3] Mettler L. **Zentralbl Gynakol** 1996;118(6):379–4 **(Ger)**

[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**

[A case of ovarian malignant Sertoli–Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy] Fujimoto A, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1843–6 (Eng. Abstr.) **(Jpn)**

[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma] Kajino T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):115–7 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors] Kitada M, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):87–91 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for recurrent ovarian cancer] Nishimura H, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1124–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Phase II study of paclitaxel (BMS–181339) in patients with ovarian cancer by 3–hour intravenous infusion] Noda K, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):317–25 (Eng. Abstr.) **(Jpn)**

[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT–11 and mitomycin C] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):587–93 (Eng. Abstr.) **(Jpn)**

[Use of intraperitoneal chemotherapy in patients with clinical stage I ovarian neoplasms] Emerich J, et al. **Ginekol Pol** 1996 Apr;67(4):195–9 (Eng. Abstr.) **(Pol)**

[The individualization of the drug therapy of ovarian cancer] Novikov EG, et al. **Vopr Onkol** 1995;41(2):124–5 **(Rus)**

[The intraperitoneal chemotherapy of patients with ovarian cancer] Shparyk IaV, et al. **Vrach Delo** 1995 Jan–Feb; (1–2):29–35 (48 ref.) **(Ukr)**

ECONOMICS

Estimating the costs attributable to a disease with application to ovarian cancer. Etzioni R, et al. **J Clin Epidemiol** 1996 Jan;49(1):95–103

EMBRYOLOGY

Two cases of twisted fetal ovarian cysts. Yokoyama Y, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):85–8

ENZYMOLOGY

NM23 in Ovarian Cancer. Correlation with clinicopathological and biochemical parameters. Ferrandina G, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:509–12

Tissue and serum metalloproteinase (MMP–2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Garzetti GG, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2799–804

Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Kitawaki J, et al. **Anticancer Res** 1996 Jan–Feb;16(1):91–7

Glutathione–S–transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Wrigley EC, et al. **Br J Cancer** 1996 Mar;73(6):763–9

Evidence for coupling of phosphotyrosine phosphatase to gonadotropin–releasing hormone receptor in ovarian carcinoma membrane. Imai A, et al. **Cancer** 1996 Jan 1; 77(1):132–7

Urokinase plasminogen activator in ovarian cancer. Gleeson NC, et al. **Eur J Gynaecol Oncol** 1996;17(2):110–3

The effect of insulin and insulin–like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal–like tumor cell model. McGee EA, et al. **Fertil Steril** 1996 Jan;65(1):87–93

Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Young TN, et al. **Gynecol Oncol** 1996 Jul;62(1):89–99

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin–based chemotherapy in advanced ovarian carcinoma. Cornarotti M, et al. **Int J Cancer** 1996 Aug 7;67(4):479–84

Trypsinogen expression in human ovarian carcinomas. Hirahara F, et al. **Int J Cancer** 1995 Oct 9;63(2):176–81

Immunohistochemical expression of glutathione S–transferase pi (GST–pi) and chemotherapy response in malignant ovarian tumors. Hirazono K, et al. **J Obstet Gynaecol** 1995 Jun;21(3):305–12

[An immunohistological study on expression of glutathione S–transferase pi (form) in human ovarian carcinoma] Satoh T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):931–8 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record–linkage study. Bergfeldt K, et al. **Acta Oncol** 1995;34(6):771–7

Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Auranen A, et al. **Am J Epidemiol** 1996 Sep 15;144(6):548–53

Univariate and multivariate analysis of risk factors for ovarian cancer: case–control study, Mexico City. Bernal A, et al. **Arch Med Res** 1995 Autumn;26(3):245–9

Cancer incidence in the first–degree relatives of ovarian cancer patients. Auranen A, et al. **Br J Cancer** 1996 Jul; 74(2):280–4

Long–term follow–up of patients with advanced ovarian cancer treated in randomised clinical trials. Warwick J, et al. **Br J Cancer** 1995 Dec;72(6):1513–7

The genetic attributable risk of breast and ovarian cancer. Claus EB, et al. **Cancer** 1996 Jun 1;77(11):2318–24

Neoplastic and non–neoplastic ovarian disease in Zimbabwean women. Stanczuk G. **Cent Afr J Med** 1995 Sep;41(9):274–8

Physical activity, waist–to–hip ratio, and other risk factors for ovarian cancer: a follow–up study of older women. Mink PJ, et al. **Epidemiology** 1996 Jan;7(1):38–45

Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case–control study. Survey of Women's Health Study Group. Purdie D, et al. **Int J Cancer** 1995 Sep 15;62(6):678–84

The epidemiology of ovarian cancer. Tortolero–Luna G, et al. **J Cell Biochem Suppl** 1995;23:200–7 (55 ref.)

Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in The Netherlands. Koper NP, et al. **Obstet Gynecol** 1996 Sep;88(3):387–93

[Epidemiology of ovarian cancer] Mosgaard BJ, et al. **Ugeskr Laeger** 1996 Sep 9;158(37):5150–3 (40 ref.) (Eng. Abstr.) **(Dan)**

[Homogeneity of the spatial distribution of cancers of the female reproductive tract in Quebec] Drapeau A, et al. **Soc Sci Med** 1995 Oct;41(7):949–55 (Eng. Abstr.) **(Fre)**

[Ovarian teratomas: some clinical and statistical factors based on 456 patients operated on in the Institute of Gynecology and Obstetrics Academy of Medicine in Lodz] Gwóźdź AZ, et al. **Ginekol Pol** 1996 Mar;67(3):129–34 (Eng. Abstr.) **(Pol)**

[Ovarian cancer and selected life style habits] Pawlęga J, et al. **Ginekol Pol** 1995 Jan;66(1):41–5 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case–control study. Risch HA, et al. **Am J Epidemiol** 1996 Aug 15;144(4):363–72

Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Cramer DW, et al. **Ann Epidemiol** 1995 Jul;5(4):310–4

Ovarian cancers related to minimal access surgery [see comments] Crawford RA, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):726–30. Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):185–6. Comment in: Br J Obstet Gynaecol 1996 May;103(5):486.

Ovarian cancers related to minimal access surgery [letter; comment] O'Connor H, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):185–6. Comment on: Br J Obstet Gynaecol 1995 Sep;102(9):726–30.

A prospective study of reproductive factors and risk of epithelial ovarian cancer. Hankinson SE, et al. **Cancer** 1995 Jul 15;76(2):284–90

Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Risch HA, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):447–51

Increased reproductive tract tumors in the female offspring of mice fed a high fat diet during the fetal stage of pregnancy. Walker BE, et al. **Cancer Lett** 1995 Oct 20; 97(1):57–60

Ovulation induction, infertility, and ovarian cancer risk. Bristow RE, et al. **Fertil Steril** 1996 Oct;66(4):499–507 (49 ref.)

Characteristics relating to ovarian cancer: implication for prevention and detection [letter; comment] Menczer J. **Gynecol Oncol** 1996 Feb;60(2):331. Comment on: Gynecol Oncol 1994 Dec;55(3 Pt 2):S15–9.

A case–control investigation on cancer of the ovary in Bangalore, India. Nandakumar A, et al. **Int J Cancer** 1995 Nov 3;63(3):361–5

A meta–analytical approach examining the potential relationship between talc exposure and ovarian cancer. Gross AJ, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):181–95

Breast and ovarian cancer incidence after infertility and in vitro fertilisation [see comments] Venn A, et al. **Lancet** 1995 Oct 14;346(8981):995–1000. Comment in: Lancet 1995 Dec 16;346(8990):1627–8. Comment in: Lancet 1995 Dec 16;346(8990):1628.

Mechanisms of hormone–mediated carcinogenesis of the ovary in mice. Capen CC, et al. **Mutat Res** 1995 Dec; 333(1–2):143–51 (23 ref.)

Hormones and cancer in humans. Key TJ. **Mutat Res** 1995 Dec;333(1–2):59–67 (85 ref.)

Chemically associated toxicity and carcinogenicity of the ovary. Davis BJ, et al. **Prog Clin Biol Res** 1996;394:285–308 (72 ref.)

GENETICS

Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Auranen A, et al. **Am J Epidemiol** 1996 Sep 15;144(6):548–53

A common BRCA1 mutation in Norwegian breast and ovarian cancer families? [letter] Andersen TI, et al. **Am J Hum Genet** 1996 Aug;59(2):486–7

Two distinct origins of a common BRCA1 mutation in breast–ovarian cancer families: a genetic study of 15 185delAG–mutation kindreds. Berman DB, et al. **Am J Hum Genet** 1996 Jun;58(6):1166–76

Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Ford D, et al. **Am J Hum Genet** 1995 Dec;57(6):1457–62

Rapid detection of regionally clustered germ–line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Gayther SA, et al. **Am J Hum Genet** 1996 Mar;58(3):451–6

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Johannsson O, et al. **Am J Hum Genet** 1996 Mar;58(3):441–50

Genetic heterogeneity of breast–ovarian cancer revisited. Breast Cancer Linkage Consortium [letter] Narod S, et al. **Am J Hum Genet** 1995 Oct;57(4):957–8

A high incidence of BRCA1 mutations in 20 breast–ovarian cancer families. Serova O, et al. **Am J Hum Genet** 1996 Jan;58(1):42–51

Segregation of two BRCA1 mutations in a single family [letter] Stoppa–Lyonnet D, et al. **Am J Hum Genet** 1996 Aug;59(2):479–81

Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. Tsuchiya K, et al. **Am J Hum Genet** 1995 Dec;57(6):1400–7

Evidence for a unifocal origin in familial ovarian cancer. Gallion HH, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1102–6; discussion 1106–8

Monoallelic expression of the insulin–like growth factor–2 gene in ovarian cancer. Yun K, et al. **Am J Pathol** 1996 Apr;148(4):1081–7

Ovarian cancer. A model system to study cancer genetics. Arzimanoglou II, et al. **Ann N Y Acad Sci** 1995 Sep 30; 768:253–6

BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Feunteun J, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):177–80 (42 ref.)

Gonadotropin–releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Blaakaer J, et al. **Biol Reprod** 1995 Oct;53(4):775–9

Cancer incidence in the first–degree relatives of ovarian cancer patients. Auranen A, et al. **Br J Cancer** 1996 Jul; 74(2):280–4

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Bartlett JM, et al. **Br J Cancer** 1996 Feb;73(3):301–6

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour–suppressor loci. Devlin J, et al. **Br J Cancer** 1996 Feb;73(4):420–3

The genetics of breast and ovarian cancer. Ford D, et al. **Br J Cancer** 1995 Oct;72(4):805–12 (69 ref.)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Foulkes WD, et al. **Br J Cancer** 1995 Oct;72(4):883–8

Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1–21. Tavassoli M, et al. **Br J Cancer** 1996 Jul;74(1):115–9

WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Wan M, et al. **Br J Cancer** 1996 Jun;73(11):1398–400

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Legal and ethical issues in genetic testing and counseling for susceptibility to breast, ovarian and colon cancer. Dickens BM, et al. **Can Med Assoc J** 1996 Mar 15; 154(6):813–8

A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer.

Macdonald KG, et al. **Can Med Assoc J** 1996 Feb 15; 154(4):457–64

Familial ovarian cancer. Update and clinical applications. Claus EB, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1998–2003 (62 ref.)

Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Demirel D, et al. **Cancer** 1996 Apr 15;77(8):1494–500

The molecular basis of ovarian cancer. Gallion HH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1992–7 (37 ref.)

Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Jishi MF, et al. **Cancer** 1995 Oct 15;76(8):1416–21

The role of DNA flow cytometry in borderline malignant ovarian tumors. Lai CH, et al. **Cancer** 1996 Aug 15; 78(4):794–802

Overexpression or mutation of the p53 tumor suppressor gene does not occur in malignant ovarian germ cell tumors [see comments] Liu FS, et al. **Cancer** 1995 Jul 15;76(2):291–5 . Comment in: Cancer 1996 Jul 1;78(1):179–81.

Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage [see comments] Marcus JN, et al. **Cancer** 1996 Feb 15;77(4):697–709. Comment in: Cancer 1996 Feb 15;77(4):599–601.

Overexpression or mutation of the p53 tumor suppressor gene does not occur in malignant ovarian germ cell tumors [letter; comment] Marx L, et al. **Cancer** 1996 Jul 1; 78(1):179–81. Comment on: Cancer 1995 Jul 15;76(2):291–5.

Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium. Shenson DL, et al. **Cancer** 1995 Aug 15; 76(4):650–7

Significance of lymphocytic sister chromatid exchange frequencies in ovarian cancer patients. Dhar PK, et al. **Cancer Genet Cytogenet** 1996 Jul 15;89(2):105–8

p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Lee JH, et al. **Cancer Genet Cytogenet** 1995 Nov;85(1):43–50

Monosomy 22 in two ovarian granulosa cell tumors. Lindgren V, et al. **Cancer Genet Cytogenet** 1996 Jul 15; 89(2):93–7

Cytogenetic findings in four malignant mixed mesodermal tumors of the ovary. Pejovic T, et al. **Cancer Genet Cytogenet** 1996 May;88(1):53–6

Amplification of 19q13.1–q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Thompson FH, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):55–62

A unique clonal chromosome 2 deletion in endomyometriosis. Verhest A, et al. **Cancer Genet Cytogenet** 1996 Feb; 86(2):174–6

Chromosome abnormalities in primary endometrioid ovarian carcinoma. Yonescu R, et al. **Cancer Genet Cytogenet** 1996 Apr;87(2):167–71

Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. Lorigan PC, et al. **Cancer Lett** 1996 Jun 24;104(1):27–30

A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Phillips NJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):85–90

Inheritance of abnormal expression of SOS-like response in xeroderma pigmentosum and hereditary cancer-prone syndromes. Abrahams PJ, et al. **Cancer Res** 1996 Jun 1; 56(11):2621–5

Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S, et al. **Cancer Res** 1996 Jul 1; 56(13):3087–90

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Berman DB, et al. **Cancer Res** 1996 Aug 1;56(15):3409–14

Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Bryan EJ, et al. **Cancer Res** 1996 Feb 15;56(4):719–21

Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Davis M, et al. **Cancer Res** 1996 Feb 15;56(4):741–4

Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Foster KA, et al. **Cancer Res** 1996 Aug 15;56(16):3622–5

Definition and refinement of a region of loss of heterozygosity at 11q23.3–q24.3 in epithelial ovarian cancer associated with poor prognosis. Gabra H, et al. **Cancer Res** 1996 Mar 1;56(5):950–4

Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Iwabuchi H, et al. **Cancer Res** 1995 Dec 15;55(24):6172–80

Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Jiang X, et al. **Cancer Res** 1996 Aug 1;56(15):3534–9

High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Johannesdottir G, et al. **Cancer Res** 1996 Aug 15;56(16):3663–5

Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Muto MG, et al. **Cancer Res** 1996 Mar 15; 56(6):1250–2

X chromosome inactivation and microsatellite instability in early and advanced bilateral ovarian carcinomas. Park TW, et al. **Cancer Res** 1995 Nov 1;55(21):4793–6

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P, et al. **Cancer Res** 1996 Feb 1; 56(3):556–62

Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Phillips NJ, et al. **Cancer Res** 1996 Feb 1; 56(3):606–11

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Righetti SC, et al. **Cancer Res** 1996 Feb 15;56(4):689–93

Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Risinger JI, et al. **Cancer Res** 1995 Dec 1;55(23):5664–9

Mutations of the BRCA2 gene in ovarian carcinomas. Takahashi H, et al. **Cancer Res** 1996 Jun 15;56(12):2738–41

Frequent microsatellite instability in epithelial borderline ovarian tumors. Tangir J, et al. **Cancer Res** 1996 Jun 1; 56(11):2501–5

Amplifications of proto-oncogenes in ovarian carcinoma. Bian M, et al. **Chin Med J (Engl)** 1995 Nov;108(11):844–8

Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas. Volm M, et al. **Clin Exp Metastasis** 1996 May;14(3):209–14

Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Foulkes WD, et al. **Clin Invest Med** 1995 Dec;18(6):473–83 (52 ref.)

Ovarian tumors display persistent microsatellite instability caused by mutation in the mismatch repair gene hMSH-2. Orth K, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:349–56

Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. Foster K, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2392–5

Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner Familial Ovarian Cancer Registry. Piver MS, et al. **Eur J Gynaecol Oncol** 1996;17(3):169–76

Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Cooke IE, et al. **Genes Chromosomes Cancer** 1996 Apr;15(4):223–33

Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Kobayashi K, et al. **Genes Chromosomes Cancer** 1995 Oct;14(2):128–32

AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. Saha V, et al. **Genes Chromosomes Cancer** 1995 Nov; 14(3):220–2

An investigation to determine whether clusters of cancer types exist in nine breast-ovary families. Bansal A, et al. **Genet Epidemiol** 1995;12(6):841–6

A gene (DLG2) located at 17q12–q21 encodes a new homologue of the Drosophila tumor suppressor dlg-A. Mazoyer S, et al. **Genomics** 1995 Jul 1;28(1):25–31

Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Wong YF, et al. **Gynecol Obstet Invest** 1995;40(3):209–12

DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Medl M, et al. **Gynecol Oncol** 1995 Dec;59(3):321–6

DNA index reflects the biological behavior of ovarian carcinoma stage I–IIa. Schueler JA, et al. **Gynecol Oncol** 1996 Jul;62(1):59–66

p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Skilling JS, et al. **Gynecol Oncol** 1996 Jan;60(1):72–80

p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Skilling JS, et al. **Gynecol Oncol** 1996 May; 61(2):180–8

DNA index by flow cytometric analysis: an additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation. Zanetta G, et al. **Gynecol Oncol** 1996 Aug;62(2):208–12

Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Zanetta GM, et al. **Gynecol Oncol** 1996 Feb; 60(2):213–6

Genetic counseling for familial cancer risk. Weitzel JN. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):57–69 (17 ref.)

Detection of chromosome aberrations in paraffin sections of seven gonadal yolk sac tumors of childhood. Jenderny J, et al. **Hum Genet** 1995 Dec;96(6):644–50

The murine homolog of the human breast and ovarian cancer susceptibility gene Brca1 maps to mouse chromosome 11D. Schröck E, et al. **Hum Genet** 1996 Feb;97(2):256–9

Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Matsushima M, et al. **Hum Mol Genet** 1995 Oct;4(10):1953–6

Detection of BRCA1 mutations by the protein truncation test. Plummer SJ, et al. **Hum Mol Genet** 1995 Oct; 4(10):1989–91

Inherited breast and ovarian cancer. Szabo CI, et al. **Hum Mol Genet** 1995;4 Spec No:1811–7 (64 ref.)

Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Chuaqui RF, et al. **Hum Pathol** 1996 Feb;27(2):165–71

Ovarian small cell carcinoma with K-ras mutation: a case report with genetic analysis. Idei Y, et al. **Hum Pathol** 1996 Jan;27(1):77–9

LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Campbell IG, et al. **Int J Cancer** 1995 Oct 9;63(2):222–5

Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Courjal F, et al. **Int J Cancer** 1996 Aug 22;69(4):247–53

Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Easton DF, et al. **Int J Cancer** 1996 Jan 26; 65(3):284–94

Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Fujita M, et al. **Int J Cancer** 1995 Dec 20;64(6):361–6

Risk modifiers in carriers of BRCA1 mutations. Narod SA, et al. **Int J Cancer** 1995 Dec 20;64(6):394–8

Genetic alterations distinguish different types of ovarian tumors. Pieretti M, et al. **Int J Cancer** 1995 Dec 20; 64(6):434–40

Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Yamada A, et al. **Int J Cancer** 1995 Dec 20;64(6):388–93

Evaluation of chromosome 12 copy number in ovarian granulosa cell tumors using interphase cytogenetics. Halperin D, et al. **Int J Gynecol Pathol** 1995 Oct; 14(4):319–23

Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. Drummond JT, et al. **J Biol Chem** 1996 Aug 16;271(33):19645–8

nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. Scambia G, et al. **J Clin Oncol** 1996 Feb; 14(2):334–42

Molecular genetics of familial breast-ovarian cancer. van Rensburg EJ, et al. **J Clin Pathol** 1995 Sep;48(9):789–95 (64 ref.)

Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic. Gregory H, et al. **J Med Genet** 1996 Mar; 33(3):187–92

Familial cluster of ovarian small cell carcinoma: a new mendelian entity? Longy M, et al. **J Med Genet** 1996 Apr; 33(4):333–5

BRCA2 as a low-penetrance cancer gene [letter] Boyd J. **J Natl Cancer Inst** 1996 Oct 2;88(19):1408–9

Role of the X chromosome in cancer [editorial; comment] Brown CJ. **J Natl Cancer Inst** 1996 Apr 17;88(8):480–2. Comment on: J Natl Cancer Inst 1996 Apr 17;88(8):510–8.

Potential role of the inactivated X chromosome in ovarian epithelial tumor development [see comments] Cheng PC, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):510–8. Comment in: J Natl Cancer Inst 1996 Apr 17;88(8):480–2.

Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. Lancaster JM, et al. **J Natl Cancer Inst** 1996 Apr 17; 88(8):552–4

Hereditary Breast, Ovarian, and Colon Cancer. Proceedings of a workshop. Washington, D.C., April 27–29, 1994. **J Natl Cancer Inst Monogr** 1995;(17):i–vii, 1–137

Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations. Couch FJ, et al. **J Natl Cancer Inst Monogr** 1995;(17):9–14

Developing intervention/prevention strategies for individuals at high risk of developing hereditary ovarian cancer. Gallion HH, et al. **J Natl Cancer Inst Monogr** 1995; (17):103–6

Defining, identifying, and studying high-risk families: developing cohorts for epidemiologic study. Harrington DP, et al. **J Natl Cancer Inst Monogr** 1995;(17):91–4

Scale-up technology: moving predictive tests for inherited breast, ovarian, and colon cancers from the bench to the bedside and beyond. Holtzman NA. **J Natl Cancer Inst Monogr** 1995;(17):95–7

Hereditary cancers: from discovery to intervention. Knudson AG Jr. **J Natl Cancer Inst Monogr** 1995;(17):5–7

Translational research on hereditary colon, breast, and ovarian cancers. Li FP. **J Natl Cancer Inst Monogr** 1995; (17):1–4 (26 ref.)

Prophylactic oophorectomy in inherited breast/ovarian cancer families. Struewing JP, et al. **J Natl Cancer Inst Monogr** 1995;(17):33–5

Women at risk of ovarian cancer. Wardle J. **J Natl Cancer Inst Monogr** 1995;(17):81–5

Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. Chen KC, et al. **J Obstet Gynaecol** 1995 Dec;21(6):619–24

Familial risk factors for a second primary malignancy in endometrial or ovarian carcinoma. Shiromizu K, et al. **J Obstet Gynaecol** 1995 Jun;21(3):269–72

p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. McManus DT, et al. **J Pathol** 1996 Jun;179(2):177–82

3-Year-old phenotypic female with campomelic dysplasia and bilateral gonadoblastoma. Hong JR, et al. **J Pediatr Surg** 1995 Dec;30(12):1735–7

Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. Hatta Y, et al. **J Urol** 1995 Nov;154(5):1954–7

BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes [see comments] Lerman C, et al. **JAMA** 1996

Jun 26;275(24):1885–92. Comment in: JAMA 1996 Jun 26;275(24):1928–9.
p53 polymorphism in ovarian and breast cancer [letter; comment] Campbell IG, et al. **Lancet** 1996 Feb 10; 347(8998):393–4. Comment on: Lancet 1995 Apr 15;345(8955):994.
BRCA1 mutations in young women with breast cancer [letter] Struewing JP, et al. **Lancet** 1996 May 25; 347(9013):1493
New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families [letter] Wagner TM, et al. **Lancet** 1996 May 4;347(9010):1263
Association of BRCA1 expression with gonadotropin–responsive cells [letter] Wan M, et al. **Lancet** 1996 Jul 20;348(9021):192–3
Behold BRCA2! [editorial; comment] **Nat Genet** 1996 Mar; 12(3):222. Comment on: Nat Genet 1996 Mar;12(3):333–7.
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation. Gayther SA, et al. **Nat Genet** 1995 Dec; 11(4):428–33
A common BRCA1 mutation in the Ashkenazim [news; comment] Goldgar DE, et al. **Nat Genet** 1995 Oct; 11(2):113–4. Comment on: Nat Genet 1995 Oct;11(2):198–200.
Box BRCA1 tumour inhibition [news; comment] Goodman L. **Nat Genet** 1996 Mar;12(3):224. Comment on: Nat Genet 1996 Mar;12(3):298–302.
Growth retardation and tumour inhibition by BRCA1 [see comments] Holt JT, et al. **Nat Genet** 1996 Mar; 12(3):298–302. Comment in: Nat Genet 1996 Mar;12(3):223–5.
BRCA1 is secreted and exhibits properties of a granin [see comments] Jensen RA, et al. **Nat Genet** 1996 Mar; 12(3):303–8. Comment in: Nat Genet 1996 Mar;12(3):223–5. Comment in: Nat Genet 1996 Jul;13(3):264–5. Comment in: Nat Genet 1996 Jul;13(3):268; discussion 269–72. Comment in: Nat Genet 1996 Jul;13(3):268–9; discussion 269–72.
BRCA2 mutations in primary breast and ovarian cancers. Lancaster JM, et al. **Nat Genet** 1996 Jun;13(2):238–40
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Neuhausen S, et al. **Nat Genet** 1996 May;13(1):126–8
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Phelan CM, et al. **Nat Genet** 1996 Mar;12(3):309–11
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals [see comments] Struewing JP, et al. **Nat Genet** 1995 Oct; 11(2):198–200. Comment in: Nat Genet 1995 Oct;11(2):113–4.
Panel softens cancer gene test warning [news] Wadman M. **Nature** 1996 Apr 18;380(6575):573
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast–ovarian cancer susceptibility gene. Lancaster JM, et al. **Obstet Gynecol** 1996 Feb;87(2):306–9
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl–2. Eliopoulos AG, et al. **Oncogene** 1995 Oct 5;11(7):1217–28
Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Rodabaugh KJ, et al. **Oncogene** 1995 Oct 5;11(7):1249–54
A gene on 6q 14–21 restores senescence to immortal ovarian tumor cells. Sandhu AK, et al. **Oncogene** 1996 Jan 18; 12(2):247–52
An abundance of p53 null mutations in ovarian carcinoma. Skilling JS, et al. **Oncogene** 1996 Jul 4;13(1):117–23
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Tangir J, et al. **Oncogene** 1996 Feb 15;12(4):735–40
Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Wertheim I, et al. **Oncogene** 1996 May 16;12(10):2147–53
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):136–40
Molecular genetic features of ovarian cancer. Berchuck A, et al. **Prog Clin Biol Res** 1996;394:269–84 (85 ref.)
Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)
[Amplification of proto–oncogenes C–myc, C–N–ras, C–Ki–ras, C–erbB2 in ovarian carcinoma] Bian M, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):406–9 (Eng. Abstr.) **(Chi)**
[Hereditary ovarian cancer syndrome] Chen W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr;31(4):249–51 (24 ref.) **(Chi)**
[Vaginal cancer in a woman with a family history of ovarian cancer] Bőeze P, et al. **Orv Hetil** 1995 Dec 10; 136(50):2731–2 (Eng. Abstr.) **(Hun)**
[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study] Nagai N. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1004–9 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Familial ovarian cancer, uterine cancer] Fushiki H, et al. **Nippon Rinsho** 1995 Nov;53(11):2769–72 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of familial aggregation of ovarian and breast cancer in patients with ovarian cancer] Ichikawa Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):901–6 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Development and characterization of an interleukin–2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. Santin AD, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):633–40
Establishment of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. Neungton N, et al. **Asian Pac J Allergy Immunol** 1995 Jun; 13(1):47–53
Polymorphic epithelial mucin (MUC–1)–containing circulating immune complexes in carcinoma patients. Gourevitch MM, et al. **Br J Cancer** 1995 Oct;72(4):934–8
A novel tumor–associated antigen expressed in human uterine and ovarian carcinomas. Sonoda K, et al. **Cancer** 1996 Apr 15;77(8):1501–9
Change in MIB–1 staining between primary and recurrent epithelial ovarian cancer. Geisler JP, et al. **Eur J Gynaecol Oncol** 1995;16(5):343–5
Ascitic fluid–associated lymphocytes in patients with metastatic ovarian cancer. Analysis of lymphocyte subsets and of phenotypical changes induced by "in vitro". Loiudice L, et al. **Eur J Gynaecol Oncol** 1995;16(4):301–6
Expression of A, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. Welshinger M, et al. **Gynecol Oncol** 1996 Jul; 62(1):106–12
Transduction of rIL–2 expanded CD4+ and CD8+ ovarian TIL–derived T cell lines with the G1Na (neor) replication–deficient retroviral vector. Nash MA, et al. **Hum Gene Ther** 1995 Nov;6(11):1379–89
Evaluation of tumor immunity in patients with ovarian cancer after immunoscintigraphy in a long–term follow–up. Donnerstag B, et al. **Hybridoma** 1995 Apr;14(2):191–7
Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti–CA125 murine monoclonal antibody B43.13. Madiyalakan R, et al. **Hybridoma** 1995 Apr;14(2):199–203
Serum soluble interleukin–2 receptors in epithelial ovarian cancer patients. Pavlidis NA, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):75–80
Clinical significance of the tumour markers CA 125 II and CA 72–4 in ovarian carcinoma. Hasholzner U, et al. **Int J Cancer** 1996 Aug 22;69(4):329–34
Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Yin BW, et al. **Int J Cancer** 1996 Feb 8;65(4):406–12
Distribution of OV–TL 3 and MOv18 in normal and malignant ovarian tissue. Buist MR, et al. **J Clin Pathol** 1995 Jul;48(7):631–6
Spontaneous release of interleukin–6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. Burger RA, et al. **J Interferon Cytokine Res** 1995 Mar;15(3):255–60
Relationship of preoperative serum CA–125 to survival in epithelial ovarian carcinoma. Geisler JP, et al. **J Reprod Med** 1996 Mar;41(3):140–2
Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. Taylor DD, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):289–94
Humoral anti–OV–TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients. Tibben JG, et al. **Nucl Med Commun** 1995 Oct;16(10):853–9
[Immunostimulating protein 90K in ovarian carcinoma] Zeimet AG, et al. **Gynakol Geburtshilfliche Rundsch** 1996; 36(1):44–5 (Eng. Abstr.) **(Ger)**

METABOLISM

Parathyroid hormone–related protein in benign lesions [editorial; comment] Bruns DE, et al. **Am J Clin Pathol** 1996 Apr;105(4):377–9. Comment on: Am J Clin Pathol 1996 Apr;105(4):487–92.
The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.). Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.
The effect of transforming growth factor–beta on steroidogenesis and expression of key steroidogenic enzymes with a human ovarian thecal–like tumor cell model. Carr BR, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1109–16; discussion 1116–7
Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Kauppila S, et al. **Am J Pathol** 1996 Feb;148(2):539–48
Energetic characteristics of cisplatin resistant ovarian carcinoma cells. Dorward AM, et al. **Anticancer Res** 1996 Jan–Feb;16(1):443–7
nm23 expression in advanced and borderline ovarian carcinoma. Schneider J, et al. **Anticancer Res** 1996 May–Jun;16(3A):1197–202
Expression of alpha–fetoprotein by ovarian Sertoli–Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075–9 (29 ref.)
Metabolism of irinotecan to SN–38 in a tissue–isolated tumor model. Atsumi R, et al. **Biol Pharm Bull** 1995 Jul; 18(7):1024–6
Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer. Aitokallio–Tallberg A, et al. **Br J Cancer** 1995 Oct;72(4):1020–2
Expression and prognostic significance of Bcl–2 in ovarian tumours. Henriksen R, et al. **Br J Cancer** 1995 Nov; 72(5):1324–9
Increased insulin–like growth factor binding protein–2 (IGFBP–2) gene expression and protein production lead to high IGFBP–2 content in malignant ovarian cyst fluid. Kanety H, et al. **Br J Cancer** 1996 May;73(9):1069–73
Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Ottensmeier C, et al. **Br J Cancer** 1996 Aug;74(3):446–52
A case of ovarian carcinoma with production of granulocyte colony–stimulating factor. Sudo S, et al. **Br J Haematol** 1996 Jan;92(1):137–9
Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Weiner LM, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):141–50
Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. el–akawi Z, et al. **Cancer Lett** 1996 Jul 19;105(1):5–14
MDR1 and multidrug resistance–associated protein (MRP) gene expression in epithelial ovarian tumors. Kavallaris M, et al. **Cancer Lett** 1996 Apr 19;102(1–2):7–16
The prognostic significance of Bcl–2 and p53 expression in ovarian carcinoma. Herod JJ, et al. **Cancer Res** 1996 May 1;56(9):2178–84
Taxol–dependent transcriptional activation of IL–8 expression in a subset of human ovarian cancer. Lee LF, et al. **Cancer Res** 1996 Mar 15;56(6):1303–8
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Lewis GD, et al. **Cancer Res** 1996 Mar 15;56(6):1457–65
Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Pizer ES, et al. **Cancer Res** 1996 Mar 15;56(6):1189–93
Expression of nm23–H1 gene product in thyroid, ovary, and breast cancers. Okubo T, et al. **Cell Biophys** 1995 Jun; 26(3):205–13
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Di Simone N, et al. **Endocrinology** 1996 Feb;137(2):486–94
Expression of sex hormone–binding globulin mRNA in human ovarian cancers. Misao R, et al. **Eur J Endocrinol** 1995 Sep;133(3):327–34
EGF–R and PCNA expression in ovarian carcinomas—correlation with classic prognostic factors. Minguillon C, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):197–201
Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gercel–Taylor C, et al. **Gynecol Oncol** 1996 Jan;60(1):35–41
Mitotic count, nuclear atypia, and immunohistochemical determination of Ki–67, c–myc, p21–ras, c–erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki–67 are indicators of poor prognosis. King LA, et al. **Gynecol Oncol** 1996 May;61(2):227–32
Overexpression of p53 is not a feature of ovarian granulosa cell tumors. Liu FS, et al. **Gynecol Oncol** 1996 Apr; 61(1):50–3
Characterization of the protein synthesis independent TNFalpha lytic mechanism in human ovarian and cervical carcinoma cell lines. Powell CB, et al. **Gynecol Oncol** 1996 Jul;62(1):42–8
Subcellular localization of accumulated p53 in ovarian cancer cells. Runnebaum IB, et al. **Gynecol Oncol** 1996 May; 61(2):266–71
Differential effects of high–dose gamma irradiation on the production of transforming growth factor–beta in fresh and established human ovarian cancer. Santin AD, et al. **Gynecol Oncol** 1996 Jun;61(3):403–8
Small cell carcinoma of the ovary of the hypercalcemic type: p53 protein accumulation and clinicopathologic features. Seidman JD. **Gynecol Oncol** 1995 Nov;59(2):283–7
Transfection of human ovarian cancer cells with the HER–2/neu receptor tyrosine kinase induces a selective increase in PTP–H1, PTP–1B, PTP–alpha expression. Wiener JR, et al. **Gynecol Oncol** 1996 May;61(2):233–40
A paradoxical inhibition of androgenic hyperproduction by a Sertoli–Leydig cell tumour ovary. Amato G, et al. **Hum Reprod** 1995 Nov;10(11):2967–9
Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. Portela A, et al. **In Vivo** 1995 Jul–Aug;9(4):341–6
Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Barboule N, et al. **Int J Cancer** 1995 Nov 27; 63(5):611–5
Implication of the alpha v beta 3 integrin in the adhesion of the ovarian–adenocarcinoma cell line IGROV1. Carreiras F, et al. **Int J Cancer** 1995 Nov 15;63(4):530–6
Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. McGuckin MA, et al. **Int J Cancer** 1995 Nov 3;63(3):412–8
DNA–binding properties of novel cis– and trans

platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Mellish KJ, et al. **Int J Cancer** 1995 Sep 15;62(6):717-23

Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Moser TL, et al. **Int J Cancer** 1996 Sep 4;67(5):695-701

MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas [letter] Russo V, et al. **Int J Cancer** 1996 Jul 29;67(3):457-60

Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Santin AD, et al. **Int J Cancer** 1996 Mar 1;65(5):688-94

c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Wiechen K, et al. **Int J Cancer** 1995 Nov 15;63(4):604-8

72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. De Nictolis M, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):102-9

Resting energy expenditure of patients with gynecologic malignancies [see comments] Dickerson RN, et al. **J Am Coll Nutr** 1995 Oct;14(5):448-54. Comment in: J Am Coll Nutr 1995 Oct;14(5):409-10.

Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. Imai A, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3249-53

Human ovarian tumor cells: a potential model for thecal cell steroidogenesis. Rainey WE, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):257-63

EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. Meden H, et al. **J Obstet Gynaecol** 1995 Apr;21(2):167-78

SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. Hua W, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3-4):279-89

Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Abu-Jawdeh GM, et al. **Lab Invest** 1996 Jun;74(6):1105-15

Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Neyns B, et al. **Oncogene** 1996 Mar 21;12(6):1247-57

The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Cameron MR, et al. **Oncol Res** 1995;7(3-4):145-56

Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation. Suzuki M, et al. **Oncology** 1996 Mar-Apr;53(2):99-103

Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Clinton GM, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):316-20

MORTALITY

Ovarian cancer [letter; comment] Hall JA. **CA Cancer J Clin** 1995 Nov-Dec;45(6):375-6. Comment on: CA Cancer J Clin 1994 Mar-Apr;44(2):71-80.

Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Bolis G, et al. **Cancer** 1996 Jan 1;77(1):128-31

Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Massi D, et al. **Cancer** 1996 Mar 15;77(6):1131-6

Ovarian cancer mortality among immigrants in Australia and Canada. Kliewer EV, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):453-8

A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Allen DG, et al. **Eur J Gynaecol Oncol** 1995;16(5):349-56

Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer. Kruitwagen RF, et al. **Gynecol Oncol** 1996 Feb;60(2):233-7

Incidence and effects on survival of abdominal wall metastases at trocar [letter] van Dam PA. **Gynecol Oncol** 1996 Aug;62(2):322-4

Long-term follow-up of women with borderline ovarian tumors. Kehoe S, et al. **Int J Gynaecol Obstet** 1996 May; 53(2):139-43

nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. Scambia G, et al. **J Clin Oncol** 1996 Feb; 14(2):334-42

Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. Geisler JP, et al. **J Reprod Med** 1996 Mar;41(3):140-2

Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in The Netherlands. Koper NP, et al. **Obstet Gynecol** 1996 Sep;88(3):387-93

-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results- Nagele E, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):79-82 (Eng. Abstr.) (Ger)

NURSING

Specialist breast and ovarian cancer clinics should be staffed by oncologist nurses [letter; comment] Stoll BA. **BMJ** 1996 Apr 6;312(7035):913. Comment on: BMJ 1995 Dec 16;311(7020):1584-5.

PATHOLOGY

Diagnostic efficacy of endometrial cytology with the Abradul cell sampler supplemented by laser scanning confocal microscopy. Boon ME, et al. **Acta Cytol** 1996 Mar-Apr;40(2):277-82

Neuroblastoma arising in a mature ovarian teratoma [letter] Imai S, et al. **Acta Cytol** 1996 Mar-Apr;40(2):380-2

Serous surface papillary carcinoma of the ovary metastatic to a cervical polyp. A case report. Jiménez-Ayala M, et al. **Acta Cytol** 1996 Jul-Aug;40(4):765-9

The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer. Engblom PR, et al. **Acta Oncol** 1995; 34(6):783-5

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122-4 (8 ref.)

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Diebold J, et al. **Am J Clin Pathol** 1996 Mar; 105(3):341-9

Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology. Harlozińska A, et al. **Am J Clin Pathol** 1996 Mar;105(3):334-40

Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Risch HA, et al. **Am J Epidemiol** 1996 Aug 15;144(4):363-72

Growth modulatory effects of granulocyte-macrophage colony-stimulating factor on human cell lines derived from gynecologic malignancies. Herzog TJ, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):161-8

The role of tumor necrosis factor receptors in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines. Kost ER, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):145-53

Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Wolf NG, et al. **Am J Pathol** 1996 Aug;149(2):511-20

Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Yeo TK, et al. **Am J Pathol** 1996 Jun;148(6):1733-40

Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Clement PB, et al. **Am J Surg Pathol** 1996 Sep;20(9):1067-80

Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Cuatrecasas M, et al. **Am J Surg Pathol** 1996 Jun;20(6):739-46

Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm. Analysis of six cases. Nogales FF, et al. **Am J Surg Pathol** 1996 Sep;20(9):1056-66

Primary squamous cell carcinoma of the ovary. Report of 37 cases. Pins MR, et al. **Am J Surg Pathol** 1996 Jul; 20(7):823-33

Unclassified ovarian gonadal stromal tumors. A clinicopathologic study of 32 cases. Seidman JD. **Am J Surg Pathol** 1996 Jun;20(6):699-706

Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Tornos C, et al. **Am J Surg Pathol** 1995 Dec;19(12):1343-53

Struma ovarii with metaplasia [letter; comment] Tresserra F, et al. **Am J Surg Pathol** 1996 Feb;20(2):251. Comment on: Am J Surg Pathol 1995 Jan;19(1):21-9.

Volume-weighted mean nuclear volume and nuclear area in advanced ovarian carcinoma. An investigation of sampling methods, sample size and reproducibility. Brinkhuis M, et al. **Anal Quant Cytol Histol** 1995 Aug; 17(4):284-90

Sensitivity of breast and ovarian cancer cells for interferons (IFNs) and retinoids. Daxenbichler G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:294-303

Development of murine (OC-147) and human (H-106) monoclonal antibodies reactive with a 53-kDa ovarian tumor-associated antigen. Mruthinti S, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:264-8

Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Cormio G, et al. **Ann Oncol** 1995 Jul;6(6):571-4

Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Saunders DE, et al. **Anticancer Drugs** 1995 Aug;6(4):562-9

Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line. Griffon G, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):177-87

nm23 expression in advanced and borderline ovarian carcinoma. Schneider J, et al. **Anticancer Res** 1996 May-Jun;16(3A):1197-202

CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. Speiser P, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2767-9

Growth regulation of multidrug resistant ovarian cancer cells by 1D7 monoclonal antibody. Yang X, et al. **Anticancer Res** 1996 Jan-Feb;16(1):273-6

Postmenopausal virilization due to ovarian hyperthecosis. Agorastos T, et al. **Arch Gynecol Obstet** 1995;256(4):209-11

A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue. Nakanishi T, et al. **Arch Gynecol Obstet** 1995;256(4):177-84

Multiple primary neoplasms. Ovarian carcinoid tumor, mucinous cystadenoma of low malignant potential tumor of left ovary, and adenocarcinoma of the colon. Capaldo GR, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):393-6

Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075-9 (29 ref.)

Steroid cell tumor of the broad ligament arising in an accessory ovary. Roth LM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):405-9

Practice protocol for the examination of specimens removed from patients with ovarian tumors. A basis for checklists. Cancer Committee, College of American Pathologists. Task Force on the Examination of Specimens Removed from Patients with Ovarian Tumors. Scully RE, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1012-22

Gonadal mixed germ cell tumor combined with a large hemangiomatous lesion [letter; comment] Talerman A. **Arch Pathol Lab Med** 1995 Nov;119(11):992-3. Comment on: Arch Pathol Lab Med 1994 Nov;118(11):1135-8.

Luteinized thecoma with sclerosing peritonitis. Werness BA. **Arch Pathol Lab Med** 1996 Mar;120(3):303-6 (9 ref.)

Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. O'Dwyer PJ, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):21-7

Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Ross AA, et al. **Bone Marrow Transplant** 1995 Jun;15(6):929-33

The prognostic value of morphometry in advanced epithelial ovarian cancers. Katsoulis M, et al. **Br J Cancer** 1995 Oct; 72(4):958-63

Recurrent adenocarcinoma of the ovary presenting as skin nodules [letter] Mills CM, et al. **Br J Dermatol** 1996 May; 134(5):986-7

Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Demirel D, et al. **Cancer** 1996 Apr 15;77(8):1494-500

The borderland between benign and malignant surface epithelial ovarian tumors. Current controversy over the nature and nomenclature of "borderline" ovarian tumors. Lawrence WD. **Cancer** 1995 Nov 15;76(10 Suppl):2138-42

Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Massi D, et al. **Cancer** 1996 Mar 15;77(6):1131-6

Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Onda T, et al. **Cancer** 1996 Aug 15;78(4):803-8

Practice protocol for the examination of specimens removed from patients with ovarian tumors. A basis for checklists. Members of the Cancer Committee, College of American Pathologists, Task Force on the Examination of Specimens Removed from Patients with Ovarian Tumors. Scully RE, et al. **Cancer** 1996 Aug 15;78(4):927-40

Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Taniki T, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):295-302

Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. McIlwrath AJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):423-8

Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). Moorehead RA, et al. **Cancer Chemother Pharmacol** 1996; 38(3):245-53

Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells. Ohishi Y, et al. **Cancer Chemother Pharmacol** 1996;38(2):141-6

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Ormerod MG, et al. **Cancer Chemother Pharmacol** 1996;37(5):463-71

Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Krtolica A, et al. **Cancer Res** 1996 Mar 1;56(5):1168-73

Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16 Mirakhur B, et al. **Cancer Res** 1996 May 15; 56(10):2256-62

X chromosome inactivation and microsatellite instability in early and advanced bilateral ovarian carcinomas. Park TW, et al. **Cancer Res** 1995 Nov 1;55(21):4793-6

Ovarian tumours in Africans: a study of 512 cases. Lancaster EJ, et al. **Cent Afr J Med** 1995 Aug;41(8):245-8 (13 ref.)

Ovarian sclerosing stromal tumor with minor sex cord elements. Guo L, et al. **Chin Med J (Engl)** 1995 Dec; 108(12):935-7

Adenosquamous carcinoma and schneiderian papilloma-like

lesion in a mature cystic teratoma of the ovary: a case report. Hsu CY, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1996 May;57(5):375–9
Fine-needle aspiration cytology of the ovary. Ganjei P.
Clin Lab Med 1995 Sep;15(3):705–26 (19 ref.)
New developments in sex cord-stromal and germ cell tumors of the ovary. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):595–610 (50 ref.)
Epithelial neoplasms of the ovary. An update on current concepts. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):575–93 (46 ref.)
SR8—the establishment and characterisation of a new ovarian carcinoma cell line and xenograft model. Han X, et al. **Eur J Cancer** 1996 Jan;32A(1):160–7
Sertoli–Leydig cell tumor of the ovary: a clinicopathologic study of 10 cases. Ayhan A, et al.
Eur J Gynaecol Oncol 1996;17(1):75–8
Squamous cell carcinoma arising from mature cystic teratoma: a report of three cases. Bontis J, et al.
Eur J Gynaecol Oncol 1996;17(1):49–52 (20 ref.)
Primary ovarian lymphoma with liver metastases: report of one case. Breda E, et al. **Eur J Gynaecol Oncol** 1996; 17(1):53–4
Early ovarian cancer: value of a negative staging laparotomy. Faught W, et al. **Eur J Gynaecol Oncol** 1996;17(3):200–3
Thyroid carcinoma originating in a teratoma of the ovary. Ferrer J, et al. **Eur J Gynaecol Oncol** 1995;16(5):396–402 (24 ref.)
Ovarian fibroma. A report of three cases. Gargano G, et al. **Eur J Gynaecol Oncol** 1995;16(6):509–15
Change in MIB–1 staining between primary and recurrent epithelial ovarian cancer. Geisler JP, et al.
Eur J Gynaecol Oncol 1995;16(5):343–5
Primary lymphoma of the ovary. A case report and critical review of the literature. Grȣnovsky–Grisaru S, et al.
Eur J Gynaecol Oncol 1995;16(5):392–5 (14 ref.)
Cytologic assessment of metastatic ovarian carcinoma. Kuwashima Y, et al. **Eur J Gynaecol Oncol** 1996; 17(2):123–7
Pathological aspects of normal-sized ovarian carcinoma. Kuwashima Y, et al. **Eur J Gynaecol Oncol** 1996; 17(1):17–23
Cell dynamics of undifferentiated carcinomas of the ovary. Immunohistochemical estimation of their growth fraction and apoptotic status. Kuwashima Y, et al.
Eur J Gynaecol Oncol 1995;16(4):268–73
Ovarian surface serous papillary carcinomas: a clinicopathologic study. Liapis A, et al.
Eur J Gynaecol Oncol 1996;17(1):79–82
Epithelial ovarian tumors in young women under 35 years. Marchetti M, et al. **Eur J Gynaecol Oncol** 1995;16(6):488–93
Hepatobiliary cystadenoma with mesenchymal stroma (CMS) in association with unilateral mucinous cystadenoma of the ovary (MCO): case report and review of the literature. Skopelitou A, et al. **Eur J Gynaecol Oncol** 1996; 17(3):234–40
In vivo analysis of the 'bystander effect': a cytokine cascade. Ramesh R, et al. **Exp Hematol** 1996 Jun;24(7):829–38
Virilizing stromal Leydig cell tumor (Leydig cell–containing thecoma) of the ovary in pregnancy. A case report with extensive immunohistochemical investigation of the tumor cells. Horny HP, et al. **Gen Diagn Pathol** 1995 May; 141(1):57–60
Proliferative activity and p53 over-expression of ovarian epithelial tumors. Kuwata T, et al. **Gen Diagn Pathol** 1995 Oct;141(2):131–9
Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Alama A, et al. **Gynecol Oncol** 1996 Jul;62(1):82–8
Platinum–based chemotherapy for advanced–stage serous ovarian carcinoma of low malignant potential. Barakat RR, et al. **Gynecol Oncol** 1995 Dec;59(3):390–3
Laparoscopic surgical staging of ovarian cancer. Childers JM, et al. **Gynecol Oncol** 1995 Oct;59(1):25–33 (30 ref.)
Primary ovarian carcinoid tumors. Davis KP, et al.
Gynecol Oncol 1996 May;61(2):259–65 (46 ref.)
Transitional cell bladder carcinoma with presentation mimicking ovarian carcinoma. Erickson DR, et al.
Gynecol Oncol 1996 May;61(2):294–6
Pilomatricoma–like endometrioid adenosquamous carcinoma of the ovary with neuroendocrine differentiation. Fang J, et al. **Gynecol Oncol** 1996 May;61(2):291–3
Malignant degeneration of a mature cystic teratoma five decades after discovery. Griffiths D, et al.
Gynecol Oncol 1995 Dec;59(3):427–9
Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer. Guidozzi F, et al.
Gynecol Oncol 1996 May;61(2):204–9
Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Kadar N, et al. **Gynecol Oncol** 1995 Dec; 59(3):394–7
Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Karlan BY, et al. **Gynecol Oncol** 1995 Oct;59(1):67–74
Serous psammocarcinoma of the ovary in an adolescent female. Kelley JL, et al. **Gynecol Oncol** 1995 Nov; 59(2):309–11
Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309–13
The accuracy of a frozen section diagnosis of borderline ovarian malignancy. Menzin AW, et al. **Gynecol Oncol** 1995 Nov;59(2):183–5
Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. O'Hanlan KA, et al. **Gynecol Oncol** 1995 Nov; 59(2):200–6
The prognostic implication of ascites in advanced–stage ovarian cancer. Puls LE, et al. **Gynecol Oncol** 1996 Apr; 61(1):109–12
Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Sainz de la Cuesta R, et al.
Gynecol Oncol 1996 Feb;60(2):238–44
DNA index reflects the biological behavior of ovarian carcinoma stage I–IIa. Schueler JA, et al.
Gynecol Oncol 1996 Jul;62(1):59–66
Primary lymphatic dissemination of malignant elements in a mature cystic ovarian teratoma [letter; comment] Shetty MR. **Gynecol Oncol** 1996 Apr;61(1):156. Comment on: Gynecol Oncol 1995 May;57(2):250–3.
Epithelial ovarian carcinoma metastatic to the central nervous system: a report on two cases with review of literature. Sood A, et al. **Gynecol Oncol** 1996 Jul; 62(1):113–8 (36 ref.)
Incidence and effects on survival of abdominal wall metastases at trocar [letter] van Dam PA.
Gynecol Oncol 1996 Aug;62(2):322–4
Squamous cell carcinoma of the ovary. Ellis JR, et al.
Hawaii Med J 1995 Aug;54(8):704–5, 707
Strumal carcinoid of the ovary associated with hyperinsulinaemic hypoglycaemia and cutaneous melanosis. Ashton MA. **Histopathology** 1995 Nov;27(5):463–7
Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB–1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. Costa MJ, et al.
Hum Pathol 1996 Mar;27(3):274–81
Microinvasion in low malignant potential tumors of the ovary. Nayar R, et al. **Hum Pathol** 1996 Jun;27(6):521–7 (17 ref.)
Low malignant potential tumors of the ovary: does microinvasion matter? [editorial] Powell DE.
Hum Pathol 1996 Jun;27(6):517–8
The value of cyst puncture in the differential diagnosis of benign ovarian tumours. Vercellini P, et al.
Hum Reprod 1995 Jun;10(6):1465–9
Malignant mixed mesodermal (Mullerian) tumour of ovary. Vaideeswar P, et al. **Indian J Pathol Microbiol** 1994 Dec; 37 Suppl:S21–2
Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Barboule N, et al. **Int J Cancer** 1995 Nov 27; 63(5):611–5
Epithelial–mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor–beta1. Kitagawa K, et al.
Int J Cancer 1996 Mar 28;66(1):91–7
Growth of ovarian–carcinoma cell lines at physiological folate concentration: effect on folate–binding protein expression in vitro and in vivo. Miotti S, et al.
Int J Cancer 1995 Nov 3;63(3):395–401
c–jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines. Spinner DM, et al. **Int J Cancer** 1995 Nov 3;63(3):423–7
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Supino R, et al. **Int J Cancer** 1996 Feb 8;65(4):491–7
Malignant ovarian germ cell tumors. Chow SN, et al.
Int J Gynaecol Obstet 1996 May;53(2):151–8
Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Scully RE.
Int J Gynaecol Obstet 1995 Jul;49 Suppl:S9–15 (13 ref.)
Transvaginal trucut biopsy in patients with abdominopelvic mass. Sheth SS, et al. **Int J Gynaecol Obstet** 1995 Jul; 50(1):27–31
Synchronous primary carcinomas of the endometrium and ovary. Sheu BC, et al. **Int J Gynaecol Obstet** 1995 Nov; 51(2):141–6
Limited invasiveness to assess retroperitoneal spread in stage I–II ovarian carcinoma. Zanetta G, et al.
Int J Gynaecol Obstet 1995 Nov;51(2):133–40
Sertoliform endometrial adenocarcinoma: a study of four cases. Eichhorn JH, et al. **Int J Gynecol Pathol** 1996 Apr; 15(2):119–26
Neuroendocrine carcinoma arising in an ovarian mucinous cystadenoma. Jones K, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):167–70
Mixed strumal and mucinous carcinoid tumor of the ovary. Matías–Guiu X, et al. **Int J Gynecol Pathol** 1995 Apr; 14(2):179–83
Lipid cell (steroid cell) tumor of the ovary: immunophenotype with analysis of potential pitfall due to endogenous biotin–like activity. Seidman JD, et al.
Int J Gynecol Pathol 1995 Oct;14(4):331–8
Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type. Siriaunkgul S, et al.
Int J Gynecol Pathol 1995 Jul;14(3):198–208
Transitional cell carcinoma arising within a paratubal cyst: report of a case. Thomason RW, et al.
Int J Gynecol Pathol 1995 Jul;14(3):270–3
Mucosal epithelial proliferation of the fallopian tube: a particular association with ovarian serous tumor of low malignant potential? Yanai–Inbar I, et al.
Int J Gynecol Pathol 1995 Apr;14(2):107–13
Desmoplastic small cell tumor of the ovary: a unique polyphenotypic tumor with an unfavorable prognosis. Zaloudek C, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):260–5 (28 ref.)
Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Thames HD, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):951–62
Pathology of ovarian cancer precursors. Scully RE.
J Cell Biochem Suppl 1995;23:208–18 (23 ref.)
Targeted tumor killing via an intracellular antibody against erbB–2. Deshane J, et al. **J Clin Invest** 1995 Dec; 96(6):2980–9
Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. Barnhill DR, et al.
J Clin Oncol 1995 Nov;13(11):2752–6
Carcinosarcoma arising in a dermoid cyst of the ovary. Arora DS, et al. **J Clin Pathol** 1996 Jun;49(6):519–21
Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. Brinkhuis M, et al. **J Clin Pathol** 1996 Feb;49(2):142–8
Gonadoblastoma and chroiocarcinoma in dysgenic gonads: report of a case. Liu YC, et al. **J Formos Med Assoc** 1995 Sep;94(9):568–71
Ovarian serous cystadenoma associated with Sertoli–Leydig cell tumor—a case report. Seo EJ, et al.
J Korean Med Sci 1996 Feb;11(1):84–7
Primary ovarian carcinoid: a mixture of insular, trabecular and mucinous components. Kasantikul V, et al.
J Med Assoc Thai 1996 Mar;79(3):200–4
Malignant Brenner tumor of the ovary: two cases of unusual histologic features of relapsed tumors. Kataoka A, et al.
J Obstet Gynaecol 1995 Jun;21(3):249–56
Ovarian mucinous cystadenocarcinoma with sarcoma–like mural nodules. Kataoka A, et al.
J Obstet Gynaecol Res 1996 Feb;22(1):51–6
Ascitic positive cytology and intraperitoneal metastasis in ovarian dysgerminoma. Mandai M, et al.
J Obstet Gynaecol Res 1996 Feb;22(1):89–94
Immunologic characterization of tumor markers in human ovarian cancer cell lines. Kutteh WH, et al.
J Soc Gynecol Investig 1996 Jul–Aug;3(4):216–22
"Adenoid cystic" and basaloid carcinomas of the ovary: evidence for a surface epithelial lineage. A report of 12 cases. Eichhorn JH, et al. **Mod Pathol** 1995 Sep;8(7):731–40
Ovarian granulosa cell tumors with bizarre nuclei: an immunohistochemical analysis. Gaffey MJ, et al.
Mod Pathol 1996 Mar;9(3):308–15
Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Kupryjanczyk J, et al.
Mod Pathol 1996 Mar;9(3):166–73
Transformation of ovarian dysgerminoma to yolk sac tumor: evidence for a histogenetic continuum. Parkash V, et al.
Mod Pathol 1995 Oct;8(8):881–7
Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha–subunit promoter/simian virus T–antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin–responsive granulosa cell lines. Kananen K, et al. **Mol Endocrinol** 1995 May; 9(5):616–27
The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases. Corn BW, et al. **Obstet Gynecol** 1995 Dec;86(6):955–9 (17 ref.)
Ovarian lipoma of teratomatous origin. Gardella C, et al.
Obstet Gynecol 1996 May;87(5 Pt 2):874–5
Laparotomy to complete staging of presumed early ovarian cancer. Stier EA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):737–40
Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Wertheim I, et al. **Oncogene** 1996 May 16;12(10):2147–53
Liposome–mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER–2/neu. Yu D, et al. **Oncogene** 1995 Oct 5; 11(7):1383–8
Mucinous carcinoma of the ovary. Clinicopathologic analysis. Kikkawa F, et al. **Oncology** 1996 Jul–Aug; 53(4):303–7
Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Sekiguchi I, et al.
Oncology 1996 Jan–Feb;53(1):19–26
p53 mutation in carcinomas arising in ovarian cystic teratomas. Fujii T, et al. **Pathol Int** 1995 Sep;45(9):649–54
Clear cell carcinoma simulating the "endometrioid–like variant" of yolk sac tumor. Ballotta MR, et al.
Pathologica 1995 Feb;87(1):87–90
Ovarian Sertoli–Leydig cell tumor with retiform pattern. Moyles K, et al. **Pathology** 1995 Oct;27(4):371–3
Ovarian cancer: staging with CT and MR imaging. Forstner R, et al. **Radiology** 1995 Dec;197(3):619–26
Mixed tumor: mucinous papillary cystadenocarcinoma associated with arrhenoblastoma. Curea M, et al.
Rom J Morphol Embryol 1995 Jul–Dec;41(3–4):129–31
Indications for laparoscopic surgery of ovarian tumors. Konno R, et al. **Tohoku J Exp Med** 1996 Mar;178(3):225–31

Gonadoblastoma with coexistent features of mixed germ cell–sex cord stroma tumor: a case report. Colafranceschi M, et al. **Tumori** 1995 May–Jun;81(3):215–8

Estrogen activates migration potential of endometrial cancer cells through basement membrane. Fujimoto J, et al. **Tumour Biol** 1996;17(1):48–57

Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Kurbacher CM, et al. **Tumour Biol** 1995; 16(6):374–84

Recurrent granulosa cell tumor with associated Müllerian epithelium. Hammar SP. **Ultrastruct Pathol** 1996 Jan–Feb; 20(1):73–78

Monomorphic (basal cell) salivary adenoma of ovary: report of a case. Russell P, et al. **Ultrastruct Pathol** 1995 Sep–Oct; 19(5):431–8

[Malignant Müllerian mixed tumors of the female genitalia] Mainkhard K, et al. **Akush Ginekol (Sofiia)** 1995;34(2):39–41 (Eng. Abstr.) **(Bul)**

[Combined neoplasms in the Mayer–RokLitansky–Küster syndrome] Savov I, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):60–2 (Eng. Abstr.) **(Bul)**

[Synergistic effects of tumor necrosis factor interferon–gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro] Li J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):429–31 (Eng. Abstr.) **(Chi)**

[Gonadotropins stimulate the proliferation of human epithelial ovarian cancer cell] Feng Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):166–8 (Eng. Abstr.) **(Chi)**

[Androgen receptors and effects of sex hormones on growth of a human ovarian carcinoma cell line] Lu J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):360–2 (Eng. Abstr.) **(Chi)**

[Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells] Wu L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):166–8 (Eng. Abstr.) **(Chi)**

[Autocrine transforming growth factor–beta stimulates human ovarian cancer cell growth in vitro and in vivo] Xiong S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):22–4 (Eng. Abstr.) **(Chi)**

[Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo] Zhou Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan; 31(1):25–8 (Eng. Abstr.) **(Chi)**

[Establishment and characterization of a model of highly metastatic human ovarian cancer transplanted subcutaneously into nude mice] Xu S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Feb;25(1):33–5 (Eng. Abstr.) **(Chi)**

[Two case of androgen–secreting ovary tumor] Dai W, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug;17(4):317–20 (Eng. Abstr.) **(Chi)**

[The induction and differentiation of a human teratocarcinoma cell line (PA–1) in vitro] Xia SL, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Dec;28(4):397–407 (Eng. Abstr.) **(Chi)**

[Histogenesis of ovarian tumors] Jirásek JE. **Ceska Gynekol** 1996 Apr;61(2):108–11 **(Cze)**

[Ovarian carcinomas. Retrospective study of 318 cases] Randrianjafisamindrakotroka NS, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):711–6 (Eng. Abstr.) **(Fre)**

[Struma ovarii. A case report] Barhmi R, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):539–41 (10 ref.) (Eng. Abstr.) **(Fre)**

[Struma ovarii. Three malignant cases and one benign case] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):542–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Histology and cytology of laparoscopically operated "simple ovarian cysts"] Gerber B, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):369–73 (Eng. Abstr.) **(Ger)**

[Do cell cycle changes of human ovarian carcinoma cells after exposure to cytostatic drugs in vitro correlate with cytotoxicity?] Petru E, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:15–8 (Eng. Abstr.) **(Ger)**

[Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course] Reles A, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:93–7 (Eng. Abstr.) **(Ger)**

[Struma ovarii—case report of a rare ovarian tumor] Roegglen T, et al. **Zentralbl Gynakol** 1995;117(8):439–41 (Eng. Abstr.) **(Ger)**

[Value of prognostic factors in early stage ovarian carcinoma] Sevelda P. **Zentralbl Gynakol** 1996;118(6):326–9 (11 ref.) (Eng. Abstr.) **(Ger)**

[A mucinous ovarian tumor with foci of anaplastic carcinoma] Buzzi A, et al. **Minerva Ginecol** 1996 Apr; 48(4):163–6 (5 ref.) (Eng. Abstr.) **(Ita)**

[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

[Prognostic factors in ovarian epithelial cancer] Nishida T. **Gan To Kagaku Ryoho** 1996 May;23(6):805–9 (40 ref.) (Eng. Abstr.) **(Jpn)**

[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):945–7 **(Jpn)**

[Clinical features of epithelial ovarian cancer in young reproductive women] Nasu K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):911–6 (Eng. Abstr.) **(Jpn)**

[Homogeneous dysgerminoma of the ovary. Analysis of 25 cases] Kojs Z, et al. **Ginekol Pol** 1995 Apr;66(4):220–2 (Eng. Abstr.) **(Pol)**

[Carcinoma on the base of the ovarian struma] Szwalski J, et al. **Ginekol Pol** 1995 May;66(5):309–11 (Eng. Abstr.) **(Pol)**

[Comparative characteristics of the efficacy of cisplatin and carboplatin in relation to human primary ovarian cancer cells] Sviridova IK, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):208–10 **(Rus)**

[Bronchial obstruction due to carcinoma with psammoma and metastasis (clinical conference)] **Medicina (B Aires)** 1995;55(1):51–7 **(Spa)**

[Malignant melanoma in an ovarian dermoid cyst] Otero E, et al. **Rev Chil Obstet Ginecol** 1995;60(1):43–5 (Eng. Abstr.) **(Spa)**

[Cystic teratoma of the ovary and cancer: structural and histochemical study] Oviedo de Albiero M, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):23–5 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Wan M, et al. **Br J Cancer** 1996 Jun;73(11):1398–400

Transforming growth factor–alpha promotes tumor markers secretion from human ovarian cancers in vitro. Kurachi H, et al. **Cancer** 1996 Sep 1;78(5):1049–54

Intracellular antibody against erbB–2 mediates targeted tumor cell eradication by apoptosis. Deshane J, et al. **Cancer Gene Ther** 1996 Mar–Apr;3(2):89–98

Tumor–stromal cytokine interactions in ovarian neoplasms. Kacinski BM. **EXS** 1995;74:181–90 (59 ref.)

Adrenal function following high–dose steroids in ovarian cancer patients. Del Priore G, et al. **Gynecol Oncol** 1995 Oct;59(1):102–4

Sensitization of human ovarian tumor cells by subtoxic CDDP to anti–fas antibody–mediated cytotoxicity and apoptosis. Uslu R, et al. **Gynecol Oncol** 1996 Aug; 62(2):282–91

Transvaginal color flow imaging in the diagnosis of ovarian tumors. Tepper R, et al. **J Ultrasound Med** 1995 Oct; 14(10):731–4

Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Kurbacher CM, et al. **Tumour Biol** 1995; 16(6):374–84

PREVENTION & CONTROL

A survey of the practice of prophylactic oophorectomy by gynecologists in the state of Alaska. Conklin BH, et al. **Alaska Med** 1996 Apr–Jun;38(2):71–4

Prevention of ovarian cancer with bilateral oophorectomy at time of hysterectomy. McGuire PA, et al. **Alaska Med** 1996 Apr–Jun;38(2):69–70, 81 (13 ref.)

Development and characterization of an interleukin–2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. Santin AD, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):633–40

Gonadotropin–releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Blaakaer J, et al. **Biol Reprod** 1995 Oct;53(4):775–9

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Prophylactic bilateral oophorectomy to prevent epithelial carcinoma. Number 2—December 1994. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Jan;52(1):101–2

Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1–5, 1995. **J Cell Biochem Suppl** 1995; 23:1–250

Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)

Molecular approaches to prevention and detection of epithelial ovarian cancer. Bast RC Jr, et al. **J Cell Biochem Suppl** 1995;23:219–22 (21 ref.)

Prospective on ovarian cancer: why prevent? Hoskins WJ. **J Cell Biochem Suppl** 1995;23:189–99 (15 ref.)

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)

Is screening for ovarian cancer worthwhile? [letter] Vessey MP. **J Med Screen** 1995;2(1):57

Developing intervention/prevention strategies for individuals at high risk of developing hereditary ovarian cancer. Gallion HH, et al. **J Natl Cancer Inst Monogr** 1995; (17):103–6

Prophylactic oophorectomy in inherited breast/ovarian cancer families. Struewing JP, et al. **J Natl Cancer Inst Monogr** 1995;(17):33–5

PSYCHOLOGY

What I learned on my sabbatical [see comments] Barnard D. **Acad Med** 1996 Mar;71(3):257. Comment in: Acad Med 1996 Mar;71(3):256.

Save a seat on the bus for me. Cristo MG. **Am J Nurs** 1995 Sep;95(9):72

Case report: psychological response of a woman with schizo–affective disorder on discovering she had ovarian cancer. Morris MR, et al. **Br J Med Psychol** 1995 Dec;68 (Pt 4):349–51

New fears in gynecologic cancer. Smith PM, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2133–7

Quality of life of women with ovarian cancer. Kornblith AB, et al. **Gynecol Oncol** 1995 Nov;59(2):231–42

The effect of feedback on anxiety levels during ultrasound scanning for ovarian cancer. Tadmor OP, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):135–9

RADIOGRAPHY

Enhancing ascites: an aid to CT diagnosis. Wise SW, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):67–8

Mature cystic teratomas of the ovary: CT and MR findings. Guinet C, et al. **Eur J Radiol** 1995 Jul;20(2):137–43

Intravascular gas within an ovarian tumor: a CT sign of ovarian torsion. Kawahara Y, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):154–6

Imaging features of ovarian metastases from colonic adenocarcinoma in adolescents. Kauffman WM, et al. **Pediatr Radiol** 1995;25(4):286–8

Clinics in diagnostic imaging (7). Omental caking due to ovarian carcinoma. Helpert C, et al. **Singapore Med J** 1995 Dec;36(6):667–9

RADIONUCLIDE IMAGING

The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. Method MW, et al. **Cancer** 1996 Jun 1;77(11):2286–93

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

Radioimmunoscintigraphy of ovarian tumours with technetium–99m labelled monoclonal antibody–170: first clinical experiences. Alexander C, et al. **Eur J Nucl Med** 1995 Jul;22(7):645–51

Evaluation of tumor immunity in patients with ovarian cancer after immunoscintigraphy in a long–term follow–up. Donnerstag B, et al. **Hybridoma** 1995 Apr;14(2):191–7

Metabolic imaging of ovarian tumors with carbon–11–methionine: a PET study. Lapela M, et al. **J Nucl Med** 1995 Dec;36(12):2196–200

Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti–CA125 monoclonal antibody. Sakahara H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):655–61

[Image fusion of MRI and immunoscintigraphy with MAb–170 in ovarian tumors] Alexander C, et al. **Nuklearmedizin** 1995 Oct;34(5):173–8 (Eng. Abstr.) **(Ger)**

[Methodology and clinical usefulness of radioimmunoimaging using radiolabeled monoclonal antibodies] Endo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1604–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Comparison of monoclonal antibodies 17–1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Kievit E, et al. **Br J Cancer** 1996 Feb; 73(4):457–64

Radiotherapy as a cisplatin–sensitizer in a resistant ovarian carcinoma cell line. Siler DF, et al. **Cancer** 1996 May 1; 77(9):1850–3

Radiation–absorbed dose estimates to normal organs following intraperitoneal 186Re–labeled monoclonal antibody: methods and results. Breitz HB, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5817s–5822s

Radiotherapy with iodine–131 in recurrent malignant struma ovarii. Brenner W, et al. **Eur J Nucl Med** 1996 Jan; 23(1):91–4

Pharmacokinetics and biodistribution of samarium–153–labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Kraeber–Bodéré F, et al. **Eur J Nucl Med** 1996 May; 23(5):560–7

Abdomino pelvic irradiation after second–look laparotomy for stage III ovarian carcinoma. Chapet S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):43–8

Differential effects of high–dose gamma irradiation on the production of transforming growth factor–beta in fresh and established human ovarian cancer. Santin AD, et al. **Gynecol Oncol** 1996 Jun;61(3):403–8

Radioimmunotherapy of ovarian cancer. Syrigos KN, et al. **Hybridoma** 1995 Apr;14(2):121–4 (45 ref.)

Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case–control study. Kaldor JM, et al. **Int J Cancer** 1995 Sep 27;63(1):1–6

Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Thames HD, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):951–62

PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1073–9

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium–177–CC49. Meredith RF, et al. **J Nucl Med** 1996 Sep;37(9):1491–6

Pleuroperitoneal migration of intraperitoneal phosphorus–32–chromic phosphate therapy for stage I ovarian carcinoma. Wilkinson RH Jr. **J Nucl Med** 1996 Apr;37(4):636–9

Late renal function following whole abdominal irradiation. Irwin C, et al. **Radiother Oncol** 1996 Mar;38(3):257–61

SECONDARY

Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Abeln EC, et al. **Br J Cancer** 1995 Nov;72(5):1330–6

Prolactin–secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814–20 (43 ref.)

Renal cell carcinoma metastatic to the ovary. Ultrasound and CT appearance. Fields S, et al. **Clin Imaging** 1996 Jan–Mar;20(1):42–4

Reversible neurotoxicity during interleukin–2 therapy for metastatic renal cell carcinoma [letter] van Laar JM, et al. **Eur J Cancer** 1995 Oct;31A(11):1895–7

Cytologic assessment of metastatic ovarian carcinoma. Kuwashima Y, et al. **Eur J Gynaecol Oncol** 1996; 17(2):123–7

Gastric carcinoma presenting as a Krukenberg tumor in the 24th week of gestation. Tamussino K, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):251–2

Clinical implications of metastases to the ovary. Fujiwara K, et al. **Gynecol Oncol** 1995 Oct;59(1):124–8

Adrenal 4–binding protein in common epithelial and metastatic tumors of the ovary. Sasano H, et al. **Hum Pathol** 1996 Jun;27(6):595–8

Endometrial stromal sarcoma with focal smooth muscle differentiation: recurrence after 17 years: a follow–up report with discussion of the nomenclature. Khalifa MA, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):171–6

Malignant tumors metastatic to the ovaries. Ayhan A, et al. **J Surg Oncol** 1995 Dec;60(4):268–76

[Unilateral ovarian metastatic localization revealing a squamous cell carcinoma of the uterine cervix (letter)] Marais–Saint Frison MH, et al. **Ann Pathol** 1995; 15(6):455–6 **(Fre)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Metastatic malignant melanoma of the ovary] Tribbia G, et al. **Minerva Ginecol** 1996 Apr;48(4):159–62 (10 ref.) (Eng. Abstr.) **(Ita)**

SECRETION

Virilizing ovarian leiomyoma: androgen production by lining stromal cells. Carpén O, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):72–6

IL–6 secretion by human peritoneal mesothelial and ovarian cancer cells. Offner FA, et al. **Cytokine** 1995 Aug; 7(6):542–7

A two–site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma–derived cell line (PA–1). Wang QF, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1434–41

A case of ovarian serous adenocarcinoma suggestive of transformation to an AFP–producing tumor during chemotherapy. Kataoka A, et al. **J Obstet Gynaecol** 1995 Oct;21(5):451–9

SURGERY

Use of tetranectin, CA–125 and CASA to predict residual tumor and survival at second– and third–look operations for ovarian cancer. Høgdall CK, et al. **Acta Oncol** 1996; 35(1):63–9

Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. van Dam PA, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):943–50

Primary debulking surgery in advanced ovarian carcinoma. Kehoe S. **Br J Obstet Gynaecol** 1996 Apr;103(4):291–3

Ovarian cancer presenting in a laparoscopy scar and metastatic to the spleen. Lane G, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):386–7

Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation–embryo transfer. Lawal AH, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):931–2

Ovarian cancers related to minimal access surgery [letter; comment] Shepherd JH, et al. **Br J Obstet Gynaecol** 1996 May;103(5):486. Comment on: Br J Obstet Gynaecol 1995 Sep;102(9):726–30.

Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Eisenkop SM, et al. **Cancer** 1995 Nov 1;76(9):1606–14

Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long–term follow–up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Kennedy AW, et al. **Cancer** 1996 Jul 15; 78(2):278–86

Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Muntz HG, et al. **Cancer** 1995 Oct 1; 76(7):1209–13

Second–look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Muderspach L, et al. **Cancer Treat Rev** 1996 Nov;21(6):499–511 (60 ref.)

Vaginal ovarian cystectomy during vaginal hysterectomy. A case report. Gad N. **Clin Exp Obstet Gynecol** 1996; 23(1):39–40

Laparoscopic lymphadenectomy. Melendez TD, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):307–10 (20 ref.)

Surgery in ovarian cancer: the concept of cytoreductive surgery. Peter A, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):8–11 (15 ref.)

A meta–analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Allen DG, et al. **Eur J Gynaecol Oncol** 1995;16(5):349–56

Radiotherapy with iodine–131 in recurrent malignant struma ovarii. Brenner W, et al. **Eur J Nucl Med** 1996 Jan; 23(1):91–4

Laparoscopic management of malignant ovarian cysts: a 78–case national survey. Part 2: Follow–up and final treatment. Blanc B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):147–50

Epithelial ovarian carcinoma of low malignant potential. Darai E, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):141–5

Pelvic and periaortic pertioneal closure or non–closure at lymphadenectomy in ovarian cancer: effects on morbidity and adhesion formation. Kadanali S, et al. **Eur J Surg Oncol** 1996 Jun;22(3):282–5

Abdominal myomectomy: results of a simple operative technique. Acién P, et al. **Fertil Steril** 1996 Jan;65(1):41–51

Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852–9

Primary ovarian carcinoid tumors. Davis KP, et al. **Gynecol Oncol** 1996 May;61(2):259–65 (46 ref.)

ACOG Committee opinion. Second–look laparotomy for epithelial ovarian cancer. Number 165, December 1995 (replaces no. 100, November 1991). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Apr; 53(1):81–3

Lymphadenectomy in stage–III serous cystadenocarcinoma of the ovary. Fukasawa H, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):239–45

Conservative management of ovarian cancer in a 15–year–old patient. Shah S, et al. **Int J Gynaecol Obstet** 1995 Nov; 51(2):147–9

Surgical management of benign cystic teratoma. Laparoscopy vs. laparotomy. Howard FM. **J Reprod Med** 1995 Jul; 40(7):495–9

Laparoscopic surgery in patients with a ventriculoperitoneal shunt. A case report. Tobias DH, et al. **J Reprod Med** 1996 Feb;41(2):129–31

Removal of a 130 pound ovarian neoplasm. Puls LE, et al. **J S C Med Assoc** 1996 May;92(5):216–9

Ovarian cancer—1996 [editorial] Averette HE. **J Surg Oncol** 1996 Aug;62(4):237–8

Is there a role for second–look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy. Culine S, et al. **J Surg Oncol** 1996 May;62(1):40–5

Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. Kikkawa F, et al. **J Surg Oncol** 1995 Dec; 60(4):227–31

Reassessment of second look operation for epithelial ovarian cancer. Ushijima K, et al. **Kurume Med J** 1996;43(1):17–24

The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Benedetti–Panici P, et al. **Obstet Gynecol** 1996 Apr;87(4):532–8

Second surgical treatment of retroperitoneal persistent disease in epithelial ovarian cancer. Lupi G, et al. **Tumori** 1996 Jan–Feb;82(1):81–4

[Dysgerminoma of the ovary: a clinical retrospective analysis of 60 cases] Zhang R, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):550–2 (Eng. Abstr.) **(Chi)**

[Therapy of ovarian carcinoma in pregnancy] Rob L, et al. **Ceska Gynekol** 1996 Apr;61(2):99–101 **(Cze)**

[Role of laparoscopy in ovarian cancer (editorial)] Kadoch O, et al. **Ann Chir** 1996;50(3):217–8 **(Fre)**

[Borderline tumors and cancers of the ovary. Laparoscopic–surgical evaluation] Nicoloso E, et al. **Presse Med** 1995 Oct 21;24(31):1421–4 (Eng. Abstr.) **(Fre)**

[Ambulatory endoscopic surgery—ovary and leiomyoma] Gallinat A. **Arch Gynecol Obstet** 1995;257(1–4):17–21 **(Ger)**

[Contra endoscopic ovarian surgery] Kindermann G. **Arch Gynecol Obstet** 1995;257(1–4):107–15 **(Ger)**

[Pro endoscopic ovarian surgery] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):97–106 **(Ger)**

[Total pelviscopic removal of ovarian tumors in a bag bag posterior colpotomy] Bratschi HU, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):383–6 (Eng. Abstr.) **(Ger)**

[Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics] Kindermann G, et al. **Geburtshilfe Frauenheilkd** 1995 Dec; 55(12):687–94 (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of adnexa tumors using endobag extraction Kühn T, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):684–6 (Eng. Abstr.) **(Ger)**

[Morley inter–iliac transverse incision in gynecologic operations] Lellé RJ, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):695–8 (Eng. Abstr.) **(Ger)**

[Struma ovarii—a case report] Schutz R, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):154–5 (Eng. Abstr.) **(Ger)**

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[The future of surgical gynecology: from dogma to science—from science to practice standard] Sevelda P. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):149–52 (7 ref.) (Eng. Abstr.) **(Ger)**

[Isovolemic hemodilution for avoiding homologous blood transfusions: effectiveness in large gynecologic interventions] Oberhauser M, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):15–23 (Eng. Abstr.) **(Ger)**

[Preoperative diagnosis of malignancy of ovarian space–occupying lesions with special reference to new, laparoscopic surgical techniques] Roch G. **Wien Klin Wochenschr** 1995;107(17):529–31 **(Ger)**

[Characteristics of rare ovarian tumors—possibilities of organ preservation] Grischke EM, et al. **Zentralbl Gynakol** 1996; 118(6):322–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Ovarian tumors and pregnancy] Hahn U, et al. **Zentralbl Gynakol** 1996;118(6):334–5 (Eng. Abstr.) **(Ger)**

[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

[Hemoperitoneum from post–traumatic ovarian cystoma. Videolaparoscopic treatment] Saccia A. **Minerva Chir** 1995 Nov;50(11):1005–7 (Eng. Abstr.) **(Ita)**

[Clinical study on six cases of immature ovarian teratoma with special reference to the preservation of fertility] Fukuda T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):69–72 **(Jpn)**

[Conservative surgery for future pregnancy in young women with ovarian cancer] Miyazaki Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May;48(5):355–8 **(Jpn)**

[Characterization of intraoperative rupture of epithelial ovarian cancer at early stage] Nasu K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):907–10 (Eng. Abstr.) **(Jpn)**

[Teratoma of the ovary. Analysis of prognostic factors] Kojs Z, et al. **Ginekol Pol** 1995 Jul;66(7):416–9 (Eng. Abstr.) **(Pol)**

[Role of second–look surgery in treatment of ovarian neoplasms] Markowska J, et al. **Ginekol Pol** 1996 Apr; 67(4):200–4 (Eng. Abstr.) **(Pol)**

[Comparative study of observer agreement on location and size of ovarian tumor in transvaginal and transabdominal ultrasonic examinations with intraoperative evaluations from material of patients operated on in the Gynecology–Obstetrics Department of the Ministry of Internal Affairs Clinic in the years 1991–1994] Pietrzak P, et al. **Ginekol Pol** 1996 Mar;67(3):140–3 (Eng. Abstr.) **(Pol)**

[The surgical treatment of ovarian formations by a laparoscopic approach] Beloglazova SE, et al. **Akush Ginekol (Mosk)** 1995;(5):7–9 (Eng. Abstr.) **(Rus)**

[The endoscopic treatment of mature teratomas] Kudrina EA, et al. **Akush Ginekol (Mosk)** 1995;(5):10–2 **(Rus)**

[Possibilities of preserving reproductive function after therapy for early malignancies of the cervix uteri, endometrium and ovaries] Chissov VI, et al. **Vopr Onkol** 1996;42(2):107–11 (Eng. Abstr.) **(Rus)**

[Laparoscopy: an alternative to second–look laparotomy in ovarian cancer] Mayerson D, et al. **Rev Chil Obstet Ginecol** 1994;59(5):388–9 (Eng. Abstr.) **(Spa)**

THERAPY

The role of cul–de–sac aspiration cytology in the follow–up of ovarian cancer. Engblom PR, et al. **Acta Oncol** 1995; 34(6):783–5

Sensitivity of breast and ovarian cancer cells for interferons (IFNs) and retinoids. Daxenbichler G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:294–303

Early ovarian cancer: treat now, later or never? [editorial; comment] McGuire WP. **Ann Oncol** 1995 Nov;6(9):865–6 . Comment on: Ann Oncol 1995 Nov;6(9):887–93.

Effects of interferon gamma (IFN gamma) and tumor necrosis factor alpha (TNF alpha) association in intraperitoneal radioimmunotherapy: studies on an in vitro micrometastasis model. Imbert–Marcille BM, et al. **Anticancer Drug Des** 1995 Sep;10(6):491–505

Tumour targeting of the anti–ovarian carcinoma x anti–CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC, et al. **Anticancer Res** 1995 Sep–Oct;

15(5B):2169–74

Growth regulation of multidrug resistant ovarian cancer cells by 1D7 monoclonal antibody. Yang X, et al. **Anticancer Res** 1996 Jan–Feb;16(1):273–6

Long–term follow–up of patients with advanced ovarian cancer treated in randomised clinical trials. Warwick J, et al. **Br J Cancer** 1995 Dec;72(6):1513–7

The effect of the GM–CSF/IL–3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. Gheilmini M, et al. **Br J Haematol** 1996 Apr;93(1):6–12

The combination of erythropoietin and granulocyte colony–stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Pierelli L, et al. **Br J Haematol** 1996 Feb;92(2):287–94

Tandem high–dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Lotz JP, et al. **Cancer** 1996 Jun 15;77(12):2550–9

A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment. Raaphorst GP, et al. **Cancer Chemother Pharmacol** 1996;37(6):574–80

Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Weiner LM, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):141–50

Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice. Zhao E, et al. **Chin Med J (Engl)** 1995 Aug;108(8):571–5

Treatment of advanced epithelial ovarian cancer: past, present and future. Hoskins PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):41–59 (201 ref.)

Prognosis and management of borderline tumours of the ovary. Tropé C, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):12–6 (15 ref.)

Biologic therapies for gynecologic cancer. Bookman MA. **Curr Opin Oncol** 1995 Sep;7(5):478–84 (73 ref.)

Abdomino pelvic irradiation after second–look laparotomy for stage III ovarian carcinoma. Chapet S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):43–8

Mixed mesodermal sarcoma of the ovary in a young patient. Fowler JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):249–53

p53–based gene therapy of ovarian cancer: magic bullet? [editorial; comment] Berchuck A, et al. **Gynecol Oncol** 1995 Nov;59(2):169–70. Comment on: Gynecol Oncol 1995 Nov;59(2):171–8.

Targeted eradication of ovarian cancer mediated by intracellular expression of anti–erbB–2 single–chain antibody [see comments] Deshane J, et al. **Gynecol Oncol** 1995 Oct;59(1):8–14. Comment in: Gynecol Oncol 1995 Oct;59(1):6–7.

The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gogas H, et al. **Gynecol Oncol** 1996 Apr;61(1):22–6

Combination anti–gene therapy targeting c–myc and p53 in ovarian cancer cell lines. Janicek MF, et al. **Gynecol Oncol** 1995 Oct;59(1):87–92

Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian–American comparative study. LoCoco S, et al. **Gynecol Oncol** 1995 Nov;59(2):194–9

A phase I study of intraperitoneal interferon–alpha 2b and intravenous cis–platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Adenovirus–based p53 gene therapy in ovarian cancer [see comments] Santoso JT, et al. **Gynecol Oncol** 1995 Nov; 59(2):171–8. Comment in: Gynecol Oncol 1995 Nov;59(2):169–70.

In vivo gene therapy of ovarian cancer by adenovirus–mediated thymidine kinase gene transduction and ganciclovir administration. Tong XW, et al. **Gynecol Oncol** 1996 May;61(2):175–9

The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Freeman SM, et al. **Hum Gene Ther** 1995 Jul;6(7):927–39

A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor–associated antigen CA 125 for immunotherapy of ovarian cancer. Schlebusch H, et al. **Hybridoma** 1995 Apr;14(2):167–74

Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Schmolling J, et al. **Hybridoma** 1995 Apr;14(2):183–6

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Tibben JG, et al. **Int J Cancer** 1996 May 16;66(4):477–83

Concomitant low dose–rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Raaphorst GP, et al. **Int J Radiat Biol** 1996 May;69(5):623–31

Abdomino–pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology. Formenti SC, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):993–1001

Factoring outcomes in ovarian cancer [editorial] Bookman MA, et al. **J Clin Oncol** 1996 Feb;14(2):325–7

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second–look laparotomy. Pujade–Lauraine E, et al. **J Clin Oncol** 1996 Feb;14(2):343–50

High–dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor–cell support: a phase I trial. Stemmer SM, et al. **J Clin Oncol** 1996 May; 14(5):1463–72

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. Canevari S, et al. **J Hematother** 1995 Oct;4(5):423–7

Clinical trials of bispecific antibody MDX–210 in women with advanced breast or ovarian cancer that overexpresses HER–2/neu. Valone FH, et al. **J Hematother** 1995 Oct; 4(5):471–5

HER–2/neu gene bumped into the limelight [news] Holzman D. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):147–8

Treatment of inoperable ovarian cancer with interleukin–2 and carboplatinum [letter] Malaguarnera M, et al. **Lancet** 1995 Dec 16;346(8990):1627

Blood stem cells to the rescue in ovarian cancer [news] Fricker J. **Mol Med Today** 1996 May;2(5):181

Gene therapy for HER–2–related cancer [news] Holzmann D. **Mol Med Today** 1996 Apr;2(4):138–9

Interleukin–1 alpha–induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Wang Z, et al. **Mol Pharmacol** 1996 Feb;49(2):269–75

Epithelial ovarian cancer: future prospects for treatment. Shelling AN, et al. **N Z Med J** 1996 Apr 26;109(1020):131–2

Adenoviral–mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Mujoo K, et al. **Oncogene** 1996 Apr 18;12(8):1617–23

Antibody with two targets may boost immunotherapy benefit [news] **Oncology (Huntingt)** 1996 Apr;10(4):620

Outcome issues in ovarian cancer. Ozols RF. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):135–9 (33 ref.)

The treatment of early stage ovarian cancer. Young RC. **Semin Oncol** 1995 Oct;22(5 Suppl 12):76–9 (7 ref.)

Quality of life in patients with ovarian cancer: current state of research. Montazeri A, et al. **Support Care Cancer** 1996 May;4(3):169–79 (60 ref.)

[Primary malignant lymphoma of the female genital tract clinical analysis of 15 cases] Bai P, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):614–7 (Eng. Abstr.) **(Chi)**

[Study of autologous bone marrow transplantation in the treatment of gynecologic carcinoma] Tu C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):475–8 (Eng. Abstr.) **(Chi)**

[Ovarian carcinoma in the elderly; a diagnostic and therapeutic dilemma] Wymenga AN, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):650–3 (42 ref.) **(Dut)**

[Epithelial ovarian cancer: what is the consensus in 1995?] Chevallier B, et al. **Bull Cancer (Paris)** 1995 Nov; 82(11):923–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[High–dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic approach to epithelial cancer of the ovary at CHU Sart Tilman. Conclusions of the interdisciplinary meeting of 22 March 1995. Consensus Group] Jerusalem G, et al. **Rev Med Liege** 1995 Nov;50(11):469–71 (9 ref.) **(Fre)**

[Generation and activation of tumor–infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK–TIL therapy) in patients with advanced breast and ovarian carcinoma] Mallmann P, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:161–5 (Eng. Abstr.) **(Ger)**

[Animal experiment, pharmacokinetic and clinical studies of intraperitoneal therapy with interleukin–2 (n Il–2) in patients with ovarian carcinoma] Schröder W, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:46–52 (Eng. Abstr.) **(Ger)**

[Ovarian carcinoma—diagnosis and treatment. Consensus conference of the National Institute of Health] Bornkessel B. **Med Monatsschr Pharm** 1995 Oct;18(10):292–6 (0 ref.) **(Ger)**

[The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?] Souchon R, et al. **Strahlenther Onkol** 1995 Nov; 171(11):630–40 (83 ref.) (Eng. Abstr.) **(Ger)**

[High–dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis] Hayakawa S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1756–61 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Combined effects of sizofiran and rG–CSF on myelosuppression in cancer chemotherapy] Hoshino T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):206–12 (Eng. Abstr.) **(Jpn)**

[A case of malignant ovarian granulosa cell tumor with poor prognosis] Tokuoka S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1393–6 **(Jpn)**

ULTRASONOGRAPHY

Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Franchi M, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):734–9

Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Tekay A, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):316–29 (89 ref.)

Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Fleischer AC, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):101–6

Transvaginal ultrasonography of pelvic masses: evaluation of B–mode technique and Doppler ultrasonography. Rehn M, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):97–104

Pre–operative morphological and colour Doppler features of borderline ovarian tumours. Zanetta G, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):990–6

Ovarian cancer screening. The role of ultrasound in early detection. **Karlan BY, et al. Cancer** 1995 Nov 15;76(10 Suppl):2011–5 (35 ref.)

Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Vuento MH, et al. **Cancer** 1995 Oct 1;76(7):1214–8

Current role of ultrasound in ovarian cancer screening. Crvenkovic G, et al. **Clin Obstet Gynecol** 1996 Mar; 39(1):259–67

Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Antonić J, et al. **Eur J Gynaecol Oncol** 1996;17(1):29–35

Trans–vaginal ultrasound examination of ovarian masses in premenopausal women. Botta G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):37–41

Conflicting Doppler data on the assessment of pelvic tumors vascularity [editorial] Kurjak A. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):1–2

Colour Doppler sonography improves the pre–operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Leeners B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):79–85

Abdominal mycobacterial infection mimicking a gynecologic neoplasm: a case report with sonographic findings. Uzelmeier WJ, et al. **J Okla State Med Assoc** 1995 Dec; 88(12):515–7

Ovarian dysgerminoma: color Doppler ultrasonographic findings and comparison with CT and MR imaging findings. Kim SH, et al. **J Ultrasound Med** 1995 Nov; 14(11):843–8

Transvaginal color flow imaging in the diagnosis of ovarian tumors. Tepper R, et al. **J Ultrasound Med** 1995 Oct; 14(10):731–4

Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Anandakumar C, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):280–4

Detection of ovarian malignancy—authors' reply [letter; comment] Breyer B, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):230. Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):422.

Pathognomonic echo patterns of benign cystic teratomas of the ovary: classification, incidence and accuracy rate of sonographic diagnosis. Caspi B, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):275–9

Color Doppler and ovarian masses: familiarity breeds confidence [letter] Crade M, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):373–4

Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)

Detection of ovarian malignancy [letter; comment] [see comments] Schoenfeld A. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):422. Comment on: Ultrasound Obstet Gynecol 1995 Mar;5(3):209–10. Comment in: Ultrasound Obstet Gynecol 1995 Sep;6(3):230.

The effect of feedback on anxiety levels during ultrasound scanning for ovarian cancer. Tadmor OP, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):135–9

[Initial experiences with laparoscopic intraoperative ultrasound] Sohn C, et al. **Geburtshilfe Frauenheilkd** 1995 Aug;55(8):468–72 (Eng. Abstr.) **(Ger)**

[Malignant neoplasms after kidney transplantation: value of an annual radiological screening program] Heinz–Peer G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):250–5 (Eng. Abstr.) **(Ger)**

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

[Ovarian tumors in menopausal patients] Struzziero E, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):17–8 (Eng. Abstr.) **(Ita)**

[Preclinical lymph node metastasis in ovarian cancer. Report of a case] Triolo O, et al. **Minerva Ginecol** 1996 Mar; 48(3):107–10 (Eng. Abstr.) **(Ita)**

[Comparative study of observer agreement on location and size of ovarian tumor in transvaginal and transabdominal ultrasonic examinations with intraoperative evaluations from material of patients operated on in the Gynecology–Obstetrics Department of the Ministry of Internal Affairs Clinic in the years 1991–1994] Pietrzak P, et al. **Ginekol Pol** 1996 Mar;67(3):140–3 (Eng. Abstr.) **(Pol)**

[The evaluation of ovarian tumor vascularization using color

Doppler transvaginal ultrasonography] Szpurek D, et al. **Ginekol Pol** 1995 Jan;66(1):32–5 (Eng. Abstr.) **(Pol)**

[Prognostic value of vaginal ultrasound with color Doppler in differentiating the malignancy of ovarian tumors] Szpurek D, et al. **Ginekol Pol** 1995 Feb;66(2):97–102 (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

Prognostic significance of receptors for epidermal growth factor, estrogen, and progesterone in ovarian cancer. Scambia G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:202–8

Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Kitawaki J, et al. **Anticancer Res** 1996 Jan–Feb;16(1):91–7

Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A, et al. **Gynecol Oncol** 1996 Feb;60(2):203–12

Signet-ring stromal and related tumors of the ovary. Dickersin GR, et al. **Ultrastruct Pathol** 1995 Sep–Oct; 19(5):401–19

Endometrioid-like variant of ovarian yolk sac tumor with foci of carcinoid: an ultrastructural study. Dickersin GR, et al. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):421–9

Recurrent granulosa cell tumor with associated Müllerian epithelium. Hammar SP. **Ultrastruct Pathol** 1996 Jan–Feb; 20(1):73–78

[Nucleolus organizers in the epithelium of serous ovarian tumors] Iakovtsova II. **Tsitol Genet** 1995 Sep–Oct; 29(5):38–41 (Eng. Abstr.) **(Rus)**

VETERINARY

Granulosa cell tumor in an ovariohysterectomized dog. Pluhar GE, et al. **J Am Vet Med Assoc** 1995 Oct 15; 207(8):1063–5

Sclerosing stromal tumour in a cow. Ashida Y, et al. **Zentralbl Veterinarmed A** 1995 Mar;42(1):27–34

[Spontaneous tumors in the Mongolian gerbil (Meriones unguiculatus)] Matsuoka K, et al. **Exp Anim** 1995 Oct; 43(5):755–60 (Eng. Abstr.) **(Jpn)**

VIROLOGY

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients [letter] Runnebaum IB, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):573–5

[Herpes simplex virus and ovarian malignancies] Cokić-Damjanović J, et al. **Med Pregl** 1995;48(9–10):311–4 (Eng. Abstr.) **(Scr)**

OVARIECTOMY

A survey of the practice of prophylactic oophorectomy by gynecologists in the state of Alaska. Conklin BH, et al. **Alaska Med** 1996 Apr–Jun;38(2):71–4

Prevention of ovarian cancer with bilateral oophorectomy at time of hysterectomy. McGuire PA, et al. **Alaska Med** 1996 Apr–Jun;38(2):69–70, 81 (13 ref.)

Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Cline JM, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):93–100

Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethindrone or norgestimate. Vanin CM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1491–8

Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats. Gallagher AC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E407–12

Effect of prepuberal and postpuberal gonadectomy on heat production measured by indirect calorimetry in male and female domestic cats. Root MV, et al. **Am J Vet Res** 1996 Mar;57(3):371–4

Intercellular communication within the rat anterior pituitary gland: VI. Development of gap junctions between folliculo-stellate cells under the influence of ovariectomy and sex steroids in the female rat. Kurono C. **Anat Rec** 1996 Mar;244(3):366–73

Bone histomorphometric changes in the femoral neck of aging and ovariectomized rats. Yamamoto N, et al. **Anat Rec** 1995 Oct;243(2):175–85

Clodronate increases bone mineral density in young growing oophorectomized beagles. Tarvainen R, et al. **Ann Chir Gynaecol** 1995;84(3):304–8

Effects of ovariectomy upon performance of a maze learning paradigm in the adult female rat. Struse H. **Arch Ital Biol** 1996 Mar;134(2):197–200

Effects of estrogen and progesterone on platelet-activating factor acetylhydrolase activity in ovariectomised rats. Ohshige A, et al. **Artery** 1994;21(4):234–42

Ovariectomy decreases plasma triglyceride levels in analbuminaemic rats by lowering hepatic triglyceride secretion. Joles JA, et al. **Atherosclerosis** 1995 Sep; 117(1):51–9

Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroid-treated ewes and during the estrous cycle and early pregnancy. Hampton AL, et al. **Biol Reprod** 1995 Aug;53(2):302–11

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Ke HZ, et al. **Bone** 1995 Nov; 17(5):491–6

Measurement of bone resorption by strontium excretion in prelabelled rats. Kollenkirchen U. **Bone** 1995 Oct;17(4 Suppl):455S–460S

Effect of protein restriction on the messenger RNA contents of bone-matrix proteins, insulin-like growth factors and insulin-like growth factor binding proteins in femur of ovariectomized rats. Higashi Y, et al. **Br J Nutr** 1996 Jun; 75(6):811–23

Progesterone administration to ovariectomized rats reduces water and salt intake induced by central administration of angiotensin II. do-Vale CF, et al. **Braz J Med Biol Res** 1995 Sep;28(9):999–1002

Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Meakin JW, et al. **Breast Cancer Res Treat** 1996;37(1):11–9

Analysis of relationships between sex hormone dynamics and bone metabolism and changes in bone mass in surgically induced menopause. Satoh Y, et al. **Calcif Tissue Int** 1995 Oct;57(4):258–66

The pars tuberalis of the ewe: no effect of season or ovariectomy on the distribution, density or presence of immunoreactive cells. Skinner DC, et al. **Cell Tissue Res** 1996 Apr;284(1):117–23

The effect of oophorectomy and hormone replacement on neurohypophyseal hormone secretion in women. Forsling ML, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):39–44

Effects of etidronate and oophorectomy on the zeta potential of rat bone. Kowalchuk RM, et al. **Clin Orthop** 1996 Jul; (328):241–9

Laparoscopic oophorectomy. Russell JB. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):295–8 (20 ref.)

Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Rincon J, et al. **Diabetes** 1996 May;45(5):615–21

Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. Suzuki A, et al. **EMBO J** 1996 Jan 15;15(2):211–15

Effect of 1alpha-vitamin D3 and estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. Aerssens J, et al. **Endocrinology** 1996 Apr; 137(4):1358–64

RU486 on an estrogen background blocks the rise in serum follicle-stimulating hormone induced by antiserum to inhibin or ovariectomy. Knox KL, et al. **Endocrinology** 1996 Apr;137(4):1226–32

Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Shah GV, et al. **Endocrinology** 1996 May;137(5):1814–22

An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats. Yokose S, et al. **Endocrinology** 1996 Feb;137(2):469–78

Distinct effects of ovarian transplantation and exogenous 17 beta-oestradiol on cancellous bone of osteopenic ovariectomized rats. Gallagher AC, et al. **Eur J Endocrinol** 1995 Oct;133(4):483–8

The effect of surgical castration on lipid metabolism in premenopausal and postmenopausal women. Goldman GA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun; 66(2):133–6

Effect of chronic stress on estradiol action in the uterus of ovariectomized rats. Gunin AG. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):169–74

The role of prolactin in realization of estradiol action in the uterus of ovariectomized rats. Gunin AG. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):119–27

The inhibitory effect of beta-endorphin on LH release in ovariectomized rats does not involve the preoptic GABAergic system. Jarry H, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):317–23

Effect of human chorionic gonadotropin on uterine blood flow in intact and ovariectomized gilts. Ziecik AJ, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):158–63

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. Sato M, et al. **FASEB J** 1996 Jun; 10(8):905–12

The effect of ovariectomy on concentrations of plasma prolactin and LH and parental behavior in the domestic fowl. Lea RW, et al. **Gen Comp Endocrinol** 1996 Jan; 101(1):115–21

Effects of administration of some monoamine-synthesis blockers and precursors on ovariectomy-induced rise in plasma gonadotropin II in the catfish Heteropneustes fossilis. Senthilkumaran B, et al. **Gen Comp Endocrinol** 1996 Feb;101(2):220–6

Effects of IGF-I, alone and in combination with 17 beta-oestradiol, on bone remodelling parameters in ovariectomised rats. Verhaeghe J, et al. **Growth Regul** 1995 Dec;5(4):210–7

Gonadotrophins and prolactin rise after bilateral oophorectomy for benign conditions. Crosignani PG, et al. **Hum Reprod** 1995 Sep;10(9):2277–9

Blunted pressure natriuresis in ovariectomized Dahl-Iwai salt-sensitive rats. Otsuka K, et al. **Hypertension** 1996 Jan; 27(1):119–24

Prophylactic bilateral oophorectomy to prevent epithelial carcinoma. Number 2—December 1994. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Jan;52(1):101–2

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. Rivkin SE, et al. **J Clin Oncol** 1996 Jan;14(1):46–51

Effects of ovariectomy and estrogen replacement on attractivity and receptivity in the red-sided garter snake (Thamnophis sirtalis parietalis). Mendonça MT, et al. **J Comp Physiol [A]** 1996;178(3):373–81

Suppression of LH secretion in food-restricted lactating females: effects of ovariectomy and bromocryptine treatment. Walker CD, et al. **J Endocrinol** 1995 Jul; 146(1):95–104

Prophylactic oophorectomy in inherited breast/ovarian cancer families. Struewing JP, et al. **J Natl Cancer Inst Monogr** 1995;(17):33–5

A 5-day estradiol therapy, in amounts reproducing concentrations of the early-mid follicular phase, prevents the activation of the hypothalamo-pituitary-adrenal axis by interleukin-1 alpha in the ovariectomized rhesus monkey. Xia-Zhang L, et al. **J Neuroendocrinol** 1995 May; 7(5):387–92

Ovariectomy decreases osteogenetic activity in rat bone. Goseki MS, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb; 42(1):55–67

Dopamine and GABAA receptor imbalance after ovariectomy in rats: model of menopause. Bossé R, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):364–71

Alpha-methyl-proline restores normal levels of bone collagen Type I synthesis in ovariectomized rats. Lubec G, et al. **Life Sci** 1995;57(24):2245–52

Immunoreactive inhibin decreases following bilateral ovariectomy and during the postovulatory rise of FSH in Syrian hamsters. McAsey ME, et al. **Life Sci** 1995; 57(22):2057–71

The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism. Hashimoto K, et al. **Maturitas** 1995 Nov;22(3):185–91

Prevention of post-oophorectomy bone loss with Tibolone. Lyritis GP, et al. **Maturitas** 1995 Nov;22(3):247–53

Effect of gonadectomy on the development of diabetes mellitus, hypertension, and albuminuria in the rat model. Iwase M, et al. **Metabolism** 1996 Feb;45(2):155–61

Ovariectomy and age alter gonadotropin hormone releasing hormone-noradrenergic interactions. Miller MM, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):613–25

Acute stress suppresses the N-methyl-D-aspartate-induced luteinizing hormone release in the ovariectomized estrogen-primed rat. Akema T, et al. **Neuroendocrinology** 1995 Sep;62(3):270–6

Steroid treatment fails to induce an afternoon luteinizing hormone or prolactin surge in rats exposed to short-term constant light at the time of ovariectomy. Sterner MR, et al. **Neuroendocrinology** 1995 Sep;62(3):231–7

Osmolality- and angiotensin-induced responses in the AV3V neurons are affected by estrogen in the ovariectomized rat. Akaishi T, et al. **Neurosci Lett** 1996 Jan 5;202(3):153–6

Vagus nerve mediates the increase in estrogen receptors in the hypothalamic paraventricular nucleus and nucleus of the solitary tract during fasting in ovariectomized rats. Estacio MA, et al. **Neurosci Lett** 1996 Apr 12;208(1):25–8

Effects of long-term ovariectomy and ovarian steroids on somatogenic binding sites in rat brain and liver. Mustafa A, et al. **Neurosci Lett** 1995 Jul 21;194(3):193–6

SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. Santarelli R, et al. **Oncogene** 1996 Feb 1; 12(3):495–505

Effect of ovariectomy on intraosseous vascularization and bone remodelling in rats: action of tiludronate. Laroche M, et al. **Osteoporos Int** 1996;6(2):127–9

Differential effects of gonadectomy on the thymocyte phenotypic profile in male and female rats. Leposavić G, et al. **Pharmacol Biochem Behav** 1996 May;54(1):269–76

Eicosanoid production and phospholipase A2 activity in uterine tissue from castrated rats with non-insulin dependent diabetes mellitus. Jawerbaum A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):341–5

Effects of ovariectomy on mechanical properties and collagen content in rabbit lower urinary tract smooth muscle. Persson K, et al. **Scand J Urol Nephrol** 1996 Feb; 30(1):7–14

Effect of ovariectomy on bone histology and plasma parameters of bone metabolism in nulliparous and multiparous sows. Scholz-Ahrens KE, et al. **Z Ernahrungswiss** 1996 Mar;35(1):13–21

[Systen--transdermal estradiol for substitution following surgical menopause] Rachev E, et al. **Akush Ginekol (Sofiia)** 1995;34(3):74–6 (Eng. Abstr.) **(Bul)**

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Isovolemic hemodilution for avoiding homologous blood transfusions: effectiveness in large gynecologic interventions] Oberhauser M, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):15–23 (Eng. Abstr.) **(Ger)**

[Studies on the bone metabolisms in either after natural menopause or surgical menopause: implications of IGF–IGFBP system for postmenopausal osteoporosis] Itatsu S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec;47(12):1329–36 (Eng. Abstr.) **(Jpn)**

[The effect of sodium fluoride on bone mineral density and bone strength in ovariectomized rats] Nakahara H. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1182–92 (Eng. Abstr.) **(Jpn)**

[Effect of ovariectomy and natural menopause on levels of selected pituitary hormones, 17–beta estradiol and lipid profile in blood serum] Halerz–Nowakowska B. **Ginekol Pol** 1995 Oct;66(10):553–60 (Eng. Abstr.) **(Pol)**

[Cholesterol and its fractions in women after ovariectomy treated with estraderm TTS] Matuszewski W, et al. **Ginekol Pol** 1996 Apr;67(4):186–9 (Eng. Abstr.) **(Pol)**

[A comparative study of the status of bone tissue during hormone replacement therapy and with human fetal tissue transplantation in women after ovariectomy] Kulakov VI, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):428–30 **(Rus)**

[Possibility of correcting ovariectomy syndrome by transplanting human fetal tissue] Kulakov VI, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):430–3 **(Rus)**

[Neoadjuvant drug therapy as a predictor of the efficacy of castration] Bogdanova NV, et al. **Vopr Onkol** 1995; 41(2):130–1 **(Rus)**

[Serum lipids in surgical and natural postmenopause] Curčić A, et al. **Med Pregl** 1995;48(7–8):226–9 (Eng. Abstr.) **(Scr)**

[Nutritional status in women and estrogen production in surgical menopause] Curčić A, et al. **Med Pregl** 1996; 49(1–2):54–6 (Eng. Abstr.) **(Scr)**

[Acetylcholinesterase–positive innervation of the thymus in old rats after ovariectomy] Dorko F, et al. **Bratisl Lek Listy** 1996 May;97(5):298–300 (Eng. Abstr.) **(Slo)**

[Ovariectomy in a perimenopausal woman] Escudero Fernández M. **An R Acad Nac Med (Madr)** 1995; 112(4):727–40; discussion 740–3 **(Spa)**

ADVERSE EFFECTS

Stereological analysis of the urethra in sexually intact and spayed female dogs. Augsburger HR, et al. **Acta Anat (Basel)** 1995;154(2):135–42

Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993. Lafferty HW, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):641–5 (23 ref.)

Natural versus surgical menopause: implications for the pathogenesis of osteoporosis. Kudo Y, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1002–4

Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Sasco AJ, et al. **Epidemiology** 1996 Jan;7(1):9–13

Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. Jussofie A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):196–204

Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. Gambacciani M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):131–5

Effect of surgically induced hypoestrinism on immunoregulation in perimenopausal women. Zofková I, et al. **Horm Metab Res** 1996 Apr;28(4):187–9

Central sensitization as a result of surgical pain: investigation of the pre–emptive value of pethidine for ovariohysterectomy in the rat. Lascelles BD, et al. **Pain** 1995 Aug;62(2):201–12

[Bone histomorphometric osteopenia induced by ovariectomy or diabetes mellitus in rat] Nagasawa T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):699–707 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Role of ovarian ablation for premenopausal patients in adjuvant systemic therapy of breast cancer [letter] Harder H. **Trop Doct** 1996 Apr;26(2):85

[Surgical treatment of ovarian cysts: economic analysis as a means for the evaluation of alternative technics. Results of a biennial study] Garcea N, et al. **Minerva Ginecol** 1996 Mar;48(3):77–83 (Eng. Abstr.) **(Ita)**

HISTORY

100 years of the endocrine battle against breast cancer. Leake R. **Lancet** 1996 Jun 29;347(9018):1780–1

INSTRUMENTATION

[Pro endoscopic ovarian surgery] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):97–106 **(Ger)**

[Total pelviscopic removal of ovarian tumors in a bag bag posterior colpotomy] Bratschi HU, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):383–6 (Eng. Abstr.) **(Ger)**

METHODS

Transvaginal endoscopic oophorectomy [letter; comment] Yuen PM. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):976–7 . Comment on: Am J Obstet Gynecol 1995 Jan;172(1 Pt 1):123–4.

A prospective study to evaluate oophorectomy at the time of vaginal hysterectomy. Davies A, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):915–20

Laparoscopic oöphorectomy: description and report of an initial series. O'Boyle CJ, et al. **Br J Surg** 1996 Jul;83(7):986

A comparative study of outcome of laparoscopic salpingo–oophorectomy versus open salpingo–oophorectomy. Leetanaporn R, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):79–83

Transvaginal mobilization and removal of ovaries and fallopian tubes after vaginal hysterectomy. Ballard LA, et al. **Obstet Gynecol** 1996 Jan;87(1):35–9

An anatomical approach to oophorectomy during vaginal hysterectomy. Jelen I, et al. **Obstet Gynecol** 1996 Jan; 87(1):137–9

An anatomical approach to oophorectomy during vaginal hysterectomy [letter] Kovac SR. **Obstet Gynecol** 1996 Apr; 87(4):639–40

Removal of gonads in Y–chromosome–bearing gonadal dysgenesis and in androgen insensitivity syndrome by laparoscopic surgery. Ulrich U, et al. **Surg Endosc** 1996 Apr;10(4):422–5

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Questions effectiveness of Spay Day [letter] Buelke DL. **J Am Vet Med Assoc** 1996 Aug 1;209(3):538–9

Use of umbilical cord clamps for ovariectomy in cows. Youngquist RS, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):474–5

Effects of growth hormone and ovariectomy on performance, serum hormones, insulin–like growth factor–binding proteins, and muscle fiber properties of prepubertal Friesian heifers. Vestergaard M, et al. **J Anim Sci** 1995 Dec; 73(12):3574–84

Ovarian remnant syndrome in dogs and cats: 46 cases (1988–1992). Miller DM. **J Vet Diagn Invest** 1995 Oct; 7(4):572–4

Light and scanning electron microscopy of endometrium of ovariectomized cows treated with oestradiol. Kummer V, et al. **Vet Med (Praha)** 1995 Sep;40(9):265–71

Obstipation following ovariohysterectomy in a cat. Smith MC, et al. **Vet Rec** 1996 Feb 17;138(7):163

Ventral abdominal approach for laparoscopic ovariectomy in horses. Ragle CA, et al. **Vet Surg** 1995 Nov–Dec; 24(6):492–7

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**

OVARY

consider also terms at OOPHOR– and THEC–

see related

OVARIECTOMY

Supernumerary ovary with an endometrioma and osseous metaplasia: a case report. Badawy SZ, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1623–4

Sonographic investigation of female infants with inguinal masses. Munden M, et al. **Clin Radiol** 1995 Oct;50(10):696–8

Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol–sucrose as cryoprotectants. Hovatta O, et al. **Hum Reprod** 1996 Jun; 11(6):1268–72

Freezing ovary tissue may help cancer patients preserve fertility [news] Law C. **J Natl Cancer Inst** 1996 Sep 4; 88(17):1184–5

Development to blastocysts of domestic cat oocytes matured and fertilized in vitro after prolonged cold storage. Wolfe BA, et al. **J Reprod Fertil** 1996 Jan;106(1):135–41

[Ovarian pregnancy apropos of 2 cases] Cissé CT, et al. **Dakar Med** 1994;39(1):69–75 (Eng. Abstr.) **(Fre)**

ABNORMALITIES

The ovarian dysgenesis normally induced by neonatal thymectomy is prevented by the prior administration of estrogen. Chapman JC, et al. **Am J Reprod Immunol** 1995 Sep;34(3):195–9

Steroid cell tumor of the broad ligament arising in an accessory ovary. Roth LM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):405–9

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

Ovarian maldescent. Verkauf BS, et al. **Fertil Steril** 1996 Jan; 65(1):189–92

Aod2, the locus controlling development of atrophy in neonatal thymectomy–induced autoimmune ovarian dysgenesis, co–localizes with Il2, Fgfb, and Idd3. Teuscher C, et al. **J Exp Med** 1996 Feb 1;183(2):631–7

Familial blepharophimosis: an uncommon marker of ovarian dysgenesis. Nicolino M, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):127–33

Splenic–gonadal fusion of the continuous type in an adult female. Alujevic A, et al. **Pathol Int** 1995 Nov;45(11):871–4

ANATOMY & HISTOLOGY

De mulierum organis generationi inservientibus tractatus novus... Longo LD. **Am J Obstet Gynecol** 1996 Feb; 174(2):794–5

Morphological and hormonal changes after superovulation in cows treated with Neutra–PMSG. Boryczko Z, et al. **Arch Vet Pol** 1994;34(1–2):117–26

Comparison of endocrinological and clinical profiles and outcome of IVF cycles in patients with one ovary and two ovaries. Nargund G, et al. **J Assist Reprod Genet** 1995 Aug;12(7):458–60

Ovotestis variability in young and adult females of the mole Talpa occidentalis (insectivora, mammalia). Jiménez R, et al. **J Exp Zool** 1996 Feb 1;274(2):130–7

Normal ovaries and functional cysts: MR appearance. Outwater EK, et al. **Radiology** 1996 Feb;198(2):397–402

Serum levels of prolactin and alpha–melanotrophin and structure of the ovary during the reproductive cycle of Columba livia (domestic pigeon). Castagnino RA, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):5–10

BLOOD SUPPLY

Pelvic congestion syndrome: a new approach to an unusual problem. Mathis BV, et al. **Am Surg** 1995 Nov; 61(11):1016–8

Simple or repeated induction of superovulation: a study on ovulation rates and microvessel corrosion casts in ovaries of golden hamsters. Löseke A, et al. **Anat Anz** 1996 Jan; 178(1):5–14

Pseudothrombosis of the right ovarian vein. Pitfall of abdominal spiral CT. Cranston PE, et al. **Clin Imaging** 1995 Jul–Sep;19(3):176–9

17 alpha–Hydroxyprogesterone suppresses neovascularization induced by HPLC–purified ovarian hyaluronic acid–like glycosaminoglycan in mice. Okada M, et al. **Endocr J** 1995 Oct;42(5):675–81

Occurrence and coexistence of some neuropeptides in nerve fibers supplying the bovine ovary and its extrinsic blood vessels. Kaleczyc J, et al. **Folia Histochem Cytobiol** 1995; 33(3):163–9

Extrarenal anastomoses of intrarenal fetal arteries with the arteries of surrounding structures. Kosinski H. **Folia Morphol (Warsz)** 1995;54(3):173–80

An unusual cause of fatal postpartum embolism. Gevirtz C, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):135–7

Doppler colour flow analysis of uterine and ovarian arteries prior to and after surgery for tubal sterilization: a prospective study. Geber S, et al. **Hum Reprod** 1996 Jun; 11(6):1195–8

Laparoscopic unwinding of hyperstimulated ischaemic ovaries during the second trimester of pregnancy. Levy T, et al. **Hum Reprod** 1995 Jun;10(6):1478–80

Ovarian stromal blood flow in women with polycystic ovaries—a possible new marker for diagnosis? Zaidi J, et al. **Hum Reprod** 1995 Aug;10(8):1992–6

Increased uterine and ovarian vascular resistance following Filshie clip sterilization: preliminary findings obtained with color Doppler ultrasonography. Sumiala S, et al. **J Clin Ultrasound** 1995 Nov–Dec;23(9):511–6

Unusual course of the gonadal vein: a case report of postpartum ovarian vein thrombosis mimicking acute appendicitis clinically and sonographically. Adkins J, et al. **J Ultrasound Med** 1996 May;15(5):409–12

Quantitative differences in neoglycoprotein binding for vascular endothelial cells from porcine brain, ovary, and testis in vitro. Plendl J, et al. **Microvasc Res** 1995 Sep; 50(2):199–214

Doppler parameters of the ovarian and uterine blood circulation in ovarian hyperstimulation syndrome. Tekay A, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):50–3

[Uncomplicated course of pregnancy after previous ligation of both internal iliac arteries and left ovarian artery] Szramik Z, et al. **Ginekol Pol** 1996 Jan;67(1):45–7 (Eng. Abstr.) **(Pol)**

[Transcatheter embolization in chronic pain syndrome caused by varicose dilatation of ovarian veins] Tarazov PG, et al. **Akush Ginekol (Mosk)** 1995;(4):48–9 **(Rus)**

[Ovarian vein syndrome] Ferrero Doria R, et al. **Actas Urol Esp** 1996 Apr;20(4):380–3 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Asbestos exposure and ovarian fiber burden. Heller DS, et al. **Am J Ind Med** 1996 May;29(5):435–9

Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Kämäräinen M, et al. **Am J Pathol** 1996 May; 148(5):1435–43

Follicle–stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Zheng W, et al. **Am J Pathol** 1996 Jan;148(1):47–53

Proteoglycans and proteins in the extracellular matrix of mouse cumulus cell–oocyte complexes. Camaioni A, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):190–8

Expression and selective cellular localization of granulocyte-macrophage colony-stimulating factor (GM-CSF) and GM-CSF alpha and beta receptor messenger ribonucleic acid and protein in human ovarian tissue. Zhao Y, et al. **Biol Reprod** 1995 Oct;53(4):923–30

Identification of beta-adrenoceptor subtypes in bovine ovarian and myometrial cell membranes. Re G, et al. **Br Vet J** 1995 Sep-Oct;151(5):567–78

Concentration of PCBs, HCB, DDT, and HCH isomers in the ovaries, mammary gland, and liver of cows. Sitarska E, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):865–9

The heat-stable protein kinase C (PKC) stimulatory factor in the rat ovary may allow PKC to be active independent of cell membrane lipids. Eyster KM. **Cell Signal** 1995 Jul; 7(5):457–61

Parvalbumin expression during developmental differentiation of the rat ovary. Pohl V, et al. **Differentiation** 1995 Nov; 59(4):235–42

D-aspartate in the male and female reproductive system of Octopus vulgaris lam. D'Aniello A, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):69–72

Immunocytochemical localization of IGF-I in the ovary of the red seabream, Pagrus major. Kagawa H, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):307–15

Estrous cycle- and acute stress-related changes of rat ovarian immunoreactive corticotropin-releasing factor. Nappi RE, et al. **Gynecol Endocrinol** 1996 Apr;10(2):75–82

Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Carreiras F, et al. **Gynecol Oncol** 1996 Aug;62(2):260–7

Cloning and characterization of an ovarian-specific protein that associates with the short form of the prolactin receptor. Duan WR, et al. **J Biol Chem** 1996 Jun 28;271(26):15602–7

Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. Gordon JD, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):353–9

Insulin-like growth factor I (IGF-I), IGF-II and type-I IGF receptor gene expression in the ovary of the laying hen. Armstrong DG, et al. **J Reprod Fertil** 1996 Jan;106(1):101–6

Epidermal growth factor and epidermal growth factor receptor in the ovary of the domestic cat (Felis catus). Göritz F, et al. **J Reprod Fertil** 1996 Jan;106(1):117–24

Molecular cloning of DNA for inhibin alpha-subunit from equine ovary. Yamanouchi K, et al. **J Vet Med Sci** 1995 Oct;57(5):905–9

Association of BRCA1 expression with gonadotropin-responsive cells [letter] Wan M, et al. **Lancet** 1996 Jul 20;348(9021):192–3

Effect of phospholipids on the reconstitution and thermal stability of delipidated rat ovarian luteinizing hormone/human chorionic gonadotropin receptors in proteoliposomes. Kolena J, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):53–60

Identification of ovarian enhancer-binding factors which bind to ovarian enhancer 1 of the Drosophila genes yp1 and yp2. Chung YD, et al. **Mol Gen Genet** 1996 Jun 12; 251(3):347–51

Distribution of the intermediate filament proteins vimentin, keratin, and desmin in the bovine ovary. van den Hurk R, et al. **Mol Reprod Dev** 1995 Aug;41(4):459–67

Expression of integrins in marmoset (Callithrix jacchus) ovary during folliculogenesis. Giebel J, et al. **Tissue Cell** 1996 Aug;28(4):379–85

CYTOLOGY

Inhibition of nitric oxide: effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Bonello N, et al. **Biol Reprod** 1996 Feb;54(2):436–45

Patterns of ovarian cell proliferation in rats during the embryonic period and the first three weeks postpartum. Hirshfield AN, et al. **Biol Reprod** 1995 Nov;53(5):1208–21

Apoptosis occurs in granulosa cells but not cumulus cells in the atretic antral follicles in pig ovaries. Manabe N, et al. **Experientia** 1996 Jul 15;52(7):647–51

Immunohistochemical localization of insulin-like growth factor-II in the perinatal rat gonad. Koike S, et al. **Growth Regul** 1995 Dec;5(4):185–89

Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Karlan BY, et al. **Gynecol Oncol** 1995 Oct;59(1):67–74

Extracorporeal development and ultrarapid freezing of human fetal ova. Zhang J, et al. **J Assist Reprod Genet** 1995 Jul;12(6):361–8

Formation of actin filament bundles in the ring canals of developing Drosophila follicles. Tilney LG, et al. **J Cell Biol** 1996 Apr;133(1):61–74

Cell turnover in normal cycling human ovary. Funayama Y, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):828–34

Localization of apoptotic cells by direct immunogold detection of digoxigenin-labeled genomic DNA in semithin sections. Van Nassauw L, et al. **J Histochem Cytochem** 1996 Feb;44(2):183–5

Gonadal cell apoptosis. Hsueh AJ, et al. **Recent Prog Horm Res** 1996;51:433–55; discussion 455–6 (66 ref.)

DRUG EFFECTS

Assessment of follicle destruction in chemical-induced ovarian toxicity. Hoyer PB, et al. **Annu Rev Pharmacol Toxicol** 1996;36:307–31 (122 ref.)

Systemic treatment in the rat with epidermal growth factor causes polycystic growth of the ovaries. Christiansen JJ, et al. **APMIS** 1996 Feb;104(2):147–52

On the nature of the follicle-stimulating signal delivered to the ovary during exogenously controlled follicular maturation. A search into the immunological and biological attributes and the molecular composition of two preparations of urofollitropin. Ulloa-Aguirre A, et al. **Arch Med Res** 1995;26 Spec No:S219–30

Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Belcourt MF, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1669–78

Ovarian toxicity of 4-vinylcyclohexene and related olefins in B6C3F1 mice: role of diepoxides. Doerr JK, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):963–9

Mifepristone and ovarian function. Curry TE Jr, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):486–97 (64 ref.)

In vivo and in vitro effects of graded doses of the pesticide heptachlor on female sex steroid hormone production in rats. Oduma JA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):191–6

Ovarian function during low-dose oral contraceptive use. Egarter C, et al. **Contraception** 1995 Jun;51(6):329–33

Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Yoshimura Y, et al. **Endocrinology** 1996 Apr;137(4):1204–11

Insulin-like growth factor binding protein-3 inhibits gonadotropin-induced ovulation, oocyte maturation, and steroidogenesis in rabbit ovary. Yoshimura Y, et al. **Endocrinology** 1996 Feb;137(2):438–46

Hormonal regulation of aldose reductase in rat ovary during the estrous cycle. Iwata N, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):444–8

Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Barbosa I, et al. **Fertil Steril** 1996 Apr;65(4):724–9

Ovarian response to recombinant human follicle-stimulating hormone in luteinizing hormone-depleted women: examination of the two cell, two gonadotropin theory. Ben-Chetrit A, et al. **Fertil Steril** 1996 Apr;65(4):711–7

Relationship of timing of agonist administration in the cycle phase to the ovarian response to gonadotropins in the long down-regulation protocols for assisted reproductive technologies. Ferraretti AP, et al. **Fertil Steril** 1996 Jan; 65(1):114–21

Effect of corticotropin-releasing factor on the pituitary-ovary axis in human luteal phase. Apa R, et al. **Gynecol Endocrinol** 1995 Dec;9(4):271–6

Somatostatin action on rat ovarian steroidogenesis. Andreani CL, et al. **Hum Reprod** 1995 Aug;10(8):1968–73

The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233–7 (55 ref.)

Immunolocalization of transforming growth factor-beta 1 and transforming growth factor-beta 2 in the mouse ovary during gonadotrophin-induced follicular maturation. Ghiglieri C, et al. **Hum Reprod** 1995 Aug;10(8):2115–9

Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)

Timely administration of extract of Ferula jaeschkeana causes luteolysis in the ovary of cyclic guineapig. Pathak S, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):395–9

GnRH analog administration in patients with polycystic ovarian disease. Meden-Vrtovec H. **Int J Gynaecol Obstet** 1995 Aug;50(2):179–83

Endocrine and ovarian responses to exogenous estradiol-17 beta in 6-month-old heifers previously immunized against growth hormone-releasing factor. Schoppee PD, et al. **J Anim Sci** 1995 Jul;73(7):2071–8

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

Effect of hypothyroidism induced by propylthiouracil and thiourea on male and female reproductive systems of neonatal mice. Chan WY, et al. **J Exp Zool** 1995 Oct 1; 273(2):160–9

The evaluation of a new 7-day gonadotropin-releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization. Yang TS, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):133–7

Effect of continuous infusion of thyrotrophin-releasing hormone on plasma prolactin and on ovarian activity in melatonin-treated ewes. Robinson JJ, et al. **J Reprod Fertil** 1996 May;107(1):17–22

The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. Kudoh M, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5-6):265–71

An in vitro bioassay for testing the direct effect of luteinizing hormone-releasing hormone agonists on progesterone secretion by rat ovarian cells. Chu YH, et al. **Life Sci** 1995; 57(22):2031–9

Metallothionein in the ovaries of laying hens exposed to cadmium. Sato S, et al. **Life Sci** 1996;58(18):1561–7

Gonadal function following chemotherapy for childhood Hodgkin's disease. Mackie EJ, et al. **Med Pediatr Oncol** 1996 Aug;27(2):74–8

Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Castelo-Branco C, et al. **Metabolism** 1996 Jan;45(1):24–7

The effect of prostaglandin E2 and prostaglandin F2 alpha on ovarian tissue in the Florida crayfish Procambarus paeninsulanus. Spaziani EP, et al. **Prostaglandins** 1995 Oct; 50(4):189–200

Effects of tumour necrosis factor alpha (TNF alpha) on ovulation in the rat ovary. Brännström M, et al. **Reprod Fertil Dev** 1995;7(1):67–73

The influence of beer, cognac and ethanol upon the follicular state of mouse ovaries on day 4 of pregnancy. Sandor S, et al. **Rom J Morphol Embryol** 1995 Jan-Jun;41(1-2):3–6

The effects of buserelin microparticles on ovarian function in healthy women. Meyer BH, et al. **S Afr Med J** 1995 Aug;85(8):766–7

Accumulation of trace elements in sheep and the effects upon qualitative and quantitative ovarian changes. Bires J, et al. **Vet Hum Toxicol** 1995 Aug;37(4):349–56

Toxic effects of butylated triphenyl phosphate-based hydraulic fluid and tricresyl phosphate in female F344 rats. Latendresse JR, et al. **Vet Pathol** 1995 Jul;32(4):394–402

[Changes in the weight of the uterus, ovaries and adrenal glands in sexually mature rats treated with estradiol and reserpine] Borisov I, et al. **Akush Ginekol (Sofiia)** 1994; 33(2):18–20 (Eng. Abstr.) **(Bul)**

[Acridine mutagen ICR-170 induced developmental suppression of ovary and vitelline gland in female Schistosoma japonicum] Lu Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):200–2 (Eng. Abstr.) **(Chi)**

[The effect of estradiol, norethisterone and testosterone on regional circulation and relative weight of the testes, ovaries and uterus in rats] Kapitola J, et al. **Sb Lek** 1994; 95(3):189–98 (Eng. Abstr.) **(Cze)**

[The role of thymic peptides in regulating ovarian morphogenesis] Butorina OG. **Morfologiia** 1994 Jul-Dec; 107(7-12):128–40 (Eng. Abstr.) **(Rus)**

[The rate of polyploid fertilization of ovocytes in in vitro fertilization in patients with an increased ovarian response] Tabi N, et al. **Med Pregl** 1994;47(11-12):381–3 (Eng. Abstr.) **(Scr)**

EMBRYOLOGY

Patterns of ovarian cell proliferation in rats during the embryonic period and the first three weeks postpartum. Hirshfield AN, et al. **Biol Reprod** 1995 Nov;53(5):1208–21

Steroid production by equine fetal gonads: a speculative view [editorial; comment] Raeside JI. **Equine Vet J** 1995 Sep; 27(5):324–5. Comment on: Equine Vet J 1995 Sep;27(5):334–40. Comment on: Equine Vet J 1995 Sep;27(5):342–7.

Sex differentiation — gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)

Extracorporeal development and ultrarapid freezing of human fetal ova. Zhang J, et al. **J Assist Reprod Genet** 1995 Jul;12(6):361–8

Localization of mRNA encoding c-kit during the initiation of folliculogenesis in ovine fetal ovaries. Clark DE, et al. **J Reprod Fertil** 1996 Mar;106(2):329–35

Molecular aspects of the ontogeny of the pituitary-gonadal axis. Huhtaniemi I. **Reprod Fertil Dev** 1995;7(5):1025–35 (57 ref.)

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126–39 (17 ref.) (Eng. Abstr.) **(Fre)**

[Morphological evaluation of intercellular junctions in the ovary of chick embryos: action of steroid and gonadotropic hormones in vitro] Avila RE, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):5–10 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Sterol 14-demethylase P450 activity expressed in rat gonads: contribution to the formation of mammalian meiosis-activating sterol. Yoshida Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):534–8

Characterization of multiple prohormone convertase PC1/3 transcripts in porcine ovary. Dai G, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):1–6

Expression and activity of ovarian tissue inhibitors of metalloproteinases during pseudopregnancy in the rat. Nothnick WB, et al. **Biol Reprod** 1995 Sep;53(3):684–91

Transforming growth factor-beta inhibits ovarian 17 alpha-hydroxylase activity by a direct noncompetitive mechanism. Fournet N, et al. **Endocrinology** 1996 Jan; 137(1):166–74

Diabetes-mediated decreases in ovarian superoxide dismutase activity are related to blood-follicle barrier and ovulation defects. Powers RW, et al. **Endocrinology** 1996 Jul; 137(7):3101–10

Hormonal regulation of aldose reductase in rat ovary during the estrous cycle. Iwata N, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):444–8

Subcellular distribution of oxygen free radical scavenging enzymes in goat ovary. Biswas SC, et al. **Indian J Exp Biol** 1995 Oct;33(10):785–7

Expression and localization of inducible and endothelial nitric oxide synthase in the rat ovary. Effects of gonadotropin stimulation in vivo. Van Voorhis BJ, et al. **J Clin Invest** 1995 Dec;96(6):2719–26

Expression of collagenase-3 in the rat ovary during the ovulatory process. Balbín M, et al. **J Endocrinol** 1996 Jun; 149(3):405–15

Partial purification and some properties of a neutral proteinase in rat ovary. Higuchi M, et al. **J Vet Med Sci** 1995 Aug;57(4):743–6

Functional ovarian and placental isoforms of porcine aromatase. Corbin CJ, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):29–37

The rat hepatic lipase gene is expressed into two different proteins in liver, adrenals and ovaries. Verhoeven AJ, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:54–5

GROWTH & DEVELOPMENT

Functional maturation of neuroendocrine gonadal axis is altered by specific phase relations of circadian neurotransmitter activity in Japanese quail. Phillips D, et al. **Biomed Environ Sci** 1995 Dec;8(4):367–77

hedgehog is required for the proliferation and specification of ovarian somatic cells prior to egg chamber formation in Drosophila. Forbes AJ, et al. **Development** 1996 Apr; 122(4):1125–35

Reproductive development and functions in the rat after repeated maternal deprivation stress. Lau C, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):298–301

Interrelationship of day length and temperature on the control of gonadal development, body mass, and fat score in white-crowned sparrows, Zonotrichia leucophrys gambelii. Wingfield JC, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):242–55

Immunoreactive inhibin concentrations in human gonads and adrenals during the first years of life. Brennemann W, et al. **Horm Res** 1995;44(3):115–20

Endocrine and metabolic responses to realimentation in feed-restricted prepubertal gilts: associations among gonadotropins, metabolic hormones, glucose, and uteroovarian development. Booth PJ, et al. **J Anim Sci** 1996 Apr;74(4):840–8

Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. Kondo H, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2702–10

Development of the gonads in the triploid (ZZW and ZZZ) fowl, Gallus domesticus, and comparison with normal diploid males (ZZ) and females (ZW). Lin M, et al. **Reprod Fertil Dev** 1995;7(5):1185–97

Pubertal maturation of the internal genitalia [comment] Balen A, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):164–5. Comment on: Ultrasound Obstet Gynecol 1995 Sep;6(3):175–81.

Pubertal maturation of the internal genitalia: an ultrasound evaluation of 166 healthy girls [see comments] Holm K, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):175–81. Comment in: Ultrasound Obstet Gynecol 1995 Sep;6(3):164–5.

[The histophysiological characteristics of ovarian development with an altered level of thymic peptides at infancy in mice] Butorina OG, et al. **Morfologiia** 1996; 109(1):95–9 (Eng. Abstr.) **(Rus)**

[The initiation of normal follicular growth and in imbalance of the stromal and follicular components of the ovary in the mouse] Petropavlovskaia MS. **Morfologiia** 1994 Jul-Dec;107(7–12):140–8 (Eng. Abstr.) **(Rus)**

[The thyroid gland as a modulator of ovarian development and histophysiology] Borovaia TG, et al. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):47–60 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Ovarian autoimmunity and corticotherapy in an in-vitro fertilization attempt. Barbarino-Monnier P, et al. **Hum Reprod** 1995 Aug;10(8):2006–7

Antiovarian antibodies and their effect on the outcome of assisted reproduction. Narayanan M, et al. **J Assist Reprod Genet** 1995 Oct;12(9):599–605

Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. Kondo H, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2702–10

Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. Buist MR, et al. **J Clin Pathol** 1995 Jul;48(7):631–6

Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: implication in autoimmune disease pathogenesis and B cell tolerance. Lou YH, et al. **J Immunol** 1996 May 1;156(9):3535–40

Circulating ovarian autoantibodies and FSH and LH levels in adolescent girls with primary menstrual cycle disorders. Hořejší J, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):74–8

INNERVATION

Is ovarian adrenergic innervation essential to gonadal function in adult rats? Albuquerque-Araújo WI, et al. **Arch Physiol Biochem** 1995 Apr;103(1):109–13

The primate ovary contains a population of catecholaminergic neuron-like cells expressing nerve growth factor receptors. Dees WL, et al. **Endocrinology** 1995 Dec;136(12):5760–8

Occurrence and coexistence of some neuropeptides in nerve fibers supplying the bovine ovary and its extrinsic blood vessels. Kaleczyc J, et al. **Folia Histochem Cytobiol** 1995; 33(3):163–9

Suppression of oocyte release in rats by local administration of the noradrenergic neurotoxin DSP4. Goldman JM, et al. **J Reprod Fertil** 1996 Mar;106(2):275–83

METABOLISM

Ovarian levels of epidermal growth factor receptor mRNA in the rat--a postovulatory decrease. Assarsson B, et al. **Acta Physiol Scand** 1995 Jun;154(2):177–83

Oxytocin receptors in human ovaries during the menstrual cycle. Behrens O, et al. **Adv Exp Med Biol** 1995;395:485–6

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407–10 (19 ref.)

Down-regulation of beta-adrenergic receptors and up-regulation of estrogen and progesterone receptors induced in the reproductive system of female veal calves by dietary clenbuterol. Re G, et al. **Am J Vet Res** 1995 Nov;56(11):1493–7

Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Brömme D, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):379–84

Gonadotropins in lactating sows exposed to long or short days during pregnancy and lactation: serum concentrations and ovarian receptors. Kermabon AY, et al. **Biol Reprod** 1995 Nov;53(5):1095–102

Estradiol-17 beta, insulin-like growth factor-I, and luteinizing hormone inhibit secretion of transforming growth factor beta by rat ovarian theca-interstitial cells. Magoffin DA, et al. **Biol Reprod** 1995 Sep;53(3):627–35

Transforming growth factor beta expression in the porcine ovary: evidence that theca cells are the major secretory source during antral follicle development. May JV, et al. **Biol Reprod** 1996 Feb;54(2):485–96

Stress-induced genetic expression of a selective corticotropin-releasing factor-receptor subtype within the rat ovaries: an effect dependent on the ovulatory cycle. Nappi RE, et al. **Biol Reprod** 1995 Dec;53(6):1417–28

Regulation of insulin-like growth factor-I and progesterone synthesis by insulin and growth hormone in the ovine ovary. Wathes DC, et al. **Biol Reprod** 1995 Oct;53(4):882–9

Concentration of PCBs, HCB, DDT, and HCH isomers in the ovaries, mammary gland, and liver of cows. Sitarska E, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):865–9

Immunohistochemical localization of inositol 1,4,5-trisphosphate receptors in non-neural tissues, with special reference to epithelia, the reproductive system, and muscular tissues. Nakanishi S, et al. **Cell Tissue Res** 1996 Aug;285(2):235–51

Genome reorganization from polyteny to polyploidy in the nurse cells found in onion fly (Delia antiqua) and cabbage root fly (Delia radicum) ovaries (Diptera, Anthomyiidae). Hartman TP, et al. **Chromosome Res** 1995 Aug;3(5):271–80

Progesterone receptors: expression and regulation in the mammalian ovary. Pinter JH, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):424–35 (85 ref.)

Purification and molecular cloning of carp ovarian cystatin. Tsai YJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):573–80

aubergine enhances oskar translation in the Drosophila ovary. Wilson JE, et al. **Development** 1996 May;122(5):1631–9

Developmental expression of heat shock protein 60 (HSP60) in the rat testis and ovary. Paranko J, et al. **Differentiation** 1996 Jun;60(3):159–67

Ca2+ triggers massive exocytosis in Chinese hamster ovary cells. Coorssen JR, et al. **EMBO J** 1996 Aug 1; 15(15):3787–91

Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Baarends WM, et al. **Endocrinology** 1995 Nov;136(11):4951–62

Ovarian expression of insulin-like growth factor-I (IGF-I), IGF binding proteins, and growth hormone (GH) receptor in heifers actively immunized against GH-releasing factors. Cohick WS, et al. **Endocrinology** 1996 May;137(5):1670–7

A stimulatory role of cyclic adenosine 3',5'-monophosphate in follicle-stimulating hormone-activated mitogen-activated protein kinase signaling pathway in rat ovarian granulosa cells. Das S, et al. **Endocrinology** 1996 Mar;137(3):967–74

Nature of endothelin binding in the porcine ovary. Flores JA, et al. **Endocrinology** 1995 Nov;136(11):5014–9

Prostaglandin F2 alpha mediates ovarian sterol carrier protein-2 expression during luteolysis. McLean MP, et al. **Endocrinology** 1995 Nov;136(11):4963–72

Localization of messenger ribonucleic acids for insulin-like growth factor I (IGF-I), IGF-II, and the type 1 IGF receptor in the ovine ovary throughout the estrous cycle. Perks CM, et al. **Endocrinology** 1995 Dec;136(12):5266–73

Gonadal steroidogenesis in vitro from juvenile alligators obtained from contaminated or control lakes. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:31–6

Differences in expression of angiotensin II receptors and renin in porcine and bovine ovaries. Nielsen AH, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):332–8

Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Mushayandebvu T, et al. **Fertil Steril** 1996 Apr;65(4):721–3

Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Zanagnolo V, et al. **Fertil Steril** 1996 May;65(5):1036–43

Gonadal in vitro androstenedione metabolism and changes in some plasma and gonadal steroid hormones during sex inversion of the protandrous sea bass, Lates calcarifer. Guiguen Y, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):106–18

Mouse autosomal homolog of DAZ, a candidate male sterility gene in humans, is expressed in male germ cells before and after puberty. Reijo R, et al. **Genomics** 1996 Jul 15; 35(2):346–52

Are estradiol-producing cells incompletely endowed? A chronicle of the emergence of certitude from conjecture. Lieberman S. **Gynecol Obstet Invest** 1996;41(3):147–72 (152 ref.)

Immunoreactive inhibin concentrations in human gonads and adrenals during the first years of life. Brennemann W, et al. **Horm Res** 1995;44(3):115–20

Endocrine function of the peri- and postmenopausal ovary. Ushiroyama T, et al. **Horm Res** 1995;44(2):64–8

A murine homologue of the human DAZ gene is autosomal and expressed only in male and female gonads. Cooke HJ, et al. **Hum Mol Genet** 1996 Apr;5(4):513–6

Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227–33 (58 ref.)

The influence of dietary sodium restriction on renal and ovarian renin and prorenin production during ovarian stimulation. Beerendonk CC, et al. **Hum Reprod** 1996 May; 11(5):956–61

In-vivo studies on ovarian insulin-like growth factor I concentrations in human preovulatory follicles and human ovarian circulation. Pellegrini S, et al. **Hum Reprod** 1995 Jun;10(6):1341–5

Expression of epidermal growth factors and epidermal growth factor receptor in normal cycling human ovaries. Tamura M, et al. **Hum Reprod** 1995 Jul;10(7):1891–6

Requirement of cysteine residues in exons 1–6 of the extracellular domain of the luteinizing hormone receptor for gonadotropin binding. Zhang R, et al. **J Biol Chem** 1996 Mar 8;271(10):5755–60

Insulin-like growth factor (IGF) I and II, IGF-binding proteins, and IGF-binding protein proteases are produced by theca and stroma of normal and polycystic human ovaries. Mason HD, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):276–84

Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. Willis D, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):302–9

Changes in inhibin-A (alpha-beta A dimer) and total alpha inhibin in the peripheral circulation and ovaries of rats after gonadotrophin-induced follicular development and during the normal oestrous cycle. Fahy PA, et al. **J Endocrinol** 1995 Nov;147(2):271–83

Comparison of cellular distribution of LH receptors and steroidogenic enzymes in the porcine ovary. Meduri G, et al. **J Endocrinol** 1996 Mar;148(3):435–46

Characterization of transforming growth factor-alpha receptors in the avian ovary: alterations in ligand binding to granulosa cells during follicular maturation. Onagbesan OM, et al. **J Endocrinol** 1996 Apr;149(1):171–9

Cellular localization of P-glycoprotein in brain versus gonadal capillaries. Stewart PA, et al. **J Histochem Cytochem** 1996 Jul;44(7):679–85

Expression of IGF-I mRNA in the ovine ovary. Leeuwenberg BR, et al. **J Mol Endocrinol** 1995 Dec; 15(3):251–8

Molecular cloning of cDNA for equine ovarian inhibin/activin beta A subunit. Yoshida S, et al. **J Vet Med Sci** 1995 Jun;57(3):469–73

Ovarian carbonyl reductase delayed onset of persistent estrus in the offspring of parathyroidectomized mother rats. Inazu N, et al. **Jpn J Pharmacol** 1995 Sep;69(1):17–22

Metallothionein in the ovaries of laying hens exposed to cadmium. Sato S, et al. **Life Sci** 1996;58(18):1561–7

Wilms' tumor protein WT1 as an ovarian transcription factor: decreases in expression during follicle development and repression of inhibin-alpha gene promoter. Hsu SY, et al. **Mol Endocrinol** 1995 Oct;9(10):1356–66

Immunocytochemical analysis of the expression of gap junction protein connexin 43 in the rat ovary. Mayerhofer A, et al. **Mol Reprod Dev** 1995 Jul;41(3):331–8

SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Mok SC, et al. **Oncogene** 1996 May 2;12(9):1895–901

Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Neyns B, et al. **Oncogene** 1996 Mar 21;12(6):1247–57

Beta-endorphin inhibits prostaglandin synthesis in rat ovaries and blocks induced ovulation. Faletti A, et al. **Prostaglandins** 1995 Feb;49(2):93–103

Effect of an oxytocin receptor antagonist on ovarian and uterine synthesis and release of prostaglandin F2 alpha in pseudopregnant rats. Motta AB, et al.

Prostaglandins Leukot Essent Fatty Acids 1996 Feb; 54(2):95–100

Localization and quantitation of angiotensin AT1 and AT2 receptors in the pregnant and non-pregnant sheep uterus. Moeller I, et al. **Regul Pept** 1996 Mar 22;61(3):213–8

Testosterone concentrations in chicken gonads and plasma during the peri-etching period. Motelica-Heino I. **Reprod Fertil Dev** 1995;7(5):1253–60

Composition of the ovarian fluid in 4 salmonid species: Oncorhynchus mykiss, Salmo trutta f lacustris, Salvelinus alpinus and Hucho hucho. Lahnsteiner F, et al. **Reprod Nutr Dev** 1995;35(5):465–74

Potential leukocyte attractants in the bovine peri-ovulatory ovary. Sirotkin AV, et al. **Reprod Nutr Dev** 1995; 35(6):675–83

[Comparative study of HCG receptors in rat ovary and testis] Zhang R, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):257–60 (Eng. Abstr.) **(Chi)**

[Progress in the study of inhibin subunit gene expression and regulation in mammalian ovary] Kong DJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):204–8 (17 ref.) (Eng. Abstr.) **(Chi)**

[Tissue levels of EGF and collagen in ovaries of women] Postawski K, et al. **Ginekol Pol** 1996 Apr;67(4):190–4 (Eng. Abstr.) **(Pol)**

[Human ovarian ceramides and gangliosides in aging] Diatlovitskaia EV, et al. **Biokhimiia** 1995 Aug;60(8):1302–6 (Eng. Abstr.) **(Rus)**

[Biosynthesis of steroids in the ovaries] Suchanek E. **Lijec Vjesn** 1996 Mar;118 Suppl 1:11–2 (Eng. Abstr.) **(Scr)**

PATHOLOGY

Morphologic changes and immunohistochemical detection of viral antigen in ovaries from cattle persistently infected with bovine viral diarrhea virus. Grooms DL, et al. **Am J Vet Res** 1996 Jun;57(6):830–3

Steroid cell tumor of the broad ligament arising in an accessory ovary. Roth LM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):405–9

Gonadotrophin secretion in ewes with bilateral gonadal hypoplasia. Wright PJ, et al. **Aust Vet J** 1996 Apr; 73(4):157–8

Fine-needle aspiration cytology of the ovary. Ganjei P. **Clin Lab Med** 1995 Sep;15(3):705–26 (19 ref.)

Morphology and steroidogenesis of cultured granulosa cells from endometrioidally changed ovaries. Skrzypczak J. **Exp Clin Endocrinol Diabetes** 1995;103(4):228–32

Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Seifer DB, et al. **Fertil Steril** 1996 Oct;66(4):593–8

Light and electron microscopic changes in the ovary of zinc deficient BALB/c mice. Kaswan S, et al. **Indian J Exp Biol** 1995 Jul;33(7):469–79

Transvaginal trucut biopsy in patients with abdominopelvic mass. Sheth SS, et al. **Int J Gynaecol Obstet** 1995 Jul; 50(1):27–31

Postmortem findings in congenital generalized lipodystrophy. Chandalia M, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3077–81

Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders. Herter LD, et al. **J Clin Ultrasound** 1996 Jun;24(5):243–8

Ovarian remnant syndrome in dogs and cats: 46 cases (1988–1992). Miller DM. **J Vet Diagn Invest** 1995 Oct; 7(4):572–4

Ovarian changes in Sprague-Dawley rats produced by nocturnal exposure to low intensity light. Beys E, et al. **Lab Anim** 1995 Jul;29(3):335–8

Ovarian lipoma of teratomatous origin. Gardella C, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):874–5

Testosterone-producing solitary ovarian cyst with luteinized stromal-cell hyperplasia. Goudas VT, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):870–2

Neonatal exposures to technical methoxychlor alters ovaries in adult mice. Eroschenko VP, et al. **Reprod Toxicol** 1995 Jul–Aug;9(4):379–87

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

[MR appearance of fat distribution in ovarian teratoma: pathologic correlation] Hatanaka Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun; 56(7):477–81 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Ovarian activity at naturally attained oestrus in the sow. An ultrasonographic and LH study. Dalin AM, et al. **Acta Vet Scand** 1995;36(3):377–82

Effects of calf removal at parturition on postpartum ovarian activity in Zebu (Bos indicus) cows in the humid tropics. Toribio RE, et al. **Acta Vet Scand** 1995;36(3):343–52

Ovarian function after seven years' use of a levonorgestrel IUD. Barbosa I, et al. **Adv Contracept** 1995 Jun;11(2):85–95

Paracrine regulation of the bovine ovarian prorenin-renin-angiotensin-system. Brunswig-Spickenheier B, et al. **Adv Exp Med Biol** 1995; 377:399–406

The ovarian renin-angiotensin system. A paracrine-intracrine regulator of ovarian function. Pepperell JR, et al. **Adv Exp Med Biol** 1995;377:379–89 (85 ref.)

Immunohistochemical studies of the adult human ovary: possible contribution of immune and epithelial factors to folliculogenesis. Bukovský A, et al. **Am J Reprod Immunol** 1995 Apr;33(4):323–40

Kinetics of the humoral immune response to multiple treatments with exogenous gonadotropins and relation to ovarian responsiveness in domestic cats. Swanson WF, et al. **Am J Vet Res** 1996 Mar;57(3):302–7

Is ovarian adrenergic innervation essential to gonadal function in adult rats? Albuquerque-Araújo WI, et al. **Arch Physiol Biochem** 1995 Apr;103(1):109–13

Ovarian and adrenal contributions to postnatal growth and differentiation of the rat uterus. Branham WS, et al. **Biol Reprod** 1995 Oct;53(4):863–72

Influence of hypothalamus and ovary on pituitary function in transgenic mice expressing the bovine growth hormone gene and in growth hormone-deficient Ames dwarf mice. Chandrashekar V, et al. **Biol Reprod** 1996 May;54(5):1002–8

Follicular and luteal progesterone play different roles synchronizing pituitary and ovarian events in the 4-day cyclic rat. Tébar M, et al. **Biol Reprod** 1995 Nov; 53(5):1183–9

Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Chen HK, et al. **Bone** 1995 Oct;17(4 Suppl):175S–179S

Intermittent treatment of prostaglandin E2 with risedronate is more anabolic than prostaglandin E2 alone in the proximal tibial metaphysis of ovariectomized rats. Chen HK, et al. **Bone** 1995 Oct;17(4 Suppl):285S–289S

Estrogen dose required to maintain parathyroid hormone mediated bone gain in osteopenic ovariectomized rats is probably higher than in preventive treatment with estrogen. Cheng PT, et al. **Bone** 1995 Oct;17(4 Suppl):329S–334S

Intravenous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitometric and tomographic (pQCT) study. Cointry GR, et al. **Bone** 1995 Oct;17(4 Suppl):373S–378S

Skeletal changes in the ovariectomised ewe and subsequent response to treatment with 17 beta oestradiol. Hornby SB, et al. **Bone** 1995 Oct;17(4 Suppl):389S–394S

Development of osteopenia in ovariectomized cynomolgus monkeys (Macaca fascicularis). Jerome CP, et al. **Bone** 1995 Oct;17(4 Suppl):403S–408S

Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Jerome CP, et al. **Bone** 1995 Oct;17(4 Suppl):415S–420S

Risedronate pretreatment does not hamper the anabolic effects of prostaglandin E2 in ovx rats. Li QN, et al. **Bone** 1995 Oct;17(4 Suppl):261S–266S

Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats. Liang HH, et al. **Bone** 1995 Oct;17(4 Suppl):335S–339S

Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. Ma Y, et al. **Bone** 1995 Oct;17(4 Suppl):267S–272S

A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1-34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats. Mashiba T, et al. **Bone** 1995 Oct; 17(4 Suppl):273S–278S

The effect of oophorectomy on calcium homeostasis. Morris HA, et al. **Bone** 1995 Oct;17(4 Suppl):169S–174S

The effect of ovariectomy on bone metabolism in rats. Omi N, et al. **Bone** 1995 Oct;17(4 Suppl):163S–168S

Intermittent treatments of prostaglandin E2 plus risedronate and prostaglandin E2 alone are equally anabolic on tibial shaft of ovariectomized rats. Pan Z, et al. **Bone** 1995 Oct; 17(4 Suppl):291S–296S

Comparative x-ray densitometry of bones from ovariectomized rats. Sato M. **Bone** 1995 Oct;17(4 Suppl):157S–162S

Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Turner AS, et al. **Bone** 1995 Oct;17(4 Suppl):395S–402S

Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes. Turner AS, et al. **Bone** 1995 Oct;17(4 Suppl):421S–427S

Discrepancy of response of hPTH administration and its withdrawal between trabecular and cortical bone sites in OVX rats. Yamamoto N, et al. **Bone** 1995 Oct;17(4 Suppl):279S–283S

Tamoxifen treatment of ovariectomized mice alters dopamine release from striatal tissue fragments superfused in vitro. McDermott JL, et al. **Brain Res** 1995 Nov 6; 698(1-2):248–52

Hemostatic profile of bovine ovarian follicular fluid. Yamada M, et al. **Can J Physiol Pharmacol** 1995 May;73(5):624–9

Increased oxidative DNA damage in livers of 2,3,7,8-tetrachlorodibenzo-p-dioxin treated intact but not ovariectomized rats. Tritscher AM, et al. **Cancer Lett** 1996 Jan 2;98(2):219–25

Identification and behavior of epithelial stem cells in the Drosophila ovary. Margolis J, et al. **Development** 1995 Nov; 121(11):3797–807

Localization of oskar RNA regulates oskar translation and requires Oskar protein. Rongo C, et al. **Development** 1995 Sep;121(9):2737–46

The ovarian insulin and insulin-like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Leptin is a metabolic signal to the reproductive system. Barash IA, et al. **Endocrinology** 1996 Jul;137(7):3144–7

Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats. Markaverich BM, et al. **Environ Health Perspect** 1995 Jun;103(6):574–81

Paracrine mechanism of ovarian regulation. Dor J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):25–8 (26 ref.)

Effects of gonadotropin administration on follicular growth and in vitro fertilization in female hypogonadal mice. Hashizume K, et al. **Exp Anim** 1995 Jul;44(3):241–4

Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Barbosa I, et al. **Fertil Steril** 1996 Apr;65(4):724–9

Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome. Farhi J, et al. **Fertil Steril** 1995 Nov;64(5):930–5

A novel method of ovarian stimulation for in vitro fertilization: bromocriptine-rebound method. Jinno M, et al. **Fertil Steril** 1996 Aug;66(2):271–4

Estrogen biosynthesis—regulation, action, remote effects, and value of monitoring in ovarian stimulation cycles. Shoham Z, et al. **Fertil Steril** 1996 Apr;65(4):687–701 (161 ref.)

Comparative study of oestrogen excretion in female New World Monkeys: an overview of non-invasive ovarian monitoring and a new application in evolutionary biology. Pryce CR, et al. **Folia Primatol (Basel)** 1995;64(3):107–23

Transdermal estrogen replacement therapy in normal perimenopausal women: effects on pituitary-ovarian function. De Leo V, et al. **Gynecol Endocrinol** 1996 Feb; 10(1):49–53

Evaluation of different ovarian stimulation protocols for in vitro fertilization. Pados G, et al. **Gynecol Endocrinol** 1995 Jun;9(2):103–12

Effect of 1st-trimester loss on restoration of the hypothalamic-pituitary-ovarian axis. Elkas JC, et al. **Gynecol Obstet Invest** 1995;40(4):257–60

Ovarian effects upon maternal glucose tolerance. Khalil A, et al. **Gynecol Obstet Invest** 1996;41(3):173–6

Endometrial and placental protein markers and ovarian steroids in serum during in-vitro fertilization cycles. Bersinger NA, et al. **Hum Reprod** 1995 Aug;10(8):2149–54

Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Candy CJ, et al. **Hum Reprod** 1995 Sep;10(9):2334–8

Follicular selection in the cyclic hamster: a 1960 model. Greenwald GS. **Hum Reprod** 1995 Sep;10(9):2225–7

Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2–5. Hansen LM, et al. **Hum Reprod** 1996 Mar;11(3):486–9

Effects of aging on the female reproductive system. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:77–83 (37 ref.)

Donor-recipient synchronization and the use of gonadotrophin-releasing hormone agonists to avoid the premature luteinizing hormone surge in oocyte donation. Remohí J, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:84–90

Ovarian response after gonadotropin treatment of heifers immunized against gonadotropin-releasing hormone. Bishop DK, et al. **J Anim Sci** 1996 May;74(5):1092–7

Effects of single or primary plus booster prostaglandin F2 alpha immunization regimens on immune, ovarian, and growth responses of heifers. Crowe MA, et al. **J Anim Sci** 1995 Aug;73(8):2406–17

Immunization of heifers against gonadotropin-releasing hormone: antibody titers, ovarian function, body growth, and carcass characteristics. Prendiville DJ, et al. **J Anim Sci** 1995 Aug;73(8):2382–9

Immunization of prepubertal beef heifers against gonadotropin-releasing hormone: immune, estrus, ovarian, and growth responses. Prendiville DJ, et al. **J Anim Sci** 1995 Oct;73(10):3030–7

Ovarian function in relation to the outcome of in vitro fertilization (IVF) treatment in regularly menstruating women with tubal infertility. Csemiczky G, et al. **J Assist Reprod Genet** 1995 Nov;12(10):683–8

Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. Paoletti AM, et al. **J Assist Reprod Genet** 1995 Apr;12(4):263–8

Ovarian activity during follicular-phase down regulation in in vitro fertilization is associated with advanced maternal age and a high recurrence rate in subsequent cycles. Session DR, et al. **J Assist Reprod Genet** 1995 May;12(5):301–4

The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? van Hooff MH. **J Assist Reprod Genet** 1995 Apr;12(4):233–5 (13 ref.)

Effect of ovariectomy on cancellous bone in the hypophysectomized rat. Chen MM, et al. **J Bone Miner Res** 1995 Sep;10(9):1334–42

Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. Miyaura C, et al. **J Bone Miner Res** 1995 Sep;10(9):1365–73

Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. Seifer DB, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):736–9

Effects of ovariectomy and estrogen replacement on attractivity and receptivity in the red-sided garter snake

(Thamnophis sirtalis parietalis). Mendonça MT, et al. **J Comp Physiol [A]** 1996;178(3):373–81

Photothermal effects on ovarian growth and function in the soft-shelled turtle Lissemys punctata punctata. Sarkar S, et al. **J Exp Zool** 1996 Jan 1;274(1):41–55

Response of cynomolgus macaques to immunization against a synthetic peptide from the human zona pellucida. Mahi-Brown CA, et al. **J Med Primatol** 1995 Dec; 24(4):258–70

Effects of pineal indoles on ovarian response to gonadotropin-induced ovulation in mice. Chan WY, et al. **J Neural Transm Gen Sect** 1995;100(3):239–46

Estrogens and non-estrogenic ovarian influences combine to promote the recruitment and decrease the turnover of new neurons in the adult female canary brain. Hidalgo A, et al. **J Neurobiol** 1995 Aug;27(4):470–87

Functional role of follicular cells in the generation of osmolarity-dependent Cl- currents in Xenopus follicles. Arellano RO, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):351–7

Methodology and characterization of an in vitro perfusion model for the mouse ovary. Brännström M, et al. **J Reprod Fertil** 1995 Nov;105(2):177–83

Effects of chronic treatment with a gonadotrophin-releasing hormone agonist on peripheral concentrations of FSH and LH, and ovarian function in heifers. Gong JG, et al. **J Reprod Fertil** 1995 Nov;105(2):263–70

Evidence for a local role of inhibin or inhibin alpha subunits in compensatory ovarian hypertrophy. King BF, et al. **J Reprod Fertil** 1995 Jul;104(2):291–5

Follicular atresia as an apoptotic process: atresia-associated increase in the ovarian expression of the putative apoptotic marker sulfated glycoprotein-2. Hurwitz A, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):199–208

The endocrinology of the menopause. Burger HG. **Maturitas** 1996 Mar;23(2):129–36 (44 ref.)

The estrous cycle and pituitary-ovarian function in Lewis and Fischer rats. Smith CC, et al. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):231–5

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

The role of ovarian hormones, age and mammary gland development in polyomavirus mammary tumorigenesis. Rondinelli RH, et al. **Oncogene** 1995 Nov 2;11(9):1817–27

Short day-induced depletion of lipid stores is fat pad- and gender-specific in Siberian hamsters. Bartness TJ. **Physiol Behav** 1995 Sep;58(3):539–50

Discrimination of ovarian steroids by rats. Gorzalka BB, et al. **Physiol Behav** 1995 Nov;58(5):1003–11

Twenty-four hour feline excretion patterns in entire and castrated cats. Hendriks WH, et al. **Physiol Behav** 1995 Sep;58(3):467–9

Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Leonardsson G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12446–50

Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones. Poole TM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5848–53

Heterosexual activity: relationship with ovarian function. Burleson MH, et al. **Psychoneuroendocrinology** 1995; 20(4):405–21

The advent of menopause [letter] Knobil E, et al. **Science** 1996 Oct 4;274(5284):18–20

Menopause: the aging of multiple pacemakers. Wise PM, et al. **Science** 1996 Jul 5;273(5271):67–70 (67 ref.)

Influence of season and housing on ovarian activity of indigenous goats in Zimbabwe. Llewelyn CA, et al. **Trop Anim Health Prod** 1995 Aug;27(3):175–85

Ovarian regulation of sperm progression in the fallopian tubes. Hunter RH. **Zygote** 1994 Nov;2(4):363–6 (22 ref.)

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

[Regulation of hypothalamo—hypophyseal—ovarian function] Ibuki Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):809–13 (15 ref.) **(Jpn)**

[Most common neoplasms of female genital organs and hypo-thalamic-hypophysial-ovarian regulation in the postmenopausal period] Rzepka-Górska I, et al. **Ginekol Pol** 1995 Jan;66(1):36–40 (Eng. Abstr.) **(Pol)**

[Insulin-like growth factors and ovarian function] Suchanek E. **Lijec Vjesn** 1996 Mar;118 Suppl 1:38–40 (Eng. Abstr.) **(Scr)**

[The effect of epiphysectomy and destruction of the lateral septal nucleus of the brain on the genital system in juvenile rats under different light regimens (the interaction of gonadostat++ and photoperiodic mechanisms in the regulation of ovarian functions)] Slaetna OV, et al. **Fiziol Zh** 1995 Jan-Apr;41(1-2):67–73 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Are adrenal and ovarian function normal in true precocious puberty? [comment] Rosenfield RL. **Eur J Endocrinol** 1995 Oct;133(4):399–400. Comment on: Eur J Endocrinol 1995 Oct;133(4):403–6. Comment on: Eur J Endocrinol 1995 Oct;133(4):407–11.

Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Paoletti AM, et al. **Fertil Steril** 1995 Dec;64(6):1094–8

The impact of ovarian cystectomy on ovarian response to stimulation during in-vitro fertilization cycles. Nargund G, et al. **Hum Reprod** 1996 Jan;11(1):81–3

Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Scott RT, et al. **Hum Reprod** 1995 Jul;10(7):1706–10

Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ghizzoni L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):601–6

Effect of hypothyroidism on the pituitary-gonadal axis in the adult female rat. Mattheij JA, et al. **J Endocrinol** 1995 Jul;146(1):87–94

Corticotropin-releasing factor (CRF) and stress-related reproductive failure: the brain as a state of the art or the ovary as a novel clue? Nappi RE, et al. **J Endocrinol Invest** 1995 Dec;18(11):872–80 (89 ref.)

Effects of splenectomy on luteolysis in pseudopregnant rabbits. Nariai K, et al. **J Vet Med Sci** 1995 Jun;57(3):503–5

Ovaries in systemic lupus erythematosus [letter; comment] Praprotnik S, et al. **Lupus** 1995 Oct;4(5):418. Comment on: Lupus 1995 Feb;4(1):39–45.

The hypothalamus-pituitary-ovary and hypothalamus-pituitary-thyroid axes in spinal cord-injured women. Huang TS, et al. **Metabolism** 1996 Jun;45(6):718–22

A study of ovarian function in rheumatoid arthritis. Flaisler F, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):549–54

[Effects of ACM sequential chemotherapy on ovarian function in trophoblastic tumors] Shi Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):45–8 (Eng. Abstr.) **(Chi)**

[Status of ovarian function in experimental modeling of hyperthyroidism and hyperthyrotropinemia] Volkova OV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):422–4 **(Rus)**

RADIATION EFFECTS

Selective fallopian tube catheterisation in female infertility: clinical results and absorbed radiation dose. Nakamura K, et al. **Eur Radiol** 1996;6(4):465–9

Prolonged amenorrhea associated with total nodal irradiation for Hodgkin's disease. Halyard MY, et al. **J Nati Med Assoc** 1996 Jun;88(6):391–3

[The demonstration of heritable lethal mutations in the progeny of x-ray-irradiated CHO cells by micronucleus count in clone cells] Hagemann G, et al. **Strahlenther Onkol** 1996 Jun;172(6):320–5 (Eng. Abstr.) **(Ger)**

SECRETION

Predictors of ovarian steroid secretion in reproductive-age women. Westhoff C, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):381–8

Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Karlan BY, et al. **Gynecol Oncol** 1995 Oct;59(1):67–74

Role of gonadotrophin releasing hormone baseline concentrations in the control of pituitary gonadotrophin and ovarian steroid secretion in the pseudopregnant rat. Schuiling GA, et al. **Hum Reprod** 1996 Jan;11(1):13–8

The effect of ovarian arterial infusion of human recombinant inhibin and bovine follicular fluid on ovarian hormone secretion by ewes with an autotransplanted ovary. Campbell BK, et al. **J Endocrinol** 1996 Jun;149(3):531–40

The in vivo effects of fibroblast growth factor and epidermal growth factor on the secretion of oestradiol, androstenedione and progesterone by the autotransplanted ovary in the ewe. Scaramuzzi RJ, et al. **J Endocrinol** 1995 Aug;146(2):301–11

Effect of acute immunoneutralization of inhibin in ewes during the late luteal phase of the oestrous cycle on ovarian hormone secretion and follicular development during the subsequent follicular phase. Campbell BK, et al. **J Reprod Fertil** 1995 Jul;104(2):337–45

SURGERY

No more radiogenic castration in women with Hodgkin's disease? [letter] De Wilde RL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1639

Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Clough KB, et al. **Cancer** 1996 Jun 15;77(12):2638–45

Laparoscopic ovarian transposition. Covens AL, et al. **Eur J Gynaecol Oncol** 1996;17(3):177–82

Reconstruction of the ovary containing large endometriomas by an extraovarian endosurgical technique. Brosens IA, et al. **Fertil Steril** 1996 Oct;66(4):517–21

Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease. Taskin O, et al. **Fertil Steril** 1996 Jun;65(6):1115–8

Use of fibrin sealant for reproductive surgery: a randomized study in the rabbit model. Marana R, et al. **Gynecol Obstet Invest** 1996;41(3):199–202

A laparoscopic technique for lateral oophoropexy to conserve ovarian function prior to abdominopelvic irradiation [letter] Letterie GS. **Surg Endosc** 1995 Oct; 9(10):1144–5

[Pregnancy after transposition and repositioning of the ovaries in a patient with clear-cell adenocarcinoma] Gerbaulet A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):534–8 (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Distinct effects of ovarian transplantation and exogenous 17 beta-oestradiol on cancellous bone of osteopenic ovariectomized rats. Gallagher AC, et al. **Eur J Endocrinol** 1995 Oct;133(4):483–8

Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Candy CJ, et al. **Hum Reprod** 1995 Sep;10(9):2334–8

Mummy was a fetus: motherhood and fetal ovarian transplantation. Berkowitz JM. **J Med Ethics** 1995 Oct; 21(5):298–304

[Functional outcome of laparoscopically transposed ovaries in the multidisciplinary treatment of cervical cancers. Analysis of risk factors] Stöckle E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):244–52 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Vuento MH, et al. **Cancer** 1995 Oct 1;76(7):1214–8

Polycystic ovaries in pre and post-menopausal women. Birdsall MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):269–76

Ovarian morphology and insulin sensitivity in women with bulimia nervosa. Raphael FJ, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):451–5

Ovarian volume: a novel outcome predictor for assisted reproduction. Syrop CH, et al. **Fertil Steril** 1995 Dec; 64(6):1167–71

Ovaries in systemic lupus erythematosus [letter; comment] Praprotnik S, et al. **Lupus** 1995 Oct;4(5):418. Comment on: Lupus 1995 Feb;4(1):39–45.

Normal US appearance of ovaries and uterus in four patients with Turner's syndrome and 45,X karyotype. Boechat MI, et al. **Pediatr Radiol** 1996;26(1):37–9

Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Venturoli S, et al. **Pediatr Res** 1995 Dec;38(6):974–80

Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Anandakumar C, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):280–4

Pubertal maturation of the internal genitalia [comment] Balen A, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):164–5. Comment on: Ultrasound Obstet Gynecol 1995 Sep;6(3):175–81.

Clinical application of volume estimation based on three-dimensional ultrasonography. Brunner M, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):358–61

Pathognomonic echo patterns of benign cystic teratomas of the ovary: classification, incidence and accuracy rate of sonographic diagnosis. Caspi B, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):275–9

Pubertal maturation of the internal genitalia: an ultrasound evaluation of 166 healthy girls [see comments] Holm K, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):175–81. Comment in: Ultrasound Obstet Gynecol 1995 Sep;6(3):164–5.

Transvaginal gray-scale and Doppler ultrasound examinations of the uterus and ovaries in healthy postmenopausal women. Sladkevicius P, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):81–90

[Optimization of embryo transfer programs in ewes by transrectal ultrasonographic ovary diagnosis (B-mode) in superovulated donors] Kaulfuss KH, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):208–12 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Structure of the multiorgan renal lymph node after selective blockade of its afferent lymphatics from female reproductive organs in the Wistar rats. Marniok B, et al. **Folia Morphol (Warsz)** 1995;54(2):123–8

[Morphological evaluation of intercellular junctions in the ovary of chick embryos: action of steroid and gonadotropic hormones in vitro] Avila RE, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):5–10 (Eng. Abstr.) **(Spa)**

OVER-THE-COUNTER DRUGS see **DRUGS, NON-PRESCRIPTION**

OVERALL AND GORHAM BRIEF PSYCHIATRIC RATING SCALE see **BRIEF PSYCHIATRIC RATING SCALE**

OVERDENTURE see **DENTURE, OVERLAY**

OVERDOSE

Acute isoniazid overdose in a compliant adolescent patient. Wilcox WD, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):213–4

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154–71 (137 ref.)

Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344–51 (47 ref.)

OVERDOSE

[Fatal cases of poisonings among drug addicts in the county of Funen in 1993] Jensen BT, et al. **Ugeskr Laeger** 1995 Nov 13;157(46):6434–7 (Eng. Abstr.) **(Dan)**

BLOOD

Drugs in blood samples from unconscious drug addicts after the intake of an overdose. Steentoft A, et al. **Int J Legal Med** 1996;108(5):248–51

COMPLICATIONS

Shock, metabolic acidosis, and coma following ibuprofen overdose in a child. Zuckerman GB, et al. **Ann Pharmacother** 1995 Sep;29(9):869–71

Laryngeal dystonia [letter] Murray V. **Br J Psychiatry** 1995 Nov;167(5):698–9

Delayed onset generalised dystonia after cyanide poisoning. Borgohain R, et al. **Clin Neurol Neurosurg** 1995 Aug; 97(3):213–5

Carbohydrate-deficient transferrin for identification of drug overdose patients at risk of an alcohol withdrawal syndrome. Köppel C, et al. **J Toxicol Clin Toxicol** 1996; 34(3):297–300

[Cerebral infarct in chronic acetylsalicylic acid poisoning] Treib J, et al. **Nervenarzt** 1996 Apr;67(4):333–4 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Limited toxicology screening: end of a controversy [editorial; comment] Catrou PG, et al. **Am J Clin Pathol** 1996 May; 105(5):527–8. Comment on: Am J Clin Pathol 1996 May;105(5):572–5.

Acute confusion in a chronic benzodiazepine patient. Withdrawal-related nonconvulsive status epilepticus misdiagnosed as acute intoxication [letter] Primavera A, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):460–2

Assessment and referral patterns of patients admitted after deliberate self-poisoning. Brown DH, et al. **Scott Med J** 1995 Oct;40(5):144–6

ECONOMICS

The cost of antidepressant overdose. D'Mello DA, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):454–5

EPIDEMIOLOGY

Changes in the pattern of deliberate self-poisoning presenting at Craigavon Area Hospital: 1976, 1986 and 1991. Quigley N, et al. **Ulster Med J** 1994 Oct;63(2):155–61

ETIOLOGY

Prevention of rickets and vitamin D intoxication in China [letter] [see comments] Li T, et al. **Acta Paediatr** 1995 Aug; 84(8):940. Comment in: Acta Paediatr 1995 Aug;84(8):848.

Acute encephalopathy and polyneuropathy after disulfiram intoxication. Zorzon M, et al. **Alcohol Alcohol** 1995 Sep; 30(5):629–31

MORTALITY

Drug abuse and intoxication in alcoholics. Thomsen JL, et al. **Alcohol Alcohol** 1995 May;30(3):379–83

Trazodone for the treatment of depression in alcoholics [letter] Hershberg PI. **J Subst Abuse Treat** 1995 Jul–Aug; 12(4):297

[Fatalities associated with methadone administration in the Geneva canton (1987–1993)] La Harpe R, et al. **Arch Kriminol** 1995 Jul–Aug;196(1–2):24–9 (Eng. Abstr.) **(Ger)**

[Current aspects of para-suicidal poisoning] Weilemann LS, et al. **Med Klin** 1996 Jun 15;91(6):355–8 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. Rubinstein D, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1492–4

Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Fineschi V, et al. **Int J Legal Med** 1996;108(5):272–5

Fatal cerebellar haemorrhage due to phenprocoumon poisoning. Höhler T, et al. **Int J Legal Med** 1996; 108(5):268–71

[Fatal sodium azide poisoning in a hospital: a preventable accident] Herbold M, et al. **Arch Kriminol** 1995 Nov–Dec; 196(5–6):143–8 (Eng. Abstr.) **(Ger)**

[Drowning by aspiration of oral saline administration] Kropp S, et al. **Arch Kriminol** 1996 Mar–Apr;197(3–4):76–80 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Parents beware of accidental overdose of acetaminophen [news] Laino C. **AORN J** 1995 Sep;62(3):429

Paracetamol overdose [letter] Friedman T. **Br J Psychiatry** 1996 Apr;168(4):519

PSYCHOLOGY

Correlates and short-term course of self-poisoning in adolescents. Kerfoot M, et al. **Br J Psychiatry** 1996 Jan; 168(1):38–42

THERAPY

Intentional drug overdose: predictors of clinical course in the intensive care unit. Heyman EN, et al. **Heart Lung** 1996 May–Jun;25(3):246–52

Gastric emptying in acute overdose: a prospective randomised controlled trial [see comments] Pond SM, et al. **Med J Aust** 1995 Oct 2;163(7):345–9. Comment in: Med J Aust 1995 Oct 2;163(7):340–1.

Progress in clinical toxicology: from case reports to toxicoepidemiology [editorial; comment] Whyte IM, et al. **Med J Aust** 1995 Oct 2;163(7):340–1. Comment on: Med J Aust 1995 Oct 2;163(7):345–9.

Assessment and referral patterns of patients admitted after deliberate self-poisoning. Brown DH, et al. **Scott Med J** 1995 Oct;40(5):144–6

VETERINARY

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

OVEREATING see **HYPERPHAGIA**

OVERPOPULATION see **POPULATION DENSITY**

OVERUSE SYNDROMES see **REPETITION STRAIN INJURY**

OVERUTILIZATION OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

OVIDUCTS

ANATOMY & HISTOLOGY

Morphologic characteristics of oviducts from hens producing eggs of different Haugh units caused by genetics and by feeding vanadium as determined with computer software-integrated digitizing technology. Toussant MJ, et al. **Poult Sci** 1995 Oct;74(10):1671–6

CHEMISTRY

An oviposition-inducing peptide: isolation, localization, and function of avian galanin in the quail oviduct. Li D, et al. **Endocrinology** 1996 May;137(5):1618–26

D-aspartate in the male and female reproductive system of Octopus vulgaris lam. D'Aniello A, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):69–72

Effects of presence of an egg and calcium deposition in the shell gland on levels of messenger ribonucleic acid of CaBP-D28K and of vitamin D3 receptor in the shell gland of the laying hen. Ieda T, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):145–51

CYTOLOGY

Development of T-lymphocyte subpopulations in the postnatal chicken oviduct. Khan MZ, et al. **Cell Tissue Res** 1996 May;284(2):317–25

Vitamin A is involved in estrogen-induced cell proliferation but not in cytodifferentiation of the chicken oviduct. Ninomiya Y, et al. **J Endocrinol** 1996 Feb;148(2):257–65

Induction of ciliogenesis in oviduct epithelium. Chailley B, et al. **Methods Cell Biol** 1995;47:75–81

ENZYMOLOGY

Characterization of oviductal aromatase in the northern leopard frog, Rana pipiens. Kobayashi F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):653–7

Chicken oviductal ecto-ATP-diphosphohydrolase. Purification and characterization. Strobel RS, et al. **J Biol Chem** 1996 Jul 5;271(27):16323–31

METABOLISM

Modulation of transcriptional activity of the chicken ovalbumin gene promoter in primary cultures of chicken oviduct cells: effects of putative regulatory elements in the 5'-flanking region. Park HM, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):811–6

Induction of ovalbumin mRNA by ascorbic acid in primary cultures of tubular gland cells of the chicken oviduct. Muramatsu T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):209–16

Radioligand and immunochemical studies of turtle oviduct progesterone and estrogen receptors: correlations with hormone treatment and oviduct contractility. Giannoukos G, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):63–75

Cyclic nucleotide-induced termination of vitellogenin uptake by Hyalophora cecropia follicles. Wang Y, et al. **Insect Biochem Mol Biol** 1996 Jan;26(1):85–94

Fluctuations in levels of various gangliosides in the different tracts of the oviduct of the frog (Rana esculenta) during the reproductive cycle. Giuliani A, et al. **Ital J Biochem** 1995 Mar–Apr;44(2):75–88

Regulation of the chicken ovalbumin gene by estrogen and corticosterone requires a novel DNA element that binds a labile protein, Chirp-1. Dean DM, et al. **Mol Cell Biol** 1996 May;16(5):2015–24

Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Smith DF, et al. **Mol Cell Biol** 1995 Dec;15(12):6804–12

PHYSIOLOGY

Non-linear dynamics of neurochemical modulation of mosquito oviduct and hindgut contractions. Messer AC, et al. **J Exp Biol** 1995 Nov;198 (Pt 11):2325–36

OVIDUCTS, MAMMALIAN see **FALLOPIAN TUBES**

OVINE-CAPRINE LENTIVIRUSES see **LENTIVIRUSES, OVINE-CAPRINE**

OVINE CATARRHAL FEVER VIRUS see **BLUETONGUE VIRUS**

OVIPOSITION

The Edinburgh modified cage for laying hens. Appleby MC, et al. **Br Poult Sci** 1995 Dec;36(5):707–18

Divergent selection for residual food intake in Rhode Island red egg-laying lines: gross carcase composition, carcase adiposity and lipid contents of tissues. El-Kazzi M, et al. **Br Poult Sci** 1995 Dec;36(5):719–28

Examination of egg number and egg weight variables and their effects on daily management in aviary systems for laying hens. Lokhorst C, et al. **Br Poult Sci** 1995 Dec; 36(5):693–705

A test for photorefractoriness in high-producing stocks of laying pullets. Morris TR, et al. **Br Poult Sci** 1995 Dec; 36(5):763–9

New intermittent lighting programme (the Reading system) for laying pullets. Morris TR, et al. **Br Poult Sci** 1995 Sep; 36(4):531–5

Laying hen responses to acute heat stress and carbon dioxide supplementation: II. Changes in plasma enzymes, metabolites and electrolytes. Koelkebeck KW, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):119–22

Effects of organic enrichment on temporal distribution and abundance of culicine egg rafts. Beehler JW, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):167–71

Oviposition preferences of Culex pipiens and Culex restuans for infusion-baited traps. Lampman RL, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):23–32

Diel rhythms of oviposition and fecundity of Anopheles aquasalis (Diptera:Culicidae) under laboratory conditions. Chadee DD, et al. **J Med Entomol** 1996 Jul;33(4):686–8

Effects of constant temperatures on oviposition and immature development of Simulium bidentatum (Diptera: Simuliidae), a vector of bovine Onchocerca (Nematoda: Onchocercidae) in central Kyushu, Japan. Hadi UK, et al. **J Med Entomol** 1995 Nov;32(6):801–6

Egg deposition of the intestinal nematode Heterakis spumosa: stimulation by soluble colon factors of mice. Harder A, et al. **J Parasitol** 1995 Oct;81(5):733–5

Mutations in a C. elegans Gqalpha gene disrupt movement, egg laying, and viability. Brundage L, et al. **Neuron** 1996 May;16(5):999–1009

Quantitative determination of spermatozoa penetration of the perivitelline layer of the hen's ovum as assessed on oviposited eggs. Bramwell RK, et al. **Poult Sci** 1995 Nov; 74(11):1875–83

A Drosophila seminal fluid protein, Acp26Aa, stimulates egg laying in females for 1 day after mating. Herndon LA, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10114–8

Discrete clutch sizes, local mate competition, and the evolution of precise sex allocation. Nagelkerke CJ. **Theor Popul Biol** 1996 Jun;49(3):314–43

[Micro-morphology of the ovipositor in Hymenoptera and evolution from phytophagous Symphyta to parasitoid Apocrita] Nénon JP, et al. **C R Acad Sci III** 1995 Oct; 318(10):1045–51 (Eng. Abstr.) **(Fre)**

[Incorporation and mobilization of vitamin A in laying hens] Richter G. **Arch Tierernahr** 1995;48(4):337–45 (Eng. Abstr.) **(Ger)**

[The dependence of egg-laying activity on the number of Leptopsylla segnis (Siphonaptera: Leptopsyllidae) fleas on the host] Vatsenok VS. **Parazitologiia** 1995 Jul–Aug; 29(4):267–71 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

An oviposition-inducing peptide: isolation, localization, and function of avian galanin in the quail oviduct. Li D, et al. **Endocrinology** 1996 May;137(5):1618–26

Response of gravid Phlebotmus papatasi females to an oviposition attractant/stimulant associated with conspecific eggs. Srinivasan R, et al. **Indian J Exp Biol** 1995 Oct; 33(10):757–60

Anti-oviposition and insecticidal activity of Imperata cylindrica (Gramineae). Mohsen ZH, et al. **Med Vet Entomol** 1995 Oct;9(4):441–2

Influence of calcium and environmental temperature on performance of first-cycle (phase 1) commercial leghorns. Roland DA Sr, et al. **Poult Sci** 1996 Jan;75(1):62–8

The sterilizing effect of pour-on flumethrin on the camel tick, Hyalomma dromedarii (Acari: Ixodidae). El-Azazy OM, et al. **Vet Parasitol** 1996 Feb;61(3–4):339–43

GENETICS

Genetic correlation and heritabilities for purebred and crossbred performance in poultry egg production traits. Wei M, et al. **J Anim Sci** 1995 Aug;73(8):2220–6

Insulin-like growth factor I (IGF-I), IGF-II and type-I IGF receptor gene expression in the ovary of the laying hen. Armstrong DG, et al. **J Reprod Fertil** 1996 Jan;106(1):101-6

Heterosis in egg-laying lines under divergent selection for residual feed consumption. Bordas A, et al. **Poult Sci** 1996 Jan;75(1):20-4

Correlated responses to long-term divergent selection for eight-week body weight in chickens: growth, sexual maturity, and egg production. Liu G, et al. **Poult Sci** 1995 Aug;74(8):1259-68

PHYSIOLOGY

Effect of temperature and humidity on longevity of unfed adults and on oviposition of engorged females of Dermacentor reticulatus (Ixodidae). Zahler M, et al. **Appl Parasitol** 1995 Aug;36(3):200-11

Effect of diet and natural variations in climates on the performance of laying hens. Njoya J. **Br Poult Sci** 1995 Sep;36(4):537-54

Effects of presence of an egg and calcium deposition in the shell gland on levels of messenger ribonucleic acid of CaBP-D28K and of vitamin D3 receptor in the shell gland of the laying hen. Ieda T, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):145-51

Seasonal and acute changes in adrenocortical responsiveness in an arctic-breeding bird. Astheimer LB, et al. **Horm Behav** 1995 Dec;29(4):442-57

Influence of the presence of chicks on the ability to resume incubation behavior in domestic hens (Gallus domesticus). Richard-Yris MA, et al. **Horm Behav** 1995 Dec; 29(4):425-41

Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. Weinshenker D, et al. **J Neurosci** 1995 Oct;15(10):6975-85

Selection for high and low threshold body weight at first egg in broiler strain females. 6. Threshold weight for onset of photosensitivity in females of the selection lines. Eitan Y, et al. **Poult Sci** 1996 Apr;75(4):459-63

Two-way selection for threshold body weight at first egg in broiler strain females. 5. Replication of results in a two-generation selection experiment. Eitan Y, et al. **Poult Sci** 1995 Oct;74(10):1561-5

The effect of Lactobacillus acidophilus on the production and chemical composition of hen's eggs. Haddadin MS, et al. **Poult Sci** 1996 Apr;75(4):491-4

Ability of commercial laying hens producing different egg outputs to meet their methionine and energy requirements when fed the same diet. Harms RH, et al. **Poult Sci** 1996 Apr;75(4):519-21

Effects of population density on layer performance. Lee K, et al. **Poult Sci** 1995 Nov;74(11):1754-60

Interaction of feeding time and temperature and their relationship to performance of the broiler breeder hen. Samara MH, et al. **Poult Sci** 1996 Jan;75(1):34-41

Evaluation of early feed restriction on egg size and hen performance. Sandoval DM, et al. **Poult Sci** 1996 Mar; 75(3):311-4

Effects of sex-linked imperfect albinism (sal-s) in the chicken on the relationships of plasma concentrations of progesterone and 17 beta-estradiol with egg production. Su H, et al. **Poult Sci** 1996 Jan;75(1):13-9

The long-term productivity of hens housed in battery cages and an aviary. Taylor AA, et al. **Poult Sci** 1996 Jan; 75(1):47-51

Chemical egg defense in a green lacewing (Ceraeochrysa smithi) Eisner T, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3280-3

Comparison of performance and mortality in the hybro normal and hybro giant meat poultry breeders and their offspring. Barbour EK, et al. **Vet Res Commun** 1996; 20(1):1-7

[Rapeseed and rapeseed meal as components in diets of laying hens] Richter G, et al. **Arch Tierernahr** 1996;49(3):229-41 (Eng. Abstr.) **(Ger)**

[The attraction of the female urban mosquito Culex pipiens (Diptera, Culicidae) for oviposition by different attractants] Rasnitsyn SP, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar; (1):29-33 (Eng. Abstr.) **(Rus)**

OVOCYTES see **OOCYTES**

OVOMUCIN

CHEMISTRY

The absence of chiral recognition ability in ovomucoid: ovoglycoprotein-bonded HPLC stationary phases for chiral recognition. Haginaka J, et al. **Anal Chem** 1995 Aug 1;67(15):2539-47

The determinants of pKas in proteins. Antosiewicz J, et al. **Biochemistry** 1996 Jun 18;35(24):7819-33

Temperature and pH dependences of hydrogen exchange and global stability for ovomucoid third domain. Swint-Kruse L, et al. **Biochemistry** 1996 Jan 9;35(1):171-80

Analysis of transverse cross relaxation in proteins within a simplified relaxation submatrix: BD-ROESY. Hoogstraten CG, et al. **J Magn Reson B** 1995 Oct;109(1):76-9

Atomic solvation parameters in the analysis of protein-protein docking results. Cummings MD, et al. **Protein Sci** 1995 Oct;4(10):2087-99

Comparison of the accuracy of protein solution structures derived from conventional and network-edited NOESY data. Hoogstraten CG, et al. **Protein Sci** 1995 Nov; 4(11):2289-99

Water molecules participate in proteinase-inhibitor interactions: crystal structures of Leu18, Ala18, and Gly18 variants of turkey ovomucoid inhibitor third domain complexed with Streptomyces griseus proteinase B. Huang K, et al. **Protein Sci** 1995 Oct;4(10):1985-97

ISOLATION & PURIFICATION

Protein binding chiral discrimination of HPLC stationary phases made with whole, fragmented, and third domain turkey ovomucoid. Pinkerton TC, et al. **Anal Chem** 1995 Jul 15;67(14):2354-67

METABOLISM

The determinants of pKas in proteins. Antosiewicz J, et al. **Biochemistry** 1996 Jun 18;35(24):7819-33

Temperature and pH dependences of hydrogen exchange and global stability for ovomucoid third domain. Swint-Kruse L, et al. **Biochemistry** 1996 Jan 9;35(1):171-80

An ovomucin-like protein on the surface of migrating primordial germ cells of the chick and rat. Halfter W, et al. **Development** 1996 Mar;122(3):915-23

Water molecules participate in proteinase-inhibitor interactions: crystal structures of Leu18, Ala18, and Gly18 variants of turkey ovomucoid inhibitor third domain complexed with Streptomyces griseus proteinase B. Huang K, et al. **Protein Sci** 1995 Oct;4(10):1985-97

OVOMUCOID see **OVOMUCIN**

OVOTRANSFERRIN see **CONALBUMIN**

OVULATION

Simple or repeated induction of superovulation: a study on ovulation rates and microvessel corrosion casts in ovaries of golden hamsters. Löseke A, et al. **Anat Anz** 1996 Jan; 178(1):5-14

Follicular development and ovulation in macrophage colony-stimulating factor-deficient mice homozygous for the osteopetrosis (op) mutation. Araki M, et al. **Biol Reprod** 1996 Feb;54(2):478-84

Role of estrogen and prostaglandin F2 alpha in premature luteal regression in monovulatory and superovulated red deer (Cervus elaphus). Bainbridge DR, et al. **Biol Reprod** 1996 Feb;54(2):347-54

Effects of a very low fat, high fiber diet on serum hormones and menstrual function. Implications for breast cancer prevention. Bagga D, et al. **Cancer** 1995 Dec 15; 76(12):2491-6

Diabetes-mediated decreases in ovarian superoxide dismutase activity are related to blood-follicle barrier and ovulation defects. Powers RW, et al. **Endocrinology** 1996 Jul; 137(7):3101-10

Insulin-like growth factor binding protein-3 inhibits gonadotropin-induced ovulation, oocyte maturation, and steroidogenesis in rabbit ovary. Yoshimura Y, et al. **Endocrinology** 1996 Feb;137(2):438-46

Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development. Brache V, et al. **Fertil Steril** 1996 Jun;65(6):1110-4

Disappearance of the ovulation stigma in baboons (Papio anubis, Papio cynocephalus) as determined by serial laparoscopies during the luteal phase. D'Hooghe TM, et al. **Fertil Steril** 1996 Jun;65(6):1219-23

The effects of post-ovulatory administration of onapristone on the developmnent of a secretory endometrium. Cameron ST, et al. **Hum Reprod** 1996 Jan;11(1):40-9

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Clark AM, et al. **Hum Reprod** 1995 Oct;10(10):2705-12

Pre-ovulatory oxytocin administration promotes the onset of the luteinizing hormone surge in human females. Hull ML, et al. **Hum Reprod** 1995 Sep;10(9):2266-9

The control of ovulation in mothers of dizygotic twins. Gilfillan CP, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1557-62

Reduction of ovulation rate in the rat by administration of a neutrophil-depleting monoclonal antibody. Brännström M, et al. **J Reprod Immunol** 1995 Oct;29(3):265-70

Pregnancy and the timing of intercourse [letter; comment] Hilgers TW. **N Engl J Med** 1996 May 9;334(19):1267; discussion 1267-8. Comment on: N Engl J Med 1995 Dec 7;333(23):1517-21.

Pregnancy and the timing of intercourse [editorial; comment] [see comments] Simpson JL. **N Engl J Med** 1995 Dec 7; 333(23):1563-5. Comment on: N Engl J Med 1995 Dec 7;333(23):1517-21. Comment in: N Engl J Med 1995 May 9;334(19):1267; discussion 1268.

Pregnancy and the timing of intercourse [letter; comment] Strickler RC. **N Engl J Med** 1996 May 9;334(19):1266-7; discussion 1267-8. Comment on: N Engl J Med 1995 Dec 7;333(23):1517-21.

Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby [see comments] Wilcox AJ, et al. **N Engl J Med** 1995 Dec 7;333(23):1517-21. Comment in: N Engl J Med 1995 Dec 7;333(23):1563-5. Comment in: N Engl J Med 1995 May 9;334(19):1266; discussion 1267-8. Comment in: N Engl J Med 1995 May 9;334(19):1266-7; discussion 1267-8. Comment in: N Engl J Med 1995 May 9;334(19):1267; discussion 1267-8.

The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women. Miller PB, et al. **Obstet Gynecol** 1996 Jan;87(1):13-7

Potential leukocyte attractants in the bovine peri-ovulatory ovary. Sirotkin AV, et al. **Reprod Nutr Dev** 1995; 35(6):675-83

[A prospective study on causal factors of female infertility with laparoscopy and transvaginal B-ultrasound] Gu L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):18-21 (Eng. Abstr.) **(Chi)**

[The effect of experimental metabolic stress on ovulation and blood progesterone levels in cows] Vinkler A, et al. **Vet Med (Praha)** 1996 Mar;41(3):65-9 (Eng. Abstr.) **(Cze)**

[Sex and pregnancy] Olsen J, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3477-8 **(Dan)**

[Control of the menstrual cycle and ovulation] Knobil E. **Contracept Fertil Sex** 1995 Dec;23(12):705-9 **(Fre)**

BLOOD

Atrial natriuretic peptide, oestradiol and progesterone in women undergoing spontaneous and gonadotrophin-stimulated ovulatory cycles. Yeko TR, et al. **Hum Reprod** 1995 Nov;10(11):2872-4

Periovulatory endocrinology in high ovulating Meishan sows. Hunter MG, et al. **J Endocrinol** 1996 Jul;150(1):141-7

DRUG EFFECTS

Acceleration and timing of fertile ovulation in cyclic mares with a deslorelin implant. Gånheim A, et al. **Acta Vet Scand** 1995;36(4):393-400

The effect of unkei-to on pituitary gonadotropin secretion and ovulation in anovulatory cycles of young women. Ushiroyama T, et al. **Am J Chin Med** 1995;23(3-4):223-30

Inhibition of nitric oxide: effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Bonello N, et al. **Biol Reprod** 1996 Feb;54(2):436-45

Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Smith G, et al. **Br J Rheumatol** 1996 May;35(5):458-62

Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Cameron ST, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):407-14

Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Heikinheimo O, et al. **Contraception** 1996 Jan;53(1):55-64

Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480-94 (91 ref.)

Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364-95 (128 ref.)

Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Zanagnolo V, et al. **Fertil Steril** 1996 May;65(5):1036-43

Induction of ovulation with the sole use of clomiphene citrate in late-onset 21-hydroxylase deficiency. Laohaprasitiporn C, et al. **Gynecol Obstet Invest** 1996;41(3):224-6

Ultrasonographic monitoring of ovarian follicles in women using norethisterone for contraception. Chitlange SM, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):31-4

Ovulation rate and the concentrations of gonadotrophins and metabolic hormones in ewes infused with glucose during the late luteal phase of the oestrous cycle. Downing JA, et al. **J Endocrinol** 1995 Sep;146(3):403-10

Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release. Kovács M, et al. **J Neuroendocrinol** 1993 Dec;5(6):603-8

Suppression of oocyte release in rats by local administration of the noradrenergic neurotoxin DSP4. Goldman JM, et al. **J Reprod Fertil** 1996 Mar;106(2):275-83

Effects of macrophage colony-stimulating factor on folliculogenesis in gonadotrophin-primed immature rats. Nishimura K, et al. **J Reprod Fertil** 1995 Jul;104(2):325-30

Effect of oxytocin treatment during oestrus on the ovulation rate of Merino ewes. King PR, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):42-3

Blockade of ovulation in rabbits by RU-486, a competitive progesterone antagonist. Kanayama K, et al. **J Vet Med Sci** 1996 Mar;58(3):275-6

Modulation of water diffusion during gonadotropin-induced ovulation: NMR microscopy of the ovarian follicle. Tempel C, et al. **Magn Reson Med** 1995 Aug;34(2):213-8

Midcycle administration of a progesterone synthesis inhibitor prevents ovulation in primates. Hibbert ML, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1897-901

Effects of tumour necrosis factor alpha (TNF alpha) on ovulation in the rat ovary. Brännström M, et al. **Reprod Fertil Dev** 1995;7(1):67-73

Clomiphene-induced ovulation and the risk of neural tube defects [letter] Lammer EJ. **Reprod Toxicol** 1995 Sep-Oct; 9(5):491-3

Ovulation induction by clomiphene and neural tube defects [letter] Shaw GM, et al. **Reprod Toxicol** 1995 Jul-Aug; 9(4):399-400

OVULATION

[Effect of progesterone on ovulation length and duration of the ovarian cycle induced by the male effect in the Barbarine ewe and the local Tunisian goat] Lassoued N, et al. **Reprod Nutr Dev** 1995;35(4):415–26 (Eng. Abstr.) **(Fre)**

[Do 3rd-generation ovulation inhibitors have a new risk profile? (editorial)] Heinemann LA. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1037–9 **(Ger)**

[Control of ovulation in the mare with Ovuplant (short-term release of the GnRH analog deslorelin acetate). Overview of investigations from 1990 to 1994] Jöchle W. **Tierarztl Prax** 1995 Aug;23(4):381–93 (Eng. Abstr.) **(Ger)**

GENETICS

A search for quantitative trait loci for ovulation rate in cattle. Blattman AN, et al. **Anim Genet** 1996 Jun;27(3):157–62

Genetic evidence that ovulation reduces sexual receptivity in Drosophila melanogaster females. Fuyama Y. **Behav Genet** 1995 Nov;25(6):581–7

Alterations in follicular function associated with selection on ovulation rate in Finn ewes. Driancourt MA, et al. **J Anim Sci** 1996 Jan;74(1):199–210

Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Leonardsson G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12446–50

IMMUNOLOGY

Cellular and humoral immunity to sperm in ovulatory cervical mucus from infertile women. Ulcová-Gallová Z, et al. **Adv Exp Med Biol** 1995;371A:395–7

METABOLISM

Intrafollicular insulin-like growth factor-II levels in normally ovulating women and in patients with polycystic ovary syndrome. Barreca A, et al. **Fertil Steril** 1996 Apr; 65(4):739–45

Expression of collagenase-3 in the rat ovary during the ovulatory process. Balbín M, et al. **J Endocrinol** 1996 Jun; 149(3):405–15

High androgen production by ovarian thecal interstitial cells: a mechanism for delayed ovulation in a tropical vespertilionid bat, Scotophilus heathi. Abhilasha, et al. **J Reprod Fertil** 1996 Mar;106(2):207–11

[Neuroendocrine control of ovulation in sheep] Caraty A, et al. **Ann Endocrinol (Paris)** 1995;56(5):539–42 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The effect of energy balance on ovarian activity in a herd of Norwegian cattle. Ljøkjel K, et al. **Acta Vet Scand** 1995; 36(4):533–42

Follicular development and ovulation in sows: effect of hCG and GnRH treatment. Nissen AK, et al. **Acta Vet Scand** 1995;36(1):123–33

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)

Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Tsafriri A. **Adv Exp Med Biol** 1995; 377:121–40 (191 ref.)

Retardation by restricted feeding of age-related changes in steroidogenic activity of rat pre- and post-ovulatory follicles. Merry BJ, et al. **Age Ageing** 1996 May;25(3):250–5

Stress-induced genetic expression of a selective corticotropin-releasing factor-receptor subtype within the rat ovaries: an effect dependent on the ovulatory cycle. Nappi RE, et al. **Biol Reprod** 1995 Dec;53(6):1417–28

Impairment in follicle-stimulating hormone secretion by different treatments with follicular fluid as a source of inhibin blocks the ability of pulsatile luteinizing hormone to induce preovulatory surges of gonadotropins in prepubertal ewe lambs. Tortonese DJ, et al. **Biol Reprod** 1996 Feb;54(2):387–93

Ovulatory premenopausal women lose cancellous spinal bone: a five year prospective study. Prior JC, et al. **Bone** 1996 Mar;18(3):261–7

Differential effects of unilateral lesions in the medial amygdala on spontaneous and induced ovulation. Sanchez MA, et al. **Brain Res Bull** 1995;38(4):313–7

Hemostatic profile of bovine ovarian follicular fluid. Yamada M, et al. **Can J Physiol Pharmacol** 1995 May;73(5):624–9

Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Gebbie AE, et al. **Contraception** 1995 Oct;52(4):221–2

A role for trkA nerve growth factor receptors in mammalian ovulation. Dissen GA, et al. **Endocrinology** 1996 Jan; 137(1):198–209

Effect of restraint stress on the preovulatory luteinizing hormone profile and ovulation in the rat. Roozendaal MM, et al. **Eur J Endocrinol** 1995 Sep;133(3):347–53

Correlations between periovulatory serum and follicular fluid CA-125 and granulosa cell hormones after controlled ovarian hyperstimulation. Saraf VK, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):95–9

Experimental extension of the time interval between oocyte maturation and ovulation: effect on fertilization and first cleavage. Dekel N, et al. **Fertil Steril** 1995 Nov; 64(5):1023–8

Successful pregnancy outcome after cryopreservation of all fresh embryos with subsequent transfer into an unstimulated cycle. Frederick JL, et al. **Fertil Steril** 1995 Nov; 64(5):987–90

Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Licciardi FL, et al. **Fertil Steril** 1995 Nov;64(5):991–4

"Nothing succeeds like success" [letter; comment] van der Weiden RM. **Fertil Steril** 1995 Nov;64(5):1046. Comment on: Fertil Steril 1995 Feb;63(2):262–7.

Egg production of cockatiels (Nymphicus hollandicus) is influenced by number of eggs in nest after incubation begins. Millam JR, et al. **Gen Comp Endocrinol** 1996 Feb; 101(2):205–10

Steroid metabolism in theca externa cells from preovulatory follicles of domestic hen (Gallus domesticus). Rodríguez-Maldonado E, et al. **Gen Comp Endocrinol** 1996 Feb;101(2):173–9

Relationship of endometrial thickness and sonographic echo pattern to endometriosis in non-in vitro fertilization cycles. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):113–6

Is there seasonality in human ovulation? Stolwijk AM, et al. **Hum Biol** 1996 Aug;68(4):563–71

Description of circadian rhythm in uterine artery blood flow during the peri-ovulatory period. Zaidi J, et al. **Hum Reprod** 1995 Jul;10(7):1642–6

Restricting calf presence without suckling compared with weaning prolongs postpartum anovulation in beef cattle. Hoffman DP, et al. **J Anim Sci** 1996 Jan;74(1):190–8

Relationship of weaning-to-estrus interval to timing of ovulation and fertilization in sows. Kemp B, et al. **J Anim Sci** 1996 May;74(5):944–9

Estimates of heritabilities and genetic and environmental correlations for left- and right-side uterine capacity and ovulation rate in mice. Nielsen MK, et al. **J Anim Sci** 1996 Mar;74(3):529–34

Metabolic and luteal sequelae to heightened dietary fat intake in undernourished, anestrous beef cows induced to ovulate. Ryan DP, et al. **J Anim Sci** 1995 Jul;73(7):2086–93

Differential response of the luteal phase and fertility in cattle following ovulation of the first-wave follicle with human chorionic gonadotropin or an agonist of gonadotropin-releasing hormone. Schmitt EJ, et al. **J Anim Sci** 1996 May;74(5):1074–83

Comparison of endocrinological and clinical profiles and outcome of IVF cycles in patients with one ovary and two ovaries. Nargund G, et al. **J Assist Reprod Genet** 1995 Aug;12(7):458–60

Serum and follicular fluid sex hormone-binding globulin in stimulated and unstimulated cycles. Phocas I, et al. **J Assist Reprod Genet** 1995 Jul;12(6):348–53

High success with gestational carriers and oocyte donors using synchronized cycles. Ziegler WF, et al. **J Assist Reprod Genet** 1995 May;12(5):297–300

emo-1, a Caenorhabditis elegans Sec61p gamma homologue, is required for oocyte development and ovulation. Iwasaki K, et al. **J Cell Biol** 1996 Aug;134(3):699–714

Interactions between insulin-like growth factor-I (IGF-I) and the renin-angiotensin system in follicular growth and ovulation. Yoshimura Y, et al. **J Clin Invest** 1996 Jul 15; 98(2):308–16

Metabolic status and interval to first ovulation in postpartum dairy cows. Zurek E, et al. **J Dairy Sci** 1995 Sep; 78(9):1909–20

Comparison of cellular distribution of LH receptors and steroidogenic enzymes in the porcine ovary. Meduri G, et al. **J Endocrinol** 1996 Mar;148(3):435–46

Effects of pineal indoles on ovarian response to gonadotropin-induced ovulation in mice. Chan WY, et al. **J Neural Transm Gen Sect** 1995;100(3):239–46

Ingestion of n-3 polyunsaturated fatty acids and ovulation in rats. Trujillo EP, et al. **J Reprod Fertil** 1995 Nov; 105(2):197–203

Advanced ovulation in gilts by the intrauterine application of a low molecular mass pronase-sensitive fraction of boar seminal plasma. Waberski D, et al. **J Reprod Fertil** 1995 Nov;105(2):247–52

Effect of endurance exercise on ovulation in the rat. Chatterton RT Jr, et al. **Med Sci Sports Exerc** 1995 Nov; 27(11):1509–15

Characteristics of cyclicity in maiden thoroughbred mares in the United Kingdom. Watson ED, et al. **Vet Rec** 1994 Jul 30;135(5):104–6

Ovulation as determined by transrectal ultrasonography in multiparous sows: relationships with oestrous symptoms and hormonal profiles. Mburu JN, et al. **Zentralbl Veterinarmed A** 1995 Jun;42(4):285–92

[Effect of interleukin-2 and interleukin-6 on ovary in the ovulatory period—establishment of the new ovarian perfusion system and influence of interleukins on ovulation rate and steroid secretion] Mikuni M. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):561–72 (Eng. Abstr.) **(Jpn)**

URINE

Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Baird DD, et al. **Epidemiology** 1995 Sep;6(5):547–50

OVULATION DETECTION

METHODS

Comparison of single serum progesterone and endometrial biopsy for confirmation of ovulation in infertile Nigerian women. Ilesanmi AO, et al. **Afr J Med Med Sci** 1995 Mar; 24(1):97–101

The assessment of LH surge for predicting ovulation time using clinical, hormonal, and ultrasonic indices in infertile women with an ensemble of neural networks. Gürgen FS, et al. **Comput Biol Med** 1995 Jul;25(4):405–13

Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Baird DD, et al. **Epidemiology** 1995 Sep;6(5):547–50

Vaginal temperature sensing using UHF radio telemetry. McCreesh Z, et al. **Med Eng Phys** 1996 Mar;18(2):110–4

Endometrial dating correlated with multiple luteal progesterone levels in confirming ovulation and luteal function in infertile Nigerian women. Ilesanmi AO. **West Afr J Med** 1995 Jul-Sep;14(3):152–6

[Clinical study of ovulatory cervical mucus] Chrétien FC, et al. **Contracept Fertil Sex** 1996 May;24(5):359–67 (18 ref.) **(Fre)**

OVULATION INDUCTION

see related
OVARIAN HYPERSTIMULATION SYNDROME

The effect of ovulation induction on the concentration of maternal serum relaxin in twin pregnancies. Haning RV Jr, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):227–32

What proportion of multiple births are due to ovulation induction? A register-based study in Italy. Corchia C, et al. **Am J Public Health** 1996 Jun;86(6):851–4

Hormonal induction of ovulation stimulates atresia of antral follicles in gilts. Dufour JJ, et al. **Biol Reprod** 1995 Oct; 53(4):806–13

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231–47 (72 ref.)

Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Yoshimura Y, et al. **Endocrinology** 1996 Apr;137(4):1204–11

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Felberbaum RE, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):151–5

Correlations between periovulatory serum and follicular fluid CA-125 and granulosa cell hormones after controlled ovarian hyperstimulation. Saraf VK, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):95–9

The role of the GnRH dose and the route of administration on treatment outcome and complications. Schoemaker J. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S13–6 (13 ref.)

Cotreatment with growth hormone and gonadotropin for ovulation induction in hypogonadotropic patients: a prospective, randomized, placebo-controlled, dose-response study. European and Australian Multicenter Study [see comments] **Fertil Steril** 1995 Nov;64(5):917–23 . Comment in: Fertil Steril 1996 Jun;65(6):1259–61.

Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Casson PR, et al. **Fertil Steril** 1996 May;65(5):950–3

Gonadotropin-releasing hormone agonist and human menopausal gonadotropin (hMG) short protocol, but not hMG alone, rescues the corpus luteum from the preceding cycle. Castracane VD, et al. **Fertil Steril** 1996 Oct; 66(4):577–81

Experience with transvaginal ultrasound-guided aspiration of supernumerary follicles for the prevention of multiple pregnancies after ovulation induction and intrauterine insemination. De Geyter C, et al. **Fertil Steril** 1996 Jun; 65(6):1163–8

A follicular scoring system for monitoring ovulation induction in polycystic ovary syndrome patients based solely on ultrasonographic estimation of follicular development. Ellenbogen A, et al. **Fertil Steril** 1996 Jun; 65(6):1175–7

Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Filicori M, et al. **Fertil Steril** 1996 Feb;65(2):387–93

The role for the uterine insulin-like growth factor I in early embryonic loss after superovulation in the rat. Katagiri S, et al. **Fertil Steril** 1996 Feb;65(2):426–36

Ovulation induction with gonadotropins as sole treatment in infertile couples with open tubes: a randomized prospective comparison between intrauterine insemination and timed vaginal intercourse. Melis GB, et al. **Fertil Steril** 1995 Dec;64(6):1088–93

Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome. Schoot DC, et al. **Fertil Steril** 1995 Dec;64(6):1081–7

The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with follicle-stimulating hormone in polycystic ovary syndrome: a randomized study. van der Meer M, et al. **Fertil Steril** 1996 Oct;66(4):571–6

Comparison of androgen levels in conception vs.

non-conception cycles following controlled ovarian stimulation using the luteal phase gonadotropin-releasing hormone agonist protocol. Check JH, et al. **Gynecol Endocrinol** 1995 Sep;9(3):209-14

Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Kulikowski M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):97-102

Evaluation of different ovarian stimulation protocols for in vitro fertilization. Pados G, et al. **Gynecol Endocrinol** 1995 Jun;9(2):103-12

Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome? Senöz S, et al. **Gynecol Endocrinol** 1995 Jun;9(2):91-6

Comparison of efficacy of high-dose pure follicle-stimulating hormone versus human menopausal gonadotropins for in vitro fertilization. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):117-9

Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227-33 (58 ref.)

The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233-7 (55 ref.)

The influence of dietary sodium restriction on renal and ovarian renin and prorenin production during ovarian stimulation. Beerendonk CC, et al. **Hum Reprod** 1996 May; 11(5):956-61

Laparoscopic removal of an abdominal pregnancy adherent to the appendix after ovulation induction with human menopausal gonadotrophin. Ben-Rafael Z, et al. **Hum Reprod** 1995 Jul;10(7):1804-5

Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile? Corsan G, et al. **Hum Reprod** 1996 May;11(5):1109-12

Infant sex ratio after hormonal ovulation induction [letter] Dickey RP, et al. **Hum Reprod** 1995 Sep;10(9):2465-6

Effect of ovulation induction on uterine blood flow and oestradiol and progesterone concentrations in early pregnancy. Dickey RP, et al. **Hum Reprod** 1995 Nov; 10(11):2875-9

Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial. Homburg R, et al. **Hum Reprod** 1995 Oct;10(10):2550-3

Clomiphene citrate, gonadotrophin and sex ratio of offspring [letter; comment] James WH. **Hum Reprod** 1995 Sep; 10(9):2465. Comment on: Hum Reprod 1995 Apr;10(4):761-2.

Successful induction ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Kousta E, et al. **Hum Reprod** 1996 Jan;11(1):70-1

Discrimination between chronological and ovarian age in infertile women aged 35 years and older: predicting pregnancy using basal follicle stimulating hormone, age and number of ovulation induction/intra-uterine insemination cycles. Magarelli PC, et al. **Hum Reprod** 1996 Jun; 11(6):1214-9

Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon). Mitchell R, et al. **Hum Reprod** 1996 May;11(5):962-7

A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Olivennes F, et al. **Hum Reprod** 1996 Jun; 11(6):1169-72

Does the absence or presence of seminal fluid matter in patients undergoing ovulation induction with intrauterine insemination? Qasim SM, et al. **Hum Reprod** 1996 May; 11(5):1008-10

Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219-24 (47 ref.)

Endometrial responses to corpus luteum products in cycles with induced ovulation: theoretical and practical considerations. Seppälä M, et al. **Hum Reprod** 1995 Dec; 10 Suppl 2:67-76 (101 ref.)

Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination treatment cycles. Shalev E, et al. **Hum Reprod** 1995 Sep;10(9):2244-7

Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment. Shalev E, et al. **Hum Reprod** 1995 Oct;10(10):2541-4

Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. van Dessel HJ, et al. **Hum Reprod** 1996 Mar;11(3):478-85

Morphological and cytogenetic observations of unfertilized human oocytes and abnormal embryos obtained after ovarian stimulation with pure follicle stimulating hormone following pituitary desensitization. Wójcik C, et al. **Hum Reprod** 1995 Oct;10(10):2617-22

Atrial natriuretic peptide, oestradiol and progesterone in women undergoing spontaneous and gonadotrophin-stimulated ovulatory cycles. Yeko TR, et al. **Hum Reprod** 1995 Nov;10(11):2872-4

The empty follicle syndrome: a pharmaceutical industry syndrome. Zegers-Hochschild F, et al. **Hum Reprod** 1995 Sep;10(9):2262-5

Ovulation induction in the era of recombinant gonadotropins and GnRH analogues. Insler V, et al. **Isr J Med Sci** 1996 Feb;32(2):79-89 (68 ref.)

Color-Doppler velocimetry of uterine arteries in pregnant and nonpregnant patients during multiovulation induction for IVF. Levi-Setti PE, et al. **J Assist Reprod Genet** 1995 Aug;12(7):413-7

Recombinant-human luteinizing hormone (r-hLH) as ovulatory stimulus in superovulated does. Peinado JA, et al. **J Assist Reprod Genet** 1995 Jan;12(1):61-4

Serum and follicular fluid sex hormone-binding globulin in stimulated and unstimulated cycles. Phocas I, et al. **J Assist Reprod Genet** 1995 Jul;12(6):348-53

Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist. Schmidt-Sarosi C, et al. **J Assist Reprod Genet** 1995 Mar;12(3):167-74

Ovarian activity during follicular-phase down regulation in in vitro fertilization is associated with advanced maternal age and a high recurrence rate in subsequent cycles. Session DR, et al. **J Assist Reprod Genet** 1995 May;12(5):301-4

Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome. Wada I, et al. **J Assist Reprod Genet** 1995 Apr;12(4):252-7

Predictive value of endometrial sonography in ovulation induction for intrauterine insemination. Tsai YC, et al. **J Formos Med Assoc** 1995 Oct;94(10):626-9

Sex ratio in triplets. Mordel N, et al. **J Perinat Med** 1995; 23(4):265-71

Differential sensitivity of ovarian follicles to gonadotrophin stimulation in broiler and layer lines of domestic fowl. Hocking PM, et al. **J Reprod Fertil** 1995 Sep;105(1):49-55

Production of exogenous gonadotrophin-neutralizing immunoglobulins in cats after repeated eCG-hCG treatment and relevance for assisted reproduction in felids. Swanson WF, et al. **J Reprod Fertil** 1995 Sep;105(1):35-41

Spontaneous pregnancies despite failed attempts at ovulation induction in a woman with latrogenic premature ovarian failure. Menashe Y, et al. **J Reprod Med** 1996 Mar; 41(3):207-10

Development of hydrosalpinx during ovulation induction. Schiller VL, et al. **J Ultrasound Med** 1995 Nov; 14(11):799-803

Beta-endorphin inhibits prostaglandin synthesis in rat ovaries and blocks induced ovulation. Faletti A, et al. **Prostaglandins** 1995 Feb;49(2):93-103

Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease. Espinosa de los Monteros A, et al. **Rev Invest Clin** 1995 Sep-Oct;47(5):347-53

[GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation] Felberbaum R, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:113-7 (Eng. Abstr.) **(Ger)**

[Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins] Ellenbogen A, et al. **Harefuah** 1995 Dec 1;129(11):455-6, 536 (Eng. Abstr.) **(Heb)**

[The clinical significance of the ratio in FSH/LH of human menopausal gonadotropins in a programmed stimulation regimen for IVF-ET] Ikenaga H. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1223-9 (Eng. Abstr.) **(Jpn)**

[Laparoscopic image of sexual organs in women after ovulation induction] Postawski K, et al. **Wiad Lek** 1994 Sep;47(17-18):668-70 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Is multiple pregnancy an unavoidable complication of ovulation induction? The case for pulsatile GnRH. Filicori M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S19-21

Ovulation induction, infertility, and ovarian cancer risk. Bristow RE, et al. **Fertil Steril** 1996 Oct;66(4):499-507 (49 ref.)

A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on-going IVF-ET twin pregnancy. Bar-Hava I, et al. **Gynecol Endocrinol** 1995 Dec;9(4):295-8

Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309-13

Complete and partial luteinized unruptured follicle syndrome after ovarian stimulation with clomiphene citrate/human menopausal gonadotrophin/human chorionic gonadotrophin. Coetsier T, et al. **Hum Reprod** 1996 Mar; 11(3):583-7

A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Ditkoff EC, et al. **Hum Reprod** 1996 May;11(5):1035-7

Aorto-subclavian thromboembolism: a rare complication associated with moderate ovarian hyperstimulation syndrome. Germond M, et al. **Hum Reprod** 1996 Jun; 11(6):1173-6

Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Levy T, et al. **Hum Reprod** 1996 Jun; 11(6):1177-9

Breast and ovarian cancer incidence after infertility and in vitro fertilisation [see comments] Venn A, et al. **Lancet** 1995 Oct 14;346(8981):995-1000. Comment in: Lancet 1995 Dec 16;346(8990):1627-8. Comment in: Lancet 1995 Dec 16;346(8990):1628.

[Update on ovarian hyperstimulation syndrome] Delbaere A, et al. **Rev Med Brux** 1995 Nov;16(5):354-60 (39 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease. Wenzl R, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):298-9

Induction of ovulation. Derman SG, et al. **Compr Ther** 1995 Oct;21(10):583-9 (16 ref.)

Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480-94 (91 ref.)

Ovulation induction with clomiphene citrate complicated by deep vein thrombosis. Benshushan A, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):261-2

Exploring the recovery phase after treatment with a gonadotrophin-releasing hormone-agonist for ovulation induction in polycystic ovary syndrome: three pilot trials. Scheele F, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):221-4

Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. Isaacs JD Jr, et al. **Fertil Steril** 1996 Feb;65(2):262-6

A novel method of ovarian stimulation for in vitro fertilization: bromocriptine-rebound method. Jinno M, et al. **Fertil Steril** 1996 Aug;66(2):271-4

Menotropins alone are superior to a clomiphene citrate and menotropin combination for superovulation induction among clomiphene citrate failures. Ransom MX, et al. **Fertil Steril** 1996 Jun;65(6):1169-74

Value of growth hormone in ovulation induction? [letter; comment] Sharara FI. **Fertil Steril** 1996 Jun;65(6):1259-61 . Comment on: Fertil Steril 1995 Nov;64(5):917-23.

Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Trott EA, et al. **Fertil Steril** 1996 Sep; 66(3):484-6

Induction of ovulation with the sole use of clomiphene citrate in late-onset 21-hydroxylase deficiency. Laohaprasitiporn C, et al. **Gynecol Obstet Invest** 1996;41(3):224-6

Further characterization of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Balasch J, et al. **Hum Reprod** 1995 Jun;10(6):1377-81

Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A, et al. **Hum Reprod** 1996 Jun; 11(6):1146-8 (31 ref.)

Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF. **Hum Reprod** 1996 Jun;11(6):1144-6 (12 ref.)

Progestogen pretreatment in the short-term protocol does not affect the prognostic value of the oestradiol flare-up in response to a GnRH agonist. Cédrin-Durnerin I, et al. **Hum Reprod** 1995 Nov;10(11):2904-8

Comparison among different ovarian stimulation regimens for assisted procreation procedures in patients with endometriosis. Chedid S, et al. **Hum Reprod** 1995 Sep; 10(9):2406-11

Time to revolutionize ovarian stimulation [editorial] Edwards RG, et al. **Hum Reprod** 1996 May;11(5):917-9

Ovulation induction in 1995: a new policy. Fanchin R, et al. **Hum Reprod** 1995 Sep;10(9):2224-5

Controlled ovarian stimulation using highly purified FSH results in a lower serum oestradiol profile in the follicular phase as compared with HMG. Fried G, et al. **Hum Reprod** 1996 Mar;11(3):474-7

Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S, et al. **Hum Reprod** 1996 Jun;11(6):1143-4 (15 ref.)

Ovulation induction using s.c. pulsatile gonadotrophin-releasing hormone: effectiveness of different pulse frequencies. Letterie GS, et al. **Hum Reprod** 1996 Jan;11(1):19-22

Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Tsai HD, et al. **Hum Reprod** 1995 Nov;10(11):2909-12

Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients. Benadiva CA, et al. **J Assist Reprod Genet** 1995 Jan; 12(1):8-12

Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study. Fisch B, et al. **J Assist Reprod Genet** 1995 Jan;12(1):26–31

Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. Tomažević T, et al. **J Assist Reprod Genet** 1996 Apr;13(4):282–6

Clinical review 81: Gonadotropin–releasing hormone analogs in ovulation induction: current status and perspectives. Filicori M. **J Clin Endocrinol Metab** 1996 Jul;81(7):2413–6 (23 ref.)

In vitro fertilization of in vitro matured oocytes obtained from the follicles without hCG exposure for prevention of severe ovarian hyperstimulation syndrome: a case report. Kodama H, et al. **J Obstet Gynaecol Res** 1996 Feb; 22(1):61–5

The evaluation of a new 7–day gonadotropin–releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization. Yang TS, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):133–7

The ovarian follicular wave pattern and induction of ovulation in the mated and non–mated one–humped camel (Camelus dromedarius). Skidmore JA, et al. **J Reprod Fertil** 1996 Mar;106(2):185–92

Advanced ovulation in gilts by the intrauterine application of a low molecular mass pronase–sensitive fraction of boar seminal plasma. Waberski D, et al. **J Reprod Fertil** 1995 Nov;105(2):247–52

Extended induction of ovulation by human menopausal gonadotropins and a gonadotropin–releasing hormone analog in high responders for in vitro fertilization and oocyte donation. Amit A, et al. **J Reprod Med** 1995 Sep; 40(9):633–7

Leuprolide acetate for inducing ovulation in women undergoing ovarian stimulation. diDonato P, et al. **J Reprod Med** 1995 Oct;40(10):715–6

Induction of ovulation in clomiphene–resistant polycystic ovary syndrome with pulsatile GnRH. Tan SL, et al. **Obstet Gynecol** 1996 Aug;88(2):221–6

Ultrasonography endometrial patterns in different hormonal treatments to induce ovulation. Beneventi F, et al. **Radiol Med (Torino)** 1995 Sep;90(3):278–83

[Which stimulation for poor responders? Critical study of results and methods of research] Antoine JM. **Contracept Fertil Sex** 1996 May;24(5):386–90 (Eng. Abstr.) **(Fre)**

[Optimizing the prescription of gonadotropins] Cohen J. **Contracept Fertil Sex** 1996 Jun;24(6):472–4 **(Fre)**

[Influence of infertility etiology and follicular stimulation protocols on pregnancy outcomes by in vitro fertilization] Merviel P, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):157–62 (Eng. Abstr.) **(Fre)**

[Highly purified FSH for stimulation of down regulated cycles in the in vitro fertilization program] Sydow P, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):146–50 (Eng. Abstr.) **(Ger)**

[A novel method of ovarian stimulation for in vitro fertilization (bromocriptine–rebound method) increases developmental potential of oocytes and pregnancy rate] Jinno M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec;47(12):1337–44 (Eng. Abstr.) **(Jpn)**

TRENDS

Time to revolutionize ovarian stimulation [editorial] Edwards RG, et al. **Hum Reprod** 1996 May;11(5):917–9

VETERINARY

Follicular development and ovulation in sows: effect of hCG and GnRH treatment. Nissen AK, et al. **Acta Vet Scand** 1995;36(1):123–33

Timing of ovulation after gonadotrophin induction and its importance to successful intrauterine insemination in the tiger (Panthera tigris). Donoghue AM, et al. **J Reprod Fertil** 1996 May;107(1):53–8

Responsiveness of ovaries to exogenous gonadotrophins and laparoscopic artificial insemination with frozen–thawed spermatozoa in ocelots (Felis pardalis). Swanson WF, et al. **J Reprod Fertil** 1996 Jan;106(1):87–94

Effects of human menopausal gonadotrophin (hMG) for superovulation in Japanese Black cattle. Sugano M, et al. **J Vet Med Sci** 1995 Dec;57(6):1113–5

OVUM

consider also terms at OO–

see related

GRAAFIAN FOLLICLE

Survival of salmonellas and Ascaris suum eggs in a thermophilic biogas plant. Plym–Forshell L. **Acta Vet Scand** 1995;36(1):79–85

A case of abnormal size in eggs and larvae of the Taiga tick, Ixodes persulcatus (Acari: Ixodidae). Belozerov VN. **Exp Appl Acarol** 1995 Sep;19(9):523–8

Ovum donation for blepharophimosis–related infertility [letter] Hovav Y, et al. **Hum Reprod** 1995 Jun;10(6):1555–6

Current attitudes towards egg donation among men and women. Kazem R, et al. **Hum Reprod** 1995 Jun;10(6):1543–8

Inter–site EEG relationships before widespread epileptiform discharges. Inouye T, et al. **Int J Neurosci** 1995 May; 82(1–2):143–53

Cold storage effects on egg hatch in laboratory–reared Culicoides variipennis sonorensis (Diptera: Ceratopogonidae). Hunt GJ, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):335–8

Pre–embryo research. Dunstan GR. **J Assist Reprod Genet** 1995 Sep;12(8):517–23

Aedes albopictus (Diptera: Culicidae) eggs: field survivorship during northern Indiana winters. Hanson SM, et al. **J Med Entomol** 1995 Sep;32(5):599–604

Recovery of helminth eggs from archeological excavations of the Grand Louvre (Paris, France). Bouchet F. **J Parasitol** 1995 Oct;81(5):785–7

Intracytoplasmic testicular sperm injection: an effective treatment for otherwise intractable obstructive azoospermia [see comments] Gil–Salom M, et al. **J Urol** 1995 Dec; 154(6):2074–7. Comment in: J Urol 1995 Dec;154(6):2078–9.

HET–CAM test. Spielmann H. **Methods Mol Biol** 1995; 43:199–204

[Morphology in intracytoplasmic sperm injection] Küpker W, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:132–6 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Purification and characterization of cystatin from duck egg white. Warwas M, et al. **Acta Biochim Pol** 1995;42(3):351–6

Purification and mass spectrometric analysis of ADP–ribosylation factor proteins from Xenopus egg cytosol. Boman AL, et al. **Biochemistry** 1996 Jun 25; 35(25):8244–51

Dioxins, furans and AHH–active PCB congeners in eggs of two gull species from the western Mediterranean. Pastor D, et al. **Chemosphere** 1995 Sep;31(6):3397–411

Sea urchin egg tropomyosin isoforms with muscle–type and nonmuscle–type antigenicities. Ishimoda–Takagi T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):415–27

Xenopus laevis egg jelly coats consist of small diffusible proteins bound to a complex system of structurally stable networks composed of high–molecular–weight glycoconjugates. Bonnell BS, et al. **Dev Biol** 1996 Feb 25; 174(1):32–42

Isolation and structures of glycoprotein–derived free oligosaccharides from the unfertilized eggs of Scyliorhinus caniculus. Characterization of the sequences galactose(alpha 1–4)galactose(beta 1–3)–N–acetylglucosamine and N–acetylneuraminic acid(alpha 2–6)galactose(beta 1–3)–N–acetylglucosamine. Plancke Y, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):199–206

Occurrence and structural analysis of highly sulfated multiantennary N–linked glycan chains derived from a fertilization–associated carbohydrate–rich glycoprotein in unfertilized eggs of Tribolodon hakonensis. Taguchi T, et al. **Eur J Biochem** 1996 Jun 1;238(2):357–67

A precise structural analysis of a fertilization–associated carbohydrate–rich glycopeptide isolated from the fertilized eggs of euryhaline killi fish (Fundulus heteroclitus). Novel penta–antennary N–glycan chains with a bisecting N–acetylglucosaminyl residue. Taguchi T, et al. **Glycobiology** 1995 Sep;5(6):611–24

Structural analysis of a novel triphosphonoglycosphingolipid from the egg of the sea hare, Aplysia kurodai. Yamada S, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):794–9

The occurrence of novel 9–O–sulfated N–glycolylneuraminic acid–capped alpha2–>5–Oglycolyl–linked oligo/polyNeu5Gc chains in sea urchin egg cell surface glycoprotein. Identification of a new chain termination signal for polysialyltransferase. Kitazume S, et al. **J Biol Chem** 1996 Mar 22;271(12):6694–701

A novel cysteine protease inhibitor of the egg of chum salmon, containing a cysteine–rich thyroglobulin–like motif. Yamashita M, et al. **J Biol Chem** 1996 Jan 19; 271(3):1282–4

A novel low molecular weight ecdysiotropin in post–diapause, pre–hatch eggs of the gypsy moth, Lymantria dispar L. (Lepidoptera: Lymantriidae). Kelly TJ, et al. **Regul Pept** 1995 Jun 27;57(3):253–61

CYTOLOGY

Analysis of the calcium transient at NEB during the first cell cycle in dividing sea urchin eggs. Browne CL, et al. **Biol Bull** 1996 Aug;191(1):5–16

Nuclear transplantation in mammalian eggs and embryos. Sun FZ, et al. **Curr Top Dev Biol** 1995;30:147–76 (137 ref.)

Lectin staining of trichostrongylid nematode eggs of sheep: rapid identification of Haemonchus contortus eggs with peanut agglutinin. Palmer DG, et al. **Int J Parasitol** 1996 Apr;26(4):447–50

Cell cycle regulation of dynein association with membranes modulates microtubule–based organelle transport. Niclas J, et al. **J Cell Biol** 1996 May;133(3):585–93

Genesis and acid/base. Carlin K, et al. **Med Hypotheses** 1995 May;44(5):339–46

Flow–cytometry analysis of sheep–nematode egg populations. Kerboeuf D, et al. **Parasitol Res** 1996; 82(4):358–63

Biological activity assays of cell–free reassembled nuclei—injecting cell–free reassembled nuclei into unfertilized eggs can induce the eggs to cleave and reconstitute asters, and the injected nuclei undergo cell cycle changes. Zhang C, et al. **Sci China B** 1995 Sep; 38(9):1075–83

[Human gonadal hilar cells—histogenesis, differentiation, role] Kędzia A, et al. **Ginekol Pol** 1995 Oct;66(10):578–85 (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Calcium–independent, meiotic spindle–dependent metaphase–to–interphase transition in phorbol ester–treated mouse eggs. Moses RM, et al. **Dev Biol** 1995 Sep; 171(1):111–22

Potency of a complex mixture of polychlorinated dibenzo–p–dioxin, dibenzofuran, and biphenyl congeners compared to 2,3,7,8–tetrachlorodibenzo–p–dioxin in causing fish early life stage mortality. Walker MK, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):178–86

Fate of unfertilized ova in male rodent dominant lethal assays: extension of the studies by Kratochvilova. Tinwell H, et al. **Mutat Res** 1996 Jul 5;368(3–4):309–17

Feeding the mosquito Aedes aegypti with TMOF and its analogs; effect on trypsin biosynthesis and egg development. Borovsky D, et al. **Regul Pept** 1995 Jun 27; 57(3):273–81

[Acridine mutagen ICR–170 induced developmental suppression of ovary and vitelline gland in female Schistosoma japonicum] Lu Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):200–2 (Eng. Abstr.) **(Chi)**

[The effect of a synthetic analog of the gonadotropin–releasing hormone and of dopamine antagonists on the maturation and quality of loach ova] Poponov SIu, et al. **Ontogenez** 1995 Nov–Dec;26(6):453–9 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

DNA–helicase activity from sea urchin mitochondria. Roberti M, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):134–9

Potential role of mitogen–activated protein kinase in pronuclear envelope assembly and disassembly following fertilization of mouse eggs. Moos J, et al. **Biol Reprod** 1995 Sep;53(3):692–9

Imaging protein kinase C activation in living sea urchin eggs after fertilization. Olds JL, et al. **Dev Biol** 1995 Dec; 172(2):675–82

DNA–binding sperm proteins with oligo–arginine clusters function as potent activators for egg CK–II. Ohtsuki K, et al. **FEBS Lett** 1996 Jan 8;378(2):115–20

Detection of undegraded oligonucleotides in vivo by fluorescence resonance energy transfer. Nuclease activities in living sea urchin eggs. Uchiyama H, et al. **J Biol Chem** 1996 Jan 5;271(1):380–4

Calcium requirements during mitotic cdc2 kinase activation and cyclin degradation in Xenopus egg extracts. Lindsay HD, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3557–68

Molecular cloning of the first metazoan beta–1,3 glucanase from eggs of the sea urchin Strongylocentrotus purpuratus. Bachman ES, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6808–13

[Change in the activity of antioxidant enzymes in the process of early ontogenesis of various species of Black Sea fishes] Rudneva–Titova II. **Ukr Biokhim Zh** 1995 Jan–Feb; 67(1):92–5 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)

Actin–membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101–37 (131 ref.)

Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277–320 (95 ref.)

Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343–81 (144 ref.)

Development and evolution of an egg cytoskeletal domain in ascidians. Jeffery WR. **Curr Top Dev Biol** 1995;31:243–76 (77 ref.)

Eggshell assembly in Drosophila: processing and localization of vitelline membrane and chorion proteins. Pascucci T, et al. **Dev Biol** 1996 Aug 1;177(2):590–8

Extracorporeal development and ultrarapid freezing of human fetal ova. Zhang J, et al. **J Assist Reprod Genet** 1995 Jul;12(6):361–8

[Anti–embryonation immunity and cultivation of schistosoma japonicum eggs in vitro] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Mar;76(3):218–21 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Early development and progression of lymphocyte–stimulatory cross–reactive idiotypes expressed on antibodies to soluble egg antigens during Schistosoma mansoni infection of mice. Bosshardt SC, et al. **Eur J Immunol** 1996 Jan;26(1):272–5

Human basophils release interleukin–4 after stimulation with Schistosoma mansoni egg antigen. Falcone FH, et al. **Eur J Immunol** 1996 May;26(5):1147–55

Onchocerca volvulus: identification and characterization of an immunogenic eggshell protein (Oveg1). Tume C, et al. **Exp Parasitol** 1995 Dec;81(4):445–52

A cloned major Schistosoma mansoni egg antigen with homologies to small heat shock proteins elicits Th1 responsiveness. Cai Y, et al. **Infect Immun** 1996 May; 64(5):1750–5

METABOLISM

Inhibition of cADPR–Hydrolase by ADP–ribose potentiates cADPR synthesis from beta–NAD+. Genazzani AA, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):502–7

Nicotinate–adenine dinucleotide phosphate–induced Ca(2+)–release does not behave as a Ca(2+)–induced Ca(2+)–release system. Chini EN, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):709–11

Ca2+ release triggered by nicotinate adenine dinucleotide phosphate in intact sea urchin eggs. Perez–Terzic CM, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):955–9

Evidence for inositol tetrakisphosphate–activated Ca2+ influx pathway refilling inositol trisphosphate–sensitive Ca2+ stores in hamster eggs. Shirakawa H, et al. **Cell Calcium** 1995 Jan;17(1):1–13

Novel postfertilization inward Ca2+ current in ascidian eggs ensuring a calcium entry throughout meiosis. Arnoult C, et al. **Dev Biol** 1996 Mar 15;174(2):322–34

Maternal mRNA encoding the orphan steroid receptor SpCOUP–TF is localized in sea urchin eggs. Vlahou A, et al. **Development** 1996 Feb;122(2):521–6

Cyclic aristeromycin diphosphate ribose: a potent and poorly hydrolysable Ca(2+)–mobilising mimic of cyclic adenosine diphosphate ribose. Bailey VC, et al. **FEBS Lett** 1996 Feb 5;379(3):227–30

A sperm membrane protein that binds in a species–specific manner to the egg extracellular matrix is homologous to von Willebrand factor. Hardy DM, et al. **J Biol Chem** 1995 Nov 3;270(44):26025–8

Characterization of a large conductance, cation–selective channel from sea urchin eggs that is sensitive to sulfhydryl reducing agents. Lii T, et al. **J Membr Biol** 1996 Mar; 150(1):27–35

Murine polo like kinase 1 gene is expressed in meiotic testicular germ cells and oocytes. Matsubara N, et al. **Mol Reprod Dev** 1995 Aug;41(4):407–15

Calcium oscillations in mammalian eggs triggered by a soluble sperm protein. Parrington J, et al. **Nature** 1996 Jan 25;379(6563):364–8

Heteromeric connexons in lens gap junction channels. Jiang JX, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1287–91

PARASITOLOGY

Flow–cytometry analysis of sheep–nematode egg populations. Kerboeuf D, et al. **Parasitol Res** 1996; 82(4):358–63

PATHOLOGY

Placenta increta occurring in a blighted ovum. Gist RS, et al. **South Med J** 1996 May;89(5):545–7

PHYSIOLOGY

An early increase in cGMP follows fertilization of sea urchin eggs. Ciapa B, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):633–6

Such hydrophobic peptides as dansylated mastoparan can elevate the fertilization membrane of sea urchin eggs. Saito K, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):828–34

Molecular basis of mammalian egg activation. Schultz RM, et al. **Curr Top Dev Biol** 1995;30:21–62 (186 ref.)

Mechanisms of calcium regulation in sea urchin eggs and their activities during fertilization. Shen SS. **Curr Top Dev Biol** 1995;30:63–101 (270 ref.)

Activation of Xenopus eggs by RGD–containing peptides accompanied by intracellular Ca2+ release. Iwao Y, et al. **Dev Biol** 1996 Aug 1;177(2):558–67

Protein tyrosine kinase activity during egg activation is important for morphogenesis at gastrulation in the sea urchin embryo. Kinsey WH. **Dev Biol** 1995 Dec; 172(2):704–7

Effect on sperm–induced activation current and increase of cytosolic Ca2+ by agents that modify the mobilization of [Ca2+]i. I. Heparin and pentosan polysulfate. Mohri T, et al. **Dev Biol** 1995 Nov;172(1):139–57

Regulated processing of dec–1 eggshell proteins in Drosophila. Noguerón MI, et al. **Dev Biol** 1995 Nov; 172(1):272–9

The sperm entry point defines the orientation of the calcium–induced contraction wave that directs the first phase of cytoplasmic reorganization in the ascidian egg. Roegiers F, et al. **Development** 1995 Oct;121(10):3457–66

Using loss of heterozygosity data in affected pedigree member linkage tests. Lustbader Ed, et al. **Genet Epidemiol** 1995;12(4):339–50

Nitric oxide–induced mobilization of intracellular calcium via the cyclic ADP–ribose signaling pathway. Willmott N, et al. **J Biol Chem** 1996 Feb 16;271(7):3699–705

Direct membrane retrieval into large vesicles after exocytosis in sea urchin eggs. Whalley T, et al. **J Cell Biol** 1995 Dec; 131(5):1183–92

Two–dimensional cardiogenic ballistic movements of avian eggs. Sakamoto Y, et al. **Med Biol Eng Comput** 1995 Jul; 33(4):611–4

Genesis and acid/base. Carlin K, et al. **Med Hypotheses** 1995 May;44(5):339–46

Viability of Ascaris suum, Ascaris lumbricoides and Trichuris muris eggs to alkaline pH and different temperatures. Ghiglietti R, et al. **Parassitologia** 1995 Dec;37(2–3):229–32

Eggstraordinary? [letter] Overfield ND. **Vet Rec** 1995 Nov 25;137(22):572

Absence of an intracellular pH change following fertilisation of the mouse egg. Kline D, et al. **Zygote** 1995 Nov; 3(4):305–11

Long–lasting exocytosis and massive structural reorganisation in the egg periphery during cortical reaction in Platynereis dumerilii (Annelida, Polychaeta). Kluge B, et al. **Zygote** 1995 May;3(2):141–56

Stages leading to and following fusion of sperm and egg plasma membranes. Longo FJ, et al. **Zygote** 1994 Nov; 2(4):317–31

Bovine oocyte plasma membrane binding sites for sperm plasma membrane during in vitro oocyte maturation and fertilisation. Wheeler E, et al. **Zygote** 1996 Feb;4(1):67–72

Development and loss of the ability of mouse oolemma to fuse with spermatozoa. Zuccotti M, et al. **Zygote** 1994 Nov; 2(4):333–9

RADIATION EFFECTS

Effect of different intensities of fluorescent light on the early development of chick embryos in ovo. Ghatpande A, et al. **Cell Mol Biol Res** 1995;41(6):613–21

[Regularities of radiation effects in ontogenesis of progeny of the 1st generation of Wistar rats after irradiation of germ cells of both parents at different stages of gametogenesis] Nefëdov IIu. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):381–7 (Eng. Abstr.) **(Rus)**

SECRETION

Response of gravid Phlebotmus papatasi females to an oviposition attractant/stimulant associated with conspecific eggs. Srinivasan R, et al. **Indian J Exp Biol** 1995 Oct; 33(10):757–60

TRANSPLANTATION

An unusual case of fetomaternal incompatibility [letter; comment] Inderbitzen PE. **Transfusion** 1996 Jan;36(1):84. Comment on: Transfusion 1995 Jan;35(1):61–2.

ULTRASTRUCTURE

Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)

Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)

Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197–235 (57 ref.)

Sea urchin microtubules. Suprenant KA, et al. **Curr Top Dev Biol** 1995;31:65–99 (206 ref.)

Xenopus laevis egg jelly coats consist of small diffusible proteins bound to a complex system of structurally stable networks composed of high–molecular–weight glycoconjugates. Bonnell BS, et al. **Dev Biol** 1996 Feb 25; 174(1):32–42

Formation of the female pronucleus and reorganization and disassembly of the first interphase cytoskeleton in the egg of the glossiphoniid leech Theromyzon rude. Fernandez J, et al. **Dev Biol** 1995 Oct;171(2):541–53

Description of the egg of Aedeomyia squamipennis (Diptera: Culicidae). Petersen JL, et al. **J Med Entomol** 1995 Nov; 32(6):888–94

Structural features of the abalone egg extracellular matrix and its role in gamete interaction during fertilization. Mozingo NM, et al. **Mol Reprod Dev** 1995 Aug; 41(4):493–502

Producing exposed coat–free embryos. Daily MF, et al. **Zygote** 1994 Aug;2(3):221–5

[Comparative studies on the ultrastructure, homology and analogy of egg envelopes in trematodes and cestodes] Swiderski Z. **Wiad Parazytol** 1996;42(1):81–93 (Eng. Abstr.) **(Pol)**

OVUM DONATION see OOCYTE DONATION

OVUM IMPLANTATION

Prevalence and significance of implantation site trophoblastic atypia in hydatidiform moles and spontaneous abortions. Montes M, et al. **Am J Clin Pathol** 1996 Apr;105(4):411–6

Impaired implantation after in vitro fertilisation treatment associated with hydrosalpinx. Fleming C, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):268–72

Impaired implantation after in vitro fertilisation treatment associated with hydrosalpinx [letter] Voss E, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):851

Molecular cloning of cytochrome P450 aromatase complementary deoxyribonucleic acid from periimplantation porcine and equine blastocysts identifies multiple novel 5'–untranslated exons expressed in embryos, endometrium, and placenta. Choi I, et al. **Endocrinology** 1996 Apr;137(4):1457–67

Oocyte donation program: pregnancy and implantation rates in women of different ages sharing oocytes from single donor. Borini A, et al. **Fertil Steril** 1996 Jan;65(1):94–7

Autoantibodies and embryo implantation rates [letter] Cahill DJ, et al. **Fertil Steril** 1996 Jan;65(1):208–9; discussion 209–10

Serum is more effective than albumin in promoting human embryo development and implantation. Hargreaves CA, et al. **Fertil Steril** 1995 Dec;64(6):1162–6

Autoantibodies and embryo implantation rates [letter] Shulman S. **Fertil Steril** 1996 Jan;65(1):207–8; discussion 209–10

Hydrosalpinx affects the implantation of previously cryopreserved embryos. Akman MA, et al. **Hum Reprod** 1996 May;11(5):1013–4 (8 ref.)

Implantation failure and immunotherapy. Coulam CB. **Hum Reprod** 1995 Jun;10(6):1338–40

Human embryo implantation following in–vitro fertilization: is there a seasonal variation? Dunphy BC, et al. **Hum Reprod** 1995 Jul;10(7):1825–7

Embryo score to predict implantation after in–vitro fertilization: based on 957 single embryo transfers. Giorgetti C, et al. **Hum Reprod** 1995 Sep;10(9):2427–31

Differential implantation rates and variations in the sex ratio. Mittwoch U. **Hum Reprod** 1996 Jan;11(1):8–9 (14 ref.)

A comparative analysis of embryo implantation potential in patients with severe teratozoospermia undergoing in–vitro fertilization with a high insemination concentration or intracytoplasmic sperm injection. Oehninger S, et al. **Hum Reprod** 1996 May;11(5):1086–9

Exploring the mechanism(s) of endometriosis–related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)

A light microscopical morphometric study of the luminal epithelium of human endometrium during the peri–implantation period. Saleh MI, et al. **Hum Reprod** 1995 Jul;10(7):1828–32

Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Simón C, et al. **Hum Reprod** 1995 Sep;10(9):2432–7

The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Tabibzadeh S, et al. **Hum Reprod** 1995 Jun;10(6):1579–602 (200 ref.)

Optimization of implantation in the in–vitro fertilization laboratory. Veiga A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:98–106

Active immunization of rats with chicken egg thiamin carrier protein results in early embryonic loss at periimplantation stages. Subramanian S, et al. **Indian J Exp Biol** 1996 Apr; 34(4):302–6

Superovulation affects glucosamine trisaccharides in the glycocalyx of the rat endometrium at the time of implantation. Peverini S, et al. **J Anat** 1995 Oct;187 (Pt 2):487–90

Effect of coculture on subsequent survival and implantation of cryopreserved human embryos. Tucker MJ, et al. **J Assist Reprod Genet** 1995 Nov;12(10):689–92

Differential expression of vascular endothelial growth factor and its receptor mRNAs in the mouse uterus around the time of implantation. Chakraborty I, et al. **J Endocrinol** 1995 Nov;147(2):339–52

Endothelin–1 and endothelin receptors are present in the sheep uterus and conceptus at implantation. Riley SC, et al. **J Endocrinol** 1995 Nov;147(2):235–44

T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN–gamma and TNF and reduced IL–10 production by placental cells. Krishnan L, et al. **J Immunol** 1996 Jan 15;156(2):653–62

A biological model for the regulation of peri–implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):159–65 (79 ref.)

Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. Cullinan EB, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3115–20

Immunolocalization of estrogen receptor protein in the mouse blastocyst during normal and delayed implantation. Hou Q, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2376–81

Establishing the timing of implantation in the Harlan Porcellus Dutch and New Zealand White rabbit and the Han Wistar rat. Garside DA, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):69–73

Endometrial thickness, morphology, vascular penetration and velocimetry in predicting implantation in an in vitro fertilization program. Zaidi J, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):191–8

DRUG EFFECTS

Effects of alcohol on blastocyst implantation site blood flow in the rat. Mitchell JA, et al. **Alcohol Alcohol** 1996 Jan; 31(1):81–7

In vivo immunosuppressive effects of recombinant ovine interferon–tau (trophoblastin): r.oTP (r.oIFN–tau) inhibits local GVH reaction in mice (PLN assay), prevents fetal

resorptions, and favors embryo survival and implantation in the CBA/J x DBA/2 mice combination. Assal-Meliani A, et al. **Am J Reprod Immunol** 1995 Mar;33(3):267-75

Anti-implantation activity of 2 derivatives of o-hydroxy naphthaquinones in rats. Dhar SK, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):471-2

The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate. Devreker F, et al. **Fertil Steril** 1996 Jan;65(1):122-6

Uterine vascularity during stimulation and its correlation with implantation in in-vitro fertilization. Bassil S, et al. **Hum Reprod** 1995 Jun;10(6):1497-501

The minimum requirements for oestradiol to induce uterine sensitivity for implantation and decidualization in mice. Milligan SR, et al. **Hum Reprod** 1995 Jun;10(6):1502-6

Hormonal anti-implantation agents: antiprogestins. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:140-50

Sterility in neonatally androgenized female rats and the decidual cell reaction. Ohta Y. **Int Rev Cytol** 1995;160:1-52 (250 ref.)

The influence of supraphysiologic estradiol levels on human nidation. Gelety TJ, et al. **J Assist Reprod Genet** 1995 Aug; 12(7):406-12

Effects of platelet activating factor on mouse embryo implantation in vitro. Nishi O, et al. **J Assist Reprod Genet** 1995 May;12(5):330-4

Pregnancy terminating effect of Jatropha curcas in rats. Goonasekera MM, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):117-23

Radiographical and histological evaluation of canine decidual reaction induced by intralumenal injection of bouillon solution mixed with or without barium sulfate. Nomura K. **J Vet Med Sci** 1996 Feb;58(2):145-9

Platelet-activating factor-antagonists reduce implantation in mice at low doses only. O'Neill C. **Reprod Fertil Dev** 1995; 7(1):51-7

Cigarette smoke inhalation affects the reproductive system of female hamsters. Magers T, et al. **Reprod Toxicol** 1995 Nov-Dec;9(6):513-25

The effect of ethanol upon early development in mice and rats. XX. The effect of chronic biparental beer intake in mice upon early implantation events. Fazakas-Todea I. **Rom J Morphol Embryol** 1995 Jan-Jun;41(1-2):7-12

IMMUNOLOGY

A monoclonal antibody to an early pregnancy factor-induced suppressor factor (EPF-S1) disrupts implantation in mice. Athanasas-Platsis S, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):259-66

Anti-Mac-1 antibodies and early pregnancy loss in mice. Savion S, et al. **J Reprod Fertil** 1996 May;107(1):7-10

[Early immunosuppression and implantation] Chaouat G. **Contracept Fertil Sex** 1995 Oct;23(10):617-21 (38 ref.) (Eng. Abstr.) **(Fre)**

[Adhesion molecules and trophoblastic invasion] Loke YW, et al. **Contracept Fertil Sex** 1995 Sep;23(9):573-5 (40 ref.) (Eng. Abstr.) **(Fre)**

[The interleukin-1 system during human implantation] Simon C, et al. **Contracept Fertil Sex** 1995 Oct;23(10):626-30 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Transition from lacunar to villous stage of implantation in the macaque, including establishment of the trophoblastic shell. Enders AC. **Acta Anat (Basel)** 1995;152(3):151-69

Differential expression of CD44 in rabbit uterine epithelium during early pregnancy. Hohn HP, et al. **Acta Anat (Basel)** 1995;152(3):185-94

Loss of laminin and type IV collagen in uterine luminal epithelial basement membranes during blastocyst implantation in the mouse. Blankenship TN, et al. **Anat Rec** 1995 Sep;243(1):27-36

Progression of trophoblast into the endometrium during implantation in the western spotted skunk. Enders AC, et al. **Anat Rec** 1996 Mar;244(3):297-315

MUC1, endometrium and embryo implantation. Aplin JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):826-31 (49 ref.)

Ovine endometrial expression of transforming growth factor beta isoforms during the peri-implantation period. Doré JJ Jr, et al. **Biol Reprod** 1996 May;54(5):1080-7

Localization of insulin-like growth factor binding protein-4 expression in the mouse uterus during the peri-implantation period. Markoff E, et al. **Biol Reprod** 1995 Nov; 53(5):1103-9

Changes in uterine estrogen and progesterone receptors during delayed implantation and early implantation in the spotted skunk. Mead RA, et al. **Biol Reprod** 1995 Oct; 53(4):827-33

Regulation of urokinase plasminogen activator production in implanting mouse embryo: effect of embryo interaction with extracellular matrix. Zhang X, et al. **Biol Reprod** 1996 May;54(5):1052-8

Implantation and the endometrium. Cooke ID. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):233-8

Aging of the human endometrium: peri-implantation phase endometrium does not show any age-dependent variation in lectin binding. Noci I, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):11-21

The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. Hull MG, et al. **Fertil Steril** 1996 Apr;65(4):783-90

A new method to study the process of implantation of a human blastocyst in vitro. Landgren BM, et al. **Fertil Steril** 1996 May;65(5):1067-70

Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Pellicer A, et al. **Fertil Steril** 1996 Jun;65(6):1190-5

Female age predicts embryonic implantation after ICSI: a case-controlled study. Devroey P, et al. **Hum Reprod** 1996 Jun;11(6):1324-7

Physiological and molecular aspects of human implantation. Edwards RG. **Hum Reprod** 1995 Dec;10 Suppl 2:1-13

Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60-6 (26 ref.)

Decidua in human implantation. Loke YW, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:14-21 (62 ref.)

Role of embryonic factors in human implantation. Polan ML, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:22-9 (32 ref.)

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30-42 (105 ref.)

Interleukin-1 system crosstalk between embryo and endometrium in implantation. Simón C, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:43-54 (67 ref.)

Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Tabibzadeh S, et al. **Hum Reprod** 1995 Oct;10(10):2793-9

Luteal estrogen is not required for the establishment of pregnancy in the human. Zegers-Hochschild F, et al. **J Assist Reprod Genet** 1995 Mar;12(3):224-8

The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human implantation. Nachtigall MJ, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):801-6

Blood vessel growth and endothelial cell density in rat endometrium. Goodger AM, et al. **J Reprod Fertil** 1995 Nov;105(2):259-61

Corticotropin-releasing hormone (CRH) is expressed at the implantation sites of early pregnant rat uterus. Makrigiannakis A, et al. **Life Sci** 1995;57(20):1869-75

Blood vessel growth in the endometrium. Goodger AM, et al. **Microcirculation** 1995 Dec;2(4):329-43 (102 ref.)

Amphiregulin is an implantation-specific and progesterone-regulated gene in the mouse uterus. Das SK, et al. **Mol Endocrinol** 1995 Jun;9(6):691-705

Differential distribution of mRNA for the alpha- and beta-subunits of chorionic gonadotrophin in the implantation stage blastocyst of the marmoset monkey [published erratum appears in Placenta 1995 Sep;16(6):567] Lopata A, et al. **Placenta** 1995 Jun;16(4):335-46

Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Kundu GC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2915-9

Current studies on human implantation. a brief overview. Rogers PA. **Reprod Fertil Dev** 1995;7(6):1395-9 (24 ref.)

[In vitro modulation of the production of the cytokine HILDA/LIF, secreted by human endometrial explants: preliminary results] Delage G, et al. **Contracept Fertil Sex** 1995 Oct;23(10):622-5 (Eng. Abstr.) **(Fre)**

[Determining implantation time frame of the trophoblast by hCG level monitoring] Büscher U, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):661-5 (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Nutritional stress-induced implantation failure in laboratory mice: inhibition by continuous illumination. Archunan G, et al. **Indian J Exp Biol** 1995 Apr;33(4):241-3

OVUM IMPLANTATION, DELAYED

A sporadic case of delayed implantation after in-vitro fertilization in the human? Grinsted J, et al. **Hum Reprod** 1996 Mar;11(3):651-4

Immunolocalization of estrogen receptor protein in the mouse blastocyst during normal and delayed implantation. Hou Q, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2376-81

DRUG EFFECTS

A phorbol ester that activates protein kinase C mimics the action of estradiol or epidermal growth factor for initiating embryo implantation in the delayed implanting hypophysectomized rat. Johnson DC. **Life Sci** 1996; 58(10):861-7

PHYSIOLOGY

Changes in uterine estrogen and progesterone receptors during delayed implantation and early implantation in the spotted skunk. Mead RA, et al. **Biol Reprod** 1995 Oct; 53(4):827-33

Establishing the timing of implantation in the Harlan Porcellus Dutch and New Zealand White rabbit and the Han Wistar rat. Garside DA, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):69-73

OVUM PROTEINS see **EGG PROTEINS**

OVUM-SPERM INTERACTIONS see **SPERM-OVUM INTERACTIONS**

OVUM TRANSPORT

PHYSIOLOGY

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307-10 (12 ref.)

OWL MONKEY see **AOTINAE**

OWNERSHIP

see related
INTELLECTUAL PROPERTY

Health enhancement and companion animal ownership. Beck AM, et al. **Annu Rev Public Health** 1996;17:247-57 (60 ref.)

Pass the parcel—the public hospital sector in action [editorial] Chalmers J. **Aust N Z J Med** 1996 Apr;26(2):143-4

Doctor wins claim over patent ownership [news] Dyer C, et al. **BMJ** 1995 Nov 11;311(7015):1248

Whose radiograph is it anyway? [letter] McConnell DJ. **Br Dent J** 1996 Apr 20;180(8):285

An ethicist's commentary on how the veterinarian should deal with an injured, unowned dog. Rollin BE. **Can Vet J** 1996 Feb;37(2):74-6

Reverse mortgages and the economic status of elderly women. Morgan BA, et al. **Gerontologist** 1996 Jun; 36(3):400-5

Racial differences in home ownership and home equity among preretirement-aged households. Myers SL Jr, et al. **Gerontologist** 1996 Jun;36(3):350-60

The effects of ownership, operating environment, and strategic choices on nursing home efficiency. Rosko MD, et al. **Med Care** 1995 Oct;33(10):1001-21

Selling/buying a dental practice. Winter L. **N Y State Dent J** 1995 Aug-Sep;61(7):52-5

Gene donors' rights at risk [editorial] **Nature** 1996 May 2; 381(6577):1

Whose genes are they anyway? [news] [see comments] Dickson D. **Nature** 1996 May 2;381(6577):11, 13-4. Comment in: Nature 1996 Jul 4;382(6586):17.

Ownership of human genes [letter; comment] Lebovitz RM. **Nature** 1996 Jul 4;382(6586):17. Comment on: Nature 1996 May 2;381(6577):11, 13-4.

Collaboration and data sharing [letter; comment] Stevens AR. **Science** 1995 Dec 15;270(5243):1741. Comment on: Science 1995 Nov 10;270(5238):927-8.

A Kantian argument in favor of unimpeded access to health care [see comments] Heubel F. **Theor Med** 1995 Jun; 16(2):199-213. Comment in: Theor Med 1995 Jun;16(2):215-22.

ECONOMICS

The effects of ownership and ownership change on nursing home industry costs. Holmes JS. **Health Serv Res** 1996 Aug; 31(3):327-46

Valuation of a dental practice. Mastracchio NJ Jr. **N Y State Dent J** 1996 Jan;62(1):46-50

STATISTICS & NUMERICAL DATA

Hospital ownership of post-acute care: does it increase access to post-acute care services? Blewett LA, et al. **Inquiry** 1995-96 Winter;32(4):457-67

Differences in mortality by housing tenure and by car access from the OPCS Longitudinal Study. Filakti H, et al. **Popul Trends** 1995 Autumn;(81):27-30

A survey of urban pet ownership in Bali. Margawani KR, et al. **Vet Rec** 1995 Nov 4;137(19):486-8

1-OXACEPHALOSPORIN see **MOXALACTAM**

OXACILLIN

PHARMACOKINETICS

Effect of liver intoxication by carbon tetrachloride on hepatic local disposition of oxacillin using moment characteristics as index. Yasui H, et al. **Drug Metab Dispos** 1995 Aug; 23(8):779-85

Antibiotic penetration into cervical discs. Rhoten RL, et al. **Neurosurgery** 1995 Sep;37(3):418-21

PHARMACOLOGY

An evaluation of the necessity of 24-hour incubation for oxacillin minimum inhibitory concentrations. Wasilauskas BL, et al. **Am J Clin Pathol** 1996 Apr;105(4):380-3

Triton X-100 alters the resistance level of methicillin-resistant Staphylococcus aureus to oxacillin. Komatsuzawa H, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):209-12

Evaluation of Rapid ATB Staph for 5-hour antimicrobial susceptibility testing of Staphylococcus aureus. Groupement pour le Dépistage, L'Etude et la Prévention des Infections Hospitalières-Groep ter Opsporing, Studie en Preventie van Infecties in de Ziekenhuizen. Struelens MJ, et al. **J Clin Microbiol** 1995 Sep;33(9):2395-9

[Comparison of different phenotypic methods with

polymerase chain reaction (PCR) for the detection of resistance to oxacillin in coagulase negative staphylococci] Zambardi G, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):310–4 (Eng. Abstr.) **(Fre)**

[High incidence of oxacillin-resistant Staphylococcus aureus in a general hospital (letter; comment)] Ronchetto F, et al. **Recenti Prog Med** 1995 Nov;86(11):463. Comment on: Recenti Prog Med 1995 Feb;86(2):78–80. **(Ita)**

[Serotypes and antimicrobial susceptibility of Streptococcus pneumoniae from clinical specimens] Ikeda N. **Kansenshogaku Zasshi** 1995 Oct;69(10):1093–102 (Eng. Abstr.) **(Jpn)**

[Appearance of antibacterial activity of oxacillin against methicillin resistant Staphylococcus aureus (MRSA) in the presence of catechin] Takahashi O, et al. **Kansenshogaku Zasshi** 1995 Oct;69(10):1126–34 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Corden TE, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):323–6

OXADIAZOLES

Determination of free fatty acids in blood, tagged with 4-(2-carbazoylpyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl)- 2,1,3-benzoxadiazole, by high-performance liquid chromatography with fluorescence detection. Toyo'oka T, et al. **Biomed Chromatogr** 1995 Jul–Aug;9(4):162–70

ANALYSIS

Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. Harfenist M, et al. **J Med Chem** 1996 Apr 26;39(9):1857–63

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

CHEMICAL SYNTHESIS

Synthesis and pharmacological evaluation of some novel 5-(pyrazol-3-yl)thiadiazole and oxadiazole derivatives as potential hypoglycemic agents. Hanna MA, et al. **Arzneimittelforschung** 1995 Oct;45(10):1074–8

High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex. Jacobsen EJ, et al. **J Med Chem** 1996 Jan 5;39(1):158–75

CHEMISTRY

Thiol oxidation by 1,2,3-oxadiazolinium ions, presumed carcinogens. Loeppky RN, et al. **Chem Res Toxicol** 1995 Sep;8(6):817–20

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

PHARMACOLOGY

Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Guo JP, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1122–31

Intracoronary nitric oxide improves postischemic coronary blood flow and myocardial contractile function. Pabla R, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1113–21

Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Gauthier TW, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1652–9

Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. Cellek S, et al. **Br J Pharmacol** 1996 May;118(1):137–40

Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist. De Vries P, et al. **Br J Pharmacol** 1996 May;118(1):85–92

Photosensitization of oesophageal smooth muscle by 3-NO2-1, 4-dihydropyridines: evidence for two cyclic GMP-dependent effector pathways. Martin-Caraballo M, et al. **Br J Pharmacol** 1995 Dec;116(8):3293–301

Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Pauwels PJ, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):141–5

Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1D alpha, 5-HT1D beta, 5-HT1A and opossum 5-HT1B receptors. Pauwels PJ, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):95–103

Differences in the effects of ketanserin and GR127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pig jugular vein. Razzaque Z, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):199–206

K+ channel openers produce epithelium-dependent relaxation of the guinea-pig trachea. Shikada K, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):193–7

GR127935 is a potent antagonist of the 5-HT1-like receptor mediating contraction in the canine coronary artery. Terrón JA. **Eur J Pharmacol** 1996 Apr 4;300(1-2):109–12

The activity of 5-HT1D receptor ligands at cloned human 5-HT1D alpha and 5-HT1D beta receptors. Walsh DM, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):79–84

Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. Brunner F, et al. **FEBS Lett** 1995 Dec 4;376(3):262–6

Developmental studies on Drosophila melanogaster glutathione S-transferase and its induction by oxadiazolone. Hunaiti AA, et al. **Insect Biochem Mol Biol** 1995 Dec; 25(10):1115–9

K+ channel-opening properties of a novel compound, NIP-121, in guinea pig myocardium as compared with those of cromakalim. Matsuda T, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):608–13

The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities. Fruttero R, et al. **J Med Chem** 1995 Dec 8; 38(25):4944–9

High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex. Jacobsen EJ, et al. **J Med Chem** 1996 Jan 5;39(1):158–75

Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. Brunner F, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):48–53

U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. Tang AH, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):761–7

Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats. Yamashita T, et al. **Jpn J Pharmacol** 1995 Jun; 68(2):145–52

Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Schrammel A, et al. **Mol Pharmacol** 1996 Jul; 50(1):1–5

The effects of GR127935, a putative 5-HT1D receptor antagonist, on brain 5-HT metabolism, extracellular 5-HT concentration and behaviour in the guinea pig. Hutson PH, et al. **Neuropharmacology** 1995 Apr;34(4):383–92

Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Skingle M, et al. **Neuropharmacology** 1995 Apr;34(4):377–82

Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Boulton CL, et al. **Neuroscience** 1995 Dec;69(3):699–703

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Moro MA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1480–5

THERAPEUTIC USE

Activity of a new oxadiazole compound, against experimental infections with Entamoeba histolytica and Giardia lamblia in animal models. Bhopale KK, et al. **Ann Trop Med Parasitol** 1993 Apr;87(2):169–78

TOXICITY

Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Bacon JA, et al. **Toxicology** 1996 Apr 15;108(1-2):9–16

OXALAMIC ACID see OXAMIC ACID

OXALATES

see related
HYPEROXALURIA
HYPEROXALURIA, PRIMARY

ANALYSIS

Organic acid production by Aspergillus niger in recycling culture analyzed by capillary electrophoresis. Schrickx JM, et al. **Anal Biochem** 1995 Oct 10;231(1):175–81

Reduction of oxalate content of foods by the oxalate degrading bacterium, Eubacterium lentum WYH-1. Ito H, et al. **Int J Urol** 1996 Jan;3(1):31–4

Plasma and urine measurements for monitoring of treatment in the primary hyperoxaluric patient. Kasidas GP. **Nephrol Dial Transplant** 1995;10 Suppl 8:8–10 (25 ref.)

Effect of blanching on the content of antinutritional factors in selected vegetables. Mosha TC, et al. **Plant Foods Hum Nutr** 1995 Jun;47(4):361–7

[Oxalic acid] Isshiki G, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:593–6 (11 ref.) **(Jpn)**

BLOOD

Are there guidelines for a strategy according to glomerular filtration rate, plasma oxalate determination and the risk of oxalate accumulation? Barratt TM, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:22–3

CHEMISTRY

Snapshot of an enzyme reaction intermediate in the structure of the ATP-Mg2+-oxalate ternary complex of Escherichia coli PEP carboxykinase [see comments] Tari LW, et al. **Nat Struct Biol** 1996 Apr;3(4):355–63. Comment in: Nat Struct Biol 1996 Apr;3(4):307–9.

Beeturia and colonic oxalic acid. Eastwood MA, et al. **QJM** 1995 Oct;88(10):711–7

METABOLISM

Sulfate/oxalate exchange by lobster hepatopancreatic basolateral membrane vesicles. Gerencser GA, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R572–7

Generation of a proton motive force by the anaerobic oxalate-degrading bacterium Oxalobacter formigenes. Kuhner CH, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2494–500

Oxalate binding to rat kidney mitochondria: induction by oxidized glutathione. Selvam R, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):62–5

Cloning, sequencing, and expression in escherichia coli of OxlT, the oxalate:formate exchange protein of Oxalobacter formigenes. Abe K, et al. **J Biol Chem** 1996 Mar 22; 271(12):6789–93

Pathways for oxalate transport in rabbit renal microvillus membrane vesicles. Kuo SM, et al. **J Biol Chem** 1996 Jun 28;271(26):15491–7

Characterization of oxalate transport by the human erythrocyte band 3 protein. Jennings ML, et al. **J Gen Physiol** 1996 Jan;107(1):145–59

Characterization of nuclear oxalate binding protein of rat and human kidney. Selvam R, et al. **J Urol** 1996 Jul; 156(1):237–42

Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. Gambaro G, et al. **Kidney Int** 1995 Nov;48(5):1549–52

Effect of (D)-penicillamine on oxalate production [letter] Baker P, et al. **Nephron** 1995;71(2):240

[Oxalosis] Cordonnier C, et al. **Ann Pathol** 1995;15(6):415–23 (88 ref.) **(Fre)**

[Primary hyperoxaluria] De Pauw L, et al. **Rev Med Brux** 1996 Apr;17(2):67–74 (25 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Immunohistochemical techniques: the effect of melanin bleaching [see comments] Foss AJ, et al. **Br J Biomed Sci** 1995 Mar;52(1):22–5. Comment in: Br J Biomed Sci 1995 Dec;52(4):325–6.

Comparative effects of inorganic phosphate and oxalate on uptake and release of Ca2+ by the sarcoplasmic reticulum in saponin skinned rat cardiac trabeculae. Steele DS, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):565–76

TOXICITY

Oxalate toxicity in LLC-PK1 cells, a line of renal epithelial cells. Scheid C, et al. **J Urol** 1996 Mar;155(3):1112–6

Alterations in MDCK and LLC-PK1 cells exposed to oxalate and calcium oxalate monohydrate crystals. Hackett RL, et al. **Scanning Microsc** 1995 Jun;9(2):587–96

URINE

Glucagon increases urinary oxalate excretion in the guinea pig. Holmes RP, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E568–74

Reduction of oxalate content of foods by the oxalate degrading bacterium, Eubacterium lentum WYH-1. Ito H, et al. **Int J Urol** 1996 Jan;3(1):31–4

Simultaneous determination of oxalic and citric acids in urine by high-performance liquid chromatography. Khaskhali MH, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12; 675(1):147–51

[Normal values of calcium and oxalate excretion in children] Reusz G, et al. **Orv Hetil** 1996 Apr 21;137(16):861–3 (Eng. Abstr.) **(Hun)**

OXALOACETATES

METABOLISM

Effects of divalent cations and nucleotides on the 14CO2-oxaloacetate exchange catalyzed by the phosphoenol pyruvate carboxykinase from the moderate halophile, Vibrio costicola. Salvarrey MS, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1225–34

Catalytic strategy of citrate synthase: subunit interactions revealed as a consequence of a single amino acid change in the oxaloacetate binding site. Kurz LC, et al. **Biochemistry** 1995 Oct 17;34(41):13278–88

Regulation of the supply of cytosolic oxaloacetate for mitochondrial metabolism via phosphoenolpyruvate carboxylase in barley leaf protoplasts. I. The effect of covalent modification on PEPC activity, pH response, and kinetic properties. Krömer S, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):343–50

Regulation of the supply of oxaloacetate for mitochondrial metabolism via phosphoenolpyruvate carboxylase in barley leaf protoplasts. II. Effects of metabolites on PEPC activity at different activation states of the protein. Krömer S, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):351–61

OXALURIA see HYPEROXALURIA

OXALURIA, PRIMARY

OXALURIA, PRIMARY see HYPEROXALURIA, PRIMARY

OXAMIC ACID

ANALOGS & DERIVATIVES

Effects of lodoxamide (LOD), disodium cromoglycate (DSCG) and N-acetyl-aspartyl-glutamate sodium salt (NAAGA) on ocular active anaphylaxis. Goldschmidt P, et al. **Allerg Immunol (Paris)** 1996 Apr;28(4):124-6

Lodoxamide in vernal keratoconjunctivitis. Lee S, et al. **Ann Pharmacother** 1996 May;30(5):535-7 (19 ref.)

OXAMIDIC ACID see OXAMIC ACID

OXAMNIQUINE

PHARMACOLOGY

Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody synergy. Fallon PG, et al. **Parasitology** 1996 Jan;112 (Pt 1):47-58

THERAPEUTIC USE

The efficacy of oxamniquine in selective population chemotherapy in Ethiopia. Birrie H, et al. **Ethiop Med J** 1995 Oct;33(4):235-41

Treatment of schistosomiasis: gathering stones together. Lambertucci JR. **Mem Inst Oswaldo Cruz** 1995 Mar-Apr; 90(2):161-4

Case 4-1996: paralysis due to schistosomiasis [letter; comment] Cook J, et al. **N Engl J Med** 1996 Jun 6; 334(23):1548; discussion 1548-9. Comment on: N Engl J Med 1996 Feb 8;334(6):382-9.

TOXICITY

Lethal effect of oxamniquine and praziquantel on mice experimentally infected with Schistosoma mansoni. Tonelli SM, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul-Aug; 37(4):361-3

OXANDROLONE

ADVERSE EFFECTS

Anabolic steroids and psoriasis exacerbation [letter] Lear JT, et al. **Br J Dermatol** 1996 Apr;134(4):809

PHARMACOLOGY

Induction of "male-specific" cytochrome P450 isozymes in female rats by oxandrolone. Waskiewicz MJ, et al. **Drug Metab Dispos** 1995 Nov;23(11):1291-6

THERAPEUTIC USE

Growth promotion by oxandrolone in a girl with short stature and early pubertal development treated with growth hormone and gonadotropin-releasing hormone-analogue. A case study. Hermanussen M. **Acta Paediatr** 1995 Oct; 84(10):1207-10

The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty. Schroor EJ, et al. **Eur J Pediatr** 1995 Dec;154(12):953-7

Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. Haeusler G, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):536-41

Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. Nilsson KO, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):635-40

Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. Mendenhall CL, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul-Aug;19(4):258-65

Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Wilson DM, et al. **Pediatrics** 1995 Dec;96(6):1095-100

OXAZEPAM

ADVERSE EFFECTS

Late-onset seizures in alcohol withdrawal. Mayo-Smith MF, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):656-9

Extensive fixed drug eruption induced by oxazepam [letter] Krischer J, et al. **Arch Dermatol** 1996 Jun;132(6):718

ANALYSIS

Hair analysis for nordiazepam and oxazepam by gas chromatography--negative-ion chemical ionization mass spectrometry. Kintz P, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):241-4

BLOOD

Simple high-performance liquid chromatographic separation of oxazepam and its diastereoisomeric glucuronides in serum. Applications in a pharmacokinetic study in sheep. Mawa R, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):331-8

[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats] Liu JF, et al. **Yao Hsueh Hsueh Pao** 1995; 30(9):655-61 (Eng. Abstr.) **(Chi)**

CHEMISTRY

[Characterization of lorazepam and oxazepam by the thermal behavior of their degradation product] Chauvet A. **Ann Pharm Fr** 1995;53(6):256-60 (Eng. Abstr.) **(Fre)**

METABOLISM

Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Patel M, et al. **Pharmacogenetics** 1995 Oct;5(5):287-97

PHARMACOKINETICS

Oxidative biotransformation of oxazepam to reactive and nonreactive products in rat, mouse and human microsomes. Griffin RJ, et al. **Hum Exp Toxicol** 1995 Oct;14(10):779-86

PHARMACOLOGY

A comparison of behavioural effects of prenatally administered oxazepam in mice exposed to open-fields in the laboratory and the real world. Fiore M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):72-7

Limited changes of mouse maternal care after prenatal oxazepam: dissociation from pup-related stimulus perception. Petruzzi S, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):58-65

Effects of oxazepam on event-related brain potentials, EEG frequency bands, and vigilance performance. van Leeuwen TH, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):244-62

URINE

Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. Chiba K, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):77-84

OXAZEPINES

CHEMISTRY

Digoxin dialdehyde reductive aminations. Structure proof of the perhydro-1,4-oxazepine product. Adamczyk M, et al. **Steroids** 1995 Nov;60(11):753-8

PHARMACOLOGY

Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. Campiani G, et al. **J Med Chem** 1996 Jul 5;39(14):2672-80

Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. Hallinan EA, et al. **J Med Chem** 1996 Jan 19;39(2):609-13

OXAZINES

Basic blue 148: a rapid stain for T helper cells. Kass K. **Biotech Histochem** 1995 Mar;70(2):99-104

ADMINISTRATION & DOSAGE

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP] Kimura E, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):477-81 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis of 5-HT3 receptor antagonists, [11C]Y-25130 and [11C]YM060. Ishiwata K, et al. **Appl Radiat Isot** 1995 Sep; 46(9):907-10

Potentially active antimicrobial agents from 2-benzenesulfonyloxyphenyl-3,1-benzoxazine-4-one derivative. Habib OM, et al. **Boll Chim Farm** 1995 Oct; 134(9):503-8

New 5-HT3 (serotonin-3) receptor antagonists. V. Synthesis and structure-activity relationships of pyrrolo[2,1-c][1,4]benzoxazine-6-carboxamides. Kato M, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1358-63

Design and synthesis of 6-chloro-3,4-dihydro-4-methyl-2H-1,4-benzoxazine-8-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists. Kuroita T, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):756-64

Novel potassium channel activators: synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives. Matsumoto Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):103-14

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers. Yamamoto S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):734-45

New perhydro-1,4-oxazine derivatives of arylethanolamine with beta 3-adrenoceptor agonist activity. Monge A, et al. **Pharmazie** 1995 Nov;50(11):768-9

CHEMISTRY

Use of a chromophoric reporter group to probe the active site of cytosolic aldehyde dehydrogenase. Kitson TM, et al. **Adv Exp Med Biol** 1995;372:35-43

Photocatalytic and free radical interactions of the heterocyclic N-oxide resazurin with NADH, GSH, and Dopa. Prütz WA, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):239-48

An investigation of the use of nile red as a long-wavelength fluorescent probe for the study of alpha 1-acid glycoprotein-drug interactions. Brown MB, et al. **J Pharm Biomed Anal** 1995 Jul;13(8):1011-7

[Studies on structure of light degradation products of (-)-(S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihyd ro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (T-3761) in aqueous solution and solid state] Demachi K, et al. **Yakugaku Zasshi** 1995 Sep;115(9):716-31 (Eng. Abstr.) **(Jpn)**

METABOLISM

Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Klekotka PA, et al. **Drug Metab Dispos** 1995 Dec;23(12):1434-5

Laccase-mediated formation of the phenoxazinone derivative, cinnabarinic acid. Eggert C, et al. **FEBS Lett** 1995 Dec 4;376(3):202-6

A neuronal cell protecting substance, 4-demethoxymichigazone, produced by Streptomyces halstedii. Kunigami T, et al. **J Antibiot (Tokyo)** 1996 Mar; 49(3):312-3

Molecular orbital-generated QSARs in a homologous series of alkoxyresorufins and studies of their interactive docking with P450s. Lewis DF, et al. **Xenobiotica** 1995 Dec; 25(12):1355-69

PHARMACOKINETICS

Pharmacokinetics of T-3761 in healthy volunteers. Saito A. **Drugs** 1995;49 Suppl 2:335-6

PHARMACOLOGY

Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats. Hasegawa T, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2138-40

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Young SD, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2602-5

Inhibition of NO-medicate responses by 7-ethoxyresorufin, a substrate and competitive inhibitor of cytochrome P450. Li CG, et al. **Br J Pharmacol** 1996 May;118(1):57-62

Novel potassium channel activators: synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives. Matsumoto Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):103-14

Evidence for a 5-HT1D receptor-mediated hypothermic effect of the alpha 1-adrenoceptor agonist, SDZ NVI-085, in guinea-pigs. Kalkman HO, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):313-5

A neuronal cell protecting substance, 4-demethoxymichigazone, produced by Streptomyces halstedii. Kunigami T, et al. **J Antibiot (Tokyo)** 1996 Mar; 49(3):312-3

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. Williams PD, et al. **J Med Chem** 1995 Nov 10;38(23):4634-6

Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Pugsley TA, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1355-66

Effect of the potassium channel opener YM934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. Masuda N, et al. **J Urol** 1995 Nov; 154(5):1914-20

Biochemical changes induced by pyrphenoxone in the lens of rabbits and rats. Drago F, et al. **Pharmacol Res** 1995 May;31(5):325-9

Oxadin: a new chemotherapeuticum with antistaphylococcus effect. Michajlov Y, et al. **Pharmazie** 1995 Dec;50(12):832-3

THERAPEUTIC USE

Interim results from a multicentre clinical trial of T-3761 in Japan. Kobayashi H. **Drugs** 1995;49 Suppl 2:470-1

Clinical study of T-3761 in obstetrics and gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:393-4

Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections. Shinkawa A, et al. **Drugs** 1995;49 Suppl 2:401-2

Laboratory and clinical study of T-3761, a new fluoroquinolone, in urinary tract infection. Suzuki K, et al. **Drugs** 1995;49 Suppl 2:379-81

[A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin] Tsukuda M, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1959–67 (Eng. Abstr.) **(Jpn)**

OXAZOCILLINE see **OXACILLIN**

OXAZOLES

High-performance liquid chromatography with fluorescence detection of ebiratide using 4-(N,N-dimethylamino-sulphonyl)-7-fluoro-2,1,3-benzoxadiazole as a fluorogenic reagent. Hamachi Y, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):216-20

CHEMICAL SYNTHESIS

New phospholipase A2 inhibitor: synthesis and inhibition mechanism of oxazolidinone phospholipid analog. Iwama S, et al. **Bioorg Med Chem** 1995 Oct;3(10):1397–403

Synthesis and inhibitory activity of glycosidase inhibitors, glycosylamino-oxazolines. Uchida C, et al. **Bioorg Med Chem** 1996 Feb;4(2):275–81

The chemistry of pseudomonic acid. Part 14. Synthesis and in vivo biological activity of heterocyclyl substituted oxazole derivatives. Broom NJ, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1336–44

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680–5

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673–9

CHEMISTRY

The beta-D-GalpNAc-(1—>3)-D-Galp linkage through the oxazoline glycosylation method. Colombo D, et al. **Carbohydr Res** 1995 Oct 23;276(2):437–41

Hydrolysis of the GlcNAc oxazoline: deamidation and acyl rearrangement. Jha R, et al. **Carbohydr Res** 1995 Nov 7; 277(1):125–34

A new melanin biosynthesis inhibitor, melanoxadin from fungal metabolite by using the larval haemolymph of the silkworm, Bombyx mori [letter] Hashimoto R, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1052–4

The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. Brown P, et al. **J Med Chem** 1996 Jan 19;39(2):446–57

Photooxidation of d(TpG) by riboflavin and methylene blue. Isolation and characterization of thymidylyl-(3',5')-2-amino-5-[(2-deoxy-beta-D-erythro-pentofuranosyl)amino]-4H-imidazol-4-one and its primary decomposition product thymidylyl-(3',5')-2,2-diamino-4-[(2-deoxy-beta-D-erythro-pentofuranosyl)amino]-5(2H)-oxazolone. Buchko GW, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3954–61

[Synthesis of new platelet aggregation inhibitors substituted with pyridylisoxazoles and their 4,5-dihydroanalogs] Demina OV, et al. **Bioorg Khim** 1995 Dec;21(12):933–40 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Novel antioxidants from roasted perilla seed. Nagatsu A, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):887–9

Chivosazol A, a new inhibitor of eukaryotic organisms isolated from myxobacteria. Irschik H, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):962–6

Melanoxazal, new melanin biosynthesis inhibitor discovered by using the larval haemolymph of the silkworm, Bombyx mori. Production, isolation, structural elucidation, and biological properties. Takahashi S, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):513–8

Mycalolides D and E, new cytotoxic macrolides from a collection of the stony coral Tubastrea faulkneri. Rashid MA, et al. **J Nat Prod** 1995 Jul;58(7):1120–5

The occurrence of carboxymycobactin, the siderophore of pathogenic mycobacteria, as a second extracellular siderophore in Mycobacterium smegmatis. Ratledge C, et al. **Microbiology** 1996 Aug;142 (Pt 8):2207–12

METABOLISM

1H NMR spectroscopic studies on the reactions of haloalkylamines with bicarbonate ions: formation of N-carbamates and 2-oxazolidones in cell culture media and blood plasma. Anthony ML, et al. **Chem Res Toxicol** 1995 Dec;8(8):1046–53

Metabolism of 4-methylaminorex ("EU4EA") in the rat. Henderson GL, et al. **J Anal Toxicol** 1995 Nov-Dec; 19(7):563–70

Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells. Gargalidis-Moudanos C, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S59–62

Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. Gobin J, et al. **J Exp Med** 1996 Apr 1;183(4):1527–32

Specific binding of a dichloroacetamide herbicide safener in maize at a site that also binds thiocarbamate and chloroacetanilide herbicides. Walton JD, et al. **Plant Physiol** 1995 Sep;109(1):213–9

PHARMACOKINETICS

Dose proportionality studies of novel thiazolidinedione derivatives as potent antidiabetic agents in mice. Heitzmann T, et al. **Arzneimittelforschung** 1995 Dec;45(12):1284–8

Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. Patat A, et al. **J Clin Pharmacol** 1996 Mar; 36(3):216–29

Cyclization-activated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. Vigroux A, et al. **J Med Chem** 1995 Sep 29;38(20):3983–94

PHARMACOLOGY

Reconstitution of calyculin-inhibited K-Cl cotransport in dog erythrocyte ghosts by exogenous PP-1. Krarup T, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C898–902

In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Mason EO Jr, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1039–40

SB 205952, a novel semisynthetic monic acid analog with at least two modes of action. Wilson JM, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1925–33

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Zurenko GE, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):839–45

Multiple structural domains within I kappa B alpha are required for its inducible degradation by both cytokines and phosphatase inhibitors. Good LF, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):123–8

The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):72–6

Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. Tanaka H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):291–7

Phosphatase inhibitors promote ICAM-1 and LFA-1 mediated homotypic aggregation of Jurkat and U937 cells. Weeks BS, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):82–7

The protein phosphatase inhibitor calyculin A stimulates chemokine production by human synovial cells. Jordan NJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):89–95

The effect of okadaic acid and calyculin A on cholesterol esterification in rat hepatocytes. Hernández ML, et al. **Biochem Soc Trans** 1995 Nov;23(4):580S

Reversible phosphorylation as a controlling factor for sustaining calcium oscillations in HeLa cells: Involvement of calmodulin-dependent kinase II and a calyculin A-inhibitable phosphatase. Zhu DM, et al. **Biochemistry** 1996 Jun 4;35(22):7214–23

The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension. Panfilov V, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):563–9

Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. Evans RG, et al. **Br J Pharmacol** 1995 Sep;116(1):1557–70

Ability of okadaic acid and other protein phosphatase inhibitors to mimic the stimulatory effects of 12-O-tetradecanoylphorbol-13-acetate on hydroperoxide production in mouse epidermis in vivo. Newell SW, et al. **Cancer Lett** 1996 Jan 2;98(2):241–51

Involvement of protein kinase C and of protein phosphatases 1 and/or 2A in p47 phox phosphorylation in formylmet-Leu-Phe stimulated neutrophils: studies with selective inhibitors RO 31-8220 and calyculin A. Bengis-Garber C, et al. **Cell Signal** 1995 Sep;7(7):721–32

Effects of the protein phosphatase inhibitors, tautomycin and calyculin-A, on protein phosphorylation and cytoskeleton of human platelets. Kurisaki T, et al. **Cell Struct Funct** 1995 Oct;20(5):331–43

The protein phosphatase inhibitor calyculin-A affects catecholamine secretion and granular distribution in cultured adrenomedullary chromaffin cells. Gutierrez LM, et al. **Eur J Cell Biol** 1995 Sep;68(1):88–95

Differential characteristics and localisation of [3H]oxazoline and [3H]imidazoline binding sites in rat kidney. King PR, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):341–6

Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats. Moreno A, et al. **Haemostasis** 1995 Jul-Aug;25(4):166–71

In-vitro activity of oxazolidinones against Mycobacterium avium complex. Peters J, et al. **J Antimicrob Chemother** 1995 May;35(5):675–9

Interactions of the cardiac chronotropic effects of rilmenidine with the autonomic nervous system in conscious dogs: comparison with clonidine. Boucher M, et al. **J Auton Pharmacol** 1996 Feb;16(1):13–20

Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. Harron DW, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S48–54

Carotid arterial changes produced by a centrally mediated antihypertensive agent in hypertensive rats. Levy BI, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):666–73

Brain structures involved in the hypotensive effects of rilmenidine: evaluation by [14C]2-deoxyglucose autoradiography. Macrae IM, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S55–8

Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. Smyth DD, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S63–7

Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. Patat A, et al. **J Clin Pharmacol** 1996 Mar; 36(3):216–29

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680–5

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673–9

Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. Caille D, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):265–77

Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. Chan CK, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):411–20

Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. Curet O, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):253–64

E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A. Kagaya T, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):243–51

Stimulation of motility and respiration of intact fowl spermatozoa by calyculin A, a specific inhibitor of protein phosphatase-1 and -2A, via a Ca2+-dependent mechanism. Ashizawa K, et al. **J Reprod Fertil** 1995 Sep; 105(1):109–14

Clonidine and rilmenidine suppress hypotension-induced Fos expression in the lower brainstem of the conscious rabbit. Li YW, et al. **Neuroscience** 1995 May;66(2):391–402

Comparison of the action of the stereoisomers of the psychostimulant 4-methylaminorex (4-MAX) on midbrain dopamine cells in the rat: an extracellular single unit study. Ashby CR Jr, et al. **Synapse** 1995 Aug;20(4):351–61

THERAPEUTIC USE

Cardiovascular variability after rilmenidine challenge: assessment of acute dosing effects by means of spectral analysis. Girard A, et al. **Fundam Clin Pharmacol** 1995; 9(4):366–71

Imidazoline Receptors in a Comprehensive Approach to Hypertension. Proceedings of an international symposium. Berlin, Germany, September 10, 1994. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S1–67

Rilmenidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. Mammoto T, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S40–3

Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. Panfilov V, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S44–7

Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. Scemama M, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 2:S34–9

Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. Trimarco B, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S29–33

311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Visser WH, et al. **Neurology** 1996 Feb;46(2):522–6

[Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients] Luccioni R. **Presse Med** 1995 Dec 9;24(38):1857–64 (Eng. Abstr.) **(Fre)**

OXAZOLONE

ANALOGS & DERIVATIVES

Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. Low NM, et al. **J Mol Biol** 1996 Jul 19; 260(3):359–68

Properties of a single-chain antibody containing different linker peptides. Alfthan K, et al. **Protein Eng** 1995 Jul; 8(7):725–31

IMMUNOLOGY

Regulation of chemokine gene expression by contact hypersensitivity and by oral tolerance. Yuan YS, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:434–7

Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens. Dearman RJ, et al. **Immunology** 1995 Dec;86(4):545–50

OXAZOLONE

PHARMACOLOGY

Stimulation by oxazolone of increased IL-6, but not IL-10, in the skin of mice. Holliday MR, et al. **Toxicology** 1996 Jan 8;106(1-3):237-42

TOXICITY

Cytometric profile of molybdenum-induced contact sensitization versus a strong allergen reaction to oxazolone in murine auricular lymph node (ALN) test. Abdouh M, et al. **Int J Immunopharmacol** 1995 Jul;17(7):545-54

Topical exposure to chlordane reduces the contact hypersensitivity response to oxazolone in BALB/c mice. Blaylock BL, et al. **Toxicol Lett** 1995 Nov 15; 81(2-3):205-11

OXEPINS

PHARMACOLOGY

A novel metabolite, an oxepin formed from cannabidiol with guinea-pig hepatic microsomes. Yamamoto I, et al. **J Pharm Pharmacol** 1995 Aug;47(8):683-6

OXICONUM see **OXYCODONE**

OXIDANTS

see related

ANTIOXIDANTS

A vanadate hematoxylin stain for basic proteins. Smith AA. **Biotech Histochem** 1995 Sep;70(5):258-62

Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Pino S, et al. **Clin Chem** 1996 Feb;42(2):239-43

Human cytochrome P450's are pro-oxidants in iron/ascorbate-initiated microsomal lipid peroxidation. Lambert N, et al. **Free Radic Res** 1996 Mar;24(3):177-85

ADVERSE EFFECTS

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9-19 (58 ref.)

Tolerance to phosgene is associated with a neutrophilic influx into the rat lung. Ghio AJ, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1064-71

Effect of sepsis and 3,5,3'-triiodothyronine replacement on myocardial integrity during oxidant challenge. Davidson SB, et al. **Crit Care Med** 1996 May;24(5):850-4

Role of oxidants in ischemic brain damage. Chan PH. **Stroke** 1996 Jun;27(6):1124-9 (56 ref.)

Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease [editorial] Rahman I, et al. **Thorax** 1996 Apr;51(4):348-50

ANALYSIS

H2O2 determination in rat lens: chemiluminescent versus radioisotopic methods. Devamanoharan PS, et al. **Ophthalmic Res** 1995;27 Suppl 1:39-43

CHEMISTRY

Reaction of ferrate (VI)/ferrate (V) with hydrogen peroxide and superoxide anion--a stopped-flow and premix pulse radiolysis study. Rush JD, et al. **Free Radic Res** 1996 Mar; 24(3):187-98

METABOLISM

Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Witko-Sarsat V, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1910-6

Tourniquet-induced exsanguination in patients requiring lower limb surgery. An ischemia-reperfusion model of oxidant and antioxidant metabolism. Mathru M, et al. **Anesthesiology** 1996 Jan;84(1):14-22

Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in the lung. Gutteridge JM, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1024-7

Gill diffusion as a physiological mechanism for hydrogen peroxide elimination by fish. Wilhelm-Filho D, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2879-82

Tumor progression and oxidant-antioxidant status. Saintot M, et al. **Carcinogenesis** 1996 Jun;17(6):1267-71

Dealkylation of N-nitrosodibenzylamine by metalloporphyrin/oxidant model systems for cytochrome P450. Okochi E, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec; 43(12):2173-6

Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Laurent T, et al. **Chest** 1996 Jan;109(1):163-6

Hydroxyl radical formation from Cu(II)-trolox mixtures: insights into the pro-oxidant properties of alpha-tocopherol. Burkitt MJ, et al. **FEBS Lett** 1996 Jan 22;379(1):51-4

Production of reactive nitrogen intermediates (RNI) by peritoneal macrophages from rats with experimental autoimmune prostatitis (EAP). Orsilles MA, et al. **Inflammation** 1995 Aug;19(4):415-22

Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675-86 (100 ref.)

Endothelial cell oxidant generation during K(+)-induced membrane depolarization. al-Mehdi AB, et al. **J Cell Physiol** 1996 Feb;166(2):274-80

Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Roselaar SE, et al. **Kidney Int** 1995 Jul;48(1):199-206

Plasma fatty acid profile and prooxidative-antioxidative parameters in vegetarians. Krajčovičová-Kudláčková M, et al. **Nahrung** 1995;39(5-6):452-7

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143-9 (41 ref.)

Oxidants/antioxidants in idiopathic pulmonary fibrosis. MacNee W, et al. **Thorax** 1995 Sep;50 Suppl 1:S53-8 (64 ref.)

PHARMACOLOGY

Catalase and glutathione reductase protection of human alveolar macrophages during oxidant exposure in vitro. Pietarinen P, et al. **Am J Respir Cell Mol Biol** 1995 Oct; 13(4):434-41

Permeability of human isolated airways increases after hydrogen peroxide and poly-L-arginine. Hulsmann AR, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):841-6

Modification of high- and low-density lipoproteins by cigarette smoke oxidants. Yokode M, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:245-51

Modulation of the rat alveolar macrophage respiratory burst by hydroperoxides is calcium dependent. Hoyal CR, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):166-71

Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes [corrected] [published erratum appears in Arch Biochem Biophys 1995 Dec 1;324(1):200] Salgo MG, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):500-5

Effect of H2O2 on adriamycin-induced cytotoxicity in vitro. Anuszewska EL. **Arch Immunol Ther Exp (Warsz)** 1994; 42(4):281-5

Oxidant-induced stress response in lymphoid cells. Barnett YA, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):273-81

Activation of the multicatalytic endopeptidase by oxidants. Effects on enzyme structure. Strack PR, et al. **Biochemistry** 1996 Jun 4;35(22):7142-9

Hydrogen peroxide hyperpolarizes rat CA1 pyramidal neurons by inducing an increase in potassium conductance. Seutin V, et al. **Brain Res** 1995 Jun 19;683(2):275-8

Relationship between the adaptive response to oxidants and stable menadione-resistance in Chinese hamster ovary cell lines. Vallis KA, et al. **Carcinogenesis** 1996 Apr; 17(4):649-54

Effect of sulfhydryl oxidation on ionic and gating currents associated with L-type calcium channels in isolated guinea-pig ventricular myocytes. Lacampagne A, et al. **Cardiovasc Res** 1995 Nov;30(5):799-806

Oxidant-induced activations of nuclear factor-kappa B and activator protein-1 in cardiac myocytes. Peng M, et al. **Cell Mol Biol Res** 1995;41(3):189-97

Effect of oxidative insult on young and adult cardiac muscle cells in vitro. Nag AC, et al. **Cytobios** 1996;85(340):7-27

The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Chernyak BV, et al. **Eur J Biochem** 1996 Jun 15;238(3):623-30

Redox agents as a link between hypoxia and the responses of ionic channels in rabbit pulmonary vascular smooth muscle. Park MK, et al. **Exp Physiol** 1995 Sep;80(5):835-42

Opposing effects of oxidants and antioxidants on K+ channel activity and tone in rat vascular tissue. Reeve HL, et al. **Exp Physiol** 1995 Sep;80(5):825-34

Oxidant-mediated proteolytic activation of Ca(+)-ATPase in microsomes of pulmonary smooth muscle. Ghosh SK, et al. **FEBS Lett** 1996 Jun 3;387(2-3):171-4

Involvement of intracellular Ca2+ in oxidant-induced NF-kappa B activation. Sen CK, et al. **FEBS Lett** 1996 Apr 29;385(1-2):58-62

Inverse deuterium kinetic isotope effect for peroxidation in human low-density lipoprotein (LDL): a simple test for tocopherol-mediated peroxidation of LDL lipids. Witting PK, et al. **FEBS Lett** 1995 Nov 13;375(1-2):45-9

Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. Zou MH, et al. **FEBS Lett** 1996 Mar 11;382(1-2):101-4

The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Demasi M, et al. **Free Radic Biol Med** 1996;20(3):291-9

Single-cell investigation by laser scanning confocal microscopy of cytochemical alterations resulting from extracellular oxidant challenge. Pompella A, et al. **Histochem Cell Biol** 1996 Mar;105(3):173-8

Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317-24 (80 ref.)

Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43-8 (55 ref.)

Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human endothelial cells: involvement of cyclic AMP. Franzini E, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S92-5

Detachment of cultured cells from the substratum induced by the neutrophil-derived oxidant NH2Cl: synergistic role of phosphotyrosine and intracellular Ca2+ concentration. Nakamura TY, et al. **J Cell Biol** 1995 Oct;131(2):509-24

Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. McKenzie SJ, et al. **J Clin Invest** 1996 Jul 1;98(1):136-41

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S-7S (42 ref.)

H2O2-induced chloride currents are indicative of an endogenous Na(+)-Ca2+ exchange mechanism in Xenopus oocytes. Schlief T, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):123-30

Alteration of lens sulfhydryl groups induced by oxidative stress: Raman spectroscopic study of hydrogen peroxide-treated rat lens. Tomohiro M, et al. **Jpn J Ophthalmol** 1995;39(2):130-6

Luminal exposure of oxidants alter colonic absorptive function. Bhaskar L, et al. **Life Sci** 1996;58(23):2115-23

Modifications of cysteine-rich regions in protein kinase C induced by oxidant tumor promoters and enzyme-specific inhibitors. Gopalakrishna R, et al. **Methods Enzymol** 1995; 252:132-46

The Saccharomyces cerevisiae IMP2 gene encodes a transcriptional activator that mediates protection against DNA damage caused by bleomycin and other oxidants. Masson JY, et al. **Mol Cell Biol** 1996 May;16(5):2091-100

Induction of the Escherichia coli UVM response by oxidative stress. Wang G, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):573-9

Free radical-induced endothelial membrane dysfunction at the site of blood-brain barrier: relationship between lipid peroxidation, Na,K-ATPase activity, and 51Cr release. Stanimirovic DB, et al. **Neurochem Res** 1995 Dec; 20(12):1417-27

A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Taniguchi Y, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2746-52

Intracellular high energy metabolite depletion and cell membrane injury with antioxidant enzymes during oxidant exposure in vitro. Aalto K, et al. **Toxicol Lett** 1996 May; 85(2):93-9

THERAPEUTIC USE

The effect of oxidising mouthrinses compared with chlorhexidine on salivary bacterial counts and plaque regrowth. Moran J, et al. **J Clin Periodontol** 1995 Oct; 22(10):750-5

TOXICITY

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro. Johnson WC, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:136-47

Binding of myeloperoxidase to bacteria: effect on hydroxyl radical formation and susceptibility to oxidant-mediated killing. Britigan BE, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):231-40

Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Rong Y, et al. **Biotechnol Ther** 1994-95;5(3-4):117-26

Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Oyama Y, et al. **Brain Res** 1996 Mar 18;712(2):349-52

Pro-oxidant activity of flavonoids: effects on glutathione and glutathione S-transferase in isolated rat liver nuclei. Sahu SC, et al. **Cancer Lett** 1996 Jul 12;104(2):193-6

B cell lymphoma-2 transfected P815 cells resist reactive nitrogen intermediate-mediated macrophage-dependent cytotoxicity. Albina JE, et al. **J Immunol** 1996 Jul 1; 157(1):279-83

Protein S-thiolation and dethiolation during the respiratory burst in human monocytes. A reversible post-translational modification with potential for buffering the effects of oxidant stress. Seres T, et al. **J Immunol** 1996 Mar 1; 156(5):1973-80

Peroxide damage to rat lens in vitro: protective effect of dehydroascorbate. Varma SD, et al. **J Ocul Pharmacol Ther** 1995 Winter;11(4):543-51

Differences in basal and induced DNA single-strand breaks between human peripheral monocytes and lymphocytes. Holz O, et al. **Mutat Res** 1995 Nov;332(1-2):55-62

Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Juedes MJ, et al. **Mutat Res** 1996 Jan 17;349(1):51-61

Prevention of hydrogen peroxide damage by soybean saponins to mouse fibroblasts. Yoshikoshi M, et al. **Planta Med** 1996 Jun;62(3):252-5

DNA damage profiles induced by oxidizing agents. Epe B. **Rev Physiol Biochem Pharmacol** 1996;127:223-49 (160 ref.)

Increased oxidant resistance of alveolar epithelial type II cells. Isolated from rats following repeated exposure to cadmium aerosols. Hart BA, et al. **Toxicol Lett** 1995 Nov 15;81(2-3):131-9

The localization of DMPO spin adducts of OH in endothelial cells exposed to hydrogen peroxide. Kaneko M, et al. **Toxicol Lett** 1995 Nov;81(1):73-8

OXIDANTS, PHOTOCHEMICAL

ADVERSE EFFECTS

Temperature, ambient ozone levels, and mortality during summer 1994, in Belgium. Sartor F, et al. **Environ Res** 1995 Aug;70(2):105–13

CHEMISTRY

A simple synthesis of 11,19–oxidosteroids. Boudi A, et al. **Steroids** 1995 May;60(5):411–3

[Treatment of waste dumping site effluents using the wet photochemical oxidation method] Leitzke O. **Rocz Panstw Zakl Hig** 1996;47(1):125–34 (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Bronchoscopic determination of ozone uptake in humans. Gerrity TR, et al. **J Appl Physiol** 1995 Sep;79(3):852–60

PHARMACOLOGY

Expression of ICAM–1 in airway epithelium after acute ozone exposure in the mouse. Takahashi N, et al. **J Appl Physiol** 1995 Nov;79(5):1753–61

Ozone–induced oxygen radical release from bronchoalveolar lavage cells and airway hyper–responsiveness in dogs. Stevens WH, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):257–65

Modulation of IL–1 beta, IL–6, IL–8, TNF–alpha, and TGF–beta secretions by alveolar macrophages under NO2 exposure. Kienast K, et al. **Lung** 1996;174(1):57–67

THERAPEUTIC USE

Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Bocci V. **Med Hypotheses** 1996 Feb;46(2):150–4 (40 ref.)

TOXICITY

Expression of inducible nitric oxide synthase mRNA in Brown Norway rats exposed to ozone: effect of dexamethasone. Haddad EB, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):287–90

Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357–71 (182 ref.)

Ozone–induced alteration in beta–adrenergic pharmacological modulation of pulmonary macrophages. McGovern TJ, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):51–6

Bronchiolarized metaplasia and interstitial fibrosis in rat lungs chronically exposed to high ambient levels of ozone. Stockstill BL, et al. **Toxicol Appl Pharmacol** 1995 Oct; 134(2):251–63

Chronic inhalation exposure to ozone and nitric acid elevates stress–inducible heat shock protein 70 in the rat lung. Wong CG, et al. **Toxicology** 1996 Feb 22;107(2):111–9

OXIDASES see **OXIDOREDUCTASES**

OXIDATION–REDUCTION

see related
ANTIOXIDANTS
OXIDANTS

Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Dierks EA, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1593–600

Use of gender and oxygenation as synonyms for sex and oxidation [letter] Vickers S. **Drug Metab Dispos** 1995 Oct; 23(10):1007

Redox regulation of DNA–protein interactions by biothiols. Suzuki YJ, et al. **Methods Enzymol** 1995;252:175–80

Picture story. Considering a reducing plan. Felsenfeld AL. **Nat Struct Biol** 1995 Nov;2(11):937

Oxidative metabolism in Rett syndrome: 1. Clinical studies. Haas RH, et al. **Neuropediatrics** 1995 Apr;26(2):90–4

Proximity of the manganese cluster of photosystem II to the redox–active tyrosine YZ. Gilchrist ML Jr, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9545–9

Investigation of the prebiotic synthesis of amino acids and RNA bases from CO2 using FeS/H2S as a reducing agent. Keefe AD, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11904–6

The three–dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two–electron reduction. Li R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8846–50

Photochemical energy conversion in a helical oligoproline assembly. McCafferty DG, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8200–4

Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Prestera T, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8965–9

Redox properties of the flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism. Ramsay RR, et al. **Prog Brain Res** 1995; 106:33–9

[Antioxidants in nutrition and their importance in the anti–/oxidative balance in the immune system] Biesalski HK, et al. **Immun Infekt** 1995 Oct;23(5):166–73 (72 ref.) (Eng. Abstr.) **(Ger)**

[Nitric oxide and oxidative metabolism: heads or tails in inflammatory gastric disease] Esteban Carretero J, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):423–30 (90 ref.) **(Spa)**

DRUG EFFECTS

Characterisation of novel indenoindoles. Part II. Redox–recycling with ascorbate. Björquist P, et al. **Biochem Pharmacol** 1996 May 17;51(10):1403–10

[Evaluation of the antiradical protector effect of multifermented milk serum with reiterated dosage in rats] Stella V, et al. **C R Seances Soc Biol Fil** 1995;189(6):1191–7 (Eng. Abstr.) **(Fre)**

OXIDATIVE BURST see **RESPIRATORY BURST**

OXIDATIVE PHOSPHORYLATION

see related
UNCOUPLING AGENTS

Analysis of oxidative phosphorylation complexes in cultured human fibroblasts and amniocytes by blue–native–electrophoresis using mitoplasts isolated with the help of digitonin. Klement P, et al. **Anal Biochem** 1995 Oct 10;231(1):218–24

Effect of GLUT1 glucose transporter overexpression on the stimulation of glucose transport in response to inhibition of oxidative phosphorylation. Ismail–Beigi F, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):201–7

Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? Bates TE, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):40–4

Top–down control analysis of temperature effect on oxidative phosphorylation. Dufour S, et al. **Biochem J** 1996 Mar 15; 314 (Pt 3):743–51

Compartmentation and metabolic parameters of mitochondrial hexokinase and creatine kinase depend on the rate of oxidative phosphorylation. Lipskaya TYu, et al. **Biochem Mol Med** 1995 Aug;55(2):81–9

Involvement of cytochrome c oxidase subunit III in energy coupling. Wu S, et al. **Biochemistry** 1995 Dec 19; 34(50):16298–305

Control and kinetic analysis of ischemia–damaged heart mitochondria: which parts of the oxidative phosphorylation system are affected by ischemia? Borutaite V, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):154–8

Dependence of flux size and efficiency of oxidative phosphorylation on external osmolarity in isolated rat liver mitochondria: role of adenine nucleotide carrier. Devin A, et al. **Biochim Biophys Acta** 1996 Jan 11;1273(1):13–20

Stimulation of oxidative phosphorylation by electrophoretic K+ entry associated to electroneutral K+/H+ exchange in yeast mitochondria. Manon S, et al. **Biochim Biophys Acta** 1995 Oct 10;1231(3):282–8

The substrate–specific impairment of oxidative phosphorylation in liver mitochondria from high–protein–fed chickens. Toyomizu M, et al. **Br J Nutr** 1995 Dec;74(6):797–806

Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two–dimensional resolution: normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities. Schägger H. **Electrophoresis** 1995 May;16(5):763–70

P/O ratios reassessed: mitochondrial P/O ratios consistently exceed 1.5 with succinate and 2.5 with NAD–linked substrates. Lee CP, et al. **FASEB J** 1996 Feb;10(2):345–50

Regulation of oxidative phosphorylation: the flexible respiratory network of Paracoccus denitrificans. Van Spanning RJ, et al. **J Bioenerg Biomembr** 1995 Oct; 27(5):499–512 (93 ref.)

Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts. Kobara M, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):417–28

Early–onset encephalomyopathy associated with tissue–specific mitochondrial DNA depletion: a morphological, biochemical and molecular–genetic study. Mariotti C, et al. **J Neurol** 1995 Sep;242(9):547–56

Oxidative phosphorylation defect associated with primary adrenal insufficiency. North K, et al. **J Pediatr** 1996 May; 128(5 Pt 1):688–92

Native electrophoresis for isolation of mitochondrial oxidative phosphorylation protein complexes. Schägger H. **Methods Enzymol** 1995;260:190–202

Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Faure Vigny H, et al. **Mol Carcinog** 1996 Jul;16(3):165–72

Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease. De Stefano N, et al. **Muscle Nerve** 1996 Jun;19(6):764–9

Efficiency of oxidative work performance of skeletal muscle in patients with cystic fibrosis. de Meer K, et al. **Thorax** 1995 Sep;50(9):980–3

Mitochondrial oxidative phosphorylation injuries occurring in situ and in vitro. Willet K, et al. **Transplant Proc** 1995 Oct;27(5):2827–8

Defective mitochondrial oxidative phosphorylation in varicocele–bearing testicles. Hsu HS, et al. **Urology** 1995 Oct;46(4):545–9

[Marinesco–Sjögren syndrome with chronic progressive ophthalmoplegia caused by presumed defective oxidative phosphorylation] Berio A, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):99–103 (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Inhibitory effect of 3–hydroxyacyl–CoAs and other long–chain fatty acid beta–oxidation intermediates on mitochondrial oxidative phosphorylation. Ventura FV, et al. **J Inherit Metab Dis** 1996;19(2):161–4

Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. Davey GP, et al. **J Neurochem** 1996 Apr;66(4):1617–24

Alcohol inhibits the depolarization–induced stimulation of oxidative phosphorylation in synaptosomes. Li HL, et al. **J Neurochem** 1996 Apr;66(4):1691–7

Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. Salducci MD, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):417–22

[Effects of chronic intoxication induced by components of high–temperature superconducting ceramics on respiration and oxidative phosphorylation in liver mitochondria (an experimental study)] Zeldi IP, et al. **Med Tr Prom Ekol** 1996;(1):39–42 **(Rus)**

OXIDATIVE STRESS

Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Praprotnik D, et al. **Acta Neuropathol (Berl)** 1996;91(1):1–5

Effects of hyper– and hypo– thyroidism on oxidative stress of the eye in experimental acute anterior uveitis. Bilgihan K, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):41–3

Oxidative stress in acute and chronic pancreatitis. Schoenberg MH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1306S–1314S (69 ref.)

Suppression of TCA cycle activity in the cardiac muscle cell by hydroperoxide–induced oxidant stress. Janero DR, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1735–42

Myocardial adaptation to ischemia by oxidative stress induced by endotoxin. Maulik N, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C907–16

Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Peresleni T, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F971–7

Glutathione homeostasis in alveolar epithelial cells in vitro and lung in vivo under oxidative stress. Rahman I, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L285–92

Anemia in copper–deficient rats: role of alterations in erythrocyte membrane fluidity and oxidative damage. Rock E, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1245–9

Alterations of ambient oxygen tension modulate the expression of tumor necrosis factor and macrophage inflammatory protein–1 alpha from murine alveolar macrophages. VanOtteren GM, et al. **Am J Respir Cell Mol Biol** 1995 Oct;13(4):399–409

Reflux esophagitis in humans is mediated by oxygen–derived free radicals. Wetscher GJ, et al. **Am J Surg** 1995 Dec; 170(6):552–6; discussion 556–7

Determination of ascorbic acid and dehydroascorbic acid in plasma by high–performance liquid chromatography with coulometric detection—are they reliable biomarkers of oxidative stress? Lykkesfeldt J, et al. **Anal Biochem** 1995 Aug 10;229(2):329–35

Apoptosis and oxidative stress in the aging brain. Adams JD, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:135–51

Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. Joseph JA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:112–9 (47 ref.)

Oxidative brain damage in aged mice. Protection by caloric reduction. Lal H, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:308

Oxidative stress and Parkinson's disease. Owen AD, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:217–23

Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:1–11 (44 ref.)

Oxidative stress in neurodegenerative diseases. Simonian NA, et al. **Annu Rev Pharmacol Toxicol** 1996;36:83–106 (177 ref.)

Hemoglobin oxidative stress in cancer. Della Rovere F, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2089–95

Oxidative stress detection with Escherichia coli harboring a katG'::lux fusion. Belkin S, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2252–6

Oxidant–inducible adapt 15 RNA is associated with growth arrest– and DNA damage–inducible gadd153 and gadd45. Crawford DR, et al. **Arch Biochem Biophys** 1996 May 15; 329(2):137–44

Effect of the spin–trapping compound N–tert–butyl–alpha–phenylnitrone on protein oxidation and life span. Dubey A, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):249–54

Dichlone–induced oxidative stress in a model insect species, Spodoptera eridania. Ahmad S, et al. **Arch Environ Contam Toxicol** 1995 Nov;29(4):442–8

Mineral fiber–induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236–47 (53 ref.)

Exercise–induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec;

26(3-4):49-58 (133 ref.)
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Behl C, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):473-82
Mechanism of oxidative damage of dog kidney Na/K-ATPase. Boldyrev A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):483-7
Oxidative stress response in iron-induced acute nephrotoxicity: enhanced expression of heat shock protein 90. Fukuda A, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):76-81
Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in the lung. Gutteridge JM, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1024-7
Murine peritoneal macrophages induce a novel 60-kDa protein with structural similarity to a tyrosine kinase p56lck-associated protein in response to oxidative stress. Ishii T, et al. **Biochem Biophys Res Commun** 1996 Sep 13; 226(2):456-60
Oxidative stress increases gene expression of heparin-binding EGF-like growth factor and amphiregulin in cultured rat gastric epithelial cells. Miyazaki Y, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):542-6
Studies of human and rat blood under oxidative stress: changes in plasma thiol level, antioxidant enzyme activity, protein carbonyl content, and fluidity of erythrocyte membrane. Yelinova V, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):300-3
Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. Guyton KZ, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):547-54
Oxidant stress causes alteration in the attachment of mononuclear cells to collagen. Menon RP, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):193-200
Cytotoxic effects of an oxidative stress on neuronal-like pheochromocytoma cells (PC12). Vimard F, et al. **Biochem Pharmacol** 1996 May 17;51(10):1389-95
Oxidative stress: the paradox of aerobic life. Davies KJ. **Biochem Soc Symp** 1995;61:1-31 (228 ref.)
Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al. **Biochem Soc Symp** 1995;61:139-52 (49 ref.)
The effect of antioxidant supplementation on the oxidant-induced stress response in human lymphocytes. Brennan LA, et al. **Biochem Soc Trans** 1996 Feb;24(1):75S
An investigation of the response of lymphoblastoid cells to hydrogen peroxide-derived oxidative stress. O'Farrell FJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):71S
Recombinant Phabs reactive with 7,8-dihydro-8-oxoguanine, a major oxidative DNA lesion. Bespalov IA, et al. **Biochemistry** 1996 Feb 20;35(7):2067-78
Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Babizhayev MA. **Biochim Biophys Acta** 1996 Mar 1;1315(2):87-99
Oxidative stress mediates synthesis of cytosolic phospholipase A2 after UVB injury. Chen X, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):23-33
Alteration of glutathione transferase subunits composition in the liver of young and aged rats submitted to hypoxic and hyperoxic conditions. Di Ilio C, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):125-31
Oxidative stress response in yeast: glutathione peroxidase of Hansenula mrakii is bound to the membrane of both mitochondria and cytoplasm. Inoue Y, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):325-30
Protection against oxidative injury and permeability alteration in cultured alveolar epithelium by transferrin-catalase conjugate. Rojanasakul Y, et al. **Biochim Biophys Acta** 1996 Jan 17;1315(1):21-8
Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385-93 (45 ref.)
Role of oxidative stress in non-genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators. Sai-Kato K, et al. **Biomed Environ Sci** 1995 Sep;8(3):269-79 (64 ref.)
Oxidative stress during antituberculous therapy in young and elderly patients. Walubo A, et al. **Biomed Environ Sci** 1995 Jun;8(2):106-13
Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419-36 (43 ref.)
Radiation-induced genomic instability and persisting oxidative stress in primary bone marrow cultures. Clutton SM, et al. **Carcinogenesis** 1996 Aug;17(8):1633-9
Coal tar residues produce both DNA adducts and oxidative DNA damage in human mammary epithelial cells. Leadon SA, et al. **Carcinogenesis** 1995 Dec;16(12):3021-6
Relationship between the intracellular reactive oxygen species and the induction of oxidative DNA damage in human neutrophil-like cells. Takeuchi T, et al. **Carcinogenesis** 1996 Aug;17(8):1543-8
In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Feng YH, et al. **Cardiovasc Res** 1995 Aug; 30(2):255-61
Cytotoxicity of aromatic amines in rat liver and oxidative stress. Hillesheim W, et al. **Chem Biol Interact** 1995 Oct 20;98(1):85-95
Oxidant stress enhances adenylyl cyclase activation. Tan CM, et al. **Circ Res** 1995 Oct;77(4):710-7
Nuclear magnetic resonance studies of cationic and energetic alterations with oxidant stress in the perfused heart. Modulation with pyruvate and lactate. Yanagida S, et al. **Circ Res** 1995 Oct;77(4):773-83
Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Zhou X, et al. **Circulation** 1996 Mar 15;93(6):1177-84
Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular dialysis. McGrath LT, et al. **Clin Chim Acta** 1995 Mar 31;235(2):179-88
Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579-88 (94 ref.)
Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome. Quinlan GJ, et al. **Crit Care Med** 1996 Feb;24(2):241-6
Mutants of Saccharomyces cerevisiae sensitive to oxidative and osmotic stress. Krems B, et al. **Curr Genet** 1995 Apr; 27(5):427-34
High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Ceriello A, et al. **Diabetes** 1996 Apr;45(4):471-7
Oxidative stress and diabetic vascular complications. Giugliano D, et al. **Diabetes Care** 1996 Mar;19(3):257-67 (152 ref.)
Is oxidative stress the missing link between insulin resistance and atherosclerosis? [letter] Ceriello A, et al. **Diabetologia** 1995 Dec;38(12):1484-5
The need for a 'free radical initiative' [comment] Cominacini L, et al. **Diabetologia** 1996 Mar;39(3):364-6 (20 ref.). Comment on: Diabetologia 1996 Mar;39(3):357-63.
Oxidative stress and insulin action: is there a relationship? [see comments] Paolisso G, et al. **Diabetologia** 1996 Mar; 39(3):357-63 (51 ref.). Comment in: Diabetologia 1996 Mar;39(3):364-6.
Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Rösen P, et al. **Diabetologia** 1995 Oct;38(10):1157-68
Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Loguercio C, et al. **Dig Dis Sci** 1996 Jun;41(6):1204-11
Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. Pandolfi PP, et al. **EMBO J** 1995 Nov 1;14(21):5209-15
Role of oxygen free radicals in cancer development. Dreher D, et al. **Eur J Cancer** 1996 Jan;32A(1):30-8 (115 ref.)
Skin burn injury and oxidative stress in liver and lung tissues of rabbit models. Sabeh F, et al. **Eur J Clin Chem Clin Biochem** 1995 Jun;33(6):323-8
Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Brown RK, et al. **Eur Respir J** 1996 Feb; 9(2):334-9
Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135-66 (140 ref.)
Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Oda T, et al. **Exp Neurol** 1995 Nov;136(1):22-31
Rapid development and a long life: an association expected under a stress theory of aging. Parsons PA. **Experientia** 1996 Jul 15;52(7):643-6 (54 ref.)
Differentially expressed mRNAs as a consequence of oxidative stress in intact cells. Ammendola R, et al. **FEBS Lett** 1995 Sep 11;371(3):209-13
UV-B- and oxidative stress-induced increase in nicotinamide and trigonelline and inhibition of defensive metabolism induction by poly(ADP-ribose)polymerase inhibitor in plant tissue. Berglund T, et al. **FEBS Lett** 1996 Feb 12; 380(1-2):188-93
Role of retinoic acid and oxidative stress in embryonic stem cell death and neuronal differentiation. Castro-Obregón S, et al. **FEBS Lett** 1996 Feb 26;381(1-2):93-7
Prevention of necrosis and activation of apoptosis in oxidatively injured human myeloid leukemia U937 cells. Palomba L, et al. **FEBS Lett** 1996 Jul 15;390(1):91-4
About the oxidative stress status in children with kwashiorkor. Albrecht R, et al. **Food Chem Toxicol** 1995 Dec;33(12):1081-3
Oxidative damage in human liver transplantation. Biasi F, et al. **Free Radic Biol Med** 1995 Sep;19(3):311-7
Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Dennery PA, et al. **Free Radic Biol Med** 1995 Oct;19(4):395-404
Oxidant stress and endothelial membrane transport. Elliott SJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):649-58 (98 ref.)
Cadmium resistance in A549 cells correlates with elevated glutathione content but not antioxidant enzymatic activities. Hatcher EL, et al. **Free Radic Biol Med** 1995 Dec;19(6):805-12
How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381-90 (87 ref.)
Oxidative stress by acute acetaminophen administration in mouse liver. Lores Arnaiz S, et al. **Free Radic Biol Med** 1995 Sep;19(3):303-10
Lipid peroxidation in neural tissues and fractions from vitamin E-deficient rats. MacEvilly CJ, et al. **Free Radic Biol Med** 1996;20(5):639-48
Cellular injury induced by oxidative stress is mediated through lysosomal damage. Ollinger K, et al. **Free Radic Biol Med** 1995 Nov;19(5):565-74
The role of oxidative stress in HIV disease. Pace GW, et al. **Free Radic Biol Med** 1995 Oct;19(4):523-8 (93 ref.)
Cholesterol protects the phospholipid bilayer from oxidative damage. Parasassi T, et al. **Free Radic Biol Med** 1995 Oct; 19(4):511-6
Oxidative stress in acidic conditions increases the production of inositol phosphates in chick retinal cells in culture. Rego AC, et al. **Free Radic Biol Med** 1996;20(2):175-87
Role of manganese superoxide dismutase in a mucoid isolate of Pseudomonas aeruginosa: adaptation to oxidative stress. Polack B, et al. **Infect Immun** 1996 Jun;64(6):2216-9
Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Belch JJ, et al. **Int Angiol** 1995 Dec;14(4):385-8
Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Okamoto K, et al. **Int J Cancer** 1996 Feb 8;65(4):437-41
Oxidative stress in radiation-induced interstitial pneumonitis in the rat. De AK, et al. **Int J Radiat Biol** 1995 Oct; 68(4):405-9
Oxygen radicals induce stress proteins and tolerance to oxidative stress in human lymphocytes. Marini M, et al. **Int J Radiat Biol** 1996 Sep;70(3):337-50
Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873-5 (25 ref.). Comment on: J Am Geriatr Soc 1996 Jul;44(7):823-7.
Systemic oxidative stress and its relationship with age and illness. Associazione Medica "Sabin" [see comments] Mezzetti A, et al. **J Am Geriatr Soc** 1996 Jul;44(7):823-7 . Comment in: J Am Geriatr Soc 1996 Jul;44(7):873-5.
Superoxide dismutase derivative reduces oxidative damage in skeletal muscle of rats during exhaustive exercise. Radák Z, et al. **J Appl Physiol** 1995 Jul;79(1):129-35
Intrinsic myocardial function and oxidative stress after exhaustive exercise. Seward SW, et al. **J Appl Physiol** 1995 Jul;79(1):251-5
Evaluation of oxidative stress in diabetics [letter] Singh RB, et al. **J Assoc Physicians India** 1995 Sep;43(9):654
Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43-8 (55 ref.)
Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. Cai Y, et al. **J Biochem Toxicol** 1995 Apr; 10(2):87-94
Oxidative damage to DNA constituents by iron-mediated fenton reactions. The deoxyguanosine family. Henle ES, et al. **J Biol Chem** 1996 Aug 30;271(35):21177-86
Sensitization of the HIV-1-LTR upon long term low dose oxidative stress. Kurata Si. **J Biol Chem** 1996 Sep 6; 271(36):21798-802
Oxidative damage to DNA constituents by iron-mediated fenton reactions. The deoxycytidine family. Luo Y, et al. **J Biol Chem** 1996 Aug 30;271(35):21167-76
A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. Russo T, et al. **J Biol Chem** 1995 Dec 8;270(49):29386-91
Regulation of macrophage inflammatory protein-1alpha mRNA by oxidative stress. Shi MM, et al. **J Biol Chem** 1996 Mar 8;271(10):5878-83
Cultured AIDS-related Kaposi's sarcoma (AIDS-KS) cells demonstrate impaired bioenergetic adaptation to oxidant challenge: implication for oxidant stress in AIDS-KS pathogenesis. Mallery SR, et al. **J Cell Biochem** 1995 Nov; 59(3):317-28
The oxidant stress of hyperhomocyst(e)inemia [editorial; comment] Loscalzo J. **J Clin Invest** 1996 Jul 1;98(1):5-7 . Comment on: J Clin Invest 1996 Jul 1;98(1):24-9. Comment on: J Clin Invest 1996 Jul 1;98(1):177-84.
Evidence of oxidative stress in erythrocyte phospholipid composition in the pathogenesis of familial Mediterranean fever (periodical disease). Karaguezyan KG, et al. **J Clin Pathol** 1996 Jun;49(6):453-5
Free radical damage and oxidative stress in Huntington's disease. Borlongan CV, et al. **J Fla Med Assoc** 1996 May; 83(5):335-41 (0 ref.)
Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis. Tsukamoto H, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S50-3
Oxidative status in senescence-accelerated mice. Park JW, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B337-45
Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157-61 (54 ref.)
Oxidative stress and hyperinsulinaemia in essential hypertension: different facets of increased risk. Parik T, et al. **J Hypertens** 1996 Mar;14(3):407-10
Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine. Muntané J, et al. **J Lab Clin Med** 1995 Nov;126(5):435-43

HDL antioxidant effects as assessed using a nonexchangeable probe to monitor particle-specific peroxidative stress in LDL-HDL mixtures. Tribble DL, et al. **J Lipid Res** 1995 Dec;36(12):2580-9

Detection of oxidative stress in heart by estimating the dinitrophenylhydrazine derivative of malonaldehyde. Cordis GA, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1645-53

Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. Goodman Y, et al. **J Neurochem** 1996 Feb;66(2):869-72

Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. Montoliu C, et al. **J Neurochem** 1995 Dec;65(6):2561-70

Hypoxia increases the susceptibility to oxidant stress and the permeability of the blood-brain barrier endothelial cell monolayer. Plateel M, et al. **J Neurochem** 1995 Nov; 65(5):2138-45

H2O2 and nitric oxide-mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts. Stangel M, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):36-43

PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. Cheng B, et al. **J Neurosci** 1995 Nov;15(11):7095-104

Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. Chan PH, et al. **J Neurotrauma** 1995 Oct;12(5):815-24 (63 ref.)

Modulation of corneal heme oxygenase expression by oxidative stress agents. Neil TK, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):455-68

Exogenous catalase may potentiate oxidant-mediated lung injury in the female Sprague-Dawley rat. Lardot C, et al. **J Toxicol Environ Health** 1996 Apr 19;47(6):509-22

Percutaneous absorption of 2,4-dichlorophenoxyacetic acid from soil with respect to soil load and skin contact time: in vivo absorption in rhesus monkey and in vitro absorption in human skin. Wester RC, et al. **J Toxicol Environ Health** 1996 Mar;47(4):335-44

Oxidative damage and enhanced erythrophagocytosis in canine erythrocytes infected with Babesia gibsoni. Murase T, et al. **J Vet Med Sci** 1996 Mar;58(3):259-61

Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. Ehret A, et al. **J Virol** 1996 Sep; 70(9):6502-7

Decreased glutathione levels in acute myocardial infarction. Usal A, et al. **Jpn Heart J** 1996 Mar;37(2):177-82

Inhibition of 1,2-dimethylhydrazine-induced oxidative DNA damage by green tea extract in rat. Inagake M, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1106-11

Alteration of lens sulfhydryl groups induced by oxidative stress: Raman spectroscopic study of hydrogen peroxide-treated rat lens. Tomohiro M, et al. **Jpn J Ophthalmol** 1995;39(2):130-6

Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Witko-Sarsat V, et al. **Kidney Int** 1996 May;49(5):1304-13

Role of oxidative stress in the development of diabetic nephropathy. Ha H, et al. **Kidney Int Suppl** 1995 Sep; 51:S18-21 (59 ref.)

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):43-93 (720 ref.)

Bioenergetic and oxidative stress in neurodegenerative diseases. Bowling AC, et al. **Life Sci** 1995;56(14):1151-71 (257 ref.)

Thymosin alpha 1 protects liver and aorta from oxidative damage in atherosclerotic rabbits. Gökkusu C, et al. **Life Sci** 1996;59(13):1059-67

Effects of peroxidative stress and age on the concentration of a deoxyguanosine-malondialdehyde adduct in rat DNA. Draper HH, et al. **Lipids** 1995 Oct;30(10):959-61

Increased formation and degradation of malondialdehyde-modified proteins under conditions of peroxidative stress. Mahmoodi H, et al. **Lipids** 1995 Oct; 30(10):963-6

Sudden infant death syndrome and superoxide/nitric oxide. Reid GM, et al. **Med Hypotheses** 1995 Oct;45(4):395-7

Alpha-tocopherol pretreatment improves endothelium-dependent vasodilation in aortic strips of young and aging rats exposed to oxidative stress. Guarnieri C, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):223-8

Oxidative stress and heart failure. Singh N, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):77-81 (36 ref.)

Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways. Pantopoulos K, et al. **Mol Cell Biol** 1996 Jul;16(7):3781-8

Induction of the Escherichia coli UVM response by oxidative stress. Wang G, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):573-9

Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. García-Ruiz C, et al. **Mol Pharmacol** 1995 Nov;48(5):825-34

Inhibition of succinate:ubiquinone reductase and decrease of ubiquinol in nephrotoxic cysteine S-conjugate-induced oxidative cell injury. van de Water B, et al. **Mol Pharmacol** 1995 Nov;48(5):928-37

No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Ahlskog JE, et al. **Mov Disord** 1995 Sep;10(5):566-73

Non-linear accumulation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidized DNA damage, during aging. Kaneko T, et al. **Mutat Res** 1996 May;316(5-6):277-85

Oxidative damage to DNA induced by areca nut extract. Liu TY, et al. **Mutat Res** 1996 Jan;367(1):25-31

The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Wachsman JT. **Mutat Res** 1996 Feb 19;350(1):25-34 (75 ref.)

Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25-34 (151 ref.)

Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Yan SD, et al. **Nat Med** 1995 Jul;1(7):693-9

Oxidative stress and Alzheimer's disease [comment] Choi BH. **Neurobiol Aging** 1995 Jul-Aug;16(4):675-8 (49 ref.). Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):661-74.

Modulation of N-methyl-D-aspartate receptor activity by oxidative stress conditions in chick retinal cells. Agostinho P, et al. **Neurosci Lett** 1995 Oct 6;198(3):193-6

Oxidative stress after acute and chronic application of beta-amyloid fragment 25-35 in cortical cultures. Café C, et al. **Neurosci Lett** 1996 Jan 12;203(1):61-5

Repair of products of oxidative DNA base damage in human cells. Jaruga P, et al. **Nucleic Acids Res** 1996 Apr 15; 24(8):1389-94

Oxidative stress is involved in heat-induced cell death in Saccharomyces cerevisiae. Davidson JF, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5116-21

Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Polla BS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6458-63

Overexpression of a Rrp1 transgene reduces the somatic mutation and recombination frequency induced by oxidative DNA damage in Drosophila melanogaster. Szakmary A, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1607-12

Muscle-specific expression of Drosophila hsp70 in response to aging and oxidative stress. Wheeler JC, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10408-12

Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep-Oct;38(2):129-54 (202 ref.)

Oxidative stress and antioxidant protection in degenerative psychoorganic syndrome in old agers. Negru T, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1-2):55-60

Oxidative stress and apoptosis in HIV infection [letter; comment] Baier-Bitterlich G, et al. **Science** 1996 Feb 2; 271(5249):582-3. Comment on: Science 1995 Aug 25;269(5227):1044-5.

Oxidative stress, caloric restriction, and aging. Sohal RS, et al. **Science** 1996 Jul 5;273(5271):59-63 (59 ref.)

LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560-4 (41 ref.)

Oxidative stress and antioxidant defenses in plasma of patients with Behçet's disease. Köse K, et al. **Tohoku J Exp Med** 1995 Aug;176(4):239-48

Effects of oxidative stress induced by redox-enzyme modulation on rat hepatocarcinogenesis. Denda A, et al. **Toxicol Lett** 1995 Dec;82-83:413-7

Glutathione peroxidase and oxidative stress. Doroshow JH. **Toxicol Lett** 1995 Dec;82-83:395-8

Oxidative stress in nongenotoxic carcinogenesis. Klaunig JE, et al. **Toxicol Lett** 1995 Dec;82-83:683-91

Amplification of glutamate-induced oxidative stress. Savolainen KM, et al. **Toxicol Lett** 1995 Dec;82-83:399-405 (46 ref.)

Signalling mechanisms and oxidative stress in apoptosis. Slater AF, et al. **Toxicol Lett** 1995 Dec;82-83:149-53 (24 ref.)

Gut ischemia, oxidative stress, and bacterial translocation in elevated abdominal pressure in rats. Eleftheriadis E, et al. **World J Surg** 1996 Jan;20(1):11-6

Homocysteine-induced oxidative damage: mechanisms and possible roles in neurodegenerative and atherogenic processes. Schlüssel E, et al. **Z Naturforsch [C]** 1995 Sep-Oct;50(9-10):699-707

Desialylation of low density lipoprotein--metabolic function versus oxidative damage? Schlüssel EH, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):395-400

[Oxidative stress and cell aging] Hervonen A. **Duodecim** 1994; 110(17):1653-8 (33 ref.) (Fin)

[Oxidative stress and HIV infection. A concept to be specified and a therapeutic approach to be studied] Constans J, et al. **Ann Med Interne (Paris)** 1995;146(7):514-9 (53 ref.) (Fre)

[Oxidative stress and malaria. Apropos of 24 cases of Plasmodium falciparum malaria] Djossou PF, et al. **Bull Soc Pathol Exot** 1996;89(1):17-23 (Eng. Abstr.) (Fre)

[Does nitric oxide stress exist?] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995;189(3):389-400 (42 ref.) (Eng. Abstr.) (Fre)

[Viruses and oxidative stress] Weismann H. **Dtsch Med Wochenschr** 1996 May 24;121(21):A8 (Ger)

[The oxidative stress in the cataract formation] Obara Y. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1303-41 (83 ref.) (Eng. Abstr.) (Jpn)

[Contribution of oxidative stress to pulmonary hypertension induced by chronic hypoxia] Hoshikawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1168-73 (Eng. Abstr.) (Jpn)

[The oxidative stress produced by acute myocardial infarct and its repercussion on lipid peroxidation. The effect of thrombolytic therapy] Ribeiro H, et al. **Rev Port Cardiol** 1995 Nov;14(11):919-22 (Por)

[Is Na,K-ATPase the target of oxidative stress?] Boldyrev AA, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):275-8 (Rus)

[Free radical damage to the liver during transplantation in oxidative stress] Mil'chakov VI, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):471-3 (Rus)

[A thermodynamic analysis of oxidative inactivation of influenza virus and lipid peroxidation of viral envelope lipids] Poryvaev VD. **Vopr Virusol** 1995 Nov-Dec; 40(6):273-6 (Eng. Abstr.) (Rus)

[Parameters of oxidative stress in patients with cardiopathies] Pecháň I, et al. **Bratisl Lek Listy** 1996 Jun;97(6):344-7 (Eng. Abstr.) (Slo)

DRUG EFFECTS

Oxidative stress response in iron-induced renal carcinogenesis: acute nephrotoxicity mediates the enhanced expression of glutathione S-transferase Yp isozyme. Fukuda A, et al. **Arch Biochem Biophys** 1996 May 1; 329(1):39-46

Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Simoni J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):469-86

Oxidant-induced stress response in lymphoid cells. Barnett YA, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):273-81

Bio-Catalyzer alpha . rho No. 11 (Bio-Normalizer) supplementation: effect on oxidative stress to isolated rat hearts. Haramaki N, et al. **Biochem Mol Biol Int** 1995 Aug; 36(6):1263-8

Efficacy of Bio-Catalyzer alpha.rho no.11 (Bio-Normalizer) supplementation against peroxyl radical-induced oxidative damage in rat organ homogenates. Marcocci L, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):535-41

Peroxides inhibit the glutathione S-conjugate pump. Soszyński M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):537-45

Inhibition of oxidative insult in cultured cells by a novel 6-chromanol-containing antioxidant. Decker DE, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1063-70

N,N'-bis-(3,4,5-trimethoxybenzyl) ethylenediamine N,N'-diacetic acid as a new iron chelator with potential medicinal applications against oxidative stress. Galey JB, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):103-15

Time course of the melatonin-induced increase in glutathione peroxidase activity in chick tissues. Pablos MI, et al. **Biol Signals** 1995 Nov-Dec;4(6):325-30

Intratracheally administered liposomal alpha-tocopherol protects the lung against long-term toxic effects of paraquat. Suntres ZE, et al. **Biomed Environ Sci** 1995 Dec; 8(4):289-300

Paraphenylene diamine, a contact allergen, induces oxidative stress in normal human keratinocytes in culture. Picardo M, et al. **Br J Dermatol** 1996 Apr;134(4):681-5

Dietary supplementation with carotenoids: effects on alpha-tocopherol levels and susceptibility of tissues to oxidative stress. Woodall AA, et al. **Br J Nutr** 1996 Aug; 76(2):307-17

Oxidative stress in fish exposed to model xenobiotics. Oxidatively modified forms of Cu,Zn-superoxide dismutase as potential biomarkers. Pedrajas JR, et al. **Chem Biol Interact** 1995 Dec 22;98(3):267-82

Mechanism of acetaminophen-induced hepatotoxicity: covalent binding versus oxidative stress. Gibson JD, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):580-5

Effects of vitamin E supplementation on erythrocyte antioxidant defence mechanisms of smoking and non-smoking men. Brown KM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):107-11

Effect of probucol, an oral hypocholesterolaemic agent, on acute tobacco smoke inhalation in rats. Ishizaki T, et al. **Clin Sci (Colch)** 1996 Jun;90(6):517-23

Glutathione regeneration in calcium-loaded erythrocytes: a possible relationship among calcium accumulation, ATP decrement and oxidative damage. Kurata M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):305-12

Prevention of oxidative damage to rat lens by pyruvate in vitro: possible attenuation in vivo. Varma SD, et al. **Curr Eye Res** 1995 Aug;14(8):643-9

The response regulator-like protein Pos9/Skn7 of Saccharomyces cerevisiae is involved in oxidative stress resistance. Krems B, et al. **Curr Genet** 1996 Mar; 29(4):327-34

Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Nagamatsu M, et al. **Diabetes Care** 1995 Aug;18(8):1160-7

Protection by ascorbate against apoptosis of thymocytes: implications of ascorbate-induced nonlethal oxidative stress and poly(ADP-ribosyl)ation. Maellaro E, et al. **Exp Cell Res** 1996 Jul 10;226(1):105-13

Antioxidant survey to assess antagonism to redox stress using a prokaryotic and an eukaryotic system. Baker H, et al. **Experientia** 1996 Jun 15;52(6):597–9

Nuclear DNA strand breaks during ethanol-induced oxidative stress in rat brain. Renis M, et al. **FEBS Lett** 1996 Jul 22;390(2):153–6

Effect of H2O2-induced oxidative stress on some yeast membrane functions. Gille G, et al. **Folia Microbiol (Praha)** 1994;39(6):518–9

Lead amplifies glutamate-induced oxidative stress. Naarala JT, et al. **Free Radic Biol Med** 1995 Nov;19(5):689–93

Does manganese protect cultured human skin fibroblasts against oxidative injury by UVA, dithranol and hydrogen peroxide? Parat MO, et al. **Free Radic Res** 1995 Oct; 23(4):339–51

Exacerbation of nickel induced oxidative response by vitamin E. Husain MM, et al. **Ind Health** 1995;33(3):143–52

Oxidative stress in rat liver and lung induced by furanoterpenoids isolated from Fusarium solani infected sweet potatoes. Rajendran S, et al. **Indian J Exp Biol** 1996 Jan;34(1):57–60

Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kappa B. Schmidt KN, et al. **J Biol Chem** 1995 Nov 10;270(45):27136–42

Antioxidant effects of pyruvate in isolated rat hearts. Marcengill MB, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):2059–67

Activity of ionotropic glutamate receptors in retinal cells: effect of ascorbate/Fe(2+)-induced oxidative stress. Agostinho P, et al. **J Neurochem** 1996 Sep;67(3):1153–63

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. Han SK, et al. **J Neurochem** 1996 Feb;66(2):501–10

Cyanide-induced apoptosis and oxidative stress in differentiated PC12 cells. Mills EM, et al. **J Neurochem** 1996 Sep;67(3):1039–46

Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. Atabay C, et al. **J Neurosci Res** 1996 Feb 15;43(4):465–75

Endotoxin depletes ascorbate in the guinea pig heart. Protective effects of vitamins C and E against oxidative stress. Rojas C, et al. **Life Sci** 1996;59(8):649–57

Relevance of oxidative stress to the limited replicative capacity of cultured human diploid cells: the limit of cumulative population doublings increases under low concentrations of oxygen and decreases in response to aminotriazole. Yuan H, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):159–68

Vascular effects of the 21-aminosteroid tirilazad mesylate: protection against oxidant stress. McKenna R, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):279–92

Menadione-induced oxidative stress in bovine heart microvascular endothelial cells. Kossenjans W, et al. **Microcirculation** 1996 Mar;3(1):39–47

Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Gerlach M, et al. **Neurochem Int** 1996 Jan;28(1):41–9

Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Ahlskog JE, et al. **Neurology** 1996 Mar;46(3):796–801

Comparative study of the presence of oxidative stress in sportsmen in competition and aged people, as well as the preventive effect of selenium administration. Olinescu R, et al. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):47–54

Metals, oxidative stress, and hepatic fibrogenesis. Pietrangelo A. **Semin Liver Dis** 1996 Feb;16(1):13–30 (117 ref.)

Endotoxin-induced oxidative stress in the rat small intestine: role of nitric oxide. Chamulitrat W, et al. **Shock** 1996 Mar; 5(3):217–22

Studies on the effects of monosodium glutamate (MSG) on oxidative stress in erythrocytes of adult male mice. Ahluwalia P, et al. **Toxicol Lett** 1996 Mar;84(3):161–5

Increased oxidant resistance of alveolar macrophages isolated from rats repeatedly exposed to cadmium aerosols. Hart BA, et al. **Toxicology** 1996 Mar 18;107(3):163–75

Effect of several metallothionein inducers on oxidative stress defense mechanisms in rats. Iszard MB, et al. **Toxicology** 1995 Dec 15;104(1–3):25–33

Oxidative stress and cytotoxicity of 4-(2-thienyl)butyric acid in isolated rat renal proximal tubular and distal tubular cells. Lash LH, et al. **Toxicology** 1995 Dec 10;103(3):167–75

Heme oxygenase induction by cadmium chloride: evidence for oxidative stress involvement. Ossola JO, et al. **Toxicology** 1995 Dec 15;104(1–3):141–7

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Gomer CJ, et al. **Cancer Res** 1996 May 15;56(10):2355–60

The response regulator-like protein Pos9/Skn7 of Saccharomyces cerevisiae is involved in oxidative stress resistance. Krems B, et al. **Curr Genet** 1996 Mar; 29(4):327–34

Response of Drosophila metallothionein promoters to metallic, heat shock and oxidative stresses. Bonneton F, et al. **FEBS Lett** 1996 Feb 12;380(1–2):33–8

Expression of stress response genes GADD153, c-jun, and heme oxygenase-1 in H2O2- and O2-resistant fibroblasts. Guyton KZ, et al. **Free Radic Biol Med** 1996;20(5):735–41

Oxidative stress induced heat shock factor phosphorylation and HSF-dependent activation of yeast metallothionein gene transcription. Liu XD, et al. **Genes Dev** 1996 Mar 1;10(5):592–603

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarín JJ. **Hum Reprod** 1995 Jun;10(6):1563–5 (25 ref.)

Interruption of the gpxA gene increases the sensitivity of Neisseria meningitidis to paraquat. Moore TD, et al. **J Bacteriol** 1996 Jul;178(14):4301–5

Free-radical-induced mutation vs redox regulation: costs and benefits of genes in organelles. Allen JF, et al. **J Mol Evol** 1996 May;42(5):482–92 (76 ref.)

Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Prestera T, et al. **Mol Med** 1995 Nov;1(7):827–37

Bacillus subtilis MrgA is a Dps(PexB) homologue: evidence for metalloregulation of an oxidative-stress gene. Chen L, et al. **Mol Microbiol** 1995 Oct;18(2):295–300

Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Deretic V, et al. **Mol Microbiol** 1995 Sep;17(5):889–900

The recA gene of Lactococcus lactis: characterization and involvement in oxidative and thermal stress. Duwat P, et al. **Mol Microbiol** 1995 Sep;17(6):1121–31

The role of the YAP1 and YAP2 genes in the regulation of the adaptive oxidative stress responses of Saccharomyces cerevisiae. Stephen DW, et al. **Mol Microbiol** 1995 May; 16(3):415–23

Characterization of Arabidopsis thaliana cDNAs that render yeasts tolerant toward the thiol-oxidizing drug diamide. Kushnir S, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10580–4

[Oxidative stress as a basic mechanism of the carcinogenic effect of man made mineral fibers on the human body] Lutz W, et al. **Med Pr** 1995;46(3):275–84 (18 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells. Beiqing L, et al. **J Immunol** 1996 Jul 1;157(1):160–9

PHYSIOLOGY

Lipid peroxidation in hepatocellular carcinoma. Iwagaki H, et al. **Acta Med Okayama** 1995 Dec;49(6):313–5

Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Singh RB, et al. **Am J Cardiol** 1995 Dec 15;76(17):1233–8

Oxidative damage and defense. Jacob RA, et al. **Am J Clin Nutr** 1996 Jun;63(6):985S–990S (43 ref.)

Evidence of neuronal oxidative damage in Alzheimer's disease. Good PF, et al. **Am J Pathol** 1996 Jul;149(1):21–8

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9–19 (58 ref.)

Determination of 2-oxohistidine by amino acid analysis. Lewisch SA, et al. **Anal Biochem** 1995 Nov 1;231(2):440–6

Monitoring an oxidative stress mechanism at a single human fibroblast. Arbault S, et al. **Anal Chem** 1995 Oct 1; 67(19):3382–90

Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Stein CM, et al. **Arthritis Rheum** 1996 Jul;39(7):1146–50

Evaluation of oxidative stress in patients with hyperlipidemia. Araujo FB, et al. **Atherosclerosis** 1995 Sep;117(1):61–71

Lack of evidence of oxidative damage in antioxidant-deficient strains of Saccharomyces cerevisiae. Fortuniak A, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1271–6

The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Ek A, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1339–46

Up-regulation of glutathione synthesis in rat kidney by methyl mercury. Relationship to mercury-induced oxidative stress. Woods JS, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1719–24

Deleterious effects of xanthine oxidase on rat liver endothelial cells after ischemia/reperfusion. Hamer I, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):145–52

Electrophoretic evidence for the impairment of complexes of the respiratory chain during iron/ascorbate induced peroxidation in isolated rat liver mitochondria. Reinheckel T, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):45–50

Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress. Shah GM, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):1–7

Evidence for oxidative stress in Pick disease and corticobasal degeneration. Castellani R, et al. **Brain Res** 1995 Oct 23; 696(1–2):268–71

Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Oyama Y, et al. **Brain Res** 1996 Mar 18;712(2):349–52

Acute acidosis elevates malonaldehyde in rat brain in vivo. Waterfall AH, et al. **Brain Res** 1996 Mar 11;712(1):102–6

Energy restriction and oxidative DNA damage in humans. Loft S, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug;4(5):515–9

HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Huot J, et al. **Cancer Res** 1996 Jan 15;56(2):273–9

Evolution of chlorophyll biosynthesis—the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703–5 (14 ref.)

Muscle glucose 6-phosphate dehydrogenase (G6PD) deficiency and oxidant stress during physical exercise [letter] Ninfali P, et al. **Cell Biochem Funct** 1995 Dec; 13(4):297–8

Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Cerruti C, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):381–2

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215–37 (90 ref.)

Involvement of oxidative stress in D-xylose-induced cataractogenesis in cultured rat lenses. Ohta Y, et al. **Curr Eye Res** 1996 Jan;15(1):1–7

The role of oxidative stress in neuropathy and other diabetic complications. Van Dam PS, et al. **Diabetes Metab Rev** 1995 Oct;11(3):181–92 (72 ref.)

Effects of oxidative stress and Ca2+ agonists on molecular chaperones in human umbilical vein endothelial cells. Dreher D, et al. **Electrophoresis** 1995 Jul;16(7):1205–14

Electropermeabilization of intact maize cells induces an oxidative stress. Sabri N, et al. **Eur J Biochem** 1996 Jun 15;238(3):737–43

Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. De Laurenzi V, et al. **Eur J Cancer** 1995;31A(4):463–6

Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Musarrat J, et al. **Eur J Cancer** 1996 Jun;32A(7):1209–14

Myocardial protection with and without leukocyte depletion: a comparative study on the oxidative stress. Pala MG, et al. **Eur J Cardiothorac Surg** 1995;9(12):701–6

Peroxides in human leucocytes in acute septic shock: a preliminary study of acute phase changes and mortality. Leaver HA, et al. **Eur J Clin Invest** 1995 Oct;25(10):777–83

Consumption of reduced-fat products: effects on parameters of anti-oxidative capacity. Velthuis-te Wierik EJ, et al. **Eur J Clin Nutr** 1996 Apr;50(4):214–9

Cytoskeletal oxidative changes lead to alterations of specific cell surface receptors. Malorni W, et al. **Eur J Histochem** 1994;38 Suppl 1:91–100

Oxidized BAL fluid proteins in patients with interstitial lung diseases. Lenz AG, et al. **Eur Respir J** 1996 Feb;9(2):307–12

Renal functional alterations in extrahepatic cholestasis: can oxidative stress be involved? Panozzo MP, et al. **Eur Surg Res** 1995;27(5):332–9

Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)

Variation in cellular glutathione peroxidase activity in lens epithelial cells, transgenics and knockouts does not significantly change the response to H2O2 stress. Spector A, et al. **Exp Eye Res** 1996 May;62(5):521–40

Antioxidant depletion, lipid peroxidation, and impairment of calcium transport induced by air-blast overpressure in rat lungs. Elsayed NM, et al. **Exp Lung Res** 1996 Mar–Apr; 22(2):179–200

Murine pulmonary Ca(2+)-transport system activated by allergic immune response retains sensitivity to oxidative stress. Shvedova AA, et al. **Exp Lung Res** 1995 Sep–Oct; 21(5):743–70

Tissue protection against oxidative stress. Di Meo S, et al. **Experientia** 1996 Aug 15;52(8):786–94

The flavohaemoglobin (HMP) of Escherichia coli generates superoxide in vitro and causes oxidative stress in vivo. Membrillo-Hernández J, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):141–4

Analysis of the adaptive oxidative stress response of Candida albicans. Jamieson DJ, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):83–8

Nitration of tyrosine by hydrogen peroxide and nitrite. Oury TD, et al. **Free Radic Res** 1995 Dec;23(6):537–47

Analysis of sperm movement in relation to the oxidative stress created by leukocytes in washed sperm preparations and seminal plasma. Aitken RJ, et al. **Hum Reprod** 1995 Aug; 10(8):2061–71

Oxidative stress triggers tyrosine phosphorylation in B cells through a redox- and inflammatory cytokine-sensitive mechanism. Suzuki Y, et al. **Immunology** 1996 Mar; 87(3):396–401

Does oxidant stress play a role in diabetic retinopathy? Rema M, et al. **Indian J Ophthalmol** 1995 Mar;43(1):17–21

Vitamin E protects guinea pig liver from lipid peroxidation without depressing levels of antioxidants. Cadenas S, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1175–81

Susceptibility of human melanoma cells to oxidative stress including UVA radiation. Applegate LA, et al. **Int J Cancer** 1996 Jul 29;67(3):430–4

Evidence for early oxidative stress in acute pancreatitis. Clues

for correction. **Braganza JM, et al. Int J Pancreatol** 1995 Feb;17(1):69–81

Oxidative stress in rodent closed duodenal loop pancreatitis. Peralta J, et al. **Int J Pancreatol** 1996 Feb;19(1):61–9

Role of oxidative stress in transition of hypertrophy to heart failure. Dhalla AK, et al. **J Am Coll Cardiol** 1996 Aug; 28(2):506–14

Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)

Pulmonary oxygen toxicity in mice is characterized by alterations in ascorbate redox status. Rusakow LS, et al. **J Appl Physiol** 1995 Nov;79(5):1769–76

Effect of oxidative stress on avian erythrocytes. el–Mekawi S, et al. **J Basic Clin Physiol Pharmacol** 1993 Jul–Sep; 4(3):199–211

Nucleotide changes in oxidatively stressed lymphocytes. Palace GP, et al. **J Biochem Toxicol** 1995 Jun;10(3):137–42

Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts. Spitz DR, et al. **J Cell Physiol** 1995 Dec;165(3):600–9

Oxidative stress in gastric mucosal injury: role of platelet–activating factor–activated granulocytes. Fukumura D, et al. **J Gastroenterol** 1995 Oct;30(5):565–71

Aged murine T–lymphocytes are more resistant to oxidative damage due to the predominance of the cells possessing the memory phenotype. Lohmiller JJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):B132–40

Dual role of heme oxygenase in epithelial cell injury: contrasting effects of short–term and long–term exposure to oxidant stress. da Silva JL, et al. **J Lab Clin Med** 1996 Sep;128(3):290–6

Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. Prasad K, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):375–85

Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. Ben–Yoseph O, et al. **J Neurochem** 1996 Jun;66(6):2329–37

Oxidative stress, hypoxia, and ischemia–like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. Rego AC, et al. **J Neurochem** 1996 Jun;66(6):2506–16

Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. Thorburne SK, et al. **J Neurochem** 1996 Sep;67(3):1014–22

Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. Bergeron C. **J Neurol Sci** 1995 May;129 Suppl:81–4 (57 ref.)

Short–term moderate energy restriction does not affect indicators of oxidative stress and genotoxicity in humans. Velthuis–te Wierik EJ, et al. **J Nutr** 1995 Oct; 125(10):2631–9

Catalase and superoxide dismutase activities as biomarkers of oxidative stress in workers exposed to mercury vapors. Perrin–Nadif R, et al. **J Toxicol Environ Health** 1996 Jun 7;48(2):107–19

Altered glutathione levels in ischemic and postischemic skeletal muscle: difference between severe and moderate ischemic insult. Sirsjö A, et al. **J Trauma** 1996 Jul; 41(1):123–8

Prostanoid production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. Daley JT, et al. **J Urol** 1996 Sep;156(3):1169–73

Oxidative stress–inducible protein tyrosine phosphatase in glomerulonephritis. Feng L, et al. **Kidney Int** 1995 Dec; 48(6):1920–8

Plasma protein–bound sulfhydryl group oxidation in humans following a full marathon race. Inayama T, et al. **Life Sci** 1996;59(7):573–8

Determinants of antioxidant status in humans. Papas AM. **Lipids** 1996 Mar;31 Suppl:S77–82 (66 ref.)

Decreases in protective enzymes correlates with increased oxidative damage in the aging mouse brain. Mo JQ, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):73–82

Oxidative stress and aging in the Mongolian gerbil (Meriones unguiculatus). Sohal RS, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):15–25

Test–tube simulated lipofuscinogenesis. Effect of oxidative stress on autophagocytotic degradation. Yin D, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):37–50

Increased circulating intercellular adhesion molecule–1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress. Ceriello A, et al. **Metabolism** 1996 Apr;45(4):498–501

Induction of E. coli oh8Gua endonuclease by oxidative stress: its significance in aerobic life. Kim HS, et al. **Mutat Res** 1996 Jun 12;363(2):115–23

Lipid peroxidation as an indicator of biocompatibility in haemodialysis. Sanaka T, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:34–8

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

Role of [Ca2+]i in lethal oxidative injury in rat cultured inner medullary collecting duct cells. Kuroda Y, et al. **Pflugers Arch** 1995 Sep;430(5):697–704

Activation of NF–kappa B in human skin fibroblasts by the oxidative stress generated by UVA radiation. Vile GF, et al. **Photochem Photobiol** 1995 Sep;62(3):463–8

The potential role of oxidative stress in nongenotoxic carcinogenesis in the mouse liver. Bachowski S, et al. **Prog Clin Biol Res** 1995;391:385–96 (48 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

The epididymis as protector of maturing spermatozoa. Hinton BT, et al. **Reprod Fertil Dev** 1995;7(4):731–45 (149 ref.)

Comparative study of the presence of oxidative stress in sportsmen in competition and aged people, as well as the preventive effect of selenium administration. Olinescu R, et al. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):47–54

Impact of oxidative stress on human cytomegalovirus replication and on cytokine–mediated stimulation of endothelial cells. Scholz M, et al. **Transplantation** 1996 Jun 27;61(12):1763–70

[Study of oxidative stress in the elderly] Congy F, et al. **Presse Med** 1995 Jul 1–8;24(24):1115–8 (Eng. Abstr.) **(Fre)**

[Reactive oxygen species and gene expression regulation] Jurgowiak M, et al. **Postepy Biochem** 1996;42(1):6–13 (75 ref.) **(Pol)**

[Oxidative damage repair of DNA in prokaryotes] Zastawny TH. **Postepy Biochem** 1996;42(1):31–41 (118 ref.) **(Pol)**

[Relationship between the synthesis of a new stress response component and bacterial cell metabolism] Lysak EI, et al. **Mikrobiologiia** 1995 Jul–Aug;64(4):437–41 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Resistance to ionizing radiation and antioxidative defence in yeasts. Are antioxidant–deficient cells permanently stressed? Jaruga E, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):467–73

OXIDES

see related
CYCLIC N–OXIDES

Sevoflurane degradation by soda lime in a circle breathing system. Munday IT, et al. **Anaesthesia** 1996 Jul;51(7):622–6

Optimization of biosensing using grating couplers: immobilization on tantalum oxide waveguides. Polzius R, et al. **Biosens Bioelectron** 1996;11(5):503–14

Diagnostic improvement in MRI of gynecological neoplasms. Marincek B. **J Belge Radiol** 1996 Feb;79(1):13–7

Aspects of silicone rubber as encapsulant for neurological prostheses. Part 2: Adhesion to binary oxides. Donaldson PE, et al. **Med Biol Eng Comput** 1995 May;33(3):289–92

Electrochemical and microstructural study of oxide films formed electrochemically at microcrystalline Al–Fe–V–Si alloys. Thomas SC, et al. **Microsc Res Tech** 1995 Jul 1; 31(4):285–92

[A pilot study on trihalomethane formation in water treated by chlorine dioxide] Li J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Jan;30(1):10–3 (Eng. Abstr.) **(Chi)**

[Functional magnetic resonance imaging (MRI) of hepatic ischemia in the rabbit. Contribution of a particulated contrast agent (AMI–25)] Canet E, et al. **Anat Histol Embryol** 1996 Mar;25(1):23–9 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Correction by oral adsorbent of abnormal digestive tract milieu in rats with chronic renal failure. Okada K, et al. **Nephrol Dial Transplant** 1995;10(5):671–6

ADVERSE EFFECTS

Oral fibrosis among teenagers chewing tobacco, areca nut, and Pan masala [letter] Babu S, et al. **Lancet** 1996 Sep 7; 348(9028):692

Improved nasal clearance among pulp–mill workers after the reduction of lime dust. Torén K, et al. **Scand J Work Environ Health** 1996 Apr;22(2):102–7

[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice. Kreppel H, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):239–45

BLOOD

Development and validation of a chiral high–performance liquid chromatography assay for rogletimide and rogletimide–N–oxide isomers in plasma. Etienne MC, et al. **Cancer Chemother Pharmacol** 1996;38(4):343–8

CEREBROSPINAL FLUID

Susceptibility–based MRI contrast of the CSF by intravascular superparamagnetic nanoparticles. Yu O, et al. **MAGMA** 1995 Sep–Dec;3(3–4):169–72

CHEMISTRY

Factors affecting production of compound A from the interaction of sevoflurane with Baralyme and soda lime. Fang ZX, et al. **Anesth Analg** 1996 Apr;82(4):775–81

Radicals from one–electron reduction of nitro compounds, aromatic N–oxides and quinones: the kinetic basis for hypoxia–selective, bioreductive drugs. Wardman P, et al. **Biochem Soc Symp** 1995;61:171–94 (126 ref.)

Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Shen TT, et al. **Bioconjug Chem** 1996 May–Jun;7(3):311–6

Oxygen–centered spin adducts of 5,5–dimethyl–1–pyrroline N–oxide (DMPO) and 2H–imidazole 1–oxides. Krainev AG, et al. **J Magn Reson B** 1996 Jun;111(3):272–80

Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Jung CW, et al. **Magn Reson Imaging** 1995; 13(5):661–74

Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Jung CW. **Magn Reson Imaging** 1995;13(5):675–91

Aspects of silicone rubber as encapsulant for neurological prostheses. Part 3: Adhesion to mixed oxides. Donaldson PE. **Med Biol Eng Comput** 1995 Sep;33(5):725–7

Preparation and characterization of dextran magnetite–incorporated thermosensitive liposomes: an on–line flow system for quantifying magnetic responsiveness. Viroonchatapan E, et al. **Pharm Res** 1995 Aug;12(8):1176–83

Nuclear magnetic resonance of 93Nb in LiNbO3: effect of structural distortions on lineshapes. Ivanova EN, et al. **Solid State Nucl Magn Reson** 1995 Aug;4(6):381–5

Magic–angle spinning nuclear magnetic resonance study of the structure of some PbO–Al2O3–P2O5 glasses. Lockyer MW, et al. **Solid State Nucl Magn Reson** 1995 Oct; 5(1):23–34

27Al magic–angle spinning nuclear magnetic resonance satellite transition spectroscopy of glasses in the system K2O–Al2O3–SiO2. Mundus C, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):79–88

Chemical safety of U.S. Navy Fleet soda lime. Lillo RS, et al. **Undersea Hyperb Med** 1996 Mar;23(1):43–53

DIAGNOSTIC USE

MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: influence of liver dysfunction and parenchymal pathology. Yamashita Y, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):318–23

MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. Mayo–Smith WW, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):73–7

Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions. Mergo PJ, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):379–84

Vascular enhancement with superparamagnetic iron oxide [letter] Van Gansbeke D, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):813–4

Myocardial contrast echocardiography in human beings: correlation of resting perfusion defects to sestamibi single photon emission computed tomography. Meza MF, et al. **Am Heart J** 1996 Sep;132(3):528–35

Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Schulze E, et al. **Invest Radiol** 1995 Oct;30(10):604–10

Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients. Stillman AE, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):51–5

Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases. Haldemann Heusler RC, et al. **J Magn Reson Imaging** 1995 Jul–Aug;5(4):385–91

Superparamagnetic iron oxide hepatic MR imaging: efficacy and safety using conventional and fast spin–echo pulse sequences. Schwartz LH, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):566–70

Susceptibility–based MRI contrast of the CSF by intravascular superparamagnetic nanoparticles. Yu O, et al. **MAGMA** 1995 Sep–Dec;3(3–4):169–72

An organotypical in vitro model of the liver parenchyma for uptake studies of diagnostic MR receptor agents. Bader A, et al. **Magn Reson Imaging** 1995;13(7):991–1002

Superparamagnetic iron oxide (SPIO) as an oral contrast agent in gastrointestinal (GI) magnetic resonance imaging (MRI): comparison with state–of–the–art computed tomography (CT). Johnson WK, et al. **Magn Reson Imaging** 1996;14(1):43–9

Liver. II: Iron oxide–based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)

Continuous assessment of relative cerebral blood volume in transient ischemia using steady state susceptibility–contrast MRI. Hamberg LM, et al. **Magn Reson Med** 1996 Feb; 35(2):168–73

Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume. Reimer P, et al. **Magn Reson Med** 1995 Nov;34(5):694–7

Superparamagnetic nanoparticles as blood–pool contrast agents. Contribution to MRI preclinical investigations. Benderbous S, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S248–52

European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients. Chachuat A, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S274–6

OXIDES

Detection of hepatic metastases: ferumoxides–enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography [see comments] Senéterre E, et al. **Radiology** 1996 Sep;200(3):785–92. Comment in: Radiology 1996 Sep;200(3):610–1.

Will ferumoxides–enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future [editorial; comment] Soyer P. **Radiology** 1996 Sep;200(3):610–1. Comment on: Radiology 1996 Sep;200(3):785–92.

Superparamagnetic iron oxide—enhanced versus gadolinium–enhanced MR imaging for differential diagnosis of focal liver lesions. Vogl TJ, et al. **Radiology** 1996 Mar;198(3):881–7

[New super–paramagnetic iron particles for MRI. Phase II study of malignant liver tumors] Daldrup HE, et al. **Radiologe** 1995 Aug;35(8):486–93 (Eng. Abstr.) **(Ger)**

[Overview of MRI contrast media. The case of endorem] Duroux M. **Radiologe** 1995 Nov;35(11 Suppl 2):S247–8 (Eng. Abstr.) **(Ger)**

[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Differential diagnosis of focal liver lesions with MRI using the superparamagnetic contrast medium endorem] Vogl TJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S258–66 (Eng. Abstr.) **(Ger)**

METABOLISM

Non–specific adherence of oxide particles as a means of quantifying protein adsorption on surfaces. Leduc C, et al. **J Biomater Sci Polym Ed** 1995;7(6):531–8

PHARMACOKINETICS

Mn concentration in organs of rats after implantation of battery cathode material. Janssens S, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):224–7

Use of an asialoglycoprotein receptor–targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats. Leveille–Webster CR, et al. **Hepatology** 1996 Jun; 23(6):1631–41

Selective uptake of viral and monocrystalline particles delivered intra–arterially to experimental brain neoplasms. Rainov NG, et al. **Hum Gene Ther** 1995 Dec;6(12):1543–52

Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Schulze E, et al. **Invest Radiol** 1995 Oct;30(10):604–10

Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Kroll RA, et al. **Neurosurgery** 1996 Apr; 38(4):746–52; discussion 752–4

PHARMACOLOGY

The effect of HA, TCP and ALCAP bioceramic capsules on the viability of human monocyte and monocyte derived macrophages. Ross L, et al. **Biomed Sci Instrum** 1996; 32:71–9

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl–2 expression and modulation of PML–RAR alpha/PML proteins. Chen GQ, et al. **Blood** 1996 Aug 1;88(3):1052–61

Comparison of chlorine and chlorine dioxide disinfection for control of Legionella in a hospital potable water supply [letter] Hamilton E, et al. **J Hosp Infect** 1996 Feb; 32(2):156–60

Effects of an oral adsorbent on cisplatin–induced nephropathy in rats. Sato T, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul;38(7):290–5

POISONING

The use of haemodialysis and 2,3 propanesulphonate (DMPS) to manage acute oral poisoning by lethal dose of arsenic trioxide. Kruszewska S, et al. **Int J Occup Med Environ Health** 1996;9(2):111–5

Nasal pathology and ultrastructure in patients with chronic airway inflammation (RADS and RUDS) following an irritant exposure. Meggs WJ, et al. **J Toxicol Clin Toxicol** 1996;34(4):383–96

THERAPEUTIC USE

Ancient remedy performs new tricks [news] Mervis J. **Science** 1996 Aug 2;273(5275):578

TOXICITY

Safety of silver oxide–impregnated silastic tympanostomy tubes. Chole RA, et al. **Am J Otol** 1995 Nov;16(6):722–4

Effect of DMPS and various adsorbents on the arsenic excretion in guinea–pigs after injection with As2O3. Reichl FX, et al. **Arch Toxicol** 1995;69(10):712–7

Cytotoxic and transforming effects of some iron–containing minerals in Syrian hamster embryo cells. Elias Z, et al. **Cancer Detect Prev** 1995;19(5):405–14

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362–3 (5 ref.)

Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice. Kreppel H, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):239–45

OXIDIZING AGENTS see OXIDANTS

OXIDOPAMINE

ADMINISTRATION & DOSAGE

Alteration of antioxidant status following sympathectomy: differential effects of modified plasma levels of adrenaline and noradrenaline. Toleikis PM, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):39–49

METABOLISM

Effect of ceruloplasmin on 6–hydroxydopamine oxidation. Medda R, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):721–8

Dopamine, 6–hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson's disease. Linert W, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):160–8

PHARMACOLOGY

Effects of 6–hydroxydopamine on testosterone production by mouse leydig cells in vitro. Wango EO, et al. **Acta Biol Hung** 1995;46(1):75–85

Regional characteristics of [125I]cholecystokinin octapeptide specific binding to rat brain membranes following 6–hydroxydopamine treatment. Kimura Y, et al. **Biol Pharm Bull** 1995 Mar;18(3):416–20

Neurokinin–3 receptors modulate dopamine cell function and alter the effects of 6–hydroxydopamine. Bannon MJ, et al. **Brain Res** 1995 Oct 9;695(1):19–24

Left and right 6–hydroxydopamine lesions of the medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral response to stress. Carlson JN, et al. **Brain Res** 1996 Mar 4;711(1–2):1–9

L–DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats. Ueda H, et al. **Brain Res** 1995 Nov 6;698(1–2):213–6

Effect of sympathectomy on inotropic responsiveness to alpha–adrenoceptor stimulation in developing mouse myocardia. Tanaka H, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1285–8

Effects of 6–hydroxydopamine lesions of the medial prefrontal cortex on local cerebral blood flow and D1 and D2 dopamine receptor binding in rats: a quantitative autoradiographic study. Suzuki M, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):95–101

Subsequent biological effects of chemical sympathectomy in rats undergoing unilateral testicular torsion. Karagüzel G, et al. **Eur Urol** 1995;28(2):147–51

Reduction of apomorphine–induced rotational behaviour by subthalamic lesion in 6–OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Burbaud P, et al. **Exp Brain Res** 1995;105(1):48–58

Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6–OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Zeng BY, et al. **Exp Neurol** 1996 Jun; 139(2):214–26

Differential effects of the intraventricular administration of 6–hydroxydopamine on the induction of type II beta–tubulin and tyrosine hydroxylase mRNA in the locus coeruleus of the aging Fischer 344 rat. Unnerstall JR, et al. **J Comp Neurol** 1996 Jan 8;364(2):363–81

Application of 6–hydroxydopamine into the fatpads surrounding the draining lymph nodes exacerbates adjuvant–induced arthritis. Lorton D, et al. **J Neuroimmunol** 1996 Feb;64(2):103–13

Effects of 6–Hydroxydopamine on the antibody response to the hapten dinitrophenyl in the chicken. Yasuda M, et al. **J Vet Med Sci** 1995 Dec;57(6):1073–5

GDNF protects against 6–OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Opacka–Juffry J, et al. **Neuroreport** 1995 Dec 29;7(1):348–52

Intrastriatal DNQX induces rotation and pallidal Fos in the 6–OHDA model of Parkinson's disease. Schuller JJ, et al. **Neuroreport** 1995 Dec 15;6(18):2594–8

Elevated striatal Fos immunoreactivity following 6–hydroxydopamine lesioning of the rat is mediated by excitatory amino acid transmission. Cooper AJ, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):73–6

Chronic continuous infusion of (–)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6–hydroxydopamine–lesioned rat. Blum M, et al. **Neuroscience** 1996 Jan;70(1):169–77

Functional and anatomical reconstruction of the 6–hydroxydopamine lesioned nigrostriatal system of the adult rat. Brecknell JE, et al. **Neuroscience** 1996 Apr; 71(4):913–25

Uridine reduces rotation induced by L–dopa and methamphetamine in 6–OHDA–treated rats. Myers CS, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):749–53

Glial cell line–derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6–hydroxydopamine lesion. Sauer H, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8935–9

Effect of L–dopa and 6–hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Hume SP, et al. **Synapse** 1995 Sep;21(1):45–53

THERAPEUTIC USE

Adjunctive treatment of murine neuroblastoma with 6–hydroxydopamine and Tempol. Purpura P, et al. **Cancer Res** 1996 May 15;56(10):2336–42

TOXICITY

Protective effects of pergolide on dopamine levels in the 6–hydroxydopamine–lesioned mouse brain. Asanuma M, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr; 329(2):221–30

Effects of chemical denervation with 6–hydroxydopamine on myocardial responsiveness to isoproterenol in rabbits. Tse J, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):380–7

Glia–dependent neurotoxicity and neuroprotection in mesencephalic cultures. Bronstein DM, et al. **Brain Res** 1995 Dec 15;704(1):112–6

Chronic effects of single intrastriatal injections of 6–hydroxydopamine or 1–methyl–4–phenylpyridinium studied by microdialysis in freely moving rats. Espino A, et al. **Brain Res** 1995 Oct 16;695(2):151–7

Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum. King D, et al. **Brain Res** 1995 Jul 10; 685(1–2):117–28

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB–like protein(s) in both the rodent and primate striatum. Doucet JP, et al. **Eur J Neurosci** 1996 Feb;8(2):365–81

Lateromedial gradient of the susceptibility of midbrain dopaminergic neurons to neonatal 6–hydroxydopamine toxicity. Okamura H, et al. **Exp Neurol** 1995 Dec; 136(2):136–42

Effects of unilateral 6–hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis. Roeling TA, et al. **J Chem Neuroanat** 1995 Oct;9(3):155–64

In vivo and in vitro studies on the neurotoxic potential of 6–hydroxydopamine analogs. Ma S, et al. **J Med Chem** 1995 Sep 29;38(20):4087–97

Neonatal 6–hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs. Frohna PA, et al. **Neuroscience** 1995 Sep; 68(2):505–18

Effect of 6–hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self–administration under a progressive ratio schedule of reinforcement. McGregor A, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):5–9

OXIDOREDUCTASES

ANALYSIS

A colorimetric assay for cytokinin oxidase. Libreros–Minotta CA, et al. **Anal Biochem** 1995 Nov 1;231(2):339–41

Chloroplast biogenesis 72: a [4–vinyl]chlorophyllide a reductase assay using divinyl chlorophyllide a as an exogenous substrate. Parham R, et al. **Anal Biochem** 1995 Oct 10;231(1):164–9

Measurements of oxidoreductase–like activity of intact bacterial cells by an amperometric method using a membrane–coated electrode. Ikeda T, et al. **Anal Chem** 1996 Jan 1;68(1):192–8

Identification of the molybdenum cofactor of dimethyl sulfoxide reductase from Rhodobacter sphaeroides f. sp. denitrificans as bis(molybdopterin guanine dinucleotide)molybdenum. Hilton JC, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):139–43

Properties of a Wolinella succinogenes mutant lacking periplasmic sulfide dehydrogenase (Sud). Kotzian S, et al. **Arch Microbiol** 1996 Jan;165(1):65–8

Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Fernandez–Salguero P, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1015–20

Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme–specific probe. Spaldin V, et al. **Drug Metab Dispos** 1995 Sep; 23(9):929–34

Determination of P4501A2 activity in human liver microsomes using [3–14C–methyl]caffeine. Bloomer JC, et al. **Xenobiotica** 1995 Sep;25(9):917–27

ANTAGONISTS & INHIBITORS

The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Zhai L, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2742–8

Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar. Cleaveland ES, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):654–9

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Greene S, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):861–7

Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Oetari S, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):39–45

Competition between inhibitors of the trypanosome alternative oxidase (TAO) and reduced coenzyme Q9. Pollakis G, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1207–10

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Davis JP, et al. **Biochemistry** 1996 Jan 30;35(4):1270–3

Sterol biosynthesis: strong inhibition of maize delta 5,7-sterol delta 7-reductase by novel 6-aza-B-homosteroids and other analogs of a presumptive carbocationic intermediate of the reduction reaction. Rahier A, et al. **Biochemistry** 1996 Jun 4;35(22):7069–76

Lanosterol 14 alpha-demethylase (cytochrome P-45014DM): modulation of its enzyme activity by cholesterol feeding. Sonoda Y, et al. **Biol Pharm Bull** 1995 Jul;18(7):1009–11

Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. Jia L, et al. **Blood** 1996 Mar 15; 87(6):2401–10

Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Langouët S, et al. **Cancer Res** 1995 Dec 1;55(23):5574–9

Interaction of 2,4,4'-trichloro-2'-hydroxydiphenyl ether with microsomal cytochrome P450-dependent monooxygenases in rat liver. Hanioka N, et al. **Chemosphere** 1996 Jul;33(2):265–76

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Peck R, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):22–31

Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374–84 (52 ref.)

Finasteride inhibits 5 alpha-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related skin diseases. Nguyen QH, et al. **Int J Dermatol** 1995 Oct;34(10):720–5

Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy [editorial] Bredin HC. **Ir Med J** 1996 May-Jun;89(3):86, 88

Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. Shefer S, et al. **J Clin Invest** 1995 Oct; 96(4):1779–85

Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. Iehlé C, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5-6):273–9

Primary prevention of stroke [letter; comment] Gilbert RE, et al. **N Engl J Med** 1996 Apr 25;334(17):1138–9. Comment on: N Engl J Med 1995 Nov 23;333(21):1392–400.

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments] Lepor H, et al. **N Engl J Med** 1996 Aug 22;335(8):533–9 . Comment in: N Engl J Med 1996 Aug 22;335(8):586–7.

Treatment of benign prostatic hyperplasia [editorial; comment] Walsh PC. **N Engl J Med** 1996 Aug 22; 335(8):586–7. Comment on: N Engl J Med 1996 Aug 22;335(8):533–9.

The effect of protoporphyrinogen oxidase inhibitors on microsomal and mitochondrial cytochromes. Krijt J, et al. **Obes Res** 1995 Dec;3 Suppl 5:785S–788S

5alpha-reductase inhibitors/finasteride. Stoner E. **Prostate Suppl** 1996;6:82–7 (28 ref.)

Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Sutkowski DM, et al. **Prostate Suppl** 1996;6:62–6

Aminoanthracene is a mechanism-based inactivator of CYP1A in channel catfish hepatic tissue. Watson DE, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):208–15

[The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)] Stepanov VN, et al. **Urol Nefrol (Mosk)** 1995 Sep-Oct;(5):28–30 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Aliphatic and chlorinated alkenes and epoxides as inducers of alkene monooxygenase and epoxidase activities in Xanthobacter strain Py2. Ensign SA. **Appl Environ Microbiol** 1996 Jan;62(1):61–6

Uroporphyrin accumulation associated with cytochrome P4501A induction in fish hepatoma cells exposed to aryl hydrocarbon receptor agonists, including 2,3,7,8-tetrachlorodibenzo-p-dioxin and planar chlorobiphenyls. Hahn ME, et al. **Arch Biochem Biophys** 1996 May 15;329(2):163–74

The ubiquitously expressed human CYP51 encodes lanosterol 14 alpha-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Strömstedt M, et al. **Arch Biochem Biophys** 1996 May 1;329(1):73–81

Picrotoxin is a CYP1A1 inducer in rainbow trout hepatocytes. Sadar MD, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1060–6

Sterol 14-demethylase P450 activity expressed in rat gonads: contribution to the formation of mammalian meiosis-activating sterol. Yoshida Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):534–8

Structure-dependent induction of CYP2B by polychlorinated biphenyl congeners in female Sprague-Dawley rats. Connor K, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1913–20

Induction of cytochrome P450-dependent monooxygenase in serum-free cultured Hep G2 cells. Nakama A, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1407–12

Enoxacin is an inducer of CYP1A2 in rat liver. Schulz TG, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1517–20

Expression and analysis of the gene for the catalytic beta subunit of the sodium-translocating NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Tan K, et al. **Biochem Soc Trans** 1996 Feb;24(1):12S

Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locus. Ayalogu EO, et al. **Biochim Biophys Acta** 1995 Oct 17; 1272(2):89–94

Molecular cloning of dimethyl sulfoxide reductase from Rhodobacter sphaeroides. Hilton JC, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):111–4

Heterogeneity of rat type I 5 alpha-reductase cDNA: cloning, expression and regulation by pituitary implants and dihydrotestosterone. Lopez-Solache I, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):139–44

Synergistic induction of acyl-CoA oxidase activity, an indicator of peroxisome proliferation, by arachidonic acid and retinoic acid in Morris hepatoma 7800C1 cells. Sohlenius AK, et al. **Biochim Biophys Acta** 1995 Oct 5; 1258(3):257–64

Ionic lead, but not other ionic metals (Ni2+, Co2+ and Cd2+), suppresses 2-methoxy-4-aminoazobenzene-mediated cytochrome P450IA2 (CYP1A2) induction in rat liver. Degawa M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1215–8

2-Methoxy-4-nitroaniline is a selective inducer of cytochrome P450IA2 (CYP1A2) in rat liver. Degawa M, et al. **Cancer Lett** 1995 Sep 4;96(1):95–8

The model Ah-receptor agonist beta-naphthoflavone inhibits aflatoxin B1-DNA binding in vivo in rainbow trout at dietary levels that do not induce CYP1A enzymes. Takahashi N, et al. **Carcinogenesis** 1996 Jan;17(1):79–87

Inhibition of 1,2,4-benzenetriol-generated active oxygen species and induction of phase II enzymes by green tea polyphenols. Lee SF, et al. **Chem Biol Interact** 1995 Dec 22;98(3):283–301

Temporal induction pattern of hepatic cytochrome P450 1A in thermally acclimated dab (Limanda limanda) treated with 3,3',4,4'-tetrachlorobiphenyl (CB77). Sleiderink HM, et al. **Chemosphere** 1996 Jun;32(12):2335–44

3-Methylcholanthrene and pyridine effects on CYP1A1 and CYP1A2 expression in rat renal tissue. Kim H, et al. **Drug Metab Dispos** 1995 Aug;23(8):818–24

Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Berthou L, et al. **Eur J Biochem** 1995 Aug 15;232(1):179–87

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Rizzo N, et al. **Eur J Clin Pharmacol** 1996;49(6):491–5

Induction of hepatic CYP1A by indole-3-carbinol in protection against aflatoxin B1 hepatocarcinogenesis in rainbow trout. Takahashi N, et al. **Food Chem Toxicol** 1995 Oct;33(10):841–50

Effect of microaerophilic cell growth conditions on expression of the aerobic (cyoABCDE and cydAB) and anaerobic (narGHJI, frdABCD, and dmsABC) respiratory pathway genes in Escherichia coli. Tseng CP, et al. **J Bacteriol** 1996 Feb;178(4):1094–8

Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. Honkakoski P, et al. **J Biol Chem** 1996 Apr 19;271(16):9746–53

Engineering a novel iron-sulfur cluster into the catalytic subunit of Escherichia coli dimethyl-sulfoxide reductase. Trieber CA, et al. **J Biol Chem** 1996 Mar 1;271(9):4620–6

Re: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09 [letter] Pritsos C. **J Natl Cancer Inst** 1996 Aug 21;88(16):1161–3

Relationship between CYP1A enzyme activities and protein levels in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. DeVito MJ, et al. **J Toxicol Environ Health** 1996 Mar;47(4):379–94

Rainbow trout hepatic mixed-function oxygenase induction by polychlorinated dibenzo-p-dioxins (PCDDs) as a function of time and tissue concentration. Parrott JL, et al. **J Toxicol Environ Health** 1995 Nov;46(3):301–16

Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Welsh N, et al. **Mol Med** 1995 Nov;1(7):806–20

Cloning and characterization of a melanin biosynthetic THR1 reductase gene essential for appressorial penetration of Colletotrichum lagenarium. Perpetua NS, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):323–9

DNA adducts and P450 induction in human, rat and avian liver cells after exposure to polychlorobiphenyls. Dubois M, et al. **Mutat Res** 1995 Dec;345(3-4):181–90

Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80–3 (22 ref.)

Primary structure and expression of plant homologues of animal and fungal thioredoxin-dependent peroxide reductases and bacterial alkyl hydroperoxide reductases. Baier M, et al. **Plant Mol Biol** 1996 Jun;31(3):553–64

The in vitro assembly of the NADPH-protochlorophyllide oxidoreductase in pea chloroplasts. Dahlin C, et al. **Plant Mol Biol** 1995 Oct;29(2):317–30

Identification of three cDNA clones expressed in the leaf extension zone and with altered patterns of expression in the slender mutant of barley: a tonoplast intrinsic protein, a putative structural protein and protochlorophyllide oxidoreductase. Schünmann PH, et al. **Plant Mol Biol** 1996 Jun;31(3):529–37

Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity. Cheung YL, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):203–11

Comparison of Ah receptor-mediated luciferase and ethoxyresorufin-O-deethylase induction in H4IIE cells: implications for their use as bioanalytical tools for the detection of polyhalogenated aromatic hydrocarbons. Sanderson JT, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):316–25

Effects of a single dose of the cytochrome P450 inducer, beta-naphthoflavone, on hepatic and renal covalent DNA modifications (I-compounds). Moorthy B, et al. **Toxicology** 1995 Dec 15;104(1-3):165–77

Fatty acyl-CoA oxidase activity is induced before long-chain acyl-CoA hydrolase activity and acyl-CoA binding protein in liver of rat treated with peroxisome proliferating 3-thia fatty acids. Skorve J, et al. **Xenobiotica** 1995 Nov; 25(11):1181–94

BLOOD

Purification and characterization of a glutathione dependent dehydroascorbate reductase from human erythrocytes. Xu DP, et al. **Biochem Biophys Res Commun** 1996 Apr 5; 221(1):117–21

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. McMurrough J, et al. **Br J Clin Pharmacol** 1996 May;41(5):425–7

Red blood cell antioxidant enzymes in age-related macular degeneration. De La Paz MA, et al. **Br J Ophthalmol** 1996 May;80(5):445–50

Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Fleming GF, et al. **Cancer Chemother Pharmacol** 1996;37(6):569–73

Glutathione, glutathione utilizing enzymes and thioltransferase in platelets of insulin-dependent diabetic patients: relation with platelet aggregation and with microangiopatic complications. Di Simplicio P, et al. **Eur J Clin Invest** 1995 Sep;25(9):665–9

Hormones and prostate cancer: where do we go from here? [editorial; comment] Hsing AW. **J Natl Cancer Inst** 1996 Aug 21;88(16):1093–5. Comment on: J Natl Cancer Inst 1996 Aug 21;88(16):1118–26.

[Changes in the infradian rhythm of the dehydrogenases in the blood lymphocytes of rats due to epiphysectomy and the action of weak alternating magnetic fields] Temur'iants NA, et al. **Aviakosm Ekolog Med** 1995;29(3):39–43 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Dong MS, et al. **Arch Biochem Biophys** 1996 Mar 1; 327(1):11–9

Room temperature ESR spectra of Rhus vernicifera laccase and derivatives. Sakurai T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):235–40

Secondary structure of NADPH: protochlorophyllide oxidoreductase examined by circular dichroism and prediction methods. Birve SJ, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):549–55

Bacterial morphinone reductase is related to Old Yellow Enzyme. French CE, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):671–8

Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Shalloe F, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):385–7

Peroxide complex of cytochrome bd: kinetics of generation and stability. Borisov V, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):975–82

A study of the stabilization of semiquinones by the Escherichia coli quinol oxidase cytochrome bd. Hastings SF, et al. **Biochem Soc Trans** 1996 Feb;24(1):131–2

Expression and analysis of the gene for the catalytic beta subunit of the sodium-translocating NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Tan K, et al. **Biochem Soc Trans** 1996 Feb;24(1):12S

Ferrous active site of isopenicillin N synthase: genetic and

sequence analysis of the endogenous ligands. Borovok I, et al. **Biochemistry** 1996 Feb 13;35(6):1981–7

Studies of the redox properties of CDP–6–deoxy–L–threo–D–glycero–4–hexulose–3–dehydrase (E1) and CDP–6–deoxy–L–threo–D–glycero–4–hexulose–3–dehydrase reductase (E3): two important enzymes involved in the biosynthesis of ascarylose. Burns KD, et al. **Biochemistry** 1996 Jun 18;35(24):7879–89

Methionine–393 is an axial ligand of the heme b558 component of the cytochrome bd ubiquinol oxidase from Escherichia coli. Kaysser TM, et al. **Biochemistry** 1995 Oct 17;34(41):13491–501

2'–fluoro–2'–deoxy–D–arabinoflavin: characterization of a novel flavin and its effects on the formation and stability of two–electron–reduced mercuric ion reductase. Miller SM. **Biochemistry** 1995 Oct 10;34(40):13066–73

Flavin–dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 2. Cystine disulfides involved in catalysis of peroxide reduction. Poole LB. **Biochemistry** 1996 Jan 9;35(1):65–75

The function and properties of the iron–sulfur center in spinach ferredoxin: thioredoxin reductase: a new biological role for iron–sulfur clusters. Staples CR, et al. **Biochemistry** 1996 Sep 3;35(35):11425–34

Resonance Raman studies of Escherichia coli cytochrome bd oxidase. Selective enhancement of the three heme chromophores of the "as–isolated" enzyme and characterization of the cyanide adduct. Sun J, et al. **Biochemistry** 1995 Sep 26;34(38):12144–51

Resonance Raman spectroscopic identification of a histidine ligand of b595 and the nature of the ligation of chlorin d in the fully reduced Escherichia coli cytochrome bd oxidase. Sun J, et al. **Biochemistry** 1996 Feb 20; 35(7):2403–12

Marked detergents effects on safranine T–mediated photo–induced electron transfer in cytochrome P–450 1A2. Nakano R, et al. **Biochim Biophys Acta** 1995 Oct 25; 1252(2):245–50

A study of a series of recombinant fungal laccases and bilirubin oxidase that exhibit significant differences in redox potential, substrate specificity, and stability. Xu F, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):303–11

Nitric oxide stabilizes the Mo(V) oxidation state of dimethyl sulfoxide reductase from Rhodobacter sphaeroides without inhibiting enzyme activity. Bastian NR, et al. **Biofactors** 1995 May;5(1):5–10

Electron spin–lattice relaxation of the [Cu(1.5) ... Cu(1.5)] dinuclear copper center in nitrous oxide reductase. Pfenninger S, et al. **Biophys J** 1995 Dec;69(6):2761–9

Mutation of the conserved Cys165 outside of the CuA domain destabilizes nitrous oxide reductase but maintains its catalytic activity. Evidence for disulfide bridges and a putative protein disulfide isomerase gene. Dreusch A, et al. **Eur J Biochem** 1996 Apr 15;237(2):447–53

The gene, protein and glycan structures of laccase from Pleurotus ostreatus. Giardina P, et al. **Eur J Biochem** 1996 Feb 1;235(3):508–15

Dimethylsulfide:acceptor oxidoreductase from Rhodobacter sulfidophilus. The purified enzyme contains b–type haem and a pterin molybdenum cofactor. Hanlon SP, et al. **Eur J Biochem** 1996 Jul 15;239(2):391–6

Rat pristanoyl–CoA oxidase. cDNA cloning and recognition of its C–terminal (SQL) by the peroxisomal–targeting signal 1 receptor. Vanhooren JC, et al. **Eur J Biochem** 1996 Jul 15;239(2):302–9

Structure and mechanism of the iron–sulfur flavoprotein phthalate dioxygenase reductase. Gassner GT, et al. **FASEB J** 1995 Nov;9(14):1411–8 (41 ref.)

A structural model for the membrane–integral domain of succinate: quinone oxidoreductases. Hägerhäll C, et al. **FEBS Lett** 1996 Jun 24;389(1):25–31 (59 ref.)

Purification and reconstitution of activity of Saccharomyces cerevisiae P450 61, a sterol delta 22–desaturase. Kelly SL, et al. **FEBS Lett** 1995 Dec 18;377(2):217–20

Transacylase–like structure and its role in substrate channeling of 6–hydroxymellein synthase, a multifunctional polyketide biosynthetic enzyme in carrot cell extracts. Kurosaki F. **FEBS Lett** 1996 Jan 22;379(1):97–102

The design of an alternative, covalently flavinylated 6–hydroxy–D–nicotine oxidase by replacing the FAD–binding histidine by cysteine and reconstitution of the holoenzyme with 8–(methylsulfonyl)FAD. Stoltz M, et al. **FEBS Lett** 1996 May 20;386(2–3):194–6

Succinate:quinone oxidoreductase (complex II) containing a single heme b in facultative alkaliphilic Bacillus sp. strain YN–2000. Qureshi MH, et al. **J Bacteriol** 1996 Jun; 178(11):3031–6

Purification and characterization of the 3–ketosteroid–delta 1–dehydrogenase of Arthrobacter simplex produced in Streptomyces lividans. Choi KP, et al. **J Biochem (Tokyo)** 1995 May;117(5):1043–9

Structure–function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)

EPR and Mössbauer spectroscopic studies on enoate reductase. Caldeira J, et al. **J Biol Chem** 1996 Aug 2; 271(31):18743–8

EPR study of NO complex of bd–type ubiquinol oxidase from Escherichia coli. Hori H, et al. **J Biol Chem** 1996 Apr 19; 271(16):9254–8

Conserved Glu318 at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability. Nakano R, et al. **J Biol Chem** 1996 Apr 12;271(15):8570–4

The mechanism of the acyl–carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha–demethylase of Candida albicans (other names are: lanosterol 14 alpha–demethylase, P–45014DM, and CYP51). Shyadehi AZ, et al. **J Biol Chem** 1996 May 24;271(21):12445–50

Engineering a novel iron–sulfur cluster into the catalytic subunit of Escherichia coli dimethyl–sulfoxide reductase. Trieber CA, et al. **J Biol Chem** 1996 Mar 1;271(9):4620–6

Protochlorophyllide reductase. III: Synthesis of a protochlorophyllide–dihydroflavin complex. Nayar P, et al. **Photochem Photobiol** 1996 Jan;63(1):100–5

Primary structure and expression of plant homologues of animal and fungal thioredoxin–dependent peroxide reductases and bacterial alkyl hydroperoxide reductases. Baier M, et al. **Plant Mol Biol** 1996 Jun;31(3):553–64

Identification of the overtone of the Fe–CO stretching mode in heme proteins: a probe of the heme active site. Wang J, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9402–6

Crystal structure of the membrane–exposed domain from a respiratory quinol oxidase complex with an engineered dinuclear copper center [see comments] Wilmanns M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11955–9 . Comment in: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11949–51.

Crystal structure of thioltransferase at 2.2 A resolution. Katti SK, et al. **Protein Sci** 1995 Oct;4(10):1998–2005

Crystal structure of DMSO reductase: redox–linked changes in molybdopterin coordination [see comments] Schindelin H, et al. **Science** 1996 Jun 14;272(5268):1615–21. Comment in: Science 1996 Jun 14;272(5268):1599–600.

Common themes in redox chemistry emerge from the X–ray structure of oilseed rape (Brassica napus) enoyl acyl carrier protein reductase. Rafferty JB, et al. **Structure** 1995 Sep 15;3(9):927–38

[Selection of optimal conditions for synthesis of protein A–laccase conjugates and their use in different variants of immunoenzyme analysis] Skorobogat'ko OV, et al. **Prikl Biokhim Mikrobiol** 1995 Nov–Dec;31(6):625–9 (Eng. Abstr.) **(Rus)**

DEFICIENCY

Cerebral energy metabolism in isovaleric acidaemia. Lorek AK, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 May; 74(3):F211–3

Biochemical investigations and immunoblot analyses of two unrelated patients with an isolated deficiency in complex II of the mitochondrial respiratory chain. Birch–Machin MA, et al. **Biochem Biophys Res Commun** 1996 Mar 7; 220(1):57–62

Severe 5–fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta [letter] Beuzeboc P, et al. **Eur J Cancer** 1996 Feb;32A(2):369–70

Delta 4–3–oxosteroid 5 beta–reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Clayton PT, et al. **Gut** 1996 Apr;38(4):623–8

The biochemical and phenotypic characterization of females homozygous for 5 alpha–reductase–2 deficiency. Katz MD, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3160–7

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5–fluorouracil toxicity. Wei X, et al. **J Clin Invest** 1996 Aug 1;98(3):610–5

Isovaleric acidemia appearing as diabetic ketoacidosis. Attia N, et al. **J Inherit Metab Dis** 1996;19(1):85–6

Early signs and course of disease of glutaryl–CoA dehydrogenase deficiency. Hoffmann GF, et al. **J Inherit Metab Dis** 1995;18(2):173–6

Detection of defective 3 beta–hydroxysterol delta 7–reductase activity in cultured human fibroblasts: a method for the diagnosis of Smith–Lemli–Opitz syndrome. Lund E, et al. **J Inherit Metab Dis** 1996;19(1):59–64

The metabolism of testosterone by dermal papilla cells cultured from human pubic and axillary hair follicles concurs with hair growth in 5 alpha–reductase deficiency. Hamada K, et al. **J Invest Dermatol** 1996 May; 106(5):1017–22

Glutaric aciduria type 1 in adulthood [letter] Prevett MC, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):352–3

Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Bourgeron T, et al. **Nat Genet** 1995 Oct;11(2):144–9

Variable clinical and biochemical presentation of seven Spanish cases with glutaryl–CoA–dehydrogenase deficiency. Merinero B, et al. **Neuropediatrics** 1995 Oct; 26(5):238–42

First trimester prenatal diagnosis of Smith–Lemli–Opitz syndrome (7–dehydrocholesterol reductase deficiency). Mills K, et al. **Pediatr Res** 1996 May;39(5):816–9

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Gonzalez FJ, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):325–7 (22 ref.)

[Severe 5–fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dihydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Congenital disorders of the bile acid metabolism (3 beta–hydroxy–delta 5–steroid dehydrogenase/isomerase deficiency, delta 4–3–oxosteroid 5 beta–reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

DIAGNOSTIC USE

Differences between enzymatic and diazo methods for measuring direct bilirubin. Nakayama K. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):513–7

DRUG EFFECTS

Liver microsomal levels of cytochrome P450IA1 as biomarker for exposure and bioavailability of soil–bound polycyclic aromatic hydrocarbons. Roos PH, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):107–13

Toxicological and kinetic study of musk xylene in rainbow trout, Oncorhynchus mykiss. Boleas S, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):217–22

RPR 101821, a new potent cholesterol–lowering agent: inhibition of squalene synthase and 7–dehydrocholesterol reductase. Amin D, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):233–40

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha–reductase activity in human benign prostatic hyperplasia. Weisser H, et al. **Prostate** 1996 May; 28(5):300–6

GENETICS

The alcohol dehydrogenase system. Jörnvall H, et al. **Adv Exp Med Biol** 1995;372:281–94 (51 ref.)

Short–chain dehydrogenases/reductases. Persson B, et al. **Adv Exp Med Biol** 1995;372:383–95 (38 ref.)

Elevated total plasma homocysteine and 677C–>T mutation of the 5,10–methylenetetrahydrofolate reductase gene in thrombotic vascular disease [letter] de Franchis R, et al. **Am J Hum Genet** 1996 Jul;59(1):262–4

Genetic similarity among Central and South American populations of Leishmania (Viannia) braziliensis. Kreutzer RD. **Am J Trop Med Hyg** 1996 Jul;55(1):106–10

Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Geber A, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2708–17

Cloning, sequence, and expression of mouse protoporphyrinogen oxidase. Dailey TA, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):379–84

Mutagenesis study of Asp–290 in cytochrome P450 2B11 using a fusion protein with rat NADPH–cytochrome P450 reductase. Harlow GR, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):85–92

Glycine N–methyltransferase is a mediator of cytochrome P4501A1 gene expression. Raha A, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):395–404

Protoporphyrinogen oxidase: complete genomic sequence and polymorphisms in the human gene. Puy H, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):226–30

Biophysical factors affecting the expression of isopenicillin N synthase isozymes in Escherichia coli. Tiow–Suan S, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1069–78

Response of [Ah] battery genes to compounds that protect against menadione toxicity. Vasiliou V, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1885–91

Expression of rat biliverdin reductase as a glutathione–S–transferase fusion protein. Ennis OM, et al. **Biochem Soc Trans** 1995 Aug;23(3):443S

Multiple nosZ promoters and anaerobic expression of nos genes necessary for Pseudomonas stutzeri nitrous oxide reductase and assembly of its copper centers. Cuypers H, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):183–90

Functional analysis of subunits III and IV of Bacillus subtilis aa3–600 quinol oxidase by in vitro mutagenesis and gene replacement. Villani G, et al. **Biochim Biophys Acta** 1995 Nov 21;1232(1–2):67–74

Expression of the FOX1 gene of Saccharomyces cerevisiae is regulated by carbon source, but not by the known glucose repression genes. Stanway CA, et al. **Curr Genet** 1995 Apr;27(5):404–8

The identification and characterization of four laccases from the plant pathogenic fungus Rhizoctonia solani. Wahleithner JA, et al. **Curr Genet** 1996 Mar;29(4):395–403

Genetic linkage mapping of the human steroid 5 alpha–reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23–>p22. Morissette J, et al. **Cytogenet Cell Genet** 1996;73(4):304–7

Molecular identification of zeaxanthin epoxidase of Nicotiana plumbaginifolia, a gene involved in abscisic acid biosynthesis and corresponding to the ABA locus of Arabidopsis thaliana. Marin E, et al. **EMBO J** 1996 May 15;15(10):2331–42

Mutation of the conserved Cys165 outside of the CuA domain destabilizes nitrous oxide reductase but maintains its catalytic activity. Evidence for disulfide bridges and a putative protein disulfide isomerase gene. Dreusch A, et al. **Eur J Biochem** 1996 Apr 15;237(2):447–53

The gene, protein and glycan structures of laccase from Pleurotus ostreatus. Giardina P, et al. **Eur J Biochem** 1996 Feb 1;235(3):508–15

Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation. Hirano N, et al. **Eur J Biochem** 1995 Nov 15;234(1):336-42

Human biliverdin IXalpha reductase is a zinc-metalloprotein. Characterization of purified and Escherichia coli expressed enzymes. Maines MD, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):372-81

Molecular biological analysis of a bidirectional hydrogenase from cyanobacteria. Schmitz O, et al. **Eur J Biochem** 1995 Oct 1;233(1):266-76

Purification of crotonyl-CoA reductase from Streptomyces collinus and cloning, sequencing and expression of the corresponding gene in Escherichia coli. Wallace KK, et al. **Eur J Biochem** 1995 Nov 1;233(3):954-62

Chloride transport in cultured fetal human retinal pigment epithelium. Hu JG, et al. **Exp Eye Res** 1996 Apr;62(4):443-8

Positive and negative regulation of a sterol biosynthetic gene (ERG3) in the post-squalene portion of the yeast ergosterol pathway. Arthington-Skaggs BA, et al. **FEBS Lett** 1996 Aug 26;392(2):161-5

Cloning, expression and characterization of human thioltransferase (glutaredoxin) in E. coli. Chrestensen CA, et al. **FEBS Lett** 1995 Oct 23;374(1):25-8

Phenotypic characterisation and genetic complementation of dimethylsulfoxide respiratory mutants of Rhodobacter sphaeroides and Rhodobacter capsulatus. Bonnett TC, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1-2):163-8

Isolation of an Ustilago maydis ERG11 gene and its expression in a mutant deficient in sterol 14 alpha-demethylase activity. Hargreaves JA, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2-3):203-7

Evidence that particulate methane monooxygenase and ammonia monooxygenase may be evolutionarily related. Holmes AJ, et al. **FEMS Microbiol Lett** 1995 Oct 15; 132(3):203-8

The gene encoding ammonia monooxygenase subunit A exists in three nearly identical copies in Nitrosospira sp. NpAV. Norton JM, et al. **FEMS Microbiol Lett** 1996 Jun 1; 139(2-3):181-8

Comparative analysis of gene sequences encoding ammonia monooxygenase of Nitrosospira sp. AHB1 and Nitrosolobus multiformis C-71. Rotthauwe JH, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1-2):131-5

Sequence of an ammonia monooxygenase subunit A-encoding gene from Nitrosospira sp. NpAV. Klotz MG, et al. **Gene** 1995 Sep 22;163(1):159-60

Sequences of the genes encoding the A, B and C subunits of the Haemophilus influenzae dimethylsulfoxide reductase complex. Loosmore SM, et al. **Gene** 1996 Feb 22; 169(1):137-8

Cloning and characterization of the POX2 gene in Candida maltosa. Masuda Y, et al. **Gene** 1995 Dec 29; 167(1-2):157-61

Cloning and characterization of the Saccharomyces cerevisiae C-22 sterol desaturase gene, encoding a second cytochrome P-450 involved in ergosterol biosynthesis. Skaggs BA, et al. **Gene** 1996 Feb 22;169(1):105-9

Cloning and analysis of the alternative oxidase gene of Neurospora crassa. Li Q, et al. **Genetics** 1996 Jan; 142(1):129-40

Cloning, structure, and chromosome localization of the mouse glutaryl-CoA dehydrogenase gene. Koeller DM, et al. **Genomics** 1995 Aug 10;28(3):508-12

The human protoporphyrinogen oxidase gene (PPOX): organization and location to chromosome 1. Taketani S, et al. **Genomics** 1995 Oct 10;29(3):698-703

Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Muntané-Relat J, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1143-53

Localization of D-amino acid oxidase mRNA in the mouse kidney and the effect of testosterone treatment. Koibuchi N, et al. **Histochem Cell Biol** 1995 Nov;104(5):349-55

Cloning of glutaryl-CoA dehydrogenase cDNA, and expression of wild type and mutant enzymes in Escherichia coli. Goodman SI, et al. **Hum Mol Genet** 1995 Sep; 4(9):1493-8

Partial characterization and assignment of the gene for protoporphyrinogen oxidase and variegate porphyria to human chromosome 1q23. Roberts AG, et al. **Hum Mol Genet** 1995 Dec;4(12):2387-90

Partial gene sequences for the A subunit of methyl-coenzyme M reductase (mcrI) as a phylogenetic tool for the family Methanosarcinaceae. Springer E, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):554-9

Identification of a major cis-acting DNA element controlling the bidirectionally transcribed penicillin biosynthesis genes acvA (pcbAB) and ipnA (pcbC) of Aspergillus nidulans. Bergh KT, et al. **J Bacteriol** 1996 Jul;178(13):3908-16

Aerobic isolation of an ERG24 null mutant of Saccharomyces cerevisiae. Crowley JH, et al. **J Bacteriol** 1996 May;178(10):2991-3

Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. Dhandayuthapani S, et al. **J Bacteriol** 1996 Jun; 178(12):3641-9

Cloning, sequencing, and analysis of aklaviketone reductase from Streptomyces sp. strain C5. Dickens ML, et al. **J Bacteriol** 1996 Jun;178(11):3384-8

Comamonas testosteroni 3-ketosteroid-delta 4(5 alpha)-dehydrogenase: gene and protein characterization. Florin C, et al. **J Bacteriol** 1996 Jun;178(11):3322-30

Mutagenesis of hydroxylamine oxidoreductase in Nitrosomonas europaea by transformation and recombination. Hommes NG, et al. **J Bacteriol** 1996 Jul; 178(13):3710-4

Nucleotide sequence, transcriptional analysis, and glucose regulation of the phenoxazinone synthase gene (phsA) from Streptomyces antibioticus. Hsieh CJ, et al. **J Bacteriol** 1995 Oct;177(20):5740-7

Purification of a cytochrome bd terminal oxidase encoded by the Escherichia coli app locus from a delta cyo delta cyd strain complemented by genes from Bacillus firmus OF4. Sturr MG, et al. **J Bacteriol** 1996 Mar;178(6):1742-9

Intracellular inducer $Hg2+$ concentration is rate determining for the expression of the mercury-resistance operon in cells. Yu H, et al. **J Bacteriol** 1996 May;178(9):2712-4

Cloning and characterization of the yeast HEM14 gene coding for protoporphyrinogen oxidase, the molecular target of diphenyl ether-type herbicides. Camadro JM, et al. **J Biol Chem** 1996 Apr 12;271(15):9120-8

Protoporphyrinogen oxidase of Myxococcus xanthus. Expression, purification, and characterization of the cloned enzyme. Dailey HA, et al. **J Biol Chem** 1996 Apr 12; 271(15):8714-8

Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. Honkakoski P, et al. **J Biol Chem** 1996 Apr 19;271(16):9746-53

Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol delta 7-reductase. Lecain E, et al. **J Biol Chem** 1996 May 3; 271(18):10866-73

Purification, identification, and properties of a Saccharomyces cerevisiae oleate-activated upstream activating sequence-binding protein that is involved in the activation of POX1. Luo Y, et al. **J Biol Chem** 1996 May 17;271(20):12068-75

A Chinese hamster mutant cell line with a defect in the integral membrane protein CII-3 of complex II of the mitochondrial electron transport chain. Oostveen FG, et al. **J Biol Chem** 1995 Nov 3;270(44):26104-8

Functional analysis of conserved histidine residues in Cephalosporium acremonium isopenicillin N synthase by site-directed mutagenesis. Tan DS, et al. **J Biol Chem** 1996 Jan 12;271(2):889-94

Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. Varanasi U, et al. **J Biol Chem** 1996 Jan 26;271(4):2147-55

The broad substrate chlorobenzene dioxygenase and cis-chlorobenzene dihydrodiol dehydrogenase of Pseudomonas sp. strain P51 are linked evolutionarily to the enzymes for benzene and toluene degradation. Werlen C, et al. **J Biol Chem** 1996 Feb 23;271(8):4009-16

The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. Katz MD, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3160-7

Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. Salas SD, et al. **J Exp Med** 1996 Aug 1;184(2):377-86

Assignment of the human peroxisomal palmitoyl-CoA oxidase gene to chromosome 17q23-qter by PCR technique. Moghrabi NN, et al. **J Inherit Metab Dis** 1995; 18(6):705-9

Phylogenetic analysis of the isopenicillin-N-synthetase horizontal gene transfer. Buades C, et al. **J Mol Evol** 1996 May;42(5):537-42

Methylenetetrahydrofolate reductase and neural tube defects [letter] Papapetrou C, et al. **Lancet** 1996 Jul 6;348(9019):58

P450 (cytochrome) oxidoreductase (Por) maps to mouse chromosome 5, not chromosome 6. Spearow JL. **Mamm Genome** 1995 Aug;6(8):558-9

A homologue to the Escherichia coli alkyl hydroperoxide reductase AhpC is induced by osmotic upshock in Staphylococcus aureus. Armstrong-Buisseret L, et al. **Microbiology** 1995 Jul;141 (Pt 7):1655-61

Formation of extrachromosomal circular amplicons with direct or inverted duplications in drug-resistant Leishmania tarentolae. Grondin K, et al. **Mol Cell Biol** 1996 Jul; 16(7):3587-95

5 alpha-reduced androgens play a key role in murine parturition. Mahendroo MS, et al. **Mol Endocrinol** 1996 Apr;10(4):380-92

Isolation and molecular characterisation of the gene encoding eburicol 14 alpha-demethylase (cYP51) from Penicillium italicum. van Nistelrooy JG, et al. **Mol Gen Genet** 1996 Apr 10;250(6):725-33

Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Deretic V, et al. **Mol Microbiol** 1995 Sep;17(5):889-900

Green fluorescent protein as a marker for gene expression and cell biology of mycobacterial interactions with macrophages. Dhandayuthapani S, et al. **Mol Microbiol** 1995 Sep;17(5):901-12

ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Wilson TM, et al. **Mol Microbiol** 1996 Mar;19(5):1025-34

The South African malady [news; comment] Jenkins T. **Nat Genet** 1996 May;13(1):7-9. Comment on: Nat Genet 1996 May;13(1):95-7.

A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria [see comments] Meissner PN, et al. **Nat Genet** 1996 May;13(1):95-7. Comment in: Nat Genet 1996 May;13(1):7-9.

Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Yokoi T, et al. **Pharmacogenetics** 1995;5 Spec No:S65-9

Regulation of a carotenoid biosynthesis gene promoter during plant development. Corona V, et al. **Plant J** 1996 Apr; 9(4):505-12

An Arabidopsis mutant deficient in sterol biosynthesis: heterologous complementation by ERG 3 encoding a delta 7-sterol-C-5-desaturase from yeast. Gachotte D, et al. **Plant J** 1995 Sep;8(3):407-16

Transcripts of the two NADPH protochlorophyllide oxidereductase genes PorA and PorB are differentially degraded in etiolated barley seedlings. Holtorf H, et al. **Plant Mol Biol** 1996 May;31(2):387-92

The pc-1 phenotype of Chlamydomonas reinhardtii results from a deletion mutation in the nuclear gene for NADPH:protochlorophyllide oxidoreductase. Li J, et al. **Plant Mol Biol** 1996 Jan;30(1):15-37

Cloning and characterization of a maize cDNA encoding phytoene desaturase, an enzyme of the carotenoid biosynthetic pathway. Li ZH, et al. **Plant Mol Biol** 1996 Jan;30(2):269-79

Genetic modification of respiratory capacity in potato. Hiser C, et al. **Plant Physiol** 1996 Jan;110(1):277-86

Molecular cloning of violaxanthin de-epoxidase from romaine lettuce and expression in Escherichia coli. Bugos RC, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6320-5

Genes encoding the same three subunits of respiratory complex II are present in the mitochondrial DNA of two phylogenetically distant eukaryotes. Burger G, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2328-32

Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Moskovitz J, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2095-9

Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Moskovitz J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3205-8

Mercuric ion reduction and resistance in transgenic Arabidopsis thaliana plants expressing a modified bacterial merA gene. Rugh CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3182-7

Human protoporphyrinogen oxidase: expression, purification, and characterization of the cloned enzyme. Dailey TA, et al. **Protein Sci** 1996 Jan;5(1):98-105

A putative FAD-binding domain in a distinct group of oxidases including a protein involved in plant development. Mushegian AR, et al. **Protein Sci** 1995 Jun;4(6):1243-4

Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Sherman DR, et al. **Science** 1996 Jun 14;272(5268):1641-3

IMMUNOLOGY

Anti-peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44-kDa protein from rat liver mitochondria. Knecht W, et al. **Eur J Biochem** 1996 Mar 1;236(2):609-13

ISOLATION & PURIFICATION

Purification of 2,3-dihydroxybiphenyl 1,2-dioxygenase from Pseudomonas putida OU83 and characterization of the gene (bphC). Khan AA, et al. **Appl Environ Microbiol** 1996 May; 62(5):1825-30

Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Copeland RA, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):79-86

Purification and characterization of dihydropyrimidine dehydrogenase from Alcaligenes eutrophus. Schmitt U, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):175-82

Purification and characterization of chlorobenzene cis-dihydrodiol dehydrogenase from Xanthobacter flavus 14p1. Spiess E, et al. **Arch Microbiol** 1996 Mar;165(3):201-5

Purification and characterization of a glutathione dependent dehydroascorbate reductase from human erythrocytes. Xu DP, et al. **Biochem Biophys Res Commun** 1996 Apr 5; 221(1):117-21

Affinity precipitation of dehydrogenases with bis-NADH derivatives. Irwin JA, et al. **Biochem Soc Trans** 1996 Feb; 24(1):11S

Flavin-dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 1. Purification and enzymatic activities of overexpressed AhpF and AhpC proteins. Poole LB, et al. **Biochemistry** 1996 Jan 9;35(1):56-64

Cholesterol biosynthesis from lanosterol: regulation and purification of rat hepatic sterol 14-reductase. Kim CK, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):39-48

The multiplicity of enzymatic DNA reduction: a new purification procedure for a DHA reducing protein from potato tubers. De Tullio MC, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun;71(5-6):163-70

Biochemical characterization of the

8-hydroxy-5-deazaflavin-reactive hydrogenase from Methanosarcina barkeri Fusaro. Michel R, et al. **Eur J Biochem** 1995 Nov 1;233(3):727-35

The purification of ammonia monooxygenase from Paracoccus denitrificans. Moir JW, et al. **FEBS Lett** 1996 May 27;387(1):71-4

Purification and characterization of 2-oxoglutarate:ferredoxin oxidoreductase from a thermophilic, obligately chemolithoautotrophic bacterium, Hydrogenobacter thermophilus TK-6. Yoon KS, et al. **J Bacteriol** 1996 Jun;178(11):3365-8

Purification and characterization of the 3-ketosteroid-delta 1-dehydrogenase of Arthrobacter simplex produced in Streptomyces lividans. Choi KP, et al. **J Biochem (Tokyo)** 1995 May;117(5):1043-9

sn-glycerol-1-phosphate dehydrogenase in Methanobacterium thermoautotrophicum: key enzyme in biosynthesis of the enantiomeric glycerophosphate backbone of ether phospholipids of archaebacteria. Nishihara M, et al. **J Biochem (Tokyo)** 1995 May; 117(5):933-5

Purification in an active state and properties of the 3-step phytoene desaturase from Rhodobacter capsulatus overexpressed in Escherichia coli. Raisig A, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):559-64

Purification and characterization of tetrachloroethene reductive dehalogenase from Dehalospirillum multivorans. Neumann A, et al. **J Biol Chem** 1996 Jul 12;271(28):16515-9

Identification and partial purification of a stage-specific 33 kDa mitochondrial protein as the alternative oxidase of the Trypanosoma brucei brucei bloodstream trypomastigotes. Chaudhuri M, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):467-72

Purification and characterization of a cytochrome P450 isozyme catalyzing lanosterol 14 alpha-demethylation (P45014DM) in hamster liver. Sekigawa Y, et al. **Lipids** 1995 Dec;30(12):1067-73

Flavinylation of succinate: ubiquinone oxidoreductase from Saccharomyces cerevisiae. Robinson KM, et al. **Methods Enzymol** 1995;260:34-51

Native electrophoresis for isolation of mitochondrial oxidative phosphorylation protein complexes. Schägger H. **Methods Enzymol** 1995;260:190-202

Violaxanthin de-epoxidase. Rockholm DC, et al. **Plant Physiol** 1996 Feb;110(2):697-703

METABOLISM

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Stéphan F, et al. **Am J Med** 1995 Dec;99(6):685-8

Potential role of NADH oxidoreductase-derived reactive O2 species in calf pulmonary arterial PO2-elicited responses. Mohazzab KM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L637-44

Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man. Van Kuilenburg AB, et al. **Anticancer Res** 1996 Jan-Feb;16(1):389-94

Hexavalent-chromium reduction by a chromate-resistant Bacillus sp. strain. Campos J, et al. **Antonie Van Leeuwenhoek** 1995 Oct;68(3):203-8

Polycyclic aromatic hydrocarbon-degrading capabilities of Phanerochaete laevis HHB-1625 and its extracellular ligninolytic enzymes. Bogan BW, et al. **Appl Environ Microbiol** 1996 May;62(5):1597-603

Characterization of active recombinant 2,3-dihydro-2,3-dihydroxybiphenyl dehydrogenase from Comamonas testosteroni B-356 and sequence of the encoding gene (bphB). Sylvestre M, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2710-5

Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Dong MS, et al. **Arch Biochem Biophys** 1996 Mar 1; 327(1):11-9

Effect of NADPH-associated keto-reducing domain on substrate entry into 6-hydroxymellein synthase, a multifunctional polyketide synthetic enzyme involved in phytoalexin biosynthesis in carrot. Kurosaki F. **Arch Biochem Biophys** 1996 Apr 1;328(1):213-7

Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Pacot C, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):181-8

Plant sterol biosynthesis: identification and characterization of higher plant delta 7-sterol C5(6)-desaturase. Taton M, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):279-88

Activities of liver and lung cytochrome P450-dependent monooxygenases and antioxidant enzymes in laboratory and wild Norway rats exposed to reference and contaminated soils. Fouchécourt MO, et al. **Arch Environ Contam Toxicol** 1996 May;30(4):513-22

Liver microsomal levels of cytochrome P450IA1 as biomarker for exposure and bioavailability of soil-bound polycyclic aromatic hydrocarbons. Roos PH, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):107-13

Characterization of the membranous denitrification enzymes nitrite reductase (cytochrome cd1) and copper-containing nitrous oxide reductase from Thiobacillus denitrificans. Hole UH, et al. **Arch Microbiol** 1996 Jan;165(1):55-61

Purification and characterization of chlorobenzene cis-dihydrodiol dehydrogenase from Xanthobacter flavus 14p1. Spiess E, et al. **Arch Microbiol** 1996 Mar;165(3):201-5

Export of the periplasmic NADP-containing glucose-fructose oxidoreductase of Zymomonas mobilis. Wiegert T, et al. **Arch Microbiol** 1996 Jul;166(1):32-41

Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286-302 (65 ref.)

Kinetic mechanism and substrate specificity of nitroalkane oxidase. Heasley CJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):6-10

Dehydrogenase binding to the 3'-untranslated region of GLUT1 mRNA. McGowan K, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):42-5

Preparation, purification, and spectrophotometric characterization of cytochrome P450 1A2 conjugated with polyethylene glycol monomethyl ether. Nakhgevany R, et al. **Biochem Biophys Res Commun** 1996 May 15; 222(2):406-9

Substrate stereospecificity in oxidation of (25S)-3 alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholestanoyl-CoA by peroxisomal trihydroxy-5 beta-cholestanoyl-CoA oxidase. Pedersen JI, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):37-42

Characterization of representative enzymes from a sulfate reducing bacterium implicated in the corrosion of steel. Pereira AS, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):414-21

Functional expression of two forms of rat acyl-CoA oxidase and their substrate specificities. Setoyama C, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):482-7

Effect of different solubilizing agents on the aggregation state and catalytic activity of two purified rabbit cytochrome P450 isozymes, CYP1A2 (LM4) and CYP2B4 (LM2). Viner RI, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):886-91

Reductase domain cysteines 1048 and 1114 are critical for catalytic activity of human endothelial cell nitric oxide synthase as probed by site-directed mutagenesis. Zhang JL, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):293-300

Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Hara A, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):373-6

Characterization of rat 5alpha-reductases type 1 and type 2 expressed in Saccharomyces cerevisiae. Poletti A, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1047-52

Protochlorophyllide reductase in photosynthetic prokaryotes and its role in chlorophyll synthesis. Rowe JD, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):417-24

Glutathione regulates 3,3',4,4'-tetrachlorobiphenyl induced cytochrome P450 metabolism: evidence for a cross-talk between the two major detoxication pathways. Otto DM, et al. **Biochem Mol Biol Int** 1996 May;38(6):1127-33

Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Baez S, et al. **Biochem Mol Med** 1995 Feb;54(1):12-8

Hepatic peroxisome proliferation in vitamin A-deficient mice without a simultaneous increase in peroxisomal acyl-CoA oxidase activity. Sohlenius AK, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):821-7

Reduction of dihydroxyphenylacetic acid by a novel enzyme in the rat brain. Xu CL, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1333-7

7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Yamazaki H, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):313-9

A study of the stabilization of semiquinones by the Escherichia coli quinol oxidase cytochrome bd. Hastings SF, et al. **Biochem Soc Trans** 1996 Feb;24(1):131-2

Binding of NO to the oxygen reaction site of cytochrome bd from Azotobacter vinelandii. Jünemann S, et al. **Biochem Soc Trans** 1996 Feb;24(1):38S

Studies of the redox properties of CDP-6-deoxy-L-threo-D-glycero-4-hexulose-3-dehydrase (E1) and CDP-6-deoxy-L-threo-D-glycero-4-hexulose-3-dehydrase reductase (E3): two important enzymes involved in the biosynthesis of ascarylose. Burns KD, et al. **Biochemistry** 1996 Jun 18;35(24):7879-89

Kinetics of the reductive half-reaction of the iron-sulfur flavoenzyme CDP-6-deoxy-L-threo-D-glycero-4-hexulose-3-dehydrase reductase. Gassner GT, et al. **Biochemistry** 1996 Jun 18;35(24):7752-61

Preparation and characterization of a truncated form of phthalate dioxygenase reductase that lacks an iron-sulfur domain. Gassner GT, et al. **Biochemistry** 1995 Oct 17; 34(41):13460-71

Proximity mapping the surface of a membrane protein using an artificial protease: demonstration that the quinone-binding domain of subunit I is near the N-terminal region of subunit II of cytochrome bd. Ghaim JB, et al. **Biochemistry** 1995 Sep 12;34(36):11311-5

Reconstitution of the second step in NO synthesis using the isolated oxygenase and reductase domains of macrophage NO synthase. Ghosh DK, et al. **Biochemistry** 1995 Sep 12; 34(36):11316-20

A suggested mechanism for the catalytic cycle of cytochrome bd terminal oxidase based on kinetic analysis. Jünemann S, et al. **Biochemistry** 1995 Nov 14;34(45):14861-7

Hydroxybenzoyl-CoA reductase: coupling kinetics and electrochemistry to derive enzyme mechanisms. el Kasmi A, et al. **Biochemistry** 1995 Sep 19;34(37):11668-77

Methionine-393 is an axial ligand of the heme b558 component of the cytochrome bd ubiquinol oxidase from Escherichia coli. Kaysser TM, et al. **Biochemistry** 1995 Oct 17;34(41):13491-501

Flavin-dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 1. Purification and enzymatic activities of overexpressed AhpF and AhpC proteins. Poole LB, et al. **Biochemistry** 1996 Jan 9;35(1):56-64

Flavin-dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 2. Cystine disulfides involved in catalysis of peroxide reduction. Poole LB. **Biochemistry** 1996 Jan 9;35(1):65-75

Interaction of an engineered [3Fe-4S] cluster with a menaquinol binding site of Escherichia coli DMSO reductase. Rothery RA, et al. **Biochemistry** 1996 Mar 12; 35(10):3247-57

Oxidation of phenols, anilines, and benzenethiols by fungal laccases: correlation between activity and redox potentials as well as halide inhibition. Xu F. **Biochemistry** 1996 Jun 11;35(23):7608-14

Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions. Berks BC, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):97-173 (625 ref.)

Cholesterol biosynthesis from lanosterol: regulation and purification of rat hepatic sterol 14-reductase. Kim CK, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):39-48

Oscillations in the peroxidase-oxidase reaction: a comparison of different peroxidases. Kummer U, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):397-403

Ascorbate is the major electron donor for a transmembrane oxidoreductase of human erythrocytes. May JM, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):127-36

NADPH oxidase activity of cytochrome P-450 BM3 and its constituent reductase domain. Munro AW, et al. **Biochim Biophys Acta** 1995 Oct 10;1231(3):255-64

Electrophoretic evidence for the impairment of complexes of the respiratory chain during iron/ascorbate induced peroxidation in isolated rat liver mitochondria. Reinheckel T, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):45-50

Channelling of dioxygen into the respiratory enzyme. Riistama S, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1-2):1-4

A study of a series of recombinant fungal laccases and bilirubin oxidase that exhibit significant differences in redox potential, substrate specificity, and stability. Xu F, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):303-11

Stereospecific dehydrogenation of (25R)- and (25S)-3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acids by acyl-CoA oxidase in rat liver light mitochondrial fraction. Ikegawa S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1041-4

Effects of dicarboxylic acids on fatty acid-metabolizing enzymes in cultured rat hepatocytes. Sato T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1768-9

Electron spin-lattice relaxation of the [Cu(1.5) ... Cu(1.5)] dinuclear copper center in nitrous oxide reductase. Pfenninger S, et al. **Biophys J** 1995 Dec;69(6):2761-9

Role of a laccase in the degradation of pentachlorophenol. Ricotta A, et al. **Bull Environ Contam Toxicol** 1996 Oct; 57(4):560-7

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. Haaz MC, et al. **Cancer Chemother Pharmacol** 1996;38(1):52-8

A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Horn EP, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug;4(5):529-33

Decreased levels of 13-hydroxyoctadecadienoic acid (13-HODE) dehydrogenase in neoplastic tissue of human colon biopsies. Silverman AL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):53-6

Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention. Buetler TM, et al. **Cancer Res** 1996 May 15;56(10):2306-13

Developmental changes in hepatic activation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rabbit. Rich KJ, et al. **Carcinogenesis** 1996 Mar;17(3):555-8

Lower levels of urinary 2-amino-3,8-dimethylimidazo[4,5-f]-quinoxaline (MeIQx) in humans with higher CYP1A2 activity. Sinha R, et al. **Carcinogenesis** 1995 Nov;16(11):2859-61

Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Smith TJ, et al. **Carcinogenesis** 1996 Apr;17(4):809-13

Why is DsbA such an oxidizing disulfide catalyst? Grauschopf U, et al. **Cell** 1995 Dec 15;83(6):947-55

Inducibility of ethoxyresorufin deethylase and UDP-glucuronosyltransferase activities in two human hepatocarcinoma cell lines KYN-2 and Mz-Hep-1. Abid A, et al. **Cell Biol Toxicol** 1996 Apr;12(2):115-23

Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon ortho-quinones produced by dihydrodiol dehydrogenase. Flowers-Geary L, et al. **Chem Biol Interact** 1996 Jan 5;99(1-3):55-72

Extra-adrenal effects of metyrapone include inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase: a model for 11-HSD I deficiency. Raven PW, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):637-44

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Lu Z, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):512-22

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Spigset O, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):399-403

Antioxidant enzymes of the human retina: effect of age on enzyme activity of macula and periphery. De La Paz MA, et al. **Curr Eye Res** 1996 Mar;15(3):273-8

Metabolism of 2-amino-alpha-carboline. A food-borne heterocyclic amine mutagen and carcinogen by human and rodent liver microsomes and by human cytochrome P4501A2. Raza H, et al. **Drug Metab Dispos** 1996 Apr; 24(4):395-400

Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Zhang Z, et al. **Drug Metab Dispos** 1995 Dec;23(12):1339-46

11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Jamieson PM, et al. **Endocrinology** 1995 Nov; 136(11):4754-61

Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Rafii F, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:17-9

Biochemical characterization of purified zeta-carotene desaturase from Anabaena PCC 7120 after expression in Escherichia coli. Albrecht M, et al. **Eur J Biochem** 1996 Feb 15;236(1):115-20

Reaction mechanism of thioredoxin: 3'-phospho-adenylylsulfate reductase investigated by site-directed mutagenesis. Berendt U, et al. **Eur J Biochem** 1995 Oct 1;233(1):347-56

The covalent linkage of a viologen to a flavoprotein reductase transforms it into an oxidase. Bes MT, et al. **Eur J Biochem** 1995 Oct 15;233(2):593-9

Benzoyl-coenzyme A reductase (dearomatizing), a key enzyme of anaerobic aromatic metabolism. ATP dependence of the reaction, purification and some properties of the enzyme from Thauera aromatica strain K172. Boll M, et al. **Eur J Biochem** 1995 Dec 15; 234(3):921-33

Dimethylsulfide:acceptor oxidoreductase from Rhodobacter sulfidophilus. The purified enzyme contains b-type haem and a pterin molybdenum cofactor. Hanlon SP, et al. **Eur J Biochem** 1996 Jul 15;239(2):391-6

Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline 5,6-dioxygenase from Comamonas testosteroni 63. The first two enzymes in quinoline and 3-methylquinoline degradation. Schach S, et al. **Eur J Biochem** 1995 Sep 1; 232(2):536-44

Molecular biological analysis of a bidirectional hydrogenase from cyanobacteria. Schmitz O, et al. **Eur J Biochem** 1995 Oct 1;233(1):266-76

Quinaldine 4-oxidase from Arthrobacter sp. Rü61a, a versatile procaryotic molybdenum-containing hydroxylase active towards N-containing heterocyclic compounds and aromatic aldehydes. Stephan I, et al. **Eur J Biochem** 1996 Feb 15;236(1):155-62

Rat pristanoyl-CoA oxidase. cDNA cloning and recognition of its C-terminal (SQL) by the peroxisomal-targeting signal 1 receptor. Vanhooren JC, et al. **Eur J Biochem** 1996 Jul 15;239(2):302-9

Differential subcellular distribution of rat prostatic steroid 5alpha-reductase isozyme activities. Span PN, et al. **Eur J Endocrinol** 1996 Mar;134(3):386-92

FAD is a further essential cofactor of the NAD(P)H and O2-dependent zeaxanthin-epoxidase. Büch K, et al. **FEBS Lett** 1995 Nov 27;376(1-2):45-8

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165-8 (48 ref.)

A fungal metabolite mediates degradation of non-phenolic lignin structures and synthetic lignin by laccase. Eggert C, et al. **FEBS Lett** 1996 Aug 5;391(1-2):144-8

Laccase-mediated formation of the phenoxazinone derivative, cinnabarinic acid. Eggert C, et al. **FEBS Lett** 1995 Dec 4;376(3):202-6

Divinyl ether synthase from garlic (Allium sativum L.) bulbs: sub-cellular localization and substrate regio-and stereospecificity. Grechkin AN, et al. **FEBS Lett** 1996 Jun 17;388(2-3):112-4

HiPiP oxido-reductase activity in membranes from aerobically grown cells of the facultative phototroph Rhodoferax fermentans. Hochkoeppler A, et al. **FEBS Lett** 1995 Nov 20;375(3):197-200

Altered P450 activity associated with direct selection for fungal azole resistance. Joseph-Horne T, et al. **FEBS Lett** 1995 Oct 30;374(2):174-8

Transacylase-like structure and its role in substrate channeling of 6-hydroxymellein synthase, a multifunctional polyketide biosynthetic enzyme in carrot cell extracts. Kurosaki F. **FEBS Lett** 1996 Jan 22;379(1):97-102

Peroxisomal beta-oxidation of 2-methyl-branched acyl-CoA esters: stereospecific recognition of the 2S-methyl compounds by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase. Van Veldhoven PP, et al. **FEBS Lett** 1996 Jun 10;388(1):80-4

Inhibition of the cytochrome bd-terminated NADH oxidase system in Escherichia coli K-12 by divalent metal cations. Beard SJ, et al. **FEMS Microbiol Lett** 1995 Sep 1; 131(2):205-10

A mutant of Pseudomonas aeruginosa that lacks c-type cytochromes has a functional cyanide-insensitive oxidase. Ray A, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):123-9

Degradation of chlorobiphenyls catalyzed by the bph-encoded biphenyl-2,3-dioxygenase and biphenyl-2,3-dihydrodiol-2,3-dehydrogenase of Pseudomonas sp. LB400. Seeger M, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):259-64

Identification of the 37-kd rat liver protein that forms an acetaldehyde adduct in vivo as delta 4-3-ketosteroid 5 beta-reductase. Zhu Y, et al. **Hepatology** 1996 Jan; 23(1):115-22

Reflectance enzyme histochemistry (REH): visualization of cerium-based and DAB primary reaction products of phosphatases and oxidases in cryostat sections by confocal laser scanning microscopy. Halbhuber KJ, et al. **Histochem Cell Biol** 1996 Mar;105(3):239-49

In situ determination of different dehydrogenase activity profiles in the linings of odontogenic keratocysts and radicular cysts. Mason GI, et al. **Histochem J** 1996 Mar; 28(3):187-93

Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Kall MA, et al. **Hum Exp Toxicol** 1995 Oct;14(10):801-7

Non-enzymatic and enzymatic activation of mitomycin C: identification of a unique cytosolic activity. Joseph P, et al. **Int J Cancer** 1996 Jan 17;65(2):263-71

Cytochrome cb-type nitric oxide reductase with cytochrome c oxidase activity from Paracoccus denitrificans ATCC 35512. Fujiwara T, et al. **J Bacteriol** 1996 Apr; 178(7):1866-71

Characterization of 2-ketoisovalerate ferredoxin oxidoreductase, a new and reversible coenzyme A-dependent enzyme involved in peptide fermentation by hyperthermophilic archaea. Heider J, et al. **J Bacteriol** 1996 Feb;178(3):780-7

Identification of a novel gene of pyrimidine nucleotide biosynthesis, pyrDII, that is required for dihydroorotate dehydrogenase activity in Bacillus subtilis. Kahler AE, et al. **J Bacteriol** 1996 Aug;178(16):5013-6

Maleylacetate reductases in chloroaromatic-degrading bacteria using the modified ortho pathway: comparison of catalytic properties. Müller D, et al. **J Bacteriol** 1996 Jan; 178(1):298-300

Carboxyl-terminal processing of the cytoplasmic NAD-reducing hydrogenase of Alcaligenes eutrophus requires the hoxW gene product. Thiemermann S, et al. **J Bacteriol** 1996 Apr;178(8):2368-74

Expression and kinetic properties of a recombinant 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzyme of human liver. Deyashiki Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):285-90

sn-glycerol-1-phosphate dehydrogenase in Methanobacterium thermoautotrophicum: key enzyme in biosynthesis of the enantiomeric glycerophosphate backbone of ether phospholipids of archaebacteria. Nishihara M, et al. **J Biochem (Tokyo)** 1995 May; 117(5):933-5

Subunit 8 of the Saccharomyces cerevisiae cytochrome bc1 complex interacts with succinate-ubiquinone reductase complex. Bruel C, et al. **J Bioenerg Biomembr** 1996 Feb; 28(1):59-68

Regulation of alternative oxidase activity in higher plants. Day DA, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):379-85 (41 ref.)

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387-96 (47 ref.)

Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367-77 (70 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263-74 (70 ref.)

Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397-406 (64 ref.)

Use of flavin photochemistry to probe intraprotein and interprotein electron transfer mechanisms. Tollin G. **J Bioenerg Biomembr** 1995 Jun;27(3):303-9

Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration. Albury MS, et al. **J Biol Chem** 1996 Jul 19;271(29):17062-6

Mutational analysis of photosystem I polypeptides. Role of PsaD and the lysyl 106 residue in the reductase activity of the photosystem I. Chitnis VP, et al. **J Biol Chem** 1996 May 17;271(20):11772-80

L-tryptophan 2',3'-oxidase from Chromobacterium violaceum. Substrate specificity and mechanistic implications. Genet R, et al. **J Biol Chem** 1995 Oct 6; 270(40):23540-5

Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. Heath RJ, et al. **J Biol Chem** 1995 Nov 3;270(44):26538-42

EPR study of NO complex of bd-type ubiquinol oxidase from Escherichia coli. Hori H, et al. **J Biol Chem** 1996 Apr 19; 271(16):9254-8

Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp. strain 7. III. The archaeal novel respiratory complex II (succinate:caldariellaquinone oxidoreductase complex) inherently lacks heme group. Iwasaki T, et al. **J Biol Chem** 1995 Dec 29;270(52):30902-8

Chemical modification of the N-10 ribityl side chain of flavins. Effects on properties of flavoprotein disulfide oxidoreductases. Murthy YV, et al. **J Biol Chem** 1995 Dec 1;270(48):28586-94

Two hydrophobic subunits are essential for the heme b ligation and functional assembly of complex II (succinate-ubiquinone oxidoreductase) from Escherichia coli. Nakamura K, et al. **J Biol Chem** 1996 Jan 5; 271(1):521-7

Amphibacillus xylanus NADH oxidase and Salmonella typhimurium alkyl-hydroperoxide reductase flavoprotein components show extremely high scavenging activity for both alkyl hydroperoxide and hydrogen peroxide in the presence of S. typhimurium alkyl-hydroperoxide reductase 22-kDa protein component. Niimura Y, et al. **J Biol Chem** 1995 Oct 27;270(43):25645-50

A Chinese hamster mutant cell line with a defect in the integral membrane protein CII-3 of complex II of the mitochondrial electron transport chain. Oostveen FG, et al. **J Biol Chem** 1995 Nov 3;270(44):26104-8

Heme iron reduction and catalysis by a nitric oxide synthase heterodimer containing one reductase and two oxygenase domains. Siddhanta U, et al. **J Biol Chem** 1996 Mar 29; 271(13):7309-12

Cyanide-binding site of bd-type ubiquinol oxidase from Escherichia coli. Tsubaki M, et al. **J Biol Chem** 1995 Dec 1;270(48):28565-9

Rhodoquinone and complex II of the electron transport chain in anaerobically functioning eukaryotes. Van Hellemond JJ, et al. **J Biol Chem** 1995 Dec 29;270(52):31065-70

Inhibitor probes of the quinone binding sites of mammalian complex II and Escherichia coli fumarate reductase. Yankovskaya V, et al. **J Biol Chem** 1996 Aug 30; 271(35):21020-4

Changes in free radical-metabolizing enzymes and lipid peroxides in the liver of Long-Evans with cinnamon-like coat color rats. Ohhira M, et al. **J Gastroenterol** 1995 Oct; 30(5):619-23

Combined deficiencies of NADPH- and NADH-dependent dihydropyrimidine dehydrogenases, a new finding in a family with thymine-uraciluria. van Gennip AH, et al. **J Inherit Metab Dis** 1995;18(2):185-8

Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. Mattson MP, et al. **J Neurochem** 1995 Oct;65(4):1740-51

Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. Thiffault C, et al. **J Neurochem** 1995 Dec;65(6):2725-33

Tris(2,2'-bipyridyl)ruthenium(II)-mediated photoinduced electron transfer of engineered cytochrome P450 1A2. Nakano R, et al. **J Photochem Photobiol B** 1996 Feb; 32(3):171-6

Changes in lipid peroxide and antioxidant enzyme activities in corpora lutea during pseudopregnancy in rats. Shimamura K, et al. **J Reprod Fertil** 1995 Nov;105(2):253-7

Kinetic analysis of steroid 5alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. Span PN, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):103-8

Kinetic analysis of rat steroid 5alpha-reductase activity in prostate and epididymis homogenates at neutral pH: evidence for type I activity in epididymis. Span PN, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1-2):95-101

Ovarian carbonyl reductase delayed onset of persistent estrus in the offspring of parathyroidectomized mother rats. Inazu N, et al. **Jpn J Pharmacol** 1995 Sep;69(1):17-22

Flavinylation of succinate: ubiquinone oxidoreductase from Saccharomyces cerevisiae. Robinson KM, et al. **Methods Enzymol** 1995;260:34-51

Glutathione: dehydroascorbate oxidoreductases. Wells WW, et al. **Methods Enzymol** 1995;252:30-8

A light-induced protease from barley plastids degrades NADPH:protochlorophyllide oxidoreductase complexed with chlorophyllide. Reinbothe C, et al. **Mol Cell Biol** 1995 Nov;15(11):6206-12

5 alpha-reduced androgens play a key role in murine parturition. Mahendroo MS, et al. **Mol Endocrinol** 1996 Apr;10(4):380-92

A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria [see comments] Meissner PN, et al. **Nat Genet** 1996 May;13(1):95-7. Comment in: Nat Genet 1996 May;13(1):7-9.

Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: effects of vitamins E and C. Kavutcu M, et al. **Nephron** 1996; 72(2):269-74

Cytochrome P450 mediated reactions studied in genetically engineered V79 Chinese hamster cells. Doehmer J, et al. **Pharmacogenetics** 1995;5 Spec No:S91-6

Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme

activity. Eaton DL, et al. **Pharmacogenetics** 1995 Oct; 5(5):259–74 (128 ref.)

Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Ono S, et al. **Pharmacogenetics** 1995 Jun;5(3):143–50

Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Yokoi T, et al. **Pharmacogenetics** 1995;5 Spec No:S65–9

Microsomal function in hepatitis B surface antigen healthy carriers: assessment of cytochrome P450 1A2 activity by the 14C–caffeine breath test. Horsmans Y, et al. **Pharmacol Toxicol** 1995 Oct;77(4):247–9

A novel, soluble form of phytoene desaturase from Narcissus pseudonarcissus chromoplasts is Hsp70–complexed and competent for flavinylation, membrane association and enzymatic activation. Al–Babili S, et al. **Plant J** 1996 May; 9(5):601–12

Distinct roles for light–dependent NADPH:protochlorophyllide oxidoreductases (POR) A and B during greening in higher plants. Runge S, et al. **Plant J** 1996 Apr;9(4):513–23

Violaxanthin de–epoxidase. Rockholm DC, et al. **Plant Physiol** 1996 Feb;110(2):697–703

Chromosomal localization of the mammalian peptide–methionine sulfoxide reductase gene and its differential expression in various tissues. Moskovitz J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3205–8

Mercuric ion reduction and resistance in transgenic Arabidopsis thaliana plants expressing a modified bacterial merA gene. Rugh CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3182–7

Crystal structure of the membrane–exposed domain from a respiratory quinol oxidase complex with an engineered dinuclear copper center [see comments] Wilmanns M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11955–9 . Comment in: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11949–51.

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.). Comment on: Science 1996 Mar 15;271(5255):1552–7.

A permease–oxidase complex involved in high–affinity iron uptake in yeast [see comments] Stearman R, et al. **Science** 1996 Mar 15;271(5255):1552–7. Comment in: Science 1996 Mar 15;271(5255):1510–2.

Molybdenum bolsters the bioinorganic brigade [comment] Stiefel EI. **Science** 1996 Jun 14;272(5268):1599–600. Comment on: Science 1996 Jun 14;272(5268):1615–21.

[5–alpha–reductases: physiology and pathology] Mowszowicz I, et al. **Ann Endocrinol (Paris)** 1995; 56(6):555–9 (27 ref.) (Eng. Abstr.) **(Fre)**

[Population study of dihydropyrimidine dehydrogenase in cancer patients] Etienne MC, et al. **Bull Cancer (Paris)** 1995 Sep;82(9):705–10 (Eng. Abstr.) **(Fre)**

[Effect of estradiol on 5 alpha–reductase activity in osteoblast–like cell (UMR106–01)] Suwa H, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Jul 20;71(5):651–8 (Eng. Abstr.) **(Jpn)**

[Erythrocytic enzymatic systems and their antioxidative potential in pregnant women undergoing labor induction with intracervical PGE2] Cruz AS, et al. **Acta Med Port** 1995 Jul–Aug;8(7–8):415–8 (Eng. Abstr.) **(Por)**

[Frequency and phase matching changes in dihydroorotate dehydrogenase activity rhythm in rat peripheral blood lymphocytes with changes in the rhythm of solar activity and planet periods] Strigun LM, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):294–8 **(Rus)**

[Oxidases bd and bo as primary photoacceptors during exposure to low intensity visible monochromatic irradiation of Escherichia coli cells] Afanas'eva NI, et al. **Dokl Akad Nauk** 1995 Nov;345(3):404–6 **(Rus)**

[Oxidative metabolism changes in respiratory tract cells of guinea pigs during natural development of experimental tuberculosis and under specific chemotherapy] Kaminskaia GO, et al. **Probl Tuberk** 1996;(2):33–6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Patterson AV, et al. **Br J Cancer** 1995 Nov;72(5):1144–50

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71–93 (103 ref.)

A Ti plasmid–encoded enzyme required for degradation of mannopine is functionally homologous to the T–region–encoded enzyme required for synthesis of this opine in crown gall tumors. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3285–92

Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. Asai H, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1004–9

1–Methyl–4–phenyl–1,2,3,6–tetrahydropyridine (MPTP) is N–demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's disease. Coleman T, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):685–90

Inhibition of succinate:ubiquinone reductase and decrease of ubiquinol in nephrotoxic cysteine S–conjugate–induced oxidative cell injury. van de Water B, et al. **Mol Pharmacol** 1995 Nov;48(5):928–37

Cyp1a2(–/–) null mutant mice develop normally but show deficient drug metabolism. Liang HC, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1671–6

Non–iron porphyrins cause tumbling to blue light by an Escherichia coli mutant defective in hemG. Yang H, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2459–63

RADIATION EFFECTS

Effect of magnetic fields on rodent monooxygenase enzymes. Del Carratore R, et al. **Bioelectromagnetics** 1995; 16(5):324–9

OXIDOREDUCTASES, N–DEMETHYLATING

[Gene technology to overproduce the enzymes useful as diagnostic reagents] Sugiyama M, et al. **Rinsho Byori** 1995 Aug;43(8):765–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Evidence that cytochrome P–4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4–methyl pyrazole on ethanol elimination in the perfused rat liver. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):12A–16A

CYP2E1–mediated mechanism of anti–genotoxicity of the broccoli constituent sulforaphane. Barcelo S, et al. **Carcinogenesis** 1996 Feb;17(2):277–82

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo [see comments] von Moltke LL, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):104–12. Comment in: J Clin Psychopharmacol 1996 Apr;16(2):101–3.

CYP–2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat diet. Morimoto M, et al. **J Nutr** 1995 Dec;125(12):2953–64

Inactivation and degradation of human cytochrome P4502E1 by CCl4 in a transfected HepG2 cell line. Dai Y, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1614–22

Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Kharasch ED, et al. **Lancet** 1996 May 18;347(9012):1367–71

Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6–hydroxychlorzoxazone in rats. Chen L, et al. **Life Sci** 1996;58(18):1575–85

Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Thomsen MS, et al. **Pharmacol Toxicol** 1995 Jun;76(6):395–9

BIOSYNTHESIS

Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Dong J, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):254–9

Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Kostrubsky VE, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):516–20

High inducibility of mouse renal CYP2E1 gene by tobacco smoke and its possible effect on DNA single strand breaks. Seree EM, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):429–34

Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Vieira I, et al. **Eur J Biochem** 1996 Jun 1;238(2):476–83

Stable expression of human cytochrome P450 2E1 in V79 Chinese hamster cells. Schmalix WA, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):123–31

Biogenesis of the covalently flavinylated mitochondrial enzyme dimethylglycine dehydrogenase. Otto A, et al. **J Biol Chem** 1996 Apr 19;271(16):9823–9

Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. Roberts BJ, et al. **J Biol Chem** 1995 Dec 15;270(50):29632–5

Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6–hydroxychlorzoxazone in rats. Chen L, et al. **Life Sci** 1996;58(18):1575–85

Binding of the TorR regulator to cis–acting direct repeats activates tor operon expression. Simon G, et al. **Mol Microbiol** 1995 Sep;17(5):971–80

Expression, induction, and catalytic activity of the ethanol–inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. Carpenter SP, et al. **Mol Pharmacol** 1996 Feb;49(2):260–8

Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N–dimethylnitrosamine in cytotoxicity testing. Nakagawa T, et al. **Mutat Res** 1996 Aug 8; 360(3):181–6

Fasting for less than 24 h induces cytochrome P450 2E1 and 2B1/2 activities in rats. Brown BL, et al. **Toxicol Lett** 1995 Nov;81(1):39–44

Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Damme B, et al. **Toxicology** 1996 Jan 8;106(1–3):99–103

Effects of garlic oil on rat hepatic P4502E1 expression. Kwak MK, et al. **Xenobiotica** 1995 Nov;25(10):1021–9

CHEMISTRY

Flavinylation in wild–type trimethylamine dehydrogenase and differentially charged mutant enzymes: a study of the protein environment around the N1 of the flavin isoalloxazine. Mewies M, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):267–72

Dissection of the FMN–binding site in trimethylamine dehydrogenase. Mewies M, et al. **Biochem Soc Trans** 1995 Nov;23(4):509S

Kinetic model for the regulation by substrate of intramolecular electron transfer in trimethylamine dehydrogenase. Falzon L, et al. **Biochemistry** 1996 Feb 20; 35(7):2445–52

Discovery of a third coenzyme in sarcosine oxidase. Willie A, et al. **Biochemistry** 1995 Dec 26;34(51):16703–7

Sarcosine oxidase contains a novel covalently bound FMN. Willie A, et al. **Biochemistry** 1996 Apr 23;35(16):5292–9

The primary structure of Hyphomicrobium X dimethylamine dehydrogenase. Relationship to trimethylamine dehydrogenase and implications for substrate recognition. Yang CC, et al. **Eur J Biochem** 1995 Aug 15;232(1):264–71

Protein recognition of ammonium cations using side–chain aromatics: a structural variation for secondary ammonium ligands. Raine AR, et al. **Protein Sci** 1995 Dec;4(12):2625–8

DRUG EFFECTS

Interaction of theophylline and ipriflavone at the cytochrome P450 level. Monostory K, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar;20(1):43–7

GENETICS

P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers. Goasduff T, et al. **Alcohol** 1996 May–Jun;13(3):301–8

Cytochrome P4502E1 genotypes, alcoholism, and alcoholic cirrhosis in Han Chinese and Atayal Natives of Taiwan. Carr LG, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):43–6

CYP2E1 and ALDH2 genotypes and alcohol dependence in Japanese. Iwahashi K, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):564–6

Alcohol–metabolizing enzyme polymorphisms and alcoholism in Japan. Maezawa Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):951–4

Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P–4502E1 between alcoholics and nonalcoholics. Nakamura K, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):52–5

Use of lymphocytes for assessing ethanol–mediated alterations in the expression of hepatic cytochrome P4502E1. Raucy JL, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1369–75

Effect of the cytochrome P–450IIE1 genotype on ethanol elimination rate in alcoholics and control subjects. Ueno Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):17A–21A

Acetaminophen metabolism in patients with different cytochrome P–4502E1 genotypes. Ueshima Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):25A–28A

Transcriptional inhibition of cytochrome P4502E1 by a synthetic compound, YH439. Jeong KS, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):137–44

Maintenance and activation of Cyp2e–1 gene expression in mouse hepatocytes in primary culture. Sakurai J, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):35–40

No association between the c2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. Ball DM, et al. **Drug Alcohol Depend** 1995 Oct;39(3):181–4

Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Vieira I, et al. **Eur J Biochem** 1996 Jun 1;238(2):476–83

Cytochrome P450 2E1 and glutathione S–transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Yu MW, et al. **Gastroenterology** 1995 Oct; 109(4):1266–73

An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end–stage organ damage in a Chinese population. Chao YC, et al. **Hepatology** 1995 Nov;22(5):1409–14

Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. Yamauchi M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1136–42

Reaction of the C30A mutant of trimethylamine dehydrogenase with diethylmethylamine. Huang L, et al. **J Biol Chem** 1996 Jun 7;271(23):13401–6

Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case–control study of gastric cancer and liver disease. Kato S, et al. **Pharmacogenetics** 1995;5 Spec No:S141–4

Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Lucas D, et al. **Pharmacogenetics** 1995 Oct;5(5):298–304

Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pirmohamed M, et al. **Pharmacogenetics** 1995 Dec;5(6):351–7

CYP1A1 and CYP2E1 polymorphism and lung cancer,

case-control study in Rio de Janeiro, Brazil. Sugimura H, et al. **Pharmacogenetics** 1995;5 Spec No:S145-8

IMMUNOLOGY

Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Clot P, et al. **Gastroenterology** 1996 Jul;111(1):206-16

METABOLISM

Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. Koivisto T, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):207-12

Analysis of interaction between the Arthrobacter sarcosine oxidase and the coenzyme flavin adenine dinucleotide by site-directed mutagenesis. Nishiya Y, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2405-10

Ferritin stimulation of lipid peroxidation by microsomes after chronic ethanol treatment: role of cytochrome P4502E1. Kukielka E, et al. **Arch Biochem Biophys** 1996 Aug 1; 332(1):121-7

Anaerobic O-demethylations of methoxynaphthols, methoxyfuran, and fluoroanisols by Sporomusa ovata. Stupperich E, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):770-7

Validation of the (omega-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Amet Y, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1775-82

Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. Hakkak R, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):61-9

7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Yamazaki H, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):313-9

Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Yamazaki H, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):301-9

Dissection of the FMN-binding site in trimethylamine dehydrogenase. Mewies M, et al. **Biochem Soc Trans** 1995 Nov;23(4):509S

Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Hildesheim A, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):607-10

Rat liver epithelial cells express functional cytochrome P450 2E1. Lerche C, et al. **Carcinogenesis** 1996 May;17(5):1101-6

Oxidation of 1,2-epoxy-3-butene to 1,2:3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes. Seaton MJ, et al. **Carcinogenesis** 1995 Oct;16(10):2287-93

Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Dreisbach AW, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):498-505

Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Mitra AK, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):556-66

Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Garton KJ, et al. **Drug Metab Dispos** 1995 Dec;23(12):1426-30

Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Albano E, et al. **Hepatology** 1996 Jan;23(1):155-63

Different influences of two fractions of lung cytochrome b5 on reconstituted lung benzphetamine N-demethylase system. Arinç E, et al. **Int J Biochem Cell Biol** 1995 Oct; 27(10):1095-105

Reaction of the C30A mutant of trimethylamine dehydrogenase with diethylmethylamine. Huang L, et al. **J Biol Chem** 1996 Jun 7;271(23):13401-6

The reaction of trimethylamine dehydrogenase with electron transferring flavoprotein. Huang L, et al. **J Biol Chem** 1995 Oct 13;270(41):23958-65

Characterization and mechanism of the berberine bridge enzyme, a covalently flavinylated oxidase of benzophenanthridine alkaloid biosynthesis in plants. Kutchan TM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24475-81

Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. Montoliu C, et al. **J Neurochem** 1995 Dec;65(6):2561-70

The influence of aging on dimethylnitrosamine-demethylase enzyme kinetics in rat liver microsomes. Van Asten JG, et al. **Mech Ageing Dev** 1995 Aug 8;82(2-3):63-72

Expression of cytochrome P4502E1 in rat fetal hepatocyte culture. Wu D, et al. **Mol Pharmacol** 1996 May;49(5):802-7

Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Lucas D, et al. **Pharmacogenetics** 1995 Oct;5(5):298-304

Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Ono S, et al. **Pharmacogenetics** 1995 Jun;5(3):143-50

Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Yin H, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11076-80

The role of cytochrome P450 2E1 in the species-dependent biotransformation of 1,2-dichloro-1,1,2-trifluoroethane in rats and mice. Dekant W, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):200-7

CYP2E1-dependent bioactivation of 1,1-dichloroethylene in murine lung: formation of reactive intermediates and glutathione conjugates. Dowsley TF, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):42-8

Metabolic deglucuronidation and demethylation of estrogen conjugates as a source of parent estrogens and catecholestrogen metabolites in Syrian hamster kidney, a target organ of estrogen-induced tumorigenesis. Zhu BT, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):186-93

Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL. **Toxicology** 1995 Dec 28;105(2-3):217-24 (48 ref.)

Sex, organ and species specific bioactivation of chloromethane by cytochrome P4502E1. Dekant W, et al. **Xenobiotica** 1995 Nov;25(11):1259-65

PHARMACOLOGY

Intestinal toxicity of acrylonitrile: in vitro metabolism by intestinal cytochrome P450 2E1. Subramanian U, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):1-8

PHYSIOLOGY

Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Romkes M, et al. **Carcinogenesis** 1996 May; 17(5):1057-62

Metabolism of organochlorine pesticides: the role of human cytochrome P450 3A4. Mehmood Z, et al. **Chemosphere** 1996 Aug;33(4):759-69

Role of CYP2E1 in the hepatotoxicity of acetaminophen. Lee SS, et al. **J Biol Chem** 1996 May 17;271(20):12063-7

The emerging role of cytochrome P450 3A in psychopharmacology. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):387-98 (173 ref.)

Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. Asai H, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1004-9

Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression. Kim SG, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1058-66

Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: reduction by CYP2E1 inhibition. Tuo J, et al. **Mutat Res** 1996 Jul 5;368(3-4):213-9

Cytochemical localization of the acetone-inducible cytochrome P-450 isoform, CYP2E1, in murine colonic epithelium. Park BC, et al. **Pharmacology** 1995 Jun; 50(6):339-47

OXIDOREDUCTASES, O-DEMETHYLATING

GENETICS

Identification of elements in the PDA1 promoter of Nectria haematococca necessary for a high level of transcription in vitro. Ruan Y, et al. **Mol Gen Genet** 1996 Jan 15; 250(1):29-38

Expression of the pisatin detoxifying genes (PDA) of Nectria haematococca in vitro and in planta. Hirschi K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):483-91

Nrs1, a repetitive element linked to pisatin demethylase genes on a dispensable chromosome of Nectria haematococca. Kim HG, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug; 8(4):524-31

OXIDOREDUCTASES, NADH, NADPH see **NADH, NADPH OXIDOREDUCTASES**

OXILAPINE see **LOXAPINE**

OXIMES

In vivo evaluation of leukocyte distribution by means of technetium 99m after intravenous administration of high doses of recombinant erythropoietin [letter] Bueml M, et al. **Am J Hematol** 1996 Apr;51(4):332

Correlation of 99mTc-HMPAO SPECT with EEG monitoring: prognostic value for outcome of epilepsy surgery in children. Lynch BJ, et al. **Brain Dev** 1995 Nov-Dec;17(6):409-417

Optimised interictal HMPAO-SPECT in the evaluation of partial epilepsies. Schmitz EB, et al. **Epilepsy Res** 1995 Jun; 21(2):159-67

Crystal structures and solution studies of oxime adducts of mitochondrial aspartate aminotransferase. Marković-Housley Z, et al. **Eur J Biochem** 1996 Mar 15; 236(3):1025-32

Stabilisation of high-activity 99mTc-d,l-HMPAO preparations with cobalt chloride and their biological behaviour. Mang'era KO, et al. **Eur J Nucl Med** 1995 Oct; 22(10):1163-72

Neuropsychological tests and [99mTc]-HM PAO SPECT in the diagnosis of Alzheimer's dementia. Villa G, et al. **J Neurol** 1995 Jun;242(6):359-66

Optimization of factors affecting the state of normality of a medical image. Houston AS, et al. **Phys Med Biol** 1996 Apr;41(4):755-65

ADMINISTRATION & DOSAGE

Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Dethloff LA, et al. **Food Chem Toxicol** 1996 Apr;34(4):407-22

ANALYSIS

[Detection of oxime-2-methyl-1-diethylamine butanone-3+ inhibitor in the workplace air by thin-layer chromatography] Ledovskikh NG. **Med Tr Prom Ekol** 1995;(6):24-5 (Eng. Abstr.) **(Rus)**

BLOOD

A comparative study of 99Tcm-d,l-HMPAO and 99Tcm-d,l-CBPAO as leukocyte-labelling agents. Tsai CS, et al. **Nucl Med Commun** 1996 Jan;17(1):76-9

CHEMICAL SYNTHESIS

Synthesis and muscarinic M3 pharmacological activities of 1-azabicyclo[2.2.2]octan-3-one oxime derivatives. Plate R, et al. **Bioorg Med Chem** 1996 Feb;4(2):239-45

Syntheses and anti-inflammatory activities of O-acyloximes. II. Katagi T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):145-9

(E)-(arylmethyleneaminoxy)acetamides as analogues of neuroleptic benzamides: synthesis and D2-dopaminergic binding affinity. Macchia M, et al. **Farmaco** 1995 Oct; 50(10):719-24

Fungicidal activity of arylfurylketoximes. Massolini G, et al. **Farmaco** 1996 Apr;51(4):287-92

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site. Cai SX, et al. **J Med Chem** 1996 Aug 16;39(17):3248-55

CHEMISTRY

On the mechanism of nitric oxide formation upon oxidative cleavage of C = N(OH) bonds by NO-synthases and cytochromes P450. Mansuy D, et al. **Biochimie** 1995; 77(7-8):661-7 (28 ref.)

Determination of cobalt in vegetable animal foodstuffs by differential pulse adsorptive voltammetry using alpha-benzil dioxime. Giroussi S, et al. **Sci Total Environ** 1995 Dec 22;176(1-3):135-9

DIAGNOSTIC USE

A spurious description of hyperfixation of HMPAO [letter] Patterson J, et al. **AJNR Am J Neuroradiol** 1996 May; 17(5):998-9; discussion 999-1000

Combined study of 99mTc-HMPAO SPECT and computerized electroencephalographic topography (CET) in patients with medically refractory complex partial epilepsy. Rodrigues M, et al. **Ann Nucl Med** 1996 Feb; 10(1):113-8

Case report: chronic mesenteric ischaemia as a cause of abnormal bowel uptake of labelled leucocytes. Ingram G, et al. **Br J Radiol** 1995 Oct;68(814):1126-7

Technetium-99m-HMPAO labelled leucocytes in the detection and monitoring of inflammatory bowel disease in children. Jewell FM, et al. **Br J Radiol** 1996 Jun; 69(822):508-14

Validation of 99Tcm-HMPAO leucocyte scintigraphy in ulcerative colitis by comparison with histology. Middleton SJ, et al. **Br J Radiol** 1995 Oct;68(814):1061-6

99mTc-HMPAO brain single photon emission computerized tomography in mitochondrial encephalomyopathies. Yen TC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):287-91

Tc-99m HMPAO brain SPECT compared to CT and EEG after seizures in childhood. Alper E, et al. **Clin Nucl Med** 1995 Sep;20(9):803-6

Tc-99m HMPAO brain SPECT in frontal cortex dysfunction. A case of subcortico-cortical diaschisis. Huguet M, et al. **Clin Nucl Med** 1995 Aug;20(8):736-7

Supine lung clearance of Tc-99m DTPA and HMPAO aerosols. Kao CH, et al. **Clin Nucl Med** 1995 Jul;20(7):633-5

Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease. Kao CH, et al. **Clin Nucl Med** 1995 Sep;20(9):813-6

Brain SPECT imaging with Tc-99m HMPAO in hepatic encephalopathy. Mouratidis B, et al. **Clin Nucl Med** 1995 Sep;20(9):842

Evaluation of cerebral blood flow in patients with idiopathic orthostatic hypotension using Tc-99m HMPAO brain SPECT during postural testing. Odano I, et al. **Clin Nucl Med** 1995 Sep;20(9):807-9

Diminished Tc-99m HMPAO pulmonary uptake in ex-smokers. Shih WJ, et al. **Clin Nucl Med** 1995 Sep; 20(9):788-91

Marked lung uptake of Tc-99m HMPAO in a polysubstance-abusing marijuana and tobacco smoker. Shih WJ, et al. **Clin Nucl Med** 1996 Feb;21(2):156

Bilateral diffuse hypoperfusion of posterior temporoparietals and occipitals in Tc-99m HMPAO brain SPECT in a patient with noncommunicating hydrocephalus. Shih WJ, et al. **Clin Nucl Med** 1996 Mar;21(3):252-5

Importance of the lateral view in the evaluation of suspected brain death. Spieth M, et al. **Clin Nucl Med** 1995 Nov; 20(11):965-8

Ipsilateral lymph node uptake of Tc-99m HMPAO WBC in two men with foot infections. Vento JA, et al. **Clin Nucl Med** 1996 May;21(5):422–3

Anti-granulocyte immunoscintigraphy and [99mTc]hexamethylpropyleneamine-oxime-labeled leukocyte scintigraphy in inflammatory bowel disease. Papos M, et al. **Dig Dis Sci** 1996 Feb;41(2):412–20

Monitoring sodium methohexital distribution with [99mTc]HMPAO with single photon emission computed tomography during Wada test. Coubes P, et al. **Epilepsia** 1995 Oct;36(10):1041–9

Ictal HMPAO-single photon emission computed tomography findings in reading epilepsy in a Japanese boy. Miyamoto A, et al. **Epilepsia** 1995 Nov;36(11):1161–3

Partial epileptic seizure with versive movements examined by [99m Tc] HM-PAO brain single photon emission computed tomography: an early post study analyzed by computerized brain atlas methods. Weder B, et al. **Epilepsia** 1996 Jan;37(1):68–75

99Tcm-HMPAO labelled leucocytes and their biodistribution in the horse: a preliminary investigation [see comments] Butson RJ, et al. **Equine Vet J** 1995 Jul; 27(4):313–5. Comment in: Equine Vet J 1995 Jul;27(4):242–4.

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul; 27(4):242–4 (20 ref.). Comment on: Equine Vet J 1995 Jul;27(4):313–5.

Uptake of technetium-99m hexamethylpropylene amine oxime labelled white cells in lymph nodes involved in non-Hodgkin's lymphoma. AL-Nahhas AM, et al. **Eur J Nucl Med** 1995 Dec;22(12):1453–6

Upregulation of granulocyte CD11b (CR 3) after labelling with technetium-99m hexamethylpropylene amine oxime. Almer S, et al. **Eur J Nucl Med** 1995 Sep;22(9):1039–41

Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leucocytes than with antigranulocyte antibodies. Almers S, et al. **Eur J Nucl Med** 1996 Mar;23(3):247–55

Abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease. Alonso JC, et al. **Eur J Nucl Med** 1996 Mar;23(3):243–6

Brain single-photon emission tomography with technetium-99m hexamethylpropylene amine oxime in adolescents with initial-stage schizophrenia. Batista JF, et al. **Eur J Nucl Med** 1995 Nov;22(11):1274–7

18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus. Grünwald F, et al. **Eur J Nucl Med** 1995 Sep;22(9):1073–7

Optimum tomographic reconstruction parameters for HMPAO brain SPET imaging: a practical approach based on subjective and objective indexes. Kotzki PO, et al. **Eur J Nucl Med** 1995 Jul;22(7):671–7

Chronic osteomyelitis: diagnosis with technetium-99m-d, l-hexamethylpropylene amine oxime labelled leucocytes. Krznaric E, et al. **Eur J Nucl Med** 1996 Jul;23(7):792–7

Simultaneous administration of 111In-human immunoglobulin and 99mTc-HMPAO labelled leucocytes in inflammatory bowel disease. Mairal L, et al. **Eur J Nucl Med** 1995 Jul;22(7):664–70

Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease. Mariani G, et al. **Eur J Nucl Med** 1996 Apr;23(4):466–70

A quantitative approach to technetium-99m ethyl cysteinate dimer: a comparison with technetium-99m hexamethylpropylene amine oxime. Matsuda H, et al. **Eur J Nucl Med** 1995 Jul;22(7):633–7

The use of technetium-99m hexamethylpropylene amine oxime labelled granulocytes with single-photon emission tomography imaging in the detection and follow-up of recurrence of infective endocarditis complicating transvenous endocardial pacemaker. Ramackers JM, et al. **Eur J Nucl Med** 1995 Nov;22(11):1351–4

Effects of non-linear flow and spatial orientation on technetium-99m hexamethylpropylene amine oxime single-photon emission tomography. Stapleton SJ, et al. **Eur J Nucl Med** 1995 Sep;22(9):1009–16

Validation of automated brain contour determination in normal and abnormal cerebral single-photon emission tomography. van Elmbt LR, et al. **Eur J Nucl Med** 1995 Jun;22(6):537–42

Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods. Mansfield JC, et al. **Gut** 1995 Nov; 37(5):679–83

Comparison of 99m technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess. Weldon MJ, et al. **Gut** 1995 Oct;37(4):557–64

Myocardial kinetics of technetium-99m teboroxime in the presence of postischemic injury, necrosis and low flow reperfusion. Beanlands RS, et al. **J Am Coll Cardiol** 1996 Aug;28(2):487–94

Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography. Martin WR, et al. **J Neuroimaging** 1995 Oct;5(4):227–32

Teboroxime is a marker of reperfusion after myocardial infarction. Heller LI, et al. **J Nucl Cardiol** 1996 Jan-Feb; 3(1):2–8

Assessment of reperfusion after acute myocardial infarction: is there a role for acute technetium 99m-teboroxime imaging? [editorial] Sinusas AJ. **J Nucl Cardiol** 1996 Jan-Feb;3(1):82–5

Technetium-99m-HMPAO SPECT in Sturge-Weber syndrome. Bar-Sever Z, et al. **J Nucl Med** 1996 Jan; 37(1):81–3

What is the predictive value of increased technetium-99m-HMPAO uptake for brain survival/necrosis in the acute stage of ischemic stroke? [letter; comment] Baron JC, et al. **J Nucl Med** 1995 Dec; 36(12):2392–4. Comment on: J Nucl Med 1994 Jul;35(7):1097–103.

HMPAO as a regional cerebral blood flow tracer at high flow levels. Duncan R, et al. **J Nucl Med** 1996 Apr; 37(4):661–4

Maladaptation of vascular response in frontal area of patients with orthostatic hypotension. Hayashida K, et al. **J Nucl Med** 1996 Jan;37(1):1–4

Oxido-reductive state: the major determinant for cellular retention of technetium-99m-HMPAO. Jacquier-Sarlin MR, et al. **J Nucl Med** 1996 Aug;37(8):1413–6

Cerebral perfusion imaging evaluates pharmacologic treatment of unilateral moyamoya disease. Kuroki M, et al. **J Nucl Med** 1996 Jan;37(1):84–6

Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. Oyen WJ, et al. **J Nucl Med** 1996 Aug;37(8):1392–7

Leukocyte scintigraphy to assess disease activity in inflammatory bowel disease [letter; comment] Papós M, et al. **J Nucl Med** 1996 Feb;37(2):400. Comment on: J Nucl Med 1994 Mar;35(3):451–5.

HMPAO SPECT to assess neurologic deficits during balloon test occlusion. Ryu YH, et al. **J Nucl Med** 1996 Apr; 37(4):551–4

The role of biphasic scintigraphy with 99mTc-HMPAO leukocytes in detection of synthetic vascular graft infections--preliminary results. Davidović B, et al. **Med Pregl** 1993;46 Suppl 1:23–5

99mTc HM-PAO brain perfusion SPECT in brain death. Bonetti MG, et al. **Neuroradiology** 1995 Jul;37(5):365–9

BATO complexes derived from dimethoxy dioximes: synthesis, characterization and biodistribution. Ramalingam K, et al. **Nucl Med Biol** 1995 Jul;22(5):625–34

Imaging infection and inflammation in an African environment: comparison of 99Tcm-HMPAO-labelled leukocytes and 67Ga-citrate. Bester MJ, et al. **Nucl Med Commun** 1995 Jul;16(7):599–607

99Tcm-HMPAO SPET and 1H-MRS (proton magnetic resonance spectroscopy) in patients with ischaemic cerebral infarction. Lauriero F, et al. **Nucl Med Commun** 1996 Feb; 17(2):140–6

Serial changes in regional blood flow in the cerebrum and cerebellum of stroke patients imaged by 99Tcm-HMPAO SPET. Lin WY, et al. **Nucl Med Commun** 1996 Mar; 17(3):208–11

Dual-tracer autoradiography using 125I-iomazenil and 99Tcm-HMPAO in experimental brain ischaemia. Matsuda H, et al. **Nucl Med Commun** 1995 Jul;16(7):581–90

Brain death: the evaluation of semi-quantitative parameters and other signs in HMPAO scintigraphy. Mrhac L, et al. **Nucl Med Commun** 1995 Dec;16(12):1016–20

Gallbladder visualization in 99Tcm-HMPAO autologous white cell scintigraphy. Neilly JB, et al. **Nucl Med Commun** 1996 Mar;17(3):243–5

A high-efficiency, rapid and multi-dose procedure for white blood cell labelling with 99Tcm-HMPAO. Ozker K, et al. **Nucl Med Commun** 1996 Apr;17(4):342–5

Falsely negative 99mTc-antigranulocyte immunoscintigraphy and positive 99mTc-HMPAO-labelled leukocyte scan in active Crohn's disease. Possible effects of immunosuppressive therapy? Ivančević V, et al. **Nuklearmedizin** 1995 Dec;34(6):248–51

Failure of technetium-99m hexamethylpropylene amine oxime leukocyte scintigraphy in the evaluation of children with suspected appendicitis. Kanegaye JT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):285–90

Postoperative infections after neurosurgery and cardiosurgery: the value of labelled white blood cells. Sacchetti GM, et al. **Q J Nucl Med** 1995 Dec;39(4):274–9

SPECT using 99mTc-HMPAO versus neurological scales to predict outcome of acute cerebral infarction [letter; comment] Baron JC, et al. **Stroke** 1996 Jul;27(7):1253–4. Comment on: Stroke 1996 Jan;27(1):82–6.

Single-photon emission computed tomography using hexamethylpropyleneamine oxime in the prognosis of acute cerebral infarction [see comments] Bowler JV, et al. **Stroke** 1996 Jan;27(1):82–6. Comment in: Stroke 1996 Jul;27(7):1253–4.

Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc-HMPAO SPECT and acetazolamide in childhood Moyamoya disease. Touho H, et al. **Stroke** 1996 Feb;27(2):282–9

99mTc-HMPAO labeled leukocyte SPECT in intracranial lesions. Kim DG, et al. **Surg Neurol** 1995 Oct;44(4):338–45

[Scintigraphy using leukocytes marked with 99m-Tc-HMPAO in Crohn's disease] Dhôte R, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5–6):353–63 (Eng. Abstr.) **(Fre)**

[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Quantitative changes in cerebral blood flow of Shy-Drager syndrome induced by upright position: assessment by 99mTc-HMPAO] Gomi T, et al. **Kaku Igaku** 1995 Nov; 32(11):1255–8 (Eng. Abstr.) **(Jpn)**

[Investigation of discrepancy between 99mTc-HMPAO and 133Xe rCBF SPECT; a comparative study with X-ray CT findings] Komatani A, et al. **Kaku Igaku** 1995 Sep; 32(9):989–96 (Eng. Abstr.) **(Jpn)**

[Normal cerebral perfusion of 99mTc-HMPAO brain SPECT—evaluation by ananatomical standardization technique] Koyama M, et al. **Kaku Igaku** 1995 Sep; 32(9):969–77 (Eng. Abstr.) **(Jpn)**

[Comparison of cerebral vasoreactivity to acetazolamide in normal volunteer among 123I-IMP, 99mTc-ECD and 99mTc-HMPAO] Makino K, et al. **Kaku Igaku** 1996 May; 33(5):551–5 (Eng. Abstr.) **(Jpn)**

[Evaluation of the clinical usefulness of super dynamic 99mTc-HM-PAO SPECT in ischemic cerebrovascular disease—detection of hypo- and hyperperfusion area] Toyama H, et al. **Kaku Igaku** 1996 May;33(5):521–9 (Eng. Abstr.) **(Jpn)**

[Usefulness of change ratio map in 99mTc-HMPAO SPECT with acetazolamide enhancement] Yamamoto N. **Kaku Igaku** 1996 Apr;33(4):399–408 (Eng. Abstr.) **(Jpn)**

[Single photon emission tomography in temporal epilepsy: interictal and ictal studies with visual and semi quantitative analysis] Yacubian EM, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–A):369–83 (Eng. Abstr.) **(Por)**

IMMUNOLOGY

A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Rose K, et al. **Mol Immunol** 1995 Oct;32(14–15):1031–7

METABOLISM

Involvement of cytochrome P450 in oxime production in glucosinolate biosynthesis as demonstrated by an in vitro microsomal enzyme system isolated from jasmonic acid-induced seedlings of Sinapis alba L. Du L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12505–9

PHARMACOKINETICS

Clinical significance of increased uptake of HMPAO on brain SPECT scans in acute stroke. Alexandrov AV, et al. **J Neuroimaging** 1996 Jul;6(3):150–5

Sequential bioactivation of methoxime analogs of beta-adrenergic antagonists in the eye. Bodor N, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):305–18

A high-efficiency, rapid and multi-dose procedure for white blood cell labelling with 99Tcm-HMPAO. Ozker K, et al. **Nucl Med Commun** 1996 Apr;17(4):342–5

PHARMACOLOGY

Syntheses and anti-inflammatory activities of O-acyloximes. II. Katagi T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):145–9

Salicylaldoxime blocks K+ and Ca2+ currents in rat cardiac myocytes. Karhu S, et al. **Eur J Pharmacol** 1995 Jun 6; 279(1):7–13

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site. Cai SX, et al. **J Med Chem** 1996 Aug 16;39(17):3248–55

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Weller T, et al. **J Med Chem** 1996 Aug 2;39(16):3139–47

Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Polgar P, et al. **Life Sci** 1995;56(14):1207–13

Oxime-induced reactivation of acetylcholinesterase inhibited by phosphoramidates. Jokanović M, et al. **Toxicol Lett** 1996 Apr;85(1):35–9

THERAPEUTIC USE

A comparison of trimedoxime, obidoxime, pralidoxime and HI-6 in the treatment of oral organophosphorus insecticide poisoning in the rat. Jokanović M, et al. **Arch Toxicol** 1995; 70(2):119–23

Effects of MCI-727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models. Tachibana I, et al. **Pancreas** 1996 Mar;12(2):165–72

TOXICITY

Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Dethloff LA, et al. **Food Chem Toxicol** 1996 Apr;34(4):407–22

OXIMETRY

Time to equilibration of oxygen saturation using pulse oximetry. Gruber P, et al. **Acad Emerg Med** 1995 Sep; 2(9):810–5

Continuous noninvasive determination of pulsus paradoxus: a pilot study. Steele DW, et al. **Acad Emerg Med** 1995 Oct;2(10):894–900

The influence of patent blue V on pulse oximetry and

haemoximetry. Larsen VH, et al.
Acta Anaesthesiol Scand Suppl 1995;107:53–5
Can we prove the benefits of monitoring? Møller JT.
Acta Anaesthesiol Scand Suppl 1995;107:287–9
Notes on the apparent discordance of pulse oximetry and multi-wavelength haemoglobin photometry. Nijland R, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:49–52
From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al.
Acta Anaesthesiol Scand Suppl 1995;107:95–100 (28 ref.)
Can prehospital personnel detect hypoxemia without the aid of pulse oximeters? Brown LH, et al.
Am J Emerg Med 1996 Jan;14(1):43–4
Pulse oximeter analysis of peripheral cyanosis distal to an AV fistula. Pesola GR, et al. **Am J Emerg Med** 1996 May; 14(3):268–9
Intrapartum fetal pulse oximetry: past, present, and future. Dildy GA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):1–9 (57 ref.)
Pulse oximetry for an adult with a pulmonary disorder. Hogan BM. **Am J Occup Ther** 1995 Nov–Dec; 49(10):1062–4
Detection of cerebral venous desaturation by continuous jugular bulb oximetry following acute neurotrauma [see comments] Lewis SB, et al. **Anaesth Intensive Care** 1995 Jun;23(3):307–14. Comment in: Anaesth Intensive Care 1996 Feb;24(1):123–5.
Cerebral oximetry: a useful monitor during carotid artery surgery [see comments] Duncan LA, et al. **Anaesthesia** 1995 Dec;50(12):1041–5. Comment in: Anaesthesia 1996 Jun;51(6):610–1.
Pulse oximetry during cardiopulmonary resuscitation [letter] Griffin M, et al. **Anaesthesia** 1995 Nov;50(11):1008
Acrylic nails and pulse oximemtry [letter] Edelist G.
Anesth Analg 1995 Oct;81(4):884–5
Signal extraction technology: a better mousetrap? [editorial; comment] Pollard V, et al. **Anesth Analg** 1996 Aug; 83(2):213–4. Comment on: Anesth Analg 1996 Aug;83(2):269–72.
Validation in volunteers of a near-infrared spectroscope for monitoring brain oxygenation in vivo. Pollard V, et al. **Anesth Analg** 1996 Feb;82(2):269–77
Predictors of pulse oximetry data failure. Reich DL, et al. **Anesthesiology** 1996 Apr;84(4):859–64
Pulse oximetry monitoring: blinded by the light, lulled by the beeps [letter] Nathan SD, et al. **Ann Emerg Med** 1995 Nov;26(5):661
Use of pulse oximetry for assessing ulnar collateral flow [letter] Kruse JA. **Ann Intern Med** 1996 Sep 15;125(6):522
Cerebral oxygenation measured by near-infrared spectroscopy: comparison with jugular bulb oximetry. Daubeney PE, et al. **Ann Thorac Surg** 1996 Mar;61(3):930–4
Intraoperative determination of intestinal viability by pulse oximetry. Tollefson DF, et al. **Ann Vasc Surg** 1995 Jul; 9(4):357–60
Uses and abuses of pulse oximetry. Moyle JT.
Arch Dis Child 1996 Jan;74(1):77–80 (14 ref.)
The role of pulse oximetry. Its use as an indicator of severe respiratory disease in Peruvian children living at sea level. Respiratory Group in Peru. Madico G, et al.
Arch Pediatr Adolesc Med 1995 Nov;149(11):1259–63
Practical pulse oximetry. Overnight oximetry is easy and useful [letter; comment] Deegan PC, et al. **BMJ** 1995 Nov 11;311(7015):1302. Comment on: BMJ 1995 Aug 5;311(7001):367–70.
Practical pulse oximetry. Saturation can be normal with dangerously high pCO2 [letter; comment] Robbins PM, et al. **BMJ** 1995 Nov 11;311(7015):1302. Comment on: BMJ 1995 Aug 5;311(7001):367–70.
Uses and limitations of pulse oximetry [letter] Oyewole D, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):222
Uses and limitations of pulse oximetry. Stoneham MD.
Br J Hosp Med 1995 Jun 21–Jul 11;54(1):35–41 (21 ref.)
Effect of routine emergency department triage pulse oximetry screening on medical management. Mower WR, et al. **Chest** 1995 Nov;108(5):1297–302
Overnight pulse oximetry in normal children and in children undergoing adenotonsillectomy. Owen GO, et al.
Clin Otolaryngol 1996 Feb;21(1):59–65
Overnight pulse oximetry in snoring and non-snoring children. Owen GO, et al. **Clin Otolaryngol** 1995 Oct; 20(5):402–6
Oximetry and capnography during sedation for transesophageal echocardiography. Tobias JD, et al.
Clin Pediatr (Phila) 1995 Oct;34(10):565–6
Accuracy of pulse oximetry in hypothermic neonates and infants undergoing cardiac surgery. Iyer P, et al.
Crit Care Med 1996 Mar;24(3):507–11
Cerebral oxygenation monitoring by near-infrared spectroscopy is not clinically useful in patients with severe closed-head injury: a comparison with jugular venous bulb oximetry. Lewis SB, et al. **Crit Care Med** 1996 Aug; 24(8):1334–8
Intrapartum fetal pulse oximetry: present and future. Elchalal U, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):131–7 (33 ref.)
Computer assisted pulse oximetry for detecting children with obstructive sleep apnea syndrome. Vavrina J.
Int J Pediatr Otorhinolaryngol 1995 Nov;33(3):239–48
End-tidal oxygen concentration and pulse oximetry for monitoring oxygenation during intratracheal jet ventilation. Baer GA, et al. **J Clin Monit** 1995 Nov;11(6):373–80
Limitations of forehead pulse oximetry. Jørgensen JS, et al. **J Clin Monit** 1995 Jul;11(4):253–6
The use of midazolam with pulse oximetry in the drug-assisted interview. Marcum JM. **J Clin Psychiatry** 1996 Mar;57(3):111–3
The use of pulse oximetry in the emergency department [editorial] Panacek EA. **J Emerg Med** 1995 Nov–Dec; 13(6):816–7
Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.). Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.
Pulse oximetry for vascular monitoring [editorial; comment] Sternbach G, et al. **J Emerg Med** 1995 Nov–Dec; 13(6):815–6. Comment on: J Emerg Med 1995 Nov–Dec;13(6):753–6.
SjvO2 monitoring in head-injured patients. Robertson CS, et al. **J Neurotrauma** 1995 Oct;12(5):891–6
Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)
Correlation between NIR spectroscopy and pulse oximetry in the fetus. Seelbach-Göbel B. **J Perinat Med** 1996; 24(1):69–75
Multiple scattering effect in transmission pulse oximetry. Fine I, et al. **Med Biol Eng Comput** 1995 Sep;33(5):709–12
Correlation of jugular venous oxygen saturation to spontaneous fluctuations of cerebral perfusion pressure in patients with severe head injury. Murr R, et al.
Neurol Res 1995 Oct;17(5):329–33
Pulse oximetry monitoring during non-sedated upper gastrointestinal endoscopy. Melleney EM, et al.
Postgrad Med J 1995 Jul;71(837):433–4
A successful protocol for the use of pulse oximetry to classify arterial oxygenation into four fuzzy categories. Sailors RM, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:248–52
Can pulse oximetry detect raised intracompartmental pressure? Mars M, et al. **S Afr J Surg** 1994 Jun;32(2):48–50
Cerebral oximetry in patients undergoing carotid endarterectomy under regional anesthesia [letter] Fearn SJ, et al. **Stroke** 1996 Aug;27(8):1436–7
Cerebral oximetry in patients undergoing carotid endarterectomy under regional anesthesia. Samra SK, et al. **Stroke** 1996 Jan;27(1):49–55
Validation of British Thoracic Society guidelines for the diagnosis of the sleep apnoea/hypopnoea syndrome: can polysomnography be avoided? Ryan PJ, et al. **Thorax** 1995 Sep;50(9):972–5
Pulse oximetry for assessing oxygen status of neonatal calves [letter] Norton J, et al. **Vet Rec** 1996 Apr 6;138(14):340
[The use of pulse oximetry in prilocaine induced methemoglobinemia] Rudlof B, et al. **Anaesthesist** 1995 Dec;44(12):887–91 (Eng. Abstr.) **(Ger)**
[Cerebral monitoring with trancranial doppler-sonography and cerebrovenous oximetry during resuscitation] von Knobelsdorff G, et al. **Anaesthesist** 1995 Oct;44(10):705–8 (Eng. Abstr.) **(Ger)**
-Diagnostic shunt oximetry of atrial septal defect in adulthood- Preisack MB, et al. **Z Kardiol** 1996 Feb; 85(2):90–6 (Eng. Abstr.) **(Ger)**
[Accuracy of a pulse oximeter during hypoxia] Tachibana C, et al. **Masui** 1996 Apr;45(4):479–82 (Eng. Abstr.) **(Jpn)**
[Prognostic value of nocturnal pulse-oximetry in patients with chronic obstructive pulmonary disease treated with oxygen at home] Gorzelak K. **Pol Arch Med Wewn** 1995 Dec;94(6):475–81 (Eng. Abstr.) **(Pol)**
[Use of cerebral oximetry in early diagnosis of cerebral ischemia in neurosurgical patients with cerebrovascular diseases] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):55–9 (Eng. Abstr.) **(Rus)**
[Alarming lack of knowledge of pulse oximetry (letter)] Götell P. **Lakartidningen** 1995 Nov 29;92(48):4541–2 **(Swe)**

ADVERSE EFFECTS

Digital sensory loss without pulse oximeter malfunction [letter; comment] Donahue PJ, et al. **Anesth Analg** 1995 Dec;81(6):1312. Comment on: Anesth Analg 1995 Apr;80(4):855.
Avoid rubber fingers [letter] Metz S. **Anesth Analg** 1996 Jan; 82(1):217
Skin burn associated with pulse oximetry during perioperative photodynamic therapy. Farber NE, et al.
Anesthesiology 1996 Apr;84(4):983–5
[Skin lesions caused by oxygen saturation monitor probe: pathogenetic considerations concerning 2 neonatal cases] Trevisanuto D, et al. **Pediatr Med Chir** 1995 Jul–Aug; 17(4):373–4 (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

A comparative study of two near infrared spectrophotometers for the assessment of cerebral haemodynamics. Colier WN, et al.
Acta Anaesthesiol Scand Suppl 1995;107:101–5
The accuracy of a fiberoptic oximeter over a wide range of arterial oxygen saturation values in piglets. Nijland R, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:71–6
From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al.
Acta Anaesthesiol Scand Suppl 1995;107:95–100 (28 ref.)
Transcranial cerebral oximetry and carotid cavernous fistula occlusion. Technical note. Dujovny M, et al.
Acta Neurochir (Wien) 1995;133(1–2):83–6
Use of transcranial cerebral oximetry to monitor regional cerebral oxygen saturation during neuroendovascular procedures. Hernandez-Avila G, et al.
AJNR Am J Neuroradiol 1995 Sep;16(8):1618–25
Near infrared spectroscopy [letter] Duncan LA, et al.
Anaesthesia 1996 Jul;51(7):710–1
Movement and pulse oximetry [letter; comment] [see comments] Miller DE. **Anaesthesia** 1995 Sep;50(9):831. Comment on: Anaesthesia 1995 May;50(5):423–6. Comment in: Anaesthesia 1996 Jan;51(1):94–95.
Digital sensory loss without pulse oximeter malfunction [letter; comment] Donahue PJ, et al. **Anesth Analg** 1995 Dec;81(6):1312. Comment on: Anesth Analg 1995 Apr;80(4):855.
Clinical evaluation of a prototype motion artifact resistant pulse oximeter in the recovery room [see comments] Dumas C, et al. **Anesth Analg** 1996 Aug;83(2):269–72. Comment in: Anesth Analg 1996 Aug;83(2):213–4.
Cost-effective buccal oximetry [letter] Groudine SB.
Anesthesiology 1996 Feb;84(2):484
Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67–75 (60 ref.)
The use of a critikon cerebral redox research monitor model 2001 for assessing tissue viability during reconstructive surgery. Thorniley MS, et al. **Biochem Soc Trans** 1995 Nov; 23(4):526S
Validation of the Edslab dual lumen oximetry catheter for continuous monitoring of jugular bulb oxygen saturation after severe head injury. Souter MJ, et al.
Br J Anaesth 1996 May;76(5):744–6
Oximetry catheters in diagnostic heart catheterization in children. Oxhøj H. **Cardiology** 1995;86(5):384–7
Role of oximeter error in the diagnosis of shunts. Shepherd AP, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):435–46
Negative methaemoglobin results obtained with the IL 482 CO-Oximeter [letter] Doelman CJ, et al.
Eur J Clin Chem Clin Biochem 1996 Jan;34(1):63
Interference in a pulse oximeter from a nerve stimulator. Block FE Jr, et al. **J Clin Monit** 1995 Nov;11(6):392–3
Accuracy of continuous jugular bulb venous oximetry during intracranial surgery. Gunn HC, et al.
J Neurosurg Anesthesiol 1995 Jul;7(3):174–7
Subcutaneous tissue oxygen pressure: a reliable index of peripheral perfusion in humans after injury. Drucker W, et al. **J Trauma** 1996 Mar;40(3 Suppl):S116–22
Development of a portable tissue oximeter using near infra-red spectroscopy. Shiga T, et al.
Med Biol Eng Comput 1995 Jul;33(4):622–6
Somanetics INVOS 3100 cerebral oximeter [letter; comment] Dujovny M, et al. **Neurosurgery** 1995 Jul;37(1):160. Comment on: Neurosurgery 1994 Oct;35(4):796.
A comparison of conventional versus electronic monitoring of sedated pediatric dental patients. Croswell RJ, et al.
Pediatr Dent 1995 Sep–Oct;17(5):332–9
Monitoring of nocturnal oxygen desaturation using pulse oximeter and apnomonitor in patients with chronic pulmonary disease. Miyahara Y, et al. **Respiration** 1995; 62(6):348–52
[Clinical results of pulse oximetry sub partu for measuring fetal arterial oxygen saturation] Butterwegge M, et al.
Geburtshilfe Frauenheilkd 1995 Nov;55(11):634–41 (Eng. Abstr.) **(Ger)**
[Evaluating pulse oximetry in the fetus. Case control study for detection of undesirable complications] Luttkus A, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):278–82 (Eng. Abstr.) **(Ger)**
[Value of measuring fetal oxygen saturation for reducing the need for fetal blood analysis in abnormal cardiotocogram. Experiences with 2 sensor generations of fetal reflexion pulse oximetry] Luttkus A, et al.
Gynakol Geburtshilfliche Rundsch 1995;35 Suppl 1:122–5 (Eng. Abstr.) **(Ger)**
[Fetal heart rate and pulse oximetry] Butterwegge M, et al.
Z Geburtshilfe Neonatol 1995 May–Jun;199(3):120–2 **(Ger)**

METHODS

Fetal pulse oximetry. A methodogical study. Maesel A, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):144–8
Two methods of measuring oxygen saturation: why the Bland and Altman statistical technique is necessary [letter; comment] Malagon I, et al. **Anaesth Intensive Care** 1996 Feb;24(1):123–5. Comment on: Anaesth Intensive Care 1995 Jun;23(3):307–14.
Another site for the pulse oximeter probe [letter] Cook TM, et al. **Anaesthesia** 1995 Dec;50(12):1096–7
Cerebral oximetry: a useful monitor during carotid artery surgery [letter; comment] Fearn SJ, et al. **Anaesthesia** 1996 Jun;51(6):610–1. Comment on: Anaesthesia 1995 Dec;50(12):1041–5.
Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. Vinogradov SA, et al. **Biophys J** 1996 Apr;70(4):1609–17
Assessment of cerebral pO2 by EPR oximetry in rodents: effects of anesthesia, ischemia, and breathing gas. Liu KJ, et al. **Brain Res** 1995 Jul 10;685(1–2):91–8
Comparison of oxygen saturation by pulse oximetry and co-oximetry during exercise testing in patients with COPD.

McGovern JP, et al. **Chest** 1996 May;109(5):1151–5
Reflectance pulse oximetry in neonates. Faisst K, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):117–22
The use of pulse oximetry in dentistry. Gandy SR. **J Am Dent Assoc** 1995 Sep;126(9):1274–6, 1278
Reflectance pulse oximetry at the forehead improves by pressure on the probe. Dassel AC, et al. **J Clin Monit** 1995 Jul;11(4):237–44
Development of biocompatible implants of fusinite for in vivo EPR oximetry. Gallez B, et al. **MAGMA** 1996 Mar; 4(1):71–5
Oximetry by dynamic nuclear polarization. Grucker D, et al. **Magn Reson Med** 1995 Aug;34(2):219–26
A computer algorithm for differentiating valid from distorted pulse oximeter waveforms in neonates. Adams JA, et al. **Pediatr Pulmonol** 1995 May;19(5):307–11
A dynamic phantom brain model for near-infrared spectroscopy. Kurth CD, et al. **Phys Med Biol** 1995 Dec; 40(12):2079–92
A simple and novel algorithm for time-resolved multiwavelength oximetry. Oda M, et al. **Phys Med Biol** 1996 Mar;41(3):551–62
The effect of overlying tissue on the spatial sensitivity profile of near-infrared spectroscopy. Okada E, et al. **Phys Med Biol** 1995 Dec;40(12):2093–108
Noninvasive mitigation of peripheral vasoconstriction [letter; comment] Freda JJ. **Reg Anesth** 1995 Nov–Dec;20(6):548–9 . Comment on: Reg Anesth 1995 Jan–Feb;20(1):82–3.
[Preliminary study of the use of fetal pulse oximetry during labor] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):756–62 (Eng. Abstr.) **(Fre)**
[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**
[Transcutaneous pulse oximetry] Gorzelak K. **Pneumonol Alergol Pol** 1995;63(7–8):460–8 (37 ref.) **(Pol)**
[Cerebral oximetry] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):85–90 (50 ref.) **(Rus)**

STANDARDS

Evaluation of pulse oximetry in sickle cell anemia patients presenting to the emergency department in acute vasoocclusive crisis. Comber JT, et al. **Am J Emerg Med** 1996 Jan;14(1):16–8
Comparing fetal pulse oximetry with scalp pH. Johnson N, et al. **J Reprod Med** 1995 Oct;40(10):717–20
The relationship between oxygen saturation and the clinical assessment of acutely wheezing infants and children. Alario AJ, et al. **Pediatr Emerg Care** 1995 Dec;11(6):331–39

VETERINARY

Evaluation of pulse oximetry in horses surgically treated for colic. Matthews NS, et al. **Equine Vet J** 1994 Mar; 26(2):114–6
[Oximetry in veterinary anesthesia: the continuous determination of mixed venous oxygen saturation in dogs and horses] Alef M, et al. **Tierarztl Prax** 1996 Apr; 24(2):117–28 (Eng. Abstr.) **(Ger)**

OXIMETRY, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

OXINE see **OXYQUINOLINE**

OXIPURINOL see **OXYPURINOL**

2-OXO ACID CARBOXY-LYASE see **PYRUVATE DECARBOXYLASE**

3-OXOACYL (ACYL CARRIER PROTEIN) SYNTHASE

ANTAGONISTS & INHIBITORS

Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. Heath RJ, et al. **J Biol Chem** 1996 May 3; 271(18):10996–1000

BIOSYNTHESIS

A jojoba beta-Ketoacyl-CoA synthase cDNA complements the canola fatty acid elongation mutation in transgenic plants. Lassner MW, et al. **Plant Cell** 1996 Feb;8(2):281–92

OXOCHOLESTEROLS see **KETOCHOLESTEROLS**

OXOGLUTARATES see **KETOGLUTARIC ACIDS**

OXONIC ACID

ADMINISTRATION & DOSAGE

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Shirasaka T, et al. **Cancer Res** 1996 Jun 1;56(11):2602–6

6-OXO-PGF1 ALPHA see **6-KETOPROSTAGLANDIN F1 ALPHA**

5-OXOPROLYL-PEPTIDASE see **PYROGLUTAMYL-PEPTIDASE I**

OXOPROPANAL see **PYRUVALDEHYDE**

6-OXOPROSTAGLANDIN F1 ALPHA see **6-KETOPROSTAGLANDIN F1 ALPHA**

OXOQUINOLINES see **QUINOLONES**

3-OXOSTEROID ISOMERASES see **STEROID ISOMERASES**

17-OXOSTEROIDS see **17-KETOSTEROIDS**

OXOSUCCINATES see **OXALOACETATES**

OXOTREMORINE

METABOLISM

Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes. Sharif NA, et al. **Neurochem Res** 1995 Jun;20(6):669–74

PHARMACOLOGY

Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Esqueda EE, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):643–58
Enhancement by nifedipine of cholinergic-induced depression of locomotor activity in mice. Sansone M, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):163–7
Ionic mechanisms involved in the regulation of insulin secretion by muscarinic agonists. Bordin S, et al. **J Membr Biol** 1995 Nov;148(2):177–84
Role of the stretch reflex in oxotremorine tremor. Decima EE. **Life Sci** 1996;58(22):2041–7
Amygdala beta-noradrenergic influences on memory storage involve cholinergic activation. Introini-Collison IB, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):57–64
Enhancement of the post-training cholinergic tone antagonizes the impairment of retention induced by a nitric oxide synthase inhibitor in mice. Kopf SR, et al. **Neurobiol Learn Mem** 1996 May;65(3):207–12
Stria terminalis lesions attenuate memory enhancement produced by intracaudate nucleus injections of oxotremorine. Packard MG, et al. **Neurobiol Learn Mem** 1996 May;65(3):278–82
Acetylcholine muscarinic M2 receptor stimulated [35S]GTP gamma S binding shows regional selective changes in Alzheimer's disease postmortem brain. Cowburn RF, et al. **Neurodegeneration** 1996 Mar;5(1):19–26
Effects of galanin on passive avoidance response, elevated plus-maze learning, and spontaneous alternation performance in mice. Ukai M, et al. **Peptides** 1995; 16(7):1283–6

TOXICITY

Method for screening drug and chemical effects in laboratory rats using computerized quantitative electroencephalography. Jones RD, et al. **Vet Hum Toxicol** 1995 Dec;37(6):521–7

OXPRENOLOL

ANALYSIS

Determination of analytical error function for beta-blockers as a possible weighting method for the estimation of the regression parameters. Modamio P, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):401–8

CHEMISTRY

Analysis of drug distribution in hydrogels using fourier transform infrared microscopy. am Ende MT, et al. **Pharm Res** 1995 Dec;12(12):2030–5

PHARMACOKINETICS

Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. Laethem ME, et al. **Chirality** 1995;7(8):616–22
Effect of probenecid on the enantioselective pharmacokinetics of oxprenolol and its glucuronides in the rabbit. Laethem ME, et al. **Pharm Res** 1995 Dec; 12(12):1964–7

PHARMACOLOGY

Chronic administration of oxprenolol and metoprolol attenuate sympathetic cardiovascular responses only in non-adrenalectomized pithed rats. Vila E, et al. **J Auton Pharmacol** 1995 Oct;15(5):393–402

OXYAMPHETAMINE see **P-HYDROXYAMPHETAMINE**

OXYBATE SODIUM see **SODIUM OXYBATE**

OXYCEPHALY see **CRANIOSYNOSTOSES**

OXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

OXYCHLOROQUINE see **HYDROXYCHLOROQUINE**

OXYCODEINON see **OXYCODONE**

OXYCODONE

PHARMACOKINETICS

Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Kaiko RF, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):52–61
The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. Kirvela M, et al. **J Clin Anesth** 1996 Feb;8(1):13–8

OXYETHYLENE OXYPROPYLENE POLYMER see **POLOXALENE**

OXYFEDRINE

PHARMACOKINETICS

Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Wetzelsberger N, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):185–91

OXYGEN

see related
ANOXEMIA
ANOXIA
HYPEROXIA

Increased Po2 alters the bioelectric properties of fetal distal lung epithelium. Pitkänen O, et al. **Am J Physiol** 1996 Jun; 270(6 Pt 1):L1060–6
The use of heliox and the laryngeal mask airway in a child with an anterior mediastinal mass. Polaner DM. **Anesth Analg** 1996 Jan;82(1):208–10
Color of compressed gas cylinders [letter] Priestley M. **Anesthesiology** 1996 Aug;85(2):445–6
Singlet oxygen (1 delta g) generation from coproporphyrin in Propionibacterium acnes on irradiation. Arakane K, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):578–82
Effects of fumonisin B1 on oxygen transport in membranes. Yin JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5; 225(1):250–5
Comparison of photosensitized plasma membrane damage caused by singlet oxygen and free radicals. Kochevar IE, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):223–30
Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Ullman EF, et al. **Clin Chem** 1996 Sep;42(9):1518–26
Positive and negative elements involved in the differential regulation by heme and oxygen of the HEM13 gene (coproporphyrinogen oxidase) in Saccharomyces cerevisiae. Amillet JM, et al. **Curr Genet** 1995 Nov; 28(6):503–11
Oxygen bubbling can improve the labelling of pentavalent technetium-99m dimercaptosuccinic acid. Kobayashi H, et al. **Eur J Nucl Med** 1995 Jun;22(6):559–62
Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. Lee R, et al. **J Appl Physiol** 1995 Jul;79(1):236–42
Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. Kharitonov VG, et al. **J Biol Chem** 1995 Nov 24;270(47):28158–64
Artifacts in functional magnetic resonance imaging from gaseous oxygen. Bates S, et al. **J Magn Reson Imaging** 1995 Jul–Aug;5(4):443–5
Photochemical formation of singlet molecular oxygen (1O2) in illuminated aqueous solutions of p-aminobenzoic acid (PABA). Allen JM, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):33–7
The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Guest JR. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29;350(1332):189–202 (61 ref.)
Oxygen-induced lung injury in the pre-term guinea pig: the role of leukotriene B4. Phillips GJ, et al. **Respir Med** 1995 Oct;89(9):607–13
Study of ejection fraction of professional divers during simulated diving in hyperbarism and various respiratory mixture. Badiu G, et al. **Rom J Physiol** 1993 Jul–Dec; 30(3–4):173–8
Study of heart rate of professional divers in hyperbarism during simulated diving in saturation with different respiratory mixture. Ceamitru N, et al. **Rom J Physiol** 1993 Jul–Dec;30(3–4):179–82
Assessment of oxygen supplementation during air travel. Cramer D, et al. **Thorax** 1996 Feb;51(2):202–3
Synthesis of high energy phosphates during cold ischemic rat liver preservation with gaseous oxygen insufflation. Minor T, et al. **Transplantation** 1996 Jan 15;61(1):20–2
[Comparison between the efficacy of oxygen and atmospheric air in sewage water purification installations] Tonelli E,

et al. **Ann Ig** 1994 Jul-Dec;6(4-6):945-52 (Eng. Abstr.) **(Ita)**

[Alterations of the brain stem and mid-latency evoked potentials under oxygen-nitrous oxide-sevoflurane anesthesia] Kadoi Y, et al. **Masui** 1995 Dec;44(12):1618-22 (Eng. Abstr.) **(Jpn)**

[The effect of the composition of an artificial gas environment under pressure up to 5.1 MPa on the oxidation-reduction reactions in the human body] Semko VV, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):76-82 (Eng. Abstr.) **(Rus)**

[The effect of acute hypoxia on the cytogenetic effect of cyclophosphamide in rat bone marrow cells, differing in resistance to oxygen deficiency] Bykovskaia NV, et al. **Genetika** 1995 Nov;31(11):1575-7 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Individual differences in ventilatory and HR responses to progressive hypoxia following 100% O2 exposure in humans. Honda Y, et al. **Adv Exp Med Biol** 1995;393:283-6

Ventilatory responses during ramp exercise in hyperoxia. Miyamoto Y, et al. **Adv Exp Med Biol** 1995;393:147-52

Investigation of central CO2-sensitivity around eucapnia in awake humans using a brief hypoxic stimulus. Roberts CA, et al. **Adv Exp Med Biol** 1995;393:347-50

Acute ventilatory response to ramp exercise while breathing hypoxic, normoxic, or hyperoxic air. Walsh ML, et al. **Adv Exp Med Biol** 1995;393:143-6

Endotracheal suctioning: ventilator vs manual delivery of hyperoxygenation breaths. Grap MJ, et al. **Am J Crit Care** 1996 May;5(3):192-7

Maternal oxygen administration and fetal well-being [letter] Adams TJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):974

Effect of varying inspired oxygen concentration on diaphragm glutathione metabolism during loaded breathing. Supinski GS, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1633-40

Intraoperative ventilation with air and oxygen during laparoscopic cholecystectomy decreases the degree of postoperative hypoxaemia. Fujii Y, et al. **Anaesth Intensive Care** 1996 Feb;24(1):42-4

The delivery of oxygen by a venturi T piece. Campbell DJ, et al. **Anaesthesia** 1996 Jun;51(6):558-60

Lung aeration. The effect of pre-oxygenation and hyperoxygenation during total intravenous anaesthesia. Reber A, et al. **Anaesthesia** 1996 Aug;51(8):733-7

Deliberate oxygen deprivation in children: ethical considerations [letter; comment] Coté CJ. **Anesth Analg** 1996 Mar;82(3):671-2. Comment on: Anesth Analg 1995 Jun;80(6):1248-9.

Total intravenous anesthesia and endotracheal oxygen insufflation for repair of tracheoesophageal fistula in an adult. Joynt GM, et al. **Anesth Analg** 1996 Mar;82(3):661-3

Preoxygenation technique is not ideal [letter; comment] Butler P, et al. **Anesthesiology** 1996 Jan;84(1):238-9. Comment on: Anesthesiology 1995 Aug;83(2):429.

Continuous oxygen insufflation using a speaking tracheostomy tube is effective in preventing aspiration during feeding. Naito Y, et al. **Anesthesiology** 1996 Feb; 84(2):448-50

Beneficial effects of oxfenicine on the hypoxic rat atria. Carregal M, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):45-9

Decrease of body temperature in armadillos experimentally covered by soil. Casanave EB, et al. **Arch Physiol Biochem** 1995 Apr;103(1):29-32

Bradycardia in armadillos experimentally covered with soil. Casanave EB, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):51-3

Development of bovine embryos in KSOM with added superoxide dismutase and taurine and with five and twenty percent O2. Liu Z, et al. **Biol Reprod** 1995 Oct;53(4):786-90

Fuzzy logic control of inspired isoflurane and oxygen concentrations using minimal flow anaesthesia. Curatolo M, et al. **Br J Anaesth** 1996 Feb;76(2):245-50

Dependence of pulmonary venous admixture on inspired oxygen fraction and time during regional hypoxia in the rabbit. O'Neill M, et al. **Br J Anaesth** 1995 Nov;75(5):603-9

Improving preoxygenation [letter; comment] Smith AF. **Br J Anaesth** 1996 May;76(5):748. Comment on: Br J Anaesth 1995 Dec;75(6):777-8.

Current concepts in the diagnosis and treatment of sudden sensorineural hearing loss. Schweinfurth JM, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):117-21

Five oxygen-nitrous oxide proportioning systems compared. Feigenwinter P, et al. **Eur J Anaesthesiol** 1996 Jan; 13(1):73-80

The influence of inspired oxygen on the oxygen uptake response to ramp exercise. Walsh ML, et al. **Eur J Appl Physiol** 1995;72(1-2):71-5

Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension. Horiuchi K, et al. **Exp Hematol** 1996 Jan;24(1):68-76

Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Dennery PA, et al. **Free Radic Biol Med** 1995 Oct;19(4):395-404

Prooxidant activity of beta-carotene under 100% oxygen pressure in rat liver microsomes. Palozza P, et al. **Free Radic Biol Med** 1995 Dec;19(6):887-92

The effect of hypothermic perfusion with oxygenated perfluorochemical during in situ extended hepatectomy of canine liver. Ohya T, et al. **J Am Coll Surg** 1996 Mar; 182(3):219-25

Use of a helium-oxygen mixture in the treatment of postextubation stridor in pediatric patients with burns. Rodeberg DA, et al. **J Burn Care Rehabil** 1995 Sep-Oct; 16(5):476-80

Potential risk associated with anesthesia machines with single oxygen cylinders [letter] McDade W, et al. **J Clin Anesth** 1996 May;8(3):260-1

Patient simulator identifies faulty H-cylinder. Euliano TY, et al. **J Clin Monit** 1995 Nov;11(6):394-5

Squid (Lolliguncula brevis) life in shallow waters: oxygen limitation of metabolism and swimming performance. Finke E, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):911-21

Altered oxygen tension modulates cytokine-induced signal transduction in polymorphonuclear leukocytes: regulation of the G PLC pathway. Derevianko A, et al. **J Surg Res** 1996 Apr;62(1):32-40

Experimental flail chest: ventilatory function with fixation of flail segment in internal and external position. Gyhra A, et al. **J Trauma** 1996 Jun;40(6):977-9

Carbon dioxide euthanasia in rats: oxygen supplementation minimizes signs of agitation and asphyxia. Coenen AM, et al. **Lab Anim** 1995 Jul;29(3):262-8

BLB oxygen mask and aviation [letter] Miller JM. **Mayo Clin Proc** 1995 Oct;70(10):1020

Duration of apnoea in anaesthetized children required for desaturation of haemoglobin to 95%: comparison of three different breathing gases. Kinouchi K, et al. **Paediatr Anaesth** 1995;5(2):115-9

Tumor oxygenation changes post-photodynamic therapy. Chen Q, et al. **Photochem Photobiol** 1996 Jan;63(1):128-31

Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Kaanders JH, et al. **Radiother Oncol** 1995 Dec;37(3):190-8

Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. van der Maazen RW, et al. **Radiother Oncol** 1995 May;35(2):118-22

Effect of exposure in vitro to ethanol and hypoxia on gamma-aminobutyric acid efflux in the hippocampus of the fetal and adult guinea-pig. Catlin MC, et al. **Reprod Fertil Dev** 1995;7(5):1339-44

Effect of 12 atmospheres helium-oxygen on the response of mice to convulsant drugs. Syapin PJ, et al. **Undersea Hyperb Med** 1996 Mar;23(1):35-41

[Postoperative ischemic ileocolitis in the elderly. Suggested therapy with intraluminal administration of oxygen and glutamine] Mangiante G, et al. **Chir Ital** 1994;46(6):80-5 (Eng. Abstr.) **(Ita)**

[The action of oxygen on Campylobacter pylori] Andreechkin IuA. **Klin Khir** 1995;(9-10):12-3 **(Rus)**

ADVERSE EFFECTS

Maternal oxygen administration and fetal well-being [letter] Adams TJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):974

Lung liquid clearance and Na,K-ATPase during acute hyperoxia and recovery in rats. Olivera WG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1229-34

Influence of inspired nitrogen concentration during anaesthesia for coronary artery bypass grafting on postoperative atelectasis. Joyce CJ, et al. **Br J Anaesth** 1995 Oct;75(4):422-7

An elevated level of copper zinc superoxide dismutase fails to prevent oxygen induced retinopathy in mice [see comments] Klaeger C, et al. **Br J Ophthalmol** 1996 May; 80(5):429-34. Comment in: Br J Ophthalmol 1996 May;80(5):387.

Evaluation of the risk of decompression sickness in saturated nitrox diving by examination of haemostasis. Olszański R, et al. **Bull Inst Marit Trop Med Gdynia** 1995;46(1-4):27-30

Basic fibroblast growth factor in fibrosing alveolitis induced by oxygen stress. Sannes PL, et al. **Chest** 1996 Mar;109(3 Suppl):44S-45S

Vaso-obliteration in the canine model of oxygen-induced retinopathy. McLeod DS, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):300-11

Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. McLeod DS, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1322-33

Lack of evidence for a role of mast cell degranulation in acute hypoxia/reoxygenation-induced injury in the isolated rat heart. van Haaster CM, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):363-73

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103-7 (83 ref.)

Toxic and therapeutic properties of oxygen--a review. Doležal V. **Sb Lek** 1995;96(3):231-4 (28 ref.)

ANALYSIS

Oxygraphy in spontaneously breathing subjects. Larsen VH, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:81-5

Preparation of solutions of dissolved hydrogen and oxygen gases using an anaerobic chamber. Axley MJ, et al. **Anal Biochem** 1996 Jul 1;238(2):211-3

Determination of gaseous and dissolved oxygen in a closed fat cell culture system. Böttcher H, et al. **Anal Biochem** 1995 Sep 1;230(1):149-53

Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: a phosphor with general application for measuring oxygen concentration in biological systems. Lo LW, et al. **Anal Biochem** 1996 Apr 5;236(1):153-60

Dual-analyte fiber-optic sensor for the simultaneous and continuous measurement of glucose and oxygen. Li L, et al. **Anal Chem** 1995 Oct 15;67(20):3746-52

Development of a submicrometer optical fiber oxygen sensor. Rosenzweig Z, et al. **Anal Chem** 1995 Aug 1;67(15):2650-4

Oxygen sensors based on luminescence quenching: interactions of pyrene with the polymer supports. Xu W, et al. **Anal Chem** 1995 Sep 15;67(18):3172-80

Characterization of carbon paste electrodes in vitro for simultaneous amperometric measurement of changes in oxygen and ascorbic acid concentrations in vivo. Lowry JP, et al. **Analyst** 1996 Jun;121(6):761-6

A method for the assessment of hypoxia in the arterial wall, with potential application in vivo. Björnheden T, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):178-85

Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. Vinogradov SA, et al. **Biophys J** 1996 Apr;70(4):1609-17

Intrapartum fetal cerebral near infrared spectroscopy: apparent change in oxygenation demonstrated in a non viable fetus. Hamilton RJ, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1004-7

Assessment of cerebral pO2 by EPR oximetry in rodents: effects of anesthesia, ischemia, and breathing gas. Liu KJ, et al. **Brain Res** 1995 Jul 10;685(1-2):91-8

Cerebral oxygenation monitoring by near-infrared spectroscopy is not clinically useful in patients with severe closed-head injury: a comparison with jugular venous bulb oximetry. Lewis SB, et al. **Crit Care Med** 1996 Aug; 24(8):1334-8

Anastomotic tissue oxygen tension during esophagectomy in patients with esophageal carcinoma. Jacobi CA, et al. **Eur Surg Res** 1996;28(1):26-31

Dopamine increases renal medullary blood flow without improving regional hypoxia. Heyman SN, et al. **Exp Nephrol** 1995 Nov-Dec;3(6):331-7

Singlet oxygen-trapping reaction as a method of (1)O2 detection: role of some reducing agents. Dzwigaj S, et al. **Free Radic Res** 1995 Aug;23(2):103-15

Influence of melanin on pO2 measurement in vitro and in vivo. Thomas CD, et al. **Int J Radiat Biol** 1996 Feb; 69(2):205-11

Differences between intracutaneous and transcutaneous skin oxygen tension in chronic venous insufficiency. Roszinski S, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):407-13

End-tidal oxygen concentration and pulse oximetry for monitoring oxygenation during intratracheal jet ventilation. Baer GA, et al. **J Clin Monit** 1995 Nov;11(6):373-80

EPR linewidth (T2) method to measure oxygen permeability of phospholipid bilayers and its use to study the effect of low ethanol concentrations. Smirnov AI, et al. **J Magn Reson B** 1996 May;111(2):149-57

Measurement of soft X-ray absorption spectra and elemental analysis in local regions of mammalian cells using an electronic zooming tube. Ito A, et al. **J Microsc** 1996 Jan; 181 (Pt 1):54-60

Adverse consequences of increased intra-abdominal pressure on bowel tissue oxygen. Bongard F, et al. **J Trauma** 1995 Sep;39(3):519-24; discussion 524-5

Testicular tissue oxygen pressure. Klotz T, et al. **J Urol** 1996 Apr;155(4):1488-91

Gaseous dynamics of the rabbit maxillary sinus. Mikula SK, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):152-5

In vivo PO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field. Thomas SR, et al. **Magn Reson Imaging** 1996;14(1):103-14

Use of EPR oximetry with India ink to measure the pO2 in the liver in vivo in mice. Nakashima T, et al. **Magn Reson Med** 1995 Dec;34(6):888-92

In vivo measurement of partial oxygen pressure in large vessels and in the reticuloendothelial system using fast 19F-MRI. Nöth U, et al. **Magn Reson Med** 1995 Nov; 34(5):738-45

Brain tissue oxygen pressure, carbon dioxide pressure and pH during ischemia. Hoffman WE, et al. **Neurol Res** 1996 Feb;18(1):54-6

Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry. Halpern HJ, et al. **Radiat Res** 1996 May;145(5):610-8

A potentially dangerous design fault in an oxygen analyser [letter; comment] James MF. **S Afr Med J** 1994 Nov; 84(11):779. Comment on: S Afr Med J 1994 Sep;84(9):633-4.

Brain tissue oxygen pressure, carbon dioxide pressure, and pH during hypothermic circulatory arrest. Hoffman WE, et al. **Surg Neurol** 1996 Jul;46(1):75-9

Superiority of HTK solution to UW solution for tissue oxygenation in living related liver transplantation. Hatano E, et al. **Transplant Proc** 1996 Jun;28(3):1880-1

[An innovative procedure of oxygen detection in medicine, biology, environmental research and biotechnology based on luminescence quenching] Barnikol WK, et al. **Biomed Tech (Berl)** 1996 Jun;41(6):170-7 (Eng. Abstr.) **(Ger)**

[Decreased oxygen content in the atmosphere--an ecological disaster imperceptibly sneaking up?] Moiseeva NI. **Aviakosm Ekolog Med** 1995;29(3):52-5 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Caffeine attenuates CNS oxygen toxicity in rats. Bitterman N, et al. **Brain Res** 1995 Oct 23;696(1-2):250-3

BLOOD

Time to equilibration of oxygen saturation using pulse oximetry. Gruber P, et al. **Acad Emerg Med** 1995 Sep; 2(9):810-5

Influence of age on circulation and arterial blood gases in man. Gunnarsson L, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):237-43

Autotransfusion after open heart surgery: the oxygen delivery capacity of shed mediastinal blood is maintained. Schmidt H, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):754-8

Central venous versus mixed venous oxygen content. Faber T. **Acta Anaesthesiol Scand Suppl** 1995;107:33-6

Blood gases, electrolytes and metabolic monitoring in children with acute failure of vital functions. Iluchev D, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:249-55

A maximal central venous oxygen saturation (SvO2max) for the surgical patient. Jenstrup M, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:29-32

The influence of patent blue V on pulse oximetry and haemoximetry. Larsen VH, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:53-5

The influence of arterial carbon dioxide on cerebral oxygenation and haemodynamics during ECMO in normoxaemic and hypoxaemic piglets. Liem KD, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:157-64

Oxygen availability in critical illness--an investigation using the oxygen status algorithm. Morgan J, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:185-7

Oxygen status during haemodialysis. The Cord-Group. Nielsen AL, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:195-200

The accuracy of a fiberoptic oximeter over a wide range of arterial oxygen saturation values in piglets. Nijland R, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:71-6

How far can we go with permissive hypercapnia? A case presentation and some biased comments with emphasis on maintaining normal haemoglobin level. Ohmura A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:209-13

Optimal values for oxygen transport during hypothermia in sepsis and ARDS. Pernerstorfer T, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:223-7

Homeostasis-securing therapy and statusmetria. Shifrin GA. **Acta Anaesthesiol Scand Suppl** 1995;107:257-9

Oxygen status algorithm, version 3, with some applications. Siggaard-Andersen M, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:13-20

The oxygen status of fetal blood. Siggaard-Andersen O, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:129-35

Oxygen and acid-base parameters of arterial and mixed venous blood, relevant versus redundant. Siggaard-Andersen O, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:21-7

Which blood gas caused the brain damage? Suwa K. **Acta Anaesthesiol Scand Suppl** 1995;107:215-8

Clinical assessment of oxygen delivery and consumption during hypotensive anaesthesia--a clinical application of The Deep Picture. Ueda N, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:189-93

Oxygen uptake/oxygen supply dependency: fact or fiction? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:229-37 (83 ref.)

Lactate, pH, and blood gas analysis in critically ill patients. Waldau T, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:267-71

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37-44 (54 ref.)

Adjustment of haemoglobin oxygen saturation measurements made with the Radiometer OSM3 for pH. Whyte RK. **Acta Anaesthesiol Scand Suppl** 1995;107:61-2

From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:95-100 (28 ref.)

Effects of intravenous nitroglycerin combined with dopamine on intracranial pressure and cerebral arteriovenous oxygen difference in patients with acute subarachnoid haemorrhage. Iwanaga H, et al. **Acta Neurochir (Wien)** 1995;136(3-4):175-80

Fetal pulse oximetry. A methodogical study. Maesel A, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):144-8

Respiratory compensation for the metabolic acidosis of severe exercise as a modulator of muscular capillary O2-unloading. Fukuba Y, et al. **Adv Exp Med Biol** 1995; 393:153-8

Phase-coupling of arterial blood gas oscillations and ventilatory kinetics during exercise in humans. Phase coupling and the exercise hyperpnoea. Ward SA, et al. **Adv Exp Med Biol** 1995;393:219-24

Oxygen desaturation on swallowing as a potential marker of aspiration in acute stroke. Zaidi NH, et al. **Age Ageing** 1995 Jul;24(4):267-70

Use of transcranial cerebral oximetry to monitor regional cerebral oxygen saturation during neuroendovascular procedures. Hernandez-Avila G, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1618-25

Susceptibility-weighted MR for evaluation of vasodilatory capacity with acetazolamide challenge. Ohnishi T, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):631-7

Alcohol-induced changes in blood gases, glucose, and lactate in pregnant and nonpregnant rats. Abel EL. **Alcohol** 1996 May-Jun;13(3):281-5

Ethanol increases uterine blood flow and fetal arterial blood oxygen tension in the near-term pregnant ewe. Reynolds JD, et al. **Alcohol** 1996 May-Jun;13(3):251-6

Effect of lateral position on arterial and venous blood gases in postoperative cardiac surgery patients. Banasik JL, et al. **Am J Crit Care** 1996 Mar;5(2):121-6

Supplemental oxygen during endoscopic variceal ligation: effects on arterial oxygenation and cardiac arrhythmia. Iwao T, et al. **Am J Gastroenterol** 1995 Dec;90(12):2186-90

Fibromyalgia syndrome: overnight falls in arterial oxygen saturation. Alvarez Lario B, et al. **Am J Med** 1996 Jul; 101(1):54-60

Umbilical cord blood acid-base state: what is normal? Helwig JT, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1807-12; discussion 1812-4

Oxygenation in fetal lambs supported by extrauterine right atrium to artery extracorporeal membrane oxygenation. Kamimura T, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):535-9

Relationship between placental histologic features and umbilical cord blood gases in preterm gestations. Salafia CM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1058-64

Umbilical plasma erythropoietin correlations with blood gases and gestational age in appropriately grown infants. Jazayeri A, et al. **Am J Perinatol** 1996 May;13(4):227-30

Effect of body position on the blood gases and ventilation volume of infants with chronic lung disease before and after feeding. Mizuno K, et al. **Am J Perinatol** 1995 Jul; 12(4):275-7

Resting oxygenation of rat and rabbit intestine: arteriolar and capillary contributions. Bohlen HG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1342-8

Effect of ACh and calmodulin inhibitor on O2 transfer from exocrine pancreatic microvessels of rats. Seiyama A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H1-7

Determination of PO2 and its heterogeneity in single capillaries. Zheng L, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H365-72

Interaction of decreased arterial PO2 and exercise on carbohydrate metabolism in the dog. Zinker BA, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E409-17

O2 supply dependence of respiration in patients with mitral stenosis undergoing valvuloplasty. Budinger GR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1034-40

Nocturnal saturation improves by target-flow inspiratory muscle training in patients with COPD. Heijdra YF, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):260-5

A physiologic basis for red blood cell transfusion decisions. Greenburg AG. **Am J Surg** 1995 Dec;170(6A Suppl):44S-48S

Abnormalities in oxygenation, coagulation, and fibrinolysis in colonic blood of horses with experimentally induced strangulation obstruction. Kawcak CE, et al. **Am J Vet Res** 1995 Dec;56(12):1642-50

A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Boyd O, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):478-84

A comparison of two transcutaneous monitors for the measurement of arterial PO2 and PCO2 in neonates. Carter B, et al. **Anaesth Intensive Care** 1995 Dec;23(6):708-14

Detection of cerebral venous desaturation by continuous jugular bulb oximetry following acute neurotrauma [see comments] Lewis SB, et al. **Anaesth Intensive Care** 1995 Jun;23(3):307-14. Comment in: Anaesth Intensive Care 1996 Feb;24(1):123-5.

Endothelin-1 concentrations and optimisation of arterial oxygenation and venous admixture by selective pulmonary artery infusion of prostaglandin E1 during thoracotomy. Chen TL, et al. **Anaesthesia** 1996 May;51(5):422-6

The effect of posture on late postoperative oxygenation. Mynster T, et al. **Anaesthesia** 1996 Mar;51(3):225-7

Improvement of arterial oxygen saturation with selective lobar bronchial block during hemorrhage in a patient with previous contralateral lobectomy. Campos JH, et al. **Anesth Analg** 1995 Nov;81(5):1095-6

The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. Lawrence CJ, et al. **Anesth Analg** 1996 Mar;82(3):544-50

Prone position and oxygenation [letter; comment] Nishikawa T. **Anesth Analg** 1996 Apr;82(4):885. Comment on: Anesth Analg 1995 May;80(5):955-60.

Validation in volunteers of a near-infrared spectroscope for monitoring brain oxygenation in vivo. Pollard V, et al. **Anesth Analg** 1996 Feb;82(2):269-77

Preventing desaturation during single-lung anesthesia [letter] Sheinbaum R. **Anesth Analg** 1996 May;82(5):1107

A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Wahr JA, et al. **Anesth Analg** 1996 Jan; 82(1):103-7

Jugular venous desaturation due to epidural hematoma after craniotomy. Walder B, et al. **Anesth Analg** 1996 Feb; 82(2):421-2

Effects of a novel hemoglobin-based oxygen carrier on percent oxygen saturation as determined with arterial blood gas analysis and pulse oximetry. Hughes GS, et al. **Ann Emerg Med** 1996 Feb;27(2):164-9

Cardiopulmonary bypass temperature, hematocrit, and cerebral oxygen delivery in humans. Cook DJ, et al. **Ann Thorac Surg** 1995 Dec;60(6):1671-7

Comparing two strategies of cardiopulmonary bypass cooling on jugular venous oxygen saturation in neonates and infants. Kern FH, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1198-202

The gastrointestinal tract: an underestimated organ as demonstrated in an experimental LVAD pig model. Miyama M, et al. **Ann Thorac Surg** 1996 Mar;61(3):817-22

Prediction of early outcome in resolving chronic lung disease of prematurity after discharge from hospital. Iles R, et al. **Arch Dis Child** 1996 Apr;74(4):304-8

Blood eosinophil counts and arterial oxygen tension in acute asthma. Spallarossa D, et al. **Arch Dis Child** 1995 Oct; 73(4):333-7

Effect of hydrocortisone treatment on oxygen metabolism and phagocytosis of peripheral blood neutrophils in asthmatic patients, sensitive and resistant to glucocorticosteroid therapy. Jankowska R, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5-6):383-6

Nitrosyl hemoglobin formation in-vivo after intravenous administration of a hemoglobin-based oxygen carrier in endotoxemic rats. Greenburg AG, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):271-6

Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):381-94 (29 ref.)

Intramolecular cross-linking of oxy hemoglobin by bis sulfosuccinimidyl suberate and sebacate: generation of cross-linked hemoglobin with reduced oxygen affinity. Manjula BN, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):311-8

Characterization of neo red cells (NRCs), their function and safety in vivo tests. Takahashi A. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):347-54

Monitoring of blood gases during prolonged experimental cardiopulmonary bypass and their relationship to brain pH, PO2, and PCO2. Briceno JC, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M344-50

Perfluorocarbons are effective oxygen carriers in cardiopulmonary bypass. Spruell RD, et al. **ASAIO J** 1995 Jul-Sep;41(3):M636-41

Improved gas exchange performance of the intravascular oxygenator by active blood mixing. Tao W, et al. **ASAIO J** 1994 Jul-Sep;40(3):M527-32

Inflight arterial saturation [letter; comment] Fowler B. **Aviat Space Environ Med** 1995 Nov;66(11):1119-20. Comment on: Aviat Space Environ Med 1995 Feb;66(2):126-30.

A comparison of visual and auditory reaction time and P300 latency thresholds to acute hypoxia. Fowler B, et al. **Aviat Space Environ Med** 1995 Jul;66(7):645-50

Rapid tracheal infusion of surfactant versus bolus instillation in rabbits: effects on oxygenation, blood pressure and surfactant distribution. Segerer H, et al. **Biol Neonate** 1996; 69(2):119-27

Role of nitric oxide in the regulation of the cerebral circulation in the lamb fetus during normoxemia and hypoxemia. van Bel F, et al. **Biol Neonate** 1995;68(3):200-10

Nonenzymatic glycation of transferrin: decrease of iron-binding capacity and increase of oxygen radical production. Fujimoto S, et al. **Biol Pharm Bull** 1995 Mar; 18(3):396-400

Increase in carotid body sensitivity during sustained hypoxia. Bisgard GE. **Biol Signals** 1995 Sep-Oct;4(5):292-7 (43 ref.)

Second messenger regulation of tyrosine hydroxylase gene expression in rat carotid body. Chen J, et al. **Biol Signals** 1995 Sep-Oct;4(5):277-85

Possible role of coupling between glomus cells in carotid body chemoreception. Eyzaguirre C, et al. **Biol Signals** 1995 Sep-Oct;4(5):263-70 (30 ref.)

Oxygen sensing in the carotid body. Gonzalez C, et al. **Biol Signals** 1995 Sep-Oct;4(5):245-56 (59 ref.)

Carotid body O2 chemoreception: respiratory and nonrespiratory aspects. Lahiri S. **Biol Signals** 1995 Sep-Oct; 4(5):257-62 (22 ref.)

G proteins in carotid body chemoreception. Prabhakar NR, et al. **Biol Signals** 1995 Sep-Oct;4(5):271-6

Compensated hemolytic anemia [letter; comment] Erslev AJ. **Blood** 1995 Nov 1;86(9):3612-3. Comment on: Blood 1994 Sep 15;84(6):1697-702.

Late systemic desaturation after total cavopulmonary shunt operations. Stümper O, et al. **Br Heart J** 1995 Sep; 74(3):282-6

Effects of changes in mean arterial pressure on SjO2 during cerebral aneurysm surgery. Moss E, et al. **Br J Anaesth** 1995 Nov;75(5):527-30

The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Brizel DM, et al. **Br J Cancer** 1995 Nov;72(5):1120-4

The effect of maternal epidural analgesia on fetal oxygen saturation. Johnson N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):776-8

Use of lightguide spectrophotometry to quantify skin oxygenation in a variable model of venous hypertension. Hanna GB, et al. **Br J Surg** 1995 Oct;82(10):1352-6

Assessment of splanchnic tissue oxygenation by gastric tonometry in patients undergoing laparoscopic and open cholecystectomy. Thaler W, et al. **Br J Surg** 1996 May; 83(5):620–4

Carbon dioxide analysers: accuracy, alarm limits and effects of interfering gases. Lauber R, et al. **Can J Anaesth** 1995 Jul;42(7):643–56

Anaerobic capacity: a maximal anaerobic running test versus the maximal accumulated oxygen deficit. Maxwell NS, et al. **Can J Appl Physiol** 1996 Feb;21(1):35–47

Short-term effects of postural drainage with clapping vs autogenic drainage on oxygen saturation and sputum recovery in patients with cystic fibrosis. Giles DR, et al. **Chest** 1995 Oct;108(4):952–4

Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Prielipp RC, et al. **Chest** 1996 May; 109(5):1291–301

The effect of norepinephrine and dobutamine on bladder epithelial oxygen tension. Rosser DM, et al. **Chest** 1995 Nov;108(5):1368–72

The effects of pentoxifylline on oxygenation, diffusion of carbon monoxide, and exercise tolerance in patients with COPD. Sasse SA, et al. **Chest** 1995 Dec;108(6):1562–7

Children's development effecting blood oxygen desaturation following apnea. Xue F, et al. **Chin Med J (Engl)** 1995 Jun;108(6):434–7

Matrix effects and the performance and selection of quality-control procedures to monitor PO2 measurements. Olafsdottir E, et al. **Clin Chem** 1996 Mar;42(3):392–6

Alterations of breathing in chronic heart failure: clinical relevance of arterial oxygen saturation instability. Mortara A, et al. **Clin Sci (Colch)** 1996;91 Suppl:72–4

The effect of inositol hexaphosphate in the high-affinity hemoglobin of the Andean chicken (Gallus gallus). Mejia O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;109(2–3):437–41

Hypertonic saline does not improve cerebral oxygen delivery after head injury and mild hemorrhage in cats. DeWitt DS, et al. **Crit Care Med** 1996 Jan;24(1):109–17

Mechanical ventilation and arterial blood gas measurements 24 hours postextracorporeal life support for survivors of pediatric respiratory failure. Moler FW, et al. **Crit Care Med** 1996 Apr;24(4):679–82

Perfluorocarbon-associated gas exchange improves oxygenation, lung mechanics, and survival in a model of adult respiratory distress syndrome. Papo MC, et al. **Crit Care Med** 1996 Mar;24(3):466–74 (40 ref.)

Improved oxygenation with reduced recirculation during venovenous extracorporeal membrane oxygenation: evaluation of a test catheter. Raïs-Bahrami K, et al. **Crit Care Med** 1995 Oct;23(10):1722–5

Splanchnic and peripheral tissue perfusion in experimental fat embolism. Rautanen M, et al. **Crit Care Med** 1996 Jun; 24(6):1018–24

Qualitative comparison of carbon dioxide-induced change in cerebral near-infrared spectroscopy versus jugular venous oxygen saturation in adults with acute brain disease [see comments] Tateishi A, et al. **Crit Care Med** 1995 Oct; 23(10):1734–8. Comment in: Crit Care Med 1995 OCT;23(10):1624–6.

Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy. Neumann C, et al. **Diabetes Res Clin Pract** 1995 May;28(2):97–102

Ventilation and dyspnoea during exercise in patients with heart failure. Andreas S, et al. **Eur Heart J** 1995 Dec; 16(12):1886–91

Monitoring of mixed venous oxygen saturation and pressure from biosensors in the right ventricle. A 24 hour study in patients with heart failure [see comments] Ohlsson A, et al. **Eur Heart J** 1995 Sep;16(9):1215–22. Comment in: Eur Heart J 1995 Sep;16(9):1164–5.

The PIO2 vs. SpO2 diagram: a non-invasive measure of pulmonary oxygen exchange. Sapsford DJ, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):375–86

Influence of hypoxic ventilatory response on arterial O2 saturation during maximal exercise in acute hypoxia. Benoit H, et al. **Eur J Appl Physiol** 1995;72(1–2):101–5

Reduction of reoxygenation injury and nitric oxide production in the cyanotic immature heart by controlling pO2. Ihnken K, et al. **Eur J Cardiothorac Surg** 1995; 9(8):410–8

Near infrared spectroscopy. Edwards AD. **Eur J Pediatr** 1995;154(8 Suppl 3):S19–21

Characterization of contractile adrenoceptors in the human umbilical artery. Bodelsson G, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):95–101

Systemic and splanchnic oxygen supply-demand relationship with fenoldopam, dopamine and noradrenaline in sheep. Schiffer ER, et al. **Eur J Pharmacol** 1995 Nov 3; 286(1):49–60

Blood gas estimations from arterialized capillary blood versus arterial puncture: are they different? [editorial; comment] Hughes JM. **Eur Respir J** 1996 Feb;9(2):184–5. Comment on: Eur Respir J 1996 Feb;9(2):186–9.

Differences in PO2 and PCO2 between arterial and arterialized earlobe samples [see comments] Sauty A, et al. **Eur Respir J** 1996 Feb;9(2):186–9. Comment in: Eur Respir J 1996 Feb;9(2):184–5.

Pediatric asthma--a correlation of clinical treatment and oxygen saturation. Cook T, et al. **Hawaii Med J** 1995 Jul; 54(7):665–8

Desaturation events during oral feedings with and without a nasogastric tube in very low birth weight infants. Shiao SY, et al. **Heart Lung** 1996 May-Jun;25(3):236–45

Comparison of calculated and measured mixed venous oxygen saturation in critically ill patients. Cieslinski G, et al. **Infusionsther Transfusionsmed** 1995 Dec;22(6):340–3

Estimation of the degree of acclimatization to high altitude by a rapid and simple physiological examination. Saito S, et al. **Int Arch Occup Environ Health** 1995;67(5):347–51

Quantitative reflection spectrophotometry: spatial and temporal variation of Hb oxygenation in human skin. Caspary L, et al. **Int J Microcirc Clin Exp** 1995 May-Jun; 15(3):131–6

Early jugular bulb oxygenation monitoring in comatose patients after an out-of-hospital cardiac arrest. van der Hoeven JG, et al. **Intensive Care Med** 1995 Jul;21(7):567–72

Differences in oxygen content between mixed venous blood and cerebral venous blood for outcome prediction after cardiac arrest. Zarzuelo R, et al. **Intensive Care Med** 1995 Jan;21(1):71–5

A quantitative physiologic model of blood oxygenation for functional magnetic resonance imaging. Hathout GM, et al. **Invest Radiol** 1995 Nov;30(11):669–82

The effect of body positioning upon maximal oxygenation of patients with unilateral lung pathology. Yeaw EM. **J Adv Nurs** 1996 Jan;23(1):55–61

Clarification on foal with cyanoses and intense murmur [letter; comment] Schott HC 2nd, et al. **J Am Vet Med Assoc** 1996 May 1;208(9):1381. Comment on: J Am Vet Med Assoc 1996 Mar 15;208(6):835–7; discussion 838–9.

Jugular bulb saturation and mixed venous saturation during cardiopulmonary bypass. Croughwell ND, et al. **J Card Surg** 1995 Jul;10(4 Suppl):503–8

Marked mixed venous hemoglobin desaturation in a patient during hypothermic cardiopulmonary bypass [clinical conference] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):764–7

Hypermetabolism during bilateral single-lung transplantation requiring cardiopulmonary bypass. Chaney MA. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):565–70

Relationship between tissue ischemia and venous endothelin-1 during abdominal aortic aneurysm surgery. Fukuda S, et al. **J Cardiothorac Vasc Anesth** 1995 Oct; 9(5):510–4

Effects of dexmedetomidine on coronary hemodynamics and myocardial oxygen balance. Jalonen J, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):519–24

Increased blood-brain permeability with hyperosmolar mannitol increases cerebral O2 consumption and O2 supply/consumption heterogeneity. Chi OZ, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):327–33

Simultaneous recording of cerebral blood oxygenation changes during human brain activation by magnetic resonance imaging and near-infrared spectroscopy. Kleinschmidt A, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):817–26

Hemodynamic comparison of direct vision versus blind oral endotracheal intubation. Kovac AL, et al. **J Clin Anesth** 1995 Aug;7(5):411–6

Oxygen administration during transport and recovery after outpatient surgery does not prevent episodic arterial desaturation. Scuderi PE, et al. **J Clin Anesth** 1996 Jun; 8(4):294–300

End-tidal oxygen concentration and pulse oximetry for monitoring oxygenation during intratracheal jet ventilation. Baer GA, et al. **J Clin Monit** 1995 Nov;11(6):373–80

Application of pulmonary vein gas analysis: a novel approach which may increase the pool of potential lung transplant donors [letter] el-Gamel AL, et al. **J Heart Lung Transplant** 1996 Mar;15(3):315–6

Interferon-gamma affects protein kinase C activity in human neutrophils. Aas V, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):777–84

Siggaard-Andersen algorithm-derived p50 parameters: perturbation by abnormal hemoglobin-oxygen affinity and acid-base disturbances. Morgan TJ, et al. **J Lab Clin Med** 1995 Oct;126(4):365–72

Functional MR imaging using gradient-echo echo-planar imaging in the presence of large static field inhomogeneities. Constable RT. **J Magn Reson Imaging** 1995 Nov-Dec;5(6):746–52

Early discovery of a traumatic carotid-cavernous sinus fistula by jugular venous oxygen saturation monitoring. Case report. Calon B, et al. **J Neurosurg** 1995 Nov;83(5):910–1

Carotid-cavernous fistula and jugular venous oxygen saturation [letter] Dujovny M, et al. **J Neurosurg** 1996 Apr; 84(4):713

Hyperventilation and head injury [letter; comment] Previgliano IJ. **J Neurosurg** 1995 Dec;83(6):1112–3; discussion 1115–7. Comment on: J Neurosurg 1995 Mar;82(3):379–85.

SjvO2 monitoring in head-injured patients. Robertson CS, et al. **J Neurotrauma** 1995 Oct;12(5):891–6

Oxygen saturations during breast and bottle feedings in infants with congenital heart disease. Marino BL, et al. **J Pediatr Nurs** 1995 Dec;10(6):360–4

Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)

The arterial oxygen status of clinically healthy dogs at an altitude of 1250 metres. Leisewitz AL, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):213–8

Evaluation of the effect of whole-blood transfusion on the oxygen status and acid-base balance of Babesia canis infected dogs using the oxygen status algorithm. Leisewitz AL, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):20–6

Studies of hypoxemic/reoxygenation injury with aortic clamping: XI. Cardiac advantages of normoxemic versus hyperoxemic management during qardiopulmonary bypass. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1255–64

Studies of hypoxemic/reoxygenation injury: with aortic clamping. XIII. Interaction between oxygen tension and cardioplegic composition in limiting nitric oxide production and oxidant damage. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1274–86

Adverse effects of hyperoxemia during cardiopulmonary bypass. Joachimsson PO, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):812–9

Studies of hypoxemic/reoxygenation injury: without aortic clamping. IX. Importance of avoiding perioperative hyperoxemia in the setting of previous cyanosis. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1235–44

Blood gas management and degree of cooling: effects on cerebral metabolism before and after circulatory arrest. Skaryak LA, et al. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1649–57

Chronic nonpulsatile blood flow. III. Effects of pump flow rate on oxygen transport and utilization in chronic nonpulsatile biventricular bypass. Tominaga R, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):863–72

Subcutaneous tissue oxygen pressure: a reliable index of peripheral perfusion in humans after injury. Drucker W, et al. **J Trauma** 1996 Mar;40(3 Suppl):S116–22

The use of oxygen consumption and delivery as endpoints for resuscitation in critically ill patients. Durham RM, et al. **J Trauma** 1996 Jul;41(1):32–9; discussion 39–40

Cerebral blood flow and blood volume in response to O2 and CO2 changes in normal humans. Fortune JB, et al. **J Trauma** 1995 Sep;39(3):463–71; discussion 471–2

The relationship of oxygen consumption measured by indirect calorimetry to oxygen delivery in critically ill patients. Yu M, et al. **J Trauma** 1996 Jul;41(1):41–8; discussion 48–50

Predicting hypoxia in children with acute lower respiratory infection: a study in the highlands of Papua New Guinea. Dyke T, et al. **J Trop Pediatr** 1995 Aug;41(4):196–201

The effect of indomethacin on liver blood flow and oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Apr;57(2):193–7

The effects of dopamine and dobutamine on liver oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Apr;57(2):287–91

The effect of hypovolemic shock and reperfusion on the hepatic oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Aug;57(4):697–702

Systemic haemodynamics and oxygenation during haemodilution in children [letter; comment] Innerhofer P, et al. **Lancet** 1996 Feb 10;347(8998):398–9. Comment on: Lancet 1995 Oct 28;346(8983):1127–9.

Systemic haemodynamics and oxygenation during haemodilution in children [see comments] van Iterson M, et al. **Lancet** 1995 Oct 28;346(8983):1127–9. Comment in: Lancet 1995 Dec 2;346(8988):1499–500. Comment in: Lancet 1996 Feb 10;347(8998):398–9.

Blood oxygenation dependence of T1 and T2 in the isolated, perfused rabbit heart at 4.7T. Atalay MK, et al. **Magn Reson Med** 1995 Oct;34(4):623–7

Decomposition of inflow and blood oxygen level-dependent (BOLD) effects with dual-echo spiral gradient-recalled echo (GRE) fMRI. Glover GH, et al. **Magn Reson Med** 1996 Mar;35(3):299–308

Oximetry by dynamic nuclear polarization. Grucker D, et al. **Magn Reson Med** 1995 Aug;34(2):219–26

Dynamic MRI sensitized to cerebral blood oxygenation and flow during sustained activation of human visual cortex. Krüger G, et al. **Magn Reson Med** 1996 Jun;35(6):797–800

NMR relaxation rates and blood oxygenation level. Meyer ME, et al. **Magn Reson Med** 1995 Aug;34(2):234–41

Comparison of different oxygen exchange models. Van der Ploeg CP, et al. **Med Biol Eng Comput** 1995 Sep;33(5):661–8

The rate of oxygen release from single sinusoid of rat liver, determined by microspectroscopy. Yoshihara H, et al. **Med J Osaka Univ** 1993 Sep;41–42(1–4):1–10

PEFIOS: an expert closed-loop oxygenation algorithm. Waisel DB, et al. **Medinfo** 1995;8 Pt 2:1132–6

Hemodynamic and oxygenation variables during radical cystectomy. Does the anesthetic technique really matter? Atallah MM, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):157–74

Effect of inhaled nedocromil sodium therapy on blood gas changes in children challenged with ultrasonically nebulized distilled water. A comparison of 8 mg versus 16 mg daily dose. Oggiano N, et al. **Minerva Pediatr** 1995 Oct;47(10):427–31

Goal-oriented hemodynamic therapy [letter; comment] Haupt MT. **N Engl J Med** 1996 Mar 21;334(12):799; discussion 800. Comment on: N Engl J Med 1995 Oct 19;333(16):1025–32.

Goal-oriented hemodynamic therapy [letter; comment] Shoemaker WC. **N Engl J Med** 1996 Mar 21; 334(12):799–800; discussion 800. Comment on: N Engl J Med 1995 Oct 19;333(16):1025–32. Comment on: N Engl J Med 1995 Oct 19;333(16):1074–5.

Continuous monitoring of partial pressure of brain tissue oxygen in patients with severe head injury. van Santbrink H, et al. **Neurosurgery** 1996 Jan;38(1):21–31

Signal changes in gradient echo images of human brain induced by hypo- and hyperoxia. Rostrup E, et al. **NMR Biomed** 1995 Feb;8(1):41–7

Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)

Duration of apnoea in anaesthetized children required for desaturation of haemoglobin to 95%: comparison of three different breathing gases. Kinouchi K, et al. **Paediatr Anaesth** 1995;5(2):115–9

Variability of continuously measured arterial pH and blood gas values in the near term fetal lamb. Woudstra BR, et al. **Pediatr Res** 1995 Oct;38(4):528–32

High-frequency oscillatory ventilation as rescue therapy in sick preterm neonates (</=1250 g): outcome and its prediction [letter; comment] Cheung PY, et al. **Pediatrics** 1996 Mar;97(3):437–8. Comment on: Pediatrics 1995 Mar;95(3):400–4.

The relationship between systemic oxygen uptake and delivery during moderate hypothermic cardiopulmonary bypass: critical values and effects of vasodilation by hydralazine. Cavaliere F, et al. **Perfusion** 1995 Sep; 10(5):315–21

Determination of optical properties and blood oxygenation in tissue using continuous NIR light. Liu H, et al. **Phys Med Biol** 1995 Nov;40(11):1983–93

A successful protocol for the use of pulse oximetry to classify arterial oxygenation into four fuzzy categories. Sailors RM, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:248–52

Nocturnal oxygen desaturation and exercise-induced desaturation in subjects with chronic obstructive pulmonary disease. Baldwin DR, et al. **Respir Med** 1995 Oct;89(9):599–601

Effects of inspiratory pressure support on oxygenation and central haemodynamics in the normal heart during the postoperative period. Nørregaard O, et al. **Respir Med** 1996 Aug;90(7):415–7

Sufficient indication of nocturnal oxygen saturation and breathing pattern in COPD patients, from a single night's study. Vos PJ, et al. **Respir Med** 1995 Oct;89(9):615–6

Hypoxic helium breathing does not reduce alveolar–arterial PO2 difference in the horse. Erickson BK, et al. **Respir Physiol** 1995 Jun;100(3):253–60

Effect of venous oxygenation on arterial desaturation rate during repetitive apneas in lambs. Wilkinson MH, et al. **Respir Physiol** 1995 Sep;101(3):321–31

Monitoring of nocturnal oxygen desaturation using pulse oximeter and apnomonitor in patients with chronic pulmonary disease. Miyahara Y, et al. **Respiration** 1995; 62(6):348–52

The hemodynamic and arterial blood gas response to asphyxiation: a canine model of pulseless electrical activity. DeBehnke DJ, et al. **Resuscitation** 1995 Oct;30(2):169–75

Continuous registration of blood oxygen tension during hemodialysis. Løkkegaard N, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):249–58

Models to study the relation between oxygen consumption and oxygen delivery during an acute reduction in blood flow: comparison of balloon filling in the inferior vena cava, tamponade, and hemorrhage. De Backer D, et al. **Shock** 1995 Aug;4(2):107–12

Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus–vein thrombosis model. Nakase H, et al. **Stroke** 1996 Apr;27(4):720–7; discussion 728

Cerebral oximetry in patients undergoing carotid endarterectomy under regional anesthesia. Samra SK, et al. **Stroke** 1996 Jan;27(1):49–55

Hemodynamic and arterial blood gas changes during carbon dioxide and helium pneumoperitoneum in pigs. Shuto K, et al. **Surg Endosc** 1995 Nov;9(11):1173–8

Effect of extraperitoneal carbon dioxide insufflation on intraoperative blood gas and hemodynamic changes. Wright DM, et al. **Surg Endosc** 1995 Nov;9(11):1169–72

Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Kiely DG, et al. **Thorax** 1995 Oct;50(10):1062–6

Oxygen delivery and autoxidation of hemoglobin. Marden MC, et al. **Transfus Clin Biol** 1995;2(6):473–80 (21 ref.)

Dopamine, dopexamine and dobutamine in liver transplant recipients: a comparison of their effects on hemodynamics, oxygen transport and hepatic venous oxygen saturation. Kaisers U, et al. **Transpl Int** 1996;9(3):214–20

Central cardiovascular responses to surgical incision at a maximal mixed venous oxygen saturation. Ejlersen E, et al. **Transplant Proc** 1995 Dec;27(6):3500

An arterial blood gas analysis in the canine bilateral sequential lung transplant model flushed with modified Euro-Collins solution. Sohn KH, et al. **Transplant Proc** 1996 Jun; 28(3):1834–5

Uvulopalatopharyngoplasty for snoring: the Belfast experience. Capper R, et al. **Ulster Med J** 1994 Apr; 63(1):8–11

Assessment of the fetal PO2 changes by cerebral and umbilical Doppler on lamb fetuses during acute hypoxia. Arbeille P, et al. **Ultrasound Med Biol** 1995;21(7):861–70

[The carotid bodies—mechanisms of hypoxia detection] Vízek M. **Cesk Fyziol** 1995 Jun;44(2):77–80 (Eng. Abstr.) **(Cze)**

[Effects of preoxygenation methods on the course of PaO2 and PaCO2 in anesthetic post-induction apnea] Fleureaux O, et al. **Cah Anesthesiol** 1995;43(4):367–70 (Eng. Abstr.) **(Fre)**

[Recombinant human hemoglobin with low oxygen affinity: additional effects of two mutations] Baudin V, et al. **Transfus Clin Biol** 1995;2(6):463–7 (Eng. Abstr.) **(Fre)**

[Efficiency of a mobile oxygen concentrator for mechanical ventilation in anesthesia. Studies with a metabolic lung model and early clinical results] Rathgeber J, et al. **Anaesthesist** 1995 Sep;44(9):643–50 (Eng. Abstr.) **(Ger)**

[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

[Anesthesia with low fresh gas flow in clinical routine use (see comments)] Hargasser S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):268–75 (79 ref.) (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265–7. **(Ger)**

[Mucosa-pH as a parameter of mucosa oxygenation in liver transplantation] Pichler B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S22–3 **(Ger)**

[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S52–4 (21 ref.) **(Ger)**

[Effect of arterial blood pressure on cerebral vein oxygen saturation in the rewarming phase of extracorporeal circulation] von Knobelsdorff G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):298–303 (Eng. Abstr.) **(Ger)**

[Oximetry in veterinary anesthesia: the continuous determination of mixed venous oxygen saturation in dogs and horses] Alef M, et al. **Tierarztl Prax** 1996 Apr; 24(2):117–28 (Eng. Abstr.) **(Ger)**

[Change in nCPAP pressure in repeated follow-up of patients with obstructive sleep apnea] Geisler P. **Wien Med Wochenschr** 1995;145(17–18):506–7 (Eng. Abstr.) **(Ger)**

[Spectral analysis of arterial oxygen saturation and RR intervals in patients with obstructive sleep apnea] Keyl C, et al. **Wien Med Wochenschr** 1995;145(17–18):515–6 (Eng. Abstr.) **(Ger)**

[Functional evaluation of an experimental model of cutaneous microcirculation and pO2 after surgical excision: traditional method vs laser CO2] Morrone G, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):909–12 discussion 912–3 (Eng. Abstr.) **(Ita)**

[Predictivity associated with oxygen-transporting hemodynamic parameters: relation between the cardiac index and oxygen extraction] Donati A, et al. **Minerva Anestesiol** 1995 Jun;61(6):241–7 (Eng. Abstr.) **(Ita)**

[Accuracy of a pulse oximeter during hypoxia] Tachibana C, et al. **Masui** 1996 Apr;45(4):479–82 (Eng. Abstr.) **(Jpn)**

[The importance of SpO2 and FIO2 for anesthetic management for Norwood's operation] Taguchi A, et al. **Masui** 1995 Sep;44(9):1269–72 (Eng. Abstr.) **(Jpn)**

[Continuous systemic venous oxygen saturation monitoring immediately after Fontan procedure] Saito S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):779–84 (Eng. Abstr.) **(Jpn)**

[Arterial oxygen tension and oxygen saturation] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:796–9 (5 ref.) **(Jpn)**

[Metabolic changes in blood oxygen in the human heart under ischemic and reperfusion conditions] Pawlicki L, et al. **Pol Arch Med Wewn** 1996 May;95(5):443–52 (Eng. Abstr.) **(Pol)**

[The role of component composition and gas transport functions of blood in the formation of fluctuating electrical properties of the epidermis and underlying tissue] Tornuev IuV. **Biull Eksp Biol Med** 1996 Jan;121(1):100–2 **(Rus)**

[An analysis of the changes in the basic parameters of lipid peroxidation and blood oxygen-transport function in pyrogenal-induced fever] Zinchuk VV, et al. **Fiziol Zh** 1995 May–Aug;41(3–4):103–8 (Eng. Abstr.) **(Rus)**

[Hemoglobin oxygen-transport activity in lymphosarcomas] Karpova IV, et al. **Gematol Transfuziol** 1995 Nov–Dec; 40(6):10–4 (Eng. Abstr.) **(Rus)**

[A comparative analysis of the oxygen-binding and antioxidant properties of the blood of laboratory animals and the muskrat Ondatra zibethica] Korobov VN, et al. **Zh Evol Biokhim Fiziol** 1995 May–Jun;31(3):369–72 (Eng. Abstr.) **(Rus)**

[Oxygen transport and consumption and oxygen saturation in the right atrium in an experimental model of neonatal septic shock] Baquero Cano M, et al. **An Esp Pediatr** 1996 Feb;44(2):149–56 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Investigating the relationship between surface chemistry and endothelial cell growth: partial least-squares regression of the static secondary ion mass spectra of oxygen-containing plasma-deposited films. Chilkoti A, et al. **Anal Chem** 1995 Sep 1;67(17):2883–91

The specificity and product of quenching singlet oxygen by 2,2,6,6-tetramethylpiperidine. Zang LY, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):283–93

EPR studies on the kinetics of quenching singlet oxygen. Zang LY, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1187–95

Redox cycling of beta-lapachone and related o-naphthoquinones in the presence of dihydrolipoamide and oxygen. Molina Portela MP, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):275–83

Stopped-flow, laser-flash photolysis studies on the reactions of CO and O2 with the cytochrome caa3 complex from Bacillus subtilis: conservation of electron transfer pathways from cytochrome c to O2. Hill BC. **Biochemistry** 1996 May 14;35(19):6136–43

A convenient synthesis of trans-sabinene hydrate from (-)-3-thujol via a highly selective ene reaction of singlet oxygen. Baeckström P, et al. **Bioorg Med Chem** 1996 Mar; 4(3):419–21

Photochemical formation of singlet molecular oxygen in illuminated aqueous solutions of several commercially available sunscreen active ingredients. Allen JM, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):605–9

Reaction between peroxynitrite and hydrogen peroxide: formation of oxygen and slowing of peroxynitrite decomposition. Alvarez B, et al. **Chem Res Toxicol** 1995 Sep;8(6):859–64

Prostaglandin H synthase-catalyzed ring oxygenation of 2-naphthylamine: evidence for two distinct oxidation pathways. Curtis JF, et al. **Chem Res Toxicol** 1995 Sep; 8(6):875–83

Reaction of singlet oxygen with 2'-deoxyguanosine and DNA. Isolation and characterization of the main oxidation products. Ravanat JL, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):379–88

Origin of the two carbonyl oxygens of bacteriochlorophyll a. Demonstration of two different pathways for the formation of ring E in Rhodobacter sphaeroides and Roseobacter denitrificans, and a common hydratase mechanism for 3-acetyl group formation. Porra RJ, et al. **Eur J Biochem** 1996 Jul 1;239(1):85–92

The role of the reactions of .NO with superoxide and oxygen in biological systems: a kinetic approach. Czapski G, et al. **Free Radic Biol Med** 1995 Dec;19(6):785–94

Interaction of melanin with carbon- and oxygen-centered radicals from methanol and ethanol. Dunford R, et al. **Free Radic Biol Med** 1995 Dec;19(6):735–40

Singlet oxygen-trapping reaction as a method of (1)O2 detection: role of some reducing agents. Dzwigaj S, et al. **Free Radic Res** 1995 Aug;23(2):103–15

Oxygen and oue reducing equivalent are both required for the conversion of alpha-hydroxyhemin to verdoheme in heme oxygenase. Matera KM, et al. **J Biol Chem** 1996 Mar 22;271(12):6618–24

Oxygen equilibrium properties of chromium (III)-iron (II) hybrid hemoglobins. Unzai S, et al. **J Biol Chem** 1996 May 24;271(21):12451–6

Quantitative generation of singlet (1 delta g) oxygen from acidified aqueous peroxynitrite produced by the reaction of nitric oxide and superoxide anion. Khan AU. **J Biolumin Chemilumin** 1995 Nov–Dec;10(6):329–33

Strange bedfellows: interactions between acidic side-chains in proteins. Flocco MM, et al. **J Mol Biol** 1995 Nov 17; 254(1):96–105

Structural determinants of activity at the GABAB receptor. A comparison of phosphoethanolamine and related GABA analogs. Klunk WE, et al. **Mol Chem Neuropathol** 1995 Sep;26(1):15–30

Reversible cleavage and formation of the dioxygen O–O bond within a dicopper complex. Halfen JA, et al. **Science** 1996 Mar 8;271(5254):1397–400

Tuning into better catalysts [comment] Labinger JA. **Science** 1995 Sep 29;269(5232):1833. Comment on: Science 1995 Sep 29;269(5232):1849–51.

DEFICIENCY see ANOXIA

DIAGNOSTIC USE

Inhaled oxygen: a brain MR contrast agent? Berthezène Y, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec; 16(10):2010–2

Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Nitzsche EU, et al. **Circulation** 1996 Jun 1;93(11):2000–6

ECONOMICS

Oxygen cost of breathing in newborn infants with long-term ventilatory support. Rozé JC, et al. **J Pediatr** 1995 Dec; 127(6):984–7

HISTORY

[Christian Bohr—a forgotten pioneer in respiratory physiology] Schaffartzik W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):239–43 **(Ger)**

METABOLISM

Do changes in cardiac output affect the inspiratory to end-trial oxygen difference? Bengtsson J, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1075–9

The effect of ketanserin upon postoperative blood pressure, cerebral blood flow and oxygen metabolism in patients subjected to craniotomy for cerebral tumours. Felding M,

et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):582–5

Oxygen, Carbon Dioxide, and Electrolytes in Critical Care. Proceedings of a workshop. Copenhagen, Denmark, January 26–27, 1995. **Acta Anaesthesiol Scand Suppl** 1995; 107:1–289

An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393–9 (17 ref.)

Excessive oxygen deficit during low-level exercise in heart failure. Chelimsky-Fallick C, et al. **Am J Cardiol** 1995 Oct 15;76(11):799–802

Danger of amiodarone therapy and elevated inspired oxygen concentrations in mice. Donica SK, et al. **Am J Cardiol** 1996 Jan 1;77(1):109–10

Relation between oxygen uptake and carbon dioxide output during constant work rate exercise in patients with mild congestive heart failure. Koike A, et al. **Am J Cardiol** 1996 Mar 15;77(8):602–5

Cardiac oxygenation by extracorporeal membrane oxygenation in exteriorized fetal lambs. Murata Y, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):864–70

Myocardial and cerebral oxygen delivery are not adversely affected by cocaine administration to early-gestation fetal sheep. Peña AE, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):1028–32

High lipid content enhances the rate of oxygen diffusion through fish skeletal muscle. Desaulniers N, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R42–7

Deoxygenation-induced alterations in sickle cell membrane cholesterol exchange. Kavecansky J, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1105–11

Potential role of NADH oxidoreductase-derived reactive O2 species in calf pulmonary arterial PO2-elicited responses. Mohazzab KM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L637–44

Determination of myoglobin saturation of frozen specimens using a reflecting cryospectrophotometer. Voter WA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1328–41

Acid aspiration results in ileal injury without altering ileal V(O2)-D(O2) relationships. Crouser ED, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1965–71

Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis. Neviere R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):191–5

Vascular injury in isolated sheep lungs. Role of ischemia, extracorporeal perfusion, and oxygen. Pearse DB, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):196–202

Cerebral oxygenation during hypothermic cardiopulmonary bypass: clinical findings support mathematical model [letter; comment] du Plessis AJ, et al. **Anesthesiology** 1996 Apr; 84(4):1008–9. Comment on: Anesthesiology 1995 Aug;83(2):405–12.

Rapid rewarming causes an increase in the cerebral metabolic rate for oxygen that is temporarily unmatched by cerebral blood flow. A study during cardiopulmonary bypass in rabbits. Enomoto S, et al. **Anesthesiology** 1996 Jun; 84(6):1392–400

Near-infrared measurement of cerebral oxygenation. Correlation with electroencephalographic ischemia during ventricular fibrillation. Levy WJ, et al. **Anesthesiology** 1995 Oct;83(4):738–46

Alveolar oxygen partial pressure, alveolar carbon dioxide partial pressure, and the alveolar gas equation [letter] Story DA. **Anesthesiology** 1996 Apr;84(4):1011

Failure to detect free radicals in the isolated perfused rat heart. Piette LH, et al. **Angiology** 1996 Jan;47(1):1–7

Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan–Feb;24(1):1–24 (97 ref.)

Dynamic model of oxygen transport for transcutaneous PO2 analysis. Talbot A, et al. **Ann Biomed Eng** 1996 Mar–Apr; 24(2):294–304

Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)

Cerebral oxygenation measured by near-infrared spectroscopy: comparison with jugular bulb oximetry. Daubeney PE, et al. **Ann Thorac Surg** 1996 Mar;61(3):930–4

Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. Thies SD, et al. **Ann Thorac Surg** 1996 May;61(5):1453–7

Catechol 2,3-dioxygenases functional in oxygen-limited (hypoxic) environments. Kukor JJ, et al. **Appl Environ Microbiol** 1996 May;62(5):1728–40

Superoxide production during reduction of molecular oxygen by assimilatory nitrate reductase. Barber MJ, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):227–32

Nitric oxide diffusion in membranes determined by fluorescence quenching. Denicola A, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):208–12

A role for molecular oxygen in the formation of DNA damage during the reduction of the carcinogen chromium (VI) by glutathione. Kortenkamp A, et al. **Arch Biochem Biophys** 1996 May 15;329(2):199–207

Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. Takehara Y, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):27–32

Continuous central venous oxygen saturation (ScvO2) measurement using a fibre optic catheter in newborn infants. van der Hoeven MA, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 May;74(3):F177–81

O2-sensing and O2-dependent gene regulation in facultatively anaerobic bacteria. Unden G, et al. **Arch Microbiol** 1995 Aug;164(2):81–90 (112 ref.)

Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Dupuis NP, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):423–9

Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation. Robinson MF, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):431–8

Monitoring of blood gases during prolonged experimental cardiopulmonary bypass and their relationship to brain pH, PO2, and PCO2. Briceno JC, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M344–50

Oxygen metabolism in animals with total artificial hearts. Chiang BY, et al. **ASAIO J** 1994 Jul–Sep;40(3):M510–3

Perfluorocarbon oxygen transport. A comparative study of four oxygenator designs. Ferguson ER, et al. **ASAIO J** 1994 Jul–Sep;40(3):M649–53

An artificial gill system for oxygen uptake from water using perfluorooctylbromide. Haramoto H, et al. **ASAIO J** 1994 Jul–Sep;40(3):M803–7

Enhanced oxygen delivery induced by perfluorocarbon emulsions in capillary tube oxygenators. Vaslef SN, et al. **ASAIO J** 1994 Jul–Sep;40(3):M643–8

Effects of inspired O2 and CO2 on ventilatory responses to LBNP–release and acute head-down tilt. Lawler JM, et al. **Aviat Space Environ Med** 1995 Aug;66(8):751–6

Flow-flash kinetics of O2 binding to cytochrome c oxidase at elevated [O2]: observations using high pressure stopped flow for gaseous reactants. Bailey JA, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1055–60

Physiological role of nitric oxide as an enhancer of oxygen transfer from erythrocytes to tissues. Kosaka H, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):749–52

Hypoxia and hypoxia/reoxygenation activate Src family tyrosine kinases and p21ras in cultured rat cardiac myocytes. Seko Y, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):530–5

Aplysia limacina myoglobin cDNA cloning: an alternative mechanism of oxygen stabilization as studied by active-site mutagenesis. Cutruzzolà F, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):83–90

Oxygen and pH regulation of protein synthesis in mitochondria from Artemia franciscana embryos. Kwast KE, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):207–13

Temperature-induced functional and structural transformations of the photosystem II oxygen-evolving complex in spinach subchloroplast preparations. Shutilova N, et al. **Biochem Mol Biol Int** 1995 May;35(6):1233–43

Oxygraphic evaluation of mitochondrial function in digitonin-permeabilized mononuclear cells and cultured skin fibroblasts of patients with chronic progressive external ophthalmoplegia. Kunz D, et al. **Biochem Mol Med** 1995 Apr;54(2):105–11

Inactivation of mouse epidermal 12-lipoxygenase by anthralin—implications for the role of oxygen radicals. Müller K, et al. **Biochem Pharmacol** 1996 May 3; 51(9):1173–9

Binding of NO to the oxygen reaction site of cytochrome bd from Azotobacter vinelandii. Jünemann S, et al. **Biochem Soc Trans** 1996 Feb;24(1):38S

Production of superoxide from hemoglobin-bound oxygen under hypoxic conditions. Balagopalakrishna C, et al. **Biochemistry** 1996 May 21;35(20):6393–8

Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Fehr MJ, et al. **Biochemistry** 1995 Dec 5;34(48):15845–8

Structural basis for ligand discrimination and response initiation in the heme-based oxygen sensor FixL. Rodgers KR, et al. **Biochemistry** 1996 Jul 23;35(29):9539–48

Reaction of cytochrome bo3 with oxygen: extra redox center(s) are present in the protein. Wang J, et al. **Biochemistry** 1995 Nov 28;34(47):15504–11

The role of Thr268 in oxygen activation of cytochrome P450BM-3. Yeom H, et al. **Biochemistry** 1995 Nov 14; 34(45):14733–40

Source of oxygen free radicals produced by rat hepatocytes during postanoxic reoxygenation. Caraceni P, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):249–54

Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson's disease. Linert W, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):160–8

Channelling of dioxygen into the respiratory enzyme. Riistama S, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):1–4

Suppression of Ca2+ flux during the transition to anoxia in turtle hepatocytes revealed by a non-invasive Ca(2+)-selective vibrating probe. Land SC, et al. **Biol Bull** 1995 Oct–Nov;189(2):228–9

Effects of the cyclooxygenase inhibitor ibuprofen on retinal and choroidal blood flow during hyperoxia in newborn piglets. Stiris TA, et al. **Biol Neonate** 1996;69(2):101–8

Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. Vinogradov SA, et al. **Biophys J** 1996 Apr;70(4):1609–17

Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Arteel GE, et al. **Br J Cancer** 1995 Oct;72(4):889–95

Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours. Horsman MR, et al. **Br J Cancer** 1995 Dec;72(6):1474–8

Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Arya R, et al. **Br J Haematol** 1996 Jun 2;93(4):817–21

Hb Arta [beta 45 (CD4) Phe—>Cys]: a new unstable haemoglobin with reduced oxygen affinity in trans with beta-thalassaemia. Vassilopoulos G, et al. **Br J Haematol** 1995 Nov;91(3):595–601

Ocular oxygen measurement. Hogeboom van Buggenum IM, et al. **Br J Ophthalmol** 1996 Jun;80(6):567–73 (110 ref.)

Inhibition of the centrally induced increases in myocardial oxygen demand in rabbits by chronic treatment with baclofen, a selective GABAB agonist. Tibiriçà E, et al. **Br J Pharmacol** 1995 Aug;115(7):1331–5

New concepts in the pathophysiology of oxygen metabolism during sepsis [letter; comment] Delicata RJ, et al. **Br J Surg** 1996 Jan;83(1):137–8. Comment on: Br J Surg 1995 Jul;82(7):870–6.

Investigation of neonatal brain cytochrome redox by NIRS. Wickramasinghe YA, et al. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):307–8

Reactive oxygen generation by azomethine H: a new antimalarial drug. Novelli EL, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1189–94

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)

Sodium nitroprusside does not influence tissue oxygen extraction capabilities during a critical reduction in oxygen delivery. Zhang H, et al. **Cardiovasc Res** 1995 Aug; 30(2):240–5

Bivascular liver perfusion in the anterograde and retrograde modes: zonation of the response to inhibitors of oxidative phosphorylation. Constantin J, et al. **Cell Biochem Funct** 1995 Sep;13(3):201–9

Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Leith JT, et al. **Cell Prolif** 1995 Aug;28(8):415–30

Tracer oxygen distribution is barrier-limited in the cerebral microcirculation. Kassissia IG, et al. **Circ Res** 1995 Dec; 77(6):1201–11

Cell-free hemoglobin as an oxygen carrier removes nitric oxide, resulting in defective thromboregulation [editorial; comment] Marcus AJ, et al. **Circulation** 1996 Jan 15; 93(2):208–9. Comment on: Circulation 1996 Jan 15;93(2):327–32.

Brain and muscle oxygen saturation during head-up-tilt-induced central hypovolaemia in humans. Madsen P, et al. **Clin Physiol** 1995 Sep;15(5):523–33

Oxygen transport proteins: I. Structure and organization of hemocyanin from scorpion (Buthus sindicus). Ali SA, et al. **Comp Biochem Physiol A Physiol** 1995 Sep; 112(1):225–32

Metabolic and ventilatory adjustments and tolerance of the bat Pteropus poliocephalus to acute hypoxic stress. Thomas SP, et al. **Comp Biochem Physiol A Physiol** 1995 Sep; 112(1):43–54

Oxygen binding properties of Eudistylia vancouverii chlorocruorin and its dodecamer subunit. Imai K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):613–8

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

Changes in skeletal muscle oxygenation during incremental exercise measured with near infrared spectroscopy. Belardinelli R, et al. **Eur J Appl Physiol** 1995;70(6):487–92

Are oxygen uptake kinetics at the onset of exercise speeded up by local metabolic status in active muscles? Yoshida T, et al. **Eur J Appl Physiol** 1995;70(6):482–6

Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing. Gleadle JM, et al. **Eur J Biochem** 1995 Nov 15;234(1):92–9

H-NMR signal of Arenicola marina myoglobin in vivo as an index of tissue oxygenation. Kreutzer U, et al. **Eur J Biochem** 1996 Feb 1;235(3):622–8

Oxygenic photosynthesis. Electron transfer in photosystem I and photosystem II. Nugent JH. **Eur J Biochem** 1996 May 1;237(3):519–31 (122 ref.)

Lack of an endogenous circadian rhythm in oxygen evolution by an ancient alga (Acicularia schenckii, Acetabulariaceae). Berger S, et al. **Eur J Cell Biol** 1995 Nov;68(3):339–44

Possible mechanism of oxygen radical production by human eosinophils mediated by K+ channel activation. Saito M, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):217–9

Magnetic resonance imaging and spectroscopy in studying exercise in children. Cooper DM, et al. **Exerc Sport Sci Rev** 1996;24:475–99 (78 ref.)

Oxygen supply and ion homeostasis of the respiratory network in the in vitro perfused brainstem of adult rats. Morawietz G, et al. **Exp Brain Res** 1995;106(2):265–74

Cell cycle defect in connection with oxygen and iron sensitivity in Fanconi anemia lymphoblastoid cells. Poot M, et al. **Exp Cell Res** 1996 Feb 1;222(2):262–8

Light-evoked oxygen responses in the isolated toad retina. Haugh-Scheidt LM, et al. **Exp Eye Res** 1995 Jul; 61(1):73–81

Microtubule-associated protein 2 expressing COS7 cells are

resistant to argyrophilia under oxygen- and glucose-free condition. Inoue K, et al. **Exp Neurol** 1996 Feb;137(2):350–6

Unassembled subunits of the photosynthetic oxygen-evolving complex present in the thylakoid lumen are long-lived and assembly-competent. Hashimoto A, et al. **FEBS Lett** 1996 Aug 5;391(1–2):29–34

Quo vadis photorespiration: a tale of two aldolases. Hixon M, et al. **FEBS Lett** 1996 Sep 2;392(3):281–4

Regulation of the gluconeogenic phosphoenolpyruvate carboxykinase and glycolytic aldolase A gene expression by O2 in rat hepatocyte cultures. Involvement of hydrogen peroxide as mediator in the response to O2. Kietzmann T, et al. **FEBS Lett** 1996 Jun 17;388(2–3):228–32

Actinic light density dependence of the O intermediate of the photocycle of bacteriorhodopsin. Luchian T, et al. **FEBS Lett** 1996 May 13;386(1):55–9

Oxygen equilibrium and electron paramagnetic resonance studies on copper(II)–iron(II) hybrid hemoglobins at room temperature. Shibayama N, et al. **FEBS Lett** 1995 Sep 18; 372(1):126–30

Effect of organic synthetic food colours on mitochondrial respiration. Reyes FG, et al. **Food Addit Contam** 1996 Jan; 13(1):5–11

Hypoxia alters the energy metabolism and aggregation of washed human platelets. Akahori M, et al. **Haematologia (Budap)** 1995;26(4):191–8

An introduction to oxygen free radicals. Kerr ME, et al. **Heart Lung** 1996 May–Jun;25(3):200–9; quiz 210–1 (52 ref.)

Oxygen metabolism in blood of patients with gastric and duodenal ulcer disease. Kedziora-Kornatowska K, et al. **Hepatogastroenterology** 1995 Jul;42(3):246–9

Clinical and enzymatic investigation of induction of oxygen free radicals by ischemia and reperfusion in human hepatocellular carcinoma and adjacent liver. Yamanoi A, et al. **HPB Surg** 1995 Jun;8(3):193–9

Unexpected low oxygen tension of intravaginal culture. Fukuda M, et al. **Hum Reprod** 1996 Jun;11(6):1293–5

Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Lee J, et al. **Int J Cancer** 1996 Jul 29;67(3):372–8

Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Mattern J, et al. **Int J Cancer** 1996 Jul 3; 67(1):20–3

Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Melillo E, et al. **Int J Microcirc Clin Exp** 1995 Mar–Apr;15(2):60–4

A multiple-radical model for radiation action on DNA and the dependence of OER on LET. Michael BD, et al. **Int J Radiat Biol** 1996 Mar;69(3):351–8

The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Nordsmark M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):701–8

Bladder epithelial oxygen tension—a new means of monitoring regional perfusion? Preliminary study in a model of exsanguination/fluid repletion. Singer M, et al. **Intensive Care Med** 1996 Apr;22(4):324–8

Adult and newborn rat inner retinal oxygenation during carbogen and 100% oxygen breathing. Comparison using magnetic resonance imaging delta Po2 mapping. Berkowitz BA. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):2089–98

Direct noninvasive measurement of tear oxygen tension beneath gas-permeable contact lenses in rabbits. Harvitt DM, et al. **Invest Ophthalmol Vis Sci** 1996 May; 37(6):1026–36

Direct noninvasive measurement of tear oxygen tension beneath gas-permeable contact lenses in rabbits [letter] Masters BR. **Invest Ophthalmol Vis Sci** 1996 Sep; 37(10):1935

Effects of a perfluorocarbon emulsion for enhanced O2 solubility on hemodynamics and O2 transport in dogs. Johnson EC, et al. **J Appl Physiol** 1995 Nov;79(5):1777–86

Progressive effect of endurance training on VO2 kinetics at the onset of submaximal exercise. Phillips SM, et al. **J Appl Physiol** 1995 Dec;79(6):1914–20

Diaphragm microvascular plasma PO2 measured in vivo. Poole DC, et al. **J Appl Physiol** 1995 Dec;79(6):2050–7

Oxygen tension in the bladder epithelium rises in both high and low cardiac output endotoxemic sepsis. Rosser DM, et al. **J Appl Physiol** 1995 Dec;79(6):1878–82

ATP-sensitive K+ channel blockade impairs O2 extraction during progressive ischemia in pig hindlimb. Vallet B, et al. **J Appl Physiol** 1995 Dec;79(6):2035–42

O2 as the regulatory signal for FNR-dependent gene regulation in Escherichia coli. Becker S, et al. **J Bacteriol** 1996 Aug;178(15):4515–21

Oxygen-controlled regulation of the flavohemoglobin gene in Bacillus subtilis. LaCelle M, et al. **J Bacteriol** 1996 Jul; 178(13):3803–8

Two-component regulatory proteins ResD-ResE are required for transcriptional activation of fnr upon oxygen limitation in Bacillus subtilis. Nakano MM, et al. **J Bacteriol** 1996 Jul;178(13):3796–802

Regulation of malate dehydrogenase (mdh) gene expression in Escherichia coli in response to oxygen, carbon, and heme availability. Park SJ, et al. **J Bacteriol** 1995 Nov; 177(22):6652–6

Dynamics in oxygen-induced changes in S-layer protein synthesis from Bacillus stearothermophilus PV72 and the S-layer-deficient variant T5 in continuous culture and studies of the cell wall composition. Sára M, et al. **J Bacteriol** 1996 Apr;178(7):2108–17

Fetal lung fibroblasts selectively down-regulate proteoglycan synthesis in response to elevated oxygen. Caniggia I, et al. **J Biol Chem** 1996 Mar 22;271(12):6625–30

Molecular oxygen modulates cytochrome c oxidase function. Chandel NS, et al. **J Biol Chem** 1996 Aug 2;271(31):18672–7

Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy. Hofhaus G, et al. **J Biol Chem** 1996 May 31;271(22):13155–61

Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp. strain 7. III. The archaeal novel respiratory complex II (succinate:caldariellaquinone oxidoreductase complex) inherently lacks heme group. Iwasaki T, et al. **J Biol Chem** 1995 Dec 29;270(52):30902–8

Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp. strain 7. I. The archaeal terminal oxidase supercomplex is a functional fusion of respiratory complexes III and IV with no c-type cytochromes. Iwasaki T, et al. **J Biol Chem** 1995 Dec 29; 270(52):30881–92

Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp. strain 7. II. Characterization of the archaeal terminal oxidase subcomplexes and implication for the intramolecular electron transfer. Iwasaki T, et al. **J Biol Chem** 1995 Dec 29;270(52):30893–901

DNA binding and dimerization of the Fe-S-containing FNR protein from Escherichia coli are regulated by oxygen. Lazazzera BA, et al. **J Biol Chem** 1996 Feb 2;271(5):2762–8

Gating effects of component B on oxygen activation by the methane monooxygenase hydroxylase component. Liu Y, et al. **J Biol Chem** 1995 Oct 20;270(42):24662–5

Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. Norris ML, et al. **J Biol Chem** 1995 Oct 6;270(40):23774–9

Kinetic pathways and barriers for ligand binding to myoglobin. Olson JS, et al. **J Biol Chem** 1996 Jul 26; 271(30):17593–6 (28 ref.)

Age dependency of changes in cerebral hemoglobin oxygenation during brain activation: a near-infrared spectroscopy study. Hock C, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1103–8

Regional alterations of ATP and heat-shock protein-72 mRNA following hypoxia-ischemia in neonatal rat brain. Kobayashi S, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1047–56

Three-dimensional imaging of nitric oxide production in the rat brain subjected to ischemia-hypoxia. Kuppusamy P, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):899–903

Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. Schulz JB, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):948–52

Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure. Marrades RM, et al. **J Clin Invest** 1996 May 1;97(9):2092–100

Cellular bioenergetics after erythropoietin therapy in chronic renal failure. Marrades RM, et al. **J Clin Invest** 1996 May 1;97(9):2101–10

Myoglobin O2 desaturation during exercise. Evidence of limited O2 transport. Richardson RS, et al. **J Clin Invest** 1995 Oct;96(4):1916–26

Rate of aerobic metabolism and superoxide production rate potential in the nematode Caenorhabditis elegans. Vanfleteren JR, et al. **J Exp Zool** 1996 Feb 1;274(2):93–100

Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal-hypertensive gastropathy: effects on gastric mucosal haemodynamics and oxygenation. Iwao T, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):216–22

Oxygen sensing by ion channels and chemotransduction in single glomus cells. Montoro RJ, et al. **J Gen Physiol** 1996 Jan;107(1):133–143

Oxygen transport by fetal bovine hemoglobin. Clementi ME, et al. **J Mol Biol** 1996 Jan 12;255(1):229–34

An allosteric theory for hemoglobin incorporating asymmetric states to test the putative molecular code for cooperativity. Edelstein SJ. **J Mol Biol** 1996 Apr 12; 257(4):737–44

Crystal structure of T state haemoglobin with oxygen bound at all four haems. Paoli M, et al. **J Mol Biol** 1996 Mar 8;256(4):775–92

Novel pathways involved in recovery of guanine nucleotides in reperfused ischaemic rat hearts and reoxygenated myocytes. Stanley PG, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1797–807

Interaction of singlet oxygen with 5'-nucleotidase in rat hearts. Zhai X, et al. **J Mol Cell Cardiol** 1995 Nov; 27(11):2453–64

Dose/response curves of lipoic acid R-and S-forms in the working rat heart during reoxygenation: superiority of the R-enantiomer in enhancement of aortic flow. Zimmer G, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1895–903

Progression of atrophy of the corpus callosum with deterioration of cerebral cortical oxygen metabolism after carotid artery occlusion: a follow up study with MRI and PET. Yamauchi H, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):420–6

Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. Schulz JB, et al. **J Neurosci** 1996 Aug 1;16(15):4696–706

Altered lipid metabolism in the presence and absence of extracellular Ca2+ during combined oxygen-glucose deprivation in primary astrocyte cultures. Murphy EJ, et al. **J Neurosci Res** 1995 Sep 1;42(1):109–16

The Q10 ratio for basal cerebral metabolic rate for oxygen in rats. Klementavicius R, et al. **J Neurosurg** 1996 Sep; 85(3):482–7

Suppression of cerebral metabolic rate for oxygen (CMRO2) by mild hypothermia compared with thiopental. Nemoto EM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):52–9

In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. Ballinger JR, et al. **J Nucl Med** 1996 Jun; 37(6):1023–31

The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. Taylor BM, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1224–31

A nitric oxide-sensitive electrode: requirement of lower oxygen concentration for detecting nitric oxide from the tissue. Ishida Y, et al. **J Pharmacol Toxicol Methods** 1996 Feb;35(1):19–24

KATP channel mediation of anoxia-induced outward current in rat dorsal vagal neurons in vitro. Trapp S, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):37–50

Non-linear relationship between O2 uptake and power output at high intensities of exercise in humans. Zoladz JA, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):211–7

Influence of culture system and oxygen tension on the development of ovine zygotes matured and fertilized in vitro. Bernardi ML, et al. **J Reprod Fertil** 1996 Mar; 106(2):161–7

Oxygenation in tumors by modified hemoglobins. Nozue M, et al. **J Surg Oncol** 1996 Jun;62(2):109–14

A theoretical analysis of intracellular oxygen diffusion. Dutta A, et al. **J Theor Biol** 1995 Oct 21;176(4):433–45

Tissue oxygenation with graded dissolved oxygen delivery during cardiopulmonary bypass. Holman WL, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):774–85

Regional generation of free oxygen radicals during cardiopulmonary bypass in children. Pesonen EJ, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):768–73

A new method of superoxide free radical determination in ischemia and reperfusion injury of rat liver. Wu WG, et al. **J Tongji Med Univ** 1995;15(3):151–3

The role of toxic oxygen metabolites in a young model of thermal injury. Horton JW, et al. **J Trauma** 1995 Sep; 39(3):563–9

Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. Levy PS, et al. **J Trauma** 1996 Sep;41(3):416–23

Decreased PO2 and rabbit aortic smooth muscle mechanics. Moreland RS, et al. **J Vasc Res** 1995 Sep–Oct;32(5):313–9

Different effects of removing extracellular Ca2+ on cytosolic Ca2+ response to anoxia of sensory neurons and carotid chemoreceptor cells from newborn rabbits. Sato M. **Jpn J Physiol** 1995;45(2):279–89

Decline in maximal oxygen uptake on work performance in rats during the developmental phase. Yano H, et al. **Jpn J Physiol** 1995;45(5):889–93

Ischemia increases neutrophil retention and worsens acute renal failure: role of oxygen metabolites and ICAM 1. Linas SL, et al. **Kidney Int** 1995 Nov;48(5):1584–91

Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. Monti JP, et al. **Kidney Int** 1995 Sep;48(3):827–31

Capsaicin-induced biphasic oxygen uptake in rat muscle: antagonism by capsazepine and ruthenium red provides further evidence for peripheral vanilloid receptor subtypes (VN1/VN2). Griffiths CD, et al. **Life Sci** 1996;59(2):105–17

Regional myocardial oxygen tension: 19F MRI of sequestered perfluorocarbon. Shukla HP, et al. **Magn Reson Med** 1996 Jun;35(6):827–33

Reactions of the Escherichia coli flavohaemoglobin (Hmp) with NADH and near-micromolar oxygen: oxygen affinity of NADH oxidase activity. Poole RK, et al. **Microbiology** 1996 May;142 (Pt 5):1141–8

Influence of microvascular architecture on oxygen exchange in skeletal muscle. Pittman RN. **Microcirculation** 1995 May; 2(1):1–18 (67 ref.)

pO2 measurements in arteriolar networks. Torres Filho IP, et al. **Microvasc Res** 1996 Mar;51(2):202–12

Arteriolar contribution to microcirculatory CO2/O2 exchange. Ye GF, et al. **Microvasc Res** 1995 Nov; 50(3):338–59

Intron-specific stimulation of anaerobic gene expression and splicing efficiency in maize cells. Köhler U, et al. **Mol Gen Genet** 1996 May 23;251(2):252–8

Effects of upstream deletions on light- and oxygen-regulated bacterio-opsin gene expression in Halobacterium halobium. Gropp F, et al. **Mol Microbiol** 1995 Apr;16(2):357–64

Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants. Duval DL, et al. **Mol Pharmacol** 1996 Aug;50(2):277–84

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comments] Graeber TG, et al. **Nature** 1996 Jan 4;379(6560):88–91. Comment in: Nature 1996 Jan 4;379(6560):19–20. Comment in: Nature 1996 Mar 14;380(6570):100.

Life (and death) in a malignant tumour [news; comment]

Kinzler KW, et al. **Nature** 1996 Jan 4;379(6560):19–20. Comment on: Nature 1996 Jan 4;379(6560):88–91.

Kinetic trapping of oxygen in cell respiration. Verkhovsky MI, et al. **Nature** 1996 Mar 21;380(6571):268–70

Evidence for a spinal origin of the effect of baclofen on the myocardial oxygen demand indexes. Monassier L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):550–6

Effect of hypoxia and reoxygenation on regional activity of nitric oxide synthase in brain of newborn piglets. Jiang K, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):199–203

Signal changes in gradient echo images of human brain induced by hypo- and hyperoxia. Rostrup E, et al. **NMR Biomed** 1995 Feb;8(1):41–7

Calcium channel blockers in experimental acute pancreatitis: effect on tissue prostanoids and oxygen free radicals. Closa D, et al. **Pancreas** 1996 Mar;12(2):178–82

Oxygen radical generation and acute pancreatitis: effects of dibutyltin dichloride/ethanol and ethanol on rat pancreas. Weber H, et al. **Pancreas** 1995 Nov;11(4):382–8

A computer algorithm for differentiating valid from distorted pulse oximeter waveforms in neonates. Adams JA, et al. **Pediatr Pulmonol** 1995 May;19(5):307–11

Influence of post-hypoxia reoxygenation conditions on energy metabolism and superoxide production in cultured neurons from the rat forebrain. Oillet J, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):598–603

Regional cerebral oxygenation during cardiopulmonary bypass. Baris RR, et al. **Perfusion** 1995 Jul;10(4):245–8

A dynamic phantom brain model for near-infrared spectroscopy. Kurth CD, et al. **Phys Med Biol** 1995 Dec; 40(12):2079–92

The effect of overlying tissue on the spatial sensitivity profile of near-infrared spectroscopy. Okada E, et al. **Phys Med Biol** 1995 Dec;40(12):2093–108

Pseudoreversion substitution at large-subunit residue 54 influences the CO2/O2 specificity of chloroplast ribulose-bisphosphate carboxylase/oxygenase. Spreitzer RJ, et al. **Plant Physiol** 1995 Oct;109(2):681–5

Reaction of the Escherichia coli quinol oxidase cytochrome bo3 with dioxygen: the role of a bound ubiquinone molecule. Puustinen A, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1545–8

Two mutations in recombinant Hb beta F41(C7)Y, K82 (EF6)D show additive effects in decreasing oxygen affinity. Dumoulin A, et al. **Protein Sci** 1996 Jan;5(1):114–20

The pO2 in a murine tumor after irradiation: an in vivo electron paramagnetic resonance oximetry study. O'Hara JA, et al. **Radiat Res** 1995 Nov;144(2):222–9

Increase in oxygen tension after intraperitoneal N-methyl-DL-aspartate in rat cerebral cortex. Hara S, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct; 90(1):165–8

Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Pournaras CJ. **Retina** 1995;15(4):332–47 (143 ref.)

Interaction of electron leak and proton leak in respiratory chain of mitochondria--proton leak induced by superoxide from an electron leak pathway of univalent reduction of oxygen. Liu S, et al. **Sci China C Life Sci** 1996 Apr; 39(2):168–78

A possible path for mercury in biological systems: the oxidation of metallic mercury by molecular oxygen in aqueous solutions. de Magalhães ME, et al. **Sci Total Environ** 1995 Sep 29;170(3):229–39

A trinuclear intermediate in the copper-mediated reduction of O2: four electrons from three coppers. Cole AP, et al. **Science** 1996 Sep 27;273(5283):1848–50

Hypoxia and modification of the endothelium: implications for regulation of vascular homeostatic properties. Pinsky DJ, et al. **Semin Cell Biol** 1995 Oct;6(5):283–94 (49 ref.)

Improvement in oxygenation after large volume paracentesis. Byrd RP Jr, et al. **South Med J** 1996 Jul;89(7):689–92

Relevant parameters for describing the oxygenation status of solid tumors. Thews O, et al. **Strahlenther Onkol** 1996 May;172(5):239–43

Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons. Touzani O, et al. **Stroke** 1995 Nov;26(11):2112–9

Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking. Roberts CM, et al. **Thorax** 1996 Aug;51(8):831–4

Mechanism of inhibiting effect of biologically active compounds on the active forms of oxygen reduction. Gromovaya VF, et al. **Ukr Biokhim Zh** 1995 Mar–Apr; 67(2):86–90

The role of phosphatidylglycerol as a functional effector and membrane anchor of the D1-core peptide from photosystem II-particles of the cyanobacterium Oscillatoria chalybea. Kruse O, et al. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):380–90

Pulmonary ventilation, mechanics, gas exchange and haemodynamics in calves following intratracheal inoculation of Pasteurella haemolytica. Linden A, et al. **Zentralbl Veterinarmed A** 1995 Oct;42(8):531–44

[A study of human keloid with electron spin resonance] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):9–11 (Eng. Abstr.) **(Chi)**

[Scavenging effects of daphnetin and its Cu, Zn complexes on superoxide radical] Hu D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):749–50, 764 (Eng. Abstr.) **(Chi)**

[In vitro experiment on scavenging oxy-radical and suppressing myocardial lipid peroxidation with sini decoction] Wu W, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):690–1, 701, inside backcover (Eng. Abstr.) **(Chi)**

[Effects of oxygen free radicals on myocardial alpha 1-adrenoceptor and its subtypes in rat] Gong HB, et al. **Sheng Li Hsueh Pao** 1996 Feb;48(1):48–52 (Eng. Abstr.) **(Chi)**

[Relations between body oxygen requirement, transport, consumption and tissue extraction] Annat G, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:1–2 **(Fre)**

[Perspectives for the use of oxygen carriers as erythrocyte substitutes in surgery] Riess JG. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:107–17 **(Fre)**

[Probable effect of hemofiltration on hemodynamics and tissue oxygenation in shock secondary to severe malaria] Hommel D, et al. **Cah Anesthesiol** 1996;44(2):163–6 (Eng. Abstr.) **(Fre)**

[Continuous measurement of myocardial oxygen saturation using near-infrared spectroscopy during warm blood cardioplegia] Yasuda T, et al. **Kyobu Geka** 1995 Oct; 48(11):915–8 (Eng. Abstr.) **(Jpn)**

[Cerebral oxygen saturation (rSo2) during open heart surgery and postoperative brain dysfunction] Konishi A, et al. **Masui** 1995 Oct;44(10):1322–6 (Eng. Abstr.) **(Jpn)**

[Active oxygens and free radicals in the eye diseases (editorial)] Hiramitsu T. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1289–90 **(Jpn)**

[Changes in vitreous structure caused by oxygen free radicals] Ueno N. **Nippon Ganka Gakkai Zasshi** 1995 Dec; 99(12):1342–60 (90 ref.) (Eng. Abstr.) **(Jpn)**

[A comparison of changes of cerebrovascular oxygen saturation in retrograde and selective cerebral perfusion during aortic arch surgery] Higami T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1919–23 (Eng. Abstr.) **(Jpn)**

[Evaluation of tissue oxygenation utilizing a tonometer in the stomach tube or colon used in substitutive esophagus after surgery for esophageal cancer] Kusano C, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):795–800 (Eng. Abstr.) **(Jpn)**

[Expired gas analysis—focused on VO2 max and anaerobic threshold] Omiya K. **Rinsho Byori** 1996 Jul;44(7):605–10 (Eng. Abstr.) **(Jpn)**

[Bacterial nutrition and respiration] Dumitrescu V. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar; 40(1):9–16 (8 ref.) **(Rum)**

[Morphological changes in erythrocytes exposed to perfluorodecalin and oxygenation] Skorik VI, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):535–9 **(Rus)**

[Role of the hemoglobin's affinity for oxygen in activating lipid peroxidation in fever] Zinchuk VV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):44–7 **(Rus)**

[Effect of short-term stimulation of muscles on affinity of hemoglobin for oxygen in cats] Irzhak LI, et al. **Dokl Akad Nauk** 1995 Sep;344(3):425–6 **(Rus)**

[Nonphosphorylating respiration as the mechanism preventing the formation of active forms of oxygen] Skulachev VP. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1199–209 (54 ref.) **(Rus)**

PHARMACOKINETICS

Assessment of dextran 10-benzene-tetracarboxylate-hemoglobin, an oxygen carrier, using guinea pig isolated bowel model. Faivre B, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):495–504

An overview on oxygen carriers in cancer therapy. Teicher BA. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):395–405 (60 ref.)

Nitrous oxide and the rate of gas uptake from an unventilated lung in dogs. Joyce CJ, et al. **Br J Anaesth** 1996 Feb; 76(2):292–6

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu-Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)

Influence of gas composition on convective and diffusive intrapulmonary gas transport. Schulz H, et al. **Exp Lung Res** 1995 Nov–Dec;21(6):853–76

The relationship between systemic oxygen uptake and delivery during moderate hypothermic cardiopulmonary bypass: critical values and effects of vasodilation by hydralazine. Cavaliere F, et al. **Perfusion** 1995 Sep; 10(5):315–21

Effect of transfusion on oxygen transport in critically ill patients. Gramm J, et al. **Shock** 1996 Mar;5(3):190–3

The role of hemoglobin based blood substitutes in transfusion medicine. Bunn HF. **Transfus Clin Biol** 1995;2(6):433–9

[Conception and development of a new generation of oxygen carriers] Samain D, et al. **Transfus Clin Biol** 1995; 2(6):449–52 **(Fre)**

[The diffusion permeability of the wall of the animal lung for oxygen, carbon dioxide, nitrogen and helium] Vetosh AN, et al. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):101–4 **(Rus)**

PHARMACOLOGY

Oxygen and carbon dioxide requirements of Helicobacter pylori. Narikawa S, et al. **Acta Microbiol Immunol Hung** 1995;42(4):367–71

The postnatal potentiation of chemoreceptor sensitivity to O2 and CO2 in the in vitro rat carotid body is blunted by chronic hypoxaemia. Development of chemosensitivity. Kumar P, et al. **Adv Exp Med Biol** 1995;393:317–22

Effects of oxygen on regional hemodynamics in hemorrhagic shock. Bitterman H, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H203–11

Adhesion of flowing neutrophils to cultured endothelial cells after hypoxia and reoxygenation in vitro. Rainger GE, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1398–406

Postnatal age at onset of hyperoxic exposure influences developmentally regulated tropoelastin gene expression in the neonatal rat lung. Bruce MC, et al. **Am J Respir Cell Mol Biol** 1996 Feb;14(2):177–85

Effect of gas density on respiratory sounds. Pasterkamp H, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1087–92

Hexokinase production from S. cerevisiae. Culture conditions. Abrahão-Neto J, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:407–12

Oxygen regulation of the cytochrome c oxidase subunit VI gene, COX6, in Saccharomyces cerevisiae. Wright RM, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):676–85

Oxygen dependence of hepatocyte susceptibility to mitochondrial respiratory inhibitors. Niknahad H, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1859–65

Effects of inspired gas composition during anaesthesia for abdominal hysterectomy on postoperative lung volumes. Joyce CJ, et al. **Br J Anaesth** 1995 Oct;75(4):417–21

Effect of inspired oxygen on the cardiovascular effects of protamine after cardiopulmonary bypass. Lomax D, et al. **Br J Anaesth** 1995 Oct;75(4):413–6

Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Koch CJ, et al. **Br J Cancer** 1995 Oct;72(4):869–74

The effect of post-asphyxial reoxygenation with 21% vs. 100% oxygen on Na+,K(+)-ATPase activity in striatum of newborn piglets. Goplerud JM, et al. **Brain Res** 1995 Oct 23;696(1-2):161–4

Transcription of the AAC1 gene encoding an isoform of mitochondrial ADP/ATP carrier in Saccharomyces cerevisiae is regulated by oxygen in a heme-independent manner. Gavurníková G, et al. **Eur J Biochem** 1996 Aug 1;239(3):759–63

Effects of low oxygen tension and antioxidants on human erythropoiesis in vitro. Ono K, et al. **Exp Hematol** 1995 Dec;23(13):1372–7

Sod and catalase inactivation by singlet oxygen and peroxyl radicals. Escobar JA, et al. **Free Radic Biol Med** 1996; 20(3):285–90

Expression of stress response genes GADD153, c-jun, and heme oxygenase-1 in H2O2- and O2-resistant fibroblasts. Guyton KZ, et al. **Free Radic Biol Med** 1996;20(5):735–41

An oxygen-induced but protein F-independent fibronectin-binding pathway in Streptococcus pyogenes. Lee JY, et al. **Infect Immun** 1996 Feb;64(2):413–21

Control of ammonia formation during Bacillus subtilis fermentation of legumes. Allagheny N, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):321–33

Influence of environmental oxygen concentration on growth and vascular density of the area vasculosa in chick embryos. Höper J, et al. **Int J Microcirc Clin Exp** 1995 Jul–Aug; 15(4):186–92

Oxygen effect in the radiolysis of proteins. IV. Myoglobin. Puchała M, et al. **Int J Pept Protein Res** 1995 Sep–Oct; 46(3–4):326–32

Repair of semi-oxidized 3,5-diiodotyrosine: radiation chemical studies in the presence of oxygen, ascorbate and superoxide anion. Das TN. **Int J Radiat Biol** 1996 Jul; 70(1):7–13

Radiation-modifying effect of oxygen in synchronized cells pre-treated with acute or prolonged hypoxia. Pettersen EO, et al. **Int J Radiat Biol** 1996 Sep;70(3):319–26

Towards noninvasive human tumor physiologic measurements [editorial; comment] Okunieff P. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):961–2. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):855–9.

Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging [see comments] Robinson SP, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):855–9. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):961–2.

Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Rojas A, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):357–65

Oxygen modulates the response of the retinal pigment epithelium to basic fibroblast growth factor and epidermal growth factor by receptor regulation. Khaliq A, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):436–43

Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Takagi H, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1311–21

Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae. König C, et al. **J Antimicrob Chemother** 1995 Sep;36(3):513–9

Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. Smith MA, et al. **J Antimicrob Chemother** 1995 Jun; 35(6):751–64

The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and beta-lactam antibiotics. Tresse O, et al. **J Antimicrob Chemother** 1995 Sep;36(3):521–6

Effect of baseline oxygenation on the ventilatory response to inhaled 100% oxygen in preterm infants. Haider AZ, et al. **J Appl Physiol** 1995 Dec;79(6):2101–5

Proteolytic degradation of dinitrogenase reductase from Anabaena variabilis (ATCC 29413) as a consequence of ATP depletion and impact of oxygen. Durner J, et al. **J Bacteriol** 1996 Feb;178(3):606–10

Electron transport-dependent taxis in Rhodobacter sphaeroides. Gauden DE, et al. **J Bacteriol** 1995 Oct; 177(20):5853–9

Effect of microaerophilic cell growth conditions on expression of the aerobic (cyoABCDE and cydAB) and anaerobic (narGHJI, frdABCD, and dmsABC) respiratory pathway genes in Escherichia coli. Tseng CP, et al. **J Bacteriol** 1996 Feb;178(4):1094–8

Adaptation of chondrocytes to low oxygen tension: relationship between hypoxia and cellular metabolism. Rajpurohit R, et al. **J Cell Physiol** 1996 Aug;168(2):424–32

Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. Liao JK, et al. **J Clin Invest** 1995 Dec;96(6):2661–6

Nematode development is inhibited by methyl viologen and high oxygen concentrations at a rate inversely proportional to life span. Hartman P, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B322–6

Oxidative modification and antioxidant protection of human low density lipoprotein at high and low oxygen partial pressures. Hatta A, et al. **J Lipid Res** 1995 Nov; 36(11):2383–93

Progression of cardiac potassium current modification after brief exposure to reactive oxygen. Tarr M, et al. **J Mol Cell Cardiol** 1995 May;27(5):1099–109

Elemental composition and water content of rat optic nerve myelinated axons and glial cells: effects of in vitro anoxia and reoxygenation. LoPachin RM Jr, et al. **J Neurosci** 1995 Oct;15(10):6735–46

Modulation of a neural network by physiological levels of oxygen in lobster stomatogastric ganglion. Massabuau JC, et al. **J Neurosci** 1996 Jun 15;16(12):3950–9

Functional inhibition of rat polymorphonuclear leukocyte B2 integrins by hyperbaric oxygen is associated with impaired cGMP synthesis. Chen Q, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):929–33

Determination of Km for oxygen of nitric oxide synthase isoforms. Rengasamy A, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):30–3

Protection of plasmid pBR322 DNA by flavonoids against single-stranded breaks induced by singlet molecular oxygen. Devasagayam TP, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):97–103

Inactivation of viruses by chemically and photochemically generated singlet molecular oxygen. Müller-Breitkreutz K, et al. **J Photochem Photobiol B** 1995 Sep;30(1):63–70

Influence of hypoxic duration and posthypoxic inspired O2 concentration on short term potentiation of breathing in humans. Dahan A, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):803–13

Oxygenation in tumors by modified hemoglobins. Nozue M, et al. **J Surg Oncol** 1996 Jun;62(2):109–14

Mechanisms of reoxygenation-induced calcium overload in cardiac myocytes: dependence on pHi. Matsuda N, et al. **J Surg Res** 1995 Dec;59(6):712–8

Fetal model of single ventricle physiology: hemodynamic effects of oxygen, nitric oxide, carbon dioxide, and hypoxia in the early postnatal period. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):437–49

Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. Daley JT, et al. **J Urol** 1996 Apr;155(4):1482–7

Endogenous reactive oxygen metabolites mediate sublethal endothelial cell dysfunction during reoxygenation. Watkins MT, et al. **J Vasc Surg** 1996 Jan;23(1):95–103

Induction of DNA polymerase beta and gamma in the lungs of age-related oxygen tolerant rats. Jinno S, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):95–107

Relevance of oxidative stress to the limited replicative capacity of cultured human diploid cells: the limit of cumulative population doublings increases under low concentrations of oxygen and decreases in response to aminotriazole. Yuan H, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):159–68

Tritrichomonas foetus and Trichomonas vaginalis: the pattern of inactivation of hydrogenase activity by oxygen and activities of catalase and ascorbate peroxidase. Page-Sharp M, et al. **Microbiology** 1996 Jan;142 (Pt 1):207–11

Expression of the thioredoxin gene (trxA) in Rhodobacter sphaeroides Y is regulated by oxygen. Pasternak C, et al. **Mol Gen Genet** 1996 Feb 5;250(2):189–96

Factors affecting the developmental competence of mouse oocytes grown in vitro: oxygen concentration. Eppig JJ, et al. **Mol Reprod Dev** 1995 Dec;42(4):447–56

Effects of beta-carotene and alpha-tocopherol on photogenotoxicity induced by 8-methoxypsoralen: the role of oxygen. Bianchi L, et al. **Mutat Res** 1996 Aug 12; 369(3–4):183–94

Oxygen concentration and the oxidation-reduction state of yeast: determination of free/bound NADH and flavins by time-resolved spectroscopy. Paul RJ, et al. **Naturwissenschaften** 1996 Jan;83(1):32–5

Postnatal rat lung retinoic acid receptor (RAR) mRNA expression and effects of dexamethasone on RAR beta mRNA. Grummer MA, et al. **Pediatr Pulmonol** 1995 Oct; 20(4):234–40

Effect of indomethacin on cerebral blood flow and oxygenation in the normal and ventilated fetal lamb. Van Bel F, et al. **Pediatr Res** 1995 Aug;38(2):243–50

Effects of variation in oxygen tension on responses of the human fetoplacental vasculature to vasoactive agents in vitro. Read MA, et al. **Placenta** 1995 Dec;16(8):667–78

Film oxygen transmission rate effects on ground chicken meat quality. Dawson PL, et al. **Poult Sci** 1995 Aug;74(8):1381–7

Radiation-induced cell lethality of Salmonella typhimurium ATCC 14028: cooperative effect of hydroxyl radical and oxygen. Kim AY, et al. **Radiat Res** 1995 Oct;144(1):36–42

Comments on "Radiation-induced apoptosis in HL60 cells: oxygen effect, relationship between apoptosis and loss of clonogenicity, and dependence of time to apoptosis on radiation dose" by Hopcia et al. (Radiat. Res. 145, 315–323, 1996) [letter] Makepeace CM, et al. **Radiat Res** 1996 Jul; 146(1):116–9

Effects of oxygen, CO2/pH and medium on the in vitro development of individually cultured porcine one- and two-cell embryos. Berthelot F, et al. **Reprod Nutr Dev** 1996;36(3):241–51

[The effects of dopa and oxygen on RNA concentrations in cultured chick embryonal retinal pigment epithelial cells] Kanda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Oct; 99(10):1123–6 (Eng. Abstr.) **(Jpn)**

[Electron microscopic studies of retinal pigment epithelial cells incubated with L-dopa in 10% and 20% oxygen] Muraki Y, et al. **Nippon Ganka Gakkai Zasshi** 1995 Nov; 99(11):1203–8 (Eng. Abstr) **(Jpn)**

PHYSIOLOGY

Hypoxic and hypercapnic ventilatory responses during isoflurane sedation and anaesthesia in women. Sollevi A, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):931–8

Maternal prepregnant weight and weight gain: relationship to placental microstructure and morphometric oxygen diffusion capacity. Stevens-Simon C, et al. **Am J Perinatol** 1995 Nov;12(6):407–12

Does sleep enhance the effect of subanesthetic isoflurane on hypoxic ventilation? Foo IT, et al. **Anesth Analg** 1995 Oct; 81(4):751–6

Monitoring lung compliance and end-tidal oxygen content for the detection of venous air embolism. Kyttä J, et al. **Br J Anaesth** 1995 Oct;75(4):447–51

Cell selective induction and transcriptional activation of immediate early genes by hypoxia. Prabhakar NR, et al. **Brain Res** 1995 Oct 30;697(1–2):266–70

Acute mountain sickness relates to sea-level partial pressure of oxygen. Savourey G, et al. **Eur J Appl Physiol** 1995; 70(6):469–76

The role of oxygen in thymocyte apoptosis. McLaughlin KA, et al. **Eur J Immunol** 1996 May;26(5):1170–4

Paradoxical transcutaneous oxygen response to cutaneous warming on the plantar foot surface: a caution for interpretation of plantar foot TcPO2 measurements. Smith DG, et al. **Foot Ankle Int** 1995 Dec;16(12):787–91

Effects of oxygen on wound responses to growth factors: Kaposi's FGF, but not basic FGF stimulates repair in ischemic wounds. Wu L, et al. **Growth Factors** 1995; 12(1):29–35

A model analysis of asymmetrical response of pulmonary VO2 during incremental and decremental ramp exercise. Niizeki K, et al. **J Appl Physiol** 1995 Nov;79(5):1816–27

High arrythmogenesis during early reperfusion of ischaemic myocardium: participation of oxygen free radicals. Ravingerova T, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct-Dec;4(4):335–46

Role of nitric oxide in the elevation of cerebral blood flow induced by acetylcholine and anoxia in the turtle. Hylland P, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):290–5

Basis for aerobic impairment in patients after heart transplantation. Bussières LM, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1073–80

Congenital heart disease with ductal-dependent systemic perfusion: Doppler ultrasonography flow velocities are altered by changes in the fraction of inspired oxygen. Day RW, et al. **J Heart Lung Transplant** 1995 Jul-Aug; 14(4):718–25

Polymorphonuclear leukocyte opsonic receptor expression after hypoxia/reoxygenation. Simms H, et al. **J Lab Clin Med** 1996 Apr;127(4):364–81

An obligate role for oxygen in the early stages of glutamate-induced, delayed neuronal death. Dubinsky JM, et al. **J Neurosci** 1995 Nov;15(11):7071–8

Effect of NaN3 on oxygen-dependent lethality of UV-A in Escherichia coli mutants lacking active oxygen-defence and DNA-repair systems. Yamada K, et al. **J Radiat Res (Tokyo)** 1996 Mar;37(1):29–37

Electrical heterogeneity and conduction block in reoxygenated guinea pig papillary muscles. Hayashi H, et al. **Jpn Heart J** 1996 May;37(3):383–91

Effects of middle ear oxygen and carbon dioxide tensions on eustachian tube ventilatory function. Shupak A, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):221–4

Lung cyclic nucleotides in exercise-trained rats attenuate hypoxic pulmonary vasoconstriction. Kashimura O, et al. **Lung** 1995;173(6):363–72

Virtually unaltered permeability-surface area products imply little capillary recruitment in brain with hypoxia. Chen JL, et al. **Microcirculation** 1994 Apr;1(1):35–47

Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Boucher Y, et al. **Microvasc Res** 1995 Sep;50(2):175–82

Little difference [letter; comment] Wenger RH, et al. **Nature** 1996 Mar 14;380(6570):100. Comment on: Nature 1996 Jan 4;379(6560):88–91.

The hemodynamic effects of maternal hypo- and hyperoxygenation in healthy term pregnancies. Polvi HJ, et al. **Obstet Gynecol** 1995 Nov;86(5):795–9

Red blood cell flow cessation and diameter reductions in skeletal muscle capillaries in vivo – the role of oxygen. Bosman J, et al. **Pflugers Arch** 1995 Sep;430(5):852–61

Oxygen consumption and body temperature rhythms in the golden spiny mouse: responses to changes in day length. Haim A, et al. **Physiol Behav** 1995 Oct;58(4):775–8

Oxygen sensing and molecular adaptation to hypoxia. Bunn HF, et al. **Physiol Rev** 1996 Jul;76(3):839–85 (388 ref.)

Bronchodilator, oxygen level, and temperature effects on ascites incidence in broiler chickens. Vanhooser SL, et al. **Poult Sci** 1995 Oct;74(10):1586–90

Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9493–8 (63 ref.)

Rat diaphragm muscle contraction with and without oxygen enrichment. Gölgeli A, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):87–95

Cardio-ventilatory control in rainbow trout: I. Pharmacology of branchial, oxygen-sensitive chemoreceptors. Burleson ML, et al. **Respir Physiol** 1995 Jun;100(3):231–8

Hypoxia-inducible gene expression. Fandrey J. **Respir Physiol** 1995 Jul;101(1):1–10 (47 ref.)

Nucleoside triphosphate levels versus oxygen affinity of rattlesnake red cells. Ragsdale FR, et al. **Respir Physiol** 1995 Oct;102(1):63–9

Integrative cybernetic model of oxygen homeostasis. Baciu I, et al. **Rom J Physiol** 1994 Jan-Dec;31(1–4):25–45

Altered oxygen tension modulates cytokine-induced signal transduction in polymorphonuclear leukocytes: regulation of the GPLD pathway. Derevianko A, et al. **Shock** 1996 Feb;5(2):97–105

Effects of glucose on rat lung preservation: report of a study conducted on an isolated lung reperfusion model utilizing. Another isolated lung as a "deoxygenator". Hanagiri T, et al. **Surg Today** 1995;25(6):542–7

Pathophysiology of myocardial reperfusion injury: role of oxygen free radicals. Ashraf M, et al. **Transplant Proc** 1995 Oct;27(5):2800–1

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

POISONING

A diving fatality due to oxygen toxicity during a "technical" dive. Lawrence CH. **Med J Aust** 1996 Sep 2;165(5):262–3

Inhibition of nitric oxide synthase on brain oxygenation in anesthetized rats exposed to hyperbaric oxygen. Zhang J, et al. **Undersea Hyperb Med** 1995 Dec;22(4):377–82

THERAPEUTIC USE

Supplemental oxygen during endoscopic variceal ligation: effects on arterial oxygenation and cardiac arrhythmia. Iwao T, et al. **Am J Gastroenterol** 1995 Dec;90(12):2186–90

The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)

Multidisciplinary education for oxygen prescription. A continuous quality improvement study. Cook DJ, et al. **Arch Intern Med** 1996 Sep 9;156(16):1797–801

Effects of hyperoxia on bacterial translocation and mortality during gut-derived sepsis. Gennari R, et al. **Arch Surg** 1996 Jan;131(1):57–62

Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Dupuis NP, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):423–9

Oxygen inhalation in nonhypoxic sickle cell patients during vaso-occlusive crisis [letter] Khoury H, et al. **Blood** 1995 Nov 15;86(10):3998

The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Brizel DM, et al. **Br J Cancer** 1995 Nov;72(5):1120–4

Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Harris A, et al. **Br J Ophthalmol** 1996 Mar; 80(3):209–13

Evaluation of heliox in children hospitalized with acute severe asthma. A randomized crossover trial. Carter ER,

et al. **Chest** 1996 May;109(5):1256–61

Heliox therapy for acute vocal cord dysfunction [letter; comment] Reisner C, et al. **Chest** 1995 Nov;108(5):1477. Comment on: Chest 1995 Mar;107(3):757–60.

Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Hjalmarsen A, et al. **Diabetes Metab** 1996 Feb;22(1):37–42

Current concepts in the diagnosis and treatment of sudden sensorineural hearing loss. Schweinfurth JM, et al. **Ear Arch Otorhinolaryngol** 1996;253(3):117–21

Heliox inhalation in status asthmaticus and respiratory acidemia: a brief report. Austan F. **Heart Lung** 1996 Mar–Apr;25(2):155–7

Efficacy of oxygenated University of Wisconsin solution containing endothelin–A receptor antagonist in twenty–four–hour heart preservation. Okada K, et al. **J Heart Lung Transplant** 1996 May;15(5):475–84

Use of simple clinical parameters to assess severity of bronchiolitis. Mai TV, et al. **J Paediatr Child Health** 1995 Oct;31(5):465–8

Predicting hypoxia in children with acute lower respiratory infection: a study in the highlands of Papua New Guinea. Dyke T, et al. **J Trop Pediatr** 1995 Aug;41(4):196–201

Heliox treatment for pneumatosis cystoides coli [letter; comment] O'Toole PA, et al. **Lancet** 1995 Dec 2; 346(8988):1498–9. Comment on: Lancet 1995 May 13;345(8959):1220–2.

Anterior chamber paracentesis and carbogen treatment of acute CRAO [letter] Gombos GM. **Ophthalmology** 1996 Jun;103(6):865

Prehospital management of asthmatic children [letter; comment] Perry RF, et al. **Pediatr Emerg Care** 1996 Feb; 12(1):71–2. Comment on: Pediatr Emerg Care 1995 Aug;11(4):217–9.

The effects of hyperoxia, mechanical ventilation, and dexamethasone on pulmonary antioxidant enzyme activity in the newborn piglet. Davis JM, et al. **Pediatr Pulmonol** 1995 Aug;20(2):107–11

Blunted peripheral chemoreceptor response to hyperoxia in a group of infants with bronchopulmonary dysplasia. Katz–Salamon M, et al. **Pediatr Pulmonol** 1995 Aug; 20(2):101–6

The hazards of using supplemental oxygen [letter; comment] Lach E. **Plast Reconstr Surg** 1996 Sep;98(3):566–7. Comment on: Plast Reconstr Surg 1995 Apr;95(5):924–8.

Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x–ray schedules. Rojas A, et al. **Radiother Oncol** 1996 Apr;39(1):53–64

Effect of oxygen and sodium thiosulfate during combined carbon monoxide and cyanide poisoning. Breen PH, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):229–34

[An initial trial of using pulsed hypoxia incorporating helium in the treatment of chronic obstructive bronchitis] Sil'vestrov VP, et al. **Ter Arkh** 1996;68(3):65–8 **(Rus)**

[Local oxygen therapy combined with ultraviolet irradiation of the suppurative wounds in lactation mastitis] Konstantinov VK, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):287–90 (Eng. Abstr.) **(Rus)**

[Local oxygenation of the area of a gunshot fracture in treating those with extremity wounds] Shapovalov VM, et al. **Voen Med Zh** 1996 Mar;317(3):26–31 **(Rus)**

[The radioprotective action of total gas hypoxia for tumors and normal tissues] Vainson AA, et al. **Vopr Onkol** 1995; 41(2):96–8 **(Rus)**

[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**

TOXICITY

Lipofuscin formation in cultured retinal pigment epithelial cells exposed to photoreceptor outer segment material under different oxygen concentrations. Wihlmark U, et al. **APMIS** 1996 Apr;104(4):265–71

Involvement of Escherichia coli exonuclease III and endonuclease IV in the repair of singlet oxygen–induced DNA damage. Agnez LF, et al. **Carcinogenesis** 1996 May; 17(5):1183–5

Pulmonary O2 toxicity: role of endogenous tumor necrosis factor. Tsan MF, et al. **Exp Lung Res** 1995 Jul–Aug; 21(4):589–97

Influence of oxygen partial pressure on human and mouse myeloid cell line characteristics. Lawrence DA, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):287–93

Oxygen toxicity and antioxidants: state of the art. Sen CK. **Indian J Physiol Pharmacol** 1995 Jul;39(3):177–96 (91 ref.)

Response of cells to radiation sensitizers: methods of analysis [letter] Scott OC, et al. **Int J Radiat Biol** 1995 Sep; 68(3):357–8

Pulmonary oxygen toxicity in mice is characterized by alterations in ascorbate redox status. Rusakow LS, et al. **J Appl Physiol** 1995 Nov;79(5):1769–76

Oxygen toxicity as a function of time and PO2. Arieli R. **J Basic Clin Physiol Pharmacol** 1994 Jan–Mar;5(1):67–87

Cellular oxygen toxicity. Oxidant injury without apoptosis. Kazzaz JA, et al. **J Biol Chem** 1996 Jun 21;271(25):15182–6

Sheep lung cytochrome P4501A1 (CYP1A1): cDNA cloning and transcriptional regulation by oxygen tension. Hazinski TA, et al. **J Clin Invest** 1995 Oct;96(4):2083–9

Intratracheal instillation of keratinocyte growth factor decreases hyperoxia–induced mortality in rats. Panos RJ, et al. **J Clin Invest** 1995 Oct;96(4):2026–33

Hypoxia and reoxygenation–induced injury of renal epithelial cells: effect of free radical scavengers. Yonehana T, et al. **Jpn J Pharmacol** 1995 Jun;68(2):231–4

The effect of flumazenil on CNS oxygen toxicity in the rat. Bitterman N, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):169–74

Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low–frequency electron paramagnetic resonance oximetry. Halpern HJ, et al. **Radiat Res** 1996 May;145(5):610–8

Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Jourdan A, et al. **Thromb Res** 1995 Jul 1;79(1):109–23

[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143–50 (15 ref.) **(Rus)**

[Functional and morphological changes in the respiratory organs of cats after long–term exposure to pure normobaric oxygen] Hanáček J, et al. **Bratisl Lek Listy** 1996 May; 97(5):251–9 (Eng. Abstr.) **(Slo)**

URINE

Monitoring urine oxygen tension during acute change in cardiac output in dogs. Kitashiro S, et al. **J Appl Physiol** 1995 Jul;79(1):202–4

OXYGEN CONSUMPTION

A comparative study of two near infrared spectrophotometers for the assessment of cerebral haemodynamics. Colier WN, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:101–5

Determination of oxygen consumption in muscle during exercise using near infrared spectroscopy. Colier WN, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:151–5

Permissive hypercapnia in ARDS and its effect on tissue oxygenation. Hickling KG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:201–8 (53 ref.)

The influence of arterial carbon dioxide on cerebral oxygenation and haemodynamics during ECMO in normoxaemic and hypoxaemic piglets. Liem KD, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:157–64

Oxygen status during haemodialysis. The Cord–Group. Nielsen AL, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:195–200

Homeostasis–securing therapy and statusmetria. Shifrin GA. **Acta Anaesthesiol Scand Suppl** 1995;107:257–9

Bladder epithelial oxygen tension as a marker of organ perfusion. Singer M, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:77–80

Which blood gas caused the brain damage? Suwa K. **Acta Anaesthesiol Scand Suppl** 1995;107:215–8

Clinical assessment of oxygen delivery and consumption during hypotensive anaesthesia--a clinical application of The Deep Picture. Ueda N, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:189–93

Oxygen uptake/oxygen supply dependency: fact or fiction? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:229–37 (83 ref.)

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37–44 (54 ref.)

Determination of cerebral oxygen consumption and blood flow by magnetic resonance imaging. Ligeti L, et al. **Acta Biomed Ateneo Parmense** 1995;66(3–4):67–74

Simulation of asymmetrical O2 uptake kinetics during incremental and decremental ramp exercise. Niizeki K, et al. **Adv Exp Med Biol** 1995;393:165–71

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)

Modelling the effect of taper on performance, maximal oxygen uptake, and the anaerobic threshold in endurance triathletes. Zarkadas PC, et al. **Adv Exp Med Biol** 1995; 393:179–86

Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production. Murris–Espin M, et al. **Allergy** 1995 Apr;50(4):334–9

Effects of blood donation on exercise performance in competitive cyclists. Panebianco RA, et al. **Am Heart J** 1995 Oct;130(4):838–40

A reassessment of center–of–mass dynamics as a determinate of the metabolic inefficiency of above–knee amputee ambulation. Gitter A, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):332–8

Exercise test in acute myocardial infarction. Hsi WL, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):263–9

Substrate–dependent alteration in O2 consumption and energy metabolism in vascular smooth muscle. Barron JT, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1869–77

Resting oxygenation of rat and rabbit intestine: arteriolar and capillary contributions. Bohlen HG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1342–8

Glucose and oxygen metabolism in the fetal foal during late gestation. Fowden AL, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1455–61

Problems of the virtual work model [letter] Hata Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2229–31

Perfusion–MVO2 mismatch during inotropic stress in CAD patients with normal contractile function. Janier MF, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H59–67

Effects of afferent neural stimulation on critical oxygen delivery: a hemodynamic explanation. Kirkman E, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1448–54

Oxygen consumption, acid–base status, and behavior during and after acute, severe hemorrhage in fetal lambs. Kwan E, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R758–66

Decrease in oxygen cost of contractility during hypocapnic alkalosis in canine hearts. Onishi K, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1905–13

Causes of differences in respiration rate of hepatocytes from mammals of different body mass. Porter RK, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1213–24

Sepsis depresses the metabolic oxygen reserve of the coronary circulation in mature sheep. Bloos FM, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1577–84

O2 supply dependence of respiration in patients with mitral stenosis undergoing valvuloplasty. Budinger GR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1034–40

Serial measures of total body oxygen consumption in an awake canine model of septic shock. Eichacker PQ, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):68–75

Oxygen cost of breathing in patients with emphysema or chronic bronchitis in acute respiratory failure [see comments] Jounieaux V, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2181–4 . Comment in: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1988–9.

Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Maltais F, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):288–93

Increases in peripheral oxygen demand affect blood flow distribution in hemorrhaged dogs. Romand JA, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):203–10

Oxygen cost of breathing in patients with emphysema or chronic bronchitis in acute respiratory failure [letter; comment] Sridhar MK. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1988–9. Comment on: Am J Respir Crit Care Med 1995 Dec;152(6 Pt 1):2181–4.

Lateral traction during shoulder arthroscopy: its effect on tissue perfusion measured by pulse oximetry. Hennrikus WL, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):444–6

Near infra–red spectroscopy [editorial] Harris DN. **Anaesthesia** 1995 Dec;50(12):1015–6 (19 ref.)

Calcium content and respiratory control index of isolated skeletal muscle mitochondria: effects of different isolation media. Madsen K, et al. **Anal Biochem** 1996 May 15; 237(1):37–41

Cerebral microregional oxygen balance during chronic versus acute hypertension in middle cerebral artery occluded rats. Chi OZ, et al. **Anesth Analg** 1996 Mar;82(3):587–92

Brain tissue oxygen, carbon dioxide, and pH in neurosurgical patients at risk for ischemia. Hoffman WE, et al. **Anesth Analg** 1996 Mar;82(3):582–6

Oxygen consumption during profound intraoperative hemodilution [letter; comment] Stemp LI. **Anesth Analg** 1995 Nov;81(5):1115–6. Comment on: Anesth Analg 1995 Feb;80(2):219–25.

Determination of specific oxygen uptake rates in human hematopoietic cultures and implications for bioreactor design. Peng CA, et al. **Ann Biomed Eng** 1996 May–Jun; 24(3):373–81

Peak oxygen uptake of 12–18–year–old boys living in a densely populated urban environment. Barnett A, et al. **Ann Hum Biol** 1995 Nov–Dec;22(6):525–32

Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Gore DC, et al. **Ann Surg** 1996 Jul;224(1):97–102

Neonatal myocardial oxygen consumption during ventricular fibrillation, hypothermia, and potassium arrest. Jessen ME, et al. **Ann Thorac Surg** 1996 Jan;61(1):82–7

Pulmonary oxygen uptake kinetics in nonsteady state. Koga S, et al. **Appl Human Sci** 1996 Jan;15(1):1–4 (26 ref.)

Peak oxygen uptake and respiratory function in persons with spinal cord injury. Yamasaki M, et al. **Appl Human Sci** 1996 Jan;15(1):14–7

Contralateral shoe–lift: effect on oxygen cost of walking with an immobilized knee. Abdulhadi HM, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):670–2

Comparison of maximal oxygen consumption with oral and nasal breathing. Morton AR, et al. **Aust J Sci Med Sport** 1995 Sep;27(3):51–5

The limits of the possible: models of power supply and demand in cycling. Olds T, et al. **Aust J Sci Med Sport** 1995 Jun;27(2):29–33

Myocardial stunning: the role of oxidative substrate metabolism. Lerch R. **Basic Res Cardiol** 1995 Jul–Aug; 90(4):276–8 (10 ref.)

Top–down control analysis of temperature effect on oxidative phosphorylation. Dufour S, et al. **Biochem J** 1996 Mar 15; 314 (Pt 3):743–51

Interrelation between mitochondrial respiration, substrate supply and redox ratio in perifused permeabilized rat hepatocytes. Boschmann M, et al. **Biochim Biophys Acta** 1996 Mar 28;1273(3):223–30

K+–dependent Na+ transport driven by respiration in Escherichia coli cells and membrane vesicles. Verkhovskaya ML, et al. **Biochim Biophys Acta** 1996 Mar 28;1273(3):207–16

Acute effects of indomethacin on cerebral hemodynamics and oxygenation. Benders MJ, et al. **Biol Neonate** 1995; 68(2):91–9

Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure. Chua TP, et al. **Br Heart J** 1995 Oct;74(4):381–5

Comparison between oxygen consumption calculated by Fick's principle using a continuous thermodilution technique and measured by indirect calorimetry. Bizouarn P, et al. **Br J Anaesth** 1995 Dec;75(6):719–23

Gastric tonometry to monitor tissue oxygenation: more than a gut feeling? [editorial] Oh TE. **Br J Anaesth** 1996 May; 76(5):604–5

A comparison of methods of predicting maximum oxygen uptake. Grant S, et al. **Br J Sports Med** 1995 Sep; 29(3):147–52

Cardiorespiratory strain of a five day jogging relay. Oksa J, et al. **Br J Sports Med** 1995 Sep;29(3):165–7

Reciprocal photolabile O2 consumption and chemoreceptor excitation by carbon monoxide in the cat carotid body: evidence for cytochrome a3 as the primary O2 sensor. Lahiri S, et al. **Brain Res** 1995 Jul 3;684(2):194–200

Monitoring tissue perfusion. Vincent JL. **Can J Anaesth** 1996 May;43(5 Pt 2):R55–60 (16 ref.) **(Eng, Fre)**

The effect of an aerobic interval training program on intermittent anaerobic performance. Gaiga MC, et al. **Can J Appl Physiol** 1995 Dec;20(4):452–64

Determination of accumulated O2 deficit in exhaustive short–duration exercise. Hill DW. **Can J Appl Physiol** 1996 Feb;21(1):63–74

Peak oxygen consumption and ventilatory thresholds on six modes of exercise. Smith TD, et al. **Can J Appl Physiol** 1996 Apr;21(2):79–89

Seated versus standing cycling in competitive road cyclists: uphill climbing and maximal oxygen uptake. Tanaka H, et al. **Can J Appl Physiol** 1996 Apr;21(2):149–54

Viability and respiratory activity of Pseudomonas syringae cells starved in buffer. Cabral JP. **Can J Microbiol** 1995 Apr–May;41(4–5):372–7

Hepatocyte injury resulting from the inhibition of mitochondrial respiration at low oxygen concentrations involves reductive stress and oxygen activation. Niknahad H, et al. **Chem Biol Interact** 1995 Oct 20;98(1):27–44

The six–minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure [see comments] Cahalin LP, et al. **Chest** 1996 Aug;110(2):325–32 . Comment in: Chest 1996 Aug;110(2):310–2.

Transient fall in oxygen intake during exercise in congestive heart failure. Cohen–Solal A, et al. **Chest** 1996 Sep; 110(3):841–4

Further increase in oxygen uptake during early active recovery following maximal exercise in chronic heart failure. Daida H, et al. **Chest** 1996 Jan;109(1):47–51

The heart in oxygen debt [editorial; comment] Han J, et al. **Chest** 1995 Oct;108(4):889–91. Comment on: Chest 1995 Oct;108(4):899–902.

Changes in cerebral oxygenation and hemodynamics during obstructive sleep apneas. Hayakawa T, et al. **Chest** 1996 Apr;109(4):916–21

Relationship between the 6–min walk test and maximal oxygen consumption [letter; comment] Jones RL. **Chest** 1996 May;109(5):1412–3. Comment on: Chest 1995 Aug;108(2):452–9.

Acute alterations of oxygen uptake and symptom–limited exercise time in patients with mitral stenosis after balloon valvuloplasty. Kölling K, et al. **Chest** 1995 Nov; 108(5):1206–13

Reproducibility of cardiopulmonary exercise parameters in patients with valvular heart disease. Lehmann G, et al. **Chest** 1996 Sep;110(3):685–92

Role of poly–ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Szabó C, et al. **Circ Res** 1996 Jun;78(6):1051–63

Role of endothelium–derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Xie YW, et al. **Circ Res** 1996 Sep;79(3):381–7

Peak oxygen consumption and resting left ventricular ejection fraction changes after cardiomyoplasty at 6–month follow–up. Bocchi EA, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II216–22

Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Iida H, et al. **Circulation** 1996 Aug 15;94(4):792–807

Determinants of cerebral oxygenation during cardiac surgery. Nollert G, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II327–33

Noninvasive quantification of regional myocardial metabolic rate of oxygen by 15O2 inhalation and positron emission tomography. Experimental validation. Yamamoto Y, et al. **Circulation** 1996 Aug 15;94(4):808–16

Changes in gut intramucosal pH and gut oxygen extraction ratio in a porcine model of peritonitis and hemorrhage. Antonsson JB, et al. **Crit Care Med** 1995 Nov; 23(11):1872–81

Relationship between early patterns of cerebral extraction of oxygen and outcome from severe acute traumatic brain swelling: cerebral ischemia or cerebral viability? Cruz J. **Crit Care Med** 1996 Jun;24(6):953–6

Evaluation of the effects of autotransfusion of unprocessed blood on hemodynamics and oxygen transport in anesthetized pigs. Filos KS, et al. **Crit Care Med** 1996 May; 24(5):855–61

Hazards with both determining and utilizing oxygen consumption measurements in the management of critically ill patients [editorial; comment] Gasman JD, et al. **Crit Care Med** 1996 Jan;24(1):6–9. Comment on: Crit Care Med 1996 Jan;24(1):86–90.

Monitoring of tissue oxygenation in shock: an experimental study in pigs. Schlichting E, et al. **Crit Care Med** 1995 Oct;23(10):1703–10

Oxygen consumption calculated from the Fick equation has limited utility [see comments] Stock MC, et al. **Crit Care Med** 1996 Jan;24(1):86–90. Comment in: Crit Care Med 1996 Jan;24(1):6–9.

Spirometric versus Fick–derived oxygen consumption: which method is better? Thrush DN. **Crit Care Med** 1996 Jan; 24(1):91–5

Measurement of oxygen consumption in disabled children by the Cosmed K2 portable telemetry system. Corry IS, et al. **Dev Med Child Neurol** 1996 Jul;38(7):585–93

Energy consumption in children with spina bifida and cerebral palsy: a comparative study. Duffy CM, et al. **Dev Med Child Neurol** 1996 Mar;38(3):238–43

Determinants of exercise capacity in patients with coronary artery disease and mild to moderate systolic dysfunction. Role of heart rate and diastolic filling abnormalities [see comments] Lele SS, et al. **Eur Heart J** 1996 Feb; 17(2):204–12. Comment in: Eur Heart J 1996 Feb;17(2):168–70.

What factors determine exercise capacity in left ventricular dysfunction? [editorial; comment] Tan LB, et al. **Eur Heart J** 1996 Feb;17(2):168–70. Comment on: Eur Heart J 1996 Feb;17(2):204–12.

Anaerobic and aerobic peak power output and the force–velocity relationship in endurance–trained athletes: effects of aging. Chamari K, et al. **Eur J Appl Physiol** 1995; 71(2–3):230–4

Maximal oxygen uptake in 153 elderly Dutch people (69–87 years) who participated in the 1993 Nijmegen 4–day march. de Wild GM, et al. **Eur J Appl Physiol** 1995;72(1–2):134–43

Oxygen cost of internal work during cycling. Francescato MP, et al. **Eur J Appl Physiol** 1995;72(1–2):51–7

Plasma sulpho–conjugated catecholamine dynamics up to 8 h after 60–min exercise at 50% and 70% maximal oxygen uptakes. Ogaki T, et al. **Eur J Appl Physiol** 1995; 72(1–2):6–11

The VCO2/VO2 relationship during heavy, constant work rate exercise reflects the rate of lactic acid accumulation. Stringer W, et al. **Eur J Appl Physiol** 1995;72(1–2):25–31

Obligatory anaerobiosis resulting from oxygen uptake–to–blood flow ratio dispersion in skeletal muscle: a model. Whipp BJ, et al. **Eur J Appl Physiol** 1995; 71(2–3):147–52

Effect of aerobic capacity on sweat rate and fluid intake during outdoor exercise in the heat. Yoshida T, et al. **Eur J Appl Physiol** 1995;71(2–3):235–9

Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high–volume plasmapheresis in fulminant hepatic failure. Larsen FS, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):261–5

The slow component of oxygen uptake kinetics in humans. Gaesser GA, et al. **Exerc Sport Sci Rev** 1996;24:35–71 (130 ref.)

Oxygen consumption in the isolated toad retina. Haugh–Scheidt LM, et al. **Exp Eye Res** 1995 Jul; 61(1):63–72

Oxygen consumption in the rat outer and inner retina: light– and pharmacologically–induced inhibition. Medrano CJ, et al. **Exp Eye Res** 1995 Sep;61(3):273–84

Nature of respiratory stimulation in hyperthyroidism: the redox behaviour of cytochrome c. Schmehl I, et al. **FEBS Lett** 1995 Nov 20;375(3):206–10

The reduction of glutathione disulfide produced by t–butyl hydroperoxide in respiring mitochondria. Liu H, et al. **Free Radic Biol Med** 1996;20(3):433–42

Conditions allowing redox–cycling ubisemiquinone in mitochondria to establish a direct redox couple with molecular oxygen. Nohl H, et al. **Free Radic Biol Med** 1996;20(2):207–13

Stimulation of mitochondrial oxygen consumption in isolated cardiomyocytes after hypoxia–reoxygenation. Smith DR, et al. **Free Radic Res** 1996 Mar;24(3):159–66

Reduced aerobic metabolic efficiency in postischemic myocardium dysfunction in rats: role of aging. Abete P, et al. **Gerontology** 1995;41(4):187–94

Gut intramucosal pH and intraluminal PO2 in a porcine model of peritonitis or haemorrhage. Antonsson JB, et al. **Gut** 1995 Dec;37(6):791–7

Percutaneous transvenous mitral commissurotomy immediately restores quick response of VO2 to mild exercise despite insignificant increases in peak VO2. Takaki H, et al. **Heart Vessels** 1995;10(6):323–7

Time courses of cardiac output and oxygen uptake following stepwise increases in exercise intensity. Leyk D, et al. **Int J Sports Med** 1995 Aug;16(6):357–63

Effect of prolonged exercise at 65 and 80% of VO2max on running economy. Xu F, et al. **Int J Sports Med** 1995 Jul; 16(5):309–13

Effects of rapid permissive hypercapnia on hemodynamics, gas exchange, and oxygen transport and consumption during mechanical ventilation for the acute respiratory distress syndrome [see comments] Thorens JB, et al. **Intensive Care Med** 1996 Mar;22(3):182–91. Comment in: Intensive Care Med 1996 Mar;22(3):179–81.

Early jugular bulb oxygenation monitoring in comatose patients after an out–of–hospital cardiac arrest. van der Hoeven JG, et al. **Intensive Care Med** 1995 Jul;21(7):567–72

Light–induced changes in retinal oxygen consumption [letter; comment] Cringle S, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):473–5. Comment on: Invest Ophthalmol Vis Sci 1995 Mar;36(3):542–54.

Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging. Hedera P, et al. **Invest Radiol** 1995 Nov;30(11):625–33

A prospective randomized study of end points of resuscitation after major trauma: global oxygen transport indices versus organ–specific gastric mucosal pH. Ivatury RR, et al. **J Am Coll Surg** 1996 Aug;183(2):145–54

Ventilatory and metabolic responses to hypoxia during moderate hypothermia in anesthetized rats. Frappell P, et al. **J Appl Physiol** 1995 Jul;79(1):256–60

Effect of [Hb] on blood flow distribution and O2 transport in maximally working skeletal muscle. Kurdak SS, et al. **J Appl Physiol** 1995 Nov;79(5):1729–35

Respiratory control determines respiration and nitrogenase activity of Rhizobium leguminosarum bacteroids. Haaker H, et al. **J Bacteriol** 1996 Aug;178(15):4555–62

A high–affinity cbb3–type cytochrome oxidase terminates the symbiosis–specific respiratory chain of Bradyrhizobium japonicum. Preisig O, et al. **J Bacteriol** 1996 Mar; 178(6):1532–8

DNA fragmentation induced in high–cell–density culture of primary rat hepatocytes is an active process dependent on energy availability, gene expression, and calmodulin. Maeda S, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1161–5

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387–96 (47 ref.)

Denitrification, a novel type of respiratory metabolism in fungal mitochondrion. Kobayashi M, et al. **J Biol Chem** 1996 Jul 5;271(27):16263–7

Marked mixed venous hemoglobin desaturation in a patient during hypothermic cardiopulmonary bypass [clinical conference] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):764–7

Relationship between increased peak oxygen uptake and modifications in skeletal muscle metabolism following rehabilitation after myocardial infarction. Cottin Y, et al. **J Cardpulm Rehabil** 1996 May–Jun;16(3):169–74

Exercise training frequency in early post–infarction cardiac rehabilitation. Influence on aerobic conditioning. Dressendorfer RH, et al. **J Cardpulm Rehabil** 1995 Jul–Aug; 15(4):269–76

Stair climbing elicits a lower cardiovascular demand than walking in claudication patients. Gardner AW, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):134–42

The effect of moderate exercise training on oxygen uptake post–aortic/mitral valve surgery. Jairath N, et al. **J Cardpulm Rehabil** 1995 Nov–Dec;15(6):424–30

Oxygen uptake and cardiac output during progressive and constant load work in patients after acute myocardial infarction. McConnell TR, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):216–24

Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle. Hansen J, et al. **J Clin Invest** 1996 Jul 15;98(2):584–96

End–tidal oxygen concentration and pulse oximetry for monitoring oxygenation during intratracheal jet ventilation. Baer GA, et al. **J Clin Monit** 1995 Nov;11(6):373–80

Design of the oxygen and substrate pathways. II. Defining the upper limits of carbohydrate and fat oxidation. Roberts TJ, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1651–8

Design of the oxygen and substrate pathways. I. Model and strategy to test symmorphosis in a network structure. Taylor CR, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1643–9 (25 ref.)

Design of the oxygen and substrate pathways. V. Structural basis of vascular substrate supply to muscle cells. Vock R, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1675–88

Design of the oxygen and substrate pathways. VI. structural basis of intracellular substrate supply to mitochondria in muscle cells. Vock R, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1689–97

Design of the oxygen and substrate pathways. IV. Partitioning energy provision from fatty acids. Weber JM, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1667–74

Design of the oxygen and substrate pathways. III. Partitioning energy provision from carbohydrates. Weber JM, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1659–66

Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699–709 (18 ref.)

Is percentage of predicted maximal exercise oxygen consumption a better predictor of survival than peak exercise oxygen consumption for patients with severe heart failure? Aaronson KD, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):981–9

Cerebral oxidative metabolism in essential hypertension: a meta–analysis. Dickinson CJ. **J Hypertens** 1995 Jun; 13(6):653–8

Intracellular [Ca2+] and Vo2 after manipulation of the free–energy of the Na+/Ca(2+)–exchanger in isolated rat ventricular myocytes. Fiolet JW, et al.

J Mol Cell Cardiol 1995 Aug;27(8):1513–25

Adaptation to chronic hypoxia alters cardiac metabolic response to beta stimulation: novel face of phosphocreatine overshoot phenomenon. Novel–Chaté V, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1679–87

Respiratory control in heart muscle during fatty acid oxidation. Energy state or substrate–level regulation by Ca2+? Vuorinen KH, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1581–91

Effect of reperfusion following cerebral ischaemia on the activity of the mitochondrial respiratory chain in the gerbil brain. Almeida A, et al. **J Neurochem** 1995 Oct; 65(4):1698–703

Changes in cerebral oxygen consumption are independent of changes in body oxygen consumption after severe head injury in childhood. Matthews DS, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):359–67

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

Oxygen cost of breathing in newborn infants with long–term ventilatory support. Rozé JC, et al. **J Pediatr** 1995 Dec; 127(6):984–7

Cerebral tissue oxygenation during hypoxia and hyperoxia using artificial placentation in lamb. Schmidt S, et al. **J Perinat Med** 1996;24(1):61–8

Reduced muscle uptake of oxygen during exercise in patients with systemic lupus erythematosus. Sakauchi M, et al. **J Rheumatol** 1995 Aug;22(8):1483–7

Energy specificity of rock climbing and aerobic capacity in competitive sport rock climbers. Billat V, et al. **J Sports Med Phys Fitness** 1995 Mar;35(1):20–4

Metabolic and ventilatory response to cross–country skiing classical and double arm poling exercise. Faria IE, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):1–6

Submaximal running economy in run–trained pre–pubertal boys. Unnithan VB, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):16–23

Assessment of aerobic and anaerobic demands of dinghy sailing at different wind velocities. Vogiatzis I, et al. **J Sports Med Phys Fitness** 1995 Jun;35(2):103–7

Recreational exercise participation and aerobic fitness in men and women: analysis of data from a national survey. Bonen A, et al. **J Sports Sci** 1995 Aug;13(4):297–303

The relationships of anxiety and self–attention to running economy in competitive male distance runners. Martin JJ, et al. **J Sports Sci** 1995 Oct;13(5):371–6

Tissue oxygenation with graded dissolved oxygen delivery during cardiopulmonary bypass. Holman WL, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):774–85

Left ventricular mechanoenergetics during asynchronous left atrial–to–aortic bypass. Effects of pumping rate on cardiac workload and myocardial oxygen consumption. Kawaguchi O, et al. **J Thorac Cardiovasc Surg** 1995 Sep; 110(3):793–9

Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand. Tao W, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):819–28

Cerebral extraction of oxygen, lactate production, and perfusion pressure in gunshot wound to the head: case report. Cruz J, et al. **J Trauma** 1996 Mar;40(3):445–8

The use of oxygen consumption and delivery as endpoints for resuscitation in critically ill patients. Durham RM, et al. **J Trauma** 1996 Jul;41(1):32–9; discussion 39–40

Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma [letter; comment] Grathwohl KW, et al. **J Trauma** 1996 May;40(5):852. Comment on: J Trauma 1995 May;38(5):780–7.

Resuscitation of uncontrolled liver hemorrhage: effects on bleeding, oxygen delivery, and oxygen consumption. Matsuoka T, et al. **J Trauma** 1996 Sep;41(3):439–45

The relationship of oxygen consumption measured by indirect calorimetry to oxygen delivery in critically ill patients. Yu M, et al. **J Trauma** 1996 Jul;41(1):41–8; discussion 48–50

Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction. Azadzoi KM, et al. **J Urol** 1996 Apr;155(4):1459–65

Does laminated intraluminal thrombus within abdominal aortic aneurysm cause anoxia of the aortic wall? [letter; comment] Vorp DA, et al. **J Vasc Surg** 1996 Mar; 23(3):540–1. Comment on: J Vasc Surg 1994 Oct;20(4):529–35; discussion 535–8.

The effect of hypovolemic shock and reperfusion on the hepatic oxygen supply–uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Aug;57(4):697–702

Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. Riddington DW, et al. **JAMA** 1996 Apr 3; 275(13):1007–12

Prediction of maximal oxygen uptake by squat test in men and women. Inoue Y, et al. **Kobe J Med Sci** 1996 Apr; 42(2):119–29

Hemorrhagic shock in rats [letter; comment] Clifford PS. **Lab Anim Sci** 1995 Aug;45(4):333. Comment on: Lab Anim Sci 1995 Apr;45(2):169–72.

Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart. Malloy CR, et al. **MAGMA** 1996 Mar;4(1):35–46

The apparent diffusion constant measured by MRI correlates with pO2 in a RIF–1 tumor. Dunn JF, et al. **Magn Reson Med** 1995 Oct;34(4):515–9

Effect of repetitive ischemia on myocardial oxygen tension in isolated perfused and hypoperfused rat hearts. Friedman BJ, et al. **Magn Reson Med** 1996 Feb;35(2):214–20

The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)

Validation of a cycle ergometry equation for predicting steady–rate VO2 in obese women. Andersen RE, et al. **Med Sci Sports Exerc** 1995 Oct;27(10):1457–60

The level and tempo of children's physical activities: an observational study. Bailey RC, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1033–41

Relationship between mean habitual daily energy expenditure and maximal oxygen uptake. Berthouze SE, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1170–9

Evaluation of the Cosmed K2 telemetry system during exercise at moderate altitude. Bigard AX, et al. **Med Sci Sports Exerc** 1995 Sep;27(9):1333–8

Maximal and ventilatory threshold responses to treadmill and water immersion running. Frangolias DD, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1007–13

Evaluation of the ACSM submaximal ergometer test for estimating VO2max. Greiwe JS, et al. **Med Sci Sports Exerc** 1995 Sep;27(9):1315–20

Criteria for maximal oxygen uptake: review and commentary. Howley ET, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1292–301 (61 ref.)

Ethnicity affects aerobic fitness in US adolescent girls. Pivarnik JM, et al. **Med Sci Sports Exerc** 1995 Dec; 27(12):1635–8

Assessment of the aerosport TEEM 100 portable metabolic measurement system. Wideman L, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):509–15

Almost simultaneous measurement of cardiovascular and gas exchange variables during maximal exercise. Wilson AF, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):436–43

Mitochondrial membrane potential monitored by JC–1 dye. Reers M, et al. **Methods Enzymol** 1995;260:406–17

Protein import into plant mitochondria. Winning BM, et al. **Methods Enzymol** 1995;260:293–302

Coordination of sucrose uptake and respiration in the yeast Debaryomyces yamadae. Kaliterna J, et al. **Microbiology** 1995 Jul;141 (Pt 7):1567–74

Hemodynamic and oxygenation variables during radical cystectomy. Does the anesthetic technique really matter? Atallah MM, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):157–74

Oxygen–dependent leishmanicidal activity of stimulated macrophages. Chakraborty R, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):23–9

Arterial oxygen saturation in Tibetan and Han infants born in Lhasa, Tibet. Niermeyer S, et al. **N Engl J Med** 1995 Nov 9;333(19):1248–52

Healthy aging, memory subsystems and regional cerebral oxygen consumption. Eustache F, et al. **Neuropsychologia** 1995 Jul;33(7):867–87

Base deficit and oxygen transport in severe preeclampsia. Wheeler TC, et al. **Obstet Gynecol** 1996 Mar;87(3):375–9

Relationship between heart rate and oxygen kinetics during constant workload exercise. Kay GN, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1853–60

Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)

Measurement of cranial optical path length as a function of age using phase resolved near infrared spectroscopy. Duncan A, et al. **Pediatr Res** 1996 May;39(5):889–94

Aerobic response to endurance exercise training in children. Rowland TW, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):654–8

Long–term dual perfusion of isolated human placental lobules with improved oxygenation for infectious diseases research. Polliotti BM, et al. **Placenta** 1996 Jan;17(1):57–68

Recovery of respiration following the SOS response of Escherichia coli requires RecA–mediated induction of 2–keto–4–hydroxyglutarate aldolase. Cayrol C, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11806–9

Oxygen supply and oxygen–dependent gene expression in differentiating embryonic stem cells. Gassmann M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2867–72

The currents of life: the terminal electron–transfer complex of respiration [comment] Ramirez BE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11949–51 (27 ref.). Comment on: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11955–9.

Aerobic demand of running shoes designed to exploit energy storage and return. Morgan DW, et al. **Res Q Exerc Sport** 1996 Mar;67(1):102–5

Physiological and perceived exertion responses to six modes of submaximal exercise. Thomas TR, et al. **Res Q Exerc Sport** 1995 Sep;66(3):239–46

Oxygen cost of ventilation in the resting horse. Gauvreau GM, et al. **Res Vet Sci** 1995 Sep;59(2):168–71

Embryogeny of oxygen consumption in 13 altricial and precocial birds [comment] Prinzinger R, et al. **Respir Physiol** 1995 Jun;100(3):283–7. Comment on: Respir Physiol 1995 Jun;100(3):289–94.

Qualitative course of embryonic O2 consumption in altricial and precocial birds [see comments] Prinzinger R, et al. **Respir Physiol** 1995 Jun;100(3):289–94. Comment in: Respir Physiol 1995 Jun;100(3):283–7.

Cold acclimation and endurance training in guinea pigs: changes in daily and maximal metabolism. Turner DL, et al. **Respir Physiol** 1995 Aug;101(2):183–8

Hemodynamics and oxygen metabolism in the pig during long–term hypothermia: comparison of 2 pH strategies. Kornberger E, et al. **Resuscitation** 1995 Aug;30(1):43–50

A maximal cycle exercise protocol to predict maximal oxygen uptake. Andersen LB. **Scand J Med Sci Sports** 1995 Jun; 5(3):143–6

Do changes in oxygen metabolism in the unaffected cerebral hemisphere underlie early neurological recovery after stroke? A positron emission tomography study. Iglesias S, et al. **Stroke** 1996 Jul;27(7):1192–9

Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Prengel AW, et al. **Stroke** 1996 Jul;27(7):1241–8

Near–infrared monitoring of cerebral oxygenation state during carotid endarterectomy. Kuroda S, et al. **Surg Neurol** 1996 May;45(5):450–8

Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Bell SC, et al. **Thorax** 1996 Feb;51(2):126–31

Comparison of peak oxygen consumption during cycle and treadmill exercise in severe chronic obstructive pulmonary disease. Mathur RS, et al. **Thorax** 1995 Aug;50(8):829–33

Graft size–matching in living related partial liver transplantation in relation to tissue oxygenation and metabolic capacity. Tanaka A, et al. **Transpl Int** 1996; 9(1):15–22

Controlling oxygen content during cardiopulmonary bypass to limit reperfusion/reoxygenation injury. Ihnken K, et al. **Transplant Proc** 1995 Oct;27(5):2809–11

Modification of mitochondrial energy metabolism in brain dead organ donor. Sztark F, et al. **Transplant Proc** 1996 Feb;28(1):52–3

Evolution of energetic metabolism: the respiration–early hypothesis. Castresana J, et al. **Trends Biochem Sci** 1995 Nov;20(11):443–8

Effects of oral endotracheal intubation on metabolic gas exchange (short communication). Lind L. **Ups J Med Sci** 1995;100(2):161–3

A pilot study of the effects of abdominal aortic cross clamping on metabolic gas exchange (short communication). Lind L. **Ups J Med Sci** 1995;100(2):165–7

[The change in tissue oxygenation after severe steam inhalation injury] Guo G, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):346–8 (Eng. Abstr.) **(Chi)**

[Influences of early enteral feeding enriched with glutamine on the gut blood flow and oxygen consumption in severely burned mini–swines] Yu B, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):37–40 (Eng. Abstr.) **(Chi)**

[Relations between body oxygen requirement, transport, consumption and tissue extraction] Annat G, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:1–2 **(Fre)**

[Severe burnt patients: hemodynamic state, oxygen transport and consumption, plasma cytokines] Gueugniaud PY, et al. **Ann Fr Anesth Reanim** 1996;15(1):27–35 (Eng. Abstr.) **(Fre)**

[Improving tissue perfusion without invasive monitoring. Apropos of a case] Gueugniaud PY, et al. **Cah Anesthesiol** 1995;43(4):385–8 (Eng. Abstr.) **(Fre)**

[Predictivity associated with oxygen–transporting hemodynamic parameters: relation between the cardiac index and oxygen extraction] Donati A, et al. **Minerva Anestesiol** 1995 Jun;61(6):241–7 (Eng. Abstr.) **(Ita)**

[Near–infrared monitoring of cerebral oxygenation during cerebral ischemia] Kuroda S. **Hokkaido Igaku Zasshi** 1995 May;70(3):401–11 (Eng. Abstr.) **(Jpn)**

[Relationship between ischemic ST depression and oxygen uptake kinetics during ramp exercise test in patients with effort angina] Yokoyama Y, et al. **J Cardiol** 1996 May; 27(5):241–6 (Eng. Abstr.) **(Jpn)**

[Cerebral hemodynamics and metabolism in patients with Moyamoya disease not demonstrating either cerebral infarct or hemorrhage on MRI] Kuwabara Y, et al. **Kaku Igaku** 1995 Dec;32(12):1355–62 (Eng. Abstr.) **(Jpn)**

[The evaluation of cerebral oxygen balance during moderate hypothermic cardiopulmonary bypass] Aoki S. **Masui** 1995 Nov;44(11):1520–6 (Eng. Abstr.) **(Jpn)**

[Association of postoperative brain dysfunction and atherosclerosis, intraoperative rSO2 and CO2 reaction in open heart surgery] Konishi A, et al. **Masui** 1996 Mar; 45(3):287–92 (Eng. Abstr.) **(Jpn)**

[Perioperative management of esophageal cancer—correlation between postoperative complication and oxygen consumption] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):654–5 **(Jpn)**

[Clinical study on measurement of cerebral metabolism and oxygenation during cardio–pulmonary bypass by near–infrared spectrophotometry] Kunihara T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1107–14 (Eng. Abstr.) **(Jpn)**

[A cross–sectional analysis on relationships between maximum oxygen uptake and risk factors for cardiovascular diseases] Tobita Y, et al. **Sangyo Eiseigaku Zasshi** 1995 Nov; 37(6):409–15 (Eng. Abstr.) **(Jpn)**

[Early physical conditioning of patients surgically treated for myocardial revascularization. Influence on the functional capacity] Trombetta IC, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):201–5 (Eng. Abstr.) **(Por)**

[Nutritional support, free radicals, and antioxidants (editorial)] Faintuch J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 May–Jun; 50(3):133–5 (Eng. Abstr.) **(Por)**

[Maximal oxygen consumption measured in the cardiopulmonary stress test versus the predicted consumption, for the Bruce protocol] Bronze L, et al. **Rev Port Cardiol** 1995 Nov;14(11):967–71 **(Por)**

[Maximal oxygen consumption measured in the cardiopulmonary stress test versus the predicted maximal consumption: an evaluation of 3 protocols] Trabulo M, et al. **Rev Port Cardiol** 1995 Nov;14(11):963–6 **(Por)**

[The use of hyperbaric oxygenation of the perfusion solution for increasing the oxygen supply to the isolated brain] Tezikov EB, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):146–53 **(Rus)**

[Changes in the generation of free oxygen radicals in shock and their significance in the irreversibility of a pathological process] Oborin AN. **Klin Khir** 1995;(6):34–8 (59 ref.) **(Rus)**

[The effect of hemocarbosorption and biohemosorption on oxygen metabolism and intoxication in patients with peritonitis in multiple organ failure] Petrenko TF, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):372–7 (Eng. Abstr.) **(Rus)**

[The correlation of liver mitochondrial respiration in mammals and reptiles at different temperatures] Akhmerov RN, et al. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):410–5 (Eng. Abstr.) **(Rus)**

[Oxygen consumption in neurotic patients] Gorozhanin VS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):48–51 (Eng. Abstr.) **(Rus)**

[Oxygen delivery and tissue extraction in septic shock] Pilaš V, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:26–8 (Eng. Abstr.) **(Scr)**

[Oxygen transport and consumption and oxygen saturation in the right atrium in an experimental model of neonatal septic shock] Baquero Cano M, et al. **An Esp Pediatr** 1996 Feb;44(2):149–56 (Eng. Abstr.) **(Spa)**

[The importance of determining oxygen consumption in the indications for a heart transplant] Gómez Sánchez MA, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:19–23 (25 ref.) (Eng. Abstr.) **(Spa)**

[Maximum oxygen consumption and serum lipids in diabetics, controls, and athletes] Carreón Govea VC, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):5–12 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Differential effects of dobutamine, dopamine, and noradrenaline on splanchnic haemodynamics and oxygenation in the pig. Priebe HJ, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1088–96

Effects of ephedrine on oxygen consumption and cardiac output. Rådström M, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1084–7

Pentoxifylline and oxygen consumption in severe sepsis—a preliminary report. Castañon-Gonzalez JA, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:219–22

Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Meier-Hellmann A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:239–48 (106 ref.)

VO2 on-transient kinetics with a centrally acting calcium channel blocker. Petrella RJ, et al. **Adv Exp Med Biol** 1995; 393:201–5

A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure. Kanda H, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):361–8

Constant-pressure perfusion of rat hindlimb shows alpha- and beta-adrenergic stimulation of oxygen consumption. Ye JM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E960–8

A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Boyd O, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):478–84

The direct effects of enflurane on coronary blood flow, myocardial oxygen consumption, and myocardial segmental shortening in in situ canine hearts. Gurevicius J, et al. **Anesth Analg** 1996 Jul;83(1):68–74

The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. Lawrence CJ, et al. **Anesth Analg** 1996 Mar;82(3):544–50

Preservation of the ration of cerebral blood flow/metabolic rate for oxygen during prolonged anesthesia with isoflurane, sevoflurane, and halothane in humans. Kuroda Y, et al. **Anesthesiology** 1996 Mar;84(3):555–61

Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Cassina A, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):309–16

Calcium indirectly increases the control exerted by the adenine nucleotide translocator over 2-oxoglutarate oxidation in rat heart mitochondria. Mildaziene V, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):130–4

Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. Borutaité V, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):295–9

Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Lizasoain I, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):877–80

Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Janssens D, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):991–9

Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. McNaught KS, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1503–11

Nicotinamide derivatives and mitochondrial respiration. O'Sullivan PE, et al. **Biochem Soc Trans** 1996 Feb;24(1):61S

Differential effects of selective beta 1-agonist stimulation on epi- and endocardial oxygen tension in anesthetized dogs. Tagami H, et al. **Biol Pharm Bull** 1995 Jul;18(7):951–6

Dobutamine increases oxygen consumption during constant flow cardiopulmonary bypass. Karzai W, et al. **Br J Anaesth** 1996 Jan;76(1):5–8

Effects of caffeine and tryptophan on rectal temperature, metabolism, total exercise time, rate of perceived exertion and heart rate. Alves MN, et al. **Braz J Med Biol Res** 1995 Jun;28(6):705–9

Oxygen tolerance of fathead minnows previously exposed to copper. Bennett WA, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):517–24

Design of an electronically operated flow-through respirometer and its use to investigate the effects of copper on the respiration rate of the amphipod Gammarus pulex (L.). Kedwards TJ, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):610–6

In vivo oxygen consumption rate of DS sarcoma cells on inhibition of DNA synthesis. Thews O, et al. **Cancer Res** 1996 May 1;56(9):2009–12

Sodium nitroprusside does not influence tissue oxygen extraction capabilities during a critical reduction in oxygen delivery. Zhang H, et al. **Cardiovasc Res** 1995 Aug; 30(2):240–5

Determination of structure-activity relationships of Annonaceous acetogenins by inhibition of oxygen uptake in rat liver mitochondria. Landolt JL, et al. **Chem Biol Interact** 1995 Oct 20;98(1):1–13

Dopexamine hydrochloride in septic shock. Hannemann L, et al. **Chest** 1996 Mar;109(3):756–60

The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients. Marik PE, et al. **Chest** 1996 Apr;109(4):1038–42

Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Hughes GS Jr, et al. **Clin Pharmacol Ther** 1995 Oct;58(4):434–43

Effects of dobutamine on the relationship between oxygen consumption and delivery in healthy volunteers: comparison with sodium nitroprusside. De Backer D, et al. **Clin Sci (Colch)** 1996 Feb;90(2):105–11

Effects of carbonic anhydrase inhibitors on oxygen consumption and lactate accumulation in skeletal muscle. Geers C, et al. **Comp Biochem Physiol A Physiol** 1995 Sep; 112(1):111–7

Ventilatory response to severe acute hypoxia in guinea-pigs and rats with high hemoglobin-oxygen affinity induced by cyanate. Rivera M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):675–80

Hypolipidemic agents alter hepatic mitochondrial respiration in vitro. Chance DS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):317–23

Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. Cernaianu AC, et al. **Crit Care Med** 1996 Feb;24(2):222–8

Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Hannemann L, et al. **Crit Care Med** 1995 Dec;23(12):1962–70

Isoproterenol-dependent decrease in oxygen uptake and respiratory enzyme activities in rat myocardial tissue and mitochondria. Poderoso JJ, et al. **Crit Care Med** 1995 Oct; 23(10):1726–33

Metabolic stress and dobutamine [letter; comment] Tan IK, et al. **Crit Care Med** 1996 Jan;24(1):181–3. Comment on: Crit Care Med 1995 Apr;23(4):674–80.

Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Tighe D, et al. **Crit Care Med** 1995 Dec;23(12):1997–2007

Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock [see comments] Zhang H, et al. **Crit Care Med** 1995 Oct;23(10):1711–21. Comment in: Crit Care Med 1995 Oct;23(10):1621–4.

Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. Vachiery F, et al. **Dig Dis Sci** 1996 Sep;41(9):1722–6

Changes in oxygen consumption and biochemical composition of the marine fouling dreissinid bivalve Mytilopsis sallei (Recluz) exposed to mercury. Devi VU. **Ecotoxicol Environ Saf** 1996 Mar;33(2):168–74

Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. Szabó C, et al. **FEBS Lett** 1996 Feb 26;381(1–2):82–6

Mitochondrial biosynthesis controls the sensitivity of Chinese hamster cells to hydrogen peroxide. Kaneko M, et al. **Free Radic Res** 1996;24(4):299–309

Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. de Vries RJ, et al. **Heart** 1996 Feb;75(2):159–64

Towards noninvasive human tumor physiologic measurements [editorial; comment] Okunieff P. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):961–2. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):855–9.

Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging [see comments] Robinson SP, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):855–9. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):961–2.

Are the effects of noradrenaline, adrenaline and dopamine infusions on VO2 and metabolism transient? Ensinger H, et al. **Intensive Care Med** 1995 Jan;21(1):50–6

Enalaprilat controls postoperative hypertension while maintaining cardiac function and systemic oxygenation after neurosurgery. Tohmo H, et al. **Intensive Care Med** 1995 Aug;21(8):651–6

In vitro ouabain-sensitive respiration and protein synthesis in rumen epithelial papillae of Hereford steers fed either timothy hay or timothy hay supplemented with cracked corn once daily. Kelly JM, et al. **J Anim Sci** 1995 Dec; 73(12):3775–84

Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. Herbertson MJ, et al. **J Appl Physiol** 1995 Aug;79(2):479–86

Down-regulation of tumor necrosis factor receptors by blockade of mitochondrial respiration. Sánchez-Alcázar JA, et al. **J Biol Chem** 1995 Oct 13;270(41):23944–50

Effects of dobutamine versus insulin on cardiac performance, myocardial oxygen demand, and total body metabolism after coronary artery bypass grafting. Hiesmayr M, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):653–8

Increased blood-brain permeability with hyperosmolar mannitol increases cerebral O2 consumption and O2 supply/consumption heterogeneity. Chi OZ, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):327–33

Effect of salbutamol on oxygen saturation in COPD. Charoenratanakul S, et al. **J Med Assoc Thai** 1996 Apr; 79(4):218–21

Surfactant treatment in the neonate with severe respiratory distress syndrome. Horpaopan S, et al. **J Med Assoc Thai** 1996 Apr;79(4):222–8

L-propionylcarnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. Broderick TL, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):331–40

Methylmalonic acid inhibits respiration in rat liver mitochondria. Toyoshima S, et al. **J Nutr** 1995 Nov; 125(11):2846–50

The effects of dopamine and dobutamine on liver oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Apr;57(2):287–91

The effect of indomethacin on liver blood flow and oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Apr;57(2):193–7

The influence of oxygen free radical scavengers on the reduction of membrane-bound Na(+)-K(+)-ATPase activity induced by ischemia/reperfusion injury in the canine kidney. Kajiwara I, et al. **Nephron** 1996;72(4):637–43

Dose-response to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report. Bührer C, et al. **Pediatr Pulmonol** 1995 May;19(5):291–8

Action of clofazimine on the Mycobacterium avium complex. Warek U, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):43–8

Effect of acetazolamide on regional cerebral oxygen saturation and regional cerebral blood flow. Kaminogo M, et al. **Stroke** 1995 Dec;26(12):2358–60

Paradoxical increase in peroxisomal cyanide-insensitive respiration following dietary exposure to WY-14,643 in the perfused liver. Bojes HK, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):202–9

[The effect of noradrenaline and dopamine agonists and antagonists on oxygen consumption in some insect and crustacean species] Weischer ML, et al. **Arzneimittelforschung** 1995 Sep;45(9):1032–5 (Eng. Abstr.) **(Ger)**

[Comparison of the effect of isoflurane and that of sevoflurane on hepatic circulation and oxygen metabolism during acute hypoxia in dogs] Sugai M. **Masui** 1996 May; 45(5):608–16 (Eng. Abstr.) **(Jpn)**

[Effect of 1-alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men] Tomten SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):37–40 (Eng. Abstr.) **(Nor)**

[Evaluation of oxygen-dependent processes in in-vitro experiments for the purpose of the hygienic regulation of chemical substances] Frolova AD, et al. **Med Tr Prom Ekol** 1995;(11):21–3 (Eng. Abstr.) **(Rus)**

GENETICS

Cloning and characterization of senC, a gene involved in both aerobic respiration and photosynthesis gene expression in Rhodobacter capsulatus. Buggy J, et al. **J Bacteriol** 1995 Dec;177(23):6958–65

Genetic modification of respiratory capacity in potato. Hiser C, et al. **Plant Physiol** 1996 Jan;110(1):277–86

IMMUNOLOGY

Increased oxygen consumption after cardiac surgery is associated with the inflammatory response to endotoxemia. Oudemans-van Straaten HM, et al. **Intensive Care Med** 1996 Apr;22(4):294–300

PHYSIOLOGY

Body weight loss during acute hypoxia: effects of increased convective oxygen transport or previous acclimation. Leal TL, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(1):9–14

Nitric oxide, produced in the upper airways, may act in an 'aerocrine' fashion to enhance pulmonary oxygen uptake in humans. Lundberg JO, et al. **Acta Physiol Scand** 1995 Dec;155(4):467–8

Index of the oxidative potential in human quadriceps muscle: simultaneous measurements of [31P]NMR and oxygen consumption during exercise. Takahashi H, et al. **Acta Physiol Scand** 1995 Sep;155(1):109–10

Effects of age on VO2 kinetics during calf and cycling exercise. Chilibeck PD, et al. **Adv Exp Med Biol** 1995; 393:195–200

VO2 on-transient kinetics with a centrally acting calcium channel blocker. Petrella RJ, et al. **Adv Exp Med Biol** 1995; 393:201–5

Subcellular control of oxygen transport. Takahashi E, et al. **Adv Exp Med Biol** 1995;393:357–61

Dynamics of the pulmonary O2 uptake to blood flow ratio (VO2/Q) during and following constant-load exercise. Yoshida T, et al. **Adv Exp Med Biol** 1995;393:207–11

Lack of a critical cardiac output and critical systemic oxygen delivery during low cardiac output in the third trimester in the pregnant sheep. Evans W, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):222–8

Determination of gaseous and dissolved oxygen in a closed fat cell culture system. Böttcher H, et al. **Anal Biochem** 1995 Sep 1;230(1):149–53

Determinants of maximal oxygen transport and utilization. Wagner PD. **Annu Rev Physiol** 1996;58:21–50 (116 ref.)

Tumor oxygenation: a matter of supply and demand. Gulledge CJ, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):741–9 (68 ref.)

Effect of temperature and yeast extract on microbial respiration of sediments from a shallow coastal subsurface and vadose zone. Chapatwala KD, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:827–35

Peculiarities of the regulation of fermentation and respiration in the crabtree-negative, xylose-fermenting yeast Pichia stipitis. Passoth V, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:201–12

Functional diffusive/convective interaction determining maximal oxygen uptake in humans: its modeling perspective. Fukuba Y, et al. **Appl Human Sci** 1995 Nov; 14(6):259–70 (47 ref.)

Changes in aerobic capacity and coronary risk factors during long-term exercise training in women with ischemic heart disease: a 36-month follow-up. Takeda M, et al. **Appl Human Sci** 1996 May;15(3):115–21

Metabolic evaluation of the criteria used to fit elbow crutches by measurement of oxygen consumption. Smith TR, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):70–4

Physiologic control of cardiac assist devices. Hall AW, et al. **Artif Organs** 1996 Mar;20(3):271–5

Gas exchange efficiency of a membrane oxygenator with use of a vibrating flow pump. Naganuma S, et al. **Artif Organs** 1995 Jul;19(7):747–9

Optimal oxygen tension conditions for functioning cultured hepatocytes in vitro. Nishikawa M, et al. **Artif Organs** 1996 Feb;20(2):169–77

Determination of native mixed venous saturation during venovenous extracorporeal circulation. Bliss DW, et al. **ASAIO J** 1995 Oct–Dec;41(4):838–41

Light microscopic visualization of plasma intrusion into microporous hollow fibers. Cheng BT, et al. **ASAIO J** 1995 Oct–Dec;41(4):863–72

Oxygen delivery with a single cannula tidal flow venovenous system for extracorporeal membrane oxygenation. Keszler M, et al. **ASAIO J** 1995 Oct–Dec;41(4):850–4

Kinetic analysis of the mitochondrial quinol-oxidizing enzymes during development of thermogenesis in Arum maculatum L. Leach GR, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):313–9

Preservation of mitochondrial respiratory function by coenzyme Q10 in aged rat skeletal muscle. Sugiyama S, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1111–20

Oxygen consumption and delivery relationship in brain-dead organ donors. Langeron O, et al. **Br J Anaesth** 1996 Jun; 76(6):783–9

Region-dependent asymmetrical or symmetrical variations in the oxygenation and hemodynamics of the brain due to different mental stimuli. Okada F, et al. **Brain Res Cogn Brain Res** 1995 Jul;2(3):215–9

Bioremediation of tannery effluent by aquatic macrophytes. Vajpayee P, et al. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):546–53

Nitric oxide. An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Shen W, et al. **Circulation** 1995 Dec 15;92(12):3505–12

Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Møller N, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):453–9

Effects of ambulation on foot oxygen tension in limbs with peripheral atherosclerosis. Carter SA. **Clin Physiol** 1996 May;16(3):199–208

Regional sympathetic nervous activation after a large meal in humans. Cox HS, et al. **Clin Sci (Colch)** 1995 Aug; 89(2):145–54

Mechanical ventilators optimized for pediatric use decrease work of breathing and oxygen consumption during pressure-support ventilation [letter; comment] Heulitt MJ, et al. **Crit Care Med** 1995 Nov;23(11):1931–3. Comment on: Crit Care Med 1994 Dec;22(12):1942–8.

Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Heyland DK, et al. **Crit Care Med** 1996 Mar;24(3):517–24 (42 ref.)

Nociceptive somatic nerve stimulation and skeletal muscle injury modify systemic hemodynamics and oxygen transport and utilization after resuscitation from hemorrhage. Rady MY, et al. **Crit Care Med** 1996 Apr; 24(4):623–30

Involvement of cyanide-resistant respiration in cell-type proportioning during Dictyostelium development. Matsuyama SI, et al. **Dev Biol** 1995 Nov;172(1):182–91

Evaluation of respirometric data: identification of features that preclude data fitting with existing kinetic expressions. Smets BF, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):88–99

Assumed oxygen consumption based on calculation from dye dilution cardiac output: an improved formula. Bergstra A, et al. **Eur Heart J** 1995 May;16(5):698–703

Effects of altitude on top speeds during 1 h unaccompanied cycling. Capelli C, et al. **Eur J Appl Physiol** 1995; 71(5):469–71

A comparative analysis of physiological responses at submaximal workloads during different laboratory simulations of field cycling. Kenny GP, et al. **Eur J Appl Physiol** 1995;71(5):409–15

Does the threshold of transcutaneous partial pressure of carbon dioxide represent the respiratory compensation point or anaerobic threshold? Liu Y, et al. **Eur J Appl Physiol** 1995;71(4):326–31

The comparison of peak oxygen uptake between swim-bench exercise and arm stroke. Ogita F, et al. **Eur J Appl Physiol** 1995;71(4):295–300

Heart rate and oxygen uptake relationship: a comparison of loaded marching and running in women. Rayson MP, et al. **Eur J Appl Physiol** 1995;71(5):405–8

The influence of inspired oxygen on the oxygen uptake response to ramp exercise. Walsh ML, et al. **Eur J Appl Physiol** 1995;72(1–2):71–5

Reduction of reoxygenation injury and nitric oxide production in the cyanotic immature heart by controlling pO2. Ihnken K, et al. **Eur J Cardiothorac Surg** 1995; 9(8):410–8

Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption. Larsen FS, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):887–92

The effect of oxygen transport resistances on the viability and functions of isolated rat hepatocytes. Catapano G, et al. **Int J Artif Organs** 1996 Jan;19(1):61–71

Techniques for measurement of oxygen consumption rates of hepatocytes during attachment and post-attachment. Smith MD, et al. **Int J Artif Organs** 1996 Jan;19(1):36–44

Prescription of exercise intensity for the obese patient: the relationship between heart rate, VO2 and perceived exertion. Jakicic JM, et al. **Int J Obes Relat Metab Disord** 1995 Jun;19(6):382–7

Reoxygenation after single irradiation in rodent tumors of different types and sizes. Murata R, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):859–65

Loss of muscle oxidative capacity after an extreme endurance run: the Paris-Dakar foot-race. Höchli D, et al. **Int J Sports Med** 1995 Aug;16(6):343–6

Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury [see comments] Jolliet P, et al. **Intensive Care Med** 1996 Apr;22(4):277–85. Comment in: Intensive Care Med 1996 Apr;22(4):275–6.

Pulmonary oxygen consumption [editorial; comment] Nunn JF. **Intensive Care Med** 1996 Apr;22(4):275–6. Comment on: Intensive Care Med 1996 Apr;22(4):277–85.

Characterization of the oxidative metabolism in lactate dehydrogenase A deficiency. Miyajima H, et al. **Intern Med** 1995 Jun;34(6):502–6

Adult and newborn rat inner retinal oxygenation during carbogen and 100% oxygen breathing. Comparison using magnetic resonance imaging delta Po2 mapping. Berkowitz BA. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):2089–98

Kinetics of oxygen consumption during and after exercise in patients with dilated cardiomyopathy. New markers of exercise intolerance with clinical implications. de Groote P, et al. **J Am Coll Cardiol** 1996 Jul;28(1):168–75

Human corneal oxygen demands at superior, central, and inferior sites. Benjamin WJ, et al. **J Am Optom Assoc** 1995 Jul;66(7):423–8

Running performance and cardiovascular capacity are not impaired in creatine-depleted rats. Adams GR, et al. **J Appl Physiol** 1995 Sep;79(3):1002–7

Role of the vascular endothelium in O2 extraction during progressive ischemia in canine skeletal muscle. Curtis SE, et al. **J Appl Physiol** 1995 Oct;79(4):1351–60

Effect of treadmill incline and speed on metabolic rate during exercise in thoroughbred horses. Eaton MD, et al. **J Appl Physiol** 1995 Sep;79(3):951–7

Metabolic responses of rat respiratory muscles to voluntary exercise training. Halseth AE, et al. **J Appl Physiol** 1995 Sep;79(3):902–7

Scaling, normalizing, and per ratio standards: an allometric modeling approach. Nevill AM, et al. **J Appl Physiol** 1995 Sep;79(3):1027–31 (28 ref.)

Scaling for the VO2-to-body size relationship among children and adults. Rogers DM, et al. **J Appl Physiol** 1995 Sep;79(3):958–67

Slow component of O2 uptake during heavy exercise: adaptation to endurance training. Womack CJ, et al. **J Appl Physiol** 1995 Sep;79(3):838–45

Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration. Albury MS, et al. **J Biol Chem** 1996 Jul 19;271(29):17062–6

Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May–Jun;16(3):160–2 (8 ref.)

Respiratory gas exchange, nitrogenous waste excretion, and fuel usage during starvation in juvenile rainbow trout, Oncorhynchus mykiss. Lauff RF, et al. **J Comp Physiol [B]** 1996;165(7):542–51

Relative heart rate, heart rate reserve, and VO2 during submaximal exercise in the elderly. Panton LB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):M165–71

Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157–61 (54 ref.)

Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon-11-acetate. Torizuka T, et al. **J Nucl Med** 1995 Nov;36(11):1981–6

Oxygen uptake and carbohydrate metabolism by in vitro derived bovine embryos. Thompson JG, et al. **J Reprod Fertil** 1996 Mar;106(2):299–306

Measurement of maximal oxygen consumption of thoroughbred horses at an altitude of 1250m using open-circuit flow-through calorimetry. Lund RJ, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):239–43

Influence of a 36-h fast on the central and peripheral components of VO2 during submaximal exercise and peak oxygen uptake. Boone WT, et al. **J Sports Sci** 1995 Aug; 13(4):279–82

Measurement of lung oxygen consumption in a patient after double-lung transplant. Lee KH, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1764–5

Defining the critical limit of oxygen extraction in the human small intestine. Desai TR, et al. **J Vasc Surg** 1996 May; 23(5):832–7; discussion 838

NMR functional imaging using a tailored RF gradient echo sequence: a true susceptibility measurement technique. Cho ZH, et al. **Magn Reson Med** 1996 Jan;35(1):1–5

Use of nitroxides for assessing perfusion, oxygenation, and viability of tissues: in vivo EPR and MRI studies. Gallez B, et al. **Magn Reson Med** 1996 Jan;35(1):97–106

Improvement of muscular oxidative capacity by training is associated with slight acidosis and ATP depletion in exercising muscles. Ravalec X, et al. **Muscle Nerve** 1996 Mar;19(3):355–61

Cerebral oxygen and glucose metabolism and blood flow in mitochondrial encephalomyopathy: a PET study. Shishido F, et al. **Neuroradiology** 1996 Feb;38(2):102–7

Brain oxygen, CO2, pH, and temperature monitoring: evaluation in the feline brain. Zauner A, et al. **Neurosurgery** 1995 Dec;37(6):1168–76; discussion 1176–7

Cardiovascular and metabolic responses to upper- and lower-extremity exercise in men with idiopathic Parkinson's disease. Protas EJ, et al. **Phys Ther** 1996 Jan; 76(1):34–40

Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165–75 (62 ref.)

Endogenous basal nitric oxide production does not control myocardial oxygen consumption or function. Sadoff JD, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):332–8

Structural determinants of maximal O2 transport in muscles of exercising foxes. Bicudo JE, et al. **Respir Physiol** 1996 Mar;103(3):243–51

The ventilatory and metabolic response to hypercapnia in newborn mammalian species. Mortola JP, et al. **Respir Physiol** 1996 Mar;103(3):263–70

Aerobic exercise capacity at sea level and at altitude in Kenyan boys, junior and senior runners compared with Scandinavian runners. Saltin B, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):209–21

Maximal and submaximal oxygen uptake during running: how should body mass be accounted for? Svedenhag J. **Scand J Med Sci Sports** 1995 Aug;5(4):175–80 (33 ref.)

Measurements of tissue oxygen tension in vascularised jejunal autografts in pigs. Nielsen IM, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):297–302

Models to study the relation between oxygen consumption and oxygen delivery during an acute reduction in blood

flow: comparison of balloon filling in the inferior vena cava, tamponade, and hemorrhage. De Backer D, et al. **Shock** 1995 Aug;4(2):107–12

Tissue oxygen saturation of human hepatic grafts after reperfusion: paradoxical elevation in poor graft function. Kiuchi T, et al. **Transpl Int** 1996;9(2):90–7

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

[Angiogenesis of human breast cancers: neovascularization in xenotransplants and oxygenation in situ in patients] Runkel S, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:68–72 (Eng. Abstr.) **(Ger)**

[Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy] Motz W, et al. **Herz** 1995 Dec;20(6):355–64 (52 ref.) (Eng. Abstr.) **(Ger)**

[Theoretical limits of "permissive anemia"] Hoeft A, et al. **Zentralbl Chir** 1995;120(8):604–13 (Eng. Abstr.) **(Ger)**

[Measured and predicted oxygen uptake in highly qualified athletes] Ratajczyk–Drobna E. **Ann Acad Med Stetin** 1995; 41:87–108 (Eng. Abstr.) **(Pol)**

[Correlation between specific oxygen consumption in the myocardium and myocardial mass in healthy people and in patients with heart defects] Vlasov IuA, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):92–9 **(Rus)**

[Gas exchange and gas transport in rats during warming after deep immersion hypothermia] Chulkin AE, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):52–9 (Eng. Abstr.) **(Rus)**

[A comparative ontogenic analysis of the correlative characteristics between oxygen consumption and the catecholamine level of the blood and its cholinesterase activity at different age periods] Arshavskiĭ IA, et al. **Zh Evol Biokhim Fiziol** 1996 Jan–Feb;32(1):82–93 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[Hypoxyradiotherapy: changes in the oxygen partial pressure distribution in the tumor and in the healthy tissue under acute respiratory hypoxia] Strnad V, et al. **Strahlenther Onkol** 1996 Aug;172(8):427–33 (Eng. Abstr.) **(Ger)**

OXYGEN DEFICIENCY see **ANOXIA**

OXYGEN INHALATION THERAPY

Effect of 100% oxygen administration on infarct size and left ventricular function in a canine model of myocardial infarction and reperfusion. Kelly RF, et al. **Am Heart J** 1995 Nov;130(5):957–65

Effects of overnight supplemental oxygen in obstructive sleep apnea in children. Aljadeff G, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):51–5

Does oxygen help dyspnea in patients with cancer? Booth S, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1515–8

Oxygen therapy for pediatric obstructive sleep apnea syndrome: how safe? How effective? [editorial] Brouillette RT, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):1–2

Comparison between nocturnal nasal positive pressure ventilation combined with oxygen therapy and oxygen monotherapy in patients with severe COPD. Lin CC. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):353–8

Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. McDonald CF, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1616–9

Supplemental oxygen during sleep in children with sleep–disordered breathing. Marcus CL, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1297–301

Oxygen therapy in the postanesthesia care unit [letter; comment] Canet J. **Anesth Analg** 1995 Dec;81(6):1311. Comment on: Anesth Analg 1995 Feb;80(2):368–72.

Preoxygenation—the importance of a good face mask seal [see comments] McGowan P, et al. **Br J Anaesth** 1995 Dec; 75(6):777–8. Comment in: Br J Anaesth 1996 May;76(5):748.

Domiciliary oxygen. Wilkinson J, et al. **Br J Clin Pract** 1996 Apr–May;50(3):151–3 (8 ref.)

Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul–Aug;49(4):205–10 (83 ref.)

Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. A 10–year analysis of ANTADIR Observatory [see comments] Chailleux E, et al. **Chest** 1996 Mar;109(3):741–9. Comment in: Chest 1996 Mar;109(3):595–6.

Outcomes of home care for life–supported persons: long–term oxygen and prolonged mechanical ventilation [editorial; comment] Goldberg AI. **Chest** 1996 Mar;109(3):595–6. Comment on: Chest 1996 Mar;109(3):741–9.

Treatment of carbon monoxide poisoning [letter; comment] Hurst RE. **Chest** 1996 Feb;109(2):591–2. Comment on: Chest 1995 May;107(5):1474.

Transtracheal oxygen catheterization with pneumomediastinum and sudden death. Kristo DA, et al. **Chest** 1996 Sep;110(3):844–6

Long–term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. ANTADIR Working Group on Oxygen Therapy. Association Nationale de Traitement à Domicile des Insuffisants Respiratories [see comments] Pépin JL, et al. **Chest** 1996 May;109(5):1144–50. Comment in: Chest 1996 May;109(5):1135–6.

Observance of long–term oxygen therapy at home [editorial; comment] Weitzenblum E. **Chest** 1996 May;109(5):1135–6 . Comment on: Chest 1996 May;109(5):1144–50.

The effectiveness of O2 administration for transient ischemic attacks in moyamoya disease in children. Fujiwara J, et al. **Childs Nerv Syst** 1996 Feb;12(2):69–75

Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. Hanson CW 3rd, et al. **Crit Care Med** 1996 Jan;24(1):23–8

Supplemental oxygen during endoscopy in patients with ischemic heart disease [letter; comment] Lee JG. **Gastrointest Endosc** 1995 Sep;42(3):275–6. Comment on: Gastrointest Endosc 1994 Nov–Dec;40(6):665–70.

Hemodynamic effects of supplemental oxygen administration in congestive heart failure. Haque WA, et al. **J Am Coll Cardiol** 1996 Feb:27(2):353–7

Oxygen administration during transport and recovery after outpatient surgery does not prevent episodic arterial desaturation. Scuderi PE, et al. **J Clin Anesth** 1996 Jun; 8(4):294–300

Against routine postoperative oxygen administration in the PACU [comment] DiBenedetto RJ, et al. **J Clin Monit** 1995 Nov;11(6):408–10. Comment on: J Clin Monit 1995 Nov;11(6):406–8.

For routine postoperative oxygen administration in the PACU [see comments] Gravenstein D. **J Clin Monit** 1995 Nov;11(6):406–8. Comment in: J Clin Monit 1995 Nov;11(6):408–10.

Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal–hypertensive gastropathy: effects on gastric mucosal haemodynamics and oxygenation. Iwao T, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):216–22

Donor lungs from ventilated cadavers: impart of a free radical scavenger. Roberts CS, et al. **J Heart Lung Transplant** 1996 Mar;15(3):275–82

Oxygen gas cylinder explosion [letter] Mishra D. **J Indian Med Assoc** 1995 Mar;93(3):114–5

Combined gas ventilation and perfluorochemical tracheal instillation as an alternative treatment for lethal congenital diaphragmatic hernia in lambs. Major D, et al. **J Pediatr Surg** 1995 Aug;30(8):1178–82

Effects of oxygen, positive end–expiratory pressure, and carbon dioxide on oxygen delivery in an animal model of the univentricular heart [see comments] Riordan CJ, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):644–54. Comment in: J Thorac Cardiovasc Surg 1996 Sep;112(3):655–7.

Commentary: simple gases and complex single ventricles [comment] Wessel DL. **J Thorac Cardiovasc Surg** 1996 Sep; 112(3):655–7. Comment on: J Thorac Cardiovasc Surg 1996 Sep;112(3):644–54.

Current thoughts regarding treatment of chronic obstructive pulmonary disease. Celli BR. **Med Clin North Am** 1996 May;80(3):589–609 (120 ref.)

Home oxygen therapy. O'Donohue WJ Jr. **Med Clin North Am** 1996 May;80(3):611–22 (38 ref.)

Cost effective computerized decision support: tracking caregiver acceptance at the point of care. Wallace CJ, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:810–3

Selection criteria for pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Jul;90(6):317–22 (36 ref.)

Long–term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. Jakobsson P, et al. **Respir Med** 1995 Aug;89(7):471–6

Obstructive sleep hypopnea syndrome in a patient with Marfan syndrome treated with oxygen therapy. Verbraecken JA, et al. **Respiration** 1995;62(6):355–8

Hypoxic pulmonary hypertension: haemodynamic changes after oxygen and various vasodilators in the same patient at different time periods. Král H, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4–5):317–24

No effect of oxygen therapy on myocardial ischaemia during gastroscopy. Rosenberg J, et al. **Scand J Gastroenterol** 1996 Feb;31(2):200–5

Review of the prescription of domiciliary long term oxygen therapy in Scotland. Morrison D, et al. **Thorax** 1995 Oct; 50(10):1103–5

Domiciliary ventilation in chronic obstructive pulmonary disease: where are we? [editorial] Wedzicha JA, et al. **Thorax** 1996 May;51(5):455–7

[Secondary pulmonary hypertension in a patient with severe chronic restrictive pulmonary insufficiency—normalized during treatment with non–invasive intranasal ventilation and oxygen] Laursen SB, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):428–9 (Eng. Abstr.) **(Dan)**

[Effects of preoxygenation methods on the course of PaO2 and PaCO2 in anesthetic post–induction apnea] Fleureaux O, et al. **Cah Anesthesiol** 1995;43(4):367–70 (Eng. Abstr.) **(Fre)**

[Nitric oxide in therapy of pulmonary hypertension after correction of congenital single atrium] Strauss JM, et al. **Anaesthesiol Reanim** 1995;20(6):162–5 (Eng. Abstr.) **(Ger)**

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. 1: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacotherapy in resuscitation] Wietlisbach M, et al. **Ther Umsch** 1996 Aug;53(8):641–5 (Eng. Abstr.) **(Ger)**

[Therapy of Cheyne–Stokes respiration with nocturnal oxygen therapy] Andreas S, et al. **Wien Med Wochenschr** 1995;145(17–18):503–4 (Eng. Abstr.) **(Ger)**

[Nocturnal oxygen administration and cardiac arrhythmias during Cheyne–Stokes respiration in patients with heart failure] Hagenah G, et al. **Z Kardiol** 1996 Jun;85(6):435–41 (Eng. Abstr.) **(Ger)**

[Oxygen therapy and pulmonary hypertension in chronic obstructive bronchopneumopathies] Gensini G, et al. **Recenti Prog Med** 1996 Feb;87(2):81–5 (31 ref.) (Eng. Abstr.) **(Ita)**

[Efficacy of the artificial ventilation for the treatment of IgE–mediated anaphylactic shock in dog] Takeuchi H, et al. **Masui** 1995 Nov;44(11):1513–9 (Eng. Abstr.) **(Jpn)**

[Home days ratio in patients treated with long–term oxygen therapy] Ando M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1086–92 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Compliance with long–term home oxygen therapy] Hayashi A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):45–51 (Eng. Abstr.) **(Jpn)**

[Predictors of survival in patients with chronic obstructive pulmonary disease with moderate hypoxemia] Gorzelak K, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):491–7 (Eng. Abstr.) **(Pol)**

[Effects of home oxygen therapy on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease] Tobiasz M. **Pol Arch Med Wewn** 1995 Jun;93(6):498–508 (Eng. Abstr.) **(Pol)**

[Long–term home oxygen therapy] Aćimović S. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):569–73 (Eng. Abstr.) **(Scr)**

[Portable oxygen therapy in the Madrid area] Díaz Lobato S, et al. **Arch Bronconeumol** 1996 Mar;32(3):148–50 (Eng. Abstr.) **(Spa)**

[Appropriate use and effectiveness of chronic domiciliary oxygen therapy in Catalonia] Granados A, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):251–3 (Eng. Abstr.) **(Spa)**

[The prescription of domiciliary oxygen therapy in patients with neoplastic diseases (letter)] Díaz Lobato S, et al. **Rev Clin Esp** 1995 Oct;195(10):737–8 **(Spa)**

[The oxygen–nurses are not optimally utilized (letter)] Bergmann E, et al. **Lakartidningen** 1995 Oct 25;92(43):3977 **(Swe)**

ADVERSE EFFECTS

Oxygen at birth and prolonged cerebral vasoconstriction in preterm infants. Lundstrøm KE, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F81–6

Going up in smoke [letter] Stobie TD, et al. **Med J Aust** 1995 Dec 4–18;163(11–12):656

The outcome at 12 months of very–low–birth–weight infants ventilated at Tygerberg Hospital. Kirsten GF, et al. **S Afr Med J** 1995 Jul;85(7):649–54

[A misleading interpretation of a case report in Riskronden (letter)] Midgren B, et al. **Lakartidningen** 1996 Aug 28; 93(35):2923 **(Swe)**

CONTRAINDICATIONS

[Obstructive lung disease. Oxygen inhalation therapy does carry a risk of carbon dioxide narcosis] **Lakartidningen** 1996 Jun 19;93(25):2445 **(Swe)**

ECONOMICS

Oxygen is cost effective [letter; comment] Groudine SB, et al. **Anesth Analg** 1995 Oct;81(4):891. Comment on: Anesth Analg 1995 Feb;80(2):368–72.

The cost of treating COPD patients with long–term oxygen therapy in a French population. Pelletier–Fleury N, et al. **Chest** 1996 Aug;110(2):411–6

HISTORY

Problems of oxygenation and oxygen transport during haemorrhage. 1964 [classical article] Nunn JF, et al. **Anaesthesia** 1995 Sep;50(9):795–800; discussion 794

From observation to experimentation: lessons from the past. Duc G. **Eur J Pediatr** 1995;154(9 Suppl 4):S18–9

INSTRUMENTATION

The delivery of oxygen by a venturi T piece. Campbell DJ, et al. **Anaesthesia** 1996 Jun;51(6):558–60

Cost–benefit analysis of nasal cannulae in non–tracheally intubated subjects. Woda RP, et al. **Anesth Analg** 1996 Mar; 82(3):506–10

Oxygen tank check [letter] Reimer DH. **Can J Anaesth** 1995 Jul;42(7):657–8

Western Medica oxygen regulator yokes incompatible with cylinder post valves. **Health Devices** 1995 Nov;24(11):477–8

Field trial of oxygen concentrators in upper Egypt. Dobson M, et al. **Lancet** 1996 Jun 8;347(9015):1597–9

Complications in the use of the subcutaneous tunnelled intratracheal oxygen catheter. in't Veen JC, et al. **Neth J Med** 1996 Jan;48(1):8–10

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7

(63 ref.)
[Nasal catheters versus Hudson face mask in oxygen therapy] Lund J, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4077–9 (Eng. Abstr.) **(Dan)**
[Hood: a bubble's story? (letter)] Almanza L. **Ann Fr Anesth Reanim** 1995;14(6):537 **(Fre)**
[Information wanted: Who knows Hood? A hint of a track! (letter; comment)] Vatelot B. **Ann Fr Anesth Reanim** 1995; 14(2):241. Comment on: Ann Fr Anesth Reanim 1994;13(3):440. **(Fre)**
[Patient compliance to the prescription of domiciliary oxygen therapy by transtracheal catheter (letter)] Díaz Lobato S, et al. **Arch Bronconeumol** 1996 Apr;32(4):210–1 **(Spa)**
[A technical evaluation of 5 brands of O2 concentrators. The Asturias Project] Diego González EG, et al. **Arch Bronconeumol** 1995 Oct;31(8):393–8 (Eng. Abstr.) **(Spa)**

METHODS

Theoretical assessment of normobaric oxygen therapy to treat pneumocephalus. Dexter F, et al. **Anesthesiology** 1996 Feb; 84(2):442–7
Efficacy of several modes of continuous-flow insufflation for resuscitation of a canine model of acute respiratory arrest. Barnas GM, et al. **Ann Emerg Med** 1996 May; 27(5):617–24
Inspired oxygen concentration alters the phospholipids and protein content in the bronchoalveolar lavage-accessible space. Godinez MH, et al. **Crit Care Med** 1996 May; 24(5):862–9
Influence of carbon monoxide (CO) on the early course of acute myocardial infarction. Elsasser S, et al. **Intensive Care Med** 1995 Sep;21(9):716–22
Respiratory effects of tracheal gas insufflation in spontaneously breathing COPD patients. Nakos G, et al. **Intensive Care Med** 1995 Nov;21(11):904–12
Use of a helium–oxygen mixture in the treatment of postextubation stridor in pediatric patients with burns. Rodeberg DA, et al. **J Burn Care Rehabil** 1995 Sep–Oct; 16(5):476–80
Intracranial hypertension and adult respiratory distress syndrome: usefulness of tracheal gas insufflation. Levy B, et al. **J Trauma** 1995 Oct;39(4):799–801
Ambulatory oxygen in chronic obstructive pulmonary disease. Wedzicha JA. **Monaldi Arch Chest Dis** 1996 Jun; 51(3):243–5
Noninvasive ventilation for exacerbations of chronic obstructive pulmonary disease [letter; comment] Baumel MJ, et al. **N Engl J Med** 1996 Mar 14;334(11):735–6. Comment on: N Engl J Med 1995 Sep 28;333(13):817–22.
Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking. Roberts CM, et al. **Thorax** 1996 Aug;51(8):831–4
[Pathophysiology of perinatal asphyxia and brain damage (letter; comment)] Groenendaal F. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2391–2. Comment on: Ned Tijdschr Geneeskd 1995 Aug 19;139(33):1673–6. **(Dut)**
[Transtracheal oxygen therapy] Muir JE, et al. **Rev Mal Respir** 1995;12(6):639–41 **(Fre)**
[Ambulatory oxygen therapy via a transtracheal catheter] Díaz Lobato S, et al. **Arch Bronconeumol** 1996 May; 32(5):225–9 (Eng. Abstr.) **(Spa)**
[Is intermittent oxygen therapy effective as palliative treatment? (letter)] Götell P. **Lakartidningen** 1995 Dec 20; 92(51–52):4870–1 **(Swe)**

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

UTILIZATION

Comparison of airline passenger oxygen systems. Byrne NJ. **Aviat Space Environ Med** 1995 Aug;66(8):780–3

OXYGEN ISOTOPES

Low-cost measurement of body composition with 18O-enriched water. Vache C, et al. **Diabete Metab** 1995 Oct;21(4):281–4
Reliability of the doubly labeled water method for the measurement of total daily energy expenditure in free-living subjects. Schoeller DA, et al. **J Nutr** 1996 Jan; 126(1):348S–354S
A silicate inclusion in Puente del Zacate, a IIIA iron meteorite. Olsen EJ, et al. **Science** 1996 Sep 6; 273(5280):1365–7

OXYGEN PARTIAL PRESSURE DETERMINATION, TRANSCUTANEOUS see **BLOOD GAS MONITORING, TRANSCUTANEOUS**

OXYGEN RADIOISOTOPES

ADMINISTRATION & DOSAGE

Dosimetry of [15O]water: a physiologic approach. Narayana S, et al. **Med Phys** 1996 Jan;23(1):159–68

ADVERSE EFFECTS

Morphological changes in rat's brain choroid plexus after exposure to low doses of high energy oxygen ions, fast neutrons, and gamma radiation. Burneva V, et al. **Aviakosm Ekolog Med** 1995;29(3):49–52

DIAGNOSTIC USE

PET and the [15O]H2O technique, Part 3: Finding the location of significant regions. Andreasen NC. **Am J Psychiatry** 1996 Feb;153(2):150
Images in neuroscience. Neuroimaging, III. PET and the [15O]H2O Technique, Part 1: Statistical Analysis of Images. Andreasen NC. **Am J Psychiatry** 1995 Dec; 152(12):1704
PET and the [15O]H2O technique, Part 2: Choosing a significance threshold. Andreasen NC. **Am J Psychiatry** 1996 Jan;153(1):6
Images in neuroscience. Neuroimaging, II. Regional cerebral blood flow with H2(15)O. Holcomb HH, et al. **Am J Psychiatry** 1995 Nov;152(11):1563
Fractal 15O-labeled water washout from the heart. Bassingthwaighte JB, et al. **Circ Res** 1995 Dec; 77(6):1212–21
Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Iida H, et al. **Circulation** 1996 Aug 15;94(4):792–807
Noninvasive quantification of regional myocardial metabolic rate of oxygen by 15O2 inhalation and positron emission tomography. Experimental validation. Yamamoto Y, et al. **Circulation** 1996 Aug 15;94(4):808–16
Assessment of effects of intravenous dipyridamole on regional myocardial perfusion in children with Kawasaki disease without angiographic evidence of coronary stenosis using positron emission tomography and H2(15)O. Ohmochi Y, et al. **Coron Artery Dis** 1995 Jul;6(7):555–9
Effect of seizures on cerebral blood flow measured with 15O-H2O and positron emission tomography. Theodore WH, et al. **Epilepsia** 1996 Aug;37(8):796–802
Evaluation of the extent and timing of the coronary hyperemic response to dipyridamole: a study with transesophageal echocardiography and positron emission tomography with oxygen 15 water. Radvan J, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):864–73
Sample size and statistical power in [15O]H2O studies of human cognition. Andreasen NC, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):804–16
Cerebral [15O]water clearance in humans determined by PET: I. Theory and normal values. Ohta S, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):765–80
Delayed data acquisition for optimal PET activation studies with oxygen-15-water in cerebral arteriovenous malformation. Okazawa H, et al. **J Nucl Med** 1995 Dec; 36(12):2149–53
Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. Taniguchi H, et al. **J Nucl Med** 1996 Sep;37(9):1522–3
The statistical power of [15O]-water PET activation studies of cognitive processes. Kapur S, et al. **Nucl Med Commun** 1995 Sep;16(9):779–84

OXYGEN SPECIES, REACTIVE see **REACTIVE OXYGEN SPECIES**

OXYGENASES

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Nitric oxide-donor compounds inhibit lipoxygenase activity. Maccarrone M, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):128–33
Difference between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450-dependent mono-oxygenases. Chen TL, et al. **Br J Anaesth** 1995 Oct;75(4):462–6
Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery. Corriu C, et al. **Br J Pharmacol** 1996 Feb;117(4):607–10
Inhibition of purified and membrane-bound flavin-containing monooxygenase 1 by (N,N-dimethylamino)stilbene carboxylates. Clement B, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):599–604
Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Shen WW. **Int J Psychiatry Med** 1995;25(3):277–90 (78 ref.)

BIOSYNTHESIS

Effects of various cytochrome P-450 inducers on testosterone metabolism and several monooxygenase activities in Sprague-Dawley (SpD), high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats. Duffy O, et al. **Alcohol Alcohol** 1995 May;30(3):329–35
Aliphatic and chlorinated alkenes and epoxides as inducers of alkene monooxygenase and epoxidase activities in Xanthobacter strain Py2. Ensign SA. **Appl Environ Microbiol** 1996 Jan;62(1):61–6
Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice. Falls JG, et al. **J Biochem Toxicol** 1995 Jun; 10(3):171–7
Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Alkayed NJ, et al. **Stroke** 1996 May;27(5):971–9

CHEMISTRY

Evidence of histidine coordination to the catalytic ferrous ion in the ring-cleaving 2,2',3-trihydroxybiphenyl dioxygenase from the dibenzofuran-degrading bacterium Sphingomonas sp. strain RW1. Bertini I, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):855–60
Active site structure of Rieske-type proteins: electron nuclear double resonance studies of isotopically labeled phthalate dioxygenase from Pseudomonas cepacia and Rieske protein from Rhodobacter capsulatus and molecular modeling studies of a Rieske center. Gurbiel RJ, et al. **Biochemistry** 1996 Jun 18;35(24):7834–45
Large kinetic isotope effects in methane oxidation catalyzed by methane monooxygenase: evidence for C-H bond cleavage in a reaction cycle intermediate. Nesheim JC, et al. **Biochemistry** 1996 Aug 6;35(31):10240–7
Recombinant toluene-4-monooxygenase: catalytic and Mössbauer studies of the purified diiron and rieske components of a four-protein complex. Pikus JD, et al. **Biochemistry** 1996 Jul 16;35(28):9106–19
Xenobiotic biotransforming enzymes in the central nervous system: an isoform of flavin-containing monooxygenase (FMO4) is expressed in rabbit brain. Blake BL, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):253–61
Site-directed mutagenesis of conserved amino acids in the alpha subunit of toluene dioxygenase: potential mononuclear non-heme iron coordination sites. Jiang H, et al. **J Bacteriol** 1996 Jun;178(11):3133–9
Characterization of active recombinant his-tagged oxygenase component of Comamonas testosteroni B-356 biphenyl dioxygenase. Hurtubise Y, et al. **J Biol Chem** 1996 Apr 5;271(14):8152–6
EPR, electron spin echo envelope modulation, and electron nuclear double resonance studies of the 2Fe2S centers of the 2-halobenzoate 1,2-dioxygenase from Burkholderia (Pseudomonas) cepacia 2CBS. Riedel A, et al. **J Biol Chem** 1995 Dec 29;270(52):30869–73
The role of copper in the pMMO of Methylococcus capsulatus bath: a structural vs. catalytic function. Semrau JD, et al. **J Inorg Biochem** 1995 Jun;58(4):235–44
Three-dimensional structures of free form and two substrate complexes of an extradiol ring-cleavage type dioxygenase, the BphC enzyme from Pseudomonas sp. strain KKS102. Senda T, et al. **J Mol Biol** 1996 Feb 9;255(5):735–52
Crystallization and preliminary crystallographic analysis of a 2,3-dihydroxybiphenyl dioxygenase from Pseudomonas sp. strain KKS102 having polychlorinated biphenyl (PCB)-degrading activity. Sugiyama K, et al. **Proteins** 1995 Jul;22(3):284–6
Crystal structure of the biphenyl-cleaving extradiol dioxygenase from a PCB-degrading pseudomonad. Han S, et al. **Science** 1995 Nov 10;270(5238):976–80
Olfactory toxicity of methimazole: dose-response and structure-activity studies and characterization of flavin-containing monooxygenase activity in the Long-Evans rat olfactory mucosa. Genter MB, et al. **Toxicol Pathol** 1995 Jul-Aug;23(4):477–86

GENETICS

Quantitation of digoxigenin-labeled DNA hybridized to DNA and RNA slot blots. Krueger SK, et al. **Anal Biochem** 1995 Aug 10;229(2):162–9
Genetic structures of the genes encoding 2,3-dihydroxybiphenyl 1,2-dioxygenase and 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid hydrolase from biphenyl- and 4-chlorobiphenyl-degrading Pseudomonas sp. strain DJ-12. Kim E, et al. **Appl Environ Microbiol** 1996 Jan;62(1):262–5
Multiple genes encoding 2,3-dihydroxybiphenyl 1,2-dioxygenase in the gram-positive polychlorinated biphenyl-degrading bacterium Rhodococcus erythropolis TA421, isolated from a termite ecosystem. Maeda M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):549–55
Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Zeldin DC, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):76–86
Structure of the pcbC gene encoding 2,3-dihydroxybiphenyl dioxygenase of Pseudomonas sp. P20. Kim CK, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):15–20
Structure of catechol 2,3-dioxygenase gene encoded in chromosomal DNA of Pseudomonas putida KF715. Lee J, et al. **Biochem Biophys Res Commun** 1996 Jul 25; 224(3):831–6
Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Dolphin CT, et al. **Eur J Biochem** 1996 Feb 1;235(3):683–9
Expression in Escherichia coli and properties of the carotene ketolase from Haematococcus pluvialis. Breitenbach J, et

al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):241–6

Evidence that particulate methane monooxygenase and ammonia monooxygenase may be evolutionarily related. Holmes AJ, et al. **FEMS Microbiol Lett** 1995 Oct 15; 132(3):203–8

Plasmids with erythromycin resistance and catechol 2,3–dioxygenase– or beta–galactosidase–encoding gene cassettes for use in Neisseria spp. Zhou D, et al. **Gene** 1996 May 24;171(1):133–4

Localization of human flavin–containing monooxygenase genes FMO2 and FMO5 to chromosome 1q. McCombie RR, et al. **Genomics** 1996 Jun 15;34(3):426–9

Formation of indigo and related compounds from indolecarboxylic acids by aromatic acid–degrading bacteria: chromogenic reactions for cloning genes encoding dioxygenases that act on aromatic acids. Eaton RW, et al. **J Bacteriol** 1995 Dec;177(23):6983–8

Characterization of a 2,3–dihydroxybiphenyl dioxygenase from the naphthalenesulfonate–degrading bacterium strain BN6. Heiss G, et al. **J Bacteriol** 1995 Oct;177(20):5865–71

Engineering hybrid pseudomonads capable of utilizing a wide range of aromatic hydrocarbons and of efficient degradation of trichloroethylene. Suyama A, et al. **J Bacteriol** 1996 Jul;178(14):4039–46

Expression and characterization of a modified flavin–containing monooxygenase 4 from humans. Itagaki K, et al. **J Biol Chem** 1996 Aug 16;271(33):20102–7

Transcriptional regulation of squalene epoxidase by sterols and inhibitors in HeLa cells. Nakamura Y, et al. **J Biol Chem** 1996 Apr 5;271(14):8053–6

The broad substrate chlorobenzene dioxygenase and cis–chlorobenzene dihydrodiol dehydrogenase of Pseudomonas sp. strain P51 are linked evolutionarily to the enzymes for benzene and toluene degradation. Werlen C, et al. **J Biol Chem** 1996 Feb 23;271(8):4009–16

Purification and characterization of recombinant squalene epoxidase. Nagumo A, et al. **J Lipid Res** 1995 Jul; 36(7):1489–97

Regulation of bacterial methane oxidation: transcription of the soluble methane mono–oxygenase operon of Methylococcus capsulatus (Bath) is repressed by copper ions. Nielsen AK, et al. **Microbiology** 1996 May;142 (Pt 5):1289–96

Accumulation of the angucycline antibiotic rabelomycin after disruption of an oxygenase gene in the jadomycin B biosynthetic gene cluster of Streptomyces venezuelae. Yang K, et al. **Microbiology** 1996 Jan;142 (Pt 1):123–32

The phylogenetic distribution of a transposable dioxygenase from the Niagara River watershed. Nakatsu CH, et al. **Mol Ecol** 1995 Oct;4(5):593–603

Genetic organization, nucleotide sequence and regulation of expression of genes encoding phenol hydroxylase and catechol 1,2–dioxygenase in Acinetobacter calcoaceticus NCIB8250. Ehrt S, et al. **Mol Microbiol** 1995 Oct; 18(1):13–20

The molecular basis of alkaptonuria [see comments] Fernández–Cañón JM, et al. **Nat Genet** 1996 Sep; 14(1):19–24. Comment in: Nat Genet 1996 Sep;14(1):5–6.

Isolation and functional identification of a novel cDNA for astaxanthin biosynthesis from Haematococcus pluvialis, and astaxanthin synthesis in Escherichia coli. Kajiwara S, et al. **Plant Mol Biol** 1995 Oct;29(2):343–52

Molecular cloning of the flavin–containing monooxygenase (form II) cDNA from adult human liver. Lomri N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9910

IMMUNOLOGY

Rapid purification of the oxygenase component of toluene dioxygenase from a polyol–responsive monoclonal antibody. Lynch NA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2133–7

ISOLATION & PURIFICATION

Identification of an alternative 2,3–dihydroxybiphenyl 1,2–dioxygenase in Rhodococcus sp. strain RHA1 and cloning of the gene. Hauschild JE, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2940–6

Rapid purification of the oxygenase component of toluene dioxygenase from a polyol–responsive monoclonal antibody. Lynch NA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2133–7

Partial purification and substrate specificity of flavin–containing monooxygenase from rat brain microsomes. Kawaji A, et al. **Biol Pharm Bull** 1995 Dec; 18(12):1657–9

Purification of the homogentisic acid oxidase from mammalian liver. Hudecová S, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1357–63

Purification and characterization of the oxygenase component of biphenyl 2,3–dioxygenase from Pseudomonas sp. strain LB400. Haddock JD, et al. **J Bacteriol** 1995 Oct; 177(20):5834–9

Purification and characterization of the Comamonas testosteroni B–356 biphenyl dioxygenase components. Hurtubise Y, et al. **J Bacteriol** 1995 Nov;177(22):6610–8

Membrane–associated methane monooxygenase from Methylococcus capsulatus (Bath). Zahn JA, et al. **J Bacteriol** 1996 Feb;178(4):1018–29

Microsomal aldehyde oxygenase (MALDO): purification and characterization of a cytochrome P450 isozyme responsible for oxidation of 9–anthraldehyde to 9–anthracenecarboxylic acid in monkey liver. Matsunaga T, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):617–25

Purification and characterization of recombinant squalene epoxidase. Nagumo A, et al. **J Lipid Res** 1995 Jul; 36(7):1489–97

METABOLISM

Role of cytochrome P–450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Burns KD, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C831–40

Pulmonary cytochrome P–450 monooxygenase system and Clara cell differentiation in rats. Ji CM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L394–402

Substrate diversity and expression of the 2,4,5–trichlorophenoxyacetic acid oxygenase from Burkholderia cepacia AC1100. Danganan CE, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4500–4

stcS, a putative P–450 monooxygenase, is required for the conversion of versicolorin A to sterigmatocystin in Aspergillus nidulans. Keller NP, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3628–32

Catechol 2,3–dioxygenases functional in oxygen–limited (hypoxic) environments. Kukor JJ, et al. **Appl Environ Microbiol** 1996 May;62(5):1728–40

Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Zeldin DC, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):87–96

Characterisation of a chromosomally encoded catechol 1,2–dioxygenase (E.C. 1.13.11.1) from Alcaligenes eutrophus CH34. Sauret–Ignazi G, et al. **Arch Microbiol** 1996 Jul;166(1):42–50

Evidence of histidine coordination to the catalytic ferrous ion in the ring–cleaving 2,2',3–trihydroxybiphenyl dioxygenase from the dibenzofuran–degrading bacterium Sphingomonas sp. strain RW1. Bertini I, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):855–60

Further characterization of rat brain flavin–containing monooxygenase. Metabolism of imipramine to its N–oxide. Bhagwat SV, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1469–75

Correction of salinity with flavin–containing monooxygenase activity but not cytochrome P450 activity in the euryhaline fish (Platichthys flesus). Schlenk D, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):815–8

Reconstitution of the second step in NO synthesis using the isolated oxygenase and reductase domains of macrophage NO synthase. Ghosh DK, et al. **Biochemistry** 1995 Sep 12; 34(36):11316–20

Large kinetic isotope effects in methane oxidation catalyzed by methane monooxygenase: evidence for C–H bond cleavage in a reaction cycle intermediate. Nesheim JC, et al. **Biochemistry** 1996 Aug 6;35(31):10240–7

Recombinant toluene–4–monooxygenase: catalytic and Mössbauer studies of the purified diiron and rieske components of a four–protein complex. Pikus JD, et al. **Biochemistry** 1996 Jul 16;35(28):9106–19

Manganese(II)–dependent extradiol–cleaving catechol dioxygenase from Arthrobacter globiformis CM–2. Whiting AK, et al. **Biochemistry** 1996 Jan 9;35(1):160–70

Hydroxylation of quinaldic acid: quinaldic acid 4–monooxygenase from Alcaligenes sp. F–2 versus quinaldic acid 4–oxidoreductases. Bubeck B, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):39–44

Hepatic biotransformation capacity in low–birth–weight infants as measured with the [15N]methacetin urine test: influences of gestational age, postnatal age, and intrauterine growth retardation. Boehm G, et al. **Biol Neonate** 1995; 68(1):19–25

3,4,5–Trimethoxyphenylacetaldehyde, an intermediate metabolite of mescaline, is a substrate for microsomal aldehyde oxygenase in the mouse liver. Watanabe K, et al. **Biol Pharm Bull** 1995 May;18(5):696–9

Activities of cytochrome P450–dependent monooxygenases and antioxidant enzymes in different organs of Norway rats (Rattus norvegicus) inhabiting reference and contaminated sites. Fouchécourt MO, et al. **Chemosphere** 1995 Dec;31(11–12):4375–86

Rat brain cytochrome P450. Reassessment of monooxygenase activities and cytochrome P450 levels. Bhagwat SV, et al. **Drug Metab Dispos** 1995 Jun;23(6):651–4

Selectivity of flavin–containing monooxygenase 5 for the (S)–sulfoxidation of short–chain aralkyl sulfides. Fisher MB, et al. **Drug Metab Dispos** 1995 Dec;23(12):1431–3

Quinoline 2–oxidoreductase and 2–oxo–1,2–dihydroquinoline 5,6–dioxygenase from Comamonas testosteroni 63. The first two enzymes in quinoline and 3–methylquinoline degradation. Schach S, et al. **Eur J Biochem** 1995 Sep 1; 232(2):536–44

Expression in Escherichia coli and properties of the carotene ketolase from Haematococcus pluvialis. Breitenbach J, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):241–6

An iron dioxygenase from Alcaligenes faecalis catalyzing the oxidation of pyruvic oxime to nitrite. Ono Y, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):103–8

Degradation of chlorobiphenyls catalyzed by the bph–encoded biphenyl–2,3–dioxygenase and biphenyl–2,3–dihydrodiol–2,3–dehydrogenase of Pseudomonas sp. LB400. Seeger M, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):259–64

In vitro measurement of beta–carotene cleavage activity: methodological considerations and the effect of other carotenoids on beta–carotene cleavage. van Vliet T, et al. **Int J Vitam Nutr Res** 1996;66(1):77–85

Isolation and characterization of a novel oxygenase that catalyzes the first step of n–alkane oxidation in Acinetobacter sp. strain M–1. Maeng JH, et al. **J Bacteriol** 1996 Jul;178(13):3695–700

2,4–Dinitrotoluene dioxygenase from Burkholderia sp. strain DNT: similarity to naphthalene dioxygenase. Suen WC, et al. **J Bacteriol** 1996 Aug;178(16):4926–34

Desaturation and oxygenation of 1,2–dihydronaphthalene by toluene and naphthalene dioxygenase. Torok DS, et al. **J Bacteriol** 1995 Oct;177(20):5799–805

Microsomal aldehyde oxygenase (MALDO): purification and characterization of a cytochrome P450 isozyme responsible for oxidation of 9–anthraldehyde to 9–anthracenecarboxylic acid in monkey liver. Matsunaga T, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):617–25

Stereoselective sulfoxidation of the pesticide methiocarb by flavin–containing monooxygenase and cytochrome P450–dependent monooxygenases of rat liver microsomes. Anticholinesterase activity of the two sulfoxide enantiomers. Buronfosse T, et al. **J Biochem Toxicol** 1995 Aug;10(4):179–89

Endothelial nitric–oxide synthase. Evidence for bidomain structure and successful reconstitution of catalytic activity from two separate domains generated by a baculovirus expression system. Chen PF, et al. **J Biol Chem** 1996 Jun 14;271(24):14631–5

Gating effects of component B on oxygen activation by the methane monooxygenase hydroxylase component. Liu Y, et al. **J Biol Chem** 1995 Oct 20;270(42):24662–5

Homoprotocatechuate 2,3–dioxygenase from Brevibacterium fuscum. A dioxygenase with catalase activity. Miller MA, et al. **J Biol Chem** 1996 Mar 8;271(10):5524–35

Heme iron reduction and catalysis by a nitric oxide synthase heterodimer containing one reductase and two oxygenase domains. Siddhanta U, et al. **J Biol Chem** 1996 Mar 29; 271(13):7309–12

Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. Wu S, et al. **J Biol Chem** 1996 Feb 16;271(7):3460–8

Increased susceptibility to Bacillus thuringiensis associated with pyrethroid resistance in Bovicola (Damalinia) ovis (Phthiraptera Mallophaga: possible role of monooxygenases. Drummond J, et al. **J Econ Entomol** 1995 Dec;88(6):1607–10

Renal cytochrome P450. Schwartzman ML, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):229–42 (58 ref.)

Dietary fish oil and cytochrome P–450 monooxygenase activity in rat liver and kidney. Valdes E, et al. **Lipids** 1995 Oct;30(10):955–8

Use of aquatic organisms as models to determine the in vivo contribution of flavin–containing monooxygenases in xenobiotic biotransformation. Schlenk D. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):323–30

Benzoic acid 2–hydroxylase, a soluble oxygenase from tobacco, catalyzes salicylic acid biosynthesis. León J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10413–7

Enzymological differences of AChE and diazinon hepatic metabolism: correlation of in vitro data with the selective toxicity of diazinon to fish species. Keizer J, et al. **Sci Total Environ** 1995 Oct 27;171(1–3):213–20

Pesticide–metabolizing enzymes. Hodgson E, et al. **Toxicol Lett** 1995 Dec;82–83:73–81 (41 ref.)

A thermodynamic QSAR analysis of the polysubstrate monooxygenase responses to xenobiotic chemicals. Hollebone BR, et al. **Toxicol Lett** 1995 Sep;79(1–3):157–68

S–oxidation of (+)–cis–3,5–dimethyl–2–(3–pyridyl)–thiazolidin–4–one hydrochloride by rat hepatic flavin–containing monooxygenase 1 expressed in yeast. Nunoya K, et al. **Xenobiotica** 1995 Dec;25(12):1283–91

Influence of partial hepatectomy in dogs on trimethadione metabolism and microsomal monooxygenases. Tanaka E, et al. **Xenobiotica** 1995 Dec;25(12):1301–10

[The mono–oxygenase system as a target in the action of hypoxia in combination with hyperthermia] Luk'ianchuk VD, et al. **Lik Sprava** 1995 May–Jun;(5–6):100–2 **(Rus)**

PHARMACOLOGY

Toluene and ethylbenzene oxidation by purified naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816–4. Lee K, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3101–6

Regio– and stereospecific oxidation of 9,10–dihydroanthracene and 9,10–dihydrophenanthrene by naphthalene dioxygenase: structure and absolute stereochemistry of metabolites. Resnick SM, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3355–9

Oxidation of aldehydes catalyzed by pig liver flavin–containing monooxygenase. Chen GP, et al. **Drug Metab Dispos** 1995 Dec;23(12):1390–3

Stereospecific dihydroxylation of the styrene vinyl group by purified naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816–4. Lee K, et al. **J Bacteriol** 1996 Jun; 178(11):3353–6

PHYSIOLOGY

In vitro hepatic metabolism of ABT–418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin–containing monooxygenase–dependent stereoselective N'–oxidation. Rodrigues AD, et al.

Drug Metab Dispos 1995 Oct;23(10):1143–52

[Cytochrome P450–dependent monooxygenase system and anesthetics] Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):185–94 (64 ref.) (Eng. Abstr.) **(Chi)**

OXYGENATION, EXTRACORPOREAL MEMBRANE see **EXTRACORPOREAL MEMBRANE OXYGENATION**

OXYGENATION, HYPERBARIC see **HYPERBARIC OXYGENATION**

OXYGENATORS

A problem with a Sechrist air/oxygen blender device [letter] Wajon P, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):518–9

Influence of hemodynamics on the performances of intravascular gas exchangers. Mihaljevic T, et al. **Ann Thorac Surg** 1995 Dec;60(6):1665–70

Beneficial effects of Duraflo II heparin–coated circuits on postperfusion lung dysfunction. Ranucci M, et al. **Ann Thorac Surg** 1996 Jan;61(1):76–81

Perfluorocarbon oxygen transport. A comparative study of four oxygenator designs. Ferguson ER, et al. **ASAIO J** 1994 Jul–Sep;40(3):M649–53

Enhanced oxygen delivery induced by perfluorocarbon emulsions in capillary tube oxygenators. Vaslef SN, et al. **ASAIO J** 1994 Jul–Sep;40(3):M643–8

ADVERSE EFFECTS

Neutrophil dynamics and retention in lung, oxygenator, and arterial filter during cardiopulmonary bypass in a pig model. Dewanjee MK, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M547–53

OXYGENATORS, MEMBRANE

Development of an intra blood circuit membrane oxygenator. Fukui Y, et al. **ASAIO J** 1994 Jul–Sep;40(3):M732–4

Synthesis of aromatic polyimides with sulfone diamine moieties for a novel membrane oxygenator. Kawakami H, et al. **ASAIO J** 1995 Jul–Sep;41(3):M379–83

Vibration analysis of vessel wall motion with intra vena caval balloon pumping. Shafi AS, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M740–2

Small intrapulmonary artery lung prototypes: design, construction, and in vitro water testing. Snider MT, et al. **ASAIO J** 1994 Jul–Sep;40(3):M533–9

Improved gas exchange performance of the intravascular oxygenator by active blood mixing. Tao W, et al. **ASAIO J** 1994 Jul–Sep;40(3):M527–32

Stragegies to reduce surface area requirements for carbon dioxide removal for an intravenacaval gas exchange device. Tao W, et al. **ASAIO J** 1995 Jul–Sep;41(3):M567–72

Reduction of ventilator settings allowed by intravenous oxygenator (IVOX) in ARDS patients. Mira JP, et al. **Intensive Care Med** 1995 Jan;21(1):11–7

Marked mixed venous hemoglobin desaturation in a patient during hypothermic cardiopulmonary bypass [clinical conference] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):764–7

In vitro uptake and elimination of isoflurane by different membrane oxygenators. Hickey S, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):352–5

Failure of a membrane oxygenation module during cardiopulmonary bypass and its implications for the cardiac anesthesiologist [letter] Hiong YT. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):620–1

Cardiopulmonary bypass with two oxygenators. Avidan A, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):63–5

[Thrombosis–resistant heparin–coated diffusion membrane oxygenators: an experimental study] Tkebuchava T, et al. **Swiss Surg Suppl** 1996;Suppl 1:36–40 (Eng. Abstr.) **(Ger)**

STANDARDS

Small pore size microporous membrane oxygenator reduces plasma leakage during prolonged extracorporeal circulation: a case report. Musch G, et al. **Int J Artif Organs** 1996 Mar;19(3):177–80

OXYHEMOGLOBINS

ANALYSIS

The influence of carbon dioxide and body position on near–infrared spectroscopic assessment of cerebral hemoglobin oxygen saturation. Pollard V, et al. **Anesth Analg** 1996 Feb;82(2):278–87

Jugular venous bulb oxyhemoglobin saturation during cardiac surgery: accuracy and reliability using a continuous monitor. Trubiano P, et al. **Anesth Analg** 1996 May; 82(5):964–8

Estimation of bloodstain age by rapid determinations of oxyhemoglobin by use of oxygen electrode and total hemoglobin. Matsuoka T, et al. **Biol Pharm Bull** 1995 Aug; 18(8):1031–5

Role of oximeter error in the diagnosis of shunts. Shepherd AP, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):435–46

Discrimination among dyshemoglobins: analytical approach to a toxicological query [letter] Zoppi F, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1300–2

Performance characteristics of Hemox–Analyzer for assessment of the hemoglobin dissociation curve. Guarnone R, et al. **Haematologica** 1995 Sep–Oct;80(5):426–30

Limitations of jugular bulb oxyhemoglobin saturation without intracranial pressure monitoring in subarachnoid hemorrhage. Chieregato A, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):21–5

The rate of oxygen release from single sinusoid of rat liver, determined by microspectroscopy. Yoshihara H, et al. **Med J Osaka Univ** 1993 Sep;41–42(1–4):1–10

Influence of blood vessels on the measurement of hemoglobin oxygenation as determined by time–resolved reflectance spectroscopy. Liu H, et al. **Med Phys** 1995 Aug; 22(8):1209–17

Somanetics INVOS 3100 cerebral oximeter [letter; comment] Dujovny M, et al. **Neurosurgery** 1995 Jul;37(1):160. Comment on: Neurosurgery 1994 Oct;35(4):796.

Measurement of cerebral venous oxyhemoglobin saturation in children by near–infrared spectroscopy and partial jugular venous occlusion. Yoxall CW, et al. **Pediatr Res** 1995 Sep;38(3):319–23

CHEMISTRY

Intramolecular cross–linking of oxy hemoglobin by bis sulfosuccinimidyl suberate and sebacate: generation of cross–linked hemoglobin with reduced oxygen affinity. Manjula BN, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):311–8

Contributions of asparagine at alpha 97 to the cooperative oxygenation process of hemoglobin. Kim HW, et al. **Biochemistry** 1996 May 28;35(21):6620–7

Conformational changes in oxyhemoglobin C (Glu beta 6—>Lys) detected by spectroscopic probing. Hirsch RE, et al. **J Biol Chem** 1996 Jan 5;271(1):372–5

The role of the dodecamer subunit in the dissociation and reassembly of the hexagonal bilayer structure of Lumbricus terrestris hemoglobin. Sharma PK, et al. **J Biol Chem** 1996 Apr 12;271(15):8754–62

The crystal structure of a high oxygen affinity species of haemoglobin (bar–headed goose haemoglobin in the oxy form). Zhang J, et al. **J Mol Biol** 1996 Jan 26;255(3):484–93

DRUG EFFECTS

Influence of ozone on haemoglobin oxygen affinity in type–2 diabetic patients with peripheral vascular disease: in vitro studies. Coppola L, et al. **Diabete Metab** 1995 Oct; 21(4):252–5

METABOLISM

In vitro effect of ketones and hyperglycemia on feline hemoglobin oxidation and D– and L–lactate production. Fallin CW, et al. **Am J Vet Res** 1996 Apr;57(4):463–7

Diving behaviour and haemoglobin function: the primary structure of the alpha– and beta–chains of the sea turtle (Caretta caretta) and its functional implications. Petruzzelli R, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):959–65

Contributions of asparagine at alpha 97 to the cooperative oxygenation process of hemoglobin. Kim HW, et al. **Biochemistry** 1996 May 28;35(21):6620–7

A model to describe the rate of oxyhaemoglobin desaturation during apnoea. Farmery AD, et al. **Br J Anaesth** 1996 Feb; 76(2):284–91

Reactivity of glutathione adducts of 4–(dimethylamino)phenol. Involvement of reactive oxygen species during the interaction with oxyhemoglobin. Ludwig E, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):363–8

Non–invasive measurement of cardiac oxygenation and haemodynamics during transient episodes of coronary artery occlusion and reperfusion in the pig. Thorniley MS, et al. **Clin Sci (Colch)** 1996 Jul;91(1):51–8

Near–infrared spectroscopy and cerebral hemodynamics [letter] Gomersall CD, et al. **Crit Care Med** 1996 Aug; 24(8):1423; discussion 1424–5

Near–infrared spectroscopy and cerebral hemodynamics [letter] Owen–Reece H, et al. **Crit Care Med** 1996 Aug; 24(8):1424; discussion 1424–5

Human erythrocyte metabolism is modulated by the O2–linked transition of hemoglobin. Messana I, et al. **FEBS Lett** 1996 Jul 15;390(1):25–8

The water effect on allosteric regulation of hemoglobin probed in water/glucose and water/glycine solutions. Colombo MF, et al. **J Biol Chem** 1996 Mar 1;271(9):4895–9

Cooperative oxygen binding to scapharca inaequivalvis hemoglobin in the crystal. Mozzarelli A, et al. **J Biol Chem** 1996 Feb 16;271(7):3627–32

Siggaard–Andersen algorithm–derived p50 parameters: perturbation by abnormal hemoglobin–oxygen affinity and acid–base disturbances. Morgan TJ, et al. **J Lab Clin Med** 1995 Oct;126(4):365–72

Regional changes in cerebral haemodynamics as a result of a visual stimulus measured by near infrared spectroscopy. Meek JH, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):351–6

Hemoglobin oxygenation kinetics and secondary ischemia in renal transplantation. Lane NJ, et al. **Transplantation** 1996 Mar 15;61(5):689–96

PHARMACOLOGY

Pro–oxidant effects of cross–linked haemoglobins explored using liposome and cytochrome c oxidase vesicle model membranes. Rogers MS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):827–33

Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle. Vollrath B, et al. **Cardiovasc Res** 1995 Oct;30(4):619–26

PHYSIOLOGY

Functional changes in cultured strips of canine cerebral arteries after prolonged exposure to oxyhemoglobin. Yoshimoto Y, et al. **J Neurosurg** 1995 Nov;83(5):867–74

OXYMETAZOLINE

ADMINISTRATION & DOSAGE

Nasal airway resistance after decongestion with a nasal spray or a bellows device. Jessen M, et al. **Rhinology** 1996 Mar; 34(1):28–31

ADVERSE EFFECTS

Cardiac arrest after oxymetazoline nasal spray. Thrush DN. **J Clin Anesth** 1995 Sep;7(6):512–4

Long–term use of oxy– and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Graf P. **Rhinology** 1996 Mar;34(1):9–13

PHARMACOLOGY

Selectivity of the imidazoline alpha–adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1–adrenoceptor subtypes. Horie K, et al. **Br J Pharmacol** 1995 Sep;116(1):1611–8

Hypothalamic alpha 2A–adrenoceptors stimulate growth hormone release in the rat. Makara GB, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):43–8

Anti–oxidant actions of oxymethazoline and xylomethazoline. Westerveld GJ, et al. **Eur J Pharmacol** 1995 Sep 15; 291(1):27–31

Effect on the nasal mucosa of long–term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Graf P, et al. **Laryngoscope** 1996 May;106(5 Pt 1):605–9

THERAPEUTIC USE

Effect of oxymetazoline nose drops on acute sinusitis in the rabbit. Bende M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):222–5

OXYMETHOLONE

ADVERSE EFFECTS

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

THERAPEUTIC USE

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV–1) infection. Hengge UR, et al. **Br J Nutr** 1996 Jan; 75(1):129–38

OXYMORPHONE

PHARMACOKINETICS

Pharmacokinetic–pharmacodynamic relationships of controlled–release oxycodone. Kaiko RF, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):52–61

PHARMACOLOGY

Oxymorphone–induced analgesia and colonic motility measured in colorectal distension. Briggs SL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):561–3

OXYNEURINE see **BETAINE**

OXYNTIC CELLS see **PARIETAL CELLS, GASTRIC**

OXYNTOMODULIN see **ENTEROGLUCAGON**

OXYPHEDRINE see **OXYFEDRINE**

OXYPROLINE see **HYDROXYPROLINE**

OXYPURINOL

PHARMACOKINETICS

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Graham S, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):299–304

Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Walter–Sack I, et al. **Eur J Clin Pharmacol** 1995;49(3):215–20

The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. Mills PC, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):451–6

OXYPURINOL

URINE

Effect of amino acids on the excretions of purine bases and oxypurinol. Yamamoto T, et al. **Nephron** 1996;73(1):41–7

OXYQUINOL see **OXYQUINOLINE**

OXYQUINOLINE

ANALOGS & DERIVATIVES

Granulocyte accumulation in the transplanted liver does not correlate with clinical and histologic evidence of dysfunction. Ziser A, et al. **Invest Radiol** 1996 Mar; 31(3):132–7

Determining the lifespan of platelets labelled with 111In oxinate—first results. Todorović-Tirnanić M, et al. **Med Pregl** 1993;46 Suppl 1:97–9

Fate of mouse macrophages radiolabelled with PKH–95 and injected intravenously. Audran R, et al. **Nucl Med Biol** 1995 Aug;22(6):817–21

DIAGNOSTIC USE

[Single photon emission tomography in temporal epilepsy: interictal and ictal studies with visual and semi quantitative analysis] Yacubian EM, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–A):369–83 (Eng. Abstr.) **(Por)**

PHARMACOLOGY

Hydroxyquinoline overcomes PCR inhibition by UV-damaged mineral oil. Gilgen M, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):4001–2

TOXICITY

Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Leanderson P, et al. **Carcinogenesis** 1996 Mar;17(3):545–50

OXYTETRACYCLINE

In vivo tetracycline labelling as a measure of rearing-system influence on chicken-bone dynamics. Vitorovic D, et al. **Anat Histol Embryol** 1995 Jun;24(2):85–6

ADMINISTRATION & DOSAGE

[Resistance to tetracycline of E. coli of chicken intestines after prophylactic treatment of animal feed with bioptivet GB] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov;108(11):412–7 (Eng. Abstr.) **(Ger)**

ANALYSIS

The effect of cooking on veterinary drug residues in food: 4. Oxytetracycline. Rose MD, et al. **Food Addit Contam** 1996 Apr;13(3):275–86

Application of reversed-phase liquid chromatography and prepacked C18 cartridges for the analysis of oxytetracycline and related compounds. Fedeniuk RW, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):291–7

PHARMACOKINETICS

Pharmacokinetics of oxytetracycline administered intravenously to 4 to 5-day-old foals. Papich MG, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):375–8

Modeling residue uptake by eggs. 1. Similar drug residue patterns in developing yolks following injection with ampicillin or oxytetracycline. Donoghue DJ, et al. **Poult Sci** 1996 Mar;75(3):321–8

PHARMACOLOGY

In vitro modulation of bovine blood neutrophils and mononuclear cells by oxytetracycline. Myers MJ, et al. **Am J Vet Res** 1995 Aug;56(8):1007–11

[Resistance to tetracycline of E. coli of chicken intestines after prophylactic treatment of animal feed with bioptivet GB] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov;108(11):412–7 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Evaluation of injections of collagenase and oxytetracycline via the umbilical artery as treatment for retained placenta in cattle. Fecteau KA, et al. **Am J Vet Res** 1996 Apr; 57(4):522–5

Treatment of ovine dermatophilosis with long-acting oxytetracycline or a lincomycin-spectinomycin combination. Jordan D, et al. **Aust Vet J** 1995 Jun; 72(6):234–6

Comparison of tilmicosin with long-acting oxytetracycline for treatment of respiratory tract disease in calves [see comments] Musser J, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):102–6. Comment in: J Am Vet Med Assoc 1996 Mar 1;208(5):655–6.

Evaluation of the use of intrauterine infusions of oxytetracycline, subcutaneous injections of fenprostalene, or a combination of both, for the treatment of retained fetal membranes in dairy cows. Stevens RD, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1612–5

OXYTHIAMINE

PHARMACOLOGY

The effects of thiamine and oxythiamine on the survival of cultured brain neurons. Geng MY, et al. **Jpn J Pharmacol** 1995 Jul;68(3):349–52

[Is oxythiamine an antivitamin?] Vinogradov VV, et al. **Biokhimiia** 1995 Oct;60(10):1564–74 (107 ref.) (Eng. Abstr.) **(Rus)**

OXYTOCICS

Oxytocin to induce labor. Shyken JM, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):232–45 (70 ref.)

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973–84 (40 ref.)

The use of oxytocin. Shyken JM, et al. **Clin Perinatol** 1995 Dec;22(4):907–31 (93 ref.)

Preinduction prostaglandin E2 gel prior to induction of labor in women with a previous cesarean section. Williams MA, et al. **Gynecol Obstet Invest** 1995;40(2):89–93

Oxytocics in developing countries. Dujardin B, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):243–51

The role of prostaglandins E2 and F2 alpha in ultraviolet radiation-induced cortical cataracts in vivo. Andley UP, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1539–48

Managing rupture of membranes at term. Kimber RC. **J Fam Pract** 1996 Jul;43(1):28

Prostaglandin gel for cervical ripening. Snyder SG, et al. **J Fam Pract** 1996 Jul;43(1):19

Prostaglandin E2 gel for cervical priming and induction of labour in unfavourable cervical state. Patnaik P, et al. **J Indian Med Assoc** 1995 Apr;93(4):140–1, 135

[Prostaglandin E2—an effective alternative for the induction of labor] Bozhinova S, et al. **Akush Ginekol (Sofiia)** 1995; 34(3):1–4 (Eng. Abstr.) **(Bul)**

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13–27 (42 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Local administration of prostaglandin E2 for cervical ripening and labor induction: the appropriate route and dose. Nuutila M, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):135–8

Cervical ripening and induction of delivery by local administration of prostaglandin E2 gel or vaginal tablets is equally effective. Rix P, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):45–7

Labor induction with intravaginal misoprostol versus intracervical prostaglandin E2 gel (Prepidil gel): randomized comparison. Chuck FJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1137–42

Randomized, double-blind trial of prostaglandin E2 intravaginal gel versus low-dose oxytocin for cervical ripening before induction of labor. Pollnow DM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1910–3; discussion 1913–6

A comparison of differing dosing regimens of vaginally administered misoprostol for preinduction cervical ripening and labor induction. Wing DA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):158–64

Induction of parturition in ewes with dexamethasone or dexamethasone and cloprostenol. Kastelic JP, et al. **Can Vet J** 1996 Feb;37(2):101–2

Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Bider D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):59–61 (13 ref.)

Preinduction cervical ripening with intravaginal prostaglandin E1 methyl analogue misoprostol: a randomized controlled trial. Srisomboon J, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):119–24

Misoprostol for third stage of labour [letter] el-Refaey H, et al. **Lancet** 1996 May 4;347(9010):1257

Cervical priming with oral misoprostol in pre-labor rupture of membranes at term. Ngai SW, et al. **Obstet Gynecol** 1996 Jun;87(6):923–6

[The role of prostaglandin E2 in cervix maturation and labor induction. Clinical experience] Rech F, et al. **Minerva Ginecol** 1995 Oct;47(10):423–9 (Eng. Abstr.) **(Ita)**

[Erythrocytic enzymatic systems and their antioxidative potential in pregnant women undergoing labor induction with intracervical PGE2] Cruz AS, et al. **Acta Med Port** 1995 Jul-Aug;8(7–8):415–8 (Eng. Abstr.) **(Por)**

DIAGNOSTIC USE

Ergonovine-echo test to assess the significance of chest pain at rest without ECG changes [see comments] Morales MA, et al. **Eur Heart J** 1995 Oct;16(10):1361–6. Comment in: Eur Heart J 1995 Oct;16(10):1312–3.

METABOLISM

Corneal endothelial repair. Regulation of prostaglandin E2 synthesis. Jumblatt MM, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1294–301

PHARMACOKINETICS

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Kévorkian JP, et al. **Clin Pharmacol Ther** 1996 May;59(5):583–92

Comparison of the bioavailability and pharmacokinetics of oral methylergometrine in men and women. de Groot AN, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):328–32

PHARMACOLOGY

The effects of the gonadotrophin releasing hormone analogue (goserelin) and prostaglandin E1 (misoprostol) on cervical resistance prior to transcervical resection of the endometrium. Cooper KG, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):375–8

Prostaglandin-induced protection of cultured rat gastric cells against ethanol is inhibited by a microtubule inhibitor. Arakawa T, et al. **Digestion** 1996;57(1):41–6

Oxytocin enhances clearance of radiocolloid from the uterine lumen of reproductively normal mares and mares susceptible to endometritis. LeBlanc M, et al. **Equine Vet J** 1994 Jul;26(4):279–82

Rebound increase in fetal breathing movements after 24-h prostaglandin E2 infusion in fetal sheep. Hollingworth SA, et al. **J Appl Physiol** 1996 Jan;80(1):166–75

Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. Adams JW, et al. **J Biol Chem** 1996 Jan 12;271(2):1179–86

Maternity and medicinal plants in Vanuatu. II. Pharmacological screening of five selected species. Bourdy G, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):139–43

[Reaction of umbilical cord arteries to PGF2 alpha and glycerol trinitrate during the first days post partum] Bartels U, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:80–2 (Eng. Abstr.) **(Ger)**

[The effect of calcium antagonists, partusisten, oxytocin and prostenon on uterine contractile activity in pregnant rats] Korkhov VV, et al. **Eksp Klin Farmakol** 1995 Nov-Dec; 58(6):40–1 (Eng. Abstr.) **(Rus)**

[The reaction of mammary tissue basophils to oxytocin] Balakina GB, et al. **Morfologiia** 1994 Jul-Dec; 107(7–12):148–54 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Misoprostol for induction of labor [letter; comment] Gonzalez Pena JC. **Am J Obstet Gynecol** 1996 Feb; 174(2):797. Comment on: Am J Obstet Gynecol 1995 Jun;172(6):1804–10. Comment on: Am J Obstet Gynecol 1995 Jun;172(6):1811–6.

Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation. Sanchez-Ramos L, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1079–84

Prevention of postpartum haemorrhage. de Groot AN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):619–31 (41 ref.)

Improved intravaginal controlled-release prostaglandin E2 insert for cervical ripening at term. The Prostaglandin E2 insert Study Group. Witter FR, et al. **J Matern Fetal Med** 1996 Mar-Apr;5(2):64–9

The use of low dose 1.5 mg prostaglandin E2 gel for cervical ripening and induction of labor at term with unfavorable cervix. Herabutya Y, et al. **J Med Assoc Thai** 1995 Nov; 78(11):590–5

A randomized comparison of prostaglandin E2, oxytocin, and the double-balloon device in inducing labor. Atad J, et al. **Obstet Gynecol** 1996 Feb;87(2):223–7

Prostaglandin E2 gel for cervical ripening in patients with an indication for delivery. Darroca RJ, et al. **Obstet Gynecol** 1996 Feb;87(2):228–30

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

OXYTOCIN

see related
OXYTOCICS
RECEPTORS, OXYTOCIN

Oxytocin to induce labor. Shyken JM, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):232–45 (70 ref.)

The use of prostaglandins and oxytocin for transcervical recovery of bovine fetuses at days 33–58 of gestation. Lavoir MC, et al. **J Reprod Fertil** 1996 Jan;106(1):95–100

ADMINISTRATION & DOSAGE

Novel approach to oxytocin induction-augmentation of labor. Application of oxytocin physiology during pregnancy. Dawood MY. **Adv Exp Med Biol** 1995; 395:585–94 (41 ref.)

Appearance of the facilitatory action of central oxytocin on milk-ejection. Independence from peri-partum steroidal changes. Housham SJ, et al. **Adv Exp Med Biol** 1995; 395:200–2

High-dose oxytocin [letter; comment] Dombrowski MP, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):240. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1874–8.

A "randomized" controlled trial without randomization [letter; comment] Grimes DA, et al.

Am J Obstet Gynecol 1996 Jul;175(1):240–1. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1874–8.

Randomized, double-blind trial of prostaglandin E2 intravaginal gel versus low-dose oxytocin for cervical ripening before induction of labor. Pollnow DM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1910–3; discussion 1913–6

Low-dose versus high-dose oxytocin augmentation of labor—a randomized trial [see comments] Xenakis EM, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1874–8. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):240. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):240–1.

A randomised controlled trial of early versus delayed use of amniotomy and oxytocin infusion in nulliparous labour. Cammu H, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):313–8

A randomised controlled trial of early versus delayed use of amniotomy and oxytocin infusion in nulliparous labour [letter] Geary M. **Br J Obstet Gynaecol** 1996 Sep; 103(9):939–40

Induction of labour: a randomised clinical trial of amniotomy versus amniotomy with oxytocin infusion. Moldin PG, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):306–12

Pre-ovulatory oxytocin administration promotes the onset of the luteinizing hormone surge in human females. Hull ML, et al. **Hum Reprod** 1995 Sep;10(9):2266–9

Influence of intraumbilical oxytocin on the third stage of labour. Dahiya P, et al. **Indian J Med Sci** 1995 Feb; 49(2):23–7

A trial of pulsatile versus continuous oxytocin administration for the induction of labor. Reid GJ, et al. **J Perinatol** 1995 Sep–Oct;15(5):364–6; quiz 367–8

Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. De Groot AN, et al. **J Pharm Pharmacol** 1995 Jul;47(7):571–5

Concentrated oxytocin plus low-dose prostaglandin E2 compared with prostaglandin E2 vaginal suppositories for second-trimester pregnancy termination. Owen J, et al. **Obstet Gynecol** 1996 Jul;88(1):110–3

ADVERSE EFFECTS

Computer analysis of fetal heart rate during induction of labor with oxytocin. Bartnicki J, et al. **Gynecol Obstet Invest** 1995;40(3):168–73

Pseudotumour cerebri from intranasal oxytocin and excessive fluid intake [letter] Mayer-Hubner B. **Lancet** 1996 Mar 2; 347(9001):623

[Critical pulmonary edema following cesarean section] Puura A, et al. **Duodecim** 1995;111(3):249–52 **(Fin)**

ANALOGS & DERIVATIVES

Structure and organization of the isotocin and vasotocin genes from teleosts. Venkatesh B, et al. **Adv Exp Med Biol** 1995;395:629–38 (24 ref.)

Cloning and functional characterization of the amphibian mesotocin receptor, a member of the oxytocin/vasopressin receptor superfamily. Akhundova A, et al. **Eur J Biochem** 1996 May 1;237(3):759–67

Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas. Cassoni P, et al. **Int J Cancer** 1996 Jun 11; 66(6):817–20

A new neurohypophysial peptide, seritocin ([Ser5,Ile8]-oxytocin), identified in a dryness-resistant African toad, Bufo regularis. Chauvet J, et al. **Int J Pept Protein Res** 1995 May;45(5):482–7

Co-evolution of ligand-receptor pairs in the vasopressin/oxytocin superfamily of bioactive peptides. van Kesteren RE, et al. **J Biol Chem** 1996 Feb 16; 271(7):3619–26

Ontogeny of vasotocinergic and mesotocinergic systems in the brain of the South African clawed frog Xenopus laevis. González A, et al. **J Chem Neuroanat** 1995 Jul;9(1):27–40

Solid-phase extraction of arginine vasotocin and isotocin in fish samples and subsequent gradient reversed-phase high-performance liquid chromatographic separation. Kulczykowska E. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):289–93

Potentiometric and spectroscopic studies on the copper(II) complexes of peptide hormones containing disulfide bridges. Danyi P, et al. **J Inorg Biochem** 1995 Oct; 60(1):69–78

A novel G protein-coupled receptor mediating both vasopressin- and oxytocin-like functions of Lys-conopressin in Lymnaea stagnalis. van Kesteren RE, et al. **Neuron** 1995 Oct;15(4):897–908

Co-localized neuropeptides conopressin and ALA-PRO-GLY-TRP-NH2 have antagonistic effects on the vas deferens of LYMNAEA. Van Golen FA, et al. **Neuroscience** 1995 Dec;69(4):1275–87

Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Fjellestad-Paulsen A, et al. **Peptides** 1995;16(6):1141–7

ELISA measurements of vasotocin and isotocin in plasma and pituitary of the rainbow trout: effect of salinity. Pierson PM, et al. **Peptides** 1995;16(5):859–65

[Transformation of genetically engineered oxytocinoyllysine into oxytocin] Mal'tsev KV, et al. **Bioorg Khim** 1996 Apr; 22(4):252–5 (Eng. Abstr.) **(Rus)**

[Genetic engineering of oxytocin: isolation of oxytocinoyllysine] Ovchinnikova TV, et al. **Bioorg Khim** 1995 Dec;21(12):899–904 (Eng. Abstr.) **(Rus)**

ANALYSIS

Enzyme immunometric assay (SPIE-IA) for oxytocin. Marnet PG, et al. **Adv Exp Med Biol** 1995;395:613–4

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Purba JS, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):137–43

Ontogeny of oxytocin-like immunoreactivity in the Brazilian opossum brain. Iqbal J, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1-2):1–16

Vasopressin gene related products are markers of human breast cancer. North WG, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):229–35

Oxytocinergic innervation to the upper thoracic sympathetic preganglionic neurons in the rat. A light and electron microscopical study using a combined retrograde transport and immunocytochemical technique. Hosoya Y, et al. **Exp Brain Res** 1995;107(1):9–16

GABA-induced facilitation of the periodic bursting activity of oxytocin neurones in suckled rats. Moos FC. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):103–14

[Results of fetal monitoring in pregnancy with enzymatic and neuroendocrinologic risk factors] Pabian W, et al. **Ginekol Pol** 1996 Apr;67(4):169–75 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)

Progress in the development of oxytocin antagonists for use in preterm labor. Pettibone DJ, et al. **Adv Exp Med Biol** 1995;395:601–12 (49 ref.)

The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Goodwin TM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):913–7

Interfering with somatosensory stimulation from pups sensitizes experienced, postpartum rat mothers to oxytocin antagonist inhibition of maternal behavior. Pedersen CA, et al. **Behav Neurosci** 1995 Oct;109(5):980–90

The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Kinsler VA, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):373–5

Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)

Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Manning M, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3-4):244–52

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. Williams PD, et al. **J Med Chem** 1995 Nov 10;38(23):4634–6

Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. Chan WY, et al. **J Pharmacol Exp Ther** 1996 May;277(2):999–1003

BIOSYNTHESIS

Synthesis and metabolism of oxytocin in late gestation in human decidua. Mitchell BF, et al. **Adv Exp Med Biol** 1995; 395:365–80 (69 ref.)

Production of hybrid oxytocin/vasopressin precursors and accumulation of oxytocin precursors in the rough endoplasmic reticulum of rat magnocellular neurons. Morris JF, et al. **Adv Exp Med Biol** 1995;395:49–58

Oxytocin and oxytocin receptor gene expression in the reproductive tract of the pregnant cow: rescue of luteal oxytocin production at term. Ivell R, et al. **Biol Reprod** 1995 Sep;53(3):553–60

Effect of hypoosmolality on the abundance, poly(A) tail length and axonal targeting of arginine vasopressin and oxytocin mRNAs in rat hypothalamic magnocellular neurons. Svane PC, et al. **FEBS Lett** 1995 Oct 2;373(1):35–8

Prostaglandin F2 alpha, progesterone and oxytocin production by cultured bovine luteal cells treated with prostaglandin E2 and pregnancy-specific protein B. Del Vecchio RP, et al. **Prostaglandins** 1995 Sep;50(3):137–50

Oxytocin synthesis and metabolism in human decidua. Mitchell BF. **Reprod Fertil Dev** 1995;7(3):319–21 (12 ref.)

[Transformation of genetically engineered oxytocinoyllysine into oxytocin] Mal'tsev KV, et al. **Bioorg Khim** 1996 Apr; 22(4):252–5 (Eng. Abstr.) **(Rus)**

BLOOD

Reduction of plasma oxytocin levels in patients suffering from major depression. Frasch A, et al. **Adv Exp Med Biol** 1995; 395:257–8

Daily and hourly temporal association between delta4-androstenedione-induced preterm myometrial contractions and maternal plasma estradiol and oxytocin concentrations in the 0.8 gestation rhesus monkey. Giussani DA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1050–5

Cocaine's effect on plasma oxytocin concentrations in the baboon during late pregnancy. Morgan MA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1026–7

Thirst induced by a suckling episode during breast feeding and relation with plasma vasopressin, oxytocin and osmoregulation. James RJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):277–82

[Oxytocin (OT)—measurement and its clinical implication] Tanaka T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:308–14 (32 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Pitts AF, et al. **Biol Psychiatry** 1995 Sep 1;38(5):330–5

CHEMISTRY

Exploration of the conformational space of oxytocin and arginine-vasopressin using the electrostatically driven Monte Carlo and molecular dynamics methods. Liwo A, et al. **Biopolymers** 1996 Feb;38(2):157–75

Alkylation of oxytocin by S-(2-chloroethyl)glutathione and characterization of adducts by tandem mass spectrometry and Edman degradation. Erve JC, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):414–21

Crystal structure of the neurophysin–oxytocin complex. Rose JP, et al. **Nat Struct Biol** 1996 Feb;3(2):163–9

DRUG EFFECTS

Antisense oligodeoxynucleotide complementary to oxytocin mRNA blocks lactation in rats. Skutella T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):191–5

GENETICS

Man and the chimaera. Selective versus neutral oxytocin evolution. Acher R, et al. **Adv Exp Med Biol** 1995; 395:615–27 (59 ref.)

Effect of gonadal steroids upon hypothalamic oxytocin expression. Amico JA, et al. **Adv Exp Med Biol** 1995; 395:23–35

Functional domains in the oxytocin gene for regulation of expression and biosynthesis of gene products. Burbach JP, et al. **Adv Exp Med Biol** 1995;395:9–21 (81 ref.)

A novel biological aspect of ovarian oxytocin: gene expression of oxytocin and oxytocin receptor in cumulus/luteal cells and the effect of oxytocin on embryogenesis in fertilized oocytes. Furuya K, et al. **Adv Exp Med Biol** 1995;395:523–8

Oxytocin mRNA in the human paraventricular nucleus in AIDS. Guldenaar SE, et al. **Adv Exp Med Biol** 1995;395:91

Sense- and antisense-targeting of oxytocinergic systems in the rat hypothalamus. Jirikowski GF, et al. **Adv Exp Med Biol** 1995;395:59–65

Rapid stimulation of oxytocin gene expression in supraoptic nucleus neurones during morphine withdrawal in rats. Johnstone LE, et al. **Adv Exp Med Biol** 1995;395:205–6

Oxytocin transgenic mice. Murphy D, et al. **Adv Exp Med Biol** 1995;395:67–78 (57 ref.)

Myometrial oxytocin messenger RNA is not increased at the onset of human labour. Thornton S, et al. **Adv Exp Med Biol** 1995;395:551–2

Regulation of oxytocin expression in the bovine corpus luteum. Orphan receptors and the oxytocin promoter. Walther N, et al. **Adv Exp Med Biol** 1995;395:79–90 (63 ref.)

Gonadal steroid regulation of oxytocin and oxytocin receptor gene expression. Zingg HH, et al. **Adv Exp Med Biol** 1995; 395:395–404

Estimation of oxytocin mRNA in the human paraventricular nucleus in AIDS by means of quantitative in situ hybridization. Guldenaar SE, et al. **Brain Res** 1995 Nov 27;700(1-2):107–14

Vasopressin gene related products are markers of human breast cancer. North WG, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):229–35

Corticotrophin-releasing hormone, proenkephalin A and oxytocin mRNA's in the paraventricular nucleus during pregnancy and parturition in the rat. Douglas AJ, et al. **Gene Ther** 1994;1 Suppl 1:S85

Bovine oxytocin transgenes in mice. Hypothalamic expression, physiological regulation, and interactions with the vasopressin gene. Ho MY, et al. **J Biol Chem** 1995 Nov 10;270(45):27199–205

Effect of ovarian steroid hormones and the presence of the fetus on oxytocin gene expression in the uterus. Higuchi T, et al. **J Endocrinol** 1995 Jul;146(1):81–5

Sequential estrogen and progesterone (P) followed by P withdrawal increases the level of oxytocin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the male rat. Thomas A, et al. **Life Sci** 1996; 58(19):1615–20

Effects of retinoic acid and estrogens on oxytocin gene expression in the rat uterus: in vitro and in vivo studies. Larcher A, et al. **Mol Cell Endocrinol** 1995 Oct 30; 114(1-2):69–76

Differential cellular localization of oestrogen receptor immunoreactivity and oxytocin mRNA and immunoreactivity in the rat preoptic area. Cruttwell CJ, et al. **Neurosci Lett** 1995 Nov 17;200(2):89–92

Vasopressin and oxytocin: molecular biology and evolution

of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235–66 (137 ref.)

[Recombinant proteins containing oxytocin oligomeric sequences] Gurevich AI, et al. **Bioorg Khim** 1996 Jan; 22(1):14–9 (Eng. Abstr.) **(Rus)**

[Genetic engineering of oxytocin: isolation of oxytocinoyllysine] Ovchinnikova TV, et al. **Bioorg Khim** 1995 Dec;21(12):899–904 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

Survival and regeneration of neurons of the supraoptic nucleus following surgical transection of neurohypophysial axons depend on the existence of collateral projections of these neurons to the dorsolateral hypothalamus. Alonso G, et al. **Brain Res** 1996 Mar 4;711(1–2):34–43

Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease. van Zwieten EJ, et al. **Brain Res** 1996 Mar 4; 711(1–2):146–52

Differential cellular localization of oestrogen receptor immunoreactivity and oxytocin mRNA and immunoreactivity in the rat preoptic area. Cruttwell CJ, et al. **Neurosci Lett** 1995 Nov 17;200(2):89–92

METABOLISM

Thyrotropin-releasing hormone (TRH) inhibits vasopressin and oxytocin release from rat hypothalamo-neurohypophysial explants in vitro. Ciosek J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):35–40

In the rat kidney the specific oxytocin binding sites have different selectivity for vasopressin in the cortex and the medulla. Arpin-Bott MP, et al. **Adv Exp Med Biol** 1995; 395:351–2

Strategies for cell biological studies in oxytocinergic neurons. Gainer H, et al. **Adv Exp Med Biol** 1995;395:1–8 (58 ref.)

Stimulus-specific expression of inducible transcription factors in identified oxytocin neurones. Luckman SM. **Adv Exp Med Biol** 1995;395:37–48

Histoautoradiographic detection of oxytocin- and vasopressin-binding sites in the amygdala of the rat. Veinante P, et al. **Adv Exp Med Biol** 1995;395:347–8

Vasopressin and oxytocin in stress. Jezova D, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:192–203

Reduced binding of oxytocin in the rat brain during aging. Arsenijevic Y, et al. **Brain Res** 1995 Nov 6;698(1–2):275–9

Hypothalamic-pituitary corticotroph function after shunting of magnocellular vasopressin and oxytocin to the hypophyseal portal circulation. Makara GB, et al. **Endocrinology** 1996 Feb;137(2):580–6

Effect of pregnancy-specific protein B on luteal cell progesterone, prostaglandin, and oxytocin production during two stages of the bovine estrous cycle. Del Vecchio RP, et al. **J Anim Sci** 1995 Sep;73(9):2662–8

Bioactive oxytocin in human and baboon corpora lutea. Khan-Dawood FS, et al. **J Endocrinol** 1995 Dec; 147(3):525–32

Vasopressin- and oxytocin-like systems in the chameleon brain. Bennis M, et al. **J Hirnforsch** 1995;36(4):445–50

Bovine luteal cell production in vitro of prostaglandin E2, oxytocin and progesterone in response to pregnancy-specific protein B and prostaglandin F2 alpha. Del Vecchio RP, et al. **J Reprod Fertil** 1996 May; 107(1):131–6

Effects of tetrodotoxin on osmotically stimulated central and peripheral vasopressin and oxytocin release. Ludwig M, et al. **Neuroendocrinology** 1995 Dec;62(6):619–27

Central stimulation of oxytocin release in the lactating rat by N-methyl-D-aspartate: requirement for coactivation through non-NMDA glutamate receptors or the glycine coagonist site. Parker SL, et al. **Neuroendocrinology** 1995 Nov;62(5):467–78

A benzodiazepine, chlordiazepoxide, blocks vasopressin and oxytocin release after footshocks but not osmotic stimulus in the rat. Yagi K, et al. **Neurosci Lett** 1996 Jan 12; 203(1):49–52

Involvement of the noradrenergic afferents from the nucleus tractus solitarii to the supraoptic nucleus in oxytocin release after peripheral cholecystokinin octapeptide in the rat. Onaka T, et al. **Neuroscience** 1995 May;66(2):403–12

Oestradiol acutely stimulates exocytosis of oxytocin and vasopressin from dendrites and somata of hypothalamic magnocellular neurons. Wang H, et al. **Neuroscience** 1995 Oct;68(4):1179–88

Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Fjellestad-Paulsen A, et al. **Peptides** 1995;16(6):1141–7

Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum. Naruki M, et al. **Peptides** 1996;17(2):257–61

Opposite changes in the content of oxytocin- and vasopressin-like immunoreactive peptides in the rat thymus during aging. Melis MR, et al. **Regul Pept** 1995 Nov 10; 59(3):335–40

Oxytocin in human intrauterine tissues at parturition. Mauri A, et al. **Reprod Fertil Dev** 1995;7(6):1481–4

Effects of prostaglandins and oestradiol-17 beta on oxytocin binding in cultured bovine luteal cells. Okuda K, et al. **Reprod Fertil Dev** 1995;7(5):1045–51

Effect of oxytocin on estrogen and progesterone receptors in the rat uterus. Garofalo EG, et al. **Vet Res** 1995; 26(4):284–91

PHARMACOKINETICS

Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. De Groot AN, et al. **J Pharm Pharmacol** 1995 Jul;47(7):571–5

Enhanced intestinal absorption of oxytocin peptide analogues in the absence of pancreatic juice in pigs. Lundin DP, et al. **Pharm Res** 1995 Oct;12(10):1478–82

PHARMACOLOGY

Sex difference in sensitivity to exogenous oxytocin in different models of sodium appetite in the rat. Polidori C, et al. **Acta Biomed Ateneo Parmense** 1994;65(5–6):261–80

Effects of estradiol and interaction with progesterone or oxytocin on term human myometrial contractile activity. Fu X, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):13–8

Oxytocin suppresses the GABAergic synaptic input in supraoptic neurones from the rat. Brussaard AB. **Adv Exp Med Biol** 1995;395:105–15

Effect of oxytocin on breast carcinoma cell growth. Bussolati G, et al. **Adv Exp Med Biol** 1995;395:553–4

A novel biological aspect of ovarian oxytocin: gene expression of oxytocin and oxytocin receptor in cumulus/luteal cells and the effect of oxytocin on embryogenesis in fertilized oocytes. Furuya K, et al. **Adv Exp Med Biol** 1995;395:523–8

Concurrent changes in the response of limbic neurones and mammary gland to exogenous oxytocin in late pregnancy. Housham SJ, et al. **Adv Exp Med Biol** 1995;395:197–9

Oxytocin regulates the secretory activity of human granulosa cells in vitro. Schaeffer HJ, et al. **Adv Exp Med Biol** 1995; 395:549–50

Luteotropic role of bovine luteal oxytocin in vitro. Schams D, et al. **Adv Exp Med Biol** 1995;395:543–4

Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Lee B, et al. **Am J Physiol** 1995 Dec; 269(6 Pt 1):E1095–100

Effect of intratesticular administration of oxytocin on testicular steroidogenesis in immature rats. Gerendai I, et al. **Andrologia** 1995 Sep-Oct;27(5):291–7

Influence of sex steroids on the production of prostaglandins F2 alpha and E2 and response to oxytocin in cultured epithelial and stromal cells of the bovine endometrium. Asselin E, et al. **Biol Reprod** 1996 Feb;54(2):371–9

Receptor-mediated uterine effects of vasopressin and oxytocin in nonpregnant women. Bossmar T, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):907–12

Electrophysiological evidence for oxytocin receptors on sympathetic preganglionic neurones—an in vitro study on the neonatal rat. Desaulles E, et al. **Brain Res** 1995 Nov 13;699(1):139–42

Effects of intrahypothalamic morphine and its interactions with oxytocin and vasopressin during food intake in rats. Gulati K, et al. **Brain Res** 1995 Aug 28;690(1):99–103

Astroglia proliferate in response to oxytocin and vasopressin. Lucas RL, et al. **Brain Res** 1995 May 29;681(1–2):218–22

Effects of corticotropin-releasing hormone, lysine vasopressin, oxytocin, and angiotensin II on adrenocorticotropin secretion from porcine anterior pituitary cells. Abraham EJ, et al. **Domest Anim Endocrinol** 1996 May;13(3):259–68

Oxytocin enhances clearance of radiocolloid from the uterine lumen of reproductively normal mares and mares susceptible to endometritis. LeBlanc M, et al. **Equine Vet J** 1994 Jul;26(4):279–82

Signal transduction in rat myometrial cells: comparison of the actions of endothelin-1, oxytocin and prostaglandin F2 alpha. Molnár M, et al. **Eur J Endocrinol** 1995 Oct; 133(4):467–74

Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Atke A, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):63–8

Gestational changes in oxytocin- and endothelin-1-induced contractility of pregnant rat myometrium. Izumi H, et al. **Eur J Pharmacol** 1995 May 24;278(3):187–94

Oxytocin-induced contractions of the rabbit corpus cavernosum. Tarhan F, et al. **Eur Urol** 1995;28(3):255–8

The release of insulin-like growth factor-I by luteinized human granulosa cells in vitro: regulation by growth hormone, oxytocin, steroids and cAMP-dependent intracellular mechanisms. Schaeffer HJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):361–6

The inhibitory effects of frusemide on Ca2+ influx pathways associated with oxytocin-induced contractions of rat myometrium. Mozhayeva MG, et al. **Gen Physiol Biophys** 1995 Oct;14(5):427–36

Interaction between oxytocin and prostaglandin F2 alpha in human corpus luteum? Bennegård-Edén B, et al. **Hum Reprod** 1995 Sep;10(9):2320–4

In-vivo and in-vitro assessment of the influence of ritodrine and oxytocin on the placental secretion of human chorionic gonadotrophin and placental lactogen. Meuris S, et al. **Hum Reprod** 1996 Mar;11(3):664–7

Oxytocin affects the release of steroids, insulin-like growth factor-I, prostaglandin F2alpha and cyclic nucleotides by human granulosa cells in vitro. Sirotkin AV, et al. **Hum Reprod** 1996 Jan;11(1):152–5

Dissociation of oxytocin effects on body weight in two variants of female Sprague-Dawley rats. Uvnäs-Moberg K, et al. **Integr Physiol Behav Sci** 1996 Jan-Mar;31(1):44–55

Exogenous oxytocin decreases interestrous interval of cyclic gilts. Prince BC, et al. **J Anim Sci** 1995 Dec;73(12):3681–6

Massage-like stroking of the abdomen lowers blood pressure in anesthetized rats: influence of oxytocin. Kurosawa M, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):26–30

Effect of oxytocin on transepithelial transport of water and Na+ in distinct ventral regions of frog skin (Rana catesbeiana). Bevevino LH, et al. **J Comp Physiol [B]** 1996; 166(2):120–30

Effects of acute administration of growth hormone-releasing hormone (GHRH) and oxytocin on somatotroph cells in sheep: morphometric study and growth hormone (GH) secretion. Rico M, et al. **J Endocrinol Invest** 1995 Jun; 18(6):442–9

Analysis of bursting responses of oxytocin neurones in the rat in late pregnancy, lactation and after weaning. Jiang QB, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):237–48

The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. Kisielewska J, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):329–39

Effects of exogenous oxytocin and progesterone on GnRH-induced short luteal phases in anoestrous ewes. Beard AP, et al. **J Reprod Fertil** 1996 Jan;106(1):55–61

Effect of oxytocin treatment during oestrus on the ovulation rate of Merino ewes. King PR, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):42–3

Oxytocin augmentation of gonadotropin-releasing hormone-stimulated luteinizing hormone release is modulated by cyclic AMP. Hurd SJ, et al. **Life Sci** 1996; 59(9):713–7

Differential effects of oxytocin on steroid production by bovine granulosa cells. Berndtson AK, et al. **Mol Cell Endocrinol** 1996 Feb 5;116(2):191–8

Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Björkstrand E, et al. **Neuroendocrinology** 1996 Apr;63(4):377–83

Testicular injection of 5,6-dihydroxytryptamine or vasectomy interferes with the local stimulatory effect of oxytocin on testicular steroidogenesis in immature rats. Gerendai I, et al. **Neuroendocrinology** 1996 Mar;63(3):284–9

Involvement of oxytocin and cholecystokinin-8 in interleukin-1 beta-induced adrenocorticotropin secretion in the rat. Watanobe H, et al. **Neuroimmunomodulation** 1995 Mar-Apr;2(2):88–91

Aged rats are still responsive to the antidepressant and memory-improving effects of oxytocin. Arletti R, et al. **Neuropeptides** 1995 Sep;29(3):177–82

Acute, sequence-specific effects of oxytocin and vasopressin antisense oligonucleotides on neuronal responses. Neumann I, et al. **Neuroscience** 1995 Dec;69(4):997–1003

Oxytocin blocks the development of heroin-fentanyl cross-tolerance in mice. Kriván M, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):591–4

Interaction between oxytocin and 'sidaverin' on the gravid and non-gravid rat uterus. Lutterodt GD. **Pharmacol Res** 1995 Jul-Aug;32(1–2):89–94

Central oxytocin increases food intake and daily weight gain in rats. Björkstrand E, et al. **Physiol Behav** 1996 Apr-May; 59(4–5):947–52

Vascular effects of oxytocin on human middle cerebral artery determined by transcranial Doppler sonography. Stolz-Born G, et al. **Regul Pept** 1996 Apr 9;62(1):37–9

Effects of oxytocin on the function and morphology of the rat adrenal cortex: in vitro and in vivo investigations. Stachowiak A, et al. **Res Exp Med (Berl)** 1995; 195(5):265–74

[The effect of calcium antagonists, partusisten, oxytocin and prostenon on uterine contractile activity in pregnant rats] Korkhov VV, et al. **Eksp Klin Farmakol** 1995 Nov-Dec; 58(6):40–1 (Eng. Abstr.) **(Rus)**

[The reaction of mammary tissue basophils to oxytocin] Balakina GB, et al. **Morfologiia** 1994 Jul-Dec; 107(7–12):148–54 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Oxytocin-induced penile erection. Role of nitric oxide. Argiolas A, et al. **Adv Exp Med Biol** 1995;395:247–54

Comparative aspects of oxytocin-like hormones in marsupials. Bathgate RA, et al. **Adv Exp Med Biol** 1995; 395:639–55 (99 ref.)

Importance of noradrenergic input in morphine withdrawal excitation of supraoptic oxytocin neurones in urethane-anaesthetised rats. Brown CH, et al. **Adv Exp Med Biol** 1995;395:203–4

Novel approach to oxytocin induction-augmentation of labor. Application of oxytocin physiology during pregnancy. Dawood MY. **Adv Exp Med Biol** 1995; 395:585–94 (41 ref.)

Pathways to parturition. Douglas AJ, et al. **Adv Exp Med Biol** 1995;395:381–94 (69 ref.)

Oxytocin: a follicular luteinisation factor in the marmoset monkey. Einspanier A, et al. **Adv Exp Med Biol** 1995; 395:517–22

Somatodendritic autoreceptors on oxytocin neurones. Freund-Mercier MJ, et al. **Adv Exp Med Biol** 1995; 395:185–94 (31 ref.)

Oxytocin and the timing of parturition. Influence of oxytocin receptor gene expression, oxytocin secretion, and

oxytocin-induced prostaglandin F2 alpha and E2 release. Fuchs AR, et al. **Adv Exp Med Biol** 1995;395:405-20

Oxytocin and the molecular basis of monogamy. Insel TR, et al. **Adv Exp Med Biol** 1995;395:227-34

Potential role of oxytocin in cell to cell communication in the corpus luteum. Khan-Dawood FS, et al. **Adv Exp Med Biol** 1995;395:507-16

Opioid-noradrenergic interactions in the control of oxytocin cells. Leng G, et al. **Adv Exp Med Biol** 1995;395:95-104

Estrogen modulation of oxytocin and its relation to behavior. McCarthy MM. **Adv Exp Med Biol** 1995;395:235-45 (67 ref.)

Pharmacological evidence for an oxytocin-like hormone in early pregnancy corpus luteum in sheep. Marnet PG, et al. **Adv Exp Med Biol** 1995;395:545-6

A proposed role for oxytocin in regulation of endometrial prostaglandin F2 alpha secretion during luteolysis in swine. Mirando MA, et al. **Adv Exp Med Biol** 1995;395:421-33

The excitatory effect of systemic cholecystokinin on oxytocin neurones is unchanged by morphine dependence and withdrawal. Murphy NP, et al. **Adv Exp Med Biol** 1995; 395:207-8

Oxytocin and prostatic function. Nicholson HD, et al. **Adv Exp Med Biol** 1995;395:529-38 (42 ref.)

Oxytocin signalling in human myometrium. Phaneuf S, et al. **Adv Exp Med Biol** 1995;395:453-67

Oxytocin and the anterior pituitary gland. Samson WK, et al. **Adv Exp Med Biol** 1995;395:355-64 (63 ref.)

Natriuretic role of oxytocin in sodium homeostasis in rats. Sjöquist M, et al. **Adv Exp Med Biol** 1995;395:353-4

Physiologically-linked structural plasticity of inhibitory and excitatory synaptic inputs to oxytocin neurons. Theodosis DT, et al. **Adv Exp Med Biol** 1995;395:155-71

Establishing behavioral and physiological functions of central oxytocin: insights from studies of oxytocin and ingestive behaviors. Verbalis JG, et al. **Adv Exp Med Biol** 1995; 395:209-25 (61 ref.)

Influence of reproductive state and ovarian steroids on facilitation of the milk-ejection reflex by central oxytocin. Wakerley JB, et al. **Adv Exp Med Biol** 1995;395:117-32 (56 ref.)

Guinea pigs (Cavia apera f. porcellus): do they show pair-bonding behavior in relationship to oxytocin? Wallner B, et al. **Adv Exp Med Biol** 1995;395:255-6

Luteotropic and luteolytic effects of oxytocin in the porcine corpus luteum. Wuttke W, et al. **Adv Exp Med Biol** 1995; 395:495-506 (42 ref.)

A gender-specific mechanism for pair bonding: oxytocin and partner preference formation in monogamous voles. Insel TR, et al. **Behav Neurosci** 1995 Aug;109(4):782-9

Parturition in the rabbit is compromised by daytime nursing: the role of oxytocin. Hudson R, et al. **Biol Reprod** 1995 Sep;53(3):519-24

Some aspects on the mechanism of human labor and delivery. Husslein P, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S3-7 (32 ref.)

Oxytocin neurones in the supraoptic nucleus (SON) are inhibited by endogenous opioids in late pregnant rats. Douglas AJ, et al. **Gene Ther** 1994;1 Suppl 1:S84

Oxytocin and female sexuality. Anderson-Hunt M, et al. **Gynecol Obstet Invest** 1995;40(4):217-21 (40 ref.)

The role of the uterus and cervix in systemic oxytocin-PGE2 facilitated lordosis behavior. Moody KM, et al. **Horm Behav** 1995 Dec;29(4):571-80

Oxytocin induces intimate behaviors. Rao GM. **Indian J Med Sci** 1995 Nov;49(11):261-6

Central oxytocin mediates stress-induced tachycardia. Morris M, et al. **J Neuroendocrinol** 1995 Jun;7(6):455-9

Analysis of bursting responses of oxytocin neurones in the rat in late pregnancy, lactation and after weaning. Jiang QB, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):237-48

Electrophysiological differences between oxytocin and vasopressin neurones recorded from female rats in vitro. Stern JE, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):701-8

A novel G protein-coupled receptor mediating both vasopressin- and oxytocin-like functions of Lys-conopressin in Lymnaea stagnalis. van Kesteren RE, et al. **Neuron** 1995 Oct;15(4):897-908

Oxytocinergic neurosecretory system in genetically selected rats differing in emotionality. A morphometric investigation. Zhukov DA, et al. **Neurosci Behav Physiol** 1995 Nov-Dec;25(6):438-41

Oxytocin antisense reduces salt intake in the baroreceptor-denervated rat. Morris M, et al. **Regul Pept** 1995 Oct 20;59(2):261-6

SECRETION

In vivo dynamics of oxytocin secretion by the ovine corpus luteum. Custer EE, et al. **Adv Exp Med Biol** 1995; 395:539-40

Daily rhythms of oxytocin secretion. Forsling ML. **Adv Exp Med Biol** 1995;395:92-3

The central oxytocin pulse generator: a pacemaker for luteolysis. McCracken JA, et al. **Adv Exp Med Biol** 1995; 395:133-54

Release of oxytocin within the supraoptic nucleus. Mechanisms, physiological significance and antisense targeting. Neumann I, et al. **Adv Exp Med Biol** 1995; 395:173-83 (44 ref.)

Oxytocin in bovine and porcine granulosa cells. Regulation of secretion and biological effects. Sirotkin AV, et al. **Adv Exp Med Biol** 1995;395:541-2 (11 ref.)

Cholecystokinin octapeptide and the daily rhythm of vasopressin and oxytocin release. Morawska-Barszczewska J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):164-71

Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on arginine vasopressin and oxytocin secretion in man. Chiodera P, et al. **Neuroreport** 1995 Jul 31;6(11):1490-2

Melatonin inhibits oxytocin and vasopressin release from the neurointermediate lobe of the hamster pituitary. Juszczak M, et al. **Neuroreport** 1995 Dec 15;6(18):2453-6

THERAPEUTIC USE

The effect of syntocinon on blood loss during first trimester suction curettage. Ali PB, et al. **Anaesthesia** 1996 May; 51(5):483-5

The use of oxytocin. Shyken JM, et al. **Clin Perinatol** 1995 Dec;22(4):907-31 (93 ref.)

Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas. Cassoni P, et al. **Int J Cancer** 1996 Jun 11; 66(6):817-20

Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group [see comments] Hannah ME, et al. **N Engl J Med** 1996 Apr 18;334(16):1005-10. Comment in: N Engl J Med 1996 Apr 18;334(16):1053-4.

A randomized comparison of prostaglandin E2, oxytocin, and the double-balloon device in inducing labor. Atad J, et al. **Obstet Gynecol** 1996 Feb;87(2):223-7

Assessment of the effect of three treatments to remove intrauterine fluid on pregnancy rate in the mare. Pycock JF, et al. **Vet Rec** 1996 Apr 6;138(14):320-3

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397-9 (15 ref.) (Eng. Abstr.) **(Fre)**

[Randomized comparative study of induced labor with oxytocin and misoprostol in prolonged pregnancies] Echeverría E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):108-11 (Eng. Abstr.) **(Spa)**

OXYTOCIN RECEPTORS see RECEPTORS, OXYTOCIN

OXYTOCINASE

ANALYSIS

[Results of fetal monitoring in pregnancy with enzymatic and neuroendocrinologic risk factors] Pabian W, et al. **Ginekol Pol** 1996 Apr;67(4):169-75 (Eng. Abstr.) **(Pol)**

BLOOD

An antibody specific to N-terminal amino acid sequence of human maternal serum cystine aminopeptidase and its applications. Watanabe Y, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):653-8

Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum. Naruki M, et al. **Peptides** 1996;17(2):257-61

[Cystine aminopeptidase] Murai T. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:307-10 (14 ref.) **(Jpn)**

GENETICS

Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. Rogi T, et al. **J Biol Chem** 1996 Jan 5;271(1):56-61

METABOLISM

Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Mizutani S, et al. **Regul Pept** 1995 Nov 10;59(3):371-8

OXYTRICHA

GENETICS

A gene-sized DNA molecule encoding heat-shock protein 70 in Oxytricha nova. Anderson RC, et al. **Gene** 1996 Feb 2;168(1):103-7

Intra- and interloop interactions in the folded G quartet structure of Oxytricha telomeric sequence. Balagurumoorthy P, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):385-90

Solution structures of unimolecular quadruplexes formed by oligonucleotides containing Oxytricha telomere repeats. Smith FW, et al. **Structure** 1995 Oct 15;3(10):997-1008

OXYURIASIS

VETERINARY

Management of Syphacia muris infestation in rat colonies [letter; comment] Taylor J, et al. **Dig Dis Sci** 1995 Sep; 40(9):1890-1. Comment on: Dig Dis Sci 1992 Jan;37(1):60-4.

OXYURIDA

CLASSIFICATION

The Enterobiinae subfam. Nov. (Nematoda, Oxyurida) pinworm parasites of primates and rodents. Hugot JP, et al. **Int J Parasitol** 1996 Feb;26(2):147-59

PATHOGENICITY

The Enterobiinae subfam. Nov. (Nematoda, Oxyurida) pinworm parasites of primates and rodents. Hugot JP, et al. **Int J Parasitol** 1996 Feb;26(2):147-59

OXYURIS VERMICULARIS see ENTEROBIUS

OXYUROIDEA

Management of Syphacia muris infestation in rat colonies [letter; comment] Taylor J, et al. **Dig Dis Sci** 1995 Sep; 40(9):1890-1. Comment on: Dig Dis Sci 1992 Jan;37(1):60-4.

ANATOMY & HISTOLOGY

Morphology and morphometrics of three oxyurids parasitic in primates with a description of Lemuricola microcebi n. sp. Hugot JP, et al. **Int J Parasitol** 1995 Sep; 25(9):1065-75

PHYSIOLOGY

Morphology and morphometrics of three oxyurids parasitic in primates with a description of Lemuricola microcebi n. sp. Hugot JP, et al. **Int J Parasitol** 1995 Sep; 25(9):1065-75

OXYVANADIUM see VANADATES

OYSTERS

In vivo chemoactivation of oyster hemocytes induced by bacterial secretion products. Alvarez MR, et al. **J Invertebr Pathol** 1995 Nov;66(3):287-92

CHEMISTRY

Bioavailability of calcium from calcium carbonate, DL-calcium lactate, L-calcium lactate and powdered oyster shell calcium in vitamin D-deficient or -replete rats. Tsugawa N, et al. **Biol Pharm Bull** 1995 May;18(5):677-82

ENZYMOLOGY

Is phospholipase in vinegared oysters a casual agent for human poisoning? Sajiki J. **J Toxicol Environ Health** 1996 Feb 23;47(3):221-32

A carbonic anhydrase from the nacreous layer in oyster pearls. Miyamoto H, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9657-60

GENETICS

Cloning, characterization and chromosomal location of a satellite DNA from the Pacific oyster, Crassostrea gigas. Clabby C, et al. **Gene** 1996 Feb 12;168(2):205-9

Anonymous nuclear DNA markers in the American oyster and their implications for the heterozygote deficiency phenomenon in marine bivalves. Hare MP, et al. **Mol Biol Evol** 1996 Feb;13(2):334-45

Genetics of scnDNA polymorphisms in juvenile oysters (Crassostrea virginica). Part I: Characterizing the inheritance of polymorphisms in controlled crosses. Hu YP, et al. **Mol Mar Biol Biotechnol** 1996 Jun;5(2):123-9

IMMUNOLOGY

In vitro interaction of Perkinsus marinus merozoites with eastern and Pacific oyster hemocytes. La Peyre JF, et al. **Dev Comp Immunol** 1995 Jul-Aug;19(4):291-304

METABOLISM

Atrial natriuretic peptide gene expression within invertebrate hearts. Poulos JE, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):61-8

MICROBIOLOGY

Behavior of Escherichia coli and male-specific bacteriophage in environmentally contaminated bivalve molluscs before and after depuration. Doré WJ, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2830-4

Uptake and retention of Vibrio cholerae O1 in the Eastern oyster, Crassostrea virginica. Murphree RL, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3656-60

Gastroenteritis associated with oysters. Perrett K, et al. **Commun Dis Rep CDR Rev** 1995 Sep 15;5(10):R153-4

Rapid detection of Vibrio parahaemolyticus in oysters by immunofluorescence microscopy. Chen HC, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):311-9

From the Centers for Disease Control and Prevention. Vibrio vulnificus infections associated with eating raw oysters--Los Angeles, 1996. **JAMA** 1996 Sep 25; 276(12):937-8

OYSTERS

PARASITOLOGY

Acute osmotic tolerance of cultured cells of the oyster pathogen Perkinsus marinus (Apicomplexa:Perkinsida). Burreson EM, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):575–82

In vitro interaction of Perkinsus marinus merozoites with eastern and Pacific oyster hemocytes. La Peyre JF, et al. **Dev Comp Immunol** 1995 Jul–Aug;19(4):291–304

Suppression of chemiluminescence of eastern oyster (Crassostrea virginica) hemocytes by the protozoan parasite Perkinsus marinus. Volety AK, et al. **Dev Comp Immunol** 1995 Mar–Apr;19(2):135–42

Effect of fetal bovine serum glycoproteins on the in vitro proliferation of the oyster parasite Perkinsus marinus: development of a fully defined medium. Gauthier JD, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):307–13

PHYSIOLOGY

Role of lectins (C-reactive protein) in defense of marine bivalves against bacteria. Olafsen JA. **Adv Exp Med Biol** 1995;371A:343–8

VIROLOGY

A virion concentration method for detection of human enteric viruses in oysters by PCR and oligoprobe hybridization. Jaykus LA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2074–80

Outbreaks of Norwalk-like virus–associated gastroenteritis traced to shellfish: coexistence of two genotypes in one specimen. Sugieda M, et al. **Epidemiol Infect** 1996 Jun; 116(3):339–46

Antibodies specific for channel catfish virus cross–react with Pacific oyster, Crassostrea gigas, herpes–like virus. Le Deuff RM, et al. **Vet Res** 1995;26(5–6):526–9

Herpes–like viruses associated with high mortality levels in larvae and spat of Pacific oysters, Crassostrea gigas: a comparative study, the thermal effects on virus detection in hatchery–reared larvae, reproduction of the disease in axenic larvae. Renault T, et al. **Vet Res** 1995;26(5–6):539–43

OZENA see RHINITIS, ATROPHIC

OZONE

Are chlorine–free compounds a solution for health problems caused by ozone–depleting substances? Valić F, et al. **Acta Med Croatica** 1996;50(2):61–3

Evaluation of patients with retinitis pigmentosa receiving electric stimulation, ozonated blood, and ocular surgery in Cuba [see comments] Berson EL, et al. **Arch Ophthalmol** 1996 May;114(5):560–3. Comment in: Arch Ophthalmol 1996 May;114(5):606–7.

Ozone depletion update. Coldiron BM. **Dermatol Surg** 1996 Mar;22(3):296–9 (11 ref.)

Ozone–friendly chemicals [news] **Environ Health Perspect** 1994 May;102(5):429–30

Sulfuric acid aerosol followed by ozone exposure in healthy and asthmatic subjects. Frampton MW, et al. **Environ Res** 1995 Apr;69(1):1–14

Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976–95 (221 ref.). Comment in: Eur Respir J 1995 Jun;8(6):883–4.

Deodorization of laboratory animal facilities by ozone. Pan TM, et al. **Exp Anim** 1995 Jul;44(3):255–9

Effect of lipid ozonation products on liposomal membranes detected by Laurdan fluorescence. Salgo MG, et al. **Free Radic Biol Med** 1995 Nov;19(5):609–16

Determination of lipid ester ozonides and core aldehydes by high–performance liquid chromatography with on–line mass spectrometry. Ravandi A, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):271–85

Biological dosimetry of solar radiation for different simulated ozone column thicknesses. Horneck G, et al. **J Photochem Photobiol B** 1996 Feb;32(3):189–96

Transmission of hepatitis C by ozone enrichment of autologous blood. [letter] Gabriel C, et al. **Lancet** 1996 Feb 24;347(9000):541

More worries about pollution [editorial] **Nature** 1996 Jun 6; 381(6582):451

[Ozone depletion—does the incidence of skin cancer increase? (editorial)] Jokela K, et al. **Duodecim** 1994; 110(19):1756–9 (20 ref.) **(Fin)**

[Lung function and prevalence of irritation of eyes and respiratory airways on days with elevated ozone concentrations] Höppe P, et al. **Immun Infekt** 1995 Oct; 23(5):161–5 (Eng. Abstr.) **(Ger)**

[Chlorination and ozonation of contaminants in water environment and role of free radicals] Hamada A. **Yakugaku Zasshi** 1995 Oct;115(10):790–804 (52 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

A portable inhalation system for personal exposure to ozone. Asplund PT, et al. **Arch Environ Health** 1996 Mar–Apr; 51(2):138–45

[The antibacterial and immunocorrective action of ozone therapy in peritonitis] Vasil'ev IT, et al. **Vestn Khir Im I I Grek** 1995;154(3):56–60 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Ozone–induced decrements in FEV1 and FVC do not correlate with measures of inflammation. Balmes JR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):904–9

Acute effects of ozone on the pulmonary function of exercising schoolchildren from Mexico City. Castillejos M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1501–7

Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. Delfino RJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):633–41

The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis. Jörres R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):56–64

Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone–induced acute inflammation. Nadziejko C, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1592–8

Greater ozone–induced inflammatory responses in subjects with asthma. Scannell C, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):24–9

Ozone exposure in humans: inflammatory, small and peripheral airway responses. Weinmann GG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1175–82

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)

Ozone and childhood wheezy episodes. Meteorological confounders must be considered [letter; comment] Ayres JG. **BMJ** 1996 Jun 22;312(7046):1607; discussion 1607–8. Comment on: BMJ 1996 Mar 16;312(7032):661–5.

Ozone and childhood wheezy episodes. Results may have been confounded by viral infections and faulty equipment [letter; comment] Bentham G, et al. **BMJ** 1996 Jun 22; 312(7046):1607; discussion 1607–8. Comment on: BMJ 1996 Mar 16;312(7032):661–5.

Association between air pollution and acute childhood wheezy episodes: prospective observational study [see comments] Buchdahl R, et al. **BMJ** 1996 Mar 16; 312(7032):661–5. Comment in: BMJ 1996 Mar 16;312(7032):649–50. Comment in: BMJ 1996 Jun 22;312(7046):1607; discussion 1607–8.

Ozone and childhood wheezy episodes. Needs testing as an a priori hypothesis [letter; comment] Evans MR, et al. **BMJ** 1996 Jun 22;312(7046):1607; discussion 1607–8. Comment on: BMJ 1996 Mar 16;312(7032):661–5.

Cigarette smoke and ozone–induced epithelial perturbation in vivo and in vitro. The role of glutathione. MacNee W, et al. **Chest** 1996 Mar;109(3 Suppl):39S

Production of reactive oxygen intermediates following exposure to ozone. Relative contribution of alveolar macrophages. Torres A, et al. **Chest** 1996 Mar;109(3 Suppl):8S

Effect of ozone exposure on maximal airway narrowing in non–asthmatic and asthmatic subjects. Hiltermann TJ, et al. **Clin Sci (Colch)** 1995 Dec;89(6):619–24

The impact of ozone [news] Breslin K. **Environ Health Perspect** 1995 Jul–Aug;103(7–8):660–4

Analysis of induced sputum after air and ozone exposures in healthy subjects. Fahy JV, et al. **Environ Res** 1995 Aug; 70(2):77–83

Temperature, ambient ozone levels, and mortality during summer 1994, in Belgium. Sartor F, et al. **Environ Res** 1995 Aug;70(2):105–13

Acute respiratory effects of low level summer smog in primary school children. Cuijpers CE, et al. **Eur Respir J** 1995 Jun;8(6):967–75

Taurine protects rat bronchioles from acute ozone–induced lung inflammation and hyperplasia. Schuller–Levis GB, et al. **Exp Lung Res** 1995 Nov–Dec;21(6):877–88

Nasal lavage as tool for health effect assessment of photochemical air pollution. Steerenberg PA, et al. **Hum Exp Toxicol** 1996 Feb;15(2):111–9

Depletion of urate in human nasal lavage following in vitro ozone exposure. Housley DG, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1153–9

Daily PM10/mortality associations: an investigations of at–risk subpopulations. Ito K, et al. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):79–95

Effects of ozone on the epithelial and inflammatory responses in the airways: role of tumor necrosis factor. Young C, et al. **J Toxicol Environ Health** 1995 Nov;46(3):329–42

Effects of chronic ozone (O3) exposure on vocal–fold mucosa in bonnet monkeys. Leonard R, et al. **J Voice** 1995 Dec; 9(4):443–8

The free radical basis of air pollution: focus on ozone. Kelly FJ, et al. **Respir Med** 1995 Nov;89(10):647–56 (77 ref.)

Ozone hole—how great the threat? [news] **S Afr Med J** 1994 Nov;84(11):15

Ozone level effect on respiratory illness: an investigation of emergency department visits. Jones GN, et al. **South Med J** 1995 Oct;88(10):1049–56

ANALYSIS

Daily surface ozone maximum concentrations at Taliarte, Canary Islands. Mura MC, et al. **Ann Ist Super Sanita** 1995; 31(3):363–7

Urban ozone plumes and population distribution by income and race: a case study of New York and Philadelphia. Liu F. **J Air Waste Manag Assoc** 1996 Mar;46(3):207–15

Measurement of organic acids, aldehydes, and ketones in residential environments and their relation to ozone. Reiss R, et al. **J Air Waste Manag Assoc** 1995 Oct;45(10):811–22

Detection of ozone on Ganymede. Noll KS, et al. **Science** 1996 Jul 19;273(5273):341–3

[Method of standards preparation for colorimetric determination of ozone in the atmosphere] Janowski TM, et al. **Rocz Panstw Zakl Hig** 1995;46(1):67–70 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Ozone induction of cytokine–induced neutrophil chemoattractant (CINC) and nuclear factor–kappa b in rat lung: inhibition by corticosteroids. Haddad EB, et al. **FEBS Lett** 1996 Feb 5;379(3):265–8

CHEMISTRY

Ozone odours and phototherapy [letter] O'Brien TJ. **Australas J Dermatol** 1996 Aug;37(3):162

Effect of lipid ozonation products on liposomal membranes detected by Laurdan fluorescence. Salgo MG, et al. **Free Radic Biol Med** 1995 Nov;19(5):609–16

The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4–18; 163(11–12):576–8 (7 ref.)

Skin cancer and the ozone hole. When is not enough likely to be too much? Marks R. **Med J Aust** 1995 Dec 4–18; 163(11–12):578–9

METABOLISM

The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)

PHARMACOKINETICS

Simulation of the uptake of a reactive gas in a rat respiratory tract model with an asymmetric tracheobronchial region patterned on complete conducting airway cast data. Overton JH, et al. **Comput Biomed Res** 1995 Jun; 28(3):171–90

Bronchoscopic determination of ozone uptake in humans. Gerrity TR, et al. **J Appl Physiol** 1995 Sep;79(3):852–60

Uptake and fate of ozone in the respiratory tract. Miller FJ. **Toxicol Lett** 1995 Dec;82–83:277–85 (43 ref.)

PHARMACOLOGY

Ozone exposure of human tracheal epithelial cells inactivates cyclooxygenase and increases 15–HETE production. Alpert SE, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L734–43

Ozone–induced alterations in glutathione in lung subcompartments of rats and monkeys. Duan X, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):70–5

4–Hydroxynonenal mimics ozone–induced modulation of macrophage function ex vivo. Hamilton RF Jr, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):275–82

Inhibition of ozone–induced nitric oxide synthase expression in the lung by endotoxin. Pendino KJ, et al. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):516–25

Stimulation of nitric oxide production in rat lung lavage cells by anti–Mac–1beta antibody: effects of ozone inhalation. Pendino KJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr; 14(4):327–33

Ozone enhances the uptake of mineral particles by tracheobronchial epithelial cells in organ culture. Churg A, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1230–3

Efficacy of ozonated water against various food–related microorganisms. Restaino L, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3471–5

Effects of age, socioeconomic status, and menstrual cycle on pulmonary response to ozone. Seal E Jr, et al. **Arch Environ Health** 1996 Mar–Apr;51(2):132–7

Bactericidal effects of ozone at nonspermicidal concentrations. Gradil C, et al. **Can J Vet Res** 1995 Jul; 59(3):183–6

Influence of ozone on haemoglobin oxygen affinity in type–2 diabetic patients with peripheral vascular disease: in vitro studies. Coppola L, et al. **Diabete Metab** 1995 Oct; 21(4):252–5

Mutation spectra in salmonella of chlorinated, chloraminated, or ozonated drinking water extracts: comparison to MX. DeMarini DM, et al. **Environ Mol Mutagen** 1995; 26(4):270–85

Products of ozonized arachidonic acid potentiate the formation of DNA single strand breaks in cultured human lung cells. Kozumbo WJ, et al. **Environ Mol Mutagen** 1996; 27(3):185–95

The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs. Stevens WH, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):251–7

Expression of ICAM–1 in airway epithelium after acute ozone exposure in the mouse. Takahashi N, et al. **J Appl Physiol** 1995 Nov;79(5):1753–61

Comparison of the effects of ozone on the modification of amino acid residues in glutamine synthetase and bovine serum albumin. Berlett BS, et al. **J Biol Chem** 1996 Feb 23;271(8):4177–82

Ozone–induced oxygen radical release from bronchoalveolar

lavage cells and airway hyper-responsiveness in dogs. Stevens WH, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):257–65

Effects of chronic ozone (O3) exposure on vocal-fold mucosa in bonnet monkeys. Leonard R, et al. **J Voice** 1995 Dec; 9(4):443–8

Expression of Arabidopsis cytosolic ascorbate peroxidase gene in response to ozone or sulfur dioxide. Kubo A, et al. **Plant Mol Biol** 1995 Nov;29(3):479–89

Isolation of a novel Arabidopsis ozone-induced cDNA by differential display. Sharma YK, et al. **Plant Mol Biol** 1995 Oct;29(1):91–8

Ultraviolet-B- and ozone-induced biochemical changes in antioxidant enzymes of Arabidopsis thaliana. Rao MV, et al. **Plant Physiol** 1996 Jan;110(1):125–36

Red blood cell antioxidants in human volunteers exposed to ozone. Vender RL, et al. **Toxicol Ind Health** 1994 Jan–Apr; 10(1–2):53–8

[Hemostatic properties of gaseous ozone] Kashperskiĭ IuP, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):62–5 **(Rus)**

THERAPEUTIC USE

Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Bocci V. **Med Hypotheses** 1996 Feb;46(2):150–4 (40 ref.)

[Therapeutic potential of ozone—possible side-effects] Avivi I, et al. **Harefuah** 1996 Mar 1;130(5):327–30 (53 ref.) **(Heb)**

TOXICITY

Vitamin A deficiency enhances ozone-induced lung injury. Paquette NC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L475–82

Neonatal capsaicin treatment increases the severity of ozone-induced lung injury. Sterner-Kock A, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):436–43

Effect of a leukotriene B4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Stevens WH, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1443–8

Neurobehavioral development of CD-1 mice after combined gestational and postnatal exposure to ozone. Dell'Omo G, et al. **Arch Toxicol** 1995;69(9):608–16

Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al. **Biochem Soc Symp** 1995;61:139–52 (49 ref.)

Two-dimensional electrophoresis of acidic proteins isolated from ozone-stressed Norway spruce needles (Picea abies L. Karst): separation method and image processing. Davidsen NB. **Electrophoresis** 1995 Jul;16(7):1305–11

Expression of inducible nitric oxide synthase mRNA in Brown Norway rats exposed to ozone: effect of dexamethasone. Haddad EB, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):287–90

Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357–71 (182 ref.)

Down-regulation of canine airway mast cell function following exposure to ozone in vivo. Spannhake EW. **Exp Lung Res** 1996 Mar–Apr;22(2):163–78

Differential susceptibility to ozone-induced airways hyperreactivity in inbred strains of mice. Zhang LY, et al. **Exp Lung Res** 1995 Jul–Aug;21(4):503–18

Phagocytosis and chemotaxis of rat alveolar macrophages after a combined or separate exposure to ozone and carbon black. Creutzenberg O, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):202–6

The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)

Medium and long-term behavioral effects in mice of extended gestational exposure to ozone. Petruzzi S, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):463–70

Differential accumulation of antioxidant mRNAs in Arabidopsis thaliana exposed to ozone. Conklin PL, et al. **Plant Physiol** 1995 Sep;109(1):203–12

Ozone-induced responses in Arabidopsis thaliana: the role of salicylic acid in the accumulation of defense-related transcripts and induced resistance. Sharma YK, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5099–104

Time-dependent changes of inflammatory mediators in the lungs of humans exposed to 0.4 ppm ozone for 2 hr: a comparison of mediators found in bronchoalveolar lavage fluid 1 and 18 hr after exposure. Devlin RB, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):176–85

Ozone-induced alteration in beta-adrenergic pharmacological modulation of pulmonary macrophages. McGovern TJ, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):51–6

Bronchiolarized metaplasia and interstitial fibrosis in rat lungs chronically exposed to high ambient levels of ozone. Stockstill BL, et al. **Toxicol Appl Pharmacol** 1995 Oct; 134(2):251–63

Long-term toxicity studies of ozone in F344/N rats and B6C3F1 mice. Boorman GA, et al. **Toxicol Lett** 1995 Dec; 82–83:301–6

Ozone-induced human respiratory dysfunction and disease. Bromberg PA, et al. **Toxicol Lett** 1995 Dec;82–83:307–16 (57 ref.)

Developmental exposure to ozone induces subtle changes in swimming navigation of adult mice. Dell'Omo G, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):91–9

Genetic susceptibility to ozone exposure. Kleeberger SR. **Toxicol Lett** 1995 Dec;82–83:295–300 (32 ref.)

A new mechanism for the toxicity of ozone. Pryor WA, et al. **Toxicol Lett** 1995 Dec;82–83:287–93 (40 ref.)

Dose-effect models for ozone exposure: tool for quantitative risk estimation. van Bree L, et al. **Toxicol Lett** 1995 Dec; 82–83:317–21 (33 ref.)

Regional deposition of gases and particles in the lung: implications for mixtures. Gerrity TR. **Toxicology** 1995 Dec 28;105(2–3):327–34

Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2–3):335–42 (48 ref.)

Chronic inhalation exposure to ozone and nitric acid elevates stress-inducible heat shock protein 70 in the rat lung. Wong CG, et al. **Toxicology** 1996 Feb 22;107(2):111–9

[Effects of the oxidizing agents ozone and nitrogen dioxide on the lung: studies of a cell culture model (see comments)] Holz O, et al. **Immun Infekt** 1995 Oct;23(5):158–60 (Eng. Abstr.). Comment in: Immun Infekt 1995 Oct;23(5):147. **(Ger)**

[Ozone: myths and reality] Gebbers JO. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):971–7 (70 ref.) (Eng. Abstr.) **(Ger)**

P0 GLYCOPROTEIN see **MYELIN P0 PROTEIN**

P0 PROTEIN see **MYELIN P0 PROTEIN**

P1 PHAGE see **BACTERIOPHAGE P1**

P1 PURINOCEPTORS see **RECEPTORS, PURINERGIC P1**

P2 PHAGE see **BACTERIOPHAGE P2**

P2 PROTEIN see **MYELIN P2 PROTEIN**

P2 PURINOCEPTORS see **RECEPTORS, PURINERGIC P2**

P21(C-HA-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-KI-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(N-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(V-HA-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P21(V-KI-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P22 PHAGE see **BACTERIOPHAGE P22**

P24(HIV) see **HIV CORE PROTEIN P24**

P27(REX) see **GENE PRODUCTS, REX**

P34CDC2 PROTEIN see **PROTEIN P34CDC2**

P37(V-MOS) see **ONCOGENE PROTEINS V-MOS**

P39(C-JUN) see **PROTO-ONCOGENE PROTEINS C-JUN**

P40 T-CELL GROWTH FACTOR see **INTERLEUKIN-9**

P40(TAX) see **GENE PRODUCTS, TAX**

P53 GENES see **GENES, P53**

P53 PROTEIN see **PROTEIN P53**

P55(C-FOS) see **PROTO-ONCOGENE PROTEINS C-FOS**

P55(V-FOS) see **ONCOGENE PROTEINS V-FOS**

P55(V-MYC) see **ONCOGENE PROTEIN P55(V-MYC)**

P62(C-MYC) see **PROTO-ONCOGENE PROTEINS C-MYC**

P65(GAG-JUN) see **ONCOGENE PROTEIN P65(GAG-JUN)**

P75(GAG-FOS-FOX) see **ONCOGENE PROTEINS V-FOS**

P85(GAG-MOS) see **ONCOGENE PROTEINS V-MOS**

P105-RB PROTEIN see **RETINOBLASTOMA PROTEIN**

P145(C-KIT) see **PROTO-ONCOGENE PROTEINS C-KIT**

P150,95 ANTIGEN see **ANTIGEN P150,95**

P185(C-NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

P300 EVENT-RELATED POTENTIALS see **EVENT-RELATED POTENTIALS, P300**

P-B ANTIBODIES see **ANTIBODIES, HETEROPHILE**

P BLOOD-GROUP SYSTEM

ANALYSIS

Differentiation between human red cells of Pk and p blood types using Pseudomonas aeruginosa PA-I lectin. Sudakevitz D, et al. **Transfusion** 1996 Feb;36(2):113–6

GENETICS

Blood group glycosphingolipid expression in kidney of an individual with the rare blood group A1 Le(a-b+) p phenotype: absence of blood group structures based on the globoseries. Lindström K, et al. **Glycoconj J** 1996 Apr; 13(2):307–13

P-CADHERINS see **CADHERINS**

P-CELL STIMULATING FACTOR see **INTERLEUKIN-3**

P-GLYCOPROTEIN

see related
DRUG RESISTANCE, MULTIPLE

[Multidrug resistance and its reversal. General review of fundamental aspects] Robert J. **Ann Biol Clin (Paris)** 1996; 54(1):3–8 (50 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Molecular study of P-glycoprotein in multidrug resistance using surface plasmon resonance. Demeule M, et al. **Anal Biochem** 1995 Sep 20;230(2):239–47

Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Verovski VN, et al. **Br J Cancer** 1996 Mar;73(5):596–602

P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Seymour L, et al. **Breast Cancer Res Treat** 1995;36(1):61–9

Identification of drug-resistant myeloid leukemic cells by measurement of DNA content, nuclear area, and detection of P-glycoprotein. Emura I, et al. **Cancer** 1996 Mar 1; 77(5):878–87

The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Moore AS, et al. **Cancer Invest** 1995;13(5):475–9

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Beck WT, et al. **Cancer Res** 1996 Jul 1;56(13):3010–20 (66 ref.)

P-glycoprotein: clinical significance and methods of analysis. van der Heyden S, et al. **Crit Rev Clin Lab Sci** 1995; 32(3):221–64 (174 ref.)

Quantitative determination of the MDR-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique. Ferrand VL, et al. **Cytometry** 1996 Feb 1; 23(2):120–5

Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Lehne G, et al. **Cytometry** 1995 Jul 1; 20(3):228–37

Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. Scala S, et al. **Diagn Mol Pathol** 1995 Jun; 4(2):136–42

How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)

Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051–61 (153 ref.)

MDR1/P-glycoprotein in haematological neoplasms. Marie JP, et al. **Eur J Cancer** 1996 Jun;32A(6):1034–8 (81 ref.)

Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N, et al. **Eur J Cell Biol** 1995 Nov;68(3):226–39

Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax). Dunn SE, et al. **Hepatology** 1996 Apr;23(4):662–8

P-170 glycoprotein expression in gastric and colorectal carcinomas and normal mucosa. An immunocytochemical study. Caruso ML, et al. **In Vivo** 1995 Mar–Apr;9(2):133–8

Tumor necrosis factor alpha is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P-170 glycoprotein. Malorni W, et al. **Int J Cancer** 1996 Jul 17; 67(2):238–47

Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation,

P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells. Patterson KK, et al. **J Cancer Res Clin Oncol** 1996;122(8):465–75

P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. Kuttesch JF, et al. **J Clin Oncol** 1996 Mar;14(3):886–900

Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. Soini Y, et al. **J Clin Pathol** 1996 Jun;49(6):470–3

Reciprocal expression of P-glycoprotein and TAP1 accompanied by higher expression of MHC class I antigens in T cells of old mice. Witkowski JM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B76–82

Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. Rao VV, et al. **J Histochem Cytochem** 1995 Dec;43(12):1187–92

Establishment and evaluation of MRK16-magnetic cell sorting assays for detecting low expression of multidrug resistance P-glycoprotein using human leukemia cell lines and peripheral blood cells from healthy donors. Okochi E, et al. **J Immunol Methods** 1995 Nov 16;187(1):127–37

Effects of multidrug resistance (MDR1) P-glycoprotein expression levels and coordination metal on the cytotoxic potency of multidentate (N4O2) (ethylenediamine)bis[propyl(R-benzylimino)]metal(III) cations. Sharma V, et al. **J Med Chem** 1996 Aug 30; 39(18):3483–90

Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. Ballinger JR, et al. **J Nucl Med** 1996 Sep;37(9):1578–82

Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. Elsinga PH, et al. **J Nucl Med** 1996 Sep;37(9):1571–5

Detection of low-level expression of P-glycoprotein in ACHN renal adenocarcinoma cells. Kawamoto S, et al. **Jpn J Cancer Res** 1996 May;87(5):475–9

Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Suwa H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):641–9

MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. Finnegan MC, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):297–302

Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome. Kaczorowski S, et al. **Leuk Lymphoma** 1995 Dec; 20(1–2):143–52

Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Sievers EL, et al. **Leukemia** 1995 Dec;9(12):2042–8

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome [see comments] Baldini N, et al. **N Engl J Med** 1995 Nov 23;333(21):1380–5. Comment in: N Engl J Med 1995 Nov 23;333(21):1417–9. Comment in: N Engl J Med 1996 May 16;334(20):1335–6; discussion 1336–7. Comment in: N Engl J Med 1996 May 16;334(20):1336; discussion 1336–7.

P-glycoprotein and multidrug resistance [letter; comment] Duensing S, et al. **N Engl J Med** 1996 May 16;334(20):1336; discussion 1336–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

P-glycoprotein and multidrug resistance [letter; comment] Johnston JM. **N Engl J Med** 1996 May 16;334(20):1336; discussion 1336–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

P-glycoprotein and multidrug resistance [letter; comment] Mesa-Tejada R. **N Engl J Med** 1996 May 16; 334(20):1335–6; discussion 1336–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Scott AM, et al. **Nucl Med Biol** 1995 May;22(4):497–504

P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Yang X, et al. **Oncol Res** 1995;7(12):619–24

Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours. Beer TW, et al. **Thorax** 1996 May;51(5):526–9

[Biology and clinical relevance of multidrug resistance associated antigen] Utsumi M, et al. **Nippon Rinsho** 1996 Jun;54(6):1690–7 (56 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Didier A, et al. **Anticancer Drugs** 1995 Oct;6(5):669–80

Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Barnes KM, et al. **Biochemistry** 1996 Apr 16;35(15):4820–7

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study. González-Manzano R, et al. **Br J Cancer** 1995 Nov; 72(5):1294–9

Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Murren JR, et al. **Cancer Chemother Pharmacol** 1996;38(1):65–70

Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Merlin JL, et al. **Cytometry** 1995 Aug 1;20(4):315–23

Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Su SF, et al. **Drug Metab Dispos** 1996 Feb; 24(2):142–7

Clinical trials of P-glycoprotein reversal in solid tumours. Ferry DR, et al. **Eur J Cancer** 1996 Jun;32A(6):1070–81 (119 ref.)

Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, et al. **Eur J Cancer** 1996 Jun;32A(6):1082–8 (69 ref.)

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM. **Eur J Cancer** 1996 Jun;32A(6):991–1001 (161 ref.)

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P. **Eur J Cancer** 1996 Jun;32A(6):1062–9 (97 ref.)

Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Didier AD, et al. **Int J Cancer** 1995 Oct 9;63(2):263–7

Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Hwang M, et al. **Int J Cancer** 1996 Jan 26;65(3):389–97

Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. Mickisch GH, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R11–6

Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. Wilson WH, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R25–9

Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. Klimecki WT, et al. **J Clin Immunol** 1995 May;15(3):152–8

Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. Hirai M, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):73–8

Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine. Kawada M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):873–8

Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Watanabe T, et al. **Jpn J Cancer Res** 1996 Feb;87(2):184–93

Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Yacyshyn BR, et al. **Scand J Immunol** 1996 Apr;43(4):449–55

[Study on the reversing effect of tripiperaquine on human multidrug resistant leukemic cell line K562/A02] Yang R, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):340–2 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Membrane transport proteins associated with drug resistance expressed in human melanoma. Schadendorf D, et al. **Am J Pathol** 1995 Dec;147(6):1545–52

MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Tóth K, et al. **Am J Pathol** 1996 Sep;149(3):853–8

Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3. Ernest S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C910–9

Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells. Valenzuela MT, et al. **Anticancer Drugs** 1995 Dec; 6(6):749–57

Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Bodey B, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2461–8

CG5/Dx human breast cancer cell line: characterization of a new doxorubicin-resistant variant. Gibelli N, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1675–81

Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Narasaki F, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2079–82

Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells. Obata NH, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):566–71

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Chianale J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):781–6

P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. Fardel O, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1427–36

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Stewart AJ, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):461–9

Biogenesis of polytopic membrane proteins: membrane segments of P-glycoprotein sequentially translocate to span the ER membrane. Borel AC, et al. **Biochemistry** 1996 Aug 20;35(33):10587–94

Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Chianale J, et al. **Biochim Biophys Acta** 1995 Dec 27;1264(3):369–76

Multidrug-resistance (MDR) phenotype of human osteosarcoma cells evaluated by quantitative morphological and electron microscopy analyses. Zini N, et al. **Biol Cell** 1995;84(3):195–204

Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. Lee WP, et al. **Cancer Chemother Pharmacol** 1996; 38(1):45–51

Functional expression of the renal organic cation transporter and P-glycoprotein in Xenopus laevis oocytes. Nelson JA, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):187–9

Functional expression of the P-glycoprotein mdr in primary cultures of bovine cerebral capillary endothelial cells. Lechardeur D, et al. **Cell Biol Toxicol** 1995 Oct; 11(5):283–93

Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Schmidt-Wolf IG, et al. **Cell Immunol** 1996 Apr 10;169(1):85–90

Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431–43 (131 ref.)

P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Gupta S. **Drugs Aging** 1995 Jul;7(1):19–29 (81 ref.)

99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue. Derebek E, et al. **Eur J Nucl Med** 1996 Aug;23(8):976–9

Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Moretti JL, et al. **Eur J Nucl Med** 1996 Aug;23(8):980–6

Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. Barrand MA, et al. **FEBS Lett** 1995 Oct 30;374(2):179–83

Experimental Mallory body formation is accompanied by modulation of the expression of multidrug-resistance genes and their products. Preisegger KH, et al. **Hepatology** 1996 Jul;24(1):248–52

High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. Esteller M, et al. **Int J Cancer** 1995 Dec 11; 63(6):798–803

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Zhou DC, et al. **Int J Cancer** 1996 Jan 26;65(3):365–71

Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. Germann UA, et al. **J Biol Chem** 1996 Jan 19; 271(3):1708–16

A conserved downstream element defines a new class of RNA polymerase II promoters. Ince TA, et al. **J Biol Chem** 1995 Dec 22;270(51):30249–52

Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. Ruetz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4154–60

Volume-sensitive chloride channel activity does not depend on endogenous P-glycoprotein. Tominaga M, et al. **J Biol Chem** 1995 Nov 17;270(46):27887–93

Human multidrug resistance 3-P-glycoprotein expression in transgenic mice induces lens membrane alterations leading to cataract. Dunia I, et al. **J Cell Biol** 1996 Feb; 132(4):701–16

Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. Begley DJ, et al. **J Neurochem** 1996 Sep;67(3):988–95

Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. Baum C, et al. **J Virol** 1995 Dec;69(12):7541–7

Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias. MacFarland A, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):135–40

Expression of MDR-1/P-glycoprotein in childhood acute megakaryoblastic leukemia cells. Ota S, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):431–6

Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Pilarski LM, et al. **Leuk Lymphoma** 1995 May; 17(5–6):367–74 (70 ref.)

P-glycoprotein expression in patients with acute leukemia-clinical relevance. Nüssler V, et al. **Leukemia** 1996 Jul;10 Suppl 3:S23–S31

Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Pearson L, et al. **Leukemia** 1996 Aug; 10(8):1274–82

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Schuetz EG, et al. **Mol Pharmacol** 1996 Feb;49(2):311–8

In vivo imaging and specific targeting of P-glycoprotein

expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Scott AM, et al. **Nucl Med Biol** 1995 May;22(4):497-504

Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines. Evans MK, et al. **Oncogene** 1996 Feb 1;12(3):651-8

A potato cDNA encoding a homologue of mammalian multidrug resistant P-glycoprotein. Wang W, et al. **Plant Mol Biol** 1996 Jun;31(3):683-7

BLOOD

Multidrug resistance in B-cell chronic lymphocytic leukemia. Grulois I, et al. **Acta Haematol** 1995;94(2):78-83

Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen. Turkina AG, et al. **Br J Haematol** 1996 Jan; 92(1):88-96

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Maillefert JF, et al. **Br J Rheumatol** 1996 May;35(5):430-5

CHEMISTRY

Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue. Mankhetkorn S, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):213-7

Determining the secondary structure and orientation of EmrE, a multi-drug transporter, indicates a transmembrane four-helix bundle. Arkin IT, et al. **Biochemistry** 1996 Jun 4;35(22):7233-8

Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. Hanna M, et al. **Biochemistry** 1996 Mar 19;35(11):3625-35

Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Liu R, et al. **Biochemistry** 1996 Sep 10;35(36):11865-73

Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism. Zhang M, et al. **Biochemistry** 1996 Jul 30;35(30):9728-36

Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Hipfner DR, et al. **Cancer Res** 1996 Jul 15;56(14):3307-14

Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Eytan GD, et al. **J Biol Chem** 1996 Feb 9; 271(6):3172-8

Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. Kast C, et al. **J Biol Chem** 1996 Apr 19;271(16):9240-8

Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. Loo TW, et al. **J Biol Chem** 1995 Sep 29;270(39):22957-61

Reconstitution of purified P-glycoprotein into liposomes. Naito M, et al. **J Cancer Res Clin Oncol** 1995; 121(9-10):582-6

[Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting] Tsuruo T. **Nippon Rinsho** 1995 Oct;53(10):2604-11 (38 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Multidrug resistance and the role of P-glycoprotein knockout mice. Schinkel AH, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1295-8 (30 ref.)

cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. Büchler M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15091-8

Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80-kDa mdr1a gene product. Thévenod F, et al. **J Biol Chem** 1996 Feb 9;271(6):3300-5

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. van Asperen J, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):994-9

DRUG EFFECTS

Detection of the multidrug resistance of P-glycoprotein in healthy tissues: the example of the blood-brain barrier. Lechardeur D, et al. **Ann Biol Clin (Paris)** 1996;54(1):31-6

Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA. Sola JE, et al. **Ann Surg Oncol** 1996 Jan;3(1):80-5

Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Orlowski S, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):515-22

Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Ahn CH, et al. **Biochem Pharmacol** 1996 Aug 9; 52(3):393-9

Effects of sphingosine stereoisomers on P-glycoprotein phosphorylation and vinblastine accumulation in multidrug-resistant MCF-7 cells. Sachs CW, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):603-12

The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters. Yelin R, et al. **FEBS Lett** 1995 Dec 18;377(2):201-7

Synthesis and antiproliferative effects of a 4'-morpholino-9-methyl anthracycline. Nafziger J, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1185-7

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32-S38 (53 ref.)

Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Chieli E, et al. **Life Sci** 1995;57(19):1741-51

Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Chiba P, et al. **Mol Pharmacol** 1996 Jun; 49(6):1122-30

GENETICS

Quantitative analysis of MDR-1 gene expression in acute myeloid leukemia by reverse transcription polymerase chain reaction [letter] Cao QX, et al. **Am J Hematol** 1996 Aug;52(4):329

The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Licht T, et al. **Ann Hematol** 1996 Apr;72(4):184-93 (118 ref.)

Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Hirsch-Ernst KI, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):179-85

Gene disruption of the P-glycoprotein related gene pgpa of Leishmania tarentolae. Papadopoulou B, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):772-8

The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Strauss BE, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):825-31

Duplication and evolution of the P-glycoprotein genes in pig. Childs S, et al. **Biochim Biophys Acta** 1996 Jun 7; 1307(2):205-12

Activation of silent MDR1 genes in revertant cells by fusion with multidrug-resistant cells. Yusa K, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):260-6

Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: in vivo model for genetically transferred chemoprotection. Schwarzenberger P, et al. **Blood** 1996 Apr 1;87(7):2723-31

A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Sokolic RA, et al. **Blood** 1996 Jan 1;87(1):42-50

Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Davies R, et al. **Br J Cancer** 1996 Feb;73(3):307-15

Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids. de Silva M, et al. **Br J Cancer** 1996 Jan;73(2):169-74

P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Lee JJ, et al. **Cancer** 1996 May 1;77(9):1892-8

Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Yamaguchi M, et al. **Cancer** 1995 Dec 1;76(11):2351-6

Multidrug resistance. Moscow JA, et al. **Cancer Chemother Biol Response Modif** 1996;16:111-31 (149 ref.)

Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. Ince TA, et al. **Cancer Res** 1996 May 1; 56(9):2021-4

High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens? Clifford SC, et al. **Carcinogenesis** 1996 Mar;17(3):601-4

Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Lecureur V, et al. **Carcinogenesis** 1996 May; 17(5):1157-60

Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Schuetz JD, et al. **Cell Growth Differ** 1995 Oct;6(10):1321-32

Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Liu C, et al. **Clin Sci (Colch)** 1996 Jul;91(1):93-8

Expression of P-glycoprotein in normal and malignant rat liver cells. Lee CH, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:607-15

Evidence that SP1 modulates transcriptional activity of the multidrug resistance-associated protein gene. Zhu Q, et al. **DNA Cell Biol** 1996 Feb;15(2):105-11

Transfer of the MDR1 gene into haematopoietic cells. Baudard M, et al. **Eur J Cancer** 1996 Jun;32A(6):1019-23 (52 ref.)

What have we learnt thus far from mice with disrupted P-glycoprotein genes? Borst P, et al. **Eur J Cancer** 1996 Jun;32A(6):985-90 (39 ref.)

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010-8 (111 ref.)

Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. Chao CC. **FEBS Lett** 1995 Oct 16; 373(3):285-90

Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein. Klugbauer N, et al. **FEBS Lett** 1996 Aug 5;391(1-2):61-5

Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p-glycoprotein gene. Groen AK, et al. **Gastroenterology** 1995 Dec;109(6):1997-2006

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Van Nieuwkerk CM, et al. **Gastroenterology** 1996 Jul;111(1):165-71

Increase in mRNA of multiple Eh pgp genes encoding P-glycoprotein homologues in emetine-resistant Entamoeba histolytica parasites. Descoteaux S, et al. **Gene** 1995 Oct 16;164(1):179-84

Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit [see comments] [published erratum appears in Gene Ther 1995 Aug;2(6):433] Hanania EG, et al. **Gene Ther** 1995 Jun;2(4):279-84. Comment in: Gene Ther 1995 Jun;2(4):233-4.

Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene [see comments] Hanania EG, et al. **Gene Ther** 1995 Jun;2(4):285-94. Comment in: Gene Ther 1995 Jun;2(4):233-4.

Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells. Kusaba H, et al. **Genome Res** 1995 Oct;5(3):245-58

Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Deleuze JF, et al. **Hepatology** 1996 Apr;23(4):904-8

Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Sugimoto Y, et al. **Hum Gene Ther** 1995 Jul;6(7):905-15

Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Hwang M, et al. **Int J Cancer** 1996 Jan 26;65(3):389-97

Expression of resistance-related proteins in nephroblastoma after chemotherapy. Volm M, et al. **Int J Cancer** 1995 Oct 9;63(2):193-7

Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. Kakehi Y, et al. **Int J Urol** 1995 Nov; 2(5):309-15

cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. Büchler M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15091-8

A conserved downstream element defines a new class of RNA polymerase II promoters. Ince TA, et al. **J Biol Chem** 1995 Dec 22;270(51):30249-52

Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. Stein U, et al. **J Cancer Res Clin Oncol** 1996;122(5):275-82

Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. Mayer R, et al. **J Cell Biol** 1995 Oct;131(1):137-50

Induction of P-glycoprotein mRNA by protein synthesis inhibition is not controlled by a transcriptional repressor protein in rat and human liver cells. Schuetz JD, et al. **J Cell Physiol** 1995 Nov;165(2):261-72

Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. Cordobes MD, et al. **J Nucl Med** 1996 Feb; 37(2):286-9

Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. Murase M, et al. **J Surg Oncol** 1996 Mar; 61(3):223-9

Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. Pu YS, et al. **J Urol** 1996 Jul;156(1):271-5

Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line. Kim WJ, et al. **Jpn J Cancer Res** 1995 Oct;86(10):969-77

Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Suwa H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):641-9

P-glycoprotein expression in the squamous cell carcinoma of the tongue base. Rabkin D, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1294-9

Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy. Gruber A, et al. **Leuk Lymphoma** 1995 Aug; 18(5-6):435-42

Expression of multidrug resistant gene (mdr-1/P-glycoprotein) in a megakaryoblastic cell line, CMK, and its enhancement during megakaryocytic differentiation. Sato T, et al. **Leuk Lymphoma** 1995 Aug; 18(5-6):515-20

Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Beck J, et al. **Leukemia** 1996 Mar;10(3):426-33

Localization of rat Pgy3 (mdr2) to the same region as Pgy2 (mdr1b) at 4q11-12. Zimonjic DB, et al. **Mamm Genome** 1996 Aug;7(8):630-1

12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. McCoy C, et al. **Mol Cell Biol** 1995 Nov;15(11):6100-8

A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Bhat UG, et al. **Mol Pharmacol** 1995 Oct; 48(4):682-9

Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1. Brown PC, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3235-41

Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Ho SP, et al. **Nucleic Acids Res** 1996 May 15;24(10):1901-7

De novo generation of simple sequence during gene amplification. Kirschner LS. **Nucleic Acids Res** 1996 Jul 15;24(14):2829-34

Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Gollapudi S, et al. **Oncol Res** 1995;7(5):213-25

Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli. Béjà O, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5969-74

The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Tommasini R, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6743-8

Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Volkman SK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8921-5

Expression of a multidrug resistance gene in human rheumatoid synovium. Jorgensen C, et al. **Rheumatol Int** 1995;15(2):83-6

Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene. Metz MZ, et al. **Virology** 1996 Mar 1;217(1):230-41

[Induction of expression of MDR 1 gene by retinoic acid and DMSO and effects on rhodamine-123 efflux in HL-60 cell lines and resistant sublines] Zhou WD, et al. **Yao Hsueh Hsueh Pao** 1996;31(1):1-5 (Eng. Abstr.) **(Chi)**

[Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias] Guerci A, et al. **Ann Biol Clin (Paris)** 1996;54(1):17-9 (Eng. Abstr.) **(Fre)**

[Expression and clinical significance of resistance proteins in initial acute lymphatic leukemia (ALL) in childhood] Sauerbrey A, et al. **Klin Padiatr** 1995 Jul-Aug;207(4):230-4 (Eng. Abstr.) **(Ger)**

[P-glycoprotein expression in osteosarcoma] Pösl M, et al. **Pathologe** 1996 Jan;17(1):50-5 (Eng. Abstr.) **(Ger)**

[Expression of the MRP gene coded conjugate transporter in human liver and its selective defect in canalicular membrane transport deficient rat hepatocytes] Möhler M, et al. **Z Gastroenterol** 1996 May;34(5):296-7 **(Ger)**

[Use of thermostable DNA polymerase from Thermus thermophilus KTP in a combined reverse transcription and amplification reaction of detecting interleukin 2alpha RNA and determining expression of the multidrug resistance gene (MDR-1)] Grebennikova TV, et al. **Mol Biol (Mosk)** 1995 Jul-Aug;29(4):930-41 (Eng. Abstr.) **(Rus)**

[The clinical significance of the expression of the multiple-drug resistance protein P-glycoprotein in chronic myeloleukemia] Turkina AG, et al. **Ter Arkh** 1995; 67(7):17-21 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Hipfner DR, et al. **Cancer Res** 1996 Jul 15;56(14):3307-14

Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Lehne G, et al. **Cytometry** 1995 Jul 1; 20(3):228-37

Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Naito M, et al. **Int J Cancer** 1996 Jul 29;67(3):435-40

Characterization and epitope mapping of several new anti-P-glycoprotein monoclonal antibodies. Shapiro AB, et al. **Int J Cancer** 1996 Jul 17;67(2):256-63

The multidrug resistance phenotype confers immunological resistance. Weisburg JH, et al. **J Exp Med** 1996 Jun 1; 183(6):2699-704

METABOLISM

Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. Lucia MB, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):893-901

Prognostic relevance of P-glycoprotein expression in breast cancer. Linn SC, et al. **Ann Oncol** 1995 Sep;6(7):679-85

p-Glycoprotein expression as a predictor of breast cancer recurrence. Gregorcyk S, et al. **Ann Surg Oncol** 1996 Jan; 3(1):8-14

Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Didier A, et al. **Anticancer Drugs** 1995 Oct;6(5):669-80

Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Lyubimov E, et al. **Anticancer Drugs** 1995 Dec;6(6):727-35

Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Zupi G, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2469-77

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Sanglard D, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2378-86

Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells. Ciaccio PJ, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):111-5

Drug-stimulated ATPase activity of a deletion mutant of the human multidrug-resistance protein (MDR1). Welker E, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):602-9

Rhodamine 123 efflux transporter in Haloferax volcanii is induced when cultured under 'metabolic stress' by amino acids: the efflux system resembles that in a doxorubicin-resistant mutant. Kaidoh K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):355-9

Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells. Aszalos A, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):889-92

Interaction of drugs with P-glycoprotein in brain capillaries. Jetté L, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1701-9

The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Mülder HS, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):967-74

Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Boer R, et al. **Biochemistry** 1996 Feb 6;35(5):1387-96

Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Chambers TC, et al. **Biochemistry** 1995 Oct 31; 34(43):14156-62

Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Piwnica-Worms D, et al. **Biochemistry** 1995 Sep 26; 34(38):12210-20

Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism. Zhang M, et al. **Biochemistry** 1996 Jul 30;35(30):9728-36

Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Ayesh S, et al. **Biochim Biophys Acta** 1996 May 24;1316(1):8-18

Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB8-5 cells. Ghauharali RI, et al. **Biochim Biophys Acta** 1996 Jan 31; 1278(2):213-22

Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Broxterman HJ, et al. **Blood** 1996 Jun 1;87(11):4809-16

The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Consoli U, et al. **Blood** 1996 Jul 15;88(2):633-44

Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Ivy SP, et al. **Blood** 1996 Jul 1;88(1):309-18

Differential modulation of P-glycoprotein, the multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells [letter] Solomon MB, et al. **Blood** 1995 Dec 1;86(11):4385-6

Comparison of P-glycoprotein expression with in vitro drug sensitivity in fresh blast cells from acute myeloid leukaemia patients. Faulkner Pulsford JF, et al. **Br J Biomed Sci** 1995 Sep;52(3):188-94

Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Budworth J, et al. **Br J Cancer** 1996 May;73(9):1063-8

Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Legrand O, et al. **Br J Haematol** 1996 Jul;94(1):23-33

Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells. Takeshita A, et al. **Br J Haematol** 1996 Apr;93(1):18-21

The detection of rhodamine 123 efflux at low levels of drug resistance. Webb M, et al. **Br J Haematol** 1996 Jun 1; 93(3):650-5

Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies. Beck J, et al. **Cancer Lett** 1996 Feb 6;99(2):197-207

Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein. Myer MS, et al. **Cancer Lett** 1996 Jan 19;99(1):73-8

Expression of P-glycoprotein, encoded by MDR 1 gene, a metabolically active efflux pump in murine mast cells. Wein D, et al. **Cancer Lett** 1996 Mar 29;101(2):241-6

Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Jedlitschky G, et al. **Cancer Res** 1996 Mar 1;56(5):988-94

Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Yang JM, et al. **Cancer Res** 1996 Aug 1;56(15):3490-4

Regulation of mdr1b gene expression in Fischer, Wistar and Sprague-Dawley rats in vivo and in vitro. Hill BA, et al. **Carcinogenesis** 1996 Mar;17(3):451-7

Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Hu X, et al. **Chemotherapy** 1995 Jul-Aug;41(4):296-305

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532-40 (78 ref.)

MDR1 gene expression in solid tumours. Goldstein LJ. **Eur J Cancer** 1996 Jun;32A(6):1039-50 (84 ref.)

MDR1/P-glycoprotein expression in colorectal cancer. Linn SC, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1291-4 (30 ref.)

Analysis of P-glycoprotein expression in osteosarcoma. Serra M, et al. **Eur J Cancer** 1995 Nov;31A(12):1998-2002

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86-92 (82 ref.)

Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells. Hegewisch-Becker S, et al. **Eur J Haematol** 1996 Jan-Feb; 56(1-2):12-22

Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Boer R, et al. **Eur J Pharmacol** 1996 Jan 11;295(2-3):253-60

The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285-9 (42 ref.)

Effect of phorbol myristate acetate (PMA) on P-glycoprotein mediated vincristine resistance of L1210 cells. Barančík M, et al. **Gen Physiol Biophys** 1995 Apr;14(2):171-5

Expression of a rat liver phosphatidylcholine translocator in Xenopus laevis oocytes. Kullak-Ublick GA, et al. **Hepatology** 1996 May;23(5):1254-9

Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Futscher BW, et al. **Int J Cancer** 1996 May 16;66(4):520-5

Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Merlin JL, et al. **Int J Hyperthermia** 1995 Nov-Dec;11(6):855-65

Membrane topology and glycosylation of the human multidrug resistance-associated protein. Bakos É, et al. **J Biol Chem** 1996 May 24;271(21):12322-6

Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. Borgnia MJ, et al. **J Biol Chem** 1996 Feb 9;271(6):3163-71

Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430. Dayan G, et al. **J Biol Chem** 1996 May 17;271(20):11652-8

Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Eytan GD, et al. **J Biol Chem** 1996 Feb 9; 271(6):3172-8

Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. Goodfellow HR, et al. **J Biol Chem** 1996 Jun 7;271(23):13668-74

Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. Gupta KP, et al. **J Biol Chem** 1996 Jan 26;271(4):2102-11

Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. Hemenway CS, et al. **J Biol Chem** 1996 Aug 2;271(31):18527-34

ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. Loe DW, et al. **J Biol Chem** 1996 Apr 19;271(16):9683-9

Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. Loe DW, et al. **J Biol Chem** 1996 Apr 19;271(16):9675-82

Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. Loo TW, et al. **J Biol Chem** 1995 Sep 29;270(39):22957-61

Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. Müller M, et al. **J Biol Chem** 1996 Jan 26;271(4):1877–83

Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. Ruetz S, et al. **J Biol Chem** 1995 Oct 27;270(43):25388–95

Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. Sachs CW, et al. **J Biol Chem** 1995 Nov 3; 270(44):26639–48

Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. Smith CD, et al. **J Biol Chem** 1995 Nov 24;270(47):28145–52

Both P-glycoprotein nucleotide-binding sites are catalytically active. Urbatsch IL, et al. **J Biol Chem** 1995 Nov 10;270(45):26956–61

Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. Zhang L, et al. **J Biol Chem** 1995 Sep 29;270(39):22859–65

Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. Takeshita H, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):366–75

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Schinkel AH, et al. **J Clin Invest** 1996 Jun 1; 97(11):2517–24

Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. Darnton SJ, et al. **J Clin Pathol** 1995 Nov;48(11):1064–6

P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine. Gala JL, et al. **J Clin Pathol** 1995 Jul;48(7):679–81

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545–56

Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. Watanabe T, et al. **J Hepatol** 1995 Oct;23(4):440–8

Cellular localization of P-glycoprotein in brain versus gonadal capillaries. Stewart PA, et al. **J Histochem Cytochem** 1996 Jul;44(7):679–85

A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Ojima I, et al. **J Med Chem** 1995 Sep 29;38(20):3891–4

Re: How does the MRP/GS-X pump export doxorubicin? [letter] Broxterman HJ, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):466–8

Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. Schuetz EG, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):1011–8

Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. Lanning CL, et al. **J Toxicol Environ Health** 1996 Mar;47(4):395–407

Beta-tubulin and P-glycoprotein: major determinants of vincristine accumulation in B-CLL cells. Reichle A, et al. **Leuk Res** 1995 Nov;19(11):823–9

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Samdani A, et al. **Leuk Res** 1996 Feb;20(2):175–80

Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Tafuri A, et al. **Leuk Res** 1995 Dec;19(12):927–31

Effect of 5637-conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF-dependent leukemic myeloid cell line. Bailly JD, et al. **Leukemia** 1995 Oct;9(10):1718–25

Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Wattel E, et al. **Leukemia** 1995 Nov;9(11):1870–4

Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Xie XY, et al. **Leukemia** 1995 Nov;9(11):1882–7

Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Albertioni F, et al. **Med Oncol** 1995 Jun; 12(2):79–86

Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mankhetkorn S, et al. **Mol Pharmacol** 1996 Mar;49(3):532–9

P-glycoprotein--a marker of cancer-cell behavior [editorial; comment] Pinedo HM, et al. **N Engl J Med** 1995 Nov 23; 333(21):1417–9. Comment on: N Engl J Med 1995 Nov 23;333(21):1380–5.

HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Dimitroulakos J, et al. **Nat Med** 1996 Mar;2(3):326–33

Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Kopnin BP, et al. **Oncol Res** 1995;7(6):299–306

Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Saitoh H, et al. **Pharm Res** 1995 Sep;12(9):1304–10

P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. de Graaf D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1238–42

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Schuetz EG, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4001–5

Differences between accumulation of 99mTc-MIBI and 201Tl-thallous chloride in tumour cells: role of P-glycoprotein. Ballinger JR, et al. **Q J Nucl Med** 1995 Jun;39(2):122–8

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Failure of P-glycoprotein (MDR1) expressed in Xenopus oocytes to produce swelling-activated chloride channel activity. Morin XK, et al. **J Physiol (Lond)** 1995 Aug 1; 486 (Pt 3):707–14

PHYSIOLOGY

P-glycoprotein: its role in drug resistance. Ling V. **Am J Med** 1995 Dec 29;99(6A):31S–34S (55 ref.)

P-glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161–83 (127 ref.)

Efficacy of the herbicide trifluralin against four P-glycoprotein-expressing strains of Leishmania. Chan MM, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1609–11

The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385–405 (135 ref.)

Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Del Poeta G, et al. **Blood** 1996 Mar 1;87(5):1997–2004

Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Drach J, et al. **Blood** 1996 Sep 1;88(5):1747–54

Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Kizaki M, et al. **Blood** 1996 Jan 15;87(2):725–33

A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Homolya L, et al. **Br J Cancer** 1996 Apr;73(7):849–55

p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Linn SC, et al. **Br J Cancer** 1996 Jul;74(1):63–8

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Dantzig AH, et al. **Cancer Res** 1996 Sep 15; 56(18):4171–9

Multidrug resistance and malignancy in human osteosarcoma. Scotlandi K, et al. **Cancer Res** 1996 May 15;56(10):2434–9

P-glycoprotein--a mediator of multidrug resistance in tumour cells. Germann UA. **Eur J Cancer** 1996 Jun; 32A(6):927–44 (280 ref.)

Biology of the multidrug resistance-associated protein, MRP. Loe DW, et al. **Eur J Cancer** 1996 Jun;32A(6):945–57 (188 ref.)

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002–9 (61 ref.)

Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Raghu G, et al. **Exp Hematol** 1996 Aug;24(10):1258–64

Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. Eymin B, et al. **Int J Cancer** 1995 Oct 9;63(2):268–75

Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Norris MD, et al. **Int J Cancer** 1996 Mar 1;65(5):613–9

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Adams DJ, et al. **Invest New Drugs** 1995;13(1):13–21

Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. Metherall JE, et al. **J Biol Chem** 1996 Feb 2;271(5):2634–40

Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80-kDa mdr1a gene product. Thévenod F, et al. **J Biol Chem** 1996 Feb 9;271(6):3300–5

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Schinkel AH, et al. **J Clin Invest** 1995 Oct;96(4):1698–705

Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. Beukeveld GJ, et al. **J Hepatol** 1996 Mar;24(3):343–52

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of p-glycoprotein. Field FJ, et al. **J Lipid Res** 1995 Jul;36(7):1533–43

Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. Begley DJ, et al. **J Neurochem** 1996 Sep;67(3):988–95

P-glycoprotein regulates a volume-activated chloride current in bovine non-pigmented ciliary epithelial cells. Wu J, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):743–55

Transduction of the macrophage colony-stimulating factor gene into human multidrug resistant cancer cells: enhanced therapeutic efficacy of monoclonal anti-P-glycoprotein antibody in nude mice. Sone S, et al. **Jpn J Cancer Res** 1996 Jul;87(7):757–64

P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. Damiani D, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):289–94

P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases [letter] Damiani D, et al. **Leukemia** 1995 Oct;9(10):1792–5

Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Archinal-Mattheis A, et al. **Oncol Res** 1995;7(12):603–10

Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Aungst BJ, et al. **Pharm Res** 1996 Jan;13(1):114–9

P-glycoprotein involvement in cuticular penetration of [14C]thiodicarb in resistant tobacco budworms. Lanning CL, et al. **Toxicol Lett** 1996 Jun;85(3):127–33

Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681–6 (51 ref.)

[Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting] Tsuruo T. **Nippon Rinsho** 1995 Oct;53(10):2604–11 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513–22 (36 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane. Loo TW, et al. **J Biol Chem** 1996 Jun 28; 271(26):15414–9

P SELECTIN see **P-SELECTIN**

PAAG see **PREGNANCY ZONE PROTEINS**

PABA see **4-AMINOBENZOIC ACID**

PACEMAKER, ARTIFICIAL

Ligature causing pseudofracture of a cardiac pacemaker lead [letter] Weissman JL, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):464–5

Evaluation and extraction of the Accufix atrial J lead. Daoud EG, et al. **Am Heart J** 1996 Feb;131(2):266–9

Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Fitzpatrick AP, et al. **Am Heart J** 1996 Mar; 131(3):499–507

Aborted sudden death in dual-chamber pacemaker treatment of hypertrophic obstructive cardiomyopathy. Rusconi P, et al. **Am Heart J** 1995 Oct;130(4):912–5

Survey of cardiac pacing and defibrillation in the United States in 1993. Bernstein AD, et al. **Am J Cardiol** 1996 Jul 15;78(2):187–96

Long-term outcome in patients with pacemakers following the Fontan operation. Fishberger SB, et al. **Am J Cardiol** 1996 Apr 15;77(10):887–9

A positive response to head-up tilt testing predicts syncopal recurrence in carotid sinus syndrome patients with permanent pacemakers. Gaggioli G, et al. **Am J Cardiol** 1995 Oct 1;76(10):720–2

Decrease in pacemaker incidence after orthotopic heart transplantation. Kratochwill C, et al. **Am J Cardiol** 1996 Apr 1;77(9):779–83

Heart rate to work rate relation throughout peak exercise in normal subjects as a guideline for rate-adaptive pacemaker programming. Lewalter T, et al. **Am J Cardiol** 1995 Oct 15;76(11):812–6

Percutaneous pacemaker lead extraction and stent implantation for superior vena cava occlusion due to pacemaker leads. Rosenthal E, et al. **Am J Cardiol** 1996 Mar 15;77(8):670–2

Complete generator extrusion as a cause of pacemaker dysfunction [letter] Binder T, et al. **Am J Emerg Med** 1995 Nov;13(6):670–1

Explorations into development of a neurally regulated cardiac pacemaker. Ikeda Y, et al. **Am J Physiol** 1995 Dec; 269(6 Pt 2):H2141–6

Transesophageal atrial pacing in patients with permanent pacemakers [letter] Roth JV. **Anesth Analg** 1996 May; 82(5):1109–10

The Shaw Hemostatic Scalpel as an alternative to electrocautery in patients with pacemakers [letter] Amar D, et al. **Anesthesiology** 1996 Jul;85(1):223

Transesophageal atrial pacing combined with dual–chamber pacing [letter] Broka SM, et al. **Anesthesiology** 1996 Feb; 84(2):472

Transesophageal atrial pacing as a trigger for intraaortic balloon pumping [letter] Broka SM, et al. **Anesthesiology** 1996 Feb;84(2):473

Permanent pacemaker for rejection episodes after heart transplantation: a poor prognostic sign. Blanche C, et al. **Ann Thorac Surg** 1995 Nov;60(5):1263–6

Pacemaker lead placement via a small cephalic vein. Gordon PJ, et al. **Ann Thorac Surg** 1996 Aug;62(2):594–5

Disopyramide stress test: a sensitive and specific tool for predicting impending high degree atrioventricular block in patients with bifascicular block. Englund A, et al. **Br Heart J** 1995 Dec;74(6):650–5

Antibiotic prophylaxis in permanent pacemaker implantation [letter; comment] Mounsey JP, et al. **Br Heart J** 1995 Aug; 74(2):206. Comment on: Br Heart J 1995 Apr;73(4):392.

Atrial electromechanical sequence in normal subjects and patients with DDD pacemakers. Wang K, et al. **Br Heart J** 1995 Oct;74(4):403–7

Basic principles of permanent cardiac pacing. Rozkovec A. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):31–7 (16 ref.)

Advances in pacing. Skehan JD. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):41–3 (6 ref.)

Thoracoscopic implantation of an epicardial pacemaker. Robles R, et al. **Br J Surg** 1996 Mar;83(3):400

The patient with a pacemaker or related device. Bourke ME. **Can J Anaesth** 1996 May;43(5 Pt 2):R24–41 (28 ref.) **(Eng, Fre)**

Pacing and atrial fibrillation. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:36A–39A (31 ref.)

Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A–50A (18 ref.)

Trends in pediatric cardiac pacing. Rao V, et al. **Can J Cardiol** 1995 Dec;11(11):993–9

Early restenosis following percutaneous transluminal balloon angioplasty for the treatment of the superior vena caval syndrome due to pacemaker–induced stenosis. Marzo KP, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):128–31

Physiologic dual chamber pacing in radiation–induced atrioventricular block [letter; comment] La Vecchia L. **Chest** 1996 Aug;110(2):580–1. Comment on: Chest 1995 Dec;108(6):1748–51.

Steroid elution improves the stimulation threshold in an active–fixation atrial permanent pacing lead. A randomized, controlled study. Model 4068 Investigators. Crossley GH, et al. **Circulation** 1995 Nov 15;92(10):2935–9

Malposition of transvenous pacing lead in the left ventricle. Raghavan C, et al. **Clin Cardiol** 1996 Apr;19(4):335–8

Local latency of conduction time during premature stimulation: a real or apparent phenomenon? [editorial; comment] Chimienti M, et al. **Eur Heart J** 1995 Dec; 16(12):1749–51. Comment on: Eur Heart J 1995 Dec;16(12):1920–4.

The chronotropic response of the sinus node to exercise: a new method of analysis and a study of pacemaker patients. Crook B, et al. **Eur Heart J** 1995 Jul;16(7):993–8

Supraventricular tachycardia detected by means of an oesophageal Holter ECG in a patient with third–degree AV block and a VVI pacemaker [letter] Grille W, et al. **Eur Heart J** 1995 Dec;16(12):2006–7

Prolongation of conduction time during premature stimulation in the human atrium is primarily caused by local stimulus response latency [see comments] Koller BS, et al. **Eur Heart J** 1995 Dec;16(12):1920–4. Comment in: Eur Heart J 1995 Dec;16(12):1749–51.

Potential for inadvertent pacing with Zoll PD 1200 defibrillator/monitor/pacemakers. **Health Devices** 1995 Aug–Sep;24(8–9):361–2

Pacemaker endocarditis. Federmann M, et al. **Heart** 1996 May;75(5):446

Extraction of permanent pacing leads: there are still controversies [editorial] Hayes DL. **Heart** 1996 Jun; 75(6):539–41

Retained surgical swab misinterpreted as epicardial pacing wire on chest x ray. McKillop G, et al. **Heart** 1996 Apr; 75(4):342

Persistent left sided and absent right sided superior vena cava complicating permanent pacemaker insertion. Rusk RA, et al. **Heart** 1996 Apr;75(4):413

Infection precautions with temporary pacing leads: a descriptive study. Beery TA, et al. **Heart Lung** 1996 May–Jun;25(3):182–9

Breast swelling after pacemaker placement in an elderly woman. Crooks G, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):173–5

Issues in cardiac pacing: optimising pacemaker therapy [editorial] Gambhir DS. **Indian Heart J** 1996 Mar–Apr; 48(2):115–7 (32 ref.)

Histamine–induced activation of ventricular ectopic pacemakers and contractile myocardium: role of histamine receptors. Kevelaitis E, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S96–7

Recurrent syncope of unknown origin: value of permanent pacemaker insertion. Fisher M, et al. **Int J Cardiol** 1995 Aug;51(1):93–5; discussion 96–7

Cellular telephones and pacemakers: urgent call or wrong number? [editorial] Ellenbogen KA, et al. **J Am Coll Cardiol** 1996 May;27(6):1478–9

Dual–chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study [see comments] Gold MR, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):967–73. Comment in: J Am Coll Cardiol 1995 Oct;26(4):974.

Dilated cardiomyopathy: to pace or not to pace [editorial; comment] Leinbach RC. **J Am Coll Cardiol** 1995 Oct; 26(4):974. Comment on: J Am Coll Cardiol 1995 Oct;26(4):967–73.

Intermittent pacemaker dysfunction caused by digital mobile telephones. Naegeli B, et al. **J Am Coll Cardiol** 1996 May; 27(6):1471–7

Identification of a malpositioned atrial pacemaker lead across a patent foramen ovale by transesophageal echocardiography. Estrada–Quintero T, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):560–2

Cardiovascular responses at the onset of static exercise in patients with dual–chamber pacemakers. Williamson JW, et al. **J Appl Physiol** 1995 Nov;79(5):1668–72

Atrioventricular sequential pacing using transesophageal atrial pacing in combination with temporary external DDD pacemaker [letter] Broka SM, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):441–2

Shockwave lithotripsy and pacemakers: experience with 20 cases. Albers DD, et al. **J Endourol** 1995 Aug;9(4):301–3

Pacemaker twiddler's syndrome: report of a case. Fang CC, et al. **J Formos Med Assoc** 1995 Oct;94(10):630–1

Long–term follow–up of heart transplant recipients requiring permanent pacemakers. Raghavan C, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1081–9

The safety of dental mini–magnets in patients with permanent cardiac pacemakers. Hiller H, et al. **J Prosthet Dent** 1995 Oct;74(4):420–1

New temporary atrial and ventricular pacing leads for patients after cardiac operations. Ohm OJ, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1725–31

I–123 metaiodobenzylguanidine cardiac scintigraphy in patients with an implanted permanent pacemaker. Nakata A, et al. **Jpn Heart J** 1995 Sep;36(5):583–91

Protrusion of retention wire from Encor–Dec passive fixation atrial pacing lead [letter] Rankin JM, et al. **Lancet** 1995 Oct 28;346(8983):1169–70

When a medical device fails—where the "buck" stops [editorial; comment] Graham KJ. **Mayo Clin Proc** 1996 Mar;71(3):314–5. Comment on: Mayo Clin Proc 1996 Mar;71(3):230–4.

Extraction of the Telectronics Accufix 330–801 atrial lead: the Mayo Clinic experience [see comments] Lloyd MA, et al. **Mayo Clin Proc** 1996 Mar;71(3):230–4. Comment in: Mayo Clin Proc 1996 Mar;71(3):314–5.

Central venous puncture versus cutdown for permanent pacemaker lead insertion: a modified double introducer technique. Kolker AR, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):39–44

Cardiac pacing [letter; comment] Barold SS. **N Engl J Med** 1996 May 30;334(22):1476–7. Comment on: N Engl J Med 1996 Jan 11;334(2):89–97.

Cardiac pacing [see comments] Kusumoto FM, et al. **N Engl J Med** 1996 Jan 11;334(2):89–97 (53 ref.). Comment in: N Engl J Med 1996 May 30;334(22):1476–7.

Images in clinical medicine. Fracture of a retention wire in an atrial J pacemaker lead. Roelke M, et al. **N Engl J Med** 1996 Jan 11;334(2):88

Initial clinical experience with a new dual sensor SSIR pacemaker controlled by body activity and minute ventilation. Alt E, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1487–95

Three–year experience with a stylet for lead extraction: a multicenter study. Alt E, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):18–25

Evolution of fracture in the atrial "J" lead retention wire. Ardesia RJ, et al. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2227–8

Compatibility of implantable cardiac pacemakers with implantable cardioverter defibrillators (ICDs) [letter; comment] Arvidson CL. **Pacing Clin Electrophysiol** 1996 Mar;19(3):380–2. Comment on: Pacing Clin Electrophysiol 1995 Jan;18(1 Pt 2):182–7. Comment on: Pacing Clin Electrophysiol 1995 Jan;18(1 Pt 2):188–93.

Missing atrial stimulus during DDD pacing. Barold SS. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1711–2

Suppression of ventricular output by noise in the atrial channel in a dual chamber pacemaker. Ben–Zur UM, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1586–8

Electrode polarity does not alter the initial ventricular activation sequence during pacing with extracardiac electrodes. Birkui PJ, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2173–9

Influence of exercise induced myocardial ischemia on right ventricular dP/dt: potential implications for rate responsive pacing. Candinas R, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2121–7

Pacemaker miniaturization: a good trend? French Group of Cardiac Pacing [editorial] Cazeau S, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):1–3

Overnight heart rate and cardiac function in patients with dual chamber pacemakers. Chew PH, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):822–8

Cardiac pacemakers in pediatric heart transplant recipients: incidence, indications, and associated factors. Pediatric Heart Transplant Group–Loma Linda. Chinnock RE, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):26–30

Should the race for pulse generator miniaturization be stopped? [editorial] Daubert JC. **Pacing Clin Electrophysiol** 1996 Jan;19(1):4–6

Activation times for "emergency backup" programs. Forney RC, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):465–71

Lead extraction in young patients with and without congenital heart disease using the subclavian approach. Friedman RA, et al. **Pacing Clin Electrophysiol** 1996 May; 19(5):778–83

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):517–8

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1728

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1975

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2235

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):387–90

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7–17 (14 ref.)

Peritoneal migration of an abdominally implanted epicardial pacemaker: a cause of intestinal obstruction. Gomez C, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2231–2

Undersensing of the tiny QRS complexes that emerged after the isolation of the right ventricle in a patient with ventricular tachycardia. Güldal M, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):868–71

Long–term thresholds of nonsteroidal permanent pacing leads: a 5–year study. Gumbrielle TP, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):829–35

Counseling and management of patients with Telectronics 330–801 Accufix leads [letter; comment] Hayes DL, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1595. Comment on: Pacing Clin Electrophysiol 1995 May;18(5 Pt 1):958–64.

Pacemaker inhibition due to anodal ring electrode contact. Henderson D, et al. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2222–4

Inconsistent response to rapid atrial rhythms in a DDD pacemaker with the fallback feature. Johnson NJ. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1458–62

Use of pacemaker diagnostic functions for recognition and management of cardiac arrhythmias. Kamalvand K, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):514–5

Migration of a fractured retention wire in the pulmonary artery from an active fixation atrial lead. Kao HL, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1966–7

Relationship between heart rate and oxygen kinetics during constant workload exercise. Kay GN, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1853–60

Treatment of malignant neurocardiogenic syncope with dual chamber cardiac pacing and fluoxetine hydrochloride. Kosinski DJ, et al. **Pacing Clin Electrophysiol** 1995 Jul; 18(7):1455–7

Preliminary evaluation of a dual chamber pacemaker with bradycardia diagnostic functions. Lascault G, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1636–43

Effects of nuclear magnetic resonance imaging on cardiac pacemakers. Lauck G, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1549–55

Spurious programming [letter; comment] Levine PA. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1968. Comment on: Pacing Clin Electrophysiol 1995 May;18(5 Pt 1):1072–4.

The "low intensity treadmill exercise" protocol for appropriate rate adaptive programming of minute ventilation controlled pacemakers. Lewalter T, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1374–87

Serial fluoroscopic evaluation of a pacing lead. Lloyd MA, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):501–4

New approach to subclavian venipuncture [letter] Magney JE, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):877

Pacemaker and defibrillator lead entrapment: case studies. Magney JE, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1509–17

Determinants of dual chamber pulse generators longevity. Markewitz A, et al. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2116–20

Atrial pacing leads: the clinical contribution of steroid elution. Mond HG, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1601–8

A randomized controlled clinical study to quantify the effect of small changes in the design of pacing electrodes on threshold voltages. Murray A, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2150–4

VDD(R) pacing: short– and long–term stability of atrial sensing with a single lead system. Naegeli B, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):455–64

Matching optimal pacemaker to patient: do we need a large scale clinical trial of pacemaker mode selection? [editorial] [see comments] Ovsyshcher IE. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1845–52. Comment in: Pacing Clin Electrophysiol 1996 Mar;19(3):382–6.

Nonthoracotomy ICD implantation: lessons to be learned from permanent pacemaker implantation [editorial] Parsonnet V, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1597–600

Spontaneous reversal of a cardiomyostimulator to asynchronous mode. Peteiro J, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):367–9

Cardiac involvement in Emery–Dreifuss muscular dystrophy: role of a diagnostic pacemaker. Rakovec P, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1721–4

Comparison of sinus node response to exercise with responses from two different activity–based rate adaptive pacemakers in healthy subjects of different age groups. Roberts DH, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1882–8

Successful long–term ventricular pacing via the coronary sinus after the Fontan operation. Rosenthal E, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2103–5

Impedance of pacemaker leads: correlation of different methods. Siegmund JB, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):90–4

Catheter aided repositioning of a displaced permanent pacemaker lead. Sochman J, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1964–5

Pacemaker upgrade for recurrent pacemaker syndrome using a redundant contralateral electrode in a patient with bilateral venous stenoses. Sulke N, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):378–9

No output or runaway? Sweesy MW, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):498–500

Clinical benefit of dual chamber pacing in hypertrophic cardiomyopathy: a case report. Teixeira JM, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):120–3

Dependence of atrial sensing function on posture in a single–lead atrial triggered ventricular (VDD) pacemaker. Toivonen L, et al. **Pacing Clin Electrophysiol** 1996 Mar; 19(3):309–13

Ethics of a randomized trial to compare VVI vs DDD pacing [letter; comment] Wagshal A. **Pacing Clin Electrophysiol** 1996 Mar;19(3):382–6. Comment on: Pacing Clin Electrophysiol 1994 Nov;17(11 Pt 1):1707–11. Comment on: Pacing Clin Electrophysiol 1995 Oct;18(10):1845–52.

Pacemaker inhibition and asystole in a pacemaker dependent patient. Yeşil M, et al. **Pacing Clin Electrophysiol** 1995 Oct; 18(10):1963

A shorter R–R interval causes a larger endocardial R wave amplitude in cases with atrial fibrillation. Yokoyama M, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2180–2

Semi–automatic external defibrillation and implanted cardiac pacemakers: understanding the interactions during resuscitation. Monsieurs KG, et al. **Resuscitation** 1995 Oct; 30(2):127–31

Miliary tuberculosis presenting as infection of a pacemaker pulse–generator pocket. Doherty JG, et al. **Scott Med J** 1996 Feb;41(1):20–1

Intramyocardial electrograms for the monitoring of allograft rejection after heart transplantation using spontaneous and paced beats. Auer T, et al. **Transplant Proc** 1995 Oct; 27(5):2621–4

[Sick sinus syndrome. Pacemaker with atrial versus ventricular stimulation] Andersen HR, et al. **Ugeskr Laeger** 1996 Feb 19;158(8):1062–7 (Eng. Abstr.) **(Dan)**

[Multifactor prevention of endocarditis and cardiac pacemakers. A prospective study apropos of 207 patients] Graux P, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar; 45(3):113–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55–62 (43 ref.) (Eng. Abstr.) **(Fre)**

[Protection systems of dual–chamber pacemakers against atrial arrhythmia] Deharo JC, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):465–70 (Eng. Abstr.) **(Fre)**

[Cardiac pacemaker dysfunction secondary to outside interference: a review] Grobéty M, et al. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):723–33 (32 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac pacemaker for the treatment of obstructive hypertrophic cardiomyopathy, a concept which is gaining ground] Kappenberger L, et al. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1950–5 (Eng. Abstr.) **(Fre)**

[Cardiac pacemaker as bridge to cardiac telemonitoring] Hutten H, et al. **Biomed Tech (Berl)** 1996 Jun;41(6):158–65 (Eng. Abstr.) **(Ger)**

[Electrocoagulation in patients with cardiac pacemakers: what should be considered?] Habicht JM, et al. **Chirurg** 1995 Aug;66(8):774–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Could C– and D–network mobile phones endanger patients with pacemakers? (see comments)] Hofgärtner F, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):646–52 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1996 May 17;121(20):645. **(Ger)**

[Low stimulation impedance in pacemaker patients with cardiac diseases. The Thera Pacemaker Study Group] Schuchert A, et al. **Dtsch Med Wochenschr** 1996 Aug 23; 121(34–35):1046–9 (Eng. Abstr.) **(Ger)**

[Could C– and D–network mobile phones endanger patients with cardiac pacemakers? (comment)] Trappe HJ. **Dtsch Med Wochenschr** 1996 May 17;121(20):645. Comment on: Dtsch Med Wochenschr 1996 May 17;121(20):646–52. **(Ger)**

[Current pacemaker treatment and technology] Candinas R, et al. **Schweiz Rundsch Med Prax** 1996 May 14; 85(20):663–70 (24 ref.) (Eng. Abstr.) **(Ger)**

[Transient pacemaker dysfunction and spontaneous arrhythmias in symptomatic and asymptomatic patients with ventricular demand pacemakers] Brandes A, et al. **Z Kardiol** 1996 Apr;85(4):237–47 (Eng. Abstr.) **(Ger)**

[DDD versus DDDR pacemaker stimulation: comparison of cardiopulmonary performance, incidence of atrial arrhythmias and quality of life] Epperlein S, et al. **Z Kardiol** 1996 Apr;85(4):226–36 (Eng. Abstr.) **(Ger)**

[Chronic frequency–adaptive pacemaker therapy in patients with heart failure] Haltern G, et al. **Z Kardiol** 1995 Oct; 84(10):834–43 (Eng. Abstr.) **(Ger)**

[Comparison of active and passive fixation of steroid emitting atrial electrodes] Schuchert A, et al. **Z Kardiol** 1996 Apr; 85(4):255–9 (Eng. Abstr.) **(Ger)**

[Low pacing thresholds of ventricular pacemaker leads: not a marker for large R–wave amplitudes and high impedance values] Schuchert A, et al. **Z Kardiol** 1995 Dec;84(12):971–6 (Eng. Abstr.) **(Ger)**

[Loss of consciousness of unusual etiology in a young patient] Radnai B, et al. **Orv Hetil** 1996 Jan 14;137(2):79–81 (Eng. Abstr.) **(Hun)**

[How to regulate the heart rate in a wearer of a cardiac pacemaker] Rossi P. **Cardiologia** 1996 Mar;41(3):227–40 (29 ref.) **(Ita)**

[Shortening of atrioventricular interval improves ventricular filling and clinical outcome in patients with DDD pacemaker and left ventricular hypertrophy] Rossi R, et al. **Cardiologia** 1996 May;41(5):441–7 (Eng. Abstr.) **(Ita)**

[Dobutamine stress echocardiography in the diagnosis of myocardial ischemia in patients with implanted pacemakers: report of two cases] Yamamoto T, et al. **J Cardiol** 1995 Dec;26(6):367–72 (Eng. Abstr.) **(Jpn)**

[An autopsy case of a pacemaker implanted patient] Haga K, et al. **Nippon Hoigaku Zasshi** 1995 Oct;49(5):304–8 (Eng. Abstr.) **(Jpn)**

[Sick sinus syndrome (extrinsic and intrinsic form) during long term observation] Ciemniewski Z, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):48–57 (Eng. Abstr.) **(Pol)**

[Adequacy of of pacemakers responsive to the volume–minute ventilation rate in heart transplantation patients] Sant'Anna JR, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):547–52 (Eng. Abstr.) **(Por)**

[Recommendations of the Department of Arrhythmia and Clinical Electrophysiology (DAEC) of the Brazilian Cardiology Society on indications for permanent pacemaker implantation, choice of stimulation mode, and indications for automatic cardioverter–defibrillator implantation] Sosa EA, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):579–83 **(Por)**

[Experience in reuse of removed electric cardiac stimulator and endocardial electrodes] Gusak VK, et al. **Klin Khir** 1995;(7–8):38–9 **(Rus)**

[Syndrome of artificial pacemaker rotation] Gusak VK, et al. **Klin Khir** 1995;(11–12):44 **(Rus)**

[The electrode–myocardium interface at the cellular level and prospects of the use of implantable pacemakers] Shal'dakh M. **Med Tekh** 1995 Sep–Oct;(5):9–20 (Eng. Abstr.) **(Rus)**

[The electrocardiographic diagnosis and clinical course of acute myocardial infarct in patients with an implanted pacemaker] Tatarchenko IP, et al. **Ter Arkh** 1995; 67(9):28–31 **(Rus)**

[Fixation of the endocardial electrode in cardiac pacing] Kozlov VL, et al. **Vestn Rentgenol Radiol** 1996 Jan–Feb; (1):16–9 (Eng. Abstr.) **(Rus)**

[Management of surgery patients with implanted cardiac pacemakers] Ugljen R, et al. **Ljec Vjesn** 1995 Sep–Oct; 117(9–10):241–5 (Eng. Abstr.) **(Scr)**

[Survival in patients with sick sinus syndrome and artificial pacemaker. Determining clinical factors] Sanjuán R, et al. **Rev Esp Cardiol** 1996 Mar;49(3):184–8 (Eng. Abstr.) **(Spa)**

[Cellular telephones may interfere with cardiac stimulators. Yuppie telephones and alarms are hazardous for patients with pacemakers] Fåhraeus T, et al. **Lakartidningen** 1995 Oct 25;92(43):4009–10 **(Swe)**

ADVERSE EFFECTS

Ventricular pacing: a cause of reversible severe mitral regurgitation. Berglund H, et al. **Am Heart J** 1996 May; 131(5):1035–7

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616–8 (8 ref.)

Massive pericardiac hematoma with severe constrictive pathophysiologic complications after insertion of an epicardial pacemaker. Vilacosta I, et al. **Am Heart J** 1995 Dec;130(6):1298–300

Transesophageal echocardiographic color Doppler evaluation of pulmonary vein flow during ventricular pacing. Amici E, et al. **Am J Card Imaging** 1996 Jan; 10(1):23–8

Pacemaker–induced superior vena cava syndrome with successful treatment by balloon venoplasty. Kastner RJ, et al. **Am J Cardiol** 1996 Apr 1;77(9):789–90

Glomerulonephritis associated with permanent pacemaker endocarditis. Barnes E, et al. **Am J Nephrol** 1995; 15(5):436–8

Morphological observation by intravascular ultrasound in superior vena cava syndrome after pacemaker implantation. Kitamura J, et al. **Cathet Cardiovasc Diagn** 1996 Jan; 37(1):83–5

Postpericardiotomy syndrome and cardiac tamponade following transvenous pacemaker placement. Miller GL, et al. **Clin Cardiol** 1996 Mar;19(3):255–6

Granulomatous dermatitis after implantation of a titanium–containing pacemaker. Viraben R, et al. **Contact Dermatitis** 1995 Dec;33(6):437

The use of technetium–99m hexamethylpropylene amine oxime labelled granulocytes with single–photon emission tomography imaging in the detection and follow–up of recurrence of infective endocarditis complicating transvenous endocardial pacemaker. Ramackers JM, et al. **Eur J Nucl Med** 1995 Nov;22(11):1351–4

Budd–Chiari syndrome due to pacemaker–induced thrombosis. Lu CL, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):355–8

Demonstration of syncope in patients after pacemaker implantation: role of head–up tilt test to distinguish neurocardiogenic vasodepressor syncope from pacemaker syndrome. Abe H, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):293–6

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1467

Salvage of infected ICDs: management without removal. Lee JH, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):437–42

An unusual complication in pacemaker therapy [letter] Markewitz A. **Pacing Clin Electrophysiol** 1996 May; 19(5):877–8

Adverse pacemaker hemodynamics evaluated by pulmonary venous flow monitoring. Stierle U, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2028–34

Fracture and migration of a pacemaker atrial lead retention wire found by fluoroscopic screening in an asymptomatic patient. Mucha E, et al. **South Med J** 1996 Aug; 89(8):798–800

[Cardiac pacemaker infections in Helsinki University Central Hospital 1989–93] Stjernvall J, et al. **Duodecim** 1994; 110(18):1695–701 **(Fin)**

[Wandering pacemaker (letter)] Wiel E, et al. **Ann Fr Anesth Reanim** 1996;15(3):390–1 **(Fre)**

[Postpericardiotomy syndrome; a rare complication of transcavitary cardiac pacing: apropos of a case] Goutal H, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1901–3 (Eng. Abstr.) **(Fre)**

[Septicemia and endocarditis related to transvenous pacing leads of pacemakers: surgical indications and results] Leprince P, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):241–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Contact dermatitis following cardiac pacemaker implantation] Moïni C, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Infections occuring on permanent endocavitary pacemaker leads: value of transesophageal echocardiography] Victor F, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1875–81 (Eng. Abstr.) **(Fre)**

[Paroxysmal nocturnal dyspnea as a severe expression of the pacemaker syndrome] Minutiello L. **Minerva Cardioangiol** 1996 Mar;44(3):133–40 (9 ref.) (Eng. Abstr.) **(Ita)**

[Removal of infected transvenous electrodes associated with giant vegetations under cardiopulmonary bypass] Okamoto H, et al. **Kyobu Geka** 1995 Nov;48(12):1050–2 (Eng. Abstr.) **(Jpn)**

[Removal of infected pacemaker leads in the elderly under extracorporeal circulation: two case reports and review of Japanese literature] Sato M, et al. **Kyobu Geka** 1995 Nov; 48(12):1009–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The pocket infection–erosion of permanent pacemakers: the results of a conservative approach without substitution of the components] Jesus I, et al. **Rev Port Cardiol** 1995 Oct; 14(10):691–5 (Eng. Abstr.) **(Por)**

[The diagnosis of the dislocation and microdislocation of an endocardiac electrode based on x–ray and electrocardiographic study data] Kozlov VL, et al. **Vestn Rentgenol Radiol** 1995 Sep–Oct;(5):32–6 (Eng. Abstr.) **(Rus)**

[Life–threatening hemorrhage caused by insertion of pacemakers and central venous catheters] **Lakartidningen** 1995 Sep 27;92(39):3574 **(Swe)**

CONTRAINDICATIONS

[Intermittent atrial fibrillation/flutter: contraindication for implantation of a dual chamber pacemaker?] Schuchert A, et al. **Z Kardiol** 1996 Apr;85(4):248–54 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

How to evaluate quality–of–life in pacemaker patients: problems and pitfalls [editorial] Linde C. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):391–7 (31 ref.)

[Two cases of depressive disorder after pacemaker implantation] Tanaka K. **Seishin Shinkeigaku Zasshi** 1995; 97(10):847–54 (Eng. Abstr.) **(Jpn)**

PACEMAKER, ARTIFICIAL

STANDARDS

Management of intracardiac device recalls: a consensus conference. Goldman BS, et al. **Can J Cardiol** 1996 Jan; 12(1):37–45 (12 ref.)

Maintaining physiological pacing in AV block using a new generation single lead VDD pacemaker. Lau C, et al. **Can J Cardiol** 1996 Jun;12(6):579–83

Reliability and variability of impedance measured by real-time telemetry. Schuchert A, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):265–71

[The Danish Pacemaker Registry. A database for quality assurance] Møller M, et al. **Ugeskr Laeger** 1996 Jun 3; 158(23):3311–5 (Eng. Abstr.) **(Dan)**

[Standards in pediatric pacemaker therapy] Antretter H, et al. **Wien Med Wochenschr** 1995;145(24):651–6 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Is there a sex bias in the selection of permanent pacemaker implantations? Raj SR, et al. **Can J Cardiol** 1996 Apr; 12(4):375–8

TRENDS

New generations of implantable pacemaker defibrillators for ventricular and atrial tachyarrhythmias. Saksena S, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:149–54

Physiologic control of cardiac assist devices. Hall AW, et al. **Artif Organs** 1996 Mar;20(3):271–5

UTILIZATION

Survey of cardiac pacing in Canada (1993). Goldman BS, et al. **Can J Cardiol** 1996 Jun;12(6):573–8

PACEMAKERS, BIOLOGICAL see **BIOLOGICAL CLOCKS**

PACHYDERMOPERIOSTOSIS see **OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC**

PACIFIC ISLAND AMERICANS see **ASIAN AMERICANS**

PACIFIERS see **INFANT CARE**

PACING, CARDIAC, ARTIFICIAL see **CARDIAC PACING, ARTIFICIAL**

PACINIAN CORPUSCLES

ANATOMY & HISTOLOGY

The structure and function of Pacinian corpuscles: a review. Bell J, et al. **Prog Neurobiol** 1994 Jan;42(1):79–128 (360 ref.)

PHYSIOLOGY

Reinnervation of rat Pacinian corpuscles after nerve crush during the postcritical period of development. Zelená J, et al. **J Neurocytol** 1995 Dec;24(12):955–64

The structure and function of Pacinian corpuscles: a review. Bell J, et al. **Prog Neurobiol** 1994 Jan;42(1):79–128 (360 ref.)

PACKAGE INSERTS see **PRODUCT LABELING**

PACKAGE INSERTS, DRUG see **DRUG LABELING**

PACKAGING, DRUG see **DRUG PACKAGING**

PACKAGING, FOOD see **FOOD PACKAGING**

PACKAGING, PRODUCT see **PRODUCT PACKAGING**

PACKAGING, VIRAL see **VIRUS ASSEMBLY**

PACKED RED-CELL VOLUME see **HEMATOCRIT**

PACLITAXEL

20th Belgian-Dutch LOF-Symposium on Pharmacognosy and Natural Products Chemistry. Paclitaxel and other taxanes as new anti-cancer drugs. Leiden, The Netherlands, 24 November 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl N):N1–14

[Paclitaxel (Taxol)] Hájek R. **Cas Lek Cesk** 1996 Jun 12; 135(12):393–6 (20 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Theoretical and practical aspects of paclitaxel scheduling [editorial; comment] Gianni L. **Ann Oncol** 1995 Nov; 6(9):861–3 (26 ref.). Comment on: Ann Oncol 1995 Nov;6(9):883–5.

Multi-day fractionated administration schedule for paclitaxel [see comments] Lokich J, et al. **Ann Oncol** 1995 Nov; 6(9):883–5. Comment in: Ann Oncol 1995 Nov;6(9):861–3.

Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Gosland MP, et al. **Cancer Chemother Pharmacol** 1996;37(6):593–600

In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Kano Y, et al. **Cancer Chemother Pharmacol** 1996;37(6):525–30

Plasma alcohol concentrations in patients following paclitaxel infusion. Webster LK, et al. **Cancer Chemother Pharmacol** 1996;37(5):499–501

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Kurbacher CM, et al. **Cancer Lett** 1996 Jun 5;103(2):183–9

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. Glantz MJ, et al. **J Clin Oncol** 1996 Feb;14(2):600–9

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. Millward MJ, et al. **J Clin Oncol** 1996 Jan; 14(1):142–8

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Nabholtz JM, et al. **J Clin Oncol** 1996 Jun;14(6):1858–67

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1996 Jun;14(6):1877–84

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1995 Oct;13(10):2575–81

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. Tolcher AW, et al. **J Clin Oncol** 1996 Jan;14(1):95–102

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. Younes A, et al. **J Clin Oncol** 1996 Feb; 14(2):543–8

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. Rischin D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1297–301

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments] McGuire WP, et al. **N Engl J Med** 1996 Jan 4;334(1):1–6. Comment in: N Engl J Med 1996 Jan 4;334(1):50–1. Comment in: N Engl J Med 1996 May 9;334(19):1268–9; discussion 1270. Comment in: N Engl J Med 1996 May 9;334(19):1269; discussion 1270.

New therapy for ovarian cancer [editorial; comment] Neijt JP. **N Engl J Med** 1996 Jan 4;334(1):50–1. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Chemotherapy for ovarian cancer [letter; comment] Parmar MK, et al. **N Engl J Med** 1996 May 9;334(19):1268–9; discussion 1270. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Development of a polymeric surgical paste formulation for taxol. Winternitz CI, et al. **Pharm Res** 1996 Mar; 13(3):368–75

Plasticizer extraction of Taxol infusion solution from various infusion devices. Mass B, et al. **Pharm World Sci** 1996 Apr; 18(2):78–82

Embryotoxicity of free and liposome-encapsulated taxol in the chick. Scialli AR, et al. **Pharmacology** 1995 Sep; 51(3):145–51

Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Belli L, et al. **Semin Oncol** 1995 Dec; 22(6 Suppl 15):29–33

Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Bolis G. **Semin Oncol** 1995 Dec;22(6 Suppl 14):32–4

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Chang AY, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):74–7

Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Chang AY, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):19–21

Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. Creaven P, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):13–6

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)

Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Glantz MJ, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):26–32

Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Hanauske AR, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):35–9

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):50–4

Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Hoffman PC, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):11–5

Single-agent paclitaxel for the treatment of breast cancer: an overview. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb; 23(1 Suppl 1):4–9 (17 ref.)

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):18–23

Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Klaassen U, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):7–11

Intraperitoneal paclitaxel in the management of ovarian cancer. Markman M. **Semin Oncol** 1995 Oct;22(5 Suppl 12):86–7

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Meerpohl HG, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):7–12

A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study. Natale RB. **Semin Oncol** 1995 Dec;22(6 Suppl 15):34–7

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)

Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):78–83

Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 1):10–2 (9 ref.)

[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer] Sculier JP, et al. **Rev Mal Respir** 1995; 12(6):609–14 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel [letter] Ramanathan RK, et al. **Ann Intern Med** 1996 Jan 15;124(2):278

Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity [letter] van Herpen CM, et al. **Ann Oncol** 1995 Oct;6(8):852

Paclitaxel-induced cardiotoxicity. An ultrastructural study. Shek TW, et al. **Arch Pathol Lab Med** 1996 Jan; 120(1):89–91

Association of acquired Pelger-Huet anomaly with taxoid therapy. Juneja SK, et al. **Br J Haematol** 1996 Apr; 93(1):139–41

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin [letter; comment] Anand A, et al. **Cancer** 1995 Sep 1;76(5):916–7. Comment on: Cancer 1995 Mar 1;75(5):1141–50.

Infusion site soft-tissue injury after paclitaxel administration. Bicher A, et al. **Cancer** 1995 Jul 1;76(1):116–20

Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Dorr RT, et al. **Cancer** 1996 Jul 1;78(1):152–6

Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Schweitzer VG, et al. **Cancer** 1995 Sep 15;76(6):1069–72

Hypertensive reactions associated with paclitaxel. Solimando DA, et al. **Cancer Invest** 1996;14(4):340–2

Pulmonary infiltrates following administration of paclitaxel. Ramanathan RK, et al. **Chest** 1996 Jul;110(1):289–92

Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. du Bois A, et al. **Gynecol Oncol** 1996 Jan;60(1):94–6

The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gogas H, et al. **Gynecol Oncol** 1996 Apr;61(1):22–6

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Einzig AI, et al. **Invest New Drugs** 1995;13(3):223–7

Cutaneous manifestations of Taxol therapy. Link CJ Jr, et al. **Invest New Drugs** 1995;13(3):261–3

A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Swain SM, et al. **Invest New Drugs** 1995;13(3):217–22

Successful parenteral desensitization to paclitaxel. Essayan DM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):42–6

Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. Young PC, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):313–4

Paclitaxel hypersensitivity revisited [letter; comment] Essayan DM, et al. **J Clin Oncol** 1996 Mar;14(3):1042. Comment on: J Clin Oncol 1993 May;11(5):885–90. Comment on: J Clin Oncol 1993 Dec;11(12):2456–7.

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961–7

Safety profile of single-dose dexamethasone premedication for paclitaxel [letter] Parikh B, et al. **J Clin Oncol** 1996 Jul;14(7):2189–90

Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Reckzeh B, et al. **J Clin Oncol** 1996 Apr;14(4):1071–6

Paclitaxel premedication regimens [letter] Boehm DK, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):463–5

Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation [letter] Hidalgo M, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1320

Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region [letter] Liu JM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):1000–2

Severe neurotoxicity from vinorelbine-paclitaxel combinations [letter; comment] Parimoo D, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1079–80. Comment on: J Nati Cancer Inst 1995 Jul 19;87(14):1072–7.

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41-3 (4 ref.)
Paclitaxel-induced radiation recall dermatitis. McCarty MJ, et al. **Med Pediatr Oncol** 1996 Sep;27(3):185-6
Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681-2
Motor neuropathy due to docetaxel and paclitaxel. Freilich RJ, et al. **Neurology** 1996 Jul;47(1):115-8
Transient encephalopathy after paclitaxel (Taxol) infusion. Perry JR, et al. **Neurology** 1996 Jun;46(6):1596-9 (15 ref.)
Use caution when managing paclitaxel and taxotere infiltrations. Goodman M, et al. **Oncol Nurs Forum** 1996 Apr;23(3):541-2
Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. Payne JY, et al. **South Med J** 1996 May;89(5):542-5

ANALOGS & DERIVATIVES

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Fumoleau P, et al. **Ann Oncol** 1996 Feb;7(2):165-71
Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13-7 (23 ref.)
Docetaxel: a new defence in the management of breast cancer. Piccart M. **Anticancer Drugs** 1995 Jul;6 Suppl 4:7-11 (12 ref.)
Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Rougier P. **Anticancer Drugs** 1995 Jul;6 Suppl 4:25-9 (16 ref.)
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Verweij J. **Anticancer Drugs** 1995 Jul;6 Suppl 4:19-24
Interaction of a fluorescent paclitaxel analogue with tubulin. Sengupta S, et al. **Biochemistry** 1995 Sep 19; 34(37):11889-94
Fluorescent and biotinylated analogues of docetaxel: synthesis and biological evaluation. Dubois J, et al. **Bioorg Med Chem** 1995 Oct;3(10):1357-68
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Adachi I, et al. **Br J Cancer** 1996 Jan;73(2):210-6
Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours. Alder JD, et al. **Br J Cancer** 1996 Mar;73(5):560-4
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Dieras V, et al. **Br J Cancer** 1996 Aug;74(4):650-6
Association of acquired Pelger-Huet anomaly with taxoid therapy. Juneja SK, et al. **Br J Haematol** 1996 Apr; 93(1):139-41
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Battafarano DF, et al. **Cancer** 1995 Jul 1;76(1):110-5
Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Launay-Iliadis MC, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):47-54
A convenient tubulin-based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound Lin CM, et al. **Cancer Chemother Pharmacol** 1996;38(2):136-40
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Ma J, et al. **Cancer Chemother Pharmacol** 1996;37(4):382-4
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11-5 (21 ref.)
Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Hennequin C, et al. **Cancer Res** 1996 Apr 15;56(8):1842-50
Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Marre F, et al. **Cancer Res** 1996 Mar 15;56(6):1296-302
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Royer I, et al. **Cancer Res** 1996 Jan 1;56(1):58-65
Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185-207 (56 ref.)
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Pronk LC, et al. **Cancer Treat Rev** 1995 Sep;21(5):463-78 (93 ref.)
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075-92 (86 ref.)
Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro M, et al. **Eur J Cancer** 1995;31A Suppl 4:S7-10 (13 ref.)
Preclinical pharmacology of docetaxel. Bissery MC. **Eur J Cancer** 1995;31A Suppl 4:S1-6 (42 ref.)
An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eisenhauer EA, et al. **Eur J Cancer** 1995;31A Suppl 4:S11-3
Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Kaye SB, et al. **Eur J Cancer** 1995;31A Suppl 4:S14-7
Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Riccardi A, et al. **Eur J Cancer** 1995;31A(4):494-9
Docetaxel in stage III and IV non-small cell lung cancer. Rigas JR. **Eur J Cancer** 1995;31A Suppl 4:S18-20
Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Tanaka M, et al. **Eur J Cancer** 1996 Feb;32A(2):226-30
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Verweij J, et al. **Eur J Cancer** 1995;31A Suppl 4:S21-4
Effect of microtubule network disturbance by nocodazole and docetaxel (Taxotere) on protein secretion in rat extraorbital lacrimal and parotid glands. Robin P, et al. **Eur J Cell Biol** 1995 Jul;67(3):227-37
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Dykes DJ, et al. **Invest New Drugs** 1995;13(1):1-11
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy [see comments] Bedikian AY, et al. **J Clin Oncol** 1995 Dec;13(12):2895-9. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.
Docetaxel. Cortes JE, et al. **J Clin Oncol** 1995 Oct; 13(10):2643-55 (104 ref.)
Docetaxel: an active drug for squamous cell carcinoma of the head and neck. Dreyfuss AI, et al. **J Clin Oncol** 1996 May;14(5):1672-8
Docetaxel: current status and future prospects [editorial; comment] Eisenhauer E. **J Clin Oncol** 1995 Dec; 13(12):2865-8. Comment on: J Clin Oncol 1995 Dec;13(12):2879-85. Comment on: J Clin Oncol 1995 Dec;13(12):2886-94. Comment on: J Clin Oncol 1995 Dec;13(12):2895-9.
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. Hudis CA, et al. **J Clin Oncol** 1996 Jan;14(1):58-65
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. Kunitoh H, et al. **J Clin Oncol** 1996 May;14(5):1649-55
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer [see comments] Ravdin PM, et al. **J Clin Oncol** 1995 Dec;13(12):2879-85. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1996 Jun;14(6):1877-84
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. Trudeau ME, et al. **J Clin Oncol** 1996 Feb; 14(2):422-8
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer [see comments] Valero V, et al. **J Clin Oncol** 1995 Dec; 13(12):2886-94. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.
Novel cytotoxic 3'-(tert-butyl) 3'-dephenyl analogs of paclitaxel and docetaxel. Ali SM, et al. **J Med Chem** 1995 Sep 15;38(19):3821-8
Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. Greenwald RB, et al. **J Med Chem** 1996 Jan 19;39(2):424-31
A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Ojima I, et al. **J Med Chem** 1995 Sep 29;38(20):3891-4
NMR and molecular modeling study of the conformations of taxol 2'-acetate in chloroform and aqueous dimethyl sulfoxide solutions. Williams HJ, et al. **J Med Chem** 1996 Mar 29;39(7):1555-9
Two new taxoids from the stem bark of Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Dec;58(12):1906-12
Immunoenzymatic methods applied to the search for bioactive taxoids from Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Jul;58(7):1015-23
Typhlitis associated with docetaxel treatment [letter] Cardenal F, et al. **J Natl Cancer Inst** 1996 Aug 7; 88(15):1078-9
Response to dexamethasone in patients with fluid retention after docetaxel [letter] Chan S, et al. **Lancet** 1996 May 25; 347(9013):1486-7
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163-72 (40 ref.)
Docetaxel neuropathy [editorial; comment] Apfel SC. **Neurology** 1996 Jan;46(1):2-3. Comment on: Neurology 1996 Jan;46(1):104-8. Comment on: Neurology 1996 Jan;46(1):108-11.
Motor neuropathy due to docetaxel and paclitaxel. Freilich RJ, et al. **Neurology** 1996 Jul;47(1):115-8
Peripheral neurotoxicity induced by docetaxel [see comments] Hilkens PH, et al. **Neurology** 1996 Jan; 46(1):104-8. Comment in: Neurology 1996 Jan;46(1):2-3.
Peripheral neuropathy secondary to docetaxel (Taxotere) [see comments] New PZ, et al. **Neurology** 1996 Jan;46(1):108-11 . Comment in: Neurology 1996 Jan;46(1):2-3.
Use caution when managing paclitaxel and taxotere infiltrations. Goodman M, et al. **Oncol Nurs Forum** 1996 Apr;23(3):541-2
A new large-scale process for taxol and related taxanes from Taxus brevifolia. Rao KV, et al. **Pharm Res** 1995 Jul; 12(7):1003-10
Rearranged taxoids from Taxus yunnanensis [letter] Yue Q, et al. **Planta Med** 1995 Aug;61(4):375-7
Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Bissery MC, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 13):3-16
Docetaxel (Taxotere) in combination: a step forward. Burris HA 3rd, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 13):35-40
The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68-75 (62 ref.)
Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29-34 (34 ref.)
Docetaxel (Taxotere): an overview of first-line monotherapy. Trudeau ME. **Semin Oncol** 1995 Dec;22(6 Suppl 13):17-21
Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. van Oosterom AT. **Semin Oncol** 1995 Dec;22(6 Suppl 13):22-8
[Taxans in the treatment of ovarian cancer] Tuxen MK, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3951-2 **(Dan)**
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials] Couteau C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):3-10 (Eng. Abstr.) **(Fre)**
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629-36 (58 ref.) (Eng. Abstr.) **(Fre)**
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group] Yoneda S, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):695-701 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Taxane-specific monoclonal antibodies: measurement of taxol, baccatin III, and "total taxanes" in Taxus brevifolia extracts by enzyme immunoassay. Grothaus PG, et al. **J Nat Prod** 1995 Jul;58(7):1003-14
Rapid screening of taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Poon GK, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1165-8

ANTAGONISTS & INHIBITORS

pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Bhalla K, et al. **Leukemia** 1995 Nov;9(11):1851-6

BIOSYNTHESIS

Purification and characterization of taxa-4(5),11(12)-diene synthase from Pacific yew (Taxus brevifolia) that catalyzes the first committed step of taxol biosynthesis. Hezari M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):437-44
Mechanism of taxadiene synthase, a diterpene cyclase that catalyzes the first step of taxol biosynthesis in Pacific yew. Lin X, et al. **Biochemistry** 1996 Mar 5;35(9):2968-77
Tissue cultures of Taxus baccata as a source of 10-deacetylbaccatin III, a precursor for the hemisynthesis of taxol. Zhiri A, et al. **Biol Chem Hoppe Seyler** 1995 Oct; 376(10):583-6
A cDNA clone for taxadiene synthase, the diterpene cyclase that catalyzes the committed step of taxol biosynthesis. Wildung MR, et al. **J Biol Chem** 1996 Apr 19; 271(16):9201-4
The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew, Taxus brevifolia. Stierle A, et al. **J Nat Prod** 1995 Sep;58(9):1315-24
Endophytic taxol-producing fungi from bald cypress, Taxodium distichum. Li JY, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2223-6
Studies on the biosynthesis of taxol: the taxane carbon skeleton is not of mevalonoid origin. Eisenreich W, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6431-6

BLOOD

Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. el-Yazigi A, et al. **Ther Drug Monit** 1995 Oct;17(5):511-5

CHEMISTRY

A convenient tubulin-based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound Lin CM, et al. **Cancer Chemother Pharmacol** 1996;38(2):136-40
Immunoenzymatic methods applied to the search for bioactive taxoids from Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Jul;58(7):1015-23
Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. Sharma US, et al.

J Pharm Sci 1995 Oct;84(10):1223–30

Paclitaxel partitioning into lipid bilayers. Wenk MR, et al. **J Pharm Sci** 1996 Feb;85(2):228–31

Development of a polymeric surgical paste formulation for taxol. Winternitz CI, et al. **Pharm Res** 1996 Mar; 13(3):368–75

ISOLATION & PURIFICATION

A new large-scale process for taxol and related taxanes from Taxus brevifolia. Rao KV, et al. **Pharm Res** 1995 Jul; 12(7):1003–10

Cover illustration—regional sources of natural products: Taxomyces andreanae. Huxtable RJ. **Proc West Pharmacol Soc** 1995;38:1–4

METABOLISM

Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells. Evidence for an alternate transport system. Parekh H, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):301–11

Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Royer I, et al. **Cancer Res** 1996 Jan 1;56(1):58–65

The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Senter PD, et al. **Cancer Res** 1996 Apr 1;56(7):1471–4

Dexamethasone induction of taxol metabolism in the rat. Anderson CD, et al. **Drug Metab Dispos** 1995 Nov; 23(11):1286–90

A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Ojima I, et al. **J Med Chem** 1995 Sep 29;38(20):3891–4

Preparation of phenolic paclitaxel metabolites. Park H, et al. **J Med Chem** 1996 Jul 5;39(14):2705–9

Variability in human cytochrome P450 paclitaxel metabolism. Sonnichsen DS, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):566–75

PHARMACOKINETICS

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Huizing MT, et al. **Ann Oncol** 1995 Sep;6(7):699–704

The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Lesser GJ, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):173–8

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Sparreboom A, et al. **Cancer Res** 1996 May 1;56(9):2112–5

Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Innocenti F, et al. **Drug Metab Dispos** 1995 Jul;23(7):713–7

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. Tolcher AW, et al. **J Clin Oncol** 1996 Apr;14(4):1173–84

Does paclitaxel penetrate into brain tumor tissue? [letter] Heimans JJ, et al. **J Natl Cancer Inst** 1995 Dec 6; 87(23):1804–5

Pharmacokinetics of paclitaxel and carboplatin in combination. Kearns CM, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):1–4; discussion 5–7

PHARMACOLOGY

Effects of Taxol on choriocarcinoma cells. Marth C, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1835–42

Apoptosis susceptibility of human carcinoma and leukemia cell lines to taxol. Relationship with cell cycle and drug concentration. Gangemi RM, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:550–4

Effects of taxol on TNF-alpha and IL-6 production by human peripheral blood cells. Losi E, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:525–8

Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Decorti G, et al. **Anticancer Res** 1996 Jan-Feb;16(1):317–20

Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue. Matsuoka H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2001–6

Endometrial cancer cell lines are sensitive to paclitaxel. Rantanen V, et al. **Anticancer Res** 1996 Jan-Feb;16(1):475–9

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):687–94 (36 ref.)

Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. ter Haar E, et al. **Biochemistry** 1996 Jan 9;35(1):243–50

Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Gately DP, et al. **Br J Cancer** 1996 Jan; 73(1):18–23

Taxol stabilizes [Ca2+]i and protects hippocampal neurons against excitotoxicity. Furukawa K, et al. **Brain Res** 1995 Aug 14;689(1):141–6

Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Taniki T, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):295–302

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Ma J, et al. **Cancer Chemother Pharmacol** 1996;37(4):382–4

Tubercidin stabilizes microtubules against vinblastine-induced depolymerization, a taxol-like effect. Mooberry SL, et al. **Cancer Lett** 1995 Sep 25;96(2):261–6

Taxol induction of p21WAF1 and p53 requires c-raf-1. Blagosklonny MV, et al. **Cancer Res** 1995 Oct 15; 55(20):4623–6

Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Dumontet C, et al. **Cancer Res** 1996 Mar 1;56(5):1091–7

Pharmacodynamics of taxol in human head and neck tumors. Gan Y, et al. **Cancer Res** 1996 May 1;56(9):2086–93

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253–5

Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Le Moyec L, et al. **Cancer Res** 1996 Aug 1;56(15):3461–7

Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Lee LF, et al. **Cancer Res** 1996 Mar 15;56(6):1303–8

Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Tishler RB, et al. **Cancer Res** 1995 Dec 15;55(24):6021–5

The secretion of urokinase-like plasminogen activator is inhibited by microtubule-interacting drugs. Santibañez JF, et al. **Cell Biochem Funct** 1995 Sep;13(3):217–25

How does taxol stabilize microtubules? Arnal I, et al. **Curr Biol** 1995 Aug 1;5(8):900–8

Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Riccardi A, et al. **Eur J Cancer** 1995;31A(4):494–9

Sinefungin and taxol effects on cell cycle and cytoskeleton of Leishmania donovani promastigotes. Moulay L, et al. **Exp Cell Res** 1996 Aug 1;226(2):283–91

Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene [see comments] Hanania EG, et al. **Gene Ther** 1995 Jun;2(4):285–94. Comment in: Gene Ther 1995 Jun;2(4):233–4.

Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines. Erlich E, et al. **Gynecol Oncol** 1996 Feb;60(2):251–4

Microtubule-disrupting agents inhibit nitric oxide production in murine peritoneal macrophages stimulated with lipopolysaccharide or paclitaxel (Taxol). Kirikae T, et al. **Infect Immun** 1996 Aug;64(8):3379–84

Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages. Perera PY, et al. **Infect Immun** 1996 Mar;64(3):878–84

Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Nishio K, et al. **Int J Cancer** 1995 Nov 27;63(5):688–93

Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. Puente J, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):457–61

Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. van Rijn J, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):635–9

No increased risk of Taxol toxicity in older patients [letter] Lichtman SM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):472–4

Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site. Gately DP, et al. **J Biol Chem** 1996 Aug 23; 271(34):20588–93

Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. Haber M, et al. **J Biol Chem** 1995 Dec 29;270(52):31269–75

Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. Pulkkinen JO, et al. **J Cancer Res Clin Oncol** 1996;122(4):214–8

RAW264 macrophages stably transfected with an HIV-1 LTR reporter gene provide a sensitive bioassay for analysis of signalling pathways in macrophages stimulated with lipopolysaccharide, TNF-alpha or taxol. Sweet MJ, et al. **J Inflamm** 1995;45(2):126–35

Microtubule-active agents mimic lipopolysaccharides in priming macrophages for enhanced arachidonic acid metabolism. Veis N, et al. **J Inflamm** 1996;46(2):106–13

Bacterial lipopolysaccharide confers resistance to G418, doxorubicin, and taxol in the murine macrophage cell line, RAW264. Sweet MJ, et al. **J Leukoc Biol** 1996 Feb; 59(2):280–6

Novel cytotoxic 3'-(tert-butyl) 3'-dephenyl analogs of paclitaxel and docetaxel. Ali SM, et al. **J Med Chem** 1995 Sep 15;38(19):3821–8

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. Greenwald RB, et al. **J Med Chem** 1996 Jan 19;39(2):424–31

Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. Milross CG, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1308–14

Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. Sharma US, et al. **J Pharm Sci** 1995 Oct;84(10):1223–30

LPS and Taxol activate Lyn kinase autophosphorylation in Lps(n), but not in Lpsd), macrophages. Henricson BE, et al. **Mol Med** 1995 May;1(4):428–35

Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Woods CM, et al. **Mol Med** 1995 Jul;1(5):506–26

p53 activity and chemotherapy [letter; comment] Delia D, et al. **Nat Med** 1996 Jul;2(7):724–5. Comment on: Nat Med 1996 Jan;2(1):72–9.

Effects of nocodazole and taxol on glycine evoked currents on rat spinal cord neurones in culture. Delon J, et al. **Neuroreport** 1995 Oct 2;6(14):1932–6

The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Cameron MR, et al. **Oncol Res** 1995;7(3-4):145–56

[Modification of the response to paclitaxel of human differentiated colon cancer line after long-term treatment at very low dose] Carles G, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):135–8 (Eng. Abstr.) **(Fre)**

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**

THERAPEUTIC USE

Taxol is active in platinum-resistant endometrial adenocarcinoma. Woo HL, et al. **Am J Clin Oncol** 1996 Jun;19(3):290–1

Study affirms primacy of paclitaxel-cisplatin in advanced ovarian cancer [news] **Am J Health Syst Pharm** 1996 Mar 1;53(5):498

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Alberola V, et al. **Ann Oncol** 1995;6 Suppl 3:S49–52

Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Phillips KA, et al. **Aust N Z J Med** 1995 Aug;25(4):337–43

Microtubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity. Hirose Y, et al. **Blood Cells Mol Dis** 1995; 21(2):119–30

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Gore ME, et al. **Br J Cancer** 1995 Oct;72(4):1016–9

Taxol inhibits osteoclastic bone resorption. Hall TJ, et al. **Calcif Tissue Int** 1995 Dec;57(6):463–5

A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Balcerzak SP, et al. **Cancer** 1995 Dec 1;76(11):2248–52

Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Chang YF, et al. **Cancer** 1996 Jan 1;77(1):14–8

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Davelaar EM, et al. **Cancer** 1996 Jul 1; 78(1):118–27

Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Freilich RJ, et al. **Cancer** 1995 Jul 15;76(2):232–6

Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Hainsworth JD, et al. **Cancer** 1996 Jun 15;77(12):2458–63

In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines. Jaakkola M, et al. **Cancer** 1996 May 1;77(9):1940–6

Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Patel SR, et al. **Cancer** 1996 Aug 15;78(4):741–4

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11–5 (21 ref.)

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Dantzig AH, et al. **Cancer Res** 1996 Sep 15; 56(18):4171–9

Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185–207 (56 ref.)

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Fountzilas G, et al. **Eur J Cancer** 1996 Jan;32A(1):47–51

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Klaassen U, et al. **Eur J Cancer** 1996 Mar; 32A(3):547–9

A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Balat O, et al. **Eur J Gynaecol Oncol** 1996; 17(3):232–3

Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy—response to paclitaxel treatment. Case report. Hornreich G, et al. **Eur J Gynaecol Oncol** 1995;16(4):263–7

Absence of an association between G-CSF support and clinical response in heavily pre-treated ovarian cancer patients receiving salvage chemotherapy with paclitaxel (Taxol). Johnston CM, et al. **Eur J Gynaecol Oncol** 1995; 16(4):251–7

Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Tresukosol D, et al. **Eur J Gynaecol Oncol** 1996;17(3):188–91

Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit [see comments] [published erratum appears in Gene Ther 1995 Aug;2(6):433] Hanania EG, et al. **Gene Ther** 1995 Jun;2(4):279–84. Comment in: Gene Ther 1995 Jun;2(4):233–4.

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Ball HG, et al. **Gynecol Oncol** 1996 Aug;62(2):278–81

Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Jones WB, et al. **Gynecol Oncol** 1996 Apr;61(1):126–30

Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice. Stearns ME. **Invasion Metastasis** 1995;15(5–6):232–41

Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(2):71–3

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961–7

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Jones DV Jr, et al. **J Clin Oncol** 1996 Aug;14(8):2306–10

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. McGuire WP, et al. **J Clin Oncol** 1996 Mar;14(3):792–5

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Markman M, et al. **J Clin Oncol** 1996 Mar; 14(3):796–9

Phase II study of paclitaxel in patients with recurrent malignant glioma. Prados MD, et al. **J Clin Oncol** 1996 Aug;14(8):2316–21

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. Sarris AH, et al. **J Clin Oncol** 1996 Jan; 14(1):233–9

The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. Kalechman Y, et al. **J Immunol** 1996 Feb 1;156(3):1101–9

Taxol plus radiation for head and neck cancer. Rosenthal DI, et al. **J Infus Chemother** 1995 Spring;5(2):46–54 (99 ref.)

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240–5 (26 ref.)

Paclitaxel in doxorubicin-resistant metastatic breast cancer patients [letter; comment] Anand A, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1642. Comment on: J Natl Cancer Inst 1995 Aug 2;87(15):1169–75.

Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Tamura T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1203–9

Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Seiter K, et al. **Leukemia** 1995 Nov;9(11):1961–6

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163–72 (40 ref.)

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Gatzemeier U, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S101–6

Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681–2

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Bruzzone M, et al. **Oncology** 1996 Sep–Oct;53(5):349–53

Paclitaxel: a unique tubulin interacting anticancer agent. Vyas DM, et al. **Prog Med Chem** 1995;32:289–337 (301 ref.)

Taxoids: new weapons against cancer. Nicolaou KC, et al. **Sci Am** 1996 Jun;274(6):94–8

The activity of paclitaxel in gastrointestinal tumors. Ajani JA, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):46–50; discussion 51–3

Paclitaxel: current developmental approaches of the National Cancer Institute. Arbuck SG. **Semin Oncol** 1995 Dec;22(6 Suppl 15):55–63

Future developments for paclitaxel in the treatment of breast cancer. Bonadonna G. **Semin Oncol** 1996 Feb;23(1 Suppl 1):65–8

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68–75 (62 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer. Davidson NG. **Semin Oncol** 1995 Dec;22(6 Suppl 14):2–6

Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Gatzemeier U, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):24–8

Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Hainsworth JD, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):45–9

Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Havemann K, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):19–22

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Paine GD, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):35–9

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29–34 (34 ref.)

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Rosell R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):12–8

The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33–40 (73 ref.)

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)

The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23–31 (30 ref.)

The role of paclitaxel in the treatment of head and neck cancer. Vokes EE, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):8–12 (27 ref.)

[Taxans in the treatment of ovarian cancer] Tuxen MK, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3951–2 **(Dan)**

[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**

[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629–36 (58 ref.) (Eng. Abstr.) **(Fre)**

[Preclinical and clinical results in the simultaneous radiochemotherapy of head and neck tumors with Paclitaxel] Hoffmann W, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:15–20 **(Ger)**

[Taxol and simultaneous radiotherapy in stage IIIA and IIIB, locally advanced, non-small-cell bronchial carcinoma. Phase-I clinical trial] Vogt HG, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:9–15 **(Ger)**

[Paclitaxel and simultaneous radiotherapy in stage-III non-small-cell bronchial carcinoma] Wolf M, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:5–8 **(Ger)**

[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**

[Use of taxol in the management of malignant tumors] Eckhardt S. **Orv Hetil** 1995 Sep 10;136(37):1987–93 (85 ref.) (Eng. Abstr.) **(Hun)**

[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] Noda K, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):317–25 (Eng. Abstr.) **(Jpn)**

TOXICITY

Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Engblom P, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1743–7

Influence of various concentrations of taxol on cell survival, micronuclei induction, and LDH activity in cultured V79 cells. Jagetia GC, et al. **Cancer Lett** 1995 Sep 25; 96(2):195–200

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, et al. **Cancer Res** 1996 Apr 15;56(8):1851–4

Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Hennequin C, et al. **Cancer Res** 1996 Apr 15;56(8):1842–50

Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Jordan MA, et al. **Cancer Res** 1996 Feb 15;56(4):816–25

Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. Boer HH, et al. **J Neurooncol** 1995;25(1):49–57

Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Akerley W, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S107–15

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Gatzemeier U, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S101–6

Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Klastersky J, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S117–25

Treatment of mice with a novel antineoplastic agent taxol before irradiation increases the frequency of micronuclei in the bone marrow. Jagetia GC, et al. **Mutat Res** 1996 Feb 1;349(2):219–27

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [see comments] Wahl AF, et al. **Nat Med** 1996 Jan;2(1):72–9. Comment in: Nat Med 1996 Jul;2(7):724–5.

Embryotoxicity of free and liposome-encapsulated taxol in the chick. Scialli AR, et al. **Pharmacology** 1995 Sep; 51(3):145–51

PACS (RADIOLOGY) see RADIOLOGY INFORMATION SYSTEMS

PADUTIN see KALLIKREIN

PAECILOMYCES

Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)

Paecilomyces varioti fungemia in a bone marrow transplant patient. Shing MM, et al. **Bone Marrow Transplant** 1996 Feb;17(2):281–3

Paecilomyces variotii contamination in the lumen of a saline-filled breast implant. Young VL, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1430–4

ISOLATION & PURIFICATION

Volatile metabolites produced by two fungal species cultivated on building materials. Sunesson AL, et al. **Ann Occup Hyg** 1996 Aug;40(4):397–410

A canine case of profound granulomatosis due to Paecillomyces fungus. Nakagawa Y, et al. **J Vet Med Sci** 1996 Feb;58(2):157–9

PHYSIOLOGY

Long-term maintenance of lyophilized fungal cultures of the genera Epidermophyton, Microsporum, Paecilomyces and Trichophyton. Rybníkář A. **Mycoses** 1995 Mar–Apr; 38(3–4):145–7

PAF-ACETHER see PLATELET ACTIVATING FACTOR

PAGET'S DISEASE, EXTRAMAMMARY

COMPLICATIONS

Paget's disease of the scrotum: report of a case with underlying carcinoma of the prostate. Koh KB, et al. **Br J Dermatol** 1995 Aug;133(2):306–7

DIAGNOSIS

Depigmented macula as an initial manifestation of extramammary Paget's disease [letter] Sawamura D, et al. **J Dermatol** 1996 Jun;23(6):429–30

[Paget disease of the vulva] Broso PR, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):45–7 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Paget's disease. Kürzl RG. **Semin Dermatol** 1996 Mar; 15(1):60–6 (62 ref.)

GENETICS

Flow cytometric DNA analysis of extramammary Paget's disease of the vulva. Cotton J, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):324–30

PATHOLOGY

Gross cystic disease fluid protein-15 reactivity in extramammary Paget's disease with and without associated internal malignancy. Kohler S, et al. **Am J Dermatopathol** 1996 Apr;18(2):118–23

Extramammary Paget's disease: a report of three cases and review of the literature. Png JC, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):636–9 (30 ref.)

Perianal Paget's disease: a case report [letter] Handberg J, et al. **Ann Oncol** 1995 Oct;6(8):851–2

Ectopic extramammary Paget's disease affecting the upper abdomen. Onishi Y, et al. **Br J Dermatol** 1996 May; 134(5):958–61 (18 ref.)

The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)

Paget's sarcoma of the mandible. Gleich LL, et al. **Head Neck** 1995 Sep–Oct;17(5):425–30 (20 ref.)

Pagetoid spread into the rete testis by intratubular germ cell neoplasia in an undescended testis [letter] Hasan NA, et al. **Histopathology** 1995 Oct;27(4):391–2

Triple cancers involving extramammary Paget's disease. Toyama K, et al. **Int J Dermatol** 1995 Oct;34(10):715–6

Flow cytometric DNA analysis of extramammary Paget's disease of the vulva. Cotton J, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):324–30

Extramammary Paget's disease: a report of 22 cases in Chinese males. Chang YT, et al. **J Dermatol** 1996 May; 23(5):320–4

Extramammary Paget's disease with distant skin metastasis. Kato N, et al. **J Dermatol** 1996 Jun;23(6):408–14

RADIOTHERAPY

Treatment of extramammary Paget's disease [letter] El-Sharkawi AM. **Br J Dermatol** 1996 Jun;134(6):1154

Perineal Paget's disease: effective treatment with fractionated high dose rate brachytherapy. Kwan WH, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):400–1

PAGET'S DISEASE, EXTRAMAMMARY

SECONDARY

Extramammary Paget's disease with distant skin metastasis. Kato N, et al. **J Dermatol** 1996 Jun;23(6):408–14

SURGERY

Extramammary Paget's disease requiring scrotectomy and scrotal reconstruction. Peters KM, et al. **Br J Urol** 1996 May;77(5):758–60

Reconstruction with bilateral gluteus maximus myocutaneous rotation flap after wide local excision for perianal extramammary Paget's disease. Report of two cases. Murakami K, et al. **Dis Colon Rectum** 1996 Feb; 39(2):227–31

Vertical subcutaneous pedicle flaps for posterior perineal reconstruction. Report of three cases. Ricchi E, et al. **Dis Colon Rectum** 1996 Mar;39(3):353–7

Internal pudendal flap anoplasty for severe anal stenosis. Report of a case. Saldana E, et al. **Dis Colon Rectum** 1996 Mar;39(3):350–2

PAGET'S DISEASE, MAMMARY

Paget's disease of the nipple–areola complex. Jamali FR, et al. **Surg Clin North Am** 1996 Apr;76(2):365–81 (82 ref.)

CHEMISTRY

[Expression of the c–erbB–2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies] Edorh A, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):584–9 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Paget's disease of breast—a special form of breast cancer] Palade R, et al. **Chirurgia (Bucur)** 1995;44(4):21–7 (Eng. Abstr.) **(Rum)**

HISTORY

Geriatrics photo quiz. Paget's disease: skeletal deformity with or without pain. Gross JS, et al. **Geriatrics** 1996 Jun; 51(6):19, 50

PATHOLOGY

Mammary Paget's disease confined to the areola and associated with multifocal Toker cell hyperplasia. van der Putte SC, et al. **Am J Dermatopathol** 1995 Oct;17(5):487–93

An electron microscopic study of clinical Paget's disease of the nipple. Jahn H, et al. **APMIS** 1995 Sep;103(9):628–34

Paget's disease [letter; comment] Kuo TT. **J Cutan Pathol** 1995 Apr;22(2):191. Comment on: J Cutan Pathol 1994 Jun;21(3):283–6.

Gynecomastia with unusual intraductal "clear cell" changes mimicking pagetoid ductal spread of lobular neoplasia. Guillou L, et al. **Pathol Res Pract** 1995 Mar;191(2):156–63; discussion 164–5

RADIOGRAPHY

Is ipsilateral mammography worthwhile in Paget's disease of the breast? Ceccherini AF, et al. **Clin Radiol** 1996 Jan; 51(1):35–8

THERAPY

Two cases of breast cancer in young women. **Eur J Surg Oncol** 1996 Feb;22(1):108–13

PAGET'S DISEASE OF BONE see **OSTEITIS DEFORMANS**

PAGET'S DISEASE OF BREAST see **PAGET'S DISEASE, MAMMARY**

PAH see **P-AMINOHIPPURIC ACID**

PAHO see **PAN AMERICAN HEALTH ORGANIZATION**

PAI-1 see **PLASMINOGEN ACTIVATOR INHIBITOR 1**

PAI-2 see **PLASMINOGEN ACTIVATOR INHIBITOR 2**

PAI-3 see **PROTEIN C INHIBITOR**

PAIN

see related
ANALGESIA
ANALGESICS
HYPERALGESIA
PAIN INSENSITIVITY, CONGENITAL
PALLIATIVE CARE

Infiltration pain and local anesthetic effects of buffered vs plain 1% diphenhydramine. Singer AJ, et al. **Acad Emerg Med** 1995 Oct;2(10):884–8

Usefulness of a clinical scoring system to anticipate difficulty of Norplant removal. Blumenthal PD, et al. **Adv Contracept** 1995 Dec;11(4):345–52

Do neonates feel pain? Bell SG. **Am J Nurs** 1995 Oct; 95(10):28

Current research on chronic pain and suicide [letter] Fishbain DA. **Am J Public Health** 1996 Sep;86(9):1320–1

Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424–6 (26 ref.)

Pediatric pain control. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):466–70 (17 ref.)

Prehospital pain research. Yealy DM. **Ann Emerg Med** 1996 Apr;27(4):471–3 (14 ref.)

A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. Munro AJ, et al. **Br J Cancer** 1996 Aug;74(4):640–7

Metabolic effects of pamidronate in patients with metastatic bone disease. Vinholes J, et al. **Br J Cancer** 1996 May; 73(9):1089–95

Pain assessment: a pilot study in an Israeli bone marrow transplant unit. Ben David Y, et al. **Cancer Nurs** 1996 Apr; 19(2):93–7

Minimizing the pain of office procedures in children. Rothman KF. **Curr Opin Pediatr** 1995 Aug;7(4):415–22 (17 ref.)

No difference in cardiac innervation of diabetic patients with painful and asymptomatic coronary artery disease. Koistinen MJ, et al. **Diabetes Care** 1996 Mar;19(3):231–3

2nd meeting, Neuroscience and Pain and 4th Pavia symposium of clinical neurophysiology, Neurophysiology of Pain. Pavia, November 4–5, 1994. Abstracts. **Funct Neurol** 1995 Jul–Oct;10(4–5):217–45

Persistent cardiovascular and behavioral nociceptive responses to subcutaneous formalin require peripheral nerve input. Taylor BK, et al. **J Neurosci** 1995 Nov; 15(11):7575–84

What do nurses know and believe about patients with pain? Results of a hospital survey. Brunier G, et al. **J Pain Symptom Manage** 1995 Aug;10(6):436–45

The management of pain in patients with advanced cancer: the importance of multidimensional assessments. Robinson K, et al. **J Palliat Care** 1995 Winter;11(4):51–3

Total coccygectomy for the relief of coccygodynia: a retrospective review. Grosso NP, et al. **J Spinal Disord** 1995 Aug;8(4):328–30

Kinematic and dynamic axial computed tomography of the patello–femoral joint in patients with anterior knee pain. Pinar H, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):170–3

Dmt–Tic–OH a highly selective and potent delta–opioid dipeptide receptor antagonist after systemic administration in the mouse. Capasso A, et al. **Life Sci** 1996;59(8):PL93–8

A Gi2alpha antisense oligonucleotide differentiates morphine antinociception, constipation and acute dependence in mice. Raffa RB, et al. **Life Sci** 1996;58(5):PL 73–6

Alpha–subunit G–protein antisense oligodeoxynucleotide effects on supraspinal (i.c.v.) alpha2–adrenoceptor antinociception in mice. Raffa RB, et al. **Life Sci** 1996; 58(5):PL 77–80

Effects of beraprost sodium, a prostacyclin analogue, on tail flick response in two models of diabetic–neuropathy in rats and its mechanism. Ueno Y, et al. **Life Sci** 1996; 59(9):PL105–10

Chronic pelvic pain. Lipscomb GH, et al. **Med Clin North Am** 1995 Nov;79(6):1411–25 (30 ref.)

Networks for pain [letter; comment] Stowell H. **Nat Med** 1995 Oct;1(10):976. Comment on: Nat Med 1995 Aug;1(8):740–1.

Pain pathways [letter; comment] Huxley A. **Nature** 1995 Dec 14;378(6558):658. Comment on: Nature 1995 Oct 5;377(6548):428–31. Comment on: Nature 1995 Oct 5;377(6548):432–5.

Painful connection for ATP [news; comment] Kennedy C, et al. **Nature** 1995 Oct 5;377(6548):385–6. Comment on: Nature 1995 Oct 5;377(6548):428–31. Comment on: Nature 1995 Oct 5;377(6548):432–5.

A Japanese boy with myalgia and cramps has a novel in–frame deletion of the dystrophin gene. Ishigaki C, et al. **Neurology** 1996 May;46(5):1347–50

Cutaneous localisation of laser induced pain in humans. Moore CE, et al. **Neurosci Lett** 1995 Jul 7;193(3):208–10

Ontogeny of nociception and antinociception. Barr GA. **NIDA Res Monogr** 1995;158:172–201 (56 ref.)

The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)

Ethical guidelines for pain research in humans. Committee on Ethical Issues of the International Association for the Study of Pain. [editorial] Charlton E. **Pain** 1995 Dec; 63(3):277–8

Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Hsieh JC, et al. **Pain** 1995 Nov;63(2):225–36

Chronic testicular pain. A workup and treatment guide for the primary care physician. Baum N, et al. **Postgrad Med** 1995 Oct;98(4):151–3, 156–8 (16 ref.)

The economics of pain. Mental health care costs among minorities. Ruiz P, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):659–70 (23 ref.)

Perimenstrual depression: its relationship to pain, bleeding, and previous history of depression. Bancroft J, et al. **Psychosom Med** 1995 Sep–Oct;57(5):445–52

Depressive symptoms associated with symptoms of the temporomandibular joint pain and dysfunction syndrome. Vimpari SS, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):439–44

Rasch analysis of Visual Analog Scale measurements before and after treatment of Patellofemoral Pain Syndrome in women. Thomeé R, et al. **Scand J Rehabil Med** 1995 Sep; 27(3):145–51

Visually evoked hyperpathia due to thalamic hemorrhage: a variant of Déjerine–Roussy syndrome [letter] Kumral E, et al. **Stroke** 1996 Apr;27(4):774–5

[Pelvic pain and pregnancy] Engelen MJ, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1961–4 **(Dut)**

[Pelvic pain caused by pregnancy; a new disease?] Mens JM. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1964–6 (11 ref.) **(Dut)**

[Pain in hospitalized children] Foussat C, et al. **Arch Pediatr** 1995 Nov;2(11):1097–100 (14 ref.) (Eng. Abstr.) **(Fre)**

[Clinical examination of the shoulder and diagnostic maneuvers] Hallez R, et al. **Rev Med Brux** 1995 Jul–Aug; 16(4):164–7 (4 ref.) (Eng. Abstr.) **(Fre)**

[What is your diagnosis? Proctalgia fugax] Landolt M, et al. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1087–8 **(Ger)**

[Chronic pain—a field to concentrate on] Gramstad L. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):472 **(Nor)**

[Patients with cancer–related pain and other chronic pain. Priorities and assessment] Skauge M, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):473–7 (Eng. Abstr.) **(Nor)**

[Current aspects of nociceptive transmission: peripheral mechanisms and spinal modulation] Baños–Díez JE, et al. **Rev Neurol** 1996 Jul;24(131):769–78 (Eng. Abstr.) **(Spa)**

[Pain—an event in the internal lanscape] Tibblin G. **Lakartidningen** 1996 Aug 28;93(35):2959–60 **(Swe)**

CEREBROSPINAL FLUID

Cerebrospinal fluid norepinephrine and acetylcholine concentrations during acute pain. Eisenach JC, et al. **Anesth Analg** 1996 Mar;82(3):621–6

CHEMICALLY INDUCED

Bicarbonate buffering of local anesthetics [letter] Schwab RA, et al. **Am J Emerg Med** 1996 May;14(3):339

Transient radicular irritation after single subarachnoid injection of isobaric 2% lignocaine for spinal anaesthesia [see comments] Hampl KF, et al. **Anaesthesia** 1996 Feb; 51(2):178–81. Comment in: Anaesthesia 1996 Jun;51(6):608–9.

Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine. Salmela L, et al. **Anaesthesia** 1996 Apr;51(4):391–3

The effect of carrier intravenous fluid speed on the injection pain of propofol [see comments] Huang CL, et al. **Anesth Analg** 1995 Nov;81(5):1087–8. Comment in: Anesth Analg 1996 May;82(5):1111.

Reducing the pain on injection of propofol [letter] Nathanson MH, et al. **Anesth Analg** 1996 Jun;82(6):1307–8

Intrathecal hyperbaric 0.5% tetracaine as a possible cause of transient neurologic toxicity. Sumi M, et al. **Anesth Analg** 1996 May;82(5):1076–7

Involvement of glutamate receptors in strychnine– and bicuculline–induced allodynia in conscious mice. Onaka M, et al. **Anesthesiology** 1996 May;84(5):1215–22

Heated lidocaine [letter; comment] Kapur A. **Ann Emerg Med** 1996 Jul;28(1):104. Comment on: Ann Emerg Med 1995 Dec;26(6):677–81.

Painful dysaesthesia with ciprofloxacin. Zehnder D, et al. **BMJ** 1995 Nov 4;311(7014):1204

Bilateral severe pain at L3–4 after spinal anaesthesia with hyperbaric 5% lignocaine. Rodríguez–Chinchilla R, et al. **Br J Anaesth** 1996 Feb;76(2):328–9

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Hickman PF, et al. **Br J Cancer** 1995 Oct;72(4):998–1003

Thiopentone pretreatment for propofol injection pain in ambulatory patients. Haugen RD, et al. **Can J Anaesth** 1995 Dec;42(12):1108–12

EMG spike trains of succinylcholine–induced fasciculations in myalgic patients. Poon PW, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):206–10

Delayed nociceptive response following cold–water swim in the formalin test: possible mechanisms of action. Fuchs PN, et al. **Exp Neurol** 1996 Jun;139(2):291–8

Restraint reduces formalin–test pain but the effect is not influenced by lesions of the hypothalamic paraventricular nucleus. Fuchs PN, et al. **Exp Neurol** 1996 Jun; 139(2):299–305

Stimulation of glucose utilization in the rat claustrum by pain. Sloniewski P, et al. **Folia Neuropathol** 1995;33(3):163–8

Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. Van Metre TE Jr, et al. **J Allergy Clin Immunol** 1996 May;97(5):1033–9

Severe atypical neuropathy associated with administration of hematopoietic colony–stimulating factors and vincristine. Weintraub M, et al. **J Clin Oncol** 1996 Mar; 14(3):935–40

Endothelin–induced nociception in mice: mediation by ETA and ETB receptors. Raffa RB, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):647–51

Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1. Godschalk M, et al. **J Urol** 1996 Sep;156(3):999–1000

Effects of formalin–induced pain on ACTH, beta–endorphin,

corticosterone and interleukin-6 plasma levels in rats. Aloisi AM, et al. **Neuroendocrinology** 1995 Jul;62(1):13-8

Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Abbott FV, et al. **Neuropharmacology** 1996 Jan;35(1):99-110

Leukemia inhibitory factor induces mechanical allodynia but not thermal hyperalgesia in the juvenile rat. Thompson SW, et al. **Neuroscience** 1996 Apr;71(4):1091-4

The development of opioid tolerance in the formalin test in the rat. Detweiler DJ, et al. **Pain** 1995 Nov;63(2):251-4

Intrathecal prostaglandin E1 produces a long-lasting allodynic state. Saito Y, et al. **Pain** 1995 Dec;63(3):303-11

Effect of anesthetic technique on acute formalin-induced pain in mice. Fu ES, et al. **Reg Anesth** 1995 May-Jun; 20(3):217-21

Pain at tumor site after vinorelbine injection: description of an unexpected side effect. Colleoni M, et al. **Tumori** 1995 May-Jun;81(3):194-6

[Effects of prostaglandin E2 and sodium hyaluronate on bradykinin induced knee joint pain in rat] Yamashita I, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):735-43 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

A strategy to assess the temporal dimension of pain in children and adolescents. Savedra MC, et al. **Nurs Res** 1995 Sep-Oct;44(5):272-6

A clinical procedure for assessment of severity of knee pain. Lewis B, et al. **Pain** 1995 Dec;63(3):361-4

Comment on C.C. Gunn--re: fibromyalgia [letter; comment] Wolfe F. **Pain** 1995 Jul;62(1):126-7. Comment on: Pain 1995 Mar;60(3):349-50.

COMPLICATIONS

Pain and depression in acute traumatic spinal cord injury: origins of chronic problematic pain? Cairns DM, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):329-35

Medical decision-making in a patient with a history of cancer and chronic non-malignant pain. Reddy SK, et al. **Clin J Pain** 1995 Sep;11(3):242-6

Memory complaints in chronic pain. Schnurr RF, et al. **Clin J Pain** 1995 Jun;11(2):103-11

Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Shelley ED, et al. **Pediatr Dermatol** 1995 Sep;12(3):215-9

[Sleep disorders in chronic pain and generalized tendomyopathy] Hemmeter U, et al. **Schweiz Med Wochenschr** 1995 Dec 9;125(49):2391-7 (Eng. Abstr.) **(Ger)**

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):747-52 (20 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Pediatric tool adapts to elderly patients [letter] Toth-Fisher C. **Am J Nurs** 1996 May;96(5):18

Mismatch: when nurses rate patients' pain. Ward S. **Am J Nurs** 1996 May;96(5):21

Where have two DSM revisions taken us for the diagnosis of pain disorder in chronic pain patients? [letter] Fishbain DA. **Am J Psychiatry** 1996 Jan;153(1):137-8

Review of pain-measurement tools. Ho K, et al. **Ann Emerg Med** 1996 Apr;27(4):427-32 (64 ref.)

Measuring pain at baseline and over time. Menegazzi J. **Ann Emerg Med** 1996 Apr;27(4):433-5 (40 ref.)

Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421-3 (28 ref.)

Clinical significance of reported changes in pain severity. Todd KH, et al. **Ann Emerg Med** 1996 Apr;27(4):485-9

Clinical versus statistical significance in the assessment of pain relief. Todd KH. **Ann Emerg Med** 1996 Apr; 27(4):439-41 (11 ref.)

Primary orbital myxoid liposarcoma presenting as orbital pain [letter] Sabb PC, et al. **Arch Ophthalmol** 1996 Mar; 114(3):353-4

A plea for uniform reporting of patient outcome in chronic pancreatitis. Frey CF, et al. **Arch Surg** 1996 Mar; 131(3):233-4

The diagnosis of chronic groin pain in athletes: a review of 189 cases. Lovell G. **Aust J Sci Med Sport** 1995 Sep; 27(3):76-9

A case of Zieve's syndrome presenting with myalgia: not to be confused with polymyalgia rheumatica [letter] Martin JC, et al. **Br J Rheumatol** 1996 May;35(5):495-6

Review: DSM-IV and pain. King SA. **Clin J Pain** 1995 Sep; 11(3):171-6 (24 ref.)

Medical decision-making in a patient with a history of cancer and chronic non-malignant pain. Reddy SK, et al. **Clin J Pain** 1995 Sep;11(3):242-6

Prediction and portrayal of repetitive stress-induced lower limb pain disorders among soldiers in basic training using videothermography. Sherman RA, et al. **Clin J Pain** 1995 Sep;11(3):236-41

Diagnostic placebo--another oxymoron? [editorial] Wilson PR. **Clin J Pain** 1995 Sep;11(3):167-8

Sports-related groin pain: evaluation with MR imaging. Ekberg O, et al. **Eur Radiol** 1996;6(1):52-5

A prospective blinded study on emergency pain assessment and therapy. Ducharme J, et al. **J Emerg Med** 1995 Jul-Aug;13(4):571-5

Central pain: clinical and physiological characteristics. Bowsher D. **J Neurol Neurosurg Psychiatry** 1996 Jul; 61(1):62-9

Pain in cognitively impaired nursing home patients. Ferrell BA, et al. **J Pain Symptom Manage** 1995 Nov;10(8):591-8

Muscle weakness and myalgia. MR imaging investigation. Fleckenstein JL. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):773-803 (43 ref.)

Patellofemoral pain syndrome in young women. I. A clinical analysis of alignment, pain parameters, common symptoms and functional activity level. Thomeé R, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):237-44

[Varicella-zoster-virus myelitis without herpes. An important differential diagnosis of the radicular syndrome] Jacobs A, et al. **Dtsch Med Wochenschr** 1996 Mar 15; 121(11):331-5 (25 ref.) (Eng. Abstr.) **(Ger)**

[Edema and pain in the leg--how to benefit from magnetic tomography?] Engebretsen L, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2636-7 **(Nor)**

[Magnetic tomography in the examination of edema and pain in the leg] Haaverstad R, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2638-41 (Eng. Abstr.) **(Nor)**

[Painless femoral neck fracture in a patient with multiple sclerosis] Holmøy T, et al. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):249 (Eng. Abstr.) **(Nor)**

DRUG EFFECTS see PAIN/drug therapy

DRUG THERAPY

Pain management in the emergency department [letter] Ducharme J, et al. **Acad Emerg Med** 1995 Sep;2(9):850-2

The effect of calcium channel antagonist administered by iontophoresis on the pain threshold. Taniguchi K, et al. **Acta Anaesthesiol Belg** 1995;46(2):69-73

Does a local anaesthetic cream (EMLA) alleviate pain from heel-lancing in neonates? Larsson BA, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1028-31

Clinical applications of excitatory amino acid antagonists in pain management. Wong CS, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):227-32 (48 ref.)

A new approach to the control of central deafferentation pain--spinal intrathecal baclofen. Taira T, et al. **Acta Neurochir Suppl (Wien)** 1995;64:136-8

Subcutaneous morphine infusion by syringe driver for terminally ill patients. Cools HJ, et al. **Age Ageing** 1996 May;25(3):206-8

Etidronate and calcitonin for cancer bone pain [letter] Schnur W. **Am Fam Physician** 1996 Sep 15;54(4):1212

Postpoliomyelitis pain treated with gabapentin [letter] Zapp JJ. **Am Fam Physician** 1996 Jun;53(8):2442, 2445

A new approach to chronic pain in the ED. MacLeod DB, et al. **Am J Emerg Med** 1996 May;14(3):323-6

Treatment of proctalgia fugax with salbutamol inhalation. Eckardt VF, et al. **Am J Gastroenterol** 1996 Apr; 91(4):686-9

Oral morphine eases chronic non-cancer pain, with little risk of addiction [news] **Am J Health Syst Pharm** 1996 Apr 15;53(8):836, 838

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S-53S (30 ref.)

Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S-24S (39 ref.)

A novel approach to the pharmacology of analgesics. Raffa RB. **Am J Med** 1996 Jul 31;101(1A):40S-46S (33 ref.)

Cancer patients and subcutaneous infusions. Coyle N, et al. **Am J Nurs** 1996 Mar;96(3):61

Motivating staff: the pain-free week. Harris P, et al. **Am J Nurs** 1996 Jul;96(7):23

Minimizing meperidine use. Hinnant DC. **Am J Nurs** 1996 Aug;96(8):18

Using high-dose fentanyl patches. Lilley LL, et al. **Am J Nurs** 1996 Jul;96(7):18-20, 22

Extended-release morphine products. McCaffery M, et al. **Am J Nurs** 1996 Apr;96(4):65

How to calculate a rescue dose. McCaffery M. **Am J Nurs** 1996 Apr;96(4):65-6

Planning for breakthrough cancer pain. McCaffery M, et al. **Am J Nurs** 1996 Jun;96(6):24

Pain during sickle-cell crises. Nichols R. **Am J Nurs** 1996 Jan;96(1):59-60

Getting physicians to change their practices. Wallace KG. **Am J Nurs** 1996 Feb;96(2):20

When patients refuse pain medications. Wallace KG. **Am J Nurs** 1996 Feb;96(2):20-1

Effect of mexiletine on spinal cord injury dysesthetic pain. Chiou-Tan FY, et al. **Am J Phys Med Rehabil** 1996 Mar-Apr;75(2):84-7

Venlafaxine for the treatment of chronic pain [letter] Songer DA, et al. **Am J Psychiatry** 1996 May;153(5):737

Analgesic, hemodynamic, and respiratory effects of caudal epidurally administered xylazine hydrochloride solution in mares. Skarda RT, et al. **Am J Vet Res** 1996 Feb; 57(2):193-200

Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Gurnani A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):32-6

Acute phantom limb pain controlled by ketamine. Knox DJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):620-2

The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Ferrante FM, et al. **Anesth Analg** 1996 Jan;82(1):91-7

Continuous intracisternal and high cervical intrathecal bupivacaine analgesia in refractory head and neck pain [see comments] Appelgren L, et al. **Anesthesiology** 1996 Feb; 84(2):256-72. Comment in: Anesthesiology 1996 Feb;84(2):249-52.

Refractory head and neck pain. A difficult problem and a new alternative therapy [editorial; comment] Carpenter RL, et al. **Anesthesiology** 1996 Feb;84(2):249-52. Comment on: Anesthesiology 1996 Feb;84(2):256-72.

Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats [see comments] Chaplan SR, et al. **Anesthesiology** 1995 Oct;83(4):775-85. Comment in: Anesthesiology 1995 Oct;83(4):654-5.

Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. Schnider TW, et al. **Anesthesiology** 1996 May;84(5):1043-50

Protracted relief of experimental neuropathic pain by systemic local anesthetics. How, where, and when [editorial; comment] Strichartz G. **Anesthesiology** 1995 Oct; 83(4):654-5. Comment on: Anesthesiology 1995 Oct;83(4):775-85.

Working with industry. Lewis RH. **Ann Emerg Med** 1996 Apr;27(4):414-5

Relationship between academia and industry: ethical considerations. Paris PM. **Ann Emerg Med** 1996 Apr; 27(4):416-7

Gender-associated differences in emergency department pain management. Raftery KA, et al. **Ann Emerg Med** 1995 Oct; 26(4):414-21

Ethical issues associated with pain research in emergency medicine. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):418-20

Local anesthetics. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):464-5 (10 ref.)

Comparison of bupivacaine and lidocaine/bupivacaine for local anesthesia/digital nerve block. Valvano MN, et al. **Ann Emerg Med** 1996 Apr;27(4):490-2

Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ripamonti C, et al. **Ann Oncol** 1995 Oct;6(8):841-3

Microbiologic and economic evaluation of multiday infusion pumps for control of cancer pain. Ohlsson LJ, et al. **Ann Pharmacother** 1995 Oct;29(10):972-6

Opioid-induced muscle activity: implications for managing chronic pain. Sylvester RK, et al. **Ann Pharmacother** 1995 Nov;29(11):1118-21

New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253-80 (193 ref.)

A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Godfrey RG. **Arch Intern Med** 1996 May 27;156(10):1047-52 (44 ref.)

Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. **BMJ** 1996 Mar 30;312(7034):823-6 (39 ref.)

Treatment for cancer pain [letter; comment] Ahmedzai S, et al. **BMJ** 1995 Oct 7;311(7010):951. Comment on: BMJ 1995 Aug 5;311(7001):387.

Modes of administration of morphine in cancer pain. Some doctors lack basic knowledge about prescribing morphine [letter] Crosby VL, et al. **BMJ** 1996 Sep 14;313(7058):687

Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. de Craen AJ, et al. **BMJ** 1996 Aug 10; 313(7053):321-5

Anticonvulsant drugs for management of pain: a systematic review. McQuay H, et al. **BMJ** 1995 Oct 21; 311(7012):1047-52 (53 ref.)

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Cresswell SM, et al. **Br J Urol** 1995 Sep;76(3):360-5

Nerve growth factor alleviates a painful peripheral neuropathy in rats. Ren K, et al. **Brain Res** 1995 Nov 20; 699(2):286-92

Each of the following has been shown to be effective for cyclical breast pain. **Can Fam Physician** 1996 Jun;42:1099, 1101

Effectiveness of notification and group education in modifying prescribing of regulated analgesics [see comments] Anderson JF, et al. **Can Med Assoc J** 1996 Jan 1;154(1):31-9. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1005-6; discussion 1006-7. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1006; discussion 1006-7. Comment in: Can Med Assoc J 1996 May 15;154(10):1470, 1472. Comment in: Can Med Assoc J 1996 May 15;154(10):1472, 1474; discussion 1476-7. Comment in: Can Med Assoc J 1996 May 15;154(10):1474; discussion 1476-7. Comment in: Can Med Assoc J 1996 May 15;154(10):1476; discussion 1476-7.

Regulated analgesics and pain control [letter; comment] Clark AJ, et al. **Can Med Assoc J** 1996 May 15;154(10):1472, 1474; discussion 1476-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Regulated analgesics and pain control [letter; comment] Goldman B. **Can Med Assoc J** 1996 May 15;154(10):1474; discussion 1476-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Regulated analgesics and pain control [letter; comment]

Hagen NA, et al. **Can Med Assoc J** 1996 May 15; 154(10):1470, 1472. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Regulated analgesics and pain control [letter; comment] Jovey RD. **Can Med Assoc J** 1996 May 15;154(10):1476; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Bruera E, et al. **Cancer** 1996 Aug 15;78(4):852–7

Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cherny NJ, et al. **Cancer** 1995 Oct 1;76(7):1283–93

Teaching cancer pain management: durability of educational effects of a role model program. Janjan NA, et al. **Cancer** 1996 Mar 1;77(5):996–1001

Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)

Palliative medicine. Problem areas in pain and symptom management. Introduction. Hanks GW. **Cancer Surv** 1994; 21:1–3

The cognitive and psychomotor effects of opioid drugs in cancer pain management. O'Neill WM. **Cancer Surv** 1994; 21:67–84

Opioids and pain. Kanjhan R. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):397–403 (72 ref.)

Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)

Clonazepam for the treatment of lancinating phantom limb pain. Bartusch SL, et al. **Clin J Pain** 1996 Mar;12(1):59–62

Long-term intrathecal administration of midazolam and clonidine. Borg PA, et al. **Clin J Pain** 1996 Mar;12(1):63–8

Moclobemide in chronic neuropathic pain: preliminary case reports. Menkes DB, et al. **Clin J Pain** 1995 Jun;11(2):134–8

Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Max MB, et al. **Clin Neuropharmacol** 1995 Aug;18(4):360–8

Pharmacology of neuropathic pain. Ollat H, et al. **Clin Neuropharmacol** 1995 Oct;18(5):391–404 (62 ref.)

Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639–57 (76 ref.)

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459–76 (111 ref.)

The use of lignocaine to reduce pain on i.v. injection of diluted nalbuphine. van den Berg AA, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):513–6

Tonic versus phasic pain: dose–related effects of ketoprofen. Hummel T, et al. **Eur J Clin Pharmacol** 1995;49(1–2):7–14

Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic. Muriel-Villoria C, et al. **Eur J Clin Pharmacol** 1995;48(2):103–7

Epidural analgesia during labor: continuous infusion or patient–controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55–6 (9 ref.)

Combined spinal and epidural blockade for analgesia in labour. Morgan B. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S59–60

Pain during childbirth [editorial] Van Aken H, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S1

Labor pain relief using bupivacaine and sufentanil: patient controlled epidural analgesia versus intermittent injections. Vandermeulen EP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S47–54

BW373U86, a delta–opioid receptor agonist, reverses bradykinin–induced thermal allodynia in rhesus monkeys. Butelman ER, et al. **Eur J Pharmacol** 1995 Apr 24; 277(2–3):285–7

Efficacy of first–time steroid injection for painful heel syndrome. Miller RA, et al. **Foot Ankle Int** 1995 Oct; 16(10):610–2

A peaceful death: how to manage pain and provide quality care. A roundtable discussion: Part 2. Butler RN, et al. **Geriatrics** 1996 Jun;51(6):32–5, 39–40, 42

Pharmacologic management of cancer pain [published erratum appears in Hosp Pract (Off Ed) 1996 Jan 15;31(1):86] Cleary J, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):41–9

Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)

Prevalence of abuse and dependency in chronic pain patients. Hoffmann NG, et al. **Int J Addict** 1995 Jun;30(8):919–27

L–acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Onofrj M, et al. **Int J Clin Pharmacol Res** 1995;15(1):9–15

Pain relief with low–dose intravenous clonidine in a child with severe burns. Lyons B, et al. **Intensive Care Med** 1996 Mar;22(3):249–51

Opioid use in HIV patients with neurological changes. Paice JA, et al. **J Assoc Nurses AIDS Care** 1995 Jul–Aug; 6(4):28–36 (27 ref.)

Femoral nerve block in extracapsular femoral neck fractures. Haddad FS, et al. **J Bone Joint Surg Br** 1995 Nov; 77(6):922–3

A randomized, double–blind, double–dummy, crossover trial comparing the safety and efficacy of oral sustained–release hydromorphone with immediate–release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. Bruera E, et al. **J Clin Oncol** 1996 May;14(5):1713–7

Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. Valentini M, et al. **J Clin Oncol** 1995 Oct;13(10):2637–42

Steady–state pharmacokinetic evaluation of a novel, controlled–release morphine suppository and subcutaneous morphine in cancer pain. Bruera E, et al. **J Clin Pharmacol** 1995 Jul;35(7):666–72

The analgesic efficacy of ketorolac for acute pain. Catapano MS. **J Emerg Med** 1996 Jan–Feb;14(1):67–75 (101 ref.)

Just a spoonful of sugar.... Ebell MH. **J Fam Pract** 1995 Oct; 41(4):403–4

Problems and pitfalls in providing acute and short–term pain relief with nonsteroidal anti–inflammatory agents. Hubbell K. **J La State Med Soc** 1996 Jan;148(1):13–8

Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. Sørensen HT, et al. **J Med Syst** 1996 Feb;20(1):57–65

North Central Cancer Treatment Group (NCCTG). Loprinzi CL. **J Natl Cancer Inst Monogr** 1996;(20):79–80

Propofol analgesia in central pain: preliminary clinical observations. Canavero S, et al. **J Neurol** 1995 Sep; 242(9):561–7

Long–term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. Winkelmüller M, et al. **J Neurosurg** 1996 Sep;85(3):458–67

Analgesic effect of topical opioids on painful skin ulcers [letter] Back IN, et al. **J Pain Symptom Manage** 1995 Oct; 10(7):493

Opioid use in advanced malignant disease: why do different centers use vastly different doses? A plea for standardized reporting. Boisvert M, et al. **J Pain Symptom Manage** 1995 Nov;10(8):632–8

Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)

Randomized evaluation of controlled–release codeine and placebo in chronic cancer pain. Dhaliwal HS, et al. **J Pain Symptom Manage** 1995 Nov;10(8):612–23

Use of patient–controlled analgesia for pain control for children receiving bone marrow transplant. Dunbar PJ, et al. **J Pain Symptom Manage** 1995 Nov;10(8):604–11

Oral methadone for managing chronic nonmalignant pain. Gardner–Nix JS. **J Pain Symptom Manage** 1996 May; 11(5):321–8

Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)

Control of cancer–related pain with MS Contin: a comparison between 12–hourly and 8–hourly administration. Mignault GG, et al. **J Pain Symptom Manage** 1995 Aug;10(6):416–22

Iontophoresis for pain management. McFadden EA. **J Pediatr Nurs** 1995 Oct;10(5):331

Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. Craft RM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1535–42

Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. Imamura Y, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):177–82

Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. Lee YW, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1642–8

Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma–aminobutyric acid(B), mu and kappa opioid receptors. Ocaña M, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1136–42

Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism. Takeshita N, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):23–30

Baseline correlates of the response to the treatment of chronic localized myofascial pain syndrome by injection of local anaesthetic. Scicchitano J, et al. **J Psychosom Res** 1996 Jan;40(1):75–85

Aspirin–mouthwash relieves pain of oral lesions. Angirish A. **J R Soc Health** 1996 Apr;116(2):105–6

Research into analgesia by inhaling analgesic. Huang X, et al. **J Tradit Chin Med** 1996 Mar;16(1):7–14

Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. Lazzeri M, et al. **J Urol** 1996 Sep;156(3):947–52

Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee [see comments] **JAMA** 1995 Dec 20; 274(23):1874–80 (67 ref.). Comment in: JAMA 1995 Dec 20;274(23):1881–2.

When will adequate pain treatment be the norm? [editorial; comment] [see comments] Hill CS Jr. **JAMA** 1995 Dec 20;274(23):1881–2. Comment on: JAMA 1995 Dec 20;274(23):1870–3. Comment on: JAMA 1995 Dec 20;274(23):1874–80. Comment in: JAMA 1996 May 1;275(17):1310; discussion 1311. Comment in: JAMA 1996 May 1;275(17):1310–1. Comment in: JAMA 1996 May 1;275(17):1311.

The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870–3 (40 ref.). Comment in: JAMA 1995 Dec 20;274(23):1881–2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835–6.

What is adequate and appropriate pain treatment? [letter; comment] Murphy D. **JAMA** 1996 May 1;275(17):1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

What is adequate and appropriate pain treatment? [letter; comment] White WG. **JAMA** 1996 May 1;275(17):1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

Exploring central issues in analgesia [news] Bonn D. **Lancet** 1996 Feb 24;347(9000):530

Nitrous oxide and morphine in children with sickle cell crisis [letter] Carbajal R, et al. **Lancet** 1996 Jun 8;347(9015):1621

Sickle cell pain crisis [letter; comment] [see comments] Forbes K, et al. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

12 years on: co–proxamol revisited. Haigh S. **Lancet** 1996 Jun 29;347(9018):1840–1

Morphine's name [letter; comment] Kiss I. **Lancet** 1996 Jul 13;348(9020):138. Comment on: Lancet 1996 May 4;347(9010):1262–3.

Sickle cell pain crisis [letter; comment] [see comments] Meltzer BA. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Randomised trial of oral morphine for chronic non–cancer pain. Moulin DE, et al. **Lancet** 1996 Jan 20;347(8995):143–7

Barriers to controlling pain in patients with cancer [see comments] Reidenberg MM. **Lancet** 1996 May 11; 347(9011):1278. Comment in: Lancet 1996 Jul 13;348(9020):134.

Morphine for relief of cancer pain [letter] [see comments] Ripamonti C, et al. **Lancet** 1996 May 4;347(9010):1262–3 . Comment in: Lancet 1996 Jul 13;348(9020):138.

Sickle cell pain crisis [letter; comment] [see comments] Simini B. **Lancet** 1996 Jan 27;347(8996):261–2. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell pain crisis [letter; comment] [see comments] Ward SJ. **Lancet** 1996 Jan 27;347(8996):261. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Antinociceptive activity of filenadol on inflammatory pain. Bustos G, et al. **Life Sci** 1995;57(14):PL181–6

Managing cancer pain: basic principles and invasive treatments. Marshall KA. **Mayo Clin Proc** 1996 May; 71(5):472–7 (10 ref.)

Oral morphine protocol for sickle cell crisis pain. Conti C, et al. **Md Med J** 1996 Jan;45(1):33–5

Painful lessons: opioids, iatrogenic dependence and professional standards [letter] Black RB. **Med J Aust** 1995 Nov 6;163(9):502–3

Effective control of bone pain by octreotide in a patient with metastatic gastrinoma. Burgess JR, et al. **Med J Aust** 1996 Jun 17;164(12):725–7

Painful lessons: opioids, iatrogenic dependence and professional standards [letter] Goucke CR, et al. **Med J Aust** 1995 Nov 6;163(9):503

Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)

Painful lessons: opioids, iatrogenic dependence and professional standards [letter] Stewart TC. **Med J Aust** 1995 Nov 6;163(9):502; discussion 503

Assessment of patients' pain [letter] Krivo S, et al. **N Engl J Med** 1996 Jan 4;334(1):59

Pharmacologic treatment of cancer pain. Levy MH. **N Engl J Med** 1996 Oct 10;335(15):1124–32 (101 ref.)

Opioids in chronic pain of non–malignant origin: an interim consensus [letter] Jones D, et al. **N Z Med J** 1995 Nov 24;108(1012):492

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76–7 (9 ref.)

Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance. Elliott KJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S66–8

Modulation of neuropathic pain in rats by intrathecally injected serotonergic agonists. Sanchez A, et al. **Neuroreport** 1995 Dec 15;6(18):2585–8

Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Lee YW, et al. **Neurosci Lett** 1995 Oct 20;199(2):111–4

The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Ossipov MH, et al. **Neurosci Lett** 1995 Oct 20;199(2):87–90

Etorphine elicits unique inhibitory–agonist and excitatory–antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234–68 (67 ref.)

Dual inhibitors of enkephalin–degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995;

147:104–45 (149 ref.)
Future directions in the pharmacological management of hyperalgesic and allodynic pain states: the NMDA receptor. Yaksh TL, et al. **NIDA Res Monogr** 1995; 147:84–103 (63 ref.)
Patterns of pain experiences and use of analgesics among hospitalized cancer patients in Korea. Lee EO, et al. **Nurs Clin North Am** 1995 Dec;30(4):647–57
Pharmacologic management of cancer pain. Niles R. **Nurs Clin North Am** 1995 Dec;30(4):745–63 (83 ref.)
Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)
Evaluation of a new topical anesthetic agent: a pilot study. Lander J, et al. **Nurs Res** 1996 Jan–Feb;45(1):50–3
Algorithm helps healthcare practitioners manage opioid–induced sedation. Skalla K. **Oncol Nurs Forum** 1996 Apr;23(3):542–3
Nurse–administered boluses enhance comfort at the end of life. Zeisberg L. **Oncol Nurs Forum** 1995 Nov–Dec; 22(10):1573–4
Efficacy of controlled–release codeine in chronic non–malignant pain: a randomized, placebo–controlled clinical trial. Arkinstall W, et al. **Pain** 1995 Aug; 62(2):169–78
Analgesia and oral opioid consumption: strengths and shortcomings of methods [letter] Backonja MM, et al. **Pain** 1996 Feb;64(2):398–401
Custom–made capsules and suppositories of methadone for patients on high–dose opioids for cancer pain. Bruera E, et al. **Pain** 1995 Aug;62(2):141–6
Spinal mu and delta, but not kappa, opioid–receptor agonists attenuate responses to noxious colorectal distension in the rat. Danzebrink RM, et al. **Pain** 1995 Oct;63(1):39–47
Dextromethorphan suppresses both formalin–induced nociceptive behavior and the formalin–induced increase in spinal cord c–fos mRNA. Elliott KJ, et al. **Pain** 1995 Jun; 61(3):401–9
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Felsby S, et al. **Pain** 1996 Feb;64(2):283–91
Comments on Pentland and Donald [letter] Genis D, et al. **Pain** 1996 Feb;64(2):402–3
A double–blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Glynn C, et al. **Pain** 1996 Feb;64(2):337–43
Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Gourlay GK, et al. **Pain** 1995 Jun;61(3):375–81
Comments on Schwarzer et al., PAIN, 58 (1994) 195–200 [letter] Graziotti P, et al. **Pain** 1995 Dec;63(3):394–6
Comments on Fitzgibbon and Galer, PAIN, 58 (1994) 429–431 [letter; comment] Lipman AG. **Pain** 1995 Oct; 63(1):135. Comment on: Pain 1994 Sep;58(3):429–31.
The effects of isoflurane on repeated nociceptive stimuli (central temporal summation). Petersen–Felix S, et al. **Pain** 1996 Feb;64(2):277–81
Expansion and comments on non–steroidal anti–inflammatory drugs and spinal nociception processing (Pain, 59 (1994) 9–43) [letter; comment] Russell AL. **Pain** 1995 Jun; 61(3):494–5. Comment on: Pain 1994 Oct;59(1):9–43.
Treatment of terminal cancer pain in France: a questionnaire study. Vainio A. **Pain** 1995 Aug;62(2):155–62
Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow–release oral morphine administration. Wolff T, et al. **Pain** 1995 Aug;62(2):147–54
Validation of World Health Organization Guidelines for cancer pain relief: a 10–year prospective study. Zech DF, et al. **Pain** 1995 Oct;63(1):65–76
A regional survey of opioid use by patients receiving specialist palliative care. Brooks DJ, et al. **Palliat Med** 1995 Jul;9(3):229–38
Use of nonsteroidal anti–inflammatory drugs in cancer. Pace V. **Palliat Med** 1995 Oct;9(4):273–86 (105 ref.)
Treatment of painful crises of Fabry disease with morphine [letter; comment] Philippart M. **Pediatr Neurol** 1995 Oct; 13(3):268. Comment on: Pediatr Neurol 1995 Apr;12(3):250–1.
Sucrose reduces pain reaction to heel lancing in preterm infants: a placebo–controlled, randomized and masked study. Bucher HU, et al. **Pediatr Res** 1995 Sep;38(3):332–5
Intravenous ketorolac for pain management in a ventilator–dependent patient with thermal injury. Tran HT, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):75–8
Analysis of pain management in critically ill patients. Whipple JK, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):592–9
Effective management of chronic pain. The analgesic dilemma. Stacey BR. **Postgrad Med** 1996 Sep;100(3):281–4, 287–90, 293 passim (27 ref.)
The management of central post–stroke pain. Bowsher D. **Postgrad Med J** 1995 Oct;71(840):598–604 (36 ref.)
A comparison of the action of mexiletine and morphine in rodent models of acute and chronic pain. Hedley LR, et al. **Proc West Pharmacol Soc** 1995;38:103–4
Rectus syndrome. Another cause of upper abdominal pain. Choi YK, et al. **Reg Anesth** 1995 Jul–Aug;20(4):347–51
The effect of preemptive fentanyl and halothane on formalin pain in mice [letter] Martin DC, et al. **Reg Anesth** 1996 May–Jun;21(3):274–5
Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Mercadante S, et al. **Reg Anesth** 1995 Jul–Aug;20(4):343–6
Interpleural block for acute combined cervical and thoracic herpes zoster [letter] Thwaites BK, et al. **Reg Anesth** 1995 May–Jun;20(3):255–6
Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Martín–Mola E, et al. **Rheumatol Int** 1995;15(3):111–6
Controlling the pain of cancer. Foley KM. **Sci Am** 1996 Sep; 275(3):164–5 (0 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)
C1–2 arthrography. Chevrot A, et al. **Skeletal Radiol** 1995 Aug;24(6):425–9
Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. Tutak U, et al. **South Med J** 1996 Mar;89(3):295–300
Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Cascinu S, et al. **Support Care Cancer** 1996 Jan;4(1):31–3
Pain medications and addiction [editorial] Miller M. **Wis Med J** 1996 Jun;95(6):332–3
[Ketamine and phantom pain (letter)] Hansen G. **Ugeskr Laeger** 1995 Nov 27;157(48):6735–6 **(Dan)**
[Antidepressive agents, the dorsal horn and pain] Eschalier A. **Cah Anesthesiol** 1995;43(4):357–61 **(Fre)**
[Patient–controlled analgesia in cancer pain: practical aspects] Lakdja F, et al. **Cah Anesthesiol** 1995;43(6):583–6 (Eng. Abstr.) **(Fre)**
[Pharma–clinics. Drug of the month. Tramadol (Dolzam)] Scheen AJ. **Rev Med Liege** 1996 Jun;51(6):443–5 **(Fre)**
[New aspects of pain research and therapy and inhalation anesthetics] Christ F, et al. **Anaesthesist** 1995 Dec; 44(12):928–9 **(Ger)**
[Oral opioids for long–term treatment of chronic non–cancer pain] Dertwinkel R, et al. **Anaesthesist** 1996 Jun; 45(6):495–505 (53 ref.) (Eng. Abstr.) **(Ger)**
[Remarks on the work of A. Willweber–Strumpf et al. Directions for treatment of chronic pain with opioids. Results from the Sertürner workshop "chronic opioid therapy"] Stadler T, et al. **Anaesthesist** 1996 Apr; 45(4):386–7 **(Ger)**
[Oral opioids in chronic non–cancer pain. Prospective controlled studies needed! (editorial)] Stein C. **Anaesthesist** 1996 Jun;45(6):493–4 **(Ger)**
[Principles of chronic pain therapy with opioids. Results of a Sertürner workshop "Chronic Opioid Therapy"] Willweber–Strumpf A, et al. **Anaesthesist** 1995 Oct; 44(10):719–23 **(Ger)**
[Pain management in cancer patients] Willenbrink HJ, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1363–6 (13 ref.) **(Ger)**
[Long–term treatment of chronic pain with tilidine–naloxone. An analysis of 50 patients with chronic pain conditions of non–malignant origin] Wörz R, et al. **Fortschr Med** 1995 Sep 30;113(27):388–92 (Eng. Abstr.) **(Ger)**
[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**
[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**
[Principles of pain therapy with local anesthesia] Klaus E. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):127–30 (Eng. Abstr.) **(Ger)**
[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**
[Pain and pain perception in the elderly (editorial)] Kruse A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):311 **(Ger)**
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415–20 (43 ref.) **(Heb)**
[The effect of alpha–glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report] Mimura M, et al. **Masui** 1996 Mar;45(3):337–9 (Eng. Abstr.) **(Jpn)**
[Analgesic and anti–inflammatory effect of (+/–)–N,N–dimethylcarbamoylmethyl 2–[7–(2–methyl–5H–[1] benzopyrano [2,3–b] pyridyl)] propionate (Y–23023), a new non–steroidal anti–inflammatory drug] Iwahisa Y, et al. **Nippon Yakurigaku Zasshi** 1995 Aug;106(2):99–111 (Eng. Abstr.) **(Jpn)**
[Effect of etimizol on development of a neuropathic pain syndrome] Gorizontova MP, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):258–61 **(Rus)**
[The effects of preparations that influence the brain monoaminergic systems in pain syndromes] Danilova EI, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):14–7 **(Rus)**
[Anti–pain effect of salmon calcitonin in bone metastases of malignant tumors with the exception of breast and prostatic carcinoma] Jelić S, et al. **Vojnosanit Pregl** 1995 Mar–Apr; 52(2):151–4 (Eng. Abstr.) **(Scr)**
[Treatment of pain and anxiety in terminal oncologic patients in the Castilla–La Mancha community] Calles Gato MD, et al. **Aten Primaria** 1995 Sep 30;16(5):276–80 (Eng. Abstr.) **(Spa)**
[Specific problems of analgesic therapy in hospital environment] Baños JE, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):222–6 (59 ref.) **(Spa)**
[Peroral selenium therapy in growth pain in children] Brahme–Isgren M, et al. **Lakartidningen** 1995 Oct 4; 92(40):3706–8 **(Swe)**
[Oral selenium therapy against growing pain in children] Brahme–Isgren M, et al. **Lakartidningen** 1995 Sep 20; 92(38):3450–2 **(Swe)**

ECONOMICS

Money matters: A meta–analytic review of the association between financial compensation and the experience and treatment of chronic pain. Rohling ML, et al. **Health Psychol** 1995 Nov;14(6):537–47

EPIDEMIOLOGY

Recurrent limb pain in schoolchildren. Abu–Arafeh I, et al. **Arch Dis Child** 1996 Apr;74(4):336–9
Incidence of chronic pain following traumatic brain injury. Lahz S, et al. **Arch Phys Med Rehabil** 1996 Sep; 77(9):889–91
Knee pain amongst the poor and affluent in Pakistan. Gibson T, et al. **Br J Rheumatol** 1996 Feb;35(2):146–9
Incidence of symptom recurrence after hysterectomy for endometriosis. Namnoum AB, et al. **Fertil Steril** 1995 Nov; 64(5):898–902
Chronic pain. Millar WJ. **Health Rep** 1996 Spring;7(4):47–53, 51–8 **(Eng, Fre)**
An epidemiological study of prevalence of pain in head & neck cancers. Saxena A, et al. **Indian J Med Res** 1995 Jul; 102:28–33
National vulvodynia questionnaire [letter] Nunns D, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):366–7
Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. Vainio A, et al. **J Pain Symptom Manage** 1996 Jul;12(1):3–10
Chronic pain: time for epidemiology [editorial] Smith BH, et al. **J R Soc Med** 1996 Apr;89(4):181–3
Prospective epidemiologic study of painful and neurologic sequelae induced by herpes zoster in patients treated early with oral acyclovir. Bruxelle J. **Neurology** 1995 Dec;45(12 Suppl 8):S78–9
Musculoskeletal pains and depression in a middle–aged Finnish population. Rajala U, et al. **Pain** 1995 Jun; 61(3):451–7
Pain in pediatric human immunodeficiency virus infection: incidence and characteristics in a single–institution pilot study [see comments] Hirschfeld S, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):449–52. Comment in: Pediatrics 1996 Sep;98(3 Pt 1):455–6.
[Study of prevalence of pain at the Juan Canalejo Hospital in La Coruña] Valero J, et al. **An Med Interna** 1995 Dec; 12(12):584–8 (Eng. Abstr.) **(Spa)**
[Prevalence of generalized pain of the locomotor system (letter; comment)] Rubio Montañés ML, et al. **Aten Primaria** 1995 Oct 15;16(6):379–80. Comment on: Aten Primaria 1995 Apr 30;15(7):449–51. **(Spa)**

ETHNOLOGY

Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67–72 (20 ref.)
Low prevalences of chronic widespread pain and shoulder disorders among the Pima Indians. Jacobsson LT, et al. **J Rheumatol** 1996 May;23(5):907–9

ETIOLOGY

Evaluation of chronic wrist pain. Arthroscopy superior to arthrography: comparison in 39 patients. Schers TJ, et al. **Acta Orthop Scand** 1995 Dec;66(6):540–2
Development of stomach–ache and headache during middle childhood: co–occurrence and psychosocial risk factors. Borge AI, et al. **Acta Paediatr** 1995 Jul;84(7):795–802
Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17–31 (37 ref.)
The os trigonum syndrome: imaging features. Karasick D, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):125–9
Diagnosis of acute flank pain: value of unenhanced helical CT. Smith RC, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):97–101
Diagnostic imaging of patients with acute scrotal pain. Barloon TJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1734–50 (17 ref.)
Hip fracture presenting as knee pain in an elderly patient [letter] Hammer SG. **Am Fam Physician** 1996 Sep 1; 54(3):872
Shoulder pain: the role of diagnostic injections. Larson HM, et al. **Am Fam Physician** 1996 Apr;53(5):1637–47 (10 ref.)
Proctalgia fugax [see comments] Nidorf DM, et al. **Am Fam Physician** 1995 Dec;52(8):2238–40. Comment in: Am Fam Physician 1996 Jul;54(1):72.
A 45–year–old woman with right shoulder pain. Coombs RJ, et al. **Am J Orthop** 1995 Nov;24(11):870–3
Factors associated with wrist pain in the young gymnast. DiFiori JP, et al. **Am J Sports Med** 1996 Jan–Feb;24(1):9–14
Carcinoma of the breast metastatic to the ureter presenting

with flank pain and recurrent urinary tract infection. López-Martínez RA, et al. **Am Surg** 1996 Sep;62(9):748–52
Does post-laparoscopy pain relate to residual carbon dioxide? Jackson SA, et al. **Anaesthesia** 1996 May;51(5):485–7
Pain on administration of rocuronium [letter] Robertson EN. **Anaesthesia** 1996 Jan;51(1):93
Skin sensitivity of the arm. van den Berg AA. **Anaesthesia** 1996 Feb;51(2):194–7
Pain on injection of rocuronium bromide [letter; comment] Steegers MA, et al. **Anesth Analg** 1996 Jul;83(1):203. Comment on: Anesth Analg 1995 May;80(5):1067.
An overview of acute scrotal pain. Chia SJ, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):720–3
Match and mismatch: identifying the neuronal determinants of pain [comment] [see comments] Casey KL. **Ann Intern Med** 1996 Jun 1;124(11):995–8 (35 ref.). Comment on: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment on: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):959–69. Comment on: Ann Intern Med 1996 Jun 1;124(11):1006–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):1008–1011. Comment in: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment in: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment in: Ann Intern Med 1996 Jun 1;124(11):959–8.
Does the brain know when the heart is ischemic? [editorial; comment] [see comments] Pepine CJ. **Ann Intern Med** 1996 Jun 1;124(11):1006–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment in: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment in: Ann Intern Med 1996 Jun 1;124(11):995–8.
Treatment of chronic paranasal sinus pain with minimal sinus disease. Acquadro MA, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):607–14
Chronic pain syndromes. Carette S. **Ann Rheum Dis** 1996 Aug;55(8):497–501 (75 ref.)
Teenager with an irritable hip, anaemia and malaise. Hertzberger-ten Cate R, et al. **Ann Rheum Dis** 1995 Sep; 54(9):701–5
Different concepts of musculoskeletal pain [letter; comment] Quintner J. **Ann Rheum Dis** 1995 Oct;54(10):859–60. Comment on: Ann Rheum Dis 1995 May;54(5):331–2.
Pathologic quiz case 1. Temporomandibular pigmented villonodular synovitis. Shapiro S, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):194, 196
Neck symptoms with subtle causes. Epstein E. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):770
Pain and depression in acute traumatic spinal cord injury: origins of chronic problematic pain? Cairns DM, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):329–35
Electromyography [letter; comment] Senelick RC. **Arch Phys Med Rehabil** 1996 Feb;77(2):212. Comment on: Arch Phys Med Rehabil 1995 Oct;76(10):947–9.
A review of subcalcaneal heel pain and plantar fasciitis. Brown C. **Aust Fam Physician** 1996 Jun;25(6):875–81; 884–5
Anterior knee pain. Brukner P. **Aust Fam Physician** 1996 Jun;25(6):908–11; 914
Painful feet in childhood. Pattinson R, et al. **Aust Fam Physician** 1996 Jun;25(6):887–9; 892–3
Metatarsalgia. Quirk R. **Aust Fam Physician** 1996 Jun; 25(6):863–5; 867–9
Soft tissue syndromes. Katz JN, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):585–98 (33 ref.)
Fibromyalgia. Raspe H, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):599–614 (80 ref.)
Evaluation of the biomaterial–interface of screw threads in patients having clinical pain. Johnson D, et al. **Biomed Sci Instrum** 1996;32:127–33
Antiabortionists hijack fetal pain argument [news] Kmietowicz Z. **BMJ** 1996 Jul 27;313(7051):188
Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Auquier P, et al. **Bone Marrow Transplant** 1995 Oct;16(4):541–7
Somatic pain—pathogenesis and prevention. Woolf CJ. **Br J Anaesth** 1995 Aug;75(2):169–76 (126 ref.)
Referred pain in pelvic metastatic disease presentation [letter] Sherry KL, et al. **Br J Gen Pract** 1994 Sep;44(386):425–6
Pain and infertility—a rationale for different treatment approaches. Martin DC. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:2–3 (20 ref.)
An unusual case of testicular pain. Mayfield M, et al. **Br J Urol** 1996 Mar;77(3):471–2
Osteoid osteoma of the clavicle. Lepore L, et al. **Bull Hosp Jt Dis** 1995;54(1):43–5
Case management study: heel pain in the adult. Hurwitz SR. **Bull Rheum Dis** 1996 Jun;45(4):1–3
Pain in burn patients. Latarjet J, et al. **Burns** 1995 Aug; 21(5):344–8
Leg pains after spinal anaesthesia [letter] Cozanitis DA. **Can J Anaesth** 1995 Jul;42(7):657
Temporary back and leg pain after bupivacaine and morphine spinal anaesthesia. Ong B, et al. **Can J Anaesth** 1995 Sep; 42(9):805–7
Expression of B1 kinin receptors mediating paw edema and formalin-induced nociception. Modulation by glucocorticoids. Campos MM, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):812–9
Incident pain. McQuay HJ, et al. **Cancer Surv** 1994;21:17–24
Prediction and portrayal of repetitive stress-induced lower limb pain disorders among soldiers in basic training using videothermography. Sherman RA, et al. **Clin J Pain** 1995 Sep;11(3):236–41
Etiologies of shoulder pain in cervical spinal cord injury. Campbell CC, et al. **Clin Orthop** 1996 Jan;(322):140–5
Knee pain in a 30-year-old man. Horowitz SM, et al. **Clin Orthop** 1996 Jan;(322):293–6, 310–1
Knee pain in a 20-year-old-woman. Horowitz SM, et al. **Clin Orthop** 1996 Aug;(329):337–8, 341–2
Scapular pain and swelling in a 60-year-old man with Paget's disease [clinical conference] Ueda T, et al. **Clin Orthop** 1996 May;(326):284–6, 310–2
Behavioral distress, fear, and pain among children hospitalized for bone marrow transplantation. Rodrigue JR, et al. **Clin Transplant** 1995 Dec;9(6):454–6
Duplex ultrasound examination of the acutely painful and swollen leg. Somjen GM, et al. **Dermatol Surg** 1996 Apr; 22(4):383–7
Which structures are sensitive to painful transcranial electric stimulation? Häkkinen V, et al. **Electromyogr Clin Neurophysiol** 1995 Oct;35(6):377–83
The sickle cell painful crisis in adults: phases and objective signs. Ballas SK. **Hemoglobin** 1995;19(6):323–33 (47 ref.)
Leg pain and kidney disease in a 38-year-old man. Hariharan R, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):119–20
Severe paroxysmal coughing and pleuritic pain in an adult. Musher DM, et al. **Hosp Pract (Off Ed)** 1995 Dec 15; 30(12):65–7
The 21st Meeting of the British Inflammation Research Society, "Inflammatory pain", King's College, London, 19th December, 1994. Cambridge H. **Inflamm Res** 1995 Jun; 44(6):228–30
Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception. Tomassoni G, et al. **J Am Coll Cardiol** 1996 Sep;28(3):695–9
Comparison of newborn circumcision pain to calcaneal heel puncture pain: is newborn circumcision pain control clinically warranted? Holton ME. **J Am Osteopath Assoc** 1996 Jan;96(1):31–3
Paget's disease of bone presenting as chronic ankle pain. Neylon TA. **J Am Podiatr Med Assoc** 1995 Oct; 85(10):556–9
Misdiagnosed recalcitrant heel pain associated with HLA-B27 antigen. Scherer PR, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):538–42
Knee pain after tibial nailing [letter] Hardy JR, et al. **J Bone Joint Surg Br** 1996 May;78(3):510–1
Knee pain after tibial nailing [letter] McCormack D, et al. **J Bone Joint Surg Br** 1996 May;78(3):511
Recurrent irritable hip in childhood. Taylor GR, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):748–51
Hip, knee, and foot pain during pregnancy and the postpartum period. Vullo VJ, et al. **J Fam Pract** 1996 Jul; 43(1):63–8
The surgical dilemma of the malunited calcaneal joint depression fracture: the VAMC Miami experience. Cohen M. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):134–43; discussion 190
Self-efficacy and pain in disability with osteoarthritis of the knee. Rejeski WJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P24–9
Intraneural ganglion of the posterior interosseous nerve with lateral elbow pain. Hashizume H, et al. **J Hand Surg [Br]** 1995 Oct;20(5):649–51
Cervical discogenic syndrome: a cause of chronic head and neck pain. Senter BS. **J Miss State Med Assoc** 1995 Aug; 36(8):231–4 (15 ref.)
Posttraumatic stress disorder occurring after painful childbirth. Fones C. **J Nerv Ment Dis** 1996 Mar; 184(3):195–6
The effect of accident mechanisms and initial findings on the long-term course of whiplash injury. Sturzenegger M, et al. **J Neurol** 1995 Jul;242(7):443–9
Somatosensory findings in patients with spinal cord injury and central dysaesthesia pain. Eide PK, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):411–5
Sensory deficits of a nerve root lesion can be objectively documented by somatosensory evoked potentials elicited by painful infrared laser stimulations: a case study. Lorenz J, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul; 61(1):107–10
Painful ophthalmoplegia caused by hemangiopericytoma of the cavernous sinus. McCall S, et al. **J Neuroophthalmol** 1995 Jun;15(2):98–101
Understanding central post-stroke pain. Segatore M. **J Neurosci Nurs** 1996 Feb;28(1):28–35 (74 ref.)
Case study: the painful os trigonum syndrome. Brown GP, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):22–5
Intertester reliability of the cyriax evaluation in assessing patients with shoulder pain. Pellecchia GL, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):34–8
Differential diagnosis in physical therapy evaluation of thigh pain in an adolescent boy. Pellecchia GL, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):51–5
Patellofemoral pain in female ballet dancers: correlation with iliotibial band tightness and tibial external rotation. Winslow J, et al. **J Orthop Sports Phys Ther** 1995 Jul; 22(1):18–21
Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. Vainio A, et al. **J Pain Symptom Manage** 1996 Jul;12(1):3–10
Pain responses of hospitalized infants and children to venipuncture and intravenous cannulation. Van Cleve L, et al. **J Pediatr Nurs** 1996 Jun;11(3):161–8
Children with cancer: the pain experience away from the health care setting. Bossert EA, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):109–20
Perthes' disease after "irritable hip": delayed bone age shows the hip is a "marked man". Keenan WN, et al. **J Pediatr Orthop** 1996 Jan-Feb;16(1):20–3
Baseline correlates of the response to the treatment of chronic localized myofascial pain syndrome by injection of local anaesthetic. Scicchitano J, et al. **J Psychosom Res** 1996 Jan;40(1):75–85
Aspirin-mouthwash relieves pain of oral lesions. Angirish A. **J R Soc Health** 1996 Apr;116(2):105–6
The pentothal test in the management of orthopaedic patients with hysterical illness. Cornell MS, et al. **J R Soc Med** 1996 Jan;89(1):37P–8P
Chronic pain: time for epidemiology [letter] Gunn CC. **J R Soc Med** 1996 Aug;89(8):479–80
Pain and corneal foreign bodies. Shah S, et al. **J R Soc Med** 1995 Jul;88(7):406P–407P
Neck pain in a young woman. **J Tenn Med Assoc** 1996 Feb; 89(2):48–9
Arthroscopy of the knee without pathological findings. Schlepckow P, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):85–7
A woman with bone pain, fractures, and malabsorption [see comments] Bertoli A, et al. **Lancet** 1996 Feb 3; 347(8997):300. Comment in: Lancet 1996 Mar 23;347(9004):829. Comment in: Lancet 1996 Mar 23;347(9004):829–30. Comment in: Lancet 1996 Apr 13;347(9007):1050.
A porter with pain in his neck. Dalmak S, et al. **Lancet** 1996 Aug 17;348(9025):444
Late whiplash syndrome [letter; comment] Freeman MD, et al. **Lancet** 1996 Jul 13;348(9020):125; discussion 125–6. Comment on: Lancet 1996 May 4;347(9010):1207–11.
The painful eye [letter; comment] Lightman S, et al. **Lancet** 1996 Feb 3;347(8997):338. Comment on: Lancet 1995 Nov 11;346(8985):1269.
A distressed woman with epigastric pain. Martin-Du Pan RC, et al. **Lancet** 1996 Aug 31;348(9027):586
Pain in the neck [letter] Schattner A. **Lancet** 1996 Aug 10; 348(9024):411–2
Magnetic resonance imaging of plantar fasciitis and other causes of heel pain. Kier R. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):97–107 (35 ref.)
Giant colonic diverticulum [letter] Silen W, et al. **N Engl J Med** 1995 Dec 14;333(24):1645
The illusion of certainty. Wolinsky AP. **N Engl J Med** 1996 Jul 4;335(1):46–8
Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103–17 (52 ref.)
Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11–6; discussion S35–6 (24 ref.)
Tardive pain [letter; comment] Howsepian AA. **Neurology** 1995 Nov;45(11):2113; discussion 2114. Comment on: Neurology 1994 Nov;44(11):2115–9.
Tardive pain [letter; comment] Montagna P, et al. **Neurology** 1995 Nov;45(11):2113–4. Comment on: Neurology 1994 Nov;44(11):2115–9.
Painful torticollis with tongue atrophy—a different neck-tongue syndrome. O'Meara M, et al. **Neuropediatrics** 1995 Oct;26(5):276–80
Relationship between atlanto-odontoid osteoarthritis and idiopathic suboccipital neck pain. Zapletal J, et al. **Neuroradiology** 1996 Jan;38(1):62–5
Patterns of pain experiences and use of analgesics among hospitalized cancer patients in Korea. Lee EO, et al. **Nurs Clin North Am** 1995 Dec;30(4):647–57
Vulvar vestibulitis—with special reference to sexual function [letter] Rendler TJ, et al. **Nurse Pract** 1995 Dec;20(12):9–10
Needle wire localization for nonpalpable breast lesions: sensations, anxiety levels, and informational needs. Kelly P, et al. **Oncol Nurs Forum** 1996 May;23(4):639–45
Diagnostic imaging and arthroscopy for chronic wrist pain. Weiss AP, et al. **Orthop Clin North Am** 1995 Oct; 26(4):759–67
Two in one: the genesis of central pain [letter] Canavero S, et al. **Pain** 1996 Feb;64(2):394–5
Comments on Pentland and Donald [letter] Genis D, et al. **Pain** 1996 Feb;64(2):402–3
Can stress-related shoulder and neck pain develop independently of muscle activity? Vasseljen O Jr, et al. **Pain** 1996 Feb;64(2):221–30
Phantom or central neuropathic pain? [letter] Vecht CJ, et al. **Pain** 1995 Dec;63(3):392–4
Pain profile in alcoholic and nonalcoholic chronic pancreatitis (CP) [letter] Ammann RW. **Pancreas** 1996 Apr; 12(3):315–8
Pain and life quality within 2 years of spinal cord injury. Anke AG, et al. **Paraplegia** 1995 Oct;33(10):555–9
Reliability and validity of the Wheelchair User's Shoulder Pain Index (WUSPI). Curtis KA, et al. **Paraplegia** 1995 Oct;33(10):595–601
Late, painful, subungual hyperkeratosis in incontinentia pigmenti. Abimelec P, et al. **Pediatr Dermatol** 1995 Dec; 12(4):340–2
Pain and human immunodeficiency virus infection in children [comment] Yaster M, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):455–6. Comment on: Pediatrics 1996 Sep;98(3 Pt

1):449–52.
Chronic pain is associated with deficits in information processing. Grigsby J, et al. **Percept Mot Skills** 1995 Oct; 81(2):403–10
NGF as a mediator of inflammatory pain. McMahon SB. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):431–40 (86 ref.)
Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Woolf CJ. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):441–8 (34 ref.)
Proctalgia fugax: would you recognize it? Babb RR. **Postgrad Med** 1996 Apr;99(4):263–4
Activity restriction mediates the association between pain and depressed affect: a study of younger and older adult cancer patients. Williamson GM, et al. **Psychol Aging** 1995 Sep;10(3):369–78
Sensory focus as therapeutic treatments for acute pain. Logan HL, et al. **Psychosom Med** 1995 Sep–Oct;57(5):475–84
Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Uppelschoten JM, et al. **Radiother Oncol** 1995 Sep;36(3):198–202
1994 ASRA Lecture. The pathogenesis of neuropathic pain. Myers RR. **Reg Anesth** 1995 May–Jun;20(3):173–84 (56 ref.)
Exercise-induced lower leg pain. Rochcongar P. **Rev Rhum Engl Ed** 1995 Nov;62(10):627–31 (35 ref.)
A case of rheumatoid arthritis with lumbar spine involvement. Biasi D, et al. **Rheumatol Int** 1995;15(3):125–6
Side-effects of chiropractic spinal manipulation: types frequency, discomfort and course. Senstad O, et al. **Scand J Prim Health Care** 1996 Mar;14(1):50–3
Validity of five common manual neck pain provoking tests. Sandmark H, et al. **Scand J Rehabil Med** 1995 Sep; 27(3):131–6
Characteristics of subjects with chronic pain, in relation to local and widespread pain report. A prospective study of symptoms, clinical findings and blood tests in subgroups of a geographically defined population. Andersson HI, et al. **Scand J Rheumatol** 1996;25(3):146–54
Controlling the pain of cancer. Foley KM. **Sci Am** 1996 Sep; 275(3):164–5 (0 ref.)
Digital subtraction arthrography in preoperative evaluation of painful total hip arthroplasty. Ginai AZ, et al. **Skeletal Radiol** 1996 May;25(4):357–63
CT determination of tibial tubercle lateralization in patients presenting with anterior knee pain. Jones RB, et al. **Skeletal Radiol** 1995 Oct;24(7):505–9
Cervical discogenic pain. Prospective correlation of magnetic resonance imaging and discography in asymptomatic subjects and pain sufferers. Schellhas KP, et al. **Spine** 1996 Feb 1;21(3):300–11; discussion 311–2
Evaluation of acute scrotal pain by color-coded duplex sonography. Schwaibold H, et al. **Urol Int** 1996;56(2):96–9
[Pelvic pain caused by pregnancy (letter)] Pel M. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2586–7 **(Dut)**
[Isolated punched-out lesions of the carpus and pain of the wrist] Dumontier C, et al. **Ann Radiol (Paris)** 1995; 38(5):287–92 (50 ref.) (Eng. Abstr.) **(Fre)**
[Bone pain revealing parathyroid adenoma (letter; comment)] Beauvais P. **Arch Pediatr** 1995 Oct;2(10):1022. Comment on: Arch Pediatr 1995 Jan;2(1):89. **(Fre)**
[Pain in lumbar puncture. Results of a 2-year discussion at the French Society of Pediatric Oncology] Bouffet E, et al. **Arch Pediatr** 1996 Jan;3(1):22–7 (Eng. Abstr.) **(Fre)**
[Painful experience of urodynamic and neurophysiological examinations (letter)] Amarenco G, et al. **Presse Med** 1996 Apr 20;25(14):688 **(Fre)**
[Comparative study of the costs for two hematopoietic cell specimen collections: cytapheresis and bone marrow collection] Le Corroller AG, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):133–43 (Eng. Abstr.) **(Fre)**
[Unusual cervical and thoracic pain in 2 young patients] Favrat B, et al. **Rev Med Suisse Romande** 1995 Aug; 115(8):591–3 **(Fre)**
[MRI of musculature in myalgia—indications and image findings] Beese MS, et al. **Aktuelle Radiol** 1996 May; 6(3):119–29 (Eng. Abstr.) **(Ger)**
[Molecular mechanisms of chronic pain] Tokunaga A, et al. **Masui** 1996 May;45(5):547–57 (63 ref.) (Eng. Abstr.) **(Jpn)**
[Pain mechanisms in reflex sympathetic dystrophy] Yokota T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):788–97 (30 ref.) **(Jpn)**
[Analysis of clinical symptoms in shoulder arthropathy] Fabiś J, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(2):133–7 (Eng. Abstr.) **(Pol)**
[Evaluation of endometrial changes in women with cyclical mastalgia] Wypych K, et al. **Ginekol Pol** 1995 Aug; 66(8):451–6 (Eng. Abstr.) **(Pol)**
[Differences in spinal dorsal horn neuronal activity in rats developing and not developing a pain syndrome after cutting the sciatic nerve] Kryzhanovskiĭ GN, et al. **Biull Eksp Biol Med** 1995 May;119(5):470–4 **(Rus)**
[Pain in the upper extremity after a stroke] Marchuk G, et al. **Lik Sprava** 1995 May–Jun;(5–6):55–61 (108 ref.) (Eng. Abstr.) **(Rus)**
[Posttuberculous cystalgia] Kul'chavenia EV. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):47–9 (Eng. Abstr.) **(Rus)**
[Acute painful neuropathy—2 case reports] Tešić D, et al. **Med Pregl** 1995;48(11–12):25–8 (Eng. Abstr.) **(Scr)**
[Treatment of pain and anxiety in terminal oncologic patients in the Castilla-La Mancha community] Calles Gato MD, et al. **Aten Primaria** 1995 Sep 30;16(5):276–80 (Eng. Abstr.) **(Spa)**

GENETICS

Antinociceptive defect of beige-J mice reversed by i.c.v. IP3 or myo-inositol. Raffa RB, et al. **Neuroreport** 1995 Jul 10; 6(10):1434–6
The genetics of pain and pain inhibition. Mogil JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3048–55 (141 ref.)

HISTORY

Advances in the practice of medicine: contributions of pain management. Raj PP. **Ann Acad Med Singapore** 1996 Jan; 25(1):152–9
Regional anesthesia and chronic pain management in the 1920s and 1930s. The influence of the American Society of Regional Anesthesia. Bacon DR, et al. **Reg Anesth** 1995 May–Jun;20(3):185–92
[The problem of treating severe pain syndromes of different origins and the contribution of Prof. N. Ia. Vasin to its study] Shevelev IN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jan–Mar; (1):37–9 **(Rus)**

IMMUNOLOGY

Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. Mnich SJ, et al. **J Immunol** 1995 Nov 1;155(9):4437–44
Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Watkins LR, et al. **Pain** 1995 Dec;63(3):289–302 (135 ref.)

METABOLISM

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S–53S (30 ref.)
Remembrance of times past: the significance of c-fos in pain [editorial; comment] Munglani R, et al. **Br J Anaesth** 1996 Jan;76(1):1–4. Comment on: Br J Anaesth 1996 Jan;76(1):99–105.
Molecular biology of pain. Munglani R, et al. **Br J Anaesth** 1995 Aug;75(2):186–92 (84 ref.)
Immunohistochemical determination of rat spinal cord substance P, and antinociceptive effect during development of thiamine deficiency. Tadano T, et al. **Brain Res** 1995 Oct 23;696(1–2):21–9
Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):854–9 (49 ref.)
Possible therapeutic application of GABAB receptor agonists and antagonists. Malcangio M, et al. **Clin Neuropharmacol** 1995 Aug;18(4):285–305 (162 ref.)
Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins. Lantéri-Minet M, et al. **Exp Brain Res** 1995;105(2):220–32
Subnuclear localization of FOS-like immunoreactivity in the rat parabrachial nucleus after nociceptive stimulation. Hermanson O, et al. **J Comp Neurol** 1996 Apr 22; 368(1):45–56
L-NAME, an inhibitor of nitric oxide synthase, blocks the established allodynia induced by intrathecal administration of prostaglandin E2. Minami T, et al. **Neurosci Lett** 1995 Dec 15;201(3):239–42
Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Abbadie C, et al. **Neuroscience** 1996 Jan;70(1):201–9
Tail pinch increases acetylcholine release in rat striatum even after toluene exposure. Stengård K. **Pharmacol Biochem Behav** 1995 Oct;52(2):261–4

MICROBIOLOGY

Staphylococcus aureus and sore nipples. Livingstone VH, et al. **Can Fam Physician** 1996 Apr;42:654–9

NURSING

Assessing pain in neonates. Bell SG. **Am J Nurs** 1995 Dec; 95(12):15–6
'My pain is God's will'. Kumasaka L, et al. **Am J Nurs** 1996 Jun;96(6):45–7
Relieving pain during ulcer healing. van Rijswijk L. **Am J Nurs** 1995 Oct;95(10):28–30
Pain and elderly patients: a survey of nurses' knowledge and experiences. Closs SJ. **J Adv Nurs** 1996 Feb;23(2):237–42
Patient suffering: a taxonomy from the nurse's perspective. Flaming D. **J Adv Nurs** 1995 Dec;22(6):1120–7
Home epidural analgesic infusion for non-cancer pain. Ploughe B. **J Neurosci Nurs** 1995 Aug;27(4):245–51
Pain management instruction in nursing curricula. Zalon ML. **J Nurs Educ** 1995 Sep;34(6):262–7
Special needs of preterm infants in the management of pain and discomfort. Stevens BJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):856–62 (65 ref.)
Pain management knowledge, attitudes and clinical practice: the impact of nurses' characteristics and education. Clarke EB, et al. **J Pain Symptom Manage** 1996 Jan;11(1):18–31
Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Grant M, et al. **Nurs Clin North Am** 1995 Dec;30(4):673–82
An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)
The impact of cancer pain education on family caregivers of elderly patients. Ferrell BR, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1211–8
The knowledge and attitudes of experience oncology nurses regarding the management of cancer-related pain. O'Brien S, et al. **Oncol Nurs Forum** 1996 Apr;23(3):515–21
Differences in pain knowledge and perception of the pain experience between outpatients with cancer and their family caregivers. Yeager KA, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1235–41
Nurses in private nursing homes: a study of their knowledge and attitudes to pain management in palliative care. Gibbs G. **Palliat Med** 1995 Jul;9(3):245–53

PHYSIOPATHOLOGY

Approach to the management of nonmalignant pain. Katz WA. **Am J Med** 1996 Jul 31;101(1A):54S–63S (64 ref.)
Mechanisms of chronic pain. Markenson JA. **Am J Med** 1996 Jul 31;101(1A):6S–18S (141 ref.)
Cardiovascular responses to noxious stimuli during isoflurane anesthesia are minimally affected by anesthetic action in the brain. Antognini JF, et al. **Anesth Analg** 1995 Oct; 81(4):843–8
Divergence of intracranial and central venous pressures in lightly anesthetized, tracheally intubated dogs that move in response to a noxious stimulus. Lanier WL, et al. **Anesthesiology** 1996 Mar;84(3):605–13
Arteriovenous differences in plasma concentrations of catechols in rats with neuropathic pain. Raja SN, et al. **Anesthesiology** 1995 Nov;83(5):1000–8
Acute pain and central nervous system arousal do not restore impaired hypoxic ventilatory response during sevoflurane sedation. Sarton E, et al. **Anesthesiology** 1996 Aug; 85(2):295–303
Effect of propofol on spinal dorsal horn neurons. Comparison with lack of ketamine effects. Uchida H, et al. **Anesthesiology** 1995 Dec;83(6):1312–22
Horizons in Pain Research. San Diego, California, May 19–21, 1995. Yaksh TL. **Anesthesiology** 1996 Jan; 84(1):245–8
Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia [comment] [see comments] Rosen SD, et al. **Ann Intern Med** 1996 Jun 1;124(11):939–49. Comment on: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):959–69. Comment on: Ann Intern Med 1995 Jun 1;124(11):995–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):1006–8. Comment in: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment in: Ann Intern Med 1996 Jun 1;124(11):959–69. Comment in: Ann Intern Med 1996 Jun 1;124(11):995–8.
More pain, more tender points: is fibromyalgia just one end of a continuous spectrum? Croft P, et al. **Ann Rheum Dis** 1996 Jul;55(7):482–5
Cerebral mechanisms operating in the presence and absence of inflammatory pain. Jones AK, et al. **Ann Rheum Dis** 1996 Jul;55(7):411–20 (83 ref.)
Pathophysiology of joint pain. Kidd BL, et al. **Ann Rheum Dis** 1996 May;55(5):276–83 (100 ref.)
Neck flexor muscle strength, efficiency, and relaxation times in normal subjects and subjects with unilateral neck pain and headache. Barton PM, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):680–7
Exercise-induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec; 26(3–4):49–58 (133 ref.)
Exposure to oscillating magnetic fields influences sensitivity to electrical stimuli. I. Experiments on pigeons. Del Seppia C, et al. **Bioelectromagnetics** 1995;16(5):290–4
Exposure to oscillating magnetic fields influences sensitivity to electrical stimuli. II. Experiments on humans. Papi F, et al. **Bioelectromagnetics** 1995;16(5):295–300
Nerve growth factor regulates nociception in human health and disease. Anand P. **Br J Anaesth** 1995 Aug;75(2):201–8 (64 ref.)
Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)
Spinal cord pharmacology of pain. Dickenson AH. **Br J Anaesth** 1995 Aug;75(2):193–200 (71 ref.)
Inflammatory mediators of pain. Dray A. **Br J Anaesth** 1995 Aug;75(2):125–31 (60 ref.)
Developmental biology of inflammatory pain. Fitzgerald M. **Br J Anaesth** 1995 Aug;75(2):177–85 (124 ref.)
Visceral pain. McMahon SB, et al. **Br J Anaesth** 1995 Aug; 75(2):132–44 (114 ref.)
Descending control of pain. Stamford JA. **Br J Anaesth** 1995 Aug;75(2):217–27 (133 ref.)
Capsaicin and pain mechanisms. Winter J, et al. **Br J Anaesth** 1995 Aug;75(2):157–68 (120 ref.)
Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects. Lötsch J, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):339–46
Effects of azapropazone on pain-related brain activity in human subjects. Lötsch J, et al. **Br J Clin Pharmacol** 1995

Dec;40(6):545–52
The contribution of NMDA receptor activation to spinal c–Fos expression in a model of inflammatory pain. Chapman V, et al. **Br J Pharmacol** 1995 Sep;116(1):1628–34
Why does an inflammation in the joint hurt? [editorial] Schaible HG. **Br J Rheumatol** 1996 May;35(5):405–6 (11 ref.)
The relationship of pain, allodynia and thermal sensation in post–herpetic neuralgia. Rowbotham MC, et al. **Brain** 1996 Apr;119 (Pt 2):347–54
Brief, prolonged and repeated stimuli applied to hyperalgesic skin areas: a psychophysical study. Arendt–Nielsen L, et al. **Brain Res** 1996 Mar 11;712(1):165–7
A pharmacological study of the modulation of neuronal and behavioural nociceptive responses in the rat trigeminal region. Cahusac PM, et al. **Brain Res** 1995 Nov 27; 700(1–2):70–82
Strain differences in autotomy levels in mice: relation to spinal excitability. Defrin R, et al. **Brain Res** 1996 Mar 4;711(1–2):241–4
Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Devillers JP, et al. **Brain Res** 1995 Nov 27;700(1–2):173–81
Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Jenab S, et al. **Brain Res** 1995 Sep 11;691(1–2):69–75
Antisense oligodeoxynucleotides to the kappa–1 receptor block the antinociceptive effects of delta 9–THC in the spinal cord. Pugh G Jr, et al. **Brain Res** 1995 Aug 14; 689(1):157–8
Cutaneous nociceptive facilitation of Ib heteronymous pathways to lower limb motoneurones in humans. Rossi A, et al. **Brain Res** 1995 Nov 27;700(1–2):164–72
Immunohistochemical determination of rat spinal cord substance P, and antinociceptive effect during development of thiamine deficiency. Tadano T, et al. **Brain Res** 1995 Oct 23;696(1–2):21–9
Basal release of Met–enkephalin and neurotensin in the ventrolateral periaqueductal gray matter of the rat: a microdialysis study of antinociceptive circuits. Williams FG, et al. **Brain Res** 1995 Sep 4;690(2):207–16
Kappa–opioid receptor modulation of the release of substance P in the dorsal horn. Zachariou V, et al. **Brain Res** 1996 Jan 8;706(1):80–8
Interaction of serotonin and norepinephrine in spinal antinociception. Zhang ZH, et al. **Brain Res Bull** 1995; 38(2):167–71
Whole head mapping of magnetic fields following painful electric finger shock. Howland EW, et al. **Brain Res Cogn Brain Res** 1995 Jul;2(3):165–72
Effects of a selective A beta afferent block on the pain–related SEP scalp topography. Dowman R, et al. **Brain Topogr** 1995 Fall;8(1):57–65
Thiopentone induced enhancement of somatic motor responses to noxious stimulation: influence of GABAA receptor modulation. Archer DP, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):503–10
Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Yang CY, et al. **Can J Anaesth** 1996 Apr;43(4):379–83
Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)
Cross–correlation between stress, pain, physical activity, and temporalis muscle EMG in tension–type headache. Clark GT, et al. **Cephalalgia** 1995 Dec;15(6):511–8, discussion 451
Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)
Complement activation during painful crisis in sickle cell anemia. Mold C, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):314–20
Differential consequences of left– and right–sided chronic pain. Gagliese L, et al. **Clin J Pain** 1995 Sep;11(3):201–7
Preemption and prevention [editorial] Wilson PR. **Clin J Pain** 1996 Mar;12(1):1–2
Bilateral painful epileptic seizures of the hands. Otani K, et al. **Dev Med Child Neurol** 1995 Oct;37(10):933–6
Comparison of functional characteristics of intradental A– and C–nerve fibres in dental pain. Ngassapa DN. **East Afr Med J** 1996 Mar;73(3):207–9 (30 ref.)
Pain–related and cognitive components of somatosensory evoked potentials following CO2 laser stimulation in man. Kanda M, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar;100(2):105–14
Pain–related somatosensory evoked magnetic fields. Kitamura Y, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec;95(6):463–74
Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Lorenz J, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):165–8
The role of spinal neurokinin–2 receptors in the processing of nociceptive information from the joint and in the generation and maintenance of inflammation–evoked hyperexcitability of dorsal horn neurons in the rat. Neugebauer V, et al. **Eur J Neurosci** 1996 Feb;8(2):249–60
The nature and consequences of childbirth pain. Brownridge P. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S9–15 (64 ref.)
Role of patient–controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39–46 (45 ref.)
Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Damaj MI, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):51–7
Buprenorphine blocks diffuse noxious inhibitory controls in the rat. Guirimand F, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):651–9
Cyclophosphamide cystitis as a model of visceral pain in rats. A survey of hindbrain structures involved in visceroception and nociception using the expression of c–Fos and Krox–24 proteins. Bon K, et al. **Exp Brain Res** 1996 Mar; 108(3):404–16
A correlogram analysis of the activity in the rostral ventromedial medulla of awake rats and in rats anesthetized with ketamine or pentobarbital following the administration of morphine. McGaraughty S, et al. **Exp Brain Res** 1995; 106(2):283–90
Hypophysectomy produces analgesia and paraventricular lesions have no effect on formalin–induced pain. Lariviere WR, et al. **Exp Neurol** 1995 Sep;135(1):74–9
Pain perception and brain evoked potentials in patients with angina despite normal coronary angiograms. Frøbert O, et al. **Heart** 1996 May;75(5):436–41
Amygdalar involvement in pain. Mena NB, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):339–46
Pain due to nerve damage: are inflammatory mediators involved? Tracey DJ, et al. **Inflamm Res** 1995 Oct; 44(10):407–11 (67 ref.)
Itch and pain. Teofoli P, et al. **Int J Dermatol** 1996 Mar; 35(3):159–66 (98 ref.)
Changes in rat bladder function following exposure to pain and water stimuli. Saito M, et al. **Int J Urol** 1995 May; 2(2):92–5
Transient hyperacute allodynia in Schneider's syndrome: an irritative genesis? Canavero S, et al. **Ital J Neurol Sci** 1995 Nov;16(8):555–7
High–potency topical corticosteroid rapidly decreases histamine–induced itch but not thermal sensation and pain in human beings. Yosipovitch G, et al. **J Am Acad Dermatol** 1996 Jul;35(1):118–20
Suppression of first pain and slow temporal summation of second pain in relation to age. Harkins SW, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M260–5
Dermatomes: pain and temperature [letter; comment] Kanpolat Y. **J Neurosurg** 1996 May;84(5):892. Comment on: J Neurosurg 1995 Jul;83(1):8–12.
Dermatomes: pain and temperature [letter; comment] Parkinson D. **J Neurosurg** 1996 May;84(5):892. Comment on: J Neurosurg 1995 Jul;83(1):8–12.
Effect of clonidine on ICP and on the hemodynamic responses to nociceptive stimuli in patients with brain tumors. Favre JB, et al. **J Neurosurg Anesthesiol** 1995 Jul; 7(3):159–67
The pain and discomfort of labor and birth. Lowe NK. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):82–92 (56 ref.)
Rearfoot posture in subjects with patellofemoral pain. Powers CM, et al. **J Orthop Sports Phys Ther** 1995 Oct;22(4):155–60
Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone. Ossipov MH, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):784–8
Effect of noxious stimulation on sympathetic vasoconstrictor outflow to human muscles. Nordin M, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):885–94
Anterior pretectal nucleus facilitation of superficial dorsal horn neurones and modulation of deafferentation pain in the rat. Rees H, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):159–69
Negative affectivity, somatic complaints, and symptoms of temporomandibular disorders. Vassend O, et al. **J Psychosom Res** 1995 Oct;39(7):889–99
Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)
An evaluation of knee extensor and knee flexor torques and EMGs in patients with patellofemoral pain syndrome in comparison with matched controls. Werner S. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):89–94
Effect of taping the patella on concentric and eccentric torque and EMG of knee extensor and flexor muscles in patients with patellofemoral pain syndrome. Werner S, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):169–77
Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas [clinical conference] [see comments] **Lancet** 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Jan 27;347(8996):261. Comment in: Lancet 1996 Jan 27;347(8996):261–2. Comment in: Lancet 1996 Jan 27;347(8996):262. Comment in: Lancet 1996 Jan 27;347(8996):263.
A unifying purinergic hypothesis for the initiation of pain. Burnstock G. **Lancet** 1996 Jun 8;347(9015):1604–5
Effect on nociception of intracerebroventricular administration of low doses of neuropeptide Y in mice. Mellado ML, et al. **Life Sci** 1996 May 24;58(26):2409–14
The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Clauw DJ. **Med Hypotheses** 1995 May;44(5):369–78 (83 ref.)
Obtaining automated diagnostic information and pain relief. Collins HW. **Med Hypotheses** 1995 Oct;45(4):389–91
No pain, some gain [news; comment] Wood JN. **Nat Genet** 1996 Aug;13(4):382–3. Comment on: Nat Genet 1996 Aug;13(4):485–8.
Are there separate central nervous system pathways for touch and pain? [see comments] Berkley KJ, et al. **Nat Med** 1995 Aug;1(8):766–73. Comment in: Nat Med 1995 Aug;1(8):740–1.
Stimulation in the human somatosensory thalamus can reproduce both the affective and sensory dimensions of previously experienced pain [see comments] Lenz FA, et al. **Nat Med** 1995 Sep;1(9):910–3. Comment in: Nat Med 1995 Sep;1(9):885–7.
The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA–IgG fusion molecule [see comments] McMahon SB, et al. **Nat Med** 1995 Aug;1(8):774–80. Comment in: Nat Med 1995 Aug;1(8):740–1.
Unpleasant pain evoked by thalamic stimulation [comment] Price DD. **Nat Med** 1995 Sep;1(9):885–7. Comment on: Nat Med 1995 Sep;1(9):910–3.
Independent mechanisms converge on pain [comment] [see comments] Wall PD. **Nat Med** 1995 Aug;1(8):740–1. Comment on: Nat Med 1995 Aug;1(8):766–73. Comment on: Nat Med 1995 Aug;1(8):774–80. Comment in: Nat Med 1995 Oct;1(10):976.
How should we measure pain in herpes zoster? Wood MJ. **Neurology** 1995 Dec;45(12 Suppl 8):S61–2 (5 ref.)
The involvement of metabotropic glutamate receptors and their intracellular signalling pathways in sustained nociceptive transmission in rat dorsal horn neurons. Young MR, et al. **Neuropharmacology** 1995 Aug;34(8):1033–41
Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Bian D, et al. **Neuroreport** 1995 Oct 23;6(15):1981–4
fMRI of human somatosensory and cingulate cortex during painful electrical nerve stimulation. Davis KD, et al. **Neuroreport** 1995 Dec 29;7(1):321–5
Neonatal treatment with 5–HT antiserum alters 5–HT metabolism and function in adult rats. Mohanakumar KP, et al. **Neuroreport** 1995 Dec 29;7(1):238–40
Nicotinic acetylcholine receptors on capsaicin–sensitive nerves. Roberts RG, et al. **Neuroreport** 1995 Jul 31; 6(11):1578–82
Intact female rats are more susceptible to the development of tactile allodynia than ovariectomized female rats following partial sciatic nerve ligation (PSNL). Coyle DE, et al. **Neurosci Lett** 1996 Jan 12;203(1):37–40
Supraspinal influences on the facilitation of rat nociceptive reflexes induced by carrageenan monoarthritis. Herrero JF, et al. **Neurosci Lett** 1996 May 3;209(1):21–4
Involvement of delta 1–opioid receptors in the antinociceptive effects of mexiletine in mice. Kamei J, et al. **Neurosci Lett** 1995 Aug 25;196(3):169–72
Mechanical allodynia is more strongly manifested in older rats in an experimental model of peripheral neuropathy. Kim YI, et al. **Neurosci Lett** 1995 Oct 20;199(2):158–60
Cortical reorganization in human amputees and mislocalization of painful stimuli to the phantom limb. Knecht S, et al. **Neurosci Lett** 1995 Dec 15;201(3):262–4
Pressor responses to distension of the ureter in anaesthetised rats: characterisation of a model of acute visceral pain. Roza C, et al. **Neurosci Lett** 1995 Sep 22;198(1):9–12
Pain due to experimental acidosis in human skin: evidence for non–adapting nociceptor excitation. Steen KH, et al. **Neurosci Lett** 1995 Oct 13;199(1):29–32
Lateral hypothalamus: site involved in pain modulation. Dafny N, et al. **Neuroscience** 1996 Jan;70(2):449–60
Central dysesthesia pain after traumatic spinal cord injury is dependent on N–methyl–D–aspartate receptor activation. Eide PK, et al. **Neurosurgery** 1995 Dec;37(6):1080–7
Dorsal horn convergent neurones: negative feedback triggered by spatial summation of nociceptive afferents. Bouhassira D, et al. **Pain** 1995 Aug;62(2):195–200
Comments on Thurston and Randich [letter] Fields HL, et al. **Pain** 1996 Feb;64(2):396–8
Plasma atrial natriuretic factor levels, impaired myocardial contractility and pain intensity in uncomplicated acute myocardial infarction. Fontana F, et al. **Pain** 1995 Aug; 62(2):213–8
Influence of eye orientation on pain as a function of anxiety. Honoré J, et al. **Pain** 1995 Nov;63(2):213–8
Traumatic nociceptive pain activates the hypothalamus and the periaqueductal gray: a positron emission tomography study. Hsieh JC, et al. **Pain** 1996 Feb;64(2):303–14
Differential response to pain by very premature neonates. Johnston CC, et al. **Pain** 1995 Jun;61(3):471–9
Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Park KM, et al. **Pain** 1995 Nov;63(2):163–72
Phrenic afferent input excites C1–C2 spinal neurons in rats. Razook JC, et al. **Pain** 1995 Oct;63(1):117–25
Responses of on and off cells in the rostral ventral medulla to stimulation of vagal afferents and changes in mean arterial blood pressure in intact and cardiopulmonary deafferented rats. Thurston CL, et al. **Pain** 1995 Jul; 62(1):19–38
Relationship between hypothalamic–pituitary–adrenal activity and blockade of tolerance to morphine analgesia by pain: a strain comparison. Vaccarino AL, et al. **Pain** 1995 Dec;63(3):385–9

Can stress-related shoulder and neck pain develop independently of muscle activity? Vasseljen O Jr, et al. **Pain** 1996 Feb;64(2):221–30

Pain in the brain and lower parts of the anatomy [letter] Wall PD. **Pain** 1995 Sep;62(3):389–93

Differential modulation of alpha 2-adrenergic and mu-opioid spinal antinociception by neuropeptide FF. Kontinen VK, et al. **Peptides** 1995;16(5):973–7

Biological rhythms in pain and in the effects of opioid analgesics. Labrecque G, et al. **Pharmacol Ther** 1995; 68(1):129–47 (80 ref.)

Excessive scapular motion in individuals recovering from painful and stiff shoulders: causes and treatment strategies. Babyar SR. **Phys Ther** 1996 Mar;76(3):226–38; discussion 239–47

Timing and intensity of vastus muscle activity during functional activities in subjects with and without patellofemoral pain. Powers CM, et al. **Phys Ther** 1996 Sep;76(9):946–55; discussion 956–67

Antinociceptive properties of steroids isolated from Phyllanthus corcovadensis in mice. Santos AR, et al. **Planta Med** 1995 Aug;61(4):329–32

The genetics of pain and pain inhibition. Mogil JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3048–55 (141 ref.)

Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Rubinstein M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3995–4000

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al. **Prog Brain Res** 1995;104:225–53 (306 ref.)

Peptidergic afferents: physiological aspects. Urban L, et al. **Prog Brain Res** 1995;104:255–69 (71 ref.)

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367–80 (80 ref.)

Neuropeptides and spinal cord reflexes. Wiesenfeld-Hallin Z. **Prog Brain Res** 1995;104:271–82 (104 ref.)

Effects of interstimulus interval on scalp topographies evoked by noxious sural nerve stimulation. Dowman R. **Psychophysiology** 1996 Jul;33(4):398–408

Parental history of hypertension and enhanced cardiovascular reactivity are associated with decreased pain ratings. France CR, et al. **Psychophysiology** 1995 Nov;32(6):571–8

Peroneal afferent nerve discharges underlying the behavioral response to the formalin test. Abram SE, et al. **Reg Anesth** 1996 May-Jun;21(3):226–33

Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming. Mizoguchi H, et al. **Regul Pept** 1995 Oct 20; 59(2):255–9

Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108-15 hybrid cells. Roerig SC, et al. **Regul Pept** 1996 Jan 16; 61(1):51–6

Patellofemoral pain syndrome in young women. II. Muscle function in patients and healthy controls. Thomeé R, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):245–51

The effect of pain reduction on perceived tension and EMG-recorded trapezius muscle activity in workers with shoulder and neck pain. Vasseljen O Jr, et al. **Scand J Rehabil Med** 1995 Dec;27(4):243–52

Are tender point scores assessed by manual palpation in fibromyalgia reliable? An investigation into the variance of tender point scores. Jacobs JW, et al. **Scand J Rheumatol** 1995;24(4):243–7

Rheumatic pains of previously undiagnosed diabetic subjects. Qiao Q, et al. **Scand J Rheumatol** 1995;24(4):234–7

Delayed muscle soreness. The inflammatory response to muscle injury and its clinical implications. MacIntyre DL, et al. **Sports Med** 1995 Jul;20(1):24–40

Thalamic stereotaxis for chronic pain: ablative lesion or stimulation? Hariz MI, et al. **Stereotact Funct Neurosurg** 1995;64(1):47–55

[The roles of thalamic nucleus submedius in nociception and pain modulation] Tang JS, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):312–6 (20 ref.) (Eng. Abstr.) **(Chi)**

[Do neonates and small infants feel pain?] Hertel SA. **Nord Med** 1995;110(11):273–4 (Eng. Abstr.) **(Dan)**

[From nociception to pain: to feel or not to feel (editorial)] Konttinen YT, et al. **Duodecim** 1994;110(6):545–8 (15 ref.) **(Fin)**

[Thrombosis of the internal jugular vein as a cause of neck pain] Putkonen M, et al. **Duodecim** 1995;111(5):447–51 **(Fin)**

[Physiology of pain in the XVIII century] Lassner J. **Cah Anesthesiol** 1995;43(3):331–5 **(Fre)**

[Rational use of analgesics] Dayer P. **Rev Med Suisse Romande** 1996 Apr;116(4):295–8 **(Fre)**

[Pain—from the physiological and internal medicine viewpoint] Lang E, et al. **Z Gerontol Geriatr** 1995 Sep-Oct; 28(5):318–27 (30 ref.) (Eng. Abstr.) **(Ger)**

[Modulation of evoked potentials following electrical tooth stimulation by pre-auditory stimulus] Inada M. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):313–33 (Eng. Abstr.) **(Jpn)**

[The participation of opioids in the antinociceptive effect induced by the stimulation of hypothalamic "pleasure zones" in 20- to 30-day-old rabbits] Butkevich IP, et al. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):200–7 (Eng. Abstr.) **(Rus)**

[The nociceptive flexor reflex: a method for studying the brain mechanisms of pain control] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(1):107–11 (63 ref.) **(Rus)**

[The effect of unilateral cortical inactivation on the perception of pain vocalizations in rats] Snarskiĭ SI. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):179–83 **(Rus)**

[Cervical pain as a clinical sign of spontaneous intracranial hypotension] Moreno MJ, et al. **Neurologia** 1996 Jun-Jul; 11(6):236–8 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

EMLA prevents pain during local anesthesia for cataract surgery. Pappa X, et al. **Acta Anaesthesiol Belg** 1995; 46(2):75–8

The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Taniguchi K, et al. **Acta Anaesthesiol Belg** 1995; 46(3-4):121–5

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al. **Am J Crit Care** 1995 Sep;4(5):368–9 (4 ref.)

Pain in the ICU: fact or fiction? [editorial] Dracup K, et al. **Am J Crit Care** 1995 Sep;4(5):337–9

Effects of interpleural bupivacaine on pleural chest tube removal pain: a randomized controlled trial. Puntillo KA. **Am J Crit Care** 1996 Mar;5(2):102–8

Does warming local anesthetic reduce the pain of subcutaneous injection? Martin S, et al. **Am J Emerg Med** 1996 Jan;14(1):10–2

A clinical investigation of the efficacy of low level laser therapy in reducing orthodontic postadjustment pain. Lim HM, et al. **Am J Orthod Dentofacial Orthop** 1995 Dec; 108(6):614–22

Naproxen premedication for laparoscopic sterilization [letter] Limb RI, et al. **Anaesth Intensive Care** 1995 Jun;23(3):405

The effect of temperature upon pain during injection of propofol. Fletcher GC, et al. **Anaesthesia** 1996 May; 51(5):498–9

Lignocaine for acute phantom limb pain reactivation by regional anaesthesia [letter] Lamacraft G. **Anaesthesia** 1996 Aug;51(8):800

Modification of pain on injection of propofol. A comparison of pethidine and lignocaine. Lyons B, et al. **Anaesthesia** 1996 Apr;51(4):394–5

Local anaesthesia and venous cannulation [letter; comment] Mehta S. **Anaesthesia** 1996 Apr;51(4):410. Comment on: Anaesthesia 1995 May;50(5):400–2. Comment on: Anaesthesia 1995 Nov;50(11):1005. Comment on: Anaesthesia 1995 Nov;50(11):1005–6.

Topical ibuprofen for skin analgesia prior to venepuncture. Smith AJ, et al. **Anaesthesia** 1996 May;51(5):495–7

Regional anaesthesia for repeat Caesarean section in a patient with phantom limb pain. Uncles DR, et al. **Anaesthesia** 1996 Jan;51(1):69–70

Reducing pain during propofol injection: the role of the solvent. Doenicke AW, et al. **Anesth Analg** 1996 Mar; 82(3):472–4

Lidocaine and no carrier fluid for the prevention of pain due to injection of propofol [letter; comment] Gozal Y. **Anesth Analg** 1996 May;82(5):1111. Comment on: Anesth Analg 1995 Nov;81(5):1087–8.

Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71

Reducing the pain on injection of propofol [letter] Nathanson MH, et al. **Anesth Analg** 1996 Jun;82(6):1307–8

Proceedings from the first international symposium on pain research in emergency medicine: Foreword. Ducharme J. **Ann Emerg Med** 1996 Apr;27(4):399–403

Studying emergency patients outside the emergency department. Sivilotti ML, et al. **Ann Emerg Med** 1996 Apr; 27(4):442–7 (24 ref.)

Joint Commission on Accreditation of Healthcare Organizations requirements for sedation. Sklar DP. **Ann Emerg Med** 1996 Apr;27(4):412–3

Randomized double-blind controlled trial comparing room-temperature and heated lidocaine for digital nerve block [see comments] Waldbillig DK, et al. **Ann Emerg Med** 1995 Dec;26(6):677–81. Comment in: Ann Emerg Med 1996 Jul;28(1):104.

Pain evaluation and management in the nursing home. Ferrell BA. **Ann Intern Med** 1995 Nov 1;123(9):681–7 (75 ref.)

Capillary blood sampling: should the heel be warmed? Barker DP, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar; 74(2):F139–40

Reduction of pain response in premature infants using intraoral sucrose. Ramenghi LA, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F126–8

Effect of non-sucrose sweet tasting solution on neonatal heel prick responses. Ramenghi LA, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F129–31

Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Nitschke LF, et al. **Arch Surg** 1996 Apr;131(4):417–23

Analgesic effect of sucrose. Cuddle deprivation may have confounded experiment [letter; comment] Jepson C. **BMJ** 1995 Sep 16;311(7007):747–8. Comment on: BMJ 1995 Jun 10;310(6993):1498–500.

Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea. Pittrof R, et al. **BMJ** 1996 Apr 6;312(7035):884

A multifactorial analysis to explain inadequate surgical analgesia after extradural block. Curatolo M, et al. **Br J Anaesth** 1995 Sep;75(3):274–81

Evaluation of an amethocaine gel preparation for percutaneous analgesia before venous cannulation in children. Lawson RA, et al. **Br J Anaesth** 1995 Sep; 75(3):282–5

Warming lignocaine reduces the pain of injection during peribulbar local anaesthesia for cataract surgery. Bell RW, et al. **Br J Ophthalmol** 1995 Nov;79(11):1015–7

Use of vecuronium to prevent suxamethonium-induced myalgia after ECT [letter] Herriot PM, et al. **Br J Psychiatry** 1996 May;168(5):653–4

Crystal balls, pain, fear, and euthanasia [editorial] Marshall S. **Can Fam Physician** 1996 Jul;42:1270–1, 1280 **(Eng, Fre)**

Pain management in children. Rice LJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R155–62 (31 ref.) **(Eng, Fre)**

Circumcision without tears [letter] Katz MS. **Can Med Assoc J** 1996 Sep 1;155(5):507–8; discussion 508–9

Circumcision without tears [letter] Tolkin J. **Can Med Assoc J** 1996 Sep 1;155(5):507; discussion 508–9

Professional negligence in the management of cancer pain. A case for urgent reforms [editorial; comment] Cherny NI, et al. **Cancer** 1995 Dec 1;76(11):2181–5. Comment on: Cancer 1995 Dec 1;76(11):2375–82.

Teaching cancer pain management: durability of educational effects of a role model program. Janjan NA, et al. **Cancer** 1996 Mar 1;77(5):996–1001

Oncologists and primary care physicians' attitudes toward pain control and morphine prescribing in France [see comments] Larue F, et al. **Cancer** 1995 Dec 1; 76(11):2375–82. Comment in: Cancer 1995 Dec 1;76(11):2181–5.

Pain and pain relief experienced by hospice patients with cancer. McMillan SC. **Cancer Nurs** 1996 Aug;19(4):298–307

New vascular sheath for subcutaneous drug administration: design, animal testing, and clinical application for pain prevention after angioplasty. Lambert CR, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):68–72

Management of painful procedures in the newborn. Stevens B. **Curr Opin Pediatr** 1996 Apr;8(2):102–7 (55 ref.)

Antinociceptive and antitussive effects of morphine in the DA-bg/bg (beige) rat. Kamei J, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):75–8

On the anesthetic effect of low-power infrared lasers with different mode of irradiation in complications after stomatologic treatment. Vladimirov S. **Folia Med (Plovdiv)** 1995;37(4A Suppl):108

Sodium nonivamide acetate: a non-pungently antinociceptive capsaicin derivative with unusual anti-inflammatory properties. Yang JM, et al. **Gen Pharmacol** 1996 Jan; 27(1):141–50

The ultimate pain relief [letter; comment] Marquis D. **Hastings Cent Rep** 1995 Nov-Dec;25(6):2–3. Comment on: Hastings Cent Rep 1994 Jul-Aug;24(4):25–6.

Cancer pain management and the role of social work: barriers and interventions. Glajchen M, et al. **Health Soc Work** 1995 Aug;20(3):200–6 (35 ref.)

Pain control in abortion. Wiebe ER, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):41–6

Pain management knowledge of hospital-based nurses in a rural Appalachian area. Kubecka KE, et al. **J Adv Nurs** 1996 May;23(5):861–7

A comparison of EMLA cream versus nitrous oxide for pediatric venous cannulation. Vetter TR. **J Clin Anesth** 1995 Sep;7(6):486–90

Using pressure to decrease the pain of intramuscular injections. Barnhill BJ, et al. **J Pain Symptom Manage** 1996 Jul;12(1):52–8

The effect of temperature on the discomfort caused by topical local anaesthesia. Callear AB. **J R Soc Med** 1995 Dec; 88(12):709p–11p

Analgesia for venous cannulation [letter; comment] Ulahannan TJ. **J R Soc Med** 1996 Apr;89(4):237. Comment on: J R Soc Med 1995 May;88(5):264–7.

Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1. Godschalk M, et al. **J Urol** 1996 Sep;156(3):999–1000

Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. Nash PA, et al. **J Urol** 1996 Feb;155(2):607–9

Painful crises in sickle-cell disease [letter; comment] Serjeant G, et al. **Lancet** 1996 Apr 27;347(9009):1190–1. Comment on: Lancet 1996 Jan 27;347(8996):261. Comment on: Lancet 1996 Jan 27;347(8996):261–2. Comment on: Lancet 1996 Jan 27;347(8996):263.

Pain palliation with strontium-89 in children with metastatic disease. Charron M, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):393–6

Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)

Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec;

30(4):683–95 (53 ref.)
The importance of nursing research design and methods in cancer pain management. Enhancing care.
Gaston-Johansson F, et al. **Nurs Clin North Am** 1995 Dec; 30(4):597–607 (90 ref.)
Evaluation of a dressing to reduce nipple pain and improve nipple skin condition in breast-feeding women. Ziemer MM, et al. **Nurs Res** 1995 Nov–Dec;44(6):347–51
Developing pain management education using guidelines. Carter LW, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1435
Standard of care for pain management interventions. Coyne PJ. **Oncol Nurs Forum** 1995 Oct;22(9):1437–8
Guidelines supplement comprehensive staff education program. Derby S, et al. **Oncol Nurs Forum** 1995 Oct; 22(9):1438
Putting guidelines to work in an ambulatory care setting. Dolan CS. **Oncol Nurs Forum** 1995 Oct;22(9):1436
Using guidelines for education, policy making, and assessing quality of care. Hagan S. **Oncol Nurs Forum** 1995 Oct; 22(9):1435–6
Implementing guidelines on acute pain management. Person L. **Oncol Nurs Forum** 1995 Oct;22(9):1436–7
Oculoplastic surgery pearl. A procedure to decrease discomfort in blepharoptosis surgery. Putterman AM. **Ophthal Plast Reconstr Surg** 1995 Dec;11(4):296
The effect of solution temperature on the pain of peribulbar anesthesia. Ursell PG, et al. **Ophthalmology** 1996 May; 103(5):839–41
Pediatric oncology procedures: to sleep or perchance to dream? [editorial; comment] Berde C. **Pain** 1995 Jul; 62(1):1–2. Comment on: Pain 1995 Jul;62(1):3–9.
Cutaneous pretreatment with the capsaicin analog NE-21610 prevents the pain to a burn and subsequent hyperalgesia. Davis KD, et al. **Pain** 1995 Sep;62(3):373–8
A comparative study of cognitive behavior therapy versus general anesthesia for painful medical procedures in children [see comments] Jay S, et al. **Pain** 1995 Jul;62(1):3–9. Comment in: Pain 1995 Jul;62(1):1–2.
Relaxation and imagery and cognitive–behavioral training reduce pain during cancer treatment: a controlled clinical trial. Syrjala KL, et al. **Pain** 1995 Nov;63(2):189–98
Mechanical unweighting effects on treadmill exercise and pain in elderly people with osteoarthritis of the knee. Mangione KK, et al. **Phys Ther** 1996 Apr;76(4):387–94
The effect of pre-emptive fentanyl on formalin pain in mice. Fu ES, et al. **Reg Anesth** 1995 Jul–Aug;20(4):291–5
Effect of anesthetic technique on acute formalin-induced pain in mice. Fu ES, et al. **Reg Anesth** 1995 May–Jun; 20(3):217–21
Peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Preliminary report. Galer BS. **Reg Anesth** 1995 Sep–Oct;20(5):444–7
Morphine for cancer pain [letter] Smit BJ. **S Afr Med J** 1994 Nov;84(11):788
Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Sörensen J, et al. **Scand J Rheumatol** 1995;24(6):360–5
Issues of control in patients with cancer pain. Vallerand AH, et al. **West J Nurs Res** 1995 Oct;17(5):467–81; discussion 481–3
[Pre-emptive analgesia] Wilder-Smith OH. **Anaesthesist** 1995 Dec;44 Suppl 3:S529–34 (49 ref.) (Eng. Abstr.) **(Ger)**
[Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication] Maruyama M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1469–72 (Eng. Abstr.) **(Jpn)**
[Action of sodium oxybutyrate in pain syndromes] Daniloova EI, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):395–8 **(Rus)**
[The effect of prophylactic administration of pentoxifylline (trental) on development of a neuropathic pain syndrome and microcirculatory disorders caused by it] Gorizontova MP, et al. **Biull Eksp Biol Med** 1995 May;119(5):485–7 **(Rus)**
[Efficacy of the EMLA cream in the reduction of pain caused by venipuncture in children premedicated with oral midazolam] Cassinello F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):360–3 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

'My pain is God's will'. Kumasaka L, et al. **Am J Nurs** 1996 Jun;96(6):45–7
Long-term follow-up of outpatient interdisciplinary pain management with a no-treatment comparison group. Lynch RT, et al. **Am J Phys Med Rehabil** 1996 May–Jun; 75(3):213–22
Attitudes to pain and pain relief in adult surgical patients. Brydon CW, et al. **Anaesthesia** 1996 Mar;51(3):279–81
Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)
Problems with pain—is the messenger to blame? Kidd BL. **Ann Rheum Dis** 1996 May;55(5):275
Psychological aspects of pain. Large RG. **Ann Rheum Dis** 1996 Jun;55(6):340–5 (48 ref.)
Specter of the crone: the experience of vertebral fracture. Paier GS. **ANS Adv Nurs Sci** 1996 Mar;18(3):27–36
Musculoskeletal pain syndromes that affect adolescents. Szer IS. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):740–7 (23 ref.)
Attrition from a pain management programme. Coughlan GM, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):471–9
Pain and pain relief experienced by hospice patients with cancer. McMillan SC. **Cancer Nurs** 1996 Aug;19(4):298–307
Display rules for anger, sadness, and pain: it depends on who is watching. Zeman J, et al. **Child Dev** 1996 Jun; 67(3):957–73
Relationship between social desirability and self-report in chronic pain patients. Deshields TL, et al. **Clin J Pain** 1995 Sep;11(3):189–93
Assessment of depression in chronic musculoskeletal pain patients. Estlander AM, et al. **Clin J Pain** 1995 Sep; 11(3):194–200
Measuring the activity of older people with chronic pain. Farrell MJ, et al. **Clin J Pain** 1996 Mar;12(1):6–12
Differential consequences of left- and right-sided chronic pain. Gagliese L, et al. **Clin J Pain** 1995 Sep;11(3):201–7
Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Katz J, et al. **Clin J Pain** 1996 Mar; 12(1):50–5
Moclobemide in chronic neuropathic pain: preliminary case reports. Menkes DB, et al. **Clin J Pain** 1995 Jun;11(2):134–8
Gender differences in the expression of depressive symptoms among chronic pain patients. Novy DM, et al. **Clin J Pain** 1996 Mar;12(1):23–9
Memory for pain after nerve-block injections. Porzelius J. **Clin J Pain** 1995 Jun;11(2):112–20
Belief in pain. Gustafson D. **Conscious Cogn** 1995 Sep; 4(3):323–45
End-of-life care: 'merit' of suffering questioned by reader [letter; comment] Longergan T. **Geriatrics** 1996 Jul;51(7):16. Comment on: Geriatrics 1996 May;51(5):8.
Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African American adults with sickle cell disease. Gil KM, et al. **Health Psychol** 1996 Jan;15(1):3–10
Attitudes toward and knowledge of chronic pain: a survey of medical social workers. Sieppert JD. **Health Soc Work** 1996 May;21(2):122–30
Gender differences in pain. Vallerand AH. **Image J Nurs Sch** 1995 Fall;27(3):235–7
Patient suffering: a taxonomy from the nurse's perspective. Flaming D. **J Adv Nurs** 1995 Dec;22(6):1120–7
Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)
Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717–30 (50 ref.)
The pain behavior check list (PBCL): psychometric properties in a college sample. Osman A, et al. **J Clin Psychol** 1995 Nov;51(6):775–82
Combining qualitative and quantitative research approaches in understanding pain. Moore R. **J Dent Educ** 1996 Aug; 60(8):709–15
The pain and discomfort of labor and birth. Lowe NK. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):82–92 (56 ref.)
A visual analogue thermometer for measuring pain intensity. Choinière M, et al. **J Pain Symptom Manage** 1996 May; 11(5):299–311
Pain, coping, and adjustment in patients with burns: preliminary findings from a prospective study. Ptacek JT, et al. **J Pain Symptom Manage** 1995 Aug;10(6):446–55
Effect of imagery on children's pain and anxiety during cardiac catheterization. Pederson C. **J Pediatr Nurs** 1995 Dec;10(6):365–74
Pain responses of hospitalized infants and children to venipuncture and intravenous cannulation. Van Cleve L, et al. **J Pediatr Nurs** 1996 Jun;11(3):161–8
Children with cancer: the pain experience away from the health care setting. Bossert EA, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):109–20
Factors associated with pain complaints in a clinical sample of postmenopausal women. Bono G, et al. **J Psychosom Obstet Gynaecol** 1995 Sep;16(3):117–21
Difficulties in the differential diagnosis of vaginismus, dyspareunia and mixed sexual pain disorder. van Lankveld JJ, et al. **J Psychosom Obstet Gynaecol** 1995 Dec; 16(4):201–9
'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737–53 (58 ref.)
Pain coping mechanisms in fibromyalgia: relationship to pain and functional outcomes. Nicassio PM, et al. **J Rheumatol** 1995 Aug;22(8):1552–8
A multidimensional model of the antecedents of stress and coping appraisals: an approach to studying patients' perceptions of post cardiac surgery pain and their coping strategies. Shih FJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Apr; 12(4):202–15 (22 ref.)
Personality in patients with long-term patellofemoral pain syndrome. Carlsson AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):178–83
Stimulation in the human somatosensory thalamus can reproduce both the affective and sensory dimensions of previously experienced pain [see comments] Lenz FA, et al. **Nat Med** 1995 Sep;1(9):910–3. Comment in: Nat Med 1995 Sep;1(9):885–7.
Unpleasant pain evoked by thalamic stimulation [comment] Price DD. **Nat Med** 1995 Sep;1(9):885–7. Comment on: Nat Med 1995 Sep;1(9):910–3.
Psychiatric aspects of chronic pain. Eisendrath SJ. **Neurology** 1995 Dec;45(12 Suppl 9):S26–34; discussion S35–6 (36 ref.)
Influence of emotional-algic stress on the activity of carboxypeptidase H—an enzyme involved in processing rat brain neuropeptides. Gengin MT, et al. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):307–10
Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)
The impact of pain on quality of life. A decade of research. Ferrell BR. **Nurs Clin North Am** 1995 Dec;30(4):609–24 (29 ref.)
Family members' perceptions of cancer pain. Comparisons with patient sensory report and by patient psychologic status. Madison JL, et al. **Nurs Clin North Am** 1995 Dec; 30(4):625–45
Development and initial validation of a scale to measure self-efficacy beliefs in patients with chronic pain. Anderson KO, et al. **Pain** 1995 Oct;63(1):77–84
The factorial structure and stability of the McGill Pain Questionnaire in patients experiencing oral mucositis following bone marrow transplantation. Donaldson GW. **Pain** 1995 Jul;62(1):101–9
Artificial ureteral calculosis in rats: behavioural characterization of visceral pain episodes and their relationship with referred lumbar muscle hyperalgesia. Giamberardino MA, et al. **Pain** 1995 Jun;61(3):459–69
Influence of eye orientation on pain as a function of anxiety. Honoré J, et al. **Pain** 1995 Nov;63(2):213–8
Concerning the homology of painful experiences and pain descriptors: a multidimensional scaling analysis. Janal MN. **Pain** 1996 Feb;64(2):373–8
Scaling the affective domain of pain: a study of the dimensionality of verbal descriptors. Morley S, et al. **Pain** 1995 Jul;62(1):39–49
Memory for labor pain: context and quality. Niven CA, et al. **Pain** 1996 Feb;64(2):387–92
Comment on D.G. Hawley and F. Wolfe [letter; comment] Owen JE. **Pain** 1995 Jul;62(1):125–6. Comment on: Pain 1994 Nov;59(2):227–34.
Chronic pain patient-spouse behavioral interactions predict patient disability. Romano JM, et al. **Pain** 1995 Dec; 63(3):353–60
The influence of colonic temperature changes in anaesthetised rats on tail skin temperatures and repeated testing of tail-flick latencies. Sapsed-Byrne S, et al. **Pain** 1995 Nov;63(2):255–61
The influence of warning signal timing and cognitive preparation on the aversiveness of cold-pressor pain. Weisenberg M, et al. **Pain** 1996 Feb;64(2):379–85
Pain in infancy: individual differences. Axia G, et al. **Percept Mot Skills** 1995 Aug;81(1):142
Correlations between the Hand Test Pathology score and Personality Assessment Inventory scales for pain clinic patients. George JM, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1377–8
Pain sensitivity and saccharin intake in alcohol-preferring and -nonpreferring rat strains. Kampov-Polevoy AB, et al. **Physiol Behav** 1996 Apr–May;59(4–5):683–8
On the belief that arthritis pain is related to the weather. Redelmeier DA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2895–6
Perspectives of chronic pain: an evaluative comparison of restrictive and comprehensive models. Novy DM, et al. **Psychol Bull** 1995 Sep;118(2):238–47 (100 ref.)
Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)
Pain and psychologic symptoms of Australian patients with whiplash. Wallis BJ, et al. **Spine** 1996 Apr 1;21(7):804–10
[Pain, suffering and loneliness in the aged] Smitka V. **Cas Lek Cesk** 1995 Nov 1;134(21):699–700 **(Cze)**
[Family emotional climate of pain patients] Gralow I, et al. **Psychother Psychosom Med Psychol** 1996 May;46(5):169–77 (Eng. Abstr.) **(Ger)**
[Psychosomatic aspects of pain perception by the elderly—results of the ELDERMEN Study] Heuft G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):349–57 (Eng. Abstr.) **(Ger)**
[Pain, independence and subjective attitude to aging—an empirical contribution from the study "Possibilities and limits of independent living by the elderly"] Hofer J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):358–68 (Eng. Abstr.) **(Ger)**
[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**
[Psychotherapy of somatoform pain disorders in the elderly] Scheidt CE, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):339–48 (Eng. Abstr.) **(Ger)**
[Psychological diagnosis of pain and pain treatment in the elderly] Wilz G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):312–7 (54 ref.) (Eng. Abstr.) **(Ger)**
[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):369–73 (22 ref.) (Eng. Abstr.) **(Ger)**
[Spontaneous use of active and passive coping strategies for pain in patients with rheumatoid arthritis] Sebro B, et al. **Reumatizam** 1993;40(1):1–4 (Eng. Abstr.) **(Scr)**
[The one thousand faces of pain (letter)] Flühmann EM.

Rev Med Chil 1995 Mar;123(3):376–7 **(Spa)**

[Psychosomatic pain in children—a psychomuscular stress reaction?] Alfvén G. **Nord Med** 1995;110(11):275–9 (15 ref.) (Eng. Abstr.) **(Swe)**

RADIOGRAPHY

[Chronic pain in the hindfoot: computed tomography as a complement in clinico-radiographic evaluation. A study of 38 cases] Cataldi A, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):22–7 (Eng. Abstr.) **(Ita)**

[Clinico-radiologic correlations in common neck pain] Pacciani E, et al. **Radiol Med (Torino)** 1996 May; 91(5):570–6 (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

The three-phase bone scan and exercise induced lower-leg pain. The tibial stress test. Samuelson DR, et al. **Clin Nucl Med** 1996 Feb;21(2):89–93

SPECT of the cervical spine in the evaluation of neck pain after trauma. Seitz JP, et al. **Clin Nucl Med** 1995 Aug; 20(8):667–73

RADIOTHERAPY

Assessing a new procedure: thoracic radiofrequency dorsal root ganglion lesions. Bogduk N. **Clin J Pain** 1996 Mar; 12(1):76–7; discussion 77–8

Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)

Heel spur: radiation therapy for refractory pain—results with three treatment concepts. Seegenschmiedt MH, et al. **Radiology** 1996 Jul;200(1):271–6

REHABILITATION

Long-term follow-up of outpatient interdisciplinary pain management with a no-treatment comparison group. Lynch RT, et al. **Am J Phys Med Rehabil** 1996 May–Jun; 75(3):213–22

A rehabilitation approach to chronic pain in rheumatologic practice. Rome JD, et al. **Curr Opin Rheumatol** 1996 Mar; 8(2):163–8 (32 ref.)

Isokinetic quadriceps training in patients with patellofemoral pain syndrome. Werner S, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):162–8

The effect of pain reduction on perceived tension and EMG-recorded trapezius muscle activity in workers with shoulder and neck pain. Vasseljen O Jr, et al. **Scand J Rehabil Med** 1995 Dec;27(4):243–52

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384–91 (55 ref.)

[Group respiratory biofeedback in complex neurorehabilitation] Barolin GS, et al. **Wien Med Wochenschr** 1995;145(19–20):547–54 (Eng. Abstr.) **(Ger)**

[Results of a double-blind, randomized comparative study of Wobenzym-placebo in patients with cervical syndrome] Tilscher H, et al. **Wien Med Wochenschr** 1996;146(5):91–5 (Eng. Abstr.) **(Ger)**

[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85–8 (25 ref.) **(Ger)**

[Pain rehabilitation is a pedagogic task. Chronic pain dealt with in a model for behavior-therapy (see comments)] Nordemar R, et al. **Lakartidningen** 1995 Oct 25; 92(43):3987–8, 3991. Comment in: Lakartidningen 1995 Dec 13;92(50):4780. **(Swe)**

[To manage chronic pain. Rehabilitation is a possible therapeutic alternative] Sjölund B. **Lakartidningen** 1995 Oct 25;92(43):3981–2 **(Swe)**

SURGERY

Pain—old and new methods of study and treatment. Sweet WH. **Acta Neurochir Suppl (Wien)** 1995;64:83–7 (24 ref.)

Annular keratotomy for the treatment of painful bullous keratopathy. Koenig SB. **Am J Ophthalmol** 1996 Jan; 121(1):93–4

Per-operative use of a balloon-occluding arterial catheter in renal arteriovenous malformation. Kumar U, et al. **Br J Urol** 1996 Feb;77(2):312–3

Renal autotransplantation [letter] Ramsey EW. **Can J Surg** 1996 Jun;39(3):253–4

The medial instep plantar fasciotomy [letter] Amarnek DL. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):182–3

The surgical dilemma of the malunited calcaneal joint depression fracture: the VAMC Miami experience. Cohen M. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):134–43; discussion 190

The effectiveness of hysterectomy for chronic pelvic pain. Hillis SD, et al. **Obstet Gynecol** 1995 Dec;86(6):941–5

Thalamic stereotaxis for chronic pain: ablative lesion or stimulation? Hariz MI, et al. **Stereotact Funct Neurosurg** 1995;64(1):47–55

Gamma Knife thalamotomy for the treatment of functional disorders. Hirato M, et al. **Stereotact Funct Neurosurg** 1995; 64 Suppl 1:164–71

[What surgical indications remain in the treatment of pain?] Muller A. **Cah Anesthesiol** 1996;44(1):23–6 (Eng. Abstr.) **(Fre)**

THERAPY

Significance of the spinal cord position in spinal cord stimulation. Holsheimer J, et al. **Acta Neurochir Suppl (Wien)** 1995;64:119–24

Acupuncture in angina pectoris: do psycho-social and neurophysiological factors relate to the effect? Ballegaard S, et al. **Acupunct Electrother Res** 1995 Apr–Jul; 20(2):101–16

NIH releases statement on behavioral and relaxation approaches for chronic pain and insomnia. **Am Fam Physician** 1996 Apr;53(5):1877–8, 1880

Digital dilatation for relief of proctalgia fugax [letter; comment] Rockefeller R. **Am Fam Physician** 1996 Jul; 54(1):72. Comment on: Am Fam Physician 1995 Dec;52(8):2238–40.

The role of adjunctive therapy in the management of chronic nonmalignant pain. Allegrante JP. **Am J Med** 1996 Jul 31; 101(1A):33S–39S (69 ref.)

Approach to the management of nonmalignant pain. Katz WA. **Am J Med** 1996 Jul 31;101(1A):54S–63S (64 ref.)

Dilemmas in the treatment of chronic pain. Lister BJ. **Am J Med** 1996 Jul 31;101(1A):2S–5S

The selling of pain [editorial] Johnson EW. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):331

Patellar taping in the treatment of patellofemoral pain. A prospective randomized study. Kowall MG, et al. **Am J Sports Med** 1996 Jan–Feb;24(1):61–6

Audit in pain clinics: changing the management of low-back and nerve-damage pain. Davies HT, et al. **Anaesthesia** 1996 Jul;51(7):641–6

The effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Liu SS, et al. **Anesth Analg** 1996 Jan;82(1):98–102

Anesthesia and perioperative medicine: a department of anesthesiology changes its name. Alpert CC, et al. **Anesthesiology** 1996 Mar;84(3):712–5

Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)

Current pain-control practices and research. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):404–7 (19 ref.)

Pain-control research opportunities and future directions. Cordell WH. **Ann Emerg Med** 1996 Apr;27(4):474–8 (7 ref.)

Analgesic practice for acute orthopedic trauma pain in Costa Rican emergency departments. Jantos TJ, et al. **Ann Emerg Med** 1996 Aug;28(2):145–50

Establishing pain policies in emergency medicine. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):408–11 (31 ref.)

Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Bellamy N, et al. **Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)

Recent advances in pain management. Siddall PJ, et al. **Aust N Z J Surg** 1995 Sep;65(9):674–85 (83 ref.)

Analgesic effect of sucrose. Heel pricks were unnecessarily painful [letter; comment] Barker D, et al. **BMJ** 1995 Sep 16;311(7007):747. Comment on: BMJ 1995 Jun 10;310(6993):1498–500.

Acute pain services. Purchasers must be prepared to pay for a multidisciplinary team [letter; comment] Susay SR. **BMJ** 1995 Oct 14;311(7011):1023. Comment on: BMJ 1995 Aug 5;311(7001):360–1.

Cannabis as a medicine [letter; comment] Notcutt WG. **Br J Anaesth** 1995 Aug;75(2):251–2. Comment on: Br J Anaesth 1995 Apr;74(4):359–61.

Attrition from a pain management programme. Coughlan GM, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):471–9

Pain in burn patients. Latarjet J, et al. **Burns** 1995 Aug; 21(5):344–8

Pain management in patients with pancreatic carcinoma. Caraceni A, et al. **Cancer** 1996 Aug 1;78(3 Suppl):639–53 (141 ref.)

Pain and symptom control in paediatric palliative care. Stevens MM, et al. **Cancer Surv** 1994;21:211–31 (47 ref.)

Nonpharmacologic pain management in terminal care. Urba SG. **Clin Geriatr Med** 1996 May;12(2):301–11 (37 ref.)

Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403–8 (30 ref.)

Association between workers' compensation and outcome following multidisciplinary treatment for chronic pain: roles of mediators and moderators. Burns JW, et al. **Clin J Pain** 1995 Jun;11(2):94–102

The pain medicine specialist as a physician-healer. Feinberg SD. **Clin J Pain** 1996 Mar;12(1):3–5

In response to article by Drs. Sundblom et al [letter; comment] Hamaty D. **Clin J Pain** 1995 Jun;11(2):157–8. Comment on: Clin J Pain 1994 Dec;10(4):296–302.

Subarachnoid neurolytic block under general anesthesia in a 3-year-old with neuroblastoma. Patt RB, et al. **Clin J Pain** 1995 Jun;11(2):143–6

Memory for pain after nerve-block injections. Porzelius J. **Clin J Pain** 1995 Jun;11(2):112–20

Pain associated with spinal cord injury. Siddall PJ, et al. **Curr Opin Neurol** 1995 Dec;8(6):447–50 (40 ref.)

Management of chronic pain. Part I. Barkin RL, et al. **Dis Mon** 1996 Jul;42(7):389–454 (242 ref.)

Management of chronic pain. Part II. Barkin RL, et al. **Dis Mon** 1996 Aug;42(8):457–507 (356 ref.)

Managing chronic pain in children. **Drug Ther Bull** 1995 Jul; 33(7):52–5 (21 ref.)

Managing acute pain in children. **Drug Ther Bull** 1995 Jun; 33(6):41–4 (25 ref.)

Recent clinical trials of pain control: impact on quality of life. Ahmedzai S. **Eur J Cancer** 1995;31A Suppl 6:S2–7 (31 ref.)

Pain relief and sedation during neonatal intensive care. Levene M. **Eur J Pediatr** 1995;154(8 Suppl 3):S22–3

Hypnosis treatment of clinical pain: understanding why hypnosis is useful. Holroyd J. **Int J Clin Exp Hypn** 1996 Jan;44(1):33–51 (130 ref.)

Assessment and management of children's pain in community hospitals. Caty S, et al. **J Adv Nurs** 1995 Oct;22(4):638–45

Analgesic effect of extracorporeal shock-wave therapy on chronic tennis elbow. Rompe JD, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):233–7

Cancer pain education: objectives for medical students and residents in primary care specialties. Palliative Oncology Education Section of the American Association for Cancer Education. **J Cancer Educ** 1996 Spring;11(1):7–10

Impacts of foot orthoses on pain and disability in rheumatoid arthritics. Conrad KJ, et al. **J Clin Epidemiol** 1996 Jan; 49(1):1–7

Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. Jadad AR, et al. **J Clin Epidemiol** 1996 Feb;49(2):235–43 (100 ref.)

A prospective blinded study on emergency pain assessment and therapy. Ducharme J, et al. **J Emerg Med** 1995 Jul–Aug;13(4):571–5

A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):530–6 (43 ref.)

A risk assessment of spinal manipulation vs. NSAIDs for the treatment of neck pain [letter] Nilsson N. **J Manipulative Physiol Ther** 1996 Mar–Apr;19(3):220–1

Panel endorses behavioral therapy for cancer pain [news] Eastman P. **J Natl Cancer Inst** 1995 Nov 15;87(22):1666–7

A controlled trial of regional sympatholysis in the treatment of photo-oculodynia syndrome. Fine PG, et al. **J Neuroophthalmol** 1995 Jun;15(2):90–4

Cortical stimulation for central pain [letter] Canavero S, et al. **J Neurosurg** 1995 Dec;83(6):1117

Trigeminal evoked potential-monitored thermorhizotomy: a novel approach for relief of trigeminal pain. Leandri M, et al. **J Neurosurg** 1996 Jun;84(6):929–39

A prospective 15-year follow up of 154 consecutive patients with trigeminal neuralgia treated by percutaneous stereotactic radiofrequency thermal rhizotomy. Taha JM, et al. **J Neurosurg** 1995 Dec;83(6):989–93

Special needs related to the pain and discomfort of patients with gynecologic cancer. Miaskowski C. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):181–8 (26 ref.)

The use of a topical refrigerant anesthetic to reduce injection pain in children. Abbott K, et al. **J Pain Symptom Manage** 1995 Nov;10(8):584–90

Mexico: status of cancer pain and palliative care. Allende S, et al. **J Pain Symptom Manage** 1996 Aug;12(2):121–3

Pediatric pain practices: a national survey of health professionals. Broome ME, et al. **J Pain Symptom Manage** 1996 May;11(5):312–20

Israel: status of cancer pain and palliative care. Cherny NI. **J Pain Symptom Manage** 1996 Aug;12(2):116–7

Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project. Elliott TE, et al. **J Pain Symptom Manage** 1995 Oct;10(7):494–504

Turkey: status of cancer pain and palliative care. Erdine S. **J Pain Symptom Manage** 1996 Aug;12(2):139–40

Chile: status of cancer pain and palliative care. Fernández A, et al. **J Pain Symptom Manage** 1996 Aug;12(2):102–3

Singapore: status of cancer pain and palliative care. Goh CR. **J Pain Symptom Manage** 1996 Aug;12(2):130–2

Femoral nerve blockade in the multidisciplinary management of intractable localized pain due to metastatic tumor: a case report. Khor KE, et al. **J Pain Symptom Manage** 1996 Jan; 11(1):57–6

France: status of cancer pain and palliative care. Larue F, et al. **J Pain Symptom Manage** 1996 Aug;12(2):106–8 (11 ref.)

The Philippines: status of cancer pain and palliative care. Laudico AV. **J Pain Symptom Manage** 1996 Aug; 12(2):133–5 (10 ref.)

Australia: status of cancer pain and palliative care. Lickiss JN. **J Pain Symptom Manage** 1996 Aug;12(2):99–101

Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87–92 (12 ref.)

Uganda: status of cancer pain and palliative care. Merriman A. **J Pain Symptom Manage** 1996 Aug;12(2):141–3

Colombia: status of cancer pain and palliative care. Moyano J. **J Pain Symptom Manage** 1996 Aug;12(2):104–5

Report from the International Association for the Study of Pain Task Force on cancer pain. Portenoy RK. **J Pain Symptom Manage** 1996 Aug;12(2):93–6

Indonesia: status of cancer pain and palliative care. Soebadi RD, et al. **J Pain Symptom Manage** 1996 Aug;12(2):112–5

The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65–72 (31 ref.)

Germany: status of cancer pain and palliative care. Strumpf

M, et al. **J Pain Symptom Manage** 1996 Aug;12(2):109–11
Republic of China: status of cancer pain and palliative care. Sun WZ, et al. **J Pain Symptom Manage** 1996 Aug; 12(2):127–9
Japan: status of cancer pain and palliative care. Takeda F. **J Pain Symptom Manage** 1996 Aug;12(2):118–20
Argentina: status of cancer pain and palliative care. Wenk R, et al. **J Pain Symptom Manage** 1996 Aug;12(2):97–8
People's Republic of China: status of cancer pain and palliative care. Zhang H, et al. **J Pain Symptom Manage** 1996 Aug;12(2):124–6
The Netherlands: status of cancer pain and palliative care. Zylicz Z. **J Pain Symptom Manage** 1996 Aug;12(2):136–8 (13 ref.)
Neurogenic pain [letter] Davies DD. **J R Soc Med** 1995 Dec; 88(12):722
Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. **JAMA** 1996 Jul 24–31;276(4):313–8 (0 ref.)
What is adequate and appropriate pain treatment? [letter; comment] Brenner SR. **JAMA** 1996 May 1;275(17):1310; discussion 1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.
What is adequate and appropriate pain treatment? [letter; comment] Jacobson L, et al. **JAMA** 1996 May 1; 275(17):1310–1. Comment on: JAMA 1995 Dec 20;274(23):1881–2.
Double-blind, placebo-controlled investigation of the effect of combined phototherapy/low intensity laser therapy upon experimental ischaemic pain in humans. Mokhtar B, et al. **Lasers Surg Med** 1995;17(1):74–81
Where are the parents? [letter] Armstrong HC. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):44–5
Effects of electrode geometry and combination on nerve fibre selectivity in spinal cord stimulation. Holsheimer J, et al. **Med Biol Eng Comput** 1995 Sep;33(5):676–82
Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11–6; discussion S35–6 (24 ref.)
Chronic pain: from theory to practical management. Rowbotham MC. **Neurology** 1995 Dec;45(12 Suppl 9):S5–10; discussion S35–6 (63 ref.)
Relaxation and the relief of cancer pain. Sloman R. **Nurs Clin North Am** 1995 Dec;30(4):697–709
Clinical practice guidelines as a new source of middle-range theory: focus on acute pain. Good M, et al. **Nurs Outlook** 1996 Mar–Apr;44(2):74–9
Issues in the economic analysis of therapies for cancer pain. Portenoy RK. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):71–8 (36 ref.)
Conservative management of mechanical neck disorders. A systematic overview and meta-analysis. Gross AR, et al. **Online J Curr Clin Trials** 1996 Jul 30;Doc No 200–201:[34457 words; 185 paragraphs]
Pain and stress in infancy and childhood—where to now? [editorial] Aynsley-Green A. **Paediatr Anaesth** 1996; 6(3):167–72
The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)
Ultrasound therapy in musculoskeletal disorders: a meta-analysis. Gam AN, et al. **Pain** 1995 Oct;63(1):85–91
The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. Scudds RA, et al. **Pain** 1995 Jul;62(1):69–77
Attenuation of pain-related hyperventilation in adjuvant arthritic rats with adrenal medullary transplants in the spinal subarachnoid space. Wang H, et al. **Pain** 1995 Dec; 63(3):313–20
Relief of suffering: where the art and science of medicine meet. O'Brien ME. **Postgrad Med** 1996 Jun;99(6):189–92, 197–200, 206–8 (14 ref.)
Progress in the treatment of pain. Mehta M. **Practitioner** 1996 Apr;240(1561):214–24 (11 ref.)
Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al. **Prog Neurobiol** 1995 Aug;46(5):507–29 (126 ref.)
Sensory focus as therapeutic treatments for acute pain. Logan HL, et al. **Psychosom Med** 1995 Sep–Oct;57(5):475–84
The use of electroconvulsive therapy in pain patients. Bloomstein JR, et al. **Psychosomatics** 1996 Jul–Aug; 37(4):374–9
Management of cancer pain. Conroy JM, et al. **South Med J** 1996 Aug;89(8):744–60; quiz 761 (153 ref.)
Eye patch treatment for the pain of corneal abrasion. Patterson J, et al. **South Med J** 1996 Feb;89(2):227–9
A technique for prevention of donor site pain associated with harvesting iliac bone grafts. Tanishima T, et al. **Surg Neurol** 1995 Aug;44(2):131–2
[Accessory nerve injury as a complication of therapeutic stretching of the shoulder] Halonen E, et al. **Duodecim** 1994;110(9):889–90 **(Fin)**
[Cupping as evaluated by the client] Vaskilampi T, et al. **Duodecim** 1994;110(16):1505–9 **(Fin)**
[Creation of a committee for pain evaluation and treatment (editorial)] Chauvin M. **Ann Fr Anesth Reanim** 1996; 15(3):257–8 (0 ref.) **(Fre)**
[Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture] Muller A, et al. **Ann Fr Anesth Reanim** 1996;15(3):271–6 (Eng. Abstr.) **(Fre)**
[Treatment of intraoperative pain. Responsibility of the care team] Vayre P. **J Chir (Paris)** 1995 Dec;132(12):499–502 **(Fre)**
[Strategy of treatment of cancer pain in children] Pichard-Léandri E, et al. **Rev Med Interne** 1995; 16(9):708–16 (28 ref.) (Eng. Abstr.) **(Fre)**
[Contributions of AINS (Anesthesiology, Intensive Care Medicine, Emergency Medicine, Pain Therapy) to qualifying graduate education (editorial)] Schmucker P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):278–9 **(Ger)**
[Dermatologic pain therapy. Selected clinical aspects] Ladner E, et al. **Hautarzt** 1995 Dec;46(12):892–906 (12 ref.) **(Ger)**
[Palliative pain therapy—medico-ethical arguments] Illhardt FJ. **Schweiz Rundsch Med Prax** 1996 Feb 27;85(9):268–71 (Eng. Abstr.) **(Ger)**
[Palliative pain therapy in terminally ill tumor patients] Lohri A, et al. **Schweiz Rundsch Med Prax** 1996 Feb 27; 85(9):261–7 (Eng. Abstr.) **(Ger)**
[Children feel pain too! (editorial)] Halvorsen S. **Nord Med** 1995;110(11):270 **(Nor)**
[Interdisciplinary treatment of pain (letter)] Bell RF. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):1012 **(Nor)**
[Movement and group discussions (letter)] Solberg EE. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1932 **(Nor)**
[Mobility and group discussions. Treatment of chronic muscle pain in women in general practice] Steihaug S, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1335–8 (Eng. Abstr.) **(Nor)**
[Conservative treatment of the painful, stiff shoulder] Maričević A, et al. **Reumatizam** 1993;40(1):15–20 (Eng. Abstr.) **(Scr)**

VETERINARY

Efficacy of intra-muscular analgesics for acute pain in sheep. Grant C, et al. **Aust Vet J** 1996 Apr;73(4):129–32
Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)
Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Owens JG, et al. **Equine Vet J** 1995 Jul;27(4):296–300
Forum article on nonhuman animal research elicits considerable dialogue [letter] Stabenow J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):550
Evaluation of detomidine-induced analgesia in horses with chronic hoof pain. Owens HG, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):179–84
Change in locomotor activity pattern in mice: a model for recognition of distress? Jansen van't Land C, et al. **Lab Anim** 1995 Jul;29(3):286–93
A field study of the effect of lameness on mechanical nociceptive thresholds in sheep. Ley SJ, et al. **Vet Rec** 1995 Jul 22;137(4):85–7
[Acute pain in the horse and one possibility for its objective evaluation] Zierz J, et al. **Tierarztl Prax** 1996 Apr; 24(2):108–12 (Eng. Abstr.) **(Ger)**

PAIN ASSESSMENT see **PAIN MEASUREMENT**

PAIN CENTERS see **PAIN CLINICS**

PAIN CLINICS

Endangered opportunities in acute pain management [letter; comment] Bromage PR. **Anaesthesia** 1995 Oct;50(10):910–1. Comment on: Anaesthesia 1995 May;50(5):383–7. Comment on: Anaesthesia 1995 May;50(5):435–8.
Pain treatment facilities referral selection criteria [letter] Fishbain DA, et al. **Clin J Pain** 1995 Jun;11(2):156–7
Quality patrol. Getting to the heart of chest pain. Morrall K. **Hosp Health Netw** 1996 Feb 20;70(4):70
An acute pain service and preventable deaths in hospitals [letter; comment] Riley RH. **Med J Aust** 1996 May 6; 164(9):573. Comment on: Med J Aust 1996 Mar 4;164(5):308–9.

LEGISLATION & JURISPRUDENCE

[Treatment of intraoperative pain. Responsibility of the care team] Vayre P. **J Chir (Paris)** 1995 Dec;132(12):499–502 **(Fre)**

ORGANIZATION & ADMINISTRATION

A day-care pain clinic—its possibilities and limitations in the treatment of cancer patients. Gralow I, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):169–79
[Evaluation of the activity of a postoperative analgesia department in a Canadian hospital] Fugère F, et al. **Ann Fr Anesth Reanim** 1996;15(3):313–9 (Eng. Abstr.) **(Fre)**
[Should postoperative pain management units be developed in France? (editorial)] Scherpereel P. **Ann Fr Anesth Reanim** 1996;15(3):255–6 **(Fre)**
[Principles of organization of a center for pain evaluation and treatment] Boureau F, et al. **Rev Med Interne** 1995; 16(9):696–704 (Eng. Abstr.) **(Fre)**

STANDARDS

Audit in pain clinics: changing the management of low-back and nerve-damage pain. Davies HT, et al. **Anaesthesia** 1996 Jul;51(7):641–6

SUPPLY & DISTRIBUTION

National provision of acute pain services. Windsor AM, et al. **Anaesthesia** 1996 Mar;51(3):228–31

TRENDS

The selling of pain [editorial] Johnson EW. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):331
Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults. Warfield CA, et al. **Anesthesiology** 1995 Nov;83(5):1090–4
[Recent trend and future in pain clinic in Japan] Suzuki H. **Masui** 1995;44 Suppl:S6–11 (18 ref.) **(Jpn)**

PAIN, FACIAL see **FACIAL PAIN**

PAIN INSENSITIVITY, CONGENITAL

GENETICS

Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis [see comments] Indo Y, et al. **Nat Genet** 1996 Aug;13(4):485–8. Comment in: Nat Genet 1996 Aug;13(4):382–3.
No pain, some gain [news; comment] Wood JN. **Nat Genet** 1996 Aug;13(4):382–3. Comment on: Nat Genet 1996 Aug;13(4):485–8.

PAIN, INTRACTABLE

see related

PALLIATIVE CARE

The debate on assisted suicide—redefining morally appropriate care for people with intractable suffering. Reitman JS. **Issues Law Med** 1995 Winter;11(3):299–329 (118 ref.)
Orofacial phantom pain: theory and phenomenology. Marbach JJ. **J Am Dent Assoc** 1996 Feb;127(2):221–9 (48 ref.)
Pain in chronic pancreatitis. Jansen JB, et al. **Scand J Gastroenterol Suppl** 1995;212:117–25 (114 ref.)

DRUG THERAPY

Use of liposome-associated bupivacaine in a cancer pain syndrome. Lafont ND, et al. **Anaesthesia** 1996 Jun; 51(6):578–9
Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine. Fitzgibbon D, et al. **Anesthesiology** 1996 Mar;84(3):729–31
Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Middleton JW, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):824–6
Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Yang CY, et al. **Can J Anaesth** 1996 Apr;43(4):379–83
Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients. Meuret G, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:137–40
Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Watanabe S, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:131–6
Gabapentin adjunctive therapy in neuropathic pain states. Rosner H, et al. **Clin J Pain** 1996 Mar;12(1):56–8
High-dose oral morphine in cancer pain management: a report of twelve cases. Radbruch L, et al. **J Clin Anesth** 1996 Mar;8(2):144–50
Tolerability of continuous subcutaneous octreotide used in combination with other drugs. Mercadante S. **J Palliat Care** 1995 Winter;11(4):14–6
Massive opioid requirements in children with disseminated central nervous system disease [letter; comment] Jones PD, et al. **J Pediatr** 1996 Jun;128(6):864–5. Comment on: J Pediatr 1995 Apr;126(4):653–7.
Controlling cancerous pain with analgesic powder for cancers. Yang G, et al. **J Tradit Chin Med** 1995 Sep; 15(3):174–7
Methadone for treatment of cancer pain [letter; comment] O'Rourke MA, et al. **JAMA** 1996 Feb 21;275(7):519. Comment on: JAMA 1995 Oct 25;274(16):1307.
Pain control and the World Health Organization analgesic ladder [letter; comment] Reidenberg MM. **JAMA** 1996 Mar 20;275(11):835; discussion 836. Comment on: JAMA 1995 Dec 20;274(23):1870–3.
Pain control and the World Health Organization analgesic ladder [letter; comment] Twycross R, et al. **JAMA** 1996 Mar 20;275(11):835; discussion 836. Comment on: JAMA 1995 Dec 20;274(23):1870–3.
Pain control and the World Health Organization analgesic ladder [letter; comment] Ventafridda V, et al. **JAMA** 1996 Mar 20;275(11):835–6. Comment on: JAMA 1995 Dec 20;274(23):1870–3.
Controlling pain in cancer [letter; comment] Lovel T. **Lancet** 1996 Jul 13;348(9020):134. Comment on: Lancet 1996 May 11;347(9011):1278.

Cancer pain. O'Neill WM. **Middle East J Anesthesiol** 1996 Feb;13(4):373–8 (7 ref.)
Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)
Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Paice JA, et al. **Neurosurgery** 1996 Jan;38(1):203–7
Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Eisenach JC, et al. **Pain** 1995 Jun;61(3):391–9
Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)
[Intrathecal administration of morphine and bupivacaine in the treatment of severe pain in chronic pancreatitis] Verheijen R, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6; 140(27):1410–2 (Eng. Abstr.) **(Dut)**
[Intraventricular morphine administration as a treatment possibility for patients with intractable pain] Seiwald M, et al. **Wien Klin Wochenschr** 1996;108(1):5–8 (Eng. Abstr.) **(Ger)**
[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**
[Additional doses of oral morphine on demand] Amano N. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:374–7 (Eng. Abstr.) **(Jpn)**
[Cancer-pain management in home care] Mizuguchi T. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1453–5 (Eng. Abstr.) **(Jpn)**
[The problems of Japanese home care for cancer pain patients] Otake T, et al. **Gan To Kagaku Ryoho** 1995 Dec; 22 Suppl 4:318–21 (Eng. Abstr.) **(Jpn)**
[Role of pharmacist in cancer pain management] Yoshida S, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:365–73 (Eng. Abstr.) **(Jpn)**
[Cancer patient care—management of intractable pain in patients with cancers] Takeda F. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):360–4 (5 ref.) **(Jpn)**

ETIOLOGY

The use of standard imaging techniques and their diagnostic value in the workup of renal colic in the setting of intractable flank pain. Gorelik U, et al. **Urology** 1996 May; 47(5):637–42
[A case of myogenic intractable pain due to thalamic hemorrhage relieved by Vim-Vo thalamotomy] Seike M, et al. **No To Shinkei** 1995 Sep;47(9):899–904 (Eng. Abstr.) **(Jpn)**
[Primary myelofibrosis with severe bone pain] Kikukawa M, et al. **Rinsho Ketsueki** 1996 Mar;37(3):228–32 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Pain dysfunction syndrome of the knee. Neuschwander D, et al. **Orthopedics** 1996 Jan;19(1):27–32

PREVENTION & CONTROL

Clinical trials referral resource. Cancer chemoprevention and control trials. Brawley OW, et al. **Oncology (Huntingt)** 1996 Apr;10(4):499–500

PSYCHOLOGY

["To submit a complaint." The language of patients with chronic pain (editorial)] Muller A. **Can Anesthesiol** 1996; 44(1):7–12 **(Fre)**

RADIOTHERAPY

Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Berna L, et al. **Eur J Nucl Med** 1995 Oct;22(10):1101–4
[153Sm-EDTMP for moderate and severe bone cancer pain] Deng H, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):391–4 (Eng. Abstr.) **(Chi)**

SURGERY

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)
Transplantation of human chromaffin cells for control of intractable cancer pain. Lazorthes Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:97–100
Electrophysiological monitoring during CT-guided percutaneous cordotomy. Zileli M, et al. **Acta Neurochir Suppl (Wien)** 1995;64:92–6
Computer-assisted multidimensional atlas for functional stereotaxy. Alesch F, et al. **Acta Neurochir (Wien)** 1995; 133(3–4):153–6
Microsurgical DREZotomy (MDT) for pain, spasticity, and hyperactive bladder: a 20-year experience. Sindou M. **Acta Neurochir (Wien)** 1995;137(1–2):1–5
Performance of local anesthetic and placebo splanchnic blocks via indwelling catheters to predict benefit from thoracoscopic splanchnicectomy in a patient with intractable pancreatic pain. Strickland TC, et al. **Anesthesiology** 1996 Apr;84(4):980–3
Thoracoscopic bilateral splanchnicotomy for pain control in unresectable pancreatic cancer. Rossi M, et al. **Chir Ital** 1995;47(2):55–7
Partial denervation for persistent neuroma pain around the knee. Dellon AL, et al. **Clin Orthop** 1996 Aug;(329):216–22
Surgical management for intractable metatarsalgia. Mann RA, et al. **Foot Ankle Int** 1995 Jun;16(6):322–7
Surgical treatment of pubic pain refractory to conservative treatment. Moyen B, et al. **Ital J Orthop Traumatol** 1993; 19(1):43–9
Islet Autotransplantation after total pancreatectomy in a child. Wahoff DC, et al. **J Pediatr Surg** 1996 Jan; 31(1):132–5; discussion 135–6
Microsurgical denervation of the spermatic cord: a surgical alternative in the treatment of chronic orchialgia. Levine LA, et al. **J Urol** 1996 Mar;155(3):1005–7
Gamma Knife thalamotomy for the treatment of persistent pain. Young RF, et al. **Stereotact Funct Neurosurg** 1995; 64 Suppl 1:172–81
Thoracoscopic splanchnicectomy for the relief of intractable abdominal pain. Takahashi T, et al. **Surg Endosc** 1996 Jan; 10(1):65–8
[Video thoracoscopic splanchnicectomy in persistent epigastric pain] Suchý T, et al. **Rozhl Chir** 1995 Sep; 74(6):277–9 (Eng. Abstr.) **(Cze)**

THERAPY

A day-care pain clinic—its possibilities and limitations in the treatment of cancer patients. Gralow I, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):169–79
Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. **Anesthesiology** 1996 May;84(5):1243–57
New technique for the neurolytic celiac plexus block: the transintervertebral disc approach. Ina H, et al. **Anesthesiology** 1996 Jul;85(1):212–7
Psoas sheath chemical neurolysis for management of intractable leg pain from metastatic liposarcoma. Calava JM, et al. **Clin J Pain** 1996 Mar;12(1):69–75
Radiosurgical pituitary ablation for cancer pain. Sloan PA, et al. **J Palliat Care** 1996 Summer;12(2):51–3
The treatment of pain in bone metastasis of cancer with the analgesic decoction of cancer and the acupoint therapeutic apparatus. Guo R, et al. **J Tradit Chin Med** 1995 Dec; 15(4):262–4
Persistent pain associated with long-term intrathecal morphine administration. Parris WC, et al. **South Med J** 1996 Apr;89(4):417–9
[Patients with cancer-related pain and other chronic pain. Priorities and assessment] Skauge M, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):473–7 (Eng. Abstr.) **(Nor)**

PAIN MEASUREMENT

see related
PAIN THRESHOLD
SENSORY THRESHOLDS

Effects of parental presence during children's venipuncture. Wolfram RW, et al. **Acad Emerg Med** 1996 Jan;3(1):58–64
Procedural pain in a paediatric surgical emergency unit. Jylli L, et al. **Acta Paediatr** 1995 Dec;84(12):1403–8
Pain in the ICU: fact or fiction? [editorial] Dracup K, et al. **Am J Crit Care** 1995 Sep;4(5):337–9
Pediatric tool adapts to elderly patients [letter] Toth-Fisher C. **Am J Nurs** 1996 May;96(5):18
Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)
Review of pain-measurement tools. Ho K, et al. **Ann Emerg Med** 1996 Apr;27(4):427–32 (64 ref.)
Measuring pain at baseline and over time. Menegazzi J. **Ann Emerg Med** 1996 Apr;27(4):433–5 (40 ref.)
Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424–6 (26 ref.)
Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Efficacy of the topical anesthetic cream, EMLA, in alleviating both needle insertion and injection pain. Raveh T, et al. **Ann Plast Surg** 1995 Dec;35(6):576–9
Problems with pain—is the messenger to blame? Kidd BL. **Ann Rheum Dis** 1996 May;55(5):275
A plea for uniform reporting of patient outcome in chronic pancreatitis. Frey CF, et al. **Arch Surg** 1996 Mar; 131(3):233–4
Relationship of running to musculoskeletal pain with age. A six-year longitudinal study. Fries JF, et al. **Arthritis Rheum** 1996 Jan;39(1):64–72
Joint and connective tissue ultrasonography in the evaluation of shoulder pain: comment on the article by Manger and Kalden [letter] Uson J, et al. **Arthritis Rheum** 1996 Aug; 39(8):1435
Relative potency of two preparations in two-way elimination of heterogeneity designs with multivariate responses. Hanusz Z. **Biometrics** 1995 Sep;51(3):1133–9
Late-onset hereditary ataxia with global thermoanalgesia and absence of fungiform papillae on the tongue in a Japanese family. Fukutake T, et al. **Brain** 1996 Jun;119 (Pt 3):1011–21
Effect of pH modification by bicarbonate on pain after subcutaneous lidocaine injection. Parham SM, et al. **Can J Surg** 1996 Feb;39(1):31–5
Pain assessment: a pilot study in an Israeli bone marrow transplant unit. Ben David Y, et al. **Cancer Nurs** 1996 Apr; 19(2):93–7
"I hardly cried when I got my shot!" Influencing children's reports about a visit to their pediatrician. Bruck M, et al. **Child Dev** 1995 Feb;66(1):193–208
Ambulance despatchers' estimation of intensity of pain and presence of associated symptoms in relation to outcome in patients who call for an ambulance because of acute chest pain [see comments] Herlitz J, et al. **Eur Heart J** 1995 Dec;16(12):1789–94. Comment in: Eur Heart J 1995 Dec;16(12):1747–8.
Patient-controlled epidural diamorphine for post-operative pain: verbal rating and visual analogue assessments of pain. Kunst G, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):117–29
Pain control in abortion. Wiebe ER, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):41–6
Pupillary and cardiovascular responses to the cold-pressor test. Tassorelli C, et al. **J Auton Nerv Syst** 1995 Oct 5; 55(1–2):45–9
Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717–30 (50 ref.)
Upper arm tourniquet pain in local anaesthetic surgery. Ogufere WE, et al. **J Hand Surg [Br]** 1995 Jun;20(3):413–4
Differential effects of hypnotic suggestion on multiple dimensions of pain. Dahlgren LA, et al. **J Pain Symptom Manage** 1995 Aug;10(6):464–70
Pain in cognitively impaired nursing home patients. Ferrell BA, et al. **J Pain Symptom Manage** 1995 Nov;10(8):591–8
Postoperative pain in children: comparison between ratings of children and nurses. Rømsing J, et al. **J Pain Symptom Manage** 1996 Jan;11(1):42–6
Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. Pelissier T, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):8–14
Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. Raffa RB, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):1–7
Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests. Fortin PR, et al. **J Rheumatol** 1995 Nov;22(11):2078–83
Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis? van der Heide A, et al. **J Rheumatol** 1995 Aug;22(8):1466–70
Assessment of patients' pain [letter] Krivo S, et al. **N Engl J Med** 1996 Jan 4;334(1):59
How should we measure pain in herpes zoster? Wood MJ. **Neurology** 1995 Dec;45(12 Suppl 8):S61–2 (5 ref.)
Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat. Khasar SG, et al. **Neuroscience** 1995 May;66(2):427–32
Family members' perceptions of cancer pain. Comparisons with patient sensory report and by patient psychologic status. Madison JL, et al. **Nurs Clin North Am** 1995 Dec; 30(4):625–45
Gender differences in pain ratings and pupil reactions to painful pressure stimuli. Ellermeier W, et al. **Pain** 1995 Jun; 61(3):435–9
Concerning the homology of painful experiences and pain descriptors: a multidimensional scaling analysis. Janal MN. **Pain** 1996 Feb;64(2):373–8
The Pain Beliefs and Perceptions Inventory: a British replication. Morley S, et al. **Pain** 1995 Jun;61(3):427–33
The influence of warning signal timing and cognitive preparation on the aversiveness of cold-pressor pain. Weisenberg M, et al. **Pain** 1996 Feb;64(2):379–85
Pain in children with juvenile rheumatoid arthritis: a descriptive study. Abu-Saad HH, et al. **Pediatr Res** 1995 Aug;38(2):194–7
Ability of middle-school soccer players to localize overuse leg pain correctly using a graphic self-report form. Gomez JE, et al. **Percept Mot Skills** 1996 Feb;82(1):335–8
Rasch analysis of Visual Analog Scale measurements before and after treatment of Patellofemoral Pain Syndrome in women. Thomeé R, et al. **Scand J Rehabil Med** 1995 Sep; 27(3):145–51
Are tender point scores assessed by manual palpation in fibromyalgia reliable? An investigation into the variance of tender point scores. Jacobs JW, et al. **Scand J Rheumatol** 1995;24(4):243–7
The reliability and validity of pain threshold measurements in osteoarthritis of the knee. Wessel J. **Scand J Rheumatol** 1995;24(4):238–42
Painless ESWL by cutaneous application of vaseline. Heidenreich A, et al. **Scand J Urol Nephrol** 1995 Jun; 29(2):155–60
[Creation of a committee for pain evaluation and treatment (editorial)] Chauvin M. **Ann Fr Anesth Reanim** 1996; 15(3):257–8 (0 ref.) **(Fre)**
[Comparison of anxiety and pain in two procedures of hematopoietic stem cell collection: cytapheresis and bone marrow collection] Macquart-Moulin G, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):582–8 (Eng. Abstr.) **(Fre)**
[Pain and tourniquet in orthopedic surgery] Estèbe JP, et al. **Can Anesthesiol** 1995;43(6):573–8 (Eng. Abstr.) **(Fre)**
[Differential indications of non-opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient-controlled analgesia] Steffen P, et al.

Anasthesiol Intensivmed Notfallmed Schmerzther 1996 May; 31(4):216–21 (Eng. Abstr.) **(Ger)**

[Assessment of experimentally–induced pain effects and their elimination by hypnosis using pupillometry studies] Grünberger J, et al. **Wien Med Wochenschr** 1995; 145(23):646–50 (Eng. Abstr.) **(Ger)**

[Pain and pain perception in the elderly (editorial)] Kruse A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):311 **(Ger)**

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Psychological diagnosis of pain and pain treatment in the elderly] Wilz G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):312–7 (54 ref.) (Eng. Abstr.) **(Ger)**

[Patients with cancer–related pain and other chronic pain. Priorities and assessment] Skauge M, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):473–7 (Eng. Abstr.) **(Nor)**

[Determination of pain severity in patients with low back pain using kinesiologic electromyography of the sacrospinal muscles] Graberski–Matasović M, et al. **Lijec Vjesn** 1995 Nov–Dec;117(11–12):265–7 (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

Analgesic efficacy of low–dose ketamine. Somatosensory–evoked responses in relation to subjective pain ratings. Kochs E, et al. **Anesthesiology** 1996 Aug; 85(2):304–14

Meta–chlorophenylpiperazine attenuates formalin–induced nociceptive responses through 5–HT1/2 receptors in both normal and diabetic mice. Takeshita N, et al. **Br J Pharmacol** 1995 Dec;116(8):3133–8

A comparison of iodixanol with iopamidol in aorto–femoral angiography. Verow P, et al. **Br J Radiol** 1995 Sep; 68(813):973–8

Lithium treatment prolongs shock–induced hypoalgesia. Teixeira NA, et al. **Braz J Med Biol Res** 1995 Jul; 28(7):791–9

Assessment of pain threshold and pain tolerance in women in labour and in the early post–partum period by pressure algometry. Shapira SC, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):495–9

Tonic versus phasic pain: dose–related effects of ketoprofen. Hummel T, et al. **Eur J Clin Pharmacol** 1995;49(1–2):7–14

Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Valverde O, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):79–93

Effects of a histamine H2 receptor agonist and antagonist on restraint–induced antinociception in female mice. Wong CL. **Eur J Pharmacol** 1995 Jun 12;279(2–3):109–13

Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital–anesthetized rats. Helmstetter FJ, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):381–8

Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model. Langerman L, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):23–7

Thermal, mechanical and chemical peripheral sensation in amphibians: opioid and adrenergic effects. Willenbring S, et al. **Life Sci** 1996;58(2):125–33

Test–dependent relationship of the antidepressant and analgesic effects of amitriptyline. Casas J, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):583–8

Effects L–NG–nitro arginine methyl ester (L–NAME), L–NG–monomethyl arginine (L–NMMA) and L–arginine on the antinociceptive effects of morphine in mice. Dambisya YM, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):577–82

Inhibition by spinal morphine of the tail–flick response is attenuated in rats with nerve ligation injury. Ossipov MH, et al. **Neurosci Lett** 1995 Oct 20;199(2):83–6

Exaggerated cardiovascular and behavioral nociceptive responses to subcutaneous formalin in the spontaneously hypertensive rat. Taylor BK, et al. **Neurosci Lett** 1995 Dec 1;201(1):9–12

ACEA–1011, a novel NMDA receptor/glycine site antagonist, produces antinociception but not tolerance in the formalin test in mice. Lutfy K, et al. **NIDA Res Monogr** 1995;147:220–33

1,3–Di–o–tolylguanidine (DTG) differentially affects acute and tonic formalin pain: antagonism by rimcazole. Kest B, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):175–8

Interaction of opioids with antidepressant–induced antinociception. Sierralta F, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):374–8

The effect of pre–emptive fentanyl on formalin pain in mice. Fu ES, et al. **Reg Anesth** 1995 Jul–Aug;20(4):291–5

A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Pu XC, et al. **Toxicon** 1995 Nov;33(11):1425–31

INSTRUMENTATION

Pressure–controlled palpation [letter; comment] Atkins CJ, et al. **Cephalalgia** 1996 Apr;16(2):127–8. Comment on: Cephalalgia 1995 Jun;15(3):205–10.

Premature Infant Pain Profile: development and initial validation. Stevens B, et al. **Clin J Pain** 1996 Mar; 12(1):13–22

A standard test of heat–pain responses using CASE IV. Dyck PJ, et al. **J Neurol Sci** 1996 Mar;136(1–2):54–63

An electromechanical stimulator system for neurophysiological and psychophysical studies of pain. Schneider W, et al. **J Neurosci Methods** 1995 Aug; 60(1–2):61–8

A visual analogue thermometer for measuring pain intensity. Choinière M, et al. **J Pain Symptom Manage** 1996 May; 11(5):299–311

Vulval algesiometer. Curnow JS, et al. **Med Biol Eng Comput** 1996 May;34(3):266–9

Palpometry: a novel concept in pain measurement. Atkins CJ, et al. **Nat Med** 1995 Nov;1(11):1138–9

The factorial structure and stability of the McGill Pain Questionnaire in patients experiencing oral mucositis following bone marrow transplantation. Donaldson GW. **Pain** 1995 Jul;62(1):101–9

METHODS

Assessment and control of pain in children [editorial] Lloyd–Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)

Incidence of chronic pain following traumatic brain injury. Lahz S, et al. **Arch Phys Med Rehabil** 1996 Sep; 77(9):889–91

Temporal summation during extradural anaesthesia. Curatolo M, et al. **Br J Anaesth** 1995 Nov;75(5):634–5

Response measures in the acute treatment of migraine. Skovlund E, et al. **Cephalalgia** 1995 Dec;15(6):519–22, discussion 450–1

Cues parents use to assess postoperative pain in their children. Reid GJ, et al. **Clin J Pain** 1995 Sep;11(3):229–35

Pain and pathology in lumbar disc hernia. Vucetic N, et al. **Clin Orthop** 1995 Nov;(320):65–72

Pain drawing in the evaluation of low back pain. Takata K, et al. **Int Orthop** 1995;19(6):361–6

Assessment and management of children's pain in community hospitals. Caty S, et al. **J Adv Nurs** 1995 Oct;22(4):638–45

Assessing pain in elderly patients who cannot respond verbally. Simons W, et al. **J Adv Nurs** 1995 Oct;22(4):663–9

Combining qualitative and quantitative research approaches in understanding pain. Moore R. **J Dent Educ** 1996 Aug; 60(8):709–15

Self–assessment of pain and discomfort in patients with temporomandibular disorders: a comparison of five different scales with respect to their precision and sensitivity as well as their capacity to register memory of pain and discomfort. Magnusson T, et al. **J Oral Rehabil** 1995 Aug;22(8):549–56

A revised measure of acute pain in infants. Taddio A, et al. **J Pain Symptom Manage** 1995 Aug;10(6):456–63

The management of pain in patients with advanced cancer: the importance of multidimensional assessments. Robinson K, et al. **J Palliat Care** 1995 Winter;11(4):51–3

Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model. Langerman L, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):23–7

Assessment of subjective pain following photorefractive keratectomy. Melbourne Excimer Laser Group. McCarty CA, et al. **J Refract Surg** 1996 Mar–Apr;12(3):365–9

Thermal, mechanical and chemical peripheral sensation in amphibians: opioid and adrenergic effects. Willenbring S, et al. **Life Sci** 1996;58(2):125–33

The use of ACTH and beta–endorphin levels to measure the stress impact and safety of extracorporeal lithotripsy. Mariani M, et al. **Med Law** 1995;14(3–4):269–73

Temporomandibular joint compression in coma. Wijdicks EF. **Neurology** 1996 Jun;46(6):1774

A strategy to assess the temporal dimension of pain in children and adolescents. Savedra MC, et al. **Nurs Res** 1995 Sep–Oct;44(5):272–6

CRIES: a new neonatal postoperative pain measurement score. Initial testing of validity and reliability. Krechel SW, et al. **Paediatr Anaesth** 1995;5(1):53–61

Avoiding fallacies in nociceptive measurements [letter] Carmody J. **Pain** 1995 Oct;63(1):136

A clinical procedure for assessment of severity of knee pain. Lewis B, et al. **Pain** 1995 Dec;63(3):361–4

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. McQuay H, et al. **Pain** 1996 Feb;64(2):331–5

Scaling the affective domain of pain: a study of the dimensionality of verbal descriptors. Morley S, et al. **Pain** 1995 Jul;62(1):39–49

A new method of recording somatosensory evoked potentials by randomized electrical tooth stimulation with 6 levels of intensity. Umino M, et al. **Pain** 1996 Feb;64(2):269–76

Reliability and validity of the Wheelchair User's Shoulder Pain Index (WUSPI). Curtis KA, et al. **Paraplegia** 1995 Oct;33(10):595–601

Different methods of assessing nicotine–induced antinociception may engage different neural mechanisms. Caggiula AR, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):301–6

Comparison of the sensitivity to change of long and short form pain measures. Jenkinson C, et al. **Qual Life Res** 1995 Aug;4(4):353–7

Nonorganic signs of significance in low back pain. Kummel BM. **Spine** 1996 May 1;21(9):1077–81

Quantified pain drawing in subacute low back pain. Validation in a nonselected outpatient industrial sample. Ohlund C, et al. **Spine** 1996 May 1;21(9):1021–30; discussion 1031

NURSING

Assessing pain in neonates. Bell SG. **Am J Nurs** 1995 Dec; 95(12):15–6

Assessment and measurement of acute pain. Dick MJ. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):843–8 (17 ref.)

Issues of assessment of pain and discomfort in neonates. Stevens BJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec;24(9):849–55 (53 ref.)

The knowledge and attitudes of experience oncology nurses regarding the management of cancer–related pain. O'Brien S, et al. **Oncol Nurs Forum** 1996 Apr;23(3):515–21

RADIATION EFFECTS

Analgesic effects of cranial laser treatment in two rat nociception models. Wedlock P, et al. **Physiol Behav** 1996 Mar;59(3):445–8

STANDARDS

Mismatch: when nurses rate patients' pain. Ward S. **Am J Nurs** 1996 May;96(5):21

Clinical significance of reported changes in pain severity. Todd KH, et al. **Ann Emerg Med** 1996 Apr;27(4):485–9

Combining qualitative and quantitative research approaches in understanding pain. Moore R. **J Dent Educ** 1996 Aug; 60(8):709–15

The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. Tunks E, et al. **J Rheumatol** 1995 May;22(5):944–52

STATISTICS & NUMERICAL DATA

Clinical versus statistical significance in the assessment of pain relief. Todd KH. **Ann Emerg Med** 1996 Apr; 27(4):439–41 (11 ref.)

Preconditions for sensitivity in measuring change: visual analogue scales compared to rating scales in a Likert format. Pfennings L, et al. **Psychol Rep** 1995 Oct; 77(2):475–80

Inconsistency and health state valuations. Dolan P, et al. **Soc Sci Med** 1996 Feb;42(4):609–15

[The Pain Perception Scale—a differentiated and change–sensitive scale for assessing chronic and acute pain] Geissner E. **Rehabilitation (Stuttg)** 1995 Nov; 34(4):XXXV–XLIII (Eng. Abstr.) **(Ger)**

PAIN, POSTOPERATIVE

Patient–controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5

Early postoperative stress: video–assisted wedge resection/lobectomy vs conventional axillary thoracotomy. Tschernko EM, et al. **Chest** 1996 Jun;109(6):1636–42

Cues parents use to assess postoperative pain in their children. Reid GJ, et al. **Clin J Pain** 1995 Sep;11(3):229–35

Post–tonsillectomy pain with selective diathermy haemostasis. Tay HL. **J Laryngol Otol** 1996 May; 110(5):446–8

Post–tonsillectomy pain: the first ten days. Toma AG, et al. **J Laryngol Otol** 1995 Oct;109(10):963–4

Residual postsurgical back pain. Jameel IM, et al. **J Med Assoc Ga** 1996 Apr;85(2):101–3, 105–7

Postoperative pain in children: comparison between ratings of children and nurses. Rømsing J, et al. **J Pain Symptom Manage** 1996 Jan;11(1):42–6

BLOOD

Metabolic responses after laparoscopic or open hernia repair. Schrenk P, et al. **Surg Endosc** 1996 Jun;10(6):628–32

COMPLICATIONS

Postoperative pulmonary complications. Obesity, pain, and sedation are important [letter; comment] Higgs A. **BMJ** 1996 May 4;312(7039):1159; discussion 1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

DIAGNOSIS

Implementation of the Agency for Health Care Policy and Research postoperative pain management guideline. Bach DM. **Nurs Clin North Am** 1995 Sep;30(3):515–27

CRIES: a new neonatal postoperative pain measurement score. Initial testing of validity and reliability. Krechel SW, et al. **Paediatr Anaesth** 1995;5(1):53–61

DRUG THERAPY

Evaluation of morphine for patient controlled analgesia with the Infusor system after opiate–free locoregional anesthesia for osteotomy of the foot. Van Lancker P, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):113–20

Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section. Baseline pain–intensity is a determinant of assay–sensitivity in a postoperative analgesic trial [see comments] Bjune K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):399–407. Comment in: Acta Anaesthesiol Scand 1996 Apr;40(4):397–8.

Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. Bülow HH, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):835–9

Comparison of preoperative with postoperative topical lidocaine spray on pain after tonsillectomy. Elhakim M, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1032–5

Effect of intravenous ketoprofen on pain after outpatient laparoscopic sterilisation. Eriksson H. **Acta Anaesthesiol Scand** 1995 Oct;39(7):975–8

Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post–cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):372–5

Better standardisation will improve the quality of analgesic studies [editorial; comment] Kalso E. **Acta Anaesthesiol Scand** 1996 Apr;40(4):397–8. Comment on: Acta Anaesthesiol Scand 1996 Apr;40(4):399–407.

Inadvertent epidural injection of potassium chloride. Report of two cases. Liu K, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1134–7

Opioid in peripheral analgesia: intra–articular morphine for pain control after arthroscopic knee surgery. Liu K, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):217–21

Intra–operative epidural morphine, fentanyl, and droperidol for control of pain after spinal surgery. A prospective, randomized, placebo–controlled, and double–blind trial. Rainov NG, et al. **Acta Neurochir (Wien)** 1996;138(1):33–9

Analgesic administration, pain intensity, and patient satisfaction in cardiac surgical patients. Meehan DA, et al. **Am J Crit Care** 1995 Nov;4(6):435–42

Standardization of epidural preparations for postoperative analgesia. Dollard JV, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2565–7

Treating neonates in pain. Bell SG. **Am J Nurs** 1996 Jan; 96(1):59

Beware of routine procedures. Lilley LL, et al. **Am J Nurs** 1995 Oct;95(10):18

Treatment of migraine headache after ocular surgery with intravenous metoclopramide hydrochloride. MacCumber MW, et al. **Am J Ophthalmol** 1996 Jan;121(1):96–7

Nonopioid analgesics shorten the duration of postoperative ileus. Ferraz AA, et al. **Am Surg** 1995 Dec;61(12):1079–83

Patient–controlled epidural analgesia following caesarean delivery: a comparison of pethidine and fentanyl. Goh JL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):45–50

Evaluation of a disposable device for patient–controlled epidural analgesia after caesarean section. Ngan Kee WD, et al. **Anaesth Intensive Care** 1996 Feb;24(1):51–5

The effect of tunnelling on epidural catheter migration. Bougher RJ, et al. **Anaesthesia** 1996 Feb;51(2):191–4

Endangered opportunities in acute pain management [letter; comment] Bromage PR. **Anaesthesia** 1995 Oct;50(10):910–1 . Comment on: Anaesthesia 1995 May;50(5):383–7. Comment on: Anaesthesia 1995 May;50(5):435–8.

A comparison of epidural infusions of fentanyl or pethidine with bupivacaine in the management of postoperative pain. Cox CR, et al. **Anaesthesia** 1996 Jul;51(7):695–8

The effect of a combination of rectal diclofenac and caudal bupivacaine on postoperative analgesia in children. Gadiyar V, et al. **Anaesthesia** 1995 Sep;50(9):820–2

Postoperative pain in children. Goddard JM, et al. **Anaesthesia** 1996 Jun;51(6):588–90

Postoperative cognitive impairment in the elderly. Choice of patient–controlled analgesia opioid. Herrick IA, et al. **Anaesthesia** 1996 Apr;51(4):356–60

Patient–controlled alfentanil. Target–controlled infusion for postoperative analgesia. Irwin MG, et al. **Anaesthesia** 1996 May;51(5):427–30

Overdose of morphine during PCA [letter] Kwan A. **Anaesthesia** 1995 Oct;50(10):919

Assessment and control of pain in children [editorial] Lloyd–Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)

A comparison of retrospective versus contemporaneous nausea scores with patient–controlled analgesia. McIndoe AK, et al. **Anaesthesia** 1996 Apr;51(4):333–7

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Mackenzie DW, et al. **Anaesthesia** 1996 Feb;51(2):200–1

Variable–dose patient–controlled analgesia. A preliminary report. Owen H, et al. **Anaesthesia** 1995 Oct;50(10):855–7

Efficacy of patient controlled analgesia may have a diurnal rhythm! [letter] Richardson NG, et al. **Anaesthesia** 1996 Apr;51(4):409–10

Attitudes and preferences of patients to routes of analgesic administration [letter] Skinner TA, et al. **Anaesthesia** 1996 Mar;51(3):290–1

Patients' experiences of patient–controlled analgesia. Taylor NM, et al. **Anaesthesia** 1996 Jun;51(6):525–8

An assessment of morphine requirement after wisdom tooth extraction under general anaesthesia. Tighe KE, et al. **Anaesthesia** 1995 Sep;50(9):816–8

Systemic piroxicam as an adjunct to patient–controlled analgesia with alfentanil for postoperative pain relief. Van Lancker P, et al. **Anaesthesia** 1996 Jul;51(7):658–62

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Whitehead PN. **Anaesthesia** 1996 Feb;51(2):200

Comparison of intravenous and epidural clonidine for postoperative patient–controlled analgesia. Bernard JM, et al. **Anesth Analg** 1995 Oct;81(4):706–12

Equivalent outcomes during postoperative patient–controlled intravenous analgesia with lidocaine plus morphine versus morphine alone. Cepeda MS, et al. **Anesth Analg** 1996 Jul; 83(1):102–6

Retrieval of catheter using guide wire [letter] Elias MA, et al. **Anesth Analg** 1996 Jul;83(1):196–7

Patient–controlled epidural analgesia after thoracotomy: a comparison of meperidine with and without bupivacaine. Etches RC, et al. **Anesth Analg** 1996 Jul;83(1):81–6

Off–label use of ketorolac [letter; comment] Finnegan MA. **Anesth Analg** 1996 Jul;83(1):197. Comment on: Anesth Analg 1995 Jun;80(6):1154–7.

Drug delivery system to improve the perioperative administration of intravenous drugs: computer assisted continuous infusion (CACI) [editorial; comment] Glass PS, et al. **Anesth Analg** 1995 Oct;81(4):665–7. Comment on: Anesth Analg 1995 Oct;81(4):671–9.

Intravenous tramadol versus epidural morphine for postthoracotomy pain relief: a placebo–controlled double–blind trial. James MF, et al. **Anesth Analg** 1996 Jul; 83(1):87–91

Patient–controlled intranasal analgesia: a method for noninvasive postoperative pain management. Striebel HW, et al. **Anesth Analg** 1996 Sep;83(3):548–51

Alfentanil dose–response relationships for relief of postoperative pain. Tverskoy M, et al. **Anesth Analg** 1996 Aug;83(2):387–93

Computer–controlled infusion of alfentanil versus patient–controlled administration of morphine for postoperative analgesia: a double–blind randomized trial [see comments] van den Nieuwenhuyzen MC, et al. **Anesth Analg** 1995 Oct;81(4):671–9. Comment in: Anesth Analg 1995 Oct;81(4):665–7.

Practice guidelines for sedation and analgesia by non–anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non–Anesthesiologists. **Anesthesiology** 1996 Feb; 84(2):459–71

Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Erichsen CJ, et al. **Anesthesiology** 1996 Apr;84(4):834–42

Preemptive analgesia: intraperitoneal local anesthetic in laparoscopic cholecystectomy. A randomized, double–blind, placebo–controlled study. Pasqualucci A, et al. **Anesthesiology** 1996 Jul;85(1):11–20

Postoperative analgesia using epidural infusions of fentanyl with bupivacaine. A prospective analysis of 1,014 patients. Scott DA, et al. **Anesthesiology** 1995 Oct;83(4):727–37

Role of magnesium sulfate in postoperative analgesia. Tramer MR, et al. **Anesthesiology** 1996 Feb;84(2):340–7

Postoperative continuous interscalene brachial plexus blockade for hand surgery. Koh DL, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):3–7

Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. McEvoy A, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):363–6

Extradural clonidine for postoperative pain relief [letter; comment] Cook B, et al. **Br J Anaesth** 1996 Jun;76(6):881–2 . Comment on: Br J Anaesth 1994 Mar;72(3):258–62. Comment on: Br J Anaesth 1996 Jan;76(1):171.

Peripheral analgesic effect of morphine [letter; comment] Mallick A, et al. **Br J Anaesth** 1995 Dec;75(6):822–3. Comment on: Br J Anaesth 1995 Jul;75(1):23–6.

Comparison of i.v. and s.c. diamorphine infusions for the treatment of acute pain in children. Semple D, et al. **Br J Anaesth** 1996 Feb;76(2):310–2

Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient–controlled analgesia after gynaecological surgery. Stanley G, et al. **Br J Anaesth** 1996 Apr;76(4):484–6

Psychological characteristics and patient–controlled analgesia [letter; comment] Thomas VJ, et al. **Br J Anaesth** 1996 Apr;76(4):595. Comment on: Br J Anaesth 1995 Sep;75(3):376.

Naproxen after day–case laparoscopic sterilization [letter; comment] Williams PI. **Br J Anaesth** 1996 Jan;76(1):168. Comment on: Br J Anaesth 1995 Jul;75(1):12–4.

Ventilatory arrest after a fluid challenge in a neonate receiving s.c. morphine. Wolf AR, et al. **Br J Anaesth** 1995 Dec;75(6):787–9

Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):15–7 (10 ref.)

The emerging roles of topical non–steroidal anti–inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)

Evaluation of different doses of soluble ibuprofen and ibuprofen tablets in postoperative dental pain. Seymour RA, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):110–4

Postoperative pain in children [letter] Finley GA, et al. **Can J Anaesth** 1996 Apr;43(4):418–9

Failure of meperidine wound infiltration to reduce pain after laparoscopic tubal ligation. Forgach L, et al. **Can J Anaesth** 1995 Dec;42(12):1085–9

Ketorolac does not decrease postoperative pain in elderly men after transvesical prostatectomy. Fredman B, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):438–41

The clinical utility of epidural midazolam for inguinal hernia repair in children [editorial; comment] Goresky GV. **Can J Anaesth** 1995 Sep;42(9):755–7. Comment on: Can J Anaesth 1995 Sep;42(9):758–64. **(Eng, Fre)**

Comparison of morphine and morphine with ketamine for postoperative analgesia. Javery KB, et al. **Can J Anaesth** 1996 Mar;43(3):212–5

Midazolam for caudal analgesia in children: comparison with caudal bupivacaine [see comments] Naguib M, et al. **Can J Anaesth** 1995 Sep;42(9):758–64. Comment in: Can J Anaesth 1995 Sep;42(9):755–7.

Midazolam for caudal analgesia in children [letter] Naguib M, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):535–6

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5

Intravenous ketorolac vs diclofenac for analgesia after maxillofacial surgery. Tarkkila P, et al. **Can J Anaesth** 1996 Mar;43(3):216–20

Post–tonsillectomy infiltration with bupivacaine reduces immediate postoperative pain in children. Wong AK, et al. **Can J Anaesth** 1995 Sep;42(9):770–4

Ketorolac versus fentanyl for postoperative pain management in outpatients. Twersky RS, et al. **Clin J Pain** 1995 Jun; 11(2):127–33

The use of topical 5% lignocaine ointment for the relief of pain associated with post–operative nasal packing. Kuo MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):357–9

A comparison of crossover versus parallel–group design in the evaluation of analgesic efficacy after molar extraction. Margarone JE, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):453–8

Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. Mehlisch DR, et al. **Clin Ther** 1995 Sep–Oct;17(5):852–60

Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)

A comparative study of ketorolac and diclofenac on post–laparoscopic cholecystectomy pain. Fredman B, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):501–4

Comparison of bupivacaine plus buprenorphine with bupivacaine alone by caudal blockade for post–operative pain relief after hip and knee arthroplasty. Gao F, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):471–6

Intramuscular NSAIDS reduce post–operative pain after minor outpatient anaesthesia. Jakobsson J, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):67–71

Patient–controlled epidural diamorphine for post–operative pain: verbal rating and visual analogue assessments of pain. Kunst G, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):117–29

Post–operative intravenous continuous analgesia: comparison of buprenorphine, fentanyl and nalbuphine. Lejus C, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):57–65

Medical management of pain for early motion in hand and wrist surgery. Miller DS. **Hand Clin** 1996 Feb;12(1):139–47

Efficacy of patient–controlled analgesia in women cholecystectomy patients. Knapp–Spooner C, et al. **Int J Nurs Stud** 1995 Oct;32(5):434–42

Epidural administration of methylprednisolone and morphine for pain after a spinal operation. A randomized, prospective, comparative study. McNeill TW, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1814–8

Comparison of intrapleural versus intravenous morphine for postthoracotomy pain management. Aykaç B, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):538–40

Pain outcomes after thoracotomy: lumbar epidural hydromorphone versus intrapleural bupivacaine. Gaeta RR, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):534–7

Lidocaine and the inhibition of postoperative pain in coronary artery bypass patients. Insler SR, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):541–6

The use of intrapleural clonidine for postoperative pain control. Canver CC, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):183–5

Low–dose caudal morphine for postoperative analgesia in infants and children: a report of 500 cases. Mayhew JF, et al. **J Clin Anesth** 1995 Dec;7(8):640–2

Ketorolac for early postoperative analgesia. Parke TJ, et al. **J Clin Anesth** 1995 Sep;7(6):465–9

Patient–controlled analgesia with sufentanil: a comparison of two different methods of administration. Sinatra RS, et al. **J Clin Anesth** 1996 Mar;8(2):123–9

Patient–controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. Striebel HW, et al. **J Clin Anesth** 1996 Feb;8(1):4–8

Intraperitoneal local anesthetic after laparoscopic cholecystectomy [letter] Mack P. **J Laparoendosc Surg** 1995 Oct;5(5):343–4

Patient–controlled analgesia in Thai patients. Sanansilp V, et al. **J Med Assoc Thai** 1995 Oct;78(10):532–41

Cost–effectiveness analysis of patient–controlled analgesia, intramuscular q.i.d. injection and p.r.n. injection for postoperative pain relief. Sanansilp V, et al. **J Med Assoc Thai** 1995 Nov;78(11):600–4

Continuous thoracic epidural infusions for postoperative analgesia after pectus deformity repair. McBride WJ, et al. **J Pediatr Surg** 1996 Jan;31(1):105–7; discussion 107–8

Control of pain after photorefractive keratectomy. Verma S, et al. **J Refract Surg** 1996 Mar–Apr;12(3):358–64 (37 ref.)

Potentiation of placebo analgesia by proglumide [letter] Benedetti F, et al. **Lancet** 1995 Nov 4;346(8984):1231

Reproducibility of postoperative courses after surgical removal of symmetrically impacted wisdom teeth. Björnsson GA, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):345–56

Enhancement of morphine analgesia by the GABAB agonist baclofen. Gordon NC, et al. **Neuroscience** 1995 Nov;

69(2):345–9

The treatment of pain following excimer laser photorefractive keratectomy: additive effect of local anesthetic drops, topical diclofenac, and bandage soft contact. Cherry PM. **Ophthalmic Surg Lasers** 1996 May; 27(5 Suppl):S477–80

Pharmacokinetics of rectal paracetamol after major surgery in children. Anderson BJ, et al. **Paediatr Anaesth** 1995; 5(4):237–42

A double-blind comparison of morphine infusion and patient controlled analgesia in children. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):121–7

Morphine consumption and respiratory depression in children receiving postoperative analgesia from continuous morphine infusion or patient controlled analgesia. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):129–34

Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Eija K, et al. **Pain** 1996 Feb; 64(2):293–302

The influence of lockout intervals and drug selection on patient-controlled analgesia following gynecological surgery. Ginsberg B, et al. **Pain** 1995 Jul;62(1):95–100

Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia. Grond S, et al. **Pain** 1995 Sep; 62(3):313–20

Intrathecal steroids to reduce pain after lumbar disc surgery: a double-blind, placebo-controlled prospective study. Langmayr JJ, et al. **Pain** 1995 Sep;62(3):357–61

Age is the best predictor of postoperative morphine requirements. Macintyre PE, et al. **Pain** 1996 Feb; 64(2):357–64

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. McQuay H, et al. **Pain** 1996 Feb;64(2):331–5

Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Stubhaug A, et al. **Pain** 1995 Jul;62(1):111–8

Comments on Stubhaug, Grimstad and Breivik, PAIN, 62 (1995) 111–118 [letter] Vielvoye-Kerkmeer PE. **Pain** 1996 Feb;64(2):401–2

Development of a HPLC-system for quantitative measurement of lidocaine and bupivacaine in patients plasma during postoperative epidural pain therapy. Sattler A, et al. **Pharmazie** 1995 Nov;50(11):741–4

Pain, pain relief and accuracy of their recall after cardiac surgery. Valdix SW, et al. **Prog Cardiovasc Nurs** 1995 Summer;10(3):3–11

Impact of patient-controlled analgesia on required nursing time and duration of postoperative recovery. Chan VW, et al. **Reg Anesth** 1995 Nov–Dec;20(6):506–14

Comparison of morphine with and without fentanyl for epidural analgesia after major abdominal surgery. Chrubasik S, et al. **Reg Anesth** 1996 May–Jun;21(3):175–81

Effects of epidural bupivacaine after thoracotomy. Liu S, et al. **Reg Anesth** 1995 Jul–Aug;20(4):303–10

Outcome of epidural analgesia versus patient-controlled analgesia in cancer patients [letter; comment] Walker S. **Reg Anesth** 1995 Nov–Dec;20(6):549. Comment on: Reg Anesth 1994 Sep–Oct;19(5):307–15.

Comparison of intravenous nalbuphine infusion versus saline as an adjuvant for epidural morphine. Wang JJ, et al. **Reg Anesth** 1996 May–Jun;21(3):214–8

Intra-articular morphine and bupivacaine for pain relief after therapeutic arthroscopic knee surgery. Chan ST. **Singapore Med J** 1995 Feb;36(1):35–7

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on postoperative pain following laparoscopy. O'Hanlon JJ, et al. **Ulster Med J** 1996 May; 65(1):51–4

[Acetylsalicylic acid matrices for use in stomatology] Rabilková M. **Ceska Slov Farm** 1996 May;45(3):123–4 (Eng. Abstr.) **(Cze)**

[Comparative study of buprenorphine and its combination to ketoprofen or propacetamol for postoperative analgesia in urologic surgery] Tauzin-Fin P, et al. **Ann Fr Anesth Reanim** 1996;15(1):41–6 (Eng. Abstr.) **(Fre)**

[Analgesia after surgery of the spine in adults and adolescents] Bernard JM, et al. **Cah Anesthesiol** 1995; 43(6):557–64 (78 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative analgesia after ligamentoplasty of the knee. Comparison of epidural morphine and intravenous nalbuphine] Brenet O, et al. **Cah Anesthesiol** 1995; 43(3):319–23 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia in children: techniques] Ecoffey C. **Cah Anesthesiol** 1995;43(3):305–6 **(Fre)**

[Efficacy of propacetamol in postoperative pain based on two modes of intravenous administration] Farhat F, et al. **Cah Anesthesiol** 1995;43(4):351–6 (Eng. Abstr.) **(Fre)**

[Analgesia with intra-articular injection of buprenorphine after surgery of the shoulder] Fellahi JL, et al. **Cah Anesthesiol** 1995;43(3):313–8 (Eng. Abstr.) **(Fre)**

[Optimal use of non opioid analgesics] Fletcher D. **Cah Anesthesiol** 1995;43(3):239–49 (Eng. Abstr.) **(Fre)**

[Optimal use of the administration of morphine derivatives] Langlade A. **Cah Anesthesiol** 1995;43(3):251–7 (66 ref.) (Eng. Abstr.) **(Fre)**

[New routes for infiltration: intraperitoneal injections] Narchi P. **Cah Anesthesiol** 1995;43(3):267–72 (Eng. Abstr.) **(Fre)**

[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16–25 (148 ref.) (Eng. Abstr.) **(Ger)**

[Early detection of opiate-induced respiratory depression in the postoperative phase] Graf R, et al. **Anaesthesiol Reanim** 1995;20(2):38–41 (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134–8 (Eng. Abstr.) **(Ger)**

[Combination of intravenous patient-controlled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69–75 (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia with clonidine and piritramide] Sümpelmann R, et al. **Anaesthesist** 1996 Jan;45(1):88–94 (Eng. Abstr.) **(Ger)**

[A concept for the improvement of postoperative pain management] Wiebalck A, et al. **Anaesthesist** 1995 Dec; 44(12):831–42 (Eng. Abstr.) **(Ger)**

[Pharmacokinetics of buprenorphine in subcutaneous administration] Gralow I, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):412–6 (Eng. Abstr.) **(Ger)**

[Differential administration of non-opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient-controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr;31(3):143–7 (Eng. Abstr.) **(Ger)**

[Differential indications of non-opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient-controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):216–21 (Eng. Abstr.) **(Ger)**

[Analgosedation with fentanyl/midazolam after correction of congenital heart defects] Michel-Behnke I, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):341–6 (Eng. Abstr.) **(Ger)**

[Pharmacotherapy aspects during Harrington's method of spinal surgery] Koch HJ. **Soz Praventivmed** 1995; 40(4):230–3 (Eng. Abstr.) **(Ger)**

[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**

[Epidural analgesia for postoperative pain in infants and children] Efrat R, et al. **Harefuah** 1996 Mar 1;130(5):304–7, 358 (28 ref.) (Eng. Abstr.) **(Heb)**

[Post-thoracotomy analgesia in pediatric heart surgery: comparison of 2 different techniques] Picardo S, et al. **Minerva Anestesiol** 1995 Jun;61(6):277–82 (Eng. Abstr.) **(Ita)**

[The relief of postoperative pain by suppositories of buprenorphine or NSAID] Akatsuka M, et al. **Masui** 1996 Mar;45(3):298–303 (Eng. Abstr.) **(Jpn)**

[Analgesic efficacy of E2078 (dynorphin analog) in patients following abdominal surgery] Fujimoto K, et al. **Masui** 1995 Sep;44(9):1233–7 (Eng. Abstr.) **(Jpn)**

[Postoperative analgesic requirements after various operations] Shima T, et al. **Masui** 1996 Mar;45(3):370–3 (Eng. Abstr.) **(Jpn)**

[Effects of preoperatively administered flurbiprofen axetil on the action of inhaled anesthesia and postoperative pain] Yamazaki Y, et al. **Masui** 1995 Sep;44(9):1238–41 (Eng. Abstr.) **(Jpn)**

[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413–9 (30 ref.) **(Jpn)**

[A method for assessing the analgesic action of drug preparations] Gorbonosov IV, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):71–3 (Eng. Abstr.) **(Rus)**

[Postoperative analgesia with epidural administration of a combination of tramadol and clonidine] Masár O, et al. **Bratisl Lek Listy** 1995 Dec;96(12):669–70 (Eng. Abstr.) **(Slo)**

[Postoperative analgesia in herniated disk surgery. Comparative study of diclofenac , lysine acetylsalicylate, and ketorolac] Izquierdo E, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):316–9 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Postoperative nausea, vomiting and pain in laparoscopic cholecystectomy: a comparison with minilaparotomy-cholecystectomy] Kobayashi N, et al. **Masui** 1996 Apr;45(4):474–8 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Testicular atrophy and neuropathy in herniorrhaphy. Skandalakis JE, et al. **Am Surg** 1996 Sep;62(9):775–82

Audit of pain after nasal surgery. Thomas DM, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):380–2

Chronic pelvic pain caused by residual ovaries and other ovarian remnants [letter; comment] Sinha R. **Br J Obstet Gynaecol** 1995 Nov;102(11):935–6. Comment on: Br J Obstet Gynaecol 1994 Nov;101(11):979–85.

Alterations in respiratory mechanics after laparoscopic and open surgical procedures. Kimberley NA, et al. **Can J Surg** 1996 Aug;39(4):312–6

Knee pain after tibial nailing: does the entry point matter? Orfaly R, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):976–7

Evaluation of pain following electrocautery tubal ligation and effect of intraoperative fentanyl. Curry CS, et al. **J Clin Anesth** 1996 May;8(3):216–9

Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain. Niesel T, et al. **Urology** 1996 Jul; 48(1):91–4

[Pain and sensory impairment following parotidectomy. A descriptive study] Faber CE, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):270–3 (Eng. Abstr.) **(Dan)**

[Pain and sensation disorders after parotidectomy (letter)] Jensen TS, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1845–7 **(Dan)**

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

[Standardized laparoscopic hernia-plasty vs. Shouldice repair] Kux M, et al. **Chirurg** 1996 Apr;67(4):465–6 **(Ger)**

[Subjective assessment of quality of life, pain and surgical success after laparotomy for Crohn disease] Post S, et al. **Chirurg** 1995 Aug;66(8):800–6 (Eng. Abstr.) **(Ger)**

[Postoperative pain in patients after conventional abdominal and endoscopic surgery hysterectomy—a comparative study] Malik E, et al. **Geburtshilfe Frauenheilkd** 1994 Nov; 54(11):598–601 (Eng. Abstr.) **(Ger)**

[Efficacy of continuous intercostal analgesia versus epidural analgesia on post-thoracotomy pain] Nicolosi M, et al. **Minerva Chir** 1996 Mar;51(3):103–7 (Eng. Abstr.) **(Ita)**

[Features and evolution of postoperative pain in patients undergoing thoracotomy] Ugolini D, et al. **Minerva Chir** 1996 Mar;51(3):109–20 (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

[Intensive pain can be caused by Clostridia. Endoscopy is part of the cause of gangrene] Danielsson P, et al. **Lakartidningen** 1996 Mar 6;93(10):903–4 **(Swe)**

NURSING

The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32–8 (34 ref.)

Implementation of the Agency for Health Care Policy and Research postoperative pain management guideline. Bach DM. **Nurs Clin North Am** 1995 Sep;30(3):515–27

Pain management facilitates early postoperative recovery. Riley LA. **Prog Cardiovasc Nurs** 1996 Winter;11(1):47–8

Impact of patient-controlled analgesia on required nursing time and duration of postoperative recovery. Chan VW, et al. **Reg Anesth** 1995 Nov–Dec;20(6):506–14

PHYSIOPATHOLOGY

Surgical pain is followed not only by spinal sensitization but also by supraspinal antinociception. Wilder-Smith OH, et al. **Br J Anaesth** 1996 Jun;76(6):816–21

Preemption and prevention [editorial] Wilson PR. **Clin J Pain** 1996 Mar;12(1):1–2

Sympathetically-maintained pain related to reproductive surgery [letter] LaValleur J, et al. **J Pain Symptom Manage** 1996 Jul;12(1):1–2

Assessment of subjective pain following photorefractive keratectomy. Melbourne Excimer Laser Group. McCarty CA, et al. **J Refract Surg** 1996 Mar–Apr;12(3):365–9

[Does neuroplasticity have a role on postoperative pain?] Viel E, et al. **Cah Anesthesiol** 1995;43(3):231–7 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Premedication with sublingual buprenorphine for out-patient arthroscopy: reduced need for postoperative pethidine but higher incidence of nausea. Juhlin-Dannfelt M, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):633–6

Acute pain management in Australia and New Zealand. Goucke CR, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):715–7

Pain and vomiting after vitreoretinal surgery: a potential role for local anaesthesia. Williams N, et al. **Anaesth Intensive Care** 1995 Aug;23(4):444–8

Patient consent and rectal drug administration [letter; comment] Bonner S, et al. **Anaesthesia** 1996 Apr; 51(4):401–2. Comment on: Anaesthesia 1995 Nov;50(11):983–4.

Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Chan A, et al. **Anaesthesia** 1996 Jun;51(6):592–5

A comparison of diclofenac with ketorolac for pain relief after knee arthroscopy. Dennis AR, et al. **Anaesthesia** 1995 Oct;50(10):904–6

Bilateral ilioinguinal nerve blocks for analgesia after total abdominal hysterectomy [letter] Kelly MC, et al. **Anaesthesia** 1996 Apr;51(4):406

Bilateral paravertebral analgesia for major abdominal vascular surgery: a preliminary report. Richardson J, et al. **Anaesthesia** 1995 Nov;50(11):995–8

The effect of pre-incisional infiltration with lignocaine on postoperative pain after molar teeth extraction under general anaesthesia. Tordoff SG, et al. **Anaesthesia** 1996

Jun;51(6):585–7

Patients' attitudes to rectal drug administration [see comments] Vyvyan HA, et al. **Anaesthesia** 1995 Nov; 50(11):983–4. Comment in: Anaesthesia 1996 Apr;51(4):401–2. Comment in: Anaesthesia 1996 Apr;51(4):402.

Postoperative analgesia in dental day case surgery. A comparison between Feldene 'Melt' (piroxicam) and diclofenac suppositories. Wakeling HG, et al. **Anaesthesia** 1996 Aug;51(8):784–6

Large–dose intrathecal morphine for coronary artery bypass grafting. Chaney MA, et al. **Anesth Analg** 1996 Aug; 83(2):215–22

Epidural clonidine or sufentanil for intraoperative and postoperative analgesia. De Kock M, et al. **Anesth Analg** 1995 Dec;81(6):1154–62

Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty. Etches RC, et al. **Anesth Analg** 1995 Dec; 81(6):1175–80

Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy. Hannibal K, et al. **Anesth Analg** 1996 Aug;83(2):376–81

The effects of intrathecal neostigmine on somatic and visceral pain: improvement by association with a peripheral anticholinergic. Lauretti GR, et al. **Anesth Analg** 1996 Mar; 82(3):617–20

Oral clonidine premedication reduces postoperative pain in children. Mikawa K, et al. **Anesth Analg** 1996 Feb; 82(2):225–30

Intraperitoneal application of bupivacaine during laparoscopic cholecystectomy—risk or benefit? Raetzell M, et al. **Anesth Analg** 1995 Nov;81(5):967–72

Analgesia after thoracotomy: effects of epidural fentanyl concentration/infusion rate. Thomson CA, et al. **Anesth Analg** 1995 Nov;81(5):973–81

Preemptive analgesia. Why its effect is not always obvious [editorial] Kissin I. **Anesthesiology** 1996 May;84(5):1015–9

Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Rockemann MG, et al. **Anesthesiology** 1996 May; 84(5):1027–34

Preincisional infiltration with bupivacaine in tonsillectomy. Johansen M, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):261–3

Postoperative pulmonary complications. Adequate pain relief is also necessary [letter; comment] Quinn AC, et al. **BMJ** 1996 May 4;312(7039):1159; discussion 1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

Postoperative pulmonary complications. Pain relief improves respiratory function [letter; comment] Sabanathan S, et al. **BMJ** 1996 May 4;312(7039):1158–9; discussion 1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

Post–operative pain control [letter] Brett I, et al. **Br Dent J** 1996 Jan 20;180(2):50

Post–operative pain [letter] Lyons HJ. **Br Dent J** 1996 Jan 6;180(1):9

A double–blind placebo–controlled study to assess the efficacy of a compound analgesic to prevent postoperative pain following oral surgery. Sandhu S, et al. **Br Dent J** 1996 May 11;180(9):335–8

Absence of an early pre–emptive effect after thoracic extradural bupivacaine in thoracic surgery. Aguilar JL, et al. **Br J Anaesth** 1996 Jan;76(1):72–6

Comparison of i.m. and local infiltration of ketorolac with and without local anaesthetic. Ben–David B, et al. **Br J Anaesth** 1995 Oct;75(4):409–12

Comparison of the effects of adrenaline, clonidine and ketamine on the duration of caudal analgesia produced by bupivacaine in children. Cook B, et al. **Br J Anaesth** 1995 Dec;75(6):698–701

Patient–controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5

Does pre–incisional thoracic extradural block combined with diclofenac reduce postoperative pain after abdominal hysterectomy? [see comments] Espinet A, et al. **Br J Anaesth** 1996 Feb;76(2):209–13. Comment in: Br J Anaesth 1996 Jul;77(1):128–9.

Rocuronium pretreatment reduces suxamethonium–induced myalgia: comparison with vecuronium. Findlay GP, et al. **Br J Anaesth** 1996 Apr;76(4):526–9

Pre–emptive analgesia with NSAID—what does it achieve? [letter; comment] Hudspith MJ, et al. **Br J Anaesth** 1996 Jul;77(1):128–9. Comment on: Br J Anaesth 1996 Feb;76(2):209–13.

NSAID for caesarean section [letter; comment] Jones SF. **Br J Anaesth** 1995 Nov;75(5):666. Comment on: Br J Anaesth 1995 Jun;74(6):643–6.

Continuous extrapleural paravertebral infusion of bupivacaine for post–thoracotomy analgesia in young infants. Karmakar MK, et al. **Br J Anaesth** 1996 Jun;76(6):811–5

Peritonsillar infiltration with low–dose tenoxicam after tonsillectomy. Knudsen KE, et al. **Br J Anaesth** 1995 Sep; 75(3):286–8

Intra–articular analgesia for arthroscopic meniscectomy. Lyons B, et al. **Br J Anaesth** 1995 Nov;75(5):552–5

Expanding the applications of patient–controlled techniques [letter] Mackenzie J. **Br J Anaesth** 1995 Sep;75(3):377

Influence of dose and timing of administration of morphine on postoperative pain and analgesic requirements. Mansfield MD, et al. **Br J Anaesth** 1996 Mar;76(3):358–61

Extradural clonidine for postoperative pain relief [letter; comment] [see comments] Nishikawa T. **Br J Anaesth** 1996 Jan;76(1):171. Comment on: Br J Anaesth 1994 Mar;72(3):258–62. Comment in: Br J Anaesth 1996 Jun;76(6):881–2.

Extradural, paravertebral and intercostal nerve blocks for post–thoracotomy pain. Perttunen K, et al. **Br J Anaesth** 1995 Nov;75(5):541–7

Postoperative analgesia by continuous extradural infusion of ropivacaine after upper abdominal surgery. Schug SA, et al. **Br J Anaesth** 1996 Apr;76(4):487–91

Continuous extradural infusion of ropivacaine for prevention of postoperative pain after major orthopaedic surgery. Turner G, et al. **Br J Anaesth** 1996 May;76(5):606–10

Comparison of continuous brachial plexus infusion of butorphanol, mepivacaine and mepivacaine–butorphanol mixtures for postoperative analgesia. Wajima Z, et al. **Br J Anaesth** 1995 Nov;75(5):548–51

Pain control after hysterectomy: an observer–blind, randomised trial of lornoxicam versus tramadol. Ilias W, et al. **Br J Clin Pract** 1996 Jun;50(4):197–202

Transcervical analgesia for laparoscopic sterilisation. Hunter A, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):378–80

Pain relief after inguinal hernia repair: a randomized double–blind study [see comments] Nehra D, et al. **Br J Surg** 1995 Sep;82(9):1245–7. Comment in: Br J Surg 1996 Mar;83(3):427.

Pain relief after inguinal hernia repair: a randomized controlled trial [letter; comment] Raithatha D, et al. **Br J Surg** 1996 Mar;83(3):427. Comment on: Br J Surg 1995 Sep;82(9):1245–7.

Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose–finding study. Badner NH, et al. **Can J Anaesth** 1996 Jan;43(1):17–22

Management of postoperative pain and emesis. White PF. **Can J Anaesth** 1995 Nov;42(11):1053–5

Peribulbar injection of bupivacaine for the control of pain and nausea in vitreoretinal surgery. Maberley DA, et al. **Can J Ophthalmol** 1995 Oct;30(6):317–9

Indomethacin and ketorolac given preoperatively are equally effective in reducing early postoperative pain after laparoscopic cholecystectomy. Forse A, et al. **Can J Surg** 1996 Feb;39(1):26–30

Continuous epidural morphine/butorphanol infusion following selective dorsal rhizotomy in children. Lawhorn CD, et al. **Childs Nerv Syst** 1995 Nov;11(11):621–4

Pain after tonsillectomy. Husband AD, et al. **Clin Otolaryngol** 1996 Apr;21(2):99–101 (44 ref.)

A comparison between ketorolac and diclofenac in laparoscopic sterilization. Chui PT, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):597–601

The post–operative analgesic action of midazolam following epidural administration. Nishiyama T. **Eur J Anaesthesiol** 1995 Jul;12(4):369–74

Pre–emptive versus post–surgical administration of ketorolac for hysterectomy. Parke TJ, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):549–53

Post–operative analgesia for craniotomy patients: current attitudes among neuroanaesthetists. Stoneham MD, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):571–5

Analgesic efficacy of topical butamben picrate. Armstrong DG, et al. **J Am Podiatr Med Assoc** 1995 Dec;85(12):738–40

Intra–articular injection of bupivacaine in knee–replacement operations. Results of use for analgesia and for preemptive blockade. Badner NH, et al. **J Bone Joint Surg Am** 1996 May;78(5):734–8

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Dodenhoff RM. **J Bone Joint Surg Am** 1996 Jun;78(6):968. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Linville D. **J Bone Joint Surg Am** 1996 Jun;78(6):967–8. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Efficacy of ketorolac in the management of pain associated with root canal treatment. Battrum D, et al. **J Can Dent Assoc** 1996 Jan;62(1):36–42

Effect of ketorolac on bleeding time and postoperative pain in children: a double–blind, placebo–controlled comparison with meperidine. Bean–Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25–30

Propofol permits tracheal intubation but does not affect postoperative myalgias. Mingus ML, et al. **J Clin Anesth** 1996 May;8(3):220–4

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations. Bigler D, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):142–5

Re: Continuous epidural anesthesia after ureteroneocystostomy in children [letter; comment] Greenberg RS, et al. **J Urol** 1996 Aug;156(2 Pt 1):482–3. Comment on: J Urol 1995 Aug;154(2 Pt 2):791–3.

Re: Continuous epidural anesthesia after ureteroneocystostomy in children [letter; comment] Krane EJ. **J Urol** 1996 Aug;156(2 Pt 1):481–2; discussion 482–3. Comment on: J Urol 1995 Aug;154(2 Pt 2):791–3.

Is intra–articular pethidine an alternative to local anaesthetics in arthroscopy? A double–blind study comparing prilocaine with pethidine. Ekblom A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):189–94

Opioids as novel intra–articular agents for analgesia following arthroscopic knee surgery [published erratum appears in Knee Surg Sports Traumatol Arthrosc 1994;2(4):202] Lehrberger K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):174–5

Local anaesthetic on Filshie clips [letter; comment] Boyd JJ. **Lancet** 1995 Oct 14;346(8981):1033; discussion 1033–4. Comment on: Lancet 1995 Jul 8;346(8967):82–5.

Local anaesthetic on Filshie clips [letter; comment] Broome SC, et al. **Lancet** 1995 Oct 14;346(8981):1032–3; discussion 1033–4. Comment on: Lancet 1995 Jul 8;346(8967):82–5.

Local anaesthetic on Filshie clips [letter; comment] Goodman NW. **Lancet** 1995 Oct 14;346(8981):1033; discussion 1033–4. Comment on: Lancet 1995 Jul 8;346(8967):82–5.

Clonidine–mepivacaine mixture vs plain mepivacaine in paediatric surgery. Ivani G, et al. **Paediatr Anaesth** 1996; 6(2):111–4

Caudal analgesia with buprenorphine for postoperative pain relief in children. Kamal RS, et al. **Paediatr Anaesth** 1995; 5(2):101–6

Intrathecal morphine (ITM) for postoperative pain control in children: a comparison with nalbuphine patient controlled analgesia (PCA). Krechel SW, et al. **Paediatr Anaesth** 1995;5(3):177–83

Postoperative pain in children: a survey of parents' expectations and perceptions of their children's experiences. Rømsing J, et al. **Paediatr Anaesth** 1996; 6(3):215–8

Transnasal butorphanol for postoperative analgesia following paediatric surgery in a Third World country. Tobias JD, et al. **Paediatr Anaesth** 1995;5(1):63–6

A comparison between ilioinguinal–iliohypogastric nerve block performed by anaesthetist or surgeon for postoperative analgesia following groin surgery in children. Trotter C, et al. **Paediatr Anaesth** 1995;5(6):363–7

Central sensitization as a result of surgical pain: investigation of the pre–emptive value of pethidine for ovariohysterectomy in the rat. Lascelles BD, et al. **Pain** 1995 Aug;62(2):201–12

Pain relief for thoracotomy. Comparison of morphine requirements using an extrapleural infusion of bupivacaine. Carabine UA, et al. **Reg Anesth** 1995 Sep–Oct;20(5):412–7

Preoperative spinal bupivacaine does not reduce postoperative morphine requirement in women undergoing total abdominal hysterectomy. Dakin MJ, et al. **Reg Anesth** 1996 Mar–Apr;21(2):99–102

Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Gwirtz KH, et al. **Reg Anesth** 1995 Sep–Oct;20(5):395–401

Double–blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered morphine for post–thoracotomy analgesia. Liu M, et al. **Reg Anesth** 1995 Sep–Oct;20(5):418–25

The relief of acute pain. Shipton EA. **S Afr J Surg** 1996 Feb;34(1):40–3

A double–blinded evaluation of intraperitoneal bupivacaine vs saline for the reduction of postoperative pain and nausea after laparoscopic cholecystectomy. Szem JW, et al. **Surg Endosc** 1996 Jan;10(1):44–8

Peripheral nerve blocks for paediatric day–stay surgery: one year's experience in a district general hospital. Keohane M, et al. **Ulster Med J** 1995 Apr;64(1):39–41

[New routes for infiltration: surgical wound infiltration] Bouaziz H, et al. **Cah Anesthesiol** 1995;43(3):273–5 (Eng. Abstr.) **(Fre)**

[Arguments for conduction anesthesia in children] Ecoffey C. **Cah Anesthesiol** 1995;43(6):529–32 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia in children: what is new?] Murat I. **Rev Med Suisse Romande** 1996 Apr;116(4):247–50 (18 ref.) **(Fre)**

[Preventive pain therapy. Preventive tramadol infusion versus bolus application in the early postoperative phase] Hartjen K, et al. **Anaesthesist** 1996 Jun;45(6):538–44 (Eng. Abstr.) **(Ger)**

[Modification of patella alta, patella ventralization en patella lateralization in patellar pain syndrome following implantation of total GSB endoprosthesis] Nebelung W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):535–8 (Eng. Abstr.) **(Ger)**

[Evaluation of postoperative pain in spinal surgery—usefulness of the administration of local anesthetics into the peridural cavity] Hashimoto K, et al. **Masui** 1996 May;45(5):634–7 (Eng. Abstr.) **(Jpn)**

[Reduction of the need for isoflurane and of postoperative pain with preanesthetic intrathecal morphine (letter; comment)] Sabaté A. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):349–51. Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):41–6. **(Spa)**

PSYCHOLOGY

Attitudes to pain and pain relief in adult surgical patients. Brydon CW, et al. **Anaesthesia** 1996 Mar;51(3):279–81

Postoperative pain. Expectation and experience after coronary artery bypass grafting. Nay PG, et al. **Anaesthesia** 1996 Aug;51(8):741–3

Acute pain after thoracic surgery predicts long–term

post-thoracotomy pain. Katz J, et al. **Clin J Pain** 1996 Mar; 12(1):50–5

Psychological management of postsurgical pain and patient adherence. Moskowitz L. **Hand Clin** 1996 Feb;12(1):129–37

Young children's behavioural responses to acute pain: strategies for getting better. Woodgate R, et al. **J Adv Nurs** 1995 Aug;22(2):243–9

"Getting better from my hurts": toward a model of the young child's pain experience. Woodgate R, et al. **J Pediatr Nurs** 1996 Aug;11(4):233–42

To control or to be controlled? From health locus of control to morphine control during patient-controlled analgesia. Reynaert C, et al. **Psychother Psychosom** 1995;64(2):74–81

RADIONUCLIDE IMAGING

Isotope bone scans in patients with painful knee replacements: do they alter management? Owen RJ, et al. **Br J Radiol** 1995 Nov;68(815):1204–7

THERAPY

A clinical audit for postoperative pain control on 1443 surgical patients. Tsui SL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):137–48

The preemptive effect of regional anesthesia on post-cesarean section pain. Wang JJ, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):211–6

Treatment of the failed back surgery syndrome due to lumbo-sacral epidural fibrosis. Fiume D, et al. **Acta Neurochir Suppl (Wien)** 1995;64:116–8

Spinal cord stimulation versus reoperation for failed back surgery syndrome: a prospective, randomized study design. North RB, et al. **Acta Neurochir Suppl (Wien)** 1995;64:106–8

The effect of cold therapy on the postoperative course of total hip and knee arthroplasty patients. Scarcella JB, et al. **Am J Orthop** 1995 Nov;24(11):847–52

Cardiac arrest following epidural overdose [letter] Dawson P. **Anaesth Intensive Care** 1995 Oct;23(5):650–5

National provision of acute pain services. Windsor AM, et al. **Anaesthesia** 1996 Mar;51(3):228–31

Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery—a dose finding study. Scott DA, et al. **Anesth Analg** 1995 Nov;81(5):982–6

Randomized, single-blinded trial of laparoscopic versus open appendectomy in children: effects on postoperative analgesia. Lejus C, et al. **Anesthesiology** 1996 Apr; 84(4):801–6

Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults. Warfield CA, et al. **Anesthesiology** 1995 Nov;83(5):1090–4

Effects of preemptive or postinjury intrathecal local anesthesia on persistent nociceptive responses in rats. Confounding influences of peripheral inflammation and the general anesthetic regimen. Yashpal K, et al. **Anesthesiology** 1996 May;84(5):1119–28

Femoral nerve block as an alternative to parenteral narcotics for pain control after anterior cruciate ligament reconstruction. Edkin BS, et al. **Arthroscopy** 1995 Aug; 11(4):404–9

Acute pain services. Work is needed to show that good quality analgesia improves outcome of surgery [letter; comment] Fischer HB, et al. **BMJ** 1995 Oct 14; 311(7011):1023–4. Comment on: BMJ 1995 Aug 5;311(7001):360–1.

Acute pain services. Low expectations of pain relief encourage persistence of poor standards [letter; comment] Garbrielczyk MR. **BMJ** 1995 Oct 14;311(7011):1024. Comment on: BMJ 1995 Aug 5;311(7001):360–1.

Postoperative analgesia for arthrolysis of the elbow joint [letter; comment] Frizelle HP, et al. **Br J Anaesth** 1995 Sep;75(3):372. Comment on: Br J Anaesth 1995 Apr;74(4):469–71.

Pain relief following iliac crest bone harvesting. Wilson PA. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):242–3

Lateral popliteal sciatic nerve block compared with ankle block for analgesia following foot surgery [published erratum appears in Can J Anaesth 1995 Nov;42(11):1065] McLeod DH, et al. **Can J Anaesth** 1995 Sep;42(9):765–9

Continuous extrapleural intercostal nerve block with continuous infusion of lidocaine after thoracotomy. A descriptive pilot study. Sullivan E, et al. **Chest** 1995 Dec; 108(6):1718–23

Psychological management of postsurgical pain and patient adherence. Moskowitz L. **Hand Clin** 1996 Feb;12(1):129–37

Pain management in video assisted thoracic surgery: evaluation of localised partial rib resection. A new technique. Richardson J, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):505–9

Blunt needle infusion of local anesthetics or narcotic analgesics into operative wounds or joints. Rozencwaig R, et al. **J La State Med Soc** 1995 Nov;147(11):516–7

Continuous epidural block for pain control in bladder exstrophy: report of a case and description of technique. Messeri A, et al. **Paediatr Anaesth** 1995;5(4):229–32

[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Comparison of extrapleural and intrapleural analgesia with bupivacaine after thoracotomy] Alaya M, et al. **Ann Fr Anesth Reanim** 1995;14(3):249–55 (Eng. Abstr.) **(Fre)**

[Evaluation of the activity of a postoperative analgesia department in a Canadian hospital] Fugère F, et al. **Ann Fr Anesth Reanim** 1996;15(3):313–9 (Eng. Abstr.) **(Fre)**

[Should postoperative pain management units be developed in France? (editorial)] Scherpereel P. **Ann Fr Anesth Reanim** 1996;15(3):255–6 **(Fre)**

[Development of locoregional anesthesia and management of postoperative pain: inadequate! (editorial)] Bonnet F. **Cah Anesthesiol** 1995;43(3):229 **(Fre)**

[Nerve block analgesia after surgery of the knee] Fayard JJ. **Cah Anesthesiol** 1995;43(6):601–3 (Eng. Abstr.) **(Fre)**

[Analgesia after surgery of the shoulder] Narchi P. **Cah Anesthesiol** 1995;43(6):579–81 (Eng. Abstr.) **(Fre)**

[Audit of the management of postoperative pain] Poisson-Salomon AS, et al. **Presse Med** 1996 Jun 22; 25(22):1013–7 (Eng. Abstr.) **(Fre)**

[Efficacy of continuous intercostal analgesia versus epidural analgesia on post-thoracotomy pain] Nicolosi M, et al. **Minerva Chir** 1996 Mar;51(3):103–7 (Eng. Abstr.) **(Ita)**

[Epidural injection for postoperative pain relief after thoracoscopic surgery] Nogimura H, et al. **Kyobu Geka** 1995 Aug;48(9):756–8 (Eng. Abstr.) **(Jpn)**

[Selective epidural nerve root block using a superfine fiberscope] Abe K, et al. **Masui** 1996 Mar;45(3):367–9 (Eng. Abstr.) **(Jpn)**

[Epidural buprenorphine does not improve diaphragmatic function after upper abdominal surgery] Fujimura N, et al. **Masui** 1996 Apr;45(4):428–32 (Eng. Abstr.) **(Jpn)**

[Postoperative management following open heart surgery by thoracic epidural anesthesia] Konishi A, et al. **Masui** 1995 Aug;44(8):1113–7 (Eng. Abstr.) **(Jpn)**

[Epidural analgesia for surgery and postoperative pain] Kosaka Y. **Masui** 1995;44 Suppl:S78–82 (28 ref.) **(Jpn)**

[Total intravenous anesthesia and postoperative continuous epidural infusion in thoracic esophageal cancer surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):661–2 **(Jpn)**

[Patient-controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):66–71 (145 ref.) **(Rus)**

[Unsatisfactory routines. Optimal treatment of postoperative pain needs cooperation and education] Lahti AM, et al. **Lakartidningen** 1996 May 15;93(20):1943–4 **(Swe)**

VETERINARY

Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. Hendrix PK, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):598–607

Comparison of intra-articular and epidural morphine for analgesia following stifle arthrotomy in dogs. Day TK, et al. **Vet Surg** 1995 Nov-Dec;24(6):522–30

PAIN RECEPTORS see **NOCICEPTORS**

PAIN RELIEF UNITS see **PAIN CLINICS**

PAIN THRESHOLD

Aging effects on the perception of noxious and non-noxious thermal stimuli applied to the face. Heft MW, et al. **Aging (Milano)** 1996 Feb;8(1):35–41

Psychological determinants of anginal pain perception during exercise testing of stable patients after recovery from acute myocardial infarction or unstable angina pectoris. Freedland KE, et al. **Am J Cardiol** 1996 Jan 1;77(1):1–4

Temporal summation during extradural anaesthesia. Curatolo M, et al. **Br J Anaesth** 1995 Nov;75(5):634–5

Impact of shock on pain reactivity: I. Whether hypo- or hyperalgesia is observed depends on how pain reactivity is tested. Illich PA, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):331–47

Impact of shock on pain reactivity: II. Evidence for enhanced pain. King TE, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):265–78

Quantitative assessment of thermal and pain sensitivity [letter] Lautenbacher S. **J Neurol Sci** 1995 Dec;134(1-2):212

Quantitative assessment of thermal and pain sensitivity reply to the letter by S. Lautenbacher (J. Neurol. Sci., 134 (1995) 211) [letter] Meh D, et al. **J Neurol Sci** 1995 Dec; 134(1-2):213–4

Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)

Modulation of pressure pain thresholds during and following isometric contraction. Kosek E, et al. **Pain** 1995 Jun; 61(3):481–6

Noxious stimuli induce an N-methyl-D-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia. Ma QP, et al. **Pain** 1995 Jun; 61(3):383–90

Mechanism of transmission and modulation of renal pain in cats; effect of nucleus raphe magnus stimulation on renal pain. Baik EJ, et al. **Yonsei Med J** 1995 Sep;36(4):348–60

[Effects of lesion or stimulation of pituitary gland and hypothalamic arcuate nucleus on pain modulation in rats] Chen QL, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):505–9 (Eng. Abstr.) **(Chi)**

[Role of locus coeruleus in analgesia caused by stimulation of supraoptic nucleus] You ZD, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):320–6 (Eng. Abstr.) **(Chi)**

[The analgesic effect of iontophoresis with magnesium sulfate] Mizutani A, et al. **Masui** 1995 Aug;44(8):1076–9 (Eng. Abstr.) **(Jpn)**

[Change in plasma morphine level and pain sensitivity in prenatally morphinized rats] Chobanov NG, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):273–5 **(Rus)**

[Study of chronobiological parameters of pain sensitivity in rats and mice] Kubynin AN, et al. **Biull Eksp Biol Med** 1995 May;119(5):537–40 **(Rus)**

[Features of hereditary sensitivity to morphine in hybrid rats F1 WAG/G-Fischer-344] Sudakov SK, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):291–3 **(Rus)**

DRUG EFFECTS

Adenosine increases the cutaneous heat pain threshold in healthy volunteers. Ekblom A, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):717–22

The effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Liu SS, et al. **Anesth Analg** 1996 Jan;82(1):98–102

Oligogenic determination of morphine analgesic magnitude: a genetic analysis of selectively bred mouse lines. Mogil JS, et al. **Behav Genet** 1995 Jul;25(4):397–406

Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Good AJ, et al. **Behav Neurosci** 1995 Aug;109(4):631–41

Surgical pain is followed not only by spinal sensitization but also by supraspinal antinociception. Wilder-Smith OH, et al. **Br J Anaesth** 1996 Jun;76(6):816–21

Effects of peripherally and centrally acting analgesics on somato-sensory evoked potentials. Moore UJ, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):111–7

Experimental pain techniques [letter] Walker JS, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):349–50

Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (CI-977) in neonatal and adult rats: comparison to kappa-opioid receptor mRNA ontogeny. McLaughlin CR, et al. **Drug Alcohol Depend** 1995 Jun; 38(3):261–9

Assessment of pain threshold and pain tolerance in women in labour and in the early post-partum period by pressure algometry. Shapira SC, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):495–9

Biphasic effects of intracerebroventricular interleukin-1 beta on mechanical nociception in the rat. Yabuuchi K, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):59–65

Intraplantar injection of nerve growth factor into the rat hind paw: local edema and effects on thermal nociceptive threshold. Amann R, et al. **Pain** 1996 Feb;64(2):323–9

Estradiol benzoate potentiates neuroactive steroids' effects on pain sensitivity. Frye CA, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):27–32

Behavioural effects of different intensities of formalin pain in rats. Aloisi AM, et al. **Physiol Behav** 1995 Sep; 58(3):603–10

[The effect of intrathecal injection of neurotensin on acupuncture analgesia in rats] Liu W, et al. **Chen Tzu Yen Chiu** 1995;20(3):13–7 (Eng. Abstr.) **(Chi)**

[Different effect of L-glutamate microinjection into medial or lateral habenular nucleu on pain threshold] Zhao H, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):292–6 (Eng. Abstr.) **(Chi)**

[Attempt at a definition of the individual anesthesia level by repetitive pain stimulation: correlation with EEG findings] Entholzner E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):155–62 (Eng. Abstr.) **(Ger)**

[Mediated participation of the opioid system in regulation of pain sensitivity by peptide fragments MP1 and MP2] Maliukova IV, et al. **Biokhimiia** 1996 Mar;61(3):440–4 (Eng. Abstr.) **(Rus)**

[A comparative analysis of the effects of the systemic and intraventricular administration of serotonin antibodies on the behavioral reactions and nociceptive sensitivity in animals] Evseev VA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):129–36 (Eng. Abstr.) **(Rus)**

[The characteristics of the effects of morphine and naloxone in rat strains differing by the excitability thresholds of their nervous systems] Shiriaeva NV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep-Oct; 45(5):976–81 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Significance of the spinal cord position in spinal cord stimulation. Holsheimer J, et al. **Acta Neurochir Suppl (Wien)** 1995;64:119–24

Facilitation of the human nociceptive reflex by stimulation of A beta-fibres in a secondary hyperalgesic area sustained by nociceptive input from the primary hyperalgesic area. Andersen OK, et al. **Acta Physiol Scand** 1995 Sep; 155(1):87–97

Sensitization of esophageal mucosa by prior acid infusion: effect of decreasing intervals between infusions. Siddiqui MA, et al. **Am J Gastroenterol** 1996 Sep;91(9):1745–8

Electrically evoked cerebral potentials during esophageal distension at perception and pain threshold. Söllenböhmer C, et al. **Am J Gastroenterol** 1996 May;91(5):970–5

Pavlovian conditional vocalizations of the rat: a model system for analyzing the fear of pain. Borszcz GS.

Behav Neurosci 1995 Aug;109(4):648–62

Tension headache [editorial; comment] Bogduk N. **Cephalalgia** 1996 Apr;16(2):77–8. Comment on: Cephalalgia 1996 Apr;16(2):97–103.

Muscular disorders in tension–type headache [see comments] Jensen R, et al. **Cephalalgia** 1996 Apr;16(2):97–103. Comment in: Cephalalgia 1996 Apr;16(2):77–8.

Perception of gastric distension. Influence of mode of distension on perception thresholds and gastric compliance. Holtmann G, et al. **Dig Dis Sci** 1995 Dec;40(12):2673–7

Possible involvement of the L–arginine–nitric oxide pathway in the modulation of stress–induced analgesia. Haulică I, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):169–73

Role of testosterone on pain threshold in rats. Pednekar JR, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):423–4

A standard test of heat–pain responses using CASE IV. Dyck PJ, et al. **J Neurol Sci** 1996 Mar;136(1–2):54–63

Response of C fibre nociceptors in the anaesthetized monkey to heat stimuli: correlation with pain threshold in humans. Tillman DB, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):767–74

Pain–related cerebral potentials in patients with frontal or parietal lobe lesions. Daum I, et al. **Neurosci Lett** 1995 Sep 8;197(2):137–40

General and segmental reduced pain thresholds in juvenile chronic arthritis. Hogeweg JA, et al. **Pain** 1995 Jul; 62(1):11–7

Mechanisms of spontaneous tension–type headaches: an analysis of tenderness, pain thresholds and EMG. Jensen R. **Pain** 1996 Feb;64(2):251–6

Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Kosek E, et al. **Pain** 1995 Dec;63(3):335–9

Increased cerebrospinal fluid Met–enkephalin immunoreactivity in patients with chronic tension–type headache. Langemark M, et al. **Pain** 1995 Oct;63(1):103–7

Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Maixner W, et al. **Pain** 1995 Dec;63(3):341–51

Cutaneous thresholds and anxiety: influence of eye orientation and lateral asymmetry. Naveteur J, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):707–16

Changes in pain threshold during the reproductive cycle of the female rat. Cruz Y, et al. **Physiol Behav** 1996 Mar; 59(3):543–7

The evolution of the painful sensitivity in acute and chronic stress. Cristea A, et al. **Rom J Physiol** 1994 Jan–Dec; 31(1–4):75–9

The reliability and validity of pain threshold measurements in osteoarthritis of the knee. Wessel J. **Scand J Rheumatol** 1995;24(4):238–42

Tonic pain evoked by pulsating heat: temporal summation mechanisms and perceptual qualities. Lautenbacher S, et al. **Somatosens Mot Res** 1995;12(1):59–70

Evaluation of pain perception after anterior capsulotomy: a case report. Talbot JD, et al. **Somatosens Mot Res** 1995; 12(2):115–26

Effects of anterolateral spinal lesions on escape responses of rats to hindpaw stimulation. Vierck CJ Jr, et al. **Somatosens Mot Res** 1995;12(2):163–74

[Incidence and regeneration time of disorders of the inferior alveolar nerve in osteosynthesis of mandibular fractures—a prospective clinical study] Schultze–Mosgau S, et al. **Fortschr Kiefer Gesichtschir** 1996;41:108–11 (Eng. Abstr.) **(Ger)**

[Assessment of experimentally–induced pain effects and their elimination by hypnosis using pupillometry studies] Grünberger J, et al. **Wien Med Wochenschr** 1995; 145(23):646–50 (Eng. Abstr.) **(Ger)**

[Structure–activity provision for pain sensitivity mechanoreceptors in tongue structures] Liubimova ZV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):357–61 **(Rus)**

RADIATION EFFECTS

Exposure to oscillating magnetic fields influences sensitivity to electrical stimuli. I. Experiments on pigeons. Del Seppia C, et al. **Bioelectromagnetics** 1995;16(5):290–4

Exposure to oscillating magnetic fields influences sensitivity to electrical stimuli. II. Experiments on humans. Papi F, et al. **Bioelectromagnetics** 1995;16(5):295–300

Cranial irradiation with Gaalas laser leads to naloxone reversible analgesia in rats. Wedlock PM, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):727–31

PAINT

Control of paint overspray in autobody repair shops. Heitbrink WA, et al. **Am Ind Hyg Assoc J** 1995 Oct; 56(10):1023–32

Neurobehavioral test performance among apprentice painters: baseline data. Bolle L, et al. **Am J Ind Med** 1996 May;29(5):539–46

Decreases in postural change in finger blood flow in ceramic painters chronically exposed to low level lead. Ishida M, et al. **Am J Ind Med** 1996 May;29(5):547–53

Intervention research in construction: a hypothetical case study of painters. Wolford R. **Am J Ind Med** 1996 Apr; 29(4):431–4

Bactericidal activity of copper and noncopper paints [see comments] Cooney TE. **Infect Control Hosp Epidemiol** 1995 Aug;16(8):444–50. Comment in: Infect Control Hosp Epidemiol 1995 Aug;16(8):442–3.

Environmental interventions to control nosocomial infections [editorial; comment] Rutala WA, et al. **Infect Control Hosp Epidemiol** 1995 Aug;16(8):442–3. Comment on: Infect Control Hosp Epidemiol 1995 Aug;16(8):444–50.

Feasibility study of respiratory questionnaire and peak flow recordings in autobody shop workers exposed to isocyanate–containing spray paint: observations and limitations. Cullen MR, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):197–204

ADVERSE EFFECTS

Migration of some toxic metals from crayons and water colors. Rastogi SC, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):527–33

Paint as another possible source of lead exposure in Saudi Arabia. al–Saleh I, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):347–50

Lead risk during pregnancy. **Can Fam Physician** 1996 Mar; 42:414–6

An unusual case of sensitization to methylchloro– and methyl–isothiazolinone (MCI/MI). Fernández de Corrès L, et al. **Contact Dermatitis** 1995 Sep;33(3):215–6

Paint dermatitis: the role of "routine" patch test series in detecting contact allergens in paint [news] Fisher AA. **Cutis** 1995 Jul;56(1):16

Abdominal pain and vomiting in a paint stripper. Hart SP, et al. **Postgrad Med J** 1996 Apr;72(846):253–5

[Skin disorders of students engaged part–time in painting] Nishitani N, et al. **Sangyo Eiseigaku Zasshi** 1996 May; 38(3):142–3 **(Jpn)**

[Ardystil syndrome (editorial)] Solé A, et al. **Med Clin (Barc)** 1995 Sep 16;105(8):295–7 **(Spa)**

[Adverse effects on the respiratory system in textile printing sprayers] Solé Jover A, et al. **Rev Clin Esp** 1996 Mar; 196(3):157–61 (Eng. Abstr.) **(Spa)**

ANALYSIS

ELPAT program report: background and current status (July 1995). Environmental Lead Proficiency Analytical Testing. Schlecht PC, et al. **Am Ind Hyg Assoc J** 1995 Oct; 56(10):1034–40

TOXICITY

Chromosomal aberrations in lymphocytes from car painters. Silva JM, et al. **Mutat Res** 1996 May;368(1):21–5

PAINTINGS

The Floating Hospital of St. John's Guild. Schatzki SC. **AJR Am J Roentgenol** 1996 Aug;167(2):380

Identification of bacteria in a biodegraded wall painting by denaturing gradient gel electrophoresis of PCR–amplified gene fragments coding for 16S rRNA. Rölleke S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2059–65

Gone to the devil: the murals of Ile Royale hospital. Davidson AJ. **BMJ** 1995 Dec 23–30;311(7021):1713–4

A painting that changed by my life [letter] Ward SJ. **Br J Hosp Med** 1995 Oct 4–17;54(7):354

Artwork. Capturing healers on canvas. Montague J. **Hosp Health Netw** 1995 Nov 20;69(22):48

Painting anatomy on anatomy. Cody J. **J Biocommun** 1995; 22(2):14–7

Facing death. Newsom B. **J S C Med Assoc** 1996 Feb;92(2):88

Incidence of the half–left profile pose in single–subject portraits. Conesa J, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):920–2

In the shadow of death. Meissner WW. **Psychoanal Rev** 1995 Aug;82(4):535–57

The tragic actor: forms and transformations of narcissism in the life and work of Edouard Manet (1832–1883). Zerbe KJ. **Psychoanal Rev** 1995 Aug;82(4):599–620

[2 new paintings for the Nederlands Tijdschrift voor Geneeskunde] Lockefeer JH. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2751–2 **(Dut)**

[Is beauty a measurable concept in medicine? (editorial)] Honigmann K. **Schweiz Rundsch Med Prax** 1995 Nov 14; 84(46):1333–4 **(Ger)**

[Confounding of occupational cancer risk in epidemiological studies due to ignorance of smoking data as exemplified by bladder and lung cancer in painters] Scherg H. **Soz Praventivmed** 1995;40(5):302–8 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

The descriptive assessment for psychiatric art. A new way of quantifying paintings by psychiatric patients. Hacking S, et al. **J Nerv Ment Dis** 1996 Jul;184(7):425–30

HISTORY

Physician and nurse: cure and care. Caelleigh AS. **Acad Med** 1996 Mar;71(3):298

Re: The Babcock Surgical Clinic [letter; comment] Pollack HM. **AJR Am J Roentgenol** 1996 Apr;166(4):990–1; discussion 992. Comment on: AJR Am J Roentgenol 1995 Aug;165(2):322.

RE: The Babcock Surgical Clinic [letter; comment] Pollack HM, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):991–2 . Comment on: AJR Am J Roentgenol 1995 Aug;165(2):322.

Medicine in American art. Family doctor. Schatzki SC. **AJR Am J Roentgenol** 1996 Sep;167(3):580

Dr. Charles Richard Drew. Schatzki SC. **AJR Am J Roentgenol** 1995 Dec;165(6):1372

Early evidence of scleroderma. Dequeker J, et al. **BMJ** 1995 Dec 23–30;311(7021):1714–5

Was Van Gogh seeing more than stars? [letter] MacCormick R. **Can Med Assoc J** 1996 Sep 1;155(5):514; discussion 514–5

One of Goya's greatest scenes [letter] Meakins JL. **Can Med Assoc J** 1996 Aug 15;155(4):370

Goya's gratitude. Seufert WD. **Can Med Assoc J** 1996 Mar 15;154(6):851 **(Eng, Fre)**

Dr. Gachet. Seufert WD. **Can Med Assoc J** 1996 May 15; 154(10):1523 **(Eng, Fre)**

The black hole in Charley Toorop's "The three generations": a neuro–iconographic analysis and reconstruction. Lakke JP. **Clin Neurol Neurosurg** 1995 Aug;97(3):269–76

The black paintings and the Vogt–Koyanagi–Harada syndrome. Vargas LM. **J Fla Med Assoc** 1995 Aug; 82(8):533–4

Art and commitment. String ST. **J Vasc Surg** 1996 Sep; 24(3):319–27

de Kooning's late colours and forms: dementia, creativity, and the healing power of art. Espinel CH. **Lancet** 1996 Apr 20;347(9008):1096–8

Masaccio's cripple: a neurological syndrome. Its art, medicine, and values [see comments] Espinel CH. **Lancet** 1995 Dec 23–30;346(8991–8992):1684–6. Comment in: Lancet 1996 Mar 2;347(9001):628.

de Kooning's dementia [letter]. Gibson PH. **Lancet** 1996 Jun 29;347(9018):1838

de Kooning's dementia [letter]. Meulenberg F. **Lancet** 1996 Jun 29;347(9018):1838

Epilepsy and art. Schachter SC. **Med J Aust** 1996 Feb 19; 164(4):245–8

Toulouse–Lautrec's diagnosis [letter] Maroteaux P. **Nat Genet** 1995 Dec;11(4):362–3

The lunatic and his seizure. deToledo J, et al. **Neurology** 1996 Jul;47(1):292–3

Ernst von Bergmann performs a brain operation by Franz Skarbina. Salcman M. **Neurosurgery** 1996 Jun;38(6):1254–5

The influence of eye disorders on the artist. Lettsomian lecture Monday, 14th March 1994. Trevor–Roper P. **Trans Med Soc Lond** 1993–94;110:63–81

[Representations of dwarfism in historical art: knowledge and humanism] Giampalmo A. **Minerva Pediatr** 1996 Apr; 48(4):165–77 (Eng. Abstr.) **(Ita)**

[Physician's role in Norwegian art of painting] Larsen IF. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3790–3 (Eng. Abstr.) **(Nor)**

[Suicidal process and suicidal motives. Suicide illustrated by the art, life and illness of Vincent van Gogh] Mehlum L. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1095–1101 (Eng. Abstr.) **(Nor)**

[Epilepsy from a metaphysical perspective: an interpretation of the biblical story of the epileptic boy and Raphael's Transfiguration] Janz D. **Gac Med Mex** 1994 Jan–Feb; 130(1):44–9 (Eng. Abstr.) **(Spa)**

[Surgical treatment of madness] Rabell J, et al. **Gac Med Mex** 1995 May–Jun;131(3):335–41 (Eng. Abstr.) **(Spa)**

[Does Piero Di Cosimo's painting "The death of Procris" represent a tracheotomy? (letter)] Araya L. **Rev Med Chil** 1995 May;123(5):646–8 **(Spa)**

PAIR BOND

Oxytocin and the molecular basis of monogamy. Insel TR, et al. **Adv Exp Med Biol** 1995;395:227–34

Guinea pigs (Cavia apera f. porcellus): do they show pair–bonding behavior in relationship to oxytocin? Wallner B, et al. **Adv Exp Med Biol** 1995;395:255–6

A gender–specific mechanism for pair bonding: oxytocin and partner preference formation in monogamous voles. Insel TR, et al. **Behav Neurosci** 1995 Aug;109(4):782–9

Spontaneous behavior and body temperature in male Central American Agoutis (Dasyprocta punctata) under different social conditions. Korz V, et al. **Physiol Behav** 1995 Oct; 58(4):761–8

Monogamy without biparental care in a dwarf antelope. Brotherton PN, et al. **Proc R Soc Lond B Biol Sci** 1996 Jan 22;263(1366):23–9

PAIRED-ASSOCIATE LEARNING

Do semantic priming effects correlate with sensory gating in schizophrenia? Vinogradov S, et al. **Biol Psychiatry** 1996 May 1;39(9):821–4

The effect of imagery on explicit and implicit tests of memory in young and old people: a double dissociation. McCauley ME, et al. **Can J Exp Psychol** 1996 Mar;50(1):34–41

Exact and conceptual repetition dissociate conceptual memory tests: problems for transfer appropriate processing theory. McDermott KB, et al. **Can J Exp Psychol** 1996 Mar;50(1):57–71

Aging and encoding in memory: false alarms and decision criteria in a word–pair recognition task. Isingrini M, et al. **Int J Aging Hum Dev** 1995;41(1):79–88

Induction of a memory retrieval strategy by young children. Ackerman BP. **J Exp Child Psychol** 1996 Jul;62(2):243–71

Morphological and orthographic similarity in visual word recognition. Drews E, et al.

J Exp Psychol Hum Percept Perform 1995 Oct; 21(5):1098–116

Summation of activation: evidence from multiple primes that converge and diverge within semantic memory. Balota DA, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):827–45

"Remembering" words not presented in lists: relevance to the current recovered/false memory controversy. Freyd JJ, et al. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):811–3; discussion 814–6

Repetition priming for newly formed and preexisting associations: perceptual and conceptual influences. Goshen-Gottstein Y, et al.
J Exp Psychol Learn Mem Cogn 1995 Sep;21(5):1229–48

Repetition priming effects for newly formed associations are perceptually based: evidence from shallow encoding and format specificity. Goshen-Gottstein Y, et al.
J Exp Psychol Learn Mem Cogn 1995 Sep;21(5):1249–62

Level-of-processing effects in word-completion priming: a neuropsychological study. Hamann SB, et al.
J Exp Psychol Learn Mem Cogn 1996 Jul;22(4):933–47

Sequential effects in lexical decision: tests of compound-cue retrieval theory. Ratcliff R, et al.
J Exp Psychol Learn Mem Cogn 1995 Sep;21(5):1380–8

Assessment of long-term verbal memory in children. Beardsworth E, et al. **Memory** 1994 Jun;2(2):129–48

Recognition failure of categorised words: further evidence of exceptions. Gardiner JM, et al. **Memory** 1995 Mar; 3(1):57–66

Norms of paired-associate recall during multitrial learning of Swahili-English translation equivalents. Nelson TO, et al. **Memory** 1994 Sep;2(3):325–35

Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test. Ragland JD, et al. **Psychiatry Res** 1996 Mar 29;60(2–3):135–45

Investigating thought disorder in schizophrenia with the lexical decision task. Blum NA, et al. **Schizophr Res** 1995 Aug 15;16(3):217–24

[Integration of prior knowledge in speech comprehension in relation to age] Beyer R, et al.
Z Psychol Z Angew Psychol 1995;203(4):361–78 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Personal name recognition and associative priming in patients with unilateral brain damage. Schweinberger SR.
Brain Cogn 1995 Oct;29(1):23–35

Functional mapping of human memory using PET: comparisons of conceptual and perceptual tasks. Blaxton TA, et al. **Can J Exp Psychol** 1996 Mar;50(1):42–56

Event-related potentials during delayed recognition of Wechsler Memory Scale-R paired associate learning. Holamon B, et al. **J Clin Psychol** 1995 May;51(3):391–5

Naming without knowing and appearance without associations: evidence for constructive processes in semantic memory? Laws KR, et al. **Memory** 1995 Sep–Dec; 3(3–4):409–33

Formation of mnemonic neuronal responses to visual paired associates in inferotemporal cortex is impaired by perirhinal and entorhinal lesions. Higuchi S, et al.
Proc Natl Acad Sci U S A 1996 Jan 23;93(2):739–43

PALATAL EXPANSION TECHNIQUE

Clinical results of the maxillary protraction in Korean children. Baik HS. **Am J Orthod Dentofacial Orthop** 1995 Dec;108(6):583–92

Long-term stability of rapid palatal expander treatment and edgewise mechanotherapy. Moussa R, et al.
Am J Orthod Dentofacial Orthop 1995 Nov;108(5):478–88

Soft tissue and dentoskeletal profile changes associated with maxillary expansion and protraction headgear treatment. Ngan P, et al. **Am J Orthod Dentofacial Orthop** 1996 Jan; 109(1):38–49

Rapid maxillary expansion. A study of the long-term effects. Velázquez P, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):361–7

The validity of maxillary expansion indices [see comments] Nimkarn Y, et al. **Angle Orthod** 1995;65(5):321–6. Comment in: Angle Orthod 1995;65(5):303.

Treatment response to maxillary expansion and protraction. Ngan P, et al. **Eur J Orthod** 1996 Apr;18(2):151–68

Stimulation of bone formation in the expanding mid-palatal suture by transforming growth factor-beta 1 in the rat. Sawada M, et al. **Eur J Orthod** 1996 Apr;18(2):169–79

Surgically assisted, rapid maxillary expansion in adults. A retrospective long-term follow-up study. Strömberg C, et al. **J Craniomaxillofac Surg** 1995 Aug;23(4):222–7

Maxillary orthopedics in the presurgical management of infants with cleft lip and palate. Sierra FJ, et al.
Pediatr Dent 1995 Nov–Dec;17(7):419–23 (24 ref.)

[Primary headache and orthognathorhinodontia in childhood] Gianni E, et al. **Ital J Neurol Sci** 1995 Nov; 16(8 Suppl):57–68 (Eng. Abstr.) **(Ita)**

[Treatment of lateral cross-bite with active plates in conditions of raised dental occlusion and by the quad-helix method] Wędrychowska-Szulc B. **Ann Acad Med Stetin** 1995;41:233–43 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Spatial and temporal repair patterns of orthodontically induced surface resorption patches. Sismanidou C, et al.
Eur J Oral Sci 1995 Oct;103(5):292–8

Nasopalatine canal cyst: a rare sequelae of surgical rapid palatal expansion [letter] Mermer RW, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):620

INSTRUMENTATION

Effects of buccal shields on the maxillary dentoalveolar structures and the midpalatal suture—histologic and biometric studies in rabbits. Kalogirou K, et al.
Am J Orthod Dentofacial Orthop 1996 May;109(5):521–30

Distal movement of buccal segments with the "en masse" removable appliance—its value in treating patients with mild Class II, Division 1 malocclusions: Part I, clinical techniques (how to do it). Orton HS, et al.
Am J Orthod Dentofacial Orthop 1996 Mar;109(3):234–43

A combined obturator and expansion appliance for use in patients with patent oral-nasal fistula. Hobson RS, et al.
Br J Orthod 1995 Nov;22(4):357–9

Palatal surgical splint for transverse stability of Le Fort I osteotomies: a technical note. Reinkingh MR, et al.
Int J Oral Maxillofac Surg 1996 Apr;25(2):105–6

PALATAL MUSCLES

Palatal palsy in enteric fever [letter] Ghosh JB, et al.
Indian Pediatr 1995 Jan;32(1):106–7

Palatal myoclonus affected by neck posture [letter] Saeed SR, et al. **J Laryngol Otol** 1996 Feb;110(2):207

Hereditary adult-onset Alexander's disease with palatal myoclonus, spastic paraparesis, and cerebellar ataxia. Schwankhaus JD, et al. **Neurology** 1995 Dec; 45(12):2266–71

EMBRYOLOGY

Histomorphologic analysis of the soft palate musculature in prenatal cleft and noncleft A/Jax mice. Trotman CA, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):455–62

INNERVATION

Proprioceptive representation of the levator veli palatini muscle in the solitary nucleus of the rat. Furusawa K, et al. **Cleft Palate Craniofac J** 1996 May;33(3):213–8

PATHOLOGY

Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Varney SM, et al.
Otolaryngol Head Neck Surg 1996 Feb;114(2):317–20

PHYSIOLOGY

Effects of gravity on velopharyngeal muscle activity during speech. Moon JB, et al. **Cleft Palate Craniofac J** 1995 Sep; 32(5):371–5

Effect of breathing, pressure and posture on palatoglossal and genioglossal tone. Mathur R, et al. **Clin Sci (Colch)** 1995 Oct;89(4):441–5

Upper airway collapsibility, and contractile and metabolic characteristics of musculus uvulae. Sériès F, et al.
FASEB J 1996 Jun;10(8):897–904

Effect of posture, route of respiration, and negative pressure on palatal muscle activity in humans. Mortimore IL, et al. **J Appl Physiol** 1995 Aug;79(2):448–54

PHYSIOPATHOLOGY

Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls. Mezzanotte WS, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1880–7

Levator veli palatini muscle activity in relation to intraoral air pressure variation in cleft palate subjects. Kuehn DP, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):376–81

Oral air pressure and nasal air flow rate on levator veli palatini muscle activity in patients wearing a speech appliance. Tachimura T, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):382–9

SURGERY

The functional palatorrhaphy in the treatment of obstructive sleep apnoea. Wiltfang J, et al.
Br J Oral Maxillofac Surg 1996 Feb;34(1):82–6

PALATAL NEOPLASMS

[Metastasizing pleomorphic adenomas. Clinical and cytometric analysis] Junquera Gutiérrez LM, et al.
Rev Stomatol Chir Maxillofac 1996;97(1):26–31 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53–5 (21 ref.)

DIAGNOSIS

[Bucco-sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Report of 3 cases of adenoid cystic carcinoma of the palate. Clinical, histological and therapeutical considerations] Caubet Biayna J, et al. **An Otorrinolaringol Ibero Am** 1996; 23(2):131–45 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Use of photodynamic therapy for the treatment of squamous cell carcinoma of the soft palate. Poate TW, et al.
Br J Oral Maxillofac Surg 1996 Feb;34(1):66–8

HISTORY

President Cleveland's secret operation: the effect of the office upon the care of the president. Deppisch LM. **Pharos** 1995 Summer;58(3):11–6

METABOLISM

In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model. Witjes MJ, et al. **Br J Cancer** 1996 Mar;73(5):573–80

PATHOLOGY

Canalicular adenoma of the palatal mucosa. Parvizi F, et al.
Br Dent J 1996 Jul 6;181(1):27–8

Epignathus: a case report with review of literature. Gera N, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S50–1

Nerve-sheath myxoma (neurothekeoma) of the oral cavity: a case report and review of the literature. Katsourakis M, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):904–6 (17 ref.)

Malignant melanoma metastatic to the tonsil. Aydogan LB, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):313–6

Minor salivary gland tumors of the palate: clinical and pathologic correlates of outcome. Beckhardt RN, et al.
Laryngoscope 1995 Nov;105(11):1155–60

RADIOGRAPHY

Osteosarcoma of the hard palate. Eustace S, et al.
Skeletal Radiol 1995 Jul;24(5):392–4

RADIOTHERAPY

[Place of iridium 192 implantation in irradiation of T1-T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo-tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40–6 (32 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Soft palate metastasis from a small cell carcinoma of the lung. Piattelli A, et al. **Acta Stomatol Belg** 1995 Mar;92(1):31–3

SURGERY

Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

[A case of palatal polymorphous low grade adenocarcinoma] Ishimoto S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1092–6 (Eng. Abstr.) **(Jpn)**

PALATAL OBTURATORS

A combined obturator and expansion appliance for use in patients with patent oral-nasal fistula. Hobson RS, et al.
Br J Orthod 1995 Nov;22(4):357–9

Use of a modified twin block appliance following partial maxillectomy: case report. Moseley HC, et al.
Br J Orthod 1996 May;23(2):103–8

Three-dimensional comparison between the palatal forms in infants with complete unilateral cleft lip, alveolus, and palate (UCLP) with and without Hotz's plate. Mishima K, et al. **Cleft Palate Craniofac J** 1996 May;33(3):245–51

Cleft lip and palate reconstruction [letter; comment] Siatkowski RE. **Cleft Palate Craniofac J** 1995 Jul; 32(4):353–5. Comment on: Cleft Palate Craniofac J 1994 Nov;31(6):494–7; discussion 497–8.

Do palatal lift prostheses stimulate velopharyngeal neuromuscular activity? Witt PD, et al.
Cleft Palate Craniofac J 1995 Nov;32(6):469–75

Complete dentures for the obturator patient. King GE, et al. **Dent Clin North Am** 1996 Jan;40(1):217–37 (26 ref.)

PALATE

Effect of treatment of palatal inflammatory papillary hyperplasia with local and systemic antifungal agents accompanied by renewal of complete dentures. Salonen MA, et al. **Acta Odontol Scand** 1996 Apr;54(2):87–91

Foreign body lodged in the palate [letter] Farid A, et al.
Am Fam Physician 1996 Sep 1;54(3):874, 878

Respiratory and laryngeal function associated with experimental coupling of the oral and nasal cavities. Sapienza CM, et al. **Cleft Palate Craniofac J** 1996 Mar; 33(2):118–26

The Orthosystem--a new implant system for orthodontic

anchorage in the palate. Wehrbein H, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):142–53 **(Eng, Ger)**

A case of symptomatic palatal myoclonus. Jha SK, et al. **J Assoc Physicians India** 1995 Apr;43(4):301–2

Brown tumor of the hard palate in secondary hyperparathyroidism. Shah BV, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):37–9

Using regions and indices in EPG data reduction. Byrd D, et al. **J Speech Hear Res** 1995 Aug;38(4):821–7

ABNORMALITIES

Malformations of the heart, kidney, palate, and skeleton in alpha–MHC–Hoxb–7 transgenic mice. Argao EA, et al. **Mech Dev** 1995 Aug;52(2–3):291–303

[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Effects of buccal shields on the maxillary dentoalveolar structures and the midpalatal suture—histologic and biometric studies in rabbits. Kalogirou K, et al. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):521–30

Stability of the palatal rugae as landmarks for analysis of dental casts in extraction and nonextraction cases. Bailey LT, et al. **Angle Orthod** 1996;66(1):73–8

BLOOD SUPPLY

Endoscopic ligation of the sphenopalatine artery (ELSA): a preliminary description. White PS. **J Laryngol Otol** 1996 Jan;110(1):27–30

Wound healing after multisegmental Le Fort I osteotomy and transection of the descending palatine vessels. Bell WH, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1425–33; discussion 1433–4

Location of the descending palatine artery in relation to the Le Fort I osteotomy. Li KK, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):822–5; discussion 826–7

Sphenopalatine artery ligation: an alternative to internal maxillary artery ligation for intractable posterior epistaxis. Winstead W. **Laryngoscope** 1996 May;106(5 Pt 1):667–9

CHEMISTRY

Distribution of basement membrane components in the mouse primary palate. Iamaroon A, et al. **J Craniofac Genet Dev Biol** 1996 Jan–Mar;16(1):48–51

CYTOLOGY

Apoptosis and heterophagy of medial edge epithelial cells of the secondary palatine shelves during fusion. Taniguchi K, et al. **Arch Histol Cytol** 1995 Jun;58(2):191–203

Effects of expansive force on the differentiation of midpalatal suture cartilage in rats. Takahashi I, et al. **Bone** 1996 Apr;18(4):341–8

Analysis of cell proliferation kinetics during the secondary palate development in quail. Hehn BM, et al. **Histol Histopathol** 1995 Jul;10(3):697–702

DRUG EFFECTS

The effects of the organophosphorous insecticides Dursban and Lorsban on the ciliated epithelium of the frog palate in vitro. Swann JM, et al. **Arch Environ Contam Toxicol** 1996 Feb;30(2):188–94

Stimulation of bone formation in the expanding mid–palatal suture by transforming growth factor–beta 1 in the rat. Sawada M, et al. **Eur J Orthod** 1996 Apr;18(2):169–79

[Changes in the thermoresistance of the isolated ciliated epithelium of the frog palate under the influence of heavy metals] Mironov AP. **Tsitologiia** 1996;38(3):363–9 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Development of a suspension organ culture of the fetal rat palate. al–Obaidi N, et al. **Arch Toxicol** 1995;69(7):472–9

Analysis of cell proliferation kinetics during the secondary palate development in quail. Hehn BM, et al. **Histol Histopathol** 1995 Jul;10(3):697–702

Antisense oligonucleotides to CRABP I and II alter the expression of TGF–beta 3, RAR–beta, and tenascin in primary cultures of embryonic palate cells. Nugent P, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul–Aug;31(7):553–8

Effects of dexamethasone on the expression of transforming growth factor–beta in mouse embryonic palatal mesenchymal cells. Potchinsky M, et al. **J Cell Physiol** 1996 Feb;166(2):380–6

Developmental regulation of various annexins in the embryonic palate of the mouse: dexamethasone affects expression of annexin–1. Chepenik KP, et al. **J Craniofac Genet Dev Biol** 1995 Oct–Dec;15(4):171–81

Distribution of basement membrane components in the mouse primary palate. Iamaroon A, et al. **J Craniofac Genet Dev Biol** 1996 Jan–Mar;16(1):48–51

Deficient and delayed primary palatal fusion and mesenchymal bridge formation in cleft lip–liable strains of mice. Wang KY, et al. **J Craniofac Genet Dev Biol** 1995 Jul–Sep;15(3):99–116

Abnormal lung development and cleft palate in mice lacking TGF–beta 3 indicates defects of epithelial–mesenchymal interaction. Kaartinen V, et al. **Nat Genet** 1995 Dec; 11(4):415–21

Transforming growth factor–beta 3 is required for secondary palate fusion. Proetzel G, et al. **Nat Genet** 1995 Dec; 11(4):409–14

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2–3):365–73 (86 ref.)

GROWTH & DEVELOPMENT

Human palatal growth evaluated on medieval crania using nerve canal openings as references. Sejrsen B, et al. **Am J Phys Anthropol** 1996 Apr;99(4):603–11

Early palatal changes after initial palatal surgery in children with cleft lip and palate. Kramer GJ, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):104–11

Prediction of early palatal growth and development in children with cleft lip and palate. Kramer GJ, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):112–7

Significance of programmed cell death (apoptosis) in mammalian limb and palate development. Mori C. **Kaibogaku Zasshi** 1995 Dec;70(6):503–8 (12 ref.)

The relationship between the palatal form and the maxillary sinus in orang–utan. Koppe T, et al. **Okajimas Folia Anat Jpn** 1996 Mar;72(6):297–306

INNERVATION

Biosynthetic processing of preprovasoactive intestinal polypeptide in parasympathetic neurons of the sphenopalatine ganglion. Nilsson C, et al. **J Neurochem** 1995 Dec;65(6):2663–70

METABOLISM

TGF–beta modulates the expression of retinoic acid–induced RAR–beta in primary cultures of embryonic palate cells. Nugent P, et al. **Exp Cell Res** 1995 Oct;220(2):495–500

Effects of dexamethasone on the expression of transforming growth factor–beta in mouse embryonic palatal mesenchymal cells. Potchinsky M, et al. **J Cell Physiol** 1996 Feb;166(2):380–6

MICROBIOLOGY

Probable BCG osteomyelitis of the hard palate: a case report. Fujimoto T, et al. **Int J Oral Maxillofac Surg** 1996 Apr; 25(2):145–6

PATHOLOGY

Torus palatinus and torus mandibularis: a review of the literature. Seah YH. **Aust Dent J** 1995 Oct;40(5):318–21 (31 ref.)

An unusual sequela to an inferior dental block injection [see comments] Heasman PA, et al. **Br Dent J** 1995 Aug 5; 179(3):97–8. Comment in: Br Dent J 1995 Oct 21;179(8 Spec No):283.

Three–dimensional comparison between the palatal forms in infants with complete unilateral cleft lip, alveolus, and palate (UCLP) with and without Hotz's plate. Mishima K, et al. **Cleft Palate Craniofac J** 1996 May;33(3):245–51

Adenomatoid hyperplasia of the palate in an Asian child. Nozaki S, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):627–8

Preliminary assessment of the epithelial nuclear–cytoplasmic ratio and nuclear volume density in human palatal lesions. Jin Y, et al. **J Oral Pathol Med** 1995 Jul;24(6):261–5

Oculopalatal myoclonus after the one–and–a–half syndrome with facial nerve palsy. Wolin MJ, et al. **Ophthalmology** 1996 Jan;103(1):177–80

Osteosarcoma of the hard palate. Eustace S, et al. **Skeletal Radiol** 1995 Jul;24(5):392–4

[Primary headache and orthognathorhinodontia in childhood] Gianni E, et al. **Ital J Neurol Sci** 1995 Nov; 16(8 Suppl):57–68 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Papers from the European Seminar on ELG and EPG, Edinburgh, July 1994. **Eur J Disord Commun** 1995; 30(2):101–277

Quantitative measures of the palate using enhanced electropalatography. Chiu WS, et al. **Eur J Disord Commun** 1995;30(2):149–60

Categorising [s], [integral of] and intermediate electropalatographic patterns: neural networks and other approaches. Holst T, et al. **Eur J Disord Commun** 1995; 30(2):161–74

New developments in EPG3 software. Jones W, et al. **Eur J Disord Commun** 1995;30(2):183–92 (22 ref.)

EPG bidimensional data reduction. Nguyen N. **Eur J Disord Commun** 1995;30(2):175–82

Co–articulatory variability and articulatory–acoustic correlations for consonants. Recasens D, et al. **Eur J Disord Commun** 1995;30(2):203–12

Electropalatography in the treatment of articulation/phonological disorders. Dagenais PA. **J Commun Disord** 1995 Dec;28(4):303–29

PHYSIOPATHOLOGY

A study of obstruent sounds in school–age children with speech disorders using electropalatography. Gibbon F, et al. **Eur J Disord Commun** 1995;30(2):213–25

Using electropalatography to treat severe acquired apraxia of speech. Howard S, et al. **Eur J Disord Commun** 1995; 30(2):246–55

Cross–linguistic study of lateral misarticulation using electropalatography. Suzuki N, et al. **Eur J Disord Commun** 1995;30(2):237–45

Electropalatographic and perceptual analysis of the speech of Cantonese children with cleft palate. Whitehill T, et al. **Eur J Disord Commun** 1995;30(2):193–202

An electropalatographic analysis of stutterers' speech. Wood SE. **Eur J Disord Commun** 1995;30(2):226–36

SURGERY

Bilateral maxillectomy and midfacial reconstruction. Panje WR, et al. **Ann Otol Rhinol Laryngol** 1995 Nov; 104(11):845–9 (12 ref.)

Patient selection for uvulopalatopharyngoplasty [letter] Carney AS, et al. **Chest** 1996 Sep;110(3):864

Poly–(L–lactic) acid membranes in palatal surgery in beagle dogs: clinical and histologic evaluation. In de Braekt MM, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):290–8

Acute obstructive sleep apnea as a complication of sphincter pharyngoplasty. Witt PD, et al. **Cleft Palate Craniofac J** 1996 May;33(3):183–9

Palatal surgery without denudation of bone favours dentoalveolar development in dogs. Leenstra TS, et al. **Int J Oral Maxillofac Surg** 1995 Dec;24(6):440–4

Surgically assisted, rapid maxillary expansion in adults. A retrospective long–term follow–up study. Strömberg C, et al. **J Craniomaxillofac Surg** 1995 Aug;23(4):222–7

Intraoperative fabrication of postsurgical palatal stents. Russell DH, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):369–70

Previous tonsillectomy as prognostic indicator for success of uvulopalatopharyngoplasty. McGuirt WF Jr, et al. **Laryngoscope** 1995 Nov;105(11):1253–5

Characterization of postoperative edema following laser–assisted uvulopalatoplasty using MRI and polysomnography: implications for the outpatient treatment of obstructive sleep apnea syndrome. Terris DJ, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):124–8

Identifying obstructive sleep apnea in patients presenting for laser–assisted uvulopalatoplasty. Vaidya AM, et al. **Laryngoscope** 1996 Apr;106(4):431–7

Outpatient cautery–assisted uvulopalatoplasty. Zinder DJ, et al. **Laryngoscope** 1995 Nov;105(11):1256–7

Upper airway resistance syndrome after uvulopalatopharyngoplasty for obstructive sleep apnea syndrome. Woodson BT. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):457–61

Surgical correction of submucous cleft palate with Furlow palatoplasty. Chen PK, et al. **Plast Reconstr Surg** 1996 May; 97(6):1136–46; discussion 1147–9

Speech characteristics associated with the Furlow palatoplasty as compared with other surgical techniques. McWilliams BJ, et al. **Plast Reconstr Surg** 1996 Sep; 98(4):610–9; discussion 620–1

ULTRASTRUCTURE

Structure of hamster palatal gingiva and intermolar mucosa after intraperitoneal dosing with N–methyl–N–nitrosourea: a scanning electron microscope study. Symes GC, et al. **J Comp Pathol** 1995 May;112(4):403–15

PALATE, SOFT

Soft palate metastasis from a small cell carcinoma of the lung. Piattelli A, et al. **Acta Stomatol Belg** 1995 Mar;92(1):31–3

Use of photodynamic therapy for the treatment of squamous cell carcinoma of the soft palate. Poate TW, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):66–8

Task dynamic and articulatory recovery of lip and velar approximations under model mismatch conditions. McGowan RS, et al. **J Acoust Soc Am** 1996 Jan; 99(1):595–608

ABNORMALITIES

Craniosynostosis with joint contractures, ear deformity, cleft palate, scoliosis, and other features. Iida A, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):489–93

ANATOMY & HISTOLOGY

Axial configuration of the velopharyngeal valve and its valving mechanism. Finkelstein Y, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):299–305

BLOOD SUPPLY

The arterial supply of the palate: implications for closure of cleft palates. Mercer NS, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1038–44

CYTOLOGY

[The histogenetic characteristics of the epithelial tissues of the mucosa of the pharyngeal and oral surfaces of the soft palate in ontogeny and under experimental conditions] Semchenko IuP, et al. **Morfologiia** 1995;108(2):54–6 (Eng. Abstr.) **(Rus)**

PALATE, SOFT

EMBRYOLOGY

Histomorphologic analysis of the soft palate musculature in prenatal cleft and noncleft A/Jax mice. Trotman CA, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):455–62

INJURIES

Soft palate perforation: a complication posterior nasal packing. Streitmann MJ, et al.
Otolaryngol Head Neck Surg 1996 Jun;114(6):806–7

INNERVATION

The innervation of taste buds in the soft palate of the rat as revealed by methylene blue staining. Müller T.
Arch Histol Cytol 1996 Mar;59(1):47–54

PATHOLOGY

Angina bullosa hemorrhagica. de las Heras ME, et al.
J Dermatol 1996 Jul;23(7):507–9

[Report of 3 cases of adenoid cystic carcinoma of the palate. Clinical, histological and therapeutical considerations] Caubet Biayna J, et al. **An Otorrinolaringol Ibero Am** 1996; 23(2):131–45 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Midsagittal velar kinematics during production of VCV sequences. Engelke W, et al. **Cleft Palate Craniofac J** 1996 May;33(3):236–44

Axial configuration of the velopharyngeal valve and its valving mechanism. Finkelstein Y, et al.
Cleft Palate Craniofac J 1995 Jul;32(4):299–305

Relationships between integrated oral–nasal differential pressure and velopharyngeal closure. Hinton VA, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):306–10

The functional role of the adenoids in speech. Finkelstein Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1–2):61–74 (73 ref.)

Articulatory organization of mandibular, labial, and velar movements during speech. Kollia HB, et al.
J Acoust Soc Am 1995 Sep;98(3):1313–24

Palatal and pharyngeal reflexes in health and in motor neuron disease. Hughes TA, et al.
J Neurol Neurosurg Psychiatry 1996 Jul;61(1):96–8

[Upper airways and sleep apnea syndrome] Pépin JL, et al. **Rev Mal Respir** 1995;12(5):441–51 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Predominance and improvement of velopharyngeal function in patients without complete closure in blowing [letter; comment] Yamaoka M, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):353. Comment on: Cleft Palate Craniofac J 1994 Jul;31(4):271–9.

Observation of the mechanism of snoring using sleep nasendoscopy. Quinn SJ, et al. **Clin Otolaryngol** 1995 Aug; 20(4):360–4

Palatal and pharyngeal reflexes in health and in motor neuron disease. Hughes TA, et al.
J Neurol Neurosurg Psychiatry 1996 Jul;61(1):96–8

RADIATION EFFECTS

[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Correction of velopharyngeal insufficiency with furlow palatoplasty. Lindsey WH, et al.
Arch Otolaryngol Head Neck Surg 1996 Aug;122(8):881–4

Objective measurement of the results of uvulopalatopharyngoplasty. Prichard AJ, et al.
Clin Otolaryngol 1995 Dec;20(6):495–8

Transpalatine excision of a cavernous hemangioma of the infratemporal fossa. Kornfehl J, et al.
Eur Arch Otorhinolaryngol 1996;253(3):172–5

Laser-assisted uvulopalatoplasty: an assessment of a technique. Wareing M, et al. **J Laryngol Otol** 1996 Mar; 110(3):232–6

Punctate diathermy of the soft palate: a new approach in the surgical management of snoring. Whinney DJ, et al. **J Laryngol Otol** 1995 Sep;109(9):849–52

Evaluation of criteria for uvulopalatoplasty (UPP) patient selection using acoustic analysis of oronasal respiration (SNAP testing). Weingarten CZ, et al. **J Otolaryngol** 1995 Dec;24(6):352–7

Snare dissection uvulopalatoplasty [letter; comment] Harris NJ. **Laryngoscope** 1996 Mar;106(3 Pt 1):370. Comment on: Laryngoscope 1995 Oct;105(10):1033–6.

Laser-assisted uvulopalatoplasty for obstructive sleep apnea. Mickelson SA. **Laryngoscope** 1996 Jan;106(1 Pt 1):10–3

Laser-assisted uvulopalatoplasty: postoperative complications. Walker RP, et al. **Laryngoscope** 1996 Jul; 106(7):834–8

Snare uvulopalatoplasty [see comments] Weingarten C. **Laryngoscope** 1995 Oct;105(10):1033–6. Comment in: Laryngoscope 1996 Mar;106(3 Pt 1):370.

Surgical correction of submucous cleft palate with Furlow palatoplasty. Chen PK, et al. **Plast Reconstr Surg** 1996 May; 97(6):1136–46; discussion 1147–9

The palatal island flap on retrospection. Seckel NG. **Plast Reconstr Surg** 1995 Nov;96(6):1262–8; discussion 1269–70

Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)

[Uvulopalatopharyngoplasty: safety managements and causes of failure] Peng P, et al.
Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1995;30(3):135–7 (Eng. Abstr.) **(Chi)**

[Uvulo-palatopharyngioplasty: indication, technique and results in relation to ronchopathy and sleep apnea syndrome] Cseh A, et al. **Schweiz Rundsch Med Prax** 1996 May 21;85(21):684–8 (Eng. Abstr.) **(Ger)**

[Morphologic and ultrastructural changes of soft palate in patients who underwent palatopharyngoplasty] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):18–23 (Eng. Abstr.) **(Ita)**

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

[Morphologic and ultrastructural changes of soft palate in patients who underwent palatopharyngoplasty] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):18–23 (Eng. Abstr.) **(Ita)**

PALATINE TONSIL see **TONSIL**

PALATOPHARYNGEAL INCOMPETENCE see **VELOPHARYNGEAL INSUFFICIENCY**

PALEODONTOLOGY

Comment on the causes of thin enamel in Neandertals. Ramirez Rozzi F. **Am J Phys Anthropol** 1996 Apr; 99(4):625–6

Dens evaginatus in a Chilean population. Sawyer DR, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):4–7

Morphological and anthropological aspects of human triangular deciduous lower first molar teeth. Kitagawa Y, et al. **Arch Oral Biol** 1996 Apr;41(4):387–91

Extraordinary diphyodonty-related change in dental function for a tooth of the extinct marsupial Ekaltadeta ima (Propleopinae, Hypsiprymnodontidae). Wroe S, et al.
Arch Oral Biol 1995 Jul;40(7):597–603

Tooth morphology and archaeology: a problem solving exercise. Tasker HN, et al. **Br Dent J** 1995 Aug 5; 179(3):107–9

Tell-tale teeth: abrasion from the traditional clay pipe. Kvaal SI, et al. **Endeavour** 1996;20(1):28–30

Alveolar bone loss on neolithic man remains on 38 skulls of Khirokitia's (Cyprus) inhabitants. Mitsis FJ, et al.
J Clin Periodontol 1995 Oct;22(10):788–93

[Gladebeck—an early medieval cemetery in Lower Saxony] Schafberg R. **Anthropol Anz** 1995 Sep;53(3):255–62 (Eng. Abstr.) **(Ger)**

METHODS

Hypoplastic area method for analyzing dental enamel hypoplasia. Ensor BE, et al. **Am J Phys Anthropol** 1995 Dec;98(4):507–17

PALEONTOLOGY

see related
MUMMIES

Paleodemography: expectancy and false hope. Bocquet-Appel JP, et al. **Am J Phys Anthropol** 1996 Apr; 99(4):571–83

Paleopediatrics: or when did human infants really become human? Conroy GC, et al. **Am J Phys Anthropol** 1995 Oct; 98(2):121–31

Ancient DNA and island endemics [letter] Cooper A, et al. **Nature** 1996 Jun 6;381(6582):484

The Oligocene bottleneck and New Zealand biota: genetic record of a past environmental crisis. Cooper A, et al.
Proc R Soc Lond B Biol Sci 1995 Sep 22;261(1362):293–302

Why mammal ears went on the move [news] Fischman J.
Science 1995 Dec 1;270(5241):1436

Amino acid racemization and the preservation of ancient DNA [see comments] Poinar HN, et al. **Science** 1996 May 10;272(5263):864–6. Comment in: Science 1996 May 10;272(5263):810.

Just how old is that DNA, anyway? [news; comment] Service RF. **Science** 1996 May 10;272(5263):810. Comment on: Science 1996 May 10;272(5263):864–6.

[First paleoparasitologic approach of the neolithic site in Chalain (Jura, France)] Bouchet F, et al.
Bull Soc Pathol Exot 1995 Apr;88(5):265–8 (Eng. Abstr.) **(Fre)**

HISTORY

Piltdown: another suspect. Sharp D. **Lancet** 1996 Jun 1; 347(9014):1502

Box of bones 'clinches' identity of Piltdown palaeontology hoaxer [news] [see comments] Gee H. **Nature** 1996 May 23;381(6580):261–2. Comment in: Nature 1996 Jun 27;381(6585):728.

Riddle of the tenth man [letter; comment] Hall ET.
Nature 1996 Jun 27;381(6585):728. Comment on: Nature 1996 May 23;381(6580):261–2.

Riddle of the tenth man [letter; comment] Lutes AO.
Nature 1996 Jun 27;381(6585):728. Comment on: Nature 1996 May 23;381(6580):261–2.

Protopithecus: rediscovering the first fossil primate. Hartwig WC. **Pubbl Stn Zool Napoli II** 1995;17(3):447–60

[Philippe-Charles Schmerling (1790–1836) reveals the antiquity of man thanks to antediluvian deposits of the Liège caves] Henderickx L. **Acta Psychiatr Belg** 1994; 94(4–6):183–212 (Eng. Abstr.) **(Fre)**

METHODS

Sex identification of archaeological human remains based on amplification of the X and Y amelogenin alleles. Faerman M, et al. **Gene** 1995 Dec 29;167(1–2):327–32

PALEOPATHOLOGY

Paleopathology, its character and contribution to understanding and distinguishing among rheumatologic diseases: perspectives on rheumatoid arthritis and spondyloarthropathy. Rothschild BM.
Clin Exp Rheumatol 1995 Sep–Oct;13(5):657–62 (31 ref.)

The identity and work of the ancient Egyptian surgeon. Sullivan R. **J R Soc Med** 1996 Aug;89(8):467–73

Osteoporosis 4000 years ago [letter; comment] Foldes AJ, et al. **N Engl J Med** 1996 Mar 14;334(11):735. Comment on: N Engl J Med 1995 Nov 30;333(22):1468.

Images in clinical medicine. Osteoporosis in a woman of the early Bronze Age [see comments] Frigo P, et al.
N Engl J Med 1995 Nov 30;333(22):1468. Comment in: N Engl J Med 1996 Mar 14;334(11):735.

California social climbers: low water prompts high status [news] Fischman J. **Science** 1996 May 10;272(5263):811–2

Incomplete spondylolysis and healing. A study of ancient Canadian Eskimo skeletons. Merbs CF. **Spine** 1995 Nov 1;20(21):2328–34

[Gladebeck—an early medieval cemetery in Lower Saxony] Schafberg R. **Anthropol Anz** 1995 Sep;53(3):255–62 (Eng. Abstr.) **(Ger)**

[Age and sex specific differences in bone density of 4,000-year-old individuals. Bone density measurement of early Bronze Age femurs from excavations in Unterhautzenthal, Lower Austria] Frigo P, et al.
Gynakol Geburtshilfliche Rundsch 1995;35(3):159–63 (Eng. Abstr.) **(Ger)**

[Paleopathology] Reverte Coma JM.
An R Acad Nac Med (Madr) 1995;112(3):483–502 **(Spa)**

HISTORY

Pre-Columbian tuberculosis in northern Chile: molecular and skeletal evidence. Arriaza BT, et al.
Am J Phys Anthropol 1995 Sep;98(1):37–45

PALEOSTRIATUM see **GLOBUS PALLIDUS**

PALESTINIANS see **ARABS**

PALLADIUM

Evaluation of inductively heated ferromagnetic alloy implants for therapeutic interstitial hyperthermia. Paulus JA, et al. **IEEE Trans Biomed Eng** 1996 Apr;43(4):406–13

Biological effects of palladium and risk of using palladium in dental casting alloys. Wataha JC, et al.
J Oral Rehabil 1996 May;23(5):309–20 (53 ref.)

Spectrophotometric and spectrofluorimetric estimation of ciprofloxacin and norfloxacin by ternary complex formation with eosin and palladium(II). el Walily AF, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):561–9

Castability optimization of palladium based alloys. Cohen SM, et al. **J Prosthet Dent** 1996 Aug;76(2):125–31

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

Radiation therapy for subretinal neovascularization. Finger PT, et al. **Ophthalmology** 1996 Jun;103(6):878–89

ADMINISTRATION & DOSAGE

Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy. Raben A, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):351–6

ADVERSE EFFECTS

Contact stomatitis due to palladium and platinum in dental alloys. Koch P, et al. **Contact Dermatitis** 1996 Apr; 34(4):253–7

ANALYSIS

The determination of palladium in fosinopril sodium (monopril) by ICP-MS. Lewen N, et al.
J Pharm Biomed Anal 1995 Jun;13(7):879–83

CHEMISTRY

The effect of matrix phase morphology on the structure of Ag–Cu–Pd dispersed phase dental amalgam. Mante F, et al. **J Oral Rehabil** 1995 Sep;22(9):711–5

Steroidal alkenylphosphonates via palladium-catalyzed

coupling reactions. Skoda-Földes R, et al. **Steroids** 1995 Dec;60(12):791-5

Palladium-catalyzed homogeneous coupling reactions of steroids with organostannanes. Skoda-Földes R, et al. **Steroids** 1995 Dec;60(12):812-6

IMMUNOLOGY

Interaction of palladium ions with the skin. Santucci B, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):207-10

PHARMACOLOGY

Inhibition of cellobiohydrolase I from Trichoderma reesei by palladium. Lassig JP, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):119-26

[The radioprotective action of efazol under different conditions of irradiation of the germ cells of male mice] Pomerantseva MD, et al. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):758-65 (Eng. Abstr.) **(Rus)**

STANDARDS

Verification of manufacturer-supplied 125I and 103Pd air-kerma strengths. Mellenberg DE Jr, et al. **Med Phys** 1995 Sep;22(9):1495-7

THERAPEUTIC USE

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Dattoli M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15; 35(5):875-9

Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study. Nori D, et al. **J Surg Oncol** 1996 Apr;61(4):300-5

TOXICITY

Comparative nephrotoxic effects of cis-platinum (II), cis-palladium (II), and cis-rhodium (III) metal coordination compounds in rat kidneys. Bikhazi AB, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):423-7

PALLIATIVE CARE

Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. Cwikiel M, et al. **Acta Oncol** 1996;35(1):75-9

Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Glimelius B, et al. **Acta Oncol** 1996;35(2):141-8

Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Stratford MR, et al. **Acta Oncol** 1996;35(2):213-9

Subcutaneous morphine infusion by syringe driver for terminally ill patients. Cools HJ, et al. **Age Ageing** 1996 May;25(3):206-8

Palliative treatment of obstructing esophageal cancer with nitinol stents: value, safety, and long-term results. Winkelbauer FW, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):79-84

Effect of older age on outcome for stage one palliation of hypoplastic left heart syndrome. Rossi AF, et al. **Am J Cardiol** 1996 Feb 1;77(4):319-21

Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Lee CK, et al. **Am J Clin Oncol** 1996 Apr; 19(2):102-7

Self-expanding metal stents for palliation of inoperable carcinoma of the esophagus and gastroesophageal junction. De Palma GD, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2140-2

Strontium chloride Sr 89 for treating pain from metastatic bone disease. Nightengale B, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2189-95 (87 ref.)

Surgical palliation for ductal adenocarcinoma of the pancreas. Deziel DJ, et al. **Am Surg** 1996 Jul;62(7):582-8

Palliative and supportive care: at the frontier of medical omnipotence. Stiefel F, et al. **Ann Oncol** 1996 Feb; 7(2):135-8 (24 ref.)

Intralesional vinblastine for treating AIDS-associated Kaposi's sarcoma of the oropharynx and larynx. Friedman M, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):272-4

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Lillemoe KD, et al. **Ann Surg** 1996 Jun;223(6):718-25; discussion 725-8

Modified hemi-Fontan operation: an alternative definitive palliation for high-risk patients. Knott-Craig CJ, et al. **Ann Thorac Surg** 1996 Dec;60(6 Suppl):S554-7

Retrosternal bypass operation for unresectable squamous cell cancer of the esophagus. Meunier B, et al. **Ann Thorac Surg** 1996 Aug;62(2):373-7

Repair of tracheogastric fistula after cervical exenteration. Trachiotis GD, et al. **Ann Thorac Surg** 1996 Feb; 61(2):719-21

The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. Cascinu S, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2781-3

Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2825-8

Combined chemo-radiation and hyperthermia for locally advanced soft tissue sarcoma: response and toxicity. Uno T, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2655-7

Terminal sedation in the care of dying patients. Rousseau P. **Arch Intern Med** 1996 Sep 9;156(16):1785-6

Diffusion of innovative approaches to managing hypoplastic left heart syndrome. Caplan WD, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):487-90

Gastric carcinoma with synchronous liver metastases: palliative gastrectomy or not? Chow LW, et al. **Aust N Z J Surg** 1995 Oct;65(10):719-23

Provision of palliative care is suboptimal [letter] Cushen M. **BMJ** 1996 Feb 3;312(7026):310

Palliative care in general practice [editorial] [see comments] Kenyon Z. **BMJ** 1995 Oct 7;311(7010):888-9. Comment in: BMJ 1995 Dec 2;311(7018):1502-3. Comment in: BMJ 1995 Dec 2;311(7018):1503.

Jack Kevorkian: a medical hero? Better palliative care is the answer [letter; comment] Twycross R. **BMJ** 1996 Jul 27; 313(7051):227. Comment on: BMJ 1994 Jun 25;308(6945):1656. Comment on: BMJ 1996 Jun 8;312(7044):1434.

Opening doors: improving access to hospice and specialist palliative care services by members of the black and minority ethnic communities. Commentary on palliative care. Gaffin J, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S51-3

A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. James LE, et al. **Br J Cancer** 1996 Jun;73(12):1563-8

Opening doors: improving access to hospice and specialist palliative care services by members of the black and minority ethnic communities. Commentary on palliative care. Gaffin J, et al. **Br J Cancer Suppl** 1996 Sep;29:S51-3

Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. Miller RS, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):553-6

Palliation of malignant dysphagia from oesophageal cancer. Ellul JP, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):272-4 (15 ref.)

Palliative medicine: a new specialty changes an old debate. Gilbert J. **Br Med Bull** 1996 Apr;52(2):296-307

Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Jong P, et al. **Can J Surg** 1995 Oct;38(5):454-7

Counselling patients before death: support for their decisions [letter; comment] Waugh D. **Can Med Assoc J** 1995 Nov 15;153(10):1417. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1340-2.

Palliation. Surgical and otherwise. Lillemoe KD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):605-14 (31 ref.)

Palliative medicine. Problem areas in pain and symptom management. Introduction. Hanks GW. **Cancer Surv** 1994; 21:1-3

Clinical audit and organizational audit in palliative care. Higginson I. **Cancer Surv** 1994;21:233-45

Pain and symptom control in paediatric palliative care. Stevens MM, et al. **Cancer Surv** 1994;21:211-31 (47 ref.)

Patient assessment in palliative cancer care. Bruera E. **Cancer Treat Rev** 1996 Jan;22 Suppl A:3-12 (15 ref.)

Perspectives of palliative medicine. Doyle D. **Cancer Treat Rev** 1996 Jan;22 Suppl A:155-61

Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point? Jäger E, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:113-5

The delivery of palliative care. Lovel T. **Cancer Treat Rev** 1996 Jan;22 Suppl A:145-9

Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Osoba D. **Cancer Treat Rev** 1996 Jan;22 Suppl A:69-73

Quality assurance by specification and achievement of goals in palliative cancer treatment. Porzsolt F, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:41-9

Advantages of laparoscopic palliative surgery in upper GI tract cancer. Rau B, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:109-11

The Rural Cancer Outreach Program: clinical and financial analysis of palliative and curative care for an underserved population. Smith TJ, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:97-101

Palliative embolization of fibrosarcoma for control of tumor-induced hypoglycemia. Lengle SJ, et al. **Cardiovasc Intervent Radiol** 1995 Jul-Aug;18(4):255-8

Quality of life and supportive care in the treatment of NSCLC. Manegold C, et al. **Chest** 1996 May;109(5 Suppl):113S-114S

Subcutaneous midazolam, diamorphine and hyoscine infusion in palliative care of a child with neurodegenerative disease. Grimshaw D, et al. **Child Care Health Dev** 1995 Nov; 21(6):377-81

Establishing a district palliative care team for children. Wallace AC, et al. **Child Care Health Dev** 1995 Nov; 21(6):383-5

Ten-year institutional experience with palliative surgery for hypoplastic left heart syndrome. Risk factors related to stage I mortality. Forbess JM, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II262-6

Hemodynamic characteristics of neonates following first stage palliation for hypoplastic left heart syndrome. Mosca RS, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II267-71

Barriers to effective palliative care of terminal patients. An international perspective. Rhymes JA. **Clin Geriatr Med** 1996 May;12(2):407-16

Continuous epidural infusion of local anesthetics and shorter duration of acute zoster-associated pain. Manabe H, et al. **Clin J Pain** 1995 Sep;11(3):220-8

External spinal skeletal fixation in the management of back pain. Bednar DA, et al. **Clin Orthop** 1996 Jan;(322):131-9

Bibliography of the current world literature: Supportive care. **Curr Opin Oncol** 1995 Jul;7(4):B51-60

Supportive care: what for? [editorial] Klastersky J. **Curr Opin Oncol** 1995 Jul;7(4):303

Hospice and palliative care. Rousseau P. **Dis Mon** 1995 Dec; 41(12):769-842 (196 ref.)

Gianturco-Z stents in the palliative treatment of malignant esophageal obstruction and esophagotracheal fistulas. Ell C, et al. **Endoscopy** 1995 Sep;27(7):495-500

Highly flexible self-expanding meshed metal stents for palliation of malignant esophagogastric obstruction. Grund KE, et al. **Endoscopy** 1995 Sep;27(7):486-94

Esophageal cancer: which stent, who places it, and where? [editorial] Lambert R. **Endoscopy** 1995 Sep;27(7):509-11

Metal stents for palliation of rectal carcinoma: a preliminary report on 12 patients. Rey JF, et al. **Endoscopy** 1995 Sep; 27(7):501-4

The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Kaasa S, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2260-3

A proposed matrix for organisational changes to improve quality of life in oncology. MacDonald N. **Eur J Cancer** 1995;31A Suppl 6:S18-21 (30 ref.)

Surgery for tetralogy of Fallot at less than six months of age. Is palliation "old-fashioned"? Sousa Uva M, et al. **Eur J Cardiothorac Surg** 1995;9(8):453-9; discussion 459-60

Update on urology--prostate cancer. 3--Systemic and palliative treatment of prostate cancer. Ekman P. **Eur J Surg Oncol** 1995 Oct;21(5):555-7; quiz 557, 567 (12 ref.)

Nd-YAG laser as a palliative treatment for malignant dysphagia. Maciel J, et al. **Eur J Surg Oncol** 1996 Feb; 22(1):69-73

Cancer of the rectum--palliative endoscopic treatment. Rupp KD, et al. **Eur J Surg Oncol** 1995 Dec;21(6):644-7

Local effects of colorectal cancer are well palliated by endoscopic laser therapy. Tan CC, et al. **Eur J Surg Oncol** 1995 Dec;21(6):648-52

Palliative treatment of neoplastic strictures by self-expanding nitinol Strecker stent. Pocek M, et al. **Eur Radiol** 1996; 6(2):230-5

The management of localised cancer of the prostate. Boccon-Gibod L. **Eur Urol** 1996;29 Suppl 2:62-8 (51 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45-8 (11 ref.)

Videoendoscopic cutaneous ureterostomy for palliative urinary diversion in advanced pelvic cancer. Puppo P, et al. **Eur Urol** 1995;28(4):328-33

Hypophysectomy produces analgesia and paraventricular lesions have no effect on formalin-induced pain. Lariviere WR, et al. **Exp Neurol** 1995 Sep;135(1):74-9

Nitinol coil esophageal prosthesis: advantages of removable self-expanding metallic stents. Axelrad AM, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):155-60

Treatment of esophageal obstruction from mediastinal compressive tumor with covered, self-expanding metallic Z-stents. De Gregorio BT, et al. **Gastrointest Endosc** 1996 May;43(5):483-9

Tandem wire mesh stents for palliation of obstructing gastroduodenal adenocarcinoma. Ho SB, et al. **Gastrointest Endosc** 1995 Oct;42(4):363-6

Self-expanding metal stents for palliative treatment of malignant biliary and duodenal stenoses. Howden CW, et al. **Gastrointest Endosc** 1995 Jul;42(1):104-5

The dangers of physician-assisted suicide. Will we choose to provide a right to euthanasia for the few or palliative care for the many? [editorial] Butler RN. **Geriatrics** 1996 Jul;51(7):14-5

Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia. May A, et al. **Gut** 1995 Sep; 37(3):309-13

Palliative care experience and training of Scottish general practitioner trainees. Millar DG. **Health Bull (Edinb)** 1996 May;54(3):248-51

Palliative Mustard operation for transposition of the great arteries: late results after 15-20 years. Sagin-Saylam G, et al. **Heart** 1996 Jan;75(1):72-7

Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy [letter; comment] Dieter RA. **Int Surg** 1995 Apr-Jun;80(2):195. Comment on: Int Surg 1994 Apr-Jun;79(2):124-9.

The palliative care quiz for nursing (PCQN): the development of an instrument to measure nurses' knowledge of palliative care. Ross MM, et al. **J Adv Nurs** 1996 Jan;23(1):126-37

Long-term clinical benefit of dynamic cardiomyoplasty [letter; comment] Andrew C, et al. **J Am Coll Cardiol** 1996 Jan;27(1):252-3. Comment on: J Am Coll Cardiol 1995 Jul;26(1):129-34.

A simplified method of passing a nasogastric tube in patients undergoing celestin intubation for unresectable carcinoma of the esophagus or gastric cardia. Craig SR, et al. **J Am Coll Surg** 1996 Apr;182(4):367–8

The process of dying [letter] Rousseau P. **J Am Geriatr Soc** 1996 May;44(5):612–3

The natural history of osteonecrosis of the femoral head in children and adolescents who have Gaucher disease. Katz K, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):14–9

Cancer pain education: objectives for medical students and residents in primary care specialties. Palliative Oncology Education Section of the American Association for Cancer Education. **J Cancer Educ** 1996 Spring;11(1):7–10

Educational interest, skills, and objectives, including some in the Athenian manner [editorial] Bakemeier RF. **J Cancer Educ** 1996 Spring;11(1):1

A randomized, double–blind, double–dummy, crossover trial comparing the safety and efficacy of oral sustained–release hydromorphone with immediate–release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. Bruera E, et al. **J Clin Oncol** 1996 May;14(5):1713–7

Schedule–dependent edatrexate toxicity [letter; comment] Perez EA. **J Clin Oncol** 1996 Jan;14(1):322–3. Comment on: J Clin Oncol 1995 Jul;13(7):1649–55.

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. Taal BG, et al. **J Clin Oncol** 1996 Jun; 14(6):1829–38

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone–resistant prostate cancer: a Canadian randomized trial with palliative end points [see comments] Tannock IF, et al. **J Clin Oncol** 1996 Jun;14(6):1756–64. Comment in: J Clin Oncol 1996 Jun;14(6):1753–5.

The Hospice Supportive Care Program: a new "transitionless" model of palliative care for patients with incurable prostate cancer [letter] Pienta KJ, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):55–6

Serving those for whom cure is no longer feasible (2) [news] Randal J. **J Natl Cancer Inst** 1996 Aug 7;88(15):1018–20

Palliative treatment needs stronger research basis [news] Reynolds T. **J Natl Cancer Inst** 1996 Jul 3;88(13):862–4

Bone marrow absorbed dose of rhenium–186–HEDP and the relationship with decreased platelet counts. de Klerk JM, et al. **J Nucl Med** 1996 Jan;37(1):38–41

Phase 1 study of rhenium–186–HEDP in patients with bone metastases originating from breast cancer [see comments] de Klerk JM, et al. **J Nucl Med** 1996 Feb;37(2):244–9. Comment in: J Nucl Med 1996 Feb;37(2):249–52.

Efficacy of rhenium–186–etidronate in prostate cancer patients with metastatic bone pain. Quirijnen JM, et al. **J Nucl Med** 1996 Sep;37(9):1511–5

Dosage and response in radiopharmaceutical therapy of painful osseous metastases [editorial; comment] Silberstein EB. **J Nucl Med** 1996 Feb;37(2):249–52. Comment on: J Nucl Med 1996 Feb;37(2):244–9.

The use of propofol in palliative medicine. Moyle J. **J Pain Symptom Manage** 1995 Nov;10(8):643–6

Management of malignant ureteral obstruction in the palliative care setting. Smith P, et al. **J Pain Symptom Manage** 1995 Aug;10(6):481–6

Factors associated with length of survival among 1081 terminally ill cancer patients. Allard P, et al. **J Palliat Care** 1995 Autumn;11(3):20–4

When does palliative care begin? A needs assessment of cancer patients with recurrent disease [letter; comment] Balfour HM. **J Palliat Care** 1995 Autumn;11(3):53. Comment on: J Palliat Care 1995 Spring;11(1):5–9.

The promise of intimacy and the fear of our own undoing. Barnard D. **J Palliat Care** 1995 Winter;11(4):22–6

Incorrect diagnosis and subsequent management of a patient labeled with cholangiocarcinoma. Crowther J, et al. **J Palliat Care** 1995 Winter;11(4):48–50

Images of palliative nursing care. Hanson EJ, et al. **J Palliat Care** 1995 Autumn;11(3):35–9

Evaluating a palliative care program: methodology and limitations. Jarvis H, et al. **J Palliat Care** 1996 Summer; 12(2):23–33

Dying of non–malignant diseases in general practice. Kurti LG, et al. **J Palliat Care** 1995 Autumn;11(3):25–31

Limits to multidisciplinary education [editorial] MacDonald N. **J Palliat Care** 1996 Summer;12(2):6

Successful management of intractable nausea with ondansetron: a case study. Pereira J, et al. **J Palliat Care** 1996 Summer;12(2):47–50

The management of pain in patients with advanced cancer: the importance of multidimensional assessments. Robinson K, et al. **J Palliat Care** 1995 Winter;11(4):51–3

Ethics and complexity in palliative care [editorial] Roy DJ. **J Palliat Care** 1995 Winter;11(4):3–4

Assessing palliative care educational needs of physicians and nurses: results of a survey. Greater Victoria Hospital Society Palliative Care Committee. Samaroo B. **J Palliat Care** 1996 Summer;12(2):20–2

Massive opioid requirements in children with disseminated central nervous system disease [letter; comment] Jones PD, et al. **J Pediatr** 1996 Jun;128(6):864–5. Comment on: J Pediatr 1995 Apr;126(4):653–7.

Total coccygectomy for the relief of coccygodynia: a retrospective review. Grosso NP, et al. **J Spinal Disord** 1995 Aug;8(4):328–30

Tumor bed implant brachytherapy for residual carcinoma after palliative esophagectomy. Kato H, et al. **J Surg Oncol** 1996 Jul;62(3):214–7

Percutaneous biliary stents for palliation of hilar malignancies. Miller DL, et al. **J Surg Oncol** 1996 Jul; 62(3):226–7

Treatment of cancerous abdominal pain by acupuncture on zusanli (ST 36)—a report of 92 cases. Xu S, et al. **J Tradit Chin Med** 1995 Sep;15(3):189–91

Controlling cancerous pain with analgesic powder for cancers. Yang G, et al. **J Tradit Chin Med** 1995 Sep; 15(3):174–7

Percutaneous intravascular ethanol injection of the supplying tumor vessel in the treatment of hepatocellular carcinoma larger than 3 cm. Lin ZY, et al. **J Ultrasound Med** 1996 Feb;15(2):155–60

Re: Long–term survival and mortality in prostate cancer treated with noncurative intent [letter; comment] Abrahamsson A, et al. **J Urol** 1996 Jan;155(1):296–8. Comment on: J Urol 1995 Aug;154(2 Pt 1):460–5.

Early complications and survival following short–term palliative radiotherapy in invasive bladder carcinoma [see comments] Holmäng S, et al. **J Urol** 1996 Jan;155(1):100–2 . Comment in: J Urol 1996 Jan;155(1):103–4.

Policies on medical decisions concerning the end of life in Dutch health care institutions. Haverkate I, et al. **JAMA** 1996 Feb 14;275(6):435–9

Pain control and the World Health Organization analgesic ladder [letter; comment] Twycross R, et al. **JAMA** 1996 Mar 20;275(11):835; discussion 836. Comment on: JAMA 1995 Dec 20;274(23):1870–3.

Palliative treatment for tetralogy of Fallot with percutaneous balloon dilatation of right ventricular outflow tract. Hwang B, et al. **Jpn Heart J** 1995 Nov;36(6):751–61

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small–cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party [see comments] Girling DJ. **Lancet** 1996 Aug 31;348(9027):563–6. Comment in: Lancet 1996 Aug 31;348(9027):559.

Decriminalisation of cannabis [letter] Harrison GR. **Lancet** 1995 Dec 23–30;346(8991–8992):1709

Palliative radiation for stage 3 non–small cell lung cancer—a prospective study of two moderately high dose regimens. Abratt RP, et al. **Lung Cancer** 1995 Oct;13(2):137–43

The assessment of communication skills in palliative medicine: a comparison of the scores of examiners and simulated patients. Finlay IG, et al. **Med Educ** 1995 Nov; 29(6):424–9

Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43–9 (23 ref.). Comment in: Med J Aust 1996 Jun 17;164(12):759–60.

Palliative care for the terminally ill [letter; comment] Cole BS. **Med J Aust** 1996 Jun 17;164(12):759–60. Comment on: Med J Aust 1996 Jan 1;164(1):43–9.

Managing HIV. Part 5: Treating secondary outcomes. 5.19 HIV and palliative care. Glare PA, et al. **Med J Aust** 1996 May 20;164(10):612–5 (9 ref.)

The euthanasia controversy. Decision–making in extreme circumstances [letter] Syme RR. **Med J Aust** 1996 Mar 4;164(5):317–8

Pain palliation with strontium–89 in children with metastatic disease. Charron M, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):393–6

Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. Moon TD, et al. **Monogr Natl Cancer Inst** 1995;(19):69–71

Chronic lymphocytic leukemia [letter; comment] Ijaz T. **N Engl J Med** 1996 Feb 15;334(7):472; discussion 472–3. Comment on: N Engl J Med 1995 Oct 19;333(16):1052–7.

Images in clinical medicine. Endoscopic palliation of malignant dysphagia. Wong RC, et al. **N Engl J Med** 1996 Aug 15;335(7):475

Palliative care in neurology. The American Academy of Neurology Ethics and Humanities Subcommittee [see comments] **Neurology** 1996 Mar;46(3):870–2. Comment in: Neurology 1996 Mar;46(3):598–9.

The knowledge and attitudes of experience oncology nurses regarding the management of cancer–related pain. O'Brien S, et al. **Oncol Nurs Forum** 1996 Apr;23(3):515–21

Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)

Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Collins JJ, et al. **Pain** 1995 Nov;63(2):271–5

Comments on P.A.J. Borg and H.J. Krijnen [letter; comment] Devulder J. **Pain** 1995 Sep;62(3):387–8. Comment on: Pain 1994 Aug;58(2):273–6.

Radiotherapy for bone pain [editorial] Hoskin PJ. **Pain** 1995 Nov;63(2):137–9 (12 ref.)

Intrathecal steroids to reduce pain after lumbar disc surgery: a double–blind, placebo–controlled prospective study. Langmayr JJ, et al. **Pain** 1995 Sep;62(3):357–61

Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Paix A, et al. **Pain** 1995 Nov;63(2):263–9

Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Park KM, et al. **Pain** 1995 Nov;63(2):163–72

Electrical stimulation of precentral cortical area in the treatment of central pain: electrophysiological and PET study. Peyron R, et al. **Pain** 1995 Sep;62(3):275–86

Effect of EMG biofeedback compared to applied relaxation training with chronic, upper extremity cumulative trauma disorders. Spence SH, et al. **Pain** 1995 Nov;63(2):199–206

Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Steen KH, et al. **Pain** 1995 Sep;62(3):339–47

Humor as a cognitive technique for increasing pain tolerance. Weisenberg M, et al. **Pain** 1995 Nov;63(2):207–12

Comparative cost of hyoscine injections [letter] Bausewein C. **Palliat Med** 1995 Jul;9(3):256

The role of embolization in palliative care. Broadley KE, et al. **Palliat Med** 1995 Oct;9(4):331–5

A regional survey of opioid use by patients receiving specialist palliative care. Brooks DJ, et al. **Palliat Med** 1995 Jul;9(3):229–38

Undergraduate education and palliative care. Coles C. **Palliat Med** 1996 Apr;10(2):93–8

Treatment of intractable hiccup in a terminal cancer patient with nebulized saline [letter] De Ruysscher D, et al. **Palliat Med** 1996 Apr;10(2):166–7

Education in palliative medicine [editorial] Doyle D. **Palliat Med** 1996 Apr;10(2):91–2

Rehydration in palliative and terminal care: if not—why not? Dunphy K, et al. **Palliat Med** 1995 Jul;9(3):221–8 (32 ref.)

Rehydration in palliative care [letter] Fainsinger RL, et al. **Palliat Med** 1996 Apr;10(2):165–6

Acupuncture for the relief of cancer–related breathlessness. Filshie J, et al. **Palliat Med** 1996 Apr;10(2):145–50

Nurses in private nursing homes: a study of their knowledge and attitudes to pain management in palliative care. Gibbs G. **Palliat Med** 1995 Jul;9(3):245–53

Blood transfusion and its benefits in palliative care. Gleeson C, et al. **Palliat Med** 1995 Oct;9(4):307–13

Palliative care for children [editorial] Goldman A. **Palliat Med** 1995 Jul;9(3):179–80

Postgraduate research training: the PhD and MD thesis. Higginson I, et al. **Palliat Med** 1996 Apr;10(2):113–8

Interventional radiology in a palliative care setting. Jones SN. **Palliat Med** 1995 Oct;9(4):319–26 (23 ref.)

Laser therapy in the palliation of dysphagia in oesophageal malignancy. Lewis–Jones CM, et al. **Palliat Med** 1995 Oct; 9(4):327–30 (15 ref.)

Is there a better way? Bioethical reflections on palliative cytotoxic drug use [editorial] McGrath P, et al. **Palliat Med** 1995 Oct;9(4):269–71

Use of embolization in palliative care [letter] McQuillan RE, et al. **Palliat Med** 1996 Apr;10(2):167–8

The role of embolization in palliative care [letter] Riley J. **Palliat Med** 1996 Apr;10(2):168

The life so short, the craft so hard to learn: a model for post–basic education in palliative care. Sheldon F, et al. **Palliat Med** 1996 Apr;10(2):99–104 (21 ref.)

A tolerable death. Shulman B. **Palliat Med** 1995 Oct; 9(4):339–40

Continuing education and short courses. Smith AM. **Palliat Med** 1996 Apr;10(2):105–11

Blood transfusion in palliative care [letter] Stone P, et al. **Palliat Med** 1996 Apr;10(2):166

An investigation of the ability of oral naloxone to correct opioid–related constipation in patients with advanced cancer. Sykes NP. **Palliat Med** 1996 Apr;10(2):135–44

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

Benign and malignant stenoses of the stomach and duodenum: treatment with self–expanding metallic endoprostheses. Binkert CA, et al. **Radiology** 1996 May;199(2):335–8

A single session of intraluminal brachytherapy in palliation of oesophageal cancer. Jager J, et al. **Radiother Oncol** 1995 Dec;37(3):237–40

Single–dose radiotherapy (6 Gy): palliation in painful bone metastases. Uppelschoten JM, et al. **Radiother Oncol** 1995 Sep;36(3):198–202

Carcinoma of the pancreatic head area. Therapy: nonoperative biliary drainage for palliation. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):326–37 (11 ref.) **(Eng, Ita)**

Initial experience with telebrachytherapy treatment in palliation of advanced oesophageal cancer. Sur RK, et al. **S Afr J Surg** 1995 Jun;33(2):67–9

Palliative and supportive care of patients with pancreatic cancer. Alter CL. **Semin Oncol** 1996 Apr;23(2):229–40 (36 ref.)

Palliative radiation therapy. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):205–8 (14 ref.)

Quality assurance in palliative care—a growing "must"? [editorial; comment] Bruera E. **Support Care Cancer** 1996 May;4(3):157. Comment on: Support Care Cancer 1996 May;4(3):163–8. Comment on: Support Care Cancer 1996 May;4(3):180–5.

Volume of hydration in terminal cancer patients. Bruera E, et al. **Support Care Cancer** 1996 Mar;4(2):147–50

Patients' beliefs about cancer management [see comments] Buchanan J, et al. **Support Care Cancer** 1996 Mar;4(2):110–7 . Comment in: Support Care Cancer 1996 Mar;4(2):73–4.

Supportive and palliative care of cancer patients at the Kantonsspital St. Gallen, Switzerland. de Stoutz ND, et

al. **Support Care Cancer** 1995 Jul;3(4):221–6

Supportive palliative treatment, psychological care and the hospice movement in Hungary. Muszbek K, et al. **Support Care Cancer** 1996 Jan;4(1):7–9 (10 ref.)

The Sacred Heart Hospice: an Australian centre for palliative medicine. Stuart–Harris R. **Support Care Cancer** 1995 Sep; 3(5):280–4

Laparoscopy for staging and palliation of gastrointestinal malignancy. Bogen GL, et al. **Surg Clin North Am** 1996 Jun;76(3):557–69 (56 ref.)

Palliation for pancreatic cancer. Feasibility of laparoscopic cholecystojejunostomy and gastrojejunostomy in a porcine model. Patel AG, et al. **Surg Endosc** 1996 Jun;10(6):639–43

Surgical palliation of cardiac malformations associated with right isomerism. Kawai T, et al. **Surg Today** 1995; 25(6):525–31

High dose rate endobronchial brachytherapy for the treatment of lung cancer: current status and indications [editorial; comment] Barber P, et al. **Thorax** 1996 Apr; 51(4):345–7. Comment on: Thorax 1996 Apr;51(4):354–8.

High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation [see comments] Hernandez P, et al. **Thorax** 1996 Apr; 51(4):354–8. Comment in: Thorax 1996 Apr;51(4):345–7.

Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope. Wilson GE, et al. **Thorax** 1996 Mar;51(3):248–52

Palliative care. A rewarding specialty [editorial] Raje D. **West Indian Med J** 1996 Jun;45(2):41–2

Clinical management of dying patients. Gavrin J, et al. **West J Med** 1995 Sep;163(3):268–77

Medical futility and care of dying patients. Jecker NS. **West J Med** 1995 Sep;163(3):287–91

Suffering and dying in cancer patients. Research frontiers in controlling confusion, cachexia, and dyspnea. MacDonald N. **West J Med** 1995 Sep;163(3):278–86

End–of–life treatment in managed care. The potential and the peril. Miles SH, et al. **West J Med** 1995 Sep; 163(3):302–5

Anorectal melanoma. Successful palliation in a 59–year–old woman. Mostafapour SP, et al. **West J Med** 1996 May; 164(5):448–50 (18 ref.)

Palliative medicine education at the Medical College of Wisconsin. Weissman DE. **Wis Med J** 1995;94(9):505–8

[Palliative treatment of malignant dysphagia] Aujeský R, et al. **Rozhl Chir** 1996 Feb;75(2):76–80 (Eng. Abstr.) **(Cze)**

[Jorma Palo and euthanasia (letter)] Hänninen J. **Duodecim** 1994;110(13):1281–3 **(Fin)**

[Palliative care and HIV infection. Medical benchmarks] Mallet D, et al. **Ann Med Interne (Paris)** 1995;146(7):510–3 (14 ref.) **(Fre)**

[Desiring to die, palliative care and medical responsibility (editorial)] Touzet J. **Nephrologie** 1996;17(4):221–3 **(Fre)**

[Palliative percutaneous treatment under x–ray computed tomographic control of inoperable pulmonary aspergilloma. Apropos of 30 cases] Giron J, et al. **Rev Mal Respir** 1995;12(6):593–9 (Eng. Abstr.) **(Fre)**

[Palliative care: various theological implications in reference to the article by E. Rivier, L. Barrelet and P. Beck (comment)] Piguet H. **Rev Med Suisse Romande** 1995 Jul; 115(7):549–53. Comment on: Rev Med Suisse Romande 1995 Feb;115(2):163–9. **(Fre)**

[Palliative treatment of facial paralysis] Gola R, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):317–24 (Eng. Abstr.) **(Fre)**

[Self–expanding metal endoprosthesis in palliation of stenosing tumors of the upper gastrointestinal tract. Comparison of experience with three stent types in 82 implantations] Ell C, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1343–8 (Eng. Abstr.) **(Ger)**

[Palliative surgical treatment of bone metastases. Improved quality of life by early intervention?] Graupe F, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):393–7 (Eng. Abstr.) **(Ger)**

[Stent implantation for the palliative therapy of upper inflow obstruction in bronchial carcinoma] Wilhelm K, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1419–25 (Eng. Abstr.) **(Ger)**

[Palliative treatment of tetralogy of Fallot using a PTFE (polytetrafluoroethylene) vascular graft] Weber UT, et al. **Schweiz Arch Tierheilkd** 1995;137(10):480–4 (Eng. Abstr.) **(Ger)**

[Palliative pain therapy––medico–ethical arguments] Illhardt FJ. **Schweiz Rundsch Med Prax** 1996 Feb 27;85(9):268–71 (Eng. Abstr.) **(Ger)**

[Palliative pain therapy in terminally ill tumor patients] Lohri A, et al. **Schweiz Rundsch Med Prax** 1996 Feb 27; 85(9):261–7 (Eng. Abstr.) **(Ger)**

[Palliative chemotherapy for metastatic soft–tissue sarcoma in adulthood––the results of a European study of the EORTC. European Organization for Research and Treatment of Cancer] Budach V. **Strahlenther Onkol** 1996 Jun;172(6):346–7 **(Ger)**

[Palliative endoscopic treatment of malignant occlusive jaundice with a balloon expandable metal stent] Zipprich B, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:154–6 (Eng. Abstr.) **(Ger)**

[Surgical therapy of bone metastases] Wirbel RJ, et al. **Zentralbl Chir** 1995;120(9):707–15 (Eng. Abstr.) **(Ger)**

[Single–dose palliative radiotherapy in inoperable non–small–cell lung carcinoma] Scolaro T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):808–11 (Eng. Abstr.) **(Ita)**

[Usefulness of palliative care for the patients with recurrent gastric cancer by home–IVH] Sairenji M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:394–401 (Eng. Abstr.) **(Jpn)**

[Prospective randomized trial comparing 1/2 FAM (5–fluorouracil (5–FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non–resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract] Takada T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):707–14 (Eng. Abstr.) **(Jpn)**

[Palliation of brain metastases: factors associated with survival] Kutuki S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 May; 56(6):426–31 (Eng. Abstr.) **(Jpn)**

[Palliative radiotherapy for symptomatic osseous metastases] Shigematsu N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):677–81 (Eng. Abstr.) **(Jpn)**

[A successful palliative arterial switch operation with arch repair for tricuspid atresia with ventriculoarterial discordance, subaortic stenosis, coarctation, and aortic arch hypoplasia] Yamagishi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1981–7 (Eng. Abstr.) **(Jpn)**

[Palliative care of patients with neoplasm] Shima Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):365–8 (5 ref.) **(Jpn)**

[Patients with cancer–related pain and other chronic pain. Priorities and assessment] Skauge M, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):473–7 (Eng. Abstr.) **(Nor)**

[Brain metastasis. Palliative treatment with radiosurgery] Faria SL, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):570–6 (Eng. Abstr.) **(Por)**

[What is modern hospice care and palliative medicine? (editorial)] Jušić A. **Lijec Vjesn** 1995 May–Jun; 117(5–6):146–9 (Eng. Abstr.) **(Scr)**

[Palliative medicine before euthanasia] Astudillo Alarcón W, et al. **Rev Med Univ Navarra** 1993 Jan–Mar;38(1):51–9 (Eng. Abstr.) **(Spa)**

[Increased knowledge is necessary for further talks about good death (letter)] Eckerdal G. **Lakartidningen** 1996 Jan 24;93(4):229–30 **(Swe)**

[Is intermittent oxygen therapy effective as palliative treatment? (letter)] Götell P. **Lakartidningen** 1995 Dec 20; 92(51–52):4870–1 **(Swe)**

[No to euthanasia––yes to palliative care! Physician–assisted suicide is unethical, too] Ottosson JO. **Lakartidningen** 1996 Apr 3;93(14):1309–10 **(Swe)**

CLASSIFICATION

Definitions in palliative care [letter; comment] Finlay IG, et al. **BMJ** 1995 Sep 16;311(7007):754. Comment on: BMJ 1995 May 27;310(6991):1410–1. Comment on: BMJ 1995 May 27;310(6991):1411.

ECONOMICS

Fontan palliation versus heart transplantation: a comparison of charges. Gajarski RJ, et al. **Am Heart J** 1996 Jun; 131(6):1169–74

A cost analysis of Nd:YAG laser ablation versus endoscopic intubation for the palliation of malignant dysphagia. Sculpher MJ, et al. **Eur J Cancer** 1995 Sep;31A(10):1640–6

Hospice services feel the pinch of managed care [news] Randal J. **J Natl Cancer Inst** 1996 Jul 3;88(13):860–2

Is humanity too costly a place to keep open? [editorial] Roy DJ. **J Palliat Care** 1995 Autumn;11(3):3–4

A randomized controlled trial of the cost–effectiveness of a district co–ordinating service for terminally ill cancer patients. Raftery JP, et al. **Palliat Med** 1996 Apr; 10(2):151–61

Palliative care services: what needs assessment? Robbins MA, et al. **Palliat Med** 1995 Oct;9(4):287–93

INSTRUMENTATION

[Highly flexible self–expanding metal mesh stents: a new kind of palliative therapy of malignant dysphagia] Grund KE, et al. **Z Gastroenterol** 1995 Jul;33(7):392–8 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Oregon's physician–assisted suicide vote: its effect on palliative care. Tilden VP, et al. **Nurs Outlook** 1996 Mar–Apr;44(2):80–3

MANPOWER

Palliative care providers' perspectives on service and education needs. Sellick SM, et al. **J Palliat Care** 1996 Summer;12(2):34–8

METHODS

Palliation of malignant obstructive jaundice. Use of self–expandable metal stents. Men S, et al. **Acta Radiol** 1996 May;37(3 Pt 1):259–66

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Biliary stents in the treatment of malignant ductal obstruction [editorial; comment] Brandon JC, et al. **Am J Gastroenterol** 1996 Apr;91(4):627–8. Comment on: Am J Gastroenterol 1996 Apr;91(4):654–9.

Wallstents versus plastic stents in malignant biliary obstruction: effects of stent patency of the first and second stent on patient compliance and survival [see comments] Schmassmann A, et al. **Am J Gastroenterol** 1996 Apr; 91(4):654–9. Comment in: Am J Gastroenterol 1996 Apr;91(4):627–8.

Palliation of carcinoma of the oesophagus with brachytherapy and the Didcott dilator. Sur RK, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):124–8

Surgical management of hypoplastic left heart syndrome. Bando K, et al. **Ann Thorac Surg** 1996 Jul;62(1):70–6; discussion 76–7

Systemic obstruction in univentricular hearts: surgical options for neonates. Serraf A, et al. **Ann Thorac Surg** 1995 Oct; 60(4):970–6; discussion 976–7

Modified surgical palliation for a rare type of L–transposition with aortic atresia. Young JN, et al. **Ann Thorac Surg** 1995 Oct;60(4):1108–9

Treatment principles in advanced colorectal cancer. Zalcberg JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):202–5 (30 ref.)

Clinical features and management of carcinoma of the pancreas. Carter DC. **Br J Hosp Med** 1995 Nov 1–14; 54(9):459–64 (31 ref.)

Short communication: A method of brachytherapeutic treatment of tracheal stoma recurrence in head and neck cancer. Schäfer U, et al. **Br J Radiol** 1996 Apr; 69(820):348–50

Self–expanding metal stents for the palliation of dysphagia due to inoperable oesophageal carcinoma [see comments] Ellul JP, et al. **Br J Surg** 1995 Dec;82(12):1678–81. Comment in: Br J Surg 1996 May;83(5):714–5.

Exenteration as palliation for patients with advanced pelvic malignancy. Woodhouse CR, et al. **Br J Urol** 1995 Sep; 76(3):315–20

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.). Comment in: Can J Surg 1996 Aug;39(4):265–6.

Percutaneous management of superior vena cava occlusions. Crowe MT, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):367–72

Self–expanding metal stents for palliative treatment of superior vena caval syndrome. Oudkerk M, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):146–51

Malignant insulinoma: permanent hepatic artery embolization of liver metastases––preliminary results. Winkelbauer FW, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec; 18(6):353–9

Airway stents. Present and future. Colt HG, et al. **Clin Chest Med** 1995 Sep;16(3):465–78 (96 ref.)

Endobronchial brachytherapy. Villanueva AG, et al. **Clin Chest Med** 1995 Sep;16(3):445–54 (45 ref.)

Superselective intra–arterial radiometabolic therapy with I–131 lipiodol in hepatocellular carcinoma. Maini CL, et al. **Clin Nucl Med** 1996 Mar;21(3):221–6

Palliation of malignant tracheo–oesophageal fistula using covered metal stents. Mohammed S, et al. **Clin Radiol** 1996 Jan;51(1):42–6

Extraperitoneal hypogastric artery ligation in control of intractable haemorrhage from advanced carcinoma of cervix and choriocarcinoma. Kwawukume EY, et al. **East Afr Med J** 1996 Feb;73(2):147–8

Palliation of malignant gastric outlet obstruction with self–expanding metal stents. Feretis C, et al. **Endoscopy** 1996 Feb;28(2):225–8

Palliative endoscopic therapy of rectal carcinoma. Dohmoto M, et al. **Eur J Cancer** 1996 Jan;32A(1):25–9 (45 ref.)

Pamidronate infusions as single–agent therapy for bone metastases: a phase II trial in patients with breast cancer. Tyrrell CT, et al. **Eur J Cancer** 1995 Nov;31A(12):1976–80

Vinorelbine for recurrent adenocarcinoma–like salivary gland malignancies [letter] Airoldi M, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):213–4

Endoscopic intubation of oesophago–gastric malignancy. Wilton A, et al. **Eur J Gastroenterol Hepatol** 1995 Jun; 7(6):559–62

Bone pain palliation with strontium–89 in breast cancer patients with bone metastases and refractory bone pain. Berna L, et al. **Eur J Nucl Med** 1995 Oct;22(10):1101–4

Stent or surgery for the palliation of malignant biliary obstruction: is the choice clear now? Pasricha PJ. **Gastroenterology** 1995 Oct;109(4):1398–400

Marking clips for the accurate positioning of self–expandable esophageal stents. de Boer WA, et al. **Gastrointest Endosc** 1995 Jul;42(1):73–6

Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. De Palma GD, et al. **Gastrointest Endosc** 1996 May;43(5):478–82

Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Lightdale CJ, et al. **Gastrointest Endosc** 1995 Dec; 42(6):507–12

Endoscopic stenting for pain relief in chronic pancreatitis: results of a standardized protocol. Ponchon T, et al. **Gastrointest Endosc** 1995 Nov;42(5):452–6

PALLIATIVE CARE

Long-term results of pancreatic stents in chronic pancreatitis. Smits ME, et al. **Gastrointest Endosc** 1995 Nov;42(5):461-7

Recurrent esophagorespiratory fistula in a patient with metastatic breast cancer: long-term palliation with endoprostheses and hormonal therapy. Taal BG, et al. **Gastrointest Endosc** 1995 Jul;42(1):84-8

Endoscopic biliary endoprosthesis for palliation of gallbladder carcinoma. Vij JC, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):121-3

Palliative resection of pancreatic adenocarcinoma. A survey of British surgeons. Johnson CD. **HPB Surg** 1995 Jun; 8(3):181-3

Laparoscopic cutaneous ureterostomy: technique for palliative upper urinary tract drainage. Loisides P, et al. **J Endourol** 1995 Aug;9(4):315-7

Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87-92 (12 ref.)

Tolerability of continuous subcutaneous octreotide used in combination with other drugs. Mercadante S. **J Palliat Care** 1995 Winter;11(4):14-6

Augmentation of pulmonary blood flow with an axillary arteriovenous fistula after a cavopulmonary shunt. Magee A, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):176-80

A woman with malignant bowel obstruction who did not want to die with tubes. Steadman K, et al. **Lancet** 1996 Apr 6;347(9006):944

Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Syrjala KL, et al. **Pain** 1995 Nov;63(2):189-98

Stents in the oesophagus. Murphy GJ. **Postgrad Med J** 1995 Aug;71(838):453-6

Palliation of malignant esophageal strictures with self-expanding nitinol stents: drawbacks and complications. Acunas B, et al. **Radiology** 1996 Jun;199(3):648-52

Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Cotten A, et al. **Radiology** 1996 Aug;200(2):525-30

Esophagorespiratory fistulae due to esophageal carcinoma: palliation with a covered Gianturco stent. Han YM, et al. **Radiology** 1996 Apr;199(1):65-70

Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Montemaggi P, et al. **Radiology** 1996 Jun;199(3):861-6

Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement. Weill A, et al. **Radiology** 1996 Apr;199(1):241-7

A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). Nestle U, et al. **Radiother Oncol** 1996 Mar;38(3):195-203 (48 ref.)

Palliative procedures for pancreatic cancer: when and which one? Shumate CR, et al. **South Med J** 1996 Jan;89(1):27-32 (28 ref.)

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418-21 (40 ref.)

Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy. Rovirosa A, et al. **Tumori** 1995 Sep-Oct; 81(5):359-63 (37 ref.)

[Longmayr's operation in malignant jaundice with a poor prognosis] Damianov D, et al. **Khirurgiia (Sofiia)** 1994; 47(6):21-3 **(Bul)**

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330-3 (23 ref.) **(Ita)**

[A new SBU report. Palliative radiotherapy of cancer should be increased] **Lakartidningen** 1996 Sep 11;93(37):3165-8 **(Swe)**

ORGANIZATION & ADMINISTRATION

Palliative care in general practice. Should GPs do it at the expense of commoner problems? [letter; comment] Brooks D. **BMJ** 1995 Dec 2;311(7018):1502-3. Comment on: BMJ 1995 Oct 7;311(7010):888-9.

Palliative care in general practice. Palliative care is integral to practice [letter; comment] Charlton R. **BMJ** 1995 Dec 2;311(7018):1503. Comment on: BMJ 1995 Oct 7;311(7010):888-9.

Effect of home care on the place of death of advanced cancer patients. De Conno F, et al. **Eur J Cancer** 1996 Jun; 32A(7):1142-7

Palliative medicine: providing care when cure is not possible. A roundtable discussion: Part I. Butler RN, et al. **Geriatrics** 1996 May;51(5):33-6, 42-4

The role of volunteers in a hospital-based palliative care service. Brazil K, et al. **J Palliat Care** 1995 Autumn; 11(3):40-2

Scarborough's Palliative 'At-home' Care Team (PACT): a model for a suburban physician palliative care team. Gardner-Nix JS, et al. **J Palliat Care** 1995 Autumn; 11(3):43-9

New EMS Palliative Care/DNR protocol will replace existing hospice protocol. Smith G. **Md Med J** 1995 Sep; 44(9):717-22

The development of a palliative care team at the Western General Hospital, Edinburgh. Hockley J. **Support Care Cancer** 1996 Mar;4(2):77-81

[The organization of palliative care for cancer patients and the outlook for its improvement] Novikov GA, et al. **Vopr Onkol** 1995;41(2):27-8 **(Rus)**

[A call to attention on the organization of palliative care in oncology (letter; comment)] Espinosa P, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):76. Comment on: Med Clin (Barc) 1995 Oct 21;105(13):516-7. **(Spa)**

[A call to attention on the organization of palliative care in oncology (letter; comment) (see comments)] Furio Marco MP, et al. **Med Clin (Barc)** 1995 Oct 21; 105(13):516-7. Comment on: Med Clin (Barc) 1995 Mar 18;104(10):375-6. Comment in: Med Clin (Barc) 1996 Jun 8;107(2):76. **(Spa)**

[Organization of palliative care (letter; comment)] Gómez Navarro R, et al. **Med Clin (Barc)** 1995 Dec 2;105(19):759 . Comment on: Med Clin (Barc) 1995 Mar 18;104(10):375-6. **(Spa)**

PSYCHOLOGY

Attitudes toward and knowledge of chronic pain: a survey of medical social workers. Sieppert JD. **Health Soc Work** 1996 May;21(2):122-30

A questionnaire to medical students on palliative care and euthanasia. Dionne L, et al. **J Palliat Care** 1996 Summer; 12(2):39-43

[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85-8 (25 ref.) **(Ger)**

STANDARDS

Comfort at the end of life: palliative care policy. Jett LG. **J Nurs Adm** 1995 Nov;25(11):55-60 (23 ref.)

What do palliative staff think about audit? Higginson I, et al. **J Palliat Care** 1995 Autumn;11(3):17-9

[No to euthanasia, yes to good palliative care!] Gravgaard AM. **Lakartidningen** 1996 Apr 24;93(17):1598, 1603 **(Swe)**

STATISTICS & NUMERICAL DATA

Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. Tsai KT, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):149-52

Characteristics of referrals to an inpatient hospice and a survey of general practitioner perceptions of palliative care. Seamark DA, et al. **J R Soc Med** 1996 Feb;89(2):79-84

National survey of drug use in palliative care. Drummond SH, et al. **Palliat Med** 1996 Apr;10(2):119-24

TRENDS

Mexico: status of cancer pain and palliative care. Allende S, et al. **J Pain Symptom Manage** 1996 Aug;12(2):121-3

Report of the European Association for Palliative Care. Blümhuber H, et al. **J Pain Symptom Manage** 1996 Aug; 12(2):82-4

Israel: status of cancer pain and palliative care. Cherny NI. **J Pain Symptom Manage** 1996 Aug;12(2):116-7

Turkey: status of cancer pain and palliative care. Erdine S. **J Pain Symptom Manage** 1996 Aug;12(2):139-40

Chile: status of cancer pain and palliative care. Fernández A, et al. **J Pain Symptom Manage** 1996 Aug;12(2):102-3

Singapore: status of cancer pain and palliative care. Goh CR. **J Pain Symptom Manage** 1996 Aug;12(2):130-2

Catalonia WHO Demonstration Project on Palliative Care Implementation 1990-1995: results in 1995. Gómez-Batiste X, et al. **J Pain Symptom Manage** 1996 Aug;12(2):73-8

France: status of cancer pain and palliative care. Larue F, et al. **J Pain Symptom Manage** 1996 Aug;12(2):106-8 (11 ref.)

The Philippines: status of cancer pain and palliative care. Laudico AV. **J Pain Symptom Manage** 1996 Aug; 12(2):133-5 (10 ref.)

Australia: status of cancer pain and palliative care. Lickiss JN. **J Pain Symptom Manage** 1996 Aug;12(2):99-101

Uganda: status of cancer pain and palliative care. Merriman A. **J Pain Symptom Manage** 1996 Aug;12(2):141-3

Colombia: status of cancer pain and palliative care. Moyano J. **J Pain Symptom Manage** 1996 Aug;12(2):104-5

Indonesia: status of cancer pain and palliative care. Soebadi RD, et al. **J Pain Symptom Manage** 1996 Aug;12(2):112-5

The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65-72 (31 ref.)

Germany: status of cancer pain and palliative care. Strumpf M, et al. **J Pain Symptom Manage** 1996 Aug;12(2):109-11

Republic of China: status of cancer pain and palliative care. Sun WZ, et al. **J Pain Symptom Manage** 1996 Aug; 12(2):127-9

Japan: status of cancer pain and palliative care. Takeda F. **J Pain Symptom Manage** 1996 Aug;12(2):118-20

Argentina: status of cancer pain and palliative care. Wenk R, et al. **J Pain Symptom Manage** 1996 Aug;12(2):97-8

People's Republic of China: status of cancer pain and palliative care. Zhang H, et al. **J Pain Symptom Manage** 1996 Aug;12(2):124-6

The Netherlands: status of cancer pain and palliative care. Zylicz Z. **J Pain Symptom Manage** 1996 Aug;12(2):136-8 (13 ref.)

Directions for palliative care nursing in Canada: report of a national survey. Kristjanson LJ, et al. **J Palliat Care** 1995 Autumn;11(3):5-8

PALLIATIVE TREATMENT see **PALLIATIVE CARE**

PALMITATES

ADVERSE EFFECTS

Surgical bone wax causing epistaxis. Tay HL, et al. **J Laryngol Otol** 1996 Mar;110(3):267-8

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121-6 (15 ref.)

METABOLISM

The effects of fasting on the thermogenic, metabolic and cardiovascular responses to infused adrenaline. Webber J, et al. **Br J Nutr** 1995 Oct;74(4):477-90

beta-Oxidation in human alcoholic and non-alcoholic hepatic steatosis. Eaton S, et al. **Clin Sci (Colch)** 1996 Apr; 90(4):307-13

Isolation of myocardial membrane long-chain fatty acid-binding protein: homology with a rat membrane protein implicated in the binding or transport of long-chain fatty acids. Tanaka T, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1613-22

Specific activity of brain palmitoyl-CoA pool provides rates of incorporation of palmitate in brain phospholipids in awake rats. Grange E, et al. **J Neurochem** 1995 Nov; 65(5):2290-8

PHARMACOKINETICS

Substrate effects on sarcolemmal permeability in the normoxic and hypoxic perfused rat heart. Lochner A, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):64-78

PHARMACOLOGY

Restricted effect of formycin A and non-glucidic nutrients upon insulin release in islets from rats with hereditary or acquired non-insulin-dependent diabetes. Giroix MH, et al. **Acta Diabetol** 1995 Oct;32(3):198-202

Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Lio YC, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):55-60

Hyperpolarization of the liver cell membrane by palmitate as affected by glucose and lactate: implications for control of feeding. Rossi R, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1-2):45-9

Effect of sulfo-N-succinimidyl palmitate on the rat heart: myocardial long-chain fatty acid uptake and cardiac hypertrophy. Kusaka Y, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1605-12

Regulation of glucose utilization by inhibition of mitochondrial fatty acid uptake in cardiac cells. Sharawi S, et al. **Pharmacol Res** 1995 Jul-Aug;32(1-2):43-7

PALMITIC ACIDS

ADMINISTRATION & DOSAGE

Effect of dietary triacylglycerol fatty acid positional distribution on plasma lipid classes and their fatty acid composition in preterm infants. Carnielli VP, et al. **Am J Clin Nutr** 1995 Oct;62(4):776-81

Opposite effects on cholesterol metabolism and their mechanisms induced by dietary oleic acid and palmitic acid in hamsters. Kurushima H, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):251-6

Different effects of palmitic and stearic acid-enriched diets on serum lipids and lipoproteins and plasma cholesteryl ester transfer protein activity in healthy young women. Schwab US, et al. **Metabolism** 1996 Feb;45(2):143-9

ANALYSIS

Further observations on the measurement of fatty acid incorporation by erythrocyte ghosts to quantify unbound palmitate concentration in albumin-palmitate mixtures. Pond SM, et al. **Anal Biochem** 1996 Jun 1;237(2):232-8

Role of palmitic acid on the isolation and properties of halorhodopsin. Corcelli A, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):173-81

[Rare gallstone (calcium carbonate calculus)] Goto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):418-20 (11 ref.) **(Jpn)**

BLOOD

Comparative lipoprotein metabolism of myristate, palmitate, and stearate in normolipidemic men. Hughes TA, et al. **Metabolism** 1996 Sep;45(9):1108-18

CHEMISTRY

Positional isomerization of trans-3-hexadecenoic acid employing 2-amino-2-methyl-propanol as a derivatizing agent for ethylenic bond location by gas chromatography/mass spectrometry. Lamberto M, et al. **Anal Biochem** 1995 Sep 20;230(2):224-8

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583-7 (36 ref.)

Localization of the palmitoylation site in the transmembrane protein p12E of Friend murine leukaemia virus. Hensel J, et al. **Eur J Biochem** 1995 Sep 1;232(2):373-80

Multiple palmitoylation of synaptotagmin and the t-SNARE SNAP-25. Veit M, et al. **FEBS Lett** 1996 Apr 29; 385(1-2):119-23

Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide. Lipp MM, et al. **Science** 1996 Aug 30;273(5279):1196-9

DIAGNOSTIC USE

Incorporation of [1-carbon-11]palmitate in monkey brain using PET. Arai T, et al. **J Nucl Med** 1995 Dec; 36(12):2261-7

ISOLATION & PURIFICATION

Palmitic acid is the major fatty acid responsible for significant anti-N-methyl-N'-nitro-N-nitroguanidine (MNNG) activity in yogurt. Nadathur SR, et al. **Mutat Res** 1996 Apr 4;359(3):179-89

[Chemical constituents of Cyclocarya paliurus (Batal.) Iljinsk] Shu R, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov; 20(11):680-1, 704 (Eng. Abstr.) **(Chi)**

METABOLISM

Effect of butter compared with tallow consumption on postprandial oxidation of myristic and palmitic acids. MacDougall DE, et al. **Am J Clin Nutr** 1996 Jun; 63(6):918-24

Fatty acylation of synaptotagmin in PC12 cells and synaptosomes. Chapman ER, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):326-32

Cysteine-699, a possible palmitoylation site of the thyrotropin receptor, is not crucial for cAMP or phosphoinositide signaling but is necessary for full surface expression. Kosugi S, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):636-40

The human asialoglycoprotein receptor is palmitoylated and fatty deacylation causes inactivation of state 2 receptors. Zeng FY, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):325-30

Metabolic fate of oleic acid, palmitic acid and stearic acid in cultured hamster hepatocytes. Bruce JS, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):847-52

Chemical inhibition of myristoylation of the G-protein Gi1 alpha by 2-hydroxymyristate does not interfere with its palmitoylation or membrane association. Evidence that palmitoylation, but not myristoylation, regulates membrane attachment. Galbiati F, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):717-20

The role of palmitoylation of the guanine nucleotide binding protein G11 alpha in defining interaction with the plasma membrane. McCallum JF, et al. **Biochem J** 1995 Sep 15; 310 (Pt 3):1021-7

Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Schülein R, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):611-6

Dynamic regulation of G-protein coupled receptor palmitoylation: potential role in receptor function. Bouvier M, et al. **Biochem Soc Trans** 1995 Aug;23(3):577-81 (35 ref.)

G(o1) alpha palmitoylation: its contribution to alpha 2C10 adrenoceptor—G(o1) alpha coupling. Grassie MA, et al. **Biochem Soc Trans** 1995 Aug;23(3):406S

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583-7 (36 ref.)

Protein palmitoylation in membrane trafficking. Mundy DI. **Biochem Soc Trans** 1995 Aug;23(3):572-6 (43 ref.)

Acylation of viral glycoproteins: structural requirements for palmitoylation of transmembrane proteins. Ponimaskin E, et al. **Biochem Soc Trans** 1995 Aug;23(3):565-8

Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Liu J, et al. **Biochemistry** 1995 Sep 26;34(38):12333-40

Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. Jochen AL, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):65-72

Effects of added l-carnitine, acetyl-CoA and CoA on peroxisomal beta-oxidation of [U-14C]hexadecanoate by isolated peroxisomal fractions. Sleboda J, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):309-18

Purification and structural characterization of a fatty acid-binding protein from the liver of the catfish Rhamdia sapo. Di Pietro SM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):503-9

Stimulation of synaptosomal free radical production by fatty acids: relation to esterification and to degree of unsaturation. Bondy SC, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):53-5

Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. Ekrami HM, et al. **FEBS Lett** 1995 Sep 11;371(3):283-6

Palmitoylation of brain capillary proteins. Poulio JF, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1133-44

Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. Dudler T, et al. **J Biol Chem** 1996 May 10;271(19):11541-7

Palmitoylation of endothelin receptor A. Differential modulation of signal transduction activity by post-translational modification. Horstmeyer A, et al. **J Biol Chem** 1996 Aug 23;271(34):20811-9

Palmitoylated cysteine 341 modulates phosphorylation of the beta2-adrenergic receptor by the cAMP-dependent protein kinase. Moffett S, et al. **J Biol Chem** 1996 Aug 30; 271(35):21490-7

Isolation of myocardial membrane long-chain fatty acid-binding protein: homology with a rat membrane protein implicated in the binding or transport of long-chain fatty acids. Tanaka T, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1613-22

Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity. Jin H, et al. **J Virol** 1996 Mar;70(3):1406-14

Prenylation and palmitoylation analysis. Hancock JF. **Methods Enzymol** 1995;255:237-45

Palmitoylation of either Cys-3 or Cys-5 is required for the biological activity of the Lck tyrosine protein kinase. Yurchak LK, et al. **Mol Cell Biol** 1995 Dec;15(12):6914-22

Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. García-Cardeña G, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6448-53

Palmitoylation of the GluR6 kainate receptor. Pickering DS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12090-4

The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Yang C, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9871-5

Palmitoylation of the murine leukemia virus envelope glycoprotein transmembrane subunits. Yang C, et al. **Virology** 1996 Jul 1;221(1):87-97

PHARMACOKINETICS

Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells. Bird DA, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1265-70

Sex differences in initial clearance of palmitate by human hepatocytes. Pond SM, et al. **Eur J Clin Invest** 1996 Jan; 26(1):76-81

PHARMACOLOGY

Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Temme EH, et al. **Am J Clin Nutr** 1996 Jun;63(6):897-903

Effects of temperature and glycerides on the enhancement of Agkistrodon piscivorus piscivorus phospholipase A2 activity by lysolecithin and palmitic acid. Bell JD, et al. **Biochemistry** 1995 Sep 12;34(36):11551-60

Difluoropalmitic acids as potential inhibitors of the biosynthesis of the sex pheromone of the Egyptian armyworm Spodoptera littoralis--IV. Bosch MP, et al. **Bioorg Med Chem** 1996 Mar;4(3):467-72

Regulation of low density lipoprotein receptor gene expression in HepG2 and Caco2 cells by palmitate, oleate, and 25-hydroxycholesterol. Srivastava RA, et al. **J Lipid Res** 1995 Jul;36(7):1434-46

Plasma lipids are affected similarly by dietary lauric or palmitic acid in gerbils and monkeys. Pronczuk A, et al. **Lipids** 1995 Dec;30(12):1157-61

The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Skaper SD, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3984-9

[Participation of the ADP/ATP-antiporter in the uncoupling action of fatty acids in liver mitochondria] Bodrova ME, et al. **Biokhimiia** 1995 Aug;60(8):1349-57 (Eng. Abstr.) **(Rus)**

[The effect of p-chloromercuribenzoate on regulation of oxidative phosphorylation by ADP and ATP and stimulation of liver mitochondrial respiration by palmitate] Samartsev VN, et al. **Biokhimiia** 1995 Oct;60(10):1706-10 (Eng. Abstr.) **(Rus)**

PALMITOYL COA see **PALMITOYL COENZYME A**

PALMITOYL COA DEACYLASE see **PALMITOYL-COA HYDROLASE**

PALMITOYL-COA HYDROLASE

GENETICS

Cloning and sequencing of rat liver carboxylesterase ES-4 (microsomal palmitoyl-CoA hydrolase). Robbi M, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):821-6

Molecular cloning and expression of cDNA encoding rat brain cytosolic acyl-coenzyme A thioester hydrolase. Broustas CG, et al. **J Biol Chem** 1996 May 3; 271(18):10470-6

ISOLATION & PURIFICATION

Long-chain acyl-CoA hydrolase from rat brain cytosol: purification, characterization, and immunohistochemical localization. Yamada J, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):106-14

METABOLISM

Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs. Vázquez M, et al. **Br J Pharmacol** 1995 Dec;116(8):3337-43

Species differences in the intracellular distribution of ciprofibroyl-CoA hydrolase. Implications for peroxisome proliferation. Urrea R, et al. **FEBS Lett** 1996 Jul 1; 389(2):219-23

PALMITOYL COENZYME A

METABOLISM

Fatty acids and anionic phospholipids alter the palmitoyl coenzyme A kinetics of hepatic monoacylglycerol acyltransferase in Triton X-100 mixed micelles. Coleman RA, et al. **Biochemistry** 1996 Jul 23;35(29):9576-83

Myelin P0 glycoprotein and a synthetic peptide containing the palmitoylation site are both autoacylated. Bharadwaj M, et al. **J Neurochem** 1995 Oct;65(4):1805-15

Specific activity of brain palmitoyl-CoA pool provides rates of incorporation of palmitate in brain phospholipids in awake rats. Grange E, et al. **J Neurochem** 1995 Nov; 65(5):2290-8

PHARMACOLOGY

Inhibitory effect of 3-hydroxyacyl-CoAs and other long-chain fatty acid beta-oxidation intermediates on mitochondrial oxidative phosphorylation. Ventura FV, et al. **J Inherit Metab Dis** 1996;19(2):161-4

PALMITOYL COENZYME A HYDROLASE see **PALMITOYL-COA HYDROLASE**

PALMITOYL THIOESTERASE see **PALMITOYL-COA HYDROLASE**

PALMITOYLCARNITINE

ANALOGS & DERIVATIVES

Effect of palmitoyl carnitine isopropyl ester on the actions of BAY K 8644 and norepinephrine in the perfused rat heart. Reeves KA, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):864-70

CHEMISTRY

Palmitoylcarnitine, a surface-active metabolite. Goñi FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1-5 (45 ref.)

PHARMACOLOGY

Palmitoyl carnitine increases the transmeningeal flux of hydrophilic but not hydrophobic compounds in vitro. Bernards CM, et al. **Anesthesiology** 1996 Feb;84(2):392-6

PHYSIOLOGY

Palmitoylcarnitine, a surface-active metabolite. Goñi FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1-5 (45 ref.)

PALMITYLCARNITINE see **PALMITOYLCARNITINE**

PALMOPLANTAR KERATODERMA see **KERATODERMA, PALMOPLANTAR**

PALMOPLANTARIS PUSTULOSIS see **PSORIASIS**

PALPATION

The palpation of pulses. Mather C, et al. **Anaesthesia** 1996 Feb;51(2):189-91

Assessment of peritonism in appendicitis [letter] Guy RJ, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234-5

Assessment of peritonism in appendicitis [letter] Hamer DB. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

Assessment of peritonism in appendicitis [letter] Thomson H. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

DRE-PSA data revisited: PSA sampling should precede DREs [letter] Douville P, et al. **Arch Intern Med** 1996 Jun 24;156(12):1352-3

Solitary thyroid nodule. Comparison between palpation and ultrasonography. Tan GH, et al. **Arch Intern Med** 1995 Dec 11-25;155(22):2418-23

Diastolic blood pressure can be reliably recorded by palpation [letter] Vaidya JS, et al. **Arch Intern Med** 1996 Jul 22;156(14):1586

Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75-9 (28 ref.)

Feeling lumps and bumps in foot surgery. Pomeroy G, et al. **Foot Ankle Int** 1995 Jul;16(7):452

Screening for prostate cancer [letter; comment] Benbassat J. **Isr J Med Sci** 1995 Sep;31(9):579-80. Comment on: Isr J Med Sci 1995 Feb-Mar;31(2-3):125-8.

Does palpability of primary cutaneous melanoma predict dermal invasion? O'Donnell BF, et al. **J Am Acad Dermatol** 1996 Apr;34(4):632-7

Results of an office-based training program in clinical breast examination for primary care physicians. Benincasa TA, et al. **J Cancer Educ** 1996 Spring;11(1):25-31

PALPATION

Putting a finger on the deep inguinal ring. Andrews BT, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):90–2

Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. Huland H, et al. **J Urol** 1996 Apr;155(4):1344–7

Usefulness of ultrasonography combined with conventional physical examination in mass screening for breast cancer: a retrospective study of Yamanashi Health Care Center results from 1989 to 1994. Okamoto H, et al. **Jpn J Cancer Res** 1996 Mar;87(3):317–23

Diabetic mastopathy: a clinicopathologic study in palpable and nonpalpable breast lesions. Morgan MC, et al. **Mod Pathol** 1995 May;8(4):349–54

Are tender point scores assessed by manual palpation in fibromyalgia reliable? An investigation into the variance of tender point scores. Jacobs JW, et al. **Scand J Rheumatol** 1995;24(4):243–7

Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen. Ciatto S, et al. **Tumori** 1995 Jul–Aug;81(4):225–9

[The value of aspiration cytology within the scope of triple diagnosis of palpable breast changes] Schuhmann R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):553–8 (Eng. Abstr.) **(Ger)**

[Detection of breast carcinoma: a statistical–epidemiological study of the current situation] Schleicher UM. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Dec;163(6):469–73 (Eng. Abstr.) **(Ger)**

[How to measure the pulse? (letter)] Ekeström S. **Lakartidningen** 1996 Apr 17;93(16):1510 **(Swe)**

ADVERSE EFFECTS

The effect of routine breast examination on serum prolactin levels. Hammond KR, et al. **Fertil Steril** 1996 Apr; 65(4):869–70

INSTRUMENTATION

Pressure-controlled palpation [letter; comment] Atkins CJ, et al. **Cephalalgia** 1996 Apr;16(2):127–8. Comment on: Cephalalgia 1995 Jun;15(3):205–10.

Palpometry: a novel concept in pain measurement. Atkins CJ, et al. **Nat Med** 1995 Nov;1(11):1138–9

Pressure-sensitive devices [letter] Bendtsen L, et al. **Pain** 1995 Aug;62(2):250

METHODS

Pressure-controlled palpation: a new technique which increases the reliability of manual palpation [see comments] Bendtsen L, et al. **Cephalalgia** 1995 Jun;15(3):205–10. Comment in: Cephalalgia 1996 Apr;16(2):127–8.

Palpable unilateral sacral prominence as a clinical sign of lower limb anisomelia: a pilot study. Montgomery DM, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug; 18(6):353–6

Comments on Bendtsen et al. (PAIN, 59 (1994) 235–239) [letter; comment] Atkins CJ, et al. **Pain** 1995 Aug; 62(2):249–50. Comment on: Pain 1994 Nov;59(2):235–9.

Optimal methods for shoulder tendon palpation: a cadaver study. Mattingly GE, et al. **Phys Ther** 1996 Feb; 76(2):166–73

STANDARDS

Assessment of noninvasive lower extremity arterial testing versus pulse exam. Kazmers A, et al. **Am Surg** 1996 Apr; 62(4):315–9

Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their relation to outcome for women with primary breast cancer. Steinberg JL, et al. **Can J Surg** 1996 Aug; 39(4):302–11

STATISTICS & NUMERICAL DATA

Is manual palpation of uterine contractions accurate? Arrabal PP, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):217–9

VETERINARY

The zygomatic branch of the auriculopalpebral nerve: can it be normally palpated in the live horse? McCarthy PH. **Anat Histol Embryol** 1996 Mar;25(1):7–10

[Intestinal perforation in a llama mare following rectal palpation (veterinary expert opinion)] Steffen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):330–1 (Eng. Abstr.) **(Ger)**

PALSY, PROGRESSIVE SUPRANUCLEAR see **SUPRANUCLEAR PALSY, PROGRESSIVE**

PALYAM VIRUS see **ORBIVIRUS**

2-PAM COMPOUNDS see **PRALIDOXIME COMPOUNDS**

PAMPHLETS

ACOG issues technical bulletin on domestic violence. American College of Obstetricians and Gynecologists. **Am Fam Physician** 1995 Dec;52(8):2387–8, 2391

Recall, retention, utilisation and acceptability of written health education materials. Newell S, et al. **Aust J Public Health** 1995 Aug;19(4):368–74

Assertions about patient information are not supported [letter; comment] Dixon M. **BMJ** 1995 Oct 7;311(7010):946. Comment on: BMJ 1995 Jul 1;311(6996):4–5.

Meat and Livestock Commission's advertising campaign. Commission emphasises nutritional value of meat in booklet for new mothers [letter] Glynn JR. **BMJ** 1996 Jan 20; 312(7024):181

Child health booklets lack illustration of meningococcal rash [letter] Watkinson M, et al. **BMJ** 1995 Dec 2;311(7018):1504

Reducing anxiety [letter; comment] Hutchison BH. **Br Dent J** 1995 Nov 25;179(10):372. Comment on: Br Dent J 1995 Sep 9;179(5):163–7.

Reducing anxiety in new dental patients by means of leaflets [see comments] Jackson C, et al. **Br Dent J** 1995 Sep 9; 179(5):163–7. Comment in: Br Dent J 1995 Nov 25;179(10):372.

Information leaflets on contraception [letter] Metson D, et al. **Br J Gen Pract** 1995 Dec;45(401):691–2

Effect of leaflets on contraception [letter] Sadler M. **Br J Gen Pract** 1996 Apr;46(405):256

Single-blind randomized controlled trial of an educational booklet for patients with chronic arthritis. Maggs FM, et al. **Br J Rheumatol** 1996 Aug;35(8):775–7

ADA and AAOM produce HIV treatment resource [news] **J Am Dent Assoc** 1995 Nov;126(11):1480

Development of a nutrition exchange booklet for Guam using culturally accepted foods. Pobocik RS, et al. **J Am Diet Assoc** 1996 Mar;96(3):285–7

Reading level, learning presentation preference, and desire for information among cancer patients. Foltz A, et al. **J Cancer Educ** 1996 Spring;11(1):32–8

Revision of "NHS breast screening: the facts": an evaluation. Patnick J, et al. **J Med Screen** 1995;2(1):15–7

Information leaflets [editorial] Smith AJ. **J Med Screen** 1995; 2(1):3–4

Personal child health record and advice booklet programme in Tuzla, Bosnia Herzegovina. McMaster P, et al. **J R Soc Med** 1996 Apr;89(4):202–4

Patient handouts from the internet [news] Zelingher J. **MD Comput** 1995 Sep–Oct;12(5):338–44, 347, 349–50 passim

Article on patient-education materials neglects literature with a general theme [letter] Agre P, et al. **Oncol Nurs Forum** 1996 Apr;23(3):422

Educating women about early detection of gynecologic cancers using a brochure. Mahon SM. **Oncol Nurs Forum** 1996 Apr;23(3):529–31

Using brochures to educate the public about the early detection of prostate and colorectal cancer. Mahon SM. **Oncol Nurs Forum** 1995 Oct;22(9):1413–20

Information for women: management of menopausal symptoms. Mayer DK, et al. **Oncol Nurs Forum** 1995 Nov–Dec;22(10):1567–70

Nurse questions readability of patient-education brochures [letter] Rowley JA. **Oncol Nurs Forum** 1996 Apr;23(3):421

Suggestions help nurses develop patient education materials. Young-McCaughan S. **Oncol Nurs Forum** 1996 Apr; 23(3):541

Parent comprehension of polio vaccine information pamphlets. Davis TC, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):804–10

All about AIDS [news] **Science** 1995 Nov 10;270(5238):919

Development of a health education booklet to enhance adherence to tuberculosis treatment. Dick J, et al. **Tuber Lung Dis** 1996 Apr;77(2):173–7

PAN see **CHIMPANSEE TROGLODYTES**

PAN AMERICAN HEALTH ORGANIZATION

Biotechnology research training grants program. **Bull Pan Am Health Organ** 1995 Sep;29(3):283–5

Elimination of congenital syphilis. **Bull Pan Am Health Organ** 1995 Dec;29(4):364–8

Health of indigenous peoples initiative. **Bull Pan Am Health Organ** 1995 Dec;29(4):369–72

Influence of PAHO publications on scientific production in the health field in Latin America and the Caribbean. Cruz A. **Bull Pan Am Health Organ** 1996 Jun;30(2):144–57

Introduction of new vaccines in the National Vaccination Programs. **Epidemiol Bull** 1996 Mar;17(1):12–4

[The 30th Meeting of the Advisory Committee on Health Research] **Bol Oficina Sanit Panam** 1995 Dec;119(6):538–46 **(Spa)**

[Influence of PAHO publications on the scientific health production in Latin America and the Caribbean] Cruz A. **Bol Oficina Sanit Panam** 1995 Dec;119(6):515–28 **(Spa)**

PANAX see **GINSENG**

PANCOAST'S SYNDROME

DIAGNOSIS

[Pancoast syndrome in a patient with malignant lymphoma arising from the pleura] Kobara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):85–9 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Treatment of Pancoast tumors. Combined irradiation and radical resection. Okubo K, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):284–6

SURGERY

Treatment of Pancoast tumors. Combined irradiation and radical resection. Okubo K, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):284–6

[Surgical treatment for Pancoast tumor of the lung] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):728–31 **(Jpn)**

[Surgical treatment of apical invading lung cancer] Okubo K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul; 43(7):941–5 (Eng. Abstr.) **(Jpn)**

PANCREAS

see related
PANCREATECTOMY
PANCREATICOJEJUNOSTOMY

Heterotopic pancreas. A difficult diagnosis. Mönig SP, et al. **Dig Dis Sci** 1996 Jun;41(6):1238–40

Esophageal heterotopic pancreas presenting as an inflammatory mass. Noffsinger AE, et al. **Dig Dis Sci** 1995 Nov;40(11):2373–9

Endoscopic and histological appearance of pancreatic metaplasia in the human gastric mucosa: a preliminary report on a recently recognized new type of gastric mucosal metaplasia. Stachura J, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):239–43

Aberrant pancreatic tissue causing gastric ulcer and pyloric obstruction. Patil PU, et al. **Indian Pediatr** 1995 Aug; 32(8):930–2

Anaplastic carcinoma arising in ectopic pancreas located in the distal esophagus. Roshe J, et al. **J Clin Gastroenterol** 1996 Apr;22(3):242–4

Complex lesion of the gastric wall: an unusual presentation of ectopic pancreas. Laurent T, et al. **J Clin Ultrasound** 1995 Sep;23(7):438–41

Preoperative ultrasound diagnosis of a gastric duplication cyst with ectopic pancreas in a child. Blais C, et al. **J Pediatr Surg** 1995 Sep;30(9):1384–6

The mechanism of action of the two-layer cold storage method in canine pancreas preservation--protection of pancreatic microvascular endothelium. Fujita H, et al. **Kobe J Med Sci** 1995 Jun;41(3):47–61

A pancreatic cyst of the anterior mediastinum. Perez-Ordonez B, et al. **Mod Pathol** 1996 Mar;9(3):210–4

Heterotopic gastrointestinal and pancreatic tissue of the tongue: a case report. Khunamornpong S, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):576–9

Adenovirus-mediated in vivo gene transfer and expression in normal rat pancreas. Raper SE, et al. **Pancreas** 1996 May;12(4):401–10

The efficacy of CMH (Collins modified with HES) solution in canine pancreatic graft preservation. Arita S, et al. **Transplant Proc** 1995 Dec;27(6):3035–6

Comparison of histidine-tryptophane-ketoglutarate (HTK) and University of Wisconsin (UW) solution for pancreas perfusion prior to islet isolation, culture and transplantation. Brandhorst H, et al. **Transplant Proc** 1995 Dec;27(6):3175–6

Organ specificity of pancreas preservation compared with kidney and heart preservation. Kin S, et al. **Transplant Proc** 1996 Feb;28(1):335–6

Prevention of reperfusion injury after rat pancreas preservation using rinse solution containing nafamostat mesilate. Urushihara T, et al. **Transplant Proc** 1996 Jun; 28(3):1874–5

Resuscitation of ischemically damaged pancreas during short-term preservation at 20 degrees C by the two-layer (University of Wisconsin solution/perfluorochemical) method. Kuroda Y, et al. **Transplantation** 1996 Jan 15; 61(1):28–30

[Papillary cystic neoplasms in the ectopic pancreas] Kövári E, et al. **Orv Hetil** 1996 Apr 28;137(17):923–5 (Eng. Abstr.) **(Hun)**

[A case of symptomatic aberrant pancreas: a diagnostic and therapeutic usefulness of endoscopic aspiration mucosectomy] Torii K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):176–80 **(Jpn)**

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360–2 (17 ref.) **(Jpn)**

[Ectopy of the pancreas in the walls of the stomach and duodenum] Shidlovs'kiĭ VO, et al. **Klin Khir** 1996;(1):8–9 **(Ukr)**

ABNORMALITIES

Pancreas divisum [letter; comment] Cotton PB. **Am J Gastroenterol** 1995 Oct;90(10):1898. Comment on: Am J Gastroenterol 1995 Feb;90(2):333.

Annular pancreas in two sisters [letter] Claviez A, et al. **Am J Med Genet** 1995 Sep 25;58(4):384

Case report: agenesis of the dorsal pancreas: a cause of diagnostic error on abdominal sonography. Deignan RW, et al. **Clin Radiol** 1996 Feb;51(2):145–7

Endoscopic approach to pancreas divisum. Kozarek RA, et al. **Dig Dis Sci** 1995 Sep;40(9):1974–81

Pancreas divisum imitating malignancy in a patient with a cystadenoma. Dohmoto M, et al. **Endoscopy** 1995 Jun; 27(5):413

Clinical course and morphological features of chronic calcifying pancreatitis associated with pancreas divisum. Barthet M, et al. **Eur J Gastroenterol Hepatol** 1995 Oct; 7(10):993–8

Complete and partial agenesis of the dorsal pancreas within one family. Schnedl WJ, et al. **Gastrointest Endosc** 1995 Nov;42(5):485–7

Absent minor papilla and an unusual drainage system in a patient with pancreas divisum. Venu RP, et al. **Gastrointest Endosc** 1995 Aug;42(2):173–5

Duodenal obstruction due to annular pancreas associated with pancreatic head carcinoma. Yasui A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1017–22

Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. Bradley EL 3rd, et al. **J Am Coll Surg** 1996 Jul;183(1):65–70

Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Renal-hepatic-pancreatic dysplasia: an autosomal recessive malformation. Torra R, et al. **J Med Genet** 1996 May; 33(5):409–12

Thrombotic thrombocytopenic purpura caused by acute pancreatitis in a woman with a pancreas divisum: a case report [letter] Malka D, et al. **Pancreas** 1996 May; 12(4):414–6

Pancreas divisum: evaluation with MR cholangiopancreatography. Bret PM, et al. **Radiology** 1996 Apr;199(1):99–103

[Annular pancreas: ultrasound endoscopy too (letter)] Davion T, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):218–9 **(Fre)**

[Familial congenital short pancreas (letter)] Latrive JP, et al. **Gastroenterol Clin Biol** 1995 May;19(5):546–7 **(Fre)**

[Acute pancreatitis disclosing an uncommon form of annular pancreas] Sevenet F, et al. **Gastroenterol Clin Biol** 1996; 20(5):494–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Cystic dystrophy on an aberrant duodenal pancreas. Apropos of a case (letter)] Barsotti P, et al. **J Chir (Paris)** 1995 Dec;132(12):503–5 (Eng. Abstr.) **(Fre)**

[Developmental anomalies and congenital diseases of the pancreas] Brambs HJ. **Radiologe** 1996 May;36(5):381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

[Annular pancreas—congenital anomaly as the cause of chronic calcifying pancreatitis in a 73-year-old patient] Stacher VR, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):347–9 **(Ger)**

[Anomalous arrangement of the pancreaticobiliary ductal system] Matsumoto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):163–6 (10 ref.) **(Jpn)**

[Annular pancreas] Korchak AM, et al. **Khirurgiia (Mosk)** 1995;(6):55–8 **(Rus)**

[High obstruction of the gastrointestinal tract due to an accessory pancreas in an 8-month-old child] Lundin GA. **Vestn Khir Im I I Grek** 1995;154(3):68 **(Rus)**

ANATOMY & HISTOLOGY

Changes in the mouse exocrine pancreas after pancreatic duct ligation: a qualitative and quantitative histological study. Watanabe S, et al. **Arch Histol Cytol** 1995 Aug;58(3):365–74

Size of the pancreas in type I diabetic children and adolescents [letter] Chiarelli F, et al. **Diabetes Care** 1995 Nov;18(11):1505–6

Enhancement of the normal pancreas: comparison of manganese-DPDP and gadolinium chelate. Kettritz U, et al. **Eur Radiol** 1996;6(1):14–8

[The modern aspects of the microsurgical anatomy of the pancreas] Zheleznov LM. **Morfologiia** 1995;108(2):76–80 (79 ref.) **(Rus)**

BLOOD SUPPLY

Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT [see comments] Loyer EM, et al. **Abdom Imaging** 1996 May–Jun;21(3):202–6. Comment in: Abdom Imaging 1996 May–Jun;21(3):207–10.

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)

Superior pancreaticoduodenal artery aneurysm rupture presenting with hemorrhage from the ampulla of Vater into the gastrointestinal tract. Krmpotich PT, et al. **Am J Gastroenterol** 1995 Nov;90(11):2046–7

Effect of ACh and calmodulin inhibitor on O2 transfer from exocrine pancreatic microvessels of rats. Seiyama A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H1–7

Multidisciplinary approach to pseudoaneurysms complicating pancreatic pseudocysts. Impact of pretreatment diagnosis. Marshall GT, et al. **Arch Surg** 1996 Mar;131(3):278–83

Alterations of insulin response to different beta cell secretagogues and pancreatic vascular resistance induced by N omega-nitro-L-arginine methyl ester. Gross R, et al. **Br J Pharmacol** 1995 Oct;116(3):1965–72

Bradykinin antagonists HOE-140 and CP-0597 diminish microcirculatory injury after ischaemia-reperfusion of the pancreas in rats. Hoffmann TF, et al. **Br J Surg** 1996 Feb; 83(2):189–95

Small-volume resuscitation restores hemorrhage-induced microcirculatory disorders in rat pancreas. Vollmar MD, et al. **Crit Care Med** 1996 Mar;24(3):445–50

Effect of microcirculatory perfusion on distribution of trypsinogen activation peptides in acute experimental pancreatitis. Foitzik T, et al. **Dig Dis Sci** 1995 Oct; 40(10):2184–8

Ischemia-reperfusion-induced pancreatic microvascular injury. An intravital fluorescence microscopic study in rats [see comments] Menger MD, et al. **Dig Dis Sci** 1996 May; 41(5):823–30. Comment in: Dig Dis Sci 1996 May;41(5):821–2.

Pancreatic arteriovenous malformation with duodenal ulcer. Demonstration by color Doppler ultrasonography. Tano S, et al. **Dig Dis Sci** 1996 Jun;41(6):1232–7

Ischemia- and reperfusion-related injury in pancreatitis [editorial; comment] Warshaw AL. **Dig Dis Sci** 1996 May; 41(5):821–2 (18 ref.). Comment on: Dig Dis Sci 1996 May;41(5):823–30.

Bleeding pancreatic pseudoaneurysms. Grønlund J, et al. **Eur J Surg** 1995 Oct;161(10):767–70

Glue embolisation of a ruptured pancreaticoduodenal artery aneurysm. Hammer FD, et al. **Eur Radiol** 1996;6(4):514–7

Extrahepatic biliary obstruction resulting from a pancreatic pseudoaneurysm. Sharara AI, et al. **Gastrointest Endosc** 1995 Aug;42(2):176–7

Pancreatic vascular regulation [letter; comment] Reber PU, et al. **Gut** 1995 Dec;37(6):849. Comment on: Gut 1995 Jan;36(1):133–6.

Role of xanthine oxidase and eicosanoids in development of pancreatic ischemia-reperfusion injury. Hotter G, et al. **Inflammation** 1995 Aug;19(4):469–78

Reflectance spectroscopy of pancreatic microcirculation. Knoefel WT, et al. **J Appl Physiol** 1996 Jan;80(1):116–23

Role of endogenous platelet-activating factor in the regulation of pancreatic blood flow during caerulein stimulation. Ogura M, et al. **J Gastroenterol** 1996 Jun; 31(3):414–9

Exogenous bradykinin enhances ischemia/reperfusion injury of pancreas in rats. Hoffmann TF, et al. **J Surg Res** 1996 Apr;62(1):144–51

Determinants of pancreatic microcirculation in acute pancreatitis in rats. Kerner T, et al. **J Surg Res** 1996 May; 62(2):165–71

Aneurysms of the pancreaticoduodenal artery. Paty PS, et al. **J Vasc Surg** 1996 Apr;23(4):710–3 (12 ref.)

alpha-Tocopherol pretreatment protects the endocrine function of grafts against ischemic damage during heterotopic pancreatic transplantation. Ikeda M, et al. **Life Sci** 1996;59(10):781–8

Effect of a platelet-activating factor antagonist on pancreas perfusion after 24 h of ischemia. Leonhardt U, et al. **Pancreas** 1995 Aug;11(2):160–4

Hyperinsulinism in children: diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Dubois J, et al. **Pediatr Radiol** 1995;25(7):512–6

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

Effects of the biguanide metformin on splanchnic blood flow in rats: preferential and dose-dependent increase in islet blood flow. Jansson L. **Pharmacology** 1995 Jun;51(1):43–7

Pancreas allograft rejection: correlation of transduodenal core biopsy with Doppler resistive index. Nelson NL, et al. **Radiology** 1996 Jul;200(1):91–4

Ischemia reperfusion of the pancreas: a new in vivo model for acute pancreatitis in rats. Hoffmann TF, et al. **Res Exp Med (Berl)** 1995;195(3):125–44

The arterial blood supply of the pancreas: a review. II. The posterior superior pancreaticoduodenal artery. An anatomical and radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(1):1–9 (51 ref.)

The arterial blood supply of the pancreas: a review. I. The superior pancreaticoduodenal and the anterior superior pancreaticoduodenal arteries. An anatomical and radiological study. Bertelli E, et al. **Surg Radiol Anat** 1995; 17(2):97–106, 1–3 (61 ref.) **(Eng, Fre)**

The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)

Evaluation of DNA injury in Langerhans' cells after warm ischemia of the pancreas in the rat. Saito T, et al. **Transplant Proc** 1996 Jun;28(3):1982–5

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahlke R, et al. **Z Gastroenterol** 1995 Jul;33(7):404–7

[Vasoconstrictor effect of uridine triphosphate on pancreatic vascular bed] Hillaire-Buys D, et al. **C R Seances Soc Biol Fil** 1995;189(2):333–8 (Eng. Abstr.) **(Fre)**

[Bradykinin antagonism in ischemia and reperfusion of the pancreas] Hoffmann T, et al. **Zentralbl Chir** 1996; 121(5):412–22; discussion 422–3 (Eng. Abstr.) **(Ger)**

[Hemorrhage caused by rupture into the duodenum of aneurysm of a branch of the pancreaticoduodenal artery (posterior superior or retroduodenal pancreaticoduodenal artery)] Maragliano S, et al. **G Chir** 1996 Jan–Feb; 17(1–2):19–21 (Eng. Abstr.) **(Ita)**

[A case of pancreatic arteriovenous malformation—understanding of its pathophysiology with a color Doppler ultrasonography] Imano E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1799–803 **(Jpn)**

[Vascular factors in the mechanism of acute pancreatitis] Sendur R, et al. **Przegl Lek** 1996;53(1):41–5 (38 ref.) (Eng. Abstr.) **(Pol)**

[Changes in blood supply of the pancreas in patients with gastric cancer after surgery] Kursov SV, et al. **Klin Khir** 1995;(5):15–7 **(Rus)**

[Deportalization of the pancreatic venous outflow in the combined treatment of diabetics] Ol'shanetskiĭ AA, et al. **Klin Khir** 1995;(9–10):3–5 **(Rus)**

CHEMISTRY

Analysis of isolated zymogen granules from rat pancreas using flow cytometry. de Dios I, et al. **Anal Cell Pathol** 1995 Oct;9(3):215–28

RNA extraction from gastrointestinal tract and pancreas by a modified Chomczynski and Sacchi method. Monstein HJ, et al. **Biotechniques** 1995 Sep;19(3):340–4

A novel profile of expressed sequence tags for zinc finger encoding genes from the poorly differentiated exocrine pancreatic cell line AR4IP. Gebelein B, et al. **Cancer Lett** 1996 Aug 2;105(2):225–31

Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Gansauge F, et al. **Cancer Res** 1995 Dec 1;55(23):5499–503

Ontogenetic development of neuropeptide Y-like-immunoreactive cells in the gastroenteropancreatic endocrine system of the dogfish. Chiba A, et al. **Cell Tissue Res** 1995 Oct;282(1):33–40

Amount and distribution of collagen in pancreatic tissue of different species in the perspective of islet isolation procedures. van Suylichem PT, et al. **Cell Transplant** 1995 Nov–Dec;4(6):609–14

Diurnal variability of cysteine and glutathione content in the pancreas and liver of the mouse. Neuschwander-Tetri BA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May;114(1):91–5

Mammalian homologue of the calcium-sensitive phosphoglycoprotein, parafusin. Wyroba E, et al. **Eur J Cell Biol** 1995 Dec;68(4):419–26

Mouse R-cadherin: expression during the organogenesis of pancreas and gastrointestinal tract. Sjödin A, et al. **Exp Cell Res** 1995 Dec;221(2):413–25

Immunocytochemical detection of islet hormones in the digestive system of Protopterus annectens. Tagliaferro G, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):288–98

In situ localization with digoxigenin-labelled probes of tau-related mRNAs in the rat pancreas. Neuville P, et al. **Histochem J** 1995 Aug;27(8):565–74

Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Shimoyama S, et al. **Int J Pancreatol** 1995 Dec;18(3):227–34

Expression of sulfated gp300 and changes in glycosylation during pancreatic development. De Lisle RC, et al. **J Histochem Cytochem** 1996 Jan;44(1):57–66

Use of post mortem and in vitro tissue specimens for X-ray microanalysis. Hongpaisan J, et al. **J Microsc** 1995 Nov; 180 (Pt 2):93–105

Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. Elgamal AA, et al. **J Urol** 1996 Aug;156(2 Pt 1):464–8

Growth factors in the regenerating pancreas of gamma-interferon transgenic mice. Arnush M, et al. **Lab Invest** 1996 Jun;74(6):985–90

Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells. Chappell MC, et al. **Peptides** 1995;16(4):741–7

Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. Monstein HJ, et al. **Scand J Gastroenterol** 1996 Apr; 31(4):383–90

[Simultaneous study of duodenal and biliopancreatic bicarbonates in rats] Lesur G, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):613–8 (Eng. Abstr.) **(Fre)**

CYTOLOGY

Neonatal rat islets of Langerhans and fetal rat pancreas. Isolation, immunohistochemical, functional, and autoradiographic evaluation. Yderstraede KB, et al. **Acta Diabetol** 1995 Jun;32(2):95–101

Giant mitochondria induced in rat pancreatic exocrine cells by ethanol and iron. Tandler B, et al. **Anat Rec** 1996 May; 245(1):65–75

Apoptosis of mouse pancreatic acinar cells after duct ligation. Abe K, et al. **Arch Histol Cytol** 1995 Jun;58(2):221–9

Protein kinase C activation inhibits receptor-evoked inositol trisphosphate formation and induction of cytosolic calcium oscillations by decreasing the affinity-state of the cholecystokinin receptor in pancreatic acinar cells. Willems PH, et al. **Cell Calcium** 1995 Dec;18(6):471–83

Establishment and characterization of a new, spontaneously immortalized, pancreatic ductal cell line from the Syrian golden hamster. Takahashi T, et al. **Cell Tissue Res** 1995 Oct;282(1):163–74

Duct– to islet–cell differentiation and islet growth in the pancreas of duct–ligated adult rats. Wang RN, et al. **Diabetologia** 1995 Dec;38(12):1405–11

Rab3D localizes to secretory granules in rat pancreatic acinar cells. Valentijn JA, et al. **Eur J Cell Biol** 1996 May; 70(1):33–41

Effect of prophylactic insulin treatment on the number of ER–MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta–cell rest? Jansen A, et al. **J Autoimmun** 1996 Jun;9(3):341–8

Fundamental cellular heterogeneity of the exocrine pancreas. Jeraldo TL, et al. **J Histochem Cytochem** 1996 Mar; 44(3):215–20

Hepatocyte growth factor is a potent mitogen for normal human pancreas cells in vitro. Vilá MR, et al. **Lab Invest** 1995 Sep;73(3):409–18

Toward understanding pancreatic disease: from architecture to cell signaling. Bockman DE. **Pancreas** 1995 Nov; 11(4):324–9 (29 ref.)

Different time courses of GTP[gamma–S]–induced exocytosis and current oscillations in isolated mouse pancreatic acinar cells. Schmid A, et al. **Pflugers Arch** 1996 Sep;432(5):876–84

Viability of islet–contaminated acinar cells as assessed by cholecystokinin stimulation. Atiya A, et al. **Transplant Proc** 1995 Dec;27(6):3245

Human pancreatic dissociation using a purified enzyme blend. Fetterhoff TJ, et al. **Transplant Proc** 1995 Dec;27(6):3282–3

Development of a cell line from the human fetal pancreas. Levine F, et al. **Transplant Proc** 1995 Dec;27(6):3410

Increase of islet yields obtained from human pancreas donor following change of pH value in collagenase digestion medium. Lu S, et al. **Transplant Proc** 1995 Dec;27(6):3202–4

Immuno–histochemical and ultrastructural study of adult porcine pancreas during the different steps of islet isolation. Vantyghem MC, et al. **Transplant Proc** 1995 Dec; 27(6):3372–4

Image analysis of human pancreatic islets: a time–course approach to the evaluation of pancreatic dissociation. Wile KJ, et al. **Transplant Proc** 1995 Dec;27(6):3246–7

[Pancreatic (acinar) metaplasia of the gastric mucosa (letter)] Grouls V. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):425 **(Ger)**

DRUG EFFECTS

Ca(2+)–dependent amylase secretion from SLO–permeabilized rat pancreatic acini requires diffusible cytosolic proteins. Padfield PJ, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G647–52

Okadaic acid disrupts Golgi structure and impairs enzyme synthesis and secretion in the rat pancreas. Waschulewski IH, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G939–47

Response of the calf pancreas to differently processed soya bean and pea diets. Le Dréan G, et al. **Ann Nutr Metab** 1995;39(3):164–76

Protein phosphatase inhibitors potentiate Ca2+/calmodulin–dependent protein kinase II activity in rat pancreatic acinar cells. Hwang J, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):520–4

Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin. Belorgey D, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):555–60

Effects of aminoguanidine on rat pancreatic islets in culture and on the pancreatic islet blood flow of anaesthetized rats. Holstad M, et al. **Biochem Pharmacol** 1996 Jun 28; 51(12):1711–7

Pesticidal impact on the protein metabolism of freshwater field crab, Oziotelphusa senex senex (Fabricius). Radhakrishnaiah K, et al. **Biomed Environ Sci** 1995 Jun; 8(2):137–48

Distribution and photodynamic effects of meso–tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Mlkvy P, et al. **Br J Cancer** 1996 Jun;73(12):1473–9

Pharmacological profile of TP–680, a new cholecystokininA receptor antagonist. Akiyama T, et al. **Br J Pharmacol** 1996 Apr;117(7):1558–64

Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Bertrand G, et al. **Br J Pharmacol** 1996 Feb;117(4):764–70

Gut peptide receptors in pancreata of azaserine–treated and normal control rats. Tang C, et al. **Carcinogenesis** 1995 Dec; 16(12):2951–6

Transforming growth factor–alpha and epidermal growth factor expression in the exocrine pancreas of azaserine–treated rats: modulation by cholecystokinin or a low fat, high fiber (caloric restricted) diet. Visser CJ, et al. **Carcinogenesis** 1995 Sep;16(9):2075–82

Inositol trisphosphate and cyclic ADP–ribose–mediated release of Ca2+ from single isolated pancreatic zymogen granules. Gerasimenko OV, et al. **Cell** 1996 Feb 9; 84(3):473–80

Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan–induced diabetes. Buko V, et al. **Cell Biochem Funct** 1996 Jun; 14(2):131–7

Nafamostat enhances IBMX and secretin–stimulated water and bicarbonate secretion in the isolated, blood–perfused dog pancreas. Horiuchi A, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):987–9

Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.

Action of CCK on CDE diet–induced acute pancreatitis in rats treated with hydrocortisone. Manso MA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):257–63

Multiple, coordinated Ca2+ –release events underlie the inositol trisphosphate–induced local Ca2+ spikes in mouse pancreatic acinar cells. Thorn P, et al. **EMBO J** 1996 Mar 1;15(5):999–1003

Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Martínez A, et al. **Endocrinology** 1996 Jun;137(6):2626–32

Diradylglycerol formation in cholecystokinin–stimulated rabbit pancreatic acini. Assessment of precursor phospholipids by means of molecular species analysis. Hermans SW, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):73–81

Ochratoxin A impairs activity of the membrane bound enzymes in rat pancreas. Zanić–Grubišić T, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):699–704

Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreatoduodenal resection. Petrin P, et al. **Eur Surg Res** 1995;27(6):371–8

Thimerosal modulates the agonist–specific cytosolic Ca2+ oscillatory patterns in single pancreatic acinar cells of mouse. Wu J, et al. **FEBS Lett** 1996 Jul 22;390(2):149–52

Acute ethanol administration induces oxidative changes in rat pancreatic tissue. Altomare E, et al. **Gut** 1996 May; 38(5):742–6

Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells. Laine VJ, et al. **Gut** 1996 May;38(5):747–52

Morphological and histochemical changes in the liver and pancreas of gilthead, Sparus auratus L., induced by acute action of the anionic detergent, sodium dodecyl sulphate. Ribelles A, et al. **Histol Histopathol** 1995 Oct;10(4):781–7

Effect of orally administered betel leaf (Piper betle Linn.) on digestive enzymes of pancreas and intestinal mucosa and on bile production in rats. Prabhu MS, et al. **Indian J Exp Biol** 1995 Oct;33(10):752–6

Structural and functional changes of rat exocrine pancreas exposed to nicotine. Chowdhury P, et al. **Int J Pancreatol** 1995 Dec;18(3):257–64

Aprotinin inhibits unspecific degradation of collagen in rat and human pancreas. López JM, et al. **Int J Pancreatol** 1996 Feb;19(1):55–60

Effect of neurotensin on pancreatic growth and pancreatic polyamine metabolism in rats. Löser C, et al. **Int J Pancreatol** 1995 Oct;18(2):107–15

Time–course of the pancreatic changes following long–term stimulation or inhibition of the CCK–A receptor. Ohlsson B, et al. **Int J Pancreatol** 1995 Aug;18(1):59–66

Chronic oral administration of synthetic trypsin inhibitor camostate reduces amylase release from isolated rat pancreatic acini. Otsuki M, et al. **Int J Pancreatol** 1995 Oct;18(2):135–43

Survival and morphology of isolated pancreatic acinar cells from rats with induced acute pancreatitis are not improved with anti–inflammatory drugs. Richter F, et al. **Int J Pancreatol** 1995 Oct;18(2):145–52

The effect of chronic intraperitoneal infusion of bacterial endotoxin on exocrine pancreas function in rats. Vaccaro MI, et al. **Int J Pancreatol** 1996 Feb;19(1):49–54

Somatostatin inhibits pancreatic exocrine secretion centrally via sympathetic nerves in conscious rats. Masuda M, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):31–7

Control of gamma–glutamyl transpeptidase expression by glucocorticoids in the rat pancreas. Correlation with granule formation. Chobert MN, et al. **J Biol Chem** 1996 May 24;271(21):12431–7

Betacellulin and activin A coordinately convert amylase–secreting pancreatic AR42J cells into insulin–secreting cells. Mashima H, et al. **J Clin Invest** 1996 Apr 1;97(7):1647–54

Duration of anti–cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally. Moriyoshi Y, et al. **J Gastroenterol** 1996 Apr;31(2):249–53

Tryptophan modulates exocrine secretory function in rat pancreatic acini. Okutani T, et al. **J Gastroenterol** 1996 Apr; 31(2):254–9

Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. Reseland JE, et al. **J Nutr** 1996 Mar;126(3):634–42

Selective activation of exocytosis by low concentrations of ACh in rat pancreatic acinar cells. Maruyama Y. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):807–14

Pancreatic injuries in rats with fecal peritonitis: protective effect of a new synthetic protease inhibitor, sepinostat mesilate (FUT–187). Hirano T. **J Surg Res** 1996 Mar; 61(2):301–6

Effect of octreotide on pancreatic endocrine function in partial pancreatectomy. Presti M, et al. **J Surg Res** 1996 Mar;61(2):449–53

Effect of L–364,718 on pancreatic endocrine function following partial pancreatectomy. Presti ME, et al. **J Surg Res** 1996 Aug;64(2):170–5

Hepatocyte growth factor is a potent mitogen for normal human pancreas cells in vitro. Vilá MR, et al. **Lab Invest** 1995 Sep;73(3):409–18

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485–92

Effects of bradykinin on the intracellular calcium concentration of pancreatic acinar AR42J cells. Saito Y, et al. **Life Sci** 1996;58(18):1569–74

Effects of the bradykinin antagonist, icatibant (Hoe 140), on pancreas and liver functions during and after caerulein–induced pancreatitis in rats. Griesbacher T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):557–64

Exogenous insulin does not influence CCK– and meal–stimulated pancreatic secretion. Berry SM, et al. **Pancreas** 1996 May;12(4):345–50

Energy metabolism in mouse pancreas in response to different dosages of a CCK analogue. Lüthen RE, et al. **Pancreas** 1995 Aug;11(2):141–6

Lazaroids protect isolated rat pancreatic acinar cells against damage induced by free radicals. Niederau C, et al. **Pancreas** 1995 Aug;11(2):107–21

Effects of MCI–727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models. Tachibana I, et al. **Pancreas** 1996 Mar;12(2):165–72

Simultaneous presence of cAMP and cGMP exert a co–ordinated inhibitory effect on the agonist–evoked Ca2+ signal in pancreatic acinar cells. Camello PJ, et al. **Pflugers Arch** 1996 Sep;432(5):775–81

Capacitative Ca2+ influx and a Ca2+–dependent nonselective cation pathway are discriminated by genistein in mouse pancreatic acinar cells. Pfeiffer F, et al. **Pflugers Arch** 1995 Oct;430(6):916–22

Stimulating activity of A–4166 on insulin release in in situ hamster pancreatic perfusion. Seto Y, et al. **Pharmacology** 1995 Oct;51(4):245–53

A protein less sensitive to trypsin, guanidinated casein, is a potent stimulator of exocrine pancreas in rats. Hara H, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):278–84

Effect of nickel on enzymatic activities in the mouse pancreas. Funakoshi T, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):245–52

Gastrin does not stimulate growth of the rat pancreas. Chen D, et al. **Scand J Gastroenterol** 1996 Apr;31(4):404–10

In vitro effects of ethanol on human gastric and pancreatic lipolytic activities/enzymes. Sternby B, et al. **Scand J Gastroenterol** 1996 Feb;31(2):146–53

Intracerebroventricular secretin enhances pancreatic volume and bicarbonate response in rats. Conter RL, et al. **Surgery** 1996 Feb;119(2):208–13

Pituitary adenylate cyclase–activating peptide stimulates amylase release and cyclic adenosine monophosphate production in pancreatic acinar cells. Kimball BC, et al. **Surgery** 1996 Sep;120(3):554–9

Pancreatic and nephrotoxicity of immunomodulator compounds. Hammond TG, et al. **Toxicol Lett** 1995 Dec; 82–83:99–105 (17 ref.)

Viability of islet–contaminated acinar cells as assessed by cholecystokinin stimulation. Atiya A, et al. **Transplant Proc** 1995 Dec;27(6):3245

[Effect of omeprazole administration on pancreatic content of enzymes in rats] Montagnini AL, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct; 50(5):272–5 (Eng. Abstr.) **(Por)**

[Enzymatic activity of the pancreas and small intestinal mucosa in modelling of toxic hepatitis by administration of heliotrine] Karimov KhIa, et al. **Patol Fiziol Eksp Ter** 1995 Oct–Dec;(4):34–6 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1–deficient mice. Ahlgren U, et al. **Development** 1996 May;122(5):1409–16

PTP–NP, a new member of the receptor protein tyrosine phosphatase family, implicated in development of nervous system and pancreatic endocrine cells. Chiang MK, et al. **Development** 1996 Jul;122(7):2239–50

Lineage–specific morphogenesis in the developing pancreas: role of mesenchymal factors. Gittes GK, et al. **Development** 1996 Feb;122(2):439–47

PDX–1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Offield MF, et al. **Development** 1996 Mar;122(3):983–95

Maturational effects of cortisol on the exocrine abomasum and pancreas in fetal sheep. Sangild PT, et al. **Reprod Fertil Dev** 1995;7(3):655–8

E–cadherin, NCAM, and EpCAM expression in human fetal pancreata. Cirulli V, et al. **Transplant Proc** 1995 Dec; 27(6):3335

Fibrillary inclusions in neoplastic and fetal acinar cells of the pancreas. Chong JM, et al. **Virchows Arch** 1996 Jul; 428(4–5):261–6

[Hypoechogenic aspects of the ventral embryonic cephalic pancreas: a large prospective clinical study] Coulier B. **J Belge Radiol** 1996 Jun;79(3):120–4 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas. López

JM, et al. **Alcohol** 1996 May-Jun;13(3):227-31

Okadaic acid disrupts Golgi structure and impairs enzyme synthesis and secretion in the rat pancreas. Waschulewski IH, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G939-47

Description of an automated method for the in vitro measurement of trypsinogen secretion from pancreatic segments. San Román JI, et al. **Anal Biochem** 1995 Nov 20;232(1):129-32

The immobilized porcine pancreatic exopeptidases and its application in casein hydrolysates debittering. Ge SJ, et al. **Appl Biochem Biotechnol** 1996 May;59(2):159-65

Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2. Laethem RM, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):8-18

Lipopolysaccharide induces manganese superoxide dismutase in the rat pancreas: its role in caerulein pancreatitis. Abe R, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1216-22

Gene expression of pancreatic glutamic acid decarboxylase in the nonobese diabetic mouse. Pleau JM, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):399-404

Glutamic acid decarboxylase (GAD 67) gene expression in the pancreas and brain of the nonobese diabetic mouse. Pleau JM, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):747-53

Increased activity of porcine pancreatic phospholipase A2 by designed long-range electrostatic stabilisation of the transition state. Sheffield PJ, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):778-84

Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue. Sévigny J, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):351-6

Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A2. Lee BI, et al. **Biochemistry** 1996 Apr 2;35(13):4231-40

Activation of phospholipase A2 by amyloid beta-peptides in vitro. Lehtonen JY, et al. **Biochemistry** 1996 Jul 23; 35(29):9407-14

Role of the prodomain in folding and secretion of rat pancreatic carboxypeptidase A1. Phillips MA, et al. **Biochemistry** 1996 May 28;35(21):6771-6

Kinetic basis for the substrate specificity during hydrolysis of phospholipids by secreted phospholipase A2. Rogers J, et al. **Biochemistry** 1996 Jul 23;35(29):9375-84

Identification of a species specific regulatory site in human pancreatic cholesterol esterase. Spilburg CA, et al. **Biochemistry** 1995 Nov 28;34(47):15532-8

Pancreatic lipase-related protein 2 but not classical pancreatic lipase hydrolyzes galactolipids. Andersson L, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):236-40

Cellular distribution of isoforms of protein kinase C (PKC) in pancreatic acini. Bastani B, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):307-15

Mutation of the catalytic site Asp177 to Glu177 in human pancreatic lipase produces an active lipase with increased sensitivity to proteases. Lowe ME. **Biochim Biophys Acta** 1996 Jul 26;1302(2):177-83

Thioesterase and protein deacylase activities of porcine pancreatic phospholipase A2. Nocito M, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):17-22

Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. Nogués MV, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):16-24 (55 ref.)

Comparison of stored and secreted rat pancreatic digestive enzymes by mass spectrometry: alpha-amylase. Young MK, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):63-71

Effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) and related benzoquinones on porcine pancreas phospholipase A2 activity. Amano T, et al. **Biol Pharm Bull** 1995 May;18(5):779-81

Reduction of pancreatic enzyme content and mortality in experimental acute pancreatitis in rats. Machado MC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):471-5

Spacer-modified oligosaccharides with basic anchoring groups are inhibitors for endo-glycanases: porcine pancreatic alpha-amylase as model enzyme. Lehmann J, et al. **Carbohydr Res** 1995 Oct 16;276(1):43-55

The effect of UW solution and its components on the collagenase digestion of human and porcine pancreas. Contractor HH, et al. **Cell Transplant** 1995 Nov-Dec; 4(6):615-9

Stereoselectivity of lipases in supercritical carbon dioxide. I. Dependence of the regio- and enantioselectivity of porcine pancreas lipase on the water content during the hydrolysis of triolein and its partial glycerides. Glowacz G, et al. **Chem Phys Lipids** 1996 Mar 29;79(2):101-6

Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Stein J, et al. **Clin Chem** 1996 Feb;42(2):222-6

Transient elevations in pancreatic enzymes in response to a cholinesterase inhibitor [letter] Pomara N, et al. **Clin Neuropharmacol** 1995 Oct;18(5):464-5

Ontogeny and tissue distribution of human GAD expression. Mally MI, et al. **Diabetes** 1996 Apr;45(4):496-501

Effect of beer, yeast-fermented glucose, and ethanol on pancreatic enzyme secretion in healthy human subjects. Chari ST, et al. **Dig Dis Sci** 1996 Jun;41(6):1216-24

Characterization and chromosomal localization of a new protein disulfide isomerase, PDIp, highly expressed in human pancreas. Desilva MG, et al. **DNA Cell Biol** 1996 Jan;15(1):9-16

The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C. Gomis-Rüth FX, et al. **EMBO J** 1995 Sep 15;14(18):4387-94

Solution structure of porcine pancreatic phospholipase A2. van den Berg B, et al. **EMBO J** 1995 Sep 1;14(17):4123-31

Regulation of the src homology 2 domain-containing protein tyrosine phosphatase PTP1C by glucocorticoids in rat pancreatic AR42J cells. Cambillau C, et al. **Endocrinology** 1995 Dec;136(12):5476-84

Targeting of porcine pancreatic phospholipase A2 to human platelets. Introduction of an RGD sequence and acyl-group by chemical modification. Bekkers AC, et al. **Eur J Biochem** 1996 May 15;238(1):70-6

Association of bile-salt-dependent lipase with membranes of human pancreatic microsomes. Bruneau N, et al. **Eur J Biochem** 1995 Oct 1;233(1):209-18

Dietary modulation of the mRNA stability of trypsin isozymes and the two forms of secretory trypsin inhibitor in the rat pancreas. Carreira S, et al. **Eur J Biochem** 1996 Jul 1;239(1):117-23

Molecular modelling of the interaction between the catalytic site of pig pancreatic alpha-amylase and amylose fragments. Casset F, et al. **Eur J Biochem** 1995 Aug 15; 232(1):284-93

Crystal structure of pig pancreatic alpha-amylase isoenzyme II, in complex with the carbohydrate inhibitor acarbose. Gilles C, et al. **Eur J Biochem** 1996 Jun 1;238(2):561-9

Indirect examination of exocrine pancreatic function in vivo by determination of chymotrypsin activity in animal intestine using a synthetic substrate. Kaštel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):311-4

Ochratoxin A impairs activity of the membrane bound enzymes in rat pancreas. Zanić-Grubišić T, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):699-704

Human pancreatic phospholipase A2 stimulates the growth of human pancreatic cancer cell line. Hanada K, et al. **FEBS Lett** 1995 Oct 2;373(1):85-7

Lysosomal enzymes and pancreatitis [letter; comment] Steer ML, et al. **Gastroenterology** 1996 Mar;110(3):965-7. Comment on: Gastroenterology 1995 Aug;109(2):573-81.

Cloning, sequencing and expression of the gene encoding a major allotypic preprocarboxypeptidase A from bovine pancreas. Goo JH, et al. **Gene** 1995 Nov 20;165(2):333-4

Characterization of the mouse pancreatic/mammary gland cholesterol esterase-encoding cDNA and gene. Mackay K, et al. **Gene** 1995 Nov 20;165(2):255-9

Inhibitory effect of thyrotropin-releasing hormone on enzyme secretion from isolated rat pancreatic acinar cells. Kemmer TP, et al. **Horm Metab Res** 1995 Aug;27(8):367-71

Ostrich (Struthio camelus) carboxypeptidase B: purification, kinetic properties and characterization of the pancreatic enzyme. Bradley G, et al. **Int J Biochem Cell Biol** 1996 May;28(5):521-9

Nucleoside phosphatase activities on pig pancreas zymogen granule membranes analyzed by non-denaturing polyacrylamide gel electrophoresis. Soriani M, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1043-54

Identification of a glycosylphosphatidylinositol-anchored glycoprotein with nucleoside phosphatase activity on the membrane of pig pancreatic zymogen granules. Soriani M, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):683-95

Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Azuma T, et al. **Int J Cancer** 1996 Aug 7;67(4):492-7

Aprotinin inhibits unspecific degradation of collagen in rat and human pancreas. López JM, et al. **Int J Pancreatol** 1996 Feb;19(1):55-60

Importance of cooking temperature and pancreatic amylase in determination of dietary fiber in dried legumes. Mongeau R, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1444-9

Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. Dabrowski A, et al. **J Biol Chem** 1996 Mar 8;271(10):5686-90

Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro. Shamir R, et al. **J Clin Invest** 1996 Apr 1;97(7):1696-704

Characterization of multiply phosphorylated peptides selectively precipitated from a pancreatic casein digest. Adamson NJ, et al. **J Dairy Sci** 1995 Dec;78(12):2653-9

Adrenalectomy induces a decrease in the light scatter properties and amylase content of isolated zymogen granules from rat pancreas as analyzed by flow cytometry. Garcia-Montero AC, et al. **J Endocrinol** 1995 Dec; 147(3):431-40

Detection of nitric oxide synthase (NOS) in somatostatin-producing cells of human and murine stomach and pancreas. Burrell MA, et al. **J Histochem Cytochem** 1996 Apr;44(4):339-46

Rat GP-3 is a pancreatic lipase with kinetic properties that differ from colipase-dependent pancreatic lipase. Jennens ML, et al. **J Lipid Res** 1995 Nov;36(11):2374-82

Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. Borowitz DS, et al. **J Pediatr** 1995 Nov;127(5):681-4 (22 ref.)

Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. O'Hare MM, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):59-63

Potentiation of cholecystokinin-induced amylase release by peptide VIP in guinea pig pancreatic acini. Tanaka K, et al. **Jpn J Physiol** 1995;45(2):241-56

Adenylate cyclase activity during exocrine pancreatic proliferation in the rat. Alvaro-Alonso I, et al. **Life Sci** 1995;57(25):2317-23

Identification of protein kinase C zeta isozyme in hamster pancreas and pancreatic carcinoma cell lines. Nair SC, et al. **Mol Carcinog** 1995 Nov;14(3):205-13

Abnormal circulating pancreatic enzyme activities in more than twenty-five percent of recent-onset insulin-dependent diabetic patients: association of hyperlipasemia with high-titer islet cell antibodies. Belgian Diabetes Registry. Semakula C, et al. **Pancreas** 1996 May;12(4):321-33

Cholecystokinin-stimulated enzyme secretion from dispersed rabbit pancreatic acinar cells: phosphorylation-dependent changes in potency and efficacy. Willems PH, et al. **Pflugers Arch** 1995 Sep;430(5):626-35

Effect of early nutrient restriction on broiler chickens. 2. Performance and digestive enzyme activities. Palo PE, et al. **Poult Sci** 1995 Sep;74(9):1470-83

The structure of human pancreatic alpha-amylase at 1.8 A resolution and comparisons with related enzymes. Brayer GD, et al. **Protein Sci** 1995 Sep;4(9):1730-42

The activation pathway of procarboxypeptidase B from porcine pancreas: participation of the active enzyme in the proteolytic processing. Villegas V, et al. **Protein Sci** 1995 Sep;4(9):1792-800

Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Dawson E, et al. **Psychiatr Genet** 1995 Winter;5(4):177-80

Effect of nickel on enzymatic activities in the mouse pancreas. Funakoshi T, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):245-52

Serial analysis of gene expression [see comments] Velculescu VE, et al. **Science** 1995 Oct 20;270(5235):484-7. Comment in: Science 1995 Oct 20;270(5235):368-9, 371.

Pancreaticobiliary maljunction-associated pancreatitis: an experimental study on the activation of pancreatic phospholipase A2. Nakamura T, et al. **World J Surg** 1996 Jun;20(5):543-50

[Pancreatic phospholipase A2] Ogawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:333-7 (5 ref.) **(Jpn)**

[Pancreatic lipase] Sugano K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:435-7 (8 ref.) **(Jpn)**

[Localization of NADPH-diaphorase activity and NOS immunoreactivity in the pancreas of rat and dog] Umehara K. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug; 92(8):1161-8 (Eng. Abstr.) **(Jpn)**

[Activity of alpha-amylase, trypsin and lipase in pancreas and duodenal contents of Ascaridia galli infected chickens fed with various proteins] Zółtowska K, et al. **Wiad Parazytol** 1995;41(2):217-20 (Eng. Abstr.) **(Pol)**

[The influence of various levels of carotene and protein in the diet on the index of invasion and digestive enzyme activity in chickens infected with Ascaridia galli] Zółtowska K, et al. **Wiad Parazytol** 1996;42(1):65-9 (Eng. Abstr.) **(Pol)**

[Effect of omeprazole administration on pancreatic content of enzymes in rats] Montagnini AL, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep-Oct; 50(5):272-5 (Eng. Abstr.) **(Por)**

[Pancreatic lipase deficiency and linear IgA disease in childhood] Olivera Olmedo JE, et al. **An Esp Pediatr** 1996 Jan;44(1):73-5 (15 ref.) **(Spa)**

GROWTH & DEVELOPMENT

Stimulation of pancreatic growth. Distal small bowel resection mediated by increased levels of cholecystokinin. Yoshinaga K, et al. **Ann Surg** 1996 Aug;224(2):139-44

Effect of hypergastrinemia and blockade of gastrin-receptors on pancreatic growth in the mouse. Niederau C, et al. **Hepatogastroenterology** 1995 Jul-Aug;42(4):423-31

IPF1, a homeodomain protein with a dual function in pancreas development. Jonsson J, et al. **Int J Dev Biol** 1995 Oct;39(5):789-98

Role of cholecystokinin (CCK)-A receptor for pancreatic growth after weaning: a study in a new rat model without gene expression of the CCK-A receptor. Miyasaka K, et al. **Pancreas** 1996 May;12(4):351-6

Nutritional influences on pancreatic development and potential links with non-insulin-dependent diabetes. Dahri S, et al. **Proc Nutr Soc** 1995 Jul;54(2):345-56 (32 ref.)

Gastrin does not stimulate growth of the rat pancreas. Chen D, et al. **Scand J Gastroenterol** 1996 Apr;31(4):404-10

In vivo maturation and growth potential of human fetal pancreases: fresh versus cultured tissue. Beattie GM, et al. **Transplant Proc** 1995 Dec;27(6):3343

Model for human islet neogenesis in vitro from adult pancreatic preparations. Kerr-Conte J, et al. **Transplant Proc** 1995 Dec;27(6):3268

IMMUNOLOGY

Detection of IgA and its receptor in the exocrine pancreas and the extrahepatic bile duct of the rat. Havaux XB, et al. **Adv Exp Med Biol** 1995;371B:1067-70

Lymphocyte function associated antigen-1, integrin alpha 4, and L-selectin mediate T-cell homing to the pancreas in the model of adoptive transfer of diabetes in NOD mice. Fabien N, et al. **Diabetes** 1996 Sep;45(9):1181-6

Treatment of IFN-gamma transgenic mice with anti-IFN-gamma reveals the remodeling capacity of the

adult pancreas. Gu D, et al. **Diabetes** 1995 Oct; 44(10):1161–4

Mucosa–associated (beta 7–integrinhigh) lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behavior. Hänninen A, et al. **Diabetes** 1996 Sep;45(9):1173–80

ICA69 is expressed equally in the human endocrine and exocrine pancreas. Mally MI, et al. **Diabetologia** 1996 Apr; 39(4):474–80

Pancreatic lymph nodes are early targets of T cells during adoptive transfer of diabetes in NOD mice. Fabien N, et al. **J Autoimmun** 1995 Jun;8(3):323–34

Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. Seibold F, et al. **J Clin Gastroenterol** 1996 Apr;22(3):202–6

Intrapancreatic interleukin–1beta gene expression by specific leukocyte populations during acute pancreatitis. Fink GW, et al. **J Surg Res** 1996 Jun;63(1):369–73

INJURIES

Is octreotide beneficial following pancreatic injury? Nwariaku FE, et al. **Am J Surg** 1995 Dec;170(6):582–5

Computed tomography: an unreliable indicator of pancreatic trauma. Akhrass R, et al. **Am Surg** 1996 Aug;62(8):647–51

Urgent endoscopic retrograde pancreatography the stable trauma patient. Clements RH, et al. **Am Surg** 1996 Jun; 62(6):446–8

Evaluation of pancreatic injury after blunt abdominal trauma. Emmick RH Jr, et al. **Ann Emerg Med** 1996 May; 27(5):658–61

Distal pancreatectomy for gunshot injuries of the distal pancreas [see comments] Degiannis E, et al. **Br J Surg** 1995 Sep;82(9):1240–2. Comment in: Br J Surg 1995 Sep;82(9):1153–4.

Operative strategies in pancreatic trauma. Farrell RJ, et al. **Br J Surg** 1996 Jul;83(7):934–7

Pancreatic trauma [editorial; comment] Johnson CD. **Br J Surg** 1995 Sep;82(9):1153–4. Comment on: Br J Surg 1995 Sep;82(9):1236–9. Comment on: Br J Surg 1995 Sep;82(9):1240–2.

Favourable prognosis after surgical drainage of gunshot, stab or blunt trauma of the pancreas [see comments] Madiba TE, et al. **Br J Surg** 1995 Sep;82(9):1236–9. Comment in: Br J Surg 1995 Sep;82(9):1153–4.

Delayed complications of pancreatic injury: role of CT in detection and management. Abd el Bagi ME, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):456–62

Demonstration of pancreatic ductal integrity by endoscopic retrograde pancreatography allows conservative surgical management. Chandler C, et al. **J Trauma** 1996 Mar; 40(3):466–8

Delayed diagnosis of pancreatic transection after blunt abdominal trauma. Smith DR, et al. **J Trauma** 1996 Jun; 40(6):1009–13

Diagnosis of pancreatic injury after blunt abdominal trauma. Lane MJ, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):177–82 (29 ref.)

Complex pancreatic injuries. Patton JH Jr, et al. **Surg Clin North Am** 1996 Aug;76(4):783–95 (39 ref.)

Gunshot injuries of the head of the pancreas: conservative approach. Degiannis E, et al. **World J Surg** 1996 Jan; 20(1):68–71; discussion 72

[Traumatic disease of the pancreas] Di Lorenzo M, et al. **Ann Ital Chir** 1995 May–Jun;66(3):353–61 (44 ref.) (Eng. Abstr.) **(Ita)**

[The role of emergent endoscopic retrograde pancreatography (ERP): its usefulness in the diagnosis of pancreatic injury] Takishima T, et al. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):569–76 (Eng. Abstr.) **(Jpn)**

[Pancreatic injuries] Ionescu A, et al. **Chirurgia (Bucur)** 1995; 44(4):65–8 **(Rum)**

[Transverse rupture of the pancreas in blunt abdominal trauma] Sorokolat AI, et al. **Klin Khir** 1995;(4):47–8 **(Rus)**

INNERVATION

Facilitating effect of CCK on nicotinic neurotransmission in cat pancreatic ganglion. Ma RC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G526–34

Anatomical localization of sympathetic postganglionic and sensory neurons innervating the pancreas of the cat. Furuzawa Y, et al. **J Vet Med Sci** 1996 Mar;58(3):243–8

Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Nakao A, et al. **Pancreas** 1996 May;12(4):357–61

[The early studies of I. P. Pavlov (1874–1880): the innervation of the pancreas and salivary glands] Khaiutin VM. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):125–34 **(Rus)**

METABOLISM

Transcription factor and liver–specific mRNA expression in facultative epithelial progenitor cells of liver and pancreas. Dabeva MD, et al. **Am J Pathol** 1995 Dec;147(6):1633–48

Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Furukawa T, et al. **Am J Pathol** 1995 Oct;147(4):889–95

Halothane and octanol block Ca2+ oscillations in pancreatic acini by multiple mechanisms. Deutsch DE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G779–88

Sulfate/oxalate exchange by lobster hepatopancreatic basolateral membrane vesicles. Gerencser GA, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R572–7

Rabbit pancreatic acini express CFTR as a cAMP–activated chloride efflux pathway. Kopelman H, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C626–31

Novel model of integration of signaling pathways in rat pancreatic acinar cells. Rivard N, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G352–62

EGF inhibits secretagogue–induced cAMP production and amylase secretion by Gi proteins in pancreatic acini. Stryjek–Kaminska D, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G676–82

High–affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion. Tsunoda Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G435–44

Induction of lithostathine/reg mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR–42J cells. Dusetti NJ, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):129–32

The occurrence of acidic fibroblast growth factor–like immunoreactivity in subpopulations of endocrine cells in the pancreas and intestine of the rat. Yamamoto M, et al. **Arch Histol Cytol** 1995 Oct;58(4):475–84

Increased expression of insulin receptor substrate–1 in human pancreatic cancer. Bergmann U, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):886–90

Intracellular control of IP3–independent Ca2+ oscillations in pancreatic acini. Tsunoda Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):265–72

Role of cyclic GMP in the control of capacitative Ca2+ entry in rat pancreatic acinar cells. Gilon P, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):649–56

Association of nucleoside diphosphate kinase with pancreatic zymogen granules: effects of local GTP generation on granule membrane characteristics. Marciniak SJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):99–106

Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1–2 proteins in pancreatic acinar membranes. Stryjek–Kaminska D, et al. **Biochem J** 1996 May 15;316 (Pt 1):87–91

Lactational changes in the rat exocrine pancreas somatostatin receptors and modulation of guanylate cyclase. Rodríguez–Martín E, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):102–8

Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Shen TT, et al. **Bioconjug Chem** 1996 May–Jun;7(3):311–6

Distribution and photodynamic effects of meso–tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Mlkvy P, et al. **Br J Cancer** 1996 Jun;73(12):1473–9

In vivo threonine oxidation in growing pigs fed on diets with graded levels of threonine. Floc'h NL, et al. **Br J Nutr** 1996 Jun;75(6):825–37

Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Buscail L, et al. **Cancer Res** 1996 Apr 15;56(8):1823–7

Uptake of the food–derived heterocyclic amine carcinogen 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine and its N–hydroxy metabolite into rat pancreatic acini and hepatocytes in vitro. Butcher NJ, et al. **Carcinogenesis** 1996 Apr;17(4):889–92

Inositol trisphosphate and cyclic ADP–ribose–mediated release of Ca2+ from single isolated pancreatic zymogen granules. Gerasimenko OV, et al. **Cell** 1996 Feb 9; 84(3):473–80

Isolation of subcellular agonist–sensitive calcium stores from the pancreatic acinar cell. Pandol SJ, et al. **Cell Calcium** 1995 Nov;18(5):364–76

A cADP–ribose antagonist does not inhibit secretagogue–, caffeine– and nitric oxide–induced Ca2+ responses in rat pancreatic beta–cells. Willmott NJ, et al. **Cell Calcium** 1995 Nov;18(5):411–9

Pancreatic calcium waves and secretion. Kasai H. **Ciba Found Symp** 1995;188:104–16; discussion 116–20 (31 ref.)

Local calcium spiking in pancreatic acinar cells. Petersen OH. **Ciba Found Symp** 1995;188:85–94; discussion 94–103 (47 ref.)

Direct double antibody sandwich immunoassay of mucin M1 epitopes in human mucus secreting pancreatic cell lines. Montserrat C, et al. **Clin Chim Acta** 1995 Dec 15; 243(1):43–52

Regulation of pancreatitis–associated protein (HIP/PAP) mRNA levels in mouse pancreas and small intestine. McKie AT, et al. **Clin Sci (Colch)** 1996 Aug;91(2):213–8

Complete sequence analysis of rat transferrin and expression of transferrin but not lactoferrin in the digestive glands. Hoshino A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):491–7

Pancreatic regenerating gene overexpression in the nonobese diabetic mouse during active diabetogenesis. Baeza NJ, et al. **Diabetes** 1996 Jan;45(1):67–70

Neurotransmitters partially restore glucose sensitivity of insulin and glucagon secretion from perfused streptozotocin–induced diabetic rat pancreas. Ito K, et al. **Diabetologia** 1995 Nov;38(11):1276–84

Possible involvement of Rab11 p24, a Ras–like small GTP–binding protein, in intracellular vesicular transport of isolated pancreatic acini. Hori Y, et al. **Dig Dis Sci** 1996 Jan;41(1):133–8

Multiple, coordinated Ca2+ –release events underlie the inositol trisphosphate–induced local Ca2+ spikes in mouse pancreatic acinar cells. Thorn P, et al. **EMBO J** 1996 Mar 1;15(5):999–1003

Dietary modulation of the mRNA stability of trypsin isozymes and the two forms of secretory trypsin inhibitor in the rat pancreas. Carreira S, et al. **Eur J Biochem** 1996 Jul 1;239(1):117–23

Diradylglycerol formation in cholecystokinin–stimulated rabbit pancreatic acini. Assessment of precursor phospholipids by means of molecular species analysis. Hermans SW, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):73–81

Expression of two FGF–2 isoforms in pancreatic acinar cells (AR4–2J). Intracellular localization and role in the regulation of the extracellular matrix biosynthesis. Monzat V, et al. **Eur J Cell Biol** 1996 Apr;69(4):316–26

Altered intracellular Ca2+ regulation in pancreatic acinar cells from acute streptozotocin–induced diabetic rats. Komabayashi T, et al. **Eur J Pharmacol** 1996 Mar 18; 298(3):299–306

Insulin stimulates cationic amino acid transport activity in the isolated perfused rat pancreas. Muñoz M, et al. **Exp Physiol** 1995 Sep;80(5):745–53

Thimerosal modulates the agonist–specific cytosolic Ca2+ oscillatory patterns in single pancreatic acinar cells of mouse. Wu J, et al. **FEBS Lett** 1996 Jul 22;390(2):149–52

Pancreatic interstitial pH in human and feline chronic pancreatitis. Patel AG, et al. **Gastroenterology** 1995 Nov; 109(5):1639–45

Role of intraduodenal proteases in plasma cholecystokinin and pancreaticobiliary responses to protein and amino acids. Thimister PW, et al. **Gastroenterology** 1996 Feb; 110(2):567–75

Progressive disruption of acinar cell calcium signaling is an early feature of cerulein–induced pancreatitis in mice. Ward JB, et al. **Gastroenterology** 1996 Aug;111(2):481–91

Pancreatic thread protein is mitogenic to pancreatic–derived cells in culture. Zenilman ME, et al. **Gastroenterology** 1996 Apr;110(4):1208–14

Sequence of the cDNA encoding human GP–2, the major membrane protein in the secretory granule of the exocrine pancreas. Wong SM, et al. **Gene** 1996 Jun 1;171(2):311–2

Localization of Ca2+ extrusion sites in pancreatic acinar cells. Belan PV, et al. **J Biol Chem** 1996 Mar 29; 271(13):7615–9

Tmp21 and p24A, two type I proteins enriched in pancreatic microsomal membranes, are members of a protein family involved in vesicular trafficking. Blum R, et al. **J Biol Chem** 1996 Jul 19;271(29):17183–9

Molecular cloning and expression of a 58–kDa cis–Golgi and intermediate compartment protein. Lahtinen U, et al. **J Biol Chem** 1996 Feb 23;271(8):4031–7

Cell type–specific modes of feedback regulation of capacitative calcium entry. Louzao MC, et al. **J Biol Chem** 1996 Jun 21;271(25):14807–13

Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreatic acinar cell receptors. Ozcelebi F, et al. **J Biol Chem** 1996 Feb 16;271(7):3750–5

Molecular cloning and expression of serum calcium–decreasing factor (caldecrin). Tomomura A, et al. **J Biol Chem** 1995 Dec 22;270(51):30315–21

Imaging of intracellular calcium stores in individual permeabilized pancreatic acinar cells. Apparent homogeneous cellular distribution of inositol 1,4,5–trisphosphate–sensitive stores in permeabilized pancreatic acinar cells. van de Put FH, et al. **J Biol Chem** 1996 Mar 1;271(9):4999–5006

Gbetagamma transduces [Ca2+]i oscillations and Galphaq a sustained response during stimulation of pancreatic acinar cells with [Ca2+]i–mobilizing agonists. Zeng W, et al. **J Biol Chem** 1996 Aug 2;271(31):18520–6

Differential distribution of alpha subunits and beta gamma subunits of heterotrimeric G proteins on Golgi membranes of the exocrine pancreas. Denker SP, et al. **J Cell Biol** 1996 Jun;133(5):1027–40

Pertussis toxin–sensitive G–proteins inhibit fibroblast growth factor–induced signaling in pancreatic acini. Piiper A, et al. **J Cell Physiol** 1996 Apr;167(1):52–9

Calcium– and CaMKII–dependent chloride secretion induced by the microsomal Ca(2+)–ATPase inhibitor 2,5–di–(tert–butyl)–1,4–hydroquinone in cystic fibrosis pancreatic epithelial cells. Chao AC, et al. **J Clin Invest** 1995 Oct;96(4):1794–801

The ovine pancreatic protein which binds insulin–like growth factor binding protein–3 is procarboxypeptidase A. Fowke PJ, et al. **J Endocrinol** 1996 Jul;150(1):51–6

Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR–1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA. Sazaki N, et al. **J Gastroenterol** 1995 Oct; 30(5):599–606

Na+, K+, and Cl– transport in resting pancreatic acinar cells. Zhao H, et al. **J Gen Physiol** 1995 Dec;106(6):1225–42

Development of GP–2 and five zymogens in the fetal and young pig: biochemical and immunocytochemical evidence of an atypical zymogen granule composition in the fetus. Lainé J, et al. **J Histochem Cytochem** 1996 May; 44(5):481–99

Possible association of chaperonin 60 with secretory proteins in pancreatic acinar cells. Le Gall IM, et al. **J Histochem Cytochem** 1996 Jul;44(7):743–9

Expression of endothelin–1 in pancreatic tissue of patients with chronic pancreatitis. Kakugawa Y, et al. **J Pathol** 1996 Jan;178(1):78–83

Ligation–induced acute pancreatitis increases pancreatic circulating trypsinogen activation peptides. Merriam LT, et al. **J Surg Res** 1996 Feb 1;60(2):417–21

Gastrin receptor expression during azaserine–induced rat pancreatic carcinogenesis. Tsuei BJ, et al. **J Surg Res** 1996 Jun;63(1):105–9

Evidence for altered cellular calcium in the pathogenetic mechanism of acute pancreatitis in rats. Zhou W, et al. **J Surg Res** 1996 Jan;60(1):147–55

Hormonal stimulation of calcium mobilization in the isolated perfused rat pancreas. Zhou W, et al. **J Surg Res** 1996 Jan; 60(1):168–75

Cholecystokinin–A specific antagonism of KSG–504 to cholecystokinin receptor binding and pancreatic secretion in mammals. Yamazaki Y, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):367–73

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485–92

The effects of arginine administration on the levels of arginine, other amino acids and related amino compounds in the plasma, heart, aorta, vena cava, bronchi and pancreas of the rat. Noeh FM, et al. **Life Sci** 1996;58(8):PL131–8

Effects of bradykinin on the intracellular calcium concentration of pancreatic acinar AR42J cells. Saito Y, et al. **Life Sci** 1996;58(18):1569–74

PAF–acetylhydrolase activity and PAF levels in pancreas and plasma of well–fed, diabetic and fasted rat. Trapali M, et al. **Life Sci** 1996;59(10):849–57

Reciprocal changes in intracellular and extracellular magnesium in rat pancreatic acinar cells in response to different secretagogues. González A, et al. **Magnes Res** 1995 Sep;8(3):215–22

Dietary energy restriction–induced modulation of protein kinase C zeta isozyme in the hamster pancreas. Nair SC, et al. **Mol Carcinog** 1995 Sep;14(1):10–5

Expression of ornithine decarboxylase in pancreatic development. Lee PC. **Mol Cell Biochem** 1995 Oct 4; 151(1):83–9

Accumulation of beta–amyloid fibrils in pancreas of transgenic mice. Kawarabayashi T, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):215–22

Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Björkstrand E, et al. **Neuroendocrinology** 1996 Apr;63(4):377–83

Carboxylic ester hydrolase and amylase in ischemic pancreatitis in the guinea pig. Blind PJ, et al. **Pancreas** 1996 May;12(4):388–95

The ratio between anionic and cationic trypsin in rat pancreas varies with CCK stimulation. Borgström A, et al. **Pancreas** 1995 Aug;11(2):179–84

Androgen receptor in the rat pancreas: genetic expression and steroid regulation. Díaz–Sánchez V, et al. **Pancreas** 1995 Oct;11(3):241–5

Energy metabolism in mouse pancreas in response to different dosages of a CCK analogue. Lüthen RE, et al. **Pancreas** 1995 Aug;11(2):141–6

Histamine–evoked potassium release in the mouse and guinea pig pancreas. Rosado JA, et al. **Pancreas** 1996 May; 12(4):396–400

Calcium induces rapid changes in protein phosphorylation in permeabilized pancreatic acini. Wagner AC, et al. **Pancreas** 1995 Oct;11(3):236–40

Somatostatin binding capacity, guanylate cyclase and tyrosine phosphatase activities during pancreatic proliferation in the rat induced by gastrectomy. Rodríguez–Martín E, et al. **Peptides** 1995;16(8):1461–7

Changes in element concentrations induced by agonist in pig pancreatic acinar cells. Sasaki S, et al. **Pflugers Arch** 1996 Jul;432(3):538–45

Decrease of acidity inside zymogen granules inhibits acetylcholine– or inositol trisphosphate–evoked cytosolic Ca2+ spiking in pancreatic acinar cells. Titievsky AV, et al. **Pflugers Arch** 1996 Sep;432(5):938–40

Expression of functional GABAA receptors in neuroendocrine gastropancreatic cells. von Blankenfeld G, et al. **Pflugers Arch** 1995 Jul;430(3):381–8

Modulation of cholecystokinin activity by albumin. Huang SC, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10312–6

Purification, cDNA cloning, functional expression, and characterization of a 26–kDa endogenous mammalian carboxypeptidase inhibitor. Normant E, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12225–9

Nitric oxide regulates insulin secretion in the isolated perfused human pancreas via a cholinergic mechanism. Atiya A, et al. **Surgery** 1996 Aug;120(2):322–7

E–cadherin, NCAM, and EpCAM expression in human fetal pancreata. Cirulli V, et al. **Transplant Proc** 1995 Dec; 27(6):3335

Tissue hydration in UW–preserved pancreas allografts: evaluation by magnetic resonance relaxometry. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3051–2

Immuno–histochemical and ultrastructural study of adult porcine pancreas during the different steps of islet isolation. Vantyghem MC, et al. **Transplant Proc** 1995 Dec; 27(6):3372–4

PATHOLOGY

Duodenojejunal intussusception with biliary obstruction and atrophy of the pancreas. Uggowitzer M, et al. **Abdom Imaging** 1996 May–Jun;21(3):240–2

Fine needle aspiration cytology in pancreatic pathology. Lerma E, et al. **Acta Cytol** 1996 Jul–Aug;40(4):683–6

Percutaneous and intraoperative aspiration biopsy cytology of pancreatic neuroendocrine tumors: cytomorphologic study with an immunocytochemical contribution. Saleh HA, et al. **Acta Cytol** 1996 Mar–Apr;40(2):182–90

Current status of MR cholangiopancreatography. Reinhold C, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1285–95

Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Furukawa T, et al. **Am J Pathol** 1995 Oct;147(4):889–95

Dynamics of pancreatic cell growth and differentiation during diabetes reversion in STZ–treated newborn rats. Ferrand N, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1250–64

The meaning of equivocal pancreatic cytology in patients thought to have pancreatic cancer. Enayati PG, et al. **Am J Surg** 1996 May;171(5):525–8

Mucin–hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively. Yamaguchi K, et al. **Am J Surg** 1996 Apr;171(4):427–31

Pancreatic metaplasia in Barrett's esophagus. An immunohistochemical study. Krishnamurthy S, et al. **Am J Surg Pathol** 1995 Oct;19(10):1172–80

Mucus retention in heterotopic pancreas of the gastric antrum: a lesion mimicking mucinous carcinoma [letter; comment] Padberg BC, et al. **Am J Surg Pathol** 1995 Dec; 19(12):1445–7. Comment on: Am J Surg Pathol 1994 Sep;18(9):953–7.

Diabetes and experimental pregnancy in rats: course of maternal blood glucose levels and its repercussions on the blood glucose levels and pancreas of newborn pups. Rudge MV, et al. **Braz J Med Biol Res** 1995 Feb;28(2):219–25

Effects of dietary beta–carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine–treated rats. Appel MJ, et al. **Carcinogenesis** 1996 Jul;17(7):1411–6

Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.

Pancreatic pathology in non–insulin dependent diabetes (NIDDM). Clark A, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S39–47 (50 ref.)

Mitochondrial DNA, diabetes and pancreatic pathology in Kearns–Sayre syndrome. Poulton J, et al. **Diabetologia** 1995 Jul;38(7):868–71

Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long–term study [see comments] Ammann RW, et al. **Gastroenterology** 1996 Jul; 111(1):224–31. Comment in: Gastroenterology 1996 Jul;111(1):258–9.

Ventromedial hypothalamic lesion–induced vagal hyperactivity stimulates rat pancreatic cell proliferation. Kiba T, et al. **Gastroenterology** 1996 Mar;110(3):885–93

Role of the necrosis–fibrosis sequence in the pathogenesis of alcoholic chronic pancreatitis [editorial; comment] Longnecker DS. **Gastroenterology** 1996 Jul;111(1):258–9. Comment on: Gastroenterology 1996 Jul;111(1):224–31.

Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Van Laethem JL, et al. **Gastroenterology** 1996 Feb; 110(2):576–82

Diagnostic utility of K–ras mutations in fine–needle aspirates of pancreatic masses. Villanueva A, et al. **Gastroenterology** 1996 May;110(5):1587–94

Biochemical and morphological changes that characterise recovery from necrotising biliary pancreatitis in the opossum. Rünzi M, et al. **Gut** 1995 Sep;37(3):427–33

Analysis of small cystic lesions of the pancreas. Kimura W, et al. **Int J Pancreatol** 1995 Dec;18(3):197–206

Sterile pancreatic necrosis: is operation necessary? [editorial; comment] Ashley SW. **J Am Coll Surg** 1995 Oct; 181(4):363–4. Comment on: J Am Coll Surg 1995 Oct;181(4):279–88.

Management of sterile necrosis in instances of severe acute pancreatitis [see comments] Rau B, et al. **J Am Coll Surg** 1995 Oct;181(4):279–88. Comment in: J Am Coll Surg 1995 Oct;181(4):363–4.

Breath–held MR cholangiopancreatography with half–averaged single shot hybrid rapid acquisition with relaxation enhancement sequence: comparison of fast GRE and SE sequences. Ichikawa T, et al. **J Comput Assist Tomogr** 1996 Sep–Oct;20(5):798–802

Adenylate cyclase activity during exocrine pancreatic proliferation in the rat. Alvaro–Alonso I, et al. **Life Sci** 1995;57(25):2317–23

Contrast–enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Effects of pancreaticobiliary duct obstruction on the exocrine and endocrine rat pancreas. Panozzo MP, et al. **Pancreas** 1995 Nov;11(4):408–14

Somatostatin binding capacity, guanylate cyclase and tyrosine phosphatase activities during pancreatic proliferation in the rat induced by gastrectomy. Rodríguez–Martín E, et al. **Peptides** 1995;16(8):1461–7

Cystic fibrosis: MR assessment of pancreatic damage. Ferrozzi F, et al. **Radiology** 1996 Mar;198(3):875–9

Pancreas allograft rejection: correlation of transduodenal core biopsy with Doppler resistive index. Nelson NL, et al. **Radiology** 1996 Jul;200(1):91–4

Hepatic transdifferentiation in the pancreas. Rao MS, et al. **Semin Cell Biol** 1995 Jun;6(3):151–6 (53 ref.)

Correlation between cystoscopic biopsy results and hypoamylasuria in bladder–drained pancreas transplants. Benedetti E, et al. **Surgery** 1995 Nov;118(5):864–72

Efficiency of percutaneous core biopsy in pancreatic tumor diagnosis. Karlson BM, et al. **Surgery** 1996 Jul;120(1):75–9

Evaluation of DNA injury in Langerhans' cells after warm ischemia of the pancreas in the rat. Saito T, et al. **Transplant Proc** 1996 Jun;28(3):1982–5

Isolated pancreas rejection in combined kidney pancreas tranplantation. Klassen DK, et al. **Transplantation** 1996 Mar 27;61(6):974–7

Ultrasound guided percutaneous fine needle aspiration cytology of pancreas: a review of 61 cases. Das DK, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):101–9

[The surgical treatment of acute necrotic pancreatitis (the experience of 37 patients)] Belchev B, et al. **Khirurgiia (Sofiia)** 1994;47(6):44–6 (Eng. Abstr.) **(Bul)**

[Management of pancreatic necrosis] Csáky G, et al. **Orv Hetil** 1995 Sep 24;136(39):2105–11 (50 ref.) (Eng. Abstr.) **(Hun)**

[Pancreatic assessment by magnetic resonance imaging: an improvement in the diagnostic results with new study technics] Catalano C, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):262–8 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Bile–pancreatic juice replacement not cholinergic– and cholecystokinin–receptor blockade reverses acinar cell hyperstimulation after bile–pancreatic duct ligation. Samuel I, et al. **Am J Surg** 1996 Jan;171(1):207–11

Influence of caecal microflora and of two dietary protein levels on the adaptation of the exocrine pancreas: comparative study in germ–free and conventional rats. Lhoste EF, et al. **Br J Nutr** 1996 Mar;75(3):433–44

Expression of Reg gene in the Syrian golden hamster pancreatic islet regeneration model. Rafaeloff R, et al. **Diabetologia** 1995 Aug;38(8):906–13

Effects of cholecystokinin and carbachol on membrane fluidity in pancreatic acini. Wang ZH, et al. **Dig Dis Sci** 1996 Jul;41(7):1511–7

Effect of octreotide on pancreatic regeneration in rats measured by bromodeoxyuridine uptake. Bufalari A, et al. **Eur J Surg** 1996 Mar;162(3):223–8

Identification of differentially expressed genes induced in pancreatic islet neogenesis. Rafaeloff R, et al. **FEBS Lett** 1996 Jan 15;378(3):219–23

Molecular cloning and characterization of a novel orphan receptor (P2P) expressed in human pancreas that shows high structural homology to the P2U purinoceptor. Stam NJ, et al. **FEBS Lett** 1996 Apr 22;384(3):260–4

Development and regulation of porcine pancreatic function. Pierzynowski SG, et al. **Int J Pancreatol** 1995 Oct; 18(2):81–94 (101 ref.)

The effect of chronic intraperitoneal infusion of bacterial endotoxin on exocrine pancreas function in rats. Vaccaro MI, et al. **Int J Pancreatol** 1996 Feb;19(1):49–54

Gastric and pancreatic functions in haemodialyzed patients. Malyszko J, et al. **Int Urol Nephrol** 1995;27(4):471–8

Imprinted and genotype–specific expression of genes at the IDDM2 locus in pancreas and leucocytes. Vafiadis P, et al. **J Autoimmun** 1996 Jun;9(3):397–403

Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80–kDa mdr1a gene product. Thévenod F, et al. **J Biol Chem** 1996 Feb 9;271(6):3300–5

Induction and involvement of endogenous IGF–I in pancreas regeneration after partial pancreatectomy in the dog. Hayakawa H, et al. **J Endocrinol** 1996 May;149(2):259–67

Effects of short–term administration of the CCK receptor antagonist, KSG–504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats. Okumura Y, et al. **J Gastroenterol** 1995 Aug;30(4):493–9

Agonist–specific regulation of [Na+]i in pancreatic acinar cells. Zhao H, et al. **J Gen Physiol** 1995 Dec;106(6):1243–63

Differential expression of reg–I and reg–II genes during aging in the normal mouse. Perfetti R, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B308–15

Evidence for involvement of a zymogen granule Na+/H+ exchanger in enzyme secretion from rat pancreatic acinar cells. Anderie I, et al. **J Membr Biol** 1996 Aug; 152(3):195–205

Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion. Bilski J, et al. **J Physiol Pharmacol** 1995 Dec;46(4):447–62

Growth factors in the regenerating pancreas of gamma–interferon transgenic mice. Arnush M, et al. **Lab Invest** 1996 Jun;74(6):985–90

Second messenger role of magnesium in pancreatic acinar cells of the rat. Singh J, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:175–82

The role of magnesium in regulating CCK–8–evoked secretory responses in the exocrine rat pancreas. Wisdom DM, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):123–32

Neurohormonal regulation of pancreatic exocrine function

in rats without gene expression of the cholecystokinin-A receptor. Miyasaka K, et al. **Pancreas** 1996 Apr;12(3):272–9

Capacitative Ca2+ influx and a Ca2+-dependent nonselective cation pathway are discriminated by genistein in mouse pancreatic acinar cells. Pfeiffer F, et al. **Pflugers Arch** 1995 Oct;430(6):916–22

PHYSIOPATHOLOGY

A noninvasive stable-isotope method to simultaneously assess pancreatic exocrine function and small bowel absorption. Deutsch JC, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2182–5

Growth and endocrine function after near total pancreatectomy for hyperinsulinaemic hypoglycaemia [see comments] Soliman AT, et al. **Arch Dis Child** 1996 May; 74(5):379–85. Comment in: Arch Dis Child 1996 May;74(5):369–72.

Catch up growth and pancreatic function in growth retarded neonates. Williams SP, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F158–61

Pancreatic function in systemic sclerosis [letter] Shawis TN, et al. **Br J Rheumatol** 1996 Mar;35(3):298–9

Exocrine pancreatic and beta-cell function in malnutrition-related diabetes among north Indians. Bhatia E, et al. **Diabetes Care** 1995 Aug;18(8):1174–8

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor(s). Rosenberg L, et al. **Diabetologia** 1996 Mar;39(3):256–62

Gallbladder and pancreatic dysfunction in celiac disease [letter] Mann NS. **Dig Dis Sci** 1995 Nov;40(11):2380–2

Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy? Ventrucci M, et al. **Dig Dis Sci** 1995 Dec;40(12):2576–81

Exocrine pancreatic function in diabetes mellitus. Gröger G, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):740–6 (70 ref.)

Pancreatic involvement in patients with Sjögren's syndrome and primary biliary cirrhosis. Nishimori I, et al. **Int J Pancreatol** 1995 Feb;17(1):47–54

Indirect parameters of pancreatic function in cystic fibrosis (CF) during a controlled double-blind trial of pancreatic supplementation. Regele S, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):68–72

Correlation of nucleolar organizer regions with secretory and regenerative process in experimental cerulein-induced pancreatitis in the rat. Rüschoff J, et al. **Pancreas** 1995 Aug; 11(2):154–9

Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Heikius B, et al. **Scand J Gastroenterol** 1996 May;31(5):517–23

Pancreatic regeneration (reg) gene expression in a rat model of islet hyperplasia. Zenilman ME, et al. **Surgery** 1996 May; 119(5):576–84

[Effect of insulin on the function of pancreatic exocrine] Yang YK, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):238–44 (Eng. Abstr.) **(Chi)**

[The functional and sonographic parallels in chronic pancreatitis] Gubergrits NB, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):51-3 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Carducci MA, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):143–50

RADIOGRAPHY

A comparison of two injection protocols using helical and dynamic acquisitions in CT examinations of the pancreas. Bonaldi VM, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):49–55

Normal variations in the lateral contour of the head and neck of the pancreas mimicking neoplasm: evaluation with dual-phase helical CT. Ross BA, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):799–801

Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Van Hoe L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1437–9

Computed tomography: an unreliable indicator of pancreatic trauma. Akhrass R, et al. **Am Surg** 1996 Aug;62(8):647–51

Findings of cholangiopancreatography in pseudotumorous pancreatitis. Hu Y, et al. **Chin Med J (Engl)** 1995 Dec; 108(12):907–9

Delayed complications of pancreatic injury: role of CT in detection and management. Abd el Bagi ME, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):456–62

Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Lu DS, et al. **Radiology** 1996 Jun; 199(3):697–701

[The role of emergent endoscopic retrograde pancreatography (ERP): its usefulness in the diagnosis of pancreatic injury] Takishima T, et al. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):569–76 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Diffuse pancreatic Ga-67 uptake in pancreatitis with markedly elevated Ca 19-9 tumor marker. Joseph UA, et al. **Clin Nucl Med** 1996 Jun;21(6):494–5

SECRETION

Regulation of cholecystokinin secretion by intraluminal releasing factors. Liddle RA. **Am J Physiol** 1995 Sep;269(3 Pt 1):G319–27 (78 ref.)

Microinjection of TRH analogue into the dorsal vagal complex stimulates pancreatic secretion in rats. Okumura T, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G328–34

Ca(2+)-dependent amylase secretion from SLO-permeabilized rat pancreatic acini requires diffusible cytosolic proteins. Padfield PJ, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G647–52

Aggregation and concentration-dependent sorting of exocrine regulated secretory proteins. Gorr SU, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):82–8

Epidermal growth factor induces the differential release of GP2 and amylase from AR4-2J cells. Koshlukova S, et al. **Cell Signal** 1995 Aug;7(6):559–69

Role of endogenous CCK in regulation of interdigestive pancreatic exocrine secretion in sheep (Ovis aries). Tachibana S, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):103–9

Secretion of insulin and glucagon by the perfused pancreas of genetically obese (fa/fa) Zucker rats and its alteration with aging. Hiramatsu S, et al. **Endocr J** 1995 Aug; 42(4):563–7

Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Martínez A, et al. **Endocrinology** 1996 Jun;137(6):2626–32

Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreatoduodenal resection. Petrin P, et al. **Eur Surg Res** 1995;27(6):371–8

Intraileal carbohydrate regulates canine postprandial pancreaticobiliary secretion and upper gut motility. Tohno H, et al. **Gastroenterology** 1995 Dec;109(6):1977–85

D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs. Iwatsuki K, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S173–4

The involvement of endogenous nitric oxide in vagal-cholinergic stimulation of exocrine and endocrine pancreas in dogs. Bilski J, et al. **Int J Pancreatol** 1995 Aug; 18(1):41–9

Plasma amino acid consumption and pancreatic secretion during and after cerulein-induced pancreatitis in rats. Fischer H, et al. **Int J Pancreatol** 1995 Oct;18(2):127–34

The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas. Kleinman R, et al. **Int J Pancreatol** 1995 Aug; 18(1):51–7

Cholecystokinin (CCK) in the amino acid uptake and enzyme protein secretion by the pancreas in humans. Konturek JW, et al. **Int J Pancreatol** 1995 Feb;17(1):55–61

Toward an animal model of chronic pancreatitis. Pancreatobiliary secretion in hamsters on long-term treatment with chemical inducers of cytochromes P450. Rutishauser SC, et al. **Int J Pancreatol** 1995 Oct; 18(2):117–26

The pattern of the circadian rhythm of pancreatic secretion in fed pigs. Thaela MJ, et al. **J Anim Sci** 1995 Nov; 73(11):3402–8

Influence of ruminal or abomasal starch hydrolysate infusion on pancreatic exocrine secretion and blood glucose and insulin concentrations in steers. Walker JA, et al. **J Anim Sci** 1995 Dec;73(12):3766–74

Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. Mashima H, et al. **J Clin Invest** 1996 Apr 1;97(7):1647–54

Immunocytochemical and cytochemical demonstration of a novel selective lysosomal pathway (SLP) of secretion in the exocrine pancreas. Grondin G, et al. **J Histochem Cytochem** 1996 Apr;44(4):357–68

Insulin secretion by pancreas of athymic mice injected with peripheral mononuclear cells from insulin-dependent diabetic patients. Arata M, et al. **Metabolism** 1995 Nov; 44(11):1435–41

Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Fujitani S, et al. **Metabolism** 1996 Feb;45(2):184–9

Exogenous insulin does not influence CCK- and meal-stimulated pancreatic secretion. Berry SM, et al. **Pancreas** 1996 May;12(4):345–50

Gastric acid-independent enhancement of exocrine pancreatic secretion by dietary protein in chronic bile-pancreatic juice diverted rats. Hara H, et al. **Pancreas** 1995 Aug;11(2):173–8

Stimulation of endocrine, but not exocrine, pancreatic secretion during 2-deoxy-D-glucose-induced neuroglycopenia in the conscious pig. Karlsson S, et al. **Pancreas** 1995 Oct;11(3):271–5

Effect of endogenous insulin on pancreatic exocrine secretion in perfused dog pancreas. Lee KY, et al. **Pancreas** 1995 Aug;11(2):190–5

Regulation of gene expression of pancreatic secretory trypsin inhibitor-61 and -56 by bile and pancreatic juice in rats. Miyasaka K, et al. **Pancreas** 1995 Oct;11(3):246–55

Study of pancreatic secretion after subtotal gastrectomy followed by different methods of reconstruction. Perez Vazquez MT, et al. **Pancreas** 1996 Mar;12(2):117–25

Effects of diet on cholecystokinin-stimulated amylase secretion by pancreatic Acini and amylase mRNA levels in rat pancreas. Takaori K, et al. **Pancreas** 1995 Nov; 11(4):402–7

Dose-response effects of VIP on the rabbit exocrine pancreatic secretion. Comparison with PACAP-27 actions. Rodríguez-López AM, et al. **Rev Esp Fisiol** 1995 Mar; 51(1):29–36

[Neurohormonal control of exocrine pancreas secretions by intra-ileal and intracolonic nutrients] Niebergall-Roth E, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):385–91 (Eng. Abstr.) **(Ger)**

[The effect of vagotomy on recurrent retardation of pancreatic secretion] Korot'ko GF, et al. **Biull Eksp Biol Med** 1995 May;119(5):465–9 **(Rus)**

[Food regulation of exocrine pancreatic secretion and bile secretion in swine] Corring T. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):70–81 (55 ref.) **(Rus)**

SURGERY

Management of the pancreatic stump during the Whipple operation. Brewer MS. **Am J Surg** 1996 Apr;171(4):438

Is octreotide beneficial following pancreatic injury? Nwariaku FE, et al. **Am J Surg** 1995 Dec;170(6):582–5

A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Yeo CJ, et al. **Ann Surg** 1995 Oct;222(4):580–8; discussion 588–92

Outcome after surgery for biliary pancreatitis. Runkel NS, et al. **Eur J Surg** 1996 Apr;162(4):307–13

A randomized trial of pefloxacin plus klindamicin and cefoxitin in hepatobiliary and pancreatic surgery. Fried M, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):306–8

Surgical results for severe acute pancreatitis—comparison of the different surgical procedures. Hwang TL, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1026–9

Treatment for dehiscence of pancreaticojejunostomy after pancreaticoduodenectomy: is resection of the residual pancreas necessary? Wu CC, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):271–4

Radical reoperation for advanced pancreatic carcinoma. Johnstone PA, et al. **J Surg Oncol** 1996 Jan;61(1):7–11; discussion 11–3

Demonstration of pancreatic ductal integrity by endoscopic retrograde pancreatography allows conservative surgical management. Chandler C, et al. **J Trauma** 1996 Mar; 40(3):466–8

Penman Lecture. From Langenbuch to laparoscopes—the growth of a specialty. Benjamin IS. **S Afr J Surg** 1995 Jun;33(2):52–60

Closure of the distal pancreatic stump with a seromuscular flap. Moriura S, et al. **Surg Today** 1995;25(11):992–4

Gunshot injuries of the head of the pancreas: conservative approach. Degiannis E, et al. **World J Surg** 1996 Jan; 20(1):68–71; discussion 72

[Prospective randomized comparison of the effects of pefloxacin and clindamycin with cefoxitin after hepatobiliary and pancreatic operations] Fried M, et al. **Rozhl Chir** 1995 Sep;74(6):290–2 (Eng. Abstr.) **(Cze)**

[Pancreatic head resection with preservation of the duodenum—the optimal surgical procedure in chronic pancreatitis] Ružička M, et al. **Rozhl Chir** 1995 Aug; 74(5):228–31 (Eng. Abstr.) **(Cze)**

[A report on pancreas-preserving operation and complications relating pancreatorrhea in total gastrectomy] Honda G, et al. **Nippon Geka Hokan** 1995 May-Jul 1; 64(3-4):85–90 (Eng. Abstr.) **(Jpn)**

[A case report: resection of the uncinate process of the pancreas for ultra-small pancreatic mucin-producing carcinoma of the branch type] Ichihara T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jun;93(6):445–50 **(Jpn)**

[Comparative study of the suture of pancreatic stump with absorbable and unabsorbable threads in rats] Costa IP, et al. **Arq Gastroenterol** 1995 Jan-Mar;32(1):24–30 (Eng. Abstr.) **(Por)**

[Pancreatoduodenectomy with pancreaticogastric anastomosis] Andronescu P, et al. **Chirurgia (Bucur)** 1995; 44(3):17–24 (Eng. Abstr.) **(Rum)**

[The modern aspects of the microsurgical anatomy of the pancreas] Zheleznov LM. **Morfologiia** 1995;108(2):76–80 (79 ref.) **(Rus)**

[Sutures in biliopancreatic surgery] Bilanović D. **Acta Chir Iugosl** 1994;41(2 Suppl 2):243–7 (Eng. Abstr.) **(Scr)**

[Sutures in reconstructive procedures in biliopancreatic surgery] Hajduković C. **Acta Chir Iugosl** 1994;41(2 Suppl 2):249–52 (Eng. Abstr.) **(Scr)**

TRANSPLANTATION see PANCREAS TRANSPLANTATION

ULTRASONOGRAPHY

Sonographic evaluation of acute pancreatic transplant rejection: morphology-Doppler analysis versus guided percutaneous biopsy. Wong JJ, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):803–7

Endoscopic sonography of the upper gastrointestinal tract and pancreas. Zerbey AL 3rd, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):45–50

Endoscopic ultrasound–guided pancreatography: a case report. Harada N, et al. **Endoscopy** 1995 Oct;27(8):612–5

Endosonography of the pancreas: normal variation versus changes of early chronic pancreatitis. Wiersema MJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):487–96 (24 ref.)

[Should fasting prior to ultrasound examination of the gallbladder, the biliary ducts and the pancreas have to include not–drinking?] Lund–Olesen LH, et al. **Ugeskr Laeger** 1995 Nov 6;157(45):6270–2 (Eng. Abstr.) **(Dan)**

[Ultrasound (letter)] Tjrñum TE. **Ugeskr Laeger** 1996 Jan 29;158(5):616 **(Dan)**

[Hypoechogenic aspects of the ventral embryonic cephalic pancreas: a large prospective clinical study] Coulier B. **J Belge Radiol** 1996 Jun;79(3):120–4 (Eng. Abstr.) **(Fre)**

[Pitfall: decreased echo contrast of the processus uncinatus in ultrasound] Brambs HJ. **Rontgenpraxis** 1996 Jun; 49(6):139–40 **(Ger)**

[The functional and sonographic parallels in chronic pancreatitis] Gubergrits NB, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):51–3 (Eng. Abstr.) **(Rus)**

[Size and echogenicity of the pancreas in Chilean adults: echotomography study in 261 patients] Guerra M, et al. **Rev Med Chil** 1995 Jun;123(6):720–6 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Correlation of nucleolar organizer regions with secretory and regenerative process in experimental cerulein–induced pancreatitis in the rat. Rüschoff J, et al. **Pancreas** 1995 Aug; 11(2):154–9

Filamentous inclusions in nonneoplastic and neoplastic pancreas: an ultrastructural and immunogold labeling study. Pasquinelli G, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):495–500

Fibrillary inclusions in neoplastic and fetal acinar cells of the pancreas. Chong JM, et al. **Virchows Arch** 1996 Jul; 428(4–5):261–6

PANCREAS, ARTIFICIAL ENDOCRINE see **INSULIN INFUSION SYSTEMS**

PANCREAS, ENDOCRINE see **ISLETS OF LANGERHANS**

PANCREAS TRANSPLANTATION

Sonographic evaluation of acute pancreatic transplant rejection: morphology–Doppler analysis versus guided percutaneous biopsy. Wong JJ, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):803–7

Evaluation using dobutamine stress echocardiography in patients with insulin–dependent diabetes mellitus before kidney and/or pancreas transplantation. Bates JR, et al. **Am J Cardiol** 1996 Jan 15;77(2):175–9

Pancreas transplantation for diabetes mellitus. Pirsch JD, et al. **Am J Kidney Dis** 1996 Mar;27(3):444–50 (56 ref.)

The role of whole organ pancreas transplantation in the treatment of type I diabetes. Kinkhabwala M, et al. **Am J Surg** 1996 May;171(5):516–20

Success and complications of pancreatic transplantation at one institution. Jones JW, et al. **Ann Surg** 1996 Jun; 223(6):757–62; discussion 762–4

Long–term peritoneal dialysis before transplantation and intra–abdominal infection after simultaneous pancreas–kidney transplantations. Papalois BE, et al. **Arch Surg** 1996 Jul;131(7):761–6

Anastomotic leak of pancreatic transplant demonstrated by radionuclide cystography. Mouratidis B, et al. **Clin Nucl Med** 1995 Aug;20(8):742–3

Worldwide Transplant Center Directory. Pancreas Transplants. **Clin Transpl** 1994;:711–4

Worldwide Transplant Center Directory. Kidney–Pancreas Transplants. **Clin Transpl** 1994;:715–24

Urethritis/dysuria after simultaneous pancreas–kidney transplantation. Ciancio G, et al. **Clin Transplant** 1996 Feb; 10(1 Pt 1):67–70

Urologic complications after simultaneous pancreas–kidney transplantation: hand–sewn versus stapled duodenocystostomy. Douzdjian V, et al. **Clin Transplant** 1995 Oct;9(5):396–400

Pancreas transplantation: a managed cure approach to diabetes. Stratta RJ, et al. **Curr Probl Surg** 1996 Sep; 33(9):709–808 (250 ref.)

Effect of pancreas transplantation on free fatty acid metabolism in uremic IDDM patients. Luzi L, et al. **Diabetes** 1996 Mar;45(3):354–60

Hepatic insulin resistance after pancreas transplantation in type I diabetes. Rooney DP, et al. **Diabetes** 1996 Feb; 45(2):134–8

A diabetes potpourri, Part 1 [news] Bloomgarden ZT. **Diabetes Care** 1995 May;18(5):734–6

Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157–63 (40 ref.)

Pancreas transplantation: a treatment option for insulin–dependent diabetes mellitus. Larsen JL, et al. **Diabetes Metab** 1996 Apr;22(2):139–46 (76 ref.)

The case for pancreas transplantation. Sutherland DE. **Diabetes Metab** 1996 Apr;22(2):132–8 (39 ref.)

Pancreas transplantation: an update. Sutherland DE, et al. **Diabetes Metab Rev** 1995 Dec;11(4):337–63 (218 ref.)

Pancreas transplantation. Stratta RJ, et al. **Int J Pancreatol** 1995 Feb;17(1):1–13 (85 ref.)

Radiologic evaluation of simultaneous pancreas–kidney transplantation. Stafford Johnson DB, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):105–8

Vascular graft thrombosis after pancreatic transplantation: univariate and multivariate operative and nonoperative risk factor analysis [see comments] Troppmann C, et al. **J Am Coll Surg** 1996 Apr;182(4):285–316. Comment in: J Am Coll Surg 1996 Apr;182(4):362–3.

Consequences of pancreas transplantation. Larsen JL, et al. **J Investig Med** 1994 Dec;42(4):622–31 (78 ref.)

Mycophenolate mofetil immunosuppression in rat pancreas allotransplantation. Schulak JA, et al. **J Surg Res** 1996 Jan; 60(1):79–83

Sonographic diagnosis of arteriovenous fistula in pancreas transplant. Keener TS, et al. **J Ultrasound Med** 1995 Feb; 14(2):149–52

Ballooning of the duodenal segment after a pancreas–kidney transplantation. de la Fuente RB, et al. **J Urol** 1996 Apr; 155(4):1384

Effect of directly ultraviolet–irradiated allografts of fetal pancreas in experimental diabetic dogs. Yasuda M, et al. **J Vet Med Sci** 1995 Aug;57(4):591–4

Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Fioretto P, et al. **Kidney Int** 1995 Aug;48(2):489–95

The mechanism of action of the two–layer cold storage method in canine pancreas preservation––protection of pancreatic microvascular endothelium. Fujita H, et al. **Kobe J Med Sci** 1995 Jun;41(3):47–61

alpha–Tocopherol pretreatment protects the endocrine function of grafts against ischemic damage during heterotopic pancreatic transplantation. Ikeda M, et al. **Life Sci** 1996;59(10):781–8

Islet and pancreatic transplantation––autoimmunity and alloimmunity [editorial; comment] Eisenbarth GS, et al. **N Engl J Med** 1996 Sep 19;335(12):888–90. Comment on: N Engl J Med 1996 Sep 19;335(12):860–3.

Transplantation of the diabetic in 1994. A personal view. Brynger H. **Nephrol Dial Transplant** 1995;10 Suppl 7:56–7

Pancreas allograft rejection: correlation of transduodenal core biopsy with Doppler resistive index. Nelson NL, et al. **Radiology** 1996 Jul;200(1):91–4

Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323–37 (85 ref.)

Correlation between cystoscopic biopsy results and hypoamylasuria in bladder–drained pancreas transplants. Benedetti E, et al. **Surgery** 1995 Nov;118(5):864–72

Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. Hartgrink HH, et al. **Transpl Int** 1995;8(5):366–73

A technique for vascular reconstruction of pancreaticoduodenal allograft. A literature review and case report. Nghiem DD. **Transpl Int** 1995;8(5):411–3

The efficacy of CMH (Collins modified with HES) solution in canine pancreatic graft preservation. Arita S, et al. **Transplant Proc** 1995 Dec;27(6):3035–6

Clinical islet transplantation: a consortium model. Brunicardi FC. **Transplant Proc** 1996 Aug;28(4):2138–40

The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. Burke GW, et al. **Transplant Proc** 1995 Dec;27(6):3123–4

Advantages of the rapid en bloc technique for pancreas/liver recovery. Dodson F, et al. **Transplant Proc** 1995 Dec; 27(6):3050

Tissue hydration in UW–preserved pancreas allografts: evaluation by magnetic resonance relaxometry. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3051–2

Combined pancreas–kidney transplants using quadruple immunosuppression therapy: a comparison between antilymphoblast and antithymocyte globulins. Fasola CG, et al. **Transplant Proc** 1995 Dec;27(6):3135–6

Conversion from cyclosporine to tacrolimus after pancreas transplantation. Hariharan S, et al. **Transplant Proc** 1995 Dec;27(6):2981–2

Outcome of combined kidney/pancreas transplantation in recipients with coronary artery disease. Kim SI, et al. **Transplant Proc** 1995 Dec;27(6):3071

Evolution of carotid vascular lesions in kidney–pancreas and kidney–alone transplanted insulin–dependent diabetic patients. La Rocca E, et al. **Transplant Proc** 1995 Dec; 27(6):3072

Is there a transfusion effect in combined pancreas–kidney transplantation? Stratta RJ, et al. **Transplant Proc** 1995 Dec; 27(6):3096

Solitary pancreas transplantation: experience with 50 consecutive cases. Stratta RJ, et al. **Transplant Proc** 1995 Dec;27(6):3022–3

Donor criteria and technical aspects of procurement in combined pancreas and kidney transplantation from non–heart–beating cadavers. Teraoka S, et al. **Transplant Proc** 1995 Dec;27(6):3097–100

Experience with 150 pancreatic transplants. Tydén G, et al. **Transplant Proc** 1995 Dec;27(6):3493–4

Obesity as a risk factor after combined pancreas/kidney transplantation. Bumgardner GL, et al. **Transplantation** 1995 Dec 27;60(12):1426–30

Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. Chapman JR, et al. **Transplantation** 1996 Jun 27;61(12):1699–704

Pancreatic transplantation in experimental non–insulin–dependent diabetic rats. Ellan N, et al. **Transplantation** 1996 Mar 15;61(5):696–700

A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Gruessner RW, et al. **Transplantation** 1996 Jan 27;61(2):261–73

Simultaneous kidney and segmental pancreas transplants from living related donors – the first two successful cases. Gruessner RW, et al. **Transplantation** 1996 Apr 27; 61(8):1265–8

Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Hariharan S, et al. **Transplantation** 1996 Apr 27; 61(8):1161–5

Kidney–pancreas transplantation. The effect of portal versus systemic venous drainage of the pancreas on the lipoprotein composition. Hughes TA, et al. **Transplantation** 1995 Dec 27;60(12):1406–12

Rapid en bloc technique for pancreas–liver procurement. Improved early liver function. Imagawa DK, et al. **Transplantation** 1996 Jun 15;61(11):1605–9

Clinical determinants of glucose homeostasis after pancreas transplantation. Nankivell BJ, et al. **Transplantation** 1996 Jun 27;61(12):1705–11

Pancreas autotransplantation in pig with systemic or portal venous drainage. Effect on the endocrine pancreatic function after transplantation. Shokouh–Amiri MH, et al. **Transplantation** 1996 Apr 15;61(7):1004–9

Delayed endocrine pancreas graft function after simultaneous pancreas–kidney transplantation. Incidence, risk factors, and impact on long–term outcome. Troppmann C, et al. **Transplantation** 1996 May 15;61(9):1323–30

Neutrophil elastase inhibitor (ONO–5046) decreases cytokine–induced neutrophil chemoattractant after reperfusion of pancreaticoduodenal transplantation in rats. Wang FS, et al. **Transplantation** 1996 Apr 15;61(7):1103–7

[Long–term treatment of diabetes with transplantation of a pancreatic segment] Saudek F, et al. **Cas Lek Cesk** 1996 May 29;135(11):348–53 (Eng. Abstr.) **(Cze)**

[Is there a role for pancreas transplantation in the treatment of type II diabetes mellitus? Experimental study] Elian N, et al. **Chirurgie** 1996;121(2):144–50 (Eng. Abstr.) **(Fre)**

[Benefits and limitations of pancreas transplantation in insulin–dependent diabetics: a study apropos of 26 patients] Kessler L, et al. **Rev Med Interne** 1996;17(2):117–24 (Eng. Abstr.) **(Fre)**

[Effect of pancreas transplantation on triglyceride metabolism] Pálos G, et al. **Orv Hetil** 1995 Nov 26; 136(48):2609–14 (Eng. Abstr.) **(Hun)**

[Technique of vascular reconstructive bench surgery in pancreas transplantation] Arcuri V, et al. **G Chir** 1996 Mar; 17(3):85–9 (Eng. Abstr.) **(Ita)**

[Personal experience with simultaneous transplantation of pancreas segment and kidney] Szmidt J, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):34–8 (Eng. Abstr.) **(Pol)**

[Historical course of surgical techniques in pancreas transplantation] Toledo–Pereyra LH, et al. **Gac Med Mex** 1994 Nov–Dec;130(6):487–94 (65 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Bladder–to–duodenal stump reflux simulating a urinoma in a patient with renal and pancreaticoduodenal transplantation. Kim CK, et al. **Clin Nucl Med** 1996 May; 21(5):402–4

Rejection with duodenal rupture after solitary pancreas transplantation: an unusual cause of severe hematuria. Esterl RM, et al. **Clin Transplant** 1995 Jun;9(3 Pt 1):155–9

Pancreatic transplantation and vascular graft thrombosis. [editorial; comment] Sollinger HW. **J Am Coll Surg** 1996 Apr;182(4):362–3. Comment on: J Am Coll Surg 1996 Apr;182(4):285–316.

Infection of the pancreatic duct following pancreas transplantation with bladder drainage. Bonatti H, et al. **J Chemother** 1995 Oct;7(5):442–5

Arteriovesical fistula after pancreatic transplantation. Nash PA, et al. **J Urol** 1995 Nov;154(5):1861–2

Cyclosporin–induced cerebellar syndrome in a pancreatico–renal transplant recipient. Rustom R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1374–5

Protease activation in the porcine pancreatic allograft during preservation. Jönsson P, et al. **Pancreas** 1995 Oct; 11(3):256–60

Analysis of the rejection markers tumor necrosis factor, ICAM–1, neopterin, interleukin–10, and soluble HLA in simultaneous pancreas and kidney transplantation with bladder drainage. Abendroth D, et al. **Transplant Proc** 1995 Dec;27(6):3114–5

Low urinary tract infections in simultaneous pancreas and kidney transplantation: comparison between bladder and enteric drainage of exocrine secretions. Baldi A, et al. **Transplant Proc** 1995 Dec;27(6):3116–7

Conservative management of intrapancreatic collections after whole pancreas transplantation: report of two cases. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3042

How to treat graft infection after pancreatic transplantation.

Bonatti H, et al. **Transplant Proc** 1995 Dec;27(6):3045–7
Late complications in kidney–pancreas transplant recipients. Bruce DS, et al. **Transplant Proc** 1995 Dec;27(6):3118
Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. Burke GW, et al. **Transplant Proc** 1995 Dec; 27(6):3119–20
Urological complications following simultaneous pancreas–kidney transplantation. Ciancio G, et al. **Transplant Proc** 1995 Dec;27(6):3125–6
Multivariate analysis of donor and recipient risk factors for renal and pancreas allograft failure after pancreas–kidney transplantation. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3128–9
Wound complications after simultaneous pancreas–kidney transplants: midline versus transverse incision. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3130–2
Fine–needle aspiration biopsy in pancreatic transplantation. Egidi MF, et al. **Transplant Proc** 1995 Dec;27(6):3055–6
Diagnosis and treatment of symptomatic peripancreatic fluid collections after pancreas transplant. Esterl RM Jr, et al. **Transplant Proc** 1995 Dec;27(6):3057–8
The effect of a pancreatic allograft distal arteriovenous fistula on islet hormone secretions. Fiedor P, et al. **Transplant Proc** 1995 Dec;27(6):3280–1
Low postoperative wound infection rates are possible following simultaneous pancreas–kidney transplantation. Freise CE, et al. **Transplant Proc** 1995 Dec;27(6):3069–70
Comparison between methylprednisolone and OKT3 treatment for the first acute rejection episode in combined kidney and pancreas transplant recipients. el–Ghoroury M, et al. **Transplant Proc** 1995 Dec;27(6):3133–4
Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir. Kohil V, et al. **Transplant Proc** 1995 Dec;27(6):2993
The magnetic resonance–derived pancreas to psoas ratio (PPR): objective and reliable noninvasive diagnosis of pancreatic rejection. Krebs T, et al. **Transplant Proc** 1995 Dec;27(6):3034
Cystoscopic management of pancreatic allograft duct obstruction. Kuhr CS, et al. **Transplant Proc** 1995 Dec; 27(6):2994–5
Carotid intima–media thickness by ultrasound measurement in pancreas transplant candidates. Larsen JL, et al. **Transplant Proc** 1995 Dec;27(6):2996
Effects of long–term exposure to urine on proliferative lesions of the duodenum in bladder–drained pancreas transplants. Nghiem DD, et al. **Transplant Proc** 1995 Dec;27(6):3004–6
Impact of ganciclovir prophylaxis on cytomegalovirus infection in cadaveric kidney vs combined kidney and pancreas transplantation. Peddi VR, et al. **Transplant Proc** 1995 Dec;27(6):3076–7
Clinical and laboratory features of pancreatic transplant bladder leaks. Rayhill SC, et al. **Transplant Proc** 1995 Dec; 27(6):3141–2
A comparison of the sensitivities of contrast and isotope voiding cystourethrograms for the detection of pancreas transplant bladder leaks. Rayhill SC, et al. **Transplant Proc** 1995 Dec;27(6):3143–4
Iliac artery–bladder fistula: a late complication of rejected pancreas transplants with bladder drainage. Sakopoulos AM, et al. **Transplant Proc** 1995 Dec;27(6):3008–9
Selection for low cardiovascular risk markedly improves patient and graft survival in pancreaticorenal transplant recipients. Sells RA, et al. **Transplant Proc** 1995 Dec; 27(6):3082
High intravesical pressures and related urologic complications in simultaneous kidney/pancreas transplant recipients. Sethi PS, et al. **Transplant Proc** 1995 Dec; 27(6):3085–6
Nafamostat mesilate prevents warm ischemia–reperfusion injury in canine pancreas autotransplantation. Shimizu Y, et al. **Transplant Proc** 1995 Dec;27(6):3191–2
Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction. Sindhi R, et al. **Transplant Proc** 1995 Dec; 27(6):3016–7
Major bacterial and fungal infections after 50 simultaneous pancreas–kidney transplantations. Smets YF, et al. **Transplant Proc** 1995 Dec;27(6):3089–90
Use of granulocyte–macrophage colony–stimulating factor for reversal of neutropenia following combined kidney–pancreas transplantation. Squiers EC, et al. **Transplant Proc** 1995 Dec;27(6):3092–3
Infection prophylaxis in pancreas transplant recipients. Stratta RJ, et al. **Transplant Proc** 1995 Dec;27(6):3018–9
Experience with protocol biopsies after solitary pancreas transplantation. Stratta RJ, et al. **Transplant Proc** 1995 Dec; 27(6):3012–3
Experience with pancreas retransplantation. Stratta RJ, et al. **Transplant Proc** 1995 Dec;27(6):3020–1
Urologic infections and problems after 50 simultaneous pancreas–kidney transplantations. Van der Pijl JW, et al. **Transplant Proc** 1995 Dec;27(6):3105
Acute carpal tunnel syndrome immediately after combined kidney and pancreas transplantation. Wadström J, et al. **Transplant Proc** 1995 Dec;27(6):3489–90
Persistent pancreatic fistula after pancreas transplantation treated with fibrin glue and octreotide. Wadström J, et al. **Transplant Proc** 1995 Dec;27(6):3491–2
Decreased graft survival rate in obese pancreas/kidney recipients. Wilson GA, et al. **Transplant Proc** 1995 Dec; 27(6):3106–7
Reflux pancreatitis after simultaneous pancreas–kidney transplantation treated by alpha 1 blocker. Ciancio G, et al. **Transplantation** 1995 Oct 15;60(7):760–1
Destructive allograft fungal arteritis following simultaneous pancreas–kidney transplantation. Ciancio G, et al. **Transplantation** 1996 Apr 27;61(8):1172–5
Hodgkin's disease after transplantation. Garnier JL, et al. **Transplantation** 1996 Jan 15;61(1):71–6
Delayed urinary bladder leak after combined kidney–pancreas transplantation. Association with penile prosthesis implantation. Pearson TC, et al. **Transplantation** 1995 Sep 27;60(6):624–6
[3 case reports of unsuccessful cadaveric pancreas transplantation] Bošković S. **Acta Chir Iugosl** 1991; 38(1):49–60 (Eng. Abstr.) **(Scr)**

ECONOMICS

Cost–effective treatment for diabetic end–stage renal disease: dialysis, kidney, or kidney–pancreas transplantation? Lenisa L, et al. **Transplant Proc** 1995 Dec;27(6):3108–13
Cost analysis of kidney–pancreas and kidney–islet transplant. Lenisa L, et al. **Transplant Proc** 1995 Dec;27(6):3061–4

IMMUNOLOGY

Lessons learned from the non–obese diabetic mouse II: Amelioration of pancreatic autoimmune isograft rejection during pregnancy. Chen HM, et al. **Am J Perinatol** 1996 May;13(4):249–54
Immunosuppressive effects of the cyclosporin derivative SDZ IMM 125 on kidney allograft in the dog and small bowel and pancreas allografts in the rat. Chen H, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):76–81
Antibody–mediated hemolytic anemia following ABO–mismatched organ transplantation: contributory role of HLA matching and polyclonal antilymphocyte globulin. Fabrega AJ, et al. **Clin Transplant** 1996 Apr;10(2):166–9
Response to Tran et al [letter; comment] Service FJ. **Diabetes Care** 1995 Apr;18(4):585. Comment on: Diabetes Care 1994 Sep;17(9):988–93.
Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR, et al. **Transplant Proc** 1996 Apr;28(2):995–7
Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption. Chapman JR, et al. **Transplant Proc** 1996 Aug; 28(4):2293–5
Anti–adhesion (anti–ICAM–1 and anti–LFA–1) therapy in a rat pancreas transplantation model. Kawabe A, et al. **Transplant Proc** 1996 Jun;28(3):1808–11
Tacrolimus–based vs cyclosporine–based immunotherapy in combined kidney–pancreas transplantation. Ketel BL, et al. **Transplant Proc** 1996 Apr;28(2):899
Fetal pig xenografts in NOD/Lt mice: lack of expression of Gal(alpha 1–3)Gal on endocrine cells and the effect of peritransplant anti–CD4 monoclonal antibody and graft immunomodification on graft survival. Koulmanda M, et al. **Transplant Proc** 1995 Dec;27(6):3570
Intracellular adhesion molecule 1 expression on rat pancreatic allografts. Ohtsuka S, et al. **Transplant Proc** 1995 Dec; 27(6):3007
Prolongation of pancreas allograft survival by mycophenolate mofetil in the rat. Qi S, et al. **Transplant Proc** 1996 Apr;28(2):932–3
Administration of tacrolimus (FK506) in hamster–to–rat pancreas xenotransplantation. Sakimoto H, et al. **Transplant Proc** 1996 Jun;28(3):1433–4
Effect of major histocompatibility disparity on mycophenolate mofetil immunosuppression in rat pancreas transplantation. Schulak JA, et al. **Transplant Proc** 1995 Dec;27(6):3010–1
FK 506 induction and rescue therapy in pancreas transplant recipients. Stratta RJ, et al. **Transplant Proc** 1996 Apr; 28(2):991–2
A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Stratta RJ, et al. **Transplant Proc** 1996 Apr;28(2):917–8
Isolated pancreas rejection in combined kidney pancreas tranplantation. Klassen DK, et al. **Transplantation** 1996 Mar 27;61(6):974–7
Transforming growth factor–beta fails to inhibit allograft rejection or virus–induced autoimmune diabetes in transgenic mice. Lee MS, et al. **Transplantation** 1996 Apr 15;61(7):1112–5
Acute graft rejection of human fetal pancreas allografts using donor–specific human peripheral blood lymphocytes in the SCID mouse. MacKenzie DA, et al. **Transplantation** 1996 May 27;61(10):1461–4
Generation of nitric oxide as a rejection marker in rat pancreas transplantation. Tanaka S, et al. **Transplantation** 1995 Oct 15;60(7):713–7
Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor–graft–derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. Uchikoshi F, et al. **Transplantation** 1996 Jun 15;61(11):1629–36
Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. Walker JA, et al. **Transplantation** 1996 Aug 27;62(4):539–43

METHODS

The utility of retroperitoneal kidney placement in simultaneous kidney pancreas transplantation. Kuo PC, et al. **Clin Transplant** 1995 Dec;9(6):457–62
Whole–organ versus islet pancreatic transplantation. Brunicardi FC, et al. **Curr Opin Gen Surg** 1994;:179–85 (37 ref.)
Simultaneous pancreas–kidney and sequential pancreas–after–kidney transplantation. Holohan TV. **Health Technol Assess** 1995 Aug;(4):1–53 (110 ref.)
Pancreas transplantation using non–suture cuff technique in the neck. Hamano M, et al. **Kobe J Med Sci** 1996 Apr; 42(2):93–104
The specificity of monoclonal fluorescence polarization immunoassay for cyclosporine in recipients of simultaneous pancreas–kidney transplants. Kaplan B, et al. **Ther Drug Monit** 1995 Oct;17(5):499–503
The impact of midline versus transverse incisions on wound complications and outcome in simultaneous pancreas–kidney transplants: a retrospective analysis. Douzdjian V, et al. **Transpl Int** 1996;9(1):62–7
Low urinary tract infections in simultaneous pancreas and kidney transplantation: comparison between bladder and enteric drainage of exocrine secretions. Baldi A, et al. **Transplant Proc** 1995 Dec;27(6):3116–7
Hemipancreatectomy, peripheral diversion of pancreatic venous drainage, and insulin sensitivity. Barron P, et al. **Transplant Proc** 1995 Dec;27(6):3040–1
Sensitivity and responsiveness of glucose removal to insulin decrease following systemic pancreatic venous drainage. Barron P, et al. **Transplant Proc** 1995 Dec;27(6):3038–9
Donor bone marrow infusion in simultaneous pancreas/kidney transplant recipients: a preliminary study. Burke GW, et al. **Transplant Proc** 1995 Dec;27(6):3121–2
Enteric drainage of pancreas transplants revisited. Corry RJ, et al. **Transplant Proc** 1995 Dec;27(6):3048–9
Hand–sewn versus stapled duodenocystostomy in bladder–drained pancreas transplants. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3053–4
Wound complications after simultaneous pancreas–kidney transplants: midline versus transverse incision. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3130–2
Pancreatic transplantation. Dubernard JM, et al. **Transplant Proc** 1995 Oct;27(5):2641–3
The effect of a pancreatic allograft distal arteriovenous fistula on islet hormone secretions. Fiedor P, et al. **Transplant Proc** 1995 Dec;27(6):3280–1
Reconstruction of the gastroduodenal artery in pancreatic transplantation. Han DJ. **Transplant Proc** 1996 Jun; 28(3):1727–8
Enteric conversion of bladder–drained pancreas allograft. Han DJ. **Transplant Proc** 1996 Jun;28(3):1729
Experience with clinical pancreatic transplantation using the bladder drainage technique. Illner WD, et al. **Transplant Proc** 1995 Dec;27(6):2983
Learning curve in pancreatic transplantation at a single center. Mittal VK, et al. **Transplant Proc** 1995 Dec; 27(6):2998–9
Rat whole pancreaticoduodenal allotransplantation treated with 15–deoxyspergualin alone and with splenectomy. Nakai I, et al. **Transplant Proc** 1995 Dec;27(6):3000–1
Pancreas transplantation with portal venous drainage and enteric exocrine drainage offers early advantages without compromising safety or allograft function. Newell KA, et al. **Transplant Proc** 1995 Dec;27(6):3002–3
Effects of long–term exposure to urine on proliferative lesions of the duodenum in bladder–drained pancreas transplants. Nghiem DD, et al. **Transplant Proc** 1995 Dec;27(6):3004–6
Experimental heterotopic autotransplantation of tail of the pancreas: immunohistochemical findings. Papalois A, et al. **Transplant Proc** 1995 Dec;27(6):2987–8
Clinical and laboratory features of pancreatic transplant bladder leaks. Rayhill SC, et al. **Transplant Proc** 1995 Dec; 27(6):3141–2
First experience with combined pancreatic–renal transplantation with extraperitoneal placement of the whole pancreatic graft. Saudek F, et al. **Transplant Proc** 1995 Dec; 27(6):3080–1
Successful pancreas–renal transplantation without anti–T–cell antibody induction. Shapiro ME, et al. **Transplant Proc** 1995 Dec;27(6):3087–8
Nafamostat mesilate prevents warm ischemia–reperfusion injury in canine pancreas autotransplantation. Shimizu Y, et al. **Transplant Proc** 1995 Dec;27(6):3191–2
Experience with enteric conversion after pancreas transplantation with bladder drainage. Sindhi R, et al. **Transplant Proc** 1995 Dec;27(6):3014–5
Experience with pancreas retransplantation. Stratta RJ, et al. **Transplant Proc** 1995 Dec;27(6):3020–1
Preliminary experience with FK 506 in pancreas transplant recipients. Stratta RJ, et al. **Transplant Proc** 1995 Dec; 27(6):3024
New technique of orthotopic segmental pancreas transplantation with portal venous drainage established by interposing the splenic vessels. Suzuki Y, et al. **Transplant Proc** 1996 Jun;28(3):1804–6
FK 506–based immunosuppression in clinical pancreas transplantation. Swanson C, et al. **Transplant Proc** 1995 Dec;27(6):3031
Conversion of pancreas transplants to FK 506 from CsA [published erratum appears in Transplant Proc 1996 Apr;28(2):1128] Tesi RJ, et al. **Transplant Proc** 1995 Dec;

27(6):3032–3
Positive duodenal segment cultures are not associated with increased surgical complications after whole organ, bladder-drained pancreas transplantation in three recipient categories. Troppmann C, et al. **Transplant Proc** 1995 Dec; 27(6):3101–3
Simplifying the technique for pancreaticoduodenal transplantation with enteric exocrine drainage. Tydén G, et al. **Transplant Proc** 1995 Dec;27(6):3027–8
Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. Bruce DS, et al. **Transplantation** 1996 Aug 27;62(4):451–6
Tissue hydration in UW-preserved pancreas allografts. Evaluation with magnetic resonance relaxometry. Douzdjian V, et al. **Transplantation** 1995 Sep 27;60(6):611–4
The effect of venous drainage on glucose homeostasis after experimental pancreas transplantation. Hawthorne WJ, et al. **Transplantation** 1996 Aug 27;62(4):435–41
Cystoscopic biopsies in pancreaticoduodenal transplantation. Are duodenal biopsies indicative of pancreas dysfunction? Nakhleh RE, et al. **Transplantation** 1995 Sep 27;60(6):541–6
Experience with protocol biopsies after solitary pancreas transplantation. Stratta RJ, et al. **Transplantation** 1995 Dec 27;60(12):1431–7
Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. van der Pijl JW, et al. **Transplantation** 1996 Aug 27;62(4):456–62
[Combined renal-pancreas transplantation in the treatment for chronic renal insufficiency of diabetic origin . Results from the Pitie Urology Clinic] Bitker MO, et al. **Prog Urol** 1996 Feb;6(1):37–43 (Eng. Abstr.) **(Fre)**
[Double kidney-total pancreas transplantation with bladder reimplantation. 25 cases] Eschwege P, et al. **Prog Urol** 1996 Feb;6(1):30–6 (Eng. Abstr.) **(Fre)**
[Long-term results in pancreas transplantation in diabetes in the pre-cyclosporin era] Largiadèr F. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1433–6 (Eng. Abstr.) **(Ger)**
[Advantages and disadvantages of combination kidney and pancreas transplantation] Marti HP, et al. **Ther Umsch** 1995 Sep;52(9):594–601 (44 ref.) (Eng. Abstr.) **(Ger)**
[Pancreas transplantation—indication, technique and results] Schilling M, et al. **Ther Umsch** 1996 May;53(5):413–8 (30 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients [see comments] Manske CL, et al. **Lancet** 1995 Dec 23–30;346(8991–8992):1658–62. Comment in: Lancet 1996 Mar 23;347(9004):826–7. Comment in: Lancet 1996 Mar 23;347(9004):827.
Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients [letter; comment] Secchi A, et al. **Lancet** 1996 Mar 23;347(9004):827. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1658–62.
Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients [letter; comment] Smets YF, et al. **Lancet** 1996 Mar 23;347(9004):826–7. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1658–62.
Neuropathy and mortality in diabetes: influence of pancreas transplantation. Navarro X, et al. **Muscle Nerve** 1996 Aug; 19(8):1009–16
Risk factors of long-term survivals in combined kidney/pancreas transplantation: a multivariate analysis of 259 recipients. Tso PL, et al. **Transplant Proc** 1995 Dec; 27(6):3104

PATHOLOGY

Specific destruction of islet transplants in NOD<-->C57BL/6 and NOD<-->C3H/Tif embryo aggregation chimeras irrespective of allelic differences in beta-cell antigens. Leijon K, et al. **J Autoimmun** 1995 Jun; 8(3):347–56
Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts [see comments] Tydén G, et al. **N Engl J Med** 1996 Sep 19;335(12):860–3. Comment in: N Engl J Med 1996 Sep 19;335(12):888–90.
In vivo maturation and growth potential of human fetal pancreases: fresh versus cultured tissue. Beattie GM, et al. **Transplant Proc** 1995 Dec;27(6):3343
Octreotide effects on pancreatic graft pancreatitis in inbred pigs. Chao SH, et al. **Transplant Proc** 1996 Jun; 28(3):1799–801
Histologic grading of pancreas acute allograft rejection in percutaneous needle biopsies. Drachenberg C, et al. **Transplant Proc** 1996 Feb;28(1):512–3
The magnetic resonance-derived pancreas to psoas ratio (PPR): objective and reliable noninvasive diagnosis of pancreatic rejection. Krebs T, et al. **Transplant Proc** 1995 Dec;27(6):3034
Cystoscopic management of pancreatic allograft duct obstruction. Kuhr CS, et al. **Transplant Proc** 1995 Dec; 27(6):2994–5
Experience with protocol biopsies after solitary pancreas transplantation. Stratta RJ, et al. **Transplant Proc** 1995 Dec; 27(6):3012–3

PHYSIOLOGY

Enzymatic digestion of the urethra after pancreatic transplantation: a case report. Mullaney JM, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):563–5
Experience with color-coded duplex sonography after combined kidney/pancreas transplantation—preliminary results. Lang H, et al. **Bildgebung** 1996 Jun;63(2):90–3
Pancreatic allograft thrombosis: diagnostic and therapeutic importance of splenic venous flow velocity. Nghiem DD. **Clin Transplant** 1995 Oct;9(5):390–5
Hypoglycaemic threshold after pancreatic transplantation [letter] Sachon C, et al. **Diabet Med** 1995 Jul;12(7):637–8
Impaired insulin-stimulated nonoxidative glucose metabolism in pancreas-kidney transplant recipients. Dose-response effects of insulin on glucose turnover. Christiansen E, et al. **Diabetes** 1996 Sep;45(9):1267–75
Glucose, insulin, and glucagon levels during exercise in pancreas transplant recipients. Redmon JB, et al. **Diabetes Care** 1995 Apr;18(4):457–62
Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. Pfeffer F, et al. **Diabetologia** 1996 Apr; 39(4):462–8
Effects of pancreas transplantation on distribution and composition of plasma lipoproteins. Föger B, et al. **Metabolism** 1996 Jul;45(7):856–61
Experience with 100 combined pancreatic renal transplantations in a single center. Di Landro D, et al. **Nephron** 1996;72(4):547–51
Serum sialic acid, a risk factor for cardiovascular disease, improves following pancreas transplantation. Auersvald LA, et al. **Transplant Proc** 1995 Dec;27(6):3037
Sensitivity and responsiveness of glucose removal to insulin decrease following systemic pancreatic venous drainage. Barron P, et al. **Transplant Proc** 1995 Dec;27(6):3038–9
Hemipancreatectomy, peripheral diversion of pancreatic venous drainage, and insulin sensitivity. Barron P, et al. **Transplant Proc** 1995 Dec;27(6):3040–1
Pregnancy after pancreas transplantation: report of four new cases and review of the literature. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3043–4 (2 ref.)
Long-term pancreatic function: potential benefits. Bartlett ST, et al. **Transplant Proc** 1996 Aug;28(4):2128–30 (18 ref.)
Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Bruce DS, et al. **Transplant Proc** 1996 Aug;28(4):2136–7
Effect of new thromboxane A2 synthesis inhibitor tetramethyl-pyrazine on pancreatic transplantation in diabetic rats. Chen S, et al. **Transplant Proc** 1996 Jun; 28(3):1802–3
Cyclosporine therapy in pancreas transplantation. Davidson I, et al. **Transplant Proc** 1996 Aug;28(4):2134–5
Stability of bladder function two years following simultaneous pancreas-kidney transplantation. Dmochowski RR, et al. **Transplant Proc** 1995 Dec; 27(6):3127
Spectrum of susceptibility to rejection of heart and multivisceral small bowel allografts using leflunomide immunosuppression. D'Silva M, et al. **Transplant Proc** 1996 Apr;28(2):948–9
Use of glucose disappearance rates to monitor beta-cell function of pancreas allografts. Elmer DS, et al. **Transplant Proc** 1995 Dec;27(6):2985–6
Pancreatic xenotransplantation in rabbits. Gupta RC, et al. **Transplant Proc** 1996 Jun;28(3):1414–5
Enteric conversion of bladder-drained pancreas allograft. Han DJ. **Transplant Proc** 1996 Jun;28(3):1729
Lipids following pancreas transplantation in recipients receiving FK 506. Henley SE, et al. **Transplant Proc** 1995 Dec;27(6):2997
Protective effect of coenzyme Q10 against warm ischemia damage in rat pancreatic transplantation. Ikeda M, et al. **Transplant Proc** 1996 Jun;28(3):1807
Combined procurement of liver and pancreas does not influence early graft function and survival. Kim SC, et al. **Transplant Proc** 1996 Jun;28(3):1882–4
Possibility of pancreas transplantation from non-heart-beating cadaver donors. Kuroda Y, et al. **Transplant Proc** 1996 Jun;28(3):1876–7
Insulin secretion and glucose tolerance evolution in kidney-pancreas graft. Matte J, et al. **Transplant Proc** 1995 Dec;27(6):3073–4
Long-term function and rehabilitation in combined kidney and pancreatic transplants. Mittal VK, et al. **Transplant Proc** 1995 Dec;27(6):3075
Evaluation of pancreas graft function by the measurement of pancreatic protein synthesis rate. Miyauchi H, et al. **Transplant Proc** 1996 Feb;28(1):361–2
Experimental heterotopic allotransplantation of the tail of the pancreas: immunohistochemical results. Papalois A, et al. **Transplant Proc** 1995 Dec;27(6):2989–90
Factors affecting oral glucose tolerance after pancreas-kidney transplantation. Pfeffer F, et al. **Transplant Proc** 1995 Dec;27(6):3078–9
Pre and posttransplant urologic work-up in simultaneous kidney/pancreas transplant: preliminary results of an ongoing study. Sethi PS, et al. **Transplant Proc** 1995 Dec; 27(6):3083–4
Improvement in nerve conduction 8 years after combined pancreatic and renal transplantation. Solders G, et al. **Transplant Proc** 1995 Dec;27(6):3091
Cyclosporine resorption in diabetic patients after simultaneous pancreas and kidney transplantation. Storck M, et al. **Transplant Proc** 1995 Dec;27(6):3094–5
Long-term function (> 5 years) of pancreas grafts from the International Pancreas Transplant Registry database. Sutherland DE, et al. **Transplant Proc** 1995 Dec; 27(6):2977–80
Metabolic control in recipients of segmental pancreatic grafts functioning beyond 8 years. Tibell A, et al. **Transplant Proc** 1995 Dec;27(6):3029–30
Prevention of reperfusion injury after rat pancreas preservation using rinse solution containing nafamostat mesilate. Urushihara T, et al. **Transplant Proc** 1996 Jun; 28(3):1874–5

PSYCHOLOGY

One-year change in quality-of-life profiles in patients receiving pancreas and kidney transplants. Gross CR, et al. **Transplant Proc** 1995 Dec;27(6):3067–8
Identification of quality-of-life outcomes distinguishing diabetic kidney-alone and pancreas-kidney recipients. Hathaway DK, et al. **Transplant Proc** 1995 Dec; 27(6):3065–6

RADIOGRAPHY

A comparison of the sensitivities of contrast and isotope voiding cystourethrograms for the detection of pancreas transplant bladder leaks. Rayhill SC, et al. **Transplant Proc** 1995 Dec;27(6):3143–4

RADIONUCLIDE IMAGING

Visualization of reflux from bladder to the duodenal portion of a pancreatic-duodenal allograft. Pinkas L, et al. **Clin Nucl Med** 1995 Dec;20(12):1100–1

REHABILITATION

Long-term function and rehabilitation in combined kidney and pancreatic transplants. Mittal VK, et al. **Transplant Proc** 1995 Dec;27(6):3075

STATISTICS & NUMERICAL DATA

Pancreas transplant results in the United Network for Organ Sharing (UNOS) United States of America (USA) Registry compared with non-USA data in the International Registry. Gruessner A, et al. **Clin Transpl** 1994;:47–68
Simultaneous kidney and pancreas transplantation at the San Raffaele Scientific Institute: clinical experience and results. Secchi A, et al. **Clin Transpl** 1994;:255–63
Pancreas transplantation: the Nebraska experience. Stratta RJ, et al. **Clin Transpl** 1994;:265–81
Pancreas and islet cell transplantation: now and then. Sutherland DE. **Transplant Proc** 1996 Aug;28(4):2131–3 (20 ref.)

TRENDS

Pancreatic transplantation and its future role in diabetes management [editorial] Landgraf R. **Diabet Med** 1995 Nov; 12(11):947–8
Transplantation of pancreas and islets of Langerhans: a review of progress. Inverardi L, et al. **Immunol Today** 1996 Jan;17(1):7–9

PANCREASE see **PANCREATIN**

PANCREATECTOMY

see related
PANCREATICOJEJUNOSTOMY

The outcome of pancreatic fistulas developed after surgery for pancreatic pseudocysts. Magyar A, et al. **Acta Chir Hung** 1995–96;35(1–2):169–76
Pitfalls of distal pancreatectomy for relief of pain in chronic pancreatitis. Rattner DW, et al. **Am J Surg** 1996 Jan; 171(1):142–5; discussion 145–6
Pancreatic or liver resection for malignancy is safe and effective for the elderly. Fong Y, et al. **Ann Surg** 1995 Oct;222(4):426–34; discussion 434–7
Growth and endocrine function after near total pancreatectomy for hyperinsulinaemic hypoglycaemia [see comments] Soliman AT, et al. **Arch Dis Child** 1996 May; 74(5):379–85. Comment in: Arch Dis Child 1996 May;74(5):369–72.
Completion pancreatectomy for surgical complications after pancreaticoduodenectomy. Farley DR, et al. **Br J Surg** 1996 Feb;83(2):176–9
An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas. Ozaki H, et al. **Cancer** 1996 Jun 1;77(11):2240–5
Long-term complication following subtotal pancreatectomy for nesidioblastosis: a case report. Chevalier SG. **Conn Med** 1996 Jun;60(6):335–8
Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomized rats. Hosokawa H, et al. **Diabetes** 1995 Nov;44(11):1328–33
Nesidioblastosis causing reversal of insulin-dependent diabetes and development of hyperinsulinemic hypoglycemia. Bell DS, et al. **Diabetes Care** 1995 Oct; 18(10):1379–80
Role of initial near total (95%) pancreatectomy in persistent neonatal hyperinsulinism (PNH). Haddad MJ, et al.

Eur J Pediatr Surg 1996 Apr;6(2):82–5
Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164–84 (159 ref.)
Effect of subtotal pancreatectomy on the rate of liver regeneration: the role of hepatic stimulator substance. Kyprianidis KG, et al. **J Surg Res** 1996 May;62(2):267–72
Effect of octreotide on pancreatic endocrine function in partial pancreatectomy. Presti M, et al. **J Surg Res** 1996 Mar;61(2):449–53
Effect of L-364,718 on pancreatic endocrine function following partial pancreatectomy. Presti ME, et al. **J Surg Res** 1996 Aug;64(2):170–5
Lymphadenectomy and pancreatico-splenectomy in gastric cancer surgery [letter; comment] Sano T, et al. **Lancet** 1996 Jul 20;348(9021):195–6. Comment on: Lancet 1996 Apr 13;347(9007):995–9.
Distal pancreatectomy for cancer: results in U.S. Department of Veterans Affairs hospitals, 1987–1991. Wade TP, et al. **Pancreas** 1995 Nov;11(4):341–4
Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Bluemke DA, et al. **Radiology** 1995 Nov;197(2):381–5
Laparoscopic pancreatectomy. Salky BA, et al. **Surg Clin North Am** 1996 Jun;76(3):539–45
Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)
Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Lai DT, et al. **Surgery** 1996 Jan;119(1):112–4
Hemipancreatectomy, peripheral diversion of pancreatic venous drainage, and insulin sensitivity. Barron P, et al. **Transplant Proc** 1995 Dec;27(6):3040–1
Combined procurement of liver and pancreas does not influence early graft function and survival. Kim SC, et al. **Transplant Proc** 1996 Jun;28(3):1882–4
Clinical islet autotransplantation after pancreatectomy: determinants of success and implications for allotransplantation? Wahoff DC, et al. **Transplant Proc** 1995 Dec;27(6):3161
[Current status and prospect of pancreas surgery in China (editorial)] Shen K. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):195–6 **(Chi)**
[Long-term outcome of surgical therapy of acute necrotizing pancreatitis] Kriwanek S, et al. **Chirurg** 1996 Mar; 67(3):244–8 (Eng. Abstr.) **(Ger)**
[Pancreas resection in cancer. Reduced mortality but morbidity is still high] Larsson J, et al. **Lakartidningen** 1995 Sep 27;92(39):3571–4 **(Swe)**

ADVERSE EFFECTS

Autologous islet transplantation to prevent diabetes after pancreatic resection. Wahoff DC, et al. **Ann Surg** 1995 Oct; 222(4):562–75; discussion 575–9
Digestive and nutritional consequences of pancreatic resections. The classical vs the pylorus-sparing procedure. Crucitti F, et al. **Int J Pancreatol** 1995 Feb;17(1):37–45
Islet Autotransplantation after total pancreatectomy in a child. Wahoff DC, et al. **J Pediatr Surg** 1996 Jan; 31(1):132–5; discussion 135–6

INSTRUMENTATION

Improving the technique of performing a pancreaticoenterostomy and pancreatoduodenectomy [letter; comment] Obertop H. **J Am Coll Surg** 1996 Jun; 182(6):557–8. Comment on: J Am Coll Surg 1995 Jul;181(1):88–90.

METHODS

Pancreaticogastrostomy: effect of partial gastrectomy on the pancreatic stump in rabbits. Nakagawa K, et al. **Acta Med Okayama** 1996 Apr;50(2):79–88
Laparoscopic distal 70% pancreatectomy and splenectomy for chronic pancreatitis. Cuschieri A, et al. **Ann Surg** 1996 Mar;223(3):280–5
Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414–6 (15 ref.)
Distal pancreatectomy for gunshot injuries of the distal pancreas [see comments] Degiannis E, et al. **Br J Surg** 1995 Sep;82(9):1240–2. Comment in: Br J Surg 1995 Sep;82(9):1153–4.
Results of extensive surgery for pancreatic carcinoma. Nagakawa T, et al. **Cancer** 1996 Feb 15;77(4):640–5
Treatment of pancreatic carcinoma. Livingston EH, et al. **Curr Opin Gen Surg** 1993;:294–8 (40 ref.)
Surgical therapy in chronic pancreatitis. Rao R, et al. **Curr Opin Gen Surg** 1993;:287–93 (30 ref.)
Extent of pancreatic resection in the treatment of nesidioblastosis [letter] Misra D. **Eur J Pediatr Surg** 1996 Feb;6(1):55
Partial or near-total pancreatectomy for nesidioblastosis? Parashar K, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):146–8
Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Ishikawa O. **Hepatogastroenterology** 1996 Mar-Apr;43(8):320–5
A new method of duodenum-preserving subtotal resection of the head of the pancreas based on the surgical anatomy. Kimura W, et al. **Hepatogastroenterology** 1996 Mar-Apr; 43(8):463–72
Alternative method for exposure of the retropancreatic mesenteric vasculature during total pancreatectomy. Leach SD, et al. **J Surg Oncol** 1996 Feb;61(2):163–5
Closure of the distal pancreatic stump with a seromuscular flap. Moriura S, et al. **Surg Today** 1995;25(11):992–4
A novel technique for successful transplantation of non-heart-beating cadaver organs. D'Silva M, et al. **Transplant Proc** 1996 Feb;28(1):205–6
New technique of orthotopic segmental pancreas transplantation with portal venous drainage established by interposing the splenic vessels. Suzuki Y, et al. **Transplant Proc** 1996 Jun;28(3):1804–6
[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**
[Pancreatic carcinoma: surgical therapy] Baer HU, et al. **Ther Umsch** 1996 May;53(5):394–400 (45 ref.) (Eng. Abstr.) **(Ger)**
[Surgical therapy in chronic pancreatitis] Büchler MW, et al. **Ther Umsch** 1996 May;53(5):365–76 (37 ref.) (Eng. Abstr.) **(Ger)**
[Technique and outcome of surgical therapy in acute pancreatitis] Uhl W, et al. **Ther Umsch** 1996 May; 53(5):346–53 (41 ref.) (Eng. Abstr.) **(Ger)**
[Risk and follow-up after multi-visceral resections including the left side of the pancreas] Böttger T, et al. **Zentralbl Chir** 1995;120(10):804–8 (Eng. Abstr.) **(Ger)**

MORTALITY

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Conlon KC, et al. **Ann Surg** 1996 Mar; 223(3):273–9
Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Fortner JG, et al. **Ann Surg** 1996 Feb;223(2):147–53
Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Lieberman MD, et al. **Ann Surg** 1995 Nov;222(5):638–45

REHABILITATION

[After-care rehabilitation after pancreas operations] Rosemeyer D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:37–40 **(Ger)**

PANCREATIC ALPHA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC BETA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC CHOLERA see **VIPOMA**

PANCREATIC CYST

CHEMISTRY

Correlation between proliferating index and prognostic factors in papillary cystic tumors of the pancreas. Cho NH, et al. **J Korean Med Sci** 1995 Oct;10(5):342–51

CONGENITAL

Congenital true pancreatic cysts in young adults: case report and literature review [letter] Casadei R, et al. **Pancreas** 1996 May;12(4):419–21

DIAGNOSIS

Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM, et al. **Am J Surg** 1996 Jan;171(1):126–9; discussion 129–30
An 81-year-old woman with a cystic pancreatic mass. Katz DS, et al. **Clin Imaging** 1995 Oct-Dec;19(4):283–8
Leiomyosarcoma of the pancreas. Aranha GV, et al. **Int J Pancreatol** 1995 Feb;17(1):95–7 (5 ref.)
Clinical assessment compared with cyst fluid analysis in the differential diagnosis of cystic lesions in the pancreas. Sand JA, et al. **Surgery** 1996 Mar;119(3):275–80
[Pancreatic hydatid cyst] Pătraşcu T, et al. **Chirurgia (Bucur)** 1995;44(2):79–83 **(Rum)**

ETIOLOGY

von Hippel Lindau syndrome presenting as obstructive jaundice with involvement of pancreas in two siblings. Issar SK, et al. **Trop Gastroenterol** 1996 Apr-Jun;17(2):30–2

METABOLISM

Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Sperti C, et al. **Cancer** 1996 Jul 15;78(2):237–43

PATHOLOGY

Analysis of small cystic lesions of the pancreas. Kimura W, et al. **Int J Pancreatol** 1995 Dec;18(3):197–206
Solitary true cyst of the pancreas in adults. Report of three cases and review of the literature. Sperti C, et al. **Int J Pancreatol** 1995 Oct;18(2):161–7 (23 ref.)
Correlation between proliferating index and prognostic factors in papillary cystic tumors of the pancreas. Cho NH, et al. **J Korean Med Sci** 1995 Oct;10(5):342–51
Solid and papillary epithelial neoplasm diagnosis and treatment: a case study. Urban JL, et al. **Md Med J** 1995 Sep;44(9):699–702
The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)
Lymphoepithelial cyst of the pancreas: a preoperatively diagnosed case based on an aspiration biopsy. Rino Y, et al. **Surg Today** 1995;25(12):1043–6 (11 ref.)
Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Mao C, et al. **Surgery** 1995 Nov;118(5):821–8 (97 ref.)
[Ambulatory ultrasound-guided puncture in abdominal tumoral pathology. Study of 131 cases] Duchmann JC, et al. **Gastroenterol Clin Biol** 1996;20(3):258–62 (Eng. Abstr.) **(Fre)**
[Atypical mucinous ductal ectasia or fissured mucinous cystadenoma? (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):118–9 **(Fre)**

SURGERY

[Cystic dystrophy on an aberrant duodenal pancreas. Apropos of a case (letter)] Barsotti P, et al. **J Chir (Paris)** 1995 Dec;132(12):503–5 (Eng. Abstr.) **(Fre)**
[The surgical treatment of pancreatic cysts and pseudocysts] Andronescu P, et al. **Chirurgia (Bucur)** 1995;44(2):1–8 (Eng. Abstr.) **(Rum)**

VETERINARY

Pancreatic pseudocyst associated with chronic-active necrotizing pancreatitis in a cat. Hines BL, et al. **J Am Anim Hosp Assoc** 1996 Mar-Apr;32(2):147–52

PANCREATIC CYSTIC FIBROSIS see **CYSTIC FIBROSIS**

PANCREATIC DELTA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC DISEASES

see related
HYPERINSULINISM

Pancreas Club Meeting. May 14, 1995 San Diego, California. **Am J Surg** 1996 Mar;171(3):306–11
From yesterday to today [editorial] Pour PM. **Int J Pancreatol** 1996 Feb;19(1):i
Pancreatic diseases in children. Lerner A, et al. **Pediatr Clin North Am** 1996 Feb;43(1):125–56 (155 ref.)
[Pancreatic abscesses] Kothaj P, et al. **Bratisl Lek Listy** 1995 May;96(5):250–3 (Eng. Abstr.) **(Cze)**
[A case of intrapancreatic duodenal duplication communicating with the biliopancreatic channel] Borocco A, et al. **J Radiol** 1996 Jan;77(1):49–51 (Eng. Abstr.) **(Fre)**

BLOOD

Non-radiological investigation of pancreatic disease. Brown CM, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):400–4 (19 ref.)
Elevated serum levels of immunoreactive anionic trypsin (but not cationic trypsin) signals pancreatic disease. Borgström A, et al. **Int J Pancreatol** 1995 Dec;18(3):221–5
Measurement of serum PSP/reg-protein concentration in various diseases with a newly developed enzyme-linked immunosorbent assay. Satomura Y, et al. **J Gastroenterol** 1995 Oct;30(5):643–50

CHEMICALLY INDUCED

Effects of prolonged ethanol intake and malnutrition on rat pancreas. López JM, et al. **Gut** 1996 Feb;38(2):285–92
[Pancreatic disease in patients with HIV treated with didanosine (DDI)] Ortega González E, et al. **Rev Esp Enferm Dig** 1996 Feb;88(2):114–7 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Pancreaticobiliary manifestations of AIDS. Miller FH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1269–74
Observations on relationship between hypergastrinemia, multiple gastric carcinoids, and pancreatic mass. Modlin IM, et al. **Dig Dis Sci** 1996 Jan;41(1):105–14
Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor. Stathopoulos G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):143–8
Pancreatic calculi superimposed upon slow growing pancreatic cancer. Noda A, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):97–101
A case of obstructive icterus caused by incarceration of a pancreatic stone in the common channel of the pancreatobiliary ducts. Kinoshita H, et al. **Kurume Med J** 1996;43(1):79–85
Nesidioblastosis-associated hypoglycaemia presenting with prominent cardiac manifestations. Galizia AC, et al. **Postgrad Med J** 1996 Apr;72(846):231–2
[Hepatobiliary and pancreatic diseases in human immunodeficiency virus infection] Roulot D.

Gastroenterol Clin Biol 1995;19(5 Pt 2):B150–6 **(Fre)**

[Pancreatic ascites] Jasiński A, et al.
Pol Arch Med Wewn 1995 Mar;93(3):253–5 (Eng. Abstr.) **(Pol)**

[Nesidioblastosis of the pancreas as a cause of hyperinsulinemic hypoglycemia in adults] Tavčar I, et al. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):73–81 (31 ref.) **(Ser)**

[Scrotal digestion caused by pancreatic ascites] Martínez Bengoechea JJ, et al. **Actas Urol Esp** 1995 Apr;19(4):320–1 (Eng. Abstr.) **(Spa)**

CONGENITAL

[Familial congenital short pancreas (letter)] Latrive JP, et al. **Gastroenterol Clin Biol** 1995 May;19(5):546–7 **(Fre)**

DIAGNOSIS

MR cholangiopancreatography using HASTE (half-Fourier acquisition single-shot turbo spin-echo) sequences. Miyazaki T, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1297–303

Isolated tuberculosis of the pancreas masquerading as a pancreatic mass. Fischer G, et al. **Am J Gastroenterol** 1995 Dec;90(12):2227–30

Serum levels of six pancreatic enzymes as related to the degree of renal dysfunction. Seno T, et al.
Am J Gastroenterol 1995 Nov;90(11):2002–5

Radiology of pancreatic tuberculosis: a report of three cases. Takhtani D, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1832–4

Nesidioblastosis unravelled [comment] Milner RD.
Arch Dis Child 1996 May;74(5):369–72 (43 ref.). Comment on: Arch Dis Child 1996 May;74(5):373–8. Comment on: Arch Dis Child 1996 May;74(5):379–85.

Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594–7 (9 ref.)

In vivo interference of heparin bolus injection with photometric continuous lipase determination. Dörner K, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):363–4

Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease. Buffet C, et al.
Eur J Gastroenterol Hepatol 1996 Feb;8(2):131–4

Granulomatous pancreatitis: Crohn's disease or sarcoidosis? [letter; comment] Boruchowicz A, et al.
Gastroenterology 1996 Jan;110(1):321–2. Comment on: Gastroenterology 1995 Apr;108(4):1246–9.

Crohn's disease of the pancreas [letter; comment] Swaroop VS. **Gastroenterology** 1996 Jan;110(1):322–3. Comment on: Gastroenterology 1995 Apr;108(4):1246–9.

Clinical usefulness of a new miniscope in the diagnosis of pancreatic disease. Ozkan H, et al. **Gastrointest Endosc** 1995 Nov;42(5):480–5

CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. Banks PA, et al.
Int J Pancreatol 1995 Dec;18(3):265–70

Radiolucent pancreatic lithiasis. Sarles J, et al.
J Pediatr Gastroenterol Nutr 1995 Jul;21(1):100–3

Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Tuberculosis of the pancreas. Varshney S, et al.
Postgrad Med J 1995 Sep;71(839):564–6

MR cholangiopancreatography after unsuccessful or incomplete ERCP. Soto JA, et al. **Radiology** 1996 Apr; 199(1):91–8

Diagnosis and treatment of symptomatic peripancreatic fluid collections after pancreas transplant. Esterl RM Jr, et al. **Transplant Proc** 1995 Dec;27(6):3057–8

[Pancreaticoscopy: experiences, possibilities and limits] Wegerle W, et al. **Bildgebung** 1996 Mar;63(1):28–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: radiologic-pathologic correlation] Helmberger T, et al. **Radiologe** 1996 May;36(5):419–26 (32 ref.) (Eng. Abstr.) **(Ger)**

[Techniques and applications of MR pancreatography in comparison with endoscopic retrograde pancreatography] Holzknecht N, et al. **Radiologe** 1996 May;36(5):427–34 (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: value of standard versus fat-suppressed pulse sequence at 0.5 T] Müller-Miny H, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jan;164(1):19–24 (Eng. Abstr.) **(Ger)**

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Rontgenpraxis** 1996 Apr;49(4):94–9 (31 ref.) **(Ger)**

[Magnetic resonance cholangiopancreatography. A new method of noninvasive biliopancreatic diagnosis] Pavone P, et al. **Radiol Med (Torino)** 1995 Oct;90(4):438–43 (Eng. Abstr.) **(Ita)**

[A case of intrapancreatic accessory spleen with epidermoid cyst] Kanemaki N, et al.
Nippon Shokakibyo Gakkai Zasshi 1995 Aug;92(8):1212–6 (12 ref.) **(Jpn)**

[Pancreatic ascites] Jasiński A, et al.
Pol Arch Med Wewn 1995 Mar;93(3):253–5 (Eng. Abstr.) **(Pol)**

[Study of salivary lactoferrin in prophylactic examinations] Sukharev AE, et al. **Klin Lab Diagn** 1996 Mar–Apr; (2):29–30 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Use of somatostatin and its long-acting analogue, octreotide, in the treatment of pancreatic diseases [letter; comment] Delmont J, et al. **Aliment Pharmacol Ther** 1995 Oct; 9(5):581–3. Comment on: Aliment Pharmacol Ther 1995 Aug;9(4):349–61.

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.). Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

How to treat graft infection after pancreatic transplantation. Bonatti H, et al. **Transplant Proc** 1995 Dec;27(6):3045–7

ENZYMOLOGY

Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury. Aleryani S, et al. **Clin Chem** 1996 Jan; 42(1):24–7

Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Azuma T, et al. **Int J Cancer** 1996 Aug 7;67(4):492–7

ETIOLOGY

Pancreatic abscess secondary to central venous catheter infection [letter] Martinez Sempere J, et al.
Am J Gastroenterol 1996 May;91(5):1059–60

Calcium administration augments pancreatic injury and ectopic trypsinogen activation after temporary systemic hypotension in rats. Mithöfer K, et al. **Anesthesiology** 1995 Dec;83(6):1266–73

Heart transplantation is associated with an increased risk for pancreaticobiliary disease. Vega KJ, et al.
Ann Intern Med 1996 Jun 1;124(11):980–3

Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy? Ventrucci M, et al. **Dig Dis Sci** 1995 Dec;40(12):2576–81

Bleeding pancreatic pseudoaneurysms. Grønlund J, et al.
Eur J Surg 1995 Oct;161(10):767–70

Bleeding of the pancreatic stump following pancreatoduodenectomy for cancer. Balladur P, et al.
Hepatogastroenterology 1996 Jan–Feb;43(7):268–70

Pancreatic panniculitis [letter] Zellman GL.
J Am Acad Dermatol 1996 Aug;35(2 Pt 1):282–3

Infection of the pancreatic duct following pancreas transplantation with bladder drainage. Bonatti H, et al.
J Chemother 1995 Oct;7(5):442–5

Pancreatic pseudotumor arising in association with Sjögren's syndrome. Eckstein RP, et al. **Pathology** 1995 Jul; 27(3):284–8

Multiple pancreatic abscesses due to Candida albicans following ERCP. Jalan R, et al. **Scott Med J** 1994 Feb; 39(1):17–8

Conservative management of intrapancreatic collections after whole pancreas transplantation: report of two cases. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3042

How to treat graft infection after pancreatic transplantation. Bonatti H, et al. **Transplant Proc** 1995 Dec;27(6):3045–7

Diagnosis and treatment of symptomatic peripancreatic fluid collections after pancreas transplant. Esterl RM Jr, et al.
Transplant Proc 1995 Dec;27(6):3057–8

[Association of pyoderma gangrenosum with hepato-pancreatic involvement in rheumatoid polyarthritis (letter)] Ferrazzi V, et al. **Rev Med Interne** 1996;17(3):266–7 **(Fre)**

[Cytokines and pancreatic diseases] Böcker U, et al.
Dtsch Med Wochenschr 1995 Nov 10;120(45):1555–60 (50 ref.) **(Ger)**

[The effect of combined toxicity on the development of alcoholic pancreatic lesions. A long-term experimental trial] Peneda J, et al. **Acta Med Port** 1995 Mar;8(3):137–43 (Eng. Abstr.) **(Por)**

GENETICS

Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Rötig A, et al.
Hum Mol Genet 1995 Aug;4(8):1327–30

[Developmental anomalies and congenital diseases of the pancreas] Brambs HJ. **Radiologe** 1996 May;36(5):381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM. Rabinovitch A, et al. **Diabetes** 1996 Jun;45(6):749–54

Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. Kägi D, et al.
J Exp Med 1996 May 1;183(5):2143–52

METABOLISM

Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (Macaca fascicularis). Nakamura S, et al. **Exp Anim** 1996 Apr;45(2):199–203

Mineralogy and pathogenesis of pancreatic calculi [letter] de Pablo-Galán L, et al. **Pancreas** 1995 Nov;11(4):415–7

PARASITOLOGY

Pancreatic hydatid disease. Barrera MC, et al.
Pediatr Radiol 1995 Nov;25 Suppl 1:S169–70

[Biliopancreatic ascariasis: an infrequent disease in our environment] de la Cruz Alvarez J, et al.
Gastroenterol Hepatol 1996 Apr;19(4):210–2 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Isolated intra-abdominal esophageal cyst. Case report and review of the literature. Harvell JD, et al.
Am J Surg Pathol 1996 Apr;20(4):476–9 (17 ref.)

Nesidioblastosis and persistent neonatal hyperinsulinism. Sempoux C, et al. **Diabete Metab** 1995 Dec;21(6):402–7 (32 ref.)

Severe islet amyloidosis in congenital generalized lipodystrophy. Garg A, et al. **Diabetes Care** 1996 Jan; 19(1):28–31

Effects of prolonged ethanol intake and malnutrition on rat pancreas. López JM, et al. **Gut** 1996 Feb;38(2):285–92

Lymphoepithelial cyst of the pancreas. Report of two cases and review of the literature. Iacono C, et al.
Int J Pancreatol 1996 Feb;19(1):71–6 (20 ref.)

Inflammatory pseudotumor of the pancreas. Kroft SH, et al. **Int J Pancreatol** 1995 Dec;18(3):277–83

Toward understanding pancreatic disease: from architecture to cell signaling. Bockman DE. **Pancreas** 1995 Nov; 11(4):324–9 (29 ref.)

Effects of pancreaticobiliary duct obstruction on the exocrine and endocrine rat pancreas. Panozzo MP, et al.
Pancreas 1995 Nov;11(4):408–14

Pancreatic fungal infections: a case report and review of the literature. Robbins EG 2nd, et al. **Pancreas** 1996 Apr; 12(3):308–12 (27 ref.)

Histopathologic study of coexistent pathologic states in pancreatic fibrosis in patients with chronic alcohol abuse: two distinct pathologic fibrosis entities with different mechanisms. Suda K, et al. **Pancreas** 1996 May;12(4):369–72

Pancreatic pseudotumor arising in association with Sjögren's syndrome. Eckstein RP, et al. **Pathology** 1995 Jul; 27(3):284–8

Ultrasound guided percutaneous fine needle aspiration cytology of pancreas: a review of 61 cases. Das DK, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):101–9

PHYSIOPATHOLOGY

Ionic control of beta cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockade [see comments] Lindley KJ, et al. **Arch Dis Child** 1996 May; 74(5):373–8. Comment in: Arch Dis Child 1996 May;74(5):369–72.

Nesidioblastosis causing reversal of insulin-dependent diabetes and development of hyperinsulinemic hypoglycemia. Bell DS, et al. **Diabetes Care** 1995 Oct; 18(10):1379–80

Is bronchial asthma a pancreatic disease? Casacó A.
Med Hypotheses 1995 Jun;44(6):516–8

Pancreatic endocrine dysfunction in rats not expressing the cholecystokinin-A receptor. Funakoshi A, et al.
Pancreas 1996 Apr;12(3):230–6

[Chronic pancreatitis and pancreatic dysfunction associated with Sjögren's syndrome] Sumii T, et al.
Nippon Rinsho 1995 Oct;53(10):2525–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.). Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

[Method of prevention of pancreatic necrosis and failure of sutures of the duodenal stump in stomach resection] Lavrov AS, et al. **Klin Khir** 1996;(1):49–50 **(Rus)**

RADIOGRAPHY

CT findings of pancreatic hydatid disease. Cosme A, et al.
J Comput Assist Tomogr 1996 Sep–Oct;20(5):815–6

Radiolucent pancreatic lithiasis. Sarles J, et al.
J Pediatr Gastroenterol Nutr 1995 Jul;21(1):100–3

The role of endoscopic retrograde cholangiopancreatography in small children and adolescents. Abu-Khalaf A.
Surg Laparosc Endosc 1995 Aug;5(4):296–300

[X-ray diagnosis of pancreatic diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1995 May–Jun;(3):5–13 (Eng. Abstr.) **(Rus)**

SURGERY

Pancreaticoduodenectomy for benign disease. Barens SA, et al. **Am J Surg** 1996 Jan;171(1):131–4; discussion 134–5

Growth and endocrine function after near total pancreatectomy for hyperinsulinaemic hypoglycaemia [see comments] Soliman AT, et al. **Arch Dis Child** 1996 May; 74(5):379–85. Comment in: Arch Dis Child 1996 May;74(5):369–72.

Delayed massive haemorrhage after pancreatic and biliary surgery. van Berge Henegouwen MI, et al. **Br J Surg** 1995 Nov;82(11):1527–31

Long-term complication following subtotal pancreatectomy

for nesidioblastosis: a case report. Chevalier SG. **Conn Med** 1996 Jun;60(6):335–8

Liver, biliary tract, and pancreas [editorial] Rikkers LF, et al. **Curr Opin Gen Surg** 1993;:233–8 (16 ref.)

Extent of pancreatic resection in the treatment of nesidioblastosis [letter] Misra D. **Eur J Pediatr Surg** 1996 Feb;6(1):55

Partial or near-total pancreatectomy for nesidioblastosis? Parashar K, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):146–8

2nd Alps-Adria Congress on Hepato-Pancreato-Biliary Surgery and Medicine. Pavia, Italy, September 13–16, 1995, Abstracts. **Hepatogastroenterology** 1995 Sep;42:1–54

A new method of duodenum-preserving subtotal resection of the head of the pancreas based on the surgical anatomy. Kimura W, et al. **Hepatogastroenterology** 1996 Mar–Apr; 43(8):463–72

Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor. Stathopoulos G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):143–8

THERAPY

Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. Ohara H, et al. **Am J Gastroenterol** 1996 Jul;91(7):1388–94

Liver, biliary tract, and pancreas [editorial] Monson JR, et al. **Curr Opin Gen Surg** 1994;:147–50

Endoscopic drainage of a pancratic abscess with a transduodenal nasopancreatic catheter. Messmann H, et al. **Endoscopy** 1995 Aug;27(6):466

Sonographically-guided extracorporeal shockwave lithotripsy for pancreatic stones in patients with chronic pancreatitis. Schreiber F, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):247–51

Washington University experience with extracorporeal shock-wave lithotripsy of pancreatic duct calculi. Wolf JS Jr, et al. **Urology** 1995 Nov;46(5):638–42

[Treatment of pancreatic stones with extracorporeal lithotripsy with sonographic localization] Beneš J, et al. **Cas Lek Cesk** 1995 Nov 15;134(22):720–2 (Eng. Abstr.) **(Cze)**

ULTRASONOGRAPHY

Endoscopic ultrasound-guided pancreatography: a case report. Harada N, et al. **Endoscopy** 1995 Oct;27(8):612–5

Endoscopic ultrasonography in pancreatobiliary disease using radial instruments. Buscail L. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):781–7 (25 ref.)

An update on echoendoscopy with a curved array transducer in the evaluation of pancreatobiliary disease. Giovannini M. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):789–93

Technique of laparoscopic ultrasound examination of the liver and pancreas. Machi J, et al. **Surg Endosc** 1996 Jun; 10(6):684–9

[Annular pancreas: ultrasound endoscopy too (letter)] Davion T, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):218–9 **(Fre)**

[Endosonography in the assessment of pancreatic tumors. A comparison of the endosonographic findings of carcinomas and segmental inflammatory changes] Nattermann C, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1571–6 (Eng. Abstr.) **(Ger)**

[Pitfall: decreased echo contrast of the processus uncinatus in ultrasound] Brambs HJ. **Rontgenpraxis** 1996 Jun; 49(6):139–40 **(Ger)**

[Diagnostic criteria of pancreatic diseases in children based on ultrasonic study data] Klimenko EF, et al. **Klin Khir** 1995;(6):20–2 **(Rus)**

[X-ray diagnosis of pancreatic diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1995 May-Jun;(3):5–13 (Eng. Abstr.) **(Rus)**

VETERINARY

Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. Wagner JD, et al. **Lab Anim Sci** 1996 Feb; 46(1):36–41

Plasma lipase concentration as an aid to the early detection of pancreas disease in farmed Atlantic salmon (Salmo salar). Grant AN, et al. **Vet Rec** 1994 Jul 30;135(5):107–8

PANCREATIC DUCTS

Resolution of panniculitis after placement of pancreatic duct stent in chronic pancreatitis. Lambiase P, et al. **Am J Gastroenterol** 1996 Sep;91(9):1835–7

Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. Ohara H, et al. **Am J Gastroenterol** 1996 Jul;91(7):1388–94

Endoscopic management of pancreatic duct leak complicated by retrogastric abscess. Sarzen CD. **Am J Gastroenterol** 1995 Nov;90(11):2039–41

The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors [see comments] van Eijck CH, et al. **Ann Surg** 1996 Aug;224(2):119–24. Comment in: Ann Surg 1996 Aug;224(2):117–8.

Complete disruption of the main pancreatic duct: endoscopic management. Devière J, et al. **Gastrointest Endosc** 1995 Nov;42(5):445–51

Clinical usefulness of a new miniscope in the diagnosis of pancreatic disease. Ozkan H, et al. **Gastrointest Endosc** 1995 Nov;42(5):480–5

Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Lygidakis NJ, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1039–52

Upper-gastrointestinal bleeding from angiodysplasia of the minor papilla. Mabee CL, et al. **J Clin Gastroenterol** 1996 Mar;22(2):138–40

Percutaneous ablation of a pancreatic remnant with intraductal injection of neoprene. Borge MA, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):762–4

Effects of pancreaticobiliary duct obstruction on the exocrine and endocrine rat pancreas. Panozzo MP, et al. **Pancreas** 1995 Nov;11(4):408–14

[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test] Arao S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1327–30 **(Jpn)**

[A case report of intraductal papillary adenoma with carcinoma in situ of the pancreas with a repeated history of acute pancreatitis] Kinoshita M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):64–7 **(Jpn)**

ABNORMALITIES

Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Hanada K, et al. **Am J Gastroenterol** 1996 May;91(5):1007–11

The significance of aductal zones on pancreatograms: an anatomo-clinical assessment. Stimec B, et al. **Am J Gastroenterol** 1996 Sep;91(9):1823–6

Aberrant biliopancreatic duct. A probable cause of acute pancreatitis? Fuchshuber PR, et al. **Arch Surg** 1995 Oct; 130(10):1139–41

Case of the month: "air-in a view". England R, et al. **Br J Radiol** 1996 Jul;69(823):681–2

K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Hanada K, et al. **Cancer** 1996 Feb 1;77(3):452–8

K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Matsubara T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1752–7

Pancreaticoduodenectomy in childhood for rare pancreatic ductal anomalies--case reports. Kazandjian V, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):305–9

Early mucosal changes of the gallbladder in patients with anomalous arrangement of the pancreaticobiliary duct. Tokiwa K, et al. **Gastroenterology** 1996 May;110(5):1614–8

Absent minor papilla and an unusual drainage system in a patient with pancreas divisum. Venu RP, et al. **Gastrointest Endosc** 1995 Aug;42(2):173–5

Coexistence of anomalous pancreaticobiliary ductal union with adenomyomatosis of the gallbladder. Wu MS, et al. **Gastrointest Endosc** 1995 Sep;42(3):265–9

Gall bladder tumour, choledochal cyst and an anomalous pancreatico-biliary junction. Toufeeq Khan TF, et al. **HPB Surg** 1995 Jun;8(3):185–6

Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. Bradley EL 3rd, et al. **J Am Coll Surg** 1996 Jul;183(1):65–70

Primary carcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. Chao TC, et al. **J Clin Gastroenterol** 1995 Dec;21(4):306–8

Pancreaticobiliary maljunction without choledochal cysts in infants and children: clinical features and surgical therapy. Ando H, et al. **J Pediatr Surg** 1995 Dec;30(12):1658–62

A new model for pancreaticobiliary maljunction without bile duct dilatation: demonstration of cell proliferation in the gallbladder epithelium. Kaneko K, et al. **J Surg Res** 1996 Jan;60(1):115–21

Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Heikius B, et al. **Scand J Gastroenterol** 1996 May;31(5):517–23

[Is anomalous junction of pancreaticobiliary duct related to pancreatitis] Tian F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):345–7 (Eng. Abstr.) **(Chi)**

[A case report of the double bile duct associated with malfusion of the pancreatobiliary duct] Matsuda M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1794–8 **(Jpn)**

ANATOMY & HISTOLOGY

Unusual variants of the tributaries of the main pancreatic duct revealed by postmortem and endoscopic pancreatography. Stimec B, et al. **Anat Anz** 1996 Apr; 178(2):169–71

Fusion and duplication variants of pancreatic duct system. Clinical and pancreatographic evaluation. Uomo G, et al. **Int J Pancreatol** 1995 Feb;17(1):23–8

CHEMISTRY

Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Ishimaru S, et al. **Cancer** 1996 Jun 1; 77(11):2233–9

CYTOLOGY

Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Furukawa T, et al. **Am J Pathol** 1996 Jun;148(6):1763–70

In vivo cell transformation: neogenesis of beta cells from pancreatic ductal cells. Rosenberg L. **Cell Transplant** 1995 Jul-Aug;4(4):371–83 (80 ref.)

Proliferation of rat pancreatic ductal-epithelial cells in vitro, and in response to partial hepatectomy and pancreatectomy in vivo. Jindal RM, et al. **Transplant Proc** 1995 Dec; 27(6):2991–2

DRUG EFFECTS

The effect of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) on cultured dog pancreatic duct epithelial cells. Oda D, et al. **Pancreas** 1996 Mar;12(2):109–16

INJURIES

Urgent endoscopic retrograde pancreatography the stable trauma patient. Clements RH, et al. **Am Surg** 1996 Jun; 62(6):446–8

Endoscopic intrapancreatic stent for traumatic duct injury. Bendahan J, et al. **Injury** 1995 Oct;26(8):553–4

Complete disruption of the main pancreatic duct: a case successfully managed by percutaneous drainage. Ohno Y, et al. **J Pediatr Surg** 1995 Dec;30(12):1741–2

Spontaneous recanalization of the pancreatic duct: case report and review. Arkovitz MS, et al. **J Trauma** 1996 Jun; 40(6):1014–6

Nonoperative treatment of traumatic pancreatic duct disruption using an endoscopically placed stent. Huckfeldt R, et al. **J Trauma** 1996 Jul;41(1):143–4

Role of repeat computed tomography after emergency endoscopic retrograde pancreatography in the diagnosis of traumatic injury to pancreatic ducts. Takishima T, et al. **J Trauma** 1996 Feb;40(2):253–7

METABOLISM

Calcium-activated chloride currents and non-selective cation channels in a novel cystic fibrosis-derived human pancreatic duct cell line. Eguiguren AL, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):505–13

Progressive development of gap junctions during growth of human pancreatic duct cells (Capan-1) in vitro and in vivo. Monzat V, et al. **Biol Cell** 1995;85(2-3):157–65

Evidence for apical Na+/H+ exchanger in bovine main pancreatic duct. Marteau C, et al. **Dig Dis Sci** 1995 Nov; 40(11):2336–40

Volume-activated chloride currents in pancreatic duct cells. Verdon B, et al. **J Membr Biol** 1995 Sep;147(2):173–83

Regulation of cyclic AMP levels in guinea pig pancreatic ducts and cultured duct epithelial monolayers. de Ondarza J, et al. **Pancreas** 1995 Oct;11(3):261–70

PATHOLOGY

Duct ectasia due to mucus-producing cancers with intraductal extension: histopathologic correlation with radiologic imagings. Kobayashi H, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):341–7

Choledocholithiasis and the pancreatobiliary ductal system: advances in imaging. Introduction. Meyers MA. **Abdom Imaging** 1996 Mar-Apr;21(2):91–2

Papillary cystic tumor of the pancreas diagnosed by preoperative brushing cytology of the pancreatic duct [letter] Kuwabara H, et al. **Acta Cytol** 1996 May-Jun; 40(3):612–3

MR cholangiopancreatography: findings on 3D fast spin-echo imaging. Soto JA, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1397–401

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147–9 (15 ref.)

Variant of intraductal carcinoma (with scant mucin production) is of main pancreatic duct origin: a clinicopathological study of four patients. Suda K, et al. **Am J Gastroenterol** 1996 Apr;91(4):798–800

Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Pour PM, et al. **Am J Pathol** 1996 Sep;149(3):1017–25

An association between villous adenomas and mucinous ductal ectasia of the pancreas. Barthet M, et al. **Endoscopy** 1995 Oct;27(8):601–3

Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease [see comments] Tada M, et al. **Gastroenterology** 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Jan;110(1):306–10. Comment in: Gastroenterology 1996 Aug;111(2):566–7.

The role of pancreatic stenting in obstructive ductal disorders other than pancreas divisum. Ashby K, et al. **Gastrointest Endosc** 1995 Oct;42(4):306–11

Decrease in a markedly elevated CA19-9 level after stenting of a benign pancreatic ductal stricture. Mauer KR, et al. **Gastrointest Endosc** 1995 Sep;42(3):261–3

Serous cystadenoma of the pancreas communicating with a pancreatic duct. Furukawa H, et al. **Int J Pancreatol** 1996 Apr;19(2):141–4

MR cholangiopancreatography after unsuccessful or incomplete ERCP. Soto JA, et al. **Radiology** 1996 Apr; 199(1):91–8

Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Hamanaka Y, et al. **Surgery** 1996 Mar;119(3):281–7

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)
Cystoscopic management of pancreatic allograft duct obstruction. Kuhr CS, et al. **Transplant Proc** 1995 Dec; 27(6):2994–5
[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**
[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625–7 (10 ref.) (Eng. Abstr.) **(Fre)**
[A case of mucinous cystadenocarcinoma of the pancreas with intraductal growth to the main pancreatic duct] Mokuno Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1981–4 **(Jpn)**

PHYSIOLOGY

Changes in the mouse exocrine pancreas after pancreatic duct ligation: a qualitative and quantitative histological study. Watanabe S, et al. **Arch Histol Cytol** 1995 Aug;58(3):365–74
Duct- to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Wang RN, et al. **Diabetologia** 1995 Dec;38(12):1405–11

PHYSIOPATHOLOGY

Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease [see comments] Tada M, et al. **Gastroenterology** 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Jan;110(1):306–10. Comment in: Gastroenterology 1996 Aug;111(2):566–7.

RADIOGRAPHY

Percutaneous pancreatography under ultrasonographic guidance. Opačić M, et al. **Acta Radiol** 1996 Jan;37(1):75–8

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)
Impaired pancreatic bicarbonate secretion in chronic malnutrition. Keni S, et al. **Indian Pediatr** 1995 Mar; 32(3):323–9

SURGERY

Mechanisms of cell death after pancreatic duct obstruction in the opossum and the rat. Gukovskaya AS, et al. **Gastroenterology** 1996 Mar;110(3):875–84
Effects of pancreatic duct ligation and aging on acute taurocholate-induced pancreatitis. Experiments in the perfused pancreas in rats. Kimura W, et al. **Int J Pancrestol** 1996 Apr;19(2):117–27
Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. Bradley EL 3rd, et al. **J Am Coll Surg** 1996 Jul;183(1):65–70
Extended resections of ductal pancreatic cancer—impact on operative risk and prognosis. Klempnauer J, et al. **Oncology** 1996 Jan–Feb;53(1):47–53
Enteric conversion of bladder-drained pancreas allograft. Han DJ. **Transplant Proc** 1996 Jun;28(3):1729
[Diffuse papillomatosis of the biliary and pancreatic ducts: a rare association and a potentially malignant disease (letter)] Denie C, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):845–7 **(Fre)**

ULTRASONOGRAPHY

Percutaneous pancreatography under ultrasonographic guidance. Opačić M, et al. **Acta Radiol** 1996 Jan;37(1):75–8

ULTRASTRUCTURE

Fine structure of the cilia in the pancreatic duct of WBN/Kob rat. Hidaka K, et al. **Int J Pancreatol** 1995 Dec; 18(3):207–13
Scanning electron microscopic observation of pancreatic ducts in WBN/Kob rats. Ashizawa N, et al. **Pancreas** 1995 Nov;11(4):389–95

PANCREATIC ELASTASE see **PANCREATOPEPTIDASE**

PANCREATIC EXTRACTS

ADMINISTRATION & DOSAGE

Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Lancellotti L, et al. **Eur J Pediatr** 1996 Apr;155(4):281–5
[Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma] Lahousen M. **Wien Med Wochenschr** 1995;145(24):663–8 (Eng. Abstr.) **(Ger)**
[Differential therapy of exocrine pancreatic insufficiency—current aspects and future prospects of substitution therapy with pancreatic enzymes] Löser C, et al. **Z Gastroenterol** 1995 Dec;33(12):715–22 (65 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements [see comments] Croft NM, et al. **Lancet** 1995 Nov 11;346(8985):1265–7. Comment in: Lancet 1996 Feb 3;347(8997):327.
Fibrosing colonopathy in children with cystic fibrosis [editorial] Littlewood JM. **Postgrad Med J** 1996 Mar; 72(845):129–30

PANCREATIC FISTULA

COMPLICATIONS

Recurrent left pleural effusion in a 44-year-old woman with a history of alcohol abuse. Iglesias JI, et al. **Chest** 1996 Aug;110(2):547–9
Case report: recurrent pancreatitis caused by a duodenal duplication cyst communicating with the pancreatic duct. Gandhi MR, et al. **Clin Radiol** 1995 Oct;50(10):726–8
[Pancreatic pleural effusion. Diagnosis and therapy] Pleskovič L, et al. **Acta Chir Iugosl** 1990;37(2):229–37 (Eng. Abstr.) **(Slv)**

DIAGNOSIS

Pancreaticobronchial fistula diagnosed by combined ERP and CT. Davidian M, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):53–4
[Acute pancreatitis complicated by pancreatic ascites. Diagnostic and therapeutic difficulties] Wereszczyńska-Siemiątkowska U, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):369–74 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Persistent pancreatic fistula after pancreas transplantation treated with fibrin glue and octreotide. Wadström J, et al. **Transplant Proc** 1995 Dec;27(6):3491–2
[Hemorrhagic pancreatic cystadenocarcinoma with colonic fistula. An unusual mode of manifestation] Demarquay JF, et al. **Gastroenterol Clin Biol** 1996;20(5):491–3 (Eng. Abstr.) **(Fre)**
[A case of intrapancreatic duodenal duplication communicating with the biliopancreatic channel] Borocco A, et al. **J Radiol** 1996 Jan;77(1):49–51 (Eng. Abstr.) **(Fre)**
[A report on pancreas-preserving operation and complications relating pancreatorrhea in total gastrectomy] Honda G, et al. **Nippon Geka Hokan** 1995 May–Jul 1; 64(3–4):85–90 (Eng. Abstr.) **(Jpn)**
[An injury caused by diagnostic biopsy performed " for safety's sake only". A man received compensation from the Patient Insurance] Larsson M. **Lakartidningen** 1996 Jun 26;93(26–27):2526 **(Swe)**

RADIOGRAPHY

Pancreaticopleural fistula visualized by computed tomographic scan combined with endoscopic retrograde pancreatography. Kawashima A, et al. **Intern Med** 1996 Jan;35(1):30–2

SURGERY

The outcome of pancreatic fistulas developed after surgery for pancreatic pseudocysts. Magyar A, et al. **Acta Chir Hung** 1995–96;35(1–2):169–76
Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)
[Endoscopic treatment of a pancreatic-pleural fistula. Apropos of a case] Duchmann JC, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):837–40 (Eng. Abstr.) **(Fre)**
[Internal pancreatic fistula: surgical treatment] Pereira-Lima L, et al. **J Chir (Paris)** 1995 Nov;132(11):442–6 (Eng. Abstr.) **(Fre)**
[A method for the closure of fully formed duodenal fistulae opening into a suppurative cavity] Grinev MBV. **Vestn Khir Im I I Grek** 1992 Feb;148(2):236–7 **(Rus)**
[A method for returning the pancreatic juice to the duodenum in a complete external pancreatic fistula] Vecherko VN, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):338 **(Rus)**

THERAPY

Endoscopic management of pancreatic duct leak complicated by retrogastric abscess. Sarzen CD. **Am J Gastroenterol** 1995 Nov;90(11):2039–41
Nutritional support in the management of external pancreatic fistulas. Madiba TE, et al. **S Afr J Surg** 1995 Jun;33(2):81–4
Persistent pancreatic fistula after pancreas transplantation treated with fibrin glue and octreotide. Wadström J, et al. **Transplant Proc** 1995 Dec;27(6):3491–2

ULTRASONOGRAPHY

Pancreaticopleural fistula diagnosed sonographically [letter] Duchmann JC, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1551

PANCREATIC FUNCTION TESTS

Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Domínguez-Muñoz JE, et al. **Am J Gastroenterol** 1995 Oct;90(10):1834–7
Non-radiological investigation of pancreatic disease. Brown CM, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):400–4 (19 ref.)
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Stein J, et al. **Clin Chem** 1996 Feb;42(2):222–6
Characteristics of choledochal cysts in neonates and early infants. Todani T, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):143–5
[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function] Stein J, et al. **Gastroenterol Clin Biol** 1996;20(5):424–9 (Eng. Abstr.) **(Fre)**

METHODS

[BT-PABA test] Koizumi M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1088–91 (12 ref.) **(Jpn)**

PANCREATIC HORMONE RECEPTORS see **RECEPTORS, PANCREATIC HORMONE**

PANCREATIC HORMONES

see related
RECEPTORS, PANCREATIC HORMONE

ANALYSIS

Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. Kogner P, et al. **Eur J Cancer** 1995;31A(4):557–60
Neuroendocrine differentiation in colorectal carcinomas. Syversen U, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):667–74
Immunolocalization of neuropeptide Y in human pancreatic endocrine tumors. Waeber G, et al. **Peptides** 1995; 16(5):921–6

BLOOD

Effects of epidermal growth factor on glucose metabolism in neonatal rats. Sato Y, et al. **Biol Neonate** 1995;68(1):26–32

IMMUNOLOGY

Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension. Sánchez-Margalet V, et al. **Neuropeptides** 1995 Aug; 29(2):97–101

METABOLISM

Downregulation of prohormone convertase-1 by a phorbol ester. Udupi V, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):495–500
Effect of nonpeptide motilin agonist EM523 on release of gut and pancreatic hormones in conscious dogs. Shiba Y, et al. **Gastroenterology** 1996 Jan;110(1):241–50
Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Björkstrand E, et al. **Neuroendocrinology** 1996 Apr;63(4):377–83

PHARMACOLOGY

Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis. Hertelendy ZI, et al. **Cell Calcium** 1996 Feb;19(2):125–32
Effects of insulin, glucagon, and somatostatin on the release of somatostatin-25 and somatostatin-14 from rainbow trout, Oncorhynchus mykiss, pancreatic islets in vitro. Eilertson CD, et al. **Gen Comp Endocrinol** 1995 Aug; 99(2):211–20
GLP-1 depolarizes the rat pancreatic beta cell in a Na(+)-dependent manner. Kato M, et al. **Regul Pept** 1996 Apr 9;62(1):23–7

PHYSIOLOGY

Pancreastatin action in the liver: dual coupling to different G proteins. Sánchez-Margalet V, et al. **Cell Signal** 1996 Jan;8(1):9–12 (53 ref.)
Pancreastatin: further evidence for its consideration as a regulatory peptide. Sánchez-Margalet V, et al. **J Mol Endocrinol** 1996 Feb;16(1):1–8 (100 ref.)

SECRETION

Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Jin L, et al. **Am J Pathol** 1996 Jun;148(6):2057–66
[Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia] Nieszporek T, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):488–94 (Eng. Abstr.) **(Pol)**

PANCREATIC INSUFFICIENCY

Intestinal morphology and cytokinetics in pancreatic insufficiency. An experimental study in the rat. Hauer-Jensen M, et al. **Dig Dis Sci** 1995 Oct;40(10):2170–6

PANCREATIC INSUFFICIENCY

BLOOD

Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Nakamura T, et al. **Acta Gastroenterol Belg** 1996 Jan-Mar;59(1):10-14

COMPLICATIONS

Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Friess H, et al. **Am J Gastroenterol** 1996 Feb;91(2):341-7

Shwachman-Diamond syndrome and matched unrelated donor BMT. Smith OP, et al. **Bone Marrow Transplant** 1995 Nov;16(5):717-8

Haematological abnormalities in Shwachman-Diamond syndrome. Smith OP, et al. **Br J Haematol** 1996 Aug; 94(2):279-84

Pancreatic insufficiency and pulmonary disease in German and Slavic cystic fibrosis patients with the R347P mutation. Varon R, et al. **Hum Mutat** 1995;6(3):219-25

Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Heikius B, et al. **Scand J Gastroenterol** 1996 May;31(5):517-23

[Liver abscess caused by Lactobacillus acidophilus] Larvol L, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):193-5 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

A noninvasive stable-isotope method to simultaneously assess pancreatic exocrine function and small bowel absorption. Deutsch JC, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2182-5

Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Stein J, et al. **Clin Chem** 1996 Feb;42(2):222-6

Shwachman-Diamond syndrome: the clinical imitator of cystic fibrosis. Lozada-Muñoz L, et al. **P R Health Sci J** 1995 Dec;14(4):275-7 (15 ref.)

[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function] Stein J, et al. **Gastroenterol Clin Biol** 1996;20(5):424-9 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial. Lancellotti L, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan; 22(1):73-8

Indirect parameters of pancreatic function in cystic fibrosis (CF) during a controlled double-blind trial of pancreatic supplementation. Regele S, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):68-72

ETIOLOGY

Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. Seibold F, et al. **J Clin Gastroenterol** 1996 Apr;22(3):202-6

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16-23;24(39):1882-7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863-70 (11 ref.) **(Jpn)**

GENETICS

Shwachman syndrome associated with de novo reciprocal translocation t(6;12)(q16.2;q21.2). Masuno M, et al. **J Med Genet** 1995 Nov;32(11):894-5

[A study evaluating the correlation between the phenotype and genotype among 65 cystic fibrosis patients] Nowakowska A, et al. **Pediatr Pol** 1995 Aug;70(8):633-8 (Eng. Abstr.) **(Pol)**

METABOLISM

No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency. Nakamura T, et al. **Int J Pancreatol** 1995 Feb;17(1):29-35

PHYSIOPATHOLOGY

Gastric emptying of oil from solid and liquid meals. Effect of human pancreatic insufficiency. Meyer JH, et al. **Dig Dis Sci** 1996 Sep;41(9):1691-9

Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Lancellotti L, et al. **Eur J Pediatr** 1996 Apr;155(4):281-5

THERAPY

Allogeneic bone marrow transplatation in a patient with Shwachman-Diamond syndrome. Arseniev L, et al. **Ann Hematol** 1996 Feb;72(2):83-4

[Differential therapy of exocrine pancreatic insufficiency--current aspects and future prospects of substitution therapy with pancreatic enzymes] Löser C, et al. **Z Gastroenterol** 1995 Dec;33(12):715-22 (65 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Increased reflectivity of the pancreas in rare hereditary pancreatic insufficiency syndromes. Barzilai M, et al. **Clin Radiol** 1996 Aug;51(8):575-6

Shwachman-Diamond syndrome: clinical, radiological and sonographic aspects. Berrocal T, et al. **Pediatr Radiol** 1995; 25(4):289-92

Shwachman-Diamond syndrome: clinical, radiological and sonographic findings. Berrocal T, et al. **Pediatr Radiol** 1995; 25(5):356-9

VETERINARY

Diabetes mellitus associated with pancreatic endocrine insufficiency in a kitten. Root MV, et al. **J Small Anim Pract** 1995 Sep;36(9):416-20

Exocrine pancreatic insufficiency [letter] Dennis HT, et al. **Vet Rec** 1996 Feb 24;138(8):192

PANCREATIC ISLETS TRANSPLANTATION see **ISLETS OF LANGERHANS TRANSPLANTATION**

PANCREATIC JUICE

see related
CHYMOTRYPSIN
CHYMOTRYPSINOGEN
TRYPSIN
TRYPSINOGEN

Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Wakabayashi T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1848-51

[Activity of the complement system in blood serum of dogs after treatment of acute necrotic pancreatitis with boiled pancreatic juice] Aganezov SA, et al. **Patol Fiziol Eksp Ter** 1995 Jul-Sep;(3):18-20 (Eng. Abstr.) **(Rus)**

[A method for returning the pancreatic juice to the duodenum in a complete external pancreatic fistula] Vecherko VN, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):338 **(Rus)**

CHEMISTRY

Glycosphingolipids in human pancreatic juice. Unique fatty acid compositions of glucosylceramides and lactosylceramides. Hamanaka Y, et al. **Int J Pancreatol** 1995 Aug;18(1):33-9

[Extraction of DNA from pancreatic and/or duodenal juice] Fukayama N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):466-8 (3 ref.) **(Jpn)**

CYTOLOGY

Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Uehara H, et al. **Am J Gastroenterol** 1996 Aug;91(8):1616-21

Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Nakaizumi A, et al. **Cancer** 1995 Sep 1;76(5):750-7

Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation. Watanabe H, et al. **Jpn J Cancer Res** 1996 May;87(5):466-74

DRUG EFFECTS

Effect of dietary canola oil and its degree of oxidation on exocrine pancreatic secretions in growing pigs. Ozimek L, et al. **Z Ernahrungswiss** 1995 Sep;34(3):224-30

ENZYMOLOGY

Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Azuma T, et al. **Int J Cancer** 1996 Aug 7;67(4):492-7

Technical note: a simple, rapid assay for alpha-amylase in bovine pancreatic juice. Walker JA, et al. **J Anim Sci** 1996 Mar;74(3):658-62

METABOLISM

Partition of oleic acid between the lymph and portal blood in rats having a diverted bile-pancreatic duct. Mathieu Y, et al. **Br J Nutr** 1996 Feb;75(2):249-61

Kinetics of amino acid and glucose absorption following pancreatic diversion in the pig. Rérat A, et al. **Br J Nutr** 1996 Feb;75(2):175-93

Regulation of gene expression of pancreatic secretory trypsin inhibitor-61 and -56 by bile and pancreatic juice in rats. Miyasaka K, et al. **Pancreas** 1995 Oct;11(3):246-55

[Biliary and pancreatic excretion of etoposide] Suda Y, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1191-6 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Bile-pancreatic juice replacement not cholinergic- and cholecystokinin-receptor blockade reverses acinar cell hyperstimulation after bile-pancreatic duct ligation. Samuel I, et al. **Am J Surg** 1996 Jan;171(1):207-11

Gastric acid-independent enhancement of exocrine pancreatic secretion by dietary protein in chronic bile-pancreatic juice diverted rats. Hara H, et al. **Pancreas** 1995 Aug;11(2):173-8

SECRETION

The pattern of the circadian rhythm of pancreatic secretion in fed pigs. Thaela MJ, et al. **J Anim Sci** 1995 Nov; 73(11):3402-8

The role of magnesium in regulating CCK-8-evoked secretory responses in the exocrine rat pancreas. Wisdom DM, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):123-32

Effect of the microtubule-disrupting drug colchicine on rat cerulein-induced pancreatitis in comparison with the microtubule stabilizer taxol. Ueda T, et al. **Pancreas** 1995 Oct;11(3):294-302

Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Hamanaka Y, et al. **Surgery** 1996 Mar;119(3):281-7

PANCREATIC NEOPLASMS

Two cases of pancreatic cancer associated with skin metastases [letter] Nakano S, et al. **Am J Gastroenterol** 1996 Feb;91(2):410-1

Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region [letter; comment] Carmichael AR, et al. **Br J Surg** 1995 Dec;82(12):1703-4. Comment on: Br J Surg 1995 Jun;82(6):820-4.

Pancreatic carcinoma in perspective. A continuing challenge. Wanebo HJ, et al. **Cancer** 1996 Aug 1;78(3 Suppl):580-91 (181 ref.)

Engineering a normally responsive bioartificial pancreas based on glucose-hypersensitive cells. Tziampazis E, et al. **Comput Biol Med** 1996 May;26(3):231-40

Pancreatic cancer. Johnson R. **Hepatogastroenterology** 1995 Jul;42(3):294-7 (41 ref.)

Pancreatoblastoma: case report and review of treatment in the literature. Murakami T, et al. **Med Pediatr Oncol** 1996 Sep;27(3):193-7 (22 ref.)

The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Wermers RA, et al. **Medicine (Baltimore)** 1996 Mar;75(2):53-63

Different terms for the same disease: intraductal mucin-producing tumor versus mucinous tumor of the pancreas [letter; comment] Itai Y. **Radiology** 1996 Jul; 200(1):285. Comment on: Radiology 1996 Jan;198(1):249-57.

Elevation of intracellular cyclic adenosine monophosphate inhibits the epidermal growth factor signal transduction pathway and cellular growth in pancreatic adenocarcinoma cell lines. Lieberman MD, et al. **Surgery** 1996 Aug; 120(2):354-9

[Solid papillary tumor of the pancreas] Jørgensen LJ. **Ugeskr Laeger** 1995 Oct 2;157(40):5549-50 (Eng. Abstr.) **(Dan)**

[Muscular metastasis of cancer of the pancreas. A propos of a case] Wafflart E, et al. **J Chir (Paris)** 1996 Jun; 133(4):167-70 (16 ref.) (Eng. Abstr.) **(Fre)**

[Vasoactive polypeptide-producing pancreatic carcinoma] Gréczi K, et al. **Orv Hetil** 1995 Sep 10;136(37):2009-11 (Eng. Abstr.) **(Hun)**

[Carcinoid of the pancreas. 2 case reports] Carcoforo P, et al. **Ann Ital Chir** 1996 Jan-Feb;67(1):99-107 (Eng. Abstr.) **(Ita)**

[First experience in transplantation of cultured cells of human insuloma to patients with diabetes mellitus] Shalimov AA, et al. **Klin Khir** 1995;(11-12):28-30 **(Rus)**

[Errors in the diagnosis and treatment of hormonally active pancreatic tumors] Volobuev NN, et al. **Klin Med (Mosk)** 1995;73(4):75-7 (Eng. Abstr.) **(Rus)**

[Cystic tumors of the pancreas: 9 case reports (letter)] Yuste R, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):444 **(Spa)**

[Burkitt's lymphoma: atypical localization] Balonga C, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):439-41 (Eng. Abstr.) **(Spa)**

[Papillary cystic tumor of the pancreas: apropos of a case (letter)] Guillaumes S, et al. **Rev Esp Enferm Dig** 1996 Jun; 88(6):454-5 **(Spa)**

BLOOD

Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Pasanen PA, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2731-7

Plasma proinsulin-like component in insulinoma: a 25-year experience. Gorden P, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2884-7

Normal serum gastrin concentration in gastrinoma [letter] [see comments] Jais P, et al. **Lancet** 1995 Nov 25; 346(8987):1421-2. Comment in: Lancet 1996 Jan 27;347(8996):270.

Elevated serum prostate-specific antigen and pancreatic carcinoma. Ranganath LR, et al. **Postgrad Med J** 1996 Jun; 72(848):363-4

[Increase of alpha-fetoprotein in pancreatic endocrine tumors with hepatic metastases. Apropos of 2 cases] Lesur G, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):204-6 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Spiral-CT in diagnosis of vascular involvement in pancreatic cancer. Gmeinwieser J, et al. **Hepatogastroenterology** 1995 Jul-Aug;42(4):418-22

CHEMICALLY INDUCED

Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserine. Visser CJ, et al. **Br J Cancer** 1996 Jul;74(1):92–8

Inhibition by verapamil of cholecystokinin–enhancement of pancreatic carcinogenesis induced by azaserine in Wistar rats. Nakaizumi A, et al. **Cancer Lett** 1996 Jul 19; 105(1):23–7

Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator. Rao MS, et al. **Cancer Lett** 1995 Nov 6;97(2):185–8

Expression of dynamin immunoreactivity in experimental pancreatic tumors induced in rat by mancozeb–nitrosomethylurea. Valentich MA, et al. **Cancer Lett** 1996 Apr 19;102(1–2):23–9

Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Baum A, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):117–20

CHEMISTRY

Microglandular carcinoma of the pancreas: immunohistochemical and ultrastructural study of an unusual variant of pancreatic carcinoma that may closely resemble a neuroendocrine neoplasm. Berho M, et al. **Am J Clin Pathol** 1996 Jun;105(6):727–32

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2659–68

Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Bramhall SR, et al. **Br J Cancer** 1996 Apr;73(8):972–8

Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Ohta T, et al. **Br J Cancer** 1995 Oct;72(4):824–31

Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Ishimaru S, et al. **Cancer** 1996 Jun 1; 77(11):2233–9

Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Gansauge F, et al. **Cancer Res** 1995 Dec 1;55(23):5499–503

Solid and cystic papillary neoplasm of the pancreas: a clinico–cytopathologic and immunocytochemical study of five new cases diagnosed by fine–needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. John M, et al. **Gut** 1996 Jan;38(1):33–9

Immunohistochemical evaluation of HER–2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Day JD, et al. **Hum Pathol** 1996 Feb; 27(2):119–24

Immunohistochemical staining for type IV collagen and laminin in the stroma of human pancreatic cancer. Imamura T, et al. **Int J Pancreatol** 1995 Oct;18(2):95–9

Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Shimoyama S, et al. **Int J Pancreatol** 1995 Dec;18(3):227–34

Immunohistochemical study of metallothionein in pancreatic carcinomas. Ohshio G, et al. **J Cancer Res Clin Oncol** 1996; 122(6):351–5

Correlation between proliferating index and prognostic factors in papillary cystic tumors of the pancreas. Cho NH, et al. **J Korean Med Sci** 1995 Oct;10(5):342–51

P53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis. Aizawa S, et al. **J Surg Oncol** 1996 Aug;62(4):279–83

Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Lundin J, et al. **Oncology** 1996 Mar–Apr;53(2):104–11

Pancreatic polypeptide immunoreactivity in sporadic gastrinoma: relationship to intraabdominal location. Howard TJ, et al. **Pancreas** 1995 Nov;11(4):350–6

Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor–associated chronic pancreatitis, and alcoholic chronic pancreatitis. Imamura T, et al. **Pancreas** 1995 Nov;11(4):357–64

[Immunohistochemistry of hormone receptors in pancreatic cancer (letter)] Truán Alonso N, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):832–3 **(Spa)**

CLASSIFICATION

[The new classification of neuroendocrine tumors from the clinical viewpoint] Schürmann G, et al. **Z Gastroenterol** 1996 Jun;34(6):402–3 **(Ger)**

COMPLICATIONS

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147–9 (15 ref.)

Gastric outlet obstruction malignant until proved otherwise [editorial; comment] Johnson CD. **Am J Gastroenterol** 1995 Oct;90(10):1740. Comment on: Am J Gastroenterol 1995 Oct;90(10):1769–70.

Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers [see comments] Shone DN, et al. **Am J Gastroenterol** 1995 Oct;90(10):1769–70. Comment in: Am J Gastroenterol 1995 Oct;90(10):1740.

Case report: pancreatic cancer presenting with paraneoplastic gastroparesis. Caras S, et al. **Am J Med Sci** 1996 Jul; 312(1):34–6

Pancreatitis associated with neuroendocrine (islet cell) tumors of the pancreas. Mao C, et al. **Am J Surg** 1996 Jun;171(6):562–4

Generalized eczéma craquelé: a sign of internal malignancy [letter] Huilgol SC, et al. **Australas J Dermatol** 1996 Aug; 37(3):161

A simplified percutaneous hepatogastric drainage technique for malignant biliary obstruction. Tipaldi L. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):333–6

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

Non–islet cell tumour–associated hypoglycaemia: 111In–octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Perros P, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):727–31

Biliary obstruction due to pancreatic insulinoma. Dhar A, et al. **Dig Dis Sci** 1995 Nov;40(11):2368–72

Palliation of malignant gastric outlet obstruction with self–expanding metal stents. Feretis C, et al. **Endoscopy** 1996 Feb;28(2):225–8

Reports of obstructive jaundice with pancreatic carcinoma and a normal pancreatogram [letter; comment] Blackstone MO. **Gastrointest Endosc** 1995 Nov;42(5):493–4. Comment on: Gastrointest Endosc 1995 Feb;41(2):158–60.

A novel technique for dilating difficult malignant biliary strictures during therapeutic ERCP. van Someren RN, et al. **Gastrointest Endosc** 1996 May;43(5):495–8

Duodenal obstruction due to annular pancreas associated with pancreatic head carcinoma. Yasui A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1017–22

Diabetes, weight loss, and depression. Papp JP, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):41–2, 44

Somatostatinoma of the pancreas associated with von Hippel–Lindau disease. Maki M, et al. **Intern Med** 1995 Jul;34(7):661–5 (20 ref.)

Pancreatic calculi superimposed upon slow growing pancreatic cancer. Noda A, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):97–101

Rapid resolution of necrolytic migratory erythema after glucagonoma resection. Smith AP, et al. **J Surg Oncol** 1996 Apr;61(4):306–9

Protein adsorption and bacterial adhesion to biliary stent materials. Yu JL, et al. **J Surg Res** 1996 Apr;62(1):69–73

New self–expandable spiral metallic stent: preliminary clinical evaluation in malignant biliary obstruction. Lee BH, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):635–40

Characterization of a cancer cachectic factor. Todorov P, et al. **Nature** 1996 Feb 22;379(6567):739–42

Neurofibromatosis and insulinoma. Fung JW, et al. **Postgrad Med J** 1995 Aug;71(838):485–6

A seizure and odd behaviour in a 79–year–old man. Jenner GH. **Postgrad Med J** 1995 Dec;71(842):761–3

Carcinoid syndrome due to a malignant somatostatinoma. Ozbakir O, et al. **Postgrad Med J** 1995 Nov;71(841):695–8

Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer [see comments] Rolston KV, et al. **Support Care Cancer** 1995 Nov; 3(6):414–7. Comment in: Support Care Cancer 1995 Nov;3(6):385–6.

Thrombocytopenia and pancreatic carcinoma. Sweeney CJ, et al. **Wis Med J** 1995 Nov;94(11):611–5

[A vasoactive–intestinal–polypeptide producing tumor (VIPoma) as an uncommon cause of life–threatening hypokalemia] Mráz L, et al. **Vnitr Lek** 1995 Aug; 41(8):535–7 (Eng. Abstr.) **(Cze)**

[Pancreatic somatostatinoma and MEN 1. Apropos of a case. Review of the literature] Roy J, et al. **Ann Endocrinol (Paris)** 1996;57(1):71–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Non bacterial thrombotic endocarditis (marantic endocarditis). Apropos of a case and value of transoesophageal echocardiography] Habib G, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):261–4 (Eng. Abstr.) **(Fre)**

[Serous cystadenoma of the pancreas revealed by choledochal stenosis (letter)] Barbe L, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):848–9 **(Fre)**

[Hemorrhagic pancreatic cystadenocarcinoma with colonic fistula. An unusual mode of manifestation] Demarquay JF, et al. **Gastroenterol Clin Biol** 1996;20(5):491–3 (Eng. Abstr.) **(Fre)**

[Diffuse papillomatosis of the biliary and pancreatic ducts: a rare association and a potentially malignant disease (letter)] Denie C, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):845–7 **(Fre)**

[Palliative celioscopic gastrojejunal anastomosis in the treatment of neoplastic duodenal stenoses] Bergamaschi R, et al. **J Chir (Paris)** 1995 Oct;132(10):391–2 (Eng. Abstr.) **(Fre)**

[Diabetes and pancreatic tumors] Löffler J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):727–31 (25 ref.) **(Fre)**

[Cachexia, ascites and kidney failure (clinical conference)] Sieber C, et al. **Schweiz Rundsch Med Prax** 1996 Mar 26; 85(13):411–5 **(Ger)**

[Segmental portal hypertension and cystic tumor of the pancreas] Acea Nebril B, et al. **An Med Interna** 1996 Mar; 13(3):133–5 (Eng. Abstr.) **(Spa)**

[Thymus carcinoid associated with type 1 multiple endocrine neoplasm syndrome] Martínez Cerezo FJ, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):21–3 (Eng. Abstr.) **(Spa)**

[Neoplastic obstructive jaundice: palliative treatment with self–expandable metallic prosthesis] Aldeano A, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):625–31 (Eng. Abstr.) **(Spa)**

CONGENITAL

Ganglioneuromatosis involving the small intestine and pancreas of a child and causing hypersecretion of vasoactive intestinal polypeptide. Shulman DI, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):212–8

DIAGNOSIS

Insulinoma: correlation of short–TI inversion–recovery (STIR) imaging and histopathologic findings. Mori M, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):337–41

Papillary cystic neoplasm of the pancreas: radiological findings. Procacci C, et al. **Abdom Imaging** 1995 Nov–Dec; 20(6):554–8

Papillary cystic tumor of the pancreas diagnosed by preoperative brushing cytology of the pancreatic duct [letter] Kuwabara H, et al. **Acta Cytol** 1996 May–Jun; 40(3):612–3

3DFT–flash MR imaging of pancreatic cancer with gadopentetate dimeglumine. Murakami T, et al. **Acta Radiol** 1996 Mar;37(2):190–4

Islet cell tumors of the pancreas: pathologic–imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. Buetow PC, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1175–9

Preoperative staging of cancer of the pancreas: value of MR angiography versus conventional angiography in detecting portal venous invasion. McFarland EG, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):37–43

Polymerase chain reaction–based K–ras mutation detection of pancreatic adenocarcinoma in routine cytology smears [see comments] Apple SK, et al. **Am J Clin Pathol** 1996 Mar;105(3):321–6. Comment in: Am J Clin Pathol 1996 Mar;105(3):257–9.

K–ras mutations and the diagnosis of pancreatic carcinoma [editorial; comment] Robinson RA. **Am J Clin Pathol** 1996 Mar;105(3):257–9. Comment on: Am J Clin Pathol 1996 Mar;105(3):321–6.

Isolated tuberculosis of the pancreas masquerading as a pancreatic mass. Fischer G, et al. **Am J Gastroenterol** 1995 Dec;90(12):2227–30

P53 levels in the evaluation of malignant/benign pancreaticobiliary disease: hope or hype? Gessner CE, et al. **Am J Gastroenterol** 1996 Feb;91(2):401–2

Early detection of pancreatic glucagonoma. Haga Y, et al. **Am J Gastroenterol** 1995 Dec;90(12):2216–23

Diagnosis of pancreatic cancer by K–ras point mutation and cytology of pancreatic juice. Uehara H, et al. **Am J Gastroenterol** 1996 Aug;91(8):1616–21

Malignant tumors missed at laparoscopic cholecystectomy. Slim K, et al. **Am J Surg** 1996 Mar;171(3):364–5

Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM, et al. **Am J Surg** 1996 Jan;171(1):126–9; discussion 129–30

National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Janes RH Jr, et al. **Ann Surg** 1996 Mar;223(3):261–72

Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. Evans DB, et al. **Ann Surg Oncol** 1996 May;3(3):241–6

Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Tumminello FM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2315–9

Cystic neoplasms of the pancreas. A clinicopathologic study, including DNA flow cytometry. Brenin DR, et al. **Arch Surg** 1995 Oct;130(10):1048–54

Isolation of DNA from stool and bodily fluids for PCR amplification. Nollau P, et al. **Biotechniques** 1996 May; 20(5):784–8

Phantom pancreatic tumours. Robinson AJ, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):170–1

CA19–9–negative pancreatic cancer mimicking renal cancer. Muraishi O, et al. **Br J Urol** 1996 May;77(5):757–8

Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Nakaizumi A, et al. **Cancer** 1995 Sep 1;76(5):750–7

An 81–year–old woman with a cystic pancreatic mass. Katz DS, et al. **Clin Imaging** 1995 Oct–Dec;19(4):283–8

Case report: agenesis of the dorsal pancreas: a cause of diagnostic error on abdominal sonography. Deignan RW, et al. **Clin Radiol** 1996 Feb;51(2):145–7

Preoperative endocrine tumor localization utilizing a cost–effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

Malignant lymphoma of the pancreas [letter] Tanaka T, et al. **Dig Dis Sci** 1996 Feb;41(2):402–4 (18 ref.)

Pancreas divisum imitating malignancy in a patient with a cystadenoma. Dohmoto M, et al. **Endoscopy** 1995 Jun; 27(5):413

Acinar cell carcinoma of the pancreas: a rare case of an alpha–fetoprotein–producing cystic tumor. Ishizaki A, et al. **Eur J Radiol** 1995 Nov;21(1):58–60

Solid and papillary epithelial neoplasm of the pancreas: CT and MR findings. Savci G, et al. **Eur Radiol** 1996;6(1):86–8

Advances in diagnosis and treatment of pancreatic cancer. Bramhall SR, et al. **Gastroenterologist** 1995 Dec;3(4):301–10 (106 ref.)

ERCP meets C–K–ras: towards an improved diagnosis of pancreatic cancer. Pasricha PJ. **Gastroenterology** 1996 Jan; 110(1):311–2; discussion 312–3

Identification of K–ras mutations: from microscope to endoscope. Tenner S, et al. **Gastroenterology** 1996 Aug; 111(2):529–31

Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306–10 (57 ref.). Comment on: Gastroenterology 1996 Jan;110(1):221–6. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Aug;111(2):566–7.

Diagnostic utility of K–ras mutations in fine–needle aspirates of pancreatic masses. Villanueva A, et al. **Gastroenterology** 1996 May;110(5):1587–94

Endoscopic ultrasound–guided fine needle aspiration in the diagnosis and staging of pancreatic tumors. Chang KJ. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):723–34

Diabetes, weight loss, and depression. Papp JP, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):41–2, 44

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):189–99 (95 ref.)

Detection of point mutations in K–ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. Ajiki T, et al. **Int J Pancreatol** 1995 Dec;18(3):215–20

Leiomyosarcoma of the pancreas. Aranha GV, et al. **Int J Pancreatol** 1995 Feb;17(1):95–7 (5 ref.)

Serous cystadenoma of the pancreas communicating with a pancreatic duct. Furukawa H, et al. **Int J Pancreatol** 1996 Apr;19(2):141–4

Localization of gastrinomas. Prinz RA. **Int J Pancreatol** 1996 Apr;19(2):79–91 (53 ref.)

Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema? Manes G, et al. **Ital J Gastroenterol** 1995 Jun;27(5):248–9

A 73–year–old man with hyperglycemia, skin rashes, anemia and weight loss. Henry JG, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2428–33

Localization of insulinomas by selective intraarterial calcium injection. O'Shea D, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1623–7

Diagnostic certainty in pancreatic cancer [letter; comment] Silverman DT, et al. **J Clin Epidemiol** 1996 May; 49(5):601–3. Comment on: J Clin Epidemiol 1994 Sep;47(9):1069–79.

MRI of pancreatic metastases from renal cancer. Kelekis NL, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):249–53

Tumour–induced hypoglycaemia in a patient with insulin–dependent diabetes mellitus. Svartberg J, et al. **J Intern Med** 1996 Feb;239(2):181–5 (16 ref.)

Yelling attacks and wasted hands. Bosboom WM, et al. **Lancet** 1996 Jul 27;348(9022):238

Contrast–enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Hypoglycaemia, Munchausen's syndrome and pseudoinsulinoma [letter] MacDonald L, et al. **Med J Aust** 1995 Sep 4;163(5):280

Chronic pancreatitis [letter; comment] Schmid RM, et al. **N Engl J Med** 1995 Nov 2;333(18):1222. Comment on: N Engl J Med 1995 Jun 1;332(22):1482–90.

Solid and papillary epithelial neoplasm of the pancreas: imaging–pathologic correlation on 56 cases. Buetow PC, et al. **Radiology** 1996 Jun;199(3):707–11

Intraductal mucin–producing tumors of the pancreas: imaging findings [see comments] Procacci C, et al. **Radiology** 1996 Jan;198(1):249–57. Comment in: Radiology 1996 Jul;200(1):285.

Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: ERCP. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):269–79 (17 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul–Sep;20(3):226–36 (66 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Diagnostic imaging: magnetic resonance imaging. Kelekis NL, et al. **Rays** 1995 Jul–Sep;20(3):289–303 (35 ref.) **(Eng, Ita)**

Diagnostic imaging and combined modality therapy of the cancer of the pancreatic head area. Marano P. **Rays** 1995 Jul–Sep;20(3):223–5 **(Eng, Ita)**

Large Brunner's gland hamartoma simulating a pancreatic mass with obstruction and bleeding. Reisner RM, et al. **Surg Endosc** 1996 Mar;10(3):341–3

Efficiency of percutaneous core biopsy in pancreatic tumor diagnosis. Karlson BM, et al. **Surgery** 1996 Jul;120(1):75–9

[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509–10 (4 ref.) **(Fre)**

[Acinar cell carcinoma of the pancreas revealed by Weber–Christian syndrome] Foulet A, et al. **Ann Pathol** 1995;15(6):438–42 (Eng. Abstr.) **(Fre)**

[Cystic tumors of the pancreas. Cystadenomas and cystadenocarcinomas. Diagnosis and management] Wakim R, et al. **J Chir (Paris)** 1996 Apr;133(2):54–60 (Eng. Abstr.) **(Fre)**

[Pancreaticoscopy: experiences, possibilities and limits] Wegerle W, et al. **Bildgebung** 1996 Mar;63(1):28–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Backache, claudicatio venosa and chronic diarrhea] Bertschinger P, et al. **Internist (Berl)** 1995 Dec; 36(12):1179–81 **(Ger)**

[Diagnosis of the origin and therapy of organic hyperinsulinism] Böttger T, et al. **Med Klin** 1995 Dec 15; 90(12):688–92 (Eng. Abstr.) **(Ger)**

[Diagnostic localization of insulinoma. Experiences with 25 patients with solitary tumors] Kisker O, et al. **Med Klin** 1996 Jun 15;91(6):349–54 (Eng. Abstr.) **(Ger)**

[Tumor in the left epigastrium. Mucinous–cystic neoplasia of the pancreatic tail (here cystadenoma)] Bahner ML, et al. **Radiologe** 1996 May;36(5):449–52 **(Ger)**

[Cost benefit considerations in modern diagnostic sectional imaging exemplified by upper abdominal organs] Hamm B. **Radiologe** 1996 Apr;36(4):292–9 (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: radiologic–pathologic correlation] Helmberger T, et al. **Radiologe** 1996 May;36(5):419–26 (32 ref.) (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: value, technique and applications] Helmberger T, et al. **Radiologe** 1996 May;36(5):413–8 (Eng. Abstr.) **(Ger)**

[Techniques and applications of MR pancreatography in comparison with endoscopic retrograde pancreatography] Holzknecht N, et al. **Radiologe** 1996 May;36(5):427–34 (Eng. Abstr.) **(Ger)**

[The value of 3–phase spiral CT and magnetic resonance tomography in preoperative diagnosis of pancreatic carcinoma] Lentschig MG, et al. **Radiologe** 1996 May; 36(5):406–12 (Eng. Abstr.) **(Ger)**

[A radiologically unclassifiable pancreatic tumor: pseudotumorous nodular lymphoplasmacellular pancreatitis. A special form of retroperitoneal fibrosis?] Beck A, et al. **Rontgenpraxis** 1996 Apr;49(4):85–9 **(Ger)**

[Prognosis in pancreatic carcinoma] Friess H, et al. **Ther Umsch** 1996 May;53(5):401–7 (43 ref.) (Eng. Abstr.) **(Ger)**

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma: diagnosis] Scheurer U. **Ther Umsch** 1996 May;53(5):377–86 (41 ref.) (Eng. Abstr.) **(Ger)**

[Benign schwannoma of the celiac tripod simulating a pancreatic neoplasm] Cedolini C, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):47–9 (15 ref.) (Eng. Abstr.) **(Ita)**

[Carcinoma of the pancreas. Typical and atypical aspects using midfield–strength magnetic resonance] Cardone G, et al. **Radiol Med (Torino)** 1995 Dec;90(6):740–6 (Eng. Abstr.) **(Ita)**

[A rare pediatric tumor of the pancreas: pancreatoblastoma] Catalano O, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):321–2 (6 ref.) **(Ita)**

[Identification of pancreatic insulinomas. The role of magnetic resonance] Pavone P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):734–9 (Eng. Abstr.) **(Ita)**

[A case of occult insulinoma localized by intra–arterial stimulation with calcium and venous sampling technic] Uchida A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1320–6 **(Jpn)**

[Quick radioimmunoassay for plasma immunoreactive gastrin—application for localizing occult gastrinoma(s) during operation] Sasakuma F, et al. **Rinsho Byori** 1996 May;44(5):471–6 (Eng. Abstr.) **(Jpn)**

[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

[The use of the artificial pancreas apparatus (Biostator) in the diagnosis and surgical treatment of insuloma patients] Shalimov AA, et al. **Klin Khir** 1995;(6):3–4 **(Rus)**

[2 cases of a papillary cystic tumor of the pancreas] Gas'maev VK. **Vestn Rentgenol Radiol** 1995 Sep–Oct;(5):39–41 **(Rus)**

[Sarcoidosis simulating carcinoma of the head of pancreas] Espinosa Aguilar MD, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):221–2 (Eng. Abstr.) **(Spa)**

[Magnetic resonance diagnosis of insulinoma] García Quintanilla F, et al. **Rev Gastroenterol Mex** 1996 Jan–Mar; 61(1):43–6 (Eng. Abstr.) **(Spa)**

[A solid epithelial papillary–cystic pancreatic tumor. A report of a clinical case and review of the literature] Chávez M, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):64–71 (29 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

High–dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Di Costanzo F, et al. **Am J Clin Oncol** 1996 Jun;19(3):307–10

Phase II trial of 5–fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. André T, et al. **Ann Oncol** 1996 Feb;7(2):173–8

A pilot study of combination therapy with interferon–alpha–2a and 5–fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Hughes MJ, et al. **Ann Oncol** 1996 Feb;7(2):208–10

Cisplatin and protracted venous infusion 5–fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma. Nicolson M, et al. **Ann Oncol** 1995 Oct;6(8):801–4

Intermittent continuous infusion of ifosfamide and 5–fluorouracil in patients with advanced adenocarcinoma of the pancreas. Poorter RL, et al. **Ann Oncol** 1995 Dec; 6(10):1048–9

Intratumoral chemotherapy with a sustained–release drug delivery system inhibits growth of human pancreatic cancer xenografts. Smith JP, et al. **Anticancer Drugs** 1995 Dec; 6(6):717–26

A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. An Z, et al. **Anticancer Res** 1996 Mar–Apr;16(2):627–31

An open–label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Fearon KC, et al. **Anticancer Res** 1996 Mar–Apr;16(2):867–74

Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Friess H, et al. **Anticancer Res** 1996 Mar–Apr;16(2):915–20

Deleterious effect of formycin A on tumor islet cells. Rasschaert J, et al. **Biochem Mol Med** 1995 Apr; 54(2):138–41

Phase II study of gemcitabine in patients with advanced pancreatic cancer. Carmichael J, et al. **Br J Cancer** 1996 Jan;73(1):101–5

A phase II study of continuous–infusion 5–fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Evans TR, et al. **Br J Cancer** 1996 May;73(10):1260–4

Chemotherapy for pancreatic carcinoma. Ahlgren JD. **Cancer** 1996 Aug 1;78(3 Suppl):654–63 (74 ref.)

Phase I/II trial of dexverapamil, epirubicin, and granulocyte–macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Kornek G, et al. **Cancer** 1995 Oct 15;76(8):1356–62

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Regional chemotherapy for inoperable pancreatic carcinoma. Muchmore JH, et al. **Cancer** 1996 Aug 1;78(3 Suppl):664–73

Clinical implications of tumor–associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC–366140). Palomino E, et al. **Cancer Chemother Pharmacol** 1996;38(5):453–8

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Stark MJ, et al. **Cancer Lett** 1995 Sep 4; 96(1):15–21

Cytotoxic, nuclear, and growth inhibitory effects of photodynamic drugs on pancreatic carcinoma cells. Ward AJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):39–47

The use of the tumour marker CA19–9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas [letter] Wong A, et al. **Eur J Cancer** 1995 Nov;31A(12):2118–9

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Arnold R, et al. **Gut** 1996 Mar;38(3):430–8

The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)

Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Muchmore JH, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):346–55

A new method of intra–arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer. Ohigashi H, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):338–45

Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer. Warren GP, et al. **Indiana Med** 1996 May–Jun; 89(3):274–7

SDZ 281–977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Cammisuli S, et al. **Int J Cancer** 1996 Jan 26;65(3):351–9

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.). Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

A phase I study of combined radiation therapy with 5–fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Hsue V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):445–50

New versus old: pancreatic cancer and chemoradiation

attempts [editorial; comment] Peacock JL. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):969–70. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):913–8.

A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma. Schwartz GK, et al. **Invest New Drugs** 1995;13(1):77–82

Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R7–10

Glucagon treatment in NICTH [letter] Vassilopoulou-Sellin R. **J Clin Endocrinol Metab** 1996 Apr;81(4):1671

Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Ito T, et al. **Jpn J Cancer Res** 1996 Feb; 87(2):113–6

Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts. Kondo Y, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1072–9

Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Okusaka T, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):215–20

"Chemotherapy for unresectable pancreatoblastoma" [letter] Hord JD, et al. **Med Pediatr Oncol** 1996 Jun;26(6):432–3

Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)

Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Di Bartolomeo M, et al. **Oncology** 1996 Jan–Feb;53(1):54–7

ODAC recommends full approval for Gemzar for pancreatic cancer [news] **Oncology (Huntingt)** 1995 Sep;9(9):799–800

All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Bold RJ, et al. **Pancreas** 1996 Mar; 12(2):189–95

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Ishii H, et al. **Pancreas** 1996 Apr;12(3):267–71

Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy [see comments] Cohen L, et al. **Radiology** 1996 Sep;200(3):627–30. Comment in: Radiology 1996 Sep;200(3):608–9.

Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy. Cellini N, et al. **Rays** 1995 Jul–Sep;20(3):350–9 (30 ref.) **(Eng, Ita)**

Chemotherapy of adenocarcinoma of the pancreas. Schnall SF, et al. **Semin Oncol** 1996 Apr;23(2):220–8 (81 ref.)

Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Lai DT, et al. **Surgery** 1996 Jan;119(1):112–4

Prolonging survival in inoperable pancreatic cancer with combination chemotherapy. Goel AK, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):141–3

Adenocarcinoma of the pancreas in childhood (pancreatoblastoma): report of a case with good response to chemotherapy. Caracciolo G, et al. **Tumori** 1995 Sep–Oct;81(5):391–4

[Adjuvant regional chemotherapy in resected advanced pancreas carcinoma] Gansauge F, et al. **Chirurg** 1996 Apr; 67(4):362–5 (Eng. Abstr.) **(Ger)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Regional chemotherapy in advanced pancreatic carcinoma] Gansauge F, et al. **Med Klin** 1995 Sep 15;90(9):501–5 (Eng. Abstr.) **(Ger)**

[A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy] Kenmotsu M, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1983–5 (Eng. Abstr.) **(Jpn)**

[Unilateral injection with the patient in lateral position. Simpler pain blockade in pancreatic cancer] Rykowski JJ, et al. **Lakartidningen** 1996 May 22;93(21):2075–7 **(Swe)**

ECONOMICS

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [letter] Douglass HO Jr, et al. **J Am Coll Surg** 1996 Sep; 183(3):291–2; discussion 294

ENZYMOLOGY

Cathepsin E expressed in pancreatic cancer. Azuma T, et al. **Adv Exp Med Biol** 1995;362:363–6

Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Soldan M, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):117–23

Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Ohta T, et al. **Br J Cancer** 1996 Jun;73(12):1511–7

Expression of dynamin immunoreactivity in experimental pancreatic tumors induced in rat by mancozeb-nitrosomethylurea. Valentich MA, et al. **Cancer Lett** 1996 Apr 19;102(1–2):23–9

Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Azuma T, et al. **Int J Cancer** 1996 Aug 7;67(4):492–7

Adenylate cyclase activity in human pancreatic adenocarcinoma cell lines. al-Nakkash L, et al. **Int J Pancreatol** 1996 Feb;19(1):39–47

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. Bergström M, et al. **J Nucl Med** 1996 Jan;37(1):32–7

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2–11

Identification of protein kinase C zeta isozyme in hamster pancreas and pancreatic carcinoma cell lines. Nair SC, et al. **Mol Carcinog** 1995 Nov;14(3):205–13

Pancreatic enzyme activity after a pylorus-preserving pancreaticoduodenectomy reconstructed with pancreaticogastrostomy. Takada T, et al. **Pancreas** 1995 Oct;11(3):276–82

EPIDEMIOLOGY

Adult pancreatoblastoma: a case report and review of the literature. Levey JM, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1841–4 (16 ref.)

Pancreatic cancer among workers processing synthetic resins. Selenskas S, et al. **Am J Ind Med** 1995 Sep;28(3):385–98

Rising incidence of pancreatic carcinoma in middle-aged and older women–time trends 1961–90 in the city of Malmö, Sweden. Hedberg M, et al. **Br J Cancer** 1996 Mar; 73(6):843–6

The National Cancer Data Base report on pancreatic cancer. Niederhuber JE, et al. **Cancer** 1995 Nov 1;76(9):1671–7

Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a case-control study in Shanghai, China. Ji BT, et al. **Cancer Causes Control** 1995 Jul;6(4):369–76

Attributable risks for pancreatic cancer in northern Italy. Fernandez E, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):23–7

Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada. Ghadirian P, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):895–9

Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China. Ji BT, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):885–93

Familial pancreatic cancer in south Louisiana. Price TF, et al. **Cancer Nurs** 1996 Aug;19(4):275–82

Alcohol and pancreatic cancer in blacks and whites in the United States. Silverman DT, et al. **Cancer Res** 1995 Nov 1;55(21):4899–905

Risk factors and their identification. Third Part: Examples. Balkau B, et al. **Diabete Metab** 1995 Oct;21(4):299–308

IDDM and pancreatic carcinoma in Sardinia [letter] Songini M. **Diabetes Care** 1996 Feb;19(2):184–5

Risk of pancreatic and periampullar cancer following cholecystectomy: a population-based cohort study. Ekbom A, et al. **Dig Dis Sci** 1996 Feb;41(2):387–91

Pancreatic cancer and occupational exposures. Kauppinen T, et al. **Epidemiology** 1995 Sep;6(5):498–502

Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Ji BT, et al. **Int J Cancer** 1996 May 16;66(4):432–7

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul–Sep;20(3):226–36 (66 ref.) **(Eng, Ita)**

Epidemiology and risk factors in pancreatic cancer. Ahlgren JD. **Semin Oncol** 1996 Apr;23(2):241–50 (127 ref.)

[Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract] Gavaldà L, et al. **Gac Sanit** 1995 Nov–Dec;9(51):334–42 (Eng. Abstr.) **(Spa)**

[Epidemiology of exocrine pancreatic cancer in the Principality of Asturias, 1973–1992] González Martínez J, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):653–7 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Alcohol and pancreatic cancer in blacks and whites in the United States. Silverman DT, et al. **Cancer Res** 1995 Nov 1;55(21):4899–905

ETIOLOGY

Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats. Appel MJ, et al. **Br J Cancer** 1996 Jan;73(1):36–43

Pancreas cancer as a second primary malignancy. A population-based study. Neugut AI, et al. **Cancer** 1995 Aug 15;76(4):589–92

Lack of inhibitory effects of beta-carotene, vitamin C, vitamin E and selenium on development of ductular adenocarcinomas in exocrine pancreas of hamsters. Appel MJ, et al. **Cancer Lett** 1996 Jun 5;103(2):157–62

Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Italian Pancreatic Cancer Study Group. Gullo L, et al. **Dig Dis Sci** 1996 Jun; 41(6):1065–8

Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Baum A, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):117–20

Chronic pancreatitis and pancreatic cancer [letter; comment] Gullo L. **Gastroenterology** 1996 Mar;110(3):968–9. Comment on: Gastroenterology 1995 Jul;109(1):247–51.

Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. Boyle P, et al. **Int J Cancer** 1996 Jul 3;67(1):63–71

Prior immunity-related medical conditions and pancreatic-cancer risk in Shanghai. Dai Q, et al. **Int J Cancer** 1995 Nov 3;63(3):337–40

Dose-response relationship between coffee and the risk of pancreas cancer. Nishi M, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):42–8 (38 ref.)

Pancreatitis and the risk of pancreatic cancer. Fernandez E, et al. **Pancreas** 1995 Aug;11(2):185–9

Coffee and cancer of the pancreas: an Italian multicenter study. The Italian Pancreatic Cancer Study Group. Gullo L, et al. **Pancreas** 1995 Oct;11(3):223–9

[Female patient with kidney transplantation with acute pancreatitis (clinical conference)] Rünzi M, et al. **Med Klin** 1996 Mar 15;91(3):136–40 **(Ger)**

[Papillary cystic neoplasms in the ectopic pancreas] Kövári E, et al. **Orv Hetil** 1996 Apr 28;137(17):923–5 (Eng. Abstr.) **(Hun)**

GENETICS

The association between tuberous sclerosis and insulinoma. Kim H, et al. **AJNR Am J Neuroradiol** 1995 Aug; 16(7):1543–4

Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Wakabayashi T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1848–51

The role of flow cytometric DNA analysis in determining prognosis of resectable ductal adenocarcinoma of the pancreas. Park CS, et al. **Am Surg** 1996 Jul;62(7):609–15; discussion 615–6

Identification of K-ras mutations in pancreatic juice [letter; comment] Gutiérrez AA, et al. **Ann Intern Med** 1996 Jun 1;124(11):1014–5. Comment on: Ann Intern Med 1995 Aug 1;123(3):188–91.

Molecular genetics of malignant insulinoma. Pavelic K, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1707–17

Isolation of DNA sequences amplified at chromosome 19q13.1–q13.2 including the AKT2 locus in human pancreatic cancer. Miwa W, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):968–74

Increased expression of keratinocyte growth factor in human pancreatic cancer. Siddiqi I, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):309–15

Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. Vincent F, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):561–4

DNA ploidy analysis of mucinous cystic tumors of the pancreas. Correlation of aneuploidy with malignancy and poor prognosis. Southern JF, et al. **Cancer** 1996 Jan 1; 77(1):58–62

Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma. Bartsch D, et al. **Cancer Lett** 1996 Apr 19;102(1–2):73–6

Identification and characterization of zinc finger encoding genes from the tumoral exocrine pancreatic cell line AR42J. Mesa K, et al. **Cancer Lett** 1996 Jun 5;103(2):143–9

Peritoneal exfoliative cytology and Ki-ras mutational analysis in patients with pancreatic adenocarcinoma. Rall CJ, et al. **Cancer Lett** 1995 Nov 6;97(2):203–11

Familial pancreatic cancer in south Louisiana. Price TF, et al. **Cancer Nurs** 1996 Aug;19(4):275–82

Chromosome 7q allelic losses in pancreatic carcinoma. Achille A, et al. **Cancer Res** 1996 Aug 15;56(16):3808–13

Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Chen ZH, et al. **Cancer Res** 1996 Mar 1;56(5):1083–90

Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Hahn SA, et al. **Cancer Res** 1995 Oct 15; 55(20):4670–5

Homozygous deletion map at 18q21.1 in pancreatic cancer. Hahn SA, et al. **Cancer Res** 1996 Feb 1;56(3):490–4

Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Huang L, et al. **Cancer Res** 1996 Mar 1;56(5):1137–41

PRG1: a novel early-response gene transcriptionally induced by pituitary adenylate cyclase activating polypeptide in a pancreatic carcinoma cell line. Schäfer H, et al. **Cancer Res** 1996 Jun 1;56(11):2641–8

An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12. Schutte M, et al. **Cancer Res** 1995 Oct 15;55(20):4570–4

Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Solinas-Toldo S, et al. **Cancer Res** 1996 Aug 15; 56(16):3803–7

High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced

by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Sugio K, et al. **Carcinogenesis** 1996 Feb;17(2):303-9

Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. Visser CJ, et al. **Carcinogenesis** 1996 Apr;17(4):779-85

Insulin-like growth factor II is focally up-regulated and functionally involved as a second signal for oncogene-induced tumorigenesis. Naik P, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:459-70

Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma. Sbraccia P, et al. **Diabetologia** 1996 Feb; 39(2):220-5

Type-1 growth factor receptors in pancreatic and gastrointestinal neoplasia. Lemoine NR, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):939-44 (74 ref.)

Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization. Paciucci R, et al. **FEBS Lett** 1996 Apr 29;385(1-2):72-6

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer [see comments] Iguchi H, et al. **Gastroenterology** 1996 Jan;110(1):221-6. Comment in: Gastroenterology 1996 Jan;110(1):306-10.

Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Naumann M, et al. **Gastroenterology** 1996 Apr; 110(4):1215-24

ERCP meets C-K-ras: towards an improved diagnosis of pancreatic cancer. Pasricha PJ. **Gastroenterology** 1996 Jan; 110(1):311-2; discussion 312-3

Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306-10 (57 ref.). Comment on: Gastroenterology 1996 Jan;110(1):221-6. Comment on: Gastroenterology 1996 Jan;110(1):227-31. Comment in: Gastroenterology 1996 Aug;111(2):566-7.

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Bartsch D, et al. **Genes Chromosomes Cancer** 1995 Nov;14(3):189-95

Massive cytogenetic heterogeneity in a pancreatic carcinoma: fifty-four karyotypically unrelated clones. Gorunova L, et al. **Genes Chromosomes Cancer** 1995 Dec;14(4):259-66

Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence-based single-strand conformation polymorphism analysis using blunt-end DNA fragments. Sugano K, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):157-64

p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Bartz C, et al. **Gut** 1996 Mar; 38(3):403-9

An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Watanabe M, et al. **Int J Cancer** 1996 Jul 17;67(2):264-8

K-ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1-6 (66 ref.)

Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Lei S, et al. **Int J Pancreatol** 1995 Feb;17(1):15-21

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Bartsch D, et al. **J Natl Cancer Inst** 1996 May 15; 88(10):680-2

Multiple genetic alterations in malignant metastatic insulinomas. Pavelić K, et al. **J Pathol** 1995 Dec; 177(4):395-400

Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Shimizu T, et al. **Jpn J Cancer Res** 1996 Mar;87(3):275-8

Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Suwa H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):641-9

T-cell receptor gene structures of HLA-A26-restricted cytotoxic T lymphocyte lines against human autologous pancreatic adenocarcinoma. Ueda D, et al. **Jpn J Cancer Res** 1995 Jul;86(7):691-7

Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation. Watanabe H, et al. **Jpn J Cancer Res** 1996 May;87(5):466-74

p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Weyrer K, et al. **Lab Invest** 1996 Jan; 74(1):279-89

Familial melanoma and pancreatic cancer [letter; comment] Bergman W, et al. **N Engl J Med** 1996 Feb 15;334(7):471-2 . Comment on: N Engl J Med 1995 Oct 12;333(15):970-4. Comment on: N Engl J Med 1995 Oct 12;333(15):975-7.

Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group [letter; comment] Ciotti P, et al. **N Engl J Med** 1996 Feb 15;334(7):469-70; discussion 471-2 . Comment on: N Engl J Med 1995 Oct 12;333(15):970-4. Comment on: N Engl J Med 1995 Oct 12;333(15):975-7.

Familial melanoma and pancreatic cancer [letter; comment] Wright FA, et al. **N Engl J Med** 1996 Feb 15;334(7):470-1; discussion 471-2. Comment on: N Engl J Med 1995 Oct 12;333(15):970-4.

Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Clarke AR, et al. **Oncogene** 1995 Nov 2;11(9):1913-20

Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. Wang H, et al. **Oncogene** 1996 Jun 20;12(12):2555-62

Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Ramel S, et al. **Pancreas** 1995 Oct;11(3):213-22

K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362-8

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Cheng JQ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3636-41

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. [see comments] Hahn SA, et al. **Science** 1996 Jan 19;271(5247):350-3. Comment in: Science 1996 Jan 19;271(5247):294.

New tumor suppressor found in pancreatic cancer [news; comment] O'Brien C. **Science** 1996 Jan 19;271(5247):294. Comment on: Science 1996 Jan 19;271(5247):350-3.

Familial pancreatic cancer: a review. Lynch HT, et al. **Semin Oncol** 1996 Apr;23(2):251-75 (208 ref.)

[Reversal of malignant phenotype of cells of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense c-myc] Li H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Feb;25(1):13-6 (Eng. Abstr.) **(Chi)**

[Reversal of malignant cell phenotype of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense Ki-ras] Li H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct;24(5):288-91 (Eng. Abstr.) **(Chi)**

[Pancreatic carcinoma: a new suppressor gene has been found] Weismann H. **Dtsch Med Wochenschr** 1996 May 24;121(21):A8-9 **(Ger)**

[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test] Arao S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1327-30 **(Jpn)**

IMMUNOLOGY

Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Lundin J, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2181-6

Tumor markers in patients with pancreatic carcinoma. Gattani AM, et al. **Cancer** 1996 Jul 1;78(1):57-62

HLA-DR-restricted T cell lines from newly diagnosed type 1 diabetic patients specific for insulinoma and normal islet beta cell proteins: lack of reactivity to glutamic acid decarboxylase. Huang GC, et al. **Clin Exp Immunol** 1995 Oct;102(1):152-8

Immune and nutritional effects of early enteral nutrition after major abdominal operations. Braga M, et al. **Eur J Surg** 1996 Feb;162(2):105-12

Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Kishimoto T, et al. **Int J Cancer** 1996 Aug 22;69(4):290-4

Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Syrigos KN, et al. **Int J Cancer** 1996 May 29;66(5):624-6

Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R, et al. **Ital J Gastroenterol** 1995 Jul-Aug;27(6):296-9

Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. Onrust SV, et al. **J Clin Invest** 1996 Jan 1;97(1):54-64

Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. Cavallo MG, et al. **J Endocrinol** 1996 Jul;150(1):113-20

T-cell receptor gene structures of HLA-A26-restricted cytotoxic T lymphocyte lines against human autologous pancreatic adenocarcinoma. Ueda D, et al. **Jpn J Cancer Res** 1995 Jul;86(7):691-7

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2-11

Humoral graft-versus-host disease after pancreas transplantation with an ABO-compatible and Rh-nonidentical donor. Case report and a rationale for preoperative screening. Sindhi R, et al. **Transplantation** 1996 May 15;61(9):1414-6

[Utility of Ca 19-9 tumor marker in pancreatic carcinoma] Barak V, et al. **Harefuah** 1995 Sep;129(5-6):217-9 **(Heb)**

METABOLISM

p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. DiGiuseppe JA, et al. **Am J Pathol** 1995 Oct;147(4):884-8

Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Furukawa T, et al. **Am J Pathol** 1995 Oct;147(4):889-95

Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Bergmann U, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):886-90

PACAP stimulates transcription of c-Fos and c-Jun and activates the AP-1 transcription factor in rat pancreatic carcinoma cells. Schäfer H, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):111-6

Downregulation of prohormone convertase-1 by a phorbol ester. Udupi V, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):495-500

Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin. Otsuji E, et al. **Br J Cancer** 1996 Aug;74(4):597-602

Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Sperti C, et al. **Cancer** 1996 Jul 15;78(2):237-43

Increased DT-diaphorase activity in transformed and tumorigenic pancreatic acinar cells. Hammons GJ, et al. **Cancer Lett** 1995 Sep 4;96(1):9-14

Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Buscail L, et al. **Cancer Res** 1996 Apr 15;56(8):1823-7

Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Shimoyama S, et al. **Cancer Res** 1996 Jun 15;56(12):2703-6

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Sleeman JP, et al. **Cancer Res** 1996 Jul 1;56(13):3134-41

Glucocorticoid receptor concentration modulates glucocorticoid-regulated gene expression in rat pancreatic AR42J cells. Kaiser A, et al. **Digestion** 1996;57(3):149-60

Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. Volz A, et al. **FEBS Lett** 1995 Oct 2; 373(1):23-9

Products of gamma-tocopherol reaction with NO2 and their formation in rat insulinoma (RINm5F) cells. Cooney RV, et al. **Free Radic Biol Med** 1995 Sep;19(3):259-69

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer [see comments] Iguchi H, et al. **Gastroenterology** 1996 Jan;110(1):221-6. Comment in: Gastroenterology 1996 Jan;110(1):306-10.

Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Baldwin RL, et al. **Int J Cancer** 1996 Jul 17;67(2):283-8

Autocrine stimulation of AR4-2J rat pancreatic tumor cell growth by glycine-extended gastrin. Nègre F, et al. **Int J Cancer** 1996 May 29;66(5):653-8

Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Oikawa T, et al. **Int J Pancreatol** 1995 Aug;18(1):15-23

A novel adhesion factor produced by hamster pancreatic cancer cell line is effective on normal and carcinoma cell lines of different species. Toshkov IA, et al. **Int J Pancreatol** 1995 Dec;18(3):249-55

Granulocyte-colony stimulating factor produced by pancreatic carcinoma. Uematsu T, et al. **Int J Pancreatol** 1996 Apr;19(2):135-9

Expression and potential role of E-cadherin in pancreatic carcinoma. Weinel RJ, et al. **Int J Pancreatol** 1996 Feb; 19(1):25-30

Pancreatic islet cells express a family of inwardly rectifying K+ channel subunits which interact to form G-protein-activated channels. Ferrer J, et al. **J Biol Chem** 1995 Nov 3;270(44):26086-91

mRNA profiling of rat islet tumors reveals nkx 6.1 as a beta-cell-specific homeodomain transcription factor. Jensen J, et al. **J Biol Chem** 1996 Aug 2;271(31):18749-58

Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. Collier JD, et al. **J Gastroenterol Hepatol** 1995 Jul-Aug;10(4):396-400

Carotenoids and tocopherols in various hepatobiliary conditions. Leo MA, et al. **J Hepatol** 1995 Nov;23(5):550-6

Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. Vaidya P, et al. **J Pathol** 1996 Feb;178(2):140-5

Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Huang L, et al. **Mol Carcinog** 1996 Feb;15(2):85-95

Different implications of Ca2+i and and Ca2+e in CCK/gastrin-induced amylase secretion in AR4-2J cells. Bertrand V, et al. **Pancreas** 1995 Oct;11(3):230-5

Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Löhr M, et al. **Pancreas** 1996 Apr;12(3):248-59

K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362-8

Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Yamada M, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):37-47

[Biliary and pancreatic excretion of etoposide] Suda Y, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1191-6 (Eng. Abstr.) **(Jpn)**

[A case report of the VIP producing tumor with liver metastasis presenting WDHA syndrome] Inoue S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1217-22 (13 ref.) **(Jpn)**

MORTALITY

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Fortner JG, et al. **Ann Surg** 1996 Feb;223(2):147–53

Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Lieberman MD, et al. **Ann Surg** 1995 Nov;222(5):638–45

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2659–68

Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the west Midlands: an epidemiological study [letter] Gudjonsson B. **Br J Surg** 1996 Jun;83(6):874

Nuclear DNA content and pathology in radically treated pancreatic carcinoma. The prognostic significance of DNA ploidy, histology and nuclear grade. Rugge M, et al. **Cancer** 1996 Feb 1;77(3):459–66

Favourable prognosis of cystadeno– over adenocarcinoma of the pancreas after curative resection. Ridder GJ, et al. **Eur J Surg Oncol** 1996 Jun;22(3):232–6

Carcinoma of the head of the pancreas: review of 67 cases and comparison with 27 additional periampullary carcinomas. Taschieri AM, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1023–5

Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas. Linder S, et al. **Int J Pancreatol** 1995 Dec; 18(3):241–8

Management of patients with carcinoma of the pancreas [editorial; comment] Gordon TA, et al. **J Am Coll Surg** 1995 Dec;181(6):558–60. Comment on: J Am Coll Surg 1995 Dec;181(6):483–503.

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.). Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

Pancreatic cancer shows modest survival gain [news] Bankhead C. **J Natl Cancer Inst** 1996 Jun 19;88(12):784–6

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Bartsch D, et al. **J Natl Cancer Inst** 1996 May 15; 88(10):680–2

Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Nakao A, et al. **Pancreas** 1996 May;12(4):357–61

[Possibilities and limitations of curative resections in cancers of the pancreas] Klempnauer J, et al. **J Chir (Paris)** 1996 May;133(3):117–22 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Duct ectasia due to mucus-producing cancers with intraductal extension: histopathologic correlation with radiologic imagings. Kobayashi H, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):341–7

Peritoneal fluid cytology in advanced mucinous cystadenocarcinoma of the pancreas. Centeno BA, et al. **Acta Cytol** 1996 Mar–Apr;40(2):191–5

Papillary cystic tumor of the pancreas diagnosed by preoperative brushing cytology of the pancreatic duct [letter] Kuwabara H, et al. **Acta Cytol** 1996 May–Jun; 40(3):612–3

Fine needle aspiration cytology in pancreatic pathology. Lerma E, et al. **Acta Cytol** 1996 Jul–Aug;40(4):683–6

Pancreatic oncocytic endocrine tumors. Cytologic features of two cases. Pacchioni D, et al. **Acta Cytol** 1996 Jul–Aug; 40(4):742–6

Percutaneous and intraoperative aspiration biopsy cytology of pancreatic neuroendocrine tumors: cytomorphologic study with an immunocytochemical contribution. Saleh HA, et al. **Acta Cytol** 1996 Mar–Apr;40(2):182–90

Fine needle aspiration cytology of acinar cell carcinoma of the pancreas: a report of two cases. Samuel LH, et al. **Acta Cytol** 1996 May–Jun;40(3):585–91

Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and MUC-1 gene product in intraductal papillary–mucinous neoplasm of the pancreas. Terada T, et al. **Am J Clin Pathol** 1996 May;105(5):613–20

Variant of intraductal carcinoma (with scant mucin production) is of main pancreatic duct origin: a clinicopathological study of four patients. Suda K, et al. **Am J Gastroenterol** 1996 Apr;91(4):798–800

The role of pancreatic islets in experimental pancreatic carcinogenicity. Ishikawa O, et al. **Am J Pathol** 1995 Nov; 147(5):1456–64

Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Pour PM, et al. **Am J Pathol** 1996 Sep;149(3):1017–25

The meaning of equivocal pancreatic cytology in patients thought to have pancreatic cancer. Enayati PG, et al. **Am J Surg** 1996 May;171(5):525–8

Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Liu CD, et al. **Am J Surg** 1996 Jan;171(1):192–6

Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively. Yamaguchi K, et al. **Am J Surg** 1996 Apr;171(4):427–31

Intraductal oncocytic papillary neoplasms of the pancreas. Adsay NV, et al. **Am J Surg Pathol** 1996 Aug;20(8):980–94

A pancreatic endocrine tumor arising within a serous cystadenoma of the pancreas. Keel SB, et al. **Am J Surg Pathol** 1996 Apr;20(4):471–5

Pancreatoblastoma. A clinicopathologic study and review of the literature. Klimstra DS, et al. **Am J Surg Pathol** 1995 Dec;19(12):1371–89 (81 ref.)

Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Zamboni G, et al. **Am J Surg Pathol** 1996 Jun;20(6):722–30

Comparison between image and flow cytometry. A priori factors that influence technique. Bowman R, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):276–83

The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Conlon KC, et al. **Ann Surg** 1996 Feb;223(2):134–40

Intraportal endovascular ultrasonography in the diagnosis of portal vein invasion by pancreatobiliary carcinoma. Kaneko T, et al. **Ann Surg** 1995 Dec;222(6):711–8

The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Basso D, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2585–8

Induction of Ley antigen by 5-aza-2'-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Yamada T, et al. **Anticancer Res** 1996 Mar–Apr;16(2):735–40

Osteoclastic giant cell tumor of the pancreas: an immunohistochemical study. Dizon MA, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):306–9

Recurrence of osteoclast-like giant cell carcinoma of the pancreas after 10 years. Mercer PM, et al. **Aust N Z J Surg** 1996 May;66(5):334–5

Advanced glycation endproducts–receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Yamamoto Y, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):700–5

Deleterious effect of formycin A on tumor islet cells. Rasschaert J, et al. **Biochem Mol Med** 1995 Apr; 54(2):138–41

Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Furukawa H, et al. **Cancer** 1996 Sep 1;78(5):986–90

Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Nuclear DNA content and pathology in radically treated pancreatic carcinoma. The prognostic significance of DNA ploidy, histology and nuclear grade. Rugge M, et al. **Cancer** 1996 Feb 1;77(3):459–66

Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Taniki T, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):295–302

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Sleeman JP, et al. **Cancer Res** 1996 Jul 1;56(13):3134–41

Malignant insulinoma: permanent hepatic artery embolization of liver metastases—preliminary results. Winkelbauer FW, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec; 18(6):353–9

Papillary and solid epithelial neoplasm of the pancreas. Lokuhetty MD, et al. **Ceylon Med J** 1995 Dec;40(4):154–5

Effects of antisense epidermal growth factor and its receptor retroviral expression vectors on cell growth of human pancreatic carcinoma cell line. Liu T, et al. **Chin Med J (Engl)** 1995 Sep;108(9):653–9

Value of image guided fine-needle aspiration cytology in the diagnosis of pancreatic malignancies. Gupta RK. **Diagn Cytopathol** 1995 Aug;13(2):120–3

Solid and cystic papillary neoplasm of the pancreas: a clinico-cytopathologic and immunocytochemical study of five new cases diagnosed by fine-needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

An association between villous adenomas and mucinous ductal ectasia of the pancreas. Barthet M, et al. **Endoscopy** 1995 Oct;27(8):601–3

Carcinoid of the pancreas: clinical characteristics and morphological features. Maurer CA, et al. **Eur J Cancer** 1996 Jun;32A(7):1109–16 (55 ref.)

Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. Thorban S, et al. **Eur J Cancer** 1996 Feb; 32A(2):363–5

Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Kawa S, et al. **Gastroenterology** 1996 May;110(5):1605–13

Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Rosewicz S, et al. **Gastroenterology** 1995 Nov; 109(5):1646–60

Staging of pancreatic cancer. Analysis of literature results. Rösch T. **Gastrointest Endosc Clin N Am** 1995 Oct; 5(4):735–9 (18 ref.)

CT-guided needle biopsy [letter] Siddiqui MA. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):28

Pancreatoblastoma. Mahajan R, et al. **Indian Pediatr** 1995 Jul;32(7):812–4

Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Baldwin RL, et al. **Int J Cancer** 1996 Jul 17;67(2):283–8

Enhancement of in vitro tumor-cell transcellular migration by tumor-cell-secreted endothelial-cell-retraction factor. Kusama T, et al. **Int J Cancer** 1995 Sep 27;63(1):112–8

Autocrine stimulation of AR4-2J rat pancreatic tumor cell growth by glycine-extended gastrin. Nègre F, et al. **Int J Cancer** 1996 May 29;66(5):653–8

Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, et al. **Int J Cancer** 1995 Oct 9;63(2):257–62

Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Robertson JF, et al. **Int J Cancer** 1995 Sep 27;63(1):69–75

Giant cell tumor of the pancreas arising in the ovarian-like stroma of a mucinous cystadenocarcinoma. Bergman S, et al. **Int J Pancreatol** 1995 Aug;18(1):71–5

Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. Frazier ML, et al. **Int J Pancreatol** 1996 Feb;19(1):31–8

Mixed pleomorphic-osteoclast-like tumor of the pancreas. Light microscopical, immunohistochemical, and molecular biological studies. Gatteschi B, et al. **Int J Pancreatol** 1995 Oct;18(2):169–75

A case of pleomorphic carcinoma of the pancreas showing sequential histological change by immunohistochemical study. Kamisawa T, et al. **Int J Pancreatol** 1995 Aug; 18(1):67–70

A case of macrocystic serous cystadenoma of the pancreas. Mori K, et al. **Int J Pancreatol** 1995 Feb;17(1):91–3 (8 ref.)

Pleomorphic nonfunctioning islet cell tumor of the pancreas. Taniguchi K, et al. **Int J Pancreatol** 1995 Feb;17(1):83–9

Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. Kobari M, et al. **J Am Coll Surg** 1996 Jan; 182(1):24–32

Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. Freeman JW, et al. **J Cell Physiol** 1995 Oct;165(1):155–63

Anaplastic carcinoma arising in ectopic pancreas located in the distal esophagus. Roshe J, et al. **J Clin Gastroenterol** 1996 Apr;22(3):242–4

Differentiation between multiple liver hemangiomas and liver metastases of gastrinomas: value of enhanced MRI. Berger JF, et al. **J Comput Assist Tomogr** 1996 May–Jun; 20(3):349–55

Pancreatic carcinoma: MR assessment of tumor invasion of the peripancreatic vessels. Sironi S, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):739–44

Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Correlation between proliferating index and prognostic factors in papillary cystic tumors of the pancreas. Cho NH, et al. **J Korean Med Sci** 1995 Oct;10(5):342–51

Panniculitis of pancreatic disease masquerading as systemic lupus erythematosus panniculitis. Feuer J, et al. **J Rheumatol** 1995 Nov;22(11):2170–2

Effect of human growth hormone on human pancreatic carcinoma growth, protein, and cell cycle kinetics. Harrison LE, et al. **J Surg Res** 1996 Mar;61(2):317–22

Endothelial leukocyte adhesion molecule-1-mediated vasoinvasion of human pancreatic adenocarcinoma. Takada M, et al. **J Surg Res** 1995 Dec;59(6):653–7

Gastrin receptor expression during azaserine-induced rat pancreatic carcinogenesis. Tsuei BJ, et al. **J Surg Res** 1996 Jun;63(1):105–9

Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Inoue S, et al. **Jpn J Cancer Res** 1995 Jul; 86(7):626–30

Solid and papillary epithelial neoplasm diagnosis and treatment: a case study. Urban JL, et al. **Md Med J** 1995 Sep;44(9):699–702

Effective control of bone pain by octreotide in a patient with metastatic gastrinoma. Burgess JR, et al. **Med J Aust** 1996 Jun 17;164(12):725–7

Multiparameter digital image analysis of biliary, ampullary, and pancreatic adenocarcinomas. Yeaton P, et al. **Mod Pathol** 1995 Oct;8(8):843–7

Multiple intracerebral metastases from an islet cell carcinoma of the pancreas: case report. Sabo RA, et al. **Neurosurgery** 1995 Aug;37(2):326–8

Hematogenous metastases of pancreatic ductal carcinoma. Kamisawa T, et al. **Pancreas** 1995 Nov;11(4):345–9

Extensive invasion of a ductal adenocarcinoma into the wall of a pancreatic pseudocyst [letter] Otani T, et al. **Pancreas** 1996 May;12(4):416–9

The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Staley CA, et al. **Pancreas** 1996 May;12(4):373–80

Duct-acinar-islet cell tumor of the pancreas. Okada Y, et al. **Pathol Int** 1995 Sep;45(9):669–76

Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in exocrine pancreatic carcinomas. Iachino C, et al. **Pathologica** 1995 Feb;87(1):56–8

Immunolocalization of neuropeptide Y in human pancreatic endocrine tumors. Waeber G, et al. **Peptides** 1995; 16(5):921–6

Inhibitors of angiotensin-converting enzyme modulate

mitosis and gene expression in pancreatic cancer cells. Reddy MK, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):221–6

Metastatic gastrinomas: localization with selective arterial injection of secretin. Gibril F, et al. **Radiology** 1996 Jan; 198(1):77–84

Tumor cell–induced platelet aggregation in vitro by human pancreatic cancer cell lines. Heinmöller E, et al. **Scand J Gastroenterol** 1995 Oct;30(10):1008–16

Cloning, expression and characterization of a single–chain antibody PS–9 targeted to pancreatic cancer. Yan X, et al. **Sci China B** 1995 Oct;38(10):1230–6

Malignant insulinoma causing liver metastasis 8 years after the initial surgery: report of a case. Sata N, et al. **Surg Today** 1995;25(7):640–2

Resected acinar cell carcinoma of the pancreas with tumor thrombus extending into the main portal vein: report of a case. Ueda T, et al. **Surg Today** 1996;26(5):357–60

Neoplastic seeding in the gallbladder fossa after laparoscopic cholecystectomy [letter] Evrard S, et al. **Surgery** 1996 Mar; 119(3):357

Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Mao C, et al. **Surgery** 1995 Nov;118(5):821–8 (97 ref.)

An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas? Mayo Clinic Pancreatic Surgery Group. Perrier ND, et al. **Surgery** 1995 Dec; 118(6):957–65; discussion 965–6

Relation between the stromal volume and liver metastasis in ductal cell carcinoma of the pancreas. Yamauchi H, et al. **Tohoku J Exp Med** 1995 Oct;177(2):179–81

Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon–SV40 T antigen transgene. Asa SL, et al. **Virchows Arch** 1996 Mar;427(6):595–606

Vinblastine and 5–fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation? Vergeylen A, et al. **Virchows Arch** 1995; 427(3):317–22

Solid and papillary neoplasms of the pancreas. Lee WJ, et al. **Yonsei Med J** 1996 Apr;37(2):131–41

[Recent advances in research on pathology of pancreatic tumors] Liu T. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):221–4 (23 ref.) **(Chi)**

[Cystadenomas of the pancreas] Dahl TW, et al. **Ugeskr Laeger** 1996 Jan 29;158(5):609–10 (Eng. Abstr.) **(Dan)**

[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**

[Solid and papillary tumor of the pancreas] Spay G, et al. **Chirurgie** 1994–95;120(12):107–10 (33 ref.) (Eng. Abstr.) **(Fre)**

[Ambulatory ultrasound–guided puncture in abdominal tumoral pathology. Study of 131 cases] Duchmann JC, et al. **Gastroenterol Clin Biol** 1996;20(3):258–62 (Eng. Abstr.) **(Fre)**

[Bilateral choroidal metastases of pancreatic carcinoma] Castillo J, et al. **J Fr Ophtalmol** 1995;18(12):795–8 (6 ref.) (Eng. Abstr.) **(Fre)**

[Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma] Thorban S, et al. **Zentralbl Chir** 1996;121(6):487–9; discussion 490–2 (Eng. Abstr.) **(Ger)**

[A case of metastatic gastrinomas in the liver visualized by 111In–DTPA–D–Phe–octreotide (111In–pentetreotide)] Tani A, et al. **Kaku Igaku** 1996 May;33(5):545–9 (Eng. Abstr.) **(Jpn)**

[A case of leiomyosarcoma of the pancreas] Ishida K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):220–5 (12 ref.) **(Jpn)**

[A case report of intraductal papillary adenoma with carcinoma in situ of the pancreas with a repeated history of acute pancreatitis] Kinoshita M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):64–7 **(Jpn)**

[Hepatic metastases of pancreatic gastrinoma associated with sclerosing hepatocellular carcinoma] Kita K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):377–81 **(Jpn)**

[A case of mucinous cystadenocarcinoma of the pancreas with intraductal growth to the main pancreatic duct] Mokuno Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1981–4 **(Jpn)**

[Morphologic diagnosis of insulinoma] Revskoĭ AIu, et al. **Arkh Patol** 1995 Sep–Oct;57(5):42–6 (Eng. Abstr.) **(Rus)**

[Papillary epithelial tumors of the pancreas] Sokolova IN, et al. **Arkh Patol** 1995 Sep–Oct;57(5):53–7 (Eng. Abstr.) **(Rus)**

[Papillary tumor of the pancreas diagnosed by fine–needle aspiration] Suárez JF, et al. **Rev Esp Enferm Dig** 1996 Jan; 88(1):53–5 (Eng. Abstr.) **(Spa)**

[Glucagonoma. A tumor disease with multiple clinical manifestations] Andersson K, et al. **Lakartidningen** 1996 Aug 28;93(35):2935–9 (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Pain management in patients with pancreatic carcinoma. Caraceni A, et al. **Cancer** 1996 Aug 1;78(3 Suppl):639–53 (141 ref.)

Thoracoscopic bilateral splanchnicotomy for pain control in unresectable pancreatic cancer. Rossi M, et al. **Chir Ital** 1995;47(2):55–7

Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. Blume N, et al. **J Clin Invest** 1995 Nov;96(5):2227–35

Induction of carcinoma cell migration on vitronectin by NF–kappa B–dependent gene expression. Yebra M, et al. **Mol Biol Cell** 1995 Jul;6(7):841–50

PREVENTION & CONTROL

Effects of dietary beta–carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine–treated rats. Appel MJ, et al. **Carcinogenesis** 1996 Jul;17(7):1411–6

Chemopreventive activity of Oltipraz against N–nitrosobis(2–oxopropyl)amine (BOP)–induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Clapper ML, et al. **Carcinogenesis** 1995 Sep;16(9):2159–65

Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N–nitrosobis(2–oxopropyl)amine–treated hamsters. Nishikawa A, et al. **Carcinogenesis** 1996 Jun;17(6):1381–4

Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. Visser CJ, et al. **Int J Cancer** 1995 Nov 27; 63(5):732–7

Soybean protease inhibitors and pancreatic carcinogenesis [letter; comment] Liener IE. **J Nutr** 1996 Feb;126(2):582–5 . Comment on: J Nutr 1995 Mar;125(3 Suppl):733S–743S.

[Screening of multiple endocrine neoplasias type 1. Reflexions of the Study Group on Multiple Endocrine Neoplasias type 1] Cougard P, et al. **Ann Chir** 1995; 49(6):500–6 (Eng. Abstr.) **(Fre)**

[Screening for hereditary neuroendocrine tumors of the gastrointestinal–pancreatic system] Scherübl H, et al. **Z Gastroenterol** 1996 Apr;34(4):XX **(Ger)**

PSYCHOLOGY

Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Passik SD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):615–26 (84 ref.)

RADIOGRAPHY

A new criterion in differentiation of pancreatitis and pancreatic carcinoma: artery–to–vein ratio using the superior mesenteric vessels. Elmas N, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):331–3

Hyperattenuating insulinoma at unenhanced CT. Kurosaki Y, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):334–6

Vascular involvement in pancreatic adenocarcinoma: reassessment by thin–section CT [see comments] Loyer EM, et al. **Abdom Imaging** 1996 May–Jun;21(3):202–6. Comment in: Abdom Imaging 1996 May–Jun;21(3):207–10.

Pancreatic adenocarcinoma [editorial; comment] Stephens DH. **Abdom Imaging** 1996 May–Jun;21(3):207–10. Comment on: Abdom Imaging 1996 May–Jun;21(3):202–6.

Intrapancreatic lipoma: first case diagnosed with CT. Di Maggio EM, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):56–7

Normal variations in the lateral contour of the head and neck of the pancreas mimicking neoplasm: evaluation with dual–phase helical CT. Ross BA, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):799–801

Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Van Hoe L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1437–9

Spiral–CT in diagnosis of vascular involvement in pancreatic cancer. Gmeinwieser J, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):418–22

The use of spiral computed tomography in the evaluation of vessel encasement for pancreatic cancer. Cunningham JD, et al. **Int J Pancreatol** 1996 Feb;19(1):9–14

CT and US findings of pancreatoblastoma. Lee JY, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):370–4

Pancreatic adenocarcinoma presenting as a splenic abscess: case report and diagnostic approach. Lastrapes RG, et al. **J Okla State Med Assoc** 1995 Aug;88(8):333–6

Papillary–cystic neoplasm of the pancreas. Poustchi–Amin M, et al. **Pediatr Radiol** 1995;25(7):509–11

Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Bluemke DA, et al. **Radiology** 1995 Nov;197(2):381–5

Two–phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Lu DS, et al. **Radiology** 1996 Jun; 199(3):697–701

Carcinoma of the pancreatic head area. Diagnostic imaging: computed tomography. Brizi MG, et al. **Rays** 1995 Jul–Sep; 20(3):249–68 (47 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: PTC. Cotroneo AR, et al. **Rays** 1995 Jul–Sep;20(3):280–8 (11 ref.) **(Eng, Ita)**

[Hydrospiral CT of the pancreas in thin section technique] Richter GM, et al. **Radiologe** 1996 May;36(5):397–405 (Eng. Abstr.) **(Ger)**

[Selective intra–arterial injection of calcium for localization of insulinomas: proposed new criteria] Hayashi T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov; 55(14):952–6 (Eng. Abstr.) **(Jpn)**

[Early diagnosis of pancreatic carcinoma and utility of helical CT] Ichikawa T, et al. **Nippon Rinsho** 1995 Nov; 53(11):2868–73 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

111In–octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment? Keymeulen B, et al. **Ann Nucl Med** 1995 Aug;9(3):149–52

Octreotide scintigraphy. A new method for diagnosing pancreatic tumors [editorial; comment] Merrell. **Ann Surg** 1996 Aug;224(2):117–8. Comment on: Ann Surg 1996 Aug;224(2):119–24.

The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors [see comments] van Eijck CH, et al. **Ann Surg** 1996 Aug;224(2):119–24. Comment in: Ann Surg 1996 Aug;224(2):117–8.

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Mariani G, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5911s–5915s

Preliminary evaluation of the usefulness of Tc–99m (V) DMSA in pancreatic neuroendocrine tumors. Banci M, et al. **Clin Nucl Med** 1996 Feb;21(2):122–4

In–111 pentetreotide. Superior imaging agent for gastrinomas. McCown JS, et al. **Clin Nucl Med** 1995 Oct; 20(10):896–8

Intense uptake of In–111 satumomab pendetide in an inflammatory mass. Silberstein EB, et al. **Clin Nucl Med** 1996 Jan;21(1):53–5

Improved tumor detection by anti–CEA chimeric Fab oligomers with disulfide linkages in a pancreatic–carcinoma–xenograft model. Kamigaki T, et al. **Int J Cancer** 1996 Apr 10;66(2):261–7

FDG–PET evaluation of indeterminate pancreatic masses. Ho CL, et al. **J Comput Assist Tomogr** 1996 May–Jun; 20(3):363–9

Differentiation of malignant from benign pancreatic mass by Tl–201 abdominal SPECT. Bom HS, et al. **J Korean Med Sci** 1995 Apr;10(2):93–6

In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon–11–DOPA to carbon–11–dopamine. Bergström M, et al. **J Nucl Med** 1996 Jan;37(1):32–7

In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium–111–DTPA–Arg1]substance P. Breeman WA, et al. **J Nucl Med** 1996 Jan;37(1):108–17

Comparison of iodine–123–vasoactive intestinal peptide receptor scintigraphy and indium–111–CYT–103 immunoscintigraphy. Raderer M, et al. **J Nucl Med** 1996 Sep;37(9):1480–7

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine–labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216–23

Superimposition of PET images using 18F–fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Benyounes H, et al. **Nucl Med Commun** 1995 Jul;16(7):575–80

[Results of positron emission tomography with fluorine–18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma] Bares R, et al. **Radiologe** 1996 May;36(5):435–40 (Eng. Abstr.) **(Ger)**

[Phase 3 multicenter clinical study of 111In–DTPA–D–octreotide (MP–1727) in patients with gastrointestinal hormone producing tumors.] Yamamoto K, et al. **Kaku Igaku** 1995 Nov;32(11):1269–80 (Eng. Abstr.) **(Jpn)**

[Evaluation of pancreatic cancers using thallium–201 single photon emission computed tomography] Kume N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):682–9 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Intraoperative radiotherapy for pancreatic carcinoma. Kasperk R, et al. **Br J Surg** 1995 Sep;82(9):1259–61

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Alisauskus R, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5743s–5748s

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Mariani G, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5911s–5915s

Brachytherapy for pancreatic cancer: a review. Dobelbower RR, et al. **Hepatogastroenterology** 1996 Mar–Apr; 43(8):333–7 (33 ref.)

Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Shibamoto Y, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):326–32

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.). Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Intraoperative radiation therapy: cut bait or keep on fishing? [editorial] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):515-7

A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Hsue V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):445-50

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Lawrence TS, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):867-72

Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma: regarding Montemaggi et al., IJROBP 32:437; 1995 [letter; comment] Mohan DS, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):773-4. Comment on: Int J Radiat Oncol Biol Phys 1995 May 15;32(2):437-43.

New versus old: pancreatic cancer and chemoradiation attempts [editorial; comment] Peacock JL. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):969-70. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):913-8.

Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy. Raben A, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):351-6

Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study. Nori D, et al. **J Surg Oncol** 1996 Apr;61(4):300-5

Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy [see comments] Cohen L, et al. **Radiology** 1996 Sep;200(3):627-30. Comment in: Radiology 1996 Sep;200(3):608-9.

Neutron therapy for pancreatic cancer: thirty years of unrealized promise [editorial; comment] Donahue BR, et al. **Radiology** 1996 Sep;200(3):608-9 (13 ref.). Comment on: Radiology 1996 Sep;200(3):627-30.

Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Montemaggi P, et al. **Radiology** 1996 Jun;199(3):861-6

Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy. Cellini N, et al. **Rays** 1995 Jul-Sep;20(3):350-9 (30 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraluminal brachytherapy. Montemaggi P, et al. **Rays** 1995 Jul-Sep; 20(3):338-49 (51 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraoperative radiotherapy. Trodella L, et al. **Rays** 1995 Jul-Sep;20(3):316-25 (65 ref.) **(Eng, Ita)**

Radiotherapy for carcinoma of the pancreas. Thomas PR. **Semin Oncol** 1996 Apr;23(2):213-9 (52 ref.)

[Intraoperative and percutaneous radiotherapy of pancreatic carcinoma] Eble MJ, et al. **Radiologe** 1996 May;36(5):441-5 (Eng. Abstr.) **(Ger)**

SECONDARY

Osteosarcoma metastatic to the pancreas in young patients. Glass RJ, et al. **Clin Radiol** 1996 Apr;51(4):293-4

Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Fabre JM, et al. **Eur J Surg Oncol** 1995 Dec;21(6):683-6 (47 ref.)

Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. A case report and surgical review. Hirota T, et al. **Int J Pancreatol** 1996 Apr; 19(2):145-53 (63 ref.)

MRI of pancreatic metastases from renal cancer. Kelekis NL, et al. **J Comput Assist Tomogr** 1996 Mar-Apr;20(2):249-53

A case of transverse colon cancer secondarily involving the liver, duodenum, and pancreas. Suzaki M, et al. **Surg Today** 1996;26(1):42-5

Late pancreatic metastases from renal cell carcinoma [letter; comment] Rivoire M, et al. **Surgery** 1996 Feb;119(2):240. Comment on: Surgery 1995 May;117(5):591-4.

[Late and multiple endocrine metastases of an adenocarcinoma of the kidney] Avisse C, et al. **Chirurgie** 1994-95;120(11):50-3 (Eng. Abstr.) **(Fre)**

[Anomalous presentation of 2 cases of pulmonary carcinoma: obstructive jaundice and pancreatitis caused by pancreatic metastasis] Rossi G, et al. **Radiol Med (Torino)** 1995 Oct; 90(4):495-7 **(Ita)**

[Study on the pathological grade in the primary and distant metastatic lesions of renal cell carcinoma] Onishi T, et al. **Hinyokika Kiyo** 1995 Dec;41(12):959-63 (Eng. Abstr.) **(Jpn)**

[Clinical characteristics of 7 renal cell carcinoma patients developing a solitary pancreatic metastasis after nephrectomy] Onishi T, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1538-42 (Eng. Abstr.) **(Jpn)**

[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):313-5 (21 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Duct ectasia due to mucus-producing cancers with intraductal extension: histopathologic correlation with radiologic imagings. Kobayashi H, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):341-7

Secretion of gelatinases by human pancreatic cancer cell lines: lack of correlation with invasive ability. Bonfil RD, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(3):185-91

Pancreatic somatostatin-secreting gangliocytic paraganglioma with lymph node metastases. Tomic S, et al. **Am J Gastroenterol** 1996 Mar;91(3):607-8 (12 ref.)

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141-6 (27 ref.)

Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis. Hertelendy ZI, et al. **Cell Calcium** 1996 Feb;19(2):125-32

gamma-Aminobutyric acid secretion from pancreatic neuroendocrine cells. Anhert-Hilger G, et al. **Gastroenterology** 1996 May;110(5):1595-604

Neuropeptide Y secretion from a human insulinoma. Waeber G, et al. **J Endocrinol Invest** 1996 Mar;19(3):190-5

Acromegaly caused by growth hormone-relating hormone in a patient with multiple endocrine neoplasia type I. Liu SW, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):49-52

Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Amikura K, et al. **Surgery** 1995 Dec;118(6):1125-30

[Diagnostic case: intraductal mucinous hypersecreting tumor or intraductal mucinous ectasia] Valette PJ, et al. **J Radiol** 1995 Dec;76(12):1133-5 **(Fre)**

[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625-7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1-5 (41 ref.) (Eng. Abstr.) **(Ger)**

[A case of insulinoma whose secretion of insulin was inexplicably low] Kobayashi A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1206-11 **(Jpn)**

SURGERY

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235-62 (87 ref.)

Mucinous ductal ectasia in an octogenarian: successful treatment with the Whipple procedure. Block KP, et al. **Am J Gastroenterol** 1996 Feb;91(2):388-90

Surgery for pancreatic tumors during pregnancy: a case report and review of the literature. Sciscione AC, et al. **Am J Perinatol** 1996 Jan;13(1):21-5 (28 ref.)

A prospective cost analysis of pancreatoduodenectomy. Holbrook RF, et al. **Am J Surg** 1996 May;171(5):508-11

Carcinoma of the periampullary region: who benefits from portal vein resection? Roder JD, et al. **Am J Surg** 1996 Jan;171(1):170-4; discussion 174-5

Surgical palliation for ductal adenocarcinoma of the pancreas. Deziel DJ, et al. **Am Surg** 1996 Jul;62(7):582-8

The role of flow cytometric DNA analysis in determining prognosis of resectable ductal adenocarcinoma of the pancreas. Park CS, et al. **Am Surg** 1996 Jul;62(7):609-15; discussion 615-6

Management of adenocarcinoma of the body and tail of the pancreas. Brennan MF, et al. **Ann Surg** 1996 May; 223(5):506-11; discussion 511-2

The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Conlon KC, et al. **Ann Surg** 1996 Feb;223(2):134-40

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Conlon KC, et al. **Ann Surg** 1996 Mar; 223(3):273-9

Pancreatic or liver resection for malignancy is safe and effective for the elderly. Fong Y, et al. **Ann Surg** 1995 Oct;222(4):426-34; discussion 434-7

Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Fuhrman GM, et al. **Ann Surg** 1996 Feb; 223(2):154-62

The effectiveness of Whipple resection in patients with pancreatic cancer at Veterans Affairs (VA) hospitals [letter; comment] Gordon TA, et al. **Ann Surg** 1996 Apr;223(4):446 . Comment on: Ann Surg 1995 Mar;221(3):241-8.

Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Lieberman MD, et al. **Ann Surg** 1995 Nov;222(5):638-45

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Lillemoe KD, et al. **Ann Surg** 1996 Jun;223(6):718-25; discussion 725-8

Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414-6 (15 ref.)

Clinical features and management of carcinoma of the pancreas. Carter DC. **Br J Hosp Med** 1995 Nov 1-14; 54(9):459-64 (31 ref.)

Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Klempnauer J, et al. **Br J Surg** 1995 Dec;82(12):1686-91

Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590-7 (88 ref.)

Survival after resection for ductal adenocarcinoma of the pancreas. Sperti C, et al. **Br J Surg** 1996 May;83(5):625-31

Adenocarcinoma of the head of the pancreas [editorial; comment] MacFarlane JK. **Can J Surg** 1996 Aug; 39(4):265-6. Comment on: Can J Surg 1996 Aug;39(4):271-83.

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271-83 (129 ref.). Comment in: Can J Surg 1996 Aug;39(4):265-6.

Results of extensive surgery for pancreatic carcinoma. Nagakawa T, et al. **Cancer** 1996 Feb 15;77(4):640-5

The place for curative surgical procedures in the treatment of sporadic and familial Zollinger-Ellison syndrome. Delcore R, et al. **Curr Opin Gen Surg** 1994;:69-76 (119 ref.)

Treatment of pancreatic carcinoma. Livingston EH, et al. **Curr Opin Gen Surg** 1993;:294-8 (40 ref.)

Endocrine tumors of the pancreas. Meko JB, et al. **Curr Opin Gen Surg** 1994;:186-94 (75 ref.)

Favourable prognosis of cystadeno- over adenocarcinoma of the pancreas after curative resection. Ridder GJ, et al. **Eur J Surg Oncol** 1996 Jun;22(3):232-6

Intraoperative ultrasonography for pancreatic insulinomas. Correnti S, et al. **Hepatogastroenterology** 1996 Jan-Feb; 43(7):207-11

Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Ishikawa O. **Hepatogastroenterology** 1996 Mar-Apr;43(8):320-5

Carcinoma of the head of the pancreas: review of 67 cases and comparison with 27 additional periampullary carcinomas. Taschieri AM, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1023-5

Interruption of hepatic arterial blood flow after resection of pancreaticobiliary carcinoma. Tsuge H, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):966-74

Palliative resection of pancreatic adenocarcinoma. A survey of British surgeons. Johnson CD. **HPB Surg** 1995 Jun; 8(3):181-3

Digestive and nutritional consequences of pancreatic resections. The classical vs the pylorus-sparing procedure. Crucitti F, et al. **Int J Pancreatol** 1995 Feb;17(1):37-45

Intraoperative radiation therapy: cut bait or keep on fishing? [editorial] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):515-7

Pancreaticoduodenectomy under epidural anesthesia without endotracheal intubation for the elderly. Nakashima H, et al. **Int Surg** 1995 Apr-Jun;80(2):125-7

Definitive surgery for duct cell carcinomas of the pancreas [letter] Bruckner HW, et al. **J Am Coll Surg** 1996 Sep; 183(3):292-4

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [letter] Douglass HO Jr, et al. **J Am Coll Surg** 1996 Sep; 183(3):291-2; discussion 294

Management of patients with carcinoma of the pancreas [editorial; comment] Gordon TA, et al. **J Am Coll Surg** 1995 Dec;181(6):558-60. Comment on: J Am Coll Surg 1995 Dec;181(6):483-503.

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483-503 (350 ref.). Comment in: J Am Coll Surg 1995 Dec;181(6):558-60.

Management of patients with carcinoma of the pancreas [letter] Gudjonsson B. **J Am Coll Surg** 1996 Sep; 183(3):290-1

Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164-84 (159 ref.)

Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review. Ettinghausen SE, et al. **J Clin Gastroenterol** 1995 Jul;21(1):48-60 (123 ref.)

Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. Evans OB, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):319-23

Radical reoperation for advanced pancreatic carcinoma. Johnstone PA, et al. **J Surg Oncol** 1996 Jan;61(1):7-11; discussion 11-3

Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. Nomoto S, et al. **Jpn J Cancer Res** 1996 Aug;87(8):793-7

Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis. Klempnauer J, et al. **Oncology** 1996 Jan-Feb;53(1):47-53

An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective. Temudom T, et al. **Pancreas** 1995 Oct;11(3):283-8

Distal pancreatectomy for cancer: results in U.S. Department of Veterans Affairs hospitals, 1987-1991. Wade TP, et al. **Pancreas** 1995 Nov;11(4):341-4

Carcinoma of the pancreatic head area. Therapy: resectability and surgical management of resectable tumors. Crucitti F, et al. **Rays** 1995 Jul-Sep;20(3):304-15 (57 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraoperative radiotherapy. Trodella L, et al. **Rays** 1995 Jul-Sep;20(3):316-25 (65 ref.) **(Eng, Ita)**

Surgical management of pancreatic carcinoma. McGrath PC, et al. **Semin Oncol** 1996 Apr;23(2):200-12 (109 ref.)

Palliation for pancreatic cancer. Feasibility of laparoscopic cholecystojejunostomy and gastrojejunostomy in a porcine model. Patel AG, et al. **Surg Endosc** 1996 Jun;10(6):639-43

Synchronous double cancers of the remnant stomach and pancreas: report of a case. Miyaguni T, et al.

Surg Today 1995;25(12):1038–42

Multiple endocrine neoplasia type 1 presenting as insulinoma, gastrinoma, and postbulbar duodenal ulcers: report of a case. Murakami S, et al. **Surg Today** 1995;25(9):848–51

Mucoepidermoid carcinoma of the pancreas: report of a case. Onoda N, et al. **Surg Today** 1995;25(9):843–7 (16 ref.)

Resected acinar cell carcinoma of the pancreas with tumor thrombus extending into the main portal vein: report of a case. Ueda T, et al. **Surg Today** 1996;26(5):357–60

Role of surgery in management of adrenocorticotropic hormone–producing islet cell tumors of the pancreas. Amikura K, et al. **Surgery** 1995 Dec;118(6):1125–30

Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Lai DT, et al. **Surgery** 1996 Jan;119(1):112–4

Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. MacFarlane MP, et al. **Surgery** 1995 Dec;118(6):973–9; discussion 979–80

[The diagnosis and treatment of insulinoma: an analysis on 20 cases] Wang J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):210–1 (Eng. Abstr.) **(Chi)**

[Pancreaticoduodenectomy (Whipple's operation) for periampullary cancer] Burcharth F, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5544–8 (Eng. Abstr.) **(Dan)**

[Melanosarcoma of the head of the pancreas with primary appearance (letter)] Petiot JM, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):322–3 **(Fre)**

[Antral exclusion. A complement to palliative gastrojejunal shunt in pancreatic cancer] Slim K, et al. **Presse Med** 1996 Apr 20;25(14):674–6 (Eng. Abstr.) **(Fre)**

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Is liver resection in metastases of exocrine pancreatic carcinoma justified?] Klempnauer J, et al. **Chirurg** 1996 Apr;67(4):366–70 (Eng. Abstr.) **(Ger)**

[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma: surgical therapy] Baer HU, et al. **Ther Umsch** 1996 May;53(5):394–400 (45 ref.) (Eng. Abstr.) **(Ger)**

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[After-care rehabilitation after pancreas operations] Rosemeyer D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:37–40 **(Ger)**

[Pancreatic carcinoma in chronic pancreatitis with inflammatory tumor of the head of the pancreas] Schlosser W, et al. **Z Gastroenterol** 1996 Jan;34(1):3–8 (Eng. Abstr.) **(Ger)**

[Risk and follow-up after multi-visceral resections including the left side of the pancreas] Böttger T, et al. **Zentralbl Chir** 1995;120(10):804–8 (Eng. Abstr.) **(Ger)**

[Extended partial Kausch–Whipple duodenopancreatectomy by resection of tumor infiltrated vascular segments] Keck H, et al. **Zentralbl Chir** 1995;120(10):809–14 (Eng. Abstr.) **(Ger)**

[Resection surgery in malignant neoplasms of the exocrine pancreas: our experience, 1987–1994] Ghidoni S, et al. **Chir Ital** 1995;47(2):50–4 (Eng. Abstr.) **(Ita)**

[Malignant tumors of the pancreas and periampullary area. Our experience] Stabilini L, et al. **Minerva Chir** 1995 Oct; 50(10):835–41 (Eng. Abstr.) **(Ita)**

[A case of carcinoma of the pancreas head associated with celiac axis compression syndrome] Doke M, et al. **Nippon Geka Gakkai Zasshi** 1995 Dec;96(12):815–8 (Eng. Abstr.) **(Jpn)**

[Recent advances in combined therapy with surgery for pancreatic cancer] Hosotani R. **Nippon Geka Hokan** 1995 Mar 1;64(2):43–4 **(Jpn)**

[A case of pancreas carcinoma observed reflux of the bile juice on cut surface of the pancreas] Dohke M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1895–8 **(Jpn)**

[A case report: resection of the uncinate process of the pancreas for ultra-small pancreatic mucin–producing carcinoma of the branch type] Ichihara T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jun;93(6):445–50 **(Jpn)**

[Progress in pancreatic endocrine tumor surgery: with special reference to the Zollinger–Ellison syndrome] Imamura M. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1905–10 (10 ref.) **(Jpn)**

[The observation over the course of 28 years of a female patient operated on three times for recurrent insulinoma] Geshelin SA, et al. **Klin Khir** 1995;(9–10):51–2 **(Rus)**

[The use of the artificial pancreas apparatus (Biostator) in the diagnosis and surgical treatment of insuloma patients] Shalimov AA, et al. **Klin Khir** 1995;(6):3–4 **(Rus)**

[Pancreas resection in cancer. Reduced mortality but morbidity is still high] Larsson J, et al. **Lakartidningen** 1995 Sep 27;92(39):3571–4 **(Swe)**

THERAPY

Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Moore DF Jr, et al. **Am J Clin Oncol** 1995 Dec;18(6):525–7

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Staley CA, et al. **Am J Surg** 1996 Jan;171(1):118–24; discussion 124–5

National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. **Janes RH Jr**, et al. **Ann Surg** 1996 Mar;223(3):261–72

Antrectomy: a safe and effective bypass for unresectable pancreatic cancer [letter; comment] Slim K, et al. **Arch Surg** 1996 Jun;131(6):676–7. Comment on: Arch Surg 1994 Aug;129(8):795–9.

Effects of neocarzinostatin–chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts. Otsuji E, et al. **Br J Cancer** 1996 May;73(10):1178–82

Systemic and adjuvant therapy for patients with pancreatic carcinoma. Clark JW, et al. **Cancer** 1996 Aug 1;78(3 Suppl):688–93 (59 ref.)

Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective. Hoffman JP, et al. **Cancer** 1996 Aug 1;78(3 Suppl):592–7 (36 ref.)

Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies. Kinsella TJ, et al. **Cancer** 1996 Aug 1;78(3 Suppl):598–604 (36 ref.)

Palliation. Surgical and otherwise. Lillemoe KD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):605–14 (31 ref.)

An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas. Ozaki H, et al. **Cancer** 1996 Jun 1;77(11):2240–5

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Rothenberg ML, et al. **Cancer** 1996 Aug 1;78(3 Suppl):627–32 (48 ref.)

Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report. Wahid NA, et al. **Cancer Invest** 1996;14(4):335–9

A monoclonal antibody–cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Juhl H, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5749s–5755s

Transjugular insertion of biliary stents (TIBS) in two patients with malignant obstruction, ascites, and coagulopathy. Amygdalos MA, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):107–9

"It feels better"—measuring clinical benefit [letter; comment] Von Hoff DD. **Eur J Cancer** 1996 Feb;32A(2):376–7. Comment on: Eur J Cancer 1995 Jun;31A(6):867–9. Comment on: Eur J Cancer 1995 Jun;31A(6):882–7.

Immune and nutritional effects of early enteral nutrition after major abdominal operations. Braga M, et al. **Eur J Surg** 1996 Feb;162(2):105–12

Advances in diagnosis and treatment of pancreatic cancer. Bramhall SR, et al. **Gastroenterologist** 1995 Dec;3(4):301–10 (106 ref.)

Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Lygidakis NJ, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1039–52

Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Muchmore JH, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):346–55

Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Shibamoto Y, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):326–32

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):189–99 (95 ref.)

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Gjertsen MK, et al. **Int J Cancer** 1996 Feb 8;65(4):450–3

Effects of sandostatin, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. Visser CJ, et al. **Int J Cancer** 1996 Mar 15; 65(6):827–32

Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Carducci MA, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):143–50

Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. Mohiuddin M, et al. **J Clin Oncol** 1995 Nov;13(11):2764–8

Pancreatic cancer shows modest survival gain [news] Bankhead C. **J Natl Cancer Inst** 1996 Jun 19;88(12):784–6

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Gjertsen MK, et al. **Lancet** 1995 Nov 25;346(8987):1399–400

Carcinoma of the pancreatic head area. Therapy: nonoperative biliary drainage for palliation. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):326–37 (11 ref.) **(Eng, Ita)**

Diagnostic imaging and combined modality therapy of the cancer of the pancreatic head area. Marano P. **Rays** 1995 Jul–Sep;20(3):223–5 **(Eng, Ita)**

Carcinoma of the pancreatic head area: follow-up. Turriziani A, et al. **Rays** 1995 Jul–Sep;20(3):360–72 **(Eng, Ita)**

Palliative and supportive care of patients with pancreatic cancer. Alter CL. **Semin Oncol** 1996 Apr;23(2):229–40 (36 ref.)

Adjuvant therapy of upper gastrointestinal tract cancers. Kelsen DP. **Semin Oncol** 1995 Dec;22(6):582–99 (78 ref.)

Pancreatic cancer. Macdonald JS. **Semin Oncol** 1996 Apr; 23(2):199

Palliative procedures for pancreatic cancer: when and which one? Shumate CR, et al. **South Med J** 1996 Jan;89(1):27–32 (28 ref.)

Management of pancreatic carcinoma. Hunstad DA, et al. **Surg Oncol** 1995;4(2):61–74 (75 ref.)

Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Clary BM, et al. **Surgery** 1996 Aug;120(2):174–81

Repeated radical resection and intraoperative irradiation for recurrent pancreatic ductal adenocarcinoma after pancreatoduodenectomy. Inoue K, et al. **Surgery** 1995 Nov; 118(5):909–11

[Pancreatic carcinoma: conservative and adjuvant therapy] Schmassmann A. **Ther Umsch** 1996 May;53(5):387–93 (20 ref.) (Eng. Abstr.) **(Ger)**

[Palliative endoscopic treatment of malignant occlusive jaundice with a balloon expandable metal stent] Zipprich B, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:154–6 (Eng. Abstr.) **(Ger)**

[Experience with the Groshong port in a home TPN patient—a case report] Inoue Y, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:378–83 (Eng. Abstr.) **(Jpn)**

[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract] Takada T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):707–14 (Eng. Abstr.) **(Jpn)**

[Recent advances in combined therapy with surgery for pancreatic cancer] Hosotani R. **Nippon Geka Hokan** 1995 Mar 1;64(2):43–4 **(Jpn)**

[Gene therapy for pancreatic cancer] Yoshida T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2727–31 (12 ref.) **(Jpn)**

ULTRASONOGRAPHY

Assessment of arterial invasion in pancreatic cancer using color Doppler ultrasonography. Tomiyama T, et al. **Am J Gastroenterol** 1996 Jul;91(7):1410–6

Utility of endoscopic ultrasonography with color Doppler function for the diagnosis of islet cell tumor. Ueno N, et al. **Am J Gastroenterol** 1996 Apr;91(4):772–6

Assessment of resectability of pancreatic head and periampullary tumors by color flow Doppler sonography. Wren SM, et al. **Arch Surg** 1996 Aug;131(8):812–7; discussion 817–8

Intraductal mucin-hypersecreting neoplasm of the pancreas: endosonographic findings. Glibert A, et al. **Endoscopy** 1996 Feb;28(2):269–70

Doppler color flow imaging for assessment and localization of pancreatic insulinoma. Namieno T, et al. **Eur J Radiol** 1995 Sep;20(3):208–9

Localization of neuroendocrine tumors utilizing linear-array endoscopic ultrasonography. Bansal R, et al. **Gastrointest Endosc** 1995 Jul;42(1):76–9

Pancreatic cancer staging. Endoscopic ultrasonography criteria for vascular invasion. Brugge WR. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):741–53

Differential diagnosis of pancreatic tumors. Forsmark CE. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):713–21 (20 ref.)

Pancreatic cancer. Influence of endoscopic ultrasonography on management and outcomes. Snady H. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):755–62 (20 ref.)

Endoscopic ultrasonography diagnosis of pancreatic cancer. Yasuda K, et al. **Gastrointest Endosc Clin N Am** 1995 Oct; 5(4):699–712

Intraoperative ultrasonography for pancreatic insulinomas. Correnti S, et al. **Hepatogastroenterology** 1996 Jan–Feb; 43(7):207–11

Extrapancreatic nerve plexus invasion by carcinoma of the head of the pancreas. Diagnosis with intraportal endovascular ultrasonography. Kaneko T, et al. **Int J Pancreatol** 1996 Feb;19(1):1–7

CT and US findings of pancreatoblastoma. Lee JY, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):370–4

Carcinoma of the pancreatic head area. Diagnostic imaging: ultrasound. De Gaetano AM, et al. **Rays** 1995 Jul–Sep; 20(3):237–48 (38 ref.) **(Eng, Ita)**

Sonographic features of liver metastases from pancreatic glucagonoma and acinar cell carcinoma. Case reports. Ferrari A, et al. **Surg Endosc** 1996 Jul;10(7):762–4

[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Indications for endosonography in tumors of the pancreas and bile ducts] Nattermann C. **Bildgebung** 1995 Oct;62 Suppl 2:35–9 (37 ref.) **(Ger)**

[Endosonography in the assessment of pancreatic tumors. A comparison of the endosonographic findings of carcinomas and segmental inflammatory changes] Nattermann C, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1571–6 (Eng. Abstr.) **(Ger)**

[Hydrosonography of the pancreas. Initial results of a pilot study] Simon C, et al. **Radiologe** 1996 May;36(5):389–96

(Eng. Abstr.) **(Ger)**

[Ultrasound differential diagnostic aspects in cystadenoma of the pancreas] Bunk A, et al. **Ultraschall Med** 1995 Oct; 16(5):210–7 (Eng. Abstr.) **(Ger)**

[Endosonography in diagnosis of insulinoma] Meyenberger C, et al. **Ultraschall Med** 1995 Oct;16(5):224–7 (Eng. Abstr.) **(Ger)**

[A case report of the asymptomatic islet cell carcinoma] Kawafune T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1804–10 **(Jpn)**

[Possibilities of interventional ultrasonography in the differential diagnosis of pancreatic malignancy] Trifunović J, et al. **Med Pregl** 1994;47(9–10):310–3 (Eng. Abstr.) **(Scr)**

[Ultrasonographic aspects of cystic papillary tumor of the pancreas. Apropos of 2 cases] Castillo Grau P, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):52–4 (Eng. Abstr.) **(Spa)**

[Echoendoscopy: pathological diagnosis using real–time puncture–aspiration] Romero Castro R, et al. **Gastroenterol Hepatol** 1996 Jun–Jul;19(6):297–301 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Microglandular carcinoma of the pancreas: immunohistochemical and ultrastructural study of an unusual variant of pancreatic carcinoma that may closely resemble a neuroendocrine neoplasm. Berho M, et al. **Am J Clin Pathol** 1996 Jun;105(6):727–32

Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserine. Visser CJ, et al. **Br J Cancer** 1996 Jul;74(1):92–8

Filamentous inclusions in nonneoplastic and neoplastic pancreas: an ultrastructural and immunogold labeling study. Pasquinelli G, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):495–500

Fibrillary inclusions in neoplastic and fetal acinar cells of the pancreas. Chong JM, et al. **Virchows Arch** 1996 Jul; 428(4–5):261–6

URINE

Urinary gonadotropin peptide in patients with cancer of digestive organs. Motoo Y, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2041–8

VETERINARY

Pancreatic adenocarcinoma in two grey collie dogs with cyclic hematopoiesis. Brabb T, et al. **Lab Anim Sci** 1995 Aug;45(4):357–62

Poorly differentiated pancreatic adenocarcinoma in a chicken. Abdul–Aziz TA. **Vet Rec** 1995 Oct 14;137(16):408

Ultrasonography of pancreatic neoplasia in the dog: a retrospective review of 16 cases. Lamb CR, et al. **Vet Rec** 1995 Jul 15;137(3):65–8

PANCREATIC POLYPEPTIDE

ANALYSIS

Pancreatic polypeptide immunoreactivity in sporadic gastrinoma: relationship to intraabdominal location. Howard TJ, et al. **Pancreas** 1995 Nov;11(4):350–6

BIOSYNTHESIS

PYY in developing murine islet cells: comparisons to development of islet hormones, NPY, and BrdU incorporation. Jackerott M, et al. **J Histochem Cytochem** 1996 Aug;44(8):809–17

BLOOD

[Human pancreatic polypeptide (hPP)] Funakoshi A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:666–9 (12 ref.) **(Jpn)**

[Pancreatic polypeptide (PP)] Seino Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:648–50 (5 ref.) **(Jpn)**

[Response of pancreatic polypeptide to a protein test meal in the evaluation of diabetic autonomic neuropathy] Kostić N, et al. **Med Pregl** 1996;49(5–6):177–9 (Eng. Abstr.) **(Scr)**

CHEMISTRY

Broad spectrum antibiotic activity of the skin–PYY. Vouldoukis I, et al. **FEBS Lett** 1996 Feb 19;380(3):237–40

Isolation and structural characterization of proglucagon–derived peptides, pancreatic polypeptide, and somatostatin from the urodele Amphiuma tridactylum. Cavanaugh ES, et al. **Gen Comp Endocrinol** 1996 Jan; 101(1):12–20

Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide–preferring receptor. Gehlert DR, et al. **Mol Pharmacol** 1996 Jul;50(1):112–8

Parametric sensitivity analysis of avian pancreatic polypeptide (APP). Zhang H, et al. **Proteins** 1995 Oct; 23(2):218–32

GENETICS

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1–11 (104 ref.)

IMMUNOLOGY

Production of a rat pancreatic polypeptide–specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. Wong HC, et al. **Hybridoma** 1995 Aug;14(4):369–76

METABOLISM

Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line. Cox HM, et al. **Br J Pharmacol** 1995 Nov;116(6):2673–8

Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. Lundell I, et al. **J Biol Chem** 1995 Dec 8; 270(49):29123–8

Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide–preferring receptor. Gehlert DR, et al. **Mol Pharmacol** 1996 Jul;50(1):112–8

The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptor. Lundell I, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):5111–5

Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. Yan H, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4661–5

Immunocytochemical colocalizations of serotonin, aromatic L–amino acid decarboxylase and polypeptide hormones in A– and PP–cells of the chicken endocrine pancreas. Takayanagi M, et al. **Tissue Cell** 1995 Aug;27(4):439–46

PHARMACOLOGY

Pancreatic polypeptide stimulates gastric acid secretion through a vagal mechanism in rats. McTigue DM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R983–7

Broad spectrum antibiotic activity of the skin–PYY. Vouldoukis I, et al. **FEBS Lett** 1996 Feb 19;380(3):237–40

Pancreatic polypeptide and splanchnic blood flow in anesthetized rats. Jansson L, et al. **Peptides** 1995; 16(7):1253–6

Pancreatic polypeptide, microinjected into the dorsal vagal complex, potentiates glucose–stimulated insulin secretion in the rat. Krowicki ZK, et al. **Regul Pept** 1995 Dec 14; 60(2–3):185–92

Effect of antrectomy and truncal vagotomy on erythromycin induced pancreatic polypeptide secretion. Masclee AA, et al. **Regul Pept** 1995 Aug 22;58(3):157–61

PHYSIOLOGY

New Discoveries within the Pancreatic Polypeptide Family: From Molecules to Medicine. APS conference. Newport Beach, California, November 8–11, 1995. Abstracts. **Physiologist** 1995 Oct;38(5):A241–61

SECRETION

Pancreatic polypeptide responses to hypoglycemia in aging and diabetes [letter] Meneilly GS. **Diabetes Care** 1996 May; 19(5):544–6

The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas. Kleinman R, et al. **Int J Pancreatol** 1995 Aug; 18(1):51–7

The effects of glucagon–like peptide–I (GLP–I) on hormone secretion from isolated human pancreatic islets. Fehmann HC, et al. **Pancreas** 1995 Aug;11(2):196–200

Effects of cholecystokinin and glucagon–like peptide 1 on the secretion of pancreatic polypeptide in mice. Ahrén B, et al. **Regul Pept** 1995 Nov 10;59(3):297–302

PANCREATIC PSEUDOCYST

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Procacci C, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):399–402 (15 ref.)

Pancreatic pseudocyst. Gumaste VV, et al. **Gastroenterologist** 1996 Mar;4(1):33–43 (88 ref.)

[Pseudocysts of the pancreas. Diagnosis, course and principles of treatment] Lesur G, et al. **Presse Med** 1996 Jun 8;25(20):939–43 (28 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of pancreatic pseudocysts] Martinenko OP. **Klin Khir** 1996;(1):10–2 **(Ukr)**

COMPLICATIONS

Subcapsular renal spread of a pancreatic pseudocyst. Blandino A, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):73–4

Pancreatic ascites in children. D'Cruz AJ, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):630–3

Multidisciplinary approach to pseudoaneurysms complicating pancreatic pseudocysts. Impact of pretreatment diagnosis. Marshall GT, et al. **Arch Surg** 1996 Mar;131(3):278–83

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Skarsgard ED, et al. **Can J Surg** 1995 Oct; 38(5):459–63

The management of bleeding from a pancreatic pseudocyst: a case report. Canakkalelioglu L, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):278–81

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahlke R, et al. **Z Gastroenterol** 1995 Jul;33(7):404–7

[Pseudoaneurysm in pancreatic pseudocysts. Report of a clinical case] Giammanco M, et al. **Minerva Chir** 1995 Dec; 50(12):1081–4 (Eng. Abstr.) **(Ita)**

[A case of pancreatic pseudocyst with splenic infarction] Sugiyama H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):293–8 (16 ref.) **(Jpn)**

CONGENITAL

Congenital pancreatic pseudocyst: a rare cause of abdominal mass in a neonate. Crowley JJ, et al. **Pediatr Radiol** 1996; 26(3):210–1

DIAGNOSIS

Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM, et al. **Am J Surg** 1996 Jan;171(1):126–9; discussion 129–30

Pyelojejunostomy: a surgical complication due to a diagnostic confusion. Batislam E, et al. **Br J Urol** 1996 Mar; 77(3):472–3

Biliary–tract diagnosis by magnetic resonance imaging. Bilbey JH, et al. **Can J Surg** 1996 Aug;39(4):268–9

[A case report of ectopic esophago–gastric duplication cyst with difficult differential diagnosis from pancreatic pseudocyst] Ikeda M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):351–6 **(Jpn)**

[Pancreatic pseudocysts in childhood] Alonso Calderón JL, et al. **An Esp Pediatr** 1996 Mar;44(3):229–33 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Pancreatic pleural effusion: an indication for emergency distal pancreatectomy and Roux–En–Y pancreatico–jejunostomy [letter; comment] Tsang TM, et al. **J Pediatr Surg** 1995 Nov;30(11):1632. Comment on: J Pediatr Surg 1994 Dec;29(12):1541–4.

ETIOLOGY

Complete disruption of the main pancreatic duct: endoscopic management. Devière J, et al. **Gastrointest Endosc** 1995 Nov;42(5):445–51

Primary hyperparathyroidism: an unusual cause of pancreatitis in adolescence [see comments] Nieves–Rivera F, et al. **P R Health Sci J** 1995 Sep;14(3):233–6. Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

Toxic 'sock' syndrome bezoar formation and pancreatitis associated with iron deficiency and pica. Adler AI, et al. **West J Med** 1995 Nov;163(5):480–2

MICROBIOLOGY

Torulopsis glabrata–infected pancreatic pseudocysts. Diagnosis and treatment. Escalante–Glorsky S, et al. **J Clin Gastroenterol** 1995 Oct;21(3):230–2

PHYSIOPATHOLOGY

Spontaneous internal drainage of a pancreatic pseudocyst: a case report. Milz J, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):282–6

RADIOGRAPHY

Retained contrast after embolization of a right gastric artery pseudoaneurysm. Winick AB, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):110–2

SECONDARY

Extensive invasion of a ductal adenocarcinoma into the wall of a pancreatic pseudocyst [letter] Otani T, et al. **Pancreas** 1996 May;12(4):416–9

SURGERY

The outcome of pancreatic fistulas developed after surgery for pancreatic pseudocysts. Magyar A, et al. **Acta Chir Hung** 1995–96;35(1–2):169–76

Percutaneous drainage of intrasplenic pancreatic pseudocyst. Case report. Tennøe B, et al. **Acta Radiol** 1996 Mar; 37(2):195–7

Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)

Endoscopic transpapillary drainage of pancreatic pseudocysts [see comments] Barthet M, et al. **Gastrointest Endosc** 1995 Sep;42(3):208–13. Comment in: Gastrointest Endosc 1995 Sep;42(3):273–5.

Transpapillary and transmural drainage of pancreatic pseudocysts [see comments] Binmoeller KF, et al. **Gastrointest Endosc** 1995 Sep;42(3):219–24. Comment in: Gastrointest Endosc 1995 Sep;42(3):273–5.

Treatment of pancreatic pseudocysts with ductal communication by transpapillary pancreatic duct endoprosthesis [see comments] Catalano MF, et al. **Gastrointest Endosc** 1995 Sep;42(3):214–8. Comment in: Gastrointest Endosc 1995 Sep;42(3):273–5.

Endoscopic management of pancreatic pseudocysts continues to evolve [editorial; comment] Lehman GA. **Gastrointest Endosc** 1995 Sep;42(3):273–5. Comment on: Gastrointest Endosc 1995 Sep;42(3):202–7. Comment on: Gastrointest Endosc 1995 Sep;42(3):208–13. Comment on: Gastrointest Endosc 1995 Sep;42(3):214–8. Comment on:

Gastrointest Endosc 1995 Sep;42(3):219–24.
The efficacy of endoscopic treatment of pancreatic pseudocysts [see comments] Smits ME, et al. **Gastrointest Endosc** 1995 Sep;42(3):202–7. Comment in: Gastrointest Endosc 1995 Sep;42(3):273–5.
Long–term results after operation for pancreatic pseudocysts [letter] Hallfeldt KK, et al. **Surgery** 1995 Nov;118(5):916
[Percutaneous cysto–gastrostomy of chronic cysts in the pancreas. A nine–year clinical experience] Henriksen FW, et al. **Ugeskr Laeger** 1996 Mar 18;158(12):1674–8 (Eng. Abstr.) **(Dan)**
[Ultrasound–guided percutaneous drainage in the treatment of retentional pseudocysts of chronic pancreatitis] Delattre JF, et al. **Chirurgie** 1996;121(1):57–65 (Eng. Abstr.) **(Fre)**
[Endoscopic drainage of pancreatic pseudocysts] Dohmoto M, et al. **Dtsch Med Wochenschr** 1995 Dec 1; 120(48):1647–51 (Eng. Abstr.) **(Ger)**
[Surgical treatment of pancreatic pseudocysts] Tucci GF, et al. **G Chir** 1996 May;17(5):242–8 (Eng. Abstr.) **(Ita)**
[The surgical treatment of pancreatic cysts and pseudocysts] Andronescu P, et al. **Chirurgia (Bucur)** 1995;44(2):1–8 (Eng. Abstr.) **(Rum)**
[Transpapillary endoscopic drainage of pancreatic pseudocyst] López Rosés L, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):903–6 (Eng. Abstr.) **(Spa)**
[The endoscopic treatment of pancreatic pseudocyst] Ruíz J, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):27–33 (Eng. Abstr.) **(Spa)**

THERAPY

When should radiologists intervene in management of pancreatic pseudocysts and other complications of acute pancreatitis? Wittich GR, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):211
Endoscopic cystgastrostomy: role of endoscopic ultrasonography. Chan AT, et al. **Am J Gastroenterol** 1996 Aug;91(8):1622–5
Percutaneous transgastric cystoduodenostomy in the treatment of a pancreatic pseudocyst: a new approach. Bilbao JI, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec; 18(6):422–5
Percutaneous cystogastrostomy with a new catheter for drainage of pancreatic pseudocysts and fluid collections. Davies RP, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):128–31
Endoscopic drainage of pancreatic pseudocysts: patient selection and evaluation of the outcome by endoscopic ultrasonography. Etzkorn KP, et al. **Endoscopy** 1995 May; 27(4):329–33
Chronic pancreatitis [letter; comment] Maule WF. **N Engl J Med** 1995 Nov 2;333(18):1221. Comment on: N Engl J Med 1995 Jun 1;332(22):1482–90.
Chronic pancreatitis [letter; comment] Ramadori G, et al. **N Engl J Med** 1995 Nov 2;333(18):1221–2. Comment on: N Engl J Med 1995 Jun 1;332(22):1482–90.
[Ultrasonically guided gastroscopically assisted percutaneous internal drainage of pancreatic pseudocysts] Fabrin K, et al. **Ugeskr Laeger** 1996 Mar 18;158(12):1670–3 (Eng. Abstr.) **(Dan)**
[Two cases of mediastinal pancreatic pseudocyst improved with conservative treatment] Muto M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):57–63 (20 ref.) **(Jpn)**
[Percutaneous internal drainage. A safe treatment of pancreatic pseudocysts] Cwikiel W, et al. **Lakartidningen** 1995 Dec 6;92(49):4684–6 **(Swe)**

ULTRASONOGRAPHY

Endoscopic drainage of pancreatic pseudocysts: patient selection and evaluation of the outcome by endoscopic ultrasonography. Etzkorn KP, et al. **Endoscopy** 1995 May; 27(4):329–33
Endoscopic ultrasonography in the diagnosis and treatment of pancreatic pseudocysts. Binmoeller KF, et al. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):805–16

PANCREATIC SECRETORY TRYPSIN INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATIC TRYPSIN SECRETORY INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATICODUODENECTOMY

Mucinous ductal ectasia in an octogenarian: successful treatment with the Whipple procedure. Block KP, et al. **Am J Gastroenterol** 1996 Feb;91(2):388–90
Pancreaticoduodenectomy for benign disease. Barens SA, et al. **Am J Surg** 1996 Jan;171(1):131–4; discussion 134–5
Management of the pancreatic stump during the Whipple operation. Brewer MS. **Am J Surg** 1996 Apr;171(4):438
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Staley CA, et al. **Am J Surg** 1996 Jan;171(1):118–24; discussion 124–5
The effectiveness of Whipple resection in patients with pancreatic cancer at Veterans Affairs (VA) hospitals [letter; comment] Gordon TA, et al. **Ann Surg** 1996 Apr;223(4):446–7. Comment on: Ann Surg 1995 Mar;221(3):241–8.
Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Lillemoe KD, et al. **Ann Surg** 1996 Jun;223(6):718–25; discussion 725–8
A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Yeo CJ, et al. **Ann Surg** 1995 Oct;222(4):580–8; discussion 588–92
Operative injury to the hepatic artery [letter; comment] Lowell JA, et al. **Arch Surg** 1996 Jul;131(7):788. Comment on: Arch Surg 1996 Feb;131(2):211–5.
Long–term results of pylorus–preserving pancreatoduodenectomy for chronic pancreatitis. Martin RF, et al. **Arch Surg** 1996 Mar;131(3):247–52
Delayed pancreatoduodenectomy followed by delayed reconstruction for trauma. Mistry BM, et al. **Br J Surg** 1996 Apr;83(4):527
Pancreaticoduodenectomy in childhood for rare pancreatic ductal anomalies—case reports. Kazandjian V, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):305–9
Reversed rotation of midgut which caused problems during Whipple's procedure. Jagannath P, et al. **Eur J Surg** 1995 Oct;161(10):765–6
Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreatoduodenal resection. Petrin P, et al. **Eur Surg Res** 1995;27(6):371–8
Secural pancreaticojejunal anastomosis for the pancreaticoduodenectomy. Hwang TL, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):275–7
Evaluation of surgical risk in preoperative biliary drainage patients by blood chemistry laboratory data—with special reference to rate of reduction of serum bilirubin levels. Nakayama T, et al. **Hepatogastroenterology** 1995 Jul–Aug; 42(4):338–42
A proposal mechanism of early delayed gastric emptying after pylorus preserving pancreatoduodenectomy. Ueno T, et al. **Hepatogastroenterology** 1995 Jul;42(3):269–74
Treatment for dehiscence of pancreaticojejunostomy after pancreaticoduodenectomy: is resection of the residual pancreas necessary? Wu CC, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):271–4
Early evaluation of abdominal/hepatic irradiation and 5–fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Carducci MA, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):143–50
Nutritional status and function in patients following Whipple procedure compared with controls. Royall D, et al. **J Am Coll Nutr** 1996 Feb;15(1):73–8
Primary duodenal adenocarcinoma: role for aggressive resection [editorial; comment] Lillemoe KD. **J Am Coll Surg** 1996 Aug;183(2):155–6. Comment on: J Am Coll Surg 1996 Aug;183(2):89–96.
Primary duodenal adenocarcinoma: a ten–year experience with 79 patients [see comments] Rose DM, et al. **J Am Coll Surg** 1996 Aug;183(2):89–96. Comment in: J Am Coll Surg 1996 Aug;183(2):155–6.
Rapid–fractionation pre–operative chemoradiation for malignant periampullary neoplasms. Evans OB, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):319–23
Pancreatic enzyme activity after a pylorus–preserving pancreaticoduodenectomy reconstructed with pancreaticogastrostomy. Takada T, et al. **Pancreas** 1995 Oct;11(3):276–82
Surgical management of pancreatic carcinoma. McGrath PC, et al. **Semin Oncol** 1996 Apr;23(2):200–12 (109 ref.)
A new method of performing continuous intraabdominal drainage after pancreaticoduodenectomy. Kayahara M, et al. **Surg Today** 1995;25(8):679–83
Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)
Repeated radical resection and intraoperative irradiation for recurrent pancreatic ductal adenocarcinoma after pancreatoduodenectomy. Inoue K, et al. **Surgery** 1995 Nov; 118(5):909–11
Outcome of major hepatectomy with pancreatoduodenectomy for advanced biliary malignancies. Miyagawa S, et al. **World J Surg** 1996 Jan;20(1):77–80

ADVERSE EFFECTS

ASA physical status and age are not factors predicting morbidity, mortality, and survival after pancreatoduodenectomy. Chijiiwa K, et al. **Am Surg** 1996 Sep;62(9):701–5
Completion pancreatectomy for surgical complications after pancreaticoduodenectomy. Farley DR, et al. **Br J Surg** 1996 Feb;83(2):176–9
Temporary use of peritoneovenous shunting for treatment of tense ascites following a Whipple procedure. Takahashi T, et al. **Dig Dis Sci** 1995 Sep;40(9):1946–50
Bleeding of the pancreatic stump following pancreatoduodenectomy for cancer. Balladur P, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):268–70
Pancreatojejunal sutural insufficiency occurring after pancreatoduodenectomy and countermeasures. Kinoshita H, et al. **Kurume Med J** 1995;42(4):221–9
Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Hamanaka Y, et al. **Surgery** 1996 Mar;119(3):281–7
[Massive lymphorrhea as a severe complication of pancreatoduodenal resection] Radnaev VU, et al. **Vestn Khir Im I I Grek** 1995;154(3):77–8 **(Rus)**

ECONOMICS

A prospective cost analysis of pancreatoduodenectomy. Holbrook RF, et al. **Am J Surg** 1996 May;171(5):508–11

METHODS

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235–62 (87 ref.)
Pancreatoduodenectomy with preservation of the pylorus and gastroduodenal artery. Nagai H, et al. **Ann Surg** 1996 Feb;223(2):194–8
Role of total pancreatectomy in the treatment of patients with end–stage chronic pancreatitis. Fleming WR, et al. **Br J Surg** 1995 Oct;82(10):1409–12
Combined liver transplantation and pancreatoduodenectomy for irresectable hilar bile duct carcinoma [letter; comment] Neuhaus P. **Br J Surg** 1996 Mar;83(3):422. Comment on: Br J Surg 1995 Mar;82(3):397–8.
Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590–7 (88 ref.)
1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.). Comment in: Can J Surg 1996 Aug;39(4):265–6.
Hepatopancreatoduodenectomy for superficially spreading bile duct carcinoma: a report of two 5 year survivals. Nakamura S, et al. **Hepatogastroenterology** 1996 Jan–Feb; 43(7):138–42
Pancreaticoduodenectomy under epidural anesthesia without endotracheal intubation for the elderly. Nakashima H, et al. **Int Surg** 1995 Apr–Jun;80(2):125–7
A new technique for pancreaticogastrointestinal anastomosis without suturing the pancreatic parenchyma. Kuroda Y, et al. **J Am Coll Surg** 1995 Oct;181(4):311–4
Adenocarcinoma of the distal duodenum: two cases managed by pylorus preserving pancreatico–duodenectomy and adjuvant chemotherapy. Fon LJ, et al. **Ulster Med J** 1994 Oct;63(2):241–5
[Pancreatoduodenal resection for carcinoid of Vater's papilla] Aleksandrova A, et al. **Khirurgiia (Sofiia)** 1994;47(6):49–51 (Eng. Abstr.) **(Bul)**
[Pancreaticoduodenectomy (Whipple's operation) for periampullary cancer] Burcharth F, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5544–8 (Eng. Abstr.) **(Dan)**
[Extended partial Kausch–Whipple duodenopancreatectomy by resection of tumor infiltrated vascular segments] Keck H, et al. **Zentralbl Chir** 1995;120(10):809–14 (Eng. Abstr.) **(Ger)**
[Pancreatoduodenectomy with pancreaticogastric anastomosis] Andronescu P, et al. **Chirurgia (Bucur)** 1995; 44(3):17–24 (Eng. Abstr.) **(Rum)**

MORTALITY

ASA physical status and age are not factors predicting morbidity, mortality, and survival after pancreatoduodenectomy. Chijiiwa K, et al. **Am Surg** 1996 Sep;62(9):701–5
Long–term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5–year survivors. Conlon KC, et al. **Ann Surg** 1996 Mar; 223(3):273–9
Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Lieberman MD, et al. **Ann Surg** 1995 Nov;222(5):638–45
"Practice makes perfect" is intuitive; the applicability of this axiom to surgical outcomes has been tenuous at best [letter; comment] Wade TP, et al. **Ann Surg** 1996 Apr;223(4):446–7. Comment on: Ann Surg 1995 Jan;221(1):43–9.

PANCREATICOJEJUNOSTOMY

A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Yeo CJ, et al. **Ann Surg** 1995 Oct;222(4):580–8; discussion 588–92
Treatment for dehiscence of pancreaticojejunostomy after pancreaticoduodenectomy: is resection of the residual pancreas necessary? Wu CC, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):271–4
Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

INSTRUMENTATION

A new technique for pancreatojejunostomy [letter; comment] Blumgart LH. **J Am Coll Surg** 1996 Jun;182(6):557. Comment on: J Am Coll Surg 1995 Jul;181(1):88–90.
Improving the technique of performing a pancreaticoenterostomy and pancreatoduodenectomy [letter; comment] Obertop H. **J Am Coll Surg** 1996 Jun; 182(6):557–8. Comment on: J Am Coll Surg 1995 Jul;181(1):88–90.

METHODS

Secural pancreaticojejunal anastomosis for the pancreaticoduodenectomy. Hwang TL, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):275–7
An easier technique for end to end pancreaticojejunostomy.

Pedrazzoli S, et al. **HPB Surg** 1996;9(3):141–3
Pancreaticoduodenojejunostomy for chronic pancreatitis presenting with an inflammatory mass in the head of the pancreas. Pedrazzoli S, et al. **Pancreas** 1995 Oct; 11(3):289–93

PANCREATIN

ADMINISTRATION & DOSAGE

Symptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis. Nasr SZ, et al. **Pediatr Pulmonol** 1995 Jun;19(6):396–7

ADVERSE EFFECTS

Fibrosing colonopathy in cystic fibrosis. Smyth RL. **Arch Dis Child** 1996 May;74(5):464–8 (24 ref.)
Gut inflammation in children with cystic fibrosis on high–dose enzyme supplements [see comments] Croft NM, et al. **Lancet** 1995 Nov 11;346(8985):1265–7. Comment in: Lancet 1996 Feb 3;347(8997):327.
Fibrosing colonopathy in a child on low–dose pancreatin [letter; comment] [see comments] Taylor CJ, et al. **Lancet** 1995 Oct 21;346(8982):1106–7. Comment on: Lancet 1995 Aug 19;346(8973):499–500. Comment in: Lancet 1995 Dec 2;346(8988):1496–7.

CHEMISTRY

Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. O'Hare MM, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):59–63

DRUG EFFECTS

Effect of adenosine and adenosine agonists on amylase release from rat pancreatic lobules. Rodríguez–Nodal F, et al. **Life Sci** 1995;57(17):PL253–8

METABOLISM

Characterization of multiply phosphorylated peptides selectively precipitated from a pancreatic casein digest. Adamson NJ, et al. **J Dairy Sci** 1995 Dec;78(12):2653–9
Calcium dependence of calcium extrusion and calcium uptake in mouse pancreatic acinar cells. Camello P, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):585–93

SECRETION

Effect of adenosine and adenosine agonists on amylase release from rat pancreatic lobules. Rodríguez–Nodal F, et al. **Life Sci** 1995;57(17):PL253–8

THERAPEUTIC USE

Pancreatic enzyme therapy in childhood celiac disease. A double–blind prospective randomized study. Carroccio A, et al. **Dig Dis Sci** 1995 Dec;40(12):2555–60
Indirect parameters of pancreatic function in cystic fibrosis (CF) during a controlled double–blind trial of pancreatic supplementation. Regele S, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):68–72
[Treatment of chronic alcoholic pancreatitis with a new acid–resistant pancreatin product] Kempelen I, et al. **Orv Hetil** 1995 Sep 17;136(38):2051–5 (Eng. Abstr.) **(Hun)**
[Evaluation of the effectiveness of the preparation Panzytrat 20,000 U in the substitute treatment of chronic pancreatitis] Rydzewska G, et al. **Wiad Lek** 1994 Oct;47(19–20):738–44 (Eng. Abstr.) **(Pol)**
[Hylacombun in inflammatory bowel diseases] Prikazska M, et al. **Bratisl Lek Listy** 1996 Feb;97(2):100–5 (Eng. Abstr.) **(Slo)**

PANCREATITIS

Antibiotic prophylaxis in severe acute pancreatitis. Johnson CD. **Br J Surg** 1996 Jul;83(7):883–4
First–trimester pancreatitis. Maternal and neonatal outcome. Legro RS, et al. **J Reprod Med** 1995 Oct;40(10):689–95
Pain in chronic pancreatitis. Jansen JB, et al. **Scand J Gastroenterol Suppl** 1995;212:117–25 (114 ref.)
Acute pancreatitis: current concepts and practice. Archampong EQ. **West Afr J Med** 1996 Jan–Mar; 15(1):64–73 (46 ref.)
[Personal experience with management of abscessing pancreatitis] Sváb J, et al. **Bratisl Lek Listy** 1995 May; 96(5):256–7 **(Cze)**
[Pancreatitis in children] Sarles J. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B74–79 (29 ref.) **(Fre)**
[Advances and perspectives in acute pancreatitis (editorial)] Di Carlo V, et al. **Chir Ital** 1995;47(2):1–8 (89 ref.) (Eng. Abstr.) **(Ita)**
[Acute hyperlipemic pancreatitis and pregnancy (letter)] Girona Torres E, et al. **Gastroenterol Hepatol** 1996 Feb; 19(2):79–80 **(Spa)**
[Chronic calcifying pancreatitis and extracorporeal pancreatic lithotripsy] Sansó Sureda A, et al. **Gastroenterol Hepatol** 1996 Jun–Jul;19(6):309–12 (Eng. Abstr.) **(Spa)**

BLOOD

Fat–soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Nakamura T, et al. **Acta Gastroenterol Belg** 1996 Jan–Mar;59(1):10–14
Induction of lithostathine/reg mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR–42J cells. Dusetti NJ, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):129–32
Is there a relationship between raised plasma osmolarity and the onset of acute pancreatitis. Banerjee AK, et al. **Biochem Soc Trans** 1995 Nov;23(4):618S
Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. de Beaux AC, et al. **Br J Surg** 1996 Mar;83(3):349–53
Micronutrient antioxidant status in black South Africans with chronic pancreatitis: opportunity for prophylaxis. Segal I, et al. **Clin Chim Acta** 1995 Jul 31;239(1):71–9
Deficiency in antioxidant factors in patients with alcohol–related chronic pancreatitis. Van Gossum A, et al. **Dig Dis Sci** 1996 Jun;41(6):1225–31
A simple, sensitive, non–stimulated photon counting system for detection of superoxide anion in whole blood. Lu FJ, et al. **Experientia** 1996 Feb 15;52(2):141–4
Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Braganza JM, et al. **Int J Pancreatol** 1995 Feb;17(1):69–81
Carbon dioxide transport in rats with acute pancreatitis. Wang X, et al. **Int J Pancreatol** 1996 Apr;19(2):103–12
Acute pancreatitis in a patient with glutaric acidemia type I [letter] Lemire EG, et al. **J Pediatr** 1996 Apr; 128(4):589–90
Serum amino–terminal propeptide of type III procollagen levels in chronic pancreatitis. Navarro S, et al. **Pancreas** 1996 Mar;12(2):153–8
Iron, ascorbate and copper status of Sowetan Blacks with calcific chronic pancreatitis. Segal I, et al. **QJM** 1996 Jan; 89(1):45–53
[Zinc in acute pancreatitis in man (letter)] Viedma JA, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):909–10 **(Spa)**

CHEMICALLY INDUCED

Meglumine antimoniate–induced pancreatitis [letter] Torrús D, et al. **Am J Gastroenterol** 1996 Apr;91(4):820–1
Propofol and postoperative pancreatitis. Leisure GS, et al. **Anesthesiology** 1996 Jan;84(1):224–7
Pancreatitis after propofol administration: is there a relationship? [letter] Wingfield TW. **Anesthesiology** 1996 Jan;84(1):236–7
Corticosteroid–induced pancreatitis [letter] Felig DM, et al. **Ann Intern Med** 1996 Jun 1;124(11):1016
Pancreatitis induced by clarithromycin [letter] Liviu L, et al. **Ann Intern Med** 1996 Oct 15;125(8):701
Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus [letter] Domingo P, et al. **Arch Intern Med** 1996 May 13; 156(9):1029, 1032
Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Madsen JS, et al. **Blood Press** 1995 Nov; 4(6):369–71
Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report. McBride CE, et al. **Cancer** 1996 Jun 15;77(12):2588–91
Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus—possible toxicity of immunosuppressive therapy. Kolk A, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):399–403 (31 ref.)
Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.
Necrotizing pancreatitis after 10 years of therapy with valproic acid. Tobias JD, et al. **Clin Pediatr (Phila)** 1995 Aug;34(8):446–8
Captopril–induced acute pancreatitis. Jeandidier N, et al. **Diabetes Care** 1995 Mar;18(3):410–1
Neutrophil elastase inhibitor (ONO–5046) prevents lung hemorrhage induced by lipopolysaccharide in rat model of cerulein pancreatitis. Guo L, et al. **Dig Dis Sci** 1995 Oct;40(10):2177–83
Cholecystokinin–8 induces edematous pancreatitis in dogs associated with short burst of trypsinogen activation. Simpson KW, et al. **Dig Dis Sci** 1995 Oct;40(10):2152–61
Alcoholic chronic pancreatitis: its relation to alcoholic acute pancreatitis [letter] Ammann RW. **Gastroenterol Clin Biol** 1996;20(3):312–4
Drug induced pancreatitis [letter] Langman MJ. **Gut** 1996 Feb;38(2):302
Drug induced acute pancreatitis: incidence and severity. Lankisch PG, et al. **Gut** 1995 Oct;37(4):565–7
The effect of chronic alcohol administration on cerulein–induced pancreatitis. Korsten MA, et al. **Int J Pancreatol** 1995 Aug;18(1):25–31
Toward an animal model of chronic pancreatitis. Pancreatobiliary secretion in hamsters on long–term treatment with chemical inducers of cytochromes P450. Rutishauser SC, et al. **Int J Pancreatol** 1995 Oct; 18(2):117–26
Granisetron–induced acute pancreatitis [letter] Rodier JM, et al. **J Cancer Res Clin Oncol** 1996;122(2):132–3
Pancreatitis and rhabdomyolysis associated with lovastatin–gemfibrozil therapy. Abdul–Ghaffar NU, et al. **J Clin Gastroenterol** 1995 Dec;21(4):340–1
Possible association of acute pancreatitis with naproxen. Castiella A, et al. **J Clin Gastroenterol** 1995 Oct;21(3):258
Valproate–associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan RD, et al. **J Clin Psychiatry** 1995 Nov;56(11):529–32
Fatal pancreatitis as a complication of therapy for HIV infection. Pelucio MT, et al. **J Emerg Med** 1995 Sep–Oct; 13(5):633–7
Angio–oedema induced by ACE inhibitors [letter] Marinella MA. **J Intern Med** 1996 Apr;239(4):371–2
Erythromycin–induced acute pancreatitis. Fang CC, et al. **J Toxicol Clin Toxicol** 1996;34(1):93–5 (13 ref.)
Acute pancreatitis following organophosphate intoxication. Hsiao CT, et al. **J Toxicol Clin Toxicol** 1996;34(3):343–7
Acute pancreatitis after ingestion of acetic acid [letter] Bergenfeldt M, et al. **Pancreas** 1996 Mar;12(2):207–9
Acute pancreatitis in an octreotide–treated AIDS patient—suggested alternative mechanisms [letter; comment] Harris AG, et al. **Pancreas** 1995 Oct;11(3):318–9 . Comment on: Pancreas 1994 May;9(3):395–7.
Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein. Pescador R, et al. **Pancreas** 1995 Aug;11(2):165–72
Effect of the microtubule–disrupting drug colchicine on rat cerulein–induced pancreatitis in comparison with the microtubule stabilizer taxol. Ueda T, et al. **Pancreas** 1995 Oct;11(3):294–302
Acute pancreatitis due to zinc phosphide ingestion. Sarma PS, et al. **Postgrad Med J** 1996 Apr;72(846):237–8
[Acute pancreatitis caused by metronidazole] de Jongh FE, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):37–8 (Eng. Abstr.) **(Dut)**
[Effect of the duration of chronic alcoholic pancreatitis on the severity of outbreaks of acute pancreatitis] Chemtob A, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):664–7 (Eng. Abstr.) **(Fre)**
[Acute pancreatitis and propylthiouracil (letter)] Collet T, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):952 **(Fre)**
[Drug–induced acute pancreatitis] Grangé JD, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B67–70 **(Fre)**
[Controversy over the possible existence of an autonomous acute alcoholic pancreatitis (letter)] Moreau J. **Gastroenterol Clin Biol** 1996;20(3):314–5 **(Fre)**
[Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy] Aurousseau MH, et al. **Rev Med Interne** 1995;16(8):622–5 (Eng. Abstr.) **(Fre)**
[Toxic differential diagnosis of drug–induced pancreatitis (letter)] Efthymiou ML, et al. **Therapie** 1995 Sep–Oct; 50(5):467–8 **(Fre)**
[Is contrast CT in acute pancreatitis harmful?] Rünzi M, et al. **Z Gastroenterol** 1995 Sep;33(9):553–4 **(Ger)**
[Treatment of chronic alcoholic pancreatitis with a new acid–resistant pancreatin product] Kempelen I, et al. **Orv Hetil** 1995 Sep 17;136(38):2051–5 (Eng. Abstr.) **(Hun)**
[An AIDS case of probable pentamidine–induced diabetic ketoacidosis and severe acute pancreatitis] Pae Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):226–30 **(Jpn)**
[Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone] Muñoz Ruiz AI, et al. **An Med Interna** 1996 Mar;13(3):125–6 (Eng. Abstr.) **(Spa)**
[Acute pancreatitis caused by valproic acid: apropos a case] Bahamonde Carrasco A, et al. **Gastroenterol Hepatol** 1996 May;19(5):253–4 (21 ref.) (Eng. Abstr.) **(Spa)**
[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin–clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**
[Acute pancreatitis and erythromycin (letter)] González Carro P, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):757–8 **(Spa)**

CLASSIFICATION

Pancreatic inflammatory disease. Sarner M. **Gut** 1995 Oct; 37(4):455–6

COMPLICATIONS

When should radiologists intervene in management of pancreatic pseudocysts and other complications of acute pancreatitis? Wittich GR, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):211
Variceal bleeding due to segmental portal hypertension caused by chronic pancreatitis [letter] Lin YL, et al. **Am J Emerg Med** 1995 Nov;13(6):676–7
Sarcoidosis, the pancreas, and diabetes mellitus [letter; comment] Cronin CC, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2068. Comment on: Am J Gastroenterol 1995 Apr;90(4):681.
Endosonography–guided celiac plexus injection for abdominal pain due to chronic pancreatitis [letter] Faigel DO, et al. **Am J Gastroenterol** 1996 Aug;91(8):1675
Increased prevalence of aortic calcification in chronic pancreatitis. Gullo L, et al. **Am J Gastroenterol** 1996 Apr; 91(4):759–61
Hyperlipidemia and pancreatitis: the chicken or the egg? Gumaste VV. **Am J Gastroenterol** 1996 Jun;91(6):1275–6
Pericardial effusion and left ventricular function in acute pancreatitis. Pezzilli R, et al. **Am J Gastroenterol** 1996 May; 91(5):997–1000
Pleural effusions: a new negative prognostic parameter for

acute pancreatitis. Response to Dr. Lankisch et al [letter; comment] Ramesh H, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1898–9. Comment on: Am J Gastroenterol 1994 Oct;89(10):1849–51.

Hemosuccus pancreaticus as a source of obscure upper gastrointestinal bleeding: three cases and literature review. Risti B, et al. **Am J Gastroenterol** 1995 Oct;90(10):1878–80 (14 ref.)

Lymphatic release of cytokines during acute lung injury complicating severe pancreatitis. Montravers P, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1527–33

The challenge of therapy for pancreatitis-related common bile duct stricture. Itani KM, et al. **Am J Surg** 1995 Dec; 170(6):543–6

Pain relapses in the first 10 years of chronic pancreatitis. Talamini G, et al. **Am J Surg** 1996 Jun;171(6):565–9

Idiopathic fibrosing pancreatitis: a rare cause of obstructive jaundice in children. Amerson JL, et al. **Am Surg** 1996 Apr;62(4):295–9 (09 ref.)

Conservative management strategy for pancreatitis-associated mesenteric venous thrombosis. Krummen DM, et al. **Am Surg** 1996 Jun;62(6):432–4 (12 ref.)

A plea for uniform reporting of patient outcome in chronic pancreatitis. Frey CF, et al. **Arch Surg** 1996 Mar; 131(3):233–4

Hyperparathyroidism presenting as pancreatitis or complicated by postoperative pancreatitis. Shepherd JJ. **Aust N Z J Surg** 1996 Feb;66(2):85–7

Long-term results of endoscopic stenting and surgical drainage for biliary stricture due to chronic pancreatitis. Smits ME, et al. **Br J Surg** 1996 Jun;83(6):764–8

Spontaneous splenic rupture: a rare complication of acute pancreatitis. Toussi HR, et al. **Br J Surg** 1996 May;83(5):632

Retained contrast after embolization of a right gastric artery pseudoaneurysm. Winick AB, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):110–2

Reversible superior mesenteric vein thrombosis in acute pancreatitis. The CT appearances. Crowe PM, et al. **Clin Radiol** 1995 Sep;50(9):628–33

Respiratory mechanics and lung morphometry in severe pancreatitis–associated acute lung injury in rats. Milani Júnior R, et al. **Crit Care Med** 1995 Nov;23(11):1882–9

Complications of acute pancreatitis and their management. Büchler M, et al. **Curr Opin Gen Surg** 1993;:282–6 (59 ref.)

A 9-year-old girl with vomiting, abdominal pain, and pancreatic and renal cysts. Kahn JA, et al. **Curr Opin Pediatr** 1996 Apr;8(2):152–6

The contribution of insulitis to diabetes development in tumor necrosis factor transgenic mice. Flavell RA, et al. **Curr Top Microbiol Immunol** 1996;206:33–50 (72 ref.)

Ascites, pleural, and pericardial effusions in acute pancreatitis. A prospective study of incidence, natural history, and prognostic role. Maringhini A, et al. **Dig Dis Sci** 1996 May;41(5):848–52

Management of cholestasis in patients with chronic pancreatitis: evaluation of a treatment protocol. Sand JA, et al. **Eur J Surg** 1995 Aug;161(8):587–92

Chronic pancreatitis and pancreatic cancer [letter; comment] Gullo L. **Gastroenterology** 1996 Mar;110(3):968–9. Comment on: Gastroenterology 1995 Jul;109(1):247–51.

Complete disruption of the main pancreatic duct: endoscopic management. Devière J, et al. **Gastrointest Endosc** 1995 Nov;42(5):445–51

Chronic pancreatitis in homocystinuria. Patil RV, et al. **Indian Pediatr** 1995 Apr;32(4):469–70 (5 ref.)

Chronic pancreatitis and extrapancreatic cancer: a retrospective study among 181 patients with chronic pancreatitis. Hansen TH, et al. **Int J Pancreatol** 1995 Dec; 18(3):235–9

Ruptured subcapsular giant hematoma of the spleen as a complication of chronic pancreatitis. Kuramitsu T, et al. **Intern Med** 1995 Jun;34(6):564–8

Alcoholic liver disease in alcoholic chronic pancreatitis: a prospective study. Gullo L, et al. **Ital J Gastroenterol** 1995 Mar;27(2):69–72

Diabetic nephropathy in fibrocalcific pancreatic diabetes [letter] Mathew TP, et al. **J Assoc Physicians India** 1995 Nov;43(11):813

CT of multiple subcapsular pseudocysts of the kidney complicating acute pancreatitis. Lo J, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):823–4

Sonographically-guided extracorporeal shockwave lithotripsy for pancreatic stones in patients with chronic pancreatitis. Schreiber F, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):247–51

Acute pancreatitis in propionic acidaemia. Burlina AB, et al. **J Inherit Metab Dis** 1995;18(2):169–72

Recurrent panniculitis as the first clinical manifestation of recurrent acute pancreatitis secondary to cholelithiasis. Cheng KS, et al. **J R Soc Med** 1996 Feb;89(2):105P–6P

Complete obstruction of the inferior vena cava due to chronic relapsing pancreatitis: a case report. Ohno T, et al. **Nippon Geka Hokan** 1994 Nov 1;63(6):215–20

Pancreatitis and the risk of pancreatic cancer. Fernandez E, et al. **Pancreas** 1995 Aug;11(2):185–9

Thrombotic thrombocytopenic purpura caused by acute pancreatitis in a woman with a pancreas divisum: a case report [letter] Malka D, et al. **Pancreas** 1996 May; 12(4):414–6

Outcome of pancreatitis in CAPD and HD patients. Joglar FM, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):264–6

Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Heikius B, et al. **Scand J Gastroenterol** 1996 May;31(5):517–23

Hyperparathyroidism and pancreatitis during pregnancy. Inabnet WB, et al. **Surgery** 1996 Jun;119(6):710–3 (32 ref.)

Intensive care management of acute pancreatitis: recognition of patients at high risk of developing severe or fatal complications. Kaufmann P, et al. **Wien Klin Wochenschr** 1996;108(1):9–15

Spontaneous bowel perforation during the course of acute pancreatitis—a case report. Cho HG, et al. **Yonsei Med J** 1996 Apr;37(2):158–64

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahlke R, et al. **Z Gastroenterol** 1995 Jul;33(7):404–7

[Massive recurrent gastric hemorrhage caused by thrombosis of the splenic vein in chronic pancreatitis] Visokai V, et al. **Rozhl Chir** 1995 Sep;74(6):287–9 (Eng. Abstr.) **(Cze)**

[Chronic pancreatitis and upper gastrointestinal hemorrhage] Larsen HC, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5551–2 (Eng. Abstr.) **(Dan)**

[Pancreatogenic panniculitis] Langeveld-Wildschut EG, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):28–31 (Eng. Abstr.) **(Dut)**

[Systemic fat necrosis and septic arthritis in acute pancreatitis] Reijnierse JE, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):31–4 (Eng. Abstr.) **(Dut)**

[A unusual cause of acute pancreatitis: obstruction of the afferent loop after gastrectomy according to Bilroth II. Apropos of a case and review of the literature] Moschopoulos C, et al. **Ann Radiol (Paris)** 1995; 38(7–8):426–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Endoscopic treatment of a pancreatic-pleural fistula. Apropos of a case] Duchmann JC, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):837–40 (Eng. Abstr.) **(Fre)**

[Early antibiotic treatment in necrotizing acute pancreatitis] Sautereau D. **Gastroenterol Clin Biol** 1996;20(3):327–8 **(Fre)**

[Acute pancreatitis in the post-partum period. Apropos of 3 cases] El Mansari O, et al. **J Chir (Paris)** 1996 May; 133(3):127–31 (Eng. Abstr.) **(Fre)**

[Internal pancreatic fistula: surgical treatment] Pereira-Lima L, et al. **J Chir (Paris)** 1995 Nov;132(11):442–6 (Eng. Abstr.) **(Fre)**

[The intestine: a central organ in the pathogenesis of septic complications in acute pancreatitis] Gianotti L, et al. **Chir Ital** 1995;47(2):14–24 (Eng. Abstr.) **(Ita)**

[Pseudoaneurysm in pancreatic pseudocysts. Report of a clinical case] Giammanco M, et al. **Minerva Chir** 1995 Dec; 50(12):1081–4 (Eng. Abstr.) **(Ita)**

[A case report of intraductal papillary adenoma with carcinoma in situ of the pancreas with a repeated history of acute pancreatitis] Kinoshita M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):64–7 **(Jpn)**

[A case of primary sclerosing cholangitis associated with Sjögren's syndrome and chronic pancreatitis] Takahashi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jun; 93(6):437–40 **(Jpn)**

[Autoimmune hemolytic anemia during the course of pancreatic abscess—case history] Sołowiej D, et al. **Przegl Lek** 1995;52(8):405–6 (Eng. Abstr.) **(Pol)**

[A rare complication of destructive pancreatitis] Poliakov ED, et al. **Klin Khir** 1995;(4):48–9 **(Rus)**

[Suppurative complications in acute pancreatitis] Ohrádka B, et al. **Bratisl Lek Listy** 1995 May;96(5):254–5 **(Slo)**

[Perinephritic abscess as clinical presentation of pancreatitis] López de Alda González A, et al. **Actas Urol Esp** 1995 May;19(5):398–400 (Eng. Abstr.) **(Spa)**

[Thrombocytopenia and acute pancreatitis: the relationship with appearance of complications (letter; comment)] Sáez-Royuela F, et al. **Med Clin (Barc)** 1996 Mar 16; 106(10):398. Comment on: Med Clin (Barc) 1995 Sep 23;105(9):334–7. **(Spa)**

[Thrombocytopenia onset in acute episodes of pancreatitis (see comments)] Vaquero E, et al. **Med Clin (Barc)** 1995 Sep 23;105(9):334–7 (Eng. Abstr.). Comment in: Med Clin (Barc) 1996 Mar 16;106(10):398. **(Spa)**

DIAGNOSIS

Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Gottlieb K, et al. **Am J Gastroenterol** 1996 Aug;91(8):1553–7

Gestational diabetes complicated by severe hypertriglyceridemia and acute pancreatitis. Bar-David J, et al. **Arch Gynecol Obstet** 1996;258(2):101–4

Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. Hedström J, et al. **BMJ** 1996 Aug 10;313(7053):333–7

Peripancreatic retroperitoneal gas mimicking necrotizing pancreatitis after laparoscopic cholecystectomy. Dowdell TR, et al. **Can J Surg** 1995 Dec;38(6):547–9

Findings of cholangiopancreatography in pseudotumorous pancreatitis. Hu Y, et al. **Chin Med J (Engl)** 1995 Dec; 108(12):907–9

Vertebral osteomyelitis mimicking chronic pancreatitis. Kortas DY, et al. **Dig Dis Sci** 1996 Jul;41(7):1527–9

Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Pezzilli R, et al. **Dig Dis Sci** 1995 Nov;40(11):2341–8

In vivo interference of heparin bolus injection with photometric continuous lipase determination. Dörner K, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):363–4

Clinical course and morphological features of chronic calcifying pancreatitis associated with pancreas divisum. Barthet M, et al. **Eur J Gastroenterol Hepatol** 1995 Oct; 7(10):993–8

Does hyperamylasemia in choledochal cyst indicate true pancreatitis? An experimental study. Urushihara N, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):139–42

Granulomatous pancreatitis: Crohn's disease or sarcoidosis? [letter; comment] Boruchowicz A, et al. **Gastroenterology** 1996 Jan;110(1):321–2. Comment on: Gastroenterology 1995 Apr;108(4):1246–9.

Pulmonary infiltrations. Sign of severe acute pancreatitis. Lankisch PG, et al. **Int J Pancreatol** 1996 Apr;19(2):113–5

Crohn's disease presenting as chronic pancreatitis with biliary tract obstruction. Evans JS, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):384–8

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

Urinary trypsinogen-2 test strip for acute pancreatitis. Hedström J, et al. **Lancet** 1996 Mar 16;347(9003):729–30

Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis. Banks PA, et al. **Pancreas** 1996 Apr;12(3):294–7

Secretin–pancreozymin test (SPT) and endoscopic retrograde cholangiopancreatography (ERCP): both are necessary for diagnosing or excluding chronic pancreatitis. Lankisch PG, et al. **Pancreas** 1996 Mar;12(2):149–52

Chronic pancreatitis: diagnosis and treatment. Sidhu S, et al. **Postgrad Med J** 1996 Jun;72(848):327–33 (51 ref.)

Clinical value of an automated granulocyte elastase assay in predicting severity of acute pancreatitis. Liras G, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):641–52 **(Eng, Spa)**

To do or not to do an endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis? Scapa E. **Surg Laparosc Endosc** 1995 Dec;5(6):453–4

[Diagnosis of chronic pancreatitis] Löser C, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):243–7 (15 ref.) **(Ger)**

[Value of the serum lipase content in diagnosing pancreatitis (letter; comment)] Riederer J. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1378. Comment on: Dtsch Med Wochenschr 1995 Jun 23;120(25–26):938–9. **(Ger)**

[HIV infection with abdominal non-Hodgkin's lymphoma presenting as necrotizing pancreatitis] Stoll M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):82–4 **(Ger)**

[A radiologically unclassifiable pancreatic tumor: pseudotumorous nodular lymphoplasmacellular pancreatitis. A special form of retroperitoneal fibrosis?] Beck A, et al. **Rontgenpraxis** 1996 Apr;49(4):85–9 **(Ger)**

[Chronic pancreatitis: diagnosis] Beglinger C. **Ther Umsch** 1996 May;53(5):354–8 (Eng. Abstr.) **(Ger)**

[Acute pancreatitis: diagnosis] Glasbrenner B, et al. **Ther Umsch** 1996 May;53(5):333–41 (30 ref.) (Eng. Abstr.) **(Ger)**

[Zymogen granule protein GP2—a new specific serum marker for acute pancreatitis?] Müller MW, et al. **Z Gastroenterol** 1996 Jan;34(1):43 **(Ger)**

[The prognostic evaluation of acute pancreatitis] Violi V, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):35–44 (Eng. Abstr.) **(Ita)**

[Computerized tomography versus nuclear magnetic resonance in acute pancreatitis] Staudacher C, et al. **Chir Ital** 1995;47(2):25–9 (Eng. Abstr.) **(Ita)**

[Acute pancreatitis: clinical-tomographic correlations] Breggia M, et al. **Minerva Gastroenterol Dietol** 1995 Sep; 41(3):217–21 (Eng. Abstr.) **(Ita)**

[Acute pancreatitis in children. Diagnosis and procedures] Dziechciarz P, et al. **Pediatr Pol** 1995 Oct;70(10):suppl 1–10 (10 ref.) **(Pol)**

[Features of insulin secretion and thromboelastography values in chronic pancreatitis] Matiushin BN, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):32–3 (Eng. Abstr.) **(Rus)**

[Complement-binding antibodies to alpha-amylase in the diagnosis of chronic pancreatitis] Amosova EN, et al. **Lik Sprava** 1995 May–Jun;(5–6):91–3 (Eng. Abstr.) **(Rus)**

[Acute pancreatitis in patients infected with the human immunodeficiency virus] Veny A, et al. **Rev Clin Esp** 1995 Sep;195(9):614–9 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Hughes CB, et al. **Am J Surg** 1996 Feb;171(2):274–80

Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Takeda K, et al. **Am J Surg** 1996 Apr;171(4):394–8

Effects of the cholecystokinin receptor antagonist L-364,718 on pancreatitis induced by a deficient in choline and supplemented with ethionine (CDE) diet in the rat. Manso MA, et al. **Arch Physiol Biochem** 1995 Aug;103(4):410–5

Phentolamine abolishes the pain of chronic pancreatitis. McCleane GJ. **Br J Hosp Med** 1996 Apr 17–30;55(8):521

Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute

pancreatitis. Kingsnorth AN, et al. **Br J Surg** 1995 Oct; 82(10):1414–20

Synthesis and antipancreatitis activities of novel N-(2-sulfonylamino-5-trifluoromethyl-3-pyridyl) carboxamide derivatives as phospholipase A2 inhibitors. Kimura H, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct; 43(10):1696–700

Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone. Manso MA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):257–63

Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Sikirić P, et al. **Dig Dis Sci** 1996 Jul; 41(7):1518–26

Alpha-1-antichymotrypsin is an effective inhibitor of pancreatitis-induced lung injury. O'Donovan DA, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):847–52

Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Mithöfer K, et al. **Gastroenterology** 1996 Jan;110(1):232–40

Pancreatic enzyme supplementation in acute pancreatitis. Patankar RV, et al. **HPB Surg** 1995 Jun;8(3):159–62

Effects of delayed administration of octreotide in acute experimental pancreatitis. Kaplan O, et al. **J Surg Res** 1996 Apr;62(1):109–17

Effect of the somatostatin analogue octreotide on experimental pancreatitis in rats. Paran H, et al. **J Surg Res** 1996 May;62(2):201–6

Antibiotics, free radicals, and acute pancreatitis [letter; comment] Banerjee A. **Lancet** 1995 Oct 7;346(8980):972. Comment on: Lancet 1995 Sep 9;346(8976):652. Comment on: Lancet 1995 Sep 9;346(8976):663–7.

Early antibiotic treatment in acute necrotising pancreatitis [letter; comment] [see comments] Baudin F, et al. **Lancet** 1995 Nov 18;346(8986):1374–5. Comment on: Lancet 1995 Sep 9;346(8976):663–7. Comment in: Lancet 1996 Feb 17;347(8999):480–1.

Early antibiotic treatment in acute necrotising pancreatitis [letter; comment] Tydén G, et al. **Lancet** 1995 Nov 18; 346(8986):1375–6. Comment on: Lancet 1995 Sep 9;346(8976):663–7.

Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics. Araida T, et al. **Pancreas** 1995 Aug;11(2):132–40

Biphasic effect of prostaglandin E1 on the severity of acute pancreatitis induced by a closed duodenal loop in rats. Pozsar J, et al. **Pancreas** 1996 Mar;12(2):159–64

Effects of MCI-727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models. Tachibana I, et al. **Pancreas** 1996 Mar;12(2):165–72

The effects of green tea catechins (Polyphenon) on DL-ethionine-induced acute pancreatitis. Takabayashi F, et al. **Pancreas** 1995 Aug;11(2):127–31

Continuous celiac plexus block in acute pancreatitis. Rykowski JJ, et al. **Reg Anesth** 1995 Nov-Dec;20(6):528–32

Influence of thyrotropin-releasing hormone on experimental pancreatitis in rats. Alhan E, et al. **Res Exp Med (Berl)** 1995;195(4):243–8

Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Norman JG, et al. **Surgery** 1996 Sep;120(3):515–21

Reflux pancreatitis after simultaneous pancreas-kidney transplantation treated by alpha 1 blocker. Ciancio G, et al. **Transplantation** 1995 Oct 15;60(7):760–1

[Local arterial infusion of 5-FU in treatment of acute necrotic pancreatitis] Gu F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):339–41 (Eng. Abstr.) **(Chi)**

[Antibiotics in the treatment of acute pancreatitis] Spičák J. **Vnitr Lek** 1996 Feb;42(2):115–6 **(Cze)**

[Therapy of chronic pancreatitis (letter; comment)] Olligs J. **Dtsch Med Wochenschr** 1996 May 24;121(21):711. Comment on: Dtsch Med Wochenschr 1996 Mar 1;121(9):277–9. **(Ger)**

[Chronic pancreatitis] Layer PH, et al. **Med Klin** 1995 Sep 15;90(9):513–4 **(Ger)**

[Value of antibiotic prophylaxis in acute necrotizing pancreatitis] Rünzi M, et al. **Z Gastroenterol** 1996 Feb; 34(2):151–3 **(Ger)**

[Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice] Kobayashi M, et al. **Nippon Yakurigaku Zasshi** 1996 Apr;107(4):183–95 (Eng. Abstr.) **(Jpn)**

[Evaluation of the effectiveness of the preparation Panzytrat 20,000 U in the substitute treatment of chronic pancreatitis] Rydzewska G, et al. **Wiad Lek** 1994 Oct;47(19–20):738–44 (Eng. Abstr.) **(Pol)**

[A trial of the use of sandostatin in patients with chronic pancreatitis] Loginov AS, et al. **Ter Arkh** 1995;67(7):60–2 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Lipopolysaccharide induces manganese superoxide dismutase in the rat pancreas: its role in caerulein pancreatitis. Abe R, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1216–22

Reduction of pancreatic enzyme content and mortality in experimental acute pancreatitis in rats. Machado MC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):471–5

Chronic increased serum lipase without evidence of pancreatitis: tumor-derived lipase? Donnelly JG, et al. **Clin Chem** 1996 Mar;42(3):462–4

Serum lipase and amylase ratio in acute alcoholic and nonalcoholic pancreatitis by using Dupont ACA discrete clinical analyzer. Ansari E, et al. **Dig Dis Sci** 1996 Sep; 41(9):1823–7

Chronic pancreatitis with alpha 1-antitrypsin deficiency: from uncontrolled trypsin activation? [letter; comment] Blackstone MO. **Dig Dis Sci** 1996 Mar;41(3):549–51. Comment on: Dig Dis Sci 1995 Sep;40(9):1997–2001.

Lysosomal enzymes and pancreatitis [letter; comment] Steer ML, et al. **Gastroenterology** 1996 Mar;110(3):965–7. Comment on: Gastroenterology 1995 Aug;109(2):573–81.

Effects of pancreatic duct ligation and aging on acute taurocholate-induced pancreatitis. Experiments in the perfused pancreas in rats. Kimura W, et al. **Int J Pancreatol** 1996 Apr;19(2):117–27

Carboxylic ester hydrolase and amylase in ischemic pancreatitis in the guinea pig. Blind PJ, et al. **Pancreas** 1996 May;12(4):388–95

Protease activation in the porcine pancreatic allograft during preservation. Jönsson P, et al. **Pancreas** 1995 Oct; 11(3):256–60

Pancreatic enzyme activity after a pylorus-preserving pancreaticoduodenectomy reconstructed with pancreaticogastrostomy. Takada T, et al. **Pancreas** 1995 Oct;11(3):276–82

[Can the L/A ratio identify acute alcoholic pancreatitis?] Deltenre P, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):222–9 (Eng. Abstr.) **(Fre)**

[The role of catalase in histologic changes of acute experimental pancreatitis] Kawaura Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):167–75 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Risk factors for morbidity and mortality in pancreatitis. Lam S, et al. **Dig Dis** 1996 Mar-Apr;14(2):83–98 (100 ref.)

Acute pancreatitis in Buskerud County, Norway. Incidence and etiology. Halvorsen FA, et al. **Scand J Gastroenterol** 1996 Apr;31(4):411–4

[Acute pancreatitis. A prospective epidemiological study in the province of Alicante. A Hospital Group for Study of Digestive Diseases in Alicante] Mínguez M, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):869–73 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Clinical outcome of post-ERCP pancreatitis: relationship to history of previous pancreatitis. Chen YK, et al. **Am J Gastroenterol** 1995 Dec;90(12):2120–3

Recurrent acute pancreatitis: an additional manifestation of the "wandering spleen" syndrome". Choi YH, et al. **Am J Gastroenterol** 1996 May;91(5):1034–8

Clinical assessment of hyperlipidemic pancreatitis. Fortson MR, et al. **Am J Gastroenterol** 1995 Dec;90(12):2134–9

Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Gottlieb K, et al. **Am J Gastroenterol** 1996 Aug;91(8):1553–7

Hyperlipidemia and pancreatitis: the chicken or the egg? Gumaste VV. **Am J Gastroenterol** 1996 Jun;91(6):1275–6

Evaluation of hypotheses on pathogenesis of alcoholic pancreatitis. Pitchumoni CS, et al. **Am J Gastroenterol** 1996 Apr;91(4):637–47 (121 ref.)

Periampullary extraluminal duodenal diverticula and acute pancreatitis: an underestimated etiological association. Uomo G, et al. **Am J Gastroenterol** 1996 Jun;91(6):1186–8

Pancreatitis secondary to percutaneous liver biopsy-associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577–80 (18 ref.)

Refractory pancreatitis associated with graft-versus-host disease in Fanconi anemia [letter] Yamamoto M, et al. **Am J Hematol** 1996 Aug;52(4):329–30

Pancreatitis associated with neuroendocrine (islet cell) tumors of the pancreas. Mao C, et al. **Am J Surg** 1996 Jun;171(6):562–4

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

Aberrant biliopancreatic duct. A probable cause of acute pancreatitis? Fuchshuber PR, et al. **Arch Surg** 1995 Oct; 130(10):1139–41

Recurrent acute pancreatitis caused by afferent loop stricture after gastrectomy. Mithöfer K, et al. **Arch Surg** 1996 May; 131(5):561–5

Subcutaneous fat necrosis following traumatic pancreatitis. Lee MS, et al. **Australas J Dermatol** 1995 Nov;36(4):196–8

TGF-beta 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-alpha, triggers insulin-dependent diabetes. Sanvito F, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1279–86

Is there a relationship between raised plasma osmolarity and the onset of acute pancreatitis. Banerjee AK, et al. **Biochem Soc Trans** 1995 Nov;23(4):618S

Case of the month: "air-in a view". England R, et al. **Br J Radiol** 1996 Jul;69(823):681–2

Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Otusbo S, et al. **Brain Dev** 1995 May-Jun;17(3):219–21 (7 ref.)

Case report: recurrent pancreatitis caused by a duodenal duplication cyst communicating with the pancreatic duct. Gandhi MR, et al. **Clin Radiol** 1995 Oct;50(10):726–8

New chronic pancreatitis model with diabetes induced by cerulein plus stress in rats. Goto M, et al. **Dig Dis Sci** 1995 Nov;40(11):2356–63

Comparison of post-ERCP biological pancreatitis in chronic alcoholic and control nonalcoholic group [letter] Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):549

Endoscopic approach to pancreas divisum. Kozarek RA, et al. **Dig Dis Sci** 1995 Sep;40(9):1974–81

Ischemia-reperfusion-induced pancreatic microvascular injury. An intravital fluorescence microscopic study in rats [see comments] Menger MD, et al. **Dig Dis Sci** 1996 May; 41(5):823–30. Comment in: Dig Dis Sci 1996 May;41(5):821–2.

Cholesterol crystal embolization to liver, gallbladder, and pancreas. Moolenaar W, et al. **Dig Dis Sci** 1996 Sep; 41(9):1819–22

Alpha 1-antitrypsin deficiency and chronic pancreatitis [see comments] Rabassa AA, et al. **Dig Dis Sci** 1995 Sep; 40(9):1997–2001. Comment in: Dig Dis Sci 1996 Mar;41(3):549–51.

Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy? Ventrucci M, et al. **Dig Dis Sci** 1995 Dec;40(12):2576–81

Ischemia- and reperfusion-related injury in pancreatitis [editorial; comment] Warshaw AL. **Dig Dis Sci** 1996 May; 41(5):821–2 (18 ref.). Comment on: Dig Dis Sci 1996 May;41(5):823–30.

Incarcerated bile duct adenoma as a rare cause of acute cholestatic pancreatitis. Körner T, et al. **Endoscopy** 1995 Oct;27(8):628

Traumatic and non-traumatic pancreatitis in pediatric surgery. Schmittenbecher PP, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):86–91

Gallstone pancreatitis: an update. Wassef W, et al. **Gastroenterologist** 1996 Mar;4(1):70–5 (66 ref.)

Hypercalcemic pancreatitis: from trypsinogen activation? [letter; comment] Blackstone MO. **Gastroenterology** 1996 Jan;110(1):324. Comment on: Gastroenterology 1995 Jul;109(1):239–46.

Role of the necrosis-fibrosis sequence in the pathogenesis of alcoholic chronic pancreatitis [editorial; comment] Longnecker DS. **Gastroenterology** 1996 Jul;111(1):258–9. Comment on: Gastroenterology 1996 Jul;111(1):224–31.

A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Johnson GK, et al. **Gastrointest Endosc** 1995 Oct;42(4):312–6

The use of long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Tenner SM, et al. **Gastrointest Endosc** 1995 Nov;42(5):497–8

Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Hofbauer B, et al. **Gut** 1996 May;38(5):753–8

Hyperlipidemia in acute pancreatitis. Cause or epiphenomenon? Domínguez-Muñoz JE, et al. **Int J Pancreatol** 1995 Oct;18(2):101–6

Von Hippel-Lindau disease complicated by acute pancreatitis and Evan's syndrome. Tenner S, et al. **Int J Pancreatol** 1995 Dec;18(3):271–5

Enteral nutritional support in acute alcoholic pancreatitis. Simpson WG, et al. **J Am Coll Nutr** 1995 Dec;14(6):662–5

Acute pancreatitis as the first manifestation of hyperparathyroidism in an otherwise asymptomatic patient. Nikolaidis LA, et al. **J Ark Med Soc** 1995 Nov;92(6):273–5

Hemobilia causing acute pancreatitis after percutaneous liver biopsy. de Ribot X, et al. **J Clin Gastroenterol** 1995 Sep; 21(2):171–2

The potential role of Clostridium perfringens alpha toxin in the pathogenesis of acute pancreatitis. Holdsworth RJ, et al. **J Clin Pathol** 1996 Jun;49(6):500–3

Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. Kratz A, et al. **J Exp Med** 1996 Apr 1; 183(4):1461–72

Bacteremia in acute pancreatitis of different etiologies. Chang KK, et al. **J Formos Med Assoc** 1995 Dec;94(12):713–8

Role of endogenous and exogenous cholecystokinin in experimental acute pancreatitis induced in rats by the duodenal loop technique. Ha SS, et al. **J Gastroenterol** 1996 Jun;31(3):404–13

Acute pancreatitis induced by hypercalcaemia associated with adult T-cell leukaemia: a case report. Ono Y, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):193–5

How safe is endoscopic sphincter of Oddi manometry? Scicchitano J, et al. **J Gastroenterol Hepatol** 1995 May-Jun; 10(3):334–6

Acute pancreatitis associated with hypercalcaemia in adult T-cell leukaemia-lymphoma [editorial] Senba M, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):180–2

Fatal necrotizing pancreatitis caused by hepatitis B virus infection in a liver transplant recipient. Cavallari A, et al. **J Hepatol** 1995 Jun;22(6):685–90

Severe acute pancreatitis as a first symptom of primary hyperparathyroid adenoma: a case report. Shimizu H, et al. **J Laryngol Otol** 1996 Jun;110(6):602–3

Pancreatitis associated with hepatitis A viral infection [letter] Garty BZ, et al. **J Pediatr** 1995 Oct;127(4):669

Acute pancreatitis in a patient with glutaric acidemia type I [letter] Lemire EG, et al. **J Pediatr** 1996 Apr; 128(4):589–90

Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Ward JB, et al. **Lancet** 1995 Oct 14;346(8981):1016–9 (42 ref.)

Early prediction of aetiology and severity of acute pancreatitis by serum amylase and lipase assays. Manes G, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):211–5

Chronic recurrent pancreatitis in pregnancy. Paternoster DM, et al. **Minerva Ginecol** 1995 Dec;47(12):561–4

Primary hyperparathyroidism: an unusual cause of pancreatitis in adolescence [see comments] Nieves–Rivera F, et al. **P R Health Sci J** 1995 Sep;14(3):233–6. Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

The involvement and sources of active oxygen in experimentally induced acute pancreatitis. Ito T, et al. **Pancreas** 1996 Mar;12(2):173–7

Pancreatitis and an abnormal sweat test at presentation in a child with non–Hodgkin's lymphoma [letter] Lucero MA, et al. **Pancreas** 1996 Mar;12(2):205–6

An unusual case of chronic pancreatitis of possible immune origin [letter] Marrano D, et al. **Pancreas** 1996 Mar; 12(2):202–4

Cigarette smoking: an independent risk factor in alcoholic pancreatitis. Talamini G, et al. **Pancreas** 1996 Mar; 12(2):131–7

Oxygen radical generation and acute pancreatitis: effects of dibutyltin dichloride/ethanol and ethanol on rat pancreas. Weber H, et al. **Pancreas** 1995 Nov;11(4):382–8

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

The pathogenesis of chronic pancreatitis. Braganza JM. **QJM** 1996 Apr;89(4):243–50 (55 ref.)

Acute pancreatitis in Buskerud County, Norway. Incidence and etiology. Halvorsen FA, et al. **Scand J Gastroenterol** 1996 Apr;31(4):411–4

Reflux pancreatitis after simultaneous pancreas–kidney transplantation treated by alpha 1 blocker. Ciancio G, et al. **Transplantation** 1995 Oct 15;60(7):760–1

Acute pancreatitis in hepatitis A infection. Amarapurkar DN, et al. **Trop Gastroenterol** 1996 Jan–Mar;17(1):30–1

Toxic 'sock' syndrome bezoar formation and pancreatitis associated with iron deficiency and pica. Adler AI, et al. **West J Med** 1995 Nov;163(5):480–2

Pancreaticobiliary maljunction–associated pancreatitis: an experimental study on the activation of pancreatic phospholipase A2. Nakamura T, et al. **World J Surg** 1996 Jun;20(5):543–50

[Is anomalous junction of pancreaticobiliary duct related to pancreatitis] Tian F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):345–7 (Eng. Abstr.) **(Chi)**

[Acute pancreatitis—induced by 5–aminosalicylic acid or an extraintestinal manifestation of ulcerative colitis?] Petersen HH, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5400–1 (Eng. Abstr.) **(Dan)**

[Acute pancreatitis caused by chylomicronemia syndrome] van de Vrie W, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6; 140(1):34–6 (Eng. Abstr.) **(Dut)**

[Fulminant pancreatitis] Haapiainen R, et al. **Duodecim** 1994; 110(20):1913–7 (23 ref.) **(Fin)**

[Anatomo–clinical conference. Pitié–Salpêtrière Hospital. Case No.1–1996. Acute pancreatitis and sudden amaurosis in a 42–year–old man] Lévy P, et al. **Ann Med Interne (Paris)** 1996;147(1):35–9 **(Fre)**

[Varicella–zoster virus pancreatitis in hematologic diseases] Pulik M, et al. **Ann Med Interne (Paris)** 1995;146(5):292–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Celioscopic treatment of cholelithiasis in benign acute biliary pancreatitis] Guibert L, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):747–50 (Eng. Abstr.) **(Fre)**

[Prognostic indices in acute pancreatitis. Practical implications] Millat B, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B33–40 **(Fre)**

[Atypical mucinous ductal ectasia or fissured mucinous cystadenoma? (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):118–9 **(Fre)**

[Acute pancreatitis disclosing an uncommon form of annular pancreas] Sevenet F, et al. **Gastroenterol Clin Biol** 1996; 20(5):494–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Biliary scintigraphy vs. ultrasonography in the etiological diagnosis of acute pancreatitis] Bolognese A, et al. **J Chir (Paris)** 1996 Apr;133(2):78–81 (Eng. Abstr.) **(Fre)**

[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**

[Acute pancreatitis, an unknown complication of acute intravascular hemolysis (letter)] Bréchignac X, et al. **Rev Med Interne** 1996;17(2):172–3 **(Fre)**

[Female patient with kidney transplantation with acute pancreatitis (clinical conference)] Rünzi M, et al. **Med Klin** 1996 Mar 15;91(3):136–40 **(Ger)**

[Etiology and pathophysiology of acute pancreatitis] Schmidt J, et al. **Ther Umsch** 1996 May;53(5):322–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[Afferent loop obstruction after total gastrectomy presenting as acute pancreatitis (clinical contribution to the etiopathogenesis)] Crescimanno R, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):893–8; Discussion 899 (Eng. Abstr.) **(Ita)**

[Anomalous presentation of 2 cases of pulmonary carcinoma: obstructive jaundice and pancreatitis caused by pancreatic metastasis] Rossi G, et al. **Radiol Med (Torino)** 1995 Oct; 90(4):495–7 **(Ita)**

[Clinical characteristics of pancreatitis after cardiovascular surgery] Ikegami H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1720–9 (Eng. Abstr.) **(Jpn)**

[Chronic pancreatitis and pancreatic dysfunction associated with Sjögren's syndrome] Sumii T, et al. **Nippon Rinsho** 1995 Oct;53(10):2525–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

[Biliary pancreatitis] Yamaguchi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):506–8 (5 ref.) **(Jpn)**

[Acute pancreatitis complicated by pancreatic ascites. Diagnostic and therapeutic difficulties] Wereszczyńska–Siemiątkowska U, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):369–74 (Eng. Abstr.) **(Pol)**

[Vascular factors in the mechanism of acute pancreatitis] Sendur R, et al. **Przegl Lek** 1996;53(1):41–5 (38 ref.) (Eng. Abstr.) **(Pol)**

[Recurrent acute pancreatitis and biliary microlithiasis] Kostić LJ, et al. **Acta Chir Iugosl** 1991;38(1):77–81 (Eng. Abstr.) **(Sec)**

[Acute pancreatitis as initial manifestation of lung carcinoma (letter)] Castiella J, et al. **An Med Interna** 1995 Jun; 12(6):312–3 **(Spa)**

[Acute pancreatitis and acquired immunodeficiency syndrome] Talens A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):155–9 (Eng. Abstr.) **(Spa)**

GENETICS

Antioxidants in hereditary pancreatitis. Mathew P, et al. **Am J Gastroenterol** 1996 Aug;91(8):1558–62

Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Keilson LM, et al. **Ann Intern Med** 1996 Feb 15; 124(4):425–8

An exceptional genealogy for hereditary chronic pancreatitis. Le Bodic L, et al. **Dig Dis Sci** 1996 Jul;41(7):1504–10

Ki–ras mutations in chronic pancreatitis: which relevance? [letter; comment] Van Laethem JL, et al. **Gastroenterology** 1996 Aug;111(2):566–7. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment on: Gastroenterology 1996 Jan;110(1):306–10.

The hereditary pancreatitis gene maps to long arm of chromosome 7. Le Bodic L, et al. **Hum Mol Genet** 1996 Apr;5(4):549–54

Hereditary pancreatitis with lithiasis in a 7–year–old boy [see comments] Gupta VK, et al. **Indian Pediatr** 1995 Jan; 32(1):111–5. Comment in: Indian Pediatr 1995 May;32(5):606.

Hereditary pancreatitis with lithiasis [letter; comment] Srivastava RN. **Indian Pediatr** 1995 May;32(5):606. Comment on: Indian Pediatr 1995 Jan;32(1):111–5.

Two forms of hereditary chronic pancreatitis. Sarles H, et al. **Pancreas** 1996 Mar;12(2):138–41

IMMUNOLOGY

Comparative study of CA242 and CA19–9 in chronic pancreatitis. Furuya N, et al. **Br J Cancer** 1996 Feb; 73(3):372–6

Immune function early in acute pancreatitis. Widdison AL, et al. **Br J Surg** 1996 May;83(5):633–6

Decreased interleukin–2 production in murine acute pancreatitis: potential for immunomodulation [see comments] Curley P, et al. **Gastroenterology** 1996 Feb; 110(2):583–8. Comment in: Gastroenterology 1996 Feb;110(2):639–42.

Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. Kino–Ohsaki J, et al. **Gastroenterology** 1996 May;110(5):1579–86

Cytokines and acute pancreatitis [editorial; comment] Kusske AM, et al. **Gastroenterology** 1996 Feb;110(2):639–42. Comment on: Gastroenterology 1996 Feb;110(2):583–8.

Serum CA 242 in pancreatic cancer. Comparison with CA 19–9 and CEA. Pezzilli R, et al. **Ital J Gastroenterol** 1995 Jul–Aug;27(6):296–9

Intrapancreatic interleukin–1beta gene expression by specific leukocyte populations during acute pancreatitis. Fink GW, et al. **J Surg Res** 1996 Jun;63(1):369–73

Transgenic animals demonstrate a role for the IL–1 receptor in regulating IL–1beta gene expression at steady–state and during the systemic stress induced by acute pancreatitis. Norman JG, et al. **J Surg Res** 1996 Jun;63(1):231–6

[Unusually high level of CA 19–9 in chronic pancreatitis (letter)] Pines E, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):641–2 **(Fre)**

[Critical evaluation of factors influencing pancreatic cytoprotection] Kisfalvi K, et al. **Orv Hetil** 1996 Apr 14; 137(15):787–91 (63 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Oxidative stress in acute and chronic pancreatitis. Schoenberg MH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1306S–1314S (69 ref.)

Effect of kinin inhibition in experimental acute pancreatitis. Lerch MM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G490–9

Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Hughes CB, et al. **Am Surg** 1996 Jan;62(1):8–13

Metabolic function of the liver in caerulein induced acute pancreatitis. Celiński K, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:21–6

Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. McKay CJ, et al. **Br J Surg** 1996 Jul;83(7):919–23

Evidence of toxic metabolite stress in black South Africans with chronic pancreatitis. Gut A, et al. **Clin Chim Acta** 1995 May 15;236(2):145–53

Effect of omeprazole on changes in gastric and upper small intestine pH levels in patients with chronic pancreatitis. Nakamura T, et al. **Clin Ther** 1995 May–Jun;17(3):448–59

Differential distribution of human epidermal growth factor receptor family in acute pancreatitis. Ebert M, et al. **Dig Dis Sci** 1995 Oct;40(10):2134–42

Effect of microcirculatory perfusion on distribution of trypsinogen activation peptides in acute experimental pancreatitis. Foitzik T, et al. **Dig Dis Sci** 1995 Oct; 40(10):2184–8

Hepatic mitochondrial and lysosomal alterations in acute experimental pancreatitis with ethanolic coetiology in rats. Poplawski C, et al. **Dig Dis Sci** 1996 Jan;41(1):139

Intracellular Ca2+ dynamics and in vitro secretory response in acute pancreatitis induced by a choline–deficient, ethionine–supplemented diet in mice. Okada N, et al. **Digestion** 1995;56(6):502–8

Pancreatic interstitial pH in human and feline chronic pancreatitis. Patel AG, et al. **Gastroenterology** 1995 Nov; 109(5):1639–45

Progressive disruption of acinar cell calcium signaling is an early feature of cerulein–induced pancreatitis in mice. Ward JB, et al. **Gastroenterology** 1996 Aug;111(2):481–91

Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis. Weidenbach H, et al. **Gut** 1995 Sep;37(3):434–40

Plasma amino acid consumption and pancreatic secretion during and after cerulein–induced pancreatitis in rats. Fischer H, et al. **Int J Pancreatol** 1995 Oct;18(2):127–34

No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency. Nakamura T, et al. **Int J Pancreatol** 1995 Feb;17(1):29–35

Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Shimoyama S, et al. **Int J Pancreatol** 1995 Dec;18(3):227–34

Nitric oxide modulates pancreatic edema formation in rat caerulein–induced pancreatitis. Abe T, et al. **J Gastroenterol** 1995 Oct;30(5):636–42

Changes in gene expression of cholecystokinin–A receptor after induction of pancreatitis by pancreatic duct occlusion in rats. Miyasaka K, et al. **J Gastroenterol** 1995 Oct; 30(5):683–5

Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. Collier JD, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):396–400

Carotenoids and tocopherols in various hepatobiliary conditions. Leo MA, et al. **J Hepatol** 1995 Nov;23(5):550–6

Expression of endothelin–1 in pancreatic tissue of patients with chronic pancreatitis. Kakugawa Y, et al. **J Pathol** 1996 Jan;178(1):78–83

Up–regulation of TNF alpha mRNA in the rat spleen following induction of acute pancreatitis. Hughes CB, et al. **J Surg Res** 1995 Dec;59(6):687–93

Ligation–induced acute pancreatitis increases pancreatic circulating trypsinogen activation peptides. Merriam LT, et al. **J Surg Res** 1996 Feb 1;60(2):417–21

Evidence for altered cellular calcium in the pathogenetic mechanism of acute pancreatitis in rats. Zhou W, et al. **J Surg Res** 1996 Jan;60(1):147–55

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485–92

Calcium channel blockers in experimental acute pancreatitis: effect on tissue prostanoids and oxygen free radicals. Closa D, et al. **Pancreas** 1996 Mar;12(2):178–82

Changes in gene expression of pancreatitis–associated protein and pancreatic secretory trypsin inhibitors in experimental pancreatitis produced by pancreatic duct occlusion in rats: comparison with gene expression of cholecystokinin and secretin. Funakoshi A, et al. **Pancreas** 1995 Aug; 11(2):147–53

Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor–associated chronic pancreatitis, and alcoholic chronic pancreatitis. Imamura T, et al. **Pancreas** 1995 Nov;11(4):357–64

LFA–1 (CD11a/CD18) and ICAM–1 (CD54) antibodies attenuate superoxide anion release from polymorphonuclear leukocytes in rats with experimental acute pancreatitis. Inoue S, et al. **Pancreas** 1996 Mar; 12(2):183–8

Detection of superoxide free radicals in rats with acute pancreatitis. Kishimoto W, et al. **Pancreas** 1995 Aug; 11(2):122–6

MICROBIOLOGY

Pathogenesis of pancreatic infection. Widdison AL. **Ann R Coll Surg Engl** 1996 Jul;78(4):350–3

Acute pancreatitis associated with streptococcal toxic shock syndrome. Chiu CH, et al. **Clin Infect Dis** 1996 Apr; 22(4):724–6

Acute pancreatitis associated with brucellosis. Odeh M, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):691–2

Staphylococcus epidermidis and acute necrotising pancreatitis [letter; comment] Wilcox M, et al. **Lancet** 1996 Feb 17;347(8999):480–1. Comment on: Lancet 1995 Nov 18;346(8986):1374–5.

Tuberculous and nontuberculous mycobacterial infection of the pancreas in a patient with AIDS [letter] Albu E, et al. **Pancreas** 1996 May;12(4):412–3

MORTALITY

Severe pancreatitis. Determinants of mortality in a tertiary referral center. Malcynski JT, et al. **Arch Surg** 1996 Mar; 131(3):242–6

Reduction of pancreatic enzyme content and mortality in experimental acute pancreatitis in rats. Machado MC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):471–5

Risk of death from acute pancreatitis. Role of early, simple "routine" data. Talamini G, et al. **Int J Pancreatol** 1996 Feb;19(1):15–24

An audit of fatal acute pancreatitis. Banerjee AK, et al. **Postgrad Med J** 1995 Aug;71(838):472–5

Morbidity and mortality in 602 patients with acute pancreatitis seen between the years 1980–1994. Lankisch PG, et al. **Z Gastroenterol** 1996 Jun;34(6):371–7 (45 ref.)

[Influence of age on severe pancreatitis] Qi Q, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):542–4 (Eng. Abstr.) **(Chi)**

NURSING

Clinical snapshot: acute pancreatitis. Ruth-Sahd LA. **Am J Nurs** 1996 Jun;96(6):38–9

PARASITOLOGY

[Acute pancreatitis caused by Ascaris lumbricoides in acute renal failure: case report] Morović-Vergles J, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:87–8 (Eng. Abstr.) **(Scr)**

PATHOLOGY

Fine needle aspiration cytology in pancreatic pathology. Lerma E, et al. **Acta Cytol** 1996 Jul–Aug;40(4):683–6

Relationship between severity, necrosis, and apoptosis in five models of experimental acute pancreatitis. Kaiser AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1295–304

Comparison between image and flow cytometry. A priori factors that influence technique. Bowman R, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):276–83

Studies of lymphocyte trafficking in a microvascular rat model of acute pancreatitis. Banerjee AK, et al. **Biochem Soc Trans** 1995 Nov;23(4):617S

Dose-dependent effect of continuous subcutaneous verapamil infusion on experimental acute pancreatitis in mice. Lake-Bakaar G, et al. **Dig Dis Sci** 1995 Nov;40(11):2349–55

Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study [see comments] Ammann RW, et al. **Gastroenterology** 1996 Jul; 111(1):224–31. Comment in: Gastroenterology 1996 Jul;111(1):258–9.

Mechanisms of cell death after pancreatic duct obstruction in the opossum and the rat. Gukovskaya AS, et al. **Gastroenterology** 1996 Mar;110(3):875–84

Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Mithöfer K, et al. **Gastroenterology** 1996 Jan;110(1):232–40

Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Van Laethem JL, et al. **Gastroenterology** 1996 Feb; 110(2):576–82

Biochemical and morphological changes that characterise recovery from necrotising biliary pancreatitis in the opossum. Rünzi M, et al. **Gut** 1995 Sep;37(3):427–33

Hereditary pancreatitis with lithiasis in a 7-year-old boy [see comments] Gupta VK, et al. **Indian Pediatr** 1995 Jan; 32(1):111–5. Comment in: Indian Pediatr 1995 May;32(5):606.

Fine structure of the cilia in the pancreatic duct of WBN/Kob rat. Hidaka K, et al. **Int J Pancreatol** 1995 Dec; 18(3):207–13

Survival and morphology of isolated pancreatic acinar cells from rats with induced acute pancreatitis are not improved with anti-inflammatory drugs. Richter F, et al. **Int J Pancreatol** 1995 Oct;18(2):145–52

Protective effect of 4-hydroxy-TEMPO, a low molecular weight superoxide dismutase mimic, on free radical toxicity in experimental pancreatitis. Sledziński Z, et al. **Int J Pancreatol** 1995 Oct;18(2):153–60

Possible origin of pancreatic fat necrosis as a septal panniculitis. Ball NJ, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 2):362–4

Evidence that Th1 lymphocytes predominate in islet inflammation and thyroiditis in the BioBreeding (BB) rat. Zipris D. **J Autoimmun** 1996 Jun;9(3):315–9

Death caused by undiagnosed acute pancreatitis. Hayase T, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):87–91

Scanning electron microscopic observation of pancreatic ducts in WBN/Kob rats. Ashizawa N, et al. **Pancreas** 1995 Nov;11(4):389–95

Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Dubner H, et al. **Pancreas** 1996 Apr;12(3):298–302

Does acute pancreatitis progress to chronic pancreatitis? A microvascular pancreatitis model in the rat. Freiburghaus AU, et al. **Pancreas** 1995 Nov;11(4):374–81

Correlation of nucleolar organizer regions with secretory and regenerative process in experimental cerulein-induced pancreatitis in the rat. Rüschoff J, et al. **Pancreas** 1995 Aug; 11(2):154–9

Histological findings in chronic pancreatitis after abdominal radiotherapy [letter] Schoonbroodt D, et al. **Pancreas** 1996 Apr;12(3):313–5

Transforming growth factor beta 1, extracellular matrix, and inflammatory cells in wound repair using a closed duodenal loop pancreatitis model rat. Immunohistochemical study. Kimura Y, et al. **Scand J Gastroenterol** 1995 Jul; 30(7):707–14

Characterization of a non-invasive, vascular model of acute necrotizing pancreatitis. Weidenbach H, et al. **Z Gastroenterol** 1996 Jan;34(1):9–14

[Necrotizing pancreatitis] Jakobsen HL, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5534–7 (40 ref.) (Eng. Abstr.) **(Dan)**

[Magnetic resonance in the study of inflammatory diseases of the pancreas] Cardone G, et al. **Radiol Med (Torino)** 1995 Jul–Aug;90(1–2):62–9 (Eng. Abstr.) **(Ita)**

[CT findings of mass-forming pancreatitis: correlation with histopathologic findings] Itoh S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):627–32 (Eng. Abstr.) **(Jpn)**

[The role of catalase in histologic changes of acute experimental pancreatitis] Kawaura Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):167–75 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical assessment of hyperlipidemic pancreatitis. Fortson MR, et al. **Am J Gastroenterol** 1995 Dec;90(12):2134–9

Pericardial effusion and left ventricular function in acute pancreatitis. Pezzilli R, et al. **Am J Gastroenterol** 1996 May; 91(5):997–1000

Active interleukin-1 receptor required for maximal progression of acute pancreatitis. Norman JG, et al. **Ann Surg** 1996 Feb;223(2):163–9

Studies of lymphocyte trafficking in a microvascular rat model of acute pancreatitis. Banerjee AK, et al. **Biochem Soc Trans** 1995 Nov;23(4):617S

The prevalence and severity of microvascular complications in pancreatic diabetes and IDDM. Levitt NS, et al. **Diabetes Care** 1995 Jul;18(7):971–4

Resting energy expenditure in patients with alcoholic chronic pancreatitis. Hébuterne X, et al. **Dig Dis Sci** 1996 Mar; 41(3):533–9

Relationship of plasma CCK to acinar cell regeneration in acute pancreatitis as studied by proliferating cell nuclear antigen. Sakagami J, et al. **Dig Dis Sci** 1996 Sep; 41(9):1828–37

Induction of apoptotic cell death by pancreatitis-associated ascitic fluid in Madin-Darby canine kidney cells. Nishikawa J, et al. **FEBS Lett** 1995 Oct 2;373(1):19–22

Relation between gastric emptying rate and rate of intraluminal lipolysis. Maes BD, et al. **Gut** 1996 Jan; 38(1):23–7

Pancreatic vascular regulation [letter; comment] Reber PU, et al. **Gut** 1995 Dec;37(6):849. Comment on: Gut 1995 Jan;36(1):133–6.

Oxidative stress in rodent closed duodenal loop pancreatitis. Peralta J, et al. **Int J Pancreatol** 1996 Feb;19(1):61–9

Complement inhibition by soluble complement receptor type 1 fails to moderate cerulein-induced pancreatitis in the rat. Weiser MR, et al. **Int J Pancreatol** 1996 Apr;19(2):129–34

Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats. Okumura Y, et al. **J Gastroenterol** 1995 Aug;30(4):493–9

Determinants of pancreatic microcirculation in acute pancreatitis in rats. Kerner T, et al. **J Surg Res** 1996 May; 62(2):165–71

Effects of the bradykinin antagonist, icatibant (Hoe 140), on pancreas and liver functions during and after caerulein-induced pancreatitis in rats. Griesbacher T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):557–64

The role of pituitary-adrenal counterregulation of inflammation in cerulein-induced pancreatitis: a comparison between Fischer and Lewis rats. Abe R, et al. **Pancreas** 1996 Apr;12(3):280–5

Pain profile in alcoholic and nonalcoholic chronic pancreatitis (CP) [letter] Ammann RW. **Pancreas** 1996 Apr; 12(3):315–8

The influence of abdominal sepsis on acute pancreatitis in rats: a study on mortality, permeability, arterial pressure, and intestinal blood flow. Andersson R, et al. **Pancreas** 1995 Nov;11(4):365–73

Natural histories of alcoholic and idiopathic chronic pancreatitis [letter] Layer PH, et al. **Pancreas** 1996 Apr; 12(3):318–20

Ischemia reperfusion of the pancreas: a new in vivo model for acute pancreatitis in rats. Hoffmann TF, et al. **Res Exp Med (Berl)** 1995;195(3):125–44

Antioxidant and calcium channel blockers counteract endothelial barrier injury induced by acute pancreatitis in rats. Wang XD, et al. **Scand J Gastroenterol** 1995 Nov; 30(11):1129–36

Tissue-specific regulation of glutamine synthetase gene expression in acute pancreatitis is confirmed by using interleukin-1 receptor knockout mice. Abcouwer SF, et al. **Surgery** 1996 Aug;120(2):255–63; discussion 263–4

[Intrathecal administration of morphine and bupivacaine in the treatment of severe pain in chronic pancreatitis] Verheijen R, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6; 140(27):1410–2 (Eng. Abstr.) **(Dut)**

[Sphincter of Oddi disfunction in idiopathic recurrent pancreatitis] Wehrmann T, et al. **Dtsch Med Wochenschr** 1996 Jun 14;121(24):781–7 (Eng. Abstr.) **(Ger)**

[Etiology and pathophysiology of acute pancreatitis] Schmidt J, et al. **Ther Umsch** 1996 May;53(5):322–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[An analysis on fat digestion in the upper small intestine after intragastric infusion of a test meal in patients with exocrine pancreatic insufficiency] Yamada N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1169–77 (Eng. Abstr.) **(Jpn)**

[The functional and sonographic parallels in chronic pancreatitis] Gubergrits NB, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):51–3 (Eng. Abstr.) **(Rus)**

[Physiopathology of acute pancreatitis] Guillaumes S, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):224–30 (100 ref.) **(Spa)**

PREVENTION & CONTROL

Effect of the oral administration of sepimostat mesilate on cerulein induced acute pancreatitis in rats. Wang ZH, et al. **Arzneimittelforschung** 1995 Oct;45(10):1082–6

Induction of apoptosis reduces the severity of caerulein-induced pancreatitis in mice. Saluja A, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):875–8

Micronutrient antioxidant status in black South Africans with chronic pancreatitis: opportunity for prophylaxis. Segal I, et al. **Clin Chim Acta** 1995 Jul 31;239(1):71–9

Protective effect of nitric oxide on development of acute pancreatitis in rats. Liu X, et al. **Dig Dis Sci** 1995 Oct; 40(10):2162–9

Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. Portiansky EL, et al. **Experientia** 1995 Nov 15;51(11):1060–2

The use of long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Tenner SM, et al. **Gastrointest Endosc** 1995 Nov;42(5):497–8

Use of corticosteroids in the prevention of post-ERCP pancreatitis. Weiner GR, et al. **Gastrointest Endosc** 1995 Dec;42(6):579–83

Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. Bradley EL 3rd, et al. **J Am Coll Surg** 1996 Jul;183(1):65–70

The protective effects of long-acting recombinant human pancreatic secretory trypsin inhibitor (R44S-PSTI) in a rat model of cerulein-induced pancreatitis. Chen YZ, et al. **J Int Med Res** 1996 Jan–Feb;24(1):59–68

Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group [see comments] Cavallini G, et al. **N Engl J Med** 1996 Sep 26; 335(13):919–23. Comment in: N Engl J Med 1996 Sep 26;335(13):961–3.

Complications of endoscopic sphincterotomy and their prevention [editorial; comment] Huibregtse K. **N Engl J Med** 1996 Sep 26;335(13):961–3. Comment on: N Engl J Med 1996 Sep 26;335(13):909–18. Comment on: N Engl J Med 1996 Sep 26;335(13):919–23.

Protective effect of the somatostatin analogue octreotide in ischemia/reperfusion-induced acute pancreatitis in rats. Hoffmann TF, et al. **Pancreas** 1996 Apr;12(3):286–93

Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Kusske AM, et al. **Surgery** 1996 Aug; 120(2):284–8; discussion 289

Octreotide effects on pancreatic graft pancreatitis in inbred pigs. Chao SH, et al. **Transplant Proc** 1996 Jun; 28(3):1799–801

[Protective effects of prostacyclin on acute necrotizing pancreatitis and its renal damage in rats] Gong S, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):197–200 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

A new criterion in differentiation of pancreatitis and pancreatic carcinoma: artery-to-vein ratio using the superior mesenteric vessels. Elmas N, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):331–3

A retrospective analysis of the effect of contrast-enhanced CT on the outcome of acute pancreatitis. McMenamin DA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1384–7

Early localization of necrosis by contrast-enhanced computed tomography can predict outcome in severe acute pancreatitis. Kemppainen E, et al. **Br J Surg** 1996 Jul; 83(7):924–9

Anterior extension of acute pancreatitis: CT findings. Fujiwara T, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):963–6

CT of multiple subcapsular pseudocysts of the kidney

complicating acute pancreatitis. Lo J, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):823–4

[Acute pancreatitis] Mehdi M, et al. **Ann Radiol (Paris)** 1996; 39(1):37–44 (Eng. Abstr.) **(Fre)**

[Annular pancreas—congenital anomaly as the cause of chronic calcifying pancreatitis in a 73-year-old patient] Stacher VR, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):347–9 **(Ger)**

[CT findings of mass-forming pancreatitis: correlation with histopathologic findings] Itoh S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):627–32 (Eng. Abstr.) **(Jpn)**

[Prognostic value of the sites of pancreatic necrosis determined by computed tomography of the abdomen] Jukemura J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 May–Jun;50(3):147–53 (Eng. Abstr.) **(Por)**

[Dynamic high-contrast computed tomography in the diagnosis of pancreatic necrosis] Campos-Campos F, et al. **Rev Gastroenterol Mex** 1995 Jul–Sep;60(3):149–53 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Diffuse pancreatic Ga-67 uptake in pancreatitis with markedly elevated Ca 19-9 tumor marker. Joseph UA, et al. **Clin Nucl Med** 1996 Jun;21(6):494–5

FDG-PET evaluation of indeterminate pancreatic masses. Ho CL, et al. **J Comput Assist Tomogr** 1996 May–Jun; 20(3):363–9

Differentiation of malignant from benign pancreatic mass by Tl-201 abdominal SPECT. Bom HS, et al. **J Korean Med Sci** 1995 Apr;10(2):93–6

Labeled granulocyte scanning for the diagnosis of infected necrosis in acute pancreatitis: what kind of labeling should be used? Heresbach D, et al. **Pancreas** 1996 May; 12(4):381–7

REHABILITATION

[Physiotherapeutic methods in the postoperative period in acute pancreatitis patients] Larionov KS, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):16–8 (Eng. Abstr.) **(Rus)**

SURGERY

A prospective cost analysis of pancreatoduodenectomy. Holbrook RF, et al. **Am J Surg** 1996 May;171(5):508–11

Pitfalls of distal pancreatectomy for relief of pain in chronic pancreatitis. Rattner DW, et al. **Am J Surg** 1996 Jan; 171(1):142–5; discussion 145–6

Quality of life after treatment for pancreatitis. Broome AH, et al. **Ann Surg** 1996 Jun;223(6):665–70; discussion 670–2

Laparoscopic distal 70% pancreatectomy and splenectomy for chronic pancreatitis. Cuschieri A, et al. **Ann Surg** 1996 Mar;223(3):280–5

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)

Long-term results of pylorus-preserving pancreatoduodenectomy for chronic pancreatitis. Martin RF, et al. **Arch Surg** 1996 Mar;131(3):247–52

Pancreatic stents in the management of chronic pancreatitis. Treacy PJ, et al. **Aust N Z J Surg** 1996 Apr;66(4):210–3

Surgical strategy and management of infected pancreatic necrosis. Farkas G, et al. **Br J Surg** 1996 Jul;83(7):930–3

Role of total pancreatectomy in the treatment of patients with end-stage chronic pancreatitis. Fleming WR, et al. **Br J Surg** 1995 Oct;82(10):1409–12

Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis [letter; comment] Frick T. **Br J Surg** 1996 Mar;83(3):422–3. Comment on: Br J Surg 1995 Sep;82(9):1270–3.

Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis [see comments] Friess H, et al. **Br J Surg** 1995 Sep;82(9):1270–3. Comment in: Br J Surg 1996 Mar;83(3):422–3.

Outcome of patients with abdominal sepsis in an intensive care unit [letter; comment] Schein M. **Br J Surg** 1995 Nov; 82(11):1575. Comment on: Br J Surg 1995 Apr;82(4):524–9.

Surgical therapy in chronic pancreatitis. Rao R, et al. **Curr Opin Gen Surg** 1993;:287–93 (30 ref.)

Traumatic and non-traumatic pancreatitis in pediatric surgery. Schmittenbecher PP, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):86–91

Outcome after surgery for biliary pancreatitis. Runkel NS, et al. **Eur J Surg** 1996 Apr;162(4):307–13

Decrease in a markedly elevated CA19-9 level after stenting of a benign pancreatic ductal stricture. Mauer KR, et al. **Gastrointest Endosc** 1995 Sep;42(3):261–3

Surgical results for severe acute pancreatitis—comparison of the different surgical procedures. Hwang TL, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1026–9

Endotherapy for chronic pancreatitis. Kozarek RA, et al. **Int J Pancreatol** 1996 Apr;19(2):93–102 (43 ref.)

Laparoscopic treatment of acute biliary pancreatitis. Targarona EM, et al. **Int Surg** 1995 Oct–Dec;80(4):365–8

Sterile pancreatic necrosis: is operation necessary? [editorial; comment] Ashley SW. **J Am Coll Surg** 1995 Oct; 181(4):363–4. Comment on: J Am Coll Surg 1995 Oct;181(4):279–88.

Management of sterile necrosis in instances of severe acute pancreatitis [see comments] Rau B, et al. **J Am Coll Surg** 1995 Oct;181(4):279–88. Comment in: J Am Coll Surg 1995 Oct;181(4):363–4.

Islet Autotransplantation after total pancreatectomy in a child. Wahoff DC, et al. **J Pediatr Surg** 1996 Jan; 31(1):132–5; discussion 135–6

Pancreaticoduodenojejunostomy for chronic pancreatitis presenting with an inflammatory mass in the head of the pancreas. Pedrazzoli S, et al. **Pancreas** 1995 Oct; 11(3):289–93

Intraabdominal hemorrhage complicating surgical management of necrotizing pancreatitis. Tsiotos GG, et al. **Pancreas** 1996 Mar;12(2):126–30

Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+mice. Hosaka N, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8558–62

Laparoscopic cholecystectomy following autogenous breast reconstruction with a TRAM flap. Williams JK, et al. **Surg Endosc** 1995 Jun;9(6):719–23

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

Indications for human islet transplantation: chronic pancreatitis and cystic fibrosis. Bühler L, et al. **Transplant Proc** 1995 Dec;27(6):3148–9

[The surgical treatment of acute necrotic pancreatitis (the experience of 37 patients)] Belchev B, et al. **Khirurgiia (Sofiia)** 1994;47(6):44–6 (Eng. Abstr.) **(Bul)**

[Surgical treatment of chronic pancreatitis and evaluation of therapeutic efficiency] Guo K, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):204–6 (Eng. Abstr.) **(Chi)**

[Study of operative indication and timing for acute necrotizing pancreatitis] Huang Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):201–3 (Eng. Abstr.) **(Chi)**

[The diagnosis and treatment of focalized pancreatitis: report of 16 cases] Wang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):207–9 (Eng. Abstr.) **(Chi)**

[Laparostomy in abscessing necrotizing pancreatitis] Vraspír V, et al. **Bratisl Lek Listy** 1995 May;96(5):257–8 **(Cze)**

[Pancreatic head resection with preservation of the duodenum--the optimal surgical procedure in chronic pancreatitis] Ružička M, et al. **Rozhl Chir** 1995 Aug; 74(5):228–31 (Eng. Abstr.) **(Cze)**

[Ultrasound-guided percutaneous drainage in the treatment of retentional pseudocysts of chronic pancreatitis] Delattre JF, et al. **Chirurgie** 1996;121(1):57–65 (Eng. Abstr.) **(Fre)**

[Long-term outcome of surgical therapy of acute necrotizing pancreatitis] Kriwanek S, et al. **Chirurg** 1996 Mar; 67(3):244–8 (Eng. Abstr.) **(Ger)**

[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[The pancreas will occupy us increasingly (interview by Klaus Reinhardt)] Büchler MW. **Ther Umsch** 1996 May; 53(5):319–21 **(Ger)**

[Surgical therapy in chronic pancreatitis] Büchler MW, et al. **Ther Umsch** 1996 May;53(5):365–76 (37 ref.) (Eng. Abstr.) **(Ger)**

[Technique and outcome of surgical therapy in acute pancreatitis] Uhl W, et al. **Ther Umsch** 1996 May; 53(5):346–53 (41 ref.) (Eng. Abstr.) **(Ger)**

[After-care rehabilitation after pancreas operations] Rosemeyer D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:37–40 **(Ger)**

[Pancreatic carcinoma in chronic pancreatitis with inflammatory tumor of the head of the pancreas] Schlosser W, et al. **Z Gastroenterol** 1996 Jan;34(1):3–8 (Eng. Abstr.) **(Ger)**

[The role of necrosectomy and continuous peritoneal lavage in the treatment of acute necrotic-hemorrhagic pancreatitis] Cogliandolo A, et al. **Chir Ital** 1995; 47(2):58–61 (Eng. Abstr.) **(Ita)**

[Open treatment in acute severe pancreatitis] Padalino P, et al. **Chir Ital** 1995;47(2):35–42 (Eng. Abstr.) **(Ita)**

[Closed surgical treatment in acute severe pancreatitis] Pederzoli P, et al. **Chir Ital** 1995;47(2):30–4 (Eng. Abstr.) **(Ita)**

[Reoperation in necrotizing acute pancreatitis: evaluation of physiopathology and surgical treatment] Serio G, et al. **Chir Ital** 1995;47(2):43–9 (Eng. Abstr.) **(Ita)**

[Drainage operations in acute pancreatitis] Kubyshkin VA. **Khirurgiia (Mosk)** 1996;(1):29–32 **(Rus)**

[Laparostomy in the treatment of severe hemorrhagic-necrotic pancreatitis] Bober J, et al. **Bratisl Lek Listy** 1995 Sep;96(9):493–5 (Eng. Abstr.) **(Slo)**

[The role of emergency therapeutic endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis] Moreira Vicente V, et al. **Rev Clin Esp** 1995 Sep; 195(9):645–8 (56 ref.) **(Spa)**

THERAPY

Resolution of panniculitis after placement of pancreatic duct stent in chronic pancreatitis. Lambiase P, et al. **Am J Gastroenterol** 1996 Sep;91(9):1835–7

Percutaneous cystogastrostomy with a new catheter for drainage of pancreatic pseudocysts and fluid collections. Davies RP, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):128–31

Endoscopic approach to pancreas divisum. Kozarek RA, et al. **Dig Dis Sci** 1995 Sep;40(9):1974–81

Endoscopic stenting for pain relief in chronic pancreatitis: results of a standardized protocol. Ponchon T, et al. **Gastrointest Endosc** 1995 Nov;42(5):452–6

Long-term results of pancreatic stents in chronic pancreatitis. Smits ME, et al. **Gastrointest Endosc** 1995 Nov;42(5):461–7

Is intervention necessary after a first episode of acute idiopathic pancreatitis? Ballinger AB, et al. **Gut** 1996 Feb; 38(2):293–5

Enteral nutritional support in acute alcoholic pancreatitis. Simpson WG, et al. **J Am Coll Nutr** 1995 Dec;14(6):662–5

Traumatic pancreatitis: method and effects of i.v. fluids and Sandostatin. Delany HM, et al. **J Surg Res** 1996 Jan; 60(1):41–8

Percutaneous ablation of a pancreatic remnant with intraductal injection of neoprene. Borge MA, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):762–4

Management of acute pancreatitis: critical assessment. Berk JE. **Keio J Med** 1995 Sep;44(3):93

Endoscopic management of biliary disease during pregnancy. Nesbitt TH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):806–9

Nonsurgical treatment of acute necrotizing pancreatitis. Uomo G, et al. **Pancreas** 1996 Mar;12(2):142–8

Chronic pancreatitis: diagnosis and treatment. Sidhu S, et al. **Postgrad Med J** 1996 Jun;72(848):327–33 (51 ref.)

Hyperoncotic dextran and systemic aprotinin in necrotizing rodent pancreatitis. Huch K, et al. **Scand J Gastroenterol** 1995 Aug;30(8):812–6

Therapeutic efficacy of an antineutrophil monoclonal antibody, Urge-8, against acute necrotizing pancreatitis in rats. Han SL, et al. **Surgery** 1996 May;119(5):585–91

Effects of granulocyte colony-stimulating factor in severe pancreatitis. Rao R, et al. **Surgery** 1996 Jun;119(6):657–63

[Role of energy metabolism in nutrition management of critically ill patients] Ren J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):346–8, 382–3 (Eng. Abstr.) **(Chi)**

[An evaluation of nonsurgical treatment for severe acute pancreatitis] Liu S, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):545–7 (Eng. Abstr.) **(Chi)**

[Effect of intralipid on patients with acute necrotic pancreatitis: a prospective clinical study] Wu H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):261–4 (Eng. Abstr.) **(Chi)**

[Therapy of chronic pancreatitis (see comments)] Löser C, et al. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):277–9. Comment in: Dtsch Med Wochenschr 1996 Mar 1;121(9):277–9. **(Ger)**

[Acute pancreatitis: conservative therapy)] Inauen W. **Ther Umsch** 1996 May;53(5):342–5 (36 ref.) (Eng. Abstr.) **(Ger)**

[Chronic pancreatitis: conservative therapy] Radun D, et al. **Ther Umsch** 1996 May;53(5):359–64 (33 ref.) (Eng. Abstr.) **(Ger)**

[Nutritional support in acute pancreatitis] Dionigi P, et al. **Chir Ital** 1995;47(2):9–13 (55 ref.) (Eng. Abstr.) **(Ita)**

[Emergency drug therapy of acute pancreatitis] Otsuki M. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1826–31 (5 ref.) **(Jpn)**

[Activity of the complement system in blood serum of dogs after treatment of acute necrotic pancreatitis with boiled pancreatic juice] Aganezov SA, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep;(3):18–20 (Eng. Abstr.) **(Rus)**

[The treatment and prevention of postoperative pancreatitis] Veronskil GI, et al. **Vestn Khir Im I I Grek** 1995;154(2):20–3 **(Rus)**

[The dynamic follow-up of the status of patients with acute pancreatitis using a degree-of-severity scale] Ivanov PA, et al. **Voen Med Zh** 1995 Feb;(2):33–5, 80 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Endoscopic ultrasonography in chronic pancreatitis. Dancygier H. **Gastrointest Endosc Clin N Am** 1995 Oct; 5(4):795–804

Endosonography of the pancreas: normal variation versus changes of early chronic pancreatitis. Wiersema MJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):487–96 (24 ref.)

[The functional and sonographic parallels in chronic pancreatitis] Gubergrits NB, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):51–3 (Eng. Abstr.) **(Rus)**

URINE

Urine trypsinogen-2 as marker of acute pancreatitis. Hedström J, et al. **Clin Chem** 1996 May;42(5):685–90

VETERINARY

Molecular phylogeny and in situ detection of the etiologic agent of necrotizing hepatopancreatitis in shrimp. Loy JK, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3439–45

Pancreatic pseudocyst associated with chronic-active

necrotizing pancreatitis in a cat. Hines BL, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr;32(2):147–52

Serum lipid and lipoprotein concentrations in obese dogs. Chikamune T, et al. **J Vet Med Sci** 1995 Aug;57(4):595–8

VIROLOGY

Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. Portiansky EL, et al. **Experientia** 1995 Nov 15;51(11):1060–2

Coxsackievirus-associated pancreatitis mimicking metastatic carcinoma. Gooby Toedt DM, et al. **South Med J** 1996 Apr;89(4):441–3

PANCREATODUODENECTOMY see **PANCREATICODUODENECTOMY**

PANCREATOJEJUNOSTOMY see **PANCREATICOJEJUNOSTOMY**

PANCREATOPEPTIDASE

ADVERSE EFFECTS

[Levels of alpha-elastin and of desmosine as indexes of elastase-induced lung injury in rats] Shiraishi M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):404–12 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Evaluation of amniotic fluid elastolytic activity: can it be a method of fetal lung maturity assessment? A comparison with Gluck's L/S test. Bażowska G, et al. **Acta Genet Med Gemellol (Roma)** 1994;43(3–4):185–92

Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Domínguez-Muñoz JE, et al. **Am J Gastroenterol** 1995 Oct;90(10):1834–7

Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Boutten A, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):336–42

Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Yoshioka A, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2127–32

Synthetic peptide substrates for a conductimetric assay of Pseudomonas aeruginosa elastase. Besson C, et al. **Anal Biochem** 1996 Jun 1;237(2):216–23

Mitogenic stimulation of human lymphocytes mediated by a cell surface elastase. Packard BZ, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):51–6

Changes in neutrophil granule protein and cytoplasmic fibrils in human acute myeloid leukemias. Mutasa HC. **Biotech Histochem** 1995 May;70(3):124–34

Immunohistological comparison of granulated cell proteins in induced immediate urticarial dermographism and delayed pressure urticaria lesions. McEvoy MT, et al. **Br J Dermatol** 1995 Dec;133(6):853–60

Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Stein J, et al. **Clin Chem** 1996 Feb;42(2):222–6

Quantitative cytochemistry of human leukocyte elastase compared with plasma elastase and acute phase proteins in inflammatory diseases. Pradella M, et al. **Clin Chim Acta** 1995 Jul 31;239(1):91–101

Neutrophil elastase-alpha 1-antitrypsin in middle ear fluid in chronic otitis media with effusion. Tierney P, et al. **Clin Otolaryngol** 1995 Jun;20(3):230–3

Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153–9

Neutrophil elastase in crevicular fluid: comparison of a middle-aged general population with healthy and periodontitis groups. Smith QT, et al. **J Clin Periodontol** 1995 Dec;22(12):935–41

Oral fluid elastase as an indicator of periodontal health. Uitto VJ, et al. **J Clin Periodontol** 1996 Jan;23(1):30–7

Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. Grinnell F, et al. **J Invest Dermatol** 1996 Feb;106(2):335–41

Distribution of human neutrophil elastase in diffuse alveolar damage and pneumonia in a case of neonatal sepsis. Fujita J, et al. **Respir Med** 1995 Aug;89(7):505–7

[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function] Stein J, et al. **Gastroenterol Clin Biol** 1996;20(5):424–9 (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Sakamaki F, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):391–7

Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Facino RM, et al. **Arch Pharm (Weinheim)** 1995 Oct; 328(10):720–4

The contribution of the conserved hinge region residues of alpha1-antitrypsin to its reaction with elastase. Hopkins PC, et al. **Biochemistry** 1995 Dec 5;34(48):15872–9

Inhibition of human leukocyte and porcine pancreatic elastase by homologues of bovine pancreatic trypsin inhibitor. Kraunsoe JA, et al. **Biochemistry** 1996 Jul 16;35(28):9090–6

Inhibition of human leukocyte elastase activity by heparins: influence of charge density. Volpi N. **Biochim Biophys Acta** 1996 Aug 13;1290(3):299–307

Effects of metals on elastase from Pseudomonas aeruginosa SES-938-1. Kocabiyik S, et al. **Biol Trace Elem Res** 1995 Oct;50(1):25–31

Synthesis and elastase inhibitory activity of 6 alpha-chloro-2,2-dimethyl-3 alpha-(pivaloyloxy)methylpenam sulfone, 6 alpha-chloro-2,2-dimethyl-3-exo-methylenepenam sulfone, benzyl and methyl 6 alpha-substituted penicillanate sulfones. Boschetti CE, et al. **Bioorg Med Chem** 1995 Jan; 3(1):95–100

Design, synthesis and biological evaluation of succinimide derivatives as potential mechanism-based inhibitors of human leukocyte elastase, cathepsin G and proteinase 3. Groutas WC, et al. **Bioorg Med Chem** 1995 Apr;3(4):375–81

Characterization of a novel elastase inhibitor from a fan coral. La Barre S, et al. **C R Acad Sci III** 1996 May;319(5):365–70

Inhibition of human leukocyte elastase by chemically and naturally oversulfated galactosaminoglycans. Bartolucci C, et al. **Carbohydr Res** 1995 Oct 23;276(2):401–8

Neutrophil elastase inhibitor (ONO-5046) prevents lung hemorrhage induced by lipopolysaccharide in rat model of cerulein pancreatitis. Guo L, et al. **Dig Dis Sci** 1995 Oct;40(10):2177–83

Neltenexine: morphological investigation of protection against elastase-induced emphysema in rats. Braga PC, et al. **Drugs Exp Clin Res** 1995;21(2):51–7

A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Yasui S, et al. **Eur Respir J** 1995 Aug;8(8):1293–9

Inhibition of neutrophil elastase by the alpha1-proteinase inhibitor-immunoglobulin A complex. Adam C, et al. **FEBS Lett** 1996 May 6;385(3):201–4

Compromised inhibition of human lung lavage cell elastases. Smith SF, et al. **FEBS Lett** 1996 Jul 22;390(2):187–90

Extract of Helicobacter pylori induces neutrophils to injure endothelial cells and contains antielastase activity. Takemura T, et al. **Gastroenterology** 1996 Jan;110(1):21–9

Characterization and chromosomal localization of ELANH2, the gene encoding human monocyte/neutrophil elastase inhibitor. Evans E, et al. **Genomics** 1995 Jul 20;28(2):235–40

YM-47141 and YM-47142, new elastase inhibitors produced by Flexibacter sp. Q17897. II. Structure elucidation. Orita M, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1430–4

YM-47141 and 47142, new elastase inhibitors produced by Flexibacter sp. Q17897. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. Yasumuro K, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1425–9

Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153–9

Lysozyme binds to elastin and protects elastin from elastase-mediated degradation. Park PW, et al. **J Invest Dermatol** 1996 May;106(5):1075–80

Antiprotease activity in urine of patients with inflammatory skin disorders. Streit V, et al. **J Invest Dermatol** 1995 Oct; 105(4):562–6

Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones. Edwards PD, et al. **J Med Chem** 1996 Mar 1;39(5):1112–24

Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles. Edwards PD, et al. **J Med Chem** 1995 Sep 29;38(20):3972–82

A novel class of cyclic beta-dicarbonyl leaving groups and their use in the design of benzisothiazolone human leukocyte elastase inhibitors. Hlasta DJ, et al. **J Med Chem** 1995 Nov 10;38(23):4687–92

Pharmacological evaluation of selected, orally active, peptidyl inhibitors of human neutrophil elastase. Janusz MJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1233–8

Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. Petrinec D, et al. **J Vasc Surg** 1996 Feb;23(2):336–46

Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Erdelmeier CA, et al. **Planta Med** 1996 Jun;62(3):241–5

The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition. Lin Y, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11044–8

Effects of a specific neutrophil elastase inhibitor (ONO-5046 Na) and neutrophil depletion using a G-1 column on lung reperfusion injury in dogs. Ohwada S, et al. **Transplant Proc** 1996 Jun;28(3):1826–7

Effects of neutrophil elastase inhibitor on reperfusion injury in the canine liver. Tomizawa N, et al. **Transplant Proc** 1996 Jun;28(3):1767–8

Neutrophil elastase inhibitor (ONO-5046) decreases cytokine-induced neutrophil chemoattractant after reperfusion of pancreaticoduodenal transplantation in rats. Wang FS, et al. **Transplantation** 1996 Apr 15;61(7):1103–7

BIOSYNTHESIS

Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Yamashita J, et al. **Chest** 1996 May;109(5):1328–34

Differences in distribution and synthesis of the functional opponents alpha 1-proteinase inhibitor and neutrophil elastase in eukaryotic cells. Davids E, et al. **Histochem Cell Biol** 1995 Sep;104(3):245–53

Expression of elastase and fibrin in venous leg ulcer biopsies: a pilot study of pentoxifylline versus placebo. Mirshahi S, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S101–5

BLOOD

Reperfusion after cardioplegic cardiac arrest--effects on intracoronary leucocyte elastase release and oxygen free radical mediated lipid peroxidation. Mair P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):960–4

PMN granulocyte elastase--an early indicator of postoperative spondylodiscitis? Schneider T, et al. **Acta Neurochir (Wien)** 1995;136(1–2):16–20

The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Nishiyama T, et al. **Anesth Analg** 1996 Jan;82(1):108–12

Relation of serum elastase activity to ultrasonographically assessed carotid artery wall lesions and cardiovascular risk factors. The EVA study. Bizbiz L, et al. **Atherosclerosis** 1996 Feb;120(1–2):47–55

Specific proteolysis of ceruloplasmin by leukocyte elastase. Sang QA. **Biochem Mol Biol Int** 1995 Oct;37(3):573–81

Nonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Liou TG, et al. **Biochemistry** 1995 Dec 12; 34(49):16171–7

Polymorphonuclear (PMN) elastase levels in depressive disorders. Değer O, et al. **Biol Psychiatry** 1996 Mar 1; 39(5):357–63

Influence of heparin thromboprophylaxis on plasma leucocyte elastase levels following lobectomy for lung carcinoma. Tian Y, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):527–30

Polymorphonuclear leukocyte elastase levels in patients with Behçet's disease. Değer O, et al. **Clin Chim Acta** 1995 May 15;236(2):129–34

The value of polymorphonuclear elastase in adult respiratory distress syndrome. Diaz J, et al. **Clin Chim Acta** 1995 May 15;236(2):119–27

Quantitative cytochemistry of human leukocyte elastase compared with plasma elastase and acute phase proteins in inflammatory diseases. Pradella M, et al. **Clin Chim Acta** 1995 Jul 31;239(1):91–101

Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. Groeneveld AB, et al. **Cytokine** 1995 Oct;7(7):746–52

Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. Amaro A, et al. **Eur Heart J** 1995 May;16(5):615–22

Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancies. Rebelo I, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):189–94

Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Blann AD, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):218–22

Changes in "inflammatory" mediators and total body water during extra-corporeal membrane oxygenation (ECMO). A preliminary study. Underwood MJ, et al. **Int J Artif Organs** 1995 Oct;18(10):627–32

Plasma interleukin 8 and polymorphonuclear leukocyte elastase concentrations in patients with septic shock. Endo S, et al. **J Inflamm** 1995;45(2):136–42

Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase. Gando S, et al. **J Trauma** 1995 Oct; 39(4):660–4

Neutrophil recruitment into the lungs is associated with increased lung elastase burden, decreased lung elastin, and emphysema in alpha 1 proteinase inhibitor-deficient mice. Cavarra E, et al. **Lab Invest** 1996 Aug;75(2):273–80

Serum elastase and alpha-1-antitrypsin levels in patients with ruptured and unruptured cerebral aneurysms. Baker CJ, et al. **Neurosurgery** 1995 Jul;37(1):56–61; discussion 61–2

Clinical value of an automated granulocyte elastase assay in predicting severity of acute pancreatitis. Liras G, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):641–52 **(Eng, Spa)**

[Changes in elastase and collagenase serum levels in patients with sclerosing connective tissue diseases treated with uropancreozymin] Hodáč V, et al. **Cas Lek Cesk** 1996 Apr 17;135(8):249–51 (Eng. Abstr.) **(Cze)**

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15–21 (49 ref.) (Eng. Abstr.) **(Hun)**

[Influence of cardiopulmonary bypass on biological response] Furunaga A, et al. **Kyobu Geka** 1995 Dec;48(13):1085–7 (Eng. Abstr.) **(Jpn)**

[Elastase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:326–8 (10 ref.) **(Jpn)**

[Human neutrophil elastase] Ishizaki T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:262–4 (17 ref.) **(Jpn)**

CHEMISTRY

Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Tsunemi M, et al. **Biochemistry** 1996 Sep 10;35(36):11570–6

Characterization of a novel elastase inhibitor from a fan coral. La Barre S, et al. **C R Acad Sci III** 1996 May;319(5):365–70

The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. Shipley JM, et al. **J Biol Chem** 1996 Feb 23; 271(8):4335–41

Purification and characterization of two pancreatic elastase isoforms from dogfish (Scyliorhinus canicula). Smine A, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):295–303

DEFICIENCY

Human eosinophils lack human leukocyte elastase. Wiedow O, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):185–7

Characterization of elastase-deficient clinical isolates of Pseudomonas aeruginosa. Hamood AN, et al. **Infect Immun** 1996 Aug;64(8):3154–60

DRUG EFFECTS

Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Kawabata K, et al. **Ann Rheum Dis** 1996 Apr;55(4):248–52

Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. Costello CM, et al. **Thorax** 1996 Jun;51(6):619–23

GENETICS

DNA hybridization analysis of the Pseudomonas aeruginosa elastase gene (lasB) from different clinical isolates. Hamood AN, et al. **Can J Microbiol** 1995 Oct;41(10):910–7

Physical mapping of the human ELA1 gene between D12S361 and D12S347 on chromosome 12q13. Davies RL, et al. **Genomics** 1995 Oct 10;29(3):766–8

Analysis of the Pseudomonas aeruginosa elastase (lasB) regulatory region. Rust L, et al. **J Bacteriol** 1996 Feb; 178(4):1134–40

C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Oelgeschläger M, et al. **Mol Cell Biol** 1996 Sep;16(9):4717–25

IMMUNOLOGY

Antibodies to neutrophil elastase: a study in patients with vasculitis. Apenberg S, et al. **Am J Kidney Dis** 1996 Aug; 28(2):178–85

ISOLATION & PURIFICATION

Elastin-derived peptides and neutrophil elastase in bronchoalveolar lavage fluid. Betsuyaku T, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):720–4

METABOLISM

Interleukin 8 and granulocyte elastase alpha 1 proteinase inhibitor complex in the tracheobronchial aspirate of infants with chronic lung disease following inter-uterine infection. Takasaki J, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):132–6

Alginate, the slime exopolysaccharide of Pseudomonas aeruginosa, binds human leukocyte elastase, retards inhibition by alpha 1-proteinase inhibitor, and accelerates inhibition by secretory leukoprotease inhibitor. Ying QL, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):283–91

Accelerated binding of secretory leukoprotease inhibitor to human leukocyte elastase mediated by single-stranded sites in DNA from tracheobronchial mucus. Ying QL, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):703–11

A kinetic study of the hydrolysis of the N-tosylalanine ester of 3-hydroxy-5-phenylpyrrole and related compounds by human leukocyte elastase. Jackson DS, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):108–14

Lesional elastase activity in psoriasis. Diagnostic and prognostic significance. Wiedow O, et al. **Arch Dermatol Res** 1995;287(7):632–5

Mechanism of inhibition of human leucocyte elastase by beta-lactams. 2. Stability, reactivation kinetics, and products of beta-lactam-derived E-I complexes. Green BG, et al. **Biochemistry** 1995 Nov 7;34(44):14331–43

Mechanism of inhibition of human leucocyte elastase by beta-lactams. 3. Use of electrospray ionization mass spectrometry and two-dimensional NMR techniques to identify beta-lactam-derived E-I complexes. Underwood DJ, et al. **Biochemistry** 1995 Nov 7;34(44):14344–55

Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Liau DF, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):117–28

Processing and activation of recombinant mouse mastocytoma histidine decarboxylase in the particulate fraction of Sf9 cells by porcine pancreatic elastase. Tanaka S, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):9–12

Role of leucocytes in coagulation induced by artificial surfaces: investigation of expression of Mac-1, granulocyte elastase release and leucocyte adhesion on modified polyurethanes. Sundaram S, et al. **Biomaterials** 1996 May; 17(10):1041–7

Neutrophil serine proteases are most probably involved in the release of CD43 (leukosialin, sialophorin) from the neutrophil membrane during cell activation [letter; comment] Halbwachs-Mecarelli L, et al. **Blood** 1996 Feb 1;87(3):1200–2. Comment on: Blood 1995 Sep 15;86(6):2395–402.

Histomorphometric parameters and susceptibility to neutrophil elastase degradation of skin elastic fibres from healthy individuals and patients with Marfan syndrome, Ehlers-Danlos type IV, and pseudoxanthoma elasticum. Berteretche MV, et al. **Br J Dermatol** 1995 Dec; 133(6):836–41

A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)

Elastase binding capacity of alpha 2-macroglobulin and its association with glucocorticoid concentration in southern African black patients with hepatocellular carcinoma. Gaillard MC, et al. **Clin Chim Acta** 1995 Sep 15; 240(2):179–85

The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Shah PL, et al. **Eur Respir J** 1996 Mar;9(3):531–4

Protease cleavage of iron-transferrin augments pyocyanin-mediated endothelial cell injury via promotion of hydroxyl radical formation. Miller RA, et al. **Infect Immun** 1996 Jan;64(1):182–8

Increased neutrophil elastase release in patients with cardiopulmonary arrest: role of elastase inhibitor. Gando S, et al. **Intensive Care Med** 1995 Aug;21(8):636–40

The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. Shipley JM, et al. **J Biol Chem** 1996 Feb 23; 271(8):4335–41

Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. Owen CA, et al. **J Cell Biol** 1995 Nov; 131(3):775–89

Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. Thompson K, et al. **J Cell Physiol** 1996 Mar;166(3):495–505

Immunocytochemical study of the degradation of elastic fibers in a living extracellular matrix. Morris SM, et al. **J Histochem Cytochem** 1995 Nov;43(11):1145–53

IL-1 beta primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. Brandolini L, et al. **J Leukoc Biol** 1996 Mar;59(3):427–34

Soluble ICAM-1 (sICAM-1) provokes PMN elastase release. Barnett CC Jr, et al. **J Surg Res** 1996 Jun;63(1):6–10

Expression of elastinolytic activity among isolates in Aspergillus section flavi. Mellon JE, et al. **Mycopathologia** 1995 Aug;131(2):115–20

The possible role of granulocyte elastase in renal damage from acute pyelonephritis. Monga M, et al. **Pediatr Nephrol** 1995 Oct;9(5):583–6

The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

Relationship between alpha-tocopherol and polymorphonuclear leukocyte elastase in septic adult respiratory distress syndrome. Nakae H, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):93–100

Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Hansen G, et al. **Respiration** 1995;62(3):117–24

Soluble intercellular adhesion molecule-1 provokes polymorphonuclear leukocyte elastase release by CD18. Barnett CC, et al. **Surgery** 1996 Aug;120(2):395–401; discussion 401–2

Impaired clot lysis in the presence of human neutrophil elastase. Bach-Gansmo ET, et al. **Thromb Res** 1995 Oct 15;80(2):153–9

Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leukocyte elastase level. Suzuki S, et al. **Thromb Res** 1995 Oct 1;80(1):93–8

PHARMACOLOGY

Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Azghani AO. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):132–40

Plasmid-liposome transfer of the alpha 1 antitrypsin gene to cystic fibrosis bronchial epithelial cells prevents elastase-induced cell detachment and cytokine release. Canonico AE, et al. **Am J Respir Cell Mol Biol** 1996 Apr; 14(4):348–55

Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Suzuki T, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1405–11

Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Heeringa P, et al. **Clin Exp Immunol** 1996 Aug;105(2):321–9

Immunocytochemical evidence for extra-cellular initiation of elastase-induced bronchial secretory cell metaplasia in hamsters. Christensen TG, et al. **Eur Respir J** 1996 Mar; 9(3):535–41

Effect of elastase on the directional migration of lung fibroblasts within a three-dimensional collagen matrix. Chetty A, et al. **Exp Lung Res** 1995 Nov-Dec;21(6):889–99

Inhibition of neutrophil elastase by the alpha1-proteinase inhibitor-immunoglobulin A complex. Adam C, et al. **FEBS Lett** 1996 May 6;385(3):201–4

Abolition of the receptor potential response of isolated mammalian outer hair cells by hair-bundle treatment with elastase: a test of the tip-link hypothesis. Preyer S, et al. **Hear Res** 1995 Sep;89(1–2):187–93

The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis. Akimoto F. **Surg Today** 1995;25(12):1027–33

PHYSIOLOGY

Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Delclaux C, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):288–95

Degradation of platelet glycoprotein Ib by elastase released from primed neutrophils. Aziz KA, et al. **Br J Haematol** 1995 Sep;91(1):46–54

Role of granulocyte elastase in the formation of hemorrhagic shock-induced gastric mucosal lesions in the rat [see comments] Kushimoto S, et al. **Crit Care Med** 1996 Jun; 24(6):1041–6. Comment in: Crit Care Med 1996 Jun;24(6):914–5.

Is granulocyte elastase the cause of gastric mucosal injury after shock? [editorial; comment] Waxman K. **Crit Care Med** 1996 Jun;24(6):914–5. Comment on: Crit Care Med 1996 Jun;24(6):1041–6.

Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. Ho JS, et al. **J Leukoc Biol** 1996 May;59(5):716–24

[Clinical evaluation of patients with cardiopulmonary bypass by plasma granulocyte elastase] Furnaga A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1716–9 (Eng. Abstr.) **(Jpn)**

[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation] Oe H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):459–64 (Eng. Abstr.) **(Jpn)**

SECRETION

Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Jansen PM, et al. **Blood** 1996 Mar 15;87(6):2337–44

THERAPEUTIC USE

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

TOXICITY

Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. Holmes DR, et al. **J Surg Res** 1996 Jun;63(1):305–9

PANCREOZYMIN see **CHOLECYSTOKININ**

PANCREOZYMIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PANCURONIUM

Synergism between mivacurium and pancuronium in adults. Rautoma P, et al. **Acta Anaesthesiol Scand** 1995 Aug; 39(6):733–7

Comparison of pancuronium and vecuronium for fetal neuromuscular blockade during invasive procedures. Watson WJ, et al. **J Matern Fetal Med** 1996 May-Jun; 5(3):151–4

ADMINISTRATION & DOSAGE

Left ventricular regional wall motion and haemodynamic changes following bolus administration of pipecuronium or pancuronium to adult patients undergoing coronary artery bypass grafting. Shorten GD, et al. **Can J Anaesth** 1995 Aug;42(8):695–700

[Profile of the effect of succinylcholine after pre-curarization with atracurium, vecuronium or pancuronium] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):304–8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Perioperative train-of-four monitoring and residual curarization. Shorten GD, et al. **Can J Anaesth** 1995 Aug; 42(8):711–5

Periarticular heterotopic ossification following pharmacologically induced paralysis. Ray TD, et al. **Skeletal Radiol** 1995 Nov;24(8):609–12

Absence of skeletal muscle lesions after experimental restraint stress induced by pancuronium in normal and stress-susceptible pigs. Bjurström S, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):129–38

[Tetraparesis in an infant after prolonged administration of

pancuronium] Bordet F, et al. **Ann Fr Anesth Reanim** 1995; 14(5):426–8 (Eng. Abstr.) **(Fre)**

ECONOMICS

Doxacurium vs. Pancuronium [letter; comment] Kantor GS, et al. **Crit Care Med** 1996 Feb;24(2):366–7. Comment on: Crit Care Med 1995 Mar;23(3):450–8.

PHARMACOKINETICS

Effects of enflurane and isoflurane anesthesia on the pharmacokinetics of pancuronium in adult patients. Xue F, et al. **Chin Med J (Engl)** 1996 Mar;109(3):233–7

PHARMACOLOGY

Perioperative monitoring of neuromuscular transmission using acceleromyography prevents residual neuromuscular block following pancuronium. Mortensen CR, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):797–801

Mivacurium when preceded by pancuronium becomes a long-acting muscle relaxant. Erkola O, et al. **Anesthesiology** 1996 Mar;84(3):562–5

Pancuronium masks the prejunctional muscarinic autoreceptor in guinea pig tracheal smooth muscle. Nagtegaal JE, et al. **Life Sci** 1995;57(25):2325–33

[Clinical research of muscular relaxation induced by alcuronium and pancuronium] Gong Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug; 17(4):301–4 (Eng. Abstr.) **(Chi)**

[Pharmacologic induction of fetal immobilization for prenatal diagnostic-therapeutic procedures] Greco P, et al. **Minerva Ginecol** 1995 May;47(5):207–10 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Conti G, et al. **Intensive Care Med** 1995 Oct;21(10):808–12

PANCYTOPENIA

Differences between the Hoyeraal-Hreidarsson syndrome and an autosomal recessive congenital intrauterine infection-like syndrome [letter; comment] Aalfs CM, et al. **Am J Med Genet** 1995 Sep 25;58(4):385. Comment on: Am J Med Genet 1994 Aug 1;52(1):58–65.

Fever and progressive pancytopenia in a 20-year-old woman with Crohn's disease [clinical conference] Sijpkens YW, et al. **Ann Hematol** 1996 Apr;72(4):286–90

The Hoyeraal-Hreidarsson syndrome: don't forget the associated immunodeficiency [letter] Berthet F, et al. **Eur J Pediatr** 1995 Dec;154(12):998

[Hemophagocytic syndromes. A series of 23 cases] Tiab M, et al. **Ann Med Interne (Paris)** 1996;147(3):138–44 (Eng. Abstr.) **(Fre)**

[Protracted fever, splenomegaly and pancytopenia in a 19-year-old man] Amital H, et al. **Harefuah** 1996 Jan 15; 130(2):135–7 **(Heb)**

CHEMICALLY INDUCED

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Gutierrez-Ureña S, et al. **Arthritis Rheum** 1996 Feb;39(2):272–6

Tamoxifen flare--an unusual case of hypercalcaemia and transient rapidly progressive pancytopenia [letter] Ellis PM, et al. **Aust N Z J Med** 1995 Aug;25(4):375–6

Toxic epidermal necrolysis, pancytopenia and adult respiratory syndrome [letter] Coakley G, et al. **Br J Rheumatol** 1995 Aug;34(8):798

Pancytopenia related eosinophilia in rheumatoid arthritis: a specific methotrexate phenomenon? Bruyn GA, et al. **J Rheumatol** 1995 Jul;22(7):1373–6

Pancytopenia due to Paludrine (proguanil hydrochloride) [letter] Houben MH, et al. **Nephron** 1995;71(3):368

Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):477–86 (108 ref.). Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):471–3.

COMPLICATIONS

Idiopathic thrombocytopenic purpura and pancytopenia in a patient with Crohn's disease: a new association [letter] Manzano ML, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1678–9

Morganella morganii pericarditis after resolvent splenectomy for immune pancytopenia following allogeneic bone marrow transplantation for acute lymphoblastic leukemia. Sica S, et al. **Clin Infect Dis** 1995 Oct;21(4):1052–3

Hyponatraemic rhabdomyolysis in Addison's disease [letter] Jolobe O, et al. **Postgrad Med J** 1995 Sep;71(839):574

CONGENITAL

Gastrointestinal problems in a child with dyskeratosis congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

DRUG THERAPY

Effect of polysaccharide-peptide (PSP), an extract from yun-zhi, on chemotherapy-induced cytopenias. Zhou LQ, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):143–6

ETIOLOGY

Pancytopenia secondary to parvovirus B19 infection in a child with acute lymphoblastic leukemia, mimicking leukemic relapse [letter] Smith TJ, et al. **Am J Hematol** 1995 Nov;50(3):226–7

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)

Pancytopenia after repeated radioiodine treatment on metastatic thyroid cancer to bone. Tanigawa K, et al. **Chin Med J (Engl)** 1995 Oct;108(10):796–7

Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report. De Giacomo T, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(3):149–51

[Fever, hemorrhagic diathesis and pancytopenia in a middle-aged woman (clinical conference)] Pettersson T. **Duodecim** 1994;110(23-24):2236–44 **(Fin)**

[25-year-old patient with pancytopenia] Meusser S, et al. **Internist (Berl)** 1995 Oct;36(10):999–1004 **(Ger)**

[Fever and pancytopenia in extrathoracic sarcoidosis] Matzdorff A, et al. **Med Klin** 1996 May 15;91(5):313–6 **(Ger)**

[Refractory anemia with excess of blasts (RAEB) with a high level of HbF that preceded apparent pancytopenia] Matsuda A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):60–4 (Eng. Abstr.) **(Jpn)**

[Splenomegalic pancytopenia of probable immune origin: cure after treatment with glucocorticoids] Fuentes A, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):263–6 (Eng. Abstr.) **(Spa)**

GENETICS

Pancytopenia with chromosomal fragility: vitamin B12 deficiency. Chintagumpala MM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):166–70

MICROBIOLOGY

Salmonella paratyphi A induced pancytopenia--a new association. Khattak BK, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):192–3

PATHOLOGY

A single cell summarizing the pathogenesis of cytopenias in hemophagocytic syndrome. Balduini CL, et al. **Haematologica** 1996 Mar-Apr;81(2):190

PHYSIOPATHOLOGY

Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Alexander WS, et al. **Blood** 1996 Mar 15;87(6):2162–70

THERAPY

In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Ohwada A, et al. **Blood** 1996 Aug 1; 88(3):778–84

Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report. De Giacomo T, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(3):149–51

[Mobilization and transplantation of autologous hematopoietic stem and progenitor cells from peripheral blood: principles and applications] Ghielmini M, et al. **Schweiz Med Wochenschr** 1996 Mar 2;126(9):348–56 (44 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Pancytopenia associated with administration of captopril to a dog. Holland M, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1683–6

VIROLOGY

Cytomegalovirus as a cause of pancytopenia. Almeida-Porada GD, et al. **Leuk Lymphoma** 1996 Apr; 21(3-4):217–23 (59 ref.)

PANENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

PANIC

Predictors of panic-fear in asthma. Carr RE, et al. **Health Psychol** 1995 Sep;14(5):421–6

Anxiety and panic in recreational scuba divers. Morgan WP. **Sports Med** 1995 Dec;20(6):398–421 (117 ref.)

DRUG EFFECTS

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Bradwejn J, et al. **Biol Psychiatry** 1995 Dec 1;38(11):742–6

Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment] Coupland N, et al. **Biol Psychiatry** 1996 Mar 15;39(6):465–6. Comment on: Biol Psychiatry 1994 Jul 15;36(2):73–83.

Sodium lactate infusion in fibromyalgia patients. Tanum L, et al. **Biol Psychiatry** 1995 Oct 15;38(8):559–61

Effects of intravenous diazepam pretreatment on lactate-induced panic. Liebowitz MR, et al. **Psychiatry Res** 1995 Sep 29;58(2):127–38

PHYSIOLOGY

Biological challenge manipulation of PCO2 levels: a test of Klein's (1993) suffocation alarm theory of panic. Schmidt NB, et al. **J Abnorm Psychol** 1996 Aug;105(3):446–54

Panic attacks and panic disorder: the great neurologic imposters. Stahl SM, et al. **Semin Neurol** 1995 Jun; 15(2):126–32 (14 ref.)

PANIC ATTACKS see **PANIC DISORDER**

PANIC DISORDER

BLOOD

Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Abelson JL, et al. **Am J Psychiatry** 1996 Jan;153(1):69–73

Elevated plasma levels of neuropeptide Y in patients with panic disorder. Boulenger JP, et al. **Am J Psychiatry** 1996 Jan;153(1):114–6

Pregnancy and estrogen-induced panic [letter; comment] Griez EJ, et al. **Am J Psychiatry** 1995 Nov;152(11):1688 . Comment on: Am J Psychiatry 1994 Aug;151(8):1246.

Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Abelson JL, et al. **Arch Gen Psychiatry** 1996 Apr; 53(4):323–31

Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. Gann H, et al. **Pharmacopsychiatry** 1995 May;28(3):80–3

CEREBROSPINAL FLUID

Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. Rimón R, et al. **Biol Psychiatry** 1995 Dec 1;38(11):737–41

CHEMICALLY INDUCED

Prospective evaluation of panic potentiation following 35% CO2 challenge in nonclinical subjects. Harrington PJ, et al. **Am J Psychiatry** 1996 Jun;153(6):823–5

The effects of alcohol consumption on laboratory-induced panic and state anxiety. Kushner MG, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):264–70

Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter] Noveske FG. **J Clin Psychiatry** 1996 Aug;57(8):374

Panic associated with combining fluoxetine and bupropion [letter] Young SJ. **J Clin Psychiatry** 1996 Apr;57(4):177–8

Symptoms essential to the experience of sodium lactate-induced panic. Goetz RR, et al. **Neuropsychopharmacology** 1996 May;14(5):355–66

Provocative agents in panic disorder. Bourin M, et al. **Therapie** 1995 Jul-Aug;50(4):301–6 (42 ref.)

COMPLICATIONS

Relation of schizophrenia and panic disorder: evidence from a controlled family study. Heun R, et al. **Am J Med Genet** 1995 Apr 24;60(2):127–32

Does ischemia occur with panic attacks? Lint DW, et al. **Am J Psychiatry** 1995 Nov;152(11):1678–80

Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Smoller JW, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):6–17 (220 ref.)

Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Gupta MA, et al. **Cutis** 1995 Jul; 56(1):53–4

[Incidence of latent tetany in patients with panic disorder] Táborská V. **Cesk Psychiatr** 1995 Jul;91(3):183–90 (Eng. Abstr.) **(Cze)**

[Comorbidity of panic disorder and alcoholism in a sample of 100 alcoholic patients] Segui J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May-Jun;22(3):137–42 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The symptom structure of panic disorder: a trial using factor and cluster analysis. Shioiri T, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):80–6

Panic disorder and the primary care physician [editorial; comment] Doyle BB. **Am Fam Physician** 1995 Nov 15; 52(7):1999–2000. Comment on: Am Fam Physician 1995 Nov 15;52(7):2055–63, 2067–8.

Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.). Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.

Evaluating CBF velocity changes with transcranial Doppler ultrasound [letter] Cerisoli M, et al. **Am J Psychiatry** 1996

Mar;153(3):447

DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. Goisman RM, et al. **Am J Psychiatry** 1995 Oct; 152(10):1438–43

Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Perna G, et al. **Am J Psychiatry** 1996 Aug;153(8):1060–4

The panic–agoraphobic syndrome: a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Roth M. **Am J Psychiatry** 1996 Jul; 153(7 Suppl):111–24 (90 ref.)

Functioning and well-being of patients with panic disorder. Sherbourne CD, et al. **Am J Psychiatry** 1996 Feb; 153(2):213–8

Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment] Coupland N, et al. **Biol Psychiatry** 1996 Mar 15;39(6):465–6. Comment on: Biol Psychiatry 1994 Jul 15;36(2):73–83.

Instructional set does not alter outcome of respiratory challenges in panic disorder. Papp LA, et al. **Biol Psychiatry** 1995 Dec 15;38(12):826–30

Anxiety sensitivity and depression: how are they related? Taylor S, et al. **J Abnorm Psychol** 1996 Aug;105(3):474–9

Personality dimensions in panic disorder and generalized anxiety disorder. Starcevic V, et al. **J Affect Disord** 1996 Apr 12;37(2–3):75–9

Panic attack or CVD? [letter] Dean CE. **J Fam Pract** 1996 Jun;42(6):623

Association of levels of N-acetyl-beta-glucosaminidase with severity of psychiatric symptoms in panic disorder. Garvey MJ, et al. **Psychiatry Res** 1996 Mar 29;60(2–3):185–90

Effects of intravenous diazepam pretreatment on lactate-induced panic. Liebowitz MR, et al. **Psychiatry Res** 1995 Sep 29;58(2):127–38

Hypersensitivity to inhalation of carbon dioxide and panic attacks. Perna G, et al. **Psychiatry Res** 1995 Aug 28; 57(3):267–73

[Capgras syndrome in adolescence: a review apropos of one case] Chabrol H, et al. **Encephale** 1995 Nov–Dec; 21(6):477–80 (31 ref.) (Eng. Abstr.) **(Fre)**

[Suicidal ideation in depressed patients with concomitant anxiety symptoms] Keller F. **Psychiatr Prax** 1996 May; 23(3):135–8 (Eng. Abstr.) **(Ger)**

[Prognostic aspects of panic disorder] Kurz A. **Versicherungsmedizin** 1996 Apr 1;48(2):53–6 (33 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.). Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.

Anxiety sensitivity [letter; comment] Fava GA. **Am J Psychiatry** 1996 Aug;153(8):1109–10. Comment on: Am J Psychiatry 1995 Aug;152(8):1156–60.

Valproic acid for panic disorder associated with multiple sclerosis [letter] Marazziti D, et al. **Am J Psychiatry** 1996 Jun;153(6):842–3

Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms. Black DW, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):181–8

Effect of nortriptyline on yohimbine-induced changes in heart rate variability [letter] Yeragani VK. **Biol Psychiatry** 1996 Mar 1;39(5):385–6

Long-term follow-up after a drug trial for panic disorder. Katschnig H, et al. **Br J Psychiatry** 1995 Oct;167(4):487–94

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Oehrberg S, et al. **Br J Psychiatry** 1995 Sep;167(3):374–9

Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Gupta MA, et al. **Cutis** 1995 Jul; 56(1):53–4

Guidelines on psychotropic drugs for the EC. Clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. **Eur Neuropsychopharmacol** 1995 Jun;5(2):151–5

Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ, et al. **J Affect Disord** 1995 Dec 13;35(3):117–23

Practical approaches to the treatment of panic disorder. **J Clin Psychiatry** 1996 Jan;57(1):45–52

Estrogen replacement therapy may reduce panic symptoms [letter; comment] Chung CK, et al. **J Clin Psychiatry** 1995 Nov;56(11):533. Comment on: J Clin Psychiatry 1992 May;53(5):163–5. Comment on: J Clin Psychiatry 1992 Jun;53(6):201–3.

An open-label trial of nefazodone in high comorbidity panic disorder. DeMartinis NA, et al. **J Clin Psychiatry** 1996 Jun; 57(6):245–8

Diazepam versus alprazolam for the treatment of panic disorder. Noyes R Jr, et al. **J Clin Psychiatry** 1996 Aug; 57(8):349–55

An open trial of fluvoxamine therapy for panic disorder complicated by depression. Spiegel DA, et al. **J Clin Psychiatry** 1996;57 Suppl 8:37–40; discussion 40–1

Effects of isoproterenol infusions on heart rate variability in patients with panic disorder. Yeragani VK, et al. **Psychiatry Res** 1995 Apr 28;56(3):289–93

Algorithm for the treatment of panic disorder with agoraphobia. Jobson KO, et al. **Psychopharmacol Bull** 1995; 31(3):483–5

Pattern of placebo response in panic disorder. Shear MK, et al. **Psychopharmacol Bull** 1995;31(2):273–8

A multiple imputation strategy for clinical trials with truncation of patient data. Lavori PW, et al. **Stat Med** 1995 Sep 15;14(17):1913–25

[Citalopram in the treatment of panic disorders and school phobia in children and adolescents] Lepola U, et al. **Duodecim** 1994;110(1):60–2 **(Fin)**

[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**

[The efficacy of alprazolam in the therapy of panic disorders] Diukova GM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):9–13 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Prospective evaluation of panic potentiation following 35% CO2 challenge in nonclinical subjects. Harrington PJ, et al. **Am J Psychiatry** 1996 Jun;153(6):823–5

Panic, agoraphobia, and vestibular dysfunction. Jacob RG, et al. **Am J Psychiatry** 1996 Apr;153(4):503–12

Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Pollack MH, et al. **Am J Psychiatry** 1996 Mar;153(3):376–81

Prevalence of panic in patients referred for pulmonary function testing at a major medical center. Pollack MH, et al. **Am J Psychiatry** 1996 Jan;153(1):110–3

Panic disorder and suicide attempt. A reanalysis of data from the Epidemiologic Catchment Area study. Hornig CD, et al. **Br J Psychiatry** 1995 Jul;167(1):76–9

Comorbidity of panic and somatization disorder: a genetic-epidemiological approach. Battaglia M, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):411–20

Panic disorder in completed suicide. Henriksson MM, et al. **J Clin Psychiatry** 1996 Jul;57(7):275–81

Panic disorder cases of Westerners in Japan. Akiyama T, et al. **J Nerv Ment Dis** 1996 Jul;184(7):444–5

Agoraphobia without panic: case illustrations of an overlooked syndrome. Pollard CA, et al. **J Nerv Ment Dis** 1996 Jan;184(1):61–2

Increasing identification and referral of panic disorder over the past decade. Gerdes T, et al. **Psychosomatics** 1995 Sep–Oct;36(5):480–6

[Comorbidity in panic disorders and alcoholism (II). Alcoholism in a sample of 148 patients with panic disorders] Segui J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):288–92 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Hyperventilation and panic attacks. Garssen B, et al. **Am J Psychiatry** 1996 Apr;153(4):513–8

Factors in the etiology and pathogenesis of panic disorder: revisiting the attachment–separation paradigm. Shear MK. **Am J Psychiatry** 1996 Jul;153(7 Suppl):125–36 (64 ref.)

Panic attacks: Klein's false suffocation alarm, Taylor and Rachman's data, and Ley's dyspneic–fear theory [letter; comment] Ley R. **Arch Gen Psychiatry** 1996 Jan;53(1):83–5 . Comment on: Arch Gen Psychiatry 1993 Apr;50(4):306–17.

Can panic disorder be considered as an angina equivalent? [letter] Gallerani M, et al. **Eur Heart J** 1995 Dec; 16(12):2013–4

Panic disorder and agoraphobia: hypothesis hothouse. Klein DF. **J Clin Psychiatry** 1996;57 Suppl 6:21–7 (38 ref.)

[Panic disorder secondary to anaphylactic reaction (letter)] Sanz-Carrillo C, et al. **Med Clin (Barc)** 1995 Sep 16; 105(8):318 **(Spa)**

GENETICS

Genetic factors in early separation anxiety: implications for the genesis of adult anxiety disorders. Silove D, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):17–24

Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder. Crawford F, et al. **Am J Med Genet** 1995 Aug 14;60(4):332–4

Relation of schizophrenia and panic disorder: evidence from a controlled family study. Heun R, et al. **Am J Med Genet** 1995 Apr 24;60(2):127–32

New segregation analysis of panic disorder. Vieland VJ, et al. **Am J Med Genet** 1996 Apr 9;67(2):147–53

Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Perna G, et al. **Am J Psychiatry** 1996 Aug;153(8):1060–4

A twin–family study of self-report symptoms of panic-phobia and somatization. Kendler KS, et al. **Behav Genet** 1995 Nov;25(6):499–515

The genes encoding the 5HT1D alpha and 5HT1D beta receptors are unchanged in patients with panic disorder. Ohara K, et al. **Biol Psychiatry** 1996 Jan 1;39(1):5–10

Comorbidity of panic and somatization disorder: a genetic-epidemiological approach. Battaglia M, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):411–20

The familial relationship between panic disorder and unipolar depression. Maier W, et al. **J Psychiatr Res** 1995 Sep–Oct; 29(5):375–88

METABOLISM

CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. Akiyoshi J, et al. **J Neurochem** 1996 Apr; 66(4):1610–6

Uncoupling of the noradrenergic–hypothalamic–pituitary–adrenal axis in panic disorder patients. Coplan JD, et al. **Neuropsychopharmacology** 1995 Aug;13(1):65–73

PHYSIOPATHOLOGY

Ambulatory monitoring of panic patients during regular activity: a preliminary report. Bystritsky A, et al. **Biol Psychiatry** 1995 Nov 15;38(10):684–9

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)

Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Toni C, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):125–33

Effect of psychological stress on airway impedance in individuals with asthma and panic disorder. Carr RE, et al. **J Abnorm Psychol** 1996 Feb;105(1):137–41

Biological challenge manipulation of PCO2 levels: a test of Klein's (1993) suffocation alarm theory of panic. Schmidt NB, et al. **J Abnorm Psychol** 1996 Aug;105(3):446–54

New insights into panic attacks. Yeragani VK. **J Psychiatr Res** 1995 Sep–Oct;29(5):343–5

Respiration disorders in panic attacks. Gorman JM. **JAMA** 1995 Nov 15;274(19):1504

Respiration disorders in panic attacks. Klein DF. **JAMA** 1995 Nov 15;274(19):1504

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681–725 (152 ref.)

[Panic attacks in wakening and during sleep] Bashmakov MIu, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):4–8 (Eng. Abstr.) **(Rus)**

[Conceptual aspects of panic disorders] Kukumberg P. **Cas Lek Cesk** 1996 Mar 20;135(6):167–9 (15 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Wiborg IM, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):689–94

PSYCHOLOGY

A psychiatrist's personal description of a panic attack [letter] Benjamin J. **Am J Psychiatry** 1996 Apr;153(4):582–3

Familial patterns in patients with infrequent panic attacks. Dumas CA, et al. **Arch Fam Med** 1995 Oct;4(10):863–7

Implicit memory bias for threat in panic disorder: application of the 'white noise' paradigm. Amir N, et al. **Behav Res Ther** 1996 Feb;34(2):157–62

Cognition-behaviour links in the persistence of panic. Salkovskis PM, et al. **Behav Res Ther** 1996 May–Jun; 34(5–6):453–8

Stability of catastrophic cognitions in panic disorder. Zoellner LA, et al. **Behav Res Ther** 1996 May–Jun; 34(5–6):399–402

Rebreathing tests in panic disorder. Papp LA, et al. **Biol Psychiatry** 1995 Aug 15;38(4):240–5

Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. Ito LM, et al. **Braz J Med Biol Res** 1995 Sep;28(9):961–5

Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls. Pichot W, et al. **Eur Arch Psychiatry Clin Neurosci** 1995; 245(6):306–8

The impact of stress, fear of fatness, and panic disorder with agoraphobia on eating disorder symptomatology: a case study. Chesler BE. **Int J Eat Disord** 1995 Sep;18(2):195–8

Expectations about arousal and nocturnal panic. Craske MG, et al. **J Abnorm Psychol** 1995 Nov;104(4):567–75

Suicidal behavior in patients with panic disorder: retrospective and prospective data. Warshaw MG, et al. **J Affect Disord** 1995 Jun 8;34(3):235–47

Estrogen replacement therapy may reduce panic symptoms [letter; comment] Chung CK, et al. **J Clin Psychiatry** 1995 Nov;56(11):533. Comment on: J Clin Psychiatry 1992 May;53(5):163–5. Comment on: J Clin Psychiatry 1992 Jun;53(6):201–3.

Childhood trauma and personality disorder in 43 women with panic disorder. Moisan D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1133–4

Panic disorder and complex partial seizures. A truly complex relationship. Handal NM, et al. **Psychosomatics** 1995 Sep–Oct;36(5):498–502

Panic attacks and panic disorder: the great neurologic imposters. Stahl SM, et al. **Semin Neurol** 1995 Jun; 15(2):126–32 (14 ref.)

[Anxiety syndrome in vertigo patients. A comparison of neuro-otologic findings in patients with and without anxiety] Aust G. **Laryngorhinootologie** 1995 Oct; 74(10):601–5 (Eng. Abstr.) **(Ger)**

[Hypnotic desensitization as a supplemental method in dental care of patients with panic disorder. Report of a case] Fábián TK. **Fogorv Sz** 1996 Feb;89(2):57–62 (19 ref.) **(Hun)**

[Are pathological (or vital) anxiety and common fear the same experiences? A controlled study] Ramos Brieva JA,

et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):119-23 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. Kaschka W, et al. **J Psychiatr Res** 1995 Sep-Oct;29(5):427-34

THERAPY

A 23-year-old woman with panic disorder treated with psychodynamic psychotherapy [clinical conference] Milrod B, et al. **Am J Psychiatry** 1996 May;153(5):698-703

Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms. Black DW, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):181-8

Patient-therapist interaction in the behavioral treatment of panic disorder with agoraphobia. Keijsers GP, et al. **Behav Modif** 1995 Oct;19(4):491-517

Psychological treatments of panic disorder without agoraphobia: cognitive therapy versus applied relaxation. Arntz A, et al. **Behav Res Ther** 1996 Feb;34(2):113-21

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Cottraux J, et al. **Br J Psychiatry** 1995 Nov;167(5):635-41

The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years. O'Rourke D, et al. **Br J Psychiatry** 1996 Apr; 168(4):462-9

Five group comparisons of treatments for anxiety disorders [letter] Sharp DM, et al. **Br J Psychiatry** 1995 Dec; 167(6):820-1

5-year prospective, naturalistic follow-up study of panic disorder. Faravelli C, et al. **Compr Psychiatry** 1995 Jul-Aug;36(4):271-7

A clinical study of autogenic training-based behavioral treatment for panic disorder. Sakai M. **Fukuoka Igaku Zasshi** 1996 Mar;87(3):77-84

Brief cognitive-behavioral versus nondirective therapy for panic disorder. Craske MG, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):113-20

Behavior therapy: endogenous serotonin therapy? Baer L. **J Clin Psychiatry** 1996;57 Suppl 6:33-5 (12 ref.)

Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Brown TA, et al. **J Consult Clin Psychol** 1995 Oct;63(5):754-65

Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Telch MJ, et al. **J Consult Clin Psychol** 1995 Oct;63(5):823-30

Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. van Balkom AJ, et al. **J Nerv Ment Dis** 1996 Feb;184(2):133-5

Integration of behavioral and pharmacological treatments for panic disorder: implications for the treatment of substance dependence. Otto MW, et al. **NIDA Res Monogr** 1995; 150:143-66

Walkfree [letter] Cohen D, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):245

Cognitive-behavior therapy and the longitudinal course of panic disorder. Otto MW, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):803-20 (78 ref.)

The longitudinal course and outcome of panic disorder. Pollack MH, et al. **Psychiatr Clin North Am** 1995 Dec; 18(4):785-801 (95 ref.)

Psychotherapy for panic disorder. Shear MK. **Psychiatr Q** 1995 Winter;66(4):321-8 (16 ref.)

Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up. Albus M, et al. **Psychopathology** 1995;28(5):229-34

Successful treatment of comorbid panic disorder and sleep apnea with continuous positive airway pressure [letter] Enns MW, et al. **Psychosomatics** 1995 Nov-Dec; 36(6):585-6

Management of panic disorder. Chee KT. **Singapore Med J** 1995 Dec;36(6):664-5

PANICUM see **MILLET**

PANLEUKOPENIA, FELINE see **FELINE INFECTIOUS ENTERITIS**

PANLEUKOPENIA VIRUS OF CATS see **PARVOVIRUS, FELINE**

PANNICULITIS

CHEMICALLY INDUCED

Bilateral jawline nodules in a child with a brain-stem glioma. Poststeroid panniculitis. Reichel M, et al. **Arch Dermatol** 1995 Dec;131(12):1448-9, 1451-2

Histiocytic cytophagic panniculitis which developed during interferon-alpha therapy. Kuno M, et al. **Intern Med** 1996 Feb;35(2):115-8

COMPLICATIONS

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Sabroe RA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):164-7 (16 ref.)

Calcifying panniculitis with renal failure: a new management approach. Elamin EM, et al. **Dermatology** 1996; 192(2):156-9

DIAGNOSIS

Eosinophilic panniculitis: diagnostic considerations and evaluation. Adame J, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 1):229-34 (37 ref.)

35-year-old woman with ulcerating skin lesions. Shields RC, et al. **Mayo Clin Proc** 1996 Jan;71(1):59-62

The fasciitis-panniculitis syndromes. Clinical and pathologic features. Naschitz JE, et al. **Medicine (Baltimore)** 1996 Jan; 75(1):6-16 (59 ref.)

DRUG THERAPY

Treatment of alpha-1-antitrypsin deficiency, massive edema, and panniculitis with alpha-1 protease inhibitor [letter] Furey NL, et al. **Ann Intern Med** 1996 Oct 15;125(8):699

Calcifying panniculitis with renal failure: a new management approach. Elamin EM, et al. **Dermatology** 1996; 192(2):156-9

35-year-old woman with ulcerating skin lesions. Shields RC, et al. **Mayo Clin Proc** 1996 Jan;71(1):59-62

ETIOLOGY

Membranocystic changes in the panniculitis of dermatomyositis. Ishikawa O, et al. **Br J Dermatol** 1996 Apr;134(4):773-6

Acute exanthem and pancreatic panniculitis in a patient with primary HIV infection and haemophagocytic syndrome. Martínez-Escribano JA, et al. **Br J Dermatol** 1996 Apr; 134(4):804-7

Scurvy and panniculitis: a case report. Ordoukhanian E, et al. **Cutis** 1995 Dec;56(6):337-41; quiz 342

Pancreatic panniculitis [letter] Zellman GL. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):282-3

Recurrent panniculitis as the first clinical manifestation of recurrent acute pancreatitis secondary to cholelithiasis. Cheng KS, et al. **J R Soc Med** 1996 Feb;89(2):105P-6P

MICROBIOLOGY

Liquefactive panniculitis in the inguinal area as the first sign of chronic renal brucellosis. Bartralot R, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):339-41

Case records of the Department of Medicine University of Mississippi Medical Center. Acute panniculitis secondary to fungal infection, most likely Aspergillus species [clinical conference] Guynes RD, et al. **J Miss State Med Assoc** 1996 Jun;37(6):610-5

[Panniculitis in an immunosuppressed patient] Maillard H, et al. **Ann Pathol** 1996;16(2):139-40 **(Fre)**

PATHOLOGY

Angiocentric immunoproliferative lesions of the skin show lobular panniculitis and are mainly disorders of large granular lymphocytes. Takeshita M, et al. **Hum Pathol** 1995 Dec;26(12):1321-8

Possible origin of pancreatic fat necrosis as a septal panniculitis. Ball NJ, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 2):362-4

Panniculitis of pancreatic disease masquerading as systemic lupus erythematosus panniculitis. Feuer J, et al. **J Rheumatol** 1995 Nov;22(11):2170-2

[Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis] Skaria AM, et al. **Hautarzt** 1995 Aug;46(8):579-81 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Resolution of panniculitis after placement of pancreatic duct stent in chronic pancreatitis. Lambiase P, et al. **Am J Gastroenterol** 1996 Sep;91(9):1835-7

VETERINARY

Feline pansteatitis: a report of five cases. Tidholm A, et al. **Acta Vet Scand** 1996;37(2):213-7

Role of Pasteurella granulomatis and Dermatobia hominis in the etiology of lechiguana in cattle. Ladeira SL, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:359-68

Sterile idiopathic pedal panniculitis in the German shepherd dog--clinical presentation and response to treatment of four cases. Paterson S. **J Small Anim Pract** 1995 Nov; 36(11):498-501

PANNICULITIS, LUPUS ERYTHEMATOSUS

CLASSIFICATION

Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Watanabe T, et al. **Br J Dermatol** 1996 Jan;134(1):123-5

ETIOLOGY

[Panniculitis-fasciitis syndrome disclosing systemic erythematous lupus] Carsuzaa F, et al. **Ann Dermatol Venereol** 1996;123(4):259-61 (23 ref.) (Eng. Abstr.) **(Fre)**

PANNICULITIS, NODULAR NONSUPPURATIVE

DIAGNOSIS

Idiopathic lobular panniculitis with specific pleural involvement. Kumagai-Kurata N, et al. **Eur Respir J** 1995 Sep;8(9):1613-5

Crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma mimicking Weber-Christian disease: immunohistochemical, ultrastructural, and gene-rearrangement studies. Harada M, et al. **Hum Pathol** 1996 Jan;27(1):84-7

Nodular nonsuppurative panniculitis in association with primary biliary cirrhosis and Hashimoto's thyroiditis. Herr W, et al. **Z Rheumatol** 1996 Mar-Apr;55(2):122-6

[Weber-Christian disease] Iino S. **Ryoikibetsu Shokogun Shirizu** 1995;(8):276-9 (12 ref.) **(Jpn)**

ETIOLOGY

[Pancreatogenic panniculitis] Langeveld-Wildschut EG, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):28-31 (Eng. Abstr.) **(Dut)**

[Acinar cell carcinoma of the pancreas revealed by Weber-Christian syndrome] Foulet A, et al. **Ann Pathol** 1995;15(6):438-42 (Eng. Abstr.) **(Fre)**

SURGERY

Subarachnoid hemorrhage of unknown origin associated with Weber-Christian disease--case report. Oyama H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):454-7

PANNICULITIS, PERITONEAL

Mesenteric panniculitis. A case report. Pizzo A, et al. **Clin Exp Obstet Gynecol** 1996;23(1):51-2

COMPLICATIONS

[A case of chylothorax caused by mesenteric panniculitis] Fujino S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul; 32(7):516-9 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Severe weight loss at the beginning of mesenteric panniculitis] Suriñach JM, et al. **An Med Interna** 1995 Dec; 12(12):597-9 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Généreau T, et al. **Dig Dis Sci** 1996 Apr; 41(4):684-8

ETIOLOGY

Mesenteritis secondary to the use of a pneumatic jackhammer [published erratum appears in Eur J Gastroenterol Hepatol 1995 Aug;7(8):following 815] van der Hulst RW, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):573-5

PATHOLOGY

[Necrotizing panniculitis of the colon--a rare form of mesenterial panniculitis] Herzig R, et al. **Swiss Surg** 1996; (3):131-3 (17 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Mesenteric panniculitis] Kienzle HF, et al. **Leber Magen Darm** 1995 Dec;25(6):272-5 (Eng. Abstr.) **(Ger)**

[Mesenteric panniculitis: computerized tomography features. Report of 5 cases] Cusati B, et al. **Radiol Med (Torino)** 1996 May;91(5):645-9 (17 ref.) **(Ita)**

PANNICULITIS, SUBACUTE NODULAR MIGRATORY see **PANNICULITIS**

PANOPHTHALMITIS

DIAGNOSIS

Postmortem diagnosis of Fusarium panophthalmitis by the polymerase chain reaction. Alexandrakis G, et al. **Am J Ophthalmol** 1996 Feb;121(2):221-3

[Ocular tuberculosis in systemic lupus erythematosus and immunosuppressive therapy] Anders N, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):368-71 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Panophthalmitis with acute scleral necrosis after brachytherapy of a malignant melanoma of the ciliary body. Bodanowitz S, et al. **Ger J Ophthalmol** 1995 Nov;4(6):380-2

PANORAMIC RADIOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANSTRONGYLUS

PARASITOLOGY

[Xenodiagnosis in chronic Chagas' disease. I. The sensitivity of Panstrongylus megistus and Triatoma infestans] Borges-Pereira J, et al. **Rev Soc Bras Med Trop** 1996 Jul-Aug;29(4):341-7 (Eng. Abstr.) **(Por)**

PANTETHEINE

ANALOGS & DERIVATIVES

Delay or inhibition of rat lens opacification using pantethine and WR-77913. Clark JI, et al. **Exp Eye Res** 1996 Jan; 62(1):75-84

Inhibition of lens opacification during the early stages of cataract formation. Hiraoka T, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2550-5

A new aromatase inhibitor, FR901537. I. Taxonomy, fermentation, isolation, physiochemical characteristics and biological activities. Oohata N, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):757-62

A new aromatase inhibitor, FR901537. II. Pharmacological and antitumor effects. Oohata N, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):763-7

PANTHERINE see **MUSCIMOL**

PANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOTHENIC ACID

ANALYSIS

Determination of pantothenic acid in infant milk formulas by high performance liquid chromatography. Romera JM, et al. **J Dairy Sci** 1996 Apr;79(4):523-6

[B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities] Kirchgessner M, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):20-4 (Eng. Abstr.) **(Ger)**

BLOOD

Pantothenic acid uptake and metabolism by red blood cells of rats. Annous KF, et al. **J Nutr** 1995 Oct;125(10):2586-93

[Pantothenic acid] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:697-700 (10 ref.) **(Jpn)**

DEFICIENCY

Pantothenic acid deficiency as the pathogenesis of acne vulgaris. Leung LH. **Med Hypotheses** 1995 Jun;44(6):490-2

PHARMACOLOGY

Pantothenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Slyshenkov VS, et al. **Free Radic Biol Med** 1995 Dec;19(6):767-72

Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). Sato M, et al. **Teratology** 1995 Sep; 52(3):143-8

THERAPEUTIC USE

Pantothenic acid deficiency as the pathogenesis of acne vulgaris. Leung LH. **Med Hypotheses** 1995 Jun;44(6):490-2

Pantothenic acid as a weight-reducing agent: fasting without hunger, weakness and ketosis. Leung LH. **Med Hypotheses** 1995 May;44(5):403-5

PANUVEITIS

COMPLICATIONS

Bilateral panuveitis in a patient with colonic adenocarcinoma and Streptococcus milleri liver abscesses [letter] Churchill AJ, et al. **Eye** 1995;9 (Pt 3):372-5

DIAGNOSIS

A change in ocular involvement in a patient suffering from ankylosing spondylitis and Behçet's disease. Beiran I, et al. **Eur J Ophthalmol** 1995 Jul-Sep;5(3):192-4

IMMUNOLOGY

Lymphocyte proliferation response to S antigen in patients with uveitis and optic neuritis. Ren P, et al. **Yen Ko Hsueh Pao** 1995 Sep;11(3):120-3

THERAPY

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H [letter] Isaacs JD, et al. **Br J Ophthalmol** 1995 Nov;79(11):1054-5

PAP-I see **ANNEXIN V**

PAP-II see **ANNEXIN IV**

PAP-III see **ANNEXIN III**

PAPAIN

ADMINISTRATION & DOSAGE

[Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma] Lahousen M. **Wien Med Wochenschr** 1995;145(24):663-8 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Inactivation of cysteine proteases. Govardhan CP, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):110-4

Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. Meara JP, et al. **J Med Chem** 1996 Aug 16;39(17):3357-66

GENETICS

Engineering nitrile hydratase activity into a cysteine protease by a single mutation. Dufour E, et al. **Biochemistry** 1995 Dec 19;34(50):16382-8

IMMUNOLOGY

Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. Baur X, et al. **Allergy** 1995 Jul;50(7):604-9

Association between sensitization to natural rubber latex and papain. Vandenplas O, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1421-4

METABOLISM

The influence of caldesmon on papain proteolysis of monomeric smooth muscle myosin. Kulikova N, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):195-202

Porous zirconia: a new support material for enzyme immobilization. Huckel M, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3-4):165-79

Plasma cholesterol-suppressing effect of papain-hydrolyzed pork meat in rats fed hypercholesterolemic diet. Morimatsu F, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr; 42(2):145-53

PHARMACOLOGY

Critical review of protease-treated red cell tests for the detection of irregular blood group antibodies during pregnancy [letter] Jemmolo G, et al. **Vox Sang** 1995; 69(2):144

THERAPEUTIC USE

The use of vegetable proteolytic enzymes in the treatment of surgical diseases. Karski J, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:125-8

TOXICITY

Effect of papain on different phases of prenatal ontogenesis in rats. Schmidt H. **Reprod Toxicol** 1995 Jan-Feb;9(1):49-55

PAPANICOLAOU SMEAR see **VAGINAL SMEARS**

PAPAVER

see related
OPIUM

CHEMISTRY

Determination of morphine and related alkaloids in crude morphine, poppy straw and opium preparations by micellar electrokinetic capillary chromatography. Trenerry VC, et al. **J Chromatogr A** 1995 Dec 1;718(1):217-25

ENZYMOLOGY

Purification and properties of codeinone reductase (NADPH) from Papaver somniferum cell cultures and differentiated plants. Lenz R, et al. **Eur J Biochem** 1995 Oct 1; 233(1):132-9

GENETICS

DNA polymorphism analysis in five endangered species of Meconopsis (Himalayan poppy) using multi-copy sequence-based probes. Sulaiman IM, et al. **Electrophoresis** 1995 Sep;16(9):1746-9

Molecular analysis of two functional homologues of the S3 allele of the Papaver rhoeas self-incompatibility gene isolated from different populations. Walker EA, et al. **Plant Mol Biol** 1996 Mar;30(5):983-94

Molecular analysis of a new member of the opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylase gene family. Maldonado-Mendoza IE, et al. **Plant Physiol** 1996 Jan;110(1):43-9

METABOLISM

Absorption, translocation, and accumulation of carbendazim in opium poppy (Papaver somniferum L.). Banerji R, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):283-8

Uncoupled defense gene expression and antimicrobial alkaloid accumulation in elicited opium poppy cell cultures. Facchini PJ, et al. **Plant Physiol** 1996 Jul;111(3):687-97

PAPAVERETUM see **OPIUM**

PAPAVERINE

ADMINISTRATION & DOSAGE

Intra-arterial infusion of papaverine combined with intravenous administration of high-dose nicardipine for cerebral vasospasm. Yoshimura S, et al. **Acta Neurochir (Wien)** 1995;135(3-4):186-90

Papaverine and prostaglandin E1 gel applications for impotence. Chiang HS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):767-9

Effect of normothermic papaverine to relieve intraoperative spasm of the internal thoracic artery. Bilgen F, et al. **Ann Thorac Surg** 1996 Sep;62(3):769-71

Intracavernosal administration of papaverine in a blind patient. Choi WH, et al. **Br J Urol** 1996 Jun;77(6):922-3

Superselective intraarterial papaverine administration: effect on regional cerebral blood flow in patients with arteriovenous malformations. Fogarty-Mack P, et al. **J Neurosurg** 1996 Sep;85(3):395-402

Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses [see comments] Bechara A, et al. **J Urol** 1996 Mar;155(3):913-4. Comment in: J Urol 1996 Mar;155(3):924-5.

[Endovascular treatment of cerebral vasospasm with intra-arterial papaverine infusion] Kinoshita Y, et al. **No Shinkei Geka** 1995 Oct;23(10):881-7 (Eng. Abstr.) **(Jpn)**

[Long-term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257-69 (25 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Papaverine injures the endothelium of the internal mammary artery. Cooper GJ, et al. **Cardiovasc Surg** 1995 Oct; 3(5):553-5

Risks of self-injection therapy for impotence [letter] Millard RJ, et al. **Med J Aust** 1996 Jul 15;165(2):117-8

ANALOGS & DERIVATIVES

[3H]A-69024: a non-benzazepine ligand for in vitro and in vivo studies of dopamine D1 receptors. Kassiou M, et al. **Life Sci** 1995;57(23):PL367-72

DIAGNOSTIC USE

Endothelial control of lower limb blood flow in chronic heart failure. Lindsay DC, et al. **Heart** 1996 May;75(5):469-76

The clinical assessment of erectile dysfunction: a comparison of nocturnal penile tumescence monitoring and intracavernosal injections. Bancroft J, et al. **Int J Impot Res** 1995 Jun;7(2):123-30

Evaluation of impotent men with intracorporeal injection of papaverine and colour Doppler ultrasound. Cetinkaya M, et al. **Int Urol Nephrol** 1995;27(6):779-82

Myocardial contrast echocardiography for assessment of papaverine vasodilator response in patients with angiographically normal coronary arteries and in patients after orthotopic heart transplantation. Klauss V, et al. **Z Kardiol** 1995 Oct;84(10):852-9

METABOLISM

Protein ligand interactions. Part 5: Isoquinoline alkaloids as inhibitors of acetylcholinesterase from Electrophorus electricus. Whiteley CG, et al. **J Enzym Inhib** 1995; 9(4):285-94

PHARMACOLOGY

Membrane transport of nucleobases: interaction with inhibitors. Kraupp M, et al. **Gen Pharmacol** 1995 Oct; 26(6):1185-90 (29 ref.)

Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study. Miller MA, et al. **Int J Impot Res** 1995 Jun;7(2):91-100

Erectile response to topical, intraurethral and intracorporal pharmacotherapy in a rat model of spinal cord injury. Rivas DA, et al. **J Spinal Cord Med** 1995 Oct;18(4):245-50

Papaverine-sensitive vasospasm and arterial contractility and compliance after subarachnoid hemorrhage in dogs. Macdonald RL, et al. **Neurosurgery** 1995 Nov;37(5):962-7; discussion 967-8

Effects of prostaglandin E1, and papaverine on non-neurogenic and neurogenic contraction of the isolated rabbit erectile tissue. Italiano G, et al. **Pharmacol Res** 1995 May;31(5):313-7

[The effect of nimodipine and papaverine on delayed cerebral vasospasm in dogs] Liu F, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):132-4 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Pharmacological management of erectile dysfunction. Montorsi F, et al. **Drugs** 1995 Sep;50(3):465-79 (59 ref.)

Paradoxical aggravation of vasospasm with papaverine infusion following aneurysmal subarachnoid hemorrhage. Case report. Clyde BL, et al. **J Neurosurg** 1996 Apr;

84(4):690–5
Dilation of the internal mammary artery by external and intraluminal papaverine application. Dregelid E, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):697–703
Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Vidal J, et al. **Rev Neurol** 1995 Mar–Apr;23(120):269–71
[Endovascular treatment of vasospasm] Bracard S, et al. **Ann Fr Anesth Reanim** 1996;15(3):382–6 (Eng. Abstr.) **(Fre)**
[Hylacombun in inflammatory bowel diseases] Príkazska M, et al. **Bratisl Lek Listy** 1996 Feb;97(2):100–5 (Eng. Abstr.) **(Slo)**

PAPER

Paper mill workers and chronic extrinsic allergic alveolitis [letter] Festa JL. **Am Fam Physician** 1996 Apr;53(5):1522–4
Decrements in spirometry values associated with chlorine gassing events and pulp mill work. Henneberger PK, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):225–31
Growth, induction, and substrate specificity of dehydroabietic acid–degrading bacteria isolated from a kraft mill effluent enrichment. Bicho PA, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3245–50
A new filter paper method to measure capillary blood lead level in children. Srivuthana K, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):498–502
Increased incidence of renal cell tumours in a cohort of cardboard workers exposed to trichloroethylene [letter] Bloemen LJ, et al. **Arch Toxicol** 1995;70(2):129–33
Increased incidence of renal cell tumours in a cohort of cardboard workers exposed to trichloroethylene [letter] Swaen GM. **Arch Toxicol** 1995;70(2):127–8, 131–3
PCDD/PCDF levels in the blood of workers at a pulp and paper mill. Rosenberg C, et al. **Chemosphere** 1995 Oct; 31(8):3933–44
Blood collection for screening children for exposure to lead [letter] Delves HT. **Clin Chem** 1996 Jun;42(6 Pt 1):983–5
Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Hoffman BR, et al. **Clin Chem** 1996 Apr;42(4):536–44
Methylmalonic acid quantification by stable isotope dilution gas chromatography–mass spectrometry from filter paper urine samples. McCann MT, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):910–4
Occupational contact dermatitis from colophony and formaldehyde in banknote paper. Koch P. **Contact Dermatitis** 1995 Jun;32(6):371–2
Glycidyl methacrylate and ethoxyethyl acrylate: new allergens in emulsions used to impregnate paper and textile materials. Matura M, et al. **Contact Dermatitis** 1995 Aug; 33(2):123–4
Tolerance to different toilet paper preparations: toxicological and allergological aspects. Blecher P, et al. **Dermatology** 1995;191(4):299–304
A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis. Interleukin-1 and interleukin-1–receptor antagonist. Hendel J, et al. **Dig Dis Sci** 1996 Sep;41(9):1775–9
Physiological toxicity of low-chlorine bleached pulp and paper mill effluent on whitefish (Coregonus lavaretus L. s.l.): a laboratory exposure simulating lake pollution. Soimasuo R, et al. **Ecotoxicol Environ Saf** 1995 Aug; 31(3):228–37
Clinical–epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)
Comparison of the repair of permanent tympanic membrane perforations by hydrocolloidal dressing and paper patch. Spandow O, et al. **J Laryngol Otol** 1995 Nov; 109(11):1041–7
The effect of chopped computer and bond paper mixed with wood shavings as a litter material on broiler performance. Martinez DF, et al. **Poult Sci** 1995 Aug;74(8):1395–9
A novel paper cuff for vascular reconstruction in canine liver transplantation. Fukumoto T, et al. **Surg Today** 1996; 26(4):295–7

PAPILLARY MUSCLES

see related
CHORDAE TENDINEAE

Pitfalls in the diagnosis and management of papillary muscle rupture: a study of four cases and review of the literature. Samman B, et al. **Clin Cardiol** 1995 Oct;18(10):591–6 (34 ref.)
Preservation of papillary muscles and chordae during mitral valve replacement: possibilities and limitations. Hetzer R, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S115–23
Transaortic video-assisted excision of a left ventricular papillary fibroelastoma. Allen KB, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):199–201
Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)
[Emergency CABG and mitral valve replacement for anterolateral papillary muscle rupture after acute myocardial infarction] Goh K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1034–8 (Eng. Abstr.) **(Jpn)**
[Papillary muscle rupture complicating acute myocardial infarction—treatment with mitral valve replacement and coronary bypass surgery in acute phase] Kyo S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):874–81 (23 ref.) (Eng. Abstr.) **(Jpn)**
[A case of papillary muscle rupture associated with acute inferior myocardial infarction] Okada M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1171–5 (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Comparison of cleft and papillary muscle position in cleft mitral valve and atrioventricular septal defect. Kohl T, et al. **Am J Cardiol** 1996 Jan 15;77(2):164–9

ANATOMY & HISTOLOGY

Variations in the papillary muscles of the normal mitral valve and their surgical relevance. Victor S, et al. **J Card Surg** 1995 Sep;10(5):597–607

CYTOLOGY

The effects of phosphocreatine introduced simultaneously into many cardiac cells. Tuganowski W. **Pflugers Arch** 1996 Feb;431(4):652–7

DRUG EFFECTS

Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium. Brown RA, et al. **Acta Diabetol** 1996 Mar;33(1):7–14
Papillary muscles split in the presence of 2,3-butanedione monoxime have normal energetic and mechanical properties. Kiriazis H, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1685–94
The effects of sevoflurane on contractile and electrophysiologic properties in isolated guinea pig papillary muscles. Azuma M, et al. **Anesth Analg** 1996 Mar; 82(3):486–91
EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium. Uhlmann R, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):365–71
Activation or block of adenosine triphosphate–sensitive potassium channel have opposite effects on postcardioplegic myocardial dysfunction, "stunning". A multivariate prediction based on relative operating characteristic curve. Puddu PE, et al. **Cardiologia** 1995 Sep; 40(9):667–77
L-NMMA blocks carbachol-induced increases in cGMP levels but not decreases in tension in the presence of forskolin in rabbit papillary muscles. Hui J, et al. **Cardiovasc Res** 1995 Sep;30(3):372–6
Effects of thapsigargin on aequorin-injected and skinned preparations of ferret ventricular muscles. Tanaka T, et al. **Cardiovasc Res** 1995 Sep;30(3):357–62
Electrophysiological effects of azelastine in isolated guinea pig atrial and ventricular fibers. Kecskeméti V. **Inflamm Res** 1995 Apr;44 Suppl 1:S98–9
Effect of propionyl-L-carnitine on the mechanics of right and left papillary muscles from volume-overloaded rat hearts. Micheletti R, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):52–7
Electromechanical effects of zatebradine on isolated guinea pig cardiac preparations. Pérez O, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):46–54
The influence of 17-beta-oestradiol and the natural oestrous cycle on alpha-adrenoceptor-mediated responses of the cardiovascular system in the rat. Austin C, et al. **J Pharm Pharmacol** 1995 Aug;47(8):656–60
Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. Sosunov EA, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):906–12
Effects of yew alkaloids and related compounds on guinea-pig isolated perfused heart and papillary muscle. Alloatti G, et al. **Life Sci** 1996;58(10):845–54
Does progesterone potentiate the in vitro effect of cocaine on papillary myocardium in Long-Evans rats? Glantz JC, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):563–70

INJURIES

Blunt traumatic rupture of a mitral papillary muscle head. Smedira NG, et al. **Ann Thorac Surg** 1996 May;61(5):1526–8
[Successful valvuloplasty for isolated tricuspid regurgitation due to traumatic ruptured papillary muscle] Noji S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov;43(11):1845–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

Skeletal and cardiac muscle protein turnover during short-term cold exposure and rewarming in young rats. Samuels SE, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1231–9
Intracellular pH and intrinsic H+ buffering capacity in normal and hypertrophied right ventricle of ferret heart. Do E, et al. **Cardiovasc Res** 1996 May;31(5):729–38
Increased resistance to acute respiratory acidosis in isolated cardiac muscle following chronic hypoxia-induced hypertrophy. Neville E, et al. **Cardiovasc Res** 1996 May; 31(5):739–46

PATHOLOGY

Cardiac papillary fibroelastoma: an immunohistochemical investigation and unusual clinical manifestations. Rubin MA, et al. **Mod Pathol** 1995 May;8(4):402–7
Postinfarct cardiac free wall rupture: the relationship of rupture site to papillary muscle insertion. Veinot JP, et al. **Mod Pathol** 1995 Aug;8(6):609–13
Papillary fibroelastoma of the mitral valve in a 3-year-old child: case report. de Menezes IC, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):194–5
[Circulatory support with Hemopump in cardiogenic shock secondary to papillary muscle rupture] Salvi L, et al. **Cardiologia** 1995 Nov;40(11):865–8 (Eng. Abstr.) **(Ita)**
[Papillary muscle rupture in myocardial infarction] Zalaquett R, et al. **Rev Med Chil** 1995 Feb;123(2):199–206 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Papillary muscles split in the presence of 2,3-butanedione monoxime have normal energetic and mechanical properties. Kiriazis H, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1685–94
Load dependence of double-exponential time constant [letter] Matsubara H, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2228–9
Mechanical restitution and recirculation fraction in cardiac myocytes and left ventricular muscle of adult rats. Ravens U, et al. **Basic Res Cardiol** 1996 Mar–Apr;91(2):123–30
Intramyocardial pressure measurements in the isolated perfused papillary muscle of rat heart. Heslinga JW, et al. **Eur J Morphol** 1996;34(1):55–62
Active force in rabbit ventricular myocytes. Bluhm WF, et al. **J Biomech** 1995 Sep;28(9):1119–22
The length dependence of work production in rat papillary muscles in vitro. Layland J, et al. **J Exp Biol** 1995 Dec; 198 (Pt 12):2491–9
Influence of muscle length on work from trabecular muscle of frog atrium and ventricle. Syme DA, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2221–7
The role of aging on the control of contractile force by Na(+)-Ca2+ exchange in rat papillary muscle. Abete P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M251–9
Influence of dietary polyunsaturated fatty acids on contractility, lusitropy and compliance of isolated rat myocardium. Chemla D, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1745–55
Quantification of the voltage-response relationship between punctate and field electrical stimulation and the function of isolated rat left atria and papillary muscles. Olson RD, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):225–30
Electrical heterogeneity and conduction block in reoxygenated guinea pig papillary muscles. Hayashi H, et al. **Jpn Heart J** 1996 May;37(3):383–91
Inhibition by multivalent cations of contraction induced by Chinese cobra venom cardiotoxin in guinea pig papillary muscle. Huang SJ, et al. **Life Sci** 1996;59(4):PL55–60
[Effects of preserving mitral apparatus on left ventricular systolic function and geometry in mitral valve replacement] Hashimoto R, et al. **Kyobu Geka** 1995 Nov;48(12):997–1001 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Excessive papillary muscle traction and dilated mitral annulus in mitral valve prolapse without mitral regurgitation. Lee TM, et al. **Am J Cardiol** 1996 Aug 15;78(4):482–5
Effect of stretch on contraction and the Ca2+ transient in ferret ventricular muscles during hypoxia and acidosis. Hongo K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C690–7
Acute infarction of the left ventricular papillary muscle: electrocardiographic pattern and recognition of its location. Dąbrowska B, et al. **Clin Cardiol** 1996 May;19(5):404–7

ULTRASONOGRAPHY

The clinical utility of transesophageal echocardiography in ischemic papillary muscle rupture. Herrera CJ, et al. **Am J Card Imaging** 1995 Jul;9(3):226–8
Comparison of cleft and papillary muscle position in cleft mitral valve and atrioventricular septal defect. Kohl T, et al. **Am J Cardiol** 1996 Jan 15;77(2):164–9
Transesophageal echocardiography as an important tool in the diagnosis of postinfarction papillary muscle rupture. Singh A, et al. **Cardiology** 1995;86(5):417–20
Transesophageal echocardiographic assessment of papillary muscle rupture. Moursi MH, et al. **Circulation** 1996 Sep 1;94(5):1003–9

ULTRASTRUCTURE

Atrioventricular valves of the mouse: III. Collagenous skeleton and myotendinous junction. Icardo JM, et al. **Anat Rec** 1995 Nov;243(3):367–75

PAPILLEDEMA

see related
OPHTHALMOSCOPY

GAPO syndrome: report on the first case in Japan. Moriya N, et al. **Am J Med Genet** 1995 Sep 11;58(3):257–61

COMPLICATIONS

Rapidly progressive optic disk neovascularization after diabetic papillopathy. Ho AC, et al. **Am J Ophthalmol** 1995 Nov;120(5):673–5
Branch retinal arterial occlusions in multifocal retinitis with

optic nerve edema. Cohen SM, et al. **Arch Ophthalmol** 1995 Oct;113(10):1271–6

Severe hypertension with lone bilateral papilloedema: a variant of malignant hypertension. Lip GY, et al. **Blood Press** 1995 Nov;4(6):339–42

DIAGNOSIS

MR of optic papilla protrusion in patients with high intracranial pressure. Jinkins JR, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):665–8

Magnetic resonance visualization of the swollen optic disc in papilledema. Brodsky MC, et al. **J Neuroophthalmol** 1995 Jun;15(2):122–4

Bilateral disc edema in an adolescent girl. Kosmorsky GS, et al. **J Neuroophthalmol** 1995 Sep;15(3):176–7

The diagnostic value of optic disc evaluation in acute elevated intracranial pressure. Steffen H, et al. **Ophthalmology** 1996 Aug;103(8):1229–32

Six signs in children with life–threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

Pickwickian syndrome and indications for surgically induced weight loss [letter; comment] Sugerman HJ, et al. **Surv Ophthalmol** 1995 Jul–Aug;40(1):87–8. Comment on: Surv Ophthalmol 1995 Jan–Feb;39(4):307–14.

[Papilledema as the first manifestation of Behçet's disease (letter)] Ginés MA, et al. **An Med Interna** 1996 May; 13(5):255–6 **(Spa)**

ETIOLOGY

Papilledema following bowtie optic atrophy. Ing EB, et al. **Arch Ophthalmol** 1996 Mar;114(3):356–7

Pigmentary irregularities and optic disc edema after heart transplantation. Klaver CC, et al. **Arch Ophthalmol** 1995 Oct;113(10):1281–5

Optic nerve diameters and perimetric thresholds in idiopathic intracranial hypertension. Salgarello T, et al. **Br J Ophthalmol** 1996 Jun;80(6):509–14

[Incidence of ophthalmologic complications in acute intracranial hypertension] Mueller AJ, et al. **Ophthalmologe** 1995 Oct;92(5):708–13 (Eng. Abstr.) **(Ger)**

[Two cases of systemic lupus erythematosus presenting with disc edema] Masai H, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jun;100(6):478–81 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Bilateral optic disc edema and multifocal retinal lesions without loss of vision in cat scratch disease [letter] Bafna S, et al. **Arch Ophthalmol** 1996 Aug;114(8):1016–7

PARASITOLOGY

[Acute Trypanosoma brucei gambiense meningoencephalitis detected by papillary edema] Zola JM, et al. **Bull Soc Pathol Exot** 1994;87(5):312–4 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Fluorescein angiography in nonischemic optic disc edema. Arnold AC, et al. **Arch Ophthalmol** 1996 Mar;114(3):293–8

Detection of dilated subarachnoid space around the optic nerve in patients with papilloedema using T2 weighted fast spin echo imaging [letter] Imamura Y, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):108–9

PHYSIOPATHOLOGY

[Increasing vision disorder (clinical conference)] Kolakovic P, et al. **Schweiz Rundsch Med Prax** 1996 Feb 27; 85(9):283–6 (Eng. Abstr.) **(Ger)**

PAPILLOMA

see related
WARTS

[Gallbladder papilloma] Ono T, et al. **Ryofkibetsu Shokogun Shirizu** 1996;(9):324–5 (17 ref.) **(Jpn)**

[Intrahepatic biliary papillomatosis] Terada T, et al. **Ryofkibetsu Shokogun Shirizu** 1995;(7):411–3 (7 ref.) **(Jpn)**

[Biliary papillomatosis] Tsuneyama K, et al. **Ryofkibetsu Shokogun Shirizu** 1996;(9):81–4 (16 ref.) **(Jpn)**

CHEMICALLY INDUCED

Lack of tumor promoting effects of KCB–1, a recombinant human basic fibroblast growth factor, on two–stage skin carcinogenesis in female CD–1 (ICR) mice. Tanaka H, et al. **Cancer Lett** 1996 Aug 2;105(2):195–202

Inhibition of 12–O–tetradecanoylphorbol–13–acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue. Tokuda H, et al. **Cancer Lett** 1996 Jun 24;104(1):91–5

Inhibitory effect of dietary flavonol quercetin on 7,12–dimethylbenz[a]anthracene–induced hamster buccal pouch carcinogenesis. Balasubramanian S, et al. **Carcinogenesis** 1996 Apr;17(4):877–9

Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Battalora MS, et al. **Carcinogenesis** 1996 May;17(5):955–60

Mutation in the p53 tumor suppressor gene in rat esophageal papillomas induced by N–nitrosomethylbenzylamine. Wang D, et al. **Carcinogenesis** 1996 Apr;17(4):625–30

Overexpression of cyclin D1 and cyclin E in N–nitrosomethylbenzylamine–induced rat esophageal tumorigenesis. Wang QS, et al. **Carcinogenesis** 1996 Aug; 17(8):1583–8

Increased risk of cancer in the descendants of Syrian hamsters exposed prenatally to diethylnitrosamine (DEN). Mohr U, et al. **Int J Cancer** 1995 Sep 27;63(1):86–91

Constitutive expression of B7–1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. Williams IR, et al. **J Immunol** 1996 May 1;156(9):3382–8

Dose–time response in mouse skin tumor induction by 7, 12–dimethylbenz[a]anthracene and 12–O–tetradecanoyl–phorbol–13–acetate. Lutz WK, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):44–8

[Skin carcinogenesis induced be neonatal administration of 5–bromo–2'–deoxyuridine and subsequent treatment with 12–O–tetradecanoylphorbol–13–acetate in mice] Anisimov VN, et al. **Vopr Onkol** 1996;42(1):82–4 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression. Van Waes C, et al. **Cancer Res** 1995 Nov 15; 55(22):5434–44

Selective reduction in alpha–hydroxypalmitic acid–containing sphingomyelin and concurrent increase in hydroxylated ceramides in murine skin tumors induced by an initiation–promotion regimen. Kitano Y, et al. **Jpn J Cancer Res** 1996 May;87(5):437–41

COMPLICATIONS

Focal dermal hypoplasia (Goltz syndrome) associated with multiple giant papillomas. Kore–Eda S, et al. **Br J Dermatol** 1995 Dec;133(6):997–9

Ichthyosis uteri associated with a uterine squamous papilloma. Kücükali T, et al. **Eur J Gynaecol Oncol** 1996; 17(1):37–41

An unusual reason for obstructive sleep apnea in a boy with hemophilia B: supraglottic papilloma. Jakubíková J, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):165–9

Intraductal papilloma as a cause of a parotid duct cyst. A case report. Alho OP, et al. **J Laryngol Otol** 1996 Mar; 110(3):277–8

[Diffuse papillomatosis of the biliary and pancreatic ducts: a rare association and a potentially malignant disease (letter)] Denie C, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):845–7 **(Fre)**

[Hemorrhagic esophageal papilloma associated with the ingestion of non–steroidal anti–inflammatory agents (letter)] Mastour M, et al. **Gastroenterol Clin Biol** 1996; 20(4):406–7 **(Fre)**

DIAGNOSIS

Transitional cell neoplasms (carcinomas and inverted papillomas) of the uterine cervix. A report of five cases. Albores–Saavedra J, et al. **Am J Surg Pathol** 1995 Oct; 19(10):1138–45

Schneiderian–type mucosal papillomas of the middle ear and mastoid. Wenig BM. **Ann Otol Rhinol Laryngol** 1996 Mar; 105(3):226–33

Choroid plexus papilloma of the III ventricle in an infant. Shuto T, et al. **Childs Nerv Syst** 1995 Nov;11(11):664–6

[2 cases of brain tumors with the primary manifestations as endocrine functional disorders] Zykova TA, et al. **Klin Med (Mosk)** 1995;73(3):58–9 **(Rus)**

DRUG THERAPY

Successful treatment of papillomatosis cutis lymphostatica with acitretin [letter] Feind–Koopmans A, et al. **Acta Derm Venereol** 1995 Sep;75(5):411

Vocal fold submucosal infusion technique in phonomicrosurgery. Kass ES, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):341–7

Efficacy of intravenous delta–aminolaevulinic acid photodynamic therapy on rabbit papillomas. Lofgren LA, et al. **Br J Cancer** 1995 Oct;72(4):857–64

Anti–tumor promoting activity of Dryopteris phlorophenone derivatives. Kapadia GJ, et al. **Cancer Lett** 1996 Aug 2; 105(2):161–5

Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C. Stanwell C, et al. **Carcinogenesis** 1996 Jun;17(6):1259–65

Confluent and reticulated papillomatosis: response to topical calcipotriol [letter] Kürkçüoğlu N, et al. **Dermatology** 1995; 191(4):341–2

Confluent and reticulated papillomatosis (Gougerot–Carteaud) treated with tetracyclines. Angeli–Besson C, et al. **Int J Dermatol** 1995 Aug; 34(8):567–9

Confluent and reticulated papillomatosis: response to minocycline. Montemarano AD, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):253–6

[Papillomatosis confluens et reticularis. Successful therapy with minocycline] Kretzschmar L, et al. **Hautarzt** 1996 Mar;47(3):209–13 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Studies of the activities of lysosomal enzymes in serum and buccal pouch tissue of hamsters during 7,12–dimethylbenz[a]anthracene–induced carcinogenesis. Balasubramanian S, et al. **Cancer Lett** 1996 Mar 19; 101(1):9–14

Increased telomerase activity in mouse skin premalignant progression. Bednarek A, et al. **Cancer Res** 1995 Oct 15; 55(20):4566–9

Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C. Stanwell C, et al. **Carcinogenesis** 1996 Jun;17(6):1259–65

Immunohistochemically demonstrated variation in expression of cathepsin E between uracil–induced papillomatosis and N–butyl–N–(4–hydroxybutyl)nitrosamine–induced preneoplastic and neoplastic changes in rat urinary bladder. Yamamoto S, et al. **Virchows Arch** 1996 Mar;427(6):589–94

EPIDEMIOLOGY

Task force on recurrent respiratory papillomas. A preliminary report. Derkay CS. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1386–91

ETIOLOGY

Confluent and reticulated papillomatosis associated with atopy. Successful treatment with topical urea and tretinoin [letter] Kägi MK, et al. **Br J Dermatol** 1996 Feb; 134(2):381–2

A case of stasis papillomatosis associated with psoriasis vulgaris. Sato T, et al. **J Dermatol** 1996 May;23(5):352–6

Modulatory influence of arecanut on the mouse hepatic xenobiotic detoxication system and skin papillomagenesis. Singh A, et al. **Teratog Carcinog Mutagen** 1995;15(3):135–46

GENETICS

Inhibition of pro–inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. Robertson FM, et al. **Carcinogenesis** 1996 Aug;17(8):1719–28

Mutation in the p53 tumor suppressor gene in rat esophageal papillomas induced by N–nitrosomethylbenzylamine. Wang D, et al. **Carcinogenesis** 1996 Apr;17(4):625–30

Infrequent Ha–ras mutations and absence of Ki–ras, N–ras, and p53 mutations in 4–nitroquinoline 1–oxide–induced rat oral lesions. Suzui M, et al. **Mol Carcinog** 1995 Dec; 14(4):294–8

High frequency of papillary renal–cell tumours in end–stage kidneys—is there a molecular genetic explanation? [editorial] Kovacs G. **Nephrol Dial Transplant** 1995; 10(5):593–6

Relating aromatic hydrocarbon–induced DNA adducts and c–H–ras mutations in mouse skin papillomas: the role of apurinic sites. Chakravarti D, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10422–6

IMMUNOLOGY

Leukocyte proliferation in vitro against cottontail rabbit papillomavirus in rabbits with persisting papillomas/cancer or after regression. Höpfl R, et al. **Arch Dermatol Res** 1995; 287(7):652–8

Enriched HLA–DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Bonagura VR, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):357–60

MAUB is a new mucin antigen associated with bladder cancer. Bergeron A, et al. **J Biol Chem** 1996 Mar 22; 271(12):6933–40

[Antibodies to alpha–2A interferon in children with juvenile respiratory papillomatosis] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):24–6 (Eng. Abstr.) **(Rus)**

[Inverted transitional–cell papilloma: the expression of the Ki–67 nuclear antigen as a prognostic factor] Valero Puerta JA, et al. **Arch Esp Urol** 1995 Nov;48(9):887–92 (Eng. Abstr.) **(Spa)**

METABOLISM

Alterations in transforming growth factor–alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. Wang QS, et al. **Mol Carcinog** 1996 Feb;15(2):144–53

PATHOLOGY

A choroid plexus papilloma arising from an incidental pineal cyst. Steven DA, et al. **AJNR Am J Neuroradiol** 1996 May; 17(5):939–42

Fibroepithelioma of Pinkus: eccrine duct spread of basal cell carcinoma [letter; comment] Sina B, et al. **Am J Dermatopathol** 1995 Dec;17(6):634–6. Comment on: Am J Dermatopathol 1994 Dec;16(6):585–7.

Oral papillary plasmacytosis cleared by radiotherapy. Lee MS, et al. **Br J Dermatol** 1996 May;134(5):945–8

Carcinogenesis in human skin grafted to SCID mice. Soballe PW, et al. **Cancer Res** 1996 Feb 15;56(4):757–64

Fluorescence spectroscopic identification of 7,12–dimethylbenz[a]anthracene–induced hamster buccal pouch carcinogenesis. Balasubramanian S, et al. **Carcinogenesis** 1995 Oct;16(10):2461–5

Adenosquamous carcinoma and schneiderian papilloma–like lesion in a mature cystic teratoma of the ovary: a case report. Hsu CY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):375–9

Squamous papilloma of the esophagus. Lio WJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun;57(6):413–7

Stomal malignant transformation of respiratory papilloma, with neck metastasis: case report. Shamboul K. **East Afr Med J** 1996 May;73(5):336–8

Vulvar papillomatosis, aceto–white lesions, and normal–looking vulvar mucosa evaluated by microscopy and human papillomavirus analysis. Strand A, et al. **Gynecol Obstet Invest** 1995;40(4):265–70

Confluent and reticulated papillomatosis (Gougerot–Carteaud) treated with tetracyclines. Angeli–Besson C, et al. **Int J Dermatol** 1995 Aug; 34(8):567–9

Lid lesions suspected of malignancy. Hilovsky JP. **J Am Optom Assoc** 1995 Aug;66(8):510–5

Papillomatous melanocytic nevi: an estrogen related phenomenon. Morgan MB, et al. **J Cutan Pathol** 1995 Oct; 22(5):446–9

Laryngeal carcinoma ex–papilloma in a non–irradiated, non–smoking patient: a clinical record and review of the literature. Hasan S, et al. **J Laryngol Otol** 1995 Aug; 109(8):762–6 (33 ref.)

Choroid plexus carcinoma in the lateral ventricle—case report. Hashizume A, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):742–4

Histologic and biomolecular aspects of papillomatosis of the vulvar vestibule in relation to human papillomavirus. de Deus JM, et al. **Obstet Gynecol** 1995 Nov;86(5):758–63

Malignant acanthosis nigricans with florid papillary oral lesions. Tyler MT, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):445–9

Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ. McKinney CD, et al. **Pathol Annu** 1995;30 Pt 2:137–78 (47 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15 ref.)

Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dendrocyte populations in human papillomavirus–associated squamous intraepithelial lesions of the cervix. al–Saleh W, et al. **Virchows Arch** 1995; 427(1):41–8

[Anti–promoting and anti–mutagenic actions of G9315] Fu N, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):349–52 (Eng. Abstr.) **(Chi)**

[Squamous esophageal papillomas] Vandenborre K, et al. **Ned Tijdschr Geneeskd** 1996 May 4;140(18):987–90 (Eng. Abstr.) **(Dut)**

[Florid oral papillomatosis: evaluation apropos of 2 cases] Stoll D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989; 110(3):303–4 (Eng. Abstr.) **(Fre)**

[Pediatric laryngeal papillomatosis: our experience (three cases)] Rodrigo Chiner O, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):365–6 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Adult onset laryngeal papillomatosis. Gardner GM, et al. **Ear Nose Throat J** 1996 Jul;75(7):404

PREVENTION & CONTROL

Inhibitory effects of chlorophyllin on chemically induced mutagenesis and carcinogenesis. Surh YJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:246–9

Anti–tumor–promoting activities of euglobals from Eucalyptus plants. Takasaki M, et al. **Biol Pharm Bull** 1995 Mar;18(3):435–8

Inhibitory effect of rikkunshi–to, a traditional Chinese herbal prescription, on tumor promotion in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Biol Pharm Bull** 1995 May;18(5):730–3

Effect of free fatty acids on two–stage skin carcinogenesis in mice. Ramesh G, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):199–209

Inhibition of 12–O–tetradecanoylphorbol–13–acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue. Tokuda H, et al. **Cancer Lett** 1996 Jun 24;104(1):91–5

Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats. Hirose Y, et al. **Carcinogenesis** 1995 Oct;16(10):2337–42

Evaluation of chemopreventive effect of dietary selenium–rich egg on mouse skin tumor induced by 2'–(4–nitrophenoxy)oxirane and 12–O–tetradecanoylphorbol–13–acetate. Oh SH, et al. **Carcinogenesis** 1995 Dec;16(12):2995–8

Modulatory influence of chlorophyllin on the mouse skin papillomagenesis and xenobiotic detoxication system. Singh A, et al. **Carcinogenesis** 1996 Jul;17(7):1459–63

Constitutive expression of B7–1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. Williams IR, et al. **J Immunol** 1996 May 1;156(9):3382–8

Effects of dietary n–3, n–6 and n–9 polyunsaturated fatty acids on benzo(a)pyrene–induced forestomach tumorigenesis in C57BL6J mice. Silva RA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):273–7

Vaccination with yeast–expressed cottontail rabbit papillomavirus (CRPV) virus–like particles protects rabbits from CRPV–induced papilloma formation. Jansen KU, et al. **Vaccine** 1995 Nov;13(16):1509–14

[Inhibition of ornithine decarboxylase activity and epidermal papilloma in mice by beta–carotene] Tan A, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):360–2 (Eng. Abstr.) **(Chi)**

[A preliminary observation of preventive and blocking effect of Gynostemma pentaphyllum (Thunb) Makino on esophageal cancer in rats] Wang C, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):430–2 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

CT imaging of the brain lateral ventricular papillomas. Złomaniec J, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:25–8

CT findings of malignant change in recurrent respiratory papillomatosis. Lui D, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):804–7

RADIOTHERAPY

Oral papillary plasmacytosis cleared by radiotherapy. Lee MS, et al. **Br J Dermatol** 1996 May;134(5):945–8

SURGERY

Vocal fold submucosal infusion technique in phonomicrosurgery. Kass ES, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):341–7

Tracheotomy in children with juvenile–onset recurrent respiratory papillomatosis: the Children's Hospital of Pittsburgh experience. Shapiro AM, et al. **Ann Otol Rhinol Laryngol** 1996 Jan;105(1):1–5

Surgical management of pulmonary carcinoma secondary to recurrent respiratory papillomatosis. Sakopoulos A, et al. **Ann Thorac Surg** 1995 Dec;60(6):1806–7

Late recurrences of laryngeal papillomatosis. Erisen L, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep; 122(9):942–4

A new guide wire papillotome for patients with Billroth II gastrectomy. Wang YG, et al. **Endoscopy** 1996 Feb; 28(2):254–5

[Differential diagnosis and prognosis of 112 excised epibulbar epithelial tumors] Seitz B, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):239–46 (Eng. Abstr.) **(Ger)**

THERAPY

[Laryngeal papillomatosis in children: therapeutic problems apropos of 39 cases at the Lomé University Hospital Center] Kpemissi E, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):335–8 (Eng. Abstr.) **(Fre)**

[The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence] Korovin AI, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):19–21 (Eng. Abstr.) **(Rus)**

VETERINARY

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)

Canine conjunctival papilloma: a review of five cases. Sansom J, et al. **J Small Anim Pract** 1996 Feb;37(2):84–6

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Suzich JA, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11553–7

Spirochetes isolated from dairy cattle with papillomatous digital dermatitis and interdigital dermatitis. Walker RL, et al. **Vet Microbiol** 1995 Dec;47(3–4):343–55

VIROLOGY

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Pou AM, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):758–62

Juvenile laryngeal papillomatosis from an HPV–positive mother. A case report. Alberico S, et al. **Clin Exp Obstet Gynecol** 1995;22(3):243–6

Ultrastructure and human papillomavirus DNA in papillomatosis of external auditory canal. Xia MY, et al. **Int J Dermatol** 1996 May;35(5):337–9

HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma. Saegusa M, et al. **J Clin Pathol** 1995 Dec;48(12):1106–10

Diet–modified sex hormone metabolism: is this the way forward in recurrent respiratory papillomatosis and squamous carcinoma prophylaxis? Colquhoun–Flannery W, et al. **J Laryngol Otol** 1995 Sep;109(9):873–5

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

Deletion in the L1 open reading frame of human papillomavirus type 6a genomes associated with recurrent laryngeal papilloma. Suzuki T, et al. **J Med Virol** 1995 Nov;47(3):191–7

Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. DiLorenzo TP, et al. **J Virol** 1995 Nov; 69(11):6865–72

High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA. Kreider JW, et al. **J Virol Methods** 1995 Oct;55(2):233–44

Detection of human papillomavirus in juvenile laryngeal papillomatosis using polymerase chain reaction. Gómez MA, et al. **Medicina (B Aires)** 1995;55(3):213–7

High efficiency, long–term clinical expression of cottontail rabbit papillomavirus (CRPV) DNA in rabbit skin following particle–mediated DNA transfer. Xiao W, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2620–2

Vaccination with yeast–expressed cottontail rabbit papillomavirus (CRPV) virus–like particles protects rabbits from CRPV–induced papilloma formation. Jansen KU, et al. **Vaccine** 1995 Nov;13(16):1509–14

[Human papillomavirus 6/11 in conjunctival papilloma] Michel JL, et al. **Ann Dermatol Venereol** 1996;123(2):90–2 (Eng. Abstr.) **(Fre)**

[A case of conjunctival raspberry tumor of viral origin] Bazin S, et al. **J Fr Ophtalmol** 1996;19(2):140–2 (Eng. Abstr.) **(Fre)**

PAPILLOMA, CHOROID PLEXUS see GLIOMA

PAPILLOMA, INTRADUCTAL

PATHOLOGY

Ductal adenoma of the breast and the Carney complex [letter] Carney JA, et al. **Am J Surg Pathol** 1996 Sep;20(9):1154–5

Technical note: magnetic resonance imaging–guided pre–operative breast localization using "freehand technique". Brenner RJ, et al. **Br J Radiol** 1995 Oct; 68(814):1095–8

Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Page DL, et al. **Cancer** 1996 Jul 15; 78(2):258–66

Fine–needle aspiration cytology of ductal adenoma: report of a case associated with a mucocele–like lesion. Mesonero CE, et al. **Diagn Cytopathol** 1995 Oct;13(3):252–6

Multiple intraductal papillomas and sclerosing adenosis in the male breast. Prabhakar BR. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S9–10

PAPILLOMA, INVERTED

Inverted papilloma isolated to the sphenoid sinus. Peters BW, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):771–7

[Urothelial inverted papilloma] Rodríguez–Rubio FI, et al. **Actas Urol Esp** 1995 Sep;19(8):611–9 (49 ref.) (Eng. Abstr.) **(Spa)**

[Synchronous manifestation of bladder inverted papilloma and transitional carcinoma of the renal pelvis] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Dec;48(10):1047–50 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Biological characteristics of inverted papilloma of the urinary bladder. Urakami S, et al. **Br J Urol** 1996 Jan;77(1):55–60

COMPLICATIONS

Inverting papilloma presenting with meningitis [letter] Granet KM, et al. **Laryngoscope** 1996 Jun;106(6):688

DIAGNOSIS

The role of cystoscopy before radical prostatectomy. Schwartz BF, et al. **Br J Urol** 1996 Jan;77(1):93–5

[Inverted papilloma. Apropos of a multicentric case] Altug T, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989; 110(3):299–301 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. Cheon J, et al. **J Korean Med Sci** 1995 Apr; 10(2):103–10

Inverted papilloma: an unusual recurrent, multiple and multifocal lesion. Rozanski TA. **J Urol** 1996 Apr; 155(4):1391

Squamous cell carcinoma arising in inverted papilloma. Lesperance MM, et al. **Laryngoscope** 1995 Feb; 105(2):178–83

Management of the frontal sinus with inverted papilloma. Shohet JA, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):649–52 (14 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15

ref.)
[Clinical studies of inverted papilloma of the bladder] Tsujimura A, et al. **Hinyokika Kiyo** 1996 Jun;42(6):423–6 (Eng. Abstr.) **(Jpn)**
[Inverted papilloma of the female urethra] Viguri Díaz A, et al. **Arch Esp Urol** 1995 Nov;48(9):954–6 (8 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Management of inverted papilloma. Graham SM, et al. **Head Neck** 1995 Mar–Apr;17(2):148–51
Bilateral lateral rhinotomy for resection of bilateral inverted papilloma. Hosal SA, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):103–5

ULTRASTRUCTURE

Inverted ductal papilloma of minor salivary gland origin: morphological aspects and cytokeratin expression. de Sousa SO, et al. **Eur Arch Otorhinolaryngol** 1995;252(6):370–3

VIROLOGY

Human papillomavirus types important in progression of inverted papilloma. Beck JC, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):558–63

PAPILLOMA, SHOPE see **TUMOR VIRUS INFECTIONS**

PAPILLOMA, SQUAMOUS CELL see **PAPILLOMA**

PAPILLOMA VIRUS DNA PROBES see **DNA PROBES, HPV**

PAPILLOMA VIRUS, SHOPE see **PAPILLOMAVIRUS SYLVILAGI**

PAPILLOMATOSIS see **PAPILLOMA**

PAPILLOMAVIRUS

see related
CONDYLOMATA ACUMINATA

Human papilloma–virus classified as carcinogenic [news] Mayor S. **BMJ** 1996 Jul 13;313(7049):70
Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Pilotti S, et al. **Diagn Mol Pathol** 1995 Dec; 4(4):239–48
Roots and perspectives of contemporary papillomavirus research. zur Hausen H. **J Cancer Res Clin Oncol** 1996; 122(1):3–13 (133 ref.)
Papillomavirus infection in raccoons (Procyon lotor). Hamir AN, et al. **J Vet Diagn Invest** 1995 Oct;7(4):549–51
[The beneficial effect of immunological and antiviral preparations in herpetic and papillomatosis infections] Topciu V, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec;40(3–4):257–60 **(Rum)**
[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja–Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Tan TM, et al. **Cancer Res** 1995 Oct 15;55(20):4599–605
Deletion in human chromosome region 12q13–15 by integration of human papillomavirus DNA in a cervical carcinoma cell line. Gallego MI, et al. **J Biol Chem** 1995 Oct 13;270(41):24321–6
Cellular factors required for papillomavirus DNA replication. Melendy T, et al. **J Virol** 1995 Dec;69(12):7857–67
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus–like particles. Heino P, et al. **Virology** 1995 Dec 20; 214(2):349–59

GROWTH & DEVELOPMENT

Human papilloma virus proliferation in a healing burn. Camilleri IG, et al. **Burns** 1996 Mar;22(2):162–3

ISOLATION & PURIFICATION

Spontaneous mutation of p53 gene in human papillomavirus type 16 E7–immortalized human laryngeal epithelial cells. Suzuki T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 522:94–8
An experimental model of multistep laryngeal carcinogenesis: combined effect of human papillomavirus type 16 genome and N–methyl–N'–nitro–N–nitrosoguanidine. Tsutsumi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:89–93
Occurrence of human papillomavirus infection in cervical intraepithelial neoplasia. A retrospective histopathological study of 317 cases treated by laser conization. Lie AK, et al. **APMIS** 1995 Oct;103(10):693–8
Detection of human cytomegalovirus in female and male anogenital lesions with papillomavirus–associated dysplastic changes. Mougin C, et al. **Cancer Detect Prev** 1995;19(4):316–24
High incidence of human papillomavirus in 146 cervical carcinomas. A study using three different pairs of consensus primers, and detecting viral genomes with putative deletions. Karlsen F, et al. **Eur J Cancer** 1995; 31A(9):1511–6

ULTRASTRUCTURE

Conserved features in papillomavirus and polyomavirus capsids. Belnap DM, et al. **J Mol Biol** 1996 Jun 7; 259(2):249–63

PAPILLOMAVIRUS, BOVINE

GENETICS

Simple procedure for creation of in–frame deletion mutations throughout an open reading frame. Ludes–Meyers JH, et al. **Biotechniques** 1996 Mar;20(3):433–8
Status and transcriptional activity of a bovine–papillomavirus–1–based expression vector in a recombinant production cell lines. Fibi MR, et al. **Biotechnol Appl Biochem** 1996 Apr;23 (Pt 2):187
Arsenic and chromium enhance transformation of bovine papillomavirus DNA–transfected C3H/10T1/2 cells. Kowalski LA, et al. **Cancer Lett** 1996 May 15;103(1):65–9
Cis and trans requirements for stable episomal maintenance of the BPV–1 replicator. Piirsoo M, et al. **EMBO J** 1996 Jan 2;15(1):1–11
Sp1 is critical for basal and E2–transactivated transcription from the bovine papillomavirus type 1 P89 promoter. Sandler AB, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):189–98
Selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site is regulated through an exonic splicing enhancer and its juxtaposed exonic splicing suppressor. Zheng ZM, et al. **J Virol** 1996 Jul;70(7):469!–9
Characterization of the single–strand–specific BPV–1 origin binding protein, SPSF I, as the HeLa Pur alpha factor. Jurk M, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2799–806
Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Hwang ES, et al. **Oncogene** 1996 Feb 15;12(4):795–803
Bovine papillomavirus type 4 DNA isolated from a skin lesion in a steer. Bloch N, et al. **Vet Rec** 1996 Apr 27; 138(17):414–6
Genetic analysis of the bovine papillomavirus E2 transcriptional activation domain. Breiding DE, et al. **Virology** 1996 Jul 1;221(1):34–43
Transformed mouse cell lines that consist predominantly of cells maintaining bovine papilloma virus at high copy number. Ravnan JB, et al. **Virology** 1995 Nov 10; 213(2):526–34
[Bovine papillomavirus vector] Ohe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2539–44 (16 ref.) **(Jpn)**

IMMUNOLOGY

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus–neutralizing antibodies. Gaukroger JM, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1577–83
Antigenicity of bovine papillomavirus type 1 (BPV–1) L1 virus–like particles compared with that of intact BPV–1 virions. Ghim SJ, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):183–8
Virus–like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Kirnbauer R, et al. **Virology** 1996 May 1;219(1):37–44

ISOLATION & PURIFICATION

Bovine papillomavirus type 4 in Australia. Bloch N, et al. **Aust Vet J** 1995 Jul;72(7):273–4

METABOLISM

Amino acids critical for the functions of the bovine papillomavirus type 1 E2 transactivator. Brokaw JL, et al. **J Virol** 1996 Jan;70(1):23–9
The bovine papillomavirus type 1 E2 transactivator and repressor proteins use different nuclear localization signals. Skiadopoulos MH, et al. **J Virol** 1996 Feb;70(2):1117–24

PHYSIOLOGY

Co–operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. Sedman J, et al. **EMBO J** 1995 Dec 15; 14(24):6218–28
Disparate replication properties of integrated and extrachromosomal forms of bovine papilloma virus in ID13 cells. Ten Hagen KG, et al. **J Mol Biol** 1995 Nov 24; 254(2):119–29
Transcriptional and replicational activation functions in the bovine papillomavirus type 1 E2 protein are encoded by different structural determinants. Abroi A, et al. **J Virol** 1996 Sep;70(9):6169–79
Suppression of cellular proliferation by the papillomavirus E2 protein. Dowhanick JJ, et al. **J Virol** 1995 Dec; 69(12):7791–9
Genetic analysis of the activation domain of bovine papillomavirus protein E2: its role in transcription and replication. Ferguson MK, et al. **J Virol** 1996 Jul; 70(7):4193–9
Replication efficiency of bovine papillomavirus type 1 DNA depends on cis–acting sequences distinct from the replication origin. Pierrefite V, et al. **J Virol** 1995 Dec; 69(12):7682–7
In vitro generation and type–specific neutralization of a human papillomavirus type 16 virion pseudotype. Roden RB, et al. **J Virol** 1996 Sep;70(9):5875–83
Perturbation of the host cell cycle and DNA replication by the bovine papillomavirus replication protein E1. Belyavskyi M, et al. **Virology** 1996 May 1;219(1):206–19
The BPV–1 E2 DNA–contact helix cysteine is required for transcriptional activation but not replication in mammalian cells. Grossel MJ, et al. **Virology** 1996 Mar 1;217(1):301–10
Early phase in the infection of cultured cells with papillomavirus virions. Zhou J, et al. **Virology** 1995 Dec 1;214(1):167–76

PAPILLOMAVIRUS, HUMAN

HPV infection in male partners of women with squamous intraepithelial neoplasia and/or high–risk HPV. Strand A, et al. **Acta Derm Venereol** 1995 Jul;75(4):312–6
Clinical and serological manifestations of genital human papillomavirus infection. Wikström A. **Acta Derm Venereol Suppl (Stockh)** 1995;193:1–85
Contraceptive use and reproductive history in women with cervical human papillomavirus infection. Sikström B, et al. **Adv Contracept** 1995 Dec;11(4):273–84
Papillomavirus vaccines: current status and future prospects. Schiller JT, et al. **Adv Dermatol** 1996;11:355–80; discussion 381 (96 ref.)
Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. Critchlow CW, et al. **AIDS** 1995 Nov; 9(11):1255–62
HIV, Ebola virus and public health measures [letter; comment] Clarke P. **Am Fam Physician** 1996 May 15; 53(7):2283–4. Comment on: Am Fam Physician 1995 Nov 1;52(6):1682.
Human papillomavirus infection: treatment options for warts [see comments] Miller DM, et al. **Am Fam Physician** 1996 Jan;53(1):135–43, 148–50 (30 ref.). Comment in: Am Fam Physician 1996 Jul;54(1):59, 62.
Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Tenti P, et al. **Am J Clin Pathol** 1996 Jul;106(1):52–6
Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Puranen M, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):694–9
Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598–601 (39 ref.)
Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69–84 (96 ref.)
Increase of genital human papillomavirus infection among men and women in Croatia. Grce M, et al. **Anticancer Res** 1996 Mar–Apr;16(2):1039–41
Human papillomavirus in nonmelanoma skin cancer? The phylogenetic tree of the papillomavirus family is not yet complete [letter; comment] Höpfl R, et al. **Arch Dermatol** 1996 Jul;132(7):834. Comment on: Arch Dermatol 1993 Dec;129(12):1585–8. Comment on: Arch Dermatol 1994 Feb;130(2):235–8. Comment on: Arch Dermatol 1995 Jan;131(1):107–8.
Psoralen plus UV–A–associated skin cancer: a likely role for human papillomavirus type 16? [letter; comment] McGregor JM, et al. **Arch Dermatol** 1996 Jan;132(1):90. Comment on: Arch Dermatol 1995 Jun;131(6):701–4.
Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Sikström B, et al. **Arch Gynecol Obstet** 1995;256(3):131–7
Task force on recurrent respiratory papillomas. A preliminary report. Derkay CS. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1386–91
Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Burger MP, et al. **Br J Cancer** 1996 Mar;73(6):831–6
p53 mutations in human papillomavirus–associated oesophageal squamous cell carcinoma [letter; comment] Cooper K. **Br J Cancer** 1995 Nov;72(5):1337. Comment on: Br J Cancer 1994 Aug;70(2):346–51.
P53 expression and human papillomavirus infection in transplant recipients and in patients with epidermodysplasia verruciformis [letter] McGregor JM, et al. **Br J Dermatol** 1996 Feb;134(2):374
The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888–901 (165 ref.)
Establishment and characterization of a human–papillomavirus negative, p53–mutation negative human cervical cancer cell line. Chou CY, et al. **Cancer Lett** 1996 Apr 19;102(1–2):173–81
Malignant transformation of human ectocervical cells immortalized by HPV 18: in vitro model of carcinogenesis by cigarette smoke. Nakao Y, et al. **Carcinogenesis** 1996 Mar;17(3):577–83
Alterations in cell–cell communication in human papillomavirus type 16 (HPV16) transformed rat myoblasts. Ennaji MM, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jun;

41(4):481–98

Human papillomavirus in cyclophosphamide and diverticulum-associated squamous cell carcinoma of urinary bladder: a case report. Wang JS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr;57(4):305–9

Topic and systemic administration of natural alfa interferon in the treatment of female and male HPV genital infections. Stentella P, et al. **Clin Exp Obstet Gynecol** 1996;23(1):29–36

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

Human papillomavirus-associated malignancies in HIV-positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437–41 (46 ref.)

Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233–46 (59 ref.)

Human papillomavirus infections. Rüdlinger R, et al. **Curr Probl Dermatol** 1996;24:67–76 (24 ref.)

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

Viral infections in the immunocompetent patient. Miller CS. **Dermatol Clin** 1996 Apr;14(2):225–41 (206 ref.)

Epidemiology of human papillomaviruses. Vittorio CC, et al. **Dermatol Clin** 1995 Jul;13(3):561–74 (165 ref.)

Improved detection of human papillomavirus infection in genital intraepithelial neoplasia in human immunodeficiency virus positive (HIV +) women by polymerase chain reaction-in situ hybridization. Walker F, et al. **Diagn Mol Pathol** 1996 Jun;5(2):136–46

Study of human papillomavirus infection in patients with anal squamous carcinoma. Ramanujam PS, et al. **Dis Colon Rectum** 1996 Jan;39(1):37–9

Human papillomavirus detection in cervical smears and cervical tissue excised by the Loop Electrosurgical Excision Procedure (LEEP). Diagnostic value of cytology, colposcopy and histology. Vardar MA, et al. **Eur J Gynaecol Oncol** 1995;16(6):494–9

Management of low-grade CIN: follow-up or treatment? Hording U, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):49–52

Squamous cell carcinomas of the anus and infection with human papillomavirus in patients with AIDS. Muñoz-Jiménez F, et al. **Eur J Surg** 1996 Mar;162(3):251–3

Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Lam KY, et al. **Eur J Surg Oncol** 1995 Dec;21(6):613–6

Human papilloma virus, vulvar dystrophy, and vulvar carcinoma: differential expression of human papillomavirus and vulvar dystrophy in the presence and absence of squamous cell carcinoma of the vulva. Sagerman PM, et al. **Gynecol Oncol** 1996 Jun;61(3):328–32

Applications of the monitoring process model to coping with severe long-term medical threats. Miller SM, et al. **Health Psychol** 1996 May;15(3):216–25

Human papillomavirus types and cervical cancer. Apgar BS. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):39–40, 43

Detection of human papillomavirus (HPV) types in precancerous and cancerous lesions of cervix in Indian women: a preliminary report. Menon MM, et al. **Indian J Cancer** 1995 Dec;32(4):154–9

Assessment of EGFR and TGF-alpha expression in relationship to HPV status and Ki-67 distribution in cervical intraepithelial neoplasms. Dellas A, et al. **Int J Cancer** 1996 Jun 21;69(3):165–9

Can papilloma virus testing be used to improve cervical cancer screening? Jenkins D, et al. **Int J Cancer** 1996 Mar 15;65(6):768–73

Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Milde-Langosch K, et al. **Int J Cancer** 1995 Nov 27;63(5):639–45

Resistance to retinoic acid and altered cytokeratin expression of human papillomavirus type 16-immortalized endocervical cells after tumorigenesis. Sarma D, et al. **Int J Cancer** 1996 Jan 26;65(3):345–50

Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Sastre-Garau X, et al. **Int J Cancer** 1996 Jun 21; 69(3):159–64

Malignant transformation of HPV 16-immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Yang X, et al. **Int J Cancer** 1996 Jan 26;65(3):338–44

Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Shah KV, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):127–30

Medical therapy of genital human papilloma virus-related disease. Lacey CJ, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):399–407 (45 ref.)

p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. Kurvinen K, et al. **J Clin Oncol** 1996 Jul;14(7):2120–30

Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. Shoji Y, et al. **J Clin Pathol** 1996 Feb;49(2):134–8

Mutations in the human papillomavirus type 16 E2 protein identify multiple regions of the protein involved in binding to E1. Piccini A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2909–13

Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. Cason J, et al. **J Med Virol** 1995 Nov;47(3):209–18

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.). Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331–2.

Treasure hunt for human papillomaviruses in nonmelanoma skin cancers [editorial; comment] Burk RD, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):781–2. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):802–11.

Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. Gregoire L, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1705–9

Consensus panel on cervical cancer highlights the HPV connection [news] McNeil C. **J Natl Cancer Inst** 1996 May 1;88(9):575

Evidence for dissociation of histone mRNA expression from cellular proliferation in cutaneous human papillomavirus infection. Hinchliffe SA, et al. **J Pathol** 1996 Mar; 178(3):249–54

p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. Tenti P, et al. **J Pathol** 1996 Jan;178(1):65–70

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments] Borysiewicz LK, et al. **Lancet** 1996 Jun 1;347(9014):1523–7 . Comment in: Lancet 1996 Jun 1;347(9014):1498–9.

Papillomavirus oncoproteins as vaccine candidates [comment] Galloway DA. **Lancet** 1996 Jun 1; 347(9014):1498–9. Comment on: Lancet 1996 Jun 1;347(9014):1523–7.

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122–4, 127–9 (55 ref.)

Histologic and biomolecular aspects of papillomatosis of the vulvar vestibule in relation to human papillomavirus. de Deus JM, et al. **Obstet Gynecol** 1995 Nov;86(5):758–63

Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells. Shin KH, et al. **Oncogene** 1996 Mar 7;12(5):1089–96

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.). Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

Human papillomavirus types important in progression of inverted papilloma. Beck JC, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):558–63

Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Arbeit JM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2930–5

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)

Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Levine LA, et al. **Urology** 1996 Apr;47(4):553–7

Analysis of p53 tumor suppressor gene mutations and human papillomavirus infection in human bladder cancers. Kim KH, et al. **Yonsei Med J** 1995 Sep;36(4):322–31

[Detection of human papilloma virus in esophageal squamous cell carcinoma and adjacent tissue specimens in Linxian] Lu S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):321–4 (Eng. Abstr.) **(Chi)**

[A study on the relationship between human papillomavirus and the incidence of cervical carcinoma] Han P, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):608–10 (Eng. Abstr.) **(Chi)**

[Clinical observation on vertical transmission of human papillomavirus] Xu S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):457–9 (Eng. Abstr.) **(Chi)**

[Human papillomavirus 6/11 in conjunctival papilloma] Michel JL, et al. **Ann Dermatol Venereol** 1996;123(2):90–2 (Eng. Abstr.) **(Fre)**

[A case of conjunctival raspberry tumor of viral origin] Bazin S, et al. **J Fr Ophtalmol** 1996;19(2):140–2 (Eng. Abstr.) **(Fre)**

[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600–3 (20 ref.) (Eng. Abstr.) **(Fre)**

[Changes in the vitamin A status in dysplastic epithelium of the cervix] Volz J, et al. **Zentralbl Gynakol** 1995; 117(9):472–5 (Eng. Abstr.) **(Ger)**

[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417–20 (37 ref.) **(Heb)**

[The value of the Pap test in the diagnostic approach to HPV infection of the cervix uteri] Pozzi M, et al. **Minerva Ginecol** 1995 Jul–Aug;47(7–8):301–4 (Eng. Abstr.) **(Ita)**

[A case of primary transitional cell carcinoma of the Bartholin gland with human papillomavirus type 18 infection] Hasegawa K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1385–8 **(Jpn)**

[Human papillomavirus (HPV) infection in sexual partners of women with condylomatous cervical dysplasia] Llopis Cartagena M, et al. **Arch Esp Urol** 1996 Mar;49(2):112–6 (Eng. Abstr.) **(Spa)**

[The pediatrician, sexual abuse and anogenital warts in prepuberty] Martínez-Roig A, et al. **Child Abuse Negl** 1996 Jan;20(1):55–62 (Eng. Abstr.) **(Spa)**

[Human papillomavirus infection in male genitalia] Cano Garfias R, et al. **Ginecol Obstet Mex** 1995 Oct;63:439–42 (Eng. Abstr.) **(Spa)**

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) **(Spa)**

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422–6 (30 ref.) (Eng. Abstr.) **(Spa)**

[Modified factors in the study of the infertile couple in women with papilloma virus cervical infection, descriptive analysis] Repper Camacho F, et al. **Ginecol Obstet Mex** 1995 Dec;63:502–4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: evidence for flexible DNA-binding regions. Liang H, et al. **Biochemistry** 1996 Feb 20;35(7):2095–103

Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles. Sapp M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2407–12

Mutational analysis of human papillomavirus type 11 E5a oncoprotein. Chen SL, et al. **J Virol** 1996 Jun;70(6):3502–8

Equilibrium dissociation and unfolding of the dimeric human papillomavirus strain-16 E2 DNA-binding domain. Mok YK, et al. **Protein Sci** 1996 Feb;5(2):310–9

CLASSIFICATION

HPV-types, cytological and histopathological findings in three groups of women with possible HPV-related disease. Frederiksson A, et al. **Acta Obstet Gynecol Scand** 1996 Jul; 75(6):556–62

A rapid method for the screening and typing of high risk HPVs using molecular biology techniques. Troungos C, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2045–8

Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Meyer T, et al. **Biotechniques** 1995 Oct;19(4):632–9

Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Syrjänen KJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):45–53 (98 ref.)

Bethesda classification of cervicovaginal smears: reproducibility and viral correlates. Joste NE, et al. **Hum Pathol** 1996 Jun;27(6):581–5

Clinical application of HPV typing in cervical cancer. Namkoong SE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S59–67

Detection of human papillomavirus (HPV) type 47 DNA in malignant lesions from epidermodysplasia verruciformis by protocols for precise typing of related HPV DNAs. Adachi A, et al. **J Clin Microbiol** 1996 Feb;34(2):369–75

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. Greer CE, et al. **J Clin Microbiol** 1995 Aug;33(8):2058–63

Serology of human papillomavirus type 16 infections: where angels fear to tread? [letter; comment] Bible JM, et al. **J Infect Dis** 1996 Jul;174(1):237–9. Comment on: J Infect Dis 1995 Dec;172(6):1425–30.

Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions [see comments] Park TW, et al. **J Natl Cancer Inst** 1996 Mar 20;88(6):355–8. Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):317–8.

Association of multiple human papillomavirus types with vulvar neoplasias. Nagano H, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):1–8

A polymerase chain reaction (PCR) investigation of oral verrucae which contain HPV types 2 and 57 by in situ hybridization. Padayachee A, et al. **J Oral Pathol Med** 1995 Aug;24(7):329–34

Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. Roden RB, et al. **J Virol** 1996 May;70(5):3298–301

Intratype variation in 12 human papillomavirus types: a worldwide perspective. Stewart AC, et al. **J Virol** 1996 May;70(5):3127–36

[HPV-5 typing with nested PCR and sequencing in epidermodysplasia verruciformis] Schaller J, et al. **Hautarzt** 1996 Jun;47(6):454–8 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Cellular and molecular analyses of interferon beta cytopathic effect on HPV-16 in vitro transformed human keratinocytes (HPK-IA). De Marco E, et al. **J Biol Regul Homeost Agents** 1995 Jan–Mar;9(1):24–30

[beta-Interferon in the therapy of cervico-vaginal papilloma

virus (HPV) infection associated with cervical intraepithelial neoplasia (CIN)] Grismondi GL, et al. **Minerva Ginecol** 1995 Dec;47(12):527–9 (Eng. Abstr.) **(Ita)**

GENETICS

Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolaou-stained cervical smears. Puranen M, et al. **Acta Cytol** 1996 May–Jun;40(3):391–5

Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Furukawa T, et al. **Am J Pathol** 1996 Jun;148(6):1763–70

Interferon response depends on viral transcription in human papillomavirus-containing lesions. Arany I, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2865–9

Differences in reactivity to cyclosporin A and interferon-gamma of normal and HPV-transformed keratinocytes. Marionnet AV, et al. **Anticancer Res** 1996 Jan–Feb;16(1):257–67

Cloning of mucosal and cutaneous HPV sequences in a metastatic squamous cell carcinoma from an epidermodysplasia verruciformis patient. Payne D, et al. **Anticancer Res** 1996 May–Jun;16(3A):1165–6

Human papillomavirus DNA in oral squamous cell carcinomas from an African population sample. Van Rensburg EJ, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):969–73

Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)

The retinoblastoma gene product negatively regulates cellular or viral oncogene promoters in vivo. Salcedo M, et al. **Arch Med Res** 1995;26 Spec No:S157–62

Aggressive conjunctival squamous cell carcinoma in three young Africans. Lewallen S, et al. **Arch Ophthalmol** 1996 Feb;114(2):215–8

Sequence variation in the L1 gene of human papillomavirus type 16 from Africa. Ramesar JE, et al. **Arch Virol** 1995; 140(10):1863–70

Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Chen YH, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):651–9

Genomic aberrations of human papillomavirus recovered from cervical cancers. Pao CC, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):116–20

Human papillomavirus 11 E5a delays the growth restriction induced by temperature shift in temperature-sensitive simian virus 40 T antigen-immortalized keratinocytes. Tsao YP, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):712–20

Elimination of false-positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples. Jiang G, et al. **Biotechniques** 1995 Oct;19(4):566–8

Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Meyer T, et al. **Biotechniques** 1995 Oct;19(4):632–9

Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Lopez-Beltran A, et al. **Br J Cancer** 1996 Jan;73(1):124–7

Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Malejczyk J, et al. **Br J Cancer** 1996 Jul; 74(2):234–9

Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Iwasawa A, et al. **Cancer** 1996 Jun 1; 77(11):2275–9

Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)

Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Shindoh M, et al. **Cancer** 1995 Nov 1;76(9):1513–21

Detection of human papillomavirus in esophageal squamous cell carcinoma. Suzuk L, et al. **Cancer** 1996 Aug 15; 78(4):704–10

Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: a nested case-control study. Franco E, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):271–5

Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Chen Z, et al. **Cancer Gene Ther** 1996 Jan–Feb;3(1):18–23

Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Chen Z, et al. **Cancer Gene Ther** 1995 Dec;2(4):263–71

Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and -18 DNA. Naghashfar Z, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):47–54

Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Steenbergen RD, et al. **Cancer Res** 1995 Nov 15;55(22):5465–71

Differential response of normal and HPV immortalized ectocervical epithelial cells to B[a]P. Sizemore N, et al. **Carcinogenesis** 1995 Oct;16(10):2413–8

Detection of human papillomavirus types 16, 18 DNA related sequences in bronchogenic carcinoma by polymerase chain reaction. Li Q, et al. **Chin Med J (Engl)** 1995 Aug; 108(8):610–4

A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. Van Doornum GJ, et al. **Clin Diagn Lab Immunol** 1994 Nov; 1(6):633–9

Cervical cancer: is herpes simplex virus type II a cofactor? Jones C. **Clin Microbiol Rev** 1995 Oct;8(4):549–56 (122 ref.)

Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes. Galloway DA, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:297–306

Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Fouret P, et al. **Diagn Mol Pathol** 1995 Jun;4(2):122–7

The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. Antinore MJ, et al. **EMBO J** 1996 Apr 15; 15(8):1950–60

Evaluation of non-radioactive temperature gradient SSCP analysis and of temperature gradient gel electrophoresis for the detection of HPV 6-variants in condylomata acuminata and Buschke-Loewenstein tumours. Rübben A, et al. **Eur J Epidemiol** 1995 Oct;11(5):501–6

Human papillomavirus deoxyribonucleic acid and ribonucleic acid in seminal plasma and sperm cells. Lai YM, et al. **Fertil Steril** 1996 May;65(5):1026–30

Preferential retention of the E6 and E7 regions of the human papilloma virus type 18 genome by human sperm cells. Pao CC, et al. **Fertil Steril** 1996 Oct;66(4):630–3

Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma. Benamouzig R, et al. **Gastroenterology** 1995 Dec;109(6):1876–81

Cloning and sequencing of the murine farnesyltransferase alpha-encoding cDNA from a cell line which expresses the human papillomavirus type-16 E6 gene. Shirasawa H, et al. **Gene** 1995 Oct 27;164(2):373–4

Genetic instability of chromosome 3 in HPV-immortalized and tumorigenic human keratinocytes. Montgomery KD, et al. **Genes Chromosomes Cancer** 1995 Oct;14(2):97–105

Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Cheng S, et al. **Genes Dev** 1995 Oct 1;9(19):2335–49

Generation of entire human papillomavirus genomes by long PCR: frequency of errors produced during amplification. Stewart AC, et al. **Genome Res** 1995 Aug;5(1):79–88

Vulvar papillomatosis, aceto-white lesions, and normal-looking vulvar mucosa evaluated by microscopy and human papillomavirus analysis. Strand A, et al. **Gynecol Obstet Invest** 1995;40(4):265–70

Uterine cervix adenocarcinoma with both human papillomavirus type 18 and tumor suppressor gene p53 mutation from a woman having an intact hymen. Craigo J, et al. **Gynecol Oncol** 1995 Dec;59(3):423–6

A transcribed human sequence related to the mouse HC1 and the human papillomavirus type 18 E5 genes is located at chromosome 7p13–14. Geisen C, et al. **Hum Mol Genet** 1995 Aug;4(8):1337–45

Nonisotopic in situ hybridization in the detection of integrated HPV 16/18 in cervical cancers [letter] Cooper K. **Hum Pathol** 1996 Jul;27(7):745

p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Furihata M, et al. **Int J Cancer** 1995 Oct 20;64(5):298–303

Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Mao EJ, et al. **Int J Cancer** 1996 Apr 22;69(2):152–8

Human papillomavirus type 18 DNA in gestational trophoblastic tissues and choriocarcinomas. Pao CC, et al. **Int J Cancer** 1995 Nov 15;63(4):505–9

Dysplasia and HPV infection initially detected by DNA analysis in cytomorphologically normal cervical smears. Saito J, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):43–8

Abrogation of P53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. Huang H, et al. **Int J Radiat Biol** 1996 Aug;70(2):151–60

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. Tatsura H, et al. **Int J Urol** 1995 Nov;2(5):347–9

Human papillomavirus DNA in genital cancers, metastases, and lymph nodes. Beyer-Finkler E, et al. **Intervirology** 1995;38(3–4):173–80

Natural history of cervical human papillomavirus lesions. Katase K, et al. **Intervirology** 1995;38(3–4):192–4

Transgenic models for papillomavirus-associated multistep carcinogenesis. Kondoh G, et al. **Intervirology** 1995; 38(3–4):181–6

False-positive polymerase chain reaction results for human papillomavirus in lichen planus. Potential laboratory pitfalls of this procedure. Boyd AS, et al. **J Am Acad Dermatol** 1996 Jul;35(1):42–6

Human papillomavirus DNA in nonanogenital keratoacanthoma and squamous cell carcinoma of patients with HIV infection. Payne D, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1047–9

Detection of human papillomavirus (HPV) type 47 DNA in malignant lesions from epidermodysplasia verruciformis by protocols for precise typing of related HPV DNAs. Adachi A, et al. **J Clin Microbiol** 1996 Feb;34(2):369–75

Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. Coutlée F, et al. **J Clin Microbiol** 1995 Aug;33(8):1973–8

Human papillomavirus type 70 genome cloned from overlapping PCR products: complete nucleotide sequence and genomic organization. Forslund O, et al. **J Clin Microbiol** 1996 Apr;34(4):802–9

Comparison of ViraPap, southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer [letter; comment] Gibbs AC. **J Clin Microbiol** 1995 Aug;33(8):2229. Comment on: J Clin Microbiol 1992 Nov;30(11):2951–9.

Intermethod variation in detection of human papillomavirus DNA in cervical smears. Smits HL, et al. **J Clin Microbiol** 1995 Oct;33(10):2631–6

Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. van Belkum A, et al. **J Clin Microbiol** 1995 Nov;33(11):2957–62

Tenascin in human papillomavirus associated lesions of the uterine cervix. Pöllänen R, et al. **J Clin Pathol** 1996 Jun; 49(6):521–3

p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16. Akutsu N, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):459–63

Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. Hofmann KJ, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):465–8

Functional promoters in the genome of human papillomavirus type 6b. Karlen S, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):11–6

Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. Kaye JN, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1139–43

Evidence for a promoter-like activity in the short non-coding region of human papillomaviruses. Maki H, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):453–8

Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. Brisson J, et al. **J Infect Dis** 1996 Apr;173(4):794–9

Interferon-alpha elicits downregulation of human papillomavirus 18 mRNA in HeLa cells by selective repression of endogenous viral transcription. Perea SE, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):495–501

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

Comparison of detection of human papillomavirus 16 DNA in cervical carcinoma tissues by Southern blot hybridisation and nested polymerase chain reaction. Chang DY, et al. **J Med Microbiol** 1995 Dec;43(6):430–5

Splice sites of human papillomavirus type 16 E6 gene or heterologous gene required for transformation by E7 and accumulation of E7 RNA. Belaguli NS, et al. **J Med Virol** 1995 Dec;47(4):445–53

Molecular analysis of cellular loci disrupted by papillomavirus 16 integration in cervical cancer: frequent viral integration in topologically destabilized and transcriptionally active chromosomal regions. Choo KB, et al. **J Med Virol** 1996 May;49(1):15–22

Deletion in the L1 open reading frame of human papillomavirus type 6a genomes associated with recurrent laryngeal papilloma. Suzuki T, et al. **J Med Virol** 1995 Nov;47(3):191–7

Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. Bosch FX, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1060–7

Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. Muñoz N, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1068–75

Prognostic factors for survival in cervical cancer--warts and all [editorial; comment] Tattersall MH, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1331–2. Comment on: J Natl Cancer Inst 1996 Oct 2;88(19):1361–8.

Labelling pattern obtained by non-isotopic in situ hybridization as a prognostic factor in HPV-associated lesions. Gómez F, et al. **J Pathol** 1996 Jul;179(3):272–5

Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. DiLorenzo TP, et al. **J Virol** 1995 Nov; 69(11):6865–72

Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. Grassmann K, et al. **J Virol** 1996 Apr;70(4):2339–49

Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. Gu Z, et al. **J Virol** 1995 Dec;69(12):8051–6

Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human

papillomavirus type 16. Sherman L, et al. **J Virol** 1996 May; 70(5):3269–79

Intratype variation in 12 human papillomavirus types: a worldwide perspective. Stewart AC, et al. **J Virol** 1996 May;70(5):3127–36

E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. Stubenrauch F, et al. **J Virol** 1996 Jan;70(1):119–26

Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. Yamada T, et al. **J Virol** 1995 Dec;69(12):7743–53

Regulation of human papillomavirus transcription by the differentiation–dependent epithelial factor Epoc–1/skn–1a. Yukawa K, et al. **J Virol** 1996 Jan;70(1):10–6

Identification of nuclear and cytoplasmic proteins that interact specifically with an AU–rich, cis–acting inhibitory sequence in the 3' untranslated region of human papillomavirus type 1 late mRNAs. Zhao C, et al. **J Virol** 1996 Jun;70(6):3659–67

Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6–E7 transcripts. Smits HL, et al. **J Virol Methods** 1995 Jul;54(1):75–81

Low–stringency single specific primer PCR, DNA sequencing and single–strand conformation polymorphism of PCR products for identification of genetic variants of human papillomavirus type 16. van Belkum A. **J Virol Methods** 1995 Nov;55(3):435–43

Prevalence of human papillomavirus DNA in female cervical lesions from Rio de Janeiro, Brazil. Cavalcanti SM, et al. **Mem Inst Oswaldo Cruz** 1994 Oct–Dec;89(4):575–80

Analysis of the papillomavirus type 16 DNA amplification by PCR in SiHa and SLT cell lines. Ratiarson A. **Microbios** 1996;85(343):127–31

Influence of human papillomavirus type 16 gene expression on in vitro differentiation of the human teratocarcinoma cell line 2102Ep. Stöppler H, et al. **Mol Carcinog** 1996 Jun; 16(2):109–14

Use of the polymerase chain reaction to specifically amplify integrated HPV–16 DNA by virtue of its linkage to interspersed repetitive DNA. Carmody MW, et al. **Mol Cell Probes** 1996 Apr;10(2):107–16

Short–term fluctuations in the detection of cervical human papillomavirus DNA. Wheeler CM, et al. **Obstet Gynecol** 1996 Aug;88(2):261–8

Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Chiba I, et al. **Oncogene** 1996 Apr 18;12(8):1663–8

Regulation of Myc and Mad during epidermal differentiation and HPV–associated tumorigenesis. Hurlin PJ, et al. **Oncogene** 1995 Dec 21;11(12):2487–501

In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation–dependent late expression. Frattini MG, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3062–7

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H, et al. **Prostate** 1996 May;28(5):318–24

Detection of human papillomaviruses in cancer of the uterine cervix [letter; comment] Molendijk LW. **S Afr Med J** 1996 Apr;86(4):379, 381. Comment on: S Afr Med J 1995 Sep;85(9):841–2.

Detection of human papillomavirus in cervical intra–epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Zehbe I, et al. **Virchows Arch** 1996 Jun;428(3):151–7

Genomic cloning and characterization of the nonoccupied allele corresponding to the integration site of human papillomavirus type 16 DNA in the cervical cancer cell line SiHa. Bauer–Hofmann R, et al. **Virology** 1996 Mar 1;217(1):33–41

Stimulation of human papillomavirus type 1a DNA replication by a multimerized AT–rich palindromic sequence. Gopalakrishnan V, et al. **Virology** 1995 Dec 1; 214(1):301–6

Differentiation–dependent transcription of the epidermodysplasia verruciformis–associated human papillomavirus type 5 in benign lesions. Haller K, et al. **Virology** 1995 Dec 1;214(1):245–55

Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Icenogle JP, et al. **Virology** 1995 Dec 20;214(2):664–9

Variability and phylogeny of the L1 capsid protein gene of human papillomavirus type 5: contribution of clusters of nonsynonymous mutations and of a 30–nucleotide duplication. Kawase M, et al. **Virology** 1996 Jul 1; 221(1):189–98

A single element mediates glucocorticoid hormone response of HPV18 with no functional interactions with AP1 or hbrm. Medina–Martinez O, et al. **Virology** 1996 Mar 1; 217(1):392–6

Characterization of human papillomavirus–11 mRNAs expressed in the context of autonomously replicating viral genomes. Renaud KJ, et al. **Virology** 1996 Jun 1; 220(1):177–85

Mapping of HPV–11 E1 binding site and determination of other important cis elements for replication of the origin. Sun YN, et al. **Virology** 1996 Feb 1;216(1):219–22

Transforming activity of the E6 gene of HPV–11gt in NIH 3T3 and REF 52 cells: correlation with the level of E6 transcription. Trujillo JM, et al. **Virology** 1996 Jun 1; 220(1):1–9

Transcriptional control of human papillomavirus type 18 oncogene expression in different cell lines: role of transcription factor YY1. Jundt F, et al. **Virus Genes** 1995; 11(1):53–8

Alterations in physical state and expression of human papillomavirus type 18 DNA following crisis and establishment of immortalized ectocervical cells. Yokoyama M, et al. **Virus Res** 1995 Jul;37(2):139–51

[Sequence analysis of PCR amplification products of old formalin fixed conisation tissue sections] Labeit D, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:148–51 (Eng. Abstr.) **(Ger)**

[Human papillomavirus type 16–gene functions relevant to molecular human carcinogenesis] Yasumoto S. **Nippon Rinsho** 1995 Nov;53(11):2858–67 (20 ref.) (Eng. Abstr.) **(Jpn)**

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Type 73 human papillomavirus in esophageal squamous cell carcinoma: a novel association. West AB, et al. **Cancer** 1996 Jun 15;77(12):2440–4

IMMUNOLOGY

Immunity to human papillomavirus–associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175–211 (187 ref.)

Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture. Hoos A, et al. **Arch Virol** 1996;141(3–4):449–58

Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Dillner L, et al. **Cancer Detect Prev** 1995;19(5):381–93

HLA–A2–restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Evans C, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):151–60

Occasional memory cytotoxic T–cell responses of patients with human papillomavirus type 16–positive cervical lesions against a human leukocyte antigen–A *0201–restricted E7–encoded epitope. Ressing ME, et al. **Cancer Res** 1996 Feb 1;56(3):582–8

A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. Van Doornum GJ, et al. **Clin Diagn Lab Immunol** 1994 Nov; 1(6):633–9

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16–induced tumors. Feltkamp MC, et al. **Eur J Immunol** 1995 Sep;25(9):2638–42

The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Fisher SG, et al. **Gynecol Oncol** 1996 Apr;61(1):73–8

Serological response to HPV16 in CIN–III and cervical cancer patients. Case–control studies in Spain and Colombia. De Sanjosé S, et al. **Int J Cancer** 1996 Mar 28; 66(1):70–4

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Kanda T, et al. **Intervirology** 1995; 38(3–4):187–91

Antibodies to human papillomavirus type 11 virus–like particles in sera of patients with genital warts and in control groups. Eisemann C, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1799–803

Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. Luxton JC, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1585–93

Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. Shepherd PS, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):593–602

Conformational and linear epitopes on virus–like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. Volpers C, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2661–7

Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence. Rasmussen M, et al. **J Immunol Methods** 1996 Jan 16; 189(1):47–58

Dendritic cells as carriers for a cytotoxic T–lymphocyte epitope–based peptide vaccine in protection against a human papillomavirus type 16–induced tumor. Ossevoort MA, et al. **J Immunother Emphasis Tumor Immunol** 1995 Aug;18(2):86–94

Divergent human papillomavirus type 16 variants are serologically cross–reactive. Cheng G, et al. **J Infect Dis** 1995 Dec;172(6):1584–7

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. Dillner J, et al. **J Infect Dis** 1996 Jun; 173(6):1394–8

Evaluation of seroreactivity to human papillomavirus type 16 virus–like particles in an incident case–control study of cervical neoplasia [see comments] Wideroff L, et al. **J Infect Dis** 1995 Dec;172(6):1425–30. Comment in: J Infect Dis 1996 Jul;174(1):237–9.

Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. Wikström A, et al. **J Med Virol** 1995 Aug;46(4):368–74

Antibodies prevalence against HPV–6b and –16 recombinant fusion proteins in Korean patients with cervical neoplasia. Park SN, et al. **J Obstet Gynaecol** 1995 Dec;21(6):609–17

Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. Ludmerer SW, et al. **J Virol** 1996 Jul;70(7):4791–4

Preventing cervical cancer. Braly P. **Nat Med** 1996 Jul; 2(7):749–51

The association of an HPV16 oncogene variant with HLA–B7 has implications for vaccine design in cervical cancer. Ellis JR, et al. **Nat Med** 1995 May;1(5):464–70

Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860–6 (30 ref.)

A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. Strickler HD, et al. **Viral Immunol** 1994;7(4):169–77

[Specific serologic studies with a novel authentic HPV antigen (virus–like particles) for HPV–6 antibodies in gynecologic patient samples] Heim K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:25–31 (Eng. Abstr.) **(Ger)**

[Interferon–alpha controls HPV infection in cervix epithelium] Labeit D, et al. **Zentralbl Gynakol** 1995; 117(11):566–77 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

No evidence of human papillomavirus infection in balanitis circumscripta plasmacellularis Zoon [letter] Kiene P, et al. **Acta Derm Venereol** 1995 Nov;75(6):496–7

Anal and penile condylomas in HIV–negative and HIV–positive men: clinical, histological and virological characteristics correlated to therapeutic outcome. von Krogh G, et al. **Acta Derm Venereol** 1995 Nov;75(6):470–4

Carbon dioxide laser miniconization for treatment of human papillomavirus infection associated with cervical intraepithelial neoplasia. Békássy Z, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):822–6

Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Persson G, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):287–90

HIV–1, HIV–2, human papillomavirus infection and cervical neoplasia in high–risk African women. Langley CL, et al. **AIDS** 1996 Apr;10(4):413–7

Detection of human papillomavirus in extragenital Bowen's disease using in situ hybridization and polymerase chain reaction. Collina G, et al. **Am J Dermatopathol** 1995 Jun; 17(3):236–41

Polymerase chain reaction search for viral etiology of vulvar vestibulitis syndrome. Bornstein J, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):139–44

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Elfgren K, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):937–42

Human papillomavirus deoxyribonucleic acid as a prognostic indicator in early–stage cervical cancer: a possible role for type 18. Rose BR, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1461–8

Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. Sun XW, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1432–7

Squamous cell carcinoma of the eyelid and the acquired immunodeficiency syndrome. Maclean H, et al. **Am J Ophthalmol** 1996 Feb;121(2):219–21

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears. Chua KL, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):221–9

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Pou AM, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):758–62

Extrachromosomal human papillomavirus (HPV) in multiple myeloma and monoclonal gammopathy of unknown significance (MGUS) patients. Payne DA, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2213–5

Prevalence of human papillomavirus in cervical scrapes, as analyzed by PCR, in a population–based sample of women with and without cervical dysplasia. Gjoen K, et al. **APMIS** 1996 Jan;104(1):68–74

Human papillomavirus infection in cervical biopsies from Norwegian gynecological in–patients. Jenkins A, et al. **APMIS** 1996 Jan;104(1):30–4

Human papillomavirus (HPV) in vulvar dysplasia and carcinoma in situ. Junge J, et al. **APMIS** 1995 Jul–Aug; 103(7–8):501–10

The association of vascular proliferation with HPV status

and epithelial PCNA positivity in cervical intraepithelial lesions. Soini Y, et al. **APMIS** 1996 Mar;104(3):183–90

Cutaneous warts: clinical, histological and virological correlations [letter; comment] Jablonska S, et al. **Arch Dermatol Res** 1995;287(6):616–8. Comment on: Arch Dermatol Res 1993;285(8):460–5.

No evidence of human papillomavirus DNA in actinic keratosis. Lu S, et al. **Arch Dermatol Res** 1995; 287(7):649–51

Detection of human papillomavirus DNA in nongenital seborrhoeic keratoses. Tsambaos D, et al. **Arch Dermatol Res** 1995;287(6):612–5

Volume-sensitive chloride channels in the primary culture cells of human cervical carcinoma. Shen MR, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):138–44

Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study [see comments] Lehtinen M, et al. **BMJ** 1996 Mar 2;312(7030):537–9. Comment in: BMJ 1996 Mar 2;312(7030):522–3.

Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology. Hinchliffe SA, et al. **Br J Cancer** 1995 Oct;72(4):943–5

Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. Woodman CB, et al. **Br J Cancer** 1996 Feb;73(4):553–6

Detection of human papillomavirus type 16 DNA in two cases of verrucous carcinoma of the foot [letter] Sasaoka R, et al. **Br J Dermatol** 1996 May;134(5):983–4

Perinatal acquisition of cervical cancer-associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853–8 (66 ref.)

Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Chua KL, et al. **Cancer** 1996 Jan 1;77(1):121–7

High prevalence of human papillomavirus in squamous cell carcinoma and matched normal esophageal mucosa: assessment by polymerase chain reaction. Fidalgo PO, et al. **Cancer** 1995 Nov 1;76(9):1522–8

Clear cell adenosquamous carcinoma of the cervix. An aggressive tumor associated with human papillomavirus-18. Fujiwara H, et al. **Cancer** 1995 Nov 1;76(9):1591–600

p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Ikenberg H, et al. **Cancer** 1995 Jul 1;76(1):57–66

Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients [letter] Runnebaum IB, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):573–5

Incidence of human papilloma virus in patients with invasive cervical carcinoma. Sobti RC, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):175–80

Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Isacson C, et al. **Cancer Res** 1996 Feb 15;56(4):669–74

Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Mullokandov MR, et al. **Cancer Res** 1996 Jan 1;56(1):197–205

Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56–62 (41 ref.)

HPV detection in cytological cases with condylomatous or dysplastic changes: a study with PCR and in situ hybridization on cytological material. Skyldberg B, et al. **Diagn Cytopathol** 1995 Jul;13(1):8–14

Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Cruz IB, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):55–62

Prognostic evaluation of HPV-associated precancerous and microinvasive carcinoma of the oral cavity: combined use of nucleolar organiser regions (AgNOR) and proliferating cell nuclear antigen (PCNA). Donofrio V, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):174–80

Cervical intraepithelial neoplasia and human papillomavirus related lesions of the genital tract in HIV positive and negative women. Branca M, et al. **Eur J Gynaecol Oncol** 1995;16(5):410–7

Expression of p53 and coexistence of HPV in premalignant lesions and in cervical cancer. Markowska J, et al. **Eur J Gynaecol Oncol** 1995;16(5):368–72

A colposcopic scoring system for grading cervical lesions. Stellato G, et al. **Eur J Gynaecol Oncol** 1995;16(4):296–300

Virologic screening. Schneider A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):61–3 (23 ref.)

Simultaneously detected aberrant p53 tumor suppressor protein and HPV-DNA localize mostly in separate keratinocytes in anogenital and common warts. Lassus J, et al. **Exp Dermatol** 1996 Apr;5(2):72–8

Human papillomaviruses and cervical screening [editorial] Etherington IJ, et al. **Genitourin Med** 1996 Jun;72(3):153–4

Detection of human papillomavirus DNA sequences in cancer of the urinary bladder by in situ hybridisation and polymerase chain reaction. Gopalkrishna V, et al. **Genitourin Med** 1995 Aug;71(4):231–3

Detection of human papillomavirus types in balanitis xerotica obliterans and other penile conditions. Lau PW, et al. **Genitourin Med** 1995 Aug;71(4):228–30

Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status. Garzetti GG, et al. **Gynecol Obstet Invest** 1995;40(1):52–6

Human papillomavirus infection in Hong Kong Chinese women with normal and abnormal cervix--detection by polymerase chain reaction method on cervical scrapes. Chan MK, et al. **Gynecol Oncol** 1996 Feb;60(2):217–23

Human papillomavirus detection of endometrioid carcinoma with squamous differentiation of the uterine corpus. Czerwenka K, et al. **Gynecol Oncol** 1996 May;61(2):210–4

Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Petry KU, et al. **Gynecol Oncol** 1996 Jan;60(1):30–4

Nonisotopic in situ hybridization in the detection of integrated HPV 16/18 in cervical cancers [letter] Cooper K. **Hum Pathol** 1996 Jul;27(7):745

Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia [see comments] Resnick M, et al. **Hum Pathol** 1996 Mar; 27(3):234–9. Comment in: Hum Pathol 1996 Mar;27(3):217–9.

HPV 16 DNA sequences in different grades of cervical lesions. Katyayani M, et al. **Indian J Exp Biol** 1996 Jan; 34(1):7–10

Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Odunsi K, et al. **Int J Cancer** 1996 Sep 4;67(5):595–602

Immunolocalization of cystatin A in condylomatous and dysplastic lesions of the human uterine cervix: correlation with the presence and type of human papillomavirus infection. Pöllänen R, et al. **Int J Gynecol Pathol** 1995 Jul; 14(3):217–22

p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. ter Harmsel B, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):125–33

Metastatic periungual squamous cell carcinoma: detection of human papillomavirus type 35 RNA in the digital tumor and axillary lymph node metastases. McHugh RW, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1080–2

Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)

The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55–60 (36 ref.)

Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. Coutlée F, et al. **J Clin Microbiol** 1995 Aug;33(8):1973–8

Comparison of ViraPap, southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer [letter; comment] Gibbs AC. **J Clin Microbiol** 1995 Aug;33(8):2229. Comment on: J Clin Microbiol 1992 Nov;30(11):2951–9.

Physical state of human papillomavirus using non-isotopic in situ hybridisation [letter] Cooper K. **J Clin Pathol** 1995 Aug;48(8):786

HPV testing in patients with low grade cervical cytological abnormalities: a follow up study. Herrington CS, et al. **J Clin Pathol** 1996 Jun;49(6):493–6

HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma. Saegusa M, et al. **J Clin Pathol** 1995 Dec;48(12):1106–10

Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. Walboomers JM, et al. **J Clin Pathol** 1995 Aug;48(8):728–32

Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. Daniel B, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2589–93

Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. Kaye JN, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1139–43

Comparison of 35S and chemiluminescence for HPV in situ hybridization in carcinoma cell lines and on human cervical intraepithelial neoplasia. Lorimier P, et al. **J Histochem Cytochem** 1996 Jul;44(7):665–71

Serology of human papillomavirus type 16 infections: where angels fear to tread? [letter; comment] Bible JM, et al. **J Infect Dis** 1996 Jul;174(1):237–9. Comment on: J Infect Dis 1995 Dec;172(6):1425–30.

Type-specific prevalence of human papillomavirus DNA among Jamaican colposcopy patients. Rattray C, et al. **J Infect Dis** 1996 Mar;173(3):718–21

Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. Unger ER, et al. **J Infect Dis** 1995 Nov;172(5):1184–90

Detection of several types of human papilloma viruses in AIDS-associated Kaposi's sarcoma. Adams V, et al. **J Med Virol** 1995 Jul;46(3):189–93

Serial quantitation of HPV-16 in the smears of women with mild and moderate dyskaryosis. Flannelly G, et al. **J Med Virol** 1995 Sep;47(1):6–9

Absence of human papillomavirus DNA from esophageal carcinoma as determined by multiple broad spectrum polymerase chain reactions. Smits HL, et al. **J Med Virol** 1995 Jul;46(3):213–5

Overexpression of the proto-oncogene c-jun in association with low-risk type specific human papillomavirus infection in condyloma acuminata. Yang YF, et al. **J Med Virol** 1996 Apr;48(4):302–7

Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients [see comments] Shamanin V, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):802–11. Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):781–2.

Detection of human papillomavirus in cervical biopsies of summer camp ROTC cadets with abnormal papanicolaou smears. Stafford EM, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):119–24

Re: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis [letter; comment] Fleiss PM. **J Urol** 1996 Jun;155(6):2034–5; discussion 2035–6. Comment on: J Urol 1995 Sep;154(3):1024–9.

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

Re: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis [letter; comment] Van Howe RS. **J Urol** 1996 Jun;155(6):2035; discussion 2035–6. Comment on: J Urol 1995 Sep;154(3):1024–9.

Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. Yamada T, et al. **J Virol** 1995 Dec;69(12):7743–53

SYBR green I DNA staining increases the detection sensitivity of viruses by polymerase chain reaction. Karlsen F, et al. **J Virol Methods** 1995 Sep;55(1):153–6

Simultaneous polymerase chain reaction detection and restriction typing for the diagnosis of human genital papillomavirus infection. Pizzighella S, et al. **J Virol Methods** 1995 Oct;55(2):245–56

Abnormal Pap smears, ASCUS still ob/gyn puzzle [news] Titus K. **JAMA** 1996 Oct 2;276(13):1014–6

Genomic organization of human papillomavirus type 18 in cervical cancer specimens. Kitagawa K, et al. **Jpn J Cancer Res** 1996 Mar;87(3):263–8

Non-detection of human papillomavirus DNA in cervical dysplasia and disease progression [letter] Iwasaka T, et al. **Lancet** 1996 Aug 3;348(9023):333–4

Detection of human papillomavirus in juvenile laryngeal papillomatosis using polymerase chain reaction. Gómez MA, et al. **Medicina (B Aires)** 1995;55(3):213–7

The use of consensus PCR and direct sequence analysis for the identification of HPV. Smits HL. **Methods Mol Biol** 1996;50:109–26

Postmenopausal squamous atypia: a spectrum including "pseudo-koilocytosis" [see comments] Jovanovic AS, et al. **Mod Pathol** 1995 May;8(4):408–12. Comment in: Mod Pathol 1996 Feb;9(2):158.

Prevalence of human papillomavirus 16 and nucleolar organizer region counts in oral exfoliated cells from normal and malignant epithelia. Mao EJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):320–9

Detection of human papilloma virus DNA sequences in oral squamous cell papillomas by the polymerase chain reaction. Ward KA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):63–6

Role of HPV-DNA typing in women with cytological diagnosis of squamous atypia. Zarcone R, et al. **Panminerva Med** 1995 Mar;37(1):8–10

Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Sano T, et al. **Pathol Int** 1995 Jul;45(7):506–12 (32 ref.)

Human papillomavirus infection and transitional cell carcinoma of the bladder. Immunohistochemistry and in situ hybridization. López-Beltrán A, et al. **Pathol Res Pract** 1996 Feb;192(2):154–9

Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Wideroff L, et al. **Prostate** 1996 Feb;28(2):117–23

Papillomavirus in cervicovaginal smears of women infected with human immunodeficiency virus. Eduardo Calore E, et al. **Rev Paul Med** 1995 Nov-Dec;113(6):1009–11

Detection of human papillomavirus DNA with in situ hybridisation in oral squamous carcinoma in a rural black population. Van Rensburg EJ, et al. **S Afr Med J** 1995 Sep;85(9):894–6

Urethral condylomata, due to human papilloma virus (HPV) type 6/11., associated with transitional cell tumors in the bladder and ureter. A case report. Olsen S, et al. **Scand J Urol Nephrol Suppl** 1995;172:51–5

Spectrum of genital human papillomavirus infection in a female adolescent population. Jamison JH, et al. **Sex Transm Dis** 1995 Jul-Aug;22(4):236–43

Expression of p53 protein related to human papillomavirus and DNA ploidy in superficial esophageal carcinoma. Nakamura T, et al. **Surg Today** 1995;25(7):591–7

HPV DNA and p53 alterations in oropharyngeal carcinomas. Barten M, et al. **Virchows Arch** 1995;427(2):153–7

Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. al-Saleh W, et al. **Virchows Arch** 1995; 427(1):41–8

Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Zehbe I, et

al. **Virchows Arch** 1996 Jun;428(3):151-7

Role of human papillomavirus and p53 tumor suppressor gene in cervical carcinogenesis. Kim KH, et al. **Yonsei Med J** 1995 Nov;36(5):412-25

[Comparison of human papilloma virus-DNA in condyloma acuminatum, cervical cancer and the female genital tract] Cui M, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar; 31(3):163-5 (Eng. Abstr.) **(Chi)**

[Detection and typing of HPV DNA in situ—improvement in diagnosis of lesions of the uterine cervix] Kotršová L, et al. **Ceska Gynekol** 1995 Oct;60(5):231-4 (Eng. Abstr.) **(Cze)**

[Quantitative evaluation of endocervical cells in women with human papillomavirus infection] Giovagnoli MR, et al. **Minerva Ginecol** 1996 Mar;48(3):65-71 (Eng. Abstr.) **(Ita)**

[Vulvo-vaginal HPV infection: immunological aspects] Zarcone R, et al. **Minerva Ginecol** 1996 Mar;48(3):61-3 (Eng. Abstr.) **(Ita)**

[Histopathological application of in situ PCR (in situ hybridization after amplification by PCR)] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):660-3 (10 ref.) **(Jpn)**

[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664-8 (21 ref.) **(Jpn)**

[Simultaneous screening of HPV-6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):93-6 (Eng. Abstr.) **(Spa)**

[DNA papillomavirus detection in head and neck benign proliferative lesions] Campos-Bañales ME, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):487-94 (Eng. Abstr.) **(Spa)**

[Cytologic-colposcopic-histopathologic correlations in preinvasive cervical lesions and cervical Human Papillomavirus infections] von der Meden Alarcón JW, et al. **Ginecol Obstet Mex** 1995 Sep;63:365-71 (Eng. Abstr.) **(Spa)**

[Extend screening for cervical cancer! Improved diagnosis with papillomavirus test and colposcopy] Rubinstein E. **Lakartidningen** 1996 Jan 31;93(5):365-6, 369 **(Swe)**

METABOLISM

A fluorescence anisotropy study of DNA binding by HPV-11 E2C protein: a hierarchy of E2-binding sites. Alexander KA, et al. **Biochemistry** 1996 Jul 30;35(30):9864-72

E6-AP directs the HPV E6-dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Huibregtse JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:237-45

The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. Antinore MJ, et al. **EMBO J** 1996 Apr 15; 15(8):1950-60

The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication. Liu JS, et al. **J Biol Chem** 1995 Nov 10;270(45):27283-91

Coincidental expression of E5a and c-jun in human papillomavirus type 6/11-infected condylomata. Chen SL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1145-9

Characterization of the helicase and ATPase activity of human papillomavirus type 6b E1 protein. Jenkins O, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1805-9

The ATP-binding and ATPase activities of human papillomavirus type 16 E1 are significantly weakened by the absence of prolines in its ATP-binding domain. Raj K, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2949-56

Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. Gu Z, et al. **J Virol** 1995 Dec;69(12):8051-6

High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. Li X, et al. **J Virol** 1996 Jul;70(7):4509-16

Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. Stacey SN, et al. **J Virol** 1995 Nov;69(11):7023-31

C/EBPbeta is a negative regulator of human papillomavirus type 11 in keratinocytes. Wang H, et al. **J Virol** 1996 Jul; 70(7):4839-44

Human papillomavirus type 11 E1--E4 and L1 proteins colocalize in the mouse xenograft system at multiple time points. Brown DR, et al. **Virology** 1995 Dec 1;214(1):259-63

Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Crook T, et al. **Virology** 1996 Mar 1;217(1):285-92

Analysis of HPV1 E4 complexes and their association with keratins in vivo. Doorbar J, et al. **Virology** 1996 Apr 1; 218(1):114-26

Domains of the E1 protein of human papillomavirus type 33 involved in binding to the E2 protein. Müller F, et al. **Virology** 1996 May 1;219(1):247-56

Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein. Qi YM, et al. **Virology** 1996 Feb 1;216(1):35-45

PATHOGENICITY

Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453-63 (69 ref.)

Promoter usage in the E7 ORF of HPV16 correlates with epithelial differentiation and is largely confined to low-grade genital neoplasia. Nilsson CH, et al. **Int J Cancer** 1996 Jan 3;65(1):6-12

HPV and cervical cancer [letter] Pontén J, et al. **Int J Cancer** 1995 Oct 9;63(2):317

Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. Snijders PJ, et al. **Int J Cancer** 1996 May 16;66(4):464-9

Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Völter C, et al. **Int J Cancer** 1996 May 16;66(4):453-6

Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix? [letter; comment] zur Hausen H. **Int J Cancer** 1995 Oct 9;63(2):315-6. Comment on: Int J Cancer 1995 Jan 3;60(1):1-26.

Primary keratinocytes can be infected by natural isolates of genital human papillomavirus. Venuti A, et al. **Intervirology** 1995;38(5):264-8

Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. Routes JM, et al. **J Virol** 1995 Dec;69(12):7639-47

PHYSIOLOGY

Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Tommasino M, et al. **Bioessays** 1995 Jun; 17(6):509-18 (62 ref.)

Malignant progression of an HPV16-immortalized human keratinocyte cell line (HPKIA) in vitro. Dürst M, et al. **Cancer Genet Cytogenet** 1995 Dec;85(2):105-12

Viral integration sites in human papilloma virus-33-immortalized cervical keratinocyte cell lines. Gilles C, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):63-9

Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Reznikoff CA, et al. **Cancer Res** 1996 Jul 1;56(13):2886-90

Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Vieira KB, et al. **Cancer Res** 1996 May 15; 56(10):2452-7

The human papillomavirus E6/E7 genes induce discordant changes in the expression of cell growth regulatory proteins. Pei XF. **Carcinogenesis** 1996 Jul;17(7):1395-401

Oral keratinocytes immortalized with the early region of human papillomavirus type 16 show elevated expression of interleukin 6, which acts as an autocrine growth factor for the derived T103C cell line. Bryan D, et al. **Cell Growth Differ** 1995 Oct;6(10):1245-50

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685-704 (81 ref.)

HPV immortalization of human oral epithelial cells: a model for carcinogenesis. Oda D, et al. **Exp Cell Res** 1996 Jul 10;226(1):164-9

Development and characterization of a novel xenograft model permissive for human papillomavirus DNA amplification and late gene expression. Sexton CJ, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3107-12

Control of HPV replication: implications for squamous neoplasia [editorial] Herrington CS. **J Pathol** 1996 Mar; 178(3):237-8

Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. Dalal S, et al. **J Virol** 1996 Feb;70(2):683-8

Suppression of cellular proliferation by the papillomavirus E2 protein. Dowhanick JJ, et al. **J Virol** 1995 Dec; 69(12):7791-9

Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. Herber R, et al. **J Virol** 1996 Mar;70(3):1873-81

Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. Roden RB, et al. **J Virol** 1996 May;70(5):3298-301

In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. Roden RB, et al. **J Virol** 1996 Sep;70(9):5875-83

Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions. Sakai H, et al. **J Virol** 1996 Mar;70(3):1602-11

Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. Xiong Y, et al. **J Virol** 1996 Feb; 70(2):999-1008

Telomerase activation by the E6 gene product of human papillomavirus type 16. Klingelhutz AJ, et al. **Nature** 1996 Mar 7;380(6569):79-82

Control of HPV 18 DNA replication by cellular and viral transcription factors. Demeret C, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4777-84

In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Frattini MG, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3062-7

The role of human papillomavirus in cervical cancer [editorial] [see comments] Cooper K. **S Afr Med J** 1995 Sep;85(9):841-2. Comment in: S Afr Med J 1996 Apr;86(4):379, 381.

Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males. Wideroff L, et al. **Viral Immunol** 1996;9(1):23-5

Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues. Maran A, et al. **Virology** 1995 Oct 1;212(2):285-94

Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Nakagawa S, et al. **Virology** 1995 Oct 1;212(2):535-42

Biologic activity of human papillomavirus type 16 E6/E7 cDNA clones isolated from SiHa cervical carcinoma cell line. Yamada T, et al. **Virus Genes** 1995;10(1):15-25

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731-40 (63 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Ultrastructure and human papillomavirus DNA in papillomatosis of external auditory canal. Xia MY, et al. **Int J Dermatol** 1996 May;35(5):337-9

PAPILLOMAVIRUS, RABBIT see **PAPILLOMAVIRUS SYLVILAGI**

PAPILLOMAVIRUS SYLVILAGI

CHEMISTRY

Transforming properties of the cottontail rabbit papillomavirus oncoproteins Le6 and SE6 and of the E8 protein. Harry JB, et al. **J Virol** 1996 Jun;70(6):3355-62

GENETICS

High efficiency, long-term clinical expression of cottontail rabbit papillomavirus (CRPV) DNA in rabbit skin following particle-mediated DNA transfer. Xiao W, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2620-2

GROWTH & DEVELOPMENT

Laboratory production of infectious stocks of rabbit oral papillomavirus. Christensen ND, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1793-8

IMMUNOLOGY

Leukocyte proliferation in vitro against cottontail rabbit papillomavirus in rabbits with persisting papillomas/cancer or after regression. Höpfl R, et al. **Arch Dermatol Res** 1995; 287(7):652-8

Protection against papillomavirus with a polynucleotide vaccine. Donnelly JJ, et al. **J Infect Dis** 1996 Feb; 173(2):314-20

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. Christensen ND, et al. **J Virol** 1996 Feb; 70(2):960-5

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Jansen KU, et al. **Vaccine** 1995 Nov;13(16):1509-14

ISOLATION & PURIFICATION

Rapid, high-level transient expression of papillomavirus-like particles in insect cells. Benincasa D, et al. **Biotechniques** 1996 May;20(5):890-5

PHYSIOLOGY

The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. Schmitt A, et al. **J Virol** 1996 Mar;70(3):1912-22

High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA. Kreider JW, et al. **J Virol Methods** 1995 Oct;55(2):233-44

PAPILLON-LEAGE AND PSAUME SYNDROME see **OROFACIODIGITAL SYNDROMES**

PAPILLON-LEFEVRE DISEASE

Dental treatment of Papillon-Lefèvre syndrome: 15-year follow-up. Tinanoff N, et al. **J Clin Periodontol** 1995 Aug; 22(8):609-12

COMPLICATIONS

Systemic retinoid medication and periodontal health in patients with Papillon-Lefèvre syndrome. Lundgren T, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):176-9

GENETICS

Occurrence of Actinobacillus actinomycetemcomitans and anti-leukotoxin antibodies in some members of an extended family affected by Papillon-Lefèvre syndrome. Stabholz A, et al. **J Periodontol** 1995 Jul;66(7):653-7

[Familial case of Papillon-Lefèvre syndrome] Budai M, et al. **Fogorv Sz** 1996 Feb;89(2):51-5 **(Hun)**

MICROBIOLOGY

Microbiological and serological investigations of oral lesions in Papillon-Lefèvre syndrome. Clerehugh V, et al.

PAPILLON-LEFEVRE DISEASE

J Clin Pathol 1996 Mar;49(3):255-7

PAPIO

The prevalence of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) increases with the duration of captivity. D'Hooghe TM, et al.
Acta Obstet Gynecol Scand 1996 Feb;75(2):98-101

Intermediate filament structure of alpha-keratin in baboon hair. James VJ, et al. **Int J Biol Macromol** 1995 Apr; 17(2):99-104

Failure of experimental infection of baboons (Papio hamadryas) with the eggs of Asian Taenia. Fall EH, et al. **J Helminthol** 1995 Dec;69(4):367-8

Is there an epidemic/epizootic of spondyloarthropathy in baboons? [letter] Rothschild BM, et al. **J Med Primatol** 1996 Jan;25(1):69-70

Periodontitis in the baboon: a potential model for human disease. Miller DR, et al. **J Periodontal Res** 1995 Nov; 30(6):404-9

Interspecies transmission of macaque simian T-cell leukemia/lymphoma virus type 1 in baboons resulted in an outbreak of malignant lymphoma. Voevodin A, et al. **J Virol** 1996 Mar;70(3):1633-9

Surgical correction of severe vaginal introital stenosis in female baboons (Papio sp.) infected with simian agent 8. Singleton WL, et al. **Lab Anim Sci** 1995 Dec;45(6):628-30

Baboon cells fail to combat AIDS [news] **Nature** 1996 Feb 15;379(6566):577

AIDS patient given baboon bone marrow [news] Lehrman S. **Nature** 1995 Dec 21-28;378(6559):756

Development of spontaneous endometriosis in baboons. D'Hooghe TM, et al. **Obstet Gynecol** 1996 Sep;88(3):462-6

Screening of baboons as potential liver donors for humans. Luo Y, et al. **Transplant Proc** 1996 Apr;28(2):855

Lack of susceptibility of baboons to infection with hepatitis B virus. Michaels MG, et al. **Transplantation** 1996 Feb 15; 61(3):350-1

ANATOMY & HISTOLOGY

Effects of age, sex, and heredity on measures of bone mass in baboons (Papio hamadryas). Kammerer CM, et al.
J Med Primatol 1995 Dec;24(4):236-42

Functional evaluation of isolated islets from baboon pancreata. Rastellini C, et al. **Transplant Proc** 1995 Dec; 27(6):3385-6

BLOOD

Low blood protein heterozygosity in zoo-bred hamadryas baboons. Wang M, et al.
Comp Biochem Physiol B Biochem Mol Biol 1996 Feb; 113(2):403-9

EMBRYOLOGY

Biphasic developmental expression of adrenocorticotropin receptor messenger ribonucleic acid levels in the baboon fetal adrenal gland. Albrecht ED, et al. **Endocrinology** 1996 Apr;137(4):1292-8

GENETICS

MspI RFLP at the CETP locus in baboons. Cole SA, et al. **Anim Genet** 1996 Feb;27(1):63

TaqI RFLP at the LIPC locus in baboons. Cole SA, et al. **Anim Genet** 1996 Feb;27(1):63

Genetic self-management in a captive colony of mandrills (Mandrillus sphinx) as revealed by DNA minisatellite fingerprints. Wickings EJ. **Electrophoresis** 1995 Sep; 16(9):1678-83

Linkage mapping in Papio baboons: conservation of a syntenic group of six markers on human chromosome 1. Rogers J, et al. **Genomics** 1995 Jul 20;28(2):251-4

GROWTH & DEVELOPMENT

Magnetic resonance imaging in vivo monitoring of T2 relaxation time: quantitative assessment of primate brain maturation. Miot E, et al. **J Med Primatol** 1995 Feb; 24(2):87-93

IMMUNOLOGY

Characterization of baboon class I major histocompatibility molecules. Implications for baboon-to-human xenotransplantation. Prilliman K, et al. **Transplantation** 1996 Apr 15;61(7):989-96

METABOLISM

Smooth muscle myosin II and alpha smooth muscle actin expression in the baboon (Papio anubis) uterus is associated with glandular secretory activity and stromal cell transformation. Christensen S, et al. **Biol Reprod** 1995 Sep; 53(3):598-608

Different molecular and messenger ribonucleic acid forms of insulin-like growth factor-binding protein-3 in the pregnant baboon (Papio anubis). Gargosky SE, et al.
J Endocrinol 1995 Dec;147(3):449-61

Bioactive oxytocin in human and baboon corpora lutea. Khan-Dawood FS, et al. **J Endocrinol** 1995 Dec; 147(3):525-32

PARASITOLOGY

Schistosoma mansoni induces in the Kenyan baboon a novel intestinal pathology that is manifestly modulated by an irradiated cercarial vaccine. Farah IO, et al. **J Parasitol** 1996 Aug;82(4):601-7

Zoonotic intestinal parasites of hamadryas baboons Papio hamadryas in the western and northern regions of Saudi Arabia. Ghandour AM, et al. **J Trop Med Hyg** 1995 Dec; 98(6):431-9

Intestinal parasite burden in five troops of olive baboons (Papio cynocephalus anubis) in Gombe Stream National Park, Tanzania. Müller-Graf CD, et al. **Parasitology** 1996 May;112 (Pt 5):489-97

Hamadryas baboons Papio hamadryas as maintenance hosts of Schistosoma mansoni in Saudi Arabia. Zahed NZ, et al. **Trop Med Int Health** 1996 Aug;1(4):449-55

PHYSIOLOGY

Social subordinance as a marker of hypercortisolism. Some unexpected subtleties. Sapolsky RM. **Ann N Y Acad Sci** 1995 Dec 29;771:626-39

Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Harker LA, et al. **Blood** 1996 Mar 1;87(5):1833-44

Cingulate kindling in Senegalese baboons, Papio papio. Wada JA, et al. **Epilepsia** 1995 Nov;36(11):1142-51

Suppression of maternal adrenal dehydroepiandrosterone and dehydroepiandrosterone sulfate production by estrogen during baboon pregnancy. Albrecht ED, et al.
J Clin Endocrinol Metab 1995 Nov;80(11):3201-8

Morphological study of changes in the baboon oviductal epithelium during the menstrual cycle. Odor DL, et al. **Microsc Res Tech** 1995 Sep 1;32(1):13-28

Baboon fertility and social status [letter; comment] Altmann J, et al. **Nature** 1995 Oct 26;377(6551):688-90. Comment on: Nature 1995 Jan 5;373(6509):60-3.

Functional evaluation of isolated islets from baboon pancreata. Rastellini C, et al. **Transplant Proc** 1995 Dec; 27(6):3385-6

VIROLOGY

Distribution of baboon endogenous virus among species of African monkeys suggests multiple ancient cross-species transmissions in shared habitats. van der Kuyl AC, et al. **J Virol** 1995 Dec;69(12):7877-87

Xenozoonoses: assessing activation of latent/unknown viruses in immunosuppressed baboons. Stark JH, et al.
Transplant Proc 1996 Apr;28(2):856-7

Characterization of a novel syncytium-inducing baboon reovirus. Duncan R, et al. **Virology** 1995 Oct 1;212(2):752-6

PAPOVAVIRIDAE

PHYSIOLOGY

Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines. Herrmann M, et al. **J Virol** 1995 Nov;69(11):6797-804

PAPOVAVIRIDAE INFECTIONS

Human papillomavirus in nonmelanoma skin cancer? The phylogenetic tree of the papillomavirus family is not yet complete [letter; comment] Höpfl R, et al.
Arch Dermatol 1996 Jul;132(7):834. Comment on: Arch Dermatol 1993 Dec;129(12):1585-8. Comment on: Arch Dermatol 1994 Feb;130(2):235-8. Comment on: Arch Dermatol 1995 Jan;131(1):107-8.

Psoralen plus UV-A-associated skin cancer: a likely role for human papillomavirus type 16? [letter; comment] McGregor JM, et al. **Arch Dermatol** 1996 Jan;132(1):90. Comment on: Arch Dermatol 1995 Jun;131(6):701-4.

BK virus encephalitis in an immunocompetent patient. Voltz R, et al. **Arch Neurol** 1996 Jan;53(1):101-3

Detection of human papillomavirus types 16, 18 DNA related sequences in bronchogenic carcinoma by polymerase chain reaction. Li Q, et al. **Chin Med J (Engl)** 1995 Aug; 108(8):610-4

Human papillomavirus types and cervical cancer. Apgar BS. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):39-40, 43

Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions [see comments] Park TW, et al. **J Natl Cancer Inst** 1996 Mar 20;88(6):355-8. Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):317-8.

[Detection of human papilloma virus in esophageal squamous cell carcinoma and adjacent tissue specimens in Linxian] Lu S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):321-4 (Eng. Abstr.) **(Chi)**

[A study on the relationship between human papillomavirus and the incidence of cervical carcinoma] Han P, et al.
Chung Hua Fu Chan Ko Tsa Chih 1995 Oct;30(10):608-10 (Eng. Abstr.) **(Chi)**

[Progresses in orodentofacial surgery in China, 1995] Qiu W. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):759-60 (0 ref.) **(Chi)**

[Epidermodysplasia verruciformis, human Papillomavirus infection, genital epithelial neoplasia and possible immunodeficiency] Rossen K, et al. **Ugeskr Laeger** 1996 Feb 12;158(7):923-4 (Eng. Abstr.) **(Dan)**

[A case of conjunctival raspberry tumor of viral origin] Bazin S, et al. **J Fr Ophtalmol** 1996;19(2):140-2 (Eng. Abstr.) **(Fre)**

[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417-20 (37 ref.) **(Heb)**

[A case of primary transitional cell carcinoma of the Bartholin gland with human papillomavirus type 18 infection] Hasegawa K, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Dec; 47(12):1385-8 **(Jpn)**

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509-13 (36 ref.) (Eng. Abstr.) **(Spa)**

[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja-Chayeb L, et al.
Salud Publica Mex 1996 Jan-Feb;38(1):47-57 (40 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

HPV infection in male partners of women with squamous intraepithelial neoplasia and/or high-risk HPV. Strand A, et al. **Acta Derm Venereol** 1995 Jul;75(4):312-6

Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. Critchlow CW, et al. **AIDS** 1995 Nov; 9(11):1255-62

Hemorrhagic cystitis associated with BKV in patients with refractory acute lymphoblastic leukemia [letter] Azzi A, et al. **Am J Hematol** 1996 Jun;52(2):121-2

Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453-63 (69 ref.)

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69-84 (96 ref.)

BK virus and a new type of JC virus excreted by HIV-1 positive patients in rural Tanzania. Agostini HT, et al.
Arch Virol 1995;140(11):1919-34

Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. Dillner J, et al.
BMJ 1995 Nov 18;311(7016):1346

Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study [see comments] Lehtinen M, et al. **BMJ** 1996 Mar 2;312(7030):537-9. Comment in: BMJ 1996 Mar 2;312(7030):522-3.

Human papilloma-virus classified as carcinogenic [news] Mayor S. **BMJ** 1996 Jul 13;313(7049):70

Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. Woodman CB, et al.
Br J Cancer 1996 Feb;73(4):553-6

P53 expression and human papillomavirus infection in transplant recipients and in patients with epidermodysplasia verruciformis [letter] McGregor JM, et al.
Br J Dermatol 1996 Feb;134(2):374

Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Chua KL, et al. **Cancer** 1996 Jan 1;77(1):121-7

Human papillomavirus in cyclophosphamide and diverticulum-associated squamous cell carcinoma of urinary bladder: a case report. Wang JS, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1996 Apr;57(4):305-9

Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56-62 (41 ref.)

The pathology of vulvar neoplasia. Lininger RA, et al.
Curr Opin Obstet Gynecol 1996 Feb;8(1):63-8 (28 ref.)

Human papillomavirus-associated malignancies in HIV-positive men and women. Palefsky J.
Curr Opin Oncol 1995 Sep;7(5):437-41 (46 ref.)

Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Pilotti S, et al. **Diagn Mol Pathol** 1995 Dec; 4(4):239-48

Prognostic evaluation of HPV-associated precancerous and microinvasive carcinoma of the oral cavity: combined use of nucleolar organiser regions (AgNOR) and proliferating cell nuclear antigen (PCNA). Donofrio V, et al.
Eur J Cancer B Oral Oncol 1995 May;31B(3):174-80

Cervical intraepithelial neoplasia and human papillomavirus related lesions of the genital tract in HIV positive and negative women. Branca M, et al.
Eur J Gynaecol Oncol 1995;16(5):410-7

Squamous cell carcinomas of the anus and infection with human papillomavirus in patients with AIDS. Muñoz-Jiménez F, et al. **Eur J Surg** 1996 Mar;162(3):251-3

Human papilloma virus, vulvar dystrophy, and vulvar carcinoma: differential expression of human papillomavirus and vulvar dystrophy in the presence and absence of squamous cell carcinoma of the vulva. Sagerman PM, et al. **Gynecol Oncol** 1996 Jun;61(3):328-32

Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Laszlo D, et al. **Haematologica** 1995 Sep-Oct;80(5):421-5

Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Kjaer SK, et al.
Int J Cancer 1996 Mar 1;65(5):601-6

Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Mao EJ, et al.
Int J Cancer 1996 Apr 22;69(2):152-8

HPV and cervical cancer [letter] Pontén J, et al. **Int J Cancer** 1995 Oct 9;63(2):317

Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix? [letter; comment] zur Hausen H. **Int J Cancer** 1995 Oct 9;63(2):315–6. Comment on: Int J Cancer 1995 Jan 3;60(1):1–26.

Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Shah KV, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):127–30

Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)

The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55–60 (36 ref.)

p53 and bcl-2 proteins as prognostic markers in human papillomavirus–associated cervical lesions. Kurvinen K, et al. **J Clin Oncol** 1996 Jul;14(7):2120–30

Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. Shoji Y, et al. **J Clin Pathol** 1996 Feb;49(2):134–8

Cervical abnormalities, human papillomavirus, and human immunodeficiency virus infections in women in Malawi. Motti PG, et al. **J Infect Dis** 1996 Mar;173(3):714–7

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.). Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331-2.

Treasure hunt for human papillomaviruses in nonmelanoma skin cancers [editorial; comment] Burk RD, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):781–2. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):802–11.

Preferential association of human papillomavirus with high-grade histologic variants of penile–invasive squamous cell carcinoma. Gregoire L, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1705–9

Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients [see comments] Shamanin V, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):802–11. Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):781–2.

Human papillomavirus in a patient with severe gingival overgrowth associated with cyclosporine therapy. A case report. Sağlam F, et al. **J Periodontol** 1996 May; 67(5):528–31

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.). Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males. Wideroff L, et al. **Viral Immunol** 1996;9(1):23–5

Analysis of p53 tumor suppressor gene mutations and human papillomavirus infection in human bladder cancers. Kim KH, et al. **Yonsei Med J** 1995 Sep;36(4):322–31

[Human papillomavirus 6/11 in conjunctival papilloma] Michel JL, et al. **Ann Dermatol Venereol** 1996;123(2):90–2 (Eng. Abstr.) **(Fre)**

[Proctology and human immunodeficiency virus] Puy-Montbrun T. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B145–9 **(Fre)**

[Simultaneous screening of HPV-6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**

[Modified factors in the study of the infertile couple in women with papilloma virus cervical infection, descriptive analysis] Repper Camacho F, et al. **Ginecol Obstet Mex** 1995 Dec;63:502–4 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

HPV infection in male partners of women with squamous intraepithelial neoplasia and/or high-risk HPV. Strand A, et al. **Acta Derm Venereol** 1995 Jul;75(4):312–6

BK virus infection in a kidney allograft diagnosed by needle biopsy. Purighalla R, et al. **Am J Kidney Dis** 1995 Oct; 26(4):671–3

Aggressive conjunctival squamous cell carcinoma in three young Africans. Lewallen S, et al. **Arch Ophthalmol** 1996 Feb;114(2):215–8

Human papillomavirus infections. Rüdlinger R, et al. **Curr Probl Dermatol** 1996;24:67–76 (24 ref.)

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

Improved detection of human papillomavirus infection in genital intraepithelial neoplasia in human immunodeficiency virus positive (HIV +) women by polymerase chain reaction–in situ hybridization. Walker F, et al. **Diagn Mol Pathol** 1996 Jun;5(2):136–46

Human papillomavirus detection in cervical smears and cervical tissue excised by the Loop Electrosurgical Excision Procedure (LEEP). Diagnostic value of cytology, colposcopy and histology. Vardar MA, et al. **Eur J Gynaecol Oncol** 1995;16(6):494–9

Dysplasia and HPV infection initially detected by DNA analysis in cytomorphologically normal cervical smears. Saito J, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):43–8

Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. Tatsura H, et al. **Int J Urol** 1995 Nov;2(5):347–9

Intermethod variation in detection of human papillomavirus DNA in cervical smears. Smits HL, et al. **J Clin Microbiol** 1995 Oct;33(10):2631–6

Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. Kaye JN, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1139–43

Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. Brisson J, et al. **J Infect Dis** 1996 Apr;173(4):794–9

Comparison of detection of human papillomavirus 16 DNA in cervical carcinoma tissues by Southern blot hybridisation and nested polymerase chain reaction. Chang DY, et al. **J Med Microbiol** 1995 Dec;43(6):430–5

Simultaneous polymerase chain reaction detection and restriction typing for the diagnosis of human genital papillomavirus infection. Pizzighella S, et al. **J Virol Methods** 1995 Oct;55(2):245–56

Human papillomavirus infection and transitional cell carcinoma of the bladder. Immunohistochemistry and in situ hybridization. López-Beltrán A, et al. **Pathol Res Pract** 1996 Feb;192(2):154–9

[Specific serologic studies with a novel authentic HPV antigen (virus-like particles) for HPV-6 antibodies in gynecologic patient samples] Heim K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:25–31 (Eng. Abstr.) **(Ger)**

[The value of the Pap test in the diagnostic approach to HPV infection of the cervix uteri] Pozzi M, et al. **Minerva Ginecol** 1995 Jul-Aug;47(7–8):301–4 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Levine LA, et al. **Urology** 1996 Apr;47(4):553–7

[Thymopentin and cervico-vaginal HPV infection associated with CIN] Grismondi GL, et al. **Minerva Ginecol** 1995 Jun; 47(6):255–7 (Eng. Abstr.) **(Ita)**

[beta-Interferon in the therapy of cervico-vaginal papilloma virus (HPV) infection associated with cervical intraepithelial neoplasia (CIN)] Grismondi GL, et al. **Minerva Ginecol** 1995 Dec;47(12):527–9 (Eng. Abstr.) **(Ita)**

[The beneficial effect of immunological and antiviral preparations in herpetic and papillomatosis infections] Topciu V, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec;40(3–4):257–60 **(Rum)**

EPIDEMIOLOGY

Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Persson G, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):287–90

Contraceptive use and reproductive history in women with cervical human papillomavirus infection. Sikström B, et al. **Adv Contracept** 1995 Dec;11(4):273–84

HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. Langley CL, et al. **AIDS** 1996 Apr;10(4):413–7

Increase of genital human papillomavirus infection among men and women in Croatia. Grce M, et al. **Anticancer Res** 1996 Mar-Apr;16(2):1039–41

Task force on recurrent respiratory papillomas. A preliminary report. Derkay CS. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1386–91

Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Burger MP, et al. **Br J Cancer** 1996 Mar;73(6):831–6

Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology. Hinchliffe SA, et al. **Br J Cancer** 1995 Oct;72(4):943–5

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

Epidemiology of human papillomaviruses. Vittorio CC, et al. **Dermatol Clin** 1995 Jul;13(3):561–74 (165 ref.)

Spectrum of genital human papillomavirus infection in a female adolescent population. Jamison JH, et al. **Sex Transm Dis** 1995 Jul-Aug;22(4):236–43

A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. Strickler HD, et al. **Viral Immunol** 1994;7(4):169–77

[Human papillomavirus (HPV) infection in sexual partners of women with condylomatous cervical dysplasia] Llopis Cartagena M, et al. **Arch Esp Urol** 1996 Mar;49(2):112–6 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Human papillomavirus infection in Hong Kong Chinese women with normal and abnormal cervix—detection by polymerase chain reaction method on cervical scrapes. Chan MK, et al. **Gynecol Oncol** 1996 Feb;60(2):217–23

ETIOLOGY

Squamous cell carcinoma of the eyelid and the acquired immunodeficiency syndrome. Maclean H, et al. **Am J Ophthalmol** 1996 Feb;121(2):219–21

Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Sikström B, et al. **Arch Gynecol Obstet** 1995;256(3):131–7

The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888–901 (165 ref.)

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)

[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600–3 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)

Human papillomavirus infection [editorial; comment] [see comments] Hines JF, et al. **BMJ** 1996 Mar 2; 312(7030):522–3. Comment on: BMJ 1996 Mar 2;312(7030):537–9. Comment in: BMJ 1996 Jun 15;312(7045):1542.

Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Lam KY, et al. **Eur J Surg Oncol** 1995 Dec;21(6):613–6

Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Milde-Langosch K, et al. **Int J Cancer** 1995 Nov 27;63(5):639–45

Human papillomavirus DNA in genital cancers, metastases, and lymph nodes. Beyer-Finkler E, et al. **Intervirology** 1995;38(3–4):173–80

Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Chiba I, et al. **Oncogene** 1996 Apr 18;12(8):1663–8

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunity to human papillomavirus-associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175–211 (187 ref.)

Leukocyte proliferation in vitro against cottontail rabbit papillomavirus in rabbits with persisting papillomas/cancer or after regression. Höpfl R, et al. **Arch Dermatol Res** 1995; 287(7):652–8

Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status. Garzetti GG, et al. **Gynecol Obstet Invest** 1995;40(1):52–6

Polyoma tumor development in neonatally polyoma-virus–infected CD4-/- and CD8-/- single knockout and CD4-/-8-/- double knockout mice. Berke Z, et al. **Int J Cancer** 1996 Jul 29;67(3):405–8

Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Odunsi K, et al. **Int J Cancer** 1996 Sep 4;67(5):595–602

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Kanda T, et al. **Intervirology** 1995; 38(3–4):187–91

T cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice. Szomolanyi-Tsuda E, et al. **J Exp Med** 1996 Feb 1;183(2):403–11

Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen. Requirement of CD8+ T lymphocytes. Zerrahn J, et al. **J Immunol** 1996 May 15; 156(10):3919–24

Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. Wikström A, et al. **J Med Virol** 1995 Aug;46(4):368–74

Antibodies prevalence against HPV-6b and -16 recombinant fusion proteins in Korean patients with cervical neoplasia. Park SN, et al. **J Obstet Gynaecol** 1995 Dec;21(6):609–17

A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity. Berke Z, et al. **J Virol** 1996 May;70(5):3093–7

Hypothesis: "Rogue cell"-type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Neel JV, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2690–5

[Interferon-alpha controls HPV infection in cervix epithelium] Labeit D, et al. **Zentralbl Gynakol** 1995; 117(11):566–77 (Eng. Abstr.) **(Ger)**

[Vulvo-vaginal HPV infection: immunological aspects] Zarcone R, et al. **Minerva Ginecol** 1996 Mar;48(3):61–3 (Eng. Abstr.) **(Ita)**

METABOLISM

Overexpression of the proto-oncogene c-jun in association with low-risk type specific human papillomavirus infection in condyloma acuminata. Yang YF, et al. **J Med Virol** 1996 Apr;48(4):302–7

Evidence for dissociation of histone mRNA expression from cellular proliferation in cutaneous human papillomavirus infection. Hinchliffe SA, et al. **J Pathol** 1996 Mar;

178(3):249–54

p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. Tenti P, et al. **J Pathol** 1996 Jan;178(1):65–70

MICROBIOLOGY

Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears. Bollen LJ, et al. **Cancer** 1996 Jun 15;77(12):2538–43

Type 73 human papillomavirus in esophageal squamous cell carcinoma: a novel association. West AB, et al. **Cancer** 1996 Jun 15;77(12):2440–4

Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Völter C, et al. **Int J Cancer** 1996 May 16;66(4):453–6

MORTALITY

Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: a nested case–control study. Franco E, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):271–5

PATHOLOGY

Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Tenti P, et al. **Am J Clin Pathol** 1996 Jul;106(1):52–6

Occurrence of human papillomavirus infection in cervical intraepithelial neoplasia. A retrospective histopathological study of 317 cases treated by laser conization. Lie AK, et al. **APMIS** 1995 Oct;103(10):693–8

Pigmented conjunctival epithelial dysplasia in an HIV positive African: detection of human papillomavirus type 16 [letter] Loeffler KU, et al. **Br J Ophthalmol** 1995 Dec; 79(12):1138–40

Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Fouret P, et al. **Diagn Mol Pathol** 1995 Jun;4(2):122–7

Immunolocalization of cystatin A in condylomatous and dysplastic lesions of the human uterine cervix: correlation with the presence and type of human papillomavirus infection. Pöllänen R, et al. **Int J Gynecol Pathol** 1995 Jul; 14(3):217–22

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)

Postmenopausal squamous atypia: a spectrum including "pseudo–koilocytosis" [see comments] Jovanovic AS, et al. **Mod Pathol** 1995 May;8(4):408–12. Comment in: Mod Pathol 1996 Feb;9(2):158.

Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105–9 (23 ref.)

Histologic and biomolecular aspects of papillomatosis of the vulvar vestibule in relation to human papillomavirus. de Deus JM, et al. **Obstet Gynecol** 1995 Nov;86(5):758–63

Urethral condylomata, due to human papilloma virus (HPV) type 6/11., associated with transitional cell tumors in the bladder and ureter. A case report. Olsen S, et al. **Scand J Urol Nephrol Suppl** 1995;172:51–5

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

[Sequence analysis of PCR amplification products of old formalin fixed conisation tissue sections] Labeit D, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:148–51 (Eng. Abstr.) **(Ger)**

[HPV–5 typing with nested PCR and sequencing in epidermodysplasia verruciformis] Schaller J, et al. **Hautarzt** 1996 Jun;47(6):454–8 (Eng. Abstr.) **(Ger)**

[Changes in the vitamin A status in dysplastic epithelium of the cervix] Volz J, et al. **Zentralbl Gynakol** 1995; 117(9):472–5 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Genetic and structural analysis of a virulence determinant in polyomavirus VP1. Bauer PH, et al. **J Virol** 1995 Dec; 69(12):7925–31

The role of ovarian hormones, age and mammary gland development in polyomavirus mammary tumorigenesis. Rondinelli RH, et al. **Oncogene** 1995 Nov 2;11(9):1817–27

PREVENTION & CONTROL

HIV, Ebola virus and public health measures [letter; comment] Clarke P. **Am Fam Physician** 1996 May 15; 53(7):2283–4. Comment on: Am Fam Physician 1995 Nov 1;52(6):1682.

Polyoma tumor development in neonatally polyoma–virus–infected CD4–/– and CD8–/– single knockout and CD4–/–8–/– double knockout mice. Berke Z, et al. **Int J Cancer** 1996 Jul 29;67(3):405–8

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus–neutralizing antibodies. Gaukroger JM, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1577–83

Protective immunity in BALB/c mice against the simian virus 40–induced mKSA tumor resulting from injection of recombinant large T antigen. Requirement of CD8+ T lymphocytes. Zerrahn J, et al. **J Immunol** 1996 May 15; 156(10):3919–24

Dendritic cells as carriers for a cytotoxic T–lymphocyte epitope–based peptide vaccine in protection against a human papillomavirus type 16–induced tumor. Ossevoort MA, et al. **J Immunother Emphasis Tumor Immunol** 1995 Aug;18(2):86–94

Protection against papillomavirus with a polynucleotide vaccine. Donnelly JJ, et al. **J Infect Dis** 1996 Feb; 173(2):314–20

Immunization with viruslike particles induces long–term protection of rabbits against challenge with cottontail rabbit papillomavirus. Christensen ND, et al. **J Virol** 1996 Feb; 70(2):960–5

Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860–6 (30 ref.)

Vaccination with yeast–expressed cottontail rabbit papillomavirus (CRPV) virus–like particles protects rabbits from CRPV–induced papilloma formation. Jansen KU, et al. **Vaccine** 1995 Nov;13(16):1509–14

PSYCHOLOGY

Applications of the monitoring process model to coping with severe long–term medical threats. Miller SM, et al. **Health Psychol** 1996 May;15(3):216–25

SURGERY

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Elfgren K, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):937–42

THERAPY

Human papillomavirus infection: treatment options for warts [see comments] Miller DM, et al. **Am Fam Physician** 1996 Jan;53(1):135–43, 148–50 (30 ref.). Comment in: Am Fam Physician 1996 Jul;54(1):59, 62.

Interferon response depends on viral transcription in human papillomavirus–containing lesions. Arany I, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2865–9

Topic and systemic administration of natural alfa interferon in the treatment of female and male HPV genital infections. Stentella P, et al. **Clin Exp Obstet Gynecol** 1996;23(1):29–36

Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233–46 (59 ref.)

Medical therapy of genital human papilloma virus–related disease. Lacey CJ, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):399–407 (45 ref.)

Induced regression of bovine papillomas by intralesional immunotherapy. Hall H, et al. **Ther Immunol** 1994 Dec; 1(6):319–24

TRANSMISSION

Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Puranen M, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):694–9

Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598–601 (39 ref.)

Non–sexual transmission of human papillomavirus [letter; comment] Mansour P, et al. **BMJ** 1996 Jun 15; 312(7045):1542. Comment on: BMJ 1996 Mar 2;312(7030):522–3.

Perinatal acquisition of cervical cancer–associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853–8 (66 ref.)

[Clinical observation on vertical transmission of human papillomavirus] Xu S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):457–9 (Eng. Abstr.) **(Chi)**

[The pediatrician, sexual abuse and anogenital warts in prepuberty] Martínez–Roig A, et al. **Child Abuse Negl** 1996 Jan;20(1):55–62 (Eng. Abstr.) **(Spa)**

[Human papillomavirus infection in male genitalia] Cano Garfias R, et al. **Ginecol Obstet Mex** 1995 Oct;63:439–42 (Eng. Abstr.) **(Spa)**

VETERINARY

Bovine papillomavirus type 4 in Australia. Bloch N, et al. **Aust Vet J** 1995 Jul;72(7):273–4

Failure of maternally derived yolk IgG to reach detectable concentrations in the sera of nestling budgerigars (Melopsittacus undulatus). Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):700–8

Production of avian polyomavirus seronegative budgerigars (Melopsittacus undulatus) from seropositive adults. Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):897–9

Characterization of the avian polyomavirus–associated glomerulopathy of nestling parrots. Phalen DN, et al. **Avian Dis** 1996 Jan–Mar;40(1):140–9

Laboratory production of infectious stocks of rabbit oral papillomavirus. Christensen ND, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1793–8

Diagnosis and clinical course of canine oral papillomavirus infection. Bredal WP, et al. **J Small Anim Pract** 1996 Mar; 37(3):138–42

Papillomavirus infection in raccoons (Procyon lotor). Hamir AN, et al. **J Vet Diagn Invest** 1995 Oct;7(4):549–51

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Suzich JA, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11553–7

Bovine papillomavirus type 4 DNA isolated from a skin lesion in a steer. Bloch N, et al. **Vet Rec** 1996 Apr 27; 138(17):414–6

Virus–like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Kirnbauer R, et al. **Virology** 1996 May 1;219(1):37–44

VIROLOGY

Carbon dioxide laser miniconization for treatment of human papillomavirus infection associated with cervical intraepithelial neoplasia. Békássy Z, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):822–6

HPV–types, cytological and histopathological findings in three groups of women with possible HPV–related disease. Frederiksson A, et al. **Acta Obstet Gynecol Scand** 1996 Jul; 75(6):556–62

Polymerase chain reaction search for viral etiology of vulvar vestibulitis syndrome. Bornstein J, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):139–44

Prevalence of human papillomavirus in cervical scrapes, as analyzed by PCR, in a population–based sample of women with and without cervical dysplasia. Gjøoen K, et al. **APMIS** 1996 Jan;104(1):68–74

Human papillomavirus infection in cervical biopsies from Norwegian gynecological in–patients. Jenkins A, et al. **APMIS** 1996 Jan;104(1):30–4

The association of vascular proliferation with HPV status and epithelial PCNA positivity in cervical intraepithelial lesions. Soini Y, et al. **APMIS** 1996 Mar;104(3):183–90

Cutaneous warts: clinical, histological and virological correlations [letter; comment] Jablonska S, et al. **Arch Dermatol Res** 1995;287(6):616–8. Comment on: Arch Dermatol Res 1993;285(8):460–5.

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

Clear cell adenosquamous carcinoma of the cervix. An aggressive tumor associated with human papillomavirus–18. Fujiwara H, et al. **Cancer** 1995 Nov 1;76(9):1591–600

Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Iwasawa A, et al. **Cancer** 1996 Jun 1; 77(11):2275–9

Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Mullokandov MR, et al. **Cancer Res** 1996 Jan 1;56(1):197–205

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685–704 (81 ref.)

Study of human papillomavirus infection in patients with anal squamous carcinoma. Ramanujam PS, et al. **Dis Colon Rectum** 1996 Jan;39(1):37–9

Evaluation of non–radioactive temperature gradient SSCP analysis and of temperature gradient gel electrophoresis for the detection of HPV 6–variants in condylomata acuminata and Buschke–Loewenstein tumours. Rübben A, et al. **Eur J Epidemiol** 1995 Oct;11(5):501–6

Management of low–grade CIN: follow–up or treatment? Hording U, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):49–52

Detection of human papillomavirus DNA sequences in cancer of the urinary bladder by in situ hybridisation and polymerase chain reaction. Gopalkrishna V, et al. **Genitourin Med** 1995 Aug;71(4):231–3

Detection of human papillomavirus types in balanitis xerotica obliterans and other penile conditions. Lau PW, et al. **Genitourin Med** 1995 Aug;71(4):228–30

Cervical dysplasia in HIV–seropositive women: role of human papillomavirus infection and immune status. Garzetti GG, et al. **Gynecol Obstet Invest** 1995;40(1):52–6

Latent BK virus infection and Kaposi's sarcoma pathogenesis. Monini P, et al. **Int J Cancer** 1996 Jun 11;66(6):717–22

Clinical application of HPV typing in cervical cancer. Namkoong SE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S59–67

Roots and perspectives of contemporary papillomavirus research. zur Hausen H. **J Cancer Res Clin Oncol** 1996; 122(1):3–13 (133 ref.)

Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. van Belkum A, et al. **J Clin Microbiol** 1995 Nov;33(11):2957–62

Development and characterization of a novel xenograft model permissive for human papillomavirus DNA amplification and late gene expression. Sexton CJ, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3107–12

Serology of human papillomavirus type 16 infections: where angels fear to tread? [letter; comment] Bible JM, et al. **J Infect Dis** 1996 Jul;174(1):237–9. Comment on: J Infect Dis 1995 Dec;172(6):1425–30.

Detection of several types of human papilloma viruses in AIDS–associated Kaposi's sarcoma. Adams V, et al. **J Med Virol** 1995 Jul;46(3):189–93

Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. Cason J, et al. **J Med Virol** 1995 Nov;47(3):209–18

Molecular analysis of cellular loci disrupted by

papillomavirus 16 integration in cervical cancer: frequent viral integration in topologically destabilized and transcriptionally active chromosomal regions. Choo KB, et al. **J Med Virol** 1996 May;49(1):15–22

Deletion in the L1 open reading frame of human papillomavirus type 6a genomes associated with recurrent laryngeal papilloma. Suzuki T, et al. **J Med Virol** 1995 Nov;47(3):191–7

Consensus panel on cervical cancer highlights the HPV connection [news] McNeil C. **J Natl Cancer Inst** 1996 May 1;88(9):575

Labelling pattern obtained by non-isotopic in situ hybridization as a prognostic factor in HPV-associated lesions. Gómez F, et al. **J Pathol** 1996 Jul;179(3):272–5

Control of HPV replication: implications for squamous neoplasia [editorial] Herrington CS. **J Pathol** 1996 Mar; 178(3):237–8

The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. Schmitt A, et al. **J Virol** 1996 Mar;70(3):1912–22

Functional comparison of PML-type and archetype strains of JC virus. Sock E, et al. **J Virol** 1996 Mar;70(3):1512–20

Genomic organization of human papillomavirus type 18 in cervical cancer specimens. Kitagawa K, et al. **Jpn J Cancer Res** 1996 Mar;87(3):263–8

Prevalence of human papillomavirus DNA in female cervical lesions from Rio de Janeiro, Brazil. Cavalcanti SM, et al. **Mem Inst Oswaldo Cruz** 1994 Oct–Dec;89(4):575–80

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122–4, 127–9 (55 ref.)

Short-term fluctuations in the detection of cervical human papillomavirus DNA. Wheeler CM, et al. **Obstet Gynecol** 1996 Aug;88(2):261–8

Detection of human papillomaviruses in cancer of the uterine cervix [letter; comment] Molendijk LW. **S Afr Med J** 1996 Apr;86(4):379, 381. Comment on: S Afr Med J 1995 Sep;85(9):841–2.

A model for mixed virus disease: co-infection with Moloney murine leukemia virus potentiates runting induced by polyomavirus (A2 strain) in Balb/c and NIH Swiss mice. Atencio IA, et al. **Virology** 1995 Oct 1;212(2):356–66

Differentiation-dependent transcription of the epidermodysplasia verruciformis-associated human papillomavirus type 5 in benign lesions. Haller K, et al. **Virology** 1995 Dec 1;214(1):245–55

DNA rearrangements impairing BK virus productive infection in urinary tract tumors. Monini P, et al. **Virology** 1995 Dec 1;214(1):273–9

[Quantitative evaluation of endocervical cells in women with human papillomavirus infection] Giovagnoli MR, et al. **Minerva Ginecol** 1996 Mar;48(3):65–71 (Eng. Abstr.) **(Ita)**

[Simultaneous screening of HPV-6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**

[Cytologic-colposcopic-histopathologic correlations in preinvasive cervical lesions and cervical Human Papillomavirus infections] von der Meden Alarcón JW, et al. **Ginecol Obstet Mex** 1995 Sep;63:365–71 (Eng. Abstr.) **(Spa)**

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo-Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

PAPP-A see **PREGNANCY-ASSOCIATED ALPHA-PLASMA PROTEIN**

PAPP-C see **PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEIN**

PAPP-D see **PLACENTAL LACTOGEN**

PAPPATACI FEVER see **PHLEBOTOMUS FEVER**

PAPPATACI FEVER VIRUS see **SANDFLY FEVER GROUP VIRUSES**

PAPULOSQUAMOUS DISORDERS see **SKIN DISEASES, PAPULOSQUAMOUS**

PARA-AMINOAZOBENZENE see **P-AMINOAZOBENZENE**

PARA-AMINOBENZOIC ACID see **4-AMINOBENZOIC ACID**

PARA-AMINOHIPPURIC ACID see **P-AMINOHIPPURIC ACID**

PARA-AMINOSALICYLIC ACID see **P-AMINOSALICYLIC ACID**

PARA-AZOBENZENEARSONATE see **P-AZOBENZENEARSONATE**

PARA-CHLOROAMPHETAMINE see **P-CHLOROAMPHETAMINE**

PARA-CHLOROPHENYLALANINE see **FENCLONINE**

PARA-DIHYDROXYBENZENES see **HYDROQUINONES**

PARA-FLUOROPHENYLALANINE see **P-FLUOROPHENYLALANINE**

PARA-HYDROXYAMPHETAMINE see **P-HYDROXYAMPHETAMINE**

PARA-HYDROXYBENZOATE HYDROXYLASE see **4-HYDROXYBENZOATE-3-MONOOXYGENASE**

PARA-HYDROXYBENZOIC ACIDS see **PARABENS**

PARA-HYDROXYPHENYLPYRUVATE HYDROXYLASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

PARA-HYDROXYPHENYLPYRUVATE OXIDASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

PARA-OCTOPAMINE see **OCTOPAMINE**

PARABENS

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative—a double-blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782–4

Esoteric contact dermatitis. part I: The paraben paradox [news] Fisher AA. **Cutis** 1996 Feb;57(2):65–6

Allergy to Unna boots in four patients. Praditsuwan P, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):906–8

CHEMICAL SYNTHESIS

New low-density lipoprotein receptor upregulators acting via a novel mechanism. Ashton MJ, et al. **J Med Chem** 1996 Aug 16;39(17):3343–56

CHEMISTRY

X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agents, thiocyanate, methylparaben, and phenol. Whittingham JL, et al. **Biochemistry** 1995 Nov 28;34(47):15553–63

METABOLISM

Repression of 4-hydroxybenzoate transport and degradation by benzoate: a new layer of regulatory control in the Pseudomonas putida beta-ketoadipate pathway. Nichols NN, et al. **J Bacteriol** 1995 Dec;177(24):7033–40

PHARMACOKINETICS

Effect of 2-hydroxypropyl-beta-cyclodextrin on percutaneous absorption of methyl paraben. Tanaka M, et al. **J Pharm Pharmacol** 1995 Nov;47(11):897–900

PHARMACOLOGY

Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Scott EM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2610–4

New low-density lipoprotein receptor upregulators acting via a novel mechanism. Ashton MJ, et al. **J Med Chem** 1996 Aug 16;39(17):3343–56

PARABIOSIS

Suppression and reversal of gld disease by parabiosis with normal mice. Kakkanaiah VN, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):6–13

[Effect of heterochronic parabiosis on liver microsomal enzyme oxidation] Frol'kis VV, et al. **Dokl Akad Nauk** 1996 Apr;347(6):828–30 **(Rus)**

PARACETAMOL see **ACETAMINOPHEN**

PARACHUTING see **AVIATION**

PARACOCCIDIOIDES

Neutrophil oxidative metabolism and killing of P. brasiliensis after air pouch infection of susceptible and resistant mice. Meloni-Bruneri LH, et al. **J Leukoc Biol** 1996 Apr; 59(4):526–33

CHEMISTRY

Structural characterization of a new galactofuranose-containing glycolipid antigen of Paracoccidioides brasiliensis. Levery SB, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):639–45

CLASSIFICATION

Expression and isoforms of gp43 in different strains of Paracoccidioides brasiliensis. Campos MC, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):223–7

An atypical isolate of Paracoccidioides brasiliensis. Hamdan JS, et al. **Mycoses** 1995 Nov–Dec;38(11–12):481–4

ENZYMOLOGY

Ornithine decarboxylase in Paracoccidioides brasiliensis. San-Blas G, et al. **Arch Microbiol** 1996 May;165(5):311–6

Isoenzyme profile of Paracoccidioides brasiliensis. Svidzinsky TI, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):281–5

GROWTH & DEVELOPMENT

Evaluation and comparison of the growth and viability of yeast-like cells of Paracoccidioides brasiliensis. de Moraes Borba C, et al. **Mycoses** 1996 Mar–Apr;39(3–4):95–8

IMMUNOLOGY

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297–304 (30 ref.)

Cloning, characterization, and epitope expression of the major diagnostic antigen of Paracoccidioides brasiliensis. Cisalpino PS, et al. **J Biol Chem** 1996 Feb 23;271(8):4553–60

Immunochemical study of a Paracoccidioides brasiliensis polysaccharide-like antigen. Mendes-Giannini MJ, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):379–83

Glycolipids from Paracoccidioides brasiliensis. Isolation of a galactofuranose-containing glycolipid reactive with sera of patients with paracoccidioidomycosis. Toledo MS, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):247–51

Optimization of a mouse immunization protocol with Paracoccidioides brasiliensis antigens. Almeida AV, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):45–9

[Isolation of an Paracoccidioides brasiliensis exoantigen from solid culture media] Gago J, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):139–45 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Addison's disease caused by Paracoccidioides brasiliensis: diagnosis by needle aspiration biopsy of the adrenal gland [letter] Faiçal S, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):461–2

In search of the natural habitat of Paracoccidioides brasiliensis. McEwen JG, et al. **Arch Med Res** 1995 Autumn;26(3):305–6 (5 ref.)

An atypical isolate of Paracoccidioides brasiliensis. Hamdan JS, et al. **Mycoses** 1995 Nov–Dec;38(11–12):481–4

Paracoccidioides brasiliensis. A mycologic and immunochemical study of a sample isolated from an armadillo (Dasipus novencinctus). Vidal MS, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):43–9

PATHOGENICITY

Granulomatous reaction in the hamster cheek pouch induced by killed Paracoccidioides brasiliensis. Arruda MS, et al. **Braz J Med Biol Res** 1995 Feb;28(2):209–12

PARACOCCIDIOIDOMYCOSIS

BLOOD

Structural characterization of a new galactofuranose-containing glycolipid antigen of Paracoccidioides brasiliensis. Levery SB, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):639–45

COMPLICATIONS

Paracoccidioidomycosis and AIDS: an overview. Goldani LZ, et al. **Clin Infect Dis** 1995 Nov;21(5):1275–81 (41 ref.)

Cryptococcosis as an opportunistic infection in immunodeficiency secondary to paracoccidioidomycosis. Benard G, et al. **Mycopathologia** 1996;133(2):65–9

Polyserositis in a patient with acute paracoccidioidomycosis and hepatosplenic schistosomiasis. Shikanai-Yasuda MA, et al. **Mycopathologia** 1995 May;130(2):75–8

Paracoccidioidomycosis associated with acquired immunodeficiency syndrome. Report of seven cases. Marques SA, et al. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):261–5

[Paracoccidioidomycosis in a patient with human immunodeficiency virus infection. A necropsy case] de Lima MA, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep; 28(3):279–84 (Eng. Abstr.) **(Por)**

[Bone involvement in chronic disseminated paracoccidioidomycosis. A report on the first cases in Rio Grande do Sul] Severo LC, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):241–4 (12 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297–304 (30 ref.)

Paracoccidioidomycosis of bones and joints. A clinical, radiologic, and pathologic study of 9 cases. Amstalden EM, et al. **Medicine (Baltimore)** 1996 Jul;75(4):213–25

DRUG THERAPY

Immunological features of chronic adult paracoccidioidomycosis: report of a case treated with

fluconazole [letter] Pereiro M Jr, et al. **Acta Derm Venereol** 1996 Jan;76(1):84–5

Cyclophosphamide effect on paracoccidioidomycosis in the rat. Blejer JL, et al. **Rev Inst Med Trop Sao Paulo** 1995 May–Jun;37(3):219–24

IMMUNOLOGY

Immunological features of chronic adult paracoccidioidomycosis: report of a case treated with fluconazole [letter] Pereiro M Jr, et al. **Acta Derm Venereol** 1996 Jan;76(1):84–5

Cellular immunity and immunostimulation in paracoccidioidomycosis. Oliveira ZN, et al. **Allergol Immunopathol (Madr)** 1996 May–Jun;24(3):98–105

Antigen–specific immunosuppression in paracoccidioidomycosis. Benard G, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):7–12

Cloning, characterization, and epitope expression of the major diagnostic antigen of Paracoccidioides brasiliensis. Cisalpino PS, et al. **J Biol Chem** 1996 Feb 23;271(8):4553–60

Neutrophil oxidative metabolism and killing of P. brasiliensis after air pouch infection of susceptible and resistant mice. Meloni–Bruneri LH, et al. **J Leukoc Biol** 1996 Apr; 59(4):526–33

Paracoccidioidomycosis in a renal transplant recipient. Shikanai–Yasuda MA, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):411–4

Glycolipids from Paracoccidioides brasiliensis. Isolation of a galactofuranose–containing glycolipid reactive with sera of patients with paracoccidioidomycosis. Toledo MS, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):247–51

Optimization of a mouse immunization protocol with Paracoccidioides brasiliensis antigens. Almeida AV, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):45–9

Effect of macrophage blockade on the resistance of inbred mice to Paracoccidioides brasiliensis infection. Kashino SS, et al. **Mycopathologia** 1995 Jun;130(3):131–40

Natural killer cell activity in experimental paracoccidioidomycosis of the Syrian hamster. Peraçoli MT, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr; 37(2):129–36

Isolation and partial characterization of a Paracoccidioides brasiliensis 58 kDa extracellular glycoprotein which is recognized by human immune sera. Figueroa JI, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):566–72

MICROBIOLOGY

Immunochemical study of a Paracoccidioides brasiliensis polysaccharide–like antigen. Mendes–Giannini MJ, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):379–83

Isoenzyme profile of Paracoccidioides brasiliensis. Svidzinsky TI, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):281–5

An atypical isolate of Paracoccidioides brasiliensis. Hamdan JS, et al. **Mycoses** 1995 Nov–Dec;38(11–12):481–4

[Imported paracoccidioidomycosis. Apropos of 2 cases (letter)] Miguélez M, et al. **Med Clin (Barc)** 1995 Dec 2; 105(19):756 **(Spa)**

PATHOLOGY

Addison's disease caused by Paracoccidioides brasiliensis: diagnosis by needle aspiration biopsy of the adrenal gland [letter] Faiçal S, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):461–2

Histopathology of paracoccidioidomycotic infection in athymic and euthymic mice: a sequential study. Burger E, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):235–42

Paracoccidioidomycosis: diagnosis by fine–needle aspiration cytology. Drut R. **Diagn Cytopathol** 1995 Jul;13(1):52–3

[The diagnosis of severe disseminated paracoccidioidomycosis in a bone marrow aspirate: a case report] Ozaki KS, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):363–6 (15 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Paracoccidioidomycosis of the central nervous system: CT findings. Rodacki MA, et al. **Neuroradiology** 1995 Nov; 37(8):636–41

PARACOCCUS

CHEMISTRY

Crystallization and preliminary X–ray analysis of electron transfer flavoproteins from human and Paracoccus denitrificans. Roberts DL, et al. **Protein Sci** 1995 Aug; 4(8):1654–7

METABOLISM

Involvement of cytochrome c oxidase subunit III in energy coupling. Wu S, et al. **Biochemistry** 1995 Dec 19; 34(50):16298–305

PARACOCCUS DENITRIFICANS

CHEMISTRY

Purification, characterization, crystallization, and preliminary X–ray results from Paracoccus denitrificans porin. Hirsch A, et al. **Proteins** 1995 Oct;23(2):282–4

ENZYMOLOGY

Subunit III of cytochrome c oxidase influences the conformation of subunits I and II: an infrared study. Echabe I, et al. **Biochemistry** 1995 Oct 17;34(41):13565–9

Structural studies of the proton–translocating NADH–quinone oxidoreductase (NDH–1) of Paracoccus denitrificans: identity, property, and stoichiometry of the peripheral subunits. Takano S, et al. **Biochemistry** 1996 Jul 16;35(28):9120–7

Cytochrome c oxidase. Ostermeier C, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):460–6 (49 ref.)

Spectroscopic and mutagenesis studies on the CuA centre from the cytochrome–c oxidase complex of Paracoccus denitrificans. Farrar JA, et al. **Eur J Biochem** 1995 Aug 15;232(1):294–303

The affinity and specificity of Ca(2+)–binding sites of cytochrome–c peroxidase from Paracoccus denitrificans. Gilmour R, et al. **Eur J Biochem** 1995 Dec 15;234(3):878–86

Perturbation of the CuA site in cytochrome–c oxidase of Paracoccus denitrificans by replacement of Met227 with isoleucine. Zickermann V, et al. **Eur J Biochem** 1995 Dec 1;234(2):686–93

Carboxyl group protonation upon reduction of the Paracoccus denitrificans cytochrome c oxidase: direct evidence by FTIR spectroscopy. Hellwig P, et al. **FEBS Lett** 1996 Apr 29;385(1–2):53–7

The purification of ammonia monooxygenase from Paracoccus denitrificans. Moir JW, et al. **FEBS Lett** 1996 May 27;387(1):71–4

Reversed electron transfer through the bc1 complex enables a cytochrome c oxidase mutant (delta aa3/cbb3) of Paracoccus denitrificans to grow on methylamine. van der Oost J, et al. **FEBS Lett** 1995 Sep 11;371(3):267–70

Cytochrome cb–type nitric oxide reductase with cytochrome c oxidase activity from Paracoccus denitrificans ATCC 35512. Fujiwara T, et al. **J Bacteriol** 1996 Apr; 178(7):1866–71

A single histidine is required for activity of cytochrome c peroxidase from Paracoccus denitrificans. McGinnity DF, et al. **J Biol Chem** 1996 May 10;271(19):11126–33

Mössbauer characterization of Paracoccus denitrificans cytochrome c peroxidase. Further evidence for redox and calcium binding–induced heme–heme interaction. Prazeres S, et al. **J Biol Chem** 1995 Oct 13;270(41):24264–9

Expression and characterization of the flavoprotein subcomplex composed of 50–kDa (NQO1) and 25–kDa (NQO2) subunits of the proton–translocating NADH–quinone oxidoreductase of Paracoccus denitrificans. Yano T, et al. **J Biol Chem** 1996 Mar 8; 271(10):5907–13

GENETICS

Analysis of beta–ketothiolase and acetoacetyl–CoA reductase genes of a methylotrophic bacterium, Paracoccus denitrificans, and their expression in Escherichia coli. Yabutani T, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1–2):85–90

Molecular analysis of the poly(3–hydroxyalkanoate) synthase gene from a methylotrophic bacterium, Paracoccus denitrificans. Ueda S, et al. **J Bacteriol** 1996 Feb; 178(3):774–9

Isolation and characterization of a novel insertion sequence element, IS1248, in Paracoccus denitrificans. Van Spanning RJ, et al. **Plasmid** 1995 Jul;34(1):11–21

METABOLISM

Dynamics of denitrification activity of Paracoccus denitrificans in continuous culture during aerobic–anaerobic changes. Baumann B, et al. **J Bacteriol** 1996 Aug;178(15):4367–74

Regulation of oxidative phosphorylation: the flexible respiratory network of Paracoccus denitrificans. Van Spanning RJ, et al. **J Bioenerg Biomembr** 1995 Oct; 27(5):499–512 (93 ref.)

Alteration of haem–attachment and signal–cleavage sites for Paracoccus denitrificans cytochrome C550 probes pathway of c–type cytochrome biogenesis in Escherichia coli. Sambongi Y, et al. **Mol Microbiol** 1996 Mar;19(6):1193–204

PARADENTIUM see **PERIODONTIUM**

PARADOXICAL SLEEP see **SLEEP, REM**

PARAFFIN

Improvement of fluorescence in situ hybridization (RNA–FISH) on human paraffin sections by propidium iodide counterstaining. Wulf M, et al. **Biotechniques** 1995 Sep;19(3):368–70, 372

ADVERSE EFFECTS

Paraffinomas of the breast: an oriental curiosity. Alagaratnam TT, et al. **Aust N Z J Surg** 1996 Mar;66(3):138–40

Late extrusion of pulmonary plombage. Gunderman RB, et al. **Chest** 1996 Apr;109(4):1103–5

Paraffinomas of the breast: mammographic, ultrasonographic and radiographic appearances with clinical and histopathological correlation. Yang WT, et al. **Clin Radiol** 1996 Feb;51(2):130–3

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90–3 (7 ref.) (Eng. Abstr.) **(Fre)**

[Acute lipoid pneumonia. Report of 2 cases] Lores L, et al. **Med Clin (Barc)** 1996 May 18;106(19):747–8 (Eng. Abstr.) **(Spa)**

[Oleogranuloma of male genital organs] Zeliak MV. **Klin Khir** 1995;(7–8):48–9 **(Ukr)**

POISONING

Towards a national paraffin safety action plan [news] Jones JS. **S Afr Med J** 1995 Sep;85(9):821

TOXICITY

Mechanistical studies of the inhibition of intercellular communication by organochlorine compounds. Wärngård L, et al. **Arch Toxicol Suppl** 1996;18:149–59

Subchronic toxicity of a medium–chain chlorinated paraffin in the rat. Poon R, et al. **J Appl Toxicol** 1995 Nov–Dec; 15(6):455–63

Variable responses of species and strains to white mineral oils and paraffin waxes. Miller MJ, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):55–68 (78 ref.)

PARAFFIN EMBEDDING

Immunohistochemical assessment of cell proliferation in plant tissues using formaldehyde–fixed paraffin–embedded material. Schumacher U. **Acta Histochem** 1995 Jul; 97(3):291–4

Guardians of the wax [letter] Geller SA. **Am J Clin Pathol** 1996 Mar;105(3):371

bc1–1 gene rearrangements in paraffin–embedded tissues [letter] Hammer RD, et al. **Am J Clin Pathol** 1996 Jun; 105(6):806–7

Use of human tissue blocks for research [editorial] LiVolsi VA. **Am J Clin Pathol** 1996 Mar;105(3):260–1

Guardians of the wax ... and the patient [editorial] Mills SE, et al. **Am J Clin Pathol** 1995 Oct;104(4):365–7

Asbestos contamination in paraffin tissue blocks [letter; comment] Longo WE. **Arch Pathol Lab Med** 1996 Mar; 120(3):225–6. Comment on: Arch Pathol Lab Med 1995 Jun;119(6):528–32.

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139–43 (48 ref.)

Criteria for consistent and high sensitivity of DNA in situ hybridization on paraffin sections: optimal proteolytic enzyme digestion. Lu QL, et al. **J Clin Lab Anal** 1995; 9(5):285–92

A cautionary note regarding the application of Ki–67 antibodies to paraffin–embedded breast cancers. Gee JM, et al. **J Pathol** 1995 Nov;177(3):285–93

A comparison between the effects of paraffin and plastic embedding of the normal and obstructed minipig detrusor muscle using the optical dissector. Nielsen KK, et al. **J Urol** 1995 Dec;154(6):2170–3

Guardians of the wax ... and the patient [editorial] Mills SE, et al. **Mod Pathol** 1995 Sep;8(7):699–700

Interphase cytogenetics on paraffin sections of paediatric extragonadal yolk sac tumours. Jenderny J, et al. **Virchows Arch** 1996 Apr;428(1):53–7 (13 ref.)

[PCR application for paraffin–embedded tissues] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):463–6 (8 ref.) **(Jpn)**

METHODS

Novel fixation of plant tissue, staining through paraffin with alcian blue and hematoxylin, and improved slide preparation. Graham ET, et al. **Biotech Histochem** 1995 Sep;70(5):263–6

[The use of methylsalicylate as an intermediate medium in paraffin embedding] Korzhevskiĭ DE. **Morfologiia** 1996; 109(1):105 **(Rus)**

TRENDS

Molecular pathology, informed consent, and the paraffin block [news] Grody WW. **Diagn Mol Pathol** 1995 Sep; 4(3):155–7

Use of human tissue blocks for research. Association of Directors of Anatomic and Surgical Pathology. LiVolsi VA. **Hum Pathol** 1996 Jun;27(6):519–20

PARAFFIN JELLY see **PETROLATUM**

PARAGANGLIA, NONCHROMAFFIN

PATHOLOGY

Oligosymptomatic glomus tympanicum and caroticum with two different histological pictures. Stanković M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):283–6

PARAGANGLIOMA

Paraganglioma of the cauda equina. A case report and review of the literature. Bak J, et al. **APMIS** 1996 Mar; 104(3):234–40 (29 ref.)

Paraganglioma of the spermatic cord: report of a case.

Attaran SY, et al. **J Urol** 1996 Feb;155(2):651

[Duodenal gangliocytic paraganglioma] Blanco Sampascual S, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):813–5 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Carotid body tumors, inheritance, and a high incidence of associated cervical paragangliomas. Gardner P, et al. **Am J Surg** 1996 Aug;172(2):196–9

DIAGNOSIS

Neuroendocrine neoplasms of the larynx. Importance of the correct diagnosis and differences between atypical carcinoid tumors and small-cell neuroendocrine carcinoma. Gripp FM, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):280–6

MRI of paraganglioma of the filum terminale. Boncoeur-Martel MP, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):162–5

Giant paraganglioma of the cauda equina in adolescence: magnetic resonance imaging demonstration. Wolansky LJ, et al. **J Neuroimaging** 1996 Jan;6(1):54–6

[Asymptomatic bladder paraganglioma. Report of a case] Tato Rodríguez J, et al. **Actas Urol Esp** 1995 May; 19(5):408–13 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

A 15-year experience with chemotherapy of patients with paraganglioma. Patel SR, et al. **Cancer** 1995 Oct 15; 76(8):1476–80

Beneficial effects of octreotide in a patient with a metastatic paraganglioma [letter] Tenenbaum F, et al. **Eur J Cancer** 1996 Apr;32A(4):737

GENETICS

Cytogenetic analysis of tissues from patients with familial paragangliomas of the head and neck. Zaslav AL, et al. **Head Neck** 1995 Mar–Apr;17(2):102–7

Familial paraganglioma. Wharton SM, et al. **J Laryngol Otol** 1996 Jul;110(7):688–90

PATHOLOGY

Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Boyle M, et al. **Br J Urol** 1996 Mar;77(3):445–8 (16 ref.)

Paraganglioma-like adenoma of thyroid. Pinto RG, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S4

Laryngeal paraganglioma. A review and report of a single case. Özünlü A, et al. **J Laryngol Otol** 1996 Jun; 110(6):519–26 (60 ref.)

A rare case of pigmented paraganglioma [letter] Küchemann K. **Virchows Arch** 1995;427(1):111–2

[Laryngeal paraganglioma: a case report] del Campo JE, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):371–5 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Primary paraganglioma of the lung. Report of two cases and review of the literature. Skødt V, et al. **APMIS** 1995 Jul–Aug;103(7–8):597–603 (57 ref.)

RADIOGRAPHY

Primary paraganglioma of the facial nerve canal. Petrus LV, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):171–4

[Gangliocytic paraganglioma of the duodenum] Heinze A, et al. **Aktuelle Radiol** 1995 Sep;5(5):325–7 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radiation therapy in the management of paragangliomas of the temporal bone. de Jong AL, et al. **Am J Otol** 1995 May;16(3):283–9

Jugulotympanic paragangliomas. Sur RK, et al. **S Afr J Surg** 1995 Sep;33(3):112–4

SECONDARY

Human monoclonal antibody developed against a metastasizing paraganglioma: preparation and preclinical studies. Freiberg B, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2489–93

SECRETION

Pancreatic somatostatin-secreting gangliocytic paraganglioma with lymph node metastases. Tomic S, et al. **Am J Gastroenterol** 1996 Mar;91(3):607–8 (12 ref.)

SURGERY

Anesthetic hazards in a previously unsuspected case of posterior mediastinal paraganglioma. Mitra S, et al. **Anesth Analg** 1995 Nov;81(5):1097–8

Paraganglioma of the interatrial septum. Cane ME, et al. **Ann Thorac Surg** 1996 Jun;61(6):1845–7

[Cervical paragangliomas. Results apropos of a series of 33 patients] Guerrier B, et al. **J Chir (Paris)** 1995 Jun–Jul; 132(6–7):287–94 (34 ref.) (Eng. Abstr.) **(Fre)**

PARAGANGLIOMA, CAROTID BODY see **CAROTID BODY TUMOR**

PARAGANGLIOMA, EXTRA-ADRENAL

Extraadrenal pheochromocytoma. Baše J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1):47–9

[Recurrences of chemodectomas and hemangiomas of the ear: their diagnosis and treatment] Popadiuk VI, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):19–21 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Life-threatening lower intestinal bleeding leading to discovery of a colonic paraganglioma [letter] Velitchkov NG, et al. **Dis Colon Rectum** 1996 Aug;39(8):943–5 (4 ref.)

Coexisting extraadrenal pheochromocytoma and renal artery stenosis: a case report and review of the pathophysiology. Pickard JL, et al. **J Pediatr Surg** 1995 Nov;30(11):1613–5

Chemodectoma of the trachea. Sing TM, et al. **Thorax** 1996 Mar;51(3):341–2

[Garcin's syndrome in a patient with malignant chemodectoma of the neck] Parkhomenko VM, et al. **Klin Med (Mosk)** 1995;73(4):84–5 **(Rus)**

DIAGNOSIS

Pathologic quiz case 2. Vagal paraganglioma. Heartfield W, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep; 122(9):1013, 1015

Non-functional malignant extra-adrenal retroperitoneal paraganglioma. Holden A. **Australas Radiol** 1995 Nov; 39(4):392–5

Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227–30 (12 ref.)

[The initial location of the tumor as a prognostic factor in chemodectomas of the neck] Matiakin EG, et al. **Stomatologiia (Mosk)** 1995;74(5):49–51 (Eng. Abstr.) **(Rus)**

GENETICS

Clonal chromosome abnormalities in two chemodectomas. Jin Y, et al. **Genes Chromosomes Cancer** 1996 Mar; 15(3):178–81

PATHOLOGY

Paraganglioma: an unusual tumour of the parathyroid gland. McCluggage WG, et al. **J Laryngol Otol** 1996 Feb; 110(2):196–9

[Malignant paraganglioma (chemodectoma) of the larynx] Klochikhin AL, et al. **Vestn Otorinolaringol** 1996 Jan–Feb; (1):53–4 **(Rus)**

RADIOTHERAPY

Control of advanced chemodectomas of the head and neck with irradiation. Mumber MP, et al. **Am J Clin Oncol** 1995 Oct;18(5):389–91

SURGERY

[Tactics of the surgeon in repeated removal of a large chemodectoma] Polishchuk NE, et al. **Klin Khir** 1995; (11–12):24–6 **(Rus)**

PARAGANGLIOMA, GANGLIOCYTIC see **PARAGANGLIOMA**

PARAGANGLIOMA, NONCHROMAFFIN see **PARAGANGLIOMA, EXTRA-ADRENAL**

PARAGONIMIASIS

Paragonimus mexicanus pericarditis: report of two cases and review of the literature. Saborio P, et al. **J Trop Med Hyg** 1995 Oct;98(5):316–8 (9 ref.)

[Paragonimus westermani pulmonary distomatosis in Gabon. First case (letter)] Vuong PN, et al. **Presse Med** 1996 Jun 29;25(23):1084–5 **(Fre)**

EPIDEMIOLOGY

[Epidemiological study of Paragonimus sp. in south Cameroon] Ollivier G, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):164–9 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antibody isotypes, including IgG subclasses, in Ecuadorian patients with pulmonary paragonimiasis. Guevara A, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):497–502

PARASITOLOGY

A case of cerebral paragonimiasis in Denmark. Case report. Møller A, et al. **APMIS** 1995 Jul–Aug;103(7–8):604–6

PATHOLOGY

Cutaneous paragonimiasis: a case report. Singh TS, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S33–4

PARAGONIMUS

A case of cerebral paragonimiasis in Denmark. Case report. Møller A, et al. **APMIS** 1995 Jul–Aug;103(7–8):604–6

[Epidemiological study of Paragonimus sp. in south Cameroon] Ollivier G, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):164–9 (Eng. Abstr.) **(Fre)**

CYTOLOGY

Two types of parenchymal cells in the lung fluke Paragonimus ohirai (Digenea: Troglotrematidae) characterized by the cytochemistry of their mitochondria. Fujino T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):387–94

ENZYMOLOGY

Purification and characterization of acid cysteine protease from metacercariae of the mammalian trematode parasite Paragonimus westermani. Yamakami K, et al. **Eur J Biochem** 1995 Oct 15;233(2):490–7

A cysteine protease of Paragonimus westermani eggs. Kang SY, et al. **Korean J Parasitol** 1995 Dec;33(4):323–30

IMMUNOLOGY

Antibody isotypes, including IgG subclasses, in Ecuadorian patients with pulmonary paragonimiasis. Guevara A, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):497–502

[Ultrastructural antigenic localization in Paragonimus iloktsuenensis during developmental stage by immunogold labeling method] Kim HS, et al. **Korean J Parasitol** 1995 Dec;33(4):365–76 (Eng. Abstr.) **(Kor)**

ISOLATION & PURIFICATION

Cutaneous paragonimiasis: a case report. Singh TS, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S33–4

PARAIMMUNOGLOBULINEMIAS see **PARAPROTEINEMIAS**

PARAINFLUENZA

COMPLICATIONS

[Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

DIAGNOSIS

Diagnosis of viral respiratory tract infections in children by using a reverse transcription–PCR panel. Gilbert LL, et al. **J Clin Microbiol** 1996 Jan;34(1):140–3

Expression of Sendai virus nucleocapsid protein in a baculovirus expression system and application to diagnostic assays for Sendai virus infection. Wan CH, et al. **J Clin Microbiol** 1995 Aug;33(8):2007–11

Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Wendt CH, et al. **Semin Respir Infect** 1995 Dec;10(4):224–31 (35 ref.)

DRUG THERAPY

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

ETIOLOGY

Orthomyxoviral and paramyxoviral infections in transplant patients. Sable CA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):987–1003 (70 ref.)

IMMUNOLOGY

Parainfluenza virus type-3 infection attenuates the respiratory effects of antigen challenge in sensitized guinea pigs. Kudlacz EM, et al. **Inflamm Res** 1995 Mar; 44(3):105–10

Semi-permissive replication and functional aspects of the immune response in a cotton rat model of human parainfluenza virus type 3 infection. Ottolini MG, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1739–43

Prior infection by respiratory syncytial virus or parainfluenza viruses augments virus-specific IgG responses induced by the measles/mumps/rubella vaccine. Ziola B, et al. **Viral Immunol** 1994;7(4):205–14

METABOLISM

Relative transcriptional inducibility of the human interferon-alpha subtypes conferred by the virus-responsive enhancer sequence. Dent CL, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):99–107

PATHOLOGY

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31–1996. An 18-month old immunosuppressed boy with bilateral pulmonary infiltrates. **N Engl J Med** 1996 Oct 10;335(15):1133–40

PARAINFLUENZA

PHYSIOPATHOLOGY

Viral infection potentiates the increase in airway blood flow produced by substance P. Yamawaki I, et al. **J Appl Physiol** 1995 Aug;79(2):398–404

Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. Kahn RM, et al. **J Clin Invest** 1996 Jul 15;98(2):299–307

THERAPY

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

VETERINARY

Comparative severity of respiratory lesions of sialodacryoadenitis virus and Sendai virus infections in LEW and F344 rats. Liang SC, et al. **Vet Pathol** 1995 Nov; 32(6):661–7

VIROLOGY

Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Cobian L, et al. **Clin Infect Dis** 1995 Oct;21(4):1040–1

PARAINFLUENZA VIRUS TYPE 1

Efficient gene transfer into mammalian cells using fusogenic liposome. Mizuguchi H, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):402–7

Efficiency of in vivo gene transfection into transplanted rat heart by coronary infusion of HVJ liposome. Sawa Y, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II479–82

Viral infection potentiates the increase in airway blood flow produced by substance P. Yamawaki I, et al. **J Appl Physiol** 1995 Aug;79(2):398–404

Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. Kahn RM, et al. **J Clin Invest** 1996 Jul 15;98(2):299–307

Relative transcriptional inducibility of the human interferon-alpha subtypes conferred by the virus-responsive enhancer sequence. Dent CL, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):99–107

DRUG EFFECTS

A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus–cell fusion: an emerging similarity with functional domains of other viruses. Rapaport D, et al. **EMBO J** 1995 Nov 15; 14(22):5524–31

GENETICS

Lack of correlation between Sendai virus P/C mRNA structure and its utilization of two AUG start sites from alternate reading frames: implications for viral bicistronic mRNAs. Gupta KC, et al. **Biochemistry** 1996 Jan 30; 35(4):1223–31

Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. Morishita R, et al. **Contrib Nephrol** 1996;118:254–64 (26 ref.)

A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. Garcin D, et al. **EMBO J** 1995 Dec 15;14(24):6087–94

A regulatory domain within the virus-response element of the interferon alpha 1 gene acts as a transcriptional repressor sequence and determinant of cell-specific gene expression. Dent CL, et al. **Eur J Biochem** 1996 Mar 15; 236(3):895–903

An AAV promoter-driven neuropeptide Y gene delivery system using Sendai virosomes for neurons and rat brain. Wu P, et al. **Gene Ther** 1996 Mar;3(3):246–53

In vitro mRNA synthesis by Sendai virus: isolation and characterization of the transcription initiation complex. Takagi T, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):390–6

Expression of Sendai virus nucleocapsid protein in a baculovirus expression system and application to diagnostic assays for Sendai virus infection. Wan CH, et al. **J Clin Microbiol** 1995 Aug;33(8):2007–11

Mutations in conserved domain I of the Sendai virus L polymerase protein uncouple transcription and replication. Chandrika R, et al. **Virology** 1995 Nov 10;213(2):352–63

Reexamination of the Sendai virus P protein domains required for RNA synthesis: a possible supplemental role for the P protein. Curran J. **Virology** 1996 Jul 1; 221(1):130–40

A Sendai virus vector leading to the efficient expression of mutant M proteins interfering with virus particle budding. Mottet G, et al. **Virology** 1996 Jul 1;221(1):159–71

GROWTH & DEVELOPMENT

Repression of beta interferon gene expression in virus-infected cells is correlated with a poly(A) tail elongation. Dehlin E, et al. **Mol Cell Biol** 1996 Feb; 16(2):468–74

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

IMMUNOLOGY

Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Mazanec MB, et al. **Adv Exp Med Biol** 1995;371A:651–4

Oral immunization against respiratory viruses in mice. Nedrud J, et al. **Adv Exp Med Biol** 1995;371B:1595–8

Failure to detect type 1 interferon production in human umbilical cord vein endothelial cells after viral exposure. Neustock P, et al. **J Interferon Cytokine Res** 1995 Feb; 15(2):129–35

Cytokines induced by Sendai virus in human peripheral blood leukocytes. Hua J, et al. **J Leukoc Biol** 1996 Jul;60(1):125–8

Binding motifs predict major histocompatibility complex class II–restricted epitopes in the Sendai virus M protein. Cole GA, et al. **J Virol** 1995 Dec;69(12):8057–60

ISOLATION & PURIFICATION

A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. Garcin D, et al. **EMBO J** 1995 Dec 15;14(24):6087–94

Comparative severity of respiratory lesions of sialodacryoadenitis virus and Sendai virus infections in LEW and F344 rats. Liang SC, et al. **Vet Pathol** 1995 Nov; 32(6):661–7

[The incidence of virus respiratory infections in small children in the season 1994–95] Wilczyński J, et al. **Przegl Epidemiol** 1996;50(1–2):39–43 (Eng. Abstr.) **(Pol)**

METABOLISM

Glycophorin as a receptor for Sendai virus. Wybenga LE, et al. **Biochemistry** 1996 Jul 23;35(29):9513–8

Conformational aberrance of the sendai virus F0 protein in thapsigargin-treated cells allowing exit from the endoplasmic reticulum but causing arrest at the Golgi complex. Ono A, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1248–54

Sendai virus P protein is constitutively phosphorylated at serine249: high phosphorylation potential of the P protein. Byrappa S, et al. **Virology** 1996 Feb 1;216(1):228–34

Paramyxovirus phosphoproteins form homotrimers as determined by an epitope dilution assay, via predicted coiled coils. Curran J, et al. **Virology** 1995 Dec 1; 214(1):139–49

PATHOGENICITY

Interaction of reconstituted Sendai viral envelopes with sperm cells: reconstituted Sendai virus envelope-induced fusion–mediated introduction of foreign material into bull sperm cells. Nussbaum O, et al. **Arch Virol** 1995; 140(9):1613–22

[Pathogenic mechanism of Sendai virus--virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

PHYSIOLOGY

F protein induced fusion of Sendai viral envelopes with mouse teratocarcinoma cells through Le(x)–Le(x) interaction. Kumar M, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):17–20

Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion. Tanabayashi K, et al. **J Virol** 1996 Sep;70(9):6112–8

Involvement of the mutated M protein in altered budding polarity of a pantropic mutant, F1–R, of Sendai virus. Tashiro M, et al. **J Virol** 1996 Sep;70(9):5990–7

Host range restriction of parainfluenza virus growth occurs at the level of virus genome replication. Tao T, et al. **Virology** 1996 Jun 1;220(1):69–77

PARAINFLUENZA VIRUS TYPE 2

[Gianotti–Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

CHEMISTRY

Identification of the sequences responsible for nuclear targeting of the V protein of human parainfluenza virus type 2. Watanabe N, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):327–38

ISOLATION & PURIFICATION

[The incidence of virus respiratory infections in small children in the season 1994–95] Wilczyński J, et al. **Przegl Epidemiol** 1996;50(1–2):39–43 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Differences in the role of the cytoplasmic domain of human parainfluenza virus fusion proteins. Yao Q, et al. **J Virol** 1995 Nov;69(11):7045–53

Identification of regions on the hemagglutinin–neuraminidase protein of human parainfluenza virus type 2 important for promoting cell fusion. Tsurudome M, et al. **Virology** 1995 Oct 20;213(1):190–203

PARAINFLUENZA VIRUS TYPE 3

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31–1996. An 18-month old immunosuppressed boy with bilateral pulmonary infiltrates. **N Engl J Med** 1996 Oct 10;335(15):1133–40

CHEMISTRY

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Lambert DM, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):2186–91

DRUG EFFECTS

Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Zhao H, et al. **Virology** 1996 Jun 15;220(2):330–8

ENZYMOLOGY

Hemagglutinin–neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle. Huberman K, et al. **Virology** 1995 Dec 1;214(1):294–300

IMMUNOLOGY

Parainfluenza virus type-3 infection attenuates the respiratory effects of antigen challenge in sensitized guinea pigs. Kudlacz EM, et al. **Inflamm Res** 1995 Mar; 44(3):105–10

Semi-permissive replication and functional aspects of the immune response in a cotton rat model of human parainfluenza virus type 3 infection. Ottolini MG, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1739–43

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. Karron RA, et al. **J Infect Dis** 1995 Dec;172(6):1445–50

ISOLATION & PURIFICATION

[The incidence of virus respiratory infections in small children in the season 1994–95] Wilczyński J, et al. **Przegl Epidemiol** 1996;50(1–2):39–43 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus. Bagai S, et al. **J Virol** 1995 Nov;69(11):6712–9

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. Ray R, et al. **J Virol** 1996 Jan; 70(1):580–4

Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion. Tanabayashi K, et al. **J Virol** 1996 Sep;70(9):6112–8

Differences in the role of the cytoplasmic domain of human parainfluenza virus fusion proteins. Yao Q, et al. **J Virol** 1995 Nov;69(11):7045–53

PARAINFLUENZA VIRUS TYPE 4 see **PARAINFLUENZA VIRUSES**

PARAINFLUENZA VIRUSES

GENETICS

Sequence analyses of human parainfluenza virus type 4A and type 4B fusion proteins. Komada H, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3205–10

IMMUNOLOGY

Variable domain sequences of mAb with high affinity for a linear oligopeptide. Hanke T, et al. **Immunogenetics** 1995; 42(5):442–3

ISOLATION & PURIFICATION

Simultaneous rapid culture for four respiratory viruses in the same cell monolayer using a differential multicolored fluorescent confirmatory stain. Brumback BG, et al. **J Clin Microbiol** 1996 Apr;34(4):798–801

PHYSIOLOGY

The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. Sieg S, et al. **J Virol** 1996 Jul;70(7):4845–8

PARAKEETS

A survey for selected viral, chlamydial, and parasitic diseases in wild dusky-headed parakeets (Aratinga weddellii) and tui parakeets (Brotogeris sanctithomae) in Peru. Gilardi KV, et al. **J Wildl Dis** 1995 Oct;31(4):523–8

PARAKERATOSIS

PATHOLOGY

Corneocytes in scaly parakeratotic diseases. Amer M, et al. **Int J Dermatol** 1996 Jun;35(6):417–21

PARAKERATOSIS VARIEGATA see **PARAPSORIASIS**

PARALLAX, OCULAR see **VISION DISPARITY**

PARALYSIS

Delayed central cord syndrome after a handstand in a child: case report. Lee KS, et al. **Paraplegia** 1996 Mar;34(3):176–8 (25 ref.)

CHEMICALLY INDUCED

Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Szlatenyi CS, et al. **Am J Emerg Med** 1996 Sep;14(5):464–6

Transient femoral nerve palsy after iliioinguinal block [letter] Derrick JL, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):115

Clindamycin–induced neuromuscular blockade. al Ahdal O, et al. **Can J Anaesth** 1995 Jul;42(7):614–7

Comparative study of the analgesic and paralytic effects induced by intrathecal dynorphin a in rats. Xue JC, et al. **Int J Neurosci** 1995 May;82(1–2):83–93

Prolonged paralysis after neuromuscular blockade [letter; comment] Kurt TL. **J Toxicol Clin Toxicol** 1996;34(2):253 . Comment on: J Toxicol Clin Toxicol 1995;33(5):419–26.

Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids. Rubio ER, et al. **South Med J** 1996 Jun;89(6):624–6

[Saxitoxin ... this paralyzing toxin (letter)] Lahbabi MS, et al. **Arch Pediatr** 1995 Dec;2(12):1224–5 **(Fre)**

COMPLICATIONS

[Intracranial hypotension and sixth cranial nerve palsy] Pondal M, et al. **Neurologia** 1995 Oct;10(8):339–41 (Eng. Abstr.) **(Spa)**

[Brachial paralysis as a presentation of giant cell arteritis] Mota R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):185–6 **(Spa)**

CONGENITAL

Neonatal hemangiomatosis associated with brachial plexus palsy. Lucas JW, et al. **J Child Neurol** 1995 Sep;10(5):411–3

Opercular malformations: clinical and MRI features in 11 children. Rolland Y, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S2–8

DIAGNOSIS

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

Vascular compressive abducens nerve palsy disclosed by magnetic resonance imaging. Ohtsuka K, et al. **Am J Ophthalmol** 1996 Sep;122(3):416–9

Magnetic resonance imaging features of Gradenigo's syndrome. Hardjasudarma M, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):247–50

Twelfth–nerve palsy. Analysis of 100 cases. Keane JR. **Arch Neurol** 1996 Jun;53(6):561–6

Congenital bilateral perisylvian syndrome in a monozygotic twin with intra–uterine death of the co–twin. Van Bogaert P, et al. **Dev Med Child Neurol** 1996 Feb;38(2):166–70

Guillain–Barré syndrome or "new" Chinese paralytic syndrome in northern China? Tang XF, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 101(2):105–9

Acquired palsy of the oculomotor, trochlear and abducens nerves. Tiffin PA, et al. **Eye** 1996;10 (Pt 3):377–84

Obstetric brachial plexus palsy associated with breech delivery. A different pattern of injury. Geutjens G, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):303–6

Angiocentric T–cell lymphoma presenting with multiple cranial nerve palsies and retrobulbar optic neuropathy. Brazis PW, et al. **J Neuroophthalmol** 1995 Sep;15(3):152–7

[Differential diagnosis of unilateral paresis and paralysis of the larynx] Chernobel'skiĭ SI. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):24–6 (Eng. Abstr.) **(Rus)**

[Biopercular lesion with inverse dissociation] Campello I, et al. **Rev Neurol** 1995 Sep–Oct;23(123):1056–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effect of 3,4–diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Adler M, et al. **Toxicon** 1996 Feb;34(2):237–49

EMBRYOLOGY

Intrauterine onset of a mononeuropathy: peroneal neuropathy in a newborn with electromyographic findings at age one day compatible with prenatal onset. Jones HR Jr, et al. **Muscle Nerve** 1996 Jan;19(1):88–91

[Development, stimulation and paralysis of embryonic motor activity] Wu KC. **Wien Klin Wochenschr** 1996; 108(10):303–5 **(Ger)**

EPIDEMIOLOGY

Epidemiology and clinical characteristics of acute flaccid paralysis associated with non–polio enterovirus isolation: the experience in the Americas. Dietz V, et al. **Bull World Health Organ** 1995;73(5):597–603

Reported annual incidence of poliomyelitis and acute flaccid paralysis (AFP), by WHO region. **Wkly Epidemiol Rec** 1996 Apr 26;71(17):128–9

[Eradication project for poliomyelitis and surveillance of acute paralysis] Chiba Y, et al. **Uirusu** 1995 Jun;45(1):53–5 **(Jpn)**

[Poliomyelitis and acute flaccid paralysis. Perspectives for its epidemiologic surveillance] Montesano–Castellanos R, et al. **Gac Med Mex** 1995 Jan–Feb;131(1):113–6 **(Spa)**

ETIOLOGY

Acute nonlymphocytic leukemia complicated by Garcin's syndrome. Kaya H, et al. **Acta Haematol** 1995;94(3):142–3

Cranial nerve palsies due to internal carotid artery dissection: seven cases. Gobert M, et al. **Acta Neurol Belg** 1996 Mar; 96(1):55–61

Postoperative dropfoot after cementless total hip arthroplasty. Linclau L, et al. **Acta Orthop Belg** 1995; 61(4):271–7

Femoral nerve palsy after arthroscopic surgery with an infusion pump irrigation system. A report of three cases. DiStefano VJ, et al. **Am J Orthop** 1996 Feb;25(2):145–8

Tourniquet paralysis in microsurgery. Landi A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):89–93

Tourniquet–induced tibial nerve palsy complicating anterior cruciate ligament reconstruction. Guanche CA. **Arthroscopy** 1995 Oct;11(5):620–2

Hypokalaemic paralysis in remote aboriginal communities. Ghose R, et al. **Aust Fam Physician** 1996 Jul;25(7):1172–3

Traumatic bilateral hypoglossal nerve palsy. Paley MD, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):239–41

Thyrotoxicosis and renal tubular acidosis presenting as hypokalaemic paralysis. Szeto CC, et al. **Br J Rheumatol** 1996 Mar;35(3):289–91

Bilateral opercular syndrome: an unusual complication of perinatal difficulties. Koeda T, et al. **Brain Dev** 1995 May–Jun;17(3):193–5

Unilateral osteoarthritis and neurological deficit [letter] Kavanagh RT, et al. **Clin Exp Rheumatol** 1995 Sep–Oct; 13(5):679–80

Recurrence of systemic lupus erythematosus in a hemodialysis patient presenting as a unilateral abducens nerve palsy. Friedman AS, et al. **Clin Nephrol** 1995 Nov; 44(5):338–9

Multiple cranial nerve palsy after otitis externa: a case report. Boringa JB, et al. **Clin Neurol Neurosurg** 1995 Nov; 97(4):332–5

Unusual cause of ulnar nerve palsy. Grobler GP. **Clin Orthop** 1996 Feb;(323):192–3

Traumatic brachial plexus lesions in the adult. Indications and results. Alnot JY. **Hand Clin** 1995 Nov;11(4):623–31

Palatal palsy in enteric fever [letter] Ghosh JB, et al. **Indian Pediatr** 1995 Jan;32(1):106–7

Multiple cranial nerve palsies in a motorcyclist caused by the helmet. Smith JC. **Injury** 1995 Jul;26(6):405–6

Isolated hypoglossal paralysis following orofacial herpes simplex infection. Kumar PD, et al. **J Assoc Physicians India** 1995 Aug;43(8):581

Septic arthritis associated with brachial plexus neuropathy. A case report. Gabriel SR, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):103–5

Peroneal nerve palsy after total knee arthroplasty. Assessment of predisposing and prognostic factors. Idusuyi OB, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):177–84

Acute posterior interosseous nerve palsy caused by a synovial haemangioma of the elbow joint. Busa R, et al. **J Hand Surg [Br]** 1995 Oct;20(5):652–4

Radial nerve palsy caused by injections. Gaur SC, et al. **J Hand Surg [Br]** 1996 Jun;21(3):338–40

Tongue paralysis following head trauma. Kacker A, et al. **J Laryngol Otol** 1995 Aug;109(8):770–1

Bilateral infarction of the rostral pontine tegmentum as a cause of isolated bilateral supranuclear sixth nerve palsy related to hypertension [letter] Lopez JM, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):238–9

Magnetic stimulation of the spinal accessory nerve: normative data and clinical utility in an isolated stretch–induced palsy. Pelliccioni G, et al. **J Neurol Sci** 1995 Sep;132(1):84–8

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

Delayed glossopharyngeal and vagus nerve paralysis following occipital condyle fracture. Case report. Urculo E, et al. **J Neurosurg** 1996 Mar;84(3):522–5

Bilateral abducens nerve palsy secondary to maxillofacial trauma: report of case with proposed mechanism of injury. Lazow SK, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1197–9

Lumbar vein malposition of inferior vena cava catheters. Miller GG, et al. **J Pediatr Surg** 1995 Oct;30(10):1500–1

Thoracoscopic release of tracheopexy stitch causing phrenic nerve paralysis in an infant. Oyarzun R, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):188–90

Acute anterior interosseous neuropathy in a patient with hereditary neuropathy with liability to pressure palsies: a clinical and electromyographic study. Felice KJ. **Muscle Nerve** 1995 Nov;18(11):1329–31

Long thoracic nerve palsy following cervical chiropractic manipulation [letter] Oware A, et al. **Muscle Nerve** 1995 Nov;18(11):1351

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37–1995. A 6–year–old boy with a rash, meningismus, and diplegia [clinical conference] [see comments] **N Engl J Med** 1995 Nov 30; 333(22):1485–93. Comment in: N Engl J Med 1996 May 9;334(19):1271.

Paddler's palsy [letter] Rhodes CH, et al. **N Engl J Med** 1996 Jan 11;334(2):125

Cranial nerve palsy in spontaneous dissection of the extracranial internal carotid artery. Mokri B, et al. **Neurology** 1996 Feb;46(2):356–9

Another kind of knapsack palsy. Pringle CE, et al. **Neurology** 1996 Feb;46(2):585–6

Bilateral radial nerve palsies from use of the standard birthing bar. Roubal PJ, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):820–1

Peroneal nerve palsy in the athlete: a result of indirect trauma. Seckler MM, et al. **Orthopedics** 1996 Apr;19(4):345–7; discussion 347–8

Massive hematoma resulting in bilateral hypoglossal nerve paralysis. Vito KJ, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):491–4

Hopkins syndrome: T2–weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

Renal tubular acidosis complicated with hypokalemic periodic paralysis. Chang YC, et al. **Pediatr Neurol** 1995 Jul;13(1):52–4

Thyrotoxic periodic paralysis in a black man. Hochberg DA, et al. **South Med J** 1996 Jul;89(7):735–7

[Accessory nerve injury as a complication of therapeutic stretching of the shoulder] Halonen E, et al. **Duodecim** 1994;110(9):889–90 **(Fin)**

[Lower limb pain and leaping progressive paraparesis (clinical conference)] Jokelainen M. **Duodecim** 1994; 110(6):622–9 **(Fin)**

[Rapidly progressive paresis and hypokalemia] Koistinen A, et al. **Duodecim** 1995;111(9):850–2 **(Fin)**

[An unusual complication of cervicofacial lift: paralysis of the external branch of the accessory spinal nerve] Costagliola M, et al. **Ann Chir Plast Esthet** 1995 Aug; 40(4):340–8 (Eng. Abstr.) **(Fre)**

[Involvement of the major hypoglossal nerve disclosing dissection of internal carotid artery] Auzou P, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(1):45–7 (Eng. Abstr.) **(Fre)**

[Synovial cyst involving isolated paralysis of the infraspinatus muscle. Ultrasonographic diagnosis and MRI] Bousquet JC, et al. **J Radiol** 1996 Apr;77(4):275–7 (Eng. Abstr.) **(Fre)**

[A case from practice (344). Neuralgic shoulder amyotrophy or plexus neuritis] Burckhardt B. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):348–50 **(Ger)**

[Multiple myeloma presenting as parasellar syndrome and cranial nerve palsies] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):260–4 (Eng. Abstr.) **(Jpn)**

[A case of multiple cranial neuropathy due to varicella–zoster virus infection: detection of involvement of cranial ganglia with MRI] Kikuchi H, et al. **Rinsho Shinkeigaku** 1995 Jul; 35(7):814–6 (Eng. Abstr.) **(Jpn)**

[Midbrain hemorrhage presenting with trochlear nerve palsy—a case report] Mon Y. **Rinsho Shinkeigaku** 1996 Jan; 36(1):71–3 (Eng. Abstr.) **(Jpn)**

[Garcin's syndrome in a patient with malignant chemodectoma of the neck] Parkhomenko VM, et al. **Klin Med (Mosk)** 1995;73(4):84–5 **(Rus)**

[Familial poisoning with Karwinskia humboldtiana] Bermúdez de Rocha MV, et al. **Gac Med Mex** 1995 Jan–Feb;131(1):100–6 (Eng. Abstr.) **(Spa)**

[Paralysis of the 6th cranial nerve secondary to spontaneous intracranial hypotension (letter)] Arjona A, et al. **Rev Clin Esp** 1996 Mar;196(3):201–2 **(Spa)**

GENETICS

A de novo case of hereditary neuropathy with liability to pressure palsies (HNPP) of maternal origin: a new mechanism for deletion in 17p11.2? LeGuern E, et al. **Hum Mol Genet** 1996 Jan;5(1):103–6

Peripheral myelin protein–22 gene deletion in two unrelated Japanese pedigrees with hereditary neuropathy with liability to pressure palsies [letter] Kaneko S, et al. **Muscle Nerve** 1996 May;19(5):675–6

Hypokalemic periodic paralysis mutations: confirmation of mutation and analysis of founder effect. Grosson CL, et al. **Neuromuscul Disord** 1996 Jan;6(1):27–31

Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV. Akiya S, et al. **Ophthalmology** 1996 Jul;103(7):1106–10

[Recurrent idiopathic facial paralysis and other cranial nerve involvements in 2 members of a family] Sangla I, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):291–3 (Eng. Abstr.) **(Fre)**

HISTORY

Brachial plexus surgery. An historical perspective. Robotti E, et al. **Hand Clin** 1995 Nov;11(4):517–33

PARALYSIS

IMMUNOLOGY

Enterovirus specific IgM responses in children with acute and chronic paralytic syndrome. Tuteja U, et al. **J Trop Med Hyg** 1995 Dec;98(6):367–72

HLA antigens typification in two Hispanic patients with thyrotoxic periodic paralysis [letter] Araya P, et al. **Muscle Nerve** 1996 May;19(5):677–8

METABOLISM

Regulation of myosin heavy chain expression in adult rat hindlimb muscles during short–term paralysis: comparison of denervation and tetrodotoxin–induced neural inactivation. Michel RN, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):39–44

Expression of myelin–specific proteins during development of normal and hypomyelinated Paralytic tremor mutant rabbits. II. Studies on the purified myelin. Sypecka J, et al. **Mol Chem Neuropathol** 1995 Sep;26(1):67–78

Expression of myelin–specific proteins during development of normal and hypomyelinated Paralytic tremor mutant rabbits. I. Studies on the brain homogenates. Sypecka J, et al. **Mol Chem Neuropathol** 1995 Sep;26(1):53–66

MICROBIOLOGY

Parrot pseudoparalysis of the upper extremities. A case report. Kocher MS, et al. **J Bone Joint Surg Am** 1996 Feb; 78(2):284–7

PATHOLOGY

Number and morphology of mechanoreceptors in the myotendinous junction of paralysed human muscle. Jozsa L, et al. **J Pathol** 1996 Feb;178(2):195–200

Hopkins syndrome: T2–weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

PHYSIOPATHOLOGY

Factors influencing neurological recovery in burst thoracolumbar fractures. Dendrinos GK, et al. **Acta Orthop Belg** 1995;61(3):226–34

Physiology of REM sleep, cataplexy, and sleep paralysis. Hishikawa Y, et al. **Adv Neurol** 1995;67:245–71 (125 ref.)

Magnetic resonance imaging features of Gradenigo's syndrome. Hardjasudarma M, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):247–50

Possible use–dependent changes in adult primate somatosensory cortex. Garraghty PE, et al. **Brain Res** 1995 Jul 17;686(1):119–21

Multiple cranial nerve palsy after otitis externa: a case report. Boringa JB, et al. **Clin Neurol Neurosurg** 1995 Nov; 97(4):332–5

Anosognosia in parietal lobe syndrome. Ramachandran VS. **Conscious Cogn** 1995 Mar;4(1):22–51

Does an ulnar nerve lesion influence the motion of the index finger? Hahn P, et al. **J Hand Surg [Br]** 1996 Apr; 21(2):252–4

Acquired bilateral opercular lesions or Foix–Chavany–Marie syndrome and eating epilepsy [letter] Mateos V, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):559–60

Energy cost and locomotive economy of handbike and rowcycle propulsion by persons with spinal cord injury. Maki KC, et al. **J Rehabil Res Dev** 1995 May;32(2):170–8

Acute anterior interosseous neuropathy in a patient with hereditary neuropathy with liability to pressure palsies: a clinical and electromyographic study. Felice KJ. **Muscle Nerve** 1995 Nov;18(11):1329–31

Drop thumb syndrome [letter] Gominak S. **Muscle Nerve** 1996 Jun;19(6):796

Intrauterine onset of a mononeuropathy: peroneal neuropathy in a newborn with electromyographic findings at age one day compatible with prenatal onset. Jones HR Jr, et al. **Muscle Nerve** 1996 Jan;19(1):88–91

Stimulation of glossopharyngeal and laryngeal nerve afferents induces expulsion only when it is applied during retching in paralyzed decerebrate dogs. Fukuda H, et al. **Neurosci Lett** 1995 Jun 30;193(2):117–20

Spontaneous synchronized neural activity in decerebrate gallamine–paralysed cats. Burke W, et al. **Neuroscience** 1995 Oct;68(3):943–53

Clinical syndromes associated with disproportionate weakness of the upper versus the lower extremities after cervical spinal cord injury. Levi AD, et al. **Neurosurgery** 1996 Jan;38(1):179–83; discussion 183–5

Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885–93 (39 ref.)

An assessment of factors affecting neurological recovery after spinal cord injury with vertebral fracture. Bravo P, et al. **Paraplegia** 1996 Mar;34(3):164–6

Motor recovery of patients presenting with motor paralysis and sensory sparing following cervical spinal cord injuries. Katoh S, et al. **Paraplegia** 1995 Sep;33(9):506–9

Ion–channel defects and aberrant excitability in myotonia and periodic paralysis. Cannon SC. **Trends Neurosci** 1996 Jan; 19(1):3–10 (59 ref.)

[Histological changes, muscle force and fatigability after electrical stimulation to experimentally paralyzed muscles] Oba M. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep; 69(9):708–20 (Eng. Abstr.) **(Jpn)**

[Intracranial hypotension and sixth cranial nerve palsy] Pondal M, et al. **Neurologia** 1995 Oct;10(8):339–41 (Eng. Abstr.) **(Spa)**

[Brachial paralysis as a presentation of giant cell arteritis] Mota R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):185–6 **(Spa)**

PREVENTION & CONTROL

Value of the staged segmental crossclamp to the aorta technique and reimplantation of intercostal arteries for the prevention of spinal complications associated with surgery for descending and thoraco–abdominal aortic aneurysms. Nakajima N, et al. **Jpn Heart J** 1996 May;37(3):275–84

PSYCHOLOGY

Imperial pathologies: medical discourse and drink in Dubliners' "Grace". Kane J. **Lit Med** 1995 Fall; 14(2):191–209

Relationship between isolated sleep paralysis and geomagnetic influences: a case study. Conesa J. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1263–73

Glad to be alive. Pollack B. **Postgrad Med** 1995 Nov;98(5):36, 38

REHABILITATION

Energy cost and locomotive economy of handbike and rowcycle propulsion by persons with spinal cord injury. Maki KC, et al. **J Rehabil Res Dev** 1995 May;32(2):170–8

[Multilevel stimulation in the treatment of patients with paralysis and paresis] Tyshkevich TG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):16–8 (Eng. Abstr.) **(Rus)**

SURGERY

Restoration of hand function after brachial plexus injury. Bonnard C, et al. **Hand Clin** 1995 Nov;11(4):647–56

The operative treatment of peroneal nerve palsy. Mont MA, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):863–9

Spontaneous anterior interosseous nerve palsy with hourglass–like fascicular constriction within the main trunk of the median nerve. Nagano A, et al. **J Hand Surg [Am]** 1996 Mar;21(2):266–70

Delayed posterior interosseous nerve palsy. Hashizume H, et al. **J Hand Surg [Br]** 1995 Oct;20(5):655–7

Constrictive paralysis of the posterior interosseous nerve without external compression. Inoue G, et al. **J Hand Surg [Br]** 1996 Apr;21(2):164–8

Levator scapulae transfer and fascia lata fasciodesis for chronic spinal accessory nerve palsy. Coessens BC, et al. **J Reconstr Microsurg** 1995 Jul;11(4):277–80

Latissimus dorsi transfer for elbow flexion in the paralytic limb. Arroyo JS, et al. **Nebr Med J** 1995 Sep;80(9):290–2

[Paralysis of the interosseous nerve by a tendinous margin of the extensor carpi radialis brevis] Witthaut J, et al. **Handchir Mikrochir Plast Chir** 1995 Nov;27(6):329–30 (Eng. Abstr.) **(Ger)**

THERAPY

Iatrogenic serratus anterior paralysis. Long–term outcome in 26 patients. Kauppila LI, et al. **Chest** 1996 Jan; 109(1):31–4

3–directional penetration needling for the treatment of paralysis. Shi N. **J Tradit Chin Med** 1996 Mar;16(1):37–40

[Treatment of limb paralysis using low–frequency deep electric stimulation] Li Khao Lin'. **Med Tr Prom Ekol** 1995; (9):33–7 (Eng. Abstr.) **(Rus)**

VETERINARY

Neosporosis and toxoplasmosis–associated paralysis in dogs in Costa Rica. Morales JA, et al. **Appl Parasitol** 1995 Aug; 36(3):179–84

Complication after the use of a combination of lignocaine and xylazine for epidural anaesthesia in a mare. Chopin JB, et al. **Aust Vet J** 1995 Sep;72(9):354–5

Hyperkalaemic periodic paralysis in Australian quarter horses. Church S. **Aust Vet J** 1995 Aug;72(8):314–6

What is your neurologic diagnosis? Neospora caninum–induced myositis. Longshore RC. **J Am Vet Med Assoc** 1996 Mar 1;208(5):667–8

Acute selenium toxicosis as a cause of paralysis in pigs [letter] Penrith ML. **J S Afr Vet Assoc** 1995 Jun;66(2):47–8

Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis. Beech J, et al. **Res Vet Sci** 1995 Sep;59(2):95–101

Physiotherapy as an aid to treatment of bilateral femoral paralysis in a calf. White AJ, et al. **Vet Rec** 1995 Nov 4; 137(19):489–91

In vitro cytotoxicity of sera of paralysed ostriches showing serological positivity for Borna disease virus. Wormser U, et al. **Vet Rec** 1996 Apr 27;138(17):418–9

[The mystery of the staggering turkeys: a differential diagnostic puzzle] Braunius WW. **Tijdschr Diergeneeskd** 1996 Aug 15;121(16):444–5 (Eng. Abstr.) **(Dut)**

VIROLOGY

Epidemiology and clinical characteristics of acute flaccid paralysis associated with non–polio enterovirus isolation: the experience in the Americas. Dietz V, et al. **Bull World Health Organ** 1995;73(5):597–603

Distribution of viral RNA in the spinal cord of DBA/2 mice developing biphasic paralysis following infection with the D variant of encephalomyocarditis virus (EMC–D). Takeda M, et al. **Int J Exp Pathol** 1995 Dec;76(6):441–7

Paralysis caused by acute myelitis in Theiler's murine encephalomyelitis virus strain GD VII infection is induced by CD4+ lymphocytes infiltrating the spinal cord. Kohanawa M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2251–6

PARALYSIS AGITANS see **PARKINSON DISEASE**

PARALYSIS, BULBAR

COMPLICATIONS

Accidental barium aspiration in a case of progressive bulbar palsy. Jha S, et al. **J Assoc Physicians India** 1995 Aug; 43(8):578

CONGENITAL

EPG treatment of a child with the Worster–Drought syndrome. MorganBarry RA. **Eur J Disord Commun** 1995; 30(2):256–63

DIAGNOSIS

The diagnosis of amyotrophic lateral sclerosis. Pouget J, et al. **Adv Neurol** 1995;68:143–52 (82 ref.)

ETIOLOGY

Delayed radiation–induced bulbar palsy. Shapiro BE, et al. **Neurology** 1996 Jun;46(6):1604–6

[Spontaneous internal carotid artery dissection as a cause of unilateral lower cranial nerve palsies] Ruiz J, et al. **Neurologia** 1995 Nov;10(9):391–3 (Eng. Abstr.) **(Spa)**

GENETICS

Infantile onset of hereditary ascending spastic paralysis with bulbar involvement. Lerman–Sagie T, et al. **J Child Neurol** 1996 Jan;11(1):54–7

PHYSIOPATHOLOGY

[Spontaneous internal carotid artery dissection as a cause of unilateral lower cranial nerve palsies] Ruiz J, et al. **Neurologia** 1995 Nov;10(9):391–3 (Eng. Abstr.) **(Spa)**

SURGERY

Anterior corpus callosotomy: effects in a patient with congenital bilateral perisylvian syndrome and oromotor seizures. Ambrosetto G, et al. **Ital J Neurol Sci** 1995 Jun; 16(5):311–4

PARALYSIS, FAMILIAL PERIODIC

[Thyrotoxic periodic paralysis: an exceptional case report in Spanish population] Lasterra Sanchez M, et al. **An Med Interna** 1995 Dec;12(12):603–5 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Hypokalaemic periodic paralysis with cardiac arrhythmia and prolonged QT interval [letter] Williams MJ, et al. **Aust N Z J Med** 1995 Oct;25(5):549

Periodic paralysis and ventricular tachycardia: possible role of calcium channel blockers. Ebeid MR, et al. **Pediatr Cardiol** 1996 Jan–Feb;17(1):31–4

DIAGNOSIS

Hypokalaemic periodic paralysis associated with thyrotoxicosis. Agarwal AK, et al. **J Indian Med Assoc** 1995 Sep;93(9):359–60, 358 (21 ref.)

A puzzling case of periodic paralysis. Griggs RC, et al. **Muscle Nerve** 1996 Mar;19(3):362–4

ETIOLOGY

Periodic paralyses. Horne M. **Aust Fam Physician** 1996 Aug; 25(8):1331

Expression and functional characterization of the cardiac L–type calcium channel carrying a skeletal muscle DHP–receptor mutation causing hypokalaemic periodic paralysis. Lerche H, et al. **Pflugers Arch** 1996 Jan; 431(3):461–3

GENETICS

Hereditary nondystrophic myotonias and periodic paralyses. Lehmann–Horn F, et al. **Curr Opin Neurol** 1995 Oct; 8(5):402–10 (62 ref.)

PHYSIOPATHOLOGY

Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells. Lapie P, et al. **FEBS Lett** 1996 Mar 18;382(3):244–8

Enhancement of "end–plate monophasic waves" during an attack of hypokalemic periodic paralysis [letter] Ertekin C, et al. **Muscle Nerve** 1996 May;19(5):680–1

VETERINARY

Hyperkalemic periodic paralysis episode during halothane anesthesia in a horse. Bailey JE, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1859–65

PARALYSIS, GENERAL see NEUROSYPHILIS

PARALYSIS, OBSTETRIC

DIAGNOSIS

An approach to obstetrical brachial plexus injuries. Clarke HM, et al. **Hand Clin** 1995 Nov;11(4):563–80; discussion 580–1 (52 ref.)

Magnetic resonance imaging of the shoulder in children with brachial pLexus birth palsy. Gudinchet F, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S125–8

ETIOLOGY

Obstetrical brachial plexus injury in newborn babies delivered by caesarean section. al–Qattan MM, et al. **J Hand Surg [Br]** 1996 Apr;21(2):263–5

Medico–legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)

REHABILITATION

Special rehabilitation considerations in the management of obstetrical brachial plexus injuries. Mulloy EM, et al. **Hand Clin** 1995 Nov;11(4):619–22

SURGERY

Palliative surgical procedures to restore shoulder function in obstetric brachial palsy. Critical analysis of Narakas' series. Egloff DV, et al. **Hand Clin** 1995 Nov;11(4):597–606

Long–term evaluation of brachial plexus surgery in obstetrical palsy. Gilbert A. **Hand Clin** 1995 Nov; 11(4):583–94; discussion 594–5

Special rehabilitation considerations in the management of obstetrical brachial plexus injuries. Mulloy EM, et al. **Hand Clin** 1995 Nov;11(4):619–22

A management approach for secondary shoulder and forearm deformities following obstetrical brachial plexus injury. Price AE, et al. **Hand Clin** 1995 Nov;11(4):607–17

Obstetrical brachial plexus palsy: results following neurolysis of conducting neuromas–in–continuity. Clarke HM, et al. **Plast Reconstr Surg** 1996 Apr;97(5):974–82; discussion 983–4

PARALYSIS, PSEUDOBULBAR see PARALYSIS

PARALYTIC ILEUS see INTESTINAL PSEUDO–OBSTRUCTION

PARAMAGNETIC RESONANCE see ELECTRON SPIN RESONANCE SPECTROSCOPY

PARAMECIUM

CHEMISTRY

Glycosylinositol–phosphoceramide in the free–living protozoan Paramecium primaurelia: modification of core glycans by mannosyl phosphate. Azzouz N, et al. **EMBO J** 1995 Sep 15;14(18):4422–33

The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107–15 (35 ref.)

CYTOLOGY

Inhibition of trichocyst exocytosis and calcium influx in Paramecium by amiloride and divalent cations. Kerboeuf D, et al. **Biol Cell** 1996;86(1):39–43

DRUG EFFECTS

Effects of calmodulin antisense oligonucleotides on chemoresponse in Paramecium. Yano J, et al. **Chem Senses** 1996 Feb;21(1):55–8

Notes on the use of invertebrates, especially ciliates, in studies on pollution and toxicity. Komala Z. **Folia Biol (Krakow)** 1995;43(1–2):25–7

Pharmacological prevention of acute lead poisoning in Paramecium. Bernal J, et al. **Toxicology** 1996 Apr 30; 108(3):165–73

ENZYMOLOGY

Stereospecificity of inositol hexakisphosphate dephosphorylation by Paramecium phytase. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):907–10

Acid phosphatase activity in mating type I and mating type II cell lines of Paramecium primaurelia. Ramoino P, et al. **Eur J Histochem** 1995;39(2):157–64

GENETICS

Structure and evolution of Paramecium hemoglobin genes. Yamauchi K, et al. **Biochim Biophys Acta** 1995 Oct 17; 1264(1):53–62

Characterization of centrin genes in Paramecium. Madeddu L, et al. **Eur J Biochem** 1996 May 15;238(1):121–8

Cytoplasm rescues an arrhythmic mutant on the circadian rhythm of mating reactivity in Paramecium bursaria. Miwa I, et al. **J Eukaryot Microbiol** 1996 May–Jun;43(3):231–6

A large multigene family codes for the polypeptides of the crystalline trichocyst matrix in Paramecium. Madeddu L, et al. **Mol Biol Cell** 1995 Jun;6(6):649–59

A single telomerase RNA is sufficient for the synthesis of variable telomeric DNA repeats in ciliates of the genus Paramecium. McGormick–Graham M, et al. **Mol Cell Biol** 1996 Apr;16(4):1871–9

METABOLISM

Caffeine inhibits Ca2+ uptake by subplasmalemmal calcium stores ('alveolar sacs') isolated from Paramecium cells. Länge S, et al. **Biochim Biophys Acta** 1996 Jan 31; 1278(2):191–6

The pegs on the decorated tubules of the contractile vacuole complex of Paramecium are proton pumps. Fok AK, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3163–70

PHYSIOLOGY

Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)

Lysozyme acts as a chemorepellent and secretagogue in Paramecium by activating a novel receptor–operated Ca++ conductance. Hennessey TM, et al. **J Membr Biol** 1995 Nov;148(1):13–25

Reactivation of extracted Paramecium models. Naitoh Y. **Methods Cell Biol** 1995;47:211–24

ULTRASTRUCTURE

Preparation of cilia and subciliary fractions from Paramecium. Nelson DL. **Methods Cell Biol** 1995;47:17–24

PARAMECIUM TETRAURELIA

ENZYMOLOGY

Cathepsin L is an intracellular and extracellular protease in Paramecium tetraurelia. Purification, cloning, sequencing and specific inhibition by its expressed propeptide. Völkel H, et al. **Eur J Biochem** 1996 May 15;238(1):198–206

Cloning of a novel ubiquitin–conjugating enzyme (E2) gene from the ciliate Paramecium tetraurelia. Okano S, et al. **FEBS Lett** 1996 Aug 5;391(1–2):1–4

Immunolocalization of protein phosphatase type 1 in Paramecium cells using antibodies against recombinant protein and peptides. Momayezi M, et al. **J Histochem Cytochem** 1996 Aug;44(8):891–905

Isolation and characterization of protein kinases from Paramecium cilia. Carlson GL, et al. **Methods Cell Biol** 1995;47:473–80

GENETICS

Cloning of a novel ubiquitin–conjugating enzyme (E2) gene from the ciliate Paramecium tetraurelia. Okano S, et al. **FEBS Lett** 1996 Aug 5;391(1–2):1–4

A Mendelian mutation affecting mating–type determination also affects developmental genomic rearrangements in Paramecium tetraurelia. Meyer E, et al. **Genetics** 1996 May; 143(1):191–202

Cloning and sequence analysis of genes coding for paramecium secretory granule (trichocyst) proteins. A unique protein fold for a family of polypeptides with different primary structures. Gautier MC, et al. **J Biol Chem** 1996 Apr 26;271(17):10247–55

The dynein genes of Paramecium tetraurelia: the structure and expression of the ciliary beta and cytoplasmic heavy chains. Kandl KA, et al. **Mol Biol Cell** 1995 Nov; 6(11):1549–62

Cloning and molecular analysis of the bifunctional dihydrofolate reductase–thymidylate synthase gene in the ciliated protozoan Paramecium tetraurelia. Schlichtherle IM, et al. **Mol Gen Genet** 1996 Apr 10;250(6):665–73

The 5' coding region of Paramecium surface antigen genes controls mutually exclusive transcription. Leeck CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2838–43

A multigene family of novel K+ channels from Paramecium tetraurelia. Jegla T, et al. **Receptors Channels** 1995; 3(1):51–60

PHYSIOLOGY

Protein phosphatase and kinase activities possibly involved in exocytosis regulation in Paramecium tetraurelia. Kissmehl R, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):65–76

Mechanochemical aspects of axonemal dynein activity studied by in vitro microtubule translocation. Hamasaki T, et al. **Biophys J** 1995 Dec;69(6):2569–79

Subplasmalemmal Ca2+ stores of probable relevance for exocytosis in Paramecium. Alveolar sacs share some but not all characteristics with sarcoplasmic reticulum [published erratum appears in Cell Calcium 1995 Jul;18(1):87] Länge S, et al. **Cell Calcium** 1995 May; 17(5):335–44

PARAMEDICAL PERSONNEL see ALLIED HEALTH PERSONNEL

PARAMEDICS see ALLIED HEALTH PERSONNEL

PARAMEDICS, EMERGENCY see EMERGENCY MEDICAL TECHNICIANS

PARAMETHASONE

ADVERSE EFFECTS

Pseudo–allergic reactions to corticosteroids: diagnosis and alternatives. Valdivieso R, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):171–4

THERAPEUTIC USE

Inverted skin changes induced by estrogen and estrogen/glucocorticoid on aging dermis. Cortés–Gallegos V, et al. **Gynecol Endocrinol** 1996 Apr;10(2):125–8

PARAMORPHAN see DIHYDROMORPHINE

PARAMYOSIN see TROPOMYOSIN

PARAMYXOVIRIDAE

CHEMISTRY

Characterization of Mapuera virus: structure, proteins and nucleotide sequence of the gene encoding the nucleocapsid protein. Henderson GW, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2509–18

Structural requirements in the membrane–spanning domain of the paramyxovirus HN protein for the formation of a stable tetramer. Parks GD, et al. **Virology** 1995 Oct 20; 213(1):263–70

GENETICS

Characterization of Mapuera virus: structure, proteins and nucleotide sequence of the gene encoding the nucleocapsid protein. Henderson GW, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2509–18

ISOLATION & PURIFICATION

Evaluation of WHO monoclonal antibody kit for diagnosis of acute respiratory viral infections. Khairullah NS, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):263–7

PARAMYXOVIRUS

CHEMISTRY

The paramyxovirus simian virus 5 hemagglutinin–neuraminidase glycoprotein, but not the fusion glycoprotein, is internalized via coated pits and enters the endocytic pathway. Leser GP, et al. **Mol Biol Cell** 1996 Jan;7(1):155–72

DRUG EFFECTS

Evaluation of the antiviral activity of N–(phosphonoacetyl)–L–aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Wyde PR, et al. **Antiviral Res** 1995 May;27(1–2):59–69

GENETICS

Inducible expression of the P, V, and NP genes of the paramyxovirus simian virus 5 in cell lines and an examination of NP–P and NP–V interactions. Precious B, et al. **J Virol** 1995 Dec;69(12):8001–10

ISOLATION & PURIFICATION

Paramyxovirus–like inclusions [letter] Tschen JA, et al. **Am J Dermatopathol** 1995 Aug;17(4):426–7

Isolation and characterization of paramyxoviruses from snakes and their relationship to avian paramyxoviruses. Blahak S. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):216–24

PHYSIOLOGY

Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus. Bagai S, et al. **J Virol** 1995 Nov;69(11):6712–9

PARAMYXOVIRUS INFECTIONS

VETERINARY

Serological survey for avian paramyxoviruses from wildfowl in aquatic habitats in Andalusia. Maldonado A, et al. **J Wildl Dis** 1995 Jan;31(1):66–9

First isolation of avian paramyxovirus serotype 3 in Israel [letter] Shihmanter E, et al. **Vet Rec** 1996 Feb 10;138(6):144

Isolation and characterization of paramyxoviruses from snakes and their relationship to avian paramyxoviruses. Blahak S. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):216–24

PARAMYXOVIRUS TYPE 1, AVIAN see NEWCASTLE DISEASE VIRUS

PARAMYXOVIRUSES, AVIAN

CHEMISTRY

Characterization of Bangor virus proteins by using monoclonal antibodies. Mao X, et al. **Avian Dis** 1996 Jan-Mar;40(1):150-7

IMMUNOLOGY

Antigenic heterogeneity of avian paramyxoviruses of serotype 2 ("Yucaipa-like") isolated from domestic and wild birds in Israel. Lipkind M, et al.
Comp Immunol Microbiol Infect Dis 1995 Jun;18(3):189-207

Serological survey for avian paramyxoviruses from wildfowl in aquatic habitats in Andalusia. Maldonado A, et al.
J Wildl Dis 1995 Jan;31(1):66-9

ISOLATION & PURIFICATION

First isolation of avian paramyxovirus serotype 3 in Israel [letter] Shihmanter E, et al. **Vet Rec** 1996 Feb 10;138(6):144

Isolation of Yucaipa virus [letter] Shihmanter E, et al.
Vet Rec 1995 Sep 9;137(11):276

Antigenic characterisation of avian paramyxoviruses serotype 4 isolated from wild mallard (Anas plathyrinchos) in Israel. Shihmanter E, et al. **Vet Rec** 1995 Dec 16;137(25):641-2

PARANASAL SINUS DISEASES

[Frontal sinus mucoceles apropos of 35 cases] Ndiaye I, et al. **Dakar Med** 1994;39(2):143-7 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Enophthalmos secondary to maxillary sinus disease: single-stage operative management. Beasley NJ, et al.
J Laryngol Otol 1995 Sep;109(9):868-70

Isolated third-nerve palsy associated with frontal sinus mucocele. Ehrenpreis SJ, et al. **J Neuroophthalmol** 1995 Jun;15(2):105-8

Globe ptosis secondary to maxillary sinus mucocele. Garber PF, et al. **Ophthal Plast Reconstr Surg** 1995 Dec; 11(4):254-60

DIAGNOSIS

Frontoethmoidal giant cell reparative granuloma. Felsberg GJ, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1551-4

Delayed toxic shock syndrome after functional endonasal sinus surgery. Younis RT, et al.
Arch Otolaryngol Head Neck Surg 1996 Jan;122(1):83-5

Recurrent aspergilloma of the frontoethmoid sinus in a non-immunocompromised patient. Tierney P, et al.
J R Soc Med 1996 Mar;89(3):165P-6P

Changes in paranasal sinus abnormalities found incidentally on MRI. Maly PV, et al. **Neuroradiology** 1995 Aug; 37(6):471-4

Rhinocerebral mucormycosis: predisposing factors, diagnosis, therapy, complications and survival. Butugan O, et al.
Rev Laryngol Otol Rhinol (Bord) 1996;117(1):53-5

Mucormycosis of the paranasal sinuses. Perolada Valmana JM, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):51-2

[Necrotizing sialometaplasia of the nasal cavity (letter; comment)] Zschoch H, et al. **HNO** 1995 Nov;43(11):642-3 . Comment on: HNO 1994 Nov;42(11):697-700. **(Ger)**

DRUG THERAPY

Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Patterson TS, et al. **Clin Pediatr (Phila)** 1996 May;35(5):257-60

Fluconazole in the treatment of three cases of mucormycosis [letter] Koçak R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):559-61

ETIOLOGY

The paranasal sinuses before and after radiotherapy for nasopharyngeal carcinoma: a computed tomographic study. Porter MJ, et al. **J Laryngol Otol** 1996 Jan;110(1):19-22

Sinus disease in the bone marrow transplant population: incidence, risk factors, and complications. Shibuya TY, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):705-11

MICROBIOLOGY

Bacteriology of chronic otitis media, chronic sinusitis, and paranasal mucopyocele in Japan. Ito K, et al.
Clin Infect Dis 1995 Jun;20 Suppl 2:S214-9

Paraseilar Aspergillus granuloma extending from the sphenoid sinus: report of two cases. Kurita H, et al.
Surg Neurol 1995 Nov;44(5):489-94

PATHOLOGY

Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Norlander T, et al.
Laryngoscope 1996 Feb;106(2 Pt 1):196-203

[Spherulocytosis (myospherulosis) of the paranasal sinuses] Godbersen GS, et al. **HNO** 1995 Sep;43(9):552-5 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Rhinocerebral invasive mycosis: occurrence in immunocompetent individuals. Hussain S, et al.
Eur J Radiol 1995 Jul;20(2):151-5

Abnormalities of the paranasal sinuses in patients with nasopharyngeal carcinoma: a computed tomographic study. Porter MJ, et al. **J Laryngol Otol** 1996 Jan;110(1):23-6

Sinonasal imaging. Hudgins PA. **Neuroimaging Clin N Am** 1996 May;6(2):319-31

Radiographic maxillary sinus findings in the elderly. Soikkonen K, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Oct;80(4):487-91

[Anatomo-radiologic diagnosis of mucoceles in the paranasal sinuses] Banus C, et al.
Rev Laryngol Otol Rhinol (Bord) 1989;110(3):257-60 (Eng. Abstr.) **(Fre)**

SURGERY

Functional endoscopic sinus surgery under local anaesthesia: possibilities and limitations. Jorissen M, et al.
Acta Otorhinolaryngol Belg 1996;50(1):1-12

Powered instrumentation in functional endoscopic sinus surgery. I: Surgical technique. Christmas DA Jr, et al.
Ear Nose Throat J 1996 Jan;75(1):33-6, 39-40

Powered instrumentation in functional endoscopic sinus surgery. II: A comparative study. Krouse JH, et al.
Ear Nose Throat J 1996 Jan;75(1):42-4

Lateral lamella of the cribriform plate--an important high-risk area in endoscopic sinus surgery. Ohnishi T, et al. **Ear Nose Throat J** 1995 Oct;74(10):688-90

Magnetic resonance imaging after frontal sinus surgery with fat obliteration. Keerl R, et al. **J Laryngol Otol** 1995 Nov; 109(11):1115-9

Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al.
J Laryngol Otol 1996 Mar;110(3):261-4 (26 ref.)

Advantages and disadvantages of three-dimensional computed tomography intraoperative localization for functional endoscopic sinus surgery. Roth M, et al.
Laryngoscope 1995 Dec;105(12 Pt 1):1279-86

Surgical repair of the silent sinus syndrome. Dailey RA, et al. **Ophthal Plast Reconstr Surg** 1995 Dec;11(4):261-8

Symptom outcome after functional endoscopic sinus surgery in patients with cystic fibrosis: a prospective study [see comments] Nishioka GJ, et al.
Otolaryngol Head Neck Surg 1995 Oct;113(4):440-5. Comment in: Otolaryngol Head Neck Surg 1996 Jun;114(6):840-1.

Frontal sinus obliteration [letter; comment] Sherris DA, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1744-5. Comment on: Plast Reconstr Surg 1995 Mar;95(3):580-5.

[Computer-assisted surgery of the paranasal sinuses with an opto-electronic stereotaxic system] Hauser R, et al.
Laryngorhinootologie 1996 Apr;75(4):199-207 (Eng. Abstr.) **(Ger)**

[Effects of postoperative care on wound healing after endonasal paranasal sinus surgery] Weber R, et al.
Laryngorhinootologie 1996 Apr;75(4):208-14 (Eng. Abstr.) **(Ger)**

[Operative results in fourteen cases of paranasal sinus and anterior cranial fossa lesions surgically treated by an extended transbasal approach] Kumon Y, et al.
No Shinkei Geka 1995 Oct;23(10):889-95 (Eng. Abstr.) **(Jpn)**

THERAPY

[Isolated invasive sphenoid aspergillosis] Delevaux I, et al.
Presse Med 1996 Apr 6;25(12):587-9 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Use of A-mode ultrasound in the diagnosis of maxillary sinus diseases] Zhong J, et al.
Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1995;30(3):166-8 (Eng. Abstr.) **(Chi)**

VETERINARY

Mycotic osteomyelitis in a dog following nasal aspergillosis. Moore AH, et al. **Vet Rec** 1995 Sep 30;137(14):349-50

PARANASAL SINUS NEOPLASMS

Inverted papilloma isolated to the sphenoid sinus. Peters BW, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):771-7

[Features of rhinologic and otoneurologic symptoms and complications in intracranial tumors growing into the nose and paranasal sinuses] Blagoveshchenskaia NS, et al.
Vestn Otorinolaringol 1995 Nov-Dec;(6):5-10 (Eng. Abstr.) **(Rus)**

[Large osteoma of the frontal sinus] Kudrin AI.
Vestn Otorinolaringol 1996 Mar-Apr;(2):52-3 **(Rus)**

CHEMICALLY INDUCED

Ethmoid sinus leiomyosarcoma after cyclophosphamide treatment. Reich DS, et al.
Otolaryngol Head Neck Surg 1995 Oct;113(4):495-8

COMPLICATIONS

Tension pneumocephalus: a complication of invasive ossifying fibroma of the paranasal sinuses. Tobey JD, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):711-3

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al.
Neurochirurgie 1995;41(5):367-71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Unilateral amaurosis caused by osteoma of the sphenoid sinus associated with mucocele. Apropos of a case] Noterman J, et al. **Neurochirurgie** 1995;41(6):419-23 (Eng. Abstr.) **(Fre)**

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279-82 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Neuroradiology case of the day. Meningioma. Dix JE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):260, 264

Intranasal schwannoma: magnetic resonance and computed tomography appearance. Dublin AB, et al.
Am J Otolaryngol 1995 Jul-Aug;16(4):251-4

Intracranial development of the transient form of nasal-pharyngeal cavity structures carcinoma. Pilarczyk M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:5-8

Pathologic quiz case 2. Sinonasal undifferentiated carcinoma (SNUC). Pitman KT, et al.
Arch Otolaryngol Head Neck Surg 1995 Oct;121(10):1201, 1203

Clinical assessment of squamous cell carcinoma of the nasal cavity proper. Kida A, et al. **Auris Nasus Larynx** 1995; 22(3):172-7

Rhabdomyosarcoma of the paranasal sinuses in an adult. Koenigsberg RA, et al. **Clin Imaging** 1995 Oct-Dec; 19(4):234-6

Pituitary adenoma presenting as sinonasal tumor: pitfalls in diagnosis. Luk IS, et al. **Hum Pathol** 1996 Jun;27(6):605-9

Burkitt's lymphoma of the skull base presenting as cavernous sinus syndrome in early childhood. Kalina P, et al.
Pediatr Radiol 1996;26(6):416-7

Usefulness of electron microscopy in the diagnosis of "small" round cell tumors of the sinonasal region. Min KW.
Ultrastruct Pathol 1995 Sep-Oct;19(5):347-63

[Primary lymphoma of the sphenoid sinus. Report of a case and review of the literature] Ferrario F, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(6):298-302 (44 ref.) (Eng. Abstr.) **(Fre)**

[Bucco-sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244-7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Extracranial meningioma: apropos of a case developing in the nasal cavity and paranasal sinuses] Jurado Ramos A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):289-91 (Eng. Abstr.) **(Fre)**

[Churg-Strauss syndrome. A differential diagnosis in chronic polypoid sinusitis] Trittel C, et al. **Laryngorhinootologie** 1995 Sep;74(9):577-80 (23 ref.) (Eng. Abstr.) **(Ger)**

[Solitary naso-sinusal fibrous tumor] Martínez V, et al.
Acta Otorrinolaringol Esp 1995 Jul-Aug;46(4):323-6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Brasnu D, et al.
Arch Otolaryngol Head Neck Surg 1996 Jul;122(7):765-8

ECONOMICS

[Magnetic resonance and computed tomography compared in the staging of rhinosinusal neoplasms. A cost-effectiveness evaluation] Maroldi R, et al.
Radiol Med (Torino) 1996 Mar;91(3):211-8 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Occupational exposure to dust and sinonasal cancer. An analysis of 386 cases reported to the N.C.C.S.F. Cancer Registry. Van den Oever R. **Acta Otorhinolaryngol Belg** 1996;50(1):19-24

Wood dust and sino-nasal cancer: pooled reanalysis of twelve case-control studies. Demers PA, et al. **Am J Ind Med** 1995 Aug;28(2):151-66

Sinonasal non-Hodgkin's lymphoma in patients infected with human immunodeficiency virus: report of three cases and review. Pomilla PV, et al. **Clin Infect Dis** 1995 Jul; 21(1):137-49 (117 ref.)

GENETICS

K-ras-2 and p53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Wu TT, et al. **Mod Pathol** 1996 Mar;9(3):199-204

[Genetic disposition to chronic polypoid sinusitis and alpha 1-proteinase inhibitor deficiency types] Maune S, et al.
HNO 1995 Sep;43(9):537-9 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma. Harabuchi Y, et al.
Ann Otol Rhinol Laryngol 1996 Aug;105(8):634-42

METABOLISM

Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value. Klapan I, et al.
Am J Otolaryngol 1995 Nov-Dec;16(6):396-402

Prognostic implications of Sialosyl-Tn antigen expression in sinonasal intestinal-type adenocarcinoma. Franchi A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):123-7

PATHOLOGY

Orbital presentation of ethmoid sinus adenocarcinoma. Seregard S, et al. **Acta Ophthalmol Scand** 1995 Oct; 73(5):457-9

Pathologic quiz case 1. Adenoid cystic carcinoma (ACC) of the ethmoid sinus. Chen AY, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov;121(11):1320, 1322-3

Sinonasal mucosal melanoma. Pathologic quiz case 2. Prichett DD, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr; 122(4):441, 443-4

Clinical assessment of squamous cell carcinoma of the nasal cavity proper. Kida A, et al. **Auris Nasus Larynx** 1995; 22(3):172-7

Aggressive psammomatoid ossifying fibromas of the sinonasal region: a clinicopathologic study of a distinct group of fibro-osseous lesions. Wenig BM, et al. **Cancer** 1995 Oct 1;76(7):1155-65

Management of malignant schwannomas of the paranasal sinuses and anterior skull base. DiNardo LJ, et al. **Ear Nose Throat J** 1996 Jun;75(6):377-80

Nonsquamous cell malignant neoplasms of the nasal cavities and paranasal sinuses. Spiro JD, et al. **Head Neck** 1995 Mar-Apr;17(2):114-8

Sinonasal neuroendocrine carcinoma exhibiting amphicrine differentiation. McCluggage WG, et al. **Histopathology** 1995 Jul;27(1):79-82

Ectopic nonfunctioning pituitary adenoma in the sphenoid sinus [letter; comment] Siegert B, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):430-1. Comment on: J Clin Endocrinol Metab 1995 Jun;80(6):1774-7.

Ethmoidal myofibroblastoma. Samuel D, et al. **J Otolaryngol** 1995 Oct;24(5):313-6 (18 ref.)

Sinonasal malignant melanoma--a clinicopathologic analysis of 18 cases. Crawford RI, et al. **Melanoma Res** 1995 Aug; 5(4):261-5 (34 ref.)

Oncocytic adenocarcinoma of the lacrimal sac: report of a case with paranasal sinus and orbital extension. Perlman JI, et al. **Ophthalmic Surg** 1995 Jul-Aug;26(4):377-9

Management of the frontal sinus with inverted papilloma. Shohet JA, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):649-52 (14 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113-7 (15 ref.)

Magnetic resonance imaging of massive intracranial invasion by an ethmoidal adenoid cystic carcinoma (cylindroma). Veillon BJ, et al. **South Med J** 1996 Mar;89(3):321-3 (10 ref.)

[Osteomas of frontal sinus] Dobroś W, et al. **Otolaryngol Pol** 1995;49(4):352-5 (Eng. Abstr.) **(Pol)**

[Hemangiosarcoma of the nasal cavity] Martín Vázquez C, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):149-52 (Eng. Abstr.) **(Spa)**

[Paranasal sinus pleomorphic adenoma] Sánchez-Alcón MD, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):71-3 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Another CT sign of sinonasal polyposis: truncation of the bony middle turbinate. Liang EY, et al. **Eur Radiol** 1996; 6(4):553-6

The influence of computer tomography on treatment strategies and follow-up in tumors of the nasopharynx and the paranasal sinuses. A retrospective study on 104 patients. Reisner K, et al. **Strahlenther Onkol** 1996 Jan;172(1):1-8

[Primary pleomorphic adenoma of the principal paranasal sinus] Flöttmann T, et al. **HNO** 1995 Oct;43(10):624-6 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission tomography. Böni R, et al. **Arch Dermatol** 1996 Aug;132(8):875-6

RADIOTHERAPY

Electron-photon field matching in the treatment of paranasal sinus tumors: a case report. Roeske JC, et al. **Med Dosim** 1996 Spring;21(1):31-6

The influence of computer tomography on treatment strategies and follow-up in tumors of the nasopharynx and the paranasal sinuses. A retrospective study on 104 patients. Reisner K, et al. **Strahlenther Onkol** 1996 Jan;172(1):1-8

Visual loss following treatment of sphenoid sinus carcinoma. Ebner R, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):62-8

SECONDARY

A case of prostatic cancer metastatic to the orbit and ethmoid sinus [letter; comment] Saleh HA. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):584. Comment on: Ann Otol Rhinol Laryngol 1996 Jan;105(1):70-1.

Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission tomography. Böni R, et al. **Arch Dermatol** 1996 Aug;132(8):875-6

Breast carcinoma metastatic to paranasal sinuses. Austin JR, et al. **Head Neck** 1995 Mar-Apr;17(2):161-5 (20 ref.)

Renal cell carcinoma presenting as a solitary paranasal sinus metastasis. Homer JJ, et al. **J Laryngol Otol** 1995 Oct; 109(10):986-9

Metastatic adenocarcinoma of the ethmoids in a patient with previous gastric adenocarcinoma: a case report. Owa AO, et al. **J Laryngol Otol** 1995 Aug;109(8):759-61

Electron-photon field matching in the treatment of paranasal sinus tumors: a case report. Roeske JC, et al. **Med Dosim** 1996 Spring;21(1):31-6

Papillary thyroid carcinoma metastasizing to the sphenoid-ethmoid sinuses and skull base. Freeman JL, et al. **Thyroid** 1996 Feb;6(1):59-61

SURGERY

Repair of anterior base of skull with free latissimus dorsi flap. Bootz F, et al. **Acta Neurochir (Wien)** 1995; 133(3-4):195-200

Extended middle fossa approach for petroclival lesions. Goel A. **Acta Neurochir (Wien)** 1995;135(1-2):78-83

Madreporic coral for cranial base reconstruction. 8 years experience. Roux FX, et al. **Acta Neurochir (Wien)** 1995; 133(3-4):201-5

Complete sphenoethmoidectomy and computer-assisted surgery. Gunkel AR, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):257-61

The role of endoscopy in the management of paranasal sinus tumours. Jorissen M. **Acta Otorhinolaryngol Belg** 1995; 49(3):225-8

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Brasnu D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):765-8

Preservation of the eye in the treatment of sinonasal malignant neoplasms with orbital involvement. A confirmation of the original treatise. McCary WS, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):657-9

Management of malignant schwannomas of the paranasal sinuses and anterior skull base. DiNardo LJ, et al. **Ear Nose Throat J** 1996 Jun;75(6):377-80

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar-Apr; 17(2):152-6 (22 ref.)

Enhanced magnetic resonance imaging and subtraction techniques in postoperative evaluation of craniofacial resection for sinonasal malignancy. Lund VJ, et al. **Laryngoscope** 1996 May;106(5 Pt 1):553-8

Ethmoidal cemento-ossifying fibroma: the transglabellar/subcranial approach. Cox VS, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):335-8

Craniofacial resection. An alternative incision and skull base repair. Dhillon RS, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):309-13

[Contralateral approach to clivus tumors using the transmaxillary-transethmoid approach] Osterwald L, et al. **HNO** 1996 Mar;44(3):130-3 (Eng. Abstr.) **(Ger)**

[Transfacial approach, craniofacial resection and midfacial degloving in surgery of malignant tumors of the anterior cranial base and adjacent paranasal sinuses] Plinkert PK, et al. **HNO** 1996 Apr;44(4):192-200 (Eng. Abstr.) **(Ger)**

[Current aspects of frontal sinus surgery. IV: On therapy of frontal sinus osteoma] Weber R, et al. **HNO** 1995 Aug; 43(8):482-6 (Eng. Abstr.) **(Ger)**

[Solitary naso-sinusal fibrous tumor] Martínez V, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):323-6 (Eng. Abstr.) **(Spa)**

VETERINARY

Squamous cell carcinoma of the canine nasal cavity and frontal sinus: eight cases. Rogers KS, et al. **J Am Anim Hosp Assoc** 1996 Mar-Apr;32(2):103-10

AgNOR count as a marker in ethmoid carcinoma in bovids. Chandrasekar V, et al. **Vet Rec** 1995 Jul 1;137(1):24-5

VIROLOGY

Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells. Kanavaros P, et al. **J Pathol** 1996 Mar; 178(3):297-302

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Kanavaros P, et al. **Leukemia** 1996 Jun;10 Suppl 2:s84-7 (44 ref.)

PARANASAL SINUSES

Manometric rhinometry: a new method of measuring nasal volume. Porter M, et al. **Rhinology** 1995 Jun;33(2):86-8

[Endonasal ethmoidectomy in naso-sinusal polyposis. Results in 110 surgically treated patients] Simon D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):359-66 (35 ref.) (Eng. Abstr.) **(Fre)**

[Anesthetic management of patients with Young's syndrome] Fujiwara M, et al. **Masui** 1995 Dec;44(12):1695-9 (Eng. Abstr.) **(Jpn)**

[Possibilities of the use of the sinus catheter IaMIK in rhinology] Markov GI. **Vestn Otorinolaringol** 1995 Nov-Dec;(6):41-3 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Paranasal sinuses:anatomic terminology and nomenclature. The Anatomic Terminology Group. Stammberger HR, et al. **Ann Otol Rhinol Laryngol Suppl** 1995 Oct;167:7-16

[The thesis of Reininger (1722) in the history of pituitary sinuses] Terrier G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):131-7 (Eng. Abstr.) **(Fre)**

[Morphology and histochemistry of lymphatic vessels of the upper aerodigestive tract: a clinically oriented study] Werner JA. **Laryngorhinootologie** 1995 Sep;74(9):568-76 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Effect of ibudilast on ciliary activity of human paranasal sinus mucosa in vitro. Ganbo T, et al. **Arzneimittelforschung** 1995 Aug;45(8):883-6

Comparison of chloroform-induced toxicity in the kidneys, liver, and nasal passages of male Osborne-Mendel and F-344 rats. Templin MV, et al. **Cancer Lett** 1996 Jun 24; 104(1):71-8

[Azithromycin: tissue pharmacology] Bergogne-Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498-504 (29 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

The role of functional endoscopic sinus surgery in the management of recurrent sinus barotrauma. O'Reilly BJ, et al. **Aviat Space Environ Med** 1995 Sep;66(9):876-9

Air gun pellets in the sinuses. O'Connell JE, et al. **J Laryngol Otol** 1995 Nov;109(11):1097-100

[Current aspects of sinus barotrauma. The impact on treatment, prevention and fitness] Bernard C, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):261-5 (Eng. Abstr.) **(Fre)**

METABOLISM

Concentration of cephalosporins in tissues of the head and neck after parenteral infusion. Maier W, et al. **Chemotherapy** 1995 Nov-Dec;41(6):421-6

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:57-63 (18 ref.)

High nitric oxide production in human paranasal sinuses. Lundberg JO, et al. **Nat Med** 1995 Apr;1(4):370-3

Distribution of topical agents in the frontal sinuses and nasal cavity of dogs: comparison between current protocols for treatment of nasal aspergillosis and a new noninvasive technique. Richardson EF, et al. **Vet Surg** 1995 Nov-Dec; 24(6):476-83

MICROBIOLOGY

Adherence of nontypeable Haemophilus influenzae to respiratory epithelium of otitis-prone and normal children. Faden H, et al. **Ann Otol Rhinol Laryngol** 1996 May; 105(5):367-70

PATHOLOGY

Management of malignant schwannomas of the paranasal sinuses and anterior skull base. DiNardo LJ, et al. **Ear Nose Throat J** 1996 Jun;75(6):377-80

[Histopathologic observation and 3DCT reconstruction of the nasal cavity and paranasal sinuses in children with cleft palates] Wang R, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):160-2 (Eng. Abstr.) **(Chi)**

[The presence of fluid in the paranasal sinuses in comparison with other diagnostic signs of drowning] Hottmar P. **Soud Lek** 1995 Dec;40(4):34-6 (Eng. Abstr.) **(Cze)**

[Hemangiosarcoma of the nasal cavity] Martín Vázquez C, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):149-52 (Eng. Abstr.) **(Spa)**

[Paranasal sinus pleomorphic adenoma] Sánchez-Alcón MD, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):71-3 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Manometric rhinometry. Porter MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):303-4

A role for the nasal cycle in respiratory defence. Eccles R. **Eur Respir J** 1996 Feb;9(2):371-6 (58 ref.)

PHYSIOPATHOLOGY

Treatment of chronic paranasal sinus pain with minimal sinus disease. Acquadro MA, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):607-14

RADIATION EFFECTS

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465-74 (63 ref.)

RADIOGRAPHY

Relationship of the optic nerve to the posterior paranasal sinuses: a CT anatomic study. DeLano MC, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):669-75

Radiation dose to the eye lens from coronal CT scanning of the sinuses [letter] Spencer DH. **Clin Radiol** 1996 Sep; 51(9):666

Radiation dose to the lens from coronal CT scanning of the sinuses [letter] Zammit-Maempel I. **Clin Radiol** 1996 Feb; 51(2):151

Abnormalities of the paranasal sinuses in patients with nasopharyngeal carcinoma: a computed tomographic study. Porter MJ, et al. **J Laryngol Otol** 1996 Jan;110(1):23–6

The paranasal sinuses before and after radiotherapy for nasopharyngeal carcinoma: a computed tomographic study. Porter MJ, et al. **J Laryngol Otol** 1996 Jan;110(1):19–22

Development of a standardized proforma for reporting computerized tomographic images of the paranasal sinuses. Elahi M, et al. **J Otolaryngol** 1996 Apr;25(2):113–20

Sinonasal imaging. Hudgins PA. **Neuroimaging Clin N Am** 1996 May;6(2):319–31

Paranasal sinus computed tomography scan findings in patients with cystic fibrosis. Nishioka GJ, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):394–9

SURGERY

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Optimal CT evaluation for functional endoscopic sinus surgery. Melhem ER, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):181–8

Bilateral maxillectomy and midfacial reconstruction. Panje WR, et al. **Ann Otol Rhinol Laryngol** 1995 Nov; 104(11):845–9 (12 ref.)

Management of dural lesions occurring during endonasal sinus surgery. Weber R, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):732–6

Powered instrumentation in dissection of the frontal recess. Christmas DA Jr, et al. **Ear Nose Throat J** 1996 Jun; 75(6):359–60, 363–4

Management of malignant schwannomas of the paranasal sinuses and anterior skull base. DiNardo LJ, et al. **Ear Nose Throat J** 1996 Jun;75(6):377–80

Albumin and immunoglobulin levels in nasal secretions of patients with nasal polyps treated with endoscopic sinus surgery and topical corticosteroids. Biewenga J, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):334–40

An animal model for training in endoscopic nasal and sinus surgery. Gardiner Q, et al. **J Laryngol Otol** 1996 May; 110(5):425–8

Endoscopic sinus surgery [letter; comment] Low WK. **J Laryngol Otol** 1995 Jul;109(7):693–4. Comment on: J Laryngol Otol 1994 Sep;108(9):749–53.

Endoscopic sinus surgery with partial middle turbinate resection: effects on olfaction. Friedman M, et al. **Laryngoscope** 1996 Aug;106(8):977–81

Complications of endoscopic sinus surgery in a residency training program. Kinsella JB, et al. **Laryngoscope** 1995 Oct;105(10):1029–32

Power microdebrider for functional endoscopic sinus surgery. Goode RL. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):676–7

Functional endoscopic sinus surgery. Slack R, et al. **Practitioner** 1995 Oct;239(1555):591–5 (3 ref.)

Endoscopic sinus surgery for nasal polyps in children: results. Bolt RJ, et al. **Rhinology** 1995 Sep;33(3):148–51

Endoscopic sinus surgery in sinusitis. Massegur H, et al. **Rhinology** 1995 Jun;33(2):89–92

Minimal follow-up after functional endoscopic sinus surgery. Does it affect outcome? Ryan RM, et al. **Rhinology** 1996 Mar;34(1):44–5

Functional endoscopic sinus surgery—the South African experience. van der Merwe J. **S Afr J Surg** 1994 Jun; 32(2):67–9

[In vitro studies of the specifications for methodological and technical equipment requirements of endoscopic infrared diaphanoscopy] Mesecke-von Rheinbaben I, et al. **Biomed Tech (Berl)** 1995 Sep;40(9):255–62 (Eng. Abstr.) **(Ger)**

[Coronal CT in the indication of the endoscopic surgery of the sinus] Meloni F, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):214–8 (Eng. Abstr.) **(Ita)**

[Efficacy and complications of topical cocaine anesthesia in functional endoscopic sinus surgery] Kubo N, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1263–9 (Eng. Abstr.) **(Jpn)**

[Main principles of functional intranasal surgery of paranasal sinuses] Lopatin AS, et al. **Vestn Otorinolaringol** 1995 Nov-Dec;(6):35–40 (Eng. Abstr.) **(Rus)**

[Solitary naso-sinusal fibrous tumor] Martínez V, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):323–6 (Eng. Abstr.) **(Spa)**

VIROLOGY

[DNA papillomavirus detection in head and neck benign proliferative lesions] Campos-Bañales ME, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):487–94 (Eng. Abstr.) **(Spa)**

PARANEOPLASTIC SYNDROMES

Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Cohen PR. **Adv Dermatol** 1996;11:215–52; discussion 253 (146 ref.)

Bazex's acrokeratosis paraneoplastica. Laccourreye O, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):487–9

Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Kellner U, et al. **Br J Ophthalmol** 1995 Aug;79(8):746–52

Paraneoplastic syndromes. Eckhardt SJ. **Cancer Surv** 1994; 21:197–209 (63 ref.)

Genetic and acquired cutaneous disorders associated with internal malignancy. Loucas E, et al. **Int J Dermatol** 1995 Nov;34(11):749–58 (128 ref.)

Paraneoplastic syndromes. Agarwala SS. **Med Clin North Am** 1996 Jan;80(1):173–84 (35 ref.)

[Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case] Rougier MB, et al. **J Fr Ophtalmol** 1995;18(5):396–403 (16 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic seropositive polyarthritis (letter)] Olive P, et al. **Rev Med Interne** 1995;16(11):865 **(Fre)**

[Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia] Rodot S, et al. **Rev Med Interne** 1995;16(12):938–43 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pure cerebellar syndrome associated with anti-Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**

[A rare case of nonmetastatic paraneoplastic hypercalcemia (humoral hypercalcemia of malignancy) associated with mucinous carcinoma of the stomach] Mariani S, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):307–10 (Eng. Abstr.) **(Ita)**

[Cutaneous vasculitis, mixed cryoglobulinemia in a patient with non-secreting monolateral pheochromocytoma. A likely paraneoplastic syndrome] Perrone A, et al. **Recenti Prog Med** 1995 Dec;86(12):499–502 (Eng. Abstr.) **(Ita)**

[Paraneoplastic syndrome of hepatocellular carcinoma] Tagawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):453–5 (13 ref.) **(Jpn)**

[Clinical and epidemiologic aspects of paraneoplastic dermatoses in hospitalized patients treated at the Clinic for Dermatologic and Venereal Diseases in Novi Sad over a 10-year period (1980–1990)] Stojanović S, et al. **Med Pregl** 1995;48(1–2):44–7 (Eng. Abstr.) **(Scr)**

[Polymyalgia rheumatica presenting pulmonary epidermoid carcinoma (letter)] Fernández Guerra J, et al. **Arch Bronconeumol** 1996 Mar;32(3):155 **(Spa)**

[Thrombocytopenic purpura and nephrotic syndrome preceding the diagnosis of Hodgkin's disease (letter)] Llorca Ferrándiz C, et al. **Med Clin (Barc)** 1996 Feb 17; 106(6):237–8 **(Spa)**

BLOOD

Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy. Bundred NJ, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):354–8

Red blood cell polyamines, anaemia and tumour growth in the rat. Quemener V, et al. **Eur J Cancer** 1996 Feb; 32A(2):316–21

Orthostatic hypotension and vasodilatory peptides in bronchial carcinoma. Gosney MA, et al. **J Clin Pathol** 1995 Dec;48(12):1102–5

CHEMICALLY INDUCED

Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine [letter; comment] Bazarbachi A, et al. **Ann Oncol** 1995 Sep; 6(7):730–1. Comment on: Ann Oncol 1995 Mar;6(3):300–1.

COMPLICATIONS

Paraneoplastic cerebellar degeneration in association with Hodgkin's disease: a report of two cases. Cehreli C, et al. **Acta Haematol** 1995;94(4):210–3

Hyperthyroxinemia and elevated lipids as paraneoplastic phenomena in hepatocellular carcinoma. A case report. Nizam R, et al. **J Clin Gastroenterol** 1995 Oct;21(3):246–8

Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. Uchuya M, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):388–92

Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Warzocha K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):343–6

Non-Hodgkin lymphoma and glomerulonephritis. What kind of relation? Fernando PB, et al. **Nephrol Dial Transplant** 1996 May;11(5):854–6

Ophthalmic complications of systemic disease. To K, et al. **R I Med** 1995 Dec;78(12):346–51

CONGENITAL

Non-malignant tumors that can mimic cancer during the neonatal period. Martinez-Climent J, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):156–9

DIAGNOSIS

If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an 'abortive' one, it must be mycosis fungoides! Ackerman AB. **Arch Dermatol** 1996 May; 132(5):562–6

Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Burg G, et al. **Arch Dermatol** 1996 May;132(5):567–72

Fine tuning of epitopic dominance induced by lung cancer on the IgG response to bovine betalactoglobulin: towards a paraneoplastic immune marker. Michils A, et al. **Cancer** 1996 Feb 15;77(4):657–64

Generalized melanosis caused by melanoma of the rectum. Klaus MV, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):295–7

Solitary focal demyelination in the brain as a paraneoplastic disorder. Jaster JH, et al. **Med Pediatr Oncol** 1996 Feb; 26(2):111–5

[Paraneoplastic cerebellar degeneration: case report of a patient with breast carcinoma] Huober J, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):214–6 (Eng. Abstr.) **(Ger)**

[Pyoderma gangrenosum as a precursor of myeloid leukemia] Maier H, et al. **Hautarzt** 1995 Sep;46(9):647–50 (Eng. Abstr.) **(Ger)**

[Paraneoplastic neurologic syndromes. Classification and diagnosis] Grisold W, et al. **Nervenarzt** 1995 Oct; 66(10):736–44 (107 ref.) (Eng. Abstr.) **(Ger)**

[61-year-old patient with rapidly progressive cerebellar symptoms] Becker K, et al. **Pneumologie** 1995 Dec; 49(12):700–3 (Eng. Abstr.) **(Ger)**

[Paraneoplastic syndromes] Kaboth U, et al. **Urologe A** 1995 Sep;34(5):431–6 (0 ref.) **(Ger)**

[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma-polyarthritis or bypass arthritis] Kanzler S, et al. **Z Gastroenterol** 1995 Aug;33(8):449–53 (Eng. Abstr.) **(Ger)**

[Bronchioalveolar carcinoma and the paraneoplastic syndrome (letter)] Pasto Aguila M, et al. **An Med Interna** 1996 May;13(5):251 **(Spa)**

DRUG THERAPY

Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome. Alderman CP, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7–8):710–3

Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. Bewley AP, et al. **Br J Dermatol** 1996 Jun;134(6):1101–4

ENZYMOLOGY

The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Adamus G, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):120–9

ETIOLOGY

Transient acantholytic dermatosis associated with superior vena caval syndrome in a patient with carcinoid tumour of the thymus [letter] Miralles ES, et al. **Acta Derm Venereol** 1995 Sep;75(5):410

Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient. Nešković-Konstantinović Z, et al. **Acta Oncol** 1996; 35(4):501–3

Parathyroid hormone-related protein in benign lesions [editorial; comment] Bruns DE, et al. **Am J Clin Pathol** 1996 Apr;105(4):377–9. Comment on: Am J Clin Pathol 1996 Apr;105(4):487–92.

Ovarian dermoid cyst-associated autoimmune hemolytic anemia: a case report with emphasis on pathogenic mechanisms. Cobo F, et al. **Am J Clin Pathol** 1996 May; 105(5):567–71

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.). Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.

Paraneoplastic pemphigus in a patient with non-Hodgkin's lymphoma. Plumb R, et al. **Am J Hematol** 1996 May; 52(1):58–9

Cutaneous paraneoplastic syndromes in solid tumors. Kurzrock R, et al. **Am J Med** 1995 Dec;99(6):662–71 (70 ref.)

Mucocutaneous paraneoplastic manifestations of hematologic malignancies [letter] Naschitz JE, et al. **Am J Med** 1996 Aug;101(2):231–3

Case report: pancreatic cancer presenting with paraneoplastic gastroparesis. Caras S, et al. **Am J Med Sci** 1996 Jul; 312(1):34–6

Cancer-associated retinopathy with presumed vasculitis. Suzuki T, et al. **Am J Ophthalmol** 1996 Jul;122(1):125–7

Paraneoplastic cone dysfunction: an unusual visual remote effect of cancer [letter] Jacobson DM, et al. **Arch Ophthalmol** 1995 Dec;113(12):1580–2

Paraneoplastic pemphigus triggered by radiotherapy. Lee MS, et al. **Australas J Dermatol** 1995 Nov;36(4):206–10

Epstein-Barr virus-associated CD3- large granular lymphocyte leukemia presenting with polycranial nerve palsies [letter] Taniguchi S, et al. **Blood** 1996 Jun 1; 87(11):4914–5

Burning mouth syndrome [letter] Graham RM, et al. **Br Dent J** 1996 Jun 8;180(11):407

Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Lucker GP, et al. **Br J Dermatol** 1995 Aug;133(2):322–5

Diagnosis of cancer-associated vascular disorders. Naschitz JE, et al. **Cancer** 1996 May 1;77(9):1759–67 (110 ref.)

The occurrence of serum autoantibodies against enolase in

cancer-associated retinopathy. Adamus G, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):120-9

Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome. Barnes J, et al. **Cutis** 1995 Nov;56(5):270-2

Non-small-cell lung cancer with multiple paraneoplastic syndromes. Monsieur I, et al. **Eur Respir J** 1995 Jul; 8(7):1231-4

Pyoderma gangrenosum in a patient with gastric carcinoma. Gallo R, et al. **Int J Dermatol** 1995 Oct;34(10):713-4

Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma. Mori H, et al. **J Dermatol** 1996 Jul;23(7):460-2

Tripe palms: a cutaneous marker of internal malignancy. Requena L, et al. **J Dermatol** 1995 Jul;22(7):492-5

Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Tanaka R, et al. **Jpn J Clin Oncol** 1996 Apr; 26(2):88-94

Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome? [letter] Ouvrier R, et al. **Lancet** 1995 Nov 11; 346(8985):1298

Opsoclonus/myoclonus: paraneoplastic syndrome of neuroblastoma [clinical conference] Janss A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):272-9

Paraneoplastic encephalomyelitis in a child with neuroblastoma. Meyer JJ, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S99-101

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Darnell RB. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4529-36 (107 ref.)

Carcinoid tumor and the nephrotic syndrome: a novel association between neoplasia and glomerular disease. Becker BN, et al. **South Med J** 1996 Feb;89(2):240-2

Tripe palms: a cutaneous paraneoplastic syndrome. Mullans EA, et al. **South Med J** 1996 Jun;89(6):626-7

Lung cancer with visual loss. Ing EB, et al. **Surv Ophthalmol** 1996 May-Jun;40(6):505-10

[Small-cell carcinoma of the lung with paraneoplastic cerebellar degeneration] Miyashita N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):380-3 (Eng. Abstr.) **(Jpn)**

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov-Dec;58(11-12):647-50 (21 ref.) **(Pol)**

[A case of a malignant kidney tumor with the nephrogenic liver dysfunction syndrome] Kochetova EV, et al. **Klin Med (Mosk)** 1995;73(3):102-3 **(Rus)**

GENETICS

Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers [see comments] Kishimoto Y, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1224-9. Comment in: J Natl Cancer Inst 1995 Aug 16;87(16):1201-2.

Importance of chromosome 9p loss in human lung cancer [editorial; comment] Sidransky D. **J Natl Cancer Inst** 1995 Aug 16;87(16):1201-2. Comment on: J Natl Cancer Inst 1995 Aug 16;87(16):1224-9.

IMMUNOLOGY

Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Dropcho EJ. **Ann Neurol** 1996 May;39(5):659-67

The immunobiology and clinical features of paraneoplastic syndromes. Anderson NE. **Curr Opin Neurol** 1995 Dec; 8(6):424-9 (64 ref.)

Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. Honnorat J, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):270-8

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. Buckanovich RJ, et al. **J Neurosci** 1996 Feb 1;16(3):1114-22

Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. Gahring LC, et al. **Mol Med** 1995 Mar; 1(3):245-53

Paraneoplastic antibodies [letter; comment] Drlicek M, et al. **Neurology** 1995 Nov;45(11):2120-2. Comment on: Neurology 1994 Dec;44(12):2236-40. Comment on: Neurology 1994 Dec;44(12):2241-6.

Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Moll JW, et al. **Neurology** 1995 Oct;45(10):1937-41

Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Sillevis-Smitt P, et al. **Neurology** 1996 Jun;46(6):1739-41

Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Sillevis Smitt PA, et al. **Neurology** 1995 Oct;45(10):1873-8

[Subacute paraneoplastic cerebellar degeneration with anti-neuronal antibodies and gynecological cancers. A case report of a bilateral ovarian cancer where the classic "anti-YO" antibody is associated with another antineuronal antibody] Tremouilhac C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):253-6 (Eng. Abstr.) **(Fre)**

[Antibodies of IgM type against small cell lung carcinoma and 29 kD neuronal antigen of rat in a patient with paraneoplastic sensory neuropathy] Azuma A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):241-6 (Eng. Abstr.) **(Jpn)**

[Optimal fixation for the detection of anti-neuronal antibody by immunohistochemistry in the paraneoplastic syndrome] Kanazawa N, et al. **Rinsho Byori** 1996 Jul;44(7):640-6 (Eng. Abstr.) **(Jpn)**

[Paraneoplastic cerebellar degeneration—characterization of anti-Yo antibody and underlying cancer] Tanaka K, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):770-4 (Eng. Abstr.) **(Jpn)**

[Neurologic paraneoplastic syndromes and anti-neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361-5 (44 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. Gahring LC, et al. **Mol Med** 1995 Mar; 1(3):245-53

Expression of messenger RNA encoding a paraneoplastic cerebellar degeneration-associated antigen in the rat hippocampus. Sakai K, et al. **Neurosci Lett** 1995 Sep 1; 197(1):33-6

PATHOLOGY

Digital necrosis associated with chronic myeloid leukemia: a rare paraneoplastic phenomenon [see comments] D'Hondt L, et al. **Acta Clin Belg** 1995;50(5):297-300. Comment in: Acta Clin Belg 1996;51(1):61-2.

Paraneoplastic cerebellar degeneration: a rare presentation of Hodgkin's disease [letter; comment] Tappin JA, et al. **Clin Lab Haematol** 1995 Jun;17(2):206. Comment on: Clin Lab Haematol 1994 Dec;16(4):359-62.

Paraneoplastic pemphigus: the first case report from Japan. Nishibori Y, et al. **Dermatology** 1995;191(1):39-42

Sign of Leser-Trélat. Schwartz RA. **J Am Acad Dermatol** 1996 Jul;35(1):88-95 (129 ref.)

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397-404 (24 ref.)

Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600-5 (22 ref.)

Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Krakauer J, et al. **Neurology** 1996 May;46(5):1486-7

PREVENTION & CONTROL

Palliative embolization of fibrosarcoma for control of tumor-induced hypoglycemia. Lengle SJ, et al. **Cardiovasc Intervent Radiol** 1995 Jul-Aug;18(4):255-8

THERAPY

Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis [letter] Izaki S, et al. **Br J Dermatol** 1996 May;134(5):987-9

PARANOIA see **PARANOID DISORDERS**

PARANOID DISORDER, SHARED see **SHARED PARANOID DISORDER**

PARANOID DISORDERS

COMPLICATIONS

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):133-7 (27 ref.)

[Successful therapy of the psychiatric patient with catatonic paranoidal syndrome and monitoring of induced cytokine production] Leszek J, et al. **Psychiatr Pol** 1996 Jan-Feb; 30(1):65-74 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

The study of paranoia and suspiciousness [editorial] Kirkpatrick B, et al. **Biol Psychiatry** 1995 Oct 15; 38(8):496-7

Delusional disorder: the recognition and management of paranoia. Manschreck TC. **J Clin Psychiatry** 1996;57 Suppl 3:32-8; discussion 49 (43 ref.)

Clinical and cognitive diversity of psychotic states arising in late life (late paraphrenia). Almeida OP, et al. **Psychol Med** 1995 Jul;25(4):699-714

[Dementia-paranoid syndrome as the initial manifestation of AIDS. Case report and diagnostic overview] Sobanski T, et al. **Nervenarzt** 1996 Jan;67(1):68-71 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Drug-induced asterixis amplified by relative hypoglycemia] Poersch M, et al. **Nervenarzt** 1996 Apr;67(4):323-6 (Eng. Abstr.) **(Ger)**

[Successful therapy of the psychiatric patient with catatonic paranoidal syndrome and monitoring of induced cytokine production] Leszek J, et al. **Psychiatr Pol** 1996 Jan-Feb; 30(1):65-74 (Eng. Abstr.) **(Pol)**

HISTORY

[Pathography and biography—background on the Schreber and Klug cases] Pohlmeier H. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):297-302 **(Ger)**

PSYCHOLOGY

Violence: the scientific medical perspective. Pincus JH. **Isr J Med Sci** 1996 Jul;32(7):511-4 (24 ref.)

Self-discrepancies and persecutory delusions: evidence for a model of paranoid ideation. Kinderman P, et al. **J Abnorm Psychol** 1996 Feb;105(1):106-13

The return of the projected: some thoughts on paranoia and a recent trend in horror films. Benton RJ. **Psychoanal Rev** 1995 Dec;82(6):903-31

THERAPY

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):133-7 (27 ref.)

An overview of treatment in paranoia/delusional disorder. Munro A, et al. **Can J Psychiatry** 1995 Dec;40(10):616-22 (132 ref.)

PARANOID PERSONALITY DISORDER

URINE

Urinary excretion of bufotenin (N,N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confirmatory study. Kärkkäinen J, et al. **Psychiatry Res** 1995 Sep 29; 58(2):145-52

PARANOID PSYCHOSES see **PARANOID DISORDERS**

PARANOID SCHIZOPHRENIA see **SCHIZOPHRENIA, PARANOID**

PARAOXON

ANALOGS & DERIVATIVES

Comparison of the action of an organophosphorus insecticide and its metabolite on chloride and sulfate transport in erythrocyte membrane. Blasiak J. **Z Naturforsch [C]** 1996 Mar-Apr;51(3-4):226-32

ANALYSIS

A biotinylated undecylthiophene copolymer bioconjugate for surface immobilization: creating an alkaline phosphatase chemiluminescence-based biosensor. Pande R, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):159-64

Gas chromatographic determination of parathion and paraoxon in fish plasma and tissues. Abbas R, et al. **J Anal Toxicol** 1996 May-Jun;20(3):151-4

ANTAGONISTS & INHIBITORS

[The antagonism of phosphorus-containing heterocyclics with the anticholinesterase agent Phosphacol (paraoxon)] Garaev RS. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):68-70 (Eng. Abstr.) **(Rus)**

METABOLISM

Identification and isolation of two rat serum proteins with A-esterase activity toward paraoxon and chlorpyrifos-oxon. Pond AL, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):363-9

Cooperative binding of the organophosphate paraoxon to the (Na+ + K+)-ATPase. Blasiak J. **Z Naturforsch [C]** 1995 Sep-Oct;50(9-10):660-3

PHARMACOKINETICS

Toxicokinetics of parathion and paraoxon in rainbow trout after intravascular administration and water exposure. Abbas R, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):194-9

Relationship between parathion and paraoxon toxicokinetics, lung metabolic activity, and cholinesterase inhibition in guinea pig and rabbit lungs. Lessire F, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):201-10

PHARMACOLOGY

Mutagenic synergy between paraoxon and plant-activated m-phenylenediamine or 2-acetoxyacetylaminofluorene. Gichner T, et al. **Environ Mol Mutagen** 1996;27(1):59-66

POISONING

[Structural changes in rat erythrocytes due to phosphacol poisoning] Prozorovskiĭ VB, et al. **Biull Eksp Biol Med** 1995 May;119(5):517-20 **(Rus)**

TOXICITY

Prevention of organophosphate-induced toxicity in mice.

PARAOXON

Ozkutlu U, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):331-42

The effects of phenobarbital pretreatment on the metabolism and toxicity of paraoxon in the mouse. Vitarius JA, et al. **Pharmacol Toxicol** 1995 Jul;77(1):16-22

Relationship between parathion and paraoxon toxicokinetics, lung metabolic activity, and cholinesterase inhibition in guinea pig and rabbit lungs. Lessire F, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):201-10

Modification of acetylcholinesterase during adaptation to chronic, subacute paraoxon application in rat. Milatovic D, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):20-8

PARAPARESIS, TROPICAL SPASTIC

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP): recent perspectives. Ijichi S, et al. **Intern Med** 1995 Aug; 34(8):713-21 (126 ref.)

Idiopathic progressive spastic paraparesis. Bird TD. **JAMA** 1995 Oct 18;274(15):1191

BLOOD

Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis. Saarloos MN, et al. **J Infect Dis** 1995 Oct;172(4):1095-7

CEREBROSPINAL FLUID

HTLV-I associated tropical spastic paraparesis. Cerebral spinal fluid evolutive aspects in 128 cases. Moreno-Carvalho OA, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3-B):604-7

HTLV-I associated myelopathy in patients from Brazil and Iran: neurological manifestations and cerebrospinal fluid findings. Puccioni-Sohler M, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):213-7

COMPLICATIONS

Human T-cell lymphotropic virus type 1-associated myelopathy, Sjögren syndrome, and lymphocytic pneumonitis. Kompoliti A, et al. **Arch Neurol** 1996 Sep; 53(9):940-2 (31 ref.)

Lymphomatous meningoencephalitis in a patient with HAM/TSP. Gomes I, et al. **Arq Neuropsiquiatr** 1995 Mar; 53(1):123-5

HTLV-I associated retinochoroidal degeneration. Ohba N, et al. **Jpn J Ophthalmol** 1996;40(1):71-8

HTLV-I positive progressive spastic paraparesis (TSP) associated with a lymphoid disorder in three Chilean patients. Cartier L, et al. **Leuk Lymphoma** 1995 May; 17(5-6):459-64

Spastic paraparesis and sensory neuropathy. Tenembaum SN, et al. **Muscle Nerve** 1996 May;19(5):649-53

Hereditary adult-onset Alexander's disease with palatal myoclonus, spastic paraparesis, and cerebellar ataxia. Schwankhaus JD, et al. **Neurology** 1995 Dec; 45(12):2266-71

DIAGNOSIS

Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique. Smadja D, et al. **Acta Neurol Scand** 1995 Sep;92(3):206-12

[Tropical spastic paraparesis due to HTLV-I. 4 case reports and literature review] Ossemann M, et al. **Acta Neurol Belg** 1996 Jun;96(2):117-25 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Krämer A, et al. **Am J Epidemiol** 1995 Dec 1;142(11):1212-20

HTLV-I associated myelopathy/tropical spastic paraparesis. Report of the first cases in Rio Grande do Sul, Brazil. Haussen SR, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3-B):608-12

Detection and isolation of human T-cell leukemia/lymphoma virus type I (HTLV-I) from cultured lymphocytes of a Brazilian TSP/HAM patient. Andrada-Serpa MJ, et al. **Braz J Med Biol Res** 1995 Jan;28(1):51-7

Human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in São Paulo, Brazil. Domingues RB, et al. **Clin Infect Dis** 1995 Jun; 20(6):1540-2

Geographical considerations on HAM/TSP in Japan [letter] Leon FE, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar-Apr;37(2):185-6

HTLV-1 infection and tropical spastic paraparesis in Esmeraldas Province of Ecuador [see comments] Guderian R, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug; 88(4):399-400. Comment in: Trans R Soc Trop Med Hyg 1995 May-Jun;89(3):342.

HTLV-I-associated illnesses in Spain. HTLV Spanish Study Group [letter] Soriano V, et al. **Vox Sang** 1995;69(3):261-2

[Seroprevalence of HTLV-I in relatives of patients with spastic paraparesis (HAM/TSP and PEP)] Cartier L, et al. **Rev Med Chil** 1995 Jan;123(1):7-11 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Dietary determinants of a non-progressive spastic paraparesis (Konzo): a case-referent study in a high incidence area of Zaire. Tylleskär T, et al. **Int J Epidemiol** 1995 Oct; 24(5):949-56

Human T lymphocyte virus type I-induced myeloneuropathy in rats: implication of local activation of the pX and tumor necrosis factor-alpha genes in pathogenesis. Tomaru U, et al. **J Infect Dis** 1996 Aug;174(2):318-23

Thoracic spondylosis presenting with spastic paraparesis. Chana JS, et al. **Postgrad Med J** 1996 Apr;72(846):243-4

Primary xanthoma of thoracic spine presenting with myelopathy. Robertson DP, et al. **Spine** 1995 Sep 1; 20(17):1933-7

GENETICS

Co-dominant inheritance of hyperekplexia and spastic paraparesis. Baxter P, et al. **Dev Med Child Neurol** 1996 Aug;38(8):739-43

Patterns of HTLV-I infection among family members of patients with adult T-cell leukemia/lymphoma and HTLV-I associated myelopathy/tropical spastic paraparesis [letter] Wilks R, et al. **Int J Cancer** 1996 Jan 17;65(2):272-3

Spastic paraparesis and mutations in the prion protein gene [letter] Yamada M, et al. **J Neurol Sci** 1995 Dec; 134(1-2):215-6

IMMUNOLOGY

Specificity of intrathecal IgG synthesis for HTLV-1 core and envelope proteins in HAM/TSP. Kitze B, et al. **Acta Neurol Scand** 1995 Sep;92(3):213-7

HLA DRB1*DQB1* haplotype in HTLV-I-associated familial infective dermatitis may predict development of HTLV-I-associated myelopathy/tropical spastic paraparesis. LaGrenade L, et al. **Am J Med Genet** 1996 Jan 2;61(1):37-41

Differential effect of TGF-beta 1 on the in vitro activation of HTLV-I and the proliferative response of CD8+ T lymphocytes in patients with HTLV-I-associated myelopathy (HAM/TSP). Nagai M, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):324-31

Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Jacobson S. **Curr Opin Neurol** 1995 Jun;8(3):179-83 (35 ref.)

Konzo, an epidemic spastic paraparesis in Africa, is not associated with antibodies to HTLV-I, HIV, or HIV gag-encoded proteins [letter] Tylleskär T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):317-8

The association of antibodies against human T cell lymphotropic virus type I (HTLV-I) pX gene mutant products with HTLV-I-associated myelopathy/tropical spastic paraparesis. Suzuki J, et al. **J Infect Dis** 1996 May; 173(5):1115-22

Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease. Elovaara I, et al. **J Neuroimmunol** 1995 Dec;63(1):47-53

Anti-viral and immunomodulatory effects of interferon-alpha on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP). Ijichi S, et al. **J Neuroimmunol** 1995 Sep;61(2):213-21

Characterization of humoral and cellular immunity in the central nervous system of HAM/TSP. Matsui M, et al. **J Neurol Sci** 1995 Jun;130(2):183-9

Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. Utz U, et al. **J Virol** 1996 Feb;70(2):843-51

High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Daenke S, et al. **Virology** 1996 Mar 1; 217(1):139-46

[Tropical spastic paraparesis due to HTLV-I. 4 case reports and literature review] Ossemann M, et al. **Acta Neurol Belg** 1996 Jun;96(2):117-25 (Eng. Abstr.) **(Fre)**

METABOLISM

Spontaneous proliferation of and cytokine production by T cells adherent to human endothelial cells in patients with human T-lymphotropic virus type I-associated myelopathy. Nakamura T, et al. **Intern Med** 1996 Mar; 35(3):195-9

PATHOLOGY

Characterization of cerebral white matter lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis in comparison with multiple sclerosis and collagen-vasculitis: a semiquantitative MRI study. Godoy AJ, et al. **J Neurol Sci** 1995 Nov;133(1-2):102-11

Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Cavrois M, et al. **Oncogene** 1996 Jun 6;12(11):2419-23

PHYSIOPATHOLOGY

Clinical neurophysiological comparative study on HTLV-1 associated myelopathy/tropical spastic paraparesis. Leon FE, et al. **Arch Med Res** 1995 Winter;26(4):397-403

A follow-up study on spastic paraparesis in Japanese HAM/TSP. Kuroda Y, et al. **J Neurol Sci** 1995 Oct; 132(2):174-6

TRANSMISSION

Infantile onset of HTLV-I-associated myelopathy (HAM/TSP) [letter] Bhigjee AI, et al. **S Afr Med J** 1995 Jul;85(7):687-8

VIROLOGY

Molecular characterization of human T-lymphotropic virus, type 1 (HTLV-1) found in Kuwait: close similarity with HTLV-1 isolates originating from Mashhad, Iran. Voevodin A, et al. **AIDS Res Hum Retroviruses** 1995 Oct; 11(10):1255-9

Failure to detect HTLV-I proviral DNA in the liver of a patient with primary biliary cirrhosis and HTLV-I-associated myelopathy [letter] Ijichi T, et al. **Am J Gastroenterol** 1996 Apr;91(4):827-8

In vivo proviral burden and viral RNA expression in T cell subsets of patients with human T lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis. Cho I, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):412-8

Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Moritoyo T, et al. **Ann Neurol** 1996 Jul;40(1):84-90

Clinical neurophysiological comparative study on HTLV-1 associated myelopathy/tropical spastic paraparesis. Leon FE, et al. **Arch Med Res** 1995 Winter;26(4):397-403

Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers. Achiron A, et al. **Arch Virol** 1996; 141(1):147-53

Human T-cell-leukemia virus type I in post-transfusional spastic paraparesis: complete proviral sequence from uncultured blood cells. Bazarbachi A, et al. **Int J Cancer** 1995 Nov 15;63(4):494-9

Chronic progressive myeloneuropathy in WKAH rats induced by HTLV-I infection as an animal model for HAM/TSP in humans. Yoshiki T. **Intervirology** 1995; 38(3-4):229-37 (40 ref.)

Evolution in a chronic RNA virus infection: selection on HTLV-I tax protein differs between healthy carriers and patients with tropical spastic paraparesis. Niewiesk S, et al. **J Mol Evol** 1996 Apr;42(4):452-8

PCR-in situ hybridization detection of human T-cell lymphotropic virus type 1 (HTLV-1) tax proviral DNA in peripheral blood lymphocytes of patients with HTLV-1-associated neurologic disease. Levin MC, et al. **J Virol** 1996 Feb;70(2):924-33

Adult T cell leukemia following HTLV-I-associated myelopathy/tropical spastic paraparesis: case reports and implication to the natural course of ATL. Tamiya S, et al. **Leukemia** 1995 Oct;9(10):1768-70

Sequence analysis of human T cell lymphotropic virus type I (HTLV-I) Env genes amplified from central nervous system tissues of patients with HTLV-I-associated myelopathy or leukemia. Maroushek SR, et al. **Microb Pathog** 1995 Nov;19(5):317-33

[A case of tropical spastic paraparesis associated with HTLV1 in the Niger Republic (letter)] Develoux M, et al. **Med Trop (Mars)** 1996;56(1):100-1 **(Fre)**

[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656-9 (16 ref.) **(Jpn)**

PARAPHILIAS

see related
SEX OFFENSES

A case of necrophilia in Medunsa. Dubasi PM, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):162-3

DIAGNOSIS

Erotic obsession: relationship to hypoactive sexual desire disorder and paraphilia. Kaplan HS. **Am J Psychiatry** 1996 Jul;153(7 Suppl):30-41

Criterion-related validity of a phallometric test for paraphilic rape and sadism. Seto MC, et al. **Behav Res Ther** 1996 Feb;34(2):175-83

DRUG THERAPY

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3-4):397-426 (110 ref.)

EPIDEMIOLOGY

The lethal paraphiliac syndrome. Accidental autoerotic deaths in Denmark 1933-1990. Behrendt N, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):232-7

Review: autoerotic asphyxiation in the United States [retracted in J Forensic Sci 1995 Nov;40(6):932] Uva JL. **J Forensic Sci** 1995 Jul;40(4):574-81 (76 ref.)

METABOLISM

[Monoamine metabolism in different forms of paraphilias] Kogan BM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):52–6 (Eng. Abstr.) **(Rus)**

MORTALITY

The lethal paraphiliac syndrome. Accidental autoerotic deaths in Denmark 1933–1990. Behrendt N, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):232–7

PSYCHOLOGY

Psychic reality and perversions. Denzler B. **Int J Psychoanal** 1996 Feb;77 (Pt 1):61–6

Female perversion: scenes and strategies in analysis and culture. Springer A. **J Anal Psychol** 1996 Jul;41(3):325–38

MMPI differences among adolescent inpatients, rapists, sodomists, and sexual abusers. Herkov MJ, et al. **J Pers Assess** 1996 Feb;66(1):81–90

Auto-erotic asphyxiation: three case reports. Cooper AJ. **J Sex Marital Ther** 1996 Spring;22(1):47–53

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501–11 (22 ref.) (Eng. Abstr.) **(Fre)**

PARAPHIMOSIS

DRUG THERAPY

Reduction of paraphimosis with hyaluronidase. DeVries CR, et al. **Urology** 1996 Sep;48(3):464–5

SURGERY

CO2 laser for therapeutic circumcision in adults. Aynaud O, et al. **Eur Urol** 1995;28(1):74–6

THERAPY

ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838–40 (0 ref.). Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112–3.

PARAPHRENIA, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

PARAPLEGIA

CHEMICALLY INDUCED

Transient paraplegia following alcohol celiac plexus block. Wong GY, et al. **Reg Anesth** 1995 Jul–Aug;20(4):352–5

[Paraplegia following intrathecal chemotherapy] Beretta F, et al. **Schweiz Med Wochenschr** 1996 Jun 22; 126(25):1107–11 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Machado-Joseph disease: A proposal of spastic paraplegic subtype. Sakai T, et al. **Neurology** 1996 Mar;46(3):846–7

COMPLICATIONS

Blocks to facilitate lithotomy positioning in spastic paraplegics [letter] Muralidhar V. **Anesth Analg** 1996 Jan; 82(1):219

Penile prostheses in paraplegic men. Gross AJ, et al. **Br J Urol** 1996 Aug;78(2):262–4

Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. Schurch B, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):61–7 (42 ref.)

Morphological changes in the skin microlymphatics in recently injured paraplegic patients with ilio-femoral venous thrombosis. Scelsi R, et al. **Paraplegia** 1995 Aug; 33(8):472–5

Latent tarsal tunnel syndrome with the provocation of flexor spasms in a paraplegic person. Case report. Tachibana S, et al. **Paraplegia** 1995 Aug;33(8):482–4

[Autonomic dysreflexia: a life-threatening complication in patients with a high-level spinal cord injury] Snoek GJ. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1729–32 (Eng. Abstr.) **(Dut)**

[Neurogenic bladder, 20 years later] Perrigot M. **Presse Med** 1995 Oct 28;24(32):1523–5 (Eng. Abstr.) **(Fre)**

[A case of urethral diverticulum in a male paraplegic patient] Kawakami T, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):887–90 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Syphilitic thoracic aortic aneurysm with destruction of vertebral body, producing numbness of lower extremities and paraplegia] Miura M, et al. **Kyobu Geka** 1995 Oct; 48(11):953–6 (Eng. Abstr.) **(Jpn)**

[Bladder cancer in spinal cord injury patient. A case report] Kuwahara T, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1681–4 (Eng. Abstr.) **(Jpn)**

[A case of complicated form of hereditary spastic paraplegia associated with hypoplasia of the corpus callosum and cataracta] Tanaka M, et al. **Rinsho Shinkeigaku** 1995 Jul; 35(7):798–802 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Paraplegia secondary to hematomyelia in a neonate. Jain N, et al. **Indian Pediatr** 1996 Mar;33(3):236–8

ETIOLOGY

Delayed paraplegia following spinal anaesthesia. Spinal subdural haematoma following dural puncture with a 25 G pencil point needle at T12–L1 in a patient taking aspirin. Pryle BJ, et al. **Anaesthesia** 1996 Mar;51(3):263–5

Paraplegia in a patient who by chance missed the insertion of an epidural catheter [letter] Konstantinidou AS, et al. **Anesth Analg** 1996 May;82(5):1110

Anterior spinal artery syndrome after left celiac plexus block. Takeda J, et al. **Anesth Analg** 1996 Jul;83(1):178–9

Paraplegia, epidural analgesia, and thoracic aneurysmectomy [see comments] Fitzgibbon DR, et al. **Anesthesiology** 1995 Dec;83(6):1355–9. Comment in: Anesthesiology 1996 Jun;84(6):1519–20.

Paraplegia following post-traumatic thoracic spinal stenosis: a case report. Farooq MT, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):84–5

Thoracic spine osteochondroma causing spinal cord compression. An unusual cause of paraparesis. de Jesús O, et al. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):57–9

Paraplegia following surgical correction of scoliosis with Cotrel-Dubousset instrumentation. Bar-On Z, et al. **Bull Hosp Jt Dis** 1995;54(1):32–4

Paraparesis in an 83-year-old woman. Magid D, et al. **Clin Orthop** 1995 Nov;(320):279–82, 284–5

Pott's Paraplegia—67 cases. Moon MS, et al. **Clin Orthop** 1996 Feb;(323):122–8

Ambulation with parapodia and reciprocating gait orthoses in pediatric spinal cord injury. Vogel LC, et al. **Dev Med Child Neurol** 1995 Nov;37(11):957–64

Ischemia of spinal cord following elective operative procedures of the infrarenal abdominal aorta. Dimakakos P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):243–7

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

Paraparesis after rib penetration of the spinal canal in neurofibromatous scoliosis. Deguchi M, et al. **J Spinal Disord** 1995 Oct;8(5):363–7

A 64-year-old man with diabetes and ascending paraplegia [see comments] Gliemroth J, et al. **Lancet** 1996 Feb 24; 347(9000):516. Comment in: Lancet 1996 Apr 20;347(9008):1116.

Litigation and medical negligence: a plaintiff's view on the need for change. Bolger M. **Med Leg J** 1996;64 (Pt 2):70–81

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 4–1996. A 40-year-old woman with the rapid onset of flaccid paraplegia [clinical conference] [see comments] **N Engl J Med** 1996 Feb 8; 334(6):382–9. Comment in: N Engl J Med 1996 Jun 6;334(23):1548; discussion 1548–9. Comment in: N Engl J Med 1996 Jun 6;334(23):1548–9.

Thoracic intradural anterior epidermoid manifesting as sudden onset of paraplegia—case report. Deogaonkar M, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):678–9

Direct erosion of lumbar spine by an abdominal aortic aneurysm, resulting in paraparesis: unusual presentation. Case report. Latif S, et al. **Paraplegia** 1995 Aug;33(8):480–1

Medical-surgical treatment of progressive tuberculous (Pott's) paraplegia in Gabon. Loembe PM. **Paraplegia** 1995 Oct;33(10):579–84

Paraplegia and decompression sickness. Tournebise H, et al. **Paraplegia** 1995 Nov;33(11):636–9

Response to postblock epidural hematoma causing paraplegia [letter; comment] Hsu DT, et al. **Reg Anesth** 1995 May-Jun; 20(3):254–5. Comment on: Reg Anesth 1994 Jan–Feb;19(1):62–5.

Spinal stenosis above a healed tuberculous kyphosis. A case report. Luk KD, et al. **Spine** 1996 May 1;21(9):1098–101

Repair of a ruptured aortic arch aneurysm complicated by postoperative paraplegia: report of a case. Hadama T, et al. **Surg Today** 1996;26(1):60–3

[Myelopathy following influenza vaccination] Herderscheê D, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2152–4 (Eng. Abstr.) **(Dut)**

[Progressive paraparesis] Kuopio AM, et al. **Duodecim** 1995; 111(5):435–8 **(Fin)**

[Paraplegia after aorto-bifemoral prosthesis: systematized dysautonomic symptoms should evoke spinal cord damage] Loeb T, et al. **Ann Fr Anesth Reanim** 1995;14(3):300–2 (Eng. Abstr.) **(Fre)**

[Neurologic complications of surgery of the spine in adults] Benazet JP, et al. **Chirurgie** 1994–95;120(11):39–42 (Eng. Abstr.) **(Fre)**

[Neurologic complications of surgery of the spine in children] Carlioz H, et al. **Chirurgie** 1994–95;120(11):26–30 (Eng. Abstr.) **(Fre)**

[Neurologic complications of surgery for spinal deformities] Michel CR. **Chirurgie** 1994–95;120(11):36–8 (Eng. Abstr.) **(Fre)**

[Paraplegia after surgical treatment of primary aorto-duodenal fistula] Picard E, et al. **Presse Med** 1996 Apr 13;25(13):621–3 (Eng. Abstr.) **(Fre)**

[Athymhormic syndrome and progressive paraplegia disclosing adrenoleukomyeloneuropathy in an adult] Brosset C, et al. **Rev Neurol (Paris)** 1995 Jun–Jul; 151(6–7):388–91 (Eng. Abstr.) **(Fre)**

[Acute spinal subdural hematoma after attempted spinal anesthesia] Likar R, et al. **Anaesthesist** 1996 Jan;45(1):66–9 (Eng. Abstr.) **(Ger)**

[Permanent paraplegia following epidural and general anesthesia: two case reports] Uefuji T, et al. **Masui** 1996 Apr;45(4):453–7 (Eng. Abstr.) **(Jpn)**

[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567–72 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Confirmation of locus heterogeneity in the pure form of familial spastic paraplegia. Speer MC, et al. **Am J Med Genet** 1995 Aug 14;60(4):307–11

Novel nonsense proteolipid protein gene mutation as a cause of X-linked spastic paraplegia in twin males. Osaka H, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):835–41

Autosomal dominant spastic paraplegia with anticipation maps to a 4-cM interval on chromosome 2p21-p24 in a large German family. Bürger J, et al. **Hum Genet** 1996 Sep; 98(3):371–5

Infantile onset of hereditary ascending spastic paralysis with bulbar involvement. Lerman-Sagie T, et al. **J Child Neurol** 1996 Jan;11(1):54–7

Mutations in L1-CAM in two families with X linked complicated spastic paraplegia, MASA syndrome, and HSAS. Ruiz JC, et al. **J Med Genet** 1995 Jul;32(7):549–52

Hereditary spastic paraplegia linked to chromosome 15q: Analysis of candidate genes. Fink JK, et al. **Neurology** 1996 Mar;46(3):835–6

[A case of complicated form of hereditary spastic paraplegia associated with hypoplasia of the corpus callosum and cataracta] Tanaka M, et al. **Rinsho Shinkeigaku** 1995 Jul; 35(7):798–802 (Eng. Abstr.) **(Jpn)**

METABOLISM

Gut hormone release in patients after spinal cord injury. Saltzstein RJ, et al. **Am J Phys Med Rehabil** 1995 Sep-Oct; 74(5):339–44

PATHOLOGY

Morphological changes in the skin microlymphatics in recently injured paraplegic patients with ilio-femoral venous thrombosis. Scelsi R, et al. **Paraplegia** 1995 Aug; 33(8):472–5

Comparative pathology of dome and trigone of urinary bladder mucosa in paraplegics and tetraplegics. van Velzen D, et al. **Paraplegia** 1995 Oct;33(10):565–72

PHYSIOPATHOLOGY

Electromyographic activity of shoulder muscles during wheelchair propulsion by paraplegic persons. Mulroy SJ, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):187–93

Electromyographic analysis of the shoulder muscles during depression transfers in subjects with low-level paraplegia. Perry J, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):350–5

Energy expenditure and fatiguability in paraplegic ambulation using reciprocating gait orthosis and electric stimulation. Hirokawa S, et al. **Disabil Rehabil** 1996 Mar; 18(3):115–22

Assessment of autonomic function in traumatic quadriplegic and paraplegic patients by spectral analysis of heart rate variability. Inoue K, et al. **J Auton Nerv Syst** 1995 Sep 5;54(3):225–34

Modeling and simulation of paraplegic ambulation in a reciprocating gait orthosis. Tashman S, et al. **J Biomech Eng** 1995 Aug;117(3):300–8

Validity and reproducibility of the Spanish Version of the Sickness Impact Profile. Badía X, et al. **J Clin Epidemiol** 1996 Mar;49(3):359–65

Ergonomy of paraplegic patients working with a reciprocating gait orthosis. Bernardi M, et al. **Paraplegia** 1995 Aug;33(8):458–63

The efficiency of walking of paraplegic patients using a reciprocating gait orthosis. Bernardi M, et al. **Paraplegia** 1995 Jul;33(7):409–15

Changes in muscle force following therapeutic electrical stimulation in patients with complete paraplegia. Kagaya H, et al. **Paraplegia** 1996 Jan;34(1):24–9

Influence of electrical stimulation of the tibialis anterior muscle in paraplegic subjects. 1. Contractile properties. Rochester L, et al. **Paraplegia** 1995 Aug;33(8):437–49

Influence of electrical stimulation of the tibialis anterior muscle in paraplegic subjects. 2. Morphological and histochemical properties. Rochester L, et al. **Paraplegia** 1995 Sep;33(9):514–22

Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord section. Wilmet E, et al. **Paraplegia** 1995 Nov;33(11):674–7

PREVENTION & CONTROL

Neuroanesthesia adjunct therapy (mannitol and hyperventilation) is as effective as cerebrospinal fluid

drainage for prevention of paraplegia after descending thoracic aortic cross-clamping in the dog. Mutch WA, et al. **Anesth Analg** 1995 Oct;81(4):800–5

Neurolytic celiac plexus block: can paraplegia and death after neurolytic celiac plexus block be eliminated? [letter; comment] Moore DC. **Anesthesiology** 1996 Jun; 84(6):1522–3. Comment on: Anesthesiology 1995 Sep;83(3):632–5.

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

Epidural regional hypothermia for prevention of paraplegia after aortic occlusion: experimental evaluation in a rabbit model. Gonzalez-Fajardo J, et al. **J Vasc Surg** 1996 Mar; 23(3):446–52

Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. Safi HJ, et al. **J Vasc Surg** 1996 Feb;23(2):223–8; discussion 229

RADIOTHERAPY

Long-term response to radiotherapy of vertebral hemangioma resulting in paraplegia. Serrano M, et al. **Acta Oncol** 1996;35(4):498–9

REHABILITATION

Clinical experience with a new hip-knee-ankle-foot orthotic system using a medial single hip joint for paraplegic standing and walking. Saitoh E, et al. **Am J Phys Med Rehabil** 1996 May-Jun;75(3):198–203

Outdoor winter activities of spinal cord-injured patients. With special reference to outdoor mobility. Shirado O, et al. **Am J Phys Med Rehabil** 1995 Nov-Dec;74(6):408–14

Locomotor training in paraplegic patients [letter; comment] Dietz V. **Ann Neurol** 1995 Dec;38(6):965. Comment on: Ann Neurol 1995 May;37(5):555–6.

An electrical knee lock system for functional electrical stimulation. Kagaya H, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):870–3

Posture effect on seating interface biomechanics: comparison between two seating cushions. Koo TK, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):40–7

Ambulation with parapodia and reciprocating gait orthoses in pediatric spinal cord injury. Vogel LC, et al. **Dev Med Child Neurol** 1995 Nov;37(11):957–64

Predicting endurance limits in arm cranking exercise with a subjectively based method. Capodaglio P, et al. **Ergonomics** 1996 Jul;39(7):924–32

Functional neuromuscular stimulation for mobility in people with spinal cord injuries. The Parastep I System. Chaplin E. **J Spinal Cord Med** 1996 Apr;19(2):99–105

Effects of functional electrical stimulation on the joints of adolescents with spinal cord injury. Betz R, et al. **Paraplegia** 1996 Mar;34(3):127–36

Restoration of gait by functional electrical stimulation for spinal cord injured patients. Gallien P, et al. **Paraplegia** 1995 Nov;33(11):660–4

Changes in muscle force following therapeutic electrical stimulation in patients with complete paraplegia. Kagaya H, et al. **Paraplegia** 1996 Jan;34(1):24–9

Restoration of functional gait in paraplegic patients with the RGO-II hybrid orthosis. A multicenter controlled study. II: Physiological evaluation. Thoumie P, et al. **Paraplegia** 1995 Nov;33(11):654–9

Restoration of functional gait in paraplegic patients with the RGO-II hybrid orthosis. A multicentre controlled study. I. Clinical evaluation. Thoumie P, et al. **Paraplegia** 1995 Nov;33(11):647–53

The influence of orthosis stiffness on paraplegic ambulation and its implications for functional electrical stimulation (FES) walking systems. Stallard J, et al. **Prosthet Orthot Int** 1995 Aug;19(2):108–14

-Paraplegia and fertility (interview by C. Staehr)- Hultling C. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):X, XII **(Ger)**

[Therapeutic effect of "Ueda" method for a case of spastic paraplegia as a sequela of transverse myelitis] Tojo M. **No To Hattatsu** 1996 May;28(3):251–6 (Eng. Abstr.) **(Jpn)**

SURGERY

Early results of operative closure of pressure sores in traumatic paraplegics. Jiburum BC, et al. **Int Surg** 1995 Apr-Jun;80(2):178–80

Surgical management of lumbar neuropathic spinal arthropathy (Charcot joint) after traumatic thoracic paraplegia: report of two cases. Arnold PM, et al. **J Spinal Disord** 1995 Oct;8(5):357–62

Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function [see comments] Cheng H, et al. **Science** 1996 Jul 26;273(5274):510–3. Comment in: Science 1996 Jul 26;273(5274):451.

Frankel A paraplegia: a comparison of two spinal instrumentation systems. Stambough JL, et al. **South Med J** 1996 Jun;89(6):597–602

THERAPY

Swing-through gait with free-knees produced by surface functional electrical stimulation. Heller BW, et al. **Paraplegia** 1996 Jan;34(1):8–15

Medical-surgical treatment of progressive tuberculous (Pott's) paraplegia in Gabon. Loembe PM. **Paraplegia** 1995 Oct;33(10):579–84

Influence of electrical stimulation of the tibialis anterior muscle in paraplegic subjects. 1. Contractile properties. Rochester L, et al. **Paraplegia** 1995 Aug;33(8):437–49

VETERINARY

Central nervous system rendez-vous--canine progressive posterior paresis. Little PB. **Can Vet J** 1996 Jan;37(1):55–6

Myositis, lameness, and paraparesis associated with use of an oil-adjuvant bacterin in beef cows. McAllister MM, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):936–8

Possible role of bovine immunodeficiency virus in bovine paraplegic syndrome: evidence from immunochemical, virological and seroprevalence studies. Walder R, et al. **Res Virol** 1995 Sep-Oct;146(5):313–23

PARAPLEGIA, SPASTIC see **PARAPLEGIA**

PARAPLEGIA, SPASTIC, HEREDITARY see **SPASTIC PARAPLEGIA, HEREDITARY**

PARAPOXVIRUS

An investigation into the health and welfare of red squirrels, Sciurus vulgaris, involved in reintroduction studies. Sainsbury AW, et al. **Vet Rec** 1995 Oct 7;137(15):367–70

Parapoxvirus infection in red squirrels [letter] Sainsbury T, et al. **Vet Rec** 1996 Apr 20;138(16):400

ISOLATION & PURIFICATION

Isolation of a parapoxvirus from a grey seal (Halichoerus grypus). Nettleton PF, et al. **Vet Rec** 1995 Nov 25; 137(22):562–4

PARAPROTEINEMIAS

[Concept and classification of immunoglobulin abnormalities] Kano T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10; 84(7):1043–9 (4 ref.) **(Jpn)**

BLOOD

Quantification of serum proteins using capillary electrophoresis. Jenkins MA, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):493–7

Paraprotein interference causing pseudohyperphosphataemia: evaluation of an improved methodology. Savory DJ, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):498–501

Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Baldini L, et al. **Blood** 1996 Feb 1;87(3):912–8

Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Billadeau D, et al. **Blood** 1996 Jul 1;88(1):289–96

Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias [see comments] Ohtani K, et al. **Br J Haematol** 1995 Sep;91(1):116–20. Comment in: Br J Haematol 1996 Mar;92(3):767–8.

Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? Witzig TE, et al. **Leuk Lymphoma** 1995 Nov; 19(5-6):417–22

[Hemostasis disorders in monoclonal gammopathies] Spička I, et al. **Sb Lek** 1991;93(9-10):277–86 (Eng. Abstr.) **(Cze)**

[Interference of dysglobulinemia and lactescence on serum phosphate determination: an easy and efficient correction (letter)] Fleuret C, et al. **Ann Biol Clin (Paris)** 1995; 53(3):141–3 **(Fre)**

[Platelet glycosaminoglycans in paraproteinemic hemoblastoses] Kharchenko MF, et al. **Vopr Med Khim** 1995 Nov-Dec;41(6):55–8 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Boccadoro M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):705–19 (75 ref.)

COMPLICATIONS

Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Ito T, et al. **Acta Haematol** 1996;95(2):140–3 (24 ref.)

Light-heavy chain deposition disease progressing to multiple myeloma. Daliani D, et al. **Am J Hematol** 1995 Dec; 50(4):296–8

IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa overlap syndrome. Birchmore D, et al. **Arthritis Rheum** 1996 Apr;39(4):698–703

Monoclonal cryo-antifibrinogenemia. Euler HH, et al. **Arthritis Rheum** 1996 Jun;39(6):1066–9

Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy. Papo T, et al. **Arthritis Rheum** 1996 Feb;39(2):335–40

Arthritis associated with monoclonal gammapathy: clinical characteristics. Jorgensen C, et al. **Br J Rheumatol** 1996 Mar;35(3):241–3 (14 ref.)

Tremor associated with benign IgM paraproteinaemic neuropathy. Bain PG, et al. **Brain** 1996 Jun;119 (Pt 3):789–99

Patient with monoclonal gammopathy, thyrotoxicosis, pretibial myxedema and thyroid-associated ophthalmopathy; demonstration of direct binding of autoantibodies to the thyrotropin receptor. Tonacchera M, et al. **Eur J Endocrinol** 1996 Jan;134(1):97–103

Monoclonal gammopathy and cold agglutinin disease in non-Hodgkin's lymphoma [letter] Pascali E. **Eur J Haematol** 1996 Jan-Feb;56(1-2):114–5

POEMS syndrome and Waldenström's macroglobulinaemia. Pavord SR, et al. **J Clin Pathol** 1996 Feb;49(2):181–2

Lymphoma, paraproteinaemia, and neuropathy [clinical conference] Wokke JH, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):684–9

Neuropathies associated with monoclonal gammopathies. Kissel JT, et al. **Neuromuscul Disord** 1996 Jan;6(1):3–18 (95 ref.)

Solitary extramedullary plasmocytoma of the breast with kappa monoclonal gammopathy. Alhan E, et al. **Pathologica** 1995 Feb;87(1):71–3

[Renal involvement in monoclonal gammopathies] Spička I, et al. **Cas Lek Cesk** 1996 Jun 12;135(12):374–7 (29 ref.) (Eng. Abstr.) **(Cze)**

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Renal disorders in patients with immunoproliferative disorder] Horiuchi A, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1081–5 (5 ref.) **(Jpn)**

[Nerve lesions in patients with immunoproliferative disorders] Ito H, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1075–80 (6 ref.) **(Jpn)**

DIAGNOSIS

Role of two-dimensional electrophoretic analysis in the diagnosis and characterization of IgD monoclonal gammopathy. Spertini F, et al. **Allergy** 1995 Aug; 50(8):664–70

Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Boccadoro M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):705–19 (75 ref.)

Paraproteinaemic neuropathies. Miescher GC, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):219–32 (88 ref.)

Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes. Ong F, et al. **Blood** 1996 Jan 15;87(2):712–6

A rapid ELISA test for detection of human paraproteins. Girkontaite I, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):349–53

Lymphoma, paraproteinaemia, and neuropathy [clinical conference] Wokke JH, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):684–9

[Paraproteins and lymphoma in HIV positive patients] Drees C, et al. **Med Klin** 1996 Apr 10;91(4):193–8 (Eng. Abstr.) **(Ger)**

[Weakness, anemia, monoclonal gammopathy and the development of a nodular pulmonary infiltrate (clinical conference)] **Harefuah** 1996 Apr 15;130(8):573–7 **(Heb)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41–9 (62 ref.) **(Spa)**

DRUG THERAPY

[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun-Jul;11(6):220–8 (56 ref.) **(Spa)**

ENZYMOLOGY

Leukocyte alkaline phosphatase score in plasma cell dyscrasias: correlation with disease severity and circulating levels of granulocyte-colony stimulating factor. Stasi R, et al. **Leuk Lymphoma** 1995 May;17(5-6):479–83

EPIDEMIOLOGY

Hepatitis C virus infection and lymphoproliferative disorders [letter; comment] Andreone P, et al. **Blood** 1995 Nov 1; 86(9):3610–1. Comment on: Blood 1995 Feb 15;85(4):1144–5.

Risk of hepatitis C virus infection, Waldenström's macroglobulinemia, and monoclonal gammopathies [letter; comment] Silvestri F, et al. **Blood** 1996 Aug 1;88(3):1125–6 . Comment on: Blood 1993 Nov 1;82(9):2932. Comment on: Blood 1995 Feb 15;85(4):1144–5.

The epidemiology of monoclonal gammopathy of unknown significance: a review. Herrinton LJ. **Curr Top Microbiol Immunol** 1996;210:389–95 (22 ref.)

The incidence and epidemiology of plasma cell neoplasms. Bergsagel D. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:1–9 (56 ref.)

ETIOLOGY

Monoclonal gammopathy in patients with chronic hepatitis C virus infection [letter] Andreone P, et al. **Blood** 1996

Aug 1;88(3):1122
Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? [letter] Musto P, et al. **Blood** 1996 Jul 15;88(2):752–4
Monoclonal gammopathy of undetermined significance. Kyle RA. **Curr Top Microbiol Immunol** 1996;210:375–83
Silicone gel implants and monoclonal gammopathies: three cases of multiple myeloma and the prevalence of multiple myeloma and monoclonal gammopathy of undetermined significance. Silverman S, et al. **Curr Top Microbiol Immunol** 1996;210:367–74
POEMS and Crow–Fukase syndrome: two cases giving rise to more questions about plasma cell dyscrasias. Bonanni F, et al. **In Vivo** 1995 May–Jun;9(3):193–4
Multiple autoimmune manifestations in monoclonal gammopathy of undetermined significance and chronic lymphocytic leukemia. Jønsson V, et al. **Leukemia** 1996 Feb;10(2):327–32
Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Mangia A, et al. **Leukemia** 1996 Jul;10(7):1209–13
Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Greipp PR, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:10–21 (82 ref.)
Gammopathy associated with advanced prostate carcinoma. Abdul M, et al. **Urol Res** 1995;23(3):185–8
[Biclonal gammapathy in type I Gaucher disease (letter)] Kaminsky P, et al. **Presse Med** 1995 Oct 14;24(30):1400 **(Fre)**
[Splenic lesion and multiple monoclonal gammopathies associated with primary cytomegalovirus infection in an immunocompetent adult (letter)] Alliot C, et al. **Rev Med Interne** 1996;17(3):269–70 **(Fre)**
[Monoclonal gammopathy and primary hyperparathyroidism. Apropos of 2 cases and review of the literature] Bellou A, et al. **Rev Med Interne** 1996;17(4):325–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Transitory monoclonal gammapathy and disseminated intravascular coagulation in Mediterranean boutonneuse fever (letter)] Mediavilla Garcia JD, et al. **An Med Interna** 1995 Jun;12(6):311–2 **(Spa)**

GENETICS

Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia. Weh HJ, et al. **Ann Hematol** 1996 Feb;72(2):81–2
Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Sahota SS, et al. **Blood** 1996 Jan 15;87(2):746–55
Molecular alterations of IL–6R, lck and c–myc genes in transforming monoclonal gammopathies of undetermined significance. Gernone A, et al. **Br J Haematol** 1996 Jun 1;93(3):623–31
Deletion of genetic material from a poly(ADP–ribose) polymerase–like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cao J, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):759–63
Familial AL–amyloidosis in three Italian siblings. Miliani A, et al. **Haematologica** 1996 Mar–Apr;81(2):105–9
Low frequency of PIM3 gene in patients with monoclonal gammopathies. Jelić–Ivanović Z, et al. **Hum Hered** 1996 Mar–Apr;46(2):115–7

IMMUNOLOGY

Monoclonal IgA gammopathy in a well infant [letter] Campbell DE, et al. **Arch Dis Child** 1996 Jan;74(1):88–9
Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Moss P, et al. **Blood** 1996 Apr 15;87(8):3297–306
Idiotype–reactive T–cell subsets and tumor load in monoclonal gammopathies. Yi Q, et al. **Blood** 1995 Oct 15;86(8):3043–9
Blood clonal B–cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Isaksson E, et al. **Br J Haematol** 1996 Jan;92(1):71–6
Selective loss of myelin–associated glycoprotein from myelin correlates with anti–MAG antibody titre in demyelinating paraproteinaemic polyneuropathy. Gabriel JM, et al. **Brain** 1996 Jun;119 (Pt 3):775–87
Subclass typing of IgG paraproteins by immunofixation electrophoresis. Klouche M, et al. **Clin Chem** 1995 Oct; 41(10):1475–9
Natural killer (NK) lymphocytosis induced by Epstein–Barr virus (EBV) reactivation in monoclonal gammopathy of undetermined significance (MGUS). Ishiyama T, et al. **Clin Exp Immunol** 1996 Jul;105(1):46–51
Monoclonal gammopathies antigen driven in autoimmune diseases. Osterland CK. **Clin Exp Rheumatol** 1996 Jan–Feb; 14 Suppl 14:S37–44 (34 ref.)
Sjögren's syndrome, mixed cryoglobulinaemia and the monoclonal gammopathies. Vitali C, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S59–63 (44 ref.)
Autoimmune diseases and monoclonal gammopathies. Youinou P, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S55–8 (27 ref.)
Identification and characterization of antimitochondrial autoantibodies in sera of patients with monoclonal gammopathies. Gilbrud B, et al. **Immunol Lett** 1995 Mar; 45(3):163–6
Avidity distribution of antibodies against peripheral nerve myelin in patients with polyneuropathy associated with IgM monoclonal gammopathy and in healthy controls. Vrethem M, et al. **J Neurol Sci** 1995 Aug;131(2):190–9
[Splenic lesion and multiple monoclonal gammopathies associated with primary cytomegalovirus infection in an immunocompetent adult (letter)] Alliot C, et al. **Rev Med Interne** 1996;17(3):269–70 **(Fre)**

PATHOLOGY

Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Bataille R, et al. **Blood** 1996 Jun 1;87(11):4762–9
Malignant transformation of monoclonal gammopathy of undetermined significance among out–patients of a community hospital in southeastern Netherlands. van de Poel MH, et al. **Br J Haematol** 1995 Sep;91(1):121–5
Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy. Notermans NC, et al. **Brain** 1996 Apr;119 (Pt 2):421–7
Transformed cutaneous T cell lymphoma and biclonal gammopathy. Miralles ES, et al. **Int J Dermatol** 1996 Mar; 35(3):196–8
A new phenotypic classification of bone marrow plasmacytosis. Kawano MM, et al. **Int J Hematol** 1995 Jun; 61(4):179–88
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):27–38 (61 ref.)

THERAPY

[Multiple myeloma with double gammopathy (IgA–kappa, IgA–lambda) : induction of complete remission from plateau phase with interferon–alpha 2a therapy] Kanoh T. **Rinsho Ketsueki** 1996 Apr;37(4):335–9 (Eng. Abstr.) **(Jpn)**

VETERINARY

Consider leishmaniasis in differential for monoclonal gammopathies in dogs [letter; comment] Font A. **J Am Vet Med Assoc** 1996 Jan 15;208(2):184. Comment on: J Am Vet Med Assoc 1995 Sep 1;207(5):567–8; discussion 569–70.
Monoclonal gammopathy in a dog with chronic pyoderma. Burkhard MJ, et al. **J Vet Intern Med** 1995 Sep–Oct; 9(5):357–60

VIROLOGY

Extrachromosomal human papillomavirus (HPV) in multiple myeloma and monoclonal gammopathy of unknown significance (MGUS) patients. Payne DA, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2213–5
Natural killer (NK) lymphocytosis induced by Epstein–Barr virus (EBV) reactivation in monoclonal gammopathy of undetermined significance (MGUS). Ishiyama T, et al. **Clin Exp Immunol** 1996 Jul;105(1):46–51
HCV and monoclonal gammopathies. Mussini C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S45–9

PARAPROTEINS

ANALYSIS

Quantification of serum proteins using capillary electrophoresis. Jenkins MA, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):493–7
Paraprotein interference causing pseudohyperphosphataemia: evaluation of an improved methodology. Savory DJ, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):498–501
Monoclonal gammopathy of undetermined significance (MGUS). Kyle RA. **Baillieres Clin Haematol** 1995 Dec; 8(4):761–81 (92 ref.)
A rapid ELISA test for detection of human paraproteins. Girkontaite I, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):349–53
Familial occurrence of IgMk gammapathy: no involvement of HCV infection [letter] Custodi P, et al. **Haematologica** 1995 Sep–Oct;80(5):484–5
[Standardization of immunofixation technique for the detection and identification of serum paraproteins] Hadler MB, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):119–24 (Eng. Abstr.) **(Por)**

CLASSIFICATION

Subclass typing of IgG paraproteins by immunofixation electrophoresis. Klouche M, et al. **Clin Chem** 1995 Oct; 41(10):1475–9

IMMUNOLOGY

Complement–mediated bactericidal activity of human antibodies to poly alpha 2––>8 N–acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. Mandrell RE, et al. **J Infect Dis** 1995 Nov; 172(5):1279–89

METABOLISM

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)
Kinetics of paraprotein clearance after autografting for multiple myeloma. Singhal S, et al. **Bone Marrow Transplant** 1995 Oct;16(4):537–40
Hypercalcaemia due to calcium binding IgM paraprotein in Waldenström's macroglobulinaemia. Side L, et al. **J Clin Pathol** 1995 Oct;48(10):961–2

PARAPSORIASIS

CHEMICALLY INDUCED

Maculopapular rashes secondary to gemcitabine injection for non–small–cell lung cancer [letter] Chen YM, et al. **J Clin Oncol** 1996 May;14(5):1743–4

CLASSIFICATION

Ampicillin–induced maculopapular versus urticarial rash. Marra CA, et al. **Ann Pharmacother** 1996 Apr;30(4):401–2

DRUG THERAPY

Ofuji's papuloerythroderma: report of a new case responding to PUVA [letter] Depaire F, et al. **Acta Derm Venereol** 1996 Jan;76(1):93–4
[PUVA–induced acro–bullous dermatosis] Grabbe S, et al. **Hautarzt** 1996 Jun;47(6):465–8 (Eng. Abstr.) **(Ger)**

PARAPSORIASIS EN PLAQUES see **PARAPSORIASIS**

PARAPSYCHOLOGY

Near–death experiences. Blackmore SJ. **J R Soc Med** 1996 Feb;89(2):73–6 (44 ref.)
Roots of unitive experience. Leavy SA. **Psychoanal Rev** 1995 Jun;82(3):349–70

PARAQUAT

Paraquat tolerance of transgenic Nicotiana tabacum with enhanced activities of glutathione reductase and superoxide dismutase. Aono M, et al. **Plant Cell Physiol** 1995 Dec; 36(8):1687–91

ADVERSE EFFECTS

Risk factors for occupational illnesses associated with the use of paraquat (1,1'–dimethyl–4,4'–bipyridylium dichloride) in California. Weinbaum Z, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):341–8
Photodamage and skin cancer among paraquat workers. Jee SH, et al. **Int J Dermatol** 1995 Jul;34(7):466–9
[Paraquat–induced acute dermatitis in a child after playing with a discarded container] Villa L, et al. **Med Lav** 1995 Nov–Dec;86(6):563–8 (Eng. Abstr.) **(Ita)**

ANALYSIS

[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Detoxification of paraquat poisoning: effects of carbohydrate sulfate, alkylsulfate and alkylsulfonate on active oxygen. Tsuchiya T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1700–4

BLOOD

Paraquat and diquat interference in the analysis of creatinine by the Jaffé reaction. Price LA, et al. **Pathology** 1995 Apr; 27(2):154–6

IMMUNOLOGY

Production of a paraquat–specific murine single chain Fv fragment. Devlin CM, et al. **J Biochem (Tokyo)** 1995 Sep; 118(3):480–7

METABOLISM

Paraquat2+/H+ exchange in isolated renal brush–border membrane vesicles. Wright SH, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):18–24
Peritubular paraquat transport in isolated renal proximal tubules. Groves CE, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):926–32

PHARMACOKINETICS

Further evidence that the blood/brain barrier impedes paraquat entry into the brain. Naylor JL, et al. **Hum Exp Toxicol** 1995 Jul;14(7):587–94

PHARMACOLOGY

The area postrema is involved in paraquat–induced conditioned aversion behavior and neuroendocrine activation of the hypothalamic–pituitary–adrenal axis. Edmonds BK, et al. **Brain Res** 1996 Mar 11;712(1):127–33
Paraquat resistance and starvation conditions in the selection of longevity extremes in Drosophila melanogaster populations previously selected for long and short developmental period. da Cunha GL, et al. **Dev Genet** 1995;

17(4):352–61

Interruption of the gpxA gene increases the sensitivity of Neisseria meningitidis to paraquat. Moore TD, et al. **J Bacteriol** 1996 Jul;178(14):4301–5

Nematode development is inhibited by methyl viologen and high oxygen concentrations at a rate inversely proportional to life span. Hartman P, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B322–6

Protective effects of prostaglandin E2 on the paraquat-induced constriction of the fetal ductus arteriosus in the rat. Shirai M, et al. **J Vet Med Sci** 1995 Jun; 57(3):497–8

POISONING

Recovery of respiratory function in survivors with paraquat intoxication. Lin JL, et al. **Arch Environ Health** 1995 Nov–Dec;50(6):432–9

Intratracheally administered liposomal alpha-tocopherol protects the lung against long-term toxic effects of paraquat. Suntres ZE, et al. **Biomed Environ Sci** 1995 Dec; 8(4):289–300

Survival after paraquat poisoning in a HIV positive patient. Ragoucy-Sengler C, et al. **Hum Exp Toxicol** 1996 Apr; 15(4):286–8

Reduction of intrapulmonary shunt by low-dose inhaled nitric oxide in a patient with late-stage respiratory distress associated with paraquat poisoning [letter] Maruyama K, et al. **Intensive Care Med** 1995 Sep;21(9):778–9

Xanthine oxidase mediates paraquat-induced toxicity on cultured endothelial cell. Sakai M, et al. **Pharmacol Toxicol** 1995 Jul;77(1):36–40

Experience with acute paraquat poisoning in Crete. Tsatsakis AM, et al. **Vet Hum Toxicol** 1996 Apr;38(2):113–7

[Distribution of ventilation-perfusion ratios in paraquat-induced interstitial pneumonia in dogs] Ogasawara H. **Hokkaido Igaku Zasshi** 1996 Mar; 71(2):259–70 (Eng. Abstr.) **(Jpn)**

[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

[Poisoning by organophosphates and paraquat: apropos 14 cases] Camacho Pulido JA, et al. **Rev Clin Esp** 1995 Sep; 195(9):623–6 (Eng. Abstr.) **(Spa)**

TOXICITY

Heterologous expression of selenium-dependent glutathione peroxidase affords cellular resistance to paraquat. Kelner MJ, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):40–6

Toxicity of 3-methylindole, 1-nitronaphthalene and paraquat in precision-cut rat lung slices. Price RJ, et al. **Arch Toxicol** 1995;69(6):405–9

EPR studies of spin-trapped free radicals in paraquat-treated lung microsomes. Zang LY, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):255–62

Comparative acute toxicity of two herbicides, paraquat and glyphosate, to Daphnia magna and D. spinulata. Alberdi JL, et al. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):229–35

Lethal effects of the consumption of field levels of paraquat-contaminated plants on frog tadpoles. Bauer Dial CA, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):870–7

Antioxidative activity of 5,6,7,8-tetrahydrobiopterin and its inhibitory effect on paraquat-induced cell toxicity in cultured rat hepatocytes. Kojima S, et al. **Free Radic Res** 1995 Nov;23(5):419–30

A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. Day BJ, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1227–32

Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. Liou HH, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):34–41

N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Hoffer E, et al. **Toxicol Lett** 1996 Jan; 84(1):7–12

The detection of S-glutathionation of hepatic carbonic anhydrase III in rats treated with paraquat or diquat. Lii CK, et al. **Toxicol Lett** 1996 Feb;84(2):97–105

Thiols metabolism is altered by the herbicides paraquat, dinoseb and 2,4-D: a study in isolated hepatocytes. Palmeira CM, et al. **Toxicol Lett** 1995 Nov 15; 81(2–3):115–23

Stimulation of antioxidative enzymes by paraquat in cultured Vero cells. Garcia-Alfonso C, et al. **Vet Hum Toxicol** 1995 Oct;37(5):414–21

PARASITE EGG COUNT

Analysis of worm burden variation in human Schistosoma mansoni infections by determination of serum levels of circulating anodic antigen and circulating cathodic antigen. Van Lieshout L, et al. **J Infect Dis** 1995 Nov; 172(5):1336–42

Quantitative interpretation of coprocultures in a population infected with Oesophagostomum bifurcum. Krepel HP, et al. **Trop Geogr Med** 1995;47(4):157–9

Pathogenetic factors of acute schistosomiasis mansoni: correlation of worm burden, IgE, blood eosinophilia and intensity of clinical manifestations. Rocha MO, et al. **Trop Med Int Health** 1996 Apr;1(2):213–20

Use of a polyurethane carrier for assessing the survival of helminth eggs in liquid biological sludges. Plachý P, et al. **Vet Med (Praha)** 1995 Oct;40(10):323–6

[Clinical judgment and decision making in clinical practice. A patient with diarrhea (letter)] Mank TH G, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1141 **(Dut)**

VETERINARY

Reliability of a single fecal egg per gram determination as a measure of individual and herd values for trichostrongyle nematodes of cattle. Gasbarre LC, et al. **Am J Vet Res** 1996 Feb;57(2):168–71

An ovine lymphocyte antigen is associated with reduced faecal egg counts in four-month-old lambs following natural, predominantly Ostertagia circumcincta infection. Stear MJ, et al. **Int J Parasitol** 1996 Apr;26(4):423–8

Evaluation of anthelmintic efficacy of doramectin against gastrointestinal nematodes by fecal examination in cattle in Japan. Saeki H, et al. **J Vet Med Sci** 1995 Dec; 57(6):1057–61

Nematode burdens and immunological responses following natural challenge in Romney lambs selectively bred for low or high faecal worm egg count. Bisset SA, et al. **Vet Parasitol** 1996 Feb;61(3–4):249–63

Study on a new egg count technique for Macracanthorhynchus hirudinaceus and Ascaris suum. Dangjin L. **Vet Parasitol** 1996 Jan;61(1–2):113–7

Potential for misinterpretation of the faecal egg count reduction test for levamisole resistance in gastrointestinal nematodes of sheep. Grimshaw WT, et al. **Vet Parasitol** 1996 Apr;62(3–4):267–73

Different patterns of faecal egg output following infection of Scottish blackface lambs with Ostertagia circumcincta. Stear MJ, et al. **Vet Parasitol** 1995 Aug;59(1):29–38

Evaluation of nitroxynil and closantel activity using ELISA and egg counts against Fasciola hepatica in experimentally and naturally infected cattle. Boulard C, et al. **Vet Res** 1995; 26(4):249–55

PARASITE-HOST RELATIONS see **HOST-PARASITE RELATIONS**

PARASITEMIA

Clinical characteristics of neonatal malaria. Ibhanesebhor SE. **J Trop Pediatr** 1995 Dec;41(6):330–3

BLOOD

A new, simple method for the rapid quantification of malarial parasitaemia in stained thick blood films [letter] Rickman LR. **East Afr Med J** 1995 May;72(5):339–40

COMPLICATIONS

Studies on Plasmodium falciparum parasitemia and development of anemia in Nigerian infants during their first year of life. Achidi EA, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):138–43

Increased erythropoietin production in children with severe malarial anemia. Burchard GD, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):547–51

DIAGNOSIS

Plasmodium vivax: detection of blood parasites using fluorochrome labelled monoclonal antibodies. Perez HA, et al. **Parasite Immunol** 1995 Jun;17(6):305–12

Comparison between microscopic examination, ELISA and quantitative buffy coat analysis in the diagnosis of falciparum malaria in an endemic population. Tanpradist S, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar;26(1):38–45

[Strongyloides stercoralis hyperinfection] Gelber M, et al. **Harefuah** 1996 Jan 15;130(2):90–2, 143 (Eng. Abstr.) **(Heb)**

DRUG THERAPY

The effects of pyronaridine on the morphology of Plasmodium falciparum in Aotus trivirgatus. Kawai S, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):223–9

Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Luxemburger C, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):522–5

Atovaquone in the treatment of Babesia microti infections in hamsters. Wittner M, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):219–22

Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children. Sowunmi A, et al. **Ann Trop Paediatr** 1996 Mar;16(1):5–9

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)

Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Olivares Fontt E, et al. **Infect Immun** 1996 Aug; 64(8):3429–34

Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. de Castro SL, et al. **J Ethnopharmacol** 1995 Apr;46(1):55–8

Activity of lytic peptides against intracellular Trypanosoma cruzi amastigotes in vitro and parasitemias in mice. Barr SC, et al. **J Parasitol** 1995 Dec;81(6):974–8

Sterilisation of Babesia canis infections by imidocarb alone or in combination with diminazene. Penzhorn BL, et al. **J S Afr Vet Assoc** 1995 Sep;66(3):157–9

Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria. Adagu IS, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):422–5

Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand. Tan-ariya P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):426–9

[An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of uncomplicated falciparum malaria in an endemic area of Pará, Brazil] Cardoso B da S, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):251–7 (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Infant parasite rates and immunoglobulin M seroprevalence as a measure of exposure to Plasmodium falciparum during a randomized controlled trial of insecticide-treated bed nets on the Kenyan coast. Snow RW, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):144–9

Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996; 55(1 Suppl):17–23

Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):24–32

Malaria in a rural area of Sierra Leone. II. Parasitological and related results from pre- and post-rains clinical surveys. Barnish G, et al. **Ann Trop Med Parasitol** 1993 Apr;87(2):137–48

Prevalence of malaria parasitaemia in transfused donor blood in Benin City, Nigeria. Ibhanesebhor SE, et al. **Ann Trop Paediatr** 1996 Jun;16(2):93–5

ETIOLOGY

A rare presentation of falciparum malaria. Jain D, et al. **J Assoc Physicians India** 1995 Aug;43(8):582

Dietary iron supplementation does not aggravate experimental malaria in young rats. Cardoso MA, et al. **J Nutr** 1996 Feb;126(2):467–75

[Persistent parasitemia after treatment of Plasmodium falciparum flare-up in a non-immune patient with splenectomy (letter)] Guérin B, et al. **Ann Med Interne (Paris)** 1996;147(2):129–30 **(Fre)**

IMMUNOLOGY

Asymptomatic malaria parasitaemia and seroreactivities to Plasmodium falciparum antigens in blood donors from Ibadan, south-western Nigeria. Achidi EA, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):601–10

Analysis of roles of natural killer cells in defense against Plasmodium chabaudi in mice. Kitaguchi T, et al. **Parasitol Res** 1996;82(4):352–7

PARASITOLOGY

Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. Rogier C, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):613–9

Polymerase chain reaction-based technique for the detection of Wuchereria bancrofti in human blood samples, hydrocele fluid, and mosquito vectors. Siridewa K, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):72–6

Plasmodium falciparum: isolation of large numbers of parasite clones from infected blood samples. Kirkman LA, et al. **Exp Parasitol** 1996 Jun;83(1):147–9

Influence of anesthetics on the peripheral blood microfilaremia of Brugia malayi in the Mongolian jird, Meriones unguiculatus. Beerntsen BT, et al. **J Parasitol** 1996 Apr;82(2):327–30

Observations on the biological nature of Plasmodium vivax sporozoites. Collins WE, et al. **J Parasitol** 1996 Apr; 82(2):216–9

The individual host, a unique evolutionary island for rapidly dividing parasites: a theoretical approach. Seed JR, et al. **J Parasitol** 1996 Apr;82(2):263–7

Clinical characteristics of neonatal malaria. Ibhanesebhor SE. **J Trop Pediatr** 1995 Dec;41(6):330–3

Differentiation of a culture-adapted mutant bloodstream form of Trypanosoma brucei into the procyclic form results in growth arrest of the cells. Mutomba MC, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):215–25

The within-host cellular dynamics of bloodstage malaria: theoretical and experimental studies. Hetzel C, et al. **Parasitology** 1996 Jul;113 (Pt 1):25–38

PHYSIOPATHOLOGY

Antigenic alteration in major piroplasm surface proteins of Theileria sergenti during infection. Zhuang WZ, et al. **Vet Parasitol** 1995 Dec;60(3–4):191–8

PREVENTION & CONTROL

Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Anderson SL, et al. **Ann Intern Med** 1995 Nov 15;123(10):771–3

Distinction between parasitologic and clinical efficacy of antimalarial agents [letter; comment] Kotb M. **J Infect Dis** 1996 Jan;173(1):275–6. Comment on: J Infect Dis 1995 Jun;171(6):1569–75.

THERAPY

Effect of fatty acid treatment in cerebral malaria–susceptible and nonsusceptible strains of mice. Moumaris M, et al. **J Parasitol** 1995 Dec;81(6):997–9

Exchange transfusion for falciparum malaria [letter; comment] Van den Ende J, et al. **QJM** 1995 Sep;88(9):678 . Comment on: QJM 1994 Sep;87(9):553–7.

TRANSMISSION

Why is man an unsuitable reservoir for the transmission of Leishmania major? Schlein Y, et al. **Exp Parasitol** 1996 Apr;82(3):298–305

VETERINARY

Microfilaraemia in Australian native birds. Reppas GP, et al. **Aust Vet J** 1995 Sep;72(9):356–7

Trypanosoma congolense: high erythropoietic potential in infected yearling cattle during the acute phase of the anemia. Andrianarivo AG, et al. **Exp Parasitol** 1996 Mar; 82(2):104–11

Effects of adoptive transfer of immune spleen cells on worm growth and microfilaraemia in Brugia pahangi infection in Mongolian gerbils. Khan AI, et al. **J Helminthol** 1995 Dec;69(4):331–5

Hematozoa in thin blood smears [letter] Fedynich AM, et al. **J Wildl Dis** 1995 Jul;31(3):436–8

Survey for blood parasites in redheads (Aythya americana) wintering at the Chandeleur Islands, Louisiana. Michot TC, et al. **J Wildl Dis** 1995 Jan;31(1):90–2

Hemograms and hematozoa of sharp–shinned (Accipiter striatus) and Cooper's hawks (Accipiter cooperii) captured during spring migration in northern New York. Phalen DN, et al. **J Wildl Dis** 1995 Apr;31(2):216–22

A comparison of avian hematozoan epizootiology in two California coastal scrub communities. Super PE, et al. **J Wildl Dis** 1995 Oct;31(4):447–61

Wildlife disease and conservation in Hawaii: pathogenicity of avian malaria (Plasmodium relictum) in experimentally infected iiwi (Vestiaria coccinea). Atkinson CT, et al. **Parasitology** 1995;111 Suppl:S59–69

[Bovine setariasis in Friuli Venezia Giulia] Pietrobelli M, et al. **Parassitologia** 1995 Apr;37(1):69–74 (Eng. Abstr.) **(Ita)**

[Determination of the survival of Trypanosoma evansi in equine blood, using the microhematocrit method] Monzón CM, et al. **Rev Sci Tech** 1995 Sep;14(3):753–9 (Eng. Abstr.) **(Spa)**

VIROLOGY

Dual host infections: enhanced infectivity of eastern equine encephalitis virus to Aedes mosquitoes mediated by Brugia microfilariae. Vaughan JA, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):105–9

PARASITES

see related
ANTHELMINTICS
ANTI-INFECTIVE AGENTS
ANTIPROTOZOAL AGENTS
FOOD PARASITOLOGY
HOST-PARASITE RELATIONS

Misconceptions about the measurement of aggregation: a reply to Ploeger. Poulin R. **Int J Parasitol** 1995 Jul; 25(7):863–4

Genetics of host and parasite—implications for immunity, epidemiology and evolution. Wakelin D, et al. **Parasitology** 1996;112 Suppl:S1–4

[Micro–morphology of the ovipositor in Hymenoptera and evolution from phytophagous Symphyta to parasitoid Apocrita] Nénon JP, et al. **C R Acad Sci III** 1995 Oct; 318(10):1045–51 (Eng. Abstr.) **(Fre)**

[The environment of the Moscow megalopolis and the problems of parasitic contamination] Sonin MD, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):3–7 (Eng. Abstr.) **(Rus)**

[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP. **An R Acad Nac Med (Madr)** 1995;112(3):617–45; discussion 646 (93 ref.) **(Spa)**

CLASSIFICATION

Classification of human parasites, vectors, and similar organisms. Garcia LS. **Clin Infect Dis** 1995 Aug;21(2):281–2

[The dynamics of the species composition of nidiculous animals in different types of nests of the little suslik] Garanin OA, et al. **Parazitologiia** 1995 Jan–Feb;29(1):37–42 (Eng. Abstr.) **(Rus)**

GENETICS

The curse of the pharaoh: the evolution of virulence in pathogens with long living propagules. Bonhoeffer S, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22; 263(1371):715–21

The Second Buriti Workshop on Transfection of Parasites. Simões–Barbosa A, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):287–9

IMMUNOLOGY

Antigenic variation and the within–host dynamics of parasites. Antia R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):985–9

[When should antiparasitic vaccines be used in medicine?] Loutan L. **Schweiz Med Wochenschr** 1996 Jul 9; 126(27–28):1202–3 **(Fre)**

ISOLATION & PURIFICATION

More "misconceptions" about the measurement of aggregation. Ploeger HW. **Int J Parasitol** 1996 Feb; 26(2):223–6

Measuring parasite aggregation: defending the index of discrepancy. Poulin R. **Int J Parasitol** 1996 Feb;26(2):227–9

A coprological survey of intestinal parasites of wild lions (Panthera leo) in the Serengeti and the Ngorongoro Crater, Tanzania, east Africa. Müller–Graf CD. **J Parasitol** 1995 Oct;81(5):812–4

[Recent features of parasites detected from clinical specimens] Hokama S, et al. **Rinsho Byori** 1996 Apr; 44(4):379–83 (Eng. Abstr.) **(Jpn)**

METABOLISM

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76–85 (60 ref.)

PATHOGENICITY

The evolution of virulence: a unifying link between parasitology and ecology. Ewald PW. **J Parasitol** 1995 Oct; 81(5):659–69 (71 ref.)

The curse of the pharaoh: the evolution of virulence in pathogens with long living propagules. Bonhoeffer S, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22; 263(1371):715–21

Coinfection and the evolution of parasite virulence. May RM, et al. **Proc R Soc Lond B Biol Sci** 1995 Aug 22; 261(1361):209–15

The scope for virulence management: a comment on Ewald's view on the evolution of virulence. van Baalen M, et al. **Trends Microbiol** 1995 Nov;3(11):414–6; discussion 416–7 (11 ref.)

[Parasitic liver disease] Sekiya C. **Ryoikibetsu Shokogun Shirizu** 1995;(7):66–9 (10 ref.) **(Jpn)**

PHYSIOLOGY

The art of parasite survival. Camus D, et al. **Braz J Med Biol Res** 1995 Apr;28(4):399–413 (92 ref.)

Pathogen coexistence induced by density–dependent host mortality. Andreasen V, et al. **J Theor Biol** 1995 Nov 21; 177(2):159–65

Parasites and carotenoid–based signal intensity: how general should the relationship be? Shykoff JA, et al. **Naturwissenschaften** 1996 Mar;83(3):113–21 (66 ref.)

Patterns of macroparasite abundance and aggregation in wildlife populations: a quantitative review. Shaw DJ, et al. **Parasitology** 1995;111 Suppl:S111–27

The contagion indicator hypothesis for parasite–mediated sexual selection. Able DJ. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2229–33

The varied lifestyles of intracellular pathogens within eukaryotic vacuolar compartments. Garcia–del Portillo F, et al. **Trends Microbiol** 1995 Oct;3(10):373–80 (69 ref.)

[Molecular basis of host–parasite relations] Capron A. **Bull Mem Acad R Med Belg** 1994;149(12):487–93 **(Fre)**

PARASITIC DISEASES

Proceedings of the Third International Meeting of Tropical Medicine and Parasitology, Kunming, Yunnan Province, China. Xu Z, et al. **Chin Med J (Engl)** 1995 Oct; 108(10):774–9

Genetics of host and parasite—implications for immunity, epidemiology and evolution. Wakelin D, et al. **Parasitology** 1996;112 Suppl:S1–4

The contagion indicator hypothesis for parasite–mediated sexual selection. Able DJ. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2229–33

Late stone–age coprolite reveals evidence of prehistoric parasitism [letter] Evans AC, et al. **S Afr Med J** 1996 Mar; 86(3):274–5

[Pruritus due to obstructive jaundice, with delusions of parasitosis] Nevo A, et al. **Harefuah** 1996 Jan 15; 130(2):93–4, 143 (Eng. Abstr.) **(Heb)**

[Parasitic infections in the extrahepatic biliary tree] Nakazawa O. **Ryoikibetsu Shokogun Shirizu** 1996;(9):485–8 (6 ref.) **(Jpn)**

COMPLICATIONS

High levels of CA–125 in a case of a parasitic leiomyoma presenting as an abdominal mass. Ghamande SA, et al. **Gynecol Oncol** 1996 May;61(2):297–8

Parasitic causes of hepatomegaly in children. Hassan MM, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):177–89

The aetiologies of epilepsy in tropical Africa. Adamolekun B. **Trop Geogr Med** 1995;47(3):115–7 (29 ref.)

DIAGNOSIS

Emerging pathogens [editorial] González–Scarano F. **Curr Opin Neurol** 1995 Jun;8(3):161–3

Parasitic infections presenting as prolonged fevers. Abdel Wahab MF, et al. **J Egypt Soc Parasitol** 1996 Aug; 26(2):509–16

[Infectious diarrhea. Which germ? Which treatment?] Bricaire F. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr;32(2):97–9 **(Fre)**

DRUG THERAPY

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009–22 (73 ref.)

Effect of some parasitic infection on neurotransmitters in the brain of experimentally infected mice before and after treatment. Abdel Ghafar AE, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):497–508

Drugs for parasitic infections. **Med Lett Drugs Ther** 1995 Nov 10;37(961):99–108

Targeted chemotherapy for parasite infestations in rural black preschool children. Taylor M, et al. **S Afr Med J** 1995 Sep;85(9):870–4

EPIDEMIOLOGY

Polyparasitism in two rural communities with endemic Schistosoma mansoni infection in Machakos District, Kenya. Chunge RN, et al. **J Trop Med Hyg** 1995 Dec; 98(6):440–4

Opportunistic and non–opportunistic parasites in HIV–positive and negative patients with diarrhoea in Tanzania. Gomez Morales MA, et al. **Trop Med Parasitol** 1995 Jun;46(2):109–14

[Infections during the 1995 flood in Ostlandet. Prevention and incidence] Aavitsland P, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2038–43 (Eng. Abstr.) **(Nor)**

[The spread of the principal socially important parasitic disease on the territory of the Chukot Autonomous Okrug (ChAO)] Lebedev GB, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):52–4 (Eng. Abstr.) **(Rus)**

[Recurrent epidemics: a formal model of the self–regulation of parasitic systems] Kaminskiĭ GD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):42–3 **(Rus)**

ETIOLOGY

Foodborne and waterborne illness in children. Rivera–Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

HISTORY

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009–22 (73 ref.)

IMMUNOLOGY

Intestinal opportunistic parasites among different groups of immunocompromised hosts. Abaza SM, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):713–27

Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. Vidal S, et al. **J Leukoc Biol** 1995 Oct;58(4):382–90 (61 ref.)

PARASITOLOGY

Microsporidium in AIDS patients: a perspective. Chukwuma C Sr. **East Afr Med J** 1996 Jan;73(1):72–5 (35 ref.)

Role of nitric oxide in parasitic infections. James SL. **Microbiol Rev** 1995 Dec;59(4):533–47 (204 ref.)

Cluster randomization trials in tropical medicine: a case study. Klar N, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):454–9

[New opportunistic pathogens in AIDS] Morillon M. **Med Trop (Mars)** 1996;56(1):17–20 (20 ref.) **(Fre)**

[Pseudo–parasites in histology and cytopathology] Pierre C, et al. **Med Trop (Mars)** 1995;55(2):165–71 (24 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Pseudo–parasites in histology and cytopathology] Pierre C, et al. **Med Trop (Mars)** 1995;55(2):165–71 (24 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Effect of some parasitic infection on neurotransmitters in the brain of experimentally infected mice before and after treatment. Abdel Ghafar AE, et al.

J Egypt Soc Parasitol 1996 Aug;26(2):497–508

PREVENTION & CONTROL

Tropical diseases: new peril, new promise. Long CA. Am J Trop Med Hyg 1996 May;54(5):439–42

Reducing risk of zoonotic parasitic diseases—a shared responsibility. Roundtable: veterinarians, physicians jointly responsible [news] Allert C. J Am Vet Med Assoc 1995 Aug 15;207(4):403–4

[When should antiparasitic vaccines be used in medicine?] Loutan L. Schweiz Med Wochenschr 1996 Jul 9; 126(27–28):1202–3 (Fre)

[The current status of the problem of parasitic diseases and their prevention] Sergiev VP. Voen Med Zh 1995 Sep; (9):45–8 (12 ref.) (Rus)

PSYCHOLOGY

100 years of delusional parasitosis. Meta-analysis of 1,223 case reports. Trabert W. Psychopathology 1995; 28(5):238–46

THERAPY

[Anti-parasitic therapies: good reasons to hope....(editorial)] Dessein A. Med Trop (Mars) 1995;55(3):223–4 (Fre)

TRANSMISSION

Pathogen coexistence induced by density-dependent host mortality. Andreasen V, et al. J Theor Biol 1995 Nov 21; 177(2):159–65

Incorporating immunological ideas in epidemiological models. Dushoff J. J Theor Biol 1996 Jun 7;180(3):181–7

Current concepts on the transmission of bacteria and parasites by blood components. Wendel Neto S. Rev Paul Med 1995 Nov–Dec;113(6):1036–52 (107 ref.)

[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. Med Parazitol (Mosk) 1995 Apr–Jun;(2):51–7 (50 ref.) (Eng. Abstr.) (Rus)

[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP. An R Acad Nac Med (Madr) 1995;112(3):617–45; discussion 646 (93 ref.) (Spa)

VETERINARY

Parasite infections in Danish trout farms. Buchmann K, et al. Acta Vet Scand 1995;36(3):283–98

TRYPNET. New hemoparasite information network. Vokaty S, et al. Ann N Y Acad Sci 1996 Jul 23;791:166–71

Parasite prevalence in free-ranging farm cats, Felis silvestris catus. Yamaguchi N, et al. Epidemiol Infect 1996 Apr; 116(2):217–23

Endectocidal drugs: ecological risks and counter-measures. Herd R. Int J Parasitol 1995 Aug;25(8):875–85 (82 ref.)

Costs of major parasites to the Australian livestock industries. McLeod RS. Int J Parasitol 1995 Nov;25(11):1363–7 (25 ref.)

Parasitisms of catfish and other farm-raised food fish [see comments] Klesius P, et al. J Am Vet Med Assoc 1995 Dec 1;207(11):1473–8 (40 ref.). Comment in: J Am Vet Med Assoc 1996 Feb 1;208(3):338.

More on fish anatomy [letter; comment] [see comments] Waterstrat PR. J Am Vet Med Assoc 1996 Apr 1; 208(7):1016. Comment on: J Am Vet Med Assoc 1996 Feb 1;208(3):338. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625.

On the distribution and abundance of eel parasites in Nova Scotia: influence of pH. Marcogliese DJ, et al. J Parasitol 1996 Jun;82(3):389–99

A survey for selected viral, chlamydial, and parasitic diseases in wild dusky-headed parakeets (Aratinga weddellii) and tui parakeets (Brotogeris sanctithomae) in Peru. Gilardi KV, et al. J Wildl Dis 1995 Oct;31(4):523–8

Evolutionary pressures in the spread and persistence of infectious agents in vertebrate populations. Anderson RM. Parasitology 1995;111 Suppl:S15–31 (69 ref.)

Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. Parasitology 1995;111 Suppl:S3–14 (185 ref.)

Patterns of macroparasite abundance and aggregation in wildlife populations: a quantitative review. Shaw DJ, et al. Parasitology 1995;111 Suppl:S111–27

A 4-year study on the effectiveness of alternate grazing of cattle and sheep in the control of bovine parasitic gastro-enteritis. Bairden K, et al. Vet Parasitol 1995 Nov; 60(1–2):119–32

Study on a new egg count technique for Macracanthorhynchus hirudinaceus and Ascaris suum. Dangjin L. Vet Parasitol 1996 Jan;61(1–2):113–7

Time series analysis of the prevalence of endoparasitic infections in cats and dogs presented to a veterinary teaching hospital. Nolan TJ, et al. Vet Parasitol 1995 Sep; 59(2):87–96

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. Vet Parasitol 1995 Sep; 59(2):139–56 (54 ref.)

Controlled efficacy study of the bioequivalence of Strongid C and generic pyrantel tartrate in horses. Valdez RA, et al. Vet Parasitol 1995 Nov;60(1–2):83–102

Clinical disorders observed in anteaters (Myrmecophagidae, Edentata) in captivity. Diniz LS, et al. Vet Res Commun 1995;19(5):409–15

[Parasitoses of the wild, domestic and agricultural animals of the Moscow megapolis] Gorokhov VV. Med Parazitol (Mosk) 1996 Jan–Mar;(1):9–13 (Rus)

PARASITIC EYE INFECTIONS see EYE INFECTIONS, PARASITIC

PARASITIC INTESTINAL DISEASES see INTESTINAL DISEASES, PARASITIC

PARASITIC LIVER DISEASES see LIVER DISEASES, PARASITIC

PARASITIC LUNG DISEASES see LUNG DISEASES, PARASITIC

PARASITIC PREGNANCY COMPLICATIONS see PREGNANCY COMPLICATIONS, PARASITIC

PARASITIC SKIN DISEASES see SKIN DISEASES, PARASITIC

PARASITICIDES see ANTIPARASITIC AGENTS

PARASITOLOGY

Presentation of the President's Special Award for Distinguished Service. Desser SS. J Parasitol 1995 Dec; 81(6):851

Introduction of Richard W. Komuniecki as the Henry Baldwin Ward Medalist for 1995. Fayer R. J Parasitol 1995 Dec;81(6):847

[First paleoparasitologic approach of the neolithic site in Chalain (Jura, France)] Bouchet F, et al. Bull Soc Pathol Exot 1995 Apr;88(5):265–8 (Eng. Abstr.) (Fre)

[Parasitological monitoring in Russia (the bases of the concept)] Beér SA. Med Parazitol (Mosk) 1996 Jan–Mar; (1):3–8 (Rus)

EDUCATION

A computer-based book on medical helminthology. Arfaa F. Comput Methods Programs Biomed 1995 Aug; 47(3):253–5

HISTORY

Gwendolen Rees F.R.S. 1906–1994. Beverley-Burton M. Int J Parasitol 1995 Oct;25(10):1145–8

Presidential address. Peeling the cosmic onion. Desser SS. J Parasitol 1995 Dec;81(6):842–6

[Paleoparasitology: presumption of a case with bilharzia of the 15th century at Montbéliard (Doubs, France)] Bouchet F, et al. C R Acad Sci III 1995 Jul;318(7):811–4 (Eng. Abstr.) (Fre)

[Prof. Dr. hab. Wanda Stojałowska (obituary)] Gieryng R. Wiad Parazytol 1996;42(1):132–6 (Pol)

[Dr Med. Alexander Rydzewski (obituary)] Kasprzak W. Wiad Parazytol 1996;42(1):129–31 (Pol)

METHODS

Increasing the yield of Eimeria tenella oocysts in primary chicken kidney cells. Zhang J, et al. Avian Dis 1996 Jan–Mar;40(1):63–7

Comparison of PCR and microscopic methods for detecting Trypanosoma cruzi. Kirchhoff LV, et al. J Clin Microbiol 1996 May;34(5):1171–5

Comparative evaluation of several techniques for purification of Cryptosporidium parvum oocysts from rat feces. Suresh P, et al. J Clin Microbiol 1996 Jan;34(1):38–40

ACP Broadsheet no 148. July 1996. Laboratory diagnosis of malaria. Warhurst DC, et al. J Clin Pathol 1996 Jul; 49(7):533–8 (16 ref.)

Axenic cultivation of Entamoeba dispar Brumpt 1925, Entamoeba insolita Geiman and Wichterman 1937 and Entamoeba ranarum Grassi 1879. Clark CG. J Eukaryot Microbiol 1995 Sep–Oct;42(5):590–3

Automated reading and processing of quantitative IgG, IgM, IgA, and IgE isotypic agglutination results in microplates. Development and application in parasitology-mycology. Aubert D, et al. J Immunol Methods 1995 Oct 26; 186(2):323–8

Hematozoa in thin blood smears [letter] Fedynich AM, et al. J Wildl Dis 1995 Jul;31(3):436–8

Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north-eastern Brazil. Junqueira AC, et al. Trans R Soc Trop Med Hyg 1996 Mar–Apr;90(2):129–32

A comparison of parasitological methods for the diagnosis of gambian trypanosomiasis in an area of low endemicity in Côte d'Ivoire. Truc P, et al. Trans R Soc Trop Med Hyg 1994 Jul–Aug;88(4):419–21

A simple field method for the purification of Onchocerca ochengi microfilariae from a mixed Onchocerca infection in cattle. Hagen HE, et al. Trop Med Parasitol 1995 Sep; 46(3):201–2

Large scale collection of viable infective larvae of Loa loa. Wahl G, et al. Trop Med Parasitol 1995 Sep;46(3):203–4

Use of a polyurethane carrier for assessing the survival of helminth eggs in liquid biological sludges. Plachý P, et al. Vet Med (Praha) 1995 Oct;40(10):323–6

[Morphology of Blastocystis hominis in feces and evaluation of parasitological methods] Peréz de Suarez E, et al. G E N 1994 Oct–Dec;48(4):226–31 (Eng. Abstr.) (Spa)

STANDARDS

A practical method for cleaning Baermann glassware. Whitlaw HA, et al. J Wildl Dis 1995 Jan;31(1):93–5

TRENDS

Evolutionary and ecological parasitology: a changing of the guard? Poulin R. Int J Parasitol 1995 Jul;25(7):861–2

Parasitology year 2000. Bush AO, et al. J Parasitol 1995 Oct;81(5):835–42

[Antiparasitic therapeutics: the present] Magnaval JF. Med Trop (Mars) 1995;55(3 Suppl):10–2 (15 ref.) (Fre)

PARASYMPATHECTOMY

METHODS

Tympanic neurectomy in the management of parotid sialectasis. Daud AS, et al. J Laryngol Otol 1995 Dec; 109(12):1155–8 (12 ref.)

PARASYMPATHETIC-BLOCKING AGENTS see PARASYMPATHOLYTICS

PARASYMPATHETIC DENERVATION see PARASYMPATHECTOMY

PARASYMPATHETIC FIBERS, POSTGANGLIONIC

[Comparison of the infusion of acetylcholine into the artery of the sinoatrial node with the electric stimulation of cardiac parasympathetic nerves] Pagé PL, et al. Ann Chir 1995;49(8):719–27 (Eng. Abstr.) (Fre)

CHEMISTRY

Endogenous opioid peptides in parasympathetic, sympathetic and sensory nerves in the guinea-pig heart. Steele PA, et al. Cell Tissue Res 1996 May;284(2):331–9

PHYSIOLOGY

The high frequency component of heart rate variability reflects cardiac parasympathetic modulation rather than parasympathetic 'tone'. Hedman AE, et al. Acta Physiol Scand 1995 Nov;155(3):267–73

Site of autonomic dysfunction in a patient with Ross' syndrome and postganglionic Horner's syndrome. Wolfe GI, et al. Neurology 1995 Nov;45(11):2094–6

[The effect of electro-acupuncture at auricular & body acupoints on the curve changes of the pressure-volume of urinary bladder and the electric activity of pelvic nerves of rat] Ben H, et al. Chen Tzu Yen Chiu 1995;20(2):51–4 (Eng. Abstr.) (Chi)

PARASYMPATHETIC GANGLIA see GANGLIA, PARASYMPATHETIC

PARASYMPATHETIC NERVOUS SYSTEM

see related
PARASYMPATHECTOMY
PARASYMPATHOLYTICS
PARASYMPATHOMIMETICS

Extrapelvic cavernous nerve stimulation in erectile dysfunction. Human study. Shafik A. Andrologia 1996 May–Jun;28(3):151–6

The excitability of the micturition reflex. Morrison JF. Scand J Urol Nephrol Suppl 1995;175:21–5

CYTOLOGY

Cholinergic projections to the anterior thalamic nuclei in the rat: a combined retrograde tracing and choline acetyl transferase immunohistochemical study. Gonzalo-Ruiz A, et al. Anat Embryol (Berl) 1995 Oct;192(4):335–49

Cultured basal forebrain cholinergic neurons from postnatal rats show both overlapping and non-overlapping responses to the neurotrophins. Nonomura T, et al. Brain Res 1995 Jun 12;683(1):129–39

Immunohistochemical characterisation of sympathetic and parasympathetic pelvic neurons projecting to the distal colon in the male rat. Luckensmeyer GB, et al. Cell Tissue Res 1995 Sep;281(3):551–9

Retinoic acid induces cholinergic differentiation of NTera 2 human embryonal carcinoma cells. Zeller M, et al. Int J Dev Neurosci 1995 Aug;13(5):437–45

Cholinergic, somatostatin-immunoreactive interneurons in the guinea pig intestine: morphology, ultrastructure, connections and projections. Portbury AL, et al. J Anat 1995 Oct;187 (Pt 2):303–21

Binding and internalization of neurotensin in hybrid cells derived from septal cholinergic neurons. Faure MP, et al. Synapse 1995 Jun;20(2):106–16

DRUG EFFECTS

Differing autonomic response to dobutamine in the presence and absence of ischemia: implications for the autonomic contribution to positive inotropic intervention. Binkley PF, et al. **Am Heart J** 1995 Nov;130(5):1054–61

Pontine cholinergic mechanisms modulate the cortical electroencephalographic spindles of halothane anesthesia. Keifer JC, et al. **Anesthesiology** 1996 Apr;84(4):945–54

Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea–pig trachea by isoprenaline. Belvisi MG, et al. **Br J Pharmacol** 1996 Apr; 117(7):1413–20

192IgG–saporin–induced immunotoxic lesions of cholinergic basal forebrain system differentially affect glutamatergic and GABAergic markers in cortical rat brain regions. Rossner S, et al. **Brain Res** 1995 Oct 23;696(1–2):165–76

192IGG–saporin–induced selective lesion of cholinergic basal forebrain system: neurochemical effects on cholinergic neurotransmission in rat cerebral cortex and hippocampus. Rossner S, et al. **Brain Res Bull** 1995;38(4):371–81

Transient enhancement of cholinergic neurochemical markers induced by NGF in aged F344 rats. Santucci AC, et al. **Dementia** 1995 Jul–Aug;6(4):179–84

Effect of ciprofloxacin on cholinergic neuro–effector transmission in airway smooth muscle. Tamaoki J, et al. **Drugs** 1995;49 Suppl 2:298–300

Anterior ethmoidal glycerol rhizotomy for vasomotor rhinitis. Yue WL. **Ear Nose Throat J** 1995 Nov;74(11):764–7

Site of action of galanin in the cholinergic transmission of guinea pig small intestine. Akehira K, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):149–55

Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons. Mulvaney JM, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):97–100

Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2–adrenoceptor antagonist. Bagheri H, et al. **Fundam Clin Pharmacol** 1995; 9(3):248–54

Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Tabira T, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):241–52

The use of medicines with anticholinergic effects in older people: a population study in an urban area of Sweden. Fastbom J, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1135–40

Glial cell line–derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose–response comparison to nerve growth factor and brain–derived neurotrophic factor. Williams LR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1140–51

Rhythmical bursts induced by NMDA in guinea–pig cholinergic nucleus basalis neurones in vitro. Khateb A, et al. **J Physiol (Lond)** 1995 Sep 15;487 (Pt 3):623–38

Effects of nicotinamide on central cholinergic transmission and on spatial learning in rats. Köppen A, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):783–90

INJURIES

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121–4 (11 ref.)

METABOLISM

Identified cholinergic neurones in the adult rat brain are enriched in GAP–43 mRNA: a double in situ hybridisation study. Augood SJ, et al. **J Chem Neuroanat** 1995 Jul; 9(1):17–26

Altered cholinergic metabolism in rat CNS following aluminum exposure: implications on learning performance. Julka D, et al. **J Neurochem** 1995 Nov;65(5):2157–64

Differential effects of nerve growth factor on expression of choline acetyltransferase and sodium–coupled choline transport in basal forebrain cholinergic neurons in culture. Pongrac JL, et al. **J Neurochem** 1996 Feb;66(2):804–10

Blockade of glutamate– and cholinergic ion channels by amantadane derivatives. Magazanik LG, et al. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):13–22

Memory deficits and cholinergic impairments in apolipoprotein E–deficient mice. Gordon I, et al. **Neurosci Lett** 1995 Oct 13;199(1):1–4

Coexpression of vasoactive intestinal peptide, calcitonin gene–related peptide and substance P immunoreactivity in parasympathetic neurons of the rhesus monkey lung. Nohr D, et al. **Neurosci Lett** 1995 Oct 13;199(1):25–8

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. Sullivan JP, et al. **Proc West Pharmacol Soc** 1995;38:127–30 (29 ref.)

PATHOLOGY

Lesions of mediastinal paraganglia in chronic chagasic cardiomyopathy: cause of sudden death? [editorial] Ramos SG, et al. **Am Heart J** 1996 Feb;131(2):417–20 (32 ref.)

Effects of neonatal hypoxia on brainstem cholinergic neurons–pedunculopontine nucleus and laterodorsal tegmental nucleus. Tanaka H, et al. **Brain Dev** 1995 Jul–Aug;17(4):264–70

[Changes in the rat small intestine under conditions of disordered sympathetic and parasympathetic innervation] Eletskiĭ IuK, et al. **Morfologiia** 1994 Jul–Dec; 107(7–12):100–10 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cholinergic/GABAergic interaction in the production of EEG theta oscillations in rat hippocampal formation in vitro. Gołębiewski H, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):147–53

The migrating motor complex—the motor component of a cholinergic enteric secretomotor programme? Mellander A, et al. **Acta Physiol Scand** 1995 Jul;154(3):329–41

Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs. Furukawa Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H44–50

Prejunctional inhibition of cholinergic responses by prostaglandin E2 in human bronchi. Ellis JL, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):244–6

Parasympathetic component of 5–hydroxytryptamine–induced pulmonary dysfunctions in healthy calves. Linden AS, et al. **Am J Vet Res** 1996 Jun; 57(6):896–901

Location and characteristics of nitric oxide synthase in sheep spinal cord and its interaction with alpha(2)–adrenergic and cholinergic antinociception. Xu Z, et al. **Anesthesiology** 1996 Apr;84(4):890–9

Age–related changes in learning and memory and cholinergic neuronal function in senescence accelerated mice (SAM). Nitta A, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):49–55

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1–2):13–25 (123 ref.)

The physiology of the cerebrovascular parasympathetic innervation. Branston NM. **Br J Neurosurg** 1995; 9(3):319–29 (25 ref.)

Calcium channel subtypes for the sympathetic and parasympathetic nerves of guinea–pig atria. Hong SJ, et al. **Br J Pharmacol** 1995 Sep;116(1):1577–82

Immediate hypersensitivity in the Flinders rat: further evidence for a possible link between susceptibility to allergies and depression. Djurić VJ, et al. **Brain Behav Immun** 1995 Sep;9(3):196–206

Monoaminergic and cholinergic modulation of REM–sleep timing in rats. Benington JH, et al. **Brain Res** 1995 May 29;681(1–2):141–6

A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Pascual T, et al. **Brain Res** 1995 Oct 16; 695(2):289–92

Septo–hippocampal cholinergic system under the discrimination learning task in the rat: a microdialysis study with the dual–probe approach. Yamamuro Y, et al. **Brain Res** 1995 Jun 26;684(1):1–7

Poincaré plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Kamen PW, et al. **Clin Sci (Colch)** 1996 Aug;91(2):201–8

Heart rate variability, baroreflex sensitivity, and cardiac vagal tone. Swenne CA, et al. **Clin Sci (Colch)** 1996;91 Suppl:113–5

Adrenergic and cholinergic response of ventricular muscle from the turtle, Trachemys (Pseudemys) scripta. Ball DC, et al. **Comp Biochem Physiol A Physiol** 1996 Feb; 113(2):135–41

Noradrenergic modulation of cholinergic nucleus basalis neurons demonstrated by in vitro pharmacological and immunohistochemical evidence in the guinea–pig brain. Fort P, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1502–11

Cholinergic activation of the electrocorticogram: an amygdaloid activating system. Dringenberg HC, et al. **Exp Brain Res** 1996 Mar;108(2):285–96

Impact of gestational age on the catecholamine responses of the fetal sheep adrenal to cholinergic stimulation in vitro. Butler TG, et al. **Exp Physiol** 1995 Sep;80(5):767–77

Mechanisms of substance P–induced pulmonary oedema in the rabbit: interactions between parasympathetic and excitatory NANC nerves. Delaunois A, et al. **Fundam Clin Pharmacol** 1995;9(5):450–7

Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237–44 (74 ref.)

TrkA mediates an NGF survival response in NGF–independent sensory neurons but not in parasympathetic neurons. Allsopp TE, et al. **Gene Ther** 1994;1 Suppl 1:S59

Activins as candidate cholinergic differentiation factors in vivo. Fann MJ, et al. **Int J Dev Neurosci** 1995 Jun–Jul; 13(3–4):317–30

Cholinergic properties of neurons differentiated from an embryonal carcinoma cell–line (P19). Parnas D, et al. **Int J Dev Neurosci** 1995 Nov;13(7):767–81

Nitric oxide as a mediator of parasympathetic vasodilation in ocular and extraocular tissues in the rabbit. Nilsson SF. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):2110–9

Endothelin–1, via activation of an ETB receptor, inhibits cholinergic nerve–mediated contractions in sheep trachea. Henry PJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S117–9

Absence of parasympathetic vasodilatation in cat dental pulp. Sasano T, et al. **J Dent Res** 1995 Oct;74(10):1665–70

Cholinergic modulation of cortical oscillatory dynamics. Liljenström H, et al. **J Neurophysiol** 1995 Jul;74(1):288–97

Cholinergic, GABAergic, and glutamate–enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. Bevan MD, et al. **J Neurosci** 1995 Nov; 15(11):7105–20

Basal forebrain cholinergic lesions disrupt increments but not decrements in conditioned stimulus processing. Chiba AA, et al. **J Neurosci** 1995 Nov;15(11):7315–22

Age–associated impairments in a test of attention: evidence for involvement of cholinergic systems. Jones DN, et al. **J Neurosci** 1995 Nov;15(11):7282–92

Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis. Moises HC, et al. **J Neurosci** 1995 Dec;15(12):8131–42

Differential cholinergic regulation of dopamine release in the dorsal and ventral neostriatum of the rat: an in vivo microdialysis study. O'Connor WT, et al. **J Neurosci** 1995 Dec;15(12):8353–61

Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. Vaucher E, et al. **J Neurosci** 1995 Nov;15(11):7427–41

Endothelin ETA and ETB receptors facilitating parasympathetic neurotransmission in the rabbit trachea. Yoneyama T, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1084–9

beta–adrenergic and cholinergic modulation of the inwardly rectifying K+ current in guinea–pig ventricular myocytes. Koumi S, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):647–59

Cardiac parasympathetic nervous system activity does not increase in anticipation of sleep. Burgess HJ, et al. **J Sleep Res** 1996 Jun;5(2):83–9

Parasympathetic reflex salivary secretion in the cat parotid gland. Takahashi H, et al. **Jpn J Physiol** 1995;45(3):475–90

Ameliorating effects of histidine on learning deficits in an elevated plus–maze test in mice and the contribution of cholinergic neuronal systems. Miyazaki S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:57–63

Role of the activation of the intralaminar nuclei of the thalamus in regulating the participation of the neostriatal cholinergic system in the differentiation of acoustic signals in dogs. Shapalova KB, et al. **Neurosci Behav Physiol** 1995 Nov–Dec;25(6):504–7

Modulation of septal influences on hippocampal neurons by cholinergic substances. Vinogradova OS, et al. **Neurosci Behav Physiol** 1995 Nov–Dec;25(6):453–61

Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Cassel JC, et al. **Neuroscience** 1995 Nov;69(1):1–41 (261 ref.)

Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons. Kordower JH, et al. **Neuroscience** 1996 May; 72(1):63–77

Neurochemical, electrophysiological and immunocytochemical evidence for a noradrenergic link between the sympathetic nervous system and thymocytes. Vizi ES, et al. **Neuroscience** 1995 Oct;68(4):1263–76

Lack of cholinergic regulation of vasopressin and norepinephrine responses to hypertonic saline in humans. Pascualy M, et al. **Psychoneuroendocrinology** 1995; 20(7):679–91

Effect of slowed respiration on cardiac parasympathetic response to threat. Sakakibara M, et al. **Psychosom Med** 1996 Jan–Feb;58(1):32–7

[The dependence of the parasympathetic reaction of the mesencephalic section of the brain stem to age–, sex– and pigment–reagent–related factors] Vel'khover ES, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):36–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Role of the parasympathetic autonomic nervous system in digitalis intoxication: electrocardiographic and histological study. Princi T, et al. **Acta Med Croatica** 1996;50(2):81–5

The WAGxDA rat: an animal model of cholinergic supersensitivity. Orpen G, et al. **Biol Psychiatry** 1995 Jun 15;37(12):874–83

Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Blin J, et al. **Brain** 1995 Dec;118 (Pt 6):1485–95

Parasympathetic withdrawal precedes spontaneous blood pressure elevations in women with primary hypertension. Dąbrowska B, et al. **Cardiology** 1996 Mar–Apr;87(2):119–24

Sympathetic–parasympathetic activation during spontaneous attacks of cluster headache: evaluation by spectral analysis of heart–rate fluctuations [see comments] De Marinis M, et al. **Cephalalgia** 1995 Dec;15(6):504–10. Comment in: Cephalalgia 1995 Dec;15(6):450.

Respiratory sinus arrhythmia and central respiratory drive in humans. Al–Ani M, et al. **Clin Sci (Colch)** 1996 Mar; 90(3):235–41

Is diurnal variation of mood associated with parasympathetic activity? Rechlin T, et al. **J Affect Disord** 1995 Jun 8; 34(3):249–55

The parasympathetic system and its muscarinic receptors in hypertensive disease. van Zwieten PA, et al. **J Hypertens** 1995 Oct;13(10):1079–90 (79 ref.)

Cardiosympathetic neuropathy is independent of cardioparasympathetic neuropathy in patients with non–insulin–dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Sep–Oct;23(5):364–8

Epidural perfusion cooling protects against spinal cord

ischemia in rabbits. An evaluation of cholinergic function. Malatová Z, et al. **Mol Chem Neuropathol** 1995 Jun–Aug; 25(2–3):81–96

No change in automatic function tests during uncomplicated haemodialysis. Ligtenberg G, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):651–6

Cardiac sympathetic–parasympathetic balance in rats with experimentally–induced acute chagasic myocarditis. Davila DF, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr; 37(2):155–9

[Autoregressive analysis of variability in heart rate and blood pressure in asthmatic children—difference of severity] Korematsu S. **Arerugi** 1995 Sep;44(9):1140–9 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

[The effect of ionizing radiation on the nervous mechanisms regulating cardiac activity] Pavliuchenko VB, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):61–7 (Eng. Abstr.) **(Ukr)**

ULTRASTRUCTURE

Localization of nerves adjacent to goblet cells in rat conjunctiva. Dartt DA, et al. **Curr Eye Res** 1995 Nov; 14(11):993–1000

An ultrastructural study of cholinergic and non–cholinergic neurons in the laterodorsal and pedunculopontine tegmental nuclei in the rat. Honda T, et al. **Neuroscience** 1995 Oct;68(3):837–53

PARASYMPATHOLYTICS

see related
ANTIPARKINSON AGENTS
ANTI–ULCER AGENTS
MUSCARINIC ANTAGONISTS

Trihexyphenidyl abuse in schizophrenic patient: a case report. Lo Y, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb;57(2):157–60

[The use of an analgin–novocaine–platyphylline mixture for arresting the pain attack and treating trigeminal neuralgia] Sheshelovskii EG, et al. **Stomatologiia (Mosk)** 1996;75(1):44 **(Rus)**

ADMINISTRATION & DOSAGE

Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Szonyi G, et al. **Age Ageing** 1995 Jul;24(4):287–91

The effects of intrathecal neostigmine on somatic and visceral pain: improvement by association with a peripheral anticholinergic. Lauretti GR, et al. **Anesth Analg** 1996 Mar; 82(3):617–20

Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Enzelsberger H, et al. **Br J Obstet Gynaecol** 1995 Nov; 102(11):929–30

Barium enema: do antispasmodics really improve performance and quality? [letter; comment] Husien AM. **Clin Radiol** 1996 Apr;51(4):305. Comment on: Clin Radiol 1995 Aug;50(8):553–7.

Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results. Madersbacher H, et al. **Eur Urol** 1995;28(4):340–4

ADVERSE EFFECTS

No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients. Silver H, et al. **Biol Psychiatry** 1995 Sep 15; 38(6):413–5

Fenoverine–induced rhabdomyolysis. Chariot P, et al. **Hum Exp Toxicol** 1995 Aug;14(8):654–6

Case 7: the addled nonagenarian. Shader RI, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):378

Scopolamine administered before and after training impairs both contextual and auditory–cue fear conditioning. Rudy JW. **Neurobiol Learn Mem** 1996 Jan;65(1):73–81

ANALYSIS

Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers. Khulusi S, et al. **Gut** 1995 Aug;37(2):205–9

ANTAGONISTS & INHIBITORS

Panax ginseng extract improves the scopolamine–induced disruption of 8–arm radial maze performance in rats. Nitta H, et al. **Biol Pharm Bull** 1995 Oct;18(10):1439–42

CHEMICAL SYNTHESIS

Synthesis and structure–activity relationships of N–propyl–N–(4–pyridinyl)–1H–indol–1–amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. Klein JT, et al. **J Med Chem** 1996 Jan 19;39(2):570–81

DIAGNOSTIC USE

Evaluation of impotent men with intracorporeal injection of papaverine and colour Doppler ultrasound. Cetinkaya M, et al. **Int Urol Nephrol** 1995;27(6):779–82

Pupillary response to tropicamide in patients with Alzheimer disease. Loupe DN, et al. **Ophthalmology** 1996 Mar; 103(3):495–503

[Diagnosis of myocardial ischemia by dynamic digital echocardiography with dobutamine and atropine] Guadalajara Boo JF, et al. **Arch Inst Cardiol Mex** 1995 Jul–Aug;65(4):330–41 (Eng. Abstr.) **(Spa)**

METABOLISM

[3H]N–methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators. Christopoulos A, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):259–62

PHARMACOKINETICS

Comparison of the in vitro skin penetration of propiverine with that of terodiline. Ogiso T, et al. **Biol Pharm Bull** 1995 Jul;18(7):968–75

The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86–7480 in the conscious monkey. Hubbard JW, et al. **J Clin Pharmacol** 1995 Jul;35(7):688–96

PHARMACOLOGY

Intrathecal clonidine and tizanidine in conscious dogs: comparison of analgesic and hemodynamic effects. Kroin JS, et al. **Anesth Analg** 1996 Mar;82(3):627–35

Pharmacological activities of imidazo(1,2–alpha]pyrazine derivatives. Michel A, et al. **Arzneimittelforschung** 1995 Dec;45(12):1288–93

The lack of a role for potassium channel opening in the action of relaxin in the rat isolated uterus; a comparison with levcromakalim and salbutamol. Hughes SJ, et al. **Br J Pharmacol** 1996 Apr;117(7):1435–42

A comparison of the effects of SCA40, NS 004 and NS 1619 on large conductance Ca(2+)–activated K+ channels in bovine tracheal smooth muscle cells in culture. Macmillan S, et al. **Br J Pharmacol** 1995 Sep;116(1):1656–60

Endogenous nitric oxide signalling system and the cardiac muscarinic acetylcholine receptor–inotropic response. Sterin–Borda L, et al. **Br J Pharmacol** 1995 Aug; 115(8):1525–31

Effects of besipirdine at the voltage–dependent sodium channel. Tang L, et al. **Br J Pharmacol** 1995 Nov; 116(5):2468–72

Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat. Herremans AH, et al. **Brain Res** 1996 Mar 4; 711(1–2):102–11

Ventricular rate during atrial fibrillation before and after slow–pathway ablation. Effects of autonomic blockade and beta–adrenergic stimulation. Strickberger SA, et al. **Circulation** 1996 Sep 1;94(5):1023–6

Sympathetic regulation in rabbits with heart failure: experience using power spectral analysis of heart rate variability. Moguilevski V, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):475–7

Blockade of muscarinic transmission increases the frequency of diabetes after low–dose alloxan challenge in the mouse. Ahrén B, et al. **Diabetologia** 1996 Apr;39(4):383–90

Influence of spasmolytic analgesics on motility of sphincter of Oddi. Brandstätter G, et al. **Dig Dis Sci** 1996 Sep; 41(9):1814–8

Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine. Barbier P, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):125–32

Frequency–dependent inhibition of neurotransmitter release by besipirdine and HP 184. Tang L, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):71–4

In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]acetylcholine in the rabbit urinary bladder. Tobin G, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):1–8

Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning. Yui K, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):135–42

Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gutierrez M, et al. **Gen Pharmacol** 1996 Jan;27(1):171–6

Impaired action of levcromakalim on ATP–sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats. Ohya Y, et al. **Hypertension** 1996 Jun; 27(6):1234–9

Parasympatholytic activity of psychoactive drugs in rat brain mitochondria. Nag M, et al. **Indian J Exp Biol** 1995 Jun; 33(6):462–3

A potential strategy for decreasing milk production in the ewe at weaning using a growth hormone release blocker. Powell MR, et al. **J Anim Sci** 1995 Jul;73(7):1901–5

Inhibitory effects of Cistus populifolius on contractile responses in the isolated rat duodenum. Sánchez de Rojas VR, et al. **J Ethnopharmacol** 1995 Apr;46(1):59–62

Synthesis and structure–activity relationships of N–propyl–N–(4–pyridinyl)–1H–indol–1–amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. Klein JT, et al. **J Med Chem** 1996 Jan 19;39(2):570–81

The muscarine antagonist methscopolamine and the NMDA antagonist AP–5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions. Svensson A, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):149–57

Antinociceptive action of 2–(4–bromobenzoyl)–3–methyl–4,6–dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice. Vaz ZR, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):304–12

Urodynamic effects of intravesical oxybutynin chloride in conscious rats. Yokoyama O, et al. **J Urol** 1996 Feb; 155(2):768–71

Spasmolytic and calmodulin inhibitory effect of non–steroidal anti–inflammatory drugs in vitro. Cantabrana B, et al. **Life Sci** 1995;57(14):1333–41

Selective blockade of muscarinic M2 receptors in vivo by the new antagonist tripitramine. Angeli P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):304–7

Scopolamine administered before and after training impairs both contextual and auditory–cue fear conditioning. Rudy JW. **Neurobiol Learn Mem** 1996 Jan;65(1):73–81

Basal and scopolamine–evoked release of hippocampal acetylcholine following traumatic brain injury in rats. Dixon CE, et al. **Neurosci Lett** 1995 Sep 29;198(2):111–4

Modulation of the relationship between amylase and chymotrypsinogen secretion in atropine– and MK329–infused rats. Maouyo D, et al. **Pancreas** 1995 Nov; 11(4):330–40

Spasmolytic flavonols from Artemisia abrotanum [letter] Bergendorff O, et al. **Planta Med** 1995 Aug;61(4):370–1

Smooth muscle relaxing compounds from Dodonaea viscosa. Rojas A, et al. **Planta Med** 1996 Apr;62(2):154–9

POISONING

[Alarming increase in deptropine poisonings (letter)] Dreijer–van der Glas SM. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):628–9 **(Dut)**

[Alarming increase in deptropine poisonings (letter)] Griffioen RW. **Ned Tijdschr Geneeskd** 1996 Mar 16; 140(11):629–30 **(Dut)**

[Alarming increase in poisonings due to deptoprine (letter)] van Ommen–Koolmees RG, et al. **Ned Tijdschr Geneeskd** 1996 Mar 30;140(13):729 **(Dut)**

[Alarming increase in deptropine poisonings] van Zoelen GA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):98–9 **(Dut)**

[Alarming increase in deptropine poisonings (letter)] Vijlbrief AS, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):630 **(Dut)**

THERAPEUTIC USE

Pirenzepine versus scopolamine methyl bromide in double–contrast barium enema study of large bowel. Marraccini P, et al. **Abdom Imaging** 1996 Jul–Aug; 21(4):304–8

The reduced sensation of dyspnea during exercise by inhaled oxitropium bromide in severe COPD patients [letter; comment] Teramoto S, et al. **Chest** 1995 Nov; 108(5):1479–80. Comment on: Chest 1994 Dec;106(6):1740–5.

Intravenous antispasmodic and patient–controlled analgesia are of benefit for screening flexible sigmoidoscopy. Saunders BP, et al. **Gastrointest Endosc** 1995 Aug; 42(2):123–7

Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Casadei B, et al. **Heart** 1996 Mar;75(3):274–80

Rumination–treatment with cisapride [letter] Sood AK, et al. **J Assoc Physicians India** 1995 Apr;43(4):304–5

A double–blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. Van Outryve M, et al. **J Clin Pharm Ther** 1995 Oct;20(5):277–82

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence [see comments] Knoll LD, et al. **J Urol** 1996 Jan;155(1):144–6. Comment in: J Urol 1996 Jan;155(1):147.

Peppermint oil and colon spasm. Kingham JG. **Lancet** 1995 Oct 14;346(8981):986

Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Chisakuta AM, et al. **Paediatr Anaesth** 1995;5(2):97–100

Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Vidal J, et al. **Rev Neurol** 1995 Mar–Apr;23(120):269–71

Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose–optimizing study. Mazur D, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):289–94

Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double–blind placebo–controlled multicenter investigation. Dahm TL, et al. **Urol Int** 1995;55(4):205–8

[Comparison of the effect of HI–6 oxime and its derivatives in combination with benactyzine on cholinergic and stress effects of soman in rats] Kassa J. **Ceska Slov Farm** 1996 May;45(3):149–53 (Eng. Abstr.) **(Cze)**

PARASYMPATHOMIMETICS

see related
CHOLINESTERASE INHIBITORS

MUSCARINIC AGONISTS

Cisapride [see comments] Washabau RJ, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1285–8 (33 ref.) . Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184.

ADMINISTRATION & DOSAGE

Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Mishima HK, et al. **Am J Ophthalmol** 1996 Mar;121(3):319–21

Spontaneous versus edrophonium-induced recovery from paralysis with mivacurium. Brandom BW, et al. **Anesth Analg** 1996 May;82(5):999–1002

The effects of intrathecal neostigmine on somatic and visceral pain: improvement by association with a peripheral anticholinergic. Lauretti GR, et al. **Anesth Analg** 1996 Mar; 82(3):617–20

Dosage consideration for cisapride [letter; comment] McCauley MD. **J Am Vet Med Assoc** 1996 Jan 15; 208(2):184. Comment on: J Am Vet Med Assoc 1995 Nov 15;207(10):1285–8.

Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Hamlar DD, et al. **Laryngoscope** 1996 Aug; 106(8):972–6

ANTAGONISTS & INHIBITORS

Dantrolene blocks the tonic contractions to carbachol and histamine with smaller effects on the phasic due to release of intracellular Ca2+ in ileal longitudinal muscle. Nasu T, et al. **Gen Pharmacol** 1995 Nov;26(7):1591–6

Pressor response induced by the hippocampal administration of neostigmine is suppressed by M1 muscarinic antagonist. Hori H, et al. **Life Sci** 1995;57(20):1853–9

PHARMACOLOGY

Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1036–45

Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Kinonen T, et al. **Br J Pharmacol** 1995 Nov;116(6):2625–30

Application of a model to explore interspecies differences in acetylcholine M-receptor-stimulated gastric acid secretion. Welsh NJ, et al. **Br J Pharmacol** 1995 Jul; 115(6):961–8

Excitation and inhibition by cisapride of spontaneous and evoked electrical responses in smooth muscles of guinea-pig stomach. Ohno N, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):145–52

Carbachol-regulation of the expression of alpha i1-subunit of Gi and inositol-[1,4,5]-trisphosphate receptor in brain samples obtained from neonatal and adult rats. Singh AK. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):205–13

Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats. Giustina A, et al. **Endocr Res** 1995 Nov;21(4):719–32

Epidermal growth factor inhibits carbachol-stimulated canine parietal cell function via protein kinase C. Wang L, et al. **Gastroenterology** 1996 Feb;110(2):469–77

The additive miotic effects of dapiprazole and pilocarpine. Geyer O, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):448–51

Influence of duodenal slaframine infusion on site of nutrient disappearance from the digestive tract of steers fed a high-concentrate diet. Streeter MN, et al. **J Anim Sci** 1995 Oct;73(10):3103–10

Cholinergic modulation of immunoglobulin secretion from avian plasma cells: the role of cyclic mononucleotides. Cameron RH, et al. **J Neuroimmunol** 1995 Sep;61(2):223–30

In vitro production of interleukin-6 by human gingival, normal buccal mucosa, and oral submucous fibrosis fibroblasts treated with betel-nut alkaloids. Chen CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Nov; 11(11):604–14

POISONING

[Severe poisoning by 4-aminopyridine in a body builder] Smeets JW, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2667–9 (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

Pilocarpine for anticholinergic adverse effects associated with desipramine treatment [letter] Salah RS, et al. **Am J Psychiatry** 1996 Apr;153(4):579

Use of cisapride in the resolution of pelvic flexure impaction in a horse. Steinebach MA, et al. **Can Vet J** 1995 Oct; 36(10):624–5

Cisapride for constipation in spinal cord injured patients: a preliminary report. Longo WE, et al. **J Spinal Cord Med** 1995 Oct;18(4):240–4

Gastroparesis with multiple sclerosis [letter] Read SJ, et al. **Lancet** 1995 Nov 4;346(8984):1228

Long-term tacrine treatment in patients with Alzheimer's disease [letter] Solomon PR, et al. **Lancet** 1996 Jul 27; 348(9022):275–6

The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double-blind, placebo controlled study. Wyndaele JJ, et al. **Paraplegia** 1995 Nov;33(11):625–7

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

Cisapride as a successful treatment for acute intestinal pseudo-obstruction. Mazloum BW, et al. **South Med J** 1996 Aug;89(8):828–30

[A clinical-pharmacological case (1). Action of cisapride (Prepulsid) on bladder function] Meier C, et al. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):62–4 (Eng. Abstr.) **(Ger)**

[Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial (see comments)] Wallin A. **Lakartidningen** 1996 Jan 3;93(1–2):22–4. Comment in: Lakartidningen 1996 Mar 27;93(13):1200. **(Swe)**

TOXICITY

In-vivo genotoxicity of the alkaloid drug pilocarpine nitrate in bone marrow cells and male germ cells of mice. Hegde MJ, et al. **Mutat Res** 1995 Oct;344(3–4):103–8

Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Chesler EJ, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):619–24

PARASYSTOLE

COMPLICATIONS

Two cases of ventricular parasystole associated with ventricular tachycardia. Itoh E, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):370–3

PHYSIOPATHOLOGY

Numerology of ventricular parasystole [letter] Singh VK. **Chest** 1996 Jun;109(6):1663

Reverse effects of exercise on the sinus and parasystolic cycle lengths. Kinoshita S, et al. **J Electrocardiol** 1996 Apr; 29(2):131–7

PARATHION

ANALYSIS

Gas chromatographic determination of parathion and paraoxon in fish plasma and tissues. Abbas R, et al. **J Anal Toxicol** 1996 May-Jun;20(3):151–4

METABOLISM

A kinetic analysis of hepatic microsomal activation of parathion and chlorpyrifos in control and phenobarbital-treated rats. Ma T, et al. **J Biochem Toxicol** 1995 Apr;10(2):63–8

PHARMACOKINETICS

Toxicokinetics of parathion and paraoxon in rainbow trout after intravascular administration and water exposure. Abbas R, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):194–9

Relationship between parathion and paraoxon toxicokinetics, lung metabolic activity, and cholinesterase inhibition in guinea pig and rabbit lungs. Lessire F, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):201–10

TOXICITY

Interaction of ethanol and the organophosphorus insecticide parathion. O'Shaughnessy JA, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1925–32

Use of urinary p-nitrophenol as an index of exposure to parathion. Denga N, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):296–302

Relationship between parathion and paraoxon toxicokinetics, lung metabolic activity, and cholinesterase inhibition in guinea pig and rabbit lungs. Lessire F, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):201–10

PARATHION METHYL see METHYL PARATHION

PARATHYROID DISEASES

Mediastinal parathyroid cysts. Downey RJ, et al. **Mayo Clin Proc** 1995 Oct;70(10):946–50

COMPLICATIONS

Hypercalcemia associated with a parathyroid cyst. Cooper KJ, et al. **Ulster Med J** 1994 Oct;63(2):246–7

DIAGNOSIS

Prospective comparison of dual-phase technetium-99m-sestamibi scintigraphy and high resolution ultrasonography in the evaluation of abnormal parathyroid glands. Light VL, et al. **Am Surg** 1996 Jul;62(7):562–7; discussion 567–8

Parathyroid and thyroid imaging. Yousem DM. **Neuroimaging Clin N Am** 1996 May;6(2):435–59 (96 ref.)

Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353–65 (68 ref.)

Comparison of preoperative imaging techniques (thallium technetium scan and ultrasonography) and intraoperative staining (with methylene blue) in localizing the parathyroid glands. Müslümanoğlu M, et al. **Radiol Med (Torino)** 1995 Oct;90(4):444–7

Thyroid and parathyroid imaging. Hopkins CR, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):279–95 (76 ref.)

PATHOLOGY

Fine needle aspiration of an unsuspected parathyroid cyst. Patel KD, et al. **J Assoc Physicians India** 1995 Nov; 43(11):791

Spontaneous remission of primary hyperparathyroidism from parathyroid apoplexy. Nylen E, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1326–8

Ultrastructure of human parathyroid cells in health and disease. Cinti S, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):164–79

Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353–65 (68 ref.)

PHYSIOPATHOLOGY

The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Drüeke TB. **Kidney Int** 1995 Jul;48(1):259–72 (119 ref.)

RADIONUCLIDE IMAGING

Comparison among sonography, double-tracer subtraction scintigraphy, and double-phase scintigraphy in the detection of parathyroid lesions. Mazzeo S, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1465–70

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)

SURGERY

Issues in the surgical management of parathyroid disorders [clinical conference] Gillman GS, et al. **J Otolaryngol** 1996 Feb;25(1):59–62

Operative experience of U.S. general surgery residents in thyroid and parathyroid disease. Harness JK, et al. **Surgery** 1995 Dec;118(6):1063–9; discussion 1069–70

THERAPY

Management of a functioning mediastinal parathyroid cyst. Spitz AF. **J Clin Endocrinol Metab** 1995 Oct;80(10):2866–8

ULTRASONOGRAPHY

Comparison among sonography, double-tracer subtraction scintigraphy, and double-phase scintigraphy in the detection of parathyroid lesions. Mazzeo S, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1465–70

PARATHYROID GLANDS

see related

PARATHYROIDECTOMY

A history of the parathyroid glands. Eknoyan G. **Am J Kidney Dis** 1995 Nov;26(5):801–7

High cervical intravagal hypercellular parathyroid gland as the etiology of severe persistent primary hyperparathyroidism. Buell JF, et al. **Am Surg** 1995 Nov; 61(11):943–6

Technetium-99m-methoxyisobutylisonitrile in localization of ectopic parathyroid adenoma. Bernà L, et al. **J Nucl Med** 1996 Apr;37(4):631–3

Localization of an ectopic parathyroid adenoma by double-phase technetium-99m-sestamibi scintigraphy. Caravalho J, et al. **J Nucl Med** 1995 Oct;36(10):1840–2

Technetium-99m-sestamibi SPECT localization of mediastinal parathyroid adenoma. Teigen EL, et al. **J Nucl Med** 1996 Sep;37(9):1535–7

Morphology of parathyroids in man and animals. Introduction. Wild P. **Microsc Res Tech** 1995 Oct 1; 32(2):77–8

Comparison of preoperative imaging techniques (thallium technetium scan and ultrasonography) and intraoperative staining (with methylene blue) in localizing the parathyroid glands. Müslümanoğlu M, et al. **Radiol Med (Torino)** 1995 Oct;90(4):444–7

The subxiphoid laparoscopic approach for resection of mediastinal parathyroid adenoma after successful localization with TC-99m-sestamibi radionuclide scan. Wei JP, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):402–6

Parathyroid cyst of the thymus. McCluggage WG, et al. **Thorax** 1995 Aug;50(8):913–4

[Excision of a parathyroid adenoma of the aorto-pulmonary window under thoracoscopy] Peix JL, et al. **Presse Med** 1996 Mar 23;25(10):494–6 (Eng. Abstr.) **(Fre)**

[Total thyroidectomy with preservation of the parathyroid glands] Bartoli A, et al. **G Chir** 1996 Jan-Feb;17(1–2):49–54 (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Undescended superior parathyroid gland: a potential cause

of failed cervical exploration for hyperparathyroidism. Simeone DM, et al. **Surgery** 1995 Dec;118(6):949–56

ANATOMY & HISTOLOGY

The glandulae parathyroideae of Ivar Sandström. Contributions from two continents. Carney JA. **Am J Surg Pathol** 1996 Sep;20(9):1123–44

[Surgical anatomy of the parathyroid glands. Apropos of 200 cases. Practical implications] Gillot JC, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):91–7 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Blood vascular bed and pericapillary space in rat parathyroid glands. Murakami T, et al. **Microsc Res Tech** 1995 Oct 1;32(2):112–9

Blood supply and parathyroid hormone secretion in pathological parathyroid glands. Ander S, et al. **World J Surg** 1996 Jun;20(5):598–601; discussion 602

CHEMISTRY

Accessory carotid body within the parathyroid gland III of the chicken. Yamatsu Y, et al. **Histochem Cell Biol** 1995 Mar;103(3):197–204

CYTOLOGY

Accessory carotid body within the parathyroid gland III of the chicken. Yamatsu Y, et al. **Histochem Cell Biol** 1995 Mar;103(3):197–204

A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Brown EM, et al. **Kidney Int** 1996 Apr;49(4):1042–6 (37 ref.)

Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79–90 (113 ref.)

Morphology and physiological significance of parathyroid glands in reptilia. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):91–103 (80 ref.)

Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129–47 (172 ref.)

Mammalian parathyroids: morphological and functional implications. Wild P, et al. **Microsc Res Tech** 1995 Oct 1;32(2):120–8 (57 ref.)

[Role of the hypophysis, hormonal growth inducers and physical exercises in the regulation of function of thyrocytes, C-cells and parathyrocytes in rats during simulated weightlessness] Kaplanskiĭ AS, et al. **Aviakosm Ekolog Med** 1995;29(4):47–52 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Regulation of Ca(2+)-conducting currents in parathyroid cells by extracellular Ca(2+) and channel blockers. Chang W, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E864–77

Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells. McHenry CR, et al. **Am J Surg** 1995 Nov;170(5):484–7

Involvement of polyamines in the proliferation of bovine parathyroid cells. Imanishi Y, et al. **Miner Electrolyte Metab** 1995;21(1–3):197–200

Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism. Lai YH, et al. **Nephron** 1995;70(2):223–8

Ultrastructural changes in water-clear cells of the golden hamster parathyroid gland after streptozotocin treatment. Emura S, et al. **Okajimas Folia Anat Jpn** 1996 May; 73(1):7–13

ENZYMOLOGY

Calcium-activated proteases in the bovine parathyroid gland: potential role in degradation of parathyroid hormone to peptide fragments. Waton PH, et al. **J Mol Endocrinol** 1995 Aug;15(1):61–71

IMMUNOLOGY

Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism [see comments] Lü Y, et al. **J Clin Invest** 1996 Feb 15;97(4):910–4. Comment in: J Clin Invest 1996 Feb 15;97(4):899–90.

Expression and function of a CD3-like molecule on normal and abnormal human parathyroid cells. Hellman P, et al. **Surgery** 1995 Dec;118(6):1055–61; discussion 1062

INNERVATION

Peptide-containing nerve fibres in normal human parathyroid glands and in human parathyroid adenomas. Luts L, et al. **Eur J Endocrinol** 1995 Nov;133(5):543–51

METABOLISM

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Rossi E, et al. **Am J Hypertens** 1995 Sep;8(9):884–93

Regulation of Ca(2+)-conducting currents in parathyroid cells by extracellular Ca(2+) and channel blockers. Chang W, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E864–77

Ca(2+)-induced Ca2+ oscillations in parathyroid cells. Ridefelt P, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):903–9

Cloning and functional characterization of extracellular Ca(2+)-sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S–11S (30 ref.)

Calcium-free hemodialysis is useful for evaluating parathyroid function and bone disease in chronic hemodialysis patients. Ohira S, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S48–50

Relationship among cellular diacylglycerol, sphingosine formation, protein kinase C activity, and parathyroid hormone secretion from dispersed bovine parathyroid cells. McKay C, et al. **Endocrinology** 1996 Jun;137(6):2473–9

Defects of the respiratory chain in oxyphil and chief cells of the normal parathyroid and in hyperfunction. Müller-Höcker J, et al. **Hum Pathol** 1996 Jun;27(6):532–41

Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Kifor O, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1598–606

Effect of parathyroid hormone and calcitonin on cholinergic markers in rat parathyroid gland. Stern JE, et al. **J Neuroendocrinol** 1995 Sep;7(9):689–93

PATHOLOGY

Preoperative MR imaging in hyperparathyroidism: results and factors affecting parathyroid detection. McDermott VG, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):705–10

Inactivation of retinoblastoma gene in malignant parathyroid growths: a candidate genetic trigger? Subramaniam P, et al. **Aust N Z J Surg** 1995 Oct;65(10):714–6

Functional parathyroid cyst and hypocalciuric hypercalcemia. Lydiatt DD, et al. **Ear Nose Throat J** 1995 Oct;74(10):713–6

Defects of the respiratory chain in oxyphil and chief cells of the normal parathyroid and in hyperfunction. Müller-Höcker J, et al. **Hum Pathol** 1996 Jun;27(6):532–41

Postmortem findings in congenital generalized lipodystrophy. Chandalia M, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3077–81

Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Kifor O, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1598–606

Spontaneous remission of primary hyperparathyroidism from parathyroid apoplexy. Nylen E, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1326–8

Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. Naveh-Many T, et al. **J Clin Invest** 1995 Oct; 96(4):1786–93

MRI of mediastinal parathyroid cystic adenoma causing hyperparathyroidism. Soler R, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):166–8

MR imaging in graft-dependent recurrent hyperparathyroidism after parathyroidectomy and autotransplantation. Hergan K, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):541–4

Persistent/recurrent hyperparathyroidism: a comparison of sestamibi scintigraphy, MRI, and ultrasonography. Numerow LM, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):702–8

Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129–47 (172 ref.)

Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. Fukagawa M, et al. **Miner Electrolyte Metab** 1995;21(1–3):97–100 (22 ref.)

Growth of parathyroid gland in uremic patients on maintenance hemodialysis. Kawagishi T, et al. **Miner Electrolyte Metab** 1995;21(1–3):104–8

Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Yi H, et al. **Nephron** 1995; 70(2):242–8

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)

Quantitative analysis of stromal fat content of human parathyroid glands associated with thyroid diseases using computer image analysis. Iwasaki A, et al. **Pathol Int** 1995 Jul;45(7):483–6

DNA index and ploidy distinguish normal human parathyroids from parathyroid adenomas and primary hyperplastic parathyroids. Chryssochoos JT, et al. **Surgery** 1995 Dec;118(6):1041–9; discussion 1049–50

Persistent or recurrent hyperparathyroidism in patients with double adenomas. Tezelman S, et al. **Surgery** 1995 Dec; 118(6):1115–22; discussion 1122–4

Correct preoperative localization: does it permit a change in operative strategy for primary hyperparathyroidism? Zmora O, et al. **Surgery** 1995 Dec;118(6):932–5

[Functional changes in the structure of rat thyroid gland C-cells and parathyrocytes with extremity fracture and a deficit in the support loading] Dmitrieva NP. **Dokl Akad Nauk** 1996 Mar;347(2):268–70 **(Rus)**

PHYSIOLOGY

Histophysiological evidence for parathyroid mediation of estrogen- and prolactin-induced hypercalcemia in the toad Bufo melanostictus (Schneider). Akbarsha MA, et al. **Acta Physiol Hung** 1995;83(2):171–9

The role of the parathyroid glands in the uremic syndrome. Ritz E, et al. **Am J Kidney Dis** 1995 Nov;26(5):808–13 (53 ref.)

The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function. Brown EM, et al. **Am J Med Sci** 1996 Sep; 312(3):99–109 (69 ref.)

Morphological study of amelogenesis in the rat lower incisor after thyro-parathyroidectomy, parathyroidectomy and thyroidectomy. Acevedo AC, et al. **Cell Tissue Res** 1996 Jan;283(1):151–7

The calcium/parathyroid hormone concept of the parathyroid glands. Lewin E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):324–33 (49 ref.)

Calcium, parathyroid function, bone and aging [editorial; comment] Heaney RP. **J Clin Endocrinol Metab** 1996 May; 81(5):1697–8. Comment on: J Clin Endocrinol Metab 1996 May;81(5):1699–703.

Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption [see comments] McKane WR, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1699–703. Comment in: J Clin Endocrinol Metab 1996 May;81(5):1697–8.

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. Slatopolsky E, et al. **J Clin Invest** 1996 Jun 1; 97(11):2534–40

Morphology and physiological significance of parathyroid glands in reptilia. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):91–103 (80 ref.)

Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79–90 (113 ref.)

Mammalian parathyroids: morphological and functional implications. Wild P, et al. **Microsc Res Tech** 1995 Oct 1;32(2):120–8 (57 ref.)

Intradialytic calcium balances with different calcium dialysate levels. Effects on cardiovascular stability and parathyroid function. Fabrizi F, et al. **Nephron** 1996; 72(4):530–5

The non-effect of parathyroidectomy in the aquatic limbless newt (Apoda, Amphibia). Sasayama Y, et al. **Okajimas Folia Anat Jpn** 1996 Mar;72(6):329–32

[Relation between the parathyroid glands and arterial pressure: is there a parathyroid hypertensive factor?] Barlet JP, et al. **Presse Med** 1995 Nov 25;24(36):1703–6 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The relation of parathyroid function to pregnancy-induced hypertension. Wang W, et al. **Chin Med J (Engl)** 1995 Aug; 108(8):576–8

Parathyroid update: a review of 220 cases. Summers GW. **Ear Nose Throat J** 1996 Jul;75(7):434–9

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.). Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.

Parathyroid gland function and the set point for PTH release: understanding the available data [editorial; comment] Goodman WG, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):16–8. Comment on: Nephrol Dial Transplant 1996 Jan;11(1):81–2.

RADIONUCLIDE IMAGING

Prospective comparison of dual-phase technetium-99m-sestamibi scintigraphy and high resolution ultrasonography in the evaluation of abnormal parathyroid glands. Light VL, et al. **Am Surg** 1996 Jul;62(7):562–7; discussion 567–8

Utility of 99mTc-sestamibi scintigraphy as a first-line imaging procedure in the preoperative evaluation of hyperparathyroidism [see comments] Caixàs A, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):525–30. Comment in: Clin Endocrinol (Oxf) 1995 Nov;43(5):523–4.

Detection of pericardial effusion during Tc-99m MIBI parathyroid imaging in a patient with chronic renal failure. Fojaja MR, et al. **Clin Nucl Med** 1996 Jun;21(6):496–7

Tc-99m MIBI accumulation in remnant thymus: the cause of false-positive interpretation in parathyroid imaging [letter; comment] Moinuddin M. **Clin Nucl Med** 1995 Nov; 20(11):1038. Comment on: Clin Nucl Med 1995 Apr;20(4):379–80.

Parathyroid localization with technetium-99m-sestamibi: a prospective evaluation. McHenry CR, et al. **J Am Coll Surg** 1996 Jul;183(1):25–30

The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. Johnston LB, et al. **J Clin Endocrinol Metab** 1996 Jan; 81(1):346–52

Double phase parathyroid technetium-99m-MIBI

scintigraphy to identify functional autonomy in secondary hyperparathyroidism. Piga M, et al. **J Nucl Med** 1996 Apr; 37(4):565–9

Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306–9

Identification of auto–transplanted parathyroid tissue by Tc–99m methoxy isobutyl isonitrile scintigraphy. Lightowler C, et al. **Nephrol Dial Transplant** 1995; 10(8):1372–5

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)

Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)

[Preoperative scintigraphic localization of hyperfunctioning parathyroid glands] Zimmermann–Belsing T, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1827–31 (Eng. Abstr.) **(Dan)**

[MIBI–scintigraphy. A simple and reliable method for localization of pathological parathyroid glands] Buhovac S, et al. **Lakartidningen** 1996 Apr 17;93(16):1523–7 (Eng. Abstr.) **(Swe)**

SECRETION

Determination of residues in chromogranin A–(16–40) required for inhibition of parathyroid hormone secretion. Angeletti RH, et al. **Endocrinology** 1996 Jul;137(7):2918–22

Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Yi H, et al. **Nephron** 1995; 70(2):242–8

Parathyroid function after kidney allografting. Tajima A, et al. **Transplant Proc** 1996 Jun;28(3):1629–30

Blood supply and parathyroid hormone secretion in pathological parathyroid glands. Ander S, et al. **World J Surg** 1996 Jun;20(5):598–601; discussion 602

SURGERY

Sestamibi SPECT scintigraphy for detection of postoperative hyperfunctional parathyroid glands. Schurrer ME, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1471–4

Drainage after thyroid and parathyroid surgery [letter] Davis O. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):898

Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306–9

Outpatient thyroid and parathyroid surgery: a prospective study of feasibility, safety, and costs. Mowschenson PM, et al. **Surgery** 1995 Dec;118(6):1051–3; discussion 1053–4

TRANSPLANTATION

Parathyroid autotransplantation during thyroidectomy. Results of long–term follow–up. Olson JA Jr, et al. **Ann Surg** 1996 May;223(5):472–8; discussion 478–80

Recurrent secondary hyperparathyroidism. An argument for total parathyroidectomy. Skinner KA, et al. **Arch Surg** 1996 Jul;131(7):724–7

Experimental autotransplantation of the parathyroid gland. Prigouris S, et al. **Br J Surg** 1996 Mar;83(3):410–2

Imaging of transplanted parathyroid tissue in a patient with recurrent hyperparathyroidism. Kilgore EJ, et al. **Clin Nucl Med** 1996 May;21(5):383–6

MR imaging in graft–dependent recurrent hyperparathyroidism after parathyroidectomy and autotransplantation. Hergan K, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):541–4

Identification of auto–transplanted parathyroid tissue by Tc–99m methoxy isobutyl isonitrile scintigraphy. Lightowler C, et al. **Nephrol Dial Transplant** 1995; 10(8):1372–5

Functional and morphometric study of cryopreserved human parathyroid tissue transplanted into nude mice. Tanaka Y, et al. **World J Surg** 1996 Jul–Aug;20(6):692–9; discussion 698–9

[Modified cryopreservation of parathyroid gland tissue. Evaluation and comparison in an animal experiment] Walgenbach S, et al. **Langenbecks Arch Chir** 1995; 380(5):292–8 (Eng. Abstr.) **(Ger)**

[Long–term effect after total parathyroidectomy with autotransplantation for secondary hyperparathyroidism] Yamate T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):105–9 (Eng. Abstr.) **(Jpn)**

[Parathyroid transplants in dogs] Kato M, et al. **Nippon Geka Gakkai Zasshi** 1995 Nov;96(11):766–72 (Eng. Abstr.) **(Jpn)**

[Allotransplantation of the parathyroid in patients without immunosuppression] Tolilloczko T, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):10–1, 28 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Prospective comparison of dual–phase technetium–99m–sestamibi scintigraphy and high resolution ultrasonography in the evaluation of abnormal parathyroid glands. Light VL, et al. **Am Surg** 1996 Jul;62(7):562–7; discussion 567–8

ULTRASTRUCTURE

Effects of progesterone on the ultrastructure of the golden hamster parathyroid gland. Emura S, et al. **Histol Histopathol** 1995 Oct;10(4):907–11

Ultrastructure of human parathyroid cells in health and disease. Cinti S, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):164–79

The biological significance of storage granules in rat parathyroid cells. Setoguti T, et al. **Microsc Res Tech** 1995 Oct 1;32(2):148–63 (81 ref.)

Ultrastructural changes in water–clear cells of the golden hamster parathyroid gland after streptozotocin treatment. Emura S, et al. **Okajimas Folia Anat Jpn** 1996 May; 73(1):7–13

PARATHYROID HORMONE RECEPTORS see **RECEPTORS, PARATHYROID HORMONE**

PARATHYROID HORMONES

see related

HYPOPARATHYROIDISM

Parathyroid hormone–related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone–related peptide overexpression in HTLV–I–infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1–3):166–70 (36 ref.)

Role of parathyroid hormone–related protein in the proliferation of vascular smooth muscle cells. Jiang B, et al. **Miner Electrolyte Metab** 1995;21(1–3):157–60

Effects of C–terminal parathyroid hormone–related peptide on osteoblasts. Seitz PK, et al. **Miner Electrolyte Metab** 1995;21(1–3):180–3

ADVERSE EFFECTS

In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. Most W, et al. **J Bone Miner Res** 1995 Oct;10(10):1523–30

AGONISTS

Expression and characterization of a recombinant human parathyroid hormone partial agonist with antagonistic properties: Gly–hPTH(–1—>+84). Olstad OK, et al. **Peptides** 1995;16(6):1031–7

ANALYSIS

[Hyperparathyroidism (letter)] Chapuis Y. **J Chir (Paris)** 1996 May;133(3):145 **(Fre)**

ANTAGONISTS & INHIBITORS

Conformation of parathyroid hormone antagonists by CD, NMR, and molecular dynamics simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):485–95

22–Oxacalcitriol does not interfere with parathyroid hormone–induced phosphaturia or cyclic–AMP excretion. Friedlaender MM, et al. **Bone** 1995 Sep;17(3):301–6

Estrogen blocks parathyroid hormone (PTH)–stimulated osteoclast–like cell formation by selectively affecting PTH–responsive cyclic adenosine monophosphate pathway. Kaji H, et al. **Endocrinology** 1996 Jun; 137(6):2217–24

Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone–related protein in the rat. Schetz JA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1456–62

Expression and characterization of a recombinant human parathyroid hormone partial agonist with antagonistic properties: Gly–hPTH(–1—>+84). Olstad OK, et al. **Peptides** 1995;16(6):1031–7

Inhibitory effect of zinc–chelating dipeptide on parathyroid hormone–stimulated osteoclast–like cell formation in mouse marrow cultures: involvement of calcium signaling. Yamaguchi M, et al. **Peptides** 1995;16(4):629–33

BIOSYNTHESIS

Parathyroid hormone–related protein, bone metastases and hypercalcaemia of malignancy. Bundred NJ, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):354–8

Expression of parathyroid hormone–related protein in rat articular cartilage. Tsukazaki T, et al. **Calcif Tissue Int** 1995 Sep;57(3):196–200

In vitro production of parathyroid hormone–related protein by cholesteatoma and normal skin. Cheshire IM, et al. **Clin Otolaryngol** 1995 Oct;20(5):448–52

High–level production of human parathyroid hormone in Bombyx mori larvae and BmN cells using recombinant baculovirus. Mathavan S, et al. **Gene** 1995 Dec 29; 167(1–2):33–9

Undifferentiated carcinoma in the cardioesophageal junction which produces parathyroid hormone related protein. Nozu T, et al. **Intern Med** 1995 Jul;34(7):695–9

Parathyroid hormone–related peptide is expressed and rapidly inducible in human liver cell cultures that have a bile duct phenotype. Roskams T, et al. **J Hepatol** 1995 Aug;23(2):160–5

Establishment of a clonal cell line producing granulocyte colony–stimulating factor and parathyroid hormone–related protein from a lung cancer patient with leukocytosis and hypercalcemia. Asahi Y, et al. **Jpn J Cancer Res** 1996 May;87(5):451–8

Parathyroid hormone–related peptide expression in endocrine tumors. Nagataki S, et al. **Miner Electrolyte Metab** 1995; 21(1–3):148–51

Expression of parathyroid hormone–related peptide and its receptor mRNAs during fetal development of rats. Segre GV, et al. **Miner Electrolyte Metab** 1995;21(1–3):129–32

What stimuli control the activity of the parathyroid cell? [editorial] Silver J. **Nephrol Dial Transplant** 1995; 10(5):599–600

[Ectopic hormone producing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):99–102 (14 ref.) **(Jpn)**

BLOOD

Regulation of parathyroid hormone and vitamin D in essential hypertension. Young EW, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 1):957–64

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Qi Q, et al. **Am J Kidney Dis** 1995 Oct;26(4):622–31

Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Wang M, et al. **Am J Kidney Dis** 1995 Nov;26(5):836–44

Parathyroid–hormone–related peptide in hematologic malignancies. Kremer R, et al. **Am J Med** 1996 Apr; 100(4):406–11

Serum parathyroid hormone suppression by intravenous 1,25–dihydroxyvitamin D3 in patients on maintenance haemodialysis. Rassoul Z, et al. **Am J Nephrol** 1995; 15(6):507–11

Effects of altered diet on serum levels of 1,25–dihydroxyvitamin D and parathyroid hormone in X–linked hypophosphatemic (Hyp and Gy) mice. Meyer RA Jr, et al. **Bone** 1996 Jan;18(1):23–8

Metabolic effects of pamidronate in patients with metastatic bone disease. Vinholes J, et al. **Br J Cancer** 1996 May; 73(9):1089–95

Changes in vitamin–D metabolites and parathyroid hormone in plasma following cholecalciferol administration to pre– and postmenopausal women in the Netherlands in early spring and to postmenopausal women in Curaçao. Van Der Klis FR, et al. **Br J Nutr** 1996 Apr;75(4):637–46

Transient rise in intact parathyroid hormone concentration after surgery for primary hyperparathyroidism. Tisell LE, et al. **Br J Surg** 1996 May;83(5):665–9

Intact parathyroid hormone levels in renal insufficiency. Fajtova VT, et al. **Calcif Tissue Int** 1995 Nov;57(5):329–35

Rapid PTH assay by simple modification of Nichols intact PTH–Parathyroid Hormone Assay Kit [letter] Fleetwood MK, et al. **Clin Chem** 1996 Sep;42(9):1498

Calcium–free hemodialysis is useful for evaluating parathyroid function and bone disease in chronic hemodialysis patients. Ohira S, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S48–50

Calcitonin mRNA expression and plasma calciotropic hormones in fetal lambs. Collignon H, et al. **Domest Anim Endocrinol** 1996 May;13(3):269–76

Effect of lithium on serum calcium level and parathyroid function in manic–depressive patients. Komatsu M, et al. **Endocr J** 1995 Oct;42(5):691–5

Performance characteristics of different immunoassays for determination of parathyrin (1–84) in human plasma samples. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):307–13

Circulating levels of immunoreactive parathyroid hormone–related protein and intact parathyroid hormone in human fetuses and newborns. Papantoniou NE, et al. **Eur J Endocrinol** 1996 Apr;134(4):437–42

Influence of dexamethasone and 1,25–Dihydroxyvitamin D on Walker carcinosarcoma 256 growth and parathyroid hormone–related protein secretion [letter] Schilling T, et al. **Horm Metab Res** 1996 Apr;28(4):209–10

Intraoperative fall in plasma levels of intact parathyroid hormone in patients undergoing parathyroid adenomectomy. Tommasi M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):206–10

Evaluation of serum concentration of parathyroid hormone–related protein and its implication in hypercalcemia in squamous cell carcinoma of the head and neck. Rikimaru K, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):365–8

Changes in tissue calcium and phosphorus content and plasma concentrations of parathyroid hormone and calcitonin after long–term magnesium deficiency in rats. Planells E, et al. **J Am Coll Nutr** 1995 Jun;14(3):292–8

Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. Kipen E, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1088–91

Calcitriol and the parathyroid hormone–ionized calcium curve: a comparison of methodologic approaches. Ouseph R, et al. **J Am Soc Nephrol** 1996 Mar;7(3):497–505

Calcium decreases and parathyroid hormone increases in serum of periparturient mares. Martin KL, et al. **J Anim Sci** 1996 Apr;74(4):834–9

Several anesthetics, but not diethyl ether, cause marked elevation of serum parathyroid hormone concentration in rats. Schultz VL, et al. **J Bone Miner Res** 1995 Sep; 10(9):1298–302

Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH–related peptide levels. Kovacs CS, et al.

J Clin Endocrinol Metab 1995 Oct;80(10):3036–42

Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL–6 in cutaneous squamous cell carcinoma. Mori H, et al. **J Dermatol** 1996 Jul;23(7):460–2

Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. Silvennoinen J. **J Intern Med** 1996 Feb;239(2):131–7

Lateralization of parathyroid adenomas by intra–operative parathormone estimation. Taylor J, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):174–7

Intra–operative parathyroid hormone assay for simplified localization of parathyroid adenomas. Saharay M, et al. **J R Soc Med** 1996 May;89(5):261–4

The effects of calcium–regulating–hormone on BMC in patients with CRF. Lü YM, et al. **J Tongji Med Univ** 1995; 15(2):95–7

Calcium–regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism. Goodman WG, et al. **Kidney Int** 1995 Nov;48(5):1553–8

Surgically proven primary hyperparathyroidism with a suppressed intact parathyroid hormone. Glendenning P, et al. **Med J Aust** 1996 Aug 19;165(4):197–8

Effect of calcium and 1,25 dihydroxyvitamin D on the level of parathyroid hormone in patients with secondary hyperparathyroidism due to chronic renal insufficiency. Vučković S, et al. **Med Pregl** 1993;46 Suppl 1:40–2

Anomalous effects of hormone fragments on the measurement of parathyroid hormone by radioimmunoassay. Mbuyi–Kalala A, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):87–99

Hyperparathyroidism: is it really the major factor affecting glucose tolerance in uremia? Bergesio F, et al. **Miner Electrolyte Metab** 1996;22(1–3):187–91

Comparison of bone scans, parathyroid hormone levels and bone mineral densities in hemodialysis patients. Kobashi T, et al. **Miner Electrolyte Metab** 1995;21(1–3):114–9

Multiple sites of synthesis and action of parathyroid hormone–related protein. Martin TJ, et al. **Miner Electrolyte Metab** 1995;21(1–3):123–8

Effects of dietary vitamin D intake on plasma levels of parathyroid hormone and vitamin D metabolites in healthy Japanese. Takeuchi A, et al. **Miner Electrolyte Metab** 1995; 21(1–3):217–22

Long–term treatment with calcium–alpha–ketoglutarate corrects secondary hyperparathyroidism. Zimmermann E, et al. **Miner Electrolyte Metab** 1996;22(1–3):196–9

Calcium balance and intact PTH variations during haemodiafiltration. Argilés A, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2083–9

Effect of the mode of calcitriol administration on PTH–ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. Caravaca F, et al. **Nephrol Dial Transplant** 1995;10(5):665–70

Correction of chronic metabolic acidosis in haemodialysed patients by acetate–free biofiltration does not influence parathyroid function. de Précigout V, et al. **Nephrol Dial Transplant** 1995;10(6):821–4

Reduced speed of sound in tibial bone of haemodialysed patients: association with serum PTH level. Foldes AJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1318–21

Effect of oral calcium loading on intact PTH and calcitriol in idiopathic renal calcium stone formers and healthy controls. Hess B, et al. **Nephrol Dial Transplant** 1995; 10(9):1614–9

Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. Joffe P, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1912–7

Effect of calcium–channel blockers on calcium–phosphate metabolism in patients with end–stage renal disease. Lippuner K, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):70–4

Different effects of calcitriol and parathyroidectomy on the PTH–calcium curve in dialysis patients with severe hyperparathyroidism [see comments] Malberti F, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):81–7. Comment in: Nephrol Dial Transplant 1996 Jan;11(1):16–8.

Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients? Gonella M, et al. **Nephron** 1995;71(3):350–3

Calcitriol oral pulse therapy in children with renal osteodystrophy. Cano F, et al. **Pediatr Nephrol** 1995 Oct; 9(5):606–8

The influence of dialysate calcium concentration on the PTH level in children undergoing CAPD. Sieniawska M, et al. **Perit Dial Int** 1996;16 Suppl 1:S567–9

Determination of mineral, parathyroid hormone, and 6–keto–prostaglandin–F1 alpha levels in pregnant women with hypertension and pre–eclampsia. Sulaiman S, et al. **Singapore Med J** 1995 Dec;36(6):637–40

Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Bergenfelz A, et al. **Surgery** 1996 Jun;119(6):624–33

Can successful renal transplantation resolve secondary hyper–parathyroidism? Koyama Y, et al. **Transplant Proc** 1996 Jun;28(3):1644–5

Parathyroid function after kidney allografting. Tajima A, et al. **Transplant Proc** 1996 Jun;28(3):1629–30

[Seasonal variations of vitamin D and parathyroid hormone levels in adolescents during the pubertal growth phase (letter)] Guillemant J, et al. **Arch Pediatr** 1996 Apr; 3(4):396–7 **(Fre)**

[Hypercalcemia a sign of medullar transformation of low grade malignant lymphoma. Apropos of a case] Joly F, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):154–6 (Eng. Abstr.) **(Fre)**

[Intraoperative parathormone assay. The value of assessment of primary hyperparathyroidism in surgery] Denizot A, et al. **J Chir (Paris)** 1995 Aug–Sep;132(8–9):346–52 (Eng. Abstr.) **(Fre)**

[Parathyroid hormone (PTH)] Takuwa Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:393–6 (4 ref.) **(Jpn)**

[Parathyroid hormone–related protein (PTHrP)] Watanabe K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:397–400 (12 ref.) **(Jpn)**

[The effect of decreasing serum calcium in serum during hemodialysis on PTH levels in children with end stage renal disease] Sieniawska M, et al. **Pediatr Pol** 1995 Dec; 70(12):1017–22 (Eng. Abstr.) **(Pol)**

[The value of the parathyrin–related protein (PTH–RP) in the diagnosis of cancer–associated hypercalcemia] Sagarra E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):450–4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structure of recombinant human parathyroid hormone in solution using multidimensional NMR spectroscopy. Gronwald W, et al. **Biol Chem Hoppe Seyler** 1996 Mar; 377(3):175–86

Conformation of parathyroid hormone antagonists by CD, NMR, and molecular dynamics simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):485–95

Converting parathyroid hormone–related peptide (PTHrP) into a potent PTH–2 receptor agonist. Gardella TJ, et al. **J Biol Chem** 1996 Aug 16;271(33):19888–93

Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids. Oldenburg KR, et al. **J Biol Chem** 1996 Jul 19;271(29):17582–91

Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity. Nabuchi Y, et al. **Pharm Res** 1995 Dec;12(12):2049–52

DEFICIENCY

Haploinsufficiency of parathyroid hormone–related peptide (PTHrP) results in abnormal postnatal bone development. Amizuka N, et al. **Dev Biol** 1996 Apr 10;175(1):166–76

GENETICS

Two nuclear proteins bind to the promoter P3 region of the human parathyroid hormone–related peptide gene. Bui TD, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):222–5

Origin of a negative calcium response element in an ALU–repeat: implications for regulation of gene expression by extracellular calcium. McHaffie GS, et al. **Bone** 1995 Jul;17(1):11–4

Transcriptional control and the regulation of endocrine genes. Zajac JD, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):935–43 (68 ref.)

Overexpression of parathyroid hormone–related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Wysolmerski JJ, et al. **Development** 1995 Nov; 121(11):3539–47

Sequence analysis of hypothalamic parathyroid hormone messenger ribonucleic acid. Nutley MT, et al. **Endocrinology** 1995 Dec;136(12):5600–7

Patterns of DNA methylation of the parathyroid hormone–related protein gene in human lung carcinoma. Ganderton RH, et al. **Eur J Cancer** 1995 Sep; 31A(10):1697–700

IMMUNOLOGY

Immunochemiluminometric assay with two monoclonal antibodies against the N–terminal sequence of human parathyroid hormone. Gao P, et al. **Clin Chim Acta** 1996 Feb 9;245(1):39–59

METABOLISM

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García–Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

Effects of a gonadotropin–releasing hormone agonist on the calcium–parathyroid axis and bone turnover in women with endometriosis. Newhall–Perry K, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):824–9

Parathyroid hormone–related protein expression in the human colon: immunohistochemical evaluation. Malakouti S, et al. **Am Surg** 1996 Jul;62(7):540–4; discussion 544–5

Function and metabolism of brain synaptosomes in chronic renal failure. Smogorzewski M, et al. **Artif Organs** 1995 Aug;19(8):795–800 (55 ref.)

Functional properties of the PTH/PTHrP receptor. Jüppner H. **Bone** 1995 Aug;17(2 Suppl):39S–42S (20 ref.)

Inositol 1–,4–,5–trisphosphate–dependent Ca2+ signaling by the recombinant human PTH/PTHrP receptor stably expressed in a human kidney cell line. Pines M, et al. **Bone** 1996 Apr;18(4):381–9

Cooperative interactions between extracellular matrix, integrins and parathyroid hormone–related peptide regulate parietal endoderm differentiation in mouse embryos. Behrendtsen O, et al. **Development** 1995 Dec; 121(12):4137–48

Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl–terminal region of PTH–(1–84) [see comments] Inomata N, et al. **Endocrinology** 1995 Nov;136(11):4732–40. Comment in: Endocrinology 1995 Nov;136(11):4729–31.

Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST–PTP, in rat osteoblast–like cells. Mauro LJ, et al. **Endocrinology** 1996 Mar;137(3):925–33

The carboxy–terminus of parathyroid hormone––inert or invaluable? [editorial; comment] Orloff JJ, et al. **Endocrinology** 1995 Nov;136(11):4729–31 (20 ref.). Comment on: Endocrinology 1995 Nov;136(11):4732–40.

Immunochemical detection of parathyroid hormone–related protein in the saccus vasculosus of a teleost fish. Devlin AJ, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):83–90

Immunohistochemical detection of parathyroid hormone–related protein in a rare variant of hepatic neoplasm (sclerosing hepatic carcinoma). Albar JP, et al. **Hum Pathol** 1996 Jul;27(7):728–31

Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks. Vander Molen MA, et al. **J Biol Chem** 1996 May 24; 271(21):12165–71

Intact parathyroid hormone levels are not elevated in glucocorticoid–treated subjects. Paz–Pacheco E, et al. **J Bone Miner Res** 1995 Nov;10(11):1713–8

The effects of menopause and age on calcitropic hormones: a cross–sectional study of 655 healthy women aged 35 to 90. Prince RL, et al. **J Bone Miner Res** 1995 Jun; 10(6):835–42

Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation–dependent gene expression of parathyroid hormone (PTH)/PTH–related peptide receptor. Shukunami C, et al. **J Cell Biol** 1996 Apr; 133(2):457–68

Calcium–activated proteases in the bovine parathyroid gland: potential role in degradation of parathyroid hormone to peptide fragments. Waton PH, et al. **J Mol Endocrinol** 1995 Aug;15(1):61–71

Prostate specific antigen cleaves parathyroid hormone–related protein in the PTH–like domain: inactivation of PTHrP–stimulated cAMP accumulation in mouse osteoblasts. Cramer SD, et al. **J Urol** 1996 Aug;156(2 Pt 1):526–31

Approaches to studying the biomolecular interaction between the parathyroid hormone/parathyroid hormone–related protein receptor and its ligands. Chorev M, et al. **Miner Electrolyte Metab** 1995;21(1–3):133–9 (51 ref.)

Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1–3):87–90 (25 ref.)

Homolog–scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH–(1–34) binding determinants in the third extracellular loop. Lee C, et al. **Mol Endocrinol** 1995 Oct;9(10):1269–78

PHARMACOKINETICS

Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone–related protein in the rat. Schetz JA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1456–62

PHARMACOLOGY

Parathyroid hormone stimulates the generation of inositol 1,4,5–triphosphate in brain synaptosomes. Smogorzewski M, et al. **Am J Kidney Dis** 1995 Nov;26(5):814–7

Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70

P2 purinoceptor stimulation attenuates PTH inhibition of phosphate uptake by a G protein–dependent mechanism. Lederer ED, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F309–16

The effects of high dose of parathyroid hormone on fetal osteoclasts and their precursors in vivo: an ultrastructural–cytochemical study. Isaki H, et al. **Anat Rec** 1995 Dec;243(4):421–9

Protamine and acute depletion of magnesium limit bone response to parathyroid hormone. Ragosta KG, et al. **Anesth Analg** 1996 Jan;82(1):29–32

Pretreatment with 17 beta–estradiol attenuates basal– and PTH–stimulated membrane adenylyl cyclase activity in human osteoblast–like SAOS–2 cells. Monroe JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):320–5

Cathepsin B activity in normal human osteoblast–like cells and human osteoblastic osteosarcoma cells (MG–63): regulation by interleukin–1 beta and parathyroid hormone. Aisa MC, et al. **Biochim Biophys Acta** 1996 May 21; 1290(1):29–36

Effects of estrogen and parathyroid hormone on osteoblastic activity via regulating the binding activity of insulin–like growth factor binding protein–4 in SaOS–2 cells: implications for the pathogenesis of postmenopausal osteoporosis. Kudo Y, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):402–6

Evidence for coordinated regulation of osteoblast function by 1,25–dihydroxyvitamin D3 and parathyroid hormone.

van Leeuwen JP, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):54–62

Parathyroid hormone–activated phosphoinositide degradation and calcium channels in human dermal fibroblasts. Pun KK, et al. **Biol Signals** 1995 Jan–Feb; 4(1):19–23

Tomographic (pQCT) and biomechanical effects of hPTH(1–38) on chronically immobilized or overloaded rat femurs. Capozza R, et al. **Bone** 1995 Oct;17(4 Suppl):233S–239S

An in vivo model for the rapid assessment of the local effects of parathyroid hormone on bone histomorphometry. Cornish J, et al. **Bone** 1995 Oct;17(4 Suppl):249S–254S

The (18–48)–fragment of human parathyroid hormone is a partial agonist for cAMP–dependent actions with retained mitogenic function. Duvos C, et al. **Bone** 1995 Oct; 17(4):403–6

22–Oxacalcitriol does not interfere with parathyroid hormone–induced phosphaturia or cyclic–AMP excretion. Friedlaender MM, et al. **Bone** 1995 Sep;17(3):301–6

Assessing bone quantity by pQCT. Gasser JA. **Bone** 1995 Oct;17(4 Suppl):145S–154S

An in–vivo model for the rapid assessment of skeletal effects of anabolic agents. Li XJ, et al. **Bone** 1995 Oct;17(4 Suppl):243S–247S

The ferret as a small animal model with BMU–based remodeling for skeletal research. Mackey MS, et al. **Bone** 1995 Oct;17(4 Suppl):191S–196S

In vivo, human parathyroid hormone fragment (hPTH 1–34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Onyia JE, et al. **Bone** 1995 Nov;17(5):479–84

Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Sabatini M, et al. **Bone** 1996 Jan;18(1):59–65

Discrepancy of response of hPTH administration and its withdrawal between trabecular and cortical bone sites in OVX rats. Yamamoto N, et al. **Bone** 1995 Oct;17(4 Suppl):279S–283S

Retinoids modulate the effect of PTH and calcitriol on EGF receptor expression in UMR 106–01 cells. González EA, et al. **Calcif Tissue Int** 1996 Jun;58(6):429–34

Parathyroid hormone decreases in vivo insulin effect on glucose utilization. Saxe AW, et al. **Calcif Tissue Int** 1995 Aug;57(2):127–32

Down–regulation and differential restoration of cAMP responses upon transient phorbol ester treatment of primary osteoblastic cells. Bos MP, et al. **Cell Signal** 1995 Aug; 7(6):617–26

The human PTH2 receptor: binding and signal transduction properties of the stably expressed recombinant receptor. Behar V, et al. **Endocrinology** 1996 Jul;137(7):2748–57

Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. Friedman PA, et al. **Endocrinology** 1996 Jan;137(1):13–20

Estrogen blocks parathyroid hormone (PTH)–stimulated osteoclast–like cell formation by selectively affecting PTH–responsive cyclic adenosine monophosphate pathway. Kaji H, et al. **Endocrinology** 1996 Jun; 137(6):2217–24

Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Schmidt IU, et al. **Endocrinology** 1995 Nov;136(11):5127–34

Effects of parathyroid hormone related peptide (1–34) and 1,25–dihydroxyvitamin D on bone alkaline phosphatase activity in fetal rat calvaria cultures. Municio MJ, et al. **Horm Metab Res** 1995 Jun;27(6):296–9

Endogenous nitric oxide is not involved in acute parathyroid hormone–induced hypotension in rat: effect of hypertension and hypoparathyroid status. Schleiffer R, et al. **Horm Metab Res** 1995 Sep;27(9):415–8

Parathyroid hormone and parathyroid hormone–related peptide activate the Na+/H+ exchanger NHE–1 isoform in osteoblastic cells (UMR–106) via a cAMP–dependent pathway. Azarani A, et al. **J Biol Chem** 1995 Sep 29; 270(39):23166–72

Structurally diverse N–terminal peptides of parathyroid hormone (PTH) and PTH–related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. Azarani A, et al. **J Biol Chem** 1996 Jun 21;271(25):14931–6

Stimulation by parathyroid hormone of interleukin–6 and leukemia inhibitory factor expression in osteoblasts is an immediate–early gene response induced by cAMP signal transduction. Greenfield EM, et al. **J Biol Chem** 1996 May 3;271(18):10984–9

Domain–specific gene activation by parathyroid hormone in osteoblastic ROS17/2.8 cells. Hollnagel A, et al. **J Biol Chem** 1996 Sep 6;271(36):21870–7

Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids. Oldenburg KR, et al. **J Biol Chem** 1996 Jul 19;271(29):17582–91

Parathyroid hormone–related protein antagonizes the action of parathyroid hormone on adult cardiomyocytes. Schlüter KD, et al. **J Biol Chem** 1996 Feb 9;271(6):3074–8

A putative selectivity filter in the G–protein–coupled receptors for parathyroid hormone and secretion. Turner PR, et al. **J Biol Chem** 1996 Apr 19;271(16):9205–8

Cell–to–cell communication in osteoblastic networks: cell line–dependent hormonal regulation of gap junction function. Donahue HJ, et al. **J Bone Miner Res** 1995 Jun; 10(6):881–9

Parathyroid hormone–related protein is an autocrine modulator of rabbit proximal tubule cell growth. García–Ocaña A, et al. **J Bone Miner Res** 1995 Dec; 10(12):1875–84

A comparison of the effects of parathyroid hormone and parathyroid hormone–related protein on osteocalcin in the rat. Gundberg CM, et al. **J Bone Miner Res** 1995 Jun; 10(6):903–9

EndothelinB receptor activation enhances parathyroid hormone–induced calcium signals in UMR–106 cells. Lee SK, et al. **J Bone Miner Res** 1995 Sep;10(9):1343–51

Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1–38) in right hindlimb immobilized rats. Ma Y, et al. **J Bone Miner Res** 1995 Nov; 10(11):1726–34

A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. Qi H, et al. **J Bone Miner Res** 1995 Jun;10(6):948–55

Intact insulin–like growth factor binding protein–5 (IGFBP–5) associates with bone matrix and the soluble fragments of IGFBP–5 accumulated in culture medium of neonatal mouse calvariae by parathyroid hormone and prostaglandin E2–treatment. Hakeda Y, et al. **J Cell Physiol** 1996 Feb;166(2):370–9

Parathyroid hormone (PTH)–related protein(1–36) is equipotent to PTH(1–34) in humans. Everhart–Caye M, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):199–208

In vivo parathyroid hormone stimulates in vitro bone resorption by bovine monocytes. Hustmyer FG, et al. **J Dairy Sci** 1995 Dec;78(12):2700–8

Parathyroid hormone induces superoxide anion burst in the osteoclast: evidence for the direct instantaneous activation of the osteoclast by the hormone. Datta HK, et al. **J Endocrinol** 1996 May;149(2):269–75

Role of dopamine in the exaggerated phosphaturic response to parathyroid hormone in the remnant kidney. Isaac J, et al. **J Lab Clin Med** 1995 Nov;126(5):470–3

Effect of parathyroid hormone and calcitonin on cholinergic markers in rat parathyroid gland. Stern JE, et al. **J Neuroendocrinol** 1995 Sep;7(9):689–93

Regulation of chondrocyte maturation by fibroblast growth factor–2 and parathyroid hormone. Iwamoto M, et al. **J Orthop Res** 1995 Nov;13(6):838–45

Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Tallon S, et al. **Kidney Int** 1996 May;49(5):1441–6

Parathyroid hormone induces a rapid increase in the number of active osteoclasts by releasing histamine from mast cells. Nakamura M, et al. **Life Sci** 1996;58(21):1861–8

Growth hormone does not enhance the anabolic effect of human parathyroid hormone (1–34) on bone in aging multiparous and virgin rats. Hock JM, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):183–97

Parathyroid hormone and B cell function in dialysis patients and experimental chronic renal failure. Alexiewicz J, et al. **Miner Electrolyte Metab** 1995;21(1–3):45–9

Activation of the Ca2+ message system by parathyroid hormone is dependent on the cell cycle. Avioli LV, et al. **Miner Electrolyte Metab** 1995;21(1–3):29–34

Parathyroid hormone induces sequential c–fos expression in bone cells in vivo: a model for intercellular communication in bone. Lee K, et al. **Miner Electrolyte Metab** 1995; 21(1–3):120–2

The mechanisms responsible for the PTH–induced rise in cytosolic calcium in various cells are not uniform. Massry SG, et al. **Miner Electrolyte Metab** 1995;21(1–3):13–28 (75 ref.)

PTH–mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al. **Miner Electrolyte Metab** 1995;21(1–3):184–8 (20 ref.)

Effects of parathyroid hormone on renal tubular proteinases. Schaefer L, et al. **Miner Electrolyte Metab** 1996; 22(1–3):182–6

Signal transduction mechanisms of parathyroid hormone– and parathyroid hormone–related–peptide–stimulated osteoclast–like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)

A Ca2+ channel in renal epithelial cells introduced by parathyroid hormone. Suzuki M, et al. **Miner Electrolyte Metab** 1995;21(1–3):35–9

Impaired response of human osteosarcoma (MG–63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Yoshida O, et al. **Miner Electrolyte Metab** 1995;21(1–3):201–4

Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud I, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1292–8

Effect of parathyroid hormone on rat skeletal muscle in vivo. Thompson CH, et al. **Nephron** 1996;72(2):253–6

Positive interaction between 17 beta–Estradiol and parathyroid hormone in normal human osteoblasts cultured long term in the presence of dexamethasone. Rao LG, et al. **Osteoporos Int** 1996;6(2):111–9

Multiple calcium channel transcripts in rat osteosarcoma cells: selective activation of alpha 1D isoform by parathyroid hormone. Barry EL, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10914–8

Vascular actions of the calcium–regulating hormones. Bukoski RD, et al. **Semin Nephrol** 1995 Nov;15(6):536–49 (154 ref.)

[Effect of h–PTH on bone and bone marrow tissue in experimental osteopenia in rat] Ishigaki S. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct;69(10):992–1003 (Eng. Abstr.) **(Jpn)**

[Effect of intermittent administration of human PTH on experimental osteopenia in adult rat: a histomorphometric study of both trabecular and cortical bone of the vertebrae] Narita Y. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct; 69(10):1027–36 (Eng. Abstr.) **(Jpn)**

[Effect of human PTH on steroid–induced osteopenia: a histomorphometric study of decalcified and undecalcified trabecular bone sections in rat] Unoki E. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct;69(10):1064–75 (Eng. Abstr.) **(Jpn)**

[The effect of calcium–regulating hormones on the renal transport of calcium in hypertension] Bobrov VA, et al. **Ter Arkh** 1995;67(9):42–5 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The role of the parathyroid glands in the uremic syndrome. Ritz E, et al. **Am J Kidney Dis** 1995 Nov;26(5):808–13 (53 ref.)

Proceedings of the XII International Conference on Calcium Regulating Hormones. Melbourne, Australia, February 14–19, 1995. **Bone** 1995 Aug;17(2 Suppl):1S–111S

The food–induced stimulation of bone resorption in the rat, assessed by the urinary [3H]–tetracycline excretion, is mediated by parathyroid hormone. Mühlbauer RC, et al. **Bone** 1995 Oct;17(4 Suppl):449S–453S

Effects of thyro–parathyroidectomy and parathyroidectomy upon dentinogenesis: Part II: Electron microscopy. Acevedo AC, et al. **Connect Tissue Res** 1995;32(1–4):269–74

Effects of thyro–parathyroidectomy and parathyroidectomy upon dentinogenesis: Part I: Light microscopy. Chardin H, et al. **Connect Tissue Res** 1995;32(1–4):261–7

The calcium/parathyroid hormone concept of the parathyroid glands. Lewin E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):324–33 (49 ref.)

C–terminal fragment of parathyroid hormone–related protein, PTHrP–(107–111), stimulates membrane–associated protein kinase C activity and modulates the proliferation of human and murine skin keratinocytes. Whitfield JF, et al. **J Cell Physiol** 1996 Jan; 166(1):1–11

Role of parathyroid hormone in mediating nocturnal and age–related increases in bone resorption. Ledger GA, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3304–10

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. Klin M, et al. **J Clin Invest** 1996 May 15;97(10):2167–73

Activation of maxi–K channels by parathyroid hormone and prostaglandin E2 in human osteoblast bone cells. Moreau R, et al. **J Membr Biol** 1996 Mar;150(2):175–84

Elevated parathyroid hormone–related peptide associated with lactation and bone density loss. Sowers MF, et al. **JAMA** 1996 Aug 21;276(7):549–54

Potential role of IGF–1 in parathyroid hormone–related renal growth induced by high protein diet in uninephrectomized rats. Caverzasio J, et al. **Kidney Int** 1995 Jul;48(1):33–8

Regulation of rat renal Na/Pi–cotransporter by parathyroid hormone: immunohistochemistry [comment] Lötscher M, et al. **Kidney Int** 1996 Apr;49(4):1010–1. Comment on: Kidney Int 1996 Apr;49(4):1005–9.

Regulation of gonadotropins and parathyroid hormone by nitric oxide. Kaiser FE, et al. **Life Sci** 1996;59(12):987–92

Proceedings of the 3rd International Conference on New Actions of Parathyroid Hormone. Kyoto, Japan, April 18–24, 1994. **Miner Electrolyte Metab** 1995;21(1–3):1–241

Relation between parathyroid hormone and cardiac function in long–term hemodialysis patients. Hara S, et al. **Miner Electrolyte Metab** 1995;21(1–3):72–6

Parathyroid hormone and hypothalamo–pituitary function. Harvey S, et al. **Miner Electrolyte Metab** 1995;21(1–3):40–4 (35 ref.)

New actions of parathyroid hormone. Introduction. Morii H, et al. **Miner Electrolyte Metab** 1995;21(1–3):7–8

Effect of parathyroid hormone on left ventricular diastolic function in patients with primary hyperparathyroidism. Ohara N, et al. **Miner Electrolyte Metab** 1995;21(1–3):63–6

Non–traditional actions of parathyroid hormone: an overview. Potts JT Jr. **Miner Electrolyte Metab** 1995; 21(1–3):9–12 (12 ref.)

Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, et al. **Miner Electrolyte Metab** 1995;21(1–3):91–6 (35 ref.)

PTH, chronic renal failure and myocardium. Smogorzewski M. **Miner Electrolyte Metab** 1995;21(1–3):55–62

Implication of parathyroid hormone for the development of hypertension in young spontaneously hypertensive rats. Uchimoto S, et al. **Miner Electrolyte Metab** 1995; 21(1–3):82–6

Actions of parathyroid hormone–related peptide and its receptors [editorial; comment] Martin TJ. **N Engl J Med** 1996 Sep 5;335(10):736–8. Comment on: N Engl J Med 1996 Sep 5;335(10):708–14.

Blood–pressure–independent wall thickening of

intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Amann K, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2043–8

Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? [letter; comment] Basile C, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1942–3. Comment on: Nephrol Dial Transplant 1994;9(11):1580–5. Comment on: Nephrol Dial Transplant 1994;9(11):1586–9.

Defining the roles of parathyroid hormone–related protein in normal physiology. Philbrick WM, et al. **Physiol Rev** 1996 Jan;76(1):127–73 (293 ref.)

Parathyroid hormone–related protein. An analog of parathyroid hormone involved in regulation of growth, development, and gestation [editorial] Rizzoli R. **Rev Rhum Engl Ed** 1996 Feb;63(2):79–82 (40 ref.)

[Endocrinology update—I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24–32 (112 ref.) **(Ger)**

[Characteristics of the effect of parathyroid hormone on rat myocardial relaxation] Barabanova TA, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):410–3 **(Rus)**

[The role of parathyroid hormone in regulating the contractile activity of the portal vein in normo– and hypertensive rats of different ages] Petrova NB, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):134–42 (Eng. Abstr.) **(Rus)**

[Nifedipine reduces the increase of free intracellular calcium in primary hyperparathyroidism: role of calcium channels and PTH] Fardella C, et al. **Rev Med Chil** 1995 Mar; 123(3):277–82 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[The effect of radon baths at the Khmel'nik health resort on the central hemodynamic indices and calcium–regulating hormones in patients with essential hypertension] Korchinskii VS. **Lik Sprava** 1995 May–Jun; (5–6):84–7 (Eng. Abstr.) **(Rus)**

SECRETION

A new analog of calcitriol, 19–nor–1,25–(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Slatopolsky E, et al. **Am J Kidney Dis** 1995 Nov;26(5):852–60

Determination of residues in chromogranin A–(16–40) required for inhibition of parathyroid hormone secretion. Angeletti RH, et al. **Endocrinology** 1996 Jul;137(7):2918–22

Relationship among cellular diacylglycerol, sphingosine formation, protein kinase C activity, and parathyroid hormone secretion from dispersed bovine parathyroid cells. McKay C, et al. **Endocrinology** 1996 Jun;137(6):2473–9

In vitro parathyroid hormone release in patients with secondary hyperparathyroidism. Yano S, et al. **Int J Urol** 1996 Mar;3(2):128–33

Magnesium deficiency and parathyroid function [editorial; comment] Matsumoto T. **Intern Med** 1995 Jul;34(7):603–4 . Comment on: Intern Med 1995 Jul;34(7):666–9.

Renal refractoriness to phosphaturic action of parathyroid hormone in a patient with hypomagnesemia [see comments] Mihara M, et al. **Intern Med** 1995 Jul;34(7):666–9. Comment in: Intern Med 1995 Jul;34(7):603–4.

Differences in the dynamics of parathyroid hormone secretion in hemodialysis patients with marked secondary hyperparathyroidism. Felsenfeld AJ, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1371–8

Low–calcium dialysate stimulates parathormone secretion and its long–term use worsens secondary hyperparathyroidism. Fernández E, et al. **J Am Soc Nephrol** 1995 Jul;6(1):132–5

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. Slatopolsky E, et al. **J Clin Invest** 1996 Jun 1; 97(11):2534–40

Calcium–regulated parathyroid hormone secretion in adynamic renal osteodystrophy. Sanchez CP, et al. **Kidney Int** 1995 Sep;48(3):838–43

Intravenous calcitriol can increase bone mass in hemodialysis patients with osteitis fibrosa. Akiba T, et al. **Miner Electrolyte Metab** 1995;21(1–3):109–13

Parathyroid gland function and the set point for PTH release: understanding the available data [editorial; comment] Goodman WG, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):16–8. Comment on: Nephrol Dial Transplant 1996 Jan;11(1):81–2.

Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Yi H, et al. **Nephron** 1995; 70(2):242–8

Blood supply and parathyroid hormone secretion in pathological parathyroid glands. Ander S, et al. **World J Surg** 1996 Jun;20(5):598–601; discussion 602

THERAPEUTIC USE

Estrogen dose required to maintain parathyroid hormone mediated bone gain in osteopenic ovariectomized rats is probably higher than in preventive treatment with estrogen. Cheng PT, et al. **Bone** 1995 Oct;17(4 Suppl):329S–334S

Effect of treatment for 3 months with human parathyroid hormone 1–34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Jerome CP, et al. **Bone** 1995 Oct;17(4 Suppl):415S–420S

Effects of on/off anabolic hPTH and remodeling inhibitors on metaphyseal bone of immobilized rat femurs. Tomographical (pQCT) description and correlation with histomorphometric changes in tibial cancellous bone. Ma YF, et al. **Bone** 1995 Oct;17(4 Suppl):321S–327S

A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1–34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats. Mashiba T, et al. **Bone** 1995 Oct; 17(4 Suppl):273S–278S

Parathyroid hormone therapy accelerates recovery from immobilization–induced osteopenia. Yuan ZZ, et al. **Bone** 1995 Oct;17(4 Suppl):219S–223S

Intermittent treatment with human parathyroid hormone (hPTH[1–34]) increased trabecular bone volume but not connectivity in osteopenic rats. Lane NE, et al. **J Bone Miner Res** 1995 Oct;10(10):1470–7

Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. Shen V, et al. **J Clin Invest** 1995 Nov;96(5):2331–8

Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Winer KK, et al. **JAMA** 1996 Aug 28;276(8):631–6

A small dose of human parathyroid hormone(1–34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Sone T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):232–5

Small bone–building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382–6 (47 ref.)

[Can parathormone be used to treat osteoporosis?] Hoppe A. **Pol Tyg Lek** 1995 Nov;50(44–47):59–61 (36 ref.) **(Pol)**

PARATHYROID NEOPLASMS

BLOOD

Intra–operative parathyroid hormone assay for simplified localization of parathyroid adenomas. Saharay M, et al. **J R Soc Med** 1996 May;89(5):261–4

CHEMISTRY

Peptide–containing nerve fibres in normal human parathyroid glands and in human parathyroid adenomas. Luts L, et al. **Eur J Endocrinol** 1995 Nov;133(5):543–51

COMPLICATIONS

High cervical intravagal hypercellular parathyroid gland as the etiology of severe persistent primary hyperparathyroidism. Buell JF, et al. **Am Surg** 1995 Nov; 61(11):943–6

Multiple endocrine neoplasia type 1 presenting as rosacea. Creamer JD, et al. **Clin Exp Dermatol** 1996 Mar;21(2):170–1

Oxyphil cell carcinoma of the parathyroid: a rare cause of hyperparathyroidism. Nasser G, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):323–4

Severe acute pancreatitis as a first symptom of primary hyperparathyroid adenoma: a case report. Shimizu H, et al. **J Laryngol Otol** 1996 Jun;110(6):602–3

Primary hyperparathyroidism: an unusual cause of pancreatitis in adolescence [see comments] Nieves–Rivera F, et al. **P R Health Sci J** 1995 Sep;14(3):233–6. Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

Unusual cases of hyperparathyroidism [see comments] Vázquez–Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.). Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in a hemodialysis patient: report of a case. Tominaga Y, et al. **Surg Today** 1995;25(11):984–6

[Bone pain revealing parathyroid adenoma (letter; comment)] Beauvais P. **Arch Pediatr** 1995 Oct;2(10):1022. Comment on: Arch Pediatr 1995 Jan;2(1):89. **(Fre)**

[Primary hyperparathyroidism. Relationships of symptoms to age, sex, calcemia, anatomical lesions and weight of the glands] Mellière D, et al. **Presse Med** 1995 Dec 16–23; 24(39):1889–93 (Eng. Abstr.) **(Fre)**

[Case of primary hyperparathyroidism caused by parathyroid adenocarcinoma] Liashchuk PM. **Klin Med (Mosk)** 1995; 73(5):67 **(Rus)**

DIAGNOSIS

Depression and hypercalcemia [clinical conference] **Am J Med** 1996 Jul;101(1):111–7

Water–clear cell 'adenoma'. A new entity in the pathology of primary hyperparathyroidism [editorial; comment] Roth SI. **Arch Pathol Lab Med** 1995 Nov;119(11):996–7. Comment on: Arch Pathol Lab Med 1995 Nov;119(11):1072–4.

Ectopic parathyroid adenomas: multi–imaging modalities and its management. Moinuddin M, et al. **Clin Nucl Med** 1996 Jan;21(1):27–32

Preoperative endocrine tumor localization utilizing a cost–effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

MRI of mediastinal parathyroid cystic adenoma causing hyperparathyroidism. Soler R, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):166–8

Persistent/recurrent hyperparathyroidism: a comparison of sestamibi scintigraphy, MRI, and ultrasonography. Numerow LM, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):702–8

A woman with bone pain, fractures, and malabsorption [see comments] Bertoli A, et al. **Lancet** 1996 Feb 3; 347(8997):300. Comment in: Lancet 1996 Mar 23;347(9004):829. Comment in: Lancet 1996 Mar 23;347(9004):829–30. Comment in: Lancet 1996 Apr 13;347(9007):1050.

The diagnosis I longed to make [letter] Churcher A. **Lancet** 1995 Sep 30;346(8979):915–6

Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353–65 (68 ref.)

DNA index and ploidy distinguish normal human parathyroids from parathyroid adenomas and primary hyperplastic parathyroids. Chryssochoos JT, et al. **Surgery** 1995 Dec;118(6):1041–9; discussion 1049–50

[Comparitive study of three images examination in preoperative localization of parathyroid adenoma] Cai W. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):307–9 (Eng. Abstr.) **(Chi)**

[Favorable results of minimally invasive surgery in the treatment of primary hyperparathyroidism] van Vroonhoven TJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):304–8 (Eng. Abstr.) **(Dut)**

[Parathyroid adenoma as an ectopic carotid mass. Apropos of a case] Suc B, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):190–3 (Eng. Abstr.) **(Fre)**

[Preoperative imaging in the detection of parathyroid tumefaction in patients with primary hyperparathyroidism. The authors' own experience] Mazzeo S, et al. **Radiol Med (Torino)** 1995 Dec;90(6):747–55 (Eng. Abstr.) **(Ita)**

[The imaging diagnosis of primary hyperparathyroidism due to parathyroid adenocarcinoma. A case report] Prato N, et al. **Radiol Med (Torino)** 1995 Sep;90(3):323–6 (11 ref.) **(Ita)**

[An isolated parathyroid adenoma] Garlicka A, et al. **Pediatr Pol** 1995 Nov;70(11):965–71 (Eng. Abstr.) **(Pol)**

GENETICS

Absence of RET proto–oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland [see comments] Padberg BC, et al. **Am J Pathol** 1995 Dec; 147(6):1600–7. Comment in: Am J Pathol 1995 Dec;147(6):1539–44.

Inactivation of retinoblastoma gene in malignant parathyroid growths: a candidate genetic trigger? Subramaniam P, et al. **Aust N Z J Surg** 1995 Oct;65(10):714–6

Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Tahara H, et al. **Cancer Res** 1996 Feb 1;56(3):599–605

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.). Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.

Obvious mRNA and protein expression but absence of mutations of the RET proto–oncogene in parathyroid tumors [see comments] Kimura T, et al. **Eur J Endocrinol** 1996 Mar;134(3):314–9. Comment in: Eur J Endocrinol 1996 Mar;134(3):263–6.

Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? Dotzenrath C, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3194–6

Mutational analysis of the extracellular Ca(2+)–sensing receptor gene in human parathyroid tumors. Hosokawa Y, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3107–10

Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. Hsi ED, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1736–9

Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus [see comments] Thompson DB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3377–80. Comment in: J Clin Endocrinol Metab 1995 Nov;80(11):3105–6.

The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

METABOLISM

Primary hyperparathyroidism masked by antituberculous therapy–induced vitamin D deficiency [letter; comment] Hutchesson AJ. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):511–3 . Comment on: Clin Endocrinol (Oxf) 1994 Dec;41(6):831–6; discussion 837–8.

Obvious mRNA and protein expression but absence of mutations of the RET proto–oncogene in parathyroid tumors [see comments] Kimura T, et al. **Eur J Endocrinol** 1996 Mar;134(3):314–9. Comment in: Eur J Endocrinol 1996 Mar;134(3):263–6.

PATHOLOGY

Fine needle aspiration cytology of an ectopic parathyroid adenoma: a case report. Galloway A, et al. **Acta Cytol** 1996 Mar–Apr;40(2):315–8

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20

(45 ref.)
Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dube syndrome. Chung JY, et al. **Int J Dermatol** 1996 May;35(5):365-7
Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Kifor O, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1598-606
Paraganglioma: an unusual tumour of the parathyroid gland. McCluggage WG, et al. **J Laryngol Otol** 1996 Feb; 110(2):196-9
Successful resection of hepatic and pulmonary metastases in a patient with parathyroid carcinoma. van Haaren ER, et al. **Jpn J Clin Oncol** 1996 Apr;26(2):99-102
Parathyroid lipoadenoma: case report and review of the literature. Turner WJ, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):313-6 (19 ref.)
Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353-65 (68 ref.)
Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in a hemodialysis patient: report of a case. Tominaga Y, et al. **Surg Today** 1995;25(11):984-6
[Parathyroid adenoma and carcinoma. A comparative morphologic study] Morelli A, et al. **Medicina (B Aires)** 1991;51(6):507-10 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Gennari C, et al. **Miner Electrolyte Metab** 1995; 21(1-3):77-81

PREVENTION & CONTROL

[Screening of multiple endocrine neoplasias type 1. Reflexions of the Study Group on Multiple Endocrine Neoplasias type 1] Cougard P, et al. **Ann Chir** 1995; 49(6):500-6 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiologic manifestations of hyperparathyroidism. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Jul-Sep; 87(7-9):135-9

RADIONUCLIDE IMAGING

Technetium 99m sestamibi scan is the useful procedure to locate parathyroid adenomas before surgery [letter; comment] Takami H, et al. **Am J Surg** 1996 Jul;172(1):93 . Comment on: Am J Surg 1995 Nov;170(5):488-91.
Tc-99m sestamibi scanning in the preoperative localization of mediastinal parathyroid adenomas. Chiu NT, et al. **Ann Nucl Med** 1995 Aug;9(3):157-9
A false-positive localization of a parathyroid adenoma with technetium Tc 99m sestamibi scan secondary to a thyroid follicular carcinoma. Koss WG, et al. **Arch Surg** 1996 Feb; 131(2):216-7
Localization of parathyroid tumours [comment] Heath DA. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):523-4. Comment on: Clin Endocrinol (Oxf) 1995 Nov;43(5):525-30.
Tc-99m sestamibi uptake by parathyroid carcinoma. False-positive localization of parathyroid adenoma. Achong DM, et al. **Clin Nucl Med** 1995 Aug;20(8):735
Nuclear medicine imaging in a case of hyperfunctioning parathyroid carcinoma associated with a parathyroid adenoma. Ceriani L, et al. **Clin Nucl Med** 1995 Sep; 20(9):817-20
Tc-99m sestamibi imaging of brown tumors of primary hyperparathyroidism. Dinauer PA, et al. **Clin Nucl Med** 1996 Mar;21(3):192-6
Tc-99m tetrofosmin. A new diagnostic tracer for parathyroid imaging. Ishibashi M, et al. **Clin Nucl Med** 1995 Oct; 20(10):902-5
Parathyroid adenomas without sestamibi retention. Leslie WD, et al. **Clin Nucl Med** 1995 Aug;20(8):699-702
Ectopic parathyroid imaging with Tc-99m sestamibi. Pusuwan P, et al. **Clin Nucl Med** 1996 Jan;21(1):74
Limitations of parathyroid imaging with Tc-99m/Ti-201 subtraction and early/delayed Tc-99m MIBI imaging. Schiepers C, et al. **Clin Nucl Med** 1996 Jun;21(6):502
Tc-99m MIBI in a patient with parathyroid carcinoma. What to expect from it. Stokkel MP, et al. **Clin Nucl Med** 1996 Feb;21(2):142-3
The role of pre-operative thallium-technetium subtraction scintigraphy in the surgical management of patients with solitary parathyroid adenoma [see comments] Tsukamoto E, et al. **Clin Radiol** 1995 Oct;50(10):677-80. Comment in: Clin Radiol 1996 May;51(5):383.
The role of pre-operative thallium-technetium subtraction scintigraphy in the surgical management of patients with solitary parathyroid adenoma [letter; comment] Watura R, et al. **Clin Radiol** 1996 May;51(5):383. Comment on: Clin Radiol 1995 Oct;50(10):677-80.
Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Melon P, et al. **Eur J Nucl Med** 1995 Jun;22(6):556-8
Technetium-99m-methoxyisobutylisonitrile in localization of ectopic parathyroid adenoma. Bernà L, et al. **J Nucl Med** 1996 Apr;37(4):631-3
Localization of an ectopic parathyroid adenoma by double-phase technetium-99m-sestamibi scintigraphy. Caravalho J, et al. **J Nucl Med** 1995 Oct;36(10):1840-2
Technetium-99m-sestamibi imaging before reoperation for primary hyperparathyroidism. Chen CC, et al. **J Nucl Med** 1995 Dec;36(12):2186-91
Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma [letter; comment] Staudenherz A, et al. **J Nucl Med** 1995 Oct;36(10):1928-9. Comment on: J Nucl Med 1995 Feb;36(2):241-3.
Technetium-99m-sestamibi SPECT localization of mediastinal parathyroid adenoma. Teigen EL, et al. **J Nucl Med** 1996 Sep;37(9):1535-7
Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306-9
Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522-33 (96 ref.)
Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221-34 (62 ref.)
[Preoperative localization of parathyroid adenomas using Tc-99m-sestamibi] Stilgren LS, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1832-4 (Eng. Abstr.) **(Dan)**
[Scintigraphy of the parathyroid glands with 99mTc-MIBI] Grünwald F, et al. **Med Klin** 1995 Aug 15;90(8):450-5 (Eng. Abstr.) **(Ger)**
[Usefulness of scintigraphy using 99mTc-MIBI for localization of parathyroid adenoma] Leowska E, et al. **Pol Tyg Lek** 1995 Oct;50(40-44):23-5 (Eng. Abstr.) **(Pol)**

SURGERY

Surgical management of hyperparathyroidism. A 24 years experience. Vázquez Quintana E. **Bol Asoc Med P R** 1995 Jul-Sep;87(7-9):126-9
Intraoperative fall in plasma levels of intact parathyroid hormone in patients undergoing parathyroid adenomectomy. Tommasi M, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):206-10
Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306-9
Lateralization of parathyroid adenomas by intra-operative parathormone estimation. Taylor J, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):174-7
The subxiphoid laparoscopic approach for resection of mediastinal parathyroid adenoma after successful localization with TC-99m-sestamibi radionuclide scan. Wei JP, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):402-6
Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Bergenfelz A, et al. **Surgery** 1996 Jun;119(6):624-33

ULTRASONOGRAPHY

Underdiagnosis of parathyroid adenomas by sonography [letter] Lerner RM. **AJR Am J Roentgenol** 1996 Sep; 167(3):814-5

ULTRASTRUCTURE

Water-clear cell adenoma of the parathyroid. A case report with immunohistochemistry and electron microscopy [see comments] Grenko RT, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1072-4. Comment in: Arch Pathol Lab Med 1995 Nov;119(11):996-7.

PARATHYROIDECTOMY

Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Goldsmith DJ, et al. **Am J Kidney Dis** 1996 Jun;27(6):819-25
Preoperative needle-localized parathyroidectomy for persistent secondary hyperparathyroidism. Clements RH, et al. **Am Surg** 1996 May;62(5):413-5
Reoperation for persistent or recurrent primary hyperparathyroidism. Shen W, et al. **Arch Surg** 1996 Aug; 131(8):861-7; discussion 867-9 (20 ref.)
Recurrent secondary hyperparathyroidism. An argument for total parathyroidectomy. Skinner KA, et al. **Arch Surg** 1996 Jul;131(7):724-7
Early postoperative plasma calcium concentration as a predictor of the need for calcium supplement after parathyroidectomy. Wong WK, et al. **Br J Surg** 1996 Apr; 83(4):532-4
Morphological study of amelogenesis in the rat lower incisor after thyro-parathyroidectomy, parathyroidectomy and thyroidectomy. Acevedo AC, et al. **Cell Tissue Res** 1996 Jan;283(1):151-7
Severe secondary hyperparathyroidism: intravenous calcitriol treatment or parathyroidectomy? [letter] Goicoechea Diezhandino M, et al. **Clin Nephrol** 1996 Jan;45(1):69-70
Effects of thyro-parathyroidectomy and parathyroidectomy upon dentinogenesis: Part II: Electron microscopy. Acevedo AC, et al. **Connect Tissue Res** 1995;32(1-4):269-74
Effects of thyro-parathyroidectomy and parathyroidectomy upon dentinogenesis: Part I: Light microscopy. Chardin H, et al. **Connect Tissue Res** 1995;32(1-4):261-7
Intraoperative fall in plasma levels of intact parathyroid hormone in patients undergoing parathyroid adenomectomy. Tommasi M, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):206-10
Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954-62 (61 ref.)
Ovarian carbonyl reductase delayed onset of persistent estrus in the offspring of parathyroidectomized mother rats. Inazu N, et al. **Jpn J Pharmacol** 1995 Sep;69(1):17-22
Hyperparathyroidism: a management dilemma [editorial] Posen S. **Med J Aust** 1996 Aug 19;165(4):183
Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Hara S, et al. **Miner Electrolyte Metab** 1995;21(1-3):72-6
Effect of parathyroid hormone on left ventricular diastolic function in patients with primary hyperparathyroidism. Ohara N, et al. **Miner Electrolyte Metab** 1995;21(1-3):63-6
Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Sato S, et al. **Miner Electrolyte Metab** 1995;21(1-3):67-71
Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism [see comments] Malberti F, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):81-7. Comment in: Nephrol Dial Transplant 1996 Jan;11(1):16-8.
Effect of parathyroidectomy on thyrotropic and lactotropic function in patients with renal osteopathy. Zofková I, et al. **Nephron** 1995;71(3):284-90
[Necrotic angiodermatitis revealing a secondary hyperparathyroidism due to chronic renal insufficiency: healing after subtotal parathyroidectomy] Leray H, et al. **Nephrologie** 1995;16(6):427-30 (Eng. Abstr.) **(Fre)**
[Long-term effect after total parathyroidectomy with autotransplantation for secondary hyperparathyroidism] Yamate T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):105-9 (Eng. Abstr.) **(Jpn)**
[Indications of parathyroidectomy for bone disease associated with secondary hyperparathyroidism] Ishikawa Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):67-73 (Eng. Abstr.) **(Jpn)**
[Effects of bisphosphonates on vitamin A-induced bone resorption in thyroparathyroidectomized rat] Gen M. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov; 69(11):1193-207 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Bone scintigraphy in hungry bone syndrome following parathyroidectomy. Hardoff R, et al. **J Nucl Med** 1996 Aug;37(8):1371-3

INSTRUMENTATION

Intraoperative identification of laryngeal nerves with laryngeal electromyography. Mermelstein M, et al. **Laryngoscope** 1996 Jun;106(6):752-6
The subxiphoid laparoscopic approach for resection of mediastinal parathyroid adenoma after successful localization with TC-99m-sestamibi radionuclide scan. Wei JP, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):402-6

METHODS

Analysis of savings in operative time for primary hyperparathyroidism using localization with technetium 99m sestamibi scan [see comments] Wei JP, et al. **Am J Surg** 1995 Nov;170(5):488-91. Comment in: Am J Surg 1996 Jul;172(1):93.
Endoscopic subtotal parathyroidectomy in patients with primary hyperparathyroidism [letter] Gagner M. **Br J Surg** 1996 Jun;83(6):875
[Modified cryopreservation of parathyroid gland tissue. Evaluation and comparison in an animal experiment] Walgenbach S, et al. **Langenbecks Arch Chir** 1995; 380(5):292-8 (Eng. Abstr.) **(Ger)**

STANDARDS

Mortality of untreated primary hyperparathyroidism--a nontraditional indication for parathyroid surgery? [letter; comment] Rastad J, et al. **Am J Med** 1995 Nov;99(5):577-8 . Comment on: Am J Med 1994 Feb;96(2):99-100.

STATISTICS & NUMERICAL DATA

Parathyroidectomy in the west Midlands. Ready AR, et al. **Br J Surg** 1996 Jun;83(6):823-7
An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. The Okinawa Dialysis Study Group. Tokuyama K, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul; 38(7):309-13

PARATOPES see BINDING SITES, ANTIBODY

PARATUBERCULOSIS

BLOOD

Serum protein concentrations in clinical cases of ovine paratuberculosis (Johne's disease). Scott PR, et al. **Vet Rec** 1995 Aug 12;137(7):173

PARATUBERCULOSIS

DIAGNOSIS

Detection of Mycobacterium paratuberculosis in formalin-fixed paraffin-embedded tissues by the polymerase chain reaction. Plante Y, et al. **Can J Vet Res** 1996 Apr;60(2):115-20

Evaluation of an agar gel immunodiffusion test kit for detection of antibodies to Mycobacterium paratuberculosis in sheep. Dubash K, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):401-3

Evaluation of an enzyme-linked immunosorbent assay licensed by the USDA for use in cattle for diagnosis of ovine paratuberculosis. Dubash K, et al. **J Vet Diagn Invest** 1995 Jul;7(3):347-51

Evaluation of a commercial enzyme-linked immunosorbent assay for the diagnosis of paratuberculosis in dairy cattle. Sweeney RW, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):488-93

[What is your diagnosis? Paratuberculosis] **Tijdschr Diergeneeskd** 1995 Oct 15;120(20):603, 606-7 **(Dut)**

EPIDEMIOLOGY

Aggregate testing for the evaluation of Johne's disease herd status. Jordan D. **Aust Vet J** 1996 Jan;73(1):16-9

An abattoir-based study of the prevalence of subclinical Johne's disease in adult cattle in south west England. Cetinkaya B, et al. **Epidemiol Infect** 1996 Jun;116(3):373-9

Epidemiologic study of on-farm management practices associated with prevalence of Mycobacterium paratuberculosis infections in dairy cattle. Goodger WJ, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1877-81

First report of paratuberculosis (Johne's disease) in sheep in Morocco. Benazzi S, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):339-44

IMMUNOLOGY

Influence of vitamin D3 infusion and dietary calcium on secretion of interleukin 1, interleukin 6, and tumor necrosis factor in mice infected with Mycobacterium paratuberculosis. Stabel JR, et al. **Am J Vet Res** 1996 Jun; 57(6):825-9

Increased intestinal TNF-alpha, IL-1 beta and IL-6 expression in ovine paratuberculosis. Alzuherri HM, et al. **Vet Immunol Immunopathol** 1996 Jan;49(4):331-45

Comparison of the resistance of C57BL/6 and C3H/He mice to infection with Mycobacterium paratuberculosis. Veazey RS, et al. **Vet Microbiol** 1995 Nov;47(1-2):79-87

MICROBIOLOGY

Lack of mycobactin dependence of mycobacteria isolated on Middlebrook 7H11 from clinical cases of ovine paratuberculosis. Adúriz JJ, et al. **Vet Microbiol** 1995 Jul; 45(2-3):211-7

PATHOLOGY

Histopathology of C57BL/6 mice inoculated orally with Mycobacterium paratuberculosis. Veazey RS, et al. **J Comp Pathol** 1995 Jul;113(1):75-80

PHYSIOPATHOLOGY

Associations between subclinical paratuberculosis and milk production, milk components, and somatic cell counts in dairy herds. Nordlund KV, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1872-6

PREVENTION & CONTROL

Study on immune response of goats vaccinated with a live strain of Mycobacterium paratuberculosis. Molina JM, et al. **Comp Immunol Microbiol Infect Dis** 1996 Jan;19(1):9-15

PARATYPHOID FEVER

COMPLICATIONS

Salmonella paratyphi A induced pancytopenia--a new association. Khattak BK, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):192-3

DRUG THERAPY

Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Alam MN, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):306-11

A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever. Nelwan RH, et al. **Drugs** 1995;49 Suppl 2:463-5

Culture of Salmonella typhi and Salmonella paratyphi from blood and bone marrow in suspected typhoid fever. Gasem MH, et al. **Trop Geogr Med** 1995;47(4):164-7

EPIDEMIOLOGY

Large outbreak of Salmonella enterica serotype paratyphi B infection caused by a goats' milk cheese, France, 1993: a case finding and epidemiological study [see comments] Desenclos JC, et al. **BMJ** 1996 Jan 13;312(7023):91-4. Comment in: BMJ 1996 Jan 13;312(7023):67-8.

Raw milk cheeses and Salmonella [editorial; comment] [see comments] Rampling A. **BMJ** 1996 Jan 13;312(7023):67-8. Comment on: BMJ 1996 Jan 13;312(7023):91-4. Comment in: BMJ 1996 Apr 27;312(7038):1099. Comment in: BMJ 1996 Apr 27;312(7038):1099-100.

Salmonella typhi and Salmonella paratyphi antibodies in Kenya [see comments] Jumba MM, et al. **East Afr Med J** 1995 Dec;72(12):755-7. Comment in: East Afr Med J 1995 Dec;72(12):753-4.

ETIOLOGY

Salmonella inguinal abscess in a patient with systemic lupus erythematosus. Kumari TG, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S23

MICROBIOLOGY

Monoclonal antibodies against protein antigens of salmonellae causing paratyphoid fever and their diagnostic application. Ekpo P, et al. **Asian Pac J Allergy Immunol** 1995 Jun; 13(1):63-70

PREVENTION & CONTROL

Urgent need for effective vaccine against Salmonella paratyphi A, B and C [letter] Arya SC, et al. **Vaccine** 1995 Dec;13(17):1727-8

TRANSMISSION

Survivability of Salmonella paratyphi B var Java on experimentally infected cockroaches. Singh BR, et al. **Indian J Exp Biol** 1995 May;33(5):392-3

PARATYPHOID VACCINE see **TYPHOID-PARATYPHOID VACCINES**

PARAVENTRICULAR HYPOTHALAMIC NUCLEUS

ANATOMY & HISTOLOGY

An investigation of a possible direct projection from the medial nucleus of the cerebellum to the paraventricular nucleus of the hypothalamus in the rat: a study using retrograde WGA-HRP and Fluoro-Gold tracing techniques. Rutherford JG. **Anat Embryol (Berl)** 1995 Sep; 192(3):229-38

Descending projections from the paraventricular hypothalamic nucleus to the spinal cord: anterograde tracing study in the rat. Zheng JQ, et al. **Okajimas Folia Anat Jpn** 1995 Aug;72(2-3):119-35

CHEMISTRY

Estimation of oxytocin mRNA in the human paraventricular nucleus in AIDS by means of quantitative in situ hybridization. Guldenaar SE, et al. **Brain Res** 1995 Nov 27;700(1-2):107-14

Substance P innervation of neurons projecting to the paraventricular hypothalamic nucleus in the rat nucleus tractus solitarius. Kawano H, et al. **Brain Res** 1995 Aug 14;689(1):136-40

The hypothalamic paraventricular nucleus in two types of Wistar rats with different stress responses. II. Differential Fos-expression. Mulders WH, et al. **Brain Res** 1995 Aug 14;689(1):61-70

Sexually dimorphic expression of androgen receptor immunoreactivity by somatostatin neurones in rat hypothalamic periventricular nucleus and bed nucleus of the stria terminalis. Herbison AE. **J Neuroendocrinol** 1995 Jul;7(7):543-53

Adrenomedullin-immunoreactive neurons in the paraventricular and supraoptic nuclei of the rat. Ueta Y, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):37-40

CYTOLOGY

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Purba JS, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):137-43

Morphological heterogeneity of neurosecretory magnocellular nuclei of the guinea pig hypothalamus. II. Microscopic pattern and cytomorphological analysis of the paraventricular nucleus. Zalewska H. **Rocz Akad Med Bialymst** 1994;39:54-63

DRUG EFFECTS

Alcohol effects on paraventricular hypothalamic nucleus morphometry. Pérez-Delgado M, et al. **Acta Anat (Basel)** 1995;153(4):282-9

Area postrema mediates the formation of rapid, conditioned palatability shifts in lithium-treated rats. Eckel LA, et al. **Behav Neurosci** 1996 Feb;110(1):202-12

Regional haemodynamic effects of mu-, delta-, and kappa-opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats. Bachelard H, et al. **Br J Pharmacol** 1995 Jun;115(4):613-21

Neuropeptide Y potentiation of potassium-induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo. Pavia JM, et al. **Brain Res** 1995 Aug 28;690(1):108-11

Intracerebroventricular administration of neuropeptide Y inhibits release of noradrenaline in the hypothalamic paraventricular nucleus caused by manual restraint in the rat through an opioid system. Shibasaki T, et al. **Brain Res** 1995 Aug 7;688(1-2):189-92

Insulin and insulin-like growth factor II suppress neuropeptide Y release from the nerve terminals in the paraventricular nucleus: a putative hypothalamic site for energy homeostasis. Sahu A, et al. **Endocrinology** 1995 Dec; 136(12):5718-24

Restraint reduces formalin-test pain but the effect is not influenced by lesions of the hypothalamic paraventricular nucleus. Fuchs PN, et al. **Exp Neurol** 1996 Jun; 139(2):299-305

Cardiovascular effects of endothelin injected into brain nuclei regulating vasopressin release. Mosqueda-Garcia R, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S159-62

Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats. Rinaman L, et al. **J Comp Neurol** 1995 Sep 18;360(2):246-56

Microdialysis as a tool to measure dietary and regional effects on the complete profile of extracellular amino acids in the hypothalamus of rats. Currie PJ, et al. **Life Sci** 1995; 57(21):1911-23

Sequential estrogen and progesterone (P) followed by P withdrawal increases the level of oxytocin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the male rat. Thomas A, et al. **Life Sci** 1996; 58(19):1615-20

Early hypothalamic activation of combined Fos and CRH41 immunoreactivity and of CRH41 release in push-pull cannulated rats after systemic endotoxin challenge. Givalois L, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):171-86

Effects of acidic fibroblast growth factor on neuronal activity of the parvocellular part in rat paraventricular nucleus. Sasaki K, et al. **Neurobiology (Bp)** 1995;3(3-4):329-38

Hypercorticism induces neurotensin mRNA in rat periventricular hypothalamus. Nicot A, et al. **Neuroreport** 1995 Nov 13;6(16):2158-60

Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus. Currie PJ, et al. **Peptides** 1995;16(4):599-604

A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor. Ambühl P, et al. **Regul Pept** 1995 Oct 20; 59(2):171-82

Oxytocin antisense reduces salt intake in the baroreceptor-denervated rat. Morris M, et al. **Regul Pept** 1995 Oct 20;59(2):261-6

ENZYMOLOGY

Inhibition of hypothalamic nitric oxide synthase gene expression in the rat paraventricular nucleus by food deprivation is independent of serotonin depletion. Ueta Y, et al. **J Neuroendocrinol** 1995 Nov;7(11):861-5

GROWTH & DEVELOPMENT

Alcohol effects on paraventricular hypothalamic nucleus morphometry. Pérez-Delgado M, et al. **Acta Anat (Basel)** 1995;153(4):282-9

IMMUNOLOGY

Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats. Huang CC, et al. **J Neurosci Res** 1995 Jul 1;41(4):471-80

METABOLISM

Oxytocin mRNA in the human paraventricular nucleus in AIDS. Guldenaar SE, et al. **Adv Exp Med Biol** 1995;395:91

Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Pacák K, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:115-30

G protein-gated K+ channel (GIRK1) protein is expressed presynaptically in the paraventricular nucleus of the hypothalamus. Morishige KI, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):300-5

A cell-specific role for the adrenal gland in regulating CRH mRNA levels in rat hypothalamic neurosecretory neurons after cellular dehydration. Watts AG, et al. **Brain Res** 1995 Jul 31;687(1-2):63-70

Chlordiazepoxide attenuates stress-induced activation of neurons, corticotropin-releasing factor (CRF) gene transcription and CRF biosynthesis in the paraventricular nucleus (PVN). Imaki T, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):261-70

Effect of acetylcholine on corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Ohmori N, et al. **Endocrinology** 1995 Nov; 136(11):4858-63

Nicotine-induced cFos expression in the hypothalamic paraventricular nucleus is dependent on brainstem effects: correlations with cFos in catecholaminergic and noncatecholaminergic neurons in the nucleus tractus solitarius. Valentine JD, et al. **Endocrinology** 1996 Feb; 137(2):622-30

Pups removal enhances thyrotropin-releasing hormone mRNA in the hypothalamic paraventricular nucleus. Uribe RM, et al. **Eur J Endocrinol** 1995 Sep;133(3):354-60

Corticotrophin-releasing hormone, proenkephalin A and oxytocin mRNA's in the paraventricular nucleus during pregnancy and parturition in the rat. Douglas AJ, et al.

Gene Ther 1994;1 Suppl 1:S85

Fos expression in forebrain afferents to the hypothalamic paraventricular nucleus following swim stress. Cullinan WE, et al. **J Comp Neurol** 1996 Apr 22;368(1):88–99

In situ hybridization analysis of vasopressin gene transcription in the paraventricular and supraoptic nuclei of the rat: regulation by stress and glucocorticoids. Herman JP. **J Comp Neurol** 1995 Dec 4;363(1):15–27

Activation of magnocellular vasopressin responses to non-osmotic stress after chronic adrenal demedullation in rats. Aguilera G, et al. **J Neuroendocrinol** 1993 Oct; 5(5):501–7

Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. Aguilera G, et al. **J Neuroendocrinol** 1995 Oct;7(10):775–83

Evidence for short-loop feedback effects of ACTH on CRF and vasopressin expression in parvocellular neurosecretory neurons. Sawchenko PE, et al. **J Neuroendocrinol** 1995 Sep; 7(9):721–31

Hormonal regulation of CREB phosphorylation in the anteroventral periventricular nucleus. Gu G, et al. **J Neurosci** 1996 May 1;16(9):3035–44

Microdialysis as a tool to measure dietary and regional effects on the complete profile of extracellular amino acids in the hypothalamus of rats. Currie PJ, et al. **Life Sci** 1995; 57(21):1911–23

Altered in vivo catecholamine release in the hypothalamic paraventricular nucleus of the aged rat. Hastings JA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):161–7

Expression of Fos-related antigens, oxytocin, dynorphin and galanin in the paraventricular and supraoptic nuclei of lactating rats. Eriksson M, et al. **Neuroendocrinology** 1996 Apr;63(4):356–67

Vagus nerve mediates the increase in estrogen receptors in the hypothalamic paraventricular nucleus and nucleus of the solitary tract during fasting in ovariectomized rats. Estacio MA, et al. **Neurosci Lett** 1996 Apr 12;208(1):25–8

Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)

Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. McMahon LR, et al. **Physiol Behav** 1996 Jan;59(1):63–9

PATHOLOGY

The hypothalamic paraventricular nucleus in two types of Wistar rats with different stress responses. I. Morphometric comparison. Mulders WH, et al. **Brain Res** 1995 Aug 14; 689(1):47–60

Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Purba JS, et al. **Neuroendocrinology** 1995 Jul;62(1):62–70

PHYSIOLOGY

Effect of pregnancy on activation of central pathways following atrial distension. Deng Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R552–6

A time-structured analysis of hypothalamically induced increases in self-grooming and activity in the rat. Bressers WM, et al. **Behav Neurosci** 1995 Dec;109(6):1158–71

Time structure of self-grooming in the rat: self-facilitation and effects of hypothalamic stimulation and neuropeptides. Bressers WM, et al. **Behav Neurosci** 1995 Oct;109(5):955–64

Cardiovascular function of the paraventricular nucleus of the hypothalamus. Coote JH. **Biol Signals** 1995 May–Jun; 4(3):142–9 (31 ref.)

Direct projection from the suprachiasmatic nucleus to hypophysiotrophic corticotropin-releasing factor immunoreactive cells in the paraventricular nucleus of the hypothalamus demonstrated by means of Phaseolus vulgaris-leucoagglutinin tract tracing. Vrang N, et al. **Brain Res** 1995 Jun 26;684(1):61–9

Estrogen-receptive neurons in the anteroventral periventricular nucleus are synaptic targets of the suprachiasmatic nucleus and peri-suprachiasmatic region. Watson RE Jr, et al. **Brain Res** 1995 Aug 21;689(2):254–64

Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats. Pacak K, et al. **Endocrinology** 1995 Nov;136(11):4814–9

Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. Baker RA, et al. **J Comp Neurol** 1995 Aug 7; 358(4):518–30

Efferent projections of the paraventricular thalamic nucleus in the rat. Moga MM, et al. **J Comp Neurol** 1995 Aug 21;359(2):221–38

Formation of neurons in the sexually dimorphic anteroventral periventricular nucleus of the preoptic area of the rat: effects of prenatal treatment with testosterone propionate. Nishizuka M, et al. **J Neuroendocrinol** 1993 Oct;5(5):569–73

Neurons in the paraventricular nucleus of the hypothalamus that project to the sexually dimorphic lower lumbar spinal cord concentrate 3H-estradiol in the male rat. Wagner CK, et al. **J Neuroendocrinol** 1993 Oct;5(5):545–51

Does recurrent inhibition exist in the paraventricular magnocellular neurosecretory cells in the male rat? Ueta Y, et al. **Jpn J Physiol** 1995;45(5):913–9

Central insulin may up-regulate thyroid activity by suppressing neuropeptide Y release in the paraventricular nucleus. McCarty MF. **Med Hypotheses** 1995 Aug; 45(2):193–9 (114 ref.)

Hypothalamic paraventricular nucleus involvement in the pressor response to N-methyl-d-aspartic acid in the periaqueductal grey matter. Berrino L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):157–60

Hypothalamus regulates calcium metabolism in rats. Aou S, et al. **Neurobiology (Bp)** 1995;3(3–4):339–50

Effects of hypothalamic paraventricular nucleus: electrical stimulation produce marked analgesia in rats. Shiraishi T, et al. **Neurobiology (Bp)** 1995;3(3–4):393–403

The immunological impairment of vasopressin (AVP) neurons into paraventricular nuclei modifies AVP expression in suprachiasmatic nuclei. Rafaï H, et al. **Neurosci Lett** 1995 Oct 20;199(2):147–51

Metergoline potentiates natural feeding and antagonizes the anorectic action of medical hypothalamic 5-hydroxytryptamine. Currie PJ, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):1023–8

Diurnal rhythms of paraventricular hypothalamic norepinephrine and food intake in rats. Morien A, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):169–74

Lesion of hypothalamic paraventricular nucleus and maternal aggressive behavior in female rats. Consiglio AR, et al. **Physiol Behav** 1996 Apr–May;59(4–5):591–6

PHYSIOPATHOLOGY

Hypophysectomy produces analgesia and paraventricular lesions have no effect on formalin-induced pain. Lariviere WR, et al. **Exp Neurol** 1995 Sep;135(1):74–9

The role of the paraventricular system in the pathogenesis of cyclic vomiting. Pasricha PJ. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S29–30 (26 ref.)

Distinct mechanisms underlie activation of hypothalamic neurosecretory neurons and their medullary catecholaminergic afferents in categorically different stress paradigms. Li HY, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2359–64

SECRETION

Increased neuropeptide Y secretion in the hypothalamic paraventricular nucleus of obese (fa/fa) Zucker rats. Dryden S, et al. **Brain Res** 1995 Sep 4;690(2):185–8

ULTRASTRUCTURE

Ultrastructural study of a special type of ependymal cell at paraventricular level of the golden hamster third ventricle. Navarro A, et al. **Histol Histopathol** 1995 Oct;10(4):861–8

Ultrastructure of the hypothalamo-neurohypophysial system in rats exposed to lead. I. Magnocellular nuclei. Galasińska-Pomykol I, et al. **Rocz Akad Med Bialymst** 1994;39:100–10

PARENT-CHILD RELATIONS

Effects of parental presence during children's venipuncture. Wolfram RW, et al. **Acad Emerg Med** 1996 Jan;3(1):58–64

Parental alcohol abuse and gender as predictors of psychopathology in adult children of alcoholics. Belliveau JM, et al. **Addict Behav** 1995 Sep–Oct;20(5):619–25

Impact of the family on the sex lives of adolescents. Pick S, et al. **Adolescence** 1995 Fall;30(119):667–75

Parents and peer group as mediators of the effect of community structure on adolescent problem behavior. Simons RL, et al. **Am J Community Psychol** 1996 Feb; 24(1):145–71

Parents and children sleeping together: cosleeping prevalence and concerns. Rath FH Jr, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):411–8

Parenting: a genetic-epidemiologic perspective. Kendler KS. **Am J Psychiatry** 1996 Jan;153(1):11–20

The impact of parental presence on parental anxiety and satisfaction. Blesch P, et al. **AORN J** 1996 Apr;63(4):761–8

Food and general neophobia in Swedish families: parent-child comparisons and relationships with serving specific foods. Koivisto UK, et al. **Appetite** 1996 Apr; 26(2):107–18

Stepfamilies and children's adjustment. Dunn J. **Arch Dis Child** 1995 Dec;73(6):487–9 (23 ref.)

Divorce and marital strife and their effects on children. Hartnup T. **Arch Dis Child** 1996 Jul;75(1):1–8

A collaborative model of training for parents of children with disruptive behaviour disorders. Herbert M. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):325–42

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)

Behavioural adjustment and parental stress associated with closed head injury in children. Sokol DK, et al. **Brain Inj** 1996 Jun;10(6):439–51

Biological parents regaining their rights: a psycholegal analysis of a new era in custody disputes. Kermani EJ, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):261–7

Adjustment of children and adolescents to parental cancer. Parents' and children's perspectives. Welch AS, et al. **Cancer** 1996 Apr 1;77(7):1409–18

Threats of corporal punishment as verbal aggression: a naturalistic study. Davis PW. **Child Abuse Negl** 1996 Apr; 20(4):289–304

Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.). Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.

A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411–24 (62 ref.)

Comparative conflict resolution patterns among parent-teen dyads of four ethnic groups in Hawaii. Hartz DT. **Child Abuse Negl** 1995 Jun;19(6):681–9

The intergenerational transmission of corporal punishment: a comparison of social learning and temperament models. Muller RT, et al. **Child Abuse Negl** 1995 Nov; 19(11):1323–35

Parental levels of empathy as related to risk assessment in child protective services. Rosenstein P. **Child Abuse Negl** 1995 Nov;19(11):1349–60

Secondary prevention—serving families at risk. Thyen U, et al. **Child Abuse Negl** 1995 Nov;19(11):1337–47

Chronic childhood illnesses: what aspects of caregiving do parents value? Baine S, et al. **Child Care Health Dev** 1995 Sep;21(5):291–304

Trouble in the second year: three questions about family interaction. Belsky J, et al. **Child Dev** 1996 Apr;67(2):556–78

Parent-child relationships, family problems-solving behavior, and sibling relationship quality: the moderating role of sibling temperaments. Brody GH, et al. **Child Dev** 1996 Jun;67(3):1289–300

It takes two to replicate: a mediational model for the impact of parents' stress on adolescent adjustment. Conger RD, et al. **Child Dev** 1995 Feb;66(1):80–97

Associations among attachment classifications of mothers, fathers, and their infants. Steele H, et al. **Child Dev** 1996 Apr;67(2):541–55

Sampling communicative behaviours in children with intellectual disability in structured and unstructured situations. Iacono TA, et al. **Eur J Disord Commun** 1996; 31(2):106–20

Parent and peer communication effects on AIDS-related behavior among U.S. high school students. Holtzman D, et al. **Fam Plann Perspect** 1995 Nov–Dec;27(6):235–40, 268

Stability and change in family-of-origin recollections over the first four years of parenthood. Lewis JM, et al. **Fam Process** 1995 Dec;34(4):455–69

Scottish neonatal intensive care units; a study of staff and parental attitudes. Reid M, et al. **Health Bull (Edinb)** 1995 Sep;53(5):314–25

Negative family environment as a predictor of boys' future status on measures of hostile attitudes, interview behavior, and anger expression. Matthews KA, et al. **Health Psychol** 1996 Jan;15(1):30–7

Should gamete donation between family members be restricted? The case of a 16-year-old donor. Pierce J, et al. **Hum Reprod** 1995 Jun;10(6):1330–2; discussion 1334–7

Oocyte donation by a minor to her mother. Schenker J. **Hum Reprod** 1995 Jun;10(6):1332

Oocyte donation by a daughter. Sureau C, et al. **Hum Reprod** 1995 Jun;10(6):1334

Have I been a good parent? [editorial] Alberts M. **Iowa Med** 1995 Nov;85(11):453

The Diagnostic Interview Schedule for Children (PC-DISC v.3.0): parents and adolescents suggest reasons for expecting discrepant answers. Bidaut-Russell M, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):641–59

Impact of parent monitoring on initiation of drug use through late childhood. Chilcoat HD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):91–100

Peer and parental influences on adolescent tobacco use. Biglan A, et al. **J Behav Med** 1995 Aug;18(4):315–30

Resolving a therapeutic impasse between parents and adolescents in multidimensional family therapy. Diamond G, et al. **J Consult Clin Psychol** 1996 Jun;64(3):481–8

The discovery of marijuana use by a parent of an early adolescent. **J Dev Behav Pediatr** 1995 Jun;16(3):196–8

Parents as teachers: an integral component of a developmental and behavioral pediatrics curriculum. Appell DJ, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):105–6

Parent-child relationship disorders. Part I. Parental overprotection and the development of the Parent Protection Scale. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):244–50

Parent-child relationship disorders. Part II. The vulnerable child syndrome and its relation to parental overprotection. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug; 16(4):251–6

Young adults' relations with grandparents following recent parental divorce. Cooney TM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar;51(2):S91–5

Psychosocial factors and chronic depression. Roy A. **J Nerv Ment Dis** 1996 Aug;184(8):509–10

The relationship between parental communication deviance and relapse in schizophrenic patients in the 1-year period after hospital discharge. A pilot study. Velligan DI, et al. **J Nerv Ment Dis** 1996 Aug;184(8):490–6

Perceptual accuracy and gender-related differences in parents of children with myelomeningocele. Hobdell EF. **J Neurosci Nurs** 1995 Aug;27(4):240–4

Family involvement in the gynecologic care of adolescents.

Rosenthal SL, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):59–65

Assessing filial maturity through the use of the Filial Anxiety Scale. Murray PD, et al. **J Psychol** 1995 Sep;129(5):519–29

Parent and sibling influences on adolescent alcohol use and misuse: evidence from a U.S. adoption cohort. McGue M, et al. **J Stud Alcohol** 1996 Jan;57(1):8–18

The relationship between parent and offspring comorbid disorders. Johnson V. **J Subst Abuse** 1995;7(3):267–80

Geographical distance from parents and adjustment during adolescence and young adulthood. Dubas JS, et al. **New Dir Child Dev** 1996 Spring;(71):3–19

Expectations for and precursors to leaving home in young women. Graber JA, et al. **New Dir Child Dev** 1996 Spring; (71):21–38

Timing of childhood events early–adult household formation. Hill MS, et al. **New Dir Child Dev** 1996 Spring;(71):87–109

Adolescent–parent relationships and leaving home in young adulthood. O'Connor TG, et al. **New Dir Child Dev** 1996 Spring;(71):39–52

Leaving the parental home: predictors for young adults raised in former East and West Germany. Silbereisen RK, et al. **New Dir Child Dev** 1996 Spring;(71):71–86

Development and testing of the caregiver reciprocity scale. Carruth AK. **Nurs Res** 1996 Mar–Apr;45(2):92–7

Management of fatal illness and death in children or their parents. Barakat LP, et al. **Pediatr Rev** 1995 Nov; 16(11):419–23; quiz 424

Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759–69 (22 ref.)

Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747–58 (63 ref.)

Effects of parental involvement on the functioning of noninstitutionalized adults with schizophrenia. Brekke JS, et al. **Psychiatr Serv** 1995 Nov;46(11):1149–55

Parental perceptions of borderline personality disorders in video–recorded interviews. Hayashi N, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):35–7

Binding ties: closeness and conflict in adult children's caregiving relationships. Townsend AL, et al. **Psychol Aging** 1995 Sep;10(3):343–51

Perceived parental bonding in anorectic and bulimic patients. Sordelli A, et al. **Psychopathology** 1996;29(1):64–70

The efficacy of parent training for promoting positive parent–toddler relationships. Gross D, et al. **Res Nurs Health** 1995 Dec;18(6):489–99

Attitudes towards parental presence at induction of anaesthesia. Bösenberg AT, et al. **S Afr Med J** 1996 Jun; 86(6):664–7

Parental attachment, drug use, and facultative sexual strategies. Walsh A. **Soc Biol** 1995 Spring–Summer; 42(1–2):95–107

Philip Roth's Patrimony: narrative and ethics in a case study. Erde EL. **Theor Med** 1995 Sep;16(3):239–52

The role of shame and guilt in the intergenerational transmission of abusiveness. Dutton DG, et al. **Violence Vict** 1995 Summer;10(2):121–31

Improving care of dying children. Martinson IM. **West J Med** 1995 Sep;163(3):258–62

[Communication behavior between parents and their adolescent children and correlation with indicators of self concept] Kreppner K. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr; 45(3–4):130–47 (Eng. Abstr.) **(Ger)**

[Counseling male adolescents with homosexual orientation and their parents] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1996 May–Jun; 45(5):166–70 (35 ref.) (Eng. Abstr.) **(Ger)**

[Parent–child interaction during activity and rest behavior of inhabitants of Trobriand Islands (Papua New Guinea)] Siegmund R, et al. **Wien Med Wochenschr** 1995; 145(17–18):464–7 (Eng. Abstr.) **(Ger)**

[Parents, from the opinions of students in the first classes of general education secondary schools] Polus–Szeniawska E. **Rocz Panstw Zakl Hig** 1995;46(1):99–102 (Eng. Abstr.) **(Pol)**

PARENT, SINGLE see **SINGLE PARENT**

PARENTAL IMPRINTING see **GENOMIC IMPRINTING**

PARENTAL LEAVE

Maternity and parental leave policies at COTH hospitals: an update. Council of Teaching Hospitals. Philibert I, et al. **Acad Med** 1995 Nov;70(11):1056–8

The risk of prematurity and small–for–gestational–age birth in Mexico City: the effects of working conditions and antenatal leave. Cerón–Mireles P, et al. **Am J Public Health** 1996 Jun;86(6):825–31

Women's postpartum maternity benefits and work experience. Gjerdingen DK, et al. **Fam Med** 1995 Oct;27(9):592–8

Family practice residents' maternity leave experiences and benefits. Gjerdingen DK, et al. **Fam Med** 1995 Sep; 27(8):512–8

Parental leave for residents and pediatric training programs. American Academy of Pediatrics Committee on Early Childhood, Adoption, and Dependent Care Resident Section. **Pediatrics** 1995 Nov;96(5 Pt 1):972–3

Residency maternity leave [letter] Walter RS. **Pediatrics** 1996 Sep;98(3 Pt 1):515

[EU regulations for the protection of pregnant and breast–feeding employees] Ahlborg G Jr. **Nord Med** 1996 May;111(5):155 **(Swe)**

LEGISLATION & JURISPRUDENCE

[Maternity protection legislation: a tool for promoting mother–child health] Hernández J, et al. **Aten Primaria** 1996 Apr 30;17(7):439–44 (Eng. Abstr.) **(Spa)**

[Promotion of mother–infant health: a comparative study of legislation of pregnancy protection] Mas Pons R, et al. **Aten Primaria** 1995 Sep 30;16(5):246–50, 252 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Parental availability for the care of sick children. Heymann SJ, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):226–30

PARENTERAL FEEDING see **PARENTERAL NUTRITION**

PARENTERAL FEEDING, HOME see **PARENTERAL NUTRITION, HOME**

PARENTERAL HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

PARENTERAL INFUSIONS see **INFUSIONS, PARENTERAL**

PARENTERAL NUTRITION

see related
FAT EMULSIONS, INTRAVENOUS

Route of nutrient delivery affects insulin sensitivity and liver glucose transporter expression in rat. Colomb V, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E827–33

Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. Hadfield RJ, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1545–8

Nutritional care and candidates for small bowel transplantation. Beath SV, et al. **Arch Dis Child** 1995 Oct; 73(4):348–50

Sodium glycerophosphate in the treatment of neonatal hypophosphataemia. Costello I, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F44–5

Randomised clinical trial of parenteral selenium supplementation in preterm infants. Daniels L, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 May;74(3):F158–164

Differential expression of intestinal and splenic cytokines after parenteral nutrition. Ogle CK, et al. **Arch Surg** 1995 Dec;130(12):1301–7; discussion 1307–8

Microbial translocation in neonates and infants receiving long–term parenteral nutrition. Pierro A, et al. **Arch Surg** 1996 Feb;131(2):176–9

Septic patients in multiple organ failure can oxidize infused glucose, but non–oxidative disposal (storage) is impaired. Green CJ, et al. **Clin Sci (Colch)** 1995 Dec;89(6):601–9

The short–bowel syndrome. Nightingale JM. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):514–20 (60 ref.)

Parenteral nutrition (PN) in the management of very low birth weight (VLBW) babies—a randomized controlled trial. Vaidya UV, et al. **Indian Pediatr** 1995 Feb; 32(2):165–70

Order writing for parenteral nutrition by registered dietitians. Mueller CM, et al. **J Am Diet Assoc** 1996 Aug;96(8):764–8; quiz 769–70

Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. Denne SC, et al. **J Clin Invest** 1996 Feb 1; 97(3):746–54

The effect of minimum luminal nutrition on bacterial translocation and atrophy of the jejunum during parenteral nutrition. McCauley RD, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):65–70

Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. Hultin M, et al. **J Lipid Res** 1995 Oct;36(10):2174–84

Parenteral glycyl–L–tyrosine maintains tyrosine pools and supports growth and nitrogen balance in phenylalanine–deficient rats. Stehle P, et al. **J Nutr** 1996 Mar;126(3):663–7

Effect of parenteral amino acids on leucine and urea kinetics in preterm infants. Battista MA, et al. **J Pediatr** 1996 Jan; 128(1):130–4

Decreased cysteine and proline synthesis in parenterally fed, premature infants. Miller RG, et al. **J Pediatr Surg** 1995 Jul;30(7):953–7; discussion 957–8

A new model of intraabdominal abscess: usefulness for hydrosaline metabolism studies in parenteral nutrition associated with sepsis. Guirao X, et al. **J Surg Res** 1995 Dec;59(6):658–65

Effect of amino acid infusion on glucose production in trauma patients. Long CL, et al. **J Trauma** 1996 Mar;40(3):335–41

American Society for Parenteral and Enteral Nutrition, 20th clinical congress, January 14–17, 1996, Washington, D.C. Program and abstracts. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1 Suppl):1S–32S

Comparative evaluation of the quantitative utilization of parenterally and enterally administered leucine and L–[1–13C,15N]leucine within the whole body and the splanchnic region. Yu YM, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun;19(3):209–15

Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. Ziegler TR. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):91–2

Manganese toxicity and parenteral nutrition [letter] Forbes A, et al. **Lancet** 1996 Jun 22;347(9017):1774

Nutrition support in hospitalized patients with diabetes mellitus. McMahon MM, et al. **Mayo Clin Proc** 1996 Jun; 71(6):587–94 (9 ref.)

Nutritional modulation of the final outcome of hepatotoxic injury by energy substrates: an hypothesis for the mechanism. Chandra S, et al. **Med Hypotheses** 1996 Mar; 46(3):261–8

Intradialytic parenteral nutrition in malnourished patients on chronic haemodialysis therapy. Smolle KH, et al. **Nephrol Dial Transplant** 1995;10(8):1411–6

Medium–chain triglycerides for parenteral nutrition: kinetic profile in humans. Mingrone G, et al. **Nutrition** 1995 Sep–Oct;11(5):418–22

The effect of infused nutrients and absorbed foods on daily food intake in rats. Koopmans HS. **Obes Res** 1995 Dec;3 Suppl 5:675S–684S (62 ref.)

Neonatal enteral and parenteral nutrition. Pittard WB 3rd, et al. **Pediatr Ann** 1995 Nov;24(11):592–8 (62 ref.)

[Use of parenteral nutritional support in patients with gastric cancer: the relationship of protein turn over, immunocompetence and tumor cell kinetics] Cao W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):265–8 (Eng. Abstr.) **(Chi)**

[The dipeptide L–alanyl–L–glutamine—its preparation and therapeutic use] Veselková A, et al. **Ceska Slov Farm** 1996 Feb;45(1):14–6 (Eng. Abstr.) **(Cze)**

[Enteral vs parenteral nutrition?] Nuutinen L, et al. **Duodecim** 1994;110(20):1935–43 (42 ref.) **(Fin)**

[Recommendations of the jury. Peri–operative artificial nutrition]. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:5–16 **(Fre)**

[Respective indications of enteral or parenteral nutrition during pre– and post–operative periods] Petit J, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:127–36 (Eng. Abstr.) **(Fre)**

[60th Annual meeting of the Swiss Society of Gastroenterology and Hepatology. 12th Annual meeting of the Swiss Group for Nutrition. Autumn meeting of the Swiss Society for Nutritional Research. Saint–Gall, 31 August–2 September 1995. Abstracts] **Schweiz Med Wochenschr Suppl** 1995;71:3S–32S **(Fre, Ger)**

[Diet therapy in cancer] Lübke HJ, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1383–8 (Eng. Abstr.) **(Ger)**

[Progression in 25 years of artificial nutrition in surgery (editorial)] Dionigi R, et al. **Chir Ital** 1994;46(6):1–6 (Eng. Abstr.) **(Ita)**

[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

[Hyperintense brain lesions on T1–weighted MRI after parenteral nutrition] Saitoh Y, et al. **No To Hattatsu** 1996 Jan;28(1):39–43 (Eng. Abstr.) **(Jpn)**

[Thermogenesis during parenteral nutrition and after oral meal] Książyk J, et al. **Pediatr Pol** 1996 May;71(5):459–63 (Eng. Abstr.) **(Pol)**

[Complications of intravenous therapy. Influence of parenteral nutrition, central venous pressure and antibiotics] Armero M, et al. **Nutr Hosp** 1991 May–Jun; 6(3):186–93 (Eng. Abstr.) **(Spa)**

[Home parenteral nutrition in the management of patients with chronic idiopathic intestinal pseudo–obstruction] Chasco Yrigoyen A, et al. **Nutr Hosp** 1995 Sep–Oct; 10(5):264–7 (Eng. Abstr.) **(Spa)**

[Carbohydrates—no glucose—in parenteral nutrition. A fading concept?] García de Lorenzo A, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):17–28 (Eng. Abstr.) **(Spa)**

[Comparative study of two lipid emulsions in the parenteral nutrition of the septic patient] Garnacho Montero J, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):47–53 (Eng. Abstr.) **(Spa)**

[A comparative study of hepatic cholestasis after infusion of long chain triglycerides and a mixture of medium and long chain triglycerides] Jaurrieta E, et al. **Nutr Hosp** 1991 May–Jun;6(3):152–5 (Eng. Abstr.) **(Spa)**

[CO2 production and thermogenesis induced by enteral and parenteral nutrition] Raurich JM, et al. **Nutr Hosp** 1996 Mar–Apr;11(2):108–13 (Eng. Abstr.) **(Spa)**

[Effects of branched–chain amino acids (BCAA) in complete hypocaloric nutrition of surgical patients with neoplasms of the digestive tract] Ruiz Coracho P, et al. **Nutr Hosp** 1991 May–Jun;6(3):178–85 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Pulmonary embolism in parenteral nutrition. Dollery CM. **Arch Dis Child** 1996 Feb;74(2):95–8 (35 ref.)

ECG and echocardiographic diagnosis of pulmonary thromboembolism associated with central venous lines. Pollard AJ, et al. **Arch Dis Child** 1995 Aug;73(2):147–50

Abnormal trace elements in a patient on total parenteral nutrition with normal renal function. Leung FY, et al. **Clin Biochem** 1995 Jun;28(3):297–302

Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Benoit JL, et al. **Clin Infect Dis** 1995 Nov;21(5):1286–8

Randomised trial of effect of delayed intravenous lipid

administration on chronic lung disease in preterm neonates. Alwaidh MH, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr; 22(3):303–6

Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. Buchman AL, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):453–60

Do heparin, hydrocortisone, and glyceryl trinitrate influence thrombophlebitis during full intravenous nutrition via a peripheral vein? Tighe MJ, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):507–9

Manganese toxicity and parenteral nutrition [letter] Beath SV, et al. **Lancet** 1996 Jun 22;347(9017):1773–4

Manganese toxicity in children receiving long-term parenteral nutrition. Fell JM, et al. **Lancet** 1996 May 4; 347(9010):1218–21

Severe hypophosphataemia due to intraperitoneal nutrition in a CAPD patient. Ghattaora R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1365–6

[The change of gut barrier function and gene expression after surgical stress and parenteral nutrition] Ma Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):371–3 (Eng. Abstr.) **(Chi)**

[Hepatic complications in parenteral nutrition] Müller MJ. **Z Gastroenterol** 1996 Jan;34(1):36–40 (50 ref.) (Eng. Abstr.) **(Ger)**

[Infections of central venous catheters] Faintuch J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):52–4 (Eng. Abstr.) **(Por)**

[The epidemiology of central venous catheterization (CVC) in parenteral nutrition. The clinical implications and factors that determine the selection of germs] Llop Talaverón JM, et al. **Nutr Hosp** 1996 Mar–Apr;11(2):114–21 (Eng. Abstr.) **(Spa)**

[Incidence of phlebitis in patients with intestinal inflammatory disease undergoing peripheral parenteral nutrition] Romero Roger JA, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):63–5 (Eng. Abstr.) **(Spa)**

ECONOMICS

Proposed Health Care Financing Administration guidelines for reimbursement of enteral and parenteral nutrition. Kopple JD, et al. **Am J Kidney Dis** 1995 Dec;26(6):995–7

INSTRUMENTATION

Randomized comparison of silicone versus Teflon cannulas for peripheral intravenous nutrition [letter; comment] Everitt NJ. **Ann R Coll Surg Engl** 1996 Mar;78(2):156. Comment on: Ann R Coll Surg Engl 1995 Nov;77(6):447–9.

Randomised comparison of silicone versus Teflon cannulas for peripheral intravenous nutrition [see comments] Reynolds JV, et al. **Ann R Coll Surg Engl** 1995 Nov; 77(6):447–9. Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):156.

Fungal feeding-line infection [letter; comment] Lucas VS, et al. **J R Soc Med** 1995 Sep;88(9):543–4. Comment on: J R Soc Med 1995 May;88(5):258–63.

Permanent catheters damaged by power injection of contrast media [letter] Sunder-Plassmann G, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):428

[Complications due to correctly placed fine silicone catheters (letter)] Hernández Rastrollo R, et al. **An Esp Pediatr** 1996 Mar;44(3):297 **(Spa)**

[Colonization of a parenteral nutrition catheter by Malassezia furfur in an adult (letter)] Rivera A, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):570 **(Spa)**

METHODS

Protein-sparing therapy after major abdominal surgery: lack of clinical effects. Protein-Sparing Therapy Study Group. Doglietto GB, et al. **Ann Surg** 1996 Apr;223(4):357–62

Efficacy of glutamine-enriched enteral nutrition in an experimental model of mucosal ulcerative colitis [letter; comment] Gardiner KR, et al. **Br J Surg** 1995 Sep; 82(9):1278–9. Comment on: Br J Surg 1995 Jun;82(6):749–51.

Use of a feeding jejunostomy after oesophagogastric surgery [letter; comment] Griffith GH. **Br J Surg** 1995 Sep; 82(9):1278. Comment on: Br J Surg 1995 Jun;82(6):811–3.

Elimination of fat emulsion particles from plasma during glucose infusion. Iriyama K, et al. **Br J Surg** 1996 Jul; 83(7):946–8

Prolonged peripheral parenteral nutrition with an ultrafine cannula and low-osmolality feed. Williams N, et al. **Br J Surg** 1996 Jan;83(1):114–6

Pediatric parenteral nutrition mixtures design program: validity and stability study. Ochoa-Sangrador C, et al. **Comput Biomed Res** 1995 Aug;28(4):271–81

Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)

Techniques for the provision of parenteral nutrition. Messing B, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):507–13 (33 ref.)

An evaluation of the safety of mixed micelles in healthy subjects. Ballinger AB, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):110–2

The effect on energy and nitrogen metabolism by continuous, bolus, or sequential infusion of a defined total parenteral nutrition formulation in patients after major surgical procedures. Sandström R, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):333–40

Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Balfe JW. **Perit Dial Int** 1996;16 Suppl 1:S515–6

Tube feeding in infants on peritoneal dialysis. Geary DF, et al. **Perit Dial Int** 1996;16 Suppl 1:S517–20

[Non-surgical treatment of perforations of the thoracic esophagus] Slim K, et al. **Presse Med** 1996 Feb 3; 25(4):154–6 (Eng. Abstr.) **(Fre)**

[Home parenteral nutrition: our initial experience] López Bermejo A, et al. **An Esp Pediatr** 1996 Feb;44(2):170–2 **(Spa)**

STANDARDS

Technician checking of pharmacists computerized order entry for parenteral nutrient solutions. Fields HS. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1801–2

Enhanced enteral and parenteral nutrition practice and outcomes in an intensive care unit with a hospital-wide performance improvement process. Schwartz DB. **J Am Diet Assoc** 1996 May;96(5):484–9

NASPGN commentary on A.S.P.E.N. nutrition guidelines. North American Society for Pediatric Gastroenterology and Nutrition. American Society for Parenteral and Enteral Nutrition. Gleghorn EE. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):255–6

Early nutrition support modifies immune function in patients sustaining severe head injury. Sacks GS, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):387–92

The 1994 John M. Kinney International Award for nutrition and metabolism. Metabolic response to a high-lipid, high-nitrogen peripheral intravenous nutrition solution after major upper-gastrointestinal surgery: background. Kohlhardt SR. **Nutrition** 1995 May–Jun;11(3):312–4

STATISTICS & NUMERICAL DATA

[Home and ambulatory artificial nutrition. Parenteral nutrition. The NADYA Group] de Cos Blanco AI, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):252–7 (Eng. Abstr.) **(Spa)**

UTILIZATION

[The utilization of parenteral nutrition at Hospital de Jerez (Cádiz): a description and comparison with other hospital centers] Gómez Henry JC, et al. **Nutr Hosp** 1996 Mar–Apr; 11(2):122–30 (Eng. Abstr.) **(Spa)**

PARENTERAL NUTRITION, HOME

Clinical profile of home parenteral nutrition patients. Van Gossum A. **Acta Gastroenterol Belg** 1995 Sep–Dec; 58(5–6):366–9

Home parenteral nutrition in children. Huang FC, et al. **J Formos Med Assoc** 1996 Jan;95(1):45–50

Parenteral nutrition at home in advanced cancer patients. Mercadante S. **J Pain Symptom Manage** 1995 Aug; 10(6):476–80

Essential fatty acid status in patients on long-term home parenteral nutrition. Abushufa R, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):286–90

Harry M. Vars Research Award. Increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without vitamin D supplementation. Verhage AH, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec; 19(6):431–6

[Improved quality of life (QOL) in terminal renal carcinoma patients through home nurse visitation: some considerations] Anzai M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:322–5 (Eng. Abstr.) **(Jpn)**

[Home parenteral nutrition for terminal cancer patients—when should we tell the truth about their disease and return them to their home with HPN] Inoue Y, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:384–8 (Eng. Abstr.) **(Jpn)**

[Usefulness of palliative care for the patients with recurrent gastric cancer by home-IVH] Sairenji M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:394–401 (Eng. Abstr.) **(Jpn)**

[Experience and problems with home parenteral nutrition for patients with peritonitis carcinomatosa] Takano H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:389–93 (Eng. Abstr.) **(Jpn)**

[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871–5 (15 ref.) **(Jpn)**

[Parenteral nutrition at home] Pertkiewicz M, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):45–7, 52 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Complications of parenteral nutrition [letter; comment] Kumar A. **Gastroenterology** 1995 Oct;109(4):1408–9. Comment on: Gastroenterology 1995 Apr;108(4):1005–10.

Neurologic symptoms due to possible chromium deficiency in long-term parenteral nutrition that closely mimic metronidazole-induced syndromes. Verhage AH, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):123–7

Bone loss and oral state in patients on home parenteral nutrition. von Wowern N, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):105–9

ECONOMICS

[Study of medical economy in home parenteral nutrition] Shirotani N, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:412–6 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Experience with the Groshong port in a home TPN patient—a case report] Inoue Y, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:378–83 (Eng. Abstr.) **(Jpn)**

PARENTERAL NUTRITION, HOME TOTAL

Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. The French Multicenter Total Parenteral Nutrition Cooperative Group Study. Melchior JC, et al. **AIDS** 1996 Apr; 10(4):379–84

INSTRUMENTATION

Conservative management of septic parenteral nutrition catheters [letter; comment] Faintuch J, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):428–9 . Comment on: JPEN J Parenter Enteral Nutr 1994 Jul–Aug;18(4):297–302.

PARENTERAL NUTRITION, TOTAL

see related

PROTEIN HYDROLYSATES

Plasma lecithin: cholesterol acyltransferase and plasma lipolytic activity in preterm infants given total parenteral nutrition with 10% or 20% Intralipid. Goel R, et al. **Acta Paediatr** 1995 Sep;84(9):1060–4

New alternatives for the treatment of fistulas in Crohn's disease. Skvařilová M, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:29–31

The dairy industry protects milk from photodegradation; why not protect total parenteral nutrition solutions also? [letter] Chytil F. **Am J Clin Nutr** 1996 Mar;63(3):404–5

Debate on total nutrient admixtures continues [letter; comment] Driscoll DF. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1921–2. Comment on: Am J Health Syst Pharm 1995 Apr 15;52(8):893; discussion 894–5.

Pharmacy preparation of total nutrient admixtures [letter] James JK, et al. **Am J Health Syst Pharm** 1995 Dec 1; 52(23):2727–8

Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Kirkham JC, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1557–8

Low-dose enteral feeding is beneficial during total parenteral nutrition. Sax HC, et al. **Am J Surg** 1996 Jun;171(6):587–90

Serum phospholipid fatty acids in severely injured patients on total parenteral nutrition with medium chain/long chain triglyceride emulsions. Adolph M, et al. **Ann Nutr Metab** 1995;39(4):251–60

Route of nutritional supply influences local, systemic, and remote organ responses to intraperitoneal bacterial challenge. Lin MT, et al. **Ann Surg** 1996 Jan;223(1):84–93

Determine whether 1 week of total parenteral nutrition (TPN) in healthy subjects alters systemic responses to a subsequent dose of endotoxin [letter; comment] Lowry SF, et al. **Ann Surg** 1996 Jan;223(1):107–8. Comment on: Ann Surg 1994 Aug;220(2):155–63.

Endotoxic shock after long-term resuscitation of hemorrhage/reperfusion injury decreased splanchnic blood flow and eicosanoid release. Myers SI, et al. **Ann Surg** 1996 Aug;224(2):213–8

The effect of nutrition on intestinal epithelial barrier function [letter; comment] Riegler M, et al. **Ann Surg** 1996 Apr; 223(4):447–8. Comment on: Ann Surg 1995 Mar;221(3):299–307.

Low birthweight infants and total parenteral nutrition immediately after birth. I. Energy expenditure and respiratory quotient of ventilated and non-ventilated infants. Forsyth JS, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F4–7

Low birthweight infants and total parenteral nutrition immediately after birth. III. Randomised study of energy substrate utilisation, nitrogen balance, and carbon dioxide production. Forsyth JS, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F13–6

Low birthweight infants and total parenteral nutrition immediately after birth. II. Randomised study of biochemical tolerance of intravenous glucose, amino acids, and lipid. Murdock N, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F8–12

Pulmonary vascular resistance during lipid infusion in neonates. Prasertsom W, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F95–8

Bombesin affects mucosal immunity and gut-associated lymphoid tissue in intravenously fed mice. Li J, et al. **Arch Surg** 1995 Nov;130(11):1164–9; discussion 1169–70

Total parenteral nutrition stimulates hepatic cholesterol synthesis in the rat. Hajri T, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):188–94

Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis. Koea JB, et al. **Br J Surg** 1996 Feb;83(2):196–202

Effect of methionine-deprived total parenteral nutrition on tumor protein turnover in rats. Yoshida S, et al. **Cancer** 1995 Oct 1;76(7):1275–82

Trace elements in parenteral micronutrition. Leung FY. **Clin Biochem** 1995 Dec;28(6):561–6 (76 ref.)

Luminal epidermal growth factor is trophic to the small intestine of parenterally fed rats. Marchbank T, et al. **Clin Sci (Colch)** 1995 Aug;89(2):117–20

Nutrition support following liver transplantation: comparison of jejunal versus parenteral routes. Mehta PL, et al. **Clin Transplant** 1995 Oct;9(5):364–9

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)

The role of total parenteral nutrition in the patient with cancer. Harrison LE, et al. **Curr Probl Surg** 1995 Oct; 32(10):833–917 (225 ref.)

Effect of total parenteral nutrition containing lipid calories on hepatic drug metabolism in rats. Raftogianis RB, et al. **Drug Metab Dispos** 1996 Apr;24(4):502–5

Restorative effect of total parenteral nutrition on natural killer cell activity in malnourished cancer patients. Bozzetti F, et al. **Eur J Cancer** 1995 Nov;31A(12):2023–7

Sodium citrate supplementation in inborn argininosuccinate lyase deficiency: a study in a 5-year-old patient under total parenteral nutrition. Renner C, et al. **Eur J Pediatr** 1995 Nov;154(11):909–14

The clinical application of two newly developed lipid emulsions (Solipid 20% S&E) in critically ill patients. Widhalm K, et al. **Infusionsther Transfusionsmed** 1996 Feb; 23(1):8–12

Brain large neutral amino acids and catecholamines in parenterally nourished preterm rabbits. Lopez SM, et al. **Int J Dev Neurosci** 1995 Oct;13(6):619–26

Glucose dynamics during continuous hemodiafiltration and total parenteral nutrition. Frankenfield DC, et al. **Intensive Care Med** 1995 Dec;21(12):1016–22

Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. Ronchera-Oms CL, et al. **J Clin Pharm Ther** 1995 Oct; 20(5):253–8

A total parenteral nutrition solution supplemented with a nucleoside and nucleotide mixture sustains intestinal integrity, but does not stimulate intestinal function after massive bowel resection in rats. Iijima S, et al. **J Nutr** 1996 Mar;126(3):589–95

Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. Ohls RK, et al. **J Pediatr** 1996 Apr;128(4):518–23

Biliary lipid composition and bile acid profiles during and after enteral fast of total parenteral nutrition in the rabbit. Das JB, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan; 22(1):85–91

Cysteine supplementation increases glutathione, but not polyamine, concentrations of the small intestine and colon of parenterally fed newborn rabbits. Pollack PF, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):364–72

Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. Beath SV, et al. **J Pediatr Surg** 1996 Apr;31(4):604–6

Effect of lipid-free total parenteral nutrition on hepatic drug conjugation in rats. Raftogianis RB, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):602–8

The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. Gramm HJ, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):1–12 (75 ref.)

Don't malnourish the obese! [letter; comment] Bentsianov B, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun; 19(3):251–3. Comment on: JPEN J Parenter Enteral Nutr 1994 May–Jun;18(3):203–7.

Case management in home total parenteral nutrition: a cost-identification analysis. Curtas S, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):113–9

Insulin-like growth factor-I enhances immune response in dexamethasone-treated or surgically stressed rats maintained with total parenteral nutrition. Hinton PS, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec; 19(6):444–52

The effects of glutamine-supplemented parenteral nutrition in premature infants. Lacey JM, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):74–80

The solubility of calcium and phosphate in two specialty amino acid solutions. MacKay MW, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):63–6

Tissue manganese concentrations and antioxidant enzyme activities in rats given total parenteral nutrition with and without supplemental manganese. Malecki EA, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun;19(3):222–6

Manganese deposition in the brain during long-term total parenteral nutrition. Ono J, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):310–2

Effect of enteral and parenteral nutrition on amino acid levels in cancer patients. Pearlstone DB, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun;19(3):204–8

Structured triglycerides were well tolerated and induced increased whole body fat oxidation compared with long-chain triglycerides in postoperative patients. Sandström R, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):381–6

The effect on energy and nitrogen metabolism by continuous, bolus, or sequential infusion of a defined total parenteral nutrition formulation in patients after major surgical procedures. Sandström R, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):333–40

Muscle protein synthesis rate decreases 24 hours after abdominal surgery irrespective of total parenteral nutrition. Tjäder I, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):135–8

Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. Yoshida S, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):492–7

Preservation of intestine protein by peptide YY during total parenteral nutrition. Chance WT, et al. **Life Sci** 1996; 58(21):1785–94

NO2/NO3 and cytokine plasma profiles under different postoperative parenteral nutrition regimens [see comments] Arias-Díaz J, et al. **Nutrition** 1996 Feb;12(2):89–92. Comment in: Nutrition 1996 Feb;12(2):129–30.

Effect of lipid emulsions for total parenteral nutrition on regeneration of the liver after partial hepatectomy in rats. Ikuta K, et al. **Nutrition** 1995 Jul–Aug;11(4):365–70

Biochemical indices may not accurately reflect changes in nutritional status after allogeneic bone marrow transplantation. Muscaritoli M, et al. **Nutrition** 1995 Sep–Oct;11(5):433–6

Total parenteral nutrition in a patient with severe diabetic diarrhea [clinical conference] Thomas P, et al. **Nutrition** 1995 Sep–Oct;11(5):456–60

The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451–70 (98 ref.)

Absorption of a new oral formulation of cyclosporin A in a child on parenteral nutrition. Jewkes FE, et al. **Pediatr Nephrol** 1995 Oct;9(5):617–8

Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by 31P-NMR. Bodoky G, et al. **Physiol Behav** 1995 Sep;58(3):521–7

Biliary lithocholate and cholestasis during and after total parenteral nutrition: an experimental study. Das JB, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):253–9

Does hyperalimentation improve outcome in patients with severe head injury? Lebkowski WJ. **Rocz Akad Med Bialymst** 1994;39:117–20

Nutritional support in the management of external pancreatic fistulas. Madiba TE, et al. **S Afr J Surg** 1995 Jun;33(2):81–4

Current indications for intravenous nutritional support in oncology patients. Hill AD, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):549–63 (78 ref.)

Metabolic response to glucose overload in surgical stress: energy disposal in brown adipose tissue. Yamamoto T. **Surg Today** 1996;26(3):151–7

[Role of energy metabolism in nutrition management of critically ill patients] Ren J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):346–8, 382–3 (Eng. Abstr.) **(Chi)**

[Stability of amino acids and vitamins in total nutrient admixture] Huang D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):269–72 (Eng. Abstr.) **(Chi)**

[An evaluation of nonsurgical treatment for severe acute pancreatitis] Liu S, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):545–7 (Eng. Abstr.) **(Chi)**

[Total parenteral nutrition support for patients with major abdominal trauma] Shu Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):279–81 (Eng. Abstr.) **(Chi)**

[Parenteral and enteral nutrition in patients with diseases of the gastrointestinal tract] Bureš J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):21–35 (207 ref.) (Eng. Abstr.) **(Cze)**

[Total and prolonged parenteral nutrition at the hospital and at the patient's home: its socio-economic importance] Joyeux H, et al. **Bull Acad Natl Med** 1995 Nov; 179(8):1625–36 (Eng. Abstr.) **(Fre)**

[Fructose vs. glucose in total parenteral nutrition in critically ill patients] Adolph M, et al. **Anaesthesist** 1995 Nov; 44(11):770–81 (Eng. Abstr.) **(Ger)**

[Fürst P, Stehle P: Glutamine supplemented nutrition in clinical practice—use of glutamine containing dipeptides (letter)] Baethmann A. **Infusionsther Transfusionsmed** 1996 Apr;23(2):98–9 **(Ger)**

[The revised PEDINFUS computer program for total and added parenteral nutrition in children] Kuchenbecker J, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):35–40 (Eng. Abstr.) **(Ger)**

[Artificial nutrition in the management of lesions caused by caustic ingestion] Andreoni B, et al. **Chir Ital** 1994; 46(6):42–8 (Eng. Abstr.) **(Ita)**

[The choice of substrates in total parenteral nutrition] Chiarla C, et al. **Chir Ital** 1994;46(6):20–30 (52 ref.) (Eng. Abstr.) **(Ita)**

[The use of lipids in total parenteral nutrition] Motton G, et al. **Chir Ital** 1994;46(6):31–5 (49 ref.) (Eng. Abstr.) **(Ita)**

[Trace elements in long-term total parenteral nutrition] Itokawa Y. **Nippon Rinsho** 1996 Jan;54(1):172–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Secondary gastrointestinal amyloidosis: successful treatment with TPN, prednisolone and colchicine therapy. Report of a case] Muramatsu S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1770–5 **(Jpn)**

[Influence of resting the digestive duct in gastric emptying. Comparison of 2 nutritional modalities: glucidic enteral and total parenteral nutrition] Aznar JJ, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):59–62 (Eng. Abstr.) **(Spa)**

[Total parenteral nutrition in severe hyperemesis gravidarum] Hasbún J, et al. **Rev Chil Obstet Ginecol** 1994;59(5):378–82 (Eng. Abstr.) **(Spa)**

[Should parenteral nutrition be discontinued? An ethical dilemma in terminal care] Larsson S. **Lakartidningen** 1995 Dec 13;92(50):4798–801 **(Swe)**

[News concerning total parenteral nutrition. From hyperalimentation to nutrition pharmacology] Sandström R, et al. **Lakartidningen** 1996 Feb 21;93(8):669–70, 673 **(Swe)**

ADVERSE EFFECTS

Stroke caused by inadvertent intra-arterial parenteral nutrition. Lynch JC, et al. **Anaesth Intensive Care** 1995 Jun;23(3):358–60

Loss of upper respiratory tract immunity with parenteral feeding. Kudsk KA, et al. **Ann Surg** 1996 Jun;223(6):629–35; discussion 635–8

Polymyxin B prevents increased sympathetic activity and alveolar macrophage tumor necrosis factor release in parenterally fed rats. Johnson KM, et al. **Arch Surg** 1995 Dec;130(12):1294–9; discussion 1299–300

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans [letter; comment] Parks RW, et al. **Br J Surg** 1996 May; 83(5):713–4. Comment on: Br J Surg 1995 Dec;82(12):1663–7.

Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans [see comments] Sedman PC, et al. **Br J Surg** 1995 Dec; 82(12):1663–7. Comment in: Br J Surg 1996 May;83(5):713–4.

Total parenteral nutrition impairs bile flow and alters bile composition in newborn piglet. Duerksen DR, et al. **Dig Dis Sci** 1996 Sep;41(9):1864–70

Early cholestasis in premature infants receiving total parenteral nutrition: a possible consequence of shock and hypoxia. Jacquemin E, et al. **Eur J Pediatr Surg** 1995 Oct; 5(5):259–61

Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Buchman AL, et al. **Hepatology** 1995 Nov;22(5):1399–403

Survival to lipopolysaccharide, cytokine release and phagocyte functions in mice treated with different total parenteral nutrition regimens. Tufano MA, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):493–509

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

Intestinal immune function is unaffected by parenteral nutrition in man. Buchman AL, et al. **J Am Coll Nutr** 1995 Dec;14(6):656–61

Effects of L-glutamine on induced hepatosteatosis in rats receiving total parenteral nutrition. Yeh SL, et al. **J Formos Med Assoc** 1995 Oct;94(10):593–9

Aminosyn PF or trophamine: which provides more protection from cholestasis associated with total parenteral nutrition? Forchielli ML, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):374–82

Treatment of parenteral nutrition-associated cholestasis with cholecystokinin-octapeptide. Teitelbaum DH, et al. **J Pediatr Surg** 1995 Jul;30(7):1082–5

Parenteral nutrition infused by epicutaneous catheter: pulmonary complication. Martinez-Tallo E, et al. **J Perinat Med** 1995;23(3):223–7

Copper deficiency [letter] Hoffbrand B. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):449

Glucose response to discontinuation of parenteral nutrition in patients less than 3 years of age. Bendorf K, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):120–2

Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. Buchman AL, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):453–60

Spinal osteomyelitis after TPN catheter-induced septicemia. Corso FA, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):291–5

Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. Hill SE, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):81–7

Interrelation of intracellular proteases with total parenteral nutrition-induced gut mucosal atrophy and increase of mucosal macromolecular transmission in rats. Kishibuchi M, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun; 19(3):187–92

The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. Raftogianis RB, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):303–9

TPN-induced sympathetic activation is related to diet, bacterial translocation, and an intravenous line. Sax HC. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):419–20

Glutamine dipeptide-supplemented parenteral nutrition reverses gut atrophy, disaccharidase enzyme activity, and absorption in rats. Schröder J, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov-Dec;19(6):502-6

Growth retardation in children receiving long-term total parenteral nutrition: effects of ornithine alpha-ketoglutarate. Ziegler TR. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):420-1

Candidemia in non-neutropenic patients with an intravenous hyperalimentation catheter: good prognosis of Candida parapsilosis infection. Kataoka S, et al. **Kansenshogaku Zasshi** 1995 Sep;69(9):969-74

Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Actis GC, et al. **Liver** 1995 Dec;15(6):320-3

Total parenteral nutrition and immune system activity: a review [see comments] Gogos CA, et al. **Nutrition** 1995 Jul-Aug;11(4):339-44 (74 ref.). Comment in: Nutrition 1995 Jul-Aug;11(4):394-5.

A case of overfeeding complicating the management of adult respiratory distress syndrome. Sullivan DJ, et al. **Nutrition** 1995 Jul-Aug;11(4):375-8

Neonatal segmental myoclonus associated with hyperglycorrhachia. Bass WT, et al. **Pediatr Neurol** 1995 Jul;13(1):77-9

Venopelvic fistula: a rare complication of hyperalimentation. Aihara T, et al. **Pediatr Radiol** 1996;26(3):198-9

The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Brooks MJ, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):713-26 (76 ref.)

Preventive effect of simultaneously infused lipid emulsion against thrombophlebitis during postoperative peripheral parenteral nutrition. Matsusue S, et al. **Surg Today** 1995; 25(8):667-71

Tumor necrosis factor-alpha and total parenteral nutrition-induced anorexia. Opara EI, et al. **Surgery** 1995 Oct;118(4):756-60; discussion 760-2

[Glutamine dipeptide enriched nutritional solutions attenuate bacterial translocation in rats after 60% intestinal resections] Bai M, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):116-9 (Eng. Abstr.) **(Chi)**

[Cholestasis mimicking a bile duct obstruction] Girardot B, et al. **Ann Pathol** 1995;15(4):293-4 **(Fre)**

[Influence of total parenteral nutrition in immature rats: effect of glutamine infusion on bowel integrity] Okawa Y. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):55-68 (Eng. Abstr.) **(Jpn)**

[Clinical studies of fluconazole in patients with deep-seated fungal infection in intravenous hyperalimentation (IVH)] Takeda S, et al. **Kansenshogaku Zasshi** 1996 May; 70(5):437-40 (Eng. Abstr.) **(Jpn)**

[Total parenteral nutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):309-11 (16 ref.) **(Jpn)**

[Intrahepatic cholestasis associated with neonatal small intestinal obstruction] Tajiri H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):569-70 (9 ref.) **(Jpn)**

[An infection study of total parenteral nutrition catheters for Y-site drug administration] Gómez Palomar C, et al. **Nutr Hosp** 1996 Mar-Apr;11(2):141-7 (Eng. Abstr.) **(Spa)**

[A possible hypersensitivity reaction to total parenteral nutrition] Vázquez Mora JR, et al. **Nutr Hosp** 1996 Mar-Apr;11(2):148-50 (13 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Pharmaceutical aspects of parenteral nutrition: a historical perspective [editorial] Hardy G. **Nutrition** 1995 Nov-Dec; 11(6):767-8

INSTRUMENTATION

Hub disconnection and migration of a tunnelled central line [letter] Breusch SJ, et al. **Anaesthesia** 1996 May;51(5):516

The efficacy of heparin in maintaining peripheral infusions in neonates. Moclair A, et al. **Eur J Pediatr** 1995 Jul; 154(7):567-70

Total parenteral nutrition catheters [letter; comment] Mulloy RH. **JPEN J Parenter Enteral Nutr** 1995 May-Jun; 19(3):250-1. Comment on: JPEN J Parenter Enteral Nutr 1994 Jan-Feb;18(1):71-4.

Prevention of fatty liver and maintenance of systemic valine depletion using a newly developed dual infusion system. Nishihira T, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun;19(3):199-203

Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. Werlin SL, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):416-8

METHODS

Alanyl-glutamine dipeptide-supplemented parenteral nutrition improves intestinal metabolism and prevents increased permeability in rats. Haque SM, et al. **Ann Surg** 1996 Mar;223(3):334-41

A 24-patient experience in hyperalimentation for acute renal insufficiency: emphasis on amino acid determination. Kung SP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct; 56(4):252-7

Early metabolic treatment after liver transplant: amino acid tolerance. Iapichino G, et al. **Intensive Care Med** 1995 Oct; 21(10):802-7

Immediate metabolic effects of different nutritional regimens in critically ill medical patients. Müller TF, et al. **Intensive Care Med** 1995 Jul;21(7):561-6

Parenteral nutrition infused by epicutaneous catheter: pulmonary complication. Martinez-Tallo E, et al. **J Perinat Med** 1995;23(3):223-7

Glucose response to discontinuation of parenteral nutrition in patients less than 3 years of age. Bendorf K, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):120-2

Prevention of fatty liver and maintenance of systemic valine depletion using a newly developed dual infusion system. Nishihira T, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun;19(3):199-203

[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393-8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative infusion therapy: electrolyte solution in comparison with hypocaloric glucose and carbohydrate exchange-amino acid solutions] Jauch KW, et al. **Zentralbl Chir** 1995;120(9):682-8 (Eng. Abstr.) **(Ger)**

STANDARDS

An interdisciplinary nutrition support team improves quality of care in a teaching hospital. Fisher GG, et al. **J Am Diet Assoc** 1996 Feb;96(2):176-8

Cecal infusion of nutrients improves nutritional status of rats. Aghdassi E, et al. **J Nutr** 1995 Nov;125(11):2880-6

Cysteine supplementation and reduction of total parenteral nutrition-induced hepatic lipid accumulation in the weanling rat. Narkewicz MR, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):18-24

Nutrition support affects the distribution and organ uptake of cachectin/tumor necrosis factor in rats. Keith ME, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct; 19(5):341-50

A prospective audit of total parenteral nutrition at a major teaching hospital [see comments] Ioannides-Demos LL, et al. **Med J Aust** 1995 Sep 4;163(5):233, 235-7. Comment in: Med J Aust 1995 Sep;4;163(5):228.

Adjuvant recombinant human growth hormone does not augment endogenous glucose production in total parenteral nutrition-fed multiple trauma patients. Jeevanandam M, et al. **Metabolism** 1996 Apr;45(4):450-6

Efficacy of a mixture of medium-chain triglyceride (75%) and long-chain triglyceride (25%) fat emulsions in the nutritional management of multiple-trauma patients [see comments] Jeevanandam M, et al. **Nutrition** 1995 May-Jun; 11(3):275-84. Comment in: Nutrition 1995 May-Jun;11(3):309-10.

UTILIZATION

Current uses and abuses of total parenteral nutrition. Archer SB, et al. **Adv Surg** 1996;29:165-89 (140 ref.)

Perioperative use of total parenteral nutrition. Variations in guidelines and practice in three Norwegian hospitals. Mjaaland M, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):741-9

Evaluation of the appropriate use of parenteral nutrition in an acute care setting. Hester DD, et al. **J Am Diet Assoc** 1996 Jun;96(6):602-3

PARENTERALLY-TRANSMITTED NON-A, NON-B HEPATITIS see **HEPATITIS C**

PARENTING

see related

CHILD REARING

Variations in parenting practices: gender- and age-related differences in African adolescents. Mboya MM. **Adolescence** 1995 Winter;30(120):955-62

Identity development, parental and peer support in adolescence: results of a national Dutch survey. Meeus W, et al. **Adolescence** 1995 Winter;30(120):931-44

Teenage parents and their offspring. Kaufman J. **Ann N Y Acad Sci** 1996 Jun 18;789:17-30

Should older women be offered in vitro fertilisation? Existing children are treated differently from embryos [letter; comment] Stammers TG. **BMJ** 1995 Sep 9;311(7006):690 . Comment on: BMJ 1995 Jun 3;310(6992):1455-8.

Protection of children against sunburn: a survey of parental practice in Leicester. Bourke JF, et al. **Br J Dermatol** 1995 Aug;133(2):264-6

Child abuse potential inventory and parenting behavior: relationships with high-risk correlates. Haskett ME, et al. **Child Abuse Negl** 1995 Dec;19(12):1483-95

Outreach. Practice parenting. Hudson T. **Hosp Health Netw** 1996 Sep 5;70(17):68

Grandmother co-residence, parenting, and child development among low income, urban teen mothers. Black MM, et al. **J Adolesc Health** 1996 Mar;18(3):218-26

Adolescent and adult mothers' perceptions of hazardous situations for their children. McClure-Martinez K, et al. **J Adolesc Health** 1996 Mar;18(3):227-31

Family training: supporting mothers and fathers in the transition to parenthood. Vehviläinen-Julkunen K. **J Adv Nurs** 1995 Oct;22(4):731-7

Large group community-based parenting programs for families of preschoolers at risk for disruptive behaviour disorders: utilization, cost effectiveness, and outcome. Cunningham CE, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1141-59

Self-esteem and self-efficacy; perceived parenting and family climate; and depression in university students. Oliver JM, et al. **J Clin Psychol** 1995 Jul;51(4):467-81

Parent-child relationship disorders. Part II. The vulnerable child syndrome and its relation to parental overprotection. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug; 16(4):251-6

Parent-child relationship disorders. Part I. Parental overprotection and the development of the Parent Protection Scale. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):244-50

The attitudes of undergraduate college students toward gay parenting. Crawford I, et al. **J Homosex** 1996;30(4):63-77

Promoting healthy parenting through prenatal education [editorial] Clay LS. **J Nurse Midwifery** 1995 Sep-Oct; 40(5):397-8

Adolescent parenting: outcomes and maternal perceptions. Thompson PJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):713-8

A longitudinal study of parenting as a protective factor for children of alcoholics. Curran PJ, et al. **J Stud Alcohol** 1996 May;57(3):305-13

How can a nurse care for me? [comment] **MCN Am J Matern Child Nurs** 1995 Nov-Dec;20(6):333 . Comment on: MCN Am J Matern Child Nurs 1995 Nov-Dec;20(6):326-32.

What is a "good" parent? Gross D. **MCN Am J Matern Child Nurs** 1996 Jul-Aug;21(4):178-82

Grandparents as primary caregivers [see comments] Kelley SJ, et al. **MCN Am J Matern Child Nurs** 1995 Nov-Dec; 20(6):326-32. Comment in: MCN Am J Matern Child Nurs 1995 Nov-Dec;20(6):333.

A study of parenting of IVF and DI children. McWhinnie A. **Med Law** 1995;14(7-8):501-8

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7-8):531-41 (20 ref.)

Divorce and custody: the rights, needs, and obligations of mothers, fathers, and children. Maccoby EE. **Nebr Symp Motiv** 1995;42:135-72 (58 ref.)

Back pain and male parenthood [letter; comment] Rossignol M. **Occup Environ Med** 1995 Oct;52(10):699-700. Comment on: Occup Environ Med 1995 Jan;52(1):51-3.

Skin cancer prevention by parents of young children: health information sources, skin cancer knowledge, and sun-protection practices. Buller DB, et al. **Oncol Nurs Forum** 1995 Nov-Dec;22(10):1559-66

Corporal punishment [letter; comment] Nelson FP. **Pediatrics** 1995 Oct;96(4 Pt 1):793-4; discussion 794-5. Comment on: Pediatrics 1994 Oct;94(4 Pt 2):587-93.

Corporal punishment [letter; comment] Trumbull DA, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):792-3; discussion 794-5. Comment on: Pediatrics 1994 Oct;94(4 Pt 2):577-8. Comment on: Pediatrics 1994 Oct;94(4 Pt 2):579-86. Comment on: Pediatrics 1994 Oct;94(4 Pt 2):587-93.

Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747-58 (63 ref.)

PSYCHOLOGY

Paternal caregiving and incest [letter; comment] Bixler RH. **Am J Orthopsychiatry** 1995 Oct;65(4):584-6. Comment on: Am J Orthopsychiatry 1995 Jan;65(1):101-13.

Children of addicted mothers: effects of the 'crack epidemic' on the caregiving environment and the development of preschoolers. Hawley TL, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):364-79

Seed or soil: how does our garden grow? [editorial] Eisenberg L. **Am J Psychiatry** 1996 Jan;153(1):3-5

Parenting: a genetic-epidemiologic perspective. Kendler KS. **Am J Psychiatry** 1996 Jan;153(1):11-20

Platelet serotonin 2A (5-HT2A) receptor characteristics and parenting factors for boys at risk for delinquency: a preliminary report. Pine DS, et al. **Am J Psychiatry** 1996 Apr;153(4):538-44

Reinventing the mother-daughter relationship. van Mens-Verhulst J. **Am J Psychother** 1995 Fall;49(4):526-39 (49 ref.)

Divergent themes in maternal experience in women older than 35 years of age. Reece SM, et al. **Appl Nurs Res** 1996 Aug;9(3):148-53

Self-critical attitudes and parental criticism in young women. Brewin CR, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):69-78

A longitudinal study of the grief of mothers and fathers of children with intellectual disability. Bruce EJ, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):33-45

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157-68 (75 ref.)

A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411-24 (62 ref.)

Do first-year intervention effects endure? Follow-up during toddlerhood of a sample of Dutch irritable infants. van den Boom DC. **Child Dev** 1995 Dec;66(6):1798-816

Comment on "a theory of the value of children" [comment] Lehrer EL, et al. **Demography** 1996 Feb;33(1):133-9. Comment on: Demography 1994 Aug;31(3):375-401.

Stability and change in family-of-origin recollections over the first four years of parenthood. Lewis JM, et al.

PARENTING

Fam Process 1995 Dec;34(4):455–69
Have I been a good parent? [editorial] Alberts M. **Iowa Med** 1995 Nov;85(11):453
The effect of child negative affect on maternal discipline behavior. Arnold EH, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):585–95
Family structure, family functioning and adolescent well-being: the transcendent influence of parental style. McFarlane AH, et al. **J Child Psychol Psychiatry** 1995 Jul; 36(5):847–64
Maternal discipline of young children: context, belief, and practice. Socolar RR, et al. **J Dev Behav Pediatr** 1996 Feb; 17(1):1–8
Maternal factors related to parenting practices, developmental expectations, and perceptions of child behavior problems. Fox RA, et al. **J Genet Psychol** 1995 Dec;156(4):431–41
The experiential facilitation of memory development in the home environment. Pierce SH, et al. **J Genet Psychol** 1996 Sep;157(3):331–47
Fathers' parenting attitudes during a child's first year. Tiller CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):508–14
Creating paths: living with a very-low-birth-weight infant. Vasquez E. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):619–24
Compensatory parenting: how mothers describe parenting their 3-year-old, prematurely born children. Miles MS, et al. **J Pediatr Nurs** 1995 Aug;10(4):243–53
Personality and parenting: exploring the mediating role of transient mood and daily hassles. Belsky J, et al. **J Pers** 1995 Dec;63(4):905–29
Gender roles and alcohol abuse across the transition to parenthood. Richman JA, et al. **J Stud Alcohol** 1995 Sep; 56(5):553–7
Treatment needs of drug-addicted mothers. Integrated parenting psychotherapy interventions. Luthar SS, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):341–8 (64 ref.)
The role of parenting sensitivity, infant temperament, and dyadic interaction in attachment theory and assessment. Seifer R, et al. **Monogr Soc Res Child Dev** 1995; 60(2–3):146–74
Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255–90 (70 ref.)
Reported parental behaviour and adult affective symptoms. 1. Associations and moderating factors. Rodgers B. **Psychol Med** 1996 Jan;26(1):51–61
Reported parental behaviour and adult affective symptoms. 2. Mediating factors. Rodgers B. **Psychol Med** 1996 Jan; 26(1):63–77
Maternal characteristics of adolescent mothers and older mothers of infants. Camp BW. **Psychol Rep** 1995 Dec;77(3 Pt 2):1152–4
Parental interest and academic achievement of Xhosa children from broken and intact homes. Cherian VI. **Psychol Rep** 1995 Jun;76(3 Pt 1):761–2
Response to Sputa and Paulson's "Birth order and family size: influences on adolescents' achievement and related parenting behaviors" [comment] Nystul MS. **Psychol Rep** 1995 Jun;76(3 Pt 2):1241–2. Comment on: Psychol Rep 1995 Feb;76(1):43–51.
Negative evaluations of men's nurturant touching of young children. Rane TR, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):811–8
A grounded theory of balancing alcohol recovery and pregnancy. Brudenell I. **West J Nurs Res** 1996 Aug; 18(4):429–40
[31 years experiences with triplets. 13 years self-help for parents with the ABC Club e.V., International Triplet and Multiple Birth Initiative] Grützner-Könnecke H. **Geburtshilfe Frauenheilkd** 1995 Aug;55(8):M88–9 **(Ger)**
[Couple relationship dynamics in transition to parenthood] Simoni H, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr;46(3–4):124–30 (Eng. Abstr.) **(Ger)**

PARENTS

see related
CHILD OF IMPAIRED PARENTS
SINGLE PARENT

Effects of information on smoking behaviour in families with preschool children. Eriksen W, et al. **Acta Paediatr** 1996 Feb;85(2):209–12
Actual and perceived parental social status: effects on adolescent self-concept. Orr E, et al. **Adolescence** 1995 Fall; 30(119):603–16
Parental history of alcoholism: a risk factor for alcohol-related peripheral neuropathies. Pessione F, et al. **Alcohol Alcohol** 1995 Nov;30(6):749–54
Teacher and parent perceptions of behavior problems among a sample of African American, Hispanic, and non-Hispanic white students. Zimmerman RS, et al. **Am J Community Psychol** 1995 Apr;23(2):181–97
Physicians' children are treated differently in the emergency department. Diekema DS, et al. **Am J Emerg Med** 1996 Jan;14(1):6–9
Tracking strategies involving fourteen sources for locating a transient study sample: parents of sudden infant death syndrome infants and control infants. Klonoff-Cohen H. **Am J Epidemiol** 1996 Jul 1;144(1):98–101
Body mass index in young adults: Associations with parental body size and education in the CARDIA Study. Greenlund KJ, et al. **Am J Public Health** 1996 Apr;86(4):480–5
Parental presence during induction of anesthesia. A randomized controlled trial. Kain ZN, et al. **Anesthesiology** 1996 May;84(5):1060–7
The effects of race, household income, and parental education on nutrient intakes of 9- and 10-year-old girls. NHLBI Growth and Health Study. Crawford PB, et al. **Ann Epidemiol** 1995 Sep;5(5):360–8
Childhood cancer and parental use of alcohol and tobacco. Sorahan T, et al. **Ann Epidemiol** 1995 Sep;5(5):354–9
Putting it on tape: audio taped assessment summaries for parents. Ilett SJ. **Arch Dis Child** 1995 Nov;73(5):435–8
Airway reactivity in parents of infants and young children with recurrent wheeze: a case-control study. Rusconi F, et al. **Arch Dis Child** 1995 Nov;73(5):423–6
Missed opportunities for vaccination and the delivery of preventive care. Ball TM, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):858–61
Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Bauchner H, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):396–9
Cigarette smoking cessation programs for parents and children's caregivers: a call to children's hospitals and pediatric facilities. Cohn RC, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):114
Marital status of Down syndrome parents. Feingold M. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):650–1
Immunization status as determined by patients' hand-held cards vs medical records. Fierman AH, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):863–6
Psychiatric and developmental disorders in families of children with attention-deficit hyperactivity disorder. Roizen NJ, et al. **Arch Pediatr Adolesc Med** 1996 Feb; 150(2):203–8
Risk factors for the infant prone sleep position. Taylor JA, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):834–7
Food consumption of parents on low incomes. Buchhorn D. **Aust J Public Health** 1995 Aug;19(4):427–9
Making decisions with children. Asking children to participate in decisions about their care undermines parents' position [letter; comment] Mahaffey PJ. **BMJ** 1996 Jul 6; 313(7048):49. Comment on: BMJ 1996 Mar 30;312(7034):794.
Parental knowledge and experiences after surgery for chronic otitis media. Marais J, et al. **Br J Clin Pract** 1996 Jun; 50(4):187–9
Help available for parents of disabled children. Smith C, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):154
Parental smoking and risk of otitis media in pre-school children. Collet JP, et al. **Can J Public Health** 1995 Jul–Aug;86(4):269–73
Pediatric injuries: parental knowledge, attitudes and needs. Hu X, et al. **Can J Public Health** 1996 Mar–Apr;87(2):101–5
Assessment of adherence to dietary recommendations [editorial] Zlotkin S. **Can J Public Health** 1995 Sep–Oct; 86(5):293–5 **(Eng, Fre)**
Parents' evaluations of wheezing in their children with asthma. Lee H, et al. **Chest** 1996 Jan;109(1):91–3
Cues parents use to assess postoperative pain in their children. Reid GJ, et al. **Clin J Pain** 1995 Sep;11(3):229–35
Pediatricians' preferences for anticipatory guidance topics compared with parental anxieties. Stickler GB, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):384–7
Parental exposure to hydrocarbons in Prader-Willi syndrome. Akefeldt A, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1101–9
Parents' perceptions of caregiving: development and validation of a measure of processes. King SM, et al. **Dev Med Child Neurol** 1996 Sep;38(9):757–72
Symptoms of hypoglycemia in children with IDDM. McCrimmon RJ, et al. **Diabetes Care** 1995 Jun;18(6):858–61
Testing parents of NIDDM patients [letter] Alcolado R, et al. **Diabetologia** 1995 Dec;38(12):1482–3
Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents. Tuomilehto J, et al. **Diabetologia** 1995 Aug;38(8):975–82
Parents' estimation of psychomotor development in very low birthweight (VLBW) infants. Heiser A, et al. **Early Hum Dev** 1995 Jun 21;42(2):131–9
Small influence of parental educational level on the survival of children with leukaemia in The Netherlands between 1973 and 1979. Coebergh JW, et al. **Eur J Cancer** 1996 Feb;32A(2):286–9
Effects of welfare reform on teenage parents and their children. Aber JL, et al. **Future Child** 1995 Summer–Fall; 5(2):53–71 (60 ref.)
Parental awareness and practices in acute diarrhea. Buch NA, et al. **Indian Pediatr** 1995 Jan;32(1):76–9
Knowledge of asthma among parents of asthmatic children. Lal A, et al. **Indian Pediatr** 1995 Jun;32(6):649–55
Psychosocial functioning among adult drug users: the role of parental absence, support, and conflict. Knight DK, et al. **Int J Addict** 1995 Aug;30(10):1271–88
Memory performance among women with parental abuse histories: enhanced directed forgetting or directed remembering? Cloitre M, et al. **J Abnorm Psychol** 1996 May;105(2):204–11
A study of the attitudes of nurses to parental involvement in the initial child-protection conference, and their preparation for it. Bell M. **J Adv Nurs** 1995 Aug;22(2):250–7
Partnership nursing: influences on involvement of informal carers. Casey A. **J Adv Nurs** 1995 Dec;22(6):1058–62
Body size, parental appraisal, and self-esteem in blind children. Pierce JW, et al. **J Child Psychol Psychiatry** 1996 Feb;37(2):205–12
Pediatric ambulatory anesthesia: role of parents. Hannallah RS. **J Clin Anesth** 1995 Nov;7(7):597–9
The accuracy of environmental tobacco smoke exposure measures among asthmatic children. Emerson JA, et al. **J Clin Epidemiol** 1995 Oct;48(10):1251–9
A new measure of parent satisfaction with medical care provided in the neonatal intensive care unit. Mitchell-Dicenso A, et al. **J Clin Epidemiol** 1996 Mar; 49(3):313–8
Behavioral correlates of differences between a child's assessment and the parents' assessment of the child's self-esteem. Schor EL, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):211–9
Parental grieving after infant death [letter] Hunfeld JA, et al. **J Fam Pract** 1996 Jun;42(6):622–3
Self-reported narcissism and perceived parental permissiveness and authoritarianism. Ramsey A, et al. **J Genet Psychol** 1996 Jun;157(2):227–38
Social support in the context of caregiving: husbands' provision of support to wives involved in parent care. Franks MM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P43–52
Adolescent psychopathology as a function of informant and risk status. Fabrega H Jr, et al. **J Nerv Ment Dis** 1996 Jan; 184(1):27–34
Parent satisfaction with services in an emergency department located at a paediatric teaching hospital. Brown K, et al. **J Paediatr Child Health** 1995 Oct;31(5):435–9
Reducing the anxiety of children undergoing surgery: parental presence during anaesthetic induction. Cameron JA, et al. **J Paediatr Child Health** 1996 Feb;32(1):51–6
Value of parents' estimates of children's developmental ages. Glascoe FP, et al. **J Pediatr** 1995 Nov;127(5):831–5
Parental representations among preschoolers and fourth-grade children: integrating object relational and cognitive developmental frameworks. Priel B, et al. **J Pers Assess** 1995 Oct;65(2):372–87
Parental presence during procedures: a survey of attitudes amongst paediatricians. Pejaver RK, et al. **J R Soc Med** 1995 Sep;88(9):508–10
The influence of parental smoking on youth smoking: is the recent downplaying justified? Males M. **J Sch Health** 1995 Aug;65(6):228–31
Validity of parent report measures of vocabulary development for children with Down syndrome. Miller JF, et al. **J Speech Hear Res** 1995 Oct;38(5):1037–44
Parents' speech and children's stuttering: a critique of the literature. Nippold MA, et al. **J Speech Hear Res** 1995 Oct; 38(5):978–89 (57 ref.)
Reading grade levels and health behaviors of parents at child clinics. Fredrickson DD, et al. **Kans Med** 1995 Fall; 96(3):127–9
Where are the parents? [letter] Armstrong HC. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):44–5
How parents in a rural area of Pekan district, Pahang perceive immunisation [letter] Amal MN. **Med J Malaysia** 1995 Jun;50(2):198–200
Cancer in the parents of children with cancer [see comments] Olsen JH, et al. **N Engl J Med** 1995 Dec 14;333(24):1594–9 . Comment in: N Engl J Med 1995 Dec 14;333(24):1633–5.
Whose baby are you? [letter] [see comments] Christenfeld NJ, et al. **Nature** 1995 Dec 14;378(6558):669. Comment in: Nature 1996 Jan 25;379(6563):292.
Parental ancestry and risk of multiple sclerosis in Alberta, Canada. Warren S, et al. **Neuroepidemiology** 1996 Jan–Feb; 15(1):1–9
Parental presence during induction of anaesthesia: practice differences between the United States and Great Britain. Kain ZN, et al. **Paediatr Anaesth** 1996;6(3):187–93
Parental presence during induction of anaesthesia [editorial] Kain ZN. **Paediatr Anaesth** 1995;5(4):209–12
Parents in the anaesthetic room: a questionnaire survey of departments of anaesthesia. McCormick AS, et al. **Paediatr Anaesth** 1996;6(3):183–6
Pediatric dentists' attitudes regarding parental presence during dental procedures. Marcum BK, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):432–6
Poor validity of parent reading of skin test induration in a high risk population. Cheng TL, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):90–2
Making sense of State v Messenger. Clark FI. **Pediatrics** 1996 Apr;97(4):579–83
Parents' attitudes toward firearm injury prevention counseling in urban pediatric clinics. Haught K, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):649–53
The association between parental smoking and the diet quality of low-income children. Johnson RK, et al. **Pediatrics** 1996 Mar;97(3):312–7
Do parents and professionals agree on the developmental status of high-risk infants? Kim MM, et al. **Pediatrics** 1996 May;97(5):676–81
Pediatric care for children whose parents are gay or lesbian. Perrin EC, et al. **Pediatrics** 1996 May;97(5):629–35
On listening to parents: the sudden infant death syndrome over 25 years. Tonkin S. **Pediatrics** 1996 Jun;97(6 Pt 1):896–7
Teaching deficit disorder [letter] Van Dervoort RL Jr, et al. **Pediatrics** 1996 Jul;98(1):167–8
Advance care planning for children with special health care

needs: a survey of parental attitudes. Wharton RH, et al. **Pediatrics** 1996 May;97(5):682–7

Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)

Traumatic memory and the intergenerational transmission of Holocaust narratives. Adelman A.
Psychoanal Study Child 1995;50:343–67

Do adolescents and parents report each other's physical activity accurately? Anderssen N, et al.
Scand J Med Sci Sports 1995 Oct;5(5):302–7

Smoking behaviour in young families. Do parents take practical measures to prevent passive smoking by the children? Eriksen W, et al. **Scand J Prim Health Care** 1995 Dec;13(4):275–80

Healing fictions': stories of choosing in the aftermath of the detection of fetal anomalies. Sandelowski M, et al.
Soc Sci Med 1996 Feb;42(3):353–61

Preoperative evaluation of donors for living related liver transplantation. Chen YS, et al. **Transplant Proc** 1996 Aug; 28(4):2415–6

Living related donor liver transplantation: the Seoul experience. Lee SG, et al. **Transplant Proc** 1996 Aug; 28(4):2383–4

Conflict resolution strategies and marital distress as mediating factors in the link between witnessing interparental violence and wife battering. Choice P, et al.
Violence Vict 1995 Summer;10(2):107–19

[Presence of parents in pediatric imaging] Schmit P, et al. **J Radiol** 1996 Jan;77(1):60–3 (Eng. Abstr.) **(Fre)**

[Study of the role of parents' occupation in children's mortality] Avdeeva IA, et al. **Med Tr Prom Ekol** 1996; (3):17–22 (Eng. Abstr.) **(Rus)**

EDUCATION

Factors which influence the rate of receiving a routine second newborn screening test in Washington State. Doyle DL, et al. **Am J Med Genet** 1995 Dec 4;59(4):417–20

Educational interventions to alter pediatric emergency department utilization patterns. Chande VT, et al.
Arch Pediatr Adolesc Med 1996 May;150(5):525–8

Safe storage of handguns. What do the police recommend? Denno DM, et al. **Arch Pediatr Adolesc Med** 1996 Sep; 150(9):927–31

Madeleine's death [letter; comment] Chase C.
Can Med Assoc J 1996 Apr 15;154(8):1146. Comment on: Can Med Assoc J 1996 Jan 15;154(2):246–9.

Society's diseases. Moréjon DP, et al. **Hastings Cent Rep** 1996 May–Jun;26(3):21; discussion 21–2

Parental education related to adolescent stress–coping and substance use: development of a mediational model. Wills TA, et al. **Health Psychol** 1995 Sep;14(5):464–78

Pyramidal parent training by peers. Neef NA.
J Appl Behav Anal 1995 Fall;28(3):333–7

Education of parents of infants and very young children with asthma: a developmental evaluation of the Wee Wheezers program. Wilson SR, et al. **J Asthma** 1996;33(4):239–54

Large group community-based parenting programs for families of preschoolers at risk for disruptive behaviour disorders: utilization, cost effectiveness, and outcome. Cunningham CE, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1141–59

Maternal attachment status, psychosocial stressors and problem behaviour: follow-up after parent training courses for conduct disorder. Routh CP, et al.
J Child Psychol Psychiatry 1995 Oct;36(7):1179–98

A systematic review of parent-oriented programs to prevent children's use of alcohol and other drugs. Elmquist DL.
J Drug Educ 1995;25(3):251–79

Promoting healthy parenting through prenatal education [editorial] Clay LS. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):397–8

Psychoeducational support groups for aging parents: development and preliminary outcomes. Smith GC, et al.
Ment Retard 1996 Jun;34(3):172–81

The chain of survival and EMS–C [editorial] Schafermeyer RW. **Pediatr Emerg Care** 1995 Aug;11(4):207

Selecting and using the most appropriate car safety seats for growing children: guidelines for counseling parents. American Academy of Pediatrics. Committee on Injury and Poison Prevention. **Pediatrics** 1996 May;97(5):761–3

Parent comprehension of polio vaccine information pamphlets. Davis TC, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):804–10

Parent orientation meetings to improve attendance and access at a child psychiatric clinic. Wenning K, et al.
Psychiatr Serv 1995 Aug;46(8):831–3

Use of mouthguards and headgear in organized sports by school-aged children. Nowjack-Raymer RE, et al.
Public Health Rep 1996 Jan–Feb;111(1):82–6

The efficacy of parent training for promoting positive parent-toddler relationships. Gross D, et al.
Res Nurs Health 1995 Dec;18(6):489–99

Sustainability of a nutrition education programme to prevent night-blindness in Bangladesh. Hussain A, et al.
Trop Med Int Health 1996 Feb;1(1):43–51

[Effect of home-based family counseling on the mental health of youths—15-year follow-up study] Aronen E, et al.
Duodecim 1995;111(6):505–9 **(Fin)**

PSYCHOLOGY

Grief following the loss of a newborn twin compared to a singleton. Cuisinier M, et al. **Acta Paediatr** 1996 Mar; 85(3):339–43

Parental alcohol abuse and gender as predictors of psychopathology in adult children of alcoholics. Belliveau JM, et al. **Addict Behav** 1995 Sep–Oct;20(5):619–25

Evaluation of a preventive intervention for a self-selected subpopulation of children. Short JL, et al.
Am J Community Psychol 1995 Apr;23(2):223–47

Effects of children with Down syndrome on parents' activities. Barnett WS, et al. **Am J Ment Retard** 1995 Sep; 100(2):115–27

When a baby dies. Diaz MR. **Am J Nurs** 1995 Nov; 95(11):54–6

Disclosure of donor insemination: parental attitudes. Cook R, et al. **Am J Orthopsychiatry** 1995 Oct;65(4):549–59

Divorce mediation and resolution of child custody disputes: long-term effects. Dillon PA, et al.
Am J Orthopsychiatry 1996 Jan;66(1):131–40

Parents of children with attention-deficit/hyperactivity disorder: psychological and attentional impairment. Murphy KR, et al. **Am J Orthopsychiatry** 1996 Jan; 66(1):93–102

Impact of a natural disaster on preschool children: adjustment 14 months after a hurricane. Swenson CC, et al.
Am J Orthopsychiatry 1996 Jan;66(1):122–30

An education program for parents of children with asthma: differences in attendance between smoking and nonsmoking parents. Fish L, et al. **Am J Public Health** 1996 Feb; 86(2):246–8

The impact of parental presence on parental anxiety and satisfaction. Blesch P, et al. **AORN J** 1996 Apr;63(4):761–8

A study of bereavement care after a sudden and unexpected death. Dent A, et al. **Arch Dis Child** 1996 Jun;74(6):522–6

Content analysis of prime-time television medical news. A pediatric perspective. Prabhu NP, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):46–9

Noncompliance with scheduled revisits to a pediatric emergency department. Scarfone RJ, et al.
Arch Pediatr Adolesc Med 1996 Sep;150(9):948–53

Effects of structured encounter forms on pediatric house staff knowledge, parent satisfaction, and quality of care. A randomized, controlled trial. Zenni EA, et al.
Arch Pediatr Adolesc Med 1996 Sep;150(9):975–80

Serum screening for Down's syndrome. Creates stress for carers and parents [letter; comment] Bunn A, et al.
BMJ 1996 Apr 13;312(7036):974–5. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment on: BMJ 1996 Feb 10;312(7027):379. Comment on: BMJ 1996 Feb 10;312(7027):379–80.

Gaining patients' consent. Telling parents all relevant details might reduce recruitment of children to trials [letter] Stephenson T, et al. **BMJ** 1996 Aug 10;313(7053):362–3

Parental satisfaction with intervention: differences between respondents and non-respondents to a postal questionnaire. Stallard P. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):397–405

The effects of sickle cell disease on the families of affected children [letter] Oyedeji GA. **Cent Afr J Med** 1995 Oct; 41(10):333–4

Parental attitude and practice regarding physical punishment of school children in Santiago de Chile. Vargas NA, et al. **Child Abuse Negl** 1995 Sep;19(9):1077–82

A model of the effects of perceived parent and peer support on adolescent false self behavior. Harter S, et al.
Child Dev 1996 Apr;67(2):360–74

Parents' attributions for their children's behavior. Miller SA.
Child Dev 1995 Dec;66(6):1557–84 (110 ref.)

The long-term effects of children's early-onset disability on marital relationships. Taanila A, et al.
Dev Med Child Neurol 1996 Jul;38(7):567–77

Parental assessment of functional outcome after corpus callosotomy. Gilliam F, et al. **Epilepsia** 1996 Aug; 37(8):753–7

The structure of family perceptions among adolescents and their parents: individual satisfaction factors and family system factors. Benson MJ, et al. **Fam Process** 1995 Sep; 34(3):323–36

The McMaster Model of Family Functioning: observer and parental ratings in a nonclinical sample. Stevenson-Hinde J, et al. **Fam Process** 1995 Sep;34(3):337–47

Management of the angry parents of severely ill children. Sardesai U, et al. **Indian Pediatr** 1995 Jan;32(1):123–7

Hepatitis B vaccine acceptance among adolescents and their parents. Rosenthal SL, et al. **J Adolesc Health** 1995 Oct; 17(4):248–54

The use of qualitative methods in the study of parents' experiences of care on a children's surgical ward. Callery P, et al. **J Adv Nurs** 1996 Feb;23(2):338–45

Parent participation: a concept analysis. Coyne IT.
J Adv Nurs 1996 Apr;23(4):733–40 (78 ref.)

Parents' perceptions of caring for an infant or toddler with diabetes. Hatton DL, et al. **J Adv Nurs** 1995 Sep; 22(3):569–77

Parental divorce, self-esteem and depression: an intimate relationship as a protective factor in young adulthood. Palosaari UK, et al. **J Affect Disord** 1995 Dec 13;35(3):91–6

Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. Biederman J, et al.
J Am Acad Child Adolesc Psychiatry 1995 Nov; 34(11):1495–503

Consultation with young autistic children and their families. Wakschlag LS, et al.
J Am Acad Child Adolesc Psychiatry 1996 Jul;35(7):963–5

Brief report: variables related to parental choice to medicate their autistic children. Konstantareas M, et al.
J Autism Dev Disord 1995 Aug;25(4):443–52

Gender differences in the psychological adjustment of parents of young, developmentally disabled children. Trute B.
J Child Psychol Psychiatry 1995 Oct;36(7):1225–42

Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children. Meszaros JR, et al. **J Clin Epidemiol** 1996 Jun;49(6):697–703

Parents as teachers: an integral component of a developmental and behavioral pediatrics curriculum. Appell DJ, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):105–6

Family and parental functioning in cystic fibrosis. Ievers CE, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):48–55 (45 ref.)

Childrearing attitudes among parents of very low birth weight and normal birth weight children. Zelkowitz P, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):84–9

Attitudes towards Down's syndrome: follow up of a cohort of 280 cases. Julian-Reynier C, et al. **J Med Genet** 1995 Aug;32(8):597–9

Parents' responses to predictive genetic testing in their children: report of a single case study. Michie S, et al.
J Med Genet 1996 Apr;33(4):313–8

Holding on: parents' perceptions of premature infants' transfers. Gibbins SA, et al.
J Obstet Gynecol Neonatal Nurs 1996 Feb;25(2):147–53

Creating paths: living with a very-low-birth-weight infant. Vasquez E. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):619–24

Factors influencing parent decision making about pediatric cardiac transplantation. Higgins SS, et al.
J Pediatr Nurs 1996 Jun;11(3):152–60

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

Parenthood transition for parents of an infant diagnosed with a congenital heart condition. Svavarsdottir EK, et al.
J Pediatr Nurs 1996 Aug;11(4):207–16

Seven weeks. Shiminski-Maher T. **J Pediatr Oncol Nurs** 1995 Oct;12(4):233

Family coping with pediatric leukemia: ten years after treatment. Kupst MJ, et al. **J Pediatr Psychol** 1995 Oct; 20(5):601–17

Late psychosocial consequences for parents of children who survived cancer. Van Dongen-Melman JE, et al.
J Pediatr Psychol 1995 Oct;20(5):567–86

Pediatrician's communication style: relationship to parent's perceptions and behaviors. Worchel FF, et al.
J Pediatr Psychol 1995 Oct;20(5):633–44

Care-giver evaluation of anti-gastroesophageal reflux procedures in neurologically impaired children: what is the real-life outcome? O'Neill JK, et al. **J Pediatr Surg** 1996 Mar;31(3):375–80

Realities of a premature infant's first year: helping parents cope. Maroney DI. **J Perinatol** 1995 Sep–Oct;15(5):418–22

Cues to parent involvement in drug prevention and school activities. Hahn EJ, et al. **J Sch Health** 1996 May; 66(5):165–70

A longitudinal study of parenting as a protective factor for children of alcoholics. Curran PJ, et al. **J Stud Alcohol** 1996 May;57(3):305–13

Tonsillectomy: a family-transmissible surgical procedure [letter] Domenighetti G, et al. **Lancet** 1995 Nov 18; 346(8986):1376

How parents describe caring behaviors of nurses in pediatric intensive care. Vincent JL, et al.
MCN Am J Matern Child Nurs 1996 Jul–Aug;21(4):197–201

Donor insemination: effects on parents. Durna EM, et al.
Med J Aust 1995 Sep 4;163(5):248–51

Relationships and social support: views of parents with mental retardation/intellectual disability. Llewellyn G.
Ment Retard 1995 Dec;33(6):349–63

Grandparents as a source of support for parents of children with disabilities: a brief report. Sandler AG, et al.
Ment Retard 1995 Aug;33(4):248–50

Health status of bereaved parents. Birenbaum LK, et al.
Nurs Res 1996 Mar–Apr;45(2):105–9

Coming to terms: parents' response to a first cancer recurrence in their child. Hinds PS, et al. **Nurs Res** 1996 May–Jun;45(3):148–53

Parents' opinions concerning possible causes of cerebral palsy. Radeka N, et al. **Nurse Pract** 1996 Apr;21(4):116–8, 128

Postoperative pain in children: a survey of parents' expectations and perceptions of their children's experiences. Rømsing J, et al. **Paediatr Anaesth** 1996; 6(3):215–8

Preferences of parents for pediatric emergency physicians' attire. Gonzalez Del Rey JA, et al. **Pediatr Emerg Care** 1995 Dec;11(6):361–4

Parental stress and growth outcome in growth-deficient children. Bithoney WG, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):707–11

Parents' recollection of the initial communication of the diagnosis of cystic fibrosis. Jedlicka-Köhler I, et al.
Pediatrics 1996 Feb;97(2):204–9

Parents' attitudes toward school-based hepatitis B vaccination of their children. Woodruff BA, et al.
Pediatrics 1996 Sep;98(3 Pt 1):410–3

The use of next-of-kin in assessing handedness. Dorthe NJ, et al. **Percept Mot Skills** 1995 Aug;81(1):203–8

PARENTS

Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137–40 (33 ref.)

Questions of parental anxiety [editorial; comment] Ferguson-Smith MA. **Prenat Diagn** 1995 Dec; 15(13):1209–13. Comment on: Prenat Diagn 1995 Dec;15(13):1215–26. Comment on: Prenat Diagn 1995 Dec;15(13):1227–40. Comment on: Prenat Diagn 1995 Dec;15(13):1241–57. Comment on: Prenat Diagn 1995 Dec;15(13):1275–95. Comment on: Prenat Diagn 1995 Dec;15(13):1297–302. Comment on: Prenat Diagn 1995 Dec;15(13):1303–11.

Psychiatric morbidity and family burden among parents of disabled children. Carpiniello B, et al. **Psychiatr Serv** 1995 Sep;46(9):940–2

The families of anorexia nervosa and cystic fibrosis patients. Blair C, et al. **Psychol Med** 1995 Sep;25(5):985–93

The Child Abuse Potential Inventory: cross-validation in Croatia. Pečnik N, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):979–85

Predicting 13-year-olds' drinking using parents' self-reported alcohol use and restrictiveness compared with offspring's perception. Aas H, et al. **Scand J Psychol** 1996 Jun;37(2):113–20

Parents' perceptions of their children's recovery 5 to 10 years following day-care abuse. Burgess AW, et al. **Sch Inq Nurs Pract** 1996 Spring;10(1):75–92; discussion 93–6

Expressed emotion and language disturbances in parents of stable schizophrenia patients. Docherty NM. **Schizophr Bull** 1995;21(3):411–8

Parental perceptions and attitudes about informed consent in clinical research involving children. Harth SC, et al. **Soc Sci Med** 1995 Dec;41(12):1647–51

Pediatric critical care social work: clinical practice with parents of critically ill children. Dungan SS, et al. **Soc Work Health Care** 1995;21(1):69–80

Parent and professional perceptions about stress and coping strategies during a child's lengthy hospitalization. Horn JD, et al. **Soc Work Health Care** 1995;21(1):107–27

Alcohol expectancies and the personal and parental drinking patterns of women. Bogart CJ, et al. **Women Health** 1995; 22(4):51–66

[What is the attitude of parents to dental preventive examinations in schools and kindergarten? Results of a parent survey] Van Steenkiste M, et al. **Gesundheitswesen** 1996 Apr;58(4):237–42 (Eng. Abstr.) **(Ger)**

[Psychological aspects of Prader-Willi syndrome. Results of a parent survey] Sarimski K. **Z Kinder Jugendpsychiatr** 1995 Dec;23(4):267–74 (Eng. Abstr.) **(Ger)**

[The Parent Questionnaire in Family-Oriented Rehabilitation/Oncology--an instrument for inpatient quality assurance] Niebank K, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):291–307 (Eng. Abstr.) **(Ger)**

[Psychogenic polydipsia in infants due to the wrong parental behavior] Grela K, et al. **Pediatr Pol** 1995 Jun;70(6):511–4 (Eng. Abstr.) **(Pol)**

[Parental behavior during the most common childhood diseases] Pavlović M, et al. **Med Pregl** 1995;48(1–2):41–3 (Eng. Abstr.) **(Scr)**

[Deficient care of children with functional disabilities. Insecure relationship between child health services and parents] Janson S, et al. **Lakartidningen** 1996 May 22; 93(21):2057–60 **(Swe)**

[Why babies cry?] Michelsson K. **Nord Med** 1995; 110(11):271–2 (Eng. Abstr.) **(Swe)**

PARESIS

DIAGNOSIS

[Differential diagnosis of unilateral paresis and paralysis of the larynx] Chernobel'skiĭ SI. **Vestn Otorinolaringol** 1996 Mar-Apr;(2):24–6 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Prolonged unilateral lower limb paresis following abdominal surgery with epidural and general anaesthesia. Lyons B, et al. **Anaesth Intensive Care** 1995 Aug;23(4):507–9

Ictal contralateral paresis in complex partial seizures. Oestreich LJ, et al. **Epilepsia** 1995 Jul;36(7):671–5

Solitary involvement of the fourth thoracic vertebral body with eosinophilic granuloma and development of incomplete paraparesis. Krüger L, et al. **Eur Spine J** 1995; 4(5):313–6

Unrecognized fracture through the base of superior articular facet of cervical spine presenting with transient tetraparesis. Nyunt BA. **Injury** 1995 Oct;26(8):563–4

Traumatic abducens nerve paresis in a child. Freeman JW, et al. **J Neuroimaging** 1995 Oct;5(4):246–7

Fulminant Guillain-Barré syndrome with quadriplegia and total paresis of motor cranial nerves as a result of segmental demyelination. Tan AK, et al. **J Neurol Sci** 1995 Dec; 134(1–2):203–6

Analysis of tardy ulnar nerve palsy associated with cubitus varus deformity after a supracondylar fracture of the humerus: a report of four cases. Fujioka H, et al. **J Orthop Trauma** 1995;9(5):435–40

Images in clinical medicine. Pott's disease with paraparesis. Shaw BA. **N Engl J Med** 1996 Apr 11;334(15):958–9

Neurological complications of coronary arteriography. Mutarelli EG, et al. **Rev Paul Med** 1994 Oct-Dec; 112(4):646–8

Motor affliction of the L5 nerve root in lumbar nerve root compression syndromes. Jönsson B, et al. **Spine** 1995 Sep 15;20(18):2012–5

Reduction of decompression illness risk in pigs by use of non-linear ascent profiles. Broome JR. **Undersea Hyperb Med** 1996 Mar;23(1):19–26

[Antiphospholipid antibody syndrome as a possible cause of paresis in a child] Zecca G, et al. **Pediatr Med Chir** 1995 Sep-Oct;17(5):451–4 (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Lateralization of cutaneous inflammatory responses in patients with unilateral paresis after poliomyelitis. Tarkowski E, et al. **J Neuroimmunol** 1996 Jun;67(1):1–6

MICROBIOLOGY

Staphylococcal vertebral osteomyelitis: case report. Longe AC, et al. **East Afr Med J** 1995 Sep;72(9):609–10

PHYSIOPATHOLOGY

Monocular elevation paresis and contralateral downgaze paresis from unilateral mesodiencephalic infarction. Wiest G, et al. **J Neurol Neurosurg Psychiatry** 1996 May; 60(5):579–81

Segmental zoster paresis: an electrophysiological study. Sachs GM. **Muscle Nerve** 1996 Jun;19(6):784–6

Intracranial hypoglossal neurinoma without preoperative hypoglossal nerve paresis--case report. Kobayashi S, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):384–7

REHABILITATION

[Multilevel stimulation in the treatment of patients with paralysis and paresis] Tyshkevich TG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan-Feb;(1):16–8 (Eng. Abstr.) **(Rus)**

VETERINARY

Causes of losses including a Borna disease paralytic syndrome affecting young ostriches of one breeding organization over a five-year period (1989–1993). Ashash E, et al. **Avian Dis** 1996 Jan-Mar;40(1):240–5

[Tibial nerve and fibular nerve paresis in pigs after intramuscular injection in the caudal thigh muscle (case report)] Hafner A, et al. **Tierarztl Prax** 1995 Oct; 23(5):452–6 (Eng. Abstr.) **(Ger)**

PARESTHESIA

Does the transarterial technique of axillary block provide a higher success rate and a lower complication rate than a paresthesia technique? New evidence and old [editorial; comment] Winnie AP. **Reg Anesth** 1995 Nov-Dec; 20(6):482–5. Comment on: Reg Anesth 1995 Nov-Dec;20(6):486–92.

Area of paresthesia as determinant of sensory block in axillary brachial plexus block. Yamamoto K, et al. **Reg Anesth** 1995 Nov-Dec;20(6):493–7

CHEMICALLY INDUCED

Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Böhme A, et al. **Ann Hematol** 1995 Dec;71(6):311–2

Painful dysaesthesia with ciprofloxacin. Zehnder D, et al. **BMJ** 1995 Nov 4;311(7014):1204

Paresthesia as a side effect of the new antidepressant, nefazodone [letter] Ghaemi SN, et al. **Can J Psychiatry** 1995 Oct;40(8):499–500

Enalapril and peripheral neuropathy [letter] Ahmad S. **J Am Geriatr Soc** 1995 Oct;43(10):1182

Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline [letter; comment] Bhatara VS, et al. **J Clin Psychiatry** 1996 May;57(5):227. Comment on: J Clin Psychiatry 1995;56 Suppl 2:49–55.

Paresthesias and sensory neuropathy due to 1,1,1-trichloroethane [letter] House RA, et al. **J Occup Environ Med** 1996 Feb;38(2):123–4

COMPLICATIONS

Notalgia paresthetica and macular amyloidosis [letter; comment] Cerroni L, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):178. Comment on: Clin Exp Dermatol 1994 Jul;19(4):346–9.

DIAGNOSIS

Pharyngeal dysesthesia as an aura in temporal lobe epilepsy. Carmant L, et al. **Epilepsia** 1996 Sep;37(9):911–3

A comparison of questionnaire versus monofilament assessment of neurosensory deficit. Cunningham LL, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):454–9; discussion 459–60

[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treatment of meralgia paraesthetica with topical capsaicin [letter] Puig L, et al. **Dermatology** 1995;191(1):73–4

ETIOLOGY

Bilateral central pain. Canavero S. **Acta Neurol Belg** 1996 Jun;96(2):135–6

Avulsion fracture of the anterior superior iliac spine presenting as acute-onset meralgia paresthetica. Thanikachalam M, et al. **Ann Emerg Med** 1995 Oct; 26(4):515–7

Meralgia Paraesthetica: differential diagnosis and follow-up. Wiezer MJ, et al. **Muscle Nerve** 1996 Apr;19(4):522–4

Tingling extremities in a young man. Goldsmith DJ, et al. **Postgrad Med J** 1996 Jun;72(848):380–2

Prevention of laparoscopic surgeon's thumb [letter] Kano N, et al. **Surg Endosc** 1995 Jun;9(6):738–9

PATHOLOGY

Idiopathic distal small fiber neuropathy. Gorson KC, et al. **Acta Neurol Scand** 1995 Nov;92(5):376–82

PHYSIOPATHOLOGY

Significance of the spinal cord position in spinal cord stimulation. Holsheimer J, et al. **Acta Neurochir Suppl (Wien)** 1995;64:119–24

Transaxillary first rib resection for thoracic outlet syndrome: follow-up of 9 cases. Hussein EA, et al. **Int Angiol** 1995 Dec;14(4):404–9

Can proximal nerve lesions give rise to a "Tinel-like" sign distally? [letter] Hawley RJ. **Muscle Nerve** 1996 Aug; 19(8):1056–7

Can proximal nerve lesions give rise to a "Tinel-like" sign distally? [letter] Jabre JF. **Muscle Nerve** 1995 Dec; 18(12):1495–6

Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Eide PK, et al. **Neurosurgery** 1995 Dec;37(6):1080–7

PSYCHOLOGY

A comparison of questionnaire versus monofilament assessment of neurosensory deficit. Cunningham LL, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):454–9; discussion 459–60

RADIOTHERAPY

Preliminary study of low-level laser for treatment of long-standing sensory aberrations in the inferior alveolar nerve. Khullar SM, et al. **J Oral Maxillofac Surg** 1996 Jan; 54(1):2–7; discussion 7–8

SURGERY

Meralgia paresthetica: etiology, diagnosis, and outcome of surgical decompression. Nahabedian MY, et al. **Ann Plast Surg** 1995 Dec;35(6):590–4

Accessory slip of the palmaris longus muscle. Rubino C, et al. **Ann Plast Surg** 1995 Dec;35(6):657–9

Operative treatment of meralgia paresthetica: transection versus neurolysis. van Eerten PV, et al. **Neurosurgery** 1995 Jul;37(1):63–5

[Meralgia paraesthetica and its surgical treatment] Antoniadis G, et al. **Nervenarzt** 1995 Aug;66(8):614–7 (Eng. Abstr.) **(Ger)**

PARETIC NEUROSYPHILIS see **NEUROSYPHILIS**

PARGYLINE

ANALOGS & DERIVATIVES

Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT. Lena I, et al. **Nucl Med Biol** 1995 Aug;22(6):727–36

PHARMACOLOGY

5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Abdel-Fattah AF, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):379–84

TOXICITY

Effects of acute acetaldehyde, chronic ethanol, and pargyline treatment on agonist responses of the rat aorta. Brown RA, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):170–8

PARIETAL BONE

Intracranial chondroma arising from the cranial vault: CT and MR appearance. Abdelhamid K, et al. **J Comput Assist Tomogr** 1996 Jul-Aug;20(4):556–8

Unusual lytic intraosseous meningioma. Levin M, et al. **J Neuroimaging** 1995 Oct;5(4):247–8

Traumatic brain injury associated with an intradiploic epidermoid cyst: case report. Prall JA, et al. **Neurosurgery** 1995 Sep;37(3):523–5

[Primary non-Hodgkin's lymphoma of the skull in an 11-year-old girl. Follow-up and review of the literature] Daldrup HE, et al. **Radiologe** 1996 Apr;36(4):354–9 (31 ref.)

(Eng. Abstr.) (Ger)
[Diagnosis: plasmocytoma] Rodríguez Carbajal J. **Gac Med Mex** 1995 Jan–Feb;131(1):107–8 (Spa)

ABNORMALITIES

Delineation of a contiguous gene syndrome with multiple exostoses, enlarged parietal foramina, craniofacial dysostosis, and mental retardation, caused by deletions in the short arm of chromosome 11. Bartsch O, et al. **Am J Hum Genet** 1996 Apr;58(4):734–42

CYTOLOGY

Osteoclasts are not the major source of interleukin-6 in mouse parietal bones. Holt I, et al. **Bone** 1996 Mar;18(3):221–6

INJURIES

Insulin enhancement of in vitro wound healing in fetal rat parietal bones. Yano H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):182–6
[An unusual case of gunshot wound to the head] Stocker R, et al. **Unfallchirurgie** 1995 Dec;21(6):298–302 (Eng. Abstr.) (Ger)
[Posttraumatic pseudoaneurysm of the middle meningeal artery: a case report] Kimura T, et al. **No Shinkei Geka** 1995 Nov;23(11):1021–5 (Eng. Abstr.) (Jpn)

PATHOLOGY

Unusual CNS presentation of neuroblastoma. Egelhoff JC, et al. **Pediatr Radiol** 1996;26(1):51–4

SURGERY

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137–42 (11 ref.)
Guided bone regeneration in calvarial bone defects using polytetrafluoroethylene membranes. Bosch C, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):311–7

TRANSPLANTATION

[Results of the use of parietal bone as bone graft donor site in facial reconstruction. Apropos of 71 cases] Hemar P, et al. **Ann Chir Plast Esthet** 1995 Aug;40(4):349–56; discussion 357 (Eng. Abstr.) (Fre)
[The role of autologous parietal bone graft in alveolar cleft] Siciliano S, et al. **Minerva Stomatol** 1995 Sep;44(9):389–95 (Eng. Abstr.) (Ita)

ULTRASONOGRAPHY

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

ULTRASTRUCTURE

Junctions between early developing osteoblasts of rat calvaria as revealed by freeze–fracture and ultrathin section electron microscopy. Arana–Chavez VE, et al. **Arch Histol Cytol** 1995 Aug;58(3):285–92

PARIETAL CELLS, GASTRIC

see related
GASTRIC ACID
INTRINSIC FACTOR

CHEMISTRY

Gastrin-stimulated changes in Ca2+ concentration in parietal cells depends on adenosine 3',5'-cyclic monophosphate levels. Geibel J, et al. **Gastroenterology** 1995 Oct;109(4):1060–7
Modulation of Ca2+–activated K+ channels by Mg2+ and ATP in frog oxyntic cells. Komatsu H, et al. **Pflugers Arch** 1996 Feb;431(4):494–503

CYTOLOGY

Rab11 is an apically located small GTP-binding protein in epithelial tissues. Goldenring JR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G515–25
Heterogeneity and migration-related zonation of K(+)-ATPase activities in the oxyntic cell lineage of adult cattle. Kressin M. **Cell Tissue Res** 1996 May;284(2):231–8
Overexpression of transforming growth factor-alpha alters differentiation of gastric cell lineages. Goldenring JR, et al. **Dig Dis Sci** 1996 Apr;41(4):773–84
Identification of parietal cells in gastric body mucosa with HMFG-2 monoclonal antibody. Walker MM, et al. **J Clin Pathol** 1995 Sep;48(9):832–4
Genetic ablation of parietal cells in transgenic mice: a new model for analyzing cell lineage relationships in the gastric mucosa. Canfield V, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2431–5

DRUG EFFECTS

Epidermal growth factor inhibits carbachol-stimulated canine parietal cell function via protein kinase C. Wang L, et al. **Gastroenterology** 1996 Feb;110(2):469–77
Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide. D'Adda T, et al. **Gut** 1996 May;38(5):668–74
Inhibitory effect of leminoprazole on acid secretion in parietal cells isolated from guinea pig gastric mucosa. Saito E, et al. **Jpn J Pharmacol** 1995 May;68(1):19–23
Modulation of Ca2+–activated K+ channels by Mg2+ and ATP in frog oxyntic cells. Komatsu H, et al. **Pflugers Arch** 1996 Feb;431(4):494–503

ENZYMOLOGY

In vivo trafficking of nascent H(+)-K(+)-ATPase in rabbit parietal cells. Crothers JM Jr, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G883–91
Co-localization and functional coupling of creatine kinase B and gastric H+/K(+)-ATPase on the apical membrane and the tubulovesicular system of parietal cells. Sistermans EA, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):445–51
Heterogeneity and migration-related zonation of K(+)-ATPase activities in the oxyntic cell lineage of adult cattle. Kressin M. **Cell Tissue Res** 1996 May;284(2):231–8
Famotidine, a histamine-2-receptor antagonist, inhibits the increase in rat gastric H+/K(+)-ATPase mRNA induced by intravenous infusion of gastrin 17 and histamine. Yamamoto G, et al. **Dig Dis Sci** 1995 Sep;40(9):2064–9
Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. Suri-Payer E, et al. **J Immunol** 1996 Aug 15;157(4):1799–805

IMMUNOLOGY

Anti-parietal cell antibody in autoimmune liver diseases is associated with gastric mucosal atrophy and intestinal metaplasia. Oya H, et al. **Adv Exp Med Biol** 1995; 371B:1087–9
Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies. Bergmann C, et al. **Dig Dis Sci** 1995 Dec;40(12):2678–83
Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata. Kumar B, et al. **Int J Dermatol** 1995 Aug;34(8):542–5

METABOLISM

La3+ and pH sensitivity of Ca2+ entry and intracellular store filling in gastric parietal cells. Negulescu PA, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G770–8
Localization of mRNA for the muscarinic M1 receptor in rat stomach. Helander KG, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):158–62
GTP-binding protein-mediated production of superoxide anion in rabbit gastric parietal cells. Sakai H, et al. **Jpn J Physiol** 1995;45(4):673–9

PATHOLOGY

Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. Li Q, et al. **J Biol Chem** 1996 Feb 16;271(7):3671–6
Parietal cells in the duodenal bulb and their relation to Helicobacter pylori infection. Harris AW, et al. **J Clin Pathol** 1996 Apr;49(4):309–12
The histopathological spectrum of type A gastritis. Eidt S, et al. **Pathol Res Pract** 1996 Feb;192(2):101–6
[The parietal cell mass and acid secretion: Helicobacter pylori does not induce changes in the course of a duodenal ulcer] Testino G, et al. **Minerva Med** 1995 Dec;86(12):523–6 (Eng. Abstr.) (Ita)

PHYSIOLOGY

Gastric endocrine cells: gene expression, processing, and targeting of active products. Dockray GJ, et al. **Physiol Rev** 1996 Jul;76(3):767–98 (387 ref.)

SECRETION

Effect of pH buffers on proton secretion from gastric oxyntic cells measured with vibrating ion-selective microelectrodes. Demarest JR, et al. **Biol Bull** 1995 Oct–Nov;189(2):219–20
The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig. Association with production of vacuolating toxin by H. pylori. Kobayashi H, et al. **Scand J Gastroenterol** 1996 May; 31(5):428–33

ULTRASTRUCTURE

Ultrastructure of parietal cells before and after extended parietal cell vagotomy in patients with duodenal ulcer and their complications. Li S, et al. **Chin Med J (Engl)** 1995 Dec;108(12):898–901
Changes in parietal cell structure and function in HIV disease. Lake-Bakaar G, et al. **Dig Dis Sci** 1996 Jul;41(7):1398–408
A mini Cl- channel sensitive to external pH in the basolateral membrane of guinea-pig parietal cells. Kajita H, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):57–64
A maxi Cl- channel coupled to endothelin B receptors in the basolateral membrane of guinea-pig parietal cells. Kajita H, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):65–75
[Morphofunctional features of parietal cells from a hibernating rodent in varying physiological states] Matvienko LR, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):103–6 (Rus)

PARIETAL LOBE

A case of dysembryoplastic neuroepithelial tumor of the parietal lobe with characteristic magnetic resonance imaging. Kimura S, et al. **Acta Paediatr Jpn** 1996 Apr; 38(2):168–71
Skin burn associated with pulse oximetry during perioperative photodynamic therapy. Farber NE, et al. **Anesthesiology** 1996 Apr;84(4):983–5
Bone marrow infiltration by a parietal lobe grade III oligodendroglioma. Gerrard GE, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):321–2
Brain tumors do not affect thiopental dosing requirements. Veselis RA, et al. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):248–53
Primary intracranial epithelioid angiosarcoma--case report. Fuse T, et al. **Neurol Med Chir (Tokyo)** 1995 Jun; 35(6):364–8
[Pulmonary metastases of glioblastoma] Granjon O, et al. **Rev Mal Respir** 1995;12(5):489–91 (Eng. Abstr.) (Fre)
[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32–7 (35 ref.) (Eng. Abstr.) (Fre)
[Oligodendroglioma in childhood: a case report (letter)] del Val Río MR, et al. **An Esp Pediatr** 1996 Jan;44(1):80–2 (10 ref.) (Spa)
[Early cerebral metastasis of colonic adenocarcinoma] Serantes Gómez A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):141–3 (Eng. Abstr.) (Spa)

ABNORMALITIES

Morning Glory fundus anomaly, coloboma of the optic nerve, porencephaly and hydronephrosis in a newborn infant: MCPH entity. Merlob P, et al. **Clin Dysmorphol** 1995 Oct; 4(4):313–8
Arthrogryposis multiplex congenita and bilateral parietal polymicrogyria in association with the intrauterine death of a twin. Baker EM, et al. **Neuropediatrics** 1996 Feb; 27(1):54–6
Opercular malformations: clinical and MRI features in 11 children. Rolland Y, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S2–8

ANATOMY & HISTOLOGY

Anatomy of the parietal lobe: mapping the individual pattern. Ebeling U, et al. **Acta Neurochir (Wien)** 1995;136(1–2):8–11
MR of the cerebral operculum: topographic identification and measurement of interopercular distances in healthy infants and children. Chen CY, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1677–87
Location of the human posterior eye field with functional magnetic resonance imaging. Müri RM, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):445–8
[The rolandic line: a simple baseline for the identification of the central region. An MRI study and functional validation] Devaux B, et al. **J Neuroradiol** 1996 Jun; 23(1):6–18 (Eng. Abstr.) (Fre)

BLOOD SUPPLY

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Lehtovirta M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):644–9
Quantified electroencephalographic correlates of relative frontal or parietal hypoperfusion in dementia. Pozzi D, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):26–32
Blepharospasm and jaw closing dystonia after parietal infarcts. Jacob PC, et al. **Mov Disord** 1995 Nov;10(6):794–5
Functioning heterotopic grey matter? Increased blood flow with voluntary movement and sensory stimulation. Shimodozono M, et al. **Neuroradiology** 1995 Aug; 37(6):440–2

CYTOLOGY

A novel serpin-like protein, B-43, exists in both neurons and astrocytes: an immunohistochemical study in the parietal region of the bovine brain. Nishibori M, et al. **Neurosci Lett** 1995 Nov 17;200(2):125–8

DRUG EFFECTS

Peculiar effects of isradipine and darodipine on the rat brain dopaminergic system. Gaggi R, et al. **Gen Pharmacol** 1995 Mar;26(2):303–8
Effect of local cholecystokinin-8 administration on extracellular levels of amino acids and glycolytic products monitored by in vivo microdialysis in the fronto-parietal cortex of the rat. Godukhin O, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):29–32

GROWTH & DEVELOPMENT

Structural-functional correlates of neuroprotection in the aging rabbit by a calcium channel blocker. Nimodipine reverses neocortical dendritic atrophy and improves memory retention. Mervis RF, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:312–3

PARIETAL LOBE

INJURIES

Mild posttraumatic hypothermia reduces mortality after severe controlled cortical impact in rats. Clark RS, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):253–61

METABOLISM

Expression of Bcl-2 and Bax in the frontoparietal cortex of the rat following cardiac arrest. Jaw SP, et al. **Brain Res Bull** 1995;38(6):577–80

Histamine H3 receptor inhibition of K(+)-evoked release of acetylcholine from rat cortex in vivo. Blandina P, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S54–5

Head motion during positron emission tomography: is it significant? Ruttimann UE, et al. **Psychiatry Res** 1995 May 31;61(1):43–51

PARASITOLOGY

Cerebral sparganosis mansoni—case report. Okamura T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):909–13

PATHOLOGY

Primary Ki-1-positive T-cell lymphoma of the brain—an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37–41 (24 ref.)

[Extracerebral metastases of a glioblastoma, in the absence of surgery] Chretien F, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):342–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral cavernoma. A retrospective analysis of 24 cases] Cubo Delgado E, et al. **Neurologia** 1995 Aug–Sep; 10(7):277–82 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The role of inferior parietal cortex and fornix in route following and topographic orientation in cynomolgus monkeys. Barrow CJ, et al. **Behav Brain Res** 1996 Feb; 75(1–2):99–112

Unilateral injury of posterior parietal cortex and spatial learning in hooded rats. McDaniel WF, et al. **Behav Brain Res** 1995 Oct;70(2):165–79

Effects of lesions of the associative parietal cortex on the acquisition and use of spatial memory in egocentric and allocentric navigation tasks in the rat. Save E, et al. **Behav Neurosci** 1996 Feb;110(1):74–85

Histological evaluation of polyesterimide-insulated gold wires in brain. Yuen TG, et al. **Biomaterials** 1995 Aug; 16(12):951–6

Sex differences in interhemispheric correlation and spectral power of EEG activity. Juárez J, et al. **Brain Res Bull** 1995;38(2):149–51

The comforting substrate and the right brain. Horton PC. **Bull Menninger Clin** 1995 Fall;59(4):480–6

Encoding of intention and spatial location in the posterior parietal cortex. Andersen RA. **Cereb Cortex** 1995 Sep–Oct; 5(5):457–69 (58 ref.)

The sources of visual information to the primate frontal lobe: a novel role for the superior parietal lobule. Caminiti R, et al. **Cereb Cortex** 1996 May–Jun;6(3):319–28 (102 ref.)

Oculocentric spatial representation in parietal cortex. Colby CL, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):470–81 (38 ref.)

Deciding not to GO: neuronal correlates of response selection in a GO/NOGO task in primate premotor and parietal cortex. Kalaska JF, et al. **Cereb Cortex** 1995 Sep–Oct; 5(5):410–28

Representing spatial information for limb movement: role of area 5 in the monkey. Lacquaniti F, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):391–409

The parietal system and some higher brain functions. Mountcastle VB. **Cereb Cortex** 1995 Sep–Oct;5(5):377–90 (41 ref.)

The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Muir JL, et al. **Cereb Cortex** 1996 May–Jun;6(3):470–81

Neural mechanisms of visual guidance of hand action in the parietal cortex of the monkey. Sakata H, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):429–38

Neurophysiological evidence for a role of posterior parietal cortex in redirecting visual attention. Steinmetz MA, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):448–56

EEG findings in dementia are related to the parietal lobe syndrome. Edman A, et al. **Dementia** 1995 Nov–Dec; 6(6):323–9

Reactivity of magnetic parieto-occipital alpha rhythm during visual imagery. Salenius S, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 95(6):453–62

Eye position influence on the parieto-occipital area PO (V6) of the macaque monkey. Galletti C, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2486–501

Somatosensory activations of the parietal operculum of man. A PET study. Ledberg A, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1934–41

Fronto-parietal control of electrodermal activity in the cat. Sequeira H, et al. **J Auton Nerv Syst** 1995 Jun 25; 53(2–3):103–14

Frontal and parietal transcranial magnetic stimulation (TMS) disturbs programming of saccadic eye movements. Zangemeister WH, et al. **J Neurol Sci** 1995 Nov; 133(1–2):42–52

Covert orienting of attention in macaques. II. Contributions of parietal cortex. Robinson DL, et al. **J Neurophysiol** 1995 Aug;74(2):698–712

Specific involvement of human parietal systems and the amygdala in the perception of biological motion. Bonda E, et al. **J Neurosci** 1996 Jun 1;16(11):3737–44

Cortical stimulation for central pain [letter] Canavero S, et al. **J Neurosurg** 1995 Dec;83(6):1117

Cortical neurophysiology. Attention is everywhere [news] Britten KH. **Nature** 1996 Aug 8;382(6591):497–8

In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Möller HE, et al. **Neuropediatrics** 1995 Aug; 26(4):199–202

Do auditory stimuli activate human parietal brain regions? [letter; comment] Hämäläinen M, et al. **Neuroreport** 1995 Sep 11;6(13):1712–4. Comment on: Neuroreport 1994 Dec 30;6(1):182–4.

Direct visual pathways for reaching movements in the macaque monkey. Tanné J, et al. **Neuroreport** 1995 Dec 29;7(1):267–72

Activity of neurons of the cat motor cortex during differentiation between reactions of right and left paw placement on a support developed in response to stimulation of the parietal cortex of the different hemispheres. Maiorov VI, et al. **Neurosci Behav Physiol** 1995 May–Jun;25(3):215–24

Participation of the anterior suprasylvian cortex of the cat in the preparation of the paw extension reaction. Maiorov VI. **Neurosci Behav Physiol** 1995 May–Jun;25(3):189–95

Pain-related cerebral potentials in patients with frontal or parietal lobe lesions. Daum I, et al. **Neurosci Lett** 1995 Sep 8;197(2):137–40

Neural correlates of mental transformations of the body-in-space. Bonda E, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11180–4

Motion perception: seeing and deciding. Shadlen MN, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):628–33

Electrical microstimulation suggests two different forms of representation of head-centered space in the intraparietal sulcus of rhesus monkeys. Thier P, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4962–7

Superior parietal cortex activation during spatial attention shifts and visual feature conjunction. Corbetta M, et al. **Science** 1995 Nov 3;270(5237):802–5

The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764–9 (43 ref.)

The mental representation of hand movements after parietal cortex damage. Sirigu A, et al. **Science** 1996 Sep 13; 273(5281):1564–8

[The coherence between the frontal-parietal cortex and cardiac sympathetic nerve activity in cats] Huang ZS. **Sheng Li Hsueh Pao** 1996 Feb;48(1):1–7 (Eng. Abstr.) **(Chi)**

[The corollary neuronal activity of the parietal associative cortex in the cat during different types of voluntary movements] Khitrova-Orlova TV, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):70–5 (Eng. Abstr.) **(Rus)**

[Factors affecting endogenous evoked potentials in man] Krylov IN. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):176–80 **(Rus)**

[The synaptic responses of the neurons of the parietal associative cortex in cats to stimulation of the nucleus ruber] Papoian EV, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):64–9 **(Rus)**

[Antidromal and synaptic activation of the neurons of the associative parietal cortex in cats evoked by impulses from the pontine nuclei proper] Papoian EV. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):10–7 (Eng. Abstr.) **(Rus)**

[The afferent and efferent connections of field 7 in the parietal cortex with field 18a of the visual cortex in the rat] Nomokonova LM, et al. **Zh Evol Biokhim Fiziol** 1994 Nov–Dec;30(6):784–90 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1–2):127–42 (75 ref.)

Tumoural parietal lobe epilepsy. Clinical manifestations and outcome in 34 patients treated between 1934 and 1988. Salanova V, et al. **Brain** 1995 Oct;118 (Pt 5):1289–304

A comment on apperceptive agnosia. Warrington EK, et al. **Brain Cogn** 1995 Jul;28(2):173–7; discussion 178–9

Dissociation of ophthalmokinetic and melokinetic attention in unilateral neglect. Bisiach E, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):439–47

Distinctive forms of partial retrograde amnesia after asymmetric temporal lobe lesions: possible role of the occipitotemporal gyri in memory. Eslinger PJ, et al. **Cereb Cortex** 1996 May–Jun;6(3):530–9

Localization in impaired spatial vision. Takayama Y, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):249–52

Anosognosia in parietal lobe syndrome. Ramachandran VS. **Conscious Cogn** 1995 Mar;4(1):22–51

Transcutaneous electrical stimulation and vibration of neck muscles in neglect. Karnath HO. **Exp Brain Res** 1995; 105(2):321–4

Parietal kinetic ataxia without proprioceptive deficit. Ghika J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):531–3

Eosinophilic granuloma associated with intratumoral hemorrhage—case report. Uranishi R, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):458–61

Central motor loop oscillations in parkinsonian resting tremor revealed by magnetoencephalography. Volkmann J, et al. **Neurology** 1996 May;46(5):1359–70

Arthrogryposis multiplex congenita and bilateral parietal polymicrogyria in association with the intrauterine death of a twin. Baker EM, et al. **Neuropediatrics** 1996 Feb; 27(1):54–6

Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Maruff P, et al. **Neuropsychologia** 1995 Oct;33(10):1205–23

Is there a visual deficit in dyslexia resulting from a lesion of the right posterior parietal lobe? Polikoff BR, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):513–7

[Recurrent confusional states and periodic lateralized epileptiform discharges: a new type of non-convulsive status epilepticus?] Mateos V, et al. **Neurologia** 1995 Aug–Sep;10(7):298–301 (Eng. Abstr.) **(Spa)**

[Cerebral hemorrhage and migraine] Aldrey JM, et al. **Rev Neurol** 1996 Feb;24(126):183–6 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[Activity of neurons in the parietal associative cortex in the area of the substantia nigra in cats exposed to magnetic fields with an 8 Hz frequency] Orlova TV, et al. **Biofizika** 1995 Sep–Oct;40(5):978–82 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

TI-201 scintigraphy in cerebral neuroblastoma. Smallbane S, et al. **Clin Nucl Med** 1996 Mar;21(3):259–60

Parieto-occipital hypoperfusion in late whiplash syndrome: first quantitative SPET study using technetium-99m bicisate (ECD). Otte A, et al. **Eur J Nucl Med** 1996 Jan; 23(1):72–4

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Lehtovirta M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):644–9

Head motion during positron emission tomography: is it significant? Ruttimann UE, et al. **Psychiatry Res** 1995 May 31;61(1):43–51

SURGERY

Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Pahapill PA, et al. **Neurosurgery** 1996 Apr;38(4):822–8; discussion 828–9 (32 ref.)

How would you treat this patient? Dysembryoplastic neuroepithelial tumor. Scott RM, et al. **Surg Neurol** 1996 Jul;46(1):23–7

ULTRASTRUCTURE

An ultrastructural study of glomeruli associated with vomeronasal organs transplanted into the rat CNS. Morrison EE, et al. **Anat Embryol (Berl)** 1996 Apr; 193(4):331–9

PARITY

Slow twin conception at first birth and subsequent maternal twin proneness in a natural fertility population. Nonaka K, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3–4):215–22

Chronological changes in subjective symptoms during pregnancy in nulliparous and multiparous women. Oga M, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):784–7

The intensity of labor pain in grand multiparas. Ranta P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):250–4

The effects of parity on birthweight using successive pregnancies. Wilcox MA, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):459–3

Some factors influencing pregnancy rate and subsequent litter size in primiparous sows. Sterning M, et al. **Acta Vet Scand** 1995;36(3):353–65

Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Risch HA, et al. **Am J Epidemiol** 1996 Aug 15;144(4):363–72

The squirrel monkey as an animal model of pelvic relaxation: an evaluation of a large breeding colony. Coates KW, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1664–9; discussion 1669–70

Long-term effects of multiple pregnancies on cardiac dimensions and systolic and diastolic function. Sadaniantz A, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1061–4

Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Jorgensen C, et al. **Ann Rheum Dis** 1996 Feb;55(2):94–8

Reduced schedule of antenatal visits. Study ignored influence of parity on women's needs [letter; comment] Vause S, et al. **BMJ** 1996 Jul 20;313(7050):167; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

A randomised controlled trial of early versus delayed use of amniotomy and oxytocin infusion in nulliparous labour. Cammu H, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):313–8

The standard primipara as a basis for inter-unit comparisons

of maternity care. Cleary R, et al.
Br J Obstet Gynaecol 1996 Mar;103(3):223–9
A case–control study of reproductive variables, alcohol, and smoking in premenopausal bilateral breast cancer. Haile RW, et al. **Breast Cancer Res Treat** 1996;37(1):49–56
Breast cancer in Swedish women before age 50: evidence of a dual effect of completed pregnancy. Leon DA, et al. **Cancer Causes Control** 1995 Jul;6(4):283–91
Reproductive factors and colon cancer: the influences of age, tumor site, and family history on risk (Utah, United States). Slattery ML, et al. **Cancer Causes Control** 1995 Jul; 6(4):332–8
Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia? Thordarson G, et al. **Carcinogenesis** 1995 Nov;16(11):2847–53
Maternal age and parity correlates of handedness: gender, but no parental handedness modulation of effects. McKeever WF, et al. **Cortex** 1995 Sep;31(3):543–53
The grand multipara. Goldman GA, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Aug;61(2):105–9
Breech presentation and cesarean section in term nulliparous women. Leiberman JR, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Aug;61(2):111–5
Mother–to–child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery. Paediatric AIDS Group of Switzerland. Kind C.
Eur J Pediatr 1995 Jul;154(7):542–5
History of childbearing and colorectal cancer risk in women aged less than 60: an analysis of Swedish routine registry data 1960–1984. Broeders MJ, et al. **Int J Cancer** 1996 Apr 10;66(2):170–5
Great grand multiparity—beyond the 10th delivery. Kaplan B, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):17–9
Axillary nodal involvement and parity in breast cancer patients [letter; comment] Fentiman IS, et al.
J Cancer Res Clin Oncol 1995;121(11):694–5. Comment on: J Cancer Res Clin Oncol 1995;121(2):123–5.
Effect of parity on human chorionic gonadotrophin levels and Down's syndrome screening. Haddow JE, et al.
J Med Screen 1995;2(1):28–30
Pregnancy outcomes among active and sedentary primiparous women. Horns PN, et al.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):49–54
Gestational diabetes [letter; comment] Jarrett RJ. **Lancet** 1996 Mar 16;347(9003):758–9. Comment on: Lancet 1996 Jan 27;347(8996):208–9. Comment on: Lancet 1996 Jan 27;347(8996):227–30.
Long–term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus [see comments] Peters RK, et al. **Lancet** 1996 Jan 27;347(8996):227–30. Comment in: Lancet 1996 Jan 27;347(8996):208–9. Comment in: Lancet 1996 Mar 16;347(9003):758–9. Comment in: Lancet 1996 Mar 16;347(9003):759–60.
Linea alba pigmentation and umbilical deviation in nulliparous pregnancy: the ligamentum teres sign. Beischer NA, et al. **Obstet Gynecol** 1996 Feb;87(2):254–6
Prolonged labor in nulliparas: lessons from the active management of labor. Malone FD, et al.
Obstet Gynecol 1996 Aug;88(2):211–5
Decreased maternal serum hCG levels with increasing gravidity and parity. Mooney RA, et al.
Obstet Gynecol 1995 Dec;86(6):900–5
Correlation between presbyopia, age and number of births of mothers in the Kumasi area of Ghana. Morny FK.
Ophthalmic Physiol Opt 1995 Sep;15(5):463–6
Structure and function of the abdominal muscles in primigravid subjects during pregnancy and the immediate postbirth period. Gilleard WL, et al. **Phys Ther** 1996 Jul; 76(7):750–62
Effect of gravidity on maternal serum markers for Down's syndrome. Barkai G, et al. **Prenat Diagn** 1996 Apr; 16(4):319–22
Effect of gravidity and parity on the parameters used in serum screening for trisomy 21 [letter] Zimmermann R, et al.
Prenat Diagn 1995 Aug;15(8):781–2
How does childbearing affect fertility motivations and desires? Miller WB, et al. **Soc Biol** 1995 Fall–Winter; 42(3–4):185–98
Effect of ovariectomy on bone histology and plasma parameters of bone metabolism in nulliparous and multiparous sows. Scholz–Ahrens KE, et al.
Z Ernahrungswiss 1996 Mar;35(1):13–21
[Pregnancy and labor in 335 cases of high multiparity] Slavelkov S, et al. **Akush Ginekol (Sofiia)** 1995;34(3):4–6 (Eng. Abstr.) **(Bul)**
[Is there a correlation between postpartum depression and parity? (letter)] Godfroid IO. **Encephale** 1995 Nov–Dec; 21(6):481 **(Fre)**
[Progress of labor and neonatal morbidity in primiparity with breech presentation] Perl FM, et al.
Z Geburtshilfe Neonatol 1996 Mar–Apr;200(2):56–60 (Eng. Abstr.) **(Ger)**
[Multiparity in Nicaragua] Krüger N, et al.
Zentralbl Gynakol 1996;118(4):232–5 (Eng. Abstr.) **(Ger)**
[Active labour management in primiparas. Prospective study] Serman F, et al. **Rev Chil Obstet Ginecol** 1995;60(1):6–10; discussion 10–1 (Eng. Abstr.) **(Spa)**

GENETICS

Estimation of genetic parameters for litter size in Canadian Yorkshire and Landrace swine with each parity of farrowing treated as a different trait. Roehe R, et al.
J Anim Sci 1995 Oct;73(10):2959–70

PHYSIOLOGY

Event–time analysis of the effect of season of parturition, parity, and concurrent disease on parturition–to–conception interval in dairy cows. Harman JL, et al.
Am J Vet Res 1996 May;57(5):640–5
Multiparity and bone mass. Bererhi H, et al.
Br J Obstet Gynaecol 1996 Aug;103(8):818–21
Intrauterine contraception in nulligravid vs parous women. Dueñas JL, et al. **Contraception** 1996 Jan;53(1):23–4
The ontogeny of serum insulin–like growth factor–I concentration in foals: effects of dam parity, diet, and age at weaning. Cymbaluk NF, et al.
Domest Anim Endocrinol 1996 May;13(3):197–209
High delivery intervention rates in nulliparous women over age 35. Ezra Y, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Oct;62(2):203–7
[Comparison of prolactin levels in first, second and multiple physiological pregnancy] Jagiello–Wójtowicz E, et al.
Ginekol Pol 1995 Jul;66(7):397–401 (Eng. Abstr.) **(Pol)**

PARKINSON DISEASE

see related
ANTIPARKINSON AGENTS
LEWY BODIES

Postural stability differentiates "lower body" from idiopathic parkinsonism. Trenkwalder C, et al. **Acta Neurol Scand** 1995 Jun;91(6):444–52
Altered neurofilament expression does not contribute to Lewy body formation [see comments] Bergeron C, et al. **Am J Pathol** 1996 Jan;148(1):267–72. Comment in: Am J Pathol 1996 Aug;149(2):728–9.
Uncontrolled parkinson's disease. **Aust Fam Physician** 1995 Dec;24(12):2236; quiz 2236, 2238
Outcome measure for parkinsons disease [letter] Fitzpatrick F, et al. **Br J Gen Pract** 1995 Aug;45(397):440
Research priorities for Parkinson's recommended [news] Marwick C. **JAMA** 1995 Oct 25;274(16):1257–8
A 61–year–old man with Parkinson's disease [clinical conference] [see comments] Olanow CW. **JAMA** 1996 Mar 6;275(9):716–22. Comment in: JAMA 1996 Jul 10;276(2):103–4; discussion 104. Comment in: JAMA 1996 Jul 10;276(2):104.
Barium stone impaction in parkinsonism. Erhan Y, et al.
JPMA J Pak Med Assoc 1995 Jun;45(6):165–7
Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681–2
Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Limousin P, et al. **Mov Disord** 1995 Sep;10(5):672–4
Parkinsonism and Parkinson's disease [letter; comment] Weiner WJ, et al. **N Engl J Med** 1996 Jun 13;334(24):1611 . Comment on: N Engl J Med 1996 Jan 11;334(2):71–6.
NIH resists bill to promote research into Parkinson's [news] Wadman M. **Nature** 1996 Jun 13;381(6583):542
Rival Parkinson's bills focus US debate on fetal tissue [news] Wadman M. **Nature** 1996 Jul 25;382(6589):286
Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Faucheux BA, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9603–7
The anatomy of the basal ganglia and Parkinson's disease: a review. Lee TK, et al. **Singapore Med J** 1995 Feb; 36(1):74–6 (14 ref.)
[Drug treatment of frequent disorders in patients with Parkinson's disease] Martí Massó JF, et al. **Neurologia** 1996 Mar;11(3):109–15 (61 ref.) (Eng. Abstr.) **(Spa)**
[Initial treatment of Parkinson's disease] **Rev Neurol** 1995 Sep–Oct;23(123):1117–47 **(Spa)**

BLOOD

CSF and plasma concentrations of free norepinephrine, dopamine, 3,4–dihydroxyphenylacetic acid (DOPAC), 3,4–dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Eldrup E, et al. **Acta Neurol Scand** 1995 Aug;92(2):116–21
Plasma levels of inorganic sulfates in patients with Parkinson's disease. Jiménez–Jiménez FJ, et al.
Acta Neurol Scand 1995 Nov;92(5):369–71
Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Davis JW, et al.
Am J Epidemiol 1996 Sep 1;144(5):480–4
Changed transferrin sialylation in Parkinson's disease. van Kamp GJ, et al. **Clin Chim Acta** 1995 Mar 31;235(2):159–67
Fluorodopa positron emission tomography with an inhibitor of catechol–O–methyltransferase: effect of the plasma 3–O–methyldopa fraction on data analysis. Ishikawa T, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):854–63
Plasma levels of vitamin E in Parkinson's disease. Federico A, et al. **J Neural Transm Suppl** 1995;45:267–70
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. Ahlskog JE, et al. **J Neurol Sci** 1996 Mar;136(1–2):162–8
A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease. Chiba S, et al. **J Neurol Sci** 1995 Oct;132(2):170–3
Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases. Hurwitz A, et al. **Neurology** 1995 Oct;45(10):1903–6
Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Nagai Y, et al. **Neurology** 1996 Mar;46(3):791–5
Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Allain P, et al. **Neurotoxicology** 1995 Fall;16(3):527–9

CEREBROSPINAL FLUID

CSF and plasma concentrations of free norepinephrine, dopamine, 3,4–dihydroxyphenylacetic acid (DOPAC), 3,4–dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Eldrup E, et al. **Acta Neurol Scand** 1995 Aug;92(2):116–21
A dopaminergic neurotoxin, (R)–N–methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Maruyama W, et al. **Ann Neurol** 1996 Jul;40(1):119–22
Presence of N–methyl–norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. Moser A, et al. **J Neurol Sci** 1995 Aug;131(2):183–9
beta–Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Matsubara K, et al. **Neurology** 1995 Dec; 45(12):2240–5
Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Qureshi GA, et al. **Neuroreport** 1995 Aug 21;6(12):1642–4
Interleukin–1 beta and interleukin–6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Blum–Degen D, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):17–20
Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Hao R, et al. **Neurosci Lett** 1995 Nov 17;200(2):77–80

CHEMICALLY INDUCED see PARKINSON DISEASE, SYMPTOMATIC/chemically induced

CLASSIFICATION

Frequency of a specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson disease. Akhmedova SN, et al.
Biochem Mol Med 1995 Apr;54(2):88–90

COMPLICATIONS

Sexual problems in young patients with Parkinson's disease. Wermuth L, et al. **Acta Neurol Scand** 1995 Jun;91(6):453–5
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497–501 (30 ref.)
Early–onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA–responsive dystonia. Furukawa Y, et al. **Adv Neurol** 1996;69:327–37
A profile analysis of demented and nondemented Parkinson's disease patients. McFadden L, et al. **Adv Neurol** 1996; 69:339–41
Disorders affecting autonomic function in parkinsonian patients. Mathias CJ. **Adv Neurol** 1996;69:383–91 (20 ref.)
Ondansetron, a 5–HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L–DOPA therapy in advanced Parkinson's disease. Zoldan J, et al. **Adv Neurol** 1996;69:541–4
Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Morens DM, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):400–4
Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)
Upper airway obstruction in Parkinson's disease [see comments] Fitzpatrick AJ. **Anaesth Intensive Care** 1995 Jun;23(3):367–9. Comment in: Anaesth Intensive Care 1996 Feb;24(1):122–3.
Upper airway obstruction in Parkinson's disease [letter; comment] Willson G, et al. **Anaesth Intensive Care** 1996 Feb;24(1):122–3. Comment on: Anaesth Intensive Care 1995 Jun;23(3):367–9.
Propofol–induced dyskinesias in Parkinson's disease. Krauss JK, et al. **Anesth Analg** 1996 Aug;83(2):420–22
Pseudopheochromocytoma in a patient with Parkinson's disease [letter] Duarte J, et al. **Ann Pharmacother** 1996 May; 30(5):546
The occurrence of depression in Parkinson's disease. A community–based study. Tandberg E, et al.
Arch Neurol 1996 Feb;53(2):175–9
"Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Hillen ME, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):710–2
Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Sabaté M, et al.
Arch Phys Med Rehabil 1996 Jan;77(1):29–34
Dementia and parkinsonism: an emerging research area. Miller B, et al. **Brain Cogn** 1995 Aug;28(3):227–8
Acetylcholine and hallucinations: disease–related compared

to drug-induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)

Prepharyngeal dysphagia in Parkinson's disease [see comments] Leopold NA, et al. **Dysphagia** 1996 Winter; 11(1):14–22. Comment in: Dysphagia 1996 Winter;11(1):23–4.

Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Ali GN, et al. **Gastroenterology** 1996 Feb;110(2):383–92

Improvement of body image perception in Parkinson's disease by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):269–83

Primary laryngospasm in a patient with Parkinson's disease: treatment with CPAP via minitracheostomy following intubation [letter] Fikkers BF, et al. **Intensive Care Med** 1995 Oct;21(10):863–4

Psychotic symptoms in Parkinson's disease patients with dementia. Naimark D, et al. **J Am Geriatr Soc** 1996 Mar; 44(3):296–9

Diagnostic testing for dementia in patients with Parkinson's disease [letter] Shulman LM, et al. **J Am Geriatr Soc** 1996 Feb;44(2):214–5

Study of Alzheimer's dementia patients with parkinsonian features. Snowden MB, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):154–8

Parkinson's disease: a new risk factor for gallstone disease? [letter] Modaine P, et al. **J Hepatol** 1995 Oct;23(4):484

Dementia in Thai patients with Parkinson's disease: analysis of 132 patients. Poungvarin N, et al. **J Med Assoc Thai** 1996 May;79(5):278–84

Does reserpine induce parkinsonian rigidity? Lorenc-Koci E, et al. **J Neural Transm Park Dis Dement Sect** 1995; 9(2–3):211–23

Autonomic disorders in Parkinson's disease. Martignoni E, et al. **J Neural Transm Suppl** 1995;45:11–9 (51 ref.)

Progression of motor and cognitive impairment in Parkinson's disease. Palazzini E, et al. **J Neurol** 1995 Aug; 242(8):535–40

Movement related desynchronisation pattern preceding voluntary movement in untreated Parkinson's disease. Defebvre L, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar; 60(3):307–12

Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy. Isozaki E, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):399–402

Attentional functions in multiple system atrophy and Parkinson's disease. Meco G, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):393–8

Vocal cord abductor paralysis (VCAP) in Parkinson's disease: difference from VCAP in multiple system atrophy. Isozaki E, et al. **J Neurol Sci** 1995 Jun;130(2):197–202

Depression and disability in Parkinson's disease. Cole SA, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter; 8(1):20–5

Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. Factor SA, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):304–7

Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):1–9 (52 ref.)

Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. Dromey C, et al. **J Speech Hear Res** 1995 Aug;38(4):751–64

Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. Smith ME, et al. **J Voice** 1995 Dec;9(4):453–9

Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Singaram C, et al. **Lancet** 1995 Sep 30;346(8979):861–4

Postural finger tremor exhibited by Parkinson patients and age-matched subjects. Palmer SS, et al. **Mov Disord** 1995 Sep;10(5):658–63

Speech dysfunction in early Parkinson's disease. Stewart C, et al. **Mov Disord** 1995 Sep;10(5):562–5

Risk factors for dementia in Parkinson's disease: effect of education. Glatt SL, et al. **Neuroepidemiology** 1996 Jan–Feb;15(1):20–5

Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Del-Ser T, et al. **Neurology** 1996 Mar;46(3):682–6

Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Gearing M, et al. **Neurology** 1995 Nov;45(11):1985–90

Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Laakso MP, et al. **Neurology** 1996 Mar;46(3):678–81

MRI in patients with suspected vascular parkinsonism. Zijlmans JC, et al. **Neurology** 1995 Dec;45(12):2183–8

Are perception and memory for faces influenced by a specific age at onset factor in Parkinson's disease? Haeske-Dewick HC. **Neuropsychologia** 1996 Apr;34(4):315–20

Perceptual abnormalities in Parkinson's disease: top-down or bottom-up processes? Flowers KA, et al. **Perception** 1995;24(10):1201–21

[Subcortical dementia versus bradyphrenia in Parkinson disease (letter)] Perez Trullen JM, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):301–2

Rehabilitation of hip fracture patients with Parkinson's Disease. Jónsson B, et al. **Scand J Rehabil Med** 1995 Dec; 27(4):227–30

[Mental dysfunction in Parkinson's disease] Ružička E. **Cas Lek Cesk** 1996 Apr 3;135(7):199–203 (37 ref.) (Eng. Abstr.) **(Cze)**

[Neurogenic bladder, 20 years later] Perrigot M. **Presse Med** 1995 Oct 28;24(32):1523–5 (Eng. Abstr.) **(Fre)**

[Clozapine in the treatment of mental manifestations of Parkinson disease] Diederich N, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):251–7 (54 ref.) (Eng. Abstr.) **(Fre)**

[Fluvoxamine and serotonin syndrome in a patient with Parkinson disease (letter)] Le Cavorzin P, et al. **Therapie** 1996 Mar–Apr;51(2):195–6 **(Fre)**

[Anesthetic management of a Paget's disease patient complicated with Parkinson disease] Tomioka T, et al. **Masui** 1995 Oct;44(10):1384–7 (Eng. Abstr.) **(Jpn)**

[Osteoporosis and fractures in Parkinson's disease] Yamada T, et al. **Nippon Ronen Igakkai Zasshi** 1995 Oct; 32(10):637–40 (Eng. Abstr.) **(Jpn)**

[Prolonged QTc intervals in Parkinson's disease—relation to sudden death and autonomic dysfunction] Ishizaki F, et al. **No To Shinkei** 1996 May;48(5):443–8 (Eng. Abstr.) **(Jpn)**

[A 65-year-old man with Parkinsonism, gaze palsy, and dementia (clinical conference)] Mizuno Y, et al. **No To Shinkei** 1996 Apr;48(4):381–93 (Eng. Abstr.) **(Jpn)**

[A 75-year-old man with parkinsonism and sudden death (clinical conference)] Nagaoka M, et al. **No To Shinkei** 1995 Dec;47(12):1199–208 (Eng. Abstr.) **(Jpn)**

[Borderline mental disorders in parkinsonism patients and their drug correction] Kamenetskiĭ VK, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):36–8 (Eng. Abstr.) **(Rus)**

[Dementia, parkinsonism and myoclonic seizures in a 58-year-old woman] Molina C, et al. **Rev Neurol** 1996 May; 24(129):574–9 **(Spa)**

[Sleep disorders and Parkinson disease: study of a series] Rubio P, et al. **Rev Neurol** 1995 Mar–Apr;23(120):265–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Motor performance in normal pressure hydrocephalus assessed with an optoelectronic measurement technique. Matousek M, et al. **Acta Neurol Scand** 1995 Jun;91(6):500–5

Cerebrospinal fluid nitrate levels in patients with Parkinson's disease. Molina JA, et al. **Acta Neurol Scand** 1996 Feb–Mar; 93(2–3):123–6

The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. Albanese A, et al. **Adv Neurol** 1996; 69:393–8

The neuropathologic diagnosis of secondary parkinsonian syndromes. Jellinger KA. **Adv Neurol** 1996;69:293–303 (49 ref.)

Peripheral markers in Parkinson's disease. An overview. Oertel WH, et al. **Adv Neurol** 1996;69:283–91 (69 ref.)

Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Ballard C, et al. **Age Ageing** 1996 May;25(3):209–13

Depression in multiple system atrophy and in idiopathic Parkinson's disease: a pilot comparative study. Pilo L, et al. **Biol Psychiatry** 1996 May 1;39(9):803–7

The neuropathology of parkinsonism: an overview. Cornford ME, et al. **Brain Cogn** 1995 Aug;28(3):321–41 (72 ref.)

Lewy body diseases with dementia: pathophysiology and treatment. Cummings JL. **Brain Cogn** 1995 Aug; 28(3):266–80 (64 ref.)

Neuropsychiatric features of Lewy body disease. Filley CM. **Brain Cogn** 1995 Aug;28(3):229–39 (33 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)

The neuropsychology of Parkinson's disease. Taylor AE, et al. **Brain Cogn** 1995 Aug;28(3):281–96 (31 ref.)

Specific patterns of cortical dysfunction in dementia and Parkinson's disease demonstrated by the acceleration spectrum entropy of the EEG. Jelles B, et al. **Clin Electroencephalogr** 1995 Oct;26(4):188–92

The apomorphine test in gait disorders associated with parkinsonism. Linazasoro G. **Clin Neuropharmacol** 1996 Apr;19(2):171–6

Quantifying rigidity with a new computerized elbow device. Relja MA, et al. **Clin Neuropharmacol** 1996 Apr; 19(2):148–56

Parkinson's and Alzheimer's: new tools, new attitudes in patient care. Jenkyn LR, et al. **Geriatrics** 1996 Jan; 51(1):65–70, 72

Neuropsychiatric manifestations of diffuse Lewy body disease. Beck BJ. **J Geriatr Psychiatry Neurol** 1995 Jul; 8(3):189–96 (70 ref.)

Differentiation of the dementias of Alzheimer's and Parkinson's disease with the dementia rating scale. Paolo AM, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):184–8

Study of Alzheimer's dementia patients with parkinsonian features. Snowden MB, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):154–8

Differential diagnosis of parkinsonism. Manfredi M, et al. **J Neural Transm Suppl** 1995;45:1–9 (28 ref.)

External anal sphincter electromyography in the differential diagnosis of parkinsonism [letter] Rodi Z, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):460–1

Anorectal function in fluctuating (on–off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Ashraf W, et al. **Mov Disord** 1995 Sep; 10(5):650–7

Screening Parkinson's disease: a validated questionnaire of high specificity and sensitivity. Duarte J, et al. **Mov Disord** 1995 Sep;10(5):643–9

Parkinsonism and dilatation of the perivascular spaces (état criblé) of the striatum: a clinical, magnetic resonance imaging, and pathological study. Fénelon G, et al. **Mov Disord** 1995 Nov;10(6):754–60

Event-related potential P3 change in mild Parkinson's disease. Green J, et al. **Mov Disord** 1996 Jan;11(1):32–42

Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Louis ED, et al. **Mov Disord** 1996 Mar;11(2):185–92

Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mark MH, et al. **Mov Disord** 1995 Jul;10(4):450–4

Internal tremor in patients with Parkinson's disease. Shulman LM, et al. **Mov Disord** 1996 Jan;11(1):3–7

Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration. van Hilten JJ, et al. **Mov Disord** 1995 Jul;10(4):424–32

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Schenck CH, et al. **Neurology** 1996 Feb;46(2):388–93

MRI in patients with suspected vascular parkinsonism. Zijlmans JC, et al. **Neurology** 1995 Dec;45(12):2183–8

Apolipoprotein E and B alleles in Parkinson's patients. Poduslo SE, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):145–7

[Cognition disorders and parkinsonian syndrome: diffuse Lewy body disease?] Etcharry-Bouyx F, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):410–2 (Eng. Abstr.) **(Fre)**

[Parkinson disease. Early diagnosis and combined therapy for better prognosis] **Fortschr Med Suppl** 1993;150:1–7 **(Ger)**

[Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes] Hierholzer J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):43–51 (Eng. Abstr.) **(Ger)**

[Initial symptomatology of Parkinson disease] Fuhr P, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):175–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Urinary incontinence in patients with Parkinson syndrome] Jost WH, et al. **Wien Klin Wochenschr** 1996; 108(10):296–302 (Eng. Abstr.) **(Ger)**

[Clinical manifestations of Parkinson disease] Volc D. **Wien Med Wochenschr** 1995;145(13):290–4 (Eng. Abstr.) **(Ger)**

[A 56-year-old woman with parkinsonism and dementia with the age of onset at 41 years (clinical conference)] Hattori N, et al. **No To Shinkei** 1995 Sep;47(9):911–9 (Eng. Abstr.) **(Jpn)**

[Information giving in Parkinson's disease] Kuzuhara S. **No To Shinkei** 1996 May;48(5):417–23 (10 ref.) **(Jpn)**

[A 62-year-old man with familial parkinsonism with the onset at 24 years of the age (clinical conference)] Takubo H, et al. **No To Shinkei** 1996 Jun;48(6):587–97 (Eng. Abstr.) **(Jpn)**

[Time in neuropsychological examination of dementias: Alzheimer's disease versus Parkinson disease] Gil-Saladié D, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):299–304 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Possible neuroprotective therapy for Parkinson's disease. Ogawa N. **Acta Med Okayama** 1995 Aug;49(4):179–85 (70 ref.)

Parkinsonian rigidity, dopa-induced dyskinesia and chorea—dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording. Hirato M, et al. **Acta Neurochir Suppl (Wien)** 1995;64:5–8

A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K, et al. **Adv Neurol** 1996;69:519–30

New drugs in the treatment of Parkinson's disease. An introduction. Bracco F. **Adv Neurol** 1996;69:513–7 (66 ref.)

Parkinson's disease: progression and mortality in the L-DOPA era. Di Rocco A, et al. **Adv Neurol** 1996;69:3–11

Controversies in the therapy of Parkinson's disease. Fahn S. **Adv Neurol** 1996;69:477–86 (72 ref.)

Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes. Gasser T, et al. **Adv Neurol** 1996;69:87–95

Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease. Mestre DR, et al. **Adv Neurol** 1996; 69:503–11

Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA. Pahwa R, et al. **Adv Neurol** 1996; 69:487–91

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)

Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET

study. Pizzolato G, et al. **Adv Neurol** 1996;69:467–73

A placebo–controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L–DOPA–treated parkinsonian patients. Rascol O, et al. **Adv Neurol** 1996; 69:531–4

An open study with reversible MAO–A inhibitors in complicated Parkinson's disease. Ruggieri S, et al. **Adv Neurol** 1996;69:595–8

Treatment options for early Parkinson's disease. Stacy M, et al. **Am Fam Physician** 1996 Mar;53(4):1281–7 (29 ref.)

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. **Ann Neurol** 1996 Jul;40(1):99–107

Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Ann Neurol** 1996 Mar;39(3):400–4

Deprenyl and levodopa and Parkinson's disease progression [letter] Fowler JS, et al. **Ann Neurol** 1996 Aug;40(2):267–8

Deprenyl in Parkinson's disease [letter] Korczyn AD, et al. **Ann Neurol** 1996 Aug;40(2):268–9

Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Kushleika J, et al. **Ann Neurol** 1996 Mar;39(3):378–81

The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Nutt JG, et al. **Ann Neurol** 1996 May;39(5):561–73 (98 ref.)

The effect of deprenyl and levodopa on the progression of Parkinson's disease. Olanow CW, et al. **Ann Neurol** 1995 Nov;38(5):771–7

Deprenyl's neuroprotective action remains unresolved [letter] van Hilten JJ, et al. **Ann Neurol** 1996 Aug;40(2):266–7

Abnormalities of smooth eye and head movement control in Parkinson's disease. Waterston JA, et al. **Ann Neurol** 1996 Jun;39(6):749–60

Treatment of Parkinson's disease. Eadie MJ. **Aust Fam Physician** 1995 Sep;24(9):1685–7, 1690–2

Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Mizutani Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1729–37

Selegiline in Parkinson's disease [editorial; comment] [see comments] Calne DB. **BMJ** 1995 Dec 16;311(7020):1583–4 . Comment on: BMJ 1995 Dec 16;311(7020):1602–7. Comment in: BMJ 1996 Mar 16;312(7032):702; discussion 704–5.

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom [see comments] Lees AJ. **BMJ** 1995 Dec 16;311(7020):1602–7. Comment in: BMJ 1995 Dec 16;311(7020):1583–4. Comment in: BMJ 1996 Mar 16;312(7032):702; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):702–3; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):703; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):703–4; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704–5.

Treatment of Parkinson's disease in a patient with acute intermittent porphyria [letter] Gorchein A. **Br J Clin Pharmacol** 1995 Jul;40(1):105–6

Drug management of Parkinson's disease. Kishore A, et al. **Can Fam Physician** 1996 May;42:946–52 (13 ref.)

Levodopa reduces muscle tone and lower extremity tremor in Parkinson's disease. Burleigh A, et al. **Can J Neurol Sci** 1995 Nov;22(4):280–5

Therapeutic dilemma: psychosis and Parkinson's disease [letter] Damecour CL, et al. **Can J Psychiatry** 1995 Dec; 40(10):640–1

Experience of pergolide in the treatment of Chinese parkinsonian patients with dose–related fluctuations. Shan DE, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):312–8

Response to L–dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease. Shif M, et al. **Clin Exp Neurol** 1994;31:38–42

Color vision in Parkinson's disease: missing influence of amantadine sulphate. Büttner T, et al. **Clin Neuropharmacol** 1995 Oct;18(5):458–63

L–deprenyl as an adjunct to low–dose bromocriptine in early Parkinson's disease: a short–term, double–blind, and prospective follow–up study. Calzetti S, et al. **Clin Neuropharmacol** 1995 Jun;18(3):250–7

A longitudinal study of the effects of an L–dopa drug holiday on the course of Parkinson's disease. Corona T, et al. **Clin Neuropharmacol** 1995 Aug;18(4):325–32

Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Dalrymple–Alford JC, et al. **Clin Neuropharmacol** 1995 Aug;18(4):348–59

Acute effects of COMT inhibition on L–DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Davis TL, et al. **Clin Neuropharmacol** 1995 Aug; 18(4):333–7

Pramipexole in patients with early Parkinson's disease. Hubble JP, et al. **Clin Neuropharmacol** 1995 Aug; 18(4):338–47

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez–Jiménez FJ, et al. **Clin Neuropharmacol** 1995 Jun;18(3):277–9

Levodopa does not aggravate postural tremor in Parkinson's disease. Kulisevsky J, et al. **Clin Neuropharmacol** 1995 Oct; 18(5):435–42

Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Lang AE, et al. **Clin Neuropharmacol** 1995 Feb;18(1):39–45

Acute administration of levodopa–benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. Limousin P, et al. **Clin Neuropharmacol** 1995 Jun;18(3):258–65

Tremorlytic activity of budipine: a quantitative study with long–term tremor recordings. Spieker S, et al. **Clin Neuropharmacol** 1995 Jun;18(3):266–72

Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Management of parkinsonism and treatment of associated complications. Nutt JG. **Curr Opin Neurol** 1995 Aug; 8(4):327–30 (31 ref.)

Drugs for Parkinson's disease reviewed. **Drug Ther Bull** 1995 Jul;33(7):49–52 (25 ref.)

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Kirollos C, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):7–18

Effects of nigrostriatal denervation and L–dopa therapy on the GABAergic neurons in the striatum in MPTP–treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. Levy R, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1199–209

Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Löschmann PA, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):129–34

Evaluation of the pro–oxidant and antioxidant actions of L–DOPA and dopamine in vitro: implications for Parkinson's disease. Spencer JP, et al. **Free Radic Res** 1996 Feb;24(2):95–105

Terguride in stable Parkinson's disease. Martignoni E, et al. **Funct Neurol** 1995 May–Jun;10(3):143–6

Serotonin syndrome in Parkinson disease. Weiss DM. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):400–2

Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter] Noveske FG. **J Clin Psychiatry** 1996 Aug;57(8):374

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic–rigid syndromes. Rich SS, et al. **J Clin Psychiatry** 1995 Dec;56(12):556–9

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Sieradzan K, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):51S–59S

Treatment of Parkinson's disease. Bergus G. **J Fam Pract** 1996 May;42(5):457–8

Single vs multiple daily dosing of aminoglycosides. Newton W. **J Fam Pract** 1996 May;42(5):456–7

An open label trial of pergolide in Thai patients with Parkinson's disease. Poungvarin N, et al. **J Med Assoc Thai** 1996 Apr;79(4):205–9

L–Dopa improves colour vision in Parkinson's disease. Büttner T, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):13–9

The use of famotidine in the treatment of Parkinson's disease: a pilot study. Molinari SP, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):243–7

Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease. Volpi R, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):1–11

Old and new dopamine agonists in Parkinson's disease. Proceedings of an international congress. Pisa, Italy, December 1993. **J Neural Transm Suppl** 1995;45:1–321

Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)

Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)

Cabergoline improves motor disability without modifying L–dopa plasma levels in fluctuating Parkinson's disease patients. Del Dotto P, et al. **J Neural Transm Suppl** 1995; 45:259–65

Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO–B inhibitor selegiline. Dostert P, et al. **J Neural Transm Suppl** 1995; 45:247–57

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133–6 (22 ref.)

Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum? Melamed E. **J Neural Transm Suppl** 1995;45:57–60

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Molho ES, et al. **J Neural Transm Suppl** 1995;45:225–30

Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? Montastruc JL, et al. **J Neural Transm Suppl** 1995;45:157–61

Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F, et al. **J Neural Transm Suppl** 1995;45:187–95 (46 ref.)

Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213–24 (63 ref.)

The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis. Sampaio C, et al. **J Neural Transm Suppl** 1995;45:197–202

N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study. Traversa R, et al. **J Neural Transm Suppl** 1995;45:177–85

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on–off phenomenon. Colosimo C, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):634–7

Cholinesterase inhibition in Parkinson's disease [letter] Hutchinson M, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):324–5

Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa. Robertson LT, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):41–50

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. Ruottinen HM, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):36–40

Delayed development of symptomatic improvement by (—)–deprenyl in Parkinson's disease. Mally J, et al. **J Neurol Sci** 1995 Dec;134(1–2):143–5

Positron emission tomography of reversible intellectual impairment induced by long–term anticholinergic therapy. Nishiyama K, et al. **J Neurol Sci** 1995 Sep;132(1):89–92

Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. Chacko RC, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):471–5

Clinical analysis of Parkinson's disease treated by integration of traditional Chinese and western medicine. Li G. **J Tradit Chin Med** 1995 Sep;15(3):163–9

A 61–year–old man with Parkinson's disease [letter; comment] Hayes HD. **JAMA** 1996 Jul 10;276(2):103–4; discussion 104. Comment on: JAMA 1996 Mar 6;275(9):716–22.

Neuroprotection in Parkinson's disease [letter; comment] Montastruc JL, et al. **Lancet** 1996 Jan 20;347(8995):196. Comment on: Lancet 1995 Nov 11;346(8985):1305.

Neuroprotective mechanism of bromocriptine [letter] [see comments] Yamashita H, et al. **Lancet** 1995 Nov 11; 346(8985):1305. Comment in: Lancet 1996 Jan 20;347(8995):196.

Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic–L–amino acid decarboxylase and semicarbazide–sensitive amine oxidase in Parkinson's disease. Boomsma F, et al. **Life Sci** 1995;57(19):1753–9

Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE. **Mayo Clin Proc** 1996 Jul; 71(7):659–70 (90 ref.)

Lewy body diseases: possible new directions in prophylaxis and therapy. Oken RJ. **Med Hypotheses** 1996 Mar; 46(3):222–4

A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Bonnet AM, et al. **Mov Disord** 1995 Sep;10(5):668–71

Long–term tolerability and efficacy of cabergoline, a new long–acting dopamine agonist, in Parkinson's disease. Inzelberg R, et al. **Mov Disord** 1995 Sep;10(5):604–7

Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction. Kulisevsky J, et al. **Mov Disord** 1995 Nov;10(6):799–802

Amantadine–induced "vocal" myoclonus [letter] Pfeiffer RF. **Mov Disord** 1996 Jan;11(1):104–6

Zotepine in levodopa–induced Psychosis. Spieker S, et al. **Mov Disord** 1995 Nov;10(6):795–7

Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Tan A, et al. **Mov Disord** 1996 Mar;11(2):214–6

Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. van Laar T, et al. **Mov Disord** 1995 Jul; 10(4):433–9

Levodopa in pregnancy [letter] von Graevenitz KS, et al. **Mov Disord** 1996 Jan;11(1):115–6

A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Wenning GK, et al. **Mov Disord** 1995 Sep; 10(5):664–7

No NO prevents parkinsonism [comment] Snyder SH. **Nat Med** 1996 Sep;2(9):965–6. Comment on: Nat Med 1996 Sep;2(9):1017–21.

Functional recovery in parkinsonian monkeys treated with GDNF. Gash DM, et al. **Nature** 1996 Mar 21; 380(6571):252–5

Analysis of mortality in pergolide–treated patients with Parkinson's disease. Sayler ME, et al. **Neuroepidemiology** 1996 Jan–Feb;15(1):26–32

Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Ahlskog JE, et al. **Neurology** 1996 Mar;46(3):796–801

Improvement of levodopa–induced dyskinesia by propranolol in Parkinson's disease. Carpentier AF, et al. **Neurology** 1996 Jun;46(6):1548–51

Supplement: treatment for Parkinson's disease [letter] Muilenburg ND. **Neurology** 1995 Dec;45(12):2301–2

Levodopa–induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Tedroff J, et al. **Neurology** 1996 May;46(5):1430–6

Amantadine treatment is an independent predictor of

improved survival in Parkinson's disease. Uitti RJ, et al. **Neurology** 1996 Jun;46(6):1551–6

Effects of the catechol–O–methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Tohgi H, et al. **Neurosci Lett** 1995 Jun 16;192(3):165–8

Dopamine receptors—the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):207–18 (95 ref.)

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

Drug therapy for Parkinson's disease. Charles PD, et al. **South Med J** 1996 Sep;89(9):851–6 (22 ref.)

[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**

[L–dopa and antiparkinson agents] Delwaide PJ. **Rev Med Liege** 1996 Jan;51(1):61–4 **(Fre)**

[Levodopa + selegiline combination and increase of risk of mortality in the treatment of Parkinson disease] Dubois B, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):103–5 **(Fre)**

[Initiation of treatment in Parkinson disease] Ghika J. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1018–20 (Eng. Abstr.) **(Fre)**

[Reversible esophageal dysfunction as a side effect of levodopa] Kellner H, et al. **Bildgebung** 1996 Mar; 63(1):48–50 (Eng. Abstr.) **(Ger)**

[Levodopa and malignant melanoma—case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Effectiveness of slow release L–DOPA/benserazide in treatment of end–of–dose akinesia in Parkinson disease] Eichhorn TE, et al. **Nervenarzt** 1995 Dec;66(12):933–41 (Eng. Abstr.) **(Ger)**

[Clinical aspects and follow–up of dopamine–induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms] Heinz A, et al. **Nervenarzt** 1995 Sep;66(9):662–9 (Eng. Abstr.) **(Ger)**

[Parkinson syndrome: iatrogenic causes, iatrogenic treatment results] Burgunder JM. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):522–7 (22 ref.) (Eng. Abstr.) **(Ger)**

[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease] Dessibourg CA, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1235–8 (Eng. Abstr.) **(Ger)**

[Stage–adjusted treatment of idiopathic Parkinson syndrome] Ludin HP. **Wien Med Wochenschr** 1995;145(13):294–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects and conservative therapy of Parkinson disease] Dengler R. **Zentralbl Neurochir** 1995;56(4):148–52 (5 ref.) (Eng. Abstr.) **(Ger)**

[A long–term clinical effect of selegiline hydrochloride on Parkinson's disease] Mizuno Y, et al. **No To Shinkei** 1996 May;48(5):467–72 (Eng. Abstr.) **(Jpn)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of Parkinson disease] Cardoso F. **Arq Neuropsiquiatr** 1995 Mar;53(1):1–10 (34 ref.) (Eng. Abstr.) **(Por)**

[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease] Ferraz HB, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):245–51 (Eng. Abstr.) **(Por)**

[The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease] Fedorova NV, et al. **Ter Arkh** 1995;67(10):75–7 (Eng. Abstr.) **(Rus)**

[The use of the Sinemet–CR preparation in treating Parkinson's disease] Artem'ev DV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):31–5 (Eng. Abstr.) **(Rus)**

[Rational basis for development of a treatment program for Parkinson's disease] Jovičić A, et al. **Vojnosanit Pregl** 1995 May–Jun;52(3):253–60 **(Scr)**

[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L–dopa] Fernández Pardal MM, et al. **Medicina (B Aires)** 1991;51(6):561–7 (Eng. Abstr.) **(Spa)**

[Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine] Merello M, et al. **Medicina (B Aires)** 1995;55(1):5–10 (Eng. Abstr.) **(Spa)**

[Treatment of complicated Parkinson disease with a solution of levodopa–carbidopa and ascorbic acid] Linazasoro G, et al. **Neurologia** 1995 Jun–Jul;10(6):220–3 (Eng. Abstr.) **(Spa)**

[The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti–parkinsonian drugs] Artázcoz Sanz MT, et al. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):479–85 (Eng. Abstr.) **(Spa)**

[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease] Miranda M, et al. **Rev Med Chil** 1995 Mar;123(3):326–9 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP–treated monkey and patients with Parkinson's disease. Herrero MT, et al. **Adv Neurol** 1996;69:209–16

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Kushleika J, et al. **Ann Neurol** 1996 Mar;39(3):378–81

Substrate specificity of human platelet monoamine oxidase B activity Parkinson's and Alzheimer's disease. Fitzgerald DH, et al. **Biochem Soc Trans** 1996 Feb;24(1):63S

Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two–dimensional resolution: normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities. Schägger H. **Electrophoresis** 1995 May;16(5):763–70

The role of monoamine oxidase and catechol O–methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35–45 (60 ref.)

Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. Ishikawa T, et al. **J Nucl Med** 1996 Feb;37(2):216–22

Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic–L–amino acid decarboxylase and semicarbazide–sensitive amine oxidase in Parkinson's disease. Boomsma F, et al. **Life Sci** 1995;57(19):1753–9

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Damier P, et al. **Neurology** 1996 May;46(5):1262–9

Respiratory–chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Grupo–Centro de Trastornos del Movimiento. Martín MA, et al. **Neurology** 1996 May;46(5):1343–6

Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Hunot S, et al. **Neuroscience** 1996 May; 72(2):355–63

Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non–human primates: a cytochrome oxidase histochemistry study. Vila M, et al. **Neuroscience** 1996 Apr;71(4):903–12

Platelet MAO activities and MAO–B protein concentrations in Parkinson's disease and controls. Finch CC, et al. **Prog Brain Res** 1995;106:85–90

Aromatic L–amino acid decarboxylase modulation and Parkinson's disease. Neff NH, et al. **Prog Brain Res** 1995; 106:91–7 (39 ref.)

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Menniti–Ippolito F, et al. **Acta Neurol Scand** 1995 Jul; 92(1):49–54

Prevalence of Parkinson's disease in a population of Uruguay. Preliminary results. Chouza C, et al. **Adv Neurol** 1996; 69:13–7

Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register–based follow–up study. Breteler MM, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1300–5

The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993 [see comments] Mayeux R, et al. **Am J Epidemiol** 1995 Oct 15;142(8):820–7. Comment in: Am J Epidemiol 1996 Jul 15;144(2):198–9.

Re: "The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993" [letter; comment] Morens DM, et al. **Am J Epidemiol** 1996 Jul 15;144(2):198–9. Comment on: Am J Epidemiol 1995 Oct 15;142(8):820–7.

Frequency of dementia in Parkinson disease. Aarsland D, et al. **Arch Neurol** 1996 Jun;53(6):538–42

Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door–to–door survey of inhabitants older than 65 years. Trenkwalder C, et al. **Arch Neurol** 1995 Oct;52(10):1017–22

Neurological signs, aging, and the neurodegenerative syndromes. Waite LM, et al. **Arch Neurol** 1996 Jun; 53(6):498–502

A door–to–door survey of Parkinson's disease in a Chinese population in Kinmen. Wang SJ, et al. **Arch Neurol** 1996 Jan;53(1):66–71

The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. Mitchell SL, et al. **J Am Geriatr Soc** 1996 Apr;44(4):394–9

Age–standardized incidence and prevalence of Parkinson's disease in a Swedish community. Fall PA, et al. **J Clin Epidemiol** 1996 Jun;49(6):637–41

Parkinson's disease and the environment in early life. Martyn CN, et al. **J Neurol Sci** 1995 Oct;132(2):201–6

Prevalence of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. Louis ED, et al. **Mov Disord** 1996 Jan;11(1):63–9

Are death certificates reliable to estimate the incidence of Parkinson's disease? [letter] Paulson GW, et al. **Mov Disord** 1995 Sep;10(5):678

The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Tandberg E, et al. **Mov Disord** 1995 Sep;10(5):541–9

Prevalence of parkinsonian signs and associated mortality in a community population of older people [see comments] Bennett DA, et al. **N Engl J Med** 1996 Jan 11;334(2):71–6 . Comment in: N Engl J Med 1996 Jun 13;334(24):1611.

Neurological disease in a defined population: the results of a pilot study in two general practices. Cockerell OC, et al. **Neuroepidemiology** 1996;15(2):73–82

The "protective" influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Riggs JE. **Neurol Clin** 1996 May;14(2):353–8 (24 ref.)

Epidemiology of Parkinson's disease. Tanner CM, et al. **Neurol Clin** 1996 May;14(2):317–35 (161 ref.)

Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. de Rijk MC, et al. **Neurology** 1995 Dec; 45(12):2143–6

Case–control study of idiopathic Parkinson's disease and dietary vitamin E intake. Morens DM, et al. **Neurology** 1996 May;46(5):1270–4

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case–control study in Germany. Seidler A, et al. **Neurology** 1996 May; 46(5):1275–84

[The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti–parkinsonian drugs] Artázcoz Sanz MT, et al. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):479–85 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Morens DM, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):400–4

ETIOLOGY

Motor performance in normal pressure hydrocephalus assessed with an optoelectronic measurement technique. Matousek M, et al. **Acta Neurol Scand** 1995 Jun;91(6):500–5

Etiology of Parkinson's disease. The role of environment and heredity. De Michele G, et al. **Adv Neurol** 1996;69:19–24

Dietary lipids and antioxidants in Parkinson's disease: a population–based, case–control study. Logroscino G, et al. **Ann Neurol** 1996 Jan;39(1):89–94

Parkinson's, Alzheimer's, and motor neurone disease [editorial] [see comments] Ben–Shlomo Y, et al. **BMJ** 1996 Mar 23;312(7033):724. Comment in: BMJ 1996 Jul 6;313(7048):45.

Environmental exposures in elderly Canadians with Parkinson's disease. Chaturvedi S, et al. **Can J Neurol Sci** 1995 Aug;22(3):232–4

Nocardia species as an etiologic agent in Parkinson's disease: serological testing in a case–control study. Hubble JP, et al. **J Clin Microbiol** 1995 Oct;33(10):2768–9

How far are we in understanding the cause of Parkinson's disease? Ben–Shlomo Y. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):4–16 (165 ref.)

1–Methyl–4–phenyl–1,2,3,6–tetrahydropyridine (MPTP) is N–demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's disease. Coleman T, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):685–90

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case–control study in Germany. Seidler A, et al. **Neurology** 1996 May; 46(5):1275–84

[Etiology and pathogenesis of parkinson's disease] Mizuno Y, et al. **No To Shinkei** 1996 Jan;48(1):5–17 (136 ref.) **(Jpn)**

[Metabolic enzymes of neurotoxin: 1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

[Parkinsonism induced by sodium valproate] del Real Francia MA, et al. **Neurologia** 1995 Nov;10(9):381–3 (Eng. Abstr.) **(Spa)**

[New forms of Parkinsonism in hospice care (see comments)] Baquero M, et al. **Rev Neurol** 1995 Sep–Oct;23(123):964–8 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

[Parkinson disease or drug–induced parkinsonism? (see comments)] Martí–Massó JF. **Rev Neurol** 1995 Sep–Oct; 23(123):983–5. Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

GENETICS

Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R, et al. **Adv Neurol** 1996;69:97–100

Etiology of Parkinson's disease. The role of environment and

heredity. De Michele G, et al. **Adv Neurol** 1996;69:19–24
Recent advances in the genetics of Parkinson's disease. Duvoisin RC. **Adv Neurol** 1996;69:33–40 (55 ref.)
Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes. Gasser T, et al. **Adv Neurol** 1996;69:87–95
The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)
Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)
Glutamate receptor genes in Parkinson's disease. Penney JB, et al. **Adv Neurol** 1996;69:79–86 (30 ref.)
Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Brown MD, et al. **Am J Med Genet** 1996 Jan 22;61(3):283–9
Normal CAG and CCG repeats in the Huntington's disease genes of Parkinson's disease patients. Rubinsztein DC, et al. **Am J Med Genet** 1995 Apr 24;60(2):109–10
Accumulation of deletions and point mutations in mitochondrial genome in degenerative diseases. Tanaka M, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:102–11
Dopa–responsive parkinsonism phenotype of Machado–Joseph disease: confirmation of 14q CAG expansion. Tuite PJ, et al. **Ann Neurol** 1995 Oct;38(4):684–7
Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Parboosingh JS, et al. **Arch Neurol** 1995 Dec;52(12):1160–3
The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Egensperger R, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):484–6
Frequency of a specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson disease. Akhmedova SN, et al. **Biochem Mol Med** 1995 Apr;54(2):88–90
Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)
Familial Parkinson's disease: a clinical genetic analysis. Bonifati V, et al. **Can J Neurol Sci** 1995 Nov;22(4):272–9
Familial Alzheimer's disease and cortical Lewy bodies: is there a genetic susceptibility factor? Lippa CF, et al. **Dementia** 1995 Jul–Aug;6(4):191–4
Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido–ponto–nigral degeneration to chromosome 17q21. Wijker M, et al. **Hum Mol Genet** 1996 Jan;5(1):151–4
A genetic study of Parkinson's disease. De Michele G, et al. **J Neural Transm Suppl** 1995;45:21–5
Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. Ibarreta D, et al. **J Neurol Sci** 1995 Dec;134(1–2):146–9
A clinical and genetic study of familial cases of Parkinson's disease. Planté–Bordeneuve V, et al. **J Neurol Sci** 1995 Nov;133(1–2):164–72
Variable phenotype of rapid–onset dystonia–parkinsonism. Brashear A, et al. **Mov Disord** 1996 Mar;11(2):151–6
Environmental and genetic risk factors in Parkinson's disease: a case–control study in southern Italy. De Michele G, et al. **Mov Disord** 1996 Jan;11(1):17–23
A family with hereditary juvenile dystonia–parkinsonism. Ishikawa A, et al. **Mov Disord** 1995 Jul;10(4):482–8
Clinical analysis of 17 patients in 12 Japanese families with autosomal–recessive type juvenile parkinsonism. Ishikawa A, et al. **Neurology** 1996 Jul;47(1):160–6
Risk of Parkinson's disease among first–degree relatives: A community–based study. Marder K, et al. **Neurology** 1996 Jul;47(1):155–60
CYP2D6 allelic frequencies in young–onset Parkinson's disease. Sandy MS, et al. **Neurology** 1996 Jul;47(1):225–30
Prion analogues and twin studies in Parkinson's disease. Sommer SS, et al. **Neurology** 1996 Jan;46(1):273–5
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Nisbet AP, et al. **Neuroscience** 1995 May;66(2):361–76
Analysis of MAOA mutations in humans. Hsu YP, et al. **Prog Brain Res** 1995;106:67–75 (54 ref.)
[An unusual case of peroneal muscular atrophy with rigidity, polyneuropathy, mental retardation, and diabetes mellitus developed in familial Parkinson's disease] Saito T, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):878–83 (Eng. Abstr.) **(Jpn)**

HISTORY

More movements. Perkin GD. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):563
Living with Parkinson's disease [editorial] [see comments] Salzman EW. **N Engl J Med** 1996 Jan 11;334(2):114–6. Comment in: N Engl J Med 1996 Jul 11;335(2):130; discussion 131. Comment in: N Engl J Med 1996 Jul 11;335(2):130–1.
[Parkinsonism of Johan Sebastian Welhaven (letter; comment)] Borgen P. **Tidsskr Nor Laegeforen** 1996 Jan 30; 116(3):413–4. Comment on: Tidsskr Nor Laegeforen 1995 Dec 10;115(3):3738–9. **(Nor)**
[Johan Sebastian Welhaven's parkinsonism. An insight into the history of literature (see comments)] Kierulf H. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3738–9 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1996 Jan 30;116(3):413–4. **(Nor)**

IMMUNOLOGY

Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. Kunas RC, et al. **J Allergy Clin Immunol** 1995 Nov; 96(5 Pt 1):688–90

METABOLISM

Failure of dopamine metabolism: borderlines of parkinsonism and dementia. Tárczy M, et al. **Acta Biomed Ateneo Parmense** 1995;66(3–4):93–7
Microtubule–associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease. Gai WP, et al. **Acta Neuropathol (Berl)** 1996;91(1):78–81
Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R, et al. **Adv Neurol** 1996;69:97–100
Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Pizzolato G, et al. **Adv Neurol** 1996;69:467–73
Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: evidence that the disorders are distinct. Strong C, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):218–22
Lewy bodies: purification from diffuse Lewy body disease brains. Iwatsubo T, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:195–205
Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection. Kondo T. **Ann N Y Acad Sci** 1996 Jun 15;786:206–16 (35 ref.)
Oxidative stress and Parkinson's disease. Owen AD, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:217–23
Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Eidelberg D, et al. **Ann Neurol** 1996 Apr;39(4):450–9
Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Fernandez A, et al. **Brain** 1996 Jun;119 (Pt 3):823–30
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP–lesioned monkeys. Faucheux BA, et al. **Brain Res** 1995 Sep 11;691(1–2):115–24
Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Thibaut F, et al. **Brain Res** 1995 Sep 18; 692(1–2):233–43
Mass spectrometry in Parkinson's disease. Niwa T. **Clin Chim Acta** 1995 Oct–Nov;241–242:223–50
Pharmacodynamics of levodopa in Parkinson's disease. Nutt JG. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):837–40
Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)
Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Sam E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):27–33
Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Ge J, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):299–306
Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine–secreting cell grafting. Date I, et al. **Exp Neurol** 1996 Feb;137(2):333–44
Detection of 1–phenyl–N–methyl–1,2,3,4–tetrahydroisoquinoline and 1–phenyl–1,2,3,4–tetrahydroisoquinoline in human brain by gas chromatography–tandem mass spectrometry. Kajita M, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21; 669(2):345–51
Effects of trihexyphenidyl and L–dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography. Shinotoh H, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):35–46
Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease. Volpi R, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):1–11
Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137–41 (21 ref.)
PET studies of the striatal dopaminergic system in Parkinson's disease (PD). Piccini P, et al. **J Neural Transm Suppl** 1995;45:123–31 (57 ref.)
Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L–dopa in Parkinson's disease: a [123I]–IBZM SPET study. Pizzolato G, et al. **J Neural Transm Suppl** 1995;45:113–22
Magnetic resonance spectroscopic study of parkinsonism related to boxing [letter; comment] Chaudhuri KR, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):561–2. Comment on: J Neurol Neurosurg Psychiatry 1995 Jun;58(6):688–91.
Defective production of interleukin–2 in patients with idiopathic Parkinson's disease. Klüter H, et al. **J Neurol Sci** 1995 Nov;133(1–2):134–9
Differences in the reduced 18F–Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. Otsuka M, et al. **J Neurol Sci** 1996 Mar;136(1–2):169–73
Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. Rinne JO, et al. **J Neurol Sci** 1995 Oct;132(2):156–61
Radical formation site of cerebral complex I and Parkinson's disease. Fukushima T, et al. **J Neurosci Res** 1995 Oct 15; 42(3):385–90
Pumping iron in Parkinson's disease [news] Bonn D. **Lancet** 1996 Jun 8;347(9015):1614
Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S–adenosylmethionine: a possible role of hypermethylation in parkinsonism. Charlton CG, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):269–84
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Ahlskog JE, et al. **Mov Disord** 1995 Sep;10(5):566–73
Parkinsonian–like locomotor impairment in mice lacking dopamine D2 receptors. Baik JH, et al. **Nature** 1995 Oct 5;377(6548):424–8
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Mattammal MB, et al. **Neurodegeneration** 1995 Sep;4(3):271–81
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Ahlskog JE, et al. **Neurology** 1996 Mar;46(3):796–801
S–methylation in Parkinson's disease. Nakagawa–Hattori Y, et al. **Neurology** 1995 Dec;45(12):2279–81
Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Penn AM, et al. **Neurology** 1995 Nov;45(11):2097–9
Superoxide–dependent depletion of reduced glutathione by L–DOPA and dopamine. Relevance to Parkinson's disease. Spencer JP, et al. **Neuroreport** 1995 Jul 31;6(11):1480–4
Fos immuno–positive neurons in the subthalamic nucleus following reversal of parkinsonian symptoms by antagonism of excitatory amino acid transmission in the entopeduncular nucleus of the monoamine depleted rat. Cooper AJ, et al. **Neurosci Lett** 1995 Dec 15;201(3):251–4
Striatal expression of substance P and methionin–enkephalin in genes in patients with Parkinson's disease. Levy R, et al. **Neurosci Lett** 1995 Oct 27;199(3):220–4
Transforming growth factor–beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Mogi M, et al. **Neurosci Lett** 1995 Jun 30;193(2):129–32
Apolipoprotein E and B alleles in Parkinson's patients. Poduslo SE, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):145–7
Further observations on MxA–positive Lewy bodies in Parkinson's disease brain tissues. Yamada T. **Neurosci Lett** 1995 Jul 28;195(1):41–4
Novel sites of action for deprenyl in MPTP–parkinsonism: metabolite–mediated protection against striatal neurotoxicity and suppression of MPTP–induced increase of dopamine turnover in C57BL mice. Sziráki I, et al. **Prog Brain Res** 1995;106:155–71
PET examination of the monoamine transporter with [11C]beta–CIT and [11C]beta–CFT in early Parkinson's disease. Rinne JO, et al. **Synapse** 1995 Oct;21(2):97–103
[Parkinson disease and the neuronal dopamine uptake complex] Costentin J. **Ann Pharm Fr** 1995;53(4):145–54 (87 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

The increase of Parkinson's disease mortality could be due to a cohort effect. Chio A, et al. **Acta Neurol Scand** 1995 Aug;92(2):113–5
Mortality in patients with Parkinson's disease. Wermuth L, et al. **Acta Neurol Scand** 1995 Jul;92(1):55–8
Parkinson's disease: progression and mortality in the L–DOPA era. Di Rocco A, et al. **Adv Neurol** 1996;69:3–11
Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Schulte PA, et al. **Am J Public Health** 1996 Sep;86(9):1281–8
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients [letter; comment] Anderson KE, et al. **BMJ** 1996 Mar 16;312(7032):702; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1583–4. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used [letter; comment] Gerlach M, et al. **BMJ** 1996 Mar 16;312(7032):704; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation [letter; comment] Jellinger KA. **BMJ** 1996 Mar 16; 312(7032):704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom [see comments] Lees AJ. **BMJ** 1995 Dec 16;311(7020):1602–7. Comment in: BMJ 1995 Dec 16;311(7020):1583–4. Comment in: BMJ 1996 Mar 16;312(7032):702; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):702–3; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):703; discussion

704–5. Comment in: BMJ 1996 Mar 16;312(7032):703–4; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704–5.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages [letter; comment] MacMahon DG, et al. **BMJ** 1996 Mar 16;312(7032):703; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality [letter; comment] Mäki-Ikola O, et al. **BMJ** 1996 Mar 16;312(7032):702; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary [letter; comment] Olanow CW, et al. **BMJ** 1996 Mar 16;312(7032):702–3; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death [letter; comment] Silva MT, et al. **BMJ** 1996 Mar 16;312(7032):703; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations [letter; comment] Yu PH, et al. **BMJ** 1996 Mar 16;312(7032):703–4; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Further evidence of increased risk of mortality of Parkinson's disease [letter] Tison F, et al.
J Neurol Neurosurg Psychiatry 1996 May;60(5):592–3

Longitudinal Gompertzian analysis of Parkinson's disease mortality in Japan, 1950–1993. Imaizumi Y.
Mech Ageing Dev 1995 Nov 3;85(1):15–23

Analysis of mortality in pergolide-treated patients with Parkinson's disease. Sayler ME, et al.
Neuroepidemiology 1996 Jan–Feb;15(1):26–32

Linear rank tests for doubly censored data. Tang MX, et al. **Stat Med** 1995 Dec 15;14(23):2555–63

NURSING

Health maintenance behaviors in advanced Parkinson's disease. Vernon GM, et al. **J Neurosci Nurs** 1995 Aug; 27(4):229–35

PATHOLOGY

Microtubule-associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease. Gai WP, et al.
Acta Neuropathol (Berl) 1996;91(1):78–81

Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson's disease and multiple system atrophy. Kanda T, et al.
Acta Neuropathol (Berl) 1996;91(2):145–54

Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia. Schwab C, et al.
Acta Neuropathol (Berl) 1995;90(3):287–98

The neuropathologic diagnosis of secondary parkinsonian syndromes. Jellinger KA. **Adv Neurol** 1996;69:293–303 (49 ref.)

Pathologically diagnosed diffuse Lewy body disease and Parkinson's disease. Do the parkinsonian features differ? Louis ED, et al. **Adv Neurol** 1996;69:311–4

Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Schapira AH. **Adv Neurol** 1996; 69:161–5 (33 ref.)

Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy. Scigliano G, et al. **Adv Neurol** 1996;69:305–9

Parkinson's disease. The apoptosis hypothesis. Stern G.
Adv Neurol 1996;69:101–7 (29 ref.)

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Altered neurofilament expression does not contribute to Lewy body formation [letter; comment] Hill WD.
Am J Pathol 1996 Aug;149(2):728–9. Comment on: Am J Pathol 1996 Jan;148(1):267–72.

Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Iwatsubo T, et al. **Am J Pathol** 1996 May;148(5):1517–29

Lewy body disease and dementia. A review. Kalra S, et al.
Arch Intern Med 1996 Mar 11;156(5):487–93 (62 ref.)

Cerebral and extracerebral abnormalities in Parkinson's disease [letter; comment] Miaux Y. **Arch Neurol** 1996 May; 53(5):402–3. Comment on: Arch Neurol 1995 Feb;52(2):191–4.

Are patients with Parkinson's disease more likely to have periventricular hyperintensities develop? [letter; comment] Quinn NP. **Arch Neurol** 1996 Mar;53(3):211–2. Comment on: Arch Neurol 1995 Feb;52(2):191–4.

Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)

Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease. Hely MA, et al.
J Neurol Neurosurg Psychiatry 1996 May;60(5):531–8

Hemiballism in Parkinson's disease [letter] Lang AE, et al.
J Neurol Neurosurg Psychiatry 1996 Feb;60(2):247

Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis. Kato S, et al. **J Neurol Sci** 1995 Oct;132(2):216–21

The role of transition metals in the pathogenesis of Parkinson's disease. Kienzl E, et al. **J Neurol Sci** 1995 Dec; 134 Suppl:69–78

Neuropathology of Parkinson's disease. Forno LS.
J Neuropathol Exp Neurol 1996 Mar;55(3):259–72 (101 ref.)

Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. Litvan I, et al.
J Neuropathol Exp Neurol 1996 Jan;55(1):97–105

In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. Baunez C, et al.
J Neurosci 1995 Oct;15(10):6531–41

Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. Levivier M, et al. **J Neurosci** 1995 Dec; 15(12):7810–20

Parkinson's disease [letter] Quinn N. **J Neurosurg** 1996 Sep; 85(3):528–9

Iron in parkinsonian and control substantia nigra—a Mössbauer spectroscopy study. Galązka-Friedman J, et al.
Mov Disord 1996 Jan;11(1):8–16

Facial dystonia in pathologically proven multiple system atrophy: a video report [letter] Wenning GK, et al.
Mov Disord 1996 Jan;11(1):107–9

Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Benjamin R, et al.
Neurodegeneration 1995 Dec;4(4):443–8

Substantia nigra pars reticulata neurons in Parkinson's disease. Hardman CD, et al. **Neurodegeneration** 1996 Mar; 5(1):49–55

6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Jeon BS, et al.
Neurodegeneration 1995 Jun;4(2):131–7

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Damier P, et al.
Neurology 1996 May;46(5):1262–9

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Hulette C, et al. **Neurology** 1995 Nov; 45(11):1991–5

Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Laakso MP, et al. **Neurology** 1996 Mar;46(3):678–81

Large neurons in the tuberomammillary nucleus in patients with Parkinson's disease and multiple system atrophy. Nakamura S, et al. **Neurology** 1996 Jun;46(6):1693–6

Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Ma SY, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):341–3

Abnormal, ubiquitinated cortical neurites in patients with diffuse Lewy body disease. Pellisé A, et al.
Neurosci Lett 1996 Mar 15;206(2–3):85–8

Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Hunot S, et al. **Neuroscience** 1996 May; 72(2):355–63

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Yoritaka A, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2696–701

[Aging, disease and nerve cell death] Agid Y.
Bull Acad Natl Med 1995 Jun;179(6):1193–203; discussion 1203–7 (Eng. Abstr.) **(Fre)**

[A 78-year-old man with young onset parkinsonism and sudden death (clinical conference)] Miyasaka H, et al.
No To Shinkei 1996 May;48(5):487–95 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Asahina M, et al. **Acta Neurol Scand** 1995 Jun;91(6):437–43

Sympathetic skin response in Parkinson's disease. Hirashima F, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):127–32

The perception of head rotation in Parkinson's disease. Nakamura T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:387–91

The performance of rapid arm movements in Parkinson's disease. A review. Agostino R, et al. **Adv Neurol** 1996; 69:135–46 (61 ref.)

Characteristics of pallidal neuronal discharges in Parkinson's disease patients. Berić A, et al. **Adv Neurol** 1996;69:123–8

Basal ganglia function during normal and parkinsonian movement. PET activation studies. Brooks DJ.
Adv Neurol 1996;69:433–41 (38 ref.)

Pathophysiology of Parkinson's disease rigidity. Role of corticospinal motor projections. Cantello R, et al.
Adv Neurol 1996;69:129–33

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497–501 (30 ref.)

Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's disease and multiple system atrophy. Delalande I, et al. **Adv Neurol** 1996;69:319–25

From basal ganglia to motoneurons. Probable involvement of pathways relaying in the medulla. Delwaide PJ, et al.
Adv Neurol 1996;69:111–6 (26 ref.)

The freezing phenomenon in parkinsonism. Fahn S.
Adv Neurol 1995;67:53–63 (49 ref.)

Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Montastruc JL, et al.
Adv Neurol 1996;69:377–81 (36 ref.)

Molecular biology of catecholamine neurons in relation to Parkinson's disease. Nagatsu T, et al. **Adv Neurol** 1996; 69:147–52 (22 ref.)

Biochemical and pharmacologic assessment of autonomic function. Polinsky RJ. **Adv Neurol** 1996;69:373–6 (17 ref.)

Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Gray R, et al.
Age Ageing 1995 Nov;24(6):499–504

Reduced bone density of the hip in elderly patients with Parkinson's disease. Taggart H, et al. **Age Ageing** 1995 Jul; 24(4):326–8

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

Strength in Parkinson's disease: relationship to rate of force generation and clinical status. Corcos DM, et al.
Ann Neurol 1996 Jan;39(1):79–88

Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Rottach KG, et al.
Ann Neurol 1996 Mar;39(3):368–77

Abnormalities of smooth eye and head movement control in Parkinson's disease. Waterston JA, et al. **Ann Neurol** 1996 Jun;39(6):749–60

Effect of thalamic stimulation on gait in Parkinson disease. Defebvre L, et al. **Arch Neurol** 1996 Sep;53(9):898–903

Interaction of 1,2,3,4-tetrahydroisoquinoline with some components of cigarette smoke: potential implications for Parkinson's Disease. Soto-Otero R, et al.
Biochem Biophys Res Commun 1996 May 15;222(2):607–11

Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson's disease. Linert W, et al.
Biochim Biophys Acta 1996 Aug 23;1316(3):160–8

A neural model of basal ganglia–thalamocortical relations in normal and parkinsonian movement. Contreras-Vidal JL, et al. **Biol Cybern** 1995 Oct;73(5):467–76

Stimulation of the globus pallidus in Parkinson's disease. Iacono RP, et al. **Br J Neurosurg** 1995;9(4):505–10

Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. Mellers JD, et al. **Br J Psychiatry** 1995 Oct;167(4):522–6

Cortical inhibition in Parkinson's disease. A study with paired magnetic stimulation. Berardelli A, et al. **Brain** 1996 Feb; 119 (Pt 1):71–7

Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects [letter; comment] Bötzel K, et al. **Brain** 1996 Jun;119 (Pt 3):1045–8. Comment on: Brain 1995 Aug;118 (Pt 4):913–33.

Effects of magnetic stimulation over supplementary motor area on movement in Parkinson's disease. Cunnington R, et al. **Brain** 1996 Jun;119 (Pt 3):815–22

Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Ebersbach G, et al.
Brain 1996 Feb;119 (Pt 1):79–87

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.). Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

Effects of levodopa and viscosity on the velocity and accuracy of visually guided tracking in Parkinson's disease. Johnson MT, et al. **Brain** 1996 Jun;119 (Pt 3):801–13

Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms. Morris ME, et al.
Brain 1996 Apr;119 (Pt 2):551–68

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Morrish PK, et al.
Brain 1996 Apr;119 (Pt 2):585–91

The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson's disease. O'Boyle DJ, et al. **Brain** 1996 Feb;119 (Pt 1):51–70

The use of PET in Parkinson's disease. Shinotoh H, et al.
Brain Cogn 1995 Aug;28(3):297–310 (67 ref.)

Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Ginsberg L, et al. **Brain Res** 1995 Nov 6;698(1–2):223–6

Bone mass in Parkinson's disease: a study with three methods. Revilla M, et al. **Calcif Tissue Int** 1996 May;58(5):311–5

Memory and skill acquisition in Parkinson's disease and frontal lobe dysfunction. Daum I, et al. **Cortex** 1995 Sep; 31(3):413–32

Parkinson's disease rigidity: EMG in a small hand muscle at "rest". Cantello R, et al.
Electroencephalogr Clin Neurophysiol 1995 Oct; 97(5):215–22

Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease. Clouston PD, et al.
Electroencephalogr Clin Neurophysiol 1996 Feb;101(1):8–15

Leg muscle activation during gait in Parkinson's disease: adaptation and interlimb coordination. Dietz V, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):408–15

Impairment of posturo–kinetic co–ordination during initiation of forward oriented stepping movements in parkinsonian patients. Gantchev N, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 101(2):110–20

Components of EMG symmetry and variability in parkinsonian and healthy elderly gait. Miller RA, et al. **Electroencephalogr Clin Neurophysiol** 1996 Feb;101(1):1–7

Contingent negative variation and movement–related cortical potentials in parkinsonism. Oishi M, et al. **Electroencephalogr Clin Neurophysiol** 1995 Nov;95(5):346–9

Muscle modifications in Parkinson's disease: myoelectric manifestations. Rossi B, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):211–8

Investigation of EEG non–linearity in dementia and Parkinson's disease. Stam CJ, et al. **Electroencephalogr Clin Neurophysiol** 1995 Nov; 95(5):309–17

Electrophysiology of the palmomental reflex in normal and parkinsonian subjects. Caccia MR, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb;36(1):9–13

The internal control of action and Parkinson's disease: a kinematic analysis of visually–guided and memory–guided prehension movements. Jackson SR, et al. **Exp Brain Res** 1995;105(1):147–62

Labeling and identification of living donor cells in brain slices of recipient hemiparkinsonian model rats for physiological recordings: methods for physiological assessments of neural transplantation. Fukuda A, et al. **Exp Neurol** 1996 Feb; 137(2):309–17

Short–latency median nerve somatosensory evoked potentials in three cases of parkinsonism and dopa responsive dystonia. Margari L, et al. **Funct Neurol** 1995 Mar–Apr; 10(2):99–105

Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. Sénard JM, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S175–7

Effects of intravenous L–dopa on P300 and regional cerebral blood flow in parkinsonism. Oishi M, et al. **Int J Neurosci** 1996 Mar;85(1–2):147–54

Reversal of visuospatial deficit on the Clock Drawing Test in Parkinson's disease by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun; 82(3–4):255–68

Effect of weak electromagnetic fields on the amplitude of the pattern reversal VEP response in Parkinson's disease. Sandyk R. **Int J Neurosci** 1996 Feb;84(1–4):165–75

Visual attention and perception in patients with Huntington's disease: comparisons with other subcortical and cortical dementias. Filoteo JV, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):654–67

Modality dependent changes in event–related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease. Bodis–Wollner I, et al. **J Neural Transm Park Dis Dement Sect** 1995; 9(2–3):197–209

Neuropsychological characteristics of parkinsonian patients with lateralized motor impairment. Finali G, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):165–76

The neural mechanisms and progressive nature of symptoms of Parkinson's disease—based on clinical, neurophysiological and morphological studies. Narabayashi H. **J Neural Transm Park Dis Dement Sect** 1995;10(1):63–75 (26 ref.)

Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients. de Mari M, et al. **J Neural Transm Suppl** 1995;45:171–6

A simple model to explain the motor fluctuations seen in Parkinson's disease [letter] Bateman DE. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):555

Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of levodopa treatment. Harrison J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):499–506

Micrographia in Chinese characters. Ho SL. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):471

Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa. Robertson LT, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):41–50

Clinical correlates of motor performance during paced postural tasks in Parkinson's disease. Beckley DJ, et al. **J Neurol Sci** 1995 Oct;132(2):133–8

Resting tremor only: a variant of Parkinson's disease or of essential tremor. Chang MH, et al. **J Neurol Sci** 1995 Jun; 130(2):215–9

Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. Chia LG, et al. **J Neurol Sci** 1995 Nov; 133(1–2):73–8

Shortened silent period produced by magnetic cortical stimulation in patients with Parkinson's disease. Nakashima K, et al. **J Neurol Sci** 1995 Jun;130(2):209–14

In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. Baunez C, et al. **J Neurosci** 1995 Oct;15(10):6531–41

Sleep in older women with Parkinson's disease. Dowling GA. **J Neurosci Nurs** 1995 Dec;27(6):355–7, 360–2

Cografting with polymer–encapsulated human nerve growth factor–secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats. Date I, et al. **J Neurosurg** 1996 Jun;84(6):1006–12

Motor effects of stimulating the human cerebellar thalamus. Ashby P, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):287–98

The vesamicol receptor ligand (+)–meta–[125I]iodobenzyltrozamicol [(+)–[125I]–MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6–hydroxydopamine (6–OHDA)–lesioned rat: possible implications for Parkinson's disease. Efange SM, et al. **Life Sci** 1996; 58(16):1367–74

Motor activation time in Parkinson's disease. Segura MJ, et al. **Medicina (B Aires)** 1995;55(3):208–12

Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73–94 (165 ref.)

Walking–induced parkinsonism due to presumed idiopathic normal pressure hydrocephalus [letter] Friedman JH. **Mov Disord** 1996 Jan;11(1):99–101

Concerning "visual control of arm movement in Parkinson's disease" [letter] Inzelberg R, et al. **Mov Disord** 1996 Jan; 11(1):115

A defect of kinesthesia in Parkinson's disease. Klockgether T, et al. **Mov Disord** 1995 Jul;10(4):460–5

Lewy body disease in a patient with REM sleep disorder [letter; comment] Negro PJ Jr, et al. **Neurology** 1996 May; 46(5):1493–4. Comment on: Neurology 1995 Apr;45(4):709–12.

N30 in PD [letter; comment] Ozaki I, et al. **Neurology** 1996 Jul;47(1):304; discussion 304–6. Comment on: Neurology 1995 May;45(5):989–92.

Cutaneous electromyographic silent period findings in brachial dystonia. Pullman SL, et al. **Neurology** 1996 Feb; 46(2):503–8

N30 in PD [letter; comment] Rossini PM. **Neurology** 1996 Jul;47(1):303–4; discussion 304–6. Comment on: Neurology 1995 May;45(5):989–92.

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Schenck CH, et al. **Neurology** 1996 Feb;46(2):388–93

Levodopa–induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Tedroff J, et al. **Neurology** 1996 May;46(5):1430–6

Central motor loop oscillations in parkinsonian resting tremor revealed by magnetoencephalography. Volkmann J, et al. **Neurology** 1996 May;46(5):1359–70

Contingent and non–contingent auditory cueing in Parkinson's disease. Kritikos A, et al. **Neuropsychologia** 1995 Oct;33(10):1193–203

Micrographia in Parkinson's disease. Contreras–Vidal JL, et al. **Neuroreport** 1995 Oct 23;6(15):2089–92

Open–loop and closed–loop postural control mechanisms in Parkinson's disease: increased mediolateral activity during quiet standing. Mitchell SL, et al. **Neurosci Lett** 1995 Sep 8;197(2):133–6

Temporal stability of gait in Parkinson's disease. Morris ME, et al. **Phys Ther** 1996 Jul;76(7):763–77; discussion 778–80

Cardiovascular and metabolic responses to upper– and lower–extremity exercise in men with idiopathic Parkinson's disease. Protas EJ, et al. **Phys Ther** 1996 Jan; 76(1):34–40

Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Davies KN, et al. **Postgrad Med J** 1996 Mar;72(845):164–7

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

Day–to–day demands of Parkinson's disease. Habermann B. **West J Nurs Res** 1996 Aug;18(4):397–413

Relationship between the auditory P300 and the procedural memory function in drug–naive patients with Parkinson's disease. Kim GW, et al. **Yonsei Med J** 1995 Sep; 36(4):367–71

[Degeneration of catecholaminergic neurons (editorial)] Chatellard–Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

[Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations] Azulay JP, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):128–34 (Eng. Abstr.) **(Fre)**

[Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis] Bellon AK, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1077–83 (Eng. Abstr.) **(Ger)**

[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants] Gerlach M, et al. **Med Klin** 1996 Mar 15;91(3):163–70 (69 ref.) **(Ger)**

[Sympathetic skin response in Parkinson syndrome] Jost WH, et al. **Nervenarzt** 1995 Oct;66(10):777–80 (Eng. Abstr.) **(Ger)**

[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**

[Visual event–related potentials and reaction time in Parkinson's disease] Aragane K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Oct;32(10):628–36 (Eng. Abstr.) **(Jpn)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Neurobiology of parkinsonism. I. Neural substrates an neurochemistry of the basal ganglia] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):706–10 (13 ref.) (Eng. Abstr.) **(Por)**

[Neurobiology of parkinsonism. II. Experimental models] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):711–7 (33 ref.) (Eng. Abstr.) **(Por)**

[Effect of transcranial polarization on the state of supraspinal mechanisms of regulation of muscle tonus in patients with Parkinson's disease] Lomarev MP. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):132–3 **(Rus)**

[The characteristics of endogenous evoked potentials during normal psychomotor reactions and during basal ganglionic dysfunction in man] Krylov IN. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):51–62 (Eng. Abstr.) **(Rus)**

[Activity and function of neurons in the globus pallidus in Parkinson's disease] Marković L, et al. **Med Pregl** 1996; 49(1–2):11–6 (Eng. Abstr.) **(Scr)**

[Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine] Merello M, et al. **Medicina (B Aires)** 1995;55(1):5–10 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Image generation from long–term memory in Parkinson's disease. Appollonio I, et al. **Adv Neurol** 1996;69:349–59

Switching abilities in Parkinson's disease. Inzelberg R, et al. **Adv Neurol** 1996;69:361–9

Involvement of serotonin in clinical features of Parkinson's disease and complications of L–DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)

Effects of L–DOPA on spatiotemporal contrast sensitivity in Parkinson's disease. Mestre DR, et al. **Adv Neurol** 1996; 69:503–11

The evolution and profile of dementia in Parkinson's disease. Ross HF, et al. **Adv Neurol** 1996;69:343–7

Self–reported functioning and well–being in patients with Parkinson's disease: comparison of the short–form health survey (SF–36) and the Parkinson's Disease Questionnaire (PDQ–39). Jenkinson C, et al. **Age Ageing** 1995 Nov; 24(6):505–9

Neuropsychological impairment in Parkinson's disease with and without depression. Tröster AI, et al. **Arch Neurol** 1995 Dec;52(12):1164–9

Shifting behavior: an analysis of response patterns of Parkinson patients in discrimination learning. Joosten JP, et al. **Brain Cogn** 1995 Nov;29(2):115–26

Parkinson's disease affects automatic and spares intentional verbal learning. A stochastic approach to explicit learning processes. Faglioni P, et al. **Cortex** 1995 Dec;31(4):597–617

The internal control of action and Parkinson's disease: a kinematic analysis of visually–guided and memory–guided prehension movements. Jackson SR, et al. **Exp Brain Res** 1995;105(1):147–62

Card sorting performance in Parkinson's Disease: a comparison between acquisition and shifting performance. van Spaendonck KP, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):918–25

Meta–analytic comparison of the components of visual cognition in Parkinson's disease. Waterfall ML, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):759–72

Modality dependent changes in event–related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease. Bodis–Wollner I, et al. **J Neural Transm Park Dis Dement Sect** 1995; 9(2–3):197–209

Neuropsychological characteristics of parkinsonian patients with lateralized motor impairment. Finali G, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):165–76

Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. Ransmayr G, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):177–88

Do cognitive changes of Parkinson's disease result from dopamine depletion? Dubois B, et al. **J Neural Transm Suppl** 1995;45:27–34 (28 ref.)

Quality of life in patients with Parkinson's disease: development of a questionnaire. de Boer AG, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):70–4

Working memory in medicated patients with Parkinson's disease: the central executive seems to work. Fournet N, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):313–7

Cognitive function in patients with Parkinson's disease undergoing stereotaxic thalamotomy. Lund–Johansen M, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):564–71

Fractionation of visuoperceptual dysfunction in Parkinson's disease. Jones RD, et al. **J Neurol Sci** 1995 Jul;131(1):43–50

Psychosis in Parkinson's disease: diagnosis and treatment. Doraiswamy M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):835–46 (27 ref.)

Set–shifting aptitude in Parkinson's disease: external versus internal cues. Hsieh S, et al. **Psychol Rep** 1995 Aug; 77(1):339–49

Precued shifting of attention between cognitive sets in Parkinson patients. Hsieh S, et al. **Psychol Rep** 1996 Jun; 78(3 Pt 1):815–23

A neostriatal habit learning system in humans [see comments]

Knowlton BJ, et al. **Science** 1996 Sep 6;273(5280):1399–402 . Comment in: Science 1996 Sep 6;273(5280):1353–4.

Refining the taxonomy of memory [comment] Robbins TW. **Science** 1996 Sep 6;273(5280):1353–4 (11 ref.). Comment on: Science 1996 Sep 6;273(5280):1399–402.

Day–to–day demands of Parkinson's disease. Habermann B. **West J Nurs Res** 1996 Aug;18(4):397–413

Relationship between the auditory P300 and the procedural memory function in drug–naive patients with Parkinson's disease. Kim GW, et al. **Yonsei Med J** 1995 Sep; 36(4):367–71

[Cognitive disorders in Parkinson disease. Electroencephalographic correlations] Pereira JS, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):11–5 (Eng. Abstr.) **(Por)**

[Disorders in the perception of spatially oriented visual stimuli and Parkinsonism: role of the dopaminergic system] Iakimovskil AF, et al. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):69–72 **(Rus)**

RADIONUCLIDE IMAGING

Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Asahina M, et al. **Acta Neurol Scand** 1995 Jun;91(6):437–43

Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease. Defebvre L, et al. **Acta Neurol Scand** 1995 Sep;92(3):235–41

The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Morrish PK, et al. **Adv Neurol** 1996;69:427–31

Fluorodopa PET scanning in Parkinson's disease. Snow BJ. **Adv Neurol** 1996;69:449–57 (73 ref.)

Images in neuroscience. Neuroimaging, XII. SPECT imaging of dopamine nerve terminals. Seibyl JP, et al. **Am J Psychiatry** 1996 Sep;153(9):1131

Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Remy P, et al. **Ann Neurol** 1995 Oct; 38(4):580–8

Decreased single–photon emission computed tomographic [123I]beta–CIT striatal uptake correlates with symptom severity in Parkinson's disease. Seibyl JP, et al. **Ann Neurol** 1995 Oct;38(4):589–98

Initial clinical experiences with dopamine D2 receptor imaging by means of 2'–iodospiperone and single–photon emission computed tomography. Yonekura Y, et al. **Ann Nucl Med** 1995 Aug;9(3):131–6

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Antonini A, et al. **Arch Neurol** 1995 Dec;52(12):1183–90

An [18F]dopa–PET and clinical study of the rate of progression in Parkinson's disease. Morrish PK, et al. **Brain** 1996 Apr;119 (Pt 2):585–91

The usefulness of functional imaging in movement disorders: an illustrative case [letter] Bhatia KP, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):353–4

Clinical and [18F] dopa PET findings in early Parkinson's disease. Morrish PK, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):597–600

A SPECT study of parkinsonism in Alzheimer's disease. Starkstein SE, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):308–13

Iodine–123–iodo–lisuride SPECT in Parkinson's disease. Cordes M, et al. **J Nucl Med** 1996 Jan;37(1):22–5

Combined FDOPA and 3OMFD PET studies in Parkinson's disease. Dhawan V, et al. **J Nucl Med** 1996 Feb; 37(2):209–16

Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. Ishikawa T, et al. **J Nucl Med** 1996 Feb;37(2):216–22

Early differential diagnosis of Parkinson's disease with 18F–fluorodeoxyglucose and positron emission tomography. Eidelberg D, et al. **Neurology** 1995 Nov; 45(11):1995–2004

[123I] beta–CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi–Parkinson's disease. Marek KL, et al. **Neurology** 1996 Jan;46(1):231–7

PET examination of the monoamine transporter with [11C]beta–CIT and [11C]beta–CFT in early Parkinson's disease. Rinne JO, et al. **Synapse** 1995 Oct;21(2):97–103

[Positron–emission tomography in akinetic rigidity syndrome] Goldman S. **Rev Med Brux** 1995 Dec; 16(6):399–403 (35 ref.) (Eng. Abstr.) **(Fre)**

[Dopamine (D2) receptor SPECT with 123I–iodobenzamide (IBZM) in diagnosis of Parkinson syndrome] Reiche W, et al. **Radiologe** 1995 Nov;35(11):838–43 (Eng. Abstr.) **(Ger)**

[Impairment of benzodiazepine receptor in Parkinson's disease evaluated by 123I–iomazenil SPECT] Kawabata K, et al. **Kaku Igaku** 1996 Apr;33(4):391–7 (Eng. Abstr.) **(Jpn)**

[Positron–emission tomographic studies of the brain in parkinsonism patients] Berezhkova LV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):93–7 (43 ref.) **(Rus)**

REHABILITATION

Metronome in Parkinson's disease [letter] Enzensberger W, et al. **Lancet** 1996 May 11;347(9011):1337

Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Thaut MH, et al. **Mov Disord** 1996 Mar; 11(2):193–200

[Parkinson disease and neurologic rehabilitation] Auff E, et al. **Wien Med Wochenschr** 1995;145(13):302–5 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Anatomic and physiological considerations in pallidotomy for Parkinson's disease. Dogali M, et al. **Acta Neurochir Suppl (Wien)** 1995;64:9–12

Hitchcock's experimental series of foetal implants for Parkinson's disease: co–grafting ventral mesencephalon and striatum. Meyer CH, et al. **Acta Neurochir Suppl (Wien)** 1995;64:1–4

Computer–assisted multidimensional atlas for functional stereotaxy. Alesch F, et al. **Acta Neurochir (Wien)** 1995; 133(3–4):153–6

Effects of posteroventral pallidotomy on Parkinson's disease. Dogali M, et al. **Adv Neurol** 1996;69:585–90

Does stereotactic treatment for Parkinson's disease slow the progression of the disease? Narabayashi H. **Adv Neurol** 1996;69:557–62 (18 ref.)

Does thalamotomy alter the course of Parkinson's disease? Tasker RR, et al. **Adv Neurol** 1996;69:563–83

The laryngeal mask airway for stereotactic implantation of fetal hypophysis [letter] Silva LC, et al. **Anesth Analg** 1996 Feb;82(2):430–1

Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Eidelberg D, et al. **Ann Neurol** 1996 Apr;39(4):450–9

Gamma knife pallidotomy in advanced Parkinson's disease. Friedman JH, et al. **Ann Neurol** 1996 Apr;39(4):535–8

Stereotaxic posteroventral pallidotomy in idiopathic Parkinson's disease [letter] Quinn NP. **Ann Neurol** 1996 Jun;39(6):826

Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Price LH, et al. **Biol Psychiatry** 1995 Oct 15;38(8):498–505

Long–term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Defer GL, et al. **Brain** 1996 Feb;119 (Pt 1):41–50

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.). Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Kopyov OV, et al. **Cell Transplant** 1996 Mar–Apr;5(2):327–37

Neural transplantation. Lindvall O. **Cell Transplant** 1995 Jul–Aug;4(4):393–400 (35 ref.)

Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine–secreting cell grafting. Date I, et al. **Exp Neurol** 1996 Feb;137(2):333–44

Human ventromesencephalic grafts restore dopamine release and clearance in hemiparkinsonian rats. Wang Y, et al. **Exp Neurol** 1995 Dec;136(2):98–106

Parkinson's disease: consider pallidotomy as a therapeutic option[letter] Iacano RP, et al. **Geriatrics** 1996 Mar;51(3):26

Snake oil or miracle? [editorial] Stewart–Amidei C. **J Neurosci Nurs** 1995 Jun;27(3):137

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

Methods for microelectrode–guided posteroventral pallidotomy. Lozano A, et al. **J Neurosurg** 1996 Feb; 84(2):194–202

Superior cervical ganglion regenerating axons through peripheral nerve grafts and reversal of behavioral deficits in hemiparkinsonian rats. Pallini R, et al. **J Neurosurg** 1996 Mar;84(3):487–93

A 61–year–old man with Parkinson's disease [letter; comment] White RJ. **JAMA** 1996 Jul 10;276(2):104. Comment on: JAMA 1996 Mar 6;275(9):716–22.

Effect of GPi pallidotomy on motor function in Parkinson's disease [see comments] Lozano AM, et al. **Lancet** 1995 Nov 25;346(8987):1383–7. Comment in: Lancet 1996 May 25;347(9013):1490.

Assessing the effects of pallidotomy in Parkinson's disease [letter; comment] Obeso JA, et al. **Lancet** 1996 May 25; 347(9013):1490. Comment on: Lancet 1995 Nov 25;346(8987):1383–7.

CLECOS—P: clinical evolution control system on Parkinsonian patients undergoing neural transplantation. Morales F, et al. **Medinfo** 1995;8 Pt 1:626–30

Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Born LJ, et al. **Mov Disord** 1996 Jan;11(1):53–8

The core assessment program for intracerebral transplantation [letter; comment] Lang AE, et al. **Mov Disord** 1995 Jul;10(4):527–8. Comment on: Mov Disord 1994 Jul;9(4):390–4.

Living with Parkinson's disease [letter; comment] De Salles AA, et al. **N Engl J Med** 1996 Jul 11;335(2):130–1. Comment on: N Engl J Med 1996 Jan 11;334(2):114–6.

Living with Parkinson's disease [letter; comment] Hurtig HI, et al. **N Engl J Med** 1996 Jul 11;335(2):130; discussion 131 . Comment on: N Engl J Med 1996 Jan 11;334(2):114–6.

Stereotactic ventrolateral thalamotomy: is ventriculography necessary? Alterman RL, et al. **Neurosurgery** 1995 Oct; 37(4):717–21; discussion 721–2

Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease [letter] Chodakiewitz JW. **Neurosurgery** 1996 Jun;38(6):1261

Pallidotomy in advanced Parkinson's disease [letter; comment] Couldwell WT, et al. **Neurosurgery** 1995 Dec; 37(6):1234. Comment on: Neurosurgery 1995 Jun;36(6):1112–6; discussion 1116–7.

Two–year follow–up study of a patient with Parkinson's disease and severe motor fluctuations treated by co–grafts of adrenal medulla and peripheral nerve into bilateral caudate nuclei: case report. Date I, et al. **Neurosurgery** 1995 Sep;37(3):515–8; discussion 518–9

Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Jankovic J, et al. **Neurosurgery** 1995 Oct;37(4):680–6; discussion 686–7

Pallidotomy in Parkinson's disease [letter] Loyo–Varela M. **Neurosurgery** 1996 Jan;38(1):230; discussion 231

Pallidotomy in Parkinson's disease [letter] Madrazo I. **Neurosurgery** 1996 Jan;38(1):230–1

Thalamotomy and caudatotomy with the Gamma Knife as a treatment for parkinsonism with a comment on lesion sizes. Friehs GM, et al. **Stereotact Funct Neurosurg** 1995; 64 Suppl 1:209–21

Gamma Knife thalamotomy for the treatment of functional disorders. Hirato M, et al. **Stereotact Funct Neurosurg** 1995; 64 Suppl 1:164–71

CT analysis of postoperative changes after thalamotomy for Parkinson's disease. Zhang G, et al. **Stereotact Funct Neurosurg** 1995;64(3):115–22

[Neuropsychological testing of 5 patients with Parkinson's disease before and after neuron graft] Leroy A, et al. **Rev Neurol (Paris)** 1996 Mar;152(3):158–64 (Eng. Abstr.) **(Fre)**

[Neurosurgical methods in Parkinson disease] Alesch F. **Wien Med Wochenschr** 1995;145(13):305–9 (23 ref.) (Eng. Abstr.) **(Ger)**

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system] Nikkhah G, et al. **Zentralbl Neurochir** 1995;56(4):153–60 (29 ref.) (Eng. Abstr.) **(Ger)**

[Open questions in neurotransplantation. Attempted at an unbiased ethical analysis] Reiter–Theil S. **Zentralbl Neurochir** 1995;56(4):173–9 (8 ref.) (Eng. Abstr.) **(Ger)**

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Pallidotomy in patients with Parkinson disease] Shima F. **Fukuoka Igaku Zasshi** 1995 Sep;86(9):355–61 **(Jpn)**

[Encapsulated dopamine–secreting cells transplanted into the brain: a possible therapy for Parkinson's disease] Miyoshi Y, et al. **No Shinkei Geka** 1996 Jan;24(1):35–9 (Eng. Abstr.) **(Jpn)**

THERAPY

Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson's disease and essential tremor. Alesch F, et al. **Acta Neurochir (Wien)** 1995;136(1–2):75–81

Chronic anterior pallidal stimulation for Parkinson's disease. Iacono RP, et al. **Acta Neurochir (Wien)** 1995; 137(1–2):106–12

Effects of conventional and sensory–enhanced physiotherapy on disability of Parkinson's disease patients. Dam M, et al. **Adv Neurol** 1996;69:551–5

Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Pollak P, et al. **Adv Neurol** 1996;69:591–4

A randomized study of the efficacy of the PROPATH Program for patients with Parkinson disease [see comments] Mercer BS. **Arch Neurol** 1996 Sep;53(9):881–4. Comment in: Arch Neurol 1996 Sep;53(9):848.

Quality of life and care in Parkinson's disease. Clarke CE, et al. **Br J Clin Pract** 1995 Nov–Dec;49(6):288–93

Generation of DOPA–producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Lundberg C, et al. **Exp Neurol** 1996 May; 139(1):39–53

The effect of neurotrophin–5 on the growth and survival of nigral grafts in a rat model of Parkinson's disease. Haque NS, et al. **Gene Ther** 1994;1 Suppl 1:S60

Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA–lipofectin complex. Cao L, et al. **Hum Gene Ther** 1995 Nov;6(11):1497–501

Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1996 Mar;85(1–2):111–24

Electroconvulsive therapy in Parkinson's disease: 30 month follow up [letter] Pridmore S, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):693

Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. Benabid AL, et al. **J Neurosurg** 1996 Feb;

84(2):203–14
Parkinson's disease: moving forward [editorial] Morris JG. **Med J Aust** 1995 Sep 18;163(6):287–8
Radical directions in Parkinson's disease [comment] Fisher LJ, et al. **Nat Med** 1995 Mar;1(3):201–3 (20 ref.). Comment on: Nat Med 1995 Mar;1(3):226–31.
There is a renaissance of interest in pallidotomy for Parkinson's disease. Goetz CG, et al. **Nat Med** 1996 May; 2(5):510–4 (21 ref.)
Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease [see comments] Nakao N, et al. **Nat Med** 1995 Mar;1(3):226–31. Comment in: Nat Med 1995 Mar;1(3):201–3.
Toward trophic treatment in parkinsonism: a primate step. Olson L. **Nat Med** 1996 Apr;2(4):400–1 (18 ref.)
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Folkerth RD, et al. **Neurology** 1996 May;46(5):1219–25
One step closer to gene therapy for Parkinson's disease. Kolchinsky A. **Surg Neurol** 1996 Mar;45(3):211–2
[Future aspects of modern Parkinson therapy] Ransmayr G, et al. **Wien Med Wochenschr** 1995;145(13):299–301 (53 ref.) (Eng. Abstr.) **(Ger)**
[New vistas in the treatment of Parkinson disease] Kobayashi T. **Nippon Ronen Igakkai Zasshi** 1996 Apr;33(4):255–8 **(Jpn)**
[Present strategy and future perspective of therapy in Parkinson's disease] Kuno S. **No To Shinkei** 1996 Jan; 48(1):18–25 (35 ref.) **(Jpn)**
[A transcultural view of neurological and mental pathology in a Tzeltal Maya community of the Altos Chiapas] Carod FJ, et al. **Rev Neurol** 1996 Jul;24(131):848–54 (Eng. Abstr.) **(Spa)**

PARKINSON DISEASE, POSTENCEPHALITIC

see related
ENCEPHALITIS, EPIDEMIC

PHYSIOPATHOLOGY

Possible clinical overlap between postencephalitic parkinsonism and progressive supranuclear palsy [letter] Pramstaller PP, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):589–90
[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa] Picard F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):267–71 (Eng. Abstr.) **(Fre)**

PARKINSON DISEASE, SYMPTOMATIC

CEREBROSPINAL FLUID

CSF somatostatin increase in patients with early parkinsonian syndrome. Espino A, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):189–96
1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. Kotake Y, et al. **J Neurochem** 1995 Dec;65(6):2633–8

CHEMICALLY INDUCED

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167–76 (52 ref.)
Verapamil-induced parkinsonism. Padrell MD, et al. **Am J Med** 1995 Oct;99(4):436
Cytosine arabinoside and amphotericin B-induced parkinsonism [letter] Kulkantrakorn K, et al. **Ann Neurol** 1996 Mar;39(3):413–4
Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Kariya S, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1645–50
Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)
Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. Elsworth JD, et al. **Cell Transplant** 1996 Mar–Apr; 5(2):315–25
Parkinsonism in alcohol withdrawal: case report and review of the literature. Luijckx GJ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):336–9 (18 ref.)
Long-term production of neurotrophic factors by astrocyte cultures from hemiparkinsonian rat brain. Langan TJ, et al. **Glia** 1995 Jul;14(3):174–84
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol [letter] McSwain ML, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):284
Parkinsonism associated with fluoxetine and cimetidine: a case report. Leo RJ, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):231–3
1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. Kotake Y, et al. **J Neurochem** 1995 Dec;65(6):2633–8
Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. Bocola V, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):213–6
Increased incidence of levodopa therapy following metoclopramide use. Avorn J, et al. **JAMA** 1995 Dec 13; 274(22):1780–2
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Blanchet PJ, et al. **Mov Disord** 1996 Jan; 11(1):91–4
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Pearce RK, et al. **Mov Disord** 1995 Nov;10(6):731–40
Occupation, education, and Parkinson's disease: a case-control study in an Italian population. Rocca WA, et al. **Mov Disord** 1996 Mar;11(2):201–6
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Schneider JS, et al. **Neurodegeneration** 1995 Sep;4(3):245–55
Manganism [letter; comment] Carolei A, et al. **Neurology** 1995 Nov;45(11):2114–5. Comment on: Neurology 1994 Sep;44(9):1583–6.
Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Herrero MT, et al. **Neurology** 1996 Jul;47(1):219–24
Parkinsonism secondary to petroleum exposure [letter; comment] McCrank E. **Neurology** 1995 Nov;45(11):2112. Comment on: Neurology 1994 Jun;44(6):1051–4.
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Olanow CW, et al. **Neurology** 1996 Feb;46(2):492–8
Manganism [letter; comment] Papapetropoulos T. **Neurology** 1995 Nov;45(11):2115. Comment on: Neurology 1994 Sep;44(9):1583–6.
Biochemical evaluations in skeletal muscles of primates with MPTP Parkinson-like syndrome. Pastoris O, et al. **Pharmacol Res** 1995 Jun;31(6):361–9
[Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases] Masmoudi K, et al. **Therapie** 1995 Sep–Oct;50(5):451–4 (Eng. Abstr.) **(Fre)**
[Parkinson syndrome induced by veralipride] Franchignoni FP, et al. **Minerva Ginecol** 1995 Jun;47(6):277–9 (Eng. Abstr.) **(Ita)**
[The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome] Korshunov AM, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):7–9 (Eng. Abstr.) **(Rus)**
[Parkinsonism secondary to the use of sertraline (letter)] Cano A, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):797–8 **(Spa)**
[Parkinson's disease secondary to flunarizine or other drugs (letter)] Claps A. **Rev Med Chil** 1995 Aug;123(8):1033–6 **(Spa)**

DIAGNOSIS

MR volume estimation of subcortical brain lesions and ventricular cerebrospinal fluid: a simple and accurate stereologic method. Vogels OJ, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1441–5
Critique of DSM-IV: associated features of neuroleptic-induced parkinsonism [letter] Segraves T, et al. **Am J Psychiatry** 1996 Jun;153(6):844
[Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes] Hierholzer J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):43–51 (Eng. Abstr.) **(Ger)**
[Precocious Parkinson's disease associated with "eye-of-the-tiger" type pallidal lesions] Barbosa ER, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):294–7 (Eng. Abstr.) **(Por)**

DRUG THERAPY

N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder. Verma A, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:327
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):29–36
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):37–45
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys [see comments] Papa SM, et al. **Ann Neurol** 1996 May;39(5):574–8. Comment in: Ann Neurol 1996 May;39(5):557–8.
Amantadine treatment of a patient with anoxic brain injury. Edby K, et al. **Childs Nerv Syst** 1995 Oct;11(10):607–9
Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Kaur S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):159–66
Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism. Brunner-Guenat M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):861–9
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. Shiosaki K, et al. **J Pharmacol Exp Ther** 1996 Jan; 276(1):150–60
Botulinum A toxin for the so-called apraxia of lid opening. Lepore V, et al. **Mov Disord** 1995 Jul;10(4):525–6
An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Smith L, et al. **Mov Disord** 1996 Mar; 11(2):125–35
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons [see comments] Hantraye P, et al. **Nat Med** 1996 Sep;2(9):1017–21. Comment in: Nat Med 1996 Sep;2(9):965–6.
[Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model] Takeda M. **Hokkaido Igaku Zasshi** 1995 Nov;70(6):829–38 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. Herrero MT, et al. **Adv Neurol** 1996;69:209–16
Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Northoff G, et al. **Psychol Med** 1996 May;26(3):547–53

EPIDEMIOLOGY

A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian AM, et al. **J Clin Psychiatry** 1996 Jan;57(1):22–8
Prevalence of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. Louis ED, et al. **Mov Disord** 1996 Jan;11(1):63–9

ETIOLOGY

Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. Krauss JK, et al. **Acta Neurochir (Wien)** 1995;133(1–2):22–9
Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Kim JS, et al. **Mov Disord** 1995 Jul;10(4):510–2
Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)
[New forms of Parkinsonism in hospice care (see comments)] Baquero M, et al. **Rev Neurol** 1995 Sep–Oct;23(123):964–8 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**
[Drug-induced and masked drug parkinsonism (comment)] Giménez-Roldán S, et al. **Rev Neurol** 1996 May; 24(129):584–5. Comment on: Rev Neurol 1995 Sep–Oct;23(123):961–3. Comment on: Rev Neurol 1995 Sep–Oct;23(123):964–8. Comment on: Rev Neurol 1995 Sep–Oct;23(123):983–5. **(Spa)**
[Drug-induced extrapyramidal disorders (see comments)] Horga JF, et al. **Rev Neurol** 1995 Sep–Oct;23(123):961–3 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**
[Parkinson disease or drug-induced parkinsonism? (see comments)] Martí-Massó JF. **Rev Neurol** 1995 Sep–Oct; 23(123):983–5. Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

METABOLISM

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167–76 (52 ref.)
Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys. Parent A, et al. **Adv Neurol** 1996;69:73–7
The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. Pifl C, et al. **Adv Neurol** 1996;69:235–8 (9 ref.)
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats. Ueda H, et al. **Brain Res** 1995 Nov 6;698(1–2):213–6
Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. Jenkins BG, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):450–61
The effects of electroconvulsive shock on dopamine-1 and dopamine-2 receptor ligand binding activity in MPTP-treated mice. Sershen H, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):58–63
Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice. Kano T, et al. **Neuroreport** 1995 Nov 13;6(16):2197–200

MICROBIOLOGY

Parkinsonism in an HIV-infected patient with hypodense cerebral lesion. de la Fuente-Aguado J, et al. **Tuber Lung Dis** 1996 Apr;77(2):191–2

PATHOLOGY

Signal changes on MRI and increases in reactive microgliosis,

astrogliosis, and iron in the putamen of two patients with multiple system atrophy. Schwarz J, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):98–101

PHYSIOPATHOLOGY

HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height. Miklyaeva EI, et al. **Behav Neurosci** 1996 Feb;110(1):117–25

Functional implications of kappa opioid receptor–mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Maneuf YP, et al. **Brain Res** 1995 Jun 12;683(1):102–8

Aggravation of parkinsonian tremor by cisapride. Sempere AP, et al. **Clin Neuropharmacol** 1995 Feb;18(1):76–8

Esters of L-dopa: structure–hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism. Brunner–Guenat M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):861–9

Levodopa-induced convulsion: a case report. Nomoto M, et al. **Mov Disord** 1995 Nov;10(6):799

Simultaneous electromyography and manometry of the anal sphincters in parkinsonian patients: technical considerations [letter] Normand MM, et al. **Muscle Nerve** 1996 Jan; 19(1):110–1

Consequences of nigrostriatal denervation on the gamma–aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Vila M, et al. **Neurology** 1996 Mar;46(3):802–9

Effects of brain–derived neurotrophic factor on 1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine–induced parkinsonism in monkeys. Tsukahara T, et al. **Neurosurgery** 1995 Oct;37(4):733–9; discussion 739–41

PREVENTION & CONTROL

Riluzole prevents MPTP–induced parkinsonism in the rhesus monkey: a pilot study. Benazzouz A, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):299–307

Neuroprotective activity of alpha–dihydroergocryptine in animal models. Coppi G. **J Neural Transm Suppl** 1995; 45:307–18

[Effect of basic fibroblast growth factor on development of Parkinson syndrome in mice] Kryzhanovskiĭ GN, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):260–2 **(Rus)**

[Effect of active immunization with a serotonin–protein conjugate on development of experimental Parkinson's syndrome] Kryzhanovskiĭ GN, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):392–5 **(Rus)**

PSYCHOLOGY

Differential effects of three dopamine receptor agonists in MPTP–treated monkeys. Arai N, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):55–62

Centrally–administered AMPA antagonists increase locomotion in parkinsonian rats. Stauch Slusher B, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):145–9

Vacuous jaw movements induced by acute reserpine and low–dose apomorphine: possible model of parkinsonian tremor. Salamone J, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):179–83

RADIONUCLIDE IMAGING

Positron emission tomography with 4–[18F]fluoro–L–m–tyrosine in MPTP–induced hemiparkinsonian monkeys. Hayase N, et al. **Ann Nucl Med** 1995 Aug;9(3):119–23

Hemiatrophy, juvenile–onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult–onset hemiparkinsonism: the spectrum of hemiparkinsonism–hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)

SURGERY

Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: survival and function of graft. Nakao N, et al. **Acta Neurochir (Wien)** 1995;133(1–2):61–7

The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Haque NS, et al. **Brain Res** 1996 Mar 11;712(1):45–52

Juvenile parkinsonism treated with bilateral pallidotomies—case report. Anno Y, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):680–2

In vivo effects of kFGF on embryonic nigral grafts in a rat model of Parkinson's disease. Haque NS, et al. **Neuroreport** 1995 Nov 13;6(16):2177–81

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Maintenance ECT for treatment of therapy–resistant paranoid schizophrenia and Parkinson's disease. Höflich G, et al. **Biol Psychiatry** 1995 Jun 15;37(12):892–4

Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Yoshimoto Y, et al. **Brain Res** 1995 Sep 11; 691(1–2):25–36

Transplantation of human fetal tissue from spontaneous abortions to a rodent model of Parkinson's disease. Kondoh T, et al. **Cell Transplant** 1996 Jan–Feb;5(1):69–75

Genetically modified PC12 brain grafts: survivability and inducible nerve growth factor expression. Rohrer DC, et al. **Cell Transplant** 1996 Jan–Feb;5(1):57–68

PARKINSONIAN SYNDROME see **PARKINSON DISEASE, SYMPTOMATIC**

PAROMOMYCIN

PHARMACOLOGY

The sensitivity of Leishmania species to aminosidine. Neal RA, et al. **J Antimicrob Chemother** 1995 May;35(5):577–84

Differential antibiotic sensitivity determined by the large ribosomal subunit in thermophilic archaea. Ruggero D, et al. **J Bacteriol** 1996 Jun;178(11):3396–8

Anticryptosporidial activity of paromomycin [letter; comment] Cirioni O, et al. **J Infect Dis** 1995 Oct; 172(4):1169–70. Comment on: J Infect Dis 1994 Aug;170(2):419–24.

Ribosomes of Leishmania are a target for the aminoglycosides. Maarouf M, et al. **Parasitol Res** 1995; 81(5):421–5

[Effect of various pyrimidine derivatives on the effectiveness of levomycetin treatment of experimental infections in animals] Ismagilova AF, et al. **Antibiot Khimioter** 1995 Mar; 40(3):43–6 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Prospective trial of paromomycin for cryptosporidiosis in AIDS. Flanigan TP, et al. **Am J Med** 1996 Mar; 100(3):370–2

A randomized, placebo–controlled trial of a two–week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Asilian A, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):648–51

Evaluation of high–dose regimen of paromomycin against cryptosporidiosis in the dexamethasone–treated rat model. Verdon R, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2155–7

Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum–immunoglobulin. Tzipori S, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):450–63

A new breakthrough in treatment of visceral leishmaniasis in children. Hassan M, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):155–7

Paromomycin for nitroimidazole–resistant trichomonosis [letter] Nyirjesy P, et al. **Lancet** 1995 Oct 21;346(8982):1110

[Intestinal cryptosporidiosis in HIV infection: clinical features, course and therapy] Günthard M, et al. **Dtsch Med Wochenschr** 1996 May 24;121(21):686–92 (Eng. Abstr.) **(Ger)**

[Effectiveness of aminosidine sulphate in severe visceral leishmaniasis, resistant to the treatment with pentavalent antimony] Castro C, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):273–7 (Eng. Abstr.) **(Por)**

[Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis] Romero GA, et al. **Rev Soc Bras Med Trop** 1996 Mar–Apr; 29(2):215–6 **(Por)**

[The treatment of cryptosporidiosis in AIDS patients using paromomycin] Stefani HN, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):355–7 (Eng. Abstr.) **(Por)**

PARONYCHIA

DIAGNOSIS

Right middle finger pain. Holt SE. **Acad Emerg Med** 1995 Nov;2(11):988–9, 1010–2

ETIOLOGY

Red fingers syndrome in HIV patients [letter] Battegay M, et al. **Lancet** 1996 Sep 14;348(9029):763

SURGERY

An acute Nocardia brasiliensis infection of the hand: a case report. Shifren JD, et al. **J Hand Surg [Am]** 1996 Mar; 21(2):309–10

VIROLOGY

[Herpes simplex virus infection of the hand] Rieger H, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1090–2 (Eng. Abstr.) **(Ger)**

PAROTID DISEASES

CHEMICALLY INDUCED

Treatment of clozapine–induced parotid gland swelling [letter] Brodkin ES, et al. **Am J Psychiatry** 1996 Mar; 153(3):445

DIAGNOSIS

A comparison of MR sequences for lesions of the parotid gland. Sharafuddin MJ, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1895–902

Atypical mycobacterial adenitis presenting as a parotid abscess. Tunkel DE. **Am J Otolaryngol** 1995 Nov–Dec; 16(6):428–32

Sialadenosis of the salivary glands. Pape SA, et al. **Br J Plast Surg** 1995 Sep;48(6):419–22 (33 ref.)

Tuberculosis of the parotid gland [letter] Sharma K, et al. **Can J Surg** 1996 Jun;39(3):253

A puzzling paediatric parotid haematoma. de Carpentier JP, et al. **J Laryngol Otol** 1996 Jun;110(6):590–3

Diagnosis and treatment of lipiodol–induced foreign body reaction in the parotid gland [letter] Baurmash H. **J Oral Maxillofac Surg** 1996 Aug;54(8):1041

Nodal inclusion cysts of the parotid gland and parapharyngeal space: a discussion of lymphoepithelial, AIDS–related parotid, and branchial cysts, cystic Warthin's tumors, and cysts in Sjögren's syndrome. Som PM, et al. **Laryngoscope** 1995 Oct;105(10):1122–8

Tuberculosis: an unusual cause of dysphagia. Thomas MD, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):644–50

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti–Schefer S, et al. **Radiologe** 1995 Nov;35(11):848–65 (70 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of somatostatin analog in the management of traumatic parotid fistula [letter] Lam CM, et al. **Surgery** 1996 Apr; 119(4):481–2

ETIOLOGY

Parotid salivary fistula following rhytidectomy. Wolf K, et al. **Plast Reconstr Surg** 1996 Mar;97(3):641–2 (7 ref.)

[MRI and CT of parotid diseases in HIV–positive patients] Bindou M, et al. **J Radiol** 1996 Jul;77(7):483–7 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Sclerosing polycystic adenosis of major salivary glands. A clinicopathologic analysis of nine cases. Smith BC, et al. **Am J Surg Pathol** 1996 Feb;20(2):161–70

Unicentric angiofollicular hyperplasia (Castleman's disease) of the parotid: a case report. Leocata P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):328–32

Unilateral polycystic (dysgenetic) disease of the parotid gland. Ortiz–Hidalgo C, et al. **South Med J** 1995 Nov; 88(11):1173–5 (9 ref.)

Cell deletion by apoptosis during regression of rat parotid sialadenosis. Chisholm DM, et al. **Virchows Arch** 1995; 427(2):181–6

[Our experience with parotid cysts] Assimakopoulos D, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):313–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[A cystic lymphoepithelial lesion of the parotid in HIV–1–infected patients] Calderón–Osuna E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):461–3 (10 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Three–dimensional processing of ultrafast CT sialography for parotid masses. Szolar DH, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1889–93

Human immunodeficiency virus infection presenting with lymphoepithelial cysts in a six–year–old child. Mayer M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):242–4

RADIONUCLIDE IMAGING

Tl–201 SPECT in Kimura's disease involving the parotid glands and cervical nodes. Nagamachi S, et al. **Clin Nucl Med** 1996 Feb;21(2):125–8

SURGERY

Tympanic neurectomy in the management of parotid sialectasis. Daud AS, et al. **J Laryngol Otol** 1995 Dec; 109(12):1155–8 (12 ref.)

Use of fibrin glue in parotidectomy closure. Depondt J, et al. **Laryngoscope** 1996 Jun;106(6):784–7

THERAPY

Parotid duct stenosis: interventional radiology to the rescue [letter; comment] Langdon JD. **Ann R Coll Surg Engl** 1996 Mar;78(2):156. Comment on: Ann R Coll Surg Engl 1995 Nov;77(6):444–6.

Parotid duct stenosis: interventional radiology to the rescue [see comments] Roberts DN, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):444–6. Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):156.

Parotid duct stenosis: interventional radiology to the rescue [letter] Seward GR. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):232–3

PAROTID GLAND

Lymphoepithelial cyst of the parotid gland. Piattelli A, et al. **Acta Stomatol Belg** 1995 Sep;92(3):137–8

Obstructive sialadenitis [letter] Fordyce AM, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):131–2

Treatment planning for parotid sparing in the patient requiring bilateral neck irradiation. Marsh L, et al. **Med Dosim** 1996 Spring;21(1):7–13

ANATOMY & HISTOLOGY

The relationship of the buccal branch of the facial nerve to the parotid duct. Pogrel MA, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):71–3

CHEMISTRY

Amino acid sequence and the cellular location of the Na(+)-dependent D-glucose symporters (SGLT1) in the ovine enterocyte and the parotid acinar cell. Tarpey PS, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):293–300

Parathyroid hormone-related peptide: immunolocalisation in normal salivary glands and in pleomorphic adenomas. Sunardhi-Widyaputra S, et al. **Pathol Res Pract** 1996 Jan; 192(1):15–9

Purification and characterization of rat parotid glycosylated, basic and acidic proline-rich proteins. Bedi GS, et al. **Prep Biochem** 1995 Aug;25(3):119–32

[Effect of adrenergic beta-agonist on intracellular free calcium concentration in isolated acini of the parotid gland in rats] Sezan A, et al. **C R Seances Soc Biol Fil** 1995; 189(2):281–8 (Eng. Abstr.) **(Fre)**

CYTOLOGY

Thomsen-Friedenreich (T) antigen as marker of myoepithelial and basal cells in the parotid gland, pleomorphic adenomas and adenoid cystic carcinomas. An immunohistological comparison between T and sialosyl-T antigens, alpha-smooth muscle actin and cytokeratin 14. Therkildsen MH, et al. **APMIS** 1995 Jul-Aug; 103(7–8):558–67

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119–31 (113 ref.)

Characterization of human and rat immortalized clones parotid acinar cells with respect to specific proteins and their mRNAs, and receptor-linked adenylate cyclase. Prasad KN, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):767–72

Transplantation of immortalized, nontumorigenic parotid acinar cells into the allogeneic rat parotid gland and oral submucosa. Krause GE, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):160–4

DRUG EFFECTS

The influence of encortone on changes of some parameters of parotid serous cells of female white rats of Wistar breed. Zarębska A. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:51–6

The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Hunter KD, et al. **Arch Oral Biol** 1995 Nov; 40(11):983–9

Differential modulation of protein kinase C isozymes in rat parotid acinar cells. Relation to amylase secretion. Terzian AR, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):569–77

Staurosporine enhances Ca2+ entry induced by depletion of intracellular Ca2+ stores in rat parotid acinar cells. Tojyo Y, et al. **Cell Calcium** 1995 Jan;17(1):32–40

Short-term effects of secretagogues on the mouse parotid and sublingual gland tissular water. Materazzi S, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar;42(2):179–88

Degranulation of rat salivary glands following treatment with receptor-selective agonists. Peter B, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):330–6

Effects of vinca alkaloids on rat parotid and submandibular glands function in vivo. Dehpour AR, et al. **Gen Pharmacol** 1995 Mar;26(2):321–5

Recepto-secretory mechanism in histamine-stimulated amylase release from rat parotid gland. Hashioka T. **Inflamm Res** 1995 Jun;44(6):245–7

Vesicle-associated membrane protein 2 is essential for cAMP-regulated exocytosis in rat parotid acinar cells. The inhibition of cAMP-dependent amylase release by botulinum neurotoxin B. Fujita-Yoshigaki J, et al. **J Biol Chem** 1996 May 31;271(22):13130–4

Suppression of capacitative Ca2+ entry by serine/threonine phosphatase inhibitors in rat parotid acinar cells. Tojyo Y, et al. **Jpn J Pharmacol** 1995 Dec;69(4):381–9

Partial restoration of impaired alpha 1-adrenergic responsiveness in parotid cells of aged rats by S-adenosylmethionine treatment. Kowatch MA, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):73–7

ENZYMOLOGY

Purification and characterization of protein phosphatase 2C in rat parotid acinar cells: two forms of Mg(2+)-activated histone phosphatase and phosphorylation by cAMP-dependent protein kinase. Yokoyama N, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):1–8

The dephosphorylation of 22-kDa phosphoprotein by type 2B protein phosphatase in rat parotid acinar cells. Sugiya H, et al. **Arch Oral Biol** 1995 Aug;40(8):713–6

Protein tyrosine kinase inhibitors promote amylase secretion and inhibit ornithine decarboxylase induction in sialagogue-stimulated rat parotid explants. Kinoshita F, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):170–4

Regulation of cAMP phosphodiesterases by cyclic nucleotides in rat parotid gland. Imai A, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1029–36

Effect of genistein on amylase release and protein tyrosine phosphorylation in parotid acinar cells. Takuma T, et al. **FEBS Lett** 1996 Feb 12;380(1–2):83–6

Effect of vanadate on amylase secretion and protein tyrosine phosphatase activity in the rat parotid gland. Purushotham KR, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):87–94

Purification and characterization of multiple S6 phosphatases from the rat parotid gland. Yokoyama N. **Mol Cell Biochem** 1995 Jul 19;148(2):123–32

GROWTH & DEVELOPMENT

Effects of protein deficiency and diet consistency on the parotid gland and parotid saliva of rats. Johnson DA, et al. **J Dent Res** 1995 Aug;74(8):1444–52

METABOLISM

Decreased m3-muscarinic and alpha 1-adrenergic receptor stimulation of PIP2 hydrolysis in parotid gland membranes from aged rats: defect in activation of G alpha q/11. Sawaki K, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):319–26

Rate of oxygen consumption by parotid atrophic acinar cells from rats fed liquid diet. Scott J, et al. **Arch Oral Biol** 1995 Aug;40(8):691–4

Activation of P2z purinoceptors diminishes the muscarinic cholinergic-induced release of inositol 1,4,5-trisphosphate and stored calcium in rat parotid acini. ATP as a co-transmitter in the stimulus-secretion coupling. Jørgensen TD, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):457–64

PP2C phosphatase activity is coupled to cAMP-mediated pathway in rat parotid acinar cells. Yokoyama N, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):845–53

Anion permeability of the basolateral membrane from the ovine parotid acinar cells. Nguyen HV, et al. **Biochem Soc Trans** 1995 Aug;23(3):410S

Staurosporine enhances Ca2+ entry induced by depletion of intracellular Ca2+ stores in rat parotid acinar cells. Tojyo Y, et al. **Cell Calcium** 1995 Jan;17(1):32–40

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of human parotid salivary proteins: comparison of dansylation, coomassie blue R-250 and silver detection methods. Beeley JA, et al. **Electrophoresis** 1996 Mar; 17(3):505–6

Effect of microtubule network disturbance by nocodazole and docetaxel (Taxotere) on protein secretion in rat extraorbital lacrimal and parotid glands. Robin P, et al. **Eur J Cell Biol** 1995 Jul;67(3):227–37

Depletion of vasoactive intestinal peptide and substance P in parotid glands of atropinized rats during reflex secretion. Asztély A, et al. **Exp Physiol** 1996 Mar;81(2):297–303

Involvement of direct phosphorylation in the regulation of the rat parotid Na(+)-K(+)-2Cl- cotransporter. Tanimura A, et al. **J Biol Chem** 1995 Oct 20;270(42):25252–8

Inhibition of muscarinic stimulated phosphoinositide hydrolysis in the rat parotid gland by cAMP. Gerstin EH Jr, et al. **Life Sci** 1996;58(2):145–53

PATHOLOGY

Three cases of eosinophilic lymphfolliculoid granuloma of the soft tissue originating from the parotid gland. Mitsui M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:130–2

A comparison of MR sequences for lesions of the parotid gland. Sharafuddin MJ, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1895–902

MR imaging of the parotid gland in Sjögren's syndrome: a proposal for new diagnostic criteria. Izumi M, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1483–7

Sclerosing polycystic adenosis of major salivary glands. A clinicopathologic analysis of nine cases. Smith BC, et al. **Am J Surg Pathol** 1996 Feb;20(2):161–70

Sjoegren's syndrome: MR imaging of the parotid gland. Vogl TJ, et al. **Eur Radiol** 1996;6(1):46–51

The deep parotid lymph nodes: an anatomical and oncological study. Pisani P, et al. **J Laryngol Otol** 1996 Feb;110(2):148–50

Intraparotid facial nerve schwannoma. Elahi MM, et al. **J Otolaryngol** 1995 Dec;24(6):364–7

[Lymphoepithelial hyperplasia of the parotid gland and HIV infection] Barry B, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):387–92 (28 ref.) (Eng. Abstr.) **(Fre)**

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848–65 (70 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159–62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

[A male case of primary Sjögren's syndrome with interstitial pneumonitis and interstitial tubulo-nephritis in the absence of dry eye and dry mouth: parotid gland MRI is a useful diagnostic method for Sjögren's syndrome] Takamura N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):123–32 (Eng. Abstr.) **(Jpn)**

[Metastasis of breast carcinoma in parotid. A case report and review of the literature] Calvo Boizas E, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):391–3 (Eng. Abstr.) **(Spa)**

[Immunohistochemistry: another criterion for typing oncocytomas of the salivary gland. A case report] Gálvez J, et al. **Acta Otorrinolaringol Esp** 1995 Nov-Dec; 46(6):462–4 (Eng. Abstr.) **(Spa)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157–9 (21 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The effects of unilateral and bilateral chewing, empty clenching and simulated bruxism, on the masticatory-parotid salivary reflex in man. Anderson DJ, et al. **Exp Physiol** 1996 Mar;81(2):305–12

Effects of vinca alkaloids on rat parotid and submandibular glands function in vivo. Dehpour AR, et al. **Gen Pharmacol** 1995 Mar;26(2):321–5

The significance of membrane lipids in exocytosis: control of liposome-evoked amylase release from secretory granules isolated from the rat parotid gland. Mizuno-Kamiya M, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):693–9

Parasympathetic reflex salivary secretion in the cat parotid gland. Takahashi H, et al. **Jpn J Physiol** 1995;45(3):475–90

[The parotid gland is capable of assuming hypophyseal functions: 2] Tresguerres JA. **An R Acad Nac Med (Madr)** 1995;112(3):555–67; discussion 567–71 **(Spa)**

PHYSIOPATHOLOGY

US-guided drainage of deep neck space abscess. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:120–3

Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Nagler R, et al. **Bone Marrow Transplant** 1996 Feb;17(2):219–24

[Parotid tuberculosis] Comeche Cerverón C, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):387–90 (Eng. Abstr.) **(Spa)**

[Mucocele of the submaxillary salivary gland] Hellín Meseguer D, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):319–27 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Human immunodeficiency virus infection presenting with lymphoepithelial cysts in a six-year-old child. Mayer M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):242–4

RADIONUCLIDE IMAGING

In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. Breeman WA, et al. **J Nucl Med** 1996 Jan;37(1):108–17

Value of quantitative salivary gland scintigraphy in the early stage of Sjögren's syndrome. Bohuslavizki KH, et al. **Nucl Med Commun** 1995 Nov;16(11):917–22

Differential kinetics of parotid and submandibular gland function as demonstrated by scintigraphic means and its possible implications. Malpani BL, et al. **Nucl Med Commun** 1995 Aug;16(8):706–9

SECRETION

The role of protein kinase C in carbachol-induced and of cAMP-dependent protein kinase in isoproterenol-induced secretion in primary cultured guinea pig parotid acinar cells. Möller K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):181–7

Regulation of phosphorylation of Gi2 alpha protein controls the secretory response to isoproterenol in rat parotid tissues. Amano I, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):146–56

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119–31 (113 ref.)

Mechanisms of fluid and ion secretion by the parotid gland of the kangaroo, Macropus rufus, assessed by administration of transport-inhibiting drugs. Beal AM. **J Comp Physiol [B]** 1995;165(5):396–405

Differential kinetics of parotid and submandibular gland function as demonstrated by scintigraphic means and its possible implications. Malpani BL, et al. **Nucl Med Commun** 1995 Aug;16(8):706–9

SURGERY

Three cases of eosinophilic lymphfolliculoid granuloma of the soft tissue originating from the parotid gland. Mitsui M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:130–2

US-guided drainage of deep neck space abscess. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:120–3

Giant pleomorphic adenoma of the parotid. Lomeo PE. **Ear Nose Throat J** 1996 Jul;75(7):402

Use of fibrin glue in parotidectomy closure. Depondt J, et al. **Laryngoscope** 1996 Jun;106(6):784–7

[Pain and sensory impairment following parotidectomy. A descriptive study] Faber CE, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):270–3 (Eng. Abstr.) **(Dan)**

[Pain and sensation disorders after parotidectomy (letter)] Jensen TS, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1845–7 **(Dan)**

[Long-term results of total conservative parotidectomy for pleomorphic adenoma] Laccourreye O, et al.
Presse Med 1995 Nov 4;24(33):1563–5 (Eng. Abstr.) **(Fre)**

[The surgical treatment of chronic sialodochitis] Afanas'ev VV, et al. **Stomatologiia (Mosk)** 1995;74(5):44–6 (Eng. Abstr.) **(Rus)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al.
Acta Otorrinolaringol Esp 1996 Mar–Apr;47(2):157–9 (21 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

[The parotid gland is capable of assuming hypophyseal functions: 2] Tresguerres JA.
An R Acad Nac Med (Madr) 1995;112(3):555–67; discussion 567–71 **(Spa)**

ULTRASONOGRAPHY

Texture analysis of sonographic features of the parotid gland in Sjögren's syndrome. Ariji Y, et al.
AJR Am J Roentgenol 1996 Apr;166(4):935–41

ULTRASTRUCTURE

The main excretory duct (Stensen's) of the human parotid gland: a transmission and scanning electron microscope study. Testa-Riva F, et al. **Arch Histol Cytol** 1995 Oct; 58(4):435–48

Ca(++)-calmodulin-dependent phosphorylation and dephosphorylation of rat parotid secretion granules. Cooperstein SJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):75–81

Fine structure of the parotid gland in tree shrew (Tupaia glis). Suzuki S, et al. **Exp Anim** 1995 Oct;44(4):267–73

Fine structure of the acinar and duct cell components in the parotid and submandibular salivary glands of the rat: a TEM, SEM, and HRSEM study. Watanabe I, et al.
Histol Histopathol 1996 Jan;11(1):103–10

Ultrastructural evaluation of the rat parotid gland in the course of intoxication with lead acetate. Szynaka B, et al.
Rocz Akad Med Bialymst 1994;39:121–9

VIROLOGY

HCV RNA detection in parotid gland biopsy in a patient with chronic hepatitis C virus liver disease. Biasi D, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):465–9

PAROTID NEOPLASMS

Melanoma arising within the parotid salivary gland—a case report and review of management. Renaut AJ.
Eur J Surg Oncol 1996 Apr;22(2):201–2

[Metastasizing pleomorphic adenomas. Clinical and cytometric analysis] Junquera Gutiérrez LM, et al.
Rev Stomatol Chir Maxillofac 1996;97(1):26–31 (Eng. Abstr.) **(Fre)**

[Schwannoma of the parotid region. Apropos of a case report] Malpuech F, et al.
Rev Stomatol Chir Maxillofac 1996;97(1):22–5 (Eng. Abstr.) **(Fre)**

[Study of malignant lymphoma in the parotid gland region] Nagata M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun; 99(6):918–25 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Estrogen receptors in parotid tumors. Gaffney EV, et al.
Endocr Res 1995 Aug;21(3):635–43

Parathyroid hormone-related peptide: immunolocalisation in normal salivary glands and in pleomorphic adenomas. Sunardhi-Widyaputra S, et al. **Pathol Res Pract** 1996 Jan; 192(1):15–9

COMPLICATIONS

Diagnostic difficulties in etiology of the lesion of peripheral neuron of the facial nerve during the growth of sialoma. Kawiak W, et al.
Ann Univ Mariae Curie Sklodowska [Med] 1993;48:125–8

Intraductal papilloma as a cause of a parotid duct cyst. A case report. Alho OP, et al. **J Laryngol Otol** 1996 Mar; 110(3):277–8

Epithelial–myoepithelial carcinoma of the parotid gland. An unusual cause of ear canal stenosis. Lau DP, et al.
J Laryngol Otol 1996 May;110(5):493–5

Lipoma of the parotid gland presenting with facial palsy. Srinivasan V, et al. **J Laryngol Otol** 1996 Jan;110(1):93–5

[Facial nerve palsy as initial symptom of parotid gland cancer] Mäkitie A, et al. **Duodecim** 1994; 110(23–24):2227–30 **(Fin)**

DIAGNOSIS

Recurrent parotid adenocarcinoma occurring within the cerebellopontine angle. Stravropoulos SW, et al.
AJNR Am J Neuroradiol 1995 Aug;16(7):1529–31

Acinic cell carcinoma of the parotid in a child presenting as a pre-auricular cyst. Platt AJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):529–30

Spindle cell carcinoma of the parotid gland. Ishibashi T, et al. **J Laryngol Otol** 1995 Jul;109(7):683–6

Nodal inclusion cysts of the parotid gland and parapharyngeal space: a discussion of lymphoepithelial, AIDS-related parotid, and branchial cysts, cystic Warthin's tumors, and cysts in Sjögren's syndrome. Som PM, et al.
Laryngoscope 1995 Oct;105(10):1122–8

Acinic cell tumour of the maxillary sinus: an unusual case initially diagnosed as parotid cancer. Yoshihara T, et al.
Rhinology 1995 Sep;33(3):177–9

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848–65 (70 ref.) (Eng. Abstr.) **(Ger)**

[Fine needle aspiration in the cytologic diagnosis of swellings in the parotid and submandibular regions. Cytologic-histologic correlations in 49 cases] Bifaretti G, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):9–16 (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Comment on "Incidence of salivary gland tumors among atomic bomb survivors, 1950–1987. Evaluation of radiation-related risk" by Land et al. (Radiat. Res. 146, 28–36, 1996) [letter] Pogoda JM, et al. **Radiat Res** 1996 Sep;146(3):356

ETIOLOGY

A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Rodriguez-Cuevas S, et al.
Eur J Surg Oncol 1995 Dec;21(6):692

A case of mucoepidermoid carcinoma of the parotid gland developing in a child after the treatment of acute lymphoblastic leukemia [letter] Atahan IL, et al.
Pediatr Hematol Oncol 1995 Jul–Aug;12(4):403–5

Parotid carcinomas following the treatment of childhood acute lymphoblastic leukemia [editorial] Pratt CB.
Pediatr Hematol Oncol 1995 Sep–Oct;12(5):417–9

GENETICS

Genotypic characterization of a primary mucoepidermoid carcinoma of the parotid gland by cytogenetic, fluorescence in situ hybridization, and DNA ploidy analysis. el-Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):38–43

Cytogenetical observations in a canalicular adenoma of the minor salivary glands. Havel G, et al. **Hereditas** 1996; 124(1):105–6

METABOLISM

Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Bu R, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):257–64

PATHOLOGY

Aspiration cytodiagnosis of dermal analogue tumor, a rare subtype of salivary gland monomorphic adenoma: a case report. Gupta RK. **Acta Cytol** 1996 Mar–Apr;40(2):331–4

Fine needle aspiration of basal cell adenocarcinoma of the parotid gland. Report of a case with assessment of DNA ploidy in aspirates and tissue sections by image analysis. Moroz K, et al. **Acta Cytol** 1996 Jul–Aug;40(4):773–8

Cutaneous metastasis from a parotid adenocarcinoma. Report of a case with immunohistochemical findings and review of the literature. Tok J, et al. **Am J Dermatopathol** 1995 Jun;17(3):303–6 (9 ref.)

Fibrolipoma of the parotid in a child. Saitoh Y, et al.
Am J Otolaryngol 1995 Nov–Dec;16(6):433–5

Combined acinic cell mucoepidermoid carcinoma of the parotid gland. Report of a case with immunohistochemical study. Ballestin C, et al. **APMIS** 1996 Feb;104(2):99–102

Thomsen-Friedenreich (T) antigen as marker of myoepithelial and basal cells in the parotid gland, pleomorphic adenomas and adenoid cystic carcinomas. An immunohistological comparison between T and sialosyl-T antigens, alpha-smooth muscle actin and cytokeratin 14. Therkildsen MH, et al. **APMIS** 1995 Jul–Aug; 103(7–8):558–67

Malignant pleomorphic parotid adenoma with inflammatory cutaneous metastasis [letter] Soler E, et al.
Br J Dermatol 1996 Jan;134(1):190–2

Demonstration of monoclonal origin of human parotid gland pleomorphic adenoma. Noguchi S, et al. **Cancer** 1996 Feb 1;77(3):431–5

Tc-99m MDP detection of diffuse metastatic involvement of the liver by salivary gland mucoepidermoid carcinoma. Coates GG, et al. **Clin Nucl Med** 1995 Nov;20(11):1018–9

Clinico-pathological predictors of recurrence for acinic cell carcinoma. Timon CI, et al. **Clin Otolaryngol** 1995 Oct; 20(5):396–401

B-cell monoclonality in salivary lymphoepithelial lesions. Jordan RC, et al. **Eur J Cancer B Oral Oncol** 1996 Jan; 32B(1):38–44

Cell kinetics of pleomorphic adenomas of the parotid gland. Matturri L, et al. **Eur J Cancer B Oral Oncol** 1996 May; 32B(3):154–7

Histologic variant of the epithelial–myoepithelial carcinoma of the salivary gland: a case report. Cheung FM, et al. **Head Neck** 1995 Sep–Oct;17(5):437–44

Lymphoepithelial carcinoma of the parotid gland. Kountakis SE, et al. **Head Neck** 1995 Sep–Oct;17(5):445–50

Cytogenetical observations in a canalicular adenoma of the minor salivary glands. Havel G, et al. **Hereditas** 1996; 124(1):105–6

Pleomorphic adenoma of an unusual size in the deep lobe of the parotid gland. Uslu SS, et al.
Int J Pediatr Otorhinolaryngol 1995 Oct;33(2):163–9

Metastatic pleomorphic adenoma. Olsha O, et al.
Invasion Metastasis 1995;15(3–4):163–6

Lymphangioma of the parotid. Sen MK.
J Indian Med Assoc 1995 Aug;93(8):325

Seeding of a parotid pleomorphic adenoma. Commins DJ, et al. **J Laryngol Otol** 1995 Jul;109(7):671–3

Malignant myoepithelioma of the parotid gland: case report and review of the literature. Klumpp TR, et al.
J Laryngol Otol 1995 Oct;109(10):995–8 (27 ref.)

Leiomyosarcoma of the parotid gland. Oncel S, et al.
J Laryngol Otol 1996 Apr;110(4):401–3 (9 ref.)

Deep lobe parotid lipoma: a case report. Weiner GM, et al.
J Laryngol Otol 1995 Aug;109(8):772–3

Multiple brain metastases: a rare manifestation of adenoid cystic carcinoma of the parotid gland. Hammoud MA, et al. **J Neurooncol** 1996 Jan;27(1):61–4

Malignant peripheral nerve sheath tumor of the parotid gland: report of case. Punjabi AP, et al.
J Oral Maxillofac Surg 1996 Jun;54(6):765–9

Intraparotid facial nerve schwannoma. Elahi MM, et al.
J Otolaryngol 1995 Dec;24(6):364–7

Spindle cell malignant lymphoepithelial lesion of the parotid gland: clinical, light microscopic, ultrastructural, and in situ hybridization findings in one case. Christiansen MS, et al. **Mod Pathol** 1995 Sep;8(7):711–5

True malignant mixed tumor (carcinosarcoma) of the parotid gland. Report of a case with immunohistochemical study. Alvarez-Cañas C, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Apr;81(4):454–8

Giant cell carcinoma of the parotid gland. Hung RT, et al.
Otolaryngol Head Neck Surg 1996 Apr;114(4):657–60

Basal cell adenocarcinoma of the parotid gland. Kacker A, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):150–1

Synchronous parotid myoepithelioma and Warthin's tumor. Slavin JL, et al. **Pathology** 1995 Apr;27(2):199–200

Hyalinizing clear cell carcinoma of salivary gland. A case report. Okoń K, et al. **Pol J Pathol** 1996;47(1):33–6

[A combination chemotherapy with CDDP and 5-FU effective for pulmonary metastases in a case of parotid gland carcinoma] Furuse S, et al.
Gan To Kagaku Ryoho 1996 Jul;23(8):1059–62 (Eng. Abstr.) **(Jpn)**

[Malignant alterations in benign lymphoepithelial lesions] Mirković Z, et al. **Vojnosanit Pregl** 1994 Nov–Dec; 51(6):558–60 **(Ser)**

[Immunohistochemistry: another criterion for typing oncocytomas of the salivary gland. A case report] Gálvez J, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec; 46(6):462–4 (Eng. Abstr.) **(Spa)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al.
Acta Otorrinolaringol Esp 1996 Mar–Apr;47(2):157–9 (21 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Carcinosarcoma of the salivary gland on CT. Lai PH, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1733–5

[Hemangiopericytoma with parotid localization. Apropos of a case] Oujilal A, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(7):350–2 (17 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Imaging quiz case 1. Warthin's tumor (papillary cystadenoma lymphomatosum). Mra Z.
Arch Otolaryngol Head Neck Surg 1996 May;122(5):570, 572

RADIOTHERAPY

Setup deviations in wedged pair irradiation of parotid gland and tonsillar tumors, measured with an electronic portal imaging device. Bel A, et al. **Radiother Oncol** 1995 Nov; 37(2):153–9

SECONDARY

Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Khurana VG, et al.
Am J Surg 1995 Nov;170(5):446–50

Parotid metastasis from renal cell carcinoma. Sykes TC, et al. **Br J Urol** 1995 Sep;76(3):398–9

Metastatic carcinoma of the parotid gland resembling carcinoma of the breast [letter; comment] Pollock JL.
J Am Acad Dermatol 1996 Jun;34(6):1093. Comment on: J Am Acad Dermatol 1995 Aug;33(2 Pt 1):161–82; quiz 183–6.

Metastatic renal cell carcinoma presenting as a parotid tumor: a case report. Borghi L, et al. **Pathologica** 1995 Apr; 87(2):168–70

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159–62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

[Metastasis of breast carcinoma in parotid. A case report and review of the literature] Calvo Boizas E, et al.

Acta Otorrinolaringol Esp 1995 Sep-Oct;46(5):391-3 (Eng. Abstr.) **(Spa)**

SURGERY

An audit of surgery of the parotid gland [letter; comment] Baker NJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):396 . Comment on: Ann R Coll Surg Engl 1995 May;77(3):188-92.

Expanded polytef for reconstructing postparotidectomy defects and preventing Frey's syndrome. Shemen LJ. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1307-9

Giant pleomorphic adenoma of the parotid. Lomeo PE. **Ear Nose Throat J** 1996 Jul;75(7):402

Surgical management of lymphangiomas in adults. Curran AJ, et al. **J Laryngol Otol** 1996 Jun;110(6):586-9

Use of fibrin glue in parotidectomy closure. Depondt J, et al. **Laryngoscope** 1996 Jun;106(6):784-7

Primary small cell carcinoma of the parotid gland. Witt RL. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):826-9

[Pain and sensory impairment following parotidectomy. A descriptive study] Faber CE, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):270-3 (Eng. Abstr.) **(Dan)**

[Long-term results of total conservative parotidectomy for pleomorphic adenoma] Laccourreye O, et al. **Presse Med** 1995 Nov 4;24(33):1563-5 (Eng. Abstr.) **(Fre)**

[Lymphatic congestion of the conjunctiva after pre-auricular lymph node excision] Gugutschkova P, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):54-5 (Eng. Abstr.) **(Ger)**

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al. **Minerva Stomatol** 1995 Dec;44(12):591-6 (40 ref.) (Eng. Abstr.) **(Ita)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Malignant lympho-epithelial lesion of the salivary gland [letter] Borg M. **Australas Radiol** 1995 Nov;39(4):417

[Primary carcinoma of the parotid gland. A retrospective study of 31 cases] Coustal B, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):310-2 (Eng. Abstr.) **(Fre)**

[The interferon alfa-2a treatment of the severe form of the Kasabach-Merritt syndrome with neonatal onset] González de Dios J, et al. **An Esp Pediatr** 1996 Feb;44(2):179-83 (67 ref.) **(Spa)**

ULTRASTRUCTURE

Basal cell adenocarcinoma of the parotid gland: a case report with immunohistochemical, ultrastructural findings and review of the literature. Raslan WF, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1457-62 (15 ref.)

[True malignant mixed tumor of the parotid gland (carcinosarcoma)] Vajda K, et al. **Orv Hetil** 1995 Nov 12; 136(46):2511-4 (Eng. Abstr.) **(Hun)**

VETERINARY

Parotid salivary gland adenocarcinoma with bilateral ocular and osseous metastases in a dog. Habin DJ, et al. **J Small Anim Pract** 1995 Oct;36(10):445-9

VIROLOGY

Undifferentiated carcinoma of the parotid gland in a white patient: detection of Epstein-Barr virus by in situ hybridization. Kotsianti A, et al. **Hum Pathol** 1996 Jan; 27(1):87-90

PAROTITIS

BLOOD

[The activity of the glutathione antioxidative system in the blood of patients with acute nonepidemic parotitis] Dolgov SN, et al. **Stomatologiia (Mosk)** 1995;74(3):38-40 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Adverse events associated with MMR vaccines in Japan. Kimura M, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):205-11

Clozapine-induced parotitis: an immunological cause? [letter; comment] Hinze-Selch D, et al. **Am J Psychiatry** 1996 Jun; 153(6):840. Comment on: Am J Psychiatry 1995 Feb;152(2):297-8.

Parotid and pterygomaxillary lipogranuloma caused by oil-based contrast medium used for sialography: report of a case. Shigetaka Y, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):350-3

CLASSIFICATION

[Chronic suppurative parotitis: proposed classification] Wang S, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):158-60 **(Chi)**

COMPLICATIONS

Acute suppurative parotitis and facial paralysis. Pang YT, et al. **J Laryngol Otol** 1996 Jan;110(1):91-2

DIAGNOSIS

[Suppurative parotitis as a sequela of infection with Salmonella enteritidis] Moser G, et al. **Laryngorhinootologie** 1995 Sep;74(9):581-2 (Eng. Abstr.) **(Ger)**

[The lysosomal hydrolase activity in the blood of patients with inflammatory processes in the parotid gland with surgical pathology of the organs of the abdominal cavity] Dolgov SN, et al. **Stomatologiia (Mosk)** 1995;74(4):16-8 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Self-induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426-9 (28 ref.)

Parotitis due to Torulopsis glabrata. Pujol F, et al. **Clin Infect Dis** 1995 Nov;21(5):1342-3

Chronic recurrent parotitis complicated by salmonellosis in a renal transplant patient. John R, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S61-2

Wegener's granulomatosis presenting as major salivary gland enlargement. Ah-See KW, et al. **J Laryngol Otol** 1996 Jul; 110(7):691-3

[Acute bacterial parotitis caused by Serratia marcescens (letter)] Dominguez Herrera JM, et al. **Rev Clin Esp** 1996 Apr;196(4):271-2 **(Spa)**

HISTORY

[Tietze and cytomegalovirus infection of the salivary glands] Diosi P. **Gesnerus** 1996;53(1-2):87-99 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Clozapine-induced parotitis: an immunological cause? [letter; comment] Hinze-Selch D, et al. **Am J Psychiatry** 1996 Jun; 153(6):840. Comment on: Am J Psychiatry 1995 Feb;152(2):297-8.

Serum autoantibodies in recurrent parotitis in children. Babál P, et al. **Bratisl Lek Listy** 1995 Jul;96(7):384-8

MICROBIOLOGY

Atypical mycobacterial adenitis presenting as a parotid abscess. Tunkel DE. **Am J Otolaryngol** 1995 Nov-Dec; 16(6):428-32

Tuberculous parotitis: two cases in Libyan patients. Adalla SA, et al. **Br J Clin Pract** 1996 Jan-Feb;50(1):62-3

Chronic recurrent parotitis complicated by salmonellosis in a renal transplant patient. John R, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S61-2

Pneumococcal parotitis in a human immunodeficiency virus-infected child. Hanekom WA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1113-4

PATHOLOGY

Tuberculous parotitis: limiting the role of surgery. Weiner GM, et al. **J Laryngol Otol** 1996 Jan;110(1):96-7

SURGERY

[The surgical treatment of chronic sialodochitis] Afanas'ev VV, et al. **Stomatologiia (Mosk)** 1995;74(5):44-6 (Eng. Abstr.) **(Rus)**

THERAPY

Management of parotid swelling. Krause GE, et al. **Compr Ther** 1996 Apr;22(4):256-61 (17 ref.)

ULTRASONOGRAPHY

Ultrasonographic features of recurrent parotitis in childhood [letter; comment] Nolasco AM, et al. **Pediatr Radiol** 1995; 25(5):402. Comment on: Pediatr Radiol 1994;24(2):98-100.

VIROLOGY

Acute Sjögren-like syndrome as the first manifestation of a generalized CMV infection in a patient with AIDS. Van Vooren JP, et al. **J Laryngol Otol** 1995 Nov;109(11):1113-4

PAROVARIAN CYST

DIAGNOSIS

Parovarian borderline malignancy in pregnancy. Fine BA, et al. **Arch Gynecol Obstet** 1996;258(2):105-8

SURGERY

Treatment of nonendometriotic benign adnexal cysts: a randomized comparison of laparoscopy and laparotomy. Mais V, et al. **Obstet Gynecol** 1995 Nov;86(5):770-4

PAROXETINE

ADMINISTRATION & DOSAGE

Incentive bias? [letter; comment] Gammon GD. **J Clin Psychiatry** 1996 Jun;57(6):265; discussion 267-9. Comment on: J Clin Psychiatry 1994 Dec;55 Suppl:3-15; discussion 16-7.

ADVERSE EFFECTS

Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Devulder J, et al. **Acta Clin Belg** 1996;51(3):184-6

Recurrent hyponatremia associated with fluoxetine and paroxetine [letter] Flint AJ, et al. **Am J Psychiatry** 1996 Jan;153(1):134

Possible paroxetine-zolpidem interaction [letter] Katz SE. **Am J Psychiatry** 1995 Nov;152(11):1689

Exacerbation of extrapyramidal symptoms with paroxetine [letter] Arya DK, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):521-2

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195-7

Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):122-4 (40 ref.)

Withdrawal syndromes after paroxetine and sertraline discontinuation [letter] Fava GA, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):374-5

Paroxetine-induced SIADH [letter] Ayonrinde OT, et al. **Med J Aust** 1995 Oct 2;163(7):390

Adverse events after the abrupt discontinuation of paroxetine. Dominguez RA, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):778-80

Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Clayton AH, et al. **Psychopharmacol Bull** 1995;31(2):397-413

[Adverse effects: priapism caused by paroxetine] Bertholon F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):145-6; discussion 146-7 (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Synthesis and characterization of an aryl-azidoparoxetine. A novel photo-affinity probe for serotonin-transporter. Chudzik J, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1211-5

ANALYSIS

Paroxetine level in breast milk [letter] Spigset O, et al. **J Clin Psychiatry** 1996 Jan;57(1):39

DIAGNOSTIC USE

Serotonin indices and impulsivity in normal volunteers. Reist C, et al. **Psychiatry Res** 1996 Mar 29;60(2-3):177-84

ECONOMICS

Economics of treatment of depression [letter; comment] Owens DW. **Br J Psychiatry** 1995 Jul;167(1):112. Comment on: Br J Psychiatry 1994 May;164(5):665-73.

Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y, et al. **Can J Psychiatry** 1995 Sep;40(7):370-7

METABOLISM

Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Coccaro EF, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):531-6

Serotonin turnover rate, [3H]paroxetine binding sites, and 5-HT1A receptors in the hippocampus of rats subchronically treated with clonazepam. Lima L, et al. **Neuropharmacology** 1995 Oct;34(10):1327-33

Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Gurevich EV, et al. **Neuropsychopharmacology** 1996 May;14(5):309-23

PHARMACOKINETICS

Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder. Nelson EC, et al. **Psychiatry Res** 1995 Sep 29;58(2):117-25

PHARMACOLOGY

Acute subjective responses to paroxetine in normal volunteers. Brauer LH, et al. **Drug Alcohol Depend** 1995 Oct;39(3):223-30

Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Le Poul E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):141-8

THERAPEUTIC USE

Effect of paroxetine on seizure length during electroconvulsive therapy. Curran S. **Acta Psychiatr Scand** 1995 Sep;92(3):239-40

Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Moon CA, et al. **Br J Clin Pract** 1996 Jul-Aug;50(5):240-4

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Oehrberg S, et al. **Br J Psychiatry** 1995 Sep;167(3):374-9

Five group comparisons of treatments for anxiety disorders

PAROXETINE

[letter] Sharp DM, et al. **Br J Psychiatry** 1995 Dec; 167(6):820–1

Paroxetine in the treatment of premature ejaculation. Ludovico GM, et al. **Br J Urol** 1996 Jun;77(6):881–2

Paroxetine in the treatment of Chinese patients with depressive episode: a double–blind randomized comparison with imipramine. Chiu HJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):418–23

A multicenter double–blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate–to–severe depression. Baldwin DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:46–52

Paroxetine treatment of anger associated with depression. Albritton J, et al. **J Nerv Ment Dis** 1995 Oct;183(10):666–7

Paroxetine in the elderly: a comparative meta–analysis against standard antidepressant pharmacotherapy. Dunbar GC. **Pharmacology** 1995 Sep;51(3):137–44

Assessment of paroxetine–induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Clayton AH, et al. **Psychopharmacol Bull** 1995;31(2):397–413

Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double–blind randomized trial in major depression. Staner L, et al. **Sleep** 1995 Jul;18(6):470–7

[Paroxetine in the treatment of depressive disorders (pilot study)] Svestka J, et al. **Cesk Psychiatr** 1995 Jul; 91(3):135–42 (Eng. Abstr.) **(Cze)**

[Adverse effects: priapism caused by paroxetine] Bertholon F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):145–6; discussion 146–7 (Eng. Abstr.) **(Fre)**

PARROTS

Characterization of the avian polyomavirus–associated glomerulopathy of nestling parrots. Phalen DN, et al. **Avian Dis** 1996 Jan–Mar;40(1):140–9

A new breed of parasuicide patient. Doyle G. **BMJ** 1995 Dec 23–30;311(7021):1696

Ascites and hepatic cirrhosis in a cockatiel (Nymphicus hollandicus). Battison AL, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):237–42

Idiopathic moult in parrots [letter] Keymer IF. **Vet Rec** 1996 May 18;138(20):504

ABNORMALITIES

Idiopathic moult in the African grey parrot (Psittacus erithacus) in a tropical environment. Adene DF, et al. **Vet Rec** 1996 May 4;138(18):445–7

BLOOD

Plasma bile acid concentration in the cockatiel. Battison AL, et al. **Can Vet J** 1996 Apr;37(4):233–4

IMMUNOLOGY

Failure of maternally derived yolk IgG to reach detectable concentrations in the sera of nestling budgerigars (Melopsittacus undulatus). Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):700–8

PARASITOLOGY

[What is your diagnosis? An infection by Trichomonas sp. in a budgerigar] Hoop RK, et al. **Schweiz Arch Tierheilkd** 1995;137(8):389–90 **(Ger)**

PHYSIOLOGY

Egg production of cockatiels (Nymphicus hollandicus) is influenced by number of eggs in nest after incubation begins. Millam JR, et al. **Gen Comp Endocrinol** 1996 Feb; 101(2):205–10

Effects of mydriatic agents in cockatoos, African gray parrots, and Blue–fronted Amazon parrots. Ramer JC, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):227–30

VIROLOGY

Production of avian polyomavirus seronegative budgerigars (Melopsittacus undulatus) from seropositive adults. Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):897–9

PARS PLANITIS

BLOOD

Identification, quantitation, and purification of a 36 kDa circulating protein associated with active pars planitis. Bora NS, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1870–6

Molecular cloning, sequencing, and expression of the 36 kDa protein present in pars planitis. Sequence homology with yeast nucleopore complex protein. Bora NS, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1877–83

COMPLICATIONS

2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Park SE, et al. **Arch Ophthalmol** 1995 Oct;113(10):1277–80

DIAGNOSIS

Ocular Lyme borreliosis diagnosed by polymerase chain reaction on vitreous fluid [letter] Hilton E, et al. **Ann Intern Med** 1996 Sep 1;125(5):424–5

EPIDEMIOLOGY

Pars planitis: epidemiology and clinical outcome in a large community hospital in Mexico City. Ortega–Larrocea G, et al. **Int Ophthalmol** 1995;19(2):117–20

ETIOLOGY

Coats'–like response in a patient with pars planitis [letter] Chen PP, et al. **Br J Ophthalmol** 1996 Jul;80(7):675–6

THERAPY

Pars planitis: epidemiology and clinical outcome in a large community hospital in Mexico City. Ortega–Larrocea G, et al. **Int Ophthalmol** 1995;19(2):117–20

ULTRASONOGRAPHY

Ultrasound biomicroscopy in pars planitis. Garcia–Feijoo J, et al. **Am J Ophthalmol** 1996 Feb;121(2):214–5

PARSONAGE–TURNER SYNDROME see CERVICO–BRACHIAL NEURALGIA

PARTHENOGENESIS

Parthenogenesis–inducing microorganisms in Aphytis (Hymenoptera: Aphelinidae). Zchori–Fein E, et al. **Insect Mol Biol** 1995 Aug;4(3):173–8

ENDO A cytokeratin expression in the inner cell mass of parthenogenetic mouse embryos. Uranga JA, et al. **Int J Dev Biol** 1995 Aug;39(4):659–62

Analysis of the chromosome complement of frozen–thawed mouse oocytes after parthenogenetic activation. Bos–Mikich A, et al. **Mol Reprod Dev** 1995 Oct; 42(2):254–60

Parthenogenesis in man [news; comment] Surani MA. **Nat Genet** 1995 Oct;11(2):111–3. Comment on: Nat Genet 1995 Oct;11(2):164–9.

Distribution of parthenogenetic cells in the mouse brain and their influence on brain development and behavior. Allen ND, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10782–6

Development in vitro and in vivo of aggregated parthenogenetic bovine embryos. Boediono A, et al. **Reprod Fertil Dev** 1995;7(5):1073–9

DRUG EFFECTS

Making males from females: the effects of aromatase inhibitors on a parthenogenetic species of whiptail lizard. Wennstrom KL, et al. **Gen Comp Endocrinol** 1995 Sep; 99(3):316–22

Highly effective method of human oocyte activation. Levron J, et al. **Zygote** 1995 May;3(2):157–61

GENETICS

Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. Kaneko–Ishino T, et al. **Nat Genet** 1995 Sep;11(1):52–9

Epigenetic modifications during oocyte growth correlates with extended parthenogenetic development in the mouse. Kono T, et al. **Nat Genet** 1996 May;13(1):91–4

A human parthenogenetic chimaera [see comments] Strain L, et al. **Nat Genet** 1995 Oct;11(2):164–9. Comment in: Nat Genet 1995 Oct;11(2):111–3.

Molecular characterization of cyclic and obligate parthenogens in the aphid Rhopalosiphum padi (L.). Simon JC, et al. **Proc R Soc Lond B Biol Sci** 1996 Apr 22; 263(1369):481–6

PHYSIOLOGY

Parthenogenic activation of pig oocytes by protein kinase inhibition. Mayes MA, et al. **Biol Reprod** 1995 Aug; 53(2):270–5

Defective chorioallantoic fusion in mid–gestation lethality of parthenogenone<–>tetraploid chimeras. Spindle A, et al. **Dev Biol** 1996 Feb 1;173(2):447–58

A cell cycle–associated change in Ca2+ releasing activity leads to the generation of Ca2+ transients in mouse embryos during the first mitotic division. Kono T, et al. **J Cell Biol** 1996 Mar;132(5):915–23

Decrease of histone H1 kinase activity in relation to parthenogenetic activation of pig follicular oocytes matured and aged in vitro. Kikuchi K, et al. **J Reprod Fertil** 1995 Nov;105(2):325–30

Effects of cumulus cells and follicle–stimulating hormone during in vitro maturation on parthenogenetic activation of bovine oocytes. Chian RC, et al. **Mol Reprod Dev** 1995 Dec;42(4):425–31

PARTIAL MASTECTOMY see MASTECTOMY, SEGMENTAL

PARTIAL MONOSOMY see CHROMOSOME DELETION

PARTIAL THROMBOPLASTIN TIME

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in–hospital clinical events in unstable angina and non–Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)

Lack of in vitro interaction between heparin and nitroglycerin. Barnes AD, et al. **Am J Clin Pathol** 1996 Mar;105(3):298–300

Lupus anticoagulants: first French interlaboratory Etalonorme survey. Roussi J, et al. **Am J Clin Pathol** 1996 Jun;105(6):788–93

Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Zehnder JL, et al. **Am J Clin Pathol** 1996 Jul;106(1):107–11

Another perspective on monitoring anticoagulation therapy [editorial; comment] Burnakis TG. **Ann Pharmacother** 1995 Oct;29(10):1045–6. Comment on: Ann Pharmacother 1995 Oct;29(10):1015–21.

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015–21; quiz 1061 (36 ref.). Comment in: Ann Pharmacother 1995 Oct;29(10):1045–6.

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Anand S, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1677–81

Predictors of the effect of heparin during cardiac catheterization. Laslett L, et al. **Cardiology** 1995; 86(5):380–3

Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO–I trial. Granger CB, et al. **Circulation** 1996 Mar 1;93(5):870–8

Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Low CL, et al. **Clin Nephrol** 1996 Feb;45(2):120–4

Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor. Despotis GJ, et al. **Crit Care Med** 1995 Oct;23(10):1674–9

Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz–type protease inhibitor domain of the amyloid beta–protein precursor. Van Nostrand WE, et al. **J Biol Chem** 1995 Sep 29;270(39):22827–30

The effect of protein adsorption on the anticoagulant activity of surface immobilized heparin. van Delden CJ, et al. **J Biomater Sci Polym Ed** 1996;7(8):727–40

Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass [see comments] Nuttall GA, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):355–61. Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):353–4.

Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. Kitchen S, et al. **J Clin Pathol** 1996 Jan;49(1):10–4

Testing for Passovoy defect in children with prolonged activated partial thromboplastin time (APTT) [see comments] Hayani A, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):262–5. Comment in: J Pediatr Hematol Oncol 1996 Aug;18(3):247–8.

Evaluation of the minimally prolonged APTT: Passovoy factor or lupus anticoagulant? [editorial; comment] Triplett DA. **J Pediatr Hematol Oncol** 1996 Aug;18(3):247–8. Comment on: J Pediatr Hematol Oncol 1996 Aug;18(3):262–5.

The effect of simultaneous intravenous administration of nitroglycerin and heparin on partial thromboplastin time. Williams H, et al. **Mil Med** 1995 Sep;160(9):449–52

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.). Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

Acquired activated protein C–resistance in patients with lupus anticoagulants [letter] Ehrenforth S, et al. **Thromb Haemost** 1995 Aug;74(2):797–8

Diagnosis of APC resistance in patients on standard or low molecular weight heparin [letter] Gilmore G, et al. **Thromb Haemost** 1996 Feb;75(2):372–3

False positive activated protein C resistance test due to anti–phospholipid antibodies is corrected by platelet extract [letter; comment] Martorell JR, et al. **Thromb Haemost** 1995 Aug;74(2):796–7. Comment on: Thromb Haemost 1994 Oct;72(4):645–6.

Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers [letter] van den Besselaar AM, et al. **Thromb Haemost** 1995 Nov; 74(5):1383–4

A more discriminating test for APC resistance and a possible screening test to include protein C and protein S. Denson KW, et al. **Thromb Res** 1996 Jan 1;81(1):151–6

The detection of lupus anticoagulant using the kaolin clotting time test: a comparative study of the different forms of analysis. Forero Y, et al. **Thromb Res** 1995 Aug 1; 79(3):289–96

False–positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with

platelets [letter] Shizuka R, et al. **Thromb Res** 1995 Apr 15;78(2):189–90

[Thromboplastin time, INR reporting and recommendations for anticoagulant therapy (letter)] Syrjälä M. **Duodecim** 1994;110(2):171–2 **(Fin)**

[Variability of INR due to thromboplastin. Comparison of two recombinant thromboplastins and one rabbit thromboplastin] Renier JL, et al. **Ann Biol Clin (Paris)** 1995; 53(6):353–6 (Eng. Abstr.) **(Fre)**

[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308–12, 324 (49 ref.) **(Ger)**

–Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty– Kunert M, et al. **Z Kardiol** 1996 Feb;85(2):118–24 (Eng. Abstr.) **(Ger)**

[Activated partial thromboplastin time (APTT), partial thromboplastin time (PTT)] Fukutake K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:6–9 (3 ref.) **(Jpn)**

[Diagnostic value of soybean reagent for determination of activated partial thromboplastin time] Shanskaia AI, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):41–3 **(Rus)**

[Use of fractionated soy phospholipids in a test of activated partial thromboplastin time] Staritsyna NN, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):36–8 (Eng. Abstr.) **(Rus)**

VETERINARY

[Applicability of activated partial thromboplastin time (APTT) as a screening test of milk to medium deficiencies of coagulation factors in cats] Deniz A, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):206–8 (Eng. Abstr.) **(Ger)**

PARTICLE ACCELERATORS

see related
RADIOSURGERY

Dose rates and energy spectra in the maze of a linear accelerator treatment room. Morgan S, et al. **Br J Radiol** 1995 Nov;68(815):1237–41

Dose equivalent measurements at a 2.7 GeV proton accelerator and comparison with the Moyer model. Bourgois L, et al. **Health Phys** 1996 Jan;70(1):36–40

On residual dose rate within particle accelerator enclosures. Cossairt JD. **Health Phys** 1996 Sep;71(3):315–9

Harvesting backscatter electrons for radiation therapy. Das IJ, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15; 33(3):695–703

Head and neck radiotherapy without "hot spots"? Regarding Sohn et al. IJROBP 32:809–813; 1995 [letter; comment] Harari PM. **Int J Radiat Oncol Biol Phys** 1995 Nov 1; 33(4):971–2. Comment on: Int J Radiat Oncol Biol Phys 1995 Jun 15;32(3):809–13.

Collimator (head) scatter at extended distances in linear accelerator-generated photon beams. Khan FM, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):605–8

Clinical implementation of a commercial multileaf collimator: dosimetry, networking, simulation, and quality assurance. Klein EE, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1195–208

Treatment planning optimization for multiple arcs stereotactic radiosurgery using a linear accelerator. Lam CF, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15; 33(3):647–57

Use of a 1 mm collimator to test the accuracy of stereotactic radiotherapy. Tsai JS, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):579–86

A dual computed tomography linear accelerator unit for stereotactic radiation therapy: a new approach without cranially fixated stereotactic frames. Uematsu M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):587–92

Collimator-related radiation dose for different cobalt machines and linear accelerators. van der Giessen PH. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):399–405

Neutron generator at Hiroshima University for use in radiobiology study. Endo S, et al. **J Radiat Res (Tokyo)** 1995 Jun;36(2):91–102

A simple method of obtaining off-axis half-value layers for megavoltage photon beams. Barish RJ. **Med Phys** 1995 Sep; 22(9):1467–8

Measured electron energy and angular distributions from clinical accelerators. Deasy JO, et al. **Med Phys** 1996 May; 23(5):675–84

Evaluation of bremsstrahlung spectra generated by a 4–MeV linear accelerator. Krmar M, et al. **Med Phys** 1996 May; 23(5):651–4

Flattening-filter-based empirical methods to parametrize the head scatter factor. Lam KL, et al. **Med Phys** 1996 Mar; 23(3):343–52

Beam characteristics of a new generation 50 MeV racetrack microtron. Masterson ME, et al. **Med Phys** 1995 Jun; 22(6):781–92

A method for modifying a commercial extended travel range patient support assembly to achieve controlled rotation during arc therapy. Nelson SJ. **Med Phys** 1995 Feb; 22(2):239–40

Extrafocal radiation: a unified approach to the prediction of beam penumbra and output factors for megavoltage x-ray beams. Sharpe MB, et al. **Med Phys** 1995 Dec; 22(12):2065–74

Calculation of x-ray spectra for radiosurgical beams. Sixel KE, et al. **Med Phys** 1995 Oct;22(10):1657–61

X-ray source and the output factor. Zhu TC, et al. **Med Phys** 1995 Jun;22(6):793–8

A method for calculating the dose due to capture gamma rays in accelerator mazes. McGinley PH, et al. **Phys Med Biol** 1995 Sep;40(9):1467–73

Computer-aided design optimization with the use of a fast dose model for linear-accelerator-based stereotactic radiosurgery. Suh TS, et al. **Phys Med Biol** 1996 Apr; 41(4):675–96

[Applications of protons in the treatment of malignant tumors (letter)] Wolbers JG. **Ned Tijdschr Geneeskd** 1996 Feb 3; 140(5):276–7 **(Dut)**

[Prospects for the use in medicine of new detectors of ionizing radiation] Charpak G. **Bull Acad Natl Med** 1996 Jan;180(1):161–8; discussion 168–9 (Eng. Abstr.) **(Fre)**

[Radiosurgery by linear accelerators in the treatment of 84 arteriovenous malformations] Schlienger M, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:581s–585s (25 ref.) (Eng. Abstr.) **(Fre)**

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Technical note: thyratron performance––dependence on mounting in a medical linear accelerator. Balakrishnan IS, et al. **Br J Radiol** 1995 Nov;68(815):1242–3

Dosimetric evaluation of the conformation of the multileaf collimator to irregularly shaped fields. Frazier A, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1229–38

Effects of treatment setup variation on beam's eye view dosimetry for radiation therapy using the multileaf collimator vs. the cerrobend block. Frazier A, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1247–56

Wedge factor changes with depth and field size on a linear accelerator with a motorized wedge. Raffaele L, et al. **Radiol Med (Torino)** 1995 Sep;90(3):304–6

[Medical linear accelerators. The features of their use and technical characteristics] Gorlachev GE. **Vopr Onkol** 1995; 41(2):107–8 **(Rus)**

STANDARDS

Short communication: a system for remote monitoring of a hospital linear accelerator. Jennings CS. **Br J Radiol** 1996 May;69(821):469–71

A novel comprehensive quality control instrument for medical accelerators. Wielopolski L, et al. **Med Phys** 1995 Jun;22(6):799–801

Experimental determination of the beam quality dependence factors, kQ, for ionization chambers used in photon and electron dosimetry. Guerra AS, et al. **Phys Med Biol** 1995 Jul;40(7):1177–90

UTILIZATION

Workload and use factor of medical linear accelerators in radiotherapy. Kron T, et al. **Health Phys** 1995 Dec; 69(6):971–5

PARTICLE-INDUCED X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

PARTICLE SIZE

The evaluation of sizing accuracy of particle counters for parenteral drugs. Fujishita O, et al. **PDA J Pharm Sci Technol** 1995 Nov–Dec;49(6):267–71

PARTNER NOTIFICATION see **CONTACT TRACING**

PARTNERSHIP PRACTICE

Cultural partnerships. Texas physicians team up with colleagues from the former Soviet Union. Jones TL. **Tex Med** 1995 Nov;91(11):22–5

Getting organized. Pros and cons of business structures for medical practice. Stern MZ. **Tex Med** 1995 Sep;91(9):24–6

ORGANIZATION & ADMINISTRATION

Community partnership primary care: a new paradigm for primary care. Courtney R. **Public Health Nurs** 1995 Dec; 12(6):366–73

PARTURIENT PARESIS

BLOOD

Postparturient hypocalcemia of dairy cows: a model for the study of the interdependence of Ca, Pi, and Mg homeostasis. Riond JL, et al. **Bone** 1995 Oct;17(4 Suppl):429S–434S

DRUG THERAPY

Slow recovery from milk fever [letter] Stead MC. **Vet Rec** 1996 Feb 3;138(5):120

METABOLISM

Milk fever and dietary cation-anion balance effects on concentration of vitamin D receptor in tissue of periparturient dairy cows. Goff JP, et al. **J Dairy Sci** 1995 Nov;78(11):2388–94

Parathyroid hormone-related protein in the colostrum of paretic post parturient dairy cows. Riond JL, et al. **Vet Rec** 1996 Apr 6;138(14):333–4

PHYSIOPATHOLOGY

Studies on the pathogenesis of bovine ephemeral fever. IV: A comparison with the inflammatory events in milk fever of cattle. St. George TD, et al. **Vet Microbiol** 1995 Sep; 46(1–3):131–42

PREVENTION & CONTROL

Field trials of an oral calcium propionate paste as an aid to prevent milk fever in periparturient dairy cows. Goff JP, et al. **J Dairy Sci** 1996 Mar;79(3):378–83

PARTURITION see **LABOR**

PARVALBUMINS

ANALYSIS

Detection of a beta-parvalbumin isoform in the mammalian inner ear. Thalmann I, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):142–7

Localization of the Ca(2+)-binding alpha-parvalbumin and its mRNA in epiphyseal plate cartilage and bone of growing rats. Toury R, et al. **Bone** 1995 Aug;17(2):121–30

Distribution of parvalbumin in specific fibre types of chicken skeletal muscles. Nishida J, et al. **Br Poult Sci** 1995 Sep; 36(4):585–97

Beta-amyloid (1–42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Harkany T, et al. **Brain Res** 1995 Nov 6; 698(1–2):270–4

Allocation of perineuronal nets and parvalbumin-, calbindin-D28k- and glutamic acid decarboxylase-immunoreactivity in the amygdala of the rhesus monkey. Härtig W, et al. **Brain Res** 1995 Nov 6; 698(1–2):265–9

Coexistence of parvalbumin and GABA in nonpyramidal neurons of the rat entorhinal cortex. Miettinen M, et al. **Brain Res** 1996 Jan 8;706(1):113–22

Parvalbumin expression during developmental differentiation of the rat ovary. Pohl V, et al. **Differentiation** 1995 Nov; 59(4):235–42

Intrathymic distribution of the two avian thymic parvalbumins. Hapak RC, et al. **Exp Cell Res** 1996 Jan 10;222(1):234–45

Parvalbumin-immunoreactive neurons are not affected by trimethyltin-induced neurodegeneration in the rat hippocampus. Geloso MC, et al. **Exp Neurol** 1996 Jun; 139(2):269–77

Co-localization of somatostatin mRNA and parvalbumin in the dorsal rat hippocampus after cerebral ischemia. Bering R, et al. **Hippocampus** 1995;5(4):341–8

A light and electron microscopic study of NADPH-diaphorase-, calretinin- and parvalbumin-containing neurons in the rat nucleus accumbens. Hussain Z, et al. **J Chem Neuroanat** 1996 Feb; 10(1):19–39

Distribution of parvalbumin-containing interneurons in the hippocampus of the gerbil––a qualitative and quantitative statistical analysis. Nitsch C, et al. **J Chem Neuroanat** 1995 Aug;9(2):135–47

Complementary expression of parvalbumin and calbindin D-28k delineates subdivisions of the rabbit medial geniculate body. de Venecia RK, et al. **J Comp Neurol** 1995 Sep 4;359(4):595–612

Histological identification of premotor neurons for horizontal saccades in monkey and man by parvalbumin immunostaining. Horn AK, et al. **J Comp Neurol** 1995 Aug 21;359(2):350–63

Fate of GABAergic septohippocampal neurons after fimbria-fornix transection as revealed by in situ hybridization for glutamate decarboxylase mRNA and parvalbumin immunocytochemistry. Kermer P, et al. **J Comp Neurol** 1995 Nov 20;362(3):385–99

Pattern of selected calcium-binding proteins in the vestibular nuclear complex of two rodent species. Kevetter GA. **J Comp Neurol** 1996 Feb 19;365(4):575–84

Transient co-localization of calretinin, parvalbumin, and calbindin-D28K in developing visual cortex of monkey. Yan YH, et al. **J Neurocytol** 1995 Nov;24(11):825–37

Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease. Solodkin A, et al. **J Neurosci** 1996 May 15;16(10):3311–21

Substantia nigra pars reticulata neurons in Parkinson's disease. Hardman CD, et al. **Neurodegeneration** 1996 Mar; 5(1):49–55

Decreased parvalbumin immunoreactivity in surviving Purkinje cells of patients with spinocerebellar ataxia-1. Vig PJ, et al. **Neurology** 1996 Jul;47(1):249–53

Immunohistochemical investigations of parvalbumin localization in the skeletal muscle fibers of rats. Annoh H, et al. **Okajimas Folia Anat Jpn** 1995 Oct;72(4):221–6

BIOSYNTHESIS

Dynamics of parvalbumin expression in

PARVALBUMINS

low-frequency-stimulated fast-twitch rat muscle. Huber B, et al. **Eur J Biochem** 1996 Mar 15;236(3):814-9

CHEMISTRY

Assignment of 13C resonances and analysis of relaxation properties and internal dynamics of pike parvalbumin by 13C-NMR at natural abundance. Alattia T, et al. **Eur J Biochem** 1996 May 1;237(3):561-74

GENETICS

Developmental expression of parvalbumin mRNA in the cerebral cortex and hippocampus of the rat. de Lecea L, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):1-13

Developmental expression and functional characterization of the potassium-channel subunit Kv3.1b in parvalbumin-containing interneurons of the rat hippocampus. Du J, et al. **J Neurosci** 1996 Jan 15; 16(2):506-18

IMMUNOLOGY

Parvalbumin-immunoreactive proteins in the nervous system of planarians. Hutticher A, et al. **Cell Mol Neurobiol** 1995 Aug;15(4):401-10

Changes in open field behavior, spatial memory, and hippocampal parvalbumin immunoreactivity following enrichment in rats exposed to neonatal anoxia. Iuvone L, et al. **Exp Neurol** 1996 May;139(1):25-33

Development of parvalbumin immunoreactivity in the chick Edinger Westphal nucleus. Fujii JT, et al. **J Comp Neurol** 1995 Oct 2;360(4):612-20

Distribution of parvalbumin-immunoreactive cells and fibers in the human amygdaloid complex. Sorvari H, et al. **J Comp Neurol** 1995 Sep 18;360(2):185-212

METABOLISM

Survival of parvalbumin-immunoreactive neurons in the gerbil hippocampus following transient forebrain ischemia does not depend on HSP-70 protein induction. Ferrer I, et al. **Brain Res** 1995 Sep 18;692(1-2):41-6

Heterogeneous distribution of neurons containing calbindin D-28k and/or parvalbumin in the rat red nucleus. Hontanilla B, et al. **Brain Res** 1995 Oct 23;696(1-2):121-6

Parvalbumin-like immunoreactivity of layer V pyramidal cells in the motor and somatosensory cortex of adult primates. Preuss TM, et al. **Brain Res** 1996 Mar 18; 712(2):353-7

Molecular cloning and expression of alpha parvalbumin in the guinea pig cochlea. Soto-Prior A, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):337-42

Prenatal development of parvalbumin immunoreactivity in the human striate cortex. Cao QL, et al. **Cereb Cortex** 1996 Jul-Aug;6(4):620-30

Transfected parvalbumin alters calcium homeostasis in teratocarcinoma PCC7 cells. Müller BK, et al. **Eur J Cell Biol** 1996 Apr;69(4):360-7

Binding of acrylonitrile to parvalbumin. Lech JJ, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):260-6

Calcium-binding proteins in the spiral ganglion of the monkey, Callithrix jacchus. Spatz WB, et al. **Hear Res** 1995 Jun;86(1-2):89-99

Slowing of relaxation and [Ca2+]i during prolonged tetanic stimulation of single fibres from Xenopus skeletal muscle. Westerblad H, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):723-36

Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Anderson SA, et al. **Neuroscience** 1995 Jul;67(1):7-22

Differential distribution of calbindin-D28k and parvalbumin in somatic and visceral sensory neurons. Honda CN. **Neuroscience** 1995 Oct;68(3):883-92

Electron microscopic serial-sectioning/reconstruction study of parvalbumin-containing neurons in the external plexiform layer of the rat olfactory bulb. Toida K, et al. **Neuroscience** 1996 May;72(2):449-66

Immunohistochemical studies of GABA and parvalbumin in the developing human cerebellum. Yu MC, et al. **Neuroscience** 1996 Jan;70(1):267-76

PHYSIOLOGY

The Ca2+(-)binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Pauls TL, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):39-54 (168 ref.)

The surface evoked potential and parvalbumin-immunoreactivity in the somatosensory cortex of the developing rat. Seo-Hiraiwa ML, et al. **Dev Psychobiol** 1995 Sep;28(6):337-51

ULTRASTRUCTURE

Bulbar morphology and expression of bulbar dopamine and parvalbumin in experimentally-induced anosmic rats. Tsukatani T, et al. **Acta Otolaryngol (Stockh)** 1995 Jul; 115(4):539-42

PARVOVIRIDAE

GENETICS

Parvoviral vectors for the gene therapy of cancer. Shaughnessy E, et al. **Semin Oncol** 1996 Feb;23(1):159-71 (116 ref.)

IMMUNOLOGY

Financial evaluation of vaccination and testing alternatives for control of parvovirus-induced reproductive failure in swine. Gardner IA, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):863-9

ISOLATION & PURIFICATION

Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Zanella A, et al. **Transfusion** 1995 Sep;35(9):769-72

PARVOVIRIDAE INFECTIONS

COMPLICATIONS

Parvovirus B19 as a trigger for spontaneous bacterial peritonitis in a patient with cirrhotic ascites. Yamamoto T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1857-9

Insulin-dependent diabetes mellitus associated with parvovirus B19 infection [letter] Kasuga A, et al. **Ann Intern Med** 1996 Oct 15;125(8):700-1

Prevalence of human parvovirus B19 infection in children with Henoch-Schönlein purpura. Ferguson PJ, et al. **Arthritis Rheum** 1996 May;39(5):880-1

Engraftment failure associated with peripheral blood stem cell transplantation after B19 parvovirus infection [letter] Solano C, et al. **Blood** 1996 Aug 15;88(4):1515-7

Parvovirus B19 infection in Behçet's disease. Kiraz S, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):71-3

Sero-epidemiological analysis of the risk of virus infections for childhood leukaemia. Schlehofer B, et al. **Int J Cancer** 1996 Mar 1;65(5):584-90

DIAGNOSIS

Parvovirus infection mimicking a systematic onset of juvenile chronic arthritis (Still's disease) [letter] Rodrigo de Liria C, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):105-6

Cytodiagnosis of parvovirus B19 infection from ascites fluid of hydrops fetalis: report of a case. Iwa N, et al. **Diagn Cytopathol** 1995 Aug;13(2):139-41

Retrospective diagnosis of sickle cell-hemoglobin C disease and parvovirus infection by molecular DNA analysis of postmortem tissue. Goldstein LJ, et al. **Hum Pathol** 1995 Dec;26(12):1375-8

A simple and sensitive DNA hybridization assay used for the routine diagnosis of human parvovirus B19 infection. Hicks KE, et al. **J Clin Microbiol** 1995 Sep;33(9):2473-5

Fetal hydrops secondary to human parvovirus infection in early pregnancy. Petrikovsky BM, et al. **Prenat Diagn** 1996 Apr;16(4):342-4

Parvovirus B19 infection in patients with hemophilia. Ragni MV, et al. **Transfusion** 1996 Mar;36(3):238-41

[[Human parvovirus B19 and its clinical significance] Schwarz TF, et al. **Hautarzt** 1995 Dec;46(12):831-5 (44 ref.) (Eng. Abstr.) **(Ger)**

[Infection with parvovirus B19 in pregnant women] Oszukowski P, et al. **Ginekol Pol** 1996 Mar;67(3):114-6 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Prevalence of human parvovirus B19 infection in children with Henoch-Schönlein purpura. Ferguson PJ, et al. **Arthritis Rheum** 1996 May;39(5):880-1

A study by means of a new assay of the relationship between an outbreak of erythema infectiosum and non-immune hydrops fetalis caused by human parvovirus B19. Yaegashi N, et al. **J Infect** 1995 Nov;31(3):195-200

ETIOLOGY

Transient blood plasmacytosis in parvovirus B19 infection: a report of two cases. Koduri PR, et al. **Ann Hematol** 1996 Jan;72(1):49-51

Diverse hematologic effects of parvovirus B19 infection. Mustafa MM, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):809-21 (70 ref.)

GENETICS

Minute virus of mice (MVM) nucleic acid production in susceptible and resistant strains of mice and F1 hybrids. Kapil S. **Comp Immunol Microbiol Infect Dis** 1995 Sep; 18(4):245-52

Retrospective diagnosis of sickle cell-hemoglobin C disease and parvovirus infection by molecular DNA analysis of postmortem tissue. Goldstein LJ, et al. **Hum Pathol** 1995 Dec;26(12):1375-8

IMMUNOLOGY

A nonlethal rat parvovirus infection suppresses rat T lymphocyte effector functions. McKisic MD, et al. **J Immunol** 1995 Oct 15;155(8):3979-86

Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. McKisic MD, et al. **Transplantation** 1996 Jan 27;61(2):292-9

PREVENTION & CONTROL

Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Langeveld JP, et al. **Vaccine** 1995 Aug;13(11):1033-7

Raccoon poxvirus feline panleukopenia virus VP2 recombinant protects cats against FPV challenge. Hu L, et al. **Virology** 1996 Apr 1;218(1):248-52

THERAPY

Parvovirus associated fetal hydrops: reversal of pregnancy induced proteinuric hypertension by in utero fetal transfusion. Duthie SJ, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1011-3

TRANSMISSION

Parvovirus B19 and hemodialysis [letter] Guiserix J, et al. **Nephron** 1996;72(4):719

Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Zanella A, et al. **Transfusion** 1995 Sep;35(9):769-72

VETERINARY

Age-specific prevalence of porcine parvovirus antibody in feral pigs from a site in the Northern Territory. Caley P, et al. **Aust Vet J** 1995 Jan;72(1):36-7

Central nervous system rendez-vous--canine progressive posterior paresis. Little PB. **Can Vet J** 1996 Jan;37(1):55-6

Financial evaluation of vaccination and testing alternatives for control of parvovirus-induced reproductive failure in swine. Gardner IA, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):863-9

Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982-1991). Houston DM, et al. **J Am Vet Med Assoc** 1996 Feb 15;208(4):542-6

Detection of newly recognized rodent parvoviruses by PCR. Besselsen DG, et al. **J Clin Microbiol** 1995 Nov; 33(11):2859-63

An outbreak of goose parvovirus infection in Japan. Takehara K, et al. **J Vet Med Sci** 1995 Aug;57(4):777-9

Effectiveness of an inactivated goose parvovirus vaccine in Muscovy ducks. Takehara K, et al. **J Vet Med Sci** 1995 Dec;57(6):1093-5

Experimental infection of pigs with a parvovirus isolated from the diarrheic feces of a pig. Yasuhara H, et al. **J Vet Med Sci** 1995 Aug;57(4):629-34

Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Langeveld JP, et al. **Vaccine** 1995 Aug;13(11):1033-7

Diagnosis of fetal infection with porcine parvovirus by in situ hybridization. Waldvogel AS, et al. **Vet Microbiol** 1995 Dec;47(3-4):377-85

Coinfection of a bearded dragon, Pogona vitticeps, with adenovirus- and dependovirus-like viruses. Jacobson ER, et al. **Vet Pathol** 1996 May;33(3):343-6

Feline parvovirus in pedigree kittens [letter] Addie DD, et al. **Vet Rec** 1996 Feb 3;138(5):119

Antigenic types of canine parvoviruses prevailing in Taiwan. Chang WL, et al. **Vet Rec** 1996 May 4;138(18):447

Comparison of isolates of canine parvovirus by monoclonal antibody and restriction enzyme analysis. Greenwood NM, et al. **Vet Rec** 1996 May 18;138(20):495-6

Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Truyen U, et al. **Vet Rec** 1996 Apr 13;138(15):365-6

[Diagnosis of bovine parvoviruses in feces of calves] Elschner M. **Berl Munch Tierarztl Wochenschr** 1995 Jul; 108(7):256-60 (Eng. Abstr.) **(Ger)**

[Rapid enzymatic test for diagnosis of parvovirus infections in dogs] Kuffer M, et al. **Tierarztl Prax** 1995 Aug; 23(4):415-7 (Eng. Abstr.) **(Ger)**

[Evolution of canine parvovirus: loss and gain of the feline host] Truyen U. **Tierarztl Prax** 1996 Jun;24(3):316-8 (Eng. Abstr.) **(Ger)**

VIROLOGY

A prospective study of antibodies against parvovirus B19 in pregnancy. Skjöldebrand-Sparre L, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):336-9

Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Lowenthal EA, et al. **Am J Hematol** 1996 Mar;51(3):207-13

Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Jordan JA. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):37-42

Viral arthritis including HIV. Naides SJ. **Curr Opin Rheumatol** 1995 Jul;7(4):337-42 (36 ref.)

[Parvovirus B19--a ubiquitous, little know virus. From erythema infectiosum and arthropathy to chronic anemia] Frickhofen N. **Fortschr Med** 1995 Sep 10;113(25):351-3 **(Ger)**

PARVOVIRUS

Prevalence of human parvovirus B19 infection in children with Henoch-Schönlein purpura. Ferguson PJ, et al. **Arthritis Rheum** 1996 May;39(5):880-1

An outbreak of goose parvovirus infection in Japan. Takehara K, et al. **J Vet Med Sci** 1995 Aug;57(4):777-9

Diagnosis of fetal infection with porcine parvovirus by in situ hybridization. Waldvogel AS, et al. **Vet Microbiol** 1995

Dec;47(3–4):377–35
[Diagnosis of bovine parvoviruses in feces of calves] Elschner M. **Berl Munch Tierarztl Wochenschr** 1995 Jul; 108(7):256–60 (Eng. Abstr.) **(Ger)**

GENETICS

Detection of newly recognized rodent parvoviruses by PCR. Besselsen DG, et al. **J Clin Microbiol** 1995 Nov; 33(11):2859–63
Expression of recombinant parvovirus NS1 protein by a baculovirus and application to serologic testing of rodents. Riley LK, et al. **J Clin Microbiol** 1996 Feb;34(2):440–4
Molecular characterization of newly recognized rodent parvoviruses. Besselsen DG, et al. **J Gen Virol** 1996 May; 77 (Pt 5):899–911
Genome organization of the Kresse strain of porcine parvovirus: identification of the allotropic determinant and comparison with those of NADL-2 and field isolates. Bergeron J, et al. **J Virol** 1996 Apr;70(4):2508–15
Analysis of the complete nucleotide sequences of goose and muscovy duck parvoviruses indicates common ancestral origin with adeno-associated virus 2. Zádori Z, et al. **Virology** 1995 Oct 1;212(2):562–73

GROWTH & DEVELOPMENT

Suppression of canine parvovirus growth in CRFK cells by canine distemper virus. Gemma T, et al. **J Vet Med Sci** 1995 Jun;57(3):535–7

IMMUNOLOGY

Age-specific prevalence of porcine parvovirus antibody in feral pigs from a site in the Northern Territory. Caley P, et al. **Aust Vet J** 1995 Jan;72(1):36–7
Expression of recombinant parvovirus NS1 protein by a baculovirus and application to serologic testing of rodents. Riley LK, et al. **J Clin Microbiol** 1996 Feb;34(2):440–4
Development and evaluation of capture immunoglobulin G and M hemadherence assays by using human type O erythrocytes and recombinant parvovirus B19 antigen. Wang QY, et al. **J Clin Microbiol** 1995 Sep;33(9):2466–7
A nonlethal rat parvovirus infection suppresses rat T lymphocyte effector functions. McKisic MD, et al. **J Immunol** 1995 Oct 15;155(8):3979–86
Effectiveness of an inactivated goose parvovirus vaccine in Muscovy ducks. Takehara K, et al. **J Vet Med Sci** 1995 Dec;57(6):1093–5
Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. McKisic MD, et al. **Transplantation** 1996 Jan 27;61(2):292–9

ISOLATION & PURIFICATION

Transient blood plasmacytosis in parvovirus B19 infection: a report of two cases. Koduri PR, et al. **Ann Hematol** 1996 Jan;72(1):49–51
Development and biochemical characterization of a double-virus-inactivated factor VIII preparation. Robinson S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S40–7
A simple and sensitive DNA hybridization assay used for the routine diagnosis of human parvovirus B19 infection. Hicks KE, et al. **J Clin Microbiol** 1995 Sep;33(9):2473–5
Experimental infection of pigs with a parvovirus isolated from the diarrheic feces of a pig. Yasuhara H, et al. **J Vet Med Sci** 1995 Aug;57(4):629–34

PATHOGENICITY

Kilham rat triggers T-cell-dependent autoimmune diabetes in multiple strains of rat. Ellerman KE, et al. **Diabetes** 1996 May;45(5):557–62

PHYSIOLOGY

Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus. Spitzer AL, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1787–92
DNA double-strand break repair functions defend against parvovirus infection. Tauer TJ, et al. **J Virol** 1996 Sep; 70(9):6446–9

PARVOVIRUS B19, HUMAN

see related

ERYTHEMA INFECTIOSUM

Parvovirus B19 as a trigger for spontaneous bacterial peritonitis in a patient with cirrhotic ascites. Yamamoto T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1857–9
Fifth disease after immunoglobulin administration in an AIDS patient with parvovirus-induced red cell aplasia. French AL, et al. **Am J Med** 1996 Jul;101(1):108–9
An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Katz VL, et al. **Am J Perinatol** 1996 Jan;13(1):43–5
Neonatal meningitis with human parvovirus B19 infection [letter; comment] Suzuki N, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F196–7 . Comment on: Arch Dis Child 1993 Jun;68(6):784–5. Comment on: Arch Dis Child 1994 Jan;70(1):71.
Pure red blood cell aplasia associated with parvovirus B19 infection in large granular lymphocyte leukemia [letter] Ergas D, et al. **Blood** 1996 Apr 15;87(8):3523–4
Prevalence of parvovirus B19 infection in Portugal [letter] Araújo FM, et al. **Blood Coagul Fibrinolysis** 1995 Oct; 6(7):687
Parvovirus B19 infection and hematopoiesis. Brown KE, et al. **Blood Rev** 1995 Sep;9(3):176–82 (30 ref.)
Parvovirus infection and its treatment. Young NS. **Clin Exp Immunol** 1996 May;104 Suppl 1:26–30 (31 ref.)
Parvovirus B19 infection in Behçet's disease. Kiraz S, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):71–3
Aseptic meningitis caused by parvovirus B19. Koduri PR, et al. **Clin Infect Dis** 1995 Oct;21(4):1053
Kawasaki disease associated with parvovirus B19 infection. Holm JM, et al. **Eur J Pediatr** 1995 Aug;154(8):633–4
Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Langnas AN, et al. **Hepatology** 1995 Dec;22(6):1661–5
Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)
Acute transient hemolytic anemia with a positive Donath-Landsteiner test following parvovirus B19 infection. Chambers LA, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):178–81
B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):175–7
Parvovirus B19 and hemodialysis [letter] Guiserix J, et al. **Nephron** 1996;72(4):719
New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)
Transient aplastic crisis in a leukemic child caused by parvovirus B19 infection. Mihál V, et al. **Pediatr Hematol Oncol** 1996 Mar-Apr;13(2):173–7
A case of severe thrombocytopenia due to parvovirus B19 virus. Yildirmak Y, et al. **Pediatr Hematol Oncol** 1996 Mar-Apr;13(2):183–5
Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection. Gratacós E, et al. **Prenat Diagn** 1995 Dec; 15(12):1109–13
Parvovirus B19 infection—persistence and genetic variation. Kerr JR, et al. **Scand J Infect Dis** 1995;27(6):551–7
Parvovirus B19 infection in patients with hemophilia. Ragni MV, et al. **Transfusion** 1996 Mar;36(3):238–41
[[Human parvovirus B19 and its clinical significance] Schwarz TF, et al. **Hautarzt** 1995 Dec;46(12):831–5 (44 ref.) (Eng. Abstr.) **(Ger)**
[25-year-old patient with pancytopenia] Meusser S, et al. **Internist (Berl)** 1995 Oct;36(10):999–1004 **(Ger)**
[The first case in Japan of unstable hemoglobin, Hb Buenos Aires [beta 85 (F1) Phe-->Ser], with parvovirus B19 infection (first case in Japan)] Hiratake S, et al. **Rinsho Ketsueki** 1995 Dec;36(12):1342–6 (Eng. Abstr.) **(Jpn)**
[Postpartum parvovirus B19-associated acute pure red cell aplasia and hemophagocytic syndrome] Tsuda H, et al. **Rinsho Ketsueki** 1995 Jul;36(7):672–6 (Eng. Abstr.) **(Jpn)**
[Description of 31 pediatric cases of infection caused by human Parvovirus B 19] Azúa B, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):21–6 (Eng. Abstr.) **(Spa)**
[Intrafamily infection caused by Parvovirus B19: different manifestations according to age (letter)] López-Expósito R, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):66–7 **(Spa)**
[Parvovirus B19 infection in different shapes. But more laboratories have refined the diagnostic methods] Jorup C, et al. **Lakartidningen** 1995 Nov 15;92(46):4331–4 **(Swe)**

GENETICS

Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Jordan JA. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):37–42
Sequence analysis of a parvovirus B19 isolate and baculovirus expression of the non-structural protein. Hicks KE, et al. **Arch Virol** 1996;141(7):1319–27
Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Saldanha J, et al. **Br J Haematol** 1996 Jun 1;93(3):714–9
Incidence of human parvovirus B19 DNA detection in blood donors. Yoto Y, et al. **Br J Haematol** 1995 Dec;91(4):1017–8
Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products. Lefrere JJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):985–8
Application of a low-light imaging device and chemiluminescent substrates for quantitative detection of viral DNA in hybridization reactions. Girotti S, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1693–7
Detection of parvovirus B19 DNA in bone marrow cells by chemiluminescence in situ hybridization. Musiani M, et al. **J Clin Microbiol** 1996 May;34(5):1313–6
Sequence variability among different parvovirus B19 isolates. Hemauer A, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1781–5
A new genome type of human parvovirus B19 present in sera of patients with encephalopathy. Umene K, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2645–51
Large-scale screening for human parvovirus B19 DNA in clinical specimens by dot blot hybridization and polymerase chain reaction. Yoto Y, et al. **J Med Virol** 1995 Dec; 47(4):438–41
Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. Ponnazhagan S, et al. **J Virol** 1995 Dec;69(12):8096–101
Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Wang XS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12416–20

IMMUNOLOGY

A prospective study of antibodies against parvovirus B19 in pregnancy. Skjöldebrand-Sparre L, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):336–9
Leukophagocytosis in human parvovirus B19-induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)
Diagnosis of parvovirus B19 infection by detection of specific immunoglobulin M antibody in saliva. Cubel RC, et al. **J Clin Microbiol** 1996 Jan;34(1):205–7
Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. Söderlund M, et al. **J Infect Dis** 1995 Dec;172(6):1431–6
Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. von Poblotzki A, et al. **J Infect Dis** 1995 Nov;172(5):1356–9
A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays. Kock WC. **J Virol Methods** 1995 Sep;55(1):67–82
[Seroprevalence of IgG antibodies against parvovirus B19 in the population of the Czech Republic] Sodja I, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):171–4 (Eng. Abstr.) **(Cze)**
[Parvovirus B19 infection as the cause of hepatitis and neutrophil granulocytosis in a 20-year old woman] Wiggers H, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5994–5 (Eng. Abstr.) **(Dan)**
[Seroepidemiology of human parvovirus B19 using recombinant VP1 + VP2 particle antigen] Matsunaga Y, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1371–5 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Lowenthal EA, et al. **Am J Hematol** 1996 Mar;51(3):207–13
Acquired pure red cell aplasia: a study of six cases. Gilsanz F, et al. **Ann Hematol** 1995 Oct;71(4):181–3
High frequency of parvovirus B19 in patients tested for rheumatoid factor. Jobanputra P, et al. **BMJ** 1995 Dec 9; 311(7019):1542
Parvovirus B19 in rheumatoid arthritis: comment on the article by Kerr et al [letter; comment] Nikkari S, et al. **Br J Rheumatol** 1996 May;35(5):494. Comment on: Br J Rheumatol 1995 Sep;34(9):809–13.
Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products. Lefrere JJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):985–8
Cytodiagnosis of parvovirus B19 infection from ascites fluid of hydrops fetalis: report of a case. Iwa N, et al. **Diagn Cytopathol** 1995 Aug;13(2):139–41
A school outbreak of parvovirus B19 infection investigated using salivary antibody assays. Rice PS, et al. **Epidemiol Infect** 1996 Jun;116(3):331–8
Detection of parvovirus B19 DNA in bone marrow cells by chemiluminescence in situ hybridization. Musiani M, et al. **J Clin Microbiol** 1996 May;34(5):1313–6
A study by means of a new assay of the relationship between an outbreak of erythema infectiosum and non-immune hydrops fetalis caused by human parvovirus B19. Yaegashi N, et al. **J Infect** 1995 Nov;31(3):195–200
Parvovirus B19 clearance from peripheral blood after acute infection. Musiani M, et al. **J Infect Dis** 1995 Nov; 172(5):1360–3
Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. von Poblotzki A, et al. **J Infect Dis** 1995 Nov;172(5):1356–9
Evaluation of 4 commercial test kits for parvovirus B19-specific IgM. Cohen BJ, et al. **J Virol Methods** 1995 Sep;55(1):11–25
Automated detection of digoxigenin-labelled B19 parvovirus amplicons by a capture hybridization assay. Zerbini M, et al. **J Virol Methods** 1995 Sep;55(1):1–9
Screening blood donations for parvovirus B19 [letter; comment] Cohen B, et al. **Lancet** 1995 Dec 16; 346(8990):1631. Comment on: Lancet 1995 Nov 4;346(8984):1237–8.
Human parvovirus B19 infection and hepatitis [letter; comment] Naides SJ, et al. **Lancet** 1996 Jun 1; 347(9014):1563–4. Comment on: Lancet 1996 Mar 30;347(9005):868–9.
Screening of blood donors for human parvovirus B19 [letter] [see comments] Sato H, et al. **Lancet** 1995 Nov 4; 346(8984):1237–8. Comment in: Lancet 1995 Dec 16;346(8990):1631.
Human parvovirus B19 infection associated with acute hepatitis [see comments] Yoto Y, et al. **Lancet** 1996 Mar

30;347(9005):868–9. Comment in: Lancet 1996 Jun 1;347(9014):1563–4.
Severe aplastic anaemia due to B19 parvovirus infection in renal transplant recipient. Bertoni E, et al. **Nephrol Dial Transplant** 1995;10(8):1462–3
Infection–associated hemophagocytic syndrome complicated by infectious lymphoproliferation: a case report. Syručková Z, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):143–50
Fetal hydrops secondary to human parvovirus infection in early pregnancy. Petrikovsky BM, et al. **Prenat Diagn** 1996 Apr;16(4):342–4
Parvovirus B19 infection associated with encephalitis in a patient suffering from malignant lymphoma. Heegaard ED, et al. **Scand J Infect Dis** 1995;27(6):631–3
Human parvovirus B19 infection in blood donors. Tsujimura M, et al. **Vox Sang** 1995;69(3):206–12
[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**
[Dermatologic symptoms of parvovirus B19 infections] Frank R, et al. **Hautarzt** 1996 May;47(5):365–8 (Eng. Abstr.) **(Ger)**
[Infection with parvovirus B19 in pregnant women] Oszukowski P, et al. **Ginekol Pol** 1996 Mar;67(3):114–6 (Eng. Abstr.) **(Pol)**

PATHOGENICITY

Parvovirus B19: an expanding spectrum of disease. Cohen B. **BMJ** 1995 Dec 9;311(7019):1549–52 (45 ref.)
Diverse hematologic effects of parvovirus B19 infection. Mustafa MM, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):809–21 (70 ref.)
[Parvovirus B19—a ubiquitous, little know virus. From erythema infectiosum and arthropathy to chronic anemia] Frickhofen N. **Fortschr Med** 1995 Sep 10;113(25):351–3 **(Ger)**
[Parvovirus B19 (PV–B19) and the human diseases it causes] Iavorkovskiĭ LI. **Ter Arkh** 1995;67(11):56–8 (30 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno–associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non–permissive for AAV infection. Ponnazhagan S, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1111–22
Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. Cooling LL, et al. **J Infect Dis** 1995 Nov; 172(5):1198–205

PARVOVIRUS, CANINE

Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982–1991). Houston DM, et al. **J Am Vet Med Assoc** 1996 Feb 15;208(4):542–6
[Evolution of canine parvovirus: loss and gain of the feline host] Truyen U. **Tierarztl Prax** 1996 Jun;24(3):316–8 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Antigenic types of canine parvoviruses prevailing in Taiwan. Chang WL, et al. **Vet Rec** 1996 May 4;138(18):447
Comparison of isolates of canine parvovirus by monoclonal antibody and restriction enzyme analysis. Greenwood NM, et al. **Vet Rec** 1996 May 18;138(20):495–6
Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Truyen U, et al. **Vet Rec** 1996 Apr 13;138(15):365–6
Differentiation of wild– and vaccine–type canine parvoviruses by PCR and restriction–enzyme analysis. Hirasawa T, et al. **Zentralbl Veterinarmed [B]** 1995 Dec; 42(10):601–10

IMMUNOLOGY

Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence. Casal JI, et al. **J Virol** 1995 Nov;69(11):7274–7
Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose. Buonavoglia C, et al. **New Microbiol** 1995 Oct;18(4):371–5
Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Langeveld JP, et al. **Vaccine** 1995 Aug;13(11):1033–7

ISOLATION & PURIFICATION

A simple touch–down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces. Schunck B, et al. **J Virol Methods** 1995 Nov; 55(3):427–33
[Rapid enzymatic test for diagnosis of parvovirus infections in dogs] Kuffer M, et al. **Tierarztl Prax** 1995 Aug; 23(4):415–7 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus. Spitzer AL, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1787–92
Evolution of canine parvovirus involved loss and gain of feline host range. Truyen U, et al. **Virology** 1996 Jan 15; 215(2):186–9

PARVOVIRUS, FELINE

CLASSIFICATION

Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Truyen U, et al. **Vet Rec** 1996 Apr 13;138(15):365–6

IMMUNOLOGY

Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Langeveld JP, et al. **Vaccine** 1995 Aug;13(11):1033–7
Raccoon poxvirus feline panleukopenia virus VP2 recombinant protects cats against FPV challenge. Hu L, et al. **Virology** 1996 Apr 1;218(1):248–52

ISOLATION & PURIFICATION

Study of hereditary cerebellar degeneration in cats. Inada S, et al. **Am J Vet Res** 1996 Mar;57(3):296–301
A simple touch–down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces. Schunck B, et al. **J Virol Methods** 1995 Nov; 55(3):427–33
Feline parvovirus in pedigree kittens [letter] Addie DD, et al. **Vet Rec** 1996 Feb 3;138(5):119

PHYSIOLOGY

Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus. Spitzer AL, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1787–92
Evolution of canine parvovirus involved loss and gain of feline host range. Truyen U, et al. **Virology** 1996 Jan 15; 215(2):186–9

PARVOVIRUS INFECTIONS see **PARVOVIRIDAE INFECTIONS**

PARVOVIRUS, RACCOON see **PARVOVIRUS, FELINE**

PAS see **P–AMINOSALICYLIC ACID**

PAS REACTION see **PERIODIC ACID–SCHIFF REACTION**

PASSIVE ADDICTION, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

PASSIVE ANTIBODY TRANSFER see **IMMUNIZATION, PASSIVE**

PASSIVE CUTANEOUS ANAPHYLAXIS

Ability of histamine to increase nasal mucosal permeability to macromolecules in guinea pigs. Kaise T, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):969–73
Passive cutaneous anaphylaxis in diabetic rats. Casacó A, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct; 5(5):283–5

DRUG EFFECTS

Pharmacological characteristics of Sho–seiryu–to, an antiallergic Kampo medicine without effects on histamine H1 receptors and muscarinic cholinergic system in the brain. Sakaguchi M, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb;18(1):41–7
[Effect of mao–bushi–saishin–to (MBST), a formula of Chinese medicines, on 48 hr homologous passive cutaneous anaphylaxis in rats] Shibata H, et al. **Arerugi** 1995 Sep; 44(9):1167–75 (Eng. Abstr.) **(Jpn)**
[Pharmacological studies on KW–4679, an antiallergic drug. (1): Inhibitory effect on passive cutaneous anaphylaxis (PCA) and experimental asthma in rats and guinea pigs] Ishii H, et al. **Nippon Yakurigaku Zasshi** 1995 Oct; 106(4):289–98 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Effects of cyclosporine and dexamethasone on IgE antibody response in mice, and on passive cutaneous anaphylaxis in the rat. Puigneró V, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):142–7
Augmented humoral and anaphylactic responses in Fc gamma RII–deficient mice. Takai T, et al. **Nature** 1996 Jan 25;379(6563):346–9

PASSIVE–DEPENDENT PERSONALITY see **DEPENDENT PERSONALITY DISORDER**

PASSIVE MOTION THERAPY, CONTINUOUS see **MOTION THERAPY, CONTINUOUS PASSIVE**

PASSIVE RANGE OF MOTION see **RANGE OF MOTION, ARTICULAR**

PASSIVE SMOKING see **TOBACCO SMOKE POLLUTION**

PASSIVE TRANSFER OF IMMUNITY see **IMMUNIZATION, PASSIVE**

PASSIVE TRANSFER TEST see **INTRADERMAL TESTS**

PASTES see **OINTMENTS**

PASTEURELLA

CLASSIFICATION

Molecular characterization of Pasteurella testudinis isolated from desert tortoises (Gopherus agassizii) with and without upper respiratory tract disease. Snipes KP, et al. **J Wildl Dis** 1995 Jan;31(1):22–9
Reclassification of 30 Pasteurellaceae strains isolated from rodents. Boot R, et al. **Lab Anim** 1995 Jul;29(3):314–9
[Proteins from the outer membrane of Pasteurella—1. Polyacrylamide gel electrophoresis of outer membrane proteins—a possibility for differentiation of Pasteurella haemolytica strains] Feist H, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):249–52 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Isolation of a spermatozoa motility inhibiting factor from chicken seminal plasma with antibacterial property. Mohan J, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):407–13
In–vitro susceptibility to thirteen antibiotics of Pasteurella spp. and related bacteria isolated from humans [letter] Gaillot O, et al. **J Antimicrob Chemother** 1995 Nov; 36(5):878–80
In vitro efficacy of cefquinome (INN) and other anti–infective drugs against bovine bacterial isolates from Belgium, France, Germany, The Netherlands, and the United Kingdom. Böttner A, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):377–83
[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Cloning and sequence of the groESL heat–shock operon of Pasteurella multocida. Love BC, et al. **Gene** 1995 Dec 1; 166(1):179–80

IMMUNOLOGY

An enzyme–linked immunosorbent assay (ELISA) for monitoring rodent colonies for Pasteurella pneumotropica antibodies. Boot R, et al. **Lab Anim** 1995 Jul;29(3):307–13

ISOLATION & PURIFICATION

The use of polymerase chain reaction to identify Pasteurella granulomatis from cattle. Veit HP, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:350–8
Rederivation of mice by means of in vitro fertilization and embryo transfer. Suzuki H, et al. **Exp Anim** 1996 Jan; 45(1):33–8
Detection of Pasteurella pneumotropica in laboratory mice and rats by polymerase chain reaction. Wang RF, et al. **Lab Anim Sci** 1996 Feb;46(1):81–5

PATHOGENICITY

Adherence and invasive capacities of the fish pathogen Pasteurella piscicida. Magariños B, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):29–34

PHYSIOLOGY

Adherence and invasive capacities of the fish pathogen Pasteurella piscicida. Magariños B, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):29–34

PASTEURELLA HAEMOLYTICA

Effect of supplemental chromium on antibody responses of newly arrived feeder calves to vaccines and ovalbumin. Chang GX, et al. **Can J Vet Res** 1996 Apr;60(2):140–4
Purified Pasteurella haemolytica leukotoxin induces expression of inflammatory cytokines from bovine alveolar macrophages. Yoo HS, et al. **Microb Pathog** 1995 Apr; 18(4):237–52
Isolation of an ovine pulmonary surfactant–associated anionic peptide bactericidal for Pasteurella haemolytica. Brogden KA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):412–6
Evaluation of the nebulisation of sodium ceftiofur in the treatment of experimental Pasteurella haemolytica bronchopneumonia in calves. Sustronck B, et al. **Res Vet Sci** 1995 Nov;59(3):267–71
Bronchopneumonia in mice caused by Pasteurella haemolytica A2 after predisposition by ovine Bordetella

parapertussis. Porter JF, et al. **Vet Microbiol** 1995 Oct; 46(4):393–400

CLASSIFICATION

Phylogenetic relationships and diversity within the Pasteurella haemolytica complex based on 16S rRNA sequence comparison and outer membrane protein and lipopolysaccharide analysis. Davies RL, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):736–44

Coagglutination test for serotyping Pasteurella haemolytica. Fodor L, et al. **J Clin Microbiol** 1996 Feb;34(2):393–7

Intra-specific diversity and host specificity within Pasteurella haemolytica based on variation of capsular polysaccharide, lipopolysaccharide and outer-membrane proteins. Davies RL, et al. **Microbiology** 1996 Jul;142 (Pt 7):1895–907

The distribution of Pasteurella haemolytica serotypes among cattle, sheep, and goats in South Africa and their association with diseases. Odendaal MW, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):223–6

Serotypes of Pasteurella multocida and Pasteurella haemolytica isolated from pneumonic lesions in cattle and sheep from México. Blanco-Viera FJ, et al. **Rev Latinoam Microbiol** 1995 Apr-Jun;37(2):121–6

[Proteins from the outer membrane of Pasteurella—1. Polyacrylamide gel electrophoresis of outer membrane proteins—a possibility for differentiation of Pasteurella haemolytica strains] Feist H, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):249–52 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[Resistance pattern of bovine Pasteurella] Hörmansdorfer S, et al. **Berl Munch Tierarztl Wochenschr** 1996 May; 109(5):168–71 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

The Pasteurella haemolytica O-sialoglycoprotein endopeptidase is inhibited by zinc ions and does not cleave fetuin. Cladman WM, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):141–6

Evidence of bovine immunoglobulin G1 (IgG1) protease activity in partially purified culture supernate of Pasteurella haemolytica A1. Lee CW, et al. **Can J Vet Res** 1996 Apr; 60(2):127–32

Occurrence of [copper, zinc]-cofactored superoxide dismutase in Pasteurella haemolytica and its serotype distribution. Lainson FA, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):11–7

Cloning and characterization of the galE locus of Pasteurella haemolytica A1. Potter MD, et al. **Infect Immun** 1996 Mar; 64(3):855–60

GENETICS

Sequence analysis of leukotoxin secretion determinants from a Pasteurella haemolytica-like organism. Chang YF, et al. **DNA Seq** 1995;5(5):291–7

Cloning and characterization of the galE locus of Pasteurella haemolytica A1. Potter MD, et al. **Infect Immun** 1996 Mar; 64(3):855–60

Tetracycline resistance determinants, Tet B and Tet M, detected in Pasteurella haemolytica and Pasteurella multocida from bovine herds. Chaslus-Dancla E, et al. **J Antimicrob Chemother** 1995 Nov;36(5):815–9

GROWTH & DEVELOPMENT

Colonization of the tonsils and nasopharynx of calves by a rifampicin-resistant Pasteurella haemolytica and its inhibition by vaccination. Frank GH, et al. **Am J Vet Res** 1995 Jul;56(7):866–9

IMMUNOLOGY

Colonization of the tonsils and nasopharynx of calves by a rifampicin-resistant Pasteurella haemolytica and its inhibition by vaccination. Frank GH, et al. **Am J Vet Res** 1995 Jul;56(7):866–9

Vaccination of cattle with outer membrane protein-enriched fractions of Pasteurella haemolytica and resistance against experimental challenge exposure. Morton RJ, et al. **Am J Vet Res** 1995 Jul;56(7):875–9

Definition of chemiluminescence and superoxide production responses of bovine neutrophils to selected soluble and particulate stimulants, and comparisons with the responses to Pasteurella haemolytica. Watson GL, et al. **Am J Vet Res** 1995 Aug;56(8):1045–54

Effects of various vaccination protocols on passive and active immunity to Pasteurella haemolytica and Haemophilus somnus in beef calves. Van Donkersgoed J, et al. **Can Vet J** 1995 Jul;36(7):424–9

Characterization of bovine pulmonary and serum antibody responses after parenteral or intrapulmonary vaccination with live Pasteurella haemolytica. McBride JW, et al. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):99–115

Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84

Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1. Confer AW, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1-2):101–10

Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Srinand S, et al. **Vet Microbiol** 1996 Apr; 49(3-4):181–95

ISOLATION & PURIFICATION

Partial characterization of the leukotoxin of Pasteurella haemolytica-like bacteria isolated from swine enteritis. DeSilva RT, et al. **Vet Microbiol** 1995 Aug;45(4):319–29

METABOLISM

Binding-protein-dependent arginine transport in Pasteurella haemolytica. Caskey LS, et al. **Microbiology** 1996 Jul;142 (Pt 7):1739–47

Chaotropic agents cause disaggregation and enhanced activity of Pasteurella haemolytica leukotoxin. Clinkenbeard KD, et al. **Vet Microbiol** 1995 Jul; 45(2-3):201–9

PATHOGENICITY

Pasteurella haemolytica leukotoxin induces bovine leukocytes to undergo morphologic changes consistent with apoptosis in vitro. Stevens PK, et al. **Infect Immun** 1996 Jul; 64(7):2687–94

Predisposition of specific pathogen-free lambs to Pasteurella haemolytica pneumonia by Bordetella parapertussis infection. Porter JF, et al. **J Comp Pathol** 1995 May; 112(4):381–9

Intra-specific diversity and host specificity within Pasteurella haemolytica based on variation of capsular polysaccharide, lipopolysaccharide and outer-membrane proteins. Davies RL, et al. **Microbiology** 1996 Jul;142 (Pt 7):1895–907

PHYSIOLOGY

Pulmonary ventilation, mechanics, gas exchange and haemodynamics in calves following intratracheal inoculation of Pasteurella haemolytica. Linden A, et al. **Zentralbl Veterinarmed A** 1995 Oct;42(8):531–44

PASTEURELLA INFECTIONS

[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)

Waterhouse-Friderichsen syndrome complicating primary biliary sepsis due to Pasteurella multocida in a patient with cirrhosis. Ip M, et al. **J Clin Pathol** 1995 Aug;48(8):775–7

[Pulmonary infection caused by Pasteurella multocida (letter)] Sebastian Royo M, et al. **An Med Interna** 1995 Oct;12(10):519 **(Spa)**

DIAGNOSIS

Pasteurella multocida isolation from a tuboovarian abscess. A case report. Lukban JC, et al. **J Reprod Med** 1995 Aug; 40(8):603–5

Pasteurella multocida tubo-ovarian abscess in a virgin. Teng FY, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):883

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361–6 (38 ref.)

Persistent postoperative wound infection with Pasteurella multocida: case report and literature review [letter] Cook PP. **Infection** 1995 Jul-Aug;23(4):252 (4 ref.)

Pasteurella multocida infection in continuous ambulatory peritoneal dialysis. Kitching AR, et al. **N Z Med J** 1996 Feb 23;109(1016):59

[Dog bite and Pasteurella multocida pneumonia (letter)] Pascal I, et al. **Med Clin (Barc)** 1996 May 18;106(19):757 **(Spa)**

IMMUNOLOGY

Colonization of the tonsils and nasopharynx of calves by a rifampicin-resistant Pasteurella haemolytica and its inhibition by vaccination. Frank GH, et al. **Am J Vet Res** 1995 Jul;56(7):866–9

Vaccination of cattle with outer membrane protein-enriched fractions of Pasteurella haemolytica and resistance against experimental challenge exposure. Morton RJ, et al. **Am J Vet Res** 1995 Jul;56(7):875–9

METABOLISM

Serial pleural fluid analysis in a new experimental model of empyema. Sasse SA, et al. **Chest** 1996 Apr;109(4):1043–8

MICROBIOLOGY

Syphilitic aortic aneurysm and squamous cell carcinoma of the penis: a case report. el-Gadi SM, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):356–60

Splenic abscess associated with Pasteurella multocida in an immunocompetent patient. Talbodec N, et al. **J Clin Gastroenterol** 1995 Jul;21(1):76

Meningitis in infancy caused by Pasteurella multocida. Boocock GR, et al. **J Infect** 1995 Sep;31(2):161–2

Pasteurella multocida septicaemia in Milroy's disease [letter] Namnyak S, et al. **J Infect** 1995 Sep;31(2):175–6

Pasteurella multocida—an uncommon cause of obstetric and gynaecological sepsis. Riley UB, et al. **J Infect** 1995 Jul; 31(1):51–3

Pasteurella multocida from a dog causing Ludwig's angina [letter] Dryden MS, et al. **Lancet** 1996 Jan 13;347(8994):123

Chronic lung abscess due to Pasteurella multocida. Machiels P, et al. **Thorax** 1995 Sep;50(9):1017–8

[Pasteurella multocida meningitis in the adult (letter)] Aubry O, et al. **Presse Med** 1995 Jun 24;24(23):1088 **(Fre)**

PREVENTION & CONTROL

Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84

TRANSMISSION

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

Three cases of Pasteurella multocida skin infection from pet cats. Matsui T, et al. **J Dermatol** 1996 Jul;23(7):502–4

Pasteurella "SP" group infection after a guinea pig bite [letter] Lion C, et al. **Lancet** 1995 Sep 30;346(8979):901–2

VETERINARY

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Role of Pasteurella granulomatis and Dermatobia hominis in the etiology of lechiguana in cattle. Ladeira SL, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:359–68

The use of polymerase chain reaction to identify Pasteurella granulomatis from cattle. Veit HP, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:350–8

In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):35–6

A pathogenic challenge model for adult northern bobwhite (Colinus virginianus) using a vaccine strain of Pasteurella multocida type 3. Dabbert CB, et al. **Avian Dis** 1996 Jan-Mar;40(1):99–102

Experimental reproduction of endocarditis with Pasteurella gallinarum in mature leghorn chickens. Tjahjowati G, et al. **Avian Dis** 1995 Jul-Sep;39(3):489–98

Pasteurella multocida isolated from wild birds of North America: a serotype and DNA fingerprint study of isolates from 1978 to 1993. Wilson MA, et al. **Avian Dis** 1995 Jul-Sep;39(3):587–93

Effect of supplemental chromium on antibody responses of newly arrived feeder calves to vaccines and ovalbumin. Chang GX, et al. **Can J Vet Res** 1996 Apr;60(2):140–4

Comparison of protection of experimentally challenged cattle vaccinated once or twice with a Pasteurella haemolytica bacterial extract vaccine. Conlon JA, et al. **Can J Vet Res** 1995 Jul;59(3):179–82

Effects of various vaccination protocols on passive and active immunity to Pasteurella haemolytica and Haemophilus somnus in beef calves. Van Donkersgoed J, et al. **Can Vet J** 1995 Jul;36(7):424–9

Characterization of bovine pulmonary and serum antibody responses after parenteral or intrapulmonary vaccination with live Pasteurella haemolytica. McBride JW, et al. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):99–115

Serological potency testing of vaccines against progressive atrophic rhinitis. Oppling V, et al. **Dev Biol Stand** 1996; 86:339

Pili of Pasteurella multocida of porcine origin. Isaacson RE, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):247–51

Outbreaks of fowl cholera in Muscovy ducks (Cairina moschata) on a farm in Aomori Prefecture. Takahashi S, et al. **J Vet Med Sci** 1996 Mar;58(3):269–72

Molecular characterization of Pasteurella testudinis isolated from desert tortoises (Gopherus agassizii) with and without upper respiratory tract disease. Snipes KP, et al. **J Wildl Dis** 1995 Jan;31(1):22–9

An enzyme-linked immunosorbent assay (ELISA) for monitoring rodent colonies for Pasteurella pneumotropica antibodies. Boot R, et al. **Lab Anim** 1995 Jul;29(3):307–13

Protective immunity to Pasteurella multocida heat-labile toxin by intranasal immunization in rabbits. Suckow MA, et al. **Lab Anim Sci** 1995 Oct;45(5):526–32

Detection of Pasteurella pneumotropica in laboratory mice and rats by polymerase chain reaction. Wang RF, et al. **Lab Anim Sci** 1996 Feb;46(1):81–5

Detection and partial characterization of Pasteurella

multocida found in feline skin lesions. Hoshuyama S, et al. **Microbios** 1995;83(336):161–6

The distribution of Pasteurella haemolytica serotypes among cattle, sheep, and goats in South Africa and their association with diseases. Odendaal MW, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):223–6

The influence of major histocompatibility complex genotypes on resistance to Pasteurella multocida and Newcastle disease virus in turkeys. Nestor KE, et al. **Poult Sci** 1996 Jan;75(1):29–33

Evaluation of the nebulisation of sodium ceftiofur in the treatment of experimental Pasteurella haemolytica bronchopneumonia in calves. Sustronck B, et al. **Res Vet Sci** 1995 Nov;59(3):267–71

Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84

Occurrence of T lymphocytes in perivascular regions of the lung after intratracheal infection of swine with Pasteurella multocida. Berndt A, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):143–59

Partial characterization of the leukotoxin of Pasteurella haemolytica-like bacteria isolated from swine enteritis. DeSilva RT, et al. **Vet Microbiol** 1995 Aug;45(4):319–29

Molecular studies on avian strains of Pasteurella multocida in Australia. Diallo IS, et al. **Vet Microbiol** 1995 Sep; 46(1–3):335–42

Stimulation of avian respiratory phagocytes by Pasteurella multocida: effects of the route of exposure, bacterial dosage and strain, and the age of chickens. Hassanin HH, et al. **Vet Microbiol** 1995 Oct;46(4):401–13

Bronchopneumonia in mice caused by Pasteurella haemolytica A2 after predisposition by ovine Bordetella parapertussis. Porter JF, et al. **Vet Microbiol** 1995 Oct; 46(4):393–400

[Resistance pattern of bovine Pasteurella] Hörmansdorfer S, et al. **Berl Munch Tierarztl Wochenschr** 1996 May; 109(5):168–71 (Eng. Abstr.) **(Ger)**

PASTEURELLA MULTOCIDA

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361–6 (38 ref.)

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Serial pleural fluid analysis in a new experimental model of empyema. Sasse SA, et al. **Chest** 1996 Apr;109(4):1043–8

Persistent postoperative wound infection with Pasteurella multocida: case report and literature review [letter] Cook PP. **Infection** 1995 Jul–Aug;23(4):252 (4 ref.)

Syphilitic aortic aneurysm and squamous cell carcinoma of the penis: a case report. el-Gadi SM, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):356–60

Splenic abscess associated with Pasteurella multocida in an immunocompetent patient. Talbodec N, et al. **J Clin Gastroenterol** 1995 Jul;21(1):76

Waterhouse-Friderichsen syndrome complicating primary biliary sepsis due to Pasteurella multocida in a patient with cirrhosis. Ip M, et al. **J Clin Pathol** 1995 Aug;48(8):775–7

Three cases of Pasteurella multocida skin infection from pet cats. Matsui T, et al. **J Dermatol** 1996 Jul;23(7):502–4

Outbreaks of fowl cholera in Muscovy ducks (Cairina moschata) on a farm in Aomori Prefecture. Takahashi S, et al. **J Vet Med Sci** 1996 Mar;58(3):269–72

Pasteurella multocida infection in continuous ambulatory peritoneal dialysis. Kitching AR, et al. **N Z Med J** 1996 Feb 23;109(1016):59

Pasteurella multocida tubo-ovarian abscess in a virgin. Teng FY, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):883

The influence of major histocompatibility complex genotypes on resistance to Pasteurella multocida and Newcastle disease virus in turkeys. Nestor KE, et al. **Poult Sci** 1996 Jan;75(1):29–33

Occurrence of T lymphocytes in perivascular regions of the lung after intratracheal infection of swine with Pasteurella multocida. Berndt A, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):143–59

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary infection caused by Pasteurella multocida (letter)] Sebastian Royo M, et al. **An Med Interna** 1995 Oct;12(10):519 **(Spa)**

[Dog bite and Pasteurella multocida pneumonia (letter)] Pascal I, et al. **Med Clin (Barc)** 1996 May 18;106(19):757 **(Spa)**

CHEMISTRY

The 32 kDa major outer-membrane protein of Pasteurella multocida capsular serotype D. Vasfi Marandi M, et al. **Microbiology** 1996 Jan;142 (Pt 1):199–206

Biochemical characterization of lipopolysaccharides extracted from a hydrophobic strain of Pasteurella multocida. Conrad RS, et al. **Vet Res Commun** 1996; 20(3):195–204

CLASSIFICATION

Pasteurella multocida isolated from wild birds of North America: a serotype and DNA fingerprint study of isolates from 1978 to 1993. Wilson MA, et al. **Avian Dis** 1995 Jul–Sep;39(3):587–93

Serotypes of Pasteurella multocida and Pasteurella haemolytica isolated from pneumonic lesions in cattle and sheep from México. Blanco-Viera FJ, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):121–6

Molecular studies on avian strains of Pasteurella multocida in Australia. Diallo IS, et al. **Vet Microbiol** 1995 Sep; 46(1–3):335–42

Phenotypic characterisation of Pasteurella multocida isolates from Australian poultry. Fegan N, et al. **Vet Microbiol** 1995 Dec;47(3–4):281–6

Influence of chondroitinase on indirect hemagglutination titers and phagocytosis of Pasteurella multocida serogroups A, D and F. Rimler RB, et al. **Vet Microbiol** 1995 Dec; 47(3–4):287–94

DRUG EFFECTS

In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):35–6

[Resistance pattern of bovine Pasteurella] Hörmansdorfer S, et al. **Berl Munch Tierarztl Wochenschr** 1996 May; 109(5):168–71 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Enzymological characterization of the Pasteurella multocida hyaluronic acid synthase. DeAngelis PL. **Biochemistry** 1996 Jul 30;35(30):9768–71

Characterization of neuraminidases produced by various serotypes of Pasteurella multocida. Straus DC, et al. **Infect Immun** 1996 Apr;64(4):1446–9

GENETICS

Cloning, sequencing, expression, and protective capacity of the oma87 gene encoding the Pasteurella multocida 87-kilodalton outer membrane antigen. Ruffolo CG, et al. **Infect Immun** 1996 Aug;64(8):3161–7

Tetracycline resistance determinants, Tet B and Tet M, detected in Pasteurella haemolytica and Pasteurella multocida from bovine herds. Chaslus-Dancla E, et al. **J Antimicrob Chemother** 1995 Nov;36(5):815–9

Identification of Pasteurella multocida tryptophan synthase beta-subunit by antisera against strain P1059. Jablonski PE, et al. **Microbiology** 1996 Jan;142 (Pt 1):115–21

The Pasteurella multocida txaR gene is expressed in Escherichia coli but does not repress transcription of the P. multocida toxin gene toxA [letter] Hoskins IC, et al. **Mol Microbiol** 1995 Oct;18(2):377

Phenotypic characterisation of Pasteurella multocida isolates from Australian poultry. Fegan N, et al. **Vet Microbiol** 1995 Dec;47(3–4):281–6

Pasteurellosis in elk (Cervus elaphus): DNA fingerprinting of isolates. Wilson MA, et al. **Vet Rec** 1995 Aug 19; 137(8):195–6

GROWTH & DEVELOPMENT

A minimal medium for growth of Pasteurella multocida. Jablonski PE, et al. **FEMS Microbiol Lett** 1996 Jul 1; 140(2–3):165–9

IMMUNOLOGY

A pathogenic challenge model for adult northern bobwhite (Colinus virginianus) using a vaccine strain of Pasteurella multocida type 3. Dabbert CB, et al. **Avian Dis** 1996 Jan–Mar;40(1):99–102

Serological potency testing of vaccines against progressive atrophic rhinitis. Oppling V, et al. **Dev Biol Stand** 1996; 86:339

Protective immunity to Pasteurella multocida heat-labile toxin by intranasal immunization in rabbits. Suckow MA, et al. **Lab Anim Sci** 1995 Oct;45(5):526–32

Stimulation of avian respiratory phagocytes by Pasteurella multocida: effects of the route of exposure, bacterial dosage and strain, and the age of chickens. Hassanin HH, et al. **Vet Microbiol** 1995 Oct;46(4):401–13

Effect of storage on the prevalent alum-precipitated hemorrhagic septicaemia vaccine in Pakistan and preparation of a more efficient oil adjuvant vaccine using dense culture of Pasteurella multocida Roberts type 1 on an improved culture medium. Sheikh MA, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):28–34

ISOLATION & PURIFICATION

An outbreak of haemorrhagic septicaemia associated with Pasteurella multocida subsp gallicida in large pig herd. Cameron RD, et al. **Aust Vet J** 1996 Jan;73(1):27–9

Pasteurella multocida isolated from wild birds of North America: a serotype and DNA fingerprint study of isolates from 1978 to 1993. Wilson MA, et al. **Avian Dis** 1995 Jul–Sep;39(3):587–93

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)

Meningitis in infancy caused by Pasteurella multocida. Boocock GR, et al. **J Infect** 1995 Sep;31(2):161–2

Pasteurella multocida septicaemia in Milroy's disease [letter] Namnyak S, et al. **J Infect** 1995 Sep;31(2):175–6

Pasteurella multocida—an uncommon cause of obstetric and gynaecological sepsis. Riley UB, et al. **J Infect** 1995 Jul; 31(1):51–3

Pasteurella multocida isolation from a tuboovarian abscess. A case report. Lukban JC, et al. **J Reprod Med** 1995 Aug; 40(8):603–5

Recovery of Pasteurella multocida from experimentally-exposed freshwater snails. Miller SL, et al. **J Wildl Dis** 1995 Jul;31(3):358–63

Pasteurella multocida from a dog causing Ludwig's angina [letter] Dryden MS, et al. **Lancet** 1996 Jan 13;347(8994):123

Detection and partial characterization of Pasteurella multocida found in feline skin lesions. Hoshuyama S, et al. **Microbios** 1995;83(336):161–6

Chronic lung abscess due to Pasteurella multocida. Machiels P, et al. **Thorax** 1995 Sep;50(9):1017–8

[Pasteurella multocida meningitis in the adult (letter)] Aubry O, et al. **Presse Med** 1995 Jun 24;24(23):1088 **(Fre)**

METABOLISM

Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. Lacerda HM, et al. **J Biol Chem** 1996 Jan 5;271(1):439–45

PATHOGENICITY

The effect of plasmid acquisition on potential virulence attributes of Pasteurella multocida. Lee MD, et al. **Avian Dis** 1995 Jul–Sep;39(3):451–7

Pasteurella multocida toxin is a mitogen for bone cells in primary culture. Mullan PB, et al. **Infect Immun** 1996 Mar; 64(3):959–65

Colorimetric assay using XTT for assessing virulence of avian Pasteurella multocida strains. Choi KH, et al. **Vet Microbiol** 1995 Jul;45(2–3):191–200

PHYSIOLOGY

The goat as a model for studies of pneumonic pasteurellosis caused by Pasteurella multocida. Zamri-Saad M, et al. **Br Vet J** 1996 Jul;152(4):453–8

ULTRASTRUCTURE

Pili of Pasteurella multocida of porcine origin. Isaacson RE, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):247–51

PASTEURELLA PESTIS see **YERSINIA PESTIS**

PASTEURELLA TULARENSIS see **FRANCISELLA TULARENSIS**

PASTEURELLACEAE

CLASSIFICATION

Reclassification of 30 Pasteurellaceae strains isolated from rodents. Boot R, et al. **Lab Anim** 1995 Jul;29(3):314–9

PATHOGENICITY

Bacterial transferrin and lactoferrin receptors. Gray-Owen SD, et al. **Trends Microbiol** 1996 May;4(5):185–91 (49 ref.)

PASTEURELLACEAE INFECTIONS

VETERINARY

An enzyme-linked immunosorbent assay (ELISA) for monitoring rodent colonies for Pasteurella pneumotropica antibodies. Boot R, et al. **Lab Anim** 1995 Jul;29(3):307–13

PASTEURELLOSIS see **PASTEURELLA INFECTIONS**

PASTEURELLOSIS, PNEUMONIC

EPIDEMIOLOGY

Effect of time of year, weather, and the pattern of auction market sales on fatal fibrinous pneumonia (shipping fever) in calves in a large feedlot in Alberta (1985–1988). Ribble CS, et al. **Can J Vet Res** 1995 Jul;59(3):167–72

ETIOLOGY

Pasteurella pneumotropica pneumonia in a patient with AIDS [letter] Cuadrado-Gómez LM, et al. **Clin Infect Dis** 1995 Aug;21(2):445–6

IMMUNOLOGY

Increased tumor necrosis factor-alpha and interleukin-1 beta expression in the lungs of calves with experimental pneumonic pasteurellosis. Yoo HS, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):15–28

Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Srinand S, et al. **Vet Microbiol** 1996 Apr; 49(3–4):181–95

MICROBIOLOGY

Serotypes of Pasteurella multocida and Pasteurella haemolytica isolated from pneumonic lesions in cattle and sheep from México. Blanco–Viera FJ, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):121–6

MORTALITY

The pattern of fatal fibrinous pneumonia (shipping fever) affecting calves in a large feedlot in Alberta (1985–1988). Ribble CS, et al. **Can Vet J** 1995 Dec;36(12):753–7

PATHOLOGY

The goat as a model for studies of pneumonic pasteurellosis caused by Pasteurella multocida. Zamri–Saad M, et al. **Br Vet J** 1996 Jul;152(4):453–8

PHYSIOPATHOLOGY

Pulmonary ventilation, mechanics, gas exchange and haemodynamics in calves following intratracheal inoculation of Pasteurella haemolytica. Linden A, et al. **Zentralbl Veterinarmed A** 1995 Oct;42(8):531–44

PREVENTION & CONTROL

Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84

Serum antibody responses of cattle to iron–regulated outer membrane proteins of Pasteurella haemolytica A1. Confer AW, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1–2):101–10

TRANSMISSION

Effect of time of year, weather, and the pattern of auction market sales on fatal fibrinous pneumonia (shipping fever) in calves in a large feedlot in Alberta (1985–1988). Ribble CS, et al. **Can J Vet Res** 1995 Jul;59(3):167–72

PASTORAL CARE

The spiritual needs of pediatric patients and their families. Fina DK. **AORN J** 1995 Oct;62(4):556–64

Spiritual healing among Norwegian hospitalised cancer patients and patients' religious needs and preferences of pastoral services. Risberg T, et al. **Eur J Cancer** 1996 Feb; 32A(2):274–81

A critical analysis of nursing: meeting the spiritual needs of patients. Oldnall A. **J Adv Nurs** 1996 Jan;23(1):138–44 (43 ref.)

[Palliative care: various theological implications in reference to the article by E. Rivier, L. Barrelet and P. Beck (comment)] Piguet H. **Rev Med Suisse Romande** 1995 Jul; 115(7):549–53. Comment on: Rev Med Suisse Romande 1995 Feb;115(2):163–9. **(Fre)**

LEGISLATION & JURISPRUDENCE

Regulating pastoral counseling practice: the problem of sexual misconduct. Young JL, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):421–32 (32 ref.)

PATAS MONKEY see **ERYTHROCEBUS PATAS**

PATCH–CLAMP TECHNIQUES

The cardiac Na–Ca exchanger in giant membrane patches. Hilgemann DW. **Ann N Y Acad Sci** 1996 Apr 15;779:136–58 (28 ref.)

Influence of conductance changes on patch clamp capacitance measurements using a lock–in amplifier and limitations of the phase tracking technique. Debus K, et al. **Biophys J** 1995 Dec;69(6):2808–22

The double–ticker: an improved fast drug–application system reveals desensitization of the glutamate channel from a closed state. Tour O, et al. **Eur J Neurosci** 1995 Oct 1; 7(10):2093–100

The transient outward current of isolated bovine adrenal zona fasciculata cells: comparison between standard and perforated patch recording methods. Bilbaut A, et al. **J Membr Biol** 1996 Feb;149(3):233–47

Effects of voltage clamping on epithelial cell composition in toad urinary bladder studied with x–ray microanalysis. Bowler JM, et al. **J Membr Biol** 1995 May;145(2):175–85

Patch clamp detection of transcription factor translocation along the nuclear pore complex channel. Bustamante JO, et al. **J Membr Biol** 1995 Aug;146(3):253–61

Patch clamp and atomic force microscopy demonstrate TATA–binding protein (TBP) interactions with the nuclear pore complex. Bustamante JO, et al. **J Membr Biol** 1995 Aug;146(3):263–72

Evaluation of single–channel gating kinetics produced after amplitude–based separation of unitary currents. Peppelenbosch MP, et al. **J Neurosci Methods** 1995 May; 58(1–2):49–59

Patch–clamping plant cells. Maathuis FJ, et al. **Methods Cell Biol** 1995;49:293–302

Persistence: a new statistic for characterizing ion–channel activity. Fredkin DR, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Dec 29; 350(1334):353–67

Membrane transport mechanisms probed by capacitance measurements with megahertz voltage clamp. Lu CC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11220–4

[Oil–gap method for internal perfusion and voltage clamp of single cardiac cells] Mitsuiye T. **Nippon Seirigaku Zasshi** 1995;57(6):283–8 **(Jpn)**

INSTRUMENTATION

Linear prediction and single–channel recording. Carter AA, et al. **J Neurosci Methods** 1995 Aug;60(1–2):69–78

Advanced computer control of electrophysiological experimentation. Thomsen L, et al. **J Neurosci Methods** 1996 Mar;65(1):19–26

Glass–funnel technique for the recording of membrane currents and intracellular perfusion of Xenopus oocytes. Shuba YM, et al. **Pflugers Arch** 1996 Jul;432(3):562–70

METHODS

Molecular biology and physiology at the single–cell level. Monyer H, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):382–7 (21 ref.)

Probing dendritic function with patch pipettes. Stuart G, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):389–94 (27 ref.)

The application of in vitro isolation, cryopreservation and patch–clamp microelectrode recording methods to adult rat thymic nurse cells. Downing JE, et al. **J Immunol Methods** 1995 Nov 16;187(1):103–10

Correlation of open cell–attached and excised patch clamp techniques. Filipovic D, et al. **J Membr Biol** 1995 Nov; 148(1):79–82

Persistent Na+ conductance in medium–sized neostriatal neurons: characterization using infrared videomicroscopy and whole cell patch–clamp recordings. Cepeda C, et al. **J Neurophysiol** 1995 Sep;74(3):1343–8

Use of the whole–cell patch–clamp method in studies on the role of cAMP in regulating the spontaneous firing of locus coeruleus neurons. Alreja M, et al. **J Neurosci Methods** 1995 Jun;59(1):67–75

Patch–clamping in brain slices: synaptic transmission from ATP to long–term potentiation. Edwards FA. **J Neurosci Methods** 1995 Jun;59(1):59–65

Repetitive depletion and recovery of intracellular K+ in retinal Müller glial cells during whole–cell voltage–clamp. Francke M, et al. **J Neurosci Methods** 1995 Sep–Oct; 61(1–2):169–84

The use of brain slices and dissociated neurones to explore the multiplicity of actions of 5–HT in the central nervous system. Larkman PM, et al. **J Neurosci Methods** 1995 Jun; 59(1):31–9

Improvement and testing of a concentration–clamp system for oocytes of Xenopus laevis. Madeja M, et al. **J Neurosci Methods** 1995 Dec;63(1–2):211–3

A Windows software package to record from voltage–clamped Xenopus oocytes. Nguyen QT, et al. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):213–9

A method allowing intracellular and extracellular single–unit recordings from brain slices in the grease–gap chamber. Stewart M, et al. **J Neurosci Methods** 1995 May; 58(1–2):17–24

A supercharger for single electrode voltage and current clamping. Strickholm A. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):47–52

A single electrode voltage, current– and patch–clamp amplifier with complete stable series resistance compensation. Strickholm A. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):53–66

Single–channel and whole–cell studies of calcium currents in young and aged rat hippocampal slice neurons. Thibault O, et al. **J Neurosci Methods** 1995 Jun;59(1):77–83

A numerical procedure to estimate kinetic and steady–state characteristics of inactivating ionic currents. Tóth TI, et al. **J Neurosci Methods** 1995 Dec;63(1–2):1–12

Adapters for combined intrapipette pressure pulses and patch pipette step movements during 'blind' cell search in brain slices. Velumian AA, et al. **J Neurosci Methods** 1995 Nov; 62(1–2):129–34

PATCH TESTS

Positivity of patch tests in cutaneous reaction to aminocaproic acid: two case reports. González Gutiérrez ML, et al. **Allergy** 1995 Sep;50(9):745–6

Budesonide patch testing [letter] Rietschel RL. **Arch Dermatol** 1995 Dec;131(12):1466–7

Allergic contact dermatitis from doxepin cream. One–year patch test clinic experience. Taylor JS, et al. **Arch Dermatol** 1996 May;132(5):515–8

Studies on the reproducibility of allergic contact dermatitis. Memon AA, et al. **Br J Dermatol** 1996 Feb;134(2):208–14

Alcohol flushing, patch test, and ADH and ALDH genotypes in Brazilian ethnic groups. Santos BR, et al. **Braz J Med Biol Res** 1995 May;28(5):513–8

Oral mucosal diseases investigated by patch testing with a dental screening series. Alanko K, et al. **Contact Dermatitis** 1996 Apr;34(4):263–7

Effect of pentoxifylline on patch test response. Balato N, et al. **Contact Dermatitis** 1996 Feb;34(2):153

Screening for corticosteroid contact hypersensitivity. Boffa MJ, et al. **Contact Dermatitis** 1995 Sep;33(3):149–51

Sensitization to white petrolatum used as a vehicle for patch testing. Conti A, et al. **Contact Dermatitis** 1995 Sep; 33(3):201–2

Patch testing with fragrances: results of a multicenter study of the European Environmental and Contact Dermatitis Research Group with 48 frequently used constituents of perfumes. Frosch PJ, et al. **Contact Dermatitis** 1995 Nov; 33(5):333–42

No cross–sensitization between MCI/MI, benzisothiazolinone and octylisothiazolinone. Geier J, et al. **Contact Dermatitis** 1996 Feb;34(2):148–9

Human repeated insult patch test of 2–butoxyethanol. Greenspan AH, et al. **Contact Dermatitis** 1995 Jul; 33(1):59–60

Long–lasting allergic patch test reactions to nickel sulfate: analysis by nickel quantification and immunocytochemistry. Handley J, et al. **Contact Dermatitis** 1996 Feb;34(2):101–5

Comparison of patch test results in 2 clinics reflecting different populations. Harrison PV, et al. **Contact Dermatitis** 1995 Jul;33(1):54

Patch testing with preservatives at St John's from 1982 to 1993. Jacobs MC, et al. **Contact Dermatitis** 1995 Oct; 33(4):247–54

Variation in response of human skin to irritant challenge. Judge MR, et al. **Contact Dermatitis** 1996 Feb;34(2):115–7

Cross–reactive type IV hypersensitivity reactions to benzodiazepines revealed by patch testing. Kämpgen E, et al. **Contact Dermatitis** 1995 Nov;33(5):356–7

Patch test results in hairdressers with contact dermatitis in Greece (1985–1994). Katsarou A, et al. **Contact Dermatitis** 1995 Nov;33(5):347–8

Allergic and irritant patch test reactions and atopic disease. Klas PA, et al. **Contact Dermatitis** 1996 Feb;34(2):121–4

Patch testing in an unusual case of toxic epidermal necrolysis. Klein CE, et al. **Contact Dermatitis** 1995 Dec;33(6):448–9

A clinical and patch test study of contact dermatitis from traditional Chinese medicinal materials. Li LF. **Contact Dermatitis** 1995 Dec;33(6):392–5

In vitro skin irritancy: application of keratinocytes cell culture and its correlation with human patch test responses. Eun HC. **Curr Probl Dermatol** 1995;22:231–6

Allergic reaction to nonrubber products by testing with rubber mixes. Part IV: the carba mix [news] Fisher AA. **Cutis** 1995 Dec;56(6):314

Allergic reactions to nonrubber products by testing with rubber mixes. Part II: The mercapto mix [news] Fisher AA. **Cutis** 1995 Oct;56(4):197

The rubber mixes: allergic reactions to nonrubber products by testing with rubber mixes. Part I: The thiuram mix [news] Fisher AA. **Cutis** 1995 Sep;56(3):131

The role of routine patch tests in allergic contact dermatitis due to metal–working fluids. Fisher AA. **Cutis** 1996 Jan; 57(1):11–2

Paint dermatitis: the role of "routine" patch test series in detecting contact allergens in paint [news] Fisher AA. **Cutis** 1995 Jul;56(1):16

Contact allergy testing alternatives: 1996. Scheman A. **Cutis** 1996 Apr;57(4):235–40 (22 ref.)

Gene rearrangement in positive patch tests. Wolff–Sneedorff A, et al. **Exp Dermatol** 1995 Oct;4(5):322–6

Supplemental tests in the evaluation of occupational hand dermatitis in soldiers. Wolf R, et al. **Int J Dermatol** 1996 Mar;35(3):173–6

Combined skin prick and patch testing enhances identification of food allergy in infants with atopic dermatitis. Isolauri E, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):9–15

Comparison of the irritancy of hand dishwashing liquids with modified patch testing methods. Grammer–West NY, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):258–60

Human and economic impact of allergic contact dermatitis and the role of patch testing. Rietschel RL. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):812–5

Reproducibility of patch–test results. Rietschel RL. **Lancet** 1996 May 4;347(9010):1202

A study of chromium induced allergic contact dermatitis with 54 volunteers: implications for environmental risk assessment [letter] Stern AH, et al. **Occup Environ Med** 1995 Oct;52(10):701–4

[Results of patch tests with mite components in atopic dermatitis patients] Sakurai M. **Arerugi** 1996 Apr; 45(4):398–408 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Psychological and somatic subjective symptoms as a result of dermatological patch testing with metallic mercury and phenyl mercuric acetate. Marcusson JA. **Toxicol Lett** 1996 Feb;84(2):113–22

HISTORY

Towards a history of patch testing [letter] Burry JN. **Contact Dermatitis** 1995 Nov;33(5):362–3

METHODS

Contact dermatitis: clinical review of 800 patients tested using the standard European series. Serra–Baldrich E, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):67–72

Adding p–aminoazobenzene may increase the sensitivity of the European standard series in detecting contact allergy

to dyes, but carries the risk of active sensitization. Arnold WP, et al. **Contact Dermatitis** 1995 Dec;33(6):444

In vivo assessment of irritants made simple and subject-friendly. Bahmer FA. **Contact Dermatitis** 1995 Sep; 33(3):210-1

Evaluation of patch test results by use of the reaction index. An analysis of data recorded by the Information Network of Departments of Dermatology (IVDK). Brasch J, et al. **Contact Dermatitis** 1995 Dec;33(6):375-80

A study on expert reading of patch test reactions: inter-individual accordance. Bruze M, et al. **Contact Dermatitis** 1995 Jun;32(6):331-7

Is the European standard series suitable for patch testing in Riyadh, Saudi Arabia? el-Rab MO, et al. **Contact Dermatitis** 1995 Nov;33(5):310-4

Pretreatment of the test area with 1-day occlusion improves the response rate to NiSO4 5% pet. patch tests in subjects with a positive history of nickel allergy. Seidenari S, et al. **Contact Dermatitis** 1995 Sep;33(3):152-6

Pre-treatment of nickel test areas with sodium lauryl sulfate detects nickel sensitivity in subjects reacting negatively to routinely performed patch tests. Seidenari S, et al. **Contact Dermatitis** 1996 Feb;34(2):88-92

Placebo-controlled oral challenge with cobalt in patients with positive patch tests to cobalt. Veien NK, et al. **Contact Dermatitis** 1995 Jul;33(1):54-5

Clinical standardization of the TRUE Test formaldehyde patch. Fischer T, et al. **Curr Probl Dermatol** 1995;22:24-30

STANDARDS

Thimerosal is a frequent sensitizer but is not in the standard series. Aberer W, et al. **Contact Dermatitis** 1995 Jun; 32(6):367-8

The European standard series. European Environmental and Contact Dermatitis Research Group (EECDRG). Bruynzeel DP, et al. **Contact Dermatitis** 1995 Sep; 33(3):145-8 (16 ref.)

Clinical standardization of the TRUE Test formaldehyde patch. Fischer T, et al. **Curr Probl Dermatol** 1995;22:24-30

[Patch tests should be performed by experiences dermatologists. Many allergens can cause contact dermatitis] Lindberg M, et al. **Lakartidningen** 1995 Oct 4; 92(40):3673-5 **(Swe)**

PATELLA

Bilateral congenital dislocation of the patella. Carpintero P, et al. **Acta Orthop Belg** 1996 Jun;62(2):113-5

Patellar tilt in total knee arthroplasty. Laughlin RT, et al. **Am J Orthop** 1996 Apr;25(4):300-4

Outcome and clinical signs of arthroscopically graded patellar chondromalacia with or without lateral release. Korkala OL, et al. **Ann Chir Gynaecol** 1995;84(3):276-9

Bone transmitted patella percussion [letter] Mitchell P. **Ann R Coll Surg Engl** 1995 Jul;77(4):315

Reflex sympathetic dystrophy of both patellae following burns. Isakov E, et al. **Burns** 1995 Dec;21(8):616-8

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul-Aug; 80(3):323-8 (30 ref.)

Osteonecrosis and resorption of the patella after total knee replacement: a case report. Holtby RM, et al. **Clin Orthop** 1996 Jul;(328):155-8

The effects of patellar thickness on patellofemoral forces after resurfacing. Star MJ, et al. **Clin Orthop** 1996 Jan; (322):279-84

Unusual small bone metastases from epithelial malignancies: diagnosis by fine-needle aspiration cytology with histologic confirmation. Singh HK, et al. **Diagn Cytopathol** 1995 Oct; 13(3):192-5

Screening of vibroarthrographic signals via adaptive segmentation and linear prediation modeling. Moussavi ZM, et al. **IEEE Trans Biomed Eng** 1996 Jan;43(1):15-23

Unicameral bone cyst of the patella. A case report. Saglik Y, et al. **Int Orthop** 1995;19(5):280-1 (15 ref.)

Magnetic resonance imaging of patellar tendonitis. Johnson DP, et al. **J Bone Joint Surg Br** 1996 May;78(3):452-7

Nerve regeneration during patellar tendon autograft remodelling after anterior cruciate ligament reconstruction: an experimental and clinical study. Aune AK, et al. **J Orthop Res** 1996 Mar;14(2):193-9

Intraoperative force-setting did not improve the mechanical properties of an augmented bone-tendon-bone anterior cruciate ligament graft in a goat model. Smith JJ, et al. **J Orthop Res** 1996 Mar;14(2):209-15

Erythrocyte sedimentation rate and C reactive protein in the assessment of suspected bone infection--are they reliable indices? Perry M. **J R Coll Surg Edinb** 1996 Apr; 41(2):116-8

Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939-41 (22 ref.)

Patellar tendonitis: clinical and literature review [published erratum appears in Knee Surg Sports Traumatol Arthrosc 1996;3(4):233] Duri ZA, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):95-100

Surgical treatment of patellar tendinitis. Fritschy D, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):131-3

The correlation of bone scintigraphy and histological findings in patellar tendinitis. Green JS, et al. **Nucl Med Commun** 1996 Mar;17(3):231-4

Patella tendon rupture: a late complication of a tibial nail. Kretzler JE, et al. **Orthopedics** 1995 Nov;18(11):1109-11

Timing and intensity of vastus muscle activity during functional activities in subjects with and without patellofemoral pain. Powers CM, et al. **Phys Ther** 1996 Sep;76(9):946-55; discussion 956-67

Patellar tendinitis: MR imaging features, with suggested pathogenesis and proposed classification. McLoughlin RF, et al. **Radiology** 1995 Dec;197(3):843-8

Patellar tendinitis--a case report of elongation and ossification of the inferior pole of the patella. Grossfeld SL, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):308-10

Patellofemoral pain syndrome in young women. I. A clinical analysis of alignment, pain parameters, common symptoms and functional activity level. Thomeé R, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):237-44

Treatment of a coxofemoral luxation secondary to upward fixation of the patella in a Shetland pony. Clegg PD, et al. **Vet Rec** 1996 Feb 10;138(6):134-7

[The puncture of the knee] Wybier M, et al. **Ann Radiol (Paris)** 1995;38(5):284-6 (Eng. Abstr.) **(Fre)**

[Quadriceps dysplasia and patellar tilt in objective patellar instability] Nove-Josserand L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):497-504 (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Small patella syndrome. Kozlowski K, et al. **Am J Med Genet** 1995 Jul 17;57(4):558-61

Complications of extensor mechanism surgery for patellar malalignment. Flandry F, et al. **Am J Orthop** 1995 Jul; 24(7):534-43 (25 ref.)

Dorsal defect of the patella: an uncommon cause of knee pain. Narváez J, et al. **Arthritis Rheum** 1996 Jul; 39(7):1244-5

Bone-scintigraphy in painful bipartite patella. Iossifidis A, et al. **Eur J Nucl Med** 1995 Oct;22(10):1212-3

Double congenital patella: case report and review of the literature. Visconti D, et al. **Eur Radiol** 1996;6(4):566-9 (7 ref.)

Double patella syndrome with a form of multiple epiphyseal dysplasia. Yochum TR, et al. **J Manipulative Physiol Ther** 1995 Jul-Aug;18(6):407-10 (11 ref.)

[Modification of patella alta, patella ventralization en patella lateralization in patellar pain syndrome following implantation of total GSB endoprosthesis] Nebelung W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov-Dec;133(6):535-8 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Patellar height on sagittal MR imaging of the knee. Miller TT, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):339-41

The thickness of the subchondral plate and its correlation with the thickness of the uncalcified articular cartilage in the human patella. Milz S, et al. **Anat Embryol (Berl)** 1995 Nov;192(5):437-44

Patella of selected bats: patterns of occurrence or absence and associated modifications of the quadriceps femoris tendon. Smith BJ, et al. **Anat Rec** 1995 Aug;242(4):575-80

Influence of patellar thickness on patellar tracking and patellofemoral contact characteristics after total knee arthroplasty. Hsu HC, et al. **J Arthroplasty** 1996 Jan; 11(1):69-80

Assessment of patellar height after autogenous patellar tendon anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Orthopedics** 1995 Nov;18(11):1073-7

Thickness of patellofemoral articular cartilage as measured on MR imaging: sequence comparison of accuracy, reproducibility, and interobserver variation. van Leersum MD, et al. **Skeletal Radiol** 1995 Aug;24(6):431-5

CHEMISTRY

Proteoglycan depletion and size reduction in lesions of early grade chondromalacia of the patella. Väätäinen U, et al. **Ann Rheum Dis** 1995 Oct;54(10):831-5

INJURIES

Late presentation of bilateral habitual dislocation of the patella on flexion. Marston RA, et al. **Acta Orthop Belg** 1995;61(3):235-7

Stress fracture of the patella. Piétu G, et al. **Acta Orthop Scand** 1995 Oct;66(5):481-2

Subtle fractures about the knee: innocuous-appearing yet indicative of significant internal derangement. Delzell PB, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):699-703

Instrumented measurement of patellar mobility. Fithian DC, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):607-15

Acute dislocation of the patella. A correlative pathoanatomic study. Sallay PI, et al. **Am J Sports Med** 1996 Jan-Feb; 24(1):52-60

Post-traumatic differential osteoporosis of the patella. Satku K, et al. **Ann Acad Med Singapore** 1995 May;24(3):479-81

Biodegradable wire fixation in olecranon and patella fractures combined with biodegradable screws or plugs and compared with metallic fixation. Juutilainen T, et al. **Arch Orthop Trauma Surg** 1995;114(6):319-23

Patellar dislocation after total knee arthroplasty. Wang ST, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May; 57(5):348-54

External tibial torsion: an underrecognized cause of recurrent patellar dislocation. Cameron JC, et al. **Clin Orthop** 1996 Jul;(328):177-84

Biodegradable pin fixation of osteochondral fragments of the knee. Matsusue Y, et al. **Clin Orthop** 1996 Jan;(322):166-73

An unusual case of irreducible intra-articular patellar dislocation with vertical axis rotation. Gidden DJ, et al. **Injury** 1995 Nov;26(9):643-4

Acute traumatic patellar dislocation: the importance of skyline views [letter] Newman JH. **Injury** 1995 Dec; 26(10):709

Mechanical responses of the rabbit patello-femoral joint to blunt impact. Haut RC, et al. **J Biomech Eng** 1995 Nov; 117(4):402-8

An analytical model to study blunt impact response of the rabbit P-F joint. Li X, et al. **J Biomech Eng** 1995 Nov; 117(4):485-91

Demonstration of avulsion fracture of the inferior pole of the patella by magnetic resonance imaging. A case report. Shands PA, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1721-3

Subfracture insult to the human cadaver patellofemoral joint produces occult injury. Atkinson PJ, et al. **J Orthop Res** 1995 Nov;13(6):936-44

Open fractures of the patella: long-term functional outcome. Catalano JB, et al. **J Trauma** 1995 Sep;39(3):439-44

Early development of patella infera after knee fractures. Mariani PP, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):166-9

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401-11 (30 ref.)

Patellar tendinosis (jumper's knee): findings at histopathologic examination, US, and MR imaging. Victorian Institute of Sport Tendon Study Group. Khan KM, et al. **Radiology** 1996 Sep;200(3):821-7

Patellar fatigue fractures. Mason RW, et al. **Skeletal Radiol** 1996 May;25(4):329-32

[Patellar subluxation: where are we in 1995? (see comments)] Dupont JY. **Acta Orthop Belg** 1995;61(3):155-68 (43 ref.) (Eng. Abstr.). Comment in: Acta Orthop Belg 1996 Mar;62(1):71. **(Fre)**

[Patellar subluxation: where are we today in 1995? Acta Orthopaedica Belgica 61:155-168, 1995. J.Y. Dupont (letter; comment)] Handelberg F, et al. **Acta Orthop Belg** 1996 Mar;62(1):71. Comment on: Acta Orthop Belg 1995;61(3):155-68. **(Fre)**

[Progressive fragmentation of a bipartite patella: apropos of a case] Eberhard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):78-80 (Eng. Abstr.) **(Fre)**

[Inter-trochleo-bicondylar fracture of the femur. An unusually traumatic lesion. Mechanism. Therapeutic implications] Vichard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):736-40 (Eng. Abstr.) **(Fre)**

[Differential indications for so-called "lateral release" in treatment of chondropathia patellae] Schultz W, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):13-8 (Eng. Abstr.) **(Ger)**

[Critical assessment of indications for arthroscopic lateral release and medial tightening of the knee joint] Schneider T, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun; 134(3):238-45 (Eng. Abstr.) **(Ger)**

PATHOLOGY

MR diagnosis of retropatellar chondral lesions under compression. A comparison with histological findings. Andresen R, et al. **Acta Radiol** 1996 Jan;37(1):91-7

Immunohistologic analysis of synovium in infrapatellar fat pad after anterior cruciate ligament injury. Murakami S, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):763-8

Pathological infrapatellar plica: a report of two cases and literature review. Kim SJ, et al. **Arthroscopy** 1996 Apr; 12(2):236-9 (18 ref.)

Knee pain after tibial nailing [letter] McCormack D, et al. **J Bone Joint Surg Br** 1996 May;78(3):511

MR imaging of the patellofemoral compartment. Quinn SF, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):425-40 (53 ref.)

Hemorrhagic prepatellar bursitis. Donahue F, et al. **Skeletal Radiol** 1996 Apr;25(3):298-301

[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21-9 (37 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Effect of medial displacement of the tibial tubercle on patellar position after rotational malposition of the femoral component in total knee arthroplasty. Nagamine R, et al. **J Arthroplasty** 1996 Jan;11(1):104-10

The biomechanics of the human patella during passive knee flexion. Heegaard J, et al. **J Biomech** 1995 Nov; 28(11):1265-79

PHYSIOPATHOLOGY

Patellar taping in the treatment of patellofemoral pain. A prospective randomized study. Kowall MG, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):61-6

Patellar taping: a radiographic examination of the medial

glide technique. Larsen B, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):465–71

Effects of restressing on the mechanical properties of stress–shielded patellar tendons in rabbits. Yamamoto N, et al. **J Biomech Eng** 1996 May;118(2):216–20

Biomechanical effects of stress shielding of the rabbit patellar tendon depend on the degree of stress reduction. Majima T, et al. **J Orthop Res** 1996 May;14(3):377–83

Electrical stimulation of vastus medialis and stretching of lateral thigh muscles in patients with patello–femoral symptoms. Werner S, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(2):85–92

Effect of taping the patella on concentric and eccentric torque and EMG of knee extensor and flexor muscles in patients with patellofemoral pain syndrome. Werner S, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):169–77

Patellofemoral pain syndrome in young women. II. Muscle function in patients and healthy controls. Thomeé R, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):245–51

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al.
Sports Med 1996 May;21(5):384–91 (55 ref.)

RADIATION EFFECTS

Dose–dependent response of gamma irradiation on mechanical properties and related biochemical composition of goat bone–patellar tendon–bone allografts. Salehpour A, et al. **J Orthop Res** 1995 Nov;13(6):898–906

RADIOGRAPHY

Patellofemoral joint study via image processing. Gao JX, et al. **Biomed Sci Instrum** 1996;32:151–60

Axial radiography or CT in the measurement of patellofemoral malalignment indices in children and adolescents? Vähäsarja V, et al. **Clin Radiol** 1996 Sep; 51(9):639–43

Patellar fatigue fractures. Mason RW, et al.
Skeletal Radiol 1996 May;25(4):329–32

[Practical value of the descending ray angle in the axial femoropatellar study. Sensitizing role of external rotation of the skeleton of the leg in the 30 degree F.P angle] Patrux C. **Ann Radiol (Paris)** 1995;38(5):237–43 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Bone–scintigraphy in painful bipartite patella. Iossifidis A, et al. **Eur J Nucl Med** 1995 Oct;22(10):1212–3

SURGERY

Arthroscopic proximal patella realignment and stabilization. Henry JE, et al. **Arthroscopy** 1995 Aug;11(4):424–5

Is there a place for patellofemoral arthroplasty? Argenson JN, et al. **Clin Orthop** 1995 Dec;(321):162–7

Resurfacing versus not resurfacing the patella during total knee replacement. Bourne RB, et al. **Clin Orthop** 1995 Dec; (321):156–61

Patellofemoral arthroplasty. A 2– to 18–year followup study. Krajca–Radcliffe JB, et al. **Clin Orthop** 1996 Sep; (330):143–51

Patellar reconstruction of the condyles in giant cell tumours of the knee. Farooque M, et al. **Int Orthop** 1995;19(6):355–8

The influence of the position of the patellar component on tracking in total knee arthroplasty. Nelissen RG, et al.
Int Orthop 1995;19(4):224–8

Management of patellar clunk under local anesthesia. Messieh M. **J Arthroplasty** 1996 Feb;11(2):202–3

Patellar clunk syndrome in total knee arthroplasty without patellar resurfacing. Shoji H, et al. **J Arthroplasty** 1996 Feb;11(2):198–201

Total knee arthroplasty after a previous patellectomy. Paletta GA Jr, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1708–12

Patellar resurfacing versus retention in total knee arthroplasty. Feller JA, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):226–8

Fixation strength of a biodegradable screw in anterior cruciate ligament reconstruction. Kousa P, et al.
J Bone Joint Surg Br 1995 Nov;77(6):901–5

Open fractures of the patella: long–term functional outcome. Catalano JB, et al. **J Trauma** 1995 Sep;39(3):439–44

Patellectomy and osteoarthritis: arthroscopic findings following previous patellectomy. Feller JA, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(3–4):159–61

Prospective long–term results of operative treatment in primary dislocation of the patella. Harilainen A, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(2):100–3

Donor–site morbidity after harvest of a bone–tendon–bone patellar tendon autograft. Kohn D, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(4):219–23

A new surgical procedure for the treatment of patella infera. Mariani PP. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(4):238–41

Controversial issues in knee arthroplasty. Rorabeck CH, et al. **Orthopedics** 1995 Sep;18(9):905–14

Comparison of arthroscopy and arthrotomy for the treatment of osteochondritic lesions in the femoropatellar joint of horses. Vatistas NJ, et al. **Vet Rec** 1995 Dec 16; 137(25):629–32

[Treatment of posterior cruciate ligament rupture and recent knee dislocations by olecranisation of the patella without surgical repair] Rouvillain JL, et al. **Int Orthop** 1995; 19(5):269–74 (Eng. Abstr.) **(Fre)**

[Postoperative low patella. Treatment by lengthening of the patellar tendon] Dejour D, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(4):286–95 (Eng. Abstr.) **(Fre)**

[Patellar osteochondrosis dissecans––results of surgical therapy] Bruns J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb;134(1):7–10 (Eng. Abstr.) **(Ger)**

[Modification of patella alta, patella ventralization en patella lateralization in patellar pain syndrome following implantation of total GSB endoprosthesis] Nebelung W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):535–8 (Eng. Abstr.) **(Ger)**

[Lateral release of the patella. I—Diagnostics, indications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(3):231–4 (19 ref.) (Eng. Abstr.) **(Pol)**

[Lateral release of the patella. II. Arthroscopic technique of subcutaneous lateral release, complications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994;59(3):235–8 (19 ref.) (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Autograft bone–patella tendon–bone plug comminution with loss of ligament fixation and stability. Berg EE.
Arthroscopy 1996 Apr;12(2):232–5

An unusual intrinsic complication of a patellar tendon allograft and recommendations for tissue banking. Tarandy DI, et al. **Arthroscopy** 1995 Aug;11(4):475–7

ULTRASONOGRAPHY

The association of patellar ultrasound transmissions and forearm densitometry with vertebral fracture, number and severity: the Saunders County Bone Quality Study. Stegman MR, et al. **Osteoporos Int** 1996;6(2):130–5

PATELLAR LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
MEDIAL COLLATERAL LIGAMENT, KNEE
POSTERIOR CRUCIATE LIGAMENT

Early development of patella infera after knee fractures. Mariani PP, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):166–9

[Imaging of external instabilities of the patella. State of the art] Frot B, et al. **J Radiol** 1996 Jan;77(1):5–15 (36 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

The medial patellofemoral ligament revisited: an anatomical study. Feller JA, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(3–4):184–6

INJURIES

Quasi–synchronous patellar tendon rupture. N'Dow J, et al.
Bull Hosp Jt Dis 1995;54(1):46–8

Late reconstruction of patellar ligament ruptures using Ilizarov external fixation. Isiklar ZU, et al. **Clin Orthop** 1996 Jan;(322):174–8

Demonstration of avulsion fracture of the inferior pole of the patella by magnetic resonance imaging. A case report. Shands PA, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1721–3

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)

PHYSIOLOGY

A biomechanical comparison between the central one–third patellar tendon and the residual tendon. Matava MJ, et al. **Br J Sports Med** 1995 Sep;29(3):178–84

Human myotatic reflex development of the lower extremities. Leonard CT, et al. **Early Hum Dev** 1995 Aug 30;43(1):75–93

Transient introduction of a foreign gene into healing rat patellar ligament. Nakamura N, et al. **J Clin Invest** 1996 Jan 1;97(1):226–31

SURGERY

Biomechanical assessment of the healing response of the rabbit patellar tendon after removal of its central third. Beynnon BD, et al. **Am J Sports Med** 1995 Jul–Aug; 23(4):452–7

Late reconstruction of patellar ligament ruptures using Ilizarov external fixation. Isiklar ZU, et al. **Clin Orthop** 1996 Jan;(322):174–8

Bilateral upward patellar fixation in two pregnant beef heifers. Husband JA, et al. **Vet Rec** 1995 Oct 28; 137(18):464–5

TRANSPLANTATION

Strategies for attachment site locations and twist of the intraarticular anterior cruciate ligament graft. Draganich LF, et al. **Am J Sports Med** 1996 May–Jun;24(3):342–9

Radiographic evaluation of native anterior cruciate ligament attachments and graft placement for reconstruction. A cadaveric study. Lintner DM, et al. **Am J Sports Med** 1996 Jan–Feb;24(1):72–8

Anterior cruciate ligament graft rotation. Reproduction of normal graft rotation. Samuelson TS, et al.
Am J Sports Med 1996 Jan–Feb;24(1):67–71

Timing of surgery in acute anterior cruciate ligament tears on the return of quadriceps muscle strength after reconstruction using an autogenous patellar tendon graft. Shelbourne KD, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):686–9

Patellar tendon graft harvesting using horizontal incisions for anterior cruciate ligament reconstruction. Mishra AK, et al. **Arthroscopy** 1995 Dec;11(6):749–52

Use of the "blue dot" in femoral bone plug of bone–patellar tendon–bone graft in anterior cruciate ligament reconstruction. Lonner JH, et al. **Bull Hosp Jt Dis** 1993–95; 53(4):45–7

Arthroscopically assisted ACL reconstruction using central third patellar tendon autograft with press fit femoral fixation. Malek MM, et al. **Instr Course Lect** 1996;45:287–95

Intraoperative complications of arthroscopically assisted ACL reconstruction using patellar tendon autograft. Malek MM, et al. **Instr Course Lect** 1996;45:297–302

ACL reconstruction using the autogenous bone–patellar tendon–bone graft: open two–incision technique. Shelbourne KD, et al. **Instr Course Lect** 1996;45:245–52

Reconstruction of the anterior cruciate ligament with human allograft. Comparison of early and later results. Noyes FR, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):524–37

The tendon defect after anterior cruciate ligament reconstruction using the midthird patellar tendon––a problem for the patellofemoral joint? Breitfuss H, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):194–8

[Distal reconstruction of the Achilles tendon with a bone–tendon graft from extensor system of the knee] Besse JL, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(5):453–7 (Eng. Abstr.) **(Fre)**

[Clinical relevance of tunnel position and interference screw location after replacement–plasty of the anterior cruciate ligament with a patellar ligament transplant] Rupp S, et al. **Unfallchirurg** 1995 Dec;98(12):650–4 (Eng. Abstr.) **(Ger)**

PATENCY, VASCULAR see **VASCULAR PATENCY**

PATENT MEDICINES see **DRUGS, NON-PRESCRIPTION**

PATENTS

The usefulness of method patents for surgical procedures. Longacre JR, et al. **Ann Vasc Surg** 1996 Jan;10(1):1–3

Patenting gene sequences [editorial] Caplan AL, et al.
BMJ 1996 Apr 13;312(7036):926

Europe needs gene patent laws [news] Dorozynski A.
BMJ 1996 Apr 6;312(7035):868

Doctor wins claim over patent ownership [news] Dyer C, et al. **BMJ** 1995 Nov 11;311(7015):1248

US awards patent for tribesman's DNA [news] Dyer O.
BMJ 1995 Dec 2;311(7018):1452

Researchers face patent race for breast cancer gene [news] Dyer O. **BMJ** 1996 Jan 6;312(7022):12

US gene discovery leads to patent war [news] Roberts J.
BMJ 1996 Jun 1;312(7043):1378

The GATT TRIPS agreement and health care in India. Otten A. **Ceylon Med J** 1995 Sep;40(3):91–3

Innovators. A doc who doubles as inventor. Turner S.
Hosp Health Netw 1996 Feb 20;70(4):62

Bioluminescence and chemiluminescence literature. The 1994 Literature: Part 3. Kricka LJ, et al.
J Biolumin Chemilumin 1995 Sep–Oct;10(5):301–22

Biotech's uncertain present [editorial] [see comments]
Lancet 1996 Jun 1;347(9014):1497. Comment in: Lancet 1996 Jul 27;348(9022):263–4.

FISH tales [news] Featherstone C. **Mol Med Today** 1996 Mar;2(3):92

Go fish for patents [editorial; comment] **Nature** 1995 Nov 30;378(6556):424. Comment on: Nature 1995 Nov 30;378(6556):425.

One way out of a patent quagmire [editorial] **Nature** 1996 May 16;381(6579):175

US coalition counters breast gene patents [news] **Nature** 1996 May 23;381(6580):265

European proposal reopens debate over patenting of human genes [news] [see comments] Abbott A. **Nature** 1995 Dec 21–28;378(6559):756. Comment in: Nature 1996 Feb 22;379(6567):672.

Europe tries again on biotechnology patents [news] Abbott A. **Nature** 1995 Nov 23;378(6555):328

Oncomouse hearing ends up in confusion [news] Abbott A.
Nature 1995 Nov 30;378(6556):427

Application for patent opposed [letter] Asano S, et al.
Nature 1996 Sep 5;383(6595):17

Genes, patents and insurance [letter; comment] Aston DJ. **Nature** 1996 Feb 22;379(6567):672. Comment on: Nature 1995 Dec 7;378(6557):534–6.

Patents and indigenous lore [letter; comment] Balasubramanian D. **Nature** 1995 Dec 7;378(6557):532. Comment on: Nature 1995 Sep 14;377(6545):89–90.

US company comes under fire over patent on umbilical cord cells [news] Butler D. **Nature** 1996 Jul 11;382(6587):99

Why genes can be patented [letter; comment] Carey NH. **Nature** 1996 Feb 8;379(6565):484. Comment on: Nature 1995 Dec 7;378(6557):534–6. Comment on: Nature 1996 Jan 11;379(6561):111.

PATENTS

Merck, SmithKline and patents [letter; comment] Caskey CT, et al. **Nature** 1996 May 30;381(6581):360. Comment on: Nature 1995 Dec 7;378(6557):534–6.
Ownership of human genes [letter; comment] Cook-Deegan RM, et al. **Nature** 1996 Jul 4;382(6586):17–8. Comment on: Nature 1996 Apr 4;380(6573):387–8.
Gene patenting [letter; comment] [see comments] Davison F. **Nature** 1996 Jan 11;379(6561):111. Comment on: Nature 1995 Dec 7;378(6557):534–6. Comment in: Nature 1996 Feb 8;379(6565):484.
Roche fails to get European patent on Taq polymerase [news] Dickson D. **Nature** 1996 Jul 11;382(6587):100
Open access to sequence data 'will boost hunt for breast cancer gene' [news][see comments] Dickson D. **Nature** 1995 Nov 30;378(6556):425. Comment in: Nature 1995 Nov 30;378(6556):424.
UK court rejects appeal over hepatitis C kits [news] Dickson D. **Nature** 1995 Nov 30;378(6556):425
'Leak' rumours fuel debate on gene patent [news] Dickson D. **Nature** 1996 Feb 15;379(6566):574
Patents versus transplants [letter] Gluckman E, et al. **Nature** 1996 Jul 11;382(6587):108
Anthropologist cleared in patent dispute [news] Lehrman S. **Nature** 1996 Apr 4;380(6573):374
The case for genomic patenting [see comments] Poste G. **Nature** 1995 Dec 7;378(6557):534–6. Comment in: Nature 1996 Jan 11;379(6561):111. Comment in: Nature 1996 Jan 25;379(6563):294. Comment in: Nature 1996 Feb 8;379(6565):484. Comment in: Nature 1996 Feb 22;379(6567):672. Comment in: Nature 1996 May 30;381(6581):360.
Ethics of genomic patenting [letter; comment] Shapiro D. **Nature** 1996 Jan 25;379(6563):294. Comment on: Nature 1995 Dec 7;378(6557):534–6.
Genes, patents and insurance [letter; comment] Stevenson P. **Nature** 1996 Feb 22;379(6567):672. Comment on: Nature 1995 Dec 21–28;378(6559):756.
Ownership of the human genome [see comments] Thomas SM, et al. **Nature** 1996 Apr 4;380(6573):387–8. Comment in: Nature 1996 Jul 4;382(6586):17–8.
The development and dissemination of non-patentable therapies (NPTs). Root-Bernstein RS. **Perspect Biol Med** 1995 Autumn;39(1):110–7 (26 ref.)
Promega wins round in fight over Taq [news] Barinaga M. **Science** 1996 Aug 23;273(5278):1039
Genetic patents [letter; comment] Bereano PL. **Science** 1996 Jan 5;271(5245):14. Comment on: Science 1995 Nov 17;270(5239):1112.
Religion and gene patenting. Cole-Turner R. **Science** 1995 Oct 6;270(5233):52
Patent law closes drug loophole [news] Caillag C. **Science** 1996 May 17;272(5264):945–6
New anticoagulant prompts bad blood between partners [news] [see comments] Friedly J. **Science** 1996 Mar 29; 271(5257):1800–1. Comment in: Science 1996 May 24;272(5265):1085. Comment in: Science 1996 May 24;272(5265):1086.
Patents. New biotech law shores up U.S. firms [news] Kaiser J. **Science** 1995 Nov 3;270(5237):728
Rifkin's latest target: genetic testing [news] Marshall E. **Science** 1996 May 24;272(5265):1094
DNA Patents. Patent office faces 90-year backlog [news] Marshall E. **Science** 1996 May 3;272(5262):643
Trial set to focus on peer review [news] Marshall E. **Science** 1996 Aug 30;273(5279):1162–4
Scientists attacked for 'patenting' Pacific tribe [news] [see comments] Taubes G. **Science** 1995 Nov 17;270(5239):1112 . Comment in: Science 1996 Jan 5;271(5245):14.

HISTORY

What's in a name? Henry Dale and adrenaline, 1906. Tansey EM. **Med Hist** 1995 Oct;39(4):459–76
[Patents in the pharmaceutical field: history and development of the institution] Neri M. **Boll Chim Farm** 1995 Jul–Aug; 134(7):364–8 (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Changes in U.S. patent law for pharmaceuticals. Bruderle TP. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2088, 2091
Patently unethical [editorial] Morain WD. **Ann Plast Surg** 1996 Mar;36(3):334
US could ban patents on medical procedures [news] Gene-McDaniel C. **BMJ** 1996 Apr 20;312(7037):997
Why the European Parliament rejected the patenting of human genes [editorial] Grace M. **Gene Ther** 1995 Oct; 2(8):509–11
The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM. **J Contemp Health Law Policy** 1996 Spring;12(2):607–36 (176 ref.)
Patenting of pure surgical and other medical procedures. Medical community's response and need for a legislative solution. Coble YD Jr, et al. **J Fla Med Assoc** 1996 May; 83(5):329–31
Researchers coping with sensitive patent issues [news] McIntosh H. **J Natl Cancer Inst** 1996 Sep 4;88(17):1180–2
Roche faces charges over Taq patent claim [news] Abbott A. **Nature** 1996 Aug 22;382(6593):660

PATERNAL AGE

The relationship between paternal age, sex ratios, and aneuploidy frequencies in human sperm, as assessed by multicolor FISH. Martin RH, et al. **Am J Hum Genet** 1995 Dec;57(6):1395–9
The ages of fathers in California adolescent births, 1993. Males M, et al. **Am J Public Health** 1996 Apr;86(4):565–8
Parental age and breast cancer mortality. Holmberg L, et al. **Epidemiology** 1995 Jul;6(4):425–7
Paternal age and Down syndrome in British Columbia [letter; comment] Hook EB. **Epidemiology** 1995 Nov;6(6):640–1. Comment on: Epidemiology 1995 May;6(3):282–8.
How old are U.S. fathers? Landry DJ, et al. **Fam Plann Perspect** 1995 Jul–Aug;27(4):159–61, 165
High parental age is associated with sporadic hereditary retinoblastoma: the Dutch retinoblastoma register 1862–1994. Moll AC, et al. **Hum Genet** 1996 Jul; 98(1):109–12
Non-disjunction in human sperm: evidence for an effect of increasing paternal age. Griffin DK, et al. **Hum Mol Genet** 1995 Dec;4(12):2227–32
Intrauterine growth retardation as an endpoint in mutation epidemiology: an evaluation based on paternal age. Olshan AF, et al. **Mutat Res** 1995 Aug;344(1–2):89–94

PATERNAL BEHAVIOR

Triadic male-female-infant relationships and bridging behaviour among Tibetan macaques (Macaca thibetana). Ogawa H. **Folia Primatol (Basel)** 1995;64(3):153–7
The effects of paternity on interactions between adult male and immature chimpanzees in captivity. Pruetz JD, et al. **Folia Primatol (Basel)** 1995;65(3):174–80
Heritability of nestling growth in cross-fostered European Starlings Sturnus vulgaris. Smith HG, et al. **Genetics** 1995 Oct;141(2):657–65
Hormonal responses of male gerbils to stimuli from their mate and pups. Brown RE, et al. **Horm Behav** 1995 Dec; 29(4):474–91
Preoptic area lesions disrupt prolactin-induced parental feeding behavior in ring doves. Slawski BA, et al. **Horm Behav** 1995 Jun;29(2):248–66
Parent–child relationship disorders. Part I. Parental overprotection and the development of the Parent Protection Scale. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):244–50
Parent–child relationship disorders. Part II. The vulnerable child syndrome and its relation to parental overprotection. Thomasgard M, et al. **J Dev Behav Pediatr** 1995 Aug; 16(4):251–6
Inhibitory effects of naltrexone on the induction of parental behavior in juvenile rats. Zaias J, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):987–93
DNA fingerprinting reveals female preference for male parental care in Savannah Sparrows. Freeman-Gallant CR. **Proc R Soc Lond B Biol Sci** 1996 Feb 22;263(1367):157–60
Negative evaluations of men's nurturant touching of young children. Rane TR, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):811–8

PATERNAL DEPRIVATION

Familial prolactinoma [letter; comment] Sobrinho LG. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):511. Comment on: Clin Endocrinol (Oxf) 1995 May;42(5):483–6.
Responses of infant titi monkeys, Callicebus moloch, to removal of one or both parents: evidence for paternal attachment. Hoffman KA, et al. **Dev Psychobiol** 1995 Nov; 28(7):399–407
Childhood parental loss and alcoholism in women: a causal analysis using a twin-family design. Kendler KS, et al. **Psychol Med** 1996 Jan;26(1):79–95
Parental loss and family violence as correlates of suicide and violence risk. Botsis AJ, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):253–60

PATERNAL EXPOSURE

see related
MATERNAL EXPOSURE

Take-home lead poisoning in a child from his father's occupational exposure. Gerson M, et al. **Am J Ind Med** 1996 May;29(5):507–8
Childhood cancer and paternal exposure to ionizing radiation: a second report from the Oxford Survey of Childhood Cancers. Sorahan T, et al. **Am J Ind Med** 1995 Jul; 28(1):71–8
Leukaemia and non-Hodgkin's lymphoma in young persons resident in small areas of West Cumbria in relation to paternal preconceptional irradiation. Wakeford R, et al. **Br J Cancer** 1996 Mar;73(5):672–9
Life span and tumours in the first-generation offspring of the gamma-irradiated male mouse. Iwasaki T, et al. **Int J Radiat Biol** 1996 Apr;69(4):487–92
Reduced fertility after the crash of a U.S. bomber carrying nuclear weapons? A register-based study on male fertility. Juel K. **J Clin Epidemiol** 1995 Oct;48(10):1261–7
Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908–14 (48 ref.)
Reproductive epidemiology in sulfonamide factory workers. Prasad MH, et al. **J Toxicol Environ Health** 1996 Feb 9; 47(2):109–14
Developmental exposure to ozone induces subtle changes in swimming navigation of adult mice. Dell'Omo G, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):91–9

ADVERSE EFFECTS

Testicular cancer and parental use of fertilizers in agriculture. Kristensen P, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):3–9
Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)
Dibromochloropropane (DBCP): a 17-year reassessment of testicular function and reproductive performance. Potashnik G, et al. **J Occup Environ Med** 1995 Nov; 37(11):1287–92
Health of children born to medical radiographers. Roman E, et al. **Occup Environ Med** 1996 Feb;53(2):73–9
Male-mediated risk of spontaneous abortion with reference to stainless steel welding. Hjollund NH, et al. **Scand J Work Environ Health** 1995 Aug;21(4):272–6

PATERNITY

see related
DNA FINGERPRINTING

Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay. Delahunty C, et al. **Am J Hum Genet** 1996 Jun; 58(6):1239–46
Prenatal paternity testing with deoxyribonucleic acid techniques. Strom CM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1849–53; discussion 1853–4
Successful paternity of twins following bone marrow transplantation with busulfan, melphalan and cyclophosphamide conditioning. Shepherd JD, et al. **Bone Marrow Transplant** 1996 Mar;17(3):461–2
Polymorphic human specific Alu insertions as markers for human identification. Novick GE, et al. **Electrophoresis** 1995 Sep;16(9):1596–601
Oligonucleotide (CAC)5 fingerprinting: validity and reliability in paternity testing. Papiha SS, et al. **Electrophoresis** 1995 Sep;16(9):1624–6
DNA fingerprinting to determine paternity in laboratory rat sperm competition experiments. Shimmin GA, et al. **Electrophoresis** 1995 Sep;16(9):1627–32
The effects of paternity on interactions between adult male and immature chimpanzees in captivity. Pruetz JD, et al. **Folia Primatol (Basel)** 1995;65(3):174–80
The STR system hTPO: population and segregation data. Gusmão L, et al. **Int J Legal Med** 1995;108(3):167–9
Paternity evaluation in cases lacking a mother and nondetectable alleles [letter; comment] Luque JA, et al. **Int J Legal Med** 1996;108(4):229. Comment on: Int J Legal Med 1994;107(3):127–31.
Observation of null alleles apparently due to deletions. Möller A, et al. **Int J Legal Med** 1995;108(2):90–2
High-resolution vertical PAGE: an alternative electrophoretic system with multiple forensic applications. Schneider HR, et al. **Int J Legal Med** 1996;108(5):276–9
Paternity exclusion by DNA markers: effects of paternal mutations. Chakraborty R, et al. **J Forensic Sci** 1996 Jul; 41(4):671–7
A validation study of four single locus probes (MS1, MS31, MS43 and g3) in a Korean population—further evaluation for paternity testing. Lee KO, et al. **J Korean Med Sci** 1995 Aug;10(4):243–9
Socioendocrine and morphological correlates of paternity in rhesus macaques (Macaca mulatta). Bercovitch FB, et al. **J Reprod Fertil** 1996 May;107(1):59–68
Dog parentage testing using canine microsatellites. Binns MM, et al. **J Small Anim Pract** 1995 Nov;36(11):493–7
Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception [letter; comment] Robillard PY, et al. **Lancet** 1996 Mar 2;347(9001):619. Comment on: Lancet 1994 Oct 8;344(8928):973–5.
Characterization of four microsatellites in an Italian population and their application to paternity testing. Sirchia SM, et al. **Mol Cell Probes** 1996 Apr;10(2):155–8
Two deficiency cases of disputed paternity: sibling or half-sibling? Kishida T, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):78–81
Microsatellite typing in a paternity case against a deceased man whose two brothers were available for testing. Tamaki Y, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):82–6
Preparation of multi-locus DNA probe cocktail by liquid-phase reassociation. Tamaki Y, et al. **Nippon Hoigaku Zasshi** 1995 Aug;49(4):251–4
Human histocompatibility complex (HLA). The distribution of HLA-ABC antigens and structure of exclusions in investigations on disputable paternity in population of north-eastern Poland. Pepiński W, et al. **Rocz Akad Med Bialymst** 1994;39:31–7
Disputed paternity: experience in Ile-Ife, Nigeria. Durosinmi MA, et al. **West Afr J Med** 1995 Apr–Jun;14(2):88–90
[An unusual case of paternity dispute resolved by examination of HLA antigens of a former wife, daughter and a sister of the deceased man] Májský A. **Cas Lek Cesk** 1996 Apr 17;135(8):255 (Eng. Abstr.) **(Cze)**
[Paternity determination using the RFLP method in DNA

probes] Lászik A, et al. **Orv Hetil** 1995 Sep 24; 136(39):2117–9 (Eng. Abstr.) **(Hun)**

[A molecular genetic approach to the forensic medical expertise of biological relationship at the early stages of embryonic development] Gyské LI, et al. **Sud Med Ekspert** 1995 Jul–Sep;38(3):36–40 (Eng. Abstr.) **(Rus)**

[Paternity study applying DNA polymorphism: evaluation of methods traditionally used in Chile] Armanet L, et al. **Rev Med Chil** 1995 May;123(5):560–6 (Eng. Abstr.) **(Spa)**

PATERNITY LEAVE see **PARENTAL LEAVE**

PATEY MASTECTOMY see **MASTECTOMY, MODIFIED RADICAL**

PATHOGEN-FREE ORGANISMS see **SPECIFIC PATHOGEN-FREE ORGANISMS**

PATHOGENS, BLOOD-BORNE see **BLOOD-BORNE PATHOGENS**

PATHOLOGICAL WASTE see **MEDICAL WASTE**

PATHOLOGY

Cytopathology in the Socialist Republic of Vietnam. Raab SS. **Acta Cytol** 1996 May–Jun;40(3):541–5

Cumulative index Vol. 1–30, 1951–1980. **Acta Pathol Jpn** 1983;:1–200

Alternate site testing. The decision-making process. Geyer SJ. **Arch Pathol Lab Med** 1995 Oct;119(10):907–8

Pathologists: supply and demand [letter; comment] West R. **Can Med Assoc J** 1995 Dec 15;153(12):1710–1. Comment on: Can Med Assoc J 1995 Sep 15;153(6):805–8.

Cell adhesion and human disease. Chairman's introduction. Hynes RO. **Ciba Found Symp** 1995;189:1

Meetings of the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, the American Association of Immunologists. New Orleans, Louisiana, June 2–6, 1996. Abstracts. **FASEB J** 1996 Apr 30;10(6):A959–1617

Confession of ignorance of causation in coroners' necropsies—a common problem? Davison AM, et al. **J Clin Pathol** 1996 Jun;49(6):439–43

Pathological Society of Great Britain and Ireland 173rd meeting. Southampton, 10–12 July 1996. Abstracts. **J Pathol** 1996;179 Suppl:1A–53A

Pathological Society of Great Britain and Ireland, 172nd meeting. London, 3–5 January 1996. Abstracts. **J Pathol** 1996;178 Suppl:1A–56A

Hazard to pathologists and anatomists from vena-caval (Greenfield) filters [letter] Abraham JL, et al. **Lancet** 1995 Oct 21;346(8982):1100

Correspondence re: Ivan Damjanov. Saxon genitive of eponyms. Mod Pathol 8:343, 1995 [letter; comment] Henson DE. **Mod Pathol** 1995 Oct;8(8):888. Comment on: Mod Pathol 1995 Apr;8(3):343.

XVth European Congress of Pathology. Copenhagen, Denmark, September 3–8, 1995. Abstracts. **Pathol Res Pract** 1995 Aug;191(7–8):604–826

XIV International Symposium of the Society of Toxicologic Pathologists. Toxicologic pathology of the liver. June 11–15, 1995, San Diego, California. Abstracts. **Toxicol Pathol** 1995 Nov–Dec;23(6):747–74

[Directory of the Society of Exotic Pathology. 1995] **Bull Soc Pathol Exot** 1995;88(2):1–78 **(Fre)**

[IVth National Congress of the Italian Federation of the Society of Pathologic Anatomy and Diagnostic Cytology. Abano Terme, 11–14 October 1995. Abstracts] **Pathologica** 1995 Aug;87(4):335–472 **(Ita)**

[The normal and the pathological] Hofmann B. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3800–2 (Eng. Abstr.) **(Nor)**

[On co-authors and pathologists (letter)] Stavem P, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):110–1 **(Nor)**

[Diagnostic errors concerning outpatients and inpatients from the pathologist-anatomist viewpoint] Shmurun RI. **Klin Med (Mosk)** 1995;73(5):79–81 **(Rus)**

EDUCATION

Viability of the autopsy outside the institutions [letter; comment] Bryant J. **Arch Pathol Lab Med** 1996 Jan; 120(1):9–10. Comment on: Arch Pathol Lab Med 1995 Mar;119(3):289–91.

Certification and training in molecular pathology [letter; comment] Arber DA, et al. **Hum Pathol** 1996 Apr; 27(4):430–1. Comment on: Hum Pathol 1995 May;26(5):467–8. Comment on: Hum Pathol 1995 Oct;26(10):1051–4.

Audit of continuing medical education for pathologists: strategies and implications. du Boulay C. **J Clin Pathol** 1996 Feb;49(2):100–1 (16 ref.)

Computer networked scanning electron microscope for teaching, research, and industry applications. Chumbley LS, et al. **Microsc Res Tech** 1995 Nov 1;32(4):330–6

The teaching of pathology in European undergraduate programs in medicine: quality assurance. Discussion of the validity and reliability of various forms of examination. Iversen OH. **Pathol Res Pract** 1996 Feb;192(2):97–100

Initial perspective from the 1995 Ad Hoc Examination Committee [letter] **Vet Pathol** 1996 Mar;33(2):252–6

Town Hall meeting on subspecialization [letter] Stephens LC, et al. **Vet Pathol** 1996 Mar;33(2):249

Town Hall meeting on subspecialization [letter] Stromberg PC. **Vet Pathol** 1996 Mar;33(2):249–52

[60-th anniversary of the Chair of Pathology at Izhevsk Medical Institute] Glumov VIa, et al. **Arkh Patol** 1995 Nov–Dec;57(6):76–7 **(Rus)**

HISTORY

In recognition of Rolla B. Bill, Jr., MD (1929–1996). Anderson RE. **Arch Pathol Lab Med** 1996 Aug; 120(8):699–701

The recent history of the autopsy. Hill RB, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):702–12

The Army Medical Museum/Armed Forces Institute of Pathology and Emerging Infections: from camp fevers and diarrhea during the American Civil War in the 1860's to global molecular epidemiology and pathology in the 1990s. Nelson AM, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):129–33 (21 ref.)

The paintings of pathological anatomy by Sir Robert Carswell (1793–1857). Hollman A. **Br Heart J** 1995 Nov; 74(5):566–70

Pathology and treatment: the case of ulcers. Crenner C. **Caduceus** 1995 Autumn;11(2):127–40

Ophthalmic pathology and the American Academy of Ophthalmology. Spencer WH. **Ophthalmology** 1996 Aug; 103(8 Suppl):S109–17

Gaetano Giulio Zumbo. The founder of anatomic wax modeling. Puccetti ML, et al. **Pathol Annu** 1995;30 Pt 2:269–81

Pierre Dustin (1914–1993), founder of the European Society of Pathology [editorial] Nezelof C. **Pathol Res Pract** 1995 Jul;191(6):487–9

Pathological anatomy in Denmark, a historical survey. Schiødt T. **Pathol Res Pract** 1995 Aug;191(7–8):599–601

[Brief history of Chinese Journal of Pathology in the past 40 years] Ding L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):200–4 **(Chi)**

[Essay on the history of the Pathology service in the Soviet Army] Smol'iannikov AV, et al. **Arkh Patol** 1995 Sep–Oct; 57(5):6–14 **(Rus)**

[The Lvov school of clinical pathologists] Zerbino DD. **Lik Sprava** 1995 May–Jun;(5–6):183–9 (Eng. Abstr.) **(Ukr)**

INSTRUMENTATION

[Computer-assisted speech recognition in diagnostic pathology. Development of the DragonDictate-30 K system for documentation] Kolles H, et al. **Pathologe** 1995 Nov;16(6):439–42 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Establishing standards of care [letter] Skoumal SM. **Diagn Cytopathol** 1996 May;14(3):284–5

Pathologists enter debate on consent for genetic research on stored tissue [news] Stephenson J. **JAMA** 1996 Feb 21; 275(7):503–4

[How unpolitical may in current times pathology actually be? (editorial)] Schwarze EW. **Pathologe** 1996 May; 17(3):177–80 **(Ger)**

METHODS

Image management in pathology. Weinberg DS, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S54–9 (20 ref.)

Image cytometric analysis in pathology. Cohen C. **Hum Pathol** 1996 May;27(5):482–93

Image cytometric analysis in pathology [editorial] Herman CJ. **Hum Pathol** 1996 May;27(5):435–6

Morphometric applications in anatomic pathology. True LD. **Hum Pathol** 1996 May;27(5):450–67

SENEX: a CLOS/CLIM application for molecular pathology. Ball SS, et al. **Ismb** 1993;1:38–46

Artificial neural networks in pathology and medical laboratories [see comments] Dybowski R, et al. **Lancet** 1995 Nov 4;346(8984):1203–7 (34 ref.). Comment in: Lancet 1995 Nov 4;346(8984):1175–7. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.

Guardians of the wax ... and the patient [editorial] Mills SE, et al. **Mod Pathol** 1995 Sep;8(7):699–700

Fractals in pathology: are they really useful? Losa GA. **Pathologica** 1995 Jun;87(3):310–7 (74 ref.)

[In situ gene amplification on tissue sections (in situ PCR). A new technique for pathologists] Walker F, et al. **Ann Pathol** 1995;15(6):459–65 (Eng. Abstr.) **(Fre)**

[Microsensory systems in cell biology basic research and medical diagnostics] Brischwein M, et al. **Naturwissenschaften** 1996 May;83(5):193–200 (28 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

College of American Pathologists Conference XXIX on restructuring autopsy practice for health care reform. Let's make this autopsy conference matter. Lundberg GD. **Arch Pathol Lab Med** 1996 Aug;120(8):736–8 (11 ref.)

Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)

Pitfalls in establishing a molecular diagnostic laboratory. Ferreira-Gonzalez A, et al. **Hum Pathol** 1996 May; 27(5):437–40

STANDARDS

Establishing standards of care [letter] Skoumal SM. **Diagn Cytopathol** 1996 May;14(3):284–5

Registry of toxicologic pathology for animals [letter] Nold JB. **Toxicol Pathol** 1995 Sep–Oct;23(5):622–3

Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

[Complaints in pathology (letter)] Peoc'h M, et al. **Ann Pathol** 1996;16(1):56 **(Fre)**

[SNOMed—international system for coding changes in medicine] Bardadin K. **Pol J Pathol** 1995;46(3):203–5 **(Pol)**

STATISTICS & NUMERICAL DATA

How to develop and use a Bayesian Belief Network. Montironi R, et al. **J Clin Pathol** 1996 Mar;49(3):194–201

TRENDS

Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Walker DH, et al. **Infect Agents Dis** 1995 Sep; 4(3):167–70 (8 ref.)

Pathology and laboratory medicine. Herman CJ, et al. **JAMA** 1996 Jun 19;275(23):1839–41

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.). Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

The pathologist in virology. Campbell RS. **Vet Microbiol** 1995 Sep;46(1–3):233–42

[Progresses in pathology in China, 1995] Wang W, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):776–7 (0 ref.) **(Chi)**

PATHOLOGY, CLINICAL

President, American Society of Clinical Pathologists. Burke MD. **Am J Clin Pathol** 1996 Jan;105(1):127–8

The Armed Forces Institute of Pathology: an underutilized repository of case material [letter] Peterson MR. **Am J Public Health** 1996 Apr;86(4):592

To judge the judges—kappa, ROC or what? Taube A. **Arch Anat Cytol Pathol** 1995;43(4):227–33

Desirable performance standards for imprecision and bias in alternate sites. The views of laboratory professionals. Fraser CG, et al. **Arch Pathol Lab Med** 1995 Oct; 119(10):909–13

College of American Pathologists Conference XXVIII on alternate site testing: breakout sessions. Orians MA, et al. **Arch Pathol Lab Med** 1995 Oct;119(10):952–61

US company fined for reckless deaths [news] Gunn E. **BMJ** 1996 Mar 9;312(7031):597

Should perinatal postmortems be carried out by specialist pathologists [letter; comment] Hickey K, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):757–8. Comment on: Br J Obstet Gynaecol 1991 Jul;98(7):624–7.

Why pathologists should take needle aspirates [letter] Polacarz SV. **Cytopathology** 1995 Oct;6(5):358

Why pathologists should not take fine needle aspirates [letter] Stephenson TJ, et al. **Cytopathology** 1995 Oct;6(5):358–60

Benefits of immediate printing of blood test results within an A&E department [letter] Clancy MJ, et al. **J Accid Emerg Med** 1996 Mar;13(2):149–50

Role of the pathologist in biomarker studies. Wilkinson EJ, et al. **J Cell Biochem Suppl** 1995;23:10–8 (29 ref.)

Job description of MLSOs [letter] Kondratowicz GM. **J Clin Pathol** 1995 Nov;48(11):1074

Evidence-based pathology [editorial] Fleming KA. **J Pathol** 1996 Jun;179(2):127–8

Pathologist or laboratory physician [letter] Arya SC. **Lancet** 1995 Sep 30;346(8979):904

Pathologist or laboratory physician? [letter; comment] al-Jubouri MA. **Lancet** 1995 Sep 30;346(8979):903. Comment on: Lancet 1995 Jul 22;346(8969):258.

Pathologist or laboratory physician [letter; comment] Zanetto U. **Lancet** 1995 Sep 30;346(8979):903–4. Comment on: Lancet 1995 Jul 22;346(8969):258.

Error rates in Australian chemical pathology laboratories [see comments] Khoury M, et al. **Med J Aust** 1996 Aug 5; 165(3):128–30. Comment in: Med J Aust 1996 Aug 5;165(3):125–6.

A model for medical knowledge representation application to the analysis of descriptive pathology reports. Smart JF, et al. **Methods Inf Med** 1995 Sep;34(4):352–60

Enquiring about test results [letter; comment] Burt D. **N Z Med J** 1995 Oct 13;108(1009):416. Comment on: N Z Med J 1995 Jul 14;108(1003):280. Comment on: N Z Med J 1995 Sep 8;108(1007):370.

A lost pathological specimen [letter; comment] [see comments] Mein JN. **N Z Med J** 1995 Sep 8;108(1007):370 . Comment on: N Z Med J 1995 Jul 14;108(1003):280. Comment in: N Z Med J 1995 Oct 13;108(1009):416.

Reality versus processed images [editorial] Benjamin DR. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):iii–iv

Chemical pathology—to be or not to be? [editorial] Berger GM. **S Afr Med J** 1995 Dec;85(12):1271–2

[Clinical pathology: myths and limits (or how to interpret a pathology report] Abadjian G. **J Med Liban** 1995; 43(1):36–8 **(Fre)**

[42nd meeting of the Japanese Society of Clinical Pathology. Utsunomia City, Japan. October 16–18, 1995. Abstracts] **Rinsho Byori** 1995;43 Suppl:1–322 **(Jpn)**

[Quick Return Service in endocrinological tests] Hashimoto T. **Rinsho Byori** 1995 Oct;43(10):1034–7 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Management of total laboratory system and its efficacy] Higashihata M, et al. **Rinsho Byori** 1995 Dec;43(12):1223–9 (Eng. Abstr.) **(Jpn)**

[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Laboratory management] Kawai T. **Rinsho Byori** 1995 Oct; 43(10):991–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

[The assessment of quick turnaround service in clinical laboratories] Kondoh T, et al. **Rinsho Byori** 1995 Oct; 43(10):1038–43 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Systematization in the Central Clinical Laboratory of Kyoto University Hospital] Okamura K. **Rinsho Byori** 1995 Dec; 43(12):1230–4 (Eng. Abstr.) **(Jpn)**

[Cost performance and TQC in laboratory management from the aspect of a commercial laboratory] Takahashi M. **Rinsho Byori** 1995 Oct;43(10):999–1004 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Present and future of classification for white cells and leukemic cells in the routine clinical laboratory] Tatsumi N, et al. **Rinsho Byori** 1995 Sep;43(9):913–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Role of clinical laboratories in eradication project for poliomyelitis in China] Hara M. **Uirusu** 1995 Jun;45(1):65–6 **(Jpn)**

[Pathobiochemistry and clinical chemistry as component parts of biochemistry] Todorov I. **Klin Lab Diagn** 1996 Jan–Feb;(1):12–3 **(Rus)**

EDUCATION

Results of autopsy survey [letter; comment] Marley EF. **Am J Clin Pathol** 1996 Jul;106(1):155–6. Comment on: Am J Clin Pathol 1996 Feb;105(2):144–8.

American Society of Clinical Pathologists—Resident Physician Section. Results of autopsy survey (Winter 1994–1995) [see comments] Nayar R, et al. **Am J Clin Pathol** 1996 Feb;105(2):144–8. Comment in: Am J Clin Pathol 1996 Jul;106(1):155–6.

The HOME tutor: a new tool for training in microscope skills. Gray E, et al. **Anal Cell Pathol** 1995 Oct;9(3):179–89

Cytopathology and the pathology resident. A survey of residency program directors. Davey DD, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):101–4

Steps for residency training in cytology [letter; comment] Hoda RS. **Diagn Cytopathol** 1995 Oct;13(3):277. Comment on: Diagn Cytopathol 1995 Mar;12(2):186–7.

Academic cytopathology: a specialty in transition [editorial] Powers CN. **Diagn Cytopathol** 1995 Oct;13(3):189–91

Training in molecular pathology [editorial] [see comments] Kant JA. **Hum Pathol** 1995 Oct;26(10):1051–4. Comment in: Hum Pathol 1996 Apr;27(4):430–1.

[Strategy for getting many experts in clinical pathology] Ohkubo A. **Rinsho Byori** 1995 Oct;43(10):1010–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

Editors on editors [editorial] **J Clin Pathol** 1995 Dec; 48(12):1075–7

Organized quantitative pathology. Short review of the activities of the Committee for Diagnostic Quantitative Pathology from 1981 to the foundation of the International Society of Diagnostic Quantitative Pathology in 1994. Collan YU, et al. **Pathologica** 1995 Jun;87(3):318–25

David Fitzpatrick's histopathology slide collection [letter] Hayman J. **Pathology** 1995 Apr;27(2):212–3

Thomas Houston and the founding of clinical pathology at the Royal Victoria Hospital, Belfast. Nelson MG. **Ulster Med J** 1994 Oct;63(2):223–34

[The role of Prof. Frantiŝek Subík in the development of pathology in Slovakia] Kopecký S. **Bratisl Lek Listy** 1996 Feb;97(2):109–12 **(Slo)**

INSTRUMENTATION

How to evaluate the quality in a system of video–microscopy in the field of anatomic pathology. Gonçalves L, et al. **Arch Anat Cytol Pathol** 1995;43(4):251–2

Selection and implementation of a laboratory computer system. Moritz VA, et al. **Pathology** 1995 Jul;27(3):260–7

LEGISLATION & JURISPRUDENCE

[Telemedicine and medical responsibility] Allaert FA, et al. **Arch Anat Cytol Pathol** 1995;43(4):200–5 (Eng. Abstr.) **(Fre)**

METHODS

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3–5 (26 ref.)

Pathologists, the death certificate, and hospital quality [letter; comment] Hanzlick R. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S128. Comment on: Am J Clin Pathol 1995 Apr;103(4 Suppl 1):S24–9.

STAT testing? A guideline for meeting clinician turnaround time requirements. Practice parameter. Hilborne L, et al. **Am J Clin Pathol** 1996 Jun;105(6):671–5

Beneath the surface of the mud... [editorial] Swanson PE. **Am J Clin Pathol** 1996 Jul;106(1):1–2 (9 ref.)

The HOME tutor: a new tool for training in microscope skills. Gray E, et al. **Anal Cell Pathol** 1995 Oct;9(3):179–89

Expert consultation by use of telepathology—the Heidelberg experiences. Kayser K, et al. **Anal Cell Pathol** 1995 Jul; 9(1):53–60

Aspects of telepathology in routinary diagnostic work with specific emphasis on ISDN. Kayser K, et al. **Arch Anat Cytol Pathol** 1995;43(4):216–8

Telepathology in France. Justifications and developments. Martin E, et al. **Arch Anat Cytol Pathol** 1995;43(4):191–5

Telemicroscopy stations for telepathology based on broadband and ISDN connections. Schwarzmann P, et al. **Arch Anat Cytol Pathol** 1995;43(4):209–15

Specimen collection and storage for diagnostic molecular pathology investigation. Farkas DH, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):591–6 (50 ref.)

Susceptibility testing of Mycobacterium avium complex in clinical laboratories. Results of a questionnaire and proficiency test performance by participants in the College of American Pathologists Mycobacteriology E Survey. Woods GL, et al. **Arch Pathol Lab Med** 1996 May; 120(5):436–9

Why pathologists should take needle aspiration specimens [letter] Hoda RS. **Cytopathology** 1995 Dec;6(6):419–20

Why pathologists should take needle aspiration specimens [letter] Howat AJ. **Cytopathology** 1995 Dec;6(6):419

Telepathology: a tool to aid in diagnosis and quality assurance in cervicovaginal cytology. Marsan C, et al. **Cytopathology** 1995 Oct;6(5):339–42

Computerised image handling in pathology. Cheong SK, et al. **J Clin Pathol** 1995 Sep;48(9):796–802 (4 ref.)

Confocal laser scanning microscopy: a new optical microscopic technique for applications in pathology and dermatology. Fink-Puches R, et al. **J Cutan Pathol** 1995 Jun;22(3):252–9 (27 ref.)

Whose tissue is it anyway? [editorial] Bateman AC, et al. **J Pathol** 1996 Jul;179(3):229–31

Morphometry in pathology [letter; comment] Furness PN. **J Pathol** 1995 Dec;177(4):441. Comment on: J Pathol 1995 Apr;175(4):369–79.

Self–similarity and fractal irregularity in pathologic tissues. Losa GA, et al. **Mod Pathol** 1996 Mar;9(3):174–82 (79 ref.)

Role of cytology in intraoperative diagnosis. A practical guide. Czerniak B, et al. **Pathol Annu** 1995;30 Pt 2:83–102 (52 ref.)

Applications of neural networks in histopathology. Becker RL JR. **Pathologica** 1995 Jun;87(3):246–54 (82 ref.)

Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)

Unbiased stereologic techniques for practical use in diagnostic histopathology. Sørensen FB. **Pathologica** 1995 Jun;87(3):263–78 (86 ref.)

Syntactic structure analysis. van Diest PJ, et al. **Pathologica** 1995 Jun;87(3):255–62 (41 ref.)

3D reconstruction and quantitation of pathological tissues. Whimster WF, et al. **Pathologica** 1995 Jun;87(3):279–85 (40 ref.)

Selection and implementation of a laboratory computer system. Moritz VA, et al. **Pathology** 1995 Jul;27(3):260–7

[Digitization and image reconstruction: application to iconography of surgical pathology specimens] Vuong PN, et al. **Ann Pathol** 1996;16(2):141–3 (Eng. Abstr.) **(Fre)**

[VISIOPATH: system of telediagnosis and digital image processing] Joyez JC. **Arch Anat Cytol Pathol** 1995; 43(4):300–4 (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Workflow computing. Improving management and efficiency of pathology diagnostic services. Buffone GJ, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S17–24 (7 ref.)

A national telepathology trial in Sweden feasibility and assessment. Olsson S, et al. **Arch Anat Cytol Pathol** 1995; 43(4):234–41

Multimedic system for telepathology and interdisciplinary councils between doctors and various hospitals. Richter HA, et al. **Arch Anat Cytol Pathol** 1995;43(4):296–9

Pathology consultation services via the Arizona–International Telemedicine Network. Weinstein RS, et al. **Arch Anat Cytol Pathol** 1995;43(4):219–26

STANDARDS

STAT testing? A guideline for meeting clinician turnaround time requirements. Practice parameter. Hilborne L, et al. **Am J Clin Pathol** 1996 Jun;105(6):671–5

Laboratory turnaround time. Valenstein P. **Am J Clin Pathol** 1996 Jun;105(6):676–88 (59 ref.)

Previous experience in teleradiology could serve as a first lesson to telepathologists. Coen H. **Arch Anat Cytol Pathol** 1995;43(4):206–8

Telepathology in Europe. Its practical use. Kayser K. **Arch Anat Cytol Pathol** 1995;43(4):196–9

Communication and cytopathology—Part IV: Cytohistologic correlation and patient care [editorial] Davey DD, et al. **Diagn Cytopathol** 1995 Jul;13(1):1–2

Coping with change: adopting a new paradigm. Iverson DK. **Diagn Cytopathol** 1995 Aug;13(2):172–3

Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Weingand K, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):198–201 (26 ref.)

Counting mitoses [letter; comment] Rippey JJ. **Hum Pathol** 1995 Dec;26(12):1390. Comment on: Hum Pathol 1995 Jan;26(1):47–52.

Role of re–screening of cervical smears in internal quality control. Baker A, et al. **J Clin Pathol** 1995 Nov; 48(11):1002–4

Ensuring quality in all phases of the pathology cycle [editorial; comment] Bryant SJ. **Med J Aust** 1996 Aug 5; 165(3):125–6. Comment on: Med J Aust 1996 Aug 5;165(3):128–30.

Quality assurance in pediatric anatomic pathology: the Society for Pediatric Pathology slide survey program. Rutledge JC. **Pediatr Pathol Lab Med** 1995 Nov–Dec; 15(6):957–65

Quality control in cytopathology applied to screening for cervical carcinoma. Marsan C. **Pol J Pathol** 1995; 46(4):245–8

[Issue of certification of clinical pathologists (specialists, doctor of second, first and highest category)] Avtandilov GG, et al. **Arkh Patol** 1996 Mar–Apr;58(2):67–70 **(Rus)**

STATISTICS & NUMERICAL DATA

Can information on breast pathology reports be used to audit the UK Breast Screening Programme? Twaddle S, et al. **Health Bull (Edinb)** 1996 Mar;54(2):123–5

TRENDS

The challenge of managing laboratory information in a managed care environment. Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S3–9 (23 ref.)

The future of the medical examiner system. First Milton Helpern Laureate Award address, National Association of Medical Examiners, Hawaii, September, 1991. Davis JH. **Am J Forensic Med Pathol** 1995 Dec;16(4):265–9

College of American Pathologists Conference XXVIII: Alternate Site Testing. January 29–February 1, 1995. **Arch Pathol Lab Med** 1995 Oct;119(10):867–983

Alternate site testing. The old and new paradigm or the past is prologue. Bachner P. **Arch Pathol Lab Med** 1995 Oct; 119(10):881–5 (31 ref.)

Atypical squamous cells of undetermined significance. Current laboratory practices of participants in the College of American Pathologists Interlaboratory. Comparison Program in Cervicovaginal Cytology. Davey DD, et al. **Arch Pathol Lab Med** 1996 May;120(5):440–4

Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: introduction. Handorf CR. **Arch Pathol Lab Med** 1995 Oct;119(10):867–73 (9 ref.)

Future practices in diagnostic medicine. Hannan RE. **Arch Pathol Lab Med** 1995 Oct;119(10):890–3

College of American Pathologists Conference XXVIII on alternate site testing. What must we now do? Howanitz PJ. **Arch Pathol Lab Med** 1995 Oct;119(10):979–83 (30 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: keynote address. Global view of how alternate site testing fits in with medical care. O'Leary D. **Arch Pathol Lab Med** 1995 Oct;119(10):877–80

College of American Pathologists Conference XXVIII on alternate site testing: keynote address. Reflections on a C major scale. Woodruff KH. **Arch Pathol Lab Med** 1995 Oct;119(10):876

Molecular pathology, informed consent, and the paraffin block [news] Grody WW. **Diagn Mol Pathol** 1995 Sep; 4(3):155–7

Academic anatomic pathology—a perspective [editorial] Murphy WM. **Mod Pathol** 1996 Feb;9(2):91–4

Update of immunocytochemistry in cytopathology. van Hoeven KH, et al. **Pathol Annu** 1995;30 Pt 2:245–67 (84 ref.)

The pendulum [editorial] Benjamin DR. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):iii–iv

The bright future of clinical pathology [editorial] Benjamin DR. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):iii–v

[Perspective of clinical pathology/laboratory medicine in Japan] Kawai T. **Rinsho Byori** 1996 May;44(5):401–5 (Eng. Abstr.) **(Jpn)**

PATHOLOGY DEPARTMENT, HOSPITAL

HISTORY

Thomas Houston and the founding of clinical pathology at the Royal Victoria Hospital, Belfast. Nelson MG. **Ulster Med J** 1994 Oct;63(2):223–34

STANDARDS

The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED.

Arch Pathol Lab Med 1996 Aug;120(8):739–42 (0 ref.)
Errors by locums. Histopathology departments already audit diagnostic errors [letter] Ramsay AD. **BMJ** 1996 Jul 13; 313(7049):117

STATISTICS & NUMERICAL DATA

High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)

PATHOLOGY, ORAL

Geneticist/oral pathologist earns 1995 Ross Award [news] **J Am Dent Assoc** 1995 Oct;126(10):1344, 1346
Development of the bulletin board for oral pathology. Drinnan AJ, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):267–9

EDUCATION

Use of oral pathology services by general histopathologists and their attitudes to training of oral pathologists. Barret AW, et al. **J Clin Pathol** 1996 Jul;49(7):565–9

ORGANIZATION & ADMINISTRATION

Managed care and its relationship to oral and maxillofacial pathology [editorial] Allen CM.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Apr;81(4):375

STANDARDS

Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Abbey LM, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Aug;80(2):188–91

TRENDS

"I'd really like to be an oral pathologist, but..." [editorial] Allen CM.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Sep;80(3):251

PATHOLOGY, SURGICAL

Use of human tissue blocks for research [editorial] LiVolsi VA. **Am J Clin Pathol** 1996 Mar;105(3):260–1
Polyps and polypectomy surveillance--role of the histopathologist. Riddell RH. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1138–40 (6 ref.)
Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. **Hum Pathol** 1996 Mar;27(3):220–4
Phraseology in pathology reports. A comparative study of interpretation among pathologists and surgeons. Attanoos RL, et al. **J Clin Pathol** 1996 Jan;49(1):79–81
Recommendations for the reporting of resected primary lung carcinomas. Association of Directors of Anatomic and Surgical Pathology. **Mod Pathol** 1995 Sep;8(7):796–8
Processing of adenoid and tonsil specimens in children: a national survey of standard practices and a five-year review of the experience at the Children's Hospital of Pittsburgh. Dohar JE, et al.
Otolaryngol Head Neck Surg 1996 Jul;115(1):94–7

EDUCATION

Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology.
Virchows Arch 1996 Apr;428(1):1–3 (6 ref.)

HISTORY

Sir James Paget and his contributions to pathology. Turk JL. **Int J Exp Pathol** 1995 Dec;76(6):449–56

METHODS

Recommendations for the reporting of resected primary lung carcinomas. Association of Directors of Anatomic and Surgical Pathology. **Am J Clin Pathol** 1995 Oct; 104(4):371–4
Recommendations for the reporting of resected large intestinal carcinomas. Association of Directors of Anatomic and Surgical Pathology. **Am J Clin Pathol** 1996 Jul; 106(1):12–5
Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Amin MB, et al. **Am J Clin Pathol** 1996 Jun;105(6):667–70
Intraoperative consultations by pathologists at the Mayo Clinic: a unique experience [editorial; comment] Page DL, et al. **Mayo Clin Proc** 1995 Dec;70(12):1222–3. Comment on: Mayo Clin Proc 1995 Dec;70(12):1137–41.
Quantitation in immunohistochemistry. A research method or a diagnostic tool in surgical pathology? Fritz P, et al. **Pathologica** 1995 Jun;87(3):300–9 (76 ref.)
Evaluation of a telepathology system between Boston (USA) and Dijon (France): glass slides versus telediagnostic TV-monitor. Allaert FA, et al.
Proc Annu Symp Comput Appl Med Care 1995;:596–600
Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology.
Virchows Arch 1996 Apr;428(1):1–3 (6 ref.)

ORGANIZATION & ADMINISTRATION

Workflow computing. Improving management and efficiency of pathology diagnostic services. Buffone GJ, et al.
Am J Clin Pathol 1996 Apr;105(4 Suppl 1):S17–24 (7 ref.)

STANDARDS

Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. **Am J Clin Pathol** 1995 Dec;104(6):614–9
Guardians of the wax [letter] Geller SA.
Am J Clin Pathol 1996 Mar;105(3):371
Prospective peer review in surgical pathology. Lind AC, et al. **Am J Clin Pathol** 1995 Nov;104(5):560–6
Rescreening in gynecologic cytology. Rescreening of 8096 previous cases for current low-grade and indeterminate-grade squamous intraepithelial lesion diagnoses--a College of American Pathologists Q-Probes study of 323 laboratories. Jones BA.
Arch Pathol Lab Med 1996 Jun;120(6):519–22
Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Jones BA, et al.
Arch Pathol Lab Med 1996 Jun;120(6):523–31
Surgical pathology specimen identification and accessioning: A College of American Pathologists Q-Probes Study of 1 004 115 cases from 417 institutions. Nakhleh RE, et al.
Arch Pathol Lab Med 1996 Mar;120(3):227–33
Intralaboratory timeliness of surgical pathology reports. Results of two College of American Pathologists Q-Probes studies of biopsies and complex specimens. Zarbo RJ, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):234–44
Indications and immediate patient outcomes of pathology intraoperative consultations. College of American Pathologists/Centers for Disease Control and Prevention Outcomes Working Group Study. Zarbo RJ, et al.
Arch Pathol Lab Med 1996 Jan;120(1):19–25
Recommendations for the reporting of resected large intestinal carcinomas. Association of Directors of Anatomic and Surgical Pathology. **Hum Pathol** 1996 Jan;27(1):5–8
Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester [see comments] Ferreiro JA, et al.
Mayo Clin Proc 1995 Dec;70(12):1137–41. Comment in: Mayo Clin Proc 1995 Dec;70(12):1222–3.
Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)

TRENDS

Ensuring a role as a "bit" player in laboratory medicine [editorial] Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S1–2
"Post-Toronto" reflections on the state of academic surgical pathology [editorial] Dehner LP, et al. **Mod Pathol** 1995 Oct;8(8):801–2
Academic anatomic pathology--a perspective [editorial] Murphy WM. **Mod Pathol** 1996 Feb;9(2):91–4

PATHOLOGY, VETERINARY

AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Association of Avian Pathologists (AAAP). Wages DP. **J Am Vet Med Assoc** 1995 Oct 1;207(7):880–1; discussion 890–4

PATIENT ABANDONMENT see **REFUSAL TO TREAT**

PATIENT ACCEPTANCE OF HEALTH CARE

Patient evaluation of a new injection pen for growth hormone treatment in children and adults. Sjöblom K, et al.
Acta Paediatr Suppl 1995 Sep;411:63–5
A nationwide representative sample of treatment-seeking alcoholics: a study of psychiatric comorbidity. Tómasson K, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):378–85
Characteristics of youth and young adults seeking residential treatment for substance use problems: an exploratory study. Ogborne AC. **Addict Behav** 1995 Sep–Oct;20(5):675–8
Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Schober R, et al.
Addict Behav 1996 Jan–Feb;21(1):81–92 (96 ref.)
Cognitive therapy techniques in continuing care planning with substance-dependent patients. Whorley LW.
Addict Behav 1996 Mar–Apr;21(2):223–31
Psychopathology and alcohol consumption among treatment-seeking alcoholics: a prospective study. Tómasson K, et al. **Addiction** 1996 Jul;91(7):1019–30
Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD, et al. **AIDS** 1995 Sep;9(9):1079–83
Toward an alcohol treatment model: a comparison of treated and untreated respondents with DSM-IV alcohol use disorders in the general population. Grant BF.
Alcohol Clin Exp Res 1996 Apr;20(2):372–8
Outcome of patients who refused out-of-hospital medical assistance. Burstein JL, et al. **Am J Emerg Med** 1996 Jan; 14(1):23–6
EMS characteristics in an Asian Metropolis. Hu SC, et al. **Am J Emerg Med** 1996 Jan;14(1):82–5
Prevalence and detection of HIV risk behavior in primary care: implications for clinical preventive services. Ward J, et al. **Am J Prev Med** 1995 Jul–Aug;11(4):224–30
Will uninsured people volunteer for voluntary health insurance? Experience from Washington State. Diehr P, et al. **Am J Public Health** 1996 Apr;86(4):529–32
Management of varicose veins according to reason for presentation. O'Leary DP, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):214–6
One patient, two unusual conditions and three basic lessons. Gardner-Medwin JM, et al. **Ann Rheum Dis** 1996 Jun; 55(6):350–2
The health care experience of patients with low literacy. Baker DW, et al. **Arch Fam Med** 1996 Jun;5(6):329–34
The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)
Breaking the silence. Battered women's perspectives on medical care. Rodriguez MA, et al. **Arch Fam Med** 1996 Mar;5(3):153–8
Electromyography: do the diagnostic ends justify the means? [see comments] Kothari MJ, et al.
Arch Phys Med Rehabil 1995 Oct;76(10):947–9. Comment in: Arch Phys Med Rehabil 1996 Feb;77(2):212.
Recall, retention, utilisation and acceptability of written health education materials. Newell S, et al.
Aust J Public Health 1995 Aug;19(4):368–74
Primary care in accident and emergency departments. Parents practise triage for paediatric attendances [letter; comment] Bradley T, et al. **BMJ** 1995 Nov 25; 311(7017):1438. Comment on: BMJ 1995 Aug 12;311(7002):423–6.
Long-term outcome of patients with neurotic illness in general practice. Lloyd KR, et al. **BMJ** 1996 Jul 6; 313(7048):26–8
Commentary: the basis of a more rational method of funding primary medical care? [comment] Majeed A. **BMJ** 1996 Apr 20;312(7037):1012–3. Comment on: BMJ 1996 Apr;312(7037):1008–12.
Information about prenatal testing does not necessarily increase uptake [letter; comment] Moore WM. **BMJ** 1996 Feb 24;312(7029):508. Comment on: BMJ 1995 Oct 28;311(7013):1127–30.
Retrospective study of influence of deprivation on uptake of cardiac rehabilitation. Pell J, et al. **BMJ** 1996 Aug 3; 313(7052):267–8
Threats and opportunities in accident and emergency [news] Smith J. **BMJ** 1995 Dec 2;311(7018):1456
Want or need? [editorial] Grace M. **Br Dent J** 1995 Nov 11;179(9):319
Patient decision-making [letter; comment] Lane A.
Br Dent J 1995 Oct 21;179(8 Spec No):284. Comment on: Br Dent J 1995 Jul 8;179(1):11–8.
Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)
The health beliefs and behaviours of orthodox and complementary medicine clients. Furnham A, et al.
Br J Clin Psychol 1996 Feb;35 (Pt 1):49–61
Why do patients turn to complementary medicine? An empirical study. Vincent C, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):37–48
Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Harris H, et al. **Br J Gen Pract** 1996 Apr; 46(405):225–7
Infertility and the seeking of infertility treatment in a representative population. Schmidt L, et al.
Br J Obstet Gynaecol 1995 Dec;102(12):978–84
Determinants of treatment-seeking behaviour for urinary symptoms in older men. Macfarlane GJ, et al.
Br J Urol 1995 Dec;76(6):714–8
Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia. Myers RE, et al. **Cancer** 1996 Aug 1; 78(3):471–9
Factors associated with entry into therapy in children evaluated for sexual abuse. Tingus KD, et al.
Child Abuse Negl 1996 Jan;20(1):63–8
Factors related to the choice between traditional Chinese medicine and modern Western medicine among patients with two-method treatment. Kang JT, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1996 Jun; 57(6):405–12
Factors influencing the desire for long-term growth hormone replacement in adults. Holmes SJ, et al.
Clin Endocrinol (Oxf) 1995 Aug;43(2):151–7
Acceptability of medical abortion with methotrexate and misoprostol. Creinin MD, et al. **Contraception** 1995 Jul; 52(1):41–4
Assessing the acceptability of Norplant contraceptive in four patient populations. Dugoff L, et al. **Contraception** 1995 Jul;52(1):45–9
Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Johnson S, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):20S–35S
Prenatal and delivery care and childhood immunization in

Guatemala: do family and community matter? Pebley AR, et al. **Demography** 1996 May;33(2):231–47
Preliminary comparison of the polyurethane female condom with the latex male condom in Kenya. Ruminjo JK, et al. **East Afr Med J** 1996 Feb;73(2):101–6
Obstetrics service utilisation by the community in Lebowa, northern Transvaal. Uyirwoth GP, et al. **East Afr Med J** 1996 Feb;73(2):91–4
Reasons underlying failure to seek dental treatment among Nairobi University students. Wakiaga JM, et al. **East Afr Med J** 1996 May;73(5):320–2
Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy [see comments] Bremnes RM, et al. **Eur J Cancer** 1995 Nov;31A(12):1955–9 . Comment in: Eur J Cancer 1995 Nov;31A(12):1917–8.
Five-year survival curves: how much data are enough for patient–physician decision making in general surgery? Mazur DJ, et al. **Eur J Surg** 1996 Feb;162(2):101–4
Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)
Why do people consult the doctor? Campbell SM, et al. **Fam Pract** 1996 Feb;13(1):75–83 (111 ref.)
Acceptability of shared care for asymptomatic HIV-positive patients. Grun L, et al. **Fam Pract** 1995 Sep;12(3):299–302
Frequent attenders [letter; comment] Neal RD. **Fam Pract** 1995 Sep;12(3):370. Comment on: Fam Pract 1994 Dec;11(4):424–30. Comment on: Fam Pract 1994 Dec;11(4):431–7.
The relationship between complaint–related cognitions in referred patients with irritable bowel syndrome and subsequent health care seeking behaviour in primary care. van Dulmen AM, et al. **Fam Pract** 1996 Feb;13(1):12–7
Why do men with urethritis in Cameroon prefer to seek care in the informal health sector? Crabbé F, et al. **Genitourin Med** 1996 Jun;72(3):220–2
Elders' acceptability ratings of behavioral treatments and pharmacotherapy for the management of geriatric behavioral disturbances. Burgio LD, et al. **Geroatologist** 1995 Oct;35(5):630–6
The introduction of a new contraceptive; two years experience with Norplant. Davie J, et al. **Health Bull (Edinb)** 1996 Jul;54(4):314–7
Health check-ups in general practice: a patient perspective. Emslie M, et al. **Health Bull (Edinb)** 1996 May;54(3):241–7
Worker participation in an integrated health promotion/health protection program: results from the WellWorks project. Sorensen G, et al. **Health Educ Q** 1996 May;23(2):191–203
Predicting participation in a dietary intervention to lower cholesterol among individuals with hyperlipidemia. McCann BS, et al. **Health Psychol** 1996 Jan;15(1):61–4
Normal coronary angiograms: financial victory from the brink of clinical defeat? Keavney B, et al. **Heart** 1996 Jun; 75(6):623–5
Treatment with growth hormone. What do children know and how do they accept it? López Siguero JP, et al. **Horm Res** 1995;44 Suppl 3:18–25
Consumers. Surfing the Web for a doctor [news] **Hosp Health Netw** 1996 May 5;70(9):15
Managed care. More docs to pick from. Lumsdon K. **Hosp Health Netw** 1995 Dec 5;69(23):51
Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970–1992: a review of concepts, measurements and results. Schmidt L, et al. **Hum Reprod** 1995 Jun;10(6):1407–18 (32 ref.)
Changing trends in the intraocular lens acceptance in rural Tamil Nadu. Prajna NV, et al. **Indian J Ophthalmol** 1995 Dec;43(4):177–9
ACOG committee opinion. End-of-life decision making: understanding the goals of care. Number 156—May 1995 (replaces no. 38, June 1985). Committee on Ethics. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Aug;50(2):208–14
Determinants of help-seeking behaviour in cases of epilepsy attending a teaching hospital in India: an indigenous explanatory model. Banerjee T, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):217–30
Hepatitis B vaccine acceptance among adolescents and their parents. Rosenthal SL, et al. **J Adolesc Health** 1995 Oct; 17(4):248–54
Help-seeking preceding mental health clinic intake among African-American, "Latino, and Caucasian youths. McMiller WP, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1086–94
Invest now for the future [editorial] [see comments] Meskin LH. **J Am Dent Assoc** 1995 Sep;126(9):1200, 1202. Comment in: J Am Dent Assoc 1996 Feb;127(2):158.
The natural history of Alzheimer's disease [letter; comment] Boersma F, et al. **J Am Geriatr Soc** 1996 Jun;44(6):734. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1248–55.
How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. Mazur DJ, et al. **J Am Geriatr Soc** 1996 Aug;44(8):934–7
Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials. Aaronson NK, et al. **J Clin Oncol** 1996 Mar; 14(3):984–96
Perceptions of cervical cancer and Pap smear screening behavior by women's sexual orientation. Price JH, et al. **J Community Health** 1996 Apr;21(2):89–105
Attitude of African–Americans regarding prostate cancer clinical trials. Robinson SB, et al. **J Community Health** 1996 Apr;21(2):77–87
An examination of differential follow-up rates in breast cancer screening. Webber PA, et al. **J Community Health** 1996 Apr;21(2):123–32
Adherence to screening mammography recommendations in a university general medicine clinic [see comments] Dolan NC, et al. **J Gen Intern Med** 1995 Jun;10(6):299–306. Comment in: J Gen Intern Med 1995 Jun;10(6):349–50.
Acceptance of screening for colorectal cancer by flexible sigmoidoscopy. Cockburn J, et al. **J Med Screen** 1995; 2(2):79–83
Personality disorder and sexual risk taking among homosexually active and heterosexually active men attending a genito-urinary medicine clinic. Ellis D, et al. **J Psychosom Res** 1995 Oct;39(7):901–10
The acceptability of psychological treatment in patients with medically unexplained physical symptoms. Speckens AE, et al. **J Psychosom Res** 1995 Oct;39(7):855–63
Why do people go to their doctors? Calnan M. **J R Soc Med** 1995 Dec;88(12):702p–3p
Assessing the effectiveness of a screening campaign: who is missed by 80% cervical screening coverage? Orbell S, et al. **J R Soc Med** 1995 Jul;88(7):389–94
Harmful effects of drinking and the use and perceived effectiveness of treatment. Burton TL, et al. **J Stud Alcohol** 1995 Nov;56(6):611–5
Mastectomy as the preferred treatment for breast cancer among new immigrants from the former USSR. Kaufman Z, et al. **J Surg Oncol** 1995 Nov;60(3):168–73
Access to health care and preventable hospitalizations [letter; comment] Baker DW. **JAMA** 1995 Dec 13;274(22):1759; discussion 1760. Comment on: JAMA 1995 Jul 26;274(4):305–11.
Women's anticipations of hormonal replacement therapy. Wardell DW, et al. **Maturitas** 1995 Nov;22(3):177–83
Measuring heart patients' willingness to pay for changes in angina symptoms. Chestnut LG, et al. **Med Decis Making** 1996 Jan–Mar;16(1):65–77
Attitudes of patients to medical student participation: general practice consultations on the Cambridge Community–Based Clinical Course. Jones S, et al. **Med Educ** 1996 Jan;30(1):14–7
Cultural barriers to health care for refugees and immigrants. Providers' perceptions. Ohmans P, et al. **Minn Med** 1996 May;79(5):26–30
Cancer fatalism among African–Americans: a review of the literature. Powe BD. **Nurs Outlook** 1996 Jan–Feb; 44(1):18–21 (25 ref.)
The prevalence of clinical preventive services utilization by older women. Bergman–Evans B, et al. **Nurse Pract** 1996 Apr;21(4):88, 90, 99–100, passim
A healthy weight-loss program includes provider involvement and client acceptance [letter] Turner S. **Nurse Pract** 1996 Apr;21(4):161–2
Digital rectal examinations and prostate cancer screening: attitudes of African American men. Gelfand DE, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1253–5
Many factors prevent women with breast cancer symptoms from seeking medical help quickly [news] **Oncology (Huntingt)** 1995 Aug;9(8):780
You can help promote use of mammogram benefit. Queenan E, et al. **Pa Med** 1995 Oct;98(10):26–8
A randomized study of ondansetron syrup in children: evaluation of taste acceptability and tolerance. Stevens R, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):199–202
Psychological considerations in colonoscopy. Wagner PJ, et al. **Prim Care** 1995 Sep;22(3):479–89
Filters on the pathway to mental health care, II. Sociodemographic factors. Gallo JJ, et al. **Psychol Med** 1995 Nov;25(6):1149–60
Is seeking treatment for depression predicted by a history of depression in relatives? Implications for family studies of affective disorder. Kendler KS. **Psychol Med** 1995 Jul; 25(4):807–14
Factors that influence professional employees willingness to seek counseling. Powell GN, et al. **Psychol Rep** 1995 Dec; 77(3 Pt 1):872–4
Blood donor centres can effectively publicise cancer screening. Hart AR, et al. **Public Health** 1996 Jul; 110(4):247–9
Factors associated with influenza vaccination coverage among the elderly: role of health care personnel. Honkanen PO, et al. **Public Health** 1996 May;110(3):163–8
Adult immunisation—too little, too late? [editorial] Slack R. **Public Health** 1995 Sep;109(5):309–10
Patient delay in seeking help for potential breast cancer. Caplan LS. **Public Health Rev** 1995;23(3):263–74
Underutilization of influenza vaccine in Jerusalem. Slater PE, et al. **Public Health Rev** 1995;23(4):357–66
Women's experiences at cervical screening. Crombie IK, et al. **Scott Med J** 1995 Jun;40(3):81–2
Religiosity and help-seeking in a rural and an urban area. Sørgaard KW, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):180–5
Strategy of risk approach in antenatal care: evaluation of the referral compliance [letter; comment] Akalin MZ, et al. **Soc Sci Med** 1995 Aug;41(4):595–6. Comment on: Soc Sci Med 1995 Feb;40(4):529–35.
Acceptability of prenatal diagnosis of sickle cell anaemia (SCA) by female patients and parents of SCA patients in Nigeria. Durosinmi MA, et al. **Soc Sci Med** 1995 Aug; 41(3):433–6
Global immunization and culture: compliance and resistance in large-scale public health campaigns. Greenough P. **Soc Sci Med** 1995 Sep;41(5):605–7
Cancer screening utilization: is there a role for social work in cancer prevention? Plaskon PP, et al. **Soc Work Health Care** 1995;21(4):59–70
Pathways to psychiatric care in Ibadan, Nigeria. Gureje O, et al. **Trop Geogr Med** 1995;47(3):125–9
Health seeking behaviour for child illness in rural Guatemala. Van der Stuyft P, et al. **Trop Med Int Health** 1996 Apr; 1(2):161–70
A comparison of patient tolerance of hysterosalpingo–contrast sonography (HyCoSy) with Echovist–200 and X-ray hysterosalpingography for outpatient investigation of infertile women. Ayida G, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):201–4
Elder care recipients' care-seeking process. Russell CK. **West J Nurs Res** 1996 Feb;18(1):43–62
[Participation of women in cervical cancer screening] Kallio M, et al. **Duodecim** 1994;110(11):1061–7 **(Fin)**
[Comparative study of the acceptability of Tilade Syncroner and Tilade Standard by mildly asthmatic patients. Syncroner Trial Research Group] Pujet JC, et al. **Allerg Immunol (Paris)** 1995 Dec;27(10):377–83 (Eng. Abstr.) **(Fre)**
[5 years neuroblastoma screening in Austria: rate of participation, results and a comparison with other screening areas] Kerbl R, et al. **Wien Klin Wochenschr** 1996; 108(13):398–403 (Eng. Abstr.) **(Ger)**
[Acceptability of high colonoscopy using different premedication—a comparison of the effect of midazolam versus midazolam and pethidine from the viewpoint of the patient and the physician] Ehrle UB, et al. **Z Gastroenterol** 1995 Dec;33(12):704–8 (Eng. Abstr.) **(Ger)**
[How can acceptance by psychiatric patients of group psychotherapy be improved? An empirical study of the effect of combined individual and group psychotherapy on attitude to group psychotherapy] Teusch L, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):355–63 (Eng. Abstr.) **(Ger)**
[Assessment by the primary care physician of his influence on the patient's hospital choice and of his own ability to evaluate hospital quality] Gross R, et al. **Harefuah** 1995 Aug;129(3–4):90–5, 159 (Eng. Abstr.) **(Heb)**
[Characteristics of medical institutions visited by patients with 26 intractable diseases who are residents of Saitama Prefecture (comparison of the data for 1984 and 1988)] Wakabayashi K, et al. **Nippon Eiseigaku Zasshi** 1995 Oct; 50(4):839–48 (Eng. Abstr.) **(Jpn)**
[The frequency of the use of hospital emergency services: the motivations and characteristics of pediatric emergencies] Sansa Pérez L, et al. **An Esp Pediatr** 1996 Feb;44(2):97–104 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Health-care-seeking behaviors related to bowel complaints. Hispanics versus non-Hispanic whites. Zuckerman MJ, et al. **Dig Dis Sci** 1996 Jan;41(1):77–82
Latino male attitudes and behaviors on their spouses' and partners' cancer-screening behavior: focus group findings. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):87–93
Community level cancer control in a Texas barrio: Part II—Base-line and preliminary outcome findings. McAlister AL, et al. **J Natl Cancer Inst Monogr** 1995;(18):123–6
Por La Vida intervention model for cancer prevention in Latinas. Navarro AM, et al. **J Natl Cancer Inst Monogr** 1995;(18):137–45
Use of cancer-screening tests in the San Francisco Bay area: comparison of Latinos and Anglos. Pérez-Stable EJ, et al. **J Natl Cancer Inst Monogr** 1995;(18):147–53
Community level cancer control in a Texas barrio: Part I—Theoretical basis, implementation, and process evaluation. Ramirez AG, et al. **J Natl Cancer Inst Monogr** 1995;(18):117–22

PSYCHOLOGY

Correlation of orthodontic treatment demand with treatment need assessed using two indices. Tang EL, et al. **Angle Orthod** 1995;65(6):443–50
Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Aaron LA, et al. **Arthritis Rheum** 1996 Mar; 39(3):436–45
Women's decision to seek care for symptoms of acute myocardial infarction. Dempsey SJ, et al. **Heart Lung** 1995 Nov–Dec;24(6):444–56
Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. Stall R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):151–60
Patients' willingness to accept life-sustaining treatment when the expected outcome is a diminished mental health state: an exploratory study. Mazur DJ, et al. **J Am Geriatr Soc** 1996 May;44(5):565–8
The primary care pathway to mammography: a long and winding road [editorial; comment] Burack RC.

J Gen Intern Med 1995 Jun;10(6):349–50. Comment on: J Gen Intern Med 1995 Jun;10(6):299–306.

Office or emergency department: what's the difference? Schwartz MP. **South Med J** 1995 Oct;88(10):1020–4

[Motivations for breast reconstruction after mastectomy. A comparative study] Charavel M, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):46–53 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Screening mammography use: the importance of a population perspective. McCarthy BD, et al. **Am J Prev Med** 1996 Mar–Apr;12(2):91–5

Need and desire for preventive care measures in emergency department patients. Rodriguez RM, et al. **Ann Emerg Med** 1995 Nov;26(5):615–20

Written discharge advice sheets reduce visits to the general practitioner. Raine C, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1 Suppl):19–20

Where do persons with blindness caused by cataracts in rural areas of India seek treatment and why? Gupta SK, et al. **Arch Ophthalmol** 1995 Oct;113(10):1337–40

Socioeconomic determinants of rates of consultation in general practice based on fourth national morbidity survey of general practices [see comments] Carr-Hill RA, et al. **BMJ** 1996 Apr 20;312(7037):1008–12. Comment in: BMJ 1996 Apr 20;312(7037):1012–3.

Patients who reattend after head injury: a high risk group [see comments] Voss M, et al. **BMJ** 1995 Nov 25; 311(7017):1395–8. Comment in: BMJ 1996 Mar 16;312(7032):707–8.

Differences in preferences between diabetic patients and diabetologists regarding quality of care: a matter of continuity and efficiency of care? Casparie AF, et al. **Diabet Med** 1995 Sep;12(9):828–32

Attendance and compliance at an oral cancer screening programme in a general medical practice. Jullien JA, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):202–6

Payment and attendance at general practice preventive health examinations. Christensen B. **Fam Med** 1995 Sep; 27(8):531–4

Patient expectations: what do primary care patients want from the GP and how far does meeting expectations affect patient satisfaction? Williams S, et al. **Fam Pract** 1995 Jun; 12(2):193–201

Do primary care patients accept psychological treatments? Arean PA, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):22–7

Use of care and subsequent mortality: the importance of gender. Franks P, et al. **Health Serv Res** 1996 Aug; 31(3):347–63

Consumers. Phoning in for medical advice [news] **Hosp Health Netw** 1996 Feb 5;70(3):16

Epidemiological measures of participation in community health promotion projects. Oddy WH, et al. **Int J Epidemiol** 1995 Oct;24(5):1013–21

The health care seeking behavior of schizophrenic patients in 6 East Asian areas. Rhi BY, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):190–209

A profile of patients in six dental school clinics and implications for the future. Damiano PC, et al. **J Dent Educ** 1995 Dec;59(12):1084–90

AA and other helpseeking for alcohol problems: former drinkers in the U.S. general population. Hasin DS, et al. **J Subst Abuse** 1995;7(3):281–92

Patient's choice of hospital or office for Medicaid ambulatory care in Alabama. Bronstein JM, et al. **Med Care** 1996 Apr; 34(4):348–60

Conservation of energy, uncertainty reduction, and swift utilization of medical care among the elderly: study II. Leventhal EA, et al. **Med Care** 1995 Oct;33(10):988–1000

Provider choice and continuity for the treatment of depression. Sturm R, et al. **Med Care** 1996 Jul;34(7):723–34

Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Lincoln CV, et al. **Psychiatr Serv** 1995 Nov;46(11):1166–71 (89 ref.)

Factors related to patients' decisions to visit the psychiatric emergency service. Thienhaus OJ, et al. **Psychiatr Serv** 1995 Dec;46(12):1227–8

Factors associated with participation in a preventive cardiology service by patients with coronary heart disease. Dignan MB, et al. **South Med J** 1995 Oct;88(10):1057–61

[Acceptance and effectiveness of surgical vascular consultation—is it worthwhile?] Graupe F, et al. **Chirurg** 1995 Dec;66(12):1239–44; discussion 1245–6 (Eng. Abstr.) **(Ger)**

PATIENT ADMISSION

see related
PATIENT READMISSION

Decreasing hospital admissions for childhood asthma in Sweden [editorial] Foucard T. **Acta Paediatr** 1996 Feb; 85(2):131

Decreasing admissions for childhood asthma to a Swedish county hospital. Strömberg L. **Acta Paediatr** 1996 Feb; 85(2):173–6

A prospective three-year follow-up study of borderline personality disorder inpatients. Antikainen R, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):327–35

Entering treatment for alcohol abuse: a stress and coping model. Finney JW, et al. **Addiction** 1995 Sep;90(9):1223–40

Psychiatric status and HIV risk reduction among residential drug abuse treatment clients. McCusker J, et al. **Addiction** 1995 Oct;90(10):1377–87

First steps in building ACME—an admission case-mix system for the elderly. Dunstan EJ, et al. **Age Ageing** 1996 Mar; 25(2):102–8

Do cage scores predict readiness to reduce alcohol consumption in medical in-patients? Dent TH, et al. **Alcohol Alcohol** 1995 Sep;30(5):577–80

Physical morbidity in patients admitted to a private hospital for detoxification from alcohol. Wylie AS, et al. **Alcohol Alcohol** 1995 Sep;30(5):641–3

Multi-dimensional adolescent treatment with American Indians. Husted J, et al. **Am Indian Alsk Native Ment Health Res** 1995;6(3):23–30

Healing the warrior: admission of two American Indian war-veteran cohort groups to a specialized inpatient PTSD unit. Scurfield RM. **Am Indian Alsk Native Ment Health Res** 1995;6(3):1–22

Craving in hospitalized cocaine abusers as a predictor of outcome. Weiss RD, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):289–301

Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals [see comments] Hartert TV, et al. **Am J Med** 1996 Apr;100(4):386–94. Comment in: Am J Med 1996 Apr;100(4):381–2.

Stress management for psychiatric patients in a state hospital setting. Starkey D, et al. **Am J Orthopsychiatry** 1995 Jul; 65(3):446–50

A case-control study of rapid readmission in a state hospital population. Craig TJ, et al. **Ann Clin Psychiatry** 1995 Jun; 7(2):79–85

Medication treatment in first-admission patients with psychotic affective disorders: preliminary findings on research-facility diagnostic agreement and rehospitalization. Fennig S, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):87–90

Triage: limitations in predicting need for emergent care and hospital admission [see comments] Brillman JC, et al. **Ann Emerg Med** 1996 Apr;27(4):493–500. Comment in: Ann Emerg Med 1996 Apr;27(4):506–8.

Triage and emergency department services [editorial; comment] Williams RM. **Ann Emerg Med** 1996 Apr; 27(4):506–8. Comment on: Ann Emerg Med 1996 Apr;27(4):493–500.

Patient characteristics, safety, and benefits of same-day admission for coronary artery bypass grafting. Arom KV, et al. **Ann Thorac Surg** 1996 Apr;61(4):1136–9; discussion 1139–40

Borderline personality disorder: a challenge for mental health services. Clarke M, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):409–14

Intensive care unit admissions following laparoscopic surgery: what lessons can be learned? [see comments] Hayes C, et al. **Aust N Z J Surg** 1996 Apr;66(4):206–9. Comment in: Aust N Z J Surg 1996 Apr;66(4):201.

Phenomenology and comorbidity of adolescents hospitalized for the treatment of acute mania. West SA, et al. **Biol Psychiatry** 1996 Mar 15;39(6):458–60

Emergency delays [letter; comment] Rosen M. **BMJ** 1995 Sep 16;311(7007):754. Comment on: BMJ 1995 May 6;310(6988):1199.

Aversive stimulation by staff and violence by psychiatric patients. Whittington R, et al. **Br J Clin Psychol** 1996 Feb; 35 (Pt 1):11–20

Incorporating psychological debriefing techniques within a brief group psychotherapy programme for the treatment of post-traumatic stress disorder. Busuttil W, et al. **Br J Psychiatry** 1995 Oct;167(4):495–502

Repeat prescription antidepressants and residential care [letter] Farmer A. **Br J Psychiatry** 1995 Sep;167(3):408–9

Residential care in hospital and in the community—quality of care and quality of life. Shepherd G, et al. **Br J Psychiatry** 1996 Apr;168(4):448–56

Effect of age on the outcome of hospital treated depression. Tuma TA. **Br J Psychiatry** 1996 Jan;168(1):76–81

Patterns of symptomatic change in depressed patients in a private inpatient mood disorders program. Neimeyer RA, et al. **Bull Menninger Clin** 1995 Fall;59(4):460–71

Retrospective evaluation of admission criteria for paediatric electrical injuries. Wallace BH, et al. **Burns** 1995 Dec; 21(8):590–3

Comparative analysis of Native admissions and registrations to northwestern Ontario treatment facilities: hospital and community sectors. Dalrymple AJ, et al. **Can J Psychiatry** 1995 Oct;40(8):467–73

Hospital epistaxis admission rate and ambient temperature. Tomkinson A, et al. **Clin Otolaryngol** 1995 Jun;20(3):239–40

Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Ottevanger EA. **Encephale** 1995 Jul–Aug;21(4):317–21

Treatment goal-planning: outcome findings of a British prospective multi-centre study of adolescent inpatient units. Rothery D, et al. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):209–20

The importance of reducing delay in acute myocardial infarction [editorial; comment] Herlitz J. **Eur Heart J** 1996 Mar;17(3):338–40. Comment on: Eur Heart J 1996 Mar;17(3):429–37.

Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. The TRACE Study Group. Trandolapril Cardiac Evaluation [see comments] Ottesen MM, et al. **Eur Heart J** 1996 Mar;17(3):429–37. Comment in: Eur Heart J 1996 Mar;17(3):338–40.

Emergency hospital admissions. Blower AL. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):11–2

Rationalising ophthalmic admissions. Wright MR, et al. **Eye** 1995;9 (Pt 6 Su):65–6

Delirium in critical care unit patients admitted through an emergency room. Kishi Y, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):371–9

Admission after head injury: how many occur and how many are recorded? Moss NE, et al. **Injury** 1996 Apr;27(3):159–61

Quality of alcohol use histories collected at intake to substance user treatment. Turner CF, et al. **Int J Addict** 1995 Jun;30(8):963–89

Attributions for admission to Zomba Mental Hospital: implications for the development of mental health services in Malawi. MacLachlan M, et al. **Int J Soc Psychiatry** 1995 Summer;41(2):79–87

The treatment of acute psychosis without neuroleptics: six-week psychopathology outcome data from The Soteria Project. Mosher LR, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):157–73

Divergent views—patient, career and staff perceptions of diagnosis and reasons for psychiatric admission to a district general hospital. Round A, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):210–6

Issues in drug administration in a psychiatric rehabilitation unit. Trauer T, et al. **Int J Soc Psychiatry** 1995 Autumn; 41(3):174–9

The effects of hospital admission on drug prescribing in an elderly population. Sheehan J, et al. **Ir Med J** 1996 May–Jun;89(3):115

Tripartite structure of positive and negative affect, depression, and anxiety in child and adolescent psychiatric inpatients. Joiner TE Jr, et al. **J Abnorm Psychol** 1996 Aug; 105(3):401–9

An examination of family functioning utilizing the circumplex model in psychiatrically hospitalized children with depression. Kashani JH, et al. **J Affect Disord** 1995 Oct 9;35(1–2):65–73

The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy. Blaauw PJ, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):39–47

Motor activity and severity of depression in hospitalized prepubertal children. Aronen ET, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):752–63

"Madness" in the countertransference: evocative encounters in hospital treatment. Stamm I. **J Am Acad Psychoanal** 1995 Spring;23(1):115–36

Prevalence of use of beta blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. Aronow WS. **J Am Geriatr Soc** 1996 Sep;44(9):1075–7

Hospital admission risk profile (HARP): identifying older patients at risk for functional decline following acute medical illness and hospitalization. Sager MA, et al. **J Am Geriatr Soc** 1996 Mar;44(3):251–7

Admission health status differences of black and white indigent nursing home residents. Stegbauer CC, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1103–6

Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. Hefley FG Jr, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):581–3

The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Disegni E, et al. **J Clin Epidemiol** 1995 Oct;48(10):1197–205

Dimensional characteristics of the SCL-90-R: evaluation of gender differences in dually diagnosed inpatients. Carpenter KM, et al. **J Clin Psychol** 1995 May;51(3):383–90

Comparative concurrent validities of five alcoholism measures in a psychiatric hospital. Watson CG, et al. **J Clin Psychol** 1995 Sep;51(5):676–84

Admission to a neonatal intensive care unit as a predictor of long-term health: a 12-year follow-up. Speechley KN, et al. **J Dev Behav Pediatr** 1995 Dec;16(6):397–405

Risk factors for nursing home use after hospitalization for medical illness. Rudberg MA, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M189–94

Incidence of previously undetected disease in routine paediatric otolaryngology admissions. Zeitoun H, et al. **J Laryngol Otol** 1996 Jun;110(6):557–8

The significance and work-up of minor gastrointestinal bleeding in hospitalized nursing home patients. Suatengco R, et al. **J Natl Med Assoc** 1995 Oct;87(10):749–50

Reliability and validity of a new preadmission acuity tool for long-term care. Swanson EA, et al. **J Nurs Meas** 1995 Summer;3(1):77–88

MMPI differences among adolescent inpatients, rapists, sodomists, and sexual abusers. Herkov MJ, et al. **J Pers Assess** 1996 Feb;66(1):81–90

The risk of seclusion and the menstrual cycle in female psychiatric patients. Van Heeringen K, et al. **J Psychosom Res** 1995 Jul;39(5):629–32

Paediatric hospital services: are we satisfying our adolescent patients? Black W, et al. **J Qual Clin Pract** 1995 Sep; 15(3):161–7

A study of appropriateness of acute geriatric admissions and an assessment of the Appropriateness Evaluation Protocol.

Tsang P, et al. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):311–4

Age–related geriatric medicine: relevance of special skills of geriatric medicine to elderly people admitted to hospital as medical emergencies. Kafetz K, et al. **J R Soc Med** 1995 Nov;88(11):629–33

Alcohol–related risk factors associated with HIV infection among patients entering alcoholism treatment: implications for prevention. Boscarino JA, et al. **J Stud Alcohol** 1995 Nov;56(6):642–53

Problems in the application of the Addiction Severity Index (ASI) in rural substance abuse services. Wertz JS, et al. **J Subst Abuse** 1995;7(2):175–88

Individual Assessment Profile (IAP). Standardizing the assessment of substance abusers. Flynn PM, et al. **J Subst Abuse Treat** 1995 May–Jun;12(3):213–21

Combining behavioral and self–help approaches in the inpatient management of dually diagnosed patients. Franco H, et al. **J Subst Abuse Treat** 1995 May–Jun;12(3):227–32

Utility of admission chemistry and coagulation profiles in trauma patients: a reappraisal of traditional practice. Namias N, et al. **J Trauma** 1996 Jul;41(1):21–5

Discovering asymptomatic biochemical abnormalities on a Baltimore internal medicine service. Ferguson RP, et al. **Md Med J** 1996 Jul;45(7):543–6

Snakes and ladders: getting patients into public hospitals [editorial; comment] Buchan H, et al. **Med J Aust** 1995 Oct 16;163(8):396. Comment on: Med J Aust 1995 Oct 16;163(8):401–5.

Bureaucratic intrusion impedes patient care [letter] Hunt RW. **Med J Aust** 1996 Sep 2;165(5):295

Difficulties in admitting patients to metropolitan public hospitals: the view of medical practitioners [letter; comment] Vinen J. **Med J Aust** 1996 Feb 5;164(3):191. Comment on: Med J Aust 1995 Oct 16;163(8):401–5.

Factors impacting the success of computerized preadmission screening. Hales JW, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:728–32

Studying inpatient treatment practices in schizophrenia: an integrated methodology. Boyer CA, et al. **Psychiatr Q** 1995 Winter;66(4):293–320

Use of a token economy with seriously mentally ill patients: criticisms and misconceptions. Corrigan PW. **Psychiatr Serv** 1995 Dec;46(12):1258–63 (52 ref.)

Factors contributing to nurses' difficulty in treating patients in short–stay psychiatric settings. Lancee WJ, et al. **Psychiatr Serv** 1995 Jul;46(7):724–6

Informational needs of patients hospitalized for bipolar disorder. Pollack LE. **Psychiatr Serv** 1995 Nov; 46(11):1191–4

A method for understanding admission decision making in a psychiatric emergency room. Rabinowitz J, et al. **Psychiatr Serv** 1995 Oct;46(10):1055–60

Treatment of Hassidic Jewish patients in a general hospital medical–psychiatric unit. Trappler B, et al. **Psychiatr Serv** 1995 Aug;46(8):833–5

Initial assessment of hospital treatment by patients with paranoid schizophrenia: a predictor of outcome. Bröker M, et al. **Psychiatry Res** 1995 Sep 8;58(1):77–81

Screening psychiatric admissions for anticardiolipin antibody. Oomen HA, et al. **Psychiatry Res** 1995 Sep 8;58(1):83–8

Treatment, expressed emotion and relapse in recent onset schizophrenic disorders. Linszen D, et al. **Psychol Med** 1996 Mar;26(2):333–42

Familial depression versus depression identified in a control group: are they the same? Winokur G, et al. **Psychol Med** 1995 Jul;25(4):797–806

Dissociation and somatization in adolescent inpatients with and without history of abuse. Atlas JA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1101–2

Seclusion in treatment of adolescents on an acute inpatient unit [comment] Atlas JA. **Psychol Rep** 1995 Oct;77(2):577–8 . Comment on: Psychol Rep 1995 Feb;76(1):147–57.

Differential diagnostics and treatment of an inpatient adolescent showing pervasive developmental disorder and mania. Atlas JA, et al. **Psychol Rep** 1995 Aug;77(1):207–10

Vulnerability Scale scores in female inpatients diagnosed with self–injurious behaviour, dissociative identity disorder, and major depression. Glover H, et al. **Psychol Rep** 1995 Dec; 77(3 Pt 1):987–93

Inpatient treatment of mood disorders [see comments] Mendelberg HE. **Psychol Rep** 1995 Jun;76(3 Pt 1):819–24 . Comment in: Psychol Rep 1995 Dec;77(3 Pt 1):1041–2.

Comment on the inpatient treatment of mood disorders [comment] Peeters FP, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):1041–2. Comment on: Psychol Rep 1995 Jun;76(3 Pt 1):819–24.

Patterns of use and changes in diagnosis during first admission. National Case Register Study. Ginath Y, et al. **Psychopathology** 1996;29(1):39–45

Cognitive functioning in chronically hospitalized schizophrenic patients: age–related changes and age disorientation as a predictor of impairment. Harvey PD, et al. **Schizophr Res** 1995 Sep;17(1):15–24

Relations between social skills and ward behavior in chronic schizophrenia. Penn DL, et al. **Schizophr Res** 1995 Aug 15;16(3):225–32

Factors delaying hospital admission after acute stroke. Fogelholm R, et al. **Stroke** 1996 Mar;27(3):398–400

Comparison of nursing home residents admitted from home or hospital. Tracey F, et al. **Ulster Med J** 1995 Oct; 64(2):137–41

[Psychiatric admissions in Amsterdam according to ethnic background and diagnosis (letter)] Bogers JP. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1286–7 **(Dut)**

[Favorable development of ability to function in patients during admission in a geriatric unit of a psychiatric hospital] Maas HA, et al. **Ned Tijdschr Geneeskd** 1995 Dec 2; 139(48):2494–8 (Eng. Abstr.) **(Dut)**

[Standardized behavior assessment plays a minor role in arriving at indications for admission to a psychogeriatric nursing home] Janzing JG, et al. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):200–4 (Eng. Abstr.) **(Dut)**

[Interobserver variation of the Global Assessment Scale. Study of 59 patients at admission to a general adult psychiatric unit] Meur F, et al. **Encephale** 1996 Mar–Apr; 22(2):111–7 (Eng. Abstr.) **(Fre)**

[Non–hospitalization orders for subjects with presumed alcoholic intoxication] Dequin PF, et al. **Presse Med** 1996 May 25;25(18):833–6 (Eng. Abstr.) **(Fre)**

[Descriptive study of a stay in Treatment and Rehabilitation Centers in Vaud. Characteristics of the patients and developments] Santos–Eggimann B, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):823–30 **(Fre)**

[Opinion and attitude of physicians regarding organization and participation on a multidisciplinary alcoholism unit] Boitel S, et al. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):19–24 (Eng. Abstr.) **(Fre)**

[The "fate" of family practice prescriptions in the hospital. About 50%of prescriptions were changed] Tabache M. **Fortschr Med** 1995 Aug 30;113(24):342 **(Ger)**

[Aspects of process quality in quality assurance regarding inpatient psychosomatic rehabilitation] Mans EJ. **Gesundheitswesen** 1995 Jul;57(7):380–6 (Eng. Abstr.) **(Ger)**

[Treatment of drug dependent patients in a psychiatric department] Grischke–Silber J, et al. **Psychiatr Prax** 1995 Sep;22(5):193–6 (Eng. Abstr.) **(Ger)**

[Results of integrated inpatient detoxification and motivation treatment of alcohol dependent patients] Stetter F, et al. **Psychiatr Prax** 1995 Sep;22(5):189–92 (Eng. Abstr.) **(Ger)**

[Study of the practicability of qualitative and quantitative documentation of outcome in inpatient psychotherapy] Heuft G, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct;45(9–10):303–9 (Eng. Abstr.) **(Ger)**

[Effects of sexual abuse experiences on therapeutic outcome: study of eating disordered patients 2 years after inpatient psychotherapy] Köpp W, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):131–8 (Eng. Abstr.) **(Ger)**

[Effects of psychological treatment in the general hospital: follow–up study of patients with somatoform behavior] Lupke U, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct;45(9–10):358–65 (Eng. Abstr.) **(Ger)**

[Using the method of central relationship conflict topic in a study of the process and outcome of long–term inpatient group psychotherapy] Strauss B, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):342–50 (Eng. Abstr.) **(Ger)**

[Functions of the social worker in a multi–professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119–25 (27 ref.) (Eng. Abstr.) **(Ger)**

[Effectiveness of health promotion measures: a study of quality assurance in inpatient rehabilitation treatment of patients with chronic obstructive respiratory tract diseases] Wilkening R, et al. **Rehabilitation (Stuttg)** 1996 May; 35(2):93–102 (Eng. Abstr.) **(Ger)**

[Admission documentation of multiple trauma patients using the Zurich Trauma Protocol—initial experiences] Heinzelmann M, et al. **Swiss Surg** 1996;(2):35–41 (Eng. Abstr.) **(Ger)**

[Results of early treatment can now be proven (interview by Klaus Reinhardt)] Mattle HP, et al. **Ther Umsch** 1996 Jul;53(7):505–6 **(Ger)**

[Comprehensive geriatric assessment and pharmacotherapy in the clinic] Schulz R, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):429–34 (Eng. Abstr.) **(Ger)**

[The reciprocal reflecting team. A further modification of the reflecting team in inpatient child psychiatry] Menz W, et al. **Z Kinder Jugenpsychiatr** 1995 Sep;23(3):195–200 (Eng. Abstr.) **(Ger)**

[Goal attaining scale. Reliability and practical experiences in 397 psychiatric treatment courses. 2: Practical experiences with a simplified version of Goal Attainment Scaling in clinical practice and intermediate length rehabilitational treatment] Bolm W. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):75–88 (Eng. Abstr.) **(Ger)**

[Individual therapy goals: on outcome documentation of inpatient psychotherapy from the patient and therapist viewpoint] Heuft G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):186–99 (Eng. Abstr.) **(Ger)**

[Inpatient–ambulatory psychoanalytic group therapy, a useful concept] Senf W. **Z Psychosom Med Psychoanal** 1995; 41(4):293–305 (Eng. Abstr.) **(Ger)**

[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?] Engebråten O, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2913–6 (Eng. Abstr.) **(Nor)**

[Emergency hospital admissions. A survey and consumer assessment of conditions in an emergency department admission office] Engebråten O, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2917–20 (Eng. Abstr.) **(Nor)**

[Admissions and readmissions from a unit of ambulatory surgery. Experiences after 2 411 surgical interventions] Grøgaard B, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28; 116(6):742–5 (Eng. Abstr.) **(Nor)**

[Olympic games 1994 and the Medical Department, Lillehammer county hospital] Rolstad OJ, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1107–8 (Eng. Abstr.) **(Nor)**

[Why are patients patients admitted at the hospital as emergencies? (letter; comment) (see comments)] Jiménez Murillo L, et al. **Med Clin (Barc)** 1995 Sep 30;105(10):397–8 . Comment on: Med Clin (Barc) 1994 Oct 15;103(12):452–3. Comment in: Med Clin (Barc) 1991 Feb 2;96(4):132–4. **(Spa)**

[Should stroke patients be admitted into the intensive care units?] Arboix A. **Rev Neurol** 1995 Jan–Feb;23(119):235–6 **(Spa)**

[Should patients with acute cerebrovascular disorders be admitted to the intensive care units?] Chamorro A. **Rev Neurol** 1995 Mar–Apr;23(120):465–6 **(Spa)**

[Should patients with acute cerebrovascular diseases be admitted to intensive care units?] Dávalos Errando A. **Rev Neurol** 1995 Mar–Apr;23(120):461–2 **(Spa)**

[A comparative study of mortality and infectious complications in patients admitted to neurological and general wards] González MJ, et al. **Rev Neurol** 1995 Mar–Apr;23(120):385–9 (Eng. Abstr.) **(Spa)**

[Should patien** with acute cerebrovascular disorders be admitted to intensive care units?] González Marcos JR. **Rev Neurol** 1995 Mar–Apr;23(120):462–3 **(Spa)**

[Should patients with acute cerebrovascular disorders be admitted to intensive care units?] Klamburg i Pujol J. **Rev Neurol** 1995 Mar–Apr;23(120):463–4 **(Spa)**

[Should patients with acute cerebrovascular disorders be admitted to intensive care units?] Mallofré F. **Rev Neurol** 1995 Mar–Apr;23(120):464–5 **(Spa)**

[Should the stroke patients be admitted in intensive care units?] Mostacero Miguel E. **Rev Neurol** 1995 Mar–Apr; 23(120):461–2 **(Spa)**

[Unnecessary admissions to departments of internal medicine. The contact with primary health care must be improved] Bergstad B, et al. **Lakartidningen** 1996 Jun 12;93(24):2344–5 **(Swe)**

ECONOMICS

Utility of routine admission serum chemistry panels in adult trauma patients. Tortella BJ, et al. **Acad Emerg Med** 1995 Mar;2(3):190–4

In–patient care for symptomatic, HIV–infected persons: a longitudinal study of hospitalizations, in–patient drug use, and related costs. Dijkgraaf MG, et al. **AIDS Care** 1995; 7(3):321–36

Brief psychiatric hospitalization: preliminary experience with an urban short–stay unit. Mok H, et al. **Can J Psychiatry** 1995 Sep;40(7):415–7

Counting the cost of diabetic hospital admissions from a multi–ethnic population in Trinidad. Gulliford MC, et al. **Diabet Med** 1995 Dec;12(12):1077–85

Pediatric hospitalization due to ambulatory care–sensitive conditions in Valencia (Spain). Casanova C, et al. **Int J Qual Health Care** 1996 Feb;8(1):51–9

An economic evaluation of short–term inpatient rehabilitation for children with severe asthma. Weinstein AG, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):264–73

Variations in the incidence, management and outcome of stroke in residents under the age of 75 in two health districts of southern England. Wolfe CD, et al. **J Public Health Med** 1995 Dec;17(4):411–8

Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Dartnell JG, et al. **Med J Aust** 1996 Jun 3;164(11):659–62

Snakes and ladders: getting patients into metropolitan public hospitals [letter] [see comments] Jones KS. **Med J Aust** 1996 Jan 1;164(1):55–6. Comment in: Med J Aust 1996 Apr 15;164(8):512.

Socioeconomic equity in Finnish hospital care in relation to need. Keskimäki I, et al. **Soc Sci Med** 1995 Aug; 41(3):425–31

LEGISLATION & JURISPRUDENCE

After the ADA: service dogs on inpatient psychiatric units. Houghtalen RP, et al. **Bull Am Acad Psychiatry Law** 1995; 23(2):211–7

Howe v. Hull. Kidd TW Jr. **Issues Law Med** 1995 Fall; 11(2):193–5

[Criteria for admission of drug dependent criminals for withdrawal treatment according to section 64 StGB with reference to the newest legal guidelines] Möller A, et al. **Gesundheitswesen** 1996 May;58(5):283–7 (Eng. Abstr.) **(Ger)**

[What can the hospital deliver? What must the hospital deliver?] Pannike A. **Unfallchirurgie** 1995 Aug;21(4):204–18 (68 ref.) **(Ger)**

STANDARDS

Evaluation of appropriateness of paediatric admission.

Werneke U, et al. **Arch Dis Child** 1996 Mar;74(3):268–73 (24 ref.)
Quality assurance at the Swan District Hospital. Hughes C. **Aust Clin Rev** 1991;11:103–5
Appropriateness of admissions: the French experience. Lang T, et al. **Int J Qual Health Care** 1995 Sep;7(3):233–8 (16 ref.)
A pilot study of the use of clinical guidelines to determine appropriateness of patient placement on intensive and high dependency care unit. Donnelly P, et al. **J Public Health Med** 1995 Sep;17(3):305–10
Appropriateness of acute geriatric admissions [letter] Wilson PR. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):446–7
Appropriate placement of nursing-home residents in lower levels of care. Spector WD, et al. **Milbank Q** 1996; 74(1):139–60

STATISTICS & NUMERICAL DATA

Incidence of eating disorders in psychiatric hospitals and wards in Denmark, 1970–1993. Munk-Jørgensen P, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):91–6
Age distribution of patients treated in hospital for chronic obstructive pulmonary disease. Vilkman S, et al. **Age Ageing** 1996 Mar;25(2):109–12
ED census and day of the week [letter] Leo PJ, et al. **Am J Emerg Med** 1996 Jan;14(1):114–5
Seasons and bipolar disorder. D'Mello DA, et al. **Ann Clin Psychiatry** 1995 Mar;7(1):11–8
Improving the primary management of emergency surgical admissions: a controlled trial. Gaskell DJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5 Suppl):239–41
Should all patients with ureteric colic be admitted? Morris SB, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):450–2
The relationship between social factors and frequent use of psychiatric services. Kent S, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):403–8
Acute psychiatric beds: distribution and staffing in NSW and ACT. Rosenman S. **Aust N Z J Psychiatry** 1995 Jun; 29(2):238–47
The effect on hospital admissions of psychiatric case management involving general practitioners: preliminary results. Wood K, et al. **Aust N Z J Psychiatry** 1995 Jun; 29(2):223–9
Alternatives to hospital care: what are they and who should decide? [see comments] Coast J, et al. **BMJ** 1996 Jan 20; 312(7024):162–6. Comment in: BMJ 1996 Apr 27;312(7038):1102.
Prescribing and hospital admissions for asthma in east London. Griffiths C, et al. **BMJ** 1996 Feb 24; 312(7029):481–2
Socioeconomic variation in admission for diseases of female genital system and breast in a national cohort aged 15–43. Kuh D, et al. **BMJ** 1995 Sep 30;311(7009):840–3
Waiting list dynamics and the impact of earmarked funding. Newton JN, et al. **BMJ** 1995 Sep 23;311(7008):783–5
First admission incidence study of mania, 1975–1981. Daly I, et al. **Br J Psychiatry** 1995 Oct;167(4):463–8
Social deprivation and psychiatric admission rates among different diagnostic groups. Harrison J, et al. **Br J Psychiatry** 1995 Oct;167(4):456–62
Statistical design, analysis and further correspondence [letter; comment] Marks I. **Br J Psychiatry** 1995 Aug;167(2):270 . Comment on: Br J Psychiatry 1995 Apr;166(4):540. Comment on: Br J Psychiatry 1995 Apr;166(4):543–4.
Excess mortality among elderly psychiatric in-patients with organic mental disorder. Rössler W, et al. **Br J Psychiatry** 1995 Oct;167(4):527–32
Low incidence of mania in northern Finland [letter] Veijola J, et al. **Br J Psychiatry** 1996 Apr;168(4):520–1
Differential use of admission status in a psychiatric emergency room. Rabinowitz J, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):595–606
Short-term efficacy of interventions by a youth crisis team. Greenfield B, et al. **Can J Psychiatry** 1995 Aug;40(6):320–4
Small area variation in the utilization of mental health services: implications for health planning and allocation of resources. Kelly A, et al. **Can J Psychiatry** 1995 Nov; 40(9):527–32
Comorbid disorders in hospitalized bipolar adolescents compared with unipolar depressed adolescents. Borchardt CM, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):11–8
Seasonal pattern of posttraumatic stress disorder admissions. Solt V, et al. **Compr Psychiatry** 1996 Jan–Feb;37(1):40–2
Suicidality in hospitalized patients with a primary diagnosis of personality disorder [see comments] Ahrens B, et al. **Crisis** 1996;17(2):59–63. Comment in: Crisis 1996;17(2):50.
Acute admissions to medical departments. A comparison between an urban and a rural district. Hilsted JC, et al. **Dan Med Bull** 1995 Sep;42(4):371–3
Short-term effects of air pollution on hospital emergency outpatient visits and admissions in the greater Athens, Greece area. Pantazopoulou A, et al. **Environ Res** 1995 Apr;69(1):31–6
Predicting nursing home admissions among incontinent older adults: a comparison of residential differences across six years. Coward RT, et al. **Gerontologist** 1995 Dec; 35(6):732–43
The pattern of increase in emergency hospital admissions in Scotland. Kendrick S. **Health Bull (Edinb)** 1996 Mar; 54(2):169–83
Self-funding and community care admissions to nursing homes in Aberdeen. Newnham DM, et al. **Health Bull (Edinb)** 1996 Jul;54(4):301–6
Measuring hospital use without claims: a comparison of patient and provider reports. Clark RE, et al. **Health Serv Res** 1996 Jun;31(2):153–69
Physician impact on hospital admission and on mortality rates in the Medicare population. Krakauer H, et al. **Health Serv Res** 1996 Jun;31(2):191–211
An epidemiological study of eating disorders in Norwegian psychiatric institutions. Götestam KG, et al. **Int J Eat Disord** 1995 Nov;18(3):263–8
Factors associated with inappropriate emergency hospital admission in the UK. Coast J, et al. **Int J Qual Health Care** 1996 Feb;8(1):31–9
The decline of admissions for xerophthalmia at Cicendo Eye Hospital, Indonesia, 1981–1992. Semba RD, et al. **Int Ophthalmol** 1995;19(1):39–42
Who gets hospitalized in a continuum of care? Bickman L, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan; 35(1):74–80
Psychiatric and behavioral disorders in hospitalized preschoolers with developmental disabilities. Johnson CR, et al. **J Autism Dev Disord** 1995 Apr;25(2):169–82
Burn units' share of Canada's total burn care. Snelling CF. **J Burn Care Rehabil** 1995 Sep–Oct;16(5):519–24
Epidemiology and patterns of hospital use after parasuicide in the south west of England. Gunnell DJ, et al. **J Epidemiol Community Health** 1996 Feb;50(1):24–9
Comparing measures of variation [letter] Newton J, et al. **J Epidemiol Community Health** 1996 Apr;50(2):228
Acute meningitis of unknown aetiology: analysis of 219 cases admitted to hospital between 1977 and 1990. Andersen J, et al. **J Infect** 1995 Sep;31(2):115–22
A system to project injury and illness incidence during military operations. Blood CG, et al. **J Med Syst** 1995 Dec; 19(6):457–64
Compliance with short-term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia. al-Shammari SA, et al. **J R Soc Health** 1995 Aug; 115(4):231–4
Preventing the admission of difficult psychiatric patients--a questionnaire survey. Neeleman J, et al. **J R Soc Med** 1996 Mar;89(3):149–51
Influence of alcoholism on the prognosis of schizophrenic patients. Kozarić-Kovačić D, et al. **J Stud Alcohol** 1995 Nov;56(6):622–7
The effects of patient volume and level of care at the hospital of birth on neonatal mortality. Phibbs CS, et al. **JAMA** 1996 Oct 2;276(13):1054–9
Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions [letter] Barton SB, et al. **Lancet** 1995 Oct 21;346(8982):1102
The impact of practicing in multiple hospitals on physician profiles. Miller ME, et al. **Med Care** 1996 May;34(5):455–62
Difficulties in admitting patients to metropolitan public hospitals: the view of medical practitioners [see comments] Baume P, et al. **Med J Aust** 1995 Oct 16;163(8):401–5. Comment in: Med J Aust 1995 Oct 16;163(8):396. Comment in: Med J Aust 1996 Feb 5;164(3):191.
An evaluation of care coordination in controlling inpatient hospital utilization of people with developmental disabilities. Criscione T, et al. **Ment Retard** 1995 Dec; 33(6):364–73
Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988–91. Doughty R, et al. **N Z Med J** 1995 Nov 24;108(1012):473–5
Services given and help perceived during home care for terminal cancer. Hinton J. **Palliat Med** 1996 Apr; 10(2):125–34
Clinical and administrative consequences of a reduced census on a psychiatric intensive care unit. Citrome L, et al. **Psychiatr Q** 1995 Fall;66(3):209–17
Heavy utilization of inpatient and outpatient services in a public mental health service. Kent S, et al. **Psychiatr Serv** 1995 Dec;46(12):1254–7
Factors influencing disposition decisions for patients seen in a psychiatric emergency service. Rabinowitz J, et al. **Psychiatr Serv** 1995 Jul;46(7):712–8
Schizophrenic subjects with no history of admission to hospital. Geddes JR, et al. **Psychol Med** 1995 Jul; 25(4):859–68
Service utilization by schizophrenic patients in Groningen and South-Verona: an event-history analysis. Sytema S, et al. **Psychol Med** 1996 Jan;26(1):109–19
Increasing age is a risk factor for psychosis in the elderly. van Os J, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Jul;30(4):161–4
Short-term association between air pollution and emergency room visits for asthma in Barcelona. Castellsague J, et al. **Thorax** 1995 Oct;50(10):1051–6
Hospital admission rates for asthma and respiratory disease in the West Midlands: their relationship to air pollution levels. Walters S, et al. **Thorax** 1995 Sep;50(9):948–54
Patterns of admission and discharge in an acute geriatric medical ward. Taylor IC, et al. **Ulster Med J** 1995 Apr; 64(1):58–63
Admission of nursing home patients to geriatric medical wards. Taylor IC, et al. **Ulster Med J** 1994 Oct;63(2):170–5
[Psychiatric admissions in Amsterdam according to ethnic background and diagnosis] Dekker J, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):368–71 (Eng. Abstr.) **(Dut)**
[Comorbidity in a sample of hospitalized depressed patients] Corruble E, et al. **Encephale** 1996 Mar–Apr;22(2):119–26 (Eng. Abstr.) **(Fre)**
[Inpatient management in Germany in comparison with other countries] Jelastopulu E. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):M51–4 **(Ger)**
[Longitudinal analysis of utilization of inpatient treatment based on insurance data of mandatory health insurance] Dörning H, et al. **Gesundheitswesen** 1995 Oct;57(10):631–7 (Eng. Abstr.) **(Ger)**
[Psychiatric disorders in hospitalized internal medicine and surgical patients. Prevalence and need for treatment] Arolt V, et al. **Nervenarzt** 1995 Sep;66(9):670–7 (Eng. Abstr.) **(Ger)**
[Geriatric assessment—case finding by screening hospitalized patients] Kruse WH, et al. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):293–8 (Eng. Abstr.) **(Ger)**
[Hospital admissions for respiratory diseases in the aftermath of the great Hanshin earthquake] Maeda H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):164–73 (Eng. Abstr.) **(Jpn)**
[Evaluation of adequacy of admission and stay in patients admitted at a tertiary hospital through the emergency service (letter; comment)] García Palomar I, et al. **Med Clin (Barc)** 1995 Sep 30;105(10):396–7. Comment on: Med Clin (Barc) 1994 Oct 15;103(12):441–4. **(Spa)**

TRENDS

Trends in burn admissions in Scotland during 1970–92. Sarhadi NS, et al. **Burns** 1995 Dec;21(8):612–5
Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma. Wennergren G, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):742–8
Decline in hospital utilization and cost inflation under managed care in California. Robinson JC. **JAMA** 1996 Oct 2;276(13):1060–4
Trends in admission and case fatality for acute malnutrition (Kingston 1982–1991). Cooper ES, et al. **West Indian Med J** 1996 Mar;45(1):22–4
[No contemporary psychiatric care without sectorization! (editorial; comment)] Bauer M. **Psychiatr Prax** 1996 Mar; 23(2):53. Comment on: Psychiatr Prax 1996 Mar;23(2):55–62. **(Ger)**
[2 class psychiatry (see comments)] Häfner H, et al. **Psychiatr Prax** 1996 Mar;23(2):55–62 (Eng. Abstr.). Comment in: Psychiatr Prax 1996 Mar;23(2):53. Comment in: Psychiatr Prax 1996 Mar;23(2):54. **(Ger)**
[Contemporary psychiatric care without sectorization? (editorial; comment)] Hoffmann-Richter U. **Psychiatr Prax** 1996 Mar;23(2):54. Comment on: Psychiatr Prax 1996 Mar;23(2):55–62. **(Ger)**
[The status of after-care rehabilitation between acute clinic and ambulatory care] von Stetten D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:6–13 **(Ger)**

PATIENT ADVOCACY

Elder law and health care [letter] Kapp MB. **Acad Med** 1995 Dec;70(12):1059
Professional confidentiality is a major right to which our patients are entitled [letter] Bach-Gansmo T. **Acta Radiol** 1996 Jan;37(1):121
Continuity of care in addictions treatment: the role of advocacy and coordination in case management. Graham K, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):433–51
Patient advocacy and interests of the pharmacist's employer [letter] Sloan HS. **Am J Health Syst Pharm** 1996 Feb 1; 53(3):315
Withdrawal from dialysis: the role of autonomy and community-based values. Eiser AR. **Am J Kidney Dis** 1996 Mar;27(3):451–7
Patients' rights to laboratory data: trinucleotide repeat length in Huntington disease [editorial] Burgess MM, et al. **Am J Med Genet** 1996 Mar 1;62(1):6–9
Attending an ethics committee meeting. Edwards BS. **Am J Nurs** 1996 Mar;96(3):62–4
Power, professionalism, and patient advocacy. Flynn MB. **Am J Surg** 1995 Nov;170(5):407–9
Emergency medicine is not a Ford Pinto [letter] Heilicser B. **Ann Emerg Med** 1996 May;27(5):676
Withholding and withdrawing medical treatment: an emergency medicine perspective. Iserson KV. **Ann Emerg Med** 1996 Jul;28(1):51–4 (14 ref.)
Competent patients, incompetent decisions. Kerridge I, et al. **Ann Intern Med** 1995 Dec 1;123(11):878–81
Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)
On advancing advance directives. Why should we believe the promise? [editorial; comment] McIntyre KM. **Arch Intern Med** 1995 Nov 27;155(21):2271–3 (12 ref.). Comment on: Arch Intern Med 1994 Oct 24;154(20):2299–308.
Marked improvement in recognition and completion of health care proxies. A randomized controlled trial of counseling by hospital patient representatives. Meier DE, et al. **Arch Intern Med** 1996 Jun 10;156(11):1227–32
Ethics and organ use [letter; comment] Weinrauch LA. **Arch Intern Med** 1995 Oct 9;155(18):2013, 2017. Comment on: Arch Intern Med 1995 Jan 9;155(1):29–40.
Health care rationing. Who will be patients' advocate if doctors assume the rationing role? [letter; comment] de

Zulueta P. **BMJ** 1996 May 11;312(7040):1230. Comment on: BMJ 1996 Jan 20;312(7024):167–9.

WMA rethinks patients' rights [news] Dyer O. **BMJ** 1995 Sep 16;311(7007):709

Are second opinions a right or a concession? Case history breached confidentiality [letter; comment] Kerwin R. **BMJ** 1995 Dec 2;311(7018):1506. Comment on: BMJ 1995 Sep 9;311(7006):670–2.

Patients' understanding of consent form should be checked before participation in trial [letter; comment] Melby T, et al. **BMJ** 1996 Mar 30;312(7034):847. Comment on: BMJ 1995 Sep 16;311(7007):734–7.

Are second opinions a right or a concession? New developments have transformed outlook for patients with schizophrenia [letter; comment] Murray RM. **BMJ** 1995 Dec 2;311(7018):1506–7. Comment on: BMJ 1995 Sep 9;311(7006):670–2.

Second opinions: a right or a concession? [see comments] Pelosi AJ, et al. **BMJ** 1995 Sep 9;311(7006):670–2. Comment in: BMJ 1995 Dec 2;311(7018):1506. Comment in: BMJ 1995 Dec 2;311(7018):1506–7.

Are second opinions a right or a concession? An important political issue [letter; comment] Rippere V. **BMJ** 1995 Dec 2;311(7018):1506. Comment on: BMJ 1995 Sep 9;311(7006):670–2.

Should doctors be more proactive as advocates for victims of violence? Shepherd J, et al. **BMJ** 1995 Dec 16; 311(7020):1617–21

Code is needed to protect inpatients from press publicity [letter] Smith A, et al. **BMJ** 1996 May 4;312(7039):1163

Advance directives increase personal autonomy [letter; comment] Tonks CM. **BMJ** 1995 Nov 11;311(7015):1302–3 . Comment on: BMJ 1995 Jun 3;310(6992):1433–8.

Ombudsman plans to locate blame in complaints cases [news] Warden J. **BMJ** 1996 Jan 6;312(7022):10

Rights and responsibilities [editorial] Grace M. **Br Dent J** 1996 Aug 10;181(3):79

Anaesthesia with failed intubations [letter; comment] Lim W, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):414. Comment on: Br J Hosp Med 1995 Apr 5–18;53(7):359.

Anaesthesia with failed intubations [letter; comment] Williams EG. **Br J Hosp Med** 1995 Oct 18–31;54(8):414. Comment on: Br J Hosp Med 1995 Apr 5–18;53(7):359.

Supporting and advocating for HIV–positive health care workers. Schatz B. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):263–72

The provider as advocate. Zealand TP. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):300–8

The feisty family. Brock G, et al. **Can Fam Physician** 1995 Sep;41:1483, 1485

Respectful treatment of the elderly [editorial] Nixon M. **Can Fam Physician** 1996 Mar;42:385–6, 395–7 **(Eng, Fre)**

Anti–circumcision groups criticized [letter; comment] Chorn R. **Can Med Assoc J** 1995 Oct 1;153(7):885. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1873–6.

Selecting your surgeon an advantage Canada has over the UK [letter; comment] Dowell AJ. **Can Med Assoc J** 1996 Jul 1;155(1):20. Comment on: Can Med Assoc J 1996 Feb 1;154(3):378–81.

Anti–circumcision groups criticized [letter; comment] Gregory BW. **Can Med Assoc J** 1995 Oct 1;153(7):885–6 . Comment on: Can Med Assoc J 1995 Jun 1;152(11):1873–6.

Physician–assisted suicide and euthanasia: let me count the ways [letter; comment] Harris JD. **Can Med Assoc J** 1995 Oct 1;153(7):884–5. Comment on: Can Med Assoc J 1995 Jun 15;152(12):1961.

Ethical decision–making near the end of life. Finucane TE, et al. **Clin Geriatr Med** 1996 May;12(2):369–77

The case of Baby L revisited [editorial] Goldworth A, et al. **Clin Pediatr (Phila)** 1995 Aug;34(8):452–6

Enhancing family advocacy networks: an analysis of the roles of sponsoring organizations. Briggs HE, et al. **Community Ment Health J** 1995 Aug;31(4):317–33

Medicine and Mephistopheles [editorial] Bone RC. **Crit Care Med** 1996 Jul;24(7):1099–100

Critical care in 1996: Doing too much? Doing too little? Keeping the patient in focus during a time of smoke and fire. The presidential address from the 25th Educational and Scientific Symposium of the Society of Critical Care Medicine. Hoyt JW. **Crit Care Med** 1996 May;24(5):890–2

Well–child care and IDDM: whose responsibility? Wilson SL, et al. **Diabetes Care** 1995 Oct;18(10):1381–2

IRBs and hospital ethics advisory boards [letter] Seibel MM. **Fertil Steril** 1996 Oct;66(4):671

Decision making, responsibility, and advocacy in geriatric medicine: physician dilemmas with elderly in the community. Kaufman SR. **Gerontologist** 1995 Aug; 35(4):481–8

The relationship between volunteer long–term care ombudsmen and regulatory nursing home actions. Nelson HW, et al. **Gerontologist** 1995 Aug;35(4):509–14

From consumer choice to consumer welfare. Schneider CE. **Hastings Cent Rep** 1995 Nov–Dec;25(6):S25–8

Preservation of life or property? [letter; comment] Welsh F. **Hastings Cent Rep** 1995 Nov–Dec;25(6):2. Comment on: Hastings Cent Rep 1994 Nov–Dec;24(6):S1.

Medical necessity: do we need it? Bergthold LA. **Health Aff (Millwood)** 1995 Winter;14(4):180–90

The role of the health service ombudsman. Reid WK. **Health Bull (Edinb)** 1995 Nov;53(6):349–52

Gag clauses in managed care. Brunton SA. **Hosp Pract (Off Ed)** 1996 May 15;31(5):118–9

The patient's charter [letter; comment] Jackson M. **J Accid Emerg Med** 1996 Mar;13(2):150. Comment on: J Accid Emerg Med 1994 Dec;11(4):264–5.

Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882–6 (51 ref.)

HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)

Examining the exam [letter] Gray EJ. **J Am Dent Assoc** 1996 Aug;127(8):1154, 1156

The use of physical restraints and the absence of kindness [editorial; comment] Frengley JD. **J Am Geriatr Soc** 1996 Sep;44(9):1125–7. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1086–92. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1130–3.

Historical notes on restraint reduction: the legacy of Dr. Philippe Pinel [see comments] Levine JM. **J Am Geriatr Soc** 1996 Sep;44(9):1130–3. Comment in: J Am Geriatr Soc 1996 Sep;44(9):1125–7.

Life–sustaining treatment decisions by spouses of patients with Alzheimer's disease. Mezey M, et al. **J Am Geriatr Soc** 1996 Feb;44(2):144–50

From advocacy to tenacity: finding the limits [editorial; comment] Morreim EH. **J Am Geriatr Soc** 1995 Oct; 43(10):1170–2. Comment on: J Am Geriatr Soc 1995 Oct;43(10):1174.

When the bill comes due for the autonomy of demented older adults, who pays? [editorial; comment] Rhymes JA, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1437–8. Comment on: J Am Geriatr Soc 1995 Dec;43(12):1423–9.

The threat of the new managed practice of medicine to patients' autonomy [see comments] Chervenak FA, et al. **J Clin Ethics** 1995 Winter;6(4):320–3. Comment in: J Clin Ethics 1995 Winter;6(4):324–6.

Partiality and the pediatrician. Ladd RE. **J Clin Ethics** 1996 Spring;7(1):29–34

Physician advocacy for patients under managed care. Orentlicher D. **J Clin Ethics** 1995 Winter;6(4):333–4

Managed care and the new medical paternalism [comment] Sulmasy DP. **J Clin Ethics** 1995 Winter;6(4):324–6. Comment on: J Clin Ethics 1995 Winter;6(4):320–3.

The patient as commodity: managed care and the question of ethics. Zoloth–Dorfman L, et al. **J Clin Ethics** 1995 Winter;6(4):339–57 (70 ref.)

The patient's last advocate [editorial] Stulc JP. **J Ky Med Assoc** 1996 Apr;94(4):161

Advocate participation in the context of genetic testing for hereditary cancers. Beard T. **J Natl Cancer Inst Monogr** 1995;(17):123–4

Communicating risk: nuclear physicians as patient advocate [news] Steuer J. **J Nucl Med** 1996 Feb;37(2):11N–12N, 15N

Iowa nurses' knowledge of living wills and perceptions of patient autonomy. Weiler K, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):245–52

On timeless principles in changing times. Boyd CR. **J Trauma** 1995 Nov;39(5):815–7

Birthing pools and infection control [letter] Elsy S. **Lancet** 1996 Jul 27;348(9022):274

Hippocratic Oath [letter; comment] Sher L. **Lancet** 1996 Mar 23;347(9004):834. Comment on: Lancet 1996 Jan 13;347(8994):101–2.

The need for limits in medicine [letter] Jones PD. **Med J Aust** 1995 Oct 16;163(8):448

New legislation on civil commitment in Hungary. Dósa A. **Med Law** 1995;14(7–8):581–7 (15 ref.)

Consent—Scots law and the patient's right to know. Griffiths JR. **Med Law** 1996;15(1):1–6

Constitutional aspects of the right to health care in Slovenia. Kristan I. **Med Law** 1995;14(3–4):239–44

The use of cost–value analysis to judge patients' right to treatment. Nord E. **Med Law** 1995;14(7–8):553–8

Informed consent: the nurse's dilemma. Tabak N. **Med Law** 1996;15(1):7–16

Deception in medical and behavioral research: is it ever acceptable? Wendler D. **Milbank Q** 1996;74(1):87–114 (18 ref.)

BRIDGE: a community–based advocacy program for battered women in the emergency department. Muelleman RL, et al. **Mo Med** 1995 Nov;92(11):685–7

Barriers to patients' rights [letter; comment] Balducci L. **N Engl J Med** 1996 Jul 11;335(2):136; discussion 136–7. Comment on: N Engl J Med 1996 Feb 22;334(8):532–4.

Patient advocacy in the 1990s [letter; comment] Goldberg MJ. **N Engl J Med** 1996 Jul 11;335(2):137; discussion 137–8 . Comment on: N Engl J Med 1996 Feb 22;334(8):543–4.

Patient advocacy in the 1990s [letter; comment] Hopefl A. **N Engl J Med** 1996 Jul 11;335(2):137; discussion 137–8. Comment on: N Engl J Med 1996 Feb 22;334(8):543–4.

Social, institutional, and economic barriers to the exercise of patients' rights [see comments] Levinsky NG. **N Engl J Med** 1996 Feb 22;334(8):532–4. Comment in: N Engl J Med 1996 Jul 11;335(2):136; discussion 136–7.

Barriers to patients' rights [letter; comment] Peters SG. **N Engl J Med** 1996 Jul 11;335(2):136; discussion 136–7. Comment on: N Engl J Med 1996 Feb 22;334(8):532–4.

Barriers to patients' rights [letter; comment] Salmon D, et al. **N Engl J Med** 1996 Jul 11;335(2):136; discussion 136–7 . Comment on: N Engl J Med 1996 Feb 22;334(8):532–4.

Patient advocacy in the 1990s [see comments] Weston B, et al. **N Engl J Med** 1996 Feb 22;334(8):543–4. Comment in: N Engl J Med 1996 Jul 11;335(2):137; discussion 137–8.

Rising health–care costs inevitable [editorial] [see comments] Culliton BJ. **Nat Med** 1995 Oct;1(10):975. Comment in: Nat Med 1996 Jan;2(1):5.

Current challenges. Dincin J. **New Dir Ment Health Serv** 1995 Winter;(68):95–105

HIV infection. Clinical research. Considerations for prospective participants. Hutchins SA, et al. **Nurs Clin North Am** 1996 Mar;31(1):125–35 (17 ref.)

A patient's self–determination is sometimes difficult to accept. Rohaly–Davis J. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):118

Patient rights and surrogacy. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):186–90

Becoming an advocate for the elderly. Hoepfer M. **Pa Med** 1995 Nov;98(11):24–6

You are not alone. Advocacy for children and young adults with rheumatic diseases. Spurrier K, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1299–309

A patient in the teaching hospital: balancing privacy and education [see comments] Sargeant RR. **Pharos** 1995 Summer;58(3):29–34. Comment in: Pharos 1995 Summer;58(3):43.

AIDS researchers, activists fight crisis in clinical trials [news] Nowak R. **Science** 1995 Sep 22;269(5231):1666–7

Patient rights and physician responsibility: four problems in AIDS care. Cooke M. **Semin Dermatol** 1995 Sep; 14(3):252–8

Supporting patient autonomy: decision making in home care. Davitt JK, et al. **Soc Work** 1996 Jan;41(1):41–50

The effects of managed behavioral health care utilization review on hospital substance abuse detoxification. Gray MC. **Soc Work Health Care** 1995;21(2):71–81

The advocacy role in hospital social work. Herbert M, et al. **Soc Work Health Care** 1996;22(3):71–83

Surprising gains. New patient protection regulations limit HMO powers. Jones TL. **Tex Med** 1996 Jul;92(7):29–32

Protecting rights of human subjects. Pranulis MF. **West J Nurs Res** 1996 Aug;18(4):474–8

Physicians can reduce the incidence of domestic violence. Jones RF 3rd. **Womens Health Issues** 1995 Winter;5(4):157

Women's health and the pharmacy profession—an alliance whose time has come [letter] Ponte CD. **Womens Health Issues** 1995 Fall;5(3):155–6

[Patients' right and physicians' power] Lindqvist M. **Duodecim** 1995;111(1):96–9 **(Fin)**

[Missions of medicine and the foundation of medical morals] Daher M. **J Med Liban** 1995;43(1):33–5 **(Fre)**

[What is our approach to patients in persistent vegetative state? (editorial)] Roth F. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1187–90 (20 ref.) **(Ger)**

[Nursing staff between physician and patient] Beeler R. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):454–8 (Eng. Abstr.) **(Ger)**

[How much truth can the patient endure?] Uchtenhagen A. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):451–3 (Eng. Abstr.) **(Ger)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

[No one can freely decide about life, neither about his own life nor about the lives of others. On conflict between patients' autonomy and the obligation to help] Hafting M. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):595–6 **(Nor)**

[Patients' experiences may yield valuable information on quality assurance] Husom N. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1626–7 **(Nor)**

[The fight against "health criminality" (letter)] von Hanno T. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):1014 **(Nor)**

[The right to work and the non–discrimination of individuals infected with the human immunodeficiency virus, HIV/AIDS. The fitness test (editorial)] Torgal J. **Acta Med Port** 1995 Jul–Aug;8(7–8):401–4 **(Por)**

[Bioethics and terminal illness (letter; comment)] Jolín L. **Aten Primaria** 1995 Sep 30;16(5):293. Comment on: Aten Primaria 1995 Jan;151(1):36, 38, 40 passim. **(Spa)**

[From paternalism to democracy: beneficence—person and current bioethics in Puerto Rico] Lugo E. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):67–71 **(Spa)**

[More penalties without reason by the disciplinary board. Criticism against the handling of appendicitis] Andersson R. **Lakartidningen** 1996 Jun 26;93(26–27):2524–5 **(Swe)**

[Patients' position is weakened again! (letter)] Fabian C. **Lakartidningen** 1996 Jan 31;93(5):334 **(Swe)**

[Decisions made by insurance companies should be questioned. An offended patient should receive assistance to a legal trial] Johansson B. **Lakartidningen** 1996 May 15; 93(20):1971–2 **(Swe)**

[The health data committee wants law regulations on personal registries in health care] Johnson K. **Lakartidningen** 1996 May 8;93(19):1795 **(Swe)**

[What principles should be used when medical records are to be destroyed? (letter)] Jonsson PH, et al. **Lakartidningen** 1996 Aug 28;93(34):2820 **(Swe)**

[A seminar on autonomy and integrity in health care. Who decides the limits of medical self–determination?] Lennholm B. **Lakartidningen** 1996 Feb 28;93(9):803–6 **(Swe)**

[Supervisory groups for better treatment of patients] Lind J. **Lakartidningen** 1996 Jun 19;93(25):2398–402 **(Swe)**

[Patients must have right to test available therapy (letter)] Lindahl C. **Lakartidningen** 1996 Mar 27;93(13):1203–4 **(Swe)**

[A new element presented at a medical congress. Violation of autonomy may cause disease] Lynöe N. **Lakartidningen** 1996 Jan 3;93(1–2):14 **(Swe)**

[Legal protection of patient status. A way to strengthen the patient's right to health care?] Nielsen MK. **Lakartidningen** 1995 Oct 11;92(41):3765–6 **(Swe)**

[Patients' rights are too physician-oriented] Orn P. **Lakartidningen** 1996 May 22;93(21):2012 **(Swe)**

[Women, arise from the delivery bed and protest! (letter; comment)] Thulin L. **Lakartidningen** 1996 Jun 26; 93(26–27):2494. Comment on: Lakartidningen 1996 May 29;93(22):2148–9. **(Swe)**

[Patients' rights—a Scandinavian perspective] Fallberg LH. **Nord Med** 1996 Mar;111(3):67–70 (15 ref.) **(Swe)**

ECONOMICS

Current challenges to the principles of medical law and their new interpretation. Paaso I. **Med Law** 1995;14(7–8):611–21 (15 ref.)

HISTORY

In memoriam: David Byar as an AIDS activist. Harrington M. **Control Clin Trials** 1995 Aug;16(4):270–5

LEGISLATION & JURISPRUDENCE

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)

Legal & ethical safeguards: protection of society's most vulnerable participants in a commercialized organ transplantation system. Banks GJ. **Am J Law Med** 1995; 21(1):45–110 (505 ref.)

In camera inspections of privileged records in sexual assault trials: balancing defendants' rights and state interests under Massachusetts's Bishop Test. Crowley EM. **Am J Law Med** 1995;21(1):131–64 (313 ref.)

Local research and legal advocacy for the medically indigent in Orange County, California. Rimsha N, et al. **Am J Public Health** 1996 Jun;86(6):883–5

Special report: protection and advocacy: what nurses need to know. Schauer C. **Arch Psychiatr Nurs** 1995 Oct; 9(5):233–9 (15 ref.)

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)

From a Dutch perspective: response to "Rights of the Terminally Ill Act of the Australian Northern Territory" by Robert L. Schwartz (CQ vol 5, no 1). Kimsma GK, et al. **Camb Q Healthc Ethics** 1996 Spring;5(2):278–80

A different kind of "prisoner's dilemma". Schneiderman LJ, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):530–45

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.). Comment in: Crit Care Med 1996 May;24(5):730–2.

The American Gastroenterological Association legislative and public policy program: advocating for the patient, the clinician, and the academician. Eastwood GL. **Gastroenterology** 1996 Apr;110(4):1263–5

Rights of the patient vs. rights of the public in the "Treatment of the Mentally Ill Law—1991". Bazak J. **Isr J Psychiatry Relat Sci** 1995;32(2):94–101

Problems in implementing the 1991 Treatment of Mental Patients Law in Israel. Mester R, et al. **Isr J Psychiatry Relat Sci** 1995;32(2):102–7; discussion 108

The 1994 Multi-Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3–29 (87 ref.)

Privacy and autonomy in the physician–patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

The Georgia Comprehensive Patient Protection Act: part of the health reform puzzle. Pope DA. **J Med Assoc Ga** 1996 Jan;85(1):45–6

Smokers' rights to health care. Persaud R. **J Med Ethics** 1995 Oct;21(5):281–7

Balancing judicial interests in HIV cases. Part 1, Issues for nurse administrators. Zachary MK. **J Nurs Adm** 1995 Oct; 25(10):51–5

Medical records: law, paternalism and harm. Feenan D. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):401–4

Formal complaints and disciplinary proceedings involving medical practitioners: recent developments in New South Wales, Australia. Buetow SA. **Med Law** 1995; 14(7–8):559–69 (33 ref.)

Inclusionary standard for determining sexual consent for individuals with developmental disabilities. Ames TR, et al. **Ment Retard** 1995 Aug;33(4):264–8

The law hath not been dead: protecting adults with mental retardation from sexual abuse and violation of their sexual freedom. Parker T, et al. **Ment Retard** 1995 Aug; 33(4):257–63

Physicians must provide auxiliary aids/services to assure effective communication with hearing impaired patients. McGraw S, et al. **Mich Med** 1995 Aug;94(8):10–1

The use of media to impact on legislation. Shelov SP. **Pediatr Ann** 1995 Aug;24(8):419–20, 422–5

The adolescent's right to confidential care when considering abortion. American Academy of Pediatrics. Committee on Adolescence. **Pediatrics** 1996 May;97(5):746–51

Do hospitalized psychiatric patients have a right to smoke? Appelbaum PS. **Psychiatr Serv** 1995 Jul;46(7):653–4, 660

Implementation and activities of protection and advocacy programs for persons with mental illness. Sundram CJ. **Psychiatr Serv** 1995 Jul;46(7):702–6

Doctor, your file is open [editorial] Pretorius R. **S Afr Med J** 1996 Apr;86(4):330–2

Patient protection rules a good first step [letter] Rodrigue J. **Tex Med** 1995 Oct;91(10):7

Governor's veto hurts physicians and patients [letter] [see comments] Shah AK. **Tex Med** 1995 Oct;91(10):7–10. Comment in: Tex Med 1995 Dec;91(12):7–8.

Physicians should take note of Governor Bush's veto [letter] West RV. **Tex Med** 1995 Aug;91(8):7

Difference is significant between bureaucratic regulation and individual right to sue [letter; comment] West RV. **Tex Med** 1995 Dec;91(12):7–8. Comment on: Tex Med 1995 Oct;91(10):7–10.

[The Law on Medical Treatment Agreement: common ground with medical education and medical specialist] Brölmann HA, et al. **Ned Tijdschr Geneeskd** 1995 Sep 2; 139(35):1795–8 **(Dut)**

[A stamp with emphasis points as practical aid in the information interview in the framework of the Law on Medical Treatment Agreement] Roding TJ. **Ned Tijdschr Geneeskd** 1995 Sep 2;139(35):1780–1 **(Dut)**

[Incompetency, medical practice and 3rd-party interests: where are the borderlines?] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2746–9 **(Dut)**

[HIV infection in hemophilia patients; report from the National Ombudsman] van Aken WG, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2228–31 **(Dut)**

[Retrospective study of restraining measures in a population of patients admitted under a regimen of involuntary commitment] Dumont F, et al. **Acta Psychiatr Belg** 1995 Jul–Oct;95(4–5):246–59 (Eng. Abstr.) **(Fre)**

[Changes in the liquidation right in the revised Federal Health Insurance regulation] Jansen C Jr. **Dtsch Med Wochenschr** 1996 May 10;121(19):639–40 **(Ger)**

[Compulsory commitment to a psychiatric hospital—the status in Austria] Haberfellner EM, et al. **Psychiatr Prax** 1996 May;23(3):139–42 (Eng. Abstr.) **(Ger)**

[Patient rights alone are not enough, too many rights can also be harmful] Barolin GS. **Wien Med Wochenschr** 1996; 146(4):79–84 (Eng. Abstr.) **(Ger)**

[The patient's right to make decisions, where does it start and where does it end? (letter)] Kazy Z. **Orv Hetil** 1995 Dec 10;136(50):2759–60 **(Hun)**

[Declaration or legislation on patients' rights? (editorial)] Aärimaa M. **Nord Med** 1996 Mar;111(3):66 **(Swe)**

PATIENT APPOINTMENTS see **APPOINTMENTS AND SCHEDULES**

PATIENT CARE EPISODES see **EPISODE OF CARE**

PATIENT CARE PLANNING

see related
AFTERCARE
CONSUMER PARTICIPATION

Cognitive therapy techniques in continuing care planning with substance-dependent patients. Whorley LW. **Addict Behav** 1996 Mar–Apr;21(2):223–31

Beyond futility to an ethic of care [letter; comment] Brett AS, et al. **Am J Med** 1995 Oct;99(4):443–4. Comment on: Am J Med 1994 Feb;96(2):110–4.

Imaging on a budget. Joy HL. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):665–6

Video cephalometric diagnosis (VCD): a new concept in treatment planning? Sarver DM. **Am J Orthod Dentofacial Orthop** 1996 Aug;110(2):128–36

Reversing a history of unmet needs: approaches to care for persons with co-occurring addictive and mental disorders. Osher FC, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):4–11 (40 ref.)

Communication in orthodontic treatment planning: bioethical and informed consent issues [see comments] Ackerman JL, et al. **Angle Orthod** 1995;65(4):253–61. Comment in: Angle Orthod 1995;65(4):243. Comment in: Angle Orthod 1995;65(4):243.

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412–5 (18 ref.)

Predicting clinical states in individual patients. Braitman LE, et al. **Ann Intern Med** 1996 Sep 1;125(5):406–12 (28 ref.)

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Population requirements for capitation planning in pediatric cardiac surgery. Davis JT, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):257–9

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S45–51 (58 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 3. Cancer rehabilitation. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S52–8 (38 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. Hertanu JS, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S38–44 (92 ref.)

Focused review: physiatric management of HIV-related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

Care management. Care programme approach constitutes good management [letter; comment] Phelan M. **BMJ** 1996 Jun 15;312(7045):1539–40. Comment on: BMJ 1996 Mar 2;312(7030):523–4.

Teeth for life [letter] Crowley R. **Br Dent J** 1996 May 11; 180(9):326

The impact of medical libraries and literature on patient care in New Zealand. Burton JE. **Bull Med Libr Assoc** 1995 Oct;83(4):425–30

Individualizing the treatment of gout. George TM, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):150–5 (16 ref.)

Brief child assessment battery to assist with treatment planning and program evaluation. Goldman J, et al. **Community Ment Health J** 1995 Oct;31(5):437–48

Context trees: representing co-operative healthcare activities in IREP. Florit AM, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):175–81

Data entry in computer-based care planning. Heathfield HA, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):103–7

Computerized support for case management ISAACC. Bliss-Holtz J. **Comput Nurs** 1995 Nov–Dec;13(6):289–94

Project Cybernurse. Part II. Implementation. Yensen J. **Comput Nurs** 1996 Jan–Feb;14(1):17–8

Patient evaluation and treatment planning for complete-denture therapy. Engelmeier RL, et al. **Dent Clin North Am** 1996 Jan;40(1):1–18

Treatment goal-planning: outcome findings of a British prospective multi-centre study of adolescent inpatient units. Rothery D, et al. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):209–20

Integration of three-dimensional cephalometry and 3D-skull models in combined orthodontic/surgical treatment planning. Fuhrmann R, et al. **Fortschr Kieferorthop** 1996 Feb;57(1):32–45 **(Eng, Ger)**

Decision-making situations in health care. Murdach AD. **Health Soc Work** 1995 Aug;20(3):187–91 (37 ref.)

Discharge planning: comparison of patients and nurses' perceptions of patients following hospital discharge. Reiley P, et al. **Image J Nurs Sch** 1996 Summer;28(2):143–7

Towards an individualized client's care: implication for education. The transcultural approach. Abdullah SN. **J Adv Nurs** 1995 Oct;22(4):715–20 (36 ref.)

Case study of a female client on a regional secure unit. Duff A. **J Adv Nurs** 1996 Apr;23(4):771–5

Deputed power of medical control: the hidden message in the ritual of oral shift reports. Ekman I, et al. **J Adv Nurs** 1995 Nov;22(5):1006–11

Care planning as a strategy to manage variation in practice: from care plan to integrated person-based record. Hoy JD, et al. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):260–6

Image- and model-based surgical planning in otolaryngology. Korves B, et al. **J Otolaryngol** 1995 Oct; 24(5):265–70

Perspective of facial esthetics in dental treatment planning. Mack MR. **J Prosthet Dent** 1996 Feb;75(2):169–76 (48 ref.)

An 85-year-old woman with a history of falls [clinical conference] Lipsitz LA. **JAMA** 1996 Jul 3;276(1):59–66

Another health care idea: disease management [news] Marwick C. **JAMA** 1995 Nov 8;274(18):1416–7

Users guides to the medical literature. X. How to use an article reporting variations in the outcomes of health services. The Evidence-Based Medicine Working Group. Naylor CD, et al. **JAMA** 1996 Feb 21;275(7):554–8

Optimizing, diagnostic, and therapeutic strategies using decision-theoretic planning: principles and applications. Kahn CE Jr, et al. **Medinfo** 1995;8 Pt 2:894–8

A decision support database for nurse care planning as part of a hospital information system. Newton C. **Medinfo** 1995; 8 Pt 2:1394–8

Integration of a hospital information system in a Greek cardiac surgery hospital through specific education programs for health care personnel: development of nursing documentation. Tsirintani M. **Medinfo** 1995;8 Pt 2:1407–11

"This is your meeting": a qualitative study of person-centered planning. Hagner D, et al. **Ment Retard** 1996 Jun; 34(3):159–71

Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721–8 (41 ref.)

An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)

Standard of care for pain management interventions. Coyne PJ. **Oncol Nurs Forum** 1995 Oct;22(9):1437–8

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995

Oct;22(9):1395–400 (22 ref.)
Leukemia during pregnancy. Ramirez-Smiley M, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1363–8 (16 ref.)
Prescription planning for peritoneal dialysis: a practice challenge. Krapf R, et al. **Perit Dial Int** 1995;15(5 Suppl):S53–8
The role of the radiologist in surgical management: an audit of clinico-radiological conferences. Dennison AR, et al. **Postgrad Med J** 1996 Aug;72(850):481–3
Treatment planning: implications for structure of the CPR. Hammond KW.
Proc Annu Symp Comput Appl Med Care 1995;:362–6
Hand-held computing in the patient care setting: a pilot project. Karshmer JF, et al.
Proc Annu Symp Comput Appl Med Care 1995;:7–11
On-line documentation of patient care orders. Prophet CM.
Proc Annu Symp Comput Appl Med Care 1995;:464–8
Using intermediate states to improve the ability of the Arden Syntax to implement care plans and reuse knowledge. Sherman EH, et al.
Proc Annu Symp Comput Appl Med Care 1995;:238–42
Use of the Rorschach in planning psychotherapy. Frank G. **Psychol Rep** 1995 Oct;77(2):607–10
Patients education: self-care guides. Rhodes VA, et al. **Semin Oncol Nurs** 1995 Nov;11(4):298–304
Medicare and HMOs [letter] Pelofsky S, et al. **Surg Neurol** 1996 May;45(5):504
[Psychiatric therapeutic programs--practical design] Lauritsen BJ. **Ugeskr Laeger** 1996 Sep 9;158(37):5148–9 (Eng. Abstr.) **(Dan)**
[Hormonal replacement treatment: therapeutic protocols] Jamin C. **Contracept Fertil Sex** 1996 Feb;24(2):147–52 (39 ref.) (Eng. Abstr.) **(Fre)**
[Targeted periodontal maintenance] Defleur P, et al. **Rev Belge Med Dent** 1995;50(4):53–62 (Eng. Abstr.) **(Fre)**
[Treatment plan for removable partial prostheses] Maes J, et al. **Rev Belge Med Dent** 1995;50(4):37–52 (47 ref.) (Eng. Abstr.) **(Fre)**
[Optimizing complicated treatments in dental medicine indirectly through the coordination center. Current challenges] Opdebeeck HM. **Rev Belge Med Dent** 1995; 50(4):28–36 (Eng. Abstr.) **(Fre)**
[Treatment planning. Learning to solve complicated dental problems] Verdonschot EH. **Rev Belge Med Dent** 1995; 50(4):9–27 (Eng. Abstr.) **(Fre)**
[Abdominal irradiation in seminomas: improvement in its planning with MRT] Zimmermann FB, et al. **Strahlenther Onkol** 1996 Jun;172(6):295–300 (Eng. Abstr.) **(Ger)**
[The usefulness of computer tomography in planning cochlear implant surgery] Fava C, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):39–45 (Eng. Abstr.) **(Ita)**
[The importance of using computed tomographic scanning in breast irradiation after conservative treatment] Sciacero P, et al. **Radiol Med (Torino)** 1996 Apr;91(4):448–51 (Eng. Abstr.) **(Ita)**
[An analysis of the mortality in the planned surgery for peptic ulcer] Skatin LI, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):352–5 **(Rus)**
[The use of x-ray computed tomography and a simulator in the planning of radiation therapy] Molchanov GV, et al. **Vopr Onkol** 1995;41(2):115 **(Rus)**
[Modern means for planning radiation therapy] Sushchikhina MA. **Vopr Onkol** 1995;41(2):109–10 **(Rus)**
[Unlimited cooperation (letter)] Nylander Lundqvist E, et al. **Lakartidningen** 1995 Dec 20;92(51-52):4870 **(Swe)**

CLASSIFICATION

The impact of do-not-resuscitate and patient care category policies on CPR and ventilator support rates. Davila F. **Arch Intern Med** 1996 Feb 26;156(4):405–8
Validity and reliability of standard terms and codes for patient care data. Ozbolt JG, et al.
Proc Annu Symp Comput Appl Med Care 1995;:37–41

ECONOMICS

Managed caring(!)(?) [editorial] Bryan CS. **J S C Med Assoc** 1995 Dec;91(12):507–8

ORGANIZATION & ADMINISTRATION

How to improve your shift report. Mosher C, et al. **Am J Nurs** 1996 Aug;96(8):32–4
Reduced resource utilization through standardized outcome-focused care plans. Adams CE, et al. **J Nurs Adm** 1995 Oct;25(10):43–50
Establishing an interdisciplinary patient care team: collaboration at the bedside and beyond. McHugh M, et al. **J Nurs Adm** 1996 Apr;26(4):21–7
Patient care coordinators: successfully merging utilization management and discharge planning. McNamara ST, et al. **J Nurs Adm** 1995 Nov;25(11):33–8
The hospital information system as a source for the planning and feed-back of specialized health care. Liebelt P, et al. **Medinfo** 1995;8 Pt 1:542
New care model shifts accountability from manager to staff nurses. McArt N. **Oncol Nurs Forum** 1995 Sep;22(8):1288

STANDARDS

Ethical and legal issues in nursing home care. Hayley DC, et al. **Arch Intern Med** 1996 Feb 12;156(3):249–56 (65 ref.)
Communication and cytopathology--Part IV: Cytohistologic correlation and patient care [editorial] Davey DD, et al. **Diagn Cytopathol** 1995 Jul;13(1):1–2
Assessing quality of nursing home care: the foundation for improving resident outcomes. Rantz MJ, et al. **J Nurs Care Qual** 1996 Jul;10(4):1–9
A piece of my mind. Standards of Care. Argy O. **JAMA** 1996 May 1;275(17):1296
Another standard of care--the patient [letter] Kellerman R. **JAMA** 1996 Aug 14;276(6):450
User's guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. Wilson MC, et al. **JAMA** 1995 Nov 22-29;274(20):1630–2
Using clinical practice improvement: an interview with Susan Horn [interview by Steven Berman] Horn SD. **Jt Comm J Qual Improv** 1995 Jun;21(6):301–8
A community trial of a written self management plan for children with asthma. Asthma Foundation of NZ Children's Action. Gillies J, et al. **N Z Med J** 1996 Feb 9;109(1015):30–3

STATISTICS & NUMERICAL DATA

Developing an outcomes infrastructure for nursing. The Outcomes Taskforce. Lush MT, et al.
Proc Annu Symp Comput Appl Med Care 1995;:625–9

PATIENT CARE TEAM

Bridging the professions: an integrated and interdisciplinary approach to teaching health care ethics. Browne A, et al. **Acad Med** 1995 Nov;70(11):1002–5
The neuroradiologist's contribution to stereotactic neuro-radio-surgery. Schindler E.
Acta Neurochir Suppl (Wien) 1995;63:9–15
Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al.
Acta Neurochir (Wien) 1996;138(2):119–31 (46 ref.)
Normality and abnormality in behavioural aspect. Rhi BY. **Acta Neurochir (Wien)** 1995;132(4):164–8
Routine evaluation of mental health: reliable information or worthless "guesstimates"? Loevdahl H, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):125–8
Spiritual distress: an indigenous model of nonpsychotic mental illness in primary care in Harare, Zimbabwe. Patel V. **Acta Psychiatr Scand** 1995 Aug;92(2):103–7
Alcohol, other drugs, and what we gain from our patients [editorial] Edwards G. **Addiction** 1995 Aug;90(8):1021–3
Can outreach work? [letter] Morrison CL, et al. **Addiction** 1995 Oct;90(10):1401–4
Management and treatment efficacy of drug and alcohol problems: what do doctors believe? Roche AM, et al. **Addiction** 1995 Oct;90(10):1357–66
Delay in the diagnosis of bacteraemic urinary tract infection in elderly patients. Barkham TM, et al. **Age Ageing** 1996 Mar;25(2):130–2
Collaboration with orthopaedic surgeons [letter] Elliot JR, et al. **Age Ageing** 1996 May;25(3):259
Collaboration with orthopaedic surgeons [letter] Gibson PD. **Age Ageing** 1995 Jul;24(4):367
A proposal for an integrated multidisciplinary assessment battery in elderly stroke patients. Kalra L. **Aging (Milano)** 1995 Jun;7(3):197–201 (57 ref.)
A randomized trial of multidisciplinary in-home care for frail elderly patients awaiting hospital discharge. Melin AL. **Aging (Milano)** 1995 Jun;7(3):247–50
A simple geriatric assessment measure to assist a consultative team decision for nursing home placement. Quartararo M, et al. **Aging (Milano)** 1995 Jun;7(3):184–7
Somatic care wanted by HIV-infected intravenous drug abusers: the patients' opinions and experiences. Krook A, et al. **AIDS Care** 1995;7(3):375–9
Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)
Multi-dimensional adolescent treatment with American Indians. Husted J, et al.
Am Indian Alsk Native Ment Health Res 1995;6(3):23–30
Effects of psychiatric care for dual diagnosis patients treated in a drug dependence clinic. Saxon AJ, et al.
Am J Drug Alcohol Abuse 1995 Aug;21(3):303–13
Introduction to pharmacist participation in measuring and monitoring patients' health-related quality of life. Bungay KM, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S19–23
The kindness of strangers. Dajczman E. **Am J Med** 1996 Aug;101(2):226–7
Comment on correction of a severe Class II malocclusion case report [letter; comment] Grubb JE.
Am J Orthod Dentofacial Orthop 1996 Jan;109(1):20A. Comment on: Am J Orthod Dentofacial Orthop 1995 Oct;108(4):421–7.
The rehabilitation team. Heruti RJ, et al.
Am J Phys Med Rehabil 1995 Nov-Dec;74(6):466–8
Ideological singularity as a defense against clinical complexity. Schultz-Ross RA. **Am J Psychother** 1995 Fall; 49(4):540–7 (35 ref.)
Unearthing shame in the supervisory experience. Talbot NL. **Am J Psychother** 1995 Summer;49(3):338–49
The pharmacist's role on the hospital patient management team. Ronshagen J. **Am Pharm** 1995 Sep;NS35(9):54–9; quiz 59–60
Gastro-oesophageal reflux and oesophageal motility diseases. Who should perform antireflux surgery? Little AG. **Ann Chir Gynaecol** 1995;84(2):103–5
Interrater and observer/self-report correlation of psychopathology in routine clinical practice. Craig TJ, et al. **Ann Clin Psychiatry** 1995 Mar;7(1):25–31
Pressure ulcers [letter; comment] Francis J Jr, et al. **Ann Intern Med** 1996 Sep 1;125(5):421–2. Comment on: Ann Intern Med 1995 Sep 15;123(6):433–42.
Pressure ulcers [letter; comment] Landi F, et al. **Ann Intern Med** 1996 Sep 1;125(5):422. Comment on: Ann Intern Med 1995 Sep 15;123(6):433–42.
Physician-controlled utilization management [letter] Temianka D. **Ann Intern Med** 1996 May 1;124(9):856
Hand sensibility measures used by therapists. Mielke K, et al. **Ann Plast Surg** 1996 Mar;36(3):292–6
The trauma team concept and its implementation in a district general hospital [letter; comment] Hardern RD. **Ann R Coll Surg Engl** 1995 Jul;77(4):316. Comment on: Ann R Coll Surg Engl 1995 Jan;77(1):45–52.
The trauma team concept and its implementation in a district general hospital [letter; comment] Morrison MC. **Ann R Coll Surg Engl** 1995 Jul;77(4):316. Comment on: Ann R Coll Surg Engl 1995 Jan;77(1):45–52.
Evolution and vision [letter] Stonnington HH. **Arch Phys Med Rehabil** 1996 Jul;77(7):734
Sharing care between allied health professionals and general practitioners [editorial] Moorhead R. **Aust Fam Physician** 1995 Nov;24(11):1985
Morning report: essential part of training and patient care in internal medicine [letter] Nair BR, et al. **Aust N Z J Med** 1995 Dec;25(6):740
Borderline personality disorder: a challenge for mental health services. Clarke M, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):409–14
An Afghan airlift. Seibold MA. **Aviat Space Environ Med** 1995 Sep;66(9):905
How can new behavioral knowledge and proven aids to treatment enter the teaching and practice of obstetrics? [comment] Good RS, et al. **Behav Med** 1995 Fall; 21(3):123–9. Comment on: Behav Med 1995 Fall;21(3):101–12. Comment on: Behav Med 1995 Fall;21(3):113–22.
An integrated behavioral medicine approach to improving care of patients with diabetes mellitus. Jenkins CD. **Behav Med** 1995 Summer;21(2):53–65; discussion 66–8 (19 ref.)
Integrating pharmacy into the primary care team. Freedom from the dispensary is essential [letter; comment] Bradley M. **BMJ** 1995 Sep 16;311(7007):753. Comment on: BMJ 1995 Jun 24;310(6995):1620–1.
Morbidity and severity of illness during interhospital transfer: impact of a specialised paediatric retrieval team [see comments] Britto J, et al. **BMJ** 1995 Sep 30; 311(7009):836–9. Comment in: BMJ 1996 Jan 13;312(7023):119; discussion 121. Comment in: BMJ 1996 Jan 13;312(7023):119–20. Comment in: BMJ 1996 Jan 13;312(7023):120. Comment in: BMJ 1996 Jan 13;312(7023):120; discussion 121. Comment in: BMJ 1996 Jan 13;312(7023):120–1.
Impact of specialised paediatric retrieval teams. London group's findings supported by study in Leeds [letter; comment] Cray SH. **BMJ** 1996 Jan 13;312(7023):120. Comment on: BMJ 1995 Sep 30;311(7009):836–9.
Integrating pharmacy into the primary care team. "One stop clinic" has advantages for patients [letter; comment] Crowe G, et al. **BMJ** 1995 Sep 16;311(7007):753. Comment on: BMJ 1995 Jun 24;310(6995):1620–1.
Specialist surgeons and survival in breast cancer. A multidisciplinary approach is needed [letter; comment] Dixon JM, et al. **BMJ** 1996 May 4;312(7039):1155–6. Comment on: BMJ 1996 Jan 20;312(7024):145–8.
Impact of specialized paediatric retrieval teams. Criteria indicating physiological morbidity were too non-specific [letter; comment] [see comments] Kelleher A, et al. **BMJ** 1996 Jan 13;312(7023):119–20. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.
Impact of specialised paediatric retrieval teams. A regionally based retrieval service is warranted [letter; comment] [see comments] Mok Q, et al. **BMJ** 1996 Jan 13;312(7023):119; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.
Impact of specialised paediatric retrieval teams. Comparison of teams is difficult [letter; comment] [see comments] Morrison A, et al. **BMJ** 1996 Jan 13;312(7023):119; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.
Impact of specialised paediatric retrieval teams. Children are still transferred by non-specialist teams [letter; comment] Sharples A, et al. **BMJ** 1996 Jan 13;312(7023):120–1. Comment on: BMJ 1995 Sep 30;311(7009):836–9.
Community care and general practice. Multidisciplinary, proactive care is needed [letter; comment] Singleton A, et al. **BMJ** 1996 Jan 20;312(7024):184. Comment on: BMJ

1995 Sep 30;311(7009):823–4.
Combining specialist and primary health care teams for HIV positive patients: retrospective and prospective studies. Smith S, et al. **BMJ** 1996 Feb 17;312(7028):416–20
Acute pain services. Purchasers must be prepared to pay for a multidisciplinary team [letter; comment] Susay SR. **BMJ** 1995 Oct 14;311(7011):1023. Comment on: BMJ 1995 Aug 5;311(7001):360–1.
Community care of patients with schizophrenia: the role of the primary health care team. King M, et al. **Br J Gen Pract** 1996 Apr;46(405):231–7 (89 ref.)
Family systems ideas in the 10-minute consultation: using a reflecting partner or observing team in a surgery. Mayer R, et al. **Br J Gen Pract** 1996 Apr;46(405):229–30
The gasman and the water board: let's work together [editorial] Barton IK, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):160–1
Bullous emphysema: the role of the surgeon. Briffa N, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):213–7 (20 ref.)
Cystic fibrosis: adult clinical aspects. Conway SP. **Br J Hosp Med** 1996 Mar 6–19;55(5):248–52 (20 ref.)
Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):171–5 (23 ref.)
Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):15–7 (10 ref.)
Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)
The team approach to percutaneous endoscopic gastrostomy feeding. Hussain A, et al. **Br J Hosp Med** 1995 Oct 4–17; 54(7):308–12
The 6-week postnatal visit [letter] Oates S. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):222
Revisiting the psychological aspects of AIDS: has the crisis passed? [editorial] Ratigan BJ. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):158–9
The eye in systemic disease. Stanbury RM, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):19–26 (16 ref.)
Cystic fibrosis: paediatric aspects. Wallis C. **Br J Hosp Med** 1996 Mar 6–19;55(5):241–7 (32 ref.)
Family therapy with 'invisible families'. Hay J, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):125–33
Skull base surgery [editorial] Uttley D. **Br J Neurosurg** 1995; 9(4):437–9
Keeping count for the community [letter] Blackwell M. **Br J Psychiatry** 1995 Dec;167(6):823
Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104–11 (65 ref.)
A comparison of the characteristics of chronic fatigue syndrome in primary and tertiary care. Euga R, et al. **Br J Psychiatry** 1996 Jan;168(1):121–6
Repeat prescription antidepressants and residential care [letter] Farmer A. **Br J Psychiatry** 1995 Sep;167(3):408–9
Psychological debriefing [letter; comment] Gillham AB. **Br J Psychiatry** 1995 Sep;167(3):407. Comment on: Br J Psychiatry 1995 May;166(5):676–7.
The essence of supportive psychotherapy [letter] Lucas RN. **Br J Psychiatry** 1996 Jan;168(1):128
The use of environmental strategies and psychotropic medication in the management of delirium. Meagher DJ, et al. **Br J Psychiatry** 1996 Apr;168(4):512–5
The Edinburgh Primary Care Depression Study: personality disorder and outcome. Patience DA, et al. **Br J Psychiatry** 1995 Sep;167(3):324–30
Effect of early life experiences and personality on the reporting of psychosocial distress in general practice. A preliminary investigation. Weich S, et al. **Br J Psychiatry** 1996 Jan;168(1):116–20
An evaluation of community-based psychiatric care for people with treated long-term mental illness. Wilkinson G, et al. **Br J Psychiatry** 1995 Jul;167(1):26–37; discussion 38–40
Models of brain injury rehabilitation. Burke DC. **Brain Inj** 1995 Oct;9(7):735–43 (34 ref.)
Team development and memory training in traumatic brain injury rehabilitation: two birds with one stone. Finset A, et al. **Brain Inj** 1995 Jul;9(5):495–507
The function of the multidisciplinary team in child psychiatry—clinical and educational aspects. Benierakis CE. **Can J Psychiatry** 1995 Aug;40(6):348–53
Conceptual models and integrative therapy: anorexia nervosa as a prototype. Greben DH, et al. **Can J Psychiatry** 1995 Dec;40(10):584–92 (65 ref.)
The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)
Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study. Patten SB, et al. **Can J Psychiatry** 1995 Jun;40(5):264–9
Depression in the medically ill [editorial; comment] Stenn PG. **Can J Psychiatry** 1996 Mar;41(2):65–6. Comment on: Can J Psychiatry 1996 Mar;41(2):67–74.
The role of research in systems reform. Wasylenki DA, et al. **Can J Psychiatry** 1995 Jun;40(5):247–51
A study of the variability of training and beliefs among professionals who interview children to investigate suspected sexual abuse. Davey RI, et al. **Child Abuse Negl** 1995 Aug;19(8):933–42
Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.). Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.
Sexual abuse evaluations in the emergency department: is the history reliable? Gordon S, et al. **Child Abuse Negl** 1996 Apr;20(4):315–22
Exploring new territory: police organizational responses to child sexual abuse. Humphreys C. **Child Abuse Negl** 1996 Apr;20(4):337–44
Whatever happened on the way to counselling? Hurdles in the interagency environment. Humphreys C. **Child Abuse Negl** 1995 Jul;19(7):801–9
The helping alliance in work with families where children have been abused or neglected [editorial; comment] Jones DP. **Child Abuse Negl** 1996 Apr;20(4):345–7. Comment on: Child Abuse Negl 1996 Apr;20(4):349–61.
Interdisciplinary training in the evaluation of child sexual abuse. Palusci VJ, et al. **Child Abuse Negl** 1995 Sep; 19(9):1031–8
Childhood sexually transmitted diseases and child sexual abuse: results of a Canadian survey of three professional groups. Thomas BH, et al. **Child Abuse Negl** 1995 Sep; 19(9):1019–29
Client and worker satisfaction in a child protection agency. Winefield HR, et al. **Child Abuse Negl** 1995 Aug; 19(8):897–905
Importance of communication training for psychiatric residents and mental health trainees. Giddan JJ, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):19–28
Compliance enhancement. A call for multidisciplinary team approaches [editorial] Hill MN, et al. **Circulation** 1996 Jan 1;93(1):4–6
The team approach to cleft and craniofacial disorders—the down side [editorial] Sidman JD. **Cleft Palate Craniofac J** 1995 Sep;32(5):362
Evolving across disciplines. Strauss RP. **Cleft Palate Craniofac J** 1995 Jul;32(4):268
A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35–9 (0 ref.)
Barriers to social network interventions with persons with severe and persistent mental illness: a survey of mental health case managers. Biegel DE, et al. **Community Ment Health J** 1995 Aug;31(4):335–49
Routine assessment of patient progress: a multiformat, change-sensitive nurses' instrument for assessing psychotic inpatients. Ehmann TS, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):289–95
Selected topics in dermatology for the primary care physician. Bentz MA, et al. **Compr Ther** 1996 Mar; 22(3):135–43 (25 ref.)
Porphyria cutanea tarda: a clinical review. Cohen DJ, et al. **Compr Ther** 1996 Mar;22(3):175–8 (11 ref.)
Calculation of patient's complexity: paramedical and nursing facets. Delacrétaz AC, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):97–102
Inaccurate medical student introductions: frequency and motivation. Beatty ME, et al. **Conn Med** 1995 Aug; 59(8):455–60
Electroconvulsive therapy patient/family education. Dillon P. **Convuls Ther** 1995 Sep;11(3):188–91
Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al-Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)
Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Larsson J, et al. **Diabet Med** 1995 Sep; 12(9):770–6
Esophageal cancer: which stent, who places it, and where? [editorial] Lambert R. **Endoscopy** 1995 Sep;27(7):509–11
Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. 15 year follow-up study. Hämäläinen H, et al. **Eur Heart J** 1995 Dec;16(12):1839–44
The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Wiklund T, et al. **Eur J Cancer** 1996 Feb;32A(2):269–73
Paediatrician attendance at caesarean section. Ng PC, et al. **Eur J Pediatr** 1995 Aug;154(8):672–5
Acceptability of shared care for asymptomatic HIV-positive patients. Grun L, et al. **Fam Pract** 1995 Sep;12(3):299–302
The relationship between complaint-related cognitions in referred patients with irritable bowel syndrome and subsequent health care seeking behaviour in primary care. van Dulmen AM, et al. **Fam Pract** 1996 Feb;13(1):12–7
Do primary care patients accept psychological treatments? Arean PA, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):22–7
Overdiagnosis of depression in the general hospital. Boland RJ, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):28–35
The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414–24 (43 ref.)
Functioning and well-being of patients in a consultation-liaison psychiatry clinic. Epstein SA, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):3–7
Patients' threats. Expanded definition of assault. Flannery RB Jr, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):451–3
Treating the patient who is disfigured by head and neck cancer. Kunkel EJ, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):444–50
An interdisciplinary mental health consultation team in a nursing home. Joseph C, et al. **Gerontologist** 1995 Dec; 35(6):836–9
Nutrition support teams: an integral part of developing a gastroenterology service. Reynolds N, et al. **Gut** 1995 Dec; 37(6):740–2 (19 ref.)
Abortion and the maternal-fetal medicine physician [letter] Hilgers TW. **Hastings Cent Rep** 1995 Sep–Oct;25(5):2–3
Abortion and the maternal-fetal medicine physician [letter; comment] Klaus H. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.
Abortion and the maternal-fetal medicine physician [letter; comment] Meilaender G. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.
Abortion and the maternal-fetal medicine physician [letter; comment] Wechter DJ. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.
An audit of medical paediatric out-patient appointments and letters. Brown DC, et al. **Health Bull (Edinb)** 1995 Sep; 53(5):269–73
Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374–80 (50 ref.)
Introduction to the special section: the neglected psychological-physical interface. Melamed BG. **Health Psychol** 1995 Sep;14(5):371–3
Interdisciplinary expectations of the medical social worker in the hospital setting: Part 2. Cowles LA, et al. **Health Soc Work** 1995 Nov;20(4):279–86
Primary health care physicians' treatment of psychosocial problems: implications for social work. Gross R, et al. **Health Soc Work** 1996 May;21(2):89–95
Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)
Home health—the nursing circuit. Lumsdon K. **Hosp Health Netw** 1995 Oct 5;69(19):80
Evidence-based medicine: the Cochrane Collaboration [editorial] Ramirez G. **Hosp Pract (Off Ed)** 1996 Apr 15; 31(4):11–4
Awareness on AIDS among health care professionals. Dobe M. **Indian J Public Health** 1995 Jul–Sep;39(3):105–8
Management of congenital anorectal malformations. Wakhlu AK. **Indian Pediatr** 1995 Nov;32(11):1239–42 (0 ref.)
Teamwork improves breast cancer management in the community. Friend G, et al. **Indiana Med** 1995 Nov–Dec; 88(6):458–9
A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)
A treatment model for women substance users. Wald R, et al. **Int J Addict** 1995 May;30(7):881–8
Treating bulimia nervosa in primary care: a pilot study. Waller D, et al. **Int J Eat Disord** 1996 Jan;19(1):99–103
A shared care approach in obesity management: the general practitioner and a hospital based service. Richman RM, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):413–9
Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221–38 (74 ref.)
Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137–72 (179 ref.)
Psychological distress and cognitive impairment in neurological in-patients: its prevalence and its recognition by residents. Zlot SI. **Int J Psychiatry Med** 1995; 25(2):203–13
Multidisciplinary mental health teams. Slade M, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):180–9
The pastoral myth of the mental hospital: a personal account. Stevenson V, et al. **Int J Soc Psychiatry** 1995 Summer; 41(2):147–51
What provision is made by practicing physicians for psychogeriatric patients in western Germany? Hornung WP, et al. **Int Psychogeriatr** 1995 Spring;7(1):105–14
Ability of a trained primary healthcare nurse to discriminate dementia from other psychogeriatric disorders. Sjöbeck B, et al. **Int Psychogeriatr** 1995 Spring;7(1):9–16
Learning in a health care team. Nelson R. **Iowa Med** 1995 Oct;85(10):415
Interhospital transfer of the critically ill trauma patient: the potential role of a specialist transport team in a trauma system. McGinn GH, et al. **J Accid Emerg Med** 1996 Mar; 13(2):90–2
Nurse-physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)
International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders. Uhlenhuth EH, et al. **J Affect Disord** 1995 Dec 18; 35(4):153–62
Hearing loss and congenital symptomatic cytomegalovirus infection: a case report of multidisciplinary longitudinal assessment and intervention. McCollister FP, et al. **J Am Acad Audiol** 1996 Apr;7(2):57–62
Consultation with young autistic children and their families. Wakschlag LS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):963–5
The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)

An interdisciplinary nutrition support team improves quality of care in a teaching hospital. Fisher GG, et al. **J Am Diet Assoc** 1996 Feb;96(2):176–8

Disciplined decision making in an interdisciplinary environment: some implications for clinical applications of statistical process control. Hantula DA. **J Appl Behav Anal** 1995 Fall;28(3):371–7

Training residential supervisors to provide feedback for maintaining staff teaching skills with people who have severe disabilities. Parsons MB, et al. **J Appl Behav Anal** 1995 Fall;28(3):317–22

Pyramidal staff training in the extension of treatment for severe behavior disorders. Shore BA, et al. **J Appl Behav Anal** 1995 Fall;28(3):323–32

Communicating behavioral views and techniques to practicing clinicians. Hayes SC, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):107–12

Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99–105 (29 ref.)

The advantage of the burn team approach. Demling RH. **J Burn Care Rehabil** 1995 Nov–Dec;16(6):569–72

Physician and nurse considerations for receiving a "fast-track" patient in the intensive care unit. Papadakos PJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):21–3

Consultation section. What would you advise for a patient who has had episodic pupillary capture? **J Cataract Refract Surg** 1996 Jan–Feb;22(1):8–13

Somatisation in children. Garralda ME. **J Child Psychol Psychiatry** 1996 Jan;37(1):13–33 (125 ref.)

Burnout and collegial support in state psychiatric hospital staff. Corrigan PW, et al. **J Clin Psychol** 1995 Sep; 51(5):703–10

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)

Introduction to the special section on contemporary issues in human sexuality: research and practice. Ackerman MD. **J Consult Clin Psychol** 1995 Dec;63(6):859–61

Psychology's role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Ackerman MD, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):862–76 (185 ref.)

Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891–906 (130 ref.)

Increased attention to human sexuality can improve HIV-AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907–18 (120 ref.)

Treatment of sexual disorders in the 1990s: an integrated approach. Rosen RC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):877–90 (185 ref.)

Student operator–assistant pairs. Qualtrough AJ. **J Dent Educ** 1996 Jun;60(6):527–32

Dyslexia: empowering parents to become their child's educational advocate. Linday LA. **J Dev Behav Pediatr** 1995 Oct;16(5):359–61

School underachievement in the fifth grade. Stein MT, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):109–13

A survey of physician use of treatment methods for functional enuresis. Vogel W, et al. **J Dev Behav Pediatr** 1996 Apr; 17(2):90–3

Late-onset Huntington's disease: a geriatric psychiatry perspective. Shulman KI, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):26–9

Measurement of attitudes of trainee professionals to people with disabilities. Beckwith JB, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):255–62

Beliefs and emotional reactions of care staff working with people with challenging behaviour. Bromley J, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):341–52

Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295–305 (43 ref.)

Personality and trait disturbances in an adult mental retardation population: significance for psychiatric management. Goldberg B, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):284–94

Staff strategies and explanations for intervening with challenging behaviodrs. Hastings RP. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):166–75

Offending by adults with learning disabilities and the attitudes of staff to offending behaviour: implications for service development. Lyall I, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):501–8

Care dependence and individual care provision. Maaskant MA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):306–15

Vision care requirements among intellectually disabled adults: a residence-based pilot study. McCulloch DL, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):140–50

Recognizing the allergic child. Jones EA Jr, et al. **J Ky Med Assoc** 1996 Jul;94(7):278–85

A controlled clinical trial of multidisciplinary team approach in the general medical wards of Chulalongkorn Hospital. Jitapunkul S, et al. **J Med Assoc Thai** 1995 Nov; 78(11):618–23

Recovery from aphasia. Farmer LJ. **J Miss State Med Assoc** 1996 Aug;37(8):690–3 (52 ref.)

Memorial Sloan-Kettering goes electronic to manage patient care [news] McIntosh H. **J Natl Cancer Inst** 1996 Aug 7;88(15):1024–6

Pilot project on functional outcome in stroke. Hinkle JL, et al. **J Neurosci Nurs** 1996 Feb;28(1):13–8

Client assessment tool: a means to enhance nurse–client–physician collaboration. Kennedy D, et al. **J Neurosci Nurs** 1995 Oct;27(5):312–8

Myasthenia gravis: pathophysiology, diagnosis and collaborative care. Kernich CA, et al. **J Neurosci Nurs** 1995 Aug;27(4):207–15; quiz 216–8 (18 ref.)

Intrathecal baclofen for spasticity of cerebral palsy: project coordination and nursing care. Rawlins P. **J Neurosci Nurs** 1995 Jun;27(3):157–63

Brain attack: a body of knowledge, a coalition of support [editorial] Stewart-Amidei C. **J Neurosci Nurs** 1996 Feb; 28(1):3

The dilemma of the hasty discharge. Jackson BS. **J Nurs Adm** 1996 Jun;26(6):7–9

A patient care team approach to multicultural patient care issues. Peterson R, et al. **J Nurs Care Qual** 1996 Apr; 10(3):75–9

Intensive immersion of nursing students in rural interdisciplinary care. Erkel EA, et al. **J Nurs Educ** 1995 Nov;34(8):359–65

A perinatal continuing education program: its effects on the knowledge and practices of health professionals. Harris JK, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):829–35

Jungle medicine revisited: an Oklahoma medical team visits Bolivia. Edde RR, et al. **J Okla State Med Assoc** 1995 Nov;88(11):476–8

The importance of a multidisciplinary approach to the assessment of patients with obstructive sleep apnoea. L'Estrange PR, et al. **J Oral Rehabil** 1995 Aug;22(8):607–12

Palliative care providers' perspectives on service and education needs. Sellick SM, et al. **J Palliat Care** 1996 Summer;12(2):34–8

Women's mental health issues. Reflections on past attitudes and present practices. Cowan PJ. **J Psychosoc Nurs Ment Health Serv** 1996 Apr;34(4):20–4

International cooperation to improve the psychiatric care of the general hospital patient: the ECLW Collaborative Study. European Consultation/Liaison Work Group [editorial] Fulop G. **J Psychosom Res** 1996 Feb;40(2):121–2

The ECLW Collaborative study II: patient registration form (PRF) instrument, training and reliability. European Consultation/Liaison Work group. Lobo A, et al. **J Psychosom Res** 1996 Feb;40(2):143–56

Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)

Continuous quality improvement in a day ward. Senior S, et al. **J Qual Clin Pract** 1995 Sep;15(3):177–81

Informing the patient [see comments] Griffin JP, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):107–11. Comment in: J R Coll Physicians Lond 1996 Mar–Apr;30(2):102–3.

Resolution from alcohol problems with and without treatment: reasons for change. Cunningham JA, et al. **J Subst Abuse** 1995;7(3):365–72

Recovering substance abuse staff members' beliefs about addiction. Humphreys K, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):75–8

Attitudes toward nicotine dependence among chemical dependence unit staff—before and after a smoking cessation trial. Hurt RD, et al. **J Subst Abuse Treat** 1995 Jul–Aug; 12(4):247–52

Key ingredients to effective addictions treatment. Waltman D. **J Subst Abuse Treat** 1995 Nov–Dec;12(6):429–39 (50 ref.)

Penetrating wound to the shoulder: a case report that illustrates the need for a multisystem approach to injury. Manitzas ND, et al. **J Tenn Med Assoc** 1996 Feb;89(2):45–6

Institutionalizing continuous improvement in South Carolina: taking it "bird by bird". Chessman A, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):177–87

Changing health care practices in Medicare's Health Care Quality Improvement Program. Jencks SF. **Jt Comm J Qual Improv** 1995 Jul;21(7):343–7

The community clinical oncology program: its effect on clinical practice [comment] Warnecke RB, et al. **Jt Comm J Qual Improv** 1995 Jul;21(7):336–9. Comment on: Jt Comm J Qual Improv 1995 Jul;21(7):347–51.

Caring and sharing [comment] Orton P. **Lancet** 1995 Oct 14;346(8981):984. Comment on: Lancet 1995 Oct 14;990–4.

Herodotus and the multidisciplinary clinic. Schipper H, et al. **Lancet** 1995 Nov 18;346(8986):1312–3

Authority and authoritative knowledge in American birth. Hays BM. **Med Anthropol Q** 1996 Jun;10(2):291–4

Clown doctors: shaman healers of Western medicine. Van Blerkom LM. **Med Anthropol Q** 1995 Dec;9(4):462–75

Managing chronic back pain: impact of an interdisciplinary team approach. Flavell HA, et al. **Med J Aust** 1996 Sep 2;165(5):253–5

Coordinating shared care using electronic data interchange. Branger P, et al. **Medinfo** 1995;8 Pt 2:1669

An evaluation of care coordination in controlling inpatient hospital utilization of people with developmental disabilities. Criscione T, et al. **Ment Retard** 1995 Dec; 33(6):364–73

Family-centered/interdisciplinary team approach to working with families of children who have mental retardation. Lubetsky MJ, et al. **Ment Retard** 1995 Aug;33(4):251–6

Marathon day. A view from the medical tent. Crouse BJ. **Minn Med** 1996 Jul;79(7):10–1

Building bridges to combat cancer. Feldman MK. **Minn Med** 1996 Apr;79(4):6–8

Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Cancer research and treatment. When money, morals, and medical science converge [editorial] Meyer CR. **Minn Med** 1996 Apr;79(4):5

Team spirit. Moriarity JM. **Minn Med** 1996 Jul;79(7):12–8

Inner sanctum. Ta K. **Minn Med** 1996 Jan;79(1):6–7, 56

Postpartum psychiatric disorders. A guide for the practicing physician. Shepard CP, et al. **N C Med J** 1995 Aug; 56(8):386–8

The interdisciplinary geriatric team evaluation project. A new approach to the delivery of geriatric medicine in geographically remote locations. Williams ME, et al. **N C Med J** 1995 Oct;56(10):502–5

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201–22 (114 ref.)

Diagnostic reasoning in neurology. Gifford DR, et al. **Neurol Clin** 1996 Feb;14(1):223–38 (59 ref.)

Roles and functions of the hospital pharmacist on the nutrition support team. Lee HS. **Nutrition** 1996 Feb; 12(2):140

Teamwork in rural practice. Cunningham WF, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):19–22 (45 ref.)

Physical therapists play an important role in treating lymphedema [letter] Augustine E. **Oncol Nurs Forum** 1996 Apr;23(3):421–32

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr; 23(3):478–87 (70 ref.)

Education in palliative medicine [editorial] Doyle D. **Palliat Med** 1996 Apr;10(2):91–2

Home health and respite care. Watson AR. **Perit Dial Int** 1996;16 Suppl 1:S551–3

Studying inpatient treatment practices in schizophrenia: an integrated methodology. Boyer CA, et al. **Psychiatr Q** 1995 Winter;66(4):293–320

Psychiatrists as treatment team leaders: pitfalls and rewards. Rodenhauser P. **Psychiatr Q** 1996 Spring;67(1):11–31 (100 ref.)

Two-year outcome of team-based intensive case management for patients with schizophrenia. Aberg-Wistedt A, et al. **Psychiatr Serv** 1995 Dec; 46(12):1263–6

Pathways to mental health care in Nigeria. Abiodun OA. **Psychiatr Serv** 1995 Aug;46(8):823–6

Clinical decision making during assessment for involuntary psychiatric admission. Anderson J, et al. **Psychiatr Serv** 1995 Jul;46(7):727–8

What's a psychiatrist to do? [letter; comment] Berman LH. **Psychiatr Serv** 1995 Nov;46(11):1194. Comment on: Psychiatr Serv 1995 Aug;46(8):757–8.

Modifying the PACT model to serve homeless persons with severe mental illness. Dixon LB, et al. **Psychiatr Serv** 1995 Jul;46(7):684–8

Special section on assertive community treatment: an introduction. Drake RE, et al. **Psychiatr Serv** 1995 Jul; 46(7):667–8

Consumers as peer specialists on intensive case management teams: impact on client outcomes. Felton CJ, et al. **Psychiatr Serv** 1995 Oct;46(10):1037–44

Contact between psychotherapists and psychiatric residents who provide medication backup. Hansen-Grant S, et al. **Psychiatr Serv** 1995 Aug;46(8):774–7

Psychiatric kibitzing. Houghton MA. **Psychiatr Serv** 1995 Aug;46(8):764–5

Partnerships for people with serious mental illness who live below the poverty line. Lafave HG, et al. **Psychiatr Serv** 1995 Oct;46(10):1071–3

Outcome for psychiatric emergency patients seen by an outreach police-mental health team. Lamb HR, et al. **Psychiatr Serv** 1995 Dec;46(12):1267–71

A multisite study of client outcomes in assertive community treatment. McGrew JH, et al. **Psychiatr Serv** 1995 Jul; 46(7):696–701

Factors predicting patients' satisfaction with managed mental health care. Pickett SA, et al. **Psychiatr Serv** 1995 Jul; 46(7):722–3

Cost-effective communication skills training for state hospital employees. Smoot SL, et al. **Psychiatr Serv** 1995 Aug; 46(8):819–22

Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. Teague GB, et al. **Psychiatr Serv** 1995 Jul;46(7):689–95

Treatment of Hassidic Jewish patients in a general hospital medical-psychiatric unit. Trappler B, et al. **Psychiatr Serv** 1995 Aug;46(8):833–5

Public-academic liaisions in psychiatric residency training in New York State. Tucker W. **Psychiatr Serv** 1995 Dec; 46(12):1289–91

The value of case management for a consumer. Ware T. **Psychiatr Serv** 1995 Dec;46(12):1231–2

Reliability of diagnoses made by psychiatric residents in a

general emergency department. Warner MD, et al. **Psychiatr Serv** 1995 Dec;46(12):1284–6

Clinical practice, measurement and information technology [editorial] Andrews G, et al. **Psychol Med** 1995 May; 25(3):443–6

People with learning disabilities and challenging behaviour: the characteristics of those referred and not referred to specialist teams. Lowe K, et al. **Psychol Med** 1995 May; 25(3):595–603

The Cardinal Needs Schedule—a modified version of the MRC Needs for Care Assessment Schedule. Marshall M, et al. **Psychol Med** 1995 May;25(3):605–17

Concepts of mental illness and medical pluralism in Harare. Patel V, et al. **Psychol Med** 1995 May;25(3):485–93

Transient and persistent hypochondriacal worry in primary care. Robbins JM, et al. **Psychol Med** 1996 May; 26(3):575–89

Causal attributions about common somatic sensations among frequent general practice attenders. Sensky T, et al. **Psychol Med** 1996 May;26(3):641–6

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

Delirium presenting with symptoms of depression. Nicholas LM, et al. **Psychosomatics** 1995 Sep–Oct;36(5):471–9

Rating scales for the psychosocial evaluation of organ transplant candidates. Comparison of the PACT and TERS with bone marrow transplant patients. Presberg BA, et al. **Psychosomatics** 1995 Sep–Oct;36(5):458–61

Psychosocial needs of breast cancer patients in RI. Laliberte L, et al. **R I Med** 1995 Sep;78(9):264–9

Illness and the psyche [editorial] Freeman JW. **S D J Med** 1995 Aug;48(8):236–7

Treatment outcomes in schizophrenia: implications for practice, policy, and research. Lehman AF, et al. **Schizophr Bull** 1995;21(4):669–75 (15 ref.)

Determinants of informal caregivers' satisfaction with services for dying cancer patients. Fakhoury W, et al. **Soc Sci Med** 1996 Mar;42(5):721–31

Variation in diagnoses: influence of specialists' training on selecting and ranking relevant information in geriatric case vignettes. Kalf AJ, et al. **Soc Sci Med** 1996 Mar; 42(5):705–12

General practitioners' assessment of and interest in alternative medicine in Canada. Verhoef MJ, et al. **Soc Sci Med** 1995 Aug;41(4):511–5

The impact on unemployment of an intervention to increase recognition of previously untreated anxiety among primary care physicians. Yelin E, et al. **Soc Sci Med** 1996 Apr; 42(7):1069–75

Occupational exposure of health care workers (HCWs) to human immunodeficiency virus (HIV): stress reactions and counseling interventions. Armstrong K, et al. **Soc Work Health Care** 1995;21(3):61–80

Occupational stress among AIDS social service providers. Cushman LF, et al. **Soc Work Health Care** 1995; 21(3):115–31

Social work and the new integrative hospital. Globerman J, et al. **Soc Work Health Care** 1995;21(3):1–21; discussion 23–7

Research in adolescent suicide: implications for training, service delivery, and public policy. Brent DA, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):222–30 (40 ref.)

Diffusion of responsibility in the care of a difficult patient. Maltsberger JT. **Suicide Life Threat Behav** 1995 Fall; 25(3):415–21

Tuberculosis in the community: 2. The perceptions of members of a tuberculosis health team towards a voluntary health worker programme. Dick J, et al. **Tuber Lung Dis** 1996 Aug;77(4):380–3

Management of venous leg ulcers. Hafner J, et al. **Vasa** 1996; 25(2):161–7 (49 ref.)

Unproven (questionable) cancer therapies. Brigden ML. **West J Med** 1995 Nov;163(5):463–9 (39 ref.)

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul–Aug;20(6):687–91 (36 ref.)

[The patient record form in psychiatry: nomenclature of the types of management] Houssou C, et al. **Encephale** 1996 Jan–Feb;22(1):23–33 (Eng. Abstr.) **(Fre)**

[Interobserver variation of the Global Assessment Scale. Study of 59 patients at admission to a general adult psychiatric unit] Meur F, et al. **Encephale** 1996 Mar–Apr; 22(2):111–7 (Eng. Abstr.) **(Fre)**

[Optimizing complicated treatments in dental medicine indirectly through the coordination center. Current challenges] Opdebeeck HM. **Rev Belge Med Dent** 1995; 50(4):28–36 (Eng. Abstr.) **(Fre)**

[Opinion and attitude of physicians regarding organization and participation on a multidisciplinary alcoholism unit] Boitel S, et al. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):19–24 (Eng. Abstr.) **(Fre)**

[Extracorporeal membrane oxygenation of the newborn infant—an example of interdisciplinary project management] Bartsch H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):420–5 (Eng. Abstr.) **(Ger)**

[Technical prerequisites, required personnel and practical implementation of hyperbaric oxygenation] Hipp R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):108–10 **(Ger)**

[Natural family planning in the physician's office—cooperation with specialized counselors] Freundl G. **Arch Gynecol Obstet** 1995;257(1–4):643–50 **(Ger)**

[Psycho-oncology] Lau HU. **Arch Gynecol Obstet** 1995; 257(1–4):634–8 **(Ger)**

[The cancer patient between academic medicine and alternative medicine—therapeutic concepts] Nagel GA. **Arch Gynecol Obstet** 1995;257(1–4):283–94 (13 ref.) **(Ger)**

[Marketing and teamwork in gynecologic practice] Riegl GF. **Arch Gynecol Obstet** 1995;257(1–4):736–9 **(Ger)**

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):129–35 (8 ref.) **(Ger)**

[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

[Rheumatism: a too long pathway to adequate therapy. Experiences of a physician as rheumatism patient] Genth-Stolzenburg S. **Fortschr Med** 1996 Jan 20; 114(1–2):19 **(Ger)**

[Management of demented patients is typically the primary care physician's responsibility. Interview on the topic "The primary care physician as case manager" (interview by Dr. med. Klaus Janssen)] Jarmatz H, et al. **Fortschr Med** 1996 Apr 30;114(12):55–6 **(Ger)**

[Behavior therapy—a current form of psychotherapy. Psychotherapy series, 10: Behavior therapy in primary care] Köhler H. **Fortschr Med** 1995 Oct 20;113(29):16–8, 20 **(Ger)**

[Role of the family physician in treatment of alcoholic patients] Kuth N, et al. **Fortschr Med** 1995 Nov 30; 113(33):473–5 (Eng. Abstr.) **(Ger)**

[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ. **Fortschr Med** 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[The "fate" of family practice prescriptions in the hospital. About 50%of prescriptions were changed] Tabache M. **Fortschr Med** 1995 Aug 30;113(24):342 **(Ger)**

[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**

[Endometriosis—diagnosis and therapy. Results of a current survey of 6,700 gynecologists] Christensen B, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):674–9 (Eng. Abstr.) **(Ger)**

[Psychological status of tumor patients. Observations and recommendations from the viewpoint of inpatient cancer after-care and oncologic rehabilitation] Delbrück H. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):M77–80 **(Ger)**

[Breast carcinoma and breast saving therapy—a critical comment from the viewpoint of the pathologist] Prechtel K, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):184–9 (Eng. Abstr.) **(Ger)**

[Breast and genital cancer patients—psychosocial examination in the pre- and postoperative phase] Stauber M. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M66–8 **(Ger)**

[Family practice management of risk patients with reference to preclinical emergency medicine] Flesche CW, et al. **Gesundheitswesen** 1996 May;58(5):266–71 (Eng. Abstr.) **(Ger)**

[The ruby laser: can removal of pigmented skin changes with the ruby laser be done by non-physician personnel?] Michel S, et al. **Gesundheitswesen** 1996 Jun;58(6):319–21 (Eng. Abstr.) **(Ger)**

[New methods for managing substance abuse by the public health office] Niessen J, et al. **Gesundheitswesen** 1995 Aug–Sep;57(8–9):494–6 **(Ger)**

[Psychiatry and gynecology] **Gynakologe** 1995 Dec; 28(6):401–2 **(Ger)**

[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412–9 (33 ref.) **(Ger)**

[Psychiatric diseases and pregnancy] Fuchs U. **Gynakologe** 1995 Dec;28(6):440–5 (16 ref.) **(Ger)**

[Observations on ethics in prenatal diagnosis from the viewpoint of the pediatrician] Lenard HG. **Gynakologe** 1995 Oct;28(5):384–8 **(Ger)**

[Psychiatric manifestations in climacteric. Diagnostic difficulties and therapeutic possibilities] Nijs P, et al. **Gynakologe** 1995 Dec;28(6):420–5 (22 ref.) **(Ger)**

[Self-injury behavior] Rechenberger I. **Gynakologe** 1995 Dec; 28(6):446–51 (13 ref.) **(Ger)**

[Psychiatric diseases with onset in puerperium] Woitalla D, et al. **Gynakologe** 1995 Dec;28(6):434–9 (33 ref.) **(Ger)**

[Value of dental treatment in interdisciplinary management of a child with epidermolysis bullosa dystrophica hereditaria (Hallopeau-Siemens)] Finke C, et al. **Hautarzt** 1996 Apr;47(4):307–10 (Eng. Abstr.) **(Ger)**

[Indications for psychosomatically-oriented dermatologic rehabilitation] Wehrmann J. **Hautarzt** 1996 Apr;47(4):253–7 (34 ref.) (Eng. Abstr.) **(Ger)**

[Comment on the interview with R. F. Schmidt and G. Thews. Clinical principles and medical decision making (letter)] Scheler F. **Internist (Berl)** 1995 Oct;36(10):1018 **(Ger)**

[After-care of children and young adults surviving cancer. Initial recommendations by the late sequelae study group] Beck JD, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):186–92 (Eng. Abstr.) **(Ger)**

[Oncologic after-care—a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients] Duffner U, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):193–203 (55 ref.) (Eng. Abstr.) **(Ger)**

[Interdisciplinary therapeutic concept in severe bacterial infections of the central respiratory tract in childhood] Damm M, et al. **Laryngorhinootologie** 1996 May; 75(5):293–300 (Eng. Abstr.) **(Ger)**

[Surgical therapy of oropharyngeal carcinoma within the scope of interdisciplinary tumor surgery] Esser D, et al. **Laryngorhinootologie** 1995 Dec;74(12):738–41 (Eng. Abstr.) **(Ger)**

[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[Responsibilities and goals of the Hannover Tumor Center: prospects of medical telecommunication] Günther B. **Med Klin** 1996 Apr 12;91 Suppl 3:72–4 **(Ger)**

["Med.-Psych.": combined internal medicine-psychiatric graduate education in the USA versus "specialist in psychotherapeutic medicine". Differences and common ground] Loew TH, et al. **Med Klin** 1995 Dec 15; 90(12):716–9 **(Ger)**

[Therapy of germ cell tumors. Model for interdisciplinary treatment approach] Schmoll HJ. **Med Klin** 1996 Apr 12; 91 Suppl 3:80–4 (41 ref.) **(Ger)**

[Tobacco smoking cessation. Methods and aids] Jork K. **Med Monatsschr Pharm** 1996 Jun;19(6):158–63 **(Ger)**

[Concept for a functional status and handicap-adjustment treatment and rehabilitation service chain in neurologic and neurosurgical management in Germany ("phase model")] Schupp W. **Nervenarzt** 1995 Dec;66(12):907–14 (Eng. Abstr.) **(Ger)**

[Contribution of the ophthalmologist to presymptomatic diagnosis of familial adenomatous polyposis (FAP)] Sommer E, et al. **Ophthalmologe** 1995 Dec;92(6):809–16 (Eng. Abstr.) **(Ger)**

[Pitfalls and typical false interpretations in bone tumors. From the viewpoint of long-term consultation] Salzer-Kuntschik M. **Pathologe** 1996 Jan;17(1):1–5 (Eng. Abstr.) **(Ger)**

[Are "behaviorally disordered" migrant children of "noncompliant" parents treatable? Interdisciplinary cooperation between system-oriented school psychology and psychoanalytically oriented therapy] Lanfranchi A, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Sep; 44(7):260–70 (Eng. Abstr.) **(Ger)**

[The value of child development psychological models for child and adolescent psychiatry] Lehmkuhl U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr; 45(3–4):78–82 (Eng. Abstr.) **(Ger)**

[Child and adolescent psychiatry and child and adolescent welfare: general interprofessional relations—results of a study] Martinius J, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 May–Jun; 45(5):170–3 (Eng. Abstr.) **(Ger)**

[Appropriate distance in the relationship between supervisor and candidate] Haesler L. **Psyche (Stuttg)** 1996 Apr; 50(4):321–36 **(Ger)**

[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240–3 (27 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of a borderline patient in a community psychiatry team center] Porath A. **Psychiatr Prax** 1996 Mar;23(2):98 **(Ger)**

[Psychiatric treatment in another specialty clinic?] Schneider A, et al. **Psychiatr Prax** 1996 Mar;23(2):101 **(Ger)**

[An unusual somatic symptom in a severe depressive episode] Schröder A, et al. **Psychiatr Prax** 1996 May;23(3):143 **(Ger)**

[Follow-up and typologic description of requirements in an intensive care unit] Laubach W, et al. **Psychother Psychosom Med Psychol** 1995 Nov;45(11):381–8 (Eng. Abstr.) **(Ger)**

[Effects of psychological treatment in the general hospital: follow-up study of patients with somatoform behavior] Lupke U, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct;45(9–10):358–65 (Eng. Abstr.) **(Ger)**

[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Different phases in neurologic rehabilitation. Association of German Pension Insurance Carriers] **Rehabilitation (Stuttg)** 1995 Aug;34(3):119–27 (Eng. Abstr.) **(Ger)**

[Scope recommendations for ambulatory medical rehabilitation of 2 November 1995. Federal Study Group for Rehabilitation] **Rehabilitation (Stuttg)** 1996 May; 35(2):86–92 **(Ger)**

[North Rhine-Westphalia Living Help organizes the Academy for Rehabilitation Occupations] Brinker R. **Rehabilitation (Stuttg)** 1996 May;35(2):132–3 **(Ger)**

[An integrated concept for vocational rehabilitation of brain injured patients—a catamnestic study of occupational

outcome 1 to 2 years later] Drechsler R, et al. **Rehabilitation (Stuttg)** 1995 Nov;34(4):193–202 (Eng. Abstr.) (Ger)

[Follow-up of rehabilitation after stroke—the practical work of an interdisciplinary team of an acute clinic for geriatrics] Hübschen S. **Rehabilitation (Stuttg)** 1996 Feb;35(1):49–53 (Eng. Abstr.) (Ger)

[Functions of the social worker in a multi-professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119–25 (27 ref.) (Eng. Abstr.) (Ger)

[Possibilities for geriatric psychosomatic rehabilitation] Peters M. **Rehabilitation (Stuttg)** 1995 Nov;34(4):207–12 (Eng. Abstr.) (Ger)

[Assessment of capacity and job requirements at the interface between medical and occupational rehabilitation] Schian HM. **Rehabilitation (Stuttg)** 1996 Feb;35(1):19–22 (Eng. Abstr.) (Ger)

[Occupational rehabilitation of psychiatric patients in the Michaelshoven/Cologne vocational training center—an integrated overall concept] van de Sand WH, et al. **Rehabilitation (Stuttg)** 1995 Nov;34(4):179–92 (Eng. Abstr.) (Ger)

[Effectiveness of health promotion measures: a study of quality assurance in inpatient rehabilitation treatment of patients with chronic obstructive respiratory tract diseases] Wilkening R, et al. **Rehabilitation (Stuttg)** 1996 May; 35(2):93–102 (Eng. Abstr.) (Ger)

[Theory and practice of psychodynamic supervision in psychiatry] Küchenhoff J. **Schweiz Arch Neurol Psychiatr** 1996;147(1):25–30 (Eng. Abstr.) (Ger)

[Interdisciplinary therapy of anal carcinoma] Döker R, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1389–97 (43 ref.) (Eng. Abstr.) (Ger)

[Reiter's disease—a review of an interdisciplinary disease] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Sep 12; 84(37):989–99 (66 ref.) (Eng. Abstr.) (Ger)

[Preoperative measures in emergencies] Leutenegger A. **Swiss Surg** 1995;(3):148–51 (Eng. Abstr.) (Ger)

[Preoperative assessment in an area without continuous medical anesthesia service] Scharplatz D. **Swiss Surg** 1995; (3):162–4 (Eng. Abstr.) (Ger)

[Preoperative assessment from the viewpoint of the anesthetist (editorial] Scheidegger D. **Swiss Surg** 1995; (3):128–9 (Ger)

[Current aspects of gynecology and obstetrics (editorial)] Ludwig H. **Ther Umsch** 1996 Jun;53(6):429–30 (Ger)

[Recommendations by the Urogynecology Working Group for sonography of the lower urinary tract within the scope of urogynecologic functional diagnosis] Schär G, et al. **Ultraschall Med** 1996 Feb;17(1):38–41 (Ger)

[Interdisciplinary surgical therapy of renal tumors with intracardiac tumor thrombi] Akçetin Z, et al. **Urologe A** 1996 Mar;35(2):115–9 (Eng. Abstr.) (Ger)

[25 years kidney replacement therapy in childhood and adolescence—success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) (Ger)

[Rehabilitation of children and adolescents after organ transplantation] Pichlmayr R, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):80–5 (Eng. Abstr.) (Ger)

[Rehabilitation after myocardial infarct—a multidisciplinary responsibility (editorial)] Benzer W, et al. **Wien Klin Wochenschr** 1995;107(24):755 (Ger)

[Assessment and evaluation of leisure activity of participants in heart rehabilitation groups] Frey I, et al. **Wien Klin Wochenschr** 1995;107(24):774–7 (Eng. Abstr.) (Ger)

[Parkinson disease and neurologic rehabilitation] Auff E, et al. **Wien Med Wochenschr** 1995;145(13):302–5 (27 ref.) (Eng. Abstr.) (Ger)

[Free love, wild marriage—on the gradual dissolution of marriage by love"] Barolin GS. **Wien Med Wochenschr** 1996;146(5):108–11 (Eng. Abstr.) (Ger)

[Neurorehabilitation/geriatric rehabilitation—goals achieved and aims from the viewpoint of the so-called "Vorarlberg Model"] Barolin GS. **Wien Med Wochenschr** 1995; 145(19–20):568–76 (Eng. Abstr.) (Ger)

[Frequent injuries of the shoulder joint] Gaudernak T. **Wien Med Wochenschr** 1996;146(6–7):130–4 (16 ref.) (Eng. Abstr.) (Ger)

[Management and treatment of elderly psychiatric patients by the general practitioner] Lingg A, et al. **Wien Med Wochenschr** 1995;145(19–20):541–4 (Eng. Abstr.) (Ger)

[Health promotion and nutrition counseling for obese patients—a responsibility of medical care] Dittrich A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):382–5 (Eng. Abstr.) (Ger)

[The psychiatric emergency] Felber W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):707–10 (2 ref.) (Eng. Abstr.) (Ger)

[Homeopathy from the viewpoint of the clinical pharmacologist] Haustein KO. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):97–101 (Eng. Abstr.) (Ger)

[Saxony training program for cardiopulmonary resuscitation] Kramer C, et al. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):771–2 (Ger)

[Preclinical management of the emergency by the established physician] Sefrin P. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):693–702 (Eng. Abstr.) (Ger)

[The Ostringer (Prevention) Model. Results of family medicine supervised "community behavioral medicine"] Wiesemann A, et al. **Z Arztl Fortbild (Jena)** 1996 Feb; 90(1):59–66 (Eng. Abstr.) (Ger)

[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85–8 (25 ref.) (Ger)

[Management of chronic illness: need for psychosomatic treatment] Dossmann R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:51–4 (Ger)

[Type II diabetes mellitus: therapeutic concepts] Frank M. **Z Gastroenterol** 1996 Jun;34 Suppl 2:72–4 (Ger)

[Expectations of the family physician from inpatient rehabilitation exemplified by patients recovering from gastrectomy] Jork K. **Z Gastroenterol** 1996 Jun;34 Suppl 2:26–8 (Ger)

[Optimizing occupational reintegration/model trial for further development of inpatient rehabilitation] Keck M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:89–92 (Ger)

[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41–6 (71 ref.) (Eng. Abstr.) (Ger)

[Didactic concepts of diabetes counseling and education] Risse A. **Z Gastroenterol** 1996 Jun;34 Suppl 2:66–8 (Ger)

[Need for rehabilitation from the viewpoint of the stoma patient. Experiences of the German ILCO] Schröter H. **Z Gastroenterol** 1996 Jun;34 Suppl 2:62–3 (Ger)

[What is the advantage of after-care rehabilitation in chronic inflammatory bowel diseases?] Zillessen E. **Z Gastroenterol** 1996 Jun;34 Suppl 2:47–50 (Ger)

[After-care rehabilitation after liver transplantation] Zilly W. **Z Gastroenterol** 1996 Jun;34 Suppl 2:34–6 (Ger)

[Joint recommendation of the Professional Diabetes and Pregnancy Group, the German Diabetes Society, the German Society of Gynecology and Obstetrics, the German-Austrian Society of Neonatology and Pediatric Intensive Care Medicine and the German Society of Perinatal Medicine for managing newborn infants of diabetic mothers] **Z Geburtshilfe Neonatol** 1996 Mar-Apr; 200(2):79 (Ger)

[Para-spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):99–102 (Eng. Abstr.) (Ger)

[Interdisciplinary management of fetal obstructive uropathy] Störmann J, et al. **Z Geburtshilfe Neonatol** 1995 Nov-Dec; 199(6):257–61 (Eng. Abstr.) (Ger)

[Guidelines for integrated management of demented patients in nursing homes for the elderly] Höft B, et al. **Z Gerontol Geriatr** 1996 Mar-Apr;29(2):150–8 (Eng. Abstr.) (Ger)

[Pain and pain perception in the elderly (editorial)] Kruse A. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):311 (Ger)

[Interdisciplinary team—responsibilities and problems in the assessment of aging processes] Lehr U. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):382–7 (Ger)

[The reciprocal reflecting team. A further modification of the reflecting team in inpatient child psychiatry] Menz W, et al. **Z Kinder Jugendpsychiatr** 1995 Sep;23(3):195–200 (Eng. Abstr.) (Ger)

[Psychosomatic medicine between explanation and understanding] Lamprecht F. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):213–9 (Eng. Abstr.) (Ger)

[The Parent Questionnaire in Family-Oriented Rehabilitation/Oncology—an instrument for inpatient quality assurance] Niebank K, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):291–307 (Eng. Abstr.) (Ger)

[Quality assurance in lymphology] Herpertz U. **Z Lymphol** 1995 Dec;19(2):58–63 (Eng. Abstr.) (Ger)

[Manual lymph drainage in new federal Germany] Klimaschewski H. **Z Lymphol** 1995 Dec;19(2):48–50 (Eng. Abstr.) (Ger)

[Is treatment of lymphedema an interdisciplinary treatment?] Kloster C, et al. **Z Lymphol** 1995 Aug;19(1):45–7 (Ger)

[A case of secret self-mutilation—artificial hand edema by hand self-constriction] Schneider W. **Z Lymphol** 1995 Dec; 19(2):51–4 (Eng. Abstr.) (Ger)

[Fine tuning an analytic supervision] Hartkamp N, et al. **Z Psychosom Med Psychoanal** 1995;41(3):253–67 (Eng. Abstr.) (Ger)

[Foot salvage in diabetic gangrene] Jung V. **Zentralbl Chir** 1996;121(5):387–92; discussion 392–3 (Eng. Abstr.) (Ger)

[Conservative therapy of obesity] Wechsler JG. **Zentralbl Chir** 1996;121(5):358–62 (Eng. Abstr.) (Ger)

[Principles and practice of control of hospital infection] Ohta M, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):765–75 (7 ref.) (Jpn)

[A health system that does not live up to expectations. A primary health care team attempt at an integrated approach to a case (letter)] Cárdenas Rodríguez M, et al. **Aten Primaria** 1996 Feb 29;17(3):232–3 (Spa)

ECONOMICS

Cost comparison of psychiatric outpatient clinics based in hospitals and in primary care (general practice health center). Shah A. **Acta Psychiatr Scand** 1995 Jul;92(1):30–4

Ethics, funding and alcohol research. Plant M, et al. **Alcohol Alcohol** 1996 Jan;31(1):17–25

Prediction of cost, rates, and staffing by provider and client characteristics. Campbell EM, et al. **Am J Ment Retard** 1995 Jul;100(1):17–35

Quality, cost-effective psychiatric treatment: A CNS—MD collaborative practice model. Saur CD, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):332–7 (15 ref.)

Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Apelqvist J, et al. **Foot Ankle Int** 1995 Jul;16(7):388–94

Initiating a capitated program for HMO patients. Rofman ES, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):278–86

Nursing home 'excess' adds to Medicaid costs [letter] Gerritts JF. **Geriatrics** 1996 Feb;51(2):13

Balancing the health care workforce [letter] Caton LE. **Health Aff (Millwood)** 1995 Fall;14(3):281–2

Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78–89 (15 ref.)

The patient focused approach: a better way to run a hospital? Heymann TD, et al. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):142–4

Changes in clinical practice in response to reductions in reimbursement: physician autonomy and resistance to bureaucratization. Posner KL, et al. **Med Anthropol Q** 1995 Dec;9(4):476–92

A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Raftery JP, et al. **Palliat Med** 1996 Apr; 10(2):151–61

The value of consultation-liaison interventions to the general hospital. Hall RC, et al. **Psychiatr Serv** 1996 Apr; 47(4):418–20

Elements of a successful short-stay inpatient psychiatric service. Jayaram G, et al. **Psychiatr Serv** 1996 Apr; 47(4):407–12

The treatment of common mental disorders by a community team based in primary care: a cost-effectiveness study. Goldberg D, et al. **Psychol Med** 1996 May;26(3):487–92

Clinical guidelines. Now or never [editorial] Gruman J, et al. **Psychosomatics** 1995 Nov-Dec;36(6):519–21

Combining sports medicine, rehabilitation and family clinical care makes physical and fiscal sense for UW clinics. Muckian M. **Wis Med J** 1996 Jan;95(1):37–40

[Alcohol drinking—problems in assessing the public economic impact] Neumann M, et al. **Fortschr Med** 1995 Nov 30;113(33):476–9 (Eng. Abstr.) (Ger)

[Health economic aspects of dental medicine consultation and expert assessment by the health insurance medical service] Seger W, et al. **Gesundheitswesen** 1995 Dec;57(12):773–7 (Eng. Abstr.) (Ger)

[Comment on W. Brand: Ambulatory rehabilitation—effectiveness and cost savings (letter; comment)] Emde, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):234–5. Comment on: Versicherungsmedizin 1995 Jun 1;47(3):95–6. (Ger)

[Alternative medicine—a true alternative or only another market?] Ziegenhagen DJ. **Versicherungsmedizin** 1996 Apr 1;48(2):33–5 (Ger)

[The established rheumatologist in the tension field between health care deficits and cost control in public health] Stroehmann I, et al. **Z Rheumatol** 1995 Jul-Aug; 54(4):198–201 (Eng. Abstr.) (Ger)

LEGISLATION & JURISPRUDENCE

Assessment of mental capacity: a dilemma [letter] Paul M. **Br J Psychiatry** 1996 Apr;168(4):519

Civil commitment viewed from three perspectives: professional, family, and police. Husted JR, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):533–46

When patient care is shared, who is the most responsible physician? Capen K. **Can Med Assoc J** 1996 Mar 15; 154(6):885–6

Reasonable cause: a qualitative study of mandated reporting. Deisz R, et al. **Child Abuse Negl** 1996 Apr;20(4):275–87

Primary care equals primary responsibility. Avery JK. **J Ark Med Soc** 1996 Jan;92(8):399

Laws prohibiting physician self-referrals. The impact on health care integration in Minnesota. Struthers MS, et al. **Minn Med** 1996 Jan;79(1):29–32

[Treatment of intraoperative pain. Responsibility of the care team] Vayre P. **J Chir (Paris)** 1995 Dec;132(12):499–502 (Fre)

[Cooperation, community practice and practice community] Ratzel R. **Arch Gynecol Obstet** 1995;257(1–4):720–7 (Ger)

[Change in automobile driving capacity assessment—a contribution to the correlation between diagnosis and therapy] Pund B, et al. **Blutalkohol** 1996 Jan;33(1):31–43 (Eng. Abstr.) (Ger)

[German Interdisciplinary Society of Intensive and Emergency Medicine: comments on the emergency service in Europe] **Chirurg** 1995 Aug;66(8):suppl 180 (Ger)

[Common recommendations of the German Interdisciplinary Society of Intensive and Emergency Medicine and representatives of the Federal Medical Office on quality management in emergency medicine] **Chirurg** 1995 Aug; 66(8):suppl 181–2 (Ger)

[Liquidation of elective anesthesiological performance in delegation and representation—revision of GOA (1996)] Weissauer W. **Chirurg** 1996 Jun;67(6):Suppl 127–32 (Ger)

[Ring trials in expert assessment—a practicable procedure for quality assurance?] Lederer P, et al. **Gesundheitswesen** 1996 Mar;58(3):169–72 (Eng. Abstr.) (Ger)

[Interdisciplinary cooperation in primary care of elderly patients—results of results with consequences for general practice] Schick B, et al. **Gesundheitswesen** 1996 Mar; 58(3):126–31 (Eng. Abstr.) **(Ger)**

[Theory and practice in rehabilitation of emotionally handicapped young patients] Fegert JM. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):350–9 (Eng. Abstr.) **(Ger)**

[Rehabilitation access for emotionally handicapped children and adolescents: qualification of standard institutions—construction of special institutions] Günter M. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):366–9 (Eng. Abstr.) **(Ger)**

[Conflicts between parenteral expectations and children's needs in child guidance clinics] Salgo L. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):359–65 (Eng. Abstr.) **(Ger)**

[Social work in the child and adolescent psychiatric clinic—aspects of quality assurance within the scope of the psychiatric personnel regulation] Schepker R, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Sep;44(7):280–7 (Eng. Abstr.) **(Ger)**

[Modification of rehabilitation possibilities by psychiatric disorders. Concepts and explanations in implementing section 35 of the child and adolescent welfare regulation] Specht F. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov; 44(9):343–9 (Eng. Abstr.) **(Ger)**

[Responsibility of youth assistance teams for rehabilitation of mentally handicapped young adults] Wiesner R. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):341–2 (Eng. Abstr.) **(Ger)**

[Forensic practice between commonality, the law and psychiatry. 2] Hoffmann-Richter U, et al. **Psychiatr Prax** 1996 May;23(3):150–4 (16 ref.) **(Ger)**

[Legal liability in consultation of physicians of different specialties from the legal viewpoint] Biermann E. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):626–32 (Eng. Abstr.) **(Ger)**

[Liability in consultation of physicians from different specialties from the physician's viewpoint] Hempel K. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):632–4; discussion 635–7 (Eng. Abstr.) **(Ger)**

[Special treatment methods in general practice—legal medicine viewpoint] Wagner HJ. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):123–5 (Eng. Abstr.) **(Ger)**

[Legal liability of subordinate physicians, legal liability for management responsibility from the jurisprudence viewpoint] Weissauer W. **Z Arztl Fortbild (Jena)** 1995 Nov; 89(6):613–20 (Eng. Abstr.) **(Ger)**

[Structural prerequisites for ambulatory geriatric rehabilitation—the ambulatory rehabilitation team] Finger C. **Z Gastroenterol** 1996 Jun;34 Suppl 2:106–8 **(Ger)**

[New occupational classifications and responsibilities in rehabilitation] Hackhausen W. **Z Gastroenterol** 1996 Jun; 34 Suppl 2:109–11 **(Ger)**

[Legal problems in transportation of pregnant patients in premature labor from the viewpoint of basic and defined management] Ratzel R. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):126–7 **(Ger)**

ORGANIZATION & ADMINISTRATION

Two HIV/AIDS community support teams: patient characteristics, problems at referral and during the last 6 weeks of life. Butters E, et al. **AIDS Care** 1995;7(5):593–603

The key to pharmacist prescribing: collaboration. Galt KA. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1696–9

Bolstering requests for more personnel. Steffen WM, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1006–7

Prescribing medications: changing the paradigm for a changing health care system [see comments] Webb CE. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1693–5. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

The interdisciplinary team conference in rehabilitation medicine. Jelles F, et al. **Am J Phys Med Rehabil** 1995 Nov–Dec;74(6):464–5

Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care [see comments] Shaffer J, et al. **Arch Intern Med** 1995 Nov 27;155(21):2330–5. Comment in: Arch Intern Med 1996 Jul 8;156(13):1476, 1479.

The benefits of a shared-care prostate clinic. Booth CM, et al. **Br J Urol** 1996 Jun;77(6):830–5

Cancer in remission. Challenge in collaboration for family physicians and oncologists. Wood ML, et al. **Can Fam Physician** 1996 May;42:899–904; 907–10

Collaborative care receives stamp of approval in CMA, CNA study involving HIV/AIDS. Walters D, et al. **Can Med Assoc J** 1996 Jun 15;154(12):1898–9

Establishing a district palliative care team for children. Wallace AC, et al. **Child Care Health Dev** 1995 Nov; 21(6):383–5

An interdisciplinary model for the rehabilitation of visually impaired and blind people: application of the ICIDH concepts. van Hof C, et al. **Disabil Rehabil** 1995 Oct; 17(7):391–9

Shared care and HIV: is there more to say? [letter] Singh S. **Fam Pract** 1996 Apr;13(2):209

Trauma team concepts in the UK: tailoring resources to meet demand [letter; comment] Hassan TB, et al. **J Accid Emerg Med** 1995 Jun;12(2):162–3. Comment on: J Accid Emerg Med 1994 Sep;11(3):183–5.

Critique of collaboration [letter] Baggs JG. **J Adv Nurs** 1996 Feb;23(2):421

The multifaceted role of the nurse in the day hospital. Booth J, et al. **J Adv Nurs** 1995 Oct;22(4):700–6

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

Primary health care team workshop: team members' perspectives. Long S. **J Adv Nurs** 1996 May;23(5):935–41

Multidisciplinary collaboration: life line or drowning pool for nurse researchers? [editorial] Lorentzon M. **J Adv Nurs** 1995 Nov;22(5):825–6

Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)

The CARE Program: a nurse-managed collaborative outpatient program to improve function of frail older people. Collaborative Assessment and Rehabilitation for Elders. Evans LK, et al. **J Am Geriatr Soc** 1995 Oct; 43(10):1155–60

Team management of congestive heart failure across the continuum. Venner GH, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):71–84

Coordination as a critical element of managed care. Allred CA, et al. **J Nurs Adm** 1995 Dec;25(12):21–8

Geriatric patients with depression. Improving outcomes using a multidisciplinary clinical path model. Bultema JK, et al. **J Nurs Adm** 1996 Jan;26(1):31–8

A model for collegiality among staff nurses in acute care. Hansen HE. **J Nurs Adm** 1995 Dec;25(12):11–20

The effect of a professional practice model on staff nurse perception of work groups and nurse leaders. Ingersoll GL, et al. **J Nurs Adm** 1996 May;26(5):52–60

Establishing an interdisciplinary patient care team: collaboration at the bedside and beyond. McHugh M, et al. **J Nurs Adm** 1996 Apr;26(4):21–7

Project management. Lessons learned from introducing a multitask environmental worker program. Pischke-Winn K, et al. **J Nurs Adm** 1996 Jun;26(6):31–8

Quality field [editorial] Schroeder P. **J Nurs Care Qual** 1996 Jul;10(4):viii

Scarborough's Palliative 'At-home' Care Team (PACT): a model for a suburban physician palliative care team. Gardner-Nix JS, et al. **J Palliat Care** 1995 Autumn; 11(3):43–9

Emergency psychiatric assessment: the nurse, psychiatrist, and counselor roles during the process. Eppard J, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Oct;33(10):17–23

A collaborative protocol for encopresis management in school-aged children. Chaney CA. **J Sch Health** 1995 Nov; 65(9):360–4

Internal fixation in pelvic fractures and primary repairs of associated genitourinary disruptions: a team approach. Routt ML, et al. **J Trauma** 1996 May;40(5):784–90

Effectiveness of joint consultation sessions of general practitioners and orthopaedic surgeons for locomotor-system disorders [see comments] Vierhout WP, et al. **Lancet** 1995 Oct 14;346(8981):990–4. Comment in: Lancet 1995 Oct 14;346(8981):984.

Benefits of the collaborative model [letter; comment] Miller T, et al. **Phys Ther** 1995 Dec;75(12):1137–9. Comment on: Phys Ther 1995 Jun;75(6):503–10.

"Carving in," and keeping in, mental health care in the managed care setting. Slay JD Jr, et al. **Psychiatr Serv** 1995 Nov;46(11):1119–20, 1125

Re-engineering via patient-centered care. Dowd SB, et al. **Radiol Technol** 1996 May–Jun;67(5):421–4 (9 ref.)

Cost-efficient radical prostatectomy. Koch MO. **Semin Urol Oncol** 1995 Aug;13(3):197–203

Interdisciplinary teams in health care: integration of family caregivers. Saltz CC, et al. **Soc Work Health Care** 1996; 22(3):59–70

The development of a palliative care team at the Western General Hospital, Edinburgh. Hockley J. **Support Care Cancer** 1996 Mar;4(2):77–81

[Communication in the patient care team about palliative situations' results of a survey at the Laennec Hospital, Paris] Perard M, et al. **Ann Med Psychol (Paris)** 1995 Oct; 153(8):542–6 (Eng. Abstr.) **(Fre)**

[Integration, organization and results of ambulatory surgery in a central hospital] Rotzer A, et al. **Swiss Surg** 1995; (6):307–10; discussion 310 (Eng. Abstr.) **(Ger)**

[Diabetic foot syndrome in clinical practice. I. A model of a Diabetic Foot Consulting Unit] Sieradzki J, et al. **Przegl Lek** 1996;53(1):3–5 (Eng. Abstr.) **(Pol)**

[Diabetic foot syndrome in clinical practice. II. Results after one year at the Diabetic Foot Consulting Unit] Sieradzki J, et al. **Przegl Lek** 1996;53(1):6–8 (Eng. Abstr.) **(Pol)**

[The advantages and disadvantages of decentralizing team management (editorial)] Corrales Nadal A. **Aten Primaria** 1996 May 31;17(9):547–8 **(Spa)**

STANDARDS

Computerized program for evaluating performance of a nutritional support team [letter] Chan DS. **Am J Health Syst Pharm** 1996 Mar 15;53(6):683–4

Cerebrovascular accident patients: an interdisciplinary/multidisciplinary audit. Penman GM, et al. **Aust Clin Rev** 1991;11:106–10

Are community mental health teams providing an equitable service? Comparison of source of referrals with inpatient care. Laugharne R, et al. **BMJ** 1996 Aug 24;313(7055):476

Who decides? Patients, parents, or gatekeepers: pediatric decisions in the craniofacial setting. Mouradian WE. **Cleft Palate Craniofac J** 1995 Nov;32(6):510–4

Craniofacial surgery and the ethics of decision-making. Persing JA. **Cleft Palate Craniofac J** 1995 Nov;32(6):504–6

Neonatal intensive care as a locus for ethical decisions. Saal HM. **Cleft Palate Craniofac J** 1995 Nov;32(6):500–3

Ethical decision-making in interdisciplinary team care. Sharp HM. **Cleft Palate Craniofac J** 1995 Nov;32(6):495–9

General hospital psychiatry and the ethics of managed care. Sabin JE. **Gen Hosp Psychiatry** 1995 Jul;17(4):293–8

From the students: learning continuous improvement by doing it. Alexander GC, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):198–205

The Pennsylvania Local Interdisciplinary Team: journey into collaborative learning and community health improvement. Balestreire JJ, et al. **Jt Comm J Qual Improv** 1996 Mar; 22(3):171–7

Stakeholders and reflections on improving health professions education: what's next? Batalden PB. **Jt Comm J Qual Improv** 1996 Mar;22(3):229–32

Institutionalizing continuous improvement in South Carolina: taking it "bird by bird". Chessman A, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):177–87

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213–22 (27 ref.)

Blessed are the flexible: the George Team. Harman LB, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):188–97

Working from upstream to improve health care: the IHI interdisciplinary professional education collaborative. Headrick LA, et al. **Jt Comm J Qual Improv** 1996 Mar; 22(3):149–64

Using learning cycles to build an interdisciplinary curriculum in CI for health professions students in Cleveland. Moore SM, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):165–71

Compassionate mental health care for persons with HIV and AIDS. Grady HIV/AIDS Mental Health Program, Grady Health System Infectious Disease Program and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta. **Psychiatr Serv** 1995 Oct;46(10):1061–4

Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)

STATISTICS & NUMERICAL DATA

The prescription of psychotropic drugs in primary health care. Joukamaa M, et al. **Acta Psychiatr Scand** 1995 Nov; 92(5):359–64

Screening for depression in primary care. Development and validation of the Depression Scale, a screening instrument for depression. Salokangas RK, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):10–6

To what extent is female alcohol dependence and abuse known in the health care system? The use of multi-source information in a Swedish population survey. Spak F. **Acta Psychiatr Scand** 1996 Feb;93(2):87–91

Hospital services for patients with acute stroke in the United Kingdom: the Stroke Association Survey of consultant opinion. Lindley RI, et al. **Age Ageing** 1995 Nov; 24(6):525–32

Multidisciplinary education for oxygen prescription. A continuous quality improvement study. Cook DJ, et al. **Arch Intern Med** 1996 Sep 9;156(16):1797–801

Acute psychiatric beds: distribution and staffing in NSW and ACT. Rosenman S. **Aust N Z J Psychiatry** 1995 Jun; 29(2):238–47

The effect on hospital admissions of psychiatric case management involving general practitioners: preliminary results. Wood K, et al. **Aust N Z J Psychiatry** 1995 Jun; 29(2):223–9

Data-gathering tools for "real world" clinical settings: a multisite feasibility study. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):55–66

Obstetric physicians: are they needed? The workload of a medical complications in pregnancy clinic. Nelson-Piercy C, et al. **J R Coll Physicians Lond** 1996 Mar–Apr; 30(2):150–4

Needlestick/sharps injuries and HIV exposure among health care workers. National estimates based on a survey of U.S. hospitals. Henry K, et al. **Minn Med** 1995 Nov;78(11):41–4

Pediatric and neonatal critical care transport: a comparison of therapeutic interventions. Kronick JB, et al. **Pediatr Emerg Care** 1996 Feb;12(1):23–6

A computer-based model for analyzing staffing needs of psychiatric treatment programs. Atkins RM. **Psychiatr Serv** 1995 Dec;46(12):1272–8

Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Nizami SQ, et al. **Soc Sci Med** 1996 Apr;42(8):1133–9

[Psychosocial services in pediatric oncology. Results of a country-wide survey] Griessmeier B. **Klin Padiatr** 1995 Jul–Aug;207(4):174–80 (Eng. Abstr.) **(Ger)**

[Psychiatric disorders in hospitalized internal medicine and surgical patients. Prevalence and need for treatment] Arolt V, et al. **Nervenarzt** 1995 Sep;66(9):670–7 (Eng. Abstr.) **(Ger)**

[Self-assessment of prescribing behavior of psychotropic drugs for children and adolescence. Results of a survey of established physicians] Trott GE, et al.

Psychiatr Prax 1995 Nov;22(6):235–9 (Eng. Abstr.) **(Ger)**

[Psychotherapy in general practice of physicians and psychologists] Driessen M, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):90–5 (Eng. Abstr.) **(Ger)**

[Need for psychosocial counseling—a comparison of women and men in East and West Germany] Egartner E, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):321–8 (Eng. Abstr.) **(Ger)**

[Epidemiology of rheumatologic health care in Germany] Zink A. **Z Rheumatol** 1995 Jul–Aug;54(4):184–91 (7 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Psychotherapy supervision in the 1990s: some observations and reflections. Watkins CE Jr. **Am J Psychother** 1995 Fall; 49(4):568–81 (87 ref.)

Workforce deployment: reconciling demands and resources. Andrews G. **Aust N Z J Psychiatry** 1995 Sep;29(3):394–402 (20 ref.)

Consultation–liaison psychiatry in general medical units. Clarke DM, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):424–32

Approaches to delivering child and adolescent mental health services: the South Australian experience. Sawyer MG, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):230–7

The evolution of the clinician–scientist model of neurological rehabilitation. Peters MD, et al. **Brain Inj** 1995 Aug–Sep; 9(6):543–52 (28 ref.)

Treatment of psychotic disorders in the United States and France: three comparisons. Kowalski S, et al. **Bull Menninger Clin** 1995 Summer;59(3):385–92

Pathways to a child mental health service. Godfrey JM. **Child Care Health Dev** 1995 Jul;21(4):223–32

General hospital psychiatry and the new behavioral health care delivery system. Geraty RD. **Gen Hosp Psychiatry** 1995 Jul;17(4):245–50

The future of consultation–liaison psychiatry and medical–psychiatric units in the era of managed care. Goldberg RJ, et al. **Gen Hosp Psychiatry** 1995 Jul; 17(4):268–77 (55 ref.)

The continuum of care in a general hospital setting. Lefkovitz PM. **Gen Hosp Psychiatry** 1995 Jul;17(4):260–7

Managed care: a catalyst for integrated medicine [editorial] Lipsitt DR. **Gen Hosp Psychiatry** 1995 Jul;17(4):243–4

The effect of managed care on the treatment outcome of substance use disorders. Renz EA, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):287–92

Wagons ho: forward on the managed care trail. Summergrad P, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):251–9

The National Panel: past, present and future. Ewing DJ, et al. **Health Bull (Edinb)** 1995 Sep;53(5):307–10

Psychoanalysis and its vicissitudes: the doctor's dilemma. Kestenbaum CJ. **J Am Acad Psychoanal** 1995 Fall; 23(3):501–14

Promoting an empiricist agenda within the human services: an ethical and humanistic imperative. Thyer BA. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):93–8

Keeping care in health care reform. Imperato PJ. **J Community Health** 1996 Jun;21(3):155–8

Health care delivery—the roads not taken [editorial] Sarbadhikari SN. **J Indian Med Assoc** 1995 Sep; 93(9):329–30

Crisis in radiology: are radiologists really necessary? Williams HS. **J Natl Med Assoc** 1995 Oct;87(10):773–6

Review of forty years of rehabilitation issues in spinal cord injury. Stover SL. **J Spinal Cord Med** 1995 Jul;18(3):175–82

Medical pluralism in the United States: a review. Baer HA. **Med Anthropol Q** 1995 Dec;9(4):493–502

Toward a more comprehensive medical anthropology: the case of adolescent psychopathology. Fabrega H Jr, et al. **Med Anthropol Q** 1995 Dec;9(4):431–61 (185 ref.)

Shifting balance of power. Reed M. **Minn Med** 1995 Oct; 78(10):15–8

Defining the NP role [letter] Henson RJ. **Nurse Pract** 1996 Apr;21(4):8, 13

Dissemination of assertive community treatment programs. Deci PA, et al. **Psychiatr Serv** 1995 Jul;46(7):676–8

Implementing assertive community treatment teams. Essock SM, et al. **Psychiatr Serv** 1995 Jul;46(7):679–83

Holding the line against wrong–headed changes [editorial; comment] Fink PJ. **Psychiatr Serv** 1995 Aug;46(8):753. Comment on: Psychiatr Serv 1995 Aug;46(8):769–77.

New developments in employee assistance programs. White RK, et al. **Psychiatr Serv** 1996 Apr;47(4):387–91

A comprehensive public mental health programme in Guinea–Bissau: a useful model for African, Asian and Latin–American countries. de Jong JT. **Psychol Med** 1996 Jan;26(1):97–108

A tale of two societies. Wise TN. **Psychosom Med** 1995 Jul–Aug;57(4):303–9

The pediatric medical–psychiatric unit in a psychiatric hospital. Campo JV, et al. **Psychosomatics** 1995 Sep–Oct; 36(5):438–44

The future of organ transplant psychiatry. Freeman AM 3rd, et al. **Psychosomatics** 1995 Sep–Oct;36(5):429–37 (68 ref.)

Mental health in remote rural developing areas. Concepts and cases. Committee on Therapeutic Care. Group for the Advancement of Psychiatry. **Rep Group Adv Psychiatry** 1995;(139):1–230

What resources? Addressing the needs of the epilepsy community. Brown SW. **Seizure** 1995 Sep;4(3):207–10

Graduates comment on issues related to the decline of Wisconsin family physicians providing maternity care. Turkal N, et al. **Wis Med J** 1996 Jan;95(1):17–21

[From psychiatry to commitment] Marty–Lavauzelle A. **Encephale** 1996 May;22 Spec No 1:75–7 **(Fre)**

[Mental health prospects in France] Massé G. **Encephale** 1996 May;22 Spec No 1:49–56 (Eng. Abstr.) **(Fre)**

[Excessive medical care menace quality] Martinoli S. **Swiss Surg** 1995;(1):77–80 (Eng. Abstr.) **(Fre)**

[The future of radiology. Specialized radiology versus complete radiology—position of the Specialized Radiology Study Group of combined professional societies] **Chirurg** 1995 Sep;66(9):suppl 210–2 **(Ger)**

[Preventive and after–care of elderly patients from the viewpoint of the established physician. Recommendations for new structures in ambulatory medical management of the elderly] Zeller W. **Fortschr Med** 1996 May 30; 114(15):191–2 **(Ger)**

[Comments on theory development in "public health". Berlin Public Health Research Committee—partial projects "Goals and goal indicators for public health in East and West Berlin"] Baier WK, et al. **Gesundheitswesen** 1995 Aug–Sep;57(8–9):499–501 (Eng. Abstr.) **(Ger)**

[The hospital, a site for prevention? From prevention of drug dependence to general drug promotion] Fleischmann H, et al. **Gesundheitswesen** 1996 Jun;58(6):315–8 (Eng. Abstr.) **(Ger)**

[Surgery in the macular foramen—pro and contra (editorial)] Richard G. **Klin Monatsbl Augenheilkd** 1996 Feb; 208(2):aA1–2 **(Ger)**

[No contemporary psychiatric care without sectorization! (editorial; comment)] Bauer M. **Psychiatr Prax** 1996 Mar; 23(2):53. Comment on: Psychiatr Prax 1996 Mar;23(2):55–62. **(Ger)**

[2 class psychiatry (see comments)] Häfner H, et al. **Psychiatr Prax** 1996 Mar;23(2):55–62 (Eng. Abstr.). Comment in: Psychiatr Prax 1996 Mar;23(2):53. Comment in: Psychiatr Prax 1996 Mar;23(2):54. **(Ger)**

[Contemporary psychiatric care without sectorization? (editorial; comment)] Hoffmann–Richter U. **Psychiatr Prax** 1996 Mar;23(2):54. Comment on: Psychiatr Prax 1996 Mar;23(2):55–62. **(Ger)**

[Discussion: has social psychiatric service reached an end? (letter)] Kamcili S, et al. **Psychiatr Prax** 1995 Nov;22(6):257 **(Ger)**

[Current status so far: psychotherapy in transition!] Hillecke T, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr;46(3–4):96–101 (Eng. Abstr.) **(Ger)**

[Psychotherapeutic care and public health] Novak P. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):111–5 (Eng. Abstr.) **(Ger)**

[Organization of cardiologic rehabilitation in central Europe: retrospect, present, future outlook] Halhuber MJ. **Wien Klin Wochenschr** 1995;107(24):756–9 (6 ref.) (Eng. Abstr.) **(Ger)**

[Plastic surgery in the tension field of surgery] Scharnagl E. **Wien Klin Wochenschr** 1995;107(23):742–7 (Eng. Abstr.) **(Ger)**

[Seaside Zechlin/Brandenburg Clinic. First lymphology specialty clinical in new unified Germany] Herpertz U. **Z Lymphol** 1995 Aug;19(1):35–6 **(Ger)**

[Basic principles of community, continuous and cooperative management of patients with chronic rheumatic diseases in Germany] Raspe H. **Z Rheumatol** 1995 Jul–Aug; 54(4):192–7 (Eng. Abstr.) **(Ger)**

[Rheumatologic patient management and research in Berlin at the intersection between East and West] Sieper J. **Z Rheumatol** 1995 Jul–Aug;54(4):213–4 (Eng. Abstr.) **(Ger)**

[A cooperative model of the German Ministry of Health funded rheumatic disease centers] Zeidler H. **Z Rheumatol** 1995 Jul–Aug;54(4):215–22 (Eng. Abstr.) **(Ger)**

UTILIZATION

The Nordic comparative study on sectorized psychiatry. II. Resources of the psychiatric services and treated incidence. Saarento O, et al. **Acta Psychiatr Scand** 1995 Sep; 92(3):202–7

The epidemiology of psychiatric disorders and the de facto mental health care system. Norquist GS, et al. **Annu Rev Med** 1996;47:473–9 (29 ref.)

Detecting psychological distress among patients attending secondary health care clinics. Self–report and physician rating. Feldman D, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):425–32

Epidemiologic research in an integrated regional medical care system: the Marshfield Epidemiologic Study Area. DeStefano F, et al. **J Clin Epidemiol** 1996 Jun;49(6):643–52

A statewide, toll–free telephone service to improve obstetric care. Rayburn WF, et al. **J Okla State Med Assoc** 1995 Aug;88(8):342–4

Increasing identification and referral of panic disorder over the past decade. Gerdes T, et al. **Psychosomatics** 1995 Sep–Oct;36(5):480–6

Role of primary care physicians in the care of epileptic patients. al–Shammari SA, et al. **Public Health** 1996 Jan; 110(1):47–8

Health care utilization as a function of subjective health status, job satisfaction and gender among health care workers in Guangzhou, southern China. Fielding R, et al. **Soc Sci Med** 1995 Oct;41(8):1103–10

[The epidemiology of depression] Kovess V. **Encephale** 1996 May;22 Spec No 1:3–7 (Eng. Abstr.) **(Fre)**

[Depressed patients: prevalence, characteristics and medical consultation] Lecomte T. **Encephale** 1996 May;22 Spec No 1:33–8 (Eng. Abstr.) **(Fre)**

[Acceptance and effectiveness of surgical vascular consultation—is it worthwhile?] Graupe F, et al. **Chirurg** 1995 Dec;66(12):1239–44; discussion 1245–6 (Eng. Abstr.) **(Ger)**

PATIENT–CENTERED CARE

Multidisciplinarity and multimedia in quality of care—education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)

Time use and physicians' exploration of the reason for the office visit. Bergh KD. **Fam Med** 1996 Apr;28(4):264–70

For whom we care. Curry SL. **Gynecol Oncol** 1996 Aug; 62(2):148–50

The role of the nurse in patient–focused care: models of competence and implications for education and training. Burchell H, et al. **Int J Nurs Stud** 1996 Feb;33(1):67–75 (42 ref.)

Patient–centered medicine [letter; comment] Reyes–Ortiz CA. **JAMA** 1996 Apr 17;275(15):1156; discussion 1157. Comment on: JAMA 1996 Jan 10;275(2):152–6.

Patient–centered medicine [letter; comment] Strouse DS. **JAMA** 1996 Apr 17;275(15):1156–7. Comment on: JAMA 1996 Jan 10;275(2):152–6.

Medication decision–making and management: a client–centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)

[Organization of hospitals in clinical centers] Holand H, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2194–7 **(Nor)**

ECONOMICS

Effects of availability of patient–related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501–6 (44 ref.)

ORGANIZATION & ADMINISTRATION

The "P–C" world of medicine: a commentary on the current medical scene. Griffen WO Jr. **Am Surg** 1996 Sep; 62(9):693–700

Patient–focused. A kinder, gentler ER. Lumsdon K. **Hosp Health Netw** 1996 Feb 5;70(3):43, 46

Reengineering. Crafting care centers. Turner S. **Hosp Health Netw** 1995 Nov 20;69(22):56, 58

Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family–centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)

Patient–centred evaluation and rehabilitative care. Grenville J, et al. **J Adv Nurs** 1995 Nov;22(5):965–72

Preparing for redesign education. Pfefferbaum R, et al. **J Nurs Adm** 1995 Dec;25(12):6, 20

Project management. Lessons learned from introducing a multitask environmental worker program. Pischke–Winn K, et al. **J Nurs Adm** 1996 Jun;26(6):31–8

Quality with a human face? The Samuels Planetree model hospital unit. Blank AE, et al. **Jt Comm J Qual Improv** 1995 Jun;21(6):289–99

Ambulatory care of the HIV–infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

Physician training for patient–centered nutrition counseling in a lipid intervention trial. Ockene JK, et al. **Prev Med** 1995 Nov;24(6):563–70

Reconceptualizing family caregiving: family–based illness care during chemotherapy. Schumacher KL. **Res Nurs Health** 1996 Aug;19(4):261–71

Women's health and the pharmacy profession—an alliance whose time has come [letter] Ponte CD. **Womens Health Issues** 1995 Fall;5(3):155–6

The National Survey of Women's Health Centers: current models of women–centered care. Weisman CS, et al. **Womens Health Issues** 1995 Fall;5(3):103–17

STANDARDS

ASHP statement on the role of the pharmacist in patient–focused care. American Society of Health–System Pharmacists. **Am J Health Syst Pharm** 1995 Aug 15; 52(16):1808–10

Concept paper: service delivery in occupational therapy. American Occupational Therapy Association. **Am J Occup Ther** 1995 Nov–Dec;49(10):1029–31

An analysis of posthospitalization telephone survey data. Minnick A, et al. **Nurs Res** 1995 Nov–Dec;44(6):371–5

STATISTICS & NUMERICAL DATA

Pharmacy involvement in patient–focused care in Florida hospitals. Schultz DM, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2121–4

PATIENT COMPLIANCE

see related
PATIENT DROPOUTS

TREATMENT REFUSAL

Drug compliance and cognitive-behavioral therapy in schizophrenia. Lecompte D. **Acta Psychiatr Belg** 1995 Mar-Apr;95(2):91-100

Zidovudine adherence among individuals with HIV infection. Muma RD, et al. **AIDS Care** 1995;7(4):439-47

Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. Freeman RC, et al. **AIDS Educ Prev** 1996 Feb;8(1):58-71

H1-antihistamines and prescription compliance. Angeles Gonzalo M, et al. **Allergol Immunopathol (Madr)** 1995 Nov-Dec;23(6):290-4

Wallstents versus plastic stents in malignant biliary obstruction: effects of stent patency of the first and second stent on patient compliance and survival [see comments] Schmassmann A, et al. **Am J Gastroenterol** 1996 Apr; 91(4):654-9. Comment in: Am J Gastroenterol 1996 Apr;91(4):627-8.

Medication-compliance recommendations target health professionals, industry groups, patients [news] **Am J Health Syst Pharm** 1995 Nov 1;52(21):2394

The tablet splitter: barrier to compliance or cost-saving instrument? Carr-Lopez SM, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2707-8

Relationship between medication compliance and medical outcomes. Cramer JA. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S27-9

Deciding between once- and twice-daily dosing. Garrett SS. **Am J Health Syst Pharm** 1996 Apr 1;53(7):730-1

Failure of educational videotapes to improve medication compliance in a health maintenance organization. Powell KM, et al. **Am J Health Syst Pharm** 1995 Oct 15; 52(20):2196-9

A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Friedman RH, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):285-92

Compliance in the treatment of hypertension. A need for action. Sanson-Fisher RW, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):82S-88S (57 ref.)

Physician implementation of and patient adherence to recommendations from comprehensive geriatric assessment [see comments] Reuben DB, et al. **Am J Med** 1996 Apr; 100(4):444-51. Comment in: Am J Med 1996 Apr;100(4):383-5.

Estrogen replacement therapy in practice: trends and issues. Thompson W. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):990-3 (21 ref.)

Duty to follow up on recommended care. Jerrold L. **Am J Orthod Dentofacial Orthop** 1995 Nov;108(5):565-6

Hypertension prevalence, awareness, treatment, and control among African Americans in the 1990s: estimates from the Maywood Cardiovascular Survey. Freeman V, et al. **Am J Prev Med** 1996 May-Jun;12(3):177-85

Breast cancer screening behaviors and intentions among asymptomatic women 50 years of age and older. Friedman LC, et al. **Am J Prev Med** 1995 Jul-Aug;11(4):218-23

The CDC's proposed revision of polio immunization policy: is it wise? [letter] Judelsohn R. **Am J Public Health** 1996 Jun;86(6):890

Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. el-Sadr W, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1146-9

Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. Waisbren SE, et al. **Am J Public Health** 1995 Dec;85(12):1636-41

Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994 [see comments] Wilkinson D, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1094-7. Comment in: Am J Public Health 1996 Aug;86(8 Pt 1):1071-3.

Compliance with antimalarial chemoprophylaxis and the subsequent development of malaria: a matched case-control study. Gyorkos TW, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):511-7

Does counseling improve compliance? Herrier RN, et al. **Am Pharm** 1995 Sep;NS35(9):11-2, 61

Myths about patient compliance. Herrier RN, et al. **Am Pharm** 1995 Dec;NS35(12):12-3

Clinic follow-up from the emergency department: do patients show up? Murray MJ, et al. **Ann Emerg Med** 1996 Jan; 27(1):56-8

Adherence to colorectal cancer screening. A brief overview. Vernon SW. **Ann N Y Acad Sci** 1995 Sep 30;768:292-5 (19 ref.)

Benign breast surgery: is there a need for outpatient follow-up? Wakefield SE, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):457-9

Clinicopathologic factors and patient perceptions associated with surgical breast-conserving treatment. Kotwall CA, et al. **Ann Surg Oncol** 1996 Mar;3(2):169-75

Self-care limitations of persons after acute myocardial infarction. Beach EK, et al. **Appl Nurs Res** 1996 Feb; 9(1):24-8

Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Burney KD, et al. **Arch Fam Med** 1996 May;5(5):297-300

Directly observed preventive therapy. Turning the tide against tuberculosis. Kohn MR, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):727-9

Erythrocyte membrane fatty acid composition as a marker of dietary compliance in hyperlipidaemic subjects. Tynan MB, et al. **Atherosclerosis** 1995 Oct;117(2):245-52

Compliance issues in adolescence: practical strategies. Blair S, et al. **Aust Fam Physician** 1995 Nov;24(11):2037-40

Predicting nonattendance for colposcopy clinic follow-up after referral for an abnormal Pap smear. Kavanagh AM, et al. **Aust N Z J Public Health** 1996 Jun;20(3):266-71

Compliance therapy in psychotic patients. Authors were wrong to compare treatment with no treatment [letter; comment] Dubourg GO. **BMJ** 1996 May 18;312(7041):1302 . Comment on: BMJ 1996 Feb 10;312(7027):345-9.

Compliance therapy in psychotic patients. Many ethical questions arise from study [letter; comment] Gray R. **BMJ** 1996 May 18;312(7041):1302. Comment on: BMJ 1996 Feb 10;312(7027):345-9.

Compliance therapy in psychotic patients: randomised controlled trial [see comments] Kemp R, et al. **BMJ** 1996 Feb 10;312(7027):345-9. Comment in: BMJ 1996 May 18;312(7041):1302.

Directly observed treatment for tuberculosis. Could be provided by community pharmacists supervising consumption of methadone [letter] Sell L, et al. **BMJ** 1996 Jul 6;313(7048):45

Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Lennard L, et al. **Br J Cancer** 1995 Oct; 72(4):1004-6

Does encouraging good compliance improve patients' clinical condition in heart failure? [see comments] Goodyer LI, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):173-6. Comment in: Br J Clin Pract 1995 Jul-Aug;49(4):171.

Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. de Klerk E, et al. **Br J Rheumatol** 1996 Jan;35(1):60-5

Compliance with medication among outpatients with uncontrolled hypertension in the Seychelles. Hungerbuhler P, et al. **Bull World Health Organ** 1995;73(4):437-42

The management of age-related macular degeneration: patterns of referral and compliance in seeking low-vision aids. Koenekoop RK, et al. **Can J Ophthalmol** 1995 Jun; 30(4):208-10

Compliance with the screening mammography program of British Columbia: will she return? Johnson MM, et al. **Can J Public Health** 1996 May-Jun;87(3):176-80

Factors determining compliance with screening mammography [see comments] Beaulieu MD, et al. **Can Med Assoc J** 1996 May 1;154(9):1335-43. Comment in: Can Med Assoc J 1996 May 1;154(9):1353-5.

How should we interpret noncompliance with screening mammography? [editorial; comment] Bryant H. **Can Med Assoc J** 1996 May 1;154(9):1353-5. Comment on: Can Med Assoc J 1996 May 1;154(9):1335-43.

Self-reported use of CPAP and benefits of CPAP therapy: a patient survey [see comments] Engleman HM, et al. **Chest** 1996 Jun;109(6):1470-6. Comment in: Chest 1996 Jun;109(6):1416-7.

Enhancing patient compliance in asthma management [letter] Marino JT. **Chest** 1996 Sep;110(3):862

Long-term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. ANTADIR Working Group on Oxygen Therapy. Association Nationale de Traitement à Domicile des Insuffisants Respiratories [see comments] Pépin JL, et al. **Chest** 1996 May;109(5):1144-50. Comment in: Chest 1996 May;109(5):1135-6.

Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. Simmons MS, et al. **Chest** 1996 Apr;109(4):963-8

Compliance enhancement. A call for multidisciplinary team approaches [editorial] Hill MN, et al. **Circulation** 1996 Jan 1;93(1):4-6

Compliance with antihypertensive treatment. Costa FV. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):463-72 (20 ref.)

Physician factors affecting patient willingness to comply with exercise recommendations. Harsha DM, et al. **Clin J Sport Med** 1996 Apr;6(2):112-8

Miscompliance by proxy. Jamieson MJ, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):594

Introducing medical students to medication noncompliance. Kastrissios H, et al. **Clin Pharmacol Ther** 1996 May; 59(5):577-82

A comparative evaluation of oral contraceptive use and associated compliance issues in a rural population. Miller LG. **Clin Ther** 1995 May-Jun;17(3):541-51; discussion 516

Compliance and oral contraceptives: a review. Rosenberg MJ, et al. **Contraception** 1995 Sep;52(3):137-41 (35 ref.)

Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789-816 (39 ref.)

Feasibility and acceptability of a proposed infant feeding intervention trial for the prevention of type I diabetes. Gerstein HC, et al. **Diabetes Care** 1995 Jul;18(7):940-2

Empirical validation for a family-centered model of care. Hanson CL, et al. **Diabetes Care** 1995 Oct;18(10):1347-56

Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Martin TL, et al. **Diabetes Care** 1995 Aug;18(8):1124-32

Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Cramer J, et al. **Epilepsia** 1995 Nov;36(11):1111-7

Benefits of adherence to anti-hypertensive drug therapy. Flack JM, et al. **Eur Heart J** 1996 Mar;17 Suppl A:16-20

Therapeutic implications of drug 'holidays'. Meredith PA. **Eur Heart J** 1996 Mar;17 Suppl A:21-4

Who complied with COMA 1984 dietary fat recommendations among a nationally representative sample of British adults in 1986-7 and what did they eat? Pryer J, et al. **Eur J Clin Nutr** 1995 Oct;49(10):718-28

Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Boissel JP, et al. **Eur J Clin Pharmacol** 1996;50(1-2):63-7

Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. Uematsu T, et al. **Eur J Clin Pharmacol** 1996;50(1-2):109-13

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Lee CR, et al. **Eur J Gynaecol Oncol** 1996;17(2):99-103

Compliance with therapy in children with respiratory diseases. Schöni MH, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S77-81

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124-31 (62 ref.)

Managing patients [editorial] [see comments] Johnson TM. **Fam Med** 1995 Jul-Aug;27(7):460-2. Comment in: Fam Med 1995 Nov-Dec;27(10):632-3.

The effect of droperidol on objective markers of patient cooperation and vital signs during esophagogastroduodenoscopy: a randomized, double-blind, placebo-controlled, prospective investigation. Barthel JS, et al. **Gastrointest Endosc** 1995 Jul;42(1):45-50

Psychological management of postsurgical pain and patient adherence. Moskowitz L. **Hand Clin** 1996 Feb;12(1):129-37

Predictors of compliance with diet 6 months after heart transplantation. Grady KL, et al. **Heart Lung** 1995 Sep-Oct;24(5):359-68

Testing compliance of drug taking--a simple bed side method. Thilothammal N, et al. **Indian Pediatr** 1995 Mar; 32(3):295-9

Estimated versus predicted creatinine generation as an indicator of compliance with the prescribed dose of continuous peritoneal dialysis. Tzamaloukas AH, et al. **Int J Artif Organs** 1996 Mar;19(3):151-5

The impact of different HRT regimens on compliance. Dören M, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb; 41(1):29-39 (49 ref.)

Compliance to hormone replacement therapy. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:23-32 (51 ref.)

Hormone replacement therapy: aspects of bleeding problems and compliance. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):11-5 (20 ref.)

Effect of blister calendar packs in enhancing compliance with MDT; the Kaduna State (Nigeria) experience [letter] Awofeso N, et al. **Int J Lepr Other Mycobact Dis** 1995 Sep;63(3):453-4

An audit of hepatitis B vaccination compliance rates in two genitourinary medicine clinics. Stevenson M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):364-5

Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. Chaisson RE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):455-9

Five-year follow-up of a nurse-initiated intervention to improve mammography recommendation [see comments] Foley EC, et al. **J Am Board Fam Pract** 1995 Nov-Dec; 8(6):452-6. Comment in: J Am Board Fam Pract 1996 Mar-Apr;9(2):153-4.

Compliance with influenza immunization: a survey of high-risk patients at a family medicine clinic. Hutchinson HL, et al. **J Am Board Fam Pract** 1995 Nov-Dec; 8(6):448-51

Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study. Coyne T, et al. **J Am Diet Assoc** 1995 Nov;95(11):1301-6

Factors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease Study. Milas NC, et al. **J Am Diet Assoc** 1995 Nov; 95(11):1295-300

Use of astemizole in a large group practice. Craig TJ, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):352-4

Can an excess of estimated over-predicted creatinine generation be a discriminating test for noncompliance in continuous ambulatory peritoneal dialysis? [letter; comment] Tzamaloukas AH. **J Am Soc Nephrol** 1995 Nov; 6(5):1519-20. Comment on: J Am Soc Nephrol 1994 Feb;4(8):1627-9.

Compliance with asthma therapy: a case for shared responsibility [editorial; comment] Bender B, et al. **J Asthma** 1996;33(4):199-202. Comment on: J Asthma 1996;33(4):203-11.

Medication compliance and asthma: overlooking the trees because of the forest [see comments] Creer TL, et al. **J Asthma** 1996;33(4):203-11 (45 ref.). Comment in: J Asthma 1996;33(4):199-202.

Effect of interventions on stage of mammography adoption. Champion V, et al. **J Behav Med** 1995 Apr;18(2):169-87

Comparison of two scoring systems used to monitor diets in outpatient clinical trials. Harris WS, et al. **J Cardiovasc Risk** 1995 Aug;2(4):359-65

Adherence in cardiac and pulmonary rehabilitation. Emery

CF. **J Cardpulm Rehabil** 1995 Nov–Dec;15(6):420–3
Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76–82; discussion 83–5 (20 ref.)
Breast screening: a randomised controlled trial in UK general practice of three interventions designed to increase uptake. Sharp DJ, et al. **J Epidemiol Community Health** 1996 Feb; 50(1):72–6
Physician ability to predict appointment–keeping behavior of prenatal patients. Feierabend RH. **J Fam Pract** 1996 May;42(5):482–6
A randomised controlled trial of strategies to prompt attendance for a Pap smear. Bowman J, et al. **J Med Screen** 1995;2(4):211–8
Compliance after 17 years of breast cancer screening. Scaf–Klomp W, et al. **J Med Screen** 1995;2(4):195–9
Improving breast screening uptake: persuading initial non–attenders to attend. Turner KM, et al. **J Med Screen** 1994 Jul;1(3):199–202
Retrospective evaluation of patient compliance with supportive periodontal treatment. Demirel K, et al. **J Nihon Univ Sch Dent** 1995 Sep;37(3):131–7
Endomysial antibodies as unreliable markers for slight dietary transgressions in adolescents with celiac disease. Troncone R, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):69–72
Measurement of compliances with occlusion therapy [letter; comment] Moseley MJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov–Dec; 32(6):399–400. Comment on: J Pediatr Ophthalmol Strabismus 1995 Mar–Apr;32(2):98–101.
Compliance with supportive periodontal therapy. Novaes AB, et al. **J Periodontol** 1996 Mar;67(3):213–6
Postpartum women in outpatient drug abuse treatment: correlates of retention/completion. Strantz IH, et al. **J Psychoactive Drugs** 1995 Oct–Dec;27(4):357–73
Mystery series character is a role model for those who struggle with mental illness [letter] Masters JC. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):43
Compliance with short–term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia. al–Shammari SA, et al. **J R Soc Health** 1995 Aug; 115(4):231–4
Compliance with annual urologic evaluations and preservation of renal function in persons with spinal cord injury. Waites KB, et al. **J Spinal Cord Med** 1995 Oct; 18(4):251–4
Attitude toward recovery and completion of a substance abuse treatment program. Britt GC, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):349–53
Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence. Diokno A, et al. **J Urol** 1995 Nov; 154(5):1727–30; discussion 1731
An analysis of social and economic factors associated with followup of patients with vesicoureteral reflux. Wan J, et al. **J Urol** 1996 Aug;156(2 Pt 2):668–72
Healing of venous ulcers in an ambulatory care program: the roles of chronic venous insufficiency and patient compliance. Erickson CA, et al. **J Vasc Surg** 1995 Nov; 22(5):629–36
Quality of outpatient care: diabetes [letter; comment] Bowman MA, et al. **JAMA** 1995 Nov 22–29;274(20):1584; discussion 1585. Comment on: JAMA 1995 May 17;273(19):1503–8. Comment on: JAMA 1995 May 17;273(19):1534–7.
Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Haynes RB, et al. **Lancet** 1996 Aug 10;348(9024):383–6 (26 ref.)
Compliance with long–term oral hormonal replacement therapy. Eiken P, et al. **Maturitas** 1995 Sep;22(2):97–103
Breast cancer screening and compliance and evaluation of lesions. Schapira DV, et al. **Med Clin North Am** 1996 Jan; 80(1):15–26 (42 ref.)
Compliance with medication: some things change little [letter] Buchanan N. **Med J Aust** 1996 Jul 1;165(1):63–4
Are health undertakings effective in the follow–up of migrants for tuberculosis? King K, et al. **Med J Aust** 1995 Oct 16;163(8):407–11
Patient informatics: using a computerized system to monitor patient compliance in the treatment of hypertension. Casebeer L, et al. **Medinfo** 1995;8 Pt 2:1500–2
Impact of pharmacist counseling on medication knowledge and compliance. Williford SL, et al. **Mil Med** 1995 Nov; 160(11):561–4
Empowerment of patients: a threat or a help? [editorial] Molema J, et al. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):337–9
The effects of a cognitive behavioural intervention in asthmatic patients. Sommaruga M, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):398–402
Vitamin K administration in neonates: survey of compliance with recommended practices in the Dunedin area. Doran O, et al. **N Z Med J** 1995 Aug 25;108(1006):337–9
A lost pathological specimen [letter; comment] [see comments] Mein JN. **N Z Med J** 1995 Sep 8;108(1007):370 . Comment on: N Z Med J 1995 Jul 14;108(1003):280. Comment in: N Z Med J 1995 Oct 13;108(1009):416.
The biological basis of mental illness. Dincin J. **New Dir Ment Health Serv** 1995 Winter;(68):11–9
Predictors of retention in therapeutic communities. Condelii WS. **NIDA Res Monogr** 1994;144:117–27 (22 ref.)
Combining pharmacotherapy with psychotherapy for substance abusers with borderline personality disorder: strategies for enhancing compliance. Linehan MM. **NIDA Res Monogr** 1995;150:129–42
Follow–up appointment compliance of discharged patients from a pediatric emergency department [letter] Polacek TL, et al. **Nurse Pract** 1996 Mar;21(3):150, 152–3
Obesity treatment and attrition: no relationship to obesity level [letter] Ek A, et al. **Obes Res** 1996 May;4(3):295–6
Compliance with contraceptives and other treatments. Cramer JA. **Obstet Gynecol** 1996 Sep;88(3 Suppl):4S–12S (42 ref.)
The impact of mailing fecal occult blood test kits on return rate in a community cancer screening center. Mahon SM. **Oncol Nurs Forum** 1995 Sep;22(8):1259–63
Determining crucial correlates of breast self–examination in older women with low incomes. Morrison C. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):83–93
Compliance is poor among HIV–infected children with unmet dental needs. Broder HL, et al. **Pediatr Dent** 1996 Mar–Apr;18(2):137–8
Randomized, double blind comparison of brand and generic antibiotic suspensions: II. A study of taste and compliance in children. El–Chaar GM, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):18–22
Enhancing patient compliance in pediatrics. Liptak GS. **Pediatr Rev** 1996 Apr;17(4):128–34
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)
Assessment of immunization compliance among children in the Department of Defense health care system. Lopreiato JO, et al. **Pediatrics** 1996 Mar;97(3):308–11
Low–dose hepatitis B vaccine for adolescents [letter] Middleman AB. **Pediatrics** 1996 Jun;97(6 Pt 1):928–9
Compliance study in peritoneal dialysis using PD Adequest software. Amici G, et al. **Perit Dial Int** 1996;16 Suppl 1:S176–8
Accuracy or bias in nurses' ratings of patient compliance: a comparison of treatment modality. Edelman R, et al. **Perit Dial Int** 1996 May–Jun;16(3):321–5
How much compliance is enough? Urquhart J. **Pharm Res** 1996 Jan;13(1):10–1 (17 ref.)
The effects of a computer–assisted reminder system on patient compliance with recommended health maintenance procedures. Vincent EC, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:656–60
Physician education and management of hypercholesterolemia and compliance issues. Drown DJ. **Prog Cardiovasc Nurs** 1995 Summer;10(3):42
Women's compliance with cardiac rehabilitation programs. Ginzel AR. **Prog Cardiovasc Nurs** 1996 Winter;11(1):30–5 (38 ref.)
The management of non–compliance with referral to out–patient after–care among attempted suicide patients: a controlled intervention study. Van Heeringen C, et al. **Psychol Med** 1995 Sep;25(5):963–70
Client characteristics associated with not keeping appointments for public health nursing home visits. Josten LE, et al. **Public Health Nurs** 1995 Oct;12(5):305–11
Asthma management and morbidity in Australian general practice: the relationship between patient and doctor estimates. Bauman A, et al. **Respir Med** 1995 Nov; 89(10):665–72
Patient education and compliance issues associated with access devices. McDermott MK. **Semin Oncol Nurs** 1995 Aug;11(3):221–6 (19 ref.)
The impact of patient compliance on drug concentration profile in multiple doses. Wang W, et al. **Stat Med** 1996 Mar 30;15(6):659–69
Compliance with treatment in adult patients with cystic fibrosis. Conway SP, et al. **Thorax** 1996 Jan;51(1):29–33
Compliance with inhaled asthma medication in preschool children. Gibson NA, et al. **Thorax** 1995 Dec;50(12):1274–9
Compliance with oral corticosteroids during steroid trials in chronic airways obstruction. Hatton MQ, et al. **Thorax** 1996 Mar;51(3):323–4
Medication compliance after renal transplantation. Hilbrands LB, et al. **Transplantation** 1995 Nov 15;60(9):914–20
Noncompliance in children and adolescents after renal transplantation. Meyers KE, et al. **Transplantation** 1996 Jul 27;62(2):186–9
Completion rates of hospital–based tuberculosis treatment [letter] Ramasamy R. **Trop Doct** 1996 Jan;26(1):42
A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Whitworth JA, et al. **Trop Med Int Health** 1996 Feb;1(1):52–8
Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania. Chum HJ, et al. **Tuber Lung Dis** 1995 Aug;76(4):286–9
Tuberculosis in the community: 1. Evaluation of a volunteer health worker programme to enhance adherence to anti–tuberculosis treatment. Dick J, et al. **Tuber Lung Dis** 1996 Jun;77(3):274–9
Development of a health education booklet to enhance adherence to tuberculosis treatment. Dick J, et al. **Tuber Lung Dis** 1996 Apr;77(2):173–7
Non–compliance with tuberculosis treatment: patients and physicians [letter] Ollé–Goig JE. **Tuber Lung Dis** 1995 Jun; 76(3):277–8
[Compliance with tuberculosis treatment in Hualien aborigines] Wong CK. **J Formos Med Assoc** 1995 Jun;94 Suppl 1:S34–8 (Eng. Abstr.) **(Chi)**
[Behavior of patients with mild–to–moderate arterial hypertension in relation to their treatment. Contribution of an electronic pillbox] Mallion JM, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):597–605 (Eng. Abstr.) **(Fre)**
[Tuberculosis and patient compliance: proposition for a study methodology of patient dropouts] Comolet T, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):68–71 (Eng. Abstr.) **(Fre)**
[Therapeutic compliance in adolescents with chronic disease] Alvin P, et al. **Arch Pediatr** 1995 Sep;2(9):874–82 (86 ref.) (Eng. Abstr.) **(Fre)**
[Compliance and missed pills in France in 1995] Oddens B, et al. **Contracept Fertil Sex** 1996 Apr;24(4):290–6 (Eng. Abstr.) **(Fre)**
[Reflections on compliance in menopause hormone replacement therapy] Berthet J, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):548–51 (0 ref.) (Eng. Abstr.) **(Fre)**
[Estrogens following menopause. Methods of hormone replacement] Robyn C. **Rev Med Brux** 1995 Jul–Aug; 16(4):291–4 (Eng. Abstr.) **(Fre)**
[Compliance with hormone replacement therapy] Rozenberg S, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):295–8 (Eng. Abstr.) **(Fre)**
[Motivation to acquire and use impregnated mosquito nets in a stable malaria zone in Burundi] Van Bortel W, et al. **Trop Med Int Health** 1996 Feb;1(1):71–80 (Eng. Abstr.) **(Fre)**
[The effects of a self–medication program on compliance and drug knowledge in older patients] **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1607 **(Ger)**
[Effectiveness and acceptance of powder inhalants] Köhler D. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1401–4 **(Ger)**
[Compliance with nasal positive pressure (CPAP) in obstructive sleep apnea syndrome] Kaplan V, et al. **Schweiz Med Wochenschr** 1996 Jan 9;126(1–2):15–21 (Eng. Abstr.) **(Ger)**
[Patient compliance of hypertensive patients in the physician's practice] Magometschnigg D. **Wien Med Wochenschr** 1995;145(15–16):360–4 (Eng. Abstr.) **(Ger)**
[Problems of geriatric patients with managing drug containers] Nikolaus T, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):415–9 (Eng. Abstr.) **(Ger)**
[Effects of a prosthetic dental device used to treat obstructive sleep apnea syndrome, and compliance of patients using the device] Ichioka M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1191–7 (Eng. Abstr.) **(Jpn)**
[Patient compliance to the prescription of domiciliary oxygen therapy by transtracheal catheter (letter)] Díaz Lobato S, et al. **Arch Bronconeumol** 1996 Apr;32(4):210–1 **(Spa)**
[Therapeutic observance in arterial hypertension. Reliability of indirect methods assessing therapeutic compliance] Márquez Contreras E, et al. **Aten Primaria** 1995 Nov 15; 16(8):496–500 (Eng. Abstr.) **(Spa)**
[The degree of compliance with the radiology requests from primary care] Martínez A, et al. **Aten Primaria** 1996 Jun 15;18(1):32–4 (Eng. Abstr.) **(Spa)**
[Social evaluation and the noncompliance problem] Souchet MM. **Bol Asoc Med P R** 1995 May–Jun;87(5–6):114–5 **(Spa)**

PSYCHOLOGY

Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males. Cox WM, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):327–31
Innovative combination clinical trial designs/patient compliance: a community perspective. Bahlman W. **Antiviral Res** 1996 Jan;29(1):115–7
Homework compliance, perceptions of control, and outcome of cognitive–behavioral treatment of social phobia. Leung AW, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):423–32
Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)
The practitioner, the patient and resistance to change: recent ideas on compliance. Butler C, et al. **Can Med Assoc J** 1996 May 1;154(9):1357–62
The psychological factors associated with poor compliance with treatment in asthma. Bosley CM, et al. **Eur Respir J** 1995 Jun;8(6):899–904
Recent life events, gender differences, and the control of insulin–dependent diabetes mellitus. A 2–year follow–up study. Stenström U, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):433–9
Issues in drug administration in a psychiatric rehabilitation unit. Trauer T, et al. **Int J Soc Psychiatry** 1995 Autumn; 41(3):174–9
The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)
Predicting diabetic control from competence, adherence, adjustment, and psychopathology. Daviss WB, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1629–36

Family functioning: a correlate of diabetic control? Gowers SG, et al. **J Child Psychol Psychiatry** 1995 Sep; 36(6):993–1001

Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children. Meszaros JR, et al. **J Clin Epidemiol** 1996 Jun;49(6):697–703

Psychological intervention in patients with poor compliance. Weinstein R, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):283–8

Pediatric compliance and the roles of distinct treatment characteristics, treatment attitudes, and family stress: a preliminary report. Van Sciver MM, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):350–8

The difficult patient: prevalence, psychopathology, and functional impairment [see comments] Hahn SR, et al. **J Gen Intern Med** 1996 Jan;11(1):1–8. Comment in: J Gen Intern Med 1996 Jan;11(1):56–7.

Patient compliance for psychotropic medications: a group model for an expanding psychiatric inpatient unit. Crane K, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jan; 34(1):8–15

Heeding the alcoholic beverage warning label during pregnancy: multiparae versus nulliparae. Hankin JR, et al. **J Stud Alcohol** 1996 Mar;57(2):171–7

Self-efficacy, standards, and abstinence violation: a comparison between newly sober and long-term sober alcoholics. Ross SM, et al. **J Subst Abuse** 1988–89; 1(2):221–9

Compliance among heavy alcohol users in clinical drug trials. Sullivan JT, et al. **J Subst Abuse** 1988–89;1(2):183–94

Family behavior, adaptation, and treatment adherence of pediatric nephrology patients. Davis MC, et al. **Pediatr Nephrol** 1996 Apr;10(2):160–6

Prescribing in the elderly. Walley T, et al. **Postgrad Med J** 1995 Aug;71(838):466–71

Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Weiden P, et al. **Psychiatr Serv** 1995 Oct;46(10):1049–54

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)

Compliance with follow-up care among adolescent males with sexually transmitted diseases. Weinman ML, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):840–2

Self-esteem, compliance, and cervical screening. Wilson JR, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):891–8

The influence of comorbid disorders and of continuation light treatment on remission and recurrence in winter depression. Partonen T, et al. **Psychopathology** 1995;28(5):256–62

Determinants of persistent compliance with screening for colorectal cancer. Neilson AR, et al. **Soc Sci Med** 1995 Aug;41(3):365–74 (36 ref.)

Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Johansson E, et al. **Tuber Lung Dis** 1996 Apr; 77(2):178–83

[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas] Graupe F, et al. **Chirurg** 1996 Jun;67(6):604–9; discussion 609–10 (Eng. Abstr.) **(Ger)**

[The problem of drug compliance in schizophrenic patients (editorial)] Albus M. **Psychiatr Prax** 1995 Nov;22(6):221–2 **(Ger)**

[Compliance with nCPAP therapy: is prediction possible?] Broderick A, et al. **Wien Med Wochenschr** 1995; 145(17–18):504–5 (Eng. Abstr.) **(Ger)**

[Long-term follow-up of CPAP therapy in patients with obstructive sleep apnea] Hohenhaus-Beer A, et al. **Wien Med Wochenschr** 1995;145(17–18):512–4 (Eng. Abstr.) **(Ger)**

PATIENT COOPERATION see PATIENT COMPLIANCE

PATIENT CREDIT AND COLLECTION

Payment—putting the tab on plastic [news] **Hosp Health Netw** 1995 Oct 5;69(19):28

LEGISLATION & JURISPRUDENCE

When a patient is bankrupt. Jerrold L. **Am J Orthod Dentofacial Orthop** 1996 Mar;109(3):332–3

METHODS

"Lien on me"—veterinary liens for accounts receivable. Matthew B, et al. **Can Vet J** 1996 May;37(5):312–4 **(Eng, Fre)**

Accounting. Getting patients to pay up. Foti SK. **Hosp Health Netw** 1995 Dec 20;69(24):80

PATIENT DATA PRIVACY see CONFIDENTIALITY

PATIENT DISCHARGE

Collaborative discharge planning in the hospital inpatient setting. Lynd-Porter C. **Adv Ren Replace Ther** 1996 Apr; 3(2):180–1

Prognostic value of predischarge exercise stress echocardiography after acute myocardial infarction. Quintana M, et al. **Am J Cardiol** 1995 Dec 1;76(16):1115–21

Emergency department discharge instructions and patient literacy: a problem of disparity. Williams DM, et al. **Am J Emerg Med** 1996 Jan;14(1):19–22

Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Gillis S, et al. **Am J Hematol** 1996 Jan;51(1):26–31

The effects of newborn early discharge on hospital readmissions. Fox MH, et al. **Am J Med Qual** 1995 Winter; 10(4):206–12

Ten tools of continuous quality improvement: a review and case example of hospital discharge. Ziegenfuss JT JR, et al. **Am J Med Qual** 1995 Winter;10(4):213–20 (8 ref.)

Coordinating a successful discharge plan. Hester LE. **Am J Nurs** 1996 Jun;96(6):35–7

Computerised discharge letters from the intensive care unit [letter] Wallis CB, et al. **Anaesthesia** 1995 Nov;50(11):1013

Discharge information for emergency department patients [letter] Hart RG, et al. **Ann Emerg Med** 1996 Mar;27(3):392

Simplification of emergency department discharge instructions improves patient comprehension. Jolly BT, et al. **Ann Emerg Med** 1995 Oct;26(4):443–6

Studying emergency patients outside the emergency department. Sivilotti ML, et al. **Ann Emerg Med** 1996 Apr; 27(4):442–7 (24 ref.)

Inpatient and post-discharge wound infections in general surgery [see comments] Keeling NJ, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):245–7. Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):464.

Written discharge advice sheets reduce visits to the general practitioner. Raine C, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1 Suppl):19–20

Early removal of drains and discharge of breast cancer surgery patients: a controlled prospective clinical trial. Yii M, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):377–9

Discharging patients who are undergoing mechanical circulatory support. Winowich S, et al. **Ann Thorac Surg** 1996 Jan;61(1):478–9

Postconceptional age of surviving preterm low-birth-weight infants at hospital discharge. Rawlings JS, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):260–2

The effect of early discharge and other factors on readmission rates of newborns. Soskolne EI, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):373–9

Early discharge after open appendicectomy. Lord RV, et al. **Aust N Z J Surg** 1996 Jun;66(6):361–5

Going home [editorial] Bethell HJ. **BMJ** 1996 Jun 1; 312(7043):1372–3

Experience of medical senior house officers in preparing discharge summaries. Frain JP, et al. **BMJ** 1996 Feb 10; 312(7027):350

US warns against early discharge of babies [news] Roberts J. **BMJ** 1995 Oct 21;311(7012):1041–2

Suicide after discharge from psychiatric hospitals in Scotland [letter; comment] Stark C, et al. **BMJ** 1995 Nov 18; 311(7016):1368–9. Comment on: BMJ 1995 Aug 5;311(7001):357–60.

One and two year outcomes for adults with learning disabilities discharged to the community. Donnelly M, et al. **Br J Psychiatry** 1996 May;168(5):598–606

Prospective audit of discharge summary errors. Macaulay EM, et al. **Br J Surg** 1996 Jun;83(6):788–90

Late rehabilitation for closed head injury: a follow-up study of patients 1 year from time of discharge. Anderson SI, et al. **Brain Inj** 1996 Feb;10(2):115–24

Long hospital stays and need for alternate level of care at discharge. Does family make a difference for elderly patients? McClaran J, et al. **Can Fam Physician** 1996 Mar; 42:449–54, 457–61

Uncertainty, symptom distress, and information needs after surgery for cancer of the colon. Galloway SC, et al. **Cancer Nurs** 1996 Apr;19(2):112–7

Early discharge after direct angioplasty for acute myocardial infarction [editorial; comment] Guy SR. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):191. Comment on: Cathet Cardiovasc Diagn 1995 Jul;35(3):187–90.

Early hospital discharge after direct angioplasty for acute myocardial infarction [see comments] Hanlon JT, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):187–90. Comment in: Cathet Cardiovasc Diagn 1995 Jul;35(3):191.

A critical review of studies of newborn discharge timing. Margolis LH. **Clin Pediatr (Phila)** 1995 Dec;34(12):626–34

Controversies of early discharge of infants from the well-newborn nursery. Dershewitz R, et al. **Curr Opin Pediatr** 1995 Oct;7(5):494–501

The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)

In-hospital mortality and disposition of diabetic amputees in The Netherlands. Lavery LA, et al. **Diabet Med** 1996 Feb;13(2):192–7

Multiple perceptions of discharge planning in one urban hospital. Clemens EL. **Health Soc Work** 1995 Nov; 20(4):254–61

Job satisfaction among social work discharge planners. Kadushin G, et al. **Health Soc Work** 1995 Aug;20(3):174–86

Discharge planning: comparison of patients and nurses' perceptions of patients following hospital discharge. Reiley P, et al. **Image J Nurs Sch** 1996 Summer;28(2):143–7

Termination in inpatient groups. Brabender V, et al. **Int J Group Psychother** 1996 Jan;46(1):81–98 (25 ref.)

The effects of a discharge information intervention on recovery outcomes following coronary artery bypass surgery. Moore SM. **Int J Nurs Stud** 1996 Apr;33(2):181–9

Pediatric tracheotomy discharge teaching: a comprehensive checklist format. Hotaling AJ, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):113–26

Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar–Apr; 43(2):53–7 (19 ref.)

Subjective perception of additional support requirements of elderly patients discharged from accident and emergency departments. Farnsworth TA, et al. **J Accid Emerg Med** 1995 Jun;12(2):107–10

Ongoing work of older adults at home after hospitalization. Lough MA. **J Adv Nurs** 1996 Apr;23(4):804–9

Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Newby LK, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):625–32

Use of post-hospital care by Medicare patients. Kane RL, et al. **J Am Geriatr Soc** 1996 Mar;44(3):242–50

Geriatric targeting criteria as predictors of survival and health care utilization. Satish S, et al. **J Am Geriatr Soc** 1996 Aug;44(8):914–21

An intervention on discharge polypharmacy. Smith DM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):416–9

Care of asthmatics on discharge from hospital: a hospital audit. Schilling RJ, et al. **J Asthma** 1995;32(2):161–3

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)

Assessment of postdischarge concerns of coronary artery bypass graft patients. Wu CY. **J Cardiovasc Nurs** 1995 Oct; 10(1):1–7

A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. Chung F, et al. **J Clin Anesth** 1995 Sep;7(6):500–6

Promoting hospital discharge of infants in safety seats. Wolf D, et al. **J Community Health** 1995 Aug;20(4):345–57

Effects of a postdischarge clinic on housestaff satisfaction and utilization of hospital services. Diem SJ, et al. **J Gen Intern Med** 1996 Mar;11(3):179–81

Who leaves against medical advice? Jeremiah J, et al. **J Gen Intern Med** 1995 Jul;10(7):403–5

Functional and residential status transitions among nursing home residents. Gillen P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M29–36

Surgical site infections occurring after hospital discharge. Sands K, et al. **J Infect Dis** 1996 Apr;173(4):963–70

The dilemma of the hasty discharge. Jackson BS. **J Nurs Adm** 1996 Jun;26(6):7–9

Patient care coordinators: successfully merging utilization management and discharge planning. McNamara ST, et al. **J Nurs Adm** 1995 Nov;25(11):33–8

Congestive heart failure: a continuum of care. Welsh C, et al. **J Nurs Care Qual** 1996 Jul;10(4):24–32

A discharge check list for psychiatric patients. Hochberger JM. **J Psychosoc Nurs Ment Health Serv** 1995 Dec; 33(12):35–8 (13 ref.)

Mortality soon after discharge from a major teaching hospital: linking mortality and morbidity. O'Hara D, et al. **J Qual Clin Pract** 1996 Mar;16(1):39–48

Is a pre-discharge checklist useful? Hunter J, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):162–3

Content of a discharge summary from a medical ward: views of general practitioners and hospital doctors. Solomon JK, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):307–10

Early patient discharge following appendicectomy: safety and feasibility. Salam IM, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):300–2

Adequacy of hospital discharge data for determining trauma morbidity patterns [letter; comment] Berenholz G, et al. **J Trauma** 1996 Jul;41(1):168–70. Comment on: J Trauma 1995 Nov;39(5):935–40.

Adequacy of hospital discharge data for determining trauma morbidity patterns [see comments] Kramer CF, et al. **J Trauma** 1995 Nov;39(5):935–40. Comment in: J Trauma 1996 Jul;41(1):168–70.

An analysis of Hospital Discharge Index as a trauma data base. Mullins RJ, et al. **J Trauma** 1995 Nov;39(5):941–8

Need to evaluate discharge data [letter] Sniezek JE, et al. **J Trauma** 1996 Sep;41(3):575–8

Developing time-based protocols. Barnes LP. **MCN Am J Matern Child Nurs** 1996 Jul–Aug;21(4):177

Automated coding of patient discharge summaries using conceptual graphs. Delamarre D, et al. **Methods Inf Med** 1995 Sep;34(4):345–51

To stay or not to stay? That is the question [comment] [see comments] Parisi VM, et al. **N Engl J Med** 1995 Dec 14; 333(24):1635–7. Comment on: N Engl J Med 1995 Dec 14;333(24):1647–51. Comment in: N Engl J Med 1996 Apr 25;334(17):1134; discussion 1135.

Controversial issues surrounding early postpartum discharge. Brown LP, et al. **Nurs Clin North Am** 1996 Jun;31(2):333–9 (23 ref.)

Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)

Summary of workshop: early discharge and neonatal hyperbilirubinemia. Catz C, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):743–5

Early discharge, in the end: maternal abuse, child neglect, and physician harassment. Charles S, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):746–7

Maternal postpartum cognitive deficits and early discharge of infants [letter] Eidelman AI, et al. **Pediatrics** 1996 Sep; 98(3 Pt 1):516

Discharging patients with prescriptions instead of medications: sequelae in a teaching hospital. Johnson KB, et al. **Pediatrics** 1996 Apr;97(4):481–5

Early discharge: in the end, it is judgment. Kessel W, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):739–42

Early discharge alert [comment] Lawrence RA. **Pediatrics** 1995 Nov;96(5 Pt 1):966–7. Comment on: Pediatrics 1995 Nov;96(5 Pt 1):957–60.

Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. MacDonald MG. **Pediatrics** 1995 Oct;96(4 Pt 1):734–8

Thyroid screening for early discharged infants. Saslow JG, et al. **Pediatrics** 1996 Jul;98(1):41–4

Phenylketonuria screening: effect of early newborn discharge. Sinai LN, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):605–8

Perceived consequences to the predictor: a variable in the release of psychiatric patients. Stevens HB, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1371–8

Using hospital discharge data for disease surveillance. Huff L, et al. **Public Health Rep** 1996 Jan–Feb;111(1):78–81

The ethics of discharge planning for older adults: an ethnographic analysis. Dill AE. **Soc Sci Med** 1995 Nov; 41(9):1289–99

Factors precluding patients' discharge to the community. A geropsychiatric hospital survey. Vieweg V, et al. **Va Med Q** 1995 Fall;122(4):275–8

[Mediocre quality of discharge reports concerning psychiatric patients] Beyaert EW, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):365–8 (Eng. Abstr.) **(Dut)**

[Patient discharge criteria following surgery in day care] Zuurmond WW, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):422–4 **(Dut)**

[Ambulatory care of depressed patients. Retrospective study of 60 patients hospitalized for an episode of major depression] Oreve-Mauratille MJ, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):461–6 **(Fre)**

[The Mannheim long-term study of schizophrenia. Initial results of follow-up of the illness over 14 years after initial inpatient treatment] an der Heiden W, et al. **Nervenarzt** 1995 Nov;66(11):820–7 (Eng. Abstr.) **(Ger)**

[Rehospitalization of very-low-birth-weight infants after discharge from neonatal intensive care units] Bar-Oz B, et al. **Harefuah** 1995 Jun 1;128(11):687–9, 743 (Eng. Abstr.) **(Heb)**

[Stratification of risk at discharge after acute myocardial infarction: prognostic significance of advanced age (letter; comment)] Azzarelli A, et al. **G Ital Cardiol** 1995 Jul; 25(7):933–6. Comment on: G Ital Cardiol 1994 Nov;24(11):1415–22. **(Ita)**

[The effectiveness of discharge planning (DSP) in home care—comparison of conditions of cancer patient shifted to home treatment before and after DSP introduction] Watanabe A, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:331–8 (Eng. Abstr.) **(Jpn)**

[Factors related to ADL of stroke patients three months after discharge] Ishikawa R, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):354–63 (Eng. Abstr.) **(Jpn)**

[Transition of patients with chronic neurological diseases from hospital to home] Naito H. **No To Hattatsu** 1996 May; 28(3):211–3 (Eng. Abstr.) **(Jpn)**

[Hospital physicians—general practitioners and continuity of health care (letter)] Nordlander NB. **Lakartidningen** 1996 May 22;93(21):2042 **(Swe)**

[The need for care of patients with available health care services provided by counties or municipalities (letter)] Resmark M. **Lakartidningen** 1995 Dec 6;92(49):4676 **(Swe)**

ECONOMICS

The costs and effects of early discharge in the management of fractured hip—a correction [letter] Shiell A. **Age Ageing** 1995 Jul;24(4):367

Discharge planning for dementia patients: factors influencing caregiver decisions and satisfaction. Cox CB. **Health Soc Work** 1996 May;21(2):97–104

Competition versus regulation: constraining hospital discharge costs. Weil TP. **J Health Care Finance** 1996 Spring;22(3):62–74

LEGISLATION & JURISPRUDENCE

Mental health tribunals [letter; comment] Crimlisk H, et al. **Br J Psychiatry** 1995 Jul;167(1):116–7. Comment on: Br J Psychiatry 1993 Jan;162:14–22.

Involuntary transfers and discharges of nursing home residents under federal and state law. Knepper K. **J Leg Med** 1996 Jun;17(2):215–75

Women and children first [see comments] Annas GJ. **N Engl J Med** 1995 Dec 14;333(24):1647–51. Comment in: N Engl J Med 1995 Dec 14;333(24):1635–7.

[Treatment after and patient education before tonsillectomy] Wienke A. **Laryngorhinootologie** 1996 Mar;75(3):184–5 **(Ger)**

STANDARDS

Sulfa drug reaction. Lilley LL, et al. **Am J Nurs** 1996 Jan; 96(1):14

Protocol for releasing Novacor left ventricular assist system patients out-of-hospital. Pristas JM, et al. **ASAIO J** 1995 Jul–Sep;41(3):M539–43

Adult discharge planning and nursing home placement: a study of risk factors for quality assurance. Cooper L. **Aust Clin Rev** 1991;11:95–102

Postpartum safety and satisfaction following early discharge. Dalby DM, et al. **Can J Public Health** 1996 Mar–Apr; 87(2):90–4

Implementation of discharge plans for chronically ill elders discharged home. Proctor EK, et al. **Health Soc Work** 1996 Feb;21(1):30–40

Pediatric discharge planning: complications, efficiency, and adequacy. Proctor EK, et al. **Soc Work Health Care** 1995; 22(1):1–18

Predictors of patient and proxy satisfaction with discharge plans. Showers N, et al. **Soc Work Health Care** 1995; 22(1):19–35

Patient understanding of emergency department discharge instructions. Logan PD, et al. **South Med J** 1996 Aug; 89(8):770–4

[Are early unforseen rehospitalizations inevitable?] Chaput-Toupin E, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):221–7 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Using administratively collected hospital discharge data for AIDS surveillance. Payne SM, et al. **Ann Epidemiol** 1995 Sep;5(5):337–46

Predicting discharge destination of stroke patients using a mathematical model based on six items from the Functional Independence Measure. Mauthe RW, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):10–3

Investigating discharge destinations for schizophrenic patients. Bland R, et al. **Aust N Z J Psychiatry** 1995 Jun; 29(2):288–92

A cluster analytic study of functional outcome after psychiatric hospitalization. Goethe JW, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):115–21

Racial differences in discharge planning. Morrow-Howell N, et al. **Health Soc Work** 1996 May;21(2):131–9

Application of multivariable optimal discriminant analysis in general internal medicine. Yarnold PR, et al. **J Gen Intern Med** 1995 Nov;10(11):601–6

Analyses of data quality in registries concerning diabetes mellitus—a comparison between a population based hospital discharge and an insulin prescription registry. Nielsen GL, et al. **J Med Syst** 1996 Feb;20(1):1–10

Oral cavity and pharyngeal cancer among Department of Veterans Affairs hospital discharges. Fedele DJ, et al. **J Public Health Dent** 1995 Summer;55(3):143–7

A review of hospital discharge rates in a population around Camelford in North Cornwall up to the fifth anniversary of an episode of aluminium sulphate absorption. Owen PJ, et al. **J Public Health Med** 1995 Jun;17(2):200–4

Neonatal mortality and length of newborn hospital stay. Beebe SA, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):231–5

Physician experience with pediatric inpatient care in Washington State. Melzer SM, et al. **Pediatrics** 1996 Jan; 97(1):65–70

Deaths among former psychiatric inpatients in an outreach case management program. Curtis JL, et al. **Psychiatr Serv** 1996 Apr;47(4):398–402

Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Rawson NS, et al. **Stat Med** 1995 Dec 30;14(24):2627–43

Patterns of admission and discharge in an acute geriatric medical ward. Taylor IC, et al. **Ulster Med J** 1995 Apr; 64(1):58–63

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1993. Graves EJ. **Vital Health Stat 13** 1995 Oct;(122):1–288

[Epidemiological aspects of acute respiratory infections in childhood: hospital discharge data from Modena (USL no. 16) and the Emilia Romagna region] Fantuzzi G, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):599–608 (Eng. Abstr.) **(Ita)**

[The epidemiologic potential of neonatology units in the occurrence of acute diarrheal diseases in outpatient newborns] Deac L, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):199–200 **(Rum)**

TRENDS

Discharge criteria—a new trend. Chung F. **Can J Anaesth** 1995 Nov;42(11):1056–8

PATIENT DROPOUTS

Factors associated with premature termination of psychotherapy by children. Chung WS, et al. **Adolescence** 1995 Fall;30(119):717–21

Patient factors related to early attrition from an outpatient cocaine research clinic. Agosti V, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):29–39

Factors predicting participant attrition in a community-based, culturally specific smoking-cessation program for Hispanic smokers. Nevid JS, et al. **Health Psychol** 1996 May;15(3):226–9

The use of a structured assessment interview as an intervention to reduce dropout rates in outpatient relapse prevention groups for "problem" drinkers. Keaney F, et al. **Int J Addict** 1995 Aug;30(10):1355–62

The process of termination in long-term psychoanalytic group therapy. Fieldsteel ND. **Int J Group Psychother** 1996 Jan;46(1):25–39

Introduction to special section on termination and group therapy. Klein RH. **Int J Group Psychother** 1996 Jan; 46(1):1–4

Premature termination of group therapy: a clinical perspective. Rice CA. **Int J Group Psychother** 1996 Jan; 46(1):5–23

Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group. Raboud JM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):46–55

Riluzole and amyotrophic lateral sclerosis [letter; comment] Guiloff RJ, et al. **Lancet** 1996 Aug 3;348(9023):336–7. Comment on: Lancet 1996 May 25;347(9013):1425–31.

Retention in therapeutic communities: challenges for the nineties. Lewis BF, et al. **NIDA Res Monogr** 1994; 144:99–116 (45 ref.)

Obesity treatment and attrition: no relationship to obesity level [letter] Ek A, et al. **Obes Res** 1996 May;4(3):295–6

Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)

Effect of non-random missing data mechanisms in clinical trials. Choi SC, et al. **Stat Med** 1995 Dec 30;14(24):2675–84

Nurturing longitudinal samples. Weinert C, et al. **West J Nurs Res** 1996 Jun;18(3):360–4

[Characterization of "non-attenders" in an organized screening against cancer of cervix uteri] Larsen LP, et al. **Ugeskr Laeger** 1996 May 20;158(21):2987–91 (Eng. Abstr.) **(Dan)**

[Tuberculosis and patient compliance: proposition for a study methodology of patient dropouts] Comolet T, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):68–71 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)

Effects of halfway house placement on retention of patients in substance abuse aftercare. Hitchcock HC, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):379–90

Binge eating disorder, retention, and dropout in an adult obesity program. Ho KS, et al. **Int J Eat Disord** 1995 Nov; 18(3):291–4

Life stress and treatment course of recurrent depression: II. Postrecovery associations with attrition, symptom course, and recurrence over 3 years. Monroe SM, et al. **J Abnorm Psychol** 1996 Aug;105(3):313–28

Rorschach and MMPI-2 indices of early psychotherapy termination. Hilsenroth MJ, et al. **J Consult Clin Psychol** 1995 Dec;63(6):956–65

Determinants of research follow-up participation in an alcohol treatment outcome trial. Stout RL, et al. **J Consult Clin Psychol** 1996 Jun;64(3):614–8

The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program. Araujo L, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):61–6

Identifying early dropouts from a rehabilitation program for psychiatric outpatients. Cohen K, et al. **Psychiatr Serv** 1995 Oct;46(10):1076–8

Parent orientation meetings to improve attendance and access at a child psychiatric clinic. Wenning K, et al. **Psychiatr Serv** 1995 Aug;46(8):831–3

Childhood abuse as a factor in attrition from drug rehabilitation. Palmer JA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):879–82

Perception and social consequences of tuberculosis: a focus group study of tuberculosis patients in Sialkot, Pakistan. Liefooghe R, et al. **Soc Sci Med** 1995 Dec;41(12):1685–92

Physicians' attitudes and retention of patients in their methadone maintenance programs. Caplehorn JR, et al. **Subst Use Misuse** 1996 May;31(6):663–77

[Suicidal adolescents: psychotherapy and treatment interruption. Results of a controlled study] Ottino J. **Psychiatr Enfant** 1995;38(2):573–602 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Patients dropping out of treatment in Italy. Morlino M, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):1–6

Manic depressive (bipolar) disorder [letter; comment] Petri ML. **Acta Psychiatr Scand** 1995 Nov;92(5):398. Comment on: Acta Psychiatr Scand 1994 Feb;89(2):102–10.

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16–20 (20 ref.)

How to deal with the drop-out in clinical follow-up studies: results of a long-term follow-up study of orthodontically treated patients. Kahl B, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):415–20

Discontinued orthodontic treatment in the general dental service and community dental service in England and

Wales during the summer of 1991. Eaton KA, et al. **Br J Orthod** 1996 May;23(2):125–8

Discontinued orthodontic treatment in the general dental services of England and Wales (1990–1991). Richmond S, et al. **Br J Orthod** 1995 Aug;22(3):263–8

Why do patients default from follow-up at a genitourinary clinic?: a multivariate analysis. Ross JD, et al. **Genitourin Med** 1995 Dec;71(6):393–5

An audit study of defaulters of regular psychiatric outpatient appointments in Hong Kong. Pang AH, et al. **Int J Soc Psychiatry** 1995 Summer;41(2):103–7

Effects of an appointment reminder call on patient show rates. Gariti P, et al. **J Subst Abuse Treat** 1995 May–Jun; 12(3):207–12

Disenrollment of Medicare cancer patients from health maintenance organizations. Riley GF, et al. **Med Care** 1996 Aug;34(8):826–36

Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. **NIDA Res Monogr** 1994;144:128–61 (28 ref.)

Infertility treatment dropout and insurance coverage. Gleicher N, et al. **Obstet Gynecol** 1996 Aug;88(2):289–93

IUD discontinuation patterns and correlates in four counties in north China. Tu P. **Stud Fam Plann** 1995 May–Jun; 26(3):169–79

PATIENT DUMPING see PATIENT TRANSFER

PATIENT EDUCATION

Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients. Domenech MI, et al. **Acta Diabetol** 1995 Oct;32(3):143–7

Current status of pediatric home peritoneal dialysis training in the United States. Miller DH, et al. **Adv Perit Dial** 1995; 11:274–6

Improved training techniques and UltraBag system resulted in lowered peritonitis rate in an inner-city population. Rubin JE, et al. **Adv Perit Dial** 1995;11:208–9

Decreasing the complications of renal osteodystrophy secondary to high phosphorus levels by using an innovative self-monitoring educational program. Zagaroli AM, et al. **Adv Perit Dial** 1995;11:254–7

Home hemodialysis—yes, it can be learned. Stevens JE. **Adv Ren Replace Ther** 1996 Apr;3(2):120–3

A randomized trial of an education and support program for HIV-infected individuals. Cleary PD, et al. **AIDS** 1995 Nov;9(11):1271–8

Consumer campaign is directed at women with HIV or AIDS [news] **Am Fam Physician** 1996 Feb 1;53(2):466

AAFP's role in public education about antibiotic resistance [letter] Comstock LK. **Am Fam Physician** 1996 May 15; 53(7):2283

Panic disorder and the primary care physician [editorial; comment] Doyle BB. **Am Fam Physician** 1995 Nov 15; 52(7):1999–2000. Comment on: Am Fam Physician 1995 Nov 15;52(7):2055–63, 2067–8.

Counseling for healthy lifestyles: exercise prescription [editorial; comment] Kallenberg G. **Am Fam Physician** 1996 Feb 1;53(2):484–6. Comment on: Am Fam Physician 1996 Feb 1;53(2):579–86.

Diabetes and 'normal' lifestyle [letter; comment] Matuschka P. **Am Fam Physician** 1995 Nov 15;52(7):2011–2. Comment on: Am Fam Physician 1995 Jun;51(8):1953–62, 1966–8.

Prescribing exercise for health: a simple framework for primary care [see comments] Will PM, et al. **Am Fam Physician** 1996 Feb 1;53(2):579–85 (16 ref.). Comment in: Am Fam Physician 1996 Feb 1;53(2):484–6.

An update on vaccine safety. Zimmerman RK, et al. **Am Fam Physician** 1996 Jul;54(1):185–93 (43 ref.)

Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Shrestha M, et al. **Am J Emerg Med** 1996 Jul;14(4):380–4

Postmarketing surveillance indicates need for better education of patients taking alendronate [news] **Am J Health Syst Pharm** 1996 May 1;53(9):986

Medication-compliance recommendations target health professionals, industry groups, patients [news] **Am J Health Syst Pharm** 1995 Nov 1;52(21):2394

Informing a patient about a homeopathic preparation. Kaatz BL, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2437; discussion 2437–41

Opinions on useful patient drug information aired at FDA workshop. Opposition to MedGuide proposal runs strong [news] Thompson CA. **Am J Health Syst Pharm** 1996 Apr 1;53(7):712–4

The role of adjunctive therapy in the management of chronic nonmalignant pain. Allegrante JP. **Am J Med** 1996 Jul 31; 101(1A):33S–39S (69 ref.)

The effect of developing patient compendiums for critical pathways on patient satisfaction. Shulkin DJ, et al. **Am J Med Qual** 1996 Spring;11(1):43–5

Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Kelso TM, et al. **Am J Med Sci** 1996 Jun;311(6):272–80

Educate the patient. Lilley LL, et al. **Am J Nurs** 1996 Apr; 96(4):14,16

What every woman should know about menopause. Wasaha S, et al. **Am J Nurs** 1996 Jan;96(1):24–32; quiz 33 (9 ref.)

Clinical preventive medical specialist [letter] Koenig J. **Am J Prev Med** 1996 Mar–Apr;12(2):71

Does counseling improve compliance? Herrier RN, et al. **Am Pharm** 1995 Sep;NS35(9):11–2, 61

The Amsterdam Preoperative Anxiety and Information Scale (APAIS) [see comments] Moerman N, et al. **Anesth Analg** 1996 Mar;82(3):445–51. Comment in: Anesth Analg 1996 Mar;82(3):443–4.

How much do they really want to know? Preoperative patient interviews and the anesthesiologist [editorial; comment] Roizen MF, et al. **Anesth Analg** 1996 Mar; 82(3):443–4. Comment on: Anesth Analg 1996 Mar;82(3):445–51.

Video as a patient teaching tool: does it add to the preoperative anesthetic visit? Zvara DA, et al. **Anesth Analg** 1996 May;82(5):1065–8

How patients determine when to replace their metered-dose inhalers. Ogren RA, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):485–9

Involving family physicians in education programs for cervical cancer screening. McGregor SE, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:289–91

Community physician willingness to refer cancer patients for treatment education. Myers RE, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:323–6

The adequacy of consent forms for informing patients entering oncological clinical trials. Olver IN, et al. **Ann Oncol** 1995 Nov;6(9):867–70

Readability of patient education materials: implications for clinical practice. Albright J, et al. **Appl Nurs Res** 1996 Aug; 9(3):139–43 (37 ref.)

Current management of acute bronchitis in ambulatory care [letter] Benz D. **Arch Fam Med** 1996 Sep;5(9):440

Educating patients about cystic fibrosis carrier screening in a primary care setting. Bernhardt BA, et al. **Arch Fam Med** 1996 Jun;5(6):336–40

Promoting the use of advance directives: an empirical study [letter; comment] Coleman MT, et al. **Arch Fam Med** 1996 Jul–Aug;5(7):382–3. Comment on: Arch Fam Med 1995 Jul;4(7):609–15.

Cholesterol-lowering intervention program. Effect of the step I diet in community office practices [see comments] Caggiula AW, et al. **Arch Intern Med** 1996 Jun 10; 156(11):1205–13. Comment in: Arch Intern Med 1996 Jun 10;156(11):1138–9.

Efficacy of the National Cholesterol Education Program Step I diet. A randomized trial incorporating quick-service foods. Davidson MH, et al. **Arch Intern Med** 1996 Feb 12;156(3):305–12

Involvement of cardiovascular rehabilitation programs in advance directive education. Heffner JE, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1746–51

Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Lewis CE, et al. **Arch Intern Med** 1996 Feb 26;156(4):377–85

Exercise decreases the risk of development of diabetes mellitus, So... [editorial; comment] Nugent CA. **Arch Intern Med** 1996 Jun 24;156(12):1258. Comment on: Arch Intern Med 1996 Jun 24;156(12):1307–14.

Promoting completion of health care proxies following hospitalization. A randomized controlled trial in a community hospital. Reilly BM, et al. **Arch Intern Med** 1995 Nov 13;155(20):2202–6

Informed consent. From bodily invasion to the seemingly mundane [editorial; comment] Ubel PA. **Arch Intern Med** 1996 Jun 24;156(12):1262–3. Comment on: Arch Intern Med 1996 Jun 24;156(12):1333–6.

The impact of informed consent on patient interest in prostate-specific antigen screening [see comments] Wolf AM, et al. **Arch Intern Med** 1996 Jun 24;156(12):1333–6. Comment in: Arch Intern Med 1996 Jun 24;156(12):1262–3.

Home program of physical therapy: effect on disabilities of patients with total hip arthroplasty. Sashika H, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):273–7

The information needs of patients with breast cancer. Perez DJ, et al. **Aust N Z J Med** 1995 Oct;25(5):521–2

Compliance problems in paediatric atopic eczema. Fischer G. **Australas J Dermatol** 1996 May;37 Suppl 1:S10–3

Psycho-educational interventions in the treatment of arthritis. Hawley DJ. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):803–23 (46 ref.)

3rd European workshop on drug information Helsinki, Finland, June 14–16, 1995. Wallenius K. **Biol Neonate** 1995; 68(6):426–8

Patient education campaign launched [news] Beecham L. **BMJ** 1996 Mar 2;312(7030):531

Assertions about patient information are not supported [letter; comment] Dixon M. **BMJ** 1995 Oct 7;311(7010):946. Comment on: BMJ 1995 Jul 1;311(6996):4–5.

History of chicken pox and steroid cards: a new warning? [see comments] Feher MD, et al. **BMJ** 1996 Mar 2; 312(7030):542–3. Comment in: BMJ 1996 Jun 22;312(7046):1608. Comment in: BMJ 1996 Jun 22;312(7046):1608–9.

Advising women on which pill to take [editorial; comment] [see comments] Guillebaud J. **BMJ** 1995 Oct 28; 311(7013):1111–2. Comment on: BMJ 1995 Oct 28;311(7013):1112. Comment in: BMJ 1995 Nov 4;311(7014):1232.

Informing patients about the drugs they take [editorial] Meredith B. **BMJ** 1996 Aug 10;313(7053):315

Information about prenatal testing does not necessarily increase uptake [letter; comment] Moore WM. **BMJ** 1996 Feb 24;312(7029):508. Comment on: BMJ 1995 Oct 28;311(7013):1127–30.

Television and radio should be used to disseminate important information [letter] Murty J, et al. **BMJ** 1996 Jun 29; 312(7047):1672

Hepatitis B vaccination. Information for patients is vital [letter; comment] Pallecaros A, et al. **BMJ** 1996 Mar 23; 312(7033):777. Comment on: BMJ 1995 Dec 2;311(7018):1500.

Women need to be fully informed about risks of hormone replacement therapy [letter; comment] Price EH, et al. **BMJ** 1996 May 18;312(7041):1301. Comment on: BMJ 1995 Nov 25;311(7017):1399–401.

A randomised trial of three methods of giving information about prenatal testing [see comments] Thornton JG, et al. **BMJ** 1995 Oct 28;311(7013):1127–30. Comment in: BMJ 1996 Feb 24;312(7029):508.

A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. Mohide EA, et al. **Br J Cancer** 1996 Jun;73(12):1588–93

Does encouraging good compliance improve patients' clinical condition in heart failure? [see comments] Goodyer LI, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):173–6. Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):171.

Women's knowledge of taking oral contraceptive pills correctly and of emergency contraception: effect of providing information leaflets in general practice. Smith LF, et al. **Br J Gen Pract** 1995 Aug;45(397):409–14

The combined oral contraceptive pill: what advice should we give when pills are missed? [letter; comment] Davies MC. **Br J Obstet Gynaecol** 1996 Feb;103(2):186–7. Comment on: Br J Obstet Gynaecol 1995 Aug;102(8):601–7.

The combined oral contraceptive pill: what advice should we give when pills are missed? [letter; comment] Yoong AF. **Br J Obstet Gynaecol** 1996 Feb;103(2):186. Comment on: Br J Obstet Gynaecol 1995 Aug;102(8):601–7.

Advice to car drivers with rheumatoid arthritis [letter] Dawson JK, et al. **Br J Rheumatol** 1995 Aug;34(8):796–7

The provision of rheumatological information [editorial] Denman AM. **Br J Rheumatol** 1996 Jun;35(6):503–5

Patient education: treatment or nice extra [editorial] Lorig K. **Br J Rheumatol** 1995 Aug;34(8):703–4

Single-blind randomized controlled trial of an educational booklet for patients with chronic arthritis. Maggs FM, et al. **Br J Rheumatol** 1996 Aug;35(8):775–7

A comprehensive cognitive-behavioral/educational program for schizophrenic patients. Gallagher RE, et al. **Bull Menninger Clin** 1995 Summer;59(3):357–71

What exacerbates asthma? [letter] Abelsohn A, et al. **Can Fam Physician** 1996 Apr;42:620

Equality in health promotion [letter] Mills JK. **Can Fam Physician** 1996 Mar;42:406, 408, 410

Self-measurement of blood pressure: issues related to the training of patients. Canadian Coalition for High Blood Pressure Prevention and Control. Birkett NJ, et al. **Can J Cardiol** 1995 Nov;11 Suppl H:23H–27H

Common drugs and the progress of cancer [letter; comment] Brown JH. **Can Med Assoc J** 1996 Jan 1;154(1):16–7. Comment on: Can Med Assoc J 1995 Sep 1;153(5):569–71.

Resources available to help family physicians provide advice to travellers. Lechky O. **Can Med Assoc J** 1995 Oct 1; 153(7):996–8

Uncertainty, symptom distress, and information needs after surgery for cancer of the colon. Galloway SC, et al. **Cancer Nurs** 1996 Apr;19(2):112–7

Factors influencing registered nurses teaching breast self-examination to female clients. Han Y, et al. **Cancer Nurs** 1996 Jun;19(3):197–203

Does asthma education change behavior? To know is not to do [editorial; comment] Blessing-Moore J. **Chest** 1996 Jan;109(1):9–11. Comment on: Chest 1996 Jan;109(1):86–90.

Advance directive education during pulmonary rehabilitation [see comments] Heffner JE, et al. **Chest** 1996 Feb; 109(2):373–9. Comment in: Chest 1996 Feb;109(2):299.

Assessment of practical knowledge of self-management of acute asthma [see comments] Kolbe J, et al. **Chest** 1996 Jan;109(1):86–90. Comment in: Chest 1996 Jan;109(1):9–11.

Are advance directives becoming an endangered species? [editorial; comment] Perkins HS. **Chest** 1996 Feb;109(2):299 . Comment on: Chest 1996 Feb;109(2):373–9.

Exercise and hypertension: common questions. Halperin AK. **Cleve Clin J Med** 1996 Jul–Aug;63(4):201–3

How to implement an asthma education program. Kohler CL, et al. **Clin Chest Med** 1995 Dec;16(4):557–65 (18 ref.)

Education proposals for the population at risk. Badger C. **Clin Dermatol** 1995 Sep–Oct;13(5):507–9

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Clinical implications of patients' knowledge. Mahmud T, et al. **Clin Rheumatol** 1995 Nov;14(6):627–30

Measuring of impact of patient counseling in the outpatient pharmacy setting: development and implementation of the counseling models for the Kaiser Permanente/USC Patient Consultation Study. Johnson KA, et al. **Clin Ther** 1995 Sep–Oct;17(5):988–1002

Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser Permanente/USC patient consultation study. McCombs JS, et al. **Clin Ther** 1995 Nov–Dec;17(6):1188–206

Electroconvulsive therapy patient/family education. Dillon

P. **Convuls Ther** 1995 Sep;11(3):188–91

Survival kit: The five-minute education kit. A document for health care providers and patients. Diabetes education study group of the European Association for the Study of Diabetes. **Diabet Med** 1995 Nov;12(11):1022–42

Education and the diabetic foot. Edmonds ME, et al. **Diabet Med** 1996;13 Suppl 1:S61–4 (25 ref.)

Comprehensive diabetes care in North Tyneside. Whitford DL, et al. **Diabet Med** 1995 Aug;12(8):691–5

Patient empowerment. Results of a randomized controlled trial. Anderson RM, et al. **Diabetes Care** 1995 Jul; 18(7):943–9

Diabetes self-management education. Clement S. **Diabetes Care** 1995 Aug;18(8):1204–14 (114 ref.)

A multicenter evaluation of blood glucose awareness training–II. Cox D, et al. **Diabetes Care** 1995 Apr; 18(4):523–8

Trends in cigarette smoking and physicians' advice to quit smoking among people with diabetes in the U.S. Malarcher AM, et al. **Diabetes Care** 1995 May;18(5):694–7

Evaluation of a structured outpatient group education program for intensive insulin therapy. Pieber TR, et al. **Diabetes Care** 1995 May;18(5):625–30

Effects of an individual intensive educational control program for insulin-dependent diabetic subjects with poor metabolic control. Conget I, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):189–92

Glycemic control, growth and complications in children with insulin-dependent diabetes mellitus—a study of children enrolled in a Summer camp program for diabetics in Kinki district, Japan. Izumi K, et al. **Diabetes Res Clin Pract** 1995 Jun;28(3):185–90

Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. 15 year follow-up study. Hämäläinen H, et al. **Eur Heart J** 1995 Dec;16(12):1839–44

Evaluation of the informed consent procedure in cancer patients candidate to immunotherapy. Négrier S, et al. **Eur J Cancer** 1995 Sep;31A(10):1650–2

Improved metabolic control in patients with non-insulin-dependent diabetes mellitus is associated with a slower accumulation of glycation products in collagen. Salmela PI, et al. **Eur J Clin Invest** 1995 Jul;25(7):494–500

Nutrition guidance by primary-care physicians: perceived barriers and low involvement. Hiddink GJ, et al. **Eur J Clin Nutr** 1995 Nov;49(11):842–51

The understanding and use of counselling by speech and language therapists at different levels of experience. Parkinson K, et al. **Eur J Disord Commun** 1996;31(2):140–52

Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study. Verver S, et al. **Fam Pract** 1996 Feb;13(1):35–40

Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135–48 (80 ref.)

A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. Lerman C, et al. **Health Psychol** 1996 Mar; 15(2):75–83

Older people's responses to education about advance directives. Bailly DJ, et al. **Health Soc Work** 1995 Aug; 20(3):223–8

The most cost-effective health care. Fromer LM. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):46–7

Helping patients live with asthma. Rachelefsky GS. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):51–6, 59–64 (14 ref.)

A randomised controlled trial of stress reduction for hypertension in older African Americans. Schneider RH, et al. **Hypertension** 1995 Nov;26(5):820–7

Counselling in HIV/AIDS—an Indian perspective. Banerjee K, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):121–4

Informing, educating and communicating with people iodine deficiency disorders elimination drive in Madhya Pradesh. Chaurasia A. **Indian J Public Health** 1995 Oct–Dec; 39(4):160–3

Initiation of breastfeeding in cesarean section mothers: antenatal advise versus postnatal assistance. Banapurmath CR, et al. **Indian Pediatr** 1995 Aug;32(8):902–5

Use of milk based commercial weaning foods amongst scheduled caste communities in Haryana. Kapil U, et al. **Indian Pediatr** 1995 Aug;32(8):905–8

Free telephone service offers HIV information [news] **Indiana Med** 1996 Jan–Feb;89(1):92

Development, refinement and future usage of the scale: "attitudes toward learning in pregnancy". Jackson MS, et al. **Int J Nurs Stud** 1996 Feb;33(1):37–46

The effects of a discharge information intervention on recovery outcomes following coronary artery bypass surgery. Moore SM. **Int J Nurs Stud** 1996 Apr;33(2):181–9

The role of the continence adviser in England and Wales. Rhodes P, et al. **Int J Nurs Stud** 1995 Oct;32(5):423–33

Information on marketed drugs for doctors and patients. Experience in six European countries. Brown P, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):410–6

Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485–508 (138 ref.)

Written patient information on prescription drugs. The evolution of government and voluntary programs in the United States. Nightingale SL. **Int J Technol Assess Health Care** 1995 Summer; 11(3):399–409

SOFT Issues in asthma management. McGovern SJ, et al. **Ir Med J** 1995 Nov–Dec;88(6):217–8

Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. Chaisson RE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):455–9

Information needs and sources of information for women with breast cancer: a follow-up study. Luker KA, et al. **J Adv Nurs** 1996 Mar;23(3):487–95

The information needs of women newly diagnosed with breast cancer. Luker KA, et al. **J Adv Nurs** 1995 Jul; 22(1):134–41

Maternal behaviour during spontaneous and directed pushing in the second stage of labour. Thomson AM. **J Adv Nurs** 1995 Dec;22(6):1027–34

Compliance with influenza immunization: a survey of high-risk patients at a family medicine clinic. Hutchinson HL, et al. **J Am Board Fam Pract** 1995 Nov–Dec; 8(6):448–51

Counseling postmenopausal women about preventive hormone therapy. AGS Clinical Practice Committee. **J Am Geriatr Soc** 1996 Sep;44(9):1120–2

Pharmacist counseling of older people [letter] Kimminau KS, et al. **J Am Geriatr Soc** 1996 Mar;44(3):335–6

Advance directives and older adults: a critical care perspective [letter] Nuckton TJ. **J Am Geriatr Soc** 1996 Jun;44(6):733–4

An atmosphere of mistrust. Ponte CD. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):322

The pharmacist as self-care advisor. Pray WS. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):329–40; quiz 340–2

An asthma self-management program for children, including instruction in peak flow monitoring by school nurses. Persaud DI, et al. **J Asthma** 1996;33(1):37–43

Screening by the prostate-specific antigen test: what do the patients know? Diefenbach PN, et al. **J Cancer Educ** 1996 Spring;11(1):32–8

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)

Cardiac rehabilitation based on group light exercise and discussion. An Australian hospital model. Hare DL, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):186–92 (27 ref.)

The effect of a submaximal exercise orientation on cardiopulmonary cycle ergometer stress test results in older adults. Shaw CE, et al. **J Cardpulm Rehabil** 1996 Mar–Apr; 16(2):93–9

Psychoeducational groups for young adults with genital herpes: training group facilitators. Madrid E, et al. **J Community Health Nurs** 1995;12(4):189–98

Implementation of a tobacco cessation program in the student clinics. Barker GJ, et al. **J Dent Educ** 1995 Aug;59(8):850–5

Effects of intensification of antihypertensive care in diabetic nephropathy. Sawicki PT, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):315–7

A comparison of three measures of perceived distress: results from a study of angina patients in general practice in Northern Ireland. O'Neill C, et al. **J Epidemiol Community Health** 1996 Apr;50(2):202–6

The impact of a summer asthma camp experience on asthma education and morbidity in children. Sorrells VD, et al. **J Fam Pract** 1995 Nov;41(5):465–8

The test of functional health literacy in adults: a new instrument for measuring patients' literacy skills. Parker RM, et al. **J Gen Intern Med** 1995 Oct;10(10):537–41

Do patients want to be informed? Do they want to decide? [editorial; comment] Stoeckle JD. **J Gen Intern Med** 1995 Nov;10(11):643–4. Comment on: J Gen Intern Med 1995 Nov;10(11):593–600.

The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group. Johannesson M, et al. **J Intern Med** 1996 Jul;240(1):23–9

Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study. Lindholm LH, et al. **J Intern Med** 1996 Jul;240(1):13–22

Physicians, smoking and hospitals. Committee on Chronic Diseases. **J La State Med Soc** 1995 Dec;147(12):531–2

Client centred hypnotherapy in the management of tinnitus—is it better than counselling? Mason JD, et al. **J Laryngol Otol** 1996 Feb;110(2):117–20

Information leaflets [editorial] Smith AJ. **J Med Screen** 1995; 2(1):3–4

AMA survey—American's know little or nothing about health care advance directives. **J Miss State Med Assoc** 1995 Dec;36(11):387–8

America's failure to use advance directives—helping your patients shape their health care future. **J Miss State Med Assoc** 1995 Dec;36(11):389–93

Healthy People 2000 Goal 1.12: primary care physicians and exercise counseling. Royals G, et al. **J Miss State Med Assoc** 1996 Jun;37(6):605–8

Testing and counseling adults for heritable cancer risk. Biesecker BB, et al. **J Natl Cancer Inst Monogr** 1995; (17):115–8

Health maintenance behaviors in advanced Parkinson's disease. Vernon GM, et al. **J Neurosci Nurs** 1995 Aug; 27(4):229–35

Preparing couples for home birth. Practical suggestions. Dancy RB, et al. **J Nurse Midwifery** 1995 Nov–Dec; 40(6):522–8

Colposcopy: sensory information for client education. Nugent LS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr;25(3):225–31

Meeting patients' needs for educational materials. Hirtz SA. **J Pediatr Nurs** 1995 Aug;10(4):271–2

Audit of the support for breastfeeding mothers in Fife maternity hospitals using adapted 'Baby Friendly Hospital' materials. Campbell H, et al. **J Public Health Med** 1995 Dec;17(4):450–4

Informing the patient [see comments] Griffin JP, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):107–11. Comment in: J R Coll Physicians Lond 1996 Mar–Apr;30(2):102–3.

Should drug information be an integral part of health care? [see comments] Hemminki E, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):104–6. Comment in: J R Coll Physicians Lond 1996 Mar–Apr;30(2):102–3.

Alcohol liaison in action. The Canterbury experience. Rake MO, et al. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):275–9

Patient factors influencing variation in the use of preventive interventions for alcohol abuse by primary care physicians. Volk RJ, et al. **J Stud Alcohol** 1996 Mar;57(2):203–9

Group intervention with pre-recovery patients. Martin K, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):33–41

Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. Rutherford EJ, et al. **J Trauma** 1995 Sep;39(3):448–52

Improving care of patients with hypertension [letter] Black HR. **JAMA** 1996 Oct 2;276(13):1036–7

What is adequate and appropriate pain treatment? [letter; comment] Jacobson L, et al. **JAMA** 1996 May 1; 275(17):1310–1. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

A piece of my mind. Managed care and mandatory movies. Kapp MB. **JAMA** 1996 Oct 2;276(13):1023

From the Food and Drug Administration. Nightingale SL. **JAMA** 1995 Oct 11;274(14):1109

The Pine Ridge–Mayo National Aeronautics and Space Administration telemedicine project: program activities and participant reactions [see comments] Kottke TE, et al. **Mayo Clin Proc** 1996 Apr;71(4):329–37. Comment in: Mayo Clin Proc 1996 Apr;71(4):420–1.

Developing time-based protocols. Barnes LP. **MCN Am J Matern Child Nurs** 1996 Jul–Aug;21(4):177

Developing hospital-wide standards for i.v. conscious sedation. Barnes LP. **MCN Am J Matern Child Nurs** 1995 Sep–Oct;20(5):283

Patient handouts from the internet [news] Zelingher J. **MD Comput** 1995 Sep–Oct;12(5):338–44, 347, 349–50 passim

Training medical students in HIV/AIDS test counselling: results of a randomized trial. Campbell E, et al. **Med Educ** 1996 Mar;30(2):134–41

Diabetes and hypertension [letter; comment] Gale AE. **Med J Aust** 1996 Feb 19;164(4):254. Comment on: Med J Aust 1995 Oct 2;163(7):372–5.

The National Breast Cancer Centre. Redman S, et al. **Med J Aust** 1995 Oct 16;163(8):432–3

Impact of pharmacist counseling on medication knowledge and compliance. Williford SL, et al. **Mil Med** 1995 Nov; 160(11):561–4

Talking to your patients about gun violence and gun safety. Hamilton S. **Minn Med** 1995 Sep;78(9):20–2

An update of GEPOR project activity. Donner CF, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):228–9

Patients' interest in educational programmes on asthma. Moscato G, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):319–22

The effects of a cognitive behavioural intervention in asthmatic patients. Sommaruga M, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):398–402

If the shoe fits, wear it. Foot facts. American Academy of Orthopaedic Surgeons & the National Shoe Retailers Association. **N C Med J** 1995 Dec;56(12):619–22

Education may help reduce Yersinia sepsis from blood transfusion [letter] Morris A, et al. **N Z Med J** 1996 Jan 26;109(1014):19

Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24–8 (27 ref.)

The HIV antibody test. **Nurse Pract** 1996 Mar;21(3):121–2

Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Wadden TA, et al. **Obes Res** 1995 Nov;3(6):549–57

Article on patient-education materials neglects literature with a general theme [letter] Agre P, et al. **Oncol Nurs Forum** 1996 Apr;23(3):422

Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy [published erratum appears in Oncol Nurs Forum 1995 Nov–Dec;22(10):1476] Cartwright-Alcarese F. **Oncol Nurs Forum** 1995 Sep; 22(8):1227–32 (27 ref.)

Commentary: the clinician and the ethicist. Glover JJ, et al. **Oncol Nurs Forum** 1996 Apr;23(3):433–4

Shorter hospital stays necessitate changes in breast cancer

patient education [letter; comment] Gross RE. **Oncol Nurs Forum** 1995 Jul;22(6):887. Comment on: Oncol Nurs Forum 1995 Jan-Feb;22(1):131-7.

Needle wire localization for nonpalpable breast lesions: sensations, anxiety levels, and informational needs. Kelly P, et al. **Oncol Nurs Forum** 1996 May;23(4):639-45

Educating women about early detection of gynecologic cancers using a brochure. Mahon SM. **Oncol Nurs Forum** 1996 Apr;23(3):529-31

Information for women: management of menopausal symptoms. Mayer DK, et al. **Oncol Nurs Forum** 1995 Nov-Dec;22(10):1567-70

Nurse questions readability of patient-education brochures [letter] Rowley JA. **Oncol Nurs Forum** 1996 Apr;23(3):421

Do you like the things that life is showing you? The sensitive self-image of the person with cancer. Shell JA. **Oncol Nurs Forum** 1995 Jul;22(6):907-11

Suggestions help nurses develop patient education materials. Young-McCaughan S. **Oncol Nurs Forum** 1996 Apr; 23(3):541

Strategies to support families of children with end-stage renal failure. Watson AR. **Pediatr Nephrol** 1995 Oct;9(5):628-31 (22 ref.)

Weight loss and psychopathology: a three-cluster MMPI typology. Valtolina G. **Percept Mot Skills** 1996 Feb; 82(1):275-81

Help for diabetic patients [letter] Warshaw HS. **Postgrad Med** 1996 Sep;100(3):50

Communicating with young adults with cystic fibrosis. Webb AK. **Postgrad Med J** 1995 Jul;71(837):385-9

Does counselling for angina and hypertension work? Browne D. **Practitioner** 1995 Nov;239(1556):679-81 (13 ref.)

Informational needs of patients hospitalized for bipolar disorder. Pollack LE. **Psychiatr Serv** 1995 Nov; 46(11):1191-4

Psychoeducation in first-episode psychosis: a therapeutic process. McGorry PD. **Psychiatry** 1995 Nov;58(4):313-28 (41 ref.)

Can patients accurately predict how illness will change their lives? Alford JW. **R I Med** 1995 Oct;78(10):284-5

Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385-6 (15 ref.)

Patient satisfaction with information provided at an outpatient clinic for respiratory diseases. Papagiannis A, et al. **Respir Med** 1995 Nov;89(10):673-6

A long-term follow-up of 108 vasectomized men. Good counselling routines are important. Ehn BE, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):477-81

Patients education: self-care guides. Rhodes VA, et al. **Semin Oncol Nurs** 1995 Nov;11(4):298-304

Health promotion in primary care: physician-patient communication and decision making about prescription medications. Makoul G, et al. **Soc Sci Med** 1995 Nov; 41(9):1241-54

Pitfalls of patient education. Limited success of a program for back pain in primary care. Cherkin DC, et al. **Spine** 1996 Feb 1;21(3):345-55

Educational group support for patients with gynaecological cancer and their families [see comments] Carlsson ME, et al. **Support Care Cancer** 1996 Mar;4(2):102-9. Comment in: Support Care Cancer 1996 Mar;4(2):73-4.

A short-term psychoeducational intervention for patients newly diagnosed with cancer. Fawzy FI. **Support Care Cancer** 1995 Jul;3(4):235-8

Randomised trial of an asthma self-management programme for adults. Allen RM, et al. **Thorax** 1995 Jul;50(7):731-8

Compliance with treatment in adult patients with cystic fibrosis. Conway SP, et al. **Thorax** 1996 Jan;51(1):29-33

The effect of preoperative structured teaching on renal transplantation outcome. Taghavi R. **Transplant Proc** 1995 Oct;27(5):2597-8

An out-patient audit of the insulin administration technique of patients with diabetes mellitus in Blantyre, Malawi. Maher D, et al. **Trop Doct** 1996 Jan;26(1):36-7

Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control [editorial] Iseman MD. **Tuber Lung Dis** 1996 Apr;77(2):101

Patient education materials nurses use in community health. Wilson FL. **West J Nurs Res** 1996 Apr;18(2):195-205

WAPC position statement. Human immunodeficiency virus (HIV) education and testing in the perinatal period. Wisconsin Association for Perinatal Care. **Wis Med J** 1996 Jan;95(1):30-5

Informing breast surgery patients about treatment options. Gold JA. **Wis Med J** 1995;94(7):403-4

Listening and learning from women about mifepristone: implications for counseling and health education. Castle MA, et al. **Womens Health Issues** 1995 Fall;5(3):130-8

[Short-term hospitalization for patient education--effect on metabolic compensation in type I diabetics] Kvapil M. **Vnitr Lek** 1996 Jan;42(1):12-6 (Eng. Abstr.) **(Cze)**

[Acquired experience with diabetes mellitus] Ernould C, et al. **Arch Pediatr** 1996;3 Suppl 1:315s-317s (5 ref.) **(Fre)**

[Breast neoplasms: information in question(s). A survey of patients and physicians at a cancer treatment center] Vennin P, et al. **Bull Cancer (Paris)** 1995 Sep;82(9):698-704 (Eng. Abstr.) **(Fre)**

[Should patients be informed of potential but not confirmed risks of cancer linked to menopausal hormone replacement treatment?] Elia D, et al. **Contracept Fertil Sex** 1996 Mar; 24(3):184-7 **(Fre)**

-Optimizing patient information- Gröbly U. **Arch Gynecol Obstet** 1995;256 Suppl:S128-34 **(Ger)**

[Degree of patient education retardation preoperative autologous blood donation at a university clinic (see comments)] Nussbaumer W, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):67-70 (Eng. Abstr.). Comment in: Infusionsther Transfusionsmed 1996 Apr;23(2):66. **(Ger)**

[Recommendations for structured patient training in obstructive respiratory tract diseases. Patient Education Study group of the German Society of Pneumology and the German Respiratory Tract League of the German Society of Pneumology] **Med Klin** 1995 Sep 15;90(9):515-9 **(Ger)**

[Uncertainty of prognosis in patient education--communication on the way to diagnosis] Avenarius HJ. **Med Klin** 1996 Apr 12;91 Suppl 3:93-6 **(Ger)**

[Recommendations for patient education in poor prognosis. Australian Consensus Document] Bornkessel B. **Med Monatsschr Pharm** 1996 May;19(5):143-5 (0 ref.) **(Ger)**

[Psychoeducational-psychotherapeutic treatment of schizophrenic patients and their caregivers. Results of a 1-year catamnestic study] Hornung WP, et al. **Nervenarzt** 1995 Nov;66(11):828-34 (Eng. Abstr.) **(Ger)**

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452-6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Free from tobacco. Counseling of smokers in medical practice--experiences from the Swiss campaign] Burkhalter AK. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):531-6 (Eng. Abstr.) **(Ger)**

[Health promotion and nutrition counseling for obese patients--a responsibility of medical care] Dittrich A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):382-5 (Eng. Abstr.) **(Ger)**

[Pedagogic aspects of diet counseling] Hirsch A. **Z Gastroenterol** 1996 Jun;34 Suppl 2:77-9 **(Ger)**

[Didactic concepts of diabetes counseling and education] Risse A. **Z Gastroenterol** 1996 Jun;34 Suppl 2:66-8 **(Ger)**

[Breech presentation--information, anxiety and pattern of expectations of established obstetricians and pregnant patients. 2: Results of a survey of women with breech presentation] Fischer T, et al. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):61-5 (Eng. Abstr.) **(Ger)**

[Pre- and postpartum management of hypoplastic left heart syndrome (letter)] Kattner. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):75 **(Ger)**

[Patient education--a contribution to improvement of long-term management of patients with rheumatism] Langer HE. **Z Rheumatol** 1995 Jul-Aug;54(4):207-12 (Eng. Abstr.) **(Ger)**

[What to do? Modern methods of patient information in the practice of oral surgery] Fábián B, et al. **Fogorv Sz** 1995 May;88(5):173-7 (Eng. Abstr.) **(Hun)**

[Postoperative care of continent urinary reservoirs] Mori Y. **Hinyokika Kiyo** 1995 Nov;41(11):937-40 (Eng. Abstr.) **(Jpn)**

[Psychoeducation--special reference to social skill training] Sarata Y. **Seishin Shinkeigaku Zasshi** 1995;97(7):522-8 (9 ref.) **(Jpn)**

[Patient information and conditioning for allogeneic stem cell transplantation] Brinch L. **Nord Med** 1995;110(12):318-9, 322 (16 ref.) (Eng. Abstr.) **(Nor)**

[Ambulatory surgery. Patients and patient education] Bredland T, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):610-4 (Eng. Abstr.) **(Nor)**

[The Norwegian calendar for emergency services. An important initiative in cases of childhood emergencies (letter)] Juvkam PC. **Tidsskr Nor Laegeforen** 1996 Mar 20; 116(8):1013 **(Nor)**

[Dietary information after radiotherapy of head and neck cancer] Løvik A, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2303-6 (Eng. Abstr.) **(Nor)**

[Health education as a method of treating psycho-emotional disorders in patients with diabetes mellitus] Tatoń J, et al. **Pol Tyg Lek** 1996 Jan;51(1-5):46-9 (38 ref.) **(Pol)**

[Scientific basis for self care of chronically ill patients: medical education as a new form of care--in light of personal observations] Totoń J. **Pol Tyg Lek** 1996 Jan; 51(1-5):50-4 **(Pol)**

[The factors determining the late outcome in bronchial asthma: the role of the quality of medical care and of patient education] Ovcharenko SI, et al. **Ter Arkh** 1996;68(3):41-4 (Eng. Abstr.) **(Rus)**

[Recommendations for education of patients with asthma] López Viña A, et al. **Arch Bronconeumol** 1996 Apr;32 Suppl 1:10-4 **(Spa)**

[Hospital-based evaluation of knowledge about their illness in a diabetic population] Campo Ordás JM, et al. **Aten Primaria** 1995 Dec;16(10):623-7 (Eng. Abstr.) **(Spa)**

[Crucial role of education of transplant patients] Zayas E. **Bol Asoc Med P R** 1995 May-Jun;87(5-6):111-3 **(Spa)**

[Rehabilitation pedagogy (letter; comment)] Brodin H. **Lakartidningen** 1995 Dec 13;92(50):4780. Comment on: Lakartidningen 1995 Oct 25;92(43):3987-8, 3991. **(Swe)**

[Children with not confirmed diagnosis of brain diseases. "Anonymous"--a network for support and information] Hagberg B, et al. **Lakartidningen** 1996 May 29; 93(22):2157-8 **(Swe)**

[Pain rehabilitation is a pedagogic task. Chronic pain dealt with in a model for behavior-therapy (see comments)] Nordemar R, et al. **Lakartidningen** 1995 Oct 25; 92(43):3987-8, 3991. Comment in: Lakartidningen 1995 Dec 13;92(50):4780. **(Swe)**

[Tape recorded consultations are a good support (letter)] Nyquist K, et al. **Lakartidningen** 1996 Jun 26;93(26-27):2493 **(Swe)**

LEGISLATION & JURISPRUDENCE

The patient information and education initiative. Rheinstein PH, et al. **Am Fam Physician** 1995 Dec;52(8):2377-8, 2381-2

Informed consent revisited. Goldworth A. **Camb Q Healthc Ethics** 1996 Spring;5(2):214-20

Seven ways to avoid frivolous malpractice claims. Muller J. **Indiana Med** 1996 Jan-Feb;89(1):22-4

Incidental findings: patients' knowledge, rights, and preferences [see comments] Parker LS, et al. **J Clin Ethics** 1995 Summer;6(2):176-9. Comment in: J Clin Ethics 1995 Summer;6(2):180-2. Comment in: J Clin Ethics 1995 Summer;6(2):182-4.

Informed consent: process and clinical issues. Berry DL, et al. **Oncol Nurs Forum** 1996 Apr;23(3):507-12 (19 ref.)

[Relative exigencies in informed consent by the patient] Guillod O. **Swiss Surg** 1995;(3):130-5 (Eng. Abstr.) **(Fre)**

[Counseling as procedural model for illegal, but not punishable abortion] Schreiber HL. **Arch Gynecol Obstet** 1995;257(1-4):381-8 **(Ger)**

[Responsibility for patient education and explanation of consent for treatment] Ulsenheimer K. **Chirurg** 1996 Mar; 67(3):suppl 74-9 **(Ger)**

[The duty to explain the risks of intolerance in drug administration. The judgement of the Cologne Higher Regional Court of 22 May 1995] Rieger HJ. **Dtsch Med Wochenschr** 1996 Aug 2;121(31-32):997-8 **(Ger)**

[Administering injections--legal questions. Areas of responsibilities for the physician--patient education responsibility--case report: injections by the physicians assistant] Binder G. **Fortschr Med** 1996 Jun 20; 114(17):221-2 **(Ger)**

[Responsibility for patient education and incidence of homologous blood transfusions in unilateral breast cancer operations] Gerber B, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):572-6 (Eng. Abstr.) **(Ger)**

[Patient education about autologous blood donation (editorial; comment)] Weissauer W. **Infusionsther Transfusionsmed** 1996 Apr;23(2):66. Comment on: Infusionsther Transfusionsmed 1996 Apr;23(2):67-70. **(Ger)**

[Treatment after and patient education before tonsillectomy] Wienke A. **Laryngorhinootologie** 1996 Mar;75(3):184-5 **(Ger)**

[Legal responsibility of the physician for treatment, organization and patient education errors] Ulsenheimer K. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):562-70 (Eng. Abstr.) **(Ger)**

[Physicians sued for missed information. Demand a "receipt" to be on the safe side!] Bastling K. **Lakartidningen** 1996 Jan 17;93(3):124-5 **(Swe)**

METHODS

Communicating information to patients: the use of cartoon illustrations to improve comprehension of instructions [see comments] Delp C, et al. **Acad Emerg Med** 1996 Mar; 3(3):264-70. Comment in: Acad Emerg Med 1996 Mar;3(3):200-1.

Visual aids for communicating information to patients: an excellent second step [editorial; comment] Klamen D, et al. **Acad Emerg Med** 1996 Mar;3(3):200-1. Comment on: Acad Emerg Med 1996 Mar;3(3):264-70.

Improving patient education for patients with low literacy skills. Mayeaux EJ Jr, et al. **Am Fam Physician** 1996 Jan; 53(1):205-11 (34 ref.)

Educational and long-term therapeutic intervention in the ED: effect on outcomes in adult indigent minority asthmatics. Kelso TM, et al. **Am J Emerg Med** 1995 Nov; 13(6):632-7

Failure of educational videotapes to improve medication compliance in a health maintenance organization. Powell KM, et al. **Am J Health Syst Pharm** 1995 Oct 15; 52(20):2196-9

Simplification of emergency department discharge instructions improves patient comprehension. Jolly BT, et al. **Ann Emerg Med** 1995 Oct;26(4):443-6

Written discharge advice sheets reduce visits to the general practitioner. Raine C, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1 Suppl):19-20

Primary care physicians' use of office resources in the provision of preventive care. Dickey LL, et al. **Arch Fam Med** 1996 Jul-Aug;5(7):399-404

Evaluation of the 'Best Start' breast-feeding education program. Hartley BM, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):868-71

Recall, retention, utilisation and acceptability of written health education materials. Newell S, et al. **Aust J Public Health** 1995 Aug;19(4):368-74

Reducing anxiety in new dental patients by means of leaflets [see comments] Jackson C, et al. **Br Dent J** 1995 Sep 9; 179(5):163–7. Comment in: Br Dent J 1995 Nov 25;179(10):372.

Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Bashir K, et al. **Br J Gen Pract** 1994 Sep;44(386):408–12

Patient education: treatment or nice extra. The British experience [letter] Curson D, et al. **Br J Rheumatol** 1996 Aug;35(8):805–7

The role of the rheumatology nurse practitioner in primary care: an experiment in the further education of the practice nurse. Grahame R, et al. **Br J Rheumatol** 1996 Jun; 35(6):581–8

Functions and preferred methods of receiving information related to radiotherapy. Perceptions of patients with cancer. Hinds C, et al. **Cancer Nurs** 1995 Oct;18(5):374–84

Teaching symptom management of HIV/AIDS using algorithms. Lietzau J. **Cancer Nurs** 1996 Aug;19(4):263–8

End-user satisfaction of a patient education tool manual versus computer-generated tool. Tronni C, et al. **Comput Nurs** 1996 Jul–Aug;14(4):235–8

Integrated control of Onchocerca volvulus infection in a hyperendemic zone in Sierra Leone. Gbakima AA. **East Afr Med J** 1996 Mar;73(3):159–63

Outreach. Aural support for cancer sufferers. Nordhaus-Bike AM. **Hosp Health Netw** 1996 May 20;70(10):42

A randomised comparison of two forms of a brief, group, psychoeducational program for cancer patients: weekly sessions versus a "weekend intensive". Cunningham AJ, et al. **Int J Psychiatry Med** 1995;25(2):173–89

Enhancement of proxy appointment for older persons: physician counselling in the ambulatory setting. Meier DE, et al. **J Am Geriatr Soc** 1996 Jan;44(1):37–43

Computer-based patient education: observations on effective communication in the clinical setting. Sechrest RC, et al. **J Biocommun** 1996;23(1):8–12

Preparatory information for myelogram. Cason CL, et al. **J Neurosci Nurs** 1995 Jun;27(3):182–7

Regaining self-esteem: strategies and interventions for the infertile woman. Johnson CL. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):291–5

Developing education materials for families. Ethier AA. **J Pediatr Oncol Nurs** 1996 Jul;13(3):146–9

Patient compliance for psychotropic medications: a group model for an expanding psychiatric inpatient unit. Crane K, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jan; 34(1):8–15

Using the telephone in patient and family teaching. Barnes LP. **MCN Am J Matern Child Nurs** 1995 Nov–Dec; 20(6):341

Effects of patient education on decisions about breast cancer treatments: a preliminary report. Chapman GB, et al. **Med Decis Making** 1995 Jul–Sep;15(3):231–9

Application of computers in diabetes care—a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):303–29 (147 ref.)

Well born: development of pregnancy. Barros SM, et al. **Medinfo** 1995;8 Pt 2:1190

An interactive patient information and education system (Medical HouseCall) based on a physician expert system (Iliad). Bouhaddou O, et al. **Medinfo** 1995;8 Pt 2:1181–5

Prevention of AIDS and living together with an HIV-infected patient. Fahik FT, et al. **Medinfo** 1995;8 Pt 2:1191

Developing patient education programs with multimedia technology incorporating patient feedback into program design. Mercer Z, et al. **Medinfo** 1995;8 Pt 2:1186–9

An interactive consultation multimedia software for orthodontic patients. Miyawaki S, et al. **Medinfo** 1995;8 Pt 2:1308

"Informed consent" interactive videodisc for patients having a colonoscopy, a polypectomy, and an endoscopy. Pernotto DA, et al. **Medinfo** 1995;8 Pt 2:1699

Computer assisted instruction on multimedia environment for patients. Tomita M, et al. **Medinfo** 1995;8 Pt 2:1192

A multimedia guide to spinal cord injury: empowerment through self instruction. Van Biervliet A, et al. **Medinfo** 1995;8 Pt 2:1701

Relaxation and the relief of cancer pain. Sloman R. **Nurs Clin North Am** 1995 Dec;30(4):697–709

Information needs, sources of information, and decisional roles in women with breast cancer. Bilodeau BA, et al. **Oncol Nurs Forum** 1996 May;23(4):691–6

Patient literacy and the readability of written cancer educational materials. Cooley ME, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1345–51

Information and decision-making preferences of men with prostate cancer. Davison BJ, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1401–8

The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Devine EC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1369–81

The effects of informational audiotapes on knowledge and self-care behaviors of patients undergoing radiation therapy. Hagopian GA. **Oncol Nurs Forum** 1996 May; 23(4):697–700

The healing power of story. Heiney SP. **Oncol Nurs Forum** 1995 Jul;22(6):899–904

Hypnosis: teaching children self-regulation. Sugarman LI. **Pediatr Rev** 1996 Jan;17(1):5–11 (35 ref.)

Expert system for management of urinary incontinence in women. Gorman R. **Proc Annu Symp Comput Appl Med Care** 1995;:527–31

A comparison of patient teaching outcomes among postoperative coronary artery bypass graft (CABG) patients. Barnason S, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):11–20

Counseling patients about therapy for localized prostate cancer. Middleton RG. **Semin Urol Oncol** 1995 Aug; 13(3):187–90 (8 ref.)

The write stuff. Simple guidelines can help you write and design effective patient education materials. Kripalani S. **Tex Med** 1995 Aug;91(8):40–5

[Increase of degree of vaccination against influenza in at-risk patients by directed primary care invitation] Davidse W, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2149–52 (Eng. Abstr.) **(Dut)**

[More psychological preparation in heart surgery for certain patients is beneficial] de Wit P, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1720–3 (Eng. Abstr.) **(Dut)**

[Effect of the formulation of information on side effects on patients' interpretation and on reported side effects (letter)] Kerkhof PL, et al. **Ned Tijdschr Geneeskd** 1996 May 4; 140(18):1000 **(Dut)**

[Effect of 2 types of diet changes on dietary habits, body weight and cholesterol levels in high risk cardiovascular patients] Massari A, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1101–4 (Eng. Abstr.) **(Fre)**

[Patient Education Study Group of the German Society of Pneumology and the German Respiratory League of the German Society of Pneumology. Recommendations for structuring patient training in obstructive respiratory tract diseases] **Pneumologie** 1995 Aug;49(8):455–60 **(Ger)**

[Pedagogic responsibilities in rehabilitation of brain damaged patients] Stadler H. **Rehabilitation (Stuttg)** 1996 May; 35(2):109–18 (25 ref.) (Eng. Abstr.) **(Ger)**

[Patient counseling by the physician in smoking cessation—conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Home medication injection among Latina women in Los Angeles: implications for health education and prevention. Flaskerud JH, et al. **AIDS Care** 1996 Feb;8(1):95–102

A cross-national trial of brief interventions with heavy drinkers. WHO Brief Intervention Study Group. **Am J Public Health** 1996 Jul;86(7):948–55

Promoting inpatient directives about life-sustaining treatments in a community hospital. Results of a 3-year time-series intervention trial. Reilly BM, et al. **Arch Intern Med** 1995 Nov 27;155(21):2317–23

Back school in a first episode of compensated acute low back pain: a clinical trial to assess efficacy and prevent relapse. Leclaire R, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):673–9

Preventing skin cancer [letter] Jones R. **Br J Gen Pract** 1995 Aug;45(397):443

Ontario's health-information service: a province-wide resource for patients [published erratum appears in Can Med Assoc J 1995 Dec 1;153(11):1569] Koba H. **Can Med Assoc J** 1995 Oct 1;153(7):990–1

An empowerment-centered, church-based asthma education program for African American adults. Ford ME, et al. **Health Soc Work** 1996 Feb;21(1):70–5

Evaluation of a self-medication program. Pereles L, et al. **J Am Geriatr Soc** 1996 Feb;44(2):161–5

Inpatient cardiac rehabilitation. Patient education implementation and documentation. Cupples SA. **J Cardpulm Rehabil** 1995 Nov–Dec;15(6):412–7

Efficacy of comprehensive rehabilitation programs and back school for patients with low back pain: a meta-analysis. Di Fabio RP. **Phys Ther** 1995 Oct;75(10):865–78

[Tuberculosis and patient compliance: proposition for a study methodology of patient dropouts] Comolet T, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):68–71 (Eng. Abstr.) **(Fre)**

STANDARDS

Emergency department discharge instructions and patient literacy: a problem of disparity. Williams DM, et al. **Am J Emerg Med** 1996 Jan;14(1):19–22

Ensuring the readability of patient education materials is one way to demonstrate perioperative nurses' value [editorial] Giordano BP. **AORN J** 1996 Apr;63(4):699–700

Designing user instructions. Callan JR. **Biomed Instrum Technol** 1996 Mar–Apr;30(2):115–9

Ethical issues in urology: the patient's perspective. Wilkie P. **Br J Urol** 1995 Nov;76 Suppl 2:5–7 (6 ref.)

National Standards for Diabetes Self-Management Education Programs and American Diabetes Association review criteria. **Diabetes Care** 1995 May;18(5):737–41

A survey of lung cancer patient-education materials. Sarna L, et al. **Oncol Nurs Forum** 1995 Nov–Dec;22(10):1545–50

Preliminary results from a psychoeducational program to rehabilitate chronic patients. Halford WK, et al. **Psychiatr Serv** 1995 Nov;46(11):1189–91

Meta-analysis of the effects of psychoeducational care in adults with asthma. Devine EC. **Res Nurs Health** 1996 Oct; 19(5):367–76

Patient understanding of emergency department discharge instructions. Logan PD, et al. **South Med J** 1996 Aug; 89(8):770–4

STATISTICS & NUMERICAL DATA

Patient desire for information and decision making in health care decisions: the Autonomy Preference Index and the Health Opinion Survey [see comments] Nease RF Jr, et al. **J Gen Intern Med** 1995 Nov;10(11):593–600. Comment in: J Gen Intern Med 1995 Nov;10(11):643–4.

TRENDS

Patients' desire for information about anaesthesia: change in Scottish attitudes over five years. Kennedy S, et al. **Health Bull (Edinb)** 1996 Mar;54(2):118–21

PATIENT-FAMILY LODGING see **HOUSING**

PATIENT-FOCUSED CARE see **PATIENT-CENTERED CARE**

PATIENT IDENTIFICATION SYSTEMS

Development of computer-assisted patient control for use in the hospital setting during mass casualty incidents. Noordergraaf GJ, et al. **Am J Emerg Med** 1996 May; 14(3):257–61

Management of anaphylactic reactions to food [letter; comment] Vickers D. **Arch Dis Child** 1995 Aug;73(2):184–5 . Comment on: Arch Dis Child 1995 Mar;72(3):274.

Successive Ontario governments forced to grapple with problem of health care fraud. Shu A. **Can Med Assoc J** 1996 May 1;154(9):1412–4

MedicAlert Foundation turns 35, issues warning to MDs about lookalike bracelets. Wharry S. **Can Med Assoc J** 1996 Mar 15;154(6):919–20

Logical observation identifier names and codes (LOINC) database: a public use set of codes and names for electronic reporting of clinical laboratory test results. Forrey AW, et al. **Clin Chem** 1996 Jan;42(1):81–90

Payment—putting the tab on plastic [news] **Hosp Health Netw** 1995 Oct 5;69(19):28

Australian healthcare: a smart card for a clever country. Morris S, et al. **Int J Biomed Comput** 1995 Oct;40(2):101–5 (14 ref.)

Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. Sørensen HT, et al. **J Med Syst** 1996 Feb;20(1):57–65

Record linkage strategies, outpatient procedures, and administrative data. Roos LL, et al. **Med Care** 1996 Jun; 34(6):570–82

Can a patient smart card improve decision making in a clinical setting?. Bérubé J, et al. **Medinfo** 1995;8 Pt 1:337–9

Integrating a health IC card system into a hospital information system. Chen TS, et al. **Medinfo** 1995;8 Pt 1:358

A microprocessor card software server to support the Quebec health microprocessor card project. Durant P, et al. **Medinfo** 1995;8 Pt 1:340–3

The smart card: an ideal tool for a computer-based patient record. Engelbrecht R, et al. **Medinfo** 1995;8 Pt 1:344–8

Smart practice: smart card design considerations in health care. Lindley RA, et al. **Medinfo** 1995;8 Pt 1:349–53

The registration function as a critical dependency in a lifetime clinical record (LCR). Mercer L, et al. **Medinfo** 1995;8 Pt 1:461

CQL: a database in smart card for health care applications. Paradinas PC, et al. **Medinfo** 1995;8 Pt 1:354–7

Introducing smartcards in healthcare in the Netherlands. van den Broek L. **Medinfo** 1995;8 Pt 1:359

An automated system for bedside verification of the match between patient identification and blood unit identification [see comments] Jensen NJ, et al. **Transfusion** 1996 Mar; 36(3):216–21. Comment in: Transfusion 1996 Mar;36(3):200–2.

ECONOMICS

A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion [see comments] AuBuchon JP, et al. **Transfusion** 1996 Mar; 36(3):222–6. Comment in: Transfusion 1996 Mar;36(3):200–2.

METHODS

Health care delivery reorganization innovative outcome: universal computerized patient identification. Murray CL, et al. **Medinfo** 1995;8 Pt 2:1637

STANDARDS

Closing the loop: standardization is the key [editorial; comment] Steane EA, et al. **Transfusion** 1996 Mar; 36(3):200–2. Comment on: Transfusion 1996 Mar;36(3):216–21. Comment on: Transfusion 1996 Mar;36(3):222–6.

PATIENT ISOLATION

The use of continuous quality improvement to achieve proper isolation of patients with suspected tuberculosis. Cook JD, et al. **Am J Infect Control** 1995 Oct;23(5):323–8

Isolated despite negative sputum TB tests. Petrec CA. **Am J Nurs** 1996 Jun;96(6):20

The design of isolation rooms [editorial; comment] Marier RL. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):3–4. Comment on: Infect Control Hosp Epidemiol 1996 Jan;17(1):5–10.

Studies of ventilation efficiency in a protective isolation room by the use of a scale model [see comments] Marshall JW, et al. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):5–10. Comment in: Infect Control Hosp Epidemiol 1996 Jan;17(1):3–4.

Staffing levels and seclusion use. Morrison P, et al. **J Adv Nurs** 1995 Dec;22(6):1193–1202

An investigation into nurses' perceptions of secluding patients on closed psychiatric wards. Muir–Cochrane E. **J Adv Nurs** 1996 Mar;23(3):555–63

Is isolation needed for anti–HCV–positive hemodialysis patients? [letter; comment] Beccari M, et al. **Nephron** 1996; 72(2):372. Comment on: Nephron 1994;68(4):514.

Hepatitis C: is isolation essential? [letter] al Shohaib S, et al. **Nephron** 1996;73(1):109

Seclusion in treatment of adolescents on an acute inpatient unit [comment] Atlas JA. **Psychol Rep** 1995 Oct;77(2):577–8 . Comment on: Psychol Rep 1995 Feb;76(1):147–57.

Isolation for anti–HCV–positive hemodialysis patients? [letter] Beccari M. **Ren Fail** 1995 Nov;17(6):775–6

[The use of coercion at psychiatric departments for adults, Hillerød hospital. A descriptive study of the period 10 January 1991–31 August 1992] Hansen HS, et al. **Ugeskr Laeger** 1996 May 6;158(19):2700–5 (Eng. Abstr.) **(Dan)**

[Use of restraints before and after the new psychiatric law] Pedersen AG, et al. **Ugeskr Laeger** 1996 May 6; 158(19):2697–9 (Eng. Abstr.) **(Dan)**

LEGISLATION & JURISPRUDENCE

Involuntarily detained HIV–infected patients in Sweden: reasons for referral and psychiatric diagnoses. Alexius B, et al. **Med Law** 1995;14(7–8):491–500

METHODS

Effectiveness of contact isolation during a hospital outbreak of methicillin–resistant Staphylococcus aureus. Jernigan JA, et al. **Am J Epidemiol** 1996 Mar 1;143(5):496–504

Guideline for isolation precautions in hospitals. Part II. Recommendations for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. **Am J Infect Control** 1996 Feb;24(1):32–52

Protective isolation: who needs it? Fenelon LE. **J Hosp Infect** 1995 Jun;30 Suppl:218–22

ORGANIZATION & ADMINISTRATION

[Isolation rooms in the psychiatric environment] Morello R, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):214–20 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

The risk of seclusion and the menstrual cycle in female psychiatric patients. Van Heeringen K, et al. **J Psychosom Res** 1995 Jul;39(5):629–32

Place attachment, isolation, and the power of a window in a hospital environment: a case study. Baird CL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):847–50

STANDARDS

Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Garner JS. **Am J Infect Control** 1996 Feb;24(1):24–31

Development of a research–based protocol to rule out tuberculosis by means of continuous quality improvement techniques. Harmon JC, et al. **Am J Infect Control** 1995 Oct;23(5):329–36

STATISTICS & NUMERICAL DATA

A study of the official records of seclusion. Morrison P, et al. **Int J Nurs Stud** 1996 Apr;33(2):223–35

A national survey on seclusion and restraint in state psychiatric hospitals. Crenshaw WB, et al. **Psychiatr Serv** 1995 Oct;46(10):1026–31

Use of restraint and seclusion in psychiatric settings in New York State. Ray NK, et al. **Psychiatr Serv** 1995 Oct; 46(10):1032–7

PATIENT MONITORING see **MONITORING, PHYSIOLOGIC**

PATIENT NON–COMPLIANCE see **TREATMENT REFUSAL**

PATIENT OMBUDSMEN see **PATIENT ADVOCACY**

PATIENT OUTCOME ASSESSMENT see **OUTCOME ASSESSMENT (HEALTH CARE)**

PATIENT PARTICIPATION

Internet solicitation of research subjects for genetic studies [letter] Biesecker LG, et al. **Am J Hum Genet** 1995 Nov; 57(5):1255–6

Topics for our times: can we learn from the care of persons with mental illness in developing countries? [editorial] Susser E, et al. **Am J Public Health** 1996 Jul;86(7):926–8

Characteristics of physicians with participatory decision–making styles [see comments] Kaplan SH, et al. **Ann Intern Med** 1996 Mar 1;124(5):497–504. Comment in: Ann Intern Med 1996 Mar 1;124(5):511–3.

Sisyphus or Pegasus? The physician interviewer in the era of corporatization of care [editorial; comment] Lipkin M Jr. **Ann Intern Med** 1996 Mar 1;124(5):511–3. Comment on: Ann Intern Med 1996 Mar 1;124(5):497–504.

Estimating treatment benefits for the elderly: the effect of competing risks. Welch HG, et al. **Ann Intern Med** 1996 Mar 15;124(6):577–84

Patient participation in medical consensus conferences. Ferguson JH. **Ann Oncol** 1995;6 Suppl 2:3–4

The semeiology of arthritis: discriminating between patients on the basis of their symptoms. Helliwell PS. **Ann Rheum Dis** 1995 Nov;54(11):924–6

Patient satisfaction with decision–making for breast cancer therapy. Weiss SM, et al. **Ann Surg Oncol** 1996 May; 3(3):285–9

Demographics and patient treatment choice in stage I breast cancer. Graling PR, et al. **AORN J** 1995 Sep;62(3):376–84

The impact of informed consent on patient interest in prostate–specific antigen screening [see comments] Wolf AM, et al. **Arch Intern Med** 1996 Jun 24;156(12):1333–6. Comment in: Arch Intern Med 1996 Jun 24;156(12):1262–3.

Home versus hospital delivery. Good quality evidence is lacking [letter; comment] Lang H, et al. **BMJ** 1996 Jun 29;312(7047):1673–4. Comment on: BMJ 1996 Mar 23;312(7033):753–7.

Ensuring that guidelines are effective. Pilot of patient held guidelines is under way [letter; comment] Rao JN, et al. **BMJ** 1995 Oct 14;311(7011):1023. Comment on: BMJ 1995 Jul 22;311(6999):237–42.

Ensuring that guidelines are effective. Give them to the patient [letter; comment] Williamson C. **BMJ** 1995 Oct 14; 311(7011):1023. Comment on: BMJ 1995 Jul 22;311(6999):237–42.

Breast cancer: asking patients what they want [editorial] Williamson C. **BMJ** 1996 Aug 31;313(7056):506–7

Want or need [letter] Brenchley ML. **Br Dent J** 1996 Jan 20;180(2):51

Public and patient involvement in health and health care. Calman K. **Br Dent J** 1996 Jan 6;180(1):31–6

Want or need [letter] Johnson ND. **Br Dent J** 1996 Jan 20; 180(2):51

Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Sandison AJ, et al. **Br J Surg** 1996 Jul;83(7):994–6

Common drugs and the progress of cancer [letter; comment] Brown JH. **Can Med Assoc J** 1996 Jan 1;154(1):16–7. Comment on: Can Med Assoc J 1995 Sep 1;153(5):569–71.

Increasing patient involvement in choosing treatment for early breast cancer. Street RL Jr, et al. **Cancer** 1995 Dec 1;76(11):2275–85

Advance directives. Changing our expectations [editorial; comment] Drought TS, et al. **Chest** 1996 Sep;110(3):589–91 . Comment on: Chest 1996 Sep;110(3):816–22.

Who shall decide? [editorial; comment] Coates A. **Eur J Cancer** 1995 Nov;31A(12):1917–8. Comment on: Eur J Cancer 1995 Nov;31A(12):1955–9.

The influence of audiotapes on patient participation in the cancer consultation. Ford S, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2264–9

Five–year survival curves: how much data are enough for patient–physician decision making in general surgery? Mazur DJ, et al. **Eur J Surg** 1996 Feb;162(2):101–4

A contextual approach for understanding individual autonomy in managed community long–term care. Capitman J, et al. **Gerontologist** 1995 Aug;35(4):533–40 (55 ref.)

Through the looking glass: decision making and chemotherapy. Cohodes DR. **Health Aff (Millwood)** 1995 Winter;14(4):203–8

An empowerment–centered, church–based asthma education program for African American adults. Ford ME, et al. **Health Soc Work** 1996 Feb;21(1):70–5

When the patient chooses: describing unaided decisions in health care. Pierce PF. **Hum Factors** 1996 Jun;38(2):278–87 (30 ref.)

Quality of life: the patient's endpoint [editorial; comment] Wasserman TH, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):965–6. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):901–6.

RTOG's first quality of life study—RTOG 90–20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer [see comments] Watkins–Bruner D, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):901–6. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):965–6.

Choice and daily activities for people with disabilities. Frost PA. **Int J Rehabil Res** 1996 Mar;19(1):89–91

Strategies for health education for adolescent patients: a preliminary investigation. Schubiner H, et al. **J Adolesc Health** 1995 Jul;17(1):37–41

Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)

A selective review of the literature on nurse–patient communication: has the patient's contribution been neglected? Jarrett N, et al. **J Adv Nurs** 1995 Jul;22(1):72–8 (51 ref.)

Promoting participation of informal caregivers in the hospital care of the elderly patient: informal caregivers' perceptions. Laitinen P, et al. **J Adv Nurs** 1996 May;23(5):942–7

Health–promoting nursing practice: the demise of the nursing process? Lindsey E, et al. **J Adv Nurs** 1996 Jan;23(1):106–12 (24 ref.)

"But doctor, I'd prefer to have a cesarean section": when public policy conflicts with patient preference [editorial] Wall EM. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):414–6

Medical decision–making in older hospitalized patients [letter] Dellasega C, et al. **J Am Geriatr Soc** 1996 Mar; 44(3):336–7

Advance directives and older adults: a critical care perspective [letter] Nuckton TJ. **J Am Geriatr Soc** 1996 Jun;44(6):733–4

Measuring patient and relative satisfaction with level or aggressiveness of care and involvement in care decisions in the context of life threatening illness. Guyatt GH, et al. **J Clin Epidemiol** 1995 Oct;48(10):1215–24

Managed care and the new medical paternalism [comment] Sulmasy DP. **J Clin Ethics** 1995 Winter;6(4):324–6. Comment on: J Clin Ethics 1995 Winter;6(4):320–3.

Factors influencing the selection of restorative materials in dental care in Finland. Forss H, et al. **J Dent** 1996 Jul; 24(4):257–62

Clinical decision–making in the face of scientific uncertainty: hormone replacement therapy as an example. Mort EA. **J Fam Pract** 1996 Feb;42(2):147–51

Personal decision [letter] Moglevang C. **J Fla Med Assoc** 1996 May;83(5):344

Individual responsibility [letter] Robinson HN. **J Fla Med Assoc** 1996 May;83(5):343–4

Do patients want to be informed? Do they want to decide? [editorial; comment] Stoeckle JD. **J Gen Intern Med** 1995 Nov;10(11):643–4. Comment on: J Gen Intern Med 1995 Nov;10(11):593–600.

Rational non–interventional paternalism: why doctors ought to make judgments of what is best for their patients. Savulescu J. **J Med Ethics** 1995 Dec;21(6):327–31

A pilot study to evaluate in–hospital care by mothers. Evans M. **J Pediatr Oncol Nurs** 1996 Jul;13(3):138–45

What factors influence patient preferences regarding cardiopulmonary resuscitation? Mead GE, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):295–8

An appropriate admission depends on your viewpoint [letter] Wright N. **J R Coll Physicians Lond** 1995 Nov–Dec; 29(6):550

Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. Bakker C, et al. **J Rheumatol** 1995 Jul;22(7):1304–10

Is mortality rate what it is all about in congestive heart failure? [letter] Girbes AR, et al. **Lancet** 1995 Dec 2; 346(8988):1501–2

Hippocratic Oath [letter; comment] Sher L. **Lancet** 1996 Mar 23;347(9004):834. Comment on: Lancet 1996 Jan 13;347(8994):101–2.

Patient and visit characteristics related to physicians' participatory decision–making style. Results from the Medical Outcomes Study. Kaplan SH, et al. **Med Care** 1995 Dec;33(12):1176–87

Patient satisfaction with health care decisions: the satisfaction with decision scale. Holmes–Rovner M, et al. **Med Decis Making** 1996 Jan–Mar;16(1):58–64

A tool for matching physically impaired people with suitable technical aids: the merits and demerits of a laser disk consultation tool. Takahashi T, et al. **Medinfo** 1995;8 Pt 2:1022–4

Empowerment of patients: a threat or a help? [editorial] Molema J, et al. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):337–9

Management of acute mesenteric ischemia [letter; comment] Donnelly WJ. **N Engl J Med** 1996 Aug 22;335(8):595–6; discussion 596. Comment on: N Engl J Med 1996 Apr 4;334(14):908–11.

Screening for prostate cancer [letter; comment] Hensel WA. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.

Clinical problem solving. The invisible patient [see comments] Sirmon M, et al. **N Engl J Med** 1996 Apr 4; 334(14):908–11. Comment in: N Engl J Med 1996 Aug 22;335(8):594; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):594–5; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):595; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):595–6; discussion 596.

Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S–47S (31 ref.)

Information needs, sources of information, and decisional roles in women with breast cancer. Bilodeau BA, et al. **Oncol Nurs Forum** 1996 May;23(4):691–6

Information and decision–making preferences of men with prostate cancer. Davison BJ, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1401–8

Therapeutic decisions involving disparate clinical outcomes: patient preference survey for treatment of central retinal artery occlusion. Margo CE, et al. **Ophthalmology** 1996 Apr;103(4):691–6

Informed consent, parental permission, and assent in pediatric practice [letter; comment] Bartholome WG. **Pediatrics** 1995 Nov;96(5 Pt 1):981–2. Comment on: Pediatrics 1995

Feb;95(2):314–7.
Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)
Consumers as peer specialists on intensive case management teams: impact on client outcomes. Felton CJ, et al. **Psychiatr Serv** 1995 Oct;46(10):1037–44
The partnership model: working with individuals, families, and communities toward a new vision of health. Courtney R, et al. **Public Health Nurs** 1996 Jun;13(3):177–86
Medication decision–making and management: a client–centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)
[Breast neoplasms: information in question(s). A survey of patients and physicians at a cancer treatment center] Vennin P, et al. **Bull Cancer (Paris)** 1995 Sep;82(9):698–704 (Eng. Abstr.) **(Fre)**
[Patient involvement in medical care] Tidhar M, et al. **Harefuah** 1995 Nov 15;129(10):385–8, 447 (Eng. Abstr.) **(Heb)**

ECONOMICS

Clinical and economic consequences of patients as producers. Hart JT. **J Public Health Med** 1995 Dec;17(4):383–6
Prenatal screening vouchers. Lilford RJ, et al. **J R Soc Med** 1996 Mar;89(3):130–1

LEGISLATION & JURISPRUDENCE

Detours on the road to autonomy. A critique of the New York State do–not–resuscitate law. Pollack S. **Arch Intern Med** 1996 Jul 8;156(13):1369–71
[Patient rights alone are not enough, too many rights can also be harmful] Barolin GS. **Wien Med Wochenschr** 1996; 146(4):79–84 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Motivation for participation in clinical trials of drugs for the treatment of asthma, seasonal allergic rhinitis, and perennial nonallergic rhinitis. Aby JS, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):348–54
What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Turner S, et al. **Br J Cancer** 1996 Jan;73(2):222–7
Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. Rimer BK, et al. **Cancer** 1996 Jun 1; 77(11):2348–55
The social production of authoritative knowledge in pregnancy and childbirth. Davis–Floyd R, et al. **Med Anthropol Q** 1996 Jun;10(2):111–20
Activists and delegators: elderly patients' preferences about control at the end of life. Kelner M. **Soc Sci Med** 1995 Aug;41(4):537–45

STATISTICS & NUMERICAL DATA

What role do patients wish to play in treatment decision making? Deber RB, et al. **Arch Intern Med** 1996 Jul 8; 156(13):1414–20
Differences in participation in experimental drug trials among persons with AIDS. Diaz T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):562–8
Patient desire for information and decision making in health care decisions: the Autonomy Preference Index and the Health Opinion Survey [see comments] Nease RF Jr, et al. **J Gen Intern Med** 1995 Nov;10(11):593–600. Comment in: J Gen Intern Med 1995 Nov;10(11):643–4.
Physician–assisted suicide and euthanasia in Washington State. Patient requests and physician responses [see comments] Back AL, et al. **JAMA** 1996 Mar 27; 275(12):919–25. Comment in: JAMA 1996 Jul 17;276(3):196–7.
Attitudes of medical students and primary care physicians regarding input of older and younger patients in medical decisions. Beisecker AE, et al. **Med Care** 1996 Feb; 34(2):126–37
Consumer–directed models of personal care: lessons from Medicaid. Doty P, et al. **Milbank Q** 1996;74(3):377–409

TRENDS

Family centered intrapartum care: revisiting an old concept. Tomlinson PS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):331–7
Client movement in Europe: its past, present and future. van der Male R. **Seishin Shinkeigaku Zasshi** 1995;97(7):517–21

PATIENT READMISSION

Identifying modifiable risk factors for rehospitalization: a case–control study of seriously mentally ill persons in Mississippi. Sullivan G, et al. **Am J Psychiatry** 1995 Dec; 152(12):1749–56
The effect of early discharge and other factors on readmission rates of newborns. Soskolne EI, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):373–9
Psychological predictors of subsequent medical care among patients hospitalized with cardiac disease. Levine JB, et al. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):109–16
Selection bias, indexes of "burden," and risk [letter; comment] Peiro S, et al. **J Clin Epidemiol** 1996 Apr;49(4):495. Comment on: J Clin Epidemiol 1994 Nov;47(11):1229–36.
The stability of DNR orders on hospital readmission. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Wenger NS, et al. **J Clin Ethics** 1996 Spring;7(1):48–54
Performance on the Wisconsin Card Sorting Test as a predictor of rehospitalization in schizophrenia. Lysaker PH, et al. **J Nerv Ment Dis** 1996 May;184(5):319–21
A trial of increased access to primary care [letter] Burack JH. **N Engl J Med** 1996 Sep 19;335(12):897; discussion 897–8
A trial of increased access to primary care [letter] Corey GA. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8
A trial of increased access to primary care [letter] Rich MW. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8
A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure [see comments] Rich MW, et al. **N Engl J Med** 1995 Nov 2; 333(18):1190–5. Comment in: N Engl J Med 1995 Nov 2;333(18):1213–4.
Questions about the value of early intervention [editorial; comment] Welch HG. **N Engl J Med** 1996 May 30; 334(22):1472–3. Comment on: N Engl J Med 1996 May 30;334(22):1441–7.
Hospital readmission due to neonatal hyperbilirubinemia. Seidman DS, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):727–9
Clozapine and recidivism [letter] Gordon BJ, et al. **Psychiatr Serv** 1995 Oct;46(10):1079
Factors affecting the success of community placement: the TAPS project 26. Gooch C, et al. **Psychol Med** 1996 May; 26(3):511–20
[Rehospitalization of very–low–birth–weight infants after discharge from neonatal intensive care units] Bar–Oz B, et al. **Harefuah** 1995 Jun 1;128(11):687–9, 743 (Eng. Abstr.) **(Heb)**
[Admissions and readmissions from a unit of ambulatory surgery. Experiences after 2 411 surgical interventions] Grøgaard B, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28; 116(6):742–5 (Eng. Abstr.) **(Nor)**
[The problem of the frequent hospitalizations of the mentally ill] Dolgov SA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):103–6 (73 ref.) **(Rus)**
[Factors associated with emergency hospital readmission in digestive and hepatobiliary diseases] Peiró S, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):4–13 (Eng. Abstr.) **(Spa)**
[Emergency readmissions are common within 14 days. A 2–year study at a department of internal medicine] Hallert C. **Lakartidningen** 1995 Oct 4;92(40):3670–2 **(Swe)**

ECONOMICS

The value of consultation–liaison interventions to the general hospital. Hall RC, et al. **Psychiatr Serv** 1996 Apr; 47(4):418–20
Cost of relapse in schizophrenia. Weiden PJ, et al. **Schizophr Bull** 1995;21(3):419–29

STANDARDS

[Are early unforseen rehospitalizations inevitable?] Chaput–Toupin E, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):221–7 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Factors predicting readmissions in personality disorders and other nonpsychotic illnesses. A retrospective study on 64 first–ever admissions to the Psychiatric Clinic of Turku, Finland. Korkeila JA, et al. **Acta Psychiatr Scand** 1995 Aug; 92(2):138–44
PTSD substance abuse comorbidity and treatment utilization. Brown PJ, et al. **Addict Behav** 1995 Mar–Apr;20(2):251–4
The effects of newborn early discharge on hospital readmissions. Fox MH, et al. **Am J Med Qual** 1995 Winter; 10(4):206–12
Retrospective study of 2,200 involuntary psychiatric admissions and readmissions. Sanguineti VR, et al. **Am J Psychiatry** 1996 Mar;153(3):392–6
Four–year follow–up of the influence of psychological comorbidity on medical rehospitalization. Saravay SM, et al. **Am J Psychiatry** 1996 Mar;153(3):397–403
Hospitalizations for injury in New Zealand: prior injury as a risk factor for assaultive injury. Dowd MD, et al. **Am J Public Health** 1996 Jul;86(7):929–34
Association between shorter length of stay (LOS) and readmission for complication exists [letter] Rosenblatt MS. **Ann Surg** 1996 Aug;224(2):236–8
Readmissions to hospital: the contribution of morbidity data to the evaluation of asthma management. Rushworth RL, et al. **Aust J Public Health** 1995 Aug;19(4):363–7
Patients who reattend after head injury: a high risk group [see comments] Voss M, et al. **BMJ** 1995 Nov 25; 311(7017):1395–8. Comment in: BMJ 1996 Mar 16;312(7032):707–8.
Epidemiology and patterns of hospital use after parasuicide in the south west of England. Gunnell DJ, et al. **J Epidemiol Community Health** 1996 Feb;50(1):24–9
Application of multivariable optimal discriminant analysis in general internal medicine. Yarnold PR, et al. **J Gen Intern Med** 1995 Nov;10(11):601–6
Newborn readmissions. Brodt AL, et al. **J Nurs Adm** 1996 Mar;26(3):5
Association between duration of neonatal hospital stay and readmission rate [see comments] Lee KS, et al. **J Pediatr** 1995 Nov;127(5):758–66. Comment in: J Pediatr 1995 Nov;127(5):736–7.
Validation of a 28 day interval between discharge and readmission for emergency readmission rates. Sibbritt DW. **J Qual Clin Pract** 1995 Dec;15(4):211–20
A trial of increased access to primary care [letter] Starfield B, et al. **N Engl J Med** 1996 Sep 19;335(12):895–6; discussion 897–8
Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission [see comments] Weinberger M, et al. **N Engl J Med** 1996 May 30; 334(22):1441–7. Comment in: N Engl J Med 1996 May 30;334(22):1472–3.
Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Grant M, et al. **Nurs Clin North Am** 1995 Dec;30(4):673–82
Readmission of older heart failure patients. Jaarsma T, et al. **Prog Cardiovasc Nurs** 1996 Winter;11(1):15–20
Identifying multiple recidivists in a state hospital population. Casper ES. **Psychiatr Serv** 1995 Oct;46(10):1074–5
Quality of life and clinical predictors of rehospitalization of persons with severe mental illness. Postrado LT, et al. **Psychiatr Serv** 1995 Nov;46(11):1161–5
Postdischarge follow–up of psychiatric inpatients and readmission in an HMO setting. Schoenbaum SC, et al. **Psychiatr Serv** 1995 Sep;46(9):943–5
Diagnosis and hospital readmission rates of female veterans with substance–related disorders. Walker RD, et al. **Psychiatr Serv** 1995 Sep;46(9):932–7
Risk screening for adverse outcomes in subacute care. Evans RL, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):1043–8
Morbidity and injury recurrence in victims of firearm injuries. Ponzer S, et al. **Public Health** 1996 Jan;110(1):42–6
The early hospital readmission of elderly people. Colledge NR, et al. **Scott Med J** 1994 Apr;39(2):51–2
Effect of readmissions on increasing hospital admissions for asthma in children. Senthilselvan A. **Thorax** 1995 Sep; 50(9):934–6
Repeat victims of violence in an urban trauma center. Buss TF, et al. **Violence Vict** 1995 Fall;10(3):183–94

TRENDS

Acute and chronic psychiatric care: establishing boundaries. Sederer LI, et al. **Psychiatr Q** 1995 Fall;66(3):263–74

PATIENT RECRUITMENT see **PATIENT SELECTION**

PATIENT REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

PATIENT REPRESENTATIVES see **PATIENT ADVOCACY**

PATIENT SATISFACTION

see related
PATIENT ACCEPTANCE OF HEALTH CARE

Inability to follow up ED patients by telephone: there must be 50 ways to leave your number. Adams SL, et al. **Acad Emerg Med** 1996 Mar;3(3):271–3
Relating patient satisfaction to waiting time perceptions and expectations: the disconfirmation paradigm. Thompson DA, et al. **Acad Emerg Med** 1995 Dec;2(12):1057–62
Life satisfaction and sexuality in patients operated for epilepsy. Christianson SA, et al. **Acta Neurol Scand** 1995 Jul;92(1):1–6
Hearing aids: statistical study and satisfaction survey of patients in an ENT practice. Robillard T, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):115–20
Coercive measures in psychiatric care. Reports and reactions of patients and other people involved. Eriksson KI, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):225–30
Beliefs about Depo–Provera among three groups of contraceptors. Cushman LF, et al. **Adv Contracept** 1996 Mar;12(1):43–52
Patient satisfaction following rhinoplasty. Guyuron B, et al. **Aesthetic Plast Surg** 1996 Mar–Apr;20(2):153–7
Subperiosteal facelifting: complications and the dissatisfied patient. Scheflan M, et al. **Aesthetic Plast Surg** 1996 Winter; 20(1):33–6
Patients' and carers' satisfaction with acute stroke management. Wellwood I, et al. **Age Ageing** 1995 Nov; 24(6):519–24
Evaluating health services: the importance of patients' preferences and quality of life [see comments] Yin D, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1323–8. Comment in: AJR Am J Roentgenol 1995 Dec;165(6):1329–30.
Randomized comparison of flexible versus nonflexible femoral sheaths on patient comfort after angioplasty. Waksman R, et al. **Am Heart J** 1996 Jun;131(6):1076–8
Analgesic administration, pain intensity, and patient satisfaction in cardiac surgical patients. Meehan DA, et al. **Am J Crit Care** 1995 Nov;4(6):435–42
A new approach to chronic pain in the ED. MacLeod DB, et al. **Am J Emerg Med** 1996 May;14(3):323–6
Patient tolerance: an important factor of dissatisfaction for

colonoscopy [letter; comment] Froehlich F, et al. **Am J Gastroenterol** 1995 Nov;90(11):2068–9. Comment on: Am J Gastroenterol 1994 Sep;89(9):1476–9.

What is it patients want? [editorial; comment] LaCombe MA. **Am J Med** 1995 Dec;99(6):588–9. Comment on: Am J Med 1995 Dec;99(6):590–6.

Evaluation of an ethics consultation service: patient and family perspective. Orr RD, et al. **Am J Med** 1996 Aug; 101(2):135–41

Patients' perceptions of office medical practice: judging quality through the patients' eyes. Epstein KR, et al. **Am J Med Qual** 1996 Summer;11(2):73–80

Consumer information, patient satisfaction surveys, and public reports. Turnbull JE, et al. **Am J Med Qual** 1996 Spring;11(1):S42–5

Assessment tools: functional health status and patient satisfaction. Ware JE Jr, et al. **Am J Med Qual** 1996 Spring; 11(1):S50–3

The accuracy and patient preference for self-collected group B Streptococcus cultures. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1325–8

Client-centered approach to develop a seating clinic satisfaction questionnaire: a qualitative study. McComas J, et al. **Am J Occup Ther** 1995 Nov–Dec;49(10):980–5

Presurgical satisfaction with facial appearance in orthognathic surgery patients. van Steenbergen E, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):653–9

Cochlear implantation in the elderly. Kelsall DC, et al. **Am J Otol** 1995 Sep;16(5):609–15

Switching Swiss enrollees from indemnity health insurance to managed care: the effect on health status and stisfaction with care. Perneger TV, et al. **Am J Public Health** 1996 Mar;86(3):388–93

Review of efficiencies and patient satisfaction in Australian and New Zealand day surgery units: a pilot study. Rudkin GE, et al. **Anaesth Intensive Care** 1996 Feb;24(1):74–8

Patient satisfaction with general anaesthesia. Too difficult to measure? Whitty PM, et al. **Anaesthesia** 1996 Apr; 51(4):327–32

Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)

Important elements of outpatient care: a comparison of patients' and physicians' opinions. Laine C, et al. **Ann Intern Med** 1996 Oct 15;125(8):640–5

Lasting success in teenage reduction mammaplasty. McMahan JD, et al. **Ann Plast Surg** 1995 Sep;35(3):227–31

Patient satisfaction with decision-making for breast cancer therapy. Weiss SM, et al. **Ann Surg Oncol** 1996 May; 3(3):285–9

A randomized study of the efficacy of the PROPATH Program for patients with Parkinson disease [see comments] Mercer BS. **Arch Neurol** 1996 Sep;53(9):881–4. Comment in: Arch Neurol 1996 Sep;53(9):848.

Effects of structured encounter forms on pediatric house staff knowledge, parent satisfaction, and quality of care. A randomized, controlled trial. Zenni EA, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):975–80

Clinical outcomes and satisfaction of patients of clinical nurse specialists in psychiatric-mental health nursing. Baradell JG. **Arch Psychiatr Nurs** 1995 Oct;9(5):240–50

Perception of indoor patients on the services of some Thana Health Complexes. Roy SR, et al. **Bangladesh Med Res Counc Bull** 1995 Apr;21(1):46–9

Reduced schedule of antenatal visits. Postnatal care also requires evaluation [letter; comment] Bell R. **BMJ** 1996 Jul 20;313(7050):168; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

Patints prefer hospital follow up for cancer [letter; comment] Glynne-Jones R, et al. **BMJ** 1995 Dec 9;311(7019):1574–5 . Comment on: BMJ 1995 Mar 18;310(6981):685–6. Comment on: BMJ 1995 Jul 1;311(6996):54.

Reduced schedule of antenatal visits. Attention should be paid to what women want [letter; comment] Hinshaw K, et al. **BMJ** 1996 Jul 20;313(7050):168; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):524–5. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

Reduced schedule of antenatal visits. Differences in psychosocial outcomes between groups were not large [letter; comment] O'Connell T. **BMJ** 1996 Jul 20; 313(7050):167; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

Reduced schedule of antenatal visits. Effect of fewer visits on postnatal depression is important [letter; comment] Tincello D. **BMJ** 1996 Jul 20;313(7050):167–8; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

Reduced schedule of antenatal visits. Study ignored influence of parity on women's needs [letter; comment] Vause S, et al. **BMJ** 1996 Jul 20;313(7050):167; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

Practical marketing for dentistry. 3. Relationship marketing and patient/customer satisfaction. Ball R. **Br Dent J** 1996 Jun 22;180(12):467–72

Patient comfort in audiological testing. Beynon GJ, et al. **Br J Audiol** 1995 Feb;29(1):1–5

Patient perception of the diskus inhaler: a comparison with the turbuhaler inhaler. Schlaeppi M, et al. **Br J Clin Pract** 1996 Jan–Feb;50(1):14–9

What type of general practice do patients prefer? Exploration of practice characteristics influencing patient satisfaction. Baker R, et al. **Br J Gen Pract** 1995 Dec;45(401):654–9

On throwing out the baby and keeping the bathwater [letter] Bradley C. **Br J Gen Pract** 1996 Apr;46(405):253

Development of a questionnaire to measure patients' satisfaction with general practitioners' services. Grogan S, et al. **Br J Gen Pract** 1995 Oct;45(399):525–9

Characteristics of drug misusers and their perceptions of general practitioner care. Hindler C, et al. **Br J Gen Pract** 1996 Mar;46(404):149–52

Women's views of their first antenatal visit [letter] Hirst J, et al. **Br J Gen Pract** 1996 May;46(406):319

Addressing the patient's agenda in the reorganization of antenatal and infant health care: experience in one general practice. Mellor J, et al. **Br J Gen Pract** 1995 Aug; 45(397):423–5

Use of the consultation satisfaction questionnaire to examine patients' satisfaction with general practitioners and community nurses: reliability, replicability and discriminant validity. Poulton BC. **Br J Gen Pract** 1996 Jan; 46(402):26–31

Epilepsy monitoring and advice recorded: general practitioners' views, current practice and patients' preferences. Ridsdale L, et al. **Br J Gen Pract** 1996 Jan; 46(402):11–4

Patients' views of low back pain and its management in general practice. Skelton AM, et al. **Br J Gen Pract** 1996 Mar;46(404):153–6

Patient choice of general practice [letter] Taylor MB. **Br J Gen Pract** 1996 Mar;46(404):200

Refractive and visual results and patient satisfaction after excimer laser photorefractive keratectomy for myopia. Halliday BL. **Br J Ophthalmol** 1995 Oct;79(10):881–7

Refractive and visual results and patient satisfaction after excimer laser keratectomy for myopia. Rosen E. **Br J Ophthalmol** 1996 Apr;80(4):380

How effective is an integrated approach to low vision rehabilitation? Two year follow up results from south Devon [see comments] Shuttleworth GN, et al. **Br J Ophthalmol** 1995 Aug;79(8):719–23. Comment in: Br J Ophthalmol 1995 Aug;79(8):715–6.

Patient satisfaction with implant-retained mandibular overdentures. A comparison with new complete dentures not retained by implants—a multicentre randomized clinical trial. Boerrigter EM, et al. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):282–8

Patients' views towards care received from psychiatrists. Barker DA, et al. **Br J Psychiatry** 1996 May;168(5):641–6

Quality of care and patient satisfaction. Haslock I. **Br J Rheumatol** 1996 Apr;35(4):382–4

Needs for CME in geriatrics. Part 1: Perceptions of patients and community informants. Pereles L, et al. **Can Fam Physician** 1996 Mar;42:437–45

Postpartum safety and satisfaction following early discharge. Dalby DM, et al. **Can J Public Health** 1996 Mar–Apr; 87(2):90–4

Elderly clients' perceptions: individual health counselling and group sessions [see comments] Viverais-Dresler GA, et al. **Can J Public Health** 1995 Jul–Aug;86(4):234–7. Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3.

Health care the tie that binds [letter; comment] Brown AD, et al. **Can Med Assoc J** 1996 Aug 1;155(3):274. Comment on: Can Med Assoc J 1996 Mar 1;154(5):693–6.

Life-satisfaction in patients with head and neck cancer. Morton RP. **Clin Otolaryngol** 1995 Dec;20(6):499–503

Patient mobility in Australian dentistry. Thomson WM, et al. **Community Dent Health** 1996 Jun;13(2):99–104

Why should physicians worry about patient satisfaction? Applying some of the principles used in the emergency department to hospital and office-based practices. Sutherland SF, et al. **Del Med J** 1996 Jan;68(1):19–22

Cryosurgery of actinic keratoses: the patient's perspective [letter] Kalivas J. **Dermatol Surg** 1996 May;22(5):486

Pulsed dye laser treatment of port-wine stains. A patient questionnaire. Tan E, et al. **Dermatol Surg** 1996 Feb; 22(2):119–22

Comprehensive diabetes care in North Tyneside. Whitford DL, et al. **Diabet Med** 1995 Aug;12(8):691–5

A geriatric day hospital in Hong Kong: an analysis of activities and costs. Hui E, et al. **Disabil Rehabil** 1995 Nov–Dec;17(8):418–23

Patients' experiences of and satisfaction with care for their epilepsy. Buck D, et al. **Epilepsia** 1996 Sep;37(9):841–9

Recommendation of early surgery from the viewpoint of daily quality of life. Mihara T, et al. **Epilepsia** 1996;37 Suppl 3:33–6

The satisfaction and savings of early discharge with drain in situ following axillary lymphadenectomy in the treatment of breast cancer. Holcombe C, et al. **Eur J Surg Oncol** 1995 Dec;21(6):604–6

Patients' evaluations of their consultations with primary health clinic doctors in the United Arab Emirates. Harrison A. **Fam Pract** 1996 Feb;13(1):59–66

A comparison of methods for measuring patient satisfaction with consultations in primary care. Kinnersley P, et al. **Fam Pract** 1996 Feb;13(1):41–51

A new measure of patient satisfaction with mammography. Validation by factor analytic technique. Loeken K, et al. **Fam Pract** 1996 Feb;13(1):67–74

Assessment of the combined orthodontic-surgical treatment from the patients' point of view. A longitudinal study. Hugo B, et al. **Fortschr Kieferorthop** 1996 Apr;57(2):88–101 **(Eng, Ger)**

Is day case liver biopsy underutilised? Douds AC, et al. **Gut** 1995 Oct;37(4):574–5

Knee arthroscopy under local anaesthesia: results and evaluation of patients' satisfaction. Iossifidis A. **Injury** 1996 Jan;27(1):43–4

HRT: the woman's perspective. Graziottin A. **Int J Gynaecol Obstet** 1996 Mar;52 Suppl 1:S11–6

Denture satisfaction in a comparative study of implant-retained mandibular overdentures: a randomized clinical trial. Geertman ME, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):194–200

Outpatients in neurological rehabilitation. Barnes MP, et al. **Int J Rehabil Res** 1996 Mar;19(1):39–45

Survey of patient satisfaction in a community hospital [see comments] Hart J, et al. **Isr J Med Sci** 1996 Jul;32(7):551–4 . Comment in: Isr J Med Sci 1996 Jul;32(7):570–2.

Israelis evaluate their health care system [see comments] Shmueli A. **Isr J Med Sci** 1996 Jul;32(7):555–61. Comment in: Isr J Med Sci 1996 Jul;32(7):570–2.

What should doctors wear in the accident and emergency department? Patients' perception [letter; comment] Stell M. **J Accid Emerg Med** 1995 Jun;12(2):161–2. Comment on: J Accid Emerg Med 1994 Sep;11(3):175–7.

Satisfying solutions? A review of some unresolved issues in the measurement of patient satisfaction. Avis M, et al. **J Adv Nurs** 1995 Aug;22(2):316–22 (60 ref.)

The use of qualitative methods in the study of parents' experiences of care on a children's surgical ward. Callery P, et al. **J Adv Nurs** 1996 Feb;23(2):338–45

The experience of reassurance: patients' perspectives. Fareed A. **J Adv Nurs** 1996 Feb;23(2):272–9

Forty years on: reflections on national health service management [editorial] Moores B. **J Adv Nurs** 1995 Jul; 22(1):1–2

Measuring patients' satisfaction with nursing: 1990–1994. Thomas LH, et al. **J Adv Nurs** 1996 Apr;23(4):747–56 (48 ref.)

Patients' posttermination representations of their psychotherapists. Wzontek N, et al. **J Am Acad Psychoanal** 1995 Fall;23(3):395–410

The emotional experience of hospitalization: its moderators and its role in patient satisfaction with foodservices. Bélanger MC, et al. **J Am Diet Assoc** 1996 Apr;96(4):354–60

Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study. Coyne T, et al. **J Am Diet Assoc** 1995 Nov;95(11):1301–6

Patient satisfaction and normative decision theory. Brennan PF. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):250–9 (34 ref.)

Satisfaction with home healthcare services for clients with HIV: preliminary findings. Foley ME, et al. **J Assoc Nurses AIDS Care** 1995 Sep–Oct;6(5):20–5

Patients' opinions on respiratory care: do doctors fulfill their needs? Koning CJ, et al. **J Asthma** 1995;32(5):355–63

Proximal tibial osteotomy. A subjective outcome study. Nagel A, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1353–8

Women's and men's preferences for cardiac rehabilitation program features. Moore SM, et al. **J Cardpulm Rehabil** 1996 May–Jun;16(3):163–8

Women's views of cardiac rehabilitation programs. Moore SM. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):123–9

Measuring patient and relative satisfaction with level or aggressiveness of care and involvement in care decisions in the context of life threatening illness. Guyatt GH, et al. **J Clin Epidemiol** 1995 Oct;48(10):1215–24

Self-perceived unmet health care needs of persons enrolled in HIV care. Bonuck KA, et al. **J Community Health** 1996 Jun;21(3):183–98

Cost-effectiveness v patient preference in the choice of treatment for distal ureteral calculi: a literature-based decision analysis. Wolf JS Jr, et al. **J Endourol** 1995 Jun; 9(3):243–8

Antibiotics and respiratory infections: are patients more satisfied when expectations are met? Hamm RM, et al. **J Fam Pract** 1996 Jul;43(1):56–62

Patients with personality disorders: functional status, health care utilization, and satisfaction with care. Hueston WJ, et al. **J Fam Pract** 1996 Jan;42(1):54–60

Health education and patient satisfaction. Schauffler HH, et al. **J Fam Pract** 1996 Jan;42(1):62–8

Medical patients' assessments of their care during hospitalization: insights for internists. Delbanco TL, et al. **J Gen Intern Med** 1995 Dec;10(12):679–85

Effects of a physician communication intervention on patient care outcomes [see comments] Joos SK, et al. **J Gen Intern Med** 1996 Mar;11(3):147–55. Comment in: J Gen Intern Med 1996 Mar;11(3):187–8.

Improving patient quality of life with feedback to physicians about functional status. Rubenstein LV, et al. **J Gen Intern Med** 1995 Nov;10(11):607–14

The impact of media coverage on practice [letter] Sulmasy DP. **J Gen Intern Med** 1996 Jan;11(1):62

Speech assessment of patients using three types of indwelling tracheo-oesophageal voice prostheses. Heaton JM, et al. **J Laryngol Otol** 1996 Apr;110(4):343–7

Behavior modification in the treatment of obesity: acceptability profiles. Roongpisuthipong C, et al. **J Med Assoc Thai** 1995 May;78(5):232–7

The Practice Environment Project. A process for outcome evaluation. Grindel CG, et al. **J Nurs Adm** 1996 May; 26(5):43–51

Characterization of an acute inpatient hospice palliative care unit in a U.S. teaching hospital. Kellar N, et al. **J Nurs Adm** 1996 Mar;26(3):16–20

Data-driven interventions to improve patient satisfaction. Luther KM. **J Nurs Care Qual** 1996 Jul;10(4):33–9

Perceptions of quality in long-term care: a satisfaction survey. Meister C, et al. **J Nurs Care Qual** 1996 Jul; 10(4):40–7

A cognitive approach to patient satisfaction with emergency department nursing care. Raper JL. **J Nurs Care Qual** 1996 Jul;10(4):48–58

Understanding the new era in health care accountability: report cards. Ribnick PG, et al. **J Nurs Care Qual** 1995 Oct;10(1):1–8

Patient satisfaction with nursing care: concept clarification. Eriksen LR. **J Nurs Meas** 1995 Summer;3(1):59–76 (50 ref.)

Perceptions of nurses' caring by mothers experiencing postpartum depression. Beck CT.
J Obstet Gynecol Neonatal Nurs 1995 Nov–Dec; 24(9):819–25

Patient satisfaction and chewing ability with implant-retained mandibular overdentures: a comparison with new complete dentures with or without preprosthetic surgery. Boerrigter EM, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1167–73

The impact of interpersonal support on patient satisfaction with orthognathic surgery. Holman AR, et al.
J Oral Maxillofac Surg 1995 Nov;53(11):1289–97; discussion 1297–9

Satisfaction with complete immediate dentures and complete immediate overdentures. A 1 year survey. Jonkman RE, et al. **J Oral Rehabil** 1995 Nov;22(11):791–6

Care-giver evaluation of anti-gastroesophageal reflux procedures in neurologically impaired children: what is the real-life outcome? O'Neill JK, et al. **J Pediatr Surg** 1996 Mar;31(3):375–80

Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC.
J Prof Nurs 1996 Jul–Aug;12(4):207–16 (47 ref.)

Dental care satisfaction: the reliability and validity of the DSQ in a low-income population. Golletz D, et al.
J Public Health Dent 1995 Fall;55(4):210–7

Paediatric hospital services: are we satisfying our adolescent patients? Black W, et al. **J Qual Clin Pract** 1995 Sep; 15(3):161–7

The efficacy of staff training on improving internal customer satisfaction in a rural health setting. Hartley R, et al.
J Qual Clin Pract 1995 Sep;15(3):169–75

Varicose vein surgery: patient satisfaction. Davies AH, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):298–9

Patient satisfaction following photorefractive keratectomy for myopia. Hamberg-Nyström H, et al. **J Refract Surg** 1995 May–Jun;11(3 Suppl):S335–6

Re: A survey of marginal wheelchair users JRRD 31(4):297–302 [letter] Ham R. **J Rehabil Res Dev** 1995 May; 32(2):xvi

Patients' perspective on the process of change in substance abuse treatment. Lovejoy M, et al. **J Subst Abuse Treat** 1995 Jul–Aug;12(4):269–82

Women in recovery. Their perceptions of treatment effectiveness. Nelson-Zlupko L, et al.
J Subst Abuse Treat 1996 Jan–Feb;13(1):51–9

Coverage and quality of natal and postnatal care: women's perceptions, Saudi Arabia. Baldo MH, et al.
J Trop Pediatr 1995;41 Suppl 1:30–7

Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction. Gheorghiu S, et al. **J Urol** 1996 Jul;156(1):80–1

Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. Kaplan SA, et al. **J Urol** 1996 Apr;155(4):1305–8

Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. Limoge JP, et al. **J Urol** 1996 Apr;155(4):1276–9

Satisfaction with penile appearance after hypospadias surgery: the patient and surgeon view. Mureau MA, et al.
J Urol 1996 Feb;155(2):703–6

Functional outcome after surgical treatment for intermittent claudication. Zannetti S, et al. **J Vasc Surg** 1996 Jul; 24(1):65–73

Does medical treatment mean patient benefit? Pickering WG.
Lancet 1996 Feb 10;347(8998):379–80

Randomised, controlled trial of efficacy of midwife-managed care [see comments] Turnbull D, et al. **Lancet** 1996 Jul 27;348(9022):213–8. Comment in: Lancet 1996 Jul 27;348(9022):208.

Women's responses to Depo-Provera. Comerford Freda M, et al. **MCN Am J Matern Child Nurs** 1996 Jul–Aug; 21(4):183–6

The importance of sense of community on people's perceptions of their health-care experiences. Ahern MM, et al. **Med Care** 1996 Sep;34(9):911–23

Does sponsorship matter in patient satisfaction surveys? A randomized trial. Etter JF, et al. **Med Care** 1996 Apr; 34(4):327–35

Self-report measures for assessing treatment outcomes in cardiac surgery patients. McCarthy MJ Jr, et al.
Med Care 1995 Oct;33(10 Suppl):OS76–85

Patient satisfaction with health care decisions: the satisfaction with decision scale. Holmes-Rovner M, et al.
Med Decis Making 1996 Jan–Mar;16(1):58–64

Coronary heart disease complaints against health care personnel in Finland. Aaltonen S, et al. **Med Law** 1995; 14(3–4):207–14

Capturing patients' perceptions in the computer-based patient record: essential prerequisites to the measurement of health-related outcomes. Holzemer WL, et al. **Medinfo** 1995;8 Pt 1:266–70

A patient satisfaction survey: a basis for changing delivery of services. Gonzalves PE, et al. **Mil Med** 1995 Oct; 160(10):486–8

A trial of increased access to primary care [letter] Adams WL. **N Engl J Med** 1996 Sep 19;335(12):897; discussion 897–8

Outcomes and costs of care for acute low back pain [letter; comment] Barrett S. **N Engl J Med** 1996 Feb 1;334(5):329; discussion 330. Comment on: N Engl J Med 1995 Oct 5;333(14):913–7.

Patients' perception of health on renal replacement therapy: evaluation using a new instrument. Khan IH, et al.
Nephrol Dial Transplant 1995;10(5):684–9

Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S–47S (31 ref.)

Impact of silicone implants on the lives of women with breast cancer. Coleman EA, et al. **Oncol Nurs Forum** 1995 Nov–Dec;22(10):1493–500

Patient preferences and comparative ocular responses to rigid and soft contact lenses. Fonn D, et al. **Optom Vis Sci** 1995 Dec;72(12):857–63

Patients equate quality with service. Lance MP. **Pa Med** 1995 Jun;98(6):16–7

Fine needle sampling without aspiration. Kumarasinghe MP, et al. **Pathology** 1995 Oct;27(4):330–2

The efficacy of breast augmentation: breast size increase, patient satisfaction, and psychological effects [letter; comment] Bates RL. **Plast Reconstr Surg** 1995 Oct; 96(5):1237–8. Comment on: Plast Reconstr Surg 1994 Dec;94(7):958–69.

Rhinoplasty patients' critical self-evaluations of their noses. Bonne OB, et al. **Plast Reconstr Surg** 1996 Sep;98(3):436–9; discussion 440–1

Reduction mammaplasty: long-term efficacy, morbidity, and patient satisfaction. Davis GM, et al.
Plast Reconstr Surg 1995 Oct;96(5):1106–10

Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Fee-Fulkerson K, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1420–6

Predictors of and satisfaction with bilateral prophylactic mastectomy. Stefanek ME, et al. **Prev Med** 1995 Jul; 24(4):412–9

Computers in the examining room: the patient's perspective. Aydin CE, et al.
Proc Annu Symp Comput Appl Med Care 1995;:824–8

HealthDesk for Hemophilia: an interactive computer and communications system for chronic illness self-management. Carl F, et al.
Proc Annu Symp Comput Appl Med Care 1995;:829–33

Pain, pain relief and accuracy of their recall after cardiac surgery. Valdix SW, et al. **Prog Cardiovasc Nurs** 1995 Summer;10(3):3–11

Consumer vs. patient [letter] Bosley W. **Psychiatr Serv** 1995 Jul;46(7):732

Personal accounts. Can institution-induced anger prolong hospitalization for patients who repress anger? Watson BE.
Psychiatr Serv 1996 Apr;47(4):363–4

Initial assessment of hospital treatment by patients with paranoid schizophrenia: a predictor of outcome. Bröker M, et al. **Psychiatry Res** 1995 Sep 8;58(1):77–81

Some interpersonal and attitudinal factors characterizing patients satisfied with medical care. Twemlow SW, et al. **Psychol Rep** 1995 Aug;77(1):51–9

Patient satisfaction at health centres in Trinidad and Tobago. Singh H, et al. **Public Health** 1996 Jul;110(4):251–5

Characteristics of pregnant women, utilization, and satisfaction with prenatal services in St. Petersburg, Russia. Dennis LI, et al. **Public Health Nurs** 1995 Dec;12(6):374–7

Development of the home care client satisfaction instrument. Westra BL, et al. **Public Health Nurs** 1995 Dec;12(6):393–9

Life style intervention in general practice: effects on psychological well-being and patient satisfaction. Meland E, et al. **Qual Life Res** 1996 Jun;5(3):348–54

Well-being and treatment satisfaction in adults with diabetes: a Swedish population-based study. Wredling R, et al.
Qual Life Res 1995 Dec;4(6):515–22

Predictors of patient satisfaction with regional anesthesia. De Andrés J, et al. **Reg Anesth** 1995 Nov–Dec;20(6):498–505

A comparison of the clinical efficacy and patient acceptability of terbutaline Turbuhaler and salbutamol Rotahaler, in adult patients with asthma. Gioulekas D, et al.
Respir Med 1996 Apr;90(4):205–9

Patient satisfaction with information provided at an outpatient clinic for respiratory diseases. Papagiannis A, et al. **Respir Med** 1995 Nov;89(10):673–6

Assessment of patient's benefit from rhinoplasty. Stewart EJ, et al. **Rhinology** 1996 Mar;34(1):57–9

A long-term follow-up of 108 vasectomized men. Good counselling routines are important. Ehn BE, et al.
Scand J Urol Nephrol 1995 Dec;29(4):477–81

A medical audit and patient survey of hysterectomies performed for menstrual disorders. Roberts RN, et al.
Scott Med J 1996 Apr;41(2):44–6

Patients' opinions: having a say in epilepsy service provision down under. Averis AK. **Seizure** 1996 Mar;5(1):57–61

Living with epilepsy: a qualitative study investigating the experiences of young people attending outpatients clinics in Leicester. Wilde M, et al. **Seizure** 1996 Mar;5(1):63–72

Age and health status in a patient satisfaction survey. Cohen G. **Soc Sci Med** 1996 Apr;42(7):1085–93

Correlates of health care satisfaction in inner-city patients with hypertension and chronic renal insufficiency. Harris LE, et al. **Soc Sci Med** 1995 Dec;41(12):1639–45

Pre-marital genetic counselling to consanguineous couples: attitudes, beliefs and decisions among counselled, noncounselled and unrelated couples in Israel. Shiloh S, et al. **Soc Sci Med** 1995 Nov;41(9):1301–10

Quality of care: a comparison of preferences between medical specialists and patients with chronic diseases. van der Waal MA, et al. **Soc Sci Med** 1996 Mar;42(5):643–9

Clients' views of social work services in the hospital setting in Israel. Auslander GK, et al. **Soc Work Health Care** 1996; 22(3):39–57

Predictors of patient and proxy satisfaction with discharge plans. Showers N, et al. **Soc Work Health Care** 1995; 22(1):19–35

Breast forms after mastectomy--patient's issues. Münstedt K, et al. **Support Care Cancer** 1995 Nov;3(6):428–31

Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Klein EA, et al. **Urology** 1996 Aug;48(2):269–76

Patient satisfaction with current impotence therapy. Dewire DM, et al. **Wis Med J** 1995 Oct;94(10):542–4

[Patient satisfaction with treatment at the Psychiatric Hospital in Brno] Machü V, et al. **Ceska Slov Psychiatr** 1995 Nov;91(5):270–6 (Eng. Abstr.) **(Cze)**

[Patient assessment in ambulatory surgery. A questionnaire study] Nielsen TR, et al. **Ugeskr Laeger** 1996 Mar 25; 158(13):1823–6 (Eng. Abstr.) **(Dan)**

[Quality of psychiatric treatment. Determined by patient satisfaction] Tehrani ES, et al. **Ugeskr Laeger** 1996 Jan 8; 158(2):158–62 (Eng. Abstr.) **(Dan)**

[Patient evaluation of the quality of anesthesia management] Penon C, et al. **Ann Fr Anesth Reanim** 1995;14(4):374–5 (Eng. Abstr.) **(Fre)**

[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M.
J Gynecol Obstet Biol Reprod (Paris) 1995;24 Suppl 1:116–9 (22 ref.) **(Fre)**

[Patient satisfaction in the ambulatory setting: validation of a scale and identification of associated factors] Perneger TV, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):864–71 (Eng. Abstr.) **(Fre)**

[Subjective assessment of quality of life, pain and surgical success after laparotomy for Crohn disease] Post S, et al.
Chirurg 1995 Aug;66(8):800–6 (Eng. Abstr.) **(Ger)**

[The determination of patient satisfaction as a part of quality management in the hospital] Klotz T, et al.
Dtsch Med Wochenschr 1996 Jul 12;121(28–29):889–95 (Eng. Abstr.) **(Ger)**

[Donor site defect after removal of free and pedicled forearm flaps: functional and cosmetic results] Hülsbergen-Krüger S, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):70–5 (Eng. Abstr.) **(Ger)**

[Subjective and objective evaluation of the outcome of rhinoplasty. A retrospective study] Gräber I, et al.
Laryngorhinootologie 1995 Aug;74(8):495–9 (Eng. Abstr.) **(Ger)**

[The Patient Satisfaction Questionnaire: a suitable tool for quality control in the physician-patient relationship?] Langewitz W, et al.
Psychother Psychosom Med Psychol 1995 Sep–Oct; 45(9–10):351–7 (Eng. Abstr.) **(Ger)**

[Perception of patients in magnetic resonance tomography] Heuck A, et al. **Rontgenpraxis** 1995 Dec;48(12):349–52 **(Ger)**

[Individual therapy goals: on outcome documentation of inpatient psychotherapy from the patient and therapist viewpoint] Heuft G, et al.
Z Klin Psychol Psychopathol Psychother 1996;44(2):186–99 (Eng. Abstr.) **(Ger)**

[Satisfaction among patients of a homeopathic clinic] Peer O, et al. **Harefuah** 1996 Jan 15;130(2):86–9, 143 (Eng. Abstr.) **(Heb)**

[Medical fees from the radiologist's viewpoint (satisfaction instead of gratitude) (letter)] Fehérvári S. **Orv Hetil** 1996 Jan 21;137(3):158 **(Hun)**

[Life satisfaction and its related factors among institutionalized patients at a Hansen's disease sanatorium] Kataoka M, et al. **Nippon Eiseigaku Zasshi** 1995 Dec; 50(5):939–46 (Eng. Abstr.) **(Jpn)**

[Emergency hospital admissions. A survey and consumer assessment of conditions in an emergency department admission office] Engebråten O, et al.
Tidsskr Nor Laegeforen 1995 Sep 30;115(23):2917–20 (Eng. Abstr.) **(Nor)**

[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?] Engebråten O, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2913–6 (Eng. Abstr.) **(Nor)**

[What is the benefit for patients and their parents in a stay at the Geilomo pediatric hospital?] Grangård EH.
Tidsskr Nor Laegeforen 1996 Feb 10;116(4):536 **(Nor)**

[Results of radial keratotomy as evaluated by patients] Kałużny JJ. **Klin Oczna** 1995 Mar–Apr;97(3–4):93–4 (Eng. Abstr.) **(Pol)**

[Influence of the organizational model on user satisfaction] Delgado A, et al. **Aten Primaria** 1995 Oct 15;16(6):314–8, 320–1 (Eng. Abstr.) **(Spa)**

[User satisfaction with primary care teams: related to doctor's

training in the field of physician–patient relations] Iragüen Eguskiza P, et al. **Aten Primaria** 1995 Nov 15;16(8):485–90 (Eng. Abstr.) **(Spa)**

–Factors of dissatisfaction with health care. A Delphi study– Maderuelo Fernández JA, et al. **Aten Primaria** 1996 Mar 31;17(5):348–52 (Eng. Abstr.) **(Spa)**

[Evaluation of the acceptability of a formula for children with diarrhea in a marginal community] Hernández Ramírez BD, et al. **G E N** 1995 Apr–Jun;49(2):123–31 (Eng. Abstr.) **(Spa)**

[Patient satisfaction (editorial; comment)] Bohigas L. **Gac Sanit** 1995 Sep–Oct;9(50):283–6. Comment on: Gac Sanit 1995 Sep–Oct;9(50):311–5. **(Spa)**

[Measurement of health care satisfaction: Andalucia 1984–1992 (see comments)] Rodríguez–Legido C. **Gac Sanit** 1995 Sep–Oct;9(50):311–5 (Eng. Abstr.). Comment in: Gac Sanit 1995 Sep–Oct;9(50):283–6. **(Spa)**

[Methods of user participation in the evaluation and improvement of the quality of health services] Saturno Hernández PJ. **Rev Esp Salud Publica** 1995 Mar–Apr; 69(2):163–75 (Eng. Abstr.) **(Spa)**

[Can health services learn something from industry? Read issue 51–52/95! What happened since?] Blomgren B. **Lakartidningen** 1996 Jun 5;93(23):2219–20 **(Swe)**

[Soften punishment in malpractive cases! Prevent occurrence of a culture of dissatisfaction and revenge!] Jacobsson L. **Lakartidningen** 1995 Nov 29;92(48):4534, 4539 **(Swe)**

[Utilization of patient questionnaires. A new promising method tested at three different ophthalmology clinics] Westlund AH, et al. **Lakartidningen** 1996 May 22; 93(21):2078–81 **(Swe)**

ECONOMICS

The costs and benefits of asking patients for their opinions about general practice. Hearnshaw H, et al. **Fam Pract** 1996 Feb;13(1):52–8

LEGISLATION & JURISPRUDENCE

Seven ways to avoid frivolous malpractice claims. Muller J. **Indiana Med** 1996 Jan–Feb;89(1):22–4

STATISTICS & NUMERICAL DATA

A study of patient satisfaction and adherence to preventive care practice guidelines [see comments] Weingarten SR, et al. **Am J Med** 1995 Dec;99(6):590–6. Comment in: Am J Med 1995 Dec;99(6):588–9.

The effect of developing patient compendiums for critical pathways on patient satisfaction. Shulkin DJ, et al. **Am J Med Qual** 1996 Spring;11(1):43–5

Postmastectomy reconstruction: comparative analysis of the psychosocial, functional, and cosmetic effects of transverse rectus abdominis musculocutaneous flap versus breast implant reconstruction. Cederna PS, et al. **Ann Plast Surg** 1995 Nov;35(5):458–68

A survey of post–operative care after day case surgery. Wedderburn AW, et al. **Ann R Coll Surg Engl** 1996 Mar; 78(2 Suppl):70–1

Consumer satisfaction with a rehabiiitation mobile outreach program. Wilson KG, et al. **Arch Phys Med Rehabil** 1995 Oct;76(10):899–904

After–hours telephone calls in a family practice residency: volume, seriousness, and patient satisfaction. Greenhouse DL, et al. **Fam Med** 1995 Sep;27(8):525–30

Patient expectations: what do primary care patients want from the GP and how far does meeting expectations affect patient satisfaction? Williams S, et al. **Fam Pract** 1995 Jun; 12(2):193–201

All payer, single payer, managed care, no payer: patients' perspectives in three nations. Donelan K, et al. **Health Aff (Millwood)** 1996 Summer;15(2):254–65

Managed care ... most recipients enrolled in Medicare HMOs are generally satisfied with their care [news] **Hosp Health Netw** 1996 Jan 5;70(1):15–6

Fewer gripes from Medicare HMO patients [news] **Hosp Health Netw** 1996 May 5;70(9):13

Health plan satisfaction and risk of disenrollment among social/HMO and fee–for–service recipients. Newcomer R, et al. **Inquiry** 1996 Summer;33(2):144–54

Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. Lieberman JR, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):835–8

Application of multivariable optimal discriminant analysis in general internal medicine. Yarnold PR, et al. **J Gen Intern Med** 1995 Nov;10(11):601–6

How wide is the gap in defining quality care? Comparison of patient and nurse perceptions of important aspects of patient care. Young WB, et al. **J Nurs Adm** 1996 May; 26(5):15–20

Consumer satisfaction with nursing care in a rural community hospital emergency department. Clark CA, et al. **J Nurs Care Qual** 1996 Jan;10(2):49–57

Evaluation of Medicaid managed care. Satisfaction, access, and use. Sisk JE, et al. **JAMA** 1996 Jul 3;276(1):50–5

Consumer–directed models of personal care: lessons from Medicaid. Doty P, et al. **Milbank Q** 1996;74(3):377–409

Factors predicting patients' satisfaction with managed mental health care. Pickett SA, et al. **Psychiatr Serv** 1995 Jul; 46(7):722–3

PATIENT SCHEDULES see **APPOINTMENTS AND SCHEDULES**

PATIENT SELECTION

Sonographic assessment of the vaginal vault following hysterectomy [letter; comment] Neri A, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):192–3. Comment on: Acta Obstet Gynecol Scand 1995 Mar;74(3):220–3.

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

Targeting elders for geriatric evaluation and management: reliability, validity, and practicality of a questionnaire. Boult C, et al. **Aging (Milano)** 1995 Jun;7(3):159–64

Angiographic selection criteria for living related liver transplant donors. Kostelic JK, et al. **AJR Am J Roentgenol** 1996 May;166(5):1103–8

Angiographic correlates of lesion relevance and suitability for percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in the Bypass Angioplasty Revascularization Investigation study (BARI). Botas J, et al. **Am J Cardiol** 1996 Apr 15;77(10):805–14

Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal [see comments] Finkelstein MO, et al. **Am J Public Health** 1996 May;86(5):691–5. Comment in: Am J Public Health 1996 May;86(5):622–3.

Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples [see comments] Finkelstein MO, et al. **Am J Public Health** 1996 May; 86(5):696–705. Comment in: Am J Public Health 1996 May;86(5):622–3.

Patient selection and treatment modalities for chronic anal fissure. Sharp FR. **Am J Surg** 1996 May;171(5):512–5

Organ transplantation from victims of carbon monoxide poisoning [letter; comment] Hantson P, et al. **Ann Emerg Med** 1996 May;27(5):673–4. Comment on: Ann Emerg Med 1995 Nov;26(5):652–5.

Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Vernon SW, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:300

Radiological predictors of response to renovascular reconstructive surgery. Lamawansa MD, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):337–41

Lung volume reduction surgery. Case selection, operative technique, and clinical results. Daniel TM, et al. **Ann Surg** 1996 May;223(5):526–31; discussion 532–3

Preoperative assessment of the high–risk patient for lung resection. Pate P, et al. **Ann Thorac Surg** 1996 May; 61(5):1494–500

Patient selection for mechanical bridging to transplantation. Stevenson LW. **Ann Thorac Surg** 1996 Jan;61(1):380–7; discussion 391–2

Coronary operations in octogenarians: can we select the patients? [editorial; comment] Weintraub WS. **Ann Thorac Surg** 1995 Oct;60(4):875–6. Comment on: Ann Thorac Surg 1995 Oct;60(4):1033–7. Comment on: Ann Thorac Surg 1995 Oct;60(4):1038–43.

Bone marrow transplant for sickle cell disease—an update. Davies SC, et al. **Arch Dis Child** 1996 Jul;75(1):3–6

Recruiting patients to clinical trials: lessons from studies of growth hormone treatment in renal failure [letter; comment] Postlethwaite RJ, et al. **Arch Dis Child** 1996 Jan; 74(1):91. Comment on: Arch Dis Child 1995 Jul;73(1):30–5.

Gender differences in device therapy for malignant ventricular arrhythmias. Horton HL, et al. **Arch Intern Med** 1995 Nov 27;155(21):2342–5

Referral for dialysis in Ontario. Mendelssohn DC, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2473–8

Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Pierson SH, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):717–21

Selection criteria for preoperative endoscopic retrograde cholangiopancreatography in the laparoscopic era. Robertson GS, et al. **Arch Surg** 1996 Jan;131(1):89–94

Patient selection for hepatic resection of colorectal metastases. Wanebo HJ, et al. **Arch Surg** 1996 Mar; 131(3):322–9

Use of historical marker data for assessing treatment effects in phase I/II trials when subject selection is determined by baseline marker level. Lin HM, et al. **Biometrics** 1995 Sep;51(3):1053–63

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter] Estey E, et al. **Blood** 1996 Jul 15;88(2):756

Patients often present too late for inclusion in trials [letter; comment] Dische S, et al. **BMJ** 1995 Dec 9;311(7019):1570. Comment on: BMJ 1995 May 20;310(6990):1277–8.

French drug lottery idea causes uproar [news] Dorozynski A. **BMJ** 1996 Mar 9;312(7031):599–600

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. French JK, et al. **BMJ** 1996 Jun 29;312(7047):1637–41

Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. The European Secondary Prevention Study Group. Ketley D, et al. **Br Heart J** 1995 Sep;74(3):224–8

Dobutamine echocardiography and thallium–201 imaging predict functional improvement after revascularisation in severe ischaemic left ventricular dysfunction. Senior R, et al. **Br Heart J** 1995 Oct;74(4):358–64

Postural control and vestibulospinal function in patients selected for cochlear implantation. Magnusson M, et al. **Br J Audiol** 1995 Aug;29(4):231–6

Appendiceal mass: interval appendicectomy should not be the rule. Adalla SA. **Br J Clin Pract** 1996 Apr–May; 50(3):168–9

Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres. Hjorth M, et al. **Br J Haematol** 1995 Sep;91(1):109–15

Relative erythroid hyperplasia in the bone marrow at diagnosis of aplastic anaemia: a predictive marker for a favourable response to cyclosporine therapy. Nakao S, et al. **Br J Haematol** 1996 Feb;92(2):318–23

Practical management of treatment–resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):501–6 (58 ref.)

Decision–making in surgery: splenectomy. Carroll A, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):147–9

Patient selection may be the key for the success of shared care for glaucoma [letter] Rao GP, et al. **Br J Ophthalmol** 1996 Apr;80(4):381

Dilemmas in care of the elderly. **Can Fam Physician** 1996 May;42:861

Assessing appropriateness of treatment: a case study of transplantation in older patients with congestive heart failure. Montague T, et al. **Can J Cardiol** 1996 Jan; 12(1):47–52 (33 ref.)

Cholecystectomy also on rise in Alberta [letter] Hilsden RJ, et al. **Can Med Assoc J** 1996 Jul 15;155(2):161–2

Preventive therapies: weighing the pros and cons [editorial; comment] Laupacis A. **Can Med Assoc J** 1996 May 15; 154(10):1510–2. Comment on: Can Med Assoc J 1996 May 15;154(10):1493–9.

Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.). Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.

Factor V Leiden: who should be tested? [editorial; comment] Solymoss S. **Can Med Assoc J** 1996 Aug 1;155(3):296–8. Comment on: Can Med Assoc J 1996 Aug 1;155(3):285–9.

Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. Rimer BK, et al. **Cancer** 1996 Jun 1; 77(11):2348–55

Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Yeomans–Kinney A, et al. **Cancer** 1995 Jul 1;76(1):46–56

Local surgical treatment of rectal cancer [see comments] Baron PL, et al. **Cancer Invest** 1995;13(6):612–6 (22 ref.) . Comment in: Cancer Invest 1995;13(6):660–1.

Timing of adult cardiac transplantation. Stevenson LW. **Cardiologia** 1996 Feb;41(2):117–28

Need for change in female sterilisation procedure and selection [letter] Sirisena J, et al. **Ceylon Med J** 1995 Sep; 40(3):128

Patient selection for uvulopalatopharyngoplasty [letter] Carney AS, et al. **Chest** 1996 Sep;110(3):864

Three hundred patients referred for lung transplantation. Experiences of the Dutch Lung Transplantation Program. Groningen Lung Transplantation Group. Mannes GP, et al. **Chest** 1996 Feb;109(2):408–13

Volume reduction surgery. How selective should we be? [letter] Miller JD, et al. **Chest** 1996 Apr;109(4):1129–30

Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. Torre–Amione G, et al. **Chest** 1996 Jan;109(1):223–32 (63 ref.)

Screening scale predicts patients successfully receiving long–term implantable left ventricular assist devices. Oz MC, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II169–73

Target heart failure populations for newer therapies. Stevenson LW, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II174–81

Preoperative selection of patients with severely impaired left ventricular function for coronary revascularization. Role of low–dose dobutamine echocardiography and exercise–redistribution–reinjection thallium SPECT. Vanoverschelde JL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II37–44

Endoscopic adrenalectomy: the adrenals under the scope? Cuesta MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):349–51

'Subclinical hypothyroidism': to treat or not to treat, that is the question [comment] Franklyn J. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):443–4. Comment on: Clin Endocrinol (Oxf) 1995 Oct;43(4):445–9.

Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)

Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)

Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)

Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)

Maximizing recruitment efforts in a drug lipid–lowering trial

with dietary intervention to lower LDL cholesterol. Dolecek TA, et al. **Control Clin Trials** 1996 Feb;17(1):33–45

Clinical trial enrollers vs. nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Gorkin L, et al. **Control Clin Trials** 1996 Feb; 17(1):46–59

Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. Kornhuber J, et al. **Convuls Ther** 1995 Jun;11(2):104–9

Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. Dellavalle A, et al. **Coron Artery Dis** 1995 Jun; 6(6):513–20

Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. Hunt SA, et al. **Crit Care Med** 1996 Sep;24(9):1599–601

Management of severe preeclampsia. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):110–3

Should HIV status alter indications for hemorrhoidectomy? Hewitt WR, et al. **Dis Colon Rectum** 1996 Jun;39(6):615–8

Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? [editorial] Lynch HT. **Dis Colon Rectum** 1996 Jan;39(1):109–10

Patient selection is integral to the success of the electrically stimulated gracilis neosphincter [letter; comment] Mander BJ, et al. **Dis Colon Rectum** 1996 Jun;39(6):712–3. Comment on: Dis Colon Rectum 1995 Dec;38(12):1331–3.

Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? [see comments] Perrone F, et al. **Eur J Cancer** 1996 Jan;32A(1):41–6. Comment in: Eur J Cancer 1996 Jan;32A(1):7–8.

Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. Sibbering DM, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2191–5

Rational antidepressant selection in the elderly. Christensen DD. **Geriatrics** 1995 Oct;50 Suppl 1:S41–50 (41 ref.)

The use of operative laparoscopy in determining eligibility for pelvic exenteration in patients with recurrent cervical cancer. Plante M, et al. **Gynecol Oncol** 1995 Dec; 59(3):401–4

Self-funding and community care admissions to nursing homes in Aberdeen. Newnham DM, et al. **Health Bull (Edinb)** 1996 Jul;54(4):301–6

Trends in pacemaker mode prescription 1984–1994: a single centre study of 3710 patients. Aggarwal RK, et al. **Heart** 1996 May;75(5):518–21

Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. Haywood GA, et al. **Heart** 1996 May;75(5):455–62

Cigarette smoking in British men and selection for coronary artery bypass surgery [see comments] Morris RW, et al. **Heart** 1996 Jun;75(6):557–62. Comment in: Heart 1996 Jun;75(6):544–5.

Coronary artery bypass surgery in smokers [comment] Shelley E. **Heart** 1996 Jun;75(6):544–5. Comment on: Heart 1996 Jun;75(6):557–62.

Colour doppler valvar and subvalvar flow diameter imaging versus echo score in mitral stenosis: comparison with type of surgery. Veyrat C, et al. **Heart** 1996 May;75(5):486–91

Technology. Finding the right clinical trial—fast. Morall K. **Hosp Health Netw** 1996 Feb 5;70(3):48

CPR: a plea for patient selection [editorial] Combs AH. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):13–6

Balloon mitral valvotomy: an autopsy study. Deshpande J, et al. **Int J Cardiol** 1995 Nov 10;52(1):67–76

Sample selection. Orav J. **Int J Qual Health Care** 1995 Sep; 7(3):285–7

Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Stock RG, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1; 33(4):815–21

International variation in intervention rates. What are the implications for patient selection? Black N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):719–32

Awaiting heart transplantation—a race for survival? [editorial; comment] Aravot D. **Isr J Med Sci** 1996 May; 32(5):316–8. Comment on: Isr J Med Sci 1996 May;32(5):282–7.

Lung transplantation: a rational vision [editorial; comment] Yellin A. **Isr J Med Sci** 1996 May;32(5):318–20. Comment on: Isr J Med Sci 1996 May;32(5):292–6.

Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. Harrison K, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):386–90

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. Califf RM, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1007–19 (68 ref.)

Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Newby LK, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):625–32

Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. Jacquet P, et al. **J Am Coll Surg** 1995 Dec;181(6):530–8

When to transplant: Recipient selection for heart transplantation. Grady KL. **J Cardiovasc Nurs** 1996 Jan; 10(2):58–70 (55 ref.)

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)

Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104–12 (43 ref.)

Selective screening for dyslipidemia in a Canadian population. Reeder BA, et al. **J Clin Epidemiol** 1996 Feb; 49(2):217–22

Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes. Morsy MA, et al. **J Clin Invest** 1996 Feb 1;97(3):826–32

Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials. Aaronson NK, et al. **J Clin Oncol** 1996 Mar; 14(3):984–96

Reducing patient eligibility criteria in cancer clinical trials. George SL. **J Clin Oncol** 1996 Apr;14(4):1364–70 (24 ref.)

Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)

Framework for the selection of subjects in human gene therapy and diagnostic trials. Modell SM. **J Investig Med** 1996 Jun;44(5):228–37 (59 ref.)

The use of a CT scan to predict the feasibility of decompression of the first segment of the facial nerve via the transattical approach. Pellicer M, et al. **J Laryngol Otol** 1995 Oct;109(10):935–40

On giving preference to prior volunteers when allocating organs for transplantation [editorial; comment] Gillon R. **J Med Ethics** 1995 Aug;21(4):195–6. Comment on: J Med Ethics 1995 Aug;21(4):199–204.

Join the club: a modest proposal to increase availability of donor organs [see comments] Jarvis R. **J Med Ethics** 1995 Aug;21(4):199–204. Comment in: J Med Ethics 1995 Aug;21(4):195–6.

These sorts of people don't do very well': race and allocation of health care resources. Lowe M, et al. **J Med Ethics** 1995 Dec;21(6):356–60

An automated patient registration and treatment randomization system. Papaconstantinou C, et al. **J Med Syst** 1995 Dec;19(6):445–56

Recruiting minorities into clinical trials: toward a participant-friendly system [see comments] Swanson GM, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1747–59 (107 ref.). Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377.

Head injury [letter; comment] Coakley F, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):358. Comment on: J Neurol Neurosurg Psychiatry 1995 May;58(5):526–39.

Psychiatric disorders in candidates for surgery for epilepsy. Manchanda R, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):82–9

Carotid endarterectomy: a nursing perspective. Leonard A. **J Neurosci Nurs** 1996 Apr;28(2):99

Controversies in the management of carotid stenosis. Macdonald RL. **J Neurosci Nurs** 1996 Apr;28(2):93–8 (33 ref.)

Guidelines for client selection in the home birth midwifery practice. Vedam S, et al. **J Nurse Midwifery** 1995 Nov-Dec;40(6):508–21

Evaluation of criteria for uvulopalatoplasty (UPP) patient selection using acoustic analysis of oronasal respiration (SNAP testing). Weingarten CZ, et al. **J Otolaryngol** 1995 Dec;24(6):352–7

Family research: consideration of who to study. Lynn MR. **J Pediatr Nurs** 1995 Dec;10(6):383–4

Selection biases during recruitment of patients and relatives for a family study in the elderly. Heun R, et al. **J Psychiatr Res** 1995 Nov-Dec;29(6):491–504

A pilot study of the use of clinical guidelines to determine appropriateness of patient placement on intensive and high dependency care unit. Donnelly P, et al. **J Public Health Med** 1995 Sep;17(3):305–10

Transplant candidate's clinical status rather than right ventricular function defines need for univentricular versus biventricular support. Kormos RL, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):773–82; discussion 782–3

Transcervical gunshot injuries: mandatory operation is not necessary. Demetriades D, et al. **J Trauma** 1996 May; 40(5):758–60

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. Parra RO, et al. **J Urol** 1996 Feb;155(2):612–5

How should cadaver kidneys be allocated? Chang RW. **Lancet** 1996 Aug 17;348(9025):453–4

Cadaver kidneys: the rules of rationing. Guttmann RD. **Lancet** 1996 Aug 17;348(9025):456–7

Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage [see comments] Rockall TA, et al. **Lancet** 1996 Apr 27; 347(9009):1138–40. Comment in: Lancet 1996 Apr 27;347(9009):1130. Comment in: Lancet 1996 Jul 20;348(9021):201. Comment in: Lancet 1996 Jul 20;348(9021):201–2.

The politics of grafting cadaver kidneys. Starzl TE, et al. **Lancet** 1996 Aug 17;348(9025):454–5

Variations by specialty in physician ratings of the appropriateness and necessity of indications for procedures. Kahan JP, et al. **Med Care** 1996 Jun;34(6):512–23

The use of cost-value analysis to judge patients' right to treatment. Nord E. **Med Law** 1995;14(7-8):553–8

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7-8):531–41 (20 ref.)

Liver transplantation. Patient selection and organ allocation. Trotter JF, et al. **N C Med J** 1996 Jul-Aug;57(4):249–52

The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06 [see comments] Christian MC, et al. **N Engl J Med** 1995 Nov 30;333(22):1469–74. Comment in: N Engl J Med 1995 Nov 30;333(22):1496–8.

Survey of patient selection for cadaveric renal transplantation in the United Kingdom. McMillan MA, et al. **Nephrol Dial Transplant** 1995;10(6):855–8

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)

Changes in laryngeal preservation study help increase accrual [news] **Oncology (Huntingt)** 1995 Nov;9(11):1220

Evaluation of life expectancy in selection of patients undergoing percutaneous cervical cordotomy or subarachnoid phenol block for pain control of costopleural syndrome [letter; comment] Orlandini G. **Pain** 1995 Jun; 61(3):492–3. Comment on: Pain 1994 Sep;58(3):325–30.

Usefulness of [18F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Snead OC 3rd, et al. **Pediatr Neurol** 1996 Feb;14(2):98–107

Patient selection caveats [letter] Hutchison RL. **Plast Reconstr Surg** 1996 Sep;98(3):575

Selective or universal neonatal BCG immunization: what policy for a district with a high incidence of tuberculosis? Pharoah PD, et al. **Public Health** 1996 May;110(3):179–83

Matching versus cultural competence in research: methodological considerations. Sawyer L, et al. **Res Nurs Health** 1995 Dec;18(6):557–67

Selection criteria for pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Jul;90(6):317–22 (36 ref.)

A way to select on clinical grounds patients with high risk for pulmonary embolism: a retrospective analysis in a nested case-control study. Donnamaria V, et al. **Respiration** 1995;62(4):201–4

Multidisciplinary experience in the selection of patients for tubal sterilization. Barini R, et al. **Rev Paul Med** 1995 Jan-Feb;113(1):715–20 (8 ref.)

The selection of infants for surfactant replacement therapy under conditions of limited financial resources [see comments] Ballot DE, et al. **S Afr Med J** 1995 Jul; 85(7):640–3. Comment in: S Afr Med J 1995 Nov;85(11):1192, 1195–6.

Identifying patients for research in general practice [letter] Olesen F, et al. **Scand J Prim Health Care** 1996 Mar; 14(1):62–3

Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167–73 (37 ref.)

Selection and treatment of candidates for heart transplantation. Costanzo MR. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):113–25 (88 ref.)

Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)

Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS. **Semin Urol Oncol** 1995 Aug;13(3):204–14 (47 ref.)

Decisions regarding the order of opening multiple high-risk cases: a pilot study in an urban hospital. Holden G, et al. **Soc Work Health Care** 1995;22(1):37–55

A personal view of some controversies in allocating treatment to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661–74 (41 ref.). Comment in: Stat Med 1996 Jan 15;15(1):113–6.

An application of decision theory to patient screening for an autologous tumour vaccine trial. Shannon WD, et al. **Stat Med** 1995 Oct 15;14(19):2099–110

Selection of patients for transesophageal echocardiography after stroke and systemic embolic events. Role of transthoracic echocardiography. Leung DY, et al. **Stroke** 1995 Oct;26(10):1820–4

"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11–23 (42 ref.)

Magnetic resonance imaging-derived parameter of portal flow predicts volume-mediated pulmonary hypertension in liver transplantation candidates. Kuo PC, et al. **Surgery** 1995 Oct;118(4):685–91; discussion 691–2

Patient selection for breast conservation therapy with magnification mammography. Morrow M, et al. **Surgery** 1995 Oct;118(4):621–6

The ultimate lottery. Life, death, and transplant surgeons. BeSaw L. **Tex Med** 1996 Jan;92(1):30–5

Dynamic cardiomyoplasty: indication, surgical technique, and results. Lange R, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):243–51

Referral for lung transplantation: experience of a Birmingham Adult Cystic Fibrosis Centre between 1987 and 1994. Ryan PJ, et al. **Thorax** 1996 Mar;51(3):302–5

Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation. Godfrey-Faussett P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):354–8

Infectious disease markers in homologous blood and 'selected' autologous blood suitable for homologous use [letter] Mazzei C, et al. **Transfus Med** 1995 Dec;5(4):303–4

Heart transplant candidates at high risk can be identified at the time of initial evaluation. Deng MC, et al. **Transpl Int** 1996;9(1):38–45

Guidelines for donor selection and an overview of the donor operation in living related liver transplantation. Morimoto T, et al. **Transpl Int** 1996;9(3):208–13

Should we revisit recipient selection? Johnson RW. **Transplant Proc** 1996 Feb;28(1):36–41

Evaluation of a regional cadaver donor kidney allocation policy. Wujciak T, et al. **Transplant Proc** 1996 Feb; 28(1):234–5

Patient selection for experimental adjuvant therapy after radical prostatectomy [letter; comment] Douglas TH, et al. **Urology** 1996 Feb;47(2):284–5. Comment on: Urology 1995 May;45(5):831–8.

Laparoscopic treatment of nonparasitic liver cysts: adequate selection of patients and surgical technique. Gigot JF, et al. **World J Surg** 1996 Jun;20(5):556–61

[Selection of patients for kidney transplantation; how to deal with scarcities in clinical practice] Varekamp I, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):556–60 (Eng. Abstr.) **(Dut)**

[Problem of indications in psychotherapy] Huber W. **Acta Psychiatr Belg** 1996 May–Aug;96(3–4):135–53 (Eng. Abstr.) **(Fre)**

[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?] Carde P. **Bull Cancer (Paris)** 1995 Aug;82(8):637–49 (58 ref.) (Eng. Abstr.) **(Fre)**

[Cancer of the breast: primary prevention of breast cancer by tamoxifen, eligibility criteria, alternatives to English proposals] Serin D. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:168s–171s (Eng. Abstr.) **(Fre)**

[Surgical cure of varicocele and male infertility: for or against?] Adjiman M. **Contracept Fertil Sex** 1996 Jun; 24(6):439–41 (16 ref.) **(Fre)**

[Is cervical screening justified in adolescents?] Barrasso R, et al. **Contracept Fertil Sex** 1996 Feb;24(2):101–3 **(Fre)**

[Ethical problems with the decision of refusal to a request for intra-conjugal in vitro fertilization] Pierre F, et al. **Contracept Fertil Sex** 1996 Apr;24(4):326–36 (Eng. Abstr.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the pediatrician] Dehan M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:94–6 (5 ref.) **(Fre)**

[Stage I and II endometrial cancer: should lymphadenectomy still be done?] Descamps P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):794–801 (48 ref.) (Eng. Abstr.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of the epidemiologist] Goffinet F. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:108–15 (21 ref.) **(Fre)**

[Ethical problems raised by the current French practice of therapeutic abortions. Part I: prospective study for 24 months at the University Hospital of Tours (76 cases)] Gold F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(6):586–94 **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the anesthesiologist] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:97–107 (49 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the midwife] Kovacs C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:89–93 (22 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the obstetrician in hospital practice] Maria B. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:67–77 (52 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78–88 (40 ref.) **(Fre)**

[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120–8 (0 ref.) **(Fre)**

[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57–61 (39 ref.) **(Fre)**

[The epidemiologists' point of view on medical indications for induced labor] Subtil D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:62–6 (29 ref.) **(Fre)**

[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

[Hartmann procedure, indications and results in Yaounde (letter)] Masso-Misse P, et al. **Med Trop (Mars)** 1995; 55(2):187–8 **(Fre)**

[Decisional criteria in the management of vesico-ureteral reflux in children with congenital neurogenic bladder] Steyaert H, et al. **Prog Urol** 1996 Feb;6(1):76–80 (Eng. Abstr.) **(Fre)**

[Objective and subjective determinants in the benefits of home help services for the elderly] Colvez A, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):163–72 (Eng. Abstr.) **(Fre)**

[Current indications for medical treatment of ectopic pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423–30 (26 ref.) (Eng. Abstr.) **(Fre)**

[Geriatric assessment—case finding by screening hospitalized patients] Kruse WH, et al. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):293–8 (Eng. Abstr.) **(Ger)**

[The request for consent in clinical research: a randomized study in healthy subjects] Perrone F, et al. **Epidemiol Prev** 1995 Sep;19:282–90 (Eng. Abstr.) **(Ita)**

[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

[The selection of patients who are candidates for lung transplantation] Venuta F, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):5–10 (Eng. Abstr.) **(Ita)**

[Current status and aspect of cochlear implant] Komune S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):425–31 (5 ref.) **(Jpn)**

[Diseases relevant to gene therapy] Niitsu Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2496–7 (4 ref.) **(Jpn)**

[Ambulatory surgery. Patients and patient education] Bredland T, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):610–4 (Eng. Abstr.) **(Nor)**

[Selection of patients for ambulatory surgery] Kvalsvik O. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):500–3 (Eng. Abstr.) **(Nor)**

[Ambulatory surgery, preoperative anamnesis and clinical examination (letter)] Noess PA. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1258 **(Nor)**

[Clinical and angiographic profile and selection of patients for coronary angioplasty of restenosis (editorial; comment)] Gottschall CA. **Arq Bras Cardiol** 1995 Sep;65(3):259–61. Comment on: Arq Bras Cardiol 1995 Sep;65(3):215–9. **(Por)**

[The results of the evaluation of 208 patients referred in the first 4 years to a lung transplantation program. The Lung Transplantation Group of Hospital Vall d'Hebron] Morell F, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):280–4 (Eng. Abstr.) **(Spa)**

[For whom and when is a heart transplant indicated] Anguita M, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:13–8 (Eng. Abstr.) **(Spa)**

[The exclusion of cases (letter; comment)] Murphy Stack E. **Rev Invest Clin** 1995 May–Jun;47(3):251–2. Comment on: Rev Invest Clin 1995 Jan–Feb;47(1):35–41. **(Spa)**

[Ambulatory surgery must follow the rules of the game! Strict patient selection is important] Enlund M. **Lakartidningen** 1995 Sep 27;92(39):3598–9 **(Swe)**

PATIENT SIMULATION

Validation of standardized-patient assessment: a meaning for clinical competence. Colliver JA. **Acad Med** 1995 Dec; 70(12):1062–4

Do housestaff interview standardized patients differently from real ones? [letter] Griffith CH 3rd, et al. **Acad Med** 1995 Dec;70(12):1060–1

Simulation: it's a start [editorial; comment] Davies JM, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):425–9. Comment on: Can J Anaesth 1996 May;43(5 Pt 1):430–4. **(Eng, Fre)**

Anaesthesia crisis resource management training: an intimidating concept, a rewarding experience [see comments] Kurrek MM, et al. **Can J Anaesth** 1996 May; 43(5 Pt 1):430–4. Comment in: Can J Anaesth 1996 May;43(5 Pt 1):425–9.

Using interactive video to add physical assessment data to computer-based patient simulations in nursing. White JE. **Comput Nurs** 1995 Sep-Oct;13(5):233–5

The use of simulated clients to develop the clinical skills of speech and language therapy students. Syder D. **Eur J Disord Commun** 1996;31(2):181–92

Virtual training. A high-tech dress rehearsal. Montague J. **Hosp Health Netw** 1996 Jun 5;70(11):66, 68

Implementing and evaluating a patient instructor program. Broder HL, et al. **J Dent Educ** 1996 Sep;60(9):755–62

Effectiveness of standardized patient instruction. Johnson JA, et al. **J Dent Educ** 1996 Mar;60(3):262–66

Checklist agreement between standardized patients and faculty. Kopp KC, et al. **J Dent Educ** 1995 Aug;59(8):824–9

Simulated patients for the practical examination of medical students: intentions, procedures and experiences. Baerheim A, et al. **Med Educ** 1995 Nov;29(6):410–3

The assessment of communication skills in palliative medicine: a comparison of the scores of examiners and simulated patients. Finlay IG, et al. **Med Educ** 1995 Nov; 29(6):424–9

Actors play patients. Using surrogate patients to look into private practice [see comments] Hazelkorn HM, et al. **Public Health Rep** 1996 Mar–Apr;111(2):129–32. Comment in: Public Health Rep 1996 Mar–Apr;111(2):133–4.

The simulated patient [comment] Lerman LG. **Public Health Rep** 1996 Mar–Apr;111(2):133–4. Comment on: Public Health Rep 1996 Mar–Apr;111(2):129–32.

[Better consultations with patients' help—a method for quality assurance in general practice] Jøssang O, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3120–4 (Eng. Abstr.) **(Nor)**

[Standardized patients in general practice—a new method for quality assurance in Noway] Saebø L, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3117–9 (Eng. Abstr.) **(Nor)**

PATIENT TRANSFER

A tool for the emergency medicine evaluation of psychiatric patients [letter] Zun LS, et al. **Am J Emerg Med** 1996 May; 14(3):329–33

The diversion of mentally ill persons from jails to community-based services: a profile of programs [see comments] Steadman HJ, et al. **Am J Public Health** 1995 Dec;85(12):1630–5. Comment in: Am J Public Health 1995 Dec;85(12):1611–3.

Patient transfer; what to do about the 'spaghetti' [letter] [see comments] Cook TM, et al. **Anaesthesia** 1996 Jan;51(1):90–1 . Comment in: Anaesthesia 1996 Jun;51(6):610.

Capnometers for 'out-of-hospital' use [letter; comment] Junker H, et al. **Anaesthesia** 1996 Jan;51(1):91–2. Comment on: Anaesthesia 1995 Aug;50(8):703–5.

Injury to an anaesthetist during patient transfer [letter] Toomey PJ. **Anaesthesia** 1996 Mar;51(3):294

Residents on the transport team. Balancing service and education. Durbin DR, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):529–34

Morbidity and severity of illness during interhospital transfer: impact of a specialised paediatric retrieval team [see comments] Britto J, et al. **BMJ** 1995 Sep 30; 311(7009):836–9. Comment in: BMJ 1996 Jan 13;312(7023):119; discussion 121. Comment in: BMJ 1996 Jan 13;312(7023):119–20. Comment in: BMJ 1996 Jan 13;312(7023):120. Comment in: BMJ 1996 Jan 13;312(7023):120; discussion 121. Comment in: BMJ 1996 Jan 13;312(7023):120–1.

Impact of specialised paediatric retrieval teams. Transfers within hospitals can be as risky as those between hospitals [letter; comment] Cooper RM. **BMJ** 1996 Jan 13; 312(7023):120; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9.

Impact of specialised paediatric retrieval teams. London group's findings supported by study in Leeds [letter; comment] Cray SH. **BMJ** 1996 Jan 13;312(7023):120. Comment on: BMJ 1995 Sep 30;311(7009):836–9.

Impact of specialized paediatric retrieval teams. Criteria indicating physiological morbidity were too non-specific [letter; comment] [see comments] Kelleher A, et al. **BMJ** 1996 Jan 13;312(7023):119–20. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.

Impact of specialised paediatric retrieval teams. A regionally based retrieval service is warranted [letter; comment] [see comments] Mok Q, et al. **BMJ** 1996 Jan 13;312(7023):119; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.

Impact of specialised paediatric retrieval teams. Comparison of teams is difficult [letter; comment] [see comments] Morrison A, et al. **BMJ** 1996 Jan 13;312(7023):119; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9. Comment in: BMJ 1996 Feb 24;312(7029):507–8.

Impact of specialised paediatric retrieval teams. Intensive care provided by local hospitals should be improved [letter; comment] Raffles A. **BMJ** 1996 Jan 13;312(7023):120; discussion 121. Comment on: BMJ 1995 Sep 30;311(7009):836–9.

Impact of specialised paediatric retrieval teams. Children are still transferred by non-specialist teams [letter; comment] Sharples A, et al. **BMJ** 1996 Jan 13;312(7023):120–1. Comment on: BMJ 1995 Sep 30;311(7009):836–9.

Providing intensive care. Severe problems with interhospital transfer of critically ill children will continue [letter; comment] Sharples A, et al. **BMJ** 1996 Jun 29; 312(7047):1672. Comment on: BMJ 1996 Mar 16;312(7032):655.

A moving experience: reconfiguring a special care unit for Alzheimer's patients. Hepburn K, et al. **Gerontologist** 1995 Dec;35(6):831–5

PATIENT TRANSFER

Increased fall rates in nursing home residents after relocation to a new facility. Friedman SM, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1237–42

Nurse information needs for efficient care continuity across patient units. Patterson PK, et al. **J Nurs Adm** 1995 Oct; 25(10):28–36

Holding on: parents' perceptions of premature infants' transfers. Gibbins SA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):147–53

Toxic shock syndrome and burns [letter] Kay AR, et al. **J R Soc Med** 1996 Jul;89(7):420

Medical transfer programmes for Bosnia and Herzegovina [letter] Southall D, et al. **Lancet** 1996 Jun 29; 347(9018):1838–9

Impact of interhospital transfers on outcomes in an academic medical center. Implications for profiling hospital quality. Gordon HS, et al. **Med Care** 1996 Apr;34(4):295–309

Transport of the critically ill patient: an example of an integrated model. Havill JH, et al. **N Z Med J** 1995 Sep 22;108(1008):378–80

Responses of noninterviewable long-term care patients before and after interinstitutional relocation. Mirotznik J. **Psychol Rep** 1995 Jun;76(3 Pt 2):1267–80

What happens to patients after nursing home placement? Bartlett MC, et al. **Soc Work Health Care** 1995;22(1):69–79

Development of postoperative delirium in relation to a room change in the general surgical unit. Tsutsui S, et al. **Surg Today** 1996;26(4):292–4

[Patient transfer between 2 hospital services: informing patients] Huber P, et al. **Ann Med Interne (Paris)** 1996; 147(1):5–9 (Eng. Abstr.) **(Fre)**

[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) **(Fre)**

[A patient switches wards: significance for the therapeutic process in inpatient psychotherapy] Neumeier R. **Z Psychosom Med Psychoanal** 1996;42(2):139–53 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Federal anti-patient-dumping provisions: the first decade [editorial; comment] Schiff RL, et al. **Ann Emerg Med** 1996 Jul;28(1):77–9. Comment on: Ann Emerg Med 1996 Jul;28(1):45–50.

What is left of futility? The convergence of anencephaly and the Emergency Medical Treatment and Active Labor Act. Diekema DS. **Arch Pediatr Adolesc Med** 1995 Oct; 149(10):1156–9

Helen L. v. DiDario (known as Idell S. v. Snider). Altomare J, et al. **Issues Law Med** 1995 Fall;11(2):187–91

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

An overview and analysis of the impact of the Emergency Medical Treatment and Active Labor Act. Furrow BR. **J Leg Med** 1995 Sep;16(3):325–55 (157 ref.)

Involuntary transfers and discharges of nursing home residents under federal and state law. Knepper K. **J Leg Med** 1996 Jun;17(2):215–75

METHODS

The 'spaghetti' problem [letter; comment] Haldane GJ, et al. **Anaesthesia** 1996 Jun;51(6):610. Comment on: Anaesthesia 1996 Jan;51(1):90–1.

ORGANIZATION & ADMINISTRATION

How to transfer patients to other units. Stahl L. **Am J Nurs** 1996 Aug;96(8):57–8

Shared care for open heart surgery: 21 years' experience. FitzGibbon GM, et al. **Can J Cardiol** 1996 Jan;12(1):59–64

A review of United States Air Force aeromedical evacuation of acute myocardial infarction patients in Europe. Connor SB, et al. **Mil Med** 1995 Oct;160(10):491–3

STANDARDS

Adult discharge planning and nursing home placement: a study of risk factors for quality assurance. Cooper L. **Aust Clin Rev** 1991;11:95–102

Interhospital transfers: decision-making in critical care areas. Lee A, et al. **Crit Care Med** 1996 Apr;24(4):618–22

Interhospital transfer of the critically ill trauma patient: the potential role of a specialist transport team in a trauma system. McGinn GH, et al. **J Accid Emerg Med** 1996 Mar; 13(2):90–2

STATISTICS & NUMERICAL DATA

Comparing the hospitalizations of transfer and non-transfer patients in an academic medical center. Bernard AM, et al. **Acad Med** 1996 Mar;71(3):262–6

Analysis of federally imposed penalties for violations of the Consolidated Omnibus Reconciliation Act [see comments] Levine RJ, et al. **Ann Emerg Med** 1996 Jul;28(1):45–50. Comment in: Ann Emerg Med 1996 Jul;28(1):77–9.

Interactions between hospital and nursing home use. Freiman MP, et al. **Public Health Rep** 1995 Sep–Oct;110(5):546–54; discussion 545

PATIENTS

see related
INPATIENTS
OUTPATIENTS

Medical ethics and patient belief systems. Clouser KD, et al. **Altern Ther Health Med** 1996 Jan;2(1):92–3

Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. Canadian Collaborative Study for Predictive Testing for Huntington Disease. Copley TT, et al. **Am J Med Genet** 1995 Jul 31; 58(1):59–69

What's in a name? [letter; comment] Balon R. **Am J Psychiatry** 1996 Jun;153(6):849. Comment on: Am J Psychiatry 1995 Aug;152(8):1107–9.

What's in a name? [letter; comment] Blackwell B. **Am J Psychiatry** 1996 Jun;153(6):849. Comment on: Am J Psychiatry 1995 Aug;152(8):1107–9.

Resource use implications of do not resuscitate orders for intensive care unit patients. Rapoport J, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):185–90

Is economic hardship on the families of the seriously ill associated with patient and surrogate care preferences? SUPPORT Investigators. Covinsky KE, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1737–41

A comparison of patients attending general dental practices employing or not employing dental hygienists. Brown LF. **Aust Dent J** 1996 Feb;41(1):47–52

Confidentiality of medical records: the patient's perspective. Carman D, et al. **Br J Gen Pract** 1995 Sep;45(398):485–8

Building a hybrid patient's model for augmented reality in surgery: a registration problem. Lavallée S, et al. **Comput Biol Med** 1995 Mar;25(2):149–64

Patient empowerment and the traditional medical model. A case of irreconcilable differences? Anderson RM. **Diabetes Care** 1995 Mar;18(3):412–5

Patients' and nurses' knowledge of cardiac-related symptoms and cardiac misconceptions. Newens AJ, et al. **Heart Lung** 1996 May–Jun;25(3):190–9

Patients' knowledge about their drug allergies. Wyatt JP. **J Accid Emerg Med** 1996 Mar;13(2):114–5

Spirituality and the treatment of the dually diagnosed: an investigation of patient and staff attitudes. McDowell D, et al. **J Addict Dis** 1996;15(2):55–68

Patients' attitudes about gifts to physicians from pharmaceutical companies. Blake RL Jr, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):457–64

The life situation of cancer patients in an oncology department [letter] Brobäck G, et al. **J Cancer Educ** 1995 Fall;10(3):177

Family involvement in routine health care: a survey of patients' behaviors and preferences. Botelho RJ, et al. **J Fam Pract** 1996 Jun;42(6):572–6

Sequential continuity of care by general practitioners: which patients change doctor? Pilotto LS, et al. **Med J Aust** 1996 Apr 15;164(8):463–6

The patient and the public good. Hellman S. **Nat Med** 1995 May;1(5):400–2

Commodity trading and PC [editorial] Asher RL. **Nebr Med J** 1996 Apr;81(4):106

Support groups: a neglected resource in obstetrics and gynecology [editorial] Nettles JB. **Obstet Gynecol Surv** 1995 Jul;50(7):495–6

Ethical and educational aspects of clinical training. A study in the experience and attitudes of medical students. Lynöe N, et al. **Scand J Soc Med** 1995 Sep;23(3):216–9

The Camberwell Assessment of Need (CAN): comparison of assessments by staff and patients of the needs of the severely mentally ill. Slade M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun; 31(3–4):109–13

[The new patient] Imbert C. **Bull Acad Natl Med** 1996 Jan; 180(1):33–40 **(Fre)**

[Physician as patient (editorial)] Modan B. **Harefuah** 1995 Nov 15;129(10):395–6 **(Heb)**

[Communication with the patient: a duty useful to physicians, a benefit to patients] Bonomo L. **Recenti Prog Med** 1995 Sep;86(9):331 **(Ita)**

[What does the primary care physician now about his deceased patients? A study of deaths in a group practice] Kristoffersen JE. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):869–71 (Eng. Abstr.) **(Nor)**

[Rational use of drugs. Viewpoint of the users in the 3d Health Area of Saragossa] Astier Peña MP, et al. **Aten Primaria** 1995 Oct 15;16(6):344–50 (Eng. Abstr.) **(Spa)**

[How are the patients informed at a hospital emergency service?] Domínguez Navarro D, et al. **Aten Primaria** 1996 Mar 15;17(4):280–3 (Eng. Abstr.) **(Spa)**

[How ill are my patients?] Fernández de Sanmamed Santos MJ, et al. **Aten Primaria** 1996 May 15;17(8):531–7, 539–41 **(Spa)**

[Prior appointment, profile of the patient and accessibility] Gómez-Calcerrada D, et al. **Aten Primaria** 1996 Mar 15; 17(4):288–91 (Eng. Abstr.) **(Spa)**

[Medicosocial profile of the crucial caregiver. Is he/she an occult patient?] Rubio Montañés ML, et al. **Aten Primaria** 1995 Sep 15;16(4):181–6 (Eng. Abstr.) **(Spa)**

[Description and validation of a predictive model of the geographic distribution of chronic home-bound patients] Segura Noguera JM, et al. **Aten Primaria** 1996 Mar 15; 17(4):292–4 (Eng. Abstr.) **(Spa)**

[Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract] Gavaldà L, et al. **Gac Sanit** 1995 Nov–Dec;9(51):334–42 (Eng. Abstr.) **(Spa)**

[Why client and not patient in health services? (letter)] Priego Alvarez H. **Salud Publica Mex** 1995 Sep–Oct;37(5):381–2 **(Spa)**

[Training of clinical skills in undergraduate medical education. Professional patients as educators] Axelsson O, et al. **Lakartidningen** 1995 Sep 20;92(38):3456–9 **(Swe)**

[Disclosure of X-ray results by the radiologist? Yes, say the patients. May be, say the physicians] Storby G. **Lakartidningen** 1996 Mar 6;93(10):927–30 (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Functional gain and length of stay for major rehabilitation impairment categories. Patterns revealed by function related groups. Stineman MG, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):68–78

"Archaic" coding needs update [letter] Frankford R. **Can Fam Physician** 1995 Dec;41:2085

Calculation of patient's complexity: paramedical and nursing facets. Delacrétaz AC, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):97–102

Measuring the essence of nursing: a guide for future practice. Peters DA, et al. **J Prof Nurs** 1995 Nov–Dec;11(6):358–63

Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)

Extraction, preparation, and presentation of patient classification-data for the benefit of management overviews. Kooijman CJ, et al. **Medinfo** 1995;8 Pt 2:1382–5

Acuity scheduling systems: a case study in radiology. Maddala T. **Radiol Technol** 1996 May–Jun;67(5):415–20

[Utilization of computerized classification system of primary care: three years of experience] Leduc Y, et al. **Can Fam Physician** 1995 Aug;41:1338–45 (Eng. Abstr.) **(Fre)**

[Formation of clinical-statistical groups of oncologic patients] Shalimov SO, et al. **Klin Khir** 1995;(5):5–6 **(Ukr)**

EDUCATION see PATIENT EDUCATION

PSYCHOLOGY

Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Risberg T, et al. **Acta Oncol** 1995;34(7):893–8

A preliminary study of patients' concerns related to GI endoscopy. Drossman DA, et al. **Am J Gastroenterol** 1996 Feb;91(2):287–91

When a doctor is a patient. Kirsch M. **Am J Gastroenterol** 1996 Jul;91(7):1299–300

The impact of disease severity on the informed consent process in clinical research. Schaeffer MH, et al. **Am J Med** 1996 Mar;100(3):261–8

When your patient is in denial. Goetzke E. **Am J Nurs** 1995 Sep;95(9):18–21

Surgical patients' attitudes regarding participation in clinical anesthesia research [see comments] Mingus ML, et al. **Anesth Analg** 1996 Feb;82(2):332–7. Comment in: Anesth Analg 1996 Aug;83(2):438.

A questionnaire-based survey of patients' knowledge of psoriasis at the National Skin Centre. Tham SN, et al. **Ann Acad Med Singapore** 1995 May;24(3):415–20

Insight. Moore ME. **Ann Intern Med** 1996 Mar 15; 124(6):609–10

In the eye of the beholder. Hux JE, et al. **Arch Intern Med** 1995 Nov 27;155(21):2277–80

Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Rosenfeld KE, et al. **Arch Intern Med** 1996 Jul 22;156(14):1558–64

Patients' views of priority setting in health care: an interview survey in one practice [see comments] Dicker A, et al. **BMJ** 1995 Oct 28;311(7013):1137–9. Comment in: BMJ 1996 Feb 17;312(7028):447.

Patients' prerogatives and perceptions of benefit. Kee F. **BMJ** 1996 Apr 13;312(7036):958–60

Videotaped consultations [letter] [see comments] Bain JE, et al. **Br J Gen Pract** 1995 Aug;45(397):443–4. Comment in: Br J Gen Pract 1995 Nov;45(400):631. Comment in: Br J Gen Pract 1995 Nov;45(400):631–2.

Do patients prefer women doctors? Cockburn J, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):2–3

Prednisolone non-compliance and its related factors in patients with systemic lupus erythematosus. Lin WS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct; 56(4):244–51

Patient perceptions regarding the risks of morbidity and complications of lower third molar removal. Armstrong RA, et al. **Community Dent Health** 1996 Mar;13(1):17–21

Opening Pandora's box: patients' attitudes towards trainees.

Dublin General Practice Vocational Training Scheme Third Year Group 1991–1992. Murphy AW. **Fam Pract** 1995 Sep;12(3):318–23

Preliminary study into the opinions of patients about the presence of medical students in the general practice consultation. Morrison JM, et al. **Health Bull (Edinb)** 1995 Nov;53(6):343–4

Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)

DSM–III mental disorders in general medical sector: predictors of outcome. Berti Ceroni F, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):45–57

Neuroticism in a family practice population in India. Sood R, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):58–67

Subjective perception of additional support requirements of elderly patients discharged from accident and emergency departments. Farnsworth TA, et al. **J Accid Emerg Med** 1995 Jun;12(2):107–10

The reactions of patients and doctors in the united arab emirates towards smoking. Harrison A, et al. **J Addict Dis** 1996;15(1):75–92

At the bedside. Influencing a patient's religious beliefs: mandate or no–man's land? Howe EG. **J Clin Ethics** 1995 Fall;6(3):194–201 (29 ref.)

How do medical residents discuss resuscitation with patients? Tulsky JA, et al. **J Gen Intern Med** 1995 Aug;10(8):436–42

Relationship of religion and perceived social support to self–esteem and depression in nursing home residents. Commerford MC, et al. **J Psychol** 1996 Jan;130(1):35–50

The patient's perspective. Garfein JL. **JAMA** 1996 May 1; 275(17):1371

A piece of my mind. When you come into my room. Schmidt SA. **JAMA** 1996 Aug 21;276(7):512

Patients' preferences and randomised trials [letter; comment] Bradley C. **Lancet** 1996 Apr 20;347(9008):1118–9. Comment on: Lancet 1996 Jan 20;347(8995):171–4.

Patients' preferences and randomised trials [letter; comment] Brewin T. **Lancet** 1996 Apr 20;347(9008):1118; discussion 1119. Comment on: Lancet 1996 Jan 20;347(8995):171–4.

Patients' preferences and randomised trials [letter; comment] Gore SM. **Lancet** 1996 Apr 20;347(9008):1119. Comment on: Lancet 1996 Jan 20;347(8995):171–4.

Patients' preferences and randomised trials [letter; comment] McPherson K. **Lancet** 1996 Apr 20;347(9008):1119. Comment on: Lancet 1996 Jan 20;347(8995):171–4.

Patients' preferences and randomised trials [see comments] Silverman WA, et al. **Lancet** 1996 Jan 20;347(8995):171–4. Comment in: Lancet 1996 Apr 20;347(9008):1118; discussion 1119. Comment in: Lancet 1996 Apr 20;347(9008):1118–9. Comment in: Lancet 1996 Apr 20;347(9008):1119.

Patients' preferences and randomised trials [letter; comment] Thornton H. **Lancet** 1996 Apr 20;347(9008):1118; discussion 1119. Comment on: Lancet 1996 Jan 20;347(8995):171–4.

The sex of the general practitioner: a comparison of characteristics, patients, and medical conditions managed. Britt H, et al. **Med Care** 1996 May;34(5):403–15

Assessment of the need for care 15 years after onset of a Dutch cohort of patients with schizophrenia, and an international comparison. Wiersma D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun; 31(3–4):114–21

The patient's contract with the doctor [editorial] Ausman JI. **Surg Neurol** 1995 Jun;43(6):612

What do people expect from their doctors? Boland M. **World Health Forum** 1995;16(3):221–7; discussion 227–47

[The user facing the hospital: an Algerian perspective] el–Djounid H. **Cah Sociol Demogr Med** 1995 Jan–Mar; 35(1):21–31 (Eng. Abstr.) **(Fre)**

[Opinion of patients on the functioning of an ophthalmologic surgical outpatient center within a hospital. Analysis and consequences] Lebuisson DA, et al. **J Fr Ophtalmol** 1995; 18(8–9):490–501 (Eng. Abstr.) **(Fre)**

[Communication of bad information: general indications and guidelines] Saltini A, et al. **Recenti Prog Med** 1995 Oct; 86(10):409–17 (12 ref.) (Eng. Abstr.) **(Ita)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

[Factors related to choice of medical facilities by residents] Sugisawa H, et al. **Nippon Koshu Eisei Zasshi** 1995 Jul; 42(7):463–71 (Eng. Abstr.) **(Jpn)**

[Awareness and feelings of elderly patients and their families concerning disease during terminal hospitalization—malignancy versus non–malignancy] Nagura E, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep;32(8–9):571–80 (Eng. Abstr.) **(Jpn)**

[Psychology of severe somatic diseases] Knežević A. **Med Pregl** 1994;47(9–10):334–5 (Eng. Abstr.) **(Scr)**

[Interferences of human solidarity in intensive care (editorial)] Torrabadella de Reynoso P. **Med Clin (Barc)** 1996 Mar 23;106(11):414–6 **(Spa)**

STATISTICS & NUMERICAL DATA

Do we practice what we preach? Comparing the patients of faculty and residents. Scheid D, et al. **Fam Med** 1995 Sep;27(8):519–24

A profile of patients in six dental school clinics and implications for the future. Damiano PC, et al. **J Dent Educ** 1995 Dec;59(12):1084–90

A profile of patients in six dental schools [letter] Schneider DA, et al. **J Dent Educ** 1996 Jan;60(1):79–80

PATIENTS' RIGHTS see **PATIENT ADVOCACY**

PATIENTS' ROOMS

Measuring ventilation of patient care areas in hospitals. Description of a new protocol. Menzies R, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1992–9

Association of pre mortem diagnosis and autopsy findings in pediatric intensive care unit versus emergency department versus ward patients. Goldstein B, et al. **Crit Care Med** 1996 Apr;24(4):683–6

Niche delivery. Deluxe in da hospital. Nordhaus–Bike AM. **Hosp Health Netw** 1996 Apr 5;70(7):50, 52

Pulmonary scintigraphy at the bedside in intensive care patients with suspected pulmonary embolism. Jolliet P, et al. **Intensive Care Med** 1995 Sep;21(9):723–8

Bedside coagulation monitoring [editorial; comment] Ammar T, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):353–4. Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):355–61.

Chamber for indirect calorimetry with improved transient response. Henning B, et al. **Med Biol Eng Comput** 1996 May;34(3):207–12

[Hepatitis C virus infections in hospital roommates? (news)] Eisenburg J. **Fortschr Med** 1995 Sep 10;113(25):6–8 **(Ger)**

[The ward laboratory (editorial)] Marsden PD. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):311–3 **(Por)**

UTILIZATION

Head injuries and the observation ward [letter; comment] Jones A, et al. **J Accid Emerg Med** 1995 Jun;12(2):160–1. Comment on: J Accid Emerg Med 1994 Sep;11(3):144–8.

PATIENTS' VISITORS see **VISITORS TO PATIENTS**

PATTERN RECOGNITION

Definition and application of a fourier domain texture measure: applications to histological image segmentation. Gibson D, et al. **Comput Biol Med** 1995 Nov;25(6):551–7

Patterns of attractor dimensions of sleep EEG. Pradhan N, et al. **Comput Biol Med** 1995 Sep;25(5):455–62

Fuzzy sets for feature identification in biomedical signals with self–assessment of reliability: an adaptable algorithm modeling human procedure in BAEP analysis. Piater J, et al. **Comput Biomed Res** 1995 Oct;28(5):335–53

Nuclear pattern recognition by two–parameter texture analysis. Diaz G, et al. **Comput Methods Programs Biomed** 1996 Jan;49(1):1–9

Pattern recognition in five–phase bone scintigraphy: diagnostic patterns of reflex sympathetic dystrophy in adults. Leitha T, et al. **Eur J Nucl Med** 1996 Mar; 23(3):256–62

Free recall and recognition of slowly and rapidly presented words in very old age: a community–based study. Wahlin A, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):251–71

Supporting perception in the service of dynamic decision making. Kirlik A, et al. **Hum Factors** 1996 Jun;38(2):288–99

A new approach to differential diagnosis of diseases. Ortíz–Posadas MR, et al. **Int J Biomed Comput** 1996 Jan; 40(3):179–85

Recognition of Telugu characters using neural networks. Sukhaswami MB, et al. **Int J Neural Syst** 1995 Sep; 6(3):317–57

Quantitative analysis of computed tomography scans of the lungs for the diagnosis of pulmonary emphysema. A validation study of a semiautomated contour detection technique. Zagers R, et al. **Invest Radiol** 1995 Sep; 30(9):552–62

The value of prior knowledge in discovering motifs with MEME. Bailey TL, et al. **Ismb** 1995;3:21–9

PALM—a pattern language for molecular biology. Helgesen C, et al. **Ismb** 1993;1:172–80

A small automaton for word recognition in DNA sequences and its application to consensus analysis of regulatory elements in DNA regions controlling gene expression. Lefèvre C, et al. **Ismb** 1993;1:243–50

Pattern discovery in gene regulation; designing an analysis environment. Veretnik S, et al. **Ismb** 1993;1:411–9

Algorithms for protein structural motif recognition. Berger B. **J Comput Biol** 1995 Spring;2(1):125–38

A simplified procedure for entry of raw genotypic data. Rohrer GA, et al. **J Comput Biol** 1994 Summer;1(2):111–9

Method for calculation of probability of matching a bounded regular expression in a random data string. Sewell RF, et al. **J Comput Biol** 1995 Spring;2(1):25–31

Automated feature extraction for the classification of human in vivo 13C NMR spectra using statistical pattern recognition and wavelets. Tate AR, et al. **Magn Reson Med** 1996 Jun;35(6):834–40

Discrimination between artefacts and contractions in pressure signals from the gastrointestinal tract by pattern recognition method. Andersen MB, et al. **Med Biol Eng Comput** 1996 Mar;34(2):127–32

Comparison of neural network and k–NN classification methods in medical image and voice recognitions. Kim EK, et al. **Med J Osaka Univ** 1993 Sep;41–42(1–4):11–6

Computer assisted bone age assessment. Dickhaus H, et al. **Medinfo** 1995;8 Pt 1:709–13

Structure optimization of neural networks with A*–algorithm application in EEG pattern analysis. Doering A, et al. **Medinfo** 1995;8 Pt 1:814–7

Application of optimized pattern recognition units in EEG analysis: common optimization of preprocessing and weights of neural networks as well as structure optimization. Witte H, et al. **Medinfo** 1995;8 Pt 1:833–7

LeRec: a NN/HMM hybrid for on–line handwriting recognition. Bengio Y, et al. **Neural Comput** 1995 Nov; 7(6):1289–303

The Helmholtz machine. Dayan P, et al. **Neural Comput** 1995 Sep;7(5):889–904

Self–organizing hierarchic networks for pattern recognition in protein sequence. Hanke J, et al. **Protein Sci** 1996 Jan; 5(1):72–82

Finding flexible patterns in unaligned protein sequences. Jonassen I, et al. **Protein Sci** 1995 Aug;4(8):1587–95

Hippocampal MR imaging morphometry by means of general pattern matching. Haller JW, et al. **Radiology** 1996 Jun; 199(3):787–91

[Detection of patients with pheochromocytoma using a cybernetic analysis method of the signs and symptoms of the disease] Balažovjech I, et al. **Ann Urol (Paris)** 1996; 30(1):7–13 (Eng. Abstr.) **(Fre)**

PATTERN RECOGNITION, VISUAL

The effects of variation of an irrelevant dimension on same–different visual judgments. Ballesteros S, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):1–16

Does perceptual analysis continue during selection and production of a speeded response? Levy J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):245–60

Inattention and the perception of visual feature conjunctions. Modigliani V, et al. **Acta Psychol (Amst)** 1996 Mar; 91(2):121–9

Discrete vs. continuous processing: the fate of an incompletely processed perceptual dimension. Sanders AF. **Acta Psychol (Amst)** 1995 Nov;90(1–3):211–27

Information integration in cross–modal pattern recognition: an argument for acquired modularity. Thompson LA, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):79–104

SORT: a validation study with stroke patients. Salford Objective Recognition Test. Yeo D, et al. **Age Ageing** 1996 Mar;25(2):121–4

Spatial learning deficits in preschool children of alcoholics. Schandler SL, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1067–72

Visual versus auditory memory stimulation in patients with probable Alzheimer's disease. A PET study with 18 FDG. Kessler J, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:233–8

Recognition–by–parts: a computational approach to human learning and generalization of shapes. Jüttner M, et al. **Biol Cybern** 1996 Jun;74(6):521–35

Are visual search procedures adapted to the nature of the script? Green DW, et al. **Br J Psychol** 1996 May;87 (Pt 2):311–26

The relationship between articulation time and memory performance in verbal and visuospatial tasks. Smyth MM, et al. **Br J Psychol** 1996 May;87 (Pt 2):179–91

Emotional expression in upside–down faces: evidence for configurational and componential processing. McKelvie SJ. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):325–34

Identification of famous faces and famous names in early Alzheimer's disease. Relationship to anterograde episodic and general semantic memory. Greene JD, et al. **Brain** 1996 Feb;119 (Pt 1):111–28

Timing and competition in networks representing ambiguous figures. Gómez C, et al. **Brain Cogn** 1995 Nov;29(2):103–14

On functional brain asymmetries in perceptual priming. Koivisto M. **Brain Cogn** 1995 Oct;29(1):36–53

Recognition potential latency and word image degradation. Rudell AP, et al. **Brain Lang** 1995 Nov;51(2):229–41

Visual specificity effects on word stem completion: beyond transfer appropriate processing? Curran T, et al. **Can J Exp Psychol** 1996 Mar;50(1):22–33

Infants' forgetting of correlated attributes and object recognition. Bhatt RS, et al. **Child Dev** 1996 Feb; 67(1):172–87

The development of perceptual completion abilities: infants' perception of stationary, partially occluded objects. Craton LG. **Child Dev** 1996 Jun;67(3):890–904

The dynamics of preschoolers' categorization choices. Deák GO, et al. **Child Dev** 1996 Jun;67(3):740–67

Individual differences in infant visual attention: recognition of degraded visual forms by four–month–olds. Frick JE, et al. **Child Dev** 1996 Feb;67(1):188–204

What can be learned from something's not being named. Merriman WE, et al. **Child Dev** 1995 Dec;66(6):1890–908

There's more to the picture than meets the eye: young children's difficulty understanding biased interpretation. Pillow BH, et al. **Child Dev** 1996 Jun;67(3):803–19

The development of hierarchical representation of two–dimensional space. Sandberg EH, et al. **Child Dev** 1996 Jun;67(3):721–39

Smiling and fussing in seven–month–old preterm and full–term black infants in the still–face situation. Segal LB, et al. **Child Dev** 1995 Dec;66(6):1829–43

Waiting to use a symbol: the effects of delay on children's use of models. Uttal D, et al. **Child Dev** 1995 Dec;

66(6):1875–89
Infant affective reactions to the resumption of maternal interaction after the still-face. Weinberg MK, et al. **Child Dev** 1996 Jun;67(3):905–14
Young children's understanding of thought bubbles and of thoughts. Wellman HM, et al. **Child Dev** 1996 Jun; 67(3):768–88
Functional aspects of recollective experience in face recognition. Parkin AJ, et al. **Conscious Cogn** 1995 Dec; 4(4):387–98
Visual search performance with complete and incomplete visual lobe areas. Courtney AJ, et al. **Ergonomics** 1996 May; 39(5):749–56
Difference of EEG spectral powers observed between binocular rivalry and binocular fusion. Kobayashi T, et al. **Front Med Biol Eng** 1996;7(1):11–9
Correlation of pattern discrimination perimetry to the optic disc and visual field in ocular hypertensive and chronic open-angle glaucoma patients. Stewart WC, et al. **Int Ophthalmol** 1995;19(2):101–7
Dot Enumeration Perceptual Organization Task (DEPOT): evidence for a short-term visual memory deficit in schizophrenia. Rabinowicz EF, et al. **J Abnorm Psychol** 1996 Aug;105(3):336–48
Anxiety and the use of strategies in the performance of a sentence-picture verification task. Richards A, et al. **J Abnorm Psychol** 1996 Feb;105(1):132–6
More evidence for generalized poor performance in facial emotion perception in schizophrenia. Salem JE, et al. **J Abnorm Psychol** 1996 Aug;105(3):480–3
Stimulus configuration and context effects in perceptual organization in schizophrenia. Silverstein SM, et al. **J Abnorm Psychol** 1996 Aug;105(3):410–20
A comparison of reinforcer assessment methods: the utility of verbal and pictorial choice procedures. Northup J, et al. **J Appl Behav Anal** 1996 Summer;29(2):201–12
Effect of type of practice in a computer-aided design environment in visualizing three-dimensional objects from two-dimensional orthographic projections] Duesbury RT, et al. **J Appl Psychol** 1996 Jun;81(3):249–60
Visuo-spatial working memory limitations in low visuo-spatial high verbal intelligence children. Cornoldi C, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1053–64
Construct validity of various verbal and visual memory tests. Larrabee GJ, et al. **J Clin Exp Neuropsychol** 1995 Aug; 17(4):536–47
Reliability of the Rey-Osterrieth Complex Figure in use with memory-impaired patients. Tupler LA, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):566–79
Orientation invariant pattern recognition by pigeons (Columba livia) and humans (Homo sapiens). Delius JD, et al. **J Comp Psychol** 1995 Sep;109(3):278–90
A computer touch-screen apparatus for training visual discriminations in rats. Markham MR, et al. **J Exp Anal Behav** 1996 Jan;65(1):173–82
On the experimental analysis of naming and the formation of stimulus classes. Stromer R. **J Exp Anal Behav** 1996 Jan;65(1):250–2
The development of phonological rules and visual strategies in average and poor spellers. Lennox C, et al. **J Exp Child Psychol** 1996 Jun;62(1):60–83
Habituation of the orienting response to stimuli of different functional values in 4-month old infants. Malcuit G, et al. **J Exp Child Psychol** 1996 Jul;62(2):272–91
Valuing of identity, distribution of attention, and perceptual salience in free and rule-governed classifications. Odom RD, et al. **J Exp Child Psychol** 1996 Mar;61(2):173–89
Children's performance on "animal tests" of oddity: implications for cognitive processes required for tests of oddity and delayed nonmatch to sample. Overman W, et al. **J Exp Child Psychol** 1996 Jul;62(2):223–42
Performance demands in the selection of objects for counting. Towse JN, et al. **J Exp Child Psychol** 1996 Feb;61(1):67–79
Conditions affecting beliefs about visual perception among children and adults. Winer GA, et al. **J Exp Child Psychol** 1996 Mar;61(2):93–115
Discrimination of relative numerosity and stimulus mixture by pigeons with comparable tasks. Honig WK, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):348–62
Attentional persistence for features of hierarchical patterns. Robertson LC. **J Exp Psychol Gen** 1996 Sep;125(3):227–49
Detection of smooth three-dimensional surfaces from optic flow. Andersen GJ. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):945–57
Repetition deficit in rapid-serial-visual-presentation displays: encoding failure or retrieval failure? Armstrong IT, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):1044–52
Configural processing in the perception of apparent biological motion. Chatterjee SH, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):916–29
Morphological and orthographic similarity in visual word recognition. Drews E, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):1098–116
Texture segmentation along the horizontal meridian: nonmonotonic changes in performance with eccentricity. Gurnsey R, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):738–57
Spatial precues affect target discrimination in the absence of visual noise. Henderson JM. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):780–7
Effects of lighting on the perception of facial surfaces. Hill H, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):986–1004
Surface range and attitude probing in stereoscopically presented dynamic scenes. Koenderink JJ, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):869–78
Visual stability across saccades while viewing complex pictures. McConkie GW, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):563–81
Perceptual separability, decisional separability, and the identification-speeded classification relationship. Maddox WT, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):795–817
The relevance of action in perceiving affordances: perception of catchableness of fly balls. Oudejans RR, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):879–91
Perception of local three-dimensional shape. Phillips F, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):930–44
Conceptual effects on representational momentum. Reed CL, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):839–50
Inversion and processing of component and spatial-relational information in faces. Searcy JH, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):904–15
Is there feature-based attentional selection in visual search? Shih SI, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):758–79
Audiovisual links in endogenous covert spatial attention. Spence C, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug;22(4):1005–30
Face preference at birth. Valenza E, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):892–903
Anticipating arrival: is the tau margin a specious theory? Wann JP. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):1031–48
A constructive-associative model of the contextual dependence of unidimensional similarity. Wedell DH. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):634–61
Effects of color and pattern on implicit and explicit picture memory. Cave CB, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):639–53
A syntactic complexity effect with visual patterns: evidence for the syntactic nature of the memory representation. Chechile RA, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):654–69
Interactions of stimulus attributes, base rates, and feedback in recognition. Estes WK, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1075–95
Alignment-based nonmonotonicities in similarity. Goldstone RL. **J Exp Psychol Learn Mem Cogn** 1996 Jul; 22(4):988–1001
Representational momentum, centripetal force, and curvilinear impetus. Hubbard TL. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):1049–60
Attribute conjunctions and the part configuration advantage in object category learning. Saiki J, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):1002–19
The effects of category distinctiveness and stimulus relations on young children's use of retrieval clustering strategies. Nida RE, et al. **J Gen Psychol** 1995 Oct;122(4):345–53
Children's assignment of gender to animal characters in pictures. Arthur AG, et al. **J Genet Psychol** 1996 Sep; 157(3):297–301
Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. Scheltens P, et al. **J Neurol** 1995 Sep;242(9):557–60
Classifying illusory contours by means of orientation discrimination. Westheimer G, et al. **J Neurophysiol** 1996 Feb;75(2):523–37
Objects and properties: a study of the breakdown of semantic memory. Funnell E. **Memory** 1995 Sep-Dec;3(3-4):497–518
Probing sensory and associative semantics for animals and objects in normal subjects. Laws KR, et al. **Memory** 1995 Sep-Dec;3(3-4):397–408
Danegeld remembered: taxing further the coin head illusion. Martin M, et al. **Memory** 1995 Mar;3(1):97–104
Evidence for a global scanpath strategy in viewing abstract compared with realistic images. Zangemeister WH, et al. **Neuropsychologia** 1995 Aug;33(8):1009–25
Dissociation of pathways for object and spatial vision: a PET study in humans. Köhler S, et al. **Neuroreport** 1995 Oct 2;6(14):1865–8
Does "Touching Four" on the Worth 4-dot test indicate fusion in young children? A computer simulation. Lueder GT, et al. **Ophthalmology** 1996 Aug;103(8):1237–40
Solution of an insight problem at different age levels. Antonietti A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1215–8
Measuring the typicality of objects included in environmental scenes: a logistic model for atypicality. Beltran FS, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1343–52
Comparison of two multidimensional coordinate systems for facial expressions. Bimler D, et al. **Percept Mot Skills** 1996 Feb;82(1):289–90
Pop-out in visual search requires practice. Boersema T, et al. **Percept Mot Skills** 1996 Apr;82(2):355–65
Inaccurate feedback and performance on the Müller-Lyer illusion. Brosvic GM, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 1):896–8
Incidence of the half-left profile pose in single-subject portraits. Conesa J, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):920–2
Effects of instruction on a divided visual-field task of face processing. Cormier P, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 1):923–30
A virtual pattern generator for designing motor behavior tasks. Del Rey P, et al. **Percept Mot Skills** 1996 Feb; 82(1):64–6
Benussi effect as an integration of disparity by motion. Deni JR, et al. **Percept Mot Skills** 1996 Apr;82(2):607–10
Differences in visuospatial judgement in reading-disabled and normal children. Eden GF, et al. **Percept Mot Skills** 1996 Feb;82(1):155–77
Visual inspection alone produces a decrement in the horizontal-vertical illusion. Glaser ML, et al. **Percept Mot Skills** 1995 Aug;81(1):323–30
Effects of stimulus duration, temporal delay, and complexity on the judgments of dot location. Hanari T. **Percept Mot Skills** 1996 Apr;82(2):459–66
The horizontal vertical illusion: evidence for strategic factors in feedback-induced illusion decrement. Harris KM, et al. **Percept Mot Skills** 1996 Feb;82(1):79–87
Human analog tests of the sixth stage of object permanence. Heishman M, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1059–68
Effects of color on children's naming of pictures. Johnson CJ. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1091–101
Digit and shape memory function in soroban learners: are soroban learners superior in general? Kawakami A. **Percept Mot Skills** 1995 Aug;81(1):75–80
Reexamining the Snodgrass and Corwin 1988 picture identification norms. Koch C, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):763–9
In similarity judgments hunter-gatherers prefer shapes over spatial relations in contrast to literate groups. Pontius AA. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1027–41
Dream recall and visual memory. Schredl M, et al. **Percept Mot Skills** 1995 Aug;81(1):256–8
Effect of task demand and stimulus relevance on preattentive processing. Schweizer K. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1123–8
Effects of report order, identification method, and stimulus characteristics on multidimensional stimulus identification. Shieh KK, et al. **Percept Mot Skills** 1996 Feb;82(1):99–111
A new method for examining the judgment of bigness. Shimizu M. **Percept Mot Skills** 1996 Apr;82(2):611–6
Effects of vibrating movement on geometrical illusions and illusory contours. Sohmiya T, et al. **Percept Mot Skills** 1995 Aug;81(1):189–90
Explanation of illusory contours in terms of strength of pattern and its spread effect. Sohmiya T, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1003–20
A looming-recession threshold. Steele KM, et al. **Percept Mot Skills** 1996 Apr;82(2):604–6
Figure-ground organization in different phases of the perceptual alternation phenomenon. Tuccio MT. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1043–58
Performance differences as a function of stimulus-response compatibility with rapid serial visual presentation and spatially distributed presentation styles. Utesch BS, et al. **Percept Mot Skills** 1996 Apr;82(2):643–7
Analysis by gender and Visual Imagery Reactivity of conventional and imagery Rorschach. Yanovski A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1319–40
Figural and semantic factors in change in the Ebbinghaus illusion across four age groups of children. Zanuttini L. **Percept Mot Skills** 1996 Feb;82(1):15–8
More about the difference between men and women: evidence from linear neural networks and the principal-component approach. Abdi H, et al. **Perception** 1995;24(5):539–62
Respective contribution of orientation contrast and illusion of self-tilt to the rod-and-frame effect. Cian C, et al. **Perception** 1995;24(6):623–30
Spatial-gradient limit on perception of multiple motion. Hermush Y, et al. **Perception** 1995;24(11):1247–56
Temporal-discontinuity detection with contrast-modulated gratings. Ichihara S, et al. **Perception** 1995;24(11):1257–64
The contribution of stimulus attributes of three-dimensional solid forms and level of discrimination to the visual and haptic percept of balance. Locher P, et al. **Perception** 1995; 24(6):647–63
'Reversed' illusion with three-dimensional Müller-Lyer shapes. Nijhawan R. **Perception** 1995;24(11):1281–96
Local-level and global-level form characteristics in apparent-motion correspondence. Palmer T, et al. **Perception** 1995;24(11):1233–45
The microgenesis of illusory figures: evidence for visual hypothesis testing. Parks TE. **Perception** 1995;24(6):681–4
Trajectory mapping: a new nonmetric scaling technique. Richards W, et al. **Perception** 1995;24(11):1315–31
Phenomena of illusory form: can we bridge the gap between levels of explanation? Spillmann L, et al. **Perception** 1995; 24(11):1333–64
The effect of curvature on visual interpolation. Takeichi H. **Perception** 1995;24(9):1011–20
Varying the strength of the Munker-White effect by

stereoscopic viewing. Taya R, et al. **Perception** 1995; 24(6):685–94
Multiple completions primed by occlusion patterns. van Lier RJ, et al. **Perception** 1995;24(7):727–40
The discrimination of dynamic orientation changes in gratings. Wright MJ, et al. **Perception** 1995;24(6):665–79
Judgment of gender through facial parts. Yamaguchi MK, et al. **Perception** 1995;24(5):563–75
Age-related differences in the detection of three-dimensional surfaces from optic flow. Andersen GJ, et al. **Psychol Aging** 1995 Dec;10(4):650–8
Attentional flexibility and aging: you don't need to be 20 years of age to split the beam. Hahn S, et al. **Psychol Aging** 1995 Dec;10(4):597–609
Adult age differences in the inhibition of return of visual attention. Hartley AA, et al. **Psychol Aging** 1995 Dec; 10(4):670–83
Age-related impairment in an event-based prospective-memory task. Maylor EA. **Psychol Aging** 1996 Mar;11(1):74–8
Contextual constraint facilitates semantic decisions about object pictures by Alzheimer patients. Nebes RD, et al. **Psychol Aging** 1995 Dec;10(4):590–6
Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)
Listening to Mozart may not enhance performance on the revised Minnesota Paper Form Board Test. Carstens CB, et al. **Psychol Rep** 1995 Aug;77(1):111–4
Delayed matching to complex samples and the formation of stimulus classes in children. Maguire RW, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1059–76
A dotted line assimilates in visibility to a solid line. King DL, et al. **Psychol Res** 1996;59(1):4–15
Action planning during the presentation of stimulus sequences: effects of compatible and incompatible stimuli. Müsseler J, et al. **Psychol Res** 1996;59(1):48–63
A formal theory of feature binding in object perception. Ashby FG, et al. **Psychol Rev** 1996 Jan;103(1):165–92
Reconciling simplicity and likelihood principles in perceptual organization. Chater N. **Psychol Rev** 1996 Jul;103(3):566–81 (80 ref.)
Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)
Dissociating face processing skills: decision about lip-read speech, expression, and identity. Campbell R, et al. **Q J Exp Psychol A** 1996 May;49(2):295–314
Implicit learning and concept learning. Frick RW, et al. **Q J Exp Psychol A** 1995 Aug;48(3):762–82
An analysis of errors in the learning, overlearning, and forgetting of sequences. Lansdale M, et al. **Q J Exp Psychol A** 1996 May;49(2):341–56
Contrasting effects of letter-spacing in alexia: further evidence that different strategies generate word length effects in reading. Price CJ, et al. **Q J Exp Psychol A** 1995 Aug;48(3):573–97
An associative interpretation of the indirect McCollough effect. Eissenberg T, et al. **Q J Exp Psychol B** 1995 Aug; 48(3):262–86
Perceptual unit formation in simple motion patterns. Ahlström U. **Scand J Psychol** 1995 Dec;36(4):343–54
Preferential looking: a sudden shift in visual fixation pattern at 32 months of age. Jacobsen K, et al. **Scand J Psychol** 1995 Sep;36(3):323–6
Durable improvements in Wisconsin Card Sorting Test performance in schizophrenic patients. Vollema MG, et al. **Schizophr Res** 1995 Aug 15;16(3):209–15
Scaffolded instruction and the remediation of Wisconsin Card Sorting Test deficits in chronic schizophrenia. Young DA, et al. **Schizophr Res** 1995 Aug 15;16(3):199–207
Superior parietal cortex activation during spatial attention shifts and visual feature conjunction. Corbetta M, et al. **Science** 1995 Nov 3;270(5237):802–5
Direct perception of three-dimensional motion from patterns of visual motion. Fermüller C, et al. **Science** 1995 Dec 22; 270(5244):1973–6
[Interaction effects in the lateral visual field: an extension of Bouma's (1970) approach] Heller D, et al. **Z Exp Psychol** 1995;42(3):386–418 (Eng. Abstr.) **(Ger)**
[Recall errors in locating cities on a map] Pohl R, et al. **Z Exp Psychol** 1995;42(1):63–93 (Eng. Abstr.) **(Ger)**
[Effects of presentation mode on visual-spatial working memory performance in children and adults] Schumann-Hengsteler R, et al. **Z Exp Psychol** 1995; 42(4):594–616 (Eng. Abstr.) **(Ger)**
[Working memory and work with memory: visual-spatial and further components of processing] Velichkovsky BM, et al. **Z Exp Psychol** 1995;42(4):672–701 (Eng. Abstr.) **(Ger)**
[Priming effects in picture problems: preliminary solutions] Wippich W, et al. **Z Exp Psychol** 1995;42(2):324–52 (Eng. Abstr.) **(Ger)**
[Two types of facial impression judgments and recognition memory for faces] Yoshikawa S. **Shinrigaku Kenkyu** 1995 Aug;66(3):191–8 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Pyrithiamine-induced thiamine deficiency impairs object recognition in rats. Mumby DG, et al. **Behav Neurosci** 1995 Dec;109(6):1209–14
omega-Conotoxin GVIA disrupts memory formation in the day-old chick. Clements MP, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):276–84

PHYSIOLOGY

Variability analysis of visual evoked potentials in humans by pattern recognition in phase domain. Achimowicz JZ. **Acta Neurobiol Exp (Warsz)** 1995;55(3):177–91
Event-related potentials and information processing in infants with and without Down syndrome. Karrer R, et al. **Am J Ment Retard** 1995 Sep;100(2):146–59
The representation of shape in the temporal lobe. Gochin PM. **Behav Brain Res** 1996 Apr;76(1–2):99–116 (155 ref.)
Processing of visual motion direction in the fronto-parallel plane in the stationary or moving observer. Probst T, et al. **Behav Brain Res** 1995 Oct;70(2):133–44
Fornix-fimbria section and working memory deficits in rats: stimulus complexity and stimulus size. Cassaday HJ, et al. **Behav Neurosci** 1995 Aug;109(4):594–606
Ischemia-induced object-recognition deficits in rats are attenuated by hippocampal ablation before or soon after ischemia. Mumby DG, et al. **Behav Neurosci** 1996 Apr; 110(2):266–81
Intraocular transfer and simultaneous processing of stimuli presented in different visual fields of the pigeon. Roberts WA, et al. **Behav Neurosci** 1996 Apr;110(2):290–9
Lesions of rat perirhinal cortex exacerbate the memory deficit observed following damage to the fimbria-fornix. Wiig KA, et al. **Behav Neurosci** 1995 Aug;109(4):620–30
When global information and local information collide: a brain potential analysis of the locus of interference effects. Ridderinkhof KR, et al. **Biol Psychol** 1995 Aug;41(1):29–53
Recognition memory for words and faces following unilateral temporal lobectomy. Morris RG, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):571–6
An event-related potential study of recognition memory with and without retrieval of source. Wilding EL, et al. **Brain** 1996 Jun;119 (Pt 3):889–905
Personal name recognition and associative priming in patients with unilateral brain damage. Schweinberger SR. **Brain Cogn** 1995 Oct;29(1):23–35
Induction of c-fos protein by patterned visual stimulation in central visual pathways of the rat. Montero VM, et al. **Brain Res** 1995 Sep 4;690(2):189–99
Changes in neuronal activity related to the repetition and relative familiarity of visual stimuli in rhinal and adjacent cortex of the anaesthetised rat. Zhu XO, et al. **Brain Res** 1995 Aug 14;689(1):101–10
P300 differences between sinistrals and dextrals. Alexander JE, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):277–82
Functional mapping of human memory using PET: comparisons of conceptual and perceptual tasks. Blaxton TA, et al. **Can J Exp Psychol** 1996 Mar;50(1):42–56
Pattern-reversal VEP [editorial; comment] Jacobson G. **Cephalalgia** 1996 Apr;16(2):78. Comment on: Cephalalgia 1996 Apr;16(2):104–6.
Pattern reversal visual evoked potentials in children with migraine or tension-type headache [see comments] Rossi LN, et al. **Cephalalgia** 1996 Apr;16(2):104–6. Comment in: Cephalalgia 1996 Apr;16(2):78.
Temporal and spatial processing in reading disabled and normal children. Eden GF, et al. **Cortex** 1995 Sep; 31(3):451–68
Cross-form priming in normal aging and in mild dementia of the Alzheimer type. Ergis AM, et al. **Cortex** 1995 Dec; 31(4):699–710
Maximizing the bilateral field advantage on verbal and nonverbal matching tasks. Ludwig TE, et al. **Cortex** 1996 Mar;32(1):131–41
The role of visual discrimination disorders and neglect in perceptual categorization deficits in right and left hemisphere damaged patients. Mulder JL, et al. **Cortex** 1995 Sep;31(3):487–501
Covert face recognition in prosopagnosia: a dissociable function? Schweinberger SR, et al. **Cortex** 1995 Sep; 31(3):517–29
Pattern recognition in insects. Heisenberg M. **Curr Opin Neurobiol** 1995 Aug;5(4):475–81 (68 ref.)
The recognition potential and conscious awareness. Rudell AP, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 98(4):309–18
Pattern recognition in equine locomotion [editorial; comment] Dalin G. **Equine Vet J** 1994 May;26(3):173–4. Comment on: Equine Vet J 1994 May;26(3):230–4. Comment on: Equine Vet J 1994 May;26(3):235–40.
Interactions between memory scanning and visual scanning in display monitoring. Liu Y. **Ergonomics** 1996 Aug; 39(8):1038–53
Visual movement and pattern are important for the development of a map of auditory space in the guinea pig superior colliculus. Thornton SK, et al. **Exp Brain Res** 1995;106(2):257–64
Physiological response in healthy subjects and in patients after myocardial infarction, elicited by a new computerised version of the Raven Coloured PM 47 as a mental stress test. Pruneti CA, et al. **Funct Neurol** 1995 Jul-Oct; 10(4–5):195–201
Weak electromagnetic fields increase the amplitude of the pattern reversal VEP response in patients with multiple sclerosis. Sandyk R. **Int J Neurosci** 1996 Mar;85(1–2):79–91
Event-related brain potentials elicited by rhyming and non-rhyming pictures differentiate subgroups of reading disabled adolescents. McPherson WB, et al. **Integr Physiol Behav Sci** 1996 Jan-Mar;31(1):3–17
Assessing adult receptive vocabulary with event-related potentials: an investigation of cross-modal and cross-form priming. Connolly JF, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):548–65
Magnetic coil suppression of visual perception at an extracalcarine site. Epstein CM, et al. **J Clin Neurophysiol** 1996 May;13(3):247–52
Magnetic coil suppression of extrafoveal visual perception using disappearance targets. Epstein CM, et al. **J Clin Neurophysiol** 1996 May;13(3):242–6
Event-related potentials during the Continuous Visual Memory Test. Retzlaff PD, et al. **J Clin Psychol** 1996 Jan; 52(1):43–7
Information flow and temporal coding in primate pattern vision. Heller J, et al. **J Comput Neurosci** 1995 Sep; 2(3):175–93
Fast spin-echo characteristics of visual stimulation-induced signal changes in the human brain. Gao JH, et al. **J Magn Reson Imaging** 1995 Nov-Dec;5(6):709–14
Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Berman KF, et al. **Neuropsychologia** 1995 Aug;33(8):1027–46
Evoked brain potentials and memory: more positivity in response to forgotten items. Jordan JS, et al. **Neuroreport** 1995 Oct 2;6(14):1913–6
Neural correlates of working memory in a visual letter monitoring task: an fMRI study. Mellers JD, et al. **Neuroreport** 1995 Dec 29;7(1):109–12
Category-specific brain activation in fMRI during picture naming. Spitzer M, et al. **Neuroreport** 1995 Nov 13; 6(16):2109–12
Mental representations of morphologically complex words: an event-related potential study with adult humans. Weyerts H, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):125–8
Hemispheric picture-naming hierarchies in stuttering subjects. Rastatter MP, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):899–908
Visual pattern memory without shape recognition. Dill M, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Aug 29; 349(1328):143–52
Face encoding and recognition in the human brain. Haxby JV, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):922–7
Learning and recall of form discriminations during reversible cooling deactivation of ventral-posterior suprasylvian cortex in the cat. Lomber SG, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1654–8
A single photon emission computed tomography study of cerebral regional perfusion changes induced by a learning task in subjects with mild memory impairment. Robert PH, et al. **Psychiatry Res** 1995 Nov 10;61(4):231–41
Loss of vision during the retinal stabilization of letters. Topolski R, et al. **Psychol Res** 1995;58(3):155–62
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Keefe RS, et al. **Schizophr Res** 1995 Sep;17(1):25–33
Grating detection and identification dissociated by pattern adaptation. Vassilev A, et al. **Spat Vis** 1995;9(2):221–34
Discrimination of compound gratings: spatial-frequency channels or local features? Akutsu H, et al. **Vision Res** 1995 Oct;35(19):2685–95
Further evidence for monocular determinants of perceived plaid direction. Alais D, et al. **Vision Res** 1996 May; 36(9):1247–53
Development of grating acuity and contrast sensitivity in the central and peripheral visual field of the human infant. Allen D, et al. **Vision Res** 1996 Jul;36(13):1945–53
Masking of spatial frequency in visual memory depends on distal, not retinal, frequency. Bennett PJ, et al. **Vision Res** 1996 Jan;36(2):233–8
Can random-dot stereograms serve as a model for the perception of depth in relation to real three-dimensional objects? [letter] Bishop PO. **Vision Res** 1996 May; 36(10):1473–7
Isolation and interaction of ON and OFF pathways in human vision: pattern--polarity effects on contrast discrimination. Bowen RW. **Vision Res** 1995 Sep;35(17):2479–90
Unequal saccades produced by aniseikonic patterns: a model approach. Bruno P, et al. **Vision Res** 1995 Dec; 35(23–24):3473–92
Temporal impulse response functions for luminance and colour during saccades. Burr DC, et al. **Vision Res** 1996 Jul;36(14):2069–78
Apparent speed of type I symmetrical plaids. Castet E, et al. **Vision Res** 1996 Jan;36(2):223–32
Monocular dot-density cues in random-dot stereograms. Cobo-Lewis AB. **Vision Res** 1996 Feb;36(3):345–50
Binocular correlation detection with oriented dynamic random-line stereograms. Cormack LK, et al. **Vision Res** 1996 Aug;36(15):2303–10
Linear and nonlinear contributions to step responses in cat retinal ganglion cells. Cox JF, et al. **Vision Res** 1996 Jul; 36(14):2047–60
Position dependency of rapidly induced saccade disconjugacy. Eggert T, et al. **Vision Res** 1995 Dec; 35(23–24):3493–503
The time course of 2-D shape discrimination in random dot stereograms. Glennerster A. **Vision Res** 1996 Jul; 36(13):1955–68
Effect of spatial scale and background luminance on the intensive and spatial nonlinearities in texture segregation.

Graham N, et al. **Vision Res** 1996 May;36(10):1371–90

Stereopais from interocular spatial frequency differences is not robust. Halpern DL, et al. **Vision Res** 1996 Aug; 36(15):2263–70

An illusion of relative motion dependent upon spatial frequency and orientation. Hine TJ, et al. **Vision Res** 1995 Nov;35(22):3093–102

The efficiency of different cue types for reducing spatial–frequency uncertainty. Hübner R. **Vision Res** 1996 Feb;36(3):401–8

Relative size disparities and the perception of surface slant. Kaneko H, et al. **Vision Res** 1996 Jul;36(13):1919–30

A linear systems approach to the detection of both abrupt and smooth spatial variations in orientation–defined textures. Kingdom FA, et al. **Vision Res** 1996 Feb; 36(3):409–20

Coherence, cardinal directions and higher–order mechanisms. Krauskopf J, et al. **Vision Res** 1996 May; 36(9):1235–45

Fourier and non–Fourier pattern discrimination compared. Lin LM, et al. **Vision Res** 1996 Jul;36(13):1907–18

Binocular combination of contrast signals from orthogonal orientation channels. Liu L, et al. **Vision Res** 1995 Sep; 35(18):2559–67

Effects of a static textured background on motion integration. Lorenceau J, et al. **Vision Res** 1995 Aug;35(16):2303–14

Modelling the increase of contrast sensitivity with grating area and exposure time. Luntinen O, et al. **Vision Res** 1995 Aug;35(16):2339–46

A second–order pattern reveals separate strategies for encoding orientation in two–dimensional space and space–time. McOwan PW, et al. **Vision Res** 1996 Feb; 36(3):425–30

The tilt aftereffect in plaids and gratings: channel codes, local signs and "patchwise" transforms. Meese TS, et al. **Vision Res** 1996 May;36(10):1421–37

Effects of luminance contrast and phase difference on motion assimilation for sinusoidal gratings. Ohtani Y, et al. **Vision Res** 1995 Aug;35(16):2277–86

Binocular rivalry with isoluminant stimuli visible only via short–wavelength–sensitive cones. O'Shea RP, et al. **Vision Res** 1996 Jun;36(11):1561–71

Perceived texture segregation in chromatic element–arrangement patterns: high intensity interference. Pessoa L, et al. **Vision Res** 1996 Jun;36(12):1745–60

Perceived contrast following adaptation to gratings of different orientations. Ross J, et al. **Vision Res** 1996 Jun; 36(12):1811–8

The effect of noise check size and shape on grating detectability. Rovamo J, et al. **Vision Res** 1996 Jan; 36(2):271–9

Localization and discrimination of "pop–out" targets. Saarinen J. **Vision Res** 1996 Jan;36(2):313–6

Spatial frequency adaptation: threshold elevation and perceived contrast. Snowden RJ, et al. **Vision Res** 1996 Jun;36(12):1797–809

The abutting grating illusion. Soriano M, et al. **Vision Res** 1996 Jan;36(1):109–16

Brightness induction from uniform and complex surrounds: a general model. Spehar B, et al. **Vision Res** 1996 Jul; 36(13):1893–906

The critical role of relative luminance relations in White's effect and grating induction. Spehar B, et al. **Vision Res** 1995 Sep;35(18):2603–14

Investigating simple and complex mechanisms in texture segregation using the speed–accuracy tradeoff method. Sutter A, et al. **Vision Res** 1995 Oct;35(20):2825–43

Detection of first–order structure in optic flow fields. Te Pas SF, et al. **Vision Res** 1996 Jan;36(2):259–70

Characterization of spatial aliasing and contrast sensitivity in peripheral vision. Thibos LN, et al. **Vision Res** 1996 Jan;36(2):249–58

The effects of spatiotemporal integration on maximum displacement thresholds for the detection of coherent motion. Todd JT, et al. **Vision Res** 1995 Aug; 35(16):2287–302

Unequal amplitude saccades produced by aniseikonic patterns: effects of viewing distance. van der Steen J, et al. **Vision Res** 1995 Dec;35(23–24):3459–71

Hyperacuity for spatial localization of contrast–modulated patterns. Volz H, et al. **Vision Res** 1996 May;36(9):1329–39

Depth release of illusory contour shape in the Ehrenstein grid. Watanabe T, et al. **Vision Res** 1995 Oct;35(20):2845–51

The effects of dot pattern parameters and constraints on the relative salience of vertical bilateral symmetry. Wenderoth P. **Vision Res** 1996 Aug;36(15):2311–20

Integration across directions in dynamic random dot displays: vector summation or winner take all? Zohary E, et al. **Vision Res** 1996 Aug;36(15):2321–31

[Parallel visual processing characteristics in healthy alexithymic subjects. Administration of the Toronto Alexithymia Scale and the parallel visual information test (see comments)] Montreuil M, et al. **Encephale** 1995 Sep–Oct;21(5):589–95 (Eng. Abstr.). Comment in: Encephale 1996 Jan–Feb;22(1):69–70. **(Fre)**

[Effect of task difficulty on hemispheric differences in visual image processing] Hildebrandt H, et al. **Z Exp Psychol** 1995;42(2):256–79 (Eng. Abstr.) **(Ger)**

[Influence of pattern stimulus modality on visual evoked potentials] Sobieszczańska M, et al. **Klin Oczna** 1995 Nov–Dec;97(11–12):353–5 (17 ref.) (Eng. Abstr.) **(Pol)**

[Positron–emission tomographic study of human brain processing of various characteristics of visually presented words. I. Processing of visual properties of stimuli (color)] Medvedev SV, et al. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):47–54 **(Rus)**

PATULIN

ANALYSIS

Rapid reversed–phase liquid chromatographic determination of patulin in apple juice. Gökmen V, et al. **J Chromatogr A** 1996 Apr 12;730(1–2):53–8

CHEMISTRY

Destruction of patulin and some other mycotoxins using potassium permanganate under alkaline conditions. Castegnaro M, et al. **IARC Sci Publ** 1991;(113):35–40

Degradation of patulin using ammoniation. Fremy JM, et al. **IARC Sci Publ** 1991;(113):41–5

Destruction of patulin in animal litter using ammoniation. Lunn G, et al. **IARC Sci Publ** 1991;(113):31–33

TOXICITY

Kinetic analysis of the chronology of patulin– and gossypol–induced cytotoxicity in vitro. Barhoumi R, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):290–7

PAUL–BUNNELL ANTIBODIES see **ANTIBODIES, HETEROPHILE**

PAUL–BUNNELL ANTIGENS see **ANTIGENS, HETEROPHILE**

PAVOR NOCTURNUS see **SLEEP DISORDERS**

PC12 CELLS

CHEMISTRY

A 56,000 Mr phosphoseryl protein in PC12 cell lysates strongly associates with protein–A sepharose beads and was observed in immune complex kinase assays for PP60c–src. Buensuceso C, et al. **Cell Signal** 1995 Nov;7(8):765–71

CYTOLOGY

Cytosine arabinoside differentially alters survival and neurite outgrowth of neuronal PC12 cells. Chang JY, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):753–8

Electrochemical monitoring of individual exocytotic events from the varicosities of differentiated PC12 cells. Zerby SE, et al. **Brain Res** 1996 Mar 11;712(1):1–10

Expression levels of B–50/GAP–43 in PC12 cells are decisive for the complexity of their neurites and growth cones. Jap Tjoen San ER, et al. **J Mol Neurosci** 1995;6(3):185–200

Beta–amyloid–induced cell toxicity: enhancement of 3–(4,5–dimethylthiazol–2–yl)–2,5–diphenyltetrazolium bromide–dependent cell death. Hertel C, et al. **J Neurochem** 1996 Jul;67(1):272–6

Role of Ca2+ in differentiation mediated by nerve growth factor and dibutyryl cyclic AMP in PC12 cells. Huang CM, et al. **J Neurochem** 1996 Aug;67(2):530–9

Ras–regulated hypophosphorylation of the retinoblastoma protein mediates neuronal differentiation in PC12 cells. Li H, et al. **J Neurochem** 1996 Jun;66(6):2287–94

A convenient in vitro assay for the inhibition of neurite outgrowth by adult mammalian CNS myelin using immortalized neuronal cells. Lozano AM, et al. **J Neurosci Methods** 1995 Dec;63(1–2):23–8

Hierarchical analysis of the nerve growth factor–dependent and nerve growth factor–independent differentiation signaling pathways in PC12 cells with protein kinase inhibitors. Campbell XZ, et al. **J Neurosci Res** 1995 Oct 1;42(2):207–19

A heterogeneous set of urea–insoluble proteins in dividing PC12 pheochromocytoma cells is passed on to at least the generation of great–granddaughter cells. Weber DJ, et al. **J Protein Chem** 1995 Jul;14(5):283–9

DRUG EFFECTS

Protective effect of interleukin–6 against the death of PC12 cells caused by serum deprivation or by the addition of a calcium ionophore. Umegaki H, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):911–6

Inhibition by Zn2+ of uridine 5'–triphosphate–induced Ca(2+)–influx but not Ca(2+)–mobilization in rat phaeochromocytoma cells. Koizumi S, et al. **Br J Pharmacol** 1995 Aug;115(8):1502–8

GAP–43 mRNA suppression by the ribozyme in PC12 cells and inhibition of evoked dopamine release. Imaizumi K, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):338–41

Biosynthesis of large dense–core vesicles in PC12 cells: effects of depolarization and second messengers on the mRNA levels of their constituents. Tschernitz C, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1–2):131–40

GTP and guanosine synergistically enhance NGF–induced neurite outgrowth from PC12 cells. Gysbers JW, et al. **Int J Dev Neurosci** 1996 Feb;14(1):19–34

Src homologous and collagen (Shc) protein binds to F–actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells. Thomas D, et al. **J Biol Chem** 1995 Dec 1;270(48):28924–31

Nerve growth factor stimulates tyrosine phosphorylation and activation of Src homology–containing protein–tyrosine phosphatase 1 in PC12 cells. Vambutas V, et al. **J Biol Chem** 1995 Oct 27;270(43):25629–33

Comparison of the effects of retinoic acid and nerve growth factor on PC12 cell proliferation, differentiation, and gene expression. Cosgaya JM, et al. **J Neurochem** 1996 Jan; 66(1):89–98

Nerve growth factor, epidermal growth factor, and insulin differentially potentiate ATP–induced [Ca2+]i rise and dopamine secretion in PC12 cells. Huang CM, et al. **J Neurochem** 1996 Jan;66(1):124–30

Cyanide–induced apoptosis and oxidative stress in differentiated PC12 cells. Mills EM, et al. **J Neurochem** 1996 Sep;67(3):1039–46

Cyclic AMP–independent inhibition of voltage–sensitive calcium channels by forskolin in PC12 cells. Park TJ, et al. **J Neurochem** 1996 Jan;66(1):83–8

Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. Farinelli SE, et al. **J Neurosci** 1996 Feb 1;16(3):1150–62

The fibroblast growth factor receptor–1 is necessary for the induction of neurite outgrowth in PC12 cells by aFGF. Lin HY, et al. **J Neurosci** 1996 Aug 1;16(15):4579–87

Purine and pyrimidine nucleotides activate distinct signalling pathways in PC12 cells. de Souza LR, et al. **J Neurosci Res** 1995 Aug 15;41(6):753–63

Treatment of PC12 cells by nerve growth factor, dexamethasone, and forskolin. Effects on cell morphology and expression of neurotensin and tyrosine hydroxylase. Caillaud T, et al. **Mol Neurobiol** 1995 Apr–Jun; 10(2–3):105–14

Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists. van der Ploeg I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):250–60

Vasoactive intestinal peptide but not galanin promotes survival of neonatal rat sympathetic neurons and neurite outgrowth of PC12 cells. Klimaschewski L, et al. **Neurosci Lett** 1995 Aug 4;195(2):133–6

Inhibitory effects of protoberberine alkaloids from the roots of Coptis japonica on catecholamine biosynthesis in PC12 cells. Lee MK, et al. **Planta Med** 1996 Feb;62(1):31–4

ENZYMOLOGY

Modulation of zeta–protein kinase C by cyclic AMP in PC12 cells occurs through phosphorylation by protein kinase A. Wooten MW, et al. **J Neurochem** 1996 Sep;67(3):1023–31

Nitric oxide delays the death of trophic factor–deprived PC12 cells and sympathetic neurons by a cGMP–mediated mechanism. Farinelli SE, et al. **J Neurosci** 1996 Apr 1; 16(7):2325–34

Increased antioxidant enzyme activity in amyloid beta protein–resistant cells. Sagara Y, et al. **J Neurosci** 1996 Jan 15;16(2):497–505

Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide–peroxynitrite pathway. Troy CM, et al. **J Neurosci** 1996 Jan;16(1):253–61

A denaturant–insoluble form of tyrosine hydroxylase in PC12 pheochromocytoma cells. Fleming–Jones RM, et al. **J Protein Chem** 1995 Jul;14(5):275–82

METABOLISM

Monitoring intracellular nitric oxide formation by dichlorofluorescin in neuronal cells. Gunasekar PG, et al. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):15–21

Myelin basic protein mRNA localization and polypeptide targeting. Boccaccio GL, et al. **J Neurosci Res** 1995 Oct 1;42(2):277–86

PHYSIOLOGY

PC12 cells as a model to study the effects of opioids on normal and tumoral adrenal chromaffin cells. Margioris AN, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:166–72

An activated mutant of the alpha subunit of G(o) increases neurite outgrowth via protein kinase C. Xie R, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):77–86

Nerve growth factor and ras regulate beta–amyloid precursor protein gene expression in PC12 cells. Cosgaya JM, et al. **J Neurochem** 1996 Jul;67(1):98–104

Glucocorticoids and nerve growth factor differentially modulate cell adhesion molecule L1 expression in PC12 cells. Grant NJ, et al. **J Neurochem** 1996 Apr;66(4):1400–8

SECRETION

Novel markers for constitutive secretion used to show that tissue plasminogen activator is sorted to the regulated pathway in transfected PC12 cells. Harrison TM, et al. **Cell Biol Int** 1996 Apr;20(4):293–9

ULTRASTRUCTURE

Overexpression of Ca2+/calmodulin–dependent protein kinase II inhibits neurite outgrowth of PC12 cells. Tashima K, et al. **J Neurochem** 1996 Jan;66(1):57–64

PCA see **PASSIVE CUTANEOUS ANAPHYLAXIS**

PCBS see **POLYCHLORINATED BIPHENYLS**

PCMBS see
4-CHLOROMERCURIBENZENESULFONATE

PCNA see PROLIFERATING CELL NUCLEAR ANTIGEN

PCP see PHENCYCLIDINE

PCP ABUSE see PHENCYCLIDINE ABUSE

PCP RECEPTORS see RECEPTORS, PHENCYCLIDINE

PCR see POLYMERASE CHAIN REACTION

PDGF RECEPTORS see RECEPTORS,
PLATELET-DERIVED GROWTH FACTOR

PDH PHOSPHATASE see PYRUVATE
DEHYDROGENASE (LIPOAMIDE)-PHOSPHATASE

PEAK EXPIRATORY FLOW RATE

Statement on self-monitoring of peak expiratory flow in the investigation of occupational asthma. Subcommittee on Occupational Allergy of the European Academy of Allergology and Clinical Immunology. Moscato G, et al. **Allergy** 1995 Sep;50(9):711–7

Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Valletta EA, et al. **Allergy** 1995 Apr;50(4):366–9

PEF variability, bronchial responsiveness and their relation to allergy markers in a random population (20–70 yr). Boezen HM, et al. **Am J Respir Crit Care Med** 1996 Jul; 154(1):30–5

Exogenous stimuli and circadian peak expiratory flow variation in allergic asthmatic children. Meijer GG, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):237–42

Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology, American Academy of Allergy and Immunology, European Respiratory Society, American College of Allergy, Asthma and Immunology. Moscato G, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):233–8

Asthma peak flow diary improves care [letter] Plaut TF. **Ann Allergy Asthma Immunol** 1996 May;76(5):476–8

Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease [see comments] Emerman CL, et al. **Ann Emerg Med** 1996 Feb;27(2):159–63. Comment in: Ann Emerg Med 1996 Feb;27(2):236–8.

Correlation versus agreement: methods of measurement in medicine [editorial; comment] Gallagher EJ. **Ann Emerg Med** 1996 Feb;27(2):236–8. Comment on: Ann Emerg Med 1996 Feb;27(2):159–63.

Evaluation of the suitability of weekly peak expiratory flow rate measurements in monitoring annual decline in lung function among patients with asthma and chronic bronchitis. Tirimanna PR, et al. **Br J Gen Pract** 1996 Jan; 46(402):15–8

Interinstrument variability of three portable peak flow meters [letter] Schmekel B. **Chest** 1996 Jun;109(6):1668

Determining the expiratory time constant [letter; comment] Pötzl G, et al. **Crit Care Med** 1996 Apr;24(4):720; discussion 720–1. Comment on: Crit Care Med 1995 Jun;23(6):1117–22.

Determining the expiratory time constant [letter; comment] Tan IK, et al. **Crit Care Med** 1996 Apr;24(4):719–20; discussion 720–1. Comment on: Crit Care Med 1995 Jun;23(6):1117–22.

Increased peak flow variability in children with asymptomatic hyperresponsiveness. Gibson PG, et al. **Eur Respir J** 1995 Oct;8(10):1731–5

Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of the European Academy of Allergology and Clinical Immunology. American Academy of Allergy and Clinical Immunology. European Respiratory Society. American College of Allergy, Asthma and Immunology. Moscato G, et al. **Eur Respir J** 1995 Sep;8(9):1605–10

Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology. Moscato G, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):295–301

An evaluation of the agreement between three peak flow meters: Wright's, Miniwright's, and Pocket, when used in children. Deng CT, et al. **J Asthma** 1996;33(2):125–30

An asthma self-management program for children, including instruction in peak flow monitoring by school nurses. Persaud DI, et al. **J Asthma** 1996;33(1):37–43

Interrelationships of peak expiratory flow rate with physical and cognitive function in the elderly: MacArthur Foundation studies of aging. Cook NR, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M317–23

Peak-expiratory-flow meters and asthma self-management. Legge JS. **Lancet** 1996 Jun 22;347(9017):1709–10

Peak flow meter use in asthma management. Thoracic Society of Australia and New Zealand. **Med J Aust** 1996 Jun 17;164(12):727–30

Feasibility study of respiratory questionnaire and peak flow recordings in autobody shop workers exposed to isocyanate-containing spray paint: observations and limitations. Cullen MR, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):197–204

Potential problems in peak expiratory flow data used to diagnose occupational asthma. Miller MR. **Occup Med (Oxf)** 1996 Jun;46(3):239–41

Spirometric patterns in childhood asthma: peak flow compared with other indices. Klein RB, et al. **Pediatr Pulmonol** 1995 Dec;20(6):372–9

The performance of Mini Wright peak flow meters after prolonged use. Miles JF, et al. **Respir Med** 1995 Oct; 89(9):603–5

The performance of mini Wright peak flow meters after prolonged use [letter] Niggemann B. **Respir Med** 1996 Jul; 90(6):371

Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma. Gannon PF, et al. **Thorax** 1996 May;51(5):484–9

Value of home peak flow monitoring for asthma control. Janson S. **West J Med** 1995 Oct;163(4):370–1

[Standard range of peak expiratory flow in normal, healthy Japanese subjects] Tsukioka K, et al. **Arerugi** 1996 May; 45(5):442–50 (Eng. Abstr.) **(Jpn)**

[Symptoms, FEV1/FVC, and peak flow as indices of the control of asthma] Zang M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):270–4 (Eng. Abstr.) **(Jpn)**

[Management of asthma based on their peak expiratory flow rate monitoring] Tamura G. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):222–6 (11 ref.) **(Jpn)**

IMMUNOLOGY

CD4 T-lymphocyte activation is associated with peak expiratory flow variability in childhood asthma. Doi S, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):955–62

PHYSIOLOGY

Relationship between airway responsiveness and peak expiratory flow variability in subjects with allergic rhinitis. Prieto L, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):273–9

Relationship between supramaximal flows and flow-limiting mechanisms. Sala H, et al. **Eur Respir J** 1996 Mar; 9(3):512–6

A model for peak expiratory flow allowing for back pressure and distensibility. Calvert JR. **Med Eng Phys** 1995 Sep; 17(6):462–5

PEANUTS

Magnetic resonance imaging of an inhaled peanut. Kimura H, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):574–6

Peanut oil in medications [letter] Weeks R. **Lancet** 1996 Sep 14;348(9029):759–60

ADVERSE EFFECTS

Clinical study of peanut and nut allergy in 62 consecutive patients: new features and associations [see comments] Ewan PW. **BMJ** 1996 Apr 27;312(7038):1074–8. Comment in: BMJ 1996 Apr 27;312(7038):1050–1.

Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: results of a questionnaire survey, skin prick testing, and food challenges. Hourihane JO, et al. **BMJ** 1996 Aug 31;313(7056):518–21

Peanut and nut allergy. Study was not designed to measure prevalence [letter] Jones S, et al. **BMJ** 1996 Aug 3; 313(7052):299–300

Peanut and nut allergy. Baby massage oils could be a hazard [letter] Joyce R, et al. **BMJ** 1996 Aug 3;313(7052):299

Peanut and nut allergy. Reduced exposure might increase allergic sensitisation [letter] Lack G, et al. **BMJ** 1996 Aug 3;313(7052):300

Peanut and nut allergy. Creams and ointments containing peanut oil may lead to sensitisation [letter] Lever LR. **BMJ** 1996 Aug 3;313(7052):299; discussion 300

Peanut and nut allergy. Sesame allergy is also a problem [letter] Perkins MS. **BMJ** 1996 Aug 3;313(7052):300

Managing peanut allergy [editorial; comment] Sampson HA. **BMJ** 1996 Apr 27;312(7038):1050–1. Comment on: BMJ 1996 Apr 27;312(7038):1074–8.

Cohort study of peanut and tree nut sensitisation by age of 4 years. Tariq SM, et al. **BMJ** 1996 Aug 31;313(7056):514–7

Peanut and nut allergy. Serious adverse reactions to adrenaline are becoming more likely [letter] Wilson JA. **BMJ** 1996 Aug 3;313(7052):299; discussion 300

Peanut anaphylaxis from food cross-contamination [letter] Kemp SF, et al. **JAMA** 1996 Jun 5;275(21):1636–7

[In young children with severe asthma, suspect allergy to peanuts (letter)] Bidat E, et al. **Arch Pediatr** 1996 Jan; 3(1):91–2 **(Fre)**

CHEMISTRY

Determination of aflatoxins in groundnut meal by high-performance liquid chromatography: a comparison of two methods of derivatisation of aflatoxin B1. Roch OG, et al. **Br J Biomed Sci** 1995 Dec;52(4):312–6

Aflatoxin B1 contamination in groundnut samples collected from different geographical regions of India: a multicentre study. Bhat RV, et al. **Food Addit Contam** 1996 Apr; 13(3):325–31

Purification and partial characterization of acyl carrier proteins from developing oil seeds of pisa (Actinodaphne hookeri) and ground nut (Arachis hypogaea). Sreenivas A, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):137–46

Evaluation of sampling plans used in the United States, United Kingdom, and The Netherlands to test raw shelled peanuts for aflatoxin. Whitaker TB, et al. **J AOAC Int** 1995 Jul-Aug;78(4):1010–8

ENZYMOLOGY

Purification and characterization of an acid phosphatase from Arachis hypogaea. Srivastava R, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):949–56

Structural influence of calcium on the heme cavity of cationic peanut peroxidase as determined by 1H-NMR spectroscopy. Barber KR, et al. **Eur J Biochem** 1995 Sep 15;232(3):825–33

A soluble preparation from developing groundnut seeds (Arachis hypogaea) catalyzes de novo synthesis of long chain fatty acids. Sreenivas A, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):213–7

GENETICS

Peanut transformation. Mansur E, et al. **Methods Mol Biol** 1995;44:87–100

Characterization of two class II chitinase genes from peanut and expression studies in transgenic tobacco plants. Kellmann JW, et al. **Plant Mol Biol** 1996 Jan;30(2):351–8

IMMUNOLOGY

Food allergen (peanut)-specific TH2 clones generated from the peripheral blood of a patient with peanut allergy. de Jong EC, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):73–81

Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity. Burks AW, et al. **J Clin Invest** 1995 Oct;96(4):1715–21

Selective expansion of T cells expressing V beta 2 in peanut allergy. Dorion BJ, et al. **Pediatr Allergy Immunol** 1995 May;6(2):95–7

MICROBIOLOGY

Bradyrhizobium (Arachis) sp. strain NC92 contains two nodD genes involved in the repression of nodA and a nolA gene required for the efficient nodulation of host plants. Gillette WK, et al. **J Bacteriol** 1996 May;178(10):2757–66

STANDARDS

Effects of overprocessing on the nutritional quality of peanut meal. Zhang Y, et al. **Poult Sci** 1996 Apr;75(4):514–8

VIROLOGY

The cDNA sequence and infectious transcripts of peanut stripe virus. Flasinski S, et al. **Gene** 1996 Jun 1; 171(2):299–300

PEAS

Response of the calf pancreas to differently processed soya bean and pea diets. Le Dréan G, et al. **Ann Nutr Metab** 1995;39(3):164–76

CHEMISTRY

Photosystem II of green plants: topology of core pigments and redox cofactors as inferred from electrochromic difference spectra. Mulkidjanian AY, et al. **Biochemistry** 1996 Mar 5;35(9):3093–107

Purification and characterization of a DNA helicase from pea chloroplast that translocates in the 3'-to-5' direction. Tuteja N, et al. **Eur J Biochem** 1996 May 15;238(1):54–63

Molecular chaperones are present in the thylakoid lumen of pea chloroplasts. Schlicher T, et al. **FEBS Lett** 1996 Feb 5;379(3):302–4

Amino acid sequence of a Bowman-Birk proteinase inhibitor from pea seeds. Ferrasson E, et al. **J Protein Chem** 1995 Aug;14(6):467–75

CYTOLOGY

Plant cells contain two functionally distinct vacuolar compartments. Paris N, et al. **Cell** 1996 May 17; 85(4):563–72

Root border cells as tools in plant cell studies. Brigham LA, et al. **Methods Cell Biol** 1995;49:377–87 (20 ref.)

ENZYMOLOGY

Glycine decarboxylase and pyruvate dehydrogenase complexes share the same dihydrolipoamide dehydrogenase in pea leaf mitochondria: evidence from mass spectrometry and primary-structure analysis. Bourguignon J, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):229–34

Protein biotinylation in higher plants: characterization of biotin holocarboxylase synthetase activity from pea (Pisum sativum) leaves. Tissot G, et al. **Biochem J** 1996 Mar 1; 314 (Pt 2):391–5

Contribution of the FAD binding site residue tyrosine 308

to the stability of pea ferredoxin-NADP+ oxidoreductase. Calcaterra NB, et al. **Biochemistry** 1995 Oct 3; 34(39):12842–8

Pattern of expression and characteristics of a cysteine proteinase cDNA from germinating seeds of pea (Pisum sativum L.). Jones CG, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):13–5

Protease inhibitor studies and cloning of a serine carboxypeptidase cDNA from germinating seeds of pea (Pisum sativum L.). Jones CG, et al. **Eur J Biochem** 1996 Feb 1;235(3):574–8

Expression, lipoylation and structure determination of recombinant pea H-protein in Escherichia coli. Macherel D, et al. **Eur J Biochem** 1996 Feb 15;236(1):27–33

Pyruvate decarboxylase from Pisum sativum. Properties, nucleotide and amino acid sequences. Mücke U, et al. **Eur J Biochem** 1996 Apr 15;237(2):373–82

Purification and characterization of a DNA helicase from pea chloroplast that translocates in the 3'-to-5' direction. Tuteja N, et al. **Eur J Biochem** 1996 May 15;238(1):54–63

The free radical site in pea seedling copper amine oxidase probed by resonance Raman spectroscopy and generated by photolysis of caged substrate. Johnson SA, et al. **FEBS Lett** 1996 Feb 12;380(1–2):183–7

Kinetic and spectral properties of pea cytosolic ascorbate peroxidase. Marquez LA, et al. **FEBS Lett** 1996 Jul 1; 389(2):153–6

Molecular cloning and pattern of expression of an alpha-L-fucosidase gene from pea seedlings. Augur C, et al. **J Biol Chem** 1995 Oct 20;270(42):24839–43

Binding site on pea chloroplast fructose-1,6-bisphosphatase involved in the interaction with thioredoxin. Hermoso R, et al. **Plant Mol Biol** 1996 Feb;30(3):455–65

Expression of arginine decarboxylase is induced during early fruit development and in young tissues of Pisum sativum (L.). Pérez-Amador MA, et al. **Plant Mol Biol** 1995 Sep; 28(6):997–1009

Analysis of cis-regulatory elements involved in the activation of a member of chalcone synthase gene family (PsChs1) in pea. Seki H, et al. **Plant Mol Biol** 1996 Jun;31(3):479–91

Molecular evolution of duplicate copies of genes encoding cytosolic glutamine synthetase in Pisum sativum. Walker EL, et al. **Plant Mol Biol** 1995 Dec;29(6):1111–25

Pea formaldehyde-active class III alcohol dehydrogenase: common derivation of the plant and animal forms but not of the corresponding ethanol-active forms (classes I and P). Shafqat J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5595–9

GENETICS

Pyruvate decarboxylase from Pisum sativum. Properties, nucleotide and amino acid sequences. Mücke U, et al. **Eur J Biochem** 1996 Apr 15;237(2):373–82

RNA editing is required for efficient excision of tRNA(Phe) from precursors in plant mitochondria. Marchfelder A, et al. **J Biol Chem** 1996 Jan 26;271(4):1898–903

Variation of repetitive DNA sequences in progenies of regenerated plants of Pisum sativum. Cavallini A, et al. **J Hered** 1996 May-Jun;87(3):233–7

Molecular characterization of the Pseudomonas syringae pv. pisi plasmid-borne avirulence gene avrPpiB which matches the R3 resistance locus in pea. Cournoyer B, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):700–8

Expression of the pisatin detoxifying genes (PDA) of Nectria haematococca in vitro and in planta. Hirschi K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):483–91

The sequence surrounding the translation initiation codon of the pea plastocyanin gene increases translational efficiency of a reporter gene. Helliwell CA, et al. **Plant Mol Biol** 1995 Nov;29(3):621–6

Light-modulated abundance of an mRNA encoding a calmodulin-regulated, chromatin-associated NTPase in pea. Hsieh HL, et al. **Plant Mol Biol** 1996 Jan;30(1):135–47

A salt- and dehydration-inducible pea gene, Cyp15a, encodes a cell-wall protein with sequence similarity to cysteine proteases. Jones JT, et al. **Plant Mol Biol** 1995 Sep; 28(6):1055–65

The pea early nodulin gene PsENOD7 maps in the region of linkage group I containing sym2 and leghaemoglobin. Kozik A, et al. **Plant Mol Biol** 1996 Apr;31(1):149–56

A cDNA from pea petals with sequence similarity to pollen allergen, cytokinin-induced and genetic tumour-specific genes: identification of a new family of related sequences. Michael AJ. **Plant Mol Biol** 1996 Jan;30(1):219–24

Isolation by PCR of a cDNA clone from pea petals with similarity to petunia and wheat zinc finger proteins. Michael AJ, et al. **Plant Mol Biol** 1996 Mar;30(5):1051–8

The Pisum sativum MAP kinase homologue (PsMAPK) rescues the Saccharomyces cerevisiae hog1 deletion mutant under conditions of high osmotic stress. Püpping B, et al. **Plant Mol Biol** 1996 May;31(2):355–63

Expression of nodulin genes in plant-determined ineffective nodules of pea. Suganuma N, et al. **Plant Mol Biol** 1995 Sep;28(6):1027–38

Sugar-binding activity of pea (Pisum sativum) lectin is essential for heterologous infection of transgenic white clover hairy roots by Rhizobium leguminosarum biovar viciae. van Eijsden R, et al. **Plant Mol Biol** 1995 Nov; 29(3):431–9

A 200 bp region of the pea ENOD12 promoter is sufficient for nodule-specific and nod factor induced expression. Vijn I, et al. **Plant Mol Biol** 1995 Sep;28(6):1103–10

Molecular evolution of duplicate copies of genes encoding cytosolic glutamine synthetase in Pisum sativum. Walker EL, et al. **Plant Mol Biol** 1995 Dec;29(6):1111–25

Molecular cloning and expression of mRNAs encoding H1 histone and an H1 histone-like sequences in root tips of pea (Psium sativum L.). Woo HH, et al. **Plant Mol Biol** 1995 Sep;28(6):1143–7

Identification of a new pea gene, PsNlec1, encoding a lectin-like glycoprotein isolated from the symbiosomes of root nodules. Kardailsky IV, et al. **Plant Physiol** 1996 May; 111(1):49–60

Characterization of an endo-beta-1,4-glucanase gene induced by auxin in elongating pea epicotyls. Wu SC, et al. **Plant Physiol** 1996 Jan;110(1):163–70

GROWTH & DEVELOPMENT

Differential activation of the primary auxin response genes, PS-IAA4/5 and PS-IAA6, during early plant development. Wong LM, et al. **Plant J** 1996 May; 9(5):587–99

Cell cycle regulation during growth-dormancy cycles in pea axillary buds. Devitt ML, et al. **Plant Mol Biol** 1995 Oct; 29(2):255–65

Hormonal regulation of S-adenosylmethionine synthase transcripts in pea ovaries. Gómez-Gómez L, et al. **Plant Mol Biol** 1996 Feb;30(4):821–32

Uridine, a cell division factor in pea roots. Smit G, et al. **Plant Mol Biol** 1995 Nov;29(4):869–73

Evolution of soluble carbohydrates during the development of pea, faba bean and lupin seeds. Frias J, et al. **Z Lebensm Unters Forsch** 1996 Jul;203(1):27–32

METABOLISM

Sequence and expression of the mRNA encoding HSP22, the mitochondrial small heat-shock protein in pea leaves. Lenne C, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):805–13

Metabolism of xyloglucan generates xylose-deficient oligosaccharide subunits of this polysaccharide in etiolated peas. Guillén R, et al. **Carbohydr Res** 1995 Nov 22; 277(2):291–311

Histidine and tyrosine phosphorylation in pea mitochondria: evidence for protein phosphorylation in respiratory redox signalling. Håkansson G, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):238–42

Unassembled subunits of the photosynthetic oxygen-evolving complex present in the thylakoid lumen are long-lived and assembly-competent. Hashimoto A, et al. **FEBS Lett** 1996 Aug 5;391(1–2):29–34

In vitro import of pre-ferredoxin-NADP+-oxidoreductase from Cyanophora paradoxa into cyanelles and into pea chloroplasts. Jakowitsch J, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):153–5

Effect of cyclosporin A on energy coupling in pea stem mitochondria. Vianello A, et al. **FEBS Lett** 1995 Sep 11; 371(3):258–60

The influence of amylose on starch granule structure. Jenkins PJ, et al. **Int J Biol Macromol** 1995 Dec;17(6):315–21

Mitochondria are a major site for folate and thymidylate synthesis in plants. Neuburger M, et al. **J Biol Chem** 1996 Apr 19;271(16):9466–72

Phytochrome regulates phosphorylation of a protein with characteristics of a nucleoside diphosphate kinase in the crude membrane fraction from stem sections of etiolated pea seedlings. Hamada T, et al. **J Photochem Photobiol B** 1996 Apr;33(2):143–51

The sequence surrounding the translation initiation codon of the pea plastocyanin gene increases translational efficiency of a reporter gene. Helliwell CA, et al. **Plant Mol Biol** 1995 Nov;29(3):621–6

Light-harvesting chlorophyll a/b-binding protein inserted into isolated thylakoids binds pigments and is assembled into trimeric light-harvesting complex. Kuttkat A, et al. **Plant Physiol** 1995 Dec;109(4):1267–76

Seed and 4-chloroindole-3-acetic acid regulation of gibberellin metabolism in pea pericarp. van Huizen R, et al. **Plant Physiol** 1995 Dec;109(4):1213–7

Membrane association of the Rieske iron-sulfur protein. Szczepaniak A, et al. **Z Naturforsch [C]** 1995 Jul-Aug; 50(7–8):535–42

MICROBIOLOGY

First report of the inhibition of arbuscular mycorrhizal infection of Pisum sativum by specific and irreversible inhibition of polyamine biosynthesis or by gibberellic acid treatment. El Ghachtouli N, et al. **FEBS Lett** 1996 May 6;385(3):189–92

Genomic heterogeneity of strains nodulating chickpeas (Cicer arietinum L.) and description of Rhizobium mediterraneum sp. nov. Nour SM, et al. **Int J Syst Bacteriol** 1995 Oct; 45(4):640–8

Fusarium solani DNase is a signal for increasing expression of nonhost disease resistance response genes, hypersensitivity, and pisatin production. Hadwiger LA, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec;8(6):871–9

Mycoflora and aflatoxin production in pigeon pea stored in jute sacks and iron bins. Bankole SA, et al. **Mycopathologia** 1995-96;132(3):155–60

PHYSIOLOGY

Effects of light and temperature on expression of ClpC, the regulatory subunit of chloroplastic Clp protease, in pea seedlings. Ostersetzer O, et al. **Plant Mol Biol** 1996 Jun; 31(3):673–6

VIROLOGY

Susceptibility of some pea cultivars to pea seed-borne mosaic virus infection and virus transmission by seeds. Gallo J, et al. **Acta Virol** 1995 Dec;39(5–6):283–6

Biological and molecular properties of a pathotype P-1 and a pathotype P-4 isolate of pea seed-borne mosaic virus. Johansen IE, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1329–33

Multiple virus genes involved in the nematode transmission of pea early browning virus. MacFarlane SA, et al. **Virology** 1996 May 15;219(2):417–22

PEAT see **SOIL**

PEAT THERAPY see **MUD THERAPY**

PECTEN OCULI see **RETINAL VESSELS**

PECTIN DEPOLYMERASE see **POLYGALACTURONASE**

PECTINASE see **POLYGALACTURONASE**

PECTINS

Evaluation of the safety of sodium pectate as a food ingredient. Borzelleca JF, et al. **Food Chem Toxicol** 1996 Jan;34(1):21–5 (18 ref.)

ANALYSIS

Neutral detergent fibre and pectic substances in pineapple and its derivates: juices and nectars. Cámara Hurtado M, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S277–80

Analysis of linear oligogalacturonic acids by negative-ion electrospray ionization mass spectrometry. Xie M, et al. **Rapid Commun Mass Spectrom** 1995;9(15):1572–5

[Dietary fiber and pectin fractions of Beta vulgaris var. conditiva] Dongowski G. **Z Lebensm Unters Forsch** 1996 Apr;202(4):285–93 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Predicting the phase diagram for a gelatin-pectin system. Clewlow AC, et al. **Biochem Soc Trans** 1995 Aug; 23(3):498S

Solution conformations of pectin polysaccharides: determination of chain characteristics by small angle neutron scattering, viscometry, and molecular modeling. Cros S, et al. **Biopolymers** 1996 Sep;39(3):339–52

Characterisation of the endo-polygalacturonase-resistant region of the pectin from Bupleurum falcatum L.—a polysaccharide with an active function in clearance of immune complexes. Matsumoto T, et al. **Carbohydr Res** 1995 Apr 30;270(2):221–9

Different populations of pectic hairy regions occur in apple cell walls. Schols HA, et al. **Carbohydr Res** 1995 Oct 2; 275(2):343–60

The backbone of the pectic polysaccharide rhamnogalacturonan I is cleaved by an endohydrolase and an endolyase. Azadi P, et al. **Glycobiology** 1995 Dec; 5(8):783–9

Conformational features of galacturonans. I. Structure and energy minimization of charged and uncharged galacturonan dimeric units. Ruggiero JR, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):205–12

Conformational features of galacturonans. II. Configurational statistics of pectic polymers. Ruggiero JR, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):213–8

Influence of pectin structure on the interaction with bile acids under in vitro conditions. Dongowski G. **Z Lebensm Unters Forsch** 1995 Oct;201(4):390–8

[Composition, physico-chemical properties and molecular superstructure of dietary fiber preparations of the cellan type] Dongowski G, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):46–54 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Characterization of a monoclonal antibody that recognizes an arabinosylated (1—>6)-beta-D-galactan epitope in plant complex carbohydrates. Steffan W, et al. **Carbohydr Res** 1995 Oct 2;275(2):295–307

An antibody Fab selected from a recombinant phage display library detects deesterified pectic polysaccharide rhamnogalacturonan II in plant cells. Williams MN, et al. **Plant Cell** 1996 Apr;8(4):673–85

METABOLISM

Cloning of a new pectate lyase gene pelC from Fusarium solani f. sp. pisi (Nectria haematococca, mating type VI) and characterization of the gene product expressed in Pichia pastoris. Guo W, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):352–60

PCR cloning and expression analysis of a cDNA encoding a pectinacetylesterase from Vigna radiata L. Breton C, et al. **FEBS Lett** 1996 Jun 17;388(2–3):139–42

New search for pectolytic yeasts. Biely P, et al. **Folia Microbiol (Praha)** 1994;39(6):485–8

Some preliminary results on the action of

rhamnogalacturonase on rhamnogalacturonan oligosaccharides from beet pulp. Renard CM, et al. **Int J Biol Macromol** 1995 Dec;17(6):333–6

Molecular cloning and characterization of a rhamnogalacturonan acetylesterase from Aspergillus aculeatus. Synergism between rhamnogalacturonan degrading enzymes. Kauppinen S, et al. **J Biol Chem** 1995 Nov 10;270(45):27172–8

PHARMACOLOGY

Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):833–41

Pectin feeding influences fecal bile acid excretion, hepatic bile acid and cholesterol synthesis and serum cholesterol in rats. Garcia-Diez F, et al. **J Nutr** 1996 Jul;126(7):1766–71

Pectin with low molecular weight and high degree of esterification increases absorption of 58Fe in growing rats. Kim M, et al. **J Nutr** 1996 Jul;126(7):1883–90

Effect of oral administration of a pectic polysaccharide fraction from a kampo (Japanese herbal) medicine "juzen-taiho-to" on antibody response of mice. Kiyohara H, et al. **Planta Med** 1995 Oct;61(5):429–34

Effects of pelleting, lactose level, polyethylene glycol 4000, and guar gum compared to pectin on growth performances, energy values, and losses of lactose, lactic acid, and water in chickens. Carré B, et al. **Poult Sci** 1995 Nov; 74(11):1810–9

Stoichiometry of pectin and glucose fermentation in Prevotella ruminicola. Marounek M, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):107–10

The short-term effect of dietary pectin on plasma levels and renal excretion of dehydroepiandrosterone sulfate. Remer T, et al. **Z Ernahrungswiss** 1996 Mar;35(1):32–8

[Structure and pharmacological activity of pectic polysaccharides from the roots of Bupleurum falcatum L.] Yamada H. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):229–37 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of pectin on the viability of Vibrio cholerae] Potievskil EG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):22–3 **(Rus)**

THERAPEUTIC USE

[The prophylactic use of pectin in chronic lead exposure in industry] Trakhtenberg IM, et al. **Vrach Delo** 1995 Jan-Feb; (1-2):132–6 (Eng. Abstr.) **(Rus)**

PECTORAL NERVES see THORACIC NERVES

PECTORALIS MUSCLES

Steindler and pectoralis major flexorplasty: a comparative analysis. Beaton DE, et al. **J Hand Surg [Am]** 1995 Sep; 20(5):747–56

ABNORMALITIES

Intrafamilial phenotypic heterogeneity of the Poland complex: a case report. Parano E, et al. **Neuropediatrics** 1995 Aug;26(4):217–9

ANATOMY & HISTOLOGY

Does the nerve supply to both the superficial and deep surfaces of pectoralis major imply two separate developmental origins? Shinohara H. **J Anat** 1996 Apr;188 (Pt 2):263–8

BLOOD SUPPLY

Takayasu's disease and the acromiothoracic axis [letter] Moss AH. **Br J Plast Surg** 1996 Mar;49(2):136

Interventional physiology. Part XIII: Role of large pectoralis branch artery in flow through a patent left internal mammary artery conduit. Kern MJ, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):240–4

GROWTH & DEVELOPMENT

Genotype and sexual influences on growth and muscle development of chicken embryos. Mitchell RD, et al. **Growth Dev Aging** 1995 Spring-Summer;59(1-2):31–44

Posthatching growth and pectoralis muscle development in broiler strain chickens, bantam chickens and the reciprocal crosses between them. Mitchell RD, et al. **Growth Dev Aging** 1995 Fall;59(3):149–61

INJURIES

A rare complication of pectoralis major rupture. Pai VS, et al. **Aust N Z J Surg** 1995 Sep;65(9):694–5 (3 ref.)

[Traumatic rupture of the greater pectoral muscle tendon] Simek K, et al. **Rozhl Chir** 1995 Sep;74(6):251–2 (Eng. Abstr.) **(Cze)**

[Traumatic total rupture of the musculus pectoralis major tendon] Zerahn B, et al. **Ugeskr Laeger** 1996 Feb 19; 158(8):1086–7 (Eng. Abstr.) **(Dan)**

METABOLISM

Relationship of protein synthesis to mRNA levels in the muscle of chicks under various nutritional conditions. Kita K, et al. **J Nutr** 1996 Jul;126(7):1827–32

SURGERY

A modification of the pectoralis major myocutaneous flap that reduces the defect at the donor site. Crosher R, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):389–91

Axillary dissection: preservation of the pectoralis minor. Singhal H. **J Surg Oncol** 1996 Apr;61(4):310

TRANSPLANTATION

Complete congenital sternal cleft in an adult: repair by autogenous tissues. Suri RK, et al. **Ann Thorac Surg** 1996 Aug;62(2):573–5

Coverage of chest wall defect with pectoralis-breast myocutaneous flap: a report of two cases. Hwang CY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):356–60

Pectoralis major myocutaneous flaps in rats. Matsuda H, et al. **J Reconstr Microsurg** 1995 Nov;11(6):439–45

Minimizing pectoralis myocutaneous flap loss with the delay principle. Attinger CE, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):148–57

Cost and outcome of osteocutaneous free-tissue transfer versus pedicled soft-tissue reconstruction for composite mandibular defects. Talesnik A, et al. **Plast Reconstr Surg** 1996 May;97(6):1167–78

PECTUS EXCAVATUM see FUNNEL CHEST

PEDIATRIC DENTISTRY

see related
DENTAL CARE FOR CHILDREN

Dental practice considerations. Griffin AP, et al. **Dent Clin North Am** 1995 Oct;39(4):861–75 (14 ref.)

Gender and the transition into practice. Solomon ES, et al. **J Dent Educ** 1995 Aug;59(8):836–40

Pediatric dentistry in care of the cancer patient. Berg J, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):257–8

Survey of pediatric dentists concerning dental sealants. Halterman CW, et al. **Pediatr Dent** 1995 Nov-Dec; 17(7):455–6

Pediatric dentists' attitudes regarding parental presence during dental procedures. Marcum BK, et al. **Pediatr Dent** 1995 Nov-Dec;17(7):432–6

Update on American Board examination results. Roche JR. **Pediatr Dent** 1996 Mar-Apr;18(2):157–8

[Esthetics is the science of beauty (after Duden). A report on the professional meeting of the Association suisse de Pédodontie (ASP) of 17 May 1995 at Lugano] Minder TL. **Schweiz Monatsschr Zahnmed** 1995;105(9):1233–4 (Fre)

[Esthetics is the science of the beautiful (Duden). A report on the technical meeting of the Swiss Union for Pediatric Dentistry (SVK) of 17 May 1995 in Lugano] Minder TL. **Schweiz Monatsschr Zahnmed** 1995;105(8):1085–6 (Ger)

ECONOMICS

Is your pediatric practice keeping pace with the improving picture of dental economics? Waldman HB. **ASDC J Dent Child** 1995 May-Jun;62(3):210–4

EDUCATION

Correction and update: interest in pediatric dentistry. Waldman HB. **ASDC J Dent Child** 1995 Nov-Dec; 62(6):426–7

An interview with Coenraad F.A. Moorrees [interview by Sidney L. Horowitz] Moorrees CF. **J Dent Res** 1996 Jun; 75(6):1342–5

The case review section. Barr ES. **Pediatr Dent** 1995 Sep-Oct;17(5):377–8

Think outside the box! [editorial] Casamassimo PS. **Pediatr Dent** 1996 Jan-Feb;18(1):8–9

Computer-based evaluation of pediatric dental residents' clinical performance. Keels MA, et al. **Pediatr Dent** 1996 Jan-Feb;18(1):74–5

A national in-service training examination in pediatric dentistry (PEDSITE): a challenge to academicians. Primosch RE. **Pediatr Dent** 1996 Jan-Feb;18(1):78–9

Identifying and quantifying graduate students' experiences during advanced education programs. Seale NS. **Pediatr Dent** 1996 Jan-Feb;18(1):75–6

A model for resident evaluation. Shelton PG. **Pediatr Dent** 1996 Jan-Feb;18(1):79

Evaluation methods of pediatric dentistry residents, faculty and programs: our current status. Wright JT. **Pediatr Dent** 1996 Jan-Feb;18(1):72–4

HISTORY

Remembrance and reminiscence. Album MM. **ASDC J Dent Child** 1995 May-Jun;62(3):169–71, 225

MANPOWER

Pediatric dental practice: the number of your employees is increasing. Waldman HB. **ASDC J Dent Child** 1995 Sep-Oct;62(5):356–9

METHODS

They are so cute at that age aren't they? Hancocks S. **Br Dent J** 1996 Jun 8;180(11):440

STATISTICS & NUMERICAL DATA

Planning for the children of your current pediatric dental patients. Waldman HB. **ASDC J Dent Child** 1995 Nov-Dec; 62(6):418–25

TRENDS

Immigrant children and pediatric dental practice. Waldman HB. **ASDC J Dent Child** 1995 Jul-Aug;62(4):288–94 (16 ref.)

It could happen [editorial] Casamassimo PS. **Pediatr Dent** 1996 Mar-Apr;18(2):101–2

Dominant research interests of pediatric dentists: dental materials, craniofacial biology and cariology. Loevy HT, et al. **Pediatr Dent** 1995 Sep-Oct;17(5):375–6

PEDIATRIC INTENSIVE CARE UNITS see INTENSIVE CARE UNITS, PEDIATRIC

PEDIATRIC NURSING

see related
MATERNAL-CHILD NURSING

Knowing the score: using predictive scoring systems in clinical practice. Zollo MB, et al. **Am J Crit Care** 1996 Mar;5(2):147–51 (21 ref.)

For Joey's sake. Edinburgh LD. **Am J Nurs** 1995 Oct; 95(10):88

Gretchen's crisis. Ott MJ. **Am J Nurs** 1996 Jul;96(7):80

Accuracy of infant emesis volume assessment. Craft MJ, et al. **Appl Nurs Res** 1996 Feb;9(1):2–8

Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)

Stress and work relationships in the neonatal intensive care unit: are they worse than in the wards? Oates PR, et al. **J Paediatr Child Health** 1996 Feb;32(1):57–9

Nurse-guided sensitive research in pediatric oncology [editorial] Hinds PS. **J Pediatr Oncol Nurs** 1996 Jul; 13(3):105–6

Neuro-oncology nurses: undaunted, hopeful, and enthusiastic [editorial] Ryan JA, et al. **J Pediatr Oncol Nurs** 1995 Oct; 12(4):179–80

Maintaining an ethical stand without jeopardizing your job. Kachoyeanos MK. **MCN Am J Matern Child Nurs** 1995 Nov-Dec;20(6):339

EDUCATION

International cooperation for improving pediatric nursing. Hendel T, et al. **J Pediatr Nurs** 1996 Jun;11(3):202–5

Pediatric/neonatal critical care respiratory crossword puzzle. Talavinia-Pasek T. **MCN Am J Matern Child Nurs** 1995 Jan-Feb;20(1):46–7, 55

METHODS

Partnership nursing: influences on involvement of informal carers. Casey A. **J Adv Nurs** 1995 Dec;22(6):1058–62

Life-threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219–23 (7 ref.)

Spiritual care of the school-age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224–31 (56 ref.)

Nursing management of children with sickle cell disease: an update. Gribbons D, et al. **J Pediatr Nurs** 1995 Aug; 10(4):232–42 (59 ref.)

Advanced HIV disease in children. Czarniecki L. **Nurs Clin North Am** 1996 Mar;31(1):207–19 (16 ref.)

ORGANIZATION & ADMINISTRATION

Pediatric hospice nursing. Martinson IM. **Annu Rev Nurs Res** 1995;13:195–214 (66 ref.)

The paediatric oncology community nurse specialist: the influence of employment location and funders on models of practice. Hunt JA. **J Adv Nurs** 1995 Jul;22(1):126–33

The community connection [editorial] Betz CL. **J Pediatr Nurs** 1996 Jun;11(3):143–4

Nursing's response to health care reform: an update [editorial] Betz CL. **J Pediatr Nurs** 1995 Oct;10(5):279

Ambulatory care of the HIV-infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

STATISTICS & NUMERICAL DATA

Attitudes of pediatric nurses facing HIV risk. Berkowitz NF, et al. **Soc Sci Med** 1996 Feb;42(3):463–9

TRENDS

Taking stock [editorial] Betz CL. **J Pediatr Nurs** 1995 Dec; 10(6):341–2

Child health and pediatric nursing in the Kingdom of Lesotho. Moiloa T, et al. **J Pediatr Nurs** 1995 Dec; 10(6):393–7

PEDIATRIC PSYCHOLOGY see CHILD PSYCHOLOGY

PEDIATRICS

Advances in pediatric pharmacology and toxicology. Berlin CM Jr. **Adv Pediatr** 1995;42:593–629 (106 ref.)

Gene therapy in pediatric medicine. Ledley FD. **Adv Pediatr** 1996;43:1–25 (90 ref.)

Hyperbaric oxygen therapy in pediatrics. Santamaria JP, et al. **Adv Pediatr** 1995;42:335–66 (48 ref.)
American academy of Pediatrics addresses meningococcal disease prevention and control strategies. **Am Fam Physician** 1996 Jul;54(1):362–4
Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)
Shortcuts for calculating the dose of pediatric medications [letter] Reynolds RD. **Am Fam Physician** 1996 Sep 1; 54(3):878
The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)
Paleopediatrics: or when did human infants really become human? Conroy GC, et al. **Am J Phys Anthropol** 1995 Oct; 98(2):121–31
"Adult" trauma surgeons with pediatric commitment: a logical solution to the pediatric trauma manpower problem. D'Amelio LF, et al. **Am Surg** 1995 Nov;61(11):968–74
Inhalational anaesthesia at the extremes of age: paediatric anaesthesia. Olsson GL. **Anaesthesia** 1995 Oct;50 Suppl:34–6 (21 ref.)
Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. American Academy of Pediatrics, American Heart Association and the European Resuscitation Council. Zaritsky A, et al. **Ann Emerg Med** 1995 Oct;26(4):487–503 (60 ref.)
Internal medicine and family medicine [letter] Onady GM. **Ann Intern Med** 1996 Sep 15;125(6):525; discussion 526
Steady-state plasma concentrations of midazolam in critically ill infants and children. Hughes J, et al. **Ann Pharmacother** 1996 Jan;30(1):27–30
Guarding paediatricians against allegations of assault. Chambers TL, et al. **Arch Dis Child** 1996 Jul;75(1):82–5
Making reading easier. Godsmark A, et al. **Arch Dis Child** 1996 Feb;74(2):180–2
Injury prevention counseling opportunities in pediatric otolaryngology. Rosenfeld RM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):609–11
Use of checklists in pediatric practice [letter; comment] Cheng TL, et al. **Arch Pediatr Adolesc Med** 1996 Jul; 150(7):768–9. Comment on: Arch Pediatr Adolesc Med 1995 Jul;149(7):740–6.
The pediatrician and cancer prevention [letter; comment] Donnelly BW. **Arch Pediatr Adolesc Med** 1995 Dec; 149(12):1399–400. Comment on: Arch Pediatr Adolesc Med 1995 Feb;149(2):133–4.
The pediatrician, sports medicine, and managed care [editorial; comment] Dyment PG. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):133. Comment on: Arch Pediatr Adolesc Med 1996 Feb;150(2):211–5.
The preparedness of pediatricians for emergencies in the office. What is broken, should we care, and how can we fix it? Flores G, et al. **Arch Pediatr Adolesc Med** 1996 Mar; 150(3):249–56
Steadfast in the 'steady state' [editorial; comment] Hostetter MK. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):897–8. Comment on: Arch Pediatr Adolesc Med 1996 Sep;150(9):971–4.
Medical informatics and pediatrics. Decision-support systems. Johnson KB, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1371–80 (74 ref.)
Improving participation and interrater agreement in scoring Ambulatory Pediatric Association abstracts. How well have we succeeded? Kemper KJ, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):380–3
ARCHIVES supports child abuse [letter] Kwasman A. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):443–4
Securing the future [editorial] McAnarney ER, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):15–6
Factors prompting referral for cardiology evaluation of heart murmurs in children [letter] McCrindle BW, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1277–9
Content analysis of prime-time television medical news. A pediatric perspective. Prabhu NP, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):46–9
On-line resources for pediatricians. Spooner SA. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1160–8 (23 ref.)
Medical informatics and pediatrics [letter] Spooner SA, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):882–3
A recipe for clinical research. Stein RE. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):320–2
Pediatric Research. National Institutes of Health support in the 'steady-state' decade, 1983–1993 [see comments] Stiehm ER. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):971–4. Comment in: Arch Pediatr Adolesc Med 1996 Sep;150(9):897–8.
Pediatric rheumatology in adult rheumatology practices in Washington state. Sherry DD, et al. **Arthritis Rheum** 1996 Jul;39(7):1218–21
Antenatal diagnosis of congenital heart disease and Down's syndrome: the potential effect on the practice of paediatric cardiology. Abu-Harb M, et al. **Br Heart J** 1995 Aug; 74(2):192–8
Preoperative fasting for paediatric anaesthesia [letter; comment] Stack CG, et al. **Br J Anaesth** 1995 Sep;75(3):375 . Comment on: Br J Anaesth 1995 Mar;74(3):349.
Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)
Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)
Pediatric poisonings. Goepp JG. **Clin Chem** 1996 Aug;42(8 Pt 2):1356–60 (11 ref.)
British Paediatric Association Surveillance Unit: ninth annual report. **Commun Dis Rep CDR Wkly** 1996 Feb 2;6(5):37
PRISM III: an updated Pediatric Risk of Mortality score. Pollack MM, et al. **Crit Care Med** 1996 May;24(5):743–52
Updates in pediatric emergency medicine for the office practitioner. Carlson DW, et al. **Curr Opin Pediatr** 1995 Oct;7(5):523–8 (37 ref.)
General pediatrics [editorial] McCarthy PL. **Curr Opin Pediatr** 1995 Oct;7(5):487–8
Minimizing the pain of office procedures in children. Rothman KF. **Curr Opin Pediatr** 1995 Aug;7(4):415–22 (17 ref.)
The treatment of infantile spasms by paediatric neurologists in the UK and Ireland [letter] Appleton RE. **Dev Med Child Neurol** 1996 Mar;38(3):278–9
Correlates of physicians' decisions to refer children with cerebral palsy for physical therapy. Campbell SK, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1062–74
When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15–24 (21 ref.)
Historical development of surgery for pediatric laryngeal stenosis. Myer CM 3rd, et al. **Ear Nose Throat J** 1995 Aug; 74(8):560–2, 564
Viral contamination of environmental surfaces on a general paediatric ward and playroom in a major referral centre in Riyadh. Akhter J, et al. **Eur J Epidemiol** 1995 Oct; 11(5):587–90
Living pediatrics. Symposium in honour of the 80th birthday of Professor E. Rossi, Berne, Switzerland. **Eur J Pediatr** 1995;154(9 Suppl 4):S1–94
Practical paediatrics in a general district hospital. D'Apuzzo V. **Eur J Pediatr** 1995;154(9 Suppl 4):S23–5
Can paediatrics be kept vivacious in future? [editorial] Gugler E. **Eur J Pediatr** 1995;154(9 Suppl 4):S1–3
Paediatric gastro-enterology: out of children's shoes? Lentze MJ. **Eur J Pediatr** 1995;154(9 Suppl 4):S11–2
Adults with congenital heart disease—the important role and obligation of the paediatric cardiologist and the general paediatrician. Stocker FP. **Eur J Pediatr** 1995;154(9 Suppl 4):S82–4
Pediatric gastrointestinal endoscopy. Haight M, et al. **Gastroenterologist** 1995 Sep;3(3):181–6 (27 ref.)
IAP's immunization time table in pediatrics. **Indian Pediatr** 1995 Dec;32(12):1329–31; discussion 1331–2
Woman abuse and pediatrics: expanding the web of detection. Barkan SE, et al. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):96–100 (81 ref.)
Survey of growth hormone treatment practices by 251 pediatric endocrinologists [see comments] Wyatt DT, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3292–7. Comment in: J Clin Endocrinol Metab 1995 Nov;80(11):3389–90.
Using humor in the office setting: a pediatric perspective [editorial] Bennett HJ. **J Fam Pract** 1996 May;42(5):462–4
Pediatrician and family physician agreement with and adoption of universal hepatitis B immunization. Freed GL, et al. **J Fam Pract** 1996 Jun;42(6):587–92
Role and responsibility of paediatricians in diarrhoea case management. Amdekar YK. **J Indian Med Assoc** 1995 Jun; 93(6):233–4
Television viewing and violence in children: pediatrician as agent for change. Sege R, et al. **J Miss State Med Assoc** 1995 Oct–Nov;36(10):318–27
Treatment network focuses on pediatric cancers [news] Law C. **J Natl Cancer Inst** 1996 May 15;88(10):639–40
Intravenous amitriptyline in pediatrics. Collins JJ, et al. **J Pain Symptom Manage** 1995 Aug;10(6):471–5
Pediatric echocardiography: current role and a review of technical advances. Rice MJ, et al. **J Pediatr** 1996 Jan; 128(1):1–14 (66 ref.)
Child Health 2000: 2nd World Congress and Exposition. Vancouver, Canada, May 30–June 3, 1995. Concurrent conferences on hematology—oncology: Challenges in childhood cancer and blood diseases. **J Pediatr Hematol Oncol** 1996 Feb;18(1):3–9
Annual Meeting of the Pediatric Orthopaedic Society of North America, Miami, Florida, April 30–May 4, 1995. Hensinger RN. **J Pediatr Orthop** 1995 Nov–Dec; 15(6):833–65
Progress in pediatric neuropsychology [editorial] Taylor HG, et al. **J Pediatr Psychol** 1995 Dec;20(6):695–701
Pediatrician's communication style: relationship to parent's perceptions and behaviors. Worchel FF, et al. **J Pediatr Psychol** 1995 Oct;20(5):633–44
Parental presence during procedures: a survey of attitudes amongst paediatricians. Pejaver RK, et al. **J R Soc Med** 1995 Sep;88(9):508–10
Pediatric Urology Medal. Victor A. Politano. Gosalbez R. **J Urol** 1996 Aug;156(2 Pt 2):811
NASPGN commentary on A.S.P.E.N. nutrition guidelines. North American Society for Pediatric Gastroenterology and Nutrition. American Society for Parenteral and Enteral Nutrition. Gleghorn EE. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):255–6
HIV and the paediatrician as the child's advocate. Duke C, et al. **Lancet** 1996 Jul 27;348(9022):247–9
A golden jubilee. Pharoah P. **Lancet** 1996 Mar 2; 347(9001):557
Examination room design for the pediatric otolaryngology practice. Cook SP. **Laryngoscope** 1996 Aug;106(8):1049–50
Exploration of a self-protective strategy in pediatric oncology staff. Grootenhuis MA, et al. **Med Pediatr Oncol** 1996 Jul;27(1):40–7
Creating a computer-aided intellectual environment for a consultative center of intensive care. Tsibulkin EK, et al. **Medinfo** 1995;8 Pt 1:611
A survey of pediatric office-based interventions on smoking. Hymowitz N. **N J Med** 1995 Oct;92(10):657–60
Paediatric cardiopulmonary resuscitation. Richmond CE, et al. **Paediatr Anaesth** 1995;5(1):11–27 (173 ref.)
Where will you send your sick neonates? [editorial] Altemeier WA 3rd. **Pediatr Ann** 1995 Oct;24(10):508, 510–2
A pediatrician's view: will managed care replace public health? [editorial] Altemeier WA 3rd. **Pediatr Ann** 1995 Dec;24(12):620, 623
A pediatrician's view: anyone for a game of bridge? [letter] Austin G. **Pediatr Ann** 1995 Oct;24(10):503, 518, 530
Environmental health during childhood: pediatrician advocacy. Carlson JE, et al. **Pediatr Ann** 1995 Dec; 24(12):624, 626–8 (19 ref.)
Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646–52 (31 ref.)
American Academy of Pediatrics section on cardiology meeting. San Francisco, California, 13–15 October 1995. Abstracts. **Pediatr Cardiol** 1995 Sep–Oct;16(5):251–60
Proceedings of the Society for Pediatric Dermatology meeting, June 29–July 1, 1995, Vancouver, British Columbia, Canada. Garzon MC, et al. **Pediatr Dermatol** 1995 Dec;12(4):376–85
Central venous catheters in the emergency department: access, utilization, and problem solving [letter; comment] Duggan C. **Pediatr Emerg Care** 1995 Oct;11(5):322. Comment on: Pediatr Emerg Care 1995 Apr;11(2):112–7.
Latex allergy in pediatric emergency department personnel. Fein JA, et al. **Pediatr Emerg Care** 1996 Feb;12(1):6–9
Prehospital management of pediatric asthma requiring hospitalization [see comments] Fisher JD, et al. **Pediatr Emerg Care** 1995 Aug;11(4):217–9. Comment in: Pediatr Emerg Care 1996 Feb;12(1):71–2.
Security in pediatric emergency departments. Graham CJ, et al. **Pediatr Emerg Care** 1995 Aug;11(4):220–2 (9 ref.)
Child life programs in the pediatric emergency department. Krebel MS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):13–5
Orthopaedic trauma in children less than three years old: the orthopaedist's and pediatrician's problem. Novkov HV, et al. **Pediatr Emerg Care** 1996 Feb;12(1):21–2
Emergency versus casual pediatric emergency medicine. Rosenberg NM. **Pediatr Emerg Care** 1995 Aug;11(4):255–8
Pediatric hematology and oncology in Italy: half a century of progress, an ongoing search for improvement. Massimo LM. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):431–8
History and current state of pediatric oncology and hematology in the United Arab Emirates. Mpofu C, et al. **Pediatr Hematol Oncol** 1996 Jan–Feb;13(1):1–7
Development of pediatric hemato-oncology in Romania. Tansanu II, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct; 12(5):429–30
The role of the pediatric infectious disease subspecialist in a large health maintenance organization. Marcy SM. **Pediatr Infect Dis J** 1995 Nov;14(11):1030–3
The pediatric infectious disease physician: current roles and importance of the specialty in the care of children. Strategic Development and Long-Range Planning Committee, Pediatric Infectious Diseases Society. Peter G. **Pediatr Infect Dis J** 1995 Oct;14(10):900–3
Hepatitis B virus serology in pregnant women: transmittal of results from obstetricians to pediatricians in California. Rosenthal P, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):927–31
Pediatric pulmonology: quo vadis? [letter] Warwick WJ. **Pediatr Pulmonol** 1995 Sep;20(3):195–9
IPR '96 Boston. Third conjoint meeting pediatric radiology: evaluating today and innovating tomorrow. Boston, Massachusetts, 25–30 May 1996. Abstracts. **Pediatr Radiol** 1996;26(8):563–627
Power doppler sonography: basic principles and clinical applications in children. Babcock DS, et al. **Pediatr Radiol** 1996;26(2):109–15
1995 Public Policy Plenary Symposium: "the crisis in clinical research". Genel M, et al. **Pediatr Res** 1996 May; 39(5):902–13
Society for Pediatric Research presidential address 1995: marrying our medicine to biology. Perlmutter DH. **Pediatr Res** 1995 Dec;38(6):830–4
Disease, war, and biology: languages for medicine—and pediatrics. Scriver CR. **Pediatr Res** 1995 Dec;38(6):819–29
1995 John Howland Award presentation to Floyd W. Denny, Jr. van Wyk JJ. **Pediatr Res** 1995 Dec;38(6):1032–8
Family-focused behavioral pediatrics: clinical techniques for primary care. Coleman WL, et al. **Pediatr Rev** 1995 Dec; 16(12):448–55; Quiz p. 456
Enhancing patient compliance in pediatrics. Liptak GS. **Pediatr Rev** 1996 Apr;17(4):128–34
Preparing for pediatric emergencies. Seidel J. **Pediatr Rev** 1995 Dec;16(12):466–72 (16 ref.)
Recommended childhood immunization schedule. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Jan;97(1):143

The role of the pediatrician in implementing the Americans with Disabilities Act: subject review. American Academy of Pediatrics Committee on Children with Disabilities. **Pediatrics** 1996 Jul;98(1):146–8 (09 ref.)

Ethics and the care of critically ill infants and children. American Academy of Pediatrics Committee on Bioethics. **Pediatrics** 1996 Jul;98(1):149–52 (58 ref.)

American Academy of Pediatrics 1996 annual meeting. Boston, Massachusetts, October 25–30, 1996. Abstracts. **Pediatrics** 1996 Sep;98(3 Pt 2):517–647

Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey. Askew GL, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):889–92

Practice and guidelines [letter; comment] Benjamin JT. **Pediatrics** 1996 Apr;97(4):604–5. Comment on: Pediatrics 1995 May;95(5):623–7.

Is the "therapeutic orphan" about to be adopted? [comment] Coté CJ, et al. **Pediatrics** 1996 Jul;98(1):118–23. Comment on: Pediatrics 1996 Jul;98(1):143–5.

What's new in pediatric surgery. Filston HC. **Pediatrics** 1995 Oct;96(4 Pt 1):748–57 (82 ref.)

The critical role of provider practices in undervaccination. Grabowsky M, et al. **Pediatrics** 1996 May;97(5):735–7

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94–9 (33 ref.)

Does surgical subspecialization in pediatrics provide high-quality, cost-effective patient care? Snow BW, et al. **Pediatrics** 1996 Jan;97(1):14–7

Pediatric office-based smoking intervention: impact on maternal smoking and relapse. Wall MA, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):622–8

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council. Zaritsky A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):765–79 (60 ref.)

Preventive health care for children. Natarajan A, et al. **Prim Care** 1995 Dec;22(4):619–36 (33 ref.)

Preventive health care for infants birth to two years of age. Sand PO, et al. **Prim Care** 1995 Dec;22(4):601–18 (25 ref.)

Analysis of paediatric prescribing profiles in two health-funding systems. Rothberg AD, et al. **S Afr Med J** 1996 Jun;86(6):672–4

Is registrarship a different experience for women? Saloojee H, et al. **S Afr Med J** 1996 Mar;86(3):253–7

The First Interim meeting of the European Society for Paediatric Neurosurgery. March 19–24, 1995; Eliat, Israel. **Surg Neurol** 1996 Jun;45(6):585–6

Pediatric lumbar disc surgery: 20 patients under 15 years of age. Shillito J Jr. **Surg Neurol** 1996 Jul;46(1):14–8

National Association of Medical Examiner's Pediatric Toxicology (PedTox) Registry. Hanzlick R. **Toxicology** 1996 Feb 22;107(2):153–8

Pediatric gastroenterology [editorial] Mittal SK. **Trop Gastroenterol** 1995 Apr–Jun;16(2):72–3

Publication potential in pediatrics in Turkey. Tinaztepe K. **Turk J Pediatr** 1996 Apr–Jun;38(2):205–16

[Molecular biological aspects of pediatrics] Brandt NJ. **Ugeskr Laeger** 1995 Dec 11;157(50):6997–8 **(Dan)**

[Pediatric anesthesia] Walther-Larsen S. **Ugeskr Laeger** 1996 Apr 15;158(16):2235–6 **(Dan)**

[XXXI Congress of the Pediatric Association of French Speaking Language. Paris, France, 1–4 May 1996. Proceedings and abstracts] **Arch Pediatr** 1996;3 Suppl 1:1s–448s **(Fre)**

[Pediatrician and school difficulties: results of a survey in ambulatory pediatrics] Bauche P, et al. **Arch Pediatr** 1996; 3 Suppl 1:34s–36s **(Fre)**

[The child and his physician (editorial)] de Paillerets F, et al. **Arch Pediatr** 1995 Oct;2(10):927–34 **(Fre)**

[Absent pediatrician or pediatrician as conductor of an orchestra] Farriaux JP. **Arch Pediatr** 1996;3 Suppl 1:32s–33s **(Fre)**

[Attitude of the pediatrician facing a therapeutic accident] Olive G, et al. **Arch Pediatr** 1996;3 Suppl 1:242s–244s **(Fre)**

[The pediatrician facing the human genome project (letter)] Philip N. **Arch Pediatr** 1996;3 Suppl 1:346s–347s **(Fre)**

[Schools facing the difficulties of pupils. Some indicators] Saint-Marc A. **Arch Pediatr** 1996;3 Suppl 1:37s–43s **(Fre)**

[Role and strategy of the pediatrician facing school difficulties] Vallée L, et al. **Arch Pediatr** 1996;3 Suppl 1:61s–64s **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the pediatrician] Dehan M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:94–6 (5 ref.) **(Fre)**

[Presence of parents in pediatric imaging] Schmit P, et al. **J Radiol** 1996 Jan;77(1):60–3 (Eng. Abstr.) **(Fre)**

[32nd Annual meeting of the Society for Pediatric Radiology. Wurzburg, 22–23 September 1995. Abstracts] **Radiologe** 1995 Aug;35(8):547–61 **(Ger)**

[Progress and prospectives in the use of hematopoietic stem cells in pediatric oncohematology] Pession A, et al. **Minerva Pediatr** 1995 Jul–Aug;47(7–8):265–76 (19 ref.) **(Ita)**

[Pediatric bioethics] Cavazzuti GB. **Pediatr Med Chir** 1996 Mar–Apr;18(2):191–5 (Eng. Abstr.) **(Ita)**

[Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster] Terada K, et al. **Kansenshogaku Zasshi** 1995 Aug; 69(8):908–12 (Eng. Abstr.) **(Jpn)**

[About specialist care for children with neoplasms (letter)] Armata J. **Pediatr Pol** 1995 Jul;70(7):617–8 **(Pol)**

[Specialist care in the field of pediatric orthopedics] Lebiedowski M. **Pediatr Pol** 1995 Dec;70(12):1072–3 **(Pol)**

[Specialist care in the rehabilitative period of children] Lebiedowski M. **Pediatr Pol** 1995 Aug;70(8):692–4 **(Pol)**

[Specialist care in pediatric ophthalmology] Szreter M. **Pediatr Pol** 1995 Sep;70(9):784–5 **(Pol)**

[Laparoscopic pediatric surgery] Olivares Arnal P. **Cir Pediatr** 1995 Jul;8(3):90–1 **(Spa)**

[Do not close down but improve child health services—and dental care too (letter)] Hallström U. **Lakartidningen** 1996 Aug 28;93(34):2814–9 **(Swe)**

CLASSIFICATION

The new BPA classification. Crawshaw P. **Arch Dis Child** 1995 Dec;73(6):563–7 (6 ref.)

ECONOMICS

Effect of debt on U.S. medical school graduates' preferences for family medicine, general internal medicine, and general pediatrics. Colquitt WL, et al. **Acad Med** 1996 Apr; 71(4):399–411

Population requirements for capitation planning in pediatric cardiac surgery. Davis JT, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):257–9

A capitation primer for pediatricians. Wilson D, et al. **Curr Opin Pediatr** 1996 Apr;8(2):176–80

Management perspective: survival of the practice of pediatric infectious diseases—yes ... but .... Grizzard MB. **Pediatr Infect Dis J** 1995 Nov;14(11):1026–9

Thriving in the 21st century: outcome assessment, practice parameters, and accountability. Bergman DA. **Pediatrics** 1995 Oct;96(4 Pt 2):831–5

Capitation adjustment for pediatric populations. Fowler EJ, et al. **Pediatrics** 1996 Jul;98(1):10–7

The economic survival of pediatric practice. Hirsch AT. **Pediatrics** 1995 Oct;96(4 Pt 2):825–9; discussion 829–31

EDUCATION

Pediatric emergency medicine training [letter; comment] Schafermeyer RW, et al. **Acad Emerg Med** 1995 Jul;2(7):665 . Comment on: Acad Emerg Med 1994 Sep–Oct;1(5):503.

Administering the American Board of Pediatrics in-training examination in a European pediatrics residency. Butzin DW, et al. **Acad Med** 1996 Apr;71(4):393

Responses of U.S. clerkship directors about the organization of their clerkships in pediatrics. Lopreiato JO. **Acad Med** 1996 Apr;71(4):393

Family practice, internal medicine, and pediatrics as partners in the education of generalists. Schatz IJ, et al. **Acad Med** 1996 Jan;71(1):35–9

The adequacy of medical ethics education in a pediatrics training program. Waz WR, et al. **Acad Med** 1995 Nov; 70(11):1041–3

Training programs in adult pulmonary disease and critical care medicine and training programs in pediatric pulmonary disease. 1995 editions. American Thoracic Society/American Lung Association. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1395–423

Writing and marking examinations for paediatrics. Clayden G. **Arch Dis Child** 1996 May;74(5):469–73

Adult learning theory, problem based learning, and paediatrics. David TJ, et al. **Arch Dis Child** 1995 Oct; 73(4):357–63

Improving awareness of ethical issues. Davies DP, et al. **Arch Dis Child** 1996 Feb;74(2):172–5

Implications of the Calman report on child health and paediatrics. Milligan DW, et al. **Arch Dis Child** 1996 Mar; 74(3):260–3

Continuing medical education for paediatricians. Shribman SJ, et al. **Arch Dis Child** 1996 Jan;74(1):68–72

Balancing pediatric otolaryngology training for fellows and residents at a children's hospital. Grundfast KM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):714–8

School health in pediatric residency training: 1994. Bradford BJ. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):315–8

Educational interventions to alter pediatric emergency department utilization patterns. Chande VT, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):525–8

Teaching residents about patient and practice termination in community-based continuity settings. DeWitt TG, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1367–70

Residents on the transport team. Balancing service and education. Durbin DR, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):529–34

Pediatric clinical clerkships are associated with an excess risk of acute infection. Gan VN, et al. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1152–5

US pediatric clerkship directors call for core curriculum. Gunzburger LK, et al. **Arch Pediatr Adolesc Med** 1996 Jul; 150(7):765–6

The effect of the pediatric clerkship on medical student attitudes toward pediatrics at 11 medical schools. Kaplowitz PB, et al. **Arch Pediatr Adolesc Med** 1996 Apr; 150(4):435–9

Teaching communication skills. An essential part of residency training. Morgan ER, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):638–42

Deficiencies in calculation and applied mathematics skills in pediatrics among primary care interns. Potts MJ, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):748–52

Sports medicine training during pediatric residency [see comments] Stirling JM, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):211–5. Comment in: Arch Pediatr Adolesc Med 1996 Feb;150(2):133.

Pediatric resident training in a school environment. A prescription for learning. Zenni EA, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):632–7

Effects of structured encounter forms on pediatric house staff knowledge, parent satisfaction, and quality of care. A randomized, controlled trial. Zenni EA, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):975–80

New college of paediatrics and child health is being set up. College must continue to be exclusively for medical practitioners [letter] Appleyard J. **BMJ** 1996 Apr 13; 312(7036):979

Core curriculum for the training of pediatric invasive/interventional cardiologists: report of the Society for Cardiac Angiography and Interventions Committee on Pediatric Cardiology Training Standards. Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):409–24

Impact of patient history on residents' evaluation on child sexual abuse. Ashworth CS, et al. **Child Abuse Negl** 1995 Aug;19(8):943–51

Educating pediatric residents in community settings. DeWitt TG, et al. **Curr Opin Pediatr** 1995 Oct;7(5):489–93 (26 ref.)

Guidelines for specialist training in paediatric cardiology. British Paediatric Association and the Specialist Advisory Committee in Cardiology of the Joint Committee on Higher Medical Training of the Royal College of Physicians. Hunter S, et al. **Heart** 1996 May;75(5):534–6

Undergraduate pediatric education in India: current concepts [editorial] Verma M, et al. **Indian Pediatr** 1995 Jan; 32(1):9–12

Factors affecting pediatric residents' intentions to screen for high risk behaviors. Middleman AB, et al. **J Adolesc Health** 1995 Aug;17(2):106–12

Education update: 1995. Training Programs in the United States in Adult Cardiology, Pediatric Cardiology and Cardiothoracic Surgery. **J Am Coll Cardiol** 1995 Oct; 26(4):1092–112

Parents as teachers: an integral component of a developmental and behavioral pediatrics curriculum. Appell DJ, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):105–6

The extent and importance of research to developmental and behavioral pediatrics. Wolraich ML. **J Dev Behav Pediatr** 1996 Apr;17(2):133–6

Survey on developmental-behavioural training experiences of Australian paediatric advanced trainees [letter; comment] Roy LP. **J Paediatr Child Health** 1995 Aug; 31(4):362–4. Comment on: J Paediatr Child Health 1994 Dec;30(6):478–82.

Does research during general surgery residency correlate with academic pursuits after pediatric surgery residency? Lessin MS, et al. **J Pediatr Surg** 1995 Sep;30(9):1310–3

Disease prevention and health promotion: a study of medical students and teachers. Meakin RP, et al. **Med Educ** 1996 Mar;30(2):97–104

FDDI information management system for centralizing interactive, computerized multimedia clinical experiences in pediatric rheumatology/Immunology. Rouhani R, et al. **Medinfo** 1995;8 Pt 2:1204–8

Teaching emergency medicine to pediatric residents: a national survey and proposed model. Fein JA, et al. **Pediatr Emerg Care** 1995 Aug;11(4):208–11

Umbilical cord teaching [letter] Graneto JW. **Pediatr Emerg Care** 1995 Oct;11(5):322

Technical skills experiences in pediatric emergency medicine fellowship programs. Paul RI, et al. **Pediatr Emerg Care** 1996 Feb;12(1):10–2

Pediatric emergency medicine fellow clinical work requirements. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1995 Dec;11(6):381–8 (13 ref.)

A curriculum in pediatric radiology for diagnostic radiology residents.Education and Training Committee, Society for Pediatric Radiology. Smith WL, et al. **Pediatr Radiol** 1995; 25(5):403–7

Parental leave for residents and pediatric training programs. American Academy of Pediatrics Committee on Early Childhood, Adoption, and Dependent Care Resident Section. **Pediatrics** 1995 Nov;96(5 Pt 1):972–3

Research in pediatric residency programs. Brouhard BH, et al. **Pediatrics** 1996 Jan;97(1):71–3

Pediatric residents' continuity clinics: how are we really doing? Dumont-Driscoll MC, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):616–21

Practice variations by population: training significance. Feigin RD, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):186–90

Managed care, re-engineering and downsizing: will medical education survive change? Greenberg LW. **Pediatrics** 1995 Dec;96(6):1146–7

Developing residents as teachers: process and content. Johnson CE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):907–16

Can pediatric training manage in managed care? Leslie LK. **Pediatrics** 1995 Dec;96(6):1143–5

Faculty development of pediatric practitioners: complexities

in teaching clinical precepting. Roberts KB, et al. **Pediatrics** 1996 Mar;97(3):389–93

Cross–platform hypermedia examinations on the Web. Williams TW Jr, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:498–501

Early impact of new health care legislation on the pediatric surgical experience of surgical residents. Smith MB, et al. **South Med J** 1996 Sep;89(9):873–6

Social paediatrics: an integral part of the training for general practitioner in The Netherlands. Voorhoeve HW, et al. **Soz Praventivmed** 1995;40(5):325–9

How to organise a year abroad. Wilson DC. **Ulster Med J** 1996 May;65(1):100–4

[Resident in pediatrics, but why? (letter)] André N. **Arch Pediatr** 1996 Mar;3(3):291 **(Fre)**

[What are the criteria for the choice of future professors of pediatrics? (editorial)] Bougnères PF, et al. **Arch Pediatr** 1995 Sep;2(9):831–2 **(Fre)**

[What is the choice of training in neonatal intensive care? Analysis of wishes from 106 neonatologists] Oriot D, et al. **Arch Pediatr** 1996 Mar;3(3):213–7 (Eng. Abstr.) **(Fre)**

[The postgraduate training of the pediatric oncologist] Susuleva NA, et al. **Vopr Onkol** 1995;41(2):73–4 **(Rus)**

[Education in cardiopulmonary resuscitation: courses in basic and advanced pediatric and neonatal cardiopulmonary resuscitation. The Spanish Group of Pediatric CPR] **An Esp Pediatr** 1996 Jan;44(1):2–6 **(Spa)**

HISTORY

Academic pediatrics: the view of New York City a century ago. Markel H. **Acad Med** 1996 Feb;71(2):146–51

Rosén von Rosenstein. His textbook and the award [editorial] Zetterström R. **Acta Paediatr** 1995 Sep;84(9):965–70

Meinhard Robinow: an appreciation. Garn SM, et al. **Am J Med Genet** 1995 Oct 23;59(1):4–7

Living history—autobiography: pediatric genetics in a New World. Robinow M. **Am J Med Genet** 1995 Oct 23; 59(1):8–13

Dr Eduard Henoch (1820–1910) of Berlin: pioneer of German paediatrics. Dunn PM. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F149–50

Henry Koplik, MD, the Good Samaritan Dispensary of New York City, and the description of Koplik's spots. Markel H. **Arch Pediatr Adolesc Med** 1996 May;150(5):535–9

Christoph Wilhelm Hufeland (1762–1836). Wiedemann HR. **Eur J Pediatr** 1995 Dec;154(12):943

Sidney Farber (1903–1973). Craig J. **J Pediatr** 1996 Jan; 128(1):160–2

Hattie E. Alexander (1901–1968). Katz M. **J Pediatr** 1996 May;128(5 Pt 1):717–8

William Mclean Wallace (1912–1968). Weil WB Jr. **J Pediatr** 1996 Sep;129(3):474–7

A brief account of the founding of the American Pediatric Surgical association. Leape LL. **J Pediatr Surg** 1996 Jan; 31(1):12–8

Pediatric surgery between 1860 and 1900. Touloukian RJ. **J Pediatr Surg** 1995 Jul;30(7):911–6

Pediatric hematology and oncology in France [editorial] Schaison GS, et al. **Pediatr Hematol Oncol** 1995 Nov–Dec; 12(6):v–xii

The foundation and early meetings of The Society for Pediatric Radiology. Griscom NT. **Pediatr Radiol** 1995; 25(8):657–60

John L. Gwinn, MD. Wood B. **Pediatr Radiol** 1996;26(2):168

The Society for Pediatric Research: from infancy to adulthood in sixty–five years. Weil WB Jr. **Pediatrics** 1996 Jan;97(1):129–36

History of pediatric radiology in the United States and Canada: images and trends. Griscom NT. **Radiographics** 1995 Nov;15(6):1399–422

[Pediatrics before the millennium] Oláh E. **Orv Hetil** 1995 Nov 12;136(46):2491–6 (Eng. Abstr.) **(Hun)**

[In memory of Doctor Hieronim Bartoszewski (1912–1993)] Pellar J. **Pediatr Pol** 1995 Sep;70(9):786–8 **(Pol)**

[History of the establishment and development of the Department of Child and Adolescent Health, Russian Medical Academy of Postgraduate Training] Fokina NS, et al. **Gig Sanit** 1996 Mar–Apr;(2):44–6 **(Rus)**

[Essay on establishment and development of pediatric radiology] Filippkin MA. **Vestn Rentgenol Radiol** 1995 Jul–Aug;(4):49–57 **(Rus)**

[The pediatric heart transplant] Concha Ruiz M. **Rev Esp Cardiol** 1995;48 Suppl 7:11–2 **(Spa)**

[A woman behind the Noonan syndrome. She described a hereditary disease in children with congenital heart defects] Wettrell G, et al. **Lakartidningen** 1996 Jan 31;93(5):382–5 **(Swe)**

INSTRUMENTATION

Use of a metal detector to track swallowed metal objects [letter] Matlin E. **Am Fam Physician** 1995 Nov 1;52(6):1678

Technology seduction: lost opportunities in child health? Stanley FJ, et al. **J Paediatr Child Health** 1995 Aug; 31(4):302–6 (26 ref.)

Magill forceps: a vital forceps. Rubio Quiñones F, et al. **Pediatr Emerg Care** 1995 Oct;11(5):302–3

LEGISLATION & JURISPRUDENCE

Clinicolegal aspects of practice guidelines for pediatric eye and vision examination. Hatch SW. **J Am Optom Assoc** 1995 Aug;66(8):501–9

Paediatric mismanagement. **N Z Med J** 1996 Feb 23; 109(1016):62

Pediatric emergency medicine: legal briefs. **Pediatr Emerg Care** 1995 Aug;11(4):259–63

Pediatric emergency medicine: legal briefs. Selbst SM. **Pediatr Emerg Care** 1995 Dec;11(6):395–6

Pediatric emergency medicine: legal briefs. Shaw KN, et al. **Pediatr Emerg Care** 1996 Feb;12(1):59–61

Internet listservers and pediatrics: newly emerging legal and clinical practice issues. II. De Ville KA. **Pediatrics** 1996 Sep;98(3 Pt 1):453–4

Internet list servers and pediatrics: newly emerging legal and clinical practice issues. Elliott SJ, et al. **Pediatrics** 1996 Mar;97(3):399–400

MANPOWER

Paediatric surgical manpower in the 1990s. Davenport M, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2 Suppl):66–9

Cryptorchidism, pediatricians, and family practitioners: patterns of practice and referral. Steckler RE, et al. **J Pediatr** 1995 Dec;127(6):948–51

Too much of a good thing?–Part II [editorial] Belman AB. **J Urol** 1996 Aug;156(2 Pt 1):492

Pediatric urology manpower report 1995. Ellen Shapiro on behalf of the American Association of Pediatric Urologists. Retik AB, et al. **J Urol** 1996 Aug;156(2 Pt 1):488–90; discussion 490–1

Headaches and the primary care pediatrician [editorial] Altemeier WA 3rd. **Pediatr Ann** 1995 Sep;24(9):446–7

Political advocacy from a pediatrician's perspective. Berkelhamer JE. **Pediatr Ann** 1995 Aug;24(8):402–4

Pediatricians: a special interest group for children. Dolins JC. **Pediatr Ann** 1995 Aug;24(8):413–7

The future of pediatric infectious diseases: manpower issues. Feigin RD. **Pediatr Infect Dis J** 1995 Nov;14(11):1023–5

Blood lead screening practices among US pediatricians. Campbell JR, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):372–7

Pediatric locum tenens provided by an academic center. Poole SR, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):403–9

[What do adolescents think about their physician: a comparison between pediatricians and physicians for adults] Suris i Granell JC, et al. **An Esp Pediatr** 1996 Apr; 44(4):326–8 (Eng. Abstr.) **(Spa)**

METHODS

Evaluation of the APEC analyzer for whole blood glucose. Testing in a pediatric setting. Harris NS, et al. **Am J Clin Pathol** 1995 Oct;104(4):477–9

How should excess admission laboratory test utilization be curtailed? —paediatricians' preferences. Feldman BM, et al. **Clin Invest Med** 1995 Dec;18(6):502–9

The Internet and the pediatrician: should there be a connection? Fikar CR. **Clin Pediatr (Phila)** 1996 May; 35(5):229–35 (19 ref.)

ORGANIZATION & ADMINISTRATION

Toward a pediatric subacute care model: clinical and administrative features. Grebin B, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC16–20

Referral of young adult patients with congenital heart disease to adult centres. The Canadian Adult Congenital Heart Network. Rosenberg HC, et al. **Can J Cardiol** 1996 Jun; 12(6):600–2

A case study: business process re–engineering (BPR) of the order–/delivery process at the pediatric clinic at the University Hospital of Lund. Lundgren PA, et al. **Medinfo** 1995;8 Pt 1:543

The prenatal visit. American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. **Pediatrics** 1996 Jan;97(1):141–2

How can pediatric care be provided in underserved areas? A view of rural pediatric care. Broffman G. **Pediatrics** 1995 Oct;96(4 Pt 2):816–21

How to integrate your practice into the new health care system. Golembesky HE. **Pediatrics** 1995 Oct;96(4 Pt 2):866–72

The computerization of ambulatory pediatric practice. Zurhellen WM. **Pediatrics** 1995 Oct;96(4 Pt 2):835–42; discussion 842–4

[Pediatric anesthesia in Denmark—a debate on the organization of pediatric anesthesia/surgery, intensive care and pain relief] Walther–Larsen S. **Ugeskr Laeger** 1996 Apr 15;158(16):2265–6 **(Dan)**

[The pediatrician and the telephone] Nouilhan P, et al. **Arch Pediatr** 1995 Sep;2(9):891–4 (Eng. Abstr.) **(Fre)**

[Specialist care of children with diabetes] Piontek E. **Pediatr Pol** 1995 Jul;70(7):613–5 **(Pol)**

[Organization of child health services in Sweden. A cooperation between pediatricians and general practitioners] Aurelius G, et al. **Lakartidningen** 1996 Jul 24;93(30–31):2647 **(Swe)**

STANDARDS

Pediatric emergency physician interpretation of plain radiographs: Is routine review by a radiologist necessary and cost–effective? Simon HK, et al. **Ann Emerg Med** 1996 Mar;27(3):295–8

Paediatricians' knowledge of cardiac arrest guidelines. Buss PW, et al. **Arch Dis Child** 1996 Jan;74(1):47–9

Evaluation of appropriateness of paediatric admission. Werneke U, et al. **Arch Dis Child** 1996 Mar;74(3):268–73 (24 ref.)

Pediatricians' knowledge and attitudes concerning diagnosis and treatment of attention deficit and hyperactivity disorders. A national survey approach. Kwasman A, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1211–6

Evaluation of vision screening practices of Illinois pediatricians. Marcinak JF, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):353–7

Leadership ... T. Berry Brazelton was recently given the 1995 C. Everett Koop Health Advocate Award [news] **Hosp Health Netw** 1995 Nov 5;69(21):19

Perinatal and infant postmortem examinations: how well are we doing? Vujanić GM, et al. **J Clin Pathol** 1995 Nov; 48(11):998–1001

The awareness–to–adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Pathman DE, et al. **Med Care** 1996 Sep; 34(9):873–89

Proposals for standards of cystic fibrosis management in New Zealand. A position statement by the Respiratory Committee of the Paediatric Society of New Zealand. Wesley AW, et al. **N Z Med J** 1996 Apr 26;109(1020):140–1

Preferences of parents for pediatric emergency physicians' attire. Gonzalez Del Rey JA, et al. **Pediatr Emerg Care** 1995 Dec;11(6):361–4

Technical skills experiences in pediatric emergency medicine fellowship programs. Paul RI, et al. **Pediatr Emerg Care** 1996 Feb;12(1):10–2

Clinical effect of a quality assurance system for radiographs in a pediatric emergency department. Shirm SW, et al. **Pediatr Emerg Care** 1995 Dec;11(6):351–4

Quality assurance in pediatric anatomic pathology: the Society for Pediatric Pathology slide survey program. Rutledge JC. **Pediatr Pathol Lab Med** 1995 Nov–Dec; 15(6):957–65

Policy on the development of immunization of tracking systems. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine. **Pediatrics** 1996 Jun; 97(6 Pt 1):927

Informed consent, parental permission, and assent in pediatric practice [letter; comment] Bartholome WG. **Pediatrics** 1995 Nov;96(5 Pt 1):981–2. Comment on: Pediatrics 1995 Feb;95(2):314–7.

Markers for primary care: missed opportunities to immunize and screen for lead and tuberculosis by private physicians serving large numbers of inner–city Medicaid–eligible children [see comments] Fairbrother G, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):785–90. Comment in: Pediatrics 1996 Jun;97(6 Pt 1):898–9.

Ingredients of urban pediatric health care: fourth world pediatrics [comment] Rosen JF. **Pediatrics** 1996 Jun;97(6 Pt 1):898–9. Comment on: Pediatrics 1996 Jun;97(6 Pt 1):785–90.

[Opposable medical references in pediatrics] Amédée–Manesme O, et al. **Arch Pediatr** 1996;3 Suppl 1:263s–264s **(Fre)**

[Example of common pathology: antibiotic prescription in current pediatric practice] Beley G. **Arch Pediatr** 1996;3 Suppl 1:272s–274s **(Fre)**

[Role of health insurance reimbursement in the application of opposable medical references] Lalardrie S. **Arch Pediatr** 1996;3 Suppl 1:261s–262s **(Fre)**

[Opposable medical references in pediatrics] Langue J. **Arch Pediatr** 1996;3 Suppl 1:265s–267s **(Fre)**

[A call for combining pediatric preventive and curative health care in Israel] Urkin J. **Harefuah** 1996 Jan 15; 130(2):126–8 **(Heb)**

STATISTICS & NUMERICAL DATA

Child health statistical review, 1995. Platt MJ, et al. **Arch Dis Child** 1995 Dec;73(6):541–8 (12 ref.)

Pediatricians' preferences for anticipatory guidance topics compared with parental anxieties. Stickler GB, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):384–7

Pediatric urology and the daily medical practice: way apart? Feitz WF, et al. **Eur Urol** 1995;28(2):158–60

Patterns of integration and clinical value of voiding cystourethrography in the work–up of urinary tract infection in children. Mussurakis S, et al. **Eur Urol** 1995; 28(2):165–70

Denominator estimation: approaches in the Hamburg paediatric sentinel network. Kellerhof M, et al. **J Epidemiol Community Health** 1995 Aug;49 Suppl 1:26–8

Pediatric emergency department utilization habits: a consumer survey. Chande VT, et al. **Pediatr Emerg Care** 1996 Feb;12(1):27–30

Characteristics of frequent pediatric emergency department users. Yamamoto LG, et al. **Pediatr Emerg Care** 1995 Dec; 11(6):340–6

Committee Report: population–to–pediatrician ratio estimates: a subject review. Committee on Careers and Opportunities. American Academy of Pediatrics. **Pediatrics** 1996 Apr;97(4):597–600

Physician experience with pediatric inpatient care in Washington State. Melzer SM, et al. **Pediatrics** 1996 Jan; 97(1):65–70

Colorado pediatricians' involvement in community activities. Brown J, et al. **West J Med** 1995 Nov;163(5):451–3

[Profile of pediatric diseases and symptoms in Southern Greenland. Experiences of a consultant visiting in 1992] Olesen T. **Ugeskr Laeger** 1996 Jan 1;158(1):52–4 (Eng.

Abstr.) **(Dan)**

TRENDS

Paediatric clinical pharmacology in the former Soviet Union: Ukraine. Rieder MJ. **Biol Neonate** 1995;68(4):276–81 (7 ref.)
Neuropaediatrics [editorial] Pavone L, et al. **Childs Nerv Syst** 1995 Sep;11(9):501–3
The future perspectives of pediatric neurosurgery. Raimondi AJ. **Childs Nerv Syst** 1996 Feb;12(2):59–62
Achievements of the paediatric surgery clinic in the last five years. Chatalbashev N. **Folia Med (Plovdiv)** 1995;37(4A Suppl):88
What's new in pediatric surgery. Harrison MR. **J Am Coll Surg** 1996 Feb;182(2):145–9 (40 ref.)
Economics and education: impact on pediatric surgery in the next decade. Grosfeld JL. **J Pediatr Surg** 1996 Jan; 31(1):3–11
Pediatrics and adolescent medicine. Walker AR, et al. **JAMA** 1996 Jun 19;275(23):1841–2
Paediatric nephrology in poor countries: an educational and cultural outlook [letter; comment] Grünberg J, et al. **Pediatr Nephrol** 1995 Aug;9(4):541. Comment on: Pediatr Nephrol 1994 Jun;8(3):383–6.
Pediatric Practice: How to Survive and Thrive in the Changing Health Care System. Proceedings of a meeting. San Diego, California, February 24–26, 1995. **Pediatrics** 1995 Oct;96(4 Pt 2):799–874
Thriving in the 21st century: outcome assessment, practice parameters, and accountability. Bergman DA. **Pediatrics** 1995 Oct;96(4 Pt 2):831–5
Child health 2000: new pediatrics in the changing environment of children's needs in the 21st century. Haggerty RJ. **Pediatrics** 1995 Oct;96(4 Pt 2):804–12
Adapting your pediatric practice to the changing health care system. Lewin LS. **Pediatrics** 1995 Oct;96(4 Pt 2):799–804
What's new in pediatric neurosurgery. Hoffman HJ. **Surg Neurol** 1995 Oct;44(4):371–2
Telemedicine: a physician extender in the delivery of primary pediatric care. Benjamin JT. **Va Med Q** 1996 Summer; 123(3):180–1
[Let us build together the European Pediatric House (editorial)] Schaack JC. **Arch Pediatr** 1996 Apr;3(4):307–8 **(Fre)**
[Society of Pediatric Oncology and Hematology—current status] Winkler K. **Klin Padiatr** 1995 Jul–Aug;207(4):133–5 **(Ger)**
[The modern problems in the clinical biochemistry of childhood] Vel'tishchev IuE, et al. **Klin Lab Diagn** 1995 Nov–Dec;(6):38–42 **(Rus)**
[The basic research results and outlook of the Institute on the Problems of Child and Adolescent Hygiene] Makarova LP, et al. **Med Tr Prom Ekol** 1995;(11):6–8 (Eng. Abstr.) **(Rus)**
[A glance into the future (the outlook for pediatric oncology)] Durnov LA. **Vopr Onkol** 1995;41(2):71–3 **(Rus)**
[Pediatric emergencies: searching for more specialized care] Benito Fernández J. **An Esp Pediatr** 1996 Apr;44(4):312–6 **(Spa)**
[Hip dislocation and urinary tract. Two trends in pediatric radiology] Jorulf H, et al. **Lakartidningen** 1995 Nov 29; 92(48):4563–6 (20 ref.) **(Swe)**

PEDICULOSIS

DIAGNOSIS

Phthirus pubis infestation of the eyelids: a marker for sexually transmitted diseases. Skinner CJ, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):451–2
Pediculosis and scabies. What to look for in patients who are crawling with clues. Forsman KE. **Postgrad Med** 1995 Dec;98(6):89–90, 93–5, 99–100

DRUG THERAPY

Human lice and their management. Burgess IF. **Adv Parasitol** 1995;36:271–342 (410 ref.)
Topical application of ivermectin for human ectoparasites. Youssef MY, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):652–3
Infestations: pediculosis. Meinking TL, et al. **Curr Probl Dermatol** 1996;24:157–63 (11 ref.)
Permethrin. Taplin D, et al. **Curr Probl Dermatol** 1996; 24:255–60 (12 ref.)
A comparative study on the efficacy of 0.4% Sumithrine and 1% Lindane in the treatment of Pediculus humanus capitis in Turkey. Budak S, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):237–41
On the efficacy of Co-trimoxazole as an oral treatment for pediculosis capitis infestation. Morsy TA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):73–7
Topical treatments for head lice. Bergus GR. **J Fam Pract** 1996 Jan;42(1):21–2
[Scalp pediculosis and its treatment: bioclinical trials of different pediculicides and repellents in Antananarivo] Combescot C, et al. **Arch Inst Pasteur Madagascar** 1994; 61(2):87–90 (Eng. Abstr.) **(Fre)**
[First cases of resistance of Pediculus capitis Linné 1758 to malathion in France (letter)] Izri MA, et al. **Presse Med** 1995 Oct 21;24(31):1444 **(Fre)**
[Lindane] Surber C, et al. **Hautarzt** 1995 Aug;46(8):528–36 (100 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Head lice resistant to pyrethroid insecticides in Britain [letter] Burgess IF, et al. **BMJ** 1995 Sep 16;311(7007):752
Infestation rate of head lice in primary school children in Inchon, Korea. Hong HK, et al. **Korean J Parasitol** 1995 Sep;33(3):243–4
[The epidemiological significance of human lice in relation to the characteristics of their parasitism] Khudobin VV. **Voen Med Zh** 1995 Oct;(10):52–8, 80 (32 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Abnormal distribution of the histocompatibility antigens (HLA) in lousy patients. Morsy TA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):227–35

PARASITOLOGY

Images in clinical medicine. Pediculosis capitis. Driscoli DM, et al. **N Engl J Med** 1996 Sep 12;335(11):790

PREVENTION & CONTROL

Britain restricts lice treatment [news] Boulton A. **BMJ** 1995 Nov 18;311(7016):1322
[Pediculosis and the problems of its control at the current stage] Frolova AI, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):51–5 (33 ref.) **(Rus)**

THERAPY

Clinical efficacy of treatment for head lice. Authors differ on assessment of flaws in trials [letter; comment] Burgess IF. **BMJ** 1995 Nov 18;311(7016):1369–70. Comment on: BMJ 1995 Sep 2;311(7005):604–8.
Topical treatments for head lice. Review's weaknesses may undermine its conclusions [letter; comment] Dixon R, et al. **BMJ** 1996 Jan 13;312(7023):123; discussion 123. Comment on: BMJ 1995 Sep 2;311(7005):604–8.
Topical treatments for head lice. Several questions remain [letter; comment] Laekeman GM. **BMJ** 1996 Jan 13; 312(7023):123. Comment on: BMJ 1995 Sep 2;311(7005):604–8.
Clinical efficacy of treatment for head lice. Counting head lice by visual inspection flaws trials' results [letter; comment] Stallbaumer M, et al. **BMJ** 1995 Nov 18; 311(7016):1369; discussion 1369–70. Comment on: BMJ 1995 Sep 2;311(7005):604–8.
Comparison of two modes of mass delousing in schoolchildren. Son WY, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):625–7

VETERINARY

Prevalence of botfly larvae and lice in studs of North Caucasus (Stawropol County, Russia). Egri B, et al. **Acta Vet Hung** 1995;43(2–3):287–9
Matrilineal distribution of louse egg-handling techniques during grooming in free-ranging Japanese macaques. Tanaka I. **Am J Phys Anthropol** 1995 Oct;98(2):197–201
The detection of lice (Bovicola ovis) in mobs of sheep: a comparison of fleece parting, the lamp test and the table locks test. Morcombe PW, et al. **Aust Vet J** 1996 May; 73(5):170–3
Comparison of local and systemic responsiveness of lymphocytes in vitro to Bovicola ovis antigen and concanavalin A in B. ovis–infested and naive lambs. Bany J, et al. **Int J Parasitol** 1995 Dec;25(12):1499–504
Kinetic disposition of an emulsifiable concentrate formulation of deltamethrin applied to sheep in a plunge-dip and its effect on lice. Johnson PW, et al. **Int J Parasitol** 1995 Dec; 25(12):1451–6
Distribution of chewing lice upon the polygynous peacock Pavo cristatus. Stewart IR, et al. **J Parasitol** 1996 Apr; 82(2):370–2
The morphology of Laemobothrion (Laemobothrion) maximum (Phthiraptera: Laemobothriidae). Perez JM, et al. **Parassitologia** 1995 Apr;37(1):45–51
The efficacy of Diflubenzuron against the body louse (Damalinia limbata) of Angora goats. Fourie LJ, et al. **Vet Parasitol** 1995 Oct;59(3–4):257–62
Evidence for the role of the sheep biting-louse Bovicola ovis in producing cockle, a sheep pelt defect. Heath AC, et al. **Vet Parasitol** 1995 Aug;59(1):53–8
Effects of the sucking louse (Linognathus vituli) on the grooming behaviour of housed calves. Weeks CA, et al. **Vet Rec** 1995 Jul 8;137(2):33–5

PEDICULUS

On the efficacy of Co-trimoxazole as an oral treatment for pediculosis capitis infestation. Morsy TA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):73–7
Permethrin resistance in the head louse Pediculus capitis from Israel. Mumcuoglu KY, et al. **Med Vet Entomol** 1995 Oct; 9(4):427–32, 447

ANATOMY & HISTOLOGY

Images in clinical medicine. Pediculosis capitis. Driscoli DM, et al. **N Engl J Med** 1996 Sep 12;335(11):790

DRUG EFFECTS

Topical application of ivermectin for human ectoparasites. Youssef MY, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):652–3

PATHOGENICITY

[The epidemiological significance of human lice in relation to the characteristics of their parasitism] Khudobin VV. **Voen Med Zh** 1995 Oct;(10):52–8, 80 (32 ref.) (Eng. Abstr.) **(Rus)**

PEDIGREE

Standardized pedigree nomenclature [letter; comment] Curtis D. **Am J Hum Genet** 1995 Oct;57(4):982–4. Comment on: Am J Hum Genet 1995 Mar;56(3):745–52.
Nonparametric simulation-based statistics for detecting linkage in general pedigrees. Davis S, et al. **Am J Hum Genet** 1996 Apr;58(4):867–80
Parametric and nonparametric linkage analysis: a unified multipoint approach. Kruglyak L, et al. **Am J Hum Genet** 1996 Jun;58(6):1347–63
Defining "proband" [letter; comment] Marazita ML. **Am J Hum Genet** 1995 Oct;57(4):981–2. Comment on: Am J Hum Genet 1995 Mar;56(3):745–52.
A pseudolikelihood approach to correcting for ascertainment bias in family studies. Rabinowitz D. **Am J Hum Genet** 1996 Sep;59(3):726–30
Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. Sobel E, et al. **Am J Hum Genet** 1996 Jun;58(6):1323–37
Whispered hints. Resta RG. **Am J Med Genet** 1995 Nov 6; 59(2):131–3
Analysis of chromosome 18 DNA markers in multiplex pedigrees with manic depression. Coon H, et al. **Biol Psychiatry** 1996 Apr 15;39(8):689–96
Testing familial aggregation. Houwing-Duistermaat JJ, et al. **Biometrics** 1995 Dec;51(4):1292–301
Genetic diagnosis of haemophilia A of Chinese origin. Lin SR, et al. **Br J Haematol** 1995 Nov;91(3):722–7
Bimodal expressivity in dominant retinitis pigmentosa genetically linked to chromosome 19q. Evans K, et al. **Br J Ophthalmol** 1995 Sep;79(9):841–6
Pedigree analysis package vs. MIXD: fitting the mixed model on a large pedigree. Olshen AB, et al. **Genet Epidemiol** 1996;13(1):91–106
Two-dimensional DNA typing of human pedigrees: spot pattern characterization and segregation. Mullaart E, et al. **Genomics** 1995 Oct 10;29(3):641–6
Repetition of the same pair of surnames in marriages in Albanian Italians, Greek Italians, and the Italian population of Campobasso Province. Biondi G, et al. **Hum Biol** 1996 Aug;68(4):573–83
A pedigree-based algorithm for finding efficient peeling sequences. Harbron C. **IMA J Math Appl Med Biol** 1995; 12(1):13–27
Use of relatives of cases as controls to identify risk factors when an interaction between environmental and genetic factors exists. Andrieu N, et al. **Int J Epidemiol** 1996 Jun; 25(3):649–57
Influences of amount of pedigree information on computing time and of model assumptions on restricted maximum-likelihood estimates of population parameters in Swiss black-brown mountain sheep. Hagger C, et al. **J Anim Sci** 1995 Aug;73(8):2213–9
Distribution of genome shared IBD by half-sibs: approximation by the Poisson clumping heuristic. Bickeböller H, et al. **Theor Popul Biol** 1996 Aug;50(1):66–90
Collection of Italian hereditary non-polyposis colorectal cancer (HNPCC) pedigrees. Arrigoni A, et al. **Tumori** 1996 Mar–Apr;82(2):151–79
[Use of the genogram in the day care center: how the personal and familial history provides sense to time arrested] Laurent M. **Acta Psychiatr Belg** 1995 Jul–Oct; 95(4–5):192–209 (Eng. Abstr.) **(Fre)**
[Family anamnesis—pedigree analysis] Müller H. **Ther Umsch** 1995 Dec;52(12):859–61 (Eng. Abstr.) **(Ger)**
[The question of genealogy for a proband] Aksenovich TI. **Genetika** 1995 Dec;31(12):1693–7 (Eng. Abstr.) **(Rus)**

PEDIOCOCCUS

GENETICS

Functional analysis of the pediocin operon of Pediococcus acidilactici PAC1.0: PedB is the immunity protein and PedD is the precursor processing enzyme. Venema K, et al. **Mol Microbiol** 1995 Aug;17(3):515–22

ISOLATION & PURIFICATION

Microbiology of mesu, a traditional fermented bamboo shoot product. Tamang JP, et al. **Int J Food Microbiol** 1996 Feb; 29(1):49–58

METABOLISM

Polysaccharide production by Pediococcus pentosaceus from wine. Manca de Nadra MC, et al. **Int J Food Microbiol** 1995 Oct;27(2–3):101–6
Pediocin 5 production and plasmid stability during continuous free and immobilized cell cultures of Pediococcus acidilactici UL5. Huang J, et al. **J Appl Bacteriol** 1996 Jun;80(6):635–44
The antimicrobial activity of lactic acid bacteria from

fermented maize (kenkey) and their interactions during fermentation. Olsen A, et al. **J Appl Bacteriol** 1995 Nov; 79(5):506–12

PEDODONTICS see **PEDIATRIC DENTISTRY**

PEDOPHILIA

DIAGNOSIS

Using the Multiphasic Sex Inventory with child molesters. Clark M, et al. **Psychol Rep** 1995 Oct;77(2):623–5

DRUG THERAPY

[Chemical castration in homosexual pedophilia] Czeizel E. **Orv Hetil** 1996 Jan 7;137(1):23–5 (Eng. Abstr.) **(Hun)**

PHYSIOPATHOLOGY

The neurophysiology of sexual desire, with particular reference to paedophilia. Howard RC. **Ann Acad Med Singapore** 1995 Sep;24(5):724–7 (11 ref.)

PSYCHOLOGY

Causal attributions for criminal offending and sexual arousal: comparison of child sex offenders with other offenders. McKay MM, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):63–75

PEEP see **POSITIVE-PRESSURE RESPIRATION**

PEEP, INTRINSIC see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

PEEP, OCCULT see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

PEER GROUP

The consistency of family and peer influences on the development of substance use in adolescence. Duncan TE, et al. **Addiction** 1995 Dec;90(12):1647–60

Effects of paternal absence on male adolescents' peer relations and self-image. Beaty LA. **Adolescence** 1995 Winter;30(120):873–80

Identity development, parental and peer support in adolescence: results of a national Dutch survey. Meeus W, et al. **Adolescence** 1995 Winter;30(120):931–44

Social support processes in early childhood friendship: a comparative study of ecological congruences in enacted support. Rizzo TA, et al. **Am J Community Psychol** 1995 Jun;23(3):389–417

Parents and peer group as mediators of the effect of community structure on adolescent problem behavior. Simons RL, et al. **Am J Community Psychol** 1996 Feb; 24(1):145–71

The role of family and peers in social self-efficacy: links to depression in adolescence. McFarlane AH, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):402–10

The Mpowerment Project: a community-level HIV prevention intervention for young gay men [see comments] Kegeles SM, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1129–36. Comment in: Am J Public Health 1996 Aug;86(8 Pt 1):1075–6.

Older women helping older women: Employing senior workers in community research. Tyrrell M, et al. **Am J Public Health** 1996 Apr;86(4):588–9

Reconsideration of the use of peer sociometrics for evaluating social-skills training. Implications of an idiographic assessment of temporal stability. Hansen DJ, et al. **Behav Modif** 1996 Jul;20(3):281–99

Perceptions and experiences of bullying in younger pupils. Smith PK, et al. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):489–500

Interviewing children about past events: the influence of peer support and misleading questions. Greenstock J, et al. **Child Abuse Negl** 1996 Jan;20(1):69–80

Why talk about mental states? The significance of children's conversations with friends, siblings, and mothers. Brown JR, et al. **Child Dev** 1996 Jun;67(3):836–49

Antisocial boys and their friends in early adolescence: relationship characteristics, quality, and interactional process. Dishion TJ, et al. **Child Dev** 1995 Feb;66(1):139–51

Getting angry at peers: associations with linking of the provocateur. Fabes RA, et al. **Child Dev** 1996 Jun; 67(3):942–56

The Pictorial Scale of Perceived Competence and Social Acceptance: does it work with low-income urban children? Fantuzzo JW, et al. **Child Dev** 1996 Jun;67(3):1071–84

Adolescent girls' relationships with mothers and best friends. Gavin LA, et al. **Child Dev** 1996 Apr;67(2):375–86

The peer relations of preschool children with communication disorders. Guralnick MJ, et al. **Child Dev** 1996 Apr; 67(2):471–89

A model of the effects of perceived parent and peer support on adolescent false self behavior. Harter S, et al. **Child Dev** 1996 Apr;67(2):360–74

A multiperspective comparison of peer sociometric status groups in childhood and adolescence. Hatzichristou C, et al. **Child Dev** 1996 Jun;67(3):1085–102

Friendship quality as a predictor of young children's early school adjustment. Ladd GW, et al. **Child Dev** 1996 Jun; 67(3):1103–18

Peer relationships and emotional well-being of youngsters with sickle cell disease. Noll RB, et al. **Child Dev** 1996 Apr;67(2):423–36

Cognitive representations of self, family, and peers in school-age children: links with social competence and sociometric status. Rudolph KD, et al. **Child Dev** 1995 Oct; 66(5):1385–402

Suicide: a review of calls to an adolescent peer listening phone service. Boehm KE, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):61–6

Differences between conduct disordered and normal control children in their tendencies to escalate or neutralize conflicts when interacting with normal peers. Matthys W, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):29–41

Aversive exchanges with peers and adjustment during early adolescence: is disclosure helpful? Vernberg EM, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):43–59

Bullying, physical disability and the paediatric patient. Dawkins JL. **Dev Med Child Neurol** 1996 Jul;38(7):603–12

Parent and peer communication effects on AIDS-related behavior among U.S. high school students. Holtzman D, et al. **Fam Plann Perspect** 1995 Nov–Dec;27(6):235–40, 268

Reducing systematic bias in studies of general practitioners: the use of a medical peer in the recruitment of general practitioners in research. Heywood A, et al. **Fam Pract** 1995 Jun;12(2):227–31

Beyond medical model of STD intervention—lessons from Sonagachi. Jana S, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):125–31

The influence of family, school, and peers on adolescent drug misuse. Adrados JL. **Int J Addict** 1995 Sep;30(11):1407–23

The effects of peer education on STD and AIDS knowledge among prisoners in Mozambique. Vaz RG, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):51–4

An evaluation of a Canadian peer-driven injury prevention programme for high-risk adolescents. Tenn L, et al. **J Adv Nurs** 1996 Feb;23(2):329–37

Using peer helpers for tuberculosis prevention. McCue M, et al. **J Am Coll Health** 1996 Jan;44(4):173–6

Feed the hungry bee: using positive peer reports to improve social interactions and acceptance of a socially rejected girl in residential care. Ervin RA, et al. **J Appl Behav Anal** 1996 Summer;29(2):251–3

Pyramidal parent training by peers. Neef NA. **J Appl Behav Anal** 1995 Fall;28(3):333–7

Increasing complex social behaviors in children with autism: effects of peer-implemented pivotal response training. Pierce K, et al. **J Appl Behav Anal** 1995 Fall;28(3):285–95

Participation of children with autism and nondisabled peers in a cooperatively structured community art program. Schleien SJ, et al. **J Autism Dev Disord** 1995 Aug; 25(4):397–413

Peer and parental influences on adolescent tobacco use. Biglan A, et al. **J Behav Med** 1995 Aug;18(4):315–30

Macaque social culture: development and perpetuation of affiliative networks. de Waal FB. **J Comp Psychol** 1996 Jun;110(2):147–54

Enmity in males at four developmental levels: cognitive bases for disliking peers. Hayes DS, et al. **J Genet Psychol** 1996 Jun;157(2):153–60

The relation of prosocial and antisocial behavior to personality and peer relationships of Hong Kong Chinese adolescents. Ma HK, et al. **J Genet Psychol** 1996 Sep; 157(3):255–66

Peer social support: a key to care giver morale and satisfaction. Gaynor SE, et al. **J Nurs Adm** 1995 Nov; 25(11):23–8

Faculty workload and collegial support related to proportion of part-time faculty composition [see comments] Adams DA. **J Nurs Educ** 1995 Oct;34(7):305–11. Comment in: J Nurs Educ 1995 Oct;34(7):294–6.

Intervention to promote safer sexual behaviors and educate peers about HIV/AIDS. Nokes KM. **J Nurs Educ** 1996 May;35(5):227–9

Comparing the accuracy of personality judgements by the self and knowledgeable others. Kolar DW, et al. **J Pers** 1996 Jun;64(2):311–37

Convergence between self and peer in the response-time processing of trait-relevant information. Fuhrman RW, et al. **J Pers Soc Psychol** 1995 Nov;69(5):961–74

A peer-led AIDS prevention program for students in an alternative school. O'Hara P, et al. **J Sch Health** 1996 May; 66(5):176–82

A review of selected school-based conflict resolution and peer mediation projects. Powell KE, et al. **J Sch Health** 1995 Dec;65(10):426–31

The motivation of Australian adolescent schoolchildren to engage in group discussions about bullying. Rigby K. **J Soc Psychol** 1995 Dec;135(6):773–4

The adverse impact of heavy episodic drinkers on other college students. Wechsler H, et al. **J Stud Alcohol** 1995 Nov;56(6):628–34

Recovering substance abuse staff members' beliefs about addiction. Humphreys K, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):75–8

Gang warfare: the medical repercussions. Song DH, et al. **J Trauma** 1996 May;40(5):810–5

The epidemic of gang-related homicides in Los Angeles County from 1979 through 1994. Hutson HR, et al. **JAMA** 1995 Oct 4;274(13):1031–6

"Copycat" suicide [letter] Hazell PL. **Med J Aust** 1996 Feb 19;164(4):256

Youth in health campaigns. Sandoval F. **Promot Educ** 1996 Jun;3(2):18–9, 46

Consumers as peer specialists on intensive case management teams: impact on client outcomes. Felton CJ, et al. **Psychiatr Serv** 1995 Oct;46(10):1037–44

Nonsmoking college students' attitudes toward smokers and smoking. Hines D. **Psychol Rep** 1996 Jun;78(3 Pt 1):860–2

Personality, peer influence, and use of alcohol and drugs by first-year university students. Valliant PM. **Psychol Rep** 1995 Oct;77(2):401–2

Peer education: a strategy for improving health education in disadvantaged areas in Belfast. McAleavy G, et al. **Public Health** 1996 Jan;110(1):31–6

Parental reports of community activity patterns: a comparison between young children with disabilities and their nondisabled peers. Ehrmann LC, et al. **Res Dev Disabil** 1995 Jul–Aug;16(4):331–43

The effect of some environmental factors on interobserver agreement. Fradenburg LA, et al. **Res Dev Disabil** 1995 Nov–Dec;16(6):425–37

Violence in the marital dyad as a predictor of violence in the peer relationships of older adolescents/young adults. Cantrell PJ, et al. **Violence Vict** 1995 Spring;10(1):35–41

PEER REVIEW

Making peer review statistically accountable [letter] Lee JT. **Am J Surg** 1996 Aug;172(2):222–4

Quality improvement of diagnostic microbiology through a peer-group proficiency assessment program. A 20-year experience in Ontario. The Microbiology Committee. Richardson H, et al. **Arch Pathol Lab Med** 1996 May; 120(5):445–55

Re: Reviewers of manuscripts submitted to The Canadian Journal of Psychiatry [letter] Oyewumi LK. **Can J Psychiatry** 1995 Sep;40(7):427–8

MAST-I: agreeing to disagree. Multicentre Acute Stroke Trial—Italy Group [comment] [see comments] Horton R. **Lancet** 1995 Dec 9;346(8989):1504. Comment on: Lancet 1995 Dec 9;346(8989):1509–14. Comment on: Lancet 1995 Dec 9;346(8989):1515. Comment in: Lancet 1996 Feb 10;347(8998):391–2; discussion 393.

Limited adverse occurrence screening: using medical record review to reduce hospital adverse patient events. Wolff AM. **Med J Aust** 1996 Apr 15;164(8):458–61

Retrospective analysis of the utilization of right-sided cardiac catheterization in association with left-sided cardiac catheterization in patients with coronary artery disease. Fortune GJ, et al. **Mo Med** 1995 Sep;92(9):588–90

Peer review works [letter] Benton RM. **N Y State Dent J** 1995 Dec;61(10):10

Confidentiality of referees [letter; comment] Case M. **Nature** 1996 Jan 25;379(6563):292. Comment on: Nature 1995 Dec 7;378(6557):521–3.

The job's not over till the paperwork's done [letter] Carey PD. **Pa Med** 1995 Jun;98(6):10

The editors' labours: separating the wheat from the chaff. Humphreys RP, et al. **Pediatr Neurosurg** 1995;22(5):223–7

Dissemination of the work of public health medicine trainees in peer-reviewed publications: an unfulfilled potential. Donaldson IJ, et al. **Public Health** 1996 Jan;110(1):61–3

Influence of a sampling review process for radiation oncology quality assurance in cooperative group clinical trials—results of the Radiation Therapy Oncology Group (RTOG) analysis. Martin LA, et al. **Radiother Oncol** 1995 Jul;36(1):9–14

Behind the scenes [editorial] Oberst MT. **Res Nurs Health** 1996 Feb;19(1):1

From collegial to codified. The evolution of modern peer review. Watts C. **Tex Med** 1995 Sep;91(9):22–4

Mediation and peer review services. **Wis Med J** 1995; 94(7):387–8

[The incomprehensible decisions of scientific committees (letter)] Caballero Oliver A, et al. **Aten Primaria** 1996 May 31;17(9):597–8 **(Spa)**

[Peer review in medical journals] Matías-Guiu J. **Rev Neurol** 1996 Jul;24(131):765–6 **(Spa)**

LEGISLATION & JURISPRUDENCE

Peer review of the expert witness: an opportunity to improve our medical liability system. Fadjo D, et al. **J Child Neurol** 1995 Sep;10(5):403–4

METHODS

Making peer review statistically accountable. Scher KS, et al. **Am J Surg** 1996 Apr;171(4):441–4

Monitoring systems to evaluate the quality of perinatal care. Lumley J. **Soz Praventivmed** 1995;40(6):338–42

STANDARDS

Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

TRENDS

The National Panel: past, present and future. Ewing DJ, et al. **Health Bull (Edinb)** 1995 Sep;53(5):307–10

Evaluation of research—a difficult but necessary task [editorial] Rantanen J. **Scand J Work Environ Health** 1995 Oct;21(5):321–4

PEER REVIEW, GRANTS see **PEER REVIEW, RESEARCH**

PEER REVIEW, HEALTH CARE

Developing a cooperative provider-based statewide peer review service: early experience. Helms CM, et al. **Am J Med Qual** 1996 Spring;11(1):46–50

A department of surgery looks at outcomes. Vogel TT. **Am J Med Qual** 1996 Fall;11(3):142–5

CSAG report: standards of care for people with diabetes [editorial] Williams DR, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):126–8

Training dental nurses in the use of the PAR Index: a pilot study. Burden DJ, et al. **Br J Orthod** 1996 May;23(2):153–5

A peer review programme to audit the management of hypertensive patients in family practices in Israel. Tabenkin H, et al. **Fam Pract** 1995 Sep;12(3):309–12

Evidence-based medicine: the Cochrane Collaboration [editorial] Ramirez G. **Hosp Pract (Off Ed)** 1996 Apr 15; 31(4):11–4

Physician advocacy for patients under managed care. Orentlicher D. **J Clin Ethics** 1995 Winter;6(4):333–4

In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):555–69 (56 ref.)

The value of the medical examiner as a member of the multidisciplinary trauma morbidity-mortality committee. Lozen YM, et al. **J Trauma** 1995 Dec;39(6):1054–7

Variations by specialty in physician ratings of the appropriateness and necessity of indications for procedures. Kahan JP, et al. **Med Care** 1996 Jun;34(6):512–23

Effect of external peer review on cesarean delivery rates: a statewide program. Bickell NA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):664–7

[Quality assessment in anesthesia] Kupperwasser B. **Ann Fr Anesth Reanim** 1996;15(1):57–70 (Eng. Abstr.) **(Fre)**

[American health services surveyed in databases. A comprehensive picture improves quality of health care] Kron B. **Lakartidningen** 1995 Nov 29;92(48):4577–80 **(Swe)**

LEGISLATION & JURISPRUDENCE

What's new with peer review? Morrow JA. **Mo Med** 1995 Dec;92(12):723–6

METHODS

Feasibility of hospital-based use of peer ratings to evaluate the performances of practicing physicians. Ramsey PG, et al. **Acad Med** 1996 Apr;71(4):364–70

Prospective peer review in surgical pathology. Lind AC, et al. **Am J Clin Pathol** 1995 Nov;104(5):560–6

Setting up interdepartmental peer review. The British Thoracic Society's scheme. Page RL, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):319–24

STANDARDS

Disposable doctors: incentives to abuse physician peer review. Fielder JH. **J Clin Ethics** 1995 Winter;6(4):327–32

TRENDS

Notes from the field: changing peer review. Wolff M. **Jt Comm J Qual Improv** 1995 Jul;21(7):360–5

PEER REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PEER REVIEW, PUBLISHING see **PEER REVIEW, RESEARCH**

PEER REVIEW, RESEARCH

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Drummond MF, et al. **BMJ** 1996 Aug 3; 313(7052):275–83

And now, evidence based editing [editorial] Smith R, et al. **BMJ** 1995 Sep 30;311(7009):826

Evidence-based medicine. Letters pages are essential for peer review [letter; comment] Spodick DH. **BMJ** 1996 Jun 22; 312(7046):1611. Comment on: BMJ 1996 Feb 10;312(7027):380.

Productivity versus promised results: one of the dilemmas of biotechnology in Brazil [see comments] Fonseca L, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2709–20. Comment in: Braz J Med Biol Res 1995 Feb;28(2):141–6.

Unpublishable research [editorial] Dixon AS. **Can Fam Physician** 1995 Sep;41:1443, 1445–7, 1459–61 **(Eng, Fre)**

What we want. Part 4: Case reports and committee reports [editorial] Leduc CP. **Can Fam Physician** 1996 Apr; 42:592–3, 604–6 **(Eng, Fre)**

Grant-in-aid application [letter; comment] Daniel EE. **Can J Cardiol** 1996 Apr;12(4):422. Comment on: Can J Cardiol 1995 Nov;11(10):864–8.

Evaluation of cardiovascular grant-in-aid applications by peer review: influence of internal and external reviewers and committees [see comments] Hodgson C. **Can J Cardiol** 1995 Nov;11(10):864–8. Comment in: Can J Cardiol 1996 Apr;12(4):422.

What's in a name? [letter] Raine CS. **Can J Neurol Sci** 1995 Aug;22(3):247

The peer reviewer should be fair—secret or otherwise [letter; comment] Ramasarma T. **FASEB J** 1995 Nov;9(14):1500. Comment on: FASEB J 1995 May;9(8):571.

Urology peer review at the National Institutes of Health. Olsson CA, et al. **J Urol** 1995 Nov;154(5):1866–9

What does authorship mean in a peer-reviewed medical journal? [editorial] Lundberg GD, et al. **JAMA** 1996 Jul 3;276(1):75

The Ingelfinger rule, embargoes, and journal peer review—part 2 [see comments] Altman LK. **Lancet** 1996 May 25;347(9013):1459–63. Comment in: Lancet 1996 May 25;347(9013):1423–4. Comment in: Lancet 1996 Jul 13;348(9020):132. Comment in: Lancet 1996 Jul 13;348(9020):132–3.

The Ingelfinger rule, embargoes, and journal peer review—Part 1 [see comments] Altman LK. **Lancet** 1996 May 18;347(9012):1382–6. Comment in: Lancet 1996 Jul 13;348(9020):132. Comment in: Lancet 1996 Jul 13;348(9020):132–3.

The Ingelfinger rule [letter; comment] Dugdale A. **Lancet** 1996 Jul 13;348(9020):132. Comment on: Lancet 1996 May 18;347(9012):1382–6. Comment on: Lancet 1996 May 25;347(9013):1423–4. Comment on: Lancet 1996 May 25;347(9013):1459–63.

Revising the research record [letter; comment] Goodman NW. **Lancet** 1996 Feb 17;347(8999):474. Comment on: Lancet 1995 Dec 16;346(8990):1610–1.

Ruling out Ingelfinger? [comment] [see comments] Horton R. **Lancet** 1996 May 25;347(9013):1423–4. Comment on: Lancet 1996 May 25;347(9013):1459–63. Comment in: Lancet 1996 Jul 13;348(9020):132. Comment in: Lancet 1996 Jul 13;348(9020):132–3. Comment in: Lancet 1996 Jul 13;348(9020):133.

The Ingelfinger rule [letter; comment] Hyams KC. **Lancet** 1996 Jul 13;348(9020):132–3. Comment on: Lancet 1996 May 18;347(9012):1382–6. Comment on: Lancet 1996 May 25;347(9013):1423–4. Comment on: Lancet 1996 May 25;347(9013):1459–63.

The Ingelfinger rule [letter; comment] Ippolito G, et al. **Lancet** 1996 Jul 13;348(9020):133. Comment on: Lancet 1996 May 25;347(9013):1423–4.

The Ingelfinger rule [letter] Matz R. **Lancet** 1996 Jul 13; 348(9020):133–4

Peer review 'still essential', say researchers [news] Butler D. **Nature** 1996 Feb 29;379(6568):758

Restoring good manners [letter; comment] Morgan MJ. **Nature** 1995 Dec 7;378(6557):533. Comment on: Nature 1995 Sep 21;377(6546):192.

Summary of critiques from the drug abuse epidemiology and prevention research review committee. Crider R, et al. **NIDA Res Monogr** 1994;139:155–69

The expert witness: the whole truth and nothing but... [editorial] Komins JI, et al. **Obstet Gynecol Surv** 1996 May; 51(5):265–6

Evaluating scientific merit [letter; comment] Danoff J. **Phys Ther** 1996 Jul;76(7):786–7. Comment on: Phys Ther 1996 Feb;76(2):175–81.

Critiquing treatment for scientific merit [letter; comment] Michels E. **Phys Ther** 1996 Jun;76(6):667–8. Comment on: Phys Ther 1996 Feb;76(2):175–81.

Electronic publishing [letter; comment] Boatright JH, et al. **Science** 1995 Oct 13;270(5234):217–8. Comment on: Science 1995 Aug 4;269(5224):615.

AIDS trials take on peer review [news] Cohen J. **Science** 1996 Jan 5;271(5245):20–1

NIH rating system [letter; comment] Gibson AR. **Science** 1996 Aug 2;273(5275):562. Comment on: Science 1996 May 31;272(5266):1257.

NIH panel urges overhaul of the rating system for grants [news] [see comments] Marshall E. **Science** 1996 May 31; 272(5266):1257. Comment in: Science 1996 Jun 28;272(5270):1857–8. Comment in: Science 1996 Aug 2;273(5275):562.

Despite anxiety, NIH begins merging neuroscience panels [news] Marshall E. **Science** 1996 Aug 9;273(5276):731

Striving for creativity [letter; comment] Sternberg RJ. **Science** 1996 Jun 28;272(5270):1857–8. Comment on: Science 1996 May 31;272(5266):1257.

[Research evaluation (letter)] Henriksen JH, et al. **Ugeskr Laeger** 1995 Dec 11;157(50):7020–1 **(Dan)**

[Qualification—should letters by readers be peer-reviewed? (letter)] Henriksen TB, et al. **Ugeskr Laeger** 1996 Apr 1; 158(14):1991 **(Dan)**

LEGISLATION & JURISPRUDENCE

Suit alleges misuse of peer review [news] Marshall E. **Science** 1995 Dec 22;270(5244):1912–4

Trial set to focus on peer review [news] Marshall E. **Science** 1996 Aug 30;273(5279):1162–4

METHODS

Medical journals and the science of peer review: raising the standard [editorial] Waeckerle JF, et al. **Ann Emerg Med** 1996 Jul;28(1):75–7

More than just a pretty face. Workings of the CFP Editorial Advisory Board [editorial] Manca DP. **Can Fam Physician** 1996 May;42:829–31; 837–9 **(Eng, Fre)**

The review process [editorial] Meakins JL. **Can J Surg** 1996 Jun;39(3):180 **(Eng, Fre)**

Peer review and refereeing in science. Lore W. **East Afr Med J** 1995 May;72(5):335–7

Enter the Web: an experiment in electronic research peer review [editorial] Bingham C, et al. **Med J Aust** 1996 Jan 1;164(1):8–9

STANDARDS

Medical journals and the science of peer review: raising the standard [editorial] Waeckerle JF, et al. **Ann Emerg Med** 1996 Jul;28(1):75–7

Improving participation and interrater agreement in scoring Ambulatory Pediatric Association abstracts. How well have we succeeded? Kemper KJ, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):380–3

Time to apply pressure [letter] Bell W. **Can Fam Physician** 1996 May;42:850; 852

Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Jefferson T, et al. **Health Econ** 1995 Sep–Oct;4(5):383–8

The peer review system—still no alternative in sight [editorial] Wick G. **Int Arch Allergy Immunol** 1996 Jan; 109(1):1–2

Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)

Practice parameters [letter; comment] Greenberg MK. **Neurology** 1995 Oct;45(10):1946. Comment on: Neurology 1994 Oct;44(10):1781–3.

Confidentiality [letter] Guenin LM. **Science** 1996 Mar 29; 271(5257):1790

[Referee system in scientific journals (letter)] Hynynen M. **Duodecim** 1994;110(5):523 **(Fin)**

TRENDS

Anonymity in peer review—time for a change? Clayson DB. **Regul Toxicol Pharmacol** 1995 Aug;22(1):101

PEFLOXACIN

ADMINISTRATION & DOSAGE

A randomized trial of pefloxacin plus klindamicin and cefoxitin in hepatobiliary and pancreatic surgery. Fried M, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):306–8

Bacterial infections transmitted from the donor: antibiotic prophylaxis in the donor. Pacholczyk MJ, et al. **Transplant Proc** 1996 Feb;28(1):184–5

[Prospective randomized comparison of the effects of pefloxacin and clindamycin with cefoxitin after hepatobiliary and pancreatic operations] Fried M, et al. **Rozhl Chir** 1995 Sep;74(6):290–2 (Eng. Abstr.) **(Cze)**

ADVERSE EFFECTS

Headache and visual disturbance. Thacker AK, et al. **Postgrad Med J** 1996 Jan;72(843):61–3

[Surgically treated chronic bilateral Achilles tendon disease, without spontaneous rupture, caused by perfloxacin (letter)] Beuchard J, et al. **Presse Med** 1996 Jun 29;25(23):1083 **(Fre)**

[Exacerbation of myasthenia gravis by pefloxacin] Vial T, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):286–7 (Eng. Abstr.) **(Fre)**

BLOOD

Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. Abanmi N, et al. **Ther Drug Monit** 1996 Apr;18(2):158–63

CHEMISTRY

Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation. Fresta M, et al. **J Pharm Sci** 1995 Jul;84(7):895–902

PHARMACOKINETICS

[Excretion of fluoroquinolones into saliva] Kelentey BA, et al. **Fogorv Sz** 1995 Sep;88(9):293–7 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

[Must pefloxacin and norfloxacin be studied separately against bacteria isolated from urinary tract infections by the API-ATB method?] Soussy CJ, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):294–9 (Eng. Abstr.) **(Fre)**

[Sensitivity of Yersinia pseudotuberculosis to pefloxacin] Zaitseva EA, et al. **Antibiot Khimioter** 1995 Jul;40(7):22–4 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Short report: pefloxacin does not potentiate quinine efficacy against Plasmodium falciparum malaria. Deloron P, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):646–7

Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomplicated gonococcal urethritis in males. Leow YH, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):515–8

Effect of subinhibitory concentrations of pefloxacin in

infection in mice due to susceptible or resistant strains. Carsenti-Etesse H, et al. **Drugs** 1995;49 Suppl 2:276–8

Release of pefloxacin bonded on catheters after intraperitoneal implantation in mice. Carsenti-Etesse H, et al. **Drugs** 1995;49 Suppl 2:304–6

Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy. Leelarasamee A, et al. **Drugs** 1995;49 Suppl 2:365–7

Protective role of the pefloxacin–IFN-gamma association in Leishmania major-infected mice. Zucca M, et al. **New Microbiol** 1996 Jan;19(1):39–46

Inefficacy of pefloxacin in steroid-responsive nephrotic syndrome [letter] Bagga A, et al. **Pediatr Nephrol** 1995 Dec; 9(6):793–4

The influence of pefloxacine on experimental adriamycin-induced nephrotic syndrome in rats. Zima T, et al. **Ren Fail** 1996 Mar;18(2):195–9

Postoperative infections in immunocompromised patients after oncological surgery. Ranchere JY, et al. **Support Care Cancer** 1995 Nov;3(6):409–13

An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis. Rao S. **Tuber Lung Dis** 1995 Jun;76(3):219–22

Pefloxacin and pulmonary tuberculosis [letter] Yew WW. **Tuber Lung Dis** 1996 Apr;77(2):194

[The effect of pefloxacin on nephrotic syndrome in experimental adriamycin nephropathy] Zima T, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):658–60 (Eng. Abstr.) **(Cze)**

[Fluoroquinolones in clinical practice. Pefloxacin (abaktal, peflacine)] Fomina IP, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11–12):70–7 (28 ref.) **(Rus)**

[Effectiveness of pefloxacin in the surgical clinic] Iakovlev VP, et al. **Antibiot Khimioter** 1995 Aug;40(8):43–5 (Eng. Abstr.) **(Rus)**

[Effectiveness of pefloxacin in brucellosis] Kurmanova KB, et al. **Antibiot Khimioter** 1995 Jul;40(7):39–42 (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of the use of pefloxacin in combined radiation-thermal injury] Makarov GF, et al. **Antibiot Khimioter** 1995 Aug;40(8):36–9 (Eng. Abstr.) **(Rus)**

PELGER-HUET ANOMALY

CHEMICALLY INDUCED

Association of acquired Pelger-Huet anomaly with taxoid therapy. Juneja SK, et al. **Br J Haematol** 1996 Apr; 93(1):139–41

COMPLICATIONS

Familial Pelger-Huet anomaly accompanied by tuberculosis and complicated by acute polyarthritis. Suzuki N, et al. **Scand J Rheumatol** 1995;24(5):319–20

GENETICS

Translocation T(4;21) associated with the Pelger-Hüet anomaly in a patient with Ph chromosome-negative CML [letter] Yermiahu T, et al. **Am J Hematol** 1996 Aug; 52(4):328–9

Familial Pelger-Huet anomaly accompanied by tuberculosis and complicated by acute polyarthritis. Suzuki N, et al. **Scand J Rheumatol** 1995;24(5):319–20

PELIOSIS HEPATIS

CHEMICALLY INDUCED

Peliosis hepatis associated with oral contraceptive use. Staub PG, et al. **Australas Radiol** 1996 May;40(2):172–4

COMPLICATIONS

Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Mohle-Boetani JC, et al. **Clin Infect Dis** 1996 May;22(5):794–800

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

[Hepatic peliosis, a still current disease (editorial)] Scoazec JY. **Gastroenterol Clin Biol** 1995 May;19(5):505–7 **(Fre)**

[Splenic peliosis. Apropos of 2 cases] Allimant P, et al. **J Chir (Paris)** 1995 Nov;132(11):451–3 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Mohle-Boetani JC, et al. **Clin Infect Dis** 1996 May;22(5):794–800

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

ETIOLOGY

Focal peliosis hepatis, a sequela of asphyxial death? Selby DM, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug; 15(4):589–96

[Peliosis hepatitis during intestinal lymphomatous polyposis treated with chemotherapy and radiotherapy. Regression after antibiotic therapy] Abdelli N, et al. **Gastroenterol Clin Biol** 1995 May;19(5):537–41 (Eng. Abstr.) **(Fre)**

[Peliosis hepatis] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995; (8):460–2 (12 ref.) **(Jpn)**

IMMUNOLOGY

Intravenous immunoglobulin therapy in an infant with autoimmune hemolytic anemia associated with necrotic hepatitis and peliosis. Lachaux A, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):99–102

PATHOLOGY

Focal peliosis hepatis, a sequela of asphyxial death? Selby DM, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug; 15(4):589–96

PELIZAEUS-MERZBACHER DISEASE see **CEREBRAL SCLEROSIS, DIFFUSE**

PELLAGRA

COMPLICATIONS

[A case for diagnosis: pellagra] Moulin C, et al. **Ann Dermatol Venereol** 1995;122(10):715–6 **(Fre)**

DIAGNOSIS

Assessment of zinc nutritional status of pellagra patients. Vannucchi H, et al. **Alcohol Alcohol** 1995 May; 30(3):297–302

ETIOLOGY

Pellagra complicating Crohn's disease. Zaki I, et al. **Postgrad Med J** 1995 Aug;71(838):496–7

PELLETS, DRUG see **DRUG IMPLANTS**

PELVIC BONES

Referred pain in pelvic metastatic disease presentation [letter] Sherry KL, et al. **Br J Gen Pract** 1994 Sep;44(386):425–6

Spontaneous remission of a bony metastasis in prostatic adenocarcinoma. Schurmans JR, et al. **J Urol** 1996 Feb; 155(2):653

Hemipelvectomy and intraoperative radiotherapy for bone and soft tissue sarcomas of the pelvic girdle. Hoekstra HJ, et al. **Radiother Oncol** 1995 Nov;37(2):160–3

[Pelvic pain caused by pregnancy (letter)] Pel M. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2586–7 **(Dut)**

[Bone metastasis for choriocarcinoma] Baklouti S, et al. **Int Orthop** 1995;19(3):190–2 (Eng. Abstr.) **(Fre)**

[A new treatment of osteoid osteoma: percutaneous sclerosis with ethanol under scanner guidance] Sanhaji L, et al. **J Radiol** 1996 Jan;77(1):37–40 (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Deformity of the pelvis in developmental dysplasia of the hip: three-dimensional evaluation by means of magnetic resonance image. Suzuki S. **J Pediatr Orthop** 1995 Nov-Dec;15(6):812–6

Oculoauriculovertebral spectrum: new manifestations. Johnson KA, et al. **Pediatr Radiol** 1995;25(6):446–8

ANATOMY & HISTOLOGY

Variation in pelvic size between males and females in nonhuman anthropoids. Tague RG. **Am J Phys Anthropol** 1995 Jul;97(3):213–33

Variation in prostate position relative to adjacent bony anatomy. Althof VG, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):709–15

Development and validation of a three-dimensional finite element model of the pelvic bone. Dalstra M, et al. **J Biomech Eng** 1995 Aug;117(3):272–8

The shapes of the female pelvis. Contributing factors. Abitbol MM. **J Reprod Med** 1996 Apr;41(4):242–50

Sexing fossils: a boy named Lucy? [news] Shreeve J. **Science** 1995 Nov 24;270(5240):1297–8

[Obstetrical study of the pelvis: a historical overview] Thiery M. **Verh K Acad Geneeskd Belg** 1995;57(3):199–228 (Eng. Abstr.) **(Dut)**

DRUG EFFECTS

Effect of neonatal exposure to diethylstilbestrol and tamoxifen on pelvis and femur in male mice. Fukazawa Y, et al. **Anat Rec** 1996 Mar;244(3):416–22

ENZYMOLOGY

[Transiliacal screw fixation of the sacrum in unstable pelvic ring fractures] Strømsøe K, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1679–81 (Eng. Abstr.) **(Nor)**

INJURIES

Pelvic ring injuries: a challenge for the trauma surgeon. Rommens PM. **Acta Chir Belg** 1996 Apr;96(2):78–84

Detection of bleeding in patients with major pelvic fractures: value of contrast-enhanced CT. Cerva DS Jr, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):131–5

MR imaging of occult traumatic fractures and muscular injuries of the hip and pelvis in elderly patients. May DA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1075–8

Refractory pelvic stress fracture in a female long-distance runner. O'Brien T, et al. **Am J Orthop** 1995 Sep;24(9):710–3

Pelvic insufficiency fractures after irradiation: diagnosis, management, and rehabilitation. Henry AP, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):414–6

Risk factors and mechanism of urethral injury in pelvic fractures. Koraitim MM, et al. **Br J Urol** 1996 Jun; 77(6):876–80

Urethroplasty for posterior urethral strictures. Mundy AR. **Br J Urol** 1996 Aug;78(2):243–7

Secular trends in osteoporotic pelvic fractures in Finland: number and incidence of fractures in 1970–1991 and prediction for the future. Parkkari J, et al. **Calcif Tissue Int** 1996 Aug;59(2):79–83

Internal fixation in unstable fractures of the pelvis. Preliminary notes. Bungaro P, et al. **Chir Organi Mov** 1995 Jul-Aug;80(3):287–92

Outcome after fixation of unstable posterior pelvic ring injuries. Cole JD, et al. **Clin Orthop** 1996 Aug;(329):160–79

Pelvic polyfractures in children. Radiographic diagnosis and treatment. Keshishyan RA, et al. **Clin Orthop** 1995 Nov; (320):28–33

Surgical management of soft tissue lesions associated with pelvic ring injury. Kottmeier SA, et al. **Clin Orthop** 1996 Aug;(329):46–53 (43 ref.)

Techniques for reduction and posterior fixation through the anterior approach. Leighton RK, et al. **Clin Orthop** 1996 Aug;(329):115–20

Internal fixation of unstable pelvic ring injuries. Matta JM, et al. **Clin Orthop** 1996 Aug;(329):129–40

Surgical treatment of pelvic nonunions and malunions. Matta JM, et al. **Clin Orthop** 1996 Aug;(329):199–206

Indications for anterior fixation of pelvic fractures. Matta JM. **Clin Orthop** 1996 Aug;(329):88–96

Pelvic ring injuries. A long term functional outcome study. Miranda MA, et al. **Clin Orthop** 1996 Aug;(329):152–9

Techniques for reduction and fixation of pelvic ring disruptions through the posterior approach. Moed BR, et al. **Clin Orthop** 1996 Aug;(329):102–14

Thromboembolic complications in patients with pelvic trauma. Montgomery KD, et al. **Clin Orthop** 1996 Aug; (329):68–87 (94 ref.)

Radiologic evaluation of the pelvis. Mostafavi HR, et al. **Clin Orthop** 1996 Aug;(329):6–14 (17 ref.)

Assessment of pelvic ring stability after injury. Indications for surgical stabilization. Olson SA, et al. **Clin Orthop** 1996 Aug;(329):15–27 (26 ref.)

Angiographic findings in pelvic fractures. O'Neill PA, et al. **Clin Orthop** 1996 Aug;(329):60–7

Indications and techniques for external fixation of the pelvis. Poka A, et al. **Clin Orthop** 1996 Aug;(329):54–9 (18 ref.)

Neurologic injuries in pelvic ring fractures. Reilly MC, et al. **Clin Orthop** 1996 Aug;(329):28–36 (32 ref.)

Proximity of iliosacral screws to neurovascular structures after internal fixation. Templeman D, et al. **Clin Orthop** 1996 Aug;(329):194–8

Outcome of operatively treated unstable posterior pelvic ring disruptions. Tornetta P 3rd, et al. **Clin Orthop** 1996 Aug; (329):186–93

Outcome of rotationally unstable pelvic ring injuries treated operatively. Tornetta P 3rd, et al. **Clin Orthop** 1996 Aug; (329):147–51

Urologic injuries in pelvic ring disruptions. Watnik NF, et al. **Clin Orthop** 1996 Aug;(329):37–45 (38 ref.)

Injuries about the hip and pelvis in the young athlete. Paletta GA Jr, et al. **Clin Sports Med** 1995 Jul;14(3):591–628 (224 ref.)

Sports-related groin pain: evaluation with MR imaging. Ekberg O, et al. **Eur Radiol** 1996;6(1):52–5

Epidemiology of pelvic ring injuries. Gänsslen A, et al. **Injury** 1996;27 Suppl 1:S-A13–20

The pelvic C-clamp for the emergency treatment of unstable pelvic ring injuries. A report on clinical experience of 30 cases. Heini PF, et al. **Injury** 1996;27 Suppl 1:S-A38–45

Classification of pelvic ring injuries. Isler B, et al. **Injury** 1996;27 Suppl 1:S-A3–12

Sexual dysfunction in women following pelvic fractures with sacro-iliac disruption. Kiely N, et al. **Injury** 1996 Jan; 27(1):45–6

Volume changes within the true pelvis during disruption of the pelvic ring--where does the haemorrhage go? Moss MC, et al. **Injury** 1996;27 Suppl 1:S-A21–3

The epidemiology of pelvic fractures in the Mersey Region. Muir L, et al. **Injury** 1996 Apr;27(3):199–204

Algorithms for early management of pelvic fractures. Nerlich M, et al. **Injury** 1996;27 Suppl 1:S-A29–37

Percutaneous transcatheter embolization in multiply injured patients with pelvic ring disruption associated with severe haemorrhage and coagulopathy. Piotin M, et al. **Injury** 1995 Dec;26(10):677–80

The pelvic fracture in childhood: a report supporting nonoperative management [letter] Pohlemann T, et al. **Injury** 1995 Dec;26(10):708–9

Surgical treatment of both-column fractures by staged combined ilioinguinal and Kocher-Langenbeck approaches [letter] Raymond E, et al. **Injury** 1996 Jun;27(5):361

Clinical experience with two types of pelvic C-clamps for

unstable pelvic ring injuries. Schütz M, et al. **Injury** 1996; 27 Suppl 1:S–A46–50

The early management of pelvic and acetabular fractures. Ward DA, et al. **Injury** 1996;27 Suppl 1:S–A24–8

Pelvic fractures following irradiation for endometrial carcinoma. Konski A, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):361–7

What is your diagnosis? Multiple pelvic fractures right sacroiliac luxation, abnormal gas densities surrounding the descending colon, and loss of abdominal detail. Cook JL, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1033–4

CT-guided trephine excision of an infected iliac pin site after pelvic fracture. Partington PF, et al.
J Bone Joint Surg Br 1996 Jul;78(4):668–9

Burst fracture of the fifth lumbar vertebra in combination with a pelvic ring injury. Fan RS, et al.
J Orthop Trauma 1995;9(4):345–9

Radiographic recognition of the sacral alar slope for optimal placement of iliosacral screws: a cadaveric and clinical study. Routt ML Jr, et al. **J Orthop Trauma** 1996; 10(3):171–7

Death from pelvic fracture: children are different. Ismail N, et al. **J Pediatr Surg** 1996 Jan;31(1):82–5

Open pelvic fracture: delayed diagnosis. Promes JT, et al. **J Tenn Med Assoc** 1996 Jan;89(1):13–4

Functional outcome of patients with unstable pelvic ring fractures stabilized with open reduction and internal fixation. Gruen GS, et al. **J Trauma** 1995 Nov;39(5):838–44; discussion 844–5

A case of rectal infarction after sigmoid colectomy for traumatic perforation in a patient with a major pelvic fracture. Hughes TM, et al. **J Trauma** 1996 Feb;40(2):302–3

Nosocomial meningitis caused by multiresistant enterococcus as a life-threatening complication of pelvic injury: case report. Lamer C, et al. **J Trauma** 1995 Sep;39(3):609–11

Functional status following orthopedic trauma in young women. McCarthy ML, et al. **J Trauma** 1995 Nov; 39(5):828–36; discussion 836–7

Internal fixation in pelvic fractures and primary repairs of associated genitourinary disruptions: a team approach. Routt ML, et al. **J Trauma** 1996 May;40(5):784–90

Unnecessary use of pelvic x-ray in blunt trauma. Yugueros P, et al. **J Trauma** 1995 Oct;39(4):722–5

Infection following acetabular and pelvic fractures. Skie MC, et al. **Orthopedics** 1996 Jan;19(1):68–72

Outcomes of patients with pelvic-ring fractures managed by open reduction internal fixation. Hakim RM, et al.
Phys Ther 1996 Mar;76(3):286–95

MR imaging in evaluation of suspected hip fracture: frequency of unsuspected bone and soft-tissue injury. Bogost GA, et al. **Radiology** 1995 Oct;197(1):263–7

Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)

[Uretero-vesival rupture with vaginal fistula following pelvic fracture. Value of early diagnosis and emergency surgery] Bittard H, et al. **J Urol (Paris)** 1995;101(3):159–62 (Eng. Abstr.) **(Fre)**

[Pelvic ring fractures in children. Apropos of 47 cases] Sy MH, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(6):538–45 (Eng. Abstr.) **(Fre)**

[External fixator in severe traumatic injuries of the pelvis: results apropos of 20 consecutive cases] Chevalley F, et al. **Swiss Surg** 1996;(2):62–6 (Eng. Abstr.) **(Fre)**

[Abdominal trauma and pelvic injury in the growth period] Rieger H, et al. **Chirurg** 1996 Mar;67(3):261–7 (Eng. Abstr.) **(Ger)**

[Traumatic loosening of apophyses in the pelvic area and the proximal femur] Hösli P, et al. **Orthopade** 1995 Sep; 24(5):429–35 (Eng. Abstr.) **(Ger)**

[Heparin-induced thrombopenia and thrombosis] Stöckli TC, et al. **Schweiz Med Wochenschr** 1996 Mar 23;126(12):483–8 (Eng. Abstr.) **(Ger)**

[Pelvic fractures: epidemiology, therapy and long-term outcome. Overview of the multicenter study of the Pelvis Study Group] Pohlemann T, et al. **Unfallchirurg** 1996 Mar; 99(3):160–7 (Eng. Abstr.) **(Ger)**

[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**

[Outcome evaluation after unstable injuries of the pelvic ring] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):249–59 (Eng. Abstr.) **(Ger)**

[Pelvic injuries: low incidence but unsatisfactory outcome (editorial)] Tscherne H, et al. **Unfallchirurg** 1996 Mar; 99(3):159 **(Ger)**

[Value of ultrasound examination in injuries of the symphysis] Weber K, et al. **Unfallchirurgie** 1996 Feb;22(1):36–8 (Eng. Abstr.) **(Ger)**

[Long-term outcome after conservative treatment of pelvic ring injuries and conclusions for current management] Fell M, et al. **Zentralbl Chir** 1995;120(11):899–904; discussion 904 (Eng. Abstr.) **(Ger)**

[Surgical management of complications of open pelvic injuries] Smektala R, et al. **Zentralbl Chir** 1995; 120(11):893–8 (Eng. Abstr.) **(Ger)**

[Unstable pelvic fracture with concomitant displacement of the uterus—case report] Mazurkiewicz Z, et al.
Chir Narzadow Ruchu Ortop Pol 1994;59(3):223–5 (Eng. Abstr.) **(Pol)**

[Pelvic trauma with retroperitoneal hematoma as a cause of the etiology of mechanical obstruction of the large intestine] Lobanov GV, et al. **Klin Khir** 1995;(4):49–50 **(Rus)**

[The nature and mechanogenesis of pelvic bone fractures in children from exposure to the impact from blunt solid objects in a diagonal direction from the front and the side] Kil'diushov EM, et al. **Sud Med Ekspert** 1996 Jan-Mar; 39(1):3–6 (Eng. Abstr.) **(Rus)**

[The possibilities for detecting pelvic injuries in children (comparative x-ray, computed tomographic and morphological studies)] Kuznetsov LE, et al.
Sud Med Ekspert 1995 Jul-Sep;38(3):3–10 (Eng. Abstr.) **(Rus)**

PARASITOLOGY

Hydatid disease of the pelvis and the femur. A case report. Wirbel RJ, et al. **Acta Orthop Scand** 1995 Oct;66(5):440–2

PATHOLOGY

Magnetic resonance imaging of pelvic bone tumors. De Beuckeleer LH, et al. **J Belge Radiol** 1996 Feb;79(1):11–3

PHYSIOLOGY

Transient osteoporosis of the hip in pregnancy: natural history of changes in bone mineral density. Funk JL, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):373–82

A model of spine, ribcage and pelvic responses to a specific lumbar manipulative force in relaxed subjects. Lee M, et al. **J Biomech** 1995 Nov;28(11):1403–8

Interinnominate motion and symmetry: comparison between gymnasts and nongymnasts. Barakatt E, et al.
J Orthop Sports Phys Ther 1996 May;23(5):309–19

RADIATION EFFECTS

Incidence and possible aetiological factors in the development of pelvic insufficiency fractures following radical radiotherapy. Bliss P, et al. **Br J Radiol** 1996 Jun; 69(822):548–54

RADIOGRAPHY

Radiologic evaluation of the pelvis. Mostafavi HR, et al. **Clin Orthop** 1996 Aug;(329):6–14 (17 ref.)

Angiographic findings in pelvic fractures. O'Neill PA, et al. **Clin Orthop** 1996 Aug;(329):60–7

Depiction of pelvic fractures using 3D volumetric holography: comparison of plain X-ray and CT. Robertson DD, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):967–74

Radiologic pelvic asymmetry in unilateral late-diagnosed developmental dysplasia of the hip. Albiñana J, et al.
J Pediatr Orthop 1995 Nov–Dec;15(6):753–62

Osteoma of the innominate bone with intraosseous and parosteal involvement. Houghton MJ, et al.
Skeletal Radiol 1995 Aug;24(6):455–7

[Calcification of the pectineal ligament. An usual radiological imaging in pediatrics] Jacquot JM, et al. **Presse Med** 1996 Feb 17;25(6):240–2 (Eng. Abstr.) **(Fre)**

[Tumorous space-occupying lesions of the pelvic skeleton. A radiological analysis of 234 cases] Erlemann R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):283–9 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Oblique angle bone SPECT imaging of the lumbar spine, pelvis, and hips. An anatomic study. Gates GF.
Clin Nucl Med 1996 May;21(5):359–62

SURGERY

High complication rates with pelvic allografts. Experience of 22 sarcoma resections. Ozaki T, et al.
Acta Orthop Scand 1996 Aug;67(4):333–8

Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Sheth DS, et al. **Cancer** 1996 Aug 15;78(4):745–50

Surgical indications for Ewing's sarcoma of the pelvis. Yang RS, et al. **Cancer** 1995 Oct 15;76(8):1388–97

Internal hemipelvectomy. Hamdi M, et al.
Eur J Surg Oncol 1996 Apr;22(2):158–61

Evaluation of the biomechanics of the hip following a triple osteotomy of the innominate bone. Hsin J, et al.
J Bone Joint Surg Am 1996 Jun;78(6):855–62

Simultaneous open reduction and Salter innominate osteotomy for developmental dysplasia of the hip. Haidar RK, et al. **J Bone Joint Surg Br** 1996 May;78(3):471–6

[Hip dysplasia in adolescence] Barthès X, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(4):302–9 (Eng. Abstr.) **(Fre)**

[Value of pelvic osteotomy in the management of the hip in children with cerebral palsy] Cesari B, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(4):310–6 (Eng. Abstr.) **(Fre)**

[Changes in the acetabular roof produced by Chiari pelvic osteotomy] Hayashi J. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1126–35 (Eng. Abstr.) **(Jpn)**

[The treatment and prosthesis after an interilioabdominal amputation for sarcomas of the bones and soft tissues] Trishkin VA, et al. **Vestn Khir Im I I Grek** 1995;154(2):53–6 (Eng. Abstr.) **(Rus)**

PELVIC EXENTERATION

Exenteration as palliation for patients with advanced pelvic malignancy. Woodhouse CR, et al. **Br J Urol** 1995 Sep; 76(3):315–20

Neovaginal cytology after total pelvic exenteration for gynecological malignancies. Selvaggi SM, et al.
Diagn Cytopathol 1995 Jul;13(1):22–5

Double-barreled wet colostomy. A simple method of urinary diversion for patients undergoing pelvic exenteration. Takada H, et al. **Dis Colon Rectum** 1995 Dec;38(12):1325–6

Pelvic exenteration for malignant melanomas of the vagina or urethra with over 3 mm of invasion. Geisler JP, et al.
Gynecol Oncol 1995 Dec;59(3):338–41

Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Morris M, et al.
Gynecol Oncol 1996 Feb;60(2):288–91

The use of operative laparoscopy in determining eligibility for pelvic exenteration in patients with recurrent cervical cancer. Plante M, et al. **Gynecol Oncol** 1995 Dec; 59(3):401–4

Pelvic exenteration in gynecologic oncology: Experience at the Mount Sinai Center, 1975–1992. Dottino PR, et al.
Mt Sinai J Med 1995 Nov;62(6):431–5

Translumbar amputation: the longest survivor—a case update. Mackenzie AR. **Mt Sinai J Med** 1995 Sep; 62(4):305–7

Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)

Neovaginal reconstruction after exenteration using an omental flap and split-thickness skin graft. Kusiak JF, et al. **Plast Reconstr Surg** 1996 Apr;97(4):775–81; discussion 783–3

[Total pelvic exenteration for local advanced rectal carcinoma: analysis of 20 patients] Wan Y, et al.
Chung Hua Wai Ko Tsa Chih 1995 Aug;33(8):458–60 (Eng. Abstr.) **(Chi)**

[The Miami pouch: a reliable continent urinary diversion after pelvic exenteration] Bladou F, et al. **Prog Urol** 1996 Apr; 6(2):217–25 (Eng. Abstr.) **(Fre)**

METHODS

Pelvic exenteration for recurrent rectal cancer.
Avradopoulos KA, et al. **Adv Surg** 1996;29:215–33 (71 ref.)

Pelvic exenteration and its modifications. Rodriguwz-Bigas MA, et al. **Am J Surg** 1996 Feb;171(2):293–8 (90 ref.)

Total pelvic exenteration for locally advanced colorectal carcinoma. Shirouzu K, et al. **Br J Surg** 1996 Jan;83(1):32–5

Modified pelvic anterior exenteration. Ng HT, et al.
Int J Gynaecol Obstet 1995 Jul;49 Suppl:S39–41

[Urinary diversion after anterior or total exenteration in advanced tumors of the female genitals] Stein R.
Geburtshilfe Frauenheilkd 1996 Apr;56(4):M45–50 **(Ger)**

[Vaginal evisceration following radiotherapy and surgery for cervico-uterine cancer. Report of a case] Luna P, et al.
Ginecol Obstet Mex 1996 Feb;64:73–5 (Eng. Abstr.) **(Spa)**

PELVIC FLOOR

Pelvic-floor rehabilitation, Part 1: Comparison of two surface electrode placements during stimulation of the pelvic-floor musculature in women who are continent using bipolar interferential currents. Dumoulin C, et al. **Phys Ther** 1995 Dec;75(12):1067–74

Pelvic-floor rehabilitation, Part 2: Pelvic-floor reeducation with interferential currents and exercise in the treatment of genuine stress incontinence in postpartum women—a cohort study. Dumoulin C, et al. **Phys Ther** 1995 Dec; 75(12):1075–81

ANATOMY & HISTOLOGY

Levator ani muscle in women with genitourinary prolapse: indirect assessment by muscle histopathology. Helt M, et al. **Neurourol Urodyn** 1996;15(1):17–29

INJURIES

Preserving the pelvic floor and perineum during childbirth—elective caesarean section? Sultan AH, et al.
Br J Obstet Gynaecol 1996 Aug;103(8):731–4 (21 ref.)

INNERVATION

Prospective comparative study of abnormal distal rectoanal excitatory reflex, pudendal nerve terminal motor latency, and single fiber density as markers of pudendal neuropathy. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jul;39(7):794–8

Unilateral pudendal neuropathy. Impact on outcome of anal sphincter repair. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jun;39(6):686–9

Clinical value of the pudendal somatosensory evoked potential. Delodovici ML, et al.
Electroencephalogr Clin Neurophysiol 1995 Nov; 96(6):509–15

Spinal influences on the pelvic floor muscles. Hanssen M.
Scand J Urol Nephrol Suppl 1995;175:37–9

[The characteristics of the impulse activity of the motor units of the muscles in the pelvic floor in the cat] Kuz'mina GI, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):74–9 (Eng. Abstr.) **(Rus)**

PELVIC FLOOR

PHYSIOLOGY

The effect of post-natal exercises to strengthen the pelvic floor muscles. Mørkved S, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):382–5

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163–82 (102 ref.)

A new treatment for premature ejaculation: the rehabilitation of the pelvic floor. La Pera G, et al. **J Sex Marital Ther** 1996 Spring;22(1):22–6

Long-term effect of pelvic floor muscle exercise 5 years after cessation of organized training. Bø K, et al. **Obstet Gynecol** 1996 Feb;87(2):261–5

Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299–307 (16 ref.)

PHYSIOPATHOLOGY

The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Bump RC, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):10–7

Efficacy of biofeedback, when included with pelvic floor muscle exercise treatment, for genuine stress incontinence. Berghmans LC, et al. **Neurourol Urodyn** 1996;15(1):37–52

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

[What is the role of the pubococcygeal and puborectal muscles in patients with obstructive defecation disorders? An electromyography study] Athanasiadis S, et al. **Chirurg** 1995 Oct;66(10):974–81 (Eng. Abstr.) **(Ger)**

[Pelvic floor conditioning with vaginal weights—post partum and in urinary incontinence] Fischer W, et al. **Zentralbl Gynakol** 1996;118(1):18–28 (Eng. Abstr.) **(Ger)**

[A computerized endurance test: efficacy of pelvic floor rehabilitation treatment in patients with stress incontinence] Guarnaschelli C, et al. **Minerva Urol Nefrol** 1995 Mar; 47(1):19–23 (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Clarifying the technique of four-contrast defecography [letter] Saclarides TJ, et al. **Dis Colon Rectum** 1996 Jul; 39(7):826

SURGERY

Minimally invasive treatment of urinary stress incontinence and laparoscopically directed repair of pelvic floor defects. Lyons TL. **Clin Obstet Gynecol** 1995 Jun;38(2):380–91 (42 ref.)

Correction of genital prolapse. Liu CY, et al. **J Endourol** 1996 Jun;10(3):259–65 (32 ref.)

Abdomino perineal repair of pulsion enterocele. Brieger GM, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):151–6

[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Postpartum ultrasound morphology of the pelvic floor] Bader W, et al. **Geburtshilfe Frauenheilkd** 1995 Dec; 55(12):716–20 (Eng. Abstr.) **(Ger)**

PELVIC HORN SYNDROME see **NAIL-PATELLA SYNDROME**

PELVIC INFECTION see **ADNEXITIS**

PELVIC INFLAMMATORY DISEASE see **ADNEXITIS**

PELVIC NEOPLASMS

[Angiosarcoma of the cavity of the pelvis minor] Kononenko NG. **Klin Khir** 1995;(7–8):47–8 **(Rus)**

COMPLICATIONS

Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-alpha. Durig J, et al. **Ann Hematol** 1996 Feb;72(2):97–9

Long-term survival after embolization of potentially lethal bleeding malignant pelvic tumours. Hendrickx P, et al. **Br J Radiol** 1995 Dec;68(816):1336–43

Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease [see comments] Lau MW, et al. **Br J Urol** 1995 Nov;76(5):565–9. Comment in: Br J Urol 1996 May;77(5):763–4.

Intestinal obstruction. Baines MJ. **Cancer Surv** 1994;21:147–56 (32 ref.)

Videoendoscopic cutaneous ureterostomy for palliative urinary diversion in advanced pelvic cancer. Puppo P, et al. **Eur Urol** 1995;28(4):328–33

Paraneoplastic encephalomyelitis in a child with neuroblastoma. Meyer JJ, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S99–101

[Giant schwannoma in the pelvic cavity presenting as renal failure: a case report] Gotoh T, et al. **Hinyokika Kiyo** 1995 Aug;41(8):621–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Huch Böni RA, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):345–52

Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions. Hawighorst H, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):401–8

Fibroid arising in a müllerian duct remnant and presenting as a pelvic mass in a patient with vaginal agenesis: an unusual finding. Baker J, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):340–1

Radiological imaging of a massive dermoid in the male pelvis. Van Gelderen WF, et al. **Australas Radiol** 1995 Nov; 39(4):408–10

Case report: benign neural tumour of small bowel presenting as a pelvic mass. Nargund G. **Clin Exp Obstet Gynecol** 1995;22(3):202–3

Clinical relevance of presenting symptoms in the preoperative evaluation of pelvic masses. Levey JA, et al. **Del Med J** 1996 Jul;68(7):345–8

Pelvic clear cell adenocarcinoma in a 14-year-old boy. Morgan TO Jr, et al. **J Urol** 1996 Jun;155(6):2062–3

Index of suspicion. Case 3. Hypertensive encephalopathy. **Pediatr Rev** 1996 Jan;17(1):32, 34–5

Actinomycosis presenting as carcinoma. Hinnie J, et al. **Postgrad Med J** 1995 Dec;71(842):749–50

Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. Kinkel K, et al. **Radiology** 1996 Aug;200(2):453–8

Fever, leukocytosis, and referred thigh pain. Dyer KA. **West J Med** 1996 Jan;164(1):81–2

[Tailgut cyst] Mäkelä J, et al. **Duodecim** 1995;111(2):162–7 **(Fin)**

[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**

[Fast and ultra-fast sequences in MRI of the pelvis and retroperitoneum] Heuck A, et al. **Radiologe** 1995 Dec; 35(12):936–44 (44 ref.) (Eng. Abstr.) **(Ger)**

[Nuclear magnetic resonance tomography of the pelvis: rectal administration of a new super-paramagnetic contrast medium] Kersting-Sommerhoff B, et al. **Rontgenpraxis** 1995 Dec;48(12):353–6 **(Ger)**

DRUG THERAPY

Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Wanebo HJ, et al. **Ann Surg Oncol** 1996 May; 3(3):295–303

Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Granvil CP, et al. **Cancer Chemother Pharmacol** 1996;37(5):451–6

CT-guided intraarterial chemotherapy in locally advanced tumors. Görich J, et al. **Radiology** 1996 May;199(2):567–70

Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Izes JK, et al. **Urology** 1996 May;47(5):756–9

IMMUNOLOGY

Immunosuppressive and cytogenetic effects of pelvic irradiation on the peripheral lymphocytes of patients with cervical cancer. One year follow-up. Vučković-Dekić L, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):63–6

MORTALITY

Pelvic neuroblastoma—implications for a new favorable subgroup: a Children's Cancer Group experience. Haase GM, et al. **Ann Surg Oncol** 1995 Nov;2(6):516–23

PATHOLOGY

Malignant sacrococcygeal germ cell tumour in an adult. Smithers BM, et al. **Aust N Z J Surg** 1996 Mar;66(3):185–9 (25 ref.)

Aggressive angiomyxoma: a clinicopathologic study of 29 female patients. Fetsch JF, et al. **Cancer** 1996 Jul 1; 78(1):79–90

Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Woolas RP, et al. **Gynecol Oncol** 1995 Oct; 59(1):111–6

Aggressive angiomyxoma of the pelvis and perineum. A case report. Fishman A, et al. **J Reprod Med** 1995 Sep; 40(9):665–9 (16 ref.)

Laparoscopic lymph node dissection in the evaluation and management of patients with pelvic malignancy. Stitt JC, et al. **Mil Med** 1995 Sep;160(9):462–4

Multicystic mesothelioma presenting as a pelvic tumour: case report and literature review. Bos SD, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):225–8

[Aggressive angiomyxoma of the perineum and pelvis. A report of two cases with pelvic and para-testicular localization] Mdimagh H, et al. **Ann Pathol** 1995; 15(4):285–7 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc-99m-IMMU-4 monoclonal antibody scanning and CT. Stomper PC, et al. **Radiology** 1995 Dec;197(3):688–92

RADIONUCLIDE IMAGING

Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc-99m-IMMU-4 monoclonal antibody scanning and CT. Stomper PC, et al. **Radiology** 1995 Dec;197(3):688–92

RADIOTHERAPY

Immunosuppressive and cytogenetic effects of pelvic irradiation on the peripheral lymphocytes of patients with cervical cancer. One year follow-up. Vučković-Dekić L, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):63–6

Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Höckel M, et al. **Cancer** 1996 May 1;77(9):1918–33

Measurement of irradiated small bowel volume in pelvic irradiation and the effect of a bellyboard. Fu YT, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):188–92

Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Mannel RS, et al. **Gynecol Oncol** 1995 Dec;59(3):376–8

The usefulness of intraoperative radiation therapy in the treatment of pelvic recurrence of cervical cancer [editorial] Abe M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15; 34(2):513–4

Effects of treatment setup variation on beam's eye view dosimetry for radiation therapy using the multileaf collimator vs. the cerrobend block. Frazier A, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1247–56

Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Martenson JA Jr, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):299–303

Topographic distribution of inguinal lymph nodes metastasis: significance in determination of treatment margin for elective inguinal lymph nodes irradiation of low pelvic tumors. Wang CJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):133–6

Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. Huddart RA, et al. **Radiother Oncol** 1996 Apr;39(1):19–29

Peroperative brachytherapy with the use of a vicryl mat in advanced or recurrent pelvic tumors. Meerwaldt JH, et al. **Radiother Oncol** 1995 Nov;37(2):167–9

Clinical implementation of an objective computer-aided protocol for intervention in intra-treatment correction using electronic portal imaging. Van den Heuvel F, et al. **Radiother Oncol** 1995 Jun;35(3):232–9

[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

[3-years results of endoprosthetic management of radiation-induced hip joint necrosis] Aigner C, et al. **Wien Klin Wochenschr** 1995;107(23):726–30 (Eng. Abstr.) **(Ger)**

SECONDARY

Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions. Hawighorst H, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):401–8

Accelerated thyrotoxicosis induced by iodinated contrast media in metastatic differentiated thyroid carcinoma. Lorberboym M, et al. **J Nucl Med** 1996 Sep;37(9):1532–5

Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. Kinkel K, et al. **Radiology** 1996 Aug;200(2):453–8

SURGERY

Pelvic exenteration and its modifications. Rodriguwz-Bigas MA, et al. **Am J Surg** 1996 Feb;171(2):293–8 (90 ref.)

Complications and outcome of external hemipelvectomy in the management of pelvic tumors. Apffelstaedt JP, et al. **Ann Surg Oncol** 1996 May;3(3):304–9

Ovarian cancers related to minimal access surgery [see comments] Crawford RA, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):726–30. Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):185–6. Comment in: Br J Obstet Gynaecol 1996 May;103(5):486.

Exenteration as palliation for patients with advanced pelvic malignancy. Woodhouse CR, et al. **Br J Urol** 1995 Sep; 76(3):315–20

Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Höckel M, et al. **Cancer** 1996 May 1;77(9):1918–33

Aggressive fibromatosis of the female pelvis. A case report and review of the literature. Fishman A, et al. **Eur J Gynaecol Oncol** 1996;17(3):208–11

The usefulness of intraoperative radiation therapy in the treatment of pelvic recurrence of cervical cancer [editorial] Abe M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;

34(2):513–4
Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)
Complex abdominal–perineal reconstruction: options after pelvic bone resection. Evans GR, et al. **Plast Reconstr Surg** 1996 Sep;98(4):735–9
Various types of hemipelvectomy for soft tissue sarcomas: complications, survival and prognostic factors. Apffelstaedt JP, et al. **Surg Oncol** 1995 Aug;4(4):217–22
Surgical management of pelvic recurrence from resected rectal cancer: technical aspects. Berard P, et al. **Tumori** 1995 May–Jun;81(3 Suppl):141–2
The use of an ultrasonic assisted lipectomy device for the treatment of obstructive pelvic lipomatosis. Halachmi S, et al. **Urology** 1996 Jul;48(1):128–30
The use of orthotopic neobladders in women undergoing cystectomy for pelvic malignancy. Stein JP, et al. **World J Urol** 1996;14(1):9–14
[Place of computer-assisted surgery in the evaluation of lymphatics metastases in pelvic cancers. Exploration by retroperitoneoscopy] Chaffanjon P, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:569s–572s (Eng. Abstr.) **(Fre)**
[The choice of urinary diversion in tumors of the small pelvis] Gotsadze DT, et al. **Vopr Onkol** 1996;42(3):82–4 (Eng. Abstr.) **(Rus)**

THERAPY

Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Lowy AM, et al. **Ann Surg** 1996 Feb;223(2):177–85
Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors. A prospectively controlled randomized study by the Radiation Therapy Group. Emami B, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1097–104
Remission of recurrent mature teratoma with interferon therapy. Ornadel D, et al. **J R Soc Med** 1995 Sep; 88(9):533P–534P
[Intra-arterial treatment of therapy-resistant residual tumors of the pelvis] Görich J, et al. **Strahlenther Onkol** 1995 Dec; 171(12):671–8 (Eng. Abstr.) **(Ger)**
[Pharmacokinetic evaluation of complete infrarenal inferior vena caval isolation and charcoal hemoperfusion for intra-arterial chemotherapy of pelvic tumors] Maeda I, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1563–5 (Eng. Abstr.) **(Jpn)**
[Treatment of patients with neurogenic neoformations of the small pelvis] Kononenko NG. **Klin Khir** 1995;(5):24–6 **(Rus)**

ULTRASONOGRAPHY

Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Franchi M, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):734–9
Presacral myelolipoma: sonographic appearance. Adetiloye VA, et al. **Pediatr Radiol** 1996;26(4):271–2 (5 ref.)
Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)
Interobserver agreement in the results of Doppler examinations of extrauterine pelvic tumors. Sladkevicius P, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):91–6

URINE

The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Wainer IW, et al. **Cancer Chemother Pharmacol** 1996;37(4):332–6

PELVIC PAIN

BLOOD

Relationship between abnormally high levels of plasma CA 125 and resolution of acute pelvic pain in two women with endometrioma. Guerriero S, et al. **Gynecol Obstet Invest** 1995;40(1):61–3

DIAGNOSIS

GnRH analogue in assessing chronic pelvic pain in women with residual ovaries. Carey MP, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):150–3
The evaluation of pelvic injury in the female athlete. Short JW, et al. **Sports Med** 1995 Dec;20(6):422–8
[Pelvic floor relaxation—a condition with many names and uncertain criteria] Endresen EH. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3271–3 (Eng. Abstr.) **(Nor)**

DRUG THERAPY

[Antalgic treatment in pelvic pain] Valade D. **Contracept Fertil Sex** 1996 Mar;24(3):207–12 (0 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Jamieson DJ, et al. **Obstet Gynecol** 1996 Jan;87(1):55–8
Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Mathias SD, et al. **Obstet Gynecol** 1996 Mar;87(3):321–7

ETIOLOGY

The intensity of labor pain in grand multiparas. Ranta P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):250–4
Menstrual disorders and pelvic pain after sterilization. Taner CE, et al. **Adv Contracept** 1995 Dec;11(4):309–15
Chronic pelvic pain caused by residual ovaries and other ovarian remnants [letter; comment] Sinha R. **Br J Obstet Gynaecol** 1995 Nov;102(11):935–6. Comment on: Br J Obstet Gynaecol 1994 Nov;101(11):979–85.
Laparoscopic and cystopic findings in patients with chronic pelvic pain in Eshowe, South Africa. Krolikowski A, et al. **Cent Afr J Med** 1995 Jul;41(7):225–6
Pyogenic sacro-iliitis, a rare cause of peripartum pelvic pain. Engelsbel S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):125–6
Endometriosis and pelvic pain: relation to disease stage and localization. Vercellini P, et al. **Fertil Steril** 1996 Feb; 65(2):299–304
Occult infection as a cause of hip pain in a patient with metastatic breast cancer. Mackey JR, et al. **J Pain Symptom Manage** 1995 Oct;10(7):569–72
Palliative care rounds: T12 epidural metastasis mimicks pelvic recurrence of cecal adenocarcinoma. Stübgen JP. **J Pain Symptom Manage** 1996 Jan;11(1):61–4
Chronic pelvic pain in adolescent women. Diagnostic laparoscopy and ultrasonography. Ozaksit G, et al. **J Reprod Med** 1995 Jul;40(7):500–2
[Pelvic pain of proctological origin] Roche B, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):316–21 (Eng. Abstr.) **(Fre)**

METABOLISM

Relationship between prostaglandin in peritoneal fluid and pelvic venous congestion after sterilization. Ruifang W, et al. **Prostaglandins** 1996 Feb;51(2):161–7

PHYSIOPATHOLOGY

Relaxin is not related to symptom-giving pelvic girdle relaxation in pregnant women. Hansen A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):245–9
[Pelvic pain and pregnancy (letter)] Driessen F. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):278–9 **(Dut)**

PSYCHOLOGY

Psychiatric diagnoses and sexual victimization in women with chronic pelvic pain. Walker EA, et al. **Psychosomatics** 1995 Nov–Dec;36(6):531–40
[Chronic pelvic pain. Expression of a psychological problem] Dellenbach P, et al. **Presse Med** 1996 Apr 13;25(13):615–20 (Eng. Abstr.) **(Fre)**

SURGERY

Pelvic congestion syndrome: a new approach to an unusual problem. Mathis BV, et al. **Am Surg** 1995 Nov; 61(11):1016–8
An analysis of the outcome of microsurgical and laparoscopic adhesiolysis for chronic pelvic pain. Saravelos HG, et al. **Hum Reprod** 1995 Nov;10(11):2895–901
Conservative management of incidental cystotomy at laparoscopy. A report of two cases. Angle HS, et al. **J Reprod Med** 1995 Nov;40(11):809–12
Endoscopic ultrasound. A new instrument for laparoscopic surgery. Hurst BS, et al. **J Reprod Med** 1996 Feb; 41(2):67–70
A simple technique for anticipating and managing secondary puncture site hemorrhage during laparoscopic surgery. A report of two cases. Lewis JE. **J Reprod Med** 1995 Oct; 40(10):729–30
The effectiveness of hysterectomy for chronic pelvic pain [letter] Smith KM, et al. **Obstet Gynecol** 1996 Apr; 87(4):641–2

THERAPY

Relationship between abnormally high levels of plasma CA 125 and resolution of acute pelvic pain in two women with endometrioma. Guerriero S, et al. **Gynecol Obstet Invest** 1995;40(1):61–3
Pain recurrence: a quality of life issue in endometriosis. Damario MA, et al. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S27–42 (99 ref.)

ULTRASONOGRAPHY

Endoscopic ultrasound. A new instrument for laparoscopic surgery. Hurst BS, et al. **J Reprod Med** 1996 Feb; 41(2):67–70

PELVIC PLEXUS see **HYPOGASTRIC PLEXUS**

PELVIMETRY

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

HISTORY

[Radiodiagnosis in obstetrics and gynecology] Mortelmans LL. **J Belge Radiol** 1995 Oct;78(5):294–6 (Eng. Abstr.) **(Dut)**
[Obstetrical study of the pelvis: a historical overview] Thiery M. **Verh K Acad Geneeskd Belg** 1995;57(3):199–228 (Eng. Abstr.) **(Dut)**

METHODS

Obstetric pelvimetry in the UK: an appraisal of current practice. Morrison JJ, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):748–50

PELVIS

see related

ADNEXITIS

Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy. Spirtos NM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1763–7; discussion 1767–8
Gemelli and obturator internus muscles: different heads of one muscle? Shinohara H. **Anat Rec** 1995 Sep;243(1):145–50
Pelvic abscess following laparoscopic appendicectomy [letter] Frizelle FA, et al. **Ann R Coll Surg Engl** 1995 Nov; 77(6):467–8
Pelvic abscess following laparoscopic appendicectomy [letter] Taylor RS. **Ann R Coll Surg Engl** 1995 Nov; 77(6):468
The association of urinary tract infection with a recent pelvic examination in women [editorial] Reed BD. **Arch Fam Med** 1996 Jun;5(6):361–2
The association of urinary tract infection with a recent pelvic examination in women. Tiemstra JD, et al. **Arch Fam Med** 1996 Jun;5(6):357–60 (18 ref.)
A combined approach for the early detection of ovarian cancer in asymptomatic women. Adonakis GL, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):221–5
Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)
Treatment of non-resectable pelvic malignancies by isolated pelvic perfusion. A preliminary study. Kocaoglu H, et al. **Eur J Surg Oncol** 1995 Oct;21(5):535–40
Chronic pelvic pain. Lipscomb GH, et al. **Med Clin North Am** 1995 Nov;79(6):1411–25 (30 ref.)
Pelvic organ prolapse and stress urinary incontinence. Rush CB, et al. **Med Clin North Am** 1995 Nov;79(6):1473–9 (16 ref.)
[Pelvic abscess induced by peritoneal tuberculosis (clinical conference)] **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct; 30(10):636–8 **(Chi)**
[Pelvic symptoms 6 months after implantation of an automatic cardioverter-defibrillator] Trappe HJ, et al. **Internist (Berl)** 1995 Aug;36(8):833–6 (Eng. Abstr.) **(Ger)**
[Extra-pelvic mesonephric cyst] Coda A, et al. **Minerva Chir** 1995 Sep;50(9):805–7 (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Laryngotracheal stenosis in thoracolaryngopelvic dysplasia: Barnes syndrome. Wood E, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):807–9

ANATOMY & HISTOLOGY

Variation in pelvic size between males and females in nonhuman anthropoids. Tague RG. **Am J Phys Anthropol** 1995 Jul;97(3):213–33
MR imaging of the female pelvis. Mayo-Smith WW, et al. **Clin Radiol** 1995 Oct;50(10):667–76 (57 ref.)
Magnetic resonance imaging techniques in the pelvis. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):161–88 (115 ref.)
[Schematic sections of the female pelvis] Lenck LC, et al. **Rev Fr Gynecol Obstet** 1995 Nov;90(11):465–70 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Existence and co-existence of vasoactive substances in nerve fibres supplying the abdomino-pelvic arterial tree of the female pig and cow. Majewski M, et al. **Acta Histochem** 1995 Jul;97(3):235–56
Successful conservative management of congenital pelvic arteriovenous malformation. Chao AS, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):185–8
Pelvic revascularization by direct hypogastric artery reconstruction. Johansen K. **Am J Surg** 1996 May; 171(5):456–9
Arterial vascularization of the abdominal and pelvic regions in the degu, Octodon degus (Rodentia, Octodontidae). Ventura J, et al. **Anat Anz** 1996 Jun;178(3):285–91
Blood supply to the abdominal and pelvic regions in the Mediterranean pine vole, Microtus duodecimcostatus (Rodentia, Arvicolidae). Ventura J, et al. **Anat Histol Embryol** 1995 Jun;24(2):133–7
Unusual cause of abdominal pain: pelvic vein thrombosis in a nonpregnant woman. Ellis JM, et al. **Ann Emerg Med** 1996 Feb;27(2):254–7
Preservation of the pelvic circulation during infrarenal aortic surgery. Connolly JE, et al. **Cardiovasc Surg** 1996 Feb;

4(1):65–70 (46 ref.)
Corona mortis. Incidence and location. Tornetta P 3rd, et al. **Clin Orthop** 1996 Aug;(329):97–101
Cost–effectiveness of colour duplex sonography compared with angiography of the pelvis and lower limb. Geitung JT, et al. **Eur Radiol** 1996;6(4):481–4
An in vitro flow model to study streaming during pelvic intra–arterial drug infusions. Lutz RJ, et al. **Gynecol Oncol** 1995 Nov;59(2):288–96
Transabdominal Doppler–sonographic measurements of blood flow differences in the main pelvic arteries during physiological spontaneous ovarian cycles. Deichert U, et al. **Hum Reprod** 1995 Jun;10(6):1531–6
Embolisation of bleeding pelvic lesions from benign origin—long–term results. Hendrickx P, et al. **J Belge Radiol** 1995 Dec;78(6):339–41
Venography of the extremities and pelvis. Spritzer CE. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):239–51 (28 ref.)
Relationship between prostaglandin in peritoneal fluid and pelvic venous congestion after sterilization. Ruifang W, et al. **Prostaglandins** 1996 Feb;51(2):161–7
Pelvic steal syndrome. Gluckman GR, et al. **Urology** 1996 Mar;47(3):426
[Uses of interventional arteriographic technics in gynecologic neoplasms] Yue D, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):435–7 (14 ref.) **(Chi)**
[Radiation exposure in interventional radiology as exemplified by the chemoembolization of hepatocellular carcinoma and laser angioplasty of the pelvic arteries] Hidajat N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):249–56 (Eng. Abstr.) **(Ger)**
[Wounds of the abdomen and pelvis with damage to the major vessels] Lokhvitskil SV, et al. **Vestn Khir Im I I Grek** 1995;154(3):65–7 (Eng. Abstr.) **(Rus)**

INJURIES

The injury impairment scale in pelvic and lower limb fractures sustained in road traffic accidents. Massoud SN, et al. **Injury** 1996 Mar;27(2):107–10
Imaging of pelvic trauma. Young JW. **J South Orthop Assoc** 1996 Spring;5(1):63–70 (23 ref.)
CT of abdominal and pelvic trauma. Roberts JL. **Semin Ultrasound CT MR** 1996 Apr;17(2):142–69 (71 ref.)
The evaluation of pelvic injury in the female athlete. Short JW, et al. **Sports Med** 1995 Dec;20(6):422–8
[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**
[Wounds of the abdomen and pelvis with damage to the major vessels] Lokhvitskil SV, et al. **Vestn Khir Im I I Grek** 1995;154(3):65–7 (Eng. Abstr.) **(Rus)**
[Reconstructive–restorative and combined operations in patients with injuries to the muscles of the pelvic floor and perineum] Nazarov LU, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):335–7 **(Rus)**

INNERVATION

Central nervous system neurons infected by pseudorabies virus injected into the rat urinary bladder following unilateral transection of the pelvic nerve. Nadelhaft I, et al. **J Comp Neurol** 1995 Aug 28;359(3):443–56
Intramural neurones appear in the urinary bladder wall following excision of the pelvic ganglion in the rat. Uvelius B, et al. **Neuroreport** 1995 Nov 13;6(16):2213–6
All pelvic neurons in male rats contain immunoreactivity for the synthetic enzymes of either noradrenaline or acetylcholine. Keast JR, et al. **Neurosci Lett** 1995 Aug 25; 196(3):209–12
[The effect of electro–acupuncture at auricular & body acupoints on the curve changes of the pressure–volume of urinary bladder and the electric activity of pelvic nerves of rat] Ben H, et al. **Chen Tzu Yen Chiu** 1995;20(2):51–4 (Eng. Abstr.) **(Chi)**

PATHOLOGY

Abdominopelvic MR imaging in the nonobstetric evaluation of pregnant patients. Forstner R, et al. **AJR Am J Roentgenol** 1996 May;166(5):1139–44
Pelvic pathology after hysterectomy. A pictorial essay. Kasales CJ, et al. **Clin Imaging** 1995 Jul–Sep;19(3):210–7 (5 ref.)
Volume changes within the true pelvis during disruption of the pelvic ring—where does the haemorrhage go? Moss MC, et al. **Injury** 1996;27 Suppl 1:S–A21–3
A comparative study between pelvic ultrasonography and laparoscopy in the detection of pelvic pathology in the initial workup of subfertile women. Preutthipan S, et al. **J Med Assoc Thai** 1995 Nov;78(11):596–9
Case of pelvic relapse in a child suffering from acute lymphoblastic leukemia. Qamruddin K, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):193–4

PHYSIOLOGY

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)
Effect of moderately increased intrapelvic pressure on renal tissue pressure and vasopressin release in rabbits. Shiotsu T, et al. **Hypertens Res** 1995 Sep;18(3):197–202

RADIATION EFFECTS

Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Clough KB, et al. **Cancer** 1996 Jun 15;77(12):2638–45
Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high–risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH–PLND): a randomized phase III trial [see comments] Curtin JP, et al. **Gynecol Oncol** 1996 Apr;61(1):3–10. Comment in: Gynecol Oncol 1996 Apr;61(1):1–2.
Relationship of pelvic radiation to intestinal blood flow. Wiseman JS, et al. **J Surg Res** 1996 Jan;60(1):239–44
Noncritical soft tissues of the female pelvis: serial MR imaging before, during, and after radiation therapy. Blomlie V, et al. **Radiology** 1996 May;199(2):461–8

RADIOGRAPHY

Detection of bleeding in patients with major pelvic fractures: value of contrast–enhanced CT. Cerva DS Jr, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):131–5
Segmental inertial parameters of the human trunk as determined from computed tomography. Pearsall DJ, et al. **Ann Biomed Eng** 1996 Mar–Apr;24(2):198–210
Imaging of pelvic trauma. Young JW. **J South Orthop Assoc** 1996 Spring;5(1):63–70 (23 ref.)
[Radiation exposure in interventional radiology as exemplified by the chemoembolization of hepatocellular carcinoma and laser angioplasty of the pelvic arteries] Hidajat N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):249–56 (Eng. Abstr.) **(Ger)**
[The preoperative staging of rectal cancer. A comparative assessment between endorectal echography and pelvic CT] Carrella G, et al. **G Chir** 1996 Apr;17(4):190–4 (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

An unusual localization of extramedullary hematopoiesis. Vardareli E, et al. **Clin Nucl Med** 1996 Mar;21(3):256–7

SURGERY

Genitourinary case of the day. Peritoneal inclusion cyst in a patient with a history of prior pelvic surgery. Moran RE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):247, 250
Femoral neuropathy after pelvic surgery. Chen SS, et al. **Urology** 1995 Oct;46(4):575–6
The laparoscope as a teaching aid in open pelvic surgery. Izes JK, et al. **Urology** 1995 Nov;46(5):713–4
[Insidious growth of peritoneal cysts several years after pelvic surgery. Ultrasonographic and x–ray computed tomographic aspects] De Blay V, et al. **J Radiol** 1996 May; 77(5):339–42 (Eng. Abstr.) **(Fre)**
[Drainage of the fatty tissues of the lesser pelvis] Iudin IaB. **Vestn Khir Im I I Grek** 1992 Mar;148(3):359–62 **(Rus)**
[Reconstructive–restorative and combined operations in patients with injuries to the muscles of the pelvic floor and perineum] Nazarov LU, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):335–7 **(Rus)**

ULTRASONOGRAPHY

ACOG releases report on gynecologic ultrasonography. **Am Fam Physician** 1996 Jul;54(1):364–5
Early pregnancy: normal and abnormal. Howe RS. **Clin Obstet Gynecol** 1996 Mar;39(1):188–98
A comparative study between pelvic ultrasonography and laparoscopy in the detection of pelvic pathology in the initial workup of subfertile women. Preutthipan S, et al. **J Med Assoc Thai** 1995 Nov;78(11):596–9
[Pelvic emergencies in women] Noblinski B, et al. **Ann Radiol (Paris)** 1996;39(2):65–71 (Eng. Abstr.) **(Fre)**

PEMOLINE

ADMINISTRATION & DOSAGE

Pemoline effects on children with ADHD: a time–response by dose–response analysis on classroom measures. Pelham WE Jr, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov;34(11):1504–13

THERAPEUTIC USE

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Geisler MW, et al. **Arch Neurol** 1996 Feb;53(2):185–8
Abnormal auditory P300 topography in attention deficit disorder predicts poor response to pemoline. Sangal JM, et al. **Clin Electroencephalogr** 1995 Oct;26(4):204–13
Pemoline effects on children with ADHD: a time–response by dose–response analysis on classroom measures. Pelham WE Jr, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov;34(11):1504–13
An open trial of pemoline in drug–dependent delinquents with attention–deficit hyperactivity disorder. Riggs PD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1018–24
Medication for attention deficit hyperactivity disorder: commentary and response [see comments] Faigel HC, et al. **J Am Coll Health** 1996 Jul;45(1):40–1; discussion 41–2 . Comment in: J Am Coll Health 1996 Jul;45(1):35–9.
Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study [comment] Heiligenstein E, et al. **J Am Coll Health** 1996 Jul;45(1):35–9 . Comment on: J Am Coll Health 1996 Jul;45(1):40–1; discussion 41–2.
Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series [letter] Rothman RB. **J Subst Abuse Treat** 1995 Nov–Dec;12(6):449–53
Fatigue therapy in multiple sclerosis: results of a double–blind, randomized, parallel trial of amantadine, pemoline, and placebo. Krupp LB, et al. **Neurology** 1995 Nov;45(11):1956–61

PEMPHIGOID, BENIGN MUCOUS MEMBRANE

Progression of disease in ocular cicatricial pemphigoid. Elder MJ, et al. **Br J Ophthalmol** 1996 Apr;80(4):292–6
Cicatricial pemphigoid: diagnosis and treatment. Nguyen QD, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):41–60 (52 ref.)

COMPLICATIONS

Sulphapyridine—a new agent for the treatment of ocular cicatricial pemphigoid. Elder MJ, et al. **Br J Ophthalmol** 1996 Jun;80(6):549–52
Giant dacryops in a patient with ocular cicatricial pemphigoid [letter] Remulla HD, et al. **Br J Ophthalmol** 1995 Nov;79(11):1052–3
Oesophageal webs associated with cicatricial pemphigoid [letter] Ostlere LS, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):176–7
Cyclosporine therapy of life–threatening cicatricial pemphigoid affecting the respiratory tract. Williams DY, et al. **Int J Dermatol** 1995 Sep;34(9):639–41
Coexistence of pemphigus vulgaris and ocular cicatricial pemphigoid. Buhac J, et al. **J Am Acad Dermatol** 1996 May; 34(5 Pt 2):884–6
Management of airway obstruction in cicatricial pemphigoid. Lazor JB, et al. **Laryngoscope** 1996 Aug;106(8):1014–7
[Nasal localization of a cicatricial pemphigoid: apropos of a case] Stoll D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):341–5 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.). Comment in: J Periodontol 1995 Aug;66(8):747–8.
Diagnosis of the conjunctival biopsy in OCP [letter] Francis IC, et al. **Ophthalmology** 1996 Apr;103(4):543–4

DRUG THERAPY

Cyclosporine therapy of life–threatening cicatricial pemphigoid affecting the respiratory tract. Williams DY, et al. **Int J Dermatol** 1995 Sep;34(9):639–41
Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.). Comment in: J Periodontol 1995 Aug;66(8):747–8.
[Cicatricial pemphigoid—a therapeutic problem] Axt M, et al. **Hautarzt** 1995 Sep;46(9):620–7 (32 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Epiligrin is decreased in papulonodular basal cell carcinoma tumor nest basement membranes and the extracellular matrix of transformed human epithelial cells. Lazarova Z, et al. **Exp Dermatol** 1995 Jun;4(3):121–9
Antiepiligrin cicatricial pemphigoid: the first case report from Japan. Hashimoto T, et al. **J Am Acad Dermatol** 1996 May; 34(5 Pt 2):940–2
Studies of patients with anti–epiligrin cicatricial pemphigoid. Yancey KB, et al. **J Dermatol** 1995 Nov;22(11):829–35 (25 ref.)
Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. Balding SD, et al. **J Invest Dermatol** 1996 Jan;106(1):141–6
Anti–basement membrane autoantibodies in patients with anti–epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. Kirtschig G, et al. **J Invest Dermatol** 1995 Oct;105(4):543–8

PATHOLOGY

Vulval cicatricial pemphigoid may mimic lichen sclerosus. Marren P, et al. **Br J Dermatol** 1996 Mar;134(3):522–4
The ocular surface as part of the mucosal immune system: conjunctival mucosa–specific lymphocytes in ocular surface pathology. Dua HS, et al. **Eye** 1995;9 (Pt 3):261–7

SURGERY

Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Tsubota K, et al. **Am J Ophthalmol** 1996 Jul; 122(1):38–52

Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid. Elder MJ, et al. **Br J Ophthalmol** 1995 Nov;79(11):1003–6

PEMPHIGOID, BULLOUS

BLOOD

Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. de la Torre B, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):345–8

CHEMICALLY INDUCED

Risperidone and bullous pemphigoid [letter] Wijeratne C, et al. **Am J Psychiatry** 1996 May;153(5):735

Drugs associated with bullous pemphigoid. A case-control study. Bastuji-Garin S, et al. **Arch Dermatol** 1996 Mar; 132(3):272–6

Bullous pemphigoid and penicillamine. Weller R, et al. **Clin Exp Dermatol** 1996 Mar;21(2):121–2

Recurrent and chronic leg ulcers secondary to furosemide-induced bullous pemphigoid [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1183–4 (7 ref.)

COMPLICATIONS

Bullous pemphigoid and ulcerative colitis: a report of two cases and description of immunoblot findings [letter] Harrison PV, et al. **Br J Dermatol** 1996 Mar;134(3):599–600

Bullous pemphigoid complicating human orf. Murphy JK, et al. **Br J Dermatol** 1996 May;134(5):929–30

Varicella zoster virus infection complicating bullous pemphigoid [letter] Cliff S, et al. **Clin Exp Dermatol** 1996 Mar;21(2):174–5

[A case of resected lung cancer associated with bullous pemphigoid] Sato Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Apr;44(4):524–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse panbronchiolitis associated with bullous pemphigoid] Oshikawa K, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Sep; 33(9):1019–23 (21 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Ghohestani R, et al. **Br J Dermatol** 1996 Jul;135(1):74–9

Childhood bullous pemphigoid—report of a case with dermal fluorescence on salt-split skin. Wakelin SH, et al.
Br J Dermatol 1995 Oct;133(4):615–8

Bullous pemphigoid: persistent lesions of eczematous/urticarial erythemas. Jeong SJ, et al. **Cutis** 1995 Oct;56(4):225–6

[Dyshidrotic pemphigoid] Beylot-Barry M, et al.
Ann Dermatol Venereol 1995;122(3):81–3 (Eng. Abstr.) **(Fre)**

[Bullous pemphigoid simulation subacute simple prurigo] Wever S, et al. **Hautarzt** 1995 Nov;46(11):789–95 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Post-bullous milia. Hisa T, et al. **Australas J Dermatol** 1996 Aug;37(3):153–4

Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Itoh T, et al.
Br J Dermatol 1996 May;134(5):931–3

Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. Bouscarat F, et al.
J Am Acad Dermatol 1996 Apr;34(4):683–4

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al.
J Dermatol 1995 Aug;22(8):582–6 (22 ref.)

[Local corticosteroid therapy in a severe form of pemphigoid gestationis (letter)] Guillaume JC, et al.
Ann Dermatol Venereol 1996;123(1):31 **(Fre)**

ETIOLOGY

Pemphigoid gestationis occurring in a patient with HELLP syndrome. Lowe PM, et al. **Australas J Dermatol** 1996 May; 37(2):89–92

Bullous pemphigoid induced by vaccination [letter] Fournier B, et al. **Br J Dermatol** 1996 Jul;135(1):153–4

Bullous pemphigoid following radiotherapy [letter; comment] Cliff S, et al. **Clin Exp Dermatol** 1995 Jul;20(4):360–1. Comment on: Clin Exp Dermatol 1995 Jan;20(1):80–2.

Bullous pemphigoid following radiotherapy [letter; comment] Delaporte E, et al. **Clin Exp Dermatol** 1995 Jul;20(4):361 . Comment on: Clin Exp Dermatol 1995 Jan;20(1):80–2.

Bullous pemphigoid induced by radiation therapy. Folliero G, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):266–7

Burn-induced bullous pemphigoid [letter; comment] Vassileva S, et al. **Int J Dermatol** 1995 Jul;34(7):516–7 (10 ref.). Comment on: Int J Dermatol 1994 Jan;33(1):55–6.

Bullous pemphigoid possibly induced by psoralen plus ultraviolet A therapy. George PM.
Photodermatol Photoimmunol Photomed 1996 Oct–Dec; 11(5–6):185–7 (15 ref.)

IMMUNOLOGY

Simultaneous occurrence of lupus anticoagulant, factor VIII inhibitor and localized pemphigoid [letter] Biron C, et al.
Am J Hematol 1996 Mar;51(3):250–1

A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens. Darling TN, et al. **Arch Dermatol** 1995 Dec;131(12):1438–42

Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. De Jong MC, et al. **Arch Dermatol** 1996 Feb;132(2):151–7

Ultrastructural localization of binding sites of sera from patients with linear IgA bullous dermatosis. Kowalewski C, et al. **Arch Dermatol Res** 1995;287(7):636–40

Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Fairley JA, et al.
Br J Dermatol 1995 Sep;133(3):385–91

Pemphigoid gestationis with autoantibodies exclusively directed to the 230-kDa bullous pemphigoid antigen (BP230Ag) [letter] Ghohestani R, et al. **Br J Dermatol** 1996 Mar;134(3):603–4

Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Tanaka M, et al.
Clin Exp Dermatol 1996 Jan;21(1):23–7

A hemidesmosomal transmembrane collagenous molecule, the 180-kDa bullous pemphigoid antigen (BPA II), is phosphorylated with 12-O-tetradecanoylphorbol-13-acetate in a human squamous cell carcinoma cell line (DJM-1). Kitajima Y, et al. **Epithelial Cell Biol** 1995;4(2):70–5

Bullous pemphigoid: serum antibody titre and antigen specificity. Pas HH, et al. **Exp Dermatol** 1995 Dec; 4(6):372–6

Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. Hirako Y, et al. **J Biol Chem** 1996 Jun 7; 271(23):13739–45

Structural analysis of the predicted coiled-coil rod domain of the cytoplasmic bullous pemphigoid antigen (BPAG1). Empirical localization of the N-terminal globular domain-rod boundary. Tang HY, et al. **J Biol Chem** 1996 Apr 19;271(16):9716–22

Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. Liu Z, et al. **J Immunol** 1995 Dec 1;155(11):5449–54

In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. Korman NJ.
J Invest Dermatol 1995 Dec;105(6):824–30

A homozygous deletion mutation in the gene encoding the 180-kDa bullous pemphigoid antigen (BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. McGrath JA, et al. **J Invest Dermatol** 1996 Apr; 106(4):771–4

An animal model of bullous pemphigoid: what can it teach us? Giudice GJ, et al. **Proc Assoc Am Physicians** 1995 Jul; 107(2):237–41 (33 ref.)

A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Delgado JC, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8569–71

[Study of epitopic sites of the major bullous pemphigoid antigen (BPAg1)] Peyron E, et al.
Ann Biol Clin (Paris) 1995;53(4):193–7 (Eng. Abstr.) **(Fre)**

[Linear IgA bullous dermatosis in children with autoantibodies against 180 kDa pemphigoid antigen] Bérard F, et al. **Arch Pediatr** 1996 Apr;3(4):345–7 (Eng. Abstr.) **(Fre)**

METABOLISM

Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. Schmidt E, et al.
J Am Acad Dermatol 1996 Feb;34(2 Pt 1):310–2

PATHOLOGY

Antigen retrieval in immunofluorescent testing of bullous pemphigoid. D'Ambra-Cabry K, et al.
Am J Dermatopathol 1995 Dec;17(6):560–3

A case of autoimmune bullous dermatosis with features of pemphigus vulgaris and bullous pemphigoid. Kore-eda S, et al. **Am J Dermatopathol** 1995 Oct;17(5):511–6

Prurigo papules with blisters. Kossard S.
Australas J Dermatol 1996 May;37(2):104–5

Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Korman NJ, et al. **Br J Dermatol** 1995 Dec;133(6):967–71

Bullous pemphigoid—a report of 86 cases from Taiwan. Chang YT, et al. **Clin Exp Dermatol** 1996 Jan;21(1):20–2

Stump pemphigoid. Brodell RT, et al. **Cutis** 1996 Apr; 57(4):245–6

A case of bullous pemphigoid with antibodies against intercellular 130 kd antigen. Takahashi H, et al.
J Dermatol 1995 Aug;22(8):576–81

VETERINARY

Canine bullous pemphigoid (BP): identification of the 180-kd canine BP antigen by circulating autoantibodies. Iwasaki T, et al. **Vet Pathol** 1995 Jul;32(4):387–93

PEMPHIGOID, CICATRICIAL see PEMPHIGOID, BENIGN MUCOUS MEMBRANE

PEMPHIGUS

Pemphigus vulgaris and pregnancy. Ruach M, et al.
Obstet Gynecol Surv 1995 Oct;50(10):755–60 (48 ref.)

BLOOD

Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. de la Torre B, et al.
Clin Exp Rheumatol 1995 May–Jun;13(3):345–8

Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Hashimoto T, et al. **Epithelial Cell Biol** 1995;4(2):63–9

CHEMICALLY INDUCED

Isotretinoin-induced pemphigus [letter] Georgala S, et al.
Acta Derm Venereol 1995 Sep;75(5):413

Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine [letter; comment] Bazarbachi A, et al. **Ann Oncol** 1995 Sep; 6(7):730–1. Comment on: Ann Oncol 1995 Mar;6(3):300–1.

D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Ciompi ML, et al.
Rheumatol Int 1995;15(3):95–7

COMPLICATIONS

Pemphigus vulgaris with asymptomatic pseudomembranous colitis. Takizawa H, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1654–5

Koebner phenomenon in pemphigus vulgaris [letter] Hameed A, et al. **Br J Dermatol** 1996 Jul;135(1):152–3

A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Shimizu K, et al.
Dermatology 1996;192(2):179–82

Pemphigus foliaceus coexisting with IgA nephropathy in a patient with psoriasis vulgaris. Perez GL, et al.
Int J Dermatol 1995 Nov;34(11):794–6

Coexistence of pemphigus vulgaris and ocular cicatricial pemphigoid. Buhac J, et al. **J Am Acad Dermatol** 1996 May; 34(5 Pt 2):884–6

Paraneoplastic pemphigus: report of a case. Izaki S, et al.
J Dermatol 1996 Jun;23(6):397–404 (24 ref.)

Coexistence of myasthenia gravis and pemphigus foliaceus. Kim HT, et al. **J Korean Med Sci** 1995 Aug;10(4):298–302

Evaluation of nutritional status in patients with endemic pemphigus foliaceus. Barraviera SR, et al.
Rev Inst Med Trop Sao Paulo 1995 Jan–Feb;37(1):51–8

[Case of Fisher syndrome with pemphigus treated by immuno-adsorption plasmapheresis] Nishikage H, et al.
Nippon Naika Gakkai Zasshi 1996 Feb 10;85(2):274–5 **(Jpn)**

DIAGNOSIS

[Severe eye involvement in pemphigus vulgaris] Baykal HE, et al. **Ophthalmologe** 1995 Dec;92(6):854–7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? [letter] Alpsoy E, et al.
Arch Dermatol 1995 Nov;131(11):1339–40

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

Minocycline is a useful adjuvant therapy for pemphigus. Gaspar ZS, et al. **Australas J Dermatol** 1996 May;37(2):93–5

Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Rhodes LE, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):155–6

Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Pasricha JS, et al. **Int J Dermatol** 1995 Dec; 34(12):875–82

Influence of treatment on the clinical course of pemphigus vulgaris. Carson PJ, et al. **J Am Acad Dermatol** 1996 Apr; 34(4):645–52

Multiple sebaceous hyperplasia in a patient with Senear-Usher syndrome under immunosuppressive therapy [letter] Yamamoto T, et al. **J Dermatol** 1996 May;23(5):372

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

EPIDEMIOLOGY

Pemphigus in Mali: a study of 30 cases. Mahé A, et al.
Br J Dermatol 1996 Jan;134(1):114–9

[Comparative epidemiology of pemphigus in Tunisia and France. Incidence of foliaceus pemphigus in young Tunisian women] Bastuji-Garin S, et al.
Ann Dermatol Venereol 1996;123(5):337–42 (Eng. Abstr.)

(Fre)
[Tunisian pemphigus. Apropos of 70 cases. (Experience of the dermatology department of La Rabta Hospital 1974–1992)] Haouet H, et al. **Ann Dermatol Venereol** 1996; 123(1):9–11 (Eng. Abstr.) (Fre)

ETIOLOGY

Paraneoplastic pemphigus in a patient with non-Hodgkin's lymphoma. Plumb R, et al. **Am J Hematol** 1996 May; 52(1):58–9
Paraneoplastic pemphigus triggered by radiotherapy. Lee MS, et al. **Australas J Dermatol** 1995 Nov;36(4):206–10
Contact pemphigus. Vozza A, et al. **Int J Dermatol** 1996 Mar;35(3):199–201
[Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia] Rodot S, et al. **Rev Med Interne** 1995;16(12):938–43 (25 ref.) (Eng. Abstr.) (Fre)

GENETICS

Pemphigus vulgaris in distant relatives of two families: association with major histocompatibility complex class II genes. Bhol K, et al. **Clin Exp Dermatol** 1996 Mar; 21(2):100–3

IMMUNOLOGY

Pemphigus: autoimmunity to epidermal cell adhesion molecules. Amagai M. **Adv Dermatol** 1996;11:319–52; discussion 353 (166 ref.)
Demonstration of antibodies to bovine desmocollin isoforms in certain pemphigus sera. Dmochowski M, et al. **Br J Dermatol** 1995 Oct;133(4):519–25
Differences in the expression of pemphigus antigens during epidermal differentiation. Iwatsuki K, et al. **Br J Dermatol** 1995 Aug;133(2):209–16
Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. Cooperative Group on Fogo Selvagem Research. Santi CG, et al. **J Am Acad Dermatol** 1996 Jan; 34(1):40–6
Recombinant desmoglein 3 has the necessary epitopes to adsorb and induce blister-causing antibodies. Memar OM, et al. **J Invest Dermatol** 1996 Feb;106(2):261–8
Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Wucherpfennig KW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11935–9
Cell and humoral immunity in endemic pemphigus foliaceus. Barraviera SR, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):25–33 (30 ref.)
[Ultrastructural localisation of pemphigus vulgaris and pemphigus foliaceus antigens by indirect immunoelectron microscopy. Apropos of 7 cases] Boulinguez S, et al. **Ann Dermatol Venereol** 1995;122(6–7):417–21 (25 ref.) (Eng. Abstr.) (Fre)
[Pemphigus: from clinical observation to molecular biology (editorial)] Thivolet J, et al. **Ann Dermatol Venereol** 1995; 122(10):660–2 (Fre)
[Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus] Trémeau-Martinage C, et al. **Ann Dermatol Venereol** 1995;122(6–7):409–11 (Eng. Abstr.) (Fre)
[A method of detecting soluble immune complexes in tissue biopsies] Beletskaia LV, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):40–2 (Eng. Abstr.) (Rus)

METABOLISM

Tissue factor and thrombomodulin expression on keratinocytes as coagulation/anti-coagulation cofactor and differentiation marker. Mizutani H, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S48–9

PATHOLOGY

A case of autoimmune bullous dermatosis with features of pemphigus vulgaris and bullous pemphigoid. Kore-eda S, et al. **Am J Dermatopathol** 1995 Oct;17(5):511–6
Pemphigus vulgaris: gingival involvement. A case report. Weinberg MA, et al. **Ann Dent** 1995 Summer–Fall; 54(1–2):8–13
Neutrophilic spongiosis in pemphigus. Hoss DM, et al. **Arch Dermatol** 1996 Mar;132(3):315–8
Neonatal pemphigus foliaceus. Walker DC, et al. **Arch Dermatol** 1995 Nov;131(11):1308–11 (21 ref.)
Paraneoplastic pemphigus: the first case report from Japan. Nishibori Y, et al. **Dermatology** 1995;191(1):39–42
Treatment-resistant pemphigus vegetans of the scalp. Rackett SC, et al. **Int J Dermatol** 1995 Dec;34(12):865–6
IgA pemphigus: report of a case with immunoelectron localization of bound IgA in the skin. Kim SC, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):852–4
Mice expressing a mutant desmosomal cadherin exhibit abnormalities in desmosomes, proliferation, and epidermal differentiation. Allen E, et al. **J Cell Biol** 1996 Jun; 133(6):1367–82
Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)
Immunofluorescence study of pemphigus from north India. Kumar S, et al. **J Dermatol** 1995 Aug;22(8):571–5
A case of bullous pemphigoid with antibodies against intercellular 130 kd antigen. Takahashi H, et al. **J Dermatol** 1995 Aug;22(8):576–81

THERAPY

Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Bewley AP, et al. **Br J Dermatol** 1996 Jul;135(1):128–9
Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis [letter] Izaki S, et al. **Br J Dermatol** 1996 May;134(5):987–9
High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris [letter] Messer G, et al. **Br J Dermatol** 1995 Dec;133(6):1014–6
Management of the immunobullous disorders. II. Pemphigus. Huilgol SC, et al. **Clin Exp Dermatol** 1995 Jul;20(4):283–93 (95 ref.)

VETERINARY

Effect of substrate on indirect immunofluorescence test for canine pemphigus foliaceus. Iwasaki T, et al. **Vet Pathol** 1996 May;33(3):332–6

PEMPHIGUS, BENIGN FAMILIAL

DRUG THERAPY

Bullous drug eruption to griseofulvin in a man with Hailey-Hailey disease. Meffert JJ, et al. **Cutis** 1995 Nov; 56(5):279–80

GENETICS

Narrowing of the Hailey-Hailey disease gene region on chromosome 3q and identification of one kindred with a deletion in this region. Peluso AM, et al. **Genomics** 1995 Nov 1;30(1):77–80

PEMPHIGUS VULGARIS see PEMPHIGUS

PENBUTOLOL

METABOLISM

[Analysis of penbutolol and its metabolites in human body fluid by gas chromatography—mass spectrometry] Shen L, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):702–5 (Eng. Abstr.) (Chi)

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Aguirre C, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):53–72

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Aguirre C, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):53–72

PENICILLAMINE

ADMINISTRATION & DOSAGE

[Copper-induced green hair. Treatment with a penicillamine containing shampoo] Munkvad S, et al. **Ugeskr Laeger** 1996 Jun 24;158(26):3791–2 (Eng. Abstr.) (Dan)
[A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780–91 (Eng. Abstr.) (Jpn)

ADVERSE EFFECTS

Bullous pemphigoid and penicillamine. Weller R, et al. **Clin Exp Dermatol** 1996 Mar;21(2):121–2
Pleural effusion associated with D-penicillamine therapy: a case report. Karkos C, et al. **J Clin Pharm Ther** 1996 Feb; 21(1):15–7
Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Gaskin G, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1925–8
Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)
D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Ciompi ML, et al. **Rheumatol Int** 1995;15(3):95–7
[Follow-up and immunologic findings in drug-induced myasthenia] Brüggemann W, et al. **Med Klin** 1996 May 15;91(5):268–71 (Eng. Abstr.) (Ger)
[Myasthenia gravis caused by D-penicillamine (letter)] Sanz Gallego PJ, et al. **Aten Primaria** 1996 Mar 31;17(5):364–5 (Spa)

ANALOGS & DERIVATIVES

Nitric oxide donor prevents hydrogen peroxide-mediated endothelial cell injury. Chang J, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L931–40
Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level. Andrew PJ, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):949–56
Nitric oxide-donor compounds inhibit lipoxygenase activity. Maccarrone M, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):128–33
Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Apr 5; 221(1):163–8
Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Askew SC, et al. **Bioorg Med Chem** 1995 Jan;3(1):1–9
Attenuation by nitrosothiol NO donors of acute intestinal microvascular dysfunction in the rat. László F, et al. **Br J Pharmacol** 1995 Jun;115(3):498–502
Inhibition of purified (Na+,K+)-ATPase activity from porcine cerebral cortex by NO generating drugs. Sato T, et al. **Brain Res** 1995 Dec 15;704(1):117–20
Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Kojda G, et al. **Circ Res** 1996 Jan; 78(1):91–101
Role of oxygen-derived metabolites in the rat gastric mucosal injury induced by nitric oxide donors. Lamarque D, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):187–94
Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. Kim YM, et al. **FEBS Lett** 1995 Oct 30; 374(2):228–32
Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Behar-Cohen FF, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1711–5
Amelioration of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet. Hoshida S, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):902–9
Regulation of calcium-activated potassium channels by S-nitrosothiol compounds and cyclic guanosine monophosphate in rabbit coronary artery myocytes. George MJ, et al. **J Investig Med** 1995 Oct;43(5):451–8
Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. Akarid K, et al. **J Virol** 1995 Nov;69(11):7001–5
Glutamate-induced disruption of the blood-brain barrier in rats. Role of nitric oxide. Mayhan WG, et al. **Stroke** 1996 May;27(5):965–9; discussion 970
[Effect of a nitric oxide donor on optic nerve head circulation] Sugiyama T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):5–10 (Eng. Abstr.) (Jpn)

IMMUNOLOGY

D-penicillamine-induced autoantibodies in a mouse model. Brik R, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):483–8

PHARMACOLOGY

In vitro and in vivo interactions of D-penicillamine with tumors. Samoszuk M, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1219–23
Penicillamine produces changes in the acute blood elimination and tissue accumulation of thallium. Careaga-Olivares J, et al. **Arch Med Res** 1995 Winter; 26(4):427–30
D-penicillamine inhibits the action of reactive oxygen species in the pig pulmonary circulation. Sanderud J, et al. **J Perinat Med** 1995;23(5):385–93
Effect of (D)-penicillamine on oxalate production [letter] Baker P, et al. **Nephron** 1995;71(2):240
Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Yoshida D, et al. **Neurosurgery** 1995 Aug;37(2):287–92; discussion 292–3

THERAPEUTIC USE

Mechanisms of pennicillamine and zinc in the treatment of Wilson's disease [letter; comment] Farinati F, et al. **Am J Gastroenterol** 1995 Dec;90(12):2264–5. Comment on: Am J Gastroenterol 1994 Mar;89(3):442–3. Comment on: Am J Gastroenterol 1995 Jun;90(6):1026.
Long term survival in Indian childhood cirrhosis treated with D-penicillamine. Bavdekar AR, et al. **Arch Dis Child** 1996 Jan;74(1):32–5
Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals [see comments] Goyer RA, et al. **Environ Health Perspect** 1995 Nov; 103(11):1048–52. Comment in: Environ Health Perspect 1995 Nov;103(11):988–9.
Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Norga K, et al. **Inflamm Res** 1995 Dec;44(12):529–34
Successful medical treatment of severely decompensated Wilson disease. Santos Silva EE, et al. **J Pediatr** 1996 Feb; 128(2):285–7
Neuromuscular transmission and acetylcholine receptor antibodies in penicillamine-treated Wilson's disease patients [letter] Anlar B, et al. **Muscle Nerve** 1996 May;19(5):676–7
[A prospective study of plasma exchange in the treatment

of diffuse scleroderma] Ding C, et al.
Chung Hua Nei Ko Tsa Chih 1995 Sep;34(9):616–9 (Eng. Abstr.) **(Chi)**

PENICILLANIC ACID

ANALOGS & DERIVATIVES

In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals. Verbist L, et al. **Acta Clin Belg** 1995;50(5):274–81
Compatibility of ondansetron hydrochloride and piperacillin sodium–tazobactam sodium during simulated Y-site administration. Chung KC, et al.
Am J Health Syst Pharm 1995 Jul 15;52(14):1554–6
Stability of piperacillin sodium–tazobactam sodium in peritoneal dialysis solutions. Park TW, et al.
Am J Health Syst Pharm 1995 Sep 15;52(18):2022–4
Spectrophotometric determination of 6–aminopenicillanic and 7–aminocephalosporanic acids as the Schiff bases with para–dimethylaminobenzaldehyde in the presence of sodium dodecyl sulfate micelles. Yatsimirskaya NT, et al.
Anal Biochem 1995 Aug 10;229(2):249–55
Bifunctional activity labels for selection of filamentous bacteriophages displaying enzymes. Vanwetswinkel S, et al. **Bioorg Med Chem** 1995 Jul;3(7):907–15
Piperacillin tazobactam compared with co–amoxiclav, ampicillin plus sulbactam and timentin against beta–lactamase–producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Traub WH, et al. **Chemotherapy** 1995 Sep–Oct;41(5):345–52
Life–threatening neutropenia secondary to piperacillin/tazobactam therapy. Gerber L, et al.
Clin Infect Dis 1995 Oct;21(4):1047–8
Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta–lactamase derepressed mutants). Higashitani F, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1027–33
Chemical modification of tazobactam. Synthesis of 2 beta–[(4–substituted)–1,2,3–triazol–1–yl]methyl penicillanic acid sulfone derivatives. Setti EL, et al.
J Antibiot (Tokyo) 1995 Nov;48(11):1320–9
Effect of pO2 and pH on synergy of tazobactam and beta–lactam antibiotics against beta–lactamase producing Enterobacteriaceae. König C, et al.
J Antimicrob Chemother 1995 Sep;36(3):513–9
Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group. Verbist L, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):285–93
High–performance liquid chromatographic determination of tazobactam by precolumn derivatization. Peyrin E, et al.
J Chromatogr B Biomed Appl 1995 Oct 6;672(1):160–4
[The effectiveness of so–called potentiated penicillins (augmentin and tazobactam) in vitro] Blahová J, et al.
Cas Lek Cesk 1995 Sep 6;134(17):558–61 (Eng. Abstr.) **(Slo)**

PENICILLIN ACYLASE see **PENICILLIN AMIDASE**

PENICILLIN AMIDASE

ANTAGONISTS & INHIBITORS

[Phosphorus–containing inhibitors of penicillin acylase. 4. Irreversible inhibition of penicillin acylase from Escherichia coli by monoaryl esters of benzylphosphonic acid] Solodenko VA, et al. **Ukr Biokhim Zh** 1995 Sep–Oct; 67(5):32–42 (Eng. Abstr.) **(Rus)**
[Inhibition of penicillin acylase from Escherichia coli by benzylalkylketones and benzylalkylcarbinols] Tserniuk VN, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):29–32 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Protein engineering of a cephalosporin C acylase from Pseudomonas strain N176. Saito Y, et al.
Ann N Y Acad Sci 1996 May 15;782:226–40
Synthesis and secretion of recombinant penicillin G acylase in bacterial L–forms. Gumpert J, et al.
J Basic Microbiol 1996;36(2):89–98

CHEMISTRY

A protein catalytic framework with an N–terminal nucleophile is capable of self–activation. Brannigan JA, et al. **Nature** 1995 Nov 23;378(6555):416–9

GENETICS

The regulation of pac gene expression by CRP and FNR. Jiang L, et al. **Chin J Biotechnol** 1995;11(2):87–92

METABOLISM

Rapid burst kinetics in the hydrolysis of 4–nitrophenyl acetate by penicillin G acylase from Kluyvera citrophila. Effects of mutation F360V on rate constants for acylation and de–acylation. Roa A, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):409–12

PENICILLIN AMIDOHYDROLASE see **PENICILLIN AMIDASE**

PENICILLIN, AMINOBENZYL see **AMPICILLIN**

PENICILLIN, DIMETHOXYPHENYL see **METHICILLIN**

PENICILLIN G

ADMINISTRATION & DOSAGE

GPs often fail to give early parenteral benzylpenicillin in suspected meningococcal infection [letter; comment] Irwin D, et al. **BMJ** 1996 Jun 15;312(7045):1538. Comment on: BMJ 1995 Jan 7;310(6971):29–30.
Efficacy of delayed administration of benzylpenicillin in the control of infection in penetrating soft tissue injuries in war. Mellor SG, et al. **J Trauma** 1996 Mar;40(3 Suppl):S128–34
Prevention of early–onset group B streptococcal disease: another look at single–dose penicillin at birth. Siegel JD, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):692–8
Influence of injection site on the absorption of benzylpenicillin sodium in the dromedary. Oukessou M.
Zentralbl Veterinarmed A 1995 Sep;42(7):431–4

ANALOGS & DERIVATIVES

Transient bisalbuminemia: separation by isoelectric focusing of human albumin fractions linked to different numbers of benzylpenicilloyl groups. Rocha J, et al. **Electrophoresis** 1995 Jun;16(6):1031–3

ANALYSIS

Residue depletion in tissues and fluids from swine fed sulfamethazine, chlortetracycline and penicillin G in combination. Korsrud GO, et al. **Food Addit Contam** 1996 Apr;13(3):287–92
Liquid chromatographic determination of benzylpenicillin and cloxacillin in animal tissues and its application to a study of the stability at –20 degrees C of spiked and incurred residues of benzylpenicillin in ovine liver. Gee HE, et al. **J AOAC Int** 1996 May–Jun;79(3):640–4

BLOOD

Comparison of four commercially available rapid test kits with liquid chromatography for detecting penicillin G residues in bovine plasma. Boison JO, et al.
J AOAC Int 1995 Sep–Oct;78(5):1144–52

CHEMISTRY

T cell recognition of penicillin G: structural features determining antigenic specificity. Padovan E, et al.
Eur J Immunol 1996 Jan;26(1):42–8
Interaction of penicillin G with the human erythrocyte membrane and models. Suwalsky M, et al.
Z Naturforsch [C] 1996 Mar–Apr;51(3–4):243–8

IMMUNOLOGY

T cell recognition of penicillin G: structural features determining antigenic specificity. Padovan E, et al.
Eur J Immunol 1996 Jan;26(1):42–8
Interleukin–4 plays a dominant role in Th1– or Th2–like responses during the primary immune response to the hapten penicillin. Kerdine S, et al. **Mol Immunol** 1996 Jan; 33(1):71–7

METABOLISM

Rapid burst kinetics in the hydrolysis of 4–nitrophenyl acetate by penicillin G acylase from Kluyvera citrophila. Effects of mutation F360V on rate constants for acylation and de–acylation. Roa A, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):409–12

PHARMACOKINETICS

Characterisation of penicillin–G uptake in rabbit small–intestinal brush–border membrane vesicles. Poschet JF, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):233–40
Disposition of penicillin G sodium following intravenous and oral administration to Equidae. Horspool LJ, et al.
Br Vet J 1995 Jul–Aug;151(4):401–12
Pharmacokinetics of penicillin G in plasma and interstitial fluid collected with dialysis fiber bundles in sheep. Cooke IM, et al. **Vet Res** 1996;27(2):147–59
Influence of injection site on the absorption of benzylpenicillin sodium in the dromedary. Oukessou M.
Zentralbl Veterinarmed A 1995 Sep;42(7):431–4

PHARMACOLOGY

Enhanced activity of the combination of penicillin G and gentamicin against penicillin–resistant viridans group streptococci. Cercenado E, et al.
Antimicrob Agents Chemother 1995 Dec;39(12):2816–8
Two–dimensional gel electrophoresis and immunoblotting of human serum albumin modified by reaction with penicillins. Marzocchi B, et al. **Electrophoresis** 1995 May;16(5):851–3
Capsular types and antimicrobial resistance of Streptococcus pneumoniae isolated in Korea. Chong Y, et al.
Eur J Clin Microbiol Infect Dis 1995 Jun;14(6):528–31
Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis. Bancsi MJ, et al.
Infect Immun 1996 Feb;64(2):448–51
Penicillin–resistant pneumococci—an emerging threat to successful therapy. McGowan JE Jr, et al.
J Hosp Infect 1995 Jun;30 Suppl:472–82
Streptococcus pneumoniae susceptible to benzylpenicillin but with reduced susceptibility to both cefotaxime and ceftriaxone [letter] Bell SM, et al. **Med J Aust** 1996 Feb 5;164(3):188
Pulsed field gel electrophoresis in Streptococcus pneumoniae isolated in France and Portugal. Carvalho C, et al.
Pathol Biol (Paris) 1996 May;44(5):430–4
FT–IR spectroscopy study of perturbations induced by antibiotic on bacteria (Escherichia coli). Zeroual W, et al.
Pathol Biol (Paris) 1995 Apr;43(4):300–5
Acyloxymethyl as a drug protecting group. Part 3. Tertiary O–amidomethyl esters of penicillin G: chemical hydrolysis and anti–bacterial activity. Moreira R, et al. **Pharm Res** 1996 Jan;13(1):70–5
Interaction of penicillin G with the human erythrocyte membrane and models. Suwalsky M, et al.
Z Naturforsch [C] 1996 Mar–Apr;51(3–4):243–8
[Evolution of the susceptibility to penicillin G of Streptococcus pneumoniae at the Limoge University Hospital Center] Ploy MC, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):241–4 (Eng. Abstr.) **(Fre)**
[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB+ +STREP strip] Romaszko JP, et al. **Pathol Biol (Paris)** 1996 May;44(5):355–7 (Eng. Abstr.) **(Fre)**
[Isolation of meningococcal strains of decreased sensitivity to penicillin G in France (letter)] Bray P, et al.
Presse Med 1995 Dec 16–23;24(39):1910 **(Fre)**
[Effect of antibiotics on glucocorticoid receptor function] Golikov PP. **Antibiot Khimioter** 1995 Jul;40(7):25–9 (Eng. Abstr.) **(Rus)**
[Use of unified methods in microbiologic monitoring of penicillin resistance in Pneumococcus] Shevchuk MS, et al. **Antibiot Khimioter** 1995 Aug;40(8):46–9 (Eng. Abstr.) **(Rus)**
[Behavioral effects of penicillin in experimental anxiety in rats] Kaluev AV, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):352–4 **(Rus)**

THERAPEUTIC USE

Penicillin prophylaxis in complicated wounds of hands and feet: a randomized, double–blind trial. Madsen MS, et al.
Injury 1996 May;27(4):275–8
Antibiotic–resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

PENICILLIN G, BENZATHINE

ADMINISTRATION & DOSAGE

Compartment syndrome in the leg requiring fasciotomy after bicillin injection in the thigh. Westrich GH, et al.
Orthopedics 1995 Nov;18(11):1113–4
A review of the rationale and advantages of various mixtures of benzathine penicillin G. Bass JW. **Pediatrics** 1996 Jun; 97(6 Pt 2):960–3
Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)
Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two– week versus four–week regimens: comparison of two brands of BPG. Kassem AS, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):992–5

ADVERSE EFFECTS

Reactivation of healed primary syphilitic ulcer: a manifestation of febrile Herxheimer reaction in secondary syphilis [letter] Khanna N, et al. **Acta Derm Venereol** 1996 Jan;76(1):91–2
Allergic reactions in rheumatic fever patients on long–term benzathine penicillin G: the role of skin testing for penicillin allergy. Markowitz M, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):981–3

BLOOD

Serum levels of penicillin in basic trainees in the U.S. Army who received intramuscular penicillin G benzathine. Bass JW, et al. **Clin Infect Dis** 1996 Apr;22(4):727–8

THERAPEUTIC USE

Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Calgüneri M, et al. **Dermatology** 1996;192(2):125–8
A review of the rationale and advantages of various mixtures of benzathine penicillin G. Bass JW. **Pediatrics** 1996 Jun; 97(6 Pt 2):960–3
Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)
Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two– week versus four–week regimens: comparison of two brands of BPG. Kassem AS, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):992–5
Three– versus four–week administration of benzathine

penicillin G: effects on incidence of streptococcal infections and recurrences of rheumatic fever. Lue HC, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):984–8

Allergic reactions in rheumatic fever patients on long-term benzathine penicillin G: the role of skin testing for penicillin allergy. Markowitz M, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):981–3

PENICILLIN G, PROCAINE

ADMINISTRATION & DOSAGE

Cognitive change after treatment for neurosyphilis. Correlation with CSF laboratory measures. Roberts MC, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):305–9

ADVERSE EFFECTS

Immediate nonallergic psychotic reaction to intramuscular procaine penicillin. Einterz EM, et al. **Int J Dermatol** 1995 Sep;34(9):627–9

PENICILLIN, METHYLPHENYLISOXAZOLYL see **OXACILLIN**

PENICILLIN, PHENOXYMETHYL see **PENICILLIN V**

PENICILLIN RESISTANCE

Case report: penicillin-resistant pneumococcal meningitis: navigating a therapeutic minefield. Greene GS, et al. **Am J Med Sci** 1996 Apr;311(4):180–5

Emergence of penicillin-resistant invasive pneumococci in a single American community. Stanek RJ, et al. **Am J Med Sci** 1995 Oct;310(4):150–5

In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Alcaide F, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2243–7

In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Blondeau JM, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2577–9

Enhanced activity of the combination of penicillin G and gentamicin against penicillin-resistant viridans group streptococci. Cercenado E, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2816–8

Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1499–504

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. París MM, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2171–5 (64 ref.)

Invasive pneumococcal infection in a community hospital, 1993 to 1995. Characteristics of resistant strains. Orenstein JB. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):809–14

Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978–1993. Nissinen A, et al. **Clin Infect Dis** 1995 Nov;21(5):1193–6

Failure of cefotaxime treatment in a patient with penicillin-resistant pneumococcal meningitis and confirmation of nosocomial spread by random amplified polymorphic DNA analysis [letter] Raymond J, et al. **Clin Infect Dis** 1995 Jul;21(1):234–5

Penicillin and multiply antibiotic-resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)

Molecular analysis by pulsed-field gel electrophoresis of penicillin-resistant Streptococcus pneumoniae from Toulouse, France. Lefèvre JC, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):491–7

Epidemiology of penicillin-resistant Neisseria gonorrhoeae in Frankfurt, Germany. Schäfer V, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):914–8

Surveillance of antibiotic resistance in Neisseria gonorrhoeae and implications for the therapy of gonorrhoea [editorial] Tapsall JW. **Int J STD AIDS** 1995 Jul–Aug;6(4):233–6 (24 ref.)

Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **J Antimicrob Chemother** 1995 Jun;35(6):883–8

Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. Visalli MA, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):77–84

Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. Zorzi W, et al. **J Bacteriol** 1996 Aug;178(16):4948–57

Problems in the management of penicillin-resistant pneumococci [letter] Boswell TC, et al. **J Hosp Infect** 1995 Jul;30(3):233–5

Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. Reichmann P, et al. **J Med Microbiol** 1995 Nov; 43(5):377–85

Therapy for penicillin-resistant Streptococcus pneumoniae [editorial] Strachan SA, et al. **J Med Microbiol** 1995 Oct; 43(4):237–8

Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee [see comments] Arnold KE, et al. **J Pediatr** 1996 Jun; 128(6):757–64. Comment in: J Pediatr 1996 Jun;128(6):729–30.

Resisting the urge to prescribe [editorial; comment] Edwards KM. **J Pediatr** 1996 Jun;128(6):729–30. Comment on: J Pediatr 1996 Jun;128(6):757–64.

Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. Wang WC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):140–4

Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity [letter] Paul J, et al. **Lancet** 1995 Oct 14;346(8981):1034–5

Penicillin tolerance among beta-hemolytic streptococci and production of the group carbohydrates, hemolysins, hyaluronidases and deoxyribonucleases. Avelino CC, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):529–34

Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Block SL, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):751–9

Colonization with penicillin-resistant Streptococcus pneumoniae in a child-care center. Boken DJ, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):879–84

Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Bradley JS, et al. **Pediatr Infect Dis J** 1995 Dec; 14(12):1037–41

Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Friedland IR. **Pediatr Infect Dis J** 1995 Oct;14(10):885–90

Penicillin-resistant pneumococci in the United States [letter] Mason EO Jr, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1017–8

Increasing incidence of penicillin- and ampicillin-resistant middle ear pathogens. Rodriguez WJ, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1075–8

Penicillin-resistant Streptococcus pneumoniae and acute pulmonary infections: prevalence and severity. Korppi M. **Pediatr Pulmonol Suppl** 1995;11:10–1

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

Another episode in the continuing conflict [editorial; comment] Barlow JF. **S D J Med** 1995 Sep;48(9):299. Comment on: S D J Med 1995 Jul;48(7):207–8.

Occurrence of pneumococci with resistance or decreased susceptibility to penicillin in southeast Sweden. Kihlström E, et al. **Scand J Infect Dis** 1995;27(5):489–94

[Problems of resistance in Streptococcus pneumoniae] Meis JF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):141–4 (25 ref.) (Eng. Abstr.) **(Dut)**

[Penicillin-resistant pneumococci are coming--are you prepared? (editorial)] Saxén H, et al. **Duodecim** 1994; 110(18):1669–71 (13 ref.) **(Fin)**

[Pneumococcal meningitis resistant to penicillin: epidemiology] Olivier C. **Arch Pediatr** 1996;3 Suppl 1:96s–98s **(Fre)**

[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[High incidence of oxacillin-resistant Staphylococcus aureus in a general hospital (letter; comment)] Ronchetto F, et al. **Recenti Prog Med** 1995 Nov;86(11):463. Comment on: Recenti Prog Med 1995 Feb;86(2):78–80. **(Ita)**

[Serotypes and antimicrobial susceptibility of Streptococcus pneumoniae from clinical specimens] Ikeda N. **Kansenshogaku Zasshi** 1995 Oct;69(10):1093–102 (Eng. Abstr.) **(Jpn)**

[Penicillin-resistant Streptococcus pneumoniae] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):292–6 (12 ref.) **(Jpn)**

[An adult case of bacterial meningitis caused by penicillin-resistant Streptococcus pneumoniae] Yamawaki M, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1044–7 (Eng. Abstr.) **(Jpn)**

[Use of unified methods in microbiologic monitoring of penicillin resistance in Pneumococcus] Shevchuk MS, et al. **Antibiot Khimioter** 1995 Aug;40(8):46–9 (Eng. Abstr.) **(Rus)**

[The therapeutic implications of pneumococcal penicillin resistance] Lior C, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):136–45 (82 ref.) **(Spa)**

[Penicillin resistant pneumococci. Do not close the day care centers for healthy children] Alestig K, et al. **Lakartidningen** 1996 Jun 12;93(24):2356–7; discussion 2357–8 **(Swe)**

[Epidemiology of penicillin-resistant pneumococci] Kristinsson KC. **Nord Med** 1996 Apr;111(4):103–8 (Eng. Abstr.) **(Swe)**

GENETICS

Target-mediated resistance to beta-lactam antibiotics. Hakenbeck R. **Biochem Pharmacol** 1995 Oct 12; 50(8):1121–7

Isolates of Neisseria gonorrhoeae in Ontario showing chromosomally-mediated resistance to penicillin combined with plasmid-mediated resistance to tetracycline. Harnett N, et al. **Can Commun Dis Rep** 1995 Aug 15;21(15):139–43 **(Eng, Fre)**

Phage-mediated conjugation in staphylococci as a means of transfer of drug-resistance. Mitra M, et al. **Indian J Exp Biol** 1995 Jul;33(7):505–8

Separation of abnormal cell wall composition from penicillin resistance through genetic transformation of Streptococcus pneumoniae. Severin A, et al. **J Bacteriol** 1996 Apr; 178(7):1788–92

Preponderance of Fis-binding sites in the R6K gamma origin and the curious effect of the penicillin resistance marker on replication of this origin in the absence of Fis. Wu F, et al. **J Bacteriol** 1996 Aug;178(16):4965–74

Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. Rice LB, et al. **J Infect Dis** 1996 Jan;173(1):151–8

IMMUNOLOGY

Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. Mauri-Hellweg D, et al. **J Immunol** 1996 Aug 1;157(3):1071–9

PHYSIOLOGY

Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. Fitoussi F, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2560–3

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

Drastic changes in the peptidoglycan composition of penicillin resistant laboratory mutants of Streptococcus pneumoniae. Severin A, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):31–5

Prevalence of penicillin resistant bacteria in acute suppurative oral infection. Lewis MA, et al. **J Antimicrob Chemother** 1995 Jun;35(6):785–91

PENICILLIN V

ADVERSE EFFECTS

Case 6: a free solution. Shader RI, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):297

[A man ate penicillin, died within an hour] Edston E, et al. **Lakartidningen** 1996 Apr 24;93(17):1639–40 **(Swe)**

ANALOGS & DERIVATIVES

Acute generalized exanthematous pustulosis (AGEP): manifestation of drug allergy to propicillin. Gebhardt M, et al. **Contact Dermatitis** 1995 Sep;33(3):204–5

THERAPEUTIC USE

Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Velasco E, et al. **Am J Clin Oncol** 1995 Oct;18(5):429–35

Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pacifico L, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1005–8

Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis. Brook I, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1405–9

Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Lindbaek M, et al. **BMJ** 1996 Aug 10;313(7053):325–9

5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Adam D, et al. **Infection** 1995;23 Suppl 2:S83–6

Penicillin prophylaxis in complicated wounds of hands and feet: a randomized, double-blind trial. Madsen MS, et al. **Injury** 1996 May;27(4):275–8

A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci. Carbon C, et al. **J Antimicrob Chemother** 1995 Jun;35(6):843–54

Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. Dykhuizen RS, et al. **J Antimicrob Chemother** 1996 Jan;37(1):133–8

Bacteraemia due to penicillin-resistant Streptococcus viridans in cancer patients, before and after prophylaxis with penicillin [letter; comment] Krcmery V, et al. **Lancet** 1995 Nov 18;346(8986):1362–3. Comment on: Lancet 1995 Jun 24;345(8965):1607–9.

Penicillin as a supplement in resolving the localized acute apical abscess. Fouad AF, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):590–5

Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten

Pharyngitis International Study Group. Pichichero ME, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S102–7

Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Holm S, et al. **Scand J Infect Dis** 1995;27(3):221–8

Prophylaxis of streptococcal bacteraemia with oral penicillin V in children undergoing bone marrow transplantation. Castagnola E, et al. **Support Care Cancer** 1995 Sep; 3(5):319–21

PENICILLINASE

BIOSYNTHESIS

Anionic properties of beta-lactam-enhancing factor on methicillin-resistant Staphylococcus aureus. Tajima Y, et al. **Res Microbiol** 1996 May;147(4):279–86

CHEMISTRY

Improved fiber-optic chemical sensor for penicillin. Healey BG, et al. **Anal Chem** 1995 Dec 15;67(24):4471–6

GENETICS

Construction of beta-lactamase-encoding ApR gene cassettes for rapid identification of cloned genes. Yokochi T, et al. **Gene** 1996 Apr 17;170(1):143–4

Sequence analysis of two chromosomally mediated inducible beta-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. Walsh TR, et al.
J Antimicrob Chemother 1995 Jul;36(1):41–52

ISOLATION & PURIFICATION

[Detection of beta-lactamase in samples obtained after tonsillectomy in children] Borderon JC, et al.
Pathol Biol (Paris) 1995 Apr;43(4):324–8 (Eng. Abstr.) **(Fre)**

METABOLISM

Continuing high prevalence of penicillinase-producing Neisseria gonorrhoeae at a central London hospital [letter] Issack MI, et al. **Genitourin Med** 1995 Aug;71(4):265

PENICILLINS

ADMINISTRATION & DOSAGE

Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. van der Hulst RW, et al.
Aliment Pharmacol Ther 1996 Apr;10(2):165–71

Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Bertoni G, et al. **Am J Gastroenterol** 1996 Feb;91(2):258–63

Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Bauchner H, et al.
Arch Pediatr Adolesc Med 1996 Apr;150(4):396–9

Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Miehlke S, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):975–8

Optimal dose of omeprazole in combination with amoxicillin in eradicating H. pylori and preventing relapses in duodenal ulcer patients. Rokkas T, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):842–6

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107–11

Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing. Nakata H, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S118–20

Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al.
J Clin Gastroenterol 1995;20 Suppl 2:S100–3

Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. Shirai T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S128–31

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. Sugiyama T, et al. **J Clin Gastroenterol** 1995; 20 Suppl 2:S104–6

Efficacy of delayed administration of benzylpenicillin in the control of infection in penetrating soft tissue injuries in war. Mellor SG, et al. **J Trauma** 1996 Mar;40(3 Suppl):S128–34

Prevention of early-onset group B streptococcal disease: another look at single-dose penicillin at birth. Siegel JD, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):692–8

Compartment syndrome in the leg requiring fasciotomy after bicillin injection in the thigh. Westrich GH, et al.
Orthopedics 1995 Nov;18(11):1113–4

Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Patel VR, et al.
Pharm Res 1996 Apr;13(4):588–93

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Hatlebakk JG, et al.
Scand J Gastroenterol 1995 Nov;30(11):1053–7

Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents. Satoh K.
Scand J Gastroenterol Suppl 1996;214:56; discussion 57–60

Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study. Labenz J, et al. **Z Gastroenterol** 1995 Oct;33(10):590–3

Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Schütze K, et al. **Z Gastroenterol** 1995 Nov;33(11):651–3

Influence of injection site on the absorption of benzylpenicillin sodium in the dromedary. Oukessou M.
Zentralbl Veterinarmed A 1995 Sep;42(7):431–4

[Indirect endolymphatic therapy of patients with erysipelas] Bondarev LS, et al. **Klin Khir** 1996;(1):13–4 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):18–20 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

[Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):99–106 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Reactivation of healed primary syphilitic ulcer: a manifestation of febrile Herxheimer reaction in secondary syphilis [letter] Khanna N, et al. **Acta Derm Venereol** 1996 Jan;76(1):91–2

Deterioration of renal function in a nephropathic diabetic patient during omeprazole plus amoxicillin therapy for Helicobacter pylori-associated duodenal ulcer [letter] Lorenzetti M, et al. **Acta Diabetol** 1995 Oct;32(3):209–10

Allergic reactions to penicillins. A changing world? Blanca M. **Allergy** 1995 Oct;50(10):777–82 (76 ref.)

Basic aspects related to penicillin-allergy skin testing: on the variability of the hapten-paratope interaction. Bondaruk J, et al. **Allergy** 1995 Aug;50(8):671–6

Allergy to penicillin and cephalosporins [letter; comment] Kelso JM. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):61 . Comment on: Ann Allergy Asthma Immunol 1995 Feb;74(2):167–70.

Ampicillin-induced maculopapular versus urticarial rash. Marra CA, et al. **Ann Pharmacother** 1996 Apr;30(4):401–2

Ampicillin-specific rashes. Adcock BB, et al.
Arch Fam Med 1996 May;5(5):301–4

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. García Rodríguez LA, et al. **Arch Intern Med** 1996 Jun 24;156(12):1327–32

Flucloxacillin hepatitis: an Australian epidemic--comment [letter; comment] Blackmore TK, et al.
Aust N Z J Med 1995 Oct;25(5):537. Comment on: Aust N Z J Med 1995 Jun;25(3):195–6.

Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age. Abrahamsson K, et al.
Biochem Mol Med 1995 Jun;55(1):77–9

Amoxycillin-induced hallucinations--a variant of Hoigne's syndrome? Stell IM, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):279

Selective fixed drug eruption to amoxycillin. Arias J, et al.
Clin Exp Dermatol 1995 Jul;20(4):339–40

Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Gerber L, et al.
Clin Infect Dis 1995 Oct;21(4):1047–8

Lymphocyte transformation test in the diagnosis of immediate type hypersensitivity reactions to penicillins. Bircher AJ. **Curr Probl Dermatol** 1995;22:31–7

An unusual drug eruption to ampicillin. Lim JT, et al.
Cutis 1995 Sep;56(3):163–4

Adverse cutaneous reactions to systemic drugs in adults seen in two referral centres in northern Saudi Arabia. Kubeyinje EP, et al. **East Afr Med J** 1996 May;73(5):313–5

Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Devereaux BM, et al.
Eur J Clin Pharmacol 1995;49(1-2):81–5 (30 ref.)

The multiple drug allergy syndrome: a matched-control retrospective study in patients allergic to penicillin. Khoury L, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):462–4

Case-control study of the association between intraoperative administration of nafcillin and acute postoperative development of azotemia. Pascoe PJ, et al.
J Am Vet Med Assoc 1996 Apr 1;208(7):1043–7

Possible granulomatous hepatitis after dicloxacillin therapy. Saab S, et al. **J Clin Gastroenterol** 1996 Mar;22(2):163–4

Case 6: a free solution. Shader RI, et al.
J Clin Psychopharmacol 1995 Aug;15(4):297

Clostridium difficile in a healthcare worker [letter] Kaplan N, et al. **J Hosp Infect** 1996 Apr;32(4):322

Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. Remick DG, et al.
J Infect Dis 1996 Sep;174(3):627–30

Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha [see comments] Fekade D, et al. **N Engl J Med** 1996 Aug 1; 335(5):311–5. Comment in: N Engl J Med 1996 Aug 1;335(5):347–8.

Agranulocytosis in a drug addict with recurrent Staphylococcus aureus septicaemia. Leung WK, et al.
Postgrad Med J 1995 Dec;71(842):757–8

[Acute hemorrhagic colitis after intake of amoxicillin (letter)] Choulot JJ, et al. **Arch Pediatr** 1996 May;3(5):508–9 **(Fre)**

[Acute cholangitis caused by an amoxicillin-clavulanic acid combination (letter)] Boucher E, et al.
Gastroenterol Clin Biol 1995 Nov;19(11):957–8 **(Fre)**

[Cholestatic jaundice induced by amoxicillin and clavulanic acid (letter)] Kurowski V. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):390–1 **(Ger)**

[Diagnostic procedures in suspected immediate type allergy to penicillins] Torricelli R, et al. **Hautarzt** 1996 May; 47(5):392–3 **(Ger)**

[Antibiotic-associated diarrhea in light of personal observations] Ellert-Zygadłowska J, et al. **Pol Tyg Lek** 1995 Sep;50(36–39):45–9 (Eng. Abstr.) **(Pol)**

[Chronic urticaria caused by penicillin. Results of monitoring cases of acute penicillin urticaria which developed into chronic urticaria] Poljački M, et al. **Med Pregl** 1995; 48(3–4):108–10 (Eng. Abstr.) **(Scr)**

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al.
Rev Esp Enferm Dig 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**

[Spektramox and liver damage] **Lakartidningen** 1996 Feb 7; 93(6):490 **(Swe)**

[A man ate penicillin, died within an hour] Edston E, et al. **Lakartidningen** 1996 Apr 24;93(17):1639–40 **(Swe)**

ANALYSIS

Improved fiber-optic chemical sensor for penicillin. Healey BG, et al. **Anal Chem** 1995 Dec 15;67(24):4471–6

Survey of airborne antibiotics. Møller NE, et al.
Contact Dermatitis 1996 Apr;34(4):300–1

Liquid chromatographic determination of benzylpenicillin and cloxacillin in animal tissues and its application to a study of the stability at -20 degrees C of spiked and incurred residues of benzylpenicillin in ovine liver. Gee HE, et al. **J AOAC Int** 1996 May-Jun;79(3):640–4

BIOSYNTHESIS

NRE, the major nitrogen regulatory protein of Penicillium chrysogenum, binds specifically to elements in the intergenic promoter regions of nitrate assimilation and penicillin biosynthetic gene clusters. Haas H, et al.
Curr Genet 1995 Jul;28(2):177–83

Enzymatic synthesis of hydrophobic penicillins. Luengo JM.
J Antibiot (Tokyo) 1995 Nov;48(11):1195–212 (96 ref.)

Identification of a major cis-acting DNA element controlling the bidirectionally transcribed penicillin biosynthesis genes acvA (pcbAB) and ipnA (pcbC) of Aspergillus nidulans. Bergh KT, et al. **J Bacteriol** 1996 Jul;178(13):3908–16

A lacZ reporter fusion method for the genetic analysis of regulatory mutations in pathways of fungal secondary metabolism and its application to the Aspergillus nidulans penicillin pathway. Pérez-Esteban B, et al. **J Bacteriol** 1995 Nov;177(21):6069–76

Analysis of the regulation of the Aspergillus nidulans penicillin biosynthesis gene aat (penDE), which encodes acyl coenzyme A:6-aminopenicillanic acid acyltransferase. Litzka O, et al. **Mol Gen Genet** 1995 Dec 15;249(5):557–69

BLOOD

Serum levels of penicillin in basic trainees in the U.S. Army who received intramuscular penicillin G benzathine. Bass JW, et al. **Clin Infect Dis** 1996 Apr;22(4):727–8

Comparison of four commercially available rapid test kits with liquid chromatography for detecting penicillin G residues in bovine plasma. Boison JO, et al.
J AOAC Int 1995 Sep-Oct;78(5):1144–52

CHEMICAL SYNTHESIS

2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics. Altamura M, et al.
J Med Chem 1995 Oct 13;38(21):4244–56

CHEMISTRY

Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions. Park TW, et al.
Am J Health Syst Pharm 1995 Sep 15;52(18):2022–4

Ciprofloxacin-ampicillin sulbactam incompatibility [letter] Melonakos TK. **Ann Pharmacother** 1996 Jan;30(1):87

ECONOMICS

Benzacilin compositum viewed in the light of the cost-effectivity problem in in-patient children's wards. Pachev H. **Folia Med (Plovdiv)** 1995;37(4A Suppl):58

HISTORY

Random recollections: Part 2. Penicillin and the Normandy landings. Fraser I. **Ann R Coll Surg Engl** 1995 Jul;77(4 Suppl):198–201 cont

The story of penicillin: the view from Oxford in the early 1950s. Joklik WK. **FASEB J** 1996 Mar;10(4):525–8

[From penicillin to the progress in beta-lactams. Chronicle of a 50th anniversary] Demonty J. **Rev Med Liege** 1996

Jan;51(1):47–9 **(Fre)**

IMMUNOLOGY

Basic aspects related to penicillin–allergy skin testing: on the variability of the hapten–paratope interaction. Bondaruk J, et al. **Allergy** 1995 Aug;50(8):671–6

Delayed hypersensitivity to penicillin. Ortiz–Frutos FJ, et al. **Allergy** 1996 Feb;51(2):134–5

Nonimmediate reactions to betalactams: prevalence and role of the different penicillins. Terrados S, et al. **Allergy** 1995 Jul;50(7):563–7

An analysis of beta–lactam–derived antigens on spleen cell and serum proteins by ELISA and Western blotting. Warbrick EV, et al. **Allergy** 1995 Nov;50(11):910–7

Cross–reactivity of cephalosporins with penicillin [letter] Miller MM. **Ann Allergy Asthma Immunol** 1996 Jun; 76(6):542

Lymphocyte transformation test in the diagnosis of immediate type hypersensitivity reactions to penicillins. Bircher AJ. **Curr Probl Dermatol** 1995;22:31–7

Activation and hapten inhibition of mast cells sensitized with monoclonal IgE anti–penicillin antibodies: evidence for two–site recognition of the penicillin derived determinant. Fernandez M, et al. **Eur J Immunol** 1995 Sep;25(9):2486–91

ISOLATION & PURIFICATION

Evaluation of liquid chromatography methods for the separation of ampicillin and its related substances. Zhu Y, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):631–9

METABOLISM

Using beta–lactams to investigate the existence of a protein complex, involving the Escherichia coli penicillin–binding proteins 1a/1b, 3 and 5. Harris F, et al. **Biochem Soc Trans** 1995 Nov;23(4):562S

The membrane–interactive properties of the low–molecular–mass penicillin–binding proteins of Escherichia coli. Phoenix DA, et al. **Biochem Soc Trans** 1995 Nov;23(4):976–80

Mass spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by beta–lactamase TEM–1 and the G238S mutant. Saves I, et al. **Biochemistry** 1995 Sep 19;34(37):11660–7

The role of penicillin–binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

Saturation of penicillin–binding protein 1 by beta–lactam antibiotics in growing cells of Bacillus licheniformis. Lepage S, et al. **Mol Microbiol** 1995 Apr;16(2):365–72

PHARMACOKINETICS

Pharmacokinetics of bacampicillin in equids. Sarasola P, et al. **Am J Vet Res** 1995 Nov;56(11):1486–92

Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Knudsen JD, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1253–8

Characterisation of penicillin–G uptake in rabbit small–intestinal brush–border membrane vesicles. Poschet JF, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):233–40

Disposition of penicillin G sodium following intravenous and oral administration to Equidae. Horspool LJ, et al. **Br Vet J** 1995 Jul–Aug;151(4):401–12

Disposition kinetics and bioavailability of piperacillin and cephapirin in mares. el–Komy AA. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):244–8

Amoxicillin concentrations in nasal secretions of patients with acute uncomplicated sinusitis and in paranasal sinus mucosa of patients with chronic sinusitis. Kment G, et al. **Eur Arch Otorhinolaryngol** 1995;252(4):236–8

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments] Goddard AF, et al. **Gastroenterology** 1996 Aug; 111(2):358–67. Comment in: Gastroenterology 1996 Aug;111(2):521–3.

Biliary excretion of mezlocillin in patients with hepatic disease. Hildebrandt R, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):384–7

Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin–loaded nanoparticles. Balland O, et al. **J Antimicrob Chemother** 1996 Jan;37(1):105–15

Penetration of the blood–brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides. Spellerberg B, et al. **J Exp Med** 1995 Oct 1;182(4):1037–43

The influence of uptake from the gastrointestinal tract and first–pass effect on oral bioavailability of (Z)–alkyloxyimino penicillins. Mizen L, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):725–30

Disposition kinetics of ampicillin administered intravenously and intraosseously to canine puppies. Lavy E, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):379–81

Antibiotic penetration into cervical discs. Rhoten RL, et al. **Neurosurgery** 1995 Sep;37(3):418–21

Pharmacokinetic–pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Nolting A, et al. **Pharm Res** 1996 Jan;13(1):91–6

Pharmacokinetics of ampicillin administered intravenously and intraosseously to kittens. Goldstein R, et al. **Res Vet Sci** 1995 Sep;59(2):186–7

Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and oral administration in goats. Carceles CM, et al. **Vet Q** 1995 Dec;17(4):134–8

Pharmacokinetics of penicillin G in plasma and interstitial fluid collected with dialysis fiber bundles in sheep. Cooke IM, et al. **Vet Res** 1996;27(2):147–59

Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats. Escudero E, et al. **Vet Res** 1996; 27(3):201–8

Depletion of the residues of colistin and amoxicillin in turkeys following simultaneous subcutaneous administration. Tomasi L, et al. **Vet Res Commun** 1996;20(2):175–82

Influence of injection site on the absorption of benzylpenicillin sodium in the dromedary. Oukessou M. **Zentralbl Veterinarmed A** 1995 Sep;42(7):431–4

Pharmacokinetics, intramuscular bio–availability, and bioequivalence of amoxycillin in donkeys. Lavy E, et al. **Zentralbl Veterinarmed [B]** 1995 Jul;42(5):284–92

[Assessment of the role of enterocyte ion exchange in the intestinal absorption of amoxicillin, based on a study of the interaction with amiloride] Westphal JF, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):590–5 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals. Verbist L, et al. **Acta Clin Belg** 1995;50(5):274–81

Effects of repeated systemic penicillin injections on nonconvulsive and convulsive epileptic seizures in the rat. Stankiewicz J, et al. **Acta Neurobiol Exp (Warsz)** 1995; 55(4):281–7

Penicillin reduces secretory capacity in rat middle ear mucosa in acute otitis media. Cayé–Thomasen P, et al. **Am J Otol** 1996 Mar;17(2):354–9

Amoxicillin dose–effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Azoulay–Dupuis E, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):941–6

In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Barry AL, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2193–6

Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Berry V, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1859–61

In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta–hemolytic streptococcal capsule. Brook I, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1565–8

Can penicillins and other beta–lactam antibiotics be used to treat tuberculosis? Chambers HF, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2620–4

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Doern GV, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):891–4

Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis [published erratum appears in Antimicrob Agents Chemother 1995 Dec;39(12):2835] Mainardi JL, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):1984–7

Activities of oral and parenteral agents against penicillin–susceptible and –resistant pneumococci. Pankuch GA, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1499–504

Effects of inhibitors of protein synthesis on lysis of Escherichia coli induced by beta–lactam antibiotics. Rodionov DG, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):899–903

Gentamicin– and methicillin–resistant Staphylococcus aureus: phenotypic and genotypic characterization of three putative nosocomial outbreak strains. Traub WH, et al. **Chemotherapy** 1996 Jan–Feb;42(1):21–36

beta–Lactamase production and penicillin susceptibility among different ribotypes of Prevotella melaninogenica simultaneously colonizing the oral cavity. Könönen E, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S364–6

Comparative in vitro activity of furopenem against aerobic bacteria isolated from pediatric patients. Mortensen JE, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):301–6

Two–dimensional gel electrophoresis and immunoblotting of human serum albumin modified by reaction with penicillins. Marzocchi B, et al. **Electrophoresis** 1995 May;16(5):851–3

Repeated penicillin–induced amygdala epileptic focus in freely moving cats. EEG, polysomnographic (23–h recording), and brain mapping study. Fernández–Guardiola A, et al. **Epilepsy Res** 1995 Oct;22(2):127–36

In vitro activity of MDL 62,879 against gram–positive bacteria and Bacteroides species. Bartoloni A, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1105–8

Capsular types and antimicrobial resistance of Streptococcus pneumoniae isolated in Korea. Chong Y, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):528–31

Detection of aminoglycoside–penicillin synergy against Enterococcus faecium using high–content aminoglycoside disks. Torres C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):878–82

A proposed standard for MIC–MBC laboratory techniques to detect penicillin tolerance in group A streptococci [letter] van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):182–3

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)

Triton X–100 alters the resistance level of methicillin–resistant Staphylococcus aureus to oxacillin. Komatsuzawa H, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):209–12

Drastic changes in the peptidoglycan composition of penicillin resistant laboratory mutants of Streptococcus pneumoniae. Severin A, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):31–5

Cochlear effects of indacrinone are not altered by penicillin. Rybak LP, et al. **Hear Res** 1995 May;85(1–2):122–6

Newer penicillins and beta–lactamase inhibitors. Bush LM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):653–86 (154 ref.)

Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis. Bancsi MJ, et al. **Infect Immun** 1996 Feb;64(2):448–51

Activity of CI–960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones. Boisivon A, et al. **J Antimicrob Chemother** 1995 Sep;36(3):527–30

Penicillin post–antibiotic effects on the biology of group A streptococci. Garcia LB, et al. **J Antimicrob Chemother** 1995 Sep;36(3):475–82

Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin–susceptible and –resistant pneumococci. Pankuch GA, et al. **J Antimicrob Chemother** 1995 Jun;35(6):883–8

Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group. Verbist L, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):285–93

Mecillinam resistance in Escherichia coli is conferred by loss of a second activity of the AroK protein. Vinella D, et al. **J Bacteriol** 1996 Jul;178(13):3818–28

Comparison of in–house and commercially prepared haemophilus test media for disk diffusion testing of ampicillin against Haemophilus species. Laue RR, et al. **J Clin Microbiol** 1995 Sep;33(9):2240–3

Evaluation of accuracy and reproducibility of E test for susceptibility testing of Streptococcus pneumoniae to penicillin, cefotaxime, and ceftriaxone. Skulnick M, et al. **J Clin Microbiol** 1995 Sep;33(9):2334–7

Evaluation of Rapid ATB Staph for 5–hour antimicrobial susceptibility testing of Staphylococcus aureus. Groupement pour le Dépistage, L'Etude et la Prévention des Infections Hospitalières–Groep ter Opsporing, Studie en Preventie van Infecties in de Ziekenhuizen. Struelens MJ, et al. **J Clin Microbiol** 1995 Sep;33(9):2395–9

Penicillin–resistant pneumococci—an emerging threat to successful therapy. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:472–82

Streptococcus pneumoniae susceptible to benzylpenicillin but with reduced susceptibility to both cefotaxime and ceftriaxone [letter] Bell SM, et al. **Med J Aust** 1996 Feb 5;164(3):188

Pulsed field gel electrophoresis in Streptococcus pneumoniae isolated in France and Portugal. Carvalho C, et al. **Pathol Biol (Paris)** 1996 May;44(5):430–4

Use of the E–test for determining antimicrobial susceptibility of anaerobic bacteria. Piérard D, et al. **Pathol Biol (Paris)** 1996 May;44(5):358–62

Acyloxymethyl as a drug protecting group. Part 3. Tertiary O–amidomethyl esters of penicillin G: chemical hydrolysis and anti–bacterial activity. Moreira R, et al. **Pharm Res** 1996 Jan;13(1):70–5

[Staphylococcus aureus resistant to methicillin. Survey of prevalence in Yvelines hospitals] Bérardi–Grassias L, et al. **Pathol Biol (Paris)** 1996 May;44(5):411–5 (Eng. Abstr.) **(Fre)**

[Molecular epidemiology of pneumococci with decreased susceptibility to penicillin isolated in a Parisian pediatric hospital] Moissenet D, et al. **Pathol Biol (Paris)** 1996 May; 44(5):423–9 (Eng. Abstr.) **(Fre)**

[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB++STREP strip] Romaszko JP, et al. **Pathol Biol (Paris)** 1996 May;44(5):355–7 (Eng. Abstr.) **(Fre)**

[Community acquired pneumonias in the region of Montpellier. Increase of pneumococci with reduced sensitivity to penicillins] Paganin F, et al. **Presse Med** 1995 Oct 7;24(29):1341–4 (Eng. Abstr.) **(Fre)**

[Appearance of antibacterial activity of oxacillin against methicillin resistant Staphylococcus aureus (MRSA) in the presence of catechin] Takahashi O, et al. **Kansenshogaku Zasshi** 1995 Oct;69(10):1126–34 (Eng. Abstr.) **(Jpn)**

POISONING

Amoxicillin overdose manifested by hematuria and acute renal failure. Belko J, et al. **Pediatr Infect Dis J** 1995 Oct; 14(10):917–9

THERAPEUTIC USE

Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis. Burton IE, et al. **Acta Haematol** 1995;94(4):196–8

Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Bell GD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):513–20

One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Labenz J, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):207–10

Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Stupnicki T, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):193–7

The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease [editorial] Roberts WC. **Am J Cardiol** 1996 Aug 1; 78(3):377–8

Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin. Adamek RJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):98–100

Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow-up with endoscopic ultrasound before and after antimicrobial therapy. Avunduk C, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1969–73

Low eradication rates of Helicobacter pylori with omeprazole plus amoxycillin combination in a Turkish population [letter] Simsek H, et al. **Am J Gastroenterol** 1996 May;91(5):1062

Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Thijs JC, et al. **Am J Gastroenterol** 1996 Jan;91(1):93–7

Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia [see comments] Anaissie EJ, et al. **Am J Med** 1996 Jan;100(1):17–23. Comment in: Am J Med 1996 Jan;100(1):15–6.

Penicillin reduces secretory capacity in rat middle ear mucosa in acute otitis media. Cayé-Thomasen P, et al. **Am J Otol** 1996 Mar;17(2):354–9

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Luft BJ, et al. **Ann Intern Med** 1996 May 1;124(9):785–91

Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. van den Hazel SJ, et al. **Ann Intern Med** 1996 Sep 15;125(6):442–7

Timing of penicillin treatment influences the course of Streptococcus pneumoniae-induced middle ear inflammation. Sato K, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1896–8

Secondary prevention of meningococcal disease. Cases are "unavoidably unpredictable" [letter; comment] Bingham P, et al. **BMJ** 1996 Jun 15;312(7045):1537. Comment on: BMJ 1996 Mar 9;312(7031):591–2.

Secondary prevention of meningococcal disease. British guidelines should have been considered [letter; comment] Jones DM. **BMJ** 1996 Jun 15;312(7045):1537. Comment on: BMJ 1996 Mar 9;312(7031):591–2.

Secondary prevention of meningococcal disease [editorial] [see comments] Kristiansen BE, et al. **BMJ** 1996 Mar 9; 312(7031):591–2. Comment in: BMJ 1996 Jun 15;312(7045):1536; discussion 1537. Comment in: BMJ 1996 Jun 15;312(7045):1536–7. Comment in: BMJ 1996 Jun 15;312(7045):1537.

Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Lindbaek M, et al. **BMJ** 1996 Aug 10;313(7053):325–9

Secondary prevention of meningococcal disease. Penicillin is not recommended in British guidelines [letter; comment] Pollard AJ, et al. **BMJ** 1996 Jun 15;312(7045):1536; discussion 1537. Comment on: BMJ 1996 Mar 9;312(7031):591–2.

Secondary prevention of meningococcal disease. No evidence exists to support use of penicillin [letter; comment] Stokes T, et al. **BMJ** 1996 Jun 15;312(7045):1536–7. Comment on: BMJ 1996 Mar 9;312(7031):591–2.

Persistent scleredema of Buschke in a diabetic: improvement with high-dose penicillin [letter] Krasagakis K, et al. **Br J Dermatol** 1996 Mar;134(3):597–8

Randomized study of antibiotic prophylaxis for general and gynaecological surgery from a single centre in rural Africa. Reggiori A, et al. **Br J Surg** 1996 Mar;83(3):356–9

Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chan TH, et al. **Chemotherapy** 1996 Mar–Apr;42(2):150–6

Treatment of otitis media [letter; comment] van der Meer JW, et al. **Clin Infect Dis** 1995 Oct;21(4):1069. Comment on: Clin Infect Dis 1994 Nov;19(5):823–33.

Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Calgüneri M, et al. **Dermatology** 1996;192(2):125–8

Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S31–4

5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Adam D, et al. **Infection** 1995;23 Suppl 2:S83–6

Penicillin prophylaxis in complicated wounds of hands and feet: a randomized, double-blind trial. Madsen MS, et al. **Injury** 1996 May;27(4):275–8

Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Marchioni CF, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):612–8

Effect of early cortical lesion on the acute model of epilepsy. Culić M, et al. **Int J Dev Neurosci** 1995 Oct;13(6):655–8

Acute haematogenous osteomyelitis—evaluation of management in the 1990s. Lane-O'Kelly A, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):285–8

Thumb cellulitis attributable to group G streptococcus [letter] Marinella MA. **J Am Geriatr Soc** 1996 Jul; 44(7):887–8

A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci. Carbon C, et al. **J Antimicrob Chemother** 1995 Jun;35(6):843–54

Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. Dykhuizen RS, et al. **J Antimicrob Chemother** 1996 Jan;37(1):133–8

Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. Landman D, et al. **J Antimicrob Chemother** 1996 Feb;37(2):323–9

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. Portier H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:83–91

Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. Zaman MM, et al. **J Antimicrob Chemother** 1996 Jan;37(1):127–32

Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy. Cammarota G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):118–22

Antibiotic use in the emergency department: I. The penicillins and cephalosporins. Pollack ES, et al. **J Emerg Med** 1996 Mar–Apr;14(2):213–22

Meningitis in infancy caused by Pasteurella multocida. Boocock GR, et al. **J Infect** 1995 Sep;31(2):161–2

Mechanisms of the spread of penicillin resistance in Streptococcus pneumoniae strains causing meningitis in children in France. Doit C, et al. **J Infect Dis** 1996 Sep; 174(3):520–8

Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility. Mannheimer SB, et al. **J Infect Dis** 1996 Sep;174(3):513–9

Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. Remick DG, et al. **J Infect Dis** 1996 Sep;174(3):627–30

Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease [see comments] Chesney PJ, et al. **J Pediatr** 1995 Oct;127(4):526–32. Comment in: J Pediatr 1996 Jun;128(6):862–3.

Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. Falletta JM, et al. **J Pediatr** 1995 Nov;127(5):685–90

Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. Zenni MK, et al. **J Pediatr** 1995 Oct;127(4):533–7

Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Corden TE, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):323–6

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Effects of chitosan on experimental abscess with Staphylococcus aureus in dogs. Okamoto Y, et al. **J Vet Med Sci** 1995 Aug;57(4):765–7

Management of acute bacterial meningitis [letter; comment] Eltringham I, et al. **Lancet** 1996 Feb 24;347(9000):537. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.

Therapeutic failure in group C streptococcal pharyngitis [letter] Hutchinson NA, et al. **Lancet** 1995 Nov 18; 346(8986):1367

Management of acute bacterial meningitis [letter; comment] McKendrick MW, et al. **Lancet** 1996 Mar 30;347(9005):903 . Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.

Management of acute bacterial meningitis [letter; comment] Williams K. **Lancet** 1996 Feb 24;347(9000):536; discussion 538–9. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.

Meconium-stained amniotic fluid-associated infectious morbidity: a randomized, double-blind trial of ampicillin-sulbactam prophylaxis. Adair CD, et al. **Obstet Gynecol** 1996 Aug;88(2):216–20

Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis. Turrentine MA, et al. **Obstet Gynecol** 1995 Dec;86(6):1021–5

Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics. Araida T, et al. **Pancreas** 1995 Aug;11(2):132–40

Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group. Pichichero ME, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S102–7

Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Holm S, et al. **Scand J Infect Dis** 1995;27(3):221–8

Treatment of acute maxillary sinusitis—comparing cefpodoxime proxetil with amoxicillin. von Sydow C, et al. **Scand J Infect Dis** 1995;27(3):229–34

Prophylaxis of streptococcal bacteraemia with oral penicillin V in children undergoing bone marrow transplantation. Castagnola E, et al. **Support Care Cancer** 1995 Sep; 3(5):319–21

Intravenous chloramphenicol plus penicillin versus intramuscular ceftriaxone for the treatment of pyogenic meningitis in Nepalese children [letter] Sharma PR, et al. **Trop Doct** 1996 Apr;26(2):84–5

Community-acquired pneumonia—is it time for the penicillin bullet to be replaced? Silva J Jr. **West J Med** 1996 Jan; 164(1):79–80

[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**

[Endocarditis caused by Corynebacterium diphtheriae tolerant to amoxicillin (letter)] Dupont C, et al. **Presse Med** 1995 Jul 1–8;24(24):1135 **(Fre)**

[Piperacillin in prevention and therapy in gynecological surgery] Giannone R, et al. **Minerva Ginecol** 1995 Jul–Aug; 47(7–8):335–9 (Eng. Abstr.) **(Ita)**

[Ruptured mycotic aneurysm of the middle cerebral artery: a case report] Suzuki K, et al. **No Shinkei Geka** 1995 Nov; 23(11):981–4 (Eng. Abstr.) **(Jpn)**

[Amoxycillin: 25 years of use in clinical practice] Iakovlev SV. **Antibiot Khimioter** 1995 Jun;40(6):49–55 (13 ref.) **(Rus)**

[Antibiotic prophylaxis in surgery of uncomplicated cholesteatoma: review of 150 patients] López Amado M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):421–6 (Eng. Abstr.) **(Spa)**

[Amoxicillin: choice in the treatment of acute otitis media (letter)] Raigal Martín MY, et al. **Aten Primaria** 1995 Sep 30;16(5):293–4 **(Spa)**

[Helicobacter pylori eradication heals the duodenal ulcer. Randomized, simple, and controlled study with omeprazole] Piñero R, et al. **G E N** 1995 Apr–Jun; 49(2):111–5 (Eng. Abstr.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

[Comparison of 2 treatment schemes to eradicate Helicobacter pylori] Hoffenberg P, et al. **Rev Med Chil** 1995 Feb;123(2):185–91 (Eng. Abstr.) **(Spa)**

PENICILLIUM

Unusual cause of fever and diarrhea in a patient with AIDS. Penicillium marneffei infection. Leung R, et al. **Dig Dis Sci** 1996 Jun;41(6):1212–5

Infection with Penicillium marneffei. Wortman PD. **Int J Dermatol** 1996 Jun;35(6):393–9 (35 ref.)

Disseminated Penicillium marneffei infection in a patient with acquired immunodeficiency syndrome. Chang CC, et al. **J Formos Med Assoc** 1995 Sep;94(9):572–5

Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? Chariyalertsak S, et al. **J Infect Dis** 1996 Jun;173(6):1490–3

Penicillium marneffei part of Southeast Asian AIDS [news] Phillips P. **JAMA** 1996 Jul 10;276(2):86–7

CHEMISTRY

Isolation of brefeldin A. Kim HL, et al. **Gen Pharmacol** 1995 Mar;26(2):363–4

[Alkaloids from Penicillium species fungi isolated from food products] Solov'eva TF, et al. **Prikl Biokhim Mikrobiol** 1995 Sep–Oct;31(5):545–50 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Taxonomy of Penicillium nalgiovense isolates from mould-fermented sausages. Andersen SJ.

PENICILLIUM

Antonie Van Leeuwenhoek 1995 Aug;68(2):165–71

DRUG EFFECTS

In vivo formation of diazepam–like 1,4–benzodiazepines by Penicillium verrucosum var. verrucosum after administration of 2–aminobenzophenones and glycine. Bringmann G, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):169–81

ENZYMOLOGY

Purification and characterization of two arabinofuranosidases from solid–state cultures of the fungus Penicillium capsulatum. Filho EX, et al. **Appl Environ Microbiol** 1996 Jan;62(1):168–73

In vitro analysis of the role of glucose oxidase from Talaromyces flavus in biocontrol of the plant pathogen Verticillium dahliae. Stosz SK, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3183–6

Purification and characterization of two acetyl xylan esterases from Penicillium purpurogenum. Egaña L, et al. **Biotechnol Appl Biochem** 1996 Aug;24 (Pt 1):33–9

Purification and characterization of an intracellular catalase–peroxidase from Penicillium simplicissimum. Fraaije MW, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):192–8

Substrate specificity of flavin–dependent vanillyl–alcohol oxidase from Penicillium simplicissimum. Evidence for the production of 4–hydroxycinnamyl alcohols from 4–allylphenols. Fraaije MW, et al. **Eur J Biochem** 1995 Nov 15;234(1):271–7

Production of feruloyl/rho–coumaroyl esterase activity by Penicillium expansum, Penicillium brevicompactum and Aspergillus niger. Donaghy JA, et al. **J Appl Bacteriol** 1995 Dec;79(6):657–62

Alkaline phosphatase activity in Penicillium roqueforti and in blue–veined cheeses. Rosenthal I, et al. **J Dairy Sci** 1996 Jan;79(1):16–9

GENETICS

Integrative and replicative transformation of Penicillium canescens with a heterologous nitrate–reductase gene. Aleksenko AY, et al. **Curr Genet** 1995 Oct;28(5):474–7

Transformations of Penicillium islandicum and Penicillium frequentans that produce anthraquinone–related compounds. Huang KX, et al. **Curr Genet** 1995 Nov; 28(6):580–4

Endoglucanase II (EGII) of Penicillium janthinellum: cDNA sequence, heterologous expression and promotor analysis. Mernitz G, et al. **Curr Genet** 1996 Apr;29(5):490–5

Nucleotide sequence and characterization of the large mitochondrial rRNA gene of Penicillium urticae, and its comparison with those of other filamentous fungi. Yamamoto H, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):888–96

Isolation and molecular characterisation of the gene encoding eburicol 14 alpha–demethylase (cYP51) from Penicillium italicum. van Nistelrooy JG, et al. **Mol Gen Genet** 1996 Apr 10;250(6):725–33

IMMUNOLOGY

Cross–reactivity between Aspergillus fumigatus and Penicillium. Brouwer J. **Int Arch Allergy Immunol** 1996 Jun;110(2):166–73

Development of specific fluorescent–antibody test for tissue form of Penicillium marneffei. Kaufman L, et al. **J Clin Microbiol** 1995 Aug;33(8):2136–8

ISOLATION & PURIFICATION

Volatile metabolites produced by two fungal species cultivated on building materials. Sunesson AL, et al. **Ann Occup Hyg** 1996 Aug;40(4):397–410

Rhizomys sumatrensis and Cannomys badius, new natural animal hosts of Penicillium marneffei. Chariyalertsak S, et al. **J Med Vet Mycol** 1996 Mar–Apr;34(2):105–10

Efficiency of the flotation method in the isolation of Penicillium marneffei from seeded soil. Vanittanakom N, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):271–3

Think fungus in HIV–infection [news] Pini P. **Lancet** 1996 Jul 27;348(9022):257

Occurrence of Penicillium marneffei infections among wild bamboo rats in Thailand. Ajello L, et al. **Mycopathologia** 1995 Jul;131(1):1–8

Disseminated Penicillium marneffei infection in human immunodeficiency virus–infected children. Sirisanthana V, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):935–40

Peritonitis due to Penicillium sp in a patient receiving continuous ambulatory peritoneal dialysis. Fahhoum J, et al. **South Med J** 1996 Jan;89(1):87–8

[Penicillium ulaiense Hsieh, Su & Tzean, a post–harvest pathogen of citrus fruits in northeastern Argentina] Carrillo L. **Rev Argent Microbiol** 1995 Apr–Jun;27(2):107–13 (Eng. Abstr.) **(Spa)**

METABOLISM

Aflavinines and other antiinsectan metabolites from the ascostromata of Eupenicillium crustaceum and related species. Wang HJ, et al. **Appl Environ Microbiol** 1995 Dec; 61(12):4429–35

Transformations of Penicillium islandicum and Penicillium frequentans that produce anthraquinone–related compounds. Huang KX, et al. **Curr Genet** 1995 Nov; 28(6):580–4

Herquline B, a new platelet aggregation inhibitor produced by Penicillium herquei Fg–372. Enomoto Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):50–3

Phenopyrrozin, a new radical scavenger produced by Penicillium sp. FO–2047. Shiomi K, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1413–8

BMS–182123, a fungal metabolite that inhibits the production of TNF–alpha by macrophages and monocytes. Warr GA, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):234–40

New isochromophilones VII and VIII produced by Penicillium sp. FO–4164. Yang DJ, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):223–9

Cometabolic degradation of o–cresol and 2,6–dimethylphenol by Penicillium frequentans Bi 7/2. Hofrichter M, et al. **J Basic Microbiol** 1995;35(5):303–13

Micellar electrokinetic capillary chromatography of fungal metabolites. Resolution optimized by experimental design. Nielsen MS, et al. **J Chromatogr A** 1996 Jan 19; 721(2):337–44

In vivo formation of diazepam–like 1,4–benzodiazepines by Penicillium verrucosum var. verrucosum after administration of 2–aminobenzophenones and glycine. Bringmann G, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):169–81

Isolation and in vitro antibacterial screening of a tricarboxylic acid anhydride from Penicillium sp. Jabbar A, et al. **Pharmazie** 1995 Oct;50(10):706–7

Biotransformation of corticosteroids by Penicillium decumbens ATCC 10436. Holland HL, et al. **Steroids** 1995 Sep;60(9):646–9

PATHOGENICITY

Development of a microbial community of bacterial and yeast antagonists to control wound–invading postharvest pathogens of fruits. Janisiewicz WJ, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3261–7

PENICILLIUM CHRYSOGENUM

ENZYMOLOGY

Amino–acid substitutions in the cleavage site of acyl–coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum: effect on proenzyme cleavage and activity. Tobin MB, et al. **Gene** 1995 Aug 30; 162(1):29–35

GENETICS

Detection of a protein which binds specifically to the upstream region of the pcbAB gene in Penicillium chrysogenum. Chu YW, et al. **Curr Genet** 1995 Jul; 28(2):184–9

Autonomously replicating plasmids carrying the AMA1 region in Penicillium chrysogenum. Fierro F, et al. **Curr Genet** 1996 Apr;29(5):482–9

Cloning, structural organization and regulation of expression of the Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity. Marx F, et al. **Gene** 1995 Dec 29;167(1–2):167–71

METABOLISM

NRE, the major nitrogen regulatory protein of Penicillium chrysogenum, binds specifically to elements in the intergenic promoter regions of nitrate assimilation and penicillin biosynthetic gene clusters. Haas H, et al. **Curr Genet** 1995 Jul;28(2):177–83

Sulfate transport in Penicillium chrysogenum plasma membranes. Hillenga DJ, et al. **J Bacteriol** 1996 Jul; 178(13):3953–6

Basic amino acid transport in plasma membrane vesicles of Penicillium chrysogenum. Hillenga DJ, et al. **J Bacteriol** 1996 Jul;178(14):3991–5

ULTRASTRUCTURE

Enrichment of Penicillium chrysogenum microbodies by isopycnic centrifugation in nycodenz as visualized with immuno–electron microscopy. Müller WH, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):215–20

PENILE DISEASES

Clinical and serological manifestations of genital human papillomavirus infection. Wikström A. **Acta Derm Venereol Suppl (Stockh)** 1995;193:1–85

Accessory scrotum located on the distal penile shaft. Coplen DE, et al. **J Urol** 1995 Nov;154(5):1908

Lichen nitidus. Davis DA, et al. **Urology** 1996 Apr;47(4):573

[Oleogranuloma of male genital organs] Zeliak MV. **Klin Khir** 1995;(7–8):48–9 **(Ukr)**

CHEMICALLY INDUCED

A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet–induced penile ulceration. Fitzgerald E, et al. **Arch Dermatol** 1995 Dec; 131(12):1449, 1452

[Ulcer in the urethral meatus and HIV infection (letter)] Len O, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):497–8 **(Spa)**

COMPLICATIONS

Human immunodeficiency virus–related bacillary angiomatosis of the penis. Eden CG, et al. **Br J Urol** 1996 Feb;77(2):323–4

[Bilateral fracture of the corpus cavernosum with complete rupture of the urethra] Hafiani M, et al. **J Urol (Paris)** 1995;101(4):200–2 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Genital candidosis. Stary A. **Curr Probl Dermatol** 1996; 24:40–9 (23 ref.)

Clinical aspects of genito–anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

'Grey case'. Sherrard J. **Int J STD AIDS** 1995 Jul–Aug; 6(4):249–50

Penile problems—hidden lesions of the sailor. Hand CJ, et al. **J R Nav Med Serv** 1995 Spring;81(1):36–8

DRUG THERAPY

Problems with the penis and prepuce in children. Lichen sclerosus should be treated with corticosteroids to reduce need for surgery [letter] Jorgensen ET, et al. **BMJ** 1996 Sep 14;313(7058):692

Successful treatment of donovanosis with ciprofloxacin [letter] Ahmed BA, et al. **Genitourin Med** 1996 Feb; 72(1):73–4

A single–blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts. Petersen CS, et al. **Genitourin Med** 1995 Dec; 71(6):391–2

Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Strand A, et al. **Genitourin Med** 1995 Dec;71(6):387–90

Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double–blind cross over trial. Wegner HE, et al. **Int J Impot Res** 1995 Dec;7(4):233–7

ETIOLOGY

Reactivation of healed primary syphilitic ulcer: a manifestation of febrile Herxheimer reaction in secondary syphilis [letter] Khanna N, et al. **Acta Derm Venereol** 1996 Jan;76(1):91–2

Debilitating silicone granuloma of the penis and scrotum. Wassermann RJ, et al. **Ann Plast Surg** 1995 Nov; 35(5):505–9; discussion 509–10

ABC of general surgery in children. Problems with the penis and prepuce [see comments] Davenport M. **BMJ** 1996 Feb 3;312(7026):299–301 (0 ref.). Comment in: BMJ 1996 May 11;312(7040):1230–1.

Trash penis [letter; comment] de Takats D. **Br J Urol** 1995 Dec;76(6):814–5. Comment on: Br J Urol 1995 May;75(5):675–6.

Trash penis [letter; comment] Kumar U, et al. **Br J Urol** 1995 Dec;76(6):814. Comment on: Br J Urol 1995 May;75(5):675–6.

Penile ectopic testis. Sylla C, et al. **Br J Urol** 1996 May; 77(5):762

Fatal genitourinary mucormycosis in a patient with undiagnosed diabetes. Williams JC, et al. **Clin Infect Dis** 1995 Sep;21(3):682–4

Sensitization to benzocaine on a condom. Placucci F, et al. **Contact Dermatitis** 1996 Apr;34(4):293

Lichen planus after genital herpes simplex virus type 2 infection [letter] Kürkçüoğlu N, et al. **Dermatology** 1995; 191(1):72–3

A case of primary localized amyloidosis of the penile urethra. Sakuma S, et al. **Int J Urol** 1996 Mar;3(2):163–4

Buried rubber band: a cause for persistent penile discharge. Bhat S, et al. **J Indian Med Assoc** 1995 Aug;93(8):327

Distal penile lymphoedema following hypospadias repair: a case report. Gaston P, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):97–8

Occult inguinal hernia, a cause of rapid onset of penile and scrotal edema in patients on chronic peritoneal dialysis. Deshmukh N, et al. **Mil Med** 1995 Nov;160(11):597–8

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

Penile edema and meatal ulceration after intravesical instillation with bacillus Calmette–Guerin. Baniel J, et al. **Urology** 1996 Jun;47(6):932–4

Ventral penile curvature following radical pelvic surgery: a variant of urethral manipulation syndrome. Grossfeld GD, et al. **Urology** 1995 Nov;46(5):707–9

[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Fellatio in the sexual transmission of Lancefield Group A beta–haemolytic streptococcus [letter] Fisk P, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):458

Syphilitic aortic aneurysm and squamous cell carcinoma of the penis: a case report. el–Gadi SM, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):356–60

PARASITOLOGY

Parasitic infection of the penis. Meyer R, et al. **J Urol** 1996 Jun;155(6):2030–1

Amebiasis of the penis. Hejase MJ, et al. **Urology** 1996 Jul; 48(1):151–4

PATHOLOGY

Anal and penile condylomas in HIV–negative and HIV–positive men: clinical, histological and virological characteristics correlated to therapeutic outcome. von Krogh G, et al. **Acta Derm Venereol** 1995 Nov;75(6):470–4

Fordyce spots on the glans penis [letter] Massmanian A, et al. **Br J Dermatol** 1995 Sep;133(3):498–500

Necrobiosis lipoidica of the glans penis [letter] Velasco–Pastor AM, et al. **Br J Dermatol** 1996 Jul; 135(1):154–5

Ossification of the penis: report of two cases. Fahal AH, et al. **East Afr Med J** 1996 Apr;73(4):276–7

Median raphe cyst of the penis with ciliated cells. Romaní J, et al. **J Cutan Pathol** 1995 Aug;22(4):378–81

Parameatal cyst of penis. Ghosh SK, et al. **J Indian Med Assoc** 1995 Aug;93(8):325

Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266–8 (13 ref.)

[Tumorous lymphedema of the penis. Report of verrucous elephantiasis. A brief case. Preliminary note] Luelmo J, et al. **Actas Urol Esp** 1995 Jul–Aug;19(7):585–7 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Mechanisms of veno–occlusion within and outside the canine corpus cavernosum penis using a pressure–flow technique and cavernoso–venography. Matsuzaka J, et al. **Int J Urol** 1996 Jan;3(1):47–53

PREVENTION & CONTROL

Problems with the penis and prepuce. Preputioplasty should be performed more often [letter; comment] Coleridge HC. **BMJ** 1996 May 11;312(7040):1230–1. Comment on: BMJ 1996 Feb 3;312(7026):299–301.

Anti–circumcision groups criticized [letter; comment] Gregory BW. **Can Med Assoc J** 1995 Oct 1;153(7):885–6 . Comment on: Can Med Assoc J 1995 Jun 1;152(11):1873–6.

SURGERY

The management of extensive penile fibrosis: a new technique of 'minimal scar–tissue excision'. George VK, et al. **Br J Urol** 1996 Feb;77(2):282–4

Cryosurgical treatment of pearly penile papules. Ocampo–Candiani J, et al. **J Am Acad Dermatol** 1996 Sep; 35(3 Pt 1):486–7

Severe injury from neodymium: yttrium–aluminum–garnet laser therapy for penile condylomata acuminata. Hrebinko RL. **Urology** 1996 Jul;48(1):155–6

[Surgical treatment of benign prostatic hypertrophy and Kelami syndrome] Bodo G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):81–3 (Eng. Abstr.) **(Ita)**

THERAPY

Human leukocyte interferon–alpha in cream for the treatment of genital herpes in Asian males. A placebo–controlled, double–blind study. Syed TA, et al. **Dermatology** 1995; 191(1):32–5

Autoimplantation technique in the treatment of anogenital warts: a clinico–immunological study. Usman N, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):55–7

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

VETERINARY

The effect of xylazine epidural anaesthesia on blood gas and acid–base parameters in rams. Aminkov BY, et al. **Br Vet J** 1995 Sep–Oct;151(5):579–85

Evidence for cryptosporidial infection as a cause of prolapse of the phallus and cloaca in ostrich chicks (Struthio camelus). Penrith ML, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):283–9

VIROLOGY

Anal and penile condylomas in HIV–negative and HIV–positive men: clinical, histological and virological characteristics correlated to therapeutic outcome. von Krogh G, et al. **Acta Derm Venereol** 1995 Nov;75(6):470–4

Lichen planus after genital herpes simplex virus type 2 infection [letter] Kürkçüoğlu N, et al. **Dermatology** 1995; 191(1):72–3

Human leukocyte interferon–alpha in cream for the treatment of genital herpes in Asian males. A placebo–controlled, double–blind study. Syed TA, et al. **Dermatology** 1995; 191(1):32–5

PENILE ERECTION

Extrapelvic cavernous nerve stimulation in erectile dysfunction. Human study. Shafik A. **Andrologia** 1996 May–Jun;28(3):151–6

A prospective trial with vacuum–assisted erection devices. Tay KP, et al. **Ann Acad Med Singapore** 1995 Sep; 24(5):705–7

Psychogenic impotence in spinal cord injury patients. Tay HP, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):391–3

Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Baltaci S, et al. **Br J Urol** 1995 Dec; 76(6):757–60

Erectile dysfunction in men with and without diabetes mellitus: a comparative study. Bancroft J, et al. **Diabet Med** 1996 Jan;13(1):84–9

Prevalence of self–reported erectile dysfunction in people with long–term IDDM. Klein R, et al. **Diabetes Care** 1996 Feb;19(2):135–41

The clinical assessment of erectile dysfunction: a comparison of nocturnal penile tumescence monitoring and intracavernosal injections. Bancroft J, et al. **Int J Impot Res** 1995 Jun;7(2):123–30

Corporeal plication for surgical correction in Peyronie's disease improves rigidity. Claes H, et al. **Int J Impot Res** 1995 Jun;7(2):119–22

Elastic fibre concentration in the tunica albuginea of corpora cavernosa and nocturnal tumescence monitoring. Iacono F, et al. **Int J Impot Res** 1995 Jun;7(2):63–70

Analysis of continuous nocturnal penile rigidity measurements with the use of the RigiScan summary analysis software program. Kropman RF, et al. **Int J Impot Res** 1995 Jun;7(2):71–82

Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double–blind cross over trial. Wegner HE, et al. **Int J Impot Res** 1995 Dec;7(4):233–7

Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. Guay AT, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2512–4

The effects of stress and coping upon the diagnostic intracavernous injection in men with erectile dysfunction. van der Borght W, et al. **J Psychosom Res** 1995 Oct; 39(7):865–73

Priapism associated with sickle cell hemoglobinopathy in children: long–term effects on potency. Chakrabarty A, et al. **J Urol** 1996 Apr;155(4):1419–23

Vacuum erection associated impotence and Peyronie's disease. Hakim LS, et al. **J Urol** 1996 Feb;155(2):534–5

Potpourri [editorial] Light JK. **J Urol** 1996 Sep;156(3):998

Erections—broken, leaking and salvaged [editorial; comment] Montague DK. **J Urol** 1996 Jan;155(1):158. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):150–4. Comment on: J Urol 1996 Jan;155(1):155–7.

Re: Potency–sparing radical retropubic prostatectomy: a simplified anatomical approach [letter; comment] Walsh PC. **J Urol** 1996 Jan;155(1):294. Comment on: J Urol 1995 Jun;153(6):1875–7.

Penile length in the flaccid and erect states: guidelines for penile augmentation. Wessells H, et al. **J Urol** 1996 Sep; 156(3):995–7

Transurethral Nd:YAG laser prostatectomy with a laterally firing fiber: local effects on tissue associated with erectile dysfunction. Breza J, et al. **Lasers Surg Med** 1995; 17(4):364–9

Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure. Giuliano F, et al. **Neurosci Lett** 1996 May 3;209(1):1–4

Clinical approach to erectile dysfunction in spinal cord injured men. A review of clinical and experimental data. Courtois FJ, et al. **Paraplegia** 1995 Nov;33(11):628–35 (60 ref.)

Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Vidal J, et al. **Rev Neurol** 1995 Mar–Apr;23(120):269–71

A brief male sexual function inventory for urology [see comments] O'Leary MP, et al. **Urology** 1995 Nov; 46(5):697–706. Comment in: Urology 1996 May;47(5):782–3.

[Erectile dysfunction: the role of Rigiscan in the diagnosis] Sattar AA, et al. **Acta Urol Belg** 1996 Mar;64(1):43–5 (Eng. Abstr.) **(Fre)**

[Radical surgery and conservation of erection in Peyronie's disease] Austoni E, et al. **Arch Ital Urol Androl** 1995 Dec; 67(5):359–64 (Eng. Abstr.) **(Ita)**

[Classification of patterns of nocturnal penile tumescence with continuous monitoring of penile rigidity: analysis of various factors affecting erection] Yasumoto R, et al. **Hinyokika Kiyo** 1996 Apr;42(4):285–8 (Eng. Abstr.) **(Jpn)**

[En bloc cystourethrectomy with preservation of potency] Kihara K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):676–81 (Eng. Abstr.) **(Jpn)**

[Treatment of erectile dysfunction in multiple sclerosis] Fernández O. **Rev Neurol** 1995 Mar–Apr;23(120):320–1 (16 ref.) **(Spa)**

DRUG EFFECTS

Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Mann K, et al. **Arch Sex Behav** 1996 Feb;25(1):1–16

Restoration of normal adult penile erectile response in aged rats by long–term treatment with androgens. Garban H, et al. **Biol Reprod** 1995 Dec;53(6):1365–72

Nitric oxide as a mediator of cocaine–induced penile erection in the rat. Chan JY, et al. **Br J Pharmacol** 1996 May; 118(1):155–61

Sildenafil, a novel effective oral therapy for male erectile dysfunction. Boolell M, et al. **Br J Urol** 1996 Aug; 78(2):257–61

Trial of pentoxifylline for diabetic impotence. Georgitis WJ, et al. **Diabetes Care** 1995 Mar;18(3):345–52

Intraurethral prostaglandin improves quality of vacuum erection therapy. John H, et al. **Eur Urol** 1996;29(2):224–6

Effects of chronic lithium pretreatment on apomorphine–induced penile erection. Dehpour AR, et al. **Gen Pharmacol** 1995 Sep;26(5):1015–20

Effects of adenosine analogues on apomorphine–induced penile erection in rats. Sharifzadeh M, et al. **Gen Pharmacol** 1995 Dec;26(8):1785–90

Effect of vasoactive intestinal peptide and acetylcholine on penile erection in the rat in vivo. Suh JK, et al. **Int J Impot Res** 1995 Jun;7(2):111–8

Erectile response to topical, intraurethral and intracorporal pharmacotherapy in a rat model of spinal cord injury. Rivas DA, et al. **J Spinal Cord Med** 1995 Oct;18(4):245–50

Involvement of raphe–hippocampal serotonergic and septo–hippocampal cholinergic mechanisms in the penile erection induced by FR121196, a putative cognitive enhancer. Maeda N, et al. **Jpn J Pharmacol** 1995 May; 68(1):85–94

Prostaglandin injection therapy for men with a reasonable level of sexual activity. Heeg MM. **N J Med** 1995 Dec; 92(12):785–8

Alprostadil for the treatment of erectile dysfunction. Kupecz D. **Nurse Pract** 1996 May;21(5):143–5

Effects of prostaglandin E1, and papaverine on non–neurogenic and neurogenic contraction of the isolated rabbit erectile tissue. Italiano G, et al. **Pharmacol Res** 1995 May;31(5):313–7

Effect of (–)–cathinone, a psychoactive alkaloid from khat (Catha edulis Forsk.) and caffeine on sexual behaviour in rats. Taha SA, et al. **Pharmacol Res** 1995 May; 31(5):299–303

The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Carani C, et al. **Psychoneuroendocrinology** 1995;20(7):743–53

Post–synaptic 5–HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Protais P, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):376–83

The effects of a new alpha–2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction. Bancroft J, et al. **Psychosom Med** 1995 Jul–Aug;57(4):345–56

Stress and the erectile response to intracavernosal prostaglandin E1 in men with erectile dysfunction. Granata A, et al. **Psychosom Med** 1995 Jul–Aug;57(4):336–44

Pharmacokinetics of moxisylyte in healthy volunteers after intravenous infusion and intracavernous administration with and without a penile tourniquet. Costa P, et al. **Ther Drug Monit** 1996 Apr;18(2):135–44

Intracavernous injection therapy for male erectile dysfunction. Fallon B. **Urol Clin North Am** 1995 Nov; 22(4):833–45 (68 ref.)

Oral and topical treatment of erectile dysfunction. Present and future. Morales A, et al. **Urol Clin North Am** 1995 Nov;22(4):879–86 (31 ref.)

7–Nitroindazole: a selective inhibitor of penile erection: an in vivo study in a rat animal model. Spiess PE, et al. **Urology** 1996 Jan;47(1):93–6

[Drugs for impotence] Lukkarinen O, et al. **Duodecim** 1995; 111(8):771–6 (25 ref.) **(Fin)**

[Management of intraoperative erection by penile block] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):352–5 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Oxytocin–induced penile erection. Role of nitric oxide. Argiolas A, et al. **Adv Exp Med Biol** 1995;395:247–54

Corpus spongiosum penis pressure and perineal muscle activity during reflexive erections in the rat. Schmidt MH, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R904–13

Self–assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age–matched control group. Fransson P, et al. **Cancer** 1996 Sep 1; 78(5):1066–78

Sexual function and erection capability among young men with spina bifida. Sandler AD, et al. **Dev Med Child Neurol** 1996 Sep;38(9):823–9

Physiological aging and penile erectile function: a study in the rat. Calabrò A, et al. **Eur Urol** 1996;29(2):240–4

Penile sympathic skin response in erectile dysfunction. Derouet H, et al. **Eur Urol** 1995;28(4):314–9

Role of cyclic adenosine monophosphate in prostaglandin E1–induced penile erection in rabbits. Lin JS, et al. **Eur Urol** 1995;28(3):259–65

Prolactin and testosterone: their role in male sexual function. Carani C, et al. **Int J Androl** 1996 Feb;19(1):48–54

New method for direct stiffness measurement of the corpora cavernosa. Hatzichristou DG, et al. **Int J Impot Res** 1995 Dec;7(4):221–31

Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Zvara P, et al. **Int J Impot Res** 1995 Dec;7(4):209–19

Genital and psychoaffective response to erotic stimulation

in sexually functional and dysfunctional men. Rowland DL, et al. **J Abnorm Psychol** 1996 May;105(2):194–203
Neural control of penile erection in the rat. Giuliano F, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1–2):36–44
Autonomic control of penile erection: modulation by testosterone in the rat. Giuliano F, et al. **J Neuroendocrinol** 1993 Dec;5(6):677–83
A nonimaging scintillation probe to measure penile hemodynamics. Zuckier LS, et al. **J Nucl Med** 1995 Dec; 36(12):2345–51
Follow-up of vacuum and nonvacuum constriction devices as treatments for erectile dysfunction. Schuetz-Mueller D, et al. **J Sex Marital Ther** 1995 Winter;21(4):229–38
The hemodynamic influence of the ischiocavernosus muscles on erectile function. Claes H, et al. **J Urol** 1996 Sep; 156(3):986–90
Correlation of nocturnal penile tumescence monitoring duplex ultrasonography and infusion cavernosometry for the diagnosis of erectile dysfunction. Sattar AA, et al. **J Urol** 1996 Apr;155(4):1274–6
Recording the corpus cavernosum electromyogram: principles and problems. Scheepe JR, et al. **J Urol** 1996 Jun;155(6):2074–9
The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)
Neural control of penile erection. Giuliano FA, et al. **Urol Clin North Am** 1995 Nov;22(4):747–66 (271 ref.)
Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Levine LA, et al. **Urol Clin North Am** 1995 Nov;22(4):775–88 (58 ref.)
[Experimental approach to reflex erection in rats: modeling and functional neuroanatomy of the involved nerve pathways] Giuliano F, et al. **Prog Urol** 1996 Feb;6(1):81–6 (Eng. Abstr.) **(Fre)**
[Temporal correlations between nocturnal spontaneous erections and sleep stages] Vesely B, et al. **Wien Med Wochenschr** 1995;145(17–18):495–6 (Eng. Abstr.) **(Ger)**
[New nocturnal penile tumescence recorder] Takahashi M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct; 86(10):1563–8 (Eng. Abstr.) **(Jpn)**
[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**
[Neurologic diagnosis of erectile dysfunction] Resel Estévez L, et al. **Arch Esp Urol** 1996 Apr;49(3):229–34 (Eng. Abstr.) **(Spa)**
[Digital inflection rigidometry in the study of erectile dysfunction. A new technique] Rosselló Barbará M. **Arch Esp Urol** 1996 Apr;49(3):221–7 (Eng. Abstr.) **(Spa)**
[Physiology of penile erection] Sáenz de Tejada Y Gorman I. **Arch Esp Urol** 1996 Apr;49(3):202–5 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Changes in sexual function after radiotherapy treatment of prostate cancer. Beckendorf V, et al. **Br J Urol** 1996 Jan; 77(1):118–23
Potency following conformal neutron/photon irradiation for localized prostate cancer. Hart KB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):881–4
Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Stock RG, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):267–72

PENILE INDURATION

DIAGNOSIS

[Induratio penis plastica: the diagnostic possibilities of gradient-echo sequences (magnetic resonance angiography)] Carriero A, et al. **Radiol Med (Torino)** 1996 Apr;91(4):429–33 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Vacuum erection associated impotence and Peyronie's disease. Hakim LS, et al. **J Urol** 1996 Feb;155(2):534–5

IMMUNOLOGY

The immunological features of Peyronie's disease. Ralph DJ, et al. **J Urol** 1996 Jan;155(1):159–62

PATHOLOGY

[An unusual case of plastic penile induration] Pacík D, et al. **Rozhl Chir** 1995 Nov;74(7):366–8 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine LA, et al. **J Urol** 1996 Apr;155(4):1270–3 (21 ref.)

SURGERY

Corporeal plication for correction of penile curvature. Tay KP, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):708–10
Peyronie curvature treated by plication of the penile fasciae. Geertsen UA, et al. **Br J Urol** 1996 May;77(5):733–5
Corporeal plication for surgical correction in Peyronie's disease improves rigidity. Claes H, et al. **Int J Impot Res** 1995 Jun;7(2):119–22
Penile dermal flap for defect reconstruction in Peyronie's disease: operative technique and four years' experience in 17 patients. Krishnamurti S. **Int J Impot Res** 1995 Dec; 7(4):195–208
Use of penile prosthetic implants in patients with penile fibrosis. Knoll LD. **Urol Clin North Am** 1995 Nov; 22(4):857–63
Surgical treatment of Peyronie's disease. Deirmenjian JM, et al. **West J Med** 1996 Apr;164(4):344
[Radical surgery and conservation of erection in Peyronie's disease] Austoni E, et al. **Arch Ital Urol Androl** 1995 Dec; 67(5):359–64 (Eng. Abstr.) **(Ita)**

THERAPY

Ultrasound and soft-tissue radiography to monitor local interferon-alpha 2B treatment in Peyronie's disease. Andresen R, et al. **Acta Radiol** 1996 May;37(3 Pt 1):352–6
Differential therapies in various stages of penile induration. Wagenknecht LV. **Arch Esp Urol** 1996 Apr;49(3):285–92
Treatment of Peyronie's disease with local interferon-alpha 2b. Wegner HE, et al. **Eur Urol** 1995;28(3):236–40
[Laser and ultrasonic therapy in simultaneous emission for the treatment of plastic penile induration] Felipetto R, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):25–9 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

An ultrasonographic study of Peyronie's disease. Muralidhar S, et al. **Australas Radiol** 1996 May;40(2):106–8

PENILE NEOPLASMS

Epidemiological and clinical aspects of carcinoma of penis at Kenyatta National Hospital. Magoha GA, et al. **East Afr Med J** 1995 Jun;72(6):359–61
Hemangiomatous penile horn. Mathur P, et al. **J Urol** 1996 May;155(5):1738
[Progress in the study of penile cancer] Zhong H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):382–4 (16 ref.) **(Chi)**
[Cancer of the penis] Popik MP, et al. **Klin Khir** 1995; (11–12):43 **(Ukr)**

COMPLICATIONS

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134–6 (3 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Appearance on magnetic resonance imaging of Buschke-Lowenstein tumour. Takezawa Y, et al. **Br J Urol** 1996 Aug;78(2):308–9
Application of the AgNOR method to distinguish pseudoepitheliomatous hyperplasia from squamous cell carcinoma. Sarda R, et al. **Indian J Cancer** 1995 Dec; 32(4):169–74
Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy. Griffin JH, et al. **J Urol** 1996 May;155(5):1701–2
Magnetic resonance imaging of vascular lesions of the scrotum and penis. Forstner R, et al. **Urology** 1995 Oct; 46(4):581–3
[Urothelial carcinoma of the navicular fossa] Kurimoto S, et al. **Urologe A** 1996 May;35(3):251–3 (Eng. Abstr.) **(Ger)**
[Cavernous hemangioma of the penis] Sergienko NF, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47–9 (3 ref.) **(Rus)**

EPIDEMIOLOGY

Falling incidence of penis cancer in an uncircumcised population (Denmark 1943–90) [see comments] Frisch M, et al. **BMJ** 1995 Dec 2;311(7018):1471. Comment in: BMJ 1996 Mar 23;312(7033):779–80.

GENETICS

Hereditary multiple glomus tumors involving the glans penis. A case report and review of the literature. Kiyosawa T, et al. **Dermatol Surg** 1995 Oct;21(10):895–9 (36 ref.)
Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Lam KY, et al. **Eur J Surg Oncol** 1995 Dec;21(6):613–6

MICROBIOLOGY

Absence of Epstein-Barr virus in penile carcinoma. A study of 42 cases using in situ hybridization. Lam KY, et al. **Cancer** 1995 Aug 15;76(4):658–60

PATHOLOGY

Surface adenosquamous carcinoma of the penis. A report of three cases. Cubilla AL, et al. **Am J Surg Pathol** 1996 Feb;20(2):156–60
Urology image quiz. Erythroplasia of Queyrat. Singh-Ranger R, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):486
Case report: spinal metastasis from carcinoma of the penis. Jacob R, et al. **Br J Radiol** 1995 Dec;68(816):1367–8
Primary Kaposi's sarcoma of the glans penis. Koyuncuoğlu M, et al. **Br J Urol** 1996 Apr;77(4):614–5
Dermacase. Squamous cell carcinoma. Enta T. **Can Fam Physician** 1996 Aug;42:1467, 1470
Unreliability of modified inguinal lymphadenectomy for clinical staging of penile carcinoma. Lopes A, et al. **Cancer** 1996 May 15;77(10):2099–102
Carcinoma of the penis: A cluster of cases in young men [letter; comment] Reynolds M, et al. **Genitourin Med** 1995 Oct;71(5):336–7. Comment on: Genitourin Med 1995 Feb;71(1):41–2.
Triple cancers involving extramammary Paget's disease. Toyama K, et al. **Int J Dermatol** 1995 Oct;34(10):715–6
Syphilitic aortic aneurysm and squamous cell carcinoma of the penis: a case report. el-Gadi SM, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):356–60
Squamous cell carcinoma of the penis. Micali G, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):432–51 (219 ref.)
Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. Gregoire L, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1705–9
Glomus tumor of the penis. Khoudary KP, et al. **J Urol** 1996 Feb;155(2):707 (3 ref.)
Accurate staging of carcinoma of the penis in men with nonpalpable inguinal lymph nodes by modified inguinal lymphadenectomy. Parra RO. **J Urol** 1996 Feb; 155(2):560–3
Glomangioma of the penile and scrotal median raphe. Waguespack RL, et al. **J Urol** 1996 Jul;156(1):179
[The value of biopsy of the inguinal lymph nodes in patients with epidermoid carcinoma of the penis] Ornellas AA, et al. **Prog Urol** 1995 Sep;5(4):544–7 (Eng. Abstr.) **(Fre)**
[Malignant schwannoma of the glans penis] Aloi F, et al. **Hautarzt** 1995 Sep;46(9):656–9 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Neonatal circumcision does not protect against penile cancer [letter; comment] [see comments] Fleiss PM, et al. **BMJ** 1996 Mar 23;312(7033):779–80. Comment on: BMJ 1995 Dec 2;311(7018):1471. Comment in: BMJ 1996 Jul 6;313(7048):46; discussion 47. Comment in: BMJ 1996 Jul 6;313(7048):47.
Neonatal circumcision and penile cancer. Evidence that circumcision is protective is overwhelming [letter; comment] Schoen EJ. **BMJ** 1996 Jul 6;313(7048):46; discussion 47. Comment on: BMJ 1996 Mar 23;312(7033):779–80.
Neonatal circumcision and penile cancer. Authors ignored main conclusion of study that they cited [letter; comment] Stanton A. **BMJ** 1996 Jul 6;313(7048):47. Comment on: BMJ 1996 Mar 23;312(7033):779–80.

RADIONUCLIDE IMAGING

Hemangioma of the scrotum and penis in a child demonstrating a perfusion-blood pool mismatch on Tc-99m RBC imaging. Gorenberg M, et al. **Clin Nucl Med** 1996 Mar;21(3):247–8

RADIOTHERAPY

Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy. Griffin JH, et al. **J Urol** 1996 May;155(5):1701–2
Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Rozan R, et al. **Radiother Oncol** 1995 Aug;36(2):83–93

SECONDARY

Penile metastasis from renal cell carcinoma. McIntyre IG, et al. **Br J Urol** 1996 May;77(5):754–5
Metastatic carcinoma of the penis. Char G, et al. **West Indian Med J** 1996 Mar;45(1):37–8
[Report of a case of penile metastasis. Review of the literature] Cuvillier X, et al. **Prog Urol** 1995 Dec; 5(6):1009–11 (17 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Neo-adjuvant and adjuvant treatment in penile squamous cell carcinoma. Horenblas S. **Acta Urol Belg** 1996 May; 64(2):99–101
Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. Pettaway CA, et al. **J Urol** 1995 Dec;154(6):1999–2003
Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. Theodorescu D, et al. **J Urol** 1996 May;155(5):1626–31
Mohs' micrographic surgery and distal urethrectomy with immediate urethral reconstruction for glanular carcinoma in situ with significant urethral extension. Nash PA, et al. **Urology** 1996 Jan;47(1):108–10
Penile cancer—is lymphadenectomy necessary in all cases? Srinivas V, et al. **Urology** 1995 Nov;46(5):710–2
[YAG:Nd laser cw in treatment of precancerous states of the penis] Kuzaka B, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):98–9 (Eng. Abstr.) **(Pol)**
[Complications of inguinal lymphadenectomy for penile carcinoma. Origin, management, and prevention] Martín Martínez JC, et al. **Actas Urol Esp** 1995 Nov–Dec; 19(10):759–71 (68 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

A retrospective analysis of 82 cases of cancer of the penis. Lindegaard JC, et al. **Br J Urol** 1996 Jun;77(6):883–90

Management of carcinoma of the penis: a review. Magoha GA. **East Afr Med J** 1995 Sep;72(9):547–50 (55 ref.)

Combined therapy with cisplatin and interferon alpha–2b (INTRON–A) in patients with penile carcinoma. Analysis of 2'5' oligo (A) synthetase and circulating interferon [letter] Mouratidou D, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):55–7

[A case of penile cancer treated with combination of chemotherapy, radiation and radical operation] Igarashi H, et al. **Hinyokika Kiyo** 1996 Jun;42(6):465–7 (Eng. Abstr.) **(Jpn)**

[Organ–preserving treatment in cancer of the penis] Gotsadze DT, et al. **Urol Nefrol (Mosk)** 1995 Nov–Dec;(6):44–7 (Eng. Abstr.) **(Rus)**

VETERINARY

Intermediate filament expression and lectin histochemical features of canine transmissible venereal tumour. Gimeno EJ, et al. **APMIS** 1995 Sep;103(9):645–50

VIROLOGY

Detection of human cytomegalovirus in female and male anogenital lesions with papillomavirus–associated dysplastic changes. Mougin C, et al. **Cancer Detect Prev** 1995;19(4):316–24

Preferential association of human papillomavirus with high–grade histologic variants of penile–invasive squamous cell carcinoma. Gregoire L, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1705–9

Re: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis [letter; comment] Fleiss PM. **J Urol** 1996 Jun;155(6):2034–5; discussion 2035–6. Comment on: J Urol 1995 Sep;154(3):1024–9.

Re: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis [letter; comment] Van Howe RS. **J Urol** 1996 Jun;155(6):2035; discussion 2035–6. Comment on: J Urol 1995 Sep;154(3):1024–9.

Serum antibodies to HPV 16 virus–like particles are not associated with penile cancer in Chinese males. Wideroff L, et al. **Viral Immunol** 1996;9(1):23–5

PENILE PROSTHESIS

Current thoughts on penile prosthetic surgery. Pryor JP. **Acta Chir Hung** 1995–96;35(1–2):129–35 (4 ref.)

Penile implant. Cartmill RA. **Ann Acad Med Singapore** 1995 Sep;24(5):745–8 (5 ref.)

Penile implant surgery—local experience with the semi–rigid, single component inflatable and the multi–component inflatable penile prostheses. Tay KP, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):711–5

Retraction method for implantation of penile prosthesis [letter] Garber BB. **Br J Urol** 1995 Sep;76(3):411

The management of extensive penile fibrosis: a new technique of 'minimal scar–tissue excision'. George VK, et al. **Br J Urol** 1996 Feb;77(2):282–4

Penile prostheses in paraplegic men. Gross AJ, et al. **Br J Urol** 1996 Aug;78(2):262–4

A guide to safe corporotomy incisions in the presence of underlying inflatable penile cylinders: results of in vitro and in vivo studies [see comments] Hakim LS, et al. **J Urol** 1996 Mar;155(3):918–23. Comment in: J Urol 1996 Mar;155(3):924–5.

Report of a multicenter clinical evaluation of the Dura–II penile prosthesis. Kearse WS Jr, et al. **J Urol** 1996 May; 155(5):1613–6

Treatment of penile fibrosis with prosthetic implantation and flap advancement with tissue debulking. Knoll LD, et al. **J Urol** 1996 Aug;156(2 Pt 1):394–7

Long–term results with Hydroflex and Dynaflex penile prostheses: device survival comparison to multicomponent inflatables. Wilson SK, et al. **J Urol** 1996 May; 155(5):1621–3

Ultrex cylinders: problems with uncontrolled lengthening (the S–shaped deformity). Wilson SK, et al. **J Urol** 1996 Jan;155(1):135–7

Prosthetic implantation after phallic construction. Alter GJ, et al. **Microsurgery** 1995;16(5):322–4

Use of penile prosthetic implants in patients with penile fibrosis. Knoll LD. **Urol Clin North Am** 1995 Nov; 22(4):857–63

Long–term results of penile prosthetic implants. Lewis RW. **Urol Clin North Am** 1995 Nov;22(4):847–56 (30 ref.)

Clinical experience with inflatable and malleable penile implants in 104 patients. Anafarta K, et al. **Urol Int** 1996; 56(2):100–4

Detection of leakage in inflatable genitourinary devices. Parulkar BG, et al. **Urology** 1996 Jan;47(1):97–101

[Implantation of inflatable penile prostheses as an effective alternative surgical treatment for erectile disorders] Pacík D, et al. **Rozhl Chir** 1995 Nov;74(7):363–5 (Eng. Abstr.) **(Cze)**

[Penile prosthesis] Fontana D, et al. **Arch Ital Urol Androl** 1995 Dec;67(5):333–7 (Eng. Abstr.) **(Ita)**

[Penile prosthesis. Indications, classification, technic, complications, and safety] Rosselló Barbará M. **Arch Esp Urol** 1996 Apr;49(3):294–302 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

A personal approach to the management of the complications of penile implant surgery. Wilson SK, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):770–4

Prevention and treatment of complications of inflatable penile prosthesis surgery: a review article. Wilson SK, et al. **Arch Esp Urol** 1996 Apr;49(3):306–11 (9 ref.)

Is the risk of multiple myeloma increased in patients with silicone implants? Tricot GJ, et al. **Curr Top Microbiol Immunol** 1996;210:357–9

The prosthesis salvage operation: immediate replacement of the infected penile prosthesis [see comments] Brant MD, et al. **J Urol** 1996 Jan;155(1):155–7. Comment in: J Urol 1996 Jan;155(1):158.

Risk factors for penile prosthetic infection. Jarow JP. **J Urol** 1996 Aug;156(2 Pt 1):402–4

Penile curvatures and aneurysmal defects with the Ultrex penile prosthesis corrected with insertion of the AMS700CX. Kowalczyk JJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):398–401

Erections—broken, leaking and salvaged [editorial; comment] Montague DK. **J Urol** 1996 Jan;155(1):158. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):150–4. Comment on: J Urol 1996 Jan;155(1):155–7.

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991–4

Penile gangrene: a complication of penile prosthesis. Kardar A, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):355–6

Delayed urinary bladder leak after combined kidney–pancreas transplantation. Association with penile prosthesis implantation. Pearson TC, et al. **Transplantation** 1995 Sep 27;60(6):624–6

[The complications of endo–corpora cavernosa prosthesis] Shcheplev PA, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct; (5):49–52 **(Rus)**

PENIS

see related

CIRCUMCISION

Foreign body in the foreskin of a former gulag prisoner [letter] Tanenbaun B, et al. **Am Fam Physician** 1996 Feb 15;53(3):865

Case report: foreign body in male penile urethra. Ghaly AF, et al. **Genitourin Med** 1996 Feb;72(1):67–8

Pustular psoriasis limited to the penis. Quan MB, et al. **Int J Dermatol** 1996 Mar;35(3):202–4 (14 ref.)

Potpourri [editorial] Light JK. **J Urol** 1996 Sep;156(3):998

ABNORMALITIES

Penoscrotal transposition and associated anomalies: report of five new cases and review of the literature. Parida SK, et al. **Am J Med Genet** 1995 Oct 23;59(1):68–75 (35 ref.)

Juberg–Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

Fetal penile and urethral development subsequent to vascular insult in the last trimester of gestation: an experimental study in goat fetuses. Kizilcan F, et al. **Br J Urol** 1995 Oct;76(4):497–500

Surgical management of the buried penis. Peng HC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):424–30

A large inguinal hernia with undescended testes and micropenis in Robinow syndrome. Türken A, et al. **Clin Dysmorphol** 1996 Apr;5(2):175–8

Peno–scrotal transposition. Diez García R, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):222–5

Cryptorchidism, micropenis and clinical anophthalmia epilepsy in a retarded boy. Izumiya K, et al. **Int Urol Nephrol** 1996;28(1):103–8

Penoplasty for buried penis. Chuang JH. **J Pediatr Surg** 1995 Sep;30(9):1256–7

Male gender assignment in penile agenesis: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Sep;30(9):1358–60 (13 ref.)

Congenital megalourethra. Wakhlu AK, et al. **J Pediatr Surg** 1996 Mar;31(3):441–3

Complete penile corporeal septation. Hollander JB, et al. **J Urol** 1996 Feb;155(2):647

Micropenis secondary to growth hormone deficiency: does treatment with growth hormone alone result in adequate penile growth? Levy JB, et al. **J Urol** 1996 Jul;156(1):214–6

True complete diphallia. Zolfaghari A, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):233–5

Penile orthoplasty using dermal grafts in the outpatient setting. Pope JC 4th, et al. **Urology** 1996 Jul;48(1):124–7

Surgical correction of a canine preputial deformity. Domínguez JC, et al. **Vet Rec** 1996 May 18;138(20):496–7

[Surgical treatment of penoscrotal transposition associated hypospadias] Kang C, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):298–300 (Eng. Abstr.) **(Chi)**

[Surgical repair of congenital penile curvature] Malossini G, et al. **Chir Ital** 1994;46(6):86–90 (Eng. Abstr.) **(Ita)**

[Morphologic changes in the penis. Impotence coeundi without erectile dysfunction] Ruiz Castañé E, et al. **Arch Esp Urol** 1996 Apr;49(3):281–4 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Use of 'normal' to describe penile appearance after circumcision [letter] Filardo TW. **Am Fam Physician** 1996 Jun;53(8):2440

The prepuce: specialized mucosa of the penis and its loss to circumcision. Taylor JR, et al. **Br J Urol** 1996 Feb; 77(2):291–5

Penile length in the flaccid and erect states: guidelines for penile augmentation. Wessells H, et al. **J Urol** 1996 Sep; 156(3):995–7

BLOOD SUPPLY

High–flow priapism in a child: treatment with superselective embolization. Stock KW, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):290–2

Venous ligation for cavernous leak impotence—a report on 30 cases. Ng FC, et al. **Ann Acad Med Singapore** 1995 Sep; 24(5):716–9

Penile revascularization: an overview. Shah RS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):749–54 (39 ref.)

Preliminary reports on morphological and ultrastructural changes in the corpora cavernosa of the rat after chronic arterial obstruction. Siracusano S, et al. **Arch Esp Urol** 1996 Mar;49(2):191–5

Involvement of nitric oxide in the non–adrenergic non–cholinergic neurotransmission of horse deep penile arteries: role of charybdotoxin–sensitive K(+)–channels. Simonsen U, et al. **Br J Pharmacol** 1995 Nov; 116(6):2582–90

A comparison of isotope penile blood flow and colour Doppler ultrasonography in the assessment of erectile dysfunction. Glass JM, et al. **Br J Urol** 1996 Apr; 77(4):566–70

High–flow priapism due to bilateral arteriosinusoidal fistulae. Göktaş S, et al. **Br J Urol** 1996 Jan;77(1):165–6

An unusual case of priapism in a child: diagnosis and treatment. Jameson JS, et al. **Br J Urol** 1996 Mar; 77(3):462–3

Penile Mondors' disease: an underestimated pathology. Sasso F, et al. **Br J Urol** 1996 May;77(5):729–32

Long–term results of penile venous ligation for corporeal venous occlusive dysfunction. Hassan AA, et al. **Can J Surg** 1995 Dec;38(6):537–41

Selective arterial embolization of idiopathic priapism. Cohen GS, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb; 19(1):47–9

Selective embolization of bilateral arterial cavernous fistulas for posttraumatic penile arterial priapism. Lazinger M, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):281–4

Dynamic infusion cavernosometry and cavernosography (DICC) in the evaluation of vasculogenic impotence. Chen KK, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr; 57(4):266–73

Mechanisms of veno–occlusion within and outside the canine corpus cavernosum penis using a pressure–flow technique and cavernoso–venography. Matsuzaka J, et al. **Int J Urol** 1996 Jan;3(1):47–53

Superficial dorsal penile vein thrombosis (penile Mondor's phlebitis): ultrasound diagnosis. Shapiro RS. **J Clin Ultrasound** 1996 Jun;24(5):272–4

Study of etiologic relationship of arterial atherosclerosis to corporal veno–occlusive dysfunction in the rabbit. Azadzoi KM, et al. **J Urol** 1996 May;155(5):1795–800

Evolving concepts in the diagnosis and treatment of arterial high flow priapism. Hakim LS, et al. **J Urol** 1996 Feb; 155(2):541–8

Complete penile corporeal septation. Hollander JB, et al. **J Urol** 1996 Feb;155(2):647

Long–term results of arterial bypass surgery for impotence secondary to segmental vascular disease. Jarow JP, et al. **J Urol** 1996 Sep;156(3):982–5

Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine LA, et al. **J Urol** 1996 Apr;155(4):1270–3 (21 ref.)

Veno–occlusive dysfunction of corpora cavernosa: comparison of diagnostic methods. Lue TF. **J Urol** 1996 Feb;155(2):786–7

Surgical management of ischemic penile gangrene in diabetics with end stage atherosclerosis. Weiner DM, et al. **J Urol** 1996 Mar;155(3):926–9

Preventive wire ligature of venae dorsales penis in radical retropubic surgery. Simon V, et al. **Sb Lek** 1995;96(1):23–6

The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)

Penile revascularization. Sharaby JS, et al. **Urol Clin North Am** 1995 Nov;22(4):821–32 (52 ref.)

Surgical treatment of penile veno–occlusive dysfunction: is it justified? Berardinucci D, et al. **Urology** 1996 Jan; 47(1):88–92

Magnetic resonance imaging of vascular lesions of the scrotum and penis. Forstner R, et al. **Urology** 1995 Oct; 46(4):581–3

Immediate impotence after penetrating perineal trauma: restoration of erections with penile artery revascularization, corpus cavernosum aneurysm repair, and deep penile venous ligation. Licht MR, et al. **Urology** 1995 Oct; 46(4):577–80

[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

[Revascularization: light and shadow] Austoni E, et al. **Arch Ital Urol Androl** 1995 Dec;67(5):339–41 (Eng. Abstr.) **(Ita)**

[High flow priapism following a straddle–injury–induced arteriocavernosal fistula: a case report] Kuwahara M, et al. **Hinyokika Kiyo** 1995 Aug;41(8):625–8 (Eng. Abstr.) **(Jpn)**

[Assessment of tobacco impact on penile vascularization with echo–Doppler and intracavernous injection] Vidal Moreno JF, et al. **Actas Urol Esp** 1996 Apr;20(4):365–71 (Eng. Abstr.) **(Spa)**

[The hair–thread tourniquet syndrome of the toes and penis] Vázquez Rueda F, et al. **An Esp Pediatr** 1996 Jan; 44(1):17–20 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Decreased immunoreactive androgen receptor levels are not the cause of isolated hypospadias. Bentvelsen FM, et al. **Br J Urol** 1995 Sep;76(3):384–8

Comparison of anti–desmin and anti–actin staining for the computerized analysis of cavernous smooth muscle density. Sattar AA, et al. **Br J Urol** 1996 Feb;77(2):266–70

Increased expression of a 68–kDa protein in the corpus cavernosum of some men with erectile dysfunction. van der Ven PF, et al. **J Androl** 1995 May–Jun;16(3):242–7

Various isoforms of myomodulin identified from the male copulatory organ of Lymnaea show overlapping yet distinct modulatory effects on the penis muscle. van Golen FA, et al. **J Neurochem** 1996 Jan;66(1):321–9

[Intra–cavernous collagen analysis in impotence] Vanegas JP, et al. **Acta Urol Belg** 1996 Mar;64(1):7–10 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Comparison of the pharmacological response of human corpus cavernosal tissue with the response of rabbit cavernosal tissue. Levin RM, et al. **Gen Pharmacol** 1995 Sep;26(5):1107–11

Effects of luteinizing hormone–releasing hormone (LH–RH) analogue on the function of the isolated rabbit corpus cavernosum. Itoh Y, et al. **Hinyokika Kiyo** 1996 Mar; 42(3):215–20

The potent relaxant effect of adenosine in rabbit corpora cavernosa is nitric oxide independent and mediated by A2 receptors. Mantelli L, et al. **J Androl** 1995 Jul–Aug; 16(4):312–7

Forskolin: a promising new adjunct to intracavernous pharmacotherapy. Cahn D, et al. **J Urol** 1996 May; 155(5):1789–94

In vitro contraction of the canine corpus cavernosum penis by direct perfusion with prolactin or growth hormone. Ra S, et al. **J Urol** 1996 Aug;156(2 Pt 1):522–5

ENZYMOLOGY

Cloning of a novel neuronal nitric oxide synthase expressed in penis and lower urinary tract. Magee T, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):145–51

Neural and endothelial nitric oxide synthase activity in rat penile erectile tissue. Dail WG, et al. **Cell Tissue Res** 1995 Oct;282(1):109–16

Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Vernet D, et al. **Endocrinology** 1995 Dec;136(12):5709–17

GROWTH & DEVELOPMENT

Reduction in penis size and plasma testosterone concentrations in juvenile alligators living in a contaminated environment. Guillette LJ Jr, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):32–42

Androgens are not major down–regulators of androgen receptor levels during growth of the immature rat penis [published erratum appears in J Steroid Biochem Mol Biol 1996 Apr;58(1):137] Shen R, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5–6):301–13

The effects of androgen administration on phallic androgen receptor expression. Levy JB, et al. **J Urol** 1996 Aug;156(2 Pt 2):775–9

Congenital adrenal hyperplasia: is there an effect on penile growth? Levy JB, et al. **J Urol** 1996 Aug;156(2 Pt 2):780–2

The effect of prepubertal androgen exposure on adult penile length. Sutherland RS, et al. **J Urol** 1996 Aug;156(2 Pt 2):783–7; discussion 787

IMMUNOLOGY

The immunological features of Peyronie's disease. Ralph DJ, et al. **J Urol** 1996 Jan;155(1):159–62

INJURIES

Removing constricting bands on the penis [letter] Meadoff TM. **Ann Emerg Med** 1995 Dec;26(6):758

Male genital self–mutilation. Romilly CS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):427–31 (24 ref.)

Male genital self–mutilation: a case report. Shimizu A, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):187–9

Penile fracture: differential diagnosis, management and outcome. Karadeniz T, et al. **Br J Urol** 1996 Feb; 77(2):279–81

Amputation of distal penile glans during neonatal ritual circumcision—a rare complication. Neulander E, et al. **Br J Urol** 1996 Jun;77(6):924–5

Fracture of the penis: magnetic resonance imaging of the rupture of the corpus cavernosum. Suzuki K, et al. **Br J Urol** 1995 Dec;76(6):803–4

Surgical management of preputial injuries in bulls: 51 cases (1986–1994). Desrochers A, et al. **Can Vet J** 1995 Sep; 36(9):553–6

Amputations with use of adult–size scissors–type circumcision clamps on infants. **Health Devices** 1995 Jul; 24(7):286–7

Recurrent ipsilateral fracture of the penis [letter; comment] Singh RB, et al. **Injury** 1995 Oct;26(8):575. Comment on: Injury 1993 Dec;24(10):685–6.

Effect of penile burns on sexual function. Balakrishnan C, et al. **J Burn Care Rehabil** 1995 Sep–Oct;16(5):508–10

Penile replantation after self–inflicted complete amputation: case report. Ishida O, et al. **J Reconstr Microsurg** 1996 Jan;12(1):23–6

Surgical repair of fracture of the os penis in a dog. Kelly SE, et al. **J Small Anim Pract** 1995 Nov;36(11):507–9

Late results of split–grafted penoscrotal avulsion injuries. Gencosmanoğlu R, et al. **J Trauma** 1995 Dec;39(6):1201–3

Organ injury scaling VII: cervical vascular, peripheral vascular, adrenal, penis, testis, and scrotum. Moore EE, et al. **J Trauma** 1996 Sep;41(3):523–4

Penile fractures: evaluation, therapeutic approaches and long–term results [see comments] Asgari MA, et al. **J Urol** 1996 Jan;155(1):148–9. Comment in: J Urol 1996 Jan;155(1):158.

Penile denudation after adult circumcision. Bettencourt MC, et al. **J Urol** 1996 Jul;156(1):177–8

The value of magnetic resonance imaging in the diagnosis of suspected penile fracture with atypical clinical findings. Fedel M, et al. **J Urol** 1996 Jun;155(6):1924–7

Penetrating trauma to the penis: functional results. Goldman HB, et al. **J Urol** 1996 Feb;155(2):551–3

Erections—broken, leaking and salvaged [editorial; comment] Montague DK. **J Urol** 1996 Jan;155(1):158. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):148–9. Comment on: J Urol 1996 Jan;155(1):150–4. Comment on: J Urol 1996 Jan;155(1):155–7.

Circumcision: successful glanular reconstruction and survival following traumatic amputation. Sherman J, et al. **J Urol** 1996 Aug;156(2 Pt 2):842–4

Recent experience of penile fracture (1989–1993). Wang CN, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):654–9

Partial amputation of glans penis during Mogen clamp circumcision. Strimling BS. **Pediatrics** 1996 Jun;97(6 Pt 1):906–7

Penis reconstruction with an island composite flap of the deep inferior epigastric vascular pedicle [letter] Xiong S, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1083–4

Severe injury from neodymium: yttrium–aluminum–garnet laser therapy for penile condylomata acuminata. Hrebinko RL. **Urology** 1996 Jul;48(1):155–6

Immediate impotence after penetrating perineal trauma: restoration of erections with penile artery revascularization, corpus cavernosum aneurysm repair, and deep penile venous ligation. Licht MR, et al. **Urology** 1995 Oct; 46(4):577–80

Suspected corpus cavernosum trauma in three dogs. Lobetti RG, et al. **Vet Rec** 1995 Nov 4;137(19):492

[Bilateral fracture of the corpus cavernosum with complete rupture of the urethra] Hafiani M, et al. **J Urol (Paris)** 1995;101(4):200–2 (Eng. Abstr.) **(Fre)**

[Homicidal versus suicidal penis amputation. A contribution to the problem of missing and conflicting stains] Madea B. **Arch Kriminol** 1995 Sep–Oct;196(3–4):70–7 (Eng. Abstr.) **(Ger)**

[Diagnostic magnetic resonance imaging (MRI) in fracture of the penis: a case report] Inoue K, et al. **Hinyokika Kiyo** 1996 Feb;42(2):139–41 (Eng. Abstr.) **(Jpn)**

[A gunshot wound of the penis and scrotum] Dmitriev DG, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47 (6 ref.) **(Rus)**

INNERVATION

Distribution and function of nitric oxide–containing nerves in canine corpus cavernosum and spongiosum. Hedlund P, et al. **Acta Physiol Scand** 1995 Dec;155(4):445–55

Extrapelvic cavernous nerve stimulation in erectile dysfunction. Human study. Shafik A. **Andrologia** 1996 May–Jun;28(3):151–6

Vasoactive intestinal peptide and impotence in experimental diabetes mellitus. Maher E, et al. **Br J Urol** 1996 Feb; 77(2):271–8

Neural control of penile erection in the rat. Giuliano F, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1–2):36–44

Importance of target innervation in recovery from axotomy–induced loss of androgen receptor in rat perineal motoneurons. al–Shamma HA, et al. **J Neurobiol** 1995 Nov; 28(3):341–53

Transurethral Nd:YAG laser prostatectomy with a laterally firing fiber: local effects on tissue associated with erectile dysfunction. Breza J, et al. **Lasers Surg Med** 1995; 17(4):364–9

Direct nitric oxide–containing innervation from the rat spinal cord to the penis. Vanhatalo S, et al. **Neurosci Lett** 1995 Oct 13;199(1):45–8

Neural control of penile erection. Giuliano FA, et al. **Urol Clin North Am** 1995 Nov;22(4):747–66 (271 ref.)

Neurogenic erectile dysfunction: the course of nicotinamide adenine dinucleotide phosphate diaphorase–positive nerve fibers on the surface of the prostate. Zvara P, et al. **Urology** 1996 Jan;47(1):146–51

[Penile block. Block of ilio–inguinal and iliohypogastric nerves in children. Techniques, indications, advantages and adverse effects] Depret V. **Cah Anesthesiol** 1995; 43(3):299–303 (Eng. Abstr.) **(Fre)**

[Experimental approach to reflex erection in rats: modeling and functional neuroanatomy of the involved nerve pathways] Giuliano F, et al. **Prog Urol** 1996 Feb;6(1):81–6 (Eng. Abstr.) **(Fre)**

[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Pituitary adenylate cyclase–activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Hedlund P, et al. **Br J Pharmacol** 1995 Oct;116(4):2258–66

Hydrolysis of cyclic guanosine monophosphate and cyclic adenosine monophosphate by the penis and aorta of the diabetic rat. Miller MA, et al. **Br J Urol** 1996 Aug; 78(2):252–6

Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study. Miller MA, et al. **Int J Impot Res** 1995 Jun;7(2):91–100

Prostanoid production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. Daley JT, et al. **J Urol** 1996 Sep;156(3):1169–73

Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. Daley JT, et al. **J Urol** 1996 Apr;155(4):1482–7

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991–4

Identification of alpha 1–adrenergic receptor subtypes in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells. Traish AM, et al. **Receptor** 1995 Fall; 5(3):145–57

Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells. Traish AM, et al. **Receptor** 1995 Fall; 5(3):159–76

MICROBIOLOGY

In vitro fertilization failure associated with sperm contamination by Trichosporon beigelii. Baudraz–Rosselet F, et al. **J Assist Reprod Genet** 1995 Aug;12(7):455–7

PATHOLOGY

Preliminary reports on morphological and ultrastructural changes in the corpora cavernosa of the rat after chronic arterial obstruction. Siracusano S, et al. **Arch Esp Urol** 1996 Mar;49(2):191–5

The seed of an ulcer. Tayal SC, et al. **Genitourin Med** 1996 Jun;72(3):181

Application of the AgNOR method to distinguish pseudoepitheliomatous hyperplasia from squamous cell carcinoma. Sarda R, et al. **Indian J Cancer** 1995 Dec; 32(4):169–74

Elastic fibre concentration in the tunica albuginea of corpora cavernosa and nocturnal tumescence monitoring. Iacono F, et al. **Int J Impot Res** 1995 Jun;7(2):63–70

Canine mucosal leishmaniasis. Font A, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr;32(2):131–7

Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis [see comments] Chen RN, et al. **J Urol** 1996 Jan;155(1):138–40. Comment in: J Urol 1996 Jan;155(1):147.

Treatment of penile fibrosis with prosthetic implantation and flap advancement with tissue debulking. Knoll LD, et al. **J Urol** 1996 Aug;156(2 Pt 1):394–7

Cavernous oxygen tension and smooth muscle fibers: relation and function. Sattar AA, et al. **J Urol** 1995 Nov; 154(5):1736–9

Penile electromyography and its smooth muscle content: interpretation of 25 impotent patients. Sattar AA, et al. **J Urol** 1996 Mar;155(3):909–12

Penectomy in a diabetic patient on haemodialysis [letter] Verde E, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1487–8

Penile gangrene: a complication of penile prosthesis. Kardar A, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):355–6

Gangrene of the penis due to strangulation by a metallic ring. Osman M, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):77–8

Use of penile prosthetic implants in patients with penile fibrosis. Knoll LD. **Urol Clin North Am** 1995 Nov; 22(4):857–63

[Induratio penis plastica: the diagnostic possibilities of

gradient-echo sequences (magnetic resonance angiography)] Carriero A, et al. **Radiol Med (Torino)** 1996 Apr;91(4):429-33 (Eng. Abstr.) **(Ita)**

[Diagnostic magnetic resonance imaging (MRI) in fracture of the penis: a case report] Inoue K, et al. **Hinyokika Kiyo** 1996 Feb;42(2):139-41 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Corpus spongiosum penis pressure and perineal muscle activity during reflexive erections in the rat. Schmidt MH, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R904-13

Assessment and modeling of the physical components of human corporovenous function. Venegas JG, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H2109-23

The Adolescent Sexual Interest Card Sort: test-retest reliability and concurrent validity in relation to phallometric assessment. Hunter JA Jr, et al. **Arch Sex Behav** 1995 Oct;24(5):555-61

Criterion-related validity of a phallometric test for paraphilic rape and sadism. Seto MC, et al. **Behav Res Ther** 1996 Feb;34(2):175-83

Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium-conductive pathway. Seftel AD, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):382-7

Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Gupta S, et al. **Br J Pharmacol** 1995 Oct; 116(4):2201-6

Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Hedlund P, et al. **Br J Pharmacol** 1995 Oct;116(4):2258-66

Electrical activity of the corpus cavernosum in patients with corporal veno-occlusive dysfunction. Kayigil O, et al. **Br J Urol** 1996 Feb;77(2):261-5

Oxytocin-induced contractions of the rabbit corpus cavernosum. Tarhan F, et al. **Eur Urol** 1995;28(3):255-8

New method for direct stiffness measurement of the corpora cavernosa. Hatzichristou DG, et al. **Int J Impot Res** 1995 Dec;7(4):221-31

The peno-motor reflex: study of the response of the puborectalis and levator ani muscles to glans penis stimulation. Shafik A. **Int J Impot Res** 1995 Dec; 7(4):239-46

Mechanisms of veno-occlusion within and outside the canine corpus cavernosum penis using a pressure-flow technique and cavernoso-venography. Matsuzaka J, et al. **Int J Urol** 1996 Jan;3(1):47-53

Study of etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit. Azadzoi KM, et al. **J Urol** 1996 May;155(5):1795-800

The hemodynamic influence of the ischiocavernosus muscles on erectile function. Claes H, et al. **J Urol** 1996 Sep; 156(3):986-90

Neurogenic nitric oxide mediates relaxation of canine corpus cavernosum. Hayashida H, et al. **J Urol** 1996 Mar; 155(3):1122-7

In vitro contraction of the canine corpus cavernosum penis by direct perfusion with prolactin or growth hormone. Ra S, et al. **J Urol** 1996 Aug;156(2 Pt 1):522-5

Recording the corpus cavernosum electromyogram: principles and problems. Scheepe JR, et al. **J Urol** 1996 Jun;155(6):2074-9

Penile sensitivity in patients with primary premature ejaculation. Xin ZC, et al. **J Urol** 1996 Sep;156(3):979-81

Penile thermal sensation. Yarnitsky D, et al. **J Urol** 1996 Aug;156(2 Pt 1):391-3

Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure. Giuliano F, et al. **Neurosci Lett** 1996 May 3;209(1):1-4

Electrical and chemical control of smooth muscle activity of rabbit corpus cavernosum in vitro. Höppner CK, et al. **Urology** 1996 Sep;48(3):512-8

[Minor symptoms in family medicine; smegma and physiological phimosis] Koning M, et al. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1632-4 **(Dut)**

PHYSIOPATHOLOGY

Penile vibratory stimulation in spinal cord injured men: optimized vibration parameters and prognostic factors. Ohl DA, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):903-5

Altered contractility of rabbit penile corpus cavernosum smooth muscle by hypoxia. Kim NN, et al. **J Urol** 1996 Feb;155(2):772-8

Penile electromyography and its smooth muscle content: interpretation of 25 impotent patients. Sattar AA, et al. **J Urol** 1996 Mar;155(3):909-12

[Classification of patterns of nocturnal penile tumescence with continuous monitoring of penile rigidity: analysis of various factors affecting erection] Yasumoto R, et al. **Hinyokika Kiyo** 1996 Apr;42(4):285-8 (Eng. Abstr.) **(Jpn)**

[Male sexual dysfunction: neuroanatomy, neurophysiology and semiology] Singer C. **Rev Neurol** 1996 Jun; 24(130):664-5 (14 ref.) **(Spa)**

SURGERY

Corporeal plication for correction of penile curvature. Tay KP, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):708-10

Rectosigmoid neocolpopoiesis for male-to-female transsexuals: Amsterdam experience. Karim RB, et al. **Ann Plast Surg** 1996 Apr;36(4):388-91

A modified Bretteville technique for hypospadias. Moir GC, et al. **Br J Plast Surg** 1996 Jun;49(4):223-7

EMLA cream anaesthesia for frenuloplasty. Brough RJ, et al. **Br J Urol** 1995 Nov;76(5):653-4

Concepts in the surgical technique of one-stage hypospadias correction. Jospeh VT. **Br J Urol** 1995 Oct;76(4):504-9

Surgical management of preputial injuries in bulls: 51 cases (1986-1994). Desrochers A, et al. **Can Vet J** 1995 Sep; 36(9):553-6

Surgical management of the buried penis. Peng HC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):424-30

Urethral advancement, glanduloplasty and preputioplasty in distal hypospadias. Keramidas DC, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):348-51

Experience with repair of 120 hypospadias using Mathieu's procedure. Meyer-Junghänel L, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):355-7

Posterior hypospadias: the French operation. Monfort G, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):352-4

Penile dermal flap for defect reconstruction in Peyronie's disease: operative technique and four years' experience in 17 patients. Krishnamurti S. **Int J Impot Res** 1995 Dec; 7(4):195-208

Antiandrogens for penile surgery [letter; comment] Paulson JE, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1058-9. Comment on: J Am Acad Dermatol 1995 Jan;32(1):1-21; quiz 22-4.

Penoplasty for buried penis. Chuang JH. **J Pediatr Surg** 1995 Sep;30(9):1256-7

Penile replantation after self-inflicted complete amputation: case report. Ishida O, et al. **J Reconstr Microsurg** 1996 Jan;12(1):23-6

Surgical repair of fracture of the os penis in a dog. Kelly SE, et al. **J Small Anim Pract** 1995 Nov;36(11):507-9

A guide to safe corporotomy incisions in the presence of underlying inflatable penile cylinders: results of in vitro and in vivo studies [see comments] Hakim LS, et al. **J Urol** 1996 Mar;155(3):918-23. Comment in: J Urol 1996 Mar;155(3):924-5.

Treatment of penile fibrosis with prosthetic implantation and flap advancement with tissue debulking. Knoll LD, et al. **J Urol** 1996 Aug;156(2 Pt 1):394-7

Complete penile disassembly for epispadias repair: the Mitchell technique. Mitchell ME, et al. **J Urol** 1996 Jan; 155(1):300-4

Re: The surgical correction of buried penis: A new technique [letter; comment] Redman JF. **J Urol** 1996 Apr;155(4):1395 . Comment on: J Urol 1995 Aug;154(2 Pt 1):550-2.

Surgical management of ischemic penile gangrene in diabetics with end stage atherosclerosis. Weiner DM, et al. **J Urol** 1996 Mar;155(3):926-9

Complications of penile lengthening and augmentation seen at 1 referral center. Wessells H, et al. **J Urol** 1996 May; 155(5):1617-20

Prosthetic implantation after phallic construction. Alter GJ, et al. **Microsurgery** 1995;16(5):322-4

Ulnar forearm phallic construction and penile reconstruction. Gilbert DA, et al. **Microsurgery** 1995;16(5):314-21

Staged approach to phallic construction and penile reconstruction. Legaillard P, et al. **Microsurgery** 1995; 16(5):309-13

Penectomy in a diabetic patient on haemodialysis [letter] Verde E, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1487-8

An unusually avulsed penis successfully replanted by using microsurgical technique [letter] Fan J, et al. **Plast Reconstr Surg** 1996 Sep;98(3):571-3

Metaidoioplasty: an alternative phalloplasty technique in transsexuals. Hage JJ. **Plast Reconstr Surg** 1996 Jan; 97(1):161-7

Utilization of the breast for penile reconstruction in a transsexual [letter] Safak T, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1483-5

Penis reconstruction with an island composite flap of the deep inferior epigastric vascular pedicle [letter] Xiong S, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1083-4

Augmentation phalloplasty. Alter GJ. **Urol Clin North Am** 1995 Nov;22(4):887-902

Penile revascularization. Sharaby JS, et al. **Urol Clin North Am** 1995 Nov;22(4):821-32 (52 ref.)

Surgical treatment of penile veno-occlusive dysfunction: is it justified? Berardinucci D, et al. **Urology** 1996 Jan; 47(1):88-92

Dressing for surgical wounds of the penis. Bishoff JT, et al. **Urology** 1996 Feb;47(2):250-1

Penile orthoplasty using dermal grafts in the outpatient setting. Pope JC 4th, et al. **Urology** 1996 Jul;48(1):124-7

Surgical correction of a canine preputial deformity. Domínguez JC, et al. **Vet Rec** 1996 May 18;138(20):496-7

Surgical treatment of Peyronie's disease. Deirmenjian JM, et al. **West J Med** 1996 Apr;164(4):344

[Revascularization: light and shadow] Austoni E, et al. **Arch Ital Urol Androl** 1995 Dec;67(5):339-41 (Eng. Abstr.) **(Ita)**

[Surgical repair of congenital penile curvature] Malossini G, et al. **Chir Ital** 1994;46(6):86-90 (Eng. Abstr.) **(Ita)**

[Experience with one stage repair of hypospadias and chordee without hyposradias using free graft of prepuce] Hayashi Y, et al. **Hinyokika Kiyo** 1995 Dec;41(12):979-83 (Eng. Abstr.) **(Jpn)**

[The variants and potentials of reconstructive surgery of the penile skin] Dmitriev DG, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):39-44 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Reproducibility of penile arterial colour duplex ultrasonography. Mills RD, et al. **Br J Urol** 1996 Jul; 78(1):109-12

The effect of intracorporeal injection plus genital and audiovisual sexual stimulation versus second injection on penile color Doppler sonography parameters. Montorsi F, et al. **J Urol** 1996 Feb;155(2):536-40

ULTRASTRUCTURE

Three-dimensional architecture of collagen fibrils in the mouse corpus cavernosum penis. Nakano T. **Acta Anat (Basel)** 1995;152(3):215-23

Scanning electron microscopy of the tunica albuginea of the corpora cavernosa in normal and impotent subjects. Iacono F, et al. **Urol Res** 1995;23(4):221-6

VIROLOGY

Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. Bosch FX, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1060-7

Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. Muñoz N, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1068-75

PENIS, ARTIFICIAL see **PENILE PROSTHESIS**

PENSIONS

Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863-9 (66 ref.)

Changes in Canada pension plan disability rules hold implications for physicians. Romaniuk A. **Can Med Assoc J** 1995 Dec 15;153(12):1777-8

Demand for insurance by elderly persons: private purchases and employer provision. Shea DG, et al. **Health Econ** 1995 Jul-Aug;4(4):315-26

The World Bank, pensions, and income (in)security in the global south. Paul SS, et al. **Int J Health Serv** 1995; 25(4):697-726

Getting the most from your employee benefits: retirement plans. Goodyear JA. **J Am Pharm Assoc (Wash)** 1996 Jun; NS36(6):383-5

[Diagnosis and management of neurotic occupational disorders (before pension application)] Stevens A, et al. **Nervenarzt** 1995 Nov;66(11):811-9 (42 ref.) (Eng. Abstr.) **(Ger)**

[Reconstruction or amputation in complex fractures of the tibia. A comparative study with special reference to insurance medicine aspects] Ramseier EW, et al. **Swiss Surg** 1995;(2):103-6 (Eng. Abstr.) **(Ger)**

[Should a physician always be a physician? (letter)] Argren B. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1504 **(Nor)**

[Disability pensions because of musculoskeletal diseases among women of different occupations] Bjerkedal T, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3522-7 (Eng. Abstr.) **(Nor)**

[Sick women and men with disability pensions. Some reflections] Grünfeld B, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):988-9 (Eng. Abstr.) **(Nor)**

[Work, health and problems of pension security of locomotive team workers] Komenskii IuN, et al. **Gig Sanit** 1995 Sep-Oct;(5):35-6 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

The first year of hyperinflation in the former Soviet Union: nutritional deprivation among elderly pensioners, 1992 [see comments] Rush D, et al. **Am J Public Health** 1996 Mar; 86(3):361-7. Comment in: Am J Public Health 1996 Mar;86(3):299-301.

PENTACHLOROPHENOL

Use of a pentachlorophenol degrading bacterium to bioremediate highly contaminated soil. Colores GM, et al. **Appl Biochem Biotechnol** 1995 Jul-Sep;54(1-3):271-5

ADVERSE EFFECTS

Exposure to pentachlorophenol as a possible cause of miscarriages. de Maeyer J, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1010-1

Reduced birthweight and length in the offspring of females exposed to PCDFs, PCP, and lindane. Karmaus W, et al. **Environ Health Perspect** 1995 Dec;103(12):1120-5

Pentachlorophenol-induced oxidative DNA damage in mouse liver and protective effect of antioxidants. Sai-Kato K, et al. **Food Chem Toxicol** 1995 Oct;33(10):877-82

ANALYSIS

[Evaluation of wood preservative pollutants of indoor air] Liebl B, et al. **Gesundheitswesen** 1995 Aug-Sep;

57(8–9):476–88 (Eng. Abstr.) **(Ger)**

METABOLISM

Introduction of a de novo bioremediation activity into anaerobic granular sludge using the dechlorinating bacterium DCB–2. Christiansen N, et al. **Antonie Van Leeuwenhoek** 1996 Jan;69(1):61–6

Veratryl alcohol–mediated indirect oxidation of pentachlorophenol by lignin peroxidase. Chung N, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):143–8

Assessment of inhibition kinetics of the growth of strain P5 on pentachlorophenol under steady–state conditions in a nutristat. Rutgers M, et al. **Arch Microbiol** 1996 Mar; 165(3):194–200

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457–60 (39 ref.)

Verification of the role of PCP 4–monooxygenase in chlorine elimination from pentachlorophenol by Flavobacterium sp. strain ATCC 39723. Lange CC, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):146–9

Effects of copper–chrome–arsenate (CCA) components on PCP degradation by Arthrobacter strain ATCC 33790. Edgehill RU. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):258–63

Role of a laccase in the degradation of pentachlorophenol. Ricotta A, et al. **Bull Environ Contam Toxicol** 1996 Oct; 57(4):560–7

Study of the reductive dechlorination of pentachlorophenol by a methanogenic consortium. Juteau P, et al. **Can J Microbiol** 1995 Oct;41(10):862–8

Peroxidase–catalyzed oxidation of pentachlorophenol. Samokyszyn VM, et al. **Chem Res Toxicol** 1995 Apr–May; 8(3):349–55

Characterization of chlorinated adducts of hemoglobin and albumin following administration of pentachlorophenol to rats. Waidyanatha S, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):647–53

Pentachlorophenol accumulation in the freshwater mussels Anodonta anatina and Pseudanodonta complanata, and some physiological consequences of laboratory maintenance. Mäkelä TP, et al. **Chemosphere** 1995 Oct; 31(7):3651–62

PHARMACOKINETICS

Biodegradability simulation studies in semicontinuous activated sludge reactors with low (microgram/L range) and standard (ppm range) chemical concentrations. Berg UT, et al. **Chemosphere** 1996 Aug;33(4):711–35

Estimation of kinetic rate constants for biodegradation of chemicals in activated sludge wastewater treatment plants using short term batch experiments and microgram/L range spiked concentrations. Nyholm N, et al. **Chemosphere** 1996 Sep;33(5):851–64

[Pentachlorophenol—results of a Bavarian human monitoring program] Liebl B, et al. **Gesundheitswesen** 1996 Jun; 58(6):332–8 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Different heat–shock proteins are constitutively overexpressed in cadmium and pentachlorophenol adapted Euglena gracilis cells. Barque JP, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):7–11

Evidence from 32P–postlabeling and the use of pentachlorophenol for a novel metabolic activation pathway of diethylstilbestrol and its dimethyl ether in mouse live: likely alpha–hydroxylation of ethyl group(s) followed by sulfate conjugation. Moorthy B, et al. **Carcinogenesis** 1995 Nov;16(11):2643–8

Protein synthesis in cadmium– and pentachlorophenol–tolerant Euglena gracilis. Barque JP, et al. **Environ Res** 1995 Jul;70(1):70–4

TOXICITY

Mutagenic activity (Ames test) of wood–preserving waste sludge applied to soil. Barbee GC, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):54–62

Effects of pentachlorophenol and biotic interactions on soil fauna and decomposition in humus soil. Salminen J, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):250–7

Oxidative DNA damage and cell proliferation in the livers of B6C3F1 mice exposed to pentachlorophenol in their diet. Umemura T, et al. **Fundam Appl Toxicol** 1996 Apr; 30(2):285–9

Co–recombinogenic and anti–mutagenic effects of diethylhexylphthalate, inactiveness of pentachlorophenol in the spot test with mice. Fahrig R, et al. **Mutat Res** 1996 Jul 5;354(1):59–67

Influence of environmental adaptation on the sensitivity of micromycetes to pentachlorophenol toxicity in microcosms. Onochie–Okeke BC, et al. **New Microbiol** 1996 Jan;19(1):77–84

URINE

Pentachlorophenol levels in human urine. Thompson TS, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):520–6

Determination of pentachlorophenol in commercially prepared lyophilized human urine control samples. Treble RG, et al. **Chemosphere** 1996 Aug;33(4):693–7

PENTAERYTHRITOL TETRANICOTINATE see **NICERITROL**

PENTAERYTHRITOL TETRANITRATE

PHARMACOLOGY

Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Kojda G, et al. **Circ Res** 1996 Jan; 78(1):91–101

Exercise increases endothelin–1 plasma concentrations in patients with coronary artery disease: modulatory role of LDL cholesterol and of pentaerithrityltetranitrate. Predel HG, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S497–501

PENTAGASTRIN

see related
GASTROINTESTINAL AGENTS

ADMINISTRATION & DOSAGE

Low doses of pentagastrin stimulate gastric lipase secretion in man. Wøjdemann M, et al. **Scand J Gastroenterol** 1995 Jul;30(7):631–4

ANTAGONISTS & INHIBITORS

Inhibition of pentagastrin–induced pressor response in conscious rats by the CCK–B receptor antagonist CI–988 and chlordiazepoxide. Webb JK, et al. **Regul Pept** 1996 Jan 16;61(1):71–6

DIAGNOSTIC USE

Thyrotropin–releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment] Coupland N, et al. **Biol Psychiatry** 1996 Mar 15;39(6):465–6. Comment on: Biol Psychiatry 1994 Jul 15;36(2):73–83.

Salivary and gastric luminal release of epidermal growth factor under basal conditions and after pentagastrin stimulation in healthy subjects and in duodenal ulcer patients before and after eradication of Helicobacter pylori. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):187–94

[Clinical case of the month. Value of a pentagastrin test in the early detection of thyroid medullary cancer] Legros JJ, et al. **Rev Med Liege** 1995 Dec;50(12):499–500 **(Fre)**

PHARMACOLOGY

Pentagastrin increases pepsin secretion without increasing its fractional synthetic rate. Corbett ME, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E418–25

Pathways mediating pentagastrin–induced mucosal blood flow response in rat stomachs. Kato S, et al. **Dig Dis Sci** 1996 Mar;41(3):485–91

Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Harris AW, et al. **Gut** 1996 May; 38(5):663–7

Effect of graded doses of methysergide on basal and pentagastrin stimulated gastric secretion in anaesthetised rats. Goel RK, et al. **Indian J Exp Biol** 1996 Feb;34(2):115–7

The role of gastric histamine release in the acid secretory response to pentagastrin and methacholine in the dog. Gerber JG, et al. **Inflamm Res** 1995 Aug;44(8):327–34

The effect of beta andrenoceptor stimulation of canine stomach on pentagastrin–stimulated histamine release. Payne NA, et al. **J Pharmacol Exp Ther** 1996 Mar; 276(3):984–8

CCK–B receptor–mediated stimulation of polyphosphoinositide turnover in GH3 pituitary cells in response to cholecystokinin and pentagastrin. Smith AJ, et al. **Life Sci** 1996;58(11):883–95

Comparison of cholecystokinin, pentagastrin, and duodenal oleate in gastroprotection in rats. Konturek SJ, et al. **Scand J Gastroenterol** 1995 Jul;30(7):620–30

Pentagastrin selectively modulates levels of mRNAs encoding apical H/K adenosine triphosphatase and basolateral Na–K–Cl cotransporter in rat gastric fundic mucosa. Klingensmith ME, et al. **Surgery** 1996 Aug; 120(2):242–6; discussion 246–7

[Effects of pentagastrin with intracerebroventricular injection on blood pressure and heart rate in rats] Wang MJ, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):297–300 (Eng. Abstr.) **(Chi)**

[Effect of pentagastrin on the survival of allogenic grafts from fetal rat intestine] Coulic V, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):883–9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[Effect of pentagastrin in ulcer patients with postgastroresection syndrome] Vakhrushev IM, et al. **Klin Med (Mosk)** 1996;74(1):67 **(Rus)**

PENTAMETHYLENETETRAZOLE see **PENTYLENETETRAZOLE**

PENTAMIDINE

ADMINISTRATION & DOSAGE

Effects of aerosolized pentamidine on glucose homeostasis and insulin secretion in HIV–positive patients: a controlled study. Uzzan B, et al. **AIDS** 1995 Aug;9(8):901–7

An effectiveness community–based clinical trial of Respirgard II and Fisoneb nebulizers for Pneumocystis carinii prophylaxis with aerosol pentamidine in HIV–infected individuals. Toronto Aerosol Pentamidine Study (TAPS) Group. McIvor RA, et al. **Chest** 1996 Jul; 110(1):141–6

Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Saukkonen K, et al. **Chest** 1996 May;109(5):1250–5

The safety of i.v. pentamidine administered in an ambulatory setting. Yeung KT, et al. **Chest** 1996 Jul;110(1):136–40

Actual pentamidine dose delivered by Respigard II nebulizer. Kim CS, et al. **Eur Respir J** 1995 Dec;8(12):2178–81

Long–term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. Principi N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):158–63

Better efficacy of twice–monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1995 Sep; 31(2):99–105

[HIV–associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?] Ewig S, et al. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):83–9 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Effects of aerosolized pentamidine on glucose homeostasis and insulin secretion in HIV–positive patients: a controlled study. Uzzan B, et al. **AIDS** 1995 Aug;9(8):901–7

Suspected vein irritation from i.v. pentamidine isethionate [letter] Andersen JM. **Am J Health Syst Pharm** 1996 Jan 15;53(2):185

Pentamidine–induced hyperglycemia and ketosis in acquired immunodeficiency syndrome [letter] Lu CP, et al. **Pancreas** 1995 Oct;11(3):315–6

Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

Acute severe autonomic insufficiency during pentamidine therapy [letter] Siddiqui MA, et al. **South Med J** 1995 Oct; 88(10):1087–8

[An AIDS case of probable pentamidine–induced diabetic ketoacidosis and severe acute pancreatitis] Pae Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):226–30 **(Jpn)**

[Hypocalcemia and hypomagnesemia associated with the treatment with pentamidine in 2 patients with HIV infection (letter)] Cortés E, et al. **Med Clin (Barc)** 1996 May 11;106(18):717 **(Spa)**

ANALOGS & DERIVATIVES

Determination of receptor–bound drug conformations by QSAR using flexible fitting to derive a molecular similarity index. Montanari CA, et al. **J Comput Aided Mol Des** 1996 Feb;10(1):67–73

METABOLISM

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen–sensitive and –resistant Trypanosoma brucei brucei. Carter NS, et al. **J Biol Chem** 1995 Nov 24; 270(47):28153–7

PHARMACOKINETICS

Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Basselin M, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):631–4

Pentamidine concentrations in a mother with AIDS and in her neonate [letter] Schwebke K, et al. **Clin Infect Dis** 1995 Jun;20(6):1569–70

Pharmacokinetic interaction between intravenous 2',3'–dideoxyinosine and pentamidine in rats. Yeh TK, et al. **Pharm Res** 1996 Apr;13(4):628–32

PHARMACOLOGY

Enhanced efficacy of a liposomal pentamidine preparation in Pneumocystis carinii in an ex vivo/in vitro culture model without feederlayer cells. Sahm M, et al. **Appl Parasitol** 1996 Jun;37(2):137–45

Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Moreno SN. **Arch Biochem Biophys** 1996 Feb 1;326(1):15–20

Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. Calonge M, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):835–41

Modification of the recognition of restriction sites of plasmid DNA by the antitumor drug Pt-pentamidine. Pérez JM, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):851-6

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Carter NS, et al. **J Biol Chem** 1995 Nov 24; 270(47):28153-7

Gel electrophoretic analysis of cellular and secreted proteins from resting and activated rat alveolar macrophages treated with pentamidine isethionate. Selkirk JK, et al. **J Chromatogr A** 1995 Sep 22;711(2):331-7

Pentamidine does not interfere with nitrite formation in activated RAW 264.7 macrophages but inhibits constitutive brain nitric oxide synthase. Baer HP, et al. **Life Sci** 1995; 57(21):1973-80

Effects of cationic diamidines on polyamine metabolism in the trypanosomatid Crithidia fasciculata. Calonge MM, et al. **Life Sci** 1996;59(12):PL191-7

Correlation between inhibition of growth and arginine transport of Leishmania donovani promastigotes in vitro by diamidines. Kandpal M, et al. **Life Sci** 1996; 59(7):PL75-80

A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Barrett MP, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1-2):223-9

Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Cox D, et al. **Thromb Haemost** 1996 Mar; 75(3):503-9

THERAPEUTIC USE

A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ioannidis JP, et al. **Arch Intern Med** 1996 Jan 22;156(2):177-88

The effect of prophylaxis on the outcome of HIV-associated Pneumocystis carinii pneumonia [letter; comment] Ewig S. **Chest** 1996 Feb;109(2):586-7. Comment on: Chest 1995 Apr;107(4):1018-23.

Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B [letter] Mishra M. **J Assoc Physicians India** 1995 Apr;43(4):306

Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1996 Mar; 32(2):123-31

Treatment of kala azar [letter] Ozsoylu S. **Lancet** 1996 Jun 15;347(9016):1701

Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Lustig V, et al. **Neth J Med** 1995 Aug; 47(2):66-9

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Nielsen TL, et al. **Scand J Infect Dis** 1995;27(3):217-20

Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Pépin J, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):183-6

[Extra-pulmonary pneumocystosis in the course of AIDS. Report of a case] Terris B, et al. **Ann Pathol** 1996;16(1):41-4 (Eng. Abstr.) **(Fre)**

URINE

Metabolism is an important route of pentamidine elimination in the rat: disposition of 14C-pentamidine and identification of metabolites in urine using liquid chromatography-tandem mass spectrometry. Bronner U, et al. **Pharmacol Toxicol** 1995 Aug;77(2):114-20

PENTAMIDINE ISETHIONATE see PENTAMIDINE

PENTANES

ANALYSIS

Breath pentane and plasma lipid peroxides in ischemic heart disease. Mendis S, et al. **Free Radic Biol Med** 1995 Nov; 19(5):679-84

Expired hydrocarbons in patients with acute myocardial infarction. Mendis S, et al. **Free Radic Res** 1995 Aug; 23(2):117-22

METABOLISM

Effect of cigarette smoking on pentane excretion in alveolar breath. Euler DE, et al. **Clin Chem** 1996 Feb;42(2):303-8

Monitoring of exposure to methylpentanes by diffusive sampling and urine analysis for alcoholic metabolites. Kawai T, et al. **Occup Environ Med** 1995 Nov; 52(11):757-63

PENTANOATES see VALERATES

PENTANOIC ACIDS

ADMINISTRATION & DOSAGE

Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats. Okumura Y, et al. **J Gastroenterol** 1995 Aug;30(4):493-9

ADVERSE EFFECTS

Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age. Abrahamsson K, et al. **Biochem Mol Med** 1995 Jun;55(1):77-9

Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid. Abrahamsson K, et al. **Br Heart J** 1995 Dec; 74(6):656-9

BLOOD

Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric analysis of glycine conjugates and urinary isovalerylglycine in isovaleric acidemia. Ito T, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18; 670(2):317-22

Isovaleric acidemia appearing as diabetic ketoacidosis. Attia N, et al. **J Inherit Metab Dis** 1996;19(1):85-6

Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. Fries MH, et al. **J Pediatr** 1996 Sep;129(3):449-52

Lessons from the late diagnosis of isovaleric acidemia in a five-year-old boy. Mehta KC, et al. **J Pediatr** 1996 Aug; 129(2):309-10

CHEMICAL SYNTHESIS

Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability. Lehr P, et al. **J Med Chem** 1996 May 10;39(10):2060-7

CHEMISTRY

Decomposition of interaction free energies in proteins and other complex systems. Brady GP, et al. **J Mol Biol** 1995 Nov 17;254(1):77-85

METABOLISM

Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs. Mizojiri K, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1445-53

The genetic basis for specific anosmia to isovaleric acid in the mouse. Griff IC, et al. **Cell** 1995 Nov 3;83(3):407-14

PHARMACOLOGY

Carnitine depletion in rat pups of lactating mothers given sodium pivalate. Davis AT. **Biol Neonate** 1995;68(3):211-20

Preferential dilation of large coronary microvessels by the mononitrates SPM-4744 and SPM-5185. Wang SY, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):587-93

Pivalate affects carnitine status but causes no severe metabolic changes in rat liver. Nakajima H, et al. **J Nutr** 1996 Jun;126(6):1683-7

2-Heteroaryl 2-substituted phenylketone derivatives and their inhibitory activity on platelet aggregation. Hsu LY, et al. **J Pharm Pharmacol** 1995 Sep;47(9):762-7

Cholecystokinin-A specific antagonism of KSG-504 to cholecystokinin receptor binding and pancreatic secretion in mammals. Yamazaki Y, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):367-73

Sodium pivalate reduces cardiac carnitine content and increases glucose oxidation without affecting cardiac functional capacity. Morris GS, et al. **Life Sci** 1995; 57(24):2237-44

[Behavioral studies of KSG-504, a new CCK-A receptor antagonist] Yamazaki Y, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):21-31 (Eng. Abstr.) **(Jpn)**

[Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions] Yamazaki Y, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):33-44 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. van der Wieken LR, et al. **Int J Cardiol** 1995 Nov 24;52(2):125-34

[Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice] Kobayashi M, et al. **Nippon Yakurigaku Zasshi** 1996 Apr;107(4):183-95 (Eng. Abstr.) **(Jpn)**

TOXICITY

Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Tang W, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):671-82

PENTANOLS see ALCOHOLS, AMYL

PENTANONES

ADMINISTRATION & DOSAGE

Central neurotoxicity induced by subchronic exposure to 2,4-pentanedione vapour. Garman RH, et al. **Hum Exp Toxicol** 1995 Aug;14(8):662-71

CHEMISTRY

Photochemistry of acetylenic ketones in micellar solutions as studied by product-yield-detected ESR and transient absorption techniques. Polyakov NE, et al. **Photochem Photobiol** 1995 Jun;61(6):545-51

PHARMACOLOGY

Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Haramaki N, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):839-43

Enhanced sensitivity to androstenone following regular exposure to pemenone. Stevens DA, et al. **Chem Senses** 1995 Aug;20(4):413-9

TOXICITY

Central neurotoxicity induced by subchronic exposure to 2,4-pentanedione vapour. Garman RH, et al. **Hum Exp Toxicol** 1995 Aug;14(8):662-71

PENTANUCLEOTIDE REPEATS see MICROSATELLITE REPEATS

PENTAZOCINE

[Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia] Lipp M, et al. **Anaesthesist** 1995 Aug;44(8):566-72 (Eng. Abstr.) **(Ger)**

METABOLISM

Chronic postnatal phencyclidine treatment on [3H](+) pentazocine binding in juvenile rat brain. Sircar R, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):224-6

PENTETATES see DTPA

PENTETRAZOLE see PENTYLENETETRAZOLE

PENTHANIL see DTPA

PENTHIOBARBITAL see THIOPENTAL

PENTOBARBITAL

Neurosteroidal modulation of social isolation-induced decrease in pentobarbital sleep in mice. Matsumoto K, et al. **Brain Res** 1996 Feb 5;708(1-2):1-6

Assessment of the effect of head and neck position on upper airway anatomy in sedated paediatric patients using magnetic resonance imaging. Shorten GD, et al. **Paediatr Anaesth** 1995;5(4):243-8

[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat] Nabeshima A, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):265-74 (Eng. Abstr.) **(Jpn)**

[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat. II: Strain differences between Lewis and Wistar-Kyoto rats] Nabeshima A, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug; 15(4):345-53 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Pentobarbital therapy for status epilepticus in children: timing of tapering. Kinoshita H, et al. **Pediatr Neurol** 1995 Sep; 13(2):164-8

Determination of cardiorespiratory function and the optimum anesthetic regimen during laparoscopic surgery in the rat model. Dalton M, et al. **Surg Endosc** 1996 Mar; 10(3):297-300

ADVERSE EFFECTS

Region-specific changes in GABAA receptor delta subunit mRNA level by tolerance to and withdrawal from pentobarbital. Lin LH, et al. **Neurosci Lett** 1996 Jan 5; 202(3):149-52

Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Levy ML, et al. **Neurosurgery** 1995 Aug;37(2):363-9; discussion 369-71

ANALYSIS

Selecting an appropriate isotopic internal standard for gas chromatography/mass spectrometry analysis of drugs of abuse--pentobarbital example. Liu RH, et al. **J Forensic Sci** 1995 Nov;40(6):983-9

ANTAGONISTS & INHIBITORS

[Montirelin hydrate (NS-3), a TRH analog, improved the disturbance of consciousness caused by head concussion

and pentobarbital in mice] Mushiroi T, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):237–45 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental [see comments] Nguyen KT, et al. **Anesth Analg** 1996 Sep;83(3):552–8. Comment in: Anesth Analg 1996 Sep;83(3):447–50.

Influence of antemortem medication on the determination of brain death. Saito T, et al. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):484–7

PHARMACOLOGY

Inhibition of a fast inwardly rectifying potassium conductance by barbiturates. Gibbons SJ, et al. **Anesth Analg** 1996 Jun;82(6):1242–6

Pentobarbital enhances cyclic adenosine monophosphate production in the brain by effects on neurons but not glia. Gonzales JM, et al. **Anesthesiology** 1996 May;84(5):1148–55

Effects of hypothermia, pentobarbital, and isoflurane on postdepolarization amino acid release during complete global cerebral ischemia. Nakashima K, et al. **Anesthesiology** 1996 Jul;85(1):161–8

Electroencephalographic burst suppression is not required to elicit maximal neuroprotection from pentobarbital in a rat model of focal cerebral ischemia. Warner DS, et al. **Anesthesiology** 1996 Jun;84(6):1475–84

Mechanism of inhibition of the plasma membrane Ca(2+)-ATPase by barbiturates. Kosk-Kosicka D, et al. **Biochemistry** 1996 Jan 23;35(3):900–5

Pharmacokinetic and pharmacodynamic studies of centrally acting drugs in rat: effect of pentobarbital and chlorpromazine on electroencephalogram in rat. Sato S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1094–103

Hyperactivity of central noradrenergic and CRF systems is involved in social isolation-induced decrease in pentobarbital sleep. Ojima K, et al. **Brain Res** 1995 Jun 26;684(1):87–94

An autoradiographic study of [3H]flunitrazepam binding sites in the brain of rat made tolerant to and dependent on pentobarbital. Suzuki T, et al. **Eur J Pharmacol** 1996 Jan 11;295(2–3):169–79

Pentobarbitone induces Fos in astrocytes: increased expression following picrotoxin and seizures. Hiscock JJ, et al. **Exp Neurol** 1996 May;139(1):115–20

The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the alpha 2 subunit. Yamakura T, et al. **FEBS Lett** 1995 Nov 6;374(3):412–4

Pentobarbital differentially inhibits N-methyl-D-aspartate and kainate-stimulated [3H]noradrenaline overflow in rat cortical slices. Brown LM. **Gen Pharmacol** 1995 Nov; 26(7):1603–6

Pentobarbital modulatory effect on GABA binding sites in developing chick optic lobe. Fiszer de Plazas S, et al. **Int J Dev Neurosci** 1995 Dec;13(8):783–9

Role of pentobarbitone anaesthesia and sympathetic tone in the haemodynamic effects of isosorbide dinitrate in rats with cirrhosis. Kirstetter P, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):230–5

Effects of drug discrimination history on the generalization of pentobarbital to other drugs. McMillan DE, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):50–61

Effects of chronic pentobarbital treatment on the GABAA receptor complex in mammalian cortical neurons. Yu R, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1442–6

Region-specific changes in GABAA receptor delta subunit mRNA level by tolerance to and withdrawal from pentobarbital. Lin LH, et al. **Neurosci Lett** 1996 Jan 5; 202(3):149–52

Does barbiturate anesthesia modify the neuronal properties of the somatosensory thalamus? A single-unit study related to nociception in the awake-pentobarbital-treated rat. Montagne-Clavel J, et al. **Neurosci Lett** 1995 Aug 18; 196(1–2):69–72

Effects of morphine, pentobarbital and amphetamine on formalin-induced behaviours in infant rats: sedation versus specific suppression of pain. Abbott FV, et al. **Pain** 1995 Sep;62(3):303–12

Effect of drugs on chemoreceptor responsiveness in fetal sheep. Boekkooi PF, et al. **Pediatr Res** 1995 Dec; 38(6):938–43

Tolerance to the anticonvulsant and ataxic effects of pentobarbital: effect of an ascending-dose regimen. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):825–9

Effects of majonoside-R2 on pentobarbital sleep and gastric lesion in psychologically stressed mice. Nguyen TT, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):957–63

Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Agmo A, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):186–94

Effect of pentobarbital anesthesia on the pressor response to agonists in vivo in normal and endotoxemic rats. Hauser GJ, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov; 90(2):289–300

Changes in pentobarbital induced sleeping-time in mice infected with Schistosoma mansoni and immunosuppressed. Tonelli SM, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar-Apr;37(2):149–53

Chronic pentobarbital administration alters gamma-aminobutyric acidA receptor alpha 6-subunit mRNA levels and diazepam-insensitive [3H]Ro15-4513 binding. Ito T, et al. **Synapse** 1996 Feb;22(2):106–13

Mechanism of prolongation of pentobarbital-induced sleeping time by empenthrin in mice. Tsuji R, et al. **Toxicology** 1996 Apr 30;108(3):185–90

POISONING

Hemodiafiltration in pentobarbital poisoning. Bironneau E, et al. **Ren Fail** 1996 Mar;18(2):299–303 (11 ref.)

THERAPEUTIC USE

Therapeutic Intervention Scoring System used in the care of patients in pentobarbital-induced coma to determine nurse-patient ratios. Myles GL, et al. **Am J Crit Care** 1996 Jan;5(1):74–9

Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Krishnamurthy KB, et al. **Epilepsia** 1996 Sep;37(9):863–7

TOXICITY

Quantification of the hemolysis associated with use of T-61 as a euthanasia agent in rabbits--a comparison with Euthanyl (pentobarbital sodium) and the impact on serum hexosaminidase measurements. Doughty MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1274–80

PENTOSAN POLYSULFATE see PENTOSAN SULFURIC POLYESTER

PENTOSAN SULFURIC POLYESTER

ADMINISTRATION & DOSAGE

Systemic use of pentosan polysulphate in the treatment of osteoarthritis. Read RA, et al. **J Small Anim Pract** 1996 Mar;37(3):108–14

ADVERSE EFFECTS

Pentosan polysulfate-induced thrombocytopenia: a case diagnosed with an ELISA test used for heparin-induced thrombocytopenia. Gironell A, et al. **Ann Hematol** 1996 Jul;73(1):51–2

Phase I trial of pentosan polysulfate. Swain SM, et al. **Invest New Drugs** 1995;13(1):55–62

METABOLISM

Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis. Ghosh P, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):43–53

PHARMACOLOGY

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. McLeskey SW, et al. **Br J Cancer** 1996 May; 73(9):1053–62

Effect on sperm-induced activation current and increase of cytosolic Ca2+ by agents that modify the mobilization of [Ca2+]i. I. Heparin and pentosan polysulfate. Mohri T, et al. **Dev Biol** 1995 Nov;172(1):139–57

Influence of sodium pentosan polysulphate and certain inhibitors on calcium oxalate crystal growth. Senthil D, et al. **Mol Cell Biochem** 1996 Mar 9;156(1):31–5

Sulfated polysaccharide anticoagulants suppress natural killer cell activity in vitro. Johann S, et al. **Thromb Haemost** 1995 Oct;74(4):998–1002

THERAPEUTIC USE

Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium. Barrington JW, et al. **Br J Urol** 1996 Jul;78(1):54–6

PENTOSE PHOSPHATE SHUNT see PENTOSEPHOSPHATE PATHWAY

PENTOSE SHUNT see PENTOSEPHOSPHATE PATHWAY

PENTOSEPHOSPHATE PATHWAY

Single-run separation and detection of multiple metabolic intermediates by anion-exchange high-performance liquid chromatography and application to cell pool extracts prepared from Escherichia coli. Bhattacharya M, et al. **Anal Biochem** 1995 Nov 20;232(1):98–106

Oxidative damage to RBC membranes and pentose phosphate shunt activity in hemodialysis patients after suspension of erythropoietin treatment. Taccone-Galluci M, et al. **ASAIO J** 1994 Jul-Sep;40(3):M663–6

Hereditary red cell enzymopathies. Arya R, et al. **Blood Rev** 1995 Sep;9(3):165–75 (155 ref.)

Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7–10 (27 ref.)

Involvement of the oxidative pentose phosphate pathway in thiamine biosynthesis in Salmonella typhimurium. Enos-Berlage JL, et al. **J Bacteriol** 1996 Mar;178(5):1476–9

Transcriptional glucose signaling through the glucose response element is mediated by the pentose phosphate pathway. Doiron B, et al. **J Biol Chem** 1996 Mar 8; 271(10):5321–4

DRUG EFFECTS

Correlation between glutathione and stimulation of the pentose phosphate cycle in situ in Chinese hamster ovary cells exposed to hydrogen peroxide. Przybytkowski E, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):91–8

The effect of phenazine methosulphate on intermediary pathways of glucose metabolism in the lens at different glycaemic levels. Muirhead RP, et al. **Exp Eye Res** 1995 Nov;61(5):619–27

Response of the rat heart to catecholamines and thyroid hormones. Zimmer HG, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):105–14

GENETICS

The molecular regulation of the reductive pentose phosphate pathway in Proteobacteria and Cyanobacteria. Gibson JL, et al. **Arch Microbiol** 1996 Sep;166(3):141–50 (69 ref.)

Expression of the cbbLcbbS and cbbM genes and distinct organization of the cbb Calvin cycle structural genes of Rhodobacter capsulatus. Paoli GC, et al. **Arch Microbiol** 1995 Dec;164(6):396–405

Genetics of pentose-phosphate pathway enzymes of Escherichia coli K-12. Sprenger GA. **Arch Microbiol** 1995 Nov;164(5):324–30 (47 ref.)

Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. Pandolfi PP, et al. **EMBO J** 1995 Nov 1;14(21):5209–15

PHYSIOLOGY

Qualitative analysis of biochemical reaction systems. Reddy VN, et al. **Comput Biol Med** 1996 Jan;26(1):9–24

The modulation of the oxidative phase of the pentose phosphate pathway in mouse liver. Velasco P, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1015–9

Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. Ben-Yoseph O, et al. **J Neurochem** 1996 Jun;66(6):2329–37

[The biorhythmology of primary and superinvasive opisthorchiasis. Seasonal changes in the circadian activity of the cyclic nucleotides and of the key enzyme of the pentosephosphate cycle (G-6-PD) in the peripheral blood of golden hamsters] Shkliar DG, et al. **Parazitologiia** 1995 Jul-Aug;29(4):298–304 (Eng. Abstr.) **(Rus)**

PENTOSEPHOSPHATES

CHEMISTRY

Large structures at high resolution: the 1.6 A crystal structure of spinach ribulose-1,5-bisphosphate carboxylase/oxygenase complexed with 2-carboxyarabinitol bisphosphate. Andersson I. **J Mol Biol** 1996 May 31;259(1):160–74

METABOLISM

A mechanism of regulation of hepatic Fru 2,6-P2 concentration upon refeeding: involvement of xylulose 5-P and cyclic-AMP. Liu YQ, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):554–8

2-Carboxyarabinitol 1-phosphate (CA1P) formation through a phosphate exchange reaction catalysed by the CA1P phosphatase from French bean (Phaseolus vulgaris L.). Andralojc PJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):389–93

Different location in dark-adapted leaves of Phaseolus vulgaris of ribulose-1,5-bisphosphate carboxylase/oxygenase and 2-carboxyarabinitol 1-phosphate. Anwaruzzaman, et al. **FEBS Lett** 1996 Jun 17;388(2-3):223–7

A mechanism for fatty acid inhibition of glucose utilization in liver. Role of xylulose 5-P. Liu YQ, et al. **J Biol Chem** 1996 Apr 12;271(15):8824–30

PHARMACOLOGY

Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Nishimura M, et al. **J Biol Chem** 1995 Nov 3;270(44):26341–6

PENTOSES

ANALYSIS

Chemistry of the lyxose-containing mycobacteriophage receptors of Mycobacterium phlei/Mycobacterium smegmatis. Khoo KH, et al. **Biochemistry** 1996 Sep 10; 35(36):11812–9

PENTOSTATIN

ADMINISTRATION & DOSAGE

Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Monfardini S, et al. **Oncology** 1996 Mar-Apr;53(2):163-8

[Successful combination chemotherapy including deoxycoformycin in a case of cutaneous T cell lymphoma] Kodama K, et al. **Rinsho Ketsueki** 1996 Jan;37(1):65-71 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case. Sakai C, et al. **Intern Med** 1995 Jun;34(6):593-6

PHARMACOLOGY

Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Golembiowska K, et al. **Brain Res** 1995 Nov 20; 699(2):315-20

Apoptosis induction with purine analogs on freshly isolated chronic myeloid leukemia cells [letter] Zinzani PL, et al. **Haematologica** 1995 Jul-Aug;80(4):390-1

Theoretical study of inhibition of adenosine deaminase by (8R)-coformycin and (8R)-deoxycoformycin. Marrone TJ, et al. **J Med Chem** 1996 Jan 5;39(1):277-84

THERAPEUTIC USE

Optimal treatment for untreated patients with hairy cell leukemia? [letter; comment] Troussard X, et al. **J Clin Oncol** 1995 Oct;13(10):2677-9. Comment on: J Clin Oncol 1995 Apr;13(4):974-82.

Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. McCowage GB, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):154-8

Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Gidday JM, et al. **Pediatr Res** 1995 Sep;38(3):306-11

PENTOSYLTRANSFERASES

ANTAGONISTS & INHIBITORS

In vivo immunosuppressive effect and the decreasing expression of MHC class II antigens by purine nucleoside phosphorylase inhibitor 8-amino-9-benzylguanine in recipient tissues of canine renal allograft rejection. Yen CY, et al. **J Surg Res** 1996 May;62(2):260-6

CHEMISTRY

X-ray absorption spectroscopy of the zinc site in tRNA-guanine transglycosylase from Escherichia coli. Garcia GA, et al. **Biochemistry** 1996 Mar 5;35(9):3133-9

Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: identification of His-219 as site of phosphorylation. Gross J, et al. **Biochemistry** 1996 Apr 2;35(13):3917-24

Limited proteolysis of Salmonella typhimurium nicotinic acid phosphoribosyltransferase reveals ATP-linked conformational change. Rajavel M, et al. **Biochemistry** 1996 Apr 2;35(13):3909-16

Crystal structure of the hypoxanthine-guanine-xanthine phosphoribosyltransferase from the protozoan parasite Tritrichomonas foetus. Somoza JR, et al. **Biochemistry** 1996 Jun 4;35(22):7032-40

Uracil phosphoribosyltransferase from the extreme thermoacidophilic archaebacterium Sulfolobus shibatae is an allosteric enzyme, activated by GTP and inhibited by CTP. Linde L, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):16-22

Active site amino acids that participate in the catalytic mechanism of nucleoside 2'-deoxyribosyltransferase. Short SA, et al. **J Biol Chem** 1996 Mar 1;271(9):4978-87

GENETICS

The sequencing expression, purification, and steady-state kinetic analysis of quinolinate phosphoribosyl transferase from Escherichia coli. Bhatia R, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):270-8

Cloning and characterization of cDNA encoding the rabbit tRNA-guanine transglycosylase 60-kilodalton subunit. Deshpande KL, et al. **Arch Biochem Biophys** 1996 Feb 1; 326(1):1-7

Halovibrin, secreted from the light organ symbiont Vibrio fischeri, is a member of a new class of ADP-ribosyltransferases. Reich KA, et al. **J Bacteriol** 1996 Jan;178(1):209-15

Selectable insertion and deletion mutagenesis of the human cytomegalovirus genome using the Escherichia coli guanosine phosphoribosyl transferase (gpt) gene. Greaves RF, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2151-60

[The characteristics of homologous DNA recombination in somatic cells. III. Intrachromosomal recombinations of the aminoglycoside phosphoribosyltransferase gene in transgenic mice] Shvemberger IN, et al. **Tsitologiia** 1996; 38(3):378-83 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Purification and characterization of the bifunctional CobU enzyme of Salmonella typhimurium LT2. Evidence for a CobU-GMP intermediate. O'Toole GA, et al. **J Biol Chem** 1995 Oct 6;270(40):23560-9

METABOLISM

The sequencing expression, purification, and steady-state kinetic analysis of quinolinate phosphoribosyl transferase from Escherichia coli. Bhatia R, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):270-8

Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii. Naguib FN, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1685-93

X-ray absorption spectroscopy of the zinc site in tRNA-guanine transglycosylase from Escherichia coli. Garcia GA, et al. **Biochemistry** 1996 Mar 5;35(9):3133-9

Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: identification of His-219 as site of phosphorylation. Gross J, et al. **Biochemistry** 1996 Apr 2;35(13):3917-24

tRNA-guanine transglycosylase from Escherichia coli: structure-activity studies investigating the role of the aminomethyl substituent of the heterocyclic substrate PreQ1. Hoops GC, et al. **Biochemistry** 1995 Nov 21; 34(46):15381-7

Mechanism-based inactivation of tRNA-guanine transglycosylase from Escherichia coli by 2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4 (3H)-one. Hoops GC, et al. **Biochemistry** 1995 Nov 28; 34(47):15539-44

Limited proteolysis of Salmonella typhimurium nicotinic acid phosphoribosyltransferase reveals ATP-linked conformational change. Rajavel M, et al. **Biochemistry** 1996 Apr 2;35(13):3909-16

Uracil phosphoribosyltransferase from the extreme thermoacidophilic archaebacterium Sulfolobus shibatae is an allosteric enzyme, activated by GTP and inhibited by CTP. Linde L, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):16-22

Probing the active site of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase using covalent modification of cysteine residues. Kanaani J, et al. **Eur J Biochem** 1996 Aug 1;239(3):764-72

Characterization of guanine and hypoxanthine phosphoribosyltransferases in Methanococcus voltae. Bowen TL, et al. **J Bacteriol** 1996 May;178(9):2521-6

Active site amino acids that participate in the catalytic mechanism of nucleoside 2'-deoxyribosyltransferase. Short SA, et al. **J Biol Chem** 1996 Mar 1;271(9):4978-87

[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations] Fukada D, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):703-6 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Regulation of exocytosis by the small GTP-binding protein Rho in rat basophilic leukemia (RBL-2H3) cells. Yonei SG, et al. **Gen Pharmacol** 1995 Nov;26(7):1583-9

ULTRASTRUCTURE

Crystal structure of tRNA-guanine transglycosylase: RNA modification by base exchange. Romier C, et al. **EMBO J** 1996 Jun 3;15(11):2850-7

PENTOXIFYLLINE

ADMINISTRATION & DOSAGE

Pentoxifylline in flush solution improves early lung allograft function. Yamashita M, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1055-61

Effect of pentoxifylline on patch test response. Balato N, et al. **Contact Dermatitis** 1996 Feb;34(2):153

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385-91 (39 ref.)

Optimal dose and duration of exposure to artificial stimulants in cryopreserved human spermatozoa. Sharma RK, et al. **J Urol** 1996 Feb;155(2):568-73

ADVERSE EFFECTS

Pentoxifylline-induced acute hepatitis [letter] Sáez-Royuela F, et al. **J Hepatol** 1995 Oct;23(4):482-4

ANALOGS & DERIVATIVES

Effects on complement activation and cytokine (TNF-alpha and IL-8) release of infusion of anti-TNF-antibodies or a xanthine derivative (HWA 138) in septic baboons. Bengtsson A, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):244-9

Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Clarke E, et al. **Cancer Res** 1996 Jan 1;56(1):105-12

Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat. Marzi I, et al. **J Trauma** 1996 Jan; 40(1):90-6

Amelioration of endotoxin-induced acute lung injury in pigs by HWA 138 and A 80 2715: new analogs of pentoxifylline. Hoffmann H, et al. **Shock** 1995 Sep;4(3):166-70

Prolongation of discordant cardiac xenotransplantation survival by Lisofylline, a phosphatidic acid inhibitor. Aziz S, et al. **Transplant Proc** 1996 Apr;28(2):740

Perioperative treatment with phosphatidic acid inhibitor (Lisofylline leads to prolonged survival of hearts in the guinea pig to rat xenotransplant model. Valdivia LA, et al. **Transplant Proc** 1996 Apr;28(2):738-9

METABOLISM

Hemorrheologic effects of metabolites of pentoxifylline (Trental). Ambrus JL, et al. **J Med** 1995;26(1-2):65-75

PHARMACOLOGY

Effects of pentoxifyllin and PentaglobinO on TNF and IL-6 production in septic patients. Mándi Y, et al. **Acta Microbiol Immunol Hung** 1995;42(3):301-8

Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. Navarro J, et al. **AIDS** 1996 May;10(5):469-75

A randomized, placebo-controlled, double-blind crossover study of the effect of pentoxifylline on ocular fundus pulsations [letter; comment] Mackay CJ. **Am J Ophthalmol** 1996 Aug;122(2):282-3. Comment on: Am J Ophthalmol 1996 Feb;121(2):169-76.

A randomized, placebo-controlled, double-blind crossover study of the effect of pentoxifylline on ocular fundus pulsations [see comments] Schmetterer L, et al. **Am J Ophthalmol** 1996 Feb;121(2):169-76. Comment in: Am J Ophthalmol 1996 Aug;122(2):282-3.

The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Boldt J, et al. **Anaesthesia** 1996 Jun;51(6):529-35

The effects of pentoxifylline on the generation of reactive oxygen species and lipid peroxidation in human spermatozoa. McKinney KA, et al. **Andrologia** 1996 Jan-Feb;28(1):15-20

Influence of pentoxifylline and its derivatives on antibiotic uptake and superoxide generation by human phagocytic cells. Hand WL, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1574-9

Effect of pentoxifylline added to freezing media on subsequent post-thaw hypoosmotic swelling test and other semen parameters. Check DJ, et al. **Arch Androl** 1995 Nov-Dec;35(3):161-3

Pentoxifylline attenuates pulmonary macromolecular leakage after intestinal ischemia-reperfusion. Carter MB, et al. **Arch Surg** 1995 Dec;130(12):1337-44

Modulation of sperm membrane conformation by pentoxifylline in oligospermia: a biophysical investigation of sperm membrane in vitro. Nivsarkar M, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):791-5

Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptors. Peterson TC. **Biochem Pharmacol** 1996 Aug 23; 52(4):597-602

Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts. Windmeier C, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):577-84

Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. Robertson FM, et al. **Carcinogenesis** 1996 Aug;17(8):1719-28

Pentoxifylline ameliorates pulmonary damage caused by Streptococcus pneumoniae infection in mouse. Cui X, et al. **Chin Med J (Engl)** 1995 Nov;108(11):864-9

Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. Soupison T, et al. **Clin Sci (Colch)** 1996 Jul; 91(1):29-33

Analysis of responses to pentoxifylline in the pulmonary vascular bed of the cat. Kaye AD, et al. **Crit Care Med** 1996 Feb;24(2):263-7

Effects of pentoxifylline on human polymorphonuclear neutrophil responses to TNF in whole blood. Elbim C, et al. **Eur Cytokine Netw** 1995 Mar-Apr;6(2):113-20

Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. De Vos AF, et al. **Exp Eye Res** 1995 Dec;61(6):667-75

Pentoxifylline-supplemented cryoprotectant improves human sperm motility after cryopreservation. Brennan AP, et al. **Hum Reprod** 1995 Sep;10(9):2308-12

Effectiveness of pentoxifylline in semen preparation for intrauterine insemination. Negri P, et al. **Hum Reprod** 1996 Jun;11(6):1236-9

Pentoxifylline therapy in HIV seropositive subjects with elevated TNF. Kruse A, et al. **Immunopharmacology** 1995 Nov;31(1):85-91

Methylxanthines with adenosine alter TNF alpha-primed PMN activation. Sullivan GW, et al. **Immunopharmacology** 1995 Nov;31(1):19-29

Inhibitory effects of pentoxifylline on LPS-induced leukocyte adhesion and macromolecular extravasation in the microcirculation. Seiffge D, et al. **Inflamm Res** 1995 Jul;44(7):281-6

Effect of pentoxifylline on the ischemia–reperfusion injury of the intestine. Mustafa NA, et al. **Int Surg** 1995 Apr–Jun; 80(2):152–5

The effects of pentoxifylline on circulating adhesion molecules in critically ill patients with acute renal failure treated by continuous veno–venous hemofiltration. Boldt J, et al. **Intensive Care Med** 1996 Apr;22(4):305–11

Inhibition of cytotoxicity and cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline. Heinkelein M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):417–24

Sperm stimulants can improve fertilization rates in male–factor cases undergoing IVF to the same extent as micromanipulation by partial zona dissection (PZD) or subzonal sperm insemination (SUZI): a randomized controlled study. Edirisinghe WR, et al. **J Assist Reprod Genet** 1995 May;12(5):312–8

An evaluation of the effect of pentoxifylline on sperm function and treatment outcome of male–factor infertility: a preliminary study. Fountain S, et al. **J Assist Reprod Genet** 1995 Nov;12(10):704–9

Successful use of pentoxifylline in male–factor infertility and previous failure of in vitro fertilization: a prospective randomized study. Rizk B, et al. **J Assist Reprod Genet** 1995 Nov;12(10):710–4

From Cyclic AMP to Cytokines. Pentoxifylline: Present and Future. Proceedings of an International Congress. Budapest, Hungary, July 7–9, 1994. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:v, S1–147

Effect of pentoxifylline on apoptosis of cultured cells. Belloc F, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S71–4

Regulatory effects of pentoxifylline on T–helper cell–derived cytokine production in human blood cells. Benbernou N, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S75–9

Pentoxifylline selectivity inhibits tumor necrosis factor synthesis in the arterial wall. Bernard C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S30–3

Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. Bienvenu J, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S80–4

Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion. Fossat C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S96–100

Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant–stimulated human endothelial cells: involvement of cyclic AMP. Franzini E, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S92–5

Leukocyte adherence in an ischemic muscle perfused by a collateral circulation. Hou X, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S119–23

Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells. Leclerc NE, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S88–91

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)

Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions. Seigneur M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S85–7

Activated leukocytes, endothelial cells, and effects of pentoxifylline: observations by VEC–DIC microscopy. Tomita M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S34–9

Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. Shohami E, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):378–84

Amelioration of reperfusion injury by pentoxifylline after lung transplantation. The Université Paris–Sud Lung Transplant Group. Chapelier A, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):676–83

Pentoxifylline fails to prevent the Jarisch–Herxheimer reaction or associated cytokine release. Remick DG, et al. **J Infect Dis** 1996 Sep;174(3):627–30

Vasomotor response to pentoxifylline mediates improved renal blood flow to bacteremia. Krysztopik RJ, et al. **J Surg Res** 1996 Jun;63(1):17–22

Effects of pentoxifylline on active oxygen–induced sister–chromatid exchange. Tanaka R. **J Toxicol Sci** 1995 Sep;20(4):401–6

Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat. Marzi I, et al. **J Trauma** 1996 Jan; 40(1):90–6

Lipopolysaccharide–, granulocyte–monocyte colony stimulating factor and pentoxifylline–mediated effects on formyl–methionyl–leucine–phenylalanine–stimulated neutrophil respiratory burst in the elderly. Tortorella C, et al. **Microbios** 1996;85(344):189–98

Effect of a combination of pentoxifylline and nimodipine on lipid peroxidation in postischemic rat brain. Noskovič P, et al. **Mol Chem Neuropathol** 1995 Jun–Aug;25(2–3):97–102

Inhibition of tumor necrosis factor production and ICAM–1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Mándi Y, et al. **Res Exp Med (Berl)** 1995; 195(5):297–307

In vivo modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Oismüller C, et al. **Shock** 1995 Sep;4(3):161–5

Pentoxifylline maintains vascular endothelial cell function during hyperdynamic and hypodynamic sepsis. Wang P, et al. **Surgery** 1996 Aug;120(2):367–73

Beneficial effects of pentoxifylline and propentofylline on preservation–reperfusion injury in rat liver transplantation. Kozaki K, et al. **Transplant Proc** 1996 Feb;28(1):333–4

Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)–mediated suppression of cell–mediated lymphocytotoxicity. Median–effect analysis for the drug dose reductions in PTX and CsA combination treatment. Khabar KS, et al. **Transplantation** 1996 Mar 15;61(5):838–41

[Effect of pentoxifylline on the vascular toxicity secondary to cyclosporine in rats] Latulippe JF, et al. **Ann Chir** 1995; 49(8):712–8 (Eng. Abstr.) **(Fre)**

[In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications] Binet JL, et al. **Bull Acad Natl Med** 1995 Oct; 179(7):1379–91; discussion 1391–2 (Eng. Abstr.) **(Fre)**

[Potential antioxidative effects of pentoxifylline] Freitas JP, et al. **C R Seances Soc Biol Fil** 1995;189(3):401–5 (Eng. Abstr.) **(Fre)**

[Pentoxifylline] Paradowski PT, et al. **Postepy Hig Med Dosw** 1995;49(2):201–20 (112 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Pentoxifylline and oxygen consumption in severe sepsis—a preliminary report. Castañon–Gonzalez JA, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:219–22

Recurrent aphthous stomatitis: treatment with pentoxifylline [letter] Pizarro A, et al. **Acta Derm Venereol** 1996 Jan; 76(1):79–80

Successful treatment of Behçet disease with pentoxifylline. Yasui K, et al. **Ann Intern Med** 1996 May 15;124(10):891–3

Dermatomyositis responding to pentoxifylline [letter] Person JR. **Br J Dermatol** 1996 Mar;134(3):593

Treatment of recurrent aphthous stomatitis with pentoxifylline [letter] Pizarro A, et al. **Br J Dermatol** 1995 Oct;133(4):659–60

The role of pentoxifylline in the treatment of erectile dysfunction due to borderline arterial insufficiency. Peşkircioğlu L, et al. **Br J Urol** 1996 Apr;77(4):563–5

The effects of pentoxifylline on oxygenation, diffusion of carbon monoxide, and exercise tolerance in patients with COPD. Sasse SA, et al. **Chest** 1995 Dec;108(6):1562–7

A pilot study of pentoxifylline for the prevention of poison ivy/oak reactions. Rietschel RL. **Contact Dermatitis** 1995 Jun;32(6):365–6

Influence of long–term continuous intravenous administration of pentoxifylline on endothelial–related coagulation in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Jun;24(6):940–6

Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double–blind, randomized, placebo–controlled study. Zeni F, et al. **Crit Care Med** 1996 Feb;24(2):207–14

Trial of pentoxifylline for diabetic impotence. Georgitis WJ, et al. **Diabetes Care** 1995 Mar;18(3):345–52

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

Oxpentifylline inhibits tumor necrosis factor–alpha mRNA transcription and protects against arthritis in mercuric chloride–treated brown Norway rats. Kiely PD, et al. **Eur J Immunol** 1995 Oct;25(10):2899–906

Pentoxifylline reduces plasma tumour necrosis factor–alpha concentration in premature infants with sepsis. Lauterbach R, et al. **Eur J Pediatr** 1996 May;155(5):404–9

Pentoxifylline attenuates acute lung injury induced by microemboli. Shen CY, et al. **Experientia** 1995 Sep 29; 51(9–10):956–60

An argument for the past and continued use of pentoxifylline in assisted reproductive technology. Matson PL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:67–71 (38 ref.)

Use of pentoxifylline in assisted reproductive technology. Tournaye H, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:72–9 (48 ref.)

Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group. **Int Angiol** 1996 Mar;15(1):75–80

Is pentoxifylline a viable alternative in the treatment of ENL? [letter] Sarno EN, et al. **Int J Lepr Other Mycobact Dis** 1995 Dec;63(4):570–1

Is pentoxifylline effective in the treatment of psoriasis? [letter; comment] Omulecki A, et al. **J Am Acad Dermatol** 1996 Apr;34(4):714–5. Comment on: J Am Acad Dermatol 1994 Apr;30(4):603–21.

Pentoxifylline and lung ischemia–reperfusion injury: application to lung transplantation. Université Paris–Sud Lung Transplant Group. Chapelier A, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S130–3

Pentoxifylline and critical leg ischemia. Colgan MP, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S58–60 (19 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139–42 (29 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène–Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

Pentoxifylline and intermittent claudication: review of clinical trials and cost–effectiveness analyses. Gillings DB. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S44–50 (20 ref.)

Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134–8 (37 ref.)

Expression of elastase and fibrin in venous leg ulcer biopsies: a pilot study of pentoxifylline versus placebo. Mirshahi S, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S101–5

Beneficial effects of pentoxifylline in neonatal rats infected with group B streptococci. Mancuso G, et al. **J Chemother** 1995 Oct;7(5):417–9

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double–blind, placebo–controlled trial. Goldberg RM, et al. **J Clin Oncol** 1995 Nov;13(11):2856–9

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. Rieckmann P, et al. **J Neuroimmunol** 1996 Feb;64(2):193–200

Pentoxifylline ameliorates postischemic delayed hypoperfusion of the cerebral cortex following cardiac arrest in cats. Tanahashi N, et al. **J Neurol Sci** 1995 Oct; 132(2):105–9

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence [see comments] Knoll LD, et al. **J Urol** 1996 Jan;155(1):144–6. Comment in: J Urol 1996 Jan;155(1):147.

Pentoxifylline may be useful in the treatment of type 2 leprosy reaction [letter] Talhari S, et al. **Lepr Rev** 1995 Sep; 66(3):261–3

A double–blind, randomized, placebo–controlled, crossover trial of pentoxifylline for the prevention of chemotherapy–induced oral mucositis. Verdi CJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):36–42

Inhibition of tumor necrosis factor production and ICAM–1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Mándi Y, et al. **Res Exp Med (Berl)** 1995; 195(5):297–307

Pentoxifylline does not prevent the cytokine–induced first dose reaction following OKT3—a randomized, double–blind placebo–controlled study. Vincenti F, et al. **Transplantation** 1996 Feb 27;61(4):573–7

Characterization of cancer–related disseminated intravascular coagulation in relation to tumor necrosis factor–alpha blood concentrations: possible therapeutic role of pentoxifylline. Lissoni P, et al. **Tumori** 1996 Jan–Feb;82(1):78–80

[The treatment of cutaneous radiation–induced fibrosis with pentoxifylline and vitamin E. An empirical report] Gottlöber P, et al. **Strahlenther Onkol** 1996 Jan;172(1):34–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Mechanisms of radiation to the lung. Pentoxifylline—a new radioprotective drug?] Remiszewski P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):349–54 (17 ref.) **(Pol)**

[The effect of prophylactic administration of pentoxifylline (trental) on development of a neuropathic pain syndrome and microcirculatory disorders caused by it] Gorizontova MP, et al. **Biull Eksp Biol Med** 1995 May;119(5):485–7 **(Rus)**

[Treatment of trophic ulcers of the lower extremities with Trental–400] Koshkin VM, et al. **Khirurgiia (Mosk)** 1996; (1):49–51 (Eng. Abstr.) **(Rus)**

TOXICITY

Differential responses of human sperm to varying concentrations of pentoxyfylline with demonstration of toxicity. Centola GM, et al. **J Androl** 1995 Mar–Apr; 16(2):136–42

Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Ohsaki Y, et al. **Oncology** 1996 Jul–Aug;53(4):327–33

PENTOXYL

ANALOGS & DERIVATIVES

On the connection between inherent DNA flexure and preferred binding of hydroxymethyluracil–containing DNA by the type II DNA–binding protein TF1. Grove A, et al. **J Mol Biol** 1996 Jul 12;260(2):196–206

PENTYLENETETRAZOLE

Opioid peptides content in the rat brain during the ictal phase and after pentylenetetrazol–kindled rats. Asai M, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):241–5

Chronic malnutrition caused by a corn–based diet lowers the threshold for pentylenetetrazol–induced seizures in rats. Palencia G, et al. **Epilepsia** 1996 Jun;37(6):583–6

Failure of chronic treatment with abecarnil to induce contigent and noncontingent tolerance in pentylenetetrazol–kindled rats. Serra M, et al. **Epilepsia** 1996 Apr;37(4):332–5

Age–specific effects of baclofen on pentylenetetrazol–induced seizures in developing rats. Velíšková J, et al. **Epilepsia** 1996 Aug;37(8):718–22

PHARMACOLOGY

Behavioral and pharmacological validation of the elevated plus maze constructed with transparent walls. Anseloni VZ, et al. **Braz J Med Biol Res** 1995 May;28(5):597–601

Differential regulation of c–fos, proenkephalin and tyrosine hydroxylase gene expression by metrazole in the hamster adrenal and hippocampus. Zhu YS, et al. **Neurosci Lett** 1995 Aug 25;196(3):197–200

Pentylenetetrazol causes polysynaptic responses to appear in the dentate gyrus. Stringer JL. **Neuroscience** 1995 Sep; 68(2):407–13

Activation of ATP–sensitive potassium channels in follicle–enclosed xenopus oocytes by the epileptogenic agent pentylenetetrazol. Klöcker N, et al. **Pflugers Arch** 1996 Mar;431(5):736–40

PTZ–kindling after colchicine lesion in the dentate gyrus of the rat hippocampus. Grecksch G, et al. **Physiol Behav** 1995 Oct;58(4):695–8

[Mice selected on the basis of low weight are more selective to the convulsant effect of pentylenetetrazole] Bogdanov NN, et al. **Biull Eksp Biol Med** 1995 May;119(5):460–2 **(Rus)**

TOXICITY

Withdrawal–like effects of pentylenetetrazol and valproate in the naive organism: a model of motivation produced by opiate withdrawal? Mucha RF, et al. **Drug Alcohol Depend** 1995 Jul;39(1):1–6

Pentylenetetrazol–induced kindling in animals: protective effect of BR–16A. Kulkarni SK, et al. **Indian J Exp Biol** 1995 Jun;33(6):424–7

PENTYMAL see **AMOBARBITAL**

PEOPLE WITH DISABILITIES see **DISABLED**

PEPSIN see **PEPSIN A**

PEPSIN A

ANALYSIS

Fluorogenic peptide substrates for assay of aspartyl proteinases. Filippova IY, et al. **Anal Biochem** 1996 Feb 15;234(2):113–8

Phosphate–specific fluorescence labeling of pepsin by BO–IMI. Wang P, et al. **Anal Biochem** 1995 Sep 20; 230(2):329–32

Electrospray mass spectrometric evidence for the occurrence of two major variants in native pig pepsin A. Green BN, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):241–4

High performance liquid chromatography enables fast determination of ratios between individual proteolytic enzymes in human gastric mucosa. Hynek R, et al. **Sb Lek** 1996;97(1):135–42

CHEMISTRY

A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region. Andreeva NS, et al. **Adv Exp Med Biol** 1995;362:19–32

Tyrosine 75 on the flap contributes to enhance catalytic efficiency of a fungal aspartic proteinase, Mucor pusillus pepsin. Beppu T, et al. **Adv Exp Med Biol** 1995;362:501–9

Molecular mass determination by electrospray mass spectrometry of human pepsins, gastricsin, and porcine pepsin A variants. Jones AT, et al. **Adv Exp Med Biol** 1995; 362:83–9

Rearranging pepsinogen and pepsin by protein engineering. Lin X, et al. **Adv Exp Med Biol** 1995;362:33–40

Site–directed mutagenesis revealed role of subsite residues of Mucor pusillus pepsin in catalytic function. Park YN, et al. **Adv Exp Med Biol** 1995;362:559–63

Evidence for electrostatic interactions in the S2 subsite of porcine pepsin. Rao C, et al. **Adv Exp Med Biol** 1995; 362:91–4

Non–mammalian vertebrate pepsinogens and pepsins: isolation and characterization. Takahashi K, et al. **Adv Exp Med Biol** 1995;362:53–65

A comparative study on amino acid sequences of three major isoforms of human pepsin A. Tarasova N, et al. **Adv Exp Med Biol** 1995;362:77–81

Ostrich pepsins I and II: a kinetic and thermodynamic investigation. Pletschke BI, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1293–302

ISOLATION & PURIFICATION

Non–mammalian vertebrate pepsinogens and pepsins: isolation and characterization. Takahashi K, et al. **Adv Exp Med Biol** 1995;362:53–65

Purification and characterization of porcine pepsinogen B and pepsin B. Nielsen PK, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):417–22

METABOLISM

Tyrosine 75 on the flap contributes to enhance catalytic efficiency of a fungal aspartic proteinase, Mucor pusillus pepsin. Beppu T, et al. **Adv Exp Med Biol** 1995;362:501–9

Site–directed mutagenesis revealed role of subsite residues of Mucor pusillus pepsin in catalytic function. Park YN, et al. **Adv Exp Med Biol** 1995;362:559–63

Evidence for electrostatic interactions in the S2 subsite of porcine pepsin. Rao C, et al. **Adv Exp Med Biol** 1995; 362:91–4

Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Lanas AI, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1065–72

Peptic proteolysis of esterified beta–casein and beta–lactoglobulin. Briand L, et al. **Int J Pept Protein Res** 1995 Jul;46(1):30–6

Meat allergy: II––Effects of food processing and enzymatic digestion on the allergenicity of bovine and ovine meats [see comments] Fiocchi A, et al. **J Am Coll Nutr** 1995 Jun; 14(3):245–50. Comment in: J Am Coll Nutr 1995 Jun;14(3):217–8.

Porous zirconia: a new support material for enzyme immobilization. Huckel M, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3–4):165–79

Restrained molecular dynamics study of the interaction between bovine kappa–casein peptide 98–111 and bovine chymosin and porcine pepsin. Plowman JE, et al. **J Dairy Res** 1995 Aug;62(3):451–67

Effect of high hydrostatic pressure on the enzymic hydrolysis of beta–lactoglobulin B by trypsin, thermolysin and pepsin. Stapelfeldt H, et al. **J Dairy Res** 1996 Feb;63(1):111–8

Susceptibility of beta–lactoglobulin and sodium caseinate to proteolysis by pepsin and trypsin. Guo MR, et al. **J Dairy Sci** 1995 Nov;78(11):2336–44

Purification of beta–lactoglobulin from whey protein concentrate by pepsin treatment. Kinekawa Y, et al. **J Dairy Sci** 1996 Mar;79(3):350–6

Protease resistance and binding of Ig light chains in myeloma–associated tubulopathies. Leboulleux M, et al. **Kidney Int** 1995 Jul;48(1):72–9

[Electrophoretic analysis on the proteolytic decomposition of of FSH preparations] Khalaf H, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct;102(10):396–9 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Modulatory impact of acid and pepsin on esophageal hydrophobicity in humans. DeRosa J, et al. **Am J Gastroenterol** 1995 Nov;90(11):2020–4

Raising the pH of the pepsin–catalysed hydrolysis of bovine whey proteins increases the antigenicity of the hydrolysates. Schmidt DG, et al. **Clin Exp Allergy** 1995 Oct;25(10):1007–17

PHYSIOLOGY

Effect of intermittent acid and pepsin exposure on burned esophageal mucosa. Messner AH, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):45–9

SECRETION

Pentagastrin increases pepsin secretion without increasing its fractional synthetic rate. Corbett ME, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E418–25

Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Hirschowitz BI. **Dig Dis Sci** 1996 Jul;41(7):1384–91

Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Feldman M, et al. **Gastroenterology** 1996 Apr;110(4):1043–52

Cholecystokinin is not a physiological regulator of gastric pepsin secretion in rats. Kawabata S, et al. **J Gastroenterol** 1995 Aug;30(4):447–51

Effect of peptide YY on gastric motor and secretory activity in vagally innervated and denervated corpus pouch dogs. Zai H, et al. **Regul Pept** 1996 Mar 22;61(3):181–8

[Factors of gastroesophageal acid reflux in severe obesity] Rigaud D, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):818–25 (Eng. Abstr.) **(Fre)**

PEPSINOGEN

ANALYSIS

Prochymosin and pepsinogen potential activity and electrophoretic study of proteolytic fractions in the gastric and duodenal mucosal extracts from the first four day old lambs. Wiśliński M, et al. **Arch Vet Pol** 1994;34(1–2):75–89

High performance liquid chromatography enables fast determination of ratios between individual proteolytic enzymes in human gastric mucosa. Hynek R, et al. **Sb Lek** 1996;97(1):135–42

BIOSYNTHESIS

Transcription of embryonic chick pepsinogen gene is affected by mesenchymal signals through its 5'–flanking region. Fukuda K, et al. **Adv Exp Med Biol** 1995;362:125–9

Effects of hydrocortisone on the pepsinogen–producing cells in rat stomach mucosa. Ichinose M, et al. **Adv Exp Med Biol** 1995;362:107–13

Effects of omeprazole, a proton pump inhibitor, on pepsinogen–producing cells, with special reference to neonatal development. Kakei N, et al. **Adv Exp Med Biol** 1995;362:115–23

Transcription regulation of human and porcine pepsinogen A. Pals G, et al. **Adv Exp Med Biol** 1995;362:67–75

Seminal progastricsin. Szecsi PB, et al. **Adv Exp Med Biol** 1995;362:101–5

Expression of soluble cloned porcine pepsinogen A in Escherichia coli. Tanaka T, et al. **Biochem J** 1996 Apr 15; 315 (Pt 2):443–6

Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis–acting element mediating its induction by androgens, glucocorticoids, and progesterone. Balbín M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15175–81

BLOOD

Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2–blocker half–dose maintenance therapy. Matsushima M, et al. **Adv Exp Med Biol** 1995;362:131–7

The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Miki K, et al. **Adv Exp Med Biol** 1995;362:139–43

Two cases of early colorectal cancer associated with gastric adenoma detected by serum pepsinogen screening method. Shimizu Y, et al. **Adv Exp Med Biol** 1995;362:149–54

A minute gastric cancer detected by a new screening method using serum pepsinogen I and II. Yahagi N, et al. **Adv Exp Med Biol** 1995;362:145–8

Circulating anti–Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Aromaa A, et al. **Am J Epidemiol** 1996 Jul 15;144(2):142–9

A novel tree–structured analysis for non–invasive diagnosis of gastric adenocarcinoma. Wu MS, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2739–43

Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Knight T, et al. **Br J Cancer** 1996 Mar;73(6):819–24

Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Santucci L, et al. **Dig Dis Sci** 1995 Sep;40(9):2074–80

Variability in serum pepsinogen levels in an asymptomatic population. Knight T, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):647–54

Helicobacter pylori, pepsinogens and gastrin: relationship with age and development of atrophic gastritis. Kuipers EJ, et al. **Eur J Gastroenterol Hepatol** 1996 Feb;8(2):153–6

Helicobacter pylori eradication and serum pepsinogens [letter; comment] Di Mario F, et al. **Gut** 1996 May;38(5):793 . Comment on: Gut 1995 Aug;37(2):210–5.

Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of helicobacter pylori in duodenal ulcer patients. A controlled study [see comments] Parente F, et al. **Gut** 1995 Aug;37(2):210–5. Comment in: Gut 1996 May;38(5):793.

Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori. Schlemper RJ, et al. **Gut** 1995 Aug;37(2):199–204

Serum pepsinogen I in childhood Helicobacter pylori gastritis: its relation to mucosal peptic activity. Yahav J, et al. **Isr J Med Sci** 1996 Jan;32(1):56–9

The clinical usefulness of serum pepsinogens, specific IgG anti–HP antibodies and gastrin for monitoring Helicobacter pylori treatment in older people. Pilotto A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):665–70

Serum pepsinogen in screening for gastric cancer. Kodoi A, et al. **J Gastroenterol** 1995 Aug;30(4):452–60

Serum pepsinogen I and pepsinogen II, and the ratio of pepsinogen I/pepsinogen II in peptic ulcer diseases: with special emphasis on the influence of the location of the ulcer crater. Wu MS, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):401–4

Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Hattori Y, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1210–5

Elevated serum pepsinogens in chronic renal failure patients. Nakahama H, et al. **Nephron** 1995;70(2):211–6

Comparison of four methods for the determination of plasma pepsinogen concentration. Scott I, et al. **Res Vet Sci** 1995 Nov;59(3):234–7

Verification of decreased basal and stimulated serum pepsinogen–I levels is a useful non–invasive method for determining the success of eradication therapy for Helicobacter pylori. Gisbert JP, et al. **Scand J Gastroenterol** 1996 Feb;31(2):103–10

Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. Janssen M, et al. **Scand J Rheumatol** 1995; 24(4):204–8

[The content of pepsinogen in the blood plasma of growing fallow deer (Dama dama L.) raised helminth free and under natural conditions in captivity] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Sep;108(9):321–5 (Eng. Abstr.) **(Ger)**

[Comparative examinations of serum pepsinogen I, II and gastric area using computed radiography in the atrophic gastritis] Tatsu Y, et al. **Kaku Igaku** 1995 Nov; 32(11):1259–62 (Eng. Abstr.) **(Jpn)**

[Serum pepsinogen response to therapy for Helicobacter pylori associated gastro–duodenal disease] Tokieda M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1825–31 (Eng. Abstr.) **(Jpn)**

PEPSINOGEN

[Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment?] Gisbert JP, et al. **Med Clin (Barc)** 1995 Nov 4;105(15):561–5 (Eng. Abstr.) **(Spa)**

[Basal levels of blood pepsinogen I and Helicobacter pylori infection in patients with duodenal ulcer and normal endoscopy] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Jan;88(1):3–8 (Eng. Abstr.) **(Spa)**

CHEMISTRY

The molecular structure of human progastricsin and its comparison with that of porcine pepsinogen. James M, et al. **Adv Exp Med Biol** 1995;362:11–8

Rearranging pepsinogen and pepsin by protein engineering. Lin X, et al. **Adv Exp Med Biol** 1995;362:33–40

Seminal progastricsin. Szecsi PB, et al.
Adv Exp Med Biol 1995;362:101–5

Non-mammalian vertebrate pepsinogens and pepsins: isolation and characterization. Takahashi K, et al.
Adv Exp Med Biol 1995;362:53–65

DRUG EFFECTS

[The effect of calcium antagonists and the potassium depolarization of plasma membranes on pepsinogen extrusion by dispersed gastric glands] Dubyts'kyĭ LO, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):108–12 (Eng. Abstr.) **(Ukr)**

GENETICS

Expression of soluble cloned porcine pepsinogen A in Escherichia coli. Tanaka T, et al. **Biochem J** 1996 Apr 15; 315 (Pt 2):443–6

Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. Balbín M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15175–81

ISOLATION & PURIFICATION

Non-mammalian vertebrate pepsinogens and pepsins: isolation and characterization. Takahashi K, et al.
Adv Exp Med Biol 1995;362:53–65

Purification and characterization of porcine pepsinogen B and pepsin B. Nielsen PK, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):417–22

METABOLISM

Increasing development of pepsinogen-altered pyloric glands and adenocarcinoma in glandular stomach of analbuminemic rats. Ogawa K, et al. **Cancer Lett** 1995 Sep 25;96(2):219–24

[The locus of pepsinogen A: molecular biologic studies in the carcinogenesis of gastric cancer] Shumakov AR, et al. **Vopr Onkol** 1996;42(2):7–11 (50 ref.) **(Rus)**

SECRETION

Differential effects of GTP gamma S on acid and pepsinogen secretion by permeable gastric glands. Miller MD, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G962–8

Actions and expression of RAB-GDP dissociation inhibitor in dispersed chief cells from guinea pig stomach. Raffaniello RD, et al. **Biochem Biophys Res Commun** 1996 Aug 5; 225(1):232–7

Gastric chief cells possess NK1 receptors which mediate pepsinogen secretion and are regulated by agents that increase cAMP and phospholipase C. Kitsukawa Y, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):105–16

Interaction among secretagogues on pepsinogen secretion from rat gastric chief cells. Tanaka T, et al.
Biol Pharm Bull 1995 Jun;18(6):859–65

A water channel closely related to rat brain aquaporin 4 is expressed in acid- and pepsinogen-secretory cells of human stomach. Misaka T, et al. **FEBS Lett** 1996 Mar 4; 381(3):208–12

Nitric oxide modulates pepsinogen secretion induced by calcium-mediated agonist in guinea pig gastric chief cells. Fiorucci S, et al. **Gastroenterology** 1995 Oct;109(4):1214–23

Central administration of cholecystokinin stimulates gastric pepsinogen secretion from anaesthetized rats. Blandizzi C, et al. **Neurosci Lett** 1995 Jun 23;193(1):13–6

[The effect of low-sodium media on pepsinogen extrusion by dispersed gastric glands] Dubyts'kyĭ LO, et al.
Fiziol Zh 1995 May–Aug;41(3–4):45–8 (Eng. Abstr.) **(Ukr)**

PEPSTATINS

CHEMISTRY

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Cutfield SM, et al. **Structure** 1995 Nov 15;3(11):1261–71

PHARMACOLOGY

Pepstatin-insensitive carboxyl proteinases. Oda K, et al.
Adv Exp Med Biol 1995;362:529–42

The primary structure of pepstatin-insensitive carboxyl proteinase produced by Pseudomonas sp. No. 101. Hayashi K, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):738–44

Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Gómez J, et al. **J Mol Biol** 1995 Sep 22;252(3):337–50

PEPTIC ULCER

see related
ANTI-ULCER AGENTS
GASTRECTOMY
ZOLLINGER-ELLISON SYNDROME

Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al.
Eur J Gastroenterol Hepatol 1995 Jul;7(7):685–99 (156 ref.)

Helicobacter pylori and peptic disease in the pediatric patient. Bujanover Y, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):213–34 (138 ref.)

[Current studies in the quality of ulcer healing] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):274–6 (16 ref.) **(Chi)**

[Development and validation of QPD 32, a specific questionnaire for measuring the quality of life of patients with peptic ulcer] De Carli G, et al.
Minerva Gastroenterol Dietol 1995 Dec;41(4):275–82 (Eng. Abstr.) **(Ita)**

BLOOD

[Lipid contents in blood of healthy subjects and patients with peptic ulcer during regular motor activity of the gastrointestinal tract] Churin BV, et al. **Klin Lab Diagn** 1995 May–Jun;(3):22–5 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Bjorkman DJ, et al. **Dig Dis** 1995 Mar–Apr;13(2):119–29 (81 ref.)

Emergency hospital admissions. Blower AL.
Eur J Rheumatol Inflamm 1994;14(3 Suppl):11–2

The risk of standardized regimens of corticosteroids for the treatment of leprosy reactions in the field [letter; comment] Richardus JH, et al. **Lepr Rev** 1995 Dec;66(4):328–9. Comment on: Lepr Rev 1991 Jun;62(2):113–21.

Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury [see comments] Lichtenberger LM, et al. **Nat Med** 1995 Feb; 1(2):154–8. Comment in: Nat Med 1995 Jul;1(7):602–3.

Risk factors for gastrointestinal complications of nonsteroidal antiinflammatory drugs. Florent C, et al.
Rev Rhum Engl Ed 1996 Feb;63(2):125–30 (44 ref.)

NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Dijkmans BA, et al.
Scand J Gastroenterol Suppl 1995;212:105–8 (26 ref.)

Protection of the gastroduodenal mucosa from the effects of diclofenac sodium: role of highly selective vagotomy and misoprostol. Giannoukas AD, et al. **World J Surg** 1996 May;20(4):501–5 discussion 505–6

[Misoprostol: prevention of ulcers caused by NSAID] Matzen P, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4782–5 **(Dan)**

CLASSIFICATION

[Classification of erosive alterations of gastric and duodenal mucosa] Grinevich VB, et al. **Klin Med (Mosk)** 1996; 74(1):75–7 **(Rus)**

[The classification of peptic ulcer in the interests of military medical expertise] Luft VM. **Voen Med Zh** 1995 Feb; (2):36–8, 80 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL.
Aliment Pharmacol Ther 1995;9 Suppl 1:43–6 (28 ref.)

Peptic ulcers and gastric cancer. Mera SL.
Br J Biomed Sci 1995 Dec;52(4):271–81 (59 ref.)

Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia. Björkholm M, et al. **Int J Hematol** 1995 Aug;62(2):117–20

Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. Siringo S, et al. **J Hepatol** 1995 Jun;22(6):633–41

Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. Thomason MH, et al. **J Trauma** 1996 Sep; 41(3):503–8

Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature. Miller CA, et al.
Surgery 1996 Jun;119(6):718–9 (14 ref.)

Acute surgical treatment of complicated peptic ulcers with special reference to the elderly. Bulut OB, et al.
World J Surg 1996 Jun;20(5):574–7

[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction] Hirai M, et al. **Kyobu Geka** 1995 Sep; 48(10):849–52 (Eng. Abstr.) **(Jpn)**

[The effect of HBO therapy in the early postoperative period on the late outcomes of "compelled" suturing in perforated gastroduodenal ulcers] Belokurov IuN, et al.
Vestn Khir Im I I Grek 1992 Feb;148(2):124–7 (Eng. Abstr.) **(Rus)**

[The significance of thrombocytic and coagulative hemostasis in the pathogenesis of peptic gastroduodenal hemorrhages] Korymasov EA. **Vestn Khir Im I I Grek** 1992 Feb; 148(2):130–4 (Eng. Abstr.) **(Rus)**

[Perforated gastroduodenal ulcers in women] Ponomarev AA, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):242–7 (56 ref.) **(Rus)**

DIAGNOSIS

Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy. Matsushima M, et al.
Adv Exp Med Biol 1995;362:131–7

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al.
Aliment Pharmacol Ther 1995 Aug;9(4):341–7 (52 ref.)

Developing a condition-specific measure of health for patients with dyspepsia and ulcer-related symptoms. Garratt AM, et al. **J Clin Epidemiol** 1996 May;49(5):565–71

Using serology to detect H pylori infection. Adelman A.
J Fam Pract 1996 Aug;43(2):118–9

Management of peptic ulcer disease in general practice [editorial] Johannessen T. **Scand J Prim Health Care** 1995 Dec;13(4):241–2

[Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases] Caspary WF, et al. **Z Gastroenterol** 1996 Jun;34(6):392–401 **(Ger)**

[Functional evaluation of the condition of patients with peptic ulcer and its changes during treatment] Tovbuchenko MP. **Klin Med (Mosk)** 1995;73(4):49–52 **(Rus)**

DRUG THERAPY

Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy. Matsushima M, et al.
Adv Exp Med Biol 1995;362:131–7

Repeat prescribing of ulcer healing drugs in general practice--prevalence and underlying diagnosis. Goudie BM, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):147–50

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Reilly TG, et al. **Aliment Pharmacol Ther** 1995 Oct; 9(5):483–90

Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). Tefera S, et al.
Am J Gastroenterol 1996 May;91(5):935–41

Gastroenterological associations recognize three antimicrobial combinations for ulcer therapy [news]
Am J Health Syst Pharm 1996 Apr 15;53(8):832, 835

Drug therapy of peptic ulcer disease. Ching CK, et al.
Br J Hosp Med 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)

Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies. Bergmann C, et al. **Dig Dis Sci** 1995 Dec;40(12):2678–83

Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Sikirić P, et al. **Dig Dis Sci** 1996 Jul; 41(7):1518–26

Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Rauws EA, et al. **Drugs** 1995 Dec; 50(6):984–90

Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Deltenre M, et al.
Eur J Gastroenterol Hepatol 1995 Aug;7 Suppl 1:S39–44

Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita M, et al.
Eur J Gastroenterol Hepatol 1995 Aug;7 Suppl 1:S31–4

Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Moayyedi P, et al. **Eur J Gastroenterol Hepatol** 1995 Sep; 7(9):835–40

Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Takimoto T, et al.
Eur J Gastroenterol Hepatol 1995 Aug;7 Suppl 1:S63–6

Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. Uemura N, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S67–9

Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)

Endoscopy or empirical treatment for peptic ulcer disease: decisions, decisions. . . Cromwell DM, et al.
Gastroenterology 1996 Apr;110(4):1314–6

Risk factors in patients with refractory peptic ulcer [letter] Massarrat S. **Gastroenterology** 1996 Jul;111(1):267–8

Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
J Clin Gastroenterol 1995;20 Suppl 2:S1–135

Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. Asaki S, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S56–8

Clinical study on the pathophysiology and treatment of PPI-resistant ulcers. Ashida K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S67–71

Quality of peptic ulcer healing induced by lansoprazole and roxatidine. Fujino MA, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S44–6

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107–11

Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration? Hoshino E, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S72–4

Factors affecting quality of ulcer healing after lansoprazole treatment. Ito G, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S62–6

Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. Katoh M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S112–4

The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. Mine T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S75–8

Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. Murakami M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S79–82

Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. Ogoshi K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S97–9

Effect of lansoprazole on peptic ulcers. Ohashi T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S83–5

Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S100–3

Treatment of Helicobacter pylori infection. Ebell MH. **J Fam Pract** 1996 Jun;42(6):568

Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. Tari A, et al. **J Gastroenterol** 1996 Apr; 31(2):167–70

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)

Healing-promoting action of the zinc-cimetidine complex on acetic acid-induced gastric ulcers in rats. Ito M, et al. **Jpn J Pharmacol** 1995 Jul;68(3):287–95

Helicobacter pylori: how often are eradication therapies prescribed? [letter] Parkes AJ. **Med J Aust** 1995 Sep 18; 163(6):334

An audit of low dose triple therapy for eradication of Helicobacter pylori. Fraser AG, et al. **N Z Med J** 1996 Aug 9;109(10 ?):290–2

The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic—a comment. Holt RJ, et al. **Pharmacotherapy** 1996 May-Jun; 16(3):480–1; discussion 482–3

The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic. Matsuyama JR, et al. **Pharmacotherapy** 1995 Sep-Oct; 15(5):608–13

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Hatlebakk JG, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1053–7

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Long-term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

Management of peptic ulcer disease in general practice [editorial] Johannessen T. **Scand J Prim Health Care** 1995 Dec;13(4):241–2

[Ulfamid Krka (famotidine) in monotherapy of peptic ulcer] Shonová O, et al. **Vnitr Lek** 1996 Feb;42(2):114 **(Cze)**

[Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis] Wilson BV, et al. **Ugeskr Laeger** 1996 Mar 18;158(12):1695–7 **(Dan)**

[Importance of ranitidine in the eradication of Helicobacter pylori] Beglinger C. **Rev Med Suisse Romande** 1995 Oct; 115(10):795–7 **(Fre)**

[Role of ranitidine in the treatment of peptic diseases (editorial)] Loizeau E. **Rev Med Suisse Romande** 1995 Oct; 115(10):765 **(Fre)**

[We hope that the responsible persons learn from the experience! (letter)] Blum AL, et al. **Leber Magen Darm** 1995 Jul;25(4):154–5 **(Ger)**

[Who is affected by blindness? (letter)] Classen M. **Leber Magen Darm** 1995 Jul;25(4):152–3 **(Ger)**

[Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study] Hotz J, et al. **Leber Magen Darm** 1995 Jul;25(4):165–70 (Eng. Abstr.) **(Ger)**

[Federal health office commentaries: false, misleading citations (letter)] Lessell S. **Leber Magen Darm** 1995 Jul; 25(4):152 **(Ger)**

[Modified triple therapy: what degree of acid inhibition is necessary? (letter)] Müller P, et al. **Leber Magen Darm** 1996 May;26(3):171–3 **(Ger)**

[What can be learned from this case? (letter)] Petersen KH, et al. **Leber Magen Darm** 1995 Jul;25(4):155 **(Ger)**

[Once again: "A sick federal health office watches over health!" (editorial; comment)] Stolte M. **Leber Magen Darm** 1995 Jul;25(4):150–1. Comment on: Leber Magen Darm 1994 Sep;24(5):183–6. Comment on: Leber Magen Darm 1995 Jan;25(1):6–8, 11. Comment on: Leber Magen Darm 1995 Jan;25(1):39, 41. **(Ger)**

[Helicobacter pylori and peptic ulcer—1995 therapeutic indications and recommendations of a Munster Expert Group] Domschke W, et al. **Z Gastroenterol** 1995 Oct; 33(10):598–601 **(Ger)**

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov SA. **Klin Med (Mosk)** 1995;73(5):11–6 (77 ref.) **(Rus)**

[Effect of the antioxidant dibunol on hemostatic parameters in patients with non-healing ulcers] Podoprigorova VG, et al. **Klin Med (Mosk)** 1996;74(1):43–5 (Eng. Abstr.) **(Rus)**

[Study of immunomodulating properties of beta-carotene in patients] Pletsityi KD, et al. **Vopr Pitan** 1995;(6):14–6 (Eng. Abstr.) **(Rus)**

[The histoenzymological and ultrastructural changes in the gastric mucosa in peptic ulcer after treatment with pirenzepine and histamine H2-receptor blockaders] Degtiareva II, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):48–51 (Eng. Abstr.) **(Rus)**

[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori] López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):422–8 (75 ref.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

[Lipid peroxidation in an experimental study of an erosion-ulcer lesion of the stomach as affected by the new high-protein products and ethonium] Fediv OI, et al. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):79–85 (Eng. Abstr.) **(Ukr)**

ECONOMICS

'Cure' of Helicobacter pylori. Clinically indicated and economically wise! [editorial; comment] Fennerty MB. **Arch Intern Med** 1995 Oct 9;155(18):1929–31. Comment on: Arch Intern Med 1995 Oct 9;155(18):1958–64.

Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

ENZYMOLOGY

Influence of Helicobacter pylori on tryptase and cathepsin D in peptic ulcer. Plebani M, et al. **Dig Dis Sci** 1995 Nov; 40(11):2473–6

EPIDEMIOLOGY

Temporal trends and geographical variations of peptic ulcer disease. Sonnenberg A. **Aliment Pharmacol Ther** 1995;9 Suppl 2:3–12 (31 ref.)

Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection [see comments] Anand BS, et al. **Am J Gastroenterol** 1996 Jun;91(6):1112–5. Comment in: Am J Gastroenterol 1996 Jun;91(6):1070–1.

Lower Helicobacter pylori infection and peptic ulcer disease prevalence in patients with AIDS and suppressed CD4 counts. Cacciarelli AG, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1783–4

The prevalence of self-reported peptic ulcer in the United States. Sonnenberg A, et al. **Am J Public Health** 1996 Feb; 86(2):200–5

Significance of various factors in patients with functional dyspepsia and peptic ulcer disease in Greece. A comparative prospective study. Archimandritis A, et al. **Ann Med Interne (Paris)** 1995;146(5):299–303

Risk factors for peptic ulcer in Shanghai. Wang JY, et al. **Int J Epidemiol** 1996 Jun;25(3):638–43

[Tell me, where the ulcers are, where have they gone? (editorial; comment)] Rösch W. **Z Gastroenterol** 1995 Jul; 33(7):379–80. Comment on: Z Gastroenterol 1995 Jul;33(7):381–4. **(Ger)**

[Incidence of peptic ulcer at the Instituto Nacional de la Nutrición "Salvador Zubirán": study of localization, associated factors and temporal trends] Bobadilla J, et al. **Rev Gastroenterol Mex** 1996 Jan-Mar;61(1):31–5 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Dyspepsia and Helicobacter pylori in Japanese employees with and without ulcer history. Schlemper RJ, et al. **J Gastroenterol Hepatol** 1995 Nov-Dec;10(6):633–8

ETIOLOGY

Giant peptic ulcers in patients undergoing maintenance hemodialysis. Troskot B, et al. **Acta Med Croatica** 1995; 49(2):59–64

Growth factors and ulcerative gastrointestinal disease. Playford RJ, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):135–49 (60 ref.)

Helicobacter pylori infection and peptic ulcer disease in children. Rowland M, et al. **Curr Opin Pediatr** 1995 Oct; 7(5):553–9 (65 ref.)

The Rapunzel syndrome (trichobezoar) causing gastric perforation in a child: a case report. Pul N, et al. **Eur J Pediatr** 1996 Jan;155(1):18–9

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5–19 (80 ref.)

Helicobacter pylori and peptic ulcer disease. Blum AL. **Scand J Gastroenterol Suppl** 1996;214:24–7; discussion 42–3 (24 ref.)

Helicobacter pylori in ulcerogenesis. Lin SK, et al. **Scand J Gastroenterol Suppl** 1995;210:64–9 (72 ref.)

To repair the fault or end the acid reign? Modlin IM. **Scand J Gastroenterol Suppl** 1995;210:1–5

History of Helicobacter infection. Rune SJ. **Scand J Gastroenterol Suppl** 1996;214:2–4; discussion 9–12

[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and gastroduodenal diseases] Nakazawa T. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):777–86 (14 ref.) **(Jpn)**

[Role of acid-base balance of the blood in the pathogenesis of acute gastroduodenal ulcers in surgery patients] Skriabin ON, et al. **Klin Med (Mosk)** 1995;73(4):100 **(Rus)**

[Acute postoperative gastroduodenal erosions and ulcers] Prilma OB. **Vestn Khir Im I I Grek** 1992 Feb;148(2):247–51 (44 ref.) **(Rus)**

[Helicobacter pylori: an etiologic factor in chronic gastritis, gastroduodenal ulcer and gastric cancer (editorial)] Ausina V. **Med Clin (Barc)** 1995 Nov 4;105(15):576–9 **(Spa)**

HISTORY

Scandinavian views on the non-surgical treatment of peptic ulcers, 1940–1975. Rationales for recommendations and results. Molinder HK. **Scand J Gastroenterol** 1995 Aug; 30(8):721–30

The centenary of Lester Dragstedt—fifty years of therapeutic vagotomy. Modlin IM, et al. **Yale J Biol Med** 1994 May-Aug;67(3–4):63–80

IMMUNOLOGY

Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. Janssen M, et al. **Scand J Rheumatol** 1995; 24(4):204–8

METABOLISM

Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. Taha AS, et al. **Am J Gastroenterol** 1996 Jul;91(7):1407–9

Trefoil peptides. Poulsom R. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):113–34 (110 ref.)

Time course of the induction of VGF mRNA in the dorsal vagal complex in rats with cysteamine-induced peptic ulcers. Kanemasa K, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):309–14

Central and peripheral dopamine D1/DA1 receptor modulation of gastric secretion and experimental gastric mucosal injury. Glavin GB, et al. **Gen Pharmacol** 1995 Oct; 26(6):1277–9

Distribution of extracellular matrix proteins in indomethacin-induced lesions in the rat stomach. Ernst H, et al. **Scand J Gastroenterol** 1995 Sep;30(9):847–53

[Changes in the lipid peroxidation processes and in the antioxidant system activity in a model of the ulcer process in the gastroduodenal area] Voronych NM. **Fiziol Zh** 1995 May-Aug;41(3–4):86–90 (Eng. Abstr.) **(Ukr)**

MICROBIOLOGY

The role of Helicobacter pylori infection in the pathogenesis of peptic ulcer disease. Proceedings from a 2nd roundtable meeting. Edinburgh, July 1995. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:1–138

The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Blaser MJ. **Aliment Pharmacol Ther** 1995;9 Suppl 1:27–30 (27 ref.)

Helicobacter pylori exotoxins and gastroduodenal diseases

associated with cytotoxic strain infection. Figura N. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:79–96

The prevalence of Helicobacter pylori in peptic ulcer disease. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:59–69 (110 ref.)

The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Mobley HL. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:57–64

No Helicobacter pylori, no Helicobacter pylori–associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39–42 (15 ref.)

Prevalence of CagA–bearing Helicobacter pylori strains detected by the anti–CagA assay in patients with peptic ulcer disease and in controls. Ching CK, et al. **Am J Gastroenterol** 1996 May;91(5):949–53

Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Fendrick AM, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1544–8

Helicobacter pylori and ulcerogenesis. Peura DA. **Am J Med** 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)

Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Marshall BJ. **Ann Med** 1995 Oct;27(5):565–8 (16 ref.)

Peptic ulcers can now be cured without operation [letter; comment] Cheng L, et al. **Ann R Coll Surg Engl** 1995 Nov; 77(6):463. Comment on: Ann R Coll Surg Engl 1995 May;77(3):168–73.

Surgery for peptic ulcer in the Helicobacter pylori era [letter] Kozol RA. **Arch Surg** 1995 Oct;130(10):1040; discussion 1041

We need to integrate new data concerning Helicobacter pylor into experimental ulcer research. Graham DY. **Dig Dis Sci** 1995 Nov;40(11):2487–9 (35 ref.)

Influence of Helicobacter pylori on tryptase and cathepsin D in peptic ulcer. Plebani M, et al. **Dig Dis Sci** 1995 Nov; 40(11):2473–6

Differences in urease activity in live Helicobacter pylori cultured from patients with gastroduodenal diseases. Ito S, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S83–8

Helicobacter pylori: who is positive and who is not? Kuipers EJ, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):533–6 (25 ref.)

H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov–Dec;42(6):827–41 (141 ref.)

Helicobacter pylori and peptic ulcer disease: current status [editorial] Groenberger NJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):11–2 (7 ref.)

Antimicrobial susceptibility pattern & biotyping of Helicobacter pylori isolates from patients with peptic ulcer diseases. Sharma S, et al. **Indian J Med Res** 1995 Dec; 102:261–6

Helicobacter pylori, oxygen–derived free radicals and histamine in peptic ulcer and inflammatory disease. Man WK, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S104–5

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107–11

Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. Katoh M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S112–4

Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. Ogoshi K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S97–9

Clinical efficacy of lansoprazole–amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S100–3

Helicobacter pylori and gastrointestinal disease. Gibaldi M. **J Clin Pharmacol** 1995 Jul;35(7):647–54 (44 ref.)

Helicobacter pylori: more than 10 years on and still catchy [editorial] Talley NJ. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):465–8

The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. Marshall BJ. **JAMA** 1995 Oct 4;274(13):1064–6

Influence of Helicobacter pylori colonization on histological grading of chronic gastritis in Korean patients with peptic ulcer. Park J, et al. **Korean J Intern Med** 1995 Jul; 10(2):125–9

Helicobacter pylori: how often are eradication therapies prescribed? [letter] Parkes AJ. **Med J Aust** 1995 Sep 18; 163(6):334

Specificity of Helicobacter pylori testing [letter] Fraser A. **N Z Med J** 1996 Aug 9;109(1027):304

Helicobacter pylori infection and its role in human disease—an overview. McColl KE. **Pharm World Sci** 1996 Apr;18(2):49–55 (84 ref.)

Suppression of Helicobacter pylori colonization with omeprazole. Fukuda Y. **Scand J Gastroenterol Suppl** 1996; 214:54–5; discussion 57–60

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Helicobacter pylori in ulcerogenesis. Lin SK, et al. **Scand J Gastroenterol Suppl** 1995;210:64–9 (72 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221–7 (68 ref.)

[Cause–targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853–9 (39 ref.) **(Fin)**

[Peptic ulcer and gastritis in the time of Helicobacter pylori] **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb; 32(1):25–34 (0 ref.) **(Fre)**

[Diagnostic efficiency of histological and simple microbiological tests for Helicobacter pylori detection in a community hospital] Mitry E, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):281–3 (Eng. Abstr.) **(Fre)**

[Importance of ranitidine in the eradication of Helicobacter pylori] Beglinger C. **Rev Med Suisse Romande** 1995 Oct; 115(10):795–7 **(Fre)**

[Helicobacter pylori as a cause of benign malignant peptic ulcer] Abou–Mouch S, et al. **Harefuah** 1995 Jun 15; 128(12):808–11 (44 ref.) **(Heb)**

[Detection of Helicobacter pylori in biopsy specimens, methodical studies] Cserni G, et al. **Orv Hetil** 1995 Oct 8;136(41):2225–30 (Eng. Abstr.) **(Hun)**

[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):313–9 (22 ref.) **(Jpn)**

[Helicobacter pylori—an etiopathogenic factor of stomach and duodenal diseases among children] Czerwionka–Szaflarska M, et al. **Pediatr Pol** 1995 Jul; 70(7):563–8 (Eng. Abstr.) **(Pol)**

[Prevalence of Helicobacter pylori infection in gastrectomy and vagotomy] Boixeda D, et al. **Rev Clin Esp** 1995 Nov; 195(11):757–60 (Eng. Abstr.) **(Spa)**

MORTALITY

[Trends of peptic ulcer mortality in São Paulo State (Brazil), 1970–1989] Lotufo PA, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):130–4 (Eng. Abstr.) **(Por)**

[An analysis of the mortality in the planned surgery for peptic ulcer] Skatin LI, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):352–5 **(Rus)**

PATHOLOGY

Histopathological evaluation of gastric mucosal environments in peptic ulcer using the endoscopic 5–point gastric biopsy method. Kobayashi H, et al. **Acta Med Okayama** 1995 Aug; 49(4):195–200

Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly? Di Mario F, et al. **Dig Dis Sci** 1996 Jan;41(1):17–21

Gastric mucormycosis. Sharma MC, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S8–9

The mast cells and an experimental gastric ulcer. Histochemical, ultrastructural and quantitative study in the rat. Rudzki Z, et al. **Pol J Pathol** 1995;46(4):225–34

[Diagnostic efficiency of histological and simple microbiological tests for Helicobacter pylori detection in a community hospital] Mitry E, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):281–3 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Helicobacter pylori and ulcerogenesis. Peura DA. **Am J Med** 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)

Role of epidermal growth factor in peptic ulcer healing. Calabrò A, et al. **Dig Dis Sci** 1995 Nov;40(11):2497–504 (63 ref.)

Risk factors associated with refractory peptic ulcers. Lanas AI, et al. **Gastroenterology** 1995 Oct;109(4):1124–33

Comparative evaluation of gastric secretory response to banana and porridge. Dadoo RC, et al. **Indian J Med Sci** 1995 Jan;49(1):5–8

Sleep and internal medicine. Shiozawa Z. **Intern Med** 1996 Jan;35(1):45–7

Clinical study on the pathophysiology and treatment of PPI–resistant ulcers. Ashida K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S67–71

[A study of the relationship between nocturnal intragastric pH and sleep stages of peptic ulcer] Watanabe M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1241–9 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double–blind study of sucralfate versus antacids. Bonten MJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1825–34

Misoprostol in patients taking non–steroidal anti–inflammatory drugs [editorial] [see comments] Maiden N, et al. **BMJ** 1995 Dec 9;311(7019):1518–9. Comment in: BMJ 1996 Mar 30;312(7034):846; discussion 847. Comment in: BMJ 1996 Mar 30;312(7034):846–7.

Peptic ulcer recurrence after Helicobacter pylori eradication: a 5–year follow–up study. Fujioka T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S35–8

Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. Thomason MH, et al. **J Trauma** 1996 Sep; 41(3):503–8

Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta–analyses. Cook DJ, et al. **JAMA** 1996 Jan 24–31;275(4):308–14

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159–61, 165–6, 168 (23 ref.)

Prevention of gastrointestinal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):131–4 (15 ref.)

Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)

Long–term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

[Prevention of stress ulcer in intensive care patients—pro] Tryba M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):509–10 **(Ger)**

[Prevention of stress ulcer in intensive care patients—contra] Wiedeck H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):507–8 **(Ger)**

[Effective prevention of indomethacin–induced gastroduodenal mucosal lesions with roxatidine acetate] Dammann HG, et al. **Arzneimittelforschung** 1995 Aug; 45(8):880–2 (Eng. Abstr.) **(Ger)**

–Development of a mouse model for Helicobacter pylori infection in the human—progress toward vaccination against ulcer disease?– Gallwitz B, et al. **Z Gastroenterol** 1996 Mar;34(3):202–4 **(Ger)**

[The influence of retinol, tocopherol and cimetidine on the ulcerogenic effect of Orthofen, indomethacin and naproxen] Stanislavchuk NA, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):33–5 (Eng. Abstr.) **(Rus)**

[The efficacy of the synthetic prostaglandin Cytotec in preventing and treating symptomatic gastropathy] Normanskil ES, et al. **Voen Med Zh** 1996 Feb;317(2):33–5 **(Rus)**

PSYCHOLOGY

Managed care, or Scope hits the Sphinx. Further thoughts [letter] Buch PS. **J Clin Gastroenterol** 1996 Mar;22(2):165

Sociodemographic characteristics, life stressors, and peptic ulcer. A prospective study. Levenstein S, et al. **J Clin Gastroenterol** 1995 Oct;21(3):185–92

RADIOGRAPHY

[Enhanced accuracy of the X–ray diagnosis of acute abdomen with patient in the supine (pregnancy standard) position] Szántó D, et al. **Orv Hetil** 1995 Oct 22;136(43):2329–32 (Eng. Abstr.) **(Hun)**

REHABILITATION

[The Infita therapy of peptic ulcer] Markarov GS, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):38–9 **(Rus)**

SURGERY

Surgery for peptic ulcer in the Helicobacter pylori era [letter] Kozol RA. **Arch Surg** 1995 Oct;130(10):1040; discussion 1041

Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al–Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)

Surgical treatment of peptic ulceration. Stabile BE. **Curr Opin Gen Surg** 1993;:206–15 (37 ref.)

Carcinogenesis after remote peptic ulcer surgery: the long–term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)

Laparoscopic management of peptic ulcer disease. Casas AT, et al. **Surg Clin North Am** 1996 Jun;76(3):515–22 (23 ref.)

Acute surgical treatment of complicated peptic ulcers with special reference to the elderly. Bulut OB, et al. **World J Surg** 1996 Jun;20(5):574–7

Minimal access surgery—the renaissance of gastric surgery? McCloy R, et al. **Yale J Biol Med** 1994 May–Aug; 67(3–4):159–66 (38 ref.)

[Surgical therapy of uncomplicated ulcer: results of a prospective epidemiologic study. DUSUK Study Group (see comments)] Imhof M, et al. **Z Gastroenterol** 1995 Jul; 33(7):381–4 (Eng. Abstr.). Comment in: Z Gastroenterol 1995 Jul;33(7):379–80. **(Ger)**

[Sequelae of stomach resection and gastrectomy and its consequences] Kirchner R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:20–3 (18 ref.) **(Ger)**

[Role of surgery in the treatment of gastroduodenal ulcer] Zoppi S, et al. **G Chir** 1995 Oct;16(10):442–4 (Eng. Abstr.) **(Ita)**

[First experience with laparoscopic vagotomy in the treatment of peptic ulcer] Balalykin AS, et al. **Khirurgiia (Mosk)** 1995;(5):9–11 **(Rus)**

[Resection of the esophagus in peptic esophagitis and ulcer] Protsenko AV, et al. **Klin Khir** 1996;(1):22–5 **(Rus)**

[Duodenogastric reflux in pathogenesis of peptic ulcer recurrence after conservative surgery with vagotomy] Ermolov AS, et al. **Klin Med (Mosk)** 1995;73(6):63–4 **(Rus)**

[Prevalence of Helicobacter pylori infection in gastrectomy and vagotomy] Boixeda D, et al. **Rev Clin Esp** 1995 Nov;

195(11):757–60 (Eng. Abstr.) **(Spa)**
[Peptic ulcer: late complications of the surgical treatment] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):273–81 (109 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

'Cure' of Helicobacter pylori. Clinically indicated and economically wise! [editorial; comment] Fennerty MB. **Arch Intern Med** 1995 Oct 9;155(18):1929–31. Comment on: Arch Intern Med 1995 Oct 9;155(18):1958–64.
Gastric acid-related disorders: GORD and peptic ulcer disease. Lambert J, et al. **Aust Fam Physician** 1995 Oct; 24(10):1889–91, 1894–6
A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. Llach J, et al. **Gastrointest Endosc** 1996 Feb; 43(2 Pt 1):117–20
Variation in the use of red blood cell transfusions. A study of four common medical and surgical conditions. Hasley PB, et al. **Med Care** 1995 Nov;33(11):1145–60
Therapeutic applications of vagotomy. Olbe L. **Yale J Biol Med** 1994 May–Aug;67(3–4):153–7 (13 ref.)
[Cause-targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853–9 (39 ref.) **(Fin)**
[Endoscopic treatment of upper gastrointestinal diseases] Kaneko E. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1528–31 (0 ref.) **(Jpn)**
[Functional evaluation of the condition of patients with peptic ulcer and its changes during treatment] Tovbuchenko MP. **Klin Med (Mosk)** 1995;73(4):49–52 **(Rus)**

PEPTIC ULCER HEMORRHAGE

CHEMICALLY INDUCED

Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Zimmerman J, et al. **Am J Gastroenterol** 1995 Nov;90(11):2032–4
Emergency! Bleeding gastric ulcer. Tolbert CG, et al. **Am J Nurs** 1996 Feb;96(2):48
When Goody's Powder is not so good. Hamdy RC, et al. **J Tenn Med Assoc** 1996 Feb;89(2):43–4

CLASSIFICATION

Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Raiford DS, et al. **Epidemiology** 1996 Jan;7(1):101–4

COMPLICATIONS

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)
Risk of further ulcer complications after an episode of peptic ulcer bleeding. Ng EK, et al. **Br J Surg** 1996 Jun; 83(6):840–4
Bleeding gastric ulcer complicating splenosis in type 1 Gaucher's disease. Chiarugi M, et al. **Eur J Surg** 1996 Jan; 162(1):63–5

DIAGNOSIS

Rebleeding rate of various stigmata of recent hemorrhage in peptic ulcer bleeding with different severity. Chen JJ, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):209–16
[The endoscopic diagnostic and therapeutic procedure in acute peptic hemorrhages from the upper gastrointestinal tract] Chobanov I. **Khirurgiia (Sofiia)** 1995;48(4):30–1 (Eng. Abstr.) **(Bul)**
[Clinical aspects and diagnosis of peptic ulcer hemorrhage—risk factors] Bosseckert H. **Bildgebung** 1995 Oct;62 Suppl 2:5–10 (11 ref.) **(Ger)**

DRUG THERAPY

Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D. **Endoscopy** 1995 Oct;27(8):622–5 (21 ref.)
Epinephrine injection therapy for peptic ulcer bleeding in hemophilia patients [letter] Kadayifci A, et al. **Eur J Haematol** 1996 May;56(5):321–2
Endoscopic appearances of hemorrhagic peptic ulcers and efficacy of H2-receptor antagonists. Fusamoto H, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):169–73
Octreotide for arrest of peptic ulcer hemorrhage—a prospective, randomized controlled trial. Lin HJ, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):856–60
Endoscopic adrenaline injection in treatment of bleeding peptic ulcers. Fock KM, et al. **Int Surg** 1995 Apr–Jun; 80(2):134–7
Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. Lanas A, et al. **J Clin Gastroenterol** 1995 Sep;21(2):103–6
[What is the effect of omeprazole in acute peptic ulcer hemorrhage? (letter)] Kohler B. **Leber Magen Darm** 1995 Jul;25(4):153 **(Ger)**
[Treatment error, negligent physical injury and negligent homicide (letter)] Rösch W. **Leber Magen Darm** 1995 Jul; 25(4):154 **(Ger)**
[Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?] Prassler R, et al. **Z Gastroenterol** 1995 Aug; 33(8):431–4 (Eng. Abstr.) **(Ger)**
[Initial experience in the use of stilamin (somatostatin) in hemorrhage of ulcer origin] Grebenev AL, et al. **Klin Med (Mosk)** 1995;73(5):31–2 **(Rus)**
[The use of tardyferon in the combined treatment of patients with chronic atrophic gastritis and peptic ulcer complicated by hemorrhage] Kharchenko NV, et al. **Lik Sprava** 1995 May–Jun;(5–6):87–91 (Eng. Abstr.) **(Rus)**
[Effect of the histamine H2-receptor antagonist zantac on lipid peroxidation an antioxidant system in patients with gastroduodenal hemorrhage of ulcer etiology] Ermolov AS, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):23–5 (Eng. Abstr.) **(Rus)**
[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM. **Vestn Khir Im I I Grek** 1995;154(3):120–3 (37 ref.) **(Rus)**
[Stress-limiting effect of zantac in duodenal ulcer bleeding] Ermolov AS, et al. **Vopr Med Khim** 1995 Sep–Oct; 41(5):56–9 (Eng. Abstr.) **(Rus)**
[Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage] Artal A, et al. **Rev Esp Enferm Dig** 1996 Mar; 88(3):191–6 (Eng. Abstr.) **(Spa)**

ECONOMICS

A cost-effective approach to the patient with peptic ulcer bleeding. Jiranek GC, et al. **Surg Clin North Am** 1996 Feb; 76(1):83–103 (124 ref.)

EPIDEMIOLOGY

Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer. Hudson N, et al. **Gut** 1995 Aug;37(2):182–6

ETIOLOGY

Risk for rebleeding of the duodenal bulbar ulcer is less than that of the gastric ulcer [letter] Koyama T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1290–1
Acid peptic disease in relation to Ramadan fasting: a preliminary endoscopic evaluation [letter] Mallk GM, et al. **Am J Gastroenterol** 1995 Nov;90(11):2076–7
A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. Yeo W, et al. **Dig Dis Sci** 1995 Dec;40(12):2516–21
Helicobacter pylori and acute bleeding peptic ulcer [see comments] Henriksson AE, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):769–71. Comment in: Eur J Gastroenterol Hepatol 1995 Aug;7(8):753–5.
Natural history of bleeding peptic ulcers with a tightly adherent blood clot: a prospective observation. Lin HJ, et al. **Gastrointest Endosc** 1996 May;43(5):470–3
[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16–23;24(39):1902–6 (58 ref.) (Eng. Abstr.) **(Fre)**
[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**
[Morphological changes in the gastric mucosa in peptic ulcer hemorrhage] Zaftsev VT, et al. **Klin Khir** 1995;(4):3–5 **(Rus)**
[The significance of thrombocytic and coagulative hemostasis in the pathogenesis of peptic gastroduodenal hemorrhages] Korymasov EA. **Vestn Khir Im I I Grek** 1992 Feb; 148(2):130–4 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Do Helicobacter pylori-positive duodenal ulcers have an increased risk of bleeding? [letter] Kadayifci A, et al. **Am J Gastroenterol** 1995 Oct;90(10):1901
Helicobacter pylori and complicated ulcer disease. Laine LA. **Am J Med** 1996 May 20;100(5A):52S–57S; discussion 57S–59S (47 ref.)
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D. **Endoscopy** 1995 Oct;27(8):622–5 (21 ref.)
The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer [comment] McColl KE. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):753–5. Comment on: Eur J Gastroenterol Hepatol 1995 Aug;7(8):769–71.

MORTALITY

Late mortality in elderly patients surviving acute peptic ulcer bleeding. Hudson N, et al. **Gut** 1995 Aug;37(2):177–81

NURSING

Emergency! Bleeding gastric ulcer. Tolbert CG, et al. **Am J Nurs** 1996 Feb;96(2):48

PATHOLOGY

Bleeding giant gastric ulcer. Yii MK, et al. **Aust N Z J Surg** 1996 Aug;66(8):540–2
Endoscopic appearances of hemorrhagic peptic ulcers and efficacy of H2-receptor antagonists. Fusamoto H, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):169–73
[Hemorrhagic stress lesions in the gastroduodenal mucosa. Incidence and therapy] Radovanović D, et al. **Med Pregl** 1995;48(5–6):178–81 (Eng. Abstr.) **(Scr)**

PHYSIOPATHOLOGY

[The central hemodynamic indices of patients with ulcerative gastroduodenal hemorrhage] Kharaberiush VA, et al. **Lik Sprava** 1995 May–Jun;(5–6):163–6 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Santander C, et al. **Am J Gastroenterol** 1996 Aug;91(8):1549–52
Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study. Chua RT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb; 57(2):139–45
How many patients must we treat for Helicobacter pylori infection to prevent a recurrent duodenal ulcer hemorrhage? [letter; comment] Howden CW. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):175. Comment on: Gastrointest Endosc 1995 Jan;41(1):1–4. Comment on: Gastrointest Endosc 1995 Jan;41(1):5–7.
Prevention of recurrent bleeding from gastric ulcer with a nonbleeding visible vessel by endoscopic injection of absolute ethanol: a prospective, controlled trial. Koyama T, et al. **Gastrointest Endosc** 1995 Aug;42(2):128–31
Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4–7 (24 ref.)
Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)
[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**
[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**
[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**
[The prophylactic taking of low doses of acetylsalicylic acid and the risk of ulcer hemorrhage] **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1759 **(Ger)**
[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer (letter)] Gisbert JP, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):910–1 **(Spa)**

SURGERY

An experimental study of optimal parameters for bipolar electrocoagulation. Dilley AV, et al. **Gastrointest Endosc** 1995 Jul;42(1):27–30
Endoscopic intervention in bleeding peptic ulcer. Palmer KR, et al. **Gut** 1995 Aug;37(2):161–4
Heater probe thermocoagulation and multipolar electrocoagulation for arrest of peptic ulcer bleeding. A prospective, randomized comparative trial. Lin HJ, et al. **J Clin Gastroenterol** 1995 Sep;21(2):99–102
Laparoscopic transgastric suturing for bleeding peptic ulcers. Potvin M, et al. **Surg Endosc** 1996 Apr;10(4):400–2
[Post-surgical intractable gastric bezoars: usefulness of laser therapy (letter)] Viala M, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):648 **(Fre)**
[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis—indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22–8 (29 ref.) (Eng. Abstr.) **(Ger)**
-Severe hemobilia after percutaneous transhepatic biliary drainage. Successful treatment by arterial catheter embolization- Neef B, et al. **Z Gastroenterol** 1996 Mar; 34(3):183–7 (Eng. Abstr.) **(Ger)**
[A case report of surgical treatment for acute mitral insufficiency associated with acute gastric lesion] Inoue A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun; 44(6):835–8 (Eng. Abstr.) **(Jpn)**
[The choice of the method for surgical intervention in patients with a hemorrhaging pyloroduodenal ulcer taking into account gastric helicobacteriosis] Zaltsev VT, et al. **Klin Khir** 1995;(9–10):10–2 **(Rus)**
[Roux gastric resection in peptic gastroduodenal hemorrhages] Voinovskii EA, et al. **Voen Med Zh** 1995 Mar;(3):41–3 **(Rus)**

THERAPY

Does haemostatic therapy improve the prognosis in upper gastrointestinal bleeding? Nikolopoulou V, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):186–8
Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Kubba AK, et al. **Br J Surg** 1996 Apr;83(4):461–8 (88 ref.)
Success of endoscopic injection therapy in correlation with

maximal one-day transfusion requirement. Chen JJ, et al. **Endoscopy** 1995 May;27(4):298–303

Comparison of injection sclerotherapy and laser photocoagulation for bleeding peptic ulcers. Pulanić R, et al. **Endoscopy** 1995 May;27(4):291–7

What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P. **Endoscopy** 1995 May;27(4):321–8 (69 ref.)

Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. Toyoda H, et al. **Endoscopy** 1995 May;27(4):304–7

Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Villanueva C, et al. **Endoscopy** 1995 May;27(4):308–12

The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer [comment] McColl KE. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):753–5. Comment on: Eur J Gastroenterol Hepatol 1995 Aug;7(8):769–71.

Factors predicting failure of endoscopic injection therapy in bleeding duodenal ulcer. Brullet E, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):111–6

A prospective outcome study of patients with clot in an ulcer and the effect of irrigation. Laine L, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):107–10

A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. Llach J, et al. **Gastrointest Endosc** 1996 Feb; 43(2 Pt 1):117–20

Prolonged evaluation of epinephrine and normal saline solution injections in an acute ulcer model with a single bleeding artery. Pinkas H, et al. **Gastrointest Endosc** 1995 Jul;42(1):51–5

Simple and effective endoscopic tamponade for duodenal bleeding. Taylor TV, et al. **Gastrointest Endosc** 1996 Feb; 43(2 Pt 1):144–5

Octreotide and heater probe thermocoagulation for arrest of peptic ulcer hemorrhage. A prospective, randomized, controlled trial. Lin HJ, et al. **J Clin Gastroenterol** 1995 Sep;21(2):95–8

Estimation of usefulness of N-butyl-2-cyanoacrylate-lipiodol mixture in transcatheter arterial embolization for urgent control of life-threatening massive bleeding from gastric or duodenal ulcer. Toyoda H, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):252–8

Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion. Grosso C, et al. **Scand J Gastroenterol** 1995 Sep;30(9):872–5

A cost-effective approach to the patient with peptic ulcer bleeding. Jiranek GC, et al. **Surg Clin North Am** 1996 Feb; 76(1):83–103 (124 ref.)

Is endoscopic injection hemostasis of bleeding gastrointestinal ulcers obsolete in 1995? Caputi Iambrenghi O, et al. **Surg Endosc** 1995 Oct;9(10):1090–2

[The endoscopic diagnostic and therapeutic procedure in acute peptic hemorrhages from the upper gastrointestinal tract] Chobanov I. **Khirurgiia (Sofiia)** 1995;48(4):30–1 (Eng. Abstr.) **(Bul)**

[Clinical application of endoscopic injection of medication for stopping gastric bleeding] Liu B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):446–8 (Eng. Abstr.) **(Chi)**

[Non-surgical treatment of bleeding gastric ulcer. A follow-up after 5–8 years] Madsen MR, et al. **Ugeskr Laeger** 1995 Oct 9;157(41):5721–4 (Eng. Abstr.) **(Dan)**

[Endoscopic hemostasis of gastroduodenal ulcerous hemorrhages] Naveau S, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B10–4 **(Fre)**

[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16–20 (29 ref.) **(Ger)**

[Bleeding peptic ulcers—concept for acute therapy (letter)] Friedrichs O. **Leber Magen Darm** 1996 Mar;26(2):114–6 **(Ger)**

[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313–8 (42 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Bleeding esophageal duplication detected in utero. Peiper M, et al. **Ann Thorac Surg** 1995 Dec;60(6):1790–1

[What is the value of endoscopic Doppler ultrasound in differential diagnosis of not actively bleeding lesions?] Kohler B. **Bildgebung** 1995 Oct;62 Suppl 2:12–5 **(Ger)**

PEPTIC ULCER PERFORATION

COMPLICATIONS

Perforated gastric ulcer in children. Case report. Dilek ON, et al. **Acta Chir Belg** 1995;95(4 Suppl):182–3

Are perforated gastroduodenal ulcers related to Helicobacter pylori infection? Debongnie JC, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr;58(2):208–12

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)

Repeated pseudo-obstruction, mental subnormality—and serious snags. Guy RJ, et al. **J R Nav Med Serv** 1995 Summer;81(2):117–9

Intramural abscess of the duodenum resulting from perforated peptic ulcer. Albu E, et al. **South Med J** 1995 Oct; 88(10):1078–80

Effect of a pneumoperitoneum on the extent and severity of peritonitis induced by gastric ulcer perforation in the rat. Bloechle C, et al. **Surg Endosc** 1995 Aug;9(8):898–901

[Severe parietal cellulitis following laparoscopy for peritonitis caused by perforated duodenal ulcer (letter)] Samama G, et al. **Gastroenterol Clin Biol** 1996 Feb; 20(1):116–8 **(Fre)**

[Pneumopericardium: a race against time! Case report and literature review] Alvarez L, et al. **Rev Med Brux** 1996 Jun;17(3):143–6 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

ECG changes with perforated duodenal ulcer mimicking acute cardiac ischemia. Sole DP, et al. **Am J Emerg Med** 1996 Jul;14(4):410–1

[Relationship of blood calcium level and manifestations of clinical symptoms of perforated gastroduodenal ulcer] Mitsura DI. **Klin Khir** 1995;(4):46–7 **(Rus)**

[Errors in the diagnosis of perforating gastroduodenal ulcers in the prehospital stage] Dzikovich VV. **Klin Med (Mosk)** 1995;73(4):91–2 **(Rus)**

DRUG THERAPY

Simple closure and follow up H2 receptor antagonists for perforated peptic ulcer—immediate survival and symptomatic outcome. Abbasakoor F, et al. **Ir Med J** 1995 Nov-Dec;88(6):207–10

EPIDEMIOLOGY

Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93–6 (43 ref.). Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82–7.

[Epidemiological behavior of perforated peptic ulcer before and after the introduction of the antisecretory drug therapy. Our experience] Sacco R, et al. **Minerva Chir** 1995 Oct; 50(10):871–8 (Eng. Abstr.) **(Ita)**

[Perforated gastroduodenal ulcers in women] Ponomarev AA, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):242–7 (56 ref.) **(Rus)**

ETIOLOGY

The Rapunzel syndrome (trichobezoar) causing gastric perforation in a child: a case report. Pul N, et al. **Eur J Pediatr** 1996 Jan;155(1):18–9

MORTALITY

Some factors associated with mortality in perforated peptic ulcer: a case-control study [see comments] McIntosh JH, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):82–7. Comment in: J Gastroenterol Hepatol 1996 Jan;11(1):93–6.

PATHOLOGY

Endoscopic appearance of a gallbladder-sealed perforated duodenal ulcer [letter] Short TP. **Am J Gastroenterol** 1995 Oct;90(10):1906–7

[Perforated stomach and duodenal ulcers: the effect of their localization on the course of the disease and its prognosis] Bachev II. **Vestn Khir Im I I Grek** 1992 Feb;148(2):127–30 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Atypical presentation in the elderly—case report of an acute abdomen. Yap KB, et al. **Singapore Med J** 1995 Feb; 36(1):96–8

[Enhanced accuracy of the X-ray diagnosis of acute abdomen with patient in the supine (pregnancy standard) position] Szántó D, et al. **Orv Hetil** 1995 Oct 22;136(43):2329–32 (Eng. Abstr.) **(Hun)**

[Computed tomography in the study of gastrointestinal perforation] Catalano O. **Radiol Med (Torino)** 1996 Mar; 91(3):247–52 (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Perforated peptic ulcer demonstrated by biliary imaging. Wang SJ, et al. **Clin Nucl Med** 1995 Nov;20(11):1031

SURGERY

Perforated gastric ulcer in children. Case report. Dilek ON, et al. **Acta Chir Belg** 1995;95(4 Suppl):182–3

Laparoscopic repair of perforated duodenal ulcers with a falciform ligament patch. Munro WS, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):390–1

A randomized study comparing laparoscopic versus open repair of perforated peptic ulcer using suture or sutureless technique. Lau WY, et al. **Ann Surg** 1996 Aug;224(2):131–8

Laparoscopic omental patch repair for perforated peptic ulcer [letter] Memon MA. **Ann Surg** 1995 Dec;222(6):761–2

Perforated pyloroduodenal ulcers [letter; comment] Schein M. **Ann Surg** 1995 Dec;222(6):768–9. Comment on: Ann Surg 1995 May;221(5):479–86; discussion 486–8.

Anaesthesia for laparoscopic closure of perforated peptic ulcer—any harm or benefit? Eypasch E, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):171–3

Changing trends in acute peptic ulcer surgery in a district surgical unit. Barry MC, et al. **Ir J Med Sci** 1996 Apr-Jun; 165(2):109–12

Simple closure and follow up H2 receptor antagonists for perforated peptic ulcer—immediate survival and symptomatic outcome. Abbasakoor F, et al. **Ir Med J** 1995 Nov-Dec;88(6):207–10

Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93–6 (43 ref.). Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82–7.

Combined laparoscopic and endoscopic treatment of perforated gastroduodenal ulcer using the ligamentum teres hepatis (LTH) [see comments] Costalat G, et al. **Surg Endosc** 1995 Jun;9(6):677–9; discussion 680. Comment in: Surg Endosc 1995 Jun;9(6):674–6.

Laparoscopic suture closure of perforated peptic ulcer. A nonrandomized comparison with open surgery. Johansson B, et al. **Surg Endosc** 1996 Jun;10(6):656–8

Ligamentum teres not the ideal ulcer patch [letter] Lewis WI. **Surg Endosc** 1996 Jun;10(6):697

Laparoscopic and conventional closure of perforated peptic ulcer. A comparison. Miserez M, et al. **Surg Endosc** 1996 Aug;10(8):831–6

Minimally invasive approach to perforated ulcer—is it? [editorial; comment] Simon IB. **Surg Endosc** 1995 Jun; 9(6):674–6. Comment on: Surg Endosc 1995 Jun;9(6):677–9; discussion 680.

[Laparoscopic suturing of perforated duodenal and prepyloric ulcers] Cejka P, et al. **Rozhl Chir** 1996 Jan; 75(1):5–7 (Eng. Abstr.) **(Cze)**

[Our experience with the treatment of duodenal perforation with suture] Bonati L, et al. **G Chir** 1995 Jun-Jul; 16(6-7):290–2 (Eng. Abstr.) **(Ita)**

[Two cases of perforated ulcer in young patients] Portnov AN. **Klin Khir** 1995;(6):51 **(Rus)**

[Closure of the duodenal stump in a penetrating low-lying ulcer] Skripnikov NS, et al. **Klin Khir** 1995;(9-10):15–7 **(Rus)**

[Features of resection of perforating pyloric-duodenal ulcer in patients with diffuse peritonitis] Zaĭtsev VT, et al. **Klin Khir** 1995;(4):14–5 **(Rus)**

[Dependence of long-term results of suturing perforating gastroduodenal ulcers on the occupation of patients] Volkov ElIu, et al. **Klin Med (Mosk)** 1995;73(4):98 **(Rus)**

[The effect of HBO therapy in the early postoperative period on the late outcomes of "compelled" suturing in perforated gastroduodenal ulcers] Belokurov IuN, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):124–7 (Eng. Abstr.) **(Rus)**

[The prevention of early postoperative complications in perforated pyloroduodenal ulcer] Kul'chiev AA, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):331–5 (Eng. Abstr.) **(Rus)**

[The choice of the surgical assistance in perforated duodenal ulcers in servicemen on active duty] Satsukevich VN, et al. **Voen Med Zh** 1995 Oct;(10):22–3 **(Rus)**

PEPTICHEMIO

THERAPEUTIC USE

A prognostic index for multiple myeloma. Grignani G, et al. **Br J Cancer** 1996 May;73(9):1101–7

PEPTIDASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE ANTIBIOTICS see **ANTIBIOTICS, PEPTIDE**

PEPTIDE CHAIN ELONGATION

see related
PEPTIDE ELONGATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

Dissection of ADP-ribose polymer synthesis into individual steps of initiation, elongation, and branching. Alvarez-Gonzalez R, et al. **Biochimie** 1995;77(6):403–7

Multienzymatic non ribosomal peptide biosynthesis: identification of the functional domains catalysing peptide elongation and epimerisation. De Crécy-Lagard V, et al. **C R Acad Sci III** 1995 Sep;318(9):927–36

Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369–75 (48 ref.)

A new translational elongation factor for selenocysteyl-tRNA in eucaryotes. Yamada K. **FEBS Lett** 1995 Dec 27;377(3):313–7

Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. Gilligan M, et al. **J Biol Chem** 1996 Jan 26; 271(4):2121–5

Codon pair utilization biases influence translational elongation step times. Irwin B, et al. **J Biol Chem** 1995 Sep 29;270(39):22801–6

Protein synthesis. An elongation factor turn-on [news; comment] Nierhaus KH. **Nature** 1996 Feb 8; 379(6565):491–2. Comment on: Nature 1996 Feb 8;379(6565):511–8.

Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis. Dodds PF. **Prog Lipid Res** 1995;34(3):219–47 (209 ref.)

DRUG EFFECTS

EF-1 alpha is a target site for an inhibitory effect of quercetin in the peptide elongation process. Marcinkiewicz C, et al. **Acta Biochim Pol** 1995;42(3):347-50

Effect of sulphur mustard on the initiation and elongation of transcription. Masta A, et al. **Carcinogenesis** 1996 Mar; 17(3):525-32

Enacyloxin IIa, an inhibitor of protein biosynthesis that acts on elongation factor Tu and the ribosome. Cetin R, et al. **EMBO J** 1996 May 15;15(10):2604-11

Mutations in the peptidyl transferase center of 23 S rRNA reveal the site of action of sparsomycin, a universal inhibitor of translation. Tan GT, et al. **J Mol Biol** 1996 Aug 16;261(2):222-30

Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24-37 (189 ref.)

GENETICS

Selection of aminoacyl-tRNAs at sense codons: the size of the tRNA variable loop determines whether the immediate 3' nucleotide to the codon has a context effect. Curran JF, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4104-8

PHYSIOLOGY

Mutants of EF-Tu defective in binding aminoacyl-tRNA. Abdulkarim F, et al. **FEBS Lett** 1996 Mar 18; 382(3):297-303

Light is required for efficient translation elongation and subsequent integration of the D1-protein into photosystem II. van Wijk KJ, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):89-93

PEPTIDE CHAIN INITIATION

see related
PEPTIDE INITIATION FACTORS
PROTEIN SYNTHESIS INHIBITORS

Regulation of GLUT4 mRNA stability by tumor necrosis factor-alpha: alterations in both protein binding to the 3' untranslated region and initiation of translation. Long SD, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):949-53

Lack of correlation between Sendai virus P/C mRNA structure and its utilization of two AUG start sites from alternate reading frames: implications for viral bicistronic mRNAs. Gupta KC, et al. **Biochemistry** 1996 Jan 30; 35(4):1223-31

Dissection of ADP-ribose polymer synthesis into individual steps of initiation, elongation, and branching. Alvarez-Gonzalez R, et al. **Biochimie** 1995;77(6):403-7

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517-20 (20 ref.)

Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor-2. Singh LP, et al. **Enzyme Protein** 1994-95; 48(2):61-80 (101 ref.)

Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747-71 (372 ref.)

Translation initiation and assembly of peripherin in cultured cells. Ho CL, et al. **Eur J Cell Biol** 1995 Oct;68(2):103-12

The 3-phosphoglycerate kinase of the hyperthermophilic archaeum Pyrococcus woesei produced in Escherichia coli: loss of heat resistance due to internal translation initiation and its restoration by site-directed mutagenesis. Hess D, et al. **Gene** 1996 Jun 12;172(1):121-4

Selective translation initiation by ribosome jumping in adenovirus-infected and heat-shocked cells. Yueh A, et al. **Genes Dev** 1996 Jun 15;10(12):1557-67

A non-AUG translational initiation event generates novel WT1 isoforms. Bruening W, et al. **J Biol Chem** 1996 Apr 12;271(15):8646-54

Mutations at two invariant nucleotides in the 3'-minor domain of Escherichia coli 16 S rRNA affecting translational initiation and initiation factor 3 function. Firpo MA, et al. **J Biol Chem** 1996 Mar 1;271(9):4693-8

Late events in translation initiation. Adjustment of fMet-tRNA in the ribosomal P-site. La Teana A, et al. **J Mol Biol** 1996 Mar 8;256(4):667-75

Position-dependent ATT initiation during plant pararetrovirus rice tungro bacilliform virus translation. Fütterer J, et al. **J Virol** 1996 May;70(5):2999-3010

Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization. Simons JN, et al. **J Virol** 1996 Sep; 70(9):6126-35

Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP.Met-tRNA(iMet) ternary complexes. Dever TE, et al. **Mol Cell Biol** 1995 Nov;15(11):6351-63

The A1 x U72 base pair conserved in eukaryotic initiator tRNAs is important specifically for binding to the eukaryotic translation initiation factor eIF2. Farruggio D, et al. **Mol Cell Biol** 1996 Aug;16(8):4248-56

Evidence for involvement of trans-acting factors in selection of the AUG start codon during eukaryotic translational initiation. McBratney S, et al. **Mol Cell Biol** 1996 Jul; 16(7):3523-34

Altered mRNA binding activity and decreased translational initiation in a nuclear mutant lacking translation of the chloroplast psbA mRNA. Yohn CB, et al. **Mol Cell Biol** 1996 Jul;16(7):3560-6

Translational initiation competence, 'leaky scanning' and translational reinitiation in areA mRNA of Aspergillus nidulans. Arst HN Jr, et al. **Mol Microbiol** 1996 Mar; 19(5):1019-24

Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Kevil C, et al. **Oncogene** 1995 Dec 7;11(11):2339-48

The sequence surrounding the translation initiation codon of the pea plastocyanin gene increases translational efficiency of a reporter gene. Helliwell CA, et al. **Plant Mol Biol** 1995 Nov;29(3):621-6

Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Rousseau D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1065-70

Protein-protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Tang H, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1119-24

The nascent-polypeptide-associated complex: having a "NAC" for fidelity in translocation [comment] Wickner W. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9433-4. Comment on: Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9435-9.

Translational control of maturation-protein synthesis in phage MS2: a role for the kinetics of RNA folding? Groeneveld H, et al. **RNA** 1995 Mar;1(1):79-88

An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region. Wang C, et al. **RNA** 1995 Jul;1(5):526-37

Cis-acting elements of the encephalomyocarditis virus internal ribosomal entry site. Witherell GW, et al. **Virology** 1995 Dec 20;214(2):660-3

[15-19-mer synthetic oligoribonucleotide as a model of the translation initiation segment of the phage fr replicase gene] Kumpin'sh VKh, et al. **Bioorg Khim** 1995 Dec;21(12):920-4 (Eng. Abstr.) (Rus)

[Internal initiation of translation in eukaryotes. Chemical probing of the encephalomyocarditis virus RNA IRES-element in the 48S preinitiation complex] Boroviagin AV, et al. **Mol Biol (Mosk)** 1995 May-Jun;29(3):679-88 (Eng. Abstr.) (Rus)

DRUG EFFECTS

Spermidine regulation of protein synthesis at the level of initiation complex formation of Met-tRNAi, mRNA and ribosomes. Shimogori T, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):544-8

Effect of sulphur mustard on the initiation and elongation of transcription. Masta A, et al. **Carcinogenesis** 1996 Mar; 17(3):525-32

GENETICS

Growth factor-independent expression of the gene encoding eukaryotic translation initiation factor 4E in transformed cell lines. Rosenwald IB. **Cancer Lett** 1995 Nov 27; 98(1):77-82

The downstream box: an efficient and independent translation initiation signal in Escherichia coli. Sprengart ML, et al. **EMBO J** 1996 Feb 1;15(3):665-74

Inhibition of translation initiation on Escherichia coli gnd mRNA by formation of a long-range secondary structure involving the ribosome binding site and the internal complementary sequence. Chang JT, et al. **J Bacteriol** 1995 Nov;177(22):6560-7

TTG serves as an initiation codon for the ribosomal protein MvaS7 from the archaeon Methanococcus vannieiii. Golderer G, et al. **J Bacteriol** 1995 Oct;177(20):5994-6

Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Borman AM, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3656-63

Non-canonical translation mechanisms in plants: efficient in vitro and in planta initiation at AUU codons of the tobacco mosaic virus enhancer sequence. Schmitz J, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):257-63

Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Calligaris R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11598-602

PHYSIOLOGY

Porcine polypyrimidine tract-binding protein stimulates translation initiation at the internal ribosome entry site of foot-and-mouth-disease virus. Niepmann M. **FEBS Lett** 1996 Jun 10;388(1):39-42

The human immunodeficiency virus type 1 5' packaging signal structure affects translation but does not function as an internal ribosome entry site structure. Miele G, et al. **J Virol** 1996 Feb;70(2):944-51

PEPTIDE CHAIN TERMINATION

see related
PEPTIDE TERMINATION FACTORS

Sequences responsible for transcription termination of the mouse gastrin gene. Noh MJ, et al. **Biochem Mol Biol Int** 1995 May;35(6):1205-13

Ccl1, a cyclin associated with protein kinase Kin28, controls the phosphorylation of RNA polymerase II largest subunit and mRNA transcription. Valay JG, et al. **C R Acad Sci III** 1996 Mar;319(3):183-9

Utilizing the GCN4 leader region to investigate the role of the sequence determinants in nonsense-mediated mRNA decay. Ruiz-Echevarria MJ, et al. **EMBO J** 1996 Jun 3; 15(11):2810-9

Coding sequence-dependent ribosomal arrest at termination of translation. Cao J, et al. **Mol Cell Biol** 1996 Feb; 16(2):603-8

Analysis of eukaryotic mRNA structures directing cotranslational incorporation of selenocysteine. Kollmus H, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1195-201

DRUG EFFECTS

Detection of mutagen specific adduct formation in DNA using sequencing methodology. Premaratne S, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):789-94

GENETICS

Structure of the C-terminal end of the nascent peptide influences translation termination. Björnsson A, et al. **EMBO J** 1996 Apr 1;15(7):1696-704

The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae. Stansfield I, et al. **EMBO J** 1995 Sep 1; 14(17):4365-73

Suppression of temperature-sensitive defects of polypeptide release factors RF-1 and RF-2 by mutations or by an excess of RF-3 in Escherichia coli. Matsumura K, et al. **J Mol Biol** 1996 May 17;258(4):588-99

Functional interaction between release factor one and P-site peptidyl-tRNA on the ribosome. Zhang S, et al. **J Mol Biol** 1996 Aug 16;261(2):98-107

PEPTIDE CHLOROMETHYL KETONES see **AMINO ACID CHLOROMETHYL KETONES**

PEPTIDE ELONGATION FACTOR TU

Phylogeny based on elongation factor Tu reflects the phenotypic features of mycoplasmas better than that based on 16S rRNA. Kamla V, et al. **Gene** 1996 May 24; 171(1):83-7

ANTAGONISTS & INHIBITORS

Enacyloxin IIa, an inhibitor of protein biosynthesis that acts on elongation factor Tu and the ribosome. Cetin R, et al. **EMBO J** 1996 May 15;15(10):2604-11

BIOSYNTHESIS

Modulation of the expression of liver-specific functions in novel human hepatocyte lines cultured in a collagen gel sandwich configuration. Kono Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):628-32

Cloning, sequence analysis and expression of mammalian mitochondrial protein synthesis elongation factor Tu. Woriax VL, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):347-56

Transcription of tufA and other chloroplast-encoded genes is controlled by a circadian clock in Chlamydomonas. Hwang S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):996-1000

CHEMISTRY

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73-120 (138 ref.)

Purification of aminoacyl-tRNA by affinity chromatography on immobilized Thermus thermophilus EF-Tu.GTP. Ribeiro S, et al. **Anal Biochem** 1995 Jul 1;228(2):330-5

Halophilic protein stabilization by the mild solubilizing agents nondetergent sulfobetaines. Vuillard L, et al. **Anal Biochem** 1995 Sep 20;230(2):290-4

Interaction of guanosine nucleotides and their analogs with elongation factor Tu from Thermus thermophilus. Wagner A, et al. **Biochemistry** 1995 Oct 3;34(39):12535-42

Properties of isolated domains of the elongation factor Tu from Thermus thermophilus HB8. Nock S, et al. **Eur J Biochem** 1995 Nov 15;234(1):132-9

Mapping Escherichia coli elongation factor Tu residues involved in binding of aminoacyl-tRNA. Wiborg O, et al. **J Biol Chem** 1996 Aug 23;271(34):20406-11

The structure of the Escherichia coli EF-Tu.EF-Ts complex at 2.5 A resolution [see comments] [published erratum appears in Nature 1996 May 9;381(6578):172] Kawashima T, et al. **Nature** 1996 Feb 8;379(6565):511-8. Comment in: Nature 1996 Feb 8;379(6565):491.

Molecular mimicry in protein synthesis? [comment] Moore PB. **Science** 1995 Dec 1;270(5241):1453-4. Comment on: Science 1995 Dec 1;270(5241):1464-72.

Crystal structure of the ternary complex of Phe-tRNAPhe, EF-Tu, and a GTP analog [see comments] Nissen P, et al. **Science** 1995 Dec 1;270(5241):1464-72. Comment in: Science 1995 Dec 1;270(5241):1453-4.

GENETICS

Rate of translation of natural mRNAs in an optimized in

vitro system. Pavlov MY, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):9–16
Translational activities of EF–Tu [G222D] which cannot be reconciled with the classical scheme of the polypeptide chain elongation cycle. Talens A, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):961–7
Nucleotide and aminoacyl–tRNA specificity of the mammalian mitochondrial elongation factor EF–Tu.Ts complex. Woriax VL, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):66–72
A growth–defective kirromycin–resistant EF–Tu Escherichia coli mutant and a spontaneously evolved suppression of the defect. Zeef LA, et al. **Gene** 1995 Nov 7;165(1):39–43
Homologous recombination between the tuf genes of Salmonella typhimurium. Abdulkarim F, et al. **J Mol Biol** 1996 Jul 26;260(4):506–22
Structure–based sequence alignment of elongation factors Tu and G with related GTPases involved in translation. Avarsson A. **J Mol Evol** 1995 Dec;41(6):1096–104
The tuf3 gene of Streptomyces coelicolor A3(2) encodes an inessential elongation factor Tu that is apparently subject to positive stringent control. van Wezel GP, et al. **Microbiology** 1995 Oct;141 (Pt 10):2519–28
Isolation, expression, and evolution of the gene encoding mitochondrial elongation factor Tu in Arabidopsis thaliana. Kuhlman P, et al. **Plant Mol Biol** 1995 Dec;29(5):1057–70

METABOLISM

Translational activities of EF–Tu [G222D] which cannot be reconciled with the classical scheme of the polypeptide chain elongation cycle. Talens A, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):961–7
Antideterminants present in minihelix(Sec) hinder its recognition by prokaryotic elongation factor Tu. Rudinger J, et al. **EMBO J** 1996 Feb 1;15(3):650–7
Limited proteolysis and amino acid replacements in the effector region of Thermus thermophilus elongation factor Tu. Zeidler W, et al. **Eur J Biochem** 1996 Jul 15; 239(2):265–71
Mutants of EF–Tu defective in binding aminoacyl–tRNA. Abdulkarim F, et al. **FEBS Lett** 1996 Mar 18; 382(3):297–303
Site–directed mutagenesis of Thermus thermophilus EF–Tu: the substitution of threonine–62 by serine or alanine. Ahmadian MR, et al. **FEBS Lett** 1995 Dec 18;377(2):253–7
Identification of the elongation factor Tu binding site on 70S E. coli ribosomes by chemical crosslinking. Nag B, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):343–50
Initial binding of the elongation factor Tu.GTP.aminoacyl–tRNA complex preceding codon recognition on the ribosome. Rodnina MV, et al. **J Biol Chem** 1996 Jan 12;271(2):646–52
Interaction of mitochondrial elongation factors Tu.Ts with aminoacyl–tRNA. Benkowski LA, et al. **Nucleic Acids Symp Ser** 1995;(33):163–6
Mass spectrometric approaches to molecular characterization of protein–nucleic acid interactions. Przybylski M, et al. **Toxicol Lett** 1995 Dec;82–83:567–75

PEPTIDE ELONGATION FACTORS

ANALYSIS

Elongation factor 1 gamma mRNA expression in oesophageal carcinoma. Mimori K, et al. **Gut** 1996 Jan;38(1):66–70
Elongation factor 1 alpha concentration is highly correlated with the lysine content of maize endosperm. Habben JE, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8640–4

ANTAGONISTS & INHIBITORS

EF–1 alpha is a target site for an inhibitory effect of quercetin in the peptide elongation process. Marcinkiewicz C, et al. **Acta Biochim Pol** 1995;42(3):347–50
Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Galasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24–37 (189 ref.)

BIOSYNTHESIS

Expression of recombinant elongation factor 1 beta from rabbit in Escherichia coli. Phosphorylation by casein kinase II. Chen CJ, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):303–11
Increased expression of Saccharomyces cerevisiae translation elongation factor 1 alpha bypasses the lethality of a TEF5 null allele encoding elongation factor 1 beta. Kinzy TG, et al. **Genetics** 1995 Oct;141(2):481–9
Molecular cloning, characterization and expression of an elongation factor 1 alpha gene in maize. Berberich T, et al. **Plant Mol Biol** 1995 Nov;29(3):611–5

CHEMISTRY

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73–120 (138 ref.)
Structure and importance of the dimerization domain in elongation factor Ts from Thermus thermophilus. Jiang Y, et al. **Biochemistry** 1996 Aug 13;35(32):10269–78
Properties of elongation factor–2 fragments obtained by partial proteolysis. Dumont–Miscopein A, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):221–7
Archaeal elongation factor 1 beta is a dimer. Primary structure, molecular and biochemical properties. Raimo G, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):106–12
Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369–75 (48 ref.)
The guanine–nucleotide–exchange complex (EF–1 beta gamma delta) of elongation factor–1 contains two similar leucine–zipper proteins EF–1 delta, p34 encoded by EF–1 delta 1 and p36 encoded by EF–1 delta 2. Minella O, et al. **Eur J Biochem** 1996 May 1;237(3):685–90
The dynamic structure of EF–G studied by fusidic acid resistance and internal revertants. Johanson U, et al. **J Mol Biol** 1996 May 10;258(3):420–32
The structure of the Escherichia coli EF–Tu.EF–Ts complex at 2.5 A resolution [see comments] [published erratum appears in Nature 1996 May 9;381(6578):172] Kawashima T, et al. **Nature** 1996 Feb 8;379(6565):511–8. Comment in: Nature 1996 Feb 8;379(6565):491.
Conserved motifs in prokaryotic and eukaryotic polypeptide release factors: tRNA–protein mimicry hypothesis. Ito K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5443–8
Molecular mimicry in protein synthesis? [comment] Moore PB. **Science** 1995 Dec 1;270(5241):1453–4. Comment on: Science 1995 Dec 1;270(5241):1464–72.

GENETICS

Organization and nucleotide sequence of a gene cluster comprising the translation elongation factor 1 alpha, ribosomal protein S10 and tRNA(Ala) from Halobacterium halobium. Fujita T, et al. **Biochem Mol Biol Int** 1995 Sep; 37(1):107–15
E2F and cell proliferation: a world turned upside down. Weinberg RA. **Cell** 1996 May 17;85(4):457–9 (10 ref.)
Cloning and characterization of a TEF gene for elongation factor 1 alpha from the yeast Arxula adeninivorans. Rösel H, et al. **Curr Genet** 1995 Sep;28(4):360–6
Integrative and replicative genetic transformation of Aureobasidium pullulans. Thornewell SJ, et al. **Curr Genet** 1995 Dec;29(1):66–72
A Xenopus laevis gene encoding EF–1 alpha S, the somatic form of elongation factor 1 alpha: sequence, structure, and identification of regulatory elements required for embryonic transcription. Johnson AD, et al. **Dev Genet** 1995;17(3):280–90
Elongation factor Ts from Thermus thermophilus—overproduction in Escherichia coli, quaternary structure and interaction with elongation factor Tu. Blank J, et al. **Eur J Biochem** 1996 Feb 15;236(1):222–7
The guanine–nucleotide–exchange complex (EF–1 beta gamma delta) of elongation factor–1 contains two similar leucine–zipper proteins EF–1 delta, p34 encoded by EF–1 delta 1 and p36 encoded by EF–1 delta 2. Minella O, et al. **Eur J Biochem** 1996 May 1;237(3):685–90
Two different macronuclear EF–1 alpha–encoding genes of the ciliate Euplotes crassus are very dissimilar in their sequences, copy numbers and transcriptional activities. Bergemann J, et al. **Gene** 1996 Feb 2;168(1):109–12
The first intron of the Arabidopsis thaliana gene coding for elongation factor 1 beta contains an enhancer–like element. Gidekel M, et al. **Gene** 1996 May 8;170(2):201–6
Cloning and characterization of the gene encoding translation elongation factor 1 alpha from Aureobasidium pullulans. Thornewell SJ, et al. **Gene** 1995 Aug 30;162(1):105–10
Structure–based sequence alignment of elongation factors Tu and G with related GTPases involved in translation. Avarsson A. **J Mol Evol** 1995 Dec;41(6):1096–104
Translation elongation factor–3 (EF–3): an evolving eukaryotic ribosomal protein? Belfield GP, et al. **J Mol Evol** 1995 Sep;41(3):376–87
Arrangement and nucleotide sequence of the gene (fus) encoding elongation factor G (EF–G) from the hyperthermophilic bacterium Aquifex pyrophilus: phylogenetic depth of hyperthermophilic bacteria inferred from analysis of the EF–G/fus sequences. Bocchetta M, et al. **J Mol Evol** 1995 Dec;41(6):803–12
Phylogenetic place of mitochondrion–lacking protozoan, Giardia lamblia, inferred from amino acid sequences of elongation factor 2. Hashimoto T, et al. **Mol Biol Evol** 1995 Sep;12(5):782–93
The tef1 box, a ubiquitous cis–acting element involved in the activation of plant genes that are highly expressed in cycling cells. Regad F, et al. **Mol Gen Genet** 1995 Oct 25;248(6):703–11
Early evolution of the Metazoa and phylogenetic status of diploblasts as inferred from amino acid sequence of elongation factor–1 alpha. Kobayashi M, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):414–22
A strong ubiquitous promoter–enhancer for development and aging of Drosophila melanogaster. Ackermann R, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2452–3
A nascent micronuclear pseudogene in the ciliate Euplotes crassus. Florian V, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3195–200
Elongation factor 1 alpha genes of the red alga Porphyra purpurea include a novel, developmentally specialized variant. Liu QY, et al. **Plant Mol Biol** 1996 Apr;31(1):77–85
Overexpression and purification of Thermus thermophilus elongation factors G, Tu, and Ts from Escherichia coli. Blank J, et al. **Protein Expr Purif** 1995 Oct;6(5):637–45

ISOLATION & PURIFICATION

Valyl–tRNA synthetase from Artemia. Purification and association with elongation factor 1. Brandsma M, et al. **Eur J Biochem** 1995 Oct 1;233(1):277–82
Overexpression and purification of Thermus thermophilus elongation factors G, Tu, and Ts from Escherichia coli. Blank J, et al. **Protein Expr Purif** 1995 Oct;6(5):637–45

METABOLISM

Identification of a rapidly dephosphorylating 95–kDa protein as elongation factor 2 during 8–Br–cAMP treatment of N1E115 neuroblastoma cells. Li H, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):131–7
Phosphorylation of eukaryotic elongation factor 2 in differentiating and proliferating HL–60 cells. Nilsson A, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):263–8
Nucleotide and aminoacyl–tRNA specificity of the mammalian mitochondrial elongation factor EF–Tu.Ts complex. Woriax VL, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):66–72
A point mutation within each of two ATP–binding motifs inactivates the functions of elongation factor 3. Yang H, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):303–8
Comparative analysis of ATPase of yeast elongation factor 3 and ATPase associated with Tetrahymena ribosomes. Kovalchuke O, et al. **Biochimie** 1995;77(9):713–18
Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369–75 (48 ref.)
Photoaffinity labeling of elongation factor–2 with 8–azido derivatives of GTP and ATP. Guillot D, et al. **Eur J Biochem** 1996 Feb 15;236(1):149–54
Phosphorylation of elongation factor 1 (EF–1) by protein kinase C stimulates GDP/GTP–exchange activity. Peters HI, et al. **Eur J Biochem** 1995 Dec 1;234(2):550–6
Rabbit translation elongation factor 1 alpha stimulates the activity of homologous aminoacyl–tRNA synthetase. Negrutskii BS, et al. **FEBS Lett** 1996 Mar 11;382(1–2):18–20
A new translational elongation factor for selenocysteyl–tRNA in eucaryotes. Yamada K. **FEBS Lett** 1995 Dec 27;377(3):313–7
Role of the conserved aspartate and phenylalanine residues in prokaryotic and mitochondrial elongation factor Ts in guanine nucleotide exchange. Zhang Y, et al. **FEBS Lett** 1996 Aug 12;391(3):330–2
A protein–RNA interaction network facilitates the template–independent cooperative assembly on RNA polymerase of a stable antitermination complex containing the lambda N protein. Mogridge J, et al. **Genes Dev** 1995 Nov 15;9(22):2831–45
Interaction of yeast elongation factor 3 with polynucleotides, ribosomal RNA and ribosomal subunits. Kovalchuke O, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):336–42
A NusG–like protein from Thermotoga maritima binds to DNA and RNA. Liao D, et al. **J Bacteriol** 1996 Jul; 178(14):4089–98
Polymerization of highly purified Tetrahymena 14–nm filament protein/citrate synthase into filaments and its possible role in regulation of enzymatic activity. Takeda T, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):869–74
Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. Foley BT, et al. **J Biol Chem** 1995 Sep 29;270(39):23218–25
Identification of protein synthesis elongation factor G as a 4.5 S RNA–binding protein in Escherichia coli. Shibata T, et al. **J Biol Chem** 1996 May 31;271(22):13162–8
Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Chow KN, et al. **Mol Cell Biol** 1996 Sep;16(9):4862–8
NusG overexpression inhibits Rho–dependent termination in Escherichia coli. Burova E, et al. **Mol Microbiol** 1995 Aug; 17(4):633–41
Protein synthesis. An elongation factor turn–on [news; comment] Nierhaus KH. **Nature** 1996 Feb 8; 379(6565):491–2. Comment on: Nature 1996 Feb 8;379(6565):511–8.
Interaction of mitochondrial elongation factors Tu.Ts with aminoacyl–tRNA. Benkowski LA, et al. **Nucleic Acids Symp Ser** 1995;(33):163–6
Truncated elongation factor G lacking the G domain promotes translocation of the 3' end but not of the anticodon domain of peptidyl–tRNA. Borowski C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4202–6
Escherichia coli transcript cleavage factors GreA and GreB stimulate promoter escape and gene expression in vivo and in vitro. Hsu LM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11588–92
Solution structure of mRNA hairpins promoting selenocysteine incorporation in Escherichia coli and their base–specific interaction with special elongation factor SELB. Hüttenhofer A, et al. **RNA** 1996 Apr;2(4):354–66
Mass spectrometric approaches to molecular characterization of protein–nucleic acid interactions. Przybylski M, et al. **Toxicol Lett** 1995 Dec;82–83:567–75
[A protein product of the tobamovirus open translation frame forms a stable complex with translation elongation factor eEF–1alpha] Fedorkin ON, et al. **Dokl Akad Nauk** 1995 Aug;343(5):703–4 **(Rus)**

PHARMACOLOGY

F–actin bundling activity of Tetrahymena elongation factor

1 alpha is regulated by Ca2+/calmodulin. Kurasawa Y, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):791–8

PHYSIOLOGY

Multifunctional proteins in Tetrahymena: 14–nm filament protein/citrate synthase and translation elongation factor–1 alpha. Numata O. **Int Rev Cytol** 1996;164:1–35 (126 ref.)

PEPTIDE FRAGMENTS

Photoimmobilization of a bioactive laminin fragment and pattern–guided selective neuronal cell attachment. Clémence JF, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):411–7

Functional topography of myelin–associated glycoprotein. II. Mapping of domains on molecular fragments. Meyer–Franke A, et al. **J Neurosci Res** 1995 Jun 15; 41(3):311–23

ADMINISTRATION & DOSAGE

Sustained–release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Muller DW, et al. **Am Heart J** 1996 Feb; 131(2):211–8

Intranasal administration of insulin peptide B: 9–23 protects NOD mice from diabetes. Daniel D, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:371–2

Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Mizuguchi H, et al. **Br J Cancer** 1996 Feb;73(4):472–6

Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth. Mizuguchi H, et al. **Cancer Lett** 1996 Feb 27;100(1–2):63–9

Lys–plasminogen as an adjunct to local intra–arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Freitag HJ, et al. **Neuroradiology** 1996 Feb;38(2):181–5

Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Blanke SR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8437–42

ANALYSIS

Influence of hormone replacement therapy (17 beta–OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin–antithrombin III complex in postmenopausal woman. Ciepluch R, et al. **Acta Haematol Pol** 1996; 27(1):21–5

The volume protective natriuretic peptide system in the inner ear. Comparison between vestibular and cochlear compartments. Meyer zum Gottesberge A, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:170–3

Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI–5 Investigators. Thrombolysis in Myocardial Infarction. Scharfstein JS, et al. **Am J Cardiol** 1996 Sep 1;78(5):503–10

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293–7

Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Smith CJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1221–5

Thrombin–antithrombin III and prothrombin fragment 1.2 levels in early respiratory distress syndrome [letter] Yurdakök M, et al. **Am J Hematol** 1996 Mar;51(3):247–8

High levels of circulating beta–amyloid peptide do not cause cerebral beta–amyloidosis in transgenic mice. Fukuchi K, et al. **Am J Pathol** 1996 Jul;149(1):219–27

P3 beta–amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Higgins LS, et al. **Am J Pathol** 1996 Aug; 149(2):585–96

Entrapment by immobilized metal ion affinity chromatography of assembled yeast mitochondrial ATP synthase containing individual subunits tagged with hexahistidine. Bateson M, et al. **Anal Biochem** 1996 Jun 15;238(1):14–8

Electrophoretic separation of betaA4 peptides (1–40) and (1–42). Klafki HW, et al. **Anal Biochem** 1996 May 15; 237(1):24–9

Quantitative assay of trypsinogen by measurement of cleaved activation peptide after activation with enterokinase. Mithöfer K, et al. **Anal Biochem** 1995 Sep 20;230(2):348–50

Visualization of alpha–chitin with a specific chitin–binding protein (CHB1) from Streptomyces olivaceoviridis. Zeltins A, et al. **Anal Biochem** 1995 Nov 1;231(2):287–94

Sequence–specific fragmentation of matrix–assisted laser–desorbed protein/peptide ions. Brown RS, et al. **Anal Chem** 1995 Nov 1;67(21):3990–9

Selective detection in RP–HPLC of Tyr–, Trp–, and sulfur–containing peptides by pulsed amperometry at platinum. van Riel JA, et al. **Anal Chem** 1995 Nov 1; 67(21):3911–5

Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Sharif M, et al. **Ann Rheum Dis** 1996 Jan;55(1):47–51

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2135–9 (35 ref.)

Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis. Milman N, et al. **APMIS** 1995 Oct;103(10):749–54

Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Manzi S, et al. **Arthritis Rheum** 1996 Jul;39(7):1178–88

Amyloid beta protein and its 3–kDa fragment are present in the axoplasm fraction of the white matter in human brain. Tokuda T, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):165–9

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Merlini PA, et al. **Blood** 1995 Nov 1;86(9):3327–32

Prothrombin fragment 1+2 and thrombin–antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Simioni P, et al. **Br J Haematol** 1996 Feb;92(2):435–41

GABAA–receptor subunit composition in the circadian timing system. Gao B, et al. **Brain Res** 1995 Nov 27; 700(1–2):142–56

Immunodetection of the large form of the gamma 2 subunit of mammalian GABAA receptor. San Juan I, et al. **Brain Res** 1995 Nov 6;698(1–2):209–12

Ultrastructural localization of delta–opioid receptor and Met5–enkephalin immunoreactivity in rat insular cortex. Svingos AL, et al. **Brain Res** 1995 Nov 27;700(1–2):25–39

Distribution of AMPA–selective glutamate receptor subunits in the human hippocampus and cerebellum. Day NC, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1–2):17–32

Antisense oligodeoxynucleotides to G–protein alpha–subunit subclasses identify a transductional requirement for the modulation of normal feeding dependent on G alpha OA subunit. Plata–Salamán CR, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):72–8

Immuno–electron–microscopic localization of types III pN–collagen and IV collagen, laminin and tenascin in developing and adult human spleen. Liakka A, et al. **Cell Tissue Res** 1995 Oct;282(1):117–27

Evaluation of the allergic/irritant potential of air pollutants: detection of proteins modified by volatile organic compounds from oilseed rape (Brassica napus ssp. oleifera) using electrospray ionization–mass spectrometry. Butcher RD, et al. **Clin Exp Allergy** 1995 Oct;25(10):985–92

Increased prothrombin fragment 1.2 concentrations in hemodialysis patients [letter] Erdem Y, et al. **Clin Nephrol** 1996 Jan;45(1):69

Post–meal coagulation activation in diabetes mellitus: the effect of acarbose. Ceriello A, et al. **Diabetologia** 1996 Apr; 39(4):469–73

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107–8

Prothrombin fragment F1+2 and thrombin–antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gadducci A, et al. **Gynecol Oncol** 1996 May;61(2):215–7

Aminoterminal propeptide of type III procollagen: a marker of hepatic fibrosis after bile duct obstruction in the monkey. Ruf G, et al. **Hepatogastroenterology** 1996 Jan–Feb; 43(7):121–6

Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. Groot K, et al. **Int J Pept Protein Res** 1995 Jun;45(6):561–6

Monoaminergic and peptidergic contributions of the superior and the inferior spermatic nerves to the innervation of the testis in the rat. Zhu BC, et al. **J Androl** 1995 May–Jun; 16(3):248–58

Precolumn fluorescence derivatization of the antagonist [Arg6,D–Trp7,9,MePhe8]–substance P[6–11] with benzoin in high–performance liquid chromatography and selective detection of arginine–containing fragments in its degradation products. Cui H, et al. **J Chromatogr A** 1996 Jun 7;736(1–2):91–6

First clinical application of the Medos–HIA ventricular support system: monitoring of the thrombotic risk by means of the biomarker prothrombin fragment F1 + 2 and scanning electron microscopy evaluation. Guldner NW, et al. **J Heart Lung Transplant** 1996 Mar;15(3):291–6

The use of dedicated peptide libraries permits the discovery of high affinity binding peptides. de Koster HS, et al. **J Immunol Methods** 1995 Nov 16;187(1):179–88

Intrafamily fragment analysis of the T cell receptor beta chain CDR3 region. Liu D, et al. **J Immunol Methods** 1995 Nov 16;187(1):139–50

Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV–I–associated myelopathy/tropical spastic paraparesis. Saarloos MN, et al. **J Infect Dis** 1995 Oct;172(4):1095–7

Levels of substance P and IgE decapeptide in nasal polyp fluid and matching sera: a preliminary study. Drake–Lee A, et al. **J Laryngol Otol** 1996 Mar;110(3):225–7

High–resolution separation of amyloid beta–peptides: structural variants present in Alzheimer's disease amyloid. Näslund J, et al. **J Neurochem** 1996 Jul;67(1):294–301

Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Stapleton AM, et al. **Kidney Int** 1996 Mar;49(3):880–8

The simultaneous determination of neurotensin and its major fragments by on–line trace enrichment HPLC with electrochemical detection. Kilts CD, et al. **Life Sci** 1996; 59(11):911–20

Association of A beta 40–positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non–demented aged individuals. Fukumoto H, et al. **Neurodegeneration** 1996 Mar;5(1):13–7

Identification of specific binding sites for glucagon–like peptide–1 on the posterior lobe of the rat pituitary. Göke R, et al. **Neuroendocrinology** 1995 Aug;62(2):130–4

Increased levels of GMAP, VIP and nitric oxide synthase, and their mRNAs, in lumbar dorsal root ganglia of the rat following systemic resiniferatoxin treatment. Farkas–Szallasi T, et al. **Neuroreport** 1995 Nov 13; 6(16):2230–4

Distribution of neurone–specific clathrin light chain b between clathrin–coated vesicle subclasses. Uriu–Mikami T, et al. **Neuroreport** 1995 Oct 2;6(14):1922–6

Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. Wenzel A, et al. **Neuroreport** 1995 Dec 29;7(1):45–8

Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Giovanella L, et al. **Q J Nucl Med** 1995 Dec;39(4):285–9

Detection of cruzipain, the major cysteine proteinase from Trypanosoma cruzi and its C–terminal extension in biological fluids during experimental infection in mice. González G, et al. **Scand J Immunol** 1996 Aug;44(2):122–8

Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Hsiao K, et al. **Science** 1996 Oct 4;274(5284):99–102

Demonstration of Rickettsia Conorii–induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. Davì G, et al. **Thromb Haemost** 1995 Aug;74(2):631–4

Prothrombin fragment F 1+2 levels are high in NIDDM patients independently of the Hb A1 c [letter; comment] Marongiu F, et al. **Thromb Haemost** 1995 Aug;74(2):805–6 . Comment on: Thromb Haemost 1994 Jun;71(6):692–7.

Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC–resistance) and/or inherited protein S deficiency. Zöller B, et al. **Thromb Haemost** 1996 Feb;75(2):270–4

[Fibrinopeptide A (FPA) and fibrinopeptide B beta 15–42 (FPB beta 15–42)] Tatsumi N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:39–42 (15 ref.) **(Jpn)**

[Cyfra 21–1—new marker for lung cancer] Luczak E, et al. **Pneumonol Alergol Pol** 1996;64(1–2):96–101 (19 ref.) (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Failure of the putative neuropeptide Y antagonists, benextramine and PYX–2, to inhibit Y2 receptors in rat isolated prostatic vas deferens. Palea S, et al. **Br J Pharmacol** 1995 Nov;116(5):2401–6

C2 region–derived peptides inhibit translocation and function of beta protein kinase C in vivo. Ron D, et al. **J Biol Chem** 1995 Oct 13;270(41):24180–7

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. Tomiyama T, et al. **J Biol Chem** 1996 Mar 22;271(12):6839–44

The inhibitory effects of growth hormone–releasing hormone (GHRH)–antagonist on GHRH, L–dopa, and clonidine–induced GH secretion in normal subjects. Hanew K, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1952–5

HL–60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase–9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. Ries C, et al. **Leukemia** 1996 Sep; 10(9):1520–6

Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Perovic S, et al. **Neurodegeneration** 1995 Dec;4(4):369–74

BIOSYNTHESIS

Nuclear and cytoplasmic localization of the beta–amyloid peptide (1–43) in transfected 293 cells. Johnstone EM, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):710–8

Controlled overexpression of selected domains of the P85 subunit of phosphatidylinositol 3–kinase reverts v–Ha–Ras transformation. Zhang QX, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):207–14

Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Ebstein RP, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):260–8

Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Hoyt EC, et al. **Diabetes** 1996 Apr;45(4):434–9

Production of intracellular amyloid–containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8

Human colon produces fully processed glucagon–like peptide–1 (7–36) amide. Deacon CF, et al. **FEBS Lett** 1995 Sep 25;372(2–3):269–72

Examining rhodopsin folding and assembly through expression of polypeptide fragments. Ridge KD, et al. **J Biol Chem** 1996 Mar 29;271(13):7860–7

Functional elimination of calmodulin within the nucleus by targeted expression of an inhibitor peptide. Wang J, et al. **J Biol Chem** 1995 Dec 22;270(51):30245–8

Redirection of tumor metastasis by expression of E-selectin in vivo. Biancone L, et al. **J Exp Med** 1996 Feb 1; 183(2):581–7

HL-60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase-9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. Ries C, et al. **Leukemia** 1996 Sep; 10(9):1520–6

Expression of protein kinase C gamma regulatory domain elements containing cysteine-rich zinc-coordinating regions as glutathione S-transferase fusion proteins. Quest AF, et al. **Methods Enzymol** 1995;252:153–67

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Gómez-Duarte OG, et al. **Vaccine** 1995 Nov;13(16):1596–602

Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response. Nehete PN, et al. **Viral Immunol** 1994;7(4):189–97

[Expression of the extracellular domain (1-341) of rat ovarian lutropin receptor in insect cells and preliminary characterization of the expressed product] Shen QX, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Dec;28(4):381–7 (Eng. Abstr.) **(Chi)**

BLOOD

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Fukase N, et al. **Acta Diabetol** 1995 Oct;32(3):165–9

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Diez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D–17D (36 ref.)

The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Høst NB, et al. **Am J Cardiol** 1995 Nov 1;76(12):869–73

Evaluation of procollagen-III peptide as a marker for veno-occlusive disease after bone marrow transplantation. Schuler U, et al. **Ann Hematol** 1996 Jul;73(1):25–8

Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Tähtelä R, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2289–93

Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis. Diagnostic specificity of new biochemical markers. Löfberg M, et al. **Arch Neurol** 1995 Dec;52(12):1210–4

The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Hunt PJ, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1175–83

Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Lubec B, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):159–62

High-performance liquid chromatography with fluorescence detection of ebiratide using 4-(N,N-dimethylamino-sulphonyl)-7-fluoro-2,1,3-benzoxadiazole as a fluorogenic reagent. Hamachi Y, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):216–20

Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Kubo T, et al. **Bone** 1995 Oct;17(4):397–401

Changes in the carboxyl-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. Pedersen BJ, et al. **Bone** 1995 Jul; 17(1):91–5

Clinical significance of serum CYFRA 21-1 in gastric cancer. Nakata B, et al. **Br J Cancer** 1996 Jun;73(12):1529–32

Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Oogarah PK, et al. **Br J Dermatol** 1995 Oct;133(4):512–8

The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. vanDooren-Greebe RJ, et al. **Br J Dermatol** 1996 Mar;134(3):481–7

Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry. Lotz J, et al. **Calcif Tissue Int** 1995 Oct;57(4):253–7

Assessment of serum CYFRA 21-1 in lung cancer. Muraki M, et al. **Cancer** 1996 Apr 1;77(7):1274–7

Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Diez J, et al. **Circulation** 1996 Mar 1;93(5):1026–32

Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Guéchot J, et al. **Clin Chem** 1996 Apr;42(4):558–63

Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. Withold W, et al. **Clin Chim Acta** 1995 Aug 14;239(2):143–51

Type III procollagen N-peptide correlates with beta-2-microglobulin in myelomatosis. Hasselbalch HC, et al. **Clin Lab Haematol** 1995 Sep;17(3):237–41

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Toft-Nielson M, et al. **Diabetes** 1996 May;45(5):552–6

Ginseng therapy in non-insulin-dependent diabetic patients. Sotaniemi EA, et al. **Diabetes Care** 1995 Oct;18(10):1373–5

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Göke B, et al. **Digestion** 1995;56(6):493–501

Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours. Comparison with the results of 99mTc-methylene bisphosphonate bone scintigraphy. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):479–85

Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):193–7

Circulating levels of immunoreactive parathyroid hormone-related protein and intact parathyroid hormone in human fetuses and newborns. Papantoniou NE, et al. **Eur J Endocrinol** 1996 Apr;134(4):437–42

Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Diot E, et al. **Eur Respir J** 1995 Sep;8(9):1559–65

Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer? Perachino M, et al. **Eur Urol** 1996;29(3):366–9

Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. Santi I, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):107–12

Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. Lieuw-A-Fa M, et al. **J Bone Miner Res** 1995 Jun;10(6):849–53

Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans. Plumpton C, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S34–6

Changes in plasma beta-cell tropin concentrations during pregnancy in rats. Davenport M, et al. **J Endocrinol** 1995 Jul;146(1):177–82

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. Conti A, et al. **J Endocrinol Invest** 1996 Feb;19(2):127–30

Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma. Pridal L, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):841–50

Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K, et al. **Jpn J Cancer Res** 1995 Jul;86(7):698–705

Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):157–63

Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer. Huang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Feb; 12(2):62–8

Anomalous effects of hormone fragments on the measurement of parathyroid hormone by radioimmunoassay. Mbuyi-Kalala A, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):87–99

Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. Joffe P, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1912–7

Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Pedersen BJ, et al. **Osteoporos Int** 1995;5(6):472–7

Serum amino-terminal propeptide of type III procollagen levels in chronic pancreatitis. Navarro S, et al. **Pancreas** 1996 Mar;12(2):153–8

Changes in dopaminergic control of circulating melanocyte-stimulating hormone-related peptides at puberty. Facchinetti F, et al. **Pediatr Res** 1995 Jul; 38(1):91–4

Prognostic value of serum hyaluronic acid and type I and III procollagen propeptides in extrahepatic biliary atresia. Trivedi P, et al. **Pediatr Res** 1995 Oct;38(4):568–73

Proteolytic degradation of hemoglobin in erythrocytes leads to biologically active peptides. Karelin AA, et al. **Peptides** 1995;16(4):693–7

Serum procollagen type I carboxyterminal propeptide in CAPD and hemodialysis patients. Gerakis A, et al. **Perit Dial Int** 1996;16 Suppl 1:S309–11

Metabolism of dynorphin A 1-13 in human blood and plasma. Müller S, et al. **Pharm Res** 1995 Aug;12(8):1165–70

Proatrial natriuretic polypeptide (31-67) in healthy individuals: day-to-day variation and influence of sex and age. Hansen JB, et al. **Scand J Clin Lab Invest** 1995 Aug; 55(5):447–52

Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder. Mungan U, et al. **Urology** 1996 Sep;48(3):496–500

Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Nauck MA, et al. **Z Gastroenterol** 1996 Mar;34(3):159–66

[Detection of serum procollagen III peptide in tuberculous patients] Yi S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):215–7, 254–5 (Eng. Abstr.) **(Chi)**

[Procollagen III and laminin in chronic viral hepatopathies] Montalto G, et al. **Presse Med** 1996 Jan 20;25(2):59–62 (Eng. Abstr.) **(Fre)**

[Increased serum level of c-erbB-2-coded protein p105 in patients with pre-eclampsia] Meden H, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:157–60 (Eng. Abstr.) **(Ger)**

[Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency] Sartorio A, et al. **Minerva Endocrinol** 1995 Jun;20(2):135–40 (Eng. Abstr.) **(Ita)**

[Procollagen type I C-propeptide in kidney transplant recipients] Vaccaro F, et al. **Minerva Med** 1996 Jun; 87(6):269–73 (Eng. Abstr.) **(Ita)**

[Mechanism of hyperinsulinemia in gastrectomized patients with oxyhyperglycemia: preliminary report] Yoshikawa T, et al. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):587 **(Jpn)**

CEREBROSPINAL FLUID

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Motter R, et al. **Ann Neurol** 1995 Oct;38(4):643–8

CHEMICAL SYNTHESIS

Synthesis of an N-methyldehydroalanine-containing fragment of microcystin by combination of solid phase peptide synthesis and beta-elimination in solution. Zetterström M, et al. **Acta Chem Scand** 1995 Sep; 49(9):696–700

Effects of synthesized elastin peptides on human leukocytes. Hauck M, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):45–55

Chemical synthesis of a Zwitterhormon, insulaxin, and of a relaxin-like bombyxin derivative. Büllesbach EE, et al. **Biochemistry** 1996 Jul 30;35(30):9754–60

A peptide derived from a tissue factor loop region functions as a tissue factor—factor VIIa antagonist. Paborsky LR, et al. **Biochemistry** 1995 Nov 21;34(46):15328–33

Coassembly of synthetic segments of shaker K+ channel within phospholipid membranes. Peled-Zehavi H, et al. **Biochemistry** 1996 May 28;35(21):6828–38

Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle. Sakura N, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1148–53

Synthesis of stereoisomers and isoforms of a tryptic heptapeptide fragment of human growth hormone and analysis by reverse-phase HPLC and capillary electrophoresis. Vinther A, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):304–9

Antagonistic peptides against human anaphylatoxin C5a. Kaneko Y, et al. **Immunology** 1995 Sep;86(1):149–54

Synthesis of potent agonists of substance P by replacement of Met11 with Glu(OBzl) and N-terminal glutamine with Glp of the C-terminal hexapeptide and heptapeptide of substance P. Stavropoulos G, et al. **Int J Pept Protein Res** 1995 Jun;45(6):508–13

Chemical synthesis and biological activities of the EGF-like domain of mouse schwannoma-derived growth factor (SDGF). Takenouchi T, et al. **Int J Pept Protein Res** 1995 Nov;46(5):391–6

Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2. Lung FD, et al. **J Med Chem** 1996 Mar 1;39(5):1136–41

Conserved cystatin segments as models for designing specific substrates and inhibitors of cysteine proteinases. Lalmanach G, et al. **J Protein Chem** 1995 Nov;14(8):645–53

[Synthesis and biological activity of dynorphin A-(1-13) analogs] Chen YL, et al. **Yao Hsueh Hsueh Pao** 1995 Dec; 30(12):904–9 (Eng. Abstr.) **(Chi)**

[Synthesis of an ethylamide of the cyclic undecapeptide sequence 593-603 of transmembrane glycoprotein gp41 of the human immunodeficiency virus type 2] Sidorova MV, et al. **Bioorg Khim** 1995 Sep;21(9):675–83 (Eng. Abstr.) **(Rus)**

[Hydrogen peroxide for disulfide bridge formation in the synthesis of peptides with the sequence of the immunodominant epitope of HIV gp41 glycoprotein] Sidorova MV, et al. **Bioorg Khim** 1996 Apr;22(4):273–9 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Influence of casein peptide conformations on textural properties of cheese. Malin EL, et al. **Adv Exp Med Biol** 1995;367:303–10

Peptic fragments of rat monomeric IgA. Vaerman JP, et al. **Adv Exp Med Biol** 1995;371A:595–8

Sequence analysis of the V1/V2 and V3 domains in an

HIV-seronegative AIDS patient. Vallejo A, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1539–41

Isolated recombinant domain of von Willebrand factor displaying increased sensitivity to ristocetin. Hayashi T, et al. **Am J Hematol** 1996 Aug;52(4):248–53

Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]–substance P [6–11] in aqueous solutions. Reubsaet JL, et al. **Anal Biochem** 1995 May 20;227(2):334–41

Immobilized liposome chromatography for analysis of interactions between lipid bilayers and peptides. Zhang Y, et al. **Anal Biochem** 1995 Aug 10;229(2):291–8

Expression of Na(+)-Ca2+ exchanger with modified C-terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110–4 (9 ref.)

Modifications of XIP, the autoinhibitory region of the Na–Ca exchanger, alter its ability to inhibit the Na–Ca exchanger in bovine sarcolemmal vesicles. Gatto C, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:284–5

Use of cysteine replacements and chemical modification to alter XIP, the autoinhibitory region of the Na–Ca exchanger. Inhibition of the activated plasma membrane Ca pump. Xu WY, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:286–7

Purification and characterization of a heterodimeric 23/20-kDa proteolytic fragment of bacterial glutathione transferase B1-1. Aceto A, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):302–8

Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution. Chen Z, et al. **Arch Biochem Biophys** 1995 Sep 10; 322(1):198–203

Involvement of the 10-kDa C-terminal fragment of hsc70 in complexing with unfolded protein. Hu SM, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):163–9

Determination of the core sequence of an antagonist of selectin-dependent leukocyte adhesion and correlation of its structure with molecular modeling studies. Kruszynski M, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):23–30

(i, i + 4) Ion pairs stabilize helical peptides derived from smooth muscle caldesmon. Wang E, et al. **Arch Biochem Biophys** 1996 May 15;329(2):156–62

Evidence that the PTH receptor binding site on PTHrP(1–34) can hinge at Arg19/Arg20. Barden JA, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):431–6

Structure of prejunctional receptor binding analog of human neuropeptide Y dimer ANA-NPY. Barden JA. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):264–71

Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Hornshaw MP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):993–9

Alzheimer's disease amyloid beta peptide 25–35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Mason RP, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):78–82

Acylation of peptide hydroxyl groups with the Bolton–Hunter reagent. Miller BT. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):377–82

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):559–65

Stabilization of helix by side-chain interactions in histatin-derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):47–53

Completion of the amino acid sequence of the C-terminal half of the porcine estradiol receptor by Edman degradation: reconfirmation of the absence of O-linked sugars and phosphates. Thole HH, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):227–30

Abnormal gel-electrophoretic behavior of presenilin 1 and it's fragment. Yamamoto A, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):536–41

Neurofilament phosphorylation. Pant HC, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):575–92 (84 ref.)

Characterization of des-(741–1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa. Donath MJ, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):49–55

The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Soto C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):701–7

1H NMR studies of peptide fragments from the N-terminus of chicken and human transthyretin. Wilce JA, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1153–9

The interaction of the neurodegenerative fragment of the beta-amyloid peptide with phospholipid membranes. van Veen M, et al. **Biochem Soc Trans** 1995 Nov;23(4):547S

Identification of the disulfide-linked peptide in irreversibly sickled cell beta-actin. Bencsath FA, et al. **Biochemistry** 1996 Apr 9;35(14):4403–8

Cell line and site specific comparative analysis of the N-linked oligosaccharides on human ICAM-1des454–532 by electrospray ionization mass spectrometry. Bloom JW, et al. **Biochemistry** 1996 Feb 13;35(6):1856–64

Proline pipe helix: structure of the tus proline repeat determined by 1H NMR. Butcher DJ, et al. **Biochemistry** 1996 Jan 23;35(3):698–703

Comparison of NMR solution structures of the receptor binding domains of Pseudomonas aeruginosa pili strains PAO, KB7, and PAK: implications for receptor binding and synthetic vaccine design. Campbell AP, et al. **Biochemistry** 1995 Dec 19;34(50):16255–68

Structural basis of antibody cross-reactivity: solution conformation of an immunogenic peptide fragment containing both T and B epitopes. Cuniasse P, et al. **Biochemistry** 1995 Oct 3;34(39):12782–9

Thermodynamics of the unfolding and spectroscopic properties of the V66W mutant of Staphylococcal nuclease and its 1–136 fragment. Eftink MR, et al. **Biochemistry** 1996 Jun 18;35(24):8084–94

Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Freedman SJ, et al. **Biochemistry** 1995 Sep 26;34(38):12126–37

Domains of macrophage N(O) synthase have divergent roles in forming and stabilizing the active dimeric enzyme. Ghosh DK, et al. **Biochemistry** 1996 Feb 6;35(5):1444–9

Kinetics of nucleotide-induced changes in the tryptophan fluorescence of the molecular chaperone Hsc70 and its subfragments suggest the ATP-induced conformational change follows initial ATP binding. Ha JH, et al. **Biochemistry** 1995 Sep 12;34(36):11635–44

Effects of trifluoroethanol on the conformations of peptides representing the entire sequence of bovine pancreatic trypsin inhibitor. Kemmink J, et al. **Biochemistry** 1995 Oct 3;34(39):12630–5

Purification and characterization of subtilisin cleaved actin lacking the segment of residues 43–47 in the DNase I binding loop. Kiessling P, et al. **Biochemistry** 1995 Nov 14;34(45):14834–42

Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Matsuka YV, et al. **Biochemistry** 1996 May 7;35(18):5810–6

Integrin receptor GPIIb/IIIa bound state conformation of the fibrinogen gamma-chain C-terminal peptide 400–411: NMR and transfer NOE studies. Mayo KH, et al. **Biochemistry** 1996 Apr 9;35(14):4434–44

Distinct phosphate backbone contacts revealed by some mutant peptides of zinc finger protein Spl: effect of protein-induced bending on DNA recognition. Nagaoka M, et al. **Biochemistry** 1996 Jul 2;35(26):8761–8

Mechanism of laminin chain assembly into a triple-stranded coiled-coil structure. Nomizu M, et al. **Biochemistry** 1996 Mar 5;35(9):2885–93

Identification of an epitope in antithrombin appearing on insertion of the reactive-bond loop into the A beta-sheet. Nordling K, et al. **Biochemistry** 1996 Aug 13; 35(32):10436–40

Solubilization of a complex of tryptic fragments of Na,K-ATPase containing occluded Rb ions and bound ouabain. Or E, et al. **Biochemistry** 1996 May 28; 35(21):6853–64

Factors that affect the stabilization of alpha-helices in short peptides by a capping box. Petukhov M, et al. **Biochemistry** 1996 Jan 16;35(2):387–97

Ionization equilibria for side-chain carboxyl groups in oxidized and reduced human thioredoxin and in the complex with its target peptide from the transcription factor NF kappa B. Qin J, et al. **Biochemistry** 1996 Jan 9;35(1):7–13

A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation. Rabenstein M, et al. **Biochemistry** 1995 Oct 17;34(41):13390–7

Self-association of spectrin's repeating segments. Ralston G, et al. **Biochemistry** 1996 Apr 23;35(16):5257–63

Type I collagen CNBr peptides: species and behavior in solution. Rossi A, et al. **Biochemistry** 1996 May 14; 35(19):6048–57

Temperature dependence of polypeptide partitioning between water and phospholipid bilayers. Russell CJ, et al. **Biochemistry** 1996 Jul 23;35(29):9526–32

The cytoplasmic fragment of the aspartate receptor displays globally dynamic behavior. Seeley SK, et al. **Biochemistry** 1996 Apr 23;35(16):5199–206

NMR solution structure of a synthetic troponin C heterodimeric domain. Shaw GS, et al. **Biochemistry** 1996 Jun 11;35(23):7429–38

Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. Vu HM, et al. **Biochemistry** 1996 Apr 23; 35(16):5158–65

Conformations of human apolipoprotein E(263–286) and E(267–289) in aqueous solutions of sodium dodecyl sulfate by CD and 1H NMR. Wang G, et al. **Biochemistry** 1996 Aug 13;35(32):10358–66

Solution and membrane bound structure of a peptide derived from the protein kinase C substrate domain of neuromodulin. Wertz SL, et al. **Biochemistry** 1996 Aug 27; 35(34):11104–12

Solution small-angle X-ray scattering study of the molecular chaperone Hsc70 and its subfragments. Wilbanks SM, et al. **Biochemistry** 1995 Sep 26;34(38):12095–106

Variable conformation and dynamics of calmodulin complexed with peptides derived from the autoinhibitory domains of target proteins. Yao Y, et al. **Biochemistry** 1996 May 28;35(21):6815–27

Structure of the third cytoplasmic loop of bovine rhodopsin. Yeagle PL, et al. **Biochemistry** 1995 Nov 14;34(45):14621–5

Structure of the pseudosubstrate recognition site of chicken smooth muscle myosin light chain kinase. Barden JA, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):106–12

Conformations of synthetic beta peptides in solid state and in aqueous solution: relation to toxicity in PC12 cells. Buchet R, et al. **Biochim Biophys Acta** 1996 Jan 17; 1315(1):40–6

MCD, EPR and NMR spectroscopic studies of rabbit hemopexin and its heme binding domain. Cox MC, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):215–23

Properties of elongation factor-2 fragments obtained by partial proteolysis. Dumont-Miscopein A, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):221–7

Isolation and characterization of domain I of ovoinhibitor. Galzie Z, et al. **Biochim Biophys Acta** 1996 Mar 7; 1293(1):113–21

Polarity-dependent conformational switching of a peptide mimicking the S4-S5 linker of the voltage-sensitive sodium channel. Helluin O, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):1–4

Preparation and characterization of a C-terminal fragment of pregnancy zone protein corresponding to the receptor-binding peptide from human alpha 2-macroglobulin. Jensen PE, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):254–8

The C-terminal region, Arg201-Gln209, of glutathione S-transferase P contributes to stability of the active-site conformation. Nishihira J, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):233–8

Conformation of human serum apolipoprotein A-I(166–185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR and CD. Evidence for specific peptide-SDS interactions. Wang G, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):174–84

Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Gaertner HF, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):38–44

Availability of phenylisothiocyanate for the amino acid sequence/configuration determination of peptides containing D/L-amino acids. Imai K, et al. **Biomed Chromatogr** 1995 Jul–Aug;9(4):195–6

Spectroscopic studies of a phosphoinositide-binding peptide from gelsolin: behavior in solutions of mixed solvent and anionic micelles. Xian W, et al. **Biophys J** 1995 Dec; 69(6):2695–702

Two-dimensional NMR studies of the interactions between a peptide of cholera toxin and monoclonal antibodies. Anglister J, et al. **Biopolymers** 1995;37(6):383–9

Conformation of parathyroid hormone antagonists by CD, NMR, and molecular dynamics simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):485–95

Monoclonal antibody directed to a fibrinogen A alpha #529–539 epitope inhibits alpha-chain crosslinking by transglutaminases. Mitkevich OV, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):85–92

Identification of an 80kD protein associated with the alpha 3 beta 1 integrin as a proteolytic fragment of the alpha 3 subunit: studies with human keratinocytes. Bishop LA, et al. **Cell Adhes Commun** 1995 Aug;3(3):243–55

Hydrolytic cleavage of pyroglutamyl-peptide bond. I. The susceptibility of pyroglutamyl-peptide bond to dilute hydrochloric acid. Hashimoto T, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2068–74

Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Power C, et al. **Curr Top Microbiol Immunol** 1995;202:89–104

Partial N-terminal amino acid sequence of the anti-neoplastic urinary protein (ANUP) and the anti-tumour effect of the N-terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1–5

Determination of residues in chromogranin A-(16–40) required for inhibition of parathyroid hormone secretion. Angeletti RH, et al. **Endocrinology** 1996 Jul;137(7):2918–22

Elimination of the carboxy-terminal sequences of parathyroid hormone-related protein 1–173 increases production and secretion of the truncated forms. Ditmer LS, et al. **Endocrinology** 1996 May;137(5):1608–17

A conformational change in the beta-subunit of the insulin-like growth factor I receptor identified by antipeptide antibodies. Gual P, et al. **Endocrinology** 1995 Dec;136(12):5298–304

Structure of glycopeptides isolated from bovine milk component PP3. Girardet JM, et al. **Eur J Biochem** 1995 Dec 15;234(3):939–46

Dissection of the basic subdomain of the c-Jun oncoprotein: a structural analysis of two peptide fragments by CD, Fourier-transform infrared and NMR. Krebs D, et al. **Eur J Biochem** 1996 Feb 1;235(3):699–712

Conformational effects of serine phosphorylation in phospholamban peptides. Quirk PG, et al. **Eur J Biochem** 1996 Feb 15;236(1):85–91

Structure of amyloid A4-(1–40)-peptide of Alzheimer's disease. Sticht H, et al. **Eur J Biochem** 1995 Oct 1; 233(1):293–8

Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. Vranken WF, et al. **Eur J Biochem** 1996 Feb 15; 236(1):100–8

Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Haurum JS, et al.

Eur J Immunol 1995 Dec;25(12):3270–6
The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306–318 and human myelin basic protein peptide 152–165 binding to several DR molecules: definition of a common extended DR binding motif. Posch PE, et al. **Eur J Immunol** 1996 Aug;26(8):1884–91
Mapping the heparin–binding domain of boar spermadhesins. Calvete JJ, et al. **FEBS Lett** 1996 Feb 5;379(3):207–11
Structure–activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. Chan WC, et al. **FEBS Lett** 1996 Jul 22;390(2):129–32
Crystallisation and preliminary X–ray analysis of the receptor–binding domain of human and bovine alpha 2–macroglobulin. Dolmer K, et al. **FEBS Lett** 1995 Sep 18;372(1):93–5
Dominant negative chimeras provide evidence for homo and heteromultimeric assembly of inward rectifier K+ channel proteins via their N–terminal end. Fink M, et al. **FEBS Lett** 1996 Jan 2;378(1):64–8
The C–terminal (haemopexin–like) domain structure of human gelatinase A (MMP2): structural implications for its function. Gohlke U, et al. **FEBS Lett** 1996 Jan 8; 378(2):126–30
Conformation of surface exposed N–terminus part of bacteriorhodopsin studied by transferred NOE technique. Pashkov VS, et al. **FEBS Lett** 1996 Feb 26;381(1–2):119–22
Comparison of the structures of the endothelin A receptor antagonists BQ123 and N–methyl leucine BQ123 with the crystal structure of the C–terminal tail of endothelin–1. Peishoff CE, et al. **FEBS Lett** 1995 Nov 6;374(3):379–83
Interaction between human amphipathic apolipoproteins and amyloid beta–peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12
An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl–prolyl cis/trans isomerase activity. Stoller G, et al. **FEBS Lett** 1996 Apr 15;384(2):117–22
Antibacterial activity of secretolytin, a chromogranin B–derived peptide (614–626), is correlated with peptide structure. Strub JM, et al. **FEBS Lett** 1996 Feb 5; 379(3):273–8
The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV–1 shows pronounced helical character in solution. Vranken WF, et al. **FEBS Lett** 1995 Oct 23;374(1):117–21
Antibacterial and immunostimulating casein–derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131–45 (49 ref.)
Characterization of a 21 amino acid peptide sequence of the laminin G2 domain that is involved in HNK–1 carbohydrate binding and cell adhesion. Hall H, et al. **Glycobiology** 1995 Jun;5(4):435–41
Peptide motifs from three cattle MHC (BoLA) class I antigens. Gaddum RM, et al. **Immunogenetics** 1996; 43(4):238–9
Motif of HLA–B*3503 peptide ligands. Steinle A, et al. **Immunogenetics** 1996;43(1–2):105–7
Receptor–binding properties of the peptides corresponding to the ACTH–like sequence of human pro–interleukin–1 alpha. Zav'yalov VP, et al. **Immunol Lett** 1995 May; 46(1–2):125–8
NMR conformational study of a model tetradecapeptide mimicking the RXVRG consensus cleavage site of a Xenopus laevis skin endoprotease. Chalaoux FR, et al. **Int J Pept Protein Res** 1995 Jun;45(6):519–28
Determination of disulfide bridge pattern in omega–conopeptides. Chung D, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):320–5
Pegylated peptides. IV. Enhanced biological activity of site–directed pegylated GRF analogs. Felix AM, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):253–64
Conformational studies of a synthetic cyclic decapeptide fragment of rat transforming growth factor–alpha. Jayaraman G, et al. **Int J Pept Protein Res** 1995 Jul; 46(1):88–96
The role of the C–terminus of the insulin B–chain in modulating structural and functional properties of the hormone. Leyer S, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):397–407
Structural and charge requirements for antimicrobial and hemolytic activity in the peptide PKLLETFLSKWIG, corresponding to the hydrophobic region of the antimicrobial protein bovine seminalplasmin. Sitaram N, et al. **Int J Pept Protein Res** 1995 Aug;46(2):166–73
Characterization of conformation and dynamics of CD4 Fragment (81–92) TYICEVEDQKEE and its benzylated derivative by 1H NMR spectroscopy and molecular modeling: Relevance of conformation to biological function. Chang DK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):222–32
Variability in heat–induced fragmentation of a protein in the presence of dodecyl sulfate: the role of an intramolecular sulfhydryl/disulfide exchange. Kubo K. **J Biochem (Tokyo)** 1995 Dec;118(6):1112–7
Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25–35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1108–11
The structure of a 19–residue fragment from the C–loop of the fourth epidermal growth factor–like domain of thrombomodulin. Adler M, et al. **J Biol Chem** 1995 Oct 6;270(40):23366–72
Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5beta HIV–1 neutralizing antibody. Faiman GA, et al. **J Biol Chem** 1996 Jun 7; 271(23):13829–33
Effect of pH on the conformation and backbone dynamics of a 27–residue peptide in trifluoroethanol. An NMR and CD Study. Fan F, et al. **J Biol Chem** 1995 Oct 20; 270(42):24693–701
Identification of the phospholipid binding site in the vitamin K–dependent blood coagulation protein factor IX. Freedman SJ, et al. **J Biol Chem** 1996 Jul 5; 271(27):16227–36
Further evidence for the structure of the subtilisin propeptide and for its interactions with mature subtilisin. Hu Z, et al. **J Biol Chem** 1996 Feb 16;271(7):3375–84
Thermodynamic studies of SHC phosphotyrosine interaction domain recognition of the NPXpY motif. Mandiyan V, et al. **J Biol Chem** 1996 Mar 1;271(9):4770–5
Occurrence of transient multimeric species during the refolding of a monomeric protein. Pecorari F, et al. **J Biol Chem** 1996 Mar 1;271(9):5270–6
Amino–terminal deletions enhance aggregation of beta–amyloid peptides in vitro. Pike CJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23895–8
Structural and electron microscopic analysis of neurocan and recombinant neurocan fragments. Retzler C, et al. **J Biol Chem** 1996 Jul 19;271(29):17107–13
Examining rhodopsin folding and assembly through expression of polypeptide fragments. Ridge KD, et al. **J Biol Chem** 1996 Mar 29;271(13):7860–7
Comparative structural and functional features of the human fibrinogen alpha C domain and the isolated alpha C fragment. Characterization using monoclonal antibodies to defined COOH–terminal A alpha chain regions. Rudchenko S, et al. **J Biol Chem** 1996 Feb 2;271(5):2523–30
Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP–19, neurogranin, and neuromodulin. Slemmon JR, et al. **J Biol Chem** 1996 Jul 5;271(27):15911–7
Structural and functional characteristics of partially disulfide–reduced intermediates of ovotransferrin N lobe. Cystine localization by indirect end–labeling approach and implications for the reduction pathway. Yamashita H, et al. **J Biol Chem** 1995 Dec 15;270(50):29806–12
Interaction of streptokinase and plasminogen. Studied with truncated streptokinase peptides. Young KC, et al. **J Biol Chem** 1995 Dec 8;270(49):29601–6
Conformational analysis of the beta–amyloid peptide fragment, beta(12–28). Jayawickrama D, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):229–44
Precolumn fluorescence derivatization of the antagonist [Arg6,D–Trp7,9,MePhe8]–substance P[6–11] with benzoin in high–performance liquid chromatography and selective detection of arginine–containing fragments in its degradation products. Cui H, et al. **J Chromatogr A** 1996 Jun 7;736(1–2):91–6
Placement of medium–sized molecular fragments into active sites of proteins. Rarey M, et al. **J Comput Aided Mol Des** 1996 Feb;10(1):41–54
Residues near the amino and carboxyl termini of staphylococcal enterotoxin E independently mediate TCR V beta–specific interactions. Lamphear JG, et al. **J Immunol** 1996 Mar 15;156(6):2178–85
Functional dissociation of CD8 alpha's Ig homologue and connecting peptide domains. Meyerson HJ, et al. **J Immunol** 1996 Jan 15;156(2):574–84
Ubiquitin–like moiety of the monoclonal nonspecific suppressor factor beta is responsible for its activity. Nakamura M, et al. **J Immunol** 1996 Jan 15;156(2):532–8
Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. Nijenhuis M, et al. **J Immunol** 1996 Mar 15;156(6):2186–95
Carboxyterminal peptides with the dimeric form of PF4 retain the inhibitory effect on the growth of human megakaryoblastic cell lines [see comments] Lebeurier I, et al. **J Lab Clin Med** 1996 Feb;127(2):179–85. Comment in: J Lab Clin Med 1996 Feb;127(2):148–50.
Water exchange filter with improved sensitivity (WEX II) to study solvent–exchangeable protons. Application to the consensus zinc finger peptide CP–1. Mori S, et al. **J Magn Reson B** 1996 Jan;110(1):96–101
Effect of the position of a basic amino acid on C–terminal rearrangement of protonated peptides upon collision–induced dissociation. Gonzalez J, et al. **J Mass Spectrom** 1996 Feb;31(2):150–8
Fungal metabolites. XXI. Characteristics of low energy collision induced dissociation of [M + 2H]2+, [M + H + Na]2+ and [M + 2Na]2+ of peptaibols using electrospray ionization mass spectrometry. Kanai M, et al. **J Mass Spectrom** 1996 Feb;31(2):177–83
Insight into a random coil conformation and an isolated helix: structural and dynamical characterisation of the C–helix peptide from hen lysozyme. Bolin KA, et al. **J Mol Biol** 1996 Aug 23;261(3):443–53
Structural studies of synthetic peptides dissected from the voltage–gated sodium channel. Doak DG, et al. **J Mol Biol** 1996 May 17;258(4):672–87
High helical propensity of the peptide fragments derived from beta–lactoglobulin, a predominantly beta–sheet protein. Hamada D, et al. **J Mol Biol** 1995 Dec 8; 254(4):737–46
Search for nucleation sites in smaller fragments of chymotrypsin inhibitor 2. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):289–304
Preferential heterodimeric parallel coiled–coil formation by synthetic Max and c–Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization. Lavigne P, et al. **J Mol Biol** 1995 Dec 1;254(3):505–20
Self–association of beta–amyloid peptide (1–40) in solution and binding to lipid membranes. Terzi E, et al. **J Mol Biol** 1995 Oct 6;252(5):633–42
1H, 15N resonance assignment and three–dimensional structure of CYP1 (HAP1) DNA–binding domain. Timmerman J, et al. **J Mol Biol** 1996 Jun 21;259(4):792–804
Calculation of relative binding free energies and configurational entropies: a structural and thermodynamic analysis of the nature of non–polar binding of thrombin inhibitors based on hirudin55–65. Wang J, et al. **J Mol Biol** 1995 Oct 27;253(3):473–92
Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. Wood SJ, et al. **J Mol Biol** 1996 Mar 15; 256(5):870–7
Zinc–induced aggregation of human and rat beta–amyloid peptides in vitro. Esler WP, et al. **J Neurochem** 1996 Feb; 66(2):723–32
Effect of transmembrane helix packing on tryptophan and tyrosine environments in detergent–solubilized bacterio–opsin. Renthal R, et al. **J Protein Chem** 1996 Apr; 15(3):281–9
Biophysical characterization of recombinant proteins expressing the leucine zipper–like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. Shugars DC, et al. **J Virol** 1996 May;70(5):2982–91
Separation of peptides and protein digests by capillary electrophoresis. Herold M, et al. **Methods Mol Biol** 1996; 52:285–308
Monomer of the B subunit of heat–labile enterotoxin from enterotoxigenic Escherichia coli has little ability to bind to GM1 ganglioside compared to its coligenoid. Tsuji T, et al. **Microbiol Immunol** 1995;39(10):817–9
The antisense homology box: a new motif within proteins that encodes biologically active peptides [see comments] Baranyi L, et al. **Nat Med** 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Sep;1(9):876–8. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
The PKD1 gene product [letter; comment] Harris PC, et al. **Nat Med** 1995 Jun;1(6):493. Comment on: Nat Med 1995 Apr;1(4):359–64.
Retrovirus envelope domain at 1.7 angstrom resolution. Fass D, et al. **Nat Struct Biol** 1996 May;3(5):465–9
Structural model for the beta–amyloid fibril based on interstrand alignment of an antiparallel–sheet comprising a C–terminal peptide [see comments] Lansbury PT Jr, et al. **Nat Struct Biol** 1995 Nov;2(11):990–8. Comment in: Nat Struct Biol 1995 Nov;2(11):926–8.
Crystal structure of the haemopexin–like C–terminal domain of gelatinase A [letter] Libson AM, et al. **Nat Struct Biol** 1995 Nov;2(11):938–42
High–resolution structural studies of the factor XIIIa crosslinking site and the first type 1 module of fibronectin [letter] Potts JR, et al. **Nat Struct Biol** 1995 Nov; 2(11):946–50
A short linear peptide derived from the N–terminal sequence of ubiquitin folds into a water–stable non–native beta–hairpin. Searle MS, et al. **Nat Struct Biol** 1995 Nov; 2(11):999–1006
NMR structure of the mouse prion protein domain PrP(121–321). Riek R, et al. **Nature** 1996 Jul 11; 382(6587):180–2
Soluble multimeric Alzheimer beta(1–40) pre–amyloid complexes in dilute solution. Levine H 3rd. **Neurobiol Aging** 1995 Sep–Oct;16(5):755–64
A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Chen J, et al. **Nucleic Acids Res** 1996 May 1;24(9):1727–33
A 15 amino acid stretch close to the Grb2–binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. Rojas JM, et al. **Oncogene** 1996 Jun 6; 12(11):2291–300
Structure of human calcitonin gene–related peptide (hCGRP) and of its antagonist hCGRP 8–37 as determined by NMR and molecular modeling. Boulanger Y, et al. **Pept Res** 1995 Jul–Aug;8(4):206–13
Selective effects of charge on G protein activation by FSH–receptor residues 551–555 and 650–653. Grasso P, et al. **Pept Res** 1995 Sep–Oct;8(5):278–84
Instability of side–chain protecting groups during MALDI–TOF mass spectrometry of peptide fragments. Schmidt M, et al. **Pept Res** 1995 Jul–Aug;8(4):238–42
Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Fujita H, et al. **Peptides** 1995;16(5):785–90
Retinoid X receptor alpha forms tetramers in solution. Kersten S, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8645–9

On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Lomakin A, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1125–9

Properties of a single-chain antibody containing different linker peptides. Alfthan K, et al. **Protein Eng** 1995 Jul; 8(7):725–31

Recombinant protein sequences can trigger methylation of N-terminal amino acids in Escherichia coli. Apostol I, et al. **Protein Sci** 1995 Dec;4(12):2616–8

Role of the N-terminal region of the skeletal muscle myosin light chain kinase target sequence in its interaction with calmodulin. Findlay WA, et al. **Protein Sci** 1995 Nov; 4(11):2375–82

Quantitative approaches to utilizing mutational analysis and disulfide crosslinking for modeling a transmembrane domain. Lee GF, et al. **Protein Sci** 1995 Jun;4(6):1100–7

Homology modeling and molecular dynamics simulation of human prothrombin fragment 1. Li L, et al. **Protein Sci** 1995 Nov;4(11):2341–8

Synthesis, activity, and preliminary structure of the fourth EGF-like domain of thrombomodulin. Meininger DP, et al. **Protein Sci** 1995 Sep;4(9):1683–95

Solvent polarity-dependent structural refolding: a CD and NMR study of a 15 residue peptide. Graf von Stosch A, et al. **Proteins** 1995 Oct;23(2):196–203

Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex. Kirchhofer D, et al. **Proteins** 1995 Aug; 22(4):419–25

Ab initio structure prediction for small polypeptides and protein fragments using genetic algorithms. Pedersen JT, et al. **Proteins** 1995 Nov;23(3):454–60

Binding affinity and physiological activity of some HVFLRFamide analogues on the oviducts of the locust, Locusta migratoria. Wang Z, et al. **Regul Pept** 1995 Jun 27;57(3):339–46

Structures of an MHC class II molecule with covalently bound single peptides [see comments] Fremont DH, et al. **Science** 1996 May 17;272(5264):1001–4. Comment in: Nature 1996 May 17;272(5264):973–4.

Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide. Lipp MM, et al. **Science** 1996 Aug 30;273(5279):1196–9

Structure of the biotinyl domain of acetyl-coenzyme A carboxylase determined by MAD phasing. Athappilly FK, et al. **Structure** 1995 Dec 15;3(12):1407–19

The crystal structure of cyclin A [see comments] Brown NR, et al. **Structure** 1995 Nov 15;3(11):1235–47. Comment in: Structure 1995 Nov 15;3(11):1131–4.

A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin. Taubenfeld SM, et al. **Thromb Haemost** 1995 Sep;74(3):923–7

The beta chain of the GPIIb molecule on ruminant leukocytes and platelets is not labelled by the sulfo-NHS-biotin method. Pintado CO, et al. **Vox Sang** 1995;69(3):248–9

[Fusion of negatively-charged liposomes under the effect of peptides from the N-terminal fragment of the HIV-1 transmembrane protein] Terletskaia IaT, et al. **Biokhimiia** 1995 Oct;60(10):1711–9 (Eng. Abstr.) **(Rus)**

[Synthesis of an ethylamide of the cyclic undecapeptide sequence 593–603 of transmembrane glycoprotein gp41 of the human immunodeficiency virus type 2] Sidorova MV, et al. **Bioorg Khim** 1995 Sep;21(9):675–83 (Eng. Abstr.) **(Rus)**

[Theoretical conformational NMR-analysis of RP342 peptide, affiliated with the immunogenic fragment of HIV-1 gp120 protein] Andrianov AM. **Dokl Akad Nauk** 1995 Oct;344(4):546–8 **(Rus)**

[A spatial structure model of the basic antigenic determinant of the human immunodeficiency virus type 1 gp120 protein] Andrianov AM, et al. **Dokl Akad Nauk** 1995 Jun; 342(4):543–5 **(Rus)**

[Fibrin fragment beta 15–118. Inhibitory and complex-forming properties] Lugovskoĭ EV, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):57–64 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Plasma growth hormone response to growth hormone-releasing hexapeptide (GH-RP-6) in children with short stature. Pombo M, et al. **Acta Paediatr** 1995 Aug;84(8):904–8

DRUG EFFECTS

Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. Gordon LM, et al. **AIDS Res Hum Retroviruses** 1995 Jun;11(6):677–86

Random copolymers containing specific ratios of negatively charged and aromatic amino acids bind V3 disulfide loop and neutralize diverse HIV type 1 isolates. Javaherian K, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1163–8

Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin. Okada T, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):571–5

A single point mutation decreases picrotoxinin sensitivity of the human GABA receptor rho 1 subunit. Enz R, et al. **Neuroreport** 1995 Jul 31;6(11):1569–72

Glucocorticoids inhibit the synthesis rate of type III collagen, but do not affect the hepatic clearance of its aminoterminal propeptide (PIIINP). Hansen M, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):543–8

Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Callebaut C, et al. **Virology** 1996 Apr 1;218(1):181–92

GENETICS

Analysis of the V3 loop sequences from 10 HIV type 1-infected AIDS patients from Paraguay. Cabello A, et al. **AIDS Res Hum Retroviruses** 1995 Sep;11(9):1135–7

Characterization of HIV type 1 from Romanian children: lack of correlation between V3 loop amino acid sequence and syncytium formation in MT-2 cells. Holm-Hansen C, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):597–603

Intrapatient variability of the human immunodeficiency virus type 2 envelope V3 loop. Sankalé JL, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):617–23

Highly divergent env sequences of HIV-1 B subtype with two novel V3 loop motifs detected in an AIDS patient in Miami, Florida. Xin KQ, et al. **AIDS Res Hum Retroviruses** 1995 Sep;11(9):1139–41

Neuropeptides and thirst: the temporal response of corticotropin-releasing hormone and neurotensin/neuromedin N gene expression in rat limbic forebrain neurons to drinking hypertonic saline. Watts AG, et al. **Behav Neurosci** 1995 Dec;109(6):1146–57

Cloning, structure and mRNA expression of human Cctg, which encodes the chaperonin subunit CCT gamma. Walkley NA, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):381–9

Molecular cloning of two types of cDNA encoding subunit RC6-1 of rat proteasomes. Ni R, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):45–52

Changes in expression of NR-1 and c-jun mRNA in rat lumbar spinal cord after neonatal common peroneal nerve crush. Hay C, et al. **Brain Res** 1995 Dec 15;704(1):145–50

GABAA receptor subunit mRNA expression in the weaver cerebellum: modulation by cell-cell interactions. Beattie CE, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):171–7

Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NMDA receptor channel. Ikeda K, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):61–71

The distribution of splice variants of the NMDAR1 subunit mRNA in adult rat brain. Laurie DJ, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):94–108

Na+ channel beta 1 subunit mRNA expression in developing rat central nervous system. Sashihara S, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):239–50

Tyrosine kinase phosphorylation of GABAA receptors. Valenzuela CF, et al. **Brain Res Mol Brain Res** 1995 Jul; 31(1–2):165–72

Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Xu HJ, et al. **Cancer Res** 1996 May 15;56(10):2245–9

Strikingly different propulsive forces generated by different dynein-deficient mutants in viscous media. Minoura I, et al. **Cell Motil Cytoskeleton** 1995;31(2):130–9

Regulated expression of a novel laminin beta subunit during the development of the chick embryo. Ybot-Gonzalez P, et al. **Differentiation** 1995 Nov;59(4):215–23

A positive regulatory sequence of hepatitis B viral small X promoter. Chol CY, et al. **Eur J Biochem** 1996 Aug 1; 239(3):579–87

Thy-1+ dendritic cells express truncated form of POMC mRNA. Farooqui JZ, et al. **Exp Dermatol** 1995 Oct; 4(5):297–301

The bovine PP3 gene is homologous to the murine GlyCAM 1 gene. Johnsen LB, et al. **Gene** 1996 Mar 9;169(2):297–8

Tissue-specific inactivation of p53 tumor suppression in the mouse. Bowman T, et al. **Genes Dev** 1996 Apr 1; 10(7):826–35

Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X. Tee MK, et al. **Genomics** 1995 Jul 20;28(2):171–8

HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. Dinges MM, et al. **Hum Gene Ther** 1995 Nov;6(11):1437–45

Deletion of a Gly-Pro-Pro repeat in the pro alpha2(I) chain of procollagen I in a family with dominant osteogenesis imperfecta type IV. Lund AM, et al. **Hum Genet** 1996 Mar; 97(3):287–90

Optimized bacterial production of nonglycosylated human transferrin and its half-molecules. de Smit MH, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):839–50

Molecular cloning of CWP1: a gene encoding a Saccharomyces cerevisiae cell wall protein solubilized with Rarobacter faecitabidus protease I. Shimoi H, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):302–11

Characterization of a 5.4 kb cDNA fragment from the Z-line region of rabbit cardiac titin reveals phosphorylation sites for proline-directed kinases. Sebestyén MG, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3029–37

Localization of alpha 7 nicotinic receptor subunit mRNA and alpha-bungarotoxin binding sites in developing mouse somatosensory thalamocortical system. Bina KG, et al. **J Comp Neurol** 1995 Dec 11;363(2):321–32

Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution. Kuiken CL, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):783–92

An Alu cassette in the cytoplasmic domain of an interferon receptor subunit. Mullersman JE, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):815–7

A variant of beta fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction. Yu Q, et al. **J Investig Med** 1996 Apr;44(4):154–9

Analysis of ENV V3 sequences from HIV-1-infected brain indicates restrained virus expression throughout the disease. Di Stefano M, et al. **J Med Virol** 1996 May;49(1):41–8

The beta subunit common to the GM-CSF, IL-3 and IL-5 receptors is highly polymorphic but pathogenic point mutations in patients with acute myeloid leukaemia (AML) are rare. Freeburn RW, et al. **Leukemia** 1996 Jan; 10(1):123–9

The complete cDNA coding sequence for the mouse pro alpha 1(I) chain of type I procollagen. Li SW, et al. **Matrix Biol** 1995 Jul;14(7):593–5

Amyloid, aluminum and the aetiology of Alzheimer's disease [letter; comment] Exley C. **Med J Aust** 1996 Feb 19; 164(4):252–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

Synergistic activation of neurotensin/neuromedin N gene expression by c-Jun and glucocorticoids: novel effects of Fos family proteins. Harrison RJ, et al. **Mol Endocrinol** 1995 Aug;9(8):981–93

Human recombinant CD4 and CD4-derived synthetic peptides agglutinate immunoglobulin-coated latex particles. Evidence that residues 25–28 and 35–38 of human CD4 form two separate immunoglobulin binding sites. Lenert P, et al. **Mol Immunol** 1995 Dec;32(17–18):1399–404

Differential expression and co-assembly of NMDA zeta 1 and epsilon subunits in the mouse cerebellum during postnatal development. Didier M, et al. **Neuroreport** 1995 Nov 13;6(16):2255–9

Retarded vestibular compensation in mutant mice deficient in delta 2 glutamate receptor subunit. Funabiki K, et al. **Neuroreport** 1995 Dec 29;7(1):189–92

cDNA sequence, ligand biding, and regulation of galanin/GMAP in mouse brain. Lundkvist J, et al. **Neurosci Lett** 1995 Nov 17;200(2):121–4

Initiation of herpes simplex virus thymidine kinase polypeptides. Ellison AR, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2073–9

Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. Kawasaki H, et al. **Nucleic Acids Res** 1996 Aug 1; 24(15):3010–6

Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1 alpha subunit mutations in females. Otero LJ, et al. **Pediatr Neurol** 1995 Nov;13(4):327–32

Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells. Aguila HL, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10192–6

Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65–78 (51 ref.)

Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Metlaš R, et al. **Viral Immunol** 1994;7(4):215–9

The Tat and C2-V3 envelope genes in the molecular epidemiology of human immunodeficiency virus-1. Lorenzo E, et al. **Virology** 1996 Jul 15;221(2):310–7

[Skin expansion and skin growth. Molecular proof of collagen synthesis in long-term skin expansion] Preyer S. **HNO** 1996 Mar;44(3):117 **(Ger)**

[Cloning fragments of the RNA polymerase gene of an attenuated variant of the foot-and-mouth disease virus A22] Lomakina NF, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):33–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Interaction of natural and synthetic peptides derived from gliadin with different cell lines. Farré MA, et al. **Adv Exp Med Biol** 1995;371B:1371–3

Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Loftus DJ, et al. **Adv Exp Med Biol** 1995; 383:201–10 (71 ref.)

Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential. Fontenot JD, et al. **AIDS** 1995 Oct;9(10):1121–9

Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. Langedijk JP, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1153–62

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. Salmon-Céron D, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1479–86

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. Vancott TC, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1379–91

Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients. Von Brunn A, et al.

AIDS Res Hum Retroviruses 1995 Dec;11(12):1459–65

Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl–terminus of the beta A4 peptide. König G, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:344–55

Coeliac disease. Pathogenesis and clinical aspects. Friis SU. **APMIS Suppl** 1996;61:1–48

Identification and analysis of drug–responsive expression of UDP–glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti–peptide antibodies. Ikushiro S, et al. **Arch Biochem Biophys** 1995 Dec 20; 324(2):267–72

Antibody binding to a peptide but not the whole protein by recognition of the C–terminal carboxy group. Liang TC, et al. **Arch Biochem Biophys** 1996 May 15; 329(2):208–14

Identification of a cyanogen bromide fragment of porcine type II collagen capable of modulating collagen arthritis in B10.RIII (H–2r) mice. Nabozny GH, et al. **Autoimmunity** 1995;20(1):39–49

Granulocyte–macrophage colony–stimulating factor: an effective adjuvant for protein and peptide–based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202–10

A human monoclonal antibody specific for the leucine–33 (P1A1, HPA–1a) form of platelet glycoprotein IIIa from a V gene phage display library. Griffin HM, et al. **Blood** 1995 Dec 15;86(12):4430–6

Monoclonal antibody directed to a fibrinogen A alpha #529–539 epitope inhibits alpha–chain crosslinking by transglutaminases. Mitkevich OV, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):85–92

Soluble MHC II–peptide complexes induce antigen–specific apoptosis in T cells. Nag B, et al. **Cell Immunol** 1996 May 25;170(1):25–33

Unique T cell antagonist properties of the exact self–correlate of a peptide antigen revealed by self–substitution of non–self–positions in the peptide sequence. Schountz T, et al. **Cell Immunol** 1996 Mar 15;168(2):193–200

Monoclonal antibodies against a C–terminal peptide of human brain acetylcholinesterase distinguish between erythrocyte and brain acetylcholinesterases. Boschetti N, et al. **Clin Chem** 1996 Jan;42(1):19–23

Immunochemiluminometric assay with two monoclonal antibodies against the N–terminal sequence of human parathyroid hormone. Gao P, et al. **Clin Chim Acta** 1996 Feb 9;245(1):39–59

Human T cell responses to peptide epitopes of the 16–kD antigen in tuberculosis. Friscia G, et al. **Clin Exp Immunol** 1995 Oct;102(1):53–7

Demonstration of virus–specific CD8+ memory T cells in measles–seropositive individuals by in vitro peptide stimulation. Nanan R, et al. **Clin Exp Immunol** 1995 Oct; 102(1):40–5

Yersinia–hsp60–reactive T cells are efficiently stimulated by peptides of 12 and 13 amino acid residues in a MHC class II (I–Ab)–restricted manner. Noll A, et al. **Clin Exp Immunol** 1996 Aug;105(2):231–7

Activation of epitope–specific memory cytotoxic T lymphocyte responses by synthetic peptides. Reali E, et al. **Clin Exp Immunol** 1996 Aug;105(2):369–75

Immunization of non–obese diabetic (NOD) mice with glutamic acid decarboxylase–derived peptide 524–543 reduces cyclophosphamide–accelerated diabetes. Saï P, et al. **Clin Exp Immunol** 1996 Aug;105(2):330–7

Mucosal tolerance and suppression of collagen–induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184–198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Staines NA, et al. **Clin Exp Immunol** 1996 Mar;103(3):368–75

A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Fu ML, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):203–7

Indirect recognition of donor MHC Class II antigens in human transplantation. Liu Z, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):228–35

Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85–100 (150 ref.)

Evaluation of a Lyme disease enzyme immunoassay using the 41–G fragment of flagellin. Cretella S, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):609–13

Unique role of thyroxine in T cell recognition of a pathogenic peptide in experimental autoimmune thyroiditis. Dawe KI, et al. **Eur J Immunol** 1996 Apr;26(4):768–72

A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex–specific monoclonal antibody. Eastman S, et al. **Eur J Immunol** 1996 Feb;26(2):385–93

Induction of diabetes in standard mice by immunization with the p277 peptide of a 60–kDa heat shock protein. Elias D, et al. **Eur J Immunol** 1995 Oct;25(10):2851–7

CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum– or helper peptides in priming for skin test reactivity to a P815AB–related peptide. Grohmann U, et al. **Eur J Immunol** 1995 Oct; 25(10):2797–802

Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Haurum JS, et al. **Eur J Immunol** 1995 Dec;25(12):3270–6

Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV–1. Laisney IL, et al. **Eur J Immunol** 1996 Jul; 26(7):1634–40

Carrier–reactive hapten–specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: implications for chemical–induced self–reactivity. Martin S, et al. **Eur J Immunol** 1995 Oct;25(10):2788–96

Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Nepom GT, et al. **Eur J Immunol** 1996 Apr;26(4):949–52

Permissive recognition during positive selection. Pawlowski TJ, et al. **Eur J Immunol** 1996 Apr;26(4):851–7

Peptides derived from IgE heavy chain constant region induce profound IgE isotype–specific tolerance. Wang Y, et al. **Eur J Immunol** 1996 May;26(5):1043–9

Orally induced, peptide–specific gamma/delta TCR+ cells suppress experimental autoimmune uveitis. Wildner G, et al. **Eur J Immunol** 1996 Sep;26(9):2140–8

Inhibition of I–Ad–, but not Db–restricted peptide–induced thymic apoptosis by glucocorticoid receptor antagonist RU486 in T cell receptor transgenic mice. Xue Y, et al. **Eur J Immunol** 1996 Feb;26(2):428–34

Plasmodium falciparum: naturally occurring rabbit immunoglobulins recognize human band 3 peptide motifs and malaria–infected red cells. Crandall I, et al. **Exp Parasitol** 1996 Jan;82(1):45–53

Characterization of an internal permissive site in the cholera toxin B–subunit and insertion of epitopes from human immunodeficiency virus–1, hepatitis B virus and enterotoxigenic Escherichia coli. Bckström M, et al. **Gene** 1995 Nov 20;165(2):163–71

Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC–1 derived peptides. Liu X, et al. **Glycoconj J** 1995 Oct;12(5):607–17

Binding of peptides of the human acetylcholine receptor alpha–subunit to HLA class II of patients with myasthenia gravis. Zisman E, et al. **Hum Immunol** 1995 Nov; 44(3):121–30

Anti–peptide monoclonal antibodies to the beta–adrenergic receptor: use in purification of beta receptor. Luxembourg A. **Hybridoma** 1995 Jun;14(3):261–4

Evidence that a single peptide–MHC complex on a target cell can elicit a cytolytic T cell response. Sykulev Y, et al. **Immunity** 1996 Jun;4(6):565–71

Alloreactive cytotoxic T–lymphocyte–defined HLA–B7 subtypes differ in peptide antigen presentation. Smith KD, et al. **Immunogenetics** 1996;43(1–2):27–37

Cellular immune responses of patients with juvenile chronic arthritis to retinal antigens and their synthetic peptides. Gupta D, et al. **Immunol Res** 1996;15(1):74–83

Restricted diversity in the T–cell repertoire [letter] Petrovsky N. **Immunol Today** 1995 Aug;16(8):408–9

Differential activation of mouse hepatitis virus–specific CD4+ cytotoxic T cells is defined by peptide length. Heemskerk MH, et al. **Immunology** 1995 Aug;85(4):517–22

The induction of respiratory syncytial virus–specific cytotoxic T–cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope. Hsu SC, et al. **Immunology** 1995 Jul;85(3):347–50

The effects of changes at peptide residues contacting MHC class II T–cell receptor on antigen recognition and human Th0 cell effector function. Lamb JR, et al. **Immunology** 1995 Jul;85(3):447–54

Induction of single and dual cytotoxic T–lymphocyte responses to viral proteins in mice using recombinant hybrid Ty–virus–like particles. Layton GT, et al. **Immunology** 1996 Feb;87(2):171–8

Evidence for monoclonal expansion of synovial T cells bearing V alpha 2.1/V beta 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens. Ostenstad B, et al. **Immunology** 1995 Oct;86(2):168–75

Immunologic characteristics of a Streptococcus mutans glucosyltransferase B sucrose–binding site peptide–cholera toxin B–subunit chimeric protein. Laloi P, et al. **Infect Immun** 1996 Jan;64(1):28–36

Antibodies to a conserved–motif peptide sequence of the Plasmodium falciparum thrombospondin–related anonymous protein and circumsporozoite protein recognize a 78–kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro. Sharma P, et al. **Infect Immun** 1996 Jun;64(6):2172–9

A mAb against HLA–A2 can be influenced both positively and negatively by the associated peptide. Barouch D, et al. **Int Immunol** 1995 Oct;7(10):1599–605

The immunosuppressive peptide of HIV–1 inhibits T and B lymphocyte stimulation. Denner J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):442–50

Reactivity of Argentine serum samples against synthetic V3–based HIV–1 peptides [letter] Pampuro SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):527–8

CD4+ T–lymphocyte lines developed from HIV–1–seropositive patients recognize different epitopes within the V3 loop. Ratto S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):128–36

Tolerance to amino acid variations in peptides binding to the major histocompatibility complex class I protein H–2Kb. Udaka K, et al. **J Biol Chem** 1995 Oct 13; 270(41):24130–4

Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell–mediated function, are present in pooled normal immunoglobulin for therapeutic use. Kaveri S, et al. **J Clin Invest** 1996 Feb 1;97(3):865–9

Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. Campos–Neto A, et al. **J Exp Med** 1995 Nov 1;182(5):1423–33

Genetic basis for T cell recognition of a major histocompatibility complex class II–restricted neo–self peptide. Cerasoli DM, et al. **J Exp Med** 1995 Nov 1; 182(5):1327–36

Myocarditis–inducing epitope of myosin binds constitutively and stably to I–Ak on antigen–presenting cells in the heart. Donermeyer DL, et al. **J Exp Med** 1995 Nov 1; 182(5):1291–300

Presentation of a self–peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus. Fedoseyeva EV, et al. **J Exp Med** 1995 Nov 1;182(5):1481–91

Strictly transporter of antigen presentation (TAP)–dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein. Hombach J, et al. **J Exp Med** 1995 Nov 1; 182(5):1615–9

T cell receptor usage and fine specificity of human immunodeficiency virus 1–specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. Kalams SA, et al. **J Exp Med** 1996 Apr 1;183(4):1669–79

T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. Morkowski S, et al. **J Exp Med** 1995 Nov 1;182(5):1403–13

Unresponsiveness to a self–peptide of mouse lysozyme owing to hindrance of T cell receptor–major histocompatibility complex/peptide interaction caused by flanking epitopic residues. Moudgil KD, et al. **J Exp Med** 1996 Feb 1; 183(2):535–46

Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell–mediated autoimmunity [see comments] Singh RR, et al. **J Exp Med** 1996 Apr 1; 183(4):1613–21. Comment in: J Exp Med 1996 Apr 1;183(4):1297–301.

An insulin peptide that binds an alternative site in class II major histocompatibility complex. Tompkins SM, et al. **J Exp Med** 1996 Mar 1;183(3):857–66

Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. Valitutti S, et al. **J Exp Med** 1996 Apr 1;183(4):1917–21

A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide–specific therapy after onset of clinical disease. Yu M, et al. **J Exp Med** 1996 Apr 1;183(4):1777–88

A protective anti–peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot–and–mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. Barnett PV, et al. **J Gen Virol** 1996 May;77 (Pt 5):1011–8

Immunodominant epitopes defined by a yeast–expressed library of random fragments of the rabies virus glycoprotein map outside major antigenic sites. Lafay F, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):339–46

Rapid selection for an N–linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. Schønning K, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):753–8

Quantitative analysis of IgA–subclass antibodies against tetanus toxoid. Engström PE, et al. **J Immunoassay** 1995 Aug;16(3):231–45

IL–12 is both required and sufficient for initiating T cell reactivity to a class I–restricted tumor peptide (P815AB) following transfer of P815AB–pulsed dendritic cells. Bianchi R, et al. **J Immunol** 1996 Aug 15;157(4):1589–97

Glutamic acid decarboxylase autoantibodies in stiff–man syndrome and insulin–dependent diabetes mellitus exhibit similarities and differences in epitope recognition. Daw K, et al. **J Immunol** 1996 Jan 15;156(2):818–25

Peptide–based, but not whole protein, vaccines elicit immunity to HER–2/neu, oncogenic self–protein. Disis ML, et al. **J Immunol** 1996 May 1;156(9):3151–8

Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin. Implications for peptide partial agonists. England RD, et al. **J Immunol** 1995 Nov 1;155(9):4295–306

Differential activation of phospholipase C–gamma 1 and mitogen–activated protein kinase in naive and antigen–primed CD4 T cells by the peptide/MHC ligand. Ericsson PO, et al. **J Immunol** 1996 Mar 15;156(6):2045–53

Prominent roles of secondary anchor residues in peptide binding to HLA–A24 human class I molecules. Kondo A, et al. **J Immunol** 1995 Nov 1;155(9):4307–12

Amino acid residues on the I–Ak alpha–chain required for the binding and stability of two antigenic peptides. Nelson

CA, et al. **J Immunol** 1996 Jan 1;156(1):176–82

Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. Nijenhuis M, et al. **J Immunol** 1996 Mar 15;156(6):2186–95

Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of hepatitis B surface antigen. Qiu X, et al. **J Immunol** 1996 May 1; 156(9):3350–6

Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. Shastri N, et al. **J Immunol** 1995 Nov 1; 155(9):4339–46

Peptides corresponding to CD4–interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo. Shen X, et al. **J Immunol** 1996 Jul 1;157(1):87–100

Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. Sijts AJ, et al. **J Immunol** 1996 Jan 15;156(2):683–92

Mucosal immunity to HIV–1: systemic and vaginal antibody responses after intranasal immunization with the HIV–1 C4/V3 peptide T1SP10 MN(A). Staats HF, et al. **J Immunol** 1996 Jul 1;157(1):462–72

Immunogenicity of new heterobifunctional cross–linking reagents used in the conjugation of synthetic peptides to liposomes. Boeckler C, et al. **J Immunol Methods** 1996 May 10;191(1):1–10

The use of dedicated peptide libraries permits the discovery of high affinity binding peptides. de Koster HS, et al. **J Immunol Methods** 1995 Nov 16;187(1):179–88

Detection and quantification of blood–derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA–A2.1–binding melanoma and viral peptide antigens. Herr W, et al. **J Immunol Methods** 1996 May 27;191(2):131–42

A dose–ranging study of a prototype synthetic HIV–1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Gorse GJ, et al. **J Infect Dis** 1996 Feb;173(2):330–9

Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. Balding SD, et al. **J Invest Dermatol** 1996 Jan;106(1):141–6

Response of cynomolgus macaques to immunization against a synthetic peptide from the human zona pellucida. Mahi–Brown CA, et al. **J Med Primatol** 1995 Dec; 24(4):258–70

Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. Bonnycastle LL, et al. **J Mol Biol** 1996 May 24; 258(5):747–62

Affinity maturation of a high–affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. Thompson J, et al. **J Mol Biol** 1996 Feb 16;256(1):77–88

The N–terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. Adelmann M, et al. **J Neuroimmunol** 1995 Dec; 63(1):17–27

A short peptide eluted from the H–2Kb molecule of a polyomavirus–positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus–specific immunity. Berke Z, et al. **J Virol** 1996 May;70(5):3093–7

Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV–specific cytotoxic T–cell responses in normal and in CD4+ cell–depleted BALB/c mice. Lapham C, et al. **J Virol** 1996 May;70(5):3084–92

Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4–binding site. Vijh–Warrier S, et al. **J Virol** 1996 Jul;70(7):4466–73

Antibody responses raised against a conformational V3 loop peptide of HIV–1. Bukawa H, et al. **Microbiol Immunol** 1995;39(8):607–14

Anti–hepatitis A virus antibody response elicited in mice by different forms of a synthetic VP1 peptide. Haro I, et al. **Microbiol Immunol** 1995;39(7):485–90

The peptide loop consisting of amino acids 139–157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse. Apostolidis VA, et al. **Mol Immunol** 1995 Aug;32(12):909–17

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin–dependent diabetes. Rudy G, et al. **Mol Med** 1995 Sep;1(6):625–33

Neutralization of HIV–1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Bukawa H, et al. **Nat Med** 1995 Jul;1(7):681–5

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Falo LD Jr, et al. **Nat Med** 1995 Jul;1(7):649–53

Regression of established murine carcinoma metastases following vaccination with tumour–associated antigen peptides [see comments] Mandelboim O, et al. **Nat Med** 1995 Nov;1(11):1179–83. Comment in: Nat Med 1995 Nov;1(11):1140.

Peptide vaccination against cancer? [comment] Strominger JL. **Nat Med** 1995 Nov;1(11):1140. Comment on: Nat Med 1995 Nov;1(11):1179–83.

Partial activation of CD8+ T cells by a self–derived peptide. Cao W, et al. **Nature** 1995 Nov 16;378(6554):295–8

Frequency of MBP and MBP peptide–reactive T cells in the HPRT mutant T–cell population of MS patients. Lodge PA, et al. **Neurology** 1996 May;46(5):1410–5

Improved specificity of Trypanosoma cruzi identification by polymerase chain reaction using an oligonucleotide derived from the amino–terminal sequence of a Tc24 protein. Taibi A, et al. **Parasitology** 1995 Dec;111 (Pt 5):581–90

Correlation of maternal cytophilic human immunodeficiency virus (HIV)–1 V3 loop peptide–specific antibodies in infants with vertical HIV transmission. Wang XP, et al. **Pediatr Res** 1995 Sep;38(3):384–9

Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette–Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Honda M, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10693–7

The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides. Niedermann G, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8572–7

Similar antigenic surfaces, rather than sequence homology, dictate T–cell epitope molecular mimicry. Quaratino S, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10398–402

Engineering disulfide–linked single–chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti–digoxin 26–10 (sFv')2 and anti–c–erbB–2 741F8 (sFv')2 made by protein folding and bonded through C–terminal cysteinyl peptides. McCartney JE, et al. **Protein Eng** 1995 Mar;8(3):301–14

Detection of antibodies to HIV–1 gp41– and HLA class II antigen–derived peptides in SLE patients. Koshino K, et al. **Scand J Rheumatol** 1995;24(5):288–92

Phenotypic analysis of antigen–specific T lymphocytes. Altman JD, et al. **Science** 1996 Oct 4;274(5284):94–6

Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype. Jarvis MA, et al. **Thromb Haemost** 1996 Feb; 75(2):318–25

The N–terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T–cell response. Berencsi K, et al. **Vaccine** 1996 Apr;14(5):369–74

Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus–specific CTL. Deprez B, et al. **Vaccine** 1996 Apr;14(5):375–82

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Hioe CE, et al. **Vaccine** 1996 Apr;14(5):412–8

Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Schreuder MP, et al. **Vaccine** 1996 Apr;14(5):383–8

Antibody and cytotoxic T–lymphocyte responses to a single liposome–associated peptide antigen. White WI, et al. **Vaccine** 1995 Aug;13(12):1111–22

Resistance to V3–directed neutralization caused by an N–linked oligosaccharide depends on the quaternary structure of the HIV–1 envelope oligomer. Schønning K, et al. **Virology** 1996 Apr 1;218(1):134–40

Anaphylactic reactions associated with anti–Chido Antibody following platelet transfusions [letter] Wibaut B, et al. **Vox Sang** 1995;69(2):150–1

[Receptor mechanism of dynorphin A in rat secondary spinal cord injuries] Li M, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):290–3 (Eng. Abstr.) **(Chi)**

[Effects of intrasubarachnoid space injection of anti dynorphin A1–13 serum or nor–BNI on the recovery of spinal cord injury in rats] Hong X, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):378–81 (Eng. Abstr.) **(Chi)**

[Antigenic structure of the Bordetella pertussis pertactin Pro–rich segment 536–566. I. Preparation and analysis of antisera to synthetic peptides] Kavun EM, et al. **Biokhimiia** 1995 Jul;60(7):1023–31 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Elastin–derived peptides and neutrophil elastase in bronchoalveolar lavage fluid. Betsuyaku T, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):720–4

Predominant HLA–class II bound self–peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Harris PE, et al. **Blood** 1996 Jun 15; 87(12):5104–12

Isolation by calcium–dependent translation to neutrophil–specific granules of a 42–kD cytosolic protein, identified as being a fragment of annexin XI. Sjölin C, et al. **Blood** 1996 Jun 1;87(11):4817–23

Casocidin–I: a casein–alpha s2 derived peptide exhibits antibacterial activity. Zucht HD, et al. **FEBS Lett** 1995 Sep 25;372(2–3):185–8

Isolation and identification of C–terminal peptides of proteins. Gu QM, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):366–71

Production of crystallizable fragments of membrane proteins. Hendrickson WA. **J Bioenerg Biomembr** 1996 Feb; 28(1):35–40 (40 ref.)

High–performance liquid chromatographic purification of extremely hydrophobic peptides: transmembrane segments. Bollhagen R, et al. **J Chromatogr A** 1995 Sep 8;711(1):181–6

Purification of Escherichia coli DNA polymerase I and Klenow fragment. Joyce CM, et al. **Methods Enzymol** 1995; 262:3–13

Dynorphin A(1–8) in human placenta: amino acid sequence determined by tandem mass spectrometry. Agbas A, et al. **Peptides** 1995;16(4):623–7

All prepro–VIP–derived peptides, except PHI/PHV, are expressed in the female rat anterior pituitary and increased by estrogen. Skakkebaek ML, et al. **Peptides** 1995; 16(7):1287–94

Isolation, identification and functional significance of [Hyp2]Met–callatostatin and des Gly–Pro Met–callatostatin, two further post–translational modifications of the blowfly neuropeptide Met–callatostatin. Duve H, et al. **Regul Pept** 1995 Jun 27; 57(3):237–45

Fragmentation of therapeutic human immunoglobulin preparations. Page M, et al. **Vox Sang** 1995;69(3):183–94

Characterization of trypsin immobilized on oxirane–acrylic beads for obtaining phosphopeptides from casein. Lorenzen PC, et al. **Z Ernahrungswiss** 1995 Jun;34(2):118–30

METABOLISM

Vasostatins, N–terminal products of chromogranin A, are released from the stimulated calf spleen in vitro. Liang F, et al. **Acta Physiol Scand** 1995 Sep;155(1):23–30

Band 3 and its peptides during aging, radiation exposure, and Alzheimer's disease: alterations and self–recognition. Kay MM, et al. **Adv Exp Med Biol** 1995;383:167–93

Characterization of V3 loop–binding protein(s) of Molt–4 and U937 cells. Xu Y, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):563–70

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

Selective binding of soluble Abeta1–40 and Abeta1–42 to a subset of senile plaques. Prior R, et al. **Am J Pathol** 1996 Jun;148(6):1749–56

C–terminal ladder sequencing via matrix–assisted laser desorption mass spectrometry coupled with carboxypeptidase Y time–dependent and concentration–dependent digestions. Patterson DH, et al. **Anal Chem** 1995 Nov 1;67(21):3971–8

Retinoic acid and interleukin–1 together promote the release of collagen fragments from bovine nasal cartilage in culture. Cawston TE, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:219–23

Expression of Na(+)–Ca2+ exchanger with modified C–terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110–4 (9 ref.)

Fluorescence of a tryptophan bearing peptide from smooth muscle myosin light chain kinase upon binding to two closely related calmodulins. Chabbert M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):429–36

Human serum immunoglobulins binding to synthetic fragments of human chorionic gonadotropin. Kochanowska IE, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(3–4):173–9

Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Smith GN Jr, et al. **Arthritis Rheum** 1996 Feb;39(2):235–44

Remnant particles and their metabolism. Eisenberg S, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):739–53 (40 ref.)

C–terminal fragments of alpha– and beta–tubulin form amyloid fibrils in vitro and associate with amyloid deposits of familial cerebral amyloid angiopathy, British type. Baumann MH, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):238–42

Neokyotorphin and neokyotorphin (1–4): cytolytic activity and comparative levels in rat tissues. Blischenko EYu, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):721–7

Human growth hormone deletion mutant (hGH44–191) binds with high affinity to lactogenic receptors but not to somatogenic receptors. Haro LS, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):421–6

Intracellular stability of alpha fragments of beta–galactosidase: effects of amino–terminally fused polypeptides. Homma T, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):452–8

Proadrenomedullin N–terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Nagatomo Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):539–43

Synergistic induction of nitric oxide by beta–amyloid and cytokines in astrocytes. Rossi F, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):474–8

Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments. Del Nery E, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):233–8

Location of smooth–muscle myosin and tropomyosin binding sites in the C–terminal 288 residues of human caldesmon. Huber PA, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):617–25

Involvement of the N–terminal part of cyclophilin B in the interaction with specific Jurkat T–cell binding sites.

Mariller C, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):571–6

Interaction of proteolytic fragments of calmodulin with caldesmon and calponin. Medvedeva MV, et al. **Biochem J** 1996 May 1;315 (Pt 3):1021–6

Acidic phospholipids inhibit the intramolecular association between the N– and C–terminal regions of vinculin, exposing actin–binding and protein kinase C phosphorylation sites. Weekes J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):827–32

Amyloid beta 1–42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Wisniewski T, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):575–80

Interactions of integrin GPIIb/IIIa–derived peptides with fibrinogen investigated by NMR spectroscopy. Yao LJ, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):161–70

Viral RNA binding properties of human immunodeficiency virus type–2 (HIV–2) nucleocapsid protein–derived synthetic peptides. Komatsu H, et al. **Biochem Mol Biol Int** 1996 May;38(6):1143–54

Modulation of glyceraldehyde 3–phosphate dehydrogenase activity in isolated pancreatic islets. Laychock SG. **Biochem Pharmacol** 1996 Sep 13;52(5):793–9

Molecular recognition by calmodulin: pressure–induced reorganization of a novel calmodulin–peptide complex. Ehrhardt MR, et al. **Biochemistry** 1996 Feb 6; 35(5):1599–605

Rapid plasmenylethanolamine–selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde–3–phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. Glaser PE, et al. **Biochemistry** 1995 Sep 26;34(38):12193–203

Characterization of mammalian C–CDC25Mm exchange factor and kinetic properties of the exchange reaction intermediate p21.C–CDC25Mm. Jacquet E, et al. **Biochemistry** 1995 Sep 26;34(38):12347–54

Interactions between dystrophin glycoprotein complex proteins. Madhavan R, et al. **Biochemistry** 1995 Sep 26; 34(38):12204–9

Kinetics of the reaction of a myelin basic protein peptide with soluble IAu. Mason K, et al. **Biochemistry** 1995 Nov 14;34(45):14874–8

Factor XIIIa–catalyzed cross–linking of recombinant alpha C fragments of human fibrinogen. Matsuka YV, et al. **Biochemistry** 1996 May 7;35(18):5810–6

Coassembly of synthetic segments of shaker K+ channel within phospholipid membranes. Peled–Zehavi H, et al. **Biochemistry** 1996 May 28;35(21):6828–38

Insertion and orientation of a synthetic peptide representing the C–terminus of the A1 domain of Shiga toxin into phospholipid membranes. Saleh MT, et al. **Biochemistry** 1996 Jul 23;35(29):9325–34

Proteolysis regulates exposure of the IIICS–1 adhesive sequence in plasma fibronectin. Ugarova TP, et al. **Biochemistry** 1996 Aug 20;35(33):10913–21

Rate–determining steps for tyrosine phosphorylation by the kinase domain of v–fps. Wang C, et al. **Biochemistry** 1996 Feb 6;35(5):1533–9

Purification and functional characterization of the C–terminal half of the lactose permease of Escherichia coli. Wu J, et al. **Biochemistry** 1996 Apr 23;35(16):5213–9

Interaction of the fluorescent probe RH421 with ribulose–1,5–bisphosphate carboxylase/oxygenase and with Na+,K(+)–ATPase membrane fragments. Frank J, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):51–64

Preparation and characterization of a C–terminal fragment of pregnancy zone protein corresponding to the receptor–binding peptide from human alpha 2–macroglobulin. Jensen PE, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):254–8

C–terminal truncation of spinach chloroplast NAD(P)–dependent glyceraldehyde–3–phosphate dehydrogenase prevents inactivation and reaggregation. Scheibe R, et al. **Biochim Biophys Acta** 1996 Sep 5; 1296(2):228–34

Receptor affinity of neurotensin message segment immobilized on liposome. Zhao J, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):249–56

Kinetics of appearance of four hemorphins from bovine hemoglobin peptic hydrolysates by HPLC coupled with photodiode array detection. Zhao Q, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):73–80

Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy–terminal fragments. Moritz T, et al. **Blood** 1996 Aug 1;88(3):855–62

Is Ca(II) ion binding to prothrombin fragment 1 intrinsically cooperative, or is the cooperative binding accounted for by self–association? Cabanias S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):464–73

Suppression of F1+2 (thrombin) generation in patients with DVT requires increased doses of heparin [letter] Korte W, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):684–6

Effects of streptozotocin–induced diabetes on prodynorphin–derived peptides in rat brain regions. Berman Y, et al. **Brain Res** 1995 Jul 10;685(1–2):129–34

Neurotensin and neuromedin N brain levels after fornix transection: evidence for an efficient neurotensin precursor processing in subicular neurons. Nicot A, et al. **Brain Res** 1995 Dec 8;702(1–2):279–83

Effect of glycosylation of a synthetic MUC1 mucin–core–related peptide on recognition by anti–mucin antibodies. Spencer DI, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):11–5

Is the glycogen synthase analogue C1–peptide a suitable fluorescent substrate for routine measurements of protein kinase C? Erdbrügger W, et al. **Cell Signal** 1995 Aug; 7(6):635–42

Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Ueki T, et al. **Clin Exp Immunol** 1996 May; 104(2):286–92

Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)

Expression and functional activity of glucagon, glucagon–like peptide I, and glucose–dependent insulinotropic peptide receptors in rat pancreatic islet cells. Moens K, et al. **Diabetes** 1996 Feb;45(2):257–61

Repression of cap–dependent translation by 4E–binding protein 1: competition with p220 for binding to eukaryotic initiation factor–4E. Haghighat A, et al. **EMBO J** 1995 Nov 15;14(22):5701–9

Elimination of the carboxy–terminal sequences of parathyroid hormone–related protein 1–173 increases production and secretion of the truncated forms. Ditmer LS, et al. **Endocrinology** 1996 May;137(5):1608–17

Targeted expression of des(1–3) human insulin–like growth factor I in transgenic mice influences mammary gland development and IGF–binding protein expression [see comments] Hadsell DL, et al. **Endocrinology** 1996 Jan; 137(1):321–30. Comment in: Endocrinology 1996 Jan;137(1):1–2.

Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl–terminal region of PTH–(1–84) [see comments] Inomata N, et al. **Endocrinology** 1995 Nov;136(11):4732–40. Comment in: Endocrinology 1995 Nov;136(11):4729–31.

Specific binding sites for proadrenomedullin N–terminal 20 peptide (PAMP) in the rat. Iwasaki H, et al. **Endocrinology** 1996 Jul;137(7):3045–50

Identification and cellular localization of thyrotropin–releasing hormone–related peptides in rat testis. Montagne JJ, et al. **Endocrinology** 1996 Jan; 137(1):185–91

The carboxy–terminus of parathyroid hormone––inert or invaluable? [editorial; comment] Orloff JJ, et al. **Endocrinology** 1995 Nov;136(11):4729–31 (20 ref.). Comment on: Endocrinology 1995 Nov;136(11):4732–40.

The third cytoplasmic domain of the GLP–1[7–36 amide] receptor is required for coupling to the adenylyl cyclase system. Takhar S, et al. **Endocrinology** 1996 May; 137(5):2175–8

Differential expression of the full–length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst. Tong BJ, et al. **Endocrinology** 1996 Apr;137(4):1492–6

Age related changes in biochemical markers of bone metabolism in horses. Price JS, et al. **Equine Vet J** 1995 May;27(3):201–7

Effects of poliovirus 2A(pro) on vaccinia virus gene expression. Feduchi E, et al. **Eur J Biochem** 1995 Dec 15; 234(3):849–54

The C–terminal bisphosphorylated proenkephalin–A–(209–237)–peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Goumon Y, et al. **Eur J Biochem** 1996 Feb 1; 235(3):516–25

Interaction of amino acid residues at positions 8–15 of secretin with the N–terminal domain of the secretin receptor. Gourlet P, et al. **Eur J Biochem** 1996 Jul 15;239(2):349–55

Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho–regulatory and angiostatin–binding factor. Kost C, et al. **Eur J Biochem** 1996 Mar 1;236(2):682–8

Lipid interaction of the 37–kDa and 58–kDa fragments of the Helicobacter pylori cytotoxin. Moll G, et al. **Eur J Biochem** 1995 Dec 15;234(3):947–52

Subcellular localization of the GABAA receptor gamma 2 subunit in the rat spinal cord. Sur C, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1323–32

Immunoreactive human chorionic gonadotropin beta core fragment in human pituitary. Hoermann R, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):324–31

NMR identification of calcineurin B residues affected by binding of a calcineurin A peptide. Anglister J, et al. **FEBS Lett** 1995 Nov 13;375(1–2):108–12

Immunopurification and characterization of a collagenase/gelatinase domain issued from basement membrane fibronectin. Boudjennah L, et al. **FEBS Lett** 1996 Aug 5;391(1–2):52–6

Generation of VV–hemorphin–7 from globin by peritoneal macrophages. Dagoussat N, et al. **FEBS Lett** 1996 Mar 11;382(1–2):37–42

Molecular cloning and functional expression of a recombinant 72.5 kDa fragment of the 110 kDa regulatory subunit of smooth muscle protein phosphatase 1M. Haystead CM, et al. **FEBS Lett** 1995 Dec 18;377(2):123–7

RGD induces conformational transition in purified platelet integrin GPIIb/IIIa–SDS system yielding multiple binding states for fibrinogen gamma–chain C–terminal peptide. Mayo KH, et al. **FEBS Lett** 1996 Jan 2;378(1):79–82

Biochemical evidence for the interaction of regulatory subunit of cAMP–dependent protein kinase with IDA (Inter–DFG–APE) region of catalytic subunit. Sahara S, et al. **FEBS Lett** 1996 Apr 15;384(2):138–42

Interaction between human amphipathic apolipoproteins and amyloid beta–peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12

Characterization of a 21 amino acid peptide sequence of the laminin G2 domain that is involved in HNK–1 carbohydrate binding and cell adhesion. Hall H, et al. **Glycobiology** 1995 Jun;5(4):435–41

Utilization of sialic acid–binding synthetic peptide sequences derived from pertussis toxin as novel anti–inflammatory agents. Heerze LD, et al. **Glycobiology** 1995 Jun; 5(4):427–33

Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease. Suou T, et al. **Hepatology** 1996 May;23(5):1154–8

Chronobiologic aspects of urinary gonadotropin peptide (UGP). Cornélissen G, et al. **In Vivo** 1995 Jul–Aug; 9(4):359–62

Kinetics of the reactions between the invariant chain (85–99) peptide and proteins of the murine class II MHC. Liang MN, et al. **Int Immunol** 1995 Sep;7(9):1397–404

Interaction of calcyclin and its cyanogen bromide fragments with annexin II and glyceraldehyde 3–phosphate dehydrogenase. Filipek A, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1123–31

Collagen metabolism in obesity: the effect of weight loss. Rasmussen MH, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):659–63

Receptor binding and biologic activity of synthetic ET–1 peptides in the retinal pericyte. McDonald DM, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1067–73

The drug–binding activity of the multidrug–responding transcriptional regulator BmrR resides in its C–terminal domain. Markham PN, et al. **J Bacteriol** 1996 Mar; 178(5):1473–5

Importance of the E–46–D–160 polypeptide segment of the non–penicillin–binding module for the folding of the low–affinity, multimodular class B penicillin–binding protein 5 of Enterococus hirae. Mollerach ME, et al. **J Bacteriol** 1996 Mar;178(6):1774–5

A 31–kDa recombinant fibronectin cell–binding domain fragment: its binding to receptor, cell adhesive activity, and fusion proteins. Hashino K, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):604–9

Messenger RNA recognition by fragments of ribosomal protein S4. Baker AM, et al. **J Biol Chem** 1995 Sep 29; 270(39):22939–45

The serpin–enzyme complex receptor recognizes soluble, nontoxic amyloid–beta peptide but not aggregated, cytotoxic amyloid–beta peptide. Boland K, et al. **J Biol Chem** 1996 Jul 26;271(30):18032–44

Recombinant N–terminal nucleotide–binding domain from mouse P–glycoprotein. Overexpression, purification, and role of cysteine 430. Dayan G, et al. **J Biol Chem** 1996 May 17;271(20):11652–8

Assembly of the human neutrophil NADPH oxidase involves binding of p67phox and flavocytochrome b to a common functional domain in p47phox. De Leo FR, et al. **J Biol Chem** 1996 Jul 19;271(29):17013–20

Isolated Sos1 PH domain exhibits germinal vesicle breakdown–inducing activity in Xenopus oocytes. de Mora JF, et al. **J Biol Chem** 1996 Jul 26;271(30):18272–6

An 11–amino acid sequence from c–met initiates epithelial chemotaxis via phosphatidylinositol 3–kinase and phospholipase C. Derman MP, et al. **J Biol Chem** 1996 Feb 23;271(8):4251–5

Cell internalization of the third helix of the Antennapedia homeodomain is receptor–independent. Derossi D, et al. **J Biol Chem** 1996 Jul 26;271(30):18188–93

The interaction between apolipoprotein E and Alzheimer's amyloid beta–peptide is dependent on beta–peptide conformation. Golabek AA, et al. **J Biol Chem** 1996 May 3;271(18):10602–6

Requirement for the immunoglobulin–like domain of granulocyte colony–stimulating factor receptor in formation of a 2:1 receptor–ligand complex. Hiraoka O, et al. **J Biol Chem** 1995 Oct 27;270(43):25928–34

Further evidence for the structure of the subtilisin propeptide and for its interactions with mature subtilisin. Hu Z, et al. **J Biol Chem** 1996 Feb 16;271(7):3375–84

A novel phosphatidylserine–binding peptide motif defined by an anti–idiotypic monoclonal antibody. Localization of phosphatidylserine–specific binding sites on protein kinase C and phosphatidylserine decarboxylase. Igarashi K, et al. **J Biol Chem** 1995 Dec 8;270(49):29075–8

Insulin resistance is mediated by a proteolytic fragment of the insulin receptor. Knutson VP, et al. **J Biol Chem** 1995 Oct 20;270(42):24972–81

Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin alpha subunit. Kundu GC, et al. **J Biol Chem** 1996 May 10;271(19):11063–6

The N terminus of antizyme promotes degradation of heterologous proteins. Li X, et al. **J Biol Chem** 1996 Feb 23;271(8):4441–6

A peptide model of basement membrane collagen alpha 1 (IV) 531–543 binds the alpha 3 beta 1 integrin. Miles AJ, et al. **J Biol Chem** 1995 Dec 8;270(49):29047–50

Cell–surface expression of an amino–terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells. Pang L, et al. **J Biol Chem** 1996 Aug 9; 271(32):19518–23

Proposed ligand binding site of the transmembrane receptor for neurotensin(8–13). Pang YP, et al. **J Biol Chem** 1996 Jun 21;271(25):15060–8

Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. Turner RS, et al. **J Biol Chem** 1996 Apr 12; 271(15):8966–70

Extracellular matrix regulates the amount of the beta-amyloid precursor protein and its amyloidogenic fragments. Bronfman FC, et al. **J Cell Physiol** 1996 Feb; 166(2):360–9

Thyroid epithelial cells produce large amounts of the Alzheimer beta-amyloid precursor protein (APP) and generate potentially amyloidogenic APP fragments. Schmitt TL, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3513–9

Restrained molecular dynamics study of the interaction between bovine kappa-casein peptide 98–111 and bovine chymosin and porcine pepsin. Plowman JE, et al. **J Dairy Res** 1995 Aug;62(3):451–67

Glucagon-like peptide-1 binding to rat hepatic membranes. Villanueva-Peñacarrillo ML, et al. **J Endocrinol** 1995 Jul; 146(1):183–9

Enzymatic conversion of IGF-I to des(1–3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action. Yamamoto H, et al. **J Endocrinol** 1995 Jul;146(1):141–8

HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. Nossner E, et al. **J Exp Med** 1996 Feb 1;183(2):339–48

The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation. Bruhn HD, et al. **J Heart Valve Dis** 1995 Mar;4(2):138–40

Ultrastructural localization of the C-propeptide released from type II procollagen in fetal bovine growth plate cartilage. Lee ER, et al. **J Histochem Cytochem** 1996 May; 44(5):433–43

The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. Carrasco-Marin E, et al. **J Immunol** 1996 Jan 15;156(2):450–8

Association of synthetic peptide fragments of human apolipoprotein A-I with phospholipids. Vanloo B, et al. **J Lipid Res** 1995 Aug;36(8):1686–96

Effects of modifications of residues in position 3 of dynorphin A(1–11)-NH2 on kappa receptor selectivity and potency. Lung FD, et al. **J Med Chem** 1996 Jun 21;39(13):2456–60

Crystal structure of three consecutive laminin-type epidermal growth factor-like (LE) modules of laminin gamma1 chain harboring the nidogen binding site. Stetefeld J, et al. **J Mol Biol** 1996 Apr 5;257(3):644–57

Self-association of beta-amyloid peptide (1–40) in solution and binding to lipid membranes. Terzi E, et al. **J Mol Biol** 1995 Oct 6;252(5):633–42

Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. Clements A, et al. **J Neurochem** 1996 Feb;66(2):740–7

Vasopressin anti-idiotypic antibody staining in the rat brain: colocalization with [35S] [pGlu4, Cyt6]AVP(4–9) binding sites. Jurzak M, et al. **J Neuroendocrinol** 1993 Oct; 5(5):523–31

Agonist and antagonist effects of dynorphin A-(1–13) in a thermal antinociception assay in rhesus monkeys. Butelman ER, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):374–80

In vitro mucosal digestion of synthetic gliadin-derived peptides in celiac disease. Cornell HJ, et al. **J Protein Chem** 1995 Jul;14(5):335–9

Interaction of synthetic Alzheimer beta-protein-derived analogs with aqueous aluminum: a low-field 27Al NMR investigation. Vyas SB, et al. **J Protein Chem** 1995 Nov; 14(8):633–44

Binding motifs predict major histocompatibility complex class II-restricted epitopes in the Sendai virus M protein. Cole GA, et al. **J Virol** 1995 Dec;69(12):8057–60

Circulating parathyroid hormone-related protein (109–141) in malignancy-associated hypercalcemia. Nagasaki K, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):6–11

Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Greco G, et al. **Leukemia** 1996 Apr; 10(4):693–9

Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Parker D, et al. **Mol Cell Biol** 1996 Feb; 16(2):694–703

Reduced affinity of iodinated forms of Tyr0 C-type natriuretic peptide for rat natriuretic peptide receptor B. Thibault G, et al. **Mol Pharmacol** 1995 Dec;48(6):1046–53

Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Lannfelt L, et al. **Nat Med** 1995 Aug;1(8):829–32

A specific structural interaction of Alzheimer's peptide A beta 1–42 with alpha 1-antichymotrypsin [letter] Janciauskiene S, et al. **Nat Struct Biol** 1996 Aug;3(8):668–71

Batten disease (ceroid-lipofuscinosis): the enigma of subunit c of mitochondrial ATP synthase accumulation. Jolly RD. **Neurochem Res** 1995 Nov;20(11):1301–4

New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Kominami E, et al. **Neurochem Res** 1995 Nov;20(11):1305–9 (26 ref.)

Binding of anti-inflammatory alpha-melanocyte-stimulating-hormone peptides and proinflammatory cytokines to receptors on melanoma cells. Lyson K, et al. **Neuroimmunomodulation** 1994 Mar–Apr; 1(2):121–6

Metabolism of galanin and galanin (1–16) in isolated cerebrospinal fluid and spinal cord membranes from rat. Bedecs K, et al. **Neuropeptides** 1995 Sep;29(3):137–43

The post-translational incorporation of arginine into a beta-amyloid peptide increases the probability of alpha-helix formation. Bongiovanni G, et al. **Neuroreport** 1995 Dec 29;7(1):326–8

Characterization of proteolytic fragments of bacteriophage T7 DNA ligase. Doherty AJ, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2281–7

Assessment of major and minor groove DNA interactions by the zinc fingers of Xenopus transcription factor IIIA. McBryant SJ, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2567–74

Neutral endopeptidase can hydrolyze beta-amyloid(1–40) but shows no effect on beta-amyloid precursor protein metabolism. Howell S, et al. **Peptides** 1995;16(4):647–52

Release of urodilatin from perfused rat kidney and from cultured neonatal rat kidney cells. Kirchhoff K, et al. **Pflugers Arch** 1995 Sep;430(5):739–44

The effect of pre-eclampsia on human placental corticotrophin-releasing hormone content and processing [published erratum appears in Placenta 1995 Sep;16(6):567] Goland RS, et al. **Placenta** 1995 Jun;16(4):375–82

Gene activation by UV light, fungal elicitor or fungal infection in Petroselinum crispum is correlated with repression of cell cycle-related genes. Logemann E, et al. **Plant J** 1995 Dec;8(6):865–76

Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Arispe N, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1710–5

Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Balagurumoorthy P, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8591–5

Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Kelly JF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6753–8

Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc2(6–20)NH2 peptide. Kong SK, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3377–82

Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Kumar V, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9510–4

The amino-terminal domain of the prokaryotic enhancer-binding protein XylR is a specific intramolecular repressor. Pérez-Martín J, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9392–6

The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Reed M, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9455–9

Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Rimm DL, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8813–7

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1–40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1–40/vector complex. Saito Y, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10227–31

A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Sellers WR, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11544–8

Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice. Tourne S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1464–9

A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. Wong WT, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9530–4

Recombinant protein sequences can trigger methylation of N-terminal amino acids in Escherichia coli. Apostol I, et al. **Protein Sci** 1995 Dec;4(12):2616–8

Identification of functionally important amino acids in the cellulose-binding domain of Trichoderma reesei cellobiohydrolase I. Linder M, et al. **Protein Sci** 1995 Jun; 4(6):1056–64

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Hupe-Sodmann K, et al. **Regul Pept** 1995 Aug 22;58(3):149–56

Binding and agonist/antagonist actions of M35, galanin(1–13)-bradykinin(2–9)amide chimeric peptide, in Rin m 5F insulinoma cells. Kask K, et al. **Regul Pept** 1995 Nov 10;59(3):341–8

Copper replacement of cadmium-binding alpha-fragment of metallothionein expressed in Escherichia coli. Kurasaki M, et al. **Res Commun Mol Pathol Pharmacol** 1996 May; 92(2):225–32

BMP-1: resurrection as procollagen C-proteinase [comment] Reddi AH. **Science** 1996 Jan 26;271(5248):463. Comment on: Science 1996 Jan 19;271(5247):360–2.

Homologous DNA pairing promoted by a 20-amino acid peptide derived from RecA [see comments] Voloshin ON, et al. **Science** 1996 May 10;272(5263):868–72. Comment in: Science 1996 May 10;272(5263):828–9.

Structural features of a polypeptide carrier promoting secretion of a beta-lactamase fusion protein in yeast. Jämsä E, et al. **Yeast** 1995 Nov;11(14):1381–91

The hsp150 delta-carrier confers secretion competence to the rat nerve growth factor receptor ectodomain in Saccharomyces cerevisiae. Simonen M, et al. **Yeast** 1996 Apr;12(5):457–66

PHARMACOKINETICS

Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin. Heinemann L, et al. **Diabete Metab** 1995 Dec;21(6):415–9

Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat. Schetz JA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1456–62

Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. Nicol P, et al. **Peptides** 1995;16(8):1343–50

PHARMACOLOGY

Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells. Fehmann HC, et al. **Acta Diabetol** 1995 Oct;32(3):176–81

Glucagon-like-peptide-1 (7–36) amide improves glucose sensitivity in beta-cells of NOD mice. Linn T, et al. **Acta Diabetol** 1996 Mar;33(1):19–24

Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression. Rand ML, et al. **Am J Hematol** 1996 Aug;52(4):288–94

Effects of urodilatin and diltiazem on renal function in ischemic acute renal failure in the rat. Schramm L, et al. **Am J Nephrol** 1995;15(5):418–26

Effect of proANF-(31—67) on sodium excretion in conscious monkeys. Benjamin BA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1351–5

Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7—36) amide. Heller RS, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G852–60

Effects on Ca(2+)-activated tension due to a synthetic NH2-terminal actin peptide in single skeletal muscle fibers. Metzger JM. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1193–9

Actions of Rab3 effector domain peptides in chief cells from guinea pig stomach. Singh G, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G400–7

An interleukin-1 receptor fragment inhibits spontaneous sleep and muramyl dipeptide-induced sleep in rabbits. Takahashi S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R101–8

Effects of glucagon-like peptide-I on glucose turnover in rats. Van Dijk G, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1015–21

The c-propeptide of type II procollagen binds to the enhancer region of the type II procollagen gene and regulates its transcription. Nakata K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:307–8

Synthesis and cytotoxic activity of peptides containing basic amino acids residues. Chillemi F, et al. **Anticancer Res** 1996 Mar-Apr;16(2):715–6

Immunosuppressive activity of C-terminal fragments of tachykinins. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):201–3

Immunosuppressive activity of analogs of tripeptide Lys-Arg-Pro with D-amino acid residues. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):205–7

Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Sixma JJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):64–71

beta-Amyloid 25–35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. Sigurdsson EM, et al. **Behav Brain Res** 1995 Dec 14; 72(1–2):141–56

Classical conditioning in the fetal rat: reinforcing properties of dynorphin A (1–13). Varlinskaya EI, et al. **Behav Neurosci** 1996 Feb;110(1):154–67

Molecular cloning and expression of receptor peptides that block human cytomegalovirus/cell fusion. Baldwin BR, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):668–73

Expression, purification and functional characterisation of a Kunitz-type module from chicken type VI collagen. Bearz A, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):1050–5

Fibronectin harbors anticell adhesive activity. Fukai F, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):394–8

Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. Heller RS, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):624–32

Active fragments and analogs of the plant growth factor,

phytosulfokine: structure-activity relationships. Matsubayashi Y, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):209–14

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):559–65

Stabilization of helix by side-chain interactions in histatin-derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):47–53

Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Satoh T, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):438–43

The hydrophilic domain of phospholamban inhibits the Ca(2+)-ATPase--the importance of the method of assay. Starling AP, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1067–70

Inhibition of basophil histamine release by a haptenic peptide mixture prepared by chymotryptic hydrolysis of wheat flour. Tanabe S, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):492–5

Intracellular control of IP3-independent Ca2+ oscillations in pancreatic acini. Tsunoda Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):265–72

Vasopressor activities of N-terminal fragments of adrenomedullin in anesthetized rat. Watanabe TX, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):59–63

Thrombin stimulates wortmannin-inhibitable phosphoinositide 3-kinase and membrane blebbing in CHRF-288 cells. Vemuri GS, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):805–10

Identification of 14-3-3 proteins in human platelets: effects of synthetic peptides on protein kinase C activation. Wheeler-Jones CP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):41–7

Effects of synthesized elastin peptides on human leukocytes. Hauck M, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):45–55

Alzheimer's peptides A beta 1-40 and A beta 1-28 inhibit the plasma cholesterol esterification rate. Koudinov AR, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):747–52

Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N-terminus. Perretti M, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1037–42

Activation of phospholipase A2 by amyloid beta-peptides in vitro. Lehtonen JY, et al. **Biochemistry** 1996 Jul 23; 35(29):9407–14

A peptide derived from a tissue factor loop region functions as a tissue factor--factor VIIa antagonist. Paborsky LR, et al. **Biochemistry** 1995 Nov 21;34(46):15328–33

Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Miki H, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):132–6

Effects of a synthetic N-terminal fragment of stanniocalcin on the metabolism of mammalian bone in vitro. Yoshiko Y, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):143–9

Hemodynamic effects of centrally administered adrenomedullin (13-52) in anesthetized rats. Wei YJ, et al. **Biol Signals** 1995 Nov-Dec;4(6):338–44

The effect of genetically expressed cardiac titin fragments on in vitro actin motility. Li Q, et al. **Biophys J** 1995 Oct; 69(4):1508–18

Recombinant scinderin, an F-actin severing protein, increases calcium-induced release of serotonin from permeabilized platelets, an effect blocked by two scinderin-derived actin-binding peptides and phosphatidylinositol 4,5-bisphosphate. Marcu MG, et al. **Blood** 1996 Jan 1; 87(1):20–4

Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Sporeno E, et al. **Blood** 1996 Jun 1;87(11):4510–9

Tomographic (pQCT) and biomechanical effects of hPTH(1-38) on chronically immobilized or overloaded rat femurs. Capozza R, et al. **Bone** 1995 Oct;17(4 Suppl):233S–239S

The (18-48)-fragment of human parathyroid hormone is a partial agonist for cAMP-dependent actions with retained mitogenic function. Duvos C, et al. **Bone** 1995 Oct; 17(4):403–6

Assessing bone quantity by pQCT. Gasser JA. **Bone** 1995 Oct;17(4 Suppl):145S–154S

In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Onyia JE, et al. **Bone** 1995 Nov;17(5):479–84

Discrepancy of response of hPTH administration and its withdrawal between trabecular and cortical bone sites in OVX rats. Yamamoto N, et al. **Bone** 1995 Oct;17(4 Suppl):279S–283S

Carboxy-terminal peptides (C1-24 and C13-24 but not C1-13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. Lebeurier I, et al. **Br J Haematol** 1996 Jan; 92(1):29–34

Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Nierodzik ML, et al. **Br J Haematol** 1996 Feb;92(2):452–7

Demonstration of a 'peptide-sensitive' inflammatory response in rat skin. Ahluwalia A, et al. **Br J Pharmacol** 1995 Oct; 116(4):2170–4

Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Gué M, et al. **Br J Pharmacol** 1996 May;118(2):237–42

Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens. Palea S, et al. **Br J Pharmacol** 1995 Nov;116(5):2401–6

Dual effects of thrombin and a 14-amino acid peptide agonist of the thrombin receptor on septal cholinergic neurons. Debeir T, et al. **Brain Res** 1996 Feb 5;708(1-2):159–66

Beta-amyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Harkany T, et al. **Brain Res** 1995 Nov 6; 698(1-2):270–4

Calcitonin gene-related peptide (CGRP) and the regulation of cerebral parenchymal vessels. Kobari M, et al. **Brain Res** 1995 Nov 6;698(1-2):95–9

Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Stoessl AJ, et al. **Brain Res** 1995 Nov 27;700(1-2):115–20

Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats. Tschöpe C, et al. **Brain Res** 1995 Aug 28;690(1):15–24

Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Woods AG, et al. **Brain Res** 1995 Oct 30;697(1-2):53–62

Opioid antagonists naloxone, beta-funaltrexamine and naltrindole, but not nor-binaltorphimine, reverse the increased hindpaw withdrawal latency in rats induced by intrathecal administration of the calcitonin gene-related peptide antagonist CGRP8-37. Yu LC, et al. **Brain Res** 1995 Nov 6;698(1-2):23–9

Kappa-opioid receptor modulation of the release of substance P in the dorsal horn. Zachariou V, et al. **Brain Res** 1996 Jan 8;706(1):80–8

Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Calvo JC, et al. **Brain Res Bull** 1995;38(5):435–9

Beta-amyloid1-40 inhibits electrically stimulated release of [3H]norepinephrine and enhances the internal calcium response to low potassium in rat cortex: prevention with a free radical scavenger. Li M, et al. **Brain Res Bull** 1996; 39(5):299–303

Reinforcing properties of the substance P C-fragment analog DiMe-C7 in Carassius auratus. Mattioli R, et al. **Braz J Med Biol Res** 1996 Apr;29(4):495–9

Vasodilator effect of human adrenomedullin(13-52) on hypertensive rats. Tian Q, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1065–9

B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. Renschler MF, et al. **Cancer Res** 1995 Dec 1;55(23):5642–7

Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. van der Pluijm G, et al. **Cancer Res** 1996 Apr 15;56(8):1948–55

Gastrulation in the sea urchin, Strongylocentrotus purpuratus, is disrupted by the small laminin peptides YIGSR and IKVAV. Hawkins RL, et al. **Cell Adhes Commun** 1995 May;3(2):163–77

Inhibition of the sarcolemmal Ca2+ pump in embryonic chick heart cells by mini-glucagon. Sauvadet A, et al. **Cell Calcium** 1995 Jul;18(1):76–85

Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells. Nag B, et al. **Cell Immunol** 1996 May 25;170(1):25–33

Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle. Sakura N, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1148–53

Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Sauvadet A, et al. **Circ Res** 1996 Jan;78(1):102–9

The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Massoud AF, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):555–62

Unique response of human arteries to endothelin B receptor agonist and antagonist. Liu JJ, et al. **Clin Sci (Colch)** 1996 Feb;90(2):91–6

The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Ryall RL, et al. **Clin Sci (Colch)** 1995 Nov;89(5):533–41

Involvement of the adenylyl cyclase signaling system in the action of insulin and mollusk insulin-like peptide. Pertseva MN, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):689–95

Partial N-terminal amino acid sequence of the anti-neoplastic urinary protein (ANUP) and the anti-tumour effect of the N-terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1–5

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Toft-Nielson M, et al. **Diabetes** 1996 May;45(5):552–6

Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Fürnsinn C, et al. **Diabetologia** 1995 Jul; 38(7):864–7

Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. Ahrén B, et al. **Endocr Res** 1995 Aug;21(3):583–94

Determination of residues in chromogranin A-(16-40) required for inhibition of parathyroid hormone secretion. Angeletti RH, et al. **Endocrinology** 1996 Jul;137(7):2918–22

The human PTH2 receptor: binding and signal transduction properties of the stably expressed recombinant receptor. Behar V, et al. **Endocrinology** 1996 Jul;137(7):2748–57

The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Guan J, et al. **Endocrinology** 1996 Mar; 137(3):893–8

Specific binding sites for proadrenomedullin N-terminal 20 peptide (PAMP) in the rat. Iwasaki H, et al. **Endocrinology** 1996 Jul;137(7):3045–50

Preprothyrotropin-releasing hormone-(178-199) does not inhibit corticotropin release. Nicholson WE, et al. **Endocrinology** 1996 May;137(5):2171–4

Human growth hormone fragments 1-43 and 44-191: in vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems. Rowlinson SW, et al. **Endocrinology** 1996 Jan;137(1):90–5

Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Wang Y, et al. **Endocrinology** 1995 Nov;136(11):4910–7

Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells. Halimi H, et al. **Eur Cytokine Netw** 1995 May-Jun;6(3):135–43

The C-terminal bisphosphorylated proenkephalin-A-(209-237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Goumon Y, et al. **Eur J Biochem** 1996 Feb 1; 235(3):516–25

A specific template-assembled peptidic agonist for the angiotensin II receptor subtype 2 (AT2) and its effect on inferior olivary neurones. Grouzmann E, et al. **Eur J Biochem** 1995 Nov 15;234(1):44–9

Peptides derived from IgE heavy chain constant region induce profound IgE isotype-specific tolerance. Wang Y, et al. **Eur J Immunol** 1996 May;26(5):1043–9

Characterisation of functional endothelin receptors in the canine isolated perfused spleen. Grassi-Kassisse DM, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):57–63

Prolyl-leucyl-glycinamide, thyrotropin-releasing hormone and beta-endorphin-(10-16), like antidepressants, antagonize melatonin-induced behavioural changes in rats. Hatta K, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):327–30

Effects of dynorphin A-(1-13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down type passive avoidance task. Hiramatsu M, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):185–91

Substance P-(1-7) and substance P-(5-11) locally modulate dopamine release in rat striatum. Khan S, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):229–33

Inhibition of catecholamine synthesis by proadrenomedullin N-terminal 20 peptide in cultured bovine adrenal medullary cells. Niina H, et al. **Eur J Pharmacol** 1995 Nov 3; 286(1):95–7

Inhibition of interleukin-1 beta-induced pyresis in the rabbit by peptide 204-212 of lipocortin 5. Palmi M, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):97–9

Cardiovascular effects of gamma-MSH/ACTH-like peptides: structure-activity relationship. Van Bergen P, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):795–803

Distinct receptors mediate gastrin-releasing peptide and neuromedin beta-induced delay of gastric of liquids in rats. Varga G, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):109–12

beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Wu J, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):R1–3

Effects of thrombin and the thrombin receptor activating peptide, SFLLRN, on redistribution of platelet alpha-granule contents are similar and independent of the extent of thromboxane formation. Suzuki H, et al. **Exp Mol Pathol** 1995 Feb;62(1):63–72

Fibronectin peptide DRVPHSRNSIT and fibronectin receptor peptide DLYYLMDL arrest gastrulation of Rana pipiens. Wang X, et al. **Experientia** 1995 Nov 15; 51(11):1097–102

Inhibition of cathepsin B by its propeptide: use of overlapping peptides to identify a critical segment. Chagas JR, et al. **FEBS Lett** 1996 Sep 2;392(3):233–6

Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. Chan WC, et al. **FEBS Lett** 1996 Jul 22;390(2):129–32

A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca(2+)-dependent exocytosis in chromaffin cells. Gutiérrez LM, et al. **FEBS Lett** 1995 Sep 18;372(1):39–43

Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. Kayser H, et al. **FEBS Lett** 1996 Mar 25;383(1-2):18–20

Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides. Lawyer C, et al. **FEBS Lett** 1996 Jul 15;390(1):95–8

Antibacterial activity of peptides homologous to a loop region in human lactoferrin. Odell EW, et al.

FEBS Lett 1996 Mar 11;382(1-2):175-8

A peptide, ALTTE, within the fimbrial subunit protein from Porphyromonas gingivalis, induces production of interleukin 6, gene expression and protein phosphorylation in human peripheral blood mononuclear cells. Ogawa T, et al. **FEMS Immunol Med Microbiol** 1995 Jun; 11(3):197-205

Effects of parathyroid hormone related peptide (1-34) and 1,25-dihydroxyvitamin D on bone alkaline phosphatase activity in fetal rat calvaria cultures. Municio MJ, et al. **Horm Metab Res** 1995 Jun;27(6):296-9

Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Benter IF, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1138-44

Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Brosnihan KB, et al. **Hypertension** 1996 Mar;27(3 Pt 2):523-8

Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Freeman EJ, et al. **Hypertension** 1996 Jul; 28(1):104-8

Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Paula RD, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1154-9

Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Santos RA, et al. **Hypertension** 1996 Apr;27(4):875-84

Atrial natriuretic peptide in chronically hypertensive dogs. Seymour AA, et al. **Hypertension** 1995 Oct;26(4):634-41

Angiotensin II and angiotensin-(1-7) effects on free cytosolic sodium, intracellular pH, and the Na(+)-H+ antiporter in vascular smooth muscle. Ye M, et al. **Hypertension** 1996 Jan;27(1):72-8

Role of G-proteins in peptidergic activation of both human and rat cutaneous mast cells. Emadi-Khiav B, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S26-7

Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line. Chu NR, et al. **Int Immunol** 1995 Jul;7(7):1057-63

Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Kobayashi H, et al. **Int J Cancer** 1995 Nov 3; 63(3):455-62

Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, et al. **Int J Cancer** 1995 Oct 9;63(2):257-62

Chemical synthesis and biological activities of the EGF-like domain of mouse schwannoma-derived growth factor (SDGF). Takenouchi T, et al. **Int J Pept Protein Res** 1995 Nov;46(5):391-6

T-cell receptor peptides that inhibit the T-cell response to allergen induce transforming growth factor-beta 1 production. Hawrylowicz CM, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):707-9

Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. Zietse R, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2057-66

Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. Azarani A, et al. **J Biol Chem** 1996 Jun 21;271(25):14931-6

A binding site for thrombin in the apple 1 domain of factor XI. Baglia FA, et al. **J Biol Chem** 1996 Feb 16; 271(7):3652-8

Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. Bitting L, et al. **J Biol Chem** 1996 Jul 5;271(27):16084-9

Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors. Divita G, et al. **J Biol Chem** 1995 Dec 1;270(48):28642-6

A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. Hebert TE, et al. **J Biol Chem** 1996 Jul 5;271(27):16384-92

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. Keyt BA, et al. **J Biol Chem** 1996 Mar 29; 271(13):7788-95

Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen. Kunapuli SP, et al. **J Biol Chem** 1996 May 10;271(19):11228-35

Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. Lerner DJ, et al. **J Biol Chem** 1996 Jun 14;271(24):13943-7

C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. Ron D, et al. **J Biol Chem** 1995 Oct 13;270(41):24180-7

A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain inhibits insulin action on glucose transport in rat adipocytes. Shibata H, et al. **J Biol Chem** 1996 Apr 19;271(16):9704-9

Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function. Donahue HJ, et al. **J Bone Miner Res** 1995 Jun; 10(6):881-9

A comparison of the effects of parathyroid hormone and parathyroid hormone-related protein on osteocalcin in the rat. Gundberg CM, et al. **J Bone Miner Res** 1995 Jun; 10(6):903-9

Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. Ma Y, et al. **J Bone Miner Res** 1995 Nov; 10(11):1726-34

In vivo hemodynamic and inotropic effects of the endothelinB agonist IRL 1620. Beyer ME, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S190-2

Effects of endothelin-1 and IRL 1620 on myocardial contractility and myocardial energy metabolism. Beyer ME, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S150-2

[Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme. Claing A, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S72-4

The function of intermediate filaments in cell shape and cytoskeletal integrity. Goldman RD, et al. **J Cell Biol** 1996 Aug;134(4):971-83

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. Everhart-Caye M, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):199-208

The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects. Hanew K, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1952-5

Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. Otonkoski T, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3779-83

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Willms B, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):327-32

Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals. Nehete PN, et al. **J Clin Immunol** 1996 Mar;16(2):115-24

Proadrenomedullin NH2-terminal 20 peptide inhibits the voltage-gated Ca2+ channel current through a pertussis toxin-sensitive G protein in rat pheochromocytoma-derived PC 12 cells. Takano K, et al. **J Clin Invest** 1996 Jul 1;98(1):14-7

Long-term somatotropic and galactopoietic effects of a (1-30) ethyl amide analog of growth hormone-releasing factor. Tucker HA, et al. **J Dairy Sci** 1995 Jul;78(7):1489-97

Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver. Trapote MA, et al. **J Endocrinol Invest** 1996 Feb; 19(2):114-8

Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. Bevec T, et al. **J Exp Med** 1996 Apr 1; 183(4):1331-8

Thrombin functions as an inflammatory mediator through activation of its receptor. Cirino G, et al. **J Exp Med** 1996 Mar 1;183(3):821-7

The cytoplasmic domains of immunoglobulin (Ig) alpha and Ig beta can independently induce the precursor B cell transition and allelic exclusion. Papavasiliou F, et al. **J Exp Med** 1995 Nov 1;182(5):1389-94

Peptides derived from C-reactive protein inhibit neutrophil alveolitis. Heuertz RM, et al. **J Immunol** 1996 May 1; 156(9):3412-7

Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. Meda L, et al. **J Immunol** 1996 Aug 1;157(3):1213-8

Carboxyterminal peptides with the dimeric form of PF4 retain the inhibitory effect on the growth of human megakaryoblastic cell lines [see comments] Lebeurier I, et al. **J Lab Clin Med** 1996 Feb;127(2):179-85. Comment in: J Lab Clin Med 1996 Feb;127(2):148-50.

A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. Labadia ME, et al. **J Leukoc Biol** 1996 Jan; 59(1):116-24

Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. Byk G, et al. **J Med Chem** 1996 Aug 2; 39(16):3174-8

Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure--activity studies. Kazmierski WM, et al. **J Med Chem** 1996 Jul 5; 39(14):2681-9

Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2. Lung FD, et al. **J Med Chem** 1996 Mar 1;39(5):1136-41

Effects of ACTH and ACTH 4-10 on aversive memory retrieval in rats. Kumar KB, et al. **J Neural Transm Gen Sect** 1995;101(1-3):223-9

The neurotrophic effects of ebiratide, an analog of ACTH4-9, on cultured septal cells and aged rats. Matsumoto T, et al. **J Neural Transm Gen Sect** 1995; 100(1):1-15

Enhancement of beta-amyloid peptide A beta(1-40)-mediated neurotoxicity by glutamine synthetase. Aksenov MYu, et al. **J Neurochem** 1995 Oct; 65(4):1899-902

Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. Harris ME, et al. **J Neurochem** 1996 Jul;67(1):277-86

beta-Amyloid1-40 increases expression of beta-amyloid precursor protein in neuronal hybrid cells. Le W, et al. **J Neurochem** 1995 Nov;65(5):2373-6

Corticotropin-releasing hormone is involved in conditioned stimulus-induced reduction of natural killer cell activity but not in conditioned alterations in cytokine production or proliferation responses. Perez L, et al. **J Neuroimmunol** 1995 Dec;63(1):1-8

Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. Kar S, et al. **J Neurosci** 1996 Feb 1;16(3):1034-40

Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse. Théodore L, et al. **J Neurosci** 1995 Nov;15(11):7158-67

Pharmacological role and degradation processes of neuromedin N in the gastrointestinal tract: an in vitro and in vivo study. Barelli H, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1300-7

Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Rodriguez de Fonseca F, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):56-64

A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion. Dahlberg PS, et al. **J Surg Res** 1996 Jun;63(1):44-8

Antithrombotic effects of hirulog in a rat carotid endarterectomy model. Jackson MR, et al. **J Surg Res** 1996 Jan;60(1):15-22

Change in membrane permeability induced by amyloid beta-protein fragment 25-35 in brain neurons dissociated from rats. Oyama Y, et al. **Jpn J Pharmacol** 1995 May; 68(1):77-83

Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Greco G, et al. **Leukemia** 1996 Apr; 10(4):693-9

Hirulog effect in rat endotoxin shock. Cicala C, et al. **Life Sci** 1995;57(20):PL307-13

Potentiation of glucagon-like peptide 1 insulinotropic action by succinic acid dimethyl ester. Leclercq-Meyer V, et al. **Life Sci** 1996;58(14):1195-9

Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. Zawalich WS, et al. **Metabolism** 1996 Feb; 45(2):273-8

Gelatin fragments block adherence of Candida albicans to extracellular matrix proteins. Klotz SA, et al. **Microbiology** 1995 Oct;141 (Pt 10):2681-4

Effects of C-terminal parathyroid hormone-related peptide on osteoblasts. Seitz PK, et al. **Miner Electrolyte Metab** 1995;21(1-3):180-3

Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Yoshida O, et al. **Miner Electrolyte Metab** 1995;21(1-3):201-4

Pharmacology of endothelins: vascular preparations for studying ETA and ETB receptors. Caló G, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):31-7

The lutropin beta-subunit N-terminus facilitates subunit combination by offsetting the inhibitory effects of residues needed for LH activity. Slaughter S, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):21-5

Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Hollenberg MD, et al. **Mol Pharmacol** 1996 Feb; 49(2):229-33

Effect of beta-endorphin on the contractile responses in mouse skeletal muscle. Khan S, et al. **Muscle Nerve** 1995 Nov;18(11):1250-6

In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Kingston IB, et al. **Nat Med** 1995 Feb;1(2):138-42

Angiostatin induces and sustains dormancy of human primary tumors in mice. O'Reilly MS, et al. **Nat Med** 1996 Jun; 2(6):689-92

Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud I, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1292-8

A visuospatial dysfunction following posterior cortex injury is attenuated by postinjury administration of the ACTH4-9 analog ORG 2766. Wells DL, et al. **Neurobiol Learn Mem** 1995 Jul;64(1):97-102

Effects of acidic fibroblast growth factor on neuronal activity of the parvocellular part in rat paraventricular nucleus. Sasaki K, et al. **Neurobiology (Bp)** 1995;3(3-4):329-38

Evidence that endogenous substance-P (SP) is involved in the maintenance of the growth and steroidogenic capacity of rat adrenal zona glomerulosa. Mazzocchi G, et al. **Neuropeptides** 1995 Jul;29(1):53-8

Inhibition of Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. McDonald RL, et al. **Neuropharmacology** 1995 Nov;34(11):1507-14

Truncated form of pro-acetylcholine receptor-inducing activity (ARIA) induces AChR alpha-subunit but not AChE transcripts in cultured chick myotubes. Pun S, et al. **Neurosci Lett** 1995 Sep 29;198(2):107-10

Reinnervation after destruction of the dopaminergic system in the rat nucleus accumbens: a quantitative

immunohistochemical analysis. Vos PE, et al. **Neurosci Lett** 1996 Mar 22;207(1):21–4

Actions of acidic fibroblast growth factor fragments on food intake in rats. Sasaki K, et al. **Obes Res** 1995 Dec;3 Suppl 5:697S–706S

Glucagon–like peptide–1(7–36)amide increases cyclic AMP accumulation in normal islets [letter] Ahren B. **Pancreas** 1996 Mar;12(2):211–3

The effects of glucagon–like peptide–I (GLP–I) on hormone secretion from isolated human pancreatic islets. Fehmann HC, et al. **Pancreas** 1995 Aug;11(2):196–200

Parallel bioassay of PG–SPI, an amphibian acidic SP–like peptide, mammalian basic substance P, and neurokinins A and B on in vitro and in vivo test systems. Broccardo M, et al. **Peptides** 1995;16(4):609–14

Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription. Fehmann HC, et al. **Peptides** 1995;16(6):1149–52

Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Fujita H, et al. **Peptides** 1995;16(5):785–90

Effect of BCH 325 (Pro–D–Phe–Pro–Gly) on central dopaminergic functions. Rauca C, et al. **Peptides** 1995; 16(4):635–40

Hypotensive effects of [D–Tyr27,36, D–Thr32]Neuropeptide Y (27–36). Roscoe AK, et al. **Peptides** 1995;16(8):1411–5

Involvement of septide–sensitive tachykinin receptors in inositol phospholipid hydrolysis in the rat urinary bladder. Torrens Y, et al. **Peptides** 1995;16(4):587–94

A single receptor transduces both inhibitory and stimulatory signals of FMRFamide–related peptides. Wang Z, et al. **Peptides** 1995;16(7):1181–6

Enhancement of NGF gene expression in rat brain by the memory–enhancing peptide AVP(4–8). Zhou AW, et al. **Peptides** 1995;16(4):581–6

ACTH(4–9) analog ORG2766 treatment 7 months delayed still improves morris maze performance of fimbria–lesioned rats. Van Rijzingen IM, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):163–9

Neuropeptide gamma: a mammalian tachykinin endowed with potent antidipsogenic action in rats. Polidori C, et al. **Physiol Behav** 1995 Sep;58(3):595–602

Peptides containing a consensus Ras binding sequence from Raf–1 and theGTPase activating protein NF1 inhibit Ras function. Clark GJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1577–81

Signaling by N– and C–terminal sequences of parathyroid hormone–related protein in hippocampal neurons. Fukayama S, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10182–6

Amyloid beta peptide potentiates cytokine secretion by interleukin–1 beta–activated human astrocytoma cells. Gitter BD, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10738–41

Bombesin antagonist prevents CO2 laser–induced promotion of oral cancer. Kozacko MF, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2953–7

A nerve growth factor peptide retards seizure development and inhibits neuronal sprouting in a rat model of epilepsy. Rashid K, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9495–9

Generation of analogs having potent antimicrobial and hemolytic activities with minimal changes from an inactive 16–residue peptide corresponding to the helical region of Staphylococcus aureus delta–toxin. Dhople VM, et al. **Protein Eng** 1995 Mar;8(3):315–8

Effects of endothelin receptor selective antagonists, BQ–123 and BQ–788, on IRL 1620 and endothelin–1 responses of airway and vascular preparations from rats. O'Donnell SR, et al. **Pulm Pharmacol** 1995 Feb;8(1):11–9

Synthetic peptides derived from the steroid binding domain block modulator and molybdate action toward the rat glucocorticoid receptor. Bodine PV, et al. **Receptor** 1995 Summer;5(2):117–22

Effects of cholecystokinin and glucagon–like peptide 1 on the secretion of pancreatic polypeptide in mice. Ahrén B, et al. **Regul Pept** 1995 Nov 10;59(3):297–302

Stimulation of natural killer (NK) and antibody–dependent cellular cytotoxicity (ADCC) activities in murine leukocytes by bombesin–related peptides requires the presence of adherent cells. Del Rio M, et al. **Regul Pept** 1995 Dec 14;60(2–3):159–66

Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics. Flüge T, et al. **Regul Pept** 1995 Nov 10;59(3):357–70

Inhibition of substance P–induced vascular leakage in rat by N–acetyl–neurotensin–(8–13). Gao GC, et al. **Regul Pept** 1995 Aug 22;58(3):117–21

Synthetic peptides corresponding to residues 551 to 555 and 650 to 653 of the rat testicular follicle–stimulating hormone (FSH) receptor are sufficient for post–receptor modulation of Sertoli cell responsiveness to FSH stimulation. Grasso P, et al. **Regul Pept** 1995 Dec 14;60(2–3):177–83

Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108–15 hybrid cells. Roerig SC, et al. **Regul Pept** 1996 Jan 16; 61(1):51–6

Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon–like peptide–1 during perifusion of short–term cultured canine isolated islets. van der Burg MP, et al. **Regul Pept** 1995 Dec 7;60(1):61–7

The effects of intrathecal galanin message–associated peptide (GMAP) on the flexor reflex in rats. Xu XJ, et al. **Regul Pept** 1995 Jul 21;58(1–2):19–24

The recombinant 23–kDa N–terminal fragment of bactericidal/permeability–increasing protein (rBPI23) decreases Escherichia coli–induced mortality and organ injury during immunosuppression–related neutropenia. Lechner AJ, et al. **Shock** 1995 Oct;4(4):298–306

Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. Ferraro L, et al. **Synapse** 1995 Aug;20(4):362–4

Characterization of endothelial cell differential attachment to fibrin and fibrinogen and its inhibition by Arg–Gly–Asp–containing peptides. Chang MC, et al. **Thromb Haemost** 1995 Aug;74(2):764–9

Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb–IIIa. Holme PA, et al. **Thromb Haemost** 1995 Dec; 74(6):1533–40

Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c–fos and PDGF–A gene expression in human vascular smooth muscle cells. Kanthou C, et al. **Thromb Haemost** 1995 Nov;74(5):1340–7

KRDS, a peptide derived from human lactotransferrin, inhibits thrombin–induced thromboxane synthesis by a cyclooxygenase–independent mechanism. Lévy–Toledano S, et al. **Thromb Haemost** 1995 May;73(5):857–61

Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1. Gralnick HR, et al. **Thromb Res** 1996 Jan 1; 81(1):113–9

Regulation of the thrombin receptor response in human endothelial cells. Storck J, et al. **Thromb Res** 1996 Jan 1; 81(1):121–31

Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom. Ferreira LA, et al. **Toxicon** 1995 Oct;33(10):1313–9

A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Woo J, et al. **Transplantation** 1995 Nov 27;60(10):1156–63

The 'septide–sensitive' tachykinin receptor: still an enigma. Glowinski J. **Trends Pharmacol Sci** 1995 Nov;16(11):365–7 (34 ref.)

[Inhibitory effect of interleukin–1 beta on insulin release from isolated rat pancreatic islets and the reversal action of testosterone] Fang HL, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):264–8 (Eng. Abstr.) **(Chi)**

[The protective effect of IL–1 beta on stress–induced gastric mucosal damage in rat] Huang Z, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):313–9 (Eng. Abstr.) **(Chi)**

[Effect of neuromedin C on gastrin secretion from isolated and perfused rat stomach] Li YY. **Sheng Li Hsueh Pao** 1996 Feb;48(1):77–82 (Eng. Abstr.) **(Chi)**

[Effects of dynorphin A (1–8) on cell cycle and total cellular protein during neuronal aging in vitro] Sun XJ, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):646–50 (Eng. Abstr.) **(Chi)**

[Immunomodulating properties of synthetic fragments of human interleukin–2] Onoprienko LV, et al. **Bioorg Khim** 1996 Mar;22(3):180–90 (Eng. Abstr.) **(Rus)**

[Vestibular–protective and anti–amnesia properties of adrenocorticotropic hormone fragments and their analogs] Iasnetsov VV, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):634–6 **(Rus)**

[Comparative study of the effect of recombinant tumor necrosis factor and synthetic peptides, corresponding to its fragments, on phagocytosis,mediated by Fc– and MF–receptors] Koniaev IG, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):304–8 **(Rus)**

[Effect of the heptapeptide Semax on the human electroencephalogram] Koroleva MV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):116–7 **(Rus)**

[Changes in the coagulating and aggregating activity of alpha–thrombin by a synthetic analog of the thymosin fragment alpha 1(24–28)] Strukova SM, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):26–9 **(Rus)**

[The effect of a caldesmon fragment with a mol. weight of 38 kDa and calponin on the capacity of actin to form a "strong" form of binding with myosin heads] Khoroshev MI, et al. **Tsitologiia** 1996;38(3):346–50 (Eng. Abstr.) **(Rus)**

[Fibrin fragment beta 15–118. Inhibitory and complex–forming properties] Lugovskoĭ EV, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):57–64 (Eng. Abstr.) **(Rus)**

[The effect of beta–casomorphin–7 on the level of food and defense motivations in different types of learning] Maklakova AS, et al. **Zh Vysh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1143–50 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

PYY and GLP–1 contribute to feedback inhibition from the canine ileum and colon. Wen J, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G945–52

An amino–terminal fragment peptide of acidic fibroblast growth factor modulates synaptic transmission in rat hippocampal slices. Sasaki K, et al. **Brain Res Bull** 1995; 38(2):185–91

Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. O'Reilly MS, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:471–82

Secretion of the amino–terminal fragment of the hedgehog protein is necessary and sufficient for hedgehog signalling in Drosophila. Fietz MJ, et al. **Curr Biol** 1995 Jun 1; 5(6):643–50

Activation of Xenopus eggs by RGD–containing peptides accompanied by intracellular Ca2+ release. Iwao Y, et al. **Dev Biol** 1996 Aug 1;177(2):558–67

Glucagon–like peptide–1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311–8 (83 ref.)

Enteral enhancement of glucose disposition by both insulin–dependent and insulin–independent processes. A physiological role of glucagon–like peptide I. D'Alessio DA, et al. **Diabetes** 1995 Dec;44(12):1433–7

The modulation of the rate of inactivation of the mKv1.1 K+ channel by the beta subunit, Kv beta 1 and lack of effect of a Kv beta 1 N–terminal peptide. Stephens GJ, et al. **FEBS Lett** 1996 Jan 15;378(3):250–2

Inhibition of Serratia marcescens nuclease secretion by a truncated nuclease peptide. Chen YC, et al. **Gene** 1996 Jun 12;172(1):9–16

Evidence for a physiological role of angiotensin–(1–7) in the control of hydroelectrolyte balance. Santos RA, et al. **Hypertension** 1996 Apr;27(4):875–84

Comparative structural and functional features of the human fibrinogen alpha C domain and the isolated alpha C fragment. Characterization using monoclonal antibodies to defined COOH–terminal A alpha chain regions. Rudchenko S, et al. **J Biol Chem** 1996 Feb 2;271(5):2523–30

C–terminal fragment of parathyroid hormone–related protein, PTHrP–(107–111), stimulates membrane–associated protein kinase C activity and modulates the proliferation of human and murine skin keratinocytes. Whitfield JF, et al. **J Cell Physiol** 1996 Jan; 166(1):1–11

Elimination of the action of glucagon–like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. D'Alessio DA, et al. **J Clin Invest** 1996 Jan 1;97(1):133–8

Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. Brnett LA, et al. **J Neuroimmunol** 1996 Feb;64(2):163–73

Human immunodeficiency virus type 1 tropism for T–lymphoid cell lines: role of the V3 loop and C4 envelope determinants. Carrillo A, et al. **J Virol** 1996 Feb; 70(2):1301–9

Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. Carrillo A, et al. **J Virol** 1996 Feb; 70(2):1310–6

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.). Comment on: Nat Med 1996 Aug;2(8):864–70.

A role for glucagon–like peptide–1 in the central regulation of feeding. Turton MD, et al. **Nature** 1996 Jan 4; 379(6560):69–72

The transactivation potential of a c–Myc N–terminal region (residues 92–143) is regulated by growth factor/Ras signaling. Colman MS, et al. **Nucleic Acids Res** 1996 May 15;24(10):1971–8

Binding affinity and physiological activity of some HVFLRFamide analogues on the oviducts of the locust, Locusta migratoria. Wang Z, et al. **Regul Pept** 1995 Jun 27;57(3):339–46

Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction. Lasne D, et al. **Thromb Haemost** 1995 Nov; 74(5):1323–8

[The role of calcitonin gene–related peptide fragments in regulating the microcirculation in rats] Akopian VA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):59–65 (Eng. Abstr.) **(Rus)**

SECRETION

GIP and GLP–1(7–36)amide secretion in response to intraduodenal infusions of nutrients in pigs. Knapper JM, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):445–50

Regulation of glucagon–like peptide–1–(7–36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Dumoulin V, et al. **Endocrinology** 1995 Nov;136(11):5182–8

Gastrin–releasing peptide is a novel mediator of proximal nutrient–induced proglucagon–derived peptide secretion from the distal gut. Roberge JN, et al. **Endocrinology** 1996 Jun;137(6):2383–8

Stereospecific effects of fatty acids on proglucagon–derived peptide secretion in fetal rat intestinal cultures. Rocca AS, et al. **Endocrinology** 1995 Dec;136(12):5593–9

Pituitary adenylate cyclase–activating polypeptide stimulates cardiodilatin/atrial natriuretic peptide (CDD/ANP–(99–126) secretion from cultured neonatal rat myocardiocytes. Bäsler I, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):335–42

Regulation of glucagon–like peptide–1 secretion from rat ileum by neurotransmitters and peptides. Herrmann–Rinke C, et al. **J Endocrinol** 1995 Oct;147(1):25–31

Role of glutamate in regulating hypothalamic proglucagon-derived peptide secretion in vitro. Stobie-Hayes KM, et al. **Life Sci** 1995 Mar 10; 56(16):1325-31

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Qualmann C, et al. **Scand J Gastroenterol** 1995 Sep;30(9):892-6

THERAPEUTIC USE

Estrogen dose required to maintain parathyroid hormone mediated bone gain in osteopenic ovariectomized rats is probably higher than in preventive treatment with estrogen. Cheng PT, et al. **Bone** 1995 Oct;17(4 Suppl):329S-334S

Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Jerome CP, et al. **Bone** 1995 Oct;17(4 Suppl):415S-420S

Effects of on/off anabolic hPTH and remodeling inhibitors on metaphyseal bone of immobilized rat femurs. Tomographical (pQCT) description and correlation with histomorphometric changes in tibial cancellous bone. Ma YF, et al. **Bone** 1995 Oct;17(4 Suppl):321S-327S

A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1-34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats. Mashiba T, et al. **Bone** 1995 Oct; 17(4 Suppl):273S-278S

Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy. Laws HJ, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):307-10

Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats. Hiramatsu M, et al. **Br J Pharmacol** 1996 May;118(2):255-60

Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Min HY, et al. **Cancer Res** 1996 May 15;56(10):2428-33

Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Beimond BJ, et al. **Circulation** 1996 Jan 1;93(1):153-60

Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Staines NA, et al. **Clin Exp Immunol** 1996 Mar;103(3):368-75

The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Elias D, et al. **Diabetes** 1996 Sep;45(9):1168-72

Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Sikirić P, et al. **Dig Dis Sci** 1996 Jul; 41(7):1518-26

Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Sikirić P, et al. **Dig Dis Sci** 1996 Aug;41(8):1604-14

Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Flüge T, et al. **Eur J Clin Invest** 1995 Oct;25(10):728-36

Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Anderson R, et al. **Infect Immun** 1996 Aug;64(8):3168-73

Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. Lane NE, et al. **J Bone Miner Res** 1995 Oct;10(10):1470-7

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments] Celluzzi CM, et al. **J Exp Med** 1996 Jan 1;183(1):283-7. Comment in: J Exp Med 1996 Jan 1;183(1):7-11.

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. Mayordomo JI, et al. **J Exp Med** 1996 Apr 1;183(4):1357-65

Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. Tian J, et al. **J Exp Med** 1996 Apr 1;183(4):1561-7

T cell receptor peptides in treatment of autoimmune disease: rationale and potential. Vandenbark AA, et al. **J Neurosci Res** 1996 Feb 15;43(4):391-402 (80 ref.)

Vitamin E deficiency and immune dysfunction in retrovirus-infected C57BL/6 mice are prevented by T-cell receptor peptide treatment. Liang B, et al. **J Nutr** 1996 May;126(5):1389-97

Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Sarembock IJ, et al. **J Vasc Res** 1996 Jul-Aug;33(4):308-14

Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Winer KK, et al. **JAMA** 1996 Aug 28;276(8):631-6

A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Sone T, et al. **Miner Electrolyte Metab** 1995; 21(1-3):232-5

Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Daniel D, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):956-60

Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Morikawa E, et al. **Stroke** 1996 May;27(5):951-5; discussion 956

Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. Hanaway MJ, et al. **Transplantation** 1996 Apr 27;61(8):1222-8

Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382-6 (47 ref.)

[Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation] Kuse ER, et al. **Anaesthesist** 1996 Apr;45(4):351-8 (Eng. Abstr.) **(Ger)**

[Analgesic efficacy of E2078 (dynorphin analog) in patients following abdominal surgery] Fujimoto K, et al. **Masui** 1995 Sep;44(9):1233-7 (Eng. Abstr.) **(Jpn)**

TOXICITY

Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Le WD, et al. **Brain Res** 1995 Jul 17;686(1):49-60

Inhibition of age-induced beta-amyloid neurotoxicity in rat hippocampal cells. Puttfarcken PS, et al. **Exp Neurol** 1996 Mar;138(1):73-81

Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25-35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1108-11

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. Roher AE, et al. **J Biol Chem** 1996 Aug 23; 271(34):20631-5

Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein. Kim SH, et al. **J Neurochem** 1996 Sep;67(3):1172-82

Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Prehn JH, et al. **Mol Pharmacol** 1996 Feb;49(2):319-28

Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Brown DR, et al. **Nature** 1996 Mar 28;380(6572):345-7

Beta amyloid is neurotoxic in hippocampal slice cultures. Harrigan MR, et al. **Neurobiol Aging** 1995 Sep-Oct; 16(5):779-89

Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35. Hope J, et al. **Neurodegeneration** 1996 Mar;5(1):1-11

Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Davis J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2996-3000

URINE

UGP in urogenital disorders: Egyptian experience. el-Ahmady O, et al. **Anticancer Res** 1996 Jul-Aug; 16(4B):2301-8

Comparative study between sonography, pathology and UGP in women with perimenopausal bleeding. el-Ahmady O, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2309-13

Urinary gonadotropin peptide in patients with cancer of digestive organs. Motoo Y, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2041-8

Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease. el-Ahmady O, et al. **Br J Cancer** 1996 Jun;73(12):1486-90

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264-70 (38 ref.)

Urinary albumin fragments as a new clinical parameter for the early detection of diabetic nephropathy. Yagame M, et al. **Intern Med** 1995 Jun;34(6):463-8

Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). Mooser V, et al. **J Clin Invest** 1996 Feb 1;97(3):858-64

Urinary gonadotropin peptide: collection of specimens and cutoff levels. Plebani M, et al. **J Clin Lab Anal** 1995; 9(4):230-3

Second-trimester levels of maternal urinary gonadotropin peptide in Down syndrome pregnancy. Canick JA, et al. **Prenat Diagn** 1995 Aug;15(8):739-44

[Involvement of urodilatin in the hydro-electrolytic modifications induced in man by a 6 degree head-down tilt] Gauquelin G, et al. **Arch Physiol Biochem** 1995 Aug; 103(4):450-5 (Eng. Abstr.) **(Fre)**

[The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21-1) in urothelial tumor] Takeuchi S, et al. **Hinyokika Kiyo** 1995 Aug; 41(8):589-92 (Eng. Abstr.) **(Jpn)**

PEPTIDE HISTIDINE-ISOLEUCINE see **PEPTIDE PHI**

PEPTIDE HORMONE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE HYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE HYDROLASES

ANALYSIS

Properties of factor IX concentrates. Berntorp E. **Acta Haematol** 1995;94 Suppl 1:8-11

Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman. Ciepluch R, et al. **Acta Haematol Pol** 1996; 27(1):21-5

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161-94 (244 ref.)

Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Scharfstein JS, et al. **Am J Cardiol** 1996 Sep 1;78(5):503-10

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293-7

Thrombin-antithrombin III and prothrombin fragment 1.2 levels in early respiratory distress syndrome [letter] Yurdakök M, et al. **Am J Hematol** 1996 Mar;51(3):247-8

Enzyme-linked immunosorbent assay for thrombin-antithrombin III complexes in horses. Topper MJ, et al. **Am J Vet Res** 1996 Apr;57(4):427-31

Use of enzyme-linked immunosorbent assay to measure thrombin-antithrombin III complexes in horses with colic. Topper MJ, et al. **Am J Vet Res** 1996 Apr;57(4):456-62

Regulatory subunit complex dissociated from 26S proteasome: isolation and characterization. Akaishi T, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):331-8

Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. Shin H, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):225-33

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107-8

Ectopic growth of endometrium depends on its structural integrity and proteolytic activity in the cynomolgus monkey (Macaca fascicularis) model of endometriosis [see comments] Sillem M, et al. **Fertil Steril** 1996 Sep; 66(3):468-73. Comment in: Fertil Steril 1996 Sep;66(3):351-3.

Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gadducci A, et al. **Gynecol Oncol** 1996 May;61(2):215-7

Characterization of the proteolytic activity of commercial proteases and strained ruminal fluid. Luchini ND, et al. **J Anim Sci** 1996 Mar;74(3):685-92

Patients undergoing reconstructive surgery versus unburned children as "controls" in studies of pediatric patients with burns. Neely AN, et al. **J Burn Care Rehabil** 1995 Jul-Aug; 16(4):418-21

Comparison of methods for obtaining serum opacity factor from group A streptococci. Rehder CD, et al. **J Clin Microbiol** 1995 Nov;33(11):2963-7

Pre-operative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Ginsberg JS, et al. **Thromb Haemost** 1995 Aug;74(2):602-5

Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Clyne N, et al. **Thromb Res** 1995 Jul 1;79(1):125-9

[Thrombin antithrombin III complex (TAT)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:48-50 (14 ref.) **(Jpn)**

[Evaluation of bradykinin levels and activation of Tame-esterase in Bronchial alveolar lavage fluid of patients with bronchial asthma] Gawlik R, et al. **Pneumonol Alergol Pol** 1995;63(5-6):268-72 (Eng. Abstr.) **(Pol)**

[The detection of proteolytic enzymes in the culture broth of Mollicutes] Skrypal' IH, et al. **Mikrobiol Z** 1996 Jan-Feb;58(1):15-22 (Eng. Abstr.) **(Ukr)**

ANTAGONISTS & INHIBITORS see PROTEASE INHIBITORS

BIOSYNTHESIS

Comparative studies on keratinase production of Trichophyton mentagrophytes strains of animal origin. Siesenop U, et al. **Mycoses** 1995 May-Jun;38(5-6):205-9

BLOOD

[Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values] Kolben M, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:126-31 (Eng. Abstr.) **(Ger)**

[Changes in the intraerythrocytic proteolysis of human hemoglobin in lymphogranulomatosis] Pivnik AV, et al. **Ter Arkh** 1995;67(7):33-4 (Eng. Abstr.) **(Rus)**

PEPTIDE HYDROLASES

CHEMISTRY

The immobilized porcine pancreatic exopeptidases and its application in casein hydrolysates debittering. Ge SJ, et al. **Appl Biochem Biotechnol** 1996 May;59(2):159–65

Proteases from Trypanosoma brucei brucei. Purification, characterisation and interactions with host regulatory molecules. Troeberg L, et al. **Eur J Biochem** 1996 Jun 15; 238(3):728–36

An IgE–binding TAME esterase in the urine of the mouse, Mus musculus domesticus. Berrens L. **Immunol Lett** 1995 Jul–Aug;47(1–2):29–32

Complete covalent structure of porcine liver acylamino acid–releasing enzyme and identification of its active site serine residue. Miyagi M, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):771–9

Subunits of the regulatory complex of the 26S protease. Dubiel W, et al. **Mol Biol Rep** 1995;21(1):27–34 (40 ref.)

Structural features of archaebacterial and eukaryotic proteasomes. Koster AJ, et al. **Mol Biol Rep** 1995; 21(1):11–20 (42 ref.)

Molecular biology of proteasomes. Tanaka K. **Mol Biol Rep** 1995;21(1):21–6 (54 ref.)

Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Rubin DM, et al. **Nature** 1996 Feb 15;379(6566):655–7

DIAGNOSTIC USE

Thrombin–antithrombin III complexes as an additional diagnostic aid in pulmonary embolism. Carmassi F, et al. **Haemostasis** 1996 Jan–Feb;26(1):16–22

DRUG EFFECTS

Increased plasma thrombin–antithrombin III complex levels in non–insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. Shimizu H, et al. **Thromb Haemost** 1995 Nov;74(5):1231–4

GENETICS

Variation of the serum opacity factor locus (sof) of Streptococcus pyogenes. Robbins JC, et al. **Dev Biol Stand** 1995;85:175–7

Genomic organization and mapping of the mouse P26s4 ATPase gene: a member of the remarkably conserved AAA gene family. Hoyle J, et al. **Genomics** 1996 Jan 1;31(1):115–8

Characterization of PepB, a group B streptococcal oligopeptidase. Lin B, et al. **Infect Immun** 1996 Aug; 64(8):3401–6

Sequence, expression in Escherichia coli, and analysis of the gene encoding a novel intracellular protease (PfpI) from the hyperthermophilic archaeon Pyrococcus furiosus. Halio SB, et al. **J Bacteriol** 1996 May;178(9):2605–12

Molecular cloning and expression of a 26 S protease subunit enriched in dileucine repeats. Deveraux Q, et al. **J Biol Chem** 1995 Oct 6;270(40):23726–9

A conditional lethal mutant in the fission yeast 26 S protease subunit mts3+ is defective in metaphase to anaphase transition. Gordon C, et al. **J Biol Chem** 1996 Mar 8; 271(10):5704–11

ISOLATION & PURIFICATION

Simple preparation of rat brain lysosomes and their proteolytic properties. Ohshita T, et al. **Anal Biochem** 1995 Sep 1;230(1):41–7

Characterization of a keratinolytic serine proteinase from Streptomyces pactum DSM 40530. Böckle B, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3705–10

Dissection of the regulator complex of the Drosophila 26S protease by limited proteolysis. Haracska L; et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):166–70

METABOLISM

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

Activation of a selective pathway of lysosomal proteolysis in rat liver by prolonged starvation. Cuervo AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1200–8

Acute effect of epinephrine on muscle proteolysis in perfused rat hindquarters. Kadowaki M, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E961–7

Tumorigenic behaviour of c–Ha–ras oncogene transfected CaCo 2 cells is associated with increased proteolytic potency. de Vries JE, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):321–6

Proteolytic activity in extracts of invasive cervical carcinoma and precursor lesions. Daneri–Navarro A, et al. **Biomed Pharmacother** 1995;49(6):304–10

Is proteolysis in the rumen of grazing animals mediated by plant enzymes? [letter] Theodorou MK, et al. **Br J Nutr** 1996 Mar;75(3):507–8

A biochemical comparison between latex from Carica candamarcensis and C. papaya. Bravo LM, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2831–42

Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Manzone H, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):521–7

Distribution of digestive enzyme activities along intestine in blue fox, mink, ferret and rat. Oleinik VM. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):55–8

Reduction of leucocyte proteolytic enzyme activity in diabetic patients with microalbuminuria and proteinuria: its possible role in diabetic nephropathy. McLennan SV, et al. **Diabet Med** 1996 Feb;13(2):145–9

Phosphorylation of proteasomes in mammalian cells. Identification of two phosphorylated subunits and the effect of phosphorylation on activity. Mason GG, et al. **Eur J Biochem** 1996 Jun 1;238(2):453–62

Molecular cloning and expression of a multiubiquitin chain binding subunit of the human 26S protease. Ferrell K, et al. **FEBS Lett** 1996 Feb 26;381(1–2):143–8

Immunological characterization and localization of a Porphyromonas gingivalis BApNA–hydrolyzing protease possessing hemagglutinating activity. Hinode D, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):211–7

High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing the Yoshida AH–130 hepatoma. Isidoro C, et al. **Invasion Metastasis** 1995;15(3–4):116–24

Sequence, expression in Escherichia coli, and analysis of the gene encoding a novel intracellular protease (PfpI) from the hyperthermophilic archaeon Pyrococcus furiosus. Halio SB, et al. **J Bacteriol** 1996 May;178(9):2605–12

Release of a soluble form of growth hormone receptors (growth hormone–binding proteins) from human IM–9 cells by proteolytic cleavage. Saito Y, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):521–5

Inhibition of ubiquitin–mediated proteolysis by the Arabidopsis 26 S protease subunit S5a. Deveraux Q, et al. **J Biol Chem** 1995 Dec 15;270(50):29660–3

Cellular internalization and degradtion of antithrombin III–thrombin, heparin cofactor II–thrombin, and alpha1–antitrypsin–trypsin complexes is mediated by the low density lipoprotein receptor–related protein. Kounnas MZ, et al. **J Biol Chem** 1996 Mar 15;271(11):6523–9

Evidence for the existence of both proteasomes and a novel high molecular weight peptidase in Entamoeba histolytica. Scholze H, et al. **J Biol Chem** 1996 Mar 15;271(11):6212–6

Peptide bond cleavage site determination of novel proteolytic enzymes found in ROS 17/2.8 cell lysates. Guidon PT Jr, et al. **J Cell Physiol** 1996 Feb;166(2):407–12

Muscle wasting in a rat model of long–lasting sepsis results from the activation of lysosomal, Ca2+ –activated, and ubiquitin–proteasome proteolytic pathways. Voisin L, et al. **J Clin Invest** 1996 Apr 1;97(7):1610–7

Clinical and biochemical studies of bone destruction in cholesteatoma. Amar MS, et al. **J Laryngol Otol** 1996 Jun; 110(6):534–9

Dopamine receptor stimulation decreases cytosolic gamma protein kinase C immunoreactivity in rat hippocampal slices: evidence for increased Ca(2+)–dependent proteolysis. Yurko–Mauro KA, et al. **J Neurochem** 1995 Oct;65(4):1622–30

Persistent activation of cAMP–dependent protein kinase by regulated proteolysis suggests a neuron–specific function of the ubiquitin system in Aplysia. Chain DG, et al. **J Neurosci** 1995 Nov;15(11):7592–603

Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase. Pepinsky RB, et al. **J Virol** 1996 May;70(5):3313–8

The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)

Degradation of c–Fos by the 26S proteasome is accelerated by c–Jun and multiple protein kinases. Tsurumi C, et al. **Mol Cell Biol** 1995 Oct;15(10):5682–7

Limited proteolytic processing of the mature form of cathepsin D in human and mouse brain: postmortem stability of enzyme structure and activity. Compaine A, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):385–96

Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. Ward PE, et al. **Peptides** 1995; 16(6):1073–8

Surface hydrophobic residues of multiubiquitin chains essential for proteolytic targeting. Beal R, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):861–6

Inactivation of neuropeptides. Csuhai E, et al. **Prog Brain Res** 1995;104:131–42 (122 ref.)

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Dahl OE, et al. **Thromb Res** 1995 Nov 15;80(4):299–306

TAT and PAP in hemodialysis patients: two cats in a bag? [letter] Haznedaroğlu IC, et al. **Thromb Res** 1995 Dec 1; 80(5):447–9

PHARMACOLOGY

Neutrophil apoptosis induced by proteolytic enzymes. Trevani AS, et al. **Lab Invest** 1996 Mar;74(3):711–21

Inhibitory effect of argatroban on thrombin–antithrombin III complex after percutaneous transluminal coronary angioplasty [letter] Sakamoto S, et al. **Thromb Haemost** 1995 Aug;74(2):801–2

PHYSIOLOGY

Regulatory features of multicatalytic and 26S proteases. Hoffman L, et al. **Curr Top Cell Regul** 1996;34:1–32 (192 ref.)

Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. O'Callaghan RJ, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):534–43

Effect of T–kinin on microvascular permeability and its modulation by peptidases in rat airways. Yamawaki I, et al. **J Appl Physiol** 1995 Oct;79(4):1129–33

Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. Rosenberg GA, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):360–6

Rate of antigen degradation by the ubiquitin–proteasome pathway influences MHC class I presentation. Grant EP, et al. **J Immunol** 1995 Oct 15;155(8):3750–8

Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W, et al. **Mol Biol Rep** 1995;21(1):3–10 (74 ref.)

URINE

An IgE–binding TAME esterase in the urine of the mouse, Mus musculus domesticus. Berrens L. **Immunol Lett** 1995 Jul–Aug;47(1–2):29–32

PEPTIDE INITIATION FACTOR EIF–2 see EIF–2

PEPTIDE INITIATION FACTORS

ANALYSIS

The subcellular distribution of eukaryotic translation initiation factor, eIF–5A, in cultured cells. Shi XP, et al. **Exp Cell Res** 1996 Jun 15;225(2):348–56

BIOSYNTHESIS

Improved recombinant tandem expression of translation initiation factor IF2 in RNASE E deficient E. coli cells. Mortensen KK, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1254–9

Upregulated expression of the genes encoding translation initiation factors eIF–4E and eIF–2alpha in transformed cells. Rosenwald IB. **Cancer Lett** 1996 Apr 19; 102(1–2):113–23

Growth factor–independent expression of the gene encoding eukaryotic translation initiation factor 4E in transformed cell lines. Rosenwald IB. **Cancer Lett** 1995 Nov 27; 98(1):77–82

Deoxyhypusine synthase gene is essential for cell viability in the yeast Saccharomyces cerevisiae. Sasaki K, et al. **FEBS Lett** 1996 Apr 15;384(2):151–4

Overexpression of the proto–oncogene/translation factor 4E in breast–carcinoma cell lines. Anthony B, et al. **Int J Cancer** 1996 Mar 15;65(6):858–63

Alternatively spliced transcripts from the Drosophila eIF4E gene produce two different Cap–binding proteins. Lavoie CA, et al. **J Biol Chem** 1996 Jul 5;271(27):16393–8

Characterization of yeast translation initiation factor 1A and cloning of its essential gene. Wei CL, et al. **J Biol Chem** 1995 Sep 29;270(39):22788–94

Sequences essential for replication of plasmid pIJ101 in Streptomyces lividans. Brasch MA, et al. **Plasmid** 1995 May;33(3):191–7

CHEMISTRY

The polypeptide chain of eukaryotic initiation factor 5A occurs in two distinct conformations in the absence of the hypusine modification. João HC, et al. **Biochemistry** 1995 Nov 14;34(45):14703–11

Isolation and structural characterization of different isoforms of the hypusine–containing protein eIF–5A from HeLa cells. Klier H, et al. **Biochemistry** 1995 Nov 14; 34(45):14693–702

A sensitive HN(CA)CO experiment for deuterated proteins. Matsuo H, et al. **J Magn Reson B** 1996 Jan;110(1):112–5

Solution structure of the ribosome–binding domain of E. coli translation initiation factor IF3. Homology with the U1A protein of the eukaryotic spliceosome. Garcia C, et al. **J Mol Biol** 1995 Nov 24;254(2):247–59

GENETICS

Upregulated expression of the genes encoding translation initiation factors eIF–4E and eIF–2alpha in transformed cells. Rosenwald IB. **Cancer Lett** 1996 Apr 19; 102(1–2):113–23

Isolation and mapping of the human EIF4A2 gene homologous to the murine protein synthesis initiation factor 4A–II gene Eif4a2. Sudo K, et al. **Cytogenet Cell Genet** 1995;71(4):385–8

Transient expression of translation initiation factor eIF–4C during the 2–cell stage of the preimplantation mouse embryo: identification by mRNA differential display and the role of DNA replication in zygotic gene activation. Davis W Jr, et al. **Dev Biol** 1996 Mar 15;174(2):190–201

Selective translation initiation by ribosome jumping in adenovirus–infected and heat–shocked cells. Yueh A, et al. **Genes Dev** 1996 Jun 15;10(12):1557–67

Host and phi X 174 mutations affecting the morphogenesis or stabilization of the 50S complex, a single–stranded DNA synthesizing intermediate. Ekechukwu MC, et al. **Genetics** 1995 Aug;140(4):1167–74

Altered (copy–up) forms of initiator protein pi suppress the point mutations inactivating the gamma origin of plasmid R6K. Urh M, et al. **J Bacteriol** 1995 Dec;177(23):6732–9

Alternatively spliced transcripts from the Drosophila eIF4E gene produce two different Cap–binding proteins. Lavoie CA, et al. **J Biol Chem** 1996 Jul 5;271(27):16393–8

Characterization of multiple mRNAs that encode mammalian translation initiation factor 5 (eIF-5). Si K, et al. **J Biol Chem** 1996 Jul 12;271(28):16934–8

Characterization of yeast translation initiation factor 1A and cloning of its essential gene. Wei CL, et al. **J Biol Chem** 1995 Sep 29;270(39):22788–94

Abundant expression of translation initiation factor EIF-4E in post-meiotic germ cells of the rat testis. Miyagi Y, et al. **Lab Invest** 1995 Dec;73(6):890–8

An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Jones RM, et al. **Mol Cell Biol** 1996 Sep;16(9):4754–64

An archaebacterial eIF-1A: new grist for the mill [letter] Keeling PJ, et al. **Mol Microbiol** 1995 Jul;17(2):399–400

Definition of constitutive gene expression in plants: the translation initiation factor 4A gene as a model. Mandel T, et al. **Plant Mol Biol** 1995 Dec;29(5):995–1004

METABOLISM

Development of an in vitro translation system from wheat germ that is dependent upon the addition of eukaryotic initiation factor 2. Benkowski LA, et al. **Anal Biochem** 1995 Nov 20;232(1):140–3

Efficient cleavage of p220 by poliovirus 2Apro expression in mammalian cells: effects on vaccinia virus. Aldabe R, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):928–36

Enhancement of helicase activity and increase of eIF-4E phosphorylation in ornithine decarboxylase-overproducing cells. Shimogori T, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):748–52

Translational regulation during activation of porcine peripheral blood lymphocytes: association and phosphorylation of the alpha and gamma subunits of the initiation factor complex eIF-4F. Morley SJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):627–35

Intracellular targeting and mRNA interactions of the eukaryotic translation initiation factor eIF4E in the yeast Saccharomyces cerevisiae. Ptushkina M, et al. **Biochim Biophys Acta** 1996 Aug 14;1308(2):142–50

Protein synthesis in eukaryotic organisms: new insights into the function of translation initiation factor eIF-3. Hannig EM. **Bioessays** 1995 Nov;17(11):915–9 (49 ref.)

Regulation of ornithine decarboxylase in a transformed cell line that overexpresses translation initiation factor eIF-4E. Shantz LM, et al. **Cancer Res** 1996 Jul 15;56(14):3265–9

Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. Haghighat A, et al. **EMBO J** 1995 Nov 15;14(22):5701–9

The C-terminal domain of eukaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E. Ohlmann T, et al. **EMBO J** 1996 Mar 15;15(6):1371–82

Primer RNA synthesis by plasmid-specified Rep protein for initiation of ColE2 DNA replication. Takechi S, et al. **EMBO J** 1995 Oct 16;14(20):5141–7

Effects of poliovirus 2A(pro) on vaccinia virus gene expression. Feduchi E, et al. **Eur J Biochem** 1995 Dec 15; 234(3):849–54

Insulin and phorbol ester stimulate initiation factor eIF-4E phosphorylation by distinct pathways in Chinese hamster ovary cells overexpressing the insulin receptor. Flynn A, et al. **Eur J Biochem** 1996 Feb 15;236(1):40–7

Analysis of the mRNA cap-binding ability of human eukaryotic initiation factor-4E by use of recombinant wild-type and mutant forms. Morino S, et al. **Eur J Biochem** 1996 Aug 1;239(3):597–601

Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747–71 (372 ref.)

Erythropoietin stimulates phosphorylation of eIF-4E and identification of a 37-kD phosphoprotein that binds mRNA caps in erythroblasts. Bu X, et al. **Exp Hematol** 1996 Feb; 24(3):423–8

Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway. Flynn A, et al. **FEBS Lett** 1996 Jul 1;389(2):162–6

Identification of the nicking tyrosine of geminivirus Rep protein. Laufs J, et al. **FEBS Lett** 1995 Dec 18; 377(2):258–62

Mutations in the NKXD consensus element indicate that GTP binds to the gamma-subunit of translation initiation factor eIF2. Naranda T, et al. **FEBS Lett** 1995 Sep 25; 372(2-3):249–52

Buffer composition mediates a switch between cooperative and independent binding of an initiator protein to DNA. Urh M, et al. **Gene** 1995 Oct 16;164(1):1–7

Role of Ser-53 phosphorylation in the activity of human translation initiation factor eIF-4E in mammalian and yeast cells. Zhang Y, et al. **Gene** 1995 Oct 3;163(2):283–8

Mutations at two invariant nucleotides in the 3'-minor domain of Escherichia coli 16 S rRNA affecting translational initiation and initiation factor 3 function. Firpo MA, et al. **J Biol Chem** 1996 Mar 1;271(9):4693–8

The phosphodiesterase inhibitor SQ 20006 selectively blocks mitogen activation of p70S6k and transition to S phase of the cell division cycle without affecting the steady state phosphorylation of eIF-4E. Frost V, et al. **J Biol Chem** 1995 Nov 3;270(44):26698–706

Internal initiation of translation directed by the 5'-untranslated region of the mRNA for eIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation. Gan W, et al. **J Biol Chem** 1996 Jan 12;271(2):623–6

Expression, purification, and mechanistic studies of bovine mitochondrial translational initiation factor 2. Ma J, et al. **J Biol Chem** 1996 Mar 8;271(10):5805–11

A reevaluation of the cap-binding protein, eIF4E, as a rate-limiting factor for initiation of translation in reticulocyte lysate. Rau M, et al. **J Biol Chem** 1996 Apr 12;271(15):8983–90

Interaction of wheat germ protein synthesis initiation factor eIF-(iso)4F and its subunits p28 and p86 with m7GTP and mRNA analogues. Sha M, et al. **J Biol Chem** 1995 Dec 15;270(50):29904–9

Mutants of eukaryotic initiation factor eIF-4E with altered mRNA cap binding specificity reprogram mRNA selection by ribosomes in Saccharomyces cerevisiae. Vasilescu S, et al. **J Biol Chem** 1996 Mar 22;271(12):7030–7

Translational initiation factor eIF-4E. A link between cardiac load and protein synthesis. Wada H, et al. **J Biol Chem** 1996 Apr 5;271(14):8359–64

Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins. Whalen SG, et al. **J Biol Chem** 1996 May 17; 271(20):11831–7

Characterization of the in vivo phosphorylation sites of the mRNA.cap-binding complex proteins eukaryotic initiation factor-4E and p20 in Saccharomyces cerevisiae. Zanchin NI, et al. **J Biol Chem** 1995 Nov 3;270(44):26505–10

Phosphorylation of eIF-4E and initiation of protein synthesis in P19 embryonal carcinoma cells. Kleijn M, et al. **J Cell Biochem** 1995 Dec;59(4):443–52

Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage. Irurzun A, et al. **J Virol** 1995 Dec;69(12):7453–60

Hybrid proteins between Pseudomonas aeruginosa exotoxin A and poliovirus 2Apro cleave p220 in HeLa cells. Novoa I, et al. **J Virol** 1996 May;70(5):3319–24

Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mèndez R, et al. **Mol Cell Biol** 1996 Jun;16(6):2857–64

SUI1/p16 is required for the activity of eukaryotic translation initiation factor 3 in Saccharomyces cerevisiae. Naranda T, et al. **Mol Cell Biol** 1996 May;16(5):2307–13

Investigating the structure and function of translation initiation factor 1 in Escherichia coli. Dahlquist K, et al. **Nucleic Acids Symp Ser** 1995;(33):170–1

Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Kevil C, et al. **Oncogene** 1995 Dec 7;11(11):2339–48

Activation of the translational suppressor 4E-BP1 following infection with encephalomyocarditis virus and poliovirus. Gingras AC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5578–83

Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Rousseau D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1065–70

In vitro RNA selection identifies RNA ligands that specifically bind to eukaryotic translation initiation factor 4B: the role of the RNA remotif. Methot N, et al. **RNA** 1996 Jan;2(1):38–50

Phosphorylation state of the cap-binding protein eIF4E during viral infection. Kleijn M, et al. **Virology** 1996 Mar 15;217(2):486–94

Proteolytically active 2A proteinase of human rhinovirus 2 is toxic for Saccharomyces cerevisiae but does not cleave the homologues of eIF-4 gamma in vivo or in vitro. Klump H, et al. **Virology** 1996 Jun 1;220(1):109–18

PHYSIOLOGY

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517–20 (20 ref.)

Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Kevil CG, et al. **Int J Cancer** 1996 Mar 15; 65(6):785–90

Physiological effects of translation initiation factor IF3 and ribosomal protein L20 limitation in Escherichia coli. Olsson CL, et al. **Mol Gen Genet** 1996 Apr 10;250(6):705–14

A transcription terminator signal necessary for plasmid ColIb-P9 replication. Mori A, et al. **Mol Microbiol** 1995 Jul;17(2):291–301

Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Bevec D, et al. **Science** 1996 Mar 29;271(5257):1858–60

PEPTIDE MAPPING

see related

PEPTIDE FRAGMENTS

Rapid tryptic mapping using enzymatically active mass spectrometer probe tips. Dogruel D, et al. **Anal Chem** 1995 Dec 1;67(23):4343–8

Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Trapp T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):286–91

Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Wasinger VC, et al. **Electrophoresis** 1995 Jul;16(7):1090–4

Extensive sequencing of tryptic peptides of a rabbit reticulocyte 66-kDa protein that promotes recycling of Hsp 70. Homology To stress-related proteins. Gross M, et al. **J Biol Chem** 1996 Jul 12;271(28):16842–9

"Peptide walking" is a novel method for mapping functional domains in proteins. Its application to the Rac1-dependent activation of NADPH oxidase. Joseph G, et al. **J Biol Chem** 1995 Dec 8;270(49):29079–82

Enhanced sensitivity for peptide mapping with electrospray liquid chromatography-mass spectrometry in the presence of signal suppression due to trifluoroacetic acid-containing mobile phases. Apffel A, et al. **J Chromatogr A** 1995 Sep 29;712(1):177–90

Capillary column high-performance liquid chromatographic-electrospray ionization triple-stage quadrupole mass spectrometric analysis of proteins separated by two-dimensional polyacrylamide gel electrophoresis. Application to cerebellar protein mapping. Nakayama H, et al. **J Chromatogr A** 1996 Apr 12; 730(1-2):279–87

INSTRUMENTATION

The development of a data system for a combination of liquid chromatography or capillary electrophoresis with an ion trap storage/reflectron time-of-flight mass detector. Qian MG, et al. **Rapid Commun Mass Spectrom** 1996; 10(10):1209–14

METHODS

A general method for mapping tertiary contacts between amino acid residues in membrane-embedded proteins. Yu H, et al. **Biochemistry** 1995 Nov 21;34(46):14963–9

Human blood platelet protein map established by two-dimensional polyacrylamide gel electrophoresis. Gravel P, et al. **Electrophoresis** 1995 Jul;16(7):1152–9

Two-dimensional electrophoresis for the study of blood/serum proteins of the otter, an endangered species. Miller I, et al. **Electrophoresis** 1995 Jul;16(7):1193–8

Inside SWISS-2DPAGE database. Sanchez JC, et al. **Electrophoresis** 1995 Jul;16(7):1131–51

Peptide mass fingerprinting of chaperonin-containing TCP-1 (CCT) and copurifying proteins. Hynes G, et al. **FASEB J** 1996 Jan;10(1):137–47

Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Pasternak GW, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):344–50 (57 ref.)

PEPTIDE PEPTIDOHYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE PEPTIDOHYDROLASES

Flow-cytometric analysis of oxidative and proteolytical activities in tissue-associated phagocytes from normal and hypertrophic muscles. Löhrke B, et al. **Anal Cell Pathol** 1995 Dec;9(4):281–93

Proteases. Nduwimana J, et al. **Ann Biol Clin (Paris)** 1995; 53(5):251–64 (120 ref.)

Fluorescent location of cells of cytological interest in cervical smears prestained with thionin. Steven FS, et al. **Anticancer Res** 1996 May-Jun;16(3A):1193–6

Detection of proteolytic bacteria in the upper respiratory tract flora of poultry. Byrum BR, et al. **Avian Dis** 1995 Jul-Sep;39(3):622–6

Probing protein structure with proteases: studies of an equilibrium intermediate in protein unfolding. Webb T, et al. **Biochem Soc Trans** 1995 Aug;23(3):477S

Molecular cloning of antiground-state proteolytic antibody fragments. Gao QS, et al. **Methods Mol Biol** 1995;51:281–96

[Proteolytic enzymes in cell physiology and pathophysiology] Chaloupka J. **Cas Lek Cesk** 1995 Oct 4; 134(19):611–4 (37 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Pancreatic enzyme supplementation in acute pancreatitis. Patankar RV, et al. **HPB Surg** 1995 Jun;8(3):159–62

ADVERSE EFFECTS

Do children with hepatic cirrhosis complicating cystic fibrosis receive too much pancreatic enzyme? [letter] Noble-Jamieson G, et al. **Arch Dis Child** 1996 Jan;74(1):88

ANALYSIS

Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Draper D, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1506–12

Inhibition of the protease activity in tracheobronchial aspirates of horses with chronic obstructive pulmonary disease. Koivunen AL, et al. **Am J Vet Res** 1996 May; 57(5):603–7

Development of a scintillation proximity assay for human cytomegalovirus protease using 33phosphorous. Baum EZ, et al. **Anal Biochem** 1996 May 15;237(1):129–34

Protease assay based on magnetic beads. Wu Y, et al. **Anal Biochem** 1995 Jul 20;229(1):143–4

A simple and rapid technique for postelectrophoretic detection of proteases using azocasein. Vázquez Peyronel D, et al. **Electrophoresis** 1995 Oct;16(10):1894–7

The recovery of proteolytic activity using the Salivette system. Lundy FT, et al.
Eur J Clin Chem Clin Biochem 1995 Jul;33(7):443–4

Proteinases in subretinal fluid. Immonen I, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Feb;234(2):105–9

Characterization of the proteolytic activity of commercial proteases and strained ruminal fluid. Luchini ND, et al.
J Anim Sci 1996 Mar;74(3):685–92

Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. Matsumoto T, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):150–5

Immunological and electrophoretic study of the proteolytic enzymes from various Lactococcus and Lactobacillus strains. Sasaki M, et al. **J Dairy Res** 1995 Nov;62(4):611–20

Assay of proteases from Actinomyces pyogenes isolated from pigs and cows by zymography. Takeuchi S, et al.
J Vet Med Sci 1995 Oct;57(5):977–9

ANTAGONISTS & INHIBITORS see PROTEASE INHIBITORS

BIOSYNTHESIS

Suppression of a sensor kinase-dependent phenotype in Pseudomonas syringae by ribosomal proteins L35 and L20. Kitten T, et al. **J Bacteriol** 1996 Mar;178(6):1548–55

Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. Gaczynska M, et al. **J Biol Chem** 1996 Jul 19;271(29):17275–80

Insulin-like growth factor (IGF) I and II, IGF-binding proteins, and IGF-binding protein proteases are produced by theca and stroma of normal and polycystic human ovaries. Mason HD, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):276–84

In-vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. Wu T, et al.
J Med Microbiol 1996 Apr;44(4):311–6

The Saccharomyces cerevisiae IMP2 gene encodes a transcriptional activator that mediates protection against DNA damage caused by bleomycin and other oxidants. Masson JY, et al. **Mol Cell Biol** 1996 May;16(5):2091–100

Effects of 5-azacytidine on physiological differentiation of Streptomyces antibioticus. Novella IS, et al.
Res Microbiol 1995 Nov-Dec;146(9):721–8

Review: biosynthesis and function of yeast vacuolar proteases. Van Den Hazel HB, et al. **Yeast** 1996 Jan; 12(1):1–16 (110 ref.)

[Biosynthesis of alkaline extracellular proteinases in Bacillus intermedius] Itskovich EL, et al. **Mikrobiologiia** 1995 Sep-Oct;64(5):623–9 (Eng. Abstr.) **(Rus)**

BLOOD

Serum proteinase activities in head and neck squamous cell carcinoma patients. Bongers V, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2763–6

Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Tsai HM. **Blood** 1996 May 15;87(10):4235–44

Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Juul A, et al. **Clin Endocrinol (Oxf)** 1996 May; 44(5):515–23

Protease activity appeared after trypsin treatment of the purified vitellogenin from eel Anguilla japonica. Komatsu M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar;113(3):565–71

Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Timmins AC, et al. **Crit Care Med** 1996 Sep;24(9):1460–6

Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in 150-kilodalton IGFBP complexes by a cation-dependent protease activity in adult rat serum promotes the release of bound IGF-I. Lee GY, et al.
Endocrinology 1996 May;137(5):2051–8

Proteolytic cleavage of VP2, an outer capsid protein of African horse sickness virus, by species-specific serum proteases enhances infectivity in Culicoides. Marchi PR, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2607–11

Actions of Vibrio vulnificus metalloprotease on human plasma proteinase-proteinase inhibitor systems: a comparative study of native protease with its derivative modified by polyethylene glycol. Miyoshi S, et al.
Microbiol Immunol 1995;39(12):959–66

CEREBROSPINAL FLUID

Neuropeptide-converting enzymes in cerebrospinal fluid: activities increased in pain from herniated lumbar dis, but not from coxarthrosis. Lindh C, et al.
Acta Orthop Scand 1996 Apr;67(2):189–92

CHEMISTRY

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

Anomalous estimation of protease molecular weights using gelatin-containing Sds-Page. Hummel KM, et al.
Anal Biochem 1996 Jan 1;233(1):140–2

Structural studies of a major hemorrhagin (rhodostoxin) from the venom of Calloselasma rhodostoma (Malayan pit viper). Chung MC, et al. **Arch Biochem Biophys** 1996 Jan 15; 325(2):199–208

Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5838–46

Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5847–55

Bacillus amyloliquefaciens possesses a second type I signal peptidase with extensive sequence similarity to other Bacillus SPases. Hoang V, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):64–8

Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Chen P, et al. **Cell** 1996 Sep 6;86(5):835–43

The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C. Gomis-Rüth FX, et al. **EMBO J** 1995 Sep 15;14(18):4387–94

X-ray absorption spectroscopy study of zinc coordination in tetanus neurotoxin, astacin, alkaline protease and thermolysin. Morante S, et al. **Eur J Biochem** 1996 Feb 1;235(3):606–12

Enzyme from the medicinal leech (Hirudo medicinalis) that specifically splits endo-epsilon(-gamma-Glu)-Lys isopeptide bonds: cDNA cloning and protein primary structure. Fradkov A, et al. **FEBS Lett** 1996 Jul 22; 390(2):145–8

NMR conformational study of a model tetradecapeptide mimicking the RXVRG consensus cleavage site of a Xenopus laevis skin endoprotease. Chalaoux FR, et al.
Int J Pept Protein Res 1995 Jun;45(6):519–28

Active human cytomegalovirus protease is a dimer. Darke PL, et al. **J Biol Chem** 1996 Mar 29;271(13):7445–9

Membrane topology of the 12- and the 25-kDa subunits of the mammalian signal peptidase complex. Kalies KU, et al. **J Biol Chem** 1996 Feb 16;271(7):3925–9

Electrophoretic and spectral characterization of wild type and mutant adenovirus protease. Keyvani-Amineh H, et al. **J Biol Chem** 1995 Oct 6;270(40):23250–3

Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases. Menéndez-Arias L, et al. **J Biol Chem** 1995 Dec 8;270(49):29162–8

Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins. Pellizzari R, et al. **J Biol Chem** 1996 Aug 23;271(34):20353–8

Studies of complexes between proteases, substrates and the protease inhibitor alpha 2-macroglobulin using capillary electrophoresis with laser-induced fluorescence detection. Reif OW, et al. **J Chromatogr A** 1995 Nov 17; 716(1-2):363–9

Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. Maeda A, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):300–9

Cytochrome-c reductase/processing peptidase complex from potato mitochondria. Braun HP, et al.
Methods Enzymol 1995;260:70–82

Structural features of archaebacterial and eukaryotic proteasomes. Koster AJ, et al. **Mol Biol Rep** 1995; 21(1):11–20 (42 ref.)

Unique fold and active site in cytomegalovirus protease. Qiu X, et al. **Nature** 1996 Sep 19;383(6597):275–9

Three-dimensional structure of human cytomegalovirus protease. Shieh HS, et al. **Nature** 1996 Sep 19; 383(6597):279–82

A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Tong L, et al.
Nature 1996 Sep 19;383(6597):272–5

Atomic solvation parameters in the analysis of protein-protein docking results. Cummings MD, et al.
Protein Sci 1995 Oct;4(10):2087–99

Paired natural cysteine mutation mapping: aid to constraining models of protein tertiary structure. Kreisberg R, et al.
Protein Sci 1995 Nov;4(11):2405–10

Crystallization of a soluble, catalytically active form of Escherichia coli leader peptidase. Paetzel M, et al.
Proteins 1995 Sep;23(1):122–5

Protein secondary structure prediction with partially recurrent neural networks. Reczko M.
SAR QSAR Environ Res 1993;1(2-3):153–9

DIAGNOSTIC USE

[The use of proteases for enhancing the sensitivity of reactions to detect group isohemagglutinins in the forensic medical study of blood stains] Sakharov RS, et al.
Sud Med Ekspert 1996 Jan-Mar;39(1):23–7 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: effect on neurotensin degradation in vitro and in vivo. Vincent B, et al.
Br J Pharmacol 1995 Jul;115(6):1053–63

The effect of non-surgical periodontal and adjunctive minocycline-HCL treatments on the activity of salivary proteases. Atilla G, et al. **J Periodontol** 1996 Jan;67(1):1–6

Protease-mediated signalling: new paradigms for cell regulation and drug development. Hollenberg MD.
Trends Pharmacol Sci 1996 Jan;17(1):3–6 (28 ref.)

GENETICS

Cloning and characterization of a gene encoding a secreted tripeptidyl aminopeptidase from Streptomyces lividans 66. Butler MJ, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):3145–50

Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. Jagasia AA, et al. **Cancer Lett** 1996 Jul 19;105(1):77–90

Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Jagasia AA, et al. **Cancer Lett** 1996 Jul 19;105(1):91–103

New protease mutants in Aspergillus niger result in strongly reduced in vitro degradation of target proteins; genetical and biochemical characterization of seven complementation groups. van den Hombergh JP, et al.
Curr Genet 1995 Sep;28(4):299–308

Genetics of peptide degradation in Lactococcus: gene cloning, construction and analysis of peptidase negative mutants. Mierau I, et al. **Dev Biol Stand** 1995;85:503–7

Genetic modification and the proteolytic system of lactococci. Venema G, et al. **Dev Biol Stand** 1995; 85:495–502

Structure of the gene encoding the sea urchin blastula protease 10 (BP10), a member of the astacin family of Zn2+-metalloproteases. Lhomond G, et al.
Eur J Biochem 1996 Jun 15;238(3):744–51

cDNA cloning of a human 100 kDa de-ubiquitinating enzyme: the 100 kDa human de-ubiquitinase belongs to the ubiquitin C-terminal hydrolase family 2 (UCH2). Falquet L, et al. **FEBS Lett** 1995 Dec 4;376(3):233–7

Enzyme from the medicinal leech (Hirudo medicinalis) that specifically splits endo-epsilon(-gamma-Glu)-Lys isopeptide bonds: cDNA cloning and protein primary structure. Fradkov A, et al. **FEBS Lett** 1996 Jul 22; 390(2):145–8

Donor-side photoinhibition in photosystem II from Chlamydomonas reinhardtii upon mutation of tyrosine-Z in the D1 polypeptide to phenylalanine. Minagawa J, et al. **FEBS Lett** 1996 Jul 1;389(2):199–202

Characterization, genetic analysis, and expression of a protease antigen (PrpRI) of Porphyromonas gingivalis W50. Aduse-Opoku J, et al. **Infect Immun** 1995 Dec; 63(12):4744–54

Conservation of the C5a peptidase genes in group A and B streptococci. Chmouryguina I, et al. **Infect Immun** 1996 Jul;64(7):2387–90

Characterization of an adherence and antigenic determinant of the ArgI protease of Porphyromonas gingivalis which is present on multiple gene products. Curtis MA, et al.
Infect Immun 1996 Jul;64(7):2532–9

Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R1pA. Bass S, et al. **J Bacteriol** 1996 Feb; 178(4):1154–61

Isolation and characterization of two genes encoding proteases associated with the mycelium of Streptomyces lividans 66. Binnie C, et al. **J Bacteriol** 1995 Nov; 177(21):6033–40

A new cell surface proteinase: sequencing and analysis of the prtB gene from Lactobacillus delbruekii subsp. bulgaricus. Gilbert C, et al. **J Bacteriol** 1996 Jun; 178(11):3059–65

Specific binding of the activator Mga to promoter sequences of the emm and scpA genes in the group A streptococcus. McIver KS, et al. **J Bacteriol** 1995 Nov;177(22):6619–24

Characterization and nucleotide sequence of pqqE and pqqF in Methylobacterium extorquens AM1. Springer AL, et al. **J Bacteriol** 1996 Apr;178(7):2154–7

Electrophoretic and spectral characterization of wild type and mutant adenovirus protease. Keyvani-Amineh H, et al. **J Biol Chem** 1995 Oct 6;270(40):23250–3

Molecular studies of CtpA, the carboxyl-terminal processing protease for the D1 protein of the photosystem II reaction center in higher plants. Oelmüller R, et al.
J Biol Chem 1996 Sep 6;271(36):21848–52

Single-chain recombinant human cytomegalovirus protease. Activity against its natural protein substrate and fluorogenic peptide substrates. Pinko C, et al.
J Biol Chem 1995 Oct 6;270(40):23634–40

Characterization of the genes, including that encoding the viral proteinase, contained in BamHI restriction fragment 9 of the pseudorabies virus genome. Camacho A, et al.
J Gen Virol 1996 Aug;77 (Pt 8):1865–74

Isolation of low molecular mass polypeptide complementary DNA clones from primitive vertebrates. Implications for the origin of MHC class I-restricted antigen presentation. Kandil E, et al. **J Immunol** 1996 Jun 1;156(11):4245–53

Cloning and characterization of the eapB and eapC genes of Cryphonectria parasitica encoding two new acid proteinases, and disruption of eapC. Jara P, et al.
Mol Gen Genet 1996 Jan 15;250(1):97–105

Differential expression of genes in the vir regulon of Streptococcus pyogenes is controlled by transcription termination. Pritchard KH, et al. **Mol Gen Genet** 1996 Feb 5;250(2):207–13

Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes. Loessner MJ, et al. **Mol Microbiol** 1995 Jun;16(6):1231–41

A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. **Nat Genet** 1995 Oct;11(2):130–6

Carboxyl-terminal processing protease for the D1 precursor protein: cloning and sequencing of the spinach cDNA. Inagaki N, et al. **Plant Mol Biol** 1996 Jan;30(1):39–50

[Sobemovirus genome from Dactylis glomerata has a luteovirus-like organization of the replicase and protease gene modules] Krutov AA, et al. **Mol Biol (Mosk)** 1996 May-Jun;30(3):564–76 **(Rus)**

IMMUNOLOGY

Cross-reactivity of antibodies raised to Pseudomonas fluorescens protease with extracellular proteins produced by meat-spoiling pseudomonads. Lundy FT, et al. **J Appl Bacteriol** 1996 Jul;81(1):1–6

Isolation of low molecular mass polypeptide complementary DNA clones from primitive vertebrates. Implications for the origin of MHC class I-restricted antigen presentation. Kandil E, et al. **J Immunol** 1996 Jun 1;156(11):4245–53

IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients. Kraat YJ, et al. **J Med Virol** 1996 Mar;48(3):289–94

Antibody response to a protease secreted by Trichinella spiralis muscle larvae. de Armas-Serra C, et al. **Parasitol Res** 1995;81(6):540–2

ISOLATION & PURIFICATION

Anomalous estimation of protease molecular weights using gelatin-containing Sds-Page. Hummel KM, et al. **Anal Biochem** 1996 Jan 1;233(1):140–2

The proteolytic system of Lactobacillus sanfrancisco CB1: purification and characterization of a proteinase, a dipeptidase, and an aminopeptidase. Gobbetti M, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3220–6

Purification and characterization of a fibrinolytic enzyme produced from Bacillus sp. strain CK 11-4 screened from Chungkook-Jang. Kim W, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2482–8

Characterization of a membrane protease from rat submaxillary-gland mitochondria that possess thrombin-like activity. Bharadwaj M, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):193–9

Proteases of germinating winged-bean (Psophocarpus tetragonolobus) seeds: purification and characterization of an acidic protease. Usha R, et al. **Biochem J** 1996 Jan 15; 313 (Pt 2):423–9

Purification and characterization of the angiotensin converting enzyme secretase. Connolly C, et al. **Biochem Soc Trans** 1995 Nov;23(4):551S

Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Chen Y, et al. **Biochemistry** 1996 Mar 12;35(10):3227–37

Purification and characterization of the proteinase ECP 32 from Escherichia coli A2 strain. Matveyev VV, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):55–62

Isolation and properties of a multicatalytic proteinase complex from Xenopus laevis skin secretion. Camarão GC, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2863–7

Isolation of a neuropeptide-degrading endopeptidase from the leech Theromyzon tessulatum. Laurent V, et al. **Eur J Biochem** 1995 Oct 1;233(1):186–91

Boophilus microplus: multiple proteolytic activities in the midgut. Mendiola J, et al. **Exp Parasitol** 1996 Jan; 82(1):27–33

Unusual chromatographic behaviour and one-step purification of a novel membrane proteinase from Bacillus cereus. Fricke B, et al. **J Chromatogr A** 1995 Nov 3; 715(2):247–58

Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. Rao CN, et al. **J Invest Dermatol** 1995 Oct;105(4):572–8

Cytochrome-c reductase/processing peptidase complex from potato mitochondria. Braun HP, et al. **Methods Enzymol** 1995;260:70–82

Purification and characterization of a fibrinogen-degrading protease in Bacteroides fragilis strain YCH46. Chen Y, et al. **Microbiol Immunol** 1995;39(12):967–77

Purification and characterization of LasD: a second staphylolytic proteinase produced by Pseudomonas aeruginosa. Park S, et al. **Mol Microbiol** 1995 Apr; 16(2):263–70

Identification and properties of a neuropeptide-degrading endopeptidase (neprilysin) of Ascaris suum muscle. Sajid M, et al. **Parasitology** 1995 Dec;111 (Pt 5):599–608

Purification and preliminary characterization of a protease from the excretion-secretion products of Trichinella spiralis muscle-stage larvae. de Armas-Serra C, et al. **Vet Parasitol** 1995 Sep;59(2):157–68

METABOLISM

MMP-8 (neutrophil collagenase) mRNA and aggrecanase cleavage products are present in normal and osteoarthritic human articular cartilage. Cole AA, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:98–102

Processing, purification, and kinetic characterization of the Gag-Pol encoded retroviral proteinase of myeloblastosis associated virus expressed in E. coli. Brynda J, et al. **Adv Exp Med Biol** 1995;362:485–8

Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

Inhibition of proteolysis in mozzarella cheese prepared from homogenized milk. Malin EL, et al. **Adv Exp Med Biol** 1995;367:237–46

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

Lysosomal and nonlysosomal protease activities of the brain in response to ethanol feeding. Bonner AB, et al. **Alcohol** 1995 Nov-Dec;12(6):505–9

Link between tumor progression, proteases, and cell motility. Pathology B workshop. Muschel RJ, et al. **Am J Pathol** 1996 Sep;149(3):1073–6

Neutral endopeptidase (EC 3.4.24.11) in labial salivary glands in healthy controls and in patients with Sjögren's syndrome. Konttinen YT, et al. **Ann Rheum Dis** 1996 Aug;55(8):513–9

Specificity of an extracellular proteinase from Brevibacterium linens ATCC 9174 on bovine alpha s1-casein. Rattray FP, et al. **Appl Environ Microbiol** 1996 Feb;62(2):501–6

Involvement of enzyme-substrate charge interactions in the caseinolytic specificity of lactococcal cell envelope-associated proteinases. Reid JR, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3934–9

Carboxy-terminal truncation of oryzacystatin II by oryzacystatin-insensitive insect digestive proteinases. Michaud D, et al. **Arch Biochem Biophys** 1995 Oct 1; 322(2):469–74

Differential effects of bovine PA28 on six peptidase activities of the lobster muscle proteasome (multicatalytic proteinase). Mykles DL. **Arch Biochem Biophys** 1996 Jan 1;325(1):77–81

Intracellular generation of amyloid beta-protein from amyloid beta-protein precursor fragment by direct cleavage with beta- and gamma-secretase. Iizuka T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):238–42

Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro. Katsura K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):298–302

Inactivation of NF-kappa B inhibitor I kappa B alpha: ubiquitin-dependent proteolysis and its degradation product. Li CC, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):292–301

Skeletal muscle of patients with Duchenne's muscular dystrophy: evidence of a mitochondrial proteolytic factor responsible for calmitine deficiency. Lucas-Heron B. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):31–5

Identification of new lens protease(s) using peptide substrates having in vivo cleavage sites. Sharma KK, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):365–70

Specific processing of native and phosphorylated tau protein by proteases. Wang X, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):591–7

Specific cleavage of recombinant protein tau3 between valine-220 and tyrosine-221 (val-309 and tyr-310 of tau4) by a double-stranded DNA-stimulated protease. Wu JM, et al. **Biochem Biophys Res Commun** 1996 Apr 16; 221(2):248–53

cDNA cloning and the identification of an aggrecanase-like cleavage site in rat brevican. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):957–63

Characterization of a membrane protease from rat submaxillary-gland mitochondria that possess thrombin-like activity. Bharadwaj M, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):193–9

Role of an aprotinin-sensitive protease in the activation of Ca(2+)-ATPase by superoxide radical (O2-.) in microsomes of pulmonary vascular smooth muscle. Chakraborti T, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):885–90

Protease-susceptible sites and properties of fragments of aortic smooth-muscle myosin. King L, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):511–8

The endopeptidase activity and the activation by Cl- of angiotensin-converting enzyme is evolutionarily conserved: purification and properties of an an angiotensin-converting enzyme from the housefly, Musca domestica. Lamango NS, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):639–46

Inhibition of autophagic proteolysis by cell swelling in hepatocytes [letter; comment] [see comments] Meijer AJ. **Biochem J** 1995 Dec 15;312 (Pt 3):987–8. Comment on: Biochem J 1995 Jun 1;308 (Pt 2):529–36. Comment in: Biochem J 1995 Dec 15;312 (Pt 3):988–9.

Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):191–5

Cell hydration and proteolysis control in liver [letter; comment] vom Dahl S, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):988–9. Comment on: Biochem J 1995 Dec 15;312 (Pt 3):987–8.

The conformation of human big endothelin-1 favours endopeptidase hydrolysis of the TRP21-VAL22 bond. Corder R. **Biochem Pharmacol** 1996 Feb 9;51(3):259–66

The role of intracellular proteolysis in the regulation of apolipoprotein B secretion by rabbit hepatocytes. Cartwright IJ, et al. **Biochem Soc Trans** 1995 Aug; 23(3):413S

Identification of the site of cleavage in angiotensin converting enzyme by its secretase. Hooper NM, et al. **Biochem Soc Trans** 1995 Nov;23(4):552S

Penems as research tools to investigate the activity of E.coli leader peptidase. Perry CR, et al. **Biochem Soc Trans** 1995 Nov;23(4):548S

Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5838–46

Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5847–55

A novel endoprotease responsible for the specific cleavage of transducin gamma subunit. Cheng H, et al. **Biochemistry** 1995 Dec 26;34(51):16662–71

Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence. Ehlers MR, et al. **Biochemistry** 1996 Jul 23;35(29):9549–59

Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. Evin G, et al. **Biochemistry** 1995 Oct 31;34(43):14185–92

Proximity mapping the surface of a membrane protein using an artificial protease: demonstration that the quinone-binding domain of subunit I is near the N-terminal region of subunit II of cytochrome bd. Ghaim JB, et al. **Biochemistry** 1995 Sep 12;34(36):11311–5

Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. Kuan CT, et al. **Biochemistry** 1996 Mar 5; 35(9):2872–7

Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Margosiak SA, et al. **Biochemistry** 1996 Apr 23;35(16):5300–7

Maduropeptin: an antitumor chromoprotein with selective protease activity and DNA cleaving properties. Zein N, et al. **Biochemistry** 1995 Sep 12;34(36):11591–7

Substrates containing phosphorylated residues adjacent to proline decrease the cleavage by proline-specific peptidases. Kaspari A, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):147–53

Mutation of the catalytic site Asp177 to Glu177 in human pancreatic lipase produces an active lipase with increased sensitivity to proteases. Lowe ME. **Biochim Biophys Acta** 1996 Jul 26;1302(2):177–83

Purification and characterization of the proteinase ECP 32 from Escherichia coli A2 strain. Matveyev VV, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):55–62

Site of action of proteinases in the activation of steroidogenesis in rat adrenal gland. Mele PG, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):260–8

Human lactase-phlorizin hydrolase is not processed by furin, PC1/PC3, PC2, PACE4 and PC5/PC6A of the family of subtilisin-like proprotein processing proteases. Wüthrich M, et al. **Biochim Biophys Acta** 1996 May 28; 1311(3):199–203

Improved method for converting an unmodified peptide to an energy-transfer substrate for a proteinase. Geoghegan KF. **Bioconjug Chem** 1996 May-Jun;7(3):385–91

Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. Putnam D, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):483–92

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385–401 (65 ref.)

A biochemical comparison between latex from Carica candamarcensis and C. papaya. Bravo LM, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2831–42

Microbial ecology of simultaneous thermophilic microbial leaching and digestion of sewage sludge. Shooner F, et al. **Can J Microbiol** 1995 Dec;41(12):1071–80

Effect of lactic acid and proteolytic enzymes on the release of organic matrix components from human root dentin. Dung SZ, et al. **Caries Res** 1995;29(6):483–9

Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Jensen TJ, et al. **Cell** 1995 Oct 6;83(1):129–35

Inactivation of neutral endopeptidase in lung cancer. Cohen AJ, et al. **Chest** 1996 Mar;109(3 Suppl):12S–13S

Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Patel YC, et al. **Ciba Found Symp** 1995; 190:26–40; discussion 40–50 (50 ref.)

Effect of neurotoxic metal ions in vitro on proteolytic enzyme activities in human cerebral cortex. Falkous G, et al. **Clin Chim Acta** 1995 Jul 14;238(2):125–35

A unique strong fibrinolytic enzyme (katsuwokinase) in skipjack "Shiokara," a Japanese traditional fermented food. Sumi H, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):543–7

LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Sibille C, et al. **Curr Biol** 1995 Aug 1;5(8):923–30

Expression in brain of amyloid precursor protein mutated in the alpha–secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. Moechars D, et al. **EMBO J** 1996 Mar 15; 15(6):1265–74

Proteolytic activity of IGFBP–3 in various clinical conditions during childhood studied by means of western immunoblotting. Hasegawa Y, et al. **Endocr J** 1995 Aug; 42(4):569–76

Proteolytic activity is involved in changes in intrafollicular insulin–like growth factor–binding protein levels during growth and atresia of ovine ovarian follicles. Besnard N, et al. **Endocrinology** 1996 May;137(5):1599–607

7S nerve growth factor is an insulin–like growth factor–binding protein protease. Rajah R, et al. **Endocrinology** 1996 Jul;137(7):2676–82

Proteolysis and antiproteolysis—a delicate balance [editorial; comment] Matthews AG. **Equine Vet J** 1994 Mar; 26(2):89–90. Comment on: Equine Vet J 1994 Mar;26(2):122–4.

Identification of Trp300 as an important residue for Escherichia coli leader peptidase activity. Kim YT, et al. **Eur J Biochem** 1995 Nov 15;234(1):358–62

Isolation of a neuropeptide–degrading endopeptidase from the leech Theromyzon tessulatum. Laurent V, et al. **Eur J Biochem** 1995 Oct 1;233(1):186–91

Degradation of pheromone biosynthesis–activating neuropeptide (PBAN) by hemolymph enzymes of the tobacco hornworm, Manduca sexta, and the corn earworm, Helicoverpa zea. Weirich GF, et al. **Experientia** 1995 Sep 29;51(9–10):961–6

The role of proteases during apoptosis. Patel T, et al. **FASEB J** 1996 Apr;10(5):587–97 (97 ref.)

Endosomal proteolysis of internalized proteins. Authier F, et al. **FEBS Lett** 1996 Jun 24;389(1):55–60 (55 ref.)

Anti–head and anti–tail antibodies against distinct epitopes in the catalytic subunit of protein kinase A. Use in the study of the kinase splitting membranal proteinase KSMP. Chestukhin A, et al. **FEBS Lett** 1996 Mar 18;382(3):265–70

Role of multiple cellular proteases in the execution of programmed cell death. Kumar S, et al. **FEBS Lett** 1995 Nov 20;375(3):169–73 (53 ref.)

Conformational changes in subdomain I of actin induced by proteolytic cleavage within the DNase I–binding loop: energy transfer from tryptophan to AEDANS. Kuznetsova I, et al. **FEBS Lett** 1996 Mar 25;383(1–2):105–8

Metabolism of angiotensins by head membranes of the leech Theromyzon tessulatum. Laurent V, et al. **FEBS Lett** 1996 Apr 15;384(2):123–7

Gelatinase A possesses a beta–secretase–like activity in cleaving the amyloid protein precursor of Alzheimer's disease. LePage RN, et al. **FEBS Lett** 1995 Dec 18; 377(2):267–70

Substrate residues N–terminal to the cleavage site of botulinum type B neurotoxin play a role in determining the specificity of its endopeptidase activity. Wictome M, et al. **FEBS Lett** 1996 May 20;386(2–3):133–6

Epidermal growth factor–binding protein activates soluble and receptor–bound single chain urokinase–type plasminogen activator. Wolf BB, et al. **FEBS Lett** 1995 Dec 4;376(3):177–80

Association of colony variation in Serratia marcescens with the differential expression of protease and type 1 fimbriae. Goluszko P, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1–2):41–5

Role of C5a–ase in group B streptococcal resistance to opsonophagocytic killing. Takahashi S, et al. **Infect Immun** 1995 Dec;63(12):4764–9

Digestion of delta–endotoxin by gut proteases may explain reduced sensitivity of advanced instar larvae of Spodoptera littoralis to CryIC. Keller M, et al. **Insect Biochem Mol Biol** 1996 Apr;26(4):365–73

Multiple protease activities in Giardia intestinalis trophozoites. Williams AG, et al. **Int J Parasitol** 1995 Jul; 25(7):771–8

Brain cathepsin B but not metalloendopeptidases degrade rAPP751 with production of amyloidogenic fragments. Comparison with synthetic peptides emulating beta– and gamma–secretase sites. Marks N, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):306–13

Comparison between 3–methylhistidine production and proteinase activity as measures of skeletal muscle breakdown in protein–deficient growing barrows. van den Hemel–Grooten HN, et al. **J Anim Sci** 1995 Aug; 73(8):2272–81

Amino acid requirements and peptidase activities of Streptococcus salivarius subsp. thermophilus. Neviani E, et al. **J Appl Bacteriol** 1995 Sep;79(3):302–7

Membrane insertion of the F–pilin subunit is Sec independent but requires leader peptidase B and the proton motive force. Majdalani N, et al. **J Bacteriol** 1996 Jul;178(13):3742–7

Multiple–peptidase mutants of Lactococcus lactis are severely impaired in their ability to grow in milk. Mierau I, et al. **J Bacteriol** 1996 May;178(10):2794–803

Site–specific proteolysis of the Escherichia coli SecA protein in vivo. Mondigler M, et al. **J Bacteriol** 1996 May; 178(10):2986–8

Carboxyl–terminal processing of the cytoplasmic NAD–reducing hydrogenase of Alcaligenes eutrophus requires the hoxW gene product. Thiemermann S, et al. **J Bacteriol** 1996 Apr;178(8):2368–74

Characterization and chillproofing activity of two enzymes from Streptomyces species. Etok CA, et al. **J Basic Microbiol** 1996;36(2):83–8

Proteolytic activity of Aeromonas caviae. Karunakaran T, et al. **J Basic Microbiol** 1995;35(4):241–7

The primary structure of pepstatin–insensitive carboxyl proteinase produced by Pseudomonas sp. No. 101. Hayashi K, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):738–44

Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase. Kamoshita K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1244–53

Molecular cloning of CWP1: a gene encoding a Saccharomyces cerevisiae cell wall protein solubilized with Rarobacter faecitabidus protease I. Shimoi H, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):302–11

Tetanus toxin inhibits neuroexocytosis even when its Zn(2+)–dependent protease activity is removed. Ashton AC, et al. **J Biol Chem** 1995 Dec 29;270(52):31386–90

Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex. Baugh RJ, et al. **J Biol Chem** 1996 Jul 5;271(27):16126–34

Cholesterol modulates alpha–secretase cleavage of amyloid precursor protein. Bodovitz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4436–40

Functional malleability of the carboxyl–terminal tail in protein kinase A. Chestukhin A, et al. **J Biol Chem** 1996 Apr 26;271(17):10175–82

Active human cytomegalovirus protease is a dimer. Darke PL, et al. **J Biol Chem** 1996 Mar 29;271(13):7445–9

Exchanging the extracellular domain of amyloid precursor protein for horseradish peroxidase does not interfere with alpha–secretase cleavage of the beta–amyloid region, but randomizes secretion in Madin–Darby canine kidney cells. De Strooper B, et al. **J Biol Chem** 1995 Dec 22; 270(51):30310–4

Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon–gamma–induced subunits LMP2 and LMP7. Gaczynska M, et al. **J Biol Chem** 1996 Jul 19;271(29):17275–80

Activation of the herpes simplex virus type 1 protease. Hall DL, et al. **J Biol Chem** 1995 Sep 29;270(39):22697–700

N– and O–glycosylation and phosphorylation of the bar secretion leader derived from the barrier protease of Saccharomyces cerevisiae. Jars MU, et al. **J Biol Chem** 1995 Oct 20;270(42):24810–7

Sequence determinants of C–terminal substrate recognition by the Tsp protease. Keiler KC, et al. **J Biol Chem** 1996 Feb 2;271(5):2589–93

Identification of active site residues of the Tsp protease. Keiler KC, et al. **J Biol Chem** 1995 Dec 1;270(48):28864–8

Single–chain recombinant human cytomegalovirus protease. Activity against its natural protein substrate and fluorogenic peptide substrates. Pinko C, et al. **J Biol Chem** 1995 Oct 6;270(40):23634–40

Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta–secretase" site occurs in the golgi apparatus. Thinakaran G, et al. **J Biol Chem** 1996 Apr 19; 271(16):9390–7

Beta–amyloid precursor protein. Location of transmembrane domain and specificity of gamma–secretase cleavage. Tischer E, et al. **J Biol Chem** 1996 Sep 6;271(36):21914–9

Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. Tözsér J, et al. **J Biol Chem** 1996 Mar 22;271(12):6781–8

Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. Wuillemin WA, et al. **J Biol Chem** 1996 May 31;271(22):12913–8

Roles of molecular chaperones in protein degradation. Hayes SA, et al. **J Cell Biol** 1996 Feb;132(3):255–8 (24 ref.)

Cleavage of the transferrin receptor by human granulocytes: differential proteolysis of the exosome–bound TFR. Johnstone RM. **J Cell Physiol** 1996 Aug;168(2):333–45

Tissue origin and extracellular matrix control neutral proteinase activity in human fibroblast three–dimensional cultures. Lorimier S, et al. **J Cell Physiol** 1996 Jul; 168(1):188–98

Suppression of UV– and interferon–alpha–refractoriness by antipain in human IFr cells established from RSa cells sensitive to both stimuli. Suzuki N. **J Cell Physiol** 1996 Apr;167(1):47–51

Proteolysis of insulin–like growth factor–binding protein–3 in the male reproductive tract. Plymate SR, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):618–24

Proteolytic cleavage and activation of pro–macrophage–stimulating protein by resident peritoneal macrophage membrane proteases. Wang MH, et al. **J Clin Invest** 1996 Feb 1;97(3):720–7

Criteria for consistent and high sensitivity of DNA in situ hybridization on paraffin sections: optimal proteolytic enzyme digestion. Lu QL, et al. **J Clin Lab Anal** 1995; 9(5):285–92

Comparison of proteolytic activities in various lactobacilli. Sasaki M, et al. **J Dairy Res** 1995 Nov;62(4):601–10

Beta–casomorphins: analysis in cheese and susceptibility to proteolytic enzymes from Lactococcus lactis ssp. cremoris. Muehlenkamp MR, et al. **J Dairy Sci** 1996 Jan;79(1):20–6

Interleukin–1 and tumor necrosis factor–alpha increase insulin–like growth factor–binding protein–3 (IGFBP–3) production and IGFBP–3 protease activity in human articular chondrocytes. Olney RC, et al. **J Endocrinol** 1995 Aug;146(2):279–86

Enzymatic conversion of IGF–I to des(1–3)IGF–I in rat serum and tissues: a further potential site of growth hormone regulation of IGF–I action. Yamamoto H, et al. **J Endocrinol** 1995 Jul;146(1):141–8

Proteolysis and the biochemistry of life–or–death decisions [comment] Ashkenas J, et al. **J Exp Med** 1996 May 1; 183(5):1947–51 (34 ref.). Comment on: J Exp Med 1996 May 1;183(5):1957–64.

Protease–resistant PrP deposition in brain and non–central nervous system tissues of a murine model of bovine spongiform encephalopathy. Farquhar CF, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1941–6

Protease–activated lymphoid cell and hepatocyte recognition site in the preS1 domain of the large woodchuck hepatitis virus envelope protein. Jin YM, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1837–46

Expression of the turnip yellow mosaic virus proteinase in Escherichia coli and determination of the cleavage site within the 206 kDa protein. Kadaré G, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2853–7

Analysis of cross reactivity of retrovirus proteases using a vaccinia virus–T7 RNA polymerase–based expression system. Luukkonen BG, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2169–80

Nucleic acid–binding properties of a bacterially expressed potato virus Y helper component–proteinase. Maia IG, et al. **J Gen Virol** 1996 May;77 (Pt 5):869–77

IL–1 beta activation in human epidermis. Nylander–Lundqvist E, et al. **J Immunol** 1996 Aug 15; 157(4):1699–704

Altered insulin–like growth factor–II (IGF–II) level and IGF–binding protein–3 (IGFBP–3) protease activity in interstitial fluid taken from the skin lesion of psoriasis. Xu S, et al. **J Invest Dermatol** 1996 Jan;106(1):109–12

Lipopolysaccharide increases fibronectin production and release from cultured lung fibroblasts partially through proteolytic activity. Adachi Y, et al. **J Lab Clin Med** 1996 May;127(5):448–55

The influence of exo–enzyme S and proteases on endogenous Pseudomonas aeruginosa bacteraemia in mice. Hirakata Y, et al. **J Med Microbiol** 1995 Oct;43(4):258–61

Effect of mucin and glucose on proteolytic and glycosidic activities of Streptococcus oralis. Rafay AM, et al. **J Med Microbiol** 1996 Jun;44(6):409–17

Calcium–activated proteases in the bovine parathyroid gland: potential role in degradation of parathyroid hormone to peptide fragments. Waton PH, et al. **J Mol Endocrinol** 1995 Aug;15(1):61–71

Inhibition of beta A4 production by specific modulation of beta–secretase activity. Urmoneit B, et al. **J Mol Neurosci** 1995;6(1):23–32

Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta–secretase proteases using peptide and amyloid precursor protein substrates. Brown AM, et al. **J Neurochem** 1996 Jun;66(6):2436–45

Regional metabolism of Met–enkephalin and cholecystokinin on intact ratbrain slices: characterization of specific peptidases. Konkoy CS, et al. **J Neurochem** 1995 Dec; 65(6):2773–82

Characterization of extracellular proteinases of Tritrichomonas foetus. Thomford JW, et al. **J Parasitol** 1996 Feb;82(1):112–7

Taenia saginata oncosphere excretory/secretory peptidases. White AC Jr, et al. **J Parasitol** 1996 Feb;82(1):7–10

Characterization of the rubella virus nonstructural protease domain and its cleavage site. Chen JP, et al. **J Virol** 1996 Jul;70(7):4707–13

Evidence that flavivirus NS1–NS2A cleavage is mediated by a membrane–bound host protease in the endoplasmic reticulum. Falgout B, et al. **J Virol** 1995 Nov; 69(11):7232–43

The bovine herpesvirus 1 maturational proteinase and scaffold proteins can substitute for the homologous herpes simplex virus type 1 proteins in the formation of hybrid type B capsids. Haanes EJ, et al. **J Virol** 1995 Nov; 69(11):7375–9

Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. Konvalinka J, et al. **J Virol** 1995 Nov;69(11):7264–8

Characterization of a soluble stable human cytomegalovirus protease and inhibition by M–site peptide mimics. LaFemina RL, et al. **J Virol** 1996 Jul;70(7):4819–24

A single hamster PrP amino acid blocks conversion to protease–resistant PrP in scrapie–infected mouse neuroblastoma cells. Priola SA, et al. **J Virol** 1995 Dec; 69(12):7754–8

The amino–terminal one–third of the influenza virus PA protein is responsible for the induction of proteolysis. Sanz–Ezquerro JJ, et al. **J Virol** 1996 Mar;70(3):1905–11

Posttranslational signal peptidase cleavage at the flavivirus C–prM junction in vitro. Stocks CE, et al. **J Virol** 1995 Dec;69(12):8123–6

Cloning, expression and characterization of the proteinase from human herpesvirus 6. Tigue NJ, et al. **J Virol** 1996 Jun;70(6):4136–41

Interrelation of intracellular proteases with total parenteral nutrition–induced gut mucosal atrophy and increase of

mucosal macromolecular transmission in rats. Kishibuchi M, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun; 19(3):187–92

Globin digest, acidic protease hydrolysate, inhibits dietary hypertriglyceridemia and Val–Val–Tyr–Pro, one of its constituents, possesses most superior effect. Kagawa K, et al. **Life Sci** 1996;58(20):1745–55

Plasmodium falciparum proteinases: cloning of the putative gene coding for the merozoite proteinase for erythrocyte invasion (MPEI) and determination of hydrolysis sites of spectrin by Pf37 proteinase. Florent I, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:47–9

Limited proteolysis of DNA polymerases as probe of functional domains. Konigsberg WH. **Methods Enzymol** 1995;262:331–46

Proteolytic breakdown of membrane-associated polypeptides in mitochondria of Saccharomyces cerevisiae. Langer T, et al. **Methods Enzymol** 1995;260:495–503

Purification and characterization of a fibrinogen-degrading protease in Bacteroides fragilis strain YCH46. Chen Y, et al. **Microbiol Immunol** 1995;39(12):967–77

Trypsin-like protease of Streptomyces exfoliatus SMF13, a potential agent in mycelial differentiation. Kim IS, et al. **Microbiology** 1996 Jul;142 (Pt 7):1797–806

Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1–3):157–61 (52 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

Effects of parathyroid hormone on renal tubular proteinases. Schaefer L, et al. **Miner Electrolyte Metab** 1996; 22(1–3):182–6

Evidence for proteolytic processing of a cuticle collagen in a plant-parasitic nematode. Ray C, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):243–6

Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Cechowska-Pasko M, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):1–8

Involvement of the molecular chaperone Ydj1 in the ubiquitin-dependent degradation of short-lived and abnormal proteins in Saccharomyces cerevisiae. Lee DH, et al. **Mol Cell Biol** 1996 Sep;16(9):4773–81

A light-induced protease from barley plastids degrades NADPH:protochlorophyllide oxidoreductase complexed with chlorophyllide. Reinbothe C, et al. **Mol Cell Biol** 1995 Nov;15(11):6206–12

The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Haass C, et al. **Nat Med** 1995 Dec;1(12):1291–6

Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Lannfelt L, et al. **Nat Med** 1995 Aug;1(8):829–32

Unique fold and active site in cytomegalovirus protease. Qiu X, et al. **Nature** 1996 Sep 19;383(6597):275–9

In vitro association of mitochondrial ATP- dependent protease with mitochondrial heat-shock proteins. Chloupková M, et al. **Neoplasma** 1995;42(6):325–9

Role of proteinases in renal hypertrophy and matrix accumulation. Schafer L, et al. **Nephrol Dial Transplant** 1995;10(6):801–7

In vitro metabolism of an insect neuropeptide by neural membrane preparations from Lymantria dispar. Masler EP, et al. **Peptides** 1996;17(2):321–6

In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. Meyer JP, et al. **Peptides** 1995; 16(7):1215–9

Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. Vaghy PL, et al. **Peptides** 1995;16(8):1367–73

Emergence of proteases in germinating cucumber cotyledons and their roles in the two-step degradation of storage protein. Yamauchi Y, et al. **Plant Cell Physiol** 1996 Apr; 37(3):279–84

Examination of the contribution of vacuolar proteases to intracellular protein degradation in Chara corallina. Moriyasu Y. **Plant Physiol** 1995 Dec;109(4):1309–15

Comparison of morphological and biochemical changes of BAL-isolated cells in experimental lung emphysema. Sulkowski S, et al. **Pol J Pathol** 1995;46(3):179–85

Comparative study of four proteases from spent culture media of Porphyromonas gingivalis (FAY-19M-1). Bedi GS. **Prep Biochem** 1995 Aug;25(3):133–54

Subunit cleavage of mosquito pro-vitellogenin by a subtilisin-like convertase. Chen JS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6186–90

Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Lazebnik YA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9042–6

C-terminal specific protein degradation: activity and substrate specificity of the Tsp protease. Keiler KC, et al. **Protein Sci** 1995 Aug;4(8):1507–15

Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al. **Reprod Fertil Dev** 1995;7(6):1431–6 (26 ref.)

Stimulation of gastric proteases in the neonatal pig by a rise in adrenocortical secretion at parturition. Sangild PT. **Reprod Fertil Dev** 1995;7(5):1293–8

Control of cell fate by a deubiquitinating enzyme encoded by the fat facets gene. Huang Y, et al. **Science** 1995 Dec 15;270(5243):1828–31

When proteins receive deadly messages at birth [comment] Jentsch S. **Science** 1996 Feb 16;271(5251):955–6. Comment on: Science 1996 Feb 16;271(5251):990–3.

The proteolytic pathway of Lactococcus lactis. Poolman B, et al. **Soc Appl Bacteriol Symp Ser** 1995;24:65S–75S (46 ref.)

Three distinct phases of fodrin proteolysis induced in postischemic hippocampus. Involvement of calpain and unidentified protease. Yokota M, et al. **Stroke** 1995 Oct; 26(10):1901–7

Thrombin prevents the expression of inducible nitric oxide synthase in vascular smooth muscle cells by a proteolytically-activated thrombin receptor. Schini-Kerth VB, et al. **Thromb Haemost** 1995 Sep;74(3):980–6

Human placental tissue factor: protease susceptibility of extracellular and cytoplasmic domains. Whittle SM, et al. **Thromb Res** 1995 Sep 15;79(5–6):451–9

Purification and preliminary characterization of a protease from the excretion-secretion products of Trichinella spiralis muscle-stage larvae. de Armas-Serra C, et al. **Vet Parasitol** 1995 Sep;59(2):157–68

Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active. Arad G, et al. **Virology** 1995 Dec 20;214(2):439–44

Identification of the cleavage site recognized by the turnip yellow mosaic virus protease. Bransom KL, et al. **Virology** 1996 Mar 1;217(1):404–6

Expression, purification, and identification of a novel self-cleavage site of the Nla C-terminal 27-kDa protease of turnip mosaic potyvirus C5. Kim DH, et al. **Virology** 1995 Nov 10;213(2):517–25

Characterization of Nla protease from turnip mosaic potyvirus exhibiting a low-temperature optimum catalytic activity. Kim DH, et al. **Virology** 1996 Jul 1;221(1):245–9

Identification of critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease. Roberts PJ, et al. **Virology** 1995 Oct 20; 213(1):140–6

[Studies on the pathogenicity of microbial proteases] Maeda H. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):921–36 (45 ref.) **(Jpn)**

[Antithrombotic effect of piavit—a substance from the medicinal leech (Hirudo medicinalis), containing prostanoid and destabilase fractions] Baskova IP, et al. **Biokhimiia** 1995 Nov;60(11):1775–83 (Eng. Abstr.) **(Rus)**

[Proteolytic enzymes and regulation of the level of active neuropeptides] Vernigora AN, et al. **Biokhimiia** 1995 Oct; 60(10):1575–9 (46 ref.) (Eng. Abstr.) **(Rus)**

[ECP 32 proteinase: characteristics of the enzyme, study of specificity] Kazanina GA, et al. **Bioorg Khim** 1995 Oct; 21(10):761–6 (Eng. Abstr.) **(Rus)**

[Hydrolyzing ability of yeast proteases in relation to protein substrates] Nekliudov AD, et al. **Prikl Biokhim Mikrobiol** 1996 Mar-Apr;32(2):231–6 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

The catabolism of intact, reactive centre-cleaved and proteinase-complexed C1 inhibitor in the guinea pig. Malek R, et al. **Clin Exp Immunol** 1996 Jul;105(1):191–7

PHARMACOLOGY

Rheumatoid synovial fibroblast adhesion to human articular cartilage. Enhancement by neutrophil proteases [see comments] McCurdy L, et al. **Arthritis Rheum** 1995 Nov; 38(11):1694–700. Comment in: Arthritis Rheum 1996 Jun;39(6):1072–3.

Differentiation of the two forms of GPIb functioning as receptors for alpha-thrombin and von Willebrand factor: Ca2+ responses of protease-treated human platelets activated with alpha-thrombin and the tethered ligand peptide. Greco NJ, et al. **Biochemistry** 1996 Jan 23; 35(3):915–21

Effect of Vibrio cholerae non-O1 protease on lysozyme, lactoferrin and secretory immunoglobulin A. Toma C, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):143–7

Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Jagels MA, et al. **Infect Immun** 1996 Jun;64(6):1984–91

Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. Caron E, et al. **J Immunol** 1996 Apr 15;156(8):2885–93

Collagenase and Dispase enzymes disrupt lymphocyte surface molecules. Abuzakouk M, et al. **J Immunol Methods** 1996 Aug 14;194(2):211–6

Tissue digestion with dispase substantially reduces lymphocyte and macrophage cell-surface antigen expression. Ford AL, et al. **J Immunol Methods** 1996 Jul 17;194(1):71–5

A putative enzyme from various secretions specifically inhibits antibody-antigen interactions. Poethke R, et al. **J Immunol Methods** 1996 May 27;191(2):149–57

Proteolytic susceptibility of platelet low density lipoprotein receptor. Pedreño J, et al. **Lipids** 1995 Oct;30(10):927–33

Effects of processing and in vitro proteolytic digestion on soybean and yambean hemagglutinins. Ojimelukwe PC, et al. **Plant Foods Hum Nutr** 1995 Jun;47(4):293–9

Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. Santulli RJ, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9151–5

Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Nowak G, et al. **Thromb Res** 1995 Nov 15;80(4):317–25

PHYSIOLOGY

Characterisation of Sxa2, a protease involved in pheromone communication in fission yeast. Ladds G, et al. **Biochem Soc Trans** 1995 Nov;23(4):565S

Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Hwa JJ, et al. **Circ Res** 1996 Apr;78(4):581–8

Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Lund LR, et al. **Development** 1996 Jan; 122(1):181–93

Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Angelloz-Nicoud P, et al. **Endocrinology** 1995 Dec; 136(12):5485–92

Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. Hamra FK, et al. **Endocrinology** 1996 Jan;137(1):257–65

Role of intraduodenal proteases in plasma cholecystokinin and pancreaticobiliary responses to protein and amino acids. Thimister PW, et al. **Gastroenterology** 1996 Feb; 110(2):567–75

A classical strain of Vibrio cholerae with diminished ability to process the proteolytically sensitive site in the A subunit of cholera toxin. Ichinose Y, et al. **Infect Immun** 1996 Mar; 64(3):1081–3

C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Ji Y, et al. **Infect Immun** 1996 Feb;64(2):503–10

Proteolytic degradation of dinitrogenase reductase from Anabaena variabilis (ATCC 29413) as a consequence of ATP depletion and impact of oxygen. Durner J, et al. **J Bacteriol** 1996 Feb;178(3):606–10

Enhancement of Schistosoma mansoni infectivity by intradermal injections of larval extracts: a putative role for larval proteases. Fallon PG, et al. **J Infect Dis** 1996 Jun; 173(6):1460–6

Proteinases in renal cell death. Yang X, et al. **J Toxicol Environ Health** 1996 Jul;48(4):319–32

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul-Aug; 11(4):382–7 (66 ref.). Comment in: Nutrition 1995 Jul-Aug;11(4):398.

Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Kopan R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1683–8

DNA degradation and proteolysis in thymocyte apoptosis. Fearnhead HO, et al. **Toxicol Lett** 1995 Dec;82–83:135–41

Are bacterial proteinases pathogenic factors? Travis J, et al. **Trends Microbiol** 1995 Oct;3(10):405–7 (28 ref.)

Protease-mediated signalling: new paradigms for cell regulation and drug development. Hollenberg MD. **Trends Pharmacol Sci** 1996 Jan;17(1):3–6 (28 ref.)

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

RADIATION EFFECTS

[Proteinases activated by gamma irradiation in the nuclei of rat peripheral blood leukocytes] Surkenova GN, et al. **Izv Akad Nauk Ser Biol** 1995 Sep-Oct;(5):521–9 (Eng. Abstr.) **(Rus)**

SECRETION

Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. Ollert MW, et al. **J Clin Microbiol** 1995 Oct;33(10):2543–9

A putative enzyme from various secretions specifically inhibits antibody-antigen interactions. Poethke R, et al. **J Immunol Methods** 1996 May 27;191(2):149–57

Entamoeba histolytica: proteinase secretion induced by collagen type I is dependent on cytoskeleton integrity. Serrano JJ, et al. **Parasitol Res** 1996;82(3):200–5

TOXICITY

Skeletal muscle necrosis and regeneration after injection of BaH1, a hemorrhagic metalloproteinase isolated from the venom of the snake Bothrops asper (Terciopelo). Gutiérrez JM, et al. **Exp Mol Pathol** 1995 Feb;62(1):28–41

In vitro activity of BaH1, the main hemorrhagic toxin of Bothrops asper snake venom on bovine endothelial cells. Borkow G, et al. **Toxicon** 1995 Oct;33(10):1387–91 (23 ref.)

PEPTIDE PHI

METABOLISM

Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species

selectivity with respect to recognition of peptide histidine isoleucineamide. Couvineau A, et al. **J Biol Chem** 1996 May 31;271(22):12795–800

PHARMACOLOGY

The interactive effects of VIP, PHI, GHRH, and SRIF on the release of growth hormone from cultured adenohypophysial cells in cattle. Soliman EB, et al. **Endocr J** 1995 Oct;42(5):717–22

VIP antagonist demonstrates differences in VIP- and PHI-mediated stimulation and inhibition of ACTH and corticosterone secretion in rats. Alexander LD, et al. **Regul Pept** 1995 Nov 10;59(3):321–33

PEPTIDE PHM see PEPTIDE PHI

PEPTIDE RECEPTORS see RECEPTORS, PEPTIDE

PEPTIDE RECEPTORS, INVERTEBRATE see RECEPTORS, INVERTEBRATE PEPTIDE

PEPTIDE SYNTHETASES

ANTAGONISTS & INHIBITORS

Synthesis and biological evaluation of N alpha-(4-amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine. Tsukamoto T, et al. **J Med Chem** 1996 Jun 21;39(13):2536–40

NG-nitro-L-arginine methyl ester and alpha-methyl-L-ornithine inhibit kyotorphin synthetase from rat brain. Kawabata A, et al. **Peptides** 1995; 16(7):1317–9

CHEMISTRY

Structural studies of Escherichia coli UDP-N-acetylmuramate:L-alanine ligase. Jin H, et al. **Biochemistry** 1996 Feb 6;35(5):1423–31

Multienzymatic non ribosomal peptide biosynthesis: identification of the functional domains catalysing peptide elongation and epimerisation. De Crécy-Lagard V, et al. **C R Acad Sci III** 1995 Sep;318(9):927–36

Reversible denaturation of cyclosporin synthetase by urea. Dittmann J, et al. **FEBS Lett** 1996 Feb 12;380(1–2):157–60

Cloning and characterization of the Neisseria gonorrhoeae MS11 folC gene. Fussenegger M, et al. **Mol Gen Genet** 1996 Feb 25;250(3):277–85

DRUG EFFECTS

The stereospecific cytotoxic potency of (6R) and (6S)-5,10-dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels. Lehman NL. **Biochimie** 1995;77(4):273–8

GENETICS

The peptide synthetase gene phsA from Streptomyces viridochromogenes is not juxtaposed with other genes involved in nonribosomal biosynthesis of peptides. Schwartz D, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):570–7

Highly conserved N-methyltransferases as an integral part of peptide synthetases. Burmester J, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):201–7

Engineered biosynthesis of peptide antibiotics. Stachelhaus T, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):177–86 (64 ref.)

Molecular cloning of murine folylpoly-gamma-glutamate synthetase. Spinella MJ, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):11–4

Structural organization of the human folypoly-gamma-glutamate synthetase gene: evidence for a single genomic locus. Taylor SM, et al. **Cancer Res** 1995 Dec 15;55(24):6030–4

Detection of a protein which binds specifically to the upstream region of the pcbAB gene in Penicillium chrysogenum. Chu YW, et al. **Curr Genet** 1995 Jul; 28(2):184–9

Toxic and non-toxic strains of the cyanobacterium Microcystis aeruginosa contain sequences homologous to peptide synthetase genes. Meissner K, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):295–303

Identification of peptide synthetase-encoding genes from filamentous fungi producing host-selective phytotoxins or analogs. Nikolskaya AN, et al. **Gene** 1995 Nov 20; 165(2):207–11

Identification of a major cis-acting DNA element controlling the bidirectionally transcribed penicillin biosynthesis genes acvA (pcbAB) and ipnA (pcbC) of Aspergillus nidulans. Bergh KT, et al. **J Bacteriol** 1996 Jul;178(13):3908–16

Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription. Roy K, et al. **J Biol Chem** 1995 Nov 10;270(45):26918–22

Evolution of structure and substrate specificity in D-alanine:D-alanine ligases and related enzymes. Evers S, et al. **J Mol Evol** 1996 Jun;42(6):706–12

A murC gene in Porphyromonas gingivalis 381. Ansai T, et al. **Microbiology** 1995 Sep;141 (Pt 9):2047–52

A new Myxococcus xanthus gene cluster for the biosynthesis of the antibiotic saframycin Mx1 encoding a peptide synthetase. Pospiech A, et al. **Microbiology** 1995 Aug;141 (Pt 8):1793–803

Cloning and characterization of the Neisseria gonorrhoeae MS11 folC gene. Fussenegger M, et al. **Mol Gen Genet** 1996 Feb 25;250(3):277–85

Effect of disruption of the enniatin synthetase gene on the virulence of Fusarium avenaceum. Herrmann M, et al. **Mol Plant Microbe Interact** 1996 May;9(4):226–32

ISOLATION & PURIFICATION

High-molecular-mass, iron-repressed cytoplasmic proteins in fluorescent Pseudomonas: potential peptide-synthetases for pyoverdine biosynthesis. Georges C, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):9–15

Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. Chen L, et al. **J Biol Chem** 1996 May 31;271(22):13077–87

[Isolation of carnosine synthetase from animal and human muscles] Bulygina ER, et al. **Vopr Med Khim** 1995 Nov-Dec;41(6):27–30 (Eng. Abstr.) **(Rus)**

METABOLISM

Molecular mechanism of the multifunctional enzyme L-delta-(alpha-aminoadipoyl)-L-cysteinyl-D-valine (ACV) synthetase. Shiau CY, et al. **Biochem Soc Trans** 1995 Nov;23(4):629S

Biochemical evidence for the formation of a covalent acyl-phosphate linkage between UDP-N-acetylmuramate and ATP in the Escherichia coli UDP-N-acetylmuramate:L-alanine ligase-catalyzed reaction. Falk PJ, et al. **Biochemistry** 1996 Feb 6; 35(5):1417–22

Gain of D-alanyl-D-lactate or D-lactyl-D-alanine synthetase activities in three active-site mutants of the Escherichia coli D-alanyl-D-alanine ligase B. Park IS, et al. **Biochemistry** 1996 Aug 13;35(32):10464–71

The stereospecific cytotoxic potency of (6R) and (6S)-5,10-dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels. Lehman NL. **Biochimie** 1995;77(4):273–8

Effect of analogues of diaminopimelic acid on the meso-diaminopimelate-adding enzyme from Escherichia coli. Auger G, et al. **FEBS Lett** 1996 Aug 5;391(1–2):171–4

Tubulin-tyrosine ligase catalyzes covalent binding of 3-fluoro-tyrosine to tubulin: kinetic and [19F]NMR studies. Monasterio O, et al. **FEBS Lett** 1995 Oct 30; 374(2):165–8

Delta-L-(alpha-aminoadipoyl)-L-cysteinyl-D-valine synthetase: isolation of L-cysteinyl-D-valine, a 'shunt' product, and implications for the order of peptide bond formation. Shiau CY, et al. **FEBS Lett** 1995 Oct 16; 373(3):303–6

The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates. Stein T, et al. **J Biol Chem** 1996 Jun 28;271(26):15428–35

Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. van der Wilt CL, et al. **Oncol Res** 1995;7(6):317–21

PEPTIDE T

ANALOGS & DERIVATIVES

Effects of peptide T derivatives on the proliferation of cultured human keratinocytes. Marastoni M, et al. **Arzneimittelforschung** 1995 Aug;45(8):891–3

PHARMACOLOGY

Effects of peptide T derivatives on the proliferation of cultured human keratinocytes. Marastoni M, et al. **Arzneimittelforschung** 1995 Aug;45(8):891–3

THERAPEUTIC USE

Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment. Talme T, et al. **Arch Dermatol Res** 1995;287(6):553–7

PEPTIDE TERMINATION FACTORS

CHEMISTRY

Conserved motifs in prokaryotic and eukaryotic polypeptide release factors: tRNA-protein mimicry hypothesis. Ito K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5443–8

GENETICS

The nuclear Kluyveromyces lactis MRF1 gene encodes a mitochondrial class I peptide chain release factor that is important for cell viability. Pel HJ, et al. **Curr Genet** 1996 Jun;30(1):19–28

Osmo-expression and fast two-step purification of Escherichia coli translation termination factor RF-3. Mortensen KK, et al. **Eur J Biochem** 1995 Dec 15; 234(3):732–6

Cloning of the Mycoplasma capricolum gene encoding peptide-chain release factor. Inagaki Y, et al. **Gene** 1996 Feb 22;169(1):101–3

Comparative characterization of release factor RF-3 genes of Escherichia coli, Salmonella typhimurium, and Dichelobacter nodosus. Kawazu Y, et al. **J Bacteriol** 1995 Oct;177(19):5547–53

Suppression of temperature-sensitive defects of polypeptide release factors RF-1 and RF-2 by mutations or by an excess of RF-3 in Escherichia coli. Matsumura K, et al. **J Mol Biol** 1996 May 17;258(4):588–99

Is the in-frame termination signal of the Escherichia coli release factor-2 frameshift site weakened by a particularly poor context? Major LL, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2673–8

IMMUNOLOGY

[Glycoprotein D (5-23) specific Th2-T-cell line induces HSV-1 keratitis] Heiligenhaus A, et al. **Ophthalmologe** 1995 Aug;92(4):484–91 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Osmo-expression and fast two-step purification of Escherichia coli translation termination factor RF-3. Mortensen KK, et al. **Eur J Biochem** 1995 Dec 15; 234(3):732–6

METABOLISM

Loss of overproduction of polypeptide release factor 3 influences expression of the tryptophanase operon of Escherichia coli. Yanofsky C, et al. **J Bacteriol** 1996 Jul; 178(13):3755–62

Conserved motifs in prokaryotic and eukaryotic polypeptide release factors: tRNA-protein mimicry hypothesis. Ito K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5443–8

Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase. Frolova L, et al. **RNA** 1996 Apr;2(4):334–41

PHYSIOLOGY

Inhibition of the release factor-dependent termination reaction on ribosomes by DnaJ and the N-terminal peptide of rhodanese. Kudlicki W, et al. **J Bacteriol** 1995 Oct; 177(19):5517–22

Mutation in the structural gene for release factor 1 (RF-1) of Salmonella typhimurium inhibits cell division. Olafsson O, et al. **J Bacteriol** 1996 Jul;178(13):3829–39

Functional interaction between release factor one and P-site peptidyl-tRNA on the ribosome. Zhang S, et al. **J Mol Biol** 1996 Aug 16;261(2):98–107

PEPTIDES

see related

AMINO ACID SEQUENCE

Flag-insulin receptor mutants. Goren HJ. **Ann N Y Acad Sci** 1995 Sep 7;766:463–5

Monocryl suture, a new ultra-pliable absorbable monofilament suture. Bezwada RS, et al. **Biomaterials** 1995 Oct;16(15):1141–8

Sequence-specific purification of nucleic acids by PNA-controlled hybrid selection. Orum H, et al. **Biotechniques** 1995 Sep;19(3):472–80

Adrenomedullin-like immunoreactivity in the nervous system of the starfish Marthasterias glacialis. Martínez A, et al. **Cell Tissue Res** 1996 Feb;283(2):169–72

Identification of a biologically significant DNA-binding peptide motif by use of a random phage display library. Cheng X, et al. **Gene** 1996 May 24;171(1):1–8

New vectors for peptide display on the surface of filamentous bacteriophage. Malik P, et al. **Gene** 1996 May 24; 171(1):49–51

A 12-residue-long polyleucine tail is sufficient to anchor synaptobrevin to the endoplasmic reticulum membrane. Whitley P, et al. **J Biol Chem** 1996 Mar 29;271(13):7583–6

Affinity selective isolation of ligands from peptide libraries through display on a lac repressor "headpiece dimer". Gates CM, et al. **J Mol Biol** 1996 Jan 26;255(3):373–86

Peptide, peptidomimetic, and organic synthetic combinatorial libraries. Eichler J, et al. **Med Res Rev** 1995 Nov; 15(6):481–96 (67 ref.)

Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50

[Characters and insecticidal polypeptide of a new strain of Bacillus thuringiensis subsp. kenyae in China] Ren G, et al. **Wei Sheng Wu Hsueh Pao** 1995 Aug;35(4):303–8 (Eng. Abstr.) **(Chi)**

[Factors with insulin-like effects: IGF-I and GLP-1] Páv J. **Vnitr Lek** 1995 Sep;41(9):624–8 (35 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):332–51 (234 ref.)

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. Milo R, et al. **J Neuroimmunol** 1995 Sep;61(2):185–93

Randomized trial of tolerance and efficacy of a small-peptide enteral feeding formula versus a whole-protein formula [see comments] Heimburger DC, et al. **Nutrition** 1995 Jul-Aug;11(4):360–4. Comment in: Nutrition 1995 Jul-Aug;11(4):395–7.

Do peptide-based enteral formulas provide any benefit over intact protein diets? [editorial; comment] McClave SA.

Nutrition 1995 Jul-Aug;11(4):395-7. Comment on: Nutrition 1995 Jul-Aug;11(4):360-4.

Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Luessen HL, et al. **Pharm Res** 1995 Sep;12(9):1293-8

Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model. Niemiec SM, et al. **Pharm Res** 1995 Aug;12(8):1184-8

Inhibition of thrombin by peptides containing Lysyl-alpha-keto carbonyl derivatives. Lewis SD, et al. **Thromb Haemost** 1995 Oct;74(4):1107-12

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

ADVERSE EFFECTS

omega-Conotoxin GVIA and prazosin, but not felodipine, cause postural hypotension in rabbits. Hawkes AL, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):711-6

AGONISTS

Tethered ligand library for discovery of peptide agonists. Chen J, et al. **J Biol Chem** 1995 Oct 6;270(40):23398-401

SH2 and SH3 domains: potential targets for anti-cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125-32 (52 ref.)

ANALYSIS

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161-94 (244 ref.)

Lack of magainin-like activity in human cervical tissue. Hansen KA, et al. **Am J Reprod Immunol** 1995 Jun; 33(6):481-4

Early pregnancy factor (EPF) as a marker for detecting subclinical embryonic loss in clomiphene citrate-treated women. Shahani SK, et al. **Am J Reprod Immunol** 1995 May;33(5):350-3

Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM, et al. **Am J Surg** 1996 Jan;171(1):126-9; discussion 129-30

The preparation and use of dispersed cells from fat body of Locusta migratoria in a filtration plate assay for adipokinetic peptides. Lee MJ, et al. **Anal Biochem** 1995 Jun 10;228(1):155-61

Radiolabeling of small peptides bound to a solid phase. Maass R, et al. **Anal Biochem** 1995 Sep 20;230(2):343-5

Spectrophotometric assay using streptavidin-alkaline phosphatase conjugate for studies on the proteolysis of polymer bead-bound peptides. Shin JS, et al. **Anal Biochem** 1996 Apr 5;236(1):9-13

Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Cohen SL, et al. **Anal Chem** 1996 Jan 1;68(1):31-7

Pulsed gas introduction for increasing peptide CID efficiency n a MALDI/quadrupole ion trap mass spectrometer. Doroshenko VM, et al. **Anal Chem** 1996 Feb 1;68(3):463-72

XPS and TOF-SIMS microanalysis of a peptide/polymer drug delivery device. John CM, et al. **Anal Chem** 1995 Nov 1;67(21):3871-8

A practical ion trap mass spectrometer for the analysis of peptides by matrix-assisted laser desorption/ionization. Qin J, et al. **Anal Chem** 1996 May 15;68(10):1784-91

Graphite surface-assisted laser desorption/ionization time-of-flight mass spectrometry of peptides and proteins from liquid solutions. Sunner J, et al. **Anal Chem** 1995 Dec 1;67(23):4335-42

Off-line coupling of capillary electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Walker KL, et al. **Anal Chem** 1995 Nov 15;67(22):4197-204

Parent ion scans of unseparated peptide mixtures. Wilm M, et al. **Anal Chem** 1996 Feb 1;68(3):527-33

On-line NMR detection of amino acids and peptides in microbore LC. Wu N, et al. **Anal Chem** 1995 Sep 15; 67(18):3101-7

Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases. Yates JR 3rd, et al. **Anal Chem** 1995 Sep 15;67(18):3202-10

Measurement of activin B in human saliva and localization of activin subunits in rat salivary glands. Bläuer M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):230-5

Immunoreactivity of PKC gammalambda and RACK1 in baker's yeast, lobster and wheat germ. Kuo WN, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):957-63

A new procedure for the labeling of peptides and amino acids. Barton DH, et al. **Bioorg Med Chem** 1995 Jan;3(1):79-84

Presence of sauvagine-like epitopes in the interrenal gland of the bullfrog Rana catesbeiana. Gonzalez GC, et al. **Cell Tissue Res** 1996 Jan;283(1):117-23

Spatial and temporal immunocytochemical analysis of drosulfakinin (Dsk) gene products in the Drosophila melanogaster central nervous system. Nichols R, et al. **Cell Tissue Res** 1996 Jan;283(1):107-16

Two different approaches for developing immunometric assays of haptens. Grassi J, et al. **Clin Chem** 1996 Sep; 42(9):1532-6

Sensitivity enhancement and second-dimensional information from solid phase extraction-capillary electrophoresis of entire high-performance liquid chromatography fractions. Strausbauch MA, et al. **Electrophoresis** 1995 Apr; 16(4):541-8

Capillary electroseparations of enkephalin-related peptides and protein kinase A peptide substrates. Thorsteinsdóttir M, et al. **Electrophoresis** 1995 Apr;16(4):564-73

Characterization of the lower-molecular-mass fraction of venoms from Dendroaspis jamesoni kaimosae and Micrurus fulvius using capillary-electrophoresis electrospray mass spectrometry. Perkins JR, et al. **Eur J Biochem** 1995 Nov 1;233(3):815-27

Circulating and tissue guanylin immunoreactivity in intestinal secretory diarrhoea. Kuhn M, et al. **Eur J Clin Invest** 1995 Dec;25(12):899-905

The value of TPS in breast cancer. Karaloglu D, et al. **Eur J Gynaecol Oncol** 1995;16(5):363-7

Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers. Khulusi S, et al. **Gut** 1995 Aug;37(2):205-9

Immunohistological localization of regulatory peptides in the midgut of the female mosquito Aedes aegypti. Veenstra JA, et al. **Histochem Cell Biol** 1995 Nov;104(5):337-47

Fowlpox virus structural protein immunogens and characterization of single band polypeptide. Mishra SS, et al. **Indian J Exp Biol** 1996 Apr;34(4):311-6

A two-dimensional electrophoretic analysis of latex peptides reacting with IgE and IgG antibodies from patients with latex allergy. Kurup VP, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):58-67

Immunoquantification of type I, III, IV and V collagen in small samples of human lung parenchyma. van Kuppevelt TH, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):775-82

Development of a new Prolifigen TPA IRMA assay using monoclonal anti-cytokeratin antibodies. Sundström BE, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):166-73

A simple and inexpensive sample-handling method for the semi-preparative RP-HPLC of polypeptides and non-polar peptide derivatives: pre-adsorption of samples. Thompson PE, et al. **J Biochem Biophys Methods** 1995 Jun; 30(2-3):153-61

Distribution and characterization of immunoreactive adrenomedullin in porcine tissue, and isolation of adrenomedullin [26-52] and adrenomedullin [34-52] from porcine duodenum. Ichiki Y, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):765-70

A 130 kDa polypeptide immunologically related to the 180 kDa catalytic subunit of DNA polymerase alpha-primase complex is detected in early embryos of Drosophila. Kuroda K, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):809-18

Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. Paone G, et al. **J Cancer Res Clin Oncol** 1996;122(8):499-503

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1-2):165-90 (72 ref.)

Use of capillary zone electrophoresis in an investigation of peptide uptake by dairy starter bacteria. Moore IL, et al. **J Chromatogr A** 1995 Dec 1;718(1):211-5

Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. Giannobile WV, et al. **J Clin Periodontol** 1995 Dec;22(12):903-10

Measurements of hormonal peptides in the bronchoalveolar fluid as tumor markers of lung cancer. Calogero AE, et al. **J Endocrinol Invest** 1995 May;18(5):354-8

Detection of undegraded beta-lactoglobulins and evaluation of the molecular weight of peptides in hydrolysate cow's milk formulae. Chiancone E, et al. **J Investig Allergol Clin Immunol** 1995 Jul-Aug;5(4):228-31

Neural isolation of the jejunoileum. Effect on tissue morphometry, mucosal disaccharidase activity, and tissue peptide content. Sarr MG, et al. **J Surg Res** 1996 Mar; 61(2):416-24

Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Taupin D, et al. **Lab Invest** 1996 Jul;75(1):25-32

Rhabdoid tumor of the kidney: a report of two cases with respective tumor markers and a specific chromosomal abnormality, del(11p13). Hirose M, et al. **Med Pediatr Oncol** 1996 Sep;27(3):174-8

Identification, cellular localization and in vitro release of a novel teleost melanin-concentrating hormone gene-related peptide. Gröneveld D, et al. **Neuroendocrinology** 1995 Nov; 62(5):498-505

Immunohistochemical localization of adrenomedullin in canine heart and aorta. Jougasaki M, et al. **Peptides** 1995; 16(4):773-5

Localization and characterization of a novel 20 kDa polypeptide in the chloroplast of the green alga Dunaliella salina. Andreasson E, et al. **Plant Cell Physiol** 1995 Dec; 36(8):1483-92

Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Giovanella L, et al. **Q J Nucl Med** 1995 Dec;39(4):285-9

The characterization of proteins and peptides by automated methods. Bonner R, et al. **Rapid Commun Mass Spectrom** 1995;9(11):1067-76

Sequencing peptides without scanning the reflectron: post-source decay with a curved-field reflectron time-of-flight mass spectrometer. Cordero MM, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1356-61

Histidyl-glycyl containing peptides. Characterization complexation properties of H(L-His-Gly)2-R with hydrogen and alkali metal ions in the gas phase. Georgi G, et al. **Rapid Commun Mass Spectrom** 1996; 10(10):1266-72

Direct database searching with MALDI-PSD spectra of peptides. Griffin PR, et al. **Rapid Commun Mass Spectrom** 1995;9(15):1546-51

Positive-ion electrospray-fourier transform ion cyclotron resonance mass spectra of polypeptides and proteins. He M, et al. **Rapid Commun Mass Spectrom** 1996;10(8):897-902

Collisionally-activated dissociation spectra of linear peptides in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Kosaka T, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1342-4

High sensitivity collisionally-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Morris HR, et al. **Rapid Commun Mass Spectrom** 1996;10(8):889-96

Peptide characterization using bioreactive mass spectrometer probe tips. Nelson RW, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1380-5

A simple method for differentiating Leu and Ile in peptides. The negative-ion mass spectra of [M-H]- ions of phenylthiohydantoin Leu and Ile. Ramsay SL, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1241-3

The application of mass spectrometry to the study of evolutionary trends in amphibians. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1996;10(1):92-5

A comparison of the positive- and negative-ion mass spectra of bio-active peptides from the dorsal secretion of the Australian red tree frog, Litoria rubella. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1243-7

Liquid secondary-ion mass spectrometry of peptides containing multiple tyrosine-O-sulfates. Yagami T, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1335-41

Bioactive peptides from lizard venoms. Raufman JP. **Regul Pept** 1996 Jan 16;61(1):1-18 (165 ref.)

Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Brewer JM, et al. **Vaccine** 1995; 13(15):1441-4

Comparative immunological detection of lipids and carotenoids on peptides of photosystem I from higher plants and cyanobacteria. Makewicz A, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):319-28

[Peptide hormone] Ohnami S, et al. **Nippon Rinsho** 1996 Jun; 54(6):1510-4 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Exposure to asbestos and levels of selected tumor biomarkers] Krajewska B, et al. **Med Pr** 1996;47(2):89-96 (Eng. Abstr.) **(Pol)**

[Plasma-desorption mass spectrometry of natural compounds. 1. Basic properties of the method and its use for analyzing proteins and peptides] Reztsova NA, et al. **Bioorg Khim** 1996 Jan;22(1):3-13 (141 ref.) (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, et al. **Int J Cancer** 1995 Oct 9;63(2):257-62

Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. Groot K, et al. **Int J Pept Protein Res** 1995 Jun;45(6):561-6

BIOSYNTHESIS

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91-41 (112 ref.)

Embryo-associated immunosuppressor factor is produced at the maternal-fetal interface in human pregnancy. Bose R, et al. **Am J Reprod Immunol** 1995 May;33(5):373-80

Sex-peptide activates juvenile hormone biosynthesis in the Drosophila melanogaster corpus allatum. Moshitzky P, et al. **Arch Insect Biochem Physiol** 1996;32(3-4):363-74

Novel polypeptides induced by the insecticide lindane (gamma-hexachlorocyclohexane) are required for its biodegradation by a Sphingomonas paucimobilis strain. Adhya TK, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):755-61

Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Fan X, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):457-62

Production in Escherichia of moricin, a novel type antibacterial peptide from the silkworm, Bombyx mori. Hara S, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):664-9

Cloning and characterization of a cDNA encoding a precursor for human uroguanylin. Miyazato M, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):644-8

Alpha endosulfine is a novel molecule, structurally related to a family of phosphoproteins. Peyrollier K, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):583-6

Autocrine regulation of the renal arterial tone by adrenomedullin. Seguchi H, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):619–25

Endotoxin markedly elevates plasma concentration and gene transcription of adrenomedullin in rat. Shoji H, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):531–7

Double tagging recombinant A1- and A2A-adenosine receptors with hexahistidine and the FLAG epitope. Development of an efficient generic protein purification procedure. Robeva AS, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):545–55

Synthesis of alpha-helix-forming peptides by gene engineering methods and their characterization by circular dichroism spectra measurements. Kojima S, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):129–37

Molecular cloning and identification of a novel porcine cathelin-like antibacterial peptide precursor. Strukelj B, et al. **Biol Chem Hoppe Seyler** 1995 Aug;376(8):507–10

Generation of diverse single-chain proteins using a universal (Gly4-Ser)3 encoding oligonucleotide. Lake DF, et al. **Biotechniques** 1995 Nov;19(5):700–2

Peptide and peptide-derived antibiotics. Vining LC, et al. **Biotechnology** 1995;28:121–7 (12 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

Prostaglandin A1 inhibits replication of Mayaro virus in Aedes albopictus cells. Barbosa JA, et al. **Braz J Med Biol Res** 1995 Jan;28(1):27–30

New disulfide bond-forming reactions for peptide and protein synthesis. Kiso Y, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2733–44 (24 ref.)

Protein biogenesis: chaperones for nascent polypeptides. Rassow J, et al. **Curr Biol** 1996 Feb 1;6(2):115–8 (29 ref.)

Parallel induction of cecropin and lysozyme in larvae of the silkworm, Bombyx mori. Morishima I, et al. **Dev Comp Immunol** 1995 Sep–Oct;19(5):357–63

Peptide YY expression is an early event in colonic endocrine cell differentiation: evidence from normal and transgenic mice. Upchurch BH, et al. **Development** 1996 Apr; 122(4):1157–63

Structure of the C-terminal end of the nascent peptide influences translation termination. Björnsson A, et al. **EMBO J** 1996 Apr 1;15(7):1696–704

A nonribosomal system of peptide biosynthesis. Kleinkauf H, et al. **Eur J Biochem** 1996 Mar 1;236(2):335–51 (273 ref.)

Incorporation of major histocompatibility complex—encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Kuckelkorn U, et al. **Eur J Immunol** 1995 Sep;25(9):2605–11

A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Fuentes JJ, et al. **Hum Mol Genet** 1995 Oct;4(10):1935–44

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359–62 (20 ref.)

Trichorzins HA and MA, antibiotic peptides from Trichoderma harzianum. I. Fermentation, isolation and biological properties. Goulard C, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1248–53

Influence of specific signal peptide mutations on the expression and secretion of the alpha-amylase inhibitor tendamistat in Streptomyces lividans. Fass SH, et al. **J Biol Chem** 1996 Jun 21;271(25):15244–52

Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. Rouillé Y, et al. **J Biol Chem** 1995 Nov 3;270(44):26488–96

Regulation of protein abundance in pluripotent cells undergoing commitment to the neural lineage. Ray WJ, et al. **J Cell Physiol** 1996 Aug;168(2):264–75

PYY in developing murine islet cells: comparisons to development of islet hormones, NPY, and BrdU incorporation. Jackerott M, et al. **J Histochem Cytochem** 1996 Aug;44(8):809–17

The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. Bremers AJ, et al. **J Immunother Emphasis Tumor Immunol** 1995 Aug; 18(2):77–85

Synthesis of human globin polypeptides mediated by recombinant adeno-associated virus vectors. Ohi S, et al. **J Pharm Sci** 1996 Mar;85(3):274–81

Functional mapping of the translation-dependent instability element of yeast MATalpha1 mRNA. Hennigan AN, et al. **Mol Cell Biol** 1996 Jul;16(7):3833–43

Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Ikeda H, et al. **Nat Genet** 1996 Jun;13(2):196–202

Picture story. Self-made molecules. Felsenfeld AL. **Nat Struct Biol** 1996 Sep;3(9):762

Self-replication. Even peptides do it [news] Kauffman S. **Nature** 1996 Aug 8;382(6591):496–7

A self-replicating peptide. Lee DH, et al. **Nature** 1996 Aug 8;382(6591):525–8

Distribution, formation, and molecular forms of the peptide xenin in various mammals. Hamscher G, et al. **Peptides** 1995;16(5):791–7

Induction of wound response genes in tomato leaves by bestatin, an inhibitor of aminopeptidases. Schaller A, et al. **Plant Cell** 1995 Nov;7(11):1893–8

Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the alpha-mating type. Wickes BL, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7327–31

BLOOD

Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Glimelius B, et al. **Acta Oncol** 1996;35(2):141–8

Increased plasma adrenomedullin levels in chronic congestive heart failure. Kobayashi K, et al. **Am Heart J** 1996 May; 131(5):994–8

Increased plasma adrenomedullin in acute myocardial infarction. Kobayashi K, et al. **Am Heart J** 1996 Apr; 131(4):676–80

Plasma adrenomedullin in patients with primary aldosteronism. Kato K, et al. **Am J Hypertens** 1995 Oct; 8(10 Pt 1):997–1000

Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Rey RA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):958–65

Gut hormone release in patients after spinal cord injury. Saltzstein RJ, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct; 74(5):339–44

Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Pujol JL, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):725–33

Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Blijlevens NM, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2711–6

Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Bremer K, et al. **Anticancer Res** 1996 Mar–Apr;16(2):905–9

TPA prognostic value in superficial bladder cancer. Filella X, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2173–5

TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M, et al. **Anticancer Res** 1996 Mar–Apr;16(2):875–81

Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Schuurman JJ, et al. **Anticancer Res** 1996 Jul–Aug; 16(4B):2169–72

Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. van Dalen A. **Anticancer Res** 1996 Jul–Aug;16(4B):2345–9

Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer. van Poppel H, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2205–7

Purification of the 11- and 5-kDa antibacterial polypeptides from guinea pig neutrophils. Yomogida S, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):219–26

Identification of biologically active and inactive human uroguanylins in plasma and urine and their increases in renal insufficiency. Nakazato M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):586–93

Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Lubec B, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):159–62

CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Devine PL, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):245–51

Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry. Lotz J, et al. **Calcif Tissue Int** 1995 Oct;57(4):253–7

Changes in serum carboxyterminal telopeptide of type I collagen in an experimental model of canine osteomyelitis. Philipov JP, et al. **Calcif Tissue Int** 1995 Aug;57(2):152–4

Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN, et al. **Cancer** 1995 Sep 1;76(5):807–13

Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro. Kurachi H, et al. **Cancer** 1996 Sep 1;78(5):1049–54

Serum levels of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen (ICTP) and osteocalcin in rachitic children in Nigeria. Scariano JK, et al. **Clin Biochem** 1995 Oct;28(5):541–5

Tissue polypeptide specific antigen, neopterin, and CRP for monitoring heart transplant recipients. Vogl M, et al. **Clin Biochem** 1995 Jun;28(3):291–5

Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Sölétormos G, et al. **Clin Chem** 1996 Apr; 42(4):564–75

Serum concentrations of the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen in chronic liver disease. Hayasaka A, et al. **Clin Chim Acta** 1995 Jun 30;238(1):85–90

Increased serum concentrations of the carboxy-terminal-cross-linked telopeptide of collagen type I in patients with acute Plasmodium falciparum malaria. Wenisch C, et al. **Clin Immunol Immunopathol** 1996 Apr; 79(1):15–9

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer. van der Gaast A, et al. **Eur J Cancer** 1995 Oct;31A(11):1790–3

Circulating levels of immunoreactive parathyroid hormone-related protein and intact parathyroid hormone in human fetuses and newborns. Papantoniou NE, et al. **Eur J Endocrinol** 1996 Apr;134(4):437–42

Tissue polypeptide specific antigen (TPS) in breast cancer—an initial evaluation. O'Hanlon DM, et al. **Eur J Surg Oncol** 1996 Feb;22(1):38–41

Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Tamakoshi K, et al. **Gynecol Oncol** 1996 Jul;62(1):67–72

Plasma adrenomedullin concentrations in essential hypertension. Kohno M, et al. **Hypertension** 1996 Jan; 27(1):102–7

Growth-blocking peptide titer during larval development of parasitized and cold-stressed armyworm. Ohnishi A, et al. **Insect Biochem Mol Biol** 1995 Dec;25(10):1121–7

Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Giovanella L, et al. **Int J Biol Markers** 1995 Jul–Sep;10(3):156–60

Determination of tissue polypeptide-specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul–Sep; 10(3):161–5

Plasma adrenomedullin in various diseases and exercise-induced change in adrenomedullin in healthy subjects. Tanaka M, et al. **Intern Med** 1995 Aug; 34(8):728–33

Increased plasma levels of adrenomedullin in patients with heart failure. Nishikimi T, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1424–31

Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. Hirata Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1449–53

Plasma adrenomedullin concentration in patients with heart failure. Kato J, et al. **J Clin Endocrinol Metab** 1996 Jan; 81(1):180–3

Cardiac secretion of adrenomedullin in human heart failure. Jougasaki M, et al. **J Clin Invest** 1996 May 15;97(10):2370–6

Tissue polypeptide specific antigen for the detection of lymphoproliferative diseases induced by cyclosporin. Vogl M, et al. **J Clin Pathol** 1995 Nov;48(11):1039–44

Effect of subtotal pancreatectomy on the rate of liver regeneration: the role of hepatic stimulator substance. Kyprianidis KG, et al. **J Surg Res** 1996 May;62(2):267–72

Application of anti-bovine CD2 monoclonal antibody to the rosette inhibition test for detection of early pregnancy factor in cattle. Yoshioka K, et al. **J Vet Med Sci** 1995 Aug;57(4):721–5

Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K, et al. **Jpn J Cancer Res** 1995 Jul;86(7):698–705

Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):157–63

Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. Vesely DL, et al. **Life Sci** 1996;59(3):243–54

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status. Buccheri G, et al. **Lung Cancer** 1995 Oct;13(2):155–68

Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Kamata K, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1267–70

Diagnostic value of collagen type I C-terminal cross-linked telopeptide in CAPD patients [letter] Smalcelj R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1500

Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. 1983 [classical article] Clowes GH Jr, et al. **Nutrition** 1995 Nov–Dec;11(6):775; discussion 774; 776–7

Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Sonoo H, et al. **Surg Today** 1996;26(4):250–7

GLUT-3 (brain-type) glucose transporter polypeptides in human blood platelets. Craik JD, et al. **Thromb Res** 1995 Sep 15;79(5–6):461–9

[Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency] Sartorio A, et al. **Minerva Endocrinol** 1995 Jun;20(2):135–40 (Eng. Abstr.) **(Ita)**

[The role of TPS in the diagnosis of prostatic carcinoma] Panella P, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):167–70 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of TPA-assay kit using monoclonal antibodies] Saga T, et al. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):615–21 (Eng. Abstr.) **(Jpn)**

[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit] Sakahara H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):733–43 (Eng. Abstr.) **(Jpn)**

[Detection of bone metastasis by serial measurement of C-terminal telopeptide of type I collagen in patients with malignancy] Yamamoto I, et al. **Kaku Igaku** 1996 Apr; 33(4):423–9 (Eng. Abstr.) **(Jpn)**

[Role of tissue polypeptide antigen as a marker in bladder cancer] Menéndez V, et al. **Actas Urol Esp** 1995 Jun; 19(6):441–4 (Eng. Abstr.) **(Spa)**

CHEMICAL SYNTHESIS

Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease. Bianchi E, et al. **Anal Biochem** 1996 Jun 1;237(2):239–44

Deprotection of S-acetamidomethyl cysteine-containing peptides by silver trifluoromethanesulfonate avoids the oxidation of methionines. Hunter MJ, et al. **Anal Biochem** 1995 Jun 10;228(1):173–7

Thiazolidine formation as a general and site-specific conjugation method for synthetic peptides and proteins. Zhang L, et al. **Anal Biochem** 1996 Jan 1;233(1):87–93

Synthesis and biological studies on analogs of cyclolinopeptide A with a shortened peptide chain. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5–6):459–65

A superactive peptidomimetic analog of a farnesylated dodecapeptide yeast pheromone. Zhang YL, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):327–31

N-peptidyl, O-acyl hydroxamates: comparison of the selective inhibition of serine and cysteine proteinases. Demuth HU, et al. **Biochim Biophys Acta** 1996 Jul 18; 1295(2):179–86

A new radioligand for the epidermal growth factor receptor: 111In labeled human epidermal growth factor derivatized with a bifunctional metal-chelating peptide. Rémy S, et al. **Bioconjug Chem** 1995 Nov–Dec;6(6):683–90

Identification of GIYWHHY as a novel peptide substrate for human p60c-src protein tyrosine kinase. Lou Q, et al. **Bioorg Med Chem** 1996 May;4(5):677–82

Targeting peptide nucleic acid-protein conjugates to structural features within duplex DNA. Norton JC, et al. **Bioorg Med Chem** 1995 Apr;3(4):437–45

Urethane-protected alpha-amino acid N-carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)

Synthesis of carboxymethylpullulan–peptide–doxorubicin conjugates and their properties. Nogusa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1931–6

Application of a unique automated synthesis system for solution–phase peptide synthesis. Sugawara T, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1272–80

Amino acids and peptides. XL. Synthesis of Ac–Tyr–Val–Ala–Asp–MCA using newly developed acetylating reagent. Taguchi H, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1336–9

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853–8

Tailoring echistatin to possess higher affinity for integrin alpha(IIb)beta(3). Yamada T, et al. **FEBS Lett** 1996 May 27;387(1):11–15

Epitope mapping of monoclonal antibodies to tumor necrosis factor–alpha by synthetic peptide approach. Nagahira K, et al. **Immunol Lett** 1995 May;46(1–2):135–41

Synthetic peptides related to the delta-receptor agonist, dermorphin gene associated peptide. Sivanandaiah KM, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):196–9

Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Manning M, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):244–52

Peptides containing the sulfonamide transition–state isostere: synthesis and structure of N-acetyl–tauryl–L–proline methylamide. Moree WJ, et al. **Int J Pept Protein Res** 1995 Jun;45(6):501–7

Solid-phase synthesis of peptide haptens containing a cysteine–sulfur mustard adduct. Noort D, et al. **Int J Pept Protein Res** 1995 Jun;45(6):497–500

Design of 16-residue peptides possessing antimicrobial and hemolytic activities or only antimicrobial activity from an inactive peptide. Thennarasu S, et al. **Int J Pept Protein Res** 1995 Dec;46(6):480–6

Synthesis of peptide amides using Fmoc–based solid–phase procedures on 4–methylbenzhydrylamine resins. Thompson PE, et al. **Int J Pept Protein Res** 1995 Aug;46(2):174–80

Synthesis and characterization of indolicidin, a tryptophan–rich antimicrobial peptide from bovine neutrophils. van Abel RJ, et al. **Int J Pept Protein Res** 1995 May;45(5):401–9

Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP–19, neurogranin, and neuromodulin. Slemmon JR, et al. **J Biol Chem** 1996 Jul 5;271(27):15911–7

A strategy for the synthesis and screening of thiol–modified peptide variants recognized by T cells. Manning TC, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):125–32

Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. Azizeh BY, et al. **J Med Chem** 1996 Jun 21;39(13):2449–55

Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle–activated carbonyl group. Costanzo MJ, et al. **J Med Chem** 1996 Aug 2;39(16):3039–43

Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B, et al. **J Med Chem** 1996 Aug 2; 39(16):3114–22

Myelin P0 glycoprotein and a synthetic peptide containing the palmitoylation site are both autoacylated. Bharadwaj M, et al. **J Neurochem** 1995 Oct;65(4):1805–15

Preparations of psi–peptide bond and peptide–aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro–atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431–40

Multiple peptide synthesis. Fox JE. **Mol Biotechnol** 1995 Jun; 3(3):249–58 (20 ref.)

Synthetic peptides in biochemical research. Hancock DC, et al. **Mol Biotechnol** 1995 Aug;4(1):73–86 (104 ref.)

Synthesis and immunological characterization of 104–mer and 102–mer peptides corresponding to the N– and C–terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17–18):1301–9

Synthetic antimicrobial peptide design. Powell WA, et al. **Mol Plant Microbe Interact** 1995 Sep–Oct;8(5):792–4

Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)

Linear presentation of variable side–chain spacing in a highly diverse combinatorial library. Krchnák V, et al. **Pept Res** 1995 Jul–Aug;8(4):198–205

Receptor–specific activity of heteromeric thyrotropin (TSH) analogs: development of synthetic TSH antagonists. Sheehan MT, et al. **Pept Res** 1995 Sep–Oct;8(5):264–71

Synthesis of two peptide scorpion toxins and their use to investigate the aortic tissue regulation. Tóth GK, et al. **Peptides** 1995;16(7):1167–72

Design of experimental synthetic peptide immunogens for prevention of HIV–1 and HTLV–I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

Structure–activity analysis of thanatin, a 21–residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1221–5

Betidamino acids: versatile and constrained scaffolds for drug discovery. Rivier JE, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2031–6

Peptide synthesis using unprotected peptides through orthogonal coupling methods. Tam JP, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12485–9

Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Kirkley JE, et al. **Scand J Immunol** 1996 Apr; 43(4):431–8

Combinatorial peptide synthesis: statistical evaluation of peptide distribution. Boutin JA, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):8–12 (14 ref.)

Priming for virus–specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Babu JS, et al. **Vaccine** 1995 Dec;13(17):1669–76

[The automated "SynChrom" system for solid–phase synthesis of peptides and liquid column chromatography. II. Use in the solid–phase synthesis of peptides and liquid column chromatography] Baru MB, et al. **Bioorg Khim** 1995 Jul; 21(7):506–16 (Eng. Abstr.) **(Rus)**

[The automated "SynChrom" system for solid–phase synthesis of peptides and liquid column chromatography. I. Principles of design and structural constituents] Baru MB, et al. **Bioorg Khim** 1995 Jul;21(7):498–505 (Eng. Abstr.) **(Rus)**

[Synthesis of octadecyl esters of hydrophobic proline–containing peptides] Iskhakova FKh, et al. **Bioorg Khim** 1995 Jul;21(7):517–23 (Eng. Abstr.) **(Rus)**

[p–Sulfotetrafluorophenyl hydrophilic activated esters of amino acids in peptide synthesis] Medvedkin VN, et al. **Bioorg Khim** 1995 Sep;21(9):684–90 (Eng. Abstr.) **(Rus)**

CHEMISTRY

CD investigations on conformation of H–X–(Pro)n–Y–OH peptides (X = Trp, Tyr; Y = Tyr, Met); models for intramolecular long range electron transfer. Wierzchowski KL, et al. **Acta Biochim Pol** 1995;42(2):259–68

Quantification of hydrophobic insoluble peptide–protein interaction using peptide–resin adduct. Guimard L, et al. **Anal Biochem** 1996 Jun 15;238(1):100–3

Polypeptide amino acid composition and isoelectric point. II. Comparison between experiment and theory. Patrickios CS, et al. **Anal Biochem** 1995 Oct 10;231(1):82–91

Formation of N–substituted 2–iminothiolanes when amino groups in proteins and peptides are modified by 2–iminothiolane. Singh R, et al. **Anal Biochem** 1996 Apr 5;236(1):114–25

High–performance collision–induced dissociation of peptide ions formed by matrix–assisted laser desorption/ionization in a quadrupole ion trap mass spectrometer. Doroshenko VM, et al. **Anal Chem** 1995 Jul 1;67(13):2180–7

Native fluorescence detection and spectral differentiation of peptides containing tryptophan and tyrosine in capillary electrophoresis. Timperman AT, et al. **Anal Chem** 1995 Oct 1;67(19):3421–6

Correlation of kinetic energy losses in high–energy collision–induced dissociation with observed peptide product ions. Vachet RW, et al. **Anal Chem** 1996 Feb 1; 68(3):522–6

Cadmium, copper and zinc complexes of poly–L–cysteine. Autry HA, et al. **Analyst** 1995 Oct;120(10):2643–7

Modifications of XIP, the autoinhibitory region of the Na–Ca exchanger, alter its ability to inhibit the Na–Ca exchanger in bovine sarcolemmal vesicles. Gatto C, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:284–5

Use of cysteine replacements and chemical modification to alter XIP, the autoinhibitory region of the Na–Ca exchanger. Inhibition of the activated plasma membrane Ca pump. Xu WY, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:286–7

Middle molecules: toxicity and removal by hemodialysis and related strategies. Vanholder R, et al. **Artif Organs** 1995 Nov;19(11):1120–5 (46 ref.)

Structural analysis of a biologically active echistatin analogue des(46–49)–[Ala8,37]–echistatin gamma with three disulfide bonds by 2D–NMR and computer graphics. Chuang LC, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):246–54

Acylation of peptide hydroxyl groups with the Bolton–Hunter reagent. Miller BT. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):377–82

Alpha endosulfine is a novel molecule, structurally related to a family of phosphoproteins. Peyrollier K, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):583–6

The hemorrhagin catrocollastatin inhibits collagen–induced platelet aggregation by binding to collagen via its disintegrin–like domain. Zhou Q, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):720–6

Toxic peptides and genes encoding toxin gamma of the Brazilian scorpions Tityus bahiensis and Tityus stigmurus. Becerril B, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):753–60

Peptide models for membrane channels. Marsh D. **Biochem J** 1996 Apr 15;315 (Pt 2):345–61 (143 ref.)

Some fluorescent properties of non–enzymic transamination and measurement of the relative molecular mass of protein. He RQ, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):447–57

The formation and stability of imidazolidinone adducts from acetaldehyde and model peptides. A kinetic study with implications for protein modification in alcohol abuse. Fowles LF, et al. **Biochem Pharmacol** 1996 May 17; 51(10):1259–67

Simulation of voltage–dependent insertion of alpha–helical peptides into lipid bilayers. Biggin PC, et al. **Biochem Soc Trans** 1996 Feb;24(1):137S

Tandem mass spectrometric characterization of modified peptides and proteins. Bolgar MS, et al. **Biochem Soc Trans** 1995 Nov;23(4):907–10

Peptide sequencing by matrix–assisted laser desorption ionization/time–of–flight mass spectrometry. Cottrell JS. **Biochem Soc Trans** 1995 Nov;23(4):914–7

Characterizing biomolecules by electrospray ionization–mass spectrometry coupled to liquid chromatography and capillary electrophoresis. Hutton T, et al. **Biochem Soc Trans** 1995 Nov;23(4):924–7

A peptide molecular dynamics study correlates structure with function. McFerran NV, et al. **Biochem Soc Trans** 1996 Feb;24(1):127S

Membrane structure of voltage–gated channel forming peptides by site–directed spin–labeling. Barranger–Mathys M, et al. **Biochemistry** 1996 Jan 16;35(2):498–505

Controlling topology and native–like behavior of de novo–designed peptides: design and characterization of antiparallel four–stranded coiled coils. Betz SF, et al. **Biochemistry** 1996 May 28;35(21):6955–62

NMR spectroscopic evidence that helodermin, unlike other members of the secretin/VIP family of peptides, is substantially structured in water. Blankenfeldt W, et al. **Biochemistry** 1996 May 14;35(19):5955–62

The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz–type inhibitor structurally homologous to BPTI. Chang JY. **Biochemistry** 1996 Sep 10; 35(36):11702–9

Design of membrane–inserting peptides: spectroscopic characterization with and without lipid bilayers. Chung LA, et al. **Biochemistry** 1996 Sep 3;35(35):11343–54

Modeling unfolded states of peptides and proteins. Creamer TP, et al. **Biochemistry** 1995 Dec 19;34(50):16245–50

Design of heterotetrameric coiled coils: evidence for increased stabilization by Glu(–)–Lys(+) ion pair interactions. Fairman R, et al. **Biochemistry** 1996 Mar 5; 35(9):2824–9

Biochemical evidence that a D–loop is part of a four–stranded PNA–DNA bundle. Nickel–mediated cleavage of duplex DNA by a Gly–Gly–His bis–PNA. Footer M, et al. **Biochemistry** 1996 Aug 20;35(33):10673–9

Nature of the unfolded state of ribonuclease A: effect of cis–trans X–Pro peptide bond isomerization. Houry WA, et al. **Biochemistry** 1996 Sep 10;35(36):11719–33

Measuring the strength of side–chain hydrogen bonds in peptide helices: the Gln.Asp (i, i + 4) interaction. Huyghues–Despointes BM, et al. **Biochemistry** 1995 Oct 17;34(41):13267–71

Interaction of fusogenic synthetic peptide with phospholipid bilayers: orientation of the peptide alpha–helix and binding isotherm. Ishiguro R, et al. **Biochemistry** 1996 Apr 16; 35(15):4976–83

Characterization of SH2–ligand interactions via library affinity selection with mass spectrometric detection. Kelly MA, et al. **Biochemistry** 1996 Sep 10;35(36):11747–55

Importance of highly conserved anionic residues and electrostatic interactions in the activity and structure of the cardiotonic polypeptide anthopleurin B. Khera PK, et al. **Biochemistry** 1996 Mar 19;35(11):3503–7

Trimeric assembly and three–dimensional structure model of the FACIT collagen COL1–NC1 junction from CD and NMR analysis. Lesage A, et al. **Biochemistry** 1996 Jul 30; 35(30):9647–60

Direct NMR measurement of folding kinetics of a trimeric peptide. Liu X, et al. **Biochemistry** 1996 Apr 9;

35(14):4306–13
The peptide backbone plays a dominant role in protein stabilization by naturally occurring osmolytes. Liu Y, et al. **Biochemistry** 1995 Oct 3;34(39):12884–91
Release of lipid vesicle contents by an antibacterial cecropin A–melittin hybrid peptide. Mancheño JM, et al. **Biochemistry** 1996 Jul 30;35(30):9892–9
Movement of the position of the transition state in protein folding. Matouschek A, et al. **Biochemistry** 1995 Oct 17; 34(41):13656–62
Analysis of i,i+5 and i,i+8 hydrophobic interactions in a helical model peptide bearing the hydrophobic staple motif. Muñoz V, et al. **Biochemistry** 1995 Nov 21;34(46):15301–6
A designed heterotrimeric coiled coil. Nautiyal S, et al. **Biochemistry** 1995 Sep 19;34(37):11645–51
Structural factors contributing to the hydrophobic effect: the partly exposed hydrophobic minicore in chymotrypsin inhibitor 2. Otzen DE, et al. **Biochemistry** 1995 Oct 10; 34(40):13051–8
Factors that affect the stabilization of alpha-helices in short peptides by a capping box. Petukhov M, et al. **Biochemistry** 1996 Jan 16;35(2):387–97
Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin. Rehse PH, et al. **Biochemistry** 1995 Sep 12;34(36):11537–44
Structure effects of double D-amino acid replacements: a nuclear magnetic resonance and circular dichroism study using amphipathic model helices. Rothemund S, et al. **Biochemistry** 1995 Oct 10;34(40):12954–62
Simulations of chaperone-assisted folding. Sfatos CD, et al. **Biochemistry** 1996 Jan 9;35(1):334–9
A host–guest set of triple-helical peptides: stability of Gly–X–Y triplets containing common nonpolar residues. Shah NK, et al. **Biochemistry** 1996 Aug 13;35(32):10262–8
Guanidine hydrochloride unfolding of peptide helices: separation of denaturant and salt effects. Smith JS, et al. **Biochemistry** 1996 Jun 4;35(22):7292–7
Conformational and functional study of magainin 2 in model membrane environments using the new approach of systematic double-D-amino acid replacement. Wieprecht T, et al. **Biochemistry** 1996 Aug 20;35(33):10844–53
Fast events in protein folding: helix melting and formation in a small peptide. Williams S, et al. **Biochemistry** 1996 Jan 23;35(3):691–7
Conformation of Vespa basalis mastoparan-B in trifluoroethanol-containing aqueous solution. Chuang CC, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):1–8
Band-shifting through polypeptide beta-sheet structures in the cyanine UV–Vis spectrum. Hermel H, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):79–86
Synthesis of alpha-helix-forming peptides by gene engineering methods and their characterization by circular dichroism spectra measurements. Kojima S, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):129–37
Proton NMR study of peptides from myelin basic protein: evidence for Lys74–His77 interaction revealed from histidine line broadening. Koshy KM, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):23–30
The removal of 2-oxoacyl residues from the N-terminus of peptides and cystatin in non-denaturing conditions. Stevens J, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):195–202
Antigenicity of topochemically related peptides. Verdoliva A, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):57–62
Improved method for converting an unmodified peptide to an energy-transfer substrate for a proteinase. Geoghegan KF. **Bioconjug Chem** 1996 May–Jun;7(3):385–91
In vitro fibril formation from alpha 1-antitrypsin-derived C-terminal peptides. Janciauskiene S, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):415–23
Development of simple fitness landscapes for peptides by artificial neural filter systems. Schneider G, et al. **Biol Cybern** 1995 Aug;73(3):245–54
New bioactivation mode for vascular prostheses made of Dacron polyester. Bonzon N, et al. **Biomaterials** 1995 Jul; 16(10):747–51
Cytarabine release from alpha, beta-poly (N-hydroxyethyl)-DL-aspartamide matrices cross-linked through gamma-radiation. Spadaro G, et al. **Biomaterials** 1996 May;17(10):953–8
Molecular diversity of peptidomimetics: approaches to the solid-phase synthesis of peptidosulfonamides. de Bont DB, et al. **Bioorg Med Chem** 1996 May;4(5):667–72
Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5–23 (66 ref.)
A comparison of the properties of the binary and ternary complexes formed by calmodulin and troponin C with two regulatory peptides of phosphorylase kinase. Steiner RF, et al. **Biophys Chem** 1996 Apr 16;59(3):277–88
Investigation of electrostatic interactions in two-stranded coiled-coils through residue shuffling. Yu Y, et al. **Biophys Chem** 1996 Apr 16;59(3):299–314
Peptide binding domains determined through chemical modification of the side-chain functional groups. Blondelle SE, et al. **Biophys J** 1995 Aug;69(2):604–11
Trans-membrane peptide and protein structures in fluid membranes via NMR. Bloom M. **Biophys J** 1995 Nov; 69(5):1631–2
In situ study by polarization modulated Fourier transform infrared spectroscopy of the structure and orientation of lipids and amphipathic peptides at the air–water interface. Cornut I, et al. **Biophys J** 1996 Jan;70(1):305–12
High resolution 1H nuclear magnetic resonance of a transmembrane peptide. Davis JH, et al. **Biophys J** 1995 Nov;69(5):1917–32
Modeling of polypeptide chains as C alpha chains, C alpha chains with C beta, and C alpha chains with ellipsoidal lateral chains. Fogolari F, et al. **Biophys J** 1996 Mar; 70(3):1183–97
Vibrational neutron spectroscopy of collagen and model polypeptides. Middendorf HD, et al. **Biophys J** 1995 Aug; 69(2):660–73
New tubular single-stranded helix of poly-L-amino acids suggested by molecular mechanics calculations: I. Homopolypeptides in isolated environments. Monoi H. **Biophys J** 1995 Sep;69(3):1130–41
A genetic algorithm that seeks native states of peptides and proteins. Sun S. **Biophys J** 1995 Aug;69(2):340–55
Proceedings of the 4th Naples Workshop on Bioactive Peptides. Capri, Italy, May 22–25, 1994. **Biopolymers** 1995 Oct;36(4):399–558
Ambidextrous molecules: cylindrical peptide structures formed by fusing left- and right-handed helices. Banerjee A, et al. **Biopolymers** 1996 Sep;39(3):279–85
X-ray crystallography of peptides: the contributions of the Italian laboratories. Benedetti E. **Biopolymers** 1996; 40(1):3–44 (273 ref.)
Influence of proline-14 substitution on the secondary structure in a synthetic analogue of alamethicin. Brachais L, et al. **Biopolymers** 1995 Oct;36(4):547–58
Design and characterization of a model alpha beta peptide. Butcher DJ, et al. **Biopolymers** 1995 Aug;36(2):109–20
Influence of sample pH on the conformational backbone dynamics of a pseudotripeptide (H-Tyr-Tic psi [CH2–NH]Phe–OH) incorporating a reduced peptide bond: an NMR investigation. Carpenter KA, et al. **Biopolymers** 1995 Dec;36(6):735–49
Conformation of parathyroid hormone antagonists by CD, NMR, and molecular dynamics simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):485–95
Conformation and interactions of bombolitin I analogues with SDS micelles and phospholipid vesicles: CD, fluorescence, two-dimensional NMR and computer simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):473–84
Exploring the peptide 3(10)–helix<—>alpha–helix equilibrium with double label electron spin resonance. Fiori WR, et al. **Biopolymers** 1995;37(6):421
Conformational characteristics of peptides containing alpha, beta–dehydroamino acid residues. Jain R, et al. **Biopolymers** 1996;40(1):105–19 (80 ref.)
Flexibility in peptide molecules and restraints imposed by hydrogen bonds, the Aib residue, and core inserts. Karle IL. **Biopolymers** 1996;40(1):157–80 (84 ref.)
Hexane-soluble octadecadepsipeptide forming hydrophobic alpha-helical rod end-capped by the C-terminal gamma-turn. Katakai R, et al. **Biopolymers** 1996 Feb; 38(2):285–90
Oxidative folding of omega-conotoxin MVIIC: effects of temperature and salt. Kubo S, et al. **Biopolymers** 1996 Jun; 38(6):733–44
Threshold hydrophobicity dictates helical conformations of peptides in membrane environments. Liu LP, et al. **Biopolymers** 1996 Sep;39(3):465–70
Predicted and trifluoroethanol-induced alpha-helicity of polypeptides. Luidens MK, et al. **Biopolymers** 1996 Sep; 39(3):367–76
Crystal structures of peptides and modified peptides. Marraud M, et al. **Biopolymers** 1996;40(1):45–83 (275 ref.)
Conformational study of linear alternating and mixed D- and L-proline oligomers using electronic and vibrational CD and Fourier transform IR. Mästle W, et al. **Biopolymers** 1995 Nov;36(5):623–31
Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. Miller C, et al. **Biopolymers** 1996;40(3):265–317 (124 ref.)
Peptides and peptoids—a quantum chemical structure comparison. Moehle K, et al. **Biopolymers** 1996 Jun; 38(6):781–90
Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)
Incorporation of diacids into the polyglycine II structure: model studies. Navarro E, et al. **Biopolymers** 1995 Dec; 36(6):711–22
Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin. Ni F, et al. **Biopolymers** 1996 Jan; 38(1):31–41
Recent structural studies of peptides in Japan. Okuyama K, et al. **Biopolymers** 1996;40(1):85–103 (28 ref.)
Solution structure of dehydropeptides: a CD investigation. Pieroni O, et al. **Biopolymers** 1996 Jan;38(1):97–108
A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Sako D, et al. **Cell** 1995 Oct 20;83(2):323–31
Highly selective cleavage of pyroglutamyl-peptide bond in concentrated hydrochloric acid. Hashimoto T, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):877–9
A computer program to aid the sequencing of peptides in collision-activated decomposition experiments. Fernández-de-Cossío J, et al. **Comput Appl Biosci** 1995 Aug;11(4):427–34
Developments in matrix-assisted laser desorption/ionization peptide mass spectrometry. Mann M, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):11–9 (74 ref.)
Immunosuppressive peptides corresponding to MHC class I sequences. Clayberger C, et al. **Curr Opin Immunol** 1995 Oct;7(5):644–8 (34 ref.)
Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Lomonossoff GP, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):176–82 (66 ref.)
Endosulfine, endogenous ligand for the sulphonylurea receptor: isolation from porcine brain and partial structural determination of the alpha form. Virsolvy–Vergine A, et al. **Diabetologia** 1996 Feb;39(2):135–41
'Peptoid' design. Horwell DC, et al. **Drug Des Discov** 1994 Jul;12(1):63–75 (35 ref.)
Effect of pH and ionic strength of running buffer on peptide behavior in capillary electrophoresis: theoretical calculation and experimental evaluation. Cifuentes A, et al. **Electrophoresis** 1995 Apr;16(4):516–24
Fluorescence-labeled peptides as isoelectric point (pI) markers in capillary isoelectric focusing with fluorescence detection. Shimura K, et al. **Electrophoresis** 1995 Aug; 16(8):1479–84
1H-NMR-derived secondary structure and the overall fold of the potent anti-mammal and anti-insect toxin III from the scorpion Leiurus quinquestriatus quinquestriatus. Landon C, et al. **Eur J Biochem** 1996 Mar 1;236(2):395–404
NMR-based structural studies of the pNR-2/pS2 single domain trefoil peptide. Similarities to porcine spasmolytic peptide and evidence for a monomeric structure. Polshakov VI, et al. **Eur J Biochem** 1995 Nov 1;233(3):847–55
Translocation of long peptides by transporters associated with antigen processing (TAP). Koopmann JO, et al. **Eur J Immunol** 1996 Aug;26(8):1720–8
Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Stryhn A, et al. **Eur J Immunol** 1996 Aug;26(8):1911–8
Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Appella E, et al. **EXS** 1995;73:105–19 (190 ref.)
Chemical techniques employed for the primary structural analysis of proteins and peptides. Inglis AS, et al. **EXS** 1995;73:141–71 (73 ref.)
Infrared evidence of a beta-hairpin peptide structure in solution. Arrondo JL, et al. **FEBS Lett** 1996 Apr 8; 384(1):35–7
Alcoholytic deblocking of N-terminally acetylated peptides and proteins for sequence analysis. Bergman T, et al. **FEBS Lett** 1996 Jul 22;390(2):199–202
N-(2-ferrocene-ethyl)maleimide: a new electroactive sulphydryl-specific reagent for cysteine-containing peptides and proteins. Di Gleria K, et al. **FEBS Lett** 1996 Jul 22;390(2):142–4
The 21-residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane alpha-helix with a mixed nonpolar/polar surface. Gustafsson M, et al. **FEBS Lett** 1996 Apr 15; 384(2):185–8
Structural requirements for alpha-mating factor activity. Houen G, et al. **FEBS Lett** 1996 Aug 5;391(1–2):162–6
Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. McLane MA, et al. **FEBS Lett** 1996 Aug 5;391(1–2):139–43
Unusually stable helical kink in the antimicrobial peptide—a derivative of gaegurin. Suh JY, et al. **FEBS Lett** 1996 Sep 2;392(3):309–12
15N labeling method of peptides using a thioredoxin gene fusion expression system: an application to ACTH-(1–24). Uegaki K, et al. **FEBS Lett** 1996 Jan 22;379(1):47–50
A recombinant polypeptide, composed of the alpha-helical neck region and the carbohydrate recognition domain of conglutinin, self-associates to give a functionally intact homotrimer. Wang JY, et al. **FEBS Lett** 1995 Nov 27; 376(1–2):6–10
Novel disulfide-constrained pentapeptides as models for beta-VIa turns in proteins. Weisshoff H, et al. **FEBS Lett** 1995 Sep 25;372(2–3):203–9
Structural identification of valine hydroperoxides and hydroxides on radical-damaged amino acid, peptide, and protein molecules. Fu S, et al. **Free Radic Biol Med** 1995 Sep;19(3):281–92
Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Smith KJ, et al. **Immunity** 1996 Mar; 4(3):215–28
Polysaccharide–peptide complexes from the cultured mycelia of the mushroom Coriolus versicolor and their culture medium activate mouse lymphocytes and macrophages. Wang HX, et al. **Int J Biochem Cell Biol** 1996 May; 28(5):601–7
Conformation and interactions of all-D-, retro-all-D- and retro-bombolitin III analogues in aqueous solution and in the presence of detergent micelles. Bisello A, et al. **Int J Biol Macromol** 1995 Oct;17(5):273–82
Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases. Basak A, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):228–37
Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic

acid at position 2. Capasso S, et al. **Int J Pept Protein Res** 1995 Jun;45(6):567–73

Determination of disulfide bridge pattern in omega-conopeptides. Chung D, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):320–5

1H and 13C NMR assignments and molecular modelling of a minor groove DNA-binding peptide from the HMG-I protein. Evans JN, et al. **Int J Pept Protein Res** 1995 Jun; 45(6):554–60

Polymethylene spacer linked bis(Ala) peptides form modified beta-sheet structures. Crystal structure and self-assembly pattern of adipoyl and suberoyl analogues. Karle IL, et al. **Int J Pept Protein Res** 1995 Jul;46(1):24–9

Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Lam KS, et al. **Int J Pept Protein Res** 1995 Jun; 45(6):587–92

Influence of serine in position i on conformation and dynamics of reverse turns. Matter H, et al. **Int J Pept Protein Res** 1995 May;45(5):430–40

D-enantiomers of 15-residue cecropin A-melittin hybrids. Merrifield EL, et al. **Int J Pept Protein Res** 1995 Sep–Oct; 46(3–4):214–20

Determination of the ratios of the aromatic amino acid residues by first- or second-derivative UV spectrometry for a simple characterization of peptides. Miclo L, et al. **Int J Pept Protein Res** 1995 Aug;46(2):186–92

Crystal and molecular structure of Boc-Phe-Val-OMe; comparison of the peptide conformation with its dehydro analogue. Rajashankar KR, et al. **Int J Pept Protein Res** 1995 Dec;46(6):487–93

Studies on conformational consequences of i to i + 3 side-chain cyclization in model cyclic tetrapeptides. Rao MH, et al. **Int J Pept Protein Res** 1995 May;45(5):418–29

NMR studies on the structure of some cyclic and linear antagonists of luteinizing hormone-releasing hormone (LHRH). Reddy DV, et al. **Int J Pept Protein Res** 1995 Jul;46(1):9–17

Linear and cyclic synthetic peptides related to the main autophosphorylation site of the Src tyrosine kinases as substrates and inhibitors of Lyn. Ruzza P, et al. **Int J Pept Protein Res** 1995 Jun;45(6):529–39

Trichorzins HA and MA, antibiotic peptides from Trichoderma harzianum. II. Sequence determination. Hlimi S, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1254–61

Dimerization of A82846B, vancomycin and ristocetin: influence on antibiotic complexation with cell wall model peptides. Linsdell H, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):181–93

Structural studies of a peptide activator of human lecithin–cholesterol acyltransferase. Buchko GW, et al. **J Biol Chem** 1996 Feb 9;271(6):3039–45

Structure of Saccharomyces cerevisiae alpha-agglutinin. Evidence for a yeast cell wall protein with multiple immunoglobulin-like domains with atypical disulfides. Chen MH, et al. **J Biol Chem** 1995 Nov 3;270(44):26168–77

Moricin, a novel type of antibacterial peptide isolated from the silkworm, Bombyx mori. Hara S, et al. **J Biol Chem** 1995 Dec 15;270(50):29923–7

Novel O-methylated terminal glucuronic acid characterizes the polar glycopeptidolipids of Mycobacterium habana strain TMC 5135. Khoo KH, et al. **J Biol Chem** 1996 May 24;271(21):12333–42

The effects of interhelical electrostatic repulsions between glutamic acid residues in controlling the dimerization and stability of two-stranded alpha-helical coiled-coils. Kohn WD, et al. **J Biol Chem** 1995 Oct 27;270(43):25495–506

Expression and characterization of recombinant caveolin. Purification by polyhistidine tagging and cholesterol-dependent incorporation into defined lipid membranes. Li S, et al. **J Biol Chem** 1996 Jan 5; 271(1):568–73

Formation of parallel and antiparallel coiled-coils controlled by the relative positions of alanine residues in the hydrophobic core. Monera OD, et al. **J Biol Chem** 1996 Feb 23;271(8):3995–4001

Functionalized protein-like structures from conformationally defined synthetic combinatorial libraries. Pérez-Payá E, et al. **J Biol Chem** 1996 Feb 23;271(8):4120–6

Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides. Shai Y, et al. **J Biol Chem** 1996 Mar 29;271(13):7305–8

Resonance assignments for Oncostatin M, a 24-kDa alpha-helical protein. Hoffman RC, et al. **J Biomol NMR** 1996 Jun;7(4):273–82

Measurement of intrinsic exchange rates of amide protons in a 15N-labeled peptide. Koide S, et al. **J Biomol NMR** 1995 Nov;6(3):306–12

Local helix content in an alanine-rich peptide as determined by the complete set of 3JHN alpha coupling constants. Millhauser GL, et al. **J Biomol NMR** 1996 Jun;7(4):331–4

Three-dimensional solid-state NMR spectroscopy of a peptide oriented in membrane bilayers. Ramamoorthy A, et al. **J Biomol NMR** 1995 Nov;6(3):329–34

Toward an exhaustive sampling of the configurational spaces of the two forms of the peptide hormone guanylin. de Groot BL, et al. **J Biomol Struct Dyn** 1996 Apr; 13(5):741–51

Calculations of the phi–psi conformational contour maps for N-acetyl alanine N'-methyl amide and of the characteristic ratios of poly-L-alanine using various molecular mechanics forcefields. Lee CH, et al. **J Biomol Struct Dyn** 1995 Oct; 13(2):201–18

Effect of mobile phase additives on peptide retention in reversed-phase chromatography with pellicular and totally porous sorbents. Corradini D, et al. **J Chromatogr A** 1996 Mar 29;728(1–2):225–33

Quantitative micellar chromatographic analysis of interaction between peptides and sodium dodecyl sulfate micelles. Lu L, et al. **J Chromatogr A** 1996 Aug 9;741(1):49–57

Self-consistent framework for standardising mobilities in free solution capillary electrophoresis: applications to oligoglycines and oligoalanines. Survay MA, et al. **J Chromatogr A** 1996 Aug 9;741(1):99–113

PRO—LIGAND: an approach to de novo molecular design. 4. Application to the design of peptides. Frenkel D, et al. **J Comput Aided Mol Des** 1995 Jun;9(3):213–25

PRO—LIGAND: an approach to de novo molecular design. 6. Flexible fitting in the design of peptides. Murray CW, et al. **J Comput Aided Mol Des** 1995 Oct;9(5):381–95

Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions. Sompuram SR, et al. **J Immunol** 1996 Feb 1;156(3):1071–81

Monomeric ferric heme peptide derivatives: model systems for hemoproteins. Carraway AD, et al. **J Inorg Biochem** 1995 Dec;60(4):267–76

Simple, distortion-free homonuclear spectra of peptides and nucleic acids in water using excitation sculpting. Callihan D, et al. **J Magn Reson B** 1996 Jul;112(1):82–5

Cross-correlation effects on NMR lineshapes and peptide conformation. Cuperlović M, et al. **J Magn Reson B** 1996 Jan;110(1):26–38

Amino-acid-type identification for deuterated proteins with a beta-carbon-edited HNCOCACB experiment. Dötsch V, et al. **J Magn Reson B** 1996 Jul;112(1):95–100

4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. Burke TR Jr, et al. **J Med Chem** 1996 Mar 1; 39(5):1021–7

Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. Kotretsou S, et al. **J Med Chem** 1995 Nov 10; 38(23):4710–9

Peptide aldehyde complexes with wheat serine carboxypeptidase II: implications for the catalytic mechanism and substrate specificity. Bullock TL, et al. **J Mol Biol** 1996 Feb 9;255(5):714–25

Structure of the transition state for folding of a protein derived from experiment and simulation. Daggett V, et al. **J Mol Biol** 1996 Mar 29;257(2):430–40

Conformational pathway of the polypeptide chain of chymotrypsin inhibitor-2 growing from its N terminus in vitro. Parallels with the protein folding pathway. de Prat Gay G, et al. **J Mol Biol** 1995 Dec 15;254(5):968–79

Comparison of the (30–51, 14–38) two-disulphide folding intermediates of the homologous proteins dendrotoxin K and bovine pancreatic trypsin inhibitor by two-dimensional 1H nuclear magnetic resonance. Kortemme T, et al. **J Mol Biol** 1996 Mar 22;257(1):188–98

Identification and characterization of the unfolding transition state of chymotrypsin inhibitor 2 by molecular dynamics simulations. Li A, et al. **J Mol Biol** 1996 Mar 29; 257(2):412–29

Carbohydrate and protein-based inhibitors of porcine pancreatic alpha-amylase: structure analysis and comparison of their binding characteristics. Machius M, et al. **J Mol Biol** 1996 Jul 19;260(3):409–21

Native-like beta-structure in a trifluoroethanol-induced partially folded state of the all-beta-sheet protein tendamistat. Schönbrunner N, et al. **J Mol Biol** 1996 Jul 19;260(3):432–45

Perturbed pKA-values in the denatured states of proteins. Tan YJ, et al. **J Mol Biol** 1995 Dec 15;254(5):980–92

TcR recognition of the MHC-peptide dimer: structural properties of a ternary complex. Vasmatzis G, et al. **J Mol Biol** 1996 Aug 9;261(1):72–89

Mechanism of protein stabilization by disulfide bridges: calorimetric unfolding studies on disulfide-deficient mutants of the alpha-amylase inhibitor tendamistat. Vogl T, et al. **J Mol Biol** 1995 Dec 1;254(3):481–96

A microscopic view of helix propagation: N and C-terminal helix growth in alanine helices. Young WS, et al. **J Mol Biol** 1996 Jun 14;259(3):560–72

Ion pairs significantly stabilize coiled-coils in the absence of electrolyte. Yu Y, et al. **J Mol Biol** 1996 Jan 26; 255(3):367–72

Methionine-containing peptides can be used as methionine sources for protein accretion in cultured C2C12 and MAC-T cells. Pan Y, et al. **J Nutr** 1996 Jan;126(1):232–41

Mechanism of the activation of proteinase inhibitor synthesis by systemin involves beta-sheet structure, a specific DNA-binding protein domain. Slósarek G, et al. **J Struct Biol** 1995 Jul–Aug;115(1):30–6

Analysis of naturally processed human histocompatibility leukocyte antigen class I-bound peptides from hepatocellular carcinoma tissues in vivo. Kobayashi H, et al. **Jpn J Cancer Res** 1995 Oct;86(10):962–8

Human T cell responses to autoantibody variable region peptides. Williams WM, et al. **Lupus** 1995 Dec;4(6):464–71

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537–60 (41 ref.)

Thermodynamic parameters from hydrogen exchange measurements. Bai Y, et al. **Methods Enzymol** 1995; 259:344–56

Simple force field for study of peptide and protein conformational properties. Creamer TP, et al. **Methods Enzymol** 1995;259:576–89

Identification of a ligand-binding site in an immunoglobulin fold domain of the Saccharomyces cerevisiae adhesion protein alpha-agglutinin. de Nobel H, et al. **Mol Biol Cell** 1996 Jan;7(1):143–53

Dependence of the murine antibody response to an anti-CDR2 VH peptide on immunogen formulation. Kanda P, et al. **Mol Immunol** 1995 Dec;32(17–18):1319–28

Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Maillère B, et al. **Mol Immunol** 1995 Dec;32(17–18):1377–85

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17–18):1301–9

Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Gehlert DR, et al. **Mol Pharmacol** 1996 Jul;50(1):112–8

De novo design and structural analysis of a model beta-hairpin peptide system. Ramírez-Alvarado M, et al. **Nat Struct Biol** 1996 Jul;3(7):604–12

Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Macias MJ, et al. **Nature** 1996 Aug 15;382(6592):646–9

MHCPEP--a database of MHC-binding peptides: update 1995. Brusic V, et al. **Nucleic Acids Res** 1996 Jan 1; 24(1):242–4

Hybridization properties of oligodeoxynucleotide pairs bridged by polyarginine peptides. Wei Z, et al. **Nucleic Acids Res** 1996 Feb 15;24(4):655–61

Stability and stabilization of insulinotropin in a dextran formulation. Qi H, et al. **PDA J Pharm Sci Technol** 1995 Nov-Dec;49(6):289–93

Modification of the carboxyl terminal group affects replacement set analysis of a cytotoxic T cell epitope. Suhrbier A, et al. **Pept Res** 1995 Sep–Oct;8(5):258–62

Rat corticostatin R4: synthesis, disulfide bridge assignment, and in vivo activity. Cervini LA, et al. **Peptides** 1995; 16(5):837–42

Distribution, formation, and molecular forms of the peptide xenin in various mammals. Hamscher G, et al. **Peptides** 1995;16(5):791–7

Structural and biosynthetic properties of peptides in cone snail venoms. Newcomb R, et al. **Peptides** 1995; 16(6):1007–17

Inhibition of pulmonary surfactant biophysical activity by cationic polyamino acids. Bummer PM, et al. **Pharm Res** 1995 Nov;12(11):1658–63

The application of crystal soaking technique to study the effect of zinc and cresol on insulinotropin crystals grown from a saline solution. Kim Y, et al. **Pharm Res** 1995 Nov; 12(11):1664–70

The electrophoretic mobility of tripeptides as a function of pH and ionic strength: comparison with iontophoretic flux data. VanOrman Huff B, et al. **Pharm Res** 1995 May; 12(5):751–5

How the first biopolymers could have evolved. Abkevich VI, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23; 93(2):839–44

Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Blanke SR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8437–42

Role of hydrophobic interactions and desolvation in determining the structural properties of a model alpha beta peptide. Butcher DJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1135–40

Molecular organization of histidine-tagged biomolecules at self-assembled lipid interfaces using a novel class of chelator lipids. Dietrich C, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9014–8

The folding mechanism of larger model proteins: role of native structure. Dinner AR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8356–61

Structure–activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1221–5

Optimization of rates of protein folding: the nucleation–condensation mechanism and its implications. Fersht AR. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):10869–73

Template-nucleated alanine-lysine helices are stabilized by position-dependent interactions between the lysine side chain and the helix barrel. Groebke K, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4025–9

Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Jardetzky TS, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):734–8

A designed beta-hairpin peptide in crystals. Karle IL, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8189–93

A structural motif for the voltage-gated potassium channel pore. Lipkind GM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9215–9

Photochemical energy conversion in a helical oligoproline

assembly. McCafferty DG, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8200–4

Interresidue hydrogen bonding in a peptide nucleic acid.RNA heteroduplex. Torres RA, et al.
Proc Natl Acad Sci U S A 1996 Jan 23;93(2):649–53

Enzyme–mediated spatial segregation on individual polymeric support beads: application to generation and screening of encoded combinatorial libraries. Vágner J, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8194–9

High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Yanofsky SD, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7381–6

The relative positions of alanine residues in the hydrophobic core control the formation of two–stranded or four–stranded alpha–helical coiled–coils. Monera OD, et al. **Protein Eng** 1996 Apr;9(4):353–63

The coming of age of mass spectrometry in peptide and protein chemistry. Biemann K. **Protein Sci** 1995 Sep; 4(9):1920–7

Prediction of polyelectrolyte polypeptide structures using Monte Carlo conformational search methods with implicit solvation modeling. Evans JS, et al. **Protein Sci** 1995 Oct; 4(10):2019–31

De novo prediction of polypeptide conformations using dihedral probability grid Monte Carlo methodology. Evans JS, et al. **Protein Sci** 1995 Jun;4(6):1203–16

Structural analysis of the N– and C–termini in a peptide with consensus sequence. Gong Y, et al. **Protein Sci** 1995 Aug; 4(8):1446–56

Homology modeling of an immunoglobulin–like domain in the Saccharomyces cerevisiae adhesion protein alpha–agglutinin. Lipke PN, et al. **Protein Sci** 1995 Oct; 4(10):2168–78

Incorporation of pairwise interactions into the Lifson–Roig model for helix prediction. Shalongo W, et al.
Protein Sci 1995 Jun;4(6):1161–6

Solution structure of P01, a natural scorpion peptide structurally analogous to scorpion toxins specific for apamin–sensitive potassium channel. Blanc E, et al.
Proteins 1996 Mar;24(3):359–69

Long timestep dynamics of peptides by the dynamics driver approach. Derreumaux P, et al. **Proteins** 1995 Apr; 21(4):282–302

Error–tolerant protein database searching using peptide product–ion spectra. Bonner R, et al.
Rapid Commun Mass Spectrom 1995;9(11):1077–80

Isolation and characterization of conopeptides by high–performance liquid chromatography combined with mass spectrometry and tandem mass spectrometry. Jones A, et al. **Rapid Commun Mass Spectrom** 1996;10(1):138–43

Collision–induced dissociation of multiply charged peptides in an ion–trap storage/reflectron time–of–flight mass spectrometer. Qian MG, et al.
Rapid Commun Mass Spectrom 1995;9(13):1275–82

Design of a monomeric 23–residue polypeptide with defined tertiary structure. Struthers MD, et al. **Science** 1996 Jan 19;271(5247):342–5

Solution structure of the cardiostimulant polypeptide anthopleurin–B and comparison with anthopleurin–A [published erratum appears in Structure 1995 Oct 15;3(10):1126] Monks SA, et al. **Structure** 1995 Aug 15; 3(8):791–803

Do we know the complete sequence of metalloproteinase and nonenzymatic platelet aggregation inhibitor (disintegrin) precursor proteins? Kini RM. **Toxicon** 1995 Sep;33(9):1151–60

Structure elucidation of azotobactin 87, isolated from Azotobacter vinelandii ATCC 12837. Schaffner EM, et al. **Z Naturforsch [C]** 1996 Mar–Apr;51(3–4):139–50

[Site–directed mutagenesis of the gene of Echistatin Leu14–Lys15–Glu16] Li H, et al. **I Chuan Hsueh Pao** 1996; 23(2):163–8 (Eng. Abstr.) **(Chi)**

[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar–Apr;40(2):260–73 (50 ref.) (Eng. Abstr.) **(Rus)**

[A specific complex between a polypeptide in the left helical conformation of polyproline type II and the B–DNA minor groove (letter)] Tumanian VG, et al. **Biofizika** 1996 Jan–Feb;41(1):246–8 (Eng. Abstr.) **(Rus)**

[Identification of immunoreactive epitopes in proteins coded by gag, env, and pol genes of the type I human T–lymphotropic virus (HTLV–I) using synthetic peptides] Iaroslavtseva NG, et al. **Bioorg Khim** 1995 Oct; 21(10):752–60 (Eng. Abstr.) **(Rus)**

[Preparation and properties of hybrid RNAase S', formed by S–protein and S–S–bound conjugates of (Nle–13,Cys–20)S–peptide with 3'–thiopropyl derivatives d(T)15] Senchenko VN, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):681–91 **(Rus)**

GENETICS

PRB1, PRB2, and PRB4 coded polymorphisms among human salivary concanavalin–A binding, II–1, and Po proline–rich proteins. Azen EA, et al.
Am J Hum Genet 1996 Jan;58(1):143–53

On the statistical distribution of amino acid residue in randomly synthesized peptides. De O Cavalcanti AR, et al. **An Acad Bras Cienc** 1995;67(4):401–2

Combinatorial peptide libraries: robotic synthesis and analysis by nuclear magnetic resonance, mass spectrometry, tandem mass spectrometry, and high–performance capillary electrophoresis techniques. Boutin JA, et al.
Anal Biochem 1996 Feb 15;234(2):126–41

Molecular cloning of the precursors of pigment dispersing hormone in crustaceans. Desmoucelles–Carette C, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):739–43

Functional analysis of the human guanylin gene promoter. Pardigol A, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):638–44

Toxic peptides and genes encoding toxin gamma of the Brazilian scorpions Tityus bahiensis and Tityus stigmurus. Becerril B, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):753–60

Molecular cloning of MADM: a catalytically active mammalian disintegrin–metalloprotease expressed in various cell types. Howard L, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):45–50

A new model for disruption of the ornithine decarboxylase gene, SPE1, in Saccharomyces cerevisiae exhibits growth arrest and genetic instability at the MAT locus. Schwartz B, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):83–90

Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes. Tomita M, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):293–7

A new human guanylate cyclase–activating peptide (GCAP–II, uroguanylin): precursor cDNA and colonic expression. Hill O, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):146–9

Molecular cloning of cDNAs encoding precursors of frog skin antimicrobial peptides from Rana rugosa. Park JM, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):23–5

A genetic algorithm that seeks native states of peptides and proteins. Sun S. **Biophys J** 1995 Aug;69(2):340–55

An allergenic polypeptide representing a variable region of hsp 70 cloned from a cDNA library of Cladosporium herbarum. Zhang L, et al. **Clin Exp Allergy** 1996 Jan; 26(1):88–95

A third P–domain peptide gene (TFF3), human intestinal trefoil factor, maps to 21q22.3. Schmitt H, et al.
Cytogenet Cell Genet 1996;72(4):299–302

Strong induction of activin expression after injury suggests an important role of activin in wound repair. Hübner G, et al. **Dev Biol** 1996 Feb 1;173(2):490–8

Structure of the C–terminal end of the nascent peptide influences translation termination. Björnsson A, et al.
EMBO J 1996 Apr 1;15(7):1696–704

The pheromone response factor coordinates filamentous growth and pathogenicity in Ustilago maydis. Hartmann HA, et al. **EMBO J** 1996 Apr 1;15(7):1632–41

Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK–STAT5 pathway. Yoshimura A, et al. **EMBO J** 1996 Mar 1;15(5):1055–63

cDNA sequences of three sheep myeloid cathelicidins. Bagella L, et al. **FEBS Lett** 1995 Dec 4;376(3):225–8

Molecular cloning and characterization of cDNA for insect biogenic peptide, growth–blocking peptide. Hayakawa Y, et al. **FEBS Lett** 1995 Dec 4;376(3):185–9

Allelic forms of the knob associated histidine–rich protein gene of Plasmodium falciparum. Kant R, et al.
FEBS Lett 1996 Feb 12;380(1–2):147–51

Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide. Mahoney MM, et al.
FEBS Lett 1995 Dec 27;377(3):519–22

15N labeling method of peptides using a thioredoxin gene fusion expression system: an application to ACTH–(1–24). Uegaki K, et al. **FEBS Lett** 1996 Jan 22;379(1):47–50

Structures of genes for two cathelin–associated antimicrobial peptides: prophenin–2 and PR–39. Zhao C, et al.
FEBS Lett 1995 Dec 4;376(3):130–4

Diminished alpha–inhibin messenger ribonucleic acid in in vitro fertilization–embryo transfer poor responders reflects declining follicle reserve. Burns WN, et al. **Fertil Steril** 1996 Feb;65(2):394–9

How do B cells differ from T cells in terms of gene expression? Lefkovits I. **Folia Microbiol (Praha)** 1995; 40(4):405–12

The gene encoding mouse intestinal trefoil factor: structural organization, partial sequence analysis and mapping to murine chromosome 17q. Chinery R, et al. **Gene** 1996 Jun 1;171(2):249–53

Probable exclusion of the cortexin–encoding gene as a candidate for mouse neurological mutants: nervous, tottering and motor neuron degeneration. Horvath DH, et al. **Gene** 1996 Jun 1;171(2):305–6

Addition of a short peptide ligand to the adenovirus fiber protein. Michael SI, et al. **Gene Ther** 1995 Nov;2(9):660–8

The Saccharomyces retrotransposon Ty5 integrates preferentially into regions of silent chromatin at the telomeres and mating loci. Zou S, et al. **Genes Dev** 1996 Mar 1;10(5):634–45

Genetic analysis of Rap1p/Sir3p interactions in telomeric and HML silencing in Saccharomyces cerevisiae. Liu C, et al.
Genetics 1996 May;143(1):81–93

The rad9 gene of Coprinus cinereus encodes a proline–rich protein required for meiotic chromosome condensation and synapsis. Seitz LC, et al. **Genetics** 1996 Apr;142(4):1105–17

Cloning of contiguous genomic fragments from human chromosome 21 harbouring three trefoil peptide genes. Beck S, et al. **Hum Genet** 1996 Aug;98(2):233–5

A new human gene from the Down syndrome critical region encodes a proline–rich protein highly expressed in fetal brain and heart. Fuentes JJ, et al. **Hum Mol Genet** 1995 Oct;4(10):1935–44

The rat cim effect: TAP allele–dependent changes in a class I MHC anchor motif and evidence against C–terminal trimming of peptides in the ER. Powis SJ, et al.
Immunity 1996 Feb;4(2):159–65

Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha. Russell JP, et al. **Infect Immun** 1996 May;64(5):1565–8

Characterization and cloning of insecticidal peptides from the primitive weaving spider Diguetia canities. Krapcho KJ, et al. **Insect Biochem Mol Biol** 1995 Oct;25(9):991–1000

Expression of a TCR V beta 8.2 polypeptide from the unrearranged gene in a murine lymphoid precursor cell line. Jolly CJ, et al. **Int Immunol** 1995 Jul;7(7):1147–56

Influence of specific signal peptide mutations on the expression and secretion of the alpha–amylase inhibitor tendamistat in Streptomyces lividans. Fass SH, et al.
J Biol Chem 1996 Jun 21;271(25):15244–52

Systematic replacement of amino acid residues within an Arg–Gly–Asp–containing loop of foot–and–mouth disease virus and effect on cell recognition. Mateu MG, et al.
J Biol Chem 1996 May 31;271(22):12814–9

Regulation of RAR beta 2 mRNA expression: evidence for an inhibitory peptide encoded in the 5'–untranslated region. Reynolds K, et al. **J Cell Biol** 1996 Aug;134(4):827–35

MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. Weskamp G, et al.
J Cell Biol 1996 Feb;132(4):717–26

Allele–specific motifs characterize HLA–DQ interactions with a diabetes–associated peptide derived from glutamic acid decarboxylase. Kwok WW, et al. **J Immunol** 1996 Mar 15;156(6):2171–7

Construction of recombinant extended single–chain antibody peptide conjugates for use in the diagnosis of HIV–1 and HIV–2. Coia G, et al. **J Immunol Methods** 1996 Jun 10; 192(1–2):13–23

How much are homologous peptides homologous? Incardona F, et al. **J Theor Biol** 1995 Aug 21;175(4):437–55

Up–regulation of rat adrenomedullin gene expression by endotoxin: relation to nitric oxide synthesis. So S, et al.
Life Sci 1996;58(19):PL309–15

Comparative mapping of sheep inhibin subunits alpha (INHA) and beta B(INHBB) to chromosome 2 in goat by FISH. Goldammer T, et al. **Mamm Genome** 1995 Sep; 6(9):685–6

Screening phage–displayed random peptide libraries for SH3 ligands. Sparks AB, et al. **Methods Enzymol** 1995; 255:498–509

Mechanism of MAT alpha donor preference during mating–type switching of Saccharomyces cerevisiae. Wu X, et al. **Mol Cell Biol** 1996 Feb;16(2):657–68

An asexual fungus has the potential for sexual development. Sharon A, et al. **Mol Gen Genet** 1996 Apr 24;251(1):60–8

Identification of the pheromone response element in Ustilago maydis. Urban M, et al. **Mol Gen Genet** 1996 Apr 24; 251(1):31–7

Real–time analysis of Oct protein–octamer interaction and transcription complex assembly. Malmborg AC, et al.
Mol Immunol 1995 Dec;32(17–18):1429–42

Toward cell–targeting gene therapy vectors: selection of cell–binding peptides from random peptide–presenting phage libraries. Barry MA, et al. **Nat Med** 1996 Mar; 2(3):299–305

Peptide–displaying phages for targeted gene delivery? Russell SJ. **Nat Med** 1996 Mar;2(3):276–7

Molecular basis for a geographic variation of varicella–zoster virus recognized by a peptide antibody. Kinchington PR, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S13–4 (7 ref.)

A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide–coding gene. Manfredi G, et al. **Neuromuscul Disord** 1995 Sep;5(5):391–8

Calcitonin gene–related peptide immunoreactivity in the trigeminal ganglion of Trimeresurus flavoviridis. Sekitani–Kumagai M, et al. **Neurosci Res** 1995 Jun; 22(3):287–95

Expression and characterization of molluscan insulin–related peptide VII from the mollusc Lymnaea stagnalis. Smit AB, et al. **Neuroscience** 1996 Jan;70(2):589–96

Drosophila immunity: a comparative analysis of the Rel proteins dorsal and Dif in the induction of the genes encoding diptericin and cecropin. Gross I, et al.
Nucleic Acids Res 1996 Apr 1;24(7):1238–45

Antisense properties of duplex– and triplex–forming PNAs. Knudsen H, et al. **Nucleic Acids Res** 1996 Feb 1; 24(3):494–500

Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Bao J, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):5037–42

Significant competitive advantage conferred by meiosis and syngamy in the yeast Saccharomyces cerevisiae. Birdsell J, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):908–12

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1–11 (104 ref.)

Antisense oligonucleotides in in vivo regulatory peptide research [editorial] Phillips MI. **Regul Pept** 1995 Oct 20; 59(2):iii–v (13 ref.)

In vivo applications of antisense oligonucleotides for peptide research. [editorial] Phillips MI, et al. **Regul Pept** 1995 Oct 20;59(2):131–41 (56 ref.)

Cell killing by the Drosophila gene reaper. White K, et al. **Science** 1996 Feb 9;271(5250):805–7

IMMUNOLOGY

Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Atassi MZ, et al. **Adv Exp Med Biol** 1995; 383:141–56 (71 ref.)

Autoantibodies against peptide–defined epitopes of T–cell receptors in retrovirally infected humans and mice. Marchalonis JJ, et al. **Adv Exp Med Biol** 1995;383:211–22

The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Nardin EH, et al. **Adv Immunol** 1995;60:105–49 (135 ref.)

A monoclonal antibody to an early pregnancy factor–induced suppressor factor (EPF–S1) disrupts implantation in mice. Athanasas–Platsis S, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):259–66

Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Nieba L, et al. **Anal Biochem** 1996 Feb 15;234(2):155–65

Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Dybwad A, et al. **Ann Rheum Dis** 1996 Jul; 55(7):437–41

Generation, translocation, and presentation of MHC class I–restricted peptides. Heemels MT, et al. **Annu Rev Biochem** 1995;64:463–91 (192 ref.)

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183–90 (85 ref.)

Production of a form–specific, inhibitory antibody against rat cytochrome P450 2B1 using a synthetic peptide antigen against a putative substrate binding site. Charnecki J, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1024–33

Presentation of N–formylated peptides by H2–M3. Lindahl KF, et al. **Biochem Soc Trans** 1995 Aug;23(3):669–74 (34 ref.)

Elucidation of T–cell epitopes: a synthetic approach with random peptide libraries. Walden P, et al. **Biochem Soc Trans** 1995 Aug;23(3):678–81 (16 ref.)

Development of a sensitive peptide–based immunoassay: application to detection of the Jun and Fos oncoproteins. Heuer KH, et al. **Biochemistry** 1996 Jul 16;35(28):9069–75

Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide–antibody recognition. Leder L, et al. **Biochemistry** 1995 Dec 19;34(50):16509–18

Natural ligand motifs of closely related HLA–DR4 molecules predict features of rheumatoid arthritis associated peptides. Friede T, et al. **Biochim Biophys Acta** 1996 Jun 7; 1316(2):85–101

Antigenicity of topochemically related peptides. Verdoliva A, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):57–62

Identification of human nonpancreatic–type ribonuclease by antibodies obtained against a synthetic peptide. Bravo MI, et al. **Biol Chem Hoppe Seyler** 1995 Sep;376(9):555–60

Presence of autoantibodies to interleukin–8 or neutrophil–activating peptide–2 in patients with heparin–associated thrombocytopenia. Amiral J, et al. **Blood** 1996 Jul 15;88(2):410–6

Activation of nonspecific cytotoxic cells with a multiple antigenic peptide: specificity and requirements for receptor crosslinkage. Jaso–Friedmann L, et al. **Cell Immunol** 1996 Jun 15;170(2):195–201

Pretreatment with T cell receptor peptides using a conventional immunization protocol does not induce effective protection against autoimmune encephalomyelitis. Tanuma N, et al. **Cell Immunol** 1996 Feb 25;168(1):85–90

HIV–1 p17 synthetic peptide vaccine HGP–30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Sarin PS, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 May;41(3):401–7

Detection of antibodies to trans–activator protein (p40taxI) of human T–cell lymphotropic virus type I by a synthetic peptide–based assay. Rudolph DL, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):176–81

Occurrence, in Crohn's disease, of antibodies directed against a species–specific recombinant polypeptide of Mycobacterium paratuberculosis. Vannuffel P, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):241–3

Peptide immunization in humans: a combined CD8+/CD4+ T cell–targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). Brander C, et al. **Clin Exp Immunol** 1996 Jul; 105(1):18–25

Peptide phage libraries can be an efficient tool for identifying antibody ligands for polyclonal antisera. Dybwad A, et al. **Clin Exp Immunol** 1995 Nov;102(2):438–42

Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Gabrielli A, et al. **Clin Exp Immunol** 1996 Jul;105(1):59–64

Binding of peptides from the N–terminal region of alpha–gliadin to the celiac disease–associated HLA–DQ2 molecule assessed in biochemical and T cell assays. Johansen BH, et al. **Clin Immunol Immunopathol** 1996 Jun; 79(3):288–93

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)

Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. Mellman I, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):564–72 (72 ref.)

Peptide modulation of allergen–specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757–61 (41 ref.)

Anti–peptide antibodies against an autoimmune epitope on human muscarinic receptor mimic functional autoantibodies against the same epitope in patients with idiopathic dilated cardiomyopathy. Fu ML. **Eur Heart J** 1995 Dec;16 Suppl O:89–91

Anti–peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44–kDa protein from rat liver mitochondria. Knecht W, et al. **Eur J Biochem** 1996 Mar 1;236(2):609–13

A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Armandola EA, et al. **Eur J Immunol** 1996 Aug; 26(8):1748–55

A biological function for the XP motif within the N terminus of major histocompatibility complex class II–associated peptides. Breloer M, et al. **Eur J Immunol** 1996 Aug; 26(8):1825–9

An HLA–B35–restricted epitope modified at an anchor residue results in an antagonist peptide. Dong T, et al. **Eur J Immunol** 1996 Feb;26(2):335–9

Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Griem P, et al. **Eur J Immunol** 1996 Feb;26(2):279–87

Prevention of murine lupus by an I–E alpha chain transgene: protective role of I–E alpha chain–derived peptides with a high affinity to I–Ab molecules. Iwamoto M, et al. **Eur J Immunol** 1996 Feb;26(2):307–14

Translocation of long peptides by transporters associated with antigen processing (TAP). Koopmann JO, et al. **Eur J Immunol** 1996 Aug;26(8):1720–8

Peptide–pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA–A*0201–binding peptides from the Melan–A/MART–1 self antigen. van Elsas A, et al. **Eur J Immunol** 1996 Aug;26(8):1683–9

Inhibition of thymocyte negative selection by T cell receptor antagonist peptides. Williams O, et al. **Eur J Immunol** 1996 Mar;26(3):532–8

Specificity and sensitivity of gp210 autoantibodies detected using an enzyme–linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Bandin O, et al. **Hepatology** 1996 May; 23(5):1020–4

Carbohydrate and peptide antigens in macrophage populations derived from human bone marrow and milk: an immunomorphological and immunochemical analysis. Baldus SE, et al. **Histochem J** 1995 Aug;27(8):630–8

Detailed motifs for peptide binding to HLA–A*0201 derived from large random sets of peptides using a cellular binding assay. Drijfhout JW, et al. **Hum Immunol** 1995 May; 43(1):1–12

HLA–DR residues accessible under the peptide–binding groove contribute to polymorphic antibody epitopes. Fu XT, et al. **Hum Immunol** 1995 Aug;43(4):243–50

Artificial insemination in RhD negative women [letter] Greiss MA, et al. **Hum Reprod** 1995 Aug;10(8):2176

The rat cim effect: TAP allele–dependent changes in a class I MHC anchor motif and evidence against C–terminal trimming of peptides in the ER. Powis SJ, et al. **Immunity** 1996 Feb;4(2):159–65

An empirical method for the prediction of T–cell epitopes. Davenport MP, et al. **Immunogenetics** 1995;42(5):392–7

Natural peptides isolated from Gly86/Val86–containing variants of HLA–DR1, –DR11, –DR13, and –DR52. Verreck FA, et al. **Immunogenetics** 1996;43(6):392–7

The effect of WSEWS pentapeptide and WSEWS–specific monoclonal antibodies on constitutive and IL–6 induced acute–phase protein production by a human hepatoma cell line, HEPG–2. Biró J, et al. **Immunol Lett** 1995 May; 46(1–2):183–7

Binding of mutated Ras– and p53–derived peptides to HLA–DR molecules. Murakami S, et al. **Immunol Lett** 1996 Mar;49(3):149–53

CD8+ T–cell protective immunity induced by immunization with Plasmodium berghei CS protein–derived synthetic peptides: evidence that localization of peptide–specific CTLs is crucial for protection against malaria. Renggli J, et al. **Immunol Lett** 1995 May;46(1–2):199–205

Passive adsorption of immunologically active and inactive synthetic peptides to polystyrene is influenced by the proportion of non–polar residues in the peptide. Sällberg M, et al. **Immunol Lett** 1995 May;46(1–2):25–30

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Parker KC, et al. **Immunol Res** 1995;14(1):34–57 (129 ref.)

Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5–31 (104 ref.)

Lupus autoimmunity: from peptides to particles. Mamula MJ. **Immunol Rev** 1995 Apr;144:301–14 (58 ref.)

Immunogenicity of peptides for B cells is not impaired by overlapping T–cell epitope topology. Harris DP, et al. **Immunology** 1996 Jul;88(3):348–54

Major histocompatibility complex class I presentation of exogenous and endogenous protein–derived peptides by a transfected human monocyte cell line. Harris PE, et al. **Immunology** 1995 Dec;86(4):606–11

Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major histocompatibility complex class I molecules. Zwickey HL, et al. **Infect Immun** 1996 May; 64(5):1870–2

Induction of antigen–specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)

Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue–specific protein. Antonia SJ, et al. **Int Immunol** 1995 May;7(5):715–25

CD4–independent in vivo priming of murine CTL by optimal MHC class I–restricted peptides derived from intracellular pathogens. Dyall R, et al. **Int Immunol** 1995 Aug; 7(8):1205–12

Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Gagliardi MC, et al. **Int Immunol** 1995 Nov;7(11):1741–52

Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice—implications for autoimmunity. Liu GY, et al. **Int Immunol** 1995 Aug;7(8):1255–63

Interactions among polymorphic and conserved residues in MHC class II proteins affect MHC–peptide conformation and T cell recognition. Tate KM, et al. **Int Immunol** 1995 May;7(5):747–61

Isolation of a human allo–peptide presented by HLA–B51 molecules. Tomiyama H, et al. **Int Immunol** 1995 Jun; 7(6):905–9

Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a Kd–restricted immunogenic peptide. Wei WZ, et al. **Int J Cancer** 1996 May 29;66(5):659–63

Selection of phage–displayed peptides mimicking type 1 diabetes–specific epitopes. Mennuni C, et al. **J Autoimmun** 1996 Jun;9(3):431–6

Peripheral T cell clones from NOD mice specific for GAD65 peptides: lack of islet responsiveness or diabetogenicity. Schloot NC, et al. **J Autoimmun** 1996 Jun;9(3):357–63

A 130 kDa polypeptide immunologically related to the 180 kDa catalytic subunit of DNA polymerase alpha–primase complex is detected in early embryos of Drosophila. Kuroda K, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):809–18

Characterization of a single–chain antibody to the beta–chain of the T cell receptor. Cho BK, et al. **J Biol Chem** 1995 Oct 27;270(43):25819–26

Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. Guichard G, et al. **J Biol Chem** 1995 Nov 3;270(44):26057–9

Topological mimicry of cross–reacting enantiomeric peptide antigens. Verdoliva A, et al. **J Biol Chem** 1995 Dec 22; 270(51):30422–7

Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma–subunit. Wangsgard WP, et al. **J Biol Chem** 1996 Aug 30;271(35):21126–33

The inter–locus recombinant HLA–B*4601 has high selectivity in peptide binding and functions characteristic of HLA–C. Barber LD, et al. **J Exp Med** 1996 Aug 1; 184(2):735–40

HLA–A2 subtypes are functionally distinct in peptide binding and presentation. Barouch D, et al. **J Exp Med** 1995 Dec 1;182(6):1847–56

Early biochemical signals arise from low affinity TCR–ligand reactions at the cell–cell interface. Beeson C, et al. **J Exp Med** 1996 Aug 1;184(2):777–82

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I–restricted cytolytic T lymphocytes. Blake J, et al. **J Exp Med** 1996 Jul 1;184(1):121–30

The presentation of a hepatitis C viral peptide by distinct major histocompatibility complex class I allotypes from two chimpanzee species. Cooper S, et al. **J Exp Med** 1996 Feb 1;183(2):663–8

T cell receptor (TCR) recognition of MHC class I variants: intermolecular second–site reversion provides evidence for peptide/MHC conformational variation. Dyall R, et al. **J Exp Med** 1996 Jul 1;184(1):253–8

The cleavage preference of the proteasome governs the yield of antigenic peptides. Eggers M, et al. **J Exp Med** 1995 Dec 1;182(6):1865–70

T cell responses affected by aminopeptidase N (CD13)–mediated trimming of major histocompatibility complex class II–bound peptides. Larsen SL, et al. **J Exp Med** 1996 Jul 1;184(1):183–9

The life span of major histocompatibility complex–peptide complexes influences the efficiency of presentation and immunogenicity of two class I–restricted cytotoxic T lymphocyte epitopes in the Epstein–Barr virus nuclear antigen 4. Levitsky V, et al. **J Exp Med** 1996 Mar 1; 183(3):915–26

The peptide–binding motif for the human transporter associated with antigen processing. van Endert PM, et al. **J Exp Med** 1995 Dec 1;182(6):1883–95

Endogenous altered peptide ligands can affect peripheral T

cell responses. Vidal K, et al. **J Exp Med** 1996 Apr 1; 183(4):1311–21

Major histocompatibility complex class II–associated peptides control the presentation of bacterial superantigens to T cells. Wen R, et al. **J Exp Med** 1996 Mar 1; 183(3):1083–92

Therapy of murine tumors with tumor peptide–pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1–associated cytokines [see comments] Zitvogel L, et al. **J Exp Med** 1996 Jan 1;183(1):87–97. Comment in: J Exp Med 1996 Jan 1;183(1):7–11.

Binding kinetics of monoclonal antibody using antigen–beta–galactosidase hybrid protein: application to measurement of peptide antigenicity. Cho EW, et al. **J Immunoassay** 1995 Nov;16(4):349–63

Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. Araga S, et al. **J Immunol** 1996 Jul 1; 157(1):386–92

Biochemical characterization of antigen–specific glycosylation–inhibiting factor from antigen–specific suppressor T cells. II. The 55–kDa glycosylation–inhibiting factor peptide is a derivative of TCR alpha–chain and a subunit of antigen–specific glycosylation–inhibiting factor. Ishii Y, et al. **J Immunol** 1996 Mar 1;156(5):1735–42

Allele–specific motifs characterize HLA–DQ interactions with a diabetes–associated peptide derived from glutamic acid decarboxylase. Kwok WW, et al. **J Immunol** 1996 Mar 15;156(6):2171–7

Binding and presentation of peptides derived from melanoma antigens MART–1 and glycoprotein–100 by HLA–A2 subtypes. Implications for peptide–based immunotherapy. Rivoltini L, et al. **J Immunol** 1996 May 15;156(10):3882–91

Immunization with short peptides from the sequence of the systemic lupus erythematosus–associated 60–kDa Ro autoantigen results in anti–Ro ribonucleoprotein autoimmunity. Scofield RH, et al. **J Immunol** 1996 May 15;156(10):4059–66

Thymus–leukemia antigen interacts with T cells and self–peptides. Sharma P, et al. **J Immunol** 1996 Feb 1; 156(3):987–96

pH dependence of MHC class I–restricted peptide presentation. Stryhn A, et al. **J Immunol** 1996 Jun 1; 156(11):4191–7

T cell tolerance is influenced by concomitant T cell recognition of cross–reactive self–peptides. Tam RC, et al. **J Immunol** 1996 May 15;156(10):3765–71

Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. Viner NJ, et al. **J Immunol** 1996 Apr 1;156(7):2365–8

Suppression of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta3 with low molecular weight antigen arrays. Watson DC, et al. **J Immunol** 1996 Apr 1;156(7):2443–50

T cell recognition of MHC class II–associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix protein19–31. Wu S, et al. **J Immunol** 1996 May 15;156(10):3815–20

Prediction of binding to MHC class I molecules. Adams HP, et al. **J Immunol Methods** 1995 Sep 25;185(2):181–90

Construction of recombinant extended single–chain antibody peptide conjugates for use in the diagnosis of HIV–1 and HIV–2. Coia G, et al. **J Immunol Methods** 1996 Jun 10; 192(1–2):13–23

Determination of T cell epitopes with random peptide libraries. Gundlach BR, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):149–55

Use of peptide immunization for porcine insulin of a very high homology with a host protein. Katoh S, et al. **J Immunol Methods** 1996 May 10;191(1):33–8

Type–specific serologic diagnosis of respiratory syncytial virus infection, based on a synthetic peptide of the attachment protein G. Langedijk JP, et al. **J Immunol Methods** 1996 Jun 21;193(2):157–66

A strategy for the synthesis and screening of thiol–modified peptide variants recognized by T cells. Manning TC, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):125–32

Cutaneous immediate and late phase reactions to schistosomin in schistosomiasis patients. Marotto PC, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct;5(5):269–71

Heat shock protein–peptide complexes for use in vaccines. Heike M, et al. **J Leukoc Biol** 1996 Aug;60(2):153–8 (75 ref.)

Preparation and characterization of anti–peptide antibodies directed against human phenol and hydroxysteroid sulphotransferases. Sharp S, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):89–95

Synthesis and application of hepatitis E virus peptides to diagnosis. Qi Z, et al. **J Virol Methods** 1995 Sep;55(1):55–66

Breast cancer imaging with radiolabelled peptide from complementarity–determining region of antitumour antibody. Sivolapenko GB, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1662–6

Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c mice. Herrera MA, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:71–6

Identification of a ligand–binding site in an immunoglobulin fold domain of the Saccharomyces cerevisiae adhesion protein alpha–agglutinin. de Nobel H, et al. **Mol Biol Cell** 1996 Jan;7(1):143–53

Protection against alpha–bungarotoxin poisoning by immunization with synthetic toxin peptides. Dolimbek BZ, et al. **Mol Immunol** 1996 May–Jun;33(7–8):681–9

Direct detection of peptide–dependent HLA variability by surface plasmon resonance. Hlavac F, et al. **Mol Immunol** 1996 Apr;33(6):573–82

Dependence of the murine antibody response to an anti–CDR2 VH peptide on immunogen formulation. Kanda P, et al. **Mol Immunol** 1995 Dec;32(17–18):1319–28

Fine chemical modifications at N– and C–termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC–complexed peptides. Maillère B, et al. **Mol Immunol** 1995 Dec;32(17–18):1377–85

Analysis of the interaction between a synthetic peptide of influenza virus hemagglutinin and monoclonal antibodies using an optical biosensor. Nice EC, et al. **Mol Immunol** 1996 May–Jun;33(7–8):659–70

Immune responses to self peptides naturally presented by murine class II major histocompatibility complex molecules. Rider BJ, et al. **Mol Immunol** 1996 May–Jun; 33(7–8):625–33

Immunological effect of a synthetic growth hormone peptide on the growth performance in swine. Wang BS, et al. **Mol Immunol** 1996 May–Jun;33(7–8):609–14

Adrenomedullin–immunoreactive neurons in the paraventricular and supraoptic nuclei of the rat. Ueta Y, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):37–40

Elucidation of monoclonal antibody polyspecificity using a synthetic combinatorial library. Pinilla C, et al. **Pept Res** 1995 Sep–Oct;8(5):250–7

Modification of the carboxyl terminal group affects replacement set analysis of a cytotoxic T cell epitope. Suhrbier A, et al. **Pept Res** 1995 Sep–Oct;8(5):258–62

Design and testing of peptide–based cytotoxic T–cell–mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847–74 (170 ref.)

Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891–905 (41 ref.)

Design of experimental synthetic peptide immunogens for prevention of HIV–1 and HTLV–I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

The MAP system. A flexible and unambiguous vaccine design of branched peptides. Nardelli B, et al. **Pharm Biotechnol** 1995;6:803–19 (57 ref.)

A recombinant antibody with the antigen–specific, major histocompatibility complex–restricted specificity of T cells. Andersen PS, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1820–4

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T–cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft–versus–host disease in vivo. Schlegel PG, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5061–6

Thoughtful cruises in oceans of peptides and T cells. Kourilsky P. **Res Immunol** 1995 May–Jun;146(4–5):309–20 (33 ref.)

Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Kirkley JE, et al. **Scand J Immunol** 1996 Apr; 43(4):431–8

Sharing of four DR–beta sequence motifs between HLA–DRB1*1601 and DRB1*1101 correlates with frequent degenerate T–cell recognition of HA306–320 peptide complexed to these two molecules. Zeliszewski D, et al. **Scand J Immunol** 1996 Feb;43(2):146–54

Immunogenicity of mastoparan B, a cationic tetradecapeptide isolated from the hornet (Vespa basalis) venom, and its structural requirements. Ho CL, et al. **Toxicon** 1995 Nov; 33(11):1443–51

Monoclonal anti–D specificity and Rh structure [letter; comment] Jones J, et al. **Transfus Med** 1995 Dec;5(4):304–5 . Comment on: Transfus Med 1995 Sep;5(3):171–84.

High frequency of alloreactive T cells is a consequence of the presentation of many peptides by allogeneic MHC molecules. Salom R, et al. **Transplant Proc** 1995 Dec; 27(6):3579

Accurate determination of adjuvant–associated protein or peptide by ninhydrin assay. Brewer JM, et al. **Vaccine** 1995; 13(15):1441–4

The use of synthetic peptides can be a misleading approach to generate vaccines against scorpion toxins. Calderon–Aranda ES, et al. **Vaccine** 1995 Sep; 13(13):1198–206

Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood–stage antigens. Chatterjee S, et al. **Vaccine** 1995;13(15):1474–81

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen–specific IgG2a production. Fernando GJ, et al. **Vaccine** 1995;13(15):1460–7

Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Hughes EE, et al. **Vaccine** 1995 Dec; 13(18):1750–3

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Levi R, et al. **Vaccine** 1995 Oct;13(14):1353–9

Immunological evaluation of three generations of anti–idiotype vaccine: study of B and T cell responses following priming with anti–idiotype, anti–idiotype peptide and its MAP structure. Rajadhyaksha M, et al. **Vaccine** 1995;13(15):1421–6

Protection of mice against lethal viral infection by synthetic peptides corresponding to B– and T–cell recognition sites of influenza A hemagglutinin. Simeckova–Rosenberg J, et al. **Vaccine** 1995 Jul;13(10):927–32

Anti–peptide antibodies to the P4502D subfamily in rat, dog and man. Nakamura A, et al. **Xenobiotica** 1995 Nov; 25(10):1103–9

Specificities of rabbit antisera to multiple antigen (MAP) peptides. Chersi A, et al. **Z Naturforsch [C]** 1995 Sep–Oct; 50(9–10):735–8

[Missing links in immunologic defense. Endogenous antibiotics are the primary protection] Wilhelmson B. **Lakartidningen** 1996 May 1;93(18):1728–33 **(Swe)**

ISOLATION & PURIFICATION

Purification and partial characterization of an early pregnancy factor–induced suppressor factor (EPF–S1). Rolfe BA, et al. **Am J Reprod Immunol** 1995 Jun; 33(6):485–94

Multiple sequential fraction collection of peptides and glycopeptides by high–performance capillary electrophoresis. Boss HJ, et al. **Anal Biochem** 1995 Sep 1;230(1):123–9

Purification of synthetic peptide libraries by affinity chromatography using the avidin–biotin system. Quesnel A, et al. **Anal Biochem** 1995 Oct 10;231(1):182–7

Detection of fast capillary electrophoresis peptide and protein separations using electrospray ionization with a time–of–flight mass spectrometer. Banks JF Jr, et al. **Anal Chem** 1996 May 1;68(9):1480–5

A microscale electrospray interface for on–line, capillary liquid chromatography/tandem mass spectrometry of complex peptide mixtures. Davis MT, et al. **Anal Chem** 1995 Dec 15;67(24):4549–56

Rapid comprehensive two–dimensional separations of peptides via RPLC–optically gated capillary zone electrophoresis. Moore AW Jr, et al. **Anal Chem** 1995 Oct 1;67(19):3448–55

Comprehensive three–dimensional separation of peptides using size exclusion chromatography/reversed phase liquid chromatography/optically gated capillary zone electrophoresis. Moore AW Jr, et al. **Anal Chem** 1995 Oct 1;67(19):3456–63

Resolution of cis and trans isomers of peptides containing proline using capillary zone electrophoresis. Moore AW Jr, et al. **Anal Chem** 1995 Oct 1;67(19):3464–75

Mixed–mode retention of peptides on phosphate–modified polybutadiene–coated zirconia. Sun L, et al. **Anal Chem** 1995 Aug 1;67(15):2517–23

Purification and characterization of bitiscetin, a novel von Willebrand factor modulator protein from Bitis arietans snake venom. Hamako J, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):273–9

Purification and characterization of a paralytic polypeptide from larvae of Myrmeleon bore. Matsuda K, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):167–71

alpha–Conotoxin EI, a new nicotinic acetylcholine receptor antagonist with novel selectivity. Martinez JS, et al. **Biochemistry** 1995 Nov 7;34(44):14519–26

The pregnant ovine endometrium constitutively expresses and secretes a highly stable bombesin–like peptide, which shares C–terminal sequence but differs structurally from gastrin–releasing peptide. Giraud A, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):189–97

Isolation and characterization of two new morphogenetically active peptides from Hydra vulgaris. Hoffmeister SA. **Development** 1996 Jun;122(6):1941–8

Endosulfine, endogenous ligand for the sulphonylurea receptor: isolation from porcine brain and partial structural determination of the alpha form. Virsolvy–Vergine A, et al. **Diabetologia** 1996 Feb;39(2):135–41

Metchnikowin, a novel immune–inducible proline–rich peptide from Drosophila with antibacterial and antifungal properties. Levashina EA, et al. **Eur J Biochem** 1995 Oct 15;233(2):694–700

Purification and characterization of an extracellular peptide factor that affects two different developmental pathways in Bacillus subtilis. Solomon JM, et al. **Genes Dev** 1996 Aug 15;10(16):2014–24

Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides. Wolpert E, et al. **Int Immunol** 1995 Jun; 7(6):919–28

Convergent solid–phase peptide synthesis. 12. Chromatographic techniques for the purification of protected peptide segments. Gairi M, et al. **Int J Pept Protein Res** 1995 Aug;46(2):119–33

Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes. Rousselle JC, et al. **J Biol Chem** 1996 Jan 12;271(2):726–35

14th International Symposium on the Separation and Analysis of Proteins, Peptides and Polynucleotides. Heidelberg, Germany, 2–4 November 1994. **J Chromatogr A** 1995 Sep 8;711(1):1–233

Facile liquid chromatographic enantioresolution of native amino acids and peptides using a teicoplanin chiral stationary phase. Berthod A, et al. **J Chromatogr A** 1996 Apr 19;731(1–2):123–37

Effect of 2,2,2–trifluoroethanol on capillary zone electrophoretic peptide separations. Castagnola M, et al. **J Chromatogr A** 1996 May 31;735(1–2):271–81

Capillary electrophoresis device with double UV detection and its application to the determination of effective mobilities of peptides. Kašička V, et al. **J Chromatogr A** 1995 Aug 11;709(1):31–8

Conformational effects in reversed–phase high–performance liquid chromatography of polypeptides. I. Resolution of insulin variants. Purcell AW, et al. **J Chromatogr A** 1995 Sep 8;711(1):61–70

Water–soluble peptides in Cheddar cheese: isolation and identification of peptides in the diafiltration retentate of the water–soluble fraction. Singh TK, et al. **J Dairy Res** 1995 Nov;62(4):629–40

Fraction collection. Altria KD. **Methods Mol Biol** 1996; 52:99–103

Separation of peptides and protein digests by capillary electrophoresis. Herold M, et al. **Methods Mol Biol** 1996; 52:285–308

Characterization of the 84–kDa protein with ABH activity in human seminal plasma. Sato I. **Nippon Hoigaku Zasshi** 1995 Oct;49(5):281–93

A novel gut tetradecapeptide isolated from the earthworm, Eisenia foetida. Ukena K, et al. **Peptides** 1995;16(6):995–9

Precipitation of insulinotropin in the presence of protamine: effect of phenol and zinc on the isophane ratio and the insulinotropin concentration in the supernatant. Kim Y, et al. **Pharm Res** 1995 Sep;12(9):1284–8

Purification and properties of Arabidopsis thaliana COR (cold–regulated) gene polypeptides COR15am and COR6.6 expressed in Escherichia coli. Gilmour SJ, et al. **Plant Physiol** 1996 May;111(1):293–9

Purification and characterization of rat parotid glycosylated, basic and acidic proline–rich proteins. Bedi GS, et al. **Prep Biochem** 1995 Aug;25(3):119–32

Biochemical characteristics of a human myeloid leukemia cell differentiation factor. Xu W, et al. **Prep Biochem Biotechnol** 1996 Feb;26(1):21–30

Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Nieland TJ, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6135–9

Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. Wang X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11480–4

Crotavirin, a potent platelet aggregation inhibitor purified from the venom of the snake Crotalus viridis. Liu CZ, et al. **Toxicon** 1995 Oct;33(10):1289–98

Identification of two new D variants, DHMi and DHMii using monoclonal anti–D. Jones J. **Vox Sang** 1995; 69(3):236–41

[Comparative study of chromatographic spectra of polypeptides extracted from pig spleen, liver, kidneys, thymus and parodontium] Kaidashev IP. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):85–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Angiotensin peptides in the brain. Campbell DJ. **Adv Exp Med Biol** 1995;377:349–55 (30 ref.)

The gp120 envelope of HIV–1 binds peptides in a similar manner to human leukocyte antigens. Sheikh MJ, et al. **AIDS** 1995 Nov;9(11):1229–35

Generation, translocation, and presentation of MHC class I–restricted peptides. Heemels MT, et al. **Annu Rev Biochem** 1995;64:463–91 (192 ref.)

A synthetic peptidic substrate of minimal size and semioptimal sequence for the protein tyrosine kinase pp60c–src. Ramdas L, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):73–8

Interaction of an anti–HIV peptide, T22, with gp120 and CD4. Tamamura H, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):555–9

The synthetic [Tyr5,12,Lys7]–polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):626–31

Investigation of the active site of oligosaccharyltransferase from pig liver using synthetic tripeptides as tools. Bause E, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):979–85

A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene–related peptide receptors. Coppock HA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):241–5

Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins. Marcinkiewicz C, et al. **Biochem J** 1996 Aug 1; 317 (Pt 3):817–25

Phosphorylation of GAP–43 (growth–associated protein of 43 kDa) by conventional, novel and atypical isotypes of the protein kinase C gene family: differences between oligopeptide and polypeptide phosphorylation. Oehrlein SA, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):219–24

Annexin II up–regulates cellular levels of p11 protein by a post–translational mechanisms. Puisieux A, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):51–5

A peptide molecular dynamics study correlates structure with function. McFerran NV, et al. **Biochem Soc Trans** 1996 Feb;24(1):127S

Interaction of protein kinase C with RACK1, a receptor for activated C–kinase: a role in beta protein kinase C mediated signal transduction. Mochly–Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596–600 (32 ref.)

A characterisation of the peptide transport system in barley seeds. Waterworth WM, et al. **Biochem Soc Trans** 1995 Nov;23(4):558S

Dissociation of the cellulosome of Clostridium thermocellum in the presence of ethylenediaminetetraacetic acid occurs with the formation of trucated polypeptides. Choi SK, et al. **Biochemistry** 1996 Apr 16;35(15):4897–905

Structural role of calcium for the organization of the cellulosome of Clostridium thermocellum. Choi SK, et al. **Biochemistry** 1996 Apr 16;35(15):4906–10

Engineering nitrile hydratase activity into a cysteine protease by a single mutation. Dufour E, et al. **Biochemistry** 1995 Dec 19;34(50):16382–8

Large activation energy barriers to chaperone–peptide complex formation and dissociation. Farr CD, et al. **Biochemistry** 1995 Nov 28;34(47):15574–82

Interaction of nucleotide–free Hsc70 with clathrin and peptide and effect of ATP analogues. Gao B, et al. **Biochemistry** 1995 Sep 19;34(37):11882–8

Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange. Ghomashchi F, et al. **Biochemistry** 1995 Sep 19;34(37):11910–8

Nature and consequences of GroEL–protein interactions. Itzhaki LS, et al. **Biochemistry** 1995 Nov 7;34(44):14581–7

An antimicrobial peptide, magainin 2, induced rapid flip–flop of phospholipids coupled with pore formation and peptide translocation. Matsuzaki K, et al. **Biochemistry** 1996 Sep 3;35(35):11361–8

Transbilayer transport of ions and lipids coupled with mastoparan X translocation. Matsuzaki K, et al. **Biochemistry** 1996 Jun 25;35(25):8450–6

Binding studies of a triple–helical peptide model of macrophage scavenger receptor to tetraplex nucleic acids. Mielewczyk SS, et al. **Biochemistry** 1996 Sep 3; 35(35):11396–402

Interaction of model class A1, class A2, and class Y amphipathic helical peptides with membranes. Mishra VK, et al. **Biochemistry** 1996 Aug 27;35(34):11210–20

Dissociation of cytochrome c from liposomes by histone H1. Comparison with basic peptides. Rytömaa M, et al. **Biochemistry** 1996 Apr 9;35(14):4529–39

Identification from a phage display library of peptides that bind to toxic shock syndrome toxin–1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules. Sato A, et al. **Biochemistry** 1996 Aug 13; 35(32):10441–7

Endocytosis inhibitors abolish the active transport of polypeptides in the mucosa of the nasal upper concha of the rabbit. Cremaschi D, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):27–33

Metabolism of peptide drugs by the microorganisms in rat cecal contents. Tozaki H, et al. **Biol Pharm Bull** 1995 Jun; 18(6):929–31

Identification of GIYWHHY as a novel peptide substrate for human p60c–src protein tyrosine kinase. Lou Q, et al. **Bioorg Med Chem** 1996 May;4(5):677–82

Pro–gastrin–releasing peptide (31–98) as a tumour marker of small–cell lung cancer: comparative evaluation with neuron–specific enolase. Takada M, et al. **Br J Cancer** 1996 May;73(10):1227–32

Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line. Cox HM, et al. **Br J Pharmacol** 1995 Nov;116(6):2673–8

Pituitary adenylate cyclase–activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Hedlund P, et al. **Br J Pharmacol** 1995 Oct;116(4):2258–66

Stereoselective uptake of beta–lactam antibiotics by the intestinal peptide transporter. Wenzel U, et al. **Br J Pharmacol** 1995 Dec;116(7):3021–7

The benzodiazepine antagonist CGS 8216 prevents hyperammonemia–induced somatostatin receptor reduction in the brain. Boyano–Adánez MC, et al. **Brain Res** 1995 Aug 7;688(1–2):1–7

Kappa–opioid receptor modulation of the release of substance P in the dorsal horn. Zachariou V, et al. **Brain Res** 1996 Jan 8;706(1):80–8

Comparative affinities of human adrenomedullin for 125I–labelled human alpha calcitonin gene related peptide ([125I]hCGRP alpha) and 125I–labelled Bolton–Hunter rat amylin ([125I]BHrAMY) specific binding sites in the rat brain. van Rossum D, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1084–8

Interaction of antigenic peptides with MHC and TCR molecules. Sette A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S168–71 (7 ref.)

Characterization of a synthetic peptide mimicking trypsin–cleavage site of rotavirus VP4. Ijaz MK, et al. **Comp Immunol Microbiol Infect Dis** 1995 Jun;18(3):145–60

Peptide hydrolysis in lens: role of leucine aminopeptidase, aminopeptidase III, prolyloligopeptidase and acylpeptidehydrolase. Sharma KK, et al. **Curr Eye Res** 1996 Apr;15(4):363–9

Genetics of peptide degradation in Lactococcus: gene cloning, construction and analysis of peptidase negative mutants. Mierau I, et al. **Dev Biol Stand** 1995;85:503–7

Glucagon–like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon–like peptide I. Orskov C, et al. **Diabetes** 1996 Jun;45(6):832–5

Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. Busch R, et al. **EMBO J** 1996 Jan 15; 15(2):418–28

In vitro binding of clathrin adaptors to sorting signals correlates with endocytosis and basolateral sorting. Heilker R, et al. **EMBO J** 1996 Jun 3;15(11):2893–9

Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. Tomazin R, et al. **EMBO J** 1996 Jul 1;15(13):3256–66

Early events in preprotein recognition in E. coli: interaction of SRP and trigger factor with nascent polypeptides. Valent QA, et al. **EMBO J** 1995 Nov 15;14(22):5494–505

Neuropeptide Y Y2 receptors in hypothalamic neuroendocrine areas are up–regulated by estradiol and decreased by progesterone cotreatment in the ovariectomized rat. Parker SL, et al. **Endocrinology** 1996 Jul;137(7):2896–900

Biochemical and antibacterial analysis of human wound and blister fluid. Frohm M, et al. **Eur J Biochem** 1996 Apr 1;237(1):86–92

Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Stryhn A, et al. **Eur J Immunol** 1996 Aug;26(8):1911–8

Peptide–pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA–A*0201–binding peptides from the Melan–A/MART–1 self antigen. van Elsas A, et al. **Eur J Immunol** 1996 Aug;26(8):1683–9

Distribution of GLP–1 binding sites in the rat brain: evidence that exendin–4 is a ligand of brain GLP–1 binding sites. Göke R, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2294–300

How peptides cross biological membranes [editorial] Nussberger S, et al. **Exp Nephrol** 1995 Jul–Aug;3(4):211–7 (37 ref.)

Peptides as active probes. Undén A, et al. **EXS** 1995; 73:229–55 (82 ref.)

Identification of a renal cell line that constitutively expresses the kidney–specific high–affinity H+/peptide cotransporter. Brandsch M, et al. **FASEB J** 1995 Nov; 9(14):1489–96

Glucagon stimulates phosphorylation of different peptides in isolated periportal and perivenous hepatocytes. Aggarwal SR, et al. **FEBS Lett** 1995 Dec 27;377(3):439–43

Tannin interactions with a full–length human salivary proline–rich protein display a stronger affinity than with single proline–rich repeats. Charlton AJ, et al. **FEBS Lett** 1996 Mar 18;382(3):289–92

Water–soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. Ekrami HM, et al. **FEBS Lett** 1995 Sep 11;371(3):283–6

Structural requirements for alpha–mating factor activity. Houen G, et al. **FEBS Lett** 1996 Aug 5;391(1–2):162–6

Golgi apparatus mammary gland casein kinase: monitoring by a specific peptide substrate and definition of specificity determinants. Lasa–Benito M, et al. **FEBS Lett** 1996 Mar 11;382(1–2):149–52

Importance of the structure of the RGD–containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. McLane MA, et al. **FEBS Lett** 1996 Aug 5;391(1–2):139–43

Efficient binding to the MHC class I K(d) molecule of synthetic peptides in which the anchoring position 2 does not fit the consensus motif. Quesnel A, et al. **FEBS Lett** 1996 May 27;387(1):42–6

NMR–titrations with complexes between ds–DNA and indole derivatives including tryptophane containing peptides. Sartorius J, et al. **FEBS Lett** 1995 Nov 6; 374(3):387–92

A recombinant polypeptide, composed of the alpha–helical neck region and the carbohydrate recognition domain of conglutinin, self–associates to give a functionally intact homotrimer. Wang JY, et al. **FEBS Lett** 1995 Nov 27; 376(1–2):6–10

Wherefore art thou guanylin? [editorial] [see comments] Cohen MB. **Gastroenterology** 1995 Dec;109(6):2039–42. Comment in: Gastroenterology 1995 Dec;109(6):1863–75.

Guanylin, an endogenous ligand for C–type guanylate cyclase, is produced by goblet cells in the rat intestine [comment] Li Z, et al. **Gastroenterology** 1995 Dec; 109(6):1863–75. Comment on: Gastroenterology 1995 Dec;109(6):2039–42.

Interaction of heparin with synthetic peptides corresponding to the C–terminal domain of intestinal mucins. Xu G, et al. **Glycoconj J** 1996 Feb;13(1):81–90

The specificity and orientation of a TCR to its peptide–MHC class II ligands. Sant'Angelo DB, et al. **Immunity** 1996 Apr; 4(4):367–76

Role of strong anchor residues in the effective binding of 10–mer and 11–mer peptides to HLA–A*2402 molecules. Ibe M, et al. **Immunogenetics** 1996;44(4):233–41

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Parker KC, et al. **Immunol Res** 1995;14(1):34–57 (129 ref.)

Structural domains of Porphyromonas gingivalis recombinant fimbrillin that mediate binding to salivary proline-rich protein and statherin. Amano A, et al. **Infect Immun** 1996 May;64(5):1631-7

TPS cytosolic levels in non-malignant breast diseases [letter] Alvarez A, et al. **Int J Biol Markers** 1995 Jul-Sep; 10(3):183-5

Determination of tissue polypeptide-specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul-Sep; 10(3):161-5

Alkaline protease catalysis of a secondary amine to form a peptide bond. Chen ST, et al. **Int J Pept Protein Res** 1995 Sep-Oct;46(3-4):314-9

Tissue distribution and plasma concentration of human guanylin. Date Y, et al. **Intern Med** 1996 Mar;35(3):171-5

Pulmonary hypertension. Response of vasoactive peptides to a nonionic contrast medium in patients undergoing pulmonary angiography. Szolar DH, et al. **Invest Radiol** 1995 Sep;30(9):511-6

Effect of intraruminal propionic acid infusion on metabolism of mesenteric- and portal-drained viscera in growing steers fed a forage diet: II. Ammonia, urea, amino acids, and peptides. Seal CJ, et al. **J Anim Sci** 1996 Jan;74(1):245-56

Characterization of 2-ketoisovalerate ferredoxin oxidoreductase, a new and reversible coenzyme A-dependent enzyme involved in peptide fermentation by hyperthermophilic archaea. Heider J, et al. **J Bacteriol** 1996 Feb;178(3):780-7

Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. Beerli RR, et al. **J Biol Chem** 1996 Mar 15; 271(11):6071-6

Leucine 18, a hydrophobic residue essential for high affinity binding of anthopleurin B to the voltage-sensitive sodium channel. Dias-Kadambi BL, et al. **J Biol Chem** 1996 Apr 19;271(16):9422-8

Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. Lundell I, et al. **J Biol Chem** 1995 Dec 8; 270(49):29123-8

p150TSP, a conserved nuclear phosphoprotein that contains multiple tetratricopeptide repeats and binds specifically to SH2 domains. Malek SN, et al. **J Biol Chem** 1996 Mar 22;271(12):6952-62

Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library. Martin EL, et al. **J Biol Chem** 1996 Jan 5;271(1):361-6

Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15. Phelps RG, et al. **J Biol Chem** 1996 Aug 2;271(31):18549-53

Reaction versus subsite stereospecificity of peptidylglycine alpha-monooxygenase and peptidylamidoglycolate lyase, the two enzymes involved in peptide amidation. Ping D, et al. **J Biol Chem** 1995 Dec 8;270(49):29250-5

Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites. Ridky TW, et al. **J Biol Chem** 1996 Mar 1;271(9):4709-17

C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. Ron D, et al. **J Biol Chem** 1995 Oct 13;270(41):24180-7

Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. Widmann C, et al. **J Biol Chem** 1996 Aug 16;271(33):19957-63

Only the first and the last hydrophobic segments in the COOH-terminal third of Na,K-ATPase alpha subunit initiate and halt, respectively, membrane translocation of the newly synthesized polypeptide. Implications for the membrane topology. Xie Y, et al. **J Biol Chem** 1996 Feb 2;271(5):2563-73

Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc. Zhou MM, et al. **J Biol Chem** 1995 Dec 29;270(52):31119-23

Lipid-modified, cysteinyl-containing peptides of diverse structures are efficiently S-acylated at the plasma membrane of mammalian cells. Schroeder H, et al. **J Cell Biol** 1996 Aug;134(3):647-60

The protease inhibitor N-acetyl-L-leucyl-L-leucyl-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum. Hughes EA, et al. **J Exp Med** 1996 Apr 1;183(4):1569-78

LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. Rotem-Yehudar R, et al. **J Exp Med** 1996 Feb 1;183(2):499-514

Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. Viner NJ, et al. **J Immunol** 1996 Apr 1;156(7):2365-8

Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. Gu ZJ, et al. **J Immunol Methods** 1996 Mar 28;190(1):21-7

Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. Guichard G, et al. **J Med Chem** 1996 May 10;39(10):2030-9

Alanine substitutions in calmodulin-binding peptides result in unexpected affinity enhancement. Montigiani S, et al. **J Mol Biol** 1996 Apr 26;258(1):6-13

Myelin P0 glycoprotein and a synthetic peptide containing the palmitoylation site are both autoacylated. Bharadwaj M, et al. **J Neurochem** 1995 Oct;65(4):1805-15

Methionine-containing peptides can be used as methionine sources for protein accretion in cultured C2C12 and MAC-T cells. Pan Y, et al. **J Nutr** 1996 Jan;126(1):232-41

Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S-34S (79 ref.)

Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. Bossuyt X, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):891-6

Alterations in calcium antagonist receptors and calcium content in senescent brain and attenuation by nimodipine and nicardipine. Yamada S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):721-7

Target-peptide-induced changes in the structure and dynamics of calmodulin as probed by frequency domain fluorimetry of bound Tb(III). O'Hara PB, et al. **J Photochem Photobiol B** 1995 Sep;30(1):15-21

Proteolysis of synthetic peptides by type A botulinum neurotoxin. Schmidt JJ, et al. **J Protein Chem** 1995 Nov; 14(8):703-8

Specific cleavage of synthetic renin substrate by mouse gamma-nerve growth factor. Uddin M, et al. **J Protein Chem** 1995 Oct;14(7):621-5

A mathematical model for biopanning (affinity selection) using peptide libraries on filamentous phage. Mandecki W, et al. **J Theor Biol** 1995 Oct 21;176(4):523-30

Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Saeki T, et al. **Jpn J Clin Oncol** 1995 Dec;25(6):240-9

HLA association with autoimmune disease: restricted binding or T-cell selection? [letter] Baum H, et al. **Lancet** 1995 Oct 14;346(8981):1042-3

Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension. Shimokubo T, et al. **Life Sci** 1995;57(19):1771-9

Evidence for the paracrine action of islet-derived corticotropin-like peptides on the regulation of insulin release. Borelli MI, et al. **Metabolism** 1996 May; 45(5):565-70

Peptide receptors in sea urchin sperm flagella. Dangott LJ. **Methods Cell Biol** 1995;47:437-44

Thermodynamic parameters from hydrogen exchange measurements. Bai Y, et al. **Methods Enzymol** 1995; 259:344-56

Use of synthetic peptides in characterization of microbial adhesins. Lee KK, et al. **Methods Enzymol** 1995;253:115-31

end5, end6, and end7: mutations that cause actin delocalization and block the internalization step of endocytosis in Saccharomyces cerevisiae. Munn AL, et al. **Mol Biol Cell** 1995 Dec;6(12):1721-42

Import of stably folded proteins into peroxisomes. Walton PA, et al. **Mol Biol Cell** 1995 Jun;6(6):675-83

Binding between lipopolysaccharide and cecropin A. De Lucca AJ, et al. **Mol Cell Biochem** 1995 Oct 18; 151(2):141-8

Regulation of the G-protein-coupled alpha-factor pheromone receptor by phosphorylation. Chen Q, et al. **Mol Cell Biol** 1996 Jan;16(1):247-57

Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Weng Z, et al. **Mol Cell Biol** 1995 Oct;15(10):5627-34

The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules. Hitzel C, et al. **Mol Immunol** 1996 Jan; 33(1):25-31

A phage display system for detection of T cell receptor-antigen interactions. Onda T, et al. **Mol Immunol** 1995 Dec;32(17-18):1387-97

Why does Escherichia coli recycle its cell wall peptides? Park JT. **Mol Microbiol** 1995 Aug;17(3):421-6 (41 ref.)

The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825-34 (59 ref.)

Structure-activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand-receptor binding. Daniels AJ, et al. **Mol Pharmacol** 1995 Sep;48(3):425-32

Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Gehlert DR, et al. **Mol Pharmacol** 1996 Jul;50(1):112-8

Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Barry MA, et al. **Nat Med** 1996 Mar; 2(3):299-305

Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Colas P, et al. **Nature** 1996 Apr 11;380(6574):548-50

Organ targeting in vivo using phage display peptide libraries. Pasqualini R, et al. **Nature** 1996 Mar 28;380(6572):364-6

Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. Bugno M, et al. **Nucleic Acids Res** 1995 Dec 25;23(24):5041-7

The proline-rich region of Vav binds to Grb2 and Grb3-3. Ramos-Morales F, et al. **Oncogene** 1995 Oct 19; 11(8):1665-9

Pulmonary gastrin-releasing peptide expression in anencephaly. Jaramillo MA, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):377-87

Characterization of receptors using cyanine 3-labeled neuropeptides. Bunnett NW, et al. **Peptides** 1995; 16(4):733-40

Immunoprecipitation and characterization of a binding protein specific for the peptide, intestinal trefoil factor. Chinery R, et al. **Peptides** 1995;16(4):749-55

Distribution of enteric neural peptide YY in the dog gastrointestinal tract. Iesaki K, et al. **Peptides** 1995; 16(8):1395-402

Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats. Fu-Cheng X, et al. **Pflugers Arch** 1995 Nov;431(1):66-75

Towards understanding the role of the first extracellular loop for the binding of peptide hormones to G-protein coupled receptors. Trumpp-Kallmeyer S, et al. **Pharm Acta Helv** 1995 Sep;70(3):255-62

Role of appendages in skin resistance and iontophoretic peptide flux: human versus snake skin. Craane-van Hinsberg WH, et al. **Pharm Res** 1995 Oct;12(10):1506-12

Permeability of peptides and proteins in human cultured alveolar A549 cell monolayer. Kobayashi S, et al. **Pharm Res** 1995 Aug;12(8):1115-9

The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Nerurkar MM, et al. **Pharm Res** 1996 Apr; 13(4):528-34

Cloning of a second Arabidopsis peptide transport gene. Song W, et al. **Plant Physiol** 1996 Jan;110(1):171-8

A recessive mutation, immune deficiency (imd), defines two distinct control pathways in the Drosophila host defense. Lemaitre B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9465-9

Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Playford RJ, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2137-42

Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2 Sparks AB, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1540-4

Localization and characterization of neuropeptide Y/peptide YY receptors in the brain of the smooth dogfish (Mustelis canis). McVey DC, et al. **Regul Pept** 1996 Mar 22; 61(3):167-73

Dependence of peptide binding by MHC class I molecules on their interaction with TAP. Grandea AG 3rd, et al. **Science** 1995 Oct 6;270(5233):105-8

Identification of D-peptide ligands through mirror-image phage display. Schumacher TN, et al. **Science** 1996 Mar 29;271(5257):1854-7

Hormone mimicry [comment] Wells JA. **Science** 1996 Jul 26;273(5274):449-50. Comment on: Science 1996 Jul 26;273(5274):458-63. Comment on: Science 1996 Jul 26;273(5274):464-71.

Decrypting class I MHC-bound peptides with peptide libraries. Udaka K. **Trends Biochem Sci** 1996 Jan;21(1):7-11 (23 ref.)

Anchorage and release of Gram-positive bacterial cell-surface polypeptides. Jenkinson HF. **Trends Microbiol** 1995 Sep;3(9):333-5 (15 ref.)

Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Babu JS, et al. **Vaccine** 1995 Dec;13(17):1669-76

Tyrosine phosphorylation of phospholipase C-gamma 1 by vaccinia virus growth factor. Kim HS, et al. **Virology** 1995 Dec 1;214(1):21-8

[Analysis of the allele specific Ag-binding site on murine class II MHC] Kajino K. **Hokkaido Igaku Zasshi** 1996 Mar; 71(2):187-203 (Eng. Abstr.) **(Jpn)**

[A family of Kex2-like endoproteases involved in processing of precursors for biologically active peptides and proteins] Nakayama K. **Seikagaku** 1995 Aug;67(8):995-1009 (95 ref.) **(Jpn)**

[Additional groups of nonapeptidergic neurosecretory cells in secretory cells of the hypothalamus and adjacent brain areas in dehydrated rats] Grinevich VV, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):268-70 **(Rus)**

[A comparative analysis of the polypeptide composition of heat shock proteins 70 synthesized in Wistar and August rat myocardium. Zamotrinskii AV, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):30-2 **(Rus)**

[Use of specific peptide-nucleic acid binding with DNA in the "Achilles heel" method] Krasil'nikova MM, et al. **Dokl Akad Nauk** 1995 Oct;344(4):552-5 **(Rus)**

[Localizing the major peptides of African swine fever virus and virus-associated enzymes in the virion structure] Kolontsov AA. **Mol Gen Mikrobiol Virusol** 1995 Jul-Sep; (3):34-8 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. Sasaki H, et al. **J Drug Target** 1995;3(2):129-35

Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. Bai JP, et al. **J Pharm Sci** 1995 Nov;84(11):1291-4

Physical model relating diffusional transport and concurrent

metabolism of peptides in metabolically active cell sheets. Steinsträsser I, et al. **J Pharm Sci** 1995 Nov;84(11):1332–41

Conformationally constrained peptide drugs targeted at the blood–brain barrier. Davis TP, et al. **NIDA Res Monogr** 1995;154:47–60 (24 ref.)

Oral peptide delivery: improving the systemic availability of small peptides and enkephalin analogs. Lee HJ, et al. **NIDA Res Monogr** 1995;154:86–106 (16 ref.)

Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. Nicol P, et al. **Peptides** 1995;16(8):1343–50

In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Chong S, et al. **Pharm Res** 1996 Jan;13(1):120–3

Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model. Niemiec SM, et al. **Pharm Res** 1995 Aug;12(8):1184–8

Transport of peptidomimetic renin inhibitors across monolayers of a human intestinal cell line (Caco-2): evidence for self-enhancement of paracellular transport route. Walter E, et al. **Pharm Res** 1995 Nov;12(11):1801–5

Cerebrovascular permeability to peptides: manipulations of transport systems at the blood–brain barrier. Zlokovic BV. **Pharm Res** 1995 Oct;12(10):1395–406 (72 ref.)

PHARMACOLOGY

Cationic bactericidal peptides. Hancock RE, et al. **Adv Microb Physiol** 1995;37:135–75 (215 ref.)

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91–41 (112 ref.)

Differential activation of the extracellular signal-regulated kinase, Jun kinase and Janus kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived Kaposi's sarcoma cells. Faris M, et al. **AIDS** 1996 Apr;10(4):369–78

Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells. Esté JA, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1355–8

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Harrington RA, et al. **Am J Cardiol** 1995 Dec 15;76(17):1222–7

Stimulation of surfactant lipid secretion from fetal type II pneumocytes by gastrin-releasing peptide. Asokananthan N, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L331–7

Central inhibitory action of peptide YY on gastric motility in rats. Chen CH, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R787–92

Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. Fukuhara M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1289–93

Hindbrain GRP receptor blockade antagonizes feeding suppression by peripherally administered GRP. Ladenheim EE, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R180–4

Regulation of colonic ion transport by GRP. I. GRP stimulates transepithelial K and Na secretion. Traynor TR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C848–58

Regulation of colonic ion transport by GRP. II. GRP modulates the epithelial response to PGE2. Traynor TR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C859–65

Permeability of human isolated airways increases after hydrogen peroxide and poly-L-arginine. Hulsmann AR, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):841–6

Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Liu CD, et al. **Am J Surg** 1996 Jan;171(1):192–6

Peptide YY: a potential proabsorptive hormone for the treatment of malabsorptive disorders. Liu CD, et al. **Am Surg** 1996 Mar;62(3):232–6

Spinal antinociceptive action of an N-Type voltage-dependent calcium channel blocker and the synergistic interaction with morphine. Omote K, et al. **Anesthesiology** 1996 Mar;84(3):636–43

Mechanism of XIP in cardiac sarcolemmal vesicles. Hale CC. **Ann N Y Acad Sci** 1996 Apr 15;779:171–81 (7 ref.)

Substrate-induced translocation of PKC-alpha to the membrane. Bruins RH, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):216–22

Synthesis and biological studies on analogs of cyclolinopeptide A with a shortened peptide chain. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5–6):459–65

Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Orvim U, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2188–94

Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Nemoto O, et al. **Arthritis Rheum** 1996 Apr;39(4):560–6

Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Cawston TE, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):377–85

Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. Chini EN, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):868–73

Modulation of adhesion-dependent cAMP signaling by echistatin and alendronate. Fong JH, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):19–24

Effect of polycation peptides on mitochondrial permeability transition. Rigobello MP, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):144–9

Such hydrophobic peptides as dansylated mastoparan can elevate the fertilization membrane of sea urchin eggs. Saito K, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):828–34

Adrenomedullin induces expression of c-fos and AP-1 activity in rat vascular smooth muscle cells and cardiomyocytes. Sato A, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):211–6

Differential mobilization of tyrosine kinases in human platelets stimulated with thrombin or thrombin receptor agonist peptide. Satoh K, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1084–9

Lactate production from the rat hindlimb is increased after glucose administration and is suppressed by a selective amylin antagonist: evidence for action of endogenous amylin in skeletal muscle. Vine W, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):554–9

Partial knockdown of G alpha i2 protein is sufficient to abolish the coupling of PYY receptors to biological response in renal proximal tubule cells. Voisin T, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):16–21

Vasopressor activities of N-terminal fragments of adrenomedullin in anesthetized rat. Watanabe TX, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):59–63

Two novel rat guanylin molecules, guanylin-94 and guanylin-16, do not increase cyclic GMP production in T84 cells. Yamaguchi H, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1204–10

A superactive peptidomimetic analog of a farnesylated dodecapeptide yeast pheromone. Zhang YL, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):327–31

Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. Blondelle SE, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):141–7

Dimerization of truncated melittin analogues results in cytolytic peptides. Rivett DE, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):525–9

Astroglia-released factor with negative allosteric modulatory properties at the GABA A receptor. Rigo JM, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):465–73

Inhibition of integrin-ligand binding by recombinant kistrins. Green LJ, et al. **Biochem Soc Trans** 1995 Nov;23(4):505S

Protein and peptide inhibitors of the F1-ATPase. Harris DA. **Biochem Soc Trans** 1995 Nov;23(4):790–3

A novel hydrophobic omega-conotoxin blocks molluscan dihydropyridine-sensitive calcium channels. Fainzilber M, et al. **Biochemistry** 1996 Jul 2;35(26):8748–52

Differentiation of the two forms of GPIb functioning as receptors for alpha-thrombin and von Willebrand factor: Ca2+ responses of protease-treated human platelets activated with alpha-thrombin and the tethered ligand peptide. Greco NJ, et al. **Biochemistry** 1996 Jan 23; 35(3):915–21

An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Matsuzaki K, et al. **Biochemistry** 1996 Sep 3;35(35):11361–8

Magainin-induced cytotoxicity in eukaryotic cells: kinetics, dose-response and channel characteristics. Haimovich B, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):149–58

Membrane permeabilization by alpha-helical peptides: a flow cytometry study. Midoux P, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):249–56

Prenylcysteine analogs mimicking the C-terminus of GTP-binding proteins stimulate exocytosis from permeabilized HIT-T15 cells: comparison with the effect of Rab3AL peptide. Regazzi R, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):269–78

Fusion of liposomes due to transient and lasting perturbation induced by synthetic amphiphilic peptides. Zhao J, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):37–44

RGD-mediated adhesion of porcine granulosa cells modulates their differentiation response to FSH in vitro. Goxe B, et al. **Biol Cell** 1995;83(2–3):169–77

Surfaces modified with covalently-immobilized adhesive peptides affect fibroblast population motility. Olbrich KC, et al. **Biomaterials** 1996 Apr;17(8):759–64

Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5–23 (66 ref.)

Interaction of mastoparan-B from venom of a hornet in Taiwan with phospholipid bilayers and its antimicrobial activity. Park NG, et al. **Biopolymers** 1995 Dec; 36(6):793–801

Mechanism of liposome destabilization by polycationic amino acids. Epand RM, et al. **Biosci Rep** 1995 Jun;15(3):151–60

RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets. Udvardy M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):481–5

Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Chiang HS, et al. **Br J Cancer** 1996 Apr;73(7):902–8

Effects of calcitonin gene-related peptide receptor antagonists on renal actions of adrenomedullin. Elhawary AM, et al. **Br J Pharmacol** 1995 Aug;115(7):1133–40

A role for Q type Ca2+ channels in neurotransmission in the rat urinary bladder. Frew R, et al. **Br J Pharmacol** 1995 Sep;116(1):1595–8

Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Gué M, et al. **Br J Pharmacol** 1996 May;118(2):237–42

Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Miura K, et al. **Br J Pharmacol** 1995 Jul;115(6):917–24

Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter. Ny L, et al. **Br J Pharmacol** 1995 Dec; 116(7):2873–80

Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Olianas MC, et al. **Br J Pharmacol** 1996 May;118(2):283–8

Contractile actions of thrombin receptor-derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems. Tay-Uyboco J, et al. **Br J Pharmacol** 1995 Jun;115(4):569–78

Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: effect on neurotensin degradation in vitro and in vivo. Vincent B, et al. **Br J Pharmacol** 1995 Jul;115(6):1053–63

New high affinity peptide antagonists to the spinal galanin receptor. Xu XJ, et al. **Br J Pharmacol** 1995 Oct; 116(3):2076–80

Transient brain ischemia in rabbits: the effect of omega-conopeptide MVIIC on hippocampal excitatory amino acids. Wu G, et al. **Brain Res** 1995 Sep 18; 692(1–2):118–22

Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors in the double-perfused mesenteric bed of the rat. Berthiaume N, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1080–3

The antitumoral compound Kahalalide F acts on cell lysosomes. García-Rocha M, et al. **Cancer Lett** 1996 Jan 19;99(1):43–50

Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cohen AJ, et al. **Cancer Res** 1996 Feb 15;56(4):831–9

B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. Renschler MF, et al. **Cancer Res** 1995 Dec 1;55(23):5642–7

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Salgaller ML, et al. **Cancer Res** 1995 Nov 1;55(21):4972–9

Gastrulation in the sea urchin, Strongylocentrotus purpuratus, is disrupted by the small laminin peptides YIGSR and IKVAV. Hawkins RL, et al. **Cell Adhes Commun** 1995 May;3(2):163–77

Specific tolerization of active cytolytic T lymphocyte responses in vivo with soluble peptides. Duarte EA, et al. **Cell Immunol** 1996 Apr 10;169(1):16–23

Synthetic octapeptide pyroGlu-Asp-Asp-Ser-Asp-Glu-Glu-Asn promotes differentiation in promyelocytic HL-60 cell line. Marsili V, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jun; 41(4):515–23

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675–87 (74 ref.)

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853–8

Studies on adrenomedullin: a novel hypotensive peptide. Tian Q, et al. **Chin Med J (Engl)** 1995 Oct;108(10):781–2

Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Horio T, et al. **Circ Res** 1995 Oct; 77(4):660–4

Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). Brander C, et al. **Clin Exp Immunol** 1996 Jul; 105(1):18–25

Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. Ishiyama Y, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):614–8

Spermicidal activity of Magainins: in vitro and in vivo studies. Reddy KV, et al. **Contraception** 1996 Apr; 53(4):205–10

Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). Geisterfer M, et al. **Cytokine** 1995 Aug;7(6):503–9

Hepatic stimulator substance administration enhances regenerative capacity of hepatocytes in cadmium-pretreated partially hepatectomized rats. Theocharis SE, et al. **Dig Dis Sci** 1996 Jul;41(7):1475–80

The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Juszkiewicz M, et al. **Drugs Exp Clin Res** 1995;21(4):153–6

A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus–cell fusion: an emerging similarity with functional domains of other viruses. Rapaport D, et al. **EMBO J** 1995 Nov 15;

14(22):5524–31
Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption [see comments] Jay PR, et al. **Endocrinology** 1996 Apr;137(4):1151–8. Comment in: Endocrinology 1996 Apr;137(4):1149–50.
Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells. Levy JB, et al. **Endocrinology** 1996 Apr; 137(4):1159–65
Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Martínez A, et al. **Endocrinology** 1996 Jun;137(6):2626–32
Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Roberge JN, et al. **Endocrinology** 1996 Jun;137(6):2383–8
A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. Oren Z, et al. **Eur J Biochem** 1996 Apr 1;237(1):303–10
Effects of pancreatic spasmolytic Polypeptide (PSP) on epithelial cell function. Otto WR, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):64–72
Surface-associated material from the bacterium Actinobacillus actinomycetemcomitans contains a peptide which, in contrast to lipopolysaccharide, directly stimulates fibroblast interleukin-6 gene transcription. Reddi K, et al. **Eur J Biochem** 1996 Mar 15;236(3):871–6
Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. Ahren B, et al. **Eur J Endocrinol** 1996 Mar;134(3):362–5
Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Griem P, et al. **Eur J Immunol** 1996 Feb;26(2):279–87
Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form. Nihira SI, et al. **Eur J Immunol** 1996 Aug;26(8):1736–42
Inhibition of thymocyte negative selection by T cell receptor antagonist peptides. Williams O, et al. **Eur J Immunol** 1996 Mar;26(3):532–8
Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects. Haynes JM, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):91–4
Mystixin-7 and mystixin-11 increase cytosolic free Ca2+ and inositol trisphosphates in human A-431 cells. Kiang JG. **Eur J Pharmacol** 1995 Oct 15;291(2):107–13
Enhancement of catalytic activities of serine proteases by tripeptides compounds. Hiwasa T, et al. **FEBS Lett** 1996 May 13;386(1):47–50
DNA-binding sperm proteins with oligo-arginine clusters function as potent activators for egg CK-II. Ohtsuki K, et al. **FEBS Lett** 1996 Jan 8;378(2):115–20
Novel effects of dendrotoxin homologues on subtypes of mammalian Kv1 potassium channels expressed in Xenopus oocytes. Robertson B, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):26–30
Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. Withers DJ, et al. **FEBS Lett** 1996 Jan 2;378(1):83–7
Myelopeptide-1 blocks the T-suppressor activity. Petrov RV, et al. **Folia Biol (Praha)** 1994;40(6):455–61
Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats [see comments] Babyatsky MW, et al. **Gastroenterology** 1996 Feb; 110(2):489–97. Comment in: Gastroenterology 1996 Feb;110(2):632–5.
Trefoil peptides: a novel modality to prevent gastric injury? [editorial; comment] Rachmilewitz D. **Gastroenterology** 1996 Feb;110(2):632–5. Comment on: Gastroenterology 1996 Feb;100(2):489–97.
Stimulation of osmoregulating processes in the perfused gill of the crab Pachygrapsus marmoratus (Crustacea, Decapoda) by a sinus gland peptide. Eckhardt E, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):169–77
Effect of omega-conotoxin GVIA on tetrodotoxin-insensitive acetylcholine release by nicotine in guinea-pig bladder. Shinkai M, et al. **Gen Pharmacol** 1995 Sep;26(5):1077–81
Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Harris AW, et al. **Gut** 1996 May; 38(5):663–7
Adrenomedullin increases inducible nitric oxide synthase in rat vascular smooth muscle cells stimulated with interleukin-1. Ikeda U, et al. **Hypertension** 1996 Jun; 27(6):1240–4
Interaction of adrenomedullin and platelet-derived growth factor on rat mesangial cell production of endothelin. Kohno M, et al. **Hypertension** 1996 Mar;27(3 Pt 2):663–7
Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. Yamaguchi T, et al. **Hypertension** 1996 Aug;28(2):308–14
Modulation of LIF expression in human melanoma cells by oncostatin M. Heymann D, et al. **Immunol Lett** 1995 Jun; 46(3):245–51
SPC3, a nontoxic peptide inhibitor of HIV infection [letter] Sabatier JM, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun; 31(6):415–8
Designing of peptides with immuno-modulatory properties using protein A as a probe. Ray PK, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):372–7
Role of YadA in resistance to killing of Yersinia enterocolitica by antimicrobial polypeptides of human granulocytes. Visser LG, et al. **Infect Immun** 1996 May; 64(5):1653–8
Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases. Basak A, et al. **Int J Pept Protein Res** 1995 Sep-Oct;46(3–4):228–37
Sperm immobilizing activity of a synthetic bioactive peptide 20–44 of 37-kDa cationic antimicrobial protein (CAP37) of human neutrophils. D'Cruz OJ, et al. **J Androl** 1995 Sep-Oct;16(5):432–40
Effect of form of nitrogen on growth of ruminal microbes in continuous culture. Griswold KE, et al. **J Anim Sci** 1996 Feb;74(2):483–91
Induction of bacteriocin production in Lactobacillus sake by a secreted peptide. Eijsink VG, et al. **J Bacteriol** 1996 Apr; 178(8):2232–7
Structural studies of a peptide activator of human lecithin-cholesterol acyltransferase. Buchko GW, et al. **J Biol Chem** 1996 Feb 9;271(6):3039–45
Mode of action of the antimicrobial peptide indolicidin. Falla TJ, et al. **J Biol Chem** 1996 Aug 9;271(32):19298–303
Promotion of fibroblast adhesion by triple-helical peptide models of type I collagen-derived sequences. Grab B, et al. **J Biol Chem** 1996 May 24;271(21):12234–40
Peptide probe of ryanodine receptor function. Imperatoxin A, a peptide from the venom of the scorpion Pandinus imperator, selectively activates skeletal-type ryanodine receptor isoforms. el-Hayek R, et al. **J Biol Chem** 1995 Dec 1;270(48):28696–704
Cloning and expression of cDNA encoding a rat adrenomedullin receptor. Kapas S, et al. **J Biol Chem** 1995 Oct 27;270(43):25344–7
Serine protease inhibition by insect peptides containing a cysteine knot and a triple-stranded beta-sheet. Kellenberger C, et al. **J Biol Chem** 1995 Oct 27; 270(43):25514–9
Identification of three subunits of the high affinity omega-conotoxin MVIIC-sensitive Ca2+ channel. Liu H, et al. **J Biol Chem** 1996 Jun 7;271(23):13804–10
Activity of the mitochondrial multiple conductance channel is independent of the adenine nucleotide translocator. Lohret TA, et al. **J Biol Chem** 1996 Mar 1;271(9):4846–9
Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin. Lu X, et al. **J Biol Chem** 1996 Jan 5;271(1):289–94
Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. Sakamoto H, et al. **J Biol Chem** 1996 Mar 1;271(9):4916–22
Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides. Shai Y, et al. **J Biol Chem** 1996 Mar 29;271(13):7305–8
Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP-19, neurogranin, and neuromodulin. Slemmon JR, et al. **J Biol Chem** 1996 Jul 5;271(27):15911–7
Upmodulation of alpha v beta 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin. Heymann D, et al. **J Cell Biochem** 1995 Jul;58(3):305–14
Recognition of two classes of oligoproline sequences in profilin-mediated acceleration of actin-based Shigella motility: Zeile WL, et al. **J Cell Biol** 1996 Apr;133(1):49–59
Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7–37). Hosokawa YA, et al. **J Clin Invest** 1996 Jan 1;97(1):180–6
Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. Nishimura F, et al. **J Dent Res** 1996 Apr;75(4):986–92
Melanin-concentrating hormone gene-related peptide stimulates ACTH, but not alpha-MSH, release from the tilapia pituitary. Gröneveld D, et al. **J Endocrinol** 1996 Jan;148(1):R1–4
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. Chauhan D, et al. **J Exp Med** 1995 Dec 1;182(6):1801–6
Mature T cell reactivity altered by peptide agonist that induces positive selection. Sebzda E, et al. **J Exp Med** 1996 Mar 1;183(3):1093–104
Modification of inactivation in cardiac sodium channels: ionic current studies with Anthopleurin-A toxin. Hanck DA, et al. **J Gen Physiol** 1995 Oct;106(4):601–16
Voltage-dependent open-state inactivation of cardiac sodium channels: gating current studies with Anthopleurin-A toxin. Sheets MF, et al. **J Gen Physiol** 1995 Oct; 106(4):617–40
Lysis of small cell carcinoma of the lung (SCCL) cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide (GRP) analog or a GRP antagonist. Chen J, et al. **J Hematother** 1995 Oct; 4(5):369–76
Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. Kano H, et al. **J Hypertens** 1996 Feb; 14(2):209–13
Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts. Richards CD, et al. **J Immunol** 1996 Jan 1;156(1):343–9
Poly-L-ornithine-mediated transfection of human keratinocytes. Nead MA, et al. **J Invest Dermatol** 1995 Nov; 105(5):668–71
Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. Hirschman SZ, et al. **J Investig Med** 1996 Aug;44(6):347–51
Screening derivatized peptide libraries for tight binding inhibitors to carbonic anhydrase II by electrospray ionization-mass spectrometry. Gao J, et al. **J Med Chem** 1996 May 10;39(10):1949–55
De novo antimicrobial peptides with low mammalian cell toxicity. Javadpour MM, et al. **J Med Chem** 1996 Aug 2; 39(16):3107–13
Conotoxin-sensitive and conotoxin-resistant Ca2+ currents in fish retinal ganglion cells. Bindokas VP, et al. **J Neurobiol** 1996 Apr;29(4):429–44
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. Teitelbaum D, et al. **J Neuroimmunol** 1996 Feb; 64(2):209–17
Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC. McDonough SI, et al. **J Neurosci** 1996 Apr 15;16(8):2612–23
Effect of human adrenomedullin on vascular resistance of the canine tibia. Kato T, et al. **J Orthop Res** 1996 Mar; 14(2):329–33
Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):484–90
Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. Bossuyt X, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):891–6
Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig. Feurle GE, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):654–61
Conformationally biased analogs of human C5a mediate changes in vascular permeability. Kawatsu R, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):432–40
Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes. Lin JT, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):285–95
Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. Prechel MM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1136–42
Preparations of psi-peptide bond and peptide-aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro-atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431–40
Chronic lateral ventricle infusion of a pineal gland-derived decapeptide alters pulsatile secretion of LH in rats. Benson B, et al. **Life Sci** 1996;58(13):1083–90
[MPR14]-rADM(14–50), a novel analog of adrenomedullin, possesses potent vasodilator activity in the hindlimb vascular bed of the cat. Champion HC, et al. **Life Sci** 1996; 59(1):PL1–7
Adrenomedullin stimulates calcium efflux from adrenal chromaffin cells in culture: possible involvement of an Na+/Ca2+ exchange mechanism. Houchi H, et al. **Life Sci** 1996;58(2):PL 35–40
Comparison of bronchodilator responses to adrenomedullin and proadrenomedullin N-terminal 20 peptide. Kanazawa H, et al. **Life Sci** 1995;57(16):PL241–5
Adrenomedullin and calcitonin gene-related peptide inhibit aldosterone secretion in rats, acting via a common receptor. Mazzocchi G, et al. **Life Sci** 1996;58(10):839–44
Endothelin analogs which distinguish vasoconstrictor and vasodilator ETB receptors. Natarajan S, et al. **Life Sci** 1995 Mar 3;56(15):1251–6
Comparison of the glucose dependency of glucagon-like peptide-1 (7–37) and glyburide in vitro and in vivo. Hargrove DM, et al. **Metabolism** 1996 Mar;45(3):404–9
Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Young AA, et al. **Metabolism** 1996 Jan; 45(1):1–3
Peptides derived from the lectin domain of selectin adhesion molecules inhibit leukocyte rolling in vivo. Norman KE, et al. **Microcirculation** 1996 Mar;3(1):29–38
Polyarginine and eosinophil-derived major basic protein increase microvascular permeability independently of histamine or nitric oxide release. Minnicozzi M, et al. **Microvasc Res** 1995 Jul;50(1):56–70
Phosphorylation and localization of Kss1, a MAP kinase of the Saccharomyces cerevisiae pheromone response pathway. Ma D, et al. **Mol Biol Cell** 1995 Jul;6(7):889–909
Yeast alpha mating factor structure-activity relationship derived from genetically selected peptide agonists and antagonists of Ste2p. Manfredi JP, et al. **Mol Cell Biol** 1996 Sep;16(9):4700–9
Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2. Balbo M, et al.

Mol Immunol 1995 Nov;32(16):1295–8

Immunological effect of a synthetic growth hormone peptide on the growth performance in swine. Wang BS, et al. **Mol Immunol** 1996 May–Jun;33(7–8):609–14

Structure–activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand–receptor binding. Daniels AJ, et al. **Mol Pharmacol** 1995 Sep;48(3):425–32

Thrombin receptor activation by thrombin and receptor–derived peptides in platelet and CHRF–288 cell membranes: receptor–stimulated GTPase and evaluation of agonists and partial agonists. Seiler SM, et al. **Mol Pharmacol** 1996 Jan;49(1):190–7

omega–Conotoxin GVIA disrupts memory formation in the day–old chick. Clements MP, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):276–84

Technical note on omega–conotoxin GVIA disrupts memory formation in the day–old chick. Deyo RA. **Neurobiol Learn Mem** 1996 Jul;66(1):89–90; discussion 91–2

An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Swartz KJ, et al. **Neuron** 1995 Oct;15(4):941–9

Affinity purification of rat cortical and chicken forebrain synaptosomes using a biotinylated derivative of omega–CgTx GVIA. Bowman D, et al. **Neuropharmacology** 1995 Jul;34(7):743–52

Presynaptic metabotropic glutamate receptors modulate omega–conotoxin–GVIA–insensitive calcium channels in the rat medulla. Glaum SR, et al. **Neuropharmacology** 1995 Aug;34(8):953–64

Inhibitory effects of newly synthesized Ser–contained GABA–peptides administered into either caudate putamen or amygdala on methamphetamine–induced hyperactivity. Watanabe Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):239–46

Nutrient intake is modulated by peripheral peptide administration. Bray GA. **Obes Res** 1995 Nov;3 Suppl 4:569S–572S (31 ref.)

HLA–derived peptides as novel immunosuppressives. Krensky AM. **Pediatr Res** 1995 Sep;38(3):275–9 (25 ref.)

A synthetic peptide corresponding to glycoprotein hormone alpha subunit residues 32–46 inhibits gonadotropin binding to receptor. Leng N, et al. **Pept Res** 1995 Sep–Oct; 8(5):272–7

Effects of peptide YY and its analogues on chloride ion secretion in fed and fasted rat jejunum. Eto B, et al. **Peptides** 1995;16(8):1403–9

Structure–activity relationships for Periplaneta americana hypertrehalosemic hormone. I: The importance of side chains and termini. Gäde G, et al. **Peptides** 1995; 16(7):1173–80

Microstructural analysis of licking behavior following peripheral administration of bombesin or gastrin–releasing peptide. Stratford TR, et al. **Peptides** 1995;16(5):903–9

Evaluation of a novel osteogenic factor, bone cell stimulating substance, in a rabbit cranial defect model. Ashby ER, et al. **Plast Reconstr Surg** 1996 Sep;98(3):420–6

Biochemical characteristics of a human myeloid leukemia cell differentiation factor. Xu W, et al. **Prep Biochem Biotechnol** 1996 Feb;26(1):21–30

High–affinity neuropeptide Y receptor antagonists. Daniels AJ, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9067–71

Potent, structurally constrained agonists and competitive antagonists of corticotropin–releasing factor. Gulyas J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10575–9

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T–cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft–versus–host disease in vivo. Schlegel PG, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5061–6

PR–39, a proline–rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Shi J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6014–8

High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Yanofsky SD, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7381–6

A fragment of human kininogen containing bradykinin blunts the diuretic effect of atrial natriuretic peptide. Croxatto HR, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):128–34

Renal effects of adrenomedullin in the rat. Vari RC, et al. **Proc Soc Exp Biol Med** 1996 Feb;211(2):178–83

Contractile actions of thrombin receptor–derived polypeptides in rat and guinea pig lung parenchymal smooth muscle. Mandhane P, et al. **Proc West Pharmacol Soc** 1995;38:93–6

Stimulation of natural killer (NK) and antibody–dependent cellular cytotoxicity (ADCC) activities in murine leukocytes by bombesin–related peptides requires the presence of adherent cells. Del Rio M, et al. **Regul Pept** 1995 Dec 14;60(2–3):159–66

GLP–1 depolarizes the rat pancreatic beta cell in a Na(+)–dependent manner. Kato M, et al. **Regul Pept** 1996 Apr 9;62(1):23–7

Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells. Masera RG, et al. **Regul Pept** 1996 Apr 9;62(1):13–21

Inhibitory effects of gastrin releasing peptide on gastric emptying in rats. Yeğen BC, et al. **Regul Pept** 1996 Mar 22;61(3):175–80

Liver regeneration following partial hepatectomy and stimulation by hepatic stimulatory substance in cirrhotic and non–cirrhotic rats. Hwang TL, et al. **Res Exp Med (Berl)** 1995;195(4):201–8

A comparison of the effect of decorsin and two disintegrins, albolabrin and eristostatin, on platelet function. McLane MA, et al. **Thromb Haemost** 1995 Nov;74(5):1316–22

Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Hathaway LJ, et al. **Vaccine** 1995 Nov;13(16):1495–500

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Levi R, et al. **Vaccine** 1995 Oct;13(14):1353–9

Effect of bursal anti–steroidogenic peptide (BASP) on cortisol biosynthesis in ACTH–stimulated canine adrenocortical carcinoma cells in vitro. Byrd JA, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1–2):35–42

Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein–mediated membrane fusion and cell death. Callebaut C, et al. **Virology** 1996 Apr 1;218(1):181–92

Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Lombardi S, et al. **Virology** 1996 Jun 15;220(2):274–84

[Observation on hypotensive action of adrenomedullin and its distribution in tissues] Song LW, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):408–11 (Eng. Abstr.) **(Chi)**

[A study on hypotensive mechanism of adrenomedullin (13–52)] Zhao D, et al. **Sheng Li Hsueh Pao** 1995 Jun; 47(3):218–24 (Eng. Abstr.) **(Chi)**

[Inflammation cytokines and peroxidation of low density lipoproteins (LDL)] Mazière JC, et al. **C R Seances Soc Biol Fil** 1995;189(5):811–25 (Eng. Abstr.) **(Fre)**

[Casein–derived peptides can promote human LDL oxidation by a peroxidase–dependent and metal–independent process] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995; 189(5):933–42 (Eng. Abstr.) **(Fre)**

[Antisecretory effects of YY peptide and neuropeptide Y at three levels of the small intestine in rats] Souli A, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):8–14 (Eng. Abstr.) **(Fre)**

[Anti–adhesive and anti–thrombotic effects of integrin–inhibiting tripeptides (Arg–Gly–Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155–9 (42 ref.) (Eng. Abstr.) **(Hun)**

[Antimicrobial peptides and resistance in animals] Kharchenko EP. **Antibiot Khimioter** 1995 Jul;40(7):45–53 (33 ref.) **(Rus)**

[Mediated participation of the opioid system in regulation of pain sensitivity by peptide fragments MP1 and MP2] Maliukova IV, et al. **Biokhimiia** 1996 Mar;61(3):440–4 (Eng. Abstr.) **(Rus)**

[Sedative and antistress action of a peptide complex isolated from human amnion] Borshchevskaia MI, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):57–9 **(Rus)**

[Stimulating effect of a polypeptide substance (Cuban stimulator) on hemopoiesis and formation of humoral immunity to murine thymus–dependent antigen] Shurygin AIa, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):511–4 **(Rus)**

[Melatonin and epithalamin inhibit the process of free radical oxidation in rats] Anisimov VN, et al. **Dokl Akad Nauk** 1995 Aug;343(4):557–9 **(Rus)**

[Protegrins—a new family of peptides of leukocytic origin, modulating the functional activity of platelets] Tkachenko SB, et al. **Dokl Akad Nauk** 1996 Mar;347(1):126–8 **(Rus)**

[The immunocorrective activity of myelopeptide–1 and myelopeptide–2 in cyclophosphane–treated mice] Shanurin SIu, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):53–6 **(Rus)**

[The effect of polypeptides released by the thrombocytes during a liberation reaction on immunity and hemostasis] Aiushiev OD, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):80–5 (Eng. Abstr.) **(Rus)**

[The opiate–like and antimicrobial bioactivities of food protein peptides] Kharchenko EP. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):71–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341–7 (52 ref.)

Myelopeptides: new immunoregulatory peptides. Petrov R. **Allergy Proc** 1995 Jul–Aug;16(4):177–84 (14 ref.)

Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Forte LR, et al. **Am J Kidney Dis** 1996 Aug;28(2):296–304 (35 ref.)

Tonic suppression of gastric acid secretion by endogenous peptides in neonatal rats. Rao RK, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G721–8

PYY and GLP–1 contribute to feedback inhibition from the canine ileum and colon. Wen J, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G945–52

Roles of bombesin–like peptides in lung development and lung injury [comment] Spindel ER. **Am J Respir Cell Mol Biol** 1996 May;14(5):407–8 (18 ref.) . Comment on: **Am J Respir Cell Mol Biol** 1996 May;14(5):409–16.

The trefoil peptide family. Sands BE, et al. **Annu Rev Physiol** 1996;58:253–73 (87 ref.)

Trefoil peptides. Poulsom R. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):113–34 (110 ref.)

Systemin—a polypeptide defense signal in plants. Schaller A, et al. **Bioessays** 1996 Jan;18(1):27–33 (69 ref.)

Unilateral exposure of Shaker B potassium channels to hyperosmolar solutions. Starkus JG, et al. **Biophys J** 1995 Sep;69(3):860–72

PU.1 (Spi–1) and C/EBP alpha regulate the granulocyte colony–stimulating factor receptor promoter in myeloid cells. Smith LT, et al. **Blood** 1996 Aug 15;88(4):1234–47

Spinal cord pharmacology of pain. Dickenson AH. **Br J Anaesth** 1995 Aug;75(2):193–200 (71 ref.)

Pituitary adenylate cyclase–activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Hedlund P, et al. **Br J Pharmacol** 1995 Oct;116(4):2258–66

The amphiphilic peptide adenoregulin enhances agonist binding to A1–adenosine receptors and [35S]GTP gamma S to brain membranes. Moni RW, et al. **Cell Mol Neurobiol** 1995 Aug;15(4):465–93

Adrenomedullin [editorial] Richards AM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):3–16 (84 ref.)

Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156–86 (431 ref.)

Regulation of peptide YY homeostasis by gastric acid and gastrin. Gomez G, et al. **Endocrinology** 1996 Apr; 137(4):1365–9

Cross talk between peptide growth factor and estrogen receptor signaling systems. Ignar–Trowbridge DM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:35–8 (34 ref.)

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)

Stoichiometry, organisation and catalytic function of protein X of the pyruvate dehydrogenase complex from bovine heart. Sanderson SJ, et al. **Eur J Biochem** 1996 Feb 15; 236(1):68–77

Basic actions of transforming growth factor–alpha and related peptides. Coffey RJ, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):923–7 (49 ref.)

A biological function for the XP motif within the N terminus of major histocompatibility complex class II–associated peptides. Breloer M, et al. **Eur J Immunol** 1996 Aug; 26(8):1825–9

Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand–induced binding site on beta 3 subunit. Juliano D, et al. **Exp Cell Res** 1996 May 25;225(1):132–42

Fat–induced ileal brake in the dog depends on peptide YY. Lin HC, et al. **Gastroenterology** 1996 May;110(5):1491–5

The role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Hautmann G, et al. **Int Angiol** 1995 Jun;14(2):138–50 (104 ref.)

Interleukin 4 or oncostatin M induces a prolonged increase in P–selectin mRNA and protein in human endothelial cells. Yao L, et al. **J Exp Med** 1996 Jul 1;184(1):81–92

Endocrine regulation of food intake and body weight. Figlewicz DP, et al. **J Lab Clin Med** 1996 Apr; 127(4):328–32 (43 ref.)

Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005–9 (52 ref.). Comment in: Kidney Int 1996 Apr;49(4):1010–1.

Preservation of intestine protein by peptide YY during total parenteral nutrition. Chance WT, et al. **Life Sci** 1996; 58(21):1785–94

Ribosome regulation by the nascent peptide. Lovett PS, et al. **Microbiol Rev** 1996 Jun;60(2):366–85 (148 ref.)

Schizosaccharomyces pombe zfs1+ encoding a zinc–finger protein functions in the mating pheromone recognition pathway. Kanoh J, et al. **Mol Biol Cell** 1995 Sep; 6(9):1185–95

Sst2, a negative regulator of pheromone signaling in the yeast Saccharomyces cerevisiae: expression, localization, and genetic interaction and physical association with Gpa1 (the G–protein alpha subunit). Dohlman HG, et al. **Mol Cell Biol** 1996 Sep;16(9):5194–209

Yeast alpha mating factor structure–activity relationship derived from genetically selected peptide agonists and antagonists of Ste2p. Manfredi JP, et al. **Mol Cell Biol** 1996 Sep;16(9):4700–9

Ca2+–calmodulin promotes survival of pheromone–induced growth arrest by activation of calcineurin and Ca2+–calmodulin–dependent protein kinase. Moser MJ, et al. **Mol Cell Biol** 1996 Sep;16(9):4824–31

Cardiovascular system related peptides and hypothalamic neurons. Yamashita H, et al. **Neurobiology (Bp)** 1995; 3(3–4):419–27

Effect of peptide YY (PYY) on food–associated conflict. Hagan MM, et al. **Physiol Behav** 1995 Oct;58(4):731–5

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold–regulated) genes of Arabidopsis thaliana on the freeze–induced fusion and leakage of liposomes. Uemura M, et al. **Plant Physiol** 1996 May;111(1):313–27

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold–regulated) genes of Arabidopsis thaliana on

dehydration-induced phase transitions of phospholipid membranes. Webb MS, et al. **Plant Physiol** 1996 May; 111(1):301-12

An abundant cell-surface polypeptide is required for swimming by the nonflagellated marine cyanobacterium Synechococcus. Brahamsha B.
Proc Natl Acad Sci U S A 1996 Jun 25;93(13):6504-9

A Drosophila seminal fluid protein, Acp26Aa, stimulates egg laying in females for 1 day after mating. Herndon LA, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10114-8

A structural motif for the voltage-gated potassium channel pore. Lipkind GM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9215-9

Effect of peptide YY on gastric motor and secretory activity in vagally innervated and denervated corpus pouch dogs. Zai H, et al. **Regul Pept** 1996 Mar 22;61(3):181-8

Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Pronk GJ, et al. **Science** 1996 Feb 9;271(5250):808-10

KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis. Rooke J, et al. **Science** 1996 Aug 30;273(5279):1227-31

Ecdysis control sheds another layer [comment] Truman JW. **Science** 1996 Jan 5;271(5245):40-1. Comment on: Science 1996 Jan 5;271(5245):88-91.

Identification of ecdysis-triggering hormone from an epitracheal endocrine system [see comments] Zitñan D, et al. **Science** 1996 Jan 5;271(5245):88-91. Comment in: Science 1996 Jan 5;271(5245):40-1.

Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al.
Semin Cell Biol 1995 Apr;6(2):95-104 (105 ref.)

[Adrenomedullin] Zeng Z. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):635-7 (14 ref.) **(Chi)**

[Role of peptidergic mechanisms in thermoregulation] Mar'ianovich AT. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):35-42 (83 ref.) **(Rus)**

[The role of thymic peptides in regulating ovarian morphogenesis] Butorina OG. **Morfologiia** 1994 Jul-Dec; 107(7-12):128-40 (Eng. Abstr.) **(Rus)**

[The histophysiological characteristics of ovarian development with an altered level of thymic peptides at infancy in mice] Butorina OG, et al. **Morfologiia** 1996; 109(1):95-9 (Eng. Abstr.) **(Rus)**

SECRETION

Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Dumoulin V, et al. **Endocrinology** 1995 Nov;136(11):5182-8

Gastric emptying and release of incretin hormones after glucose ingestion in humans. Schirra J, et al.
J Clin Invest 1996 Jan 1;97(1):92-103

A peptide hormone causing abnormal hair-growth associated with malignancy. Pilszczek FH. **Med Hypotheses** 1995 Sep; 45(3):223-4 (6 ref.)

Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Sasaki A, et al.
Neurol Med Chir (Tokyo) 1995 Jul;35(7):423-30

Cytokines suppress the shear stress-stimulated release of vasoactive peptides from human endothelial cells. Bodin P, et al. **Peptides** 1995;16(8):1433-8

Effect of carbachol on the release of peptide YY from isolated vascularly and luminally perfused rat ileum. Fujimiya M, et al. **Peptides** 1995;16(5):939-44

The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut. Taupin DR, et al. **Peptides** 1995;16(6):1001-5

Release of peptide YY by neurotransmitters and gut hormones in the isolated, vascularly perfused rat colon. Plaisancié P, et al. **Scand J Gastroenterol** 1995 Jun; 30(6):568-74

THERAPEUTIC USE

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35-40 (27 ref.)

The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Cochrane CG, et al.
Am J Respir Crit Care Med 1996 Jan;153(1):404-10

Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia. Farese AM, et al. **Blood** 1996 Jan 15;87(2):581-91

Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. MacVittie TJ, et al. **Blood** 1996 May 15; 87(10):4129-35

Evaluation of hepatocyte growth-promoting factors in treating 1687 cases of fulminant hepatitis. Zhang Y, et al.
Chin Med J (Engl) 1995 Dec;108(12):928-9

Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model. Schwartz RS, et al.
Circulation 1996 Apr 15;93(8):1542-8

Peptide therapy for treatment of allergic diseases. Wallner BP, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):105-9 (51 ref.)

Olaquindox-induced persistent light reaction treated by Escherichia coli filtrate (Colibiogene) [letter] Willa-Craps C, et al. **Dermatology** 1995;191(4):343-4

Gastrin-releasing peptide, acid secretion, Helicobacter pylori, and duodenal ulcer: another epiphenomenon? [letter; comment] Graham DY. **Gastroenterology** 1996 Apr; 110(4):1325-6. Comment on: Gastroenterology 1995 Sep;109(3):681-91.

Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Zhang M, et al. **Gastroenterology** 1996 Apr; 110(4):1150-5

Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. Araga S, et al. **J Immunol** 1996 Jul 1; 157(1):386-92

Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. Warren KG, et al.
J Neurol Sci 1995 Nov;133(1-2):85-94

Activity of lytic peptides against intracellular Trypanosoma cruzi amastigotes in vitro and parasitemias in mice. Barr SC, et al. **J Parasitol** 1995 Dec;81(6):974-8

Editorials in scientific publications [letter; comment] Feasby TE. **Neurology** 1996 Mar;46(3):883. Comment on: Neurology 1995 Jul;45(7):1245-7.

Synthetic peptide derived from the Bordetella pertussis bacterium reduces infarct volume after transient middle cerebral artery occlusion in the rat. Zhang RL, et al.
Neurology 1996 May;46(5):1437-41

Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model. Beviglia L, et al. **Oncol Res** 1995;7(1):7-20

Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Revak SD, et al. **Pediatr Res** 1996 Apr; 39(4 Pt 1):715-24

Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Zisman E, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4492-7

Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Lynch JJ Jr, et al. **Thromb Haemost** 1995 Aug; 74(2):640-5

[Glucagon peptide--new treatment for late-onset diabetes? (editorial)] Koivisto V. **Duodecim** 1994;110(1):15-7 **(Fin)**

[Effect of T-activin and irradiation with a helium-neon laser on the status of the interleukin-2-dependent component of the proliferative response of mononuclear cells in rheumatoid arthritis] Parnes Ela, et al. **Fiziol Cheloveka** 1995 Jul-Aug;21(4):143-9 **(Rus)**

[Use of epithalamin in climacteric myocardiopathy] Komarov FI, et al. **Klin Med (Mosk)** 1995;73(4):40-2 **(Rus)**

[Treatment with thymogen and myelopid of patients with bronchial asthma] Zoloedov VI, et al. **Klin Med (Mosk)** 1995;73(6):43-5 (Eng. Abstr.) **(Rus)**

[The use of tactivin for treating patients with IHD] Klimov AN, et al. **Ter Arkh** 1995;67(9):24-7 (Eng. Abstr.) **(Rus)**

[Interferon and tactivin in the treatment program for non-Hodgkin's lymphomas in children during remission] Makhonova LA, et al. **Vopr Onkol** 1995;41(2):80-1 **(Rus)**

[The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer] Lukash NV, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):53-5 (Eng. Abstr.) **(Rus)**

[The validation of the use of prostatilen and testilin for treating male infertility] Bolko MI. **Lik Sprava** 1995 May-Jun;(5-6):113-7 (Eng. Abstr.) **(Ukr)**

TOXICITY

Shiva-1: in vitro and in vivo tests of the effects of a novel, synthetic, lytic peptide on ocular cells. Shahsavari M, et al. **Int Ophthalmol** 1995;19(1):29-34

A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. Cartier GE, et al. **J Biol Chem** 1996 Mar 29;271(13):7522-8

Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. Brugnara C, et al. **J Membr Biol** 1995 Sep;147(1):71-82

Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. Weeks BS, et al.
J Neurosci Res 1995 Sep 1;42(1):34-40

Solution structure of P01, a natural scorpion peptide structurally analogous to scorpion toxins specific for apamin-sensitive potassium channel. Blanc E, et al.
Proteins 1996 Mar;24(3):359-69

[Protein composition of venoms from several species of tropical ants and their effect on mitochondrial H+-ATPase] Zaltseva LG, et al. **Bioorg Khim** 1995 Aug; 21(8):563-70 (Eng. Abstr.) **(Rus)**

URINE

Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Yao WJ, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2819-23

Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits. Sone T, et al. **Bone** 1995 Oct;17(4):335-9

Circadian variation in urinary excretion of bone collagen cross-links. Bollen AM, et al. **J Bone Miner Res** 1995 Dec; 10(12):1885-90

Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Marshall LA, et al.
Obstet Gynecol 1996 Mar;87(3):350-4

Decreased urinary peptide excretion in schizophrenic patients after neuroleptic treatment. Reichelt KL, et al.
Psychiatry Res 1995 Sep 29;58(2):171-6

PEPTIDES, CYCLIC

Improvement of Salmonella detection on motility enrichment media by ferrioxamine E-supplementation of pre-enrichment culture. Pless P, et al.
Int J Food Microbiol 1995 Oct;27(2-3):147-59

ANALYSIS

Exact mass determination for elemental analysis of ions produced by matrix-assisted laser desorption. Wu J, et al.
Anal Chem 1995 Oct 15;67(20):3788-92

Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Ueno Y, et al. **Carcinogenesis** 1996 Jun; 17(6):1317-21

Two classes of metabolites from Theonella swinhoei are localized in distinct populations of bacterial symbionts. Bewley CA, et al. **Experientia** 1996 Jul 15;52(7):716-22

Mass spectral analyses of microcystins from toxic cyanobacteria using on-line chromatographic and electrophoretic separations. Bateman KP, et al.
J Chromatogr A 1995 Sep 29;712(1):253-68

Detection of cyanobacterial toxins (microcystins) in waters of northeastern Wisconsin by a new immunoassay technique. McDermott CM, et al. **Toxicon** 1995 Nov; 33(11):1433-42

[Studies on microcystin contents in different drinking water in highly endemic area of liver cancer] Chen G, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1996 Jan;30(1):6-9 (Eng. Abstr.) **(Chi)**

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584-602 (67 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Scintillation proximity assay to measure binding of soluble fibronectin to antibody-captured alpha 5 beta 1 integrin. Pachter JA, et al. **Anal Biochem** 1995 Sep 1;230(1):101-7

BIOSYNTHESIS

Peptidolactones. Keller U. **Biotechnology** 1995;28:173-96 (74 ref.)

Saprophytic Pseudomonas syringae strain M1 of wheat produces cyclic lipodepsipeptides. Adetuyi FC, et al.
FEMS Microbiol Lett 1995 Aug 15;131(1):63-7

A novel chitinase inhibitor from a marine bacterium, Pseudomonas sp. Izumida H, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):76-80

CHEMICAL SYNTHESIS

Synthesis and biological studies on analogs of cyclolinopeptide A with a shortened peptide chain. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5-6):459-65

Key analogs of the tetrapeptide subunit of RA-VII and deoxybouvardin. Boger DL, et al. **Bioorg Med Chem** 1995 Dec;3(12):1579-93

Cyclotheonamide derivatives: synthesis and thrombin inhibition. Exploration of specific structure-function issues. Maryanoff BE, et al. **Bioorg Med Chem** 1995 Aug; 3(8):1025-38

Design of metal ion binding peptides. Fattorusso R, et al.
Biopolymers 1995;37(6):401-10

Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid support. Kakiuchi M, et al.
Chem Pharm Bull (Tokyo) 1996 May;44(5):1107-10

Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1598-600

Study on surfactin, a cyclic depsipeptide. II. Synthesis of surfactin B2 produced by Bacillus natto KMD 2311. Nagai S, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):5-10

Preparation of the very acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the synthesis of side-chain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs. Aletras A, et al. **Int J Pept Protein Res** 1995 May;45(5):488-96

Synthesis of a mixture of cyclic peptides based on the Bowman-Birk reactive site loop to screen for serine protease inhibitors. Domingo GJ, et al.
Int J Pept Protein Res 1995 Jul;46(1):79-87

New cyclic bradykinin antagonists containing disulfide and lactam bridges at the N-terminal sequence. Seyfarth L, et al. **Int J Pept Protein Res** 1995 Aug;46(2):155-65

Synthesis and biological activity of NK-1 selective,

N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. Byk G, et al. **J Med Chem** 1996 Aug 2; 39(16):3174–8

Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase. Ettmayer P, et al. **J Med Chem** 1996 Aug 16;39(17):3291–9

Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. Fukami T, et al. **J Med Chem** 1995 Oct 13;38(21):4309–24

Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. Haskell-Luevano C, et al. **J Med Chem** 1995 Nov 10;38(23):4720–9

Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic. Hirschmann R, et al. **J Med Chem** 1996 Jun 21;39(13):2441–8

Synthesis and contractile activities of cyclic thrombin receptor-derived peptide analogues with a Phe-Leu-Leu-Arg motif: importance of the Phe/Arg relative conformation and the primary amino group for activity. Matsoukas JM, et al. **J Med Chem** 1996 Aug 30; 39(18):3585–91

Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. Pearson DA, et al. **J Med Chem** 1996 Mar 29;39(7):1372–82

Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. McBride JD, et al. **J Mol Biol** 1996 Jun 21; 259(4):819–27

[Synthesis of an ethylamide of the cyclic undecapeptide sequence 593–603 of transmembrane glycoprotein gp41 of the human immunodeficiency virus type 2] Sidorova MV, et al. **Bioorg Khim** 1995 Sep;21(9):675–83 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Synthesis of an N-methyldehydroalanine-containing fragment of microcystin by combination of solid phase peptide synthesis and beta-elimination in solution. Zetterström M, et al. **Acta Chem Scand** 1995 Sep; 49(9):696–700

The cyclic depsipeptide backbone of the didemnins. Mayer SC, et al. **Acta Crystallogr C** 1995 Aug 15;51 (Pt 8):1609–14

New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Schmatz DM, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1320–3

Three-dimensional structure of the alpha-conotoxin GI at 1.2 A resolution. Guddat LW, et al. **Biochemistry** 1996 Sep 3;35(35):11329–35

Three-dimensional solution structure of mu-conotoxin GIIIB, a specific blocker of skeletal muscle sodium channels. Hill JM, et al. **Biochemistry** 1996 Jul 9; 35(27):8824–35

Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence. Katz BA. **Biochemistry** 1995 Nov 28; 34(47):15421–9

Delineation of an active fragment and poly(L-proline) II conformation for candidacidal activity of bactenecin 5. Raj PA, et al. **Biochemistry** 1996 Apr 9;35(14):4314–25

Conformational studies of microcystin-LR using NMR spectroscopy and molecular dynamics calculations. Trogen GB, et al. **Biochemistry** 1996 Mar 12;35(10):3197–205

MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.—II. Solution structure of MS-271: characteristic features of the 'lasso' structure. Katahira R, et al. **Bioorg Med Chem** 1996 Jan; 4(1):121–9

Solution structure of endothelin B receptor selective antagonist RES-701-1 determined by 1H NMR spectroscopy. Katahira R, et al. **Bioorg Med Chem** 1995 Sep;3(9):1273–80

Three more cyclotheonamides, C, D, and E, potent thrombin inhibitors from the marine sponge Theonella swinhoei. Nakao Y, et al. **Bioorg Med Chem** 1995 Aug;3(8):1115–22

MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.—I. Isolation, structural determination and biological properties of MS-271. Yano K, et al. **Bioorg Med Chem** 1996 Jan; 4(1):115–20

Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase. Barchi JJ Jr, et al. **Biopolymers** 1996 Feb;38(2):191–208

Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate. Beusen DD, et al. **Biopolymers** 1995 Aug;36(2):181–200

Solution structure of regioselectively addressable functionalized templates: an NMR and restrained molecular dynamics investigation. Dumy P, et al. **Biopolymers** 1996 Sep;39(3):297–308

Unusual conformational preferences of beta-alanine containing cyclic peptides. VII. Lombardi A, et al. **Biopolymers** 1996 Jun;38(6):683–91

Solvent-mediated conformational transition in beta-alanine containing cyclic peptides. VIII. Lombardi A, et al. **Biopolymers** 1996 Jun;38(6):693–703

Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands. Lomize AL, et al. **Biopolymers** 1996 Feb; 38(2):221–34

A search for the ideal type I beta-turn. Perczel A, et al. **Biopolymers** 1996 Jun;38(6):723–32

Multiple interconverting conformers of the cyclic tetrapeptide tentoxin, [cyclo-(L-MeAla1-L-Leu2-MePhe[(Z) delta]3-Gly4)], as seen by two-dimensional 1H-nmr spectroscopy. Pinet E, et al. **Biopolymers** 1995 Aug;36(2):135–52

Bioactive peptides: conformational studies of [Tyr4] cyclolinopeptide A. Saviano M, et al. **Biopolymers** 1995 Oct;36(4):453–60

The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. Lewis RJ, et al. **EMBO J** 1996 Mar 15;15(6):1412–20

Solution conformation of the Pseudomonas syringae pv. syringae phytotoxic lipodepsipeptide syringopeptin 25-A. Two-dimensional NMR, distance geometry and molecular dynamics. Ballio A, et al. **Eur J Biochem** 1995 Dec 15; 234(3):747–58

Comparative study on the conformation of phalloidin, viroisin, and related derivatives in aqueous solution. Kobayashi N, et al. **Eur J Biochem** 1995 Sep 15; 232(3):726–36

The solution structure of the synthetic circular peptide CGVSRQGKPYC. NMR studies of the folding of a synthetic model for the DNA-binding loop of the ssDNA-binding protein encoded by gene V of phage M13. Rietman BH, et al. **Eur J Biochem** 1996 Jun 15; 238(3):706–13

Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. Vranken WF, et al. **Eur J Biochem** 1996 Feb 15; 236(1):100–8

Structure of fuscopeptins, phytotoxic metabolites of Pseudomonas fuscovaginae. Ballio A, et al. **FEBS Lett** 1996 Mar 4;381(3):213–6

The 3D-structure of a natural inhibitor of cell adhesion molecule expression. Hommel U, et al. **FEBS Lett** 1996 Jan 22;379(1):69–73

Comparison of the structures of the endothelin A receptor antagonists BQ123 and N-methyl leucine BQ123 with the crystal structure of the C-terminal tail of endothelin-1. Peishoff CE, et al. **FEBS Lett** 1995 Nov 6;374(3):379–83

Comparison of proline and N-methylnorleucine induced conformational equilibria in cyclic pentapeptides. Weisshoff H, et al. **FEBS Lett** 1996 Jun 3;387(2-3):201–7

Computational study of the conformational profiles of model bis-cystine cyclic peptides. Fernandez Y, et al. **Int J Biol Macromol** 1996 Jun;18(4):263–74

Conformational studies of a synthetic cyclic decapeptide fragment of rat transforming growth factor-alpha. Jayaraman G, et al. **Int J Pept Protein Res** 1995 Jul; 46(1):88–96

Influence of serine in position i on conformation and dynamics of reverse turns. Matter H, et al. **Int J Pept Protein Res** 1995 May;45(5):430–40

Studies on conformational consequences of i to i + 3 side-chain cyclization in model cyclic tetrapeptides. Rao MH, et al. **Int J Pept Protein Res** 1995 May;45(5):418–29

NMR studies on the structure of some cyclic and linear antagonists of luteinizing hormone-releasing hormone (LHRH). Reddy DV, et al. **Int J Pept Protein Res** 1995 Jul;46(1):9–17

Linear and cyclic synthetic peptides related to the main autophosphorylation site of the Src tyrosine kinases as substrates and inhibitors of Lyn. Ruzza P, et al. **Int J Pept Protein Res** 1995 Jun;45(6):529–39

Antibiotic GE37468 A: a novel inhibitor of bacterial protein synthesis. II. Structure elucidation. Ferrari P, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1304–11

YM-47141 and YM-47142, new elastase inhibitors produced by Flexibacter sp. Q17897. II. Structure elucidation. Orita M, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1430–4

RES-701-2, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. II. Determination of the primary structure. Yano K, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1368–70

Solution structure of nodularin. An inhibitor of serine/threonine-specific protein phosphatases. Annila A, et al. **J Biol Chem** 1996 Jul 12;271(28):16695–702

Structure of a cyclic peptide with a catalytic triad, determined by computer simulation and NMR spectroscopy. Walse B, et al. **J Comput Aided Mol Des** 1996 Feb;10(1):11–22

Characterization of the salts of a cyclic RGD peptide. Maurin MB, et al. **Pharm Res** 1996 Mar;13(3):481–4

Cyclogossine A: a novel cyclic heptapeptide isolated from the latex of Jatropha gossypifolia. Horsten SF, et al. **Planta Med** 1996 Feb;62(1):46–50

Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1221–5

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. McDowell RS, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11165–9

Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A [see comments] Livnah O, et al. **Science** 1996 Jul 26;273(5274):464–71. Comment in: Science 1996 Jul 26;273(5274):449–50.

DIAGNOSTIC USE

[Imaging of thromboembolism by scintigraphy with the 99m-technetium-labelled synthetic peptide P280] Lastoria S, et al. **Radiol Med (Torino)** 1995 Dec;90(6):812–9 (Eng. Abstr.) **(Ita)**

GENETICS

The var genes of Plasmodium falciparum are located in the subtelomeric region of most chromosomes. Rubio JP, et al. **EMBO J** 1996 Aug 1;15(15):4069–77

IMMUNOLOGY

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Reilly TM, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2195–9

Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Bouvier M, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4583–8

ISOLATION & PURIFICATION

The GGNG peptides: novel myoactive peptides isolated from the gut and the whole body of the earthworms. Oumi T, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1072–8

Solution forms of antitumor cyclic pentapeptides with 3,4-dichlorinated proline residues, astins A and C, from Aster tataricus. Morita H, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1395–7

Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. Gudasheva TA, et al. **FEBS Lett** 1996 Aug 5; 391(1-2):149–52

Isolation of plactins A, B, C and D, novel cyclic pentapeptides that stimulate cellular fibrinolytic activity. Inoue T, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):45–9

RES-701-2, -3 and -4, novel and selective endothelin type B receptor antagonists produced by Streptomyces sp. I. Taxonomy of producing strains, fermentation, isolation, and biochemical properties. Ogawa T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1213–20

Laboratory-scale purification of microcystins using flash chromatography and reversed-phase high-performance liquid chromatography. Edwards C, et al. **J Chromatogr A** 1996 May 17;734(1):163–73

Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. Ogino J, et al. **J Nat Prod** 1996 Jun; 59(6):581–6

Keenamide A, a bioactive cyclic peptide from the marine mollusk Pleurobranchus forskalii. Wesson KJ, et al. **J Nat Prod** 1996 Jun;59(6):629–31

A novel isolation method of a stable crystalline salt of a cyclic RGD peptide zwitterion. Maurin MB, et al. **Pharm Res** 1995 Nov;12(11):1810–2

METABOLISM

Reaction of neprilysin (neutral endopeptidase) and thermolysin with cyclic peptides. Vijayaragahaven J, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):405–9

In vivo and in vitro binding of microcystin to protein phosphatases 1 and 2A. Runnegar M, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):162–9

Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. Giebel LB, et al. **Biochemistry** 1995 Nov 28;34(47):15430–5

Design of metal ion binding peptides. Fattorusso R, et al. **Biopolymers** 1995;37(6):401–10

The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. MacKintosh RW, et al. **FEBS Lett** 1995 Sep 11;371(3):236–40

Quinoxapeptins: novel chromodepsipeptide inhibitors of HIV-1 and HIV-2 reverse transcriptase. I. The producing organism and biological activity Lingham RB, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):253–9

Topochemical catalysis achieved by structure-based ligand design. Katz BA, et al. **J Biol Chem** 1995 Dec 29; 270(52):31210–8

Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. Gobin J, et al. **J Exp Med** 1996 Apr 1;183(4):1527–32

Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. Pearson DA, et al. **J Med Chem** 1996 Mar 29;39(7):1361–71

Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes. Nakamura T, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):564–72

Identification of a 29 kDa protein in the envelope of Mycobacterium smegmatis as a putative ferri-exochelin receptor. Dover LG, et al. **Microbiology** 1996 Jun;142 (

Pt 6):1521–30

A putative cyclic peptide efflux pump encoded by the TOXA gene of the plant-pathogenic fungus Cochliobolus carbonum. Pitkin JW, et al. **Microbiology** 1996 Jun;142 (Pt 6):1557–65

Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Bouvier M, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):4583–8

Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Crews CM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4316–9

Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A [see comments] Livnah O, et al. **Science** 1996 Jul 26;273(5274):464–71. Comment in: Science 1996 Jul 26;273(5274):449–50.

Identification of D-peptide ligands through mirror-image phage display. Schumacher TN, et al. **Science** 1996 Mar 29;271(5257):1854–7

Small peptides as potent mimetics of the protein hormone erythropoietin [see comments] Wrighton NC, et al.
Science 1996 Jul 26;273(5274):458–64. Comment in: Science 1996 Jul 26;273(5274):449–50.

PHARMACOKINETICS

The bioactive peptide cyclo(His-Pro) may be absorbed following ingestion of nutritional supplements that contain it. Mizuma H, et al. **J Am Coll Nutr** 1996 Apr;15(2):175–9

Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. Modi NB, et al.
J Cardiovasc Pharmacol 1996 Jan;27(1):105–12

Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes. Nakamura T, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):564–72

The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. Shin HC, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):607–13

Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Aungst BJ, et al. **Pharm Res** 1996 Jan;13(1):114–9

The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs. Burcham DL, et al. **Pharm Res** 1995 Dec; 12(12):2065–70

Microcystin uptake and inhibition of protein phosphatases: effects of chemoprotectants and self-inhibition in relation to known hepatic transporters. Runnegar M, et al.
Toxicol Appl Pharmacol 1995 Oct;134(2):264–72

Biliary excretion of biochemically active cyanobacteria (blue-green algae) hepatotoxins in fish. Sahin A, et al.
Toxicology 1996 Jan 8;106(1-3):123–30

PHARMACOLOGY

The stable VIP analogue, Ro 24-9981, potentiates bradykinin-induced increases in clearance of macromolecules. Gao XP, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 2):H1648–55

NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species. Chokekijchai S, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2345–7

GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Stieger M, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):1060–2

Synthesis and biological studies on analogs of cyclolinopeptide A with a shortened peptide chain. Siemion IZ, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5-6):459–65

Et-1 and Et-3 actions mediated by cloned ETA endothelin receptors exhibit different sensitivities to BQ-123. Gresser O, et al. **Biochem Biophys Res Commun** 1996 Jul 5; 224(1):169–71

Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Grubb DR, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1130–6

Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Satoh T, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):438–43

Effects of cyclolinopeptide A on T lymphocyte activation and peptidyl prolyl isomerase activity. Gaymes TJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):90S

Delineation of an active fragment and poly(L-proline) II conformation for candidacidal activity of bactenecin 5. Raj PA, et al. **Biochemistry** 1996 Apr 9;35(14):4314–25

MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.—I. Isolation, structural determination and biological properties of MS-271. Yano K, et al. **Bioorg Med Chem** 1996 Jan; 4(1):115–20

A mu-conotoxin-insensitive Na+ channel mutant: possible localization of a binding site at the outer vestibule. Dudley SC Jr, et al. **Biophys J** 1995 Nov;69(5):1657–65

Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments. Maguire JJ, et al.
Br J Pharmacol 1996 May;118(2):335–42

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Urdiales JL, et al. **Cancer Lett** 1996 Apr 19;102(1-2):31–7

Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. van der Pluijm G, et al.
Cancer Res 1996 Apr 15;56(8):1948–55

Cyclic peptides from higher plants. XXVIII. Antitumor activity and hepatic microsomal biotransformation of cyclic pentapeptides, astins, from Aster tataricus. Morita H, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1026–32

Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Haynes WG, et al. **Circulation** 1996 May 15;93(10):1860–70

Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats. Okada M, et al.
Clin Exp Pharmacol Physiol 1995 Oct;22(10):763–8

Pores formed in lipid bilayers and in native membranes by nodularin, a cyanobacterial toxin. Spassova M, et al.
Eur Biophys J 1995;24(2):69–76

The 3D-structure of a natural inhibitor of cell adhesion molecule expression. Hommel U, et al. **FEBS Lett** 1996 Jan 22;379(1):69–73

Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells. Johnson KL, et al.
FEBS Lett 1996 Mar 25;383(1-2):1–5

Interaction of cryptophycin 1 with tubulin and microtubules. Kerksiek K, et al. **FEBS Lett** 1995 Dec 11;377(1):59–61

Inhibitory effect of BQ-123 on endothelin-1-stimulated mitogen-activated protein kinase and cell growth of rat vascular smooth muscle cells. Guo X, et al.
Hypertens Res 1996 Mar;19(1):23–30

Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Didier AD, et al. **Int J Cancer** 1995 Oct 9;63(2):263–7

Ferrioxamine E-supplemented pre-enrichment and enrichment media improve various isolation methods for Salmonella. Reissbrodt R, et al. **Int J Food Microbiol** 1996 Feb;29(1):81–91

Inhibition of acyl-CoA: cholesterol acyltransferase by isohalobacillin, a complex of novel cyclic acylpeptides produced by Bacillus sp. A1238. Hasumi K, et al.
J Antibiot (Tokyo) 1995 Dec;48(12):1419–24

Quinoxapeptins: novel chromodepsipeptide inhibitors of HIV-1 and HIV-2 reverse transcriptase. I. The producing organism and biological activity. Lingham RB, et al.
J Antibiot (Tokyo) 1996 Mar;49(3):253–9

YM-47141 and 47142, new elastase inhibitors produced by Flexibacter sp. Q17897. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. Yasumuro K, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1425–9

Stable VIP analogue Ro-24-9981 potentiates substance P-induced plasma exudation in hamster cheek pouch. Gao XP, et al. **J Appl Physiol** 1995 Sep;79(3):968–74

Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides. Monfardini C, et al. **J Biol Chem** 1996 Feb 9;271(6):2966–71

Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. Smith CD, et al.
J Biol Chem 1996 Mar 15;271(11):6192–8

Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective ETA receptor antagonism and dual ETA/ETB receptor antagonism using BQ-123 and SB 209670. Douglas SA, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S186–9

Effect of endothelin-1 and BQ 123 on arterioles and venules of hypertensive rats. Hergenröder S, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 3:S226–9

Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, TAK-044. Kojima M, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S365–8

Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. Modi NB, et al.
J Cardiovasc Pharmacol 1995 Jun;25(6):888–97

Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. Angiolella L, et al.
J Infect Dis 1996 Mar;173(3):684–90

Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. Tang H, et al.
J Interferon Cytokine Res 1995 Nov;15(11):993–1003

Renal actions of endothelin-1 in newborn piglets: dose-effect relation and the effects of receptor antagonist (BQ-123) and cyclooxygenase inhibitor (indomethacin). Bhat R, et al. **J Lab Clin Med** 1995 Nov;126(5):458–69

Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. Byk G, et al. **J Med Chem** 1996 Aug 2; 39(16):3174–8

Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity. Fukami T, et al. **J Med Chem** 1996 Jun 7;39(12):2313–30

Structure—activity relationships of the didemnins. Sakai R, et al. **J Med Chem** 1996 Jul 5;39(14):2819–34

Design and synthesis of new linear and cyclic bradykinin antagonists. Thurieau C, et al. **J Med Chem** 1996 May 10; 39(10):2095–101

Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. McBride JD, et al. **J Mol Biol** 1996 Jun 21; 259(4):819–27

Synthetic analogues of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site. Zhou LM, et al. **J Neurochem** 1996 Feb;66(2):620–8

Lack of antidiuretic activity of lanreotide in the diabetes insipidus rat. Fan NY, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):875–81

Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist. Hegde SS, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1261–6

Involvement of endothelins in immediate and late asthmatic responses of guinea pigs. Uchida Y, et al.
J Pharmacol Exp Ther 1996 Jun;277(3):1622–9

Effects of BQ-123, an ETA recepter-selective antagonist, on changes of intraocular pressure, blood-aqueous barrier and aqueous prostaglandin concentrations caused by endothelin-1 in rabbit. Haque MS, et al.
Jpn J Ophthalmol 1996;40(1):26–32

Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes.
Matsushima-Nishiwaki R, et al. **Lipids** 1995 Nov; 30(11):1029–34

Pharmacology of endothelins: vascular preparations for studying ETA and ETB receptors. Caló G, et al.
Mol Cell Biochem 1996 Jan 12;154(1):31–7

Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Tatoud R, et al.
Mol Cell Endocrinol 1995 Sep 22;113(2):195–204

Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. McDonnell JM, et al. **Nat Struct Biol** 1996 May;3(5):419–26

Delivery of membrane-impermeant fluorescent probes into living neural cell populations by lipotransfer. Barber K, et al. **Neurosci Lett** 1996 Mar 22;207(1):17–20

Complete and reversible block by omega-grammotoxin SIA of glutamatergic synaptic transmission between cultured rat hippocampal neurons. Piser TM, et al.
Neurosci Lett 1995 Dec 8;201(2):135–8

Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Ariza RR, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):433–40

Effects of PF1022A on adult Angiostrongylus cantonensis in the pulmonary arteries and larvae migrating into the central nervous system of rats. Kachi S, et al.
Parasitol Res 1995;81(8):631–7

Immunosuppressive activity of hymenistatin I. Cebrat M, et al. **Peptides** 1996;17(2):191–6

Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Brosch G, et al. **Plant Cell** 1995 Nov;7(11):1941–50

Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al.
Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1221–5

Effects of endothelin receptor selective antagonists, BQ-123 and BQ-788, on IRL 1620 and endothelin-1 responses of airway and vascular preparations from rats. O'Donnell SR, et al. **Pulm Pharmacol** 1995 Feb;8(1):11–9

Small peptides as potent mimetics of the protein hormone erythropoietin [see comments] Wrighton NC, et al.
Science 1996 Jul 26;273(5274):458–64. Comment in: Science 1996 Jul 26;273(5274):449–50.

BQ-123, a specific endothelin (ETA) receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation. Büyükgebiz O, et al. **Transpl Int** 1996; 9(3):201–7

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al.
Acta Obstet Gynecol Scand 1996 May;75(5):432–8 (34 ref.)

THERAPEUTIC USE

A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Malfetano JH, et al.
Am J Clin Oncol 1996 Apr;19(2):184–6

The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Joos GF, et al.
Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1781–4

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Kurtz MB, et al.
Antimicrob Agents Chemother 1995 Aug;39(8):1784–9

Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian

Trials in Medical Oncology. Di Leo A, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):237–44

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Di Leo A, et al. **Cancer** 1996 Jul 1;78(1):35–42

Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Mousa SA, et al. **Circulation** 1996 Feb 1;93(3):537–43

Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. **Invest New Drugs** 1995;13(3):257–60

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995; 13(2):167–70

Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models [published erratum appears in J Antibiot (Tokyo) 1995 Nov;48(11):C-2] Conder GA, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):820–3

ETA receptor antagonists inhibit allergic inflammation in the mouse. Sampaio AL, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S416–8

Amelioration of hepatorenal syndrome with selective endothelin-A antagonist [letter] Soper CP, et al. **Lancet** 1996 Jun 29;347(9018):1842–3

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Dorr RT, et al. **Life Sci** 1996;58(20):1777–84

Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Hammes HP, et al. **Nat Med** 1996 May; 2(5):529–33

TOXICITY

Promoting activity of microcystins extracted from waterblooms in SHE cell transformation assay. Wangth HB, et al. **Biomed Environ Sci** 1996 Mar;9(1):46–51

Emesis of rhesus monkeys induced by intragastric administration with the HEp-2 vacuolation factor (cereulide) produced by Bacillus cereus. Shinagawa K, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):87–90

Hemodynamic and calorimetric changes induced by microcystin-LR in the rat. LeClaire RD, et al. **J Appl Toxicol** 1995 Jul–Aug;15(4):303–11

Effects of microcystin-LR on actin and the actin-associated proteins alpha-actinin and talin in hepatocytes. Ghosh S, et al. **Nat Toxins** 1995;3(6):405–14

PEPTIDOGLYCAN

Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? Hatch TP. **J Bacteriol** 1996 Jan;178(1):1–5 (49 ref.)

ANALYSIS

Drastic changes in the peptidoglycan composition of penicillin resistant laboratory mutants of Streptococcus pneumoniae. Severin A, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):31–5

[Heterogeneity of peptidoglycans of bacterial origin] Pozur VK, et al. **Ukr Biokhim Zh** 1995 Jan–Feb;67(1):96–100 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

The monofunctional glycosyltransferase of Escherichia coli is a member of a new class of peptidoglycan-synthesising enzymes. Di Berardino M, et al. **FEBS Lett** 1996 Aug 26; 392(2):184–8

Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. Billot-Klein D, et al. **J Bacteriol** 1996 Aug;178(15):4696–703

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911–8 (45 ref.)

Modified peptidoglycan chemical composition in shape-altered Escherichia coli. Signoretto C, et al. **Microbiology** 1996 Aug;142 (Pt 8):1919–26

CHEMISTRY

Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type. Billot-Klein D, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):711–5

A simple solid-state NMR method for determining peptidoglycan crosslinking in Bacillus subtilis. Shenouda NS, et al. **Biochim Biophys Acta** 1996 Mar 15; 1289(2):217–20

Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Griffin CC, et al. **Carbohydr Res** 1995 Oct 16;276(1):183–97

The conserved 18,000-molecular-weight outer membrane protein of Haemophilus ducreyi has homology to PAL. Spinola SM, et al. **Infect Immun** 1996 Jun;64(6):1950–5

Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. Billot-Klein D, et al. **J Bacteriol** 1996 Aug;178(15):4696–703

Primary structure of cyanelle peptidoglycan of Cyanophora paradoxa: a prokaryotic cell wall as part of an organelle envelope. Pfanzagl B, et al. **J Bacteriol** 1996 Jan; 178(2):332–9

Naturally occurring peptidoglycan variants of Streptococcus pneumoniae. Severin A, et al. **J Bacteriol** 1996 Jan; 178(1):168–74

A simple gel electrophoretic method for analyzing the muropeptide composition of bacterial peptidoglycan. Young KD. **J Bacteriol** 1996 Jul;178(13):3962–6

Determination of peptidoglycan-associated protein in Escherichia coli NCIB 8545 by capillary zone electrophoresis. Xing JZ, et al. **J Chromatogr A** 1996 Aug 2;740(2):273–8

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911–8 (45 ref.)

Modified peptidoglycan chemical composition in shape-altered Escherichia coli. Signoretto C, et al. **Microbiology** 1996 Aug;142 (Pt 8):1919–26

Proposal for a peptidoglycan-associating alpha-helical motif in the C-terminal regions of some bacterial cell-surface proteins [letter; comment] Koebnik R. **Mol Microbiol** 1995 Jun;16(6):1269–70. Comment on: Mol Microbiol 1994 Apr;12(2):333–4.

Tracheal cytotoxin structural requirements for respiratory epithelial damage in pertussis. Luker KE, et al. **Mol Microbiol** 1995 May;16(4):733–43

GENETICS

The Pseudomonas putida peptidoglycan-associated outer membrane lipoprotein is involved in maintenance of the integrity of the cell cell envelope. Rodríguez-Herva JJ, et al. **J Bacteriol** 1996 Mar;178(6):1699–706

IMMUNOLOGY

Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides. Takada H, et al. **Infect Immun** 1996 Feb;64(2):657–9

Immediate burn wound excision restores antibody synthesis to bacterial antigen. Yamamoto H, et al. **J Surg Res** 1996 Jun;63(1):157–62

METABOLISM

Altered peptidoglycan composition in vancomycin-resistant Enterococcus faecalis. de Jonge BL, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):863–9

The human and mammalian N-acetylmuramyl-L-alanine amidase: distribution, action on different bacterial peptidoglycans, and comparison with the human lysozyme activities. Vanderwinkel E, et al. **Biochem Mol Med** 1995 Feb;54(1):26–32

Lysozyme substrates. Höltje JV. **EXS** 1996;75:105–10 (34 ref.)

Lytic transglycosylases. Höltje JV. **EXS** 1996;75:425–9 (20 ref.)

Bacterial lysozymes. Höltje JV. **EXS** 1996;75:65–74 (48 ref.)

A peptidoglycan binding domain in the porin-associated protein (PAP) of Rhodospirillum rubrum FR1. Neumann U, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):55–8

A conserved motif in S-layer proteins is involved in peptidoglycan binding in Thermus thermophilus. Olabarría G, et al. **J Bacteriol** 1996 Aug;178(16):4765–72

Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori. Yoshida H, et al. **J Biol Chem** 1996 Jun 7;271(23):13854–60

Phagocytosis of splenetic neutrophils of mice enhanced by orally administered peptidoglycan from Bifidobacterium thermophilum. Sasaki T, et al. **J Vet Med Sci** 1996 Jan; 58(1):85–6

PHARMACOLOGY

Tolerance to appetite suppression induced by peptidoglycan. Biberstine KJ, et al. **Infect Immun** 1996 Sep;64(9):3641–5

Intracellular pathways involved in tumor necrosis factor-alpha release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar. Mattsson E, et al. **J Infect Dis** 1996 Jan; 173(1):212–8

A novel peptidoglycan-linked lipoprotein (ComL) that functions in natural transformation competence of Neisseria gonorrhoeae. Fussenegger M, et al. **Mol Microbiol** 1996 Mar;19(5):1095–105

TOXICITY

Tracheal cytotoxin structural requirements for respiratory epithelial damage in pertussis. Luker KE, et al. **Mol Microbiol** 1995 May;16(4):733–43

The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. De Kimpe SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10359–63

PEPTIDYL-DIPEPTIDASE A

Polymorphic inhibition of human angiotensin I-converting enzyme by enalaprilat. Lee EJ. **Eur J Clin Pharmacol** 1995; 49(3):173–5

ANALYSIS

Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Kalenga MK, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):429–33

ANTAGONISTS & INHIBITORS see ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

BIOSYNTHESIS

Tissue specific expression of testis angiotensin converting enzyme is not determined by the -32 nonconsensus TATA motif. Zhou Y, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):48–53

Secretion of human intestinal angiotensin-converting enzyme and its association with the differentiation state of intestinal cells. Naim HY. **Biochem J** 1996 May 15;316 (Pt 1):259–64

Activation of angiotensin-generating systems in the developing rat kidney. Yosipiv IV, et al. **Hypertension** 1996 Feb;27(2):281–6

Different glycosylation requirements for the synthesis of enzymatically active angiotensin-converting enzyme in mammalian cells and yeast. Sadhukhan R, et al. **J Biol Chem** 1996 Mar 15;271(11):6429–34

Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Morrell NW, et al. **J Clin Invest** 1995 Oct;96(4):1823–33

A competitive deletion mutant quantitative PCR assay for angiotensin-converting enzyme mRNA in smooth muscle cells. Lanzillo JJ, et al. **PCR Methods Appl** 1994 Dec; 4(3):167–71

BLOOD

Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Villard E, et al. **Am J Hum Genet** 1996 Jun;58(6):1268–78

Detection of the angiotensin converting enzyme gene I/D polymorphism from extremely small volumes of stored serum [letter] Davis DR, et al. **Am J Hypertens** 1996 May; 9(5):515

Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. King JN, et al. **Am J Vet Res** 1995 Dec;56(12):1620–8

Serum activity of angiotensin converting enzyme (ACE) is not affected by hepatitis B viral infection. Wen J, et al. **Chin J Physiol** 1995;38(1):19–22

Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Kreutz R, et al. **Circulation** 1995 Nov 1;92(9):2381–4

Automation of a kinetic method for determining angiotensin-converting enzyme in serum. Groff JL, et al. **Clin Chem** 1995 Nov;41(11):1662–3

Circulating angiotensin-converting enzyme, von Willebrand factor antigen and thrombomodulin in exertional heat stroke. Shieh SD, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):261–5

Association between deletion polymorphism of the angiotensin-converting enzyme gene and cerebral atherosclerosis. Sertic J, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):301–4

Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Bloem LJ, et al. **Hypertension** 1996 Jan;27(1):62–6

Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis. Letizia C, et al. **Int Urol Nephrol** 1995;27(4):465–70

Serum angiotensin converting enzyme activity in sarcoidosis and pulmonary tuberculosis. Sainani GS, et al. **J Assoc Physicians India** 1996 Jan;44(1):29–30

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):233–40

Effect of angiotensin-converting enzyme inhibition on intimal thickening in rabbit collared carotid artery. De Meyer GR, et al. **J Cardiovasc Pharmacol** 1995 Oct; 26(4):614–20

Association of angiotensin converting enzyme activity and arterial blood pressure in a population-based sample. Schunkert H, et al. **J Hypertens** 1996 May;14(5):571–5

HRT and ACE activity in postmenopausal women [letter] Scarabin PY, et al. **Lancet** 1996 Jan 13;347(8994):122

[Angiotensin-converting enzyme as a follow-up parameter in sarcoidosis] Schaberg T. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):853 **(Ger)**

[Angiotensin I converting enzyme] Wanaka Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:389–91 (16 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Neuropeptide-converting enzymes in cerebrospinal fluid: activities increased in pain from herniated lumbar dis, but not from coxarthrosis. Lindh C, et al. **Acta Orthop Scand** 1996 Apr;67(2):189–92

PEPTIDYL-DIPEPTIDASE A

CHEMISTRY

Drosophila melanogaster angiotensin I–converting enzyme expressed in Pichia pastoris resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity. Williams TA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):125–31

Assignment of free and disulfide–bonded cysteine residues in testis angiotensin–converting enzyme: functional implications. Sturrock ED, et al. **Biochemistry** 1996 Jul 23; 35(29):9560–6

Spectroscopic studies on angiotensin I–converting enzyme. Baudin B, et al. **Enzyme Protein** 1994–95;48(5–6):265–74

Effect of inhibitors on the coordination geometries of cadmium at the metal sites in angiotensin–I–converting enzyme. Carvalho E, et al. **Eur J Biochem** 1995 Dec 15; 234(3):780–5

Different glycosylation requirements for the synthesis of enzymatically active angiotensin–converting enzyme in mammalian cells and yeast. Sadhukhan R, et al. **J Biol Chem** 1996 Mar 15;271(11):6429–34

Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. Corvol P, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S3–10 (63 ref.)

Electron paramagnetic resonance studies of cobalt–substituted angiotensin I–converting enzyme. Carvalho E, et al. **J Inorg Biochem** 1996 May 1;62(2):147–53

A comparison of the N–terminal sequence of the leech Theromyzon tessulatum angiotensin converting–like enzyme with forms of vertebrate angiotensin converting enzymes. Laurent V, et al. **Neurosci Lett** 1995 Sep 22; 198(1):60–4

DRUG EFFECTS

Inhibition of both angiotensin–converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. Gonzalez W, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):573–81

[The effect of diazepam on the activity of carboxypeptidase N and the angiotensin–converting enzyme in sections of the brain of rats with differing normal emotionality and in emotional stress] Nikishin NN, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):108–13 (Eng. Abstr.) **(Rus)**

[The effect of the intraperitoneal administration of a physiological solution on rat behavior in the "open field" test and on the activity of the enzymes participating in neuropeptide metabolism] Vernigora AN, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):121–5 **(Rus)**

GENETICS

Angiotensin–converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Yoneya K, et al. **Am Heart J** 1995 Nov;130(5):1089–93

Deletion polymorphism of the angiotensin–converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Gharavi AG, et al. **Am J Cardiol** 1996 Jun 15;77(15):1315–9

Angiotensin–converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Kasi JC, et al. **Am J Cardiol** 1996 Apr 15;77(10):875–7

Angiotensin–converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Pfeufer A, et al. **Am J Cardiol** 1996 Aug 1;78(3):362–4

Lack of association between insertion/deletion polymorphism of the angiotensin–converting enzyme gene and end–stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. Sanderson JE, et al. **Am J Cardiol** 1996 May 1;77(11):1008–10

Angiotensin–converting enzyme insertion/deletion polymorphism in angina pectoris with normal coronary arteriograms. Zhang Y, et al. **Am J Cardiol** 1996 Apr 15; 77(10):877–9

Segregation and linkage analysis of serum angiotensin I–converting enzyme levels: evidence for two quantitative–trait loci. McKenzie CA, et al. **Am J Hum Genet** 1995 Dec;57(6):1426–35

Identification of new polymorphisms of the angiotensin I–converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two–QTL segregation–linkage analysis. Villard E, et al. **Am J Hum Genet** 1996 Jun;58(6):1268–78

Detection of the angiotensin converting enzyme gene I/D polymorphism from extremely small volumes of stored serum [letter] Davis DR, et al. **Am J Hypertens** 1996 May; 9(5):515

No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Schmidt S, et al. **Am J Kidney Dis** 1995 Nov;26(5):727–31

Developmental regulation of angiotensin converting enzyme and angiotensin type 1 receptor in the rat pulmonary circulation. Morrell NW, et al. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):526–37

Polymorphism of angiotensin–converting enzyme gene in sarcoidosis. Arbustini E, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):851–4

Angiotensin–converting enzyme gene polymorphism in essential hypertensive patients in Japanese population. Maguchi M, et al. **Angiology** 1996 Jul;47(7):643–8

Deletion polymorphism of the angiotensin I–converting enzyme gene is associated with increased plasma angiotensin–converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Winkelmann BR, et al. **Ann Intern Med** 1996 Jul 1;125(1):19–25

Deletion polymorphism in the angiotensin–converting enzyme gene in patients with a history of ischemic stroke. Margaglione M, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):304–9

Genotype distribution of angiotensin–converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Wang XL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):115–9

A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Ward AJ, et al. **Atherosclerosis** 1996 Feb; 120(1–2):83–91

Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population. Harn HJ, et al. **Biochem Mol Biol Int** 1995 May;35(6):1175–81

A study of chimeras constructed with the two domains of angiotensin I–converting enzyme. Williams TA, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):11–4

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Parving HH, et al. **BMJ** 1996 Sep 7;313(7057):591–4

Angiotensin converting enzyme genotypes and disease [editorial] Teo KK. **BMJ** 1995 Sep 23;311(7008):763–4

Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Arbustini E, et al. **Br Heart J** 1995 Dec;74(6):584–91

The angiotensin converting enzyme gene in cardiovascular disease [editorial] Caulfield M, et al. **Br Heart J** 1995 Sep; 74(3):207–8

Transcriptional repression of heterologous constitutive and inducible promoters by the negative element of the rabbit angiotensin–converting enzyme gene. Kessler SP, et al. **Cell Mol Biol Res** 1995;41(6):595–602

Influence of angiotensin–converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Benetos A, et al. **Circulation** 1996 Aug 15;94(4):698–703

Gene polymorphism but not catalytic activity of angiotensin I–converting enzyme is associated with coronary artery disease and myocardial infarction in low–risk patients. Gardemann A, et al. **Circulation** 1995 Nov 15;92(10):2796–9

Angiotensin–converting enzyme gene polymorphism in ischemic heart disease [letter; comment] Hellstrom HR. **Circulation** 1996 Mar 15;93(6):1256–7. Comment on: Circulation 1995 Apr 15;91(8):2120–4.

Angiotensin–converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non–insulin–dependent diabetic patients. Hosoi M, et al. **Circulation** 1996 Aug 15;94(4):704–7

Ischemic stroke and the gene for angiotensin–converting enzyme in Japanese hypertensives. Kario K, et al. **Circulation** 1996 May 1;93(9):1630–3

Genetic linkage of the ACE gene to plasma angiotensin–converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Kreutz R, et al. **Circulation** 1995 Nov 1;92(9):2381–4

The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance? Panahloo A, et al. **Circulation** 1995 Dec 15;92(12):3390–3

Lipoprotein(a), ACE, and family history of CAD [letter; comment] Payne MN, et al. **Circulation** 1995 Dec 15; 92(12):3583. Comment on: Circulation 1995 Mar 15;91(6):1655–8.

A meta–analysis of the association of the deletion allele of the angiotensin–converting enzyme gene with myocardial infarction. Samani NJ, et al. **Circulation** 1996 Aug 15; 94(4):708–12

Departure from Hardy–Weinberg equilibrium should be systematically tested in studies of association between genetic markers and disease [letter; comment] Tiret L, et al. **Circulation** 1995 Dec 1;92(11):3364–5. Comment on: Circulation 1994 Nov;90(5):2199–202. Comment on: Circulation 1995 Feb;91(4):951–4.

Angiotensin–converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. van Bockxmeer FM, et al. **Circulation** 1995 Oct 15; 92(8):2066–71

Angiotensin–converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction. Wong KK, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):438–40

Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Yorioka T, et al. **Clin Nephrol** 1995 Aug;44(2):80–5

Role of angiotensin–converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249–53 (21 ref.)

Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Nagi DK, et al. **Diabet Med** 1995 Nov;12(11):997–1001

Angiotensin I–converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Fujisawa T, et al. **Diabetes Care** 1995 Jul;18(7):983–5

A pitfall in the association study of ACE gene polymorphism [letter] Odawara M, et al. **Diabetes Care** 1996 May; 19(5):543–4

Insertion/deletion polymorphism in the angiotensin–I–converting enzyme gene [letter] Demaine A, et al. **Diabetologia** 1995 Dec;38(12):1495–6

Association between a polymorphism in the angiotensin–converting enzyme gene and microvascular complications in Japanese patients with NIDDM. Doi Y, et al. **Diabetologia** 1996 Jan;39(1):97–102

UK prospective diabetes study (UKPDS) 14: association of angiotensin–converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Keavney BD, et al. **Diabetologia** 1995 Aug;38(8):948–52

Insertion/deletion polymorphism in the angiotensin–I–converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Tarnow L, et al. **Diabetologia** 1995 Jul; 38(7):798–803

Cloning and characterisation of angiotensin–converting enzyme from the dipteran species, Haematobia irritans exigua, and its expression in the maturing male reproductive system. Wijffels G, et al. **Eur J Biochem** 1996 Apr 15; 237(2):414–23

Association between deletion polymorphism of the angiotensin–converting enzyme gene and cerebral atherosclerosis. Sertic J, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):301–4

Angiotensin I–converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Cidl K, et al. **Exp Hematol** 1996 Jun;24(7):790–4

Angiotensin–converting enzyme genotypes in the high– and low–risk area for coronary heart disease in Finland. Perola M, et al. **Genet Epidemiol** 1995;12(4):391–9

Racial difference in the relationship of an angiotensin I–converting enzyme gene polymorphism to serum angiotensin I–converting enzyme activity. Bloem LJ, et al. **Hypertension** 1996 Jan;27(1):62–6

Angiotensin I–converting enzyme genotypes and angiotensin II receptors. Response to therapy. Dieguez–Lucena JL, et al. **Hypertension** 1996 Jul;28(1):98–103

Angiotensin I–converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hiraga H, et al. **Hypertension** 1996 Mar;27(3 Pt 2):569–72

Polymorphism of the apolipoprotein E and angiotensin–converting enzyme genes in Japanese subjects with silent myocardial ischemia. Nakata Y, et al. **Hypertension** 1996 Jun;27(6):1205–9

Polymorphisms of renin–angiotensin genes among Nigerians, Jamaicans, and African Americans. Rotimi C, et al. **Hypertension** 1996 Mar;27(3 Pt 2):558–63

The DD genotype of the angiotensin–converting enzyme gene is associated with increased mortality in idiopathic heart failure. Andersson B, et al. **J Am Coll Cardiol** 1996 Jul;28(1):162–7

Insertion/deletion polymorphism in the angiotensin–converting enzyme gene and risk of and prognosis after myocardial infarction. Samani NJ, et al. **J Am Coll Cardiol** 1996 Aug;28(2):338–44

Angiotensin–converting enzyme polymorphism in patients with terminal renal failure. Schmidt A, et al. **J Am Soc Nephrol** 1996 Feb;7(2):314–7

Is the inherited ACE genotype a trump or a joker? [editorial; comment] Mitch WE. **J Clin Invest** 1995 Nov;96(5):2100–1 . Comment on: J Clin Invest 1995 Nov;96(5):2162–9.

Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. Oike Y, et al. **J Clin Invest** 1995 Dec;96(6):2975–9

Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy [see comments] Yoshida H, et al. **J Clin Invest** 1995 Nov;96(5):2162–9. Comment in: J Clin Invest 1995 Nov;96(5):2100–2.

Angiotensin–converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. Panagiotopoulos S, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):272–6

Association of angiotensin converting enzyme DD genotype with hypertension in diabetes. Wierzbicki AS, et al. **J Hum Hypertens** 1995 Aug;9(8):671–3

Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin–angiotensin system in Caucasian and Afro–Caribbean peoples. Barley J, et al. **J Hypertens** 1996 Jan;10(1):31–5

Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin–angiotensin system genes. Dudley C, et al. **J Hypertens** 1996 Feb;14(2):259–62

Ethnic differences in angiotensin converting enzyme gene polymorphism [letter] Johanning GL, et al. **J Hypertens** 1995 Jun;13(6):710–1

The angiotensin–I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. Foy CA, et al. **J Med Genet** 1996 Apr;33(4):336–7

Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus. Ukkola O, et al. **J Mol Med** 1995 Jun;73(6):307–11

Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan. Takahashi K, et al. **Jpn Heart J** 1995 Sep;36(5):557–64

Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG, et al. **Lancet** 1996 Jan 13;347(8994):94–5

Angiotensin converting enzyme gene polymorphism and renal artery resistance in patients with insulin dependent diabetes mellitus. Fukumoto S, et al. **Life Sci** 1996; 59(8):629–37

Race: a drosophila homologue of the angiotensin converting enzyme. Tatei K, et al. **Mech Dev** 1995 Jun;51(2-3):157–68

Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Ohno T, et al. **Metabolism** 1996 Feb;45(2):218–22

Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass [letter] Cambien F, et al. **N Engl J Med** 1996 Oct 3;335(14):1070; discussion 1071

Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass [letter] Cheung B. **N Engl J Med** 1996 Oct 3; 335(14):1070–1

Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. Lindpaintner K, et al. **N Engl J Med** 1996 Apr 18; 334(16):1023–8

Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757–9 (31 ref.)

Angiotensin-converting enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus. Mizuiri S, et al. **Nephron** 1995;70(4):455–9

Angiotensin-converting enzyme (ACE) polymorphisms, angiotensin II, ACE inhibitors and glomerulosclerosis—a hypothesis [letter] Roy-Chaudhury P, et al. **Nephron** 1995; 71(3):359

Expression of angiotensin I-converting enzyme in the human gastric HGT-1 cell line. Nonotte I, et al. **Regul Pept** 1995 Nov 10;59(3):379–87

Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Catto A, et al. **Stroke** 1996 Mar;27(3):435–40

Angiotensin-converting enzyme gene and lacunar stroke [letter; comment] Pullicino P, et al. **Stroke** 1996 Mar; 27(3):569–70. Comment on: Stroke 1995 Aug;26(8):1329–33.

Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Furuya K, et al. **Thorax** 1996 Aug;51(8):777–80

[Inactivation of the angiotensin I conversion gene: different effects according to sex on fertility and arterial pressure (news)] Rondeau PE. **Nephrologie** 1995;16(5):383–4 **(Fre)**

[Does an association between angiotensin I converting enzyme gene polymorphism and the prevalence of diabetic nephropathy in patients with diabetes type II exist?] Strojek K, et al. **Pol Arch Med Wewn** 1995 Sep;94(3):214–8 (Eng. Abstr.) **(Pol)**

[Analysis of angiotensin converting enzyme (ACE) polymorphism in patients with myocardial infarction in the Polish population] Trzeciak T, et al. **Pol Arch Med Wewn** 1996 Jan;95(1):35–40 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Carboxydipeptidase from Boophilus microplus: a "concealed" antigen with similarity to angiotensin-converting enzyme. Jarmey JM, et al. **Insect Biochem Mol Biol** 1995 Oct; 25(9):969–74

ISOLATION & PURIFICATION

The endopeptidase activity and the activation by Cl- of angiotensin-converting enzyme is evolutionarily conserved: purification and properties of an an angiotensin-converting enzyme from the housefly, Musca domestica. Lamango NS, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):639–46

Spectroscopic studies on angiotensin I-converting enzyme. Baudin B, et al. **Enzyme Protein** 1994–95;48(5–6):265–74

METABOLISM

Hippuryl-L-histidyl-L-leucine, a substrate for angiotensin converting enzyme. Vrielink A, et al. **Acta Crystallogr C** 1996 May 15;52 (Pt 5):1300–2

Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. Berecek KH, et al. **Adv Exp Med Biol** 1995;377:141–68 (256 ref.)

Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Dell'Italia LJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H2065–73

Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Passier RC, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1268–76

The endopeptidase activity and the activation by Cl- of angiotensin-converting enzyme is evolutionarily conserved: purification and properties of an an angiotensin-converting enzyme from the housefly, Musca domestica. Lamango NS, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):639–46

Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity. Williams TA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):125–31

Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue. Meng QC, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1445–50

Identification of the site of cleavage in angiotensin converting enzyme by its secretase. Hooper NM, et al. **Biochem Soc Trans** 1995 Nov;23(4):552S

Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence. Ehlers MR, et al. **Biochemistry** 1996 Jul 23;35(29):9549–59

Cleavage processing of angiotensin-converting enzyme by a membrane-associated metalloprotease. Ramchandran R, et al. **Biochemistry** 1995 Oct 3;34(39):12645–52

Purification and characterisation of swine serum proteinase which hydrolyses epidermal inhibitory pentapeptide. Bramucci M, et al. **Biochim Biophys Acta** 1996 Jun 4; 1290(2):184–90

Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid. Frame KL, et al. **Br J Cancer** 1996 Sep; 74(5):807–13

Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension. Challah M, et al. **Cardiovasc Res** 1995 Aug; 30(2):231–9

Monocyte- and cytokine-induced downregulation of angiotensin-converting enzyme in cultured human and porcine endothelial cells. Papapetropoulos A, et al. **Circ Res** 1996 Sep;79(3):512–23

Kininase II-type enzymes. Their putative role in muscle energy metabolism. Dragović T, et al. **Diabetes** 1996 Jan; 45 Suppl 1:S34–7

Carboxypeptidase A hydrolyses benzoylglycyl-histidyl-leucine but not furylacryloyl-phenylalanyl-glycyl-glycine, two usual substrates for angiotensin I-converting enzyme. Baudin B, et al. **Enzyme Protein** 1994–95;48(2):81–9

Expression of renin and angiotensin-converting enzyme in human hearts. Endo-Mochizuki Y, et al. **Heart Vessels** 1995;10(6):285–93

Release of angiotensin-converting enzyme (ACE) from human spermatozoa during capacitation and acrosome reaction. Köhn FM, et al. **J Androl** 1995 May-Jun; 16(3):259–65

Cell surface localization of proteolysis of human endothelial angiotensin I-converting enzyme. Effect of the amino-terminal domain in the solubilization process. Beldent V, et al. **J Biol Chem** 1995 Dec 1;270(48):28962–9

Synthesis and cleavage- secretion of enzymatically active rabbit angiotensin-converting enzyme in Pichia pastoris. Sadhukhan R, et al. **J Biol Chem** 1996 Aug 2; 271(31):18310–3

Effects of idrapril calcium on tissue angiotensin-converting enzyme in rats. Becagli P, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):27–32

Quantification of a dual angiotensin I-converting enzyme-neutral endopeptidase inhibitor and the active thiol metabolite in dog plasma by high-performance liquid chromatography with ultraviolet absorbance detection. Heath TG, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):91–101

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline [see comments] Azizi M, et al. **J Clin Invest** 1996 Feb 1;97(3):839–44. Comment in: J Clin Invest 1996 Feb 1;97(3):588.

Eotaxin: a VIC (very important chemokine) of allergic inflammation? [editorial] Baggiolini M. **J Clin Invest** 1996 Feb 1;97(3):587

News about ACE, or, the separate lives of "Siamese twin" domains [editorial; comment] Erdös EG. **J Clin Invest** 1996 Feb 1;97(3):588. Comment on: J Clin Invest 1996 Feb 1;97(3):839–44.

Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. Marie C, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1324–31

Effects of trandolapril on cardiac angiotensin I converting enzyme activity in rats with chronic heart failure following myocardial infarction. Sanbe A, et al. **Jpn Heart J** 1995 Jul;36(4):451–63

Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Jouquey S, et al. **Neuropharmacology** 1995 Dec; 34(12):1689–92

Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. Vaghy PL, et al. **Peptides** 1995;16(8):1367–73

Angiotensin I converting enzyme in glycerol-induced acute renal failure in rats. Pedraza-Chaverrí J, et al. **Ren Fail** 1995 Jul;17(4):365–75

Angiotensin I converting enzyme activity in uranyl nitrate induced acute renal failure in rats. Pedraza-Chaverrí J, et al. **Ren Fail** 1995 Jul;17(4):377–88

[Activity of converting enzyme angiotensin I to angiotensin II (ACE) in patients with diabetes type II] Zdrojewicz Z, et al. **Pol Arch Med Wewn** 1995 Apr;93(4):305–13 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Effects of inhibiting neutral endopeptidase and kininase II on coronary and systemic hemodynamics in rats. Maxwell AJ, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1016–29

The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. Hutchison FN, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1216–22

PHYSIOLOGY

Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Morrell NW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1186–94

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov-Dec; 21(6):809–34 (154 ref.)

Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Berkenboom G, et al. **Hypertension** 1995 Nov;26(5):738–43

Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. Corvol P, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S3–10 (63 ref.)

Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. Sun Y, et al. **J Lab Clin Med** 1996 Jan;127(1):94–101

Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Esther CR Jr, et al. **Lab Invest** 1996 May;74(5):953–65

Renal abnormalities in mutant mice [letter] Carpenter C, et al. **Nature** 1996 Mar 28;380(6572):292

[Inactivation of the angiotensin I conversion gene: different effects according to sex on fertility and arterial pressure (news)] Rondeau PE. **Nephrologie** 1995;16(5):383–4 **(Fre)**

[T-kinin-induced increase in airway vascular permeability and its modulation by angiotensin-converting enzyme] Takeda Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):627–31 (Eng. Abstr.) **(Jpn)**

URINE

Urinary angiotensin-converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy. Miyauchi E, et al. **Acta Diabetol** 1995 Oct;32(3):193–7

Significance of renal kininases in patients with Cushing's syndrome. Shimamoto K, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1173–82

Significance of renal kininases in patients with primary aldosteronism. Ura N, et al. **Clin Exp Hypertens** 1995 Oct; 17(7):1049–58

Urinary angiotensin I-converting enzyme activity is increased in experimental acute renal failure. Pedraza-Chaverrí J, et al. **Clin Invest Med** 1995 Dec; 18(6):424–34

Calcium channel blockers as inhibitors of angiotensin I-converting enzyme. Casarini DE, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1145–8

PEPTIDYL TRANSFERASES

ANALYSIS

Detection of methicillin-resistant Staphylococcus aureus (MRSA) with antibodies against synthetic peptides derived from penicillin-binding protein 2'. Sekiguchi K, et al. **Microbiol Immunol** 1995;39(8):545–50

ANTAGONISTS & INHIBITORS

Sparsomycin and its analogues: a new approach for evaluating their potency as inhibitors of peptide bond formation. Kallia-Raftopoulos S, et al. **Mol Pharmacol** 1996 Jun;49(6):1085–91

Peptide inhibitors of peptidyltransferase alter the conformation of domains IV and V of large subunit rRNA: a model for nascent peptide control of translation. Harrod R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8650–4

BIOSYNTHESIS

Enzyme induction by L-buthionine (S,R)-sulfoximine in cultured mouse hepatoma cells. Shertzer HG, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):431–6

CHEMISTRY

Localization of a putative second membrane association site in penicillin-binding protein 1B of Escherichia coli. Wang CC, et al. **Biochem J** 1996 May 15;316 (Pt 1):149–56

GENETICS

Identification and overexpression in Escherichia coli of a Mycobacterium leprae gene, pon1, encoding a high-molecular-mass class A penicillin-binding protein, PBP1. Basu J, et al. **J Bacteriol** 1996 Mar;178(6):1707–11

Expression and characterization of the ponA (ORF I) gene

of Haemophilus influenzae: functional complementation in a heterologous system. Sharma UK, et al. **J Bacteriol** 1995 Dec;177(23):6745–50

Characterization of a five-gene cluster required for the biogenesis of type 4 fimbriae in Pseudomonas aeruginosa. Martin PR, et al. **Mol Microbiol** 1995 May;16(3):497–508

IMMUNOLOGY

Immunological detection of penicillin-binding protein 2' of methicillin-resistant staphylococci by using monoclonal antibodies prepared from synthetic peptides. Saito M, et al. **J Clin Microbiol** 1995 Sep;33(9):2498–500

METABOLISM

Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3. Sumita Y, et al. **J Antimicrob Chemother** 1995 Jul;36(1):53–64

Hybrid proteins of the transglycosylase and the transpeptidase domains of PBP1B and PBP3 of Escherichia coli. Zijderveld CA, et al. **J Bacteriol** 1995 Nov; 177(21):6290–3

Peptide environment of the peptidyl transferase center from Escherichia coli 70 S ribosomes as determined by thermoaffinity labeling with dihydrospiramycin. Bischof O, et al. **J Biol Chem** 1995 Sep 29;270(39):23060–4

A base pair between tRNA and 23S rRNA in the peptidyl transferase centre of the ribosome [published erratum appears in Nature 1995 Nov 23;378(6555):419] Samaha RR, et al. **Nature** 1995 Sep 28;377(6547):309–14

The "DEAD box" protein DbpA interacts specifically with the peptidyltransferase center in 23S rRNA. Nicol SM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11681–5

PEPTIDYL TRANSLOCASES see **PEPTIDYL TRANSFERASES**

PEPTONES

CHEMISTRY

Calmodulin-binding peptides isolated from alpha-casein peptone. Kizawa K, et al. **J Dairy Res** 1995 Nov; 62(4):587–92

HISTORY

The discovery of heparin revisited: the peptone connection. Marcum JA. **Perspect Biol Med** 1996 Summer;39(4):610–25

PHARMACOLOGY

Peptone stimulates CCK-releasing peptide secretion by activating intestinal submucosal cholinergic neurons. Li Y, et al. **J Clin Invest** 1996 Mar 15;97(6):1463–70

Flocculation of the yeast Candida famata (Debaryomyces hansenii): an essential role for peptone. Cubells Martinez XC, et al. **Yeast** 1996 Apr;12(5):415–23

PHYSIOLOGY

[Capsaicin-sensitive afferent neurons and endogenous nitric oxide (NO) mediate the gastric acid secretion and hyperemic responses to intragastric peptone] Yan CD, et al. **Sheng Li Hsueh Pao** 1996 Feb;48(1):70–6 (Eng. Abstr.) **(Chi)**

PEPTOSTREPTOCOCCUS

Treatment of Peptostreptococcus micros endocarditis with teicoplanin [letter] Wenisch C, et al. **Clin Infect Dis** 1995 Aug;21(2):446–7

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**

[A case of the greater omentum abscess due to Peptostreptococcus ssp] Tsujimoto M, et al. **Kansenshogaku Zasshi** 1996 May;70(5):512–5 (Eng. Abstr.) **(Jpn)**

[A case of gas-producing brain abscess with subdural empyema: timing of the operation for brain abscess] Nishimura T, et al. **No Shinkei Geka** 1995 Oct;23(10):935–9 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Bioactivation of cysteine conjugates of 1-nitropyrene oxides by cysteine conjugate beta-lyase purified from Peptostreptococcus magnus. Kataoka K, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3781–7

GENETICS

Identification of interdomain sequences promoting the intronless evolution of a bacterial protein family. de Château M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8490–5

ISOLATION & PURIFICATION

The microbiology and antibiotic treatment of peritonsillar abscesses. Prior A, et al. **Clin Otolaryngol** 1995 Jun; 20(3):219–23

METABOLISM

Effect of CO2 on the fermentation capacities of the acetogen Peptostreptococcus productus U-1. Misoph M, et al. **J Bacteriol** 1996 Jun;178(11):3140–5

Crystallization and X-ray analysis of a single fab binding domain from protein L of Peptostreptococcus magnus. Sohi MK, et al. **Proteins** 1995 Dec;23(4):610–2

PERACETIC ACID

PHARMACOLOGY

Influence of peracetic acid on Escherichia coli H10407 strain in laboratory microcosms. Jolivet-Gougeon A, et al. **Can J Microbiol** 1996 Jan;42(1):60–5

Efficacy of 'Nu-Cidex' (0.35% peracetic acid) against mycobacteria and cryptosporidia [letter] Holton J, et al. **J Hosp Infect** 1995 Nov;31(3):235–7

Comparison of the mycobactericidal activity of 2% alkaline glutaraldehyde and 'Nu-Cidex' (0.35% peracetic acid) [letter] Lynam PA, et al. **J Hosp Infect** 1995 Jul; 30(3):237–40

PERAZINE

ADVERSE EFFECTS

"Sunbath polyneuritis": subacute axonal neuropathy in perazine-treated patients after intense sun exposure. Roelcke U, et al. **Muscle Nerve** 1996 Apr;19(4):438–41

A unique case of tardive dystonia induced by short-term therapy with perazin. Lohmann T, et al. **Pharmacopsychiatry** 1995 Nov;28(6):263–5

THERAPEUTIC USE

[Perazine therapy. Seminar, Hamburg, 12–14 November 1992] **Nervenarzt** 1993 Jan;64(1 Suppl):1–8 **(Ger)**

PERCA see **PERCH**

PERCEPTION

see related
SENSATION

Quality of care from the elderly person's perspective: subjective importance and perceived reality. Wilde B, et al. **Aging (Milano)** 1995 Apr;7(2):140–9

Relation between blood pressure at rest and perception of angina pectoris during exercise testing. Krittayaphong R, et al. **Am J Cardiol** 1996 Jun 1;77(14):1224–6

Patients' perceptions of environmental factors that disturb sleep after cardiac surgery. Simpson T, et al. **Am J Crit Care** 1996 May;5(3):173–81

Accuracy of maternal perception of preterm uterine activity. Beckmann CA, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):672–5

Women cannot discriminate between different paracervical block techniques applied to opposite sides of the cervix. Grossman RA. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):935–6

Adolescents with mental retardation: perceptions of sexual abuse. Podell DM, et al. **Am J Orthopsychiatry** 1996 Jan; 66(1):103–110

Perceived coercion in mental hospital admission. Pressures and process. Lidz CW, et al. **Arch Gen Psychiatry** 1995 Dec;52(12):1034–9

The prediction of Alzheimer disease. The role of patient and informant perceptions of cognitive deficits. Tierney MC, et al. **Arch Neurol** 1996 May;53(5):423–7

Regulation of breathing and perception of dyspnea in healthy pregnant women. García-Río F, et al. **Chest** 1996 Aug; 110(2):446–53

Children's perceptions of the risk of sexual abuse. Jacobs JE, et al. **Child Abuse Negl** 1995 Dec;19(12):1443–56

Patient perceptions regarding the risks of morbidity and complications of lower third molar removal. Armstrong RA, et al. **Community Dent Health** 1996 Mar;13(1):17–21

The sketchpad model. A theory of consciousness, perception, and imagery. Harth E. **Conscious Cogn** 1995 Sep; 4(3):346–68

Sex differences in plasma glucose thresholds for counterregulatory hormone release and hypoglycemia symptom perception [letter] Cox DJ, et al. **Diabetes Care** 1996 Mar;19(3):269–70

Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Lingenfelser T, et al. **Diabetes Care** 1995 Mar;18(3):321–5

The reliability and repeatability of the blood glucose response to prolonged exercise in adolescent boys with IDDM. Temple MY, et al. **Diabetes Care** 1995 Mar;18(3):326–32

Interaction of signal word and colour on warning labels: differences in perceived hazard and behavioural compliance. Braun CC, et al. **Ergonomics** 1995 Nov; 38(11):2207–20

Who's got the power? Gender differences in partners' perceptions of influence during marital problem-solving discussions. Ball FL, et al. **Fam Process** 1995 Sep; 34(3):303–21

The structure of family perceptions among adolescents and their parents: individual satisfaction factors and family system factors. Benson MJ, et al. **Fam Process** 1995 Sep; 34(3):323–36

Headache disability inventory (HDI): short-term test-retest reliability and spouse perceptions. Jacobson GP, et al. **Headache** 1995 Oct;35(9):534–9

Kinematics, kinetics, and psychophysical perceptions in symmetric and twisting pushing and pulling tasks. Resnick ML, et al. **Hum Factors** 1996 Mar;38(1):114–29

Subjective perception of additional support requirements of elderly patients discharged from accident and emergency departments. Farnsworth TA, et al. **J Accid Emerg Med** 1995 Jun;12(2):107–10

Symptom perception in pediatric asthma: relationship to functional morbidity and psychological factors. Fritz GK, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1033–41

Meta-analysis of the relationships between Kerr and Jermier's substitutes for leadership and employee job attitudes, role perceptions, and performance. Podsakoff PM, et al. **J Appl Psychol** 1996 Aug;81(4):380–99

The capacity of children with and without asthma to detect external resistive loads on breathing. Rietveld S, et al. **J Asthma** 1996;33(4):221–30

The impact of language on our perceptions as dental researchers: who do we remove "plaques" from teeth but add them to our walls? [editorial] Barnett ML. **J Dent Res** 1996 Mar;75(3):864–5

Optokinetic stimulation influences the disturbed perception of body orientation in spatial neglect. Karnath HO. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):217–20

Current perception threshold mis-evaluation [letter; comment] Katims JJ. **J Occup Environ Med** 1995 Jul; 37(7):790–3. Comment on: J Occup Med 1994 Sep;36(9):1015–21.

Evaluation of current perception threshold testing as a screening procedure for carpal tunnel syndrome [letter; comment] Lawrence RM. **J Occup Environ Med** 1995 Jul; 37(7):790. Comment on: J Occup Med 1994 Sep;36(9):1015–21.

"Getting better from my hurts": toward a model of the young child's pain experience. Woodgate R, et al. **J Pediatr Nurs** 1996 Aug;11(4):233–42

Effects of adult attachment style on the perception and search for social support. Florian V, et al. **J Psychol** 1995 Nov; 129(6):665–76

Teaching and learning clinical perception. Cox K. **Med Educ** 1996 Mar;30(2):90–6

The effects of cognitive-perceptual factors on health promotion behavior maintenance. Bottorff JL, et al. **Nurs Res** 1996 Jan-Feb;45(1):30–6

Metamemory and depression in cognitively impaired elders. McDougall GJ. **Nurs Res** 1995 Sep-Oct;44(5):306–11

The Pain Beliefs and Perceptions Inventory: a British replication. Morley S, et al. **Pain** 1995 Jun;61(3):427–33

Sports skill classification, gender, and perceptual style. Brady F. **Percept Mot Skills** 1995 Oct;81(2):611–20

Perception [editorial] Ross J. **Perception** 1995;24(8):851–3

Schizophrenic patients' perceptions of their relatives' attitudes. Tompson MC, et al. **Psychiatry Res** 1995 Jul 28; 57(2):155–67

Perceptions of life stress and chronic insomnia in older adults. Friedman L, et al. **Psychol Aging** 1995 Sep;10(3):352–7

A general procedure for the estimation of interdependence. Kenny DA, et al. **Psychol Bull** 1996 Jan;119(1):138–48

Words and sentences: event-related brain potential measures. van Petten C. **Psychophysiology** 1995 Nov;32(6):511–25 (141 ref.)

Perceptions of side effects following axillary block used for outpatient surgery. Cooper K, et al. **Reg Anesth** 1995 May-Jun;20(3):212–6

Customer perceptions of agency risk communication. Fisher A, et al. **Risk Anal** 1996 Apr;16(2):177–84

Presenting uncertainty in health risk assessment: initial studies of its effects on risk perception and trust. Johnson BB, et al. **Risk Anal** 1995 Aug;15(4):485–94

Developing a subject-derived terminology to describe perceptions of chemicals in foods. Raats MM, et al. **Risk Anal** 1996 Apr;16(2):133–46

Breathlessness perception in asthmatic patients—clinical implications. Král B. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(4):185–8

[Perception of dyspnea in asthmatics—long-term study] Král B, et al. **Vnitr Lek** 1995 Dec;41(12):810–5 (Eng. Abstr.) **(Cze)**

[Perceptions and Agnosia. Proceedings of an international meeting of the French Society of Neurology. Paris, 9–10 June 1994] **Rev Neurol (Paris)** 1995 Aug–Sep; 151(8–9):440–526 **(Fre)**

[Study of functional neuro-anatomy of perception using positron emission tomography] Baron JC. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):511–7 (58 ref.) (Eng. Abstr.) **(Fre)**

[Cognitive processes in perception: perceptive knowledge] Bonnet C. **Rev Neurol (Paris)** 1995 Aug–Sep; 151(8–9):442–50 (Eng. Abstr.) **(Fre)**

[Perception and memory: illustration of an approach of the study of visual mechanisms in cognitive neuroscience] Koenig O. **Rev Neurol (Paris)** 1995 Aug–Sep; 151(8–9):451–6 **(Fre)**

[Model of the perception of perturbed angular motion of the cockpit as part of pilot's information model] Azarskov VN,

et al. **Kosm Biol Aviakosm Med** 1991 Nov-Dec;25(6):14-7 (Eng. Abstr.) **(Rus)**

[Conscious perception of a stimulus as a somatopsychic process] Uryvaev IuV. **Vestn Ross Akad Med Nauk** 1995; (11):26-9 (Eng. Abstr.) **(Rus)**

[Our life experiences are more important than suspected (letter)] Brimstedt L. **Lakartidningen** 1996 Jul 24; 93(30-31):2650 **(Swe)**

[Olfactory perception of newborn infants is well-developed. Does the scent in the environment have any clinical significance?] Winberg J. **Lakartidningen** 1996 Jun 19; 93(25):2437-8 **(Swe)**

DRUG EFFECTS

Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. Chey WD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G821-6

The effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Liu SS, et al. **Anesth Analg** 1996 Jan;82(1):98-102

The effect of sweeteners on perceived viscosity. Theunissen MJ, et al. **Chem Senses** 1995 Aug;20(4):441-50

Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. Higgs CM, et al. **Clin Sci (Colch)** 1996 Mar;90(3):227-34

Effect of caffeine ingestion on perception of effort and subsequent work production. Cole KJ, et al. **Int J Sport Nutr** 1996 Mar;6(1):14-23

Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory. Legrand F, et al. **Psychopharmacology (Berl)** 1995 Apr;118(4):475-9

PHYSIOLOGY

Age-related changes in cortical blood flow activation during perception and memory. Grady CL. **Ann N Y Acad Sci** 1996 Jan 17;777:14-21

Frontal lobe mechanisms subserving vision-for-action versus vision-for-perception. Boussaoud D, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):1-15 (145 ref.)

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109-21 (56 ref.)

Breakthrough to awareness: a preliminary neural network model of conscious and unconscious perception in word processing. Taylor JG. **Biol Cybern** 1996 Jul;75(1):59-72

Responsiveness to the odour of amniotic fluid in the human neonate. Schaal B, et al. **Biol Neonate** 1995;67(6):397-406

Special issue: Interoception and behavior. **Biol Psychol** 1996 Jan 5;42(1-2):1-244

Interoception of respiratory resistance in asthmatic patients. Dahme B, et al. **Biol Psychol** 1996 Jan 5;42(1-2):215-29

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1-2):165-82 (55 ref.)

Visceral perception, anhedonia, and emotion. Ferguson ML, et al. **Biol Psychol** 1996 Jan 5;42(1-2):131-45

Detection, discrimination and sensation of visceral stimuli. Hölzl R, et al. **Biol Psychol** 1996 Jan 5;42(1-2):199-214

'Interoception' of heart rate, blood pressure, and myocardial metabolism during ergometric work load in healthy young subjects. Kollenbaum VE, et al. **Biol Psychol** 1996 Jan 5; 42(1-2):183-97

Somatic graviception. Mittelstaedt H. **Biol Psychol** 1996 Jan 5;42(1-2):53-74

Perception of emotions in everyday life: studies with patients and normals. Myrtek M, et al. **Biol Psychol** 1996 Jan 5; 42(1-2):147-64

Symptom reporting in asthma patients and insulin-dependent diabetics. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1-2):231-44

Event-related brain potentials and the processing of cardiac activity. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1-2):75-85

Simulated micro-gravity and cortical inhibition: a study of the hemodynamic-brain interaction. Vaitl D, et al. **Biol Psychol** 1996 Jan 5;42(1-2):87-103

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1-2):1-27 (100 ref.)

Neuronal activity in human right lateral temporal cortex related to visuospatial memory and perception. Holmes MD, et al. **Brain Res** 1996 Mar 4;711(1-2):44-9

Tutorial commentary: surprisingly small subcortical structures are needed for the state of waking consciousness, while cortical projection areas seem to provide perceptual contents of consciousness [comment] Baars BJ. **Conscious Cogn** 1995 Jun;4(2):159-62. Comment on: Conscious Cogn 1995 Jun;4(2):137-58.

Temporal integration of events within and between the cerebral hemispheres. Mason C, et al. **Cortex** 1996 Mar; 32(1):97-108

Perception and memory: action and interaction. Eacott MJ, et al. **Crit Rev Neurobiol** 1995;9(4):311-20 (50 ref.)

Binding in models of perception and brain function. von der Malsburg C. **Curr Opin Neurobiol** 1995 Aug;5(4):520-6 (70 ref.)

Spatio-temporal correlations in human gamma band electrocorticograms. Menon V, et al. **Electroencephalogr Clin Neurophysiol** 1996 Feb; 98(2):89-102

Contribution of tactile afferent information to the control of isometric finger forces. Henningsen H, et al. **Exp Brain Res** 1995;105(2):312-7

Perception and reflex responses to intestinal distention in humans are modified by simultaneous or previous stimulation. Serra J, et al. **Gastroenterology** 1995 Dec; 109(6):1742-9

Pain perception and brain evoked potentials in patients with angina despite normal coronary angiograms. Frøbert O, et al. **Heart** 1996 May;75(5):436-41

Salt taste perceptions and preferences are unrelated to sodium consumption in healthy older adults. Drewnowski A, et al. **J Am Diet Assoc** 1996 May;96(5):471-4

Light perception in the vertebrate brain: an ultrastructural analysis of opsin- and vasoactive intestinal polypeptide-immunoreactive neurons in iguanid lizards. Grace MS, et al. **J Comp Neurol** 1996 Apr 15;367(4):575-94

Cross-modal discrepancies in coarticulation and the integration of speech information: the McGurk effect with mismatched vowels. Green KP, et al. **J Exp Psychol Hum Percept Perform** 1995 Dec; 21(6):1409-26

Types and tokens unscathed: a reply to Whittlesea, Dorken, and Podrouzek (1995) and Whittlesea and Podrouzek (1995). Downing P, et al. **J Exp Psychol Learn Mem Cogn** 1995 Nov;21(6):1698-702

Verbal vulnerability of perceptual expertise. Fallshore M, et al. **J Exp Psychol Learn Mem Cogn** 1995 Nov; 21(6):1608-23

Correlation of measurements of pressure perception using the pressure-specified sensory device with electrodiagnostic testing. Tassler PL, et al. **J Occup Environ Med** 1995 Jul;37(7):862-6

Perception of movement at the human ankle: effects of leg position. Refshauge KM, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):243-8

Quantitative measurement of cutaneous perception in diabetic neuropathy [letter; comment] Cohen RP. **Muscle Nerve** 1996 Mar;19(3):404-6. Comment on: Muscle Nerve 1995 Jun;18(6):574-84.

Quantitative thermal perception testing in preschool children. Hilz MJ, et al. **Muscle Nerve** 1996 Mar;19(3):381-3

Quantitative measurement of cutaneous perception in diabetic neuropathy [letter; comment] Rendell M. **Muscle Nerve** 1996 Mar;19(3):406-7. Comment on: Muscle Nerve 1995 Jun;18(6):574-84.

Contribution of human hippocampal region to novelty detection. Knight R. **Nature** 1996 Sep 19;383(6597):256-9

Neural network models of perceptual learning of angle discrimination. Mato G, et al. **Neural Comput** 1996 Feb 15;8(2):270-99

Motor imagery: perception or action? Annett J. **Neuropsychologia** 1995 Nov;33(11):1395-417 (101 ref.)

Human flexor pollicis longus: role of peripheral inputs in weight-matching. Kilbreath SL, et al. **Neurosci Lett** 1995 Dec 15;201(3):203-6

Do schizophrenics not differentiate between perception and imagination? an EEG study using dimensional analysis. Lutzenberger W, et al. **Neurosci Lett** 1995 Oct 20; 199(2):119-22

Asymmetrical involvement of mesolimbic dopaminergic neurons in affective perception. Besson C, et al. **Neuroscience** 1995 Oct;68(4):963-8

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3-10 (45 ref.)

Rectal adaptation to distention: implications for the determination of perception thresholds. Musial F, et al. **Physiol Behav** 1995 Dec;58(6):1145-8

Perception of dyspnoea during acute changes in lung function in patients with either asthma or COPD. Noseda A, et al. **Respir Med** 1995 Aug;89(7):477-85

Cerebellum implicated in sensory acquisition and discrimination rather than motor control [see comments] Gao JH, et al. **Science** 1996 Apr 26;272(5261):545-7. Comment in: Science 1996 Apr 26;272(5261):482-3.

'My most true mind thus makes mine eye untrue'. Albright TD. **Trends Neurosci** 1995 Aug;18(8):331-3 (10 ref.)

Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S. **Trends Neurosci** 1995 Aug;18(8):359-64 (50 ref.)

[Intracranial blood flow parameters in cerebral functional changes and cognitive cerebral performance] Klingelhöfer J, et al. **Nervenarzt** 1996 Apr;67(4):283-93 (Eng. Abstr.) **(Ger)**

[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):10-20 (69 ref.) **(Rus)**

PERCEPTION, SOCIAL see **SOCIAL PERCEPTION**

PERCEPTRONS see **NEURAL NETWORKS (COMPUTER)**

PERCEPTUAL CLOSURE

The development of perceptual completion abilities: infants' perception of stationary, partially occluded objects. Craton LG. **Child Dev** 1996 Jun;67(3):890-904

Lateralization of perceptual closure ability. Fouty HE, et al. **Percept Mot Skills** 1995 Oct;81(2):547-51

A dotted line assimilates in visibility to a solid line. King DL, et al. **Psychol Res** 1996;59(1):4-15

PERCEPTUAL COMPLETION PHENOMENA see **PERCEPTUAL CLOSURE**

PERCEPTUAL DEFENSE

Percept-genetic codings of defense in chronic schizophrenia. Rubino IA, et al. **Percept Mot Skills** 1996 Apr;82(2):483-93

Predicting perceptual defense. York MW, et al. **Percept Mot Skills** 1996 Feb;82(1):185-6

PERCEPTUAL DISORDERS

CHEMICALLY INDUCED

Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD). Kawasaki A, et al. **Arch Ophthalmol** 1996 Jan;114(1):47-50

COMPLICATIONS

'When is VISION asked too much?' van der Wildt GJ, et al. **Doc Ophthalmol** 1995;90(1):99-105

Looking with one's mind's eye. Lebrun Y. **Eur J Disord Commun** 1995;30(3):279-302

Visual-perceptual disturbances in delusional misidentification. Silva JA, et al. **Isr J Psychiatry Relat Sci** 1995;32(4):286-90

DIAGNOSIS

Selective deficits in visual perception and recognition in schizophrenia. O'Donnell BF, et al. **Am J Psychiatry** 1996 May;153(5):687-92

Thought disorder, perceptual aberrations, and schizotypy. Coleman MJ, et al. **J Abnorm Psychol** 1996 Aug; 105(3):469-73

Dot Enumeration Perceptual Organization Task (DEPOT): evidence for a short-term visual memory deficit in schizophrenia. Rabinowicz EF, et al. **J Abnorm Psychol** 1996 Aug;105(3):336-48

Stimulus configuration and context effects in perceptual organization in schizophrenia. Silverstein SM, et al. **J Abnorm Psychol** 1996 Aug;105(3):410-20

Development and standardization of SCAN-A: test of auditory processing disorders in adolescents and adults. Keith RW. **J Am Acad Audiol** 1995 Jul;6(4):286-92

The development and reliability of the Mental Health Research Institute Unusual Perceptions Schedule (MUPS): an instrument to record auditory hallucinatory experience. Carter DM, et al. **Schizophr Res** 1995 Aug 1;16(2):157-65

DRUG THERAPY

Managing agitation in critically ill patients. Harvey MA. **Am J Crit Care** 1996 Jan;5(1):7-16; quiz 17-8 (72 ref.)

ETIOLOGY

Palinopsia as sensory epileptic phenomenon. Müller T, et al. **Acta Neurol Scand** 1995 Jun;91(6):433-6

Disorders of visual and spatial perception in the early stage of Alzheimer's disease. Binetti G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:221-5

A new clinical sign in Williams syndrome [letter] Withers S. **Arch Dis Child** 1996 Jul;75(1):89

Differential visuospatial dysfunction following striatal, frontal white matter, or posterior thalamic infarction. Ricker JH, et al. **Int J Neurosci** 1996 Feb;84(1-4):75-85

Perceptual abnormalities in Parkinson's disease: top-down or bottom-up processes? Flowers KA, et al. **Perception** 1995;24(10):1201-21

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32-7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Symptomatologic characteristics and psychopathology of expression of an "attack of altered perception" in schizophrenic patients] Nakamura K. **Seishin Shinkeigaku Zasshi** 1995;97(7):529-50 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Assessment of visuoperceptual disturbance in children with spastic diplegia using measurements of the lateral ventricles on cerebral MRI. Ito J, et al. **Dev Med Child Neurol** 1996 Jun;38(6):496-502

PHYSIOPATHOLOGY

Object segmentation and visual neglect. Driver J. **Behav Brain Res** 1995 Nov;71(1-2):135-46 (74 ref.)

The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1-2):127-42 (75 ref.)

Motion and shape perception in cerebral akinetopsia. Rizzo M, et al. **Brain** 1995 Oct;118 (Pt 5):1105-27

Localization in impaired spatial vision. Takayama Y, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):249-52

Optokinetic stimulation affects both vertical and horizontal deficits of position sense in unilateral neglect. Vallar G, et al. **Cortex** 1995 Dec;31(4):669-83

Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. Marinone MG, et al.

Haematologica 1996 Mar–Apr;81(2):110–5
Face and voice expression identification in patients with emotional and behavioural changes following ventral frontal lobe damage. Hornak J, et al. **Neuropsychologia** 1996 Apr;34(4):247–61
Optometric correlates of Meares–Irlen syndrome: a matched group study. Evans BJ, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):481–7

PSYCHOLOGY

Coordinate frames for naming misoriented chimerics: a case study of visuo-spatial neglect. di Pellegrino G, et al. **Cortex** 1995 Dec;31(4):767–77
Differential effects of line length on bisection judgements in hemispatial neglect. Harvey M, et al. **Cortex** 1995 Dec; 31(4):711–22
Influence of epilepsy and temporal lobe resection on olfactory function. West SE, et al. **Epilepsia** 1995 Jun; 36(6):531–42
More evidence for generalized poor performance in facial emotion perception in schizophrenia. Salem JE, et al. **J Abnorm Psychol** 1996 Aug;105(3):480–3
Disabled stereopsis may be the norm among well-educated people. Larson WL. **Med Hypotheses** 1995 May; 44(5):309–10
The phenomenology of perceptual hallucinations in alcohol-induced delirium tremens. Platz WE, et al. **Psychopathology** 1995;28(5):247–55
[Perception in melancholia (endogenous depression)] Schwering J. **Psychiatr Prax** 1995 Nov;22(6):254–6 **(Ger)**
[Acoustic and optical perceptual disorders in depressive diseases—an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4–11 (61 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Reversal of visuospatial deficit on the Clock Drawing Test in Parkinson's disease by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun; 82(3–4):255–68
Everything I learned, I learned from patients: radical positive reframing. San Blise ML.
J Psychosoc Nurs Ment Health Serv 1995 Dec;33(12):18–25

PERCEPTUAL DISTORTION

see related
PERCEPTUAL DISORDERS

Use of distortion product otoacoustic emissions to assess middle ear transducers in rhesus monkeys. Park JY, et al. **Am J Otol** 1995 Sep;16(5):576–90
Spatial disorientation [letter; comment] Cheung B.
Aviat Space Environ Med 1995 Jul;66(7):706. Comment on: Aviat Space Environ Med 1994 Dec;65(12):1153–5.
Body size estimation in eating disorder patients: testing the video distortion method on a life-size screen. Probst M, et al. **Behav Res Ther** 1995 Nov;33(8):985–90
Changes in acoustic distortion during long term electrical stimulation of the guinea pig cochlea: a preliminary study. Dodson HC, et al. **Br J Audiol** 1995 Aug;29(4):209–18
Methodological issues in assessment of the perceptual component of body image disturbance. Gardner RM. **Br J Psychol** 1996 May;87 (Pt 2):327–37
The case of Dr. John D. Frame's first memory: historical truth and psychological distortion. Erdelyi MH, et al. **Conscious Cogn** 1995 Mar;4(1):95–9
Altruism in hotline volunteers—the final distortions of caring. Seeley MF. **Crisis** 1995;16(2):52–3
Distorting reality for children: body size proportions of Barbie and Ken dolls. Brownell KD, et al.
Int J Eat Disord 1995 Nov;18(3):295–8
Distortion-product otoacoustic emissions in Mongolian gerbils with resistance to noise-induced hearing loss. Boettcher FA, et al. **J Acoust Soc Am** 1995 Dec; 98(6):3215–22
Effects of aging on the fine structure of the 2f1–f2 acoustic distortion product. He NJ, et al. **J Acoust Soc Am** 1996 Feb;99(2):1002–15
Slopes of distortion-product otoacoustic emission growth curves corrected for noise-floor levels. Nelson DA, et al. **J Acoust Soc Am** 1996 Jan;99(1):468–74
Olivocochlear reflex assays: effects of contralateral sound on compound action potentials versus ear-canal distortion products. Puria S, et al. **J Acoust Soc Am** 1996 Jan; 99(1):500–7
The role of sensory and nonsensory factors in body size estimations of eating disorder subjects. Gardner RM, et al. **J Clin Psychol** 1996 Jan;52(1):3–15
Inversion and processing of component and spatial-relational information in faces. Searcy JH, et al.
J Exp Psychol Hum Percept Perform 1996 Aug; 22(4):904–15
Body image distortion in anorexia and bulimia nervosa: the role of perceived and actual control. Waller G, et al.
J Nerv Ment Dis 1996 Apr;184(4):213–9
Distorted self-perceptions: divergent self-reports as statistical outliers in the multimethod assessment of children's social-emotional adjustment. Weinberger DA.
J Pers Assess 1996 Feb;66(1):126–43
Mental constructs and the cognitive reconstruction of the Berlin wall. Tijus CA, et al. **J Psychol** 1996 Jul; 130(4):401–11
Explaining impossible phenomena: object permanence beliefs and memory failures in adults. Subbotsky EV. **Memory** 1996 Mar;4(2):199–223
A preliminary investigation into the aetiology of Meares–Irlen syndrome. Evans BJ, et al.
Ophthalmic Physiol Opt 1996 Jul;16(4):286–96
Comparison of three psychophysical techniques for estimating body-size perception. Gardner RM, et al.
Percept Mot Skills 1995 Jun;80(3 Pt 2):1379–90
The perceptual flattening of three-dimensional scenes enclosed by a frame. Eby DW, et al. **Perception** 1995; 24(9):981–93
Auditory isochrony: time shrinking and temporal patterns. ten Hoopen G, et al. **Perception** 1995;24(5):577–93
Self-recognition and abstraction abilities in the common chimpanzee studied with distorting mirrors. Kitchen A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7405–8
Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer. Smith BL, et al.
Surgery 1996 Aug;120(2):297–303
[A case of metamorphopsia restricted to faces and different familiar objects] Seron X, et al. **Rev Neurol (Paris)** 1995 Dec;151(12):691–8 (Eng. Abstr.) **(Fre)**
[Standard parameters of distortion products] Martínez Ibargüen A, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug; 46(4):247–52 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Optometric correlates of Meares–Irlen syndrome: a matched group study. Evans BJ, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):481–7
[Distortion product otoacoustic emissions (DPOAE) in chronic noise-induced hearing loss—recommendations for expert assessment] Oeken I, et al. **Laryngorhinootologie** 1995 Aug;74(8):473–80 (Eng. Abstr.) **(Ger)**
[Amplitude changes in distortion products of otoacoustic emissions after acute noise exposure] Oeken J, et al.
Laryngorhinootologie 1996 May;75(5):265–9 (Eng. Abstr.) **(Ger)**

PERCEPTUAL MASKING

Does perceptual analysis continue during selection and production of a speeded response? Levy J, et al.
Acta Psychol (Amst) 1995 Nov;90(1–3):245–60
Impaired word recognition in noise by patients with noise-induced cochlear hearing loss: contribution of temporal resolution defect. Phillips DP, et al.
Am J Otol 1994 Sep;15(5):679–86
Backward-masking deficit in adolescents with schizophrenic disorders or attention deficit hyperactivity disorder. Rund BR, et al. **Am J Psychiatry** 1996 Sep;153(9):1154–7
Re: Cobb FE: Age-associated degeneration of backward masking task performance: evidence of declining temporal resolution abilities in normal listeners [letter] Cobb FE. **Audiology** 1995 May–Jun;34(3):160
The development of perceptual completion abilities: infants' perception of stationary, partially occluded objects. Craton LG. **Child Dev** 1996 Jun;67(3):890–904
Cepstral representation of speech motivated by time–frequency masking: an application to speech recognition. Aikawa K, et al. **J Acoust Soc Am** 1996 Jul; 100(1):603–14
Comments on "Manipulations of the duration and relative onsets of two-tone forward maskers" [J. Acoust. Soc. Am. 94, 1269–1274 (1993)] [letter] Bacon SP.
J Acoust Soc Am 1996 May;99(5):3246–8
On the relation between comodulation masking release and temporal modulation transfer functions. Berg BG.
J Acoust Soc Am 1996 Aug;100(2 Pt 1):1013–23
The effects on comodulation masking release of systemic variations in on- and off-frequency masker modulation patterns. Buss E, et al. **J Acoust Soc Am** 1996 May; 99(5):3109–18
Encoding the fundamental frequency of a complex tone in the presence of a spectrally overlapping masker. Carlyon RP. **J Acoust Soc Am** 1996 Jan;99(1):517–24
Masker asynchrony impairs the fundamental-frequency discrimination of unresolved harmonics. Carlyon RP.
J Acoust Soc Am 1996 Jan;99(1):525–33
Growth of low-pass masking of pure tones and speech for hearing-impaired and normal-hearing listeners. Dubno JR, et al. **J Acoust Soc Am** 1995 Dec;98(6):3113–24
Vibrotactile forward masking: effects of the amplitude and duration of the masking stimulus. Gescheider GA, et al.
J Acoust Soc Am 1995 Dec;98(6):3188–94
Some temporal parameters in vibrotactile forward masking. Gescheider GA, et al. **J Acoust Soc Am** 1995 Dec; 98(6):3195–9
Some factors influencing comodulation masking release and across-channel masking. Hicks ML, et al.
J Acoust Soc Am 1995 Nov;98(5 Pt 1):2504–14
Binaural masking level differences in the inferior colliculus of the guinea pig. McAlpine D, et al.
J Acoust Soc Am 1996 Jul;100(1):490–503
Decay in the effect of vibrotactile masking. Makous JC, et al. **J Acoust Soc Am** 1996 Feb;99(2):1124–9
Signal properties that reduce masking by simultaneous, random-frequency maskers. Neff DL. **J Acoust Soc Am** 1995 Oct;98(4):1909–20
The effect of level and relative frequency region on the recovery of overshoot. Overson GJ, et al.
J Acoust Soc Am 1996 Feb;99(2):1059–65
Additivity of masking in normally hearing and hearing-impaired subjects. Oxenham AJ, et al.
J Acoust Soc Am 1995 Oct;98(4):1921–34
Loudness enhancement and intensity discrimination under forward and backward masking. Plack CJ.
J Acoust Soc Am 1996 Aug;100(2 Pt 1):1024–30
Pure tone masking patterns in adult chickens before and after recovery from acoustic trauma. Saunders SS, et al.
J Acoust Soc Am 1995 Sep;98(3):1365–71
Detectability of simultaneously masked signals as a function of signal bandwidth for different signal delays. Wright BA.
J Acoust Soc Am 1995 Nov;98(5 Pt 1):2493–503
Speech recognition in noise by hearing-impaired and noise-masked normal-hearing listeners. Needleman AR, et al. **J Am Acad Audiol** 1995 Nov;6(6):414–24
Recognition of speech in noise with hearing aids using dual microphones. Valente M, et al. **J Am Acad Audiol** 1995 Nov;6(6):440–9
Recognition of multiply degraded speech by young and elderly listeners. Gordon-Salant S, et al.
J Speech Hear Res 1995 Oct;38(5):1150–6
An examination of error reductions in consonant recognition when vision and hearing are combined. Berryman L, et al. **Percept Mot Skills** 1996 Apr;82(2):558
Human analog tests of the sixth stage of object permanence. Heishman M, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1059–68
Effects of ear canal occlusion and masking on the perception of voice. Navarro R. **Percept Mot Skills** 1996 Feb; 82(1):199–208
Temporal competition between odorants: effect of different time intervals on the perception of monorhinic and dichorhinic binary mixtures. Rouby C, et al. **Perception** 1995;24(9):1083–97
The effect of a masked stimulus on the response to the masking stimulus. Klotz W, et al. **Psychol Res** 1995; 58(2):92–101
Effect of contralateral white noise masking on the mismatch negativity. Salo SK, et al. **Scand Audiol** 1995;24(3):165–73
[The effect of different types of music on the perception of speech information] Tsaneva L, et al. **Probl Khig** 1995; 20:116–21 (Eng. Abstr.) **(Bul)**
[Effects of electrical promontory stimulation and band-noise masker in the suppression of tinnitus] Ohkawara D, et al.
Nippon Jibiinkoka Gakkai Kaiho 1995 Aug;98(8):1303–9 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Short latency vestibular evoked responses to linear acceleration stimuli in small mammals: masking effects and experimental applications. Böhmer A.
Acta Otolaryngol Suppl (Stockh) 1995;520 Pt 1:120–3
Comodulation masking release in a songbird. Klump GM, et al. **Hear Res** 1995 Jul;87(1–2):157–64
Masking and pitch shift of tone bursts and clicks by low-frequency tones. Mrowinski D, et al. **Hear Res** 1995 May;85(1–2):95–102
Sensorineural hearing loss alters recovery from short-term adaptation in the C57BL/6 mouse. Walton JP, et al.
Hear Res 1995 Aug;88(1–2):19–26
Interocular suppression in cat striate cortex is not orientation selective. Sengpiel F, et al. **Neuroreport** 1995 Nov 13; 6(16):2235–9
Relation between backward masking deficits and smooth pursuit dysfunction in schizophrenia? Allen JS.
Optom Vis Sci 1995 Jul;72(7):493–501 (61 ref.)
Masking of spatial frequency in visual memory depends on distal, not retinal, frequency. Bennett PJ, et al.
Vision Res 1996 Jan;36(2):233–8
Spatial frequency channels in experimentally strabismic monkeys revealed by oblique masking. Kiper DC, et al.
Vision Res 1995 Oct;35(19):2737–42
Masking of the achromatic system: implications for saccadic suppression. Schwartz SH, et al. **Vision Res** 1996 Jun; 36(11):1551–9
[The effect of different masking noises on psychophysiological tasks] Tsaneva L, et al. **Probl Khig** 1995;20:109–15 (Eng. Abstr.) **(Bul)**
[Somatosensory evoked potentials: interference and perceptual masking of cutaneous afferents in man] el Kharroussi M, et al. **Neurophysiol Clin** 1996;26(2):85–101 (Eng. Abstr.) **(Fre)**
[Diagnosis of endolymphatic hydrops with low tone masked otoacoustic emissions] Nubel K, et al.
Laryngorhinootologie 1995 Nov;74(11):651–6 (Eng. Abstr.) **(Ger)**
[Distortion product otoacoustic emissions (DPOAE) in chronic noise-induced hearing loss—recommendations for expert assessment] Oeken I, et al. **Laryngorhinootologie** 1995 Aug;74(8):473–80 (Eng. Abstr.) **(Ger)**

PERCEPTUAL MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

PERCH

Exclusion of copper from altered hepatocytes in white perch (Morone americana) with hepatic copper storage. Bunton

TE. **J Wildl Dis** 1995 Jan;31(1):99–103

ANATOMY & HISTOLOGY

Nonuniform distribution of cell proliferation in the adult teleost retina. Kwan JW, et al. **Brain Res** 1996 Mar 11; 712(1):40–4

Ultrastructure and function of cellular components of the intercentral joint in the percoid vertebral column. Schmitz RJ. **J Morphol** 1995 Oct;226(1):1–24

GENETICS

Phylogenetic analysis of cichlid fishes using nuclear DNA markers. Sültmann H, et al. **Mol Biol Evol** 1995 Nov; 12(6):1033–47

Widespread geographical distribution of mitochondrial haplotypes in rock-dwelling cichlid fishes from Lake Tanganyika. Meyer A, et al. **Mol Ecol** 1996 Jun;5(3):341–50

Evolution of NADH dehydrogenase subunit 2 in east African cichlid fish. Kocher TD, et al. **Mol Phylogenet Evol** 1995 Dec;4(4):420–32

Mitochondrial phylogeography of rock-dwelling cichlid fishes reveals evolutionary influence of historical lake level fluctuations of Lake Tanganyika, Africa. Verheyen E, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Jun 29; 351(1341):797–805

GROWTH & DEVELOPMENT

Coconut oil and beef tallow, but not tricaprylin, can replace menhaden oil in the diet of red drum (Sciaenops ocellatus) without adversely affecting growth or fatty acid composition. Craig SR, et al. **J Nutr** 1995 Dec; 125(12):3041–8

IMMUNOLOGY

Modulation of humoral immune response by tannery effluent in Oreochromis mossambicus (Peters). Sudhan T, et al. **Indian J Exp Biol** 1995 Oct;33(10):793–5

METABOLISM

Differentiation of photoreceptors, glia, and neurons in the retina of the cichlid fish Aequidens pulcher; an immunocytochemical study. Negishi K, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):87–102

Thyroid hormone induces the generation of a novel putative protein in piscine ovarian follicle that stimulates the conversion of pregnenolone to progesterone. Bhattacharya S, et al. **Eur J Endocrinol** 1996 Jan;134(1):128–35

PARASITOLOGY

[The variability of the cestode perch parasite Proteocephalus percae in its host's geographic range] Anikieva LV. **Parazitologiia** 1995 Jul–Aug;29(4):279–88 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Ultrastructure and function of cellular components of the intercentral joint in the percoid vertebral column. Schmitz RJ. **J Morphol** 1995 Oct;226(1):1–24

VIROLOGY

Spread of epizootic haematopoietic necrosis virus (EHNV) in redfin perch (Perca fluviatilis) in southern Australia. Whittington RJ, et al. **Aust Vet J** 1996 Mar;73(3):112–4

PERCHLORIC ACID

Analysis of ethanol and acetaldehyde recovery from perchloric acid-treated blood. Whitmire D, et al. **Alcohol Alcohol** 1995 Sep;30(5):623–8

ADMINISTRATION & DOSAGE

Administration of potassium perchlorate to improve the quality of gated blood pool imaging [letter] Ercan MT, et al. **Eur J Nucl Med** 1995 Nov;22(11):1356

ANALYSIS

A critical assessment of brain metabolites: analysis of perchloric acid extracts using proton nuclear magnetic resonance. Chang C, et al. **Neurosci Lett** 1995 Aug 18; 196(1–2):134–6

DIAGNOSTIC USE

Application of a new perchloric acid treatment method to measure endotoxin by an endotoxin-specific chromogenic Limulus test in neonatal septicemia. Suda H, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):579–81

PHARMACOLOGY

Comparison of the effects of perchlorate and Bay K 8644 on the dynamics of cytoplasmic Ca2+ concentration and insulin secretion in mouse beta-cells. Larsson-Nyrén G, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):167–73

Effects of perchlorate on depolarization-induced conformational changes in the junctional foot protein and Ca2+ release from sarcoplasmic reticulum. Yano M, et al. **Biochemistry** 1995 Oct 3;34(39):12584–9

The effects of sodium perchlorate on rabbit muscle enolase--Spectral characterization of the monomer. Kornblatt MJ, et al. **Eur J Biochem** 1996 Feb 15; 236(1):78–84

[Analysis of iodine compounds in young rat skin in the period of suckling and in the adult. Effect of perchlorate] Zeghal N, et al. **Arch Physiol Biochem** 1995 Aug;103(4):502–11 (Eng. Abstr.) **(Fre)**

TOXICITY

Perchlorates. Von Burg R. **J Appl Toxicol** 1995 May–Jun; 15(3):237–41 (64 ref.)

PERCHLOROETHYLENE see **TETRACHLOROETHYLENE**

PERCIFORMES

Expression of kinesin heavy chain isoforms in retinal pigment epithelial cells. King-Smith C, et al. **Cell Motil Cytoskeleton** 1995;31(1):66–81

Morphological and histochemical changes caused by sodium dodecyl sulphate in the gills of giltheads (Sparus aurata, L.). Ribelles A, et al. **Eur J Histochem** 1995;39(2):141–8

Morphological and histochemical changes in the liver and pancreas of gilthead, Sparus auratus L., induced by acute action of the anionic detergent, sodium dodecyl sulphate. Ribelles A, et al. **Histol Histopathol** 1995 Oct;10(4):781–7

Amino-acid sequence of bone Gla protein from the African clawed toad Xenopus laevis and the fish Sparus aurata. Cancela ML, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):419–23

ANATOMY & HISTOLOGY

Phenotypic plasticity in the lower pharyngeal jaw dentition of Astatoreochromis alluaudi (Teleostei: Cichlidae). Huysseune A. **Arch Oral Biol** 1995 Nov;40(11):1005–14

Periventricular morphology in the diencephalon of antarctic notothenioid teleosts. Lannoo MJ, et al. **J Comp Neurol** 1995 Oct 9;361(1):95–107

Unusual brain nucleus in the diencephalon of a perciform (nototheniid) fish from Antarctica. Anken RH, et al. **Neuroreport** 1995 Nov 13;6(16):2113–6

BLOOD

The blood cells and haemopoiesis of Diplodus sargus L.: haematological values, cytochemistry and leukocytes' response to vaccine stimulation. Pica A, et al. **Eur J Histochem** 1996;40(1):57–66

Red drum somatolactin: development of a homologous radioimmunoassay and plasma levels after exposure to stressors or various backgrounds. Zhu Y, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):275–88

GENETICS

Highly efficient expression of fish growth hormone by Escherichia coli cells. Tsai HJ, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4116–9

Expression of ras gene in flounder (Platichthys flesus) andred mullet (Mullus barbatus). Vincent F, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):659–65

Antifreeze protein does not confer cold tolerance to transgenic Drosophila melanogaster. Duncker BP, et al. **Cryobiology** 1995 Dec;32(6):521–7

The EcoRI centromeric satellite DNA of the Sparidae family (Pisces, Perciformes) contains a sequence motive common to other vertebrate centromeric satellite DNAs. Garrido-Ramos MA, et al. **Cytogenet Cell Genet** 1995; 71(4):345–51

Use of the teleost saccule to identify genes involved in inner ear function. Davis JG, et al. **DNA Cell Biol** 1995 Oct; 14(10):833–9

Cloning of the barramundi growth hormone-encoding gene: a comparative analysis of higher and lower vertebrate GH genes. Yowe DL, et al. **Gene** 1995 Sep 11;162(2):255–9

Mitochondrial phylogeny of trematomid fishes (Notothenioidae, Perciformes) and the evolution of Antarctic fish. Ritchie PA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):383–90

GROWTH & DEVELOPMENT

Ontogeny of growth hormone protein and mRNA in the gilthead sea bream Sparus aurata. Funkenstein B, et al. **Growth Regul** 1996 Mar;6(1):16–21

IMMUNOLOGY

Nonspecific cell-mediated cytotoxicity in the seawater teleosts (Sparus aurata and Dicentrarchus labrax): ultrastructural study of target cell death mechanisms. Meseguer J, et al. **Anat Rec** 1996 Apr;244(4):499–505

Innate immune function as a bioindicator of pollution stress in fish. Rice CD, et al. **Ecotoxicol Environ Saf** 1996 Mar; 33(2):186–92

Ultrastructural localization of IgM on B-lymphocytes of Diplodus sargus [letter] Pica A, et al. **Eur J Histochem** 1996;40(1):75–6

METABOLISM

Heavy metal concentrations in the tissue of Sparus sarba Forskål, 1775 from the United Arab Emirates. al-Ghais SM. **Bull Environ Contam Toxicol** 1995 Oct;55(4):581–7

Acute effect of organotin compounds to red sea bream and red carp using biological parameters. Kawano A, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):774–81

MICROBIOLOGY

Role of extracellular products in the pathogenicity of Vibrio strains on cultured gilt-head seabream (Sparus aurata). Balebona MC, et al. **Microbiologia** 1995 Dec;11(4):439–46

PARASITOLOGY

A new nematode, Dichelyne alatae sp. n. (Cucullanidae), from Sillaginopsis panijus (Pisces) of West Bengal, India. De NC, et al. **Folia Parasitol (Praha)** 1995;42(3):220–6

Pathobiology associated with the spiruroid nematodes Camallanus oxycephalus and Spinitectus carolini in the intestine of green sunfish, Lepomis cyanellus. Meguid MA, et al. **J Parasitol** 1996 Feb;82(1):118–23

PHYSIOLOGY

Stimulation of cell elongation in teleost rod photoreceptors by distinct protein kinase inhibitors. Pagh-Roehl K, et al. **J Neurochem** 1996 Jun;66(6):2311–9

Phosducin and PP33 are in vivo targets of PKA and type 1 or 2A phosphatases, regulators of cell elongation in teleost rod inner-outer segments. Pagh-Roehl K, et al. **J Neurosci** 1995 Oct;15(10):6475–88

PERCUSSION

Percussion and physical diagnosis: separating myth from science. McGee SR. **Dis Mon** 1995 Oct;41(10):641–92 (163 ref.)

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756–60 (33 ref.)

METHODS

Bone transmitted patella percussion [letter] Mitchell P. **Ann R Coll Surg Engl** 1995 Jul;77(4):315

PERCUTANEOUS ADMINISTRATION see **ADMINISTRATION, CUTANEOUS**

PERCUTANEOUS ATHERECTOMY see **ATHERECTOMY**

PERCUTANEOUS ELECTRIC NERVE STIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

PERCUTANEOUS NEPHROLITHOTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS NEPHROSTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY see **ANGIOPLASTY, BALLOON**

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

PERCUTANEOUS ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

PERFLUOROCARBONS see **FLUOROCARBONS**

PERFORMANCE APPRAISAL, EMPLOYEE see **EMPLOYEE PERFORMANCE APPRAISAL**

PERFUME

ADVERSE EFFECTS

Inhalation challenge effects of perfume scent strips in patients with asthma. Kumar P, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):429–33

Patch testing with fragrances: results of a multicenter study of the European Environmental and Contact Dermatitis Research Group with 48 frequently used constituents of perfumes. Frosch PJ, et al. **Contact Dermatitis** 1995 Nov; 33(5):333–42

Occupational allergic contact dermatitis caused by ylang-ylang oil. Kenerva L, et al. **Contact Dermatitis** 1995 Sep;33(3):198–9

[Perfume allergy--an allergy of prosperity?] Nyfors A. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3354–5 **(Nor)**

[Contact allergy to essential oils] Selvåg E, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3369–70 (Eng. Abstr.) **(Nor)**

ANALYSIS

Occurrence of nitro and non-nitro benzenoid musk compounds in human adipose tissue. Müller S, et al.

PERFUME

Chemosphere 1996 Jul;33(1):17–28

METABOLISM

In vitro percutaneous absorption of the fragrance ingredient musk xylol. Hood HL, et al. **Food Chem Toxicol** 1996 May; 34(5):483–8

PERFUSION

Vascular injury in isolated sheep lungs. Role of ischemia, extracorporeal perfusion, and oxygen. Pearse DB, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):196–202

Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ng B, et al. **Ann Thorac Surg** 1996 Mar;61(3):969–72

Retrograde cerebral perfusion [letter; comment] Ueda Y, et al. **Ann Thorac Surg** 1996 Mar;61(3):1043–4. Comment on: Ann Thorac Surg 1995 Aug;60(2):319–27; discussion 327–8.

Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Manusama ER, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):152–7

Preconditioning of perfused rat heart inhibits reperfusion-induced release of inositol(1,4,5)trisphosphate. Anderson KE, et al. **J Mol Cell Cardiol** 1995 Nov; 27(11):2421–31

What is cerebral metabolism during retrograde perfusion? [letter; comment] Watanabe T, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):490–3. Comment on: J Thorac Cardiovasc Surg 1995 Jun;109(6):1173–81.

Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. Safi HJ, et al. **J Vasc Surg** 1996 Feb;23(2):223–8; discussion 229

Long-term dual perfusion of isolated human placental lobules with improved oxygenation for infectious diseases research. Polliotti BM, et al. **Placenta** 1996 Jan;17(1):57–68

[5th Workshop on quantification and regulation of ocular perfusion. Ulm, January 27–28, 1995] **Klin Monatsbl Augenheilkd** 1995;207 Suppl 3:1–10 **(Ger)**

ADVERSE EFFECTS

Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Hohenberger P, et al. **Eur J Surg Oncol** 1996 Apr;22(2):147–51

[The study on the mechanism of brain damage due to high flow and pressure during selective cerebral perfusion] Moro H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan; 44(1):38–46 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

A new method for exchange of perfusion fluid during in vivo micropuncture. Morsing P, et al. **Acta Physiol Scand** 1995 Jun;154(2):235–40

Twelve-hour canine heart preservation with a simple, portable hypothermic organ perfusion device. Calhoon JH, et al. **Ann Thorac Surg** 1996 Jul;62(1):91–3

Simple wide-brimmed coronary perfusion cannula for the widely patent coronary ostium. Terada Y, et al. **Ann Thorac Surg** 1996 Feb;61(2):748–9

A perfusion system for in vitro measurement of human cilia beat frequency. Selwyn DA, et al. **Br J Anaesth** 1996 Jan; 76(1):111–5

Modeling solute sorption into plastic tubing during organ perfusion and intravenous infusions. Roberts MS. **J Pharm Sci** 1996 Jun;85(6):655–65

Newly developed four-lumen catheter for in situ renal perfusion of non-heart-beating donors that provides perfusion pressure monitoring. Lloveras J, et al. **Transplant Proc** 1995 Oct;27(5):2909–11; discussion 2911–2

[Effect of interleukin-2 and interleukin-6 on ovary in the ovulatory period—establishment of the new ovarian perfusion system and influence of interleukins on ovulation rate and steroid secretion] Mikuni M. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):561–72 (Eng. Abstr.) **(Jpn)**

METHODS

Selective cerebral perfusion technique during aortic arch repair in neonates. Asou T, et al. **Ann Thorac Surg** 1996 May;61(5):1546–8

Comparative experimental study of cerebral protection during aortic arch reconstruction. Sakurada T, et al. **Ann Thorac Surg** 1996 May;61(5):1348–54

Neuronal damage after hypothermic circulatory arrest and retrograde cerebral perfusion in the pig. Ye J, et al. **Ann Thorac Surg** 1996 May;61(5):1316–22

Normothermic renal artery perfusion: a comparison of perfusates. Hughes JD, et al. **Ann Vasc Surg** 1996 Mar; 10(2):123–30

Perfusion of gills isolated from the hyper-hyporegulating crab Pachygrapsus marmoratus (Crustacea, Decapoda): adaptation of a method. Pierrot C, et al. **Arch Physiol Biochem** 1995 Aug;103(4):401–9

The isolated air perfused rat heart. Venkataraman BV, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):283–6

In situ perfusion by retrograde cannulation of a tumor artery for nephron-sparing surgery. Masaki Z, et al. **Int J Urol** 1995 Jul;2(3):161–5

Retroperfusion studies of the aqueous outflow system. Part 2: Studies in human eyes. Ethier CR, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2466–75

Retrograde cerebral perfusion with hypothermic blood provides efficient protection of the brain: a neuropathological study. Imamaki M, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):325–33

Integrated myocardial management in valvular heart disease. Buckberg GD, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S198–212; discussion S212–3

Development of an in situ isolated porcine liver perfusion model for tightly controlled physiologic and pharmacologic studies. Travis DL, et al. **J Invest Surg** 1996 Mar–Apr;9(2):131–47

Hepatic function during prolonged isolated rat liver perfusion using a new miniaturized perfusion circuit. Alexander B, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):203–10

Computer-controlled flushing for long-term cannulation in freely moving rats. Liebmann PM, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):211–4

The effect of retrograde cerebral perfusion after particulate embolization to the brain. Yerlioglu ME, et al. **J Thorac Cardiovasc Surg** 1995 Nov;110(5):1470–84; discussion 1484–5

Hemodynamic profiles during concurrent intraaortic balloon pumping and venoarterial bypass—a canine study comparing subclavian and femoral artery perfusion sites. Miyamoto S, et al. **Jpn Circ J** 1995 Oct;59(10):693–703

Hypothermic perfusion preservation of liver: the role of phosphate in stimulating ATP synthesis studied by 31P NMR. Lockett CJ, et al. **Transpl Int** 1995;8(6):440–5

Intraoperative assessment of liver perfusion by laser Doppler imaging in an animal model. Seifalian AM, et al. **Transplant Proc** 1995 Oct;27(5):2866–8

Organ procurement from non-heart-beating donors through in situ perfusion or total body cooling. Valero R, et al. **Transplant Proc** 1995 Oct;27(5):2899–900

[Cerebral protection by selective cerebral perfusion during surgery on the aortic arch] Le Mee F, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1601–7 (Eng. Abstr.) **(Fre)**

[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer] Fujimura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1610–2 (Eng. Abstr.) **(Jpn)**

[Clinical significance of selective cerebral perfusion with cold blood on the brain protection] Adachi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1605–10 (Eng. Abstr.) **(Jpn)**

[A comparison of changes of cerebrovascular oxygen saturation in retrograde and selective cerebral perfusion during aortic arch surgery] Higami T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1919–23 (Eng. Abstr.) **(Jpn)**

[Comparison between retrograde cerebral perfusion and selective cerebral perfusion by intraoperative electroencepharogram] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):175–81 (Eng. Abstr.) **(Jpn)**

[The use of hyperbaric oxygenation of the perfusion solution for increasing the oxygen supply to the isolated brain] Tezikov EB, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):146–53 **(Rus)**

PERFUSION, PULSATILE see **PULSATILE FLOW**

PERFUSION PUMPS see **INFUSION PUMPS**

PERFUSION PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERFUSION, REGIONAL

Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. Papa MZ, et al. **Am J Surg** 1996 Apr;171(4):416–20

Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Pass HI, et al. **Ann Thorac Surg** 1996 Jun;61(6):1609–17

Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. Port JL, et al. **Ann Thorac Surg** 1996 Sep;62(3):848–52

Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment [letter; comment] Allen RE Jr. **Arch Surg** 1996 Feb;131(2):220. Comment on: Arch Surg 1995 Oct;130(10):1079–84.

Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer. Gutman M, et al. **Cancer** 1996 Sep 1;78(5):1125–30

Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Zwaveling JH, et al. **Cancer Res** 1996 Sep 1;56(17):3948–53

Ultrastructural study of the dermal microvasculature in patients undergoing retrograde intravenous pressure infusions. Langer K, et al. **Dermatology** 1996;192(2):103–9

Leakage measurement during selective limb perfusion using a gamma probe. Sandrock D, et al. **Eur J Nucl Med** 1996 May;23(5):534–8

Treatment of non-resectable pelvic malignancies by isolated pelvic perfusion. A preliminary study. Kocaoglu H, et al. **Eur J Surg Oncol** 1995 Oct;21(5):535–40

Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study. Vrouenraets BC, et al. **Eur Surg Res** 1996;28(3):235–44

Recurrent intraabdominal cancer with intestinal obstruction. Averbach AM, et al. **Int Surg** 1995 Apr–Jun;80(2):141–6

Effective therapy: repeat limb perfusion for recurrent melanoma [editorial; comment] Krementz ET. **J Am Coll Surg** 1996 Jun;182(6):547–8. Comment on: J Am Coll Surg 1996 Jun;182(6):467–72.

Pulmonary toxicity of alpha tumor necrosis factor in patients treated by isolation perfusion. Villani F, et al. **J Chemother** 1995 Oct;7(5):452–4

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. Fraker DL, et al. **J Clin Oncol** 1996 Feb;14(2):479–89

Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon. Nakayama J, et al. **J Dermatol** 1996 Jan; 23(1):6–15

Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. Lejeune F, et al. **J Infus Chemother** 1995 Spring;5(2):73–81

FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. van Ginkel RJ, et al. **J Nucl Med** 1996 Jun;37(6):984–90

Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report. Dawson R, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):255–6

Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. Ratto GB, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):614–22

[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience] Lejeune F, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):561–7 (Eng. Abstr.) **(Fre)**

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors—a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769–79 (74 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Zwaveling JH, et al. **Crit Care Med** 1996 May; 24(5):765–70

Acute hypovolemia after weaning from isolated limb perfusion. p-Yam PC, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):722–4

Vascular complications of total abdominal perfusion and aortic stop-flow infusion. Klein ES, et al. **J Surg Oncol** 1996 Jan;61(1):17–9

Local and systemic toxicity in 'borderline true' hyperthermic isolated perfusion for lower limb melanoma. Pace M, et al. **Melanoma Res** 1995 Oct;5(5):371–6

INSTRUMENTATION

Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. Boiardi A, et al. **J Neurooncol** 1996 Feb;27(2):157–62

METHODS

Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. Huber R, et al. **Am J Surg** 1995 Oct;170(4):345–52

Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Averbach AM, et al. **Ann Surg Oncol** 1995 Jul;2(4):325–31

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Schneebaum S, et al. **Ann Surg Oncol** 1996 Jan;3(1):44–50

Pulmonary artery perfusion of doxorubicin with blood flow occlusion: pharmacokinetics and treatment in a metastatic sarcoma model. Wang HY, et al. **Ann Thorac Surg** 1995 Nov;60(5):1390–4

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment [see comments] Sorkin P, et al. **Arch Surg** 1995 Oct;130(10):1079–84. Comment in: Arch Surg 1996 Feb;131(2):220.

Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma. Lingam MK, et al. **Br J Surg** 1995 Oct; 82(10):1343–5

Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Barker WC, et al. **Eur J Nucl Med** 1995 Nov;22(11):1242–8

Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Ikeguchi M, et al. **Eur J Surg** 1995 Aug;161(8):581–6

Pharmacokinetics of two different delivery regimens of

doxorubicin in isolated hyperthermic limb perfusion. Pfeiffer T, et al. **Eur J Surg Oncol** 1995 Oct;21(5):551–4
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs [see comments] Klop WM, et al. **J Am Coll Surg** 1996 Jun;182(6):467–72. Comment in: J Am Coll Surg 1996 Jun;182(6):547–8.
An in vitro–in vivo validation of the isolated perfused tumor and skin flap preparation as a model of cisplatin delivery to tumors. Vaden SL, et al. **J Pharmacol Toxicol Methods** 1996 Jun;35(3):173–7

PERGOLIDE

Psychoactive properties of pergolide mesylate. Wilcox JA. **J Psychoactive Drugs** 1995 Apr–Jun;27(2):181–2

ADVERSE EFFECTS

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez–Jiménez FJ, et al. **Clin Neuropharmacol** 1995 Jun;18(3):277–9
[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease] Sánchez–Chapado M, et al. **Arch Esp Urol** 1995 Dec;48(10):979–83 (28 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Asanuma M, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr; 329(2):221–30
Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area. Zhang XX, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):423–7
Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study. Dethy S, et al. **J Neural Transm Gen Sect** 1995;101(1–3):1–11
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. Arai N, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):55–62
Analysis of mortality in pergolide-treated patients with Parkinson's disease. Sayler ME, et al. **Neuroepidemiology** 1996 Jan–Feb;15(1):26–32
Pergolide interactions with nicotine and pilocarpine in rats on the radial-arm maze. Levin ED. **Pharmacol Biochem Behav** 1995 Dec;52(4):837–40

THERAPEUTIC USE

Experience of pergolide in the treatment of Chinese parkinsonian patients with dose-related fluctuations. Shan DE, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):312–8
Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez–Jiménez FJ, et al. **Clin Neuropharmacol** 1995 Jun;18(3):277–9
An open label trial of pergolide in Thai patients with Parkinson's disease. Poungvarin N, et al. **J Med Assoc Thai** 1996 Apr;79(4):205–9
Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203–12 (48 ref.)
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Bonnet AM, et al. **Mov Disord** 1995 Sep;10(5):668–71
Analysis of mortality in pergolide-treated patients with Parkinson's disease. Sayler ME, et al. **Neuroepidemiology** 1996 Jan–Feb;15(1):26–32

PERGOLIDE MESYLATE see **PERGOLIDE**

PERHEXILINE

PHARMACOLOGY

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Kennedy JA, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):273–80

PERIADENITIS MUCOSA NECROTICA RECURRENS see **STOMATITIS, APHTHOUS**

PERIANAL GLAND NEOPLASMS see **ANAL GLAND NEOPLASMS**

PERIANAL GLANDS

[Perianal infection caused by group A beta-hemolytic Streptococcus on children] Putto-Laurila A, et al. **Duodecim** 1995;111(4):361–4 **(Fin)**

ANATOMY & HISTOLOGY

[The sex dimorphism of the hepatoid circumanal glands in the dog and the dynamics of its development] Shabadash SA, et al. **Izv Akad Nauk Ser Biol** 1995 Sep–Oct;(5):590–605 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

[Ultrastructural organization of the hepatoid gland epithelium in Phillip's dik dik, Madoqua phillipsi, and Grant's gazelle (Artiodactyla, Bovidae] Sokolov VE, et al. **Dokl Akad Nauk** 1996 Apr;347(4):556–9 **(Rus)**

PERIANEURYSMAL FIBROSIS, INFLAMMATORY see **RETROPERITONEAL FIBROSIS**

PERIAORTITIS, CHRONIC see **RETROPERITONEAL FIBROSIS**

PERIAPICAL ABSCESS

COMPLICATIONS

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)

DRUG THERAPY

Penicillin as a supplement in resolving the localized acute apical abscess. Fouad AF, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):590–5

ETIOLOGY

Abscess formation around the apex of a maxillary root form implant: clinical and microscopical aspects. A case report. Piattelli A, et al. **J Periodontol** 1995 Oct;66(10):899–903

SURGERY

Immediate implants placed into infected sites: a clinical report. Novaes Júnior AB, et al. **Int J Oral Maxillofac Implants** 1995 Sep–Oct;10(5):609–13
[Odontogenic diseases of the maxillary sinuses] Lambrecht JT. **Fortschr Kiefer Gesichtschir** 1995;40:106–13 (115 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Dentogenic sources of infection in patients with awaiting heart valve replacement] Krennmair G, et al. **Wien Klin Wochenschr** 1996;108(10):289–92 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Equipment and transducer-independent 3D ultrasound in the maxillofacial area] Sader R, et al. **Ultraschall Med** 1995 Dec;16(6):269–74 (Eng. Abstr.) **(Ger)**

PERIAPICAL CYST see **RADICULAR CYST**

PERIAPICAL DISEASES

DIAGNOSIS

An unusual facial sinus. Cheung LK, et al. **Aust Dent J** 1996 Feb;41(1):6–8

ETIOLOGY

A combined endodontic-periodontal lesion of development origin: a case report. Pack AR, et al. **N Z Dent J** 1996 Jun;92(408):46–8

MICROBIOLOGY

Endodontic cellulitis 'flare-up': clinical implications [letter; comment] Ehrmann EH. **Aust Dent J** 1996 Feb;41(1):62–3. Comment on: Aust Dent J 1995 Aug;40(4):272–3. Comment on: Aust Dent J 1995 Oct;40(5):342.
Endodontic cellulitis 'flare-up' [letter; comment] Messer HH. **Aust Dent J** 1996 Feb;41(1):61–2. Comment on: Aust Dent J 1995 Feb;40(1):36–8.

RADIOGRAPHY

Room for improvement? The accuracy of dental practitioners who diagnose bony pathoses with radiographs. Stheeman SE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):251–4
Radiology and endodontics [editorial] Walton RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):495

RADIONUCLIDE IMAGING

Intense accumulation of Tc-99m MDP and Ga-67 in multiple periapical cemental dysplasia. Taki S, et al. **Ann Nucl Med** 1995 Nov;9(4):243–5

SURGERY

A 5-year audit of outcome of apicectomies carried out in a district general hospital. Lyons AJ, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):273–7

PERIAPICAL PERIODONTITIS

ETIOLOGY

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726–34 (55 ref.)

IMMUNOLOGY

VLA-4/VCAM-1 pathway in human periodontal disease. Tsurumachi T, et al. **Adv Exp Med Biol** 1995;371B:1131–3
[Root canal overfilling. Periapical immune reactions] Bruno E, et al. **Minerva Stomatol** 1995 Oct;44(10):439–44 (Eng. Abstr.) **(Ita)**
[Activation of the immune system in periapical infection. 1. Lympho-monocytoid and plasma cellular elements of reactive soft tissue cells] Milia E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):37–48 (47 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Characterization of new periodontal and endodontic isolates of spirochetes. Dahle UR, et al. **Eur J Oral Sci** 1996 Feb; 104(1):41–7

SURGERY

Periodontal status following trapezoidal and semilunar flaps in apicectomy. Chindia ML, et al. **East Afr Med J** 1995 Sep;72(9):564–7
[Results of follow-up after apicoectomy with 2 different root canal filling materials] Herzog U, et al. **Fortschr Kiefer Gesichtschir** 1995;40:150–2 (Eng. Abstr.) **(Ger)**
[Odontogenic diseases of the maxillary sinuses] Lambrecht JT. **Fortschr Kiefer Gesichtschir** 1995;40:106–13 (115 ref.) (Eng. Abstr.) **(Ger)**
[Follow-up of tooth vitality with laser Doppler flowmetry in transplanted teeth] Mensdorff-Pouilly N, et al. **Fortschr Kiefer Gesichtschir** 1995;40:80–3 (Eng. Abstr.) **(Ger)**

THERAPY

Healing of apical periodontitis in dogs after apicoectomy and retrofilling with various filling materials. Trope M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):221–8

PERIAPICAL PERIODONTITIS, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIAPICAL TISSUE

IMMUNOLOGY

[Root canal overfilling. Periapical immune reactions] Bruno E, et al. **Minerva Stomatol** 1995 Oct;44(10):439–44 (Eng. Abstr.) **(Ita)**

INNERVATION

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726–34 (55 ref.)

PERIAQUEDUCTAL GRAY

Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Collins JJ, et al. **Pain** 1995 Nov;63(2):271–5

BLOOD SUPPLY

Traumatic nociceptive pain activates the hypothalamus and the periaqueductal gray: a positron emission tomography study. Hsieh JC, et al. **Pain** 1996 Feb;64(2):303–14

CHEMISTRY

Expression of melanocortin 1 receptor in periaqueductal gray matter. Xia Y, et al. **Neuroreport** 1995 Nov 13;6(16):2193–6

CYTOLOGY

Inhibitory effect of nitric oxide on neuronal activity in the periaqueductal grey matter of the rat. Lovick TA, et al. **Exp Brain Res** 1996 Mar;108(3):382–8
Medial preoptic area afferents to periaqueductal gray medullo-output neurons: a combined Fos and tract tracing study. Rizvi TA, et al. **J Neurosci** 1996 Jan;16(1):333–44
Anatomical evidence for inputs to ventrolateral medullary catecholaminergic neurons from the midbrain periaqueductal gray of the rat. Chen S, et al. **Neurosci Lett** 1995 Aug 4;195(2):140–4
Hypoxia sensitive neurons in the caudal hypothalamus project to the periaqueductal gray. Ryan JW, et al. **Respir Physiol** 1995 Jun;100(3):185–94

DRUG EFFECTS

The differential contribution of spinopetal projections to increases in vocalization and motor reflex thresholds generated by the microinjection of morphine into the periaqueductal gray. Borszcz GS, et al. **Behav Neurosci** 1996 Apr;110(2):368–88
Hyperpolarization by GABAB receptor agonists in mid-brain periaqueductal gray neurones in vitro. Chieng B, et al. **Br J Pharmacol** 1995 Sep;116(1):1583–8
Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. D'Amico M, et al. **Br J Pharmacol** 1995 Dec;116(7):2787–9
Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. D'Amico M, et al. **Br J Pharmacol** 1996 May;118(1):21–6
Relationship between analgesia and extracellular morphine in brain and spinal cord in awake rats. Matos FF, et al.

Brain Res 1995 Sep 25;693(1-2):187-95

Metabotropic and ionotropic glutamate receptors mediate opposite effects on periaqueductal gray matter. Leyva J, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):123-6

Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. Lichtman AH, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):585-93

Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. Lysle DT, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1533-40

Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray. Monroe PJ, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):65-73

Effects of L-name on endothelin-1-induced barrel-rolling in periaqueductal gray area of rats. D'Amico M, et al. **Life Sci** 1995;57(22):PL357-60

Hypothalamic paraventricular nucleus involvement in the pressor response to N-methyl-d-aspartic acid in the periaqueductal grey matter. Berrino L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):157-60

Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat. Ossipov MH, et al. **Pain** 1995 Sep;62(3):287-93

Effects of microinjections of mu and kappa receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Motta V, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):470-4

METABOLISM

Release into ventriculo-cisternal perfusate of beta-endorphin- and Met-enkephalin-immunoreactivity: effects of electrical stimulation in the arcuate nucleus and periaqueductal gray of the rat. Bach FW, et al. **Brain Res** 1995 Sep 4;690(2):167-76

Repeated spinal cord stimulation decreases the extracellular level of gamma-aminobutyric acid in the periaqueductal gray matter of freely moving rats. Stiller CO, et al. **Brain Res** 1995 Nov 20;699(2):231-41

Basal release of Met-enkephalin and neurotensin in the ventrolateral periaqueductal gray matter of the rat: a microdialysis study of antinociceptive circuits. Williams FG, et al. **Brain Res** 1995 Sep 4;690(2):207-16

Fos expression induced by changes in arterial pressure is localized in distinct, longitudinally organized columns of neurons in the rat midbrain periaqueductal gray. Murphy AZ, et al. **J Comp Neurol** 1995 Sep 18;360(2):286-300

Evidence for corticotropin-releasing hormone projections from Barrington's nucleus to the periaqueductal gray and dorsal motor nucleus of the vagus in the rat. Valentino RJ, et al. **J Comp Neurol** 1995 Dec 18;363(3):402-22

Developmental changes in neurotransmitter receptor binding in the human periaqueductal gray. Reddy SC, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):409-18

Capillary electrophoresis with laser-induced fluorescence detection: a sensitive method for monitoring extracellular concentrations of amino acids in the periaqueductal grey matter. Bergquist J, et al. **J Neurosci Methods** 1996 Mar; 65(1):33-42

PATHOLOGY

Down gaze palsy due to periaqueductal lesion diagnosed by magnetic resonance imaging. Ozdemir N, et al. **Ophthalmologica** 1995;209(4):225-7

PHYSIOLOGY

An electrophysiological characterization of the projection from the central nucleus of the amygdala to the periaqueductal gray of the rat: the role of opioid receptors. da Costa Gomez TM, et al. **Brain Res** 1995 Aug 14; 689(1):21-31

Effects of lesions of amygdaloid nuclei and substantia nigra on aversive responses induced by electrical stimulation of the inferior colliculus. Maisonnette SS, et al. **Brain Res Bull** 1996;40(2):93-8

Electrophysiological analysis of midbrain periaqueductal gray influence on cardiovascular neurons in the ventrolateral medulla oblongata. van der Plas J, et al. **Brain Res Bull** 1995;38(5):447-56

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759-79 (43 ref.)

Evoked potential elicited by periaqueductal grey stimulation in the pressor sites of dorsal and ventrolateral medulla in cats. Yen CT, et al. **Chin J Physiol** 1995;38(3):171-6

Ultrastructural evidence for a paucity of projections from the lumbosacral cord to the pontine micturition center or M-region in the cat: a new concept for the organization of the micturition reflex with the periaqueductal gray as central relay. Blok BF, et al. **J Comp Neurol** 1995 Aug 21;359(2):300-9

Computer analysis and quantification of periaqueductal grey-induced defence behaviour. Beckett S, et al. **J Neurosci Methods** 1995 May;58(1-2):157-61

Involvement of alpha-2 adrenoceptors in the periaqueductal gray-induced inhibition of dorsal horn cell activity in rats. Peng YB, et al. **J Pharmacol Exp Ther** 1996 Jul; 278(1):125-35

The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats. Peng YB, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):116-24

Differential inhibitory mechanisms in VPL versus intralaminar nociceptive neurons of the cat: I. Effects of periaqueductal gray stimulation. Koyama N, et al. **Jpn J Physiol** 1995;45(6):1005-27

Predatory aggression induced by hypothalamic stimulation: modulation by midbrain periaqueductal gray (PAG). Manchanda SK, et al. **Neurobiology (Bp)** 1995; 3(3-4):405-17

Ventrolateral orbital cortex and periaqueductal gray stimulation-induced effects on on- and off-cells in the rostral ventromedial medulla in the rat. Hutchison WD, et al. **Neuroscience** 1996 Jan;70(2):391-407

Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Nogueira RL, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):1-6

Functional characteristics of the midbrain periaqueductal gray. Behbehani MM. **Prog Neurobiol** 1995 Aug; 46(6):575-605 (325 ref.)

[The role of the central substantia grisea of the midbrain in regulating the sound emission process in the bat Rhinolophus ferrumequinum] Movchan EV, et al. **Zh Evol Biokhim Fiziol** 1994 Sep-Oct;30(5):667-75 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Role of periaqueductal gray matter in hypertension in spontaneously hypertensive rats. Schenberg LC, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1125-8

ULTRASTRUCTURE

Enkephalin in the caudal PAG of rat: an immunocytochemical electron microscopic study. Gioia M, et al. **J Hirnforsch** 1995;36(3):421-31

PERIARTERITIS NODOSA see **POLYARTERITIS NODOSA**

PERIARTHRITIS

COMPLICATIONS

Case report: coexistence of acute calcific periarthritis and infection. Razzaq A, et al. **Am J Med Sci** 1996 Sep; 312(3):140-1

DIAGNOSIS

[Clarification of the concept humeroscapular periarthritis] Refior HJ. **Orthopade** 1995 Nov;24(6):509-11 (Eng. Abstr.) **(Ger)**

[Analysis of clinical symptoms in shoulder arthropathy] Fabiś J, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(2):133-7 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Itokazu M, et al. **Clin Ther** 1995 Sep-Oct; 17(5):946-55

ETIOLOGY

Acute calcific periarthritis of the fingers. Gálvez J, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):602-4 (11 ref.)

[Periarthritis humeroscapularis--clinical diagnosis and analysis of the syndrome concept] Jerosch J. **Wien Med Wochenschr** 1996;146(6-7):142 (22 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

[Brachiocervical syndrome. First case report over 3,000 years ago] Decher H. **Laryngorhinootologie** 1996 Apr;75(4):255-6 **(Ger)**

METABOLISM

[Analysis of deposits in calcific periarthritis] Hamada J. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1158-69 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

[Radiotherapy of degenerative inflammatory joint diseases in the elderly. A worthwhile therapeutic measure] Merte H, et al. **Fortschr Med** 1995 Aug 20;113(22-23):323-4 **(Ger)**

THERAPY

Periomarthritis treated with pain point pressure in combination with local exercises. Ma J. **J Tradit Chin Med** 1995 Dec;15(4):289

[Frozen shoulder. Arthroscopy and manipulation in general anesthesia, followed by early passive mobilization] Andersen NH, et al. **Ugeskr Laeger** 1996 Jan 8; 158(2):147-50 (Eng. Abstr.) **(Dan)**

[Manipulation of frozen shoulder? (editorial)] Danneskiold-Samsøe B. **Ugeskr Laeger** 1996 Jan 8; 158(2):145 **(Dan)**

PERICARDIAL CYST see **MEDIASTINAL CYST**

PERICARDIAL EFFUSION

see related
CARDIAC TAMPONADE

Pericardial effusion. Robinson B, et al. **J Ark Med Soc** 1995 Nov;92(6):295-6

[Persistent pericardial effusion] Beutel K, et al. **Dtsch Med Wochenschr** 1996 Jun 14;121(24):813 **(Ger)**

CHEMICALLY INDUCED

Hemopericardium with cardiac tamponade after intravenous thrombolysis for acute myocardial infarction. Mohammad S, et al. **Clin Cardiol** 1996 May;19(5):432-4

COMPLICATIONS

[Loculated pericardial effusion leading to functional tricuspid stenosis in a case of rheumatoid arthritis] Galli CA, et al. **Cardiologia** 1995 Sep;40(9):685-8 (11 ref.) (Eng. Abstr.) **(Ita)**

[A 70-year-old woman complaining of shortness of breath despite decreased pericardial effusion] Hada Y. **J Cardiol** 1996 Apr;27(4):219-21 **(Jpn)**

DIAGNOSIS

Pericardial effusion and giant cell arteritis [letter] Pedro-Botet J, et al. **Br J Rheumatol** 1996 Feb;35(2):194-5

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Wilkes JD, et al. **Cancer** 1995 Oct 15;76(8):1377-87 (91 ref.)

The diagnosis of pericardial effusion and cardiac tamponade by 12-lead ECG. A technology assessment [see comments] Eisenberg MJ, et al. **Chest** 1996 Aug;110(2):318-24. Comment in: Chest 1996 Aug;110(2):308-10.

Pericardial effusion and cardiac tamponade diagnostic methods. Where are we headed? [editorial; comment] Scarpinato L. **Chest** 1996 Aug;110(2):308-10. Comment on: Chest 1996 Aug;110(2):318-24.

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378-85 (35 ref.)

T-cell lymphoma presenting with pericardial and pleural effusion as the initial and primary lesion: cytogenetic and molecular evidence. Yasuda H, et al. **Intern Med** 1996 Feb; 35(2):150-4

Hemopericardium and cardiac tamponade as presenting findings of anomalous left coronary artery syndrome complicated by transmural myocardial infarction. Kaminer S, et al. **Pediatr Cardiol** 1996 May-Jun;17(3):198-200

Massive pseudolymphomatous pericardial effusion in the posttransplant setting mimicking posttransplant lymphoproliferative disease. Hudnall SD, et al. **Transplantation** 1996 Jun 27;61(12):1776-8

DRUG THERAPY

[Anti-Jo-1-positive polymyositis with interstitial alveolitis and pericardial effusion. Overview of 3 years treatment] Krajnc I. **Wien Klin Wochenschr** 1995;107(19):590-2 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Adenosine deaminase in pericardial fluids. Which test is best? [letter] Miller KD. **Chest** 1995 Dec;108(6):1766

The diagnostic and prognostic value of adenosine deaminase in tuberculous pericarditis. Komsuoğlu B, et al. **Eur Heart J** 1995 Aug;16(8):1126-30

EPIDEMIOLOGY

Decreased incidence of postoperative pericardial effusions after cardiac surgery for congenital heart disease. Prabhu AS, et al. **Am J Cardiol** 1996 Apr 1;77(9):774-6

ETIOLOGY

Pericardial effusion as the initial feature of Q fever. Valéro F, et al. **Am Heart J** 1995 Dec;130(6):1308-9

Pericardial effusion and left ventricular function in acute pancreatitis. Pezzilli R, et al. **Am J Gastroenterol** 1996 May; 91(5):997-1000

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460-2 (9 ref.)

Radiation-induced pericardial disease: a case report. Doi SA, et al. **Ann Acad Med Singapore** 1995 May;24(3):459-61

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207-11 (28 ref.)

Massive pericardial effusion in scleroderma [letter] Hordon LD, et al. **Br J Rheumatol** 1996 Aug;35(8):807-8

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Wilkes JD, et al. **Cancer** 1995 Oct 15;76(8):1377-87 (91 ref.)

Sudden onset of large pericardial effusion in a 27-year-old man with AIDS. Muthuswamy P, et al. **Chest** 1995 Dec; 108(6):1739-41

Pericardial effusion in AIDS. Incidence and survival. Heidenreich PA, et al. **Circulation** 1995 Dec 1; 92(11):3229-34

Thymoma with pericardial tamponade. Woldow A, et al. **Clin Cardiol** 1995 Aug;18(8):484–5

Pericardial effusion. Unusual complication in thyroid cancer. Silva F, et al. **Clin Nucl Med** 1996 Mar;21(3):218–20

Ascites, pleural, and pericardial effusions in acute pancreatitis. A prospective study of incidence, natural history, and prognostic role. Maringhini A, et al. **Dig Dis Sci** 1996 May;41(5):848–52

Bilateral pleural and pericardial effusions complicating insertion of a central venous catheter [letter] Mineo TC, et al. **Eur J Pediatr** 1996 Jan;155(1):68–9

Recurrent Cardiac tamponade: intrapericardial teratoma. Kulthe SG, et al. **Indian Pediatr** 1995 Jan;32(1):88–91

Disseminated coccidioidomycosis with rapid progression to effusive-constrictive pericarditis. Oudiz R, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):947–52

The incidence of significant pericardial effusion and tamponade following major aortic root surgery. Alkhulaifi AM, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):385–9

Umbilical venous line related pericardial effusion in a premature neonate: report of a case. Chang LY, et al. **J Formos Med Assoc** 1995 Jun;94(6):355–7

Prenatal hypertrophic cardiomyopathy and pericardial effusion in carbohydrate-deficient glycoprotein syndrome. García Silva MT, et al. **J Inherit Metab Dis** 1996; 19(2):257–9

Extravascular extravasation of fluid as a complication of central venous lines in the neonate. Keeney SE, et al. **J Perinatol** 1995 Jul–Aug;15(4):284–8

Post-traumatic pericardial syndrome following oesophageal surgery. Hanna GB, et al. **J R Coll Surg Edinb** 1995 Dec; 40(6):395–6

Pericardial effusion and vasculitis in a patient with systemic sclerosis. Abu-Shakra M, et al. **J Rheumatol** 1995 Jul; 22(7):1386–8

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1996. A 25-year-old man with hemopericardium, bilateral hemothorax, and hemoptysis after chest trauma. **N Engl J Med** 1996 Feb 15;334(7):452–8

Isolated chylopericardium secondary to intrathymic lymphangiomatous malformation. Dogan R, et al. **Pediatr Cardiol** 1996 Nov–Dec;17(6):413–5

Hypothyroidism presenting with cardiac tamponade. Quin JD, et al. **Scott Med J** 1994 Jun;39(3):82

Massive pseudolymphomatous pericardial effusion in the posttransplant setting mimicking posttransplant lymphoproliferative disease. Hudnall SD, et al. **Transplantation** 1996 Jun 27;61(12):1776–8

Chylopericardium following right thoracotomy for lung cancer. Mizushima Y, et al. **Tumori** 1996 May–Jun; 82(3):264–5

[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):418–21 (11 ref.) (Eng. Abstr.) **(Fre)**

[Internal pancreatic fistula: surgical treatment] Pereira-Lima L, et al. **J Chir (Paris)** 1995 Nov;132(11):442–6 (Eng. Abstr.) **(Fre)**

[Purulent pericardial effusion with tamponade: a rare initial manifestation of o pneumococcal infection] Möller A, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):237–40 (Eng. Abstr.) **(Ger)**

[Differential diagnostic challenge in pericardial effusion] Wilke A, et al. **Internist (Berl)** 1995 Sep;36(9):909–11 **(Ger)**

[Pericardial effusion in heart surgery interventions] Pepi M, et al. **Cardiologia** 1995 Apr;40(4):267–72 (31 ref.) **(Ita)**

[A case of systemic lupus erythematosus with pleural effusion, ascites and pericardial effusion] Koyama K, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):614–6 **(Jpn)**

[Chylopericardium after acute pericarditis] Gabriel Martínez J, et al. **Rev Esp Cardiol** 1996 Mar;49(3):226–8 (Eng. Abstr.) **(Spa)**

[Angiosarcoma of the heart and its spontaneous rupture. A rare cause of effusive-constrictive pericarditis. A case report and review of the literature] Bértoli F, et al. **Rev Med Panama** 1995 Sep;20(3):84–91 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

[An unusual complication of pneumococcal pneumonia: tamponade caused by purulent pericarditis (letter)] Speelberg B, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9; 139(49):2587 **(Dut)**

PATHOLOGY

Diagnosis of primary cardiac lymphoma. Report of a case with cytologic examination of pericardial fluid and imprints of transvenously biopsied intracardiac tissue. Chao TY, et al. **Acta Cytol** 1995 Sep–Oct;39(5):955–9

Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis. Bardales RH, et al. **Am J Clin Pathol** 1996 Jul; 106(1):29–34

PHYSIOPATHOLOGY

How do the clinical findings in patients with pericardial effusions influence the success of aspiration? [letter; comment] Spodick DH. **Br Heart J** 1995 Oct;74(4):476. Comment on: **Br Heart J** 1995 Apr;73(4):351–4.

Clinicopathological Conference [letter; comment] Ilia R, et al. **Circulation** 1996 Feb 1;93(3):616–7. Comment on: Circulation 1995 Feb 1;91(3):882–96.

PREVENTION & CONTROL

Suppression of fluid accumulation following pericardial inflammation in a patient with primary chylopericardium. Chinushi M, et al. **Jpn Heart J** 1996 Mar;37(2):271–4

RADIOGRAPHY

Roentgenogram of the month. Bottle-shaped heart. Kabinoff GS, et al. **Chest** 1996 Mar;109(3):825–6

Images in cardiovascular medicine. Detection of normal pericardium and of pericardial effusion in the lateral chest radiograph. Wang K, et al. **Circulation** 1996 Mar 15; 93(6):1254

[Computerized tomography of pericardial diseases] Ovchinnikov VI. **Vestn Rentgenol Radiol** 1996 Jan–Feb; (1):10–5 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

Detection of pericardial effusion during Tc-99m MIBI parathyroid imaging in a patient with chronic renal failure. Fojaja MR, et al. **Clin Nucl Med** 1996 Jun;21(6):496–7

Pericardial effusion demonstrated by I-123 MIBG. Hirano T, et al. **Clin Nucl Med** 1995 Nov;20(11):1015–6

Scintigraphic assessment of pericardio-peritoneal window patency. Relevance to peritoneal dialysis. Joseph UA, et al. **Clin Nucl Med** 1995 Jul;20(7):613–4

Pericardial and mediastinal involvement from bronchogenic carcinoma demonstrated by Tl-201 imaging. Vasinrapee P, et al. **Clin Nucl Med** 1995 Nov;20(11):1027

SURGERY

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460–2 (9 ref.)

Subxiphoid pericardial window for pericardial effusion in end-stage renal disease. Figueroa W, et al. **Am J Kidney Dis** 1996 May;27(5):664–7

Thoracoscopic creation of a pericardial window for recurrent pericardial effusion after heart transplantation. Brandt M, et al. **Eur J Cardiothorac Surg** 1996;10(3):220–2

Subxiphoidal pericardial 'window' in the management of malignant pericardial effusion. Vassilopoulos PP, et al. **Eur J Surg Oncol** 1995 Oct;21(5):545–7

Video-assisted subxiphoid pericardiectomy. Yim AP, et al. **J Laparoendosc Surg** 1995 Jun;5(3):193–8

[Video-surgery for pericardial effusion. Technique and results] Nataf P, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89(2):223–8 (Eng. Abstr.) **(Fre)**

[Late pericardial effusion after open-heart surgery: usefulness of pericardiocentesis under echocardiographic guidance] Suehiro S, et al. **Kyobu Geka** 1996 Feb;49(2):105–10 (Eng. Abstr.) **(Jpn)**

THERAPY

Malignant pericardial effusion: percutaneous creation of a pericardial window [letter] Longo JM, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1305–6

Contrast echocardiography as an adjunct in hemorrhagic or complicated pericardiocentesis. Weisse AB, et al. **Am Heart J** 1996 Apr;131(4):822–5

Inoue balloon pericardiotomy for patients with recurrent pericardial effusion. Chow WH, et al. **Angiology** 1996 Jan; 47(1):57–60

Echocardiography-guided pericardiocentesis with a needle attached to a probe. Suehiro S, et al. **Ann Thorac Surg** 1996 Feb;61(2):741–2

Percutaneous balloon pericardiotomy: a double-balloon technique. Iaffaldano RA, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):79–81

Percutaneous balloon pericardiotomy for malignant pericardial tamponade. Galli M, et al. **Chest** 1995 Dec; 108(6):1499–501

Intrapericardial minocycline sclerosis for malignant pericardial effusion. Lashevsky I, et al. **Chest** 1996 Jun; 109(6):1452–4

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378–85 (35 ref.)

Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451–3 (16 ref.)

Pericardial effusion in patients with cancer: outcome with contemporary management strategies. Laham RJ, et al. **Heart** 1996 Jan;75(1):67–71

Cardiac tamponade in the pediatric oncology population: treatment by percutaneous catheter drainage. Medary I, et al. **J Pediatr Surg** 1996 Jan;31(1):197–9; discussion 199–200

Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. Maher EA, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):637–43

Suppression of fluid accumulation following pericardial inflammation in a patient with primary chylopericardium. Chinushi M, et al. **Jpn Heart J** 1996 Mar;37(2):271–4

Hemoperitoneum after pericardiocentesis in a CAPD patient [letter] Bender F. **Perit Dial Int** 1996 May-Jun;16(3):330

ULTRASONOGRAPHY

Contrast echocardiography as an adjunct in hemorrhagic or complicated pericardiocentesis. Weisse AB, et al. **Am Heart J** 1996 Apr;131(4):822–5

Timing to perform echocardiography for the detection of pericardial effusion after surgical repair of congenital heart disease [letter] Yip AS, et al. **Am J Cardiol** 1996 Sep 1; 78(5):609–10

The role of surgeon-performed ultrasound in patients with possible cardiac wounds. Rozycki GS, et al. **Ann Surg** 1996 Jun;223(6):737–44; discussion 744–6

Utility of pericardial contrast echocardiography in haemorrhagic pericardial effusion [letter] Birla BM, et al. **Indian Heart J** 1995 May-Jun;47(3):284

Trauma ultrasound workshop improves physician detection of peritoneal and pericardial fluid. Ali J, et al. **J Surg Res** 1996 Jun;63(1):275–9

A prospective study of surgeon-performed ultrasound as the primary adjuvant modality for injured patient assessment. Rozycki GS, et al. **J Trauma** 1995 Sep;39(3):492–8; discussion 498–500

Omphalocele and pericardial effusion: possible sonographic markers for the pentalogy of Cantrell or its variants. Siles C, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):840–2

Early prenatal diagnosis of ventricular diverticulum complicated by serous pericardial effusion. Carles D, et al. **Prenat Diagn** 1995 Aug;15(8):778–80

Isolated pericardial effusion: an indication for fetal karyotyping? Sharland G, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):29–32

VETERINARY

Immunosuppressive potential and pathogenicity of an avian adenovirus isolate involved in hydropericardium syndrome in broilers. Naeem K, et al. **Avian Dis** 1995 Oct–Dec; 39(4):723–8

Pericardial effusion in a dog with rhabdomyosarcoma in the right ventricular wall. Gonin-Jmaa D, et al. **J Small Anim Pract** 1996 Apr;37(4):193–6

Infectious pericardial effusion in five dogs. Aronson LR, et al. **Vet Surg** 1995 Sep–Oct;24(5):402–7

VIROLOGY

Molecular detection and differentiation of enteroviruses in endomyocardial biopsies and pericardial effusions from dilated cardiomyopathy and myocarditis. Fujioka S, et al. **Am Heart J** 1996 Apr;131(4):760–5

PERICARDIAL WINDOW TECHNIQUES

Malignant pericardial effusion: percutaneous creation of a pericardial window [letter] Longo JM, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1305–6

Subxiphoid pericardial window for pericardial effusion in end-stage renal disease. Figueroa W, et al. **Am J Kidney Dis** 1996 May;27(5):664–7

Scintigraphic assessment of pericardio-peritoneal window patency. Relevance to peritoneal dialysis. Joseph UA, et al. **Clin Nucl Med** 1995 Jul;20(7):613–4

Thoracoscopic creation of a pericardial window for recurrent pericardial effusion after heart transplantation. Brandt M, et al. **Eur J Cardiothorac Surg** 1996;10(3):220–2

Subxiphoidal pericardial 'window' in the management of malignant pericardial effusion. Vassilopoulos PP, et al. **Eur J Surg Oncol** 1995 Oct;21(5):545–7

INSTRUMENTATION

Inoue balloon pericardiotomy for patients with recurrent pericardial effusion. Chow WH, et al. **Angiology** 1996 Jan; 47(1):57–60

Percutaneous pericardiotomy using Inoue balloon catheter [letter; comment] Bahl VK, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):98–9. Comment on: Cathet Cardiovasc Diagn 1991 Apr;22(4):244–9.

Percutaneous balloon pericardiotomy: a double-balloon technique. Iaffaldano RA, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):79–81

PERICARDIECTOMY

Intraoperative monitoring of pressure-volume loops of the left ventricle in pericardectomy for constrictive pericarditis. Kuroda H, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):198–9

Pericardiectomy after two decades of constrictive pericarditis in a patient with chronic renal failure. Hateboer N, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1935–7

Life-saving pericardiectomy in cardiogenic shock due to impairment of diastolic pump function by myocardial swelling. Asou T, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):83–5

[Results of pericardiectomy in the treatment of constrictive pericarditis] Brzek V Jr, et al. **Rozhl Chir** 1996 Jan; 75(1):11–4 (Eng. Abstr.) **(Cze)**

METHODS

Pericardiectomy for pericardial constriction. Trotter MC, et al. **Am Surg** 1996 Apr;62(4):304–7

Percutaneous balloon pericardiotomy for malignant

pericardial tamponade. Galli M, et al. **Chest** 1995 Dec; 108(6):1499–501

Video-assisted subxiphoid pericardiectomy. Yim AP, et al. **J Laparoendosc Surg** 1995 Jun;5(3):193–8

PERICARDIOSTOMY see **PERICARDIAL WINDOW TECHNIQUES**

PERICARDIOTOMY see **PERICARDIECTOMY**

PERICARDITIS

Disappearance of the Dressler syndrome [letter; comment] Cheng TO. **Cardiology** 1995;86(5):444. Comment on: Cardiology 1994;85(3–4):255–8.

Pneumonitis in a lupus twin pregnancy: a case report. Comer M, et al. **Lupus** 1996 Apr;5(2):146–8

CHEMICALLY INDUCED

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

[Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity] Loizeau E. **Rev Med Suisse Romande** 1995 Nov;115(11):935–8 **(Fre)**

COMPLICATIONS

Burkitt's lymphoma in a patient with recurrent pericarditis [letter] Maor-Kendler Y, et al. **Am J Hematol** 1996 Feb; 51(2):175–6

Primary purulent pericarditis in an immunocompromized patient – an unusual cause of acute renal failure. Brodersen HP, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):374–6

Molecular identification of viruses in sudden infant death associated with myocarditis and pericarditis. Shimizu C, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):584–8

[Neonatal pericarditis of benign outcome during maternofetal group B streptococcus infection (letter)] Chalumeau M, et al. **Arch Pediatr** 1996 Feb;3(2):187–8 **(Fre)**

[Varicella complicated by pericarditis and pneumonia] Rivera Civico F, et al. **An Med Interna** 1996 Mar;13(3):130–2 (Eng. Abstr.) **(Spa)**

[Acute staphylococcal pericarditis associated with multiple myeloma (letter)] Soler Ferrer C, et al. **An Med Interna** 1996 Jan;13(1):48–9 **(Spa)**

[Cardiac tamponade in acute pericarditis: is drainage with intrapericardial catheter indicated? (letter)] Anguera I, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):555 **(Spa)**

[Chylopericardium after acute pericarditis] Gabriel Martínez J, et al. **Rev Esp Cardiol** 1996 Mar;49(3):226–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Primary human immunodeficiency virus infection presenting as myopericarditis and rhabdomyolysis [letter] Guillaume MP, et al. **Clin Infect Dis** 1995 Aug;21(2):451–2

Chest pain and ST-segment elevation in a young man with cancer. Hancock EW. **Hosp Pract (Off Ed)** 1996 May 15; 31(5):31–2

Pneumococcal pericarditis: a rare complication of pneumonia. Hood RL, et al. **J Tenn Med Assoc** 1995 Dec; 88(12):465–6

DRUG THERAPY

[Colchicine in the treatment of idiopathic recurrent pericarditis. Report of a case] Sforza G, et al. **Minerva Cardioangiol** 1995 Jun;43(6):281–5 (Eng. Abstr.) **(Ita)**

[Recurrent pericarditis: our experience with colchicine] Grande Ingelmo JM, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):765–7 (Eng. Abstr.) **(Spa)**

ETIOLOGY

The Dressler syndrome after pulmonary embolism. Jerjes-Sánchez C, et al. **Am J Cardiol** 1996 Aug 1; 78(3):343–5

The postmyocardial infarction syndrome—vanished or vanquished? A twenty-five-year follow-up. A case report. Kossowsky WA, et al. **Angiology** 1996 Jan;47(1):83–5

Cardiac manifestations of Lyme disease: a review. Nagi KS, et al. **Can J Cardiol** 1996 May;12(5):503–6 (38 ref.)

Asymptomatic pericarditis in Adamantiadis-Behçet's disease. Vaiopoulos G, et al. **Clin Exp Rheumatol** 1995 Sep–Oct; 13(5):649–51 (18 ref.)

Morganella morganii pericarditis after resolvent splenectomy for immune pancytopenia following allogeneic bone marrow transplantation for acute lymphoblastic leukemia. Sica S, et al. **Clin Infect Dis** 1995 Oct;21(4):1052–3

Recurrent perimyocarditis following a non penetrating chest trauma. A case report. De Santis A, et al. **G Ital Cardiol** 1996 Jan;26(1):57–60

Cardiac complications in children with Staphylococcus aureus bacteremia. Friedland IR, et al. **J Pediatr** 1995 Nov; 127(5):746–8

Suppression of fluid accumulation following pericardial inflammation in a patient with primary chylopericardium. Chinushi M, et al. **Jpn Heart J** 1996 Mar;37(2):271–4

[Acute pericarditis in Coxiella burnetti infection. Apropos of a case] Moustaghfir A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1657–9 (Eng. Abstr.) **(Fre)**

[Myopericarditis during hepatitis A (letter)] Bosson C, et al. **Presse Med** 1996 Jun 15;25(21):995–6 **(Fre)**

[Pericarditis secondary to anguilluliasis (letter)] Cellarier G, et al. **Presse Med** 1996 Jan 6–13;25(1):37 **(Fre)**

IMMUNOLOGY

Adenoviral pericarditis: high levels of interleukin 6 in pericardial fluid. Mistchenko AS, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1007–9

[Rheumatoid pericarditis: correlation with immunologic parameters] Alušík S, et al. **Vnitr Lek** 1995 Nov; 41(11):764–6 (Eng. Abstr.) **(Cze)**

MICROBIOLOGY

Infected sternal fracture hematoma after cardiopulmonary resuscitation initially seen as pericarditis. Wehrens XH, et al. **Am Heart J** 1996 Sep;132(3):685–6

Chest pain in patients with rheumatoid arthritis. Martin JC, et al. **Ann Rheum Dis** 1996 Mar;55(3):152–3

Microbiology of acute purulent pericarditis. A 12-year experience in a military hospital. Brook I, et al. **Arch Intern Med** 1996 Sep 9;156(16):1857–60

A case of anaerobic pericarditis [letter; comment] Rakita RM, et al. **Clin Infect Dis** 1995 Aug;21(2):454. Comment on: Clin Infect Dis 1994 Sep;19(3):435–40.

Purulent pericarditis caused by Candida species: case report and review. Schrank JH Jr, et al. **Clin Infect Dis** 1995 Jul; 21(1):182–7 (40 ref.)

Cytomegalovirus causing pericarditis with tamponade in an adolescent with cancer [letter] Razzouk BI, et al. **Med Pediatr Oncol** 1996 Jan;26(1):70

[An unusual complication of pneumococcal pneumonia: tamponade due to purulent pericarditis] Posthuma EF, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23;139(38):1913–5 **(Dut)**

[An unusual complication of pneumococcal pneumonia: tamponade caused by purulent pericarditis (letter)] Speelberg B, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9; 139(49):2587 **(Dut)**

PARASITOLOGY

Paragonimus mexicanus pericarditis: report of two cases and review of the literature. Saborio P, et al. **J Trop Med Hyg** 1995 Oct;98(5):316–8 (9 ref.)

PHYSIOPATHOLOGY

Pericarditis causing exercise test induced ST-elevations. Do TM, et al. **Am J Cardiol** 1996 Jul 15;78(2):251–2

PREVENTION & CONTROL

Immunosuppressive therapy prevents recurrent pericarditis. Marcolongo R, et al. **J Am Coll Cardiol** 1995 Nov 1; 26(5):1276–9

RADIOGRAPHY

Pneumonia with an enlarged cardiac silhouette. Tirdel GB, et al. **Chest** 1996 May;109(5):1380–2

[Computerized tomography of pericardial diseases] Ovchinnikov VI. **Vestn Rentgenol Radiol** 1996 Jan–Feb; (1):10–5 (Eng. Abstr.) **(Rus)**

SURGERY

Nocardia asteroides purulent pericarditis. Hornick P, et al. **Eur J Cardiothorac Surg** 1995;9(8):468–70

THERAPY

Biventricular assist for severe acute rheumatic pancarditis. Amsel BJ, et al. **Ann Thorac Surg** 1996 Jul;62(1):267–9

Bacterial pericarditis after heart transplantation: successful management of two cases with catheter drainage and antibiotics. Davies RA, et al. **Can J Cardiol** 1996 Jul; 12(7):641–4

Atrial defibrillation using temporary epicardial defibrillation stainless steel wire electrodes: studies in the canine sterile pericarditis model. Ortiz J, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1356–64

Purulent pericarditis: rediscovery of an old remedy. Mann-Segal DD, et al. **J Thorac Cardiovasc Surg** 1996 Feb; 111(2):487–8

VETERINARY

Mycoplasma hyponeumoniae and Mycoplasma hyosynoviae infection in cases of fibrinous pericarditis in slaughter pigs. Jensen TK, et al. **Acta Vet Scand** 1995;36(4):575–7

VIROLOGY

Enteroviruses as a possible cause of myocarditis, pericarditis and dilated cardiomyopathy in Belém, Brazil. Ferreira Júnior AG, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):869–74

PERICARDITIS, CONSTRICTIVE

CHEMICALLY INDUCED

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)

COMPLICATIONS

Calcific constructive pericarditis: a rare complication of CREST syndrome. Panchal P, et al. **Arthritis Rheum** 1996 Feb;39(2):347–50

Pericardiectomy after two decades of constrictive pericarditis in a patient with chronic renal failure. Hateboer N, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1935–7

DIAGNOSIS

Pressure waveform tracing. Constrictive pericarditis. **Chest** 1995 Dec;108(6):1735–6

Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Hurrell DG, et al. **Circulation** 1996 Jun 1; 93(11):2007–13

Clinicopathological Conference [letter; comment] Ilia R, et al. **Circulation** 1996 Feb 1;93(3):616–7. Comment on: Circulation 1995 Feb 1;91(3):882–96.

Combined restrictive cardiomyopathy and constrictive pericarditis [letter] Spodick DH. **Circulation** 1996 Feb 1; 93(3):616

Magnetic resonance imaging of pericardial constriction: comparison of cine MR angiography and spin-echo techniques. Hartnell GG, et al. **Clin Radiol** 1996 Apr; 51(4):268–72

Radionuclide angiography and magnetic resonance imaging: complementary non-invasive methods in the diagnosis of constrictive pericarditis. Furber A, et al. **Eur J Nucl Med** 1995 Nov;22(11):1292–8

Chronic constrictive pericarditis presenting as mass lesion in infancy. Dharmapuran AK, et al. **Indian Heart J** 1996 May-Jun;48(3):290–1 (7 ref.)

Clinical problem-solving: diverted by the chief complaint [letter; comment] Aderka D. **N Engl J Med** 1995 Nov 23; 333(21):1424–5; discussion 1426. Comment on: N Engl J Med 1995 Jul 6;333(1):45–8.

Clinical problem-solving: diverted by the chief complaint [letter; comment] Good CB. **N Engl J Med** 1995 Nov 23; 333(21):1425; discussion 1426. Comment on: N Engl J Med 1995 Jul 6;333(1):45–8.

Clinical problem-solving: diverted by the chief complaint [letter; comment] Haseeb M. **N Engl J Med** 1995 Nov 23; 333(21):1425; discussion 1426. Comment on: N Engl J Med 1995 Jul 6;333(1):45–8.

Clinical Problem-Solving: diverted by the chief complaint [letter; comment] Lomasky SJ. **N Engl J Med** 1995 Nov 23;333(21):1425–6. Comment on: N Engl J Med 1995 Jul 6;333(1):45–8.

Clinical problem-solving: diverted by the chief complaint [letter; comment] Sotos JG, et al. **N Engl J Med** 1995 Nov 23;333(21):1425; discussion 1426. Comment on: N Engl J Med 1995 Jul 6;333(1):45–8.

[Dwarfism with constrictive pericarditis. A case report] Alonso Falcón F, et al. **An Esp Pediatr** 1996 Mar; 44(3):279–81 (9 ref.) **(Spa)**

DRUG THERAPY

Transient tuberculous constrictive pericarditis. Gupta S, et al. **Indian Heart J** 1996 Jan-Feb;48(1):65–7

ETIOLOGY

Massive pericardiac hematoma with severe constrictive pathophysiologic complications after insertion of an epicardial pacemaker. Vilacosta I, et al. **Am Heart J** 1995 Dec;130(6):1298–300

Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma [letter] Kane GC, et al. **Ann Intern Med** 1996 Mar 1;124(5):534–5

Previously unrecognized intrapericardial hematoma leading to refractory abdominal ascites. Meleca MJ, et al. **Chest** 1995 Dec;108(6):1747–8

Disseminated coccidioidomycosis with rapid progression to effusive-constrictive pericarditis. Oudiz R, et al. **J Am Soc Echocardiogr** 1995 Nov-Dec;8(6):947–52

Constrictive pericarditis after heart transplantation: report of two cases. Roca J, et al. **J Heart Lung Transplant** 1995 Sep-Oct;14(5):1006–10

Giant organized pericardial hematoma producing constrictive pericarditis: a case report and review of the literature. Brown DL, et al. **J Trauma** 1996 Sep;41(3):558–60

Systemic lupus erythematosus presenting as effuso-constrictive pericarditis. McMechan SR, et al. **Postgrad Med J** 1995 Oct;71(840):627–9

[Constrictive pericarditis after cardiac surgery] Remadi JP, et al. **Ann Chir** 1996;50(5):397–400 (Eng. Abstr.) **(Fre)**

[Pericarditis and other cardiac disorders, late consequences of radiotherapy] Chappuis MA, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):429–39 (25 ref.) **(Fre)**

[Angiosarcoma of the heart and its spontaneous rupture. A rare cause of effusive-constrictive pericarditis. A case report and review of the literature] Bértoli F, et al. **Rev Med Panama** 1995 Sep;20(3):84–91 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Humoral response to mycobacterial heat shock proteins in patients with constrictive pericarditis caused by tuberculosis and its implications for pathogenesis. Ng TT, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):552–5

METABOLISM

Collagen network remodelling and left ventricular function in constrictive pericarditis. Chello M, et al. **Heart** 1996 Feb;75(2):184–9

PATHOLOGY

Images in cardiovascular medicine. Constrictive pericarditis. Vaitkus PT, et al. **Circulation** 1996 Feb 15;93(4):834–5

Collagen network remodelling and left ventricular function in constrictive pericarditis. Chello M, et al. **Heart** 1996 Feb;75(2):184–9

PHYSIOPATHOLOGY

Images in cardiovascular medicine. Constrictive pericarditis. Vaitkus PT, et al. **Circulation** 1996 Feb 15;93(4):834–5

Neuroendocrine response to standing and mild exercise in patients with untreated severe congestive heart failure and chronic constrictive pericarditis. Ferrari R, et al. **Heart** 1996 Jul;76(1):50–5

SURGERY

Pericardiectomy for pericardial constriction. Trotter MC, et al. **Am Surg** 1996 Apr;62(4):304–7

Intraoperative monitoring of pressure–volume loops of the left ventricle in pericardectomy for constrictive pericarditis. Kuroda H, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):198–9

Pericardiectomy after two decades of constrictive pericarditis in a patient with chronic renal failure. Hateboer N, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1935–7

[Results of pericardiectomy in the treatment of constrictive pericarditis] Brzek V Jr, et al. **Rozhl Chir** 1996 Jan; 75(1):11–4 (Eng. Abstr.) **(Cze)**

[A case of recurrent constrictive pericarditis complicated with atrial septal defect] Tanaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1195–7 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Doppler echocardiography and hemodynamic findings in localized pericardial constriction. Thomas WJ, et al. **Am Heart J** 1996 Mar;131(3):599–603

Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. Garcia MJ, et al. **J Am Coll Cardiol** 1996 Jan;27(1):108–14

Doppler evaluation of patients with constrictive pericarditis: use of tricuspid regurgitation velocity curves to determine enhanced ventricular interaction. Klodas E, et al. **J Am Coll Cardiol** 1996 Sep;28(3):652–7

PERICARDITIS, TUBERCULOUS

Tuberculous pericarditis in an HIV-infected patient. Antony SJ, et al. **Scand J Infect Dis** 1995;27(4):411–3 (26 ref.)

DIAGNOSIS

Tuberculous pericarditis in a child. Coulter JB, et al. **J Infect** 1996 Mar;32(2):157–60

Diagnosis of tuberculous pericarditis with a fluorochrome stain. Nelson CT, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1004–7

[Pericardial tuberculosis in Madagascar. 23 cases] Lesbordes JL, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):95–8 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Transient tuberculous constrictive pericarditis. Gupta S, et al. **Indian Heart J** 1996 Jan–Feb;48(1):65–7

[Pericardial tuberculosis in Madagascar. 23 cases] Lesbordes JL, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):95–8 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The diagnostic and prognostic value of adenosine deaminase in tuberculous pericarditis. Komsuoğlu B, et al. **Eur Heart J** 1995 Aug;16(8):1126–30

PERICARDIUM

see related

PERICARDIECTOMY

Massive pericardiac hematoma with severe constrictive pathophysiologic complications after insertion of an epicardial pacemaker. Vilacosta I, et al. **Am Heart J** 1995 Dec;130(6):1298–300

Contrast echocardiography as an adjunct in hemorrhagic or complicated pericardiocentesis. Weisse AB, et al. **Am Heart J** 1996 Apr;131(4):822–5

Defibrillator patch electrode constriction: an underrecognized entity [see comments] Barrington WW, et al. **Ann Thorac Surg** 1995 Oct;60(4):1112–5; discussion 1115–6 (11 ref.). Comment in: Ann Thorac Surg 1996 Mar;61(3):1042.

Autologous tissue cardiac valve for aortic valve replacement: technical aspects and early results. Gross C, et al. **Ann Thorac Surg** 1996 Jun;61(6):1759–63

A new cardiac wall substitute with high affinity for fibroblasts that can induce an endothelial cell lining. Noishiki Y, et al. **ASAIO J** 1994 Jul–Sep;40(3):M751–6

Gastropericardial fistula. Edwards JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):257–9

Case report: asbestos related pericardial disease. Cooper M, et al. **Clin Radiol** 1996 Sep;51(9):656–7

Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451–3 (16 ref.)

Air pellet gun injury. Waters D, et al. **Iowa Med** 1995 Aug; 85(8):331–2

Comparison of fresh and glutaraldehyde-treated autologous stented pericardium as pulmonary valve replacement. Kumar SP, et al. **J Card Surg** 1995 Sep;10(5):545–51

Pericardiac metastasis from advanced gastric cancer. Moriyama A, et al. **J Gastroenterol** 1995 Aug;30(4):512–6

The Mitroflow pericardial valve: clinical performance to 10 years. Mazzucotelli JP, et al. **J Heart Valve Dis** 1995 Jul; 4(4):407–13

Ovine pericardium: a new material for duraplasty. Pařízek J, et al. **J Neurosurg** 1996 Mar;84(3):508–13

Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. Maher EA, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):637–43

Giant organized pericardial hematoma producing constrictive pericarditis: a case report and review of the literature. Brown DL, et al. **J Trauma** 1996 Sep;41(3):558–60

Wegener's granulomatosis complicated by pericardial tamponade and renal failure [letter] Yildizer K, et al. **Nephron** 1996;72(2):339–40

Non-immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez-Aytes A, et al. **Prenat Diagn** 1995 Sep;15(9):859–63 (20 ref.)

[Pericardial hydatid cysts. Value of magnetic resonance imaging. Apropos of a clinical case] Tédy G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Jun–Aug;44(6):280–3 (Eng. Abstr.) **(Fre)**

[Influence of the valve position on the complications related to pericardial Carpentier–Edwards valve after 8 years] Aupart M, et al. **Arch Mal Coeur Vaiss** 1995 Jul; 88(7):967–71 (Eng. Abstr.) **(Fre)**

[Imaging of lipoma of the pericardium] Rolloy P, et al. **J Radiol** 1995 Sep;76(9):597–9 (Eng. Abstr.) **(Fre)**

[Pericardial perforation caused by an osteogenic exostosis (letter)] Etienne G, et al. **Presse Med** 1995 Dec 2; 24(37):1753 **(Fre)**

[Intrapericardial teratoma in a 3-month-old infant] Karolczak M, et al. **Pediatr Pol** 1995 Nov;70(11):985–9 (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Herniation of the left atrial appendage due to partial congenital absence of the left pericardium. Vanderheyden M, et al. **Acta Clin Belg** 1996;51(2):91–3

Pediatric case of the day. Congenital absence of the pericardium. McIlhenny J, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):270, 274–5

Combined congenital pericardial and diaphragmatic defects: a case report. Tosson R, et al. **Cardiovasc Surg** 1996 Feb; 4(1):57–9

Congenital absence of pericardium: report of 3 cases. Zheng G, et al. **Chin Med J (Engl)** 1996 Mar;109(3):252–4

Congenital partial absence of left pericardium: demonstration by computed tomography after artificial pneumothorax. Krishnan MN, et al. **Indian Heart J** 1996 Jan–Feb; 48(1):63–4

A surgically treated case of both Wolff–Parkinson–White syndrome and atrial septal defect complicating single coronary artery and partial pericardial defect. Sasaki Y, et al. **Jpn Heart J** 1995 Sep;36(5):675–80

[What is your diagnosis? Congenital pericardial defect (failure of the left-sided pericardium)] Hauser M, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1013–6 **(Ger)**

[A case report on a reconstructive operation of a traumatic tricuspid regurgitation with a congenital defect of the left pericardium] Sugimoto T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1977–80 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Appearance of the normal pericardium on coronary MR angiograms. Bogaert J, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):579–87

CHEMISTRY

Collagen fiber architecture of bovine pericardium. Sacks MS, et al. **ASAIO J** 1994 Jul–Sep;40(3):M632–7

Human pericardial fluid contains the highest amount of endothelin-1 of all mammalian biologic fluids thus far tested. Horkay F, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S502–4

CYTOLOGY

Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Mikawa T, et al. **Dev Biol** 1996 Mar 15;174(2):221–32

DRUG EFFECTS

Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. Grabenwöger M, et al. **Ann Thorac Surg** 1996 Sep;62(3):772–7

Use of the glutaraldehyde-chitosan-treated porcine pericardium as a pericardial substitute. Chanda J, et al. **Biomaterials** 1996 Jun;17(11):1087–91

Calcification of pericardial tissue pretreated with different amino acids. Jorge-Herrero E, et al. **Biomaterials** 1996 Mar; 17(6):571–5

In situ polymerization of pyrrole in animal tissue in the formation of hybrid biomaterials. Khor E, et al. **Biomaterials** 1995 May;16(8):657–61

Cytocompatibility of calf pericardium treated by glutaraldehyde and by the acyl azide methods in an organotypic culture model. Petite H, et al. **Biomaterials** 1995 Sep;16(13):1003–8

Effects of propafenone on the median frequency of ventricular fibrillation in Langendorff perfused guinea-pig hearts. Eggenreich U, et al. **Cardiovasc Res** 1996 Jun; 31(6):926–31

Use of an indwelling catheter for examining cardiovascular responses to pericardial administration of bradykinin in rat. McDermott DA, et al. **Cardiovasc Res** 1995 Jul;30(1):39–46

INJURIES

Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Chung JH, et al. **Circulation** 1996 Jun 1;93(11):2014–8

Lung injury with pleuropericardial rupture successfully treated by video-assisted thoracoscopy: case report [see comments] Hermansson U, et al. **J Trauma** 1996 Jun; 40(6):1024–5. Comment in: J Trauma 1996 Jun;40(6):1047.

[Right extrapericardial post-traumatic hernia of the heart: a peculiar symptomatology (letter; comment)] Nicolas F, et al. **Ann Fr Anesth Reanim** 1995;14(4):381. Comment on: Ann Fr Anesth Reanim 1994;13(5):734–7. **(Fre)**

[Posttraumatic pericardial laceration and cleft of the anterior mitral leaflet] Venturini E, et al. **G Ital Cardiol** 1995 Aug; 25(8):1037–41 (11 ref.) (Eng. Abstr.) **(Ita)**

[A case of traumatic diaphragmatic hernia accompanied with rupture of pericardium] Ikeda E, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1234–8 (Eng. Abstr.) **(Jpn)**

INNERVATION

Phrenic afferent input excites C1–C2 spinal neurons in rats. Razook JC, et al. **Pain** 1995 Oct;63(1):117–25

METABOLISM

Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]enkephalin. McLaughlin PJ. **Am J Physiol** 1996 Jul;271(1 Pt 2):R122–9

Effects of spontaneous myocardial oscillation on cardiac function: direct observation of the epicardial fluorescence image in calcium overloaded isolated hamster hearts. Shinozaki T, et al. **Cardiovasc Res** 1996 May;31(5):784–92

High concentrations of atrial natriuretic peptide and brain natriuretic peptide in rat pericardial fluid and their reduction by reserpine in vivo. Klemola R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):331–6

MICROBIOLOGY

Isolation of Mycoplasma pneumoniae from pericardial tissue [letter] Meseguer MA, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):825–6

PATHOLOGY

Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis. Bardales RH, et al. **Am J Clin Pathol** 1996 Jul; 106(1):29–34

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

Pericardial mesothelioma presenting as left atrial thrombus in a patient with mitral stenosis. Miyamoto Y, et al. **Cardiovasc Surg** 1996 Feb;4(1):51–2

MR evaluation of the pericardium and cardiac malignancies. White CS. **Magn Reson Imaging Clin N Am** 1996 May; 4(2):237–51 (48 ref.)

Hydropericardium syndrome in broiler chickens: its contagious nature and pathology. Abdul-Aziz TA, et al. **Res Vet Sci** 1995 Nov;59(3):219–21

A biodegradable patch used as a pericardial substitute after cardiac surgery: 6- and 24-month evaluation with CT. Duvernoy O, et al. **Thorac Cardiovasc Surg** 1995 Oct; 43(5):271–4

MR evaluation of the pericardium. White CS. **Top Magn Reson Imaging** 1995 Fall;7(4):258–66 (32 ref.)

[Periaortic fibrosis with pericardial and perirenal involvement: apropos of a case] Cerisier A, et al. **Rev Med Interne** 1996;17(2):154–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Solitary fibrous tumor of the epicardium] Flemming P, et al. **Pathologe** 1996 Mar;17(2):139–44 (Eng. Abstr.) **(Ger)**

[Nasopharyngeal natural killer cell lymphoma with pericardial infiltration] Hisatake J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):145–9 (Eng. Abstr.) **(Jpn)**

PERICARDIUM

PHYSIOLOGY

Comparison of biaxial mechanical properties of excised endocardium and epicardium. Kang T, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2169–76

Distribution of connective tissue proteins during development and neovascularization of the epicardium. Bouchey D, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E104–15

Modulation of ventricular repolarization by a premature stimulus. Role of epicardial dispersion of repolarization kinetics demonstrated by optical mapping of the intact guinea pig heart. Laurita KR, et al. **Circ Res** 1996 Sep; 79(3):493–503

Effects of pericardial constraint on left ventricular mechanoreceptor activity in cats. Wang SY, et al. **Circulation** 1995 Dec 1;92(11):3331–6

Effects of bipolar point and line stimulation in anisotropic rabbit epicardium: assessment of the critical radius of curvature for longitudinal block. Knisley SB, et al. **IEEE Trans Biomed Eng** 1995 Oct;42(10):957–66

Epicardial surface dynamics in the closed-chest normal canine. McInerney JJ, et al. **J Biomech** 1995 Nov; 28(11):1319–32

Alteration of ventricular fibrillation by propranolol and isoproterenol detected by epicardial mapping with 506 electrodes. Hillsley RE, et al. **J Cardiovasc Electrophysiol** 1995 Jun;6(6):471–85

Analysis of alternans in late potentials. Correlations between epicardial and body surface recordings. Romberg D, et al. **J Electrocardiol** 1995;28 Suppl:198–201

PHYSIOPATHOLOGY

Different responses of epicardium and endocardium to KATP channel modulators during regional ischemia. Miyoshi S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H140–7

Nonlinear analysis of epicardial atrial electrograms of electrically induced atrial fibrillation in man [see comments] Hoekstra BP, et al. **J Cardiovasc Electrophysiol** 1995 Jun; 6(6):419–40. Comment in: J Cardiovasc Electrophysiol 1995 Jun;6(6):441–2.

[Identification of deep septal ventricular tachycardia substrates from epicardial breakthrough characteristics] Kawamura Y, et al. **J Cardiol** 1995 Dec;26(6):349–55 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

RADIOGRAPHY

Images in cardiovascular medicine. Detection of normal pericardium and of pericardial effusion in the lateral chest radiograph. Wang K, et al. **Circulation** 1996 Mar 15; 93(6):1254

Congenital partial absence of left pericardium: demonstration by computed tomography after artificial pneumothorax. Krishnan MN, et al. **Indian Heart J** 1996 Jan–Feb; 48(1):63–4

RADIONUCLIDE IMAGING

Gallium–67 imaging of pericardial lymphoma in AIDS. Prvulovich EM, et al. **J Nucl Med** 1996 Jun;37(6):995–6

SURGERY

Pericardial repair after extensive resection: another use for the pedicled diaphragmatic flap. Goldstraw P, et al. **Ann Thorac Surg** 1996 Apr;61(4):1112–4

An esophagopericardial fistula successfully treated with an expandable covered metal mesh stent. Tukkie R, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):165–7

Images in clinical medicine: echinococcal cyst of the pericardium [letter; comment] Saidi F. **N Engl J Med** 1995 Dec 7;333(23):1572. Comment on: N Engl J Med 1995 Jul 20;333(3):165.

Incidence of ICD lead related complications during long-term follow-up: comparison of epicardial and endocardial electrode systems. Korte T, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2053–61

Pericardial repair depresses canine cardiac catecholamines and met-enkephalin. Barron BA, et al. **Regul Pept** 1995 Nov 10;59(3):313–20

A biodegradable patch used as a pericardial substitute after cardiac surgery: 6- and 24-month evaluation with CT. Duvernoy O, et al. **Thorac Cardiovasc Surg** 1995 Oct; 43(5):271–4

[Pulmonary vein stenosis. Description of a sutureless surgical procedure using the pericardium in situ] Lacour-Gayet F, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):633–6 (Eng. Abstr.) **(Fre)**

[Echinococcosis of the heart] Rein R, et al. **Herz** 1996 Jun; 21(3):192–7 (Eng. Abstr.) **(Ger)**

[Cardiac tamponade: emergency pericardiocentesis using a common set for central venous catheterization] Minutiello L. **Minerva Cardioangiol** 1996 Apr;44(4):209–20 (Eng. Abstr.) **(Ita)**

TRANSPLANTATION

Calcification of bovine pericardium: glutaraldehyde versus No-React biomodification. Abolhoda A, et al. **Ann Thorac Surg** 1996 Jul;62(1):169–74

Closure of ruptured coronary sinus by a pericardial patch. Aharinejad S, et al. **Ann Thorac Surg** 1996 Sep;62(3):889–91

Ventricular septal aneurysm after atrioventricular septal repair with pericardium. Burkhart HM, et al. **Ann Thorac Surg** 1996 Jun;61(6):1838–9

Pericardial patch augmentation of right atrioventricular valve in atrioventricular canal. Falk V, et al. **Ann Thorac Surg** 1996 Jul;62(1):288–90

1988: The use of autologous pericardium for ventricular aneurysm closure. Updated in 1996. Fiore AC, et al. **Ann Thorac Surg** 1996 Jan;61(1):271–2

New surgical technique for repair of ventricular septal perforation [see comments] Matsuda K, et al. **Ann Thorac Surg** 1995 Nov;60(5):1430–1. Comment in: Ann Thorac Surg 1996 May;61(5):1587–9.

Pedicled pericardial patch repair of a carinal bronchogenic cyst. Pierson RN 3rd, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1419–21

Long-term follow-up of autologous pericardial valved conduits. Schlichter AJ, et al. **Ann Thorac Surg** 1996 Jul; 62(1):155–60

Mitral valve remodeling: long-term results with posterior pericardial annuloplasty. Scrofani R, et al. **Ann Thorac Surg** 1996 Mar;61(3):895–9

Use of the glutaraldehyde-chitosan-treated porcine pericardium as a pericardial substitute. Chanda J, et al. **Biomaterials** 1996 Jun;17(11):1087–91

Critical role of the sinuses of Valsalva in the durability of valved conduits. Kumar SP, et al. **J Heart Valve Dis** 1996 Mar;5(2):160–7

Ochrobactrum anthropi meningitis in pediatric pericardial allograft transplant recipients. Chang HJ, et al. **J Infect Dis** 1996 Mar;173(3):656–60

Thoracoabdominal wall repair with glutaraldehyde-preserved bovine pericardium. Santillan-Doherty P, et al. **J Invest Surg** 1996 Jan–Feb; 9(1):45–55

Pedicled pericardium for repair of right ventricular outflow tract and pulmonary arterial stenoses in tetralogy of Fallot: a six-year experience. Khoury W, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):424–32

Ten-year experience with the Carpentier-Edwards pericardial xenograft in the tricuspid position. Nakano K, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):605–12

Reconstruction of the pulmonary artery by a conduit of autologous pericardium. Rendina EA, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):867–8

Autologous tissue cardiac valve: implantation in children. Van de Wal HJ, et al. **J Thorac Cardiovasc Surg** 1996 Sep; 112(3):846–8

From the Centers for Disease Control and Prevention. Ochrobactrum anthropi meningitis associated with cadaveric pericardial tissue processed with a contaminated solution—Utah, 1994. **JAMA** 1996 Aug 28;276(8):596

Ochrobactrum anthropi meningitis associated with cadaveric pericardial tissue processed with a contaminated solution—Utah, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Aug 9;45(31):671–3

Use of a pericardial fat pad flap for preventing bronchopleural fistula: an experimental study focusing on the angiogenesis and cytokine production of the fat pad. Ichinose Y, et al. **Surg Today** 1995;25(9):811–5

[Aortic valve replacement with pericardial bioprosthesis in patients under 60 years of age. Experience over 10 years] Aupart M, et al. **Ann Chir** 1996;50(5):367–73 (Eng. Abstr.) **(Fre)**

[Heart valve prosthesis from autologous pericardium. Preliminary results apropos of 15 patients] Vaillant A, et al. **Chirurgie** 1996;121(2):113–6 (Eng. Abstr.) **(Fre)**

[Surgical treatment for subacute left ventricular free wall rupture complicating acute myocardial infarction—pericardial patch gluing method] Komiya T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun; 44(6):806–10 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Pericardial hematoma causing saphenous vein graft compression. Shehata AR, et al. **Am Heart J** 1996 Mar; 131(3):598–9

PERICEMENTITIS see **PERIODONTITIS**

PERICORONITIS

DRUG THERAPY

[Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection] Sasaki J, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1093–118 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Pericoronitis and tonsillitis: clinical and darkfield microscopy findings. Rajasuo A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):526–32

PERIDINIUM see **DINOFLAGELLIDA**

PERIDURAL INJECTIONS see **INJECTIONS, EPIDURAL**

PERILENE see **PERYLENE**

PERILYMPH

Comparison of endoscopic and surgical explorations for perilymphatic fistulas. Poe DS, et al. **Am J Otol** 1994 Nov; 15(6):735–8

Idiopathic perilymphatic fistulas [letter] Kohut RI. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1436

[Measurement of cochlear blood flow during exploratory tympanotomy in patients suspected of having perilymphatic fistulas] Nakashima T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1297–302 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Effects of experimental round window membrane laceration on the free amino acid profile of perilymph. Haruta A, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):504–8

High resolution two-dimensional electrophoresis: technique and potential applicability to the study of inner ear disease. Thalmann I, et al. **Am J Otol** 1995 Mar;16(2):153–7

Beta-2 transferrin: limitations of use as a clinical marker for perilymph. Levenson MJ, et al. **Laryngoscope** 1996 Feb; 106(2 Pt 1):159–61

Hearing loss and trace elements Fe2+ and Zn2+ in the perilymph. Xu M, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep–Oct; 57(5):245–9

DRUG EFFECTS

Effect of cisplatin administration on the electrochemical composition of endolymph in the rat cochlea. Laurell G, et al. **Hear Res** 1995 Jul;87(1–2):16–20

METABOLISM

Comparative perilymph permeability of cephalosporins and its significance in the treatment and prevention of suppurative labyrinthitis. Sun AH, et al. **Ann Otol Rhinol Laryngol** 1996 Jan;105(1):54–7

Perilymph detection by beta 2-transferrin immunoblotting assay. Application to the diagnosis of perilymphatic fistulae. Delaroche O, et al. **Clin Chim Acta** 1996 Feb 9; 245(1):93–104

Osteopontin expression detected in adult cochleae and inner ear fluids. Lopez CA, et al. **Hear Res** 1995 May; 85(1–2):210–22

PHYSIOLOGY

Idiopathic perilymphatic fistulae: a temporal bone histopathological study. Clinical, surgical and histopathological correlations. Kohut RI, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:225–34

The accuracy of the clinical diagnosis (predictability) of patencies of the labyrinth capsule (perilymphatic fistulas): a clinical histopathologic study with statistical evaluations. Kohut RI, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:235–7

The junctions of the spindle-shaped cells of the stria vascularis: a link that completes the barrier between perilymph and endolymph. Luciano L, et al. **Hear Res** 1995 May;85(1–2):199–209

RADIOGRAPHY

[Pneumolabyrinth. Radiologic sign of perilymph fistula] Schneider W, et al. **HNO** 1995 Nov;43(11):669–71 (Eng. Abstr.) **(Ger)**

PERILYMPHATIC DUCT see **COCHLEAR AQUEDUCT**

PERIMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

PERIMENOPAUSE see **PREMENOPAUSE**

PERIMETRY

Physiology of cumulative defect curves; consequences in glaucoma perimetry. Asman P, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):197–201

The effect of perimetric experience in patients with glaucoma. Heijl A, et al. **Arch Ophthalmol** 1996 Jan; 114(1):19–22

Interrater agreement in oculo-kinetic perimetry—a screening test for glaucoma. Westling AK, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):125–8

Scotoma perception in white-noise-field campimetry and postchiasmal visual pathway lesions. Kolb M, et al. **Ger J Ophthalmol** 1995 Jul;4(4):228–33

Microperimetry in patients with central serous retinopathy. Toonen F, et al. **Ger J Ophthalmol** 1995 Sep;4(5):311–4

Establishing a reliable visual function test and applying it to screening optic nerve disease in onchocercal communities. Cheng G, et al. **Int J Biomed Comput** 1996 Mar;41(1):47–53

The psychometric function and reaction times of automated perimetry in normal and abnormal areas of the visual field

in patients with glaucoma. Wall M, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):878–85
Pupillary dilation and its effects on automated perimetry results. Kudrna GR, et al. **J Am Optom Assoc** 1995 Nov; 66(11):675–80
Automated perimetry. American Academy of Ophthalmology. **Ophthalmology** 1996 Jul;103(7):1144–51
Relative dispersion analysis enhances perimetric sensitivity. Frisén L, et al. **Vision Res** 1996 Feb;36(3):491–7
[Application of oculokinetic perimetry in examination of the eye] Wakakura M, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):551–7 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Kinetic fundus controlled perimetry with the scanning laser ophthalmoscope] Rohrschneider K, et al. **Klin Monatsbl Augenheilkd** 1995 Aug;207(2):102–10 (Eng. Abstr.) **(Ger)**
[Perimetry with a glaucoma-specific test grid. A clinical study with the GG program] Roesen B, et al. **Ophthalmologe** 1995 Aug;92(4):564–73 (Eng. Abstr.) **(Ger)**

METHODS

Scanning Laser Ophthalmoscope microperimetry compared with Octopus perimetry in normal subjects. Andersen MV. **Acta Ophthalmol Scand** 1996 Apr;74(2):135–9
Random dot motion perimetry in patients with glaucoma and in normal subjects. Wall M, et al. **Am J Ophthalmol** 1995 Nov;120(5):587–96
Effectiveness of entoptic perimetry for locating peripheral scotomas caused by cytomegalovirus retinitis. Plummer DJ, et al. **Arch Ophthalmol** 1996 Jul;114(7):828–31
Objective detection of hemifield and quadrantic field defects by visual evoked cortical potentials. Bradnam MS, et al. **Br J Ophthalmol** 1996 Apr;80(4):297–303
Analysis of visual field progression in glaucoma. Fitzke FW, et al. **Br J Ophthalmol** 1996 Jan;80(1):40–8
Spatial classification of glaucomatous visual field loss. Henson DB, et al. **Br J Ophthalmol** 1996 Jun;80(6):526–31
Automated perimetry in patients with choroidal metastases. Rahhal FM, et al. **Br J Ophthalmol** 1996 Apr;80(4):309–13
Feasibility of automated visual field examination in children between 5 and 8 years of age. Safran AB, et al. **Br J Ophthalmol** 1996 Jun;80(6):515–8
Visual field test simulation and error in threshold estimation. Spenceley SE, et al. **Br J Ophthalmol** 1996 Apr;80(4):304–8
HPR perimetry and Humphrey perimetry in glaucomatous children. Marraffa M, et al. **Doc Ophthalmol** 1995; 89(4):383–6
Glaucoma screening with oculokinetic perimetry in general practice: is its specificity acceptable? Christoffersen T, et al. **Eye** 1995;9 (Pt 6 Su):36–9
High-pass resolution perimetry and light-sense perimetry in open-angle glaucoma. Meyer JH, et al. **Ger J Ophthalmol** 1995 Jul;4(4):222–7
Automated perimetry with bright and dark stimuli. Wabbels B, et al. **Ger J Ophthalmol** 1995 Jul;4(4):217–21
Static fundus perimetry using the scanning laser ophthalmoscope with an automated threshold strategy. Rohrschneider K, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Dec;233(12):743–9
Baseline alterations in blue-on-yellow normal perimetric sensitivity. Wild JM, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Mar;234(3):141–9
Formulas for conversion between Octopus and Humphrey threshold values and indices. Zeyen T, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Oct;233(10):627–34
Clinical alternative for reducing the time needed to perform automated threshold perimetry. Fingeret M. **J Am Optom Assoc** 1995 Nov;66(11):699–705 (14 ref.)
Comparing threshold visual fields between the Dicon TKS 4000 automated perimeter and the Humphrey Field Analyzer. Wong AY, et al. **J Am Optom Assoc** 1995 Nov; 66(11):706–11
A new procedure for the registration of the visual-evoked cortical potential by multichannel recording of the gradient distribution. Sporckmann G, et al. **J Med Eng Technol** 1995 Mar-Jun;19(2–3):62–5
Differential diagnosis of macular breaks by microperimetry using the scanning laser ophthalmoscope. Kakehashi A, et al. **Jpn J Ophthalmol** 1996;40(1):116–22
Automated suprathreshold static perimetry screening for detecting neuro-ophthalmologic disease. Siatkowski RM, et al. **Ophthalmology** 1996 Jun;103(6):907–17
Field of dreamers and dreamed-up fields: functional and fake perimetry. Thompson JC, et al. **Ophthalmology** 1996 Jan; 103(1):117–25
The Glenn A. Fry Award Lecture. Early losses of visual function in glaucoma. Johnson CA. **Optom Vis Sci** 1995 Jun;72(6):359–70 (67 ref.)
Goldmann field testing in glaucoma [letter] Williams TD. **Optom Vis Sci** 1995 Jul;72(7):532–4

STATISTICS & NUMERICAL DATA

The interpretation of automated visual fields. Mikelberg FS. **Can J Ophthalmol** 1995 Aug;30(5):281–3
Formulas for conversion between Octopus and Humphrey threshold values and indices. Zeyen T, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Oct;233(10):627–34

PERINATAL CARE

Management of 168 neonates weighing more than 2000 g receiving intrapartum chemoprophylaxis for chorioamnionitis. Evaluation of an early discharge strategy. Singhal KK, et al. **Arch Pediatr Adolesc Med** 1996 Feb; 150(2):158–63
GMSC's advice on intrapartum care is unhelpful [letter] Bradbrook J, et al. **BMJ** 1996 Apr 6;312(7035):910–1
Recent advances of perinatal medicine in China. Zhou Z. **Chin Med J (Engl)** 1995 May;108(5):387–9
Management of labor and labor complications. Weinstein D, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):437–41 (37 ref.)
The grand multipara. Goldman GA, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):105–9
The regionalization of perinatal care in France—description of a missing policy. Papiernik E, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):99–103 (40 ref.)
Availability of antenatal and perinatal care in an ICDS area. Kakkar M, et al. **Indian Pediatr** 1995 May;32(5):597–9
Maternal and perinatal factors associated with non-Hodgkin's lymphoma among children. Adami J, et al. **Int J Cancer** 1996 Mar 15;65(6):774–7
Major ethical problems confronting perinatal care around the world. Dunn PM. **Int J Gynaecol Obstet** 1995 Dec; 51(3):205–10
Perinatal database in Germany. Brockerhoff PG, et al. **J Obstet Gynaecol** 1995 Apr;21(2):209–13
The perinatal nurse practitioner: an innovative model of advanced practice. McGee DC. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):602–6
Predictors of in-treatment relapse in perinatal substance abusers and impact on treatment retention: a prospective study. Ingersoll KS, et al. **J Psychoactive Drugs** 1995 Oct-Dec;27(4):375–87
Perinatal care at the threshold of viability [letter; comment] Little GA. **Pediatrics** 1996 Feb;97(2):288. Comment on: Pediatrics 1995 Nov;96(5 Pt 1):974–6.
The need for midwife obstetric units in South Africa [letter; comment] Van Coeverden de Groot HA, et al. **S Afr Med J** 1995 Nov;85(11):1190–1. Comment on: S Afr Med J 1995 Aug;85(8):762–5.
The impact of assisted reproduction on perinatal health care. Keirse MJ, et al. **Soz Praventivmed** 1995;40(6):343–51 (59 ref.)
[The third priority in perinatal care] Tišer H. **Ceska Gynekol** 1996 Feb;61(1):48–50 **(Cze)**
[Realities and perspectives of perinatal care in Sicily. Experience at an outborn neonatal unit] Distefano G, et al. **Pediatr Med Chir** 1996 Mar-Apr;18(2):161–7 (Eng. Abstr.) **(Ita)**

HISTORY

Professor Pierre Budin (1846–1907) of Paris, and modern perinatal care. Dunn PM. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F193–5

LEGISLATION & JURISPRUDENCE

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

METHODS

Practice styles. A comparison of obstetricians and nurse-midwives. Fullerton JT, et al. **J Nurse Midwifery** 1996 May-Jun;41(3):243–50
Neonatal considerations when birth occurs at home. Toepke ML, et al. **J Nurse Midwifery** 1995 Nov-Dec;40(6):529–33 (29 ref.)
Prenatal diagnosis and the pediatric surgeon: the impact of prenatal consultation on perinatal management. Crombleholme TM, et al. **J Pediatr Surg** 1996 Jan; 31(1):156–62; discussion 162–3
Second revision of mortality prevention potential of conservative neonatal care [letter] Daga SR, et al. **J Trop Pediatr** 1995 Oct;41(5):314
[The problems attendant on the use of a new protocol of labor/delivery care] Santini M, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2–3):124–5 **(Ita)**

ORGANIZATION & ADMINISTRATION

Perinatal nurse practitioners and health care reform. Gennaro S, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):597–601
Perinatal services in the era of managed care: a Kaiser Permanente physician's perspective. Wirtschafter DD. **J Perinatol** 1995 Sep-Oct;15(5):414–7

STANDARDS

Drug treatment in the perinatal period and the risk of functional teratogenicity. Benešová O. **Arch Toxicol Suppl** 1996;18:89–96 (9 ref.)
A method of proportional audit of perinatal care. Hutchon DJ. **Br J Obstet Gynaecol** 1996 May;103(5):402–4
A perinatal continuing education program: its effects on the knowledge and practices of health professionals. Harris JK, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov-Dec; 24(9):829–35
Managing a snappy birthday [editorial] Meier CF. **Obstet Gynecol Surv** 1995 Dec;50(12):837–8
Monitoring systems to evaluate the quality of perinatal care. Lumley J. **Soz Praventivmed** 1995;40(6):338–42

STATISTICS & NUMERICAL DATA

[Results of an analysis of perinatal care in the Czech Republic in 1994 and future tasks] Stembera Z. **Ceska Gynekol** 1995 Dec;60(6):307–8 **(Cze)**

PERINATAL MORTALITY see **INFANT MORTALITY**

PERINATAL NURSING see **NEONATAL NURSING**

PERINATOLOGY

see related
FETAL DISEASES
INFANT, NEWBORN, DISEASES
MATERNAL-CHILD NURSING
PERINATAL CARE
PREGNANCY COMPLICATIONS

16th Annual meeting of the Society of Perinatal Obstetricians. Kamuela, Hawaii, February 4–10, 1996. Abstracts. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 2):303–524
Society for Obstetric Anesthesia and Perinatology. Montreal, Canada, May 17–20, 1995. Camann WR, et al. **Anesthesiology** 1995 Dec;83(6):1393–4
Conference report: the Fourth International Conference on Veterinary Perinatology, Churchill College, Cambridge, 7–9 July 1995. Carter AM. **Placenta** 1995 Dec;16(8):761–2
The crucial role of definition in perinatal epidemiology. Duc G. **Soz Praventivmed** 1995;40(6):357–60
[Perinatal committees' obligation to inform (letter)] Ladehaug B. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):113 **(Nor)**

HISTORY

William Potts Dewees (1768–1841) of Pennsylvania: pioneer of perinatal medicine in America. Dunn PM. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul;75(1):F69–70

INSTRUMENTATION

[An investigation and design of apparatus for measuring fetal lung maturity] Su C, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):354–6; inside back cover (Eng. Abstr.) **(Chi)**

ORGANIZATION & ADMINISTRATION

The regionalization of perinatal care in Wales and Washington State. Rosenblatt RA, et al. **Am J Public Health** 1996 Jul;86(7):1011–5
Perinatal management at the lower margin of viability. Rennie JM. **Arch Dis Child Fetal Neonatal Ed** 1996 May; 74(3):F214–8 (36 ref.)
Themes and variations among seven comprehensive perinatal drug and alcohol abuse treatment models. Clayson Z, et al. **Health Soc Work** 1995 Aug;20(3):234–8
[Regionalization of perinatal medicine in Germany (editorial)] Pohlandt P. **Z Geburtshilfe Neonatol** 1996 Jan-Feb;200(1):1 **(Ger)**

TRENDS

The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug; 24(6):525–31 (32 ref.)

PERINEUM

Persistent perineal ulcerations. Erosive herpes simplex. Dietrich SM, et al. **Arch Dermatol** 1996 Jan;132(1):81, 84
Recurrent toxin-mediated perineal erythema. Manders SM, et al. **Arch Dermatol** 1996 Jan;132(1):57–60
The estimation of lung dose from mid-perineum ionization chamber measurements in total body irradiations: a quality control check on dose delivery. Cross P. **Australas Radiol** 1995 Nov;39(4):384–6
Perineal prostatic cancer seeding following Urocut needle biopsy. Szentgyörgyi E. **Int Urol Nephrol** 1996;28(1):87–90
Perineal herniorrhaphy: perioperative data from 100 dogs. Hosgood G, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug; 31(4):331–42
Aggressive angiomyxoma of the pelvis and perineum. A case report. Fishman A, et al. **J Reprod Med** 1995 Sep; 40(9):665–9 (16 ref.)
Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367–8 (12 ref.)
Gangrene of the perineum. Benizri E, et al. **Urology** 1996 Jun;47(6):935–9 (36 ref.)
A unique perineal herniation of large bladder diverticulum: successful surgical repair through posterior sagittal approach. Gong M, et al. **Urology** 1996 Apr;47(4):569–72
Perineal abscess after embolization for high-flow priapism. Sandock DS, et al. **Urology** 1996 Aug;48(2):308–11
[Aggressive angiomyxoma of the perineum and pelvis. A report of two cases with pelvic and para-testicular localization] Mdimagh H, et al. **Ann Pathol** 1995; 15(4):285–7 (Eng. Abstr.) **(Fre)**

[Ano-perineal fistula in MRI. Contribution of T2 weighted sequences] Tissot O, et al. **J Radiol** 1996 Apr;77(4):253–60 **(Fre)** (Eng. Abstr.)

[Accessory scrotum with lipoma: a case report] Konya E, et al. **Hinyokika Kiyo** 1996 Mar;42(3):233–6 (28 ref.) **(Jpn)** (Eng. Abstr.)

ABNORMALITIES

Congenital posterior urethral perineal fistulae: a unique form of urethral duplication. Wagner JR, et al. **Urology** 1996 Aug;48(2):277–80 (12 ref.)

INJURIES

Preserving the pelvic floor and perineum during childbirth—elective caesarean section? Sultan AH, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):731–4 (21 ref.)

Incidence of third-degree perineal tears in labour and outcome after primary repair [letter] Geary M, et al. **Br J Surg** 1996 Jul;83(7):1016–7

Incidence of third-degree perineal tears in labour and outcome after primary repair. Walsh CJ, et al. **Br J Surg** 1996 Feb;83(2):218–21

The relationship of episiotomy to third and fourth degree lacerations. Golden WE, et al. **J Ark Med Soc** 1996 Feb; 92(9):447–8 (15 ref.)

Treatment of posttraumatic chronic high-flow priapisms by superselective embolization of cavernous artery with autologous clot. Kim SC, et al. **J Trauma** 1996 Mar; 40(3):462–5

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part I. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):806–20 (189 ref.)

Blunt urogenital trauma in prepubescent female patients: more than meets the eye! Lynch JM, et al. **Pediatr Emerg Care** 1995 Dec;11(6):372–5

Immediate impotence after penetrating perineal trauma: restoration of erections with penile artery revascularization, corpus cavernosum aneurysm repair, and deep penile venous ligation. Licht MR, et al. **Urology** 1995 Oct; 46(4):577–80

[High flow priapism following a straddle-injury-induced arteriocavernosal fistula: a case report] Kuwahara M, et al. **Hinyokika Kiyo** 1995 Aug;41(8):625–8 (Eng. Abstr.) **(Jpn)**

[Reconstructive-restorative and combined operations in patients with injuries to the muscles of the pelvic floor and perineum] Nazarov LU, et al. **Vestn Khir Im I I Grek** 1992 Nov-Dec;149(11-12):335–7 **(Rus)**

INNERVATION

Motoneurons innervating guinea pig perineal muscles are sexually dimorphic in size but not number. Freeman LM, et al. **Brain Res** 1995 Aug 28;690(1):1–7

Unilateral pudendal neuropathy. Significance and implications. Sangwan YP, et al. **Dis Colon Rectum** 1996 Mar;39(3):249–51

[Neuro-perineal disorders in hemi-syndromes of the cauda equina. 30 cases (letter)] Amarenco G, et al. **Presse Med** 1995 Dec 2;24(37):1752 **(Fre)**

PATHOLOGY

[Extrapelvic endometriosis involving the perineum] Márquez J, et al. **Rev Chil Obstet Ginecol** 1995;60(1):1–4; discussion 4–5 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Corpus spongiosum penis pressure and perineal muscle activity during reflexive erections in the rat. Schmidt MH, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R904–13

Importance of target innervation in recovery from axotomy-induced loss of androgen receptor in rat perineal motoneurons. al-Shamma HA, et al. **J Neurobiol** 1995 Nov; 28(3):341–53

Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299–307 (16 ref.)

RADIOGRAPHY

Priapism caused by a perineal abscess in a patient with Crohn's disease: CT findings. Alago W Jr, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1199–200

SURGERY

Perineal wound closure with the rectus abdominis musculocutaneous flap after tumor ablation. de Haas WG, et al. **Ann Surg Oncol** 1995 Sep;2(5):400–6

Repair of the perineal defect after radical vulvar surgery: direct closure versus skin flaps reconstruction. A retrospective comparative study. Landoni F, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):300–4

Wide perineal dissection and its effect on local recurrence following potentially curative abdominoperineal resection for rectal adenocarcinoma. Volpe C, et al. **Cancer Invest** 1996;14(1):1–5

Outcome of restorative perineal graciloplasty with simultaneous excision of the anus and rectum for cancer. A ten-year experience with 81 patients. Cavina E. **Dis Colon Rectum** 1996 Feb;39(2):182–90

Vertical subcutaneous pedicle flaps for posterior perineal reconstruction. Report of three cases. Ricchi E, et al. **Dis Colon Rectum** 1996 Mar;39(3):353–7

Internal pudendal flap anoplasty for severe anal stenosis. Report of a case. Saldana E, et al. **Dis Colon Rectum** 1996 Mar;39(3):350–2

Evaluation of long-term results of surgical correction of stress urinary incontinence. Cosiski Marana HR, et al. **Gynecol Obstet Invest** 1996;41(3):214–9

Abdomino perineal repair of pulsion enterocele. Brieger GM, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):151–6

Complex abdominal-perineal reconstruction: options after pelvic bone resection. Evans GR, et al. **Plast Reconstr Surg** 1996 Sep;98(4):735–9

[Prevention and treatment of persistent perineal sinuses. Literature review and initial experience] Vykus V, et al. **Rozhl Chir** 1995 May;74(4):193–7 (Eng. Abstr.) **(Cze)**

[Rectal stenosis following prolonged use of suppositories of acetylsalicylic acid and paracetamol. Correction by perineal approach (letter)] Catheline JM, et al. **Ann Chir** 1995;49(6):551 **(Fre)**

[Immediate vaginal reconstruction with a musculocutaneous flap from the gracilis muscle after extended abdomino-perineal resection] Sezeur A, et al. **Ann Chir** 1995;49(6):534–8 (Eng. Abstr.) **(Fre)**

[Scrotal reconstruction after necrotizing cellulitis of the perineum and external genital organs. Apropos of 21 cases] Boukind H, et al. **Ann Urol (Paris)** 1995;29(5):308–12 (Eng. Abstr.) **(Fre)**

[A novel diagnostic method to study the residual pelvic cavity after Miles abdomino-pelvic resection] La Torre F, et al. **Minerva Chir** 1995 Jul-Aug;50(7-8):653–8 (Eng. Abstr.) **(Ita)**

[Reconstructive-restorative and combined operations in patients with injuries to the muscles of the pelvic floor and perineum] Nazarov LU, et al. **Vestn Khir Im I I Grek** 1992 Nov-Dec;149(11-12):335–7 **(Rus)**

ULTRASONOGRAPHY

Perineal ultrasonography in postoperative assessment of two different surgical procedures for stress urinary incontinence. Demirci F, et al. **Int Urol Nephrol** 1995; 27(3):279–87

Evaluation of urethrovesical junction mobility by perineal ultrasonography in stress urinary incontinence. Demirci F, et al. **JPMA J Pak Med Assoc** 1996 Jan;46(1):2–5

PERINEURIUM see **PERIPHERAL NERVES**

PERINEURONAL SATELLITE CELLS see **OLIGODENDROGLIA**

PERIODIC ACID

Determination of the linkage positions of reducing-end residues of oligosaccharides by partial periodate oxidation of pyridylaminated derivatives. Omichi K, et al. **Anal Biochem** 1995 May 20;227(2):404–7

CHEMISTRY

Studies on the rate and control of antibody oxidation by periodate. Wolfe CA, et al. **Anal Biochem** 1995 Oct 10; 231(1):123–30

IMMUNOLOGY

Comparative activity of peroxidase-antibody conjugates with periodate and glutaraldehyde coupling according to an enzyme immunoassay. Tresca JP, et al. **Ann Biol Clin (Paris)** 1995;53(4):227–31

PERIODIC ACID-SCHIFF REACTION

Rapid laboratory confirmation of Fabry's disease: a reminder [letter] Lacour M, et al. **Br J Dermatol** 1995 Aug; 133(2):339–40

PAS positive substance in the human embryonic thyroid gland at stage 23. Bocian-Sobkowska J, et al. **Folia Morphol (Warsz)** 1995;54(2):103–9

PERIODIC DISEASE

Children with hyperimmunoglobulinemia D and periodic fever syndrome. Grose C, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):72–7 (16 ref.)

[Neuro-brucellosis. Report of 8 cases] Dias MS, et al. **Acta Med Port** 1995 Dec;8(12):671–5 (Eng. Abstr.) **(Por)**

[Update on familial Mediterranean fever] Zaglio A. **Rev Med Univ Navarra** 1995 Jul-Sep;39(3):153–63 (50 ref.) **(Spa)**

BLOOD

Anti-neutrophil cytoplasmic antibodies in familial Mediterranean fever [letter] Simsek H, et al. **Clin Rheumatol** 1996 Mar;15(2):216–8

The effect of desmopressin on platelet aggregation defect in systemic amyloidosis: a preliminary report. Demiroğlu H, et al. **Eur J Haematol** 1996 May;56(5):283–6

CLASSIFICATION

Familial Mediterranean fever [letter] McDermott EM, et al. **Lancet** 1996 Aug 24;348(9026):554–5

COMPLICATIONS

Nephrotic syndrome and periodic fever in pregnancy [letter] Ersan F, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):59–60

Atypical PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis) in a young girl with Fanconi anemia. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):159–61

Acute orchitis in recurrent polyserositis. Moskovitz B, et al. **J Pediatr Surg** 1995 Oct;30(10):1517–8

[Hyperimmunoglobulinemia D or periodic fever syndrome. Cutaneous manifestations in 3 cases] Cartier H, et al. **Ann Dermatol Venereol** 1996;123(5):314–21 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

A 38-year-old man with nephrotic syndrome, episodic fever and abdominal pain [clinical conference] Gadallah MF, et al. **J La State Med Soc** 1995 Nov;147(11):493–9

Familial Mediterranean fever: underlying defect clearer, but diagnostic problems persist. Cook GC. **Lancet** 1996 Jun 29;347(9018):1779–80

Familial Mediterranean fever [letter] McDermott EM, et al. **Lancet** 1996 Aug 24;348(9026):554–5

Familial Mediterranean fever [letter] Matzner Y. **Lancet** 1996 Aug 24;348(9026):554; discussion 555

Induced TNF production in vitro as a test for familial Mediterranean fever. Schattner A, et al. **QJM** 1996 Mar; 89(3):205–10

DRUG THERAPY

Efficacy of colchicine in familial Mediterranean fever is well established [letter] Drenth JP. **BMJ** 1996 Jul 27; 313(7051):233

Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Fradkin A, et al. **Isr J Med Sci** 1995 Oct;31(10):616–20

[Colchicine in familial Mediterranean fever: practical problems and their solutions] Ben-Chetrit E, et al. **Harefuah** 1995 Nov 15;129(10):413–6 (31 ref.) **(Heb)**

ETIOLOGY

Evidence of oxidative stress in erythrocyte phospholipid composition in the pathogenesis of familial Mediterranean fever (periodical disease). Karaguezyan KG, et al. **J Clin Pathol** 1996 Jun;49(6):453–5

GENETICS

The gene for familial Mediterranean fever is mapped to 16p 13.3- p13.1 with evidence for homogeneity. Shohat M, et al. **Adv Exp Med Biol** 1995;371B:901–3

Localization of the familial Mediterranean fever gene (FMF) to a 250-kb interval in non-Ashkenazi Jewish founder haplotypes. The French FMF Consortium. **Am J Hum Genet** 1996 Sep;59(3):603–12

Linkage disequilibrium mapping places the gene causing familial Mediterranean fever close to D16S246. Levy EN, et al. **Am J Hum Genet** 1996 Mar;58(3):523–34

METABOLISM

Colchicine in breast milk of patients with familial Mediterranean fever. Ben-Chetrit E, et al. **Arthritis Rheum** 1996 Jul;39(7):1213–7

PATHOLOGY

Photo quiz. Familial Mediterranean fever (FMF). Jones SR. **Clin Infect Dis** 1995 Jun;20(6):1491, 1547

VIROLOGY

Human foamy virus and familial Mediterranean fever in Japan [letter] Tamura N, et al. **JAMA** 1995 Nov 15;274(19):1509

PERIODICALS

Journal club [letter] Singletary EM, et al. **Acad Emerg Med** 1995 Jun;2(6):570–3

The Royal Society for Surgery [editorial] Van de Stadt J, et al. **Acta Chir Belg** 1996 Apr;96(2):49–50

Ethics and journal publishing: taking the debate forward. Ethics as everyone's business [letter] Chowdhury AN. **Addiction** 1995 Oct;90(10):1318–20

Ethics and journal publishing: taking the debate forward. The sensible way forward [letter] Saxena S. **Addiction** 1995 Oct;90(10):1312–3

Ethics and journal publishing: taking the debate forward. A committee for scientific dishonesty—the way forward? [letter] Wells F. **Addiction** 1995 Oct;90(10):1316–7

Journal broadens awareness, reinforces nurse's beliefs [letter] Meehan MW. **Altern Ther Health Med** 1996 Sep;2(5):14, 15

Dispelling the myths of publishing [editorial] Dracup K, et al. **Am J Crit Care** 1996 May;5(3):170–2

Janus in the catbird seat: in defense of the editorial [editorial] Joel LA. **Am J Nurs** 1995 Oct;95(10):7

Authors interactive: AJO on the Internet [editorial] Straatsma

BR. **Am J Ophthalmol** 1995 Oct;120(4):523–4
Ten rules for reading clinical research reports [editorial] Yancey JM. **Am J Orthod Dentofacial Orthop** 1996 May; 109(5):558–64
Tobacco information in two grade school newsweeklies: a content analysis. Balbach ED, et al. **Am J Public Health** 1995 Dec;85(12):1650–3
The winds of change [editorial] Leach RE. **Am J Sports Med** 1996 May–Jun;24(3):257
Should renaming the specialty begin with the Journal? [letter; comment] McLoughlin TM Jr. **Anesthesiology** 1995 Nov; 83(5):1132–3. Comment on: Anesthesiology 1995 Jul;83(1):191–7.
Chart reviews in emergency medicine research: Where are the methods? Gilbert EH, et al. **Ann Emerg Med** 1996 Mar; 27(3):305–8
State of the journal. Waeckerle JF, et al. **Ann Emerg Med** 1996 Jan;27(1):73–4
Annals now and then [editorial] Davidoff F. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):67–8
Structured abstracts: still more [letter] Kulkarni H. **Ann Intern Med** 1996 Apr 1;124(7):695–6
Reading for the CSiG examination: a survey of current journals. Chesser TJ, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4 Suppl):184–6
Duplicate publication wastes readers' time, clutters the literature, violates copyright law, and delays publication of timely articles [editorial] Giordano BP. **AORN J** 1995 Aug;62(2):159–62
Books, books, books [letter] Lempert P. **Arch Ophthalmol** 1995 Dec;113(12):1582
ARCHIVES supports child abuse [letter] Kwasman A. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):443–4
Managed care in JAMA and the Archives journals. A call for papers for coordinated theme issues [editorial] Lundberg GD. **Arch Surg** 1995 Nov;130(11):1155
Professional development points and the GP [editorial] Clearihan L. **Aust Fam Physician** 1996 Jan;25(1):11
Words on numbers [comment] Ludbrook J. **Aust Vet J** 1995 Sep;72(9):321. Comment on: Aust Vet J 1995 Sep;72(9):322–8.
Assessment of statistical procedures used in papers in the Australian Veterinary Journal [see comments] McCance I. **Aust Vet J** 1995 Sep;72(9):322–8. Comment in: Aust Vet J 1995 Sep;72(9):321.
A formal discussion of the archival journal requirements for data deposition [letter] Baker EN, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):976–7
Polythenia gravis: the downside of evidence based medicine. Down End Research Group. **BMJ** 1995 Dec 23–30; 311(7021):1666–8
Launching the Nigerian edition of the BMJ: implications for Nigeria's health care. Ana J. **BMJ** 1996 Jul 13; 313(7049):105–6
Redesigning the journal: having your say. Delamothe T, et al. **BMJ** 1996 Jan 27;312(7025):232–4
How can impact factors be improved? Garfield E. **BMJ** 1996 Aug 17;313(7054):411–3
Biomedical journals not dead yet. Whimsical titles are deeply unhelpful [letter; comment] Kerr JR. **BMJ** 1995 Sep 30; 311(7009):879. Comment on: BMJ 1995 May 27;310(6991):1343–4.
BMJ should declare its own conflict of interest [letter] Mabin DC. **BMJ** 1995 Sep 30;311(7009):878–9
Evidence-Based Medicine. Commentaries should be evidence based too [letter] [see comments] Pearson NJ, et al. **BMJ** 1996 Feb 10;312(7027):380. Comment in: BMJ 1996 Jun 22;312(7046):1610; discussion 1611. Comment in: BMJ 1996 Jun 22;312(7046):1611.
Biomedical journals not dead yet. Electronic publications are hard to access [letter; comment] Quinn SE, et al. **BMJ** 1995 Sep 30;311(7009):879. Comment on: BMJ 1995 May 27;310(6991):1343–4. Comment on: BMJ 1995 May 27;310(6991):1387–90. Comment on: BMJ 1995 Jun 10;310(6993):1480–1.
US journals veto tobacco funded research [news] Rutter T. **BMJ** 1996 Jan 6;312(7022):11
Audit of reports of randomised clinical trials published in one journal over 45 years [see comments] van der Wijden CL, et al. **BMJ** 1995 Oct 7;311(7010):918. Comment in: BMJ 1996 Feb 10;312(7027):378–9.
Impact factors in anaesthesia journals [editorial] Smith G. **Br J Anaesth** 1996 Jun;76(6):753–4
The 11th World Congress of Anaesthesiology [editorial] Smith G. **Br J Anaesth** 1996 Apr;76(4):479–80
Randomised trials and the British Journal of Obstetrics and Gynaecology. Minimum requirements for publication. Grant JM. **Br J Obstet Gynaecol** 1995 Nov;102(11):849–50
The future of surgical journals in the electronic publishing era [editorial] Young AE. **Br J Surg** 1996 Mar;83(3):289–90
Experimental and clinical research: future directions in neuropsychology in general and Brain and Cognition in particular. Whitaker HA. **Brain Cogn** 1995 Aug;28(3):225–6
Systematization of academic and scientific affiliation, or how to prevent data on your publications from being lost in the national and international data base. Meneghini R. **Braz J Med Biol Res** 1995 Jun;28(6):617–9
Thoughts on cooperation among biomedical libraries in Genoa, Italy. Ugolini D, et al. **Bull Med Libr Assoc** 1995 Jul;83(3):357–9
A French voice in family medicine research [editorial] Leduc CP. **Can Fam Physician** 1995 Aug;41:1279, 1284–5 **(Eng, Fre)**
Family medicine research [editorial] Reid T. **Can Fam Physician** 1995 Aug;41:1277–9, 1282–4 **(Eng, Fre)**
Authorship in anaesthesia journals [letter] Gajraj NM, et al. **Can J Anaesth** 1995 Aug;42(8):749–50
Citation errors—there is still much to be done [letter] Vickers MD. **Can J Anaesth** 1995 Nov;42(11):1063
What's in a name? [letter] Raine CS. **Can J Neurol Sci** 1995 Aug;22(3):247
Re: Reviewers of manuscripts submitted to The Canadian Journal of Psychiatry [letter] Oyewumi LK. **Can J Psychiatry** 1995 Sep;40(7):427–8
Violence sells [letter] Soltan HC. **Can Med Assoc J** 1996 Mar 15;154(6):756, 758
About copyright and copywrong [editorial] Wegmann J. **Cell Mol Biol (Noisy-le-grand)** 1995 Sep;41(6):iii–v
The effects of a health newsletter for foster parents on their perceptions of the behavior and development of foster children. Rich H. **Child Abuse Negl** 1996 May;20(5):437–45
Publication and proprietary information. Reidenberg MM. **Clin Pharmacol Ther** 1996 Apr;59(4):367–8
A review of the statistical analysis used in papers published in Clinical Radiology and British Journal of Radiology. Goldin J, et al. **Clin Radiol** 1996 Jan;51(1):47–50 (33 ref.)
Computers in nursing interactive. Nicoll LH. **Comput Nurs** 1995 Nov–Dec;13(6):255–6
The impact factor of Dermatology [editorial] Saurat JH. **Dermatology** 1995;191(4):362
Diabetic medicine: the southbound migration continues [editorial] Boulton AJ. **Diabet Med** 1996 Jan;13(1):7–8
Diabetes, diabetes, and the American Diabetes Association [editorial] Cryer PE. **Diabetes** 1995 Dec;44(12):1351–4
Diabetes and the Internet [editorial] LaPorte RE, et al. **Diabetes Care** 1995 Jun;18(6):890–5
Publish and flourish: seasonal advice to our readers [editorial] Halban P. **Diabetologia** 1995 Dec;38(12):1375–7
The European Journal of Surgery—present situation and future strategy [editorial] Lennquist S. **Eur J Surg** 1995 Aug;161(8):543–4
Beyond the scalpel—concepts, methods, and structures for reporting surgical results [editorial] Troidl H, et al. **Eur J Surg** 1995 Aug;161(8):544
Critical reading using the READER acronym at an international workshop. MacAuley D. **Fam Pract** 1996 Feb; 13(1):104–5
Style and substance in Gastrointestinal Endoscopy [editorial] Lightdale CJ. **Gastrointest Endosc** 1995 Dec;42(6):594–6
Are guidelines for peer–reviewing economic evaluations necessary? A survey of current editorial practice. Jefferson T, et al. **Health Econ** 1995 Sep–Oct;4(5):383–8
Interest in electronic distribution of health physics [editorial] Miller KL. **Health Phys** 1996 Jun;70(6):771–2
Redundant publication in hepatology [letter] Yamauchi M, et al. **Hepatology** 1996 Jul;24(1):282
Research and resources. Show and tell. Montague J. **Hosp Health Netw** 1996 Sep 5;70(17):70
Journal and publishing characteristics for 42 nursing publications outside the United States. McConnell EA. **Image J Nurs Sch** 1995 Fall;27(3):225–9
About those abstract translations [editorial] Laney WR. **Int J Oral Maxillofac Implants** 1996 Mar–Apr;11(2):145
The conceptualisation and communication of clinical facts: a consideration of the 75th anniversary edition IJPA. Roiphe J. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1179–90
Creating a knowledge base of biological research papers. Hafner CD, et al. **Ismb** 1994;2:147–55
Trends in photoprotection in American fashion magazines, 1983–1993. will fashion make you look old and ugly? George PM, et al. **J Am Acad Dermatol** 1996 Mar; 34(3):424–8
Reading and writing biological literature. Prerequisites to research. Nagle JJ. **J Am Podiatr Med Assoc** 1995 Aug; 85(8):447–57
What do food animal practitioners want to read? Herrick JB. **J Am Vet Med Assoc** 1996 Jan 15;208(2):196–7
Recommendation for disclosure of financial interests [letter] Miller PE, et al. **J Am Vet Med Assoc** 1996 Apr 15; 208(8):1227
Perceived barriers to getting published: results of the JANAC survey. Meisenhelder JB, et al. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):57–62
Use of kappa statistic in determining validity of quality filtering for meta–analysis: a case study of the health effects of electromagnetic radiation. Sands ML, et al. **J Clin Epidemiol** 1996 Sep;49(9):1045–51
The times they are still a'changing: keeping up with the times [editorial] Varki AP. **J Clin Invest** 1996 Jan 1;97(1):1
The completeness of MEDLINE for papers published and abstracted in the Journal of Emergency Medicine. Vilke GM, et al. **J Emerg Med** 1995 Jul–Aug;13(4):457–60
Mismedicating the elderly—says who? [editorial] [see comments] Miller AE Jr. **J Fam Pract** 1995 Oct;41(4):331–6 . Comment in: J Fam Pract 1996 Apr;42(4):341–2.
A family practice article filing system. Reynolds RD. **J Fam Pract** 1995 Dec;41(6):583–90
Policies, practices, and attitudes of North American medical journal editors [see comments] Wilkes MS, et al. **J Gen Intern Med** 1995 Aug;10(8):443–50. Comment in: J Gen Intern Med 1995 Aug;10(8):474–5.
Health-related messages in consumer magazine advertising. Wofford JL, et al. **J Gen Intern Med** 1995 Sep;10(9):488–90
The dissemination of false data through inadequate citation [letter; comment] Jolobe OM. **J Intern Med** 1996 May; 239(5):461. Comment on: J Intern Med 1995 Nov;238(5):445–50.
Journal of medical screening [editorial] Wald NJ. **J Med Screen** 1994 Jan;1(1):1–2
The Journal of Neuroradiology [editorial] Picard L. **J Neuroradiol** 1995 Dec;22(4):235–6
Case reports in pediatric psychology: uses and guidelines for authors and reviewers. Drotar D, et al. **J Pediatr Psychol** 1995 Oct;20(5):549–65
New features of the Journal of Periodontology [editorial] Genco RJ. **J Periodontol** 1996 Jan;67(1):63
Brief Communications feature in the Journal of Public Health Dentistry [letter] Joshi A. **J Public Health Dent** 1995 Fall; 55(4):196
The pursuit of research publications [editorial] Payne JN, et al. **J Public Health Med** 1995 Sep;17(3):251–3
Medical textbooks and journals for Afghanistan? A visiting doctor's perspective [editorial] Pilszek FH. **J R Soc Med** 1996 Mar;89(3):121–2
The clinical section—a special case for case reports [editorial] Senapati A. **J R Soc Med** 1996 Feb;89(2):95P
Multiple authorship: trends over 50 years in the Journal of Studies on Alcohol [letter] Howard MO, et al. **J Stud Alcohol** 1996 Jan;57(1):105–6
Growth and development [editorial] Bradley D. **J Trop Med Hyg** 1995 Oct;98(5):1
Users' guides to the medical literature. XI. How to use an article about a clinical utilization review. Evidence-Based Medicine Working Group. Naylor CD, et al. **JAMA** 1996 May 8;275(18):1435–9
The Ingelfinger rule, embargoes, and journal peer review—part 2 [see comments] Altman LK. **Lancet** 1996 May 25;347(9013):1459–63. Comment in: Lancet 1996 May 25;347(9013):1423–4. Comment in: Lancet 1996 Jul 13;348(9020):132. Comment in: Lancet 1996 Jul 13;348(9020):132–3.
Will today be the day YOU hear from "J"? [letter] Booy R, et al. **Lancet** 1996 Jun 15;347(9016):1706
Impact factor as the best operational measure of medical journals [letter; comment] Brody S. **Lancet** 1995 Nov 11; 346(8985):1300–1. Comment on: Lancet 1995 Sep 30;346(8979):906.
The Ingelfinger rule [letter; comment] Dugdale A. **Lancet** 1996 Jul 13;348(9020):132. Comment on: Lancet 1996 May 18;347(9012):1382–6. Comment on: Lancet 1996 May 25;347(9013):1423–4. Comment on: Lancet 1996 May 25;347(9013):1459–63.
Impact factor as the best operational measure of medical journals [letter; comment] Foster WR. **Lancet** 1995 Nov 11;346(8985):1301. Comment on: Lancet 1995 Sep 30;346(8979):906.
In which direction The Lancet? [letter; comment] Freeman AG. **Lancet** 1996 Feb 24;347(9000):545. Comment on: Lancet 1996 Jan 6;347(8993):6.
Impact factor as a misleading tool in evaluation of medical journals [letter] [see comments] Hansson S. **Lancet** 1995 Sep 30;346(8979):906. Comment in: Lancet 1995 Nov 11;346(8985):1300–1. Comment in: Lancet 1995 Nov 11;346(8985):1301.
Influence of misleading publications on general practitioners and purchasers [letter] Hattersley AT. **Lancet** 1996 Aug 3;348(9023):343–4
Evidence-based medicine [letter; comment] Haynes B. **Lancet** 1995 Oct 28;346(8983):1171. Comment on: Lancet 1995 Sep 23;346(8978):785.
A physician's life [see comments] Horton R. **Lancet** 1996 Jan 6;347(8993):6. Comment in: Lancet 1996 Feb 24;347(9000):545. Comment in: Lancet 1996 Mar 2;347(9001):620.
Poor recall performance of journal–browsing doctors [letter] Kellett CF, et al. **Lancet** 1996 Aug 17;348(9025):479
The message, the medium, and The Lancet. McConnell J, et al. **Lancet** 1996 Jul 13;348(9020):74
Read before you cite. Steel CM. **Lancet** 1996 Jul 20; 348(9021):144
The Ingelfinger rule [letter; comment] Weissel M. **Lancet** 1996 Jul 13;348(9020):132. Comment on: Lancet 1996 May 18;347(9012):1382–6. Comment on: Lancet 1996 May 25;347(9013):1459–63.
Sources in science: who can we trust? [see comments] Wilkie T. **Lancet** 1996 May 11;347(9011):1308–11. Comment in: Lancet 1996 Jul 6;348(9019):62. Comment in: Lancet 1996 Jul 27;348(9022):270.
New visage for the "old reliable" [editorial] Prakash UB. **Mayo Clin Proc** 1996 Jan;71(1):106–7
The use of student journals in problem–based learning. Wetherell J, et al. **Med Educ** 1996 Mar;30(2):105–11
Enter the Web: an experiment in electronic research peer review [editorial] Bingham C, et al. **Med J Aust** 1996 Jan 1;164(1):8–9
Videotape quality [letter] Kaufman DM. **Mov Disord** 1995 Nov;10(6):803–4
Citation policy on sequences [letter] Dowton M. **Nature** 1996 Jun 13;381(6583):550
Nature on the Internet (at last)! [news] Maddox J. **Nature** 1995 Oct 12;377(6549):475
Valediction from an old hand [editorial] [see comments] Maddox J. **Nature** 1995 Dec 7;378(6557):521–3. Comment in: Nature 1996 Jan 25;379(6563):292. Comment in: Nature 1996 Jan 25;379(6563):293. Comment in: Nature 1996 Jun 6;381(6582):467.

Impact factors can mislead [letter] Moed HF, et al. **Nature** 1996 May 16;381(6579):186

Impact factors of Russian journals [letter] Sorokin NI. **Nature** 1996 Apr 18;380(6575):578

Drug company links test journal's policy [news] Wadman M. **Nature** 1996 Sep 5;383(6595):6

Editorials in scientific publications [letter; comment] Feasby TE. **Neurology** 1996 Mar;46(3):883. Comment on: Neurology 1995 Jul;45(7):1245–7.

Selected list of nursing books and journals. Brandon AN, et al. **Nurs Outlook** 1996 Mar–Apr;44(2):56–66

Mirror, mirror [editorial] Carroll-Johnson RM. **Oncol Nurs Forum** 1996 Apr;23(3):417

Finding good in a year of concerns [editorial] Mills JW. **Pa Med** 1995 Dec;98(12):6

PACE and advances in computing and electronic technology [editorial] Malik M, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):107–8

Three cardiology journals on CD-ROM. Mercando AD. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2088–93

Accuracy of references in Paediatric Anaesthesia [letter] Nishina K, et al. **Paediatr Anaesth** 1995;5(2):142

What is our impact? [editorial] Gorska B, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):199–200

Retrieving research studies: a comparison of bibliographic and full-text versions of the New England Journal of Medicine. Johnson ED, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:846–50

Pointillism and science [editorial] Dimsdale JE. **Psychosom Med** 1996 Jan–Feb;58(1):1

RSNA EJ: a supplement to RadioGraphics and a new venture in radiologic publishing [editorial] Ackerman LV, et al. **Radiology** 1996 Jan;198(1):13

The RSNA Electronic Journal: RSNA EJ. Ferris EJ, et al. **Radiology** 1996 Jan;198(1):32

Type of statistical techniques in rheumatology and internal medicine journals. Cardiel MH, et al. **Rev Invest Clin** 1995 May–Jun;47(3):197–201

Editing a scientific journal on communication disorders in South Africa: a unique challenge. Louw B. **S Afr J Commun Disord** 1994;41:103–7

Tobacco advertising in South Africa with specific reference to magazines. Yach D, et al. **S Afr Med J** 1994 Dec; 84(12):838–41

On prevalence and incidence [editorial] Herman J. **Scand J Prim Health Care** 1995 Sep;13(3):161–2

Electronic publishing [letter; comment] Boatright JH, et al. **Science** 1995 Oct 13;270(5234):217–8. Comment on: Science 1995 Aug 4;269(5224):615.

Faltering press embargo? [letter; comment] Campbell EW Jr. **Science** 1995 Oct 6;270(5233):13. Comment on: Science 1995 Aug 4;269(5224):627.

Electronic publishing [letter; comment] [published erratum appears in Science 1995 Nov 3;270(5237):721] Goldie P. **Science** 1995 Oct 13;270(5234):218–9. Comment on: Science 1995 Aug 4;269(5224):615.

Faltering press embargo? [letter; comment] Kleinman J. **Science** 1995 Oct 6;270(5233):13. Comment on: Science 1995 Aug 4;269(5224):627.

Electronic publishing [letter; comment] Simoni RD. **Science** 1995 Oct 13;270(5234):218. Comment on: Science 1995 Aug 4;269(5224):615.

Science journals go wired [news] Taubes G. **Science** 1996 Feb 9;271(5250):764–6

Electronic preprints point the way to 'author empowerment' [news] Taubes G. **Science** 1996 Feb 9;271(5250):767–8

Faltering press embargo? [letter; comment] Whiting S. **Science** 1995 Oct 6;270(5233):13. Comment on: Science 1995 Aug 4;269(5224):627.

Setting the agenda: does the medical literature set the agenda for articles about medicines in the newspapers? van Trigt AM, et al. **Soc Sci Med** 1995 Sep;41(6):893–9

Publication world and world publications [editorial] Slavin KV. **Surg Neurol** 1995 Jul;44(1):90

Where is smoking research published? Liguori A, et al. **Tob Control** 1996 Spring;5(1):37–8

Change and continuity in tropical medical science and international health [editorial] Bradley D. **Trop Med Int Health** 1996 Feb;1(1):1–2

Publication potential in pediatrics in Turkey. Tinaztepe K. **Turk J Pediatr** 1996 Apr–Jun;38(2):205–16

[Journal selection for Index Medicus/Medline] Petrálek J. **Cas Lek Cesk** 1996 Mar 20;135(6):186–7 **(Cze)**

[A new Nordisk Medicin (editorial)] Kristensen BR, et al. **Nord Med** 1996 Jan;111(1):2 **(Dan)**

[Science and practice—thoughts when changing editors (editorial)] Højgaard L. **Ugeskr Laeger** 1996 Jul 1; 158(27):3905 **(Dan)**

[Responsibility of the Ugeskrift for quality research (letter)] Jensen JG. **Ugeskr Laeger** 1995 Oct 16;157(42):5867 **(Dan)**

[Ugeskrift and the readers (editorial)] Krag E, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):11 **(Dan)**

[Belle époque? (editorial)] Dunning AJ. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2705–6 **(Dut)**

[Medical language based on literature references of original articles in the Nederlands Tijdschrift voor Geneeskunde (1930–1995)] Navarro FA. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1263–7 (Eng. Abstr.) **(Dut)**

[Internet, telemedicine and electronic information services by the Nederlands Tijdschrift voor Geneeskunde] Overbeke AJ. **Ned Tijdschr Geneeskd** 1996 Jan 6; 140(1):11–2 **(Dut)**

[On nostalgia and humility (editorial)] van Gijn J. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):1 **(Dut)**

[Referee system in scientific journals (letter)] Hynynen M. **Duodecim** 1994;110(5):523 **(Fin)**

[Rewarded articles in 1994: from hepatitis in hemophiliacs to infertility] Sariola H. **Duodecim** 1994;110(23–24):2191–2 **(Fin)**

[Redaction of medical articles (editorial)] Petit JY. **Ann Chir Plast Esthet** 1996 Feb;41(1):7–10 **(Fre)**

[The impact factor: "audimat", a valuable quality indicator for scientific journals? (editorial)] **Ann Fr Anesth Reanim** 1995;14(3):247–8 **(Fre)**

[Numerical expression of results] Riou B, et al. **Ann Fr Anesth Reanim** 1996;15(1):49–56 **(Fre)**

[Profile of biostatistics utilization in three medical reviews. Implications for medical education] Gagnon RJ, et al. **Can Fam Physician** 1996 May;42:888–94 (Eng. Abstr.) **(Fre)**

[Tropical medicine and the French language (editorial)] Bourgeade A. **Med Trop (Mars)** 1995;55(4):329–30 **(Fre)**

[Bibliometry of biomedical periodicals. Addendum] Similowski T, et al. **Rev Mal Respir** 1996;13(2):197–8 **(Fre)**

[Bibliometry of biomedical periodicals] Similowski T, et al. **Rev Mal Respir** 1995;12(6):543–50 (32 ref.) (Eng. Abstr.) **(Fre)**

[German clinical journals and the impact factor (editorial)] Herfarth C, et al. **Chirurg** 1996 Apr;67(4):297–9 **(Ger)**

[Check list for publications on drug treatment studies] Selbmann HK. **Fortschr Med** 1996 Apr 10;114(10):123–4 **(Ger)**

[Writing and reading scientific texts] Kuss E, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):414–24 (85 ref.) **(Ger)**

[Report of experiences with rapid reading] Paulini K. **Pathologe** 1996 Jan;17(1):105–6 **(Ger)**

[In which specialty periodicals have current faculty chair/specialty representatives for psychosomatic medicine and psychotherapy published? (editorial)] Kächele H. **Psychother Psychosom Med Psychol** 1996 May;46(5):157 **(Ger)**

[On our own account: the impact factor (editorial)] Sauer R. **Strahlenther Onkol** 1995 Sep;171(9):487–9 **(Ger)**

[How to write a scientific article] Frick T. **Swiss Surg** 1995; (1):5–6 **(Ger)**

[English—lingua franca of science: will German as the language of medicine disappear? (editorial)] Druml W. **Wien Klin Wochenschr** 1996;108(12):341–2 **(Ger)**

[The impact factor as an evaluation principle for medical periodicals] Hitzenberger G. **Wien Med Wochenschr** 1995; 145(24):668–9 **(Ger)**

[Medical history in the journal Orvosi Hetilap] Hidvégi J. **Orv Hetil** 1995 Oct 1;136(40):2177–80 **(Hun)**

[The level of use of statistical data in articles in the Orvosi Hetilap] Vitrai J, et al. **Orv Hetil** 1996 Mar 3;137(9):465–72 (46 ref.) (Eng. Abstr.) **(Hun)**

[Annali Italiani di medicina interna: present and future (editorial)] Mannucci PM. **Ann Ital Med Int** 1995 Oct–Dec; 10(4):213–4 **(Ita)**

[Knowing how to read a scientific article. 4. Knowing how to apply a diagnostic test] Coggiola M, et al. **G Ital Cardiol** 1995 Sep;25(9):1211–22 **(Ita)**

[Knowing how to read a scientific article. 3. Knowing how to assess the natural history of a disease] Longo M, et al. **G Ital Cardiol** 1995 Aug;25(8):1067–75 (30 ref.) **(Ita)**

[Role of editor's activities in the professional training] Cittadini G. **Radiol Med (Torino)** 1995 Nov;90(5):580–2 **(Ita)**

["I have read about the dinosaur". How does the Italian physician keep up with the times?] Bausano G. **Recenti Prog Med** 1995 Oct;86(10):375–7 **(Ita)**

[The Italian Cochrane Center and finding randomized clinical trials published in Italian journals: a European project] Pistotti V, et al. **Recenti Prog Med** 1996 Jan;87(1):2–3 **(Ita)**

[Literature lists—authorship (letter)] Lystad A. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3182 **(Nor)**

[Place of "Ukrainskogo biokhimicheskogo zhurnal" (Ukrainian Biochemical Journal) in the world information flow in the field of biochemistry] Donchenko GV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):113–9 (Eng. Abstr.) **(Rus)**

[Literature cited in a study of Yugoslav biomedical journals] Brkić S, et al. **Med Pregl** 1995;48(7–8):268–71 (Eng. Abstr.) **(Scr)**

[ACTA: a name, three passions, forty years] Alarcón RD. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):271–2 **(Spa)**

[One more voice] Leòn CA. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):272–3 **(Spa)**

[Number of authors in Actas Urológicas Españolas] Fariña LA. **Actas Urol Esp** 1996 Feb;20(2):194–8 (Eng. Abstr.) **(Spa)**

[The impact of our journals] Alvarez-Sala JL, et al. **Arch Bronconeumol** 1995 Oct;31(8):403–6 (19 ref.) **(Spa)**

[Analysis of information sources in the journal, Atencion Primaria] Aleixandre R, et al. **Aten Primaria** 1996 Mar 31; 17(5):321–5 (Eng. Abstr.) **(Spa)**

[Ten years of the journal Atención Primaria (1984–1993): a bbibliometric and subject analysis] Aleixandre R, et al. **Aten Primaria** 1996 Feb 29;17(3):225–30 **(Spa)**

[Influence of the journal Atención Primaria on family medicine in Mexico (letter)] Irigoyen Coria A, et al. **Aten Primaria** 1996 Apr 30;17(7):480 **(Spa)**

[Drug advertising in medical journals] Madridejos R, et al. **Aten Primaria** 1996 Apr 15;17(6):408–10 (Eng. Abstr.) **(Spa)**

[Discrepancies in primary care text (letter)] Rodríguez Moreno C, et al. **Aten Primaria** 1996 Apr 15;17(6):426–7 **(Spa)**

[Influence of PAHO publications on the scientific health production in Latin America and the Caribbean] Cruz A. **Bol Oficina Sanit Panam** 1995 Dec;119(6):515–28 **(Spa)**

[Evaluation of Mexican biomedical journals] Awad R, et al. **Gac Med Mex** 1995 Mar–Apr;131(2):205–11 (Eng. Abstr.) **(Spa)**

[Conclusions of the Fair of the Medical Book Committee] Morales-Polanco MR. **Gac Med Mex** 1995 Sep–Dec; 131(5–6):609–11 **(Spa)**

[Search strategies for retrieval of articles in Spanish journals. A case study: evaluation of the quality of information systems] Abad García MF, et al. **Gac Sanit** 1995 Nov–Dec; 9(51):363–70 (Eng. Abstr.) **(Spa)**

[Gaceta Sanitaria 1993–94: balance and perspectives (letter)] Rodríguez Artalejo F. **Gac Sanit** 1995 May–Jun;9(48):155–8 **(Spa)**

[Gaceta Sanitaria (letter; comment)] Tormo MJ, et al. **Gac Sanit** 1995 May–Jun;9(48):210–2. Comment on: Gac Sanit 1994 Nov–Dec;8(45):266–9. Comment on: Gac Sanit 1994 Nov–Dec;8(45):270–1. **(Spa)**

[Analysis of information consumption in the Gastroenterología y Hepatología journal] Aleixandre Benavent R, et al. **Gastroenterol Hepatol** 1995 Oct; 18(8):437–43 **(Spa)**

[Farewell (editorial)] Lience E. **Med Clin (Barc)** 1995 Dec 8;105(20):780 **(Spa)**

[Current use of statistics in biomedical research: a comparison of general medicine journals] Mora Ripoll R, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):451–6 (Eng. Abstr.) **(Spa)**

[Translation of titles into English in Medicina Clínica: quality and influence of the Spanish language] Navarro FA, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):298–303 (Eng. Abstr.) **(Spa)**

[Road to 2000 (editorial)] Rozman C, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):19–20 **(Spa)**

[The review Nutrición Hospitalaria included in Index Medicus and Medline (editorial)] Culebras JM, et al. **Nutr Hosp** 1991 May–Jun;6(3):141–2 **(Spa)**

["Nutrición Hospitalaria, scientific vehicle for all (editorial)] Culebras JM, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):245 **(Spa)**

[Guideline for the selection of articles (editorial)] Pérez Martín J. **Rev Alerg Mex** 1995 May–Jun;42(3):38–40 **(Spa)**

[New momentum for the journal (editorial)] López Timoneda F. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):249 **(Spa)**

[Comparison of instructions to authors of Mexican medical journals and the Vancouver requirements] Sosa-de-Martínez MC, et al. **Rev Invest Clin** 1995 May–Jun;47(3):203–10 (Eng. Abstr.) **(Spa)**

[Citations and medical journals in Spanish] Matías-Guiu J. **Rev Neurol** 1996 Aug;24(132):904–6 **(Spa)**

[Abstracts in medical journals in Spanish] Matías-Guiu J. **Rev Neurol** 1996 Jun;24(130):625–7 **(Spa)**

[Peer review in medical journals] Matías-Guiu J. **Rev Neurol** 1996 Jul;24(131):765–6 **(Spa)**

[Scientific journals in Spanish (editorial)] Matías-Guiu J. **Rev Neurol** 1996 May;24(129):506 **(Spa)**

[Opinion about the special issue, "Ten years of AIDS in Mexico" (letter)] Gómez Alcalá AV. **Salud Publica Mex** 1996 May–Jun;38(3):153–4 **(Spa)**

[Coverage of Mexican articles and journals in the database Bibliomex Salud] Loría A, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):41–6 (Eng. Abstr.) **(Spa)**

[A year of redefinitions at the National Institute of Public Health (editorial)] Sepúlveda J. **Salud Publica Mex** 1996 Mar–Apr;38(2):85–6 **(Spa)**

[A Chinese edition of Scandinavian medical journals] Drettner B, et al. **Lakartidningen** 1996 Feb 14;93(7):596 **(Swe)**

[Chubby women absolutely do not sell] Leander G. **Lakartidningen** 1996 Apr 24;93(17):1632–3 **(Swe)**

ECONOMICS

Ordering out for a pharmacy newsletter. Scoggin JA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):362, 364

BMJ should review its policy on reprints [letter] [see comments] Cummins D, et al. **BMJ** 1995 Oct 28; 311(7013):1169. Comment in: BMJ 1996 Feb 10;312(7027):381.

Notion of "virtual library" developing as medical schools cope with rising journal costs. Birenbaum R. **Can Med Assoc J** 1996 Apr 15;154(8):1261–3

The fall of the house of medicine? [editorial] Neelon FA. **N C Med J** 1995 Dec;56(12):600–1

HISTORY

Swedish radiology as reflected in Acta Radiologica 1921–96.

Boijsen E. **Acta Radiol** 1996 May;37(3 Pt 2):412–40
Radiation physics in Acta Radiologica. Walstam R. **Acta Radiol** 1996 May;37(3 Pt 2):472–80
95th anniversary of the ARRS: history of the Journal editors. American Roentgen Ray Society. Hopper KD. **AJR Am J Roentgenol** 1995 Dec;165(6):1525–32
Changing of the guard at the American Journal of Roentgenology: the Robert Berk era revisited. Zagoria RJ, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):3–5
Historical development of the neurosciences in Mexico. An overview with particular reference to publications on neurosciences in Archives of Medical Research. Feria-Velasco A. **Arch Med Res** 1995;26 Spec No:S105–7
Archives of Medical Research: an historical and subject coverage overview. Lozoya X, et al. **Arch Med Res** 1995; 26 Spec No:S1–5
Centenary year of scientific papers in the British Dental Journal. Grace M. **Br Dent J** 1995 Dec 9–23; 179(11–12):436–7
Mightier than the sword. Martinez SA. **Ear Nose Throat J** 1996 Jan;75(1):25, 29–31
A content analysis of the professional journal of the British Society of Speech Therapists. I: The first 10 years. Spotlight on Speech' 1935–1945. Armstrong L, et al. **Eur J Disord Commun** 1996;31(2):91–105
The health care system, its doctors, patients, and illnesses [editorial] Oxman TE. **Int J Psychiatry Med** 1996;26(1):1–3
Petr Skrabanek and the Lancet. Fox R. **J Clin Epidemiol** 1996 Jun;49(6):607–8
50 years of publishing social and preventive medicine and epidemiology and community health [editorial] Donnan S. **J Epidemiol Community Health** 1996 Feb;50(1):1–2
September 1845 and 1895. Colon GA. **J La State Med Soc** 1995 Sep;147(9):399–404
October 1845 and 1895. Colon GA. **J La State Med Soc** 1995 Oct;147(10):439–42
November 1845 and 1895. Colon GA. **J La State Med Soc** 1995 Nov;147(11):508–11
'A journal of our own': the Medical and Surgical Observer at the beginnings of an African-American medical profession in late 19th-century America. Part one. Savitt TL. **J Natl Med Assoc** 1996 Jan;88(1):52–60
Twenty-five years old! [editorial] Alberti PW. **J Otolaryngol** 1996 Feb;25(1):1–4 **(Eng, Fre)**
Advertisements in The Laryngoscope. Arsenauro, 1901–1904. **Laryngoscope** 1996 Aug;106(8):928
Advertisements in the Laryngoscope. The merits of cocaine—1896. **Laryngoscope** 1996 Jun;106(6):680
What's all the fuss about?: The Laryngoscope pages cause an international incident. Bailey BJ. **Laryngoscope** 1996 Aug;106(8):925–7
Appreciating MSV's founders. Reflections on 19th century enigmas. Houck PW. **Va Med Q** 1995 Fall;122(4):240–2
[History of physiology journals] Hník P. **Cesk Fysiol** 1996 Mar;45(1):47–9 (Eng. Abstr.) **(Cze)**
[The journals Acta Veterinaria (Brno), Veterinární Medicína (Prague) and Czech veterinary sciencse 1960 to 1994] Holub A. **Vet Med (Praha)** 1996 Jun;41(6):197–200 **(Cze)**
[From Dunning to van Gijn] Bosman FT. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):5–6 **(Dut)**
[Farewell to Dunning] Overbeke AJ, et al. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2706–8 **(Dut)**
[110 years of Duodecim (editorial)] Jalanko H. **Duodecim** 1995;111(1):5–6 **(Fin)**
[125 years of Acta Psychiatrica Belgica. Bulletin of the Société Royale de Médecine Mentale de Belgique] Van Renynghe de Voxvrie G. **Acta Psychiatr Belg** 1995; 95(6):291–6 **(Fre)**
[50th anniversary... (editorial)] Kulbertus H. **Rev Med Liege** 1996 Jan;51(1):1–6 **(Fre)**
[From the Revue Neurologique to the Société de Neurologie: 1893–1899] Bonduelle M. **Rev Neurol (Paris)** 1995 May; 151(5):307–10 **(Fre)**
[Therapie 1946–1995: 50 years of publication (editorial)] Cheymol G. **Therapie** 1995 Jul–Aug;50(4):295–9 (Eng. Abstr.) **(Fre)**
[SMW 100 years ago. Swiss Medical Weekly (Correspondence paper for Swiss Physicians) 1896; 26:1–2. (classical article)] Haffter E, et al. **Schweiz Med Wochenschr** 1996 Jan 9;126(1–2):50–1 **(Ger)**
[The Wiener Klinische Wochenschrift from 1938 to 1945. On the 60th anniversary of its reappearance in 1946 (editorial)] Druml W. **Wien Klin Wochenschr** 1996; 108(13):381–4 **(Ger)**
[Bath Pages—in the service of balneology] Jobst A. **Orv Hetil** 1995 Sep 17;136(38):2064–7 **(Hun)**
[Fifty years of the journal Recent Advances in Medicine] **Recenti Prog Med** 1996 Jan;87(1):1 **(Ita)**
["Klinicheskaia Meditsina" is 75-year-old] Gembitskiĭ EV. **Klin Med (Mosk)** 1995;73(4):4–6 **(Rus)**
[The first surgical journal in Russia] Grinev MV, et al. **Vestn Khir Im I I Grek** 1995;154(2):7–8 **(Rus)**
[Actas Urológicas Españolas, history and spelling (letter)] Fariña LA. **Actas Urol Esp** 1996 Jan;20(1):85 **(Spa)**
[Periodic publications of the National Academy of Medicine in the 19th century] Rodríguez ME. **Gac Med Mex** 1995 Sep–Dec;131(5–6):577–83 **(Spa)**

LEGISLATION & JURISPRUDENCE

An interpretation of copyright law [editorial] England SL, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):401–2
How does the Texaco case affect photocopying by scientists? The National Conference of Lawyers and Scientists. **Science** 1995 Dec 1;270(5241):1450–1

STANDARDS

Ethics and journal publishing: taking the debate forward. Wanted? Standard operating procedures for journals [letter] Lock S. **Addiction** 1995 Oct;90(10):1313–5
The accuracy of references in journal articles [letter] Arrowsmith JE. **Anaesthesia** 1996 May;51(5):517–8
The accuracy of references in Anaesthesia. Asano M, et al. **Anaesthesia** 1995 Dec;50(12):1080–2
Medical journals and the science of peer review: raising the standard [editorial] Waeckerle JF, et al. **Ann Emerg Med** 1996 Jul;28(1):75–7
A study of some international medical journals aiming to elicit stylistic guidelines for writing publishable papers [editorial] Pragnell MV, et al. **Ann Ital Chir** 1996 Jan–Feb; 67(1):5–10
Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Bradley CA, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):681–9
The society journal [editorial; comment] Gillies M. **Aust N Z J Ophthalmol** 1996 Feb;24(1):1–2. Comment on: Aust N Z J Ophthalmol 1996 Feb;24(1):15–26.
Better reporting of randomised controlled trials: the CONSORT statement [editorial] Altman DG. **BMJ** 1996 Sep 7;313(7057):570–1
Behavioural toxicities of antidepressants [letter; comment] Kerr JS, et al. **Br J Psychiatry** 1995 Sep;167(3):413–4. Comment on: Br J Psychiatry 1995 Apr;166(4):421–3.
Time to apply pressure [letter] Bell W. **Can Fam Physician** 1996 May;42:850; 852
More than just a pretty face. Workings of the CFP Editorial Advisory Board [editorial] Manca DP. **Can Fam Physician** 1996 May;42:829–31; 837–9 **(Eng, Fre)**
The review process [editorial] Meakins JL. **Can J Surg** 1996 Jun;39(3):180 **(Eng, Fre)**
P-value in hypothesis testing and estimation: the need to standardize its reporting in the Central African Journal of Medicine [letter] Siziya S. **Cent Afr J Med** 1996 Feb; 42(2):60–1
Peer review and refereeing in science. Lore W. **East Afr Med J** 1995 May;72(5):335–7
Gut moves towards the 3rd millennium [editorial] Farthing M. **Gut** 1996 May;38(5):643
Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)
Provide fluoxetine information vital to clinicians [letter; comment] Cohen JS. **J Clin Psychiatry** 1995 Dec;56(12):591 . Comment on: J Clin Psychiatry 1994 Dec;55(12):517–22.
Paying attention to details [editorial; comment] Laskin DM. **J Oral Maxillofac Surg** 1996 Feb;54(2):133. Comment on: J Oral Maxillofac Surg 1996 Feb;54(2):200–2.
Do authors check their references? A survey of 500 references from the Journal of Oral and Maxillofacial Surgery [see comments] Orlin W, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):200–2. Comment in: J Oral Maxillofac Surg 1996 Feb;54(2):133.
Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. **JAMA** 1993 May 5;269(17):2282–6
Improving the quality of reporting of randomized controlled trials. The CONSORT statement [see comments] Begg C, et al. **JAMA** 1996 Aug 28;276(8):637–9. Comment in: JAMA 1996 Aug 28;276(8):649.
How to report randomized controlled trials. The CONSORT statement [editorial; comment] Rennie D. **JAMA** 1996 Aug 28;276(8):649. Comment on: JAMA 1996 Aug 28;276(8):637–9.
Ruling out Ingelfinger? [comment] [see comments] Horton R. **Lancet** 1996 May 25;347(9013):1423–4. Comment on: Lancet 1996 May 25;347(9013):1459–63. Comment in: Lancet 1996 Jul 13;348(9020):132. Comment in: Lancet 1996 Jul 13;348(9020):132–3. Comment in: Lancet 1996 Jul 13;348(9020):133.
Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews [see comments] Moher D, et al. **Lancet** 1996 Feb 10;347(8998):363–6. Comment in: Lancet 1996 Mar 30;347(9005):907–8.
Completeness of reporting of trials published in languages other than English [letter; comment] Sandford P. **Lancet** 1996 Mar 30;347(9005):907–8. Comment on: Lancet 1996 Feb 10;347(8998):363–6.
Request for standardised reporting of numerical ranges [letter] Schmid GP, et al. **Lancet** 1996 Feb 10;347(8998):401
Reinforcing access to research data [editorial] **Nature** 1996 Jan 18;379(6562):191
Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. **P R Health Sci J** 1995 Sep;14(3):237–4
Editor and authors: common way. Battistella LR. **Rev Paul Med** 1995 Jan–Feb;113(1):675–7
An assessment of the statistical procedures used in original papers published in the SAMJ during 1992. Becker PJ, et al. **S Afr Med J** 1995 Sep;85(9):881–4
[Ugeskrift's 1995 survey of readers. A questionnaire study of random population of readers of Ugeskrift] Højgaard L, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):29–33 **(Dan)**
[Quantification of quality] Rehfeld JF. **Ugeskr Laeger** 1995 Oct 30;157(44):6111–4 **(Dan)**
[Swiss Surgery—the first volume in the readers' opinion (assessment of the December 1995 questionnaire) (editorial)] Matter P. **Swiss Surg** 1996;(3):77 **(Ger)**
[The Vancouver regulations and publishing in biomedical journals] Brkić S, et al. **Med Pregl** 1996;49(1–2):27–31 (Eng. Abstr.) **(Ser)**
[Actas Urológicas Españolas, history and spelling (letter)] Fariña LA. **Actas Urol Esp** 1996 Jan;20(1):85 **(Spa)**
[The quality of publications (editorial)] Jiménez Villa J. **Aten Primaria** 1996 Apr 15;17(6):367–8 **(Spa)**
[The use of statistical methods in 2 medical journals with high impact factor] Silva Ayçaguer LC, et al. **Gac Sanit** 1995 May–Jun;9(48):189–95 (Eng. Abstr.) **(Spa)**
[The creation of the World Association of Medical Editors (WAME)] **Rev Med Chil** 1995 Apr;123(4):536–9 **(Spa)**

STATISTICS & NUMERICAL DATA

Coauthors' contributions to major papers published in the AJR: frequency of undeserved coauthorship. Slone RM. **AJR Am J Roentgenol** 1996 Sep;167(3):571–9
The American Journal of Dermatopathology during its first 15 years: 1979–1993 [editorial] Mansilla-Orihuela CS. **Am J Dermatopathol** 1995 Aug;17(4):321–3
Summary of analysis of published articles. January 1 through December 31, 1995 [editorial] **Am J Obstet Gynecol** 1996 Mar;174(3):805–6
A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW. **Aviat Space Environ Med** 1995 Oct;66(10):1005–9 (4 ref.)
Improving the quality of statistics in psychiatric research [comment] Hand D, et al. **Br J Psychiatry** 1995 Nov; 167(5):689–91. Comment on: Br J Psychiatry 1995 Nov;167(5):683–8.
The use of statistics in the British Journal of Psychiatry [see comments] McGuigan SM. **Br J Psychiatry** 1995 Nov; 167(5):683–8. Comment in: Br J Psychiatry 1995 Nov;167(5):689–91.
The international rank order of clinical cardiology. de Jong JW, et al. **Eur Heart J** 1996 Jan;17(1):35–42
The British Journal of venereal disease and Genitourinary medicine in the first 70 years [letter; comment] Plummer D, et al. **Genitourin Med** 1995 Aug;71(4):270. Comment on: Genitourin Med 1994 Aug;70(4):235–9.
European participation in major intensive care journals [see comments] Shahla M, et al. **Intensive Care Med** 1995 Jan; 21(1):7–10. Comment in: Intensive Care Med 1995 Jan;21(1):3–6.
Hand searching the Journal of Epidemiology and Community Health as part of th Cochrane Collaboration. Milne R, et al. **J Epidemiol Community Health** 1996 Apr;50(2):178–81
Randomised trials in German-language journals [letter] Egger M, et al. **Lancet** 1996 Apr 13;347(9007):1047–8
A citation analysis of medical informatics journals. Sittig DF, et al. **Medinfo** 1995;8 Pt 2:1452–6
Dissemination of the work of public health medicine trainees in peer-reviewed publications: an unfulfilled potential. Donaldson IJ, et al. **Public Health** 1996 Jan;110(1):61–3
[Impact factor: reliable "audimat" of scientific journals (letter)] Boileau S. **Ann Fr Anesth Reanim** 1996;15(3):392–3 **(Fre)**
[Citation of works published in AFAR (letter)] Dubost J. **Ann Fr Anesth Reanim** 1996;15(1):104–5 **(Fre)**
[While science grows and the number of libraries decreases, what will happen to information? (Decrease of medical journals in Hungary)] Szénási E, et al. **Orv Hetil** 1995 Nov 5;136(45):2463–6 (Eng. Abstr.) **(Hun)**
[Results and main tasks of the activities of this journal (editorial)] Rumiantsev GI, et al. **Gig Sanit** 1996 Jan–Feb; (1):3–7 **(Rus)**
[The 1993 bibliographic impact factor. Public health and epidemiology (letter)] Fernández E. **Gac Sanit** 1995 May–Jun;9(48):213–4 **(Spa)**

TRENDS

The American Journal of Medicine: the next 50 years. Bennet JC. **Am J Med** 1996 Jan;100(1):9–11
A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW. **Aviat Space Environ Med** 1995 Oct;66(10):1005–9 (4 ref.)
Preparing the BMJ for the electronic revolution [editorial] Smith J, et al. **BMJ** 1996 Jun 29;312(7047):1626
Future of CMAJ may depend on publishing research [letter] Ray J. **Can Med Assoc J** 1996 Mar 15;154(6):760, 762
Quo vadis? [editorial] Berg R, et al. **Fortschr Kieferorthop** 1996 Feb;57(1):1–3 **(Eng, Ger)**
Passing the torch: a look back at our editorship [editorial] LaRusso NF, et al. **Gastroenterology** 1996 May; 110(5):1336–8
Trends in publications on clinical techniques/materials 1971–1991. Morrow LA, et al. **Int Dent J** 1995 Apr; 45(2):163–5
The first ten years: the perspective from the president's desk [editorial] Shaw CD. **Int J Qual Health Care** 1996 Feb; 8(1):1–2
Intensive care medicine—a European journal [editorial; comment] Lemaire F, et al. **Intensive Care Med** 1995 Jan; 21(1):1–2. Comment on: Intensive Care Med 1995

Jan;21(1):3–6.
The role of nursing journals in the advancement of professional nursing. Smith JP. **J Adv Nurs** 1996 Jan; 23(1):12–6 (7 ref.)
A picture is worth a thousand words [editorial] Clever LH. **West J Med** 1995 Nov;163(5):485
[Medicine Tropicale: evaluation and perspectives of the journal for the year 2000 (editorial)] Jeandel P. **Med Trop (Mars)** 1996;56(1):33–4 **(Fre)**
[Farewell and departure (editorial)] Holz J, et al. **Schweiz Monatsschr Zahnmed** 1995;105(12):1519, 1521 **(Ger, Fre)**
[The language of medicine in Austria (1920–1995)] Navarro FA. **Wien Klin Wochenschr** 1996;108(12):363–9 (Eng. Abstr.) **(Ger)**
[La Radiologia Medica in the future (editorial)] Di Guglielmo L. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):1–5 **(Ita)**

UTILIZATION

A quantitative method for measuring clinical user journal needs: a pilot study using CD Plus MEDLINE usage statistics. Dunn K, et al. **Medinfo** 1995;8 Pt 2:1428–32

PERIODICALS PUBLISHING, DENTAL see **JOURNALISM, DENTAL**

PERIODICITY

see related
BIOLOGICAL CLOCKS
CIRCADIAN RHYTHM

Multiple modes of periodic breathing during sleep. Gottschalk A, et al. **Adv Exp Med Biol** 1995;393:105–10
Periodic rectal motor activity: the intrinsic colonic gatekeeper? Rao SS, et al. **Am J Gastroenterol** 1996 May; 91(5):890–7
Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)
Patterns of luteinizing and follicle-stimulating hormone pulsatility in menopausal women: correlation with plasma testosterone level and vasomotor instability episodes. Fossum GT, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):795–800
Cardiac rhythmicity among NTS neurons and its relationship to sympathetic outflow in rabbits. Hayward LF, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H923–33
Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis. Kuwano K, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1993–9
Rhythmic electrical and mechanical activity in stomach of toad and frog. Prosser CL. **Am J Physiol** 1995 Sep;269(3 Pt 1):G386–95
Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. Engels D, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):319–24
Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)
Evidence of chaotic mood variation in bipolar disorder. Gottschalk A, et al. **Arch Gen Psychiatry** 1995 Nov; 52(11):947–59
The cycle of violence. Revisited 6 years later. Maxfield MG, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):390–5
Hyperkalaemic periodic paralysis in Australian quarter horses. Church S. **Aust Vet J** 1995 Aug;72(8):314–6
A new model for the research into rhythmic contraction activity of cardiomyocytes in vitro. Korohoda W, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):431–9
Extending the HKB model of coordinated movement to oscillators with different eigenfrequencies. Fuchs A, et al. **Biol Cybern** 1996 Jan;74(1):21–30
Synchronized oscillations in the visual cortex—a synergetic model. Tass P, et al. **Biol Cybern** 1996 Jan;74(1):31–9
Manipulation of the lighting schedule can modify the pharmacological effects of theophylline in chick embryos. Yoshiyama Y, et al. **Biol Pharm Bull** 1995 May;18(5):776–8
Population cycles in northern small mammals. Norrdahl K. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):621–37 (147 ref.)
Periodicity in the growth and shedding of hair. Courtois M, et al. **Br J Dermatol** 1996 Jan;134(1):47–54
Megakaryopoiesis in patients with cyclic thrombocytopenia. Nagasawa T, et al. **Br J Haematol** 1995 Sep;91(1):185–90
Recurrent brief episodes with psychotic features in adolescence: periodic psychosis of puberty revisited. Abe K, et al. **Br J Psychiatry** 1995 Oct;167(4):507–13
Is there a seasonal pattern of relapse in bipolar affective disorders? A dual northern and southern hemisphere cohort study. Silverstone T, et al. **Br J Psychiatry** 1995 Jul; 167(1):58–60
Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: effects of aging. ThyagaRajan S, et al. **Brain Res** 1995 Aug 14;689(1):122–8
Human platelet sulfotransferase shows seasonal rhythms. Marazziti D, et al. **Chronobiol Int** 1995 Apr;12(2):100–5
Cerebral magnetic resonance imaging pathology and cerebro-spinal fluid protein in sporadic amyotrophic lateral sclerosis (sALS). Westarp ME, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):228–32
Interactions among neural networks for behavior. Dickinson PS. **Curr Opin Neurobiol** 1995 Dec;5(6):792–8 (48 ref.)
Skin blood flow oscillations respond more effectively to rhythmic thermal stimulation than to continuous or periodic breathing in newborn infants. Jahnukainen T, et al. **Early Hum Dev** 1995 Aug 18;42(3):195–207
Periodic lateralized epileptiform discharges in multiple sclerosis. Chabolla DR, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jan;98(1):5–8
Ipsilateral independent periodic lateralized epileptiform discharges. Silbert PL, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar;98(3):223–6
Domestic cats show episodic variation in plasma concentrations of adrenocorticotropin, alpha-melanocyte-stimulating hormone (alpha-MSH), cortisol and thyroxine with circadian variation in plasma alpha-MSH concentrations. Kemppainen RJ, et al. **Eur J Endocrinol** 1996 May;134(5):602–9
Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325–34 (63 ref.)
Chronic daily headache in children and adolescents: a 2-year prospective study. Gladstein J, et al. **Headache** 1996 Jun; 36(6):349–51
Fast rhythms in the hippocampus are a part of the diffuse gamma-response system [letter] Başar E, et al. **Hippocampus** 1995;5(3):240–1 (14 ref.)
Circannual pattern of autistic births: reanalysis in three ethnic groups. Ticher A, et al. **Hum Biol** 1996 Aug;68(4):585–92
Circadian and seasonal variation of the body temperature of sheep in a tropical environment. daSilva RG, et al. **Int J Biometeorol** 1995 Nov;39(2):69–73
Mechanisms of pattern generation in co-cultures of embryonic spinal cord and skeletal muscle. Streit J. **Int J Dev Neurosci** 1996 Apr;14(2):137–48
G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Heussner P, et al. **Int J Hematol** 1995 Dec;62(4):225–34
Prevalence of cyclic changes in limb volume (volumotion) of male patients with knee injury and the effects of ischemia/reperfusion due to tourniquet. Christ F, et al. **Int J Microcirc Clin Exp** 1995 Jan–Feb;15(1):14–20
Induced periodic hemodynamics in skeletal muscle of anesthetized rabbits, studied with multiple laser Doppler flow probes. Schmidt JA, et al. **Int J Microcirc Clin Exp** 1995 Jan–Feb;15(1):28–36
Cyclic Cushing's disease: pitfalls in the diagnosis and problems with the pathogenesis [editorial; comment] Yasuda K. **Intern Med** 1996 Mar;35(3):169–70. Comment on: Intern Med 1996 Mar;35(3):207–11.
Spatial periodicity in the cochlea: the result of interaction of spontaneous emissions? van Hengel PW, et al. **J Acoust Soc Am** 1996 Jun;99(6):3566–71
The origin of periodicity in the spectrum of evoked otoacoustic emissions. Zweig G, et al. **J Acoust Soc Am** 1995 Oct;98(4):2018–47
Complex and rapid-cycling in bipolar children and adolescents: a preliminary study. Geller B, et al. **J Affect Disord** 1995 Aug 18;34(4):259–68
Effect of perception of mechanical loading on human respiratory pattern regulation. Daubenspeck JA, et al. **J Appl Physiol** 1995 Jul;79(1):83–93
Mode of pulsatile follicle-stimulating hormone secretion in gonadal hormone-sufficient and -deficient women—a clinical research center study. Booth RA Jr, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3208–14
Pulsatile growth hormone secretion in older persons is enhanced by fasting without relationship to sleep stages. Hartman ML, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2694–701
Factors influencing the development of melatonin rhythmicity in humans. Kennaway DJ, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1525–32
Alterations in pulsatile luteinizing hormone and follicle-stimulating hormone secretion in idiopathic oligoasthenospermic men: assessment by deconvolution analysis—a clinical research center study. Reyes-Fuentes A, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):524–9
An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. van den Berg G, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2460–7
Ontogeny of pulsatile gonadotropin releasing hormone secretion from midchildhood, through puberty, to adulthood in the human male: a study using deconvolution analysis and an ultrasensitive immunofluorometric assay. Wu FC, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1798–805
Biphasic annual periodicity in relapses of inflammatory bowel diseases. Gruppo di Studio per le Malattie Infiammatorie Intestinale. Minoli G, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):27–9
The role of sensory information in the control of rhythmic open-close movements in humans. van der Bilt A, et al. **J Dent Res** 1995 Oct;74(10):1658–64
Cyclical peaking of streptococcal infections: recent and historical trends [letter; comment] Samuels N, et al. **J Infect Dis** 1995 Oct;172(4):1165. Comment on: J Infect Dis 1994 Aug;170(2):265–71.
Role of local nonspiking interneurons in the generation of rhythmic motor activity in the stick insect. Büschges A. **J Neurobiol** 1995 Aug;27(4):488–512
Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. Ihara Y, et al. **J Neurol Sci** 1995 Dec;134(1–2):51–6
Increased sympathetic outflow to muscles in patients with amyotrophic lateral sclerosis: a comparison with other neuromuscular patients. Shindo K, et al. **J Neurol Sci** 1995 Dec;134(1–2):57–60
REM sleep without atonia at early stage of sporadic olivopontocerebellar atrophy. Tachibana N, et al. **J Neurol Sci** 1995 Sep;132(1):28–34
Two types of network oscillations in neocortex mediated by distinct glutamate receptor subtypes and neuronal populations. Flint AC, et al. **J Neurophysiol** 1996 Feb; 75(2):951–7
Spatiotemporal characteristics of 5-HT and dopamine-induced rhythmic hindlimb activity in the in vitro neonatal rat. Kiehn O, et al. **J Neurophysiol** 1996 Apr;75(4):1472–82
Bistability and its regulation by serotonin in the endogenously bursting neuron R15 in Aplysia. Lechner HA, et al. **J Neurophysiol** 1996 Feb;75(2):957–62
Electroresponsive properties and membrane potential trajectories of three types of inspiratory neurons in the newborn mouse brain stem in vitro. Rekling JC, et al. **J Neurophysiol** 1996 Feb;75(2):795–810
Pharmacological characterization of the rhythmic synaptic drive onto lumbosacral motoneurons in the chick embryo spinal cord. Sernagor E, et al. **J Neurosci** 1995 Nov; 15(11):7452–64
Loss of frequencies in autocorrelations and a procedure to recover them. Mehta MR, et al. **J Neurosci Methods** 1995 Nov;62(1–2):65–71
The cyclic vomiting syndrome described. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S1–5 (7 ref.)
Management of cyclic vomiting syndrome. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S52–6 (20 ref.)
Prophylactic therapy in cyclic vomiting syndrome. Forbes D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S57–9 (7 ref.)
Differential diagnosis of cyclic vomiting syndrome. Forbes D. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S11–4 (42 ref.)
Metabolic etiologies of cyclic or recurrent vomiting. Korson M. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S15–9 (11 ref.)
Cyclic vomiting syndrome. Introduction. Li BU. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:vii–viii
Cyclic vomiting: the pattern and syndrome paradigm. Li BU. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S6–10 (11 ref.)
Psychophysiologic treatment of cyclic vomiting. Magagna J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S31–6 (10 ref.)
The role of the paraventricular system in the pathogenesis of cyclic vomiting. Pasricha PJ. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S29–30 (26 ref.)
The relationship between cyclic vomiting syndrome and abdominal migraine. Symon DN, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S42–3 (18 ref.)
Treatment of cyclic vomiting in childhood with erythromycin. Vanderhoof JA, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S60–2
Historical perspectives of cyclic vomiting. Walker-Smith J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:ix–x
Brown's syndrome with cyclic characteristic: case report and review of physiopathologic mechanism. Can I, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug;32(4):243–7
Investigating the origin of cyclic changes in limb volume using mercury-in-silastic strain gauge plethysmography in man. Christ F, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):259–72
Rhythm generation in the segmented hindbrain of chick embryos. Fortin G, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):735–44
GABA-induced facilitation of the periodic bursting activity of oxytocin neurones in suckled rats. Moos FC. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):103–14
The rhythms of human sleep propensity and core body temperature. Lack LC, et al. **J Sleep Res** 1996 Mar; 5(1):1–11
Periodic limb movements of sleep in combat veterans with posttraumatic stress disorder. Brown TM, et al. **J Trauma Stress** 1996 Jan;9(1):129–36
Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319–24 (43 ref.)
Estrogen could control photoperiodic adjustment in seasonal affective disorder. Partonen T. **Med Hypotheses** 1995 Jul; 45(1):35–6
Spontaneous periodic hypothermia. Kloos RT. **Medicine (Baltimore)** 1995 Sep;74(5):268–80 (131 ref.)
HLA antigens typification in two Hispanic patients with thyrotoxic periodic paralysis [letter] Araya P, et al. **Muscle Nerve** 1996 May;19(5):677–8
Melatonin synthesis in the retina and pineal gland of Djungarian hamsters at different times of the year. Steinlechner S, et al. **Neurochem Int** 1995 Sep;27(3):245–51
What stops synchronized thalamocortical oscillations? Bal T, et al. **Neuron** 1996 Aug;17(2):297–308
Abolition of spindle oscillations by serotonin and norepinephrine in the ferret lateral geniculate and perigeniculate nuclei in vitro. Lee KH, et al. **Neuron** 1996

Aug;17(2):309–21
Issues associated with repeated neuropsychological assessments. McCaffrey RJ, et al. **Neuropsychol Rev** 1995 Sep;5(3):203–21 (55 ref.)
Oscillations for rapid selection of neural activities based on spike timing. Fukai T. **Neuroreport** 1995 Dec 29;7(1):273–7
Spontaneous periodic synchronized bursting during formation of mature patterns of connections in cortical cultures. Kamioka H, et al. **Neurosci Lett** 1996 Mar 15; 206(2–3):109–12
The 10-Hz rhythm in the sympathetic nerve activity of cats, rats and rabbits. Kubota A, et al. **Neurosci Lett** 1995 Aug 25;196(3):173–6
Long-term weight cycling in female Wistar rats: effects on metabolism. Lu H, et al. **Obes Res** 1995 Nov;3(6):521–30
Modification of rhythmical jaw movements by noxious pressure applied to the periosteum of the zygoma in decerebrate rabbits. Schwartz G, et al. **Pain** 1995 Nov; 63(2):153–61
Changes in the temporal structure of periodic breathing with postnatal development in preterm infants. Wilkinson MH, et al. **Pediatr Res** 1995 Oct;38(4):533–8
An every other year cyclic epidemic of infants hospitalized with respiratory syncytial virus [letter] Lyon JL, et al. **Pediatrics** 1996 Jan;97(1):152–3
Differentiating cyclic from chronic vomiting patterns in children: quantitative criteria and diagnostic implications. Pfau BT, et al. **Pediatrics** 1996 Mar;97(3):364–8
Geophysical variables and behavior: LXXX. Periodicities and energetic characteristics of a strobe-light luminosity during a geomagnetic storm. Persinger MA, et al.
Percept Mot Skills 1996 Apr;82(2):683–8
Localization of the central rhythm generator involved in spontaneous consummatory licking in rats: functional ablation and electrical brain stimulation studies. Brozek G, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3325–9
Creativity, depression, and circannual variation. Sitton SC, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):907–10
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al.
Recent Prog Horm Res 1996;51:261–85; discussion 285–6 (59 ref.)
Elimination of a rhythmic movement disorder with hypnosis—a case report. Rosenberg C. **Sleep** 1995 Sep; 18(7):608–9
Sleep-related periodic arm movement [letter] Yokota T, et al. **Sleep** 1995 Oct;18(8):707–8
Biting cycles of some potential vector mosquitos of Japanese encephalitis of Assam, India. Bhattacharyya DR, et al.
Southeast Asian J Trop Med Public Health 1995 Mar; 26(1):177–9
Studies on the periodicity and intravascular distribution of Wuchereria bancrofti microfilariae in paired samples of capillary and venous blood from Recife, Brazil. Dreyer G, et al. **Trop Med Int Health** 1996 Apr;1(2):264–72
[A retrospective comparison between clinical cases and graphs of biorhythms] Ruĭchev B, et al.
Akush Ginekol (Sofiia) 1995;34(3):28–9 (Eng. Abstr.) **(Bul)**
[Cyclic strabismus. Presentation of two new cases and critical review of the literature] Tapiero B, et al.
J Fr Ophtalmol 1995;18(6–7):411–20 (50 ref.) (Eng. Abstr.) **(Fre)**
[Is the length of gestation a multiple of a fundamental cycle?] Kotoujansky J, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):486–93 (Eng. Abstr.) **(Fre)**
[Ecology, adaptation and biorhythms] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(3):16–9 (17 ref.) (Eng. Abstr.) **(Rus)**
[The connection between multiday rhythms of certain indicators of systemic and cerebral hemodynamics and autonomic function with cosmophysical rhythms in patients with essential hypertension] Agulova LP, et al.
Biofizika 1995 Jul–Aug;40(4):848–55 (Eng. Abstr.) **(Rus)**
[Effect of solar activity on the physiological rhythms of biological systems] Breus TK, et al. **Biofizika** 1995 Jul–Aug; 40(4):737–48 (Eng. Abstr.) **(Rus)**
[Effect of gravitational tidal changes on the periodicity of T-lymphocyte receptor expression in vitro] Garib FIu, et al. **Biofizika** 1995 Jul–Aug;40(4):834–8 (Eng. Abstr.) **(Rus)**
[Common periodicity of solar atmosphere rotation and function of the human body] Tiagun NF. **Biofizika** 1995 Jul–Aug;40(4):822–4 (Eng. Abstr.) **(Rus)**
[Study of chronobiological parameters of pain sensitivity in rats and mice] Kubynin AN, et al.
Biull Eksp Biol Med 1995 May;119(5):537–40 **(Rus)**
[Frequency and phase matching changes in dihydroorotate dehydrogenase activity rhythm in rat peripheral blood lymphocytes with changes in the rhythm of solar activity and planet periods] Strigun LM, et al.
Biull Eksp Biol Med 1995 Sep;120(9):294–8 **(Rus)**
[Daily and seasonal changes in temperature and cardiac rhythm of the long-tailed squirrel, Citellus undulatus] Sokolov VE, et al. **Dokl Akad Nauk** 1995 Sep;344(2):282–6 **(Rus)**
[Seasonal changes in the activity rhythm of the beaver, Castor fiber] Sokolov VE, et al. **Dokl Akad Nauk** 1995 Jul;343(3):423–6 **(Rus)**
[Role of cardiac and respiratory rhythms in mechanisms of counting time] Bushov IuV, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):171–3 **(Rus)**
[Intralimbic evoked potentials and excitatory cycles under conditions of food and defensive motivations in dogs] Chilingarian LI, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):87–91 **(Rus)**
[Cyclic fasting as a factor of higher body resistance to acute lymphoid leukemia] Zinov'ev IuV, et al.
Gematol Transfuziol 1996 Jan–Feb;41(1):30–2 (Eng. Abstr.) **(Rus)**
[Differential characteristics of the temperature-sensitive period of the lawcp1 mutation on the basis of macrochaetae overexpression in Drosophila] Simonova OB, et al.
Genetika 1996 Mar;32(3):445–7 (Eng. Abstr.) **(Rus)**
[The biorhythmology of primary and superinvasive opisthorchiasis. The seasonal changes in the circadian activity of the portal (regional) lymph node in golden hamsters] Ginovker AG, et al. **Parazitologiia** 1995 May–Jun;29(3):188–97 (Eng. Abstr.) **(Rus)**
[The biorhythmology of primary and superinvasive opisthorchiasis. Seasonal changes in the circadian dynamics of the peripheral blood composition in golden hamsters] Ginovker AG, et al. **Parazitologiia** 1995 Jan–Feb; 29(1):19–25 (Eng. Abstr.) **(Rus)**
[The biorhythmological types of work capacity and the late prognosis for patients who have had a myocardial infarct] Ganelina IE, et al. **Ter Arkh** 1995;67(9):31–3 (Eng. Abstr.) **(Rus)**
[The individual manifestations of respiratory rhythms] Malkin VB, et al. **Usp Fiziol Nauk** 1996 Jan–Mar;27(1):87–99 (68 ref.) (Eng. Abstr.) **(Rus)**
[The participation of the respiration in the rhythmic interactions in the body] Malkin VB, et al.
Usp Fiziol Nauk 1996 Apr–Jun;27(2):61–77 (131 ref.) (Eng. Abstr.) **(Rus)**
[The effect of changes in the level of interoceptive afferentation on the spontaneous periodic motor activity of rat pups] Kulaev BS, et al. **Zh Evol Biokhim Fiziol** 1994 Nov–Dec;30(6):769–75 (Eng. Abstr.) **(Rus)**
[The N-cholinergic activation of the periodic activity of excitable structures in early postnatal ontogeny] Kuznetsov SV. **Zh Evol Biokhim Fiziol** 1995 Mar–Apr;31(2):190–9 (Eng. Abstr.) **(Rus)**
[World cholera pandemics as mono- and polycyclic phenomena] Arutiunov IuI.
Zh Mikrobiol Epidemiol Immunobiol 1996 Mar–Apr; (2):113–7 (26 ref.) **(Rus)**
[The dependence of striatal control over the temporal organization of behavior on the function of beta-adrenergic mechanisms] Arushanian EB, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1995 Sep–Oct; 45(5):902–8 (Eng. Abstr.) **(Rus)**
[The microstructure of the "rhythm fixation" motor program and the operation of parallel programs] Ermolaev BV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1198–201 **(Rus)**
[The epiphysis in reproduction (the diapause and the sexual cycle)] Pérez Pérez F. **An R Acad Nac Med (Madr)** 1995; 112(2):383–406 (27 ref.) **(Spa)**
[Adult cyclic neutropenia: acute ileitis as an initial clinical manifestation] Larraín C, et al. **Rev Med Chil** 1995 Jun; 123(6):751–7 (Eng. Abstr.) **(Spa)**

PERIODONTAL ABSCESS

COMPLICATIONS

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)

METABOLISM

Cefaclor concentration in pus from abscess caused by odontogenic infection after a single oral administration. Akimoto Y, et al. **Gen Pharmacol** 1996 Jan;27(1):177–9

PERIODONTAL ATTACHMENT LOSS

BLOOD

Serum cotinine levels, smoking, and periodontal attachment loss. González YM, et al. **J Dent Res** 1996 Feb; 75(2):796–802

COMPLICATIONS

Loss of periodontal attachment in HIV-seropositive military personnel. Tomar SL, et al. **J Periodontol** 1995 Jun; 66(6):421–8

DIAGNOSIS

Reliability of single and double probing attachment level measurements. Zappa U, et al. **J Clin Periodontol** 1995 Oct; 22(10):764–71

ENZYMOLOGY

Loss of attachment in the marginal periodontium of the rat incisor under non-inflammatory conditions. Expression of alkaline phosphatase activity. Experimental Oral Biology Group. Groeneveld MC, et al. **J Periodontal Res** 1996 Jan; 31(1):66–72
Stimulation of human periodontal ligament fibroblast collagenase production by a gingival epithelial cell-derived factor. Ohshima M, et al. **J Periodontal Res** 1995 May; 30(3):220–8

EPIDEMIOLOGY

Incidence of attachment loss over 3 years in older adults—new and progressing lesions. Beck JD, et al.
Community Dent Oral Epidemiol 1995 Oct;23(5):291–6
Periodontal attachment loss among adults aged 60+ in South Australia. Slade GD, et al.
Community Dent Oral Epidemiol 1995 Aug;23(4):237–42
Ten-year longitudinal study of periodontal attachment loss in healthy adults. Ship JA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):281–90

ETIOLOGY

10-year periodontal response to resin bonded bridges. Romberg E, et al. **J Periodontol** 1995 Nov;66(11):973–7

MICROBIOLOGY

Clinical and microbiological changes associated with the use of 4 adjunctive systemically administered agents in the treatment of periodontal infections. Haffajee AD, et al.
J Clin Periodontol 1995 Aug;22(8):618–27

PATHOLOGY

Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6
Effect of model fitting artifacts on the stepwise approach to identifying patterns of attachment loss. Cohen ME.
J Periodontal Res 1996 Jan;31(1):11–6

SURGERY

Maintenance of new attachment 1 and 4 years following guided tissue regeneration (GTR). Weigel C, et al.
J Clin Periodontol 1995 Sep;22(9):661–9

THERAPY

Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6
Factors associated with different responses to periodontal therapy. Haffajee AD, et al. **J Clin Periodontol** 1995 Aug; 22(8):628–36

PERIODONTAL BONE LOSS see **ALVEOLAR BONE LOSS**

PERIODONTAL CYST

[Paradental cyst] Favre-Dauvergne E, et al.
Rev Stomatol Chir Maxillofac 1996;97(1):7–11 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Report of a lateral periodontal cyst and gingival cyst occurring in the same patient. Tolson GE, et al.
J Periodontol 1996 May;67(5):541–4

EPIDEMIOLOGY

Lateral periodontal cyst. Multifactorial analysis of a previously unreported series. Carter LC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Feb;81(2):210–6

PATHOLOGY

Paradental cyst of the second molar: report of a bilateral case. Martinez-Conde R, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1212–4
Botryoid odontogenic cyst: analysis of 33 cases. Gurol M, et al. **J Periodontol** 1995 Dec;66(12):1069–73

PERIODONTAL CYST, APICAL see **RADICULAR CYST**

PERIODONTAL DISEASES

Periodontal diseases affecting children and young adults. Debevc TM, et al. **J Can Dent Assoc** 1996 Aug;62(8):650–2, 655–6 (33 ref.)
Periodontal diseases of children and adolescents.
J Periodontol 1996 Jan;67(1):57–62 (112 ref.)
[Relation between interleukin-1 and periodontal diseases] Zou S.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Jun; 17(3):234–6 (21 ref.) **(Chi)**

BLOOD

[The clinico-biochemical characteristics of periodontal diseases in subjects who are under conditions of constant, permanent stress] Akopov SE, et al.
Stomatologiia (Mosk) 1996;75(1):30–2 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Dental disease: a frequently unrecognized cause of maxillary sinus abnormalities? Abrahams JJ, et al.
AJR Am J Roentgenol 1996 May;166(5):1219–23
Comparison of periodontal disease in HIV seropositive subjects and controls (II). Microbiology, immunology and

predictors of disease progression. Cross DL, et al. **J Clin Periodontol** 1995 Jul;22(7):569–77

Comparison of periodontal disease in HIV seropositive subjects and controls (I). Clinical features. Smith GL, et al. **J Clin Periodontol** 1995 Jul;22(7):558–68

Medical status and complications in relation to periodontal disease experience in insulin-dependent diabetics. Thorstensson H, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):194–202

Long-term follow-up of cross-arch fixed partial dentures in patients with advanced periodontal destruction: evaluation of occlusion and subjective function. Yi SW, et al. **J Oral Rehabil** 1996 Mar;23(3):186–96

Diabetes and periodontal diseases. **J Periodontol** 1996 Feb; 67(2):166–76 (127 ref.)

Frequency of self-reported medical conditions in periodontal patients. Peacock ME, et al. **J Periodontol** 1995 Nov; 66(11):1004–7

Periodontal status and selected cultivable anaerobic microflora of insulin-dependent juvenile diabetics. Shordone L, et al. **J Periodontol** 1995 Jun;66(6):452–61

Relative contribution of caries and periodontal disease in adult tooth loss for an HMO dental population. Phipps KR, et al. **J Public Health Dent** 1995 Fall;55(4):250–2

DIAGNOSIS

Periodontal condition and comparison of toothcleaning using chewing sponge, chewing sticks and toothbrushes in 14-year-old schoolchildren in Ghana. Clerehugh V, et al. **Community Dent Oral Epidemiol** 1995 Oct;23(5):319–20

Assessment of periodontal status with PSR and traditional clinical periodontal examination. Khocht A, et al. **J Am Dent Assoc** 1995 Dec;126(12):1658–65

Screening for periodontal disease: radiographs vs. PSR. Khocht A, et al. **J Am Dent Assoc** 1996 Jun;127(6):749–56

PSR offers quick, easy periodontal screening. Davis T. **J Can Dent Assoc** 1995 Sep;61(9):770

Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. Lang NP, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):240–50 (102 ref.)

A multicenter clinical trial of PerioGard in distinguishing between diseased and healthy periodontal sites. (I). Study design, methodology and therapeutic outcome. Persson GR, et al. **J Clin Periodontol** 1995 Oct;22(10):794–803

The impact of new technologies to diagnose and treat periodontal disease. A look to the future. Williams RC, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):299–305

Commentary on periodontal diagnostic testing [editorial] Greenstein G. **J Periodontol** 1995 Jun;66(6):531–5

Understanding diagnostic testing for periodontal diseases. Greenstein G, et al. **J Periodontol** 1995 Aug;66(8):659–66 (22 ref.)

Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.). Comment in: J Periodontol 1995 Aug;66(8):747–8.

The diagnosis, progression, prognostic indication and classification of periodontal disease: a review (Part 3). Priestland CR. **J R Nav Med Serv** 1995 Winter;80(3):139–47

DRUG THERAPY

Coenzyme Q10 and periodontal disease [letter; comment] Lister RE. **Br Dent J** 1995 Sep 23;179(6):200–1. Comment on: Br Dent J 1995 Mar 25;178(6):209–13.

Researchers use antibiotics to fight periodontal disease [news] **J Am Dent Assoc** 1996 Aug;127(8):1158

Principles of pharmacologic intervention. Goodson JM. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):268–72 (17 ref.)

The effects on chronic periodontitis of a subgingivally-placed redox agent in a slow release device. Ower PC, et al. **J Clin Periodontol** 1995 Jun;22(6):494–500

Local and systemic chemotherapy in the management of periodontal disease: an opinion and review of the concept. Addy M, et al. **J Oral Rehabil** 1996 Apr;23(4):219–31 (101 ref.)

Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. Greenstein G. **J Periodontol** 1995 Nov;66(11):925–32 (72 ref.)

Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.). Comment in: J Periodontol 1995 Aug;66(8):747–8.

Nonsurgical treatment of patients with periodontal disease. Loesche WJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):533–43

Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: effect of micocycline therapy. Chang KM, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):303–18

[The treatment of periodontal diseases with the preparation Linco-HAP] Dmitrieva LA, et al. **Stomatologiia (Mosk)** 1995;74(3):25–8 (Eng. Abstr.) **(Rus)**

ECONOMICS

Cost effectiveness of periodontal services. Douglass CW, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):278–82

ENZYMOLOGY

Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: effect of micocycline therapy. Chang KM, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):303–18

EPIDEMIOLOGY

Multivariate contingency tables and the analysis of exchangeability. Ten Have TR, et al. **Biometrics** 1995 Sep; 51(3):1001–16

Dental problems of a rural community in Sierra Leone. Bly S, et al. **Community Dent Health** 1995 Dec;12(4):241–2

Periodontal conditions in older age cohorts aged 65 years and older in Japan, measured by CPITN and loss of attachment. Miyazaki H, et al. **Community Dent Health** 1995 Dec;12(4):216–20

Dental health and treatment needs in institutionalized psychiatric patients in Italy. Angelillo IF, et al. **Community Dent Oral Epidemiol** 1995 Dec;23(6):360–4

Oral health in Latvian 15-year-olds. Bjarnason S, et al. **Eur J Oral Sci** 1995 Oct;103(5):274–9

National survey of periodontal status and treatment need among Nigerians. Adegbembo AO, et al. **Int Dent J** 1995 Jun;45(3):197–203

Periodontal treatment needs and oral hygiene among Ethiopian immigrants. Cohen HD, et al. **Int Dent J** 1995 Jun;45(3):204–8

Oral health status of children and adults in Madagascar. Petersen PE, et al. **Int Dent J** 1996 Feb;46(1):41–7

The periodontal status of Jordanian adolescents measured by CPITN. Taani Q. **Int Dent J** 1995 Dec;45(6):382–5

Smoking and periodontal disease severity. Martinez-Canut P, et al. **J Clin Periodontol** 1995 Oct;22(10):743–9

Examiner agreement on periodontal indices during dental surveys of elders. Mojon P, et al. **J Clin Periodontol** 1996 Jan;23(1):56–9

Periodontal status in the United States, 1988–1991: prevalence, extent, and demographic variation. Brown LJ, et al. **J Dent Res** 1996 Feb;75 Spec No:672–83

Changes in periodontal treatment needs. A follow-up study of Oslo citizens from the ages of 35 to 50 years. Hansen BF, et al. **J Periodontal Res** 1995 Nov;30(6):410–7

Dental findings in geriatric populations with diverse medical backgrounds. Loesche WJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):43–54

A comparison of oral health in 70-year-old city cohorts in Umeå northern Sweden in 1981 and 1990: oral problems, dental and periodontal status. Nordström G, et al. **Swed Dent J** 1995;19(5):195–204

[Cariologic and periodontal screening of children aged 7, 12 and 14 years in the city of Debrecen. II. Periodontal status and need for treatment] Madléna M, et al. **Fogorv Sz** 1995 Apr;88(4):141–6 (Eng. Abstr.) **(Hun)**

[Evaluation of periodontium status and periodontal needs in persons aged 35–44 years in Poland] Dembowska E. **Ann Acad Med Stetin** 1995;41:245–58 (Eng. Abstr.) **(Pol)**

[Stomatologic care requirement for 12-year old children in Poland] Suszczewicz A. **Ann Acad Med Stetin** 1994; 40:117–31 (Eng. Abstr.) **(Pol)**

[Incidence, morphology and diagnostic studies of Entamoeba gingivalis, Gros, 1849] Favoreto Junior S, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):379–87 (Eng. Abstr.) **(Por)**

[Prevalence of dental caries, gingivitis and periodontal disease in pregnant diabetic women] López-Pérez R, et al. **Salud Publica Mex** 1996 Mar-Apr;38(2):101–9 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Profiles of destructive periodontal disease in different populations. Baelum V, et al. **J Periodontal Res** 1996 Jan; 31(1):17–26

ETIOLOGY

Are gingival and periodontal conditions related to salivary gland flow rates in healthy individuals? Crow HC, et al. **J Am Dent Assoc** 1995 Nov;126(11):1514–20

Systemic retinoid medication and periodontal health in patients with Papillon-Lefèvre syndrome. Lundgren T, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):176–9

Initial study of periodontal status in non-insulin-dependent diabetics in Mauritius. Morton AA, et al. **J Dent** 1995 Dec; 23(6):343–5

Tobacco use and the periodontal patient. **J Periodontol** 1996 Jan;67(1):51–6 (97 ref.)

Periodontal and microbiological changes associated with the placement of orthodontic appliances. A review. Atack NE, et al. **J Periodontol** 1996 Feb;67(2):78–85 (61 ref.)

The importance of regular dental treatment in patients with cyclic neutropenia. Follow-up of 2 cases. Pernu HE, et al. **J Periodontol** 1996 Apr;67(4):454–9

Bone loss and oral state in patients on home parenteral nutrition. von Wowern N, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):105–9

Management of periodontal disease in older patients. Kamen PR. **N Y State Dent J** 1996 Jun-Jul;62(6):48–53

[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44–51 (78 ref.) (Eng. Abstr.) **(Rus)**

[Tobacco and periodontopathies] Dini EL, et al. **Bol Oficina Sanit Panam** 1995 Oct;119(4):299–304 (Eng. Abstr.) **(Spa)**

GENETICS

Genetic influences in caries and periodontal diseases. Hassell TM, et al. **Crit Rev Oral Biol Med** 1995;6(4):319–42 (203 ref.)

IMMUNOLOGY

T-subsets and disturbed immunoregulation in patients with periodontal disease. Heumader E, et al. **Adv Exp Med Biol** 1995;371B:1123–5

Characterization of T lymphocyte clones derived from Porphyromonas gingivalis infected subjects. Gemmell E, et al. **J Periodontal Res** 1996 Jan;31(1):47–56

METABOLISM

Analysis in gingival crevicular fluid of two oligopeptides derived from human hemoglobin beta-chain. Makinen KK, et al. **J Periodontal Res** 1996 Jan;31(1):43–6

MICROBIOLOGY

Arbitrarily primed polymerase chain reaction analysis of periodontal pathogens: discriminative primers and genetic diversity. Chen C, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S301–3

The biochemical milieu of the host in the selection of anaerobic species in the oral cavity. Shah HN, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S291–300 (59 ref.)

Detection of putative periodontal pathogens in subgingival specimens by 16S ribosomal DNA amplification with the polymerase chain reaction. Slots J, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S304–7

Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum. Bolstad AI, et al. **Clin Microbiol Rev** 1996 Jan;9(1):55–71 (319 ref.)

Eubacterium minutum sp. nov., isolated from human periodontal pockets. Poco SE Jr, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):31–4

Treponema maltophilum sp. no., a small oral spirochete isolated from human periodontal lesions. Wyss C, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):745–52

Endodontic pathogens in periodontal disease augmentation. Jansson L, et al. **J Clin Periodontol** 1995 Aug;22(8):598–602

Antibody responses to suspected periodontal pathogens in elderly subjects with periodontal disease. McArthur WP, et al. **J Clin Periodontol** 1995 Nov;22(11):842–9

Microbiological monitoring. Mombelli A. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):251–7 (95 ref.)

The natural history of periodontal disease. The correlation of selected microbiological parameters with disease severity in Sri Lankan tea workers. Preus HR, et al. **J Clin Periodontol** 1995 Sep;22(9):674–8

Characterization of T lymphocyte clones derived from Porphyromonas gingivalis infected subjects. Gemmell E, et al. **J Periodontal Res** 1996 Jan;31(1):47–56

Comparison of the pro-inflammatory cytokine-stimulating activity of the surface-associated proteins of periodontopathic bacteria. Reddi K, et al. **J Periodontal Res** 1996 Feb;31(2):120–30

In vitro permeability evaluation and colonization of membranes for periodontal regeneration by Porphyromonas gingivalis. Ricci G, et al. **J Periodontol** 1996 May;67(5):490–6

Periodontal status and selected cultivable anaerobic microflora of insulin-dependent juvenile diabetics. Shordone L, et al. **J Periodontol** 1995 Jun;66(6):452–61

Haemolytic activity of Actinobacillus actinomycetemcomitans strains on different blood types. Avila-Campos MJ. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):215–7

PATHOLOGY

Dental problems in junctional epidermolysis bullosa: report of a case with treatment considerations. Putnam JJ, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):14–7

Eosinophilic granuloma of the mandible involving the periodontal tissues. A case report. Piattelli A, et al. **J Periodontol** 1995 Aug;66(8):731–6

PHYSIOPATHOLOGY

Absence of exogenous interleukin-4-induced apoptosis of gingival macrophages may contribute to chronic inflammation in periodontal diseases. Yamamoto M, et al. **Am J Pathol** 1996 Jan;148(1):331–9

The natural history of periodontal disease. The correlation of selected microbiological parameters with disease severity in Sri Lankan tea workers. Preus HR, et al. **J Clin Periodontol** 1995 Sep;22(9):674–8

Stress analysis of four-unit fixed bridges on abutment teeth with reduced periodontal support. Lee HE, et al. **J Oral Rehabil** 1995 Sep;22(9):705–10

[A mathematical analysis of the heart rhythm in assessing periodontal diseases in women] Korzhova VV, et al. **Stomatologiia (Mosk)** 1996;75(1):19–22 (Eng. Abstr.) **(Rus)**

[The function of the maxillofacial muscles in dentition defects and periodontal diseases] Omarov OG, et al. **Stomatologiia (Mosk)** 1995;74(4):53–4 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Evaluation of clinical trials of agents and procedures to prevent caries and periodontal disease: choosing products and recommending procedures. Addy M. **Int Dent J** 1995 Jun;45(3):185–96 (57 ref.)

Supportive periodontal care. Scientific basis for long-term success. Proceedings of the 7th International Congress of the Italian Society of Periodontology. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):231–305

Psychological intervention in patients with poor compliance. Weinstein R, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):283–8

Rationale of mechanical plaque control. Westfelt E. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):263–7 (54 ref.)

Retrospective evaluation of patient compliance with supportive periodontal treatment. Demirel K, et al. **J Nihon Univ Sch Dent** 1995 Sep;37(3):131–7

The importance of regular dental treatment in patients with cyclic neutropenia. Follow-up of 2 cases. Pernu HE, et al. **J Periodontol** 1996 Apr;67(4):454–9

[Targeted periodontal maintenance] Defleur P, et al. **Rev Belge Med Dent** 1995;50(4):53–62 (Eng. Abstr.) **(Fre)**

[Effect of repeated toothbrushing instructions on periodontal health in a community] Ishikawa A, et al. **Nippon Koshu Eisei Zasshi** 1995 Sep;42(9):777–82 (Eng. Abstr.) **(Jpn)**

[Methods for preventing periodontal diseases and their validation] Grudianov AI. **Stomatologiia (Mosk)** 1995; 74(3):21–4 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Panoramic and restrictive intraoral radiography in comprehensive oral radiographic diagnosis. Molander B, et al. **Eur J Oral Sci** 1995 Aug;103(4):191–8

Three-dimensional interpretation of periodontal lesions and remodeling during orthodontic treatment. Part III. Fuhrmann R. **Fortschr Kieferorthop** 1996 Aug;57(4):224–37 **(Eng, Ger)**

REHABILITATION

Long-term follow-up of cross-arch fixed partial dentures in patients with advanced periodontal destruction. Evaluation of the supporting tissues. Yi SW, et al. **Acta Odontol Scand** 1995 Aug;53(4):242–8

SURGERY

Long-time etching at low pH jeopardizes periodontal healing. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun; 22(6):459–63

Root surface etching at neutral pH promotes periodontal healing. Blomlöf J, et al. **J Clin Periodontol** 1996 Jan; 23(1):50–5

Collagen gel and membrane in guided tissue regeneration in periodontal fenestration defects in dogs. Tal H, et al. **J Clin Periodontol** 1996 Jan;23(1):1–6

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511–21 (37 ref.)

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

The potential role of bone morphogenetic proteins in periodontal reconstruction. Wozney JM. **J Periodontol** 1995 Jun;66(6):506–10 (34 ref.)

[Decision to extract for periodontal reasons] Bercy P, et al. **Rev Belge Med Dent** 1995;50(2):17–28 (Eng. Abstr.) **(Fre)**

THERAPY

Periodontal and prosthetic treatment of a cleft lip and palate patient: a case report. Santi E, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):346–9

Periodontal and soft-tissue abnormalities. Delaney JE. **Dent Clin North Am** 1995 Oct;39(4):837–50 (14 ref.)

A multicenter clinical trial of PerioGard in distinguishing between diseased and healthy periodontal sites. (I). Study design, methodology and therapeutic outcome. Persson GR, et al. **J Clin Periodontol** 1995 Oct;22(10):794–803

Dental treatment of Papillon-Lefèvre syndrome: 15-year follow-up. Tinanoff N, et al. **J Clin Periodontol** 1995 Aug; 22(8):609–12

The impact of new technologies to diagnose and treat periodontal disease. A look to the future. Williams RC, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):299–305

Definitive vs. exploratory periodontal trials: a survey of published studies. Hujoel PP. **J Dent Res** 1995 Aug; 74(8):1453–8

Gingival interleukin-6 concentration following phase I therapy. Guillot JL, et al. **J Periodontol** 1995 Aug; 66(8):667–72

Compliance with supportive periodontal therapy. Novaes AB, et al. **J Periodontol** 1996 Mar;67(3):213–6

Planning for the manpower needs for the next generation of periodontal patients. Waldman HB. **J Periodontol** 1995 Jul;66(7):599–604

Regenerative therapy. The future of periodontics. Breault MR, et al. **N Y State Dent J** 1995 Dec;61(10):34–7 (0 ref.)

[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44–51 (78 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Serum responses of cats with periodontal/gingival disease to members of the genus Porphyromonas. Norris JM, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S314–6

[Clinical case. Yorkshire terrier, male, 14 years old] Böhmer E. **Tierarztl Prax** 1995 Dec;23(6):533, 619–23 **(Ger)**

PERIODONTAL DRESSINGS

THERAPEUTIC USE

Evaluation of the healing response following placement of Coe-pak and an experimental pack after periodontal flap surgery. Cheshire PD, et al. **J Clin Periodontol** 1996 Mar; 23(3 Pt 1):188–93

PERIODONTAL INDEX

Self-assessed bleeding in monitoring gingival health among adolescents. Kallio P. **Community Dent Oral Epidemiol** 1996 Apr;24(2):128–32

The periodontal status of Jordanian adolescents measured by CPITN. Taani Q. **Int Dent J** 1995 Dec;45(6):382–5

Assessment of periodontal status with PSR and traditional clinical periodontal examination. Khocht A, et al. **J Am Dent Assoc** 1995 Dec;126(12):1658–65

Screening for periodontal disease: radiographs vs. PSR. Khocht A, et al. **J Am Dent Assoc** 1996 Jun;127(6):749–56

PSR offers quick, easy periodontal screening. Davis T. **J Can Dent Assoc** 1995 Sep;61(9):770

Examiner agreement on periodontal indices during dental surveys of elders. Mojon P, et al. **J Clin Periodontol** 1996 Jan;23(1):56–9

Detection of stable and active periodontitis sites by clinical assessment and gingival crevicular acute-phase protein levels. Adonogianaki E, et al. **J Periodontal Res** 1996 Feb; 31(2):135–43

[Oral disease epidemiologic illness indices and oral health measures--traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162–8 (50 ref.) (Eng. Abstr.) **(Ger)**

[Caries intensity and oral hygiene in adult dental patients in Budapest] Boross E, et al. **Fogorv Sz** 1995 Mar; 88(3):95–102 (Eng. Abstr.) **(Hun)**

PERIODONTAL LIGAMENT

see related
PERIODONTAL ATTACHMENT LOSS

BLOOD SUPPLY

Vascular changes in the periodontal ligament after removal of orthodontic forces. Murrell EF, et al. **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):280–6

CHEMISTRY

Maintenance of cell-type-specific cytoskeletal character in epithelial cells out of epithelial context: cytokeratins and other cytoskeletal proteins in the rests of Malassez of the periodontal ligament. Peters BH, et al. **Differentiation** 1995 Sep;59(2):113–26

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342–60 (69 ref.)

Periodontal ligament cell population: the central role of fibroblasts in creating a unique tissue. Lekic P, et al. **Anat Rec** 1996 Jun;245(2):327–41 (190 ref.)

Segregated localization of immunocompetent cells and osteoclasts in the periodontal ligament of the rat molar. Kawahara I, et al. **Arch Histol Cytol** 1995 Aug;58(3):345–55

A methodical study of shape changes in human oral cells perturbed by a simulated orthodontic strain in vitro. Norton LA, et al. **Arch Oral Biol** 1995 Sep;40(9):863–72

Morphological changes in cultured human periodontal ligament cells exposed to dental materials. Adams AM, et al. **Biomaterials** 1995 Sep;16(13):1031–5

Immunohistochemical characterization and localization of MHC class II antigen-presenting cells in the periodontal ligament of rat incisors. Kawahara I, et al. **Connect Tissue Res** 1995;33(1-3):47–56

Periodontal ligament cells are chemotactic to fibroblast collagenase. Terranova VP, et al. **J Dent Res** 1996 Apr; 75(4):993–1001

Modulation of periodontal ligament fibroblasts by cementum and alveolar bone extracts. Hou LT, et al. **J Formos Med Assoc** 1995 Jul;94(7):401–5

Comparison of the characteristics of human gingival fibroblasts and periodontal ligament cells. Ogata Y, et al. **J Periodontol** 1995 Dec;66(12):1025–31

Effects of static magnetic fields on human periodontal fibroblasts in vitro. Linder-Aronson A, et al. **Swed Dent J** 1995;19(4):131–7

[Characterization of rat periodontal ligament cells in culture] Kikukawa I. **Kokubyo Gakkai Zasshi** 1996 Jun; 63(2):296–312 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Morphological changes in cultured human periodontal ligament cells exposed to dental materials. Adams AM, et al. **Biomaterials** 1995 Sep;16(13):1031–5

Dental benefit found during orthopedic study [news] **J Am Dent Assoc** 1996 Jul;127(7):854

Human periodontal ligament and gingival fibroblast response to TGF-beta 1 stimulation. Mailhot JM, et al. **J Clin Periodontol** 1995 Sep;22(9):679–85

Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. Nishimura F, et al. **J Dent Res** 1996 Apr;75(4):986–92

LPS responsiveness in periodontal ligament cells is regulated by tumor necrosis factor-alpha. Quintero JC, et al. **J Dent Res** 1995 Nov;74(11):1802–11

ENZYMOLOGY

Alkaline phosphatase activity in the periodontal ligament and gingiva of the rat molar: its relation to cementum formation. Groeneveld MC, et al. **J Dent Res** 1995 Jul;74(7):1374–81

Effects of different magnitudes of tension-force on alkaline phosphatase activity in periodontal ligament cells. Yamaguchi M, et al. **J Dent Res** 1996 Mar;75(3):889–94

Cell-bound and extracellular matrix-associated alkaline phosphatase activity in rat periodontal ligament. Experimental Oral Biology Group. Groeneveld MC, et al. **J Periodontal Res** 1996 Jan;31(1):73–9

Stimulation of human periodontal ligament fibroblast collagenase production by a gingival epithelial cell-derived factor. Ohshima M, et al. **J Periodontal Res** 1995 May; 30(3):220–8

Growth factor effects on the expression of collagenase and TIMP-1 in periodontal ligament cells. Alvares O, et al. **J Periodontol** 1995 Jul;66(7):552–8

IMMUNOLOGY

LPS responsiveness in periodontal ligament cells is regulated by tumor necrosis factor-alpha. Quintero JC, et al. **J Dent Res** 1995 Nov;74(11):1802–11

INNERVATION

Response characteristics of periodontal mechanoreceptors to mechanical stimulation of canine and incisor teeth in the cat. Tabata T, et al. **Arch Oral Biol** 1995 Sep;40(9):873–8

Neuropeptide Y-immunoreactive primary afferents in the dental pulp and periodontal ligament following nerve injury to the inferior alveolar nerve in the rat. Wakisaka S, et al. **Brain Res** 1996 Mar 11;712(1):11–8

METABOLISM

Orthodontic forces increase tumor necrosis factor alpha in the human gingival sulcus. Lowney JJ, et al. **Am J Orthod Dentofacial Orthop** 1995 Nov;108(5):519–24

Intracellular calcium response to hydraulic pressure in human periodontal ligament fibroblasts. Nakago-Matsuo C, et al. **Am J Orthod Dentofacial Orthop** 1996 Mar;109(3):244–8

The effect of glycosylaminoglycans on the mineralization of sheep periodontal ligament in vitro. Kirkham J, et al. **Connect Tissue Res** 1995;33(1-3):23–9

Expression of neuropeptides (CGRP, substance P) during and after orthodontic tooth movement in the rat. Norevall LI, et al. **Eur J Orthod** 1995 Aug;17(4):311–25

Histamine H1 receptor-stimulated Ca2+ signaling pathway in human periodontal ligament cells. Niisato N, et al. **J Periodontal Res** 1996 Feb;31(2):113–9

Expression of matrix proteins in cloned fibroblasts derived from periodontal tissue under different cell growth densities. Hou LT, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):176–84

PATHOLOGY

New findings in the degenerating tissues of the periodontal ligament during experimental tooth movement. Nakamura Y, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr; 109(4):348–54

Periodontal ligament tissue reactions to trauma and gingival inflammation. An experimental study in the beagle dog. Biancu S, et al. **J Clin Periodontol** 1995 Oct;22(10):772–9

PHYSIOLOGY

Computer experiments using a two-dimensional model of tooth support. Halazonetis DJ. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):598–606

The role of the periodontal ligament in bone modeling: the initial development of a time-dependent finite element model. Middleton J, et al. **Am J Orthod Dentofacial Orthop** 1996 Feb;109(2):155–62

A new experimental model for studying the response of periodontal ligament cells to hydrostatic pressure. Yousefian J, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):402–9

PERIODONTAL LIGAMENT

Implications of cellular and molecular biology advances in periodontal regeneration. Amar S. **Anat Rec** 1996 Jun; 245(2):361–73 (137 ref.)

Changes in the fibre arrangement of the rat incisor periodontal ligament in relation to various loading levels in vitro. Komatsu K, et al. **Arch Oral Biol** 1996 Feb; 41(2):147–59

Mechanical stretching of periodontal ligament fibroblasts—a study on cytoskeletal involvement. Basdra EK, et al. **Fortschr Kieferorthop** 1996 Feb;57(1):24–30 **(Eng, Ger)**

Functional characteristics of gingival and periodontal ligament fibroblasts. Giannopoulou C, et al. **J Dent Res** 1996 Mar;75(3):895–902

The potential role of growth and differentiation factors in periodontal regeneration. **J Periodontol** 1996 May; 67(5):545–53 (128 ref.)

[Determination of modulus of elasticity of human periodontal membrane] Zhu Z, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):160–2 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Pulp and periodontal healing, root development and root resorption subsequent to transplantation and orthodontic rotation: a long–term study of autotransplanted premolars. Paulsen HU, et al. **Am J Orthod Dentofacial Orthop** 1995 Dec;108(6):630–40

RADIATION EFFECTS

Inhibition of prostaglandin E2 and interleukin 1–beta production by low–power laser irradiation in stretched human periodontal ligament cells. Shimizu N, et al. **J Dent Res** 1995 Jul;74(7):1382–8

SURGERY

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)

ULTRASTRUCTURE

Changes in the fibre arrangement of the rat incisor periodontal ligament in relation to various loading levels in vitro. Komatsu K, et al. **Arch Oral Biol** 1996 Feb; 41(2):147–59

The effects of aging upon the connective tissues of the periodontal ligament. Moxham BJ, et al. **Connect Tissue Res** 1995;33(1–3):31–5

Ultrastructural changes in cultured human periodontal ligament cells exposed to dental materials. Adams AM, et al. **J Biomed Mater Res** 1995 Aug;29(8):999–1004

On the developing periodontal ligament of rats, using a new specimen preparation method for SEM in comparison with histochemistry. Iwamatsu Y, et al. **Kaibogaku Zasshi** 1995 Aug;70(4):322–9

PERIODONTAL POCKET

DIAGNOSIS

Intra – and inter–examiner reproducibility in constant force probing. Wang SF, et al. **J Clin Periodontol** 1995 Dec; 22(12):918–22

An assessment of the validity of a constant force electronic probe in measuring probing depths. Hull PS, et al. **J Periodontol** 1995 Oct;66(10):848–51

DRUG THERAPY

[The effect of subgingival irrigation with acetylsalicylate on the polymorphonuclear leukocyte count in periodontal pockets of medium depth] Paolantonio M, et al. **Minerva Stomatol** 1995 Jun;44(6):265–71 (Eng. Abstr.) **(Ita)**

[Effect of doxycycline in the treatment of progressive periodontal disease] Bokor M. **Med Pregl** 1995; 48(1–2):48–50 (Eng. Abstr.) **(Scr)**

ETIOLOGY

Stimulation of human periodontal ligament fibroblast collagenase production by a gingival epithelial cell–derived factor. Ohshima M, et al. **J Periodontal Res** 1995 May; 30(3):220–8

MICROBIOLOGY

Eubacterium minutum sp. nov., isolated from human periodontal pockets. Poco SE Jr, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):31–4

Clinical and microbiological changes associated with the use of 4 adjunctive systemically administered agents in the treatment of periodontal infections. Haffajee AD, et al. **J Clin Periodontol** 1995 Aug;22(8):618–27

Simultaneous detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis by a rapid PCR method. Wahlfors J, et al. **J Dent Res** 1995 Nov;74(11):1796–801

Competition for peptides and amino acids among periodontal bacteria. Tang–Larsen J, et al. **J Periodontal Res** 1995 Nov; 30(6):390–5

Repopulation of periodontal pockets by microbial pathogens in the absence of supportive therapy. Shiloah J, et al. **J Periodontol** 1996 Feb;67(2):130–9

Butyric acid, a metabolic end product of anaerobic bacteria, inhibits B–lymphocyte function. Eftimiadi C, et al. **Minerva Stomatol** 1995 Oct;44(10):445–7

[Subgingival distribution of periodontopathic bacteria in periodontic patients and susceptibility of these bacteria to minocycline–HCl] Hagiwara S, et al. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):495–505 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6

RADIOGRAPHY

Assessment of alveolar bone loss with high resolution computed tomography. Fuhrmann RA, et al. **J Periodontal Res** 1995 Jul;30(4):258–63

RADIOTHERAPY

An evaluation of the Nd:YAG laser in periodontal pocket therapy. Radvar M, et al. **Br Dent J** 1996 Jan 20; 180(2):57–62

SURGERY

Clinical and microbiological changes associated with an altered subgingival environment induced by periodontal pocket reduction. Mombelli A, et al. **J Clin Periodontol** 1995 Oct;22(10):780–7

THERAPY

Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6

Repopulation of periodontal pockets by microbial pathogens in the absence of supportive therapy. Shiloah J, et al. **J Periodontol** 1996 Feb;67(2):130–9

PERIODONTAL PROSTHESIS

Treating the oral sequelae of an acoustic neuroma. Whitaker EJ, et al. **J Am Dent Assoc** 1996 Feb;127(2):231–3

Long–term effects of gingival fibroblast–coated hydroxylapatite graft on periodontal osseous defects. Feng F, et al. **J Formos Med Assoc** 1995 Aug;94(8):494–8

Application of implants in restorations in periodontal–prosthetic patients: a clinical report. Strygler H. **J Prosthet Dent** 1996 Jun;75(6):597–601

PERIODONTAL RESORPTION see **ALVEOLAR BONE LOSS**

PERIODONTICS

The changing marketplace: informed choices; safe action [letter] Sussman HI. **J Am Coll Dent** 1996 Summer; 63(2):4–5

The American Academy of Periodontology. Adams DF. **J Periodontol** 1996 Feb;67(2):177–9

New features of the Journal of Periodontology [editorial] Genco RJ. **J Periodontol** 1996 Jan;67(1):63

[Paro–Zermatt. A report on the 25th annual congress of the Swiss Society of Periodontics (SSP) at Zermatt from 21 to 23 September 1995] Perrier M. **Schweiz Monatsschr Zahnmed** 1995;105(11):1503–5 **(Fre)**

[Periodontology—13 years of GTR. A report on the 70th annual meeting of the German Society for Periodontology of 8 to 9 September 1995 in Bremen] Buns CE. **Schweiz Monatsschr Zahnmed** 1995;105(11):1469–72 **(Ger)**

[The periodontal health of the population and long–term treatment results. Paro–Zermatt—a report on the 25th annual meeting of the Swiss Society for Periodontology (SGP) and the annual meeting of the Swiss Society for Dentomaxillofacial Radiology (SGDMFR) of 21–23 September in Zermatt] Hofer D. **Schweiz Monatsschr Zahnmed** 1995;105(11):1477–9 **(Ger)**

[Maintenance therapy: an indispensible complement to periodontal treatment and the surgical implant] Fanali S, et al. **Minerva Stomatol** 1995 May;44(5):245–55 (89 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Intrasulcular laser Doppler readings before and after root planing. Hinrichs JE, et al. **J Clin Periodontol** 1995 Nov; 22(11):817–23

Effect of gingival wall on resistance to probing forces. Keagle JG, et al. **J Clin Periodontol** 1995 Dec;22(12):953–7

The influence of splinting procedures on the periodontal and peri–implant tissue damping characteristics. A longitudinal study with the Periotest device. Naert IE, et al. **J Clin Periodontol** 1995 Sep;22(9):703–8

Intra – and inter–examiner reproducibility in constant force probing. Wang SF, et al. **J Clin Periodontol** 1995 Dec; 22(12):918–22

Modified periodontal probe for simplified forced duction measurements. Metz HS, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug;32(4):257–9

Engineering specifics of the periodontal curet's cutting edge. Balevi B. **J Periodontol** 1996 Apr;67(4):374–8

An assessment of the validity of a constant force electronic probe in measuring probing depths. Hull PS, et al. **J Periodontol** 1995 Oct;66(10):848–51

Periodontal files—a comparative study. Pasquini R, et al. **J Periodontol** 1995 Dec;66(12):1040–6

MANPOWER

Planning for the manpower needs for the next generation of periodontal patients. Waldman HB. **J Periodontol** 1995 Jul;66(7):599–604

METHODS

[Targeted periodontal maintenance] Defleur P, et al. **Rev Belge Med Dent** 1995;50(4):53–62 (Eng. Abstr.) **(Fre)**

[The GTR technic within the framework of combined periodontal–orthodontic treatments. A case report] Stelzel M, et al. **Fortschr Kieferorthop** 1995 Nov;56(6):347–52 (28 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

[The organization and modern principles of the treatment of periodontitis in the Armed Forces] Kovalevskiĭ AM, et al. **Voen Med Zh** 1995 Aug;(8):13–7, 80 (Eng. Abstr.) **(Rus)**

TRENDS

Supportive periodontal care. Scientific basis for long–term success. Proceedings of the 7th International Congress of the Italian Society of Periodontology. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):231–305

PERIODONTITIS

see related
SUBGINGIVAL CURETTAGE

Statistical issues in periodontal research. DeRouen TA, et al. **J Dent Res** 1995 Nov;74(11):1731–7

BLOOD

Selected Th1 and Th2 cytokine mRNA expression by CD4(+) T cells isolated from inflamed human gingival tissues. Fujihashi K, et al. **Clin Exp Immunol** 1996 Mar; 103(3):422–8

Specific serum IgA titres as realistic indicators of treatment prognoses. Landry RG. **Int Dent J** 1995 Aug;45(4):267–74

Effects of Porphyromonas gingivalis culture products on the morphology of peripheral blood polymorphonuclear leucocytes from periodontitis patients and healthy subjects. Scragg MA, et al. **J Clin Periodontol** 1995 Aug; 22(8):585–90

COMPLICATIONS

Gamma/delta T lymphocytes in marginal periodontitis in patients with Down's syndrome. Søhoel DC, et al. **Adv Exp Med Biol** 1995;371B:1135–6

Effect of free and vesicle–bound cysteine proteinases of Porphyromonas gingivalis on plasma clot formation: implications for bleeding tendency at periodontitis sites. Imamura T, et al. **Infect Immun** 1995 Dec;63(12):4877–82

The influence of endodontic infection on progression of marginal bone loss in periodontitis. Jansson L, et al. **J Clin Periodontol** 1995 Oct;22(10):729–34

Case report: cheilitis granulomatosa with periodontitis. Takeshita T, et al. **J Dermatol** 1995 Oct;22(10):804–6

Microvascular angiopathy in advanced periodontal disease. Pinchback JS, et al. **J Pathol** 1996 Jun;179(2):204–9

DIAGNOSIS

Detection of stable and active periodontitis sites by clinical assessment and gingival crevicular acute–phase protein levels. Adonogianaki E, et al. **J Periodontal Res** 1996 Feb; 31(2):135–43

DRUG THERAPY

Comprehensive treatment of inflammatory diseases of parodontium by antiseptic and antiinflammatory agents made in Bulgaria. Botushanov P, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):100–1

Endodontial treatment of primary teeth by carbamide–formaldehyde agents. Indzjova K, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):105

Response to intracrevicular controlled delivery of 25% tetracycline from poly(lactide/glycolide) film strips in SPT patients. Maze GI, et al. **J Clin Periodontol** 1995 Nov; 22(11):860–7

Full– vs. partial–mouth disinfection in the treatment of periodontal infections: short–term clinical and microbiological observations. Quirynen M, et al. **J Dent Res** 1995 Aug;74(8):1459–67

The "cyclic" regimen of low–dose doxycycline for adult periodontitis: a preliminary study. Crout RJ, et al. **J Periodontol** 1996 May;67(5):506–14

Evaluation of periodontal treatments using controlled–release tetracycline fibers: clinical response. Drisko CL, et al. **J Periodontol** 1995 Aug;66(8):692–9

Evaluation of periodontal treatments using controlled–release tetracycline fibers: microbiological response. Lowenguth RA, et al. **J Periodontol** 1995 Aug;66(8):700–7

Evaluation of periodontal treatments using controlled-release tetracycline fibers: maintenance response. Michalowicz BS, et al. **J Periodontol** 1995 Aug;66(8):708–15

Microbial flora in the acute phase of periodontitis and the effect of local administration of minocycline. Umeda M, et al. **J Periodontol** 1996 Apr;67(4):422–7

[Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection] Sasaki J, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1093–118 (Eng. Abstr.) **(Jpn)**

[The experimental treatment of chronic periodontitis using ortofen] Chumakov AA, et al. **Stomatologiia (Mosk)** 1995; 74(4):8–10 **(Rus)**

[The treatment of acute periodontitis using sodium diclofenac experimentally] Chumakov AA, et al. **Stomatologiia (Mosk)** 1995;74(2):5–7 **(Rus)**

[The mechanisms of the cytoprotective action of prostacyclin in acute postoperative parotitis] Dolgov SN, et al. **Stomatologiia (Mosk)** 1995;74(2):46–7 (Eng. Abstr.) **(Rus)**

[Antibacterial therapy in the combined treatment of periodontitis] Romanov AE, et al. **Stomatologiia (Mosk)** 1996;75(1):23–5 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Comparison of host tissue and bacterial dipeptidyl peptidases in human gingival crevicular fluid by analytical isoelectric focusing. Gazi MI, et al. **Arch Oral Biol** 1995 Aug; 40(8):731–6

Expression of mRNA for matrix metalloproteinases and tissue inhibitors of metalloproteinases in periodontitis–affected human gingival tissue. Kubota T, et al. **Arch Oral Biol** 1996 Mar;41(3):253–62

Neutrophil elastase in crevicular fluid: comparison of a middle–aged general population with healthy and periodontitis groups. Smith QT, et al. **J Clin Periodontol** 1995 Dec;22(12):935–41

Oral fluid elastase as an indicator of periodontal health. Uitto VJ, et al. **J Clin Periodontol** 1996 Jan;23(1):30–7

Elevated conversion of alpha–2–macroglobulin to the complexed form in gingival crevicular fluid from adult periodontitis patients. Rosin M, et al. **J Periodontal Res** 1995 Nov;30(6):436–44

EPIDEMIOLOGY

[The effect of Kislovodsk narzan mineral water on dental caries incidence and intensity and on periodontal status] Garazha NN, et al. **Stomatologiia (Mosk)** 1996;75(1):33–6 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Ectopic supernumerary teeth as a predisposing cause in localized periodontitis. Case report. Hou GL, et al. **Aust Dent J** 1995 Aug;40(4):226–8

Increased interleukin–1 beta in the crevicular fluid of diseased implants. Kao RT, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec; 10(6):696–701

Financial stress linked to periodontal disease [news] **J Am Dent Assoc** 1995 Oct;126(10):1346

Smoking and its effects on early–onset periodontitis. Schenkein HA, et al. **J Am Dent Assoc** 1995 Aug; 126(8):1107–13

Resolution of ligature–induced peri–implantitis lesions in the dog. Marinello CP, et al. **J Clin Periodontol** 1995 Jun; 22(6):475–9

Re: Local predisposing events leading to gingivitis and periodontitis [letter] Ratcliff P. **J Periodontol** 1995 Aug; 66(8):749–50

Infantile genetic agranulocytosis (Kostmann type). A case report. Sağlam F, et al. **J Periodontol** 1995 Sep;66(9):808–10

Dietary shifts may explain the incidence of periodontitis in industrialized countries. Sewón LA, et al. **Med Hypotheses** 1996 Mar;46(3):269–75

[Familial case of Papillon–Lefèvre syndrome] Budai M, et al. **Fogorv Sz** 1996 Feb;89(2):51–5 **(Hun)**

[The pathogenetic mechanisms of periodontal tissue damage in chronic stress and spontaneous periodontitis in rats] Lytovchenko IIu, et al. **Fiziol Zh** 1995 Jan–Apr; 41(1–2):104–7 (Eng. Abstr.) **(Ukr)**

GENETICS

Genetic segregation analyses of serum IgG2 levels. Marazita ML, et al. **Am J Hum Genet** 1996 May;58(5):1042–9

Host defensive functions in a family manifesting early–onset periodontitis. Arai H, et al. **J Periodontol** 1996 Apr; 67(4):433–42

Immunological, genetic, and microbiological study of family members manifesting early–onset periodontitis. Nakagawa M, et al. **J Periodontol** 1996 Mar;67(3):254–63

IMMUNOLOGY

Gamma/delta T lymphocytes in marginal periodontitis in patients with Down's syndrome. Søhoel DC, et al. **Adv Exp Med Biol** 1995;371B:1135–6

Immunoglobulins in the saliva of diabetic patients with periodontitis. Anil S, et al. **Ann Dent** 1995 Summer–Fall; 54(1–2):30–3

Reduced CD8+ peripheral blood T lymphocytes in rapidly progressive periodontitis. Nagasawa T, et al. **Arch Oral Biol** 1995 Jul;40(7):605–8

Expression of HLA class II antigens in marginal periodontitis of patients with Down's syndrome. Søhoel DC, et al. **Eur J Oral Sci** 1995 Aug;103(4):207–13

Type–1 and type–2 CD8+ T–cell subsets isolated from chronic adult periodontitis tissue differ in surface phenotype and biological functions. Wassenaar A, et al. **Immunology** 1996 Jan;87(1):113–8

Immunochemical features of a macromolecule of Treponema denticola. Yotis WW, et al. **J Basic Microbiol** 1995; 35(4):255–68

Host response assessment in recurring periodontitis. Ebersole JL, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):258–62 (22 ref.)

The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. Lee HJ, et al. **J Clin Periodontol** 1995 Nov;22(11):885–90

Longitudinal changes in antibody avidity to Actinobacillus actinomycetemcomitans in periodontitis. O'Dell DS, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):203–11

Immunohistochemical localization of very late activation integrins in healthy and diseased human gingiva. Del Castillo LF, et al. **J Periodontal Res** 1996 Jan;31(1):36–42

Influence of sE–selectin and L–selectin on the regulation of cell migration during chronic periodontitis. Krugluger W, et al. **J Periodontal Res** 1995 May;30(3):198–203

Biased T cell receptor V gene usage in tissues with periodontal disease. Nakajima T, et al. **J Periodontal Res** 1996 Jan;31(1):2–10

Elevated conversion of alpha–2–macroglobulin to the complexed form in gingival crevicular fluid from adult periodontitis patients. Rosin M, et al. **J Periodontal Res** 1995 Nov;30(6):436–44

Presence of activated eosinophils, high IgE and sCD23 titers in gingival crevicular fluid of patients with adult periodontitis. Suzuki T, et al. **J Periodontal Res** 1995 May; 30(3):159–66

ICAM–1–expressing pocket epithelium, LFA–1–expressing T cells in gingival tissue and gingival crevicular fluid as features characterizing inflammatory cell invasion and exudation in adult periodontitis. Takeuchi Y, et al. **J Periodontal Res** 1995 Nov;30(6):426–35

Host defensive functions in a family manifesting early–onset periodontitis. Arai H, et al. **J Periodontol** 1996 Apr; 67(4):433–42

Detection of local and systemic cytokines in adult periodontitis. Prabhu A, et al. **J Periodontol** 1996 May; 67(5):515–22

Humoral immunity to commensal oral bacteria: quantitation, specificity and avidity of serum IgG and IgM antibodies reactive with Actinobacillus actinomycetemcomitans in children. Cole MF, et al. **Microbiol Immunol** 1995; 39(8):591–8

[The phagocytosis of polymorphonuclear neutrophilic granulocytes in progressive periodontitis] Konopka T, et al. **Schweiz Monatsschr Zahnmed** 1995;105(9):1129–33 (Eng. Abstr.) **(Ger)**

[The use of immunological indices for assessing the severity of the course of periodontitis and treatment efficacy] Bazhanov NN, et al. **Stomatologiia (Mosk)** 1996;75(1):15–8 (Eng. Abstr.) **(Rus)**

[The local activation of leukocytes and thrombocytes in periodontal diseases: the role of thrombocyte–activating factor] Leont'ev VK, et al. **Stomatologiia (Mosk)** 1996; 75(1):26–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Relationships between clinical parameters, Interleukin 1B and histopathologic findings of gingival tissue in periodontitis patients. Liu CM, et al. **Cytokine** 1996 Feb;8(2):161–7

Crevicular fluid osteocalcin and pyridinoline cross–linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. Giannobile WV, et al. **J Clin Periodontol** 1995 Dec;22(12):903–10

Increased release of free oxygen radicals from peripheral neutrophils in adult periodontitis after Fc delta–receptor stimulation. Gustafsson A, et al. **J Clin Periodontol** 1996 Jan;23(1):38–44

Vascular co–localization of proteolytic enzymes and proteinase inhibitors in advanced periodontitis. Pinchback JS, et al. **J Pathol** 1996 Jul;179(3):326–32

Protein composition of whole and parotid saliva in healthy and periodontitis subjects. Determination of cystatins, albumin, amylase and IgA. Henskens YM, et al. **J Periodontal Res** 1996 Jan;31(1):57–65

The effect of initial periodontal therapy on salivary platelet–activating factor levels in chronic adult periodontitis. Rasch MS, et al. **J Periodontol** 1995 Jul; 66(7):613–23

Levels of interleukin–1 beta and interleukin–8 in gingival crevicular fluids in adult periodontitis. Tsai CC, et al. **J Periodontol** 1995 Oct;66(10):852–9

[Estrogen receptors in the tissues of the marginal periodontium of patients with chronic generalized periodontitis] Kopelkin VN, et al. **Stomatologiia (Mosk)** 1995;74(4):13–4 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Comparison of host tissue and bacterial dipeptidyl peptidases in human gingival crevicular fluid by analytical isoelectric focusing. Gazi MI, et al. **Arch Oral Biol** 1995 Aug; 40(8):731–6

Purification and characterization of Porphyromonas gingivalis outer membrane antigens. Polak B, et al. **Arch Oral Biol** 1995 Oct;40(10):905–12

Refractory periodontitis in a Colombian population: predominant anaerobic bacterial flora and antibiotic susceptibility. Mejía GI, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S311–3

Polymerase chain reaction analysis of the Porphyromonas gingivalis collagenase gene. Slots J, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S167–8

Influence of anti–Actinobacillus actinomycetemcomitans Y4 (serotype b) lipopolysaccharide on severity of generalized early–onset periodontitis. Califano JV, et al. **Infect Immun** 1996 Sep;64(9):3908–10

Periodontitis–causing pathogens detected in HIV–positive children, siblings [news] **J Am Dent Assoc** 1995 Aug; 126(8):1094

Bacteria and periodontitis [editorial] Listgarten MA. **J Can Dent Assoc** 1996 Jan;62(1):12–3

Putative periodontal pathogens colonizing oral mucous membranes in denture–wearing subjects with a past history of periodontitis. Danser MM, et al. **J Clin Periodontol** 1995 Nov;22(11):854–9

Effect of periodontal treatments on serum IgG antibody titers against periodontopathic bacteria. Horibe M, et al. **J Clin Periodontol** 1995 Jul;22(7):510–5

The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. Lee HJ, et al. **J Clin Periodontol** 1995 Nov;22(11):885–90

Full– vs. partial–mouth disinfection in the treatment of periodontal infections: short–term clinical and microbiological observations. Quirynen M, et al. **J Dent Res** 1995 Aug;74(8):1459–67

Salivary levels of suspected periodontal pathogens in relation to periodontal status and treatment. von Troil–Lindén B, et al. **J Dent Res** 1995 Nov;74(11):1789–95

Distribution of Porphyromonas gingivalis and Treponema denticola in human subgingival plaque at different periodontal pocket depths examined by immunohistochemical methods. Kigure T, et al. **J Periodontal Res** 1995 Sep;30(5):332–41

Influence of periodontal bacteria and disease status on V beta expression in T cells. Mathur A, et al. **J Periodontal Res** 1995 Sep;30(5):369–73

Microflora in adult periodontitis. Petsios A, et al. **J Periodontal Res** 1995 Sep;30(5):325–31

Temperate bacteriophages are common among Actinobacillus actinomycetemcomitans isolates from periodontal pockets. Sandmeier H, et al. **J Periodontal Res** 1995 Nov;30(6):418–25

Detection of antigenic proteins in Porphyromonas gingivalis using two–dimensional electrophoresis and western blots. Tani M, et al. **J Periodontal Res** 1995 May;30(3):172–80

Characterisation of black–pigmented anaerobes isolated from diseased and healthy periodontal sites. Teanpaisan R, et al. **J Periodontal Res** 1995 Jul;30(4):245–51

Re: Comparison of DNA probe and ELISA microbial analysis methods and their association with adult periodontitis [letter; comment] Backman K. **J Periodontol** 1995 Jun;66(6):536–7. Comment on: J Periodontol 1994 Jun;65(6):576–82.

The effect of periodontal treatment on periodontal bacteria on the oral mucous membranes. Danser MM, et al. **J Periodontol** 1996 May;67(5):478–85

Evaluation of periodontal treatments using controlled–release tetracycline fibers: microbiological response. Lowenguth RA, et al. **J Periodontol** 1995 Aug;66(8):700–7

Periodontal status and detection frequency of bacteria at sites of periodontal health and gingivitis. Riviere GR, et al. **J Periodontol** 1996 Feb;67(2):109–15

Subgingival distribution of Treponema denticola, Treponema socranskii, and pathogen–related oral spirochetes: prevalence and relationship to periodontal status of sampled sites. Riviere GR, et al. **J Periodontol** 1995 Oct; 66(10):829–37

Microbial flora in the acute phase of periodontitis and the effect of local administration of minocycline. Umeda M, et al. **J Periodontol** 1996 Apr;67(4):422–7

Semiquantitative analysis of periodontopathogens by gene amplification. Sumi Y, et al. **Jpn J Med Sci Biol** 1995 Aug; 48(4):177–91

Heat shock proteins in the human periodontal disease process. Ando T, et al. **Microbiol Immunol** 1995;39(5):321–7

[Subgingival distribution of periodontopathic bacteria in periodontic patients and susceptibility of these bacteria to minocycline–HCl] Hagiwara S, et al. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):495–505 (Eng. Abstr.) **(Jpn)**

[Purification of serotype d–– and e––specific antigens from Actinobacillus actinomycetemcomitans and seroclassification of clinical isolates from periodontal patients] Yamamoto M. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):174–87 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Root cementum appearance in healthy monkeys and periodontitis–prone patients after different etching modalities. Blomlöf J. **J Clin Periodontol** 1996 Jan; 23(1):12–8

Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients.

Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6
Resolution of ligature-induced peri-implantitis lesions in the dog. Marinello CP, et al. **J Clin Periodontol** 1995 Jun; 22(6):475–9
High numbers of T cells in gingiva from patients with human immunodeficiency virus (HIV) infection. Odden K, et al. **J Oral Pathol Med** 1995 Oct;24(9):413–9
Periodontitis in the baboon: a potential model for human disease. Miller DR, et al. **J Periodontal Res** 1995 Nov; 30(6):404–9
Reproducibility and validity of furcation measurements as related to class of furcation invasion. Eickholz P. **J Periodontol** 1995 Nov;66(11):984–9
Gamma delta T lymphocytes in human periodontal disease tissue. Gemmell E, et al. **J Periodontol** 1995 Sep;66(9):780–5
Cervical cemental tears in older patients with adult periodontitis. Case reports. Ishikawa I, et al. **J Periodontol** 1996 Jan;67(1):15–20
Immunohistochemical study of gamma delta T cells in human gingival tissues. Kawahara K, et al. **J Periodontol** 1995 Sep; 66(9):775–9
Periodontal disease in HIV seropositive patients and its relation to lymphocyte subsets. Martínez-Canut P, et al. **J Periodontol** 1996 Jan;67(1):33–6

PHYSIOPATHOLOGY

Flow cytometric approach to human polymorphonuclear leukocyte activation induced by gingival crevicular fluid in periodontal disease. Biselli R, et al. **Inflammation** 1995 Aug;19(4):479–87
Effect of tetracycline HCl on periodontally-affected human root surfaces. Trombelli L, et al. **J Periodontol** 1995 Aug; 66(8):685–91
[The nervous system function of patients with periodontitis] Turbina LG, et al. **Stomatologiia (Mosk)** 1995;74(5):42–3 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Booth V, et al. **Infect Immun** 1996 Feb;64(2):422–7
Adjunctive supragingival irrigation with acetylsalicylic acid in periodontal supportive therapy. Flemmig TF, et al. **J Clin Periodontol** 1995 Jun;22(6):427–33
Long-term periodontal maintenance in private practice. Nevins M. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):273–7 (41 ref.)
Topical metronidazole application compared with subgingival scaling. A clinical and microbiological study on recall patients. Stelzel M, et al. **J Clin Periodontol** 1996 Jan;23(1):24–9
Evaluation of periodontal treatments using controlled-release tetracycline fibers: maintenance response. Michalowicz BS, et al. **J Periodontol** 1995 Aug;66(8):708–15

PSYCHOLOGY

Psychosocial factors in inflammatory periodontal diseases. A review. da Silva AM, et al. **J Clin Periodontol** 1995 Jul; 22(7):516–26 (103 ref.)

RADIOGRAPHY

[A clinical x-ray evaluation of the efficacy of hydroxyapatite with collagen in treating periodontitis and radicular cysts] Vorob'ev IuI, et al. **Stomatologiia (Mosk)** 1995;74(2):34–6 (Eng. Abstr.) **(Rus)**

RADIOTHERAPY

An evaluation of the Nd:YAG laser in periodontal pocket therapy. Radvar M, et al. **Br Dent J** 1996 Jan 20; 180(2):57–62

SURGERY

Evaluation of guided tissue regeneration in the treatment of paired periodontal defects. Pritlove-Carson S, et al. **Br Dent J** 1995 Nov 25;179(10):388–94
Bone allografts in periodontal therapy. Mellonig JT. **Clin Orthop** 1996 Mar;(324):116–25 (84 ref.)
Evaluation of the healing response following placement of Coe-pak and an experimental pack after periodontal flap surgery. Cheshire PD, et al. **J Clin Periodontol** 1996 Mar; 23(3 Pt 1):188–93
A comparative clinical study: the use of human type I collagen with and without the addition of metronidazole in the GTR method of treatment of periodontal disease. Dowell P, et al. **J Clin Periodontol** 1995 Jul;22(7):543–9
The effect of periodontal treatment on periodontal bacteria on the oral mucous membranes. Danser MM, et al. **J Periodontol** 1996 May;67(5):478–85
Fate of demineralized freeze-dried bone allografts in human intrabony defects. Reynolds MA, et al. **J Periodontol** 1996 Feb;67(2):150–7
[Alloplastic hydroxyapatite implants in treatment of periodontitis] Ziętek M, et al. **Polim Med** 1995; 25(1-2):25–32 (Eng. Abstr.) **(Pol)**

THERAPY

Specific serum IgA titres as realistic indicators of treatment prognoses. Landry RG. **Int Dent J** 1995 Aug;45(4):267–74
An open letter to all Canadian Periodontists. Perry R. **J Can Dent Assoc** 1996 Jan;62(1):13–4
Risk assessment of recurrence of disease during supportive periodontal care. Epidemiological considerations. Ainamo J, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):232–9 (141 ref.)
Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients. Claffey N, et al. **J Clin Periodontol** 1995 Sep;22(9):690–6
Influence of gingival crevicular washing on the expression of polymorphonuclear leukocyte membrane receptors before and after periodontal therapy. Di Murro C, et al. **J Clin Periodontol** 1995 Jul;22(7):578–83
Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153–9
Intrasulcular laser Doppler readings before and after root planing. Hinrichs JE, et al. **J Clin Periodontol** 1995 Nov; 22(11):817–23
Effect of periodontal treatments on serum IgG antibody titers against periodontopathic bacteria. Horibe M, et al. **J Clin Periodontol** 1995 Jul;22(7):510–5
Refractory periodontitis: critical questions in clinical management. Kornman KS. **J Clin Periodontol** 1996 Mar; 23(3 Pt 2):293–8 (48 ref.)
Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. Lang NP, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):240–50 (102 ref.)
Refractory periodontitis or recurrence of disease. Magnusson I, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):289–92 (23 ref.)
Periodontal healing and periopathogenic microflora in smokers and non-smokers. Preber H, et al. **J Clin Periodontol** 1995 Dec;22(12):946–52
The effect of non-surgical periodontal and adjunctive minocycline-HCL treatments on the activity of salivary proteases. Atilla G, et al. **J Periodontol** 1996 Jan;67(1):1–6
Effect of instrument power setting during ultrasonic scaling upon treatment outcome. Chapple IL, et al. **J Periodontol** 1995 Sep;66(9):756–60
Effect of periodontal treatment on the protein composition of whole and parotid saliva. Henskens YM, et al. **J Periodontol** 1996 Mar;67(3):205–12
Long-term evaluation of periodontal therapy: I. Response to 4 therapeutic modalities. Kaldahl WB, et al. **J Periodontol** 1996 Feb;67(2):93–102
Long-term evaluation of periodontal therapy: II. Incidence of sites breaking down. Kaldahl WB, et al. **J Periodontol** 1996 Feb;67(2):103–8
The effect of initial periodontal therapy on salivary platelet-activating factor levels in chronic adult periodontitis. Rasch MS, et al. **J Periodontol** 1995 Jul; 66(7):613–23
[The use of immunological indices for assessing the severity of the course of periodontitis and treatment efficacy] Bazhanov NN, et al. **Stomatologiia (Mosk)** 1996;75(1):15–8 (Eng. Abstr.) **(Rus)**
[The organization and modern principles of the treatment of periodontitis in the Armed Forces] Kovalevskiĭ AM, et al. **Voen Med Zh** 1995 Aug;(8):13–7, 80 (Eng. Abstr.) **(Rus)**

VETERINARY

Occurrence of gram-negative black-pigmented anaerobes in subgingival plaque during the development of canine periodontal disease. Boyce EN, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S317–9

PERIODONTITIS, APICAL see **PERIAPICAL PERIODONTITIS**

PERIODONTITIS, APICAL, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIODONTITIS, JUVENILE see **PERIODONTOSIS**

PERIODONTIUM

ANATOMY & HISTOLOGY

Examination of periodontal tissues by a cutting-grinding technique. Günhan M, et al. **Aust Dent J** 1996 Jun; 41(3):173–5
A multicenter clinical trial of PerioGard in distinguishing between diseased and healthy periodontal sites. (I). Study design, methodology and therapeutic outcome. Persson GR, et al. **J Clin Periodontol** 1995 Oct;22(10):794–803

BLOOD SUPPLY

Microvascular angiopathy in advanced periodontal disease. Pinchback JS, et al. **J Pathol** 1996 Jun;179(2):204–9
[Hemodynamics in the periodontium and gingiva] Charvát P, et al. **Cesk Fysiol** 1995 Dec;44(4):204–5 (Eng. Abstr.) **(Cze)**
[Measurement of hemodynamics in the periodontium and gingiva] Charvát P, et al. **Cesk Fysiol** 1995 Dec;44(4):204–5 (Eng. Abstr.) **(Cze)**

CHEMISTRY

[Estrogen receptors in the tissues of the marginal periodontium of patients with chronic generalized periodontitis] Kopeĭkin VN, et al. **Stomatologiia (Mosk)** 1995;74(4):13–4 (Eng. Abstr.) **(Rus)**
[Comparative study of chromatographic spectra of polypeptides extracted from pig spleen, liver, kidneys, thymus and parodontium] Kaĭdashev IP. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):85–9 (Eng. Abstr.) **(Rus)**

CYTOLOGY

Cementum specific components which influence periodontal connective tissue cells. Narayanan AS, et al. **Connect Tissue Res** 1995;33(1–3):19–21
Specific cementum attachment protein enhances selectively the attachment and migration of periodontal cells to root surfaces. Pitaru S, et al. **J Periodontal Res** 1995 Sep; 30(5):360–8

DRUG EFFECTS

Study of behaviour and endurance of Bioapatite implanted in the periodontium of the dog (closed model). Bonfil JJ, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1996 Feb-Mar;39(1–2):7–16
Periodontal tissue-vitality after different etching modalities. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun;22(6):464–8
Systemic retinoid medication and periodontal health in patients with Papillon-Lefèvre syndrome. Lundgren T, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):176–9
Agents with periodontal regenerative potential regulate cell-mediated collagen lattice contraction in vitro. MacNeil RL, et al. **J Dent Res** 1996 Mar;75(3):903–11
[Longitudinal studies on the effect of fluorine in drinking water on the periodontium during development and maturity] Adamowicz-Klepalska B. **Pol Tyg Lek** 1995 Sep; 50(36–39):75–8 (Eng. Abstr.) **(Pol)**
[The enhancement of the physiological resistance of the periodontal tissues in white rats under the action of biologically active substances from Laminaria] Drozhzhina VA, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec; 81(12):126–33 **(Rus)**

ENZYMOLOGY

Neutrophil elastase in crevicular fluid: comparison of a middle-aged general population with healthy and periodontitis groups. Smith QT, et al. **J Clin Periodontol** 1995 Dec;22(12):935–41
Loss of attachment in the marginal periodontium of the rat incisor under non-inflammatory conditions. Expression of alkaline phosphatase activity. Experimental Oral Biology Group. Groeneveld MC, et al. **J Periodontal Res** 1996 Jan; 31(1):66–72

INJURIES

An innovative method of cushioning metal clamp jaws during rubber dam isolation. Liebenberg WH. **J Can Dent Assoc** 1995 Oct;61(10):876–81

METABOLISM

In vitro assessment of bioadhesion for periodontal and buccal drug delivery. Needleman IG, et al. **Biomaterials** 1995 May; 16(8):617–24
Effects of bradykinin on Ca2+ mobilization and prostaglandin E2 release in human periodontal ligament cells. Ogata Y, et al. **Cell Biol Int** 1995 Aug;19(8):637–45
Immunohistochemical expression of extracellular matrix components of normal and healing periodontal tissues in the beagle dog. Matsuura M, et al. **J Periodontol** 1995 Jul; 66(7):579–93

MICROBIOLOGY

Rapid characterization of periodontal bacterial isolates by using fluorogenic substrate tests. Maiden MF, et al. **J Clin Microbiol** 1996 Feb;34(2):376–84
Periodontal pathogens on polytetrafluoroethylene membrane for guided tissue regeneration inhibit healing. Nowzari H, et al. **J Clin Periodontol** 1995 Jun;22(6):469–74
Volatile fatty acids, metabolic by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and cytokine production. Kurita-Ochiai T, et al. **J Dent Res** 1995 Jul;74(7):1367–73
Characterisation of black-pigmented anaerobes isolated from diseased and healthy periodontal sites. Teanpaisan R, et al. **J Periodontal Res** 1995 Jul;30(4):245–51
Periodontal status and detection frequency of bacteria at sites of periodontal health and gingivitis. Riviere GR, et al. **J Periodontol** 1996 Feb;67(2):109–15
[Microbiological studies of stomatological periodontal films containing a derivative of chlorocinnamic aldehyde] Davtian LL, et al. **Mikrobiol Z** 1995 Sep-Oct;57(5):78–83 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Morphological alterations in dental and periodontal tissues in murine mucopolysaccharidosis type VII. Gritli-Linde A, et al. **Calcif Tissue Int** 1995 Sep;57(3):178–84
Maintenance of new attachment 1 and 4 years following guided tissue regeneration (GTR). Weigel C, et al. **J Clin Periodontol** 1995 Sep;22(9):661–9
Histological observations of teeth and peridental tissues in cleidocranial dysplasia imply increased activity of

odontogenic epithelium and abnormal bone remodeling. Lukinmaa PL, et al. **J Craniofac Genet Dev Biol** 1995 Oct-Dec;15(4):212-21

[Long-term follow-up of tooth transplantation from the functional and periodontal viewpoint] Terheyden H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:84-7 (Eng. Abstr.) **(Ger)**

[Structural changes in the periodontal tissues under measured exposure to intra- and extraoral orthodontic appliances in the unstable bite] Panikarovskii VV, et al. **Stomatologiia (Mosk)** 1995;74(3):4-8 (Eng. Abstr.) **(Rus)**

[Morphological changes in the periodontium from the use of different designs of metal ceramic dentures] Panikarovskii VV, et al. **Stomatologiia (Mosk)** 1995; 74(2):8-12 (Eng. Abstr.) **(Rus)**

[The periodontium and mouth mucosa in patients with neutropenia] Zhilina VV, et al. **Stomatologiia (Mosk)** 1995; 74(2):68 **(Rus)**

[The pathogenetic mechanisms of periodontal tissue damage in chronic stress and spontaneous periodontitis in rats] Lytovchenko IIu, et al. **Fiziol Zh** 1995 Jan-Apr; 41(1-2):104-7 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Damped oscillation analysis of natural and artificial periodontal membranes. Okazaki M, et al. **Ann Biomed Eng** 1996 Mar-Apr;24(2):234-40

Immunolocalization of bone matrix macromolecules in human tissues regenerated from periodontal defects treated with expanded polytetrafluoroethylene membranes. Amar S, et al. **Arch Oral Biol** 1995 Jul;40(7):653-61

The influence of splinting procedures on the periodontal and peri-implant tissue damping characteristics. A longitudinal study with the Periotest device. Naert IE, et al. **J Clin Periodontol** 1995 Sep;22(9):703-8

Periodontal regeneration of human intrabony defects with titanium reinforced membranes. A controlled clinical trial. Cortellini P, et al. **J Periodontol** 1995 Sep;66(9):797-803

Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495-505 (58 ref.)

Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. Park JB, et al. **J Periodontol** 1995 Jun;66(6):462-77

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)

An in vitro investigation of the role of high molecular weight human salivary sulphated glycoprotein in periodontal wound healing. Zentner A, et al. **J Periodontol** 1995 Nov; 66(11):944-55

PHYSIOPATHOLOGY

[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44-51 (78 ref.) (Eng. Abstr.) **(Rus)**

[The functional status of the periodontium during the treatment of tooth crowding by the edgewise technic] Pankratova NV, et al. **Stomatologiia (Mosk)** 1996;75(1):64-5 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Efficacy of the FDA selection criteria for radiographic assessment of the periodontium. Atchison KA, et al. **J Dent Res** 1995 Jul;74(7):1424-32

SURGERY

[Experimental study of promoting the rates of dog's tooth rotation by circumferential supracrestal fiberotomy just before rotation] Duan Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):161-3 **(Chi)**

ULTRASONOGRAPHY

[The periodontal status of patients with hypoestrogenemia in relation to the severity of systemic osteoporosis] Khokhlova ElIu, et al. **Stomatologiia (Mosk)** 1995;74(2):31-3 (Eng. Abstr.) **(Rus)**

PERIODONTIUM, APICAL see **PERIAPICAL TISSUE**

PERIODONTOSIS

COMPLICATIONS

The possible association between localized juvenile periodontitis and supernumerary teeth. Odell EW, et al. **J Periodontol** 1995 Jun;66(6):449-51

ETIOLOGY

Influence of smoking and race on immunoglobulin G subclass concentrations in early-onset periodontitis patients. Quinn SM, et al. **Infect Immun** 1996 Jul;64(7):2500-5

GENETICS

Changes in neutrophil function in patients with early onset periodontitis according to family occurrence of the disease. Procházková J, et al. **Adv Exp Med Biol** 1995;371B:1127-9

Immunological, genetic, and microbiological study of family members manifesting early-onset periodontitis. Nakagawa M, et al. **J Periodontol** 1996 Mar;67(3):254-63

IMMUNOLOGY

Local antibodies and cytokine responses in crevicular fluid of patients with juvenile periodontitis. Bártová J, et al. **Adv Exp Med Biol** 1995;371B:1109-12

Influence of smoking and race on immunoglobulin G subclass concentrations in early-onset periodontitis patients. Quinn SM, et al. **Infect Immun** 1996 Jul;64(7):2500-5

Hyper-immunoglobulin G2 production by B cells from patients with localized juvenile periodontitis and its regulation by monocytes. Zhang JB, et al. **Infect Immun** 1996 Jun;64(6):2004-9

Prostaglandin E2 secretion, cell maturation, and CD14 expression by monocyte-derived macrophages from localized juvenile periodontitis patients. Shapira L, et al. **J Periodontol** 1996 Mar;67(3):224-8

MICROBIOLOGY

Microbiological study of juvenile periodontitis in Chile. López NJ, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S308-10

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365-79 (108 ref.)

Occurrence of certain bacterial species and morphotypes in juvenile periodontitis in Chile. López NJ, et al. **J Periodontol** 1995 Jul;66(7):559-67

PHYSIOPATHOLOGY

Changes in neutrophil function in patients with early onset periodontitis according to family occurrence of the disease. Procházková J, et al. **Adv Exp Med Biol** 1995;371B:1127-9

SURGERY

Comparative effectiveness of various regenerative modalities for the treatment of localized juvenile periodontitis. DiBattista P, et al. **J Periodontol** 1995 Aug;66(8):673-8

THERAPY

[The late results of the conservative and surgical treatments of chronic periodontitis of the permanent teeth in children and adolescents] Ivanova MS, et al. **Stomatologiia (Mosk)** 1995;74(3):56-9 (Eng. Abstr.) **(Rus)**

PERIOPERATIVE NURSING

see related
OPERATING ROOM NURSING
POSTANESTHESIA NURSING

Outpatient vaginal hysterectomy as a new trend in gynecology. Bran DF, et al. **AORN J** 1995 Nov;62(5):810-4

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875-81, 885-96; quiz 899-906 (31 ref.)

Multiple subpial transection for Landau-Kleffner syndrome. Buelow JM, et al. **AORN J** 1996 Apr;63(4):727-9, 732-5, 737-9; quiz 741-4 (26 ref.)

Does perioperative nursing include caring? Burchiel RN. **AORN J** 1995 Aug;62(2):257-9

Traumatic rupture of the descending thoracic aorta. Butler KL, et al. **AORN J** 1996 May;63(5):917-25 (32 ref.)

Recovery from laparoscopic cholecystectomy procedures. Cason CL, et al. **AORN J** 1996 Jun;63(6):1099-103, 1106-8, 1111-2 passim

Laparoscopic extraperitoneal herniorrhaphy. Collins LG. **AORN J** 1996 Jun;63(6):1089-94, 1096-8

Effect of continuously warmed i.v. fluids on intraoperative hypothermia. Ellis-Stoll CC, et al. **AORN J** 1996 Mar; 63(3):599-606

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739-46, 748, 750; quiz 754, 756-8 (18 ref.)

The spiritual needs of pediatric patients and their families. Fina DK. **AORN J** 1995 Oct;62(4):556-64

Laparoscopic Swenson pull-through procedure for congenital megacolon. George C, et al. **AORN J** 1995 Nov; 62(5):727-8, 731-6

Ensuring the readability of patient education materials is one way to demonstrate perioperative nurses' value [editorial] Giordano BP. **AORN J** 1996 Apr;63(4):699-700

Don't be a victim of surgical smoke [editorial] Giordano BP. **AORN J** 1996 Mar;63(3):520, 522

Perioperative care or elderly trauma patients. Keough V, et al. **AORN J** 1996 May;63(5):932-7

Surgical masks [letter] King CA. **AORN J** 1995 Aug; 62(2):164

A nurse's right to refuse a patient care assignment. Kuhn JE. **AORN J** 1995 Sep;62(3):412-4, 416, 418

Microsurgical transfer of vascularized tissue to close problem wounds. Lutz DA, et al. **AORN J** 1995 Aug;62(2):234-8, 240, 242-3

Dental restorations using titanium osseointegrated dental implants. McEwen DR, et al. **AORN J** 1995 Aug; 62(2):189-91, 193-8, 201-5; quiz 207-9 (14 ref.)

Normovolemic hemodilution in an adolescent having a spinal fusion for scoliosis. Martinelli AM. **AORN J** 1996 Apr; 63(4):788-90, 792-4

Progress on AORN's strategic plan demonstrates our continued commitment. Murphy EK. **AORN J** 1995 Aug; 62(2):151-4

Let us respect and value each other as we celebrate the nature of caring. Murphy EK. **AORN J** 1995 Nov;62(5):697, 700

Necrotizing fasciitis. Nelson-Conley CL. **AORN J** 1996 Jun; 63(6):1119-22

Video-assisted thoracoscopic releases of scoliotic anterior spines. Nymberg SM, et al. **AORN J** 1996 Mar;63(3):561-2, 565-9; 571-5; quiz 576, pass

Evaluating a revised self-efficacy scale for preoperative patients. Oetker-Black SL, et al. **AORN J** 1995 Aug; 62(2):244-6, 249-50

Intraoperative preparation of autologous fibrin gel. Pace RM. **AORN J** 1995 Oct;62(4):604-7

A perioperative nurse's perspective of a day that changed lives. Patterson K. **AORN J** 1995 Oct;62(4):608-11

Surgical management of patients with severe head injuries. Pieper DR, et al. **AORN J** 1996 May;63(5):854-64, 867 (29 ref.)

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907-16 (15 ref.)

Excision of renal cell carcinoma involving the inferior vena cava. Riddleberger S, et al. **AORN J** 1995 Oct;62(4):551-5

The use of diazepam and ketamine for i.v. conscious sedation in outpatient surgery settings. Ringler JD. **AORN J** 1995 Oct;62(4):638-45

Scalp replantation after traumatic injury. Rivera ML, et al. **AORN J** 1995 Aug;62(2):175-80, 182, 184

Active and associate AORN membership categories examined. Shumaker RP, et al. **AORN J** 1995 Sep; 62(3):420-3, 426-9

A western OR delegation to the People's Republic of China. Spry CC. **AORN J** 1996 Mar;63(3):525-8, 531-2

Pediatric fibromatosis requiring mandibular resection and reconstruction. Steuer KS. **AORN J** 1995 Aug;62(2):212, 215-24, 226

Inadvertent hypothermia in elderly surgical patients. Tappen RM, et al. **AORN J** 1996 Mar;63(3):639-44

Transcultural perioperative nursing in Berlin. Vane B, et al. **AORN J** 1996 Mar;63(3):533-7, 539, 541-4

AORN's lobbyist stresses the importance of knowledge, perseverance, and timing. Walker JF. **AORN J** 1996 Apr; 63(4):772-8

A successful device tracking program. Weed P. **AORN J** 1995 Aug;62(2):260-1, 264-5

Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. White SK, et al. **AORN J** 1996 Apr; 63(4):716-24

Separation of conjoined twins. Wirt SW, et al. **AORN J** 1995 Oct;62(4):527-40, 543-5; quiz 546-50 (25 ref.)

CLASSIFICATION

In search of perioperative nursing data elements. Kleinbeck SV. **AORN J** 1996 May;63(5):926-31

ECONOMICS

Cost v cost-effective. Belkin NL. **AORN J** 1996 Mar; 63(3):632-3

EDUCATION

Educational research [letter; comment] Brazen L. **AORN J** 1995 Jul;62(1):17. Comment on: AORN J 1995 May;61(5):852-7.

Outcomes research on one continuing education activity. Brazen L. **AORN J** 1995 Jul;62(1):92-100

A perioperative elective for college credit. Brown MB, et al. **AORN J** 1996 Mar;63(3):590-2, 595, 597-8

AORN OR Learning Lab hub of educational activity [news] Edmiston D. **AORN J** 1995 Nov;62(5):765-6

A multidisciplinary approach to intraoperative fire safety. Fennell MR. **AORN J** 1995 Oct;62(4):636-7

You can be in Jeopardy. Ford DA, et al. **AORN J** 1996 Mar;63(3):583-9

RN first assistant [letter] Fortunato N. **AORN J** 1995 Oct; 62(4):505-6

Promoting perioperative nursing through international cooperation. Hendel T, et al. **AORN J** 1996 Mar; 63(3):548-54

AORN sales professional course. Moss R, et al. **AORN J** 1996 Apr;63(4):745-9

A surgical services learning needs assessment. Piatkowski CA. **AORN J** 1995 Aug;62(2):251-4

RN first assistant [letter; comment] Proulx D, et al. **AORN J** 1995 Nov;62(5):707, 709. Comment on: AORN J 1995 Aug;62(2):164.

RN first assistant program [letter; comment] [see comments] Radzvin LC. **AORN J** 1995 Aug;62(2):164. Comment on: AORN J 1995 Mar;61(3):476-8. Comment in: AORN J 1995 Nov;62(5):707. Comment in: AORN J 1995 Nov;62(5):707, 709.

RN first assistant [letter; comment] Rothrock JC. **AORN J** 1995 Nov;62(5):707. Comment on: AORN J 1995 Aug;62(2):164.

Developing competency-based perioperative orientation programs. Schramm CA, et al. **AORN J** 1995 Oct;62(4):579, 582–90

Competency-based orientation for registered perioperative nurses. Speers AT, et al. **AORN J** 1995 Oct;62(4):567–74, 577–8

HISTORY

A salute to the nurses of World War II. Breakiron M. **AORN J** 1995 Nov;62(5):710–22

The way it was—perioperative nursing 50 years ago [editorial] Giordano BP. **AORN J** 1995 Nov;62(5):702, 704

A historical decline of educational perioperative clinical experiences. Wagner VD, et al. **AORN J** 1995 Nov; 62(5):771–2, 775–80, 782 (46 ref.)

LEGISLATION & JURISPRUDENCE

Environmental laws and the perioperative setting. Johnson LC, et al. **AORN J** 1996 Mar;63(3):645–7

Becoming knowledgeable in the legislative process can help nurses shape their own future. Porter J, et al. **AORN J** 1996 Mar;63(3):618–21; quiz 622–4 (0 ref.)

MANPOWER

A career ladder program designed by perioperative staff nurses. Day DS, et al. **AORN J** 1995 Nov;62(5):805–9

Substance abuse in the perioperative setting. Dillmann JM. **AORN J** 1995 Jul;62(1):111–2

RN first assistants. RN First Assistant Specialty Assembly 1995–1996 Governing Council. Johnson CR, et al. **AORN J** 1996 Apr;63(4):782–7

METHODS

Leech therapy in digital replantation. Golden MA, et al. **AORN J** 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059–63, 1066–79; quiz 1080–6 (38 ref.)

Hand signals in surgery [published erratum appears in AORN J 1996 May;63(5):853] Pezzella AT. **AORN J** 1996 Apr; 63(4):769–71

ORGANIZATION & ADMINISTRATION

The perioperative nurse's role in anesthesia management. Stein RH. **AORN J** 1995 Nov;62(5):794–8, 801, 803–4 (21 ref.)

STANDARDS

Proposed recommended practices for use and selection of barrier materials for surgical gowns and drapes. **AORN J** 1995 Sep;62(3):449–53

Proposed recommended practices for safe care through identification of potential hazards in the surgical environment. **AORN J** 1995 Sep;62(3):455–61

Recommended practices for safe care through identification of potential hazards in the surgical environment. Association of Operating Room Nurses. **AORN J** 1996 Apr;63(4):802–6

Recommended practices for documentation of perioperative nursing care. Association of Operating Room Nurses. **AORN J** 1996 Jun;63(6):1145, 1148, 1150

Recommended practices for use and selection of barrier materials for surgical gowns and drapes. Association of Operating Room Nurses. **AORN J** 1996 Mar;63(3):650, 653–4

Recommended practices for traffic patterns in the perioperative practice setting. Association of Operating Room Nurses. **AORN J** 1996 Mar;63(3):655–8

Proposed recommended practices for traffic patterns in the perioperative practice setting. Association of Operating Room Nurses. **AORN J** 1995 Aug;62(2):273–5

Recommended practices for selection and use of packaging systems. Association of Operating Room Nurses. **AORN J** 1996 May;63(5):949–53

Clinical issues [letter] Allen G. **AORN J** 1996 May;63(5):853

Meeting infection control standards in the OR. Allen G, et al. **AORN J** 1995 Oct;62(4):595–6, 599–602

Unsubstantiated assumptions about unlicensed assistive personnel obscure the challenge of delivering quality patient care [see comments] Murphy EK. **AORN J** 1995 Jul;62(1):8, 10. Comment in: AORN J 1995 Sep;62(3):333.

Perioperative nursing certification and recertification issues. O'Neale M. **AORN J** 1996 Mar;63(3):630–1

Dental surgery standards for perioperative nurses. Medical Center of Central Georgia. Sanders RA, et al. **AORN J** 1995 Aug;62(2):227–9, 232–3

Developing competency-based perioperative orientation programs. Schramm CA, et al. **AORN J** 1995 Oct;62(4):579, 582–90

Competency-based orientation for registered perioperative nurses. Speers AT, et al. **AORN J** 1995 Oct;62(4):567–74, 577–8

Quality circles as problem-solving tools in perioperative settings. Tuttle D. **AORN J** 1996 Mar;63(3):625, 628–9

The use of qualitative methods in the study of parents' experiences of care on a children's surgical ward. Callery P, et al. **J Adv Nurs** 1996 Feb;23(2):338–45

PERIOSTEUM

Anaerobic and aerobic isolates from a subperiosteal orbital abscess in a 4-year-old [letter] Harris GJ, et al. **Arch Ophthalmol** 1996 Jan;114(1):98

Periosteal osteosarcoma in the long head of the triceps in a dog. Cook JL, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):317–20

Periosteal Ewing sarcoma. Declerck S, et al. **J Belge Radiol** 1995 Aug;78(4):227

Effects of periosteal stripping on healing of segmental fractures in rats. Utvåg SE, et al. **J Orthop Trauma** 1996; 10(4):279–84

Parosteal lipoma. Davis RI, et al. **Ulster Med J** 1994 Oct; 63(2):235–7

[Dysphagia caused by Forestier disease and periosteophytic hematoma (letter)] Torres Almendros M, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):610–1 **(Spa)**

ABNORMALITIES

Periosteal tether causing angular growth deformity: report of two clinical cases and an experimental model. Haasbeek JF, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):677–81

ANATOMY & HISTOLOGY

Fibrocartilage associated with human tendons and their pulleys. Benjamin M, et al. **J Anat** 1995 Dec;187 (Pt 3):625–33

Histologic and biochemical analysis of osteogenic capacity of vascularized periosteum. Ishida H, et al. **Plast Reconstr Surg** 1996 Mar;97(3):512–8

BLOOD SUPPLY

Periosteal response to transient ischemia. Histological studies on the rat tibia. Svindland AD, et al. **Acta Orthop Scand** 1995 Oct;66(5):468–72

Periosteal and endosteal reaction to reaming and nailing: the possible role of revascularization on the endosteal anchorage of cementless stems. Pazzaglia UE. **Biomaterials** 1996 May;17(10):1009–14

Acute vascular response to intramedullary reaming [letter; comment] Oni OO. **J Bone Joint Surg Br** 1995 Nov; 77(6):981–2. Comment on: J Bone Joint Surg Br 1995 May;77(3):490–3.

[The periosteum: the "umbilical cord" of bone. Quantification of the blood supply of cortical bone of periosteal origin] Chanavaz M. **Rev Stomatol Chir Maxillofac** 1995; 96(4):262–7 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Periosteal insulin-like growth factor I and bone formation. Changes during tibial lengthening in rabbits. Schumacher B, et al. **Acta Orthop Scand** 1996 Jun;67(3):237–41

CYTOLOGY

Mechanically induced periosteal bone formation is paralleled by the upregulation of collagen type one mRNA in osteocytes as measured by in situ reverse transcript-polymerase chain reaction. Sun YQ, et al. **Calcif Tissue Int** 1995 Dec;57(6):456–62

EMBRYOLOGY

Expression of syndecan-3 and tenascin-C: possible involvement in periosteum development. Koyama E, et al. **J Orthop Res** 1996 May;14(3):403–12

GROWTH & DEVELOPMENT

Morphological aspects of periostal osteogenesis. Baltadjiev G. **Folia Med (Plovdiv)** 1995;37(4A Suppl):20

[Expression of growth dynamic in the structure of periosteal bone in Anas platyrhynchos] Castanet J, et al. **C R Acad Sci III** 1996 Apr;319(4):301–8 (Eng. Abstr.) **(Fre)**

INJURIES

Relationship of the subperiosteal bone collar to metaphyseal lesions in abused infants. Kleinman PK, et al. **J Bone Joint Surg Am** 1995 Oct;77(10):1471–6

METABOLISM

Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts—correlation with prostaglandin upregulation. Klein-Nulend J, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):640–8

PATHOLOGY

A periosteal ganglion of the distal part of the radius, A case report. Benedett GE, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1415–8

Periosteal ganglion: a report of three new cases including MRI findings and a review of the literature. Okada K, et al. **Skeletal Radiol** 1996 Feb;25(2):153–7 (14 ref.)

PHYSIOLOGY

Cytokines modulate phagocytosis and intracellular digestion of collagen fibrils by fibroblasts in rabbit periosteal explants. Inverse effects on procollagenase production and collagen phagocytosis. van der Zee E, et al. **J Cell Sci** 1995 Oct; 108 (Pt 10):3307–15

Modification of rhythmical jaw movements by noxious pressure applied to the periosteum of the zygoma in decerebrate rabbits. Schwartz G, et al. **Pain** 1995 Nov; 63(2):153–61

RADIOGRAPHY

Child abuse fracture through physiologic periosteal reaction. Pergolizzi R Jr, et al. **Pediatr Radiol** 1995;25(7):566–7

SURGERY

Effect of periosteal stripping on cortical bone perfusion: a laser doppler study in sheep. Kowalski MJ, et al. **Calcif Tissue Int** 1996 Jul;59(1):24–6

Bone growth and modeling changes induced by periosteal stripping in the rat. Hernández JA, et al. **Clin Orthop** 1995 Nov;(320):211–9

[Indications for mandibular periosteotomy in the treatment of cancer of the oral cavity] Belli E, et al. **Minerva Stomatol** 1995 Oct;44(10):455–65 (Eng. Abstr.) **(Ita)**

TRANSPLANTATION

Autologous pericranial graft resurfacing after high condylectomy and discectomy of the temporomandibular joint in rabbits. Wong TY, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):747–52

[Chondrogenic potential of a free autogenous periosteal graft for biological resurfacing over a half-thickness defect in a joint surface: an experimental study] Naito K. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):767–75 (Eng. Abstr.) **(Jpn)**

PERIOSTITIS

Florid reactive periostitis of the thumb. Riaz M, et al. **J Hand Surg [Br]** 1996 Apr;21(2):276–9

COMPLICATIONS

[Multifocal periostitis in SAPHO syndrome] Steinborn M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jun;164(6):514–6 **(Ger)**

DIAGNOSIS

Periosteal ganglion: a report of three new cases including MRI findings and a review of the literature. Okada K, et al. **Skeletal Radiol** 1996 Feb;25(2):153–7 (14 ref.)

[Two cases of skeletal fluorosis in the hand] Sy MH, et al. **Ann Chir Main Memb Super** 1996;15(2):109–14 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222–6 (17 ref.)

[Periostosis and Crohn disease: value of methotrexate (letter)] Pierrugues R, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):954–5 **(Fre)**

MICROBIOLOGY

Coccidioides immitis subperiosteal abscess of the temporal bone in a child. Low WS, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):189–92

Parrot pseudoparalysis of the upper extremities. A case report. Kocher MS, et al. **J Bone Joint Surg Am** 1996 Feb; 78(2):284–7

RADIOGRAPHY

Periostitis ossificans. VanDoorne I, et al. **Acta Stomatol Belg** 1995 Sep;92(3):131–6

RADIONUCLIDE IMAGING

Florid reactive periostitis. Loyens M, et al. **J Belge Radiol** 1995 Jun;78(3):175–6

SURGERY

Endoscopic vs external drainage of orbital subperiosteal abscess. Page EL, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):737–40

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)

PERIPHERAL ANGIOPATHIES see **PERIPHERAL VASCULAR DISEASES**

PERIPHERAL CATHETERIZATION see **CATHETERIZATION, PERIPHERAL**

PERIPHERAL EQUIPMENT, COMPUTER see **COMPUTER PERIPHERALS**

PERIPHERAL NERVE DISEASES see **PERIPHERAL NERVOUS SYSTEM DISEASES**

PERIPHERAL NERVE NEOPLASMS

Paraganglioma of the cauda equina. A case report and review of the literature. Bak J, et al. **APMIS** 1996 Mar; 104(3):234–40 (29 ref.)

CHEMISTRY

Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Gladson CL, et al. **Am J Pathol** 1996 May;148(5):1423–34

Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

COMPLICATIONS

Carpal tunnel syndrome due to T cell lymphoma. Chevalier X, et al. **Arthritis Rheum** 1995 Nov;38(11):1707–9

Alternating sciatica while jogging: an early symptom of cauda equina tumor. Inoue K, et al. **Clin Orthop** 1996 Jul; (328):102–7

Space-occupying lesions as a cause of tarsal tunnel syndrome [letter] Boc SF, et al. **J Am Podiatr Med Assoc** 1995 Nov; 85(11):713–5

Hand dystonia and neuralgic pain due to neurovascular contact to cervical spinal root [letter] Scaioli V, et al. **Mov Disord** 1996 Jan;11(1):102–4

[Cauda equina cavernous hemangioma associated with hydrocephalus--case report] Makino K, et al. **No To Shinkei** 1995 Aug;47(8):783–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Schwannoma of the brachial plexus. Zbaren P, et al. **Ann Otol Rhinol Laryngol** 1996 Sep;105(9):748–50

MRI of intraspinal nerve sheath tumours presenting with sciatica. Loke TK, et al. **Australas Radiol** 1995 Aug; 39(3):228–32

Alternating sciatica while jogging: an early symptom of cauda equina tumor. Inoue K, et al. **Clin Orthop** 1996 Jul; (328):102–7

Malignant granular cell tumor mimicking herniated nucleus pulposus. Saperstein AL, et al. **Clin Orthop** 1996 Mar; (324):244–50

MRI of paraganglioma of the filum terminale. Boncoeur-Martel MP, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):162–5

Giant paraganglioma of the cauda equina in adolescence: magnetic resonance imaging demonstration. Wolansky LJ, et al. **J Neuroimaging** 1996 Jan;6(1):54–6

Primitive neuroectodermal tumor of the median nerve. Case report with cytogenetic analysis. Akeyson EW, et al. **J Neurosurg** 1996 Jul;85(1):163–9

Clear cell sarcoma mimicking peripheral nerve sheath tumor. Schnarkowski P, et al. **Skeletal Radiol** 1996 Feb; 25(2):197–200

[Echography and magnetic resonance using gadolinium in a case of benign schwannoma of the sciatic popliteal nerve] Carretta G, et al. **Radiol Med (Torino)** 1995 Oct;90(4):510–3 **(Ita)**

ETIOLOGY

Neuroma of the superficial branch of the radial nerve after intravenous cannulation. Stahl S, et al. **Anesth Analg** 1996 Jul;83(1):180–2

Breast cancer recurrence in a patient with a previous history of radiation injury of the brachial plexus: a case report. Brennan MJ. **Arch Phys Med Rehabil** 1995 Oct; 76(10):974–6

GENETICS

Cytogenetic and histologic correlation of peripheral nerve sheath tumors of soft tissue. Rao UN, et al. **Cancer Genet Cytogenet** 1996 May;88(1):17–25

METABOLISM

Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191–8 (62 ref.)

Sodium channel accumulation in humans with painful neuromas. England JD, et al. **Neurology** 1996 Jul; 47(1):272–6

Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Guha A, et al. **Oncogene** 1996 Feb 1;12(3):507–13

Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Kindblom LG, et al. **Virchows Arch** 1995;427(1):19–26

PATHOLOGY

Cutaneous intraneural glomus tumor. Calonje E, et al. **Am J Dermatopathol** 1995 Aug;17(4):395–8

A case of von Recklinghausen's disease with bilateral pheochromocytoma-malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Sakaguchi N, et al. **Am J Surg Pathol** 1996 Jul; 20(7):889–97

Giant cell ependymoma of the filum terminale. A report of two cases. Zec N, et al. **Am J Surg Pathol** 1996 Sep; 20(9):1091–101

Cytogenetic and histologic correlation of peripheral nerve sheath tumors of soft tissue. Rao UN, et al. **Cancer Genet Cytogenet** 1996 May;88(1):17–25

Pathology of the major peripheral nerve sheath neoplasms. Woodruff JM. **Monogr Pathol** 1996;38:129–61 (67 ref.)

Purely epithelioid schwannoma. Two case reports and a review of the literature. Artico M, et al. **Neurochirurgie** 1996;42(1):61–5 (20 ref.)

Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

[Tumor of the peripheral nerve sheath with rhabdomyoblastic differentiation arising in a ganglioneuroma: neurilemmoma? A fortuitously detected case] Grippari JL, et al. **Ann Pathol** 1996;16(2):128–32 (Eng. Abstr.) **(Fre)**

[Malignant neoplasms of the peripheral nerve sheaths with cellular immunophenotype of perineural cells (perineural sarcoma?)] Smirtnov AV, et al. **Arkh Patol** 1995 Sep-Oct; 57(5):14–20 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[Urinary tract repercussions in patients with lipomeningocele: a review of 20 cases] Sousa Campos M, et al. **Arch Esp Urol** 1995 Nov;48(9):926–9 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Preventing neuroma formation in finger amputation. De Smet L. **Acta Orthop Belg** 1996 Mar;62(1):69–70

SECONDARY

Isolated metastases to peripheral nerves. Report of five cases involving the brachial plexus. Meller I, et al. **Cancer** 1995 Nov 15;76(10):1829–32

Perineural spread of epidermoid carcinoma in the infraorbital nerve: case report. Arcas A, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):520–2

Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)

Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)

Spinal malignant lymphoma appearing after radiation and chemotherapy of a pineal region tumor. Amagasa M, et al. **Surg Neurol** 1996 Feb;45(2):167–9; discussion 169–71

SURGERY

Primary spinal malignant schwannomas: clinical and prognostic remarks. Celli P, et al. **Acta Neurochir (Wien)** 1995;135(1-2):52–5

Results of excision of the interdigital nerve in the treatment of Morton's metatarsalgia. Dereymaeker G, et al. **Acta Orthop Belg** 1996 Mar;62(1):22–5

Schwannoma of the superficial peroneal nerve presenting as web space pain. Laurencin CT, et al. **J Foot Ankle Surg** 1995 Nov-Dec;34(6):532–3

Angiomyoma (vascular leiomyoma) of the median nerve. Piers W, et al. **J Hand Surg [Am]** 1996 Mar;21(2):285–6

Hemangiopericytoma of the sciatic notch presenting as sciatica in a young healthy man: case report. Harrison MJ, et al. **Neurosurgery** 1995 Dec;37(6):1208–11; discussion 1211–2

Intraneural neurothekeoma: case report. Kleinschmidt-DeMasters BK, et al. **Neurosurgery** 1995 Aug;37(2):333–4; discussion 334–5

Obstetrical brachial plexus palsy: results following neurolysis of conducting neuromas-in-continuity. Clarke HM, et al. **Plast Reconstr Surg** 1996 Apr;97(5):974–82; discussion 983–4

Video-assisted thoracoscopic resection of intercostal neurofibroma. Lyons MK, et al. **Surg Neurol** 1995 Jun; 43(6):542–5

[Clinical and pathologic analysis of 33 cases of brachial plexus neurinoma] Chen D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):488–9 (Eng. Abstr.) **(Chi)**

[Fibrolipoma of the median nerve. Review of 10 surgically treated cases with a mean recall of 8 years] Salon A, et al. **Ann Chir Main Memb Super** 1995;14(6):284–95 (Eng. Abstr.) **(Fre)**

[Peripheral nerve tumors: management tactics] Radek A, et al. **Neurol Neurochir Pol** 1995 May-Jun;29(3):389–99 (Eng. Abstr.) **(Pol)**

THERAPY

Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)

VETERINARY

A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. Brehm DM, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug;31(4):349–59

What is your neurologic diagnosis? Nerve root neoplasm. Sullivan SA, et al. **J Am Vet Med Assoc** 1995 Nov 1; 207(9):1165–7

PERIPHERAL NERVES

see related
NERVE FIBERS

Anatomy, function, and pathophysiology of peripheral nerves and nerve compression. Lundborg G, et al. **Hand Clin** 1996 May;12(2):185–93 (77 ref.)

Peptidergic innervation of the primate meibomian gland. Chung CW, et al. **Invest Ophthalmol Vis Sci** 1996 Jan; 37(1):238–45

Peripheral nerve blocks for paediatric day-stay surgery: one year's experience in a district general hospital. Keohane M, et al. **Ulster Med J** 1995 Apr;64(1):39–41

[Results of 466 nerve decompressions in 123 leprosy patients during polychemotherapy with a minimum follow-up of one year. Value of preventive surgery in a leprosy control program] Ramarorazana S, et al. **Arch Inst Pasteur Madagascar** 1994;61(2):115–7 (Eng. Abstr.) **(Fre)**

[Perineural metastatic spread along the infraorbital nerve in malignant neoplasms of the skin. Findings with computerized tomography and magnetic resonance in 2 cases] Biandino A, et al. **Radiol Med (Torino)** 1995 Jul-Aug; 90(1-2):129–31 **(Ita)**

ABNORMALITIES

Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. van Geel BM, et al. **Neurology** 1996 Jan;46(1):112–8

ANATOMY & HISTOLOGY

Anatomic observations on the suprascapular nerve. Ozer Y, et al. **Hand Clin** 1995 Nov;11(4):539–44

Patterns of morphological variation within myelin internodes of normal peripheral nerve: quantitative analysis by confocal microscopy. Reynolds RJ, et al. **J Anat** 1995 Oct; 187 (Pt 2):369–78

The midline posterior elbow incision. An anatomical appraisal. Dowdy PA, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):696–9

An anatomical analysis of the dorsoventral relationship between the sacral plexus and the pudendal nerve in man by use of computer aided three-dimensional reconstruction. Akita K, et al. **Okajimas Folia Anat Jpn** 1995 May; 72(1):29–35

Anatomic considerations of the peripheral nerve in compressive neuropathies of the upper extremity. George V, et al. **Orthop Clin North Am** 1996 Apr;27(2):211–8 (22 ref.)

[Loss of innervation of the anterior cruciate ligament in idiopathic gonarthrosis] Sparmann M, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):233–7 (Eng. Abstr.) **(Ger)**

[Methodological considerations concerning peripheral nerve morphometry] Cuadras J, et al. **Rev Neurol** 1995 May-Jun; 23(121):621–6 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Vasculitic neuropathy. Fathers E, et al. **Br J Hosp Med** 1996 May 15-Jun 4;55(10):643–7 (28 ref.)

CHEMISTRY

Utrophin expression during human fetal development. Rigoletto C, et al. **Int J Dev Neurosci** 1995 Oct;13(6):585–93

Connexin43 is another gap junction protein in the peripheral nervous system. Yoshimura T, et al. **J Neurochem** 1996 Sep;67(3):1252–8

Tyrosine hydroxylase, neuropeptide Y, substance P, calcitonin gene-related peptide and vasoactive intestinal peptide in nerves of rat periovarian adipose tissue: an immunohistochemical and ultrastructural investigation. Giordano A, et al. **J Neurocytol** 1996 Feb;25(2):125–36

Glutathione and protein kinase C in peripheral nervous tissue. Romero FJ, et al. **Methods Enzymol** 1995;252:146–53

Structure and function of peripheral nerve myelin proteins. Uyemura K, et al. **Prog Brain Res** 1995;105:311–8 (27 ref.)

CYTOLOGY

Sympathetic skin response and regeneration of sudomotor fibers after complete division of peripheral nerves. Ahčan U, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1-2):69–75

DRUG EFFECTS

Role of leukaemia inhibitory factor (LIF) in rat peripheral nerve regeneration. Donato R, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):94–100

Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Cotter MA, et al. **Diabetologia** 1995 Nov;38(11):1285–94

Didanosine (ddI) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits. Warner WA, et al. **Food Chem Toxicol** 1995 Dec;33(12):1047–50

Clinical and electroneurophysiological assessment of leprosy patients on dapsone monotherapy--a two year follow-up study. Rao SP, et al. **Indian J Lepr** 1995 Apr-Jun; 67(2):167–76

The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Malone JI, et al. **Metabolism** 1996 Jul;45(7):902–7

Peripheral nerve repair: role of agarose matrix density on functional recovery. Labrador RO, et al. **Neuroreport** 1995 Oct 23;6(15):2022–6

Investigation on neurotoxicity of occupational exposure to cyclohexane: a neurophysiological study. Yuasa J, et al. **Occup Environ Med** 1996 Mar;53(3):174–9

Meso–tetra–(4–sulfonatophenyl)–porphine of low neurotoxicity. Střelečková E, et al. **Sb Lek** 1995;96(1):7–13

Fibrin sealant matrix supports outgrowth of peripheral sensory axons. Zeng L, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):199–204

Evaluation of tissue adhesive to contain axonal regeneration in horses. Turner AS, et al. **Vet Surg** 1995 Jul–Aug; 24(4):308–14

EMBRYOLOGY

Neurofibromin–deficient fibroblasts fail to form perineurium in vitro. Rosenbaum T, et al. **Development** 1995 Nov; 121(11):3583–92

ENZYMOLOGY

Distribution of mu–calpain proenzyme in the brain and other neural tissues in the rat. Onizuka K, et al. **Brain Res** 1995 Oct 30;697(1–2):179–86

Scanning electron microscopic observations of nerves in the guinea–pig gallbladder after an acetylcholinesterase histochemistry. Gonda T, et al. **J Smooth Muscle Res** 1995 Aug;31(4):153–62

Glutathione and protein kinase C in peripheral nervous tissue. Romero FJ, et al. **Methods Enzymol** 1995;252:146–53

GROWTH & DEVELOPMENT

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

IMMUNOLOGY

Membrane attack complex in thickened cutaneous sensory nerves of leprosy patients. Parkash O, et al. **Acta Leprol** 1995;9(4):195–9

Role of antineural antibodies in perpetuation of a pre–existing peripheral nerve damage in leprosy. Desikan P, et al. **Indian J Lepr** 1995 Jul–Sep;67(3):293–300

Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up–regulation of cell surface expression of MAC–2 by macrophages and Schwann cells. Saada A, et al. **J Cell Biol** 1996 Apr; 133(1):159–67

Reduction in peripheral nerve allograft antigenicity with warm and cold temperature preservation. Strasberg SR, et al. **Plast Reconstr Surg** 1996 Jan;97(1):152–60

[Induction of human platelet aggregation by nerve tissue antigens and immune complexes] Matusevich LI, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):29–31 (Eng. Abstr.) **(Rus)**

INJURIES

Type of needle point and nerve damage [letter; comment] Rice AS. **Anaesthesia** 1996 Jan;51(1):98–9. Comment on: Anaesthesia 1995 Jun;50(6):573.

Ultrastructural study of peripheral nerve injury induced by monopolar and bipolar diathermy. Zohar Y, et al. **Ann Otol Rhinol Laryngol** 1996 Sep;105(9):673–7

Hand sensibility measures used by therapists. Mielke K, et al. **Ann Plast Surg** 1996 Mar;36(3):292–6

Importance of crossover innervation in digital nerve repair demonstrated by nerve isolation technique. Tadjalli HE, et al. **Ann Plast Surg** 1995 Jul;35(1):32–5

Digital nerve repair: relationship between severity of injury and sensibility recovery. Tadjalli HE, et al. **Ann Plast Surg** 1995 Jul;35(1):36–40

Shoulder arthroscopy and nerve injury: pitfalls and prevention. Stanish WD, et al. **Arthroscopy** 1995 Aug; 11(4):458–66

Nerve injury at abdominal hysterectomy [letter; comment] Rankin GL. **Br J Obstet Gynaecol** 1996 Jan;103(1):93. Comment on: Br J Obstet Gynaecol 1995 Aug;102(8):665–6.

Paradoxical clinical consequences of peripheral nerve injury [letter] Lynch G, et al. **Br J Plast Surg** 1996 Jun; 49(4):258–60

Paradoxical clinical consequences of peripheral nerve injury: a review of anatomical, neurophysiological and psychological mechanisms. McAllister RM, et al. **Br J Plast Surg** 1995 Sep;48(6):384–95 (159 ref.)

Different muscle graft denaturing methods and their use for nerve repair. Whitworth IH, et al. **Br J Plast Surg** 1995 Oct;48(7):492–9

Modulation of NMDA receptor expression in the rat spinal cord by peripheral nerve injury and adrenal medullary grafting. Hama AT, et al. **Brain Res** 1995 Jul 31; 687(1–2):103–13

Injury to infrapatellar branch of saphenous nerve in arthroscopic knee surgery. Mochida H, et al. **Clin Orthop** 1995 Nov;(320):88–94

Unilateral pudendal neuropathy. Impact on outcome of anal sphincter repair. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jun;39(6):686–9

Peripheral nerve injury and regeneration. Terenghi G. **Histol Histopathol** 1995 Jul;10(3):709–18 (71 ref.)

Pain due to nerve damage: are inflammatory mediators involved? Tracey DJ, et al. **Inflamm Res** 1995 Oct; 44(10):407–11 (67 ref.)

Prospects for the treatment of spinal cord and peripheral nerve injury [editorial] Hems TE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):176–7 (18 ref.)

Anterior interosseous nerve lesions. Clinical and electrophysiological features. Seror P. **J Bone Joint Surg Br** 1996 Mar;78(2):238–41

Nerve coaptation studies with and without a gap in rabbits. Hasegawa J, et al. **J Hand Surg [Am]** 1996 Mar;21(2):259–65

The epidemiology and management of upper limb peripheral nerve injuries in modern practice. McAllister RM, et al. **J Hand Surg [Br]** 1996 Feb;21(1):4–13

Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons. Noguchi K, et al. **J Neurosci** 1995 Nov; 15(11):7633–43

Fatty acid binding protein is induced in neurons of the dorsal root ganglia after peripheral nerve injury. De León M, et al. **J Neurosci Res** 1996 May 1;44(3):283–92

Differentially expressed genes after peripheral nerve injury. Gillen C, et al. **J Neurosci Res** 1995 Oct 1;42(2):159–71

"Electromyographic and nerve conduction changes after tibial lengthening by the Ilizarov method" [letter] Stephens RT, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):131

The effect of age on peripheral motor nerve function after crush injury in the rat. Belin BM, et al. **J Trauma** 1996 May;40(5):775–7

Surgical complications of transaxillary arteriography: a case–control study. Chitwood RW, et al. **J Vasc Surg** 1996 May;23(5):844–9; discussion 849–50

Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Lee YW, et al. **Neurosci Lett** 1995 Oct 20;199(2):111–4

Pre–emptive dynorphin and N–methyl–D–aspartate glutamate receptor antagonism alters spinal immunocytochemistry but not allodynia following complete peripheral nerve injury. Wagner R, et al. **Neuroscience** 1996 May;72(2):527–34

Nerve wound healing. An overview. Wong BJ, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):881–95 (130 ref.)

Neurotrophins and sensory neurons: role in development, maintenance and injury. A thematic summary. Mendell LM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):463–7

Neurotrophins and nerve injury in the adult. Verge VM, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):423–30 (57 ref.)

Changes in the spinal terminal pattern of the superficial radial nerve after a peripheral nerve injury. An anatomical study in cats. Liss AG, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Jun; 29(2):117–31

Blood donation–related neurologic needle injury: evaluation of 2 years' worth of data from a large blood center. Newman BH, et al. **Transfusion** 1996 Mar;36(3):213–5

[Recovery processes in interrupted peripheral nerves] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17; 140(7):348–52 (23 ref.) **(Dut)**

[Iatrogenic nerve injury and microsurgical treatment] Piza–Katzer H, et al. **Chirurg** 1995 Nov;66(11):1146–53 (Eng. Abstr.) **(Ger)**

[Value of various suture materials for defect reconstruction of peripheral nerves] Sparmann M. **Handchir Mikrochir Plast Chir** 1995 Nov;27(6):322–8 (Eng. Abstr.) **(Ger)**

[Anterior interosseus syndrome from the surgical viewpoint] Axmann HD, et al. **Nervenarzt** 1995 Aug;66(8):610–3 (44 ref.) (Eng. Abstr.) **(Ger)**

[Nerve sutures and nerve grafts for repairing a gap in peripheral nerve injury: an experimental study] Ikeda M, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct; 69(10):1014–26 (Eng. Abstr.) **(Jpn)**

[Decrease and asymmetry in taste perception in patients with nerve trunk damage] Nikulina VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):16–9 (Eng. Abstr.) **(Rus)**

[Peripheral nerve injuries during the 1991–1993 war period] Roganović Z, et al. **Vojnosanit Pregl** 1995 Sep–Oct; 52(5):455–60 (Eng. Abstr.) **(Scr)**

[Principles of surgical treatment of war injuries of the peripheral nerves] Roganović Z, et al. **Vojnosanit Pregl** 1995 Sep–Oct;52(5):483–7 (52 ref.) **(Scr)**

[Pathophysiology of injuries and regeneration of peripheral nerves] Roganović Z, et al. **Vojnosanit Pregl** 1995 Mar–Apr;52(2):160–2 **(Scr)**

METABOLISM

Strongly anionic sites in peripheral axons of the rat sciatic nerve: light and electron microscopic detection using cationic colloidal iron. Toda K, et al. **Arch Histol Cytol** 1995 Oct;58(4):485–92

Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition. Benstead TJ, et al. **Can J Neurol Sci** 1995 Aug;22(3):192–7

Characterization of peripheral benzodiazepine type sites in a cultured murine BV–2 microglial cell line. Park CH, et al. **Glia** 1996 Jan;16(1):65–70

Molecular basis of interactions between regenerating adult rat thalamic axons and Schwann cells in peripheral nerve grafts. II. Tenascin–C. Zhang Y, et al. **J Comp Neurol** 1995 Oct 16;361(2):210–24

Characterization of dp6troglycan–laminin interaction in peripheral nerve. Yamada H, et al. **J Neurochem** 1996 Apr; 66(4):1518–24

Congenital hypomyelination neuropathy: decreased expression of the P2 protein in peripheral nerve with normal DNA sequence of the coding region. Sawaishi Y, et al. **J Neurol Sci** 1995 Dec;134(1–2):150–9

Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons. Noguchi K, et al. **J Neurosci** 1995 Nov; 15(11):7633–43

Connexin32 is a myelin–related protein in the PNS and CNS. Scherer SS, et al. **J Neurosci** 1995 Dec;15(12):8281–94

An aldose reductase inhibitor but not myo–inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats. Berti–Mattera L, et al. **Metabolism** 1996 Mar;45(3):320–7

Immunocytochemical localization of vinculin in muscle and nerve. Massa R, et al. **Muscle Nerve** 1995 Nov; 18(11):1277–84

Distribution of PASII/PMP22 and connexin 32 proteins in the peripheral nervous system. Miyazaki T, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):377–83

Central and peripheral expression of galanin in response to inflammation. Ji RR, et al. **Neuroscience** 1995 Sep; 68(2):563–76

MICROBIOLOGY

Detection of Mycobacterium leprae in nerve lesions by the polymerase chain reaction. Chemouilli P, et al. **Int J Lepr Other Mycobact Dis** 1996 Mar;64(1):1–5

Viability of Mycobacterium leprae in skin and peripheral nerves and persistence of nerve destruction in multibacillary patients after 2 years of multidrug therapy. Job CK, et al. **Int J Lepr Other Mycobact Dis** 1996 Mar; 64(1):44–50

Infection of distal peripheral nerves by M. leprae in infected armadillos; an experimental model of nerve involvement in leprosy. Scollard DM, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun;64(2):146–51

PATHOLOGY

Peripheral nerve biopsies. Anthony DC, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):26–34

Proliferative responses of T cells from the skin and nerve lesions of leprosy patients. Mesret Y, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):243–52

Myxoid and globular degeneration of nerves in the shoulder joint. Hashimoto T, et al. **Clin Orthop** 1995 Nov;(320):55–64

Nerve biopsy. Vallat JM, et al. **Curr Opin Neurol** 1995 Oct; 8(5):345–8 (24 ref.)

Ultrastructural distribution of PMP22 in Charcot–Marie–Tooth disease type 1A. Haney C, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):290–9

Repeatability of nerve thickness assessment in the clinical examination for leprosy. Kolappan C, et al. **Lepr Rev** 1995 Sep;66(3):224–8

Multiexponential T2 relaxation in degenerating peripheral nerve. Does MD, et al. **Magn Reson Med** 1996 Feb; 35(2):207–13

Quantitative analysis of myelinated nerve fibers of peripheral nerve in streptozotocin–induced diabetes mellitus. Ochodnická E, et al. **Mol Chem Neuropathol** 1995 Jun–Aug; 25(2–3):225–33

Hereditary spastic paraparesis with dementia, amyotrophy and peripheral neuropathy. A neuropathological study. Ferrer I, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):255–61

MRI of peripheral nerves and pathology of sural nerves in hereditary motor and sensory neuropathy type III. Tachi N, et al. **Neuroradiology** 1995 Aug;37(6):496–9

[Significance of polyglucosan bodies in neuropathology. Clinico–pathologic study of seven cases] Vital A, et al. **Ann Pathol** 1995;15(4):269–75 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Nerve–regenerating effect of 15–deoxyspergualin. Peripheral nerve allotransplants in the rat. Muramatsu K, et al. **Acta Orthop Scand** 1996 Aug;67(4):399–402

Peripheral nerve stimulator for unassisted nerve blockade [letter] Hadžić A, et al. **Anesthesiology** 1996 Jun; 84(6):1528–9

Genetic analysis of peripheral nerve conduction velocity in twins. Rijsdijk FV, et al. **Behav Genet** 1995 Jul;25(4):341–8

Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227–55 (260 ref.)

Effectiveness of a bioabsorbable conduit in the repair of peripheral nerves. Nicoli Aldini N, et al. **Biomaterials** 1996 May;17(10):959–62

Spinal 5–HT2 receptor–mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Danuser H, et al. **Br J Pharmacol** 1996 May;118(1):150–4

Mesenteric arterial function in the rat in pregnancy: role of sympathetic and sensory–motor perivascular nerves, endothelium, smooth muscle, nitric oxide and prostaglandins. Ralevic V, et al. **Br J Pharmacol** 1996 Apr; 117(7):1463–70

Nerve regeneration. Pollock M. **Curr Opin Neurol** 1995 Oct; 8(5):354–8 (33 ref.)

Structure–function relationships within peripheral nerves in

diabetic neuropathy: the hydration hypothesis. Eaton RP, et al. **Diabetologia** 1996 Apr;39(4):439–46

Comparison of various coils used for magnetic stimulation of peripheral motor nerves: physiological considerations and consequences for diagnostic use. Bischoff C, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):332–40

Normal values of nerve conduction in children and adolescents. Hyllienmark L, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct; 97(5):208–14

Somatosensory evoked potentials following voluntary movement during upper arm compression. Nishihira Y, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb; 36(1):21–8

Magnetic stimulation of peripheral nerves. Comparison of magnetic stimulation with electrical stimulation. Ono S, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep; 35(5):317–20

Regeneration of respiratory pathways within spinal peripheral nerve grafts. Decherchi P, et al. **Exp Neurol** 1996 Jan;137(1):1–14

Single unit discrimination among discharges from neighboring myelinated fibers in human peripheral nerves: improved unit identification by interspike interval analysis of nerve responses evoked by tactile stimuli. Ekedahl R, et al. **Exp Neurol** 1996 Aug;140(2):161–71

Functional and morphological restoration of intracranial brachial lesion of the retinocollicular pathway by peripheral nerve autografts in adult hamsters. Sawai H, et al. **Exp Neurol** 1996 Jan;137(1):94–104

Peripheral nerve and muscle function in the aging Fischer 344/brown-Norway rat. Wineinger MA, et al. **Growth Dev Aging** 1995 Fall;59(3):107–19

Biomechanical properties of peripheral nerves. Grewal R, et al. **Hand Clin** 1996 May;12(2):195–204 (63 ref.)

Contribution of the proximal and distal nerve stumps to peripheral nerve regeneration in silicone chambers. Díaz-Flores L, et al. **Histol Histopathol** 1995 Oct; 10(4):937–46

Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. Ernfors P, et al. **Int J Dev Biol** 1995 Oct;39(5):799–807

Effects of nerve growth factor on sympathetic neuron development in normal and limbless chick embryos. Saltis J, et al. **Int J Dev Neurosci** 1995 Oct;13(6):577–84

Motor nerve sprouting induction by a nerve explant in normal and vitamin E-deficient rats. Cuppini C, et al. **Ital J Anat Embryol** 1995 Jul–Sep;100(3):135–46

Distribution in the central nervous system of Aplysia of afferent fibers arising from cell bodies located in the periphery. Xin Y, et al. **J Comp Neurol** 1995 Sep 4; 359(4):627–43

Comparison of the sensory threshold in healthy human volunteers with the sensory nerve response of the rat in vitro hindlimb skin and saphenous nerve preparation on cutaneous electrical stimulation. McAllister RM, et al. **J Hand Surg [Br]** 1995 Aug;20(4):437–43

Measurement of the activating function of magnetic stimulation using combined electrical and magnetic stimuli. Garnham CW, et al. **J Med Eng Technol** 1995 Mar–Jun; 19(2–3):57–61

Fatty acids from degenerating myelin lipids are conserved and reutilized for myelin synthesis during regeneration in peripheral nerve. Goodrum JF, et al. **J Neurochem** 1995 Oct;65(4):1752–9

Mating-induced FOS-like immunoreactivity in the rat forebrain: a sex comparison and a dimorphic effect of pelvic nerve transection. Wersinger SR, et al. **J Neuroendocrinol** 1993 Oct;5(5):557–68

Impaired peripheral nerve regeneration in a mutant strain of mice (Enr) with a Schwann cell defect. Rath EM, et al. **J Neurosci** 1995 Nov;15(11):7226–37

Persistent cardiovascular and behavioral nociceptive responses to subcutaneous formalin require peripheral nerve input. Taylor BK, et al. **J Neurosci** 1995 Nov; 15(11):7575–84

Rapid on-line estimation of responses to transcranial magnetic and peripheral nerve electrical stimulation in single human motoneurons. Awiszus F, et al. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):91–7

The grasping test: a simple behavioral method for objective quantitative assessment of peripheral nerve regeneration in the rat. Bertelli JA, et al. **J Neurosci Methods** 1995 May; 58(1–2):151–5

Non-invasive measurement of the input-output properties of peripheral nerve stimulating electrodes. Grill WM, et al. **J Neurosci Methods** 1996 Mar;65(1):43–50

Peripheral nerve monitoring in children undergoing neuromuscular blockade after single-stage laryngotracheoplasty. Malis DJ, et al. **Laryngoscope** 1996 Jul;106(7):919–21

Peripheral nerve regeneration in a silicone tube: effect of collagen sponge prosthesis, laminin, and pyrimidine compound administration. Ohbayashi K, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):428–33

fMRI of human somatosensory and cingulate cortex during painful electrical nerve stimulation. Davis KD, et al. **Neuroreport** 1995 Dec 29;7(1):321–5

Magnetometry of evoked fields from human peripheral nerve, brachial plexus and primary somatosensory cortex using a liquid nitrogen cooled superconducting quantum interference device. Curio G, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):204–6

Differential effects of aging on motoneurons and peripheral nerves innervating the hindlimb and forelimb muscles of rats. Hashizume K, et al. **Neurosci Res** 1995 May; 22(2):189–96

A new non-contact corneal aesthesiometer (NCCA). Murphy PJ, et al. **Ophthalmic Physiol Opt** 1996 Mar;16(2):101–7

Reinnervation of peripheral nerve segments implanted into the hemisected spinal cord estimated by transgenic mice. Matsuyama Y, et al. **Paraplegia** 1995 Jul;33(7):381–6

Possible lateralization of peripheral nerve conduction associated with gender. Tan M, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):939–43

Train-of-four: to use or not to use. Tschida SJ, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):546–50

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

Peroneal afferent nerve discharges underlying the behavioral response to the formalin test. Abram SE, et al. **Reg Anesth** 1996 May–Jun;21(3):226–33

Calcitonin gene-related peptide and peripherin immunoreactivity in nerve sheaths. Bove GM, et al. **Somatosens Mot Res** 1995;12(1):49–57

Induction of fos-like immunoreactivity by electrocutaneous stimulation of the rat hindpaw. Willcockson HH, et al. **Somatosens Mot Res** 1995;12(2):151–61

[Changes in magnetic coil orientation affect the stimulation effects of human peripheral nerve] Sun SJ. **Fukuoka Igaku Zasshi** 1996 Mar;87(3):66–76 (Eng. Abstr.) **(Jpn)**

[Age-related changes in amplitude ratio, duration ratio and area ratio in nerve conduction studies] Kurokawa K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep; 32(8–9):547–52 (Eng. Abstr.) **(Jpn)**

[Effect of stimulation of the peripheral pathways and somatosensory cortex on the neuronal activity of the medial wall of the prefrontal cortex in the white rat] Tsytsarev VIu, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):45–51 (Eng. Abstr.) **(Rus)**

[The factors supporting peripheral nerve regeneration] Chelyshev IuA. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):57–77 (220 ref.) (Eng. Abstr.) **(Rus)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May–Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Cryoglobulinaemic neuropathy: lack of progression in patients with good haematological control. Crespi V, et al. **Acta Neurol Scand** 1995 Nov;92(5):372–5

Lectin binding to Renaut bodies. Nagao M, et al. **Acta Neurol Scand** 1995 Oct;92(4):344–7

Upper limb nerve entrapments in elite wheelchair racers. Boninger ML, et al. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):170–6

Posterior interosseous nerve conduction. A new method of evaluation. Seror P. **Am J Phys Med Rehabil** 1996 Jan–Feb; 75(1):35–9

Effects of deferoxamine on ischemia/reperfusion injury after peripheral nerve compression. Li Y, et al. **Ann Plast Surg** 1996 Apr;36(4):365–9

Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Sica RE, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):156–63

Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Donaghue KC, et al. **Diabet Med** 1996 Jan;13(1):65–71

Structure-function relationships within peripheral nerves in diabetic neuropathy: the hydration hypothesis. Eaton RP, et al. **Diabetologia** 1996 Apr;39(4):439–46

The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Veves A, et al. **Diabetologia** 1996 Mar;39(3):344–8

Electrophysiological findings in peripheral fibres of subjects with and without post-herpetic neuralgia. Mondelli M, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):185–91

Ataxia-teleangectasia: neurophysiological studies in 8 patients. Lelli S, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep;35(5):311–5

Unexplained peripheral nervous conduction velocity variations in young military males. Moreno-Vazquez JM, et al. **Electromyogr Clin Neurophysiol** 1995 Dec; 35(8):479–84

Neurographic studies in hemiplegic patients. Milanov I. **Funct Neurol** 1995 Mar–Apr;10(2):77–82

The leprosy granuloma in nerve: summary of recent work. Ridley MJ. **Indian J Lepr** 1996 Jan–Mar;68(1):93–4 (5 ref.)

Assessment of nerve function under field conditions and its usefulness in leprosy. van Brakel WH. **Indian J Lepr** 1996 Jan–Mar;68(1):119–25 (33 ref.)

Neurophysiological assessment of peripheral nerve and spinal cord function in asymptomatic HIV-1 infection: results from the UCMSM/Medical Research Council neurology cohort. Connolly S, et al. **J Neurol** 1995 Jun;242(6):406–14

Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni. Vriesendorp FJ, et al. **J Neurol** 1995 Jul;242(7):460–5

Long-term results of peripheral nerve stimulation for reflex sympathetic dystrophy. Hassenbusch SJ, et al. **J Neurosurg** 1996 Mar;84(3):415–23

Correlation of measurements of pressure perception using the pressure-specified sensory device with electrodiagnostic testing. Tassler PL, et al. **J Occup Environ Med** 1995 Jul;37(7):862–6

Neuromyotonia, peripheral neuropathy and myasthenia gravis. Martinelli P, et al. **Muscle Nerve** 1996 Apr; 19(4):505–10

Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)

Disruption and restoration of dorsal horn sensory map after peripheral nerve crush and regeneration. Sugimoto T, et al. **Pain** 1995 Oct;63(1):49–54

The therapy by ischemic stress induces a durable EEG synchronization in alpha frequency band. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):169–81

[Clinical analysis of the complex repetitive discharge following M wave] Yamaguchi K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):908–10 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

[Severe neuropathy after chemo- and radiotherapy of Ewing sarcoma] Lilje C, et al. **Klin Padiatr** 1995 Jul–Aug; 207(4):204–6 (Eng. Abstr.) **(Ger)**

SURGERY

Vein, silastic, and polyglycolic acid fine mesh: a comparative study in peripheral nerve repair. Lolley RD, et al. **Ann Plast Surg** 1995 Sep;35(3):266–71

Effectiveness of a bioabsorbable conduit in the repair of peripheral nerves. Nicoli Aldini N, et al. **Biomaterials** 1996 May;17(10):959–62

The influence of social isolation and peripheral innervation on Ehrlich tumor growth in mice. Bonamin LV, et al. **Braz J Med Biol Res** 1995 May;28(5):557–62

Peripheral nerve reconstruction using denatured muscle autografts for restoring protective sensation in hands and feet of leprosy patients. Pereira JH, et al. **Indian J Lepr** 1996 Jan–Mar;68(1):83–91

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

Peripheral nerve surgery today, turning point or continuous development? Part VII. Vienna, Austria, November 23–26, 1991. **J Reconstr Microsurg** 1995 Jul;11(4):309–16

True epineural neurolysis in Morton's neuroma: a 5-year follow up. Diebold PF, et al. **Orthopedics** 1996 May; 19(5):397–400

Peripheral nerve elongation by laser Doppler flowmetry-monitored expansion: an experimental basis for future application in the management of peripheral nerve defects. van der Wey LP, et al. **Plast Reconstr Surg** 1996 Mar;97(3):568–76

[One-year follow-up of 466 nerve decompressions in 123 lepers during multidrug therapy in Madagascar] Ramarorazana S, et al. **Med Trop (Mars)** 1995;55(2):146–50 (Eng. Abstr.) **(Fre)**

[Paralysis of the interosseous nerve by a tendinous margin of the extensor carpi radialis brevis] Witthaut J, et al. **Handchir Mikrochir Plast Chir** 1995 Nov;27(6):329–30 (Eng. Abstr.) **(Ger)**

[The history of neurectomy in horses with navicular disease] Meier HP. **Schweiz Arch Tierheilkd** 1996;138(1):15–21 (Eng. Abstr.) **(Ger)**

[Nerve sutures and nerve grafts for repairing a gap in peripheral nerve injury: an experimental study] Ikeda M, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct; 69(10):1014–26 (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. Büttemeyer R, et al. **Ann Plast Surg** 1995 Oct;35(4):396–401

Vascularized allogeneic joint, muscle, and peripheral nerve transplantation. Muramatsu K, et al. **Clin Orthop** 1995 Nov; (320):194–204

Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting. Date I, et al. **Exp Neurol** 1996 Feb;137(2):333–44

Molecular basis of interactions between regenerating adult rat thalamic axons and Schwann cells in peripheral nerve grafts. II. Tenascin-C. Zhang Y, et al. **J Comp Neurol** 1995 Oct 16;361(2):210–24

Molecular basis of interactions between regenerating adult rat thalamic axons and Schwann cells in peripheral nerve grafts I. Neural cell adhesion molecules. Zhang Y, et al. **J Comp Neurol** 1995 Oct 16;361(2):193–209

Peripheral nerve explants grafted into the vitreous body of the eye promote the regeneration of retinal ganglion cell axons severed in the optic nerve. Berry M, et al. **J Neurocytol** 1996 Feb;25(2):147–70

Nerve allotransplantation following severe tibial nerve injury. Case report. Mackinnon SE. **J Neurosurg** 1996 Apr;

84(4):671–6 (67 ref.)
Nerve regeneration in different types of grafts: experimental study in rabbits. Amillo S, et al. **Microsurgery** 1995; 16(9):621–30
Nerve regenerating effect of short-course administration of cyclosporine after fresh peripheral nerve allotransplantation in the rat: comparison of nerve regeneration using different forms of donor nerve allografts. Muramatsu K, et al. **Microsurgery** 1995; 16(7):496–504
Immunosuppressive effect of monoclonal antibodies to ICAM-1 and LFA-1 on peripheral nerve allograft in mice. Nakao Y, et al. **Microsurgery** 1995;16(9):612–20
Bridging the gap in spinal cord regeneration. Schwab ME. **Nat Med** 1996 Sep;2(9):976–7
Reinnervation of peripheral nerve segments implanted into the hemisected spinal cord estimated by transgenic mice. Matsuyama Y, et al. **Paraplegia** 1995 Jul;33(7):381–6
Reduction in peripheral nerve allograft antigenicity with warm and cold temperature preservation. Strasberg SR, et al. **Plast Reconstr Surg** 1996 Jan;97(1):152–60
[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Echotexture of peripheral nerves: correlation between US and histologic findings and criteria to differentiate tendons. Silvestri E, et al. **Radiology** 1995 Oct;197(1):291–6

ULTRASTRUCTURE

Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Danuser H, et al. **Br J Pharmacol** 1996 May;118(1):150–4
Scanning electron microscopic observations of nerves in the guinea-pig gallbladder after an acetylcholinesterase histochemistry. Gonda T, et al. **J Smooth Muscle Res** 1995 Aug;31(4):153–62

PERIPHERAL NERVOUS SYSTEM

see related
NEURAL PATHWAYS

ANATOMY & HISTOLOGY

Neurohistology of the subacromial space. Soifer TB, et al. **Arthroscopy** 1996 Apr;12(2):182–6
Neurosurgery of the peripheral nervous system--Part I: basic anatomic concepts. Fernandez E, et al. **Surg Neurol** 1996 Jul;46(1):47–8

CHEMISTRY

Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Kiefer R, et al. **Am J Pathol** 1996 Jan;148(1):211–23
Distribution of Rab3a in rat nervous system: comparison with other synaptic vesicle proteins and neuropeptides. Li JY, et al. **Brain Res** 1996 Jan 8;706(1):103–12
Axonal transport and targeting of the t-SNAREs SNAP-25 and syntaxin 1 in the peripheral nervous system. Li JY, et al. **Eur J Cell Biol** 1996 May;70(1):12–22
Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. Snipes GJ, et al. **J Anat** 1995 Jun;186 (Pt 3):483–94 (120 ref.)
Ultrastructural association of hyaluronan with rat unmyelinated nerve fibres. Eggli PS, et al. **J Neurocytol** 1996 Feb;25(2):79–87
Axonal transport and distribution of synaptobrevin I and II in the rat peripheral nervous system. Li JY, et al. **J Neurosci** 1996 Jan;16(1):137–47

CYTOLOGY

Localization of N-cadherin in the normal and regenerating nerve fibers of the chicken peripheral nervous system. Shibuya Y, et al. **Neuroscience** 1995 Jul;67(1):253–61

DRUG EFFECTS

The effect of MS-818, a pyrimidine compound, on the regeneration of peripheral nerve fibers of mice after a crush injury. Jiang XM, et al. **Acta Neuropathol (Berl)** 1995; 90(2):130–4
Toxicological studies on potentiated ionophores in chickens. III. Electrotoxicological investigations. Lehel J, et al. **Acta Vet Hung** 1995;43(2–3):347–54
Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Schumacher M, et al. **Ciba Found Symp** 1995;191:90–106; discussion 106–12 (50 ref.)
Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. Abou-Donia MB. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):358–9 (5 ref.)
The peripherally acting kappa-opiate agonist EMD 61753 and analogues: opioid activity versus peripheral selectivity. Gottschlich R, et al. **Drugs Exp Clin Res** 1995;21(5):171–4
Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. Urban R, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):29–37
Proceedings of the 5th International Conference on Peripheral Dopamine. Kyoto, Japan, October 20–22, 1994. **Hypertens Res** 1995 Jun;18 Suppl 1:S1–224
Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat. Khasar SG, et al. **Neuroscience** 1995 May;66(2):427–32

EMBRYOLOGY

The function of the Drosophila argos gene product in the development of embryonic chordotonal organs. Okabe M, et al. **Dev Biol** 1996 Apr 10;175(1):37–49
Origin and specification of type II sensory neurons in Drosophila. Brewster R, et al. **Development** 1995 Sep; 121(9):2923–36
Expression of type 1 inositol 1,4,5-trisphosphate receptor during axogenesis and synaptic contact in the central and peripheral nervous system of developing rat. Dent MA, et al. **Development** 1996 Mar;122(3):1029–39
Differential effects of combined trk receptor mutations on dorsal root ganglion and inner ear sensory neurons. Minichiello L, et al. **Development** 1995 Dec;121(12):4067–75
Genetic determinants of sense organ identity in Drosophila: regulatory interactions between cut and poxn. Vervoort M, et al. **Development** 1995 Sep;121(9):3111–20
Developmental changes in NT3 signalling via TrkA and TrkB in embryonic neurons. Davies AM, et al. **EMBO J** 1995 Sep 15;14(18):4482–9
[Glial lineage of the peripheral nervous system] Cameron-Curry P. **C R Seances Soc Biol Fil** 1995; 189(2):253–61 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Nitric oxide synthase in the peripheral nervous system of the goldfish, Carassius auratus. Brüning G, et al. **Cell Tissue Res** 1996 Apr;284(1):87–98
NADPH-diaphorase localization in the CNS and peripheral tissues of the predatory sea-slug Pleurobranchaea californica. Moroz LL, et al. **J Comp Neurol** 1996 Apr 15;367(4):607–22

GROWTH & DEVELOPMENT

Roles of neurotrophin-3 during early development of the peripheral nervous system. Ockel M, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):383–7

IMMUNOLOGY

Autoimmunity in the peripheral nervous system. Hartung HP, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):1–45 (310 ref.)

INJURIES

Arteriovenous differences in plasma concentrations of catechols in rats with neuropathic pain. Raja SN, et al. **Anesthesiology** 1995 Nov;83(5):1000–8
[The use of high-intensity pulsed magnetotherapy in injuries and diseases of the locomotor apparatus and peripheral nervous system] Ushakov AA, et al. **Voen Med Zh** 1995 Feb;(2):42–3 **(Rus)**
[The use of physical factors in the combined treatment of traumatic damages to the nerve trunks of the extremities] Danda VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep-Oct;(5):21–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Expression and distribution of CD9 in myelin of the central and peripheral nervous systems. Nakamura Y, et al. **Am J Pathol** 1996 Aug;149(2):575–83
Immunohistochemical detection of secretoneurin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues. Schmid KW, et al. **Histochem J** 1995 Jun; 27(6):473–81
Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. Arber S, et al. **J Cell Biol** 1995 Nov; 131(4):1083–94
Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. Shindo H, et al. **J Clin Invest** 1996 Feb 1;97(3):736–45
Localization of N-cadherin in the normal and regenerating nerve fibers of the chicken peripheral nervous system. Shibuya Y, et al. **Neuroscience** 1995 Jul;67(1):253–61
Quantitation of mRNA species by RT-PCR on total mRNA population. Hamoui S, et al. **PCR Methods Appl** 1994 Dec; 4(3):160–6
[Pulmonary and pulmonary-related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. **Nippon Yakurigaku Zasshi** 1995 Nov; 106(5):311–20 (49 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Brück W, et al. **Acta Neuropathol (Berl)** 1995;90(6):601–7
Peripheral nerve pathology in Niemann-Pick type C mouse. Higashi Y, et al. **Acta Neuropathol (Berl)** 1995;90(2):158–63
Structural preservation of cerebellar granule cells following neurointoxication with methyl mercury: a stereological study of the rat cerebellum. Larsen JO, et al. **Acta Neuropathol (Berl)** 1995;90(3):251–6
Role of HIV in the pathogenesis of distal symmetrical peripheral neuropathy. Rizzuto N, et al. **Acta Neuropathol (Berl)** 1995;90(3):244–50
The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Soffer D, et al. **Acta Neuropathol (Berl)** 1995;90(2):213–20
Animal model for leprous neuropathy: our contribution. Shetty VP, et al. **Indian J Lepr** 1996 Jan-Mar;68(1):95–104 (28 ref.)

PHYSIOLOGY

Sensory nerve ingrowth during bone graft incorporation in the rat. Madsen JE, et al. **Acta Orthop Scand** 1996 Jun; 67(3):217–20
Distribution and function of nitric oxide-containing nerves in canine corpus cavernosum and spongiosum. Hedlund P, et al. **Acta Physiol Scand** 1995 Dec;155(4):445–55
Nitric oxide and peripheral adrenergic neuromodulation. Levi R, et al. **Adv Pharmacol** 1995;34:399–413
Nitric oxide in the peripheral nervous system. Lefebvre RA. **Ann Med** 1995 Jun;27(3):379–88
Strength-duration properties of human peripheral nerve. Mogyoros I, et al. **Brain** 1996 Apr;119 (Pt 2):439–47
Role of peripheral autonomic neurones in maintaining adequate cardiac function. Horackova M, et al. **Cardiovasc Res** 1995 Sep;30(3):326–35 (88 ref.)
The temporal/spatial evolution of optical signals in human cortex. Toga AW, et al. **Cereb Cortex** 1995 Nov-Dec; 5(6):561–5
The boundary effect in magnetic stimulation. Analysis at the peripheral nerve. Mathis J, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct; 97(5):238–45
"Slinky" coils for neuromagnetic stimulation. Zimmermann KP, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 101(2):145–52
Peripheral nerve injury and regeneration. Terenghi G. **Histol Histopathol** 1995 Jul;10(3):709–18 (71 ref.)
Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93–9 (76 ref.)
Central and peripheral sympathetic activities in rats during recovery from simulated weightlessness. Fagette S, et al. **J Appl Physiol** 1995 Dec;79(6):1991–7
PNS features of rodent optic nerve axons. Jeffery G. **J Comp Neurol** 1996 Mar 4;366(2):370–8
Recovery of function, peripheral sensitization and sensory neurone activation by novel pathways following axonal injury in Aplysia californica. Dulin MF, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2055–66
Peripheral regeneration and central sprouting of sensory neurone axons in Aplysia californica following nerve injury. Steffensen I, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2067–78
The cell biology of myelin degeneration and regeneration in the peripheral nervous system. Goodrum JF, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):943–53 (47 ref.)
Long-term potentiation in an isolated peripheral nerve-spinal cord preparation. Lozier AP, et al. **J Neurophysiol** 1995 Sep;74(3):1001–9
Laminin overrides the inhibitory effects of peripheral nervous system and central nervous system myelin-derived inhibitors of neurite growth. David S, et al. **J Neurosci Res** 1995 Nov 1;42(4):594–602
Glial fibrillary acidic protein mRNA isotypes: expression in vitro and in vivo. Galea E, et al. **J Neurosci Res** 1995 Jul 1;41(4):452–61
Efficacy of limb cooling on the salvage of peripheral nerve from ischemic fiber degeneration. Kihara M, et al. **Muscle Nerve** 1996 Feb;19(2):203–9
Functional changes of the peripheral nervous system with aging in the mouse. Verdú E, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):73–7
Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Björkstrand E, et al. **Neuroendocrinology** 1996 Apr;63(4):377–83
Pax3: a paired domain gene as a regulator in PNS myelination. Kioussi C, et al. **Neuron** 1995 Sep;15(3):553–62
Subcellular localization of synaptophysin in noradrenergic nerve terminals: a biochemical and morphological study. Annaert WG, et al. **Synapse** 1995 Sep;21(1):65–76

PHYSIOPATHOLOGY

Neurobiology of muscle fatigue. Advances and issues. Gandevia SC, et al. **Adv Exp Med Biol** 1995;384:515–25 (31 ref.)
Clinical neurophysiology and neurotransmitters. Maertens de Noordhout A, et al. **Cephalalgia** 1995;15(4):301–9
A syndrome of concurrent central and peripheral nervous system involvement due to Epstein-Barr virus infection. Morgenlander JC. **Muscle Nerve** 1996 Aug;19(8):1037–9
[Myoneuropathy in patients with chronic renal failure treated with hemodialysis (HD) and intermittent peritoneal dialysis (IPD). II. Sensory and motor nerve conduction velocity

in patients with chronic renal failure treated with intermittent peritoneal dialysis and hemodialysis] Wanic-Kossowska M, et al. **Pol Arch Med Wewn** 1996 Mar; 95(3):237-44 (Eng. Abstr.) **(Pol)**

[The effect of neurotization after a long period following its termination on the behavior of rats differing by nervous system excitability] Shiriaeva NV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):157-62 (Eng. Abstr.) **(Rus)**

SURGERY

Selective peripheral denervation for spasmodic torticollis: is the outcome predictable? Braun V, et al. **J Neurol** 1995 Aug;242(8):504-7

Neurosurgery of the peripheral nervous system—Part I: basic anatomic concepts. Fernandez E, et al. **Surg Neurol** 1996 Jul;46(1):47-8

ULTRASTRUCTURE

Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. Evans RG, et al. **Br J Pharmacol** 1995 Sep;116(1):1557-70

Peripheral and central cholecystokinin receptors regulate postprandial intestinal motility in the rat. Rodriguez-Membrilla A, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):486-93

PERIPHERAL NERVOUS SYSTEM DISEASES

see related
NEUROMUSCULAR DISEASES
SPINAL CORD DISEASES

Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Léger JM. **Curr Opin Neurol** 1995 Oct;8(5):359-63 (23 ref.)

Manual muscle strength testing and dynamometry for bilateral ulnar neuropraxia in a surgeon. Brandsma JW. **J Hand Ther** 1995 Jul-Sep;8(3):191-4

[Peripheral neuropathies: diagnosis and treatment] Suárez GA. **Rev Neurol** 1996 Jun;24(130):676-80 (6 ref.) **(Spa)**

CHEMICALLY INDUCED

Parental history of alcoholism: a risk factor for alcohol-related peripheral neuropathies. Pessione F, et al. **Alcohol Alcohol** 1995 Nov;30(6):749-54

Lovastatin and peripheral neuropathy [letter] Ahmad S. **Am Heart J** 1995 Dec;130(6):1321

Peripheral neurologic abnormalities among roofing workers: sentinel case and clinical screening. Herbert R, et al. **Arch Environ Health** 1995 Sep-Oct;50(5):349-54

Drug-induced neuropathies. Windebank AJ. **Baillieres Clin Neurol** 1995 Nov;4(3):529-73 (170 ref.)

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin [letter; comment] Anand A, et al. **Cancer** 1995 Sep 1;76(5):916-7. Comment on: Cancer 1995 Mar 1;75(5):1141-50.

Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Brummitt CF, et al. **Clin Infect Dis** 1996 May; 22(5):878-9

Toxic neuropathies. Mizisin AP, et al. **Curr Opin Neurol** 1995 Oct;8(5):367-71 (33 ref.)

Thalidomide-induced neuropathy and genetic differences in drug metabolism. Harland CC, et al. **Eur J Clin Pharmacol** 1995;49(1-2):1-6

Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy. Kurlemann G, et al. **Eur J Pediatr** 1995 Nov;154(11):928-32

The features of peripheral nerve lesions in young and adult rabbits after vincristine administration. Dąmbska M, et al. **Folia Neuropathol** 1995;33(1):21-4

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Connelly E, et al. **Gynecol Oncol** 1996 Aug;62(2):166-8

Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. Fichtenbaum CJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):169-74

Peripheral sensory disturbances related to treatment with fluoroquinolones. Hedenmalm K, et al. **J Antimicrob Chemother** 1996 Apr;37(4):831-7

Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. Weintraub M, et al. **J Clin Oncol** 1996 Mar; 14(3):935-40

Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation [letter] Hidalgo M, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1320

Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region [letter] Liu JM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):1000-2

Severe neurotoxicity from vinorelbine-paclitaxel combinations [letter; comment] Parimoo D, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1079-80. Comment on: J Natl Cancer Inst 1995 Jul 19;87(14):1072-7.

Paresthesias and sensory neuropathy due to 1,1,1-trichloroethane [letter] House RA, et al. **J Occup Environ Med** 1996 Feb;38(2):123-4

A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy. Saita K, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):231-7

Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Tamura T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1203-9

Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Warzocha K, et al. **Leuk Lymphoma** 1996 Apr;21(3-4):343-6

"Sunbath polyneuritis": subacute axonal neuropathy in perazine-treated patients after intense sun exposure. Roelcke U, et al. **Muscle Nerve** 1996 Apr;19(4):438-41

Peripheral neurotoxicity induced by docetaxel [see comments] Hilkens PH, et al. **Neurology** 1996 Jan; 46(1):104-8. Comment in: Neurology 1996 Jan;46(1):2-3.

Peripheral neuropathy secondary to docetaxel (Taxotere) [see comments] New PZ, et al. **Neurology** 1996 Jan;46(1):108-11 . Comment in: Neurology 1996 Jan;46(1):2-3.

Neurotoxicity among pesticide applicators exposed to organophosphates. Stokes L, et al. **Occup Environ Med** 1995 Oct;52(10):648-53

Cumulative blood lead levels and nerve conduction parameters. Chia SE, et al. **Occup Med (Oxf)** 1996 Feb; 46(1):59-64

Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances. Johnson MK, et al. **Toxicol Lett** 1995 Dec;82-83:459-63 (24 ref.)

Selective promotion by phenylmethanesulfonyl fluoride of peripheral and spinal cord neuropathies initiated by diisopropyl phosphorofluoridate in the hen. Peraica M, et al. **Toxicol Lett** 1995 Oct;80(1-3):115-21

[Peripheral neuropathies caused by disulfiram] Dano P, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):294-5 (Eng. Abstr.) **(Fre)**

[Acute and reversible myoclonic encephalopathy, extrapyramidal syndrome, polyneuropathy caused by chronic disulfiram poisoning] De Sèze J, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):667-9 (Eng. Abstr.) **(Fre)**

[Severe neuropathy after chemo- and radiotherapy of Ewing sarcoma] Lilje C, et al. **Klin Padiatr** 1995 Jul-Aug; 207(4):204-6 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Peripheral neuropathy associated with ischemic vascular disease of the lower limbs. Laghi Pasini F, et al. **Angiology** 1996 Jun;47(6):569-77

Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Puéchal X, et al. **Arthritis Rheum** 1995 Nov;38(11):1618-29

Non-Hodgkin malignant lymphomas and peripheral neuropathies—13 cases. Vallat JM, et al. **Brain** 1995 Oct; 118 (Pt 5):1233-45

The mystery of one red ear. Lance JW. **Clin Exp Neurol** 1994;31:13-8

Moclobemide in chronic neuropathic pain: preliminary case reports. Menkes DB, et al. **Clin J Pain** 1995 Jun;11(2):134-8

Gabapentin adjunctive therapy in neuropathic pain states. Rosner H, et al. **Clin J Pain** 1996 Mar;12(1):56-8

High thoracic neurinoma mimicking femoral neuralgia. Okuda B, et al. **Clin Neurol Neurosurg** 1995 Aug; 97(3):216-8

Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection? Apartis E, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun; 60(6):661-6

Focal posterior interosseous neuropathy in the presence of hereditary motor and sensory neuropathy, type I. Carter GT, et al. **Muscle Nerve** 1996 May;19(5):644-8

Restless legs syndrome in patients with polyneuropathy. Rutkove SB, et al. **Muscle Nerve** 1996 May;19(5):670-2

Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Bird SJ, et al. **Neurology** 1996 Mar;46(3):822-4

Chronic demyelinating polyneuropathy: Improvement after sepsis. Ropper AH. **Neurology** 1996 Mar;46(3):848-50

NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Felsby S, et al. **Pain** 1996 Feb;64(2):283-91

Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Low PA, et al. **Pain** 1995 Aug;62(2):163-8

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161-72 (20 ref.)

Reflex sympathetic dystrophy: does sympathetic dysfunction originate from peripheral neuropathy? Kurvers HA, et al. **Surgery** 1996 Mar;119(3):288-96

Peripheral neuropathy and peripheral nerve injury. Nickell K, et al. **Urol Clin North Am** 1996 Aug;23(3):491-500 (93 ref.)

[Congenital pachyonychia, neurofibromatosis and sensory-motor polyneuropathy] Bensa AF, et al. **Ann Dermatol Venereol** 1995;122(6-7):428-31 (Eng. Abstr.) **(Fre)**

[Neurogenic muscle hypertrophy: 3 cases] Deffond D, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):272-8 (45 ref.) (Eng. Abstr.) **(Fre)**

[Action of sodium oxybutyrate in pain syndromes] Danilova EI, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):395-8 **(Rus)**

[Effect of etimizol on development of a neuropathic pain syndrome] Gorizontova MP, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):258-61 **(Rus)**

[Sensory-motor polyneuropathy associated with lung tuberculosis: presentation of two new cases] Hernando I, et al. **Rev Neurol** 1996 Jul;24(131):841-2 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Sciatic endometriosis: MR evaluation. Cottier JP, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1399-401

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237-9 (8 ref.)

Peripheral nerve biopsies. Anthony DC, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):26-34

Magnetic stimulation in the assessment of peripheral nerve disorders. Benecke R. **Baillieres Clin Neurol** 1996 Mar; 5(1):115-28 (37 ref.)

Tropical neuropathies. Román GC. **Baillieres Clin Neurol** 1995 Nov;4(3):469-87 (63 ref.)

Immune neuropathies in childhood. Sladky JT. **Baillieres Clin Neurol** 1996 Mar;5(1):233-44 (31 ref.)

Immunocytochemistry as a diagnostic tool. Stoll G. **Baillieres Clin Neurol** 1996 Mar;5(1):129-42 (54 ref.)

Undiagnosed neuropathies: the impact of ancillary investigations. Thomas PK. **Baillieres Clin Neurol** 1996 Mar;5(1):157-70 (58 ref.)

Electron microscopy as a tool to diagnose neuropathies. Vallat JM. **Baillieres Clin Neurol** 1996 Mar;5(1):143-56 (8 ref.)

Leprous neuropathies. Waters MF, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):171-97 (61 ref.)

DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies [editorial; comment] Lupski JR. **Clin Chem** 1996 Jul;42(7):995-8 (46 ref.). Comment on: Clin Chem 1996 Jul;42(7):1021-5.

Molecular diagnosis of Charcot-Marie-Tooth 1A disease and hereditary neuropathy with liability to pressure palsies by quantifying CMT1A-REP sequences: consequences of recombinations at variant sites on chromosomes 17p11.2-12 [see comments] Vandenberghe A, et al. **Clin Chem** 1996 Jul;42(7):1021-5. Comment in: Clin Chem 1996 Jul;42(7):995-8.

Electrodiagnosis. Sheean GL, et al. **Curr Opin Neurol** 1995 Oct;8(5):339-44 (29 ref.)

Prospective comparative study of abnormal distal rectoanal excitatory reflex, pudendal nerve terminal motor latency, and single fiber density as markers of pudendal neuropathy. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jul;39(7):794-8

Unilateral pudendal neuropathy. Significance and implications. Sangwan YP, et al. **Dis Colon Rectum** 1996 Mar;39(3):249-51

Discriminant classification of motor unit potentials (MUPs) successfully separates neurogenic and myopathic conditions. A comparison of multi- and univariate diagnostical algorithms for MUP analysis. Pfeiffer G, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct; 97(5):191-207

Guillain-Barré syndrome or "new" Chinese paralytic syndrome in northern China? Tang XF, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 101(2):105-9

Sympathetic skin response: correlation with autonomic and somatic involvement in multiple sclerosis. Caminero AB, et al. **Electromyogr Clin Neurophysiol** 1995 Dec; 35(8):457-62

An unusual presentation of a ruptured abdominal aortic aneurysm. Haddad FS, et al. **J Accid Emerg Med** 1995 Sep; 12(3):220-1

The clinical significance of the communicating branches of the somatic sensory supply of the middle and external ear. Grey P. **J Laryngol Otol** 1995 Dec;109(12):1141-5 (35 ref.)

MRI simplifies diagnosis of peripheral nerve lesions [news] McCarthy M. **Lancet** 1996 Sep 7;348(9028):674

Does loss of nerve function equal pure neuritic leprosy? [letter] Butlin CR. **Lepr Rev** 1995 Sep;66(3):257-8

Repeatability of nerve thickness assessment in the clinical examination for leprosy. Kolappan C, et al. **Lepr Rev** 1995 Sep;66(3):224-8

Laboratory testing in peripheral nerve disease. Griffin JW, et al. **Neurol Clin** 1996 Feb;14(1):119-33 (58 ref.)

Ten steps in characterizing and diagnosing patients with peripheral neuropathy. Dyck PJ, et al. **Neurology** 1996 Jul; 47(1):10-7

MRI of peripheral nerves and pathology of sural nerves in hereditary motor and sensory neuropathy type III. Tachi N, et al. **Neuroradiology** 1995 Aug;37(6):496-9

Local cold exposure of the hands from cryosectioning work in histopathological and toxicological laboratories: signs and symptoms of peripheral neuropathy and Raynaud's phenomenon. Wieslander G, et al. **Occup Environ Med** 1996 Apr;53(4):276-80

Magnetic resonance imaging of the shoulder in children with brachial pLexus birth palsy. Gudinchet F, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S125-8

[Atypical entrapment syndrome of the distal suprascapular nerve of the incisura scapulae. Case report and overview of the literature] Röhrich E, et al. **Nervenarzt** 1995 Aug; 66(8):638–42 (28 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between vibratory sense threshold and blood lead concentration in ceramic color workers and transfer printing manufacturers] Fukaya Y, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):748–53 (Eng. Abstr.) **(Jpn)**

[Electrophysiological diagnosis and therapy of peripheral nerve demyelinating diseases] Kimura J. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):389–92 (10 ref.) **(Jpn)**

[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

[Method of detecting excitability of skin receptors in the diagnosis of vibration disease] Kolesov VG, et al. **Med Tr Prom Ekol** 1995;(8):35–8 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats [see comments] Chaplan SR, et al. **Anesthesiology** 1995 Oct;83(4):775–85. Comment in: Anesthesiology 1995 Oct;83(4):654–5.

Protracted relief of experimental neuropathic pain by systemic local anesthetics. How, where, and when [editorial; comment] Strichartz G. **Anesthesiology** 1995 Oct; 83(4):654–5. Comment on: Anesthesiology 1995 Oct;83(4):775–85.

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)

L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Onofrj M, et al. **Int J Clin Pharmacol Res** 1995;15(1):9–15

Mexiletine for painful alcoholic neuropathy. Nishiyama K, et al. **Intern Med** 1995 Jun;34(6):577–9

Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. Imamura Y, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):177–82

Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. Nichols ML, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1339–45

A catechol derivative (4-methylcatechol) accelerates the recovery from experimental acrylamide-induced neuropathy. Saita K, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):231–7

Active surveillance in leprosy: how useful is it? Croft RP. **Lepr Rev** 1996 Jun;67(2):135–40

Temporomandibular joint pain as a neuropathy [letter] Zapp JJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):621

Changes in neuronal markers in a mononeuropathic rat model relationship between neuropeptide Y, pre-emptive drug treatment and long-term mechanical hyperalgesia. Munglani R, et al. **Pain** 1995 Oct;63(1):21–31

ENZYMOLOGY

Increases in protein kinase C gamma immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy. Mao J, et al. **Neurosci Lett** 1995 Sep 29; 198(2):75–8

EPIDEMIOLOGY

Cuban epidemic neuropathy, 1991 to 1994: history repeats itself a century after the "amblyopia of the blockade". Ordúñez-García PO, et al. **Am J Public Health** 1996 May; 86(5):738–43

Epidemiology of peripheral neuropathy [editorial] Hughes RA. **Curr Opin Neurol** 1995 Oct;8(5):335–8 (22 ref.)

Effects of vibration on the hand-arm system of miners in India. Dasgupta AK, et al. **Occup Med (Oxf)** 1996 Feb; 46(1):71–8

Identifiable risk factors for secondary neurologic deterioration in the cervical spine-injured patient. Colterjohn NR, et al. **Spine** 1995 Nov 1;20(21):2293–7

ETIOLOGY

Neuritic leprosy: further progression and significance. Mishra B, et al. **Acta Leprol** 1995;9(4):187–94 (28 ref.)

Physical morbidity in patients admitted to a private hospital for detoxification from alcohol. Wylie AS, et al. **Alcohol Alcohol** 1995 Sep;30(5):641–3

Lumbosacral plexopathy after gynecologic surgery: case report and review of the literature. Alsever JD. **Am J Obstet Gynecol** 1996 Jun;174(6):1769–77; discussion 1777–8 (32 ref.)

Lyme borreliosis neuropathy. A case report. Deltombe T, et al. **Am J Phys Med Rehabil** 1996 Jul-Aug;75(4):314–6 (21 ref.)

Polyneuropathy associated with nerve angiomatosis and multiple soft tissue tumors. A newly recognized syndrome. Giannini C, et al. **Am J Surg Pathol** 1995 Nov; 19(11):1325–32

Central and peripheral nervous complications of dental treatment. Rossitti EO. **Arq Neuropsiquiatr** 1995 Sep; 53(3-A):513–7 (33 ref.)

Neurotrophic factors in the therapy of peripheral neuropathy. Apfel SC, et al. **Baillieres Clin Neurol** 1995 Nov; 4(3):593–606 (70 ref.)

Toxic neuropathies and their treatment. Ludolph AC, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):505–27 (75 ref.)

Paraneoplastic peripheral neuropathy. Smitt PS, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):443–68 (120 ref.)

Neurological symptoms attributed to epidural analgesia in labour: an observational study of seven cases. Tubridy N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):832–3

Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Rhodes LE, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):155–6

Effects of external fixation and limb lengthening on peripheral nerve function. Makarov MR, et al. **Clin Orthop** 1996 Aug;(329):310–6

Case report: Fibroma of tendon sheath in the distal forearm with associated median nerve neuropathy: US, CT and MR appearances. Bertolotto M, et al. **Clin Radiol** 1996 May; 51(5):370–2

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79–88 (51 ref.)

Retractor-induced femoral neuropathy [letter] Balz JB. **Dis Colon Rectum** 1996 May;39(5):591

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Peripheral neuropathy due to small vessel vasculitis. Behari M, et al. **J Assoc Physicians India** 1995 Jul;43(7):495–7

Vasculitic neuropathy: profile of twenty patients. Singhal BS, et al. **J Assoc Physicians India** 1995 Jul;43(7):459–61

Persistent peripheral nerve pathologies in patients with electric burns. Haberal MA, et al. **J Burn Care Rehabil** 1996 Mar-Apr;17(2):147–9

Do anti-ganglioside antibodies cause human peripheral neuropathies? [see comments] Quarles RH, et al. **J Clin Invest** 1996 Mar 1;97(5):1136–7. Comment in: J Clin Invest 1996 Mar 1;97(5):1155–64.

A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18 [see comments] Willison HJ, et al. **J Clin Invest** 1996 Mar 1; 97(5):1155–64. Comment in: J Clin Invest 1996 Mar 1;97(5):1136–7.

High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1--associated predominantly sensory polyneuropathy. Zehender G, et al. **J Infect Dis** 1995 Dec;172(6):1595–8

Sphingolipid metabolic disorders in Trembler mouse peripheral nerves in vivo result from an abnormal substrate supply. Heape AM, et al. **J Neurochem** 1995 Oct; 65(4):1665–73

Systemic passive transfer studies using IgM monoclonal antibodies to sulfatide. Nardelli E, et al. **J Neuroimmunol** 1995 Dec;63(1):29–37

Traumatic and iatrogenic neurological complications after supracondylar humerus fractures in children. Brown IC, et al. **J Pediatr Orthop** 1995 Jul-Aug;15(4):440–3

Vascular injuries and their sequelae in pediatric supracondylar humeral fractures: toward a goal of prevention. Copley LA, et al. **J Pediatr Orthop** 1996 Jan-Feb;16(1):99–103

Polyneuropathy in juvenile dermatomyositis. Vogelgesang SA, et al. **J Rheumatol** 1995 Jul;22(7):1369–72

Cutaneous nerve lesions of the shoulder and arm after arthroscopic shoulder surgery. Segmüller HE, et al. **J Shoulder Elbow Surg** 1995 Jul-Aug;4(4):254–8

Neurologic symptoms due to possible chromium deficiency in long-term parenteral nutrition that closely mimic metronidazole-induced syndromes. Verhage AH, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):123–7

Critical illness myopathy and neuropathy. Latronico N, et al. **Lancet** 1996 Jun 8;347(9015):1579–82

Hand wounds in leprosy patients. Soares D, et al. **Lepr Rev** 1995 Sep;66(3):235–8

Nerve function impairment in leprosy: an epidemiological and clinical study--Part 2: Results of steroid treatment. van Brakel WH, et al. **Lepr Rev** 1996 Jun;67(2):104–18

Vitamin B12 myeloneuropathy precipitated by nitrous oxide anaesthesia [letter] Nestor PJ, et al. **Med J Aust** 1996 Aug 5;165(3):174

"Sunbath polyneuritis": subacute axonal neuropathy in perazine-treated patients after intense sun exposure. Roelcke U, et al. **Muscle Nerve** 1996 Apr;19(4):438–41

Partial unilateral phrenic nerve paralysis caused by a large intrathoracic goitre. van Doorn LG, et al. **Neth J Med** 1996 Jun;48(6):216–9 (3 ref.)

Triglycerides and neuropathy [letter; comment] Kaufman M. **Neurology** 1995 Nov;45(11):2119–20. Comment on: Neurology 1994 Nov;44(11):2185–6.

Acute multiple mononeuropathy after accidental exposure to oven microwaves. Marchiori PE, et al. **Occup Med (Oxf)** 1995 Oct;45(5):276–7

Neurotrophins and peripheral neuropathy. Anand P. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):449–54 (55 ref.)

Brachial plexus neuropathy following attempt at subclavian vein catheterization. Case report. Trentman TL, et al. **Reg Anesth** 1996 Mar-Apr;21(2):163–5

Peripheral nerve disorders in electrical and lightning injuries. Wilbourn AJ. **Semin Neurol** 1995 Sep;15(3):241–55 (95 ref.)

Inferior brachial plexus injury during thoracoscopic sympathectomy. Lange JF. **Surg Endosc** 1995 Jul;9(7):830

Peripheral neuropathy in subclinical hypothyroidism. Misiunas A, et al. **Thyroid** 1995 Aug;5(4):283–6

[Results obtained by a mobile handicap-prevention unit at the Institut de Léprologie de Dakar] Hirzel C, et al. **Acta Leprol** 1995;9(4):183–6 (Eng. Abstr.) **(Fre)**

[Neuropathy in intensive care: a challenge for the future (editorial)] Mercatello A, et al. **Ann Fr Anesth Reanim** 1995; 14(2):147–8 **(Fre)**

[A cause of difficult weaning from artificial respiration: polyneuropathy of intensive care] Nedir P, et al. **Ann Fr Anesth Reanim** 1995;14(2):209–12 (Eng. Abstr.) **(Fre)**

[Secondary neuromuscular deficiencies in critical care patients] Souron V, et al. **Ann Fr Anesth Reanim** 1995; 14(2):213–7 (Eng. Abstr.) **(Fre)**

[Pure sensory neuropathy, disclosing primary hyperparathyroidism (letter)] Roche C, et al. **Ann Med Interne (Paris)** 1995;146(6):448–9 **(Fre)**

[Paraneoplastic peripheral neuropathy in the course of leiomyosarcoma (letter)] Dhote R, et al. **Presse Med** 1995 Sep 23;24(27):1270 **(Fre)**

[Nervous microangiopathy and POEMS syndrome] Maillot F, et al. **Rev Med Interne** 1995;16(12):934–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Benign neuropathy of the chin] Baron JC. **Rev Neurol (Paris)** 1995 Apr;151(4):284–5 (Eng. Abstr.) **(Fre)**

[Subacute distal motor neuropathy disclosing malignant non-Hodgkin lymphoma: improvement under chemotherapy] Barth P, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):208–10 (Eng. Abstr.) **(Fre)**

[Peripheral neuropathies in HIV infection] Gastaut JL. **Rev Neurol (Paris)** 1995 Oct;151(10):532–40 (96 ref.) **(Fre)**

[Conduction blocks and peripheral neuropathies] Kuntzer T, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):368–82 (163 ref.) (Eng. Abstr.) **(Fre)**

[Conference at the Salpêtrière. December 1994. Cognitive decline and peripheral neuropathy in a 70-year-old man] Vital C, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):296–300 (Eng. Abstr.) **(Fre)**

[Utility of electrophysiologic study using the blink reflex and brainstem evoked potentials for the evaluation of the course of uremic polyneuropathy] Baldini S, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):13–7 (Eng. Abstr.) **(Ita)**

[Neuro-psychiatric involvement in primary Sjögren's syndrome] Sagawa A, et al. **Nippon Rinsho** 1995 Oct; 53(10):2563–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case of diffuse idiopathic skeletal hyperostosis (DISH) with various neurological complications] Nishimura Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):186–90 (Eng. Abstr.) **(Jpn)**

[Clinical study of cervical radiculopathy after laminoplasty for cervical myelopathy] Sasai K, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1237–47 (Eng. Abstr.) **(Jpn)**

[A case of subacute sensory neuropathy associated with extraovarian serous papillary adenocarcinoma of the peritoneum] Ichinose H, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):633–7 (Eng. Abstr.) **(Jpn)**

[An unusual case of peroneal muscular atrophy with rigidity, polyneuropathy, mental retardation, and diabetes mellitus developed in familial Parkinson's disease] Saito T, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):878–83 (Eng. Abstr.) **(Jpn)**

[Progressive neuronal degeneration and childhood cirrhosis] Kumada S, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):442–5 (15 ref.) **(Jpn)**

[A case of systemic lupus erythematosus with various central and peripheral neurological disorders presenting with motor paralytic bladder as a major manifestation] Horiki T, et al. **Ryumachi** 1995 Oct;35(5):821–6 (Eng. Abstr.) **(Jpn)**

[Neuropathies in small cell lung cancer] Nowak-Michalska T, et al. **Pneumonol Pol** 1990 Nov-Dec;58(11-12):610–4 (Eng. Abstr.) **(Pol)**

[A disease of unknown etiology in Cuba (news)] Stepanchenko AV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):101 **(Rus)**

[Neuro-Behçet: a follow-up of 4 cases treated with chlorambucil] Mateos-Colino A, et al. **An Med Interna** 1995 Dec;12(12):600–2 (Eng. Abstr.) **(Spa)**

[Causes of epidemic neuropathy in Cuba (letter)] Calzada PJ. **Bol Oficina Sanit Panam** 1996 Feb;120(2):178–80 **(Spa)**

[Acute alcohol proximal (femoral) neuropathy] Uterga JM, et al. **Rev Neurol** 1995 Mar-Apr;23(120):454 **(Spa)**

[Nerve injuries in rectal surgery] Räf L. **Lakartidningen** 1996 Apr 24;93(17):1649–50 **(Swe)**

GENETICS

The gene responsible for a severe form of peripheral neuropathy and agenesis of the corpus callosum maps to chromosome 15q [see comments] Casaubon LK, et al. **Am J Hum Genet** 1996 Jan;58(1):28–34. Comment in: Am

J Hum Genet 1996 Jan;58(1):7–16.

Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7–16 (121 ref.). Comment on: Am J Hum Genet 1996 Jan;58(1):28–34.

Molecular genetics of peripheral neuropathies. Harding AE. **Baillieres Clin Neurol** 1995 Nov;4(3):383–400 (100 ref.)

Molecular diagnosis of Charcot–Marie–Tooth 1A disease and hereditary neuropathy with liability to pressure palsies by quantifying CMT1A–REP sequences: consequences of recombinations at variant sites on chromosomes 17p11.2–12 [see comments] Vandenberghe A, et al. **Clin Chem** 1996 Jul;42(7):1021–5. Comment in: Clin Chem 1996 Jul;42(7):995–8.

Molecular genetic analysis of the 17p11.2 region in patients with hereditary neuropathy with liability to pressure palsies (HNPP). Timmerman V, et al. **Hum Genet** 1996 Jan; 97(1):26–34

Coexistence of type I familial amyloid polyneuropathy and spinocerebellar ataxia type 1. Clinical and genetic studies of a Japanese family [letter] Ikeda S, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):586–8

Deletion in chromosome 17p11.2 including the peripheral myelin protein–22 (PMP–22) gene in hereditary neuropathy with liability to pressure palsies. Umehara F, et al. **J Neurol Sci** 1995 Nov;133(1–2):173–6

Hypermyelination and demyelinating peripheral neuropathy in Pmp22–deficient mice. Adlkofer K, et al. **Nat Genet** 1995 Nov;11(3):274–80

Protein zero (P0)–deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Martini R, et al. **Nat Genet** 1995 Nov; 11(3):281–6

A recombination hotspot responsible for two inherited peripheral neuropathies is located near a mariner transposon–like element. Reiter LT, et al. **Nat Genet** 1996 Mar;12(3):288–97

The molecular basis of the neuropathies of mouse and human. Snipes GJ, et al. **Prog Brain Res** 1995;105:319–25 (29 ref.)

X–linked dominant Charcot–Marie–Tooth disease and other potential gap–junction diseases of the nervous system [see comments] Spray DC, et al. **Trends Neurosci** 1995 Jun; 18(6):256–62 (92 ref.). Comment in: Trends Neurosci 1995 Dec;18(12):520–1.

IMMUNOLOGY

Membrane attack complex in thickened cutaneous sensory nerves of leprosy patients. Parkash O, et al. **Acta Leprol** 1995;9(4):195–9

Anti–GD1a ganglioside antibodies in peripheral motor syndromes. Carpo M, et al. **Ann Neurol** 1996 Apr; 39(4):539–43

Neuromyotonia: a new autoimmune disease [editorial; comment] Layzer RB. **Ann Neurol** 1995 Nov;38(5):701–2 . Comment on: Ann Neurol 1995 Nov;38(5):714–22.

Anti–ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. Salih AM, et al. **Br J Rheumatol** 1996 Aug;35(8):725–31

Selective loss of myelin–associated glycoprotein from myelin correlates with anti–MAG antibody titre in demyelinating paraproteinaemic polyneuropathy. Gabriel JM, et al. **Brain** 1996 Jun;119 (Pt 3):775–87

Immunological investigation. O'Leary C, et al. **Curr Opin Neurol** 1995 Oct;8(5):349–53 (42 ref.)

Leprous neuropathy as an autoimmune phenomenon. Desikan P. **Indian J Lepr** 1996 Jan–Mar;68(1):15–21 (34 ref.)

Anti–GM1 antibodies in polyneuropathies of unknown origin. Finsterer J, et al. **J Clin Pathol** 1996 May;49(5):422–5

Avidity distribution of antibodies against peripheral nerve myelin in patients with polyneuropathy associated with IgM monoclonal gammopathy and in healthy controls. Vrethem M, et al. **J Neurol Sci** 1995 Aug;131(2):190–9

Absence of antibody–dependent enhancement (ADE) of viral infectivity in the epidemic neuropathy in Cuba. Guzmán MG, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug; 90(4):523–4

Anti–MAG and anti–SGPG antibodies in neuropathy. Van den Berg L, et al. **Muscle Nerve** 1996 May;19(5):637–43

Immunoglobulin G from a patient with Miller–Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Buchwald B, et al. **Neurosci Lett** 1995 Dec 8;201(2):163–6

[Antibodies of IgM type against small cell lung carcinoma and 29 kD neuronal antigen of rat in a patient with paraneoplastic sensory neuropathy] Azuma A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):241–6 (Eng. Abstr.) **(Jpn)**

METABOLISM

Galactosemic neuropathy in transgenic mice for human aldose reductase. Yagihashi S, et al. **Diabetes** 1996 Jan; 45(1):56–9

Changes in neuronal markers in a mononeuropathic rat model relationship between neuropeptide Y, pre–emptive drug treatment and long–term mechanical hyperalgesia. Munglani R, et al. **Pain** 1995 Oct;63(1):21–31

MICROBIOLOGY

Symptomatic intracranial involvement by mycosis fungoides. Howlett DC, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(6):395–6

PARASITOLOGY

Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Sica RE, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):156–63

PATHOLOGY

Idiopathic distal small fiber neuropathy. Gorson KC, et al. **Acta Neurol Scand** 1995 Nov;92(5):376–82

Adenomyomatous hyperplasia of the gallbladder with perineural invasion. Albores–Saavedra J, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1173–6

Aggregation of a subpopulation of vimentin filaments in cultured human skin fibroblasts derived from patients with giant axonal neuropathy. Bousquet O, et al. **Cell Motil Cytoskeleton** 1996;33(2):115–29

Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. McMahon SB, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):616–24 (77 ref.)

Nerve biopsy. Vallat JM, et al. **Curr Opin Neurol** 1995 Oct; 8(5):345–8 (24 ref.)

Adrenal medullary implants reduce transsynaptic degeneration in the spinal cord of rats following chronic constriction nerve injury. Hama AT, et al. **Exp Neurol** 1996 Jan;137(1):81–93

Inflammatory infiltrates in sural nerve biopsies in Guillain–Barre syndrome and chronic inflammatory demyelinating neuropathy. Schmidt B, et al. **Muscle Nerve** 1996 Apr;19(4):474–87

Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. McCarthy BG, et al. **Neurology** 1995 Oct; 45(10):1848–55

Small nerve fibre dysfunction in a patient with Sjögren's syndrome. Neurophysiological and morphological confirmation. Denišlič M, et al. **Scand J Rheumatol** 1995; 24(4):257–9

Axonal atrophy is a specific component of 2,5–hexanedione peripheral neuropathy. Lehning EJ, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):58–66

PHYSIOPATHOLOGY

Fatigue brought on by malfunction of the central and peripheral nervous systems. McComas AJ, et al. **Adv Exp Med Biol** 1995;384:495–512 (59 ref.)

Posterior interosseous nerve conduction. A new method of evaluation. Seror P. **Am J Phys Med Rehabil** 1996 Jan–Feb; 75(1):35–9

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves [see comments] Shillito P, et al. **Ann Neurol** 1995 Nov; 38(5):714–22. Comment in: Ann Neurol 1995 Nov;38(5):701–2.

A cane reduces loss of balance in patients with peripheral neuropathy: results from a challenging unipedal balance test. Ashton–Miller JA, et al. **Arch Phys Med Rehabil** 1996 May;77(5):446–52

Wallerian degeneration in peripheral nerve disease. Griffin JW, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):65–75 (99 ref.)

Strokes mimicking peripheral nerve lesions. Lampl Y, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):203–7

Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure [see comments] Hund EF, et al. **Crit Care Med** 1996 Aug;24(8):1328–33. Comment in: Crit Care Med 1996 Aug;24(8):1282–3.

Prospective comparative study of abnormal distal rectoanal excitatory reflex, pudendal nerve terminal motor latency, and single fiber density as markers of pudendal neuropathy. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jul;39(7):794–8

Electrophysiologic examination of subclinical beriberi polyneuropathy. Djoenaddi W, et al. **Electromyogr Clin Neurophysiol** 1995 Nov;35(7):439–42

Nerve conduction changes in asymptomatic HIV–1 seropositive individuals in the absence of other risk factors for neuropathy. Malessa R, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb;36(1):3–8

Acoustic nerve in peripheral neuropathy: a BAEP study. Brainstem Auditory Evoked Potentials. Pareyson D, et al. **Electromyogr Clin Neurophysiol** 1995 Oct;35(6):359–64

Early detection of neurological involvement in systemic lupus erythematosus patients. Sivri A, et al. **Electromyogr Clin Neurophysiol** 1995 Jun–Jul;35(4):195–9

Leprosy neuropathy: correlation of clinical and electrophysiological tests. Brown TR, et al. **Indian J Lepr** 1996 Jan–Mar;68(1):1–14

Neuritic leprosy. Girdhar BK. **Indian J Lepr** 1996 Jan–Mar; 68(1):35–42 (22 ref.)

Nerve in reversal reaction. Job CK. **Indian J Lepr** 1996 Jan–Mar;68(1):43–7 (11 ref.)

Peripheral neuropathy in liver cirrhosis. A clinical and electrophysiological study. Perretti A, et al. **Ital J Gastroenterol** 1995 Sep;27(7):349–54

Contralateral limb during total contact casting. A dynamic pressure and thermometric analysis. Armstrong DG, et al. **J Am Podiatr Med Assoc** 1995 Dec;85(12):733–7

Demyelinating peripheral neuropathy in merosin–deficient congenital muscular dystrophy. Shorer Z, et al. **J Child Neurol** 1995 Nov;10(6):472–5

The role of neurophysiological investigation in traumatic brachial plexus lesions in adults and children. Smith SJ. **J Hand Surg [Br]** 1996 Apr;21(2):145–7 (20 ref.)

Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection? Apartis E, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun; 60(6):661–6

Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain–Barré syndrome. Dutch Guillain–Barré Study Group. Meulstee J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):482–6

Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group For Edit (Early Diabetes Intervention Trial. Albers JW, et al. **Muscle Nerve** 1996 Feb;19(2):140–6

Single–fiber electromyography in diabetic peripheral polyneuropathy. Bril V, et al. **Muscle Nerve** 1996 Jan; 19(1):2–9

Combined motor and sensory median–ulnar anastomosis: report of an electrophysiologically proven case. Claussen GC, et al. **Muscle Nerve** 1996 Feb;19(2):231–3

Dermatomal/segmental somatosensory evoked potential evaluation of L5/S1 unilateral/unilevel radiculopathies. Dumitru D, et al. **Muscle Nerve** 1996 Apr;19(4):442–9

Drop thumb syndrome [letter] Gominak S. **Muscle Nerve** 1996 Jun;19(6):796

Intrauterine onset of a mononeuropathy: peroneal neuropathy in a newborn with electromyographic findings at age one day compatible with prenatal onset. Jones HR Jr, et al. **Muscle Nerve** 1996 Jan;19(1):88–91

Mononeuropathy multiplex associated with celiac sprue. Kelkar P, et al. **Muscle Nerve** 1996 Feb;19(2):234–6

Are fibrillation potentials and positive sharp waves the same? No. Kraft GH. **Muscle Nerve** 1996 Feb;19(2):216–20

Neuromyotonia, peripheral neuropathy and myasthenia gravis. Martinelli P, et al. **Muscle Nerve** 1996 Apr; 19(4):505–10

Isaacs' syndrome associated with chronic inflammatory demyelinating polyneuropathy. Odabasi Z, et al. **Muscle Nerve** 1996 Feb;19(2):210–5

Polyneuropathy in the mtDNA base pair 3243 point mutation [letter; comment] Fang W. **Neurology** 1996 May; 46(5):1494–5; discussion 1495–6. Comment on: Neurology 1995 Jun;45(6):1188–92.

Axonal channelopathies: an evolving concept in the pathogenesis of peripheral nerve disorders. Gutmann L, et al. **Neurology** 1996 Jul;47(1):18–21

Polyneuropathy in the mtDNA base pain 3243 point mutation [letter; comment] King MD, et al. **Neurology** 1996 May; 46(5):1495–6. Comment on: Neurology 1995 Jun;45(6):1188–92.

Chronic demyelinating polyneuropathy: Improvement after sepsis. Ropper AH. **Neurology** 1996 Mar;46(3):848–50

Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats. Carlton SM, et al. **Neurosci Lett** 1995 Sep 29;198(2):115–8

Bilaterally enhanced dorsal horn postsynaptic currents in a rat model of peripheral mononeuropathy. Colvin LA, et al. **Neurosci Lett** 1996 Mar 22;207(1):29–32

Mechanical allodynia is more strongly manifested in older rats in an experimental model of peripheral neuropathy. Kim YI, et al. **Neurosci Lett** 1995 Oct 20;199(2):158–60

Peripheral neuropathy: an often–overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161–72 (20 ref.)

Small nerve fibre dysfunction in a patient with Sjögren's syndrome. Neurophysiological and morphological confirmation. Denišlič M, et al. **Scand J Rheumatol** 1995; 24(4):257–9

Remission of severe alcoholic polyneuropathy after liver transplantation. Spahn TW, et al. **Z Gastroenterol** 1995 Dec; 33(12):711–4

[Recovery processes in interrupted peripheral nerves (letter)] van Wijk JA. **Ned Tijdschr Geneeskd** 1996 Apr 20; 140(16):904–5 **(Dut)**

[Repetitive discharges of proximal origin in a patient with carcinomatous sensory neuropathy] Matsumoto S, et al. **No To Shinkei** 1995 Aug;47(8):769–71 (Eng. Abstr.) **(Jpn)**

[Clinical and electroneurographic changes in the peripheral nervous system of patients with chronic insulin–dependent diabetes (IDDM)] Grzelec H. **Ann Acad Med Stetin** 1994; 40:171–94 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Prevention of impairment in leprosy; results from a collaborative project in China. Smith WC, et al. **Int J Lepr Other Mycobact Dis** 1995 Dec;63(4):507–17

[The effect of prophylactic administration of pentoxifylline (trental) on development of a neuropathic pain syndrome and microcirculatory disorders caused by it] Gorizontova MP, et al. **Biull Eksp Biol Med** 1995 May;119(5):485–7 **(Rus)**

SURGERY

Spontaneous anterior interosseous nerve palsy with hourglass–like fascicular constriction within the main trunk of the median nerve. Nagano A, et al. **J Hand Surg [Am]** 1996 Mar;21(2):266–70

Peripheral nerve surgery today, turning point or continuous development? Part VII. Vienna, Austria, November 23–26,

1991. **J Reconstr Microsurg** 1995 Jul;11(4):309–16

Tibialis posterior transfer in the correction of footdrop due to leprosy. Soares D. **Lepr Rev** 1995 Sep;66(3):229–34

Latissimus dorsi transfer for elbow flexion in the paralytic limb. Arroyo JS, et al. **Nebr Med J** 1995 Sep;80(9):290–2

True epineural neurolysis in Morton's neuroma: a 5–year follow up. Diebold PF, et al. **Orthopedics** 1996 May; 19(5):397–400

THERAPY

Management of cervical radiculopathy. van Gijn J, et al. **Eur Neurol** 1995;35(6):309–20 (31 ref.)

[The high–dose gamma–globulin therapy for inflammatory demyelinating peripheral neuropathy: evaluations of clinical effects and serum IgG subclasses] Ishihara H, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):991–5 (Eng. Abstr.) **(Jpn)**

[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

[Plasmapheresis in the treatment of diphtheritic polyneuropathy] Postnikov AA, et al. **Klin Med (Mosk)** 1995;73(6):54–5 **(Rus)**

[The use of high–intensity pulsed magnetotherapy in injuries and diseases of the locomotor apparatus and peripheral nervous system] Ushakov AA, et al. **Voen Med Zh** 1995 Feb;(2):42–3 **(Rus)**

VETERINARY

Peripheral neuropathy of dietary riboflavin deficiency in racing pigeons. Wada Y, et al. **J Vet Med Sci** 1996 Feb; 58(2):161–3

VIROLOGY

Cytomegalovirus polyradiculopathy in HIV–infected patients. Meier PA, et al. **J Gen Intern Med** 1996 Jan; 11(1):47–9

PERIPHERAL RESISTANCE see **VASCULAR RESISTANCE**

PERIPHERAL STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

PERIPHERAL T–CELL LYMPHOMA see **LYMPHOMA, T–CELL, PERIPHERAL**

PERIPHERAL VASCULAR DISEASES

Peripheral arterial–vascular disease in women: prevalence, prognosis, and treatment. Gerhard M, et al. **Cardiology** 1995;86(4):349–55 (56 ref.)

Diseases of the aorta, pulmonary, and peripheral vessels. **Curr Opin Cardiol** 1995 Sep;10(5):B120–5

Epidural spinal cord stimulation in the treatment of limb threatening vasospasm––report of a case with a five–year follow–up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)

Critical limb ischaemia: a case against Consensus II. Belch JJ, et al. **Int Angiol** 1995 Dec;14(4):353–6

Iliac vein compression syndrome: case report and review of the literature. Akers DL Jr, et al. **J Vasc Surg** 1996 Sep; 24(3):477–81

Building a partnership between vascular medicine and vascular surgery: a coalition for the future of vascular care. Hiatt WR, et al. **J Vasc Surg** 1996 May;23(5):918–25

[Course of peripheral arterial diseases] Zanocchi M, et al. **Recenti Prog Med** 1995 Sep;86(9):336–40 (Eng. Abstr.) **(Ita)**

[A case of carcinoma of the pancreas head associated with celiac axis compression syndrome] Doke M, et al. **Nippon Geka Gakkai Zasshi** 1995 Dec;96(12):815–8 (Eng. Abstr.) **(Jpn)**

BLOOD

Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Poredoš P, et al. **Angiology** 1996 Mar;47(3):253–9

Serum levels of the TGF–beta receptor are increased in atherosclerosis. Blann AD, et al. **Atherosclerosis** 1996 Feb; 120(1–2):221–6

Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Sanderson KJ, et al. **Atherosclerosis** 1995 Nov;118(1):45–51

Influence of ozone on haemoglobin oxygen affinity in type–2 diabetic patients with peripheral vascular disease: in vitro studies. Coppola L, et al. **Diabete Metab** 1995 Oct; 21(4):252–5

Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Prior M, et al. **Int Angiol** 1995 Dec;14(4):357–63

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. Burgmann H, et al. **J Clin Pathol** 1996 Jun;49(6):508–10

Activated protein C resistance: prevalence and implications in peripheral vascular disease. Ouriel K, et al. **J Vasc Surg** 1996 Jan;23(1):46–51, Discussion 51–2

CHEMICALLY INDUCED

Dose–response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Tseng CH, et al. **Atherosclerosis** 1996 Feb;120(1–2):125–33

Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot–disease–hyperendemic villages in Taiwan. Tseng CH, et al. **Int J Microcirc Clin Exp** 1995 Jan–Feb;15(1):21–7

CLASSIFICATION

Classification and grading of chronic venous disease in the lower limbs. A consensus statement. Beebe HG, et al. **Int Angiol** 1995 Jun;14(2):197–201 (45 ref.)

COMPLICATIONS

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Schectman G, et al. **Am J Med** 1996 Feb; 100(2):197–204

Peripheral neuropathy associated with ischemic vascular disease of the lower limbs. Laghi Pasini F, et al. **Angiology** 1996 Jun;47(6):569–77

Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Tzeng CC, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1797–804

The effect of peripheral vascular disease on long–term mortality after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Birkmeyer JD, et al. **Arch Surg** 1996 Mar;131(3):316–21

Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Violi F, et al. **Atherosclerosis** 1996 Feb;120(1–2):25–35

Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease. Lee AJ, et al. **Br J Haematol** 1996 Jan;92(1):226–30

High–flow priapism due to bilateral arteriosinusoidal fistulae. Göktaş S, et al. **Br J Urol** 1996 Jan;77(1):165–6

The early effects of intravenous L–propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Persico G, et al. **Drugs Exp Clin Res** 1995;21(5):187–98

Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Belch JJ, et al. **Int Angiol** 1995 Dec;14(4):385–8

Prevalence of Candida ciferrii in elderly patients with trophic disorders of the legs. de Gentile L, et al. **Mycopathologia** 1995 Aug;131(2):99–102

Preoperative assessment of patients with coronary disease [letter] Darbar D, et al. **N Engl J Med** 1996 Apr 18; 334(16):1064; discussion 1064–5

Post–traumatic false aneurysm––a frequently missed condition in penetrating injuries. Golpak V. **P N G Med J** 1995 Mar;38(1):57–61

CONGENITAL

[Multiple arteriovenous malformations of the brain, spinal cord, kidneys and peripheral vessels] Okladnikov GI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):93–5 **(Rus)**

DIAGNOSIS

Quantitative blood flow measurements with cine phase–contrast MR imaging of subjects at rest and after exercise to assess peripheral vascular disease. Pena CS, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):153–7

Identifying chronic peripheral arterial disease. Cantwell–Gab K. **Am J Nurs** 1996 Jul;96(7):40–6; quiz 47 (11 ref.)

Postocclusive hyperaemic duplex scan: a new method of aortoiliac assessment [see comments] Currie IC, et al. **Br J Surg** 1995 Sep;82(9):1226–9. Comment in: Br J Surg 1996 Feb;83(2):280–1.

Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Koelemay MJ, et al. **Br J Surg** 1996 Mar;83(3):404–9 (48 ref.)

Magnetic resonance angiography of the distal lower extremity. McDermott VG, et al. **Clin Radiol** 1995 Nov; 50(11):741–6

Hydrostatic systolic toe pressure for diagnosis of peripheral ischaemic vessel disease in diabetes mellitus [letter] Chantelau E, et al. **Eur J Vasc Endovasc Surg** 1996 Jul; 12(1):125–6

Spinal claudication versus arterial claudication. Maher M, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):118–20

Screening for peripheral arterial disease. Marcoux RM, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):370–3

The fate of bypass grafts to angiographically occult runoff vessels detected by magnetic resonance angiography. Carpenter JP, et al. **J Vasc Surg** 1996 Mar;23(3):483–9

Prospective evaluation of peripheral vascular disease in heart transplant recipients. Erdoes LS, et al. **J Vasc Surg** 1995 Oct;22(4):434–40; discussion 440–2

Use of magnetic resonance angiography for the preoperative evaluation of patients with infrainguinal arterial occlusive disease. Hoch JR, et al. **J Vasc Surg** 1996 May; 23(5):792–800; discussion 801

Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory. Wolf YG, et al. **J Vasc Surg** 1995 Oct;22(4):417–21; discussion 421–3

Dipyridamole echocardiography and 99mTc–MIBI spect dipyridamole scintigraphy for cardiac evaluation prior to peripheral vascular surgery. Mocini D, et al. **Minerva Cardioangiol** 1995 May;43(5):185–90

Local cold exposure of the hands from cryosectioning work in histopathological and toxicological laboratories: signs and symptoms of peripheral neuropathy and Raynaud's phenomenon. Wieslander G, et al. **Occup Environ Med** 1996 Apr;53(4):276–80

[Multiple arteriovenous malformations of the brain, spinal cord, kidneys and peripheral vessels] Okladnikov GI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):93–5 **(Rus)**

DRUG THERAPY

Factors predicting the outcome of intraarterial thrombolysis in peripheral arterial and graft occlusions. Sandbaek G, et al. **Acta Radiol** 1996 May;37(3 Pt 1):299–304

Thrombolytic therapy in peripheral vascular disease. Ouriel K. **Adv Surg** 1996;29:191–206 (53 ref.)

Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. Murakami T, et al. **Arzneimittelforschung** 1995 Sep;45(9):991–4

Antithrombotic therapy in peripheral arterial occlusive disease. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):431S–443S (193 ref.)

New standard for success of thrombolytic therapy. An earnest proposal [editorial; comment] Forrester JS. **Circulation** 1995 Oct 15;92(8):2026–8. Comment on: Circulation 1995 Oct 15;92(8):2050–7.

Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase [see comments] Vanderschueren S, et al. **Circulation** 1995 Oct 15; 92(8):2050–7. Comment in: Circulation 1995 Oct 15;92(8):2026–8.

Effect of 8–day therapy with propionyl–L–carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Bolognesi M, et al. **Clin Physiol** 1995 Sep;15(5):417–23

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double–blind clinical study vs placebo. Auteri A, et al. **Int J Clin Pharmacol Res** 1995; 15(2):57–63

Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Melillo E, et al. **Int J Microcirc Clin Exp** 1995 Mar–Apr;15(2):60–4

Thrombolytic therapy compared with mechanical recanalization in non–acute peripheral arterial occlusions: a randomized trial. Meyerovitz MF, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):775–81

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. Ouriel K, et al. **J Vasc Surg** 1996 Jan;23(1):64–73; discussion 74–5

Thrombolysis of lower extremity embolic occlusions: a study of the results of the STAR Registry [see comments] Huettl EA, et al. **Radiology** 1995 Oct;197(1):141–5. Comment in: Radiology 1996 Apr;199(1):288–9.

EPIDEMIOLOGY

Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study. Wilt TJ, et al. **Angiology** 1996 Jun;47(6):533–41

Disease–based assessment of peripheral vascular disease in nursing facility patients. Gonzalez ER, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):671–5

Risk factors for lower extremity arterial disease in non–insulin–dependent diabetic persons. Katsilambros NL, et al. **Diabet Med** 1996 Mar;13(3):243–6

Peripheral vascular disease in non–insulin–dependent diabetes mellitus in south India. Mohan V, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):235–40

The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Smith I, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):402–8

Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT–I). Omoigui NA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):922–30

The prevalence of peripheral vascular disease in familial hypercholesterolaemia. Kroon AA, et al. **J Intern Med** 1995 Nov;238(5):451–9

Carotid artery stenosis in peripheral vascular disease. Alexandrova NA, et al. **J Vasc Surg** 1996 Apr;23(4):645–9

[The association between a cerebrovascular accident and peripheral arterial disease: a case–control study in Asturias, Spain] Caicoya Gómez–Morán M, et al. **Rev Clin Esp** 1995 Dec;195(12):830–5 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Epidemiology of aortic aneurysm and peripheral vascular disease may show ethnic differences [letter; comment] Lip GY, et al. **BMJ** 1996 Jul 20;313(7050):173. Comment on: BMJ 1996 Apr 13;312(7036):948.

ETIOLOGY

Arterial complications after knee arthroplasty: 4 cases and a review of the literature. Holmberg A, et al. **Acta Orthop Scand** 1996 Feb;67(1):75–8

Aneurysm complicating high tibial osteotomy: a case report. Tandon SC, et al. **Acta Orthop Scand** 1996 Feb;67(1):73–4

Fecal impaction as a cause of acute lower limb ischemia. Hoballah JJ, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2055–7

Role of transoesophageal echocardiography in determining the source of peripheral arterial embolism. Lagattolla NR, et al. **Br J Surg** 1995 Dec;82(12):1651–4

Peripheral vascular complications following coronary interventional procedures. Nasser TK, et al. **Clin Cardiol** 1995 Nov;18(11):609–14 (54 ref.)

Alcohol intake as a risk factor for peripheral arterial disease in the general population in the Edinburgh Artery Study. Jepson RG, et al. **Eur J Epidemiol** 1995 Feb;11(1):9–14

External iliac artery stenosis in a young body builder. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):499–501

Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT–I). Omoigui NA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):922–30

Prevalence and risk factors of peripheral arterial disease among older patients living in nursing homes [letter] Bo M, et al. **J Am Geriatr Soc** 1996 Jun;44(6):738–9

Microvascular angiopathy in advanced periodontal disease. Pinchback JS, et al. **J Pathol** 1996 Jun;179(2):204–9

Osteochondroma: an unusual cause of vascular disease in young adults. Eschelman DJ, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):605–13 (54 ref.)

Stenosis of the inferior vena cava caused by a traumatic diaphragmatic hernia: case report. Lee HK, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S175–7

[Vascular complications in hepatic resection] Bach TT, et al. **Chirurgie** 1994–95;120(13):179–85 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. Nityanand S, et al. **J Intern Med** 1995 Nov;238(5):437–43

METABOLISM

Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy. Kemp GJ, et al. **Clin Sci (Colch)** 1995 Dec; 89(6):581–90

Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Blann AD, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):218–22

Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Melillo E, et al. **Int J Microcirc Clin Exp** 1995 Mar–Apr;15(2):60–4

Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. Gröne HJ, et al. **J Pathol** 1995 Nov;177(3):259–67

Immunolocalization of FGF–1 and receptors in human renal allograft vasculopathy associated with chronic rejection. Kerby JD, et al. **Transplantation** 1996 Aug 27;62(4):467–75

MORTALITY

Contrasting epidemiology of aortic aneurysm and peripheral vascular disease in England and Wales [see comments] Coggon D, et al. **BMJ** 1996 Apr 13;312(7036):948. Comment in: BMJ 1996 Jul 20;313(7050):173.

Albumin excretion and vascular deaths in NIDDM. MacLeod JM, et al. **Diabetologia** 1995 May;38(5):610–6

NURSING

Identifying chronic peripheral arterial disease. Cantwell–Gab K. **Am J Nurs** 1996 Jul;96(7):40–6; quiz 47 (11 ref.)

PATHOLOGY

Neonatal Escherichia coli infection and segmental arterial necrosis: similarity to edema disease of weanling swine. de Chadarévian JP, et al. **Mod Pathol** 1995 May;8(4):446–9

Relation between hemostatic variables and increase of common carotid intima–media thickness in patients with peripheral arterial disease. Cortellaro M, et al. **Stroke** 1996 Mar;27(3):450–4

Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection. Geraghty JG, et al. **Transplantation** 1996 Aug 27;62(4):502–9

PHYSIOPATHOLOGY

Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. Darbar D, et al. **BMJ** 1996 Apr 6;312(7035):874–8; discussion 878–9

Doppler ultrasonography of the central retinal artery in patients with diabetes and vascular disease treated with topical timolol. Steigerwalt RD Jr, et al. **Eye** 1995;9 (Pt 4):495–501

Effect of acute alterations in afterload on left ventricular function in patients with combined coronary artery and peripheral vascular disease. Hencin MY, et al. **Heart** 1996 Feb;75(2):151–8

Microcirculation in venous disorders: the role of the white blood cells. Dormandy JA. **Int J Microcirc Clin Exp** 1995; 15 Suppl 1:3–8 (16 ref.)

Microcirculatory homeostasis 1930–1990: insight into microcirculatory readjustments provided by studies on the peripheral circulatory insufficiency of the shock syndrome. Zweifach BW. **Microcirculation** 1995 Sep;2(3):245–51 (44 ref.)

RADIOGRAPHY

Cine phase contrast angiography of normal and diseased peripheral arteries. Preliminary results. Krug B, et al. **Acta Radiol** 1995 Nov;36(6):649–55

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277–84 (44 ref.)

Prospective comparison of CT angiography of the legs with intraarterial digital subtraction angiography. Rieker O, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):269–76

Non–invasive assessment of arterial disease: a comparison of Quickscan with intra–arterial digital subtraction angiography. Zhang Q, et al. **Br J Surg** 1996 Feb; 83(2):231–4

Patterns of atherosclerotic occlusive disease of lower leg and pedal arteries in hypertensive patients undergoing infrainguinal bypass procedures. Karacagil S, et al. **Int Angiol** 1996 Mar;15(1):57–60

Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Prior M, et al. **Int Angiol** 1995 Dec;14(4):357–63

Lower extremity angiography: improved image quality and outflow vessel detection with bilaterally antegrade selective digital subtraction angiography. A blinded prospective intraindividual comparison with aortic flush digital subtraction angiography. Jacob AL, et al. **Invest Radiol** 1996 Apr;31(4):184–93

REHABILITATION

Exercise rehabilitation for patients with peripheral arterial disease. Regensteiner JG, et al. **Exerc Sport Sci Rev** 1995; 23:1–24 (95 ref.)

Exercise training improves functional status in patients with peripheral arterial disease. Regensteiner JG, et al. **J Vasc Surg** 1996 Jan;23(1):104–15

SURGERY

Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery. Marshall ES, et al. **Am J Cardiol** 1995 Oct 15; 76(11):817–21

General versus regional anesthesia for peripheral vascular surgery [letter; comment] de Leon–Casasola OA, et al. **Anesthesiology** 1996 Jul;85(1):224–5. Comment on: Anesthesiology 1996 Jan;84(1):1–2. Comment on: Anesthesiology 1996 Jan;84(1):3–13.

An unusual variant of popliteal artery entrapment. Gamagami RA, et al. **Ann Vasc Surg** 1995 Sep;9(5):467–70

Revascularization versus amputation for elderly patients. Bunt TJ. **AORN J** 1995 Sep;62(3):433–5 (7 ref.)

Histopathologic findings in synthetic and biologic explanted grafts used in peripheral arterial reconstruction. Wagner E, et al. **ASAIO J** 1994 Jul–Sep;40(3):M279–83

Perioperative myocardial infarction in peripheral vascular surgery. Mamode N, et al. **BMJ** 1996 Jun 1; 312(7043):1396–7

Evaluation of the pullback atherectomy catheter in the treatment of lower limb vascular disease. Grubnic S, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):152–9

The pharmacokinetics and UK usage of heparin in vascular intervention. Zaman SM, et al. **Clin Radiol** 1996 Feb; 51(2):113–6

Have the results of infrainguinal bypass improved with the widespread utilisation of postoperative surveillance? Golledge J, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):388–92

Percutaneous rotational atherectomy in peripheral vascular disease for lesions unsuitable for balloon angioplasty. Tyagi S, et al. **Indian Heart J** 1996 Jan–Feb;48(1):45–8

Patterns of atherosclerotic occlusive disease of lower leg and pedal arteries in hypertensive patients undergoing infrainguinal bypass procedures. Karacagil S, et al. **Int Angiol** 1996 Mar;15(1):57–60

Complementary distal arteriovenous fistula and deep vein interposition: a five–year experience with a new technique to improve infrapopliteal prosthetic bypass patency. Ascer E, et al. **J Vasc Surg** 1996 Jul;24(1):134–43

Is completion arteriography mandatory after reversed–vein bypass grafting? Dalman RL, et al. **J Vasc Surg** 1996 Apr; 23(4):637–44

Infrapopliteal bypasses to severely calcified, unclampable outflow arteries: two–year results. Misare BD, et al. **J Vasc Surg** 1996 Jul;24(1):6–15; discussion 15–6

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. Ouriel K, et al. **J Vasc Surg** 1996 Jan;23(1):64–73; discussion 74–5

Selection of patients for cardiac evaluation before peripheral vascular operations. Schueppert MT, et al. **J Vasc Surg** 1996 May;23(5):802–8; discussion 808–9

The influence of lower–extremity muscle force on gait characteristics in individuals with below–knee amputations secondary to vascular disease. Powers CM, et al. **Phys Ther** 1996 Apr;76(4):369–77; discussion 378–85

The effect of posture on the induction of epidural anesthesia for peripheral vascular surgery. Whalley DG, et al. **Reg Anesth** 1995 Sep–Oct;20(5):407–11

Renal–cell carcinoma with intracaval neoplastic extension: stratification and surgical technique. Stief CG, et al. **World J Urol** 1995;13(3):166–70

[Myointimal hyperplasia in peripheral artery reconstruction] Benedetti–Valentini F, et al. **Minerva Cardioangiol** 1995 May;43(5):219–29 **(Ita)**

THERAPY

Peripheral artery recanalization in humans using balloon and laser angioplasty. Barbeau GR, et al. **Clin Cardiol** 1996 Mar; 19(3):232–8

Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7–93 (228 ref.)

Variations in vascular practice and the Cochrane Collaboration [editorial] Bradbury AW, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):125–6

Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Isner JM, et al. **Hum Gene Ther** 1996 May 20;7(8):959–88

Arterial gene therapy for restenosis. Isner JM, et al. **Hum Gene Ther** 1996 May 20;7(8):989–1011

Why we need the Cochrane Collaboration [letter] Leng GC, et al. **Int Angiol** 1996 Mar;15(1):81–3

Thrombolytic therapy compared with mechanical recanalization in non–acute peripheral arterial occlusions: a randomized trial. Meyerovitz MF, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):775–81

Percutaneous aspiration thromboembolectomy [letter; comment] Rauber K. **Radiology** 1996 Apr;199(1):288–9. Comment on: Radiology 1995 Oct;197(1):141–5.

Economic implications of thrombolysis or operation as the initial treatment modality in acute peripheral arterial occlusion. Ouriel K, et al. **Surgery** 1995 Nov;118(5):810–4

ULTRASONOGRAPHY

Contrast enhancement in leg vessels. Langholz J, et al. **Clin Radiol** 1996 Feb;51 Suppl 1:31–4

Colour duplex ultrasonographic imaging and provocation of popliteal artery compression. Akkersdijk WL, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):342–5

The effect of adjacent segment disease on the accuracy of colour duplex scanning for the diagnosis of lower limb arterial disease. Sensier Y, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):238–42

Interobserver variation in duplex sonographic scanning in the femoropopliteal tract. Winter–Warnars HA, et al. **J Ultrasound Med** 1996 Jun;15(6):421–8; discussion 329–30

Nutcracker syndrome: diagnosis with Doppler US. Kim SH, et al. **Radiology** 1996 Jan;198(1):93–7

PERIPHLEBITIS see PHLEBITIS

PERIPLANETA

ANATOMY & HISTOLOGY

Central projections of the antennal cold receptor neurons and hygroreceptor neurons of the cockroach Periplaneta americana. Nishikawa M, et al. **J Comp Neurol** 1995 Oct 9;361(1):165–76

CHEMISTRY

FMRFamide–like and allatostatin–like immunoreactivity in the lateral heart nerve of Periplaneta americana: colocalization at the electron–microscopic level. Ude J, et al. **Cell Tissue Res** 1995 Oct;282(1):69–80

DRUG EFFECTS

Structure–activity relationships for Periplaneta americana hypertrehalosemic hormone. I: The importance of side chains and termini. Gäde G, et al. **Peptides** 1995; 16(7):1173–80

ENZYMOLOGY

Tyrosine hydroxylase in the cerebral ganglia of the American cockroach (Periplaneta americana L.): an immunohistochemical study. Granholm AC, et al. **Cell Tissue Res** 1995 Oct;282(1):49–57

GENETICS

Expression of engrailed in an array of identified sensory neurons: comparison with position, axonal arborization, and synaptic connectivity. Blagburn JM, et al. **J Neurobiol** 1995 Dec;28(4):493–505

IMMUNOLOGY

Identification of low molecular weight allergens of American cockroach and production of monoclonal antibodies. Wu CH, et al. **Ann Allergy Asthma Immunol** 1996 Feb; 76(2):195–203

PERIPLANETA

METABOLISM

Effect of K+ accumulation removal and high extracellular osmolarity on K+ current in insect axonal membrane. Stankiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):95–102

Pattern of potassium ion and proton currents in the ovariole of the cockroach, Periplaneta americana, indicates future embryonic polarity. Kunkel JG, et al. **Biol Bull** 1995 Oct–Nov;189(2):197–8

Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. Tomşe C, et al. **Toxicon** 1995 Apr;33(4):411–24 (61 ref.)

PHYSIOLOGY

The effect of hypoxia and ouabain on the muscle resting potential of Periplaneta americana L. Grajpel B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):103–6

A motion tracking system for simultaneous recording of rapid locomotion and neural activity from an insect. Ye S, et al. **J Neurosci Methods** 1995 Aug;60(1–2):199–210

Cold-induced amnesia blocks escape deficits in the cockroach (Periplaneta americana). Brown GE, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):1051–7

PERIPLANETA AMERICANA see **COCKROACHES**

PERISSODACTYLA

Quarantine requirements for the importation of black rhinoceros from Zimbabwe into Australia. Doyle KA, et al. **Aust Vet J** 1995 Oct;72(10):364–8 (4 ref.)

The importation of the black rhinoceros (Diceros bicornis) from Zimbabwe into Australia. Kelly JD, et al. **Aust Vet J** 1995 Oct;72(10):369–74 (10 ref.)

Epizootic of Mycobacterium bovis in a zoologic park. Stetter MD, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1618–21

PERISTALSIS

Reduction of peristaltic artifacts on magnetic resonance imaging of the abdomen: a comparative evaluation of three drugs. Martí-Bonmatí L, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):309–13

The effect of epidural analgesia on the return of peristalsis and the length of stay after elective colonic surgery. Lehman JF, et al. **Am Surg** 1995 Nov;61(11):1009–12

Jejunal duplication cyst displaying peristalsis and a five-layered appearance of the wall: a preoperative ultrasound diagnosis. Simonovský V. **Eur Radiol** 1996; 6(2):153–5

Prospective study of esophageal motor abnormalities in patients with gastroesophageal disease reflux according to the severity of endoscopic esophagitis. Csendes A, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):394–9

Iso- or antiperistaltic anastomosis: does it matter? Houghton AD, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):148–51

Megacystis–microcolon–intestinal hypoperistalsis syndrome. Kupferman JC, et al. **Pediatr Nephrol** 1995 Oct;9(5):626–7

DRUG EFFECTS

Initiation of esophageal secondary peristalsis by slow fluid infusion in the opossum: effect of hydrochloric acid. Kusano M, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G927–31

Functional characterization of the adenosine receptor mediating inhibition of peristalsis in the rat jejunum. Hancock DL, et al. **Br J Pharmacol** 1995 Jul;115(5):739–44

Postjunctional alpha 1- and beta-adrenoceptor effects of noradrenaline on electrical slow waves and phasic contractions of cat colon circular muscle. Venkova K, et al. **Br J Pharmacol** 1995 Dec;116(8):3265–73

The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. Coupar IM. **J Pharm Pharmacol** 1995 Aug;47(8):643–6

5-HT4 receptor antagonist affinities of SB207710, SB205008, and SB203186 in the human colon, rat oesophagus, and guinea-pig ileum peristaltic reflex. McLean PG, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):132–40

Effect of human gastrin-17 with and without acid suppression on human esophageal motility. Allescher HD, et al. **Z Gastroenterol** 1995 Jul;33(7):385–91

PHYSIOLOGY

Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. Holtmann G, et al. **Am J Gastroenterol** 1996 Mar;91(3):485–91

Secondary peristaltic contractions, like primary peristalsis, are preceded by inhibition in the human esophageal body. Sifrim D, et al. **Digestion** 1996;57(1):73–8

Peristaltic pumping in a circular tube in the presence of an eccentric catheter. Adabala RR, et al. **J Biomech Eng** 1995 Nov;117(4):448–54

PERISTALTIC PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERITONEAL CAVITY

see related
ASCITIC FLUID
LAPAROSCOPY

Preliminary evaluation of silver-coated peritoneal catheters in rats. Kathuria P, et al. **Adv Perit Dial** 1995;11:189–92

Internal hernia of foramen of Winslow: a rare congenital condition. Panula HE, et al. **Eur J Surg** 1995 Sep; 161(9):695–6

Threshold intrauterine perfusion pressures for intraperitoneal spill during hydrotubation and correlation with tubal adhesive disease. Baker VL, et al. **Fertil Steril** 1995 Dec; 64(6):1066–9

Loop electrosurgical excision in the peritoneal cavity. Preliminary experience with the rat model. Munro MG, et al. **J Reprod Med** 1996 Mar;41(3):143–8

"Dropped" surgical clips following laparoscopic cholecystectomy [letter] Rawson JV, et al. **Surg Endosc** 1996 Jan;10(1):77–8

Laparoscopic retrieval of disconnected ventriculoperitoneal shunt catheters: report of two cases. Tanaka J, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):263–6

[Rupture of a hydatid cyst of the liver into the peritoneal cavity. Value of computed tomography] Jouini M, et al. **J Chir (Paris)** 1995 Aug–Sep;132(8–9):358–60 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

A combined electron microscopic investigation of the peritoneal mesothelium in the rat. Michailova KN. **Eur J Morphol** 1995 Jul;33(3):265–77

Anatomic CT demonstration of the peritoneal spaces, ligaments, and mesenteries: normal and pathologic processes. DeMeo JH, et al. **Radiographics** 1995 Jul; 15(4):755–70 (18 ref.)

CYTOLOGY

A dual origin for IgA plasma cells in the murine small intestine. Kroese FG, et al. **Adv Exp Med Biol** 1995; 371A:435–40

Intraperitoneal administration of tetanus toxoid elicits a specific response of antibody-secreting cells in the peritoneal cavity. Lue C, et al. **Adv Exp Med Biol** 1995; 371A:103–6

Migration of rat dendritic cells and macrophages from the peritoneal cavity to the parathymic lymph nodes. van Vugt E, et al. **Adv Exp Med Biol** 1995;378:163–7

Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Offner FA, et al. **Am J Pathol** 1996 May;148(5):1679–88

The Na+/K(+)-pump in rat peritoneal mast cells: some aspects of regulation of activity and cellular function. Knudsen T. **Dan Med Bull** 1995 Nov;42(5):441–54 (261 ref.)

Nitric oxide-dependent killing of Candida albicans by murine peritoneal cells during an experimental infection. Rementería A, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):157–62

Peritoneal cavity CD5 (Bla) B cells: cytokine induced IgA secretion and homing to intestinal lamina propria in SCID mice. Beagley KW, et al. **Immunol Cell Biol** 1995 Oct; 73(5):425–32

Purified rat peritoneal mast cells: characteristics of the removal and binding of IgE. Vally H, et al. **Immunol Cell Biol** 1995 Jun;73(3):212–9

Effects of acrivastine, azelastine, cetirizine and noberastine on rat peritoneal mast cells. Lau HY, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S30–1

Ouabain-insensitive 86Rb+ transport in peritoneal mast cells: role in histamine release. Németh A, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S32–3

Effects of type I and type II phospholipase A2 on rat peritoneal mast cells. Roche CM, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S5–6

Effect of cyclosporin analogues on histamine release from rat peritoneal mast cells and rat basophilic leukaemia cells. Wan BY, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S10–1

Adherence of neutrophils to human peritoneal mesothelial cells: role of intercellular adhesion molecule-1. Liberek T, et al. **J Am Soc Nephrol** 1996 Feb;7(2):208–17

In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. Topley N, et al. **J Am Soc Nephrol** 1996 Feb;7(2):218–24

Characterization of extrathymic T cells induced by recombinant murine interferon-beta in the peritoneal cavity of nude mice. Moriyama M, et al. **J Interferon Cytokine Res** 1995 Nov;15(11):925–31

Age-related enhancement of tumor necrosis factor (TNF) production in mice. Han D, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):39–54

Phagocytosis and killing of suspended and adhered bacteria by peritoneal cells after dialysis. Calame W, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):320–7

Histamine release induced by human natriuretic peptide from rat peritoneal mast cells. Yoshida H, et al. **Regul Pept** 1996 Jan 16;61(1):45–9

Altered cellular biosynthesis in human peritoneal mesothelial cells exposed to dialysis solutions. Bird SD, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):319–28

Normal human immune peritoneal cells: subpopulations and functional characteristics. Kubicka U, et al. **Scand J Immunol** 1996 Aug;44(2):157–63

[Effects of high concentration glucose on cell growth and matrix biosynthesis in human peritoneal mesothelial cells] Hou F, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):326–9 (Eng. Abstr.) **(Chi)**

[Modification of the activity of murine peritoneal neutrophils upon exposure to millimeter waves at close and far distances from the emitter] Gapeev AB, et al. **Biofizika** 1996 Jan–Feb;41(1):205–19 (Eng. Abstr.) **(Rus)**

[Cytotoxic activity of murine peritoneal cavity cells during inflammation in vivo] Sukharev SA, et al. **Dokl Akad Nauk** 1995 Jul;343(3):403–5 **(Rus)**

EMBRYOLOGY

Utility of fetal intraperitoneal saline infusion in the prenatal evaluation of diaphragmatic hernia. Meagher S, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):307–10

MICROBIOLOGY

Non-dystrophic 129 REJ mice are susceptible to i.p. infection with Listeria monocytogenes despite an ability to recruit inflammatory neutrophils to the peritoneal cavity. Gahan CG, et al. **Microb Pathog** 1995 May;18(5):355–64

Effect of interferon-gamma in dialysis fluid on peritoneal defence in rats. Calame W, et al. **Nephrol Dial Transplant** 1995;10(7):1212–7

PARASITOLOGY

A consideration on the relationship between worm age and mortality of Setaria marshalli recovered from the peritoneal cavity of calves born in Tottori prefecture, Japan. Fujii T, et al. **J Vet Med Sci** 1996 Feb;58(2):171–2

PATHOLOGY

Peritoneal mast cell hyperplasia in rats after IgE antibody-antigen interaction. Inagaki N, et al. **Exp Anim** 1995 Oct;44(4):337–40

Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. Zuany-Amorim C, et al. **J Immunol** 1996 Jul 1;157(1):377–84

Imaging of the peritoneal cavity in CAPD. Wankowicz Z, et al. **Perit Dial Int** 1996;16 Suppl 1:S434–9

The SCID mouse reaction to human peripheral blood mononuclear leukocyte engraftment. Neutrophil recruitment induced expression of a wide spectrum of murine cytokines and mouse leukopoiesis, including thymic differentiation. Santini SM, et al. **Transplantation** 1995 Dec 15;60(11):1306–14

PHYSIOLOGY

Effect of in vivo corticosterone and acute food deprivation on rat resident peritoneal cell chemiluminescence after activation ex vivo. Wiik P, et al. **Acta Physiol Scand** 1995 Jul;154(3):407–16

Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Davies SJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):498–506

Physiological approaches to increase biocompatibility of peritoneal dialysis. Breborowicz A, et al. **Perit Dial Int** 1995;15(7 Suppl):S76–85; discussion S85–6 (127 ref.)

First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Brulez HF, et al. **Perit Dial Int** 1995; 15(7 Suppl):S24–33; discussion S33–4 (79 ref.)

RADIOGRAPHY

[Unilateral inguinal hernia in infants: costs, risks and benefits of herniography? Results] Lucidarme O, et al. **J Radiol** 1995 Jun;76(6):359–63 (Eng. Abstr.) **(Fre)**

[Unilateral inguinal hernia in infants: costs, risks and benefits of herniography? Methodology] Poisson-Salomon AS, et al. **J Radiol** 1995 Jun;76(6):353–8 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Another "rim sign". A patent processus vaginalis demonstrated by peritoneal Tc-99m sc scintigraphy. Turpin S, et al. **Clin Nucl Med** 1995 Aug;20(8):729–30

SURGERY

[Laparoscopic surgery of an intraperitoneal intrauterine device] Ferchiou M, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):409–11 (Eng. Abstr.) **(Fre)**

PERITONEAL DIALYSIS

see related
DIALYSIS SOLUTIONS
KIDNEY, ARTIFICIAL

Selected papers from the 15th Annual Conference on Peritoneal Dialysis. Baltimore, Maryland, February 1995. **Adv Perit Dial** 1995;11:1–312

Outcome of infants on chronic peritoneal dialysis. Ellis EN, et al. **Adv Perit Dial** 1995;11:266–9

Recombinant human growth hormone (rhGH) in dialysis patients: update 1995. Fine RN. **Adv Perit Dial** 1995; 11:261–5 (15 ref.)

Nutritional effects of KT/V in children on peritoneal dialysis: are there benefits from larger dialysis doses? Fischbach M,

et al. **Adv Perit Dial** 1995;11:306–8

Immunizations in children on PD: current guidelines and recommendations. Fivush BA, et al. **Adv Perit Dial** 1995; 11:270–3

Cross-sectional analysis of erythropoietin use in CPD: its relation to azotemic index clearances. Fox L, et al. **Adv Perit Dial** 1995;11:243–6

Variability in calculations of dialysis adequacy in patients using nightly intermittent peritoneal dialysis compared to CAPD. Friedlander MA, et al. **Adv Perit Dial** 1995;11:93–6

Hematocrit has no effect on peritoneal transport indices. Gandolfo C, et al. **Adv Perit Dial** 1995;11:41–4

Collagen markers in peritoneal dialysis patients. Graff J, et al. **Adv Perit Dial** 1995;11:24–7

Peritoneal blood flow and peritoneal transfer parameters during dialysis with administration of drugs. Grzegorzewska AE, et al. **Adv Perit Dial** 1995;11:28–32

Routine omentectomy is not required in children undergoing chronic peritoneal dialysis. Lewis M, et al. **Adv Perit Dial** 1995;11:293–5

Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients. Lin JJ, et al. **Adv Perit Dial** 1995;11:60–2

Increased peritoneal solute transport in diabetic peritoneal dialysis patients. Lin JJ, et al. **Adv Perit Dial** 1995;11:63–6

Current status of pediatric home peritoneal dialysis training in the United States. Miller DH, et al. **Adv Perit Dial** 1995; 11:274–6

Peritoneal membrane failure in children on peritoneal dialysis. Neiberger RE. **Adv Perit Dial** 1995;11:277–80

The implementation of a continuous quality improvement program in a pediatric peritoneal dialysis unit. Reilly KM, et al. **Adv Perit Dial** 1995;11:285–8

Dialysis adequacy indices in high membrane transporters treated with short-dwell peritoneal dialysis. Strauss FG, et al. **Adv Perit Dial** 1995;11:110–3

Absorption of iron dextran from the peritoneal cavity of rats. Suzuki K, et al. **Adv Perit Dial** 1995;11:57–9

Clinical experience in the treatment of infants with chronic peritoneal dialysis. Verrina E, et al. **Adv Perit Dial** 1995; 11:281–4

Role of automated peritoneal dialysis within a peritoneal dialysis program. Viglino G, et al. **Adv Perit Dial** 1995; 11:134–8

Influence of peritoneal dialysis on the progression of chronic renal failure. Wang T, et al. **Adv Perit Dial** 1995;11:139–41

Decreasing the complications of renal osteodystrophy secondary to high phosphorus levels by using an innovative self-monitoring educational program. Zagaroli AM, et al. **Adv Perit Dial** 1995;11:254–7

The significance of protein intake and catabolism. Flanigan MJ, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):330–40 (62 ref.)

Dialysis and renal transplantation in infants with irreversible renal failure. Neu AM, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):48–59 (109 ref.)

Peritoneal dialysis kinetics. Ponferrada LP, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):341–8 (29 ref.)

Comparison of five body-composition methods in peritoneal dialysis patients. Stall SH, et al. **Am J Clin Nutr** 1996 Aug; 64(2):125–30

Techniques for modelling adequacy in patients on peritoneal dialysis. Blake PG. **Am J Kidney Dis** 1996 May;27(5):750–3 (21 ref.)

Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences. Bleyer AJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):72–81

Rusty peritoneal dialysis fluid after intravenous administration of iron dextran. Carter TB, et al. **Am J Kidney Dis** 1996 Jan;27(1):147–50

Foregoing renal dialysis: a case study and review of ethical issues. The End-Stage Renal Disease Group. Tobe SW, et al. **Am J Kidney Dis** 1996 Jul;28(1):147–53 (33 ref.)

Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Wang M, et al. **Am J Kidney Dis** 1995 Nov;26(5):836–44

Correction of glucose concentration interference on Jaffé kinetic creatinine assay in peritoneal dialysis. Da Rin G, et al. **Am J Nephrol** 1995;15(6):480–7

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)

Nutritional treatment of hemodialysis and peritoneal dialysis patients. Schmicker R. **Artif Organs** 1995 Aug;19(8):837–41 (34 ref.)

Effects of euhydric peritoneal dialysis solutions containing mixture of bicarbonate and lactate or lactate alone on neutrophilic superoxide production. Yu AW, et al. **ASAIO J** 1994 Jul–Sep;40(3):M900–1

Intraperitoneal fluid volume changes during peritoneal dialysis in the rat: indicator dilution vs. volumetric measurements. Zakaria ER, et al. **Blood Purif** 1995; 13(5):255–70

Hyperkalaemic cardiac arrest successfully treated with peritoneal dialysis. Jackson MA, et al. **BMJ** 1996 May 18; 312(7041):1289–90

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. English MW, et al. **Br J Cancer** 1996 Mar;73(6):776–80

Scintigraphic assessment of pericardio-peritoneal window patency. Relevance to peritoneal dialysis. Joseph UA, et al. **Clin Nucl Med** 1995 Jul;20(7):613–4

The transport of phosphate between the plasma and dialysate compartments in peritoneal dialysis is influenced by an electric potential difference. Graff J, et al. **Clin Physiol** 1996 May;16(3):291–300

Dialysis and transplantation. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):B155–77

An update on peritoneal dialysis and hemodialysis in the pediatric population. Warady BA, et al. **Curr Opin Pediatr** 1996 Apr;8(2):135–40 (58 ref.)

Evaluation of non-linear and linear mathematical models for creatinine and glucose fitting in peritoneal dialysis. Amici G. **Int J Artif Organs** 1996 Apr;19(4):221–31

Acute renal failure in infants and children. Ehrich JH. **Int J Artif Organs** 1996 Feb;19(2):121–3 (9 ref.)

Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145–6 (4 ref.)

Neutrophil intracellular pH after exposure of neutrophils to a euhydric, lactate-based peritoneal dialysis solution and its euhydric, bicarbonate-based counterpart. Zhou XJ, et al. **Int J Artif Organs** 1995 Feb;18(2):69–72

Influence of intraperitoneal gentamicin on peritoneal transport in IPD patients. Janicka L, et al. **Int Urol Nephrol** 1995;27(2):215–21

The rapid reversal of profound hypothermia using peritoneal dialysis. Vella J, et al. **Ir J Med Sci** 1996 Apr–Jun; 165(2):113–4 (9 ref.)

Peritoneal equilibration test results are different in infants, children, and adults. Mendley SR, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1309–12

In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. Topley N, et al. **J Am Soc Nephrol** 1996 Feb;7(2):218–24

Proceedings of the Nephrology 1994 Janus and the Workshop on Peritoneal Dialysis. Bombay, India, May 15–17, 1994. **J Postgrad Med** 1994 Jul–Sep;40(3):101–93

Connecting devices in CAPD and their impact on peritonitis. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):179–84 (33 ref.)

Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations. Lemmer JH Jr, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):192–4

Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells. Brunkhorst R, et al. **Kidney Int** 1995 Jul; 48(1):177–81

Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. White R, et al. **Kidney Int** 1995 Dec;48(6):1986–93

Folic acid treatment of hyperhomocysteinemia in dialysis patients. Janssen MJ, et al. **Miner Electrolyte Metab** 1996; 22(1–3):110–4

Elimination of gadolinium-DTPA by peritoneal dialysis. Dörsam J, et al. **Nephrol Dial Transplant** 1995;10(7):1228–30

Daily short exposure of cultured mesothelial cells to lactated, high-glucose, low-pH peritoneal dialysis fluid induces a low-profile regenerative steady state. Shostak A, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):608–13

Peritoneal equilibration test: time on treatment and reference values [letter] Amici G, et al. **Nephron** 1995;70(4):506–7

Severe acute renal failure: a comparison of acute continuous hemodiafiltration and conventional dialytic therapy. Bellomo R, et al. **Nephron** 1995;71(1):59–64

Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension. James SH, et al. **Nephron** 1995;71(1):29–34

Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Moon SS, et al. **Nephron** 1995;70(4):430–7

Heme synthesis in chronic renal failure: the effects of hemodialysis, peritoneal dialysis and erythropoietin treatment. Siersema PD, et al. **Nephron** 1995;71(3):297–302

Haemophilus influenzae type b immunization in infants on peritoneal dialysis. Pediatric Peritoneal Dialysis Study Consortium. Neu AM, et al. **Pediatr Nephrol** 1996 Feb; 10(1):84–5

Literature. April–June 1995. **Perit Dial Int** 1995 Jul–Sep; 15(6):286–8

Literature. March–April 1996. **Perit Dial Int** 1996 May–Jun; 16(3):335–8

Literature, July–September 1995. **Perit Dial Int** 1995 Oct–Dec;15(8):401–5

Literature. October–December 1995. **Perit Dial Int** 1996 Jan–Feb;16(1):100–3

The influence of dialysate sampling on peritoneal equilibration test results. Amici G, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):83–4

Compliance study in peritoneal dialysis using PD Adequest software. Amici G, et al. **Perit Dial Int** 1996;16 Suppl 1:S176–8

Estimation of total creatinine clearance is unreliable in children on peritoneal dialysis. Aufricht C, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):73–7

Stability of drug additives to peritoneal dialysate. Bailie GR, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):328–35

Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)

Urea kinetics and nitrogen appearance rates in diabetic patients on peritoneal dialysis. Bernardini JY, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):259–63

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)

First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Brulez HF, et al. **Perit Dial Int** 1995; 15(7 Suppl):S24–33; discussion S33–4 (79 ref.)

The ethics of infant dialysis. Bunchman TE. **Perit Dial Int** 1996;16 Suppl 1:S505–8

Phagocytosis and killing of suspended and adhered bacteria by peritoneal cells after dialysis. Calame W, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):320–7

Biocompatibility of various osmotic solutes. Coles GA. **Perit Dial Int** 1995;15(7 Suppl):S71–5

Are solutions presently used bioincompatible? Coles GA. **Perit Dial Int** 1995;15(7 Suppl):S109–10; discussion S110–4

Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)

The spectrum of renal osteodystrophy in peritoneal dialysis patients [editorial] Delmez JA. **Perit Dial Int** 1996 Jan–Feb; 16(1):24–5

Peritoneal dialysis solution biocompatibility testing in animals. Di Paolo N, et al. **Perit Dial Int** 1995;15(7 Suppl):S61–9; discussion S69–70 (40 ref.)

Measurement of hydrostatic intraperitoneal pressure: a necessary routine test in peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996;16 Suppl 1:S84–7

The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)

Impact of the liver on peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S205–6

New strategies in clinical nutrition. Fürst P. **Perit Dial Int** 1996;16 Suppl 1:S28–35 (25 ref.)

What is our impact? [editorial] Gorska B, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):199–200

Morphology of the peritoneum: effect of peritoneal dialysis. Gotloib L, et al. **Perit Dial Int** 1995;15(7 Suppl):S9–11; discussion S11–2

Choice of chronic peritoneal dialysis: need for early assessment and education [editorial; comment] Hamburger RJ. **Perit Dial Int** 1996 Jan–Feb;16(1):19. Comment on: Perit Dial Int 1996 Jan–Feb;16(1):69–72.

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

Rapid decline of residual renal function in patients on automated peritoneal dialysis. Hiroshige K, et al. **Perit Dial Int** 1996 May–Jun;16(3):307–15

The biology of the mesothelium during peritoneal dialysis. Hjelle JT, et al. **Perit Dial Int** 1995;15(7 Suppl):S13–22; discussion S22–3 (108 ref.)

Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May–Jun;16(3):255–9 (62 ref.)

Peritoneal host defense mechanisms. Holmes CJ. **Perit Dial Int** 1996;16 Suppl 1:S124–5

Long-term peritoneal dialysis in the absence of residual renal function [see comments] Jindal KK, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):78–81. Comment in: Perit Dial Int 1996 Jan–Feb;16(1):20–3.

Heat-sterilized PD fluid blocks leukocyte adhesion and increases flow velocity in rat peritoneal venules. Jonasson P, et al. **Perit Dial Int** 1996;16 Suppl 1:S137–40

Prescription planning for peritoneal dialysis: a practice challenge. Krapf R, et al. **Perit Dial Int** 1995;15(5 Suppl):S53–8

Role of diaphragmatic, visceral, and parietal pathways in peritoneal fluid absorption in rat peritoneal dialysis. Kumano K, et al. **Perit Dial Int** 1996;16 Suppl 1:S80–3

Peritoneal dialysis and endocrinology. Lim VS. **Perit Dial Int** 1996;16 Suppl 1:S257–9 (6 ref.)

The effect of KT/V(urea) on nitrogen appearance and appetite in peritoneal dialysis. Lynn RI, et al. **Perit Dial Int** 1995;15(5 Suppl):S50–2

Industry perspectives on biocompatibility of peritoneal dialysis solutions. Martis L. **Perit Dial Int** 1995;15(7 Suppl):S96–9

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532–9 (43 ref.)

Quality of life elderly and diabetic patients on peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S406–9 (33 ref.)

Highlights of ISPD 1995 [editorial] Nolph K. **Perit Dial Int** 1995 Oct–Dec;15(8):297–300

Is it appropriate to offer dialysis to octogenarians? A modern conspiracy? [editorial] Oreopoulos DG. **Perit Dial Int** 1996 May–Jun;16(3):241–2

The effect of dialysate acidity on peritoneal solute transport in the rat. Park MS, et al. **Perit Dial Int** 1995 Oct–Dec; 15(8):312–9

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl

1:S109–13 (44 ref.)
Renal transplantation in patients undergoing chronic peritoneal dialysis. Pérez Fontán MP, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):48–51
S. aureus nasal carriage: importance and approaches [editorial] Piraino B. **Perit Dial Int** 1995 Oct–Dec; 15(8):301–2
A comparison of bone scans in uremic patients treated with intermittent peritoneal dialysis or hemodialysis. Plotast H, et al. **Perit Dial Int** 1996;16 Suppl 1:S312–6
Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19–22 (33 ref.)
Treatment modality selection in 150 consecutive patients starting ESRD therapy [see comments] Prichard SS. **Perit Dial Int** 1996 Jan–Feb;16(1):69–72. Comment in: Perit Dial Int 1996 Jan–Feb;16(1):19.
Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)
Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)
Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)
Current nutritional recommendations in peritoneal dialysis. Russell L, et al. **Perit Dial Int** 1996;16 Suppl 1:S459–60
Quality-of-life assessment in patients on peritoneal dialysis: a review of the state of the art. Salek S. **Perit Dial Int** 1996;16 Suppl 1:S398–401 (13 ref.)
Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)
Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215–9 (35 ref.)
Minoxidil selectively improves peritoneal ultrafiltration. el-Sherif AK, et al. **Perit Dial Int** 1996;16 Suppl 1:S91–4
Bioelectrical impedance analysis and dual energy x-ray absorptiometry to monitor nutritional status. Stall S, et al. **Perit Dial Int** 1995;15(5 Suppl):S59–62 (31 ref.)
PD treatment for severe congestive heart failure. Stegmayr BG, et al. **Perit Dial Int** 1996;16 Suppl 1:S231–5
What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions? [editorial] Topley N. **Perit Dial Int** 1995 Jul–Sep;15(6):205–9 (29 ref.)
Is peritoneal dialysis feasible once a large muscular patient becomes anuric? [editorial; comment] Twardowski ZJ, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):20–3. Comment on: Perit Dial Int 1996 Jan–Feb;16(1):78–81.
The solute removal index: a new name for an old concept [letter; comment] Uehlinger DE. **Perit Dial Int** 1996 Jan–Feb;16(1):94–6. Comment on: Perit Dial Int 1995;15(2):101–4.
Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402–5 (13 ref.)
Physiological approaches to increase biocompatibility of peritoneal dialysis [letter] Veech RL. **Perit Dial Int** 1996 May–Jun;16(3):332–3
Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)
Glucose degradation and cytotoxicity in PD fluids. Wieslander A, et al. **Perit Dial Int** 1996;16 Suppl 1:S114–8
Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Wieslander AP, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):348–52
Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52–9; discussion S59–60 (32 ref.)
Biocompatibility in peritoneal dialysis: definitions and mechanisms. Williams JD. **Perit Dial Int** 1995;15(7 Suppl):S5–8
Health-related quality of life in endstage renal failure. Gudex CM. **Qual Life Res** 1995 Aug;4(4):359–66
Progressive ischemic gangrene in dialysis patients: a clinicopathological correlation. el-Reshaid K, et al. **Ren Fail** 1995 Jul;17(4):437–47
Intensified dialysis treatment of ethylene glycol intoxication. Sabeel AI, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):125–9
The effect of dialysis on radiocaesium in man. Josefsson D, et al. **Sci Total Environ** 1995 Dec 1;173–174:407–11
Heterogeneity of dialysis patient lymphocyte responses to cyclosporine. Briggs WA, et al. **Transplant Proc** 1996 Aug; 28(4):2063–5
[Treatment of chronic kidney failure in diabetics with peritoneal dialysis] Bednářová V, et al. **Cas Lek Cesk** 1996 May 29;135(11):340–3 (27 ref.) (Eng. Abstr.) **(Cze)**
[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**
[25 years of dialysis and kidney transplantation in children and adolescents] Gämperli A, et al. **Schweiz Med Wochenschr** 1996 Jan 20;126(3):77–85 (Eng. Abstr.) **(Ger)**
[Peritoneal blood flow and peritoneal transfer parameters during intermittent peritoneal dialyses performed with administration of sodium nitroprusside or chlorpromazine] Grzegorzewska A, et al. **Przegl Lek** 1996;53(5):412–6 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

The efficacy of intraperitoneally administered gentamicin and rifampin as initial treatment of peritoneal dialysis-related peritonitis. Brulez HF, et al. **Adv Perit Dial** 1995;11:182–6
Pituitary dysfunctions in uremic patients undergoing peritoneal dialysis: a cross sectional descriptive study. Díez JJ, et al. **Adv Perit Dial** 1995;11:218–24
The impact of exit-site care and catheter design on the incidence of catheter-related infections. Jones LL, et al. **Adv Perit Dial** 1995;11:302–5
Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie. Klaus G, et al. **Adv Perit Dial** 1995;11:296–301
Unblocking peritoneal dialysis catheters with a combination of urokinase and Fogarty catheter manipulation. Stringel G, et al. **Adv Perit Dial** 1995;11:200–1
Subcutaneous cuff removal in persistent exit-site/tunnel infections in peritoneal dialysis. Suh H, et al. **Adv Perit Dial** 1995;11:157–9
Spontaneous peritonitis and peritoneal fibrosis in rats on peritoneal dialysis for 9 weeks. Suzuki K, et al. **Adv Perit Dial** 1995;11:52–6
The renal bone diseases in children treated with dialysis. Sanchez CP, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):14–23 (78 ref.)
Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Goldie SJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):86–91
Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)
Long-term peritoneal dialysis before transplantation and intra-abdominal infection after simultaneous pancreas-kidney transplantations. Papalois BE, et al. **Arch Surg** 1996 Jul;131(7):761–6
Cystic transformation and calcium oxalate deposits in rete testis and efferent ducts in dialysis patients. Nistal M, et al. **Hum Pathol** 1996 Apr;27(4):336–41
Fungal peritonitis complicating peritoneal dialysis. Banerjee S, et al. **Indian Pediatr** 1995 Jun;32(6):693–7
Low dose megestrol increases serum albumin in malnourished dialysis patients. Lien YH, et al. **Int J Artif Organs** 1996 Mar;19(3):147–50
The prognostic importance of left ventricular geometry in uremic cardiomyopathy. Foley RN, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2024–31
Staphylococcus aureus infections during peritoneal dialysis. Coles GA. **J Chemother** 1995 Jul;7 Suppl 3:67–70 (22 ref.)
Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. Friedlander MA, et al. **J Clin Invest** 1996 Feb 1;97(3):728–35
Peritonitis involving a Capnocytophaga sp. in a patient undergoing continuous ambulatory peritoneal dialysis. Esteban J, et al. **J Clin Microbiol** 1995 Sep;33(9):2471–2
Bacterial peritonitis associated with peritoneal dialysis. Sutcharitchan N, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S105–7
Ultrafiltration failure in CAPD. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):185–93 (47 ref.)
Pontine myelinolysis following correction of hyponatraemia. Loo CS, et al. **Med J Malaysia** 1995 Jun;50(2):180–2
Occult inguinal hernia, a cause of rapid onset of penile and scrotal edema in patients on chronic peritoneal dialysis. Deshmukh N, et al. **Mil Med** 1995 Nov;160(11):597–8
Haemophilus influenzae: a cause of peritonitis in peritoneal dialysis. Neuhaus TJ, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):199–200
Acute pneumoperitoneum in a patient on nocturnal intermittent peritoneal dialysis [letter] Albalate M, et al. **Nephron** 1996;72(2):358
Fibroadhesive form of tuberculous peritonitis: chyloperitoneum in a patient undergoing automated peritoneal dialysis. Huang CH, et al. **Nephron** 1996; 72(4):708–11
Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution. Kuizon B, et al. **Pediatr Nephrol** 1995;9 Suppl:S12–7
Combination therapy involving ciprofloxacin for peritonitis. Guest SS, et al. **Perit Dial Int** 1996 May–Jun;16(3):316–8
Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67–74 (68 ref.)
The problems of peritoneal dialysis in the management of chronic uraemia in Nigeria. Arije A, et al. **Trop Geogr Med** 1995;47(2):74–7
[Myoneuropathy in patients with chronic renal failure treated with hemodialysis (HD) and intermittent peritoneal dialysis (IPD). II. Sensory and motor nerve conduction velocity in patients with chronic renal failure treated with intermittent peritoneal dialysis and hemodialysis] Wanic-Kossowska M, et al. **Pol Arch Med Wewn** 1996 Mar; 95(3):237–44 (Eng. Abstr.) **(Pol)**
[Myoneuropathy in patients with chronic renal failure treated with hemodialysis (HD) and intermittent peritoneal dialysis (IPD). I. Evaluation of myoelectric activity of selected skeletal muscles in patients with chronic renal failure treated with hemodialysis and intermittent peritoneal dialysis] Wanic-Kossowska M, et al. **Pol Arch Med Wewn** 1996 Mar;95(3):229–36 (Eng. Abstr.) **(Pol)**
[Complication due to intraperitoneal dialysis catheter insertion] Majdan M, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):104–6 (Eng. Abstr.) **(Pol)**

ECONOMICS

Medical concerns and the national budget allocations [editorial] Berlyne GM. **Nephron** 1995;71(2):125–6
How much extra does "adequate" peritoneal dialysis cost? Blake PG, et al. **Perit Dial Int** 1996;16 Suppl 1:S171–5
Peritoneal dialysis in Asia. Cheng IK. **Perit Dial Int** 1996; 16 Suppl 1:S381–5
Health-care economics and peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S373–7 (17 ref.)
Socioeconomic and health-care policies and peritoneal dialysis. Prichard SS. **Perit Dial Int** 1996;16 Suppl 1:S378–80

INSTRUMENTATION

Infection rates in end-stage renal disease patients treated with CCPD and CAPD using the UltraBag system. Gahrmani N, et al. **Adv Perit Dial** 1995;11:164–7
Stiff wire manipulation of peritoneal dialysis catheters. Kappel JE, et al. **Adv Perit Dial** 1995;11:202–7
A longitudinal in vitro antimicrobial evaluation of two silver polymer surface treatments for peritoneal dialysis catheters. Kubey W, et al. **Adv Perit Dial** 1995;11:193–6
A new porous surface modification technology for peritoneal dialysis catheters as an exit-site cuff to reduce exit-site infections. Moncrief J, et al. **Adv Perit Dial** 1995;11:197–9
Management of catheter-related infections. Piraino B. **Am J Kidney Dis** 1996 May;27(5):754–8 (33 ref.)
Four-year experience with swan neck presternal peritoneal dialysis catheter. Twardowski ZJ, et al. **Am J Kidney Dis** 1996 Jan;27(1):99–105
Anaesthesia for the insertion of a catheter for peritoneal dialysis. Haslett RC, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):49–50
Peritoneal dialysis using guide wire inserted femoral vein catheter. Kohli HS, et al. **Indian Pediatr** 1996 Mar; 33(3):220–3
Peritoneal access. Bhatla B, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):170–8 (50 ref.)
Acute peritoneal dialysis access in infant renal failure. Bunchman TE. **Perit Dial Int** 1996;16 Suppl 1:S509–11
Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)
Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330–2 (18 ref.)
Implantation techniques for peritoneal dialysis catheters. Cruz C. **Perit Dial Int** 1996;16 Suppl 1:S319–21 (14 ref.)
How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167–70 (14 ref.)
Reinsertion of PD catheters during PD-related infections performed either simultaneously or after an intervening period. Fredensborg BB, et al. **Perit Dial Int** 1995 Oct–Dec; 15(8):374–8
Placement and management of PD catheters: experience from Hungary [letter] Karatson A, et al. **Perit Dial Int** 1996 May–Jun;16(3):327–8
The peritoneal access. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S322–6 (24 ref.)
Peritoneal dialysis access technology: the Austin Diagnostic Clinic experience. Moncrief JW, et al. **Perit Dial Int** 1996; 16 Suppl 1:S327–9
Exit-site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336–9 (28 ref.)
Which catheter is the best buy? [editorial] Piraino B. **Perit Dial Int** 1995 Oct–Dec;15(8):303–4
Adequacy and quality of life with automated peritoneal dialysis. Wrenger E, et al. **Perit Dial Int** 1996;16 Suppl 1:S153–7
[Tools for determining adequateness and dialysis dose in peritoneal dialysis (see comments)] Lameire N. **Nephrologie** 1995;16(6):407–11 (50 ref.). Comment in: Nephrologie 1995;16(6):393–7. **(Fre)**

METHODS

The method used for volume estimation significantly influences KprT/V results in peritoneal dialysis patients. Dumler F, et al. **Adv Perit Dial** 1995;11:88–92
Daily home hemodialysis: a hybrid of hemodialysis and peritoneal dialysis. Twardowski ZJ. **Adv Ren Replace Ther** 1996 Apr;3(2):124–32 (55 ref.)
Enhancement of peritoneal dialysis: the PD Plus concept. Diaz-Buxo JA. **Am J Kidney Dis** 1996 Jan;27(1):92–8
"PD Plus": is it a new concept? [letter] Twardowski ZJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):156–8
Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143–6 (17 ref.)
Prescription and assessment of tidal peritoneal dialysis delivery with a specific equilibration test. Edefonti A, et al. **Perit Dial Int** 1996 May–Jun;16(3):295–301
Peritoneal dialysis prescription for neonates. Fischbach M. **Perit Dial Int** 1996;16 Suppl 1:S512–4 (23 ref.)
Determination of individual ultrafiltration time (APEX) and purification phosphate time by peritoneal equilibration test: application to individual peritoneal dialysis modality prescription in children. Fischbach M, et al.

Perit Dial Int 1996;16 Suppl 1:S557–60

Performance and interpretation of the peritoneal equilibration test in children. Geary DF. **Perit Dial Int** 1996;16 Suppl 1:S540–2

[Tools for determining adequateness and dialysis dose in peritoneal dialysis (see comments)] Lameire N. **Nephrologie** 1995;16(6):407–11 (50 ref.). Comment in: Nephrologie 1995;16(6):393–7. **(Fre)**

[Chronic intermittent peritoneal dialysis: a 12–year experience] García R, et al. **Rev Med Chil** 1995 Apr; 123(4):457–63 (Eng. Abstr.) **(Spa)**

MORTALITY

A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. Bloembergen WE, et al. **J Am Soc Nephrol** 1995 Aug;6(2):177–83

A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. Bloembergen WE, et al. **J Am Soc Nephrol** 1995 Aug;6(2):184–91

Survival on renal replacement therapy in Europe: is there a 'centre effect'? Khan IH, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):300–7

Survival of diabetic patients on peritoneal dialysis or hemodialysis. Marcelli D, et al. **Perit Dial Int** 1996;16 Suppl 1:S283–7

Survival on chronic peritoneal dialysis: have results improved in the 1990s? Rodríguez–Carmona A, et al. **Perit Dial Int** 1996;16 Suppl 1:S410–3

NURSING

Accuracy or bias in nurses' ratings of patient compliance: a comparison of treatment modality. Edelman R, et al. **Perit Dial Int** 1996 May–Jun;16(3):321–5

A survey of the status of peritoneal dialysis nursing in Japan. Kajiura R, et al. **Perit Dial Int** 1996;16 Suppl 1:S455–8

Peritoneal dialysis in the Pacific. King MJ. **Perit Dial Int** 1996;16 Suppl 1:S448–51

PD in Europe: nursing issues. Lambert MC. **Perit Dial Int** 1996;16 Suppl 1:S443–7

PSYCHOLOGY

Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)

STATISTICS & NUMERICAL DATA

Current approach to peritoneal access in North American children: a report of the Pediatric Peritoneal Dialysis Study Consortium. Neu AM, et al. **Adv Perit Dial** 1995;11:289–92

[Active treatment of uremia in the study county of Vejle. Epidemiology 1979–1994 and future perspectives] Vestergaard P, et al. **Ugeskr Laeger** 1996 Jun 24; 158(26):3759–63 (Eng. Abstr.) **(Dan)**

TRENDS

The development of nephrology. Morrin PA. **J Postgrad Med** 1994 Jul–Sep;40(3):109–17

UTILIZATION

Peritoneal dialysis update 1994. Nolph KD. **J Postgrad Med** 1994 Jul–Sep;40(3):151–7 (60 ref.)

Ethnic differences in the use of peritoneal dialysis as initial treatment for end–stage renal disease. Barker–Cummings C, et al. **JAMA** 1995 Dec 20;274(23):1858–62

PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY

Potassium is not a good solute to estimate residual volume in CAPD. Abensur H, et al. **Adv Perit Dial** 1995;11:45–7

Low sodium concentration solution in normohydrated CAPD patients. Amici G, et al. **Adv Perit Dial** 1995; 11:78–82

Use of bethanechol chloride to increase available ultrafiltration in CAPD. Baranowska–Daca E, et al. **Adv Perit Dial** 1995;11:69–72

Reduced blood levels of coagulation inhibitors in chronic hemodialysis compared with CAPD. Bertoli SV, et al. **Adv Perit Dial** 1995;11:127–30

Modification of creatinine clearance by estimation of residual urinary creatinine and urea clearance in CAPD patients. Bhatla B, et al. **Adv Perit Dial** 1995;11:101–5

Peritoneal transport evaluation in peritonitis: comparison between methods. Borràs M, et al. **Adv Perit Dial** 1995; 11:145–8

Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. Breborowicz A, et al. **Adv Perit Dial** 1995;11:15–8

Discrepancy between weekly KT/V and weekly creatinine clearance in patients on CAPD. Chen HH, et al. **Adv Perit Dial** 1995;11:83–7

Consistency of the peritoneal equilibration test in a cohort of nonselected Mexican CAPD patients. Cueto–Manzano AM, et al. **Adv Perit Dial** 1995;11:114–8

Nitrate in stable CAPD patients and during peritonitis. Douma CE, et al. **Adv Perit Dial** 1995;11:36–40

Transfer of native insulin through the peritoneal membrane during CAPD in non–diabetic and diabetic patients. Ersoy FF, et al. **Adv Perit Dial** 1995;11:119–22

Variability in calculations of dialysis adequacy in patients using nightly intermittent peritoneal dialysis compared to CAPD. Friedlander MA, et al. **Adv Perit Dial** 1995;11:93–6

Energy metabolism during CAPD: a controlled study. Harty J, et al. **Adv Perit Dial** 1995;11:229–33

Insulin–like growth factor–I in patients on CAPD and hemodialysis: relationship to body weight and albumin level. Kagan A, et al. **Adv Perit Dial** 1995;11:234–8

Lipoprotein (a) levels and clinical correlations in CAPD patients. Lye WC, et al. **Adv Perit Dial** 1995;11:131–3

The identification of bone mineral density in CAPD in comparison with HD patients. Pasadakis P, et al. **Adv Perit Dial** 1995;11:247–53

MCP–1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Sach M, et al. **Adv Perit Dial** 1995;11:19–23

Residual renal function and nutritional parameters in CAPD. Scanziani R, et al. **Adv Perit Dial** 1995;11:106–9

Enhanced expression of TGF–beta 1 by peritoneal macrophages in CAPD patients. Wang T, et al. **Adv Perit Dial** 1995;11:11–4

The importance of monitoring dialysis adequacy in chronic peritoneal dialysis [clinical conferences]. Burkart J, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):349–61

Assessment of nutritional status in dialysis patients. Wolfson M, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):174–9 (24 ref.)

Influence of changes in peritoneal fluid on body–composition measurements by dual–energy X–ray absorptiometry in patients receiving continuous ambulatory peritoneal dialysis. Woodrow G, et al. **Am J Clin Nutr** 1996 Aug; 64(2):237–41

Stability of piperacillin sodium–tazobactam sodium in peritoneal dialysis solutions. Park TW, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2022–4

Reticulated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Tàssies D, et al. **Am J Hematol** 1995 Nov;50(3):161–6

A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Bernardini J, et al. **Am J Kidney Dis** 1996 May; 27(5):695–700

Techniques for modelling adequacy in patients on peritoneal dialysis. Blake PG. **Am J Kidney Dis** 1996 May;27(5):750–3 (21 ref.)

Peritonitis caused by Oerskovia xanthineolytica in a patient on chronic ambulatory peritoneal dialysis (CAPD) [letter] Borra S, et al. **Am J Kidney Dis** 1996 Mar;27(3):458

Tumor necrosis factor–alpha, interleukin–1 beta, and interleukin–1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Brauner A, et al. **Am J Kidney Dis** 1996 Mar;27(3):402–8

Biocompatibility of peritoneal dialysis solutions. Breborowicz A, et al. **Am J Kidney Dis** 1996 May;27(5):738–43 (54 ref.)

Low–calcium peritoneal dialysis fluid should not impact peritonitis rates in continuous ambulatory peritoneal dialysis. de Fijter CW, et al. **Am J Kidney Dis** 1996 Mar; 27(3):409–15

In vitro effects of bicarbonate– versus lactate–buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Fischer FP, et al. **Am J Kidney Dis** 1995 Dec;26(6):924–33

Symptomatic hypercalcemia in a diabetic patient undergoing continuous ambulatory peritoneal dialysis: value of bone biopsy in the diagnosis and management. Frazao J, et al. **Am J Kidney Dis** 1995 Nov;26(5):831–5

Comparison of methods for measuring albumin in peritoneal dialysis and hemodialysis patients. Joseph R, et al. **Am J Kidney Dis** 1996 Apr;27(4):566–72

Low–density lipoprotein particle size distribution in end–stage renal disease treated with hemodialysis or peritoneal dialysis. O'Neal D, et al. **Am J Kidney Dis** 1996 Jan;27(1):84–91

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Qi Q, et al. **Am J Kidney Dis** 1995 Oct;26(4):622–31

Clarithromycin–associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Steinman MA, et al. **Am J Kidney Dis** 1996 Jan;27(1):143–6

Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor–1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S, et al. **Am J Kidney Dis** 1996 Jun;27(6):848–54

"PD Plus": is it a new concept? [letter] Twardowski ZJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):156–8

Nutritional management of the continuous ambulatory peritoneal dialysis patient. Wolfson M. **Am J Kidney Dis** 1996 May;27(5):744–9 (49 ref.)

Serum CA–125 level in end–stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Bastani B, et al. **Am J Nephrol** 1995;15(6):468–72

Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. Clark EC, et al. **Am J Nephrol** 1995;15(4):353–5

Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis. Huang TP, et al. **Am J Nephrol** 1995;15(4):312–7

Urea kinetics and when to commence dialysis. Tattersall J, et al. **Am J Nephrol** 1995;15(4):283–9

Effect of an pyruvate–based peritoneal dialysis solution on the pH of a residual peritoneal dialysis fluid. Ing TS, et al. **Artif Organs** 1996 Mar;20(3):264–6

Longitudinal assessment of body composition in CAPD patients using bioelectric impedance analysis. A comparison with hemodialysis patients. Briganti M, et al. **ASAIO J** 1995 Jul–Sep;41(3):M725–7

A prospective study of the effect of noncompliance on small solute removal in continuous ambulatory peritoneal dialysis. Preliminary report. Goel S, et al. **ASAIO J** 1995 Jul–Sep;41(3):M452–6

Sleep apnea in end–stage renal disease patients on hemodialysis and continuous ambulatory peritoneal dialysis. Hallett M, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M435–41

A new approach to optimizing urea clearances in hemodialysis and continuous ambulatory peritoneal dialysis. Nolph KD, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M446–51

Reproducibility of the peritoneal equilibration test in CAPD patients. Trivedi H, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M892–5

Post dialysis fluid (CAPD) increases 3H cholesterol efflux from human skin fibroblasts. Killalea AG, et al. **Biochem Soc Trans** 1996 Feb;24(1):116S

Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Fieren MW. **Blood Purif** 1996;14(2):179–87 (60 ref.)

Effect of peritoneal dialysis on cytokine production by peritoneal cells. Topley N, et al. **Blood Purif** 1996; 14(2):188–97 (62 ref.)

Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198–216 (171 ref.)

Prostate–specific antigen levels in patients receiving long–term dialysis. Harper L, et al. **Br J Urol** 1995 Oct; 76(4):482–3

Study of the chromium binding in plasma of patients on continuous ambulatory peritoneal dialysis. Borguet F, et al. **Clin Chim Acta** 1995 Jun 30;238(1):71–84

Improved urea clearance raises the BUN in continuous peritoneal dialysis. Baltzan MA, et al. **Clin Nephrol** 1996 Mar;45(3):183–7

Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Davies SJ, et al. **Clin Nephrol** 1996 Mar;45(3):194–8

Assessment of health status in peritoneal dialysis patients: a potential outcome measure. Morton AR, et al. **Clin Nephrol** 1996 Mar;45(3):199–204

The effect of ultra–low sodium dialysate in CAPD. A kinetic and clinical analysis. Nakayama M, et al. **Clin Nephrol** 1996 Mar;45(3):188–93

Low Na concentration solution for CAPD [letter] Nakayama M, et al. **Clin Nephrol** 1996 Jan;45(1):66–8

Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Pannekeet MM, et al. **Clin Nephrol** 1995 Oct;44(4):248–54

Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations. Steffensen G, et al. **Clin Nephrol** 1996 Feb;45(2):98–103

The minimal dose of dialysis required for a target KT/V in continuous peritoneal dialysis. Tzamaloukas AH, et al. **Clin Nephrol** 1995 Nov;44(5):316–21

Peritoneal clearance of inorganic sulfate. Uribarri J, et al. **Clin Nephrol** 1995 Jul;44(1):56–9

Furosemide disposition in patients on CAPD. Martin U, et al. **Eur J Clin Pharmacol** 1995;48(5):385–90

One–year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis. Huraib S, et al. **Haemostasis** 1995 Nov–Dec;25(6):299–304

Estimated versus predicted creatinine generation as an indicator of compliance with the prescribed dose of continuous peritoneal dialysis. Tzamaloukas AH, et al. **Int J Artif Organs** 1996 Mar;19(3):151–5

Comparison of two fluorescent probes for the measurement of erythrocyte membrane fluidity in renal dialysis patients. McClean E, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):289–92

Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada–USA (CANUSA) Peritoneal Dialysis Study Group. **J Am Soc Nephrol** 1996 Feb;7(2):198–207

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end–stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. Kronenberg F, et al. **J Am Soc Nephrol** 1995 Jul; 6(1):110–20

Total body nitrogen as a prognostic marker in maintenance dialysis. Pollock CA, et al. **J Am Soc Nephrol** 1995 Jul; 6(1):82–8

Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. Ruggian JC, et al. **J Am Soc Nephrol** 1996 Mar;7(3):397–402

Sleep disorders in patients on continuous ambulatory peritoneal dialysis. Stepanski E, et al. **J Am Soc Nephrol** 1995 Aug;6(2):192–7

Symptomatic fluid retention in patients on continuous

peritoneal dialysis. Tzamaloukas AH, et al. **J Am Soc Nephrol** 1995 Aug;6(2):198–206

Can an excess of estimated over-predicted creatinine generation be a discriminating test for noncompliance in continuous ambulatory peritoneal dialysis? [letter; comment] Tzamaloukas AH. **J Am Soc Nephrol** 1995 Nov; 6(5):1519–20. Comment on: J Am Soc Nephrol 1994 Feb;4(8):1627–9.

Relationship of Na–K–ATPase inhibitors to blood–pressure regulation in continuous ambulatory peritoneal dialysis and hemodialysis. Weiler EW, et al. **J Am Soc Nephrol** 1996 Mar;7(3):454–63

Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. Lam YW, et al. **J Antimicrob Chemother** 1995 Jul;36(1):157–63

Long–term clinical experience with continuous ambulatory peritoneal dialysis: access–related problems. Paquay YC, et al. **J Invest Surg** 1996 Mar–Apr;9(2):81–93

Quality of life in peritoneal dialysis patients. Steele TE, et al. **J Nerv Ment Dis** 1996 Jun;184(6):368–74

Correction of acidosis in CAPD decreases whole body protein degradation. Graham KA, et al. **Kidney Int** 1996 May;49(5):1396–400

Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kabanda A, et al. **Kidney Int** 1995 Dec; 48(6):1946–52

Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. Kimmel PL, et al. **Kidney Int** 1996 May;49(5):1407–12

Plasma iohexol clearance as an alternative to creatinine clearance for CAPD adequacy studies. Marx MA, et al. **Kidney Int** 1995 Dec;48(6):1994–7

The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Pannekeet MM, et al. **Kidney Int** 1995 Sep; 48(3):866–75

Kt/V in CAPD by different estimations of V. Wong KC, et al. **Kidney Int** 1995 Aug;48(2):563–9

Prevalence of hyperlipidemia in a cohort of CAPD patients. Italian Cooperative Peritoneal Dialysis Study Group (ICPDSG). Cocchi R, et al. **Miner Electrolyte Metab** 1996; 22(1–3):22–5

Acremonium kiliense peritonitis complicating continuous ambulatory peritoneal dialysis: report of two cases. Lopes JO, et al. **Mycopathologia** 1995 Aug;131(2):83–5

Priorities in Dialysis. Proceedings of a conference. Vienna, Austria, July 1994. **Nephrol Dial Transplant** 1995;10 Suppl 7:1–69

Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin–bound furan dicarboxylic acid. Costigan MG, et al. **Nephrol Dial Transplant** 1995;10(5):648–52

Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Davies SJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):498–506

Increased silicon levels in dialysis patients due to high silicon content in the drinking water, inadequate water treatment procedures, and concentrate contamination: a multicentre study. D'Haese PC, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1838–44

Prognostic factors in CAPD patients: a retrospective study of a 10–year period. Genestier S, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1905–11

Increased prevalence of HCV antibodies in dialyzed Ashkenazi Jews—a possible ethnic predisposition. Golan E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):684–6

A case of tuberculous peritonitis associated with abdominal–wall pseudocyst in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). Ha SK, et al. **Nephrol Dial Transplant** 1995;10(5):706–8

Higher Kt/V is needed for adequate dialysis if the treatment time is reduced. Insights from a blood flow distribution model. Haraldsson B. **Nephrol Dial Transplant** 1995 Oct; 10(10):1845–51

Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. Joffe P, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1912–7

Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis. Joffe P, et al. **Nephrol Dial Transplant** 1995;10(9):1725–32

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

Which treatment for which patient in the future? Possible modifications in CAPD. Maiorca R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:20–6 (68 ref.)

Measurement of peritoneal fluid handling in children on continuous ambulatory peritoneal dialysis using dextran 70. Reddingius RE, et al. **Nephrol Dial Transplant** 1995; 10(6):866–70

Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Temple RM, et al. **Nephrol Dial Transplant** 1995; 10(9):1733–8

Increased activity of plasma cholesteryl ester transfer protein in children with end–stage renal disease receiving continuous ambulatory peritoneal dialysis. Asayama K, et al. **Nephron** 1996;72(2):231–6

Transperitoneal absorption and kinetics of chromium in the continuous ambulatory peritoneal dialysis patient—an experimental and mathematical analysis. Borguet F, et al. **Nephron** 1996;72(2):163–70

Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Gault MH, et al. **Nephron** 1995;70(2):155–70

Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O, et al. **Nephron** 1996; 72(2):135–44

Nutritional profile of continuous ambulatory peritoneal dialysis patients. Jacob V, et al. **Nephron** 1995;71(1):16–22

Role of peritoneal loss of albumin in the hypoalbuminemia of continuous ambulatory peritoneal dialysis patients: relationship to peritoneal transport of solutes. Kagan A, et al. **Nephron** 1995;71(3):314–20

Impaired polymorphonuclear neutrophil function in end–stage renal failure and its correction by continuous ambulatory peritoneal dialysis. Porter CJ, et al. **Nephron** 1995;71(2):133–7

School adjustment of children with end–stage renal disease. Fukunishi I, et al. **Pediatr Nephrol** 1995 Oct;9(5):553–7

Growth, development and nutritional status in Japanese children under 2 years on continuous ambulatory peritoneal dialysis. Honda M, et al. **Pediatr Nephrol** 1995 Oct; 9(5):543–8

Tuberculous osteomyelitis: an unusual case of tuberculous infection in a child undergoing continuous ambulatory peritoneal dialysis. Yalçinkaya F, et al. **Pediatr Nephrol** 1995 Aug;9(4):485–6

Serum lipids in black Africans on chronic ambulatory peritoneal dialysis [letter] Abiola OO, et al. **Perit Dial Int** 1996 May–Jun;16(3):333–4

Predictors of survival in continuous ambulatory peritoneal dialysis patients: a five–year prospective study. Avram MM, et al. **Perit Dial Int** 1996;16 Suppl 1:S190–4

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)

A usual peritoneal dialysis patient with an unusual skin disease [clinical conference] Bargman JM, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):252–8

Hemoperitoneum after pericardiocentesis in a CAPD patient [letter] Bender F. **Perit Dial Int** 1996 May–Jun;16(3):330

Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)

Technique survival and complication rates in a newly started CAPD center (five years of experience) [letter] Bistrup C, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):90–1

A critique of the Canada/USA (CANUSA) Peritoneal Dialysis Study [editorial] Blake PG. **Perit Dial Int** 1996 May–Jun;16(3):243–5

Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May–Jun;16(3):248–51 (25 ref.)

Growth hormone and malnutrition in dialysis patients. Blake PG. **Perit Dial Int** 1995 Jul–Sep;15(6):210–6 (49 ref.)

Long–term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)

Physiological approaches to increase biocompatibility of peritoneal dialysis. Breborowicz A, et al. **Perit Dial Int** 1995;15(7 Suppl):S76–85; discussion S85–6 (127 ref.)

Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Burkart JM. **Perit Dial Int** 1995;15(5 Suppl):S20–35 (94 ref.)

Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)

Comparison of three different tests for assessment of hepatitis C virus in dialysis patients. Castelnovo C, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):241–5

The predictive value of KT/V and peritoneal solute transport in CAPD patients is dependent on the type of comorbidity present. Davies SJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S158–62

Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)

Procollagen–I and collagen–I in the serum and dialysate of CAPD patients: changes over time. Digenis GE, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):371–4

Durability of the peritoneal membrane. Dobbie JW. **Perit Dial Int** 1995;15(7 Suppl):S87–91; discussion S91–2 (18 ref.)

Measurement of hydrostatic intraperitoneal pressure: a necessary routine test in peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996;16 Suppl 1:S84–7

Infectious complications in pediatric patients treated with chronic peritoneal dialysis (CPD). Edefonti A, et al. **Perit Dial Int** 1996;16 Suppl 1:S343–7 (11 ref.)

The reproducibility of the fast peritoneal equilibration test. Enia G, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):382–4

Muscle weakness in continuous ambulatory peritoneal dialysis patients. Fahal IH, et al. **Perit Dial Int** 1996;16 Suppl 1:S419–23

Acid–base balance with different CAPD solutions. Feriani M, et al. **Perit Dial Int** 1996;16 Suppl 1:S126–9

Factors affecting bicarbonate transfer with bicarbonate–containing CAPD solution. Feriani M, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):336–41

Increased response to subcutaneous erythropoietin on type I diabetic patients on CAPD: is there a synergistic effect with insulin? Fernandez–Reyes MJ, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):231–5

The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)

New strategies in clinical nutrition. Fürst P. **Perit Dial Int** 1996;16 Suppl 1:S28–35 (25 ref.)

Serum procollagen type I carboxyterminal propeptide in CAPD and hemodialysis patients. Gerakis A, et al. **Perit Dial Int** 1996;16 Suppl 1:S309–11

Videolaparoscopy: a new alternative for implantation of peritoneal catheters in ESRD patients with previous abdominal surgeries [letter] Giannattasio M, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):96–7

CAPD overview. Gokal R. **Perit Dial Int** 1996;16 Suppl 1:S13–8 (38 ref.)

Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Gokal R, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):226–30

A positive correlation of PCRN to KT/V in cross–sectional studies is not proof of a causal relationship [letter; comment] Gotch F. **Perit Dial Int** 1995 Jul–Sep;15(6):274–5 . Comment on: Perit Dial Int 1993;13(3):173–5.

The peritoneal equilibration test cannot predict the mass transfer area coefficients. Graff J, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):271–3

Lipoprotein (a) levels in patients undergoing continuous ambulatory peritoneal dialysis. Guindeo C, et al. **Perit Dial Int** 1996;16 Suppl 1:S236–40

Sleep apnea in ESRD patients on HD and CAPD. Hallett MD, et al. **Perit Dial Int** 1996;16 Suppl 1:S429–33

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Holdt B, et al. **Perit Dial Int** 1996;16 Suppl 1:S246–9

Eicosanoid precursors: potential factors for atherogenesis in diabetic CAPD patients? Holler C, et al. **Perit Dial Int** 1996;16 Suppl 1:S250–3

Peritoneal host defense mechanisms. Holmes CJ. **Perit Dial Int** 1996;16 Suppl 1:S124–5

Low turnover bone disease. Hutchison AJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S295–9 (21 ref.)

Reduced calcium dialysis fluids: what's the point? [editorial; comment] Hutchison AJ, et al. **Perit Dial Int** 1996 May–Jun;16(3):252–4. Comment on: Perit Dial Int 1996 May–Jun:16(3):260–8.

Malnutrition in peritoneal dialysis patient: etiologic factors and treatment options. Ikizler TA, et al. **Perit Dial Int** 1995; 15(5 Suppl):S63–6 (28 ref.)

213 elderly uremic patients over 75 years of age treated with long–term peritoneal dialysis: a French multicenter study. Issad B, et al. **Perit Dial Int** 1996;16 Suppl 1:S414–8

Commentary on the findings of the CANUSA Study [editorial] Jindal KK. **Perit Dial Int** 1996 May–Jun; 16(3):246–7

Outcome of pancreatitis in CAPD and HD patients. Joglar FM, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):264–6

Impact of nutritional status on serum lipoprotein (a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Kang DH, et al. **Perit Dial Int** 1996;16 Suppl 1:S241–5

Impaired initial cell reaction in CAPD–related peritonitis. Koopmans JG, et al. **Perit Dial Int** 1996;16 Suppl 1:S362–7

Markers of peritoneal membrane status. Krediet RT, et al. **Perit Dial Int** 1996;16 Suppl 1:S42–9 (89 ref.)

IgG subclasses in CAPD patients. Krediet RT, et al. **Perit Dial Int** 1996 May–Jun;16(3):288–94

Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Lambert MC, et al. **Perit Dial Int** 1996;16 Suppl 1:S492–4

CAPD—a risk factor in renal transplantation? ARF after transplantation. Lambert MC, et al. **Perit Dial Int** 1996;16 Suppl 1:S495–8

Peritoneal instillation test before CAPD in a case of severe pulmonary disease. Leblanc M, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):384–7

Hepatitis C antibodies in patients on peritoneal dialysis: prevalence and risk factors. Lee GS, et al. **Perit Dial Int** 1996;16 Suppl 1:S424–8

Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S269–74 (28 ref.)

Effect of hematocrit on D/P ratio in peritoneal dialysis [letter] Lew SQ, et al. **Perit Dial Int** 1995 Jul–Sep; 15(6):281–2

Peritoneal dialysis and endocrinology. Lim VS. **Perit Dial Int** 1996;16 Suppl 1:S257–9 (6 ref.)

Correlations between plasminogen activator inhibitor–1 and peritoneal transport in pediatric CCPD patients. Lin JJ, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):246–51

CAPD viability: a long–term comparison with hemodialysis. Maiorca R, et al. **Perit Dial Int** 1996 May–Jun;16(3):276–87

Thyroid hormone losses in CAPD. Maues MG, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):266–9

The fate of leached di(2–ethylhexyl)phthalate in patients undergoing CAPD treatment. Mettang T, et al.

Perit Dial Int 1996 Jan-Feb;16(1):58-62

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104-8 (23 ref.)

Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532-9 (43 ref.)

Pathogenesis of peritoneal fibrosis and peritoneal small vessel changes. Nakamoto M. **Perit Dial Int** 1996;16 Suppl 1:S39-41

Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Nevalainen PI, et al. **Perit Dial Int** 1996;16 Suppl 1:S288-91

Nutritional status of CAPD patients at three years. Palop L, et al. **Perit Dial Int** 1996;16 Suppl 1:S195-202

Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Pannekeet MM, et al. **Perit Dial Int** 1996;16 Suppl 1:S54-7

Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Pannekeet MM, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):217-25

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109-13 (44 ref.)

Lactate-versus bicarbonate-based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47-50; discussion S51 (33 ref.)

Hemoperitoneum in CAPD patients with hepatic tumors. Peng SJ, et al. **Perit Dial Int** 1996 Jan-Feb;16(1):84-6

Absorption and clearance of ceftazidime during CAPD. Plant WD, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):378-82

The PET: comparison of high, high-average and low, low-average PET in Indian CAPD [letter] Prakash KC, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):388-9

Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19-22 (33 ref.)

The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S207-10

Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97-103 (18 ref.)

Prescription of calcium concentration and PTH control. Ritz E, et al. **Perit Dial Int** 1996;16 Suppl 1:S300-4 (31 ref.)

Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70-5 (15 ref.)

Current nutritional recommendations in peritoneal dialysis. Russell L, et al. **Perit Dial Int** 1996;16 Suppl 1:S459-60

Autosomal dominant polycystic liver disease as an etiology for hemoperitoneum during CCPD. Rutecki GW, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):367-9 (11 ref.)

Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275-8 (33 ref.)

Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130-6 (48 ref.)

Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215-9 (35 ref.)

Transformed mesothelial cells in patients on CAPD for medium- to long-term periods. Selgas R, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):305-11

Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279-82 (26 ref.)

Nutritional status in continuous ambulatory peritoneal dialysis patients. Sheil K, et al. **Perit Dial Int** 1996;16 Suppl 1:S461-3

Continuous ambulatory peritoneal dialysis in end-stage renal disease due to multiple myeloma. Shetty A, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):236-40

Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Siamopoulos KC, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):342-7

The influence of dialysate calcium concentration on the PTH level in children undergoing CAPD. Sieniawska M, et al. **Perit Dial Int** 1996;16 Suppl 1:S567-9

Interleukin, endotoxin, and tumor necrosis factor in CAPD dialysate [letter] Snitkoff G, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):279-80

Body composition of children on CAPD. Stefanidis C, et al. **Perit Dial Int** 1996;16 Suppl 1:S561-6

Body surface area and anthropometric body water in patients on CPD. Tzamaloukas AH, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):284-5

Continuous peritoneal dialysis in heavyweight individuals: urea and creatinine clearances. Tzamaloukas AH, et al. **Perit Dial Int** 1996 May-Jun;16(3):302-6

Computational formulas for clearance indices in continuous ambulatory peritoneal dialysis [editorial] Tzamaloukas AH, et al. **Perit Dial Int** 1996 Jan-Feb;16(1):13-4

Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402-5 (13 ref.)

Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355-61 (56 ref.)

Normalization of protein equivalent of nitrogen appearance and dialytic adequacy in CAPD. Virga G, et al. **Perit Dial Int** 1996;16 Suppl 1:S185-9

Does calcitriol therapy improve muscle function in uremic patients. Wanic-Kossowska M, et al. **Perit Dial Int** 1996; 16 Suppl 1:S305-8

Paradoxes in peritoneal transport of small solutes. Waniewski J, et al. **Perit Dial Int** 1996;16 Suppl 1:S63-9

Imaging of the peritoneal cavity in CAPD. Wankowicz Z, et al. **Perit Dial Int** 1996;16 Suppl 1:S434-9

Home health and respite care. Watson AR. **Perit Dial Int** 1996;16 Suppl 1:S551-3

Glucose degradation and cytotoxicity in PD fluids. Wieslander A, et al. **Perit Dial Int** 1996;16 Suppl 1:S114-8

Diurnal blood pressure variation in CAPD patients [letter] Yamagata K, et al. **Perit Dial Int** 1996 Jan-Feb;16(1):91-3

Long-term outcome of diabetic patients receiving peritoneal dialysis. Zimmerman SW, et al. **Perit Dial Int** 1996 Jan-Feb;16(1):63-8

Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Haqqie SS, et al. **Ren Fail** 1995 Sep;17(5):611-4

CAPD adequacy and dialysis morbidity: detrimental effect of a high peritoneal equilibration rate. Heaf J. **Ren Fail** 1995 Sep;17(5):575-87

Cholecystectomy in the peritoneal dialysis patient. Unique advantages to the laparoscopic approach. Magnuson TH, et al. **Surg Endosc** 1995 Aug;9(8):908-9

[Interference observed in creatinine assays in peritoneal dialysis solutions containing amino-acids (letter)] Parent X, et al. **Ann Biol Clin (Paris)** 1995;53(6):357-8 (Fre)

[Acid-base equilibrium of peritoneal dialysis (CAPD) patients utilizing acetate, lactate, bicarbonate] Quellhorst E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30 Suppl 1:S69-72 (Ger)

[Continuous ambulatory peritoneal dialysis] Nomoto Y. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:425-8 (Eng. Abstr.) (Jpn)

[Recent progress in continuous ambulatory peritoneal dialysis] Nomoto Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1622-6 (10 ref.) (Jpn)

[Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis] Sieniawska M, et al. **Pediatr Pol** 1995 Dec; 70(12):1023-8 (Eng. Abstr.) (Pol)

[The response to the hepatitis B virus vaccine in patients undergoing hemodialysis and peritoneal dialysis--personal experience] Majdan M, et al. **Przegl Lek** 1995;52(6):307-10 (Eng. Abstr.) (Pol)

[Big weight gain differences between patients on dialysis (letter; comment)] Fernström A, et al. **Lakartidningen** 1995 Oct 4;92(40):3660-1. Comment on: Lakartidningen 1995 May 31;92(22):2291-2. Comment on: Lakartidningen 1995 May 31;92(22):2316-20. (Swe)

ADVERSE EFFECTS

Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease. Krestin GP, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):414-20

Hypotension in CAPD: role of volume and sodium depletion. Afthentopoulos IE, et al. **Adv Perit Dial** 1995;11:73-7

Dialysis-related amyloidosis in a large CAPD population. Catizone L, et al. **Adv Perit Dial** 1995;11:213-7

Thyroid function surveillance in CAPD patients. Dumler F, et al. **Adv Perit Dial** 1995;11:225-8

Frequency of various types of peritoneal catheter infections and therapeutic outcome of treatment. Gucek A, et al. **Adv Perit Dial** 1995;11:149-51

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168-71 (14 ref.)

Successful treatment of fungal peritonitis with intracatheter antifungal retention. Lee SH, et al. **Adv Perit Dial** 1995; 11:172-5

Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Locatelli A, et al. **Adv Perit Dial** 1995;11:176-8

A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Lye WC, et al. **Adv Perit Dial** 1995;11:179-81

Sleep apnea in CAPD. Rodriguez A, et al. **Adv Perit Dial** 1995;11:123-6

The effect of ultraviolet rays on the prevention of exit-site infections. Shimomura A, et al. **Adv Perit Dial** 1995; 11:152-6

Rat model of peritoneal fibrosis: preliminary observations. Wieczorowska K, et al. **Adv Perit Dial** 1995;11:48-51

Peritoneal calcification associated with continuous ambulatory peritoneal dialysis. Miller FH, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):541-2

A very rare case of continuous ambulatory peritoneal dialysis peritonitis caused by Anisakis larva [letter] Ohta M, et al. **Am J Gastroenterol** 1995 Oct;90(10):1902-3

Recovery of gastrointestinal function after renal transplantation in patients with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis [letter; comment] Bhandari S. **Am J Kidney Dis** 1996 Apr; 27(4):604. Comment on: Am J Kidney Dis 1995 Oct;26(4):658-61.

Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138-42 (24 ref.)

Bacterial peritonitis in continuous ambulatory peritoneal dialysis: effect on dialysis on host defense mechanisms. Findon G, et al. **Am J Kidney Dis** 1995 Nov;26(5):765-73

Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Golper TA, et al. **Am J Kidney Dis** 1996 Sep;28(3):428-36

Peritonitis associated with exit site and tunnel infections. Gupta B, et al. **Am J Kidney Dis** 1996 Sep;28(3):415-9

Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis [see comments] Hawley CM, et al. **Am J Kidney Dis** 1995 Oct; 26(4):658-61. Comment in: Am J Kidney Dis 1996 Apr;27(4):604.

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Nomoto Y, et al. **Am J Kidney Dis** 1996 Sep; 28(3):420-7

Peritonitis rate: traditional versus low calcium dialysate. Stein A, et al. **Am J Kidney Dis** 1995 Oct;26(4):632-3

Carpal tunnel syndrome in patients undergoing CAPD: a collaborative study in 143 centers. Nomoto Y, et al. **Am J Nephrol** 1995;15(4):295-9

Typing of coagulase-negative staphylococci from peritonitis in CAPD-patients by the PhP-CS system and REA. Jung K, et al. **APMIS** 1995 Sep;103(9):679-85

Lean body mass estimation by creatinine kinetics, bioimpedance, and dual energy x-ray absorptiometry in patients on continuous ambulatory peritoneal dialysis. Bhatla B, et al. **ASAIO J** 1995 Jul-Sep;41(3):M442-6

Persistent inhibition of neutrophil function by glucose based dialysis solutions. Dobos GJ, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M435-9

Growth of coagulase negative staphylococci in peritoneal dialysate fluid. Effect of calcium concentration. Morton AR, et al. **ASAIO J** 1994 Jul-Sep;40(3):M431-4

Differences in calcium kinetic pattern between CAPD and HD patients. Kurz P, et al. **Clin Nephrol** 1995 Oct; 44(4):255-61

Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Montenegro J, et al. **Clin Nephrol** 1995 Jul;44(1):60-3

Increased incidence of renal allograft thrombosis after continuous ambulatory peritoneal dialysis. van der Vliet JA, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):51-4

Comparison of BacT/Alert blood culture bottles with lytic media for culture of peritoneal dialysis fluid. Wüst J, et al. **Infection** 1995 Nov-Dec;23(6):378-9

Peritonitis caused by Monilia sitophila in a patient undergoing peritoneal dialysis. Radix AE, et al. **Int J Artif Organs** 1996 Apr;19(4):218-20

Elevated superoxide generation in mononuclear phagocytes by treatment with 1 alpha hydroxyvitamin D3: changes in kinetics and in oxidase cytosolic factor p47. Deutsch A, et al. **J Am Soc Nephrol** 1995 Jul;6(1):102-9

Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563-7 (33 ref.)

Continuous ambulatory peritoneal dialysis-associated peritonitis as a model device-related infection: phenotypic adaptation, the staphylococcal cell envelope and infection. Williams P, et al. **J Hosp Infect** 1995 Jun;30 Suppl:35-43

Quinolone resistance in Oligella urethralis-associated chronic ambulatory peritoneal dialysis peritonitis. Riley UB, et al. **J Infect** 1996 Mar;32(2):155-6

Entrapment of the appendix and the fallopian tube in peritoneal dialysis catheters in two children. Borghol M, et al. **J Pediatr Surg** 1996 Mar;31(3):427-9

Continuous ambulatory peritoneal dialysis impairs T lymphocyte selection in the peritoneum. Fricke H, et al. **Kidney Int** 1996 May;49(5):1386-95

Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Mamoun AH, et al. **Kidney Int** 1996 May;49(5):1276-82

Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Niwa T, et al. **Kidney Int** 1996 Mar;49(3):861-7

Is peritoneal permeability an adverse risk factor for malnutrition in CAPD patients? Harty JC, et al. **Miner Electrolyte Metab** 1996;22(1-3):97-101

Pasteurella multocida infection in continuous ambulatory peritoneal dialysis. Kitching AR, et al. **N Z Med J** 1996 Feb 23;109(1016):59

Prevalence of hepatitis C virus in dialysis patients in Spain. Spanish Multicentre Study Group. **Nephrol Dial Transplant** 1995;10 Suppl 6:78-80

Delayed bowel erosion due to functioning chronic ambulatory peritoneal dialysis catheter. Balaji V, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):368-9

Influence of methodological differences on microbiological diagnosis of CAPD peritonitis [letter] Celik A, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498-9

Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25-8 (32 ref.)

Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Faller B, et al. **Nephrol Dial Transplant** 1995;10(8):1432-7

Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. Fernandez-Reyes MJ, et al.

Nephrol Dial Transplant 1995 Nov;10(11):2090–5

Severe hypophosphataemia due to intraperitoneal nutrition in a CAPD patient. Ghattaora R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1365–6

A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Johnson DW, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):88–93

Frequent involvement of the internal cuff segment in CAPD peritonitis and exit-site infection – an ultrasound study. Korzets Z, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):336–9

Diagnostic value of collagen type I C-terminal cross-linked telopeptide in CAPD patients [letter] Smalcelj R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1500

Rhodococcus peritonitis in continuous ambulatory peritoneal dialysis. Tang S, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):201–2

Aspergillus peritonitis in peritoneal dialysis [letter] Tanis BC, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):752

Hepatitis C virus infection in patients on peritoneal dialysis, hemodialysis and in dialysis staff members in south Serbia [letter] Djordjević V, et al. **Nephron** 1996;72(4):720

Treatment of hydrothorax complicating continuous ambulatory peritoneal dialysis [letter] Funiaková S. **Nephron** 1995;71(1):111–2

Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Honda K, et al. **Nephron** 1996;72(2):171–6

Group B streptococcus and treatment of CAPD peritonitis [letter] Pagniez D, et al. **Nephron** 1995;71(4):480

Bowel perforation associated with continuous ambulatory peritoneal dialysis [letter] Thibodeaux LC. **Nephron** 1995; 70(2):265

Outcome and complications in patients treated with continuous ambulatory peritoneal dialysis (CAPD) at a single centre during 11 years. Wanten GJ, et al. **Neth J Med** 1996 Jul;49(1):4–12

Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Cameron JS. **Pediatr Nephrol** 1995 Oct;9(5):647–62 (203 ref.)

Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Hanevold CD, et al. **Pediatr Nephrol** 1995 Oct;9(5):609–11

Chylous ascites complicating neonatal peritoneal dialysis. Melnick JZ, et al. **Pediatr Nephrol** 1995 Dec;9(6):753–5

Symptomatic peripheral eosinophilia associated with peritoneal eosinophilia in a CAPD patient [letter] Abraham G, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):280–1

Flavobacterium group IIb peritonitis in a patient on chronic ambulatory peritoneal dialysis [letter] Akl ZA, et al. **Perit Dial Int** 1996 May–Jun;16(3):331–2

Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments] Bailie GR, et al. **Perit Dial Int** 1995 Jul–Sep; 15(6):269–71. Comment in: Perit Dial Int 1995 Jul–Sep;15(6):201–2.

Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients [see comments] Bartens W, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):27–33. Comment in: Perit Dial Int 1996 Jan–Feb;16(1):10–2.

Predisposing and prognostic factors of fungal peritonitis in peritoneal dialysis [letter] Bordes A, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):275–6

Inflow obstruction due to kinking of coiled catheters during placement [letter] Cacho CP, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):276–8

Peritoneal catheter colonization and peritonitis with Aureobasidium pullulans [letter] Caporale NE, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):97–8

Recurrent acute hydrothorax in a CAPD patient: successful management with small volumes of dialysate [letter] Christidou F, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):389

Cardiovascular risk in continuous ambulatory peritoneal dialysis patients [editorial; comment] Culleton B, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):10–2. Comment on: Perit Dial Int 1996 Jan–Feb;16(1):27–33.

Nutritional Markers as predictors of survival in patients on CAPD. Dombros NV, et al. **Perit Dial Int** 1995;15(5 Suppl):S10–9 (66 ref.)

Effectiveness of low-dose, intraperitoneal human gamma globulin in the treatment of refractory CAPD peritonitis [letter] Ersoy FF, et al. **Perit Dial Int** 1996 May–Jun; 16(3):328–9

Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)

CAPD-associated cough [letter] Holley JL, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):392–3

The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Johnson DW, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):34–40

CAPD catheter malposition during a roller coaster ride [letter] Jones CH. **Perit Dial Int** 1996 May–Jun; 16(3):329–30

Is atherosclerosis accelerated by CAPD? Kawaguchi Y, et al. **Perit Dial Int** 1996;16 Suppl 1:S223–30

Scanning electron microscopy studies of peritoneal catheter in CAPD peritonitis due to Aspergillus fumigatus. Park SB, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):81–3

Complicated multiorganism peritonitis [clinical conference] Piraino B, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):394–400

Use of computerized tomography in the evaluation of a CAPD patient with a foramen of Morgagni hernia: a case report. Polk D, et al. **Perit Dial Int** 1996 May–Jun; 16(3):318–20

Giardial peritonitis complicating CAPD [letter] Prakash KC. **Perit Dial Int** 1996 May–Jun;16(3):327

A case of Kluyvera cryocrescens peritonitis in a CAPD patient [letter] Sezer MT, et al. **Perit Dial Int** 1996 May–Jun;16(3):326–7

Treatment of peritonitis: how are we doing? [editorial; comment] Vas SI. **Perit Dial Int** 1995 Jul–Sep;15(6):201–2 . Comment on: Perit Dial Int 1995 Jul–Sep;15(6):269–71.

Extensive peritoneal calcification as a complication of long-term CAPD. Wakabayashi Y, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):369–71

Constipation occurs less frequently in CAPD patients than in HD patients [letter] Yasuda G, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):283

Peritonitis due to Penicillium sp in a patient receiving continuous ambulatory peritoneal dialysis. Fahhoum J, et al. **South Med J** 1996 Jan;89(1):87–8

[Effects of high concentration glucose on cell growth and matrix biosynthesis in human peritoneal mesothelial cells] Hou F, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):326–9 (Eng. Abstr.) **(Chi)**

[Peritonitis in continuous ambulatory peritoneal dialysis. An evaluation of the empiric initial antibiotic treatment] Hagelskjaer LH, et al. **Ugeskr Laeger** 1996 Apr 29; 158(18):2532–7 (Eng. Abstr.) **(Dan)**

[Peritonitis in continuous ambulatory peritoneal dialysis. Culture of peritoneal dialysate fluid] Møller JK, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2538–41 (Eng. Abstr.) **(Dan)**

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Radiological case of the week (4). Paralytic ileus in sclerosing peritonitis during CAPD] Kacl GM, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):131–2 **(Ger)**

[Protozoan infection (Blastocystis hominis) concomitant with Pseudomonas sp. peritonitis in continuous ambulatory peritoneal dialysis (CAPD)] Boccardo G, et al. **Minerva Urol Nefrol** 1996 Mar;48(1):55–8 (Eng. Abstr.) **(Ita)**

[Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability] Suyama K, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):491–6 (Eng. Abstr.) **(Jpn)**

[Comparison of the ability to control anemia in patients on hemodialysis and peritoneal dialysis considering iron reserves and plasma erythropoietin] Majdan M, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):307–12 (Eng. Abstr.) **(Pol)**

[The diagnostic value of cytology in children on continuous ambulatory peritoneal dialysis (CAPD)] Sieniawska M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):216–21 (Eng. Abstr.) **(Pol)**

[Comparative study of 2 culture methods by seeding, in hemoculture bottles, the dialysis fluid from patients in continuous ambulatory peritoneal dialysis] Echeverría MJ, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):506–10 (Eng. Abstr.) **(Spa)**

ECONOMICS

An economic evaluation of hospital-based hemodialysis and home-based peritoneal dialysis for pediatric patients. Coyte PC, et al. **Am J Kidney Dis** 1996 Apr;27(4):557–65

The use of community nurses for home peritoneal dialysis: is it cost-effective? Brunier G, et al. **Perit Dial Int** 1996; 16 Suppl 1:S479–82

INSTRUMENTATION

Two years of experience with a new device system: a multicenter study. Ballocchi S, et al. **Adv Perit Dial** 1995; 11:160–3

Improved training techniques and UltraBag system resulted in lowered peritonitis rate in an inner-city population. Rubin JE, et al. **Adv Perit Dial** 1995;11:208–9

Comparison for four techniques of catheter insertion in patients undergoing continuous ambulatory peritoneal dialysis. Hwang TL, et al. **Eur J Surg** 1995 Jun;161(6):401–4

Comparison between straight single-cuff and curled double-cuff catheters in patients on continuous ambulatory peritoneal dialysis [letter] Ateş K, et al. **Nephrol Dial Transplant** 1996 May;11(5):914

Longitudinal changes in peritoneal equilibration test with or without peritonitis in children. Nishi A, et al. **Pediatr Nephrol** 1995 Oct;9(5):562–5

Complications linked to chronic peritoneal dialysis in children after kidney transplantation: experience of the Italian Registry of Pediatric Chronic Peritoneal Dialysis. Andreetta B, et al. **Perit Dial Int** 1996;16 Suppl 1:S570–3

Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)

Inflow obstruction due to kinking of coiled catheters during placement [letter] Cacho CP, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):276–8

Peritoneal dialysis access: prospective randomized comparison of the Swan neck and Tenckhoff catheters. Eklund BH, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):353–6

Insertion of a straight peritoneal catheter in an arcuate subcutaneous tunnel by a tunneler: long-term experience. Favazza A, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):357–62

Obstructive fibrin clot in the peritoneal catheter [letter] Guiserix J, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):93

Malfunctioning peritoneal dialysis catheter repaired by laparoscopic surgery. Julian TB, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):363–6

Complications in peritoneal dialysis: peritonitis and exit-site infections. Keogh AM. **Perit Dial Int** 1996;16 Suppl 1:S464–7

Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost analysis. Li PK, et al. **Perit Dial Int** 1996;16 Suppl 1:S368–70

A prospective randomized comparison of the Swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. Lye WC, et al. **Perit Dial Int** 1996;16 Suppl 1:S333–5

Reversible catheter obstruction by omental wrapping in a CAPD patient [letter] Maccario M, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):278–9

Pseudomonas peritonitis treated with simultaneous catheter replacement and removal [letter] Mayo RR, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):389–90

The "flush" procedure of twin bag systems [letter] Straka P, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):390–2

Successful pregnancy complicated by peritonitis in a 35- year old CAPD patient. Tison A, et al. **Perit Dial Int** 1996;16 Suppl 1:S489–91

Laparoscopic introduction of a continuous ambulatory peritoneal dialysis (capd) catheter by a two-puncture technique. Nijhuis PH, et al. **Surg Endosc** 1996 Jun; 10(6):676–9

METHODS

Effect of increasing exchange volume or frequency on CAPD efficiency. Johnston JR, et al. **Adv Perit Dial** 1995; 11:97–100

Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Topley N, et al. **Kidney Int** 1996 May;49(5):1447–56

Dialysate/plasma ratio of which solute is better correlated with clinical outcome in CAPD patients [letter] Ateş K, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1499–500

Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Balfe JW. **Perit Dial Int** 1996;16 Suppl 1:S515–6

Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143–6 (17 ref.)

Low calcium dialysate and hyperparathyroidism. Duncan R, et al. **Perit Dial Int** 1996;16 Suppl 1:S499–502

Performance and interpretation of the peritoneal equilibration test in children. Geary DF. **Perit Dial Int** 1996;16 Suppl 1:S540–2

Survival of CAPD patients in a center using three two-liter exchanges as standard regime. Lo WK, et al. **Perit Dial Int** 1996;16 Suppl 1:S163–6

The "flush" procedure of twin bag systems [letter] Straka P, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):390–2

Creatinine clearance in continuous peritoneal dialysis: dialysis dose required for a minimal acceptable level. Tzamaloukas AH, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):41–7

Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)

Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group [see comments] Weinreich T, et al. **Perit Dial Int** 1996 May–Jun; 16(3):260–8. Comment in: Perit Dial Int 1996 May–Jun;16(3):252–4.

MORTALITY

Why are reported relative mortality risks for CAPD and HD so variable? (inadequacies of the Cox proportional hazards model) [editorial] Nolph KD. **Perit Dial Int** 1996 Jan–Feb; 16(1):15–8

Survival on chronic peritoneal dialysis: have results improved in the 1990s? Rodríguez-Carmona A, et al. **Perit Dial Int** 1996;16 Suppl 1:S410–3

[Actuarial survival analysis of patients in dialysis] Douthat W, et al. **Medicina (B Aires)** 1995;55(2):97–105 (Eng. Abstr.) **(Spa)**

NURSING

The team approach to the management of children on chronic peritoneal dialysis. Harvey E, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):3–13 (59 ref.)

Planes, kangaroos, and the CAPD manual. Carruthers DM, et al. **Perit Dial Int** 1996;16 Suppl 1:S452–4

A survey of the status of peritoneal dialysis nursing in Japan. Kajiura R, et al. **Perit Dial Int** 1996;16 Suppl 1:S455–8

Peritoneal dialysis in the Pacific. King MJ. **Perit Dial Int** 1996;16 Suppl 1:S448–51

PD in Europe: nursing issues. Lambert MC. **Perit Dial Int** 1996;16 Suppl 1:S443–7

The CAPData computerized data system: a valuable

communication and nursing tool. Lozowy C. **Perit Dial Int** 1996;16 Suppl 1:S483–5
Nursing involvement in research: an academic pursuit or relevant to nursing practice? Schneider AE, et al. **Perit Dial Int** 1996;16 Suppl 1:S486–8
A home visit program for CAPD. Warmington V. **Perit Dial Int** 1996;16 Suppl 1:S475–8

PSYCHOLOGY

Stressors, coping mechanisms and quality of life among dialysis patients in Australia. Lok P. **J Adv Nurs** 1996 May; 23(5):873–81
Psychosocial complications in PD. Dingwall RR. **Perit Dial Int** 1996;16 Suppl 1:S472–4
Intellectual output of children with chronic renal failure on continuous ambulatory peritoneal dialysis. Jaramillo-Solorio RM, et al. **Perit Dial Int** 1996;16 Suppl 1:S554–6
Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)
Severity of alexithymia is related to psychosocial factors in patients with peritoneal dialysis. Fukunishi I, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):763–70

STANDARDS

Does CAPD provide adequate dialysis? [editorial] Harty J, et al. **Nephrol Dial Transplant** 1995;10(7):1115–7 (19 ref.)

STATISTICS & NUMERICAL DATA

The Japanese National Registry data on pediatric CAPD patients: a ten-year experience. A report of the Study Group of Pediatric PD Conference. Honda M, et al. **Perit Dial Int** 1996 May-Jun;16(3):269–75
Comparison of patient hospitalization in chronic peritoneal dialysis and hemodialysis: a pediatric multicenter study. Verrina E, et al. **Perit Dial Int** 1996;16 Suppl 1:S574–7
[Active treatment of uremia in the study county of Vejle. Epidemiology 1979–1994 and future perspectives] Vestergaard P, et al. **Ugeskr Laeger** 1996 Jun 24; 158(26):3759–63 (Eng. Abstr.) **(Dan)**

TRENDS

Continuous ambulatory peritoneal dialysis—quo vadis? [editorial] Teehan BP, et al. **J Am Soc Nephrol** 1995 Aug; 6(2):139–43
What is new in CAPD? (highlights of the 7th Congress of the International Society of Peritoneal Dialysis, June 1995). Gokal R. **Nephrol Dial Transplant** 1996 Apr;11(4):734–6

PERITONEAL DISEASES

Primary omental torsion in children. Kimber CP, et al. **J Paediatr Child Health** 1996 Feb;32(1):22–4
[Insidious growth of peritoneal cysts several years after pelvic surgery. Ultrasonographic and x-ray computed tomographic aspects] De Blay V, et al. **J Radiol** 1996 May; 77(5):339–42 (Eng. Abstr.) **(Fre)**
[Primary torsion of the greater omentum. A case report and review of the literature] Carcoforo P, et al. **G Chir** 1996 May;17(5):235–7 (Eng. Abstr.) **(Ita)**
[Primary torsion of great epiploon (letter)] Pera Román M, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):232–3 **(Spa)**

COMPLICATIONS

Melanosis peritonei associated with enteric duplication cyst. A case report. Jung YC, et al. **Am J Surg Pathol** 1996 Feb;20(2):181–6

DIAGNOSIS

Clinical dilemmas in the management of minimal and mild endometriosis [editorial] Barry-Kinsella C, et al. **Ir Med J** 1996 Mar-Apr;89(2):52–3
Diagnostic pneumoperitoneum accurately predicts the presence of patent processus vaginalis. Downey EC, et al. **J Pediatr Surg** 1995 Sep;30(9):1271–2
Peritoneal aspergillosis—pitfalls in the diagnosis of a rare disease [editorial; comment] Geiss HK. **Nephrol Dial Transplant** 1995;10(7):1124–5. Comment on: Nephrol Dial Transplant 1995;10(7):1240–3.
[Peritoneal and tubal Schistosoma haematobium bilharziasis. Two case reports] Ekoukou D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):819–24 (20 ref.) (Eng. Abstr.) **(Fre)**
[Peritoneal sarcoidosis. A case (letter)] Leleu O, et al. **Presse Med** 1995 Oct 14;24(30):1401 **(Fre)**
[Acute pancreatitis complicated by pancreatic ascites. Diagnostic and therapeutic difficulties] Wereszczyńska-Siemiątkowska U, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):369–74 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. Barke RA, et al. **J Surg Res** 1996 Jan;60(1):101–6

ETIOLOGY

Foreign material in postoperative adhesions. Luijendijk RW, et al. **Ann Surg** 1996 Mar;223(3):242–8
Peritoneal pseudocyst—ventriculo-peritoneal shunt complications. Besson R, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):195–7
Influence of abdominal incision on the formation of postoperative peritoneal adhesions: an experimental study in rats. Moreno A, et al. **Eur J Surg** 1996 Mar;162(3):181–5
Intraperitoneal cholelithiasis after laparoscopic cholecystectomy—behavior of 'lost' concrements and their role in abscess formation. Hornof R, et al. **Eur Surg Res** 1996;28(3):179–89
Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852–9
Adhesion formation after transperitoneal nephrectomy: laparoscopic v open approach. Moore RG, et al. **J Endourol** 1995 Jun;9(3):277–80
A case of abdominal cocoon. Yoon YW, et al. **J Korean Med Sci** 1995 Jun;10(3):220–5 (18 ref.)
Symptomatic peripheral eosinophilia associated with peritoneal eosinophilia in a CAPD patient [letter] Abraham G, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):280–1
Extensive peritoneal calcification as a complication of long-term CAPD. Wakabayashi Y, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):369–71
[Fistulization of the cystic duct in a septated peritoneum after laparoscopic cholecystectomy (letter)] Gautier-Benoit C. **Ann Chir** 1996;50(1):77 **(Fre)**
[Surgical emergency disclosing sarcoidosis. Apropos of a case] Leleu O, et al. **Rev Pneumol Clin** 1996;52(3):196–8 (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Peritoneal echinococcus: report of a case] Cudazzo E, et al. **G Chir** 1995 Jun-Jul;16(6-7):302–6 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Peritoneal silicosis. Miranda RN, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):300–2
Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum are two different entities. Donnez J, et al. **Fertil Steril** 1996 Sep;66(3):362–8
Estrogen suppression of connective tissue deposition in a murine model of peritoneal adhesion formation. Frazier-Jessen MR, et al. **J Immunol** 1996 Apr 15; 156(8):3036–42
Effects of hyaluronic acid on fibroblast behavior in peritoneal injury. Klein ES, et al. **J Surg Res** 1996 Mar;61(2):473–6
Pathogenesis of peritoneal fibrosis and peritoneal small vessel changes. Nakamoto M. **Perit Dial Int** 1996;16 Suppl 1:S39–41

PHYSIOPATHOLOGY

Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing. Saba AA, et al. **Am Surg** 1996 Jul;62(7):569–72

PREVENTION & CONTROL

Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice. Brook I. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S376–7
Estrogen suppression of connective tissue deposition in a murine model of peritoneal adhesion formation. Frazier-Jessen MR, et al. **J Immunol** 1996 Apr 15; 156(8):3036–42

RADIONUCLIDE IMAGING

Tc-99m antimony sulfate lymphoscintigraphy to demonstrate lymphatic communication between the peritoneal cavity and the scrotum. Lu G, et al. **Clin Nucl Med** 1995 Aug; 20(8):706–8

SURGERY

Multiple giant endometriotic cysts of the pelvic-abdominal cavity. A case report. Bahame PS, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):596–8
Herniation through the foramen of Winslow. Report of two cases. Evrard V, et al. **Dis Colon Rectum** 1996 Sep; 39(9):1055–7
Childhood actinomycosis: report of two cases. Benammar S, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):180–3
The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. Barke RA, et al. **J Surg Res** 1996 Jan;60(1):101–6
[Common mesentery: clinical and therapeutic aspects in children. Apropos of 58 cases] Moog R, et al. **J Chir (Paris)** 1996 Apr;133(2):72–7 (Eng. Abstr.) **(Fre)**
[A retroperitoneal hydatid cyst—a rare manifestation of Echinococcus granulosus] Gutermuth L, et al. **Zentralbl Chir** 1995;120(8):660–3 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Value of gonadotropin-releasing hormone agonist in diagnosing peritoneal pseudocysts. Kurachi H, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):294–7
Hydrocele of the canal of Nuck: ultrasound appearance. Anderson CC, et al. **Am Surg** 1995 Nov;61(11):959–61
Sonographic diagnosis of peritoneal inclusion cysts. Sohaey R, et al. **J Ultrasound Med** 1995 Dec;14(12):913–7

PERITONEAL EFFUSION see **ASCITIC FLUID**

PERITONEAL FLUID see **ASCITIC FLUID**

PERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

PERITONEAL IRRIGATION see **PERITONEAL LAVAGE**

PERITONEAL LAVAGE

Simulated intraperitoneal absorption of irrigating fluid. Olsson J, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):707–13
Limiting computed tomography to patients with peritoneal lavage-positive results reduces cost and unnecessary celiotomies in blunt trauma. Schreiber MA, et al. **Arch Surg** 1996 Sep;131(9):954–8; discussion 958–9
Serosal balls detected immunocytochemically in peritoneal lavage obtained during surgery. Sasaki M, et al. **Diagn Cytopathol** 1995 Aug;13(2):124–7
Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. Saha SK. **Dig Dis Sci** 1996 Jul;41(7):1313–8
[The role of necrosectomy and continuous peritoneal lavage in the treatment of acute necrotic-hemorrhagic pancreatitis] Cogliandolo A, et al. **Chir Ital** 1995; 47(2):58–61 (Eng. Abstr.) **(Ita)**
[Prognostic evaluation of peritoneal lavage smears and gastric wall brushing smears in gastric cancer surgery] Teramoto T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1606–9 (Eng. Abstr.) **(Jpn)**
[Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer] Sugiyama Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar;48(3):213–9 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Large-volume intraoperative peritoneal lavage with an assistant device for treatment of peritonitis caused by blunt traumatic rupture of the small bowel. Sugimoto K, et al. **J Trauma** 1995 Oct;39(4):689–92

METHODS

Open diagnostic peritoneal lavage [letter] Hamid Mat Sain A. **Br J Surg** 1996 Jun;83(6):868
Open diagnostic peritoneal lavage. Potter MA, et al. **Br J Surg** 1996 Jan;83(1):87
[Use of planned intermittent peritoneal lavage (open abdomen) in severe forms of peritonitis due to gynecologic-obstetric procedures] Janczy J. **Ginekol Pol** 1995 Jun;66(6):335–9 (Eng. Abstr.) **(Pol)**

PERITONEAL MACROPHAGES see **MACROPHAGES, PERITONEAL**

PERITONEAL NEOPLASMS

Leiomyomatosis peritonealis disseminata. Two case reports. Zheng P, et al. **Chin Med J (Engl)** 1996 Apr;109(4):334–6
Mesenteric fibromatosis. Aryya NC, et al. **J Indian Med Assoc** 1995 Jul;93(7):279
Radiology/pathology conference: mesenteric cystic lymphangioma [clinical conference] Lantz AH, et al. **N J Med** 1996 Jun;93(6):33–5
[Peritoneal mesothelioma] Pitrelli N, et al. **G Chir** 1995 Mar; 16(3):100–2 (Eng. Abstr.) **(Ita)**
[Pseudomyxoma peritonei] Andreassen G. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2783 (Eng. Abstr.) **(Nor)**
[Peritoneal pseudomyxoma] Sánchez Muñoz LA, et al. **Rev Clin Esp** 1995 Nov;195(11):781–6 (20 ref.) **(Spa)**
[Peritoneal pseudomyxoma and liver metastasis (letter)] Serrano Lira F, et al. **Rev Esp Enferm Dig** 1995 Sep; 87(9):684–5 **(Spa)**

BLOOD

Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Simsek H, et al. **Tumour Biol** 1996;17(1):1–4

CHEMICALLY INDUCED

Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice. Janz S, et al. **Cancer Biochem Biophys** 1995 Jun;15(1):25–34
[Malignant peritoneal mesothelioma: its relation to asbestos] Pentimone F, et al. **Minerva Med** 1995 Oct;86(10):439–43 (38 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937–9 (12 ref.)
Syndrome of inappropriate antidiuretic hormone secretion in papillary serous surface carcinoma of the peritoneum. Resnik E, et al. **J Surg Oncol** 1996 Jan;61(1):63–5

Mesenteric lymphangioma causing bowel obstruction in a child. Troum S, et al. **South Med J** 1996 Aug;89(8):808–9

[The dilemma of 'the final laparotomy' (letter)] Helmerhorst TJ, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19;139(33):1703 **(Dut)**

[The dilemma of 'the final laparotomy' (letter; comment)] van Ooijen B, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1702. Comment on: Ned Tijdschr Geneeskd 1995 Jun 10;139(23):1161–3. **(Dut)**

[Hyponatremia disclosing abdominal cystic lymphangioma] Ben Jaballah N, et al. **Cah Anesthesiol** 1995;43(3):327–9 **(Fre)**

[Peritoneal mesothelioma revealed by episodes of recurrent spontaneous peritonitis] Fayemendy L, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):99–102 (Eng. Abstr.) **(Fre)**

[Peritoneal mesothelioma as a rare case of acute abdomen. Review of the literature] Cipollone G, et al. **Chir Ital** 1994; 46(6):73–9 (86 ref.) (Eng. Abstr.) **(Ita)**

[A case of subacute sensory neuropathy associated with extraovarian serous papillary adenocarcinoma of the peritoneum] Ichinose H, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):633–7 (Eng. Abstr.) **(Jpn)**

[Intestinal obstruction by intestinal cystic lymphangioma (letter; comment)] Moreno Sanz C, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):758–9. Comment on: Rev Esp Enferm Dig 1994 Oct;86(4):764–6. **(Spa)**

[Intestinal obstruction caused by peritoneal carcinomatosis due to signet ring cell carcinoma of the breast] Pérez JA, et al. **Rev Med Chil** 1995 May;123(5):617–23 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Fine needle aspiration diagnosis of a mesenteric myelolipoma: a case report. Bryan JA, et al. **Acta Cytol** 1996 May–Jun; 40(3):592–4

Serous surface carcinoma of the peritoneum: useful role of cytology in differential diagnosis and follow-up. Tauchi PS, et al. **Acta Cytol** 1996 May–Jun;40(3):429–36

Saline MR peritoneography. Magre GR, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):749–51

Pseudomyxoma peritonei. Walensky RP, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):471–4

Case report: pseudomyxoma extraperitonei: an unusual presentation mimicking a hugh hydronephrotic kidney. Mor Y, et al. **Clin Radiol** 1996 Mar;51(3):221–2

Case report: MRI of extrapancreatic gastrinoma. Eshkar NS, et al. **Comput Med Imaging Graph** 1995 Sep–Oct; 19(5):447–9

Laparoscopic diagnosis of peritoneal serous papillary carcinoma. Trauner M, et al. **Endoscopy** 1995 May; 27(4):337–41

Multilocular peritoneal inclusion cysts (benign cystic mesothelioma): a case report. Yaegashi N, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):129–32

Mesenteric cystic lymphangioma with myxoid degeneration: unusual CT and MR manifestations. Ko SF, et al. **Pediatr Radiol** 1995;25(7):525–7

Benign and malignant gynecologic disease: clinical importance of fluid and peritoneal enhancement in the pelvis at MR imaging. Outwater EK, et al. **Radiology** 1996 Aug;200(2):483–8

Coxsackievirus–associated pancreatitis mimicking metastatic carcinoma. Gooby Toedt DM, et al. **South Med J** 1996 Apr;89(4):441–3

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497–501 (15 ref.) (Eng. Abstr.) **(Fre)**

[Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer] Sugiyama Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar;48(3):213–9 (Eng. Abstr.) **(Jpn)**

[Malignant peritoneal mesothelioma. An infrequent cause of prolonged fever syndrome and leucocytosis in a young adult] Melero M, et al. **Medicina (B Aires)** 1995;55(1):48–50 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Schneebaum S, et al. **Ann Surg Oncol** 1996 Jan;3(1):44–50

Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. Della-Fiorentina SA, et al. **Aust N Z J Surg** 1996 Feb; 66(2):124–5

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Kondo A, et al. **Br J Cancer** 1996 May;73(10):1166–70

Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Farhat F, et al. **Cancer** 1996 Apr 1;77(7):1363–6

Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Israel VK, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):32–8

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer—review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)

Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. Menzin AW, et al. **Gynecol Oncol** 1996 Jul;62(1):55–8

Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. Niwa K, et al. **Gynecol Oncol** 1995 Dec;59(3):398–400

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961–7

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Markman M, et al. **J Clin Oncol** 1996 Mar; 14(3):796–9

Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Balthasar JP, et al. **Life Sci** 1996;58(7):535–43 (71 ref.)

[Polyvisceral and multirecurrent lymphoma (letter)] Benhamou G, et al. **Presse Med** 1995 Dec 16–23;24(39):1909 **(Fre)**

[Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis] Kitamura M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1523–6 (Eng. Abstr.) **(Jpn)**

[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis] Takamatsu S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1619–21 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Lack of apparent excess of malignant mesothelioma but increased overall malignancies of peritoneal cavity in Japanese autopsies with Thorotrast injection into blood vessels. Ishikawa Y, et al. **J Cancer Res Clin Oncol** 1995; 121(9–10):567–70

ETIOLOGY

Malignant peritoneal mesothelioma. Case report and review of the literature. Watteeuw G, et al. **Acta Clin Belg** 1995; 50(4):222–6 (18 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Primary extrauterine mullerian adenosarcoma of the peritoneum [letter; comment] Thylan S. **Gynecol Oncol** 1996 Feb;60(2):333. Comment on: Gynecol Oncol 1995 Apr;57(1):126–30.

Asbestos and cancer in Finland. Huuskonen MS, et al. **Med Lav** 1995 Sep–Oct;86(5):426–34

Mesotheliomas following exposure to asbestos used in railroads: 130 Italian cases. Maltoni C, et al. **Med Lav** 1995 Sep–Oct;86(5):461–77

Recent data on cancer due to asbestos in Germany. Rösler JA, et al. **Med Lav** 1995 Sep–Oct;86(5):440–8

Preliminary experimental findings using intraperitoneal assays to determine carcinogenic potential of man made mineral fibres: relevance to recent proposals for classification testing [letter] Collier C. **Occup Environ Med** 1995 Oct; 52(10):700–1

GENETICS

Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay. de Alava E, et al. **Am J Pathol** 1995 Dec; 147(6):1584–91

Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Zanetta GM, et al. **Gynecol Oncol** 1996 Feb; 60(2):213–6

Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Nishiyama Y, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1150–8

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.). Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

METABOLISM

Human chorionic gonadotropin–beta in the differentiation of malignancy–related and nonmalignant ascites. Gerbes AL, et al. **Digestion** 1996;57(2):113–7

Resistance to natriuresis in patients with peritonitis carcinomatosa. Mimura Y, et al. **Horm Metab Res** 1996 Apr;28(4):183–6

Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis. Pruimboom WM, et al. **Int J Immunopharmacol** 1995 May;17(5):375–84

MORTALITY

Occupational and environmental links to mesothelioma deaths occurring in Leeds during 1971–1987. Arblaster L, et al. **J Public Health Med** 1995 Sep;17(3):297–304

Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis. Coggon D, et al. **Occup Environ Med** 1995 Nov;52(11):775–7

PATHOLOGY

Serous surface carcinoma of the peritoneum: useful role of cytology in differential diagnosis and follow-up. Tauchi PS, et al. **Acta Cytol** 1996 May–Jun;40(3):429–36

Solitary fibrous tumor of the mesentery. Hardisson D, et al. **Am J Gastroenterol** 1996 Apr;91(4):810–1

Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Québec. Dufresne A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):711–8

Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Goldblum J, et al. **Am J Surg Pathol** 1995 Oct;19(10):1124–37

Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Ronnett BM, et al. **Am J Surg Pathol** 1995 Dec;19(12):1390–408

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044–9 (31 ref.)

Epithelial noncarcinoid tumors and tumor-like lesions of the appendix [letter] Carr NJ, et al. **Cancer** 1995 Dec 1; 76(11):2383–4

Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Zhou J, et al. **Cancer** 1995 Aug 1;76(3):429–36

Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Yashiro M, et al. **Clin Exp Metastasis** 1996 Jan;14(1):43–54

Cytology of pseudomyxoma peritonei. Pfitzer P, et al. **Cytopathology** 1995 Oct;6(5):304–15

Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257–9 (19 ref.)

Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Hoekman K, et al. **Eur J Cancer** 1996 Feb;32A(2):255–8

Serous surface papillary carcinoma. Ayhan A, et al. **Eur J Gynaecol Oncol** 1996;17(2):137–9

Malignant degeneration in leiomyomatosis peritonealis disseminata. Raspagliesi F, et al. **Gynecol Oncol** 1996 May; 61(2):272–4

Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Rothacker D, et al. **Int J Gynecol Pathol** 1995 Oct; 14(4):310–8

Metastatic intraperitoneal spread is initiated by phospholipase A2. Snoj M. **Med Hypotheses** 1995 May;44(5):392–4

Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Kupryjanczyk J, et al. **Mod Pathol** 1996 Mar;9(3):166–73

Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. Hardman WJ 3rd, et al. **South Med J** 1996 Mar;89(3):291–4 (22 ref.)

Appendiceal mucinous cystadenoma associated with pseudomyxoma peritonei and multicystic peritoneal mesothelioma: report of a case. Kusuyama T, et al. **Surg Today** 1995;25(8):745–9

Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma. Craft PS, et al. **Thorax** 1996 May; 51(5):552–3

[An analysis of pathologic features and prognostic factors of 10 cases with pseudomyxoma peritonei] Zhou X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):543–6 (Eng. Abstr.) **(Chi)**

[Mesocolon mass in an adolescent] Antunes L, et al. **Ann Pathol** 1996;16(1):59–60 **(Fre)**

[Giant mesenteric fibromatosis: a case report] Cianchi F, et al. **Ann Ital Chir** 1995 Jul–Aug;66(4):531–5 (Eng. Abstr.) **(Ita)**

[Peritoneal mesothelioma and abdominal hernias] Mirabella F. **Minerva Med** 1996 Jan–Feb;87(1–2):21–4 (51 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Int J Cancer** 1995 Nov 27; 63(5):716–9

Triamterene suppresses bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Jpn J Cancer Res** 1996 Jul; 87(7):730–4

[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

CT differentiation of tuberculous peritonitis and peritoneal carcinomatosis. Ha HK, et al. **AJR Am J Roentgenol** 1996

Sep;167(3):743–8
CT of leiomyomatosis peritonealis disseminata mimicking peritoneal carcinomatosis. Papadatos D, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):475–6
Mesenteric plexiform neurofibroma: computed tomography appearance. Jain R, et al. **Australas Radiol** 1996 May; 40(2):158–9
Computed tomographic and ultrasonographic findings of pseudomyxoma peritonei. Ozcan O, et al. **Australas Radiol** 1996 May;40(2):169–71
Case report: benign solitary schwannoma of the greater omentum: a rare cause of acute intraperitoneal bleeding—diagnosis by CT. Bankier AA, et al. **Clin Radiol** 1996 Jul;51(7):517–8
Intraperitoneal drop metastases from hepatocellular carcinoma: CT and angiographic findings. Kim TK, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):638–42
Peritoneal tuberculosis versus peritoneal carcinomatosis: distinction based on CT findings. Rodríguez E, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):269–72
Mesenteric cystic lymphangioma: radiologic appearance mimicking cystic teratoma. Hatten MT, et al. **Pediatr Radiol** 1996 Jul;26(7):458–60
[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[Benign peritoneal multicystic mesothelioma] Tomasini P, et al. **J Radiol** 1996 Jan;77(1):57–9 **(Fre)**

RADIONUCLIDE IMAGING

Increased uptake of I–123 IMP in peritoneal metastases of hepatocellular carcinoma. Kodama F, et al. **Clin Nucl Med** 1996 Jan;21(1):70
Intraperitoneal indium–111– and yttrium–90–labeled human IgM (AC6C3–2B12) in nude mice bearing peritoneal carcinomatosis. Quadri SM, et al. **J Nucl Med** 1996 Sep; 37(9):1545–51

RADIOTHERAPY

Intraperitoneal indium–111– and yttrium–90–labeled human IgM (AC6C3–2B12) in nude mice bearing peritoneal carcinomatosis. Quadri SM, et al. **J Nucl Med** 1996 Sep; 37(9):1545–51
[Whole abdominal irradiation for peritoneal dissemination of alimentary tract cancers] Sugahara S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):751–6 (Eng. Abstr.) **(Jpn)**

SECONDARY

Saline MR peritoneography. Magre GR, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):749–51
Peritoneal carcinomatosis [letter; comment] Noguchi M. **Ann Surg** 1995 Dec;222(6):760–1. Comment on: Ann Surg 1995 Feb;221(2):124–32.
Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Schneebaum S, et al. **Ann Surg Oncol** 1996 Jan;3(1):44–50
Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Yashiro M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1668–75
Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Yashiro M, et al. **Clin Exp Metastasis** 1996 Jan;14(1):43–54
Increased uptake of I–123 IMP in peritoneal metastases of hepatocellular carcinoma. Kodama F, et al. **Clin Nucl Med** 1996 Jan;21(1):70
Ascitic fluid–associated lymphocytes in patients with metastatic ovarian cancer. Analysis of lymphocyte subsets and of phenotypical changes induced by "in vitro". Loiudice L, et al. **Eur J Gynaecol Oncol** 1995;16(4):301–6
Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Zanetta GM, et al. **Gynecol Oncol** 1996 Feb; 60(2):213–6
Neuroendocrine carcinoma arising in an ovarian mucinous cystadenoma. Jones K, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):167–70
Endometrial stromal sarcoma with focal smooth muscle differentiation: recurrence after 17 years: a follow–up report with discussion of the nomenclature. Khalifa MA, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):171–6
Intraperitoneal drop metastases from hepatocellular carcinoma: CT and angiographic findings. Kim TK, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):638–42
Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. Canevari S, et al. **J Hematother** 1995 Oct;4(5):423–7
Ascitic positive cytology and intraperitoneal metastasis in ovarian dysgerminoma. Mandai M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):89–94
Triamterene suppresses bombesin–enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Jpn J Cancer Res** 1996 Jul; 87(7):730–4
Metastatic intraperitoneal spread is initiated by phospholipase A2. Snoj M. **Med Hypotheses** 1995 May;44(5):392–4
Clinics in diagnostic imaging (7). Omental caking due to ovarian carcinoma. Helpert C, et al. **Singapore Med J** 1995 Dec;36(6):667–9
The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells. Hubens G, et al. **Surg Endosc** 1996 Aug;10(8):809–12
Peritoneal seeding of gallbladder cancer after laparoscopic cholecystectomy. Sailer M, et al. **Surg Endosc** 1995 Dec; 9(12):1298–300
Long–term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis: report of a case. Otani S, et al. **Surg Today** 1995; 25(11):959–61
Peritoneal carcinomatosis from adenocarcinoma of the colon. Sugarbaker PH, et al. **World J Surg** 1996 Jun;20(5):585–91; discussion 592
[Intraperitoneal infusion therapy of MTX and 5–FU for advanced gastric cancer and its peritoneal metastasis] Takamatsu S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1619–21 (Eng. Abstr.) **(Jpn)**
[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Whole abdominal irradiation for peritoneal dissemination of alimentary tract cancers] Sugahara S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):751–6 (Eng. Abstr.) **(Jpn)**
[Peritoneal carcinomatosis. Review of CT findings in 107 cases] Villanueva A, et al. **Rev Esp Enferm Dig** 1995 Oct; 87(10):707–14 (Eng. Abstr.) **(Spa)**

SURGERY

Anastomotic leak after double–stapled low colorectal resection. Averbach AM, et al. **Dis Colon Rectum** 1996 Jul;39(7):780–7
Peritoneal cystic mesothelioma treated with minimally invasive approach. Navarra G, et al. **Surg Endosc** 1996 Jan; 10(1):60–1 (23 ref.)
Leiomyoma of the lesser omentum: report of a case. Ikematsu Y, et al. **Surg Today** 1996;26(1):46–8
[Therapeutic strategy for large cervical, mediastinal metastatic mature teratomas and large retro– and intraperitoneal lesions] Joyeux H, et al. **Chirurgie** 1994–95; 120(13):170–3 (Eng. Abstr.) **(Fre)**
[Lymphangioleiomyomatosis—a rare disease of the lymphatic system] Kantelhardt T, et al. **Chirurg** 1996 Jun;67(6):653–7 (Eng. Abstr.) **(Ger)**
[Leiomyosarcoma of the mesenteric root. A case report] Giordano P, et al. **Minerva Chir** 1995 Jun;50(6):595–7 (Eng. Abstr.) **(Ita)**
[Primary solid tumors of the mesentery] Vasilescu C, et al. **Chirurgia (Bucur)** 1995;44(4):55–64 (Eng. Abstr.) **(Rum)**

THERAPY

Peritoneal carcinomatosis [letter; comment] Noguchi M. **Ann Surg** 1995 Dec;222(6):760–1. Comment on: Ann Surg 1995 Feb;221(2):124–32.
Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061–5 (44 ref.)
Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Jacquet P, et al. **Cancer** 1996 Jun 15;77(12):2622–9
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I–II study of weekly cisplatin/interferon alfa–2a. Soulié P, et al. **J Clin Oncol** 1996 Mar;14(3):878–85
Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Yonemura Y, et al. **Surgery** 1996 Apr;119(4):437–44
[Desmoids: are there any new developments?] Sevčík A, et al. **Rozhl Chir** 1995 Sep;74(6):253–6 (Eng. Abstr.) **(Cze)**
[Immediate intraperitoneal chemotherapy after surgery for the reduction of peritoneal malignancies: for what purpose and for whom? (editorial)] Elias D. **Ann Chir** 1995; 49(7):567–72 (34 ref.) (Eng. Abstr.) **(Fre)**
[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer] Fujimura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1610–2 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Genitourinary case of the day. Peritoneal inclusion cyst in a patient with a history of prior pelvic surgery. Moran RE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):247, 250
Computed tomographic and ultrasonographic findings of pseudomyxoma peritonei. Ozcan O, et al. **Australas Radiol** 1996 May;40(2):169–71
Hemangiopericytoma of the greater omentum: US and CT appearance. Bertolotto M, et al. **Eur Radiol** 1996;6(4):454–6
Abdominal mycobacterial infection mimicking a gynecologic neoplasm: a case report with sonographic findings. Uzelmeier WJ, et al. **J Okla State Med Assoc** 1995 Dec; 88(12):515–7
[Radiological case of the month. Cystic lymphangioma of the omentum] Fassler C, et al. **Arch Pediatr** 1995 Aug; 2(8):793–5 **(Fre)**

ULTRASTRUCTURE

Multinucleated giant stromal tumor of the omentum: report of a case with immunohistochemical and ultrastructural investigation. Min KW, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):89–99

VETERINARY

Cystic, peritoneal mesothelioma in a dog. DiPinto MN, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):385–9
What is your diagnosis? Cranial displacement of the small intestine and substantial abdominal distention caused by a large intra–abdominal lipoma. Osborn SD, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1235–6
[Ascites as a result of peritoneal mesotheliomas in a horse] Harps O, et al. **Tierarztl Prax** 1996 Jun;24(3):270–4 (Eng. Abstr.) **(Ger)**

PERITONEOSCOPY see **LAPAROSCOPY**

PERITONEOVENOUS SHUNT

Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt [see comments] Guardiola J, et al. **Am J Gastroenterol** 1995 Dec;90(12):2097–102. Comment in: Am J Gastroenterol 1995 Dec;90(12):2086–9.
Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s [editorial; comment] Wong F, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2086–9 (39 ref.). Comment on: Am J Gastroenterol 1995 Dec;90(12):2097–102.
Hemodynamic effects of peritoneovenous shunts in hemodialysis patients with ascites. Greenberg S, et al. **Am J Kidney Dis** 1996 Sep;28(3):387–94
Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Stanley MM, et al. **Dig Dis Sci** 1996 Mar; 41(3):571–7
Temporary use of peritoneovenous shunting for treatment of tense ascites following a Whipple procedure. Takahashi T, et al. **Dig Dis Sci** 1995 Sep;40(9):1946–50
[Surgical treatment of refractory ascites with peritoneovenous shunt] Massari R, et al. **Chir Ital** 1995; 47(1):57–0 (14 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

[Complications in a patient with a jejuno–peritoneal shunt by the Le Veen technique] Fulgente R, et al. **Chir Ital** 1994;46(6):71–2 (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

A peritoneovenous shunt with an access port enables non surgical reversal of intraperitoneal catheter occlusion. Wigness BD, et al. **ASAIO J** 1994 Jul–Sep;40(3):M580–3

METHODS

A peritoneovenous shunt with an access port enables non surgical reversal of intraperitoneal catheter occlusion. Wigness BD, et al. **ASAIO J** 1994 Jul–Sep;40(3):M580–3
[Peritoneojugular shunt in the treatment of idiopathic ascites in the hemodialyzed patient: a clinical case] Massari R, et al. **Chir Ital** 1995;47(1):55–6 (Eng. Abstr.) **(Ita)**

PERITONEUM

see related
ASCITIC FLUID
LAPAROSCOPY

BLOOD SUPPLY

Peritoneal blood flow and peritoneal transfer parameters during dialysis with administration of drugs. Grzegorzewska AE, et al. **Adv Perit Dial** 1995;11:28–32
Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Honda K, et al. **Nephron** 1996;72(2):171–6
The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)
Heat–sterilized PD fluid blocks leukocyte adhesion and increases flow velocity in rat peritoneal venules. Jonasson P, et al. **Perit Dial Int** 1996;16 Suppl 1:S137–40
Pathogenesis of peritoneal fibrosis and peritoneal small vessel changes. Nakamoto M. **Perit Dial Int** 1996;16 Suppl 1:S39–41
Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)
[Peritoneal blood flow and peritoneal transfer parameters during intermittent peritoneal dialyses performed with administration of sodium nitroprusside or chlorpromazine] Grzegorzewska A, et al. **Przegl Lek** 1996;53(5):412–6 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Immunosuppressive acidic protein (IAP) level in serum and peritoneal washings, and its implication in determining multidisciplinary treatments. Takenoshita S, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2269–72

CYTOLOGY

The migration of peritoneal cells towards the gut. Sminia T, et al. **Adv Exp Med Biol** 1995;371A:61–5
T lymphocytes from the normal human peritoneum contain high frequencies of Th2–type CD8+ T cells. Birkhofer A, et al. **Eur J Immunol** 1996 Apr;26(4):957–60
An alternative medium supplement for the culturing and

growth of human peritoneal mesothelial cells [letter] Michelini-Norris MB, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul-Aug;31(7):487-91

Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Yashiro M, et al. **Int J Cancer** 1996 Jul 17;67(2):289-93

Is sepsis-induced apoptosis associated with macrophage dysfunction? Ayala A, et al. **J Trauma** 1996 Apr; 40(4):568-73; discussion 573-4

Daily short exposure of cultured mesothelial cells to lactated, high-glucose, low-pH peritoneal dialysis fluid induces a low-profile regenerative steady state. Shostak A, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):608-13

Interleukin-1 beta stimulates glucose uptake of human peritoneal mesothelial cells in vitro. Kruse M, et al. **Perit Dial Int** 1996;16 Suppl 1:S58-60

The role of TGF-beta in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Kumano K, et al. **Perit Dial Int** 1995;15(7 Suppl):S93-5 (18 ref.)

DRUG EFFECTS

L-2-Oxothiazolidine-4-carboxylate and N-acetylcysteine as precursors of intracellular glutathione in human peritoneal mesothelial cells. Breborowicz A, et al. **Blood Purif** 1996; 14(1):1-7

Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Kumano K, et al. **Blood Purif** 1996;14(2):165-9

Some studies on the effects of alpha-chymotrypsin on mast cells from the rat and other species. Emadi-Khiav B, et al. **Eur J Pharmacol** 1996 Jan 11;295(2-3):243-52

Changes in histamine and serotonin secretion from rat peritoneal mast cells caused by antidepressants. Ferjan I, et al. **Inflamm Res** 1996 Mar;45(3):141-4

Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells. Brunkhorst R, et al. **Kidney Int** 1995 Jul; 48(1):177-81

Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Gotloib L, et al. **Nephron** 1995; 70(4):466-77

Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Tsai TJ, et al. **Nephron** 1995;71(1):23-8

Biocompatibility of various osmotic solutes. Coles GA. **Perit Dial Int** 1995;15(7 Suppl):S71-5

Are solutions presently used bioincompatible? Coles GA. **Perit Dial Int** 1995;15(7 Suppl):S109-10; discussion S110-4

Peritoneal dialysis solution biocompatibility testing in animals. Di Paolo N, et al. **Perit Dial Int** 1995;15(7 Suppl):S61-9; discussion S69-70 (40 ref.)

Lactate-versus bicarbonate-based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47-50; discussion S51 (33 ref.)

EMBRYOLOGY

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285-7 (18 ref.)

ENZYMOLOGY

Proteinases of rat mast cells. Peritoneal but not intestinal mucosal mast cells express mast cell proteinase 5 and carboxypeptidase A. Befus AD, et al. **J Immunol** 1995 Nov 1;155(9):4406-11

[Formation of adhesions and change in activity of tissue plasminogen activator in the parietal peritoneum of the anterior stomach wall in rats depending on the method of restoring it] Mynbaev OA, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):328-31 **(Rus)**

IMMUNOLOGY

T lymphocytes from normal human peritoneum are phenotypically different from their counterparts in peripheral blood and CD3- lymphocyte subsets contain mRNA for the recombination activating gene RAG-1. Hartman J, et al. **Eur J Immunol** 1995 Sep;25(9):2626-31

Continuous ambulatory peritoneal dialysis impairs T lymphocyte selection in the peritoneum. Fricke H, et al. **Kidney Int** 1996 May;49(5):1386-95

Peritoneal host defense mechanisms. Holmes CJ. **Perit Dial Int** 1996;16 Suppl 1:S124-5

Peritoneal host defenses are less impaired by laparoscopy than by open operation. Collet D, et al. **Surg Endosc** 1995 Oct;9(10):1059-64

[Peritoneal immune response in endometriosis] Nava-Loya G, et al. **Ginecol Obstet Mex** 1996 Apr;64:147-53 (Eng. Abstr.) **(Spa)**

INJURIES

[Problems of the therapeutic approach in subperitoneal wounds to the rectum] Micu N, et al. **Chirurgia (Bucur)** 1995;44(1):15-20 (Eng. Abstr.) **(Rum)**

[Intestinal obstruction caused by transitional carcinoma] Vesga Molina F, et al. **Arch Esp Urol** 1996 Mar;49(2):177-9 (Eng. Abstr.) **(Spa)**

METABOLISM

Peritoneal transport evaluation in peritonitis: comparison between methods. Borràs M, et al. **Adv Perit Dial** 1995; 11:145-8

Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. Breborowicz A, et al. **Adv Perit Dial** 1995;11:15-8

Consistency of the peritoneal equilibration test in a cohort of nonselected Mexican CAPD patients. Cueto-Manzano AM, et al. **Adv Perit Dial** 1995;11:114-8

Transfer of native insulin through the peritoneal membrane during CAPD in non-diabetic and diabetic patients. Ersoy FF, et al. **Adv Perit Dial** 1995;11:119-22

Cross-sectional analysis of erythropoietin use in CPD: its relation to azotemic index clearances. Fox L, et al. **Adv Perit Dial** 1995;11:243-6

Hematocrit has no effect on peritoneal transport indices. Gandolfo C, et al. **Adv Perit Dial** 1995;11:41-4

Pyrazinoic acid decreases peritoneal transfer rates. Grzegorzewska AE, et al. **Adv Perit Dial** 1995;11:33-5

Peritoneal blood flow and peritoneal transfer parameters during dialysis with administration of drugs. Grzegorzewska AE, et al. **Adv Perit Dial** 1995;11:28-32

Multiple drug classes and hyperosmolarity alter binding of muscarinic drugs to mesothelial cells in vitro. Hjelle JT, et al. **Adv Perit Dial** 1995;11:3-6

Increased peritoneal solute transport in diabetic peritoneal dialysis patients. Lin JJ, et al. **Adv Perit Dial** 1995;11:63-6

Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients. Lin JJ, et al. **Adv Perit Dial** 1995;11:60-2

Peritoneal membrane failure in children on peritoneal dialysis. Neiberger RE. **Adv Perit Dial** 1995;11:277-80

Effect of glucose on TGF-beta 1 expression in peritoneal mesothelial cells. Wang T, et al. **Adv Perit Dial** 1995; 11:7-10

Reproducibility of the peritoneal equilibration test in CAPD patients. Trivedi H, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M892-5

Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Davies SJ, et al. **Clin Nephrol** 1996 Mar;45(3):194-8

Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients. Lin JJ, et al. **Clin Nephrol** 1995 Nov;44(5):310-5

Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Pannekeet MM, et al. **Clin Nephrol** 1995 Oct;44(4):248-54

Peritoneal clearance of inorganic sulfate. Uribarri J, et al. **Clin Nephrol** 1995 Jul;44(1):56-9

Quantitative relationship between structure and peritoneal membrane transport based on physiological pharmacokinetic concepts for acidic drugs. Nakashima E, et al. **Drug Metab Dispos** 1995 Nov;23(11):1220-4

The operative peritoneal fibrinolytic response to abdominal operation. Scott-Coombes DM, et al. **Eur J Surg** 1995 Jun; 161(6):395-9

Evaluation of non-linear and linear mathematical models for creatinine and glucose fitting in peritoneal dialysis. Amici G. **Int J Artif Organs** 1996 Apr;19(4):221-31

Influence of intraperitoneal gentamicin on peritoneal transport in IPD patients. Janicka L, et al. **Int Urol Nephrol** 1995;27(2):215-21

Small-solute transport across specific peritoneal tissue surfaces in the rat. Flessner MF. **J Am Soc Nephrol** 1996 Feb;7(2):225-33

Ultrafiltration and solute kinetics using low sodium peritoneal dialysate. Leypoldt JK, et al. **Kidney Int** 1995 Dec; 48(6):1959-66

The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Pannekeet MM, et al. **Kidney Int** 1995 Sep; 48(3):866-75

Increased peritoneal permeability to albumin in streptozotocin diabetic rats. Shostak A, et al. **Kidney Int** 1996 Mar;49(3):705-14

Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Davies SJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):498-506

Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis. Joffe P, et al. **Nephrol Dial Transplant** 1995;10(9):1725-32

Limitations of the peritoneal equilibration test [letter; comment] Twardowski ZJ, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2160-1. Comment on: Nephrol Dial Transplant 1995;10(2):252-7.

Peritoneal equilibration test: time on treatment and reference values [letter] Amici G, et al. **Nephron** 1995;70(4):506-7

Transperitoneal absorption and kinetics of chromium in the continuous ambulatory peritoneal dialysis patient—an experimental and mathematical analysis. Borguet F, et al. **Nephron** 1996;72(2):163-70

Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O, et al. **Nephron** 1996; 72(2):135-44

Longitudinal changes in peritoneal equilibration test with or without peritonitis in children. Nishi A, et al. **Pediatr Nephrol** 1995 Oct;9(5):562-5

Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May-Jun;16(3):248-51 (25 ref.)

Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Burkart JM. **Perit Dial Int** 1995;15(5 Suppl):S20-35 (94 ref.)

Prescription and assessment of tidal peritoneal dialysis delivery with a specific equilibration test. Edefonti A, et al. **Perit Dial Int** 1996 May-Jun;16(3):295-301

The reproducibility of the fast peritoneal equilibration test. Enia G, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):382-4

Factors affecting bicarbonate transfer with bicarbonate-containing CAPD solution. Feriani M, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):336-41

The peritoneal equilibration test cannot predict the mass transfer area coefficients. Graff J, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):271-3

Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May-Jun;16(3):255-9 (62 ref.)

Peritoneal instillation test before CAPD in a case of severe pulmonary disease. Leblanc M, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):384-7

Correlations between plasminogen activator inhibitor-1 and peritoneal transport in pediatric CCPD patients. Lin JJ, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):246-51

Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Pannekeet MM, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):217-25

The effect of dialysate acidity on peritoneal solute transport in the rat. Park MS, et al. **Perit Dial Int** 1995 Oct-Dec; 15(8):312-9

The PET: comparison of high, high-average and low, low-average PET in Indian CAPD [letter] Prakash KC, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):388-9

Paradoxes in peritoneal transport of small solutes. Waniewski J, et al. **Perit Dial Int** 1996;16 Suppl 1:S63-9

An evaluation of twelve nested models of transperitoneal transport of urea: the one-compartment assumption is valid. Graff J, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):331-9

Fibrinolysis in human peritoneum during operation. Holmdahl L, et al. **Surgery** 1996 Jun;119(6):701-5

[Intraperitoneal distribution of drug after gastric surgery] Nagahama T, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1602-5 (Eng. Abstr.) **(Jpn)**

[Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability] Suyama K, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):491-6 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Ingestion of Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli by human peritoneal mesothelial cells. Visser CE, et al. **Infect Immun** 1996 Aug; 64(8):3425-8

PATHOLOGY

Mesenchymal chondrosarcoma of the retroperitoneum. Report of a case diagnosed by fine needle aspiration biopsy with immunohistochemical, electron microscopic demonstration of S-100 protein in undifferentiated cells. González-Cámpora R, et al. **Acta Cytol** 1995 Nov-Dec; 39(6):1237-43

Spontaneous peritonitis and peritoneal fibrosis in rats on peritoneal dialysis for 9 weeks. Suzuki K, et al. **Adv Perit Dial** 1995;11:52-6

Rat model of peritoneal fibrosis: preliminary observations. Wieczorowska K, et al. **Adv Perit Dial** 1995;11:48-51

Recovery of gastrointestinal function after renal transplantation in patients with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis [letter; comment] Bhandari S. **Am J Kidney Dis** 1996 Apr; 27(4):604. Comment on: Am J Kidney Dis 1995 Oct;26(4):658-61.

Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Yashiro M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1668-75

Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Stanley MM, et al. **Dig Dis Sci** 1996 Mar; 41(3):571-7

Stereometric evaluation of peritoneal endometriosis and endometriotic nodules of the rectovaginal septum. Donnez J, et al. **Hum Reprod** 1996 Jan;11(1):224-8

Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. Shepherd NA, et al. **J Clin Pathol** 1995 Sep;48(9):849-55

Peritoneal cytology in gynecologic cancer: an essential adjunct [editorial; comment] LiVolsi VA. **J Natl Cancer Inst** 1996 Jul 17;88(14):939-40. Comment on: J Natl Cancer Inst 1996 Jul 17;88(14):980-7.

Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients [see comments] Zuna RE, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):980-7. Comment in: J Natl Cancer Inst 1996 Jul 17;88(14):939-40.

Natural course of postsurgical adhesions. Bakkum EA, et al. **Microsurgery** 1995;16(9):650-4

Morphology of the peritoneum: effect of peritoneal dialysis. Gotloib L, et al. **Perit Dial Int** 1995;15(7 Suppl):S9-11; discussion S11-2

Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Pannekeet MM, et al. **Perit Dial Int** 1996;16 Suppl 1:S54-7

Transformed mesothelial cells in patients on CAPD for medium- to long-term periods. Selgas R, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):305-11

Imaging of the peritoneal cavity in CAPD. Wankowicz Z, et al. **Perit Dial Int** 1996;16 Suppl 1:S434-9

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876-82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Significance of tumor necrosis factor alpha (TNF-alpha) in endometriosis] Küpker W, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):239-42 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Durability of the peritoneal membrane. Dobbie JW. **Perit Dial Int** 1995;15(7 Suppl):S87-91; discussion S91-2 (18 ref.)

The biology of the mesothelium during peritoneal dialysis. Hjelle JT, et al. **Perit Dial Int** 1995;15(7 Suppl):S13-22; discussion S22-3 (108 ref.)

[Changes of transport functions in peritoneum caused by glucose and its penetration in vitro] Szary B, et al. **Pol Arch Med Wewn** 1995 Apr;93(4):295-304 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Effect of peritoneal dialysis on cytokine production by peritoneal cells. Topley N, et al. **Blood Purif** 1996; 14(2):188-97 (62 ref.)

Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198-216 (171 ref.)

Ultrafiltration failure in CAPD. Shetty A, et al. **J Postgrad Med** 1994 Jul-Sep;40(3):185-93 (47 ref.)

The predictive value of KT/V and peritoneal solute transport in CAPD patients is dependent on the type of comorbidity present. Davies SJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S158-62

How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167-70 (14 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147-52 (18 ref.)

Charge-affected transperitoneal movement of amino acids in CAPD. Nakao T, et al. **Perit Dial Int** 1996;16 Suppl 1:S88-90

SURGERY

Closure or nonclosure of the visceral peritoneum at cesarean delivery. Nagele F, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1366-70

The saline ballooning method for peritoneal dissection during laparoscopic herniorrhaphy. Oka M, et al. **Arch Surg** 1996 Apr;131(4):448-9

Nonclosure of the visceral and parietal peritoneum at caesarean section: a randomised controlled trial. Irion O, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):690-4

Does peritoneal mobilization increase laparoscopic acidosis? Ortega AE, et al. **Dis Colon Rectum** 1995 Dec; 38(12):1296-300

Pelvic and periaortic pertioneal closure or non-closure at lymphadenectomy in ovarian cancer: effects on morbidity and adhesion formation. Kadanali S, et al. **Eur J Surg Oncol** 1996 Jun;22(3):282-5

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):40-5 (10 ref.)

Total mesorectal excision in the operative treatment of carcinoma of the rectum. Enker WE, et al. **J Am Coll Surg** 1995 Oct;181(4):335-46

Development and comparison of transperitoneal and retroperitoneal approaches to laparoscopic-assisted aortofemoral bypass in a porcine model. Jones DB, et al. **J Vasc Surg** 1996 Mar;23(3):466-71

Peritoneal closure at vaginal hysterectomy: a reassessment. Lipscomb GH, et al. **Obstet Gynecol** 1996 Jan;87(1):40-3

Malfunctioning peritoneal dialysis catheter repaired by laparoscopic surgery. Julian TB, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):363-6

The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells. Hubens G, et al. **Surg Endosc** 1996 Aug;10(8):809-12

Totally preperitoneal laparoscopic approach combined with miniantierior dissection in the treatment of indirect inguinal hernias. Himpens J, et al. **Surg Laparosc Endosc** 1995 Dec; 5(6):450-2

Laparoscopic repair of intraperitoneal bladder injury: a simple new technique. Poffenberger RJ. **Urology** 1996 Feb; 47(2):248-9

[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer] Fujimura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1610-2 (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

[A new modification of the neovagina reconstruction with peritoneum technique] Balik E, et al. **Zentralbl Gynakol** 1996;118(5):307-9 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Ultrastructural observations on the peritoneum in the mouse. Ettarh RR, et al. **J Anat** 1996 Feb;188 (Pt 1):211-5

PERITONITIS

Sclerosing encapsulating peritonitis--a review. Eldar S, et al. **S Afr J Surg** 1995 Jun;33(2):70-2 (39 ref.)

BLOOD

Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Sitter T, et al. **Nephrol Dial Transplant** 1995;10(5):677-83

[Acid-soluble blood glycoproteins in patients with diffuse purulent peritonitis] Riabov GA, et al. **Anesteziol Reanimatol** 1995 Jul-Aug;(4):44-6 (Eng. Abstr.) **(Rus)**

[Reaction of eritron and its mechanisms in inflammation] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):382-4 **(Rus)**

COMPLICATIONS

Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Bastani B, et al. **Am J Nephrol** 1995;15(6):468-72

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):141-5 (30 ref.)

Spontaneous bacterial peritonitis complicating malignancy-related ascites [letter] Bac DV, et al. **Dig Dis Sci** 1996 Jan;41(1):131-2

Luteinized thecoma with sclerosing peritonitis presenting as an acute abdomen. Spiegel GW, et al. **Gynecol Oncol** 1996 May;61(2):275-81

Spontaneous peritonitis caused by Streptococcus bovis: search for colonic neoplasia [letter] Ackerman Z, et al. **J Clin Gastroenterol** 1995 Oct;21(3):263

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876-82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Does laparoscopic treatment of abdominal infections generate bacteremias? Prospective study: 75 cases] Benoit J, et al. **J Chir (Paris)** 1995 Dec;132(12):472-7 (Eng. Abstr.) **(Fre)**

[Sudden death following bypass surgery (clinical conference)] Ritschard T, et al. **Schweiz Rundsch Med Prax** 1996 May 28;85(22):721-6 **(Ger)**

[Features of resection of perforating pyloric-duodenal ulcer in patients with diffuse peritonitis] Zaĭtsev VT, et al. **Klin Khir** 1995;(4):14-5 **(Rus)**

[Visceral pathology in peritonitis] Alekseev VG, et al. **Klin Med (Mosk)** 1995;73(3):33-6 (Eng. Abstr.) **(Rus)**

[The pathogenesis of endotoxicosis in gunshot-wound peritonitis] Mamuchishvili NK, et al. **Voen Med Zh** 1996 Jan;317(1):29-31 **(Rus)**

[Bacteremia and spontaneous peritonitis caused by serogroup C Neisseria meningitidis in a cirrhotic patient (letter)] García-Irure JJ, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):62-3 **(Spa)**

DIAGNOSIS

Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease. Krestin GP, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):414-20

Assessment of peritonism in appendicitis [letter] Guy RJ, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234-5

Assessment of peritonism in appendicitis [letter] Hamer DB. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

Assessment of peritonism in appendicitis [letter] Thomson H. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

Clinical comparison of isolator, Septi-Chek, nonvented tryptic soy broth, and direct agar plating combined with thioglycolate broth for diagnosing spontaneous bacterial peritonitis. Hay JE, et al. **J Clin Microbiol** 1996 Jan; 34(1):34-7

Leiomyoma of the jejunum presenting as peritonitis. Kulkarni SH, et al. **J Indian Med Assoc** 1995 Aug;93(8):316-7

Influence of methodological differences on microbiological diagnosis of CAPD peritonitis [letter] Celik A, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498-9

[Diagnostic aspects of spontaneous bacterial peritonitis in hepatic cirrhosis with ascites] Breda A, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):227-30 (Eng. Abstr.) **(Ita)**

[The diagnostic value of cytology in children on continuous ambulatory peritoneal dialysis (CAPD)] Sieniawska M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):216-21 (Eng. Abstr.) **(Pol)**

[A spontaneously ruptured primary hydatid cyst of the great epiploon. Hydatid peritonitis] Ionescu A, et al. **Chirurgia (Bucur)** 1995;44(3):65-7 **(Rum)**

DRUG THERAPY

The efficacy of intraperitoneally administered gentamicin and rifampin as initial treatment of peritoneal dialysis-related peritonitis. Brulez HF, et al. **Adv Perit Dial** 1995;11:182-6

Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie. Klaus G, et al. **Adv Perit Dial** 1995;11:296-301

Successful treatment of fungal peritonitis with intracatheter antifungal retention. Lee SH, et al. **Adv Perit Dial** 1995; 11:172-5

A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Lye WC, et al. **Adv Perit Dial** 1995;11:179-81

Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. Clark EC, et al. **Am J Nephrol** 1995;15(4):353-5

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348-52 (19 ref.)

Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Montenegro J, et al. **Clin Nephrol** 1995 Jul;44(1):60-3

Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Tighe D, et al. **Crit Care Med** 1995 Dec;23(12):1997-2007

Cefotaxime and metronidazole in severe intra-abdominal infection. Aprahamian C, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):183-8

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):141-5 (30 ref.)

Cefotaxime in the treatment of spontaneous bacterial peritonitis [letter; comment] Xiol X, et al. **Hepatology** 1996 Apr;23(4):941-2. Comment on: Hepatology 1995 Mar;21(3):674-9.

Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Hoogkamp-Korstanje JA. **Infection** 1995 Sep-Oct;23(5):278-82

Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563-7 (33 ref.)

An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. Arguedas A, et al. **J Chemother** 1996 Apr; 8(2):130-6

The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. Leal del Rosal P. **J Chemother** 1995 Jun;7 Suppl 2:143-8

Recurrent hemiparesis under amphotericin B for Candida albicans peritonitis. Devuyst O, et al. **Nephrol Dial Transplant** 1995;10(5):699-701

The role of surgery and itraconazole in Aspergillus peritonitis in CAPD [letter] Kitiyakara C, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498

Group B streptococcus and treatment of CAPD peritonitis [letter] Pagniez D, et al. **Nephron** 1995;71(4):480

Successful outpatient treatment of Trichosporon beigelii peritonitis with oral fluconazole. Melez KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1110-3

Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments] Bailie GR, et al. **Perit Dial Int** 1995 Jul-Sep; 15(6):269-71. Comment in: Perit Dial Int 1995 Jul-Sep;15(6):201-2.

Combination therapy involving ciprofloxacin for peritonitis. Guest SS, et al. **Perit Dial Int** 1996 May-Jun;16(3):316-8

Treatment of peritonitis: how are we doing? [editorial; comment] Vas SI. **Perit Dial Int** 1995 Jul-Sep;15(6):201-2 . Comment on: Perit Dial Int 1995 Jul-Sep;15(6):269-71.

Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Haqqie SS, et al. **Ren Fail** 1995 Sep;17(5):611-4

A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies. Aranow JS, et al. **Shock** 1996 Feb;5(2):116-21

Granulocyte colony-stimulating factor improves myelopoiesis and host defense in fulminant intra-abdominal sepsis in rats. Lundblad R, et al. **Shock** 1995 Jul;4(1):68-73

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S-33S (30 ref.) (Eng. Abstr.) **(Fre)**

[Development of 5-fluorouracil incorporated in microspheres for peritoneal carcinomatosis--animal experiments] Hagiwara A, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1638-40 (Eng. Abstr.) **(Jpn)**

[Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis] Mizuno I, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1598-601 (Eng. Abstr.) **(Jpn)**

[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective] Okabe T, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):349–53 (Eng. Abstr.) **(Jpn)**

[Therapy of carcinomatous peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration] Tsujimoto H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1527–30 (Eng. Abstr.) **(Jpn)**

[The antibacterial and immunocorrective action of ozone therapy in peritonitis] Vasil'ev IT, et al. **Vestn Khir Im I I Grek** 1995;154(3):56–60 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Role of induced nitric oxide synthase and increased NO levels in zymosan peritonitis in the rat. Boughton-Smith NK, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S149–50

EPIDEMIOLOGY

Prevalence of associated infections in community-acquired spontaneous bacterial peritonitis. Ho H, et al. **Am J Gastroenterol** 1996 Apr;91(4):735–42

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)

Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Goldie SJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):86–91

Primary peritonitis in children. Kimber CP, et al. **Aust N Z J Surg** 1996 Mar;66(3):169–70

ETIOLOGY

Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease. Krestin GP, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):414–20

Infection rates in end-stage renal disease patients treated with CCPD and CAPD using the UltraBag system. Gahrmani N, et al. **Adv Perit Dial** 1995;11:164–7

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168–71 (14 ref.)

Spontaneous peritonitis and peritoneal fibrosis in rats on peritoneal dialysis for 9 weeks. Suzuki K, et al. **Adv Perit Dial** 1995;11:52–6

Peritoneal calcification associated with continuous ambulatory peritoneal dialysis. Miller FH, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):541–2

Sclerosing peritonitis associated with luteinized thecomas. Reginella RF, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):512–3

Vernix caseosa peritonitis [letter] Nuñez C. **Am J Clin Pathol** 1996 May;105(5):657

Complications from cesarean section [letter; comment] Zellers RA, et al. **Am J Clin Pathol** 1996 Feb;105(2):251 . Comment on: Am J Clin Pathol 1995 Jun;103(6):681–4.

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

A very rare case of continuous ambulatory peritoneal dialysis peritonitis caused by Anisakis larva [letter] Ohta M, et al. **Am J Gastroenterol** 1995 Oct;90(10):1902–3

Bacterial peritonitis in continuous ambulatory peritoneal dialysis: effect on dialysis on host defense mechanisms. Findon G, et al. **Am J Kidney Dis** 1995 Nov;26(5):765–73

Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Golper TA, et al. **Am J Kidney Dis** 1996 Sep;28(3):428–36

Peritonitis associated with exit site and tunnel infections. Gupta B, et al. **Am J Kidney Dis** 1996 Sep;28(3):415–9

Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis [see comments] Hawley CM, et al. **Am J Kidney Dis** 1995 Oct; 26(4):658–61. Comment in: Am J Kidney Dis 1996 Apr;27(4):604.

Sclerosing peritonitis occurring in a hemodialysis patient. McLaughlin K, et al. **Am J Kidney Dis** 1996 May; 27(5):729–32

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Nomoto Y, et al. **Am J Kidney Dis** 1996 Sep; 28(3):420–7

Peritonitis rate: traditional versus low calcium dialysate. Stein A, et al. **Am J Kidney Dis** 1995 Oct;26(4):632–3

Laparoscopic management of generalized peritonitis due to perforated colonic diverticula. O'Sullivan GC, et al. **Am J Surg** 1996 Apr;171(4):432–4

Puncture of the gall bladder: an unusual cause of peritonitis complicating percutaneous nephrostomy. Martín E, et al. **Br J Urol** 1996 Mar;77(3):464–5

Biliary peritonitis following percutaneous nephrolithotomy. Saxby MF. **Br J Urol** 1996 Mar;77(3):465–6

Biomaterial-associated staphylococcal peritoneal infections in a neutropaenic mouse model. Rozalska B, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):307–19

Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852–9

Peritonitis caused by Monilia sitophila in a patient undergoing peritoneal dialysis. Radix AE, et al. **Int J Artif Organs** 1996 Apr;19(4):218–20

Mycobacterium avium complex peritonitis in a patient with alcoholic liver disease. Adal KA, et al. **J Clin Gastroenterol** 1996 Apr;22(3):245–6

Peritonitis involving a Capnocytophaga sp. in a patient undergoing continuous ambulatory peritoneal dialysis. Esteban J, et al. **J Clin Microbiol** 1995 Sep;33(9):2471–2

Continuous ambulatory peritoneal dialysis-associated peritonitis as a model device-related infection: phenotypic adaptation, the staphylococcal cell envelope and infection. Williams P, et al. **J Hosp Infect** 1995 Jun;30 Suppl:35–43

Quinolone resistance in Oligella urethralis-associated chronic ambulatory peritoneal dialysis peritonitis. Riley UB, et al. **J Infect** 1996 Mar;32(2):155–6

Bacterial peritonitis associated with peritoneal dialysis. Sutcharitchan N, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S105–7

Entrapment of the appendix and the fallopian tube in peritoneal dialysis catheters in two children. Borghol M, et al. **J Pediatr Surg** 1996 Mar;31(3):427–9

Connecting devices in CAPD and their impact on peritonitis. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):179–84 (33 ref.)

The retrospective study on high risk factors of subphrenic infection after hepatectomy. Xing X, et al. **J Tongji Med Univ** 1995;15(3):158–61

Pasteurella multocida infection in continuous ambulatory peritoneal dialysis. Kitching AR, et al. **N Z Med J** 1996 Feb 23;109(1016):59

Frequent involvement of the internal cuff segment in CAPD peritonitis and exit-site infection – an ultrasound study. Korzets Z, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):336–9

Outcome and complications in patients treated with continuous ambulatory peritoneal dialysis (CAPD) at a single centre during 11 years. Wanten GJ, et al. **Neth J Med** 1996 Jul;49(1):4–12

Intraperitoneal rupture of an infected urachal cyst: a rare cause of peritonitis in children. Ogbevoen JO, et al. **Pediatr Emerg Care** 1996 Feb;12(1):41–3 (19 ref.)

How would you treat a 4-year-old boy with nephrotic syndrome in relapse with ascites developed peritonitis and abdominal pain? Potter DE. **Pediatr Nephrol** 1995 Aug; 9(4):411

Flavobacterium group IIb peritonitis in a patient on chronic ambulatory peritoneal dialysis [letter] Akl ZA, et al. **Perit Dial Int** 1996 May–Jun;16(3):331–2

Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)

Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)

Peritoneal catheter colonization and peritonitis with Aureobasidium pullulans [letter] Caporale NE, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):97–8

Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)

Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodex'rin in Ambulatory Dialysis. Gokal R, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):226–30

Complications in peritoneal dialysis: peritonitis and exit-site infections. Keogh AM. **Perit Dial Int** 1996;16 Suppl 1:S464–7

Scanning electron microscopy studies of peritoneal catheter in CAPD peritonitis due to Aspergillus fumigatus. Park SB, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):81–3

Giardial peritonitis complicating CAPD [letter] Prakash KC. **Perit Dial Int** 1996 May–Jun;16(3):327

A case of Kluyvera cryocrescens peritonitis in a CAPD patient [letter] Sezer MT, et al. **Perit Dial Int** 1996 May–Jun;16(3):326–7

Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)

Effect of a pneumoperitoneum on the extent and severity of peritonitis induced by gastric ulcer perforation in the rat. Bloechle C, et al. **Surg Endosc** 1995 Aug;9(8):898–901

[Peritonitis in continuous ambulatory peritoneal dialysis. An evaluation of the empiric initial antibiotic treatment] Hagelskjaer LH, et al. **Ugeskr Laeger** 1996 Apr 29; 158(18):2532–7 (Eng. Abstr.) **(Dan)**

[Peritonitis caused by minor intestinal perforation during subacute brucellosis. Apropos of a case] Squali J, et al. **Cah Anesthesiol** 1995;43(5):477–8 **(Fre)**

[Peritoneal mesothelioma revealed by episodes of recurrent spontaneous peritonitis] Fayemendy L, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):99–102 (Eng. Abstr.) **(Fre)**

[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**

[Radiological case of the week (4). Paralytic ileus in sclerosing peritonitis during CAPD] Kacl GM, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):131–2 **(Ger)**

[Incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites. A two-year prospective study] Osztrogonácz H, et al. **Orv Hetil** 1996 Jan 28;137(4):179–82 (Eng. Abstr.) **(Hun)**

[Perforation in Crohn's ileitis and its consequences in the natural history of disease. 2. Consequences of perforation in the peritoneal cavity: diffuse septic peritonitis, abscesses, external and internal fistulas] Tonelli P. **Ann Ital Chir** 1995 Jul–Aug;66(4):457–66 (Eng. Abstr.) **(Ita)**

[Adhesive peritonitis caused by a foreign body. A case report] Brignole E, et al. **Minerva Chir** 1995 Jun;50(6):591–4 (Eng. Abstr.) **(Ita)**

[Protozoan infection (Blastocystis hominis) concomitant with Pseudomonas sp. peritonitis in continuous ambulatory peritoneal dialysis (CAPD)] Boccardo G, et al. **Minerva Urol Nefrol** 1996 Mar;48(1):55–8 (Eng. Abstr.) **(Ita)**

[Spontaneous bacterial peritonitis in liver cirrhosis. What tests to perform on the ascitic fluid?] Tincani E, et al. **Recenti Prog Med** 1996 Apr;87(4):150–3 (Eng. Abstr.) **(Ita)**

[Biliary peritonitis] Toyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):496–9 (15 ref.) **(Jpn)**

[New aspects of the pathogenesis of peritonitis] Iarovaia GA, et al. **Khirurgiia (Mosk)** 1996;(1):77–9 (45 ref.) **(Rus)**

[The perforation of a giant cyst of the common bile duct] Ivanov VV, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):302–3 **(Rus)**

[Postoperative progressive peritonitis in patients wounded in the abdomen] Mamuchishvili NK, et al. **Voen Med Zh** 1995 Nov;(11):31–3 **(Rus)**

[Asymptomatic intrauterine meconial peritonitis: apropos a case] Velasco Sánchez B, et al. **An Esp Pediatr** 1996 Jun; 44(6):599–600 **(Spa)**

[Bacteremic peritonitis caused by Aeromonas hydrophila in a woman with cirrhosis (letter)] Ramos Rincón JM, et al. **An Med Interna** 1996 Mar;13(3):154 **(Spa)**

[Multiple liver abscesses, peritonitis and acute enteritis caused by Klebsiella pneumoniae (letter)] Bujanda L, et al. **Gastroenterol Hepatol** 1996 Jun–Jul;19(6):336–7 **(Spa)**

[Development of spontaneous bacterial peritonitis in an experimental model in cirrhotic rats. Relationship with intestinal bacterial translocation] Martín L, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):632–6 (Eng. Abstr.) **(Spa)**

[Spontaneous bacterial peritonitis caused by Listeria monocytogenes] Pérez Roldán F, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):889–92 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Bacterial peritonitis in continuous ambulatory peritoneal dialysis: effect on dialysis on host defense mechanisms. Findon G, et al. **Am J Kidney Dis** 1995 Nov;26(5):765–73

Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Holzheimer RG, et al. **Arch Surg** 1995 Dec;130(12):1314–9; discussion 1319–20

CD4+ T cells mediate preexposure-induced increases in murine intraabdominal abscess formation. Sawyer RG, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):82–8

Synthesis and surface expression of ICAM-1 in polymorphonuclear neutrophilic leukocytes in normal subjects and during inflammatory disease. Elsner J, et al. **Immunobiology** 1995 Aug;193(5):456–64

Differential production of intracellular gamma interferon in alpha beta and gamma delta T-cell subpopulations in response to peritonitis. Berguer R, et al. **Infect Immun** 1995 Dec;63(12):4957–8

Colony-stimulating factor 1-dependent resident macrophages play a regulatory role in fighting Escherichia coli fecal peritonitis. Wiktor-Jedrzejczak W, et al. **Infect Immun** 1996 May;64(5):1577–81

Endogenous IL-10 protects mice from death during septic peritonitis. van der Poll T, et al. **J Immunol** 1995 Dec 1; 155(11):5397–401

Critical protective role of mast cells in a model of acute septic peritonitis [see comments] Echtenacher B, et al. **Nature** 1996 May 2;381(6577):75–7. Comment in: Nature 1996 May 2;381(6577):21–2.

Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Cameron JS. **Pediatr Nephrol** 1995 Oct;9(5):647–62 (203 ref.)

Complications linked to chronic peritoneal dialysis in children after kidney transplantation: experience of the Italian Registry of Pediatric Chronic Peritoneal Dialysis. Andreetta B, et al. **Perit Dial Int** 1996;16 Suppl 1:S570–3

Impaired initial cell reaction in CAPD-related peritonitis. Koopmans JG, et al. **Perit Dial Int** 1996;16 Suppl 1:S362–7

The cytokine network controlling peritoneal inflammation. Topley N. **Perit Dial Int** 1995;15(7 Suppl):S35–9; discussion S39–40 (39 ref.)

[Cytotoxic activity of murine peritoneal cavity cells during inflammation in vivo] Sukharev SA, et al. **Dokl Akad Nauk** 1995 Jul;343(3):403–5 **(Rus)**

METABOLISM

Nitrate in stable CAPD patients and during peritonitis. Douma CE, et al. **Adv Perit Dial** 1995;11:36–40

MCP-1 levels are elevated in peritonitis fluid from CAPD

patients due to secretion by peritoneal macrophages. Sach M, et al. **Adv Perit Dial** 1995;11:19–23

Changes in gut intramucosal pH and gut oxygen extraction ratio in a porcine model of peritonitis and hemorrhage. Antonsson JB, et al. **Crit Care Med** 1995 Nov; 23(11):1872–81

Gut intramucosal pH and intraluminal PO2 in a porcine model of peritonitis or haemorrhage. Antonsson JB, et al. **Gut** 1995 Dec;37(6):791–7

Resistance to natriuresis in patients with peritonitis carcinomatosa. Mimura Y, et al. **Horm Metab Res** 1996 Apr;28(4):183–6

Role of induced nitric oxide synthase and increased NO levels in zymosan peritonitis in the rat. Boughton-Smith NK, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S149–50

Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Török K, et al. **Inflamm Res** 1995 Jun;44(6):248–52

Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis. Pruimboom WM, et al. **Int J Immunopharmacol** 1995 May;17(5):375–84

Regulation of the transcription factor C/EBP alpha following peritoneal sepsis. Chapin RB, et al. **J Surg Res** 1995 Oct; 59(4):460–7

Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Davies SJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):498–506

Longitudinal changes in peritoneal equilibration test with or without peritonitis in children. Nishi A, et al. **Pediatr Nephrol** 1995 Oct;9(5):562–5

Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Pannekeet MM, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):217–25

Endothelin-1 expression in the small intestine during chronic peritonitis. Chou MC, et al. **Shock** 1995 Dec;4(6):411–4

Fibrinolysis in human peritoneum during operation. Holmdahl L, et al. **Surgery** 1996 Jun;119(6):701–5

Hypothesis: compartmentalization of cytokines in intraabdominal infection. Schein M, et al. **Surgery** 1996 Jun; 119(6):694–700 (80 ref.)

MICROBIOLOGY

Spontaneous bacterial peritonitis. Planas R, et al. **Acta Gastroenterol Belg** 1995 May-Aug;58(3–4):297–310 (100 ref.)

Prevalence of associated infections in community-acquired spontaneous bacterial peritonitis. Ho H, et al. **Am J Gastroenterol** 1996 Apr;91(4):735–42

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)

Parvovirus B19 as a trigger for spontaneous bacterial peritonitis in a patient with cirrhotic ascites. Yamamoto T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1857–9

Peritonitis caused by Oerskovia xanthineolytica in a patient on chronic ambulatory peritoneal dialysis (CAPD) [letter] Borra S, et al. **Am J Kidney Dis** 1996 Mar;27(3):458

Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)

Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Goldie SJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):86–91

Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Horn S, et al. **Am J Kidney Dis** 1996 Mar;27(3):441–3 (22 ref.)

Typing of coagulase-negative staphylococci from peritonitis in CAPD-patients by the PhP-CS system and REA. Jung K, et al. **APMIS** 1995 Sep;103(9):679–85

Clostridium perfringens spontaneous bacterial peritonitis [letter] Harris T, et al. **Aust N Z J Med** 1995 Aug;25(4):366

Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis. Croco JL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S339–41

Clinical correlates of anaerobic bacteriology in peritonitis. Wilson SE, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S251–6 (38 ref.)

Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Montenegro J, et al. **Clin Nephrol** 1995 Jul;44(1):60–3

Evaluation of aerobic Bactec 6A non-resin- and 16A resin-containing media for the recovery of microorganisms causing peritonitis. Blondeau JM, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):361–8

Intraperitoneal micro-organisms and the severity of peritonitis. Schoeffel U, et al. **Eur J Surg** 1995 Jul; 161(7):501–8

Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Guarner C, et al. **Gastroenterologist** 1995 Dec;3(4):311–28 (153 ref.)

Fungal peritonitis complicating peritoneal dialysis. Banerjee S, et al. **Indian Pediatr** 1995 Jun;32(6):693–7

Comparison of BacT/Alert blood culture bottles with lytic media for culture of peritoneal dialysis fluid. Wüst J, et al. **Infection** 1995 Nov-Dec;23(6):378–9

In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis. Cormican MG, et al. **J Chemother** 1995 Jun;7(3):197–200

Spontaneous peritonitis caused by Streptococcus bovis: search for colonic neoplasia [letter] Ackerman Z, et al. **J Clin Gastroenterol** 1995 Oct;21(3):263

Continuous ambulatory peritoneal dialysis-associated peritonitis as a model device-related infection: phenotypic adaptation, the staphylococcal cell envelope and infection. Williams P, et al. **J Hosp Infect** 1995 Jun;30 Suppl:35–43

Biomaterial-associated infection with Candida albicans in mice. Różalska B, et al. **Microbiol Immunol** 1995; 39(7):443–50

Acremonium kiliense peritonitis complicating continuous ambulatory peritoneal dialysis: report of two cases. Lopes JO, et al. **Mycopathologia** 1995 Aug;131(2):83–5

Haemophilus influenzae: a cause of peritonitis in peritoneal dialysis. Neuhaus TJ, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):199–200

Lysis-centrifugation method in peritonitis diagnosis [letter] Oliva JA, et al. **Nephrol Dial Transplant** 1995;10(7):1257–8

Rhodococcus peritonitis in continuous ambulatory peritoneal dialysis. Tang S, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):201–2

Aspergillus peritonitis in peritoneal dialysis: case report and a review of the literature [see comments] Tanis BC, et al. **Nephrol Dial Transplant** 1995;10(7):1240–3. Comment in: Nephrol Dial Transplant 1995;10(7):1124–5.

Aspergillus peritonitis in peritoneal dialysis [letter] Tanis BC, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):752

Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Hanevold CD, et al. **Pediatr Nephrol** 1995 Oct;9(5):609–11

Predisposing and prognostic factors of fungal peritonitis in peritoneal dialysis [letter] Bordes A, et al. **Perit Dial Int** 1995 Jul-Sep;15(6):275–6

Pseudomonas peritonitis treated with simultaneous catheter replacement and removal [letter] Mayo RR, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):389–90

Complicated multiorganism peritonitis [clinical conference] Piraino B, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):394–400

Peritonitis due to Penicillium sp in a patient receiving continuous ambulatory peritoneal dialysis. Fahhoum J, et al. **South Med J** 1996 Jan;89(1):87–8

Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Burnett RJ, et al. **Surgery** 1995 Oct;118(4):716–21; discussion 721–3

Prophylaxis against spontaneous bacterial peritonitis. Is trimethoprim-sulfamethoxazole the answer? Xavier S, et al. **Trop Gastroenterol** 1996 Jan-Mar;17(1):61–3

Primary peritonitis in previously healthy children—clinical and bacteriological features. Ofori-Kuma FK, et al. **West Afr J Med** 1996 Jan-Mar;15(1):1–5

[Peritonitis in continuous ambulatory peritoneal dialysis. Culture of peritoneal dialysate fluid] Møller JK, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2538–41 (Eng. Abstr.) **(Dan)**

[Spontaneous bacterial peritonitis: diagnostic and prognostic aspects] Henz S, et al. **Schweiz Med Wochenschr** 1995 Dec 9;125(49):2379–86 (Eng. Abstr.) **(Ger)**

[Venereal perihepatitis: Fitz-Hugh-Curtis syndrome] Durastante V, et al. **Minerva Chir** 1995 Sep;50(9):793–8 (Eng. Abstr.) **(Ita)**

[Two case of Fitz-Hugh-Curtis syndrome with Chlamydia trachomatis infection] Mizuguchi Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):195–200 **(Jpn)**

[Features of the clinical course of anaerobic peritonitis] Iareshko NA, et al. **Klin Khir** 1995;(4):45 **(Rus)**

[Bacterial virulence factors and their role in the pathogenesis of pyogenic infections of the abdominal cavity and mediastinum] Kotulová D, et al. **Bratisl Lek Listy** 1995 May;96(5):241–4 (Eng. Abstr.) **(Slo)**

[Comparative study of 2 culture methods by seeding, in hemoculture bottles, the dialysis fluid from patients in continuous ambulatory peritoneal dialysis] Echeverría MJ, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):506–10 (Eng. Abstr.) **(Spa)**

MORTALITY

Counterprotective effect of erythrocytes in experimental bacterial peritonitis is due to scavenging of nitric oxide and reactive oxygen intermediates. Kim YM, et al. **Infect Immun** 1996 Aug;64(8):3074–80

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

PARASITOLOGY

A very rare case of continuous ambulatory peritoneal dialysis peritonitis caused by Anisakis larva [letter] Ohta M, et al. **Am J Gastroenterol** 1995 Oct;90(10):1902–3

PATHOLOGY

Luteinized thecoma with sclerosing peritonitis. Werness BA. **Arch Pathol Lab Med** 1996 Mar;120(3):303–6 (9 ref.)

Sequestration patterns of transfused rat neutrophilic granulocytes under normal and inflammatory conditions. Løvås K, et al. **Eur J Haematol** 1996 Apr;56(4):221–9

Intestinal mucosal injury during porcine faecal peritonitis. Wollert S, et al. **Eur J Surg** 1995 Oct;161(10):741–50

Markers of peritoneal membrane status. Krediet RT, et al. **Perit Dial Int** 1996;16 Suppl 1:S42–9 (89 ref.)

[The repopulation and regranulation of tissue basophils at the site of acute inflammation] Klimenko NA, et al. **Morfologiia** 1996;109(1):51–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Recovery of gastrointestinal function after renal transplantation in patients with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis [letter; comment] Bhandari S. **Am J Kidney Dis** 1996 Apr; 27(4):604. Comment on: Am J Kidney Dis 1995 Oct;26(4):658–61.

Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Tighe D, et al. **Crit Care Med** 1995 Dec;23(12):1997–2007

Influence of bradykinin in gastrointestinal disorders and visceral pain induced by acute or chronic inflammation in rats. Julia V, et al. **Dig Dis Sci** 1995 Sep;40(9):1913–21

Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Burger JA, et al. **Eur J Surg** 1995 Sep;161(9):647–53

Factors associated with hyperdynamic or hypodynamic circulation and role of platelet-activating factor in hemodynamic alterations in bacterial peritonitis in conscious rats. Novo C, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):937–42

The natural history of meconium peritonitis diagnosed in utero. Dirkes K, et al. **J Pediatr Surg** 1995 Jul;30(7):979–82

[Sodium diclofenac effect, after interruption of the stercoraceous peritonitis, on the rat colon. Study of mechanical resistance and collagen concentration] Verderese LR, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep-Oct; 50(5):254–8 (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

The impact of exit-site care and catheter design on the incidence of catheter-related infections. Jones LL, et al. **Adv Perit Dial** 1995;11:302–5

Improved training techniques and UltraBag system resulted in lowered peritonitis rate in an inner-city population. Rubin JE, et al. **Adv Perit Dial** 1995;11:208–9

New options for spontaneous bacterial prophylaxis: costly or cost effective? Levy MJ, et al. **Am J Gastroenterol** 1996 May;91(5):1050–1

Trimethoprim—sulfamethoxazole prophylaxis of spontaneous bacterial peritonitis [letter; comment] Nishioka SD. **Ann Intern Med** 1995 Nov 15;123(10):810. Comment on: Ann Intern Med 1995 Apr 15;122(8):595–8.

Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Rolachon A, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1171–4

Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)

Prophylaxis against spontaneous bacterial peritonitis. Is trimethoprim-sulfamethoxazole the answer? Xavier S, et al. **Trop Gastroenterol** 1996 Jan-Mar;17(1):61–3

[Change in the non-specific anti-infection resistance of the body exposed to cholinergic stimulation] Zabrodskiĭ PF. **Biull Eksp Biol Med** 1995 Aug;120(8):164–6 **(Rus)**

RADIOGRAPHY

Peritoneal calcification associated with continuous ambulatory peritoneal dialysis. Miller FH, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):541–2

RADIONUCLIDE IMAGING

Contribution of phagocytic cells and bacteria to the accumulation of technetium-99m labelled polyclonal human immunoglobulin at sites of inflammation. Calame W, et al. **Eur J Nucl Med** 1995 Jul;22(7):638–44

SURGERY

Endoscopic management of spontaneous bile duct perforation and bile peritonitis complicating term pregnancy. Thaggard WG, et al. **Am J Gastroenterol** 1995 Nov;90(11):2054–5

Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. Saha SK. **Dig Dis Sci** 1996 Jul;41(7):1313–8

Medical treatment of postappendectomy intraperitoneal abscesses in children. Héloury Y, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):149–51

Primary small bowel anastomosis in generalised peritonitis. de Graaf JS, et al. **Eur J Surg** 1996 Jan;162(1):55–8

Laparostomy in the treatment of acute purulent peritonitis. Damianliev R, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):90

The role of surgery and itraconazole in Aspergillus peritonitis in CAPD [letter] Kitiyakara C, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498

Ostomy or intestinal anastomosis in cases of peritonitis. Rasslan S, et al. **Rev Paul Med** 1995 Nov-Dec; 113(6):1017–21

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

[Effects of intraperitoneal insufflation on hematogenous seeding of abdominal infections. Preliminary results of an experimental study in rats] Dugue L, et al. **Ann Chir** 1995; 49(5):423–6 (Eng. Abstr.) **(Fre)**

[Abdominal surgical emergencies in human immunodeficiency virus (HIV) infected patients. Apropos of 34 cases] Hammoud R, et al. **Ann Chir** 1995;49(10):922–7 (Eng. Abstr.) **(Fre)**

[Severe parietal cellulitis following laparoscopy for peritonitis caused by perforated duodenal ulcer (letter)] Samama G, et al. **Gastroenterol Clin Biol** 1996 Feb; 20(1):116–8 **(Fre)**

[Between extremes—plea for differentiated surgical therapy of intra-abdominal infections (editorial; comment)] Schumpelick V. **Leber Magen Darm** 1996 May;26(3):130–1 . Comment on: Leber Magen Darm 1996 May;26(3):144–8. Comment on: Leber Magen Darm 1996 May;26(3):151–4. **(Ger)**

[Differentiated surgical therapy of diffuse peritonitis—a prospective study (see comments)] Winkeltau GJ, et al. **Leber Magen Darm** 1996 May;26(3):144–8 (Eng. Abstr.). Comment in: Leber Magen Darm 1996 May;26(3):130–1. **(Ger)**

[Metabolic components of anesthesiological provision in surgery of suppurative-inflammatory diseases of the abdominal cavity] Tumanian SV, et al. **Anesteziol Reanimatol** 1995 Sep-Oct;(5):31–4 (Eng. Abstr.) **(Rus)**

[Open method of the treatment in acute diffuse suppurative peritonitis] Anisimov AIu. **Klin Khir** 1995;(4):18–20 **(Rus)**

[A method of laparotomy in the treatment of peritonitis] Komarov NV, et al. **Klin Khir** 1995;(4):42 **(Rus)**

[The use of laparostomy in treating peritonitis] Komarov NV, et al. **Klin Khir** 1995;(9–10):45–8 (45 ref.) **(Rus)**

[Results of treatment of diffuse peritonitis in data from the surgery department of St. Barbara Hospital in Rožňava] Paškan J, et al. **Bratisl Lek Listy** 1995 May;96(5):259–61 (Eng. Abstr.) **(Slo)**

THERAPY

Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Locatelli A, et al. **Adv Perit Dial** 1995;11:176–8

Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis. Huang TP, et al. **Am J Nephrol** 1995;15(4):312–7

Laparoscopic management of generalized peritonitis due to perforated colonic diverticula. O'Sullivan GC, et al. **Am J Surg** 1996 Apr;171(4):432–4

Management of secondary peritonitis. Wittmann DH, et al. **Ann Surg** 1996 Jul;224(1):10–8 (76 ref.)

Interleukin 10 reduces mortality from severe peritonitis in mice. Kato T, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1336–40

Prognosis and treatment of peritonitis. Do we need new scoring systems? Koperna T, et al. **Arch Surg** 1996 Feb; 131(2):180–6

Adjuvant treatments for serious infections [letter; comment] Schein M, et al. **Crit Care Med** 1996 Mar;24(3):549–51. Comment on: Crit Care Med 1995 Jun;23(6):989–91.

Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. Dunne JR, et al. **J Surg Res** 1996 Mar; 61(2):348–54

Large-volume intraoperative peritoneal lavage with an assistant device for treatment of peritonitis caused by blunt traumatic rupture of the small bowel. Sugimoto K, et al. **J Trauma** 1995 Oct;39(4):689–92

Nutritional profile of continuous ambulatory peritoneal dialysis patients. Jacob V, et al. **Nephron** 1995;71(1):16–22

Infectious complications in pediatric patients treated with chronic peritoneal dialysis (CPD). Edefonti A, et al. **Perit Dial Int** 1996;16 Suppl 1:S543–7 (11 ref.)

Effectiveness of low-dose, intraperitoneal human gamma globulin in the treatment of refractory CAPD peritonitis [letter] Ersoy FF, et al. **Perit Dial Int** 1996 May–Jun; 16(3):328–9

Successful pregnancy complicated by peritonitis in a 35- year old CAPD patient. Tison A, et al. **Perit Dial Int** 1996;16 Suppl 1:S489–91

[The management of severe pelvioperitonitis of an inflammatory genital origin] Pranchev N. **Akush Ginekol (Sofiia)** 1995;34(2):55–7 (Eng. Abstr.) **(Bul)**

[Role of energy metabolism in nutrition management of critically ill patients] Ren J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):346–8, 382–3 (Eng. Abstr.) **(Chi)**

[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer] Fujimura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1610–2 (Eng. Abstr.) **(Jpn)**

[Experience and problems with home parenteral nutrition for patients with peritonitis carcinomatosa] Takano H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:389–93 (Eng. Abstr.) **(Jpn)**

[Use of planned intermittent peritoneal lavage (open abdomen) in severe forms of peritonitis due to gynecologic-obstetric procedures] Janczy J. **Ginekol Pol** 1995 Jun;66(6):335–9 (Eng. Abstr.) **(Pol)**

[Hyperbaric oxygenation and current methods of detoxication in multimodal intensive therapy of diffuse peritonitis] Vasil'kov VG, et al. **Anesteziol Reanimatol** 1995 Sep-Oct;(5):23–7 (Eng. Abstr.) **(Rus)**

[Differentiated approach to repeated practicable cleansing of the abdominal cavity in patients with acute diffuse peritonitis] Bondarev VI, et al. **Klin Khir** 1995;(4):16–7 **(Rus)**

[The effect of hemocarbosorption and biohemosorption on oxygen metabolism and intoxication in patients with peritonitis in multiple organ failure] Petrenko TF, et al. **Vestn Khir Im I I Grek** 1992 Nov-Dec;149(11–12):372–7 (Eng. Abstr.) **(Rus)**

[The use of a low-frequency magnetic field and intraorganic electrophoresis in treating peritonitis in children] Tiktins'kyi VS, et al. **Klin Khir** 1995;(6):25–6 **(Ukr)**

ULTRASONOGRAPHY

The natural history of meconium peritonitis diagnosed in utero. Dirkes K, et al. **J Pediatr Surg** 1995 Jul;30(7):979–82

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

VETERINARY

Evaluation of the pathogenesis of vagus indigestion in cows with traumatic reticuloperitonitis. Rehage J, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1607–11

Aortic thromboembolism associated with traumatic reticuloperitonitis in a downer cow. Du Preez ER, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):254–5

Abdominal drainage in ten dogs with septic peritonitis. Maarschalkerweerd RJ, et al. **Vet Q** 1995 Apr;17 Suppl 1:S10

Ingestion of metal objects by ostriches (Struthio camelus). Deeming DC, et al. **Vet Rec** 1995 Jul 22;137(4):99–100

PERITONITIS, TUBERCULOUS see **TUBERCULOSIS, PERITONEAL**

PERITONSILLAR ABSCESS

COMPLICATIONS

Mediastinitis–a rare complication of a peritonsillar abscess. Nielsen TR, et al. **J Laryngol Otol** 1996 Feb;110(2):175–6

DRUG THERAPY

The microbiology and antibiotic treatment of peritonsillar abscesses. Prior A, et al. **Clin Otolaryngol** 1995 Jun; 20(3):219–23

ETIOLOGY

A case of multiple post-anginal complications. Kuczkowski J, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):51–5

Peritonsillar abscess following tonsillectomy. Cannon CR, et al. **J Miss State Med Assoc** 1996 May;37(5):577–9

Quinsy following tonsillectomy. Bugti AH. **JPMA J Pak Med Assoc** 1996 Jan;46(1):19

IMMUNOLOGY

Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with peritonsillar cellulitis and abscess. Brook I, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S220–1

MICROBIOLOGY

The microbiology and antibiotic treatment of peritonsillar abscesses. Prior A, et al. **Clin Otolaryngol** 1995 Jun; 20(3):219–23

Microbiological features and pathogenesis of peritonsillar abscesses. Mitchelmore IJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):870–7

Staphylococcus aureus peritonsillar abscess in an 11-week old infant. Akhtar MJ, et al. **J Laryngol Otol** 1996 Jan; 110(1):78–80 (22 ref.)

SURGERY

A prospective study of anaesthesia for quinsy tonsillectomy. Fagan JJ, et al. **Anaesthesia** 1995 Sep;50(9):783–5

Anaesthesia for quinsy tonsillectomy [letter] Ravalia A, et al. **Anaesthesia** 1996 Mar;51(3):292–3

[Present-day aspects of tonsillar problems] Antoniv VF, et al. **Vestn Otorinolaringol** 1995 Nov-Dec;(6):43–5 (Eng. Abstr.) **(Rus)**

[Abscess tonsillectomy in acute parapharyngitis] Bobrov VM. **Vestn Otorinolaringol** 1996 Mar-Apr;(2):36–8 **(Rus)**

PERIVASCULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

PERIVENTRICULAR LEUKOMALACIA see **LEUKOMALACIA, PERIVENTRICULAR**

PERMEABILITY

Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Broekemeier KM, et al. **Biochemistry** 1995 Dec 19;34(50):16440–9

Membrane permeabilization induced by cytolytic delta-endotoxin CytA from Bacillus thuringiensis var. israelensis. Butko P, et al. **Biochemistry** 1996 Sep 3; 35(35):11355–60

Permeability of the blood-brain barrier to the neurotensin8–13 analog NT1. Banks WA, et al. **Brain Res** 1995 Oct 9;695(1):59–63

Membrane permeability. **Curr Opin Cell Biol** 1996 Aug; 8(4):575–86

Membrane permeability [editorial] Jan LY, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):449–51

Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. Brett FM, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):766–75

Stereoselective hydrolysis and penetration of propranolol prodrugs: in vitro evaluation using hairless mouse skin. Ahmed S, et al. **J Pharm Sci** 1995 Jul;84(7):877–83

DRUG EFFECTS

Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. Deli MA, et al. **J Neurosci Res** 1995 Aug 15;41(6):717–26

Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. Rubas W, et al. **J Pharm Sci** 1996 Feb;85(2):165–9

A mechanistic study of the effects of the 1-alkyl-2-pyrrolidones on bilayer permeability of stratum corneum lipid liposomes: a comparison with hairless mouse skin studies. Yoneto K, et al. **J Pharm Sci** 1995 Jul; 84(7):853–61

Conformationally biased analogs of human C5a mediate changes in vascular permeability. Kawatsu R, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):432–40

Nitric oxide modulates blood-brain barrier permeability during infections with an inactivated bacterium. Shukla A, et al. **Neuroreport** 1995 Aug 21;6(12):1629–32

Vascular permeability to growth hormone in the rat central nervous system after focal spinal cord injury. Influence of a new anti-oxidant H 290/51 and age. Mustafa A, et al. **Neurosci Res** 1995 Sep;23(2):185–94

PERMEABILITY, CAPILLARY see **CAPILLARY PERMEABILITY**

PERMEABILITY, CELL MEMBRANE see **CELL MEMBRANE PERMEABILITY**

PERMEABILITY, MICROVASCULAR see **CAPILLARY PERMEABILITY**

PERMEASES

A family of homologous substrate-binding proteins with a broad range of substrate specificity and dissimilar biological functions. Wu LF, et al. **Biochimie** 1995;77(9):744–50

ANTAGONISTS & INHIBITORS

Induction of lipid-protein mismatch by xenobiotics: kinetic cooperativity. Sandermann H Jr, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):219–25

A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter. Fremeau RT Jr, et al. **Mol Pharmacol** 1996 Jun;49(6):1033–41

BIOSYNTHESIS

Chemostat selection of an Escherichia coli mutant containing permease with enhanced lactose affinity. Tsen SD, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):351–7

MIG1-dependent and MIG1-independent glucose regulation of MAL gene expression in Saccharomyces cerevisiae. Hu Z, et al. **Curr Genet** 1995 Aug;28(3):258–66

Effects of potassium on the expression and stability of the general amino acid permease of Saccharomyces. Rosas G, et al. **Folia Microbiol (Praha)** 1994;39(6):543

CHEMISTRY

Probing the conformation of the lactose permease of Escherichia coli by in situ site-directed sulfhydryl modification. Frillingos S, et al. **Biochemistry** 1996 Apr 2;35(13):3950–6

Monoclonal antibody 4B1 alters the pKa of a carboxylic acid at position 325 (helix X) of the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Aug 6;35(31):10166–71

Use of designed metal-binding sites to study helix proximity in the lactose permease of Escherichia coli. 1. Proximity of helix VII (Asp237 and Asp240) with helices X (Lys319) and XI (Lys358). He MM, et al. **Biochemistry** 1995 Dec 5;34(48):15661–6

Use of designed metal-binding sites to study helix proximity in the lactose permease of Escherichia coli. 2. Proximity of helix IX (Arg302) with helix X (His322 and Glu325). He MM, et al. **Biochemistry** 1995 Dec 5;34(48):15667–70

Membrane topology of the melibiose permease of Escherichia coli studied by melB-phoA fusion analysis. Pourcher T,

et al. **Biochemistry** 1996 Apr 2;35(13):4161–8

Association between the amino- and carboxyl-terminal halves of lactose permease is specific and mediated by multiple transmembrane domains. Sahin-Tóth M, et al. **Biochemistry** 1996 Feb 13;35(6):2016–21

Membrane topology of helices VII and XI in the lactose permease of Escherichia coli studied by lacY-phoA fusion analysis and site-directed spectroscopy. Ujwal ML, et al. **Biochemistry** 1995 Nov 14;34(45):14909–17

Physiological evidence for an interaction between Glu-325 and His-322 in the lactose carrier of Escherichia coli. Lee JI, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):111–8

Structure-function analysis of the proline permease (PRNB) of the filamentous fungus Aspergillus nidulans. Tazebay U, et al. **Folia Microbiol (Praha)** 1994;39(6):551

Topology of the phenylalanine-specific permease of Escherichia coli. Pi J, et al. **J Bacteriol** 1996 May; 178(9):2650–5

A phospholipid acts as a chaperone in assembly of a membrane transport protein. Bogdanov M, et al. **J Biol Chem** 1996 May 17;271(20):11615–8

Function of the duplicated IIB domain and oligomeric structure of the fructose permease of Escherichia coli. Charbit A, et al. **J Biol Chem** 1996 Apr 26; 271(17):9997–10003

Structural topology of transmembrane helix 10 in the lactose permease of Escherichia coli. Goswitz VC, et al. **J Biol Chem** 1996 Sep 6;271(36):21927–32

Evidence that transmembrane segment 2 of the lactose permease is part of a conformationally sensitive interface between the two halves of the protein. Jessen-Marshall AE, et al. **J Biol Chem** 1996 Jan 19;271(3):1400–4

Membrane topology analysis of the Escherichia coli cytosine permease. Danielsen S, et al. **Microbiology** 1995 Nov;141 (Pt 11):2905–13

Topological analysis of the lysine-specific permease of Escherichia coli. Ellis J, et al. **Microbiology** 1995 Aug;141 (Pt 8):1927–35

Distance determination in proteins using designed metal ion binding sites and site-directed spin labeling: application to the lactose permease of Escherichia coli. Voss J, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12300–3

Helix packing of lactose permease in Escherichia coli studied by site-directed chemical cleavage. Wu J, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9186–90

Crystal structure of the dipeptide binding protein from Escherichia coli involved in active transport and chemotaxis. Dunten P, et al. **Protein Sci** 1995 Nov; 4(11):2327–34

Fluorescence of native single-Trp mutants in the lactose permease from Escherichia coli: structural properties and evidence for a substrate-induced conformational change. Weitzman C, et al. **Protein Sci** 1995 Nov;4(11):2310–8

Phylogenetic analyses of the ATP-binding constituents of bacterial extracytoplasmic receptor-dependent ABC-type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

GENETICS

The lactose transporter in Leuconostoc lactis is a new member of the LacS subfamily of galactoside-pentose-hexuronide translocators. Vaughan EE, et al. **Appl Environ Microbiol** 1996 May;62(5):1574–82

Characterization of plasmid-encoded citrate permease (citP) genes from Leuconostoc species reveals high sequence conservation with the Lactococcus lactis citP gene. Vaughan EE, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):3172–6

Biogenesis and topology of integral membrane proteins: characterization of lactose permease-chloramphenicol acetyltransferase hybrids. Zelazny A, et al. **Biochemistry** 1996 Aug 20;35(33):10872–8

BAP2, a gene encoding a permease for branched-chain amino acids in Saccharomyces cerevisiae. Grauslund M, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):275–80

Nucleotide sequence and features of the Bacillus licheniformis gnt operon. Yoshida K, et al. **DNA Res** 1994; 1(4):157–62

Transport of lactate and its regulation in Saccharomyces cerevisiae mutants deficient in specific metabolic steps. Casal M, et al. **Folia Microbiol (Praha)** 1994;39(6):512

Candida albicans gene CAN1 is highly homologous to other yeast and E. coli genes coding for amino acid permeases. Sychrová H, et al. **Folia Microbiol (Praha)** 1994; 39(6):547–51

Amino acids induce expression of BAP2, a branched-chain amino acid permease gene in Saccharomyces cerevisiae. Didion T, et al. **J Bacteriol** 1996 Apr;178(7):2025–9

The gntP gene of Escherichia coli involved in gluconate uptake. Klemm P, et al. **J Bacteriol** 1996 Jan;178(1):61–7

Derived structure of the putative sialic acid transporter from Escherichia coli predicts a novel sugar permease domain. Martinez J, et al. **J Bacteriol** 1995 Oct;177(20):6005–10

Two transcription factors, Gln3p and Nil1p, use the same GATAAG sites to activate the expression of GAP1 of Saccharomyces cerevisiae. Stanbrough M, et al. **J Bacteriol** 1996 Apr;178(8):2465–8

Engineering the lac permease for purification and crystallization. Prive GG, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):29–34 (28 ref.)

Regulation of codBA operon expression in Escherichia coli by UTP-dependent reiterative transcription and UTP-sensitive transcriptional start site switching. Qi F, et al. **J Mol Biol** 1995 Dec 8;254(4):552–65

Transcriptional regulation of the Escherichia coli rhaT gene. Via P, et al. **Microbiology** 1996 Jul;142 (Pt 7):1833–40

Inositol transport in Saccharomyces cerevisiae is regulated by transcriptional and degradative endocytic mechanisms during the growth cycle that are distinct from inositol-induced regulation. Robinson KS, et al. **Mol Biol Cell** 1996 Jan;7(1):81–9

Effects of mutations in the Saccharomyces cerevisiae RNA14, RNA15, and PAP1 genes on polyadenylation in vivo. Mandart E, et al. **Mol Cell Biol** 1995 Dec; 15(12):6979–86

Transcriptional activation of the citrate permease P gene of Lactococcus lactis biovar diacetylactis by an insertion sequence-like element present in plasmid pCIT264. López de Felipe F, et al. **Mol Gen Genet** 1996 Mar 7;250(4):428–36

A permease-oxidase complex involved in high-affinity iron uptake in yeast [see comments] Stearman R, et al. **Science** 1996 Mar 15;271(5255):1552–7. Comment in: Science 1996 Mar 15;271(5255):1510–2.

The mae1 gene of Schizosaccharomyces pombe encodes a permease for malate and other C4 dicarboxylic acids. Grobler J, et al. **Yeast** 1995 Dec;11(15):1485–91

IMMUNOLOGY

Identification of the epitope for monoclonal antibody 4B1 which uncouples lactose and proton translocation in the lactose permease of Escherichia coli. Sun J, et al. **Biochemistry** 1996 Jan 23;35(3):990–8

ISOLATION & PURIFICATION

Engineering the lac permease for purification and crystallization. Prive GG, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):29–34 (28 ref.)

METABOLISM

Functional integration of a polytopic membrane protein of E. coli requires the bacterial signal recognition particle. MacFarlane J, et al. **Biochem Soc Trans** 1995 Nov; 23(4):560S

Monoclonal antibody 4B1 alters the pKa of a carboxylic acid at position 325 (helix X) of the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Aug 6;35(31):10166–71

Cysteine-scanning mutagenesis of helix VI and the flanking hydrophilic domains on the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Apr 23; 35(16):5333–8

Association between the amino- and carboxyl-terminal halves of lactose permease is specific and mediated by multiple transmembrane domains. Sahin-Tóth M, et al. **Biochemistry** 1996 Feb 13;35(6):2016–21

Purification and functional characterization of the C-terminal half of the lactose permease of Escherichia coli. Wu J, et al. **Biochemistry** 1996 Apr 23;35(16):5213–9

Alteration of Na(+)-coupled transport in site-directed mutants of the melibiose carrier of Escherichia coli. Franco PJ, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):240–8

Molecular biology of the lactose carrier of Escherichia coli. Varela MF, et al. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):21–34 (120 ref.)

The functional integration of a polytopic membrane protein of Escherichia coli is dependent on the bacterial signal-recognition particle. Macfarlane J, et al. **Eur J Biochem** 1995 Nov 1;233(3):766–71

In vivo phosphorylation of the purine/cytosine permease from the plasma membrane of the yeast Saccharomyces cerevisiae. Pinson B, et al. **Eur J Biochem** 1996 Jul 15; 239(2):439–44

Ser57 in the Na+/proline permease of Escherichia coli is critical for high-affinity proline uptake. Quick M, et al. **Eur J Biochem** 1996 Aug 1;239(3):732–6

Identification of a third yeast mitochondrial Tom protein with tetratrico peptide repeats. Bömer U, et al. **FEBS Lett** 1996 Mar 11;382(1-2):153–8

Endocytose and degradation of the uracil permease of S. cerevisiae under stress conditions: possible role of ubiquitin. Volland C, et al. **Folia Microbiol (Praha)** 1994;39(6):554–7

The fbpABC locus of Neisseria gonorrhoeae functions in the periplasm-to-cytosol transport of iron. Adhikari P, et al. **J Bacteriol** 1996 Apr;178(7):2145–9

Basic amino acid transport in plasma membrane vesicles of Penicillium chrysogenum. Hillenga DJ, et al. **J Bacteriol** 1996 Jul;178(14):3991–5

Identification of a site in the phosphocarrier protein, HPr, which influences its interactions with sugar permeases of the bacterial phosphotransferase system: kinetic analyses employing site-specific mutants. Koch S, et al. **J Bacteriol** 1996 Feb;178(4):1126–33

Characterization of the glucose-induced inactivation of maltose permease in Saccharomyces cerevisiae. Medintz I, et al. **J Bacteriol** 1996 Apr;178(8):2245–54

Liganded and unliganded receptors interact with equal affinity with the membrane complex of periplasmic permeases, a subfamily of traffic ATPases. Ames GFL, et al. **J Biol Chem** 1996 Jun 14;271(24):14264–70

Chaperonin-promoted post-translational membrane insertion of a multispanning membrane protein lactose permease. Bochkareva E, et al. **J Biol Chem** 1996 Sep 6; 271(36):22256–61

Kinetics and specificity of a H+/amino acid transporter from Arabidopsis thaliana. Boorer KJ, et al. **J Biol Chem** 1996 Jan 26;271(4):2213–20

Substrate specificity of the Escherichia coli 4-aminobutyrate carrier encoded by gabP. Uptake and counterflow of structurally diverse molecules. Brechtel CE, et al. **J Biol Chem** 1996 Jan 12;271(2):783–8

Ubiquitination mediated by the Npi1p/Rsp5p ubiquitin-protein ligase is required for endocytosis of the yeast uracil permease. Galan JM, et al. **J Biol Chem** 1996 May 3;271(18):10946–52

Unidirectional reconstitution into detergent-destabilized liposomes of the purified lactose transport system of Streptococcus thermophilus. Knol J, et al. **J Biol Chem** 1996 Jun 28;271(26):15358–66

NPI1, an essential yeast gene involved in induced degradation of Gap1 and Fur4 permeases, encodes the Rsp5 ubiquitin-protein ligase. Hein C, et al. **Mol Microbiol** 1995 Oct;18(1):77–87

Leaf permease1 gene of maize is required for chloroplast development. Schultes NP, et al. **Plant Cell** 1996 Mar; 8(3):463–75

Enterococcus faecalis pheromone binding protein, PrgZ, recruits a chromosomal oligopeptide permease system to import sex pheromone cCF10 for induction of conjugation. Leonard BA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):260–4

Distance determination in proteins using designed metal ion binding sites and site-directed spin labeling: application to the lactose permease of Escherichia coli. Voss J, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12300–3

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.). Comment on: Science 1996 Mar 15;271(5255):1552–7.

A permease-oxidase complex involved in high-affinity iron uptake in yeast [see comments] Stearman R, et al. **Science** 1996 Mar 15;271(5255):1552–7. Comment in: Science 1996 Mar 15;271(5255):1510–2.

The mae1 gene of Schizosaccharomyces pombe encodes a permease for malate and other C4 dicarboxylic acids. Grobler J, et al. **Yeast** 1995 Dec;11(15):1485–91

PHYSIOLOGY

The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine. Sweeney NJ, et al. **Infect Immun** 1996 Sep;64(9):3497–503

Interaction of Saccharomyces cerevisiae Pho2 with Pho4 increases the accessibility of the activation domain of Pho4. Shao D, et al. **Mol Gen Genet** 1996 Jun 12;251(3):358–64

PERMISSIVENESS

Gender and family as moderators of the relationship between music video exposure and adolescent sexual permissiveness. Strouse JS, et al. **Adolescence** 1995 Fall;30(119):505–21

Have I been a good parent? [editorial] Alberts M. **Iowa Med** 1995 Nov;85(11):453

PERODICTICUS POTTO see **LORISIDAE**

PEROMYSCUS

Ear biopsy location influences detection of Borrelia burgdorferi by PCR, but not by culture in naturally infected Peromyscus leucopus. Hofmeister EK, et al. **J Wildl Dis** 1995 Jul;31(3):345–51

Reactivity of white-footed mouse and raccoon sera to whole cell and recombinant antigens of Borrelia burgdorferi. Magnarelli LA, et al. **J Wildl Dis** 1995 Jul;31(3):339–44

Analyses of mammalian sera in enzyme-linked immunosorbent assays with different strains of Borrelia burgdorferi sensu lato. Magnarelli LA, et al. **J Wildl Dis** 1995 Apr;31(2):159–65

GENETICS

Two persistent LINE-1 lineages in Peromyscus have unequal rates of evolution. Casavant NC, et al. **Genetics** 1996 Apr; 142(4):1289–98

DNA sequence of the peromyscus leucopus MHC class II gene Aa (MhcPeleAa). Crew MD, et al. **Immunogenetics** 1996;43(5):323–4

Expressed Peromyscus maniculatus (Pema) MHC class I genes: evolutionary implications and the identification of a gene encoding a Qa1-like antigen. Crew MD, et al. **Immunogenetics** 1996;44(3):177–85

The molecular mechanism underlying the "rare allele phenomenon" in a subspecific hybrid zone of the California field mouse, Peromyscus californicus. Hoffman SM, et al. **J Mol Evol** 1995 Dec;41(6):1165–9

Retrotransposon Mys was active during evolution of the Peromyscus leucopus-maniculatus complex. Lee RN, et al. **J Mol Evol** 1996 Jan;42(1):44–51

METABOLISM

Mammalian class VI alcohol dehydrogenase. Novel types of the rodent enzymes. Höög JO, et al. **Adv Exp Med Biol** 1995;372:355–64

Alcohol dehydrogenase (ADH) isozymes in the AdhN/AdhN strain of Peromyscus maniculatus

(ADH-deermouse) and a possible role of class III ADH in alcohol metabolism. Haseba T, et al. **Biochem Genet** 1995 Oct;33(9-10):349-63

MICROBIOLOGY

Serendipity, science, and a new hantavirus [published erratum appears in FASEB J 1996 Jan;10(1):178] Wrobel S. **FASEB J** 1995 Oct;9(13):1247-54

PARASITOLOGY

Bot fly (Cuterebra fontinella fontinella) parasitism of cotton mice (Peromyscus gossypinus) on St. Catherines Island, Georgia. Durden LA. **J Parasitol** 1995 Oct;81(5):787-90

Population dynamics of two species of Eimeria (Apicomplexa: Eimeriidae) in deer mice (Peromyscus maniculatus): biotic and abiotic factors. Fuller CA. **J Parasitol** 1996 Apr;82(2):220-5

Larval density and feeding success of Ixodes scapularis on two species of Peromyscus. Hazler KR, et al. **J Parasitol** 1995 Dec;81(6):870-5

PHYSIOLOGY

Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195-200 (29 ref.)

Effects of bilateral adrenalectomy on initiation of fur growth cycles in the deer mouse (Peromyscus maniculatus). Garwood T, et al. **Lab Anim Sci** 1995 Oct;45(5):564-6

Sex differences in the expression and antagonism of swim stress-induced analgesia in deer mice vary with the breeding season. Kavaliers M, et al. **Pain** 1995 Dec; 63(3):327-34

Auditory-evoked brainstem responses in the torpid deermouse. Katbamna B, et al. **Physiol Behav** 1996 Jan; 59(1):189-94

VIROLOGY

Genetic and phylogenetic analyses of hantaviral sequences amplified from archival tissues of deer mice (Peromyscus maniculatus nubiterrae) captured in the eastern United States. Song JW, et al. **Arch Virol** 1996;141(5):959-67

Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, Peromyscus leucopus: genetic characterization of the M genome of New York virus. Hjelle B, et al. **J Virol** 1995 Dec;69(12):8137-41

Histopathology of Peromyscus leucopus naturally infected with pathogenic NY-1 hantaviruses: pathologic markers of HPS viral infection in mice. Lyubsky S, et al. **Lab Invest** 1996 Mar;74(3):627-33

PERONEAL NERVE

Peroneal nerve ganglion cyst. Spillane RM, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):682

Peroneal nerve entrapment in athletes. Mitra A, et al. **Ann Plast Surg** 1995 Oct;35(4):366-8

Peroneal nerve palsy after total knee arthroplasty. Assessment of predisposing and prognostic factors. Idusuyi OB, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):177-84

Entrapment neuropathy of the deep peroneal nerve associated with the extensor hallucis brevis. Kanbe K, et al. **J Foot Ankle Surg** 1995 Nov-Dec;34(6):560-2

Schwannoma of the superficial peroneal nerve presenting as web space pain. Laurencin CT, et al. **J Foot Ankle Surg** 1995 Nov-Dec;34(6):532-3

Recurrent ganglion cyst of the peroneal nerve: radiological and operative observations. Case report. Dubuisson AS, et al. **J Neurosurg** 1996 Feb;84(2):280-3

Proximal fibular osteochondroma with associated peroneal nerve palsy: a review of six cases. Cardelia JM, et al. **J Pediatr Orthop** 1995 Sep-Oct;15(5):574-7

Intrauterine onset of a mononeuropathy: peroneal neuropathy in a newborn with electromyographic findings at age one day compatible with prenatal onset. Jones HR Jr, et al. **Muscle Nerve** 1996 Jan;19(1):88-91

Peroneal nerve palsy in the athlete: a result of indirect trauma. Seckler MM, et al. **Orthopedics** 1996 Apr;19(4):345-7; discussion 347-8

Intraneural myxoid cyst of the common peroneal nerve. A rare cause of sciatic paralysis [letter] Maury F, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):534-6

[Mucoid pseudocyst of the common peroneal nerve. Value of MRI (report of a case)] Srour R, et al. **Neurochirurgie** 1996;42(1):66-70 (Eng. Abstr.) **(Fre)**

[Tibial nerve and fibular nerve paresis in pigs after intramuscular injection in the caudal thigh muscle (case report)] Hafner A, et al. **Tierarztl Prax** 1995 Oct; 23(5):452-6 (Eng. Abstr.) **(Ger)**

[Neuropathy of the fibular nerve in Sjögren's disease] Volkova GV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):87-8 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

The deep peroneal nerve in the foot and ankle: an anatomic study. Lawrence SJ, et al. **Foot Ankle Int** 1995 Nov; 16(11):724-8

INJURIES

Postoperative dropfoot after cementless total hip arthroplasty. Linclau L, et al. **Acta Orthop Belg** 1995; 61(4):271-7

Neurological complications of ankle arthroscopy. Ferkel RD, et al. **Arthroscopy** 1996 Apr;12(2):200-8

Ulnar and common peroneal nerve block revisited [letter] Souter AJ, et al. **Br J Anaesth** 1996 Apr;76(4):595-6

Paradoxical clinical consequences of peripheral nerve injury: conduction of nerve impulses does not occur across the site of injury immediately following nerve division and repair. McAllister RM, et al. **Br J Plast Surg** 1995 Sep; 48(6):371-83

Changes in expression of NR-1 and c-jun mRNA in rat lumbar spinal cord after neonatal common peroneal nerve crush. Hay C, et al. **Brain Res** 1995 Dec 15;704(1):145-50

Neurologic injury after vaccination in buttocks [letter] Marcuse EK, et al. **Can Med Assoc J** 1996 Aug 15; 155(4):374

Peroneal nerve palsy and compartment syndrome in bilateral femoral fractures. Carlson DA, et al. **Clin Orthop** 1995 Nov; (320):115-8

Use of spontaneous electromyography during revision and complex total hip arthroplasty. Sutherland CJ, et al. **J Arthroplasty** 1996 Feb;11(2):206-9

Intraoperative SSEP monitoring during external fixation procedures in the lower extremities. Makarov MR, et al. **J Pediatr Orthop** 1996 Mar-Apr;16(2):155-60

Does location matter in ulnar and common peroneal nerve block? McQuillan PM, et al. **Lancet** 1996 Aug 24; 348(9026):490-1

Peroneal motor nerve crush injury and hyperbaric oxygen effect. Santos PM, et al. **Laryngoscope** 1995 Oct; 105(10):1061-5

[The results of reconstructive microsurgical operations on the damaged common peroneal nerve and its deep branch in children] Govenko FS. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul-Sep;(3):20-1 (Eng. Abstr.) **(Rus)**

[Nerve injuries in rectal surgery] Räf L. **Lakartidningen** 1996 Apr 24;93(17):1649-50 **(Swe)**

PATHOLOGY

Compression of the deep branch of the peroneal nerve by the extensor hallucis brevis muscle: a variation of the anterior tarsal tunnel syndrome. Reed SC, et al. **Can J Surg** 1995 Dec;38(6):545-6

PHYSIOLOGY

Dynamic F wave from lower limbs: value and clinical application. Manganotti P, et al. **Electromyogr Clin Neurophysiol** 1995 Oct;35(6):323-9

Basic behavior of migratory Schwann cells in peripheral nerve regeneration. Torigoe K, et al. **Exp Neurol** 1996 Feb; 137(2):301-8

Single-channel analysis of a delayed rectifier K+ channel in Xenopus myelinated nerve. Koh DS, et al. **J Membr Biol** 1996 Feb;149(3):221-32

Morphological plasticity of axotomized retinal ganglion cells following intravitreal transplantation of a peripheral nerve segment. Lei JL, et al. **J Neurocytol** 1995 Jul;24(7):497-506

Influence of peripheral nerve grafts on the expression of GAP-43 in regenerating retinal ganglion cells in adult hamsters. Ng TF, et al. **J Neurocytol** 1995 Jul;24(7):487-96

Neuromuscular evaluation using rat gait analysis. Santos PM, et al. **J Neurosci Methods** 1995 Sep-Oct;61(1-2):79-84

Brain-derived neurotrophic factor and peripheral nerve regeneration: a functional evaluation. Shirley DM, et al. **Laryngoscope** 1996 May;106(5 Pt 1):629-32

Chronic muscle stimulation increases lactate transport in rat skeletal muscle. McCullagh KJ, et al. **Mol Cell Biochem** 1996 Mar 9;156(1):51-7

Macrophage and microglial cell response after common peroneal nerve cut and crush in C57BL/6J mice. He BP, et al. **Neurodegeneration** 1996 Mar;5(1):73-80

Hyperbaric oxygen treatment after rat peroneal nerve transection and entubulation. Santos PM, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):424-34

Neurobiological mechanisms of the meridian and the propagation of needle feeling along the meridian pathway. Xie Y, et al. **Sci China C Life Sci** 1996 Feb;39(1):99-112

[The regulation of deep peroneal nerve inputs on depressor response evoked by caudal ventrolateral medulla excitation in rabbits] Zhou S, et al. **Chen Tzu Yen Chiu** 1995;20(2):12-7 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Peroneal stimulator; evaluation for the correction of spastic drop foot in hemiplegia. Granat MH, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):19-24

Muscle sympathetic nerve activity is higher in intensively versus conventionally treated IDDM subjects. Hoffman RP, et al. **Diabetes Care** 1995 Mar;18(3):287-91

Restoring lower limb blood flow improves conduction velocity in diabetic patients. Young MJ, et al. **Diabetologia** 1995 Sep;38(9):1051-4

Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection? Apartis E, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun; 60(6):661-6

Nerve conduction studies in adrenomyeloneuropathy. Chaudhry V, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):181-5

Subclinical hypothyroidism does not lead to alterations either in peripheral nerves or in brainstem auditory evoked potentials (BAEPs). Ozata M, et al. **Thyroid** 1995 Jun; 5(3):201-5

SURGERY

A functional model of nerve repair. Reanastomosis vs entubulation repair. Shirley DM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):785-8

The operative treatment of peroneal nerve palsy. Mont MA, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):863-9

A composite nerve graft system: extracted rat peripheral nerve injected with cultured Schwann cells. Dumont CE, et al. **Muscle Nerve** 1996 Jan;19(1):97-9

[Bilateral lesion of the peroneal nerve with lesion of the left-sided median and ulnar nerves in multiple osteocartilaginous exostoses] Goudarzi YM, et al. **Chirurg** 1995 Nov;66(11):1158-61 (Eng. Abstr.) **(Ger)**

[The results of reconstructive microsurgical operations on the damaged common peroneal nerve and its deep branch in children] Govenko FS. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul-Sep;(3):20-1 (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Morphological plasticity of axotomized retinal ganglion cells following intravitreal transplantation of a peripheral nerve segment. Lei JL, et al. **J Neurocytol** 1995 Jul;24(7):497-506

Influence of peripheral nerve grafts on the expression of GAP-43 in regenerating retinal ganglion cells in adult hamsters. Ng TF, et al. **J Neurocytol** 1995 Jul;24(7):487-96

PEROPERATIVE CARE see **INTRAOPERATIVE CARE**

PEROPERATIVE COMPLICATIONS see **INTRAOPERATIVE COMPLICATIONS**

PEROPERATIVE PERIOD see **INTRAOPERATIVE PERIOD**

PEROXIDASE

Covalent immobilization of invertase and horseradish peroxidase on concanavalin A-Seralose via carbohydrate moieties. Husain S, et al. **Biochem Mol Biol Int** 1995 Jul; 36(3):669-77

Bombardier beetle based biosensor. Nakatani HS, et al. **Biosens Bioelectron** 1996;11(5):489-92

A differentiated silver intensification procedure for the peroxidase-diaminobenzidine reaction. Quinn B, et al. **J Histochem Cytochem** 1996 Jan;44(1):71-4

ANALYSIS

Modified ICSH method for demonstration of myeloperoxidase [letter] Kumar R, et al. **Am J Hematol** 1995 Oct;50(2):147

Bone marrow changes induced by recombinant granulocyte colony-stimulating factor resembling metastatic carcinoma: distinction with cytochemical and immunohistochemical studies [letter] Pekarske SL, et al. **Am J Hematol** 1996 Apr; 51(4):332-4

Acute lymphoblastic leukemia with myeloperoxidase activity. Wright S, et al. **Am J Hematol** 1996 Feb;51(2):147-51

Changes in neutrophil granule protein and cytoplasmic fibrils in human acute myeloid leukemias. Mutasa HC. **Biotech Histochem** 1995 May;70(3):124-34

NMR studies on human, pathologically changed synovial fluids: role of hypochlorous acid. Schiller J, et al. **Magn Reson Med** 1996 Jun;35(6):848-53

Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. Hurst DS, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):531-44

ANTAGONISTS & INHIBITORS

The influence of different fluoride salts on fluoride-mediated inhibition of peroxidase activity in human saliva. Vanden Abbeele A, et al. **Arch Oral Biol** 1995 Aug;40(8):695-8

BIOSYNTHESIS

Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. Nauseef WM, et al. **J Biol Chem** 1996 Apr 19;271(16):9546-9

BLOOD

Peroxidase-mediated bromination of unsaturated fatty acids to form bromohydrins. Carr AC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):227-33

Potential role of the peroxidase-dependent metabolism of serotonin in lowering the polymorphonuclear leukocyte bactericidal function. Salman-Tabcheh S, et al. **Free Radic Res** 1996 Jan;24(1):61-8

Effect of prolonged exercise on neutrophil myeloperoxidase secretion. Bury TB, et al. **Int J Sports Med** 1995 Aug; 16(6):410-2

Myeloperoxidase-based chemiluminescence of polymorphonuclear leukocytes and monocytes. McNally

JA, et al. **J Biolumin Chemilumin** 1996 Mar-Apr; 11(2):99-106

Rise of plasma myeloperoxidase during interferon therapy. Nakamuta M, et al. **J Gastroenterol Hepatol** 1995 May-Jun; 10(3):277-80

Oxidative stress and antioxidant defenses in plasma of patients with Behçet's disease. Köse K, et al. **Tohoku J Exp Med** 1995 Aug;176(4):239-48

A sensitive double-antibody enzyme-linked immunosorbant assay for bovine myeloperoxidase and its application to serum and neutrophil extracts. Cooray R, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):481-91

[Myeloperoxidase] Saito K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:251-3 (6 ref.) **(Jpn)**

[Thermodynamic parameters of complex formation of blood plasma fibronectin and myeloperoxidase] Iankovskil OIu, et al. **Biokhimila** 1995 Aug;60(8):1217-20 (Eng. Abstr.) **(Rus)**

[Formation of a complex between myeloperoxidase and opsonin in human blood plasma] Iankovskil OIu, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):320-2 **(Rus)**

[The myeloperoxidase of the polymorphonuclear leukocytes as a marker of the stage of Opisthorchis invasion and as an indicator of the efficacy of chemotherapy] Iakovleva VV, et al. **Med Parazitol (Mosk)** 1995 Jul-Sep;(3):34-7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Structural influence of calcium on the heme cavity of cationic peanut peroxidase as determined by 1H-NMR spectroscopy. Barber KR, et al. **Eur J Biochem** 1995 Sep 15;232(3):825-33

Pentacoordination of the heme iron of Arthromyces ramosus peroxidase shown by a 1.8 A resolution crystallographic study at pH 4.5. Kunishima N, et al. **FEBS Lett** 1996 Jan 15;378(3):291-4

DEFICIENCY

A case of eosinophil peroxidase deficiency. Kutter D, et al. **Ann Hematol** 1995 Dec;71(6):315-7

Eosinophil peroxidase deficiency in New Zealand white mice. Ohmori J, et al. **Int Arch Allergy Immunol** 1996 Sep; 111(1):30-5

DRUG EFFECTS

Nasal neutrophilia and release of myeloperoxidase induced by nasal challenge with platelet activating factor: different degrees of responsiveness in atopic and nonatopic subjects. Miadonna A, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):947-54

GENETICS

Molecular genetics of hereditary thyroid diseases due to a defect in the thyroglobulin or thyroperoxidase synthesis. Targovnik HM, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2745-57 (31 ref.)

Detection of myeloperoxidase gene expression in minimally differentiated acute myelogenous leukemia (AML-M0) using in situ hybridization. Traweek ST, et al. **Diagn Mol Pathol** 1995 Sep;4(3):212-9

Localization of the human estrogen-responsive finger protein (EEP) gene (ZNF147) within a YAC contig containing the myeloperoxidase (MPO) gene. Law DJ, et al. **Genomics** 1995 Jul 20;28(2):361-3

Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. Nauseef WM, et al. **J Biol Chem** 1996 Apr 19;271(16):9546-9

An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. Piedrafita FJ, et al. **J Biol Chem** 1996 Jun 14; 271(24):14412-20

Cis-elements in the promoter region of the human myeloperoxidase (MPO) gene. Zhao WG, et al. **Leukemia** 1996 Jul;10(7):1089-103

Linkage of the athymic nude locus with the myeloperoxidase locus in the rat. Murakumo Y, et al. **Pathol Int** 1995 Apr; 45(4):261-5

Molecular cloning and expression analysis of peroxidase genes from wheat. Båga M, et al. **Plant Mol Biol** 1995 Nov; 29(4):647-62

A thiol protease and an anionic peroxidase are induced by lowering cytokinins during callus growth in Petunia. Tournaire C, et al. **Plant Physiol** 1996 May;111(1):159-68

IMMUNOLOGY

Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Tanemoto M, et al. **Am J Kidney Dis** 1995 Nov;26(5):774-80

Antimyeloperoxidase antibodies in individuals with occupational exposure to silica. Wichmann I, et al. **Ann Rheum Dis** 1996 Mar;55(3):205-7

Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Reumaux D, et al. **Blood** 1995 Oct 15;86(8):3189-95

Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies. Chang L, et al. **Clin Exp Immunol** 1995 Oct;102(1):112-9

Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis. Short AK, et al. **Clin Exp Immunol** 1995 Oct;102(1):106-11

Analysis of immunoglobulin variable region genes of a human IgM anti-myeloperoxidase antibody derived from a patient with vasculitis. Longhurst C, et al. **Immunology** 1996 Feb; 87(2):334-8

Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Gaskin G, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1925-8

Preparation and characterization of monoclonal antibodies against bovine myeloperoxidase. Cooray R, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):211-21

[Clinical analysis of 14 patients with anti-myeloperoxidase antibody positive rapid progressive glomerulonephritic syndrome] Hiromura K, et al. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):573-9 (Eng. Abstr.) **(Jpn)**

[The production of high sensitive anti-myeloperoxidase monoclonal antibodies and their sensitivity and specificity] Okano K, et al. **Rinsho Byori** 1996 Jul;44(7):687-91 (Eng. Abstr.) **(Jpn)**

[Estimation of anti-thyroid peroxidase autoantibody (TPOAb) and anti-thyroglobulin autoantibody (TgAb) in patients with various thyroid disease--comparison between histopathological findings and serological results in patients with Hashimoto's thyroiditis] Senda Y, et al. **Rinsho Byori** 1995 Dec;43(12):1243-50 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Purification and characterization of an intracellular catalase-peroxidase from Penicillium simplicissimum. Fraaije MW, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):192-8

METABOLISM

Detection and characterization of the electron paramagnetic resonance-silent glutathionyl-5,5-dimethyl-1-pyrroline N-oxide adduct derived from redox cycling of phenoxyl radicals in model systems and HL-60 cells. Stoyanovosky DA, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):3-11

Superoxide anion reduces the ability of myeloperoxidase to damage lipids. Iwase H, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):625-32

Myeloperoxidase as a generator of drug free radicals. Uetrecht JP. **Biochem Soc Symp** 1995;61:163-70 (44 ref.)

2.3 A resolution X-ray crystal structure of the bisubstrate analogue inhibitor salicylhydroxamic acid bound to human myeloperoxidase: a model for a prereaction complex with hydrogen peroxide. Davey CA, et al. **Biochemistry** 1996 Aug 20;35(33):10967-73

Binding of myeloperoxidase to bacteria: effect on hydroxyl radical formation and susceptibility to oxidant-mediated killing. Britigan BE, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):231-40

Quantification of bovine neutrophil migration across mammary epithelium in vitro. Lin Y, et al. **Can J Vet Res** 1996 Apr;60(2):145-9

Peroxidase-catalyzed oxidation of 3,5-dimethyl acetaminophen causes cell death by selective protein thiol modification in isolated rat hepatocytes. Weis M, et al. **Chem Biol Interact** 1996 May 6;100(3):255-65

Structural influence of calcium on the heme cavity of cationic peanut peroxidase as determined by 1H-NMR spectroscopy. Barber KR, et al. **Eur J Biochem** 1995 Sep 15;232(3):825-33

Bactericidal activity against Pseudomonas aeruginosa is acquired by cultured human monocyte-derived macrophages after uptake of myeloperoxidase. Mathy-Hartert M, et al. **Experientia** 1996 Feb 15; 52(2):167-74

Antioxidant enzyme activities in different brain areas of the neurological mutant--pt rabbit. Kowalczuk K, et al. **Folia Neuropathol** 1995;33(3):169-74

Concentrations of myeloperoxidase in nasal secretions of atopic patients after nasal allergen challenge and during natural allergen exposure. Wang D, et al. **Int Arch Allergy Immunol** 1996 May;110(1):85-90

Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. Biasucci LM, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):611-6

p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. Hazen SL, et al. **J Biol Chem** 1996 Jan 26;271(4):1861-7

Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway. Jacob JS, et al. **J Biol Chem** 1996 Aug 16;271(33):19950-6

Kinetics of oxidation of tyrosine and dityrosine by myeloperoxidase compounds I and II. Implications for lipoprotein peroxidation studies. Marquez LA, et al. **J Biol Chem** 1995 Dec 22;270(51):30434-40

Immunophenotype and ultrastructural studies in blast crisis of chronic myeloid leukemia. Nair C, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):309-13

Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release. Videm V. **Scand J Immunol** 1996 Apr;43(4):385-90

2-Aminofluorene bioactivation by human term placental peroxidase. Murthy KR, et al. **Teratog Carcinog Mutagen** 1995;15(3):115-26

[Metabolites of tetracycline obtained during its irradiation with visible light or peroxidase oxidation. Their toxic properties in relation to hemoglobin] Petrenko IuM, et al. **Antibiot Khimioter** 1995 Jul;40(7):8-14 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Uptake of recombinant myeloperoxidase, free or fused to Fc gamma, by macrophages enhances killing activity toward micro-organisms. Tournay C, et al. **DNA Cell Biol** 1996 Aug;15(8):617-24

PHARMACOLOGY

Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Panousis C, et al. **Anticancer Drug Des** 1995 Dec;10(8):593-605

T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Griffith ME, et al. **Clin Exp Immunol** 1996 Feb;103(2):253-8

Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. Lefkowitz SS, et al. **J Infect Dis** 1996 May;173(5):1202-7

Bactericidal activity of the bovine myeloperoxidase system against bacteria associated with mastitis. Cooray R, et al. **Vet Microbiol** 1995 Oct;46(4):427-34

PHYSIOLOGY

Involvement of superoxide and myeloperoxidase in oxygen-dependent killing of Staphylococcus aureus by neutrophils. Hampton MB, et al. **Infect Immun** 1996 Sep; 64(9):3512-7

Function and stationary-phase induction of periplasmic copper-zinc superoxide dismutase and catalase/peroxidase in Caulobacter crescentus. Schnell S, et al. **J Bacteriol** 1995 Oct;177(20):5924-9

[Studies on functions of neutrophils in MPO-ANCA related glomerulonephiritis and plasma effect on MPO release from neutrophils] Minoshima S. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):481-90 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Peroxidase changes in barley induced by ionizing and thermal radiation. Sah NK, et al. **Int J Radiat Biol** 1996 Jan; 69(1):107-11

SECRETION

A chemiluminescence procedure for determination of the release of myeloperoxidase from activated human neutrophils. Kitamura N. **Kurume Med J** 1995;42(4):259-68

PEROXIDASE-ANTIPEROXIDASE COMPLEX TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASE-LABELED ANTIBODY TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASES

Tear glucose estimation--an alternative to blood glucose estimation. Das BN, et al. **J Indian Med Assoc** 1995 Apr; 93(4):127-8

[A variety of halogenating enzymes and their roles in organisms] Itoh N. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):256-66 (49 ref.) **(Jpn)**

ANALYSIS

A flow cytometric method for the detection of intracellular basic proteins in unseparated peripheral blood and bone marrow eosinophils. Krug N, et al. **J Immunol Methods** 1996 Apr 19;190(2):245-54

Tritrichomonas foetus and Trichomonas vaginalis: the pattern of inactivation of hydrogenase activity by oxygen and activities of catalase and ascorbate peroxidase. Page-Sharp M, et al. **Microbiology** 1996 Jan;142 (Pt 1):207-11

Free radical detoxification in Giardia duodenalis. Brown DM, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):47-56

[8 species of peroxidase isozymes and 2 varieties of Corydalis] Zhang Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan; 21(1):6-8, 62 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

Inhibition and inactivation of vanadium bromoperoxidase by the substrate hydrogen peroxide and further mechanistic studies. Soedjak HS, et al. **Biochemistry** 1995 Oct 3; 34(39):12689-96

Lignan models as inhibitors of Phanerochaete chrysosporium lignin peroxidase. Frías I, et al. **Biochimie** 1995;77(9):707-12

Inhibition of ascorbate peroxidase by salicylic acid and 2,6-dichloroisonicotinic acid, two inducers of plant defense responses. Durner J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11312-6

PEROXIDASES

BIOSYNTHESIS

cis-regulatory elements of the peroxidase gene in Arabidopsis thaliana involved in root-specific expression and responsiveness to high-salt stress. Wanapu C, et al. **Ann N Y Acad Sci** 1996 May 15;782:107-14

Heterologous expression and characterization of soybean cytosolic ascorbate peroxidase. Dalton DA, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):1-8

Overproduction of mycobacterial ribosomal protein S13 induces catalase/peroxidase activity and hypersensitivity to isoniazid in Mycobacterium smegmatis. Dubnau E, et al. **Gene** 1996 Apr 17;170(1):17-22

Phytohormone control of the tobacco anionic peroxidase promoter. Klotz KL, et al. **Plant Mol Biol** 1996 Jun; 31(3):565-73

Expression of Arabidopsis cytosolic ascorbate peroxidase gene in response to ozone or sulfur dioxide. Kubo A, et al. **Plant Mol Biol** 1995 Nov;29(3):479-89

Ascorbate peroxidase. A prominent membrane protein in oilseed glyoxysomes. Bunkelmann JR, et al. **Plant Physiol** 1996 Feb;110(2):589-98

Strategies for the suppression of peroxidase gene expression in tobacco. II. In vivo suppression of peroxidase activity in transgenic tobacco using ribozyme and antisense constructs. McIntyre CL, et al. **Transgenic Res** 1996 Jul; 5(4):263-70

Strategies for the suppression of peroxidase gene expression in tobacco. I. Designing efficient ribozymes. McIntyre CL, et al. **Transgenic Res** 1996 Jul;5(4):257-62

BLOOD

Peroxidase-mediated bromination of unsaturated fatty acids to form bromohydrins. Carr AC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):227-33

Reaction of phosphatidylcholine hydroperoxide in human plasma: the role of peroxidase and lecithin:cholesterol acyltransferase. Nagata Y, et al. **Arch Biochem Biophys** 1996 May 1;329(1):24-30

Glutathione-linked thiol peroxidase activity of human serum albumin: a possible antioxidant role of serum albumin in blood plasma. Cha MK, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):619-25

Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Cha MK, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):900-7

Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Sundaram RK, et al. **Clin Sci (Colch)** 1996 Apr;90(4):255-60

CHEMISTRY

Infrared spectroscopy of the cyanide complex of iron (II) myoglobin and comparison with complexes of microperoxidase and hemoglobin. Reddy KS, et al. **Biochemistry** 1996 Apr 30;35(17):5562-70

X-ray absorption spectroscopy comparison of the active site structures of Phanerochaete chrysosporium lignin peroxidase isoenzymes H2, H3, H4, H5, H8, and H10. Sinclair R, et al. **Biochemistry** 1995 Oct 10;34(40):13176-82

Versatility of heme coordination demonstrated in a fungal peroxidase. Absorption and resonance Raman studies of Coprinus cinereus peroxidase and the Asp245-->Asn mutant at various pH values. Smulevich G, et al. **Biochemistry** 1996 Aug 13;35(32):10576-85

The effect of manganese on the oxidation of chemicals by lignin peroxidase. Sutherland GR, et al. **Biochemistry** 1995 Oct 3;34(39):12624-9

Unfolding and refolding of Coprinus cinereus peroxidase at high pH, in urea, and at high temperature. Effect of organic and ionic additives on these processes. Tams JW, et al. **Biochemistry** 1996 Jun 11;35(23):7573-9

Structure of the native cysteine-sulfenic acid redox center of enterococcal NADH peroxidase refined at 2.8 A resolution. Yeh JI, et al. **Biochemistry** 1996 Aug 6; 35(31):9951-7

cDNAs encoding spinach stromal and thylakoid-bound ascorbate peroxidase, differing in the presence or absence of their 3'-coding regions. Ishikawa T, et al. **FEBS Lett** 1996 Apr 22;384(3):289-93

Kinetic and spectral properties of pea cytosolic ascorbate peroxidase. Marquez LA, et al. **FEBS Lett** 1996 Jul 1; 389(2):153-6

Spectral analysis of lactoperoxidase. Evidence for a common heme in mammalian peroxidases. Andersson LA, et al. **J Biol Chem** 1996 Feb 16;271(7):3406-12

An unusual dehalogenating peroxidase from the marine terebellid polychaete Amphitrite ornata. Chen YP, et al. **J Biol Chem** 1996 Mar 1;271(9):4609-12

Monomeric ferric heme peptide derivatives: model systems for hemoproteins. Carraway AD, et al. **J Inorg Biochem** 1995 Dec;60(4):267-76

DRUG EFFECTS

Effects of delmopinol on antimicrobial peroxidase systems and lysozyme in vitro and in human whole saliva. Tenovuo J, et al. **Eur J Oral Sci** 1995 Aug;103(4):247-52

GENETICS

cis-regulatory elements of the peroxidase gene in Arabidopsis thaliana involved in root-specific expression and responsiveness to high-salt stress. Wanapu C, et al. **Ann N Y Acad Sci** 1996 May 15;782:107-14

Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Pretorius GS, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2276-81

Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Rouse DA, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2472-7

Manganese peroxidase mRNA and enzyme activity levels during bioremediation of polycyclic aromatic hydrocarbon-contaminated soil with Phanerochaete chrysosporium. Bogan BW, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2381-6

Lip-like genes in Phanerochaete sordida and Ceriporiopsis subvermispora, white rot fungi with no detectable lignin peroxidase activity. Rajakumar S, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2660-3

Identification of promoter in the 5'-flanking region of the E. coli thioredoxin-linked thiol peroxidase gene: evidence for the existence of oxygen-related transcriptional regulatory protein. Kim HK, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):641-6

Expression of fungal Mn peroxidase in E. coli and refolding to yield active enzyme. Whitwam RE, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1013-7

Relation of allozyme genotype to survivorship of juvenile bream, Abramis brama L., acutely exposed to DDVP, an organophosphorus pesticide. Chuiko GM, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):738-45

Codon usage in plant peroxidase genes. Tyson H, et al. **DNA Seq** 1995;5(6):339-51

cDNAs encoding spinach stromal and thylakoid-bound ascorbate peroxidase, differing in the presence or absence of their 3'-coding regions. Ishikawa T, et al. **FEBS Lett** 1996 Apr 22;384(3):289-93

A cluster of genes encoding major isozymes of lignin peroxidase and manganese peroxidase from the white-rot fungus Trametes versicolor. Johansson T, et al. **Gene** 1996 Apr 17;170(1):31-8

Nucleotide sequences of four pathogen-induced alfalfa peroxidase-encoding cDNAs. el-Turk J, et al. **Gene** 1996 May 8;170(2):213-6

Expression of genes coding for antioxidant enzymes and heat shock proteins is altered in primary cultures of rat hepatocytes. Van Remmen H, et al. **J Cell Physiol** 1996 Feb;166(2):453-60

Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. Musser JM, et al. **J Infect Dis** 1996 Jan; 173(1):196-202

Cloning of the murine eosinophil peroxidase gene (mEPO): characterization of a conserved subgroup of mammalian hematopoietic peroxidases. Horton MA, et al. **J Leukoc Biol** 1996 Aug;60(2):285-94

KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates. Goto M, et al. **Mol Cell Probes** 1995 Dec;9(6):433-9

Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates. O'Brien KL, et al. **Mol Cell Probes** 1996 Feb;10(1):1-6

cDNA cloning of thylakoid-bound ascorbate peroxidase in pumpkin and its characterization. Yamaguchi K, et al. **Plant Cell Physiol** 1996 Apr;37(3):405-9

Phytohormone control of the tobacco anionic peroxidase promoter. Klotz KL, et al. **Plant Mol Biol** 1996 Jun; 31(3):565-73

[Specific segments of the amino acid sequence of plant peroxidase] Kazachenko Klu. **Biokhimiia** 1996 Jan; 61(1):82-4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

An enzymeimmunoassay for total thyroxine using avidin-biotin separation system and thyroxine-peroxidase conjugate. Akman S, et al. **J Immunoassay** 1995 Aug; 16(3):325-41

ISOLATION & PURIFICATION

Purification and characterization of two haloperoxidases from the glycopeptide antibiotic producer Streptomyces toyocaensis NRRL 15009. Marshall GC, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):580-3

Purification and characterization of a wound-inducible cell wall cationic peroxidase from carrot roots. Nair AR, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):254-60

The catalase-peroxidase of Synechococcus PCC 7942: purification, nucleotide sequence analysis and expression in Escherichia coli. Mutsuda M, et al. **Biochem J** 1996 May 15;316 (Pt 1):251-7

Isolation and characterisation of a novel non-haem extracellular peroxidase produced by the thermophilic actinomycete Thermonospora fusca BD25. Rob A, et al. **Biochem Soc Trans** 1995 Nov;23(4):507S

Purification and catalytic properties of two manganese peroxidase isoenzymes from Pleurotus eryngii. Martínez MJ, et al. **Eur J Biochem** 1996 Apr 15;237(2):424-32

Thioredoxin-linked "thiol peroxidase" from periplasmic space of Escherichia coli. Cha MK, et al. **J Biol Chem** 1995 Dec 1;270(48):28635-41

METABOLISM

Immobilization of manganese peroxidase from Lentinula edodes on alkylaminated Emphaze AB 1 polymer for generation of Mn3+ as an oxidizing agent. Grabski AC, et al. **Appl Biochem Biotechnol** 1996 Jul;60(1):1-17

Superactivity of peroxidase solubilized in reversed micellar systems. Setti L, et al. **Appl Biochem Biotechnol** 1995 Dec; 55(3):207-18

Polycyclic aromatic hydrocarbon-degrading capabilities of Phanerochaete laevis HHB-1625 and its extracellular ligninolytic enzymes. Bogan BW, et al. **Appl Environ Microbiol** 1996 May;62(5):1597-603

Manganese peroxidase mRNA and enzyme activity levels during bioremediation of polycyclic aromatic hydrocarbon-contaminated soil with Phanerochaete chrysosporium. Bogan BW, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2381-6

Veratryl alcohol-mediated indirect oxidation of pentachlorophenol by lignin peroxidase. Chung N, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):143-8

Comparison of isoniazid oxidation catalyzed by bacterial catalase-peroxidases and horseradish peroxidase. Hillar A, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):438-46

Oxidation of 1,2,4,5-tetramethoxybenzene by lignin peroxidase of Phanerochaete chrysosporium. Koduri RS, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):261-5

The effect of veratryl alcohol on manganese oxidation by lignin peroxidase. Sutherland GR, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):20-6

The effects of calcium on the thermal stability and activity of manganese peroxidase. Sutherland GR, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):128-34

Chorda-evoked opening of tight junctions in rat submandibular salivary acini demonstrated by microperoxidase. Takai N, et al. **Arch Oral Biol** 1995 Nov; 40(11):1077-80

Expression of lignin peroxidase H8 in Escherichia coli: folding and activation of the recombinant enzyme with Ca2+ and haem. Doyle WA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):15-9

Mechanism of indole-3-acetic acid oxidation by plant peroxidases: anaerobic stopped-flow spectrophotometric studies on horseradish and tobacco peroxidases. Gazaryan IG, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):841-7

Mode of action and active site of an extracellular peroxidase from Pleurotus ostreatus. Han YH, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):421-6

Characterization of sheep lacrimal-gland peroxidase and its major physiological electron donor. Mazumdar A, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):413-9

The catalase-peroxidase of Synechococcus PCC 7942: purification, nucleotide sequence analysis and expression in Escherichia coli. Mutsuda M, et al. **Biochem J** 1996 May 15;316 (Pt 1):251-7

Analysis of the kinetic mechanism of enterococcal NADH peroxidase reveals catalytic roles for NADH complexes with both oxidized and two-electron-reduced enzyme forms. Crane EJ 3rd, et al. **Biochemistry** 1995 Oct 31; 34(43):14114-24

The active-site histidine-10 of enterococcal NADH peroxidase is not essential for catalytic activity. Crane EJ 3rd, et al. **Biochemistry** 1996 Feb 20;35(7):2380-7

Veratryl alcohol oxidation by lignin peroxidase. Khindaria A, et al. **Biochemistry** 1995 Dec 26;34(51):16860-9

Stabilization of the veratryl alcohol cation radical by lignin peroxidase. Khindaria A, et al. **Biochemistry** 1996 May 21; 35(20):6418-24

Characterization of manganese(II) binding site mutants of manganese peroxidase. Kishi K, et al. **Biochemistry** 1996 Jul 9;35(27):8986-94

Inactivation of vanadium bromoperoxidase: formation of 2-oxohistidine. Meister Winter GE, et al. **Biochemistry** 1996 Sep 10;35(36):11805-11

Molecular characterization of Euglena ascorbate peroxidase using monoclonal antibody. Ishikawa T, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):69-75

Oscillations in the peroxidase-oxidase reaction: a comparison of different peroxidases. Kummer U, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):397-403

Hydroperoxidase activity of lipoxygenase: a kinetic study of isoproterenol oxidation. Nuñez-Delicado E, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):17-22

Kinetic studies of the oscillatory dynamics in the peroxidase-oxidase reaction catalyzed by four different peroxidases. Valeur KR, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):377-84

Oxidation of dimethoxylated aromatic compounds by lignin peroxidase from Phanerochaete chrysosporium. Joshi DK, et al. **Eur J Biochem** 1996 Apr 1;237(1):45-57

Purification and catalytic properties of two manganese peroxidase isoenzymes from Pleurotus eryngii. Martínez MJ, et al. **Eur J Biochem** 1996 Apr 15;237(2):424-32

cDNAs encoding spinach stromal and thylakoid-bound ascorbate peroxidase, differing in the presence or absence of their 3'-coding regions. Ishikawa T, et al. **FEBS Lett** 1996 Apr 22;384(3):289-93

Ascorbate is the natural substrate for plant peroxidases. Mehlhorn H, et al. **FEBS Lett** 1996 Jan 15;378(3):203-6

Thermostable peroxidase activity with a recombinant antibody L chain–porphyrin Fe(III) complex. Takagi M, et al. **FEBS Lett** 1995 Nov 20;375(3):273–6

An unusual dehalogenating peroxidase from the marine terebellid polychaete Amphitrite ornata. Chen YP, et al. **J Biol Chem** 1996 Mar 1;271(9):4609–12

The spin trap alpha–(4–pyridyl–1–oxide)–N–tert–butylnitrone stimulates peroxidase–mediated oxidation of deferoxamine. Implications for pharmacological use of spin–trapping agents. McCormick ML, et al. **J Biol Chem** 1995 Dec 8; 270(49):29265–9

Removal of hydrogen peroxide by thiol–specific antioxidant enzyme (TSA) is involved with its antioxidant properties. TSA possesses thiol peroxidase activity. Netto LES, et al. **J Biol Chem** 1996 Jun 28;271(26):15315–21

Vanadium–dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

Plant activation and its role in environmental mutagenesis and antimutagenesis. Plewa MJ, et al. **Mutat Res** 1996 Feb 19;350(1):163–71

Peroxidase activity and cell differentiation in developing salivary glands of the rats. Moriguchi K, et al. **Okajimas Folia Anat Jpn** 1995 May;72(1):13–28

Premature rats treated with propylthiouracil show enhanced pulmonary antioxidant enzyme gene expression and improved survival during prolonged exposure to hyperoxia. Chen Y, et al. **Pediatr Res** 1995 Sep;38(3):292–7

A novel isoenzyme of ascorbate peroxidase localized on glyoxysomal and leaf peroxisomal membranes in pumpkin. Yamaguchi K, et al. **Plant Cell Physiol** 1995 Sep; 36(6):1157–62

Isolation of pI 4.6 extensin peroxidase from tomato cell suspension cultures and identification of Val–Tyr–Lys as putative intermolecular cross–link site. Schnabelrauch LS, et al. **Plant J** 1996 Apr;9(4):477–89

One–electron oxidations by peroxidases. Dunford HB. **Xenobiotica** 1995 Jul;25(7):725–33

Xenobiotic metabolism in humans during early pregnancy: peroxidase–mediated oxidation and bioactivation of 2–aminofluorene. Kulkarni AP, et al. **Xenobiotica** 1995 Aug;25(8):799–810

[Casein–derived peptides can promote human LDL oxidation by a peroxidase–dependent and metal–independent process] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995; 189(5):933–42 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Inhibitory activity of soluble material from sheep eosinophils for sheep complement. Jonas W, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):197–200

Inactivation of human immunodeficiency virus type 1 by the amine oxidase–peroxidase system. Klebanoff SJ, et al. **J Clin Microbiol** 1995 Aug;33(8):2054–7

PHYSIOLOGY

Genoprotection by UDP–glucuronosyltransferases in peroxidase–dependent, reactive oxygen species–mediated micronucleus initiation by the carcinogens 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone and benzo[a]pyrene. Kim PM, et al. **Cancer Res** 1996 Apr 1; 56(7):1526–32

Cytochrome P450 peroxidase/peroxygenase mediated xenobiotic metabolic activation and cytotoxicity in isolated hepatocytes. Anari MR, et al. **Chem Res Toxicol** 1995 Dec; 8(8):997–1004

Eosinophil granule proteins activate human heart mast cells. Patella V, et al. **J Immunol** 1996 Aug 1;157(3):1219–25

PEROXIDES

see related
BENZOYL PEROXIDE
LIPID PEROXIDES

The effect of anticoagulant choice on apparent total antioxidant capacity using three different methods. Goode HF, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):413–6

Efficacy of Bio–Catalyzer alpha.rho no.11 (Bio–Normalizer) supplementation against peroxyl radical–induced oxidative damage in rat organ homogenates. Marcocci L, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):535–41

DNA methylation by tert–butyl hydroperoxide–iron (II). Hix S, et al. **Free Radic Biol Med** 1995 Sep;19(3):293–301

Induction of arthritis in mice and rats by potassium peroxochromate and assessment of disease activity by whole blood chemiluminescence and 99mpertechnetate–imaging. Miesel R, et al. **Free Radic Res** 1995 Sep;23(3):213–27

EPR studies on the effects of complexation of heme by hemopexin upon its reactions with organic peroxides. Timmins GS, et al. **Free Radic Res** 1995 Dec;23(6):559–69

Evaluation of a modified BACTEC method to study the activity of disinfectants against Mycobacterium tuberculosis. Cutler RR, et al. **Tuber Lung Dis** 1995 Jun; 76(3):254–60

[Presentation of the Proceedings of the Round Table, Experimental Updates on a Biodegradable Peroxide System. 5 February 1994] **Ann Ig** 1995 Jan–Feb;7(1):3–68 **(Ita)**

[Chemical characteristics and mechanisms of action of VIRKON] Manna F, et al. **Ann Ig** 1995 Jan–Feb;7(1):5–11 **(Ita)**

ADVERSE EFFECTS

Assessing the effects of 10 percent carbamide peroxide on oral soft tissues. Curtis JW, et al. **J Am Dent Assoc** 1996 Aug;127(8):1218–23

A cross sectional study of chemical industry workers with occupational exposure to persulphates. Merget R, et al. **Occup Environ Med** 1996 Jun;53(6):422–6

ANALYSIS

Utilization of glass HPLC autosampler vials as cuvettes in an iodometric assay of hydroperoxides. Caldwell CR. **Anal Biochem** 1996 Feb 15;234(2):234–6

Chemiluminescence detection of mono–, bis–, and tris–hydroperoxy triacylglycerols present in vegetable oils. Miyazawa T, et al. **Lipids** 1995 Nov;30(11):1001–6

ANTAGONISTS & INHIBITORS

Pycnogenol protects vascular endothelial cells from t–butyl hydroperoxide induced oxidant injury. Rong Y, et al. **Biotechnol Ther** 1994–95;5(3–4):117–26

Studies of hypoxemic/reoxygenation injury: without aortic clamping. VII. Counteraction of oxidant damage by exogenous antioxidants: coenzyme Q10. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1221–7

Nicotinamide as a precursor for NAD+ prevents apoptosis in the mouse brain induced by tertiary–butylhydroperoxide. Klaidman LK, et al. **Neurosci Lett** 1996 Mar 8;206(1):5–8

Hepatoprotective activity of xanthones and xanthonolignoids against tert–butylhydroperoxide–induced toxicity in isolated rat hepatocytes—comparison with silybin. Fernandes ER, et al. **Pharm Res** 1995 Nov;12(11):1756–60

BLOOD

Peroxides in human leucocytes in acute septic shock: a preliminary study of acute phase changes and mortality. Leaver HA, et al. **Eur J Clin Invest** 1995 Oct;25(10):777–83

CHEMISTRY

Identification of a "peroxy" intermediate in cytochrome bo3 of Escherichia coli. Morgan JE, et al. **Biochemistry** 1995 Dec 5;34(48):15633–7

Structural identification of valine hydroperoxides and hydroxides on radical–damaged amino acid, peptide, and protein molecules. Fu S, et al. **Free Radic Biol Med** 1995 Sep;19(3):281–92

Beta–carotene as an interceptor of free radicals. Ozhogina OA, et al. **Free Radic Biol Med** 1995 Nov;19(5):575–81

ESR spin trapping investigation of radical formation from the reaction between hematin and tert–Butyl hydroperoxide. Van der Zee J, et al. **Free Radic Biol Med** 1996;20(2):199–206

Dynamics of free radical formation from the reaction of peroxides with haemproteins as studied by stopped–flow chemiluminescence. Noguchi N, et al. **Free Radic Res** 1995 Oct;23(4):329–38

Reactions of sulphonyl peroxyl radicals with DNA and its components: hydrogen abstraction from the sugar backbone versus addition to pyrimidine double bonds. Razskazovskii Y, et al. **Int J Radiat Biol** 1996 Jan;69(1):75–87

[Interaction of hypochlorite with hydroperoxides and other oxidation products of phosphatidylcholine liposomes] Panasenko OM, et al. **Biokhimiia** 1995 Sep;60(9):1419–28 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

The use of t–butyl hydroperoxide as a probe for methionine oxidation in proteins. Keck RG. **Anal Biochem** 1996 Apr 5;236(1):56–62

METABOLISM

Calcitonin prevents CCl4–induced hydroperoxide generation and cytotoxicity possibly through C1b receptor in rat hepatocytes. Chen S, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):865–71

Biological fate of amino acid, peptide and protein hydroperoxides. Fu S, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):821–7

The inhibitory effects of boldine, glaucine, and probucol on TPA–induced down regulation of gap junction function. Relationships to intracellular peroxides, protein kinase C translocation, and connexin 43 phosphorylation. Hu J, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1635–43

Ebselen inhibition of apoptosis by reduction of peroxides. Ramakrishnan N, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1443–51

Different mechanisms of formation of glutathione–protein mixed disulfides of diamide and tert–butyl hydroperoxide in rat blood. Di Simplicio P, et al. **Biochim Biophys Acta** 1996 Mar 15;1289(2):252–60

Pyrone hydroperoxide formation during the Maillard reaction and its implication in biological systems. Lertsiri S, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):278–84

Cytochrome P450 2: peroxidative reactions of diversozymes. Coon MJ, et al. **FASEB J** 1996 Mar;10(4):428–34 (42 ref.)

Reactions of prostaglandin endoperoxide synthase and its compound I with hydroperoxides. Bakovic M, et al. **J Biol Chem** 1996 Jan 26;271(4):2048–56

Amphibacillus xylanus NADH oxidase and Salmonella typhimurium alkyl–hydroperoxide reductase flavoprotein components show extremely high scavenging activity for both alkyl hydroperoxide and hydrogen peroxide in the presence of S. typhimurium alkyl–hydroperoxide reductase 22–kDa protein component. Niimura Y, et al. **J Biol Chem** 1995 Oct 27;270(43):25645–50

In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide–induced formation of alkoxyl, lipid, and peroxyl radicals. Coffey MD, et al. **J Clin Invest** 1995 Oct;96(4):1866–73

Neurotrophic factors attenuate glutamate–induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. Mattson MP, et al. **J Neurochem** 1995 Oct;65(4):1740–51

Determinants of hydroperoxide detoxification in diabetic rat intestine: effect of insulin and fasting on the glutathione redox cycle. Iwakiri R, et al. **Metabolism** 1995 Nov; 44(11):1462–8

Tumor necrosis factors alpha and beta protect neurons against amyloid beta–peptide toxicity: evidence for involvement of a kappa B–binding factor and attenuation of peroxide and Ca2+ accumulation. Barger SW, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9328–32

PHARMACOLOGY

Effects of peroxide and superoxide on coronary artery: ANG II response and sarcoplasmic reticulum Ca2+ pump. Grover AK, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C546–53

Pyruvate enhances DNA single–strand break formation while abolishing cytotoxicity in U937 cells exposed to tert–butylhydroperoxide. Guidarelli A, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):70–4

Genotoxicity induced by furocoumarin hydroperoxides in mammalian cells upon UVA irradiation. Möller M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):693–701

Peroxides inhibit the glutathione S–conjugate pump. Soszyński M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):537–45

Phospholipase A stimulation in tumor cells by subtoxic concentration of tert–butyl hydroperoxide. Kondakova IV, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):297–302

Apoptosis and DNA fragmentation as induced by tertiary butylhydroperoxide in the brain. Mukherjee SK, et al. **Brain Res Bull** 1995;38(6):595–604

Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs. Abran D, et al. **Exp Eye Res** 1995 Sep;61(3):285–92

Oxidative DNA damage by t–butyl hydroperoxide causes DNA single strand breaks which is not linked to cell lysis. A mechanistic study in freshly isolated rat hepatocytes. Latour I, et al. **FEBS Lett** 1995 Oct 16;373(3):299–302

Effect of tert–butyl hydroperoxide addition on spontaneous chemiluminescence in brain. Azorin I, et al. **Free Radic Biol Med** 1995 Dec;19(6):795–803

Sod and catalase inactivation by singlet oxygen and peroxyl radicals. Escobar JA, et al. **Free Radic Biol Med** 1996; 20(3):285–90

The reduction of glutathione disulfide produced by t–butyl hydroperoxide in respiring mitochondria. Liu H, et al. **Free Radic Biol Med** 1996;20(3):433–42

Sporicidal activity of sodium dichloroisocyanurate, peroxygen and glutaraldehyde disinfectants against Bacillus subtilis. Coates D. **J Hosp Infect** 1996 Apr;32(4):283–94

Effect of peroxyl radicals on lecithin/cholesterol acyltransferase activity in human plasma. Chen C, et al. **Lipids** 1995 Jul;30(7):627–31

tBHP induced in vitro swelling of rat liver mitochondria. Kakkar P, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):39–45

Age–dependent effects of t–BuOOH on glutathione disulfide reductase, glutathione peroxidase, and malondialdehyde in the brain. Chang ML, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):95–106

Bactericidal activity of the bovine myeloperoxidase system against bacteria associated with mastitis. Cooray R, et al. **Vet Microbiol** 1995 Oct;46(4):427–34

[Evaluation of the antiviral activity of the disinfectant VIRKON] Bonfanti C, et al. **Ann Ig** 1995 Jan–Feb; 7(1):55–62 **(Ita)**

[Germicidal activity of the detergent VIRKON] Braga A. **Ann Ig** 1995 Jan–Feb;7(1):35–41 **(Ita)**

[Sporicidal activity of VIRKON] Delia S. **Ann Ig** 1995 Jan–Feb;7(1):43–7 **(Ita)**

[Evaluation of the efficacy of a peroxide system (VIRKON) with special reference to in vitro kinetics of disinfection] Gasparini R. **Ann Ig** 1995 Jan–Feb;7(1):19–25 **(Ita)**

[Evaluation of the disinfectant activity of the compound VIRKON] Ricci A, et al. **Ann Ig** 1995 Jan–Feb;7(1):27–33 **(Ita)**

[Evaluation of mycobactericidal activity of the disinfectant VIRKON by polymerase chain reaction (PCR)] Vollaro L, et al. **Ann Ig** 1995 Jan–Feb;7(1):49–53 **(Ita)**

[New tests of virucidal activity of 2 disinfectants versus HBV DNA positive sera: slot–blot and polymerase chain reaction (PCR)] Vollaro L, et al. **Ann Ig** 1995 Jan–Feb;7(1):63–8 **(Ita)**

THERAPEUTIC USE

Artemisinin and the antimalarial endoperoxides: from herbal

remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)

TOXICITY

Formation of lipofuscin in cultured retinal pigment epithelial cells exposed to pre-oxidized photoreceptor outer segments. Wihlmark U, et al. **APMIS** 1996 Apr; 104(4):272–9

The respiratory-chain poison antimycin A promotes the formation of DNA single-strand breaks and reduces toxicity in U937 cells exposed to t-butylhydroperoxide. Guidarelli A, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):371–5

Mechanism of site-selective DNA nicking by the hydrodioxyl (perhydroxyl) radical. Dix TA, et al. **Biochemistry** 1996 Apr 9;35(14):4578–83

Injury of rat thymocytes caused by exogenous peroxyl radicals in vitro. Landi L, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):207–12

Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Rong Y, et al. **Biotechnol Ther** 1994–95;5(3–4):117–26

Hibiscus protocatechuic acid protects against oxidative damage induced by tert-butylhydroperoxide in rat primary hepatocytes. Tseng TH, et al. **Chem Biol Interact** 1996 Aug 14;101(2):137–48

Evidence for dissimilar mechanisms of enhancement of inorganic and organic hydroperoxide cytotoxicity by L-histidine. Guidarelli A, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1575–82

Specificity of spontaneous and t-butyl hydroperoxide-induced mutations in delta oxyR strains of Escherichia coli differing with respect to the SOS mutagenesis proficiency and to the MutY and MutM functions. Urios A, et al. **Mutat Res** 1996 Jul 5; 354(1):95–101

Detection of oxidative mutagens in strains of Escherichia coli deficient in the OxyR or MutY functions: dependence on SOS mutagenesis. Urios A, et al. **Mutat Res** 1995 Nov; 332(1–2):9–15

Hepatoprotective activity of xanthones and xanthonolignoids against tert-butylhydroperoxide-induced toxicity in isolated rat hepatocytes—comparison with silybin. Fernandes ER, et al. **Pharm Res** 1995 Nov;12(11):1756–60

Hydroperoxide-induced nucleotide degradation and adenosine formation in isolated rat cardiomyocytes. Andersson BS, et al. **Toxicology** 1996 Jan 8;106(1–3):39–48

Susceptibility of primary cultures of proximal tubular and distal tubular cells from rat kidney to chemically induced toxicity. Lash LH, et al. **Toxicology** 1995 Nov 30; 103(2):85–103

[Study on inactivation of waste solutions of VIRKON] Manna F, et al. **Ann Ig** 1995 Jan–Feb;7(1):13–8 **(Ita)**

PEROXISOMAL DISORDERS

An overview of the symposium on 'Peroxisomes: biology and role in toxicology and disease', Aspen, Colorado, USA, June 28–July 2 1995. Bell DR. **Hum Exp Toxicol** 1995 Oct; 14(10):846–9

[Peroxisomal diseases—a survey] Theron JJ, et al. **S Afr Med J** 1996 Jun;86(6):685–90 (Eng. Abstr.) **(Afr)**

CHEMICALLY INDUCED

Hepatotumorigenicity and peroxisome proliferation induced by the hypolipidemic CI-924 in a two-year study in male and female B6C3F1 mice. Walker RM, et al. **Toxicol Pathol** 1996 May–Jun;24(3):265–72

DIAGNOSIS

Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects. Paton BC, et al. **J Clin Invest** 1996 Feb 1;97(3):681–8

Peroxisomal assembly defects: clinical, pathologic, and biochemical findings in two patients in a newly identified complementation group. Poulos A, et al. **J Pediatr** 1995 Oct;127(4):596–9

[Adult lysosomal and peroxisomal enzyme diseases and glycogenoses. I. Enzyme diseases with predominant symptoms in the fields of internal medicine, dermatology, orthopedics and ophthalmology] Elleder M. **Sb Lek** 1994; 95(3):221–30 (Eng. Abstr.) **(Cze)**

[Adult lysosomal and peroxisomal enzyme diseases and glycogenoses. II. Enzyme diseases with predominant psychiatric and neurologic symptoms] Elleder M. **Sb Lek** 1994;95(3):231–8 (Eng. Abstr.) **(Cze)**

DRUG THERAPY

Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis. Martinez M. **Lipids** 1996 Mar;31 Suppl:S145–52

GENETICS

Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Moser HW, et al. **Brain Pathol** 1995 Jul; 5(3):259–66 (72 ref.)

The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. Yahraus T, et al. **EMBO J** 1996 Jun 17; 15(12):2914–23

Disorders of peroxisome biogenesis. Braverman N, et al. **Hum Mol Genet** 1995;4 Spec No:1791–8 (115 ref.)

A new complementation assay for peroxisome-deficient cell lines. FitzPatrick DR, et al. **J Inherit Metab Dis** 1996; 19(1):94–5

Complementation analysis in patients with the clinical phenotype of a generalised peroxisomal disorder. Steinberg SJ, et al. **J Med Genet** 1996 Apr;33(4):295–9

Peroxisomal assembly defects: clinical, pathologic, and biochemical findings in two patients in a newly identified complementation group. Poulos A, et al. **J Pediatr** 1995 Oct;127(4):596–9

METABOLISM

Immunolocalization of a 43 kDa peroxisomal membrane protein in the liver of patients with generalized peroxisomal disorders. Espeel M, et al. **Eur J Cell Biol** 1995 Aug; 67(4):319–27

Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Moser HW, et al. **Lipids** 1996 Mar;31 Suppl:S141–4 (18 ref.)

Immunohistochemistry for a bifunctional protein in patients with peroxisomal disorders. Imamura A, et al. **Pediatr Neurol** 1995 May;12(4):341–5

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

PATHOLOGY

Rhizomelic chondrodysplasia punctata: report of a case with review of the literature and correlation with other peroxisomal disorders. Agamanolis DP, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):503–13 (25 ref.)

PHYSIOPATHOLOGY

[Peroxisomal diseases—oxygen and free radicals] Kremser K, et al. **Wien Klin Wochenschr** 1995;107(22):690–3 (46 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul–Aug;4(4):385–92 (71 ref.)

URINE

Glucuronic acid-conjugated dihydroxy fatty acids in the urine of patients with generalized peroxisomal disorders. Street JM, et al. **J Biol Chem** 1996 Feb 16;271(7):3507–16

PEROXISOMES see **MICROBODIES**

PEROXYACETIC ACID see **PERACETIC ACID**

PERPHENAZINE

BLOOD

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Linnet K, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):41–7

Quantitative determination of perphenazine and its metabolites in plasma by high-performance liquid chromatography and coulometric detection. Foglia JP, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):291–7

PHARMACOKINETICS

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Jerling M, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):423–8

THERAPEUTIC USE

Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment. Connor DF, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1490–4

PERSIAN GULF SYNDROME

War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Hyams KC, et al. **Ann Intern Med** 1996 Sep 1;125(5):398–405 (131 ref.)

Botulism and Gulf War syndrome [letter] Critchley EM. **Lancet** 1996 Jun 1;347(9014):1561

CHEMICALLY INDUCED

Menace in the mix [news] [see comments] **Environ Health Perspect** 1995 Sep;103(9):792–3. Comment in: Environ Health Perspect 1995 Nov;103(11):986.

Clarification: chemical synergism [letter; comment] Hodgson E. **Environ Health Perspect** 1995 Nov;103(11):986. Comment on: Environ Health Perspect 1995 Sep;103(9):792–3.

Chemicals behind Gulf War syndrome? [news] Pennisi E. **Science** 1996 Apr 26;272(5261):479–80

DIAGNOSIS

Demoralization and unexplained illness in two cohorts of American soldiers overseas. Frank JD, et al. **J Nerv Ment Dis** 1996 Jul;184(7):445–6

The "Gulf War syndrome". Is there evidence of dysfunction in the nervous system? Jamal GA, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):449–51

EPIDEMIOLOGY

Bridging the Gulf [editorial] **Lancet** 1996 Feb 10; 347(8998):341

ETIOLOGY

US responds to new suggestion of Gulf War syndrome [news] Roberts J. **BMJ** 1996 Jun 29;312(7047):1629

The search for solutions: veterinarians explore causes of Gulf War syndrome [news] Meehan SK. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1945–6

Medical mystery: Gulf war syndrome. Ficarra BJ. **J Med** 1995;26(1–2):87–94 (9 ref.)

Beef allergy and the Persian Gulf syndrome. Hollander DH. **Med Hypotheses** 1995 Sep;45(3):221–2

IMMUNOLOGY

Desert Storm syndrome and immunization [letter; comment] Reiber H, et al. **Arch Intern Med** 1996 Jan 22;156(2):217 . Comment on: Arch Intern Med 1995 Feb 13;155(3):262–8.

PATHOLOGY

Two Persian Gulf veterans with lymphadenopathy [letter] Friedman HD. **Arch Pathol Lab Med** 1996 May;120(5):425

PHYSIOPATHOLOGY

The "Gulf War syndrome". Is there evidence of dysfunction in the nervous system? Jamal GA, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):449–51

PREVENTION & CONTROL

Cholinergic symptoms and Gulf War syndrome [letter; comment] Lotti M, et al. **Nat Med** 1995 Dec;1(12):1225–6 . Comment on: Nat Med 1995 Oct;1(10):1082–5.

PERSISTENT COMMON ATRIOVENTRICULAR CANAL see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT FETAL CIRCULATION SYNDROME

CHEMICALLY INDUCED

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**

COMPLICATIONS

Delayed post-neonatal intensive care unit hearing disturbance. Kawashiro N, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):35–43

Adenosine infusion improves oxygenation in term infants with respiratory failure. Konduri GG, et al. **Pediatrics** 1996 Mar;97(3):295–300

DIAGNOSIS

[Persistent pulmonary hypertension in newborns] Ganowicz J, et al. **Pediatr Pol** 1995 Mar;70(3):249–53 (14 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Fineman JR, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):425–30 (41 ref.)

Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Abman SH, et al. **Adv Pharmacol** 1995;34:457–74 (71 ref.)

Nitric oxide in the management of persistent pulmonary hypertension of the newborn—an unusual cause of failure. Jerwood DC, et al. **Paediatr Anaesth** 1995;5(3):193–5

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: the physiology matters! [comment] [see comments] Abman SH, et al. **Pediatrics** 1995 Dec; 96(6):1153–5 (14 ref.). Comment on: Pediatrics 1995 Dec;96(6):1147–51. Comment in: Pediatrics 1996 Mar;97(3):438–9.

Inhaled nitric oxide trials: "vive la difference!" [letter; comment] Davidson D. **Pediatrics** 1996 Mar;97(3):438–9. Comment on: Pediatrics 1995 Dec;96(6):1153–5.

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: implications and strategy for future "high-tech" neonatal clinical trials [see comments] Stark AR, et al. **Pediatrics** 1995 Dec;96(6):1147–51 (19 ref.). Comment in: Pediatrics 1995 Dec;96(6):1153–5.

EPIDEMIOLOGY

Persistent pulmonary hypertension of the newborn and

smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Van Marter LJ, et al. **Pediatrics** 1996 May;97(5):658–63

ETIOLOGY

Alveolar capillary dysplasia--a cause of persistent pulmonary hypertension unresponsive to a second course of extracorporeal membrane oxygenation. Chelliah BP, et al. **Pediatrics** 1995 Dec;96(6):1159–61 (13 ref.)

METABOLISM

Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension. Castillo L, et al. **Pediatr Res** 1995 Jul;38(1):17–24

PHYSIOPATHOLOGY

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S18–23 (44 ref.)

Clinical pathophysiology of persistent pulmonary hypertension of the newborn and the role of inhaled nitric oxide therapy. Kinsella JP, et al. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S24–7 (28 ref.)

SURGERY

Orthotopic transplantation for total anomalous pulmonary venous connection associated with complex congenital heart disease. Razzouk AJ, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):713–7

THERAPY

Delayed post-neonatal intensive care unit hearing disturbance. Kawashiro N, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):35–43

ULTRASONOGRAPHY

Tolazoline-assisted Doppler echocardiography confirming normal pulmonary venous return in a neonate with severe persistent pulmonary hypertension. Cooper MJ, et al. **Am J Perinatol** 1995 Sep;12(5):367–70

PERSISTENT OSTIUM PRIMUM see **ENDOCARDIAL CUSHION DEFECTS**

PERSISTENT PULMONARY HYPERTENSION OF NEWBORN see **PERSISTENT FETAL CIRCULATION SYNDROME**

PERSISTENT VEGETATIVE STATE

Clinical incoherence about persons: the problem of the persistent vegetative state [editorial; comment] Cassell EJ. **Ann Intern Med** 1996 Jul 15;125(2):146–7. Comment on: Ann Intern Med 1996 Jul 15;125(2):104–10.

Scottish judges say court can decide in PVS cases [news] Dyer C. **BMJ** 1996 Mar 30;312(7034):797–8

The proof of the vegetable: a commentary on medical futility. Borthwick C. **J Med Ethics** 1995 Aug;21(4):205–8

Persistent vegetative state [editorial] [see comments] Kennard C, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct; 59(4):347–8. Comment in: J Neurol Neurosurg Psychiatry 1996 Jun;60(6):703–4.

Persistent vegetative state [letter; comment] Uzych L. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):703–4. Comment on: J Neurol Neurosurg Psychiatry 1995 Oct;59(4):347–8.

Euthanasia by stages [see comments] Mason JK, et al. **Lancet** 1996 Mar 23;347(9004):810–1. Comment in: Lancet 1996 May 11;347(9011):1334.

Euthanasia, physician assisted suicide, and persistent vegetative state [letter] Treloar A. **Lancet** 1996 Aug 24; 348(9026):549

CLASSIFICATION

Coma and vegetative state are not interchangeable terms [letter; comment] Tommasino C. **Anesthesiology** 1995 Oct; 83(4):888–9. Comment on: Anesthesiology 1995 Feb;82(2):393–403; discussion 27A.

Motor profile of patients in minimally responsive and persistent vegetative states. Pilon M, et al. **Brain Inj** 1996 Jun;10(6):421–37

DIAGNOSIS

Misdiagnosis of the vegetative state: retrospective study in a rehabilitation unit [see comments] Andrews K, et al. **BMJ** 1996 Jul 6;313(7048):13–6. Comment in: BMJ 1996 Jul 6;313(7048):5–6.

Misdiagnosing the persistent vegetative state [editorial; comment] Cranford R. **BMJ** 1996 Jul 6;313(7048):5–6. Comment on: BMJ 1996 Jul 6;313(7048):13–6.

The 1994 Multi-Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3–29 (87 ref.)

The permanent vegetative state. Review by a working group convened by the Royal College of Physicians and endorsed by the Conference of Medical Royal Colleges and their faculties of the United Kingdom. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):119–21

The persistence of mind [editorial] **Lancet** 1996 Jul 13; 348(9020):69

Euthanasia, physician-assisted suicide, and persistent vegetative state [letter] Berek K, et al. **Lancet** 1996 Aug 24;348(9026):549

Psychovegetative syndrome diagnosis: an automated psychophysiological investigation and mathematical modeling approach. Brelidze Z, et al. **Medinfo** 1995;8 Pt 2:953

Late improvement after post-traumatic vegetative state [letter; comment] Caplan L. **N Engl J Med** 1996 May 2; 334(18):1201–2. Comment on: N Engl J Med 1996 Jan 4;334(1):24–5.

ETIOLOGY

Can persistent cerebral damage be caused by hyperglycaemia? Bush GH, et al. **Paediatr Anaesth** 1995; 5(6):385–7

PSYCHOLOGY

The ultimate curse. Crisci C. **J Med Ethics** 1995 Oct; 21(5):277; discussion 278–80

Euthanasia, physician-assisted suicide, and persistent vegetative state [letter] Newmark RW. **Lancet** 1996 Aug 24;348(9026):549

Late improvement after post-traumatic vegetative state [letter; comment] Schwaber EA. **N Engl J Med** 1996 May 2;334(18):1201; discussion 1201–2. Comment on: N Engl J Med 1996 Jan 4;334(1):24–5.

REHABILITATION

Brief report: late improvement in consciousness after post-traumatic vegetative state [see comments] Childs NL, et al. **N Engl J Med** 1996 Jan 4;334(1):24–5. Comment in: N Engl J Med 1996 May 2;334(18):1201; discussion 1201–2. Comment in: N Engl J Med 1996 May 2;334(18):1201–2.

THERAPY

Physicians' attitudes about the care of patients in the persistent vegetative state: a national survey [see comments] Payne K, et al. **Ann Intern Med** 1996 Jul 15;125(2):104–10 . Comment in: Ann Intern Med 1996 Jul 15;125(2):146–7.

Constructing arousal profiles for vegetative state patients--a preliminary report. Wilson SL, et al. **Brain Inj** 1996 Feb; 10(2):105–13

Judicial intervention in medical decision-making: a failure of the medical system? [editorial; comment] Sprung CL, et al. **Crit Care Med** 1996 May;24(5):730–2. Comment on: Crit Care Med 1996 May;24(5):883–7.

The Quinlan case revisited: a history of the cultural politics of medicine and the law. Stevens ML. **J Health Polit Policy Law** 1996 Summer;21(2):347–66; discussion 367–72

Survey of British clinicians' views on management of patients in persistent vegetative state. Grubb A, et al. **Lancet** 1996 Jul 6;348(9019):35–40

[Medical, juridical and ethical problems in permanent vegetative state] Fahrländer H. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1191–5 (Eng. Abstr.) **(Ger)**

[What is our approach to patients in persistent vegetative state? (editorial)] Roth F. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1187–90 (20 ref.) **(Ger)**

PERSONAL CONSTRUCT THEORY

[Constructivism: a characteristic of the psychic process] Ruiz RH. **Acta Psiquiatr Psicol Am Lat** 1995 May;41(2):114–20 (17 ref.) (Eng. Abstr.) **(Spa)**

PERSONAL EXPENDITURES see **FINANCING, PERSONAL**

PERSONAL HEALTH SERVICES

Does the personal physician continue in managed care? [editorial] Scherger JE. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):67–8

STANDARDS

Consumer-directed models of personal care: lessons from Medicaid. Doty P, et al. **Milbank Q** 1996;74(3):377–409

UTILIZATION

[Age, health status and the utilization of general practitioners and specialists] Geling O, et al. **Soz Praventivmed** 1996; 41(1):36–46 (Eng. Abstr.) **(Ger)**

PERSONAL LIABILITY see **LIABILITY, LEGAL**

PERSONAL SATISFACTION

Relationship of eight basic emotions, life needs satisfaction and Type A behavior with body mass index and some biochemical characteristics in healthy blue-collar workers. Catipović-Veselica K, et al. **Acta Med Croatica** 1995; 49(4–5):169–72

Life satisfaction as a mediator between distressing events and neurotic impairment in a general population. Baruffol E, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):56–62

Successful aging, life satisfaction, and generativity in later life. Fisher BJ. **Int J Aging Hum Dev** 1995;41(3):239–50

The experience of being at home throughout the life span. Investigation of persons aged from 2 to 102. Zingmark K, et al. **Int J Aging Hum Dev** 1995;41(1):47–62

Predictors of life satisfaction amongst retired people in Paris. Iwatsubo Y, et al. **Int J Epidemiol** 1996 Feb;25(1):160–70

Gender and life satisfaction in retirement: an assessment of the male model. Calasanti TM. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):S18–29

Amount of care given and caregiving satisfaction: a latent growth curve analysis. Walker AJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):P130–42

The long-term psychosocial effects of infertility. Hirsch AM, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):517–22

Dental impacts on daily life and satisfaction with teeth in relation to dental status in adults. Rosenoer LM, et al. **J Oral Rehabil** 1995 Jul;22(7):469–80

When less is more: counterfactual thinking and satisfaction among Olympic medalists. Medvec VH, et al. **J Pers Soc Psychol** 1995 Oct;69(4):603–10

Events and subjective well-being: only recent events matter. Suh E, et al. **J Pers Soc Psychol** 1996 May;70(5):1091–102

Sexual satisfaction among Korean-American couples in the Midwestern United States. Song JA, et al. **J Sex Marital Ther** 1995 Fall;21(3):147–58

Mental activity, health, and life-satisfaction. Delin CR, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):944–6

Adolescent perceptions of body weight and weight satisfaction. Page RM, et al. **Percept Mot Skills** 1995 Aug; 81(1):81–2

Relationship of eight basic emotions with age, sex, education, satisfaction of life needs, and religion. Catipović-Veselica K, et al. **Psychol Rep** 1995 Aug;77(1):115–21

Convergent validity of the Depression-Happiness Scale with measures of happiness and satisfaction with life. Lewis CA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):876–8

Sex-role orientation and satisfaction with life. Ramanaiah NV, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1260–2

Self-actualization and empathy as predictors of marital satisfaction. Rowan DG, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):1011–6

Comparison of undergraduates with older adults on love styles and life satisfaction. Yancey GB, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1211–8

Toward a conceptual understanding of the flow experience in elite athletes. Jackson SA. **Res Q Exerc Sport** 1996 Mar; 67(1):76–90

[Quality of life, subjective health status and health and life satisfaction in rheumatoid arthritis] Sato H, et al. **Nippon Koshu Eisei Zasshi** 1995 Sep;42(9):743–54 (Eng. Abstr.) **(Jpn)**

[Global life satisfaction and its related factors in community elderly residents] Sugai K, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):374–89 (Eng. Abstr.) **(Jpn)**

[Coping strategies and psychological well-being in mothers of children with disabilities] Pisula E. **Psychiatr Pol** 1996 Mar–Apr;30(2):221–32 (Eng. Abstr.) **(Pol)**

PERSONALITY

Relationship of eight basic emotions, life needs satisfaction and Type A behavior with body mass index and some biochemical characteristics in healthy blue-collar workers. Catipović-Veselica K, et al. **Acta Med Croatica** 1995; 49(4–5):169–72

Personality traits in school children with epilepsy. Sikić N, et al. **Acta Med Croatica** 1995;49(3):121–6

Questionnaire regarding the neurosurgeon's behaviour. Brihaye J. **Acta Neurochir (Wien)** 1995;132(4):224–8

The personality of the neurosurgeon. Dan NG. **Acta Neurochir (Wien)** 1995;132(4):217–21

The neurosurgeon in the medical and civil society. Gustilo RH. **Acta Neurochir (Wien)** 1995;132(4):222–3

Differences in personality between a medical and a surgical practitioner, and between a medical neurologist and a surgical one. van den Bergh R. **Acta Neurochir (Wien)** 1995; 132(4):215–6

Confidence and accuracy in trait inference: judgment by similarity. Koehler DJ, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):33–57

A study of the development of traits of entry-level occupational therapy students. Donohue MV. **Am J Occup Ther** 1995 Jul–Aug;49(7):703–9 (22 ref.)

Hypnotizability and traumatic experience: a diathesis-stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42–63 (155 ref.)

Characteristics of emergency services personnel related to peritraumatic dissociation during critical incident exposure. Marmar CR, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):94–102

Personality and stress: an exploratory comparison of rheumatoid arthritis and osteoarthritis. Latman NS, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):796–800

The relationship between habitual anger coping style and serum lipid and lipoprotein concentrations. Müller MM, et al. **Biol Psychol** 1995 Aug;41(1):69–81

Mortality associated with wines, beers, and spirits. Australian data suggest that choice of beverage relates to lifestyle and

personality [letter; comment] Burke V, et al. **BMJ** 1995 Oct 28;311(7013):1166. Comment on: BMJ 1995 May 6;310(6988):1165–9.

Learned helplessness, attributional style, and depression in epilepsy. Bozeman Epilepsy Surgery Consortium. Hermann BP, et al. **Epilepsia** 1996 Jul;37(7):680–6

Neuroticism in temporal lobe epilepsy: assessment and implications for pre- and postoperative psychosocial adjustment and health-related quality of life. Rose KJ, et al. **Epilepsia** 1996 May;37(5):484–91

The healthy volunteer in clinical pharmacology: personality and motivation. Meyer FP, et al. **Eur J Clin Pharmacol** 1995;48(2):91–6

Personality change in dementia of the Alzheimer's type: relations to caregiver personality and burden. Welleford EA, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):295–314

Personality and the incidence of hypertension among older men: longitudinal findings from the Normative Aging Study. Spiro A 3rd, et al. **Health Psychol** 1995 Nov; 14(6):563–9

Perfectionism traits and perfectionistic self-presentation in eating disorder attitudes, characteristics, and symptoms. Hewitt PL, et al. **Int J Eat Disord** 1995 Dec;18(4):317–26

Smoking and EEG power spectra: effects of differences in arousal seeking. Cook MR, et al. **Int J Psychophysiol** 1995 Apr;19(3):247–56

Personality structure of young Chinese adults: a contrast of residents in Taiwan and rural and urban China. Ying YW, et al. **Int J Soc Psychiatry** 1995 Winter;41(4):284–91

Openness to experience and completed suicide across the second half of life. Duberstein PR. **Int Psychogeriatr** 1995 Summer;7(2):183–98

Stable trait components of hopelessness: baseline and sensitivity to depression. Young MA, et al. **J Abnorm Psychol** 1996 May;105(2):155–65

Three-Factor Eating Questionnaire and Eating Disorder Inventory in the evaluation of psychological traits and emotional reactivity in obese patients. Adami GF, et al. **J Am Diet Assoc** 1996 Jan;96(1):67–8

Effects of impression management and self-deception on the predictive validity of personality constructs. Barrick MR, et al. **J Appl Psychol** 1996 Jun;81(3):261–72

Police officer candidate MMPI-2 performance: gender, ethnic, and normative factors. Kornfeld AD. **J Clin Psychol** 1995 Jul;51(4):536–40

The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. Davis C, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):347–52

The prevalence of dental anxiety in children from low-income families and its relationship to personality traits. Randal M, et al. **J Dent Res** 1995 Aug;74(8):1439–43

Self-knowledge of an amnesic patient: toward a neuropsychology of personality and social psychology. Klein SB, et al. **J Exp Psychol Gen** 1996 Sep;125(3):250–60

Combat-related trauma as measured by ego developmental indices of defenses and identity achievement. Silverstein R. **J Genet Psychol** 1996 Jun;157(2):169–79

Who is the male homosexual? A computer-mediated exploratory study of gay male Bulletin Board System (BBS) users in New York City. Nieto DS. **J Homosex** 1996; 30(4):97–124

Personality, inner experience and compliance in advanced cancer patients treated with external pumps. Pugliese P, et al. **J Infus Chemother** 1995;5(3 Suppl 1):138–43

Personality characteristics and sexual functioning of 188 cross-dressing men. Brown GR, et al. **J Nerv Ment Dis** 1996 May;184(5):265–73

Sociotropy, autonomy, stress, and depression in Cushing syndrome. Burgess E, et al. **J Nerv Ment Dis** 1996 Jun; 184(6):362–7

Personality, functioning, and recovery from major depression. Casey P, et al. **J Nerv Ment Dis** 1996 Apr; 184(4):240–5

A preliminary study of the relationship among personality, cognitive vulnerability, symptom profile, and outcome in major depressive disorder. Scott J, et al. **J Nerv Ment Dis** 1996 Aug;184(8):503–5

Perfectionism and suicidal preoccupation. Adkins KK, et al. **J Pers** 1996 Jun;64(2):529–43

Personality and parenting: exploring the mediating role of transient mood and daily hassles. Belsky J, et al. **J Pers** 1995 Dec;63(4):905–29

Personal influences on professional work: an empirical case study of B.F. Skinner. Demorest AP, et al. **J Pers** 1996 Mar;64(1):243–61

The relations of dispositional regulation and emotionally to elder's empathy-related responding and affect while volunteering. Eisenberg N, et al. **J Pers** 1996 Mar; 64(1):157–83

Comparing the accuracy of personality judgements by the self and knowledgeable others. Kolar DW, et al. **J Pers** 1996 Jun;64(2):311–37

The prejudiced personality, racism, and anti-Semitism: the PR scale forty years later. Dunbar E. **J Pers Assess** 1995 Oct;65(2):270–7

Personality characteristics of hospice volunteers as measured by Myers-Briggs Type Indicator. Mitchell CW, et al. **J Pers Assess** 1995 Dec;65(3):521–32

Effects of MMPI-2 and MMPI-A norms on T-score elevations for 18-year-olds. Shaevel B, et al. **J Pers Assess** 1996 Aug;67(1):72–8

A framework for studying personality in the stress process. Bolger N, et al. **J Pers Soc Psychol** 1995 Nov;69(5):890–902

Savings in relearning: II. On the formation of behavior-based trait associations and inferences. Carlston DE, et al. **J Pers Soc Psychol** 1995 Sep;69(3):420–35

Factor structure of mental health measures. Compton WC, et al. **J Pers Soc Psychol** 1996 Aug;71(2):406–13

The structure of temperament and personality in Russian children. Digman JM, et al. **J Pers Soc Psychol** 1996 Aug; 71(2):341–51

Agreement among judges of personality: interpersonal relations, similarity, and acquaintanceship. Funder DC, et al. **J Pers Soc Psychol** 1995 Oct;69(4):656–72

Perceiving interpersonal conflict and reacting to it: the case for agreeableness. Graziano WG, et al. **J Pers Soc Psychol** 1996 Apr;70(4):820–35

Enduringness and change in creative personality and the prediction of occupational creativity. Helson R, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1173–83

Cross-cultural generalizability of personality dimensions: relating indigenous and imported dimensions in two cultures. Katigbak MS, et al. **J Pers Soc Psychol** 1996 Jan; 70(1):99–114

Environmental and personal determinants of support perceptions: three generalizability studies. Lakey B, et al. **J Pers Soc Psychol** 1996 Jun;70(6):1270–80

Dispositional and situational determinants of repression. Mendolia M, et al. **J Pers Soc Psychol** 1996 Apr; 70(4):856–67

Enhancing target variance in personality impressions: highlighting the person in person perception. Paulhus DL, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1233–42

Central and peripheral self-conceptions are differentially influenced by mood: tests of the differential sensitivity hypothesis. Sedikides C. **J Pers Soc Psychol** 1995 Oct; 69(4):759–77

Effects of adult attachment style on the perception and search for social support. Florian V, et al. **J Psychol** 1995 Nov; 129(6):665–76

Cognitive styles and personality characteristics strongly influence the decision to have photorefractive keratectomy. Erickson DB, et al. **J Refract Surg** 1995 Jul–Aug; 11(4):267–74; discussion 274–81

Modes of long-term coping with trauma memories: relative use and associations with personality among Vietnam veterans with chronic PTSD. Hyer L, et al. **J Trauma Stress** 1996 Apr;9(2):299–316

Congruence in personality between clinician and client: relationship to ratings of voice treatment. Andrews ML, et al. **J Voice** 1995 Sep;9(3):261–9

Personality as independent predictor of long-term mortality in patients with coronary heart disease [see comments] Denollet J, et al. **Lancet** 1996 Feb 17;347(8999):417–21. Comment in: Lancet 1996 Feb 17;347(8999):414–5.

Negative emotions and coronary heart disease: getting to the heart of the matter [comment] Lespérance F, et al. **Lancet** 1996 Feb 17;347(8999):414–5. Comment on: Lancet 1996 Feb 17;347(8999):417–21.

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul–Sep;23(3):82–9 (36 ref.)

Personality and performance of preclinical medical students. Peng R, et al. **Med Educ** 1995 Jul;29(4):283–8

Induction of changes in human behaviour by the parasitic protozoan Toxoplasma gondii. Flegr J, et al. **Parasitology** 1996 Jul;113 (Pt 1):49–54

Effects of self-efficacy and dispositional optimism on adherence to step aerobic exercise classes. Fontaine KR, et al. **Percept Mot Skills** 1995 Aug;81(1):251–5

Trait and state anxiety before and after competitive performance. Halvari H, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 2):1059–74

Handedness and personality. Lester D. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1290

Personality correlates of correctly identifying genuine suicide notes. Lester D. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):890

In similarity judgments hunter-gatherers prefer shapes over spatial relations in contrast to literate groups. Pontius AA. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1027–41

The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Oreland L, et al. **Prog Brain Res** 1995; 106:77–84 (52 ref.)

Contributions to psychohistory: XXIII. Hemingway "analyzed". Craig RJ. **Psychol Rep** 1995 Jun;76(3 Pt 2):1059–79

Personality inferences drawn about abusive mothers. Davidson WB, et al. **Psychol Rep** 1995 Oct;77(2):391–400

Alcohol consumption and health: synergistic interaction with personality. Grossarth-Maticek R, et al. **Psychol Rep** 1995 Oct;77(2):675–87

Relation among self-defeating personality, troubled eating patterns, and dissociation. Kisler V, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):780–2

Personality, peer influence, and use of alcohol and drugs by first-year university students. Valliant PM. **Psychol Rep** 1995 Oct;77(2):401–2

On the accuracy of personality judgment: a realistic approach. Funder DC. **Psychol Rev** 1995 Oct;102(4):652–70

Personality and mortality after myocardial infarction. Denollet J, et al. **Psychosom Med** 1995 Nov–Dec; 57(6):582–91

On stability of the structure of implicit personality theory over situations. Hochwälder J. **Scand J Psychol** 1995 Dec; 36(4):386–98

Perception, personality, and respiratory control in life-threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2–4 (15 ref.)

[Personality characteristics of men with psychogenic erectile dysfunction] Weiss P, et al. **Cesk Psychiatr** 1995 Jul; 91(3):162–8 (Eng. Abstr.) **(Cze)**

[Breast and genital cancer patients—psychosocial examination in the pre- and postoperative phase] Stauber M. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M66–8 **(Ger)**

[Intuitive evaluation of guilt of violent offenders in relation to offender personality] Endres J. **Z Exp Psychol** 1995; 42(3):353–85 (Eng. Abstr.) **(Ger)**

[Mental health—personality—existentialism. An empirical contribution from the existential analytic viewpoint] Wurst E, et al. **Z Klin Psychol Psychopathol Psychother** 1996; 44(2):200–12 (Eng. Abstr.) **(Ger)**

[Irrationality and risk—a problem analysis] Bergler R. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):260–75 (Eng. Abstr.) **(Ger)**

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Various personality traits of patients with psoriatic arthropathy] Giordano N, et al. **Minerva Med** 1996 Jun; 87(6):283–7 (Eng. Abstr.) **(Ita)**

[Personality determinants of effectiveness in performing duties by soldiers in active service in the landing-shock brigade] Florkowski A, et al. **Psychiatr Pol** 1996 Mar–Apr; 30(2):331–9 (Eng. Abstr.) **(Pol)**

[The personality characteristics of today's adolescents and means for their correction] Sergeta IV, et al. **Gig Sanit** 1996 Jan–Feb;(1):29–31 (Eng. Abstr.) **(Rus)**

[The frequency of behavioral type A among young myocardial infarct patients and their personality characteristics] Savchenko NA, et al. **Lik Sprava** 1995 May–Jun;(5–6):147–9 (Eng. Abstr.) **(Rus)**

[Methods for studying deviant personality behavior during the professional psychological selection of military specialists] Glushko AN. **Voen Med Zh** 1992 Feb;(2):67–9 **(Rus)**

[The psychological investigation of personality toward a multidimensional definition of characteristics] Lolas F. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):129–34 (22 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Resilient, overcontrolled, and undercontrolled boys: three replicable personality types. Robins RW, et al. **J Pers Soc Psychol** 1996 Jan;70(1):157–71

Treatment of obesity by personality classification-oriented program. Yoshida S, et al. **Obes Res** 1995 Sep;3 Suppl 2:205s–209s

DRUG EFFECTS

Neuropsychological effects of amphetamine may correlate with personality characteristics. Fleming K, et al. **Psychopharmacol Bull** 1995;31(2):357–62

GENETICS

Seed or soil: how does our garden grow? [editorial] Eisenberg L. **Am J Psychiatry** 1996 Jan;153(1):3–5

Parenting: a genetic-epidemiologic perspective. Kendler KS. **Am J Psychiatry** 1996 Jan;153(1):11–20

A multivariate genetic analysis of sensation seeking. Koopmans JR, et al. **Behav Genet** 1995 Jul;25(4):349–56

Intrapair differences in personality and cognitive ability among young monozygotic twins distinguished by chorion type. Sokol DK, et al. **Behav Genet** 1995 Sep;25(5):457–66

The D2 dopamine receptor gene, addiction, and personality: clinical correlates in cocaine abusers. Compton PA, et al. **Biol Psychiatry** 1996 Feb 15;39(4):302–4

Research finds genetic link to personality trait [news] Richards T. **BMJ** 1996 Jan 13;312(7023):75

Traits and metatraits: their reliability, stability, and shared genetic influence. Hershberger SL, et al. **J Pers Soc Psychol** 1995 Oct;69(4):673–85

Personality and divorce: a genetic analysis. Jockin V, et al. **J Pers Soc Psychol** 1996 Aug;71(2):288–99

Genetic and environmental structure of the Tridimensional Personality Questionnaire: three or four temperament dimensions? Stallings MC, et al. **J Pers Soc Psychol** 1996 Jan;70(1):127–40

Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Benjamin J, et al. **Nat Genet** 1996 Jan;12(1):81–4

Mapping genes for human personality [news] Cloninger CR, et al. **Nat Genet** 1996 Jan;12(1):3–4

Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Ebstein RP, et al. **Nat Genet** 1996 Jan;12(1):78–80

[Inheritability of personality traits measured by MMPI in families of schizophrenic patients] Alfimova MV, et al. **Genetika** 1995 Jul;31(7):1010–5 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Personality, emotions and the temporolimbic system: a

neuropsychological approach. Beeckmans K, et al. **Acta Neurol Belg** 1996 Mar;96(1):35–42 (51 ref.)

Nonlinear dynamical patterns as personality theory for neurobiology and psychiatry. Mandell AJ, et al. **Psychiatry** 1995 Nov;58(4):371–90

High self–esteem, hardiness and affective stability are associated with higher basal pituitary–adrenal hormone levels. Zorrilla EP, et al. **Psychoneuroendocrinology** 1995; 20(6):591–601

[The bioelectrical correlates of the personality anxiousness of 2 strong types of higher nervous activity] Kalashnikova IG, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug;45(4):661–8 (Eng. Abstr.) **(Rus)**

PERSONALITY ASSESSMENT

Inter–observer and test–retest reliability of the Italian version of the Karolinska Psychodynamic Profile in two groups of psychiatric patients. Turrina C, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):282–7

Reliability of a drug history questionnaire (DHQ). Sobell LC, et al. **Addict Behav** 1995 Mar–Apr;20(2):233–41

Comparison of direct interview and family history diagnoses of alcohol dependence. Rice JP, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1018–23

Persistent perfectionism, symmetry, and exactness after long–term recovery from anorexia nervosa. Srinivasagam NM, et al. **Am J Psychiatry** 1995 Nov;152(11):1630–4

The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967–76 (60 ref.)

Challenging behaviour and intellectual disability: assessment, analysis and treatment. Cullen C. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):153–6

Personality and psychosocial function after brain injury. Malia K, et al. **Brain Inj** 1995 Oct;9(7):697–712

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257–63 (30 ref.)

Firesetting during the preschool period: assessment and intervention issues. Hanson M, et al. **Can J Psychiatry** 1995 Aug;40(6):299–303

Migraine: association with personality characteristics and psychopathology. Silberstein SD, et al. **Cephalalgia** 1995 Oct;15(5):358–69; discussion 336 (64 ref.)

Assessing juvenile sex offenders to determine adequate levels of supervision. Gerdes KE, et al. **Child Abuse Negl** 1995 Aug;19(8):953–61

Sexual abuse evaluations in the emergency department: is the history reliable? Gordon S, et al. **Child Abuse Negl** 1996 Apr;20(4):315–22

The effects of state terrorism and exile on indigenous Guatemalan refugee children: a mental health assessment and an analysis of children's narratives. Miller KE. **Child Dev** 1996 Feb;67(1):89–106

Better than expected: improvements in borderline personality disorder in a 3–year prospective outcome study. Najavits LM, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):296–302

Clinical profile of comorbid major depression and alcohol use disorders in an initial psychiatric evaluation. Salloum IM, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):260–6

Suicide attempts in adolescence—"self–report" and "other–report". de Wilde EJ, et al. **Crisis** 1995;16(2):59–62, 65

Motivation in later life: theory and assessment. Vallerand RJ, et al. **Int J Aging Hum Dev** 1995;41(3):221–38

Bulimia nervosa: 5–year social outcome and relationship to eating pathology. Reiss D, et al. **Int J Eat Disord** 1995 Sep;18(2):127–33

Personality and antisocial behavior in children and adolescents: an enquiry into Eysenck's and Gray's theories. Fonseca AC, et al. **J Abnorm Child Psychol** 1995 Dec; 23(6):767–81

Household family structure and children's aggressive behavior: a longitudinal study of urban elementary school children. Vaden–Kiernan N, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):553–68

Prospective prediction of husband marital aggression within newlywed couples. Leonard KE, et al. **J Abnorm Psychol** 1996 Aug;105(3):369–80

A genetic study of maternal and paternal ratings of problem behaviors in 3–year–old twins. van den Oord EJ, et al. **J Abnorm Psychol** 1996 Aug;105(3):349–57

Asperger's syndrome [clinical conference] Volkmar FR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan; 35(1):118–23

Brief report: variables related to parental choice to medicate their autistic children. Konstantareas M, et al. **J Autism Dev Disord** 1995 Aug;25(4):443–52

Annotation: self–injurious behaviour in children with learning disabilities: recent advances in assessment and intervention. Oliver C. **J Child Psychol Psychiatry** 1995 Sep;36(6):909–27 (100 ref.)

Teacher ratings of children's behaviors and teachers' management styles: a research note. Vitaro F, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):887–98

The discovery of marijuana use by a parent of an early adolescent. **J Dev Behav Pediatr** 1995 Jun;16(3):196–8

Identity closure: a fifth identity status. Valde GA. **J Genet Psychol** 1996 Sep;157(3):245–54

Levels and domains in personality: an introduction. Emmons RA. **J Pers** 1995 Sep;63(3):341–64 (70 ref.)

Multiple identities and the integration of personality. Gregg GS. **J Pers** 1995 Sep;63(3):617–41 (35 ref.)

Self–with–other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643–79 (80 ref.)

Juxtaposed scripts, traits, and the dynamics of personality. Thorne A. **J Pers** 1995 Sep;63(3):593–616

A clinical–empirical model of personality: life after the Mischelian ice age and the NEO–lithic era. Westen D. **J Pers** 1995 Sep;63(3):495–524 (95 ref.)

Personality assessment and managed care. Acklin MW. **J Pers Assess** 1996 Feb;66(1):194–201

Validation evidence for three coping measures. Clark KK, et al. **J Pers Assess** 1995 Dec;65(3):434–55

The prejudiced personality, racism, and anti–Semitism: the PR scale forty years later. Dunbar E. **J Pers Assess** 1995 Oct;65(2):270–7

Sex, sex roles, and sexual attitudes: figure gender in the Draw–A–Person test revisited. Houston AN, et al. **J Pers Assess** 1995 Oct;65(2):343–57

Personality characteristics of hospice volunteers as measured by Myers–Briggs Type Indicator. Mitchell CW, et al. **J Pers Assess** 1995 Dec;65(3):521–32

The structure of psychological well–being revisited. Ryff CD, et al. **J Pers Soc Psychol** 1995 Oct;69(4):719–27

The relationship of patients' cognitive status and therapists' ratings of psychological distress among psychoactive substance users in long–term residential treatment. Fals–Stewart W, et al. **J Subst Abuse** 1995;7(2):205–22

Situational analysis of coping in substance–abusing patients. Schmitz JM, et al. **J Subst Abuse** 1995;7(2):189–204

Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Kalachnik JE, et al. **Ment Retard** 1995 Dec; 33(6):374–82

Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329–41 (34 ref.)

Clinical decision making during assessment for involuntary psychiatric admission. Anderson J, et al. **Psychiatr Serv** 1995 Jul;46(7):727–8

Observed behavior of patients with seasonal affective disorder and an interviewer predicts response to light treatment. Geerts E, et al. **Psychiatry Res** 1995 Aug 28; 57(3):223–30

Psychological science and the use of anatomically detailed dolls in child sexual–abuse assessments. Koocher GP, et al. **Psychol Bull** 1995 Sep;118(2):199–222 (160 ref.)

The relationship between suggestibility and anxiety among suspects detained at police stations. Gudjonsson GH, et al. **Psychol Med** 1995 Jul;25(4):875–8

Change in symptomatology of melancholic depression over two decades. Core symptoms and culturally determined symptoms. Ebert D, et al. **Psychopathology** 1995; 28(5):273–80

Personality factors in women with premenstrual syndrome. Freeman EW, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):453–9

Parental reports of community activity patterns: a comparison between young children with disabilities and their nondisabled peers. Ehrmann LC, et al. **Res Dev Disabil** 1995 Jul–Aug;16(4):331–43

Definition and measurement of sexual orientation. Gonsiorek JC, et al. **Suicide Life Threat Behav** 1995;25 Suppl:40–51

Negative attributional style for interpersonal events and the occurrence of severe interpersonal disruptions as predictors of self–reported suicidal ideation. Joiner TE Jr, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):297–304

[Viewing of horror and violence videos by adolescence. A study of speech samples of video consumers with the Gottschalk–Gleser Speech Content analysis] Hopf H, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 May–Jun; 45(5):179–85 (Eng. Abstr.) **(Ger)**

[Between isolation and new hope: the psychosocial status of HIV–infected women] Franke GH, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):310–20 (Eng. Abstr.) **(Ger)**

[Structure and structural disorder] Rudolf G, et al. **Z Psychosom Med Psychoanal** 1995;41(3):197–212 (Eng. Abstr.) **(Ger)**

HISTORY

The predelusional state: a conceptual history. Fuentenebro F, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):251–9

STATISTICS & NUMERICAL DATA

Improving the usefulness of the Karolinska Psychodynamic Profile in research: proposals from a reliability study. Haver B, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):132–7

Training in evaluation of expressed emotion using the Japanese version of the Camberwell Family Interview. Mino Y, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):183–6

Identification of "binge–prone" women: an experimentally and psychometrically validated cluster analysis in a college population. Beebe DW, et al. **Addict Behav** 1995 Jul–Aug; 20(4):451–62

Prospective screening of substance dependence: the advantages of directness. Svanum S, et al. **Addict Behav** 1995 Mar–Apr;20(2):205–13

Assessing consistency of responses to questions on cocaine use. Adair EB, et al. **Addiction** 1995 Nov;90(11):1497–502

Predictive capacity of the AUDIT questionnaire for alcohol–related harm. Conigrave KM, et al. **Addiction** 1995 Nov;90(11):1479–85

An evaluation of type A and B alcoholics. Schuckit MA, et al. **Addiction** 1995 Sep;90(9):1189–203

Ethnic differences in performance of screening instruments for identifying harmful drinking and alcohol dependence in the emergency room. Cherpitel CJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):628–34

Evaluating psychotropic drugs in people with mental retardation: where are the social validity data? Poling A, et al. **Am J Ment Retard** 1995 Sep;100(2):193–200 (48 ref.)

Personality: individual differences and clinical assessment. Butcher JN, et al. **Annu Rev Psychol** 1996;47:87–111 (240 ref.)

A comparison of alternative methods of screening for dementia in clinical settings. Mulligan R, et al. **Arch Neurol** 1996 Jun;53(6):532–6

Multiple raters of disruptive child behavior: using a genetic strategy to examine shared views and bias. Simonoff E, et al. **Behav Genet** 1995 Jul;25(4):311–26

Psychomotor retardation found in college students seeking counseling. Barkley TJ, et al. **Behav Res Ther** 1995 Nov; 33(8):977–84

Statistical power: concepts, procedures, and applications. Hallahan M, et al. **Behav Res Ther** 1996 May–Jun; 34(5–6):489–99

Confirmatory factor analysis of The Aggression Questionnaire. Harris JA. **Behav Res Ther** 1995 Nov; 33(8):991–3

Prediction of outcome in the treatment of specific phobia. A cross validation study. Hellström K, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):403–11

Multidimensional assessment and causal modelling in teacher stress research: a commentary. Chan DW. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):381–5

Scale for assessing hedonic tone [letter] Loas G, et al. **Br J Psychiatry** 1995 Oct;167(4):551

The Borderline Syndrome Index: a validation study using the personality assessment schedule. Marlowe MJ, et al. **Br J Psychiatry** 1996 Jan;168(1):72–5

Assessment of personality functioning in the transition from adolescent to adult life: preliminary findings. Naughton M, et al. **Br J Psychiatry** 1996 Jan;168(1):33–7

Seasonal changes in affective state measured prospectively and retrospectively. Nayyar K, et al. **Br J Psychiatry** 1996 May;168(5):627–32

Effect of early life experiences and personality on the reporting of psychosocial distress in general practice. A preliminary investigation. Weich S, et al. **Br J Psychiatry** 1996 Jan;168(1):116–20

Studying temperament via construction of the Toddler Behavior Assessment Questionnaire. Goldsmith HH. **Child Dev** 1996 Feb;67(1):218–35

Assessment of sexual abuse and trauma: clinical measures. Miller TW, et al. **Child Psychiatry Hum Dev** 1995 Fall; 26(1):3–10 (20 ref.)

Brief child assessment battery to assist with treatment planning and program evaluation. Goldman J, et al. **Community Ment Health J** 1995 Oct;31(5):437–48

Routine assessment of patient progress: a multiformat, change–sensitive nurses' instrument for assessing psychotic inpatients. Ehmann TS, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):289–95

Validity of psychiatric diagnoses in patients with substance use disorders: is the interview more important than the interviewer? Kranzler HR, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):278–88

The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Grant BF, et al. **Drug Alcohol Depend** 1995 Jul;39(1):37–44

Validity of intravenous drug abusers' self–reported changes in HIV high–risk drug use behaviors. Greenfield L, et al. **Drug Alcohol Depend** 1995 Aug;39(2):91–8

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210–20 (87 ref.)

Detecting psychological distress among patients attending secondary health care clinics. Self–report and physician rating. Feldman D, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):425–32

Predictors of recidivism to a juvenile assessment center. Dembo R, et al. **Int J Addict** 1995 Sep;30(11):1425–52

The Yale–Brown–Cornell Eating Disorder Scale: a new scale to assess eating disorder symptomatology. Sunday SR, et al. **Int J Eat Disord** 1995 Nov;18(3):237–45

The Diagnostic Interview Schedule for Children (PC–DISC v.3.0): parents and adolescents suggest reasons for expecting discrepant answers. Bidaut–Russell M, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):641–59

A Russian adaptation of the Child Behavior Checklist: psychometric properties and associations with child and maternal affective symptomatology and family function. Carter AS, et al. **J Abnorm Child Psychol** 1995 Dec; 23(6):661–84

Behavioral and emotional problems among Chinese and American children: parent and teacher reports for ages 6 to 13. Weine AM, et al. **J Abnorm Child Psychol** 1995 Oct; 23(5):619–39

Comparative validity of two measures of psychomotor function in patients with severe depression. Hickie I, et al. **J Affect Disord** 1996 Apr 12;37(2–3):143–9

Motor activity and severity of depression in hospitalized prepubertal children. Aronen ET, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):752–63

Child Behavior Checklist findings further support comorbidity between ADHD and major depression in a referred sample. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):734–42

Data-gathering tools for "real world" clinical settings: a multisite feasibility study. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):55–66

Predictors of comorbid alcohol and substance abuse in depressed adolescents. King CA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):743–51

Criterion validity of the NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3). Schwab-Stone ME, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):878–88

The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. Shaffer D, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):865–77

The pre-linguistic autism diagnostic observation schedule. DiLavore PC, et al. **J Autism Dev Disord** 1995 Aug; 25(4):355–79

The Developmental Behavior Checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation. Einfeld SL, et al. **J Autism Dev Disord** 1995 Apr;25(2):81–104

Questionnaire screening for comorbid pervasive developmental disorders in congenitally blind children: a pilot study. Goodman R, et al. **J Autism Dev Disord** 1995 Apr;25(2):195–203

An examination of the phenomenology and the reliability of ratings of compulsive behavior in autism. McBride JA, et al. **J Autism Dev Disord** 1995 Aug;25(4):381–96

Inconsistencies in psychosocial assessment of children after severe burns. Meyer WJ 3rd, et al. **J Burn Care Rehabil** 1995 Sep-Oct;16(5):559–68; discussion 557–8

Parental ratings of behaviour problems: a twin and general population comparison. Gjone H, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1213–24

Inter-rater reliability of global assessment of functioning in a clinical setting. Rey JM, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):787–92

Security of attachment in 8–12-year-olds: a revised version of the Separation Anxiety Test, its psychometric properties and clinical interpretation. Wright JC, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):757–74

Prediction of adolescent aggression by childhood personality measures: a comparison of projective procedures, self-report tests, and behavior ratings. Graybill D, et al. **J Clin Psychol** 1996 Jan;52(1):61–6

Development of an instrument for assessing self-efficacy in schizophrenic spectrum disorders. McDermott BE. **J Clin Psychol** 1995 May;51(3):320–31

Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Brown TA, et al. **J Consult Clin Psychol** 1995 Oct;63(5):754–65

Construction and validation of risk assessments in a six-year follow-up of forensic patients: a tridimensional analysis. Menzies R, et al. **J Consult Clin Psychol** 1995 Oct; 63(5):766–78

Violent recidivism: assessing predictive validity. Rice ME, et al. **J Consult Clin Psychol** 1995 Oct;63(5):737–48

Five methods for computing significant individual client change and improvement rates: support for an individual growth curve approach. Speer DC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):1044–8

Early-onset conduct problems: does gender make a difference? Webster-Stratton C. **J Consult Clin Psychol** 1996 Jun;64(3):540–51

Composite versus multiple-rating scales in the assessment of psychopathology in people with mental retardation. Havercamp SM, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):176–9

Response biases in interviews of individuals with limited mental ability. Heal LW, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):331–40

The Behavior Problem Inventory: a further replication of its factor structure. Sturmey P, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):353–6

Depressive tendencies and susceptibility to anxiety: differential personality correlates. Kremen AM. **J Pers** 1996 Mar;64(1):209–42

Delay of gratification, psychopathology, and personality: is low self-control specific to externalizing problems? Krueger RF, et al. **J Pers** 1996 Mar;64(1):107–29

Private and public self-consciousness and articulation of the ought self from private and public vantages. Nasby W. **J Pers** 1996 Mar;64(1):131–56

Assessment and prediction of stress-related growth. Park CL, et al. **J Pers** 1996 Mar;64(1):71–105

Relationships of objective and projective dependency scores to sex role orientation in college student participants. Bornstein RF, et al. **J Pers Assess** 1996 Jun;66(3):555–68

Object relations in abusive partner relationships: an empirical investigation. Cogan R, et al. **J Pers Assess** 1996 Feb; 66(1):106–15

Dissociative trance disorder: clinical and Rorschach findings in ten persons reporting demon possession and treated by exorcism. Ferracuti S, et al. **J Pers Assess** 1996 Jun; 66(3):525–39

Racial differences on psychological measures in combat veterans seeking treatment for PTSD. Frueh BC, et al. **J Pers Assess** 1996 Feb;66(1):41–53

The Big-Five factor structure as an integrative framework: an analysis of Clarke's AVA model. Goldberg LR, et al. **J Pers Assess** 1996 Jun;66(3):441–71

Distorted self-perceptions: divergent self-reports as statistical outliers in the multimethod assessment of children's social-emotional adjustment. Weinberger DA. **J Pers Assess** 1996 Feb;66(1):126–43

The concordance between symptom information gathered from remitted schizophrenic patients and their relatives. Dixon MJ, et al. **J Psychiatr Res** 1995 Nov-Dec; 29(6):447–56

Comorbidity in the anxiety disorders: the use of a life-chart approach. Hunt C, et al. **J Psychiatr Res** 1995 Nov-Dec; 29(6):467–80

The severity of dieting and bingeing behaviors in college women: interview validation of survey data. Kurth CL, et al. **J Psychiatr Res** 1995 May-Jun;29(3):211–25

Research diagnosis of current depressive disorder: a comparison of methods using current symptoms and lifetime history. Simon GE, et al. **J Psychiatr Res** 1995 Nov-Dec;29(6):457–65

Relationships among three general approaches to personality description. Mehrabian A. **J Psychol** 1995 Sep; 129(5):565–81

Motives for having or not having children: a comparison between questionnaire and interview methods. Wikman M, et al. **J Psychosom Obstet Gynaecol** 1995 Dec;16(4):171–80

Reliability of individual diagnostic criterion items for psychoactive substance dependence and the impact on diagnosis. Bucholz KK, et al. **J Stud Alcohol** 1995 Sep; 56(5):500–5

Assessment of disordered eating in females: instrument validation. Lundholm JK, et al. **J Subst Abuse** 1988–89; 1(2):195–202

Evaluating students' substance abuse assessment skills. Murphy SA, et al. **J Subst Abuse** 1995;7(3):357–64

Problems in the application of the Addiction Severity Index (ASI) in rural substance abuse services. Wertz JS, et al. **J Subst Abuse** 1995;7(2):175–88

Individual Assessment Profile (IAP). Standardizing the assessment of substance abusers. Flynn PM, et al. **J Subst Abuse Treat** 1995 May-Jun;12(3):213–21

The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A). An interview for assessing multiple problems of adolescents. Meyers K, et al. **J Subst Abuse Treat** 1995 May-Jun;12(3):181–93

Detecting a history of childhood sexual experiences among women substance abusers. Pearce EJ, et al. **J Subst Abuse Treat** 1995 Jul-Aug;12(4):283–7

Is it easier to use a secure mother as a secure base? Attachment Q-sort correlates of the adult attachment interview. Posada G, et al. **Monogr Soc Res Child Dev** 1995; 60(2-3):133–45

Depressive symptom experiences among older women: a comparison of alternative measurement approaches. Newmann JP, et al. **Psychol Aging** 1996 Mar;11(1):112–26

The Child and Adolescent Psychiatric Assessment (CAPA). Angold A, et al. **Psychol Med** 1995 Jul;25(4):739–53 (35 ref.)

A test-retest reliability study of child-reported psychiatric symptoms and diagnoses using the Child and Adolescent Psychiatric Assessment (CAPA-C). Angold A, et al. **Psychol Med** 1995 Jul;25(4):755–62

Measuring the need for psychiatric treatment in the general population: the community version of the MRC Needs for Care Assessment. Bebbington P, et al. **Psychol Med** 1996 Mar;26(2):229–36

Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies. Faraone SV, et al. **Psychol Med** 1996 Mar; 26(2):401–10

The reliability of the community version of the MRC Needs for Care Assessment. Lesage AD, et al. **Psychol Med** 1996 Mar;26(2):237–43

The structure of common psychiatric symptoms: how many dimensions of neurosis? Ormel J, et al. **Psychol Med** 1995 May;25(3):521–30

Sub-typing depression, III. Development of a clinical algorithm for melancholia and comparison with other diagnostic measures. Parker G, et al. **Psychol Med** 1995 Jul;25(4):833–40

Psychological distress among recent immigrants from the former Soviet Union to Israel, I. Correlates of level of distress. Zilber N, et al. **Psychol Med** 1996 May; 26(3):493–501

Psychological adjustment to hospitalization: factorial structure, antecedents, and outcome. Bruchon-Schweitzer M, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1091–100

Validity of the Amsterdam Child Behavior Checklist: a short rating scale for children. de Jong PF. **Psychol Rep** 1995 Dec;77(3 Pt 2):1139–44

Assessing Machiavellianism and Morality-Conscience Guilt. Drake DS. **Psychol Rep** 1995 Dec;77(3 Pt 2):1355–9

Evaluation status, educational setting, and behavior ratings of students with serious emotional disturbance. Hutton JB. **Psychol Rep** 1995 Dec;77(3 Pt 1):1049–50

Rating scales for the psychosocial evaluation of organ transplant candidates. Comparison of the PACT and TERS with bone marrow transplant patients. Presberg BA, et al. **Psychosomatics** 1995 Sep-Oct;36(5):458–61

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Aman MG, et al. **Res Dev Disabil** 1996 Jan-Feb;17(1):41–57

Characteristics of autism as assessed by the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Matson JL, et al. **Res Dev Disabil** 1996 Mar-Apr; 17(2):135–43

Parent- and self-ratings of anxiety in children with mental retardation: agreement levels and test-retest reliability. Sarphare G, et al. **Res Dev Disabil** 1996 Jan-Feb; 17(1):27–39

The Nisonger Child Behavior Rating Form: age and gender effects and norms. Tassé MJ, et al. **Res Dev Disabil** 1996 Jan-Feb;17(1):59–75

Development of a scale to measure core beliefs and perceived self efficacy in adults with epilepsy. Tedman S, et al. **Seizure** 1995 Sep;4(3):221–31

[Markers of depression regarding DSM and popular diagnosis: an analysis of concordance in Quebec patients] Massé R, et al. **Can J Psychiatry** 1995 Nov;40(9):551–61 (Eng. Abstr.) **(Fre)**

[Psychometric evaluation of obsessive compulsive disorder. Recent diagnostic scales] Buisson G, et al. **Encephale** 1989 May-Jun;15(3):359–67 (33 ref.) (Eng. Abstr.) **(Fre)**

[Assisted evaluation scale of quality of life] Grabot D, et al. **Encephale** 1996 May-Jun;22(3):181–5 (Eng. Abstr.) **(Fre)**

[Social relations of children in the primary school age group. A study with the SOBEKI method in 8- to 11-year-old primary school children] Berger C. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3-4):102–10 (Eng. Abstr.) **(Ger)**

[Behavioral dimensions and behavior problems in 2 1/2-year-old children] Fegert JM. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3-4):83–94 (Eng. Abstr.) **(Ger)**

[Coping in the family context: active and avoidance strategies in adolescents from divorced families] Huss M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3-4):123–30 (Eng. Abstr.) **(Ger)**

[Early attachment experiences and behavioral problems in young children in a social and cognitive test situation] Ziegenhain U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr;45(3-4):95–102 (Eng. Abstr.) **(Ger)**

[Social adjustment of psychiatric patients: evaluation of a modified version of the GAF (Global Assessment of Functioning) Scale] Meins W, et al. **Psychiatr Prax** 1995 Sep;22(5):206–8 (Eng. Abstr.) **(Ger)**

[Analysis of etiologic models of disease development and continuation of bulimia nervosa using structural equation modeling] Jäger B. **Psychother Psychosom Med Psychol** 1995 Sep-Oct;45(9–10):329–35 (Eng. Abstr.) **(Ger)**

[Evaluation and analysis of social relationships of children in clinical practice and research: "Social Relationship Scale for Children"] Roos J, et al. **Z Kinder Jugenpsychiatr** 1995 Dec;23(4):255–66 (Eng. Abstr.) **(Ger)**

[Critique of the German validation of the Child Behavior Checklist (Döpfner et al., 1994) (comment)] Sponsel R. **Z Kinder Jugenpsychiatr** 1995 Sep;23(3):209–11; discussion 212–6. Comment on: Z Kinder Jugenpsychiatr 1994 Sep;22(3):189–205. **(Ger)**

[Goal attaining scale. Reliability and practical experiences in 397 psychiatric treatment courses. 2: Practical experiences with a simplified version of Goal Attainment Scaling in clinical practice and intermediate length rehabilitational treatment] Bolm W. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):75–88 (Eng. Abstr.) **(Ger)**

[Coping strategies of children and adolescents with diabetes mellitus: the German language version of KIDCOPE] Rathner G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):49–74 (Eng. Abstr.) **(Ger)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3–32 (90 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DEVELOPMENT

see related
SOCIALIZATION

Psychological long-term coping with experience of disease and treatment in childhood cancer survivors. Boman K, et al. **Acta Paediatr** 1995 Dec;84(12):1395–402

Genetic factors in early separation anxiety: implications for the genesis of adult anxiety disorders. Silove D, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):17–24

Classifying COAs with three variations of the CAST: classification rates, stability, and gender differences. Havey JM, et al. **Addict Behav** 1995 Jul-Aug;20(4):501–7

The consistency of family and peer influences on the development of substance use in adolescence. Duncan TE, et al. **Addiction** 1995 Dec;90(12):1647–60

Preadolescent conduct disorder behaviors predict relapse and progression of addiction for adolescent alcohol and drug

abusers. Myers MG, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1528–36

Alcohol schema acquisition in preschoolers: differences between children of alcoholics and children of nonalcoholics. Zucker RA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1011–7

Effects of parental alcoholism and life stress on Hispanic and Non–Hispanic Caucasian adolescents: a prospective study. Barrera M Jr, et al. **Am J Community Psychol** 1995 Aug; 23(4):479–507

Mediation of abusive childhood experiences: depression, dissociation, and negative life outcomes. Becker–Lausen E, et al. **Am J Orthopsychiatry** 1995 Oct;65(4):560–73

Children of addicted mothers: effects of the 'crack epidemic' on the caregiving environment and the development of preschoolers. Hawley TL, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):364–79

The role of family and peers in social self–efficacy: links to depression in adolescence. McFarlane AH, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):402–10

Parents and children sleeping together: cosleeping prevalence and concerns. Rath FH Jr, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):411–8

Predicting alcohol and drug use in early adulthood: the role of internalizing and externalizing behavior problems in early adolescence. Steele RG, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):380–8

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K. **Am J Orthopsychiatry** 1995 Oct;65(4):540–8 (55 ref.)

Adolescent character formation and psychoanalytic theory. McCarthy JB. **Am J Psychoanal** 1995 Sep;55(3):245–67

Acting out and the narrative function: reconsidering Peter Blos's concept of the second individuation process. Lock J. **Am J Psychother** 1995 Fall;49(4):548–57

Munchausen syndrome by proxy abuse: a foundation for adult Munchausen syndrome. Conway SP, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):504–7

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374–84 (64 ref.)

Disruptions in childhood parental care as risk factors for major depression in adult women. Oakley Browne MA, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):437–48

Origins of common fears: effects on severity, anxiety responses and memories of onset. Withers RD, et al. **Behav Res Ther** 1995 Nov;33(8):903–15

Childhood onset of spinal cord injury: self–esteem and self–perception. Kennedy P, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):581–8

Self–critical attitudes and parental criticism in young women. Brewin CR, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):69–78

A clinical concept of the self: the experiential being. De Waele M. **Br J Med Psychol** 1995 Sep;68 (Pt 3):223–42 (85 ref.)

Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243–57 (85 ref.)

Transference and counter–transference variations in the course of the cognitive–analytic therapy of two borderline patients: the relation to the diagrammatic reformulation of self–states. Ryle A. **Br J Med Psychol** 1995 Jun;68 (Pt 2):109–24

Children in institutions [editorial] Kolvin I. **Br J Psychiatry** 1995 Jul;167(1):8–11

Lone mothers and their children [editorial] Roberts J. **Br J Psychiatry** 1995 Aug;167(2):159–62

Schizophrenia and oxymorons. Giovacchini PL. **Bull Menninger Clin** 1995 Summer;59(3):333–44

Transactions of the Topeka Psychoanalytic Society. Self–destructive behavior in young people. Twemlow SW. **Bull Menninger Clin** 1995 Fall;59(4):487–90

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75–80 (70 ref.)

Attachment organization and adaptation in sexually–abused women. Stalker CA, et al. **Can J Psychiatry** 1995 Jun; 40(5):234–40

Predicting symptomatology and self–blame among child sex abuse victims. Hazzard A, et al. **Child Abuse Negl** 1995 Jun;19(6):707–14

Childhood sexual abuse and the academic adjustment of college women. Himelein MJ. **Child Abuse Negl** 1995 Jun; 19(6):761–4

A meta–analysis of the relationship of child sexual abuse to adult psychological adjustment. Jumper SA. **Child Abuse Negl** 1995 Jun;19(6):715–28

Outcome of therapy for sexually abused children: a repeated measures study. Lanktree CB, et al. **Child Abuse Negl** 1995 Sep;19(9):1145–55

Psychological sequelae in adult females reporting childhood ritualistic abuse. Lawrence KJ, et al. **Child Abuse Negl** 1995 Aug;19(8):975–84

Munchausen by proxy victims in adulthood: a first look. Libow JA. **Child Abuse Negl** 1995 Sep;19(9):1131–42

Moderating effects of physical abuse and perceived social support on the potential to abuse. Litty CG, et al. **Child Abuse Negl** 1996 Apr;20(4):305–14

The long–term impact of the physical, emotional, and sexual abuse of children: a community study. Mullen PE, et al. **Child Abuse Negl** 1996 Jan;20(1):7–21

The intergenerational transmission of corporal punishment: a comparison of social learning and temperament models. Muller RT, et al. **Child Abuse Negl** 1995 Nov; 19(11):1323–35

Aspects of childhood physical punishment and family environment correlates in bulimia nervosa. Rorty M, et al. **Child Abuse Negl** 1995 Jun;19(6):659–67

Resilience criteria and factors associated with resilience in sexually abused girls. Spaccarelli S, et al. **Child Abuse Negl** 1995 Sep;19(9):1171–82

Siblings of a child with autism, with mental retardation and with a normal development. Roeyers H, et al. **Child Care Health Dev** 1995 Sep;21(5):305–19

How schoolchildren propose to negotiate: the role of social withdrawal, social anxiety, and locus of control. Adalbjarnardottir S. **Child Dev** 1995 Dec;66(6):1739–51

Multifaceted impact of self–efficacy beliefs on academic functioning. Bandura A, et al. **Child Dev** 1996 Jun; 67(3):1206–22

Maternal attitudes and knowledge of child–rearing: associations with family and child outcomes. Benasich AA, et al. **Child Dev** 1996 Jun;67(3):1186–205

Parent–child relationships, family problems–solving behavior, and sibling relationship quality: the moderating role of sibling temperaments. Brody GH, et al. **Child Dev** 1996 Jun;67(3):1289–300

Friendships and social networks in childhood and adolescence: fluidity, reliability, and interrelations. Cairns RB, et al. **Child Dev** 1995 Oct;66(5):1330–45

Helpfulness and the development of competence in adolescence. Call KT, et al. **Child Dev** 1995 Feb; 66(1):129–38

A developmental investigation of inattentiveness and hyperactivity. Carlson EA, et al. **Child Dev** 1995 Feb; 66(1):37–54

Temperamental origins of child and adolescent behavior problems: from age three to age fifteen. Caspi A, et al. **Child Dev** 1995 Feb;66(1):55–68

The long–term effects of parental divorce on the mental health of young adults: a developmental perspective. Chase–Lansdale PL, et al. **Child Dev** 1995 Dec; 66(6):1614–34

Emerging differentiation of folkbiology and folkpsychology: attributions of biological and psychological properties to living things. Coley JD. **Child Dev** 1995 Dec;66(6):1856–74

It takes two to replicate: a mediational model for the impact of parents' stress on adolescent adjustment. Conger RD, et al. **Child Dev** 1995 Feb;66(1):80–97

Social information–processing mechanisms in reactive and proactive aggression. Crick NR, et al. **Child Dev** 1996 Jun; 67(3):993–1002

Antisocial boys and their friends in early adolescence: relationship characteristics, quality, and interactional process. Dishion TJ, et al. **Child Dev** 1995 Feb;66(1):139–51

The relations of children's dispositional prosocial behavior to emotionality, regulation, and social functioning. Eisenberg N, et al. **Child Dev** 1996 Jun;67(3):974–92

Getting angry at peers: associations with linking of the provocateur. Fabes RA, et al. **Child Dev** 1996 Jun; 67(3):942–56

L.A. stories: aggression in preschoolers' spontaneous narratives after the riots of 1992. Farver JA, et al. **Child Dev** 1996 Feb;67(1):19–32

Frontal activation asymmetry and social competence at four years of age. Fox NA, et al. **Child Dev** 1995 Dec; 66(6):1770–84

Alternative pathways to chronic depressive symptoms in young adults: gender differences in developmental trajectories. Gjerde PF. **Child Dev** 1995 Oct;66(5):1277–300

Emotion regulation in two–year–olds: strategies and emotional expression in four contexts. Grolnick WS, et al. **Child Dev** 1996 Jun;67(3):928–41

Prosocial behavior and caring in adolescence: relations to self–understanding and social judgment. Hart D, et al. **Child Dev** 1995 Oct;66(5):1346–59

The company they keep: friendships and their developmental significance. Hartup WW. **Child Dev** 1996 Feb;67(1):1–13

A multiperspective comparison of peer sociometric status groups in childhood and adolescence. Hatzichristou C, et al. **Child Dev** 1996 Jun;67(3):1085–102

Adolescents' and young adults' conceptions of civil liberties: freedom of speech and religion. Helwig CC. **Child Dev** 1995 Feb;66(1):152–66

Attributions and responses to the Arab–Israeli conflict: a developmental analysis. Hoffman MA, et al. **Child Dev** 1996 Feb;67(1):117–28

Grade–level differences in the social value of effort: implication for self–presentation tactics of early adolescents. Juvonen J, et al. **Child Dev** 1995 Dec; 66(6):1694–705

A longitudinal study of the roots of preschoolers' conscience: committed compliance and emerging internalization. Kochanska G, et al. **Child Dev** 1995 Dec;66(6):1752–69

Children: ethnic and political violence. Ladd GW, et al. **Child Dev** 1996 Feb;67(1):14–8

The effects of systemic family violence on children's mental health. McCloskey LA, et al. **Child Dev** 1995 Oct; 66(5):1239–61

Congruence between mothers' and fathers' differential treatment of siblings: links with family relations and children's well–being. McHale SM, et al. **Child Dev** 1995 Feb;66(1):116–28

The war experiences and psychosocial development of children in Lebanon. Macksoud MS, et al. **Child Dev** 1996 Feb;67(1):70–88

Developmental and temperamental differences in emotion regulation in infancy. Mangelsdorf SC, et al. **Child Dev** 1995 Dec;66(6):1817–28

Children's gender–based reasoning about toys. Martin CL, et al. **Child Dev** 1995 Oct;66(5):1453–71

The structure and coherence of competence from childhood through adolescence. Masten AS, et al. **Child Dev** 1995 Dec;66(6):1635–59

Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557–84 (110 ref.)

The effects of work intensity on adolescent mental health, achievement, and behavioral adjustment: new evidence from a prospective study. Mortimer JT, et al. **Child Dev** 1996 Jun;67(3):1243–61

Social class effects on northeastern Brazilian children's conceptions of areas of personal choice and social regulation. Nucci L, et al. **Child Dev** 1996 Jun;67(3):1223–42

Social interactions in the home and the development of young children's conceptions of the personal. Nucci L, et al. **Child Dev** 1995 Oct;66(5):1438–52

Can ideological commitment protect children's psychological well–being in situations of political violence? Punamäki RL. **Child Dev** 1996 Feb;67(1):55–69

Interaction style, problem–solving behavior, and family problem–solving effectiveness. Rueter MA, et al. **Child Dev** 1995 Feb;66(1):98–115

Effects of mothers' simulated withdrawal and depressed affect on mother–toddler interactions. Seiner SH, et al. **Child Dev** 1995 Oct;66(5):1519–28

Like father, like son: young children's understanding of how and why offspring resemble their parents. Solomon GE, et al. **Child Dev** 1996 Feb;67(1):151–71

Kinship support and maternal and adolescent well–being in economically disadvantaged African–American families. Taylor RD, et al. **Child Dev** 1995 Dec;66(6):1585–97

Do first–year intervention effects endure? Follow–up during toddlerhood of a sample of Dutch irritable infants. van den Boom DC. **Child Dev** 1995 Dec;66(6):1798–816

Context and development in family problem solving with preadolescent children. Vuchinich S, et al. **Child Dev** 1996 Jun;67(3):1276–88

Aggressive boys' hostile perceptual and response biases: the role of attention and impulsivity. Waldman ID. **Child Dev** 1996 Jun;67(3):1015–33

Associations among adult attachment representations, maternal sensitivity, and infant–mother attachment in a sample of adolescent mothers. Ward MJ, et al. **Child Dev** 1995 Feb;66(1):69–79

Individual differences in young children's pretend play with mother and sibling: links to relationships and understanding of other people's feelings and beliefs. Youngblade LM, et al. **Child Dev** 1995 Oct;66(5):1472–92

Display rules for anger, sadness, and pain: it depends on who is watching. Zeman J, et al. **Child Dev** 1996 Jun; 67(3):957–73

Aversive exchanges with peers and adjustment during early adolescence: is disclosure helpful? Vernberg EM, et al. **Child Psychiatry Hum Dev** 1995 Fall;26(1):43–59

The case of Dr. John D. Frame's first memory: historical truth and psychological distortion. Erdelyi MH, et al. **Conscious Cogn** 1995 Mar;4(1):95–9

Metamemory and memory construction. O'Sullivan JT, et al. **Conscious Cogn** 1995 Mar;4(1):104–10

The association between childhood irritability and liability to substance use in early adolescence: a 2–year follow–up study of boys at risk for substance abuse. Tarter RE, et al. **Drug Alcohol Depend** 1995 Oct;39(3):253–61

Life events and behavioural deviances in childhood: a longitudinal study of a normal population. Höök B, et al. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):153–64

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143–52 (55 ref.)

A clinical and phenomenological study of 185 Spanish adolescents with anorexia nervosa. Toro J, et al. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):165–74

The social effects in adult life of chronic physical illness since childhood. Kokkonen J. **Eur J Pediatr** 1995 Aug; 154(8):676–81

A troubled youth: relations with somatization, depression and anxiety in adulthood. Portegijs PJ, et al. **Fam Pract** 1996 Feb;13(1):1–11

Debriefing the family: is research an intervention? Bussell DA, et al. **Fam Process** 1995 Jun;34(2):145–60

An empirically derived typology of families: II. Relationships with adolescent health. Ransom DC, et al. **Fam Process** 1995 Jun;34(2):183–97

Relational processes and identity formation in adolescence: the example of A Separate Peace. Flum H, et al. **Genet Soc Gen Psychol Monogr** 1995 Nov;121(4):369–89

Parental education related to adolescent stress–coping and substance use: development of a mediational model. Wills TA, et al. **Health Psychol** 1995 Sep;14(5):464–78

Personal and familial substance misuse patterns among eating disordered and depressed subjects. Selby MJ, et al. **Int J Addict** 1995 Jul;30(9):1169–76

Addressing the psychic reality of the borderline child. Barros EM. **Int J Psychoanal** 1996 Feb;77 (Pt 1):107–10

The expression of emotions: a contemporary psychoanalytic perspective. d'Epinay ML. **Int J Psychoanal** 1996 Feb;77

(Pt 1):117–21
Psychic reality and the psychoanalysis of the adolescent. Esman AH. **Int J Psychoanal** 1996 Feb;77 (Pt 1):111–6
Psychic reality and pathogenic beliefs: patients' theories about themselves and the relational world. LaFarge L. **Int J Psychoanal** 1996 Feb;77 (Pt 1):141–5
Psychic reality and the life cycle: the psychic reality of women. Levinson NA. **Int J Psychoanal** 1996 Feb;77 (Pt 1):123–7
The anal world of a six-year-old boy. Rosegrant J. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1233–43
Factor structure of social support and its relationship to minor psychiatric disorders among Japanese adolescents. Furukawa T. **Int J Soc Psychiatry** 1995 Summer; 41(2):88–102
Personality structure of young Chinese adults: a contrast of residents in Taiwan and rural and urban China. Ying YW, et al. **Int J Soc Psychiatry** 1995 Winter;41(4):284–91
Two kinds of change facilitating factors. Erlich HS. **Isr J Psychiatry Relat Sci** 1995;32(3):194–204
The familiar and the strange: the dynamics of change. Lazar R. **Isr J Psychiatry Relat Sci** 1995;32(3):157–66 (25 ref.)
The role of affects in the process of change in psychotherapy. Stein R. **Isr J Psychiatry Relat Sci** 1995;32(3):174–83 (26 ref.)
Personality and antisocial behavior in children and adolescents: an enquiry into Eysenck's and Gray's theories. Fonseca AC, et al. **J Abnorm Child Psychol** 1995 Dec; 23(6):767–81
Depression and attributions in children and adolescents: a meta-analytic review. Gladstone TR, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):597–606
Personality traits are differentially linked to mental disorders: a multitrait-multidiagnosis study of an adolescent birth cohort. Krueger RF, et al. **J Abnorm Psychol** 1996 Aug; 105(3):299–312
Parental divorce, self-esteem and depression: an intimate relationship as a protective factor in young adulthood. Palosaari UK, et al. **J Affect Disord** 1995 Dec 13;35(3):91–6
The effect of a history of conduct disorder in adult major depression. Rowe JB, et al. **J Affect Disord** 1996 Feb 12; 37(1):51–63
Risk factors for borderline pathology in children. Guzder J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan; 35(1):26–33
Childhood psychopathology in children from families of alcoholic female probands. Hill SY, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):725–33
Results of treatment one year later: child and adolescent partial hospitalization. Kiser LJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):81–90
Psychosocial adjustment in children with port-wine stains and prominent ears. Sheerin D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1637–47
A Latino perspective on the role of ethnicity in the development of moral values: implications for psychoanalytic theory and practice. Javier RA, et al. **J Am Acad Psychoanal** 1995 Spring;23(1):79–97
The preconceptual organization of emotion. Frosch A. **J Am Psychoanal Assoc** 1995;43(2):423–47
The process of interpretation and the moment of change. Schlesinger HJ. **J Am Psychoanal Assoc** 1995;43(3):663–88
When do interpretations make a difference? A partial answer to Fliess's Achensee question. Spence DP. **J Am Psychoanal Assoc** 1995;43(3):689–712
'Reductive' analysis in the light of modern infant research. Jacoby M. **J Anal Psychol** 1996 Jul;41(3):387–97
Brief report: a life-span perspective on the development of individuals with autism. Schroeder SR, et al. **J Autism Dev Disord** 1996 Apr;26(2):251–5
Psychological characteristics of Turner syndrome. el Abd S, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1109–25 (60 ref.)
The Twelfth Jack Tizard Memorial Lecture. The development of offending and antisocial behaviour from childhood: key findings from the Cambridge Study in Delinquent Development. Farrington DP. **J Child Psychol Psychiatry** 1995 Sep;36(6):929–64
Maternal depressive symptoms and depressive symptoms in adolescents. Fergusson DM, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1161–78
Family dynamics and school achievement in Cyprus. Georgiou SN. **J Child Psychol Psychiatry** 1995 Sep; 36(6):977–91
Family structure, family functioning and adolescent well-being: the transcendent influence of parental style. McFarlane AH, et al. **J Child Psychol Psychiatry** 1995 Jul; 36(5):847–64
4.5 to 7 years: fearful behaviour, fears and worries. Stevenson-Hinde J, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1027–38
Child and adolescent sex abuse perpetrators: a review of the research literature. Vizard E, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):731–56 (115 ref.)
Security of attachment in 8–12-year-olds: a revised version of the Separation Anxiety Test, its psychometric properties and clinical interpretation. Wright JC, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):757–74
Personality characteristics of adult children of alcoholics. Baker DE, et al. **J Clin Psychol** 1995 Sep;51(5):694–702
Codependence, narcissism, and childhood trauma. Irwin HJ. **J Clin Psychol** 1995 Sep;51(5):658–65
Personality of rape survivors as a group and by relation of survivor to perpetrator. Karp SA, et al. **J Clin Psychol** 1995 Sep;51(5):587–93
Social maladjustment indicators in PTSD patients' families of origin. Watson CG, et al. **J Clin Psychol** 1996 Jan; 52(1):21–5
Correlations among maternal rejection, dropping out of school, and drug use in adolescents: a pilot study. Younge SL, et al. **J Clin Psychol** 1996 Jan;52(1):96–102
Change processes in a creation of meaning event. Clarke KM. **J Consult Clin Psychol** 1996 Jun;64(3):465–70
An approach to psychotherapy change process research: introduction to the special section. Greenberg LS, et al. **J Consult Clin Psychol** 1996 Jun;64(3):435–8 (27 ref.)
Effectiveness of targeting the vulnerability factors of depression in cognitive therapy. Hayes AM, et al. **J Consult Clin Psychol** 1996 Jun;64(3):623–7
Parents' marital functioning and adolescent psychopathology. King CA, et al. **J Consult Clin Psychol** 1995 Oct; 63(5):749–53
Prewar factors in combat-related posttraumatic stress disorder: structural equation modeling with a national sample of female and male Vietnam veterans. King DW, et al. **J Consult Clin Psychol** 1996 Jun;64(3):520–31
Change in early sessions of dynamic therapy: universal processes and the generic model of psychotherapy. Kolden GG. **J Consult Clin Psychol** 1996 Jun;64(3):489–96
Perceived benefit from child sexual abuse. McMillen C, et al. **J Consult Clin Psychol** 1995 Dec;63(6):1037–43
Acceleration of changes in session impact during contrasting time-limited psychotherapies. Reynolds S, et al. **J Consult Clin Psychol** 1996 Jun;64(3):577–86
Five methods for computing significant individual client change and improvement rates: support for an individual growth curve approach. Speer DC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):1044–8
The relationship between vivid description, emotional arousal, and in-session resolution of problematic reactions. Watson JC. **J Consult Clin Psychol** 1996 Jun;64(3):459–64
Specificity of preventative pediatric intervention effects in early infancy. Beeghly M, et al. **J Dev Behav Pediatr** 1995 Jun;16(3):158–66
Attachment and risk for psychopathology: the early years. Crittenden PM. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S12–6 (16 ref.)
The American war zone: what children can tell us about living with violence. Garbarino J. **J Dev Behav Pediatr** 1995 Dec;16(6):431–5
To be or not to be ... noncategorical. Stein RE. **J Dev Behav Pediatr** 1996 Feb;17(1):36–7
Children's understanding of the distinction between real and apparent emotions: a training study. Bennett M, et al. **J Genet Psychol** 1996 Sep;157(3):267–74
Symbolic immunity and flexibility in preschoolers' human figure drawings. Boyatzis CJ, et al. **J Genet Psychol** 1995 Sep;156(3):293–302
Childhood aggression and unconventionality: impact on later academic achievement, drug use, and workforce involvement. Brook JS, et al. **J Genet Psychol** 1995 Dec; 156(4):393–410
Toddler adjustment: impact of parents' drug use, personality, and parent-child relations. Brook JS, et al. **J Genet Psychol** 1996 Sep;157(3):281–95
The relation of prosocial and antisocial behavior to personality and peer relationships of Hong Kong Chinese adolescents. Ma HK, et al. **J Genet Psychol** 1996 Sep; 157(3):255–66
Effects of confirmatory and contradictory stimuli and development on children's intergroup attribution. McArthur GB, et al. **J Genet Psychol** 1995 Sep; 156(3):333–43
Onset vulnerability to depression. Myers LB. **J Genet Psychol** 1995 Dec;156(4):503–4
Development of children's restrictive disclosure to friends. Rotenberg KJ. **J Genet Psychol** 1995 Sep;156(3):279–92
Identity closure: a fifth identity status. Valde GA. **J Genet Psychol** 1996 Sep;157(3):245–54
Adolescents' attachment representations and moral reasoning. van Ijzendoorn MH, et al. **J Genet Psychol** 1995 Sep; 156(3):359–72
Levels and domains in personality: an introduction. Emmons RA. **J Pers** 1995 Sep;63(3):341–64 (70 ref.)
Multiple identities and the integration of personality. Gregg GS. **J Pers** 1995 Sep;63(3):617–41 (35 ref.)
Wishes, motives, goals, and personal memories: relations of measures of human motivation. King LA. **J Pers** 1995 Dec; 63(4):985–1007
A multifactorial approach to the study of gender characteristics. Koestner R, et al. **J Pers** 1995 Sep; 63(3):681–710 (80 ref.)
The system-topics framework and the structural arrangement of systems within and around personality. Mayer JD. **J Pers** 1995 Sep;63(3):459–93 (93 ref.)
The effect of perceived challenges and skills on the quality of subjective experience. Moneta GB, et al. **J Pers** 1996 Jun;64(2):275–310
Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643–79 (80 ref.)
Assessment and prediction of stress-related growth. Park CL, et al. **J Pers** 1996 Mar;64(1):71–105
Psychological needs and the facilitation of integrative processes. Ryan RM. **J Pers** 1995 Sep;63(3):397–427 (115 ref.)
Seeing one's self: locating narrative memory in a framework of personality. Singer JA. **J Pers** 1995 Sep;63(3):429–57 (75 ref.)
Juxtaposed scripts, traits, and the dynamics of personality. Thorne A. **J Pers** 1995 Sep;63(3):593–616
Experimental personality designs: analyzing categorical by continuous variable interactions. West SG, et al. **J Pers** 1996 Mar;64(1):1–48
A clinical-empirical model of personality: life after the Mischelian ice age and the NEO-lithic era. Westen D. **J Pers** 1995 Sep;63(3):495–524 (95 ref.)
Transition from the early 40s to the early 50s in self-directed women. Wink P. **J Pers** 1996 Mar;64(1):49–69
IQ and ego-resiliency: conceptual and empirical connections and separateness. Block J, et al. **J Pers Soc Psychol** 1996 Feb;70(2):349–61
Female and male personality styles: a typological and developmental analysis. Pulkkinen L. **J Pers Soc Psychol** 1996 Jun;70(6):1288–306
Development and mental representation of stereotypes. Sherman JW. **J Pers Soc Psychol** 1996 Jun;70(6):1126–41
Assessing filial maturity through the use of the Filial Anxiety Scale. Murray PD, et al. **J Psychol** 1995 Sep;129(5):519–29
Somatoform disorders and personality traits [editorial; comment] Barsky AJ. **J Psychosom Res** 1995 May; 39(4):399–402. Comment on: J Psychosom Res 1995 May;39(4):403–27.
Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways [comment] Bass C, et al. **J Psychosom Res** 1995 May; 39(4):403–27 (99 ref.). Comment on: J Psychosom Res 1995 May;39(4):395–7.
Somatoform and personality disorders: personality and the soma [editorial; comment] Tyrer P. **J Psychosom Res** 1995 May;39(4):395–7. Comment on: J Psychosom Res 1995 May;39(4):403–27.
Conformity in the Asch task as a function of age. Walker MB, et al. **J Soc Psychol** 1996 Jun;136(3):367–72
The growth of conduct problem behaviors from middle childhood to early adolescence: sex differences and the suspected influence of early alcohol use. Johnson EO, et al. **J Stud Alcohol** 1995 Nov;56(6):661–71
The impact of coping styles and family communication on the social skills of children of alcoholics. Segrin C, et al. **J Stud Alcohol** 1996 Jan;57(1):29–33
The relationship between parent and offspring comorbid disorders. Johnson V. **J Subst Abuse** 1995;7(3):267–80
Childhood sexual abuse as a precursor to depression and self-destructive behavior in adulthood. Boudewyn AC, et al. **J Trauma Stress** 1995 Jul;8(3):445–59
The prototype hypothesis and the origins of attachment working models: adult relationships with parents and romantic partners. Owens G, et al. **Monogr Soc Res Child Dev** 1995;60(2–3):216–33
A quantitative approach to the description and classification of primary social relationships. Strayer FF, et al. **Monogr Soc Res Child Dev** 1995;60(2–3):49–70
Precepts and practices: researching identity formation among Indian Hindu adolescents in the United States. Miller BD. **New Dir Child Dev** 1995 Spring;(67):71–85
Cultural practices and the conception of individual differences: theoretical and empirical considerations. Nunes T. **New Dir Child Dev** 1995 Spring;(67):91–103
Development through participation in sociocultural activity. Rogoff B, et al. **New Dir Child Dev** 1995 Spring;(67):45–65
Familial and ecological correlates of self-esteem in African American children. Walker K, et al. **New Dir Child Dev** 1995 Summer;(68):23–34 (70 ref.)
Negative self-perception and components of stress in Canadian, British, and Hong Kong adolescents. Bagley C, et al. **Percept Mot Skills** 1995 Aug;81(1):123–7
Influence of British national curriculum physical education on teachers' behaviours associated with pupils' psychosocial development: a case study in one English town. Curtner-Smith MD, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):967–76
Personalities of women reporting incestuous abuse during childhood. Karp SA, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):955–65
Production of facial expressions of emotion in preschool children. MacDonald PM, et al. **Percept Mot Skills** 1996 Feb;82(1):76–8
Effects of induced social roles on the High School Personality Questionnaire. Merydith SP, et al. **Percept Mot Skills** 1995 Aug;81(1):51–63
Correlations of hopelessness with motivation and personality traits among Japanese school children. Shiomi K. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):717–8
Anxiety disorders of childhood, Implications for adult psychopathology. Pollock RA, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):745–66 (102 ref.)
Psychoanalytic neonate models and non-Cartesian frameworks. Berger LS. **Psychoanal Rev** 1996 Feb; 83(1):49–65
Rachel T.: an adolescent treatment case. Doctors SR. **Psychoanal Rev** 1995 Aug;82(4):499–513; discussion 529–33
Transforming psychological inquiry: clarifying and strengthening connections. Gilligan C, et al. **Psychoanal Rev** 1995 Dec;82(6):801–27

A Freudian perspective on Rachel's struggle. Levy-Warren MH. **Psychoanal Rev** 1995 Aug;82(4):515–20; discussion 529–33

The phenomenon of previewing and its contribution to the emerging sense of self. Trad PV. **Psychoanal Rev** 1996 Feb; 83(1):21–47

A relational perspective on Rachel's struggle. Warshaw SC. **Psychoanal Rev** 1995 Aug;82(4):521–8; discussion 529–33

Age and sex differences in strategies of coping and defense across the life span. Diehl M, et al. **Psychol Aging** 1996 Mar;11(1):127–39

Patterns of personality change across the life span. Jones CJ, et al. **Psychol Aging** 1996 Mar;11(1):57–65

[Precedents and contexts of generativity motivation at midlife. Peterson BE, et al. **Psychol Aging** 1996 Mar; 11(1):21–33

Moral and social reasoning and perspective taking in later life: a longitudinal study. Pratt MW, et al. **Psychol Aging** 1996 Mar;11(1):66–73

Issues in personality as diathesis for depression: the case of sociotropy–dependency and autonomy–self–criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358–78 (125 ref.)

Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25–41 (110 ref.)

Childhood parental loss and alcoholism in women: a causal analysis using a twin–family design. Kendler KS, et al. **Psychol Med** 1996 Jan;26(1):79–95

Reported parental behaviour and adult affective symptoms. 2. Mediating factors. Rodgers B. **Psychol Med** 1996 Jan; 26(1):63–77

Reported parental behaviour and adult affective symptoms. 1. Associations and moderating factors. Rodgers B. **Psychol Med** 1996 Jan;26(1):51–61

Association between history of abuse and borderline personality disorder for hospitalized adolescent girls. Atlas JA. **Psychol Rep** 1995 Dec;77(3 Pt 2):1346

Retrospective appraisals of fathers' effectiveness and psychological health of adults. Brost L, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):803–7

An exercise for increasing students' understanding of life–span developmental psychology. Ferraro FR. **Psychol Rep** 1995 Jun;76(3 Pt 2):1209–10

Correlations of grade point averages at a rural college with reports of abuse in rural families. Gibby–Smith BM. **Psychol Rep** 1995 Oct;77(2):619–22

Myths about childhood suicide. Lester D. **Psychol Rep** 1995 Aug;77(1):330

Childhood trauma and personality disorder in 43 women with panic disorder. Moisan D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1133–4

Age differences in social desirability. Mwamwenda TS. **Psychol Rep** 1995 Jun;76(3 Pt 1):825–6

Childhood antecedents of stable positive symptoms in schizophrenia. Roff JD, et al. **Psychol Rep** 1995 Aug; 77(1):323–9

An exploratory study of differences in developmental concerns of middle–aged men and women in India. Tikoo M. **Psychol Rep** 1996 Jun;78(3 Pt 1):883–7

Family background and sexual abuse associated with somatization. Kinzl JF, et al. **Psychother Psychosom** 1995; 64(2):82–7

Psychological and somatic symptoms in young adults with chronic physical diseases. Kokkonen J, et al. **Psychother Psychosom** 1995;64(2):94–101

Developmental pathways of behavior problems in the young child: factors associated with continuity and change. Borge AI. **Scand J Psychol** 1996 Jun;37(2):195–204

The impact of the Gulf armed conflict on the health and behaviour of Kuwaiti children. al–Eissa YA. **Soc Sci Med** 1995 Oct;41(7):1033–7

Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18–25 (35 ref.)

Adolescent development and the emergence of sexuality. Petersen AC, et al. **Suicide Life Threat Behav** 1995;25 Suppl:4–17 (95 ref.)

Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram–Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26–34; discussion 35–9 (60 ref.)

Suicidality in college women who were sexually and physically abused and physically punished by parents. Bryant SL, et al. **Violence Vict** 1995 Fall;10(3):195–201

Violence in the marital dyad as a predictor of violence in the peer relationships of older adolescents/young adults. Cantrell PJ, et al. **Violence Vict** 1995 Spring;10(1):35–41

Exposure to serious family violence among incarcerated boys: its association with violent offending and potential mediating variables. Spaccarelli S, et al. **Violence Vict** 1995 Fall;10(3):163–82

[Anorexia nervosa. A frequent antecedent of obsessive compulsive disorder] Zribi S, et al. **Encephale** 1989 May–Jun;15(3):355–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[White walls for black holes: essay on graffiti psychopathology] Catheline–Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**

[Early disturbances in parent–infant interactions and the construction of psychic life. The young child and his psychotic mother] Lamour M, et al. **Psychiatr Enfant** 1995; 38(2):529–54 (Eng. Abstr.) **(Fre)**

[Adolescence: child psychiatry aspects] Steck B. **Rev Med Suisse Romande** 1995 Nov;115(11):869–74 **(Fre)**

[Pathography and biography—background on the Schreber and Klug cases] Pohlmeier H. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):297–302 **(Ger)**

[Research into premorbid personality in psychiatry in German–speaking countries: the last 3 decades] von Zerssen D. **Fortschr Neurol Psychiatr** 1996 May; 64(5):168–83 (Eng. Abstr.) **(Ger)**

[Development, experience and relationship patterns: psychological health from the object attachment viewpoint] Crittenden PM. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr;45(3–4):147–55 (Eng. Abstr.) **(Ger)**

["Sceno–R": a revision of materials for the Sceno Test] Fliegner J. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul–Aug;44(6):215–21 (Eng. Abstr.) **(Ger)**

[Coping in the family context: active and avoidance strategies in adolescents from divorced families] Huss M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr; 45(3–4):123–30 (Eng. Abstr.) **(Ger)**

[Communication behavior between parents and their adolescent children and correlation with indicators of self concept] Kreppner K. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr; 45(3–4):130–47 (Eng. Abstr.) **(Ger)**

[The value of child development psychological models for child and adolescent psychiatry] Lehmkuhl U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr; 45(3–4):78–82 (Eng. Abstr.) **(Ger)**

[Predisposition for violence in adolescence] Streeck–Fischer A. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul–Aug; 44(6):209–15 (Eng. Abstr.) **(Ger)**

[Separation in the mother–son relationship: an adolescent problem in Rainer Maria Rilke's story "Silent accompaniment"] Wittstruck W. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul–Aug; 44(6):221–33 (Eng. Abstr.) **(Ger)**

[Early attachment experiences and behavioral problems in young children in a social and cognitive test situation] Ziegenhain U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar–Apr;45(3–4):95–102 (Eng. Abstr.) **(Ger)**

[Values and moral attitudes] Lichtenberg JD, et al. **Psyche (Stuttg)** 1996 May;50(5):407–43 **(Ger)**

[Development of the affect system] Moser U, et al. **Psyche (Stuttg)** 1996 Jan;50(1):32–84 (110 ref.) (Eng. Abstr.) **(Ger)**

[Psychoanalytic theories of hypochondria] Röder CH, et al. **Psyche (Stuttg)** 1995 Nov;49(11):1068–98 (65 ref.) (Eng. Abstr.) **(Ger)**

[Ontogenesis of affect regulation] Beckmann D, et al. **Psychother Psychosom Med Psychol** 1995 Dec; 45(12):427–35 (60 ref.) (Eng. Abstr.) **(Ger)**

[Effects of sexual abuse experiences on therapeutic outcome: study of eating disordered patients 2 years after inpatient psychotherapy] Köpp W, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):131–8 (Eng. Abstr.) **(Ger)**

[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation and analysis of social relationships of children in clinical practice and research: "Social Relationship Scale for Children"] Roos J, et al. **Z Kinder Jugendpsychiatr** 1995 Dec;23(4):255–66 (Eng. Abstr.) **(Ger)**

[The Brodsky & Brodsky risk factor model of schizophrenia—an empirical contribution] Mensching M, et al. **Z Klin Psychol Psychopathol Psychother** 1996; 44(1):33–48 (Eng. Abstr.) **(Ger)**

[Variants of psychosomatic personality development in diseases of the gastrointestinal tract] Korkina MV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):43–7 (Eng. Abstr.) **(Rus)**

[Prevalence and sequelae of childhood sexual abuse in Spain] López F, et al. **Child Abuse Negl** 1995 Sep;19(9):1039–50 (Eng. Abstr.) **(Spa)**

[The Mälarhospital in Eskilstuna: personal and professional development as part of internship] Lind J. **Lakartidningen** 1995 Nov 1;92(44):4061–2, 4067–9 **(Swe)**

PERSONALITY DISORDER, ANTISOCIAL see **ANTISOCIAL PERSONALITY DISORDER**

PERSONALITY DISORDER, BORDERLINE see **BORDERLINE PERSONALITY DISORDER**

PERSONALITY DISORDER, COMPULSIVE see **COMPULSIVE PERSONALITY DISORDER**

PERSONALITY DISORDER, DEPENDENT see **DEPENDENT PERSONALITY DISORDER**

PERSONALITY DISORDER, HISTRIONIC see **HISTRIONIC PERSONALITY DISORDER**

PERSONALITY DISORDER, PARANOID see **PARANOID PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOID see **SCHIZOID PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOTYPAL see **SCHIZOTYPAL PERSONALITY DISORDER**

PERSONALITY DISORDERS

The role of Axis II comorbidity in the management of patients with treatment–resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287–309 (97 ref.)

BLOOD

Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Coccaro EF, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):531–6

CLASSIFICATION

The characterological basis of multiple personality. Brenner I. **Am J Psychother** 1996 Spring;50(2):154–66 (30 ref.)

Comparative validity of MMPI–2 and MCMI–II personality disorder classifications. Wise EA. **J Pers Assess** 1996 Jun; 66(3):569–82

Resilient, overcontrolled, and undercontrolled boys: three replicable personality types. Robins RW, et al. **J Pers Soc Psychol** 1996 Jan;70(1):157–71

DIAGNOSIS

Normality and abnormality in behavioural aspect. Rhi BY. **Acta Neurochir (Wien)** 1995;132(4):164–8

Frontal lobe dementia presenting as personality disorder. Salmon E, et al. **Acta Neurol Belg** 1996 Jun;96(2):130–4

Childhood antecedents of adolescent personality disorders. Bernstein DP, et al. **Am J Psychiatry** 1996 Jul;153(7):907–13

Eye movements in spectrum personality disorders: comparison of community subjects and relatives of schizophrenic patients. Thaker GK, et al. **Am J Psychiatry** 1996 Mar;153(3):362–8

Personality disorders predict onset of Axis I disorders and impaired functioning among homosexual men with and at risk of HIV infection. Johnson JG, et al. **Arch Gen Psychiatry** 1996 Apr;53(4):350–7

The reliability and validity of two structured diagnostic interviews for personality disorders. Pilkonis PA, et al. **Arch Gen Psychiatry** 1995 Dec;52(12):1025–33

Assessment of personality functioning in the transition from adolescent to adult life: preliminary findings. Naughton M, et al. **Br J Psychiatry** 1996 Jan;168(1):33–7

Interpersonal disorder in schizoid and avoidant personality disorders: an attachment perspective. West M, et al. **Can J Psychiatry** 1995 Sep;40(7):411–4

Twelve–month test–retest reliability of the structured clinical interview for DSM–III–R personality disorders in cocaine–dependent patients. Weiss RD, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):384–9

The typology of personality disorders—diagnostic problems and their relevance for suicidal behavior [see comments] Bronisch T. **Crisis** 1996;17(2):55–8 (28 ref.). Comment in: Crisis 1996;17(2):50.

Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis. Tuinier S, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):135–46 (132 ref.)

The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)

Personality traits are differentially linked to mental disorders: a multitrait–multidiagnosis study of an adolescent birth cohort. Krueger RF, et al. **J Abnorm Psychol** 1996 Aug; 105(3):299–312

Personality dimensions in panic disorder and generalized anxiety disorder. Starcevic V, et al. **J Affect Disord** 1996 Apr 12;37(2–3):75–9

Personality traits in social phobia, I: Comparisons with healthy controls. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):560–8

Differential validity of the MMPI–2 Subtle and Obvious scales with psychiatric inpatients: scale 2. Boone D. **J Clin Psychol** 1995 Jul;51(4):526–31

Personality attributes of attention deficit hyperactivity disorder (ADHD) using the Rorschach Inkblot Test. Cotugno AJ. **J Clin Psychol** 1995 Jul;51(4):554–62

Clinical diagnoses and MCMI codetypes. Craig RJ. **J Clin Psychol** 1995 May;51(3):352–60 (75 ref.)

Issues in the assessment of personality disorder and substance abuse using the Millon Clinical Multiaxial Inventory (MCMI–II). Flynn PM, et al. **J Clin Psychol** 1995 May; 51(3):415–21 (24 ref.)

Development of a three–scale MMPI: the MMPI–TRI. Swanson SC, et al. **J Clin Psychol** 1995 May;51(3):361–74

Personality disorder correspondence among the MMPI, MBHI, and MCMI. Wise EA. **J Clin Psychol** 1995 Nov; 51(6):790–8

Self–reported narcissism and perceived parental permissiveness and authoritarianism. Ramsey A, et al. **J Genet Psychol** 1996 Jun;157(2):227–38

Defense styles, hostility, and psychological risk factors in male patients with personality disorders. Paris J, et al. **J Nerv Ment Dis** 1996 Mar;184(3):153–8

Family history of DSM–III–R dramatic personality disorder cluster and functioning in patients with major depressive disorder. Reich J. **J Nerv Ment Dis** 1995 Sep;183(9):587–92

Abnormality ratings of the DSM–III–R personality disorder criteria for males vs. females. Sprock J.

J Nerv Ment Dis 1996 May;184(5):314–6

Clinician diagnoses of personality disorders: evidence of a hierarchical structure. Herkov MJ, et al. **J Pers Assess** 1995 Oct;65(2):313–21

Diagnostic agreement between the SCID–II screening questionnaire and the Personality Disorder Examination. Jacobsberg L, et al. **J Pers Assess** 1995 Dec;65(3):428–33

An MMPI–2 portrait of narcissism. Rathvon N, et al. **J Pers Assess** 1996 Feb;66(1):1–19

Thought disorder on the WAIS–R relative to the Rorschach: assessing identity–disordered adolescents. Skelton MD, et al. **J Pers Assess** 1995 Dec;65(3):533–49

Personality disorder and sexual risk taking among homosexually active and heterosexually active men attending a genito–urinary medicine clinic. Ellis D, et al. **J Psychosom Res** 1995 Oct;39(7):901–10

MMPI profiles of patients with chronic fatigue syndrome. Schmaling KB, et al. **J Psychosom Res** 1996 Jan;40(1):67–74

Styles of regulation in the bipolar spectrum. Rubino IA, et al. **Percept Mot Skills** 1995 Oct;81(2):419–28

Chronic mood disorder and depressive personality. Shea MT, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):103–20 (42 ref.)

Personality traits in schizophrenia. Smith TE, et al. **Psychiatry** 1995 May;58(2):99–112

Relationship between the melancholic type of personality (Typus melancholicus) and DSM–III–R personality disorders in patients with major depression. Sato T, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):13–8

A comparison of Tridimensional Personality Questionnaire dimensions in bipolar disorder and unipolar depression. Young LT, et al. **Psychiatry Res** 1995 Sep 29;58(2):139–43

A comparison of DSM–III–R and ICD–10 personality disorder criteria in an out–patient population. Sara G, et al. **Psychol Med** 1996 Jan;26(1):151–60

Assessment of dissociative identity disorder with the Million Clinical Multiaxial Inventory–II. Ellason JW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):895–905

Personality disorders and psychiatric symptoms in psoriasis. Rubino IA, et al. **Psychol Rep** 1995 Oct;77(2):547–53

Correspondence between students' scores on the Millon Clinical Multiaxial Inventory–II and Personality Diagnostic Questionnaire–Revised. Wierzbicki M, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1079–82

Personality factors in women with premenstrual syndrome. Freeman EW, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):453–9

A psychiatric appraisal of "glossodynia". Miyaoka H, et al. **Psychosomatics** 1996 Jul–Aug;37(4):346–8

[Structure and structural disorder] Rudolf G, et al. **Z Psychosom Med Psychoanal** 1995;41(3):197–212 (Eng. Abstr.) **(Ger)**

[New approaches to the military medical expertise of servicemen with personality disorders] Nechiporenko VV, et al. **Voen Med Zh** 1992 Feb;(2):39–42 **(Rus)**

[Consideration to eliminate K as a factor of correction in the Mini–Mult 82] Garnier Zamora LA, et al. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):321–4 (Eng. Abstr.) **(Spa)**

[Preparation of a SCID–II–based diagnostic tool for personality disorders. Spanish version. Translation and adaptation] Villar Garcia M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):178–83 (Eng. Abstr.) **(Spa)**

[Neuropsychological evaluation of a case of organic personality disorder due to penetrating brain injury] Sanz de la Torre JC, et al. **Rev Neurol** 1996 Jun;24(130):643–9 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis. Tuinier S, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):135–46 (132 ref.)

Physiological responses to d–fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Coccaro EF, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):177–9

[Pathologic personality, temperament and treatment] Akiskal HS. **Encephale** 1995 Mar;21 Spec No 2:47–9 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Personality disorders according to DSM–III–R and thrombocyte monoamine oxidase activity in type 1 and type 2 alcoholics. Hallman J, et al. **J Stud Alcohol** 1996 Mar; 57(2):155–61

EPIDEMIOLOGY

Factors predicting readmissions in personality disorders and other nonpsychotic illnesses. A retrospective study on 64 first–ever admissions to the Psychiatric Clinic of Turku, Finland. Korkeila JA, et al. **Acta Psychiatr Scand** 1995 Aug; 92(2):138–44

Further exploration of gender differences in personality disorders [letter; comment] Akhtar S. **Am J Psychiatry** 1996 Jun;153(6):846–7. Comment on: Am J Psychiatry 1995 Apr;152(4):579–82.

Gender differences in personality disorders in psychiatrically hospitalized adolescents. Grilo CM, et al. **Am J Psychiatry** 1996 Aug;153(8):1089–91

Suicide among subjects with personality disorders. Isometsä ET, et al. **Am J Psychiatry** 1996 May;153(5):667–73

Understanding the comorbidity between early–onset dysthymia and cluster B personality disorders: a family study. Riso LP, et al. **Am J Psychiatry** 1996 Jul; 153(7):900–6

The New York High–Risk Project. Psychoses and cluster A personality disorders in offspring of schizophrenic parents at 23 years of follow–up. Erlenmeyer–Kimling L, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):857–65

Comorbidity of axis I and axis II diagnoses in a sample of Egyptian patients with neurotic disorders. Okasha A, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):95–101

Suicidality and personality disorders in adolescence [see comments] Braun–Scharm H. **Crisis** 1996;17(2):64–8. Comment in: Crisis 1996;17(2):50.

Personality antecedents of alcoholism in a national area probability sample. Cloninger CR, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):239–44

Effects of marital status and position on personality traits in engineers of a computer manufacturing plant. Ezoe S, et al. **Ind Health** 1995;33(2):77–81

Comorbidity of personality disorders and unipolar major depression: a review. Corruble E, et al. **J Affect Disord** 1996 Apr 12;37(2–3):157–70 (100 ref.)

Personality disorders and treatment outcome in methadone maintenance patients. Cacciola JS, et al. **J Nerv Ment Dis** 1996 Apr;184(4):234–9

Personality, functioning, and recovery from major depression. Casey P, et al. **J Nerv Ment Dis** 1996 Apr; 184(4):240–5

Dependent personality disorder. Age, sex, and axis I comorbidity. Loranger AW. **J Nerv Ment Dis** 1996 Jan; 184(1):17–21

Patterns of anxiety and personality disorder comorbidity. Skodol AE, et al. **J Psychiatr Res** 1995 Sep–Oct; 29(5):361–74

Axis II diagnoses and treatment refractoriness in schizophrenia. Smith TE, et al. **Psychiatr Q** 1996 Spring; 67(1):51–64

Comorbidity of DSM–III–R axis I and II disorders among female inpatients with eating disorders. Grilo CM, et al. **Psychiatr Serv** 1996 Apr;47(4):426–9

ETIOLOGY

Autobiographical memory across personalities in dissociative identity disorder: a case report. Bryant RA. **J Abnorm Psychol** 1995 Nov;104(4):625–31

Personality pathology among married adults with bipolar disorder. Carpenter D, et al. **J Affect Disord** 1995 Aug 18;34(4):269–74

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8–1996. A 28–year–old woman with the rapid development of a major personality change and global aphasia [clinical conference] **N Engl J Med** 1996 Mar 14;334(11):715–20

GENETICS

A family study on outpatients with mood and personality disorders [letter; comment] Burkart M, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):148–9. Comment on: Compr Psychiatry 1995 May–Jun;36(3):199–206.

Personality disorders and personality variations in relatives of patients with bipolar affective disorders. Maier W, et al. **J Affect Disord** 1995 Dec 18;35(4):173–81

Family history of DSM–III–R dramatic personality disorder cluster and functioning in patients with major depressive disorder. Reich J. **J Nerv Ment Dis** 1995 Sep;183(9):587–92

HISTORY

[Research into premorbid personality in psychiatry in German–speaking countries: the last 3 decades] von Zerssen D. **Fortschr Neurol Psychiatr** 1996 May; 64(5):168–83 (Eng. Abstr.) **(Ger)**

METABOLISM

Physiological responses to d–fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Coccaro EF, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):177–9

MORTALITY

Suicidality in hospitalized patients with a primary diagnosis of personality disorder [see comments] Ahrens B, et al. **Crisis** 1996;17(2):59–63. Comment in: Crisis 1996;17(2):50.

PHYSIOPATHOLOGY

[Neuropsychological evaluation of a case of organic personality disorder due to penetrating brain injury] Sanz de la Torre JC, et al. **Rev Neurol** 1996 Jun;24(130):643–9 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22–8 (7 ref.)

Self–amputation of the ear: three men amputate four ears within five months. Alroe CJ, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):508–12

Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243–57 (85 ref.)

Attachment organization and adaptation in sexually–abused women. Stalker CA, et al. **Can J Psychiatry** 1995 Jun; 40(5):234–40

Personality disorders and suicidal behavior [editorial; comment] Bronisch T, et al. **Crisis** 1996;17(2):50. Comment on: Crisis 1996;17(2):55–8. Comment on: Crisis 1996;17(2):59–63. Comment on: Crisis 1996;17(2):64–8. Comment on: Crisis 1996;17(2):69–77.

The myth of masochism. Bonime W. **J Am Acad Psychoanal** 1995 Spring;23(1):33–46

Personality traits in social phobia, II: Changes during drug treatment. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):569–73

Profile patterns, consistency, and change in the Millon Clinical Multiaxial Inventory–II in cocaine abusers. McMahon RC, et al. **J Clin Psychol** 1996 Jan;52(1):75–9

Patients with personality disorders: functional status, health care utilization, and satisfaction with care. Huesmann WJ, et al. **J Fam Pract** 1996 Jan;42(1):54–60

Temperament, character, and personality disorder in bulimia nervosa. Bulik CM, et al. **J Nerv Ment Dis** 1995 Sep; 183(9):593–8

Somatoform disorders and personality traits [editorial; comment] Barsky AJ. **J Psychosom Res** 1995 May; 39(4):399–402. Comment on: J Psychosom Res 1995 May;39(4):403–27.

Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways [comment] Bass C, et al. **J Psychosom Res** 1995 May; 39(4):403–27 (99 ref.). Comment on: J Psychosom Res 1995 May;39(4):395–7.

MMPI profiles of patients with chronic fatigue syndrome. Schmaling KB, et al. **J Psychosom Res** 1996 Jan;40(1):67–74

Somatoform and personality disorders: personality and the soma [editorial; comment] Tyrer P. **J Psychosom Res** 1995 May;39(4):395–7. Comment on: J Psychosom Res 1995 May;39(4):403–27.

Do codependent traits involve more than basic dimensions of personality and psychopathology? Gotham HJ, et al. **J Stud Alcohol** 1996 Jan;57(1):34–9

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49–111 (178 ref.)

Relationships of personality factors with clinical dimensions and school achievement. Forns–Santacana M, et al. **Percept Mot Skills** 1996 Feb;82(1):243–53

Personalities of women reporting incestuous abuse during childhood. Karp SA, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):955–65

Further validation of the Self–Defeating Personality Scale. McCutcheon LE. **Psychol Rep** 1995 Jun;76(3 Pt 2):1135–8

Childhood trauma and personality disorder in 43 women with panic disorder. Moisan D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1133–4

Self–defeating personality and depression: a closer look. Schill T, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1167–70

Social skills of persons with self–defeating personality. Schill T. **Psychol Rep** 1995 Oct;77(2):632–4

Globus pharyngis, personality, and psychological distress in the general population. Deary IJ, et al. **Psychosomatics** 1995 Nov–Dec;36(6):570–7

The empirical relationships between standardized measures of religiosity and personality/mental health. Kaldestad E. **Scand J Psychol** 1996 Jun;37(2):205–20

[Swindlers, swindling and expression of psychopathology] Puig–Verges N, et al. **Ann Med Psychol (Paris)** 1996 May; 154(2):132–5; discussion 135–6 (Eng. Abstr.) **(Fre)**

[12 patients with extended suicide––psychology, personality, motivation, previous history and psychosocial conflict environment] Okumura Y, et al. **Fortschr Neurol Psychiatr** 1996 May;64(5):184–91 (Eng. Abstr.) **(Ger)**

[Causal "cancer personality" attribution––an expression of maladaptive coping with illness?] Faller H, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):104–16 (Eng. Abstr.) **(Ger)**

[Structural thinking in psychoanalysis] Heigl F. **Z Psychosom Med Psychoanal** 1995;41(3):213–24 **(Ger)**

[Psychogenic urinary retention in childhood. A severe case treated by an integrated global approach] Bosio M, et al. **Minerva Pediatr** 1996 Mar;48(3):117–20 (Eng. Abstr.) **(Ita)**

[The influence of infertility on women's personality] Janczur–Bidzan M. **Psychiatr Pol** 1995 Jul–Aug;29(4):471–8 (Eng. Abstr.) **(Pol)**

[Split of personality in schizophrenia in traditional interpretation and according to the concept of psychopathologic proportions] Jarosz M. **Psychiatr Pol** 1996 May–Jun;30(3):485–91 (Eng. Abstr.) **(Pol)**

[The personality characteristics of today's adolescents and means for their correction] Sergeta IV, et al. **Gig Sanit** 1996 Jan–Feb;(1):29–31 (Eng. Abstr.) **(Rus)**

[Psychodynamics of aggression in neurotic structures] Hašto J. **Ceska Slov Psychiatr** 1995 Aug;91(4):208–15 (Eng. Abstr.) **(Slo)**

[Organic personality disorder as a form of presentation of Huntington's disease] Díaz Marsá M, et al.

Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 Mar-Apr;24(2):103-5 (Eng. Abstr.) **(Spa)**

THERAPY

Interactional obstacles to empathic relating in the psychotherapy of narcissistic disorders. Ivey G. **Am J Psychother** 1995 Summer;49(3):350-70

The Edinburgh Primary Care Depression Study: personality disorder and outcome. Patience DA, et al. **Br J Psychiatry** 1995 Sep;167(3):324-30

A 15-20 year follow-up of adult psychiatric patients. Psychiatric disorder and social functioning. Quinton D, et al. **Br J Psychiatry** 1995 Sep;167(3):315-23

A model of time-effective group psychotherapy for patients with personality disorders: the clinical model. Budman SH, et al. **Int J Group Psychother** 1996 Jul;46(3):329-55

Time-limited group psychotherapy for patients with personality disorders: outcomes and dropouts. Budman SH, et al. **Int J Group Psychother** 1996 Jul;46(3):357-77

A classic revisited: clinical and theoretical reflections on Stone's Widening scope of indications for psychoanalysis. Grand S. **J Am Psychoanal Assoc** 1995;43(3):741-64

Impact of Cluster C personality disorders on outcomes of contrasting brief psychotherapies for depression. Hardy GE, et al. **J Consult Clin Psychol** 1995 Dec;63(6):997-1004

Personality and trait disturbances in an adult mental retardation population: significance for psychiatric management. Goldberg B, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):284-94

Preventing the admission of difficult psychiatric patients--a questionnaire survey. Neeleman J, et al. **J R Soc Med** 1996 Mar;89(3):149-51

Effective psychiatric day treatment: historical lessons. Rosie JS, et al. **Psychiatr Serv** 1995 Oct;46(10):1019-26

Managed care. Getting managed care organizations to cover extended psychotherapy for patients with personality disorders. Sabin JE. **Psychiatr Serv** 1996 Apr;47(4):365-6

The nature and function of a pathological oedipal constellation in a female patient. Bergmann MV. **Psychoanal Q** 1995 Jul;64(3):517-32

Personality disorders and psychosocial changes after intensive psychotherapy: a prospective follow-up study of an outpatient psychotherapy project, 5 years after end of treatment. Monsen J, et al. **Scand J Psychol** 1995 Sep; 36(3):256-68

PERSONALITY, HYSTERICAL see **HISTRIONIC PERSONALITY DISORDER**

PERSONALITY INVENTORY

Assessing the psychological types of specialists to assist students in career choice. Lester WM, et al. **Acad Med** 1995 Oct;70(10):932-3

Psychometric test results associated with high achievement in basic science components of a medical curriculum. Tutton PJ. **Acad Med** 1996 Feb;71(2):181-6

Discriminant validity of the inventory to diagnose depression, lifetime version. Sakado K, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):257-60

Psychiatric symptoms in polysubstance abusers: relationship to race, sex, and age. Kendall JC, et al. **Addict Behav** 1995 Sep-Oct;20(5):685-90

Do cage scores predict readiness to reduce alcohol consumption in medical in-patients? Dent TH, et al. **Alcohol Alcohol** 1995 Sep;30(5):577-80

Revision of the Padua Inventory of obsessive compulsive disorder symptoms: distinctions between worry, obsessions, and compulsions. Burns GL, et al. **Behav Res Ther** 1996 Feb;34(2):163-73

The elusive factor structure of the Inventory of Interpersonal Problems. Savournin R, et al. **Br J Med Psychol** 1995 Dec; 68 (Pt 4):353-69

Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Gorenstein C, et al. **Braz J Med Biol Res** 1996 Apr;29(4):453-7

Personality self-representations of patients with hand injury, and its relationship with work injury. Chau N, et al. **Eur J Epidemiol** 1995 Aug;11(4):373-82

Items for assessing posthypnotic recognition amnesia with the HGSHS:A and the SHSS:C. Allen JJ, et al. **Int J Clin Exp Hypn** 1996 Jan;44(1):52-65

The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression [comment] Nelson EC, et al. **J Affect Disord** 1995 Oct 9; 35(1-2):51-7. Comment on: J Affect Disord 1994 Jan;30(1):35-46.

Personality traits in social phobia, I: Comparisons with healthy controls. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):560-8

Concurrent validity of the MCMI-II modifier indices. Blais MA, et al. **J Clin Psychol** 1995 Nov;51(6):783-9

Psychometric properties of the Holden psychological screening inventory for a psychiatric offender sample. Holden RR, et al. **J Clin Psychol** 1995 Nov;51(6):811-9

Factor structure of the Barratt impulsiveness scale. Patton JH, et al. **J Clin Psychol** 1995 Nov;51(6):768-74

Personality disorder correspondence among the MMPI, MBHI, and MCMI. Wise EA. **J Clin Psychol** 1995 Nov; 51(6):790-8

The construct validity of the Bem Sex-Role Inventory for heterosexual and gay men. Chung YB. **J Homosex** 1995; 30(2):87-97

Diagnostic agreement between the SCID-II screening questionnaire and the Personality Disorder Examination. Jacobsberg L, et al. **J Pers Assess** 1995 Dec;65(3):428-33

Exercise dependence: the relationship between two measures. Kirkby RJ, et al. **Percept Mot Skills** 1996 Apr;82(2):366

Antecedents of multidimensional competitive state anxiety and self-confidence in duathletes. Lane A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):911-9

Relationship between adherence to exercise and scores on extraversion and neuroticism. Potgieter JR, et al. **Percept Mot Skills** 1995 Oct;81(2):520-2

Percept-genetic codings of defense in chronic schizophrenia. Rubino IA, et al. **Percept Mot Skills** 1996 Apr;82(2):483-93

The prevalence of obsessive-compulsive disorder in Japan: a study of students using the Maudsley Obsessional-Compulsive Inventory and DSM-III-R. Tadai T, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):39-41

Factors related to loneliness. Barretta D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):827-30

Nurses' personality types based on the Myers-Briggs Type Indicator. Jain VK, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):938

A Czech version of the inventory of learning processes. Mareš J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(3):135-9

[Apropos of: characteristics of parallel visual process in alexithymic healthy subjects. Application of the Toronto Alexithymia Scle and the parallel visual information processing list (letter; comment)] Fremaux D, et al. **Encephale** 1996 Jan-Feb;22(1):69-70. Comment on: Encephale 1995 Sep-Oct;21(5):589-95. **(Fre)**

[Expectations of control in the context of personality. More about the factorial structure of Levenson's IPC scale] Verissimo R. **Acta Med Port** 1996 Jan;9(1):21-8 (42 ref.) (Eng. Abstr.) **(Por)**

[Psychosocial evaluation in epilepsy: experience with a version of WPSI] Tella LM, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):16-22 (Eng. Abstr.) **(Por)**

STANDARDS

Validation of the Davidson Trauma Scale in a sample of survivors of childhood sexual abuse. Zlotnick C, et al. **J Nerv Ment Dis** 1996 Apr;184(4):255-7

STATISTICS & NUMERICAL DATA

Factorial structure of the 17-item Hamilton Depression Rating Scale. Fleck MP, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):168-72

The impact of somatic morbidity on the Hamilton Depression Rating Scale in the very old. Linden M, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):150-4

Routine evaluation of mental health: reliable information or worthless "guesstimates"? Loevdahl H, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):125-8

Towards an understanding of defense style in terms of temperament and character. Mulder RT, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):99-104

Screening for depression in primary care. Development and validation of the Depression Scale, a screening instrument for depression. Salokangas RK, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):10-6

Alternative cut-point scores for the CAST-6. Hodgins DC, et al. **Addict Behav** 1995 Mar-Apr;20(2):267-70

Norms and sensitivity of the adolescent version of the drug use screening inventory. Kirisci L, et al. **Addict Behav** 1995 Mar-Apr;20(2):149-57

Prospective screening of substance dependence: the advantages of directness. Svanum S, et al. **Addict Behav** 1995 Mar-Apr;20(2):205-13

Measuring drug urges by questionnaire: do not balance scales. Sweeney CT, et al. **Addict Behav** 1996 Mar-Apr; 21(2):199-204

The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. Conigrave KM, et al. **Addiction** 1995 Oct;90(10):1349-56

Cannabis use correlates with schizotypy in healthy people. Williams JH, et al. **Addiction** 1996 Jun;91(6):869-77

Contrasting self-report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510-6 (24 ref.)

Effectiveness of the Alcohol Use Disorders Identification Test in occupational health screenings. Seppä K, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):999-1003

Influence of social desirability response set on self-report for assessing the outcome of treated alcoholics. Yoshino A, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1517-9

Behavioral and subjective scoring of the Harvard Group Scale of Hypnotic Susceptibility: further data and an extension. Kumar VK, et al. **Am J Clin Hypn** 1996 Jan; 38(3):191-9

Multiple susceptibility testing: is it helpful? Kurtz RM, et al. **Am J Clin Hypn** 1996 Jan;38(3):172-84

Self-regard: a new measure. Horowitz M, et al. **Am J Psychiatry** 1996 Mar;153(3):382-5

Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives. Sainfort F, et al. **Am J Psychiatry** 1996 Apr;153(4):497-502

Personality: individual differences and clinical assessment. Butcher JN, et al. **Annu Rev Psychol** 1996;47:87-111 (240 ref.)

The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Anton RF, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):225-31

Type A behaviour in the Australian working population. Byrne DG, et al. **Aust N Z J Psychiatry** 1995 Jun; 29(2):270-7

Validation of an Italian translation of the 30-item General Health Questionnaire for use in Australia. Febbo S, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):266-9

Sissiness, tomboyism, sex-role, sex identity and orientation. McConaghy N, et al. **Aust N Z J Psychiatry** 1995 Jun; 29(2):278-83

The reliability and validity of a sexual and physical abuse history questionnaire in female patients with gastrointestinal disorders. Leserman J, et al. **Behav Med** 1995 Fall;21(3):141-50

The Chinese Gender Role Stress scales. Factor structure and predictive validity. Tang CS, et al. **Behav Modif** 1996 Jul; 20(3):321-37

Aetiology of spider phobia: classificatory differences between two origins instruments. Kirkby KC, et al. **Behav Res Ther** 1995 Nov;33(8):955-8

Individual differences in thought suppression. The White Bear Suppression Inventory: factor structure, reliability, validity and correlates. Muris P, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):501-13

The IIP-32: a short version of the Inventory of Interpersonal Problems. Barkham M, et al. **Br J Clin Psychol** 1996 Feb; 35 (Pt 1):21-35

The Italian DAS as a screening instrument for depression in the elderly. Carpiniello B, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):577-9

The factor structure of "schizotypal" traits: a large replication study. Claridge G, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):103-15

The relations between sociotropy and autonomy, positive and negative affect and two proposed depression subtypes. Jolly JB, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):91-101

The Symptom Questionnaire: British standardization data. Zeffert S, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):85-90

Confirmatory factor analysis of the Fear Questionnaire with social phobia patients. Cox BJ, et al. **Br J Psychiatry** 1996 Apr;168(4):497-9

Present use of the Hamilton Depression Rating Scale: observation on method of assessment in research of depressive disorders. Snaith RP. **Br J Psychiatry** 1996 May; 168(5):594-7 (11 ref.)

A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Snaith RP, et al. **Br J Psychiatry** 1995 Jul;167(1):99-103

Validity of the Arabic version of the eating disorders inventory (EDI). al-Subaie AS, et al. **Br J Psychiatry** 1996 May;168(5):636-40

The five-factor model of personality in borderline and nonborderline personality disorders. Zweig-Frank H, et al. **Can J Psychiatry** 1995 Nov;40(9):523-6

The Modified Dental Anxiety Scale: validation and United Kingdom norms. Humphris GM, et al. **Community Dent Health** 1995 Sep;12(3):143-50

A validity study of the St. Louis Inventory of Community Living Skills. Fitz D, et al. **Community Ment Health J** 1995 Aug;31(4):369-77

An investigation of the Self-Report Manic Inventory as a diagnostic and severity scale for mania. Bräunig P, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):52-5

The tridimensional personality model: influencing variables in a sample of detoxified alcohol dependents. European Fluvoxamine in Alcoholism Study Group. Meszaros K, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):109-14

Development of the quality of life in epilepsy inventory. Devinsky O, et al. **Epilepsia** 1995 Nov;36(11):1089-104

Detecting psychological distress among patients attending secondary health care clinics. Self-report and physician rating. Feldman D, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):425-32

Framework for a comprehensive description and measurement of emotional states. Mehrabian A. **Genet Soc Gen Psychol Monogr** 1995 Aug;121(3):339-61

Social context and sensation seeking: gender differences in college student drinking motivations. Beck KH, et al. **Int J Addict** 1995 Jul;30(9):1101-15

A multivariate approach to the prediction of hypnotic susceptibility. Dixon M, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):250-64

Trait factors, state effects, and hypnotizability. Kumar VK, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):232-49

The eating attitudes test and the eating disorders inventory in four Bulgarian clinical and nonclinical samples. Boyadjieva S, et al. **Int J Eat Disord** 1996 Jan;19(1):93-8

Development and validation of body rating scales for adolescent females. Sherman DK, et al. **Int J Eat Disord** 1995 Dec;18(4):327-33

Controlled study of eating concerns and psychopathological traits in relatives of eating-disordered probands: do familial traits exist? Steiger H, et al. **Int J Eat Disord** 1995 Sep; 18(2):107-18

Feelings and fantasy in eating disorders: a factor analysis of the Toronto Alexithymia Scale. Troop NA, et al. **Int J Eat Disord** 1995 Sep;18(2):151-7

Factor structure of social support and its relationship to

minor psychiatric disorders among Japanese adolescents. Furukawa T. **Int J Soc Psychiatry** 1995 Summer; 41(2):88–102

Measuring abuse stress and negative cognitive appraisals in child sexual abuse: validity data on two new scales. Spaccarelli S. **J Abnorm Child Psychol** 1995 Dec; 23(6):703–27

Personality traits are differentially linked to mental disorders: a multitrait–multidiagnosis study of an adolescent birth cohort. Krueger RF, et al. **J Abnorm Psychol** 1996 Aug; 105(3):299–312

Sensation–seeking and emotional disturbances in depression: relationships and evolution. Carton S, et al. **J Affect Disord** 1995 Jun 8;34(3):219–25

Neuroticism: a vulnerability marker for depression evidence from a family study. Duggan C, et al. **J Affect Disord** 1995 Dec 13;35(3):139–43

Personality dimensions in panic disorder and generalized anxiety disorder. Starcevic V, et al. **J Affect Disord** 1996 Apr 12;37(2–3):75–9

Obsessive–compulsive characteristics: from symptoms to syndrome. Apter A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):907–12

Predicting dentists' career choices using the Myers–Briggs type indicator. Grandy TG, et al. **J Am Dent Assoc** 1996 Feb;127(2):253–8

Hopelessness predicts future depressive symptoms: a prospective analysis of cognitive vulnerability and cognitive content specificity. Alford BA, et al. **J Clin Psychol** 1995 May;51(3):331–9

Empirical analysis of factors in depressive cognition: the cognitive triad inventory. Anderson KW, et al. **J Clin Psychol** 1995 Sep;51(5):603–9

Personality characteristics of adult children of alcoholics. Baker DE, et al. **J Clin Psychol** 1995 Sep;51(5):694–702

Rey 15–item memorization and Dot counting scores in a "stress" claim worker's compensation population: relationship to personality (MCMI) scores. Boone KB, et al. **J Clin Psychol** 1995 May;51(3):457–63

Psychometric properties of the MSPSS and NOS in psychiatric outpatients. Cecil H, et al. **J Clin Psychol** 1995 Sep;51(5):593–602

Clinical diagnoses and MCMI codetypes. Craig RJ. **J Clin Psychol** 1995 May;51(3):352–60 (75 ref.)

Issues in the assessment of personality disorder and substance abuse using the Millon Clinical Multiaxial Inventory (MCMI–II). Flynn PM, et al. **J Clin Psychol** 1995 May; 51(3):415–21 (24 ref.)

Prediction of adolescent aggression by childhood personality measures: a comparison of projective procedures, self–report tests, and behavior ratings. Graybill D, et al. **J Clin Psychol** 1996 Jan;52(1):61–6

Further study of the diagnostic and screening efficiency of the ST–Depression Adjective Check Lists. Lubin B, et al. **J Clin Psychol** 1996 Jan;52(1):26–31

Prevalence estimates of alcohol problems in a Veterans Administration outpatient population: AUDIT vs. MAST. Luckie LF, et al. **J Clin Psychol** 1995 May;51(3):422–5

Profile patterns, consistency, and change in the Millon Clinical Multiaxial Inventory–II in cocaine abusers. McMahon RC, et al. **J Clin Psychol** 1996 Jan;52(1):75–9

Assessment of self–control behavior: validity analyses on a Japanese version of the self–control schedule. Nakano K. **J Clin Psychol** 1995 May;51(3):378–82

Measurement and correlates of internalized homophobia: a factor analytic study. Ross MW, et al. **J Clin Psychol** 1996 Jan;52(1):15–21

Use of the modified scale for suicidal ideation with suicide ideators and attempters. Rudd MD, et al. **J Clin Psychol** 1995 Sep;51(5):632–5

Factor structure of the state and trait versions of the depression adjective check lists. van Whitlock R, et al. **J Clin Psychol** 1995 Sep;51(5):614–25

Comparative concurrent validities of five alcoholism measures in a psychiatric hospital. Watson CG, et al. **J Clin Psychol** 1995 Sep;51(5):676–84

The relationship of various measures of time urgency to indices of physical health. Wright L, et al. **J Clin Psychol** 1995 Sep;51(5):610–4

Usefulness of the SF–36 Health Survey in measuring health outcomes in the depressed elderly. Beusterien KM, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):13–21

Dissociation and vulnerability to psychotic experience. The Dissociative Experiences Scale and the MMPI–2. Allen JG, et al. **J Nerv Ment Dis** 1995 Oct;183(10):615–22

Evidence for response set effects in structured research interviews. Alterman AI, et al. **J Nerv Ment Dis** 1996 Jul; 184(7):403–10

Adolescent psychopathology as a function of informant and risk status. Fabrega H Jr, et al. **J Nerv Ment Dis** 1996 Jan; 184(1):27–34

Rapid improvement in the defense style of depressed women and men. Kneepkens RG, et al. **J Nerv Ment Dis** 1996 Jun;184(6):358–61

Factor structure of the Private Self–Consciousness Scale. Anderson EM, et al. **J Pers Assess** 1996 Feb;66(1):144–52

Relationships of objective and projective dependency scores to sex role orientation in college student participants. Bornstein RF, et al. **J Pers Assess** 1996 Jun;66(3):555–68

Structure of the twenty–item Toronto Alexithymia Scale. Haviland MG, et al. **J Pers Assess** 1996 Feb;66(1):116–25

A comparison of Culture–Free Self–Esteem Scale means from different child and adolescent groups. Holaday M, et al. **J Pers Assess** 1996 Jun;66(3):540–54

Concurrent validity of the MMPI–2 feminine gender role (GF) and masculine gender role (GM) scales. Johnson ME, et al. **J Pers Assess** 1996 Feb;66(1):153–68

Development and preliminary validation of a self–report measure of psychopathic personality traits in noncriminal populations. Lilienfeld SO, et al. **J Pers Assess** 1996 Jun; 66(3):488–524

UCLA Loneliness Scale (Version 3): reliability, validity, and factor structure. Russell DW. **J Pers Assess** 1996 Feb; 66(1):20–40

Comparative validity of MMPI–2 and MCMI–II personality disorder classifications. Wise EA. **J Pers Assess** 1996 Jun; 66(3):569–82

Positive and negative global self–esteem: a substantively meaningful distinction or artifactors? Marsh HW. **J Pers Soc Psychol** 1996 Apr;70(4):810–9

The three faces of interpersonal dependency: structural analyses of self–report dependency measures. Pincus AL, et al. **J Pers Soc Psychol** 1995 Oct;69(4):744–58

Development and validation of the State Hope Scale. Snyder CR, et al. **J Pers Soc Psychol** 1996 Feb;70(2):321–35

When careers reach a dead end: identification of occupational crisis states. Hutri M. **J Psychol** 1996 Jul;130(4):383–99

Assessing filial maturity through the use of the Filial Anxiety Scale. Murray PD, et al. **J Psychol** 1995 Sep;129(5):519–29

Validation of the Edinburgh Postnatal Depression Scale (EPDS) in Chilean postpartum women. Jadresic E, et al. **J Psychosom Obstet Gynaecol** 1995 Dec;16(4):187–91

Motives for having or not having children: a comparison between questionnaire and interview methods. Wikman M, et al. **J Psychosom Obstet Gynaecol** 1995 Dec;16(4):171–80

Does high 'action–proneness' make people more vulnerable to chronic fatigue syndrome? A controlled psychometric study. Van Houdenhove B, et al. **J Psychosom Res** 1995 Jul;39(5):633–40

Analysis of cut points for screening instruments for alcohol problems in the emergency room. Cherpitel CJ. **J Stud Alcohol** 1995 Nov;56(6):695–700

The Driving Expectancy Questionnaire: development, psychometric assessment and predictive utility among young drink–drivers. Deery HA, et al. **J Stud Alcohol** 1996 Mar;57(2):193–202

The Adolescent Relapse Coping Questionnaire: psychometric validation. Myers MG, et al. **J Stud Alcohol** 1996 Jan; 57(1):40–6

A study examining the psychometric properties of the SMAST–13. Short Michigan Alcoholism Screening Test. Fleming MF, et al. **J Subst Abuse** 1988–89;1(2):173–82

The Drug Avoidance Self–Efficacy Scale. Martin GW, et al. **J Subst Abuse** 1995;7(2):151–63

Assessing life stressors and social resources: applications to alcoholic patients. Moos RH, et al. **J Subst Abuse** 1988–89; 1(2):135–52

Learning style consistency across cognitive and motor settings. Coker CA. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1023–6

Validity and reliability of a Mainstreaming Attitude Inventory for child–care providers. Folsom–Meek SL. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1113–4

Relationships of personality factors with clinical dimensions and school achievement. Forns–Santacana M, et al. **Percept Mot Skills** 1996 Feb;82(1):243–53

Correlations between the Hand Test Pathology score and Personality Assessment Inventory scales for pain clinic patients. George JM, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1377–8

Test–retest reliability of the survey form of the Leyton Obsessional Inventory–Child Version. King N, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1200–2

Current and ideal physique choices in exercising and nonexercising college women from a pilot athletic image scale. Lenart EB, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):831–48

A grade–six reading level key for the multiple affect adjective check list–revised. Lubin B, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):883–9

Alexithymia, affect recognition, and five factors of personality in substance abusers. Mann LS, et al. **Percept Mot Skills** 1995 Aug;81(1):35–40

Effects of induced social roles on the High School Personality Questionnaire. Merydith SP, et al. **Percept Mot Skills** 1995 Aug;81(1):51–63

Internal consistency of boredom proneness scale for a sample of Pakistani students. Nasir SJ, et al. **Percept Mot Skills** 1996 Apr;82(2):367–70

Temporal consistency and stability of three scales for measuring stress in adults. Rossini ED, et al. **Percept Mot Skills** 1996 Apr;82(2):588–90

Estimates of reliabilities for the Teacher Integration Attitude Questionnaire. Sideridis GD, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1214

Discriminant effectiveness of psychological state measures in predicting selection during field hockey trials. Terry PC, et al. **Percept Mot Skills** 1996 Apr;82(2):371–7

Clinical computing. Computer–administered symptom rating scales. Kobak KA. **Psychiatr Serv** 1996 Apr;47(4):367–9

Japan–U.S. comparison of responses to depression scale items among adult workers. Iwata N, et al. **Psychiatry Res** 1995 Oct 16;58(3):237–45

Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Prigerson HG, et al. **Psychiatry Res** 1995 Nov 29;59(1–2):65–79

Affective state dependence of the Tridimensional Personality Questionnaire. Strakowski SM, et al. **Psychiatry Res** 1995 Aug 28;57(3):209–14

A comparison of Tridimensional Personality Questionnaire dimensions in bipolar disorder and unipolar depression. Young LT, et al. **Psychiatry Res** 1995 Sep 29;58(2):139–43

The development and validation of a predictive index for postpartum depression. Cooper PJ, et al. **Psychol Med** 1996 May;26(3):627–34

Aggression and personality: association with amino acids and monoamine metabolites. Møller SE, et al. **Psychol Med** 1996 Mar;26(2):323–31

The construction and characteristics of an instrument to measure personal hopefulness. Nunn KP, et al. **Psychol Med** 1996 May;26(3):531–45

Personality traits in LLPDD and normal controls during follicular and luteal menstrual–cycle phases. Parry BL, et al. **Psychol Med** 1996 Jan;26(1):197–202

The Inventory of Depressive Symptomatology (IDS): psychometric properties. Rush AJ, et al. **Psychol Med** 1996 May;26(3):477–86

Factorial structure of the Arabic Children's Depression Inventory among Kuwaiti subjects. Abdel–Khalek AM. **Psychol Rep** 1996 Jun;78(3 Pt 1):963–7

Dimensionality of burnout: testing for invariance across Jordanian and Emirati teachers. Abu–Hilal MM. **Psychol Rep** 1995 Dec;77(3 Pt 2):1367–75

Personality traits of women with breast cancer: before and after diagnosis. Bleiker EM, et al. **Psychol Rep** 1995 Jun; 76(3 Pt 2):1139–46

Assessing effects of treatment for substance abuse: a further contribution to the validation of the Employee Reliability Inventory. Borofsky GL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):1043–9

Time perspective of substance abuse patients: comparison of the scales in Stanford Time Perspective Inventory, Beck Depression Inventory, and Beck Hopelessness Scale. Breier–Williford S, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):899–905

Some comments on a factor analysis of the 16PF and the NEO Personality Inventory–Revised. Cattell HE. **Psychol Rep** 1995 Dec;77(3 Pt 2):1307–11

Using the Multiphasic Sex Inventory with child molesters. Clark M, et al. **Psychol Rep** 1995 Oct;77(2):623–5

Continued validation of the Multidimensional Perfectionism Scale. Clavin SL, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):732–4

Executive functions of the frontal lobes: psychometric properties of a self–rating scale. Coolidge FL, et al. **Psychol Rep** 1995 Aug;77(1):24–6

16 PF profiles and typologies for patients seen in marital therapy. Craig RJ, et al. **Psychol Rep** 1995 Aug; 77(1):187–94

Self–criticism and dependency in relation to anger. Dunkley DM, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1342

Persistence of SCII scores and CPI scores of students entering a baccalaureate nursing program during a seven–year period. Strong–Campbell Interest Inventory. Dyer ED, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1362

Millon Clinical Multiaxial Inventory—II. Follow–up of patients with dissociative identity disorder. Ellason JW, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):707–16

Assessment of dissociative identity disorder with the Million Clinical Multiaxial Inventory–II. Ellason JW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):895–905

Vulnerability Scale scores in female inpatients diagnosed with self–injurious behaviour, dissociative identity disorder, and major depression. Glover H, et al. **Psychol Rep** 1995 Dec; 77(3 Pt 1):987–93

Scores of Brazilian University students on the Beck Depression and the State Trait Anxiety Inventories. Gorenstein C, et al. **Psychol Rep** 1995 Oct;77(2):635–41

Faking and its detection on the Holden Psychological Screening Inventory. Holden RR. **Psychol Rep** 1995 Jun; 76(3 Pt 2):1235–40

Psychology of computer use: XXXIV. The Computer Hassles Scale: subscales, norms, and reliability. Hudiburg RA. **Psychol Rep** 1995 Dec;77(3 Pt 1):779–82

Questionnaire format bias: when are juxtaposed scales appropriate: a call for further research. Hunt DM, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):931–41

Accounting for variance shared by measures of personality and stress–related variables: a canonical correlation analysis. Jelinek J, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):959–62

Convergent validity of the Depression–Happiness Scale with measures of happiness and satisfaction with life. Lewis CA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):876–8

A partial replication of Lippin (1990) using the Myers–Briggs type indicator with a sample of female prisoners. Long CK, et al. **Psychol Rep** 1995 Oct;77(2):467–72

Further validation of the Self–Defeating Personality Scale. McCutcheon LE. **Psychol Rep** 1995 Jun;76(3 Pt 2):1135–8

Narcissism and Machiavellianism. McHoskey J. **Psychol Rep** 1995 Dec;77(3 Pt 1):755–9

Posttraumatic stress disorder and the MCMI–II. Munley PH, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):939–44

Typological description of the chronic low back–pain syndrome using the Million Behavioral Health Inventory. Murphy MA, et al. **Psychol Rep** 1995 Jun;76(3 Pt

2):1227–34

Associations of neuroticism and introversion with academic achievement. Mwamwenda TS. **Psychol Rep** 1995 Aug; 77(1):265–6

Ethnic differences on the Outcome Questionnaire. Nebeker RS, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):875–9

The Child Abuse Potential Inventory: cross–validation in Croatia. Pečnik N, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):979–85

Preconditions for sensitivity in measuring change: visual analogue scales compared to rating scales in a Likert format. Pfennings L, et al. **Psychol Rep** 1995 Oct; 77(2):475–80

Scores on psychoticism of adolescent girls in Puerto Rico. Porrata JL. **Psychol Rep** 1995 Jun;76(3 Pt 1):808–10

The structure of psychological distress. Préville M, et al. **Psychol Rep** 1995 Aug;77(1):275–93

Split–half reliability of the Work Addiction Risk Test: development of a measure of workaholism. Robinson BE, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1226

Measuring workaholism: content validity of the Work Addiction Risk Test. Robinson BE, et al. **Psychol Rep** 1995 Oct;77(2):657–8

Development of the Relationship Beliefs Questionnaire. Romans JS, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1248–50

Retrospective self–reported symptoms of attention–deficit hyperactivity disorder: reliability of the Wender Utah Rating Scale. Rossini ED, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):751–4

The Multidimensional Perfectionism Scale: correlations with depression in college students with learning disabilities. Saddler CD, et al. **Psychol Rep** 1995 Oct;77(2):483–90

Coping and personality. Saklofske DH, et al. **Psychol Rep** 1995 Oct;77(2):481–2

A cautionary note about the cross–national and clinical validity of cut–off points for the Maslach Burnout Inventory. Schaufeli WB, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1083–90

Scores on the SF–36 scales and the Beck Depression Inventory in assessing mental health among patients on hemodialysis. Schneider B, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):719–22

Structural findings regarding the Silencing the Self Scale. Stevens HB, et al. **Psychol Rep** 1995 Aug;77(1):11–7

Self–consciousness Scale: a Brazilian version. Teixeira MA, et al. **Psychol Rep** 1995 Oct;77(2):423–7

Development and psychometric validation of the Mental, Physical, and Spiritual Well–Being Scale. Vella–Brodrick DA, et al. **Psychol Rep** 1995 Oct;77(2):659–74

Associations of scores on the White–Campbell Psychological Birth Order Inventory and the Kern Lifestyle Scale. White J, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1187–96

Correspondence between students' scores on the Millon Clinical Multiaxial Inventory–II and Personality Diagnostic Questionnaire–Revised. Wierzbicki M, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1079–82

Self–esteem and alexithymia. Yelsma P. **Psychol Rep** 1995 Dec;77(3 Pt 1):735–8

Alexithymia in inflammatory bowel disease. A case–control study. Porcelli P, et al. **Psychother Psychosom** 1995; 64(1):49–53

The empirical relationships between standardized measures of religiosity and personality/mental health. Kaldestad E. **Scand J Psychol** 1996 Jun;37(2):205–20

Psychometric properties of the Danish 16PF and EPQ. Mortensen EL, et al. **Scand J Psychol** 1996 Jun;37(2):221–5

Cross–validation of the five–factor interpretive model of the Suicide Opinion Questionnaire. Rogers JR, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):305–9

A scale for identifying "Stockholm syndrome" reactions in young dating women: factor structure, reliability, and validity. Graham DL, et al. **Violence Vict** 1995 Spring; 10(1):3–22

[French translation of the Chapman Social and Physical Anhedonia Questionnaire: validation of the French translation in controls and schizophrenic patients (see comments)] Assouly–Besse F, et al. **Encephale** 1995 Jul–Aug;21(4):273–84 (Eng. Abstr.). Comment in: Encephale 1996 Jan–Feb;22(1):71–2. **(Fre)**

[Preliminary study of a list of obsessional thoughts. Validation and factorial analysis] Bouvard M, et al. **Encephale** 1989 May–Jun;15(3):351–4 (Eng. Abstr.) **(Fre)**

[Psychometric evaluation of obsessive compulsive disorder. Recent diagnostic scales] Buisson G, et al. **Encephale** 1989 May–Jun;15(3):359–67 (33 ref.) (Eng. Abstr.) **(Fre)**

[Translation and validation of the Revised Social Anhedonia Scale (SAS Social Anhedonia Scale, M.L. Eckblad, L.J. Chapman et al., 1982). Study of the internal and concurrent validity in 126 normal subjects] Kosmadakis CS, et al. **Encephale** 1995 Nov–Dec;21(6):437–43 (Eng. Abstr.) **(Fre)**

[French translation of the Social and Physical Anhedonia Scale of Chapman (letter)] Loas G. **Encephale** 1995 Nov–Dec;21(6):484 **(Fre)**

[External validity, reliability and basic score determination of the Toronto Alexithymia Scales (TAS and TAS–20) in a group of alcoholic patients] Loas G, et al. **Encephale** 1996 Jan–Feb;22(1):35–40 (Eng. Abstr.) **(Fre)**

[Physical anhedonia and depression: distinct concepts? Study of the construct validity of these dimensions in a group of 224 normal subjects] Loas G, et al. **Encephale** 1996 May–Jun;22(3):175–9 (Eng. Abstr.) **(Fre)**

[French version of the Yale–Brown Obsessive Compulsive Scale] Mollard E, et al. **Encephale** 1989 May–Jun; 15(3):335–41 (Eng. Abstr.) **(Fre)**

[The TRIG (Texas Revised Inventory of Grief) questionnaire. French translation and validation] Paulhan I, et al. **Encephale** 1995 Jul–Aug;21(4):257–62 (Eng. Abstr.) **(Fre)**

[Grief experience by 154 young adults in the general population (value of the TRIG grief scale). Texas Revised Inventory of Grief] Paulhan I, et al. **Encephale** 1995 Jul–Aug;21(4):263–71 (Eng. Abstr.) **(Fre)**

[Apropos of: evaluation scales of anhedonia. Methodological problems in the article by F. Assouly–Besse et al.: French translation of the Chapman Social and Physical Anhedonia Questionnaire (letter; comment)] Pierson A. **Encephale** 1996 Jan–Feb;22(1):71–2. Comment on: Encephale 1995 Jul–Aug;21(4):273–84. **(Fre)**

[Assessment of grief exemplified pregnancy loss: development and initial results on the validity of the Munich Grief Scale] Beutel M, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):295–302 (Eng. Abstr.) **(Ger)**

[An empirical study of the factor structure of needs] Deneke FW, et al. **Psychother Psychosom Med Psychol** 1996 Jun; 46(6):228–33 (Eng. Abstr.) **(Ger)**

[References for evaluation scales in quality assurance in rehabilitation—6. Assessment of coping processes with the Freiburg Questionnaire of Illness Coping] Muthny FA. **Rehabilitation (Stuttg)** 1996 May;35(2):IX–XVI (Eng. Abstr.) **(Ger)**

[Subjective perception of social support in the population] Rathner G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):158–73 (Eng. Abstr.) **(Ger)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3–32 (90 ref.) (Eng. Abstr.) **(Ger)**

[Validity of the Narcissism Inventory (Deneke and Hilgenstock)] Rauchfleisch U, et al. **Z Psychosom Med Psychoanal** 1995;41(3):268–78 (Eng. Abstr.) **(Ger)**

PERSONALITY TESTS

The psychological assessment of depression: unipolars versus bipolars. Wetzler S, et al. **J Pers Assess** 1995 Dec; 65(3):557–66

[The use of the Lüscher color test for assessing the emotional status of children and adolescents with an organic central nervous system lesion and borderline psychopathology] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):44–7 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210–20 (87 ref.)

Experimental personality designs: analyzing categorical by continuous variable interactions. West SG, et al. **J Pers** 1996 Mar;64(1):1–48

Projective personality tests of children with inflammatory bowel disease. Krall V, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1341–2

PERSONALITY TYPE A see **TYPE A PERSONALITY**

PERSONNEL ADMINISTRATION, HOSPITAL

Interns' service contracts [letter] Roos J. **S Afr Med J** 1994 Nov;84(11):786

Interns' service contracts [letter] Taitz. **S Afr Med J** 1994 Nov;84(11):787–8

LEGISLATION & JURISPRUDENCE

Human resources ... decision on the Family and Medical Leave Act [news] **Hosp Health Netw** 1996 Apr 5;70(7):12, 14–5

Responses within nonfederal hospitals in Pennsylvania to the Americans with Disabilities Act of 1990. Jones DL, et al. **Phys Ther** 1996 Jan;76(1):49–60

Supervisor personal liability for ADA discrimination. Emerging issues for hospital administrators and physicians. Blanck PD, et al. **Spine** 1995 Jul 1;20(13):1528–32

METHODS

Human resources. Busting barriers. Appleby C. **Hosp Health Netw** 1995 Oct 20;69(20):47

STANDARDS

Mean streets. Five lessons from the front lines of reengineering [see comments] Lumsdon K. **Hosp Health Netw** 1995 Oct 5;69(19):44–8, 50, 52. Comment in: Hosp Health Netw 1995 Dec 5;69(23):8.

PERSONNEL DISCIPLINE see **EMPLOYEE DISCIPLINE**

PERSONNEL, HOSPITAL

Glove–induced dermal and respiratory symptoms among health care workers in one Finnish hospital. Kujala VM, et al. **Am J Ind Med** 1995 Jul;28(1):89–98

Compliance with universal precautions among health care workers at three regional hospitals. Gershon RR, et al. **Am J Infect Control** 1995 Aug;23(4):225–36

Should infection control practitioners do follow–up of staff exposures to patient blood and body fluids? Hope KM, et al. **Am J Infect Control** 1996 Apr;24(2):57–66

The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Petrosillo N, et al. **Am J Infect Control** 1995 Oct; 23(5):278–85

Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Puro V, et al. **Am J Infect Control** 1995 Oct; 23(5):273–7

Occupational exposure to hepatitis B virus and human immunodeficiency virus: a comparative risk analysis. Zuckerman AJ. **Am J Infect Control** 1995 Oct;23(5):286–9

How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44–50; quiz 51 (5 ref.)

Prevalence of latex–specific IgE antibodies in hospital personnel. Kaczmarek RG, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):51–6

Infection control and human immunodeficiency virus: perceptions of risk among nurses and hospital domestic workers. Parsons CD, et al. **Aust J Public Health** 1995 Oct;19(5):492–500

Atherosclerosis risk factors: variation in healthy hospital workers and members of local communities asymptomatic for vascular disease. Implications for normal controls. Blann AD, et al. **Br J Biomed Sci** 1995 Mar;52(1):31–4

Short communication: estimates of radiation dose to National Health Service workers in Northamptonshire from raised radon levels. Denman AR, et al. **Br J Radiol** 1996 Jan; 69(817):72–5

Wellness. Practicing what they preach. Jannot M. **Hosp Health Netw** 1996 Jan 20;70(2):44

Knowledge of the transmission of tuberculosis and infection control measures for tuberculosis among healthcare workers. Lai KK, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):168–70

Tuberculosis infection among staff at a Canadian community hospital. Liss GM, et al. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):29–35

Determinants of body size perceptions and dieting behavior in a multiethnic group of hospital staff women. Mossavar–Rahmani Y, et al. **J Am Diet Assoc** 1996 Mar; 96(3):252–6

The effects of 'in–use' surgical handwashing on the pre– and postoperative fingertip flora during cardiothoracic and orthopaedic surgery. Christensen JB, et al. **J Hosp Infect** 1995 Aug;30(4):283–93

Contact lens wear by hospital health care staff: is there cause for concern? Hay J, et al. **J Hosp Infect** 1995 Jun;30 Suppl:275–81 (40 ref.)

Clostridium difficile in a healthcare worker [letter] Kaplan N, et al. **J Hosp Infect** 1996 Apr;32(4):322

Methicillin–resistant Staphylococcus haemolyticus on the hands of health care workers: a route of transmission or a source? Perdreau–Remington F, et al. **J Hosp Infect** 1995 Nov;31(3):195–203

Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in health care workers: a multiple regression analysis of risk factors. Petrosillo N, et al. **J Hosp Infect** 1995 Aug;30(4):273–81

Carriage of Staphylococcus haemolyticus among healthcare workers [letter] Verweij PE, et al. **J Hosp Infect** 1996 Apr; 32(4):320–1

Delivery of care for hypertension. McInnes GT, et al. **J Hum Hypertens** 1995 Jun;9(6):429–33

Parvovirus B19 infection in hospital workers: community or hospital acquisition? Dowell SF, et al. **J Infect Dis** 1995 Oct;172(4):1076–9

Needlesticks and cuts with sharp objects in Siriraj Hospital 1992. Danchaivijitr S, et al. **J Med Assoc Thai** 1995 Jul; 78 Suppl 2:S108–11

Medical surveillance for ethylene oxide exposure: practices and clinical findings in Massachusetts hospitals. LaMontagne AD, et al. **J Occup Environ Med** 1996 Feb; 38(2):144–54

Determinants of the provision of ethylene oxide medical surveillance in Massachusetts hospitals. LaMontagne AD, et al. **J Occup Environ Med** 1996 Feb;38(2):155–68

Anesthetic in urine as biological index of exposure in operating–room personnel. Imbriani M, et al. **J Toxicol Environ Health** 1995 Oct;46(2):249–60

Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. Camins BC, et al. **JAMA** 1996 Apr 3;275(13):1013–5

Tuberculin skin testing of hospital workers. Miller B. **JAMA** 1996 Sep 18;276(11):855

Diphtheria immunity in health staff [letter] Hanlon M, et al. **Lancet** 1996 Jun 29;347(9018):1839–40

Teaching hospital medical staff to handwash [letter] Whitby MR, et al. **Med J Aust** 1996 Aug 5;165(3):172–3

Front-line hospital staff from six hospitals rate benefits of hospital information systems. Nauright LP, et al. **Medinfo** 1995;8 Pt 1:594-7

Follow up study of chromosome aberrations in lymphocytes in hospital workers occupationally exposed to low levels of ionizing radiation. Paz-y-Miño C, et al. **Mutat Res** 1995 Dec;335(3):245-51

Implementing tuberculosis control guidelines in a hospital environment. Walls C. **N Z Med J** 1996 Jan 26; 109(1014):12-3

Latex allergy in pediatric emergency department personnel. Fein JA, et al. **Pediatr Emerg Care** 1996 Feb;12(1):6-9

New developments in employee assistance programs. White RK, et al. **Psychiatr Serv** 1996 Apr;47(4):387-91

Occupational asthma due to latex in a hospital administrative employee. Vandenplas O, et al. **Thorax** 1996 Apr; 51(4):452-3

[Occupational allergic dermatoses in the hospital environment] Chabaux C. **Allerg Immunol (Paris)** 1995 Dec; 27(10):370, 373-4 (Eng. Abstr.) **(Fre)**

[Seroprevalence of markers of viral hepatitis A, B and C in hospital personnel at the Clermont-Ferrand University Hospital Center] Djeriri K, et al. **Presse Med** 1996 Feb 3;25(4):145-50 (Eng. Abstr.) **(Fre)**

[Ethylene oxide in hospitals--occupational medicine and hygienic aspects] Avni A, et al. **Harefuah** 1995 Nov 15; 129(10):431-5 **(Heb)**

[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681-5 (36 ref.) (Eng. Abstr.) **(Hun)**

[Prevalence of hepatitis B in a dermatological hospital] Catania G, et al. **Ann Ig** 1995 Mar-Apr;7(2):115-9 **(Ita)**

[Hepatitis B virus (HBV) infection in health personnel of a hospital for adolescents. Results of a vaccine campaign] Di Ciommo V, et al. **Pediatr Med Chir** 1995 Jul-Aug; 17(4):327-9 (Eng. Abstr.) **(Ita)**

[Hospitals as battle fields] Mellbye F. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3111-2 **(Nor)**

[Occupational conditions for hospital-employed physicians during continuing education (letter)] Wannag A. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1154 **(Nor)**

[Serological evaluation for human immunodeficiency virus (HIV) and for hepatitis B (HBV) among candidates who have passed the admission tests at a hospital institution in São Paulo] Uip DE, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):141-3 (Eng. Abstr.) **(Por)**

[Epidemiology of a hospital outbreak of scabies (letter)] Ortega L, et al. **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):495-6 **(Spa)**

[Occupational accidents and incidence of HIV infection and hepatitis B and C at a Mexican institution] Huertas MA, et al. **Rev Invest Clin** 1995 May-Jun;47(3):181-7 (Eng. Abstr.) **(Spa)**

[Hepatitis B is an occupational risk for health personnel. Preventive vaccination is recommended] Struve J, et al. **Lakartidningen** 1996 Mar 6;93(10):884-8 **(Swe)**

EDUCATION

Developing interactive computer-based simulations: an object-oriented development methodology enhances computer-assisted instruction. Jiang MZ, et al. **Comput Methods Programs Biomed** 1995 Aug;47(3):189-96

Creative infection control. Davis-Beattie M, et al. **J Hosp Infect** 1996 Feb;32(2):85-97

Training the work force--models for effective education in infection control. Seto WH. **J Hosp Infect** 1995 Jun;30 Suppl:241-7

Educating clinicians to use casemix data for decision making. Hovenga EJ, et al. **Medinfo** 1995;8 Pt 2:1247-50

Using guidelines for education, policy making, and assessing quality of care. Hagan S. **Oncol Nurs Forum** 1995 Oct; 22(9):1435-6

European Donor Hospital Education Program. van Dalen J, et al. **Transplant Proc** 1996 Feb;28(1):398-9

Overview of the European Donor Hospital Education Program. Wight C, et al. **Transplant Proc** 1996 Feb; 28(1):422-3

LEGISLATION & JURISPRUDENCE

Balancing judicial interests in HIV cases. Part 1, Issues for nurse administrators. Zachary MK. **J Nurs Adm** 1995 Oct; 25(10):51-5

Legal protection of staff of mental hospitals--a note. Andoh B. **Med Leg J** 1995;63 (Pt 4):169-71

ORGANIZATION & ADMINISTRATION see PERSONNEL ADMINISTRATION, HOSPITAL

PSYCHOLOGY

The personal experience of Australian health-care workers accidentally exposed to risk of HIV infection [letter] Treloar CJ, et al. **AIDS** 1995 Dec;9(12):1385-6

User expectations and perceptions of a patient management information system. Henderson RD, et al. **Comput Nurs** 1996 May-Jun;14(3):188-93

Job satisfaction among social work discharge planners. Kadushin G, et al. **Health Soc Work** 1995 Aug;20(3):174-86

Staff compliance with infection control practices: application of behavioural sciences. Seto WH. **J Hosp Infect** 1995 Jun; 30 Suppl:107-15

Health care professional attitudes toward donation: effect on practice and procurement. Siminoff LA, et al. **J Trauma** 1995 Sep;39(3):553-9

Predictors of hepatitis B vaccine acceptance in health care workers. Doebbeling BN, et al. **Med Care** 1996 Jan; 34(1):58-72

Stress and arousal in deployment of a combat support hospital. Hall DP Jr, et al. **Mil Med** 1995 Nov; 160(11):581-3

[Countertransference and institutional stakes. The institution grappling with the ambivalence of state limit] Lamiral B. **Acta Psychiatr Belg** 1995 Jan-Feb;95(1):44-54 (Eng. Abstr.) **(Fre)**

[Study on the prevention of HIV transmission between patients in the psychiatric hospital milieu] Charmasson C, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):512-6; discussion 516-7 (Eng. Abstr.) **(Fre)**

[Communication in the patient care team about palliative situations' results of a survey at the Laennec Hospital, Paris] Perard M, et al. **Ann Med Psychol (Paris)** 1995 Oct; 153(8):542-6 (Eng. Abstr.) **(Fre)**

[Discussion group: for caregivers confronted with death in the hospital environment] Reich M, et al. **Rev Med Brux** 1996 Feb;17(1):4-6 (Eng. Abstr.) **(Fre)**

STANDARDS

Chest compression and ventilation rates during cardiopulmonary resuscitation: the effects of audible tone guidance [see comments] Milander MM, et al. **Acad Emerg Med** 1995 Aug;2(8):708-13. Comment in: Acad Emerg Med 1995 Aug;2(8):673-4.

Radiographers as film readers in screening mammography: an assessment of competence under test and screening conditions. Pauli R, et al. **Br J Radiol** 1996 Jan;69(817):10-4

STATISTICS & NUMERICAL DATA

An outbreak of needlestick injuries in hospital employees due to needles piercing infectious waste containers. Anglim AM, et al. **Infect Control Hosp Epidemiol** 1995 Oct; 16(10):570-6

An outbreak of campylobacter food poisoning in a health care setting. Murphy O, et al. **J Hosp Infect** 1995 Jul; 30(3):225-8

Hospital smoking bans and employee smoking behavior: Results of a national survey. Longo DR, et al. **JAMA** 1996 Apr 24;275(16):1252-7

Health surveillance for hospital employees exposed to respiratory sensitizers. Smedley J, et al. **Occup Med (Oxf)** 1996 Feb;46(1):33-6

SUPPLY & DISTRIBUTION

Employment trends in hospitals, 1981-1993. Anderson GF, et al. **Inquiry** 1996 Spring;33(1):79-84

PERSONNEL, HOSPITAL, ORGANIZATION AND ADMINISTRATION see **PERSONNEL ADMINISTRATION, HOSPITAL**

PERSONNEL LOYALTY

Predictors of organizational and career commitment among Illinois pharmacists. Kong SX. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2005-11

Occupational stress and organizational commitment in nurse administrators. Lee V, et al. **J Nurs Adm** 1996 May; 26(5):21-8

PERSONNEL MANAGEMENT

see related
PERSONNEL ADMINISTRATION, HOSPITAL

10 tips for success as a nurse manager. Badzek L, et al. **Am J Nurs** 1996 Jun;96(6):48-9

Office policies and benefits update. Part II. Eash C. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):667-8

Terms and conditions of service for new specialist registrar grade are not yet established [letter] Bennie P. **BMJ** 1995 Oct 21;311(7012):1094

Creating value for your staff. Manji I. **J Can Dent Assoc** 1995 Oct;61(10):837-9

A Christmas Carol. A case study for McGregor's motivation theories X and Y. O'Connor CL. **J Nurs Adm** 1995 Dec; 25(12):7-8

Individual Mobilization Augmentation: recipe for an effective total force partnership. Hayunga EG, et al. **Mil Med** 1995 Oct;160(10):496-500

NIH discovers who counts as 'essential' [news] Appel A, et al. **Nature** 1995 Nov 23;378(6555):325

Black scientist faces inquiry at South African university [news] Cherry M. **Nature** 1995 Nov 23;378(6555):324

LEGISLATION & JURISPRUDENCE

Appeals court upholds hospital firing of HIV-positive physician [news] **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):492-3

What dentists need to know about employment law. Sfikas PM. **J Am Dent Assoc** 1996 Jan;127(1):124-6

What dentists need to know about employment law. Sfikas PM. **J Am Dent Assoc** 1996 Feb;127(2):268-9

Administrative discipline. Harty-Golder B. **J Fla Med Assoc** 1995 Dec;82(12):829-31

Noncompetition agreements in Kentucky health care. Dolson SW. **J Ky Med Assoc** 1996 Apr;94(4):154-8

When an employee becomes pregnant. Employer's rights and responsibilities. Plunkett LR. **N Y State Dent J** 1996 Jan; 62(1):9-11

METHODS

Coaching practices of first-line nurse managers in hospital wards with highly satisfied personnel. Kivimäki M, et al. **J Nurs Adm** 1995 Nov;25(11):6, 14

Creating a climate to promote internal motivation in employees. Proch ML. **J Nurs Adm** 1995 Oct;25(10):5

Helping the helpers. A unique colleague support system for mental health professionals-consumers. Fishbein SM, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Nov;33(11):41-3

Quality initiatives in a corporate toxicology laboratory. Scribner HE, et al. **Qual Assur** 1995 Sep;4(3):205-9

STANDARDS

Guide for supervision of occupational therapy personnel. American Occupational Therapy Association. **Am J Occup Ther** 1995 Nov-Dec;49(10):1027-8

Human resources. True teamwork. **Hosp Health Netw** 1996 Sep 5;70(17):62

PERSONNEL RECRUITMENT see **PERSONNEL SELECTION**

PERSONNEL SELECTION

Recruiters' new role [letter] Harper K. **Am J Nurs** 1995 Dec; 95(12):17

Chief residency in PM&R. A balance of education and administration. Young MA, et al. **Am J Phys Med Rehabil** 1996 Jul-Aug;75(4):257-62

Recruiting minorities into the profession of epidemiology. Surveying the applicants' mail. American College of Epidemiology Committee on Minority Affairs. Morssink CB, et al. **Ann Epidemiol** 1996 Jan;6(1):4-11

Child and adolescent mental disorders and the search for an NIMH director. Quo Vadis? [editorial] Barchas JD, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):873

Guidelines for the training, credentialing, use, and supervision of speech-language pathology assistants. Task Force on Support Personnel. **ASHA Suppl** 1996 Spring;38(2 Suppl 16):21-34

Factors influencing the response to advertisements for general practice vacancies. Carlisle R, et al. **BMJ** 1996 Aug 24;313(7055):468-71

The nature of general practice. Nostalgia doesn't help recruitment [letter; comment] Leech N. **BMJ** 1996 Jun 1; 312(7043):1422-3. Comment on: BMJ 1996 Feb 24;312(7029):456-7.

Recruitment to academic posts [letter] Ogden GR. **Br Dent J** 1996 Jul 6;181(1):8

US not the only country luring Canadian MDs. Wharry S. **Can Med Assoc J** 1996 Jun 1;154(11):1742

Physicians. Help wanted. **Hosp Health Netw** 1996 Jun 20; 70(12):62

The UWM Health Careers Bridge Program: an innovative approach for improving the recruitment, retention and graduation of minority students in nursing and health careers. Underwood SM, et al. **J Nurs Educ** 1996 Apr; 35(4):179-81

Changes in marketplace demand for physicians: a study of medical journal recruitment advertisements. Seifer SD, et al. **JAMA** 1996 Sep 4;276(9):695-9

International recruitment highlights need to track scientific behaviour [news] Dalton R. **Nature** 1996 Sep 12; 383(6596):107-8

The role of pharmacists in the recruitment of a cohort for postmarketing surveillance. A case study of acitretin in The Netherlands. Sturkenboom MC, et al. **Pharm World Sci** 1995 Jul 28;17(4):126-32

Hiring by radiology groups in 1994. Deitch CH, et al. **Radiology** 1996 Feb;198(2):359-64

Epilepsy and employment--employers' attitudes. Cooper M. **Seizure** 1995 Sep;4(3):193-9

Veterinary manpower and recruitment [letter; comment] Ware S. **Vet Rec** 1995 Aug 19;137(8):200. Comment on: Vet Rec 1995 Aug 12;137(7):176.

[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul-Aug;86(4):303-8 (36 ref.) (Eng. Abstr.) **(Ita)**

[Personality determinants of effectiveness in performing duties by soldiers in active service in the landing-shock brigade] Florkowski A, et al. **Psychiatr Pol** 1996 Mar-Apr; 30(2):331-9 (Eng. Abstr.) **(Pol)**

[Room for the improvement of soldier selection for the landing brigade] Szczęsny D, et al. **Psychiatr Pol** 1996 Mar-Apr;30(2):341-50 (Eng. Abstr.) **(Pol)**

[Adolescent health status and the medical problems of recruiting for the Armed Forces of Ukraine] Amosova EN, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):7-8 **(Rus)**

LEGISLATION & JURISPRUDENCE

Implications of negligent selection and retention of physicians in the age of ERISA. Dorros TA, et al. **Am J Law Med** 1995;21(4):383-418 (346 ref.)

The interview and hiring process according to the Americans

with Disabilities Act and the Equal Employment Opportunities Commission. Part I. Eash C. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):570–1

METHODS

Rural health care [letter; comment] Howe RK. **Arch Fam Med** 1995 Nov;4(11):917–8. Comment on: Arch Fam Med 1994 Feb;3(2):119–21.

Defining and measuring the "right stuff": neuropsychiatrically enhanced flight screening (N–EFS). King RE, et al. **Aviat Space Environ Med** 1995 Oct;66(10):951–6

The value of self–estimated scholastic standing in residency selection. Sklar DP, et al. **J Emerg Med** 1995 Sep–Oct; 13(5):683–5

Potential recruits referred for cardiac opinion review of 100 consecutive cases—a waste of time or an investment? Ineson N, et al. **J R Army Med Corps** 1995 Oct; 141(3):129–33

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147–50 (8 ref.)

[Methods for studying deviant personality behavior during the professional psychological selection of military specialists] Glushko AN. **Voen Med Zh** 1992 Feb;(2):67–9 **(Rus)**

[The medical aspects of manpower recruitment for the Armed Forces] Korsakov LI. **Voen Med Zh** 1992 Feb; (2):16–20, 79 (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Revisioning the recruitment of talented professionals. Wells RW, et al. **J Nurs Adm** 1996 Jan;26(1):21–30

[Stages in the formation of military medical expertise for rocket forces and the ways for its improvement] Trukhin EM, et al. **Voen Med Zh** 1992 Feb;(2):42–4 **(Rus)**

STANDARDS

Academic and training requirements in advertisements for pharmacy management and clinical positions. Wieland LD, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):289–93

A critical review of personnel standards. Peddecord KM. **Clin Chem** 1996 May;42(5):790–6 (25 ref.)

TRENDS

Recruitment and retention of family physicians. Crouse BJ. **Minn Med** 1995 Oct;78(10):29–32

Recruitment and workforce issues in late 20th century American psychiatry. Weissman S. **Psychiatr Q** 1996 Summer;67(2):125–37 (8 ref.)

PERSONNEL STAFFING AND SCHEDULING

Medical school policies for part–time faculty committed to full professional effort. Froom JD, et al. **Acad Med** 1996 Jan;71(1):91–6

Sounding the alarm. Gordon S, et al. **Am J Nurs** 1996 Jun; 96(6):21–2

How many trainees are needed in general surgery? A computer model to facilitate planning. Watkin D. **Ann R Coll Surg Engl** 1995 Jul;77(4 Suppl):180–4

Junior doctors' hours. Junior doctors need to have time for their lives outside medicine [letter; comment] Cant M. **BMJ** 1996 Apr 20;312(7037):1042. Comment on: BMJ 1996 Jan 20;312(7024):187.

New deal shifts may increase house officers' stress [letter] Grainger C, et al. **BMJ** 1995 Oct 7;311(7010):952–3

American cardiothoracic trainees want longer hours too [letter] Jacobs JP, et al. **BMJ** 1995 Dec 2;311(7018):1508

Junior doctors' hours. Shift work is poisoning juniors [letter; comment] [see comments] Kumar VV. **BMJ** 1996 Jan 20; 312(7024):187. Comment on: BMJ 1995 Sep 2;311(7005):632. Comment in: BMJ 1996 Apr 20;312(7037):1042.

Junior doctors' hours. Flexible partial shifts should be made to work [letter; comment] O'Neill E. **BMJ** 1995 Nov 11; 311(7015):1299. Comment on: BMJ 1995 Sep 2;311(7005):632. Comment on: BMJ 1995 Oct 21;311(7012):1093.

The new deal revisited. Survey showed most anaesthetists have no experience of shifts [letter; comment] Pickersgill T. **BMJ** 1995 Nov 4;311(7014):1231–2. Comment on: BMJ 1995 Jul 29;311(7000):331–2.

The new deal revisited. Obstetric trainees are against [letter; comment] Sanderson D. **BMJ** 1995 Nov 4;311(7014):1231 . Comment on: BMJ 1995 Jul 29;311(7000):331–2.

Understaffing: a risk factor for infection in the era of downsizing? [editorial; comment] Farr BM. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):147–9. Comment on: Infect Control Hosp Epidemiol 1996 Mar;17(3):150–8.

The role of understaffing in central venous catheter–associated bloodstream infections [see comments] Fridkin SK, et al. **Infect Control Hosp Epidemiol** 1996 Mar; 17(3):150–8. Comment in: Infect Control Hosp Epidemiol 1996 Mar;17(3):147–9.

The pattern and effect of on call work in transplant coordinators in the United Kingdom. Smithers F. **Int J Nurs Stud** 1995 Oct;32(5):469–83

Technology and staffing in Japanese university hospitals. Government versus private. Vogt WB, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):93–103

Organizational environment and the support of patient autonomy in nursing home care. Mattiasson AC, et al. **J Adv Nurs** 1995 Dec;22(6):1149–57

Staffing levels and seclusion use. Morrison P, et al. **J Adv Nurs** 1995 Dec;22(6):1193–1202

A voice from the night. Keeler ML. **J Emerg Med** 1996 Jan–Feb;14(1):85–6

The night float system of resident on call: what do the nurses think? Buff DD, et al. **J Gen Intern Med** 1995 Jul; 10(7):400–2

Behavioral effects and body activity level in female hospital staff nurses during work hour. Mathur K, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):1–11

Can you depend on your patient classification system? Hlusko DL, et al. **J Nurs Adm** 1996 Apr;26(4):39–44

Nursing Staff in Hospitals and Nursing Homes: is it Adequate? a review and commentary. Sovie MD. **Nurs Outlook** 1996 Mar–Apr;44(2):100–1

Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. Axelsson G, et al. **Occup Environ Med** 1996 Jun;53(6):374–8

Shiftwork and mortality from ischaemic heart disease. McNamee R, et al. **Occup Environ Med** 1996 Jun; 53(6):367–73

Overtime in the public health sector [letter] Rosochachi Z. **S Afr Med J** 1995 Oct;85(10):1036–7

ECONOMICS

Healing by design [letter; comment] Forman AD. **N Engl J Med** 1996 Feb 1;334(5):334–5; discussion 335. Comment on: N Engl J Med 1995 Sep 14;333(11):735–40.

LEGISLATION & JURISPRUDENCE

Caught short–staffed. Vieira AM. **Am J Nurs** 1996 Jun; 96(6):63

[The provisos for substitutes in formulaic elective performance agreements (comment)] Rieger HJ. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1603–4. Comment on: Dtsch Med Wochenschr 1995 Nov 17;120(46):1603–4. **(Ger)**

[The provisos for substitutes in formulaic elective performance agreements. The problems due to the new Schedule of Charges for Physicians] Rieger HJ. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):926 **(Ger)**

ORGANIZATION & ADMINISTRATION

The mentality of contraction [letter] Anshus JS. **Am J Emerg Med** 1996 Jan;14(1):114

Off–duty for consultants in the week? It can be done! Kelly MJ. **Ann R Coll Surg Engl** 1995 Sep;77(5 Suppl):257–9

Graduate nurse overhires. A cost analysis. Cardona SM, et al. **J Nurs Adm** 1996 Mar;26(3):10–5

Managing diverse needs of the technical coworker. Counsell CM, et al. **J Nurs Adm** 1996 Mar;26(3):5–6

A seasonal staffing model. Schmidt L, et al. **J Nurs Adm** 1996 Apr;26(4):52–5

Part–time nursing faculty: suggestions for change [editorial; comment] DeSevo MR. **J Nurs Educ** 1995 Oct;34(7):294–6 . Comment on: J Nurs Educ 1995 Oct;34(7):305–11.

Acuity scheduling systems: a case study in radiology. Maddala T. **Radiol Technol** 1996 May–Jun;67(5):415–20

STANDARDS

Nursing care quality: comparison of unit–hired, hospital float pool, and agency nurses. Strzalka A, et al. **J Nurs Care Qual** 1996 Jul;10(4):59–65

STATISTICS & NUMERICAL DATA

Job sharing at a children's hospital: evaluation by medical staff. Valentine JP, et al. **BMJ** 1996 Jan 13;312(7023):115–6

TRENDS

Trends in staffing an academic department of surgery in a tropical hospital: past, present, and future? Nmadu PT. **BMJ** 1996 May 25;312(7042):1345–7

UTILIZATION

Vascular laboratory personnel on–call: effect on patient management. Lohr JM, et al. **J Vasc Surg** 1995 Nov; 22(5):548–52

Pediatric locum tenens provided by an academic center. Poole SR, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):403–9

PERSONNEL STAFFING AND SCHEDULING INFORMATION SYSTEMS

Improving outpatient clinic staffing and scheduling with computer simulation. Hashimoto F, et al. **J Gen Intern Med** 1996 Mar;11(3):182–4

Expert panel method for nurse staffing and resource management. Dunn MG, et al. **J Nurs Adm** 1995 Oct; 25(10):61–7

A decision support system to meet the fluctuating needs of a hospital nursing unit. Asa AY, et al. **Medinfo** 1995;8 Pt 2:1418

A nurse duty scheduling support system with graphic user interface. Choi YS, et al. **Medinfo** 1995;8 Pt 2:1714

Extraction, preparation, and presentation of patient classification–data for the benefit of management overviews. Kooijman CJ, et al. **Medinfo** 1995;8 Pt 2:1382–5

A computer–based model for analyzing staffing needs of psychiatric treatment programs. Atkins RM. **Psychiatr Serv** 1995 Dec;46(12):1272–8

ORGANIZATION & ADMINISTRATION

Automated nurse rostering system for administrative efficiency as a subsystem of a total hospital information system. Akai Y, et al. **Medinfo** 1995;8 Pt 2:1417

PERSONNEL TURNOVER

Project has been set up to explore ways of preventing wastage of doctors [letter] Harvey J, et al. **BMJ** 1996 Aug 24;313(7055):491

Effect of staff turnover and the social environment on depressive symptoms in nursing home residents. Doyle CJ. **Int Psychogeriatr** 1995 Spring;7(1):51–61

The experience of work and turnover intentions: interactive effects of value attainment, job satisfaction, and positive mood. George JM, et al. **J Appl Psychol** 1996 Jun; 81(3):318–25

Graduate nurse overhires. A cost analysis. Cardona SM, et al. **J Nurs Adm** 1996 Mar;26(3):10–5

The interconnectedness of nurses' lives. Implications for nursing management. Glynn P, et al. **J Nurs Adm** 1996 May;26(5):36–42

The impact of sexual abuse on job attrition in military recruits. Smikle CB, et al. **Mil Med** 1996 Mar;161(3):146–8

Staff nurses' career development relationships and self–reports of professionalism, job satisfaction, and intent to stay. Yoder LH. **Nurs Res** 1995 Sep–Oct;44(5):290–7

Assessing effects of treatment for substance abuse: a further contribution to the validation of the Employee Reliability Inventory. Borofsky GL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):1043–9

The nursing practice environment, staff retention, and quality of care. Leveck ML, et al. **Res Nurs Health** 1996 Aug; 19(4):331–43

[Turnover of positions as the medically responsible physician in Norwegian municipalities 1988–91] Kolstrup N, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2671–4 (Eng. Abstr.) **(Nor)**

PERSUASION see **PERSUASIVE COMMUNICATION**

PERSUASIVE COMMUNICATION

see related
PROPAGANDA
SUGGESTION

Organ–limited autopsies: obtaining permission for postmortem examination of the urinary tract [letter; comment] [see comments] Davis GJ. **Arch Pathol Lab Med** 1995 Dec;119(12):1092. Comment on: Arch Pathol Lab Med 1995 May;119(5):440–3. Comment in: Arch Pathol Lab Med 1996 May;120(5):428.

Obtaining permission for postmortem examination [letter; comment] Hanzlick R. **Arch Pathol Lab Med** 1996 May; 120(5):428. Comment on: Arch Pathol Lab Med 1995 Dec;119(12):1092.

Seeking influence through characterizing self–categories: an analysis of anti–abortionist rhetoric. Reicher S, et al. **Br J Soc Psychol** 1996 Jun;35 (Pt 2):297–311

Attitude strength and resistance processes. Pomerantz EM, et al. **J Pers Soc Psychol** 1995 Sep;69(3):408–19

Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225–45 (8 ref.)

Creating strong attitudes: two routes to persuasion. Petty RE. **NIDA Res Monogr** 1995;155:209–24 (33 ref.)

PERTECHNETATE SODIUM see **SODIUM PERTECHNETATE TC 99M**

PERTHES DISEASE see **LEGG–PERTHES DISEASE**

PERTUSSIGEN see **PERTUSSIS TOXINS**

PERTUSSIS see **WHOOPING COUGH**

PERTUSSIS TOXINS

CHEMISTRY

A proposed mechanism of ADP–ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

Utilization of sialic acid–binding synthetic peptide sequences derived from pertussis toxin as novel anti–inflammatory agents. Heerze LD, et al. **Glycobiology** 1995 Jun; 5(4):427–33

Crystal structure of the pertussis toxin–ATP complex: a molecular sensor. Hazes B, et al. **J Mol Biol** 1996 May 17;258(4):661–71

GENETICS

The pertussis toxin liberation genes of Bordetella pertussis

are transcriptionally linked to the pertussis toxin operon. Ricci S, et al. **Infect Immun** 1996 Apr;64(4):1458–60

Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of Bordetella pertussis. Boucher PE, et al. **J Bacteriol** 1995 Nov;177(22):6486–91

BvgAS is sufficient for activation of the Bordetella pertussis ptx locus in Escherichia coli. Uhl MA, et al. **J Bacteriol** 1995 Nov;177(22):6477–85

IMMUNOLOGY

Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Kimura M, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):562–74

Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis. Frühwirth M, et al. **Adv Exp Med Biol** 1995;371B:777–83

Human antibody response to the B oligomer of pertussis toxin. Lynn F, et al. **Clin Diagn Lab Immunol** 1994 Nov; 1(6):626–32

Prevalence and incidence of adult pertussis in an urban population. Nennig ME, et al. **JAMA** 1996 Jun 5; 275(21):1672–4

Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Isacson J, et al. **Scand J Infect Dis** 1995; 27(3):273–7

Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Cropley I, et al. **Vaccine** 1995 Dec;13(17):1643–8

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Ibsen PH. **Vaccine** 1996 Apr;14(5):359–68

METABOLISM

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

Involvement of pertussis toxin-sensitive GTP-binding proteins in sphingosine 1-phosphate-induced activation of phospholipase C-Ca2+ system in HL60 leukemia cells. Okajima F, et al. **FEBS Lett** 1996 Feb 5;379(3):260–4

Pertussis toxin export genes are regulated by the ptx promoter and may be required for efficient translation of ptx mRNA in Bordetella pertussis. Baker SM, et al. **Infect Immun** 1995 Oct;63(10):3920–6

Interaction of calcium with Bordetella pertussis adenylate cyclase toxin. Characterization of multiple calcium-binding sites and calcium-induced conformational changes. Rose T, et al. **J Biol Chem** 1995 Nov 3;270(44):26370–6

Receptors coupled to pertussis toxin-sensitive G-proteins traffic to opposite surfaces in Madin-Darby canine kidney cells. A1 adenosine receptors achieve apical and alpha 2A adrenergic receptors achieve basolateral localization. Saunders C, et al. **J Biol Chem** 1996 Jan 12;271(2):995–1002

Identification of binding proteins for pertussis toxin on pancreatic beta cell-derived insulin-secreting cells. el Bayâ A, et al. **Microb Pathog** 1995 Mar;18(3):173–85

PHARMACOLOGY

Effects of fluoride and cholera and pertussis toxins on sensory transduction in the carotid body. Cachero TG, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1271–9

Adenosine A1 receptor-induced upregulation of protein kinase C: role of pertussis toxin-sensitive G protein(s). Marala RB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1619–24

Vanadate causes synthesis of endothelium-derived NO via pertussis toxin-sensitive G protein in pigs. Nakaike R, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H296–302

Effect of pertussis toxin and B-oligomer on platelet-activating factor-induced generation of inositol phosphates in porcine alveolar macrophages. Dodam JR, et al. **Am J Vet Res** 1996 Apr;57(4):574–9

Role of pertussis toxin-sensitive G-proteins in the analgesic and anesthetic actions of alpha 2-adrenergic agonists in the rat. Hayashi Y, et al. **Anesthesiology** 1995 Oct; 83(4):816–22

Modulation of calcium signalling and proliferation in monoblastoid U-937 cells. Ridefelt P, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1643–50

Dual effects of ATP on the potassium channel and intracellular Ca2+ release in smooth muscle cells of the bovine brain arteries. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1071–7

ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1022–8

alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):277–82

Cold-induced reduction in Gi alpha proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment. Svoboda P, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):761–8

Thapsigargin activates univalent- and bivalent-cation entry in human neutrophils by a SK&F 13 96365- and Gd3+-sensitive pathway and is a partial secretagogue: involvement of pertussis-toxin-sensitive G-proteins and protein phosphatases 1/2A and 2B in the signal-transduction pathway. Wenzel-Seifert K, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):679–86

Effect of pertussis toxin and PGE2 on the functioning of the IL-2 promoter in interleukin-1 treated EL4.NOB-1 thymoma cells. McCarthy LM, et al. **Biochem Soc Trans** 1996 Feb;24(1):82S

Streptococcal glycoprotein-induced tumour cell growth inhibition involves the modulation of a pertussis toxin-sensitive G protein. Yoshida J, et al. **Br J Cancer** 1996 Apr;73(8):917–23

Coupling of an endogenous 5-HT1B-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells. Dickenson JM, et al. **Br J Pharmacol** 1995 Dec;116(7):2889–96

Pertussis toxin from Bordetella pertussis blocks neutrophil migration and neutrophil-dependent edema in response to inflammation. Thomazzi SM, et al. **Braz J Med Biol Res** 1995 Jan;28(1):120–4

Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells. Kanthou C, et al. **Cell Signal** 1996 Jan;8(1):59–66

Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Hu K, et al. **Circulation** 1995 Oct 15;92(8):2259–65

Interleukin-1 beta and GTP-binding proteins [letter; comment] Sjöholm A. **Diabetologia** 1996 Feb;39(2):243–5. Comment on: Diabetologia 1995 Jul;38(7):779–84.

Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin. Poggi A, et al. **Eur J Immunol** 1996 May;26(5):967–75

Evidence for a metabostatic opioid kappa-receptor inhibiting pertussis toxin-sensitive metabotropic glutamate receptor-currents in Xenopus oocytes. Ueda H, et al. **FEBS Lett** 1995 Nov 20;375(3):201–5

Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin. Suh HW, et al. **Gen Pharmacol** 1995 Nov;26(7):1597–602

Inhibitory actions of cyclic adenosine monophosphate and pertussis toxin define two distinct epidermal growth factor-regulated pathways leading to activation of mitogen-activated protein kinase in rat hepatocytes. Ginès P, et al. **Hepatology** 1996 May;23(5):1167–73

Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). Wong WS, et al. **Immunology** 1996 May; 88(1):90–7

Nitric oxide induction by pertussis toxin in mouse spleen cells via gamma interferon. Sakurai S, et al. **Infect Immun** 1996 Apr;64(4):1309–13

Pertussis toxin-catalyzed ADP-ribosylation of Gi-2 and Gi-3 in CHO cells is modulated by inhibitors of intracellular trafficking. Xu Y, et al. **Infect Immun** 1996 Feb;64(2):593–9

Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. Anand-Srivastava MB, et al. **J Biol Chem** 1996 Aug 9;271(32):19324–9

Pertussis toxin-sensitive activation of phospholipase C'by the C5a and fMet-Leu-Phe receptors. Jiang H, et al. **J Biol Chem** 1996 Jun 7;271(23):13430–4

Pertussis toxin inhibits phospholipase C activation and Ca2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids. Okajima F, et al. **J Biol Chem** 1995 Nov 3;270(44):26332–40

Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24334–42

G(o)-protein alpha-subunits activate mitogen-activated protein kinase via a novel protein kinase C-dependent mechanism. van Biesen T, et al. **J Biol Chem** 1996 Jan 19;271(3):1266–9

Pertussis toxin-sensitive G-proteins inhibit fibroblast growth factor-induced signaling in pancreatic acini. Piiper A, et al. **J Cell Physiol** 1996 Apr;167(1):52–9

C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. Nilsson G, et al. **J Immunol** 1996 Aug 15;157(4):1693–8

Activation of the muscarinic K+ channel by P2-purinoceptors via pertussis toxin-sensitive G proteins in guinea-pig atrial cells. Matsuura H, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):659–71

Inhibition of cyclic AMP accumulation by endothelin is pertussis toxin sensitive and calcium independent in isolated adult feline cardiac myocytes. Jones LG. **Life Sci** 1996; 58(2):115–23

Effects of calcium channel antagonists and pertussis toxin on noradrenaline-induced contractions in pulmonary artery from pulmonary hypertensive rats. Tabrizchi R, et al. **Life Sci** 1995;56(14):1173–85

Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin-sensitive G protein. Sim PJ, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):257–63

(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced burst firing is mediated by a native pertussis toxin-sensitive metabotropic receptor at rat dorsolateral septal nucleus neurons. Zheng F, et al. **Neuroscience** 1995 Sep;68(2):423–34

Inhibition of platelet-activating factor-induced retinal impairments by cholera and pertussis toxins. Cluzel J, et al. **Ophthalmic Res** 1995;27(3):153–7

Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Samore MH, et al. **Vaccine** 1996 Mar;14(4):290–7

[Opinion of the expert (letter)] Bartolozzi G. **Pediatr Med Chir** 1995 Jul-Aug;17(4):385 **(Ita)**

THERAPEUTIC USE

Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis. Robbinson D, et al. **Cell Immunol** 1996 Mar 15;168(2):165–73

PERTUSSIS VACCINE

Acellular pertussis vaccines. Miller E. **Arch Dis Child** 1995 Nov;73(5):390–1 (15 ref.)

A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction. Dias WO, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2607–11

Acellular pertussis vaccines—a question of efficacy. Olin P. **J Hosp Infect** 1995 Jun;30 Suppl:503–7

Acellular pertussis vaccine is licensed for infants [news] Marwick C. **JAMA** 1996 Aug 21;276(7):516–8

Changes ahead in childhood immunization [news] [see comments] Marwick C. **JAMA** 1996 Feb 28;275(8):582. Comment in: JAMA 1996 Aug 14;276(6):449–50.

Pertussis vaccines: acellular versus whole-cell. Boughton CR. **Med J Aust** 1996 May 6;164(9):564–6

Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. **MMWR Morb Mortal Wkly Rep** 1996 Aug 9;45(31):676–7

Control of whooping cough in New Zealand; slow progress [see comments] Lennon D, et al. **N Z Med J** 1995 Dec 8;108(1013):495–7 (37 ref.). Comment in: N Z Med J 1996 Mar 8;109(1017):84. Comment in: N Z Med J 1996 Mar 22;109(1018):107–8.

[Opinion of the expert (letter)] Bartolozzi G. **Pediatr Med Chir** 1995 Jul-Aug;17(4):385 **(Ita)**

[Pertussis. Critical revision of its physiopathology. Implications] Fiore D. **Pediatr Med Chir** 1996 Jan-Feb; 18(1):109–12 (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. van der Zee A, et al. **J Infect Dis** 1996 Jul; 174(1):89–96

Inhaled Bordetella pertussis vaccine decreases airway responsiveness in guinea pigs. Vargas MH, et al. **Life Sci** 1995;57(19):PL293–9

Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Halperin SA, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):792–7

[Pertussis vaccination (letter)] Fiore D. **Pediatr Med Chir** 1995 Jul-Aug;17(4):384 **(Ita)**

[Acellular pertussis vaccine (Pa)] Magdzik W. **Przegl Epidemiol** 1995;49(3):325–9 (Eng. Abstr.) **(Pol)**

[Vaccination against whooping cough is being reintroduced] Gothefors L, et al. **Lakartidningen** 1996 Jan 17;93(3):129–32 **(Swe)**

[2 vaccine dosages for basic prevention of whooping cough in children over 2 years of age? (letter)] Gothefors L, et al. **Lakartidningen** 1996 Jul 10;93(28–29):2564 **(Swe)**

[Vaccination against whooping cough is beneficial for health economics. Results of a model analysis] Norlund A, et al. **Lakartidningen** 1996 Mar 27;93(13):1252–6 **(Swe)**

ADVERSE EFFECTS

Nothing to whoop about [comment] Brown GW. **Arch Pediatr Adolesc Med** 1996 May;150(5):461–3; discussion 464–5. Comment on: Arch Pediatr Adolesc Med 1996 May;150(5):457–60.

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment [see comments] Rosenthal S, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):457–60. Comment in: Arch Pediatr Adolesc Med 1996 May;150(5):461–3.

Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children. Meszaros JR, et al. **J Clin Epidemiol** 1996 Jun;49(6):697–703

Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. Roberts JD, et al. **J Clin Epidemiol** 1996 Jan;49(1):51–8

Lack of association between pertussis vaccination and symptoms of asthma and allergy [letter] Nilsson L, et al. **JAMA** 1996 Mar 13;275(10):760

The safety of pertussis vaccine [letter; comment] Thomson KD. **N Z Med J** 1996 Mar 8;109(1017):84. Comment on: N Z Med J 1995 Dec 8;108(1013):495–7.

The relationship between pertussis vaccine and central nervous system sequelae: continuing assessment. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Feb;97(2):279–81

ANALYSIS

Developments in pertussis vaccines leading to reduction and replacement of in vivo testing. Redhead K. **Dev Biol Stand** 1996;86:263–70

Pertussis serological potency test as an alternatively to the intracerebral mouse protection test. van der Ark A, et al. **Dev Biol Stand** 1996;86:271–81

CHEMICAL SYNTHESIS

Development of the new acellular recombinant pertussis vaccine. Rappuoli R, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):557–63

IMMUNOLOGY

Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Kimura M, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):562–74

Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Grimprel E, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):93–7

The effect of an accelerated immunisation schedule on pertussis in England and Wales. White JM, et al. **Commun Dis Rep CDR Rev** 1996 May 24;6(6):R86–91

Components of acellular pertussis vaccines [letter; comment] Bonati M, et al. **Lancet** 1996 Mar 16;347(9003):764–5. Comment on: Lancet 1996 Jan 27;347(8996):209–10.

Acellular pertussis vaccines: new vaccines for an old disease [see comments] Poland GA. **Lancet** 1996 Jan 27; 347(8996):209–10. Comment in: Lancet 1996 Mar 16;347(9003):764. Comment in: Lancet 1996 Mar 16;347(9003):764–5.

Components of acellular pertussis vaccines [letter; comment] Preston NW, et al. **Lancet** 1996 Mar 16;347(9003):764. Comment on: Lancet 1996 Jan 27;347(8996):209–10.

Pertussis: the new acellular vaccines. Grimprel E, et al. **Pediatr Pulmonol Suppl** 1995;11:84–5

Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Cropley I, et al. **Vaccine** 1995 Dec;13(17):1643–8

[Efficacy of acellular pertussis vaccines] Wirsing von König CH, et al. **Immun Infekt** 1995 Aug;23(4):125–9 (15 ref.) (Eng. Abstr.) **(Ger)**

[Vaccinal coverage for measles and pertussis: a study in 7 regions of Italy] Viviani S, et al. **Ann Ig** 1995 Jul–Aug; 7(4):243–50 (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man. Cayol M, et al. **Clin Sci (Colch)** 1995 Oct;89(4):389–96

Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Rappuoli R. **Infect Agents Dis** 1996 Jan;5(1):21–8 (51 ref.)

Validation of nested Bordetella PCR in pertussis vaccine trial. Reizenstein E, et al. **J Clin Microbiol** 1996 Apr;34(4):810–5

Inhaled Bordetella pertussis vaccine decreases airway responsiveness in guinea pigs. Vargas MH, et al. **Life Sci** 1995;57(19):PL293–9

STANDARDS

Developments in pertussis vaccines leading to reduction and replacement of in vivo testing. Redhead K. **Dev Biol Stand** 1996;86:263–70

[Compare pertussis vaccines—but do it accurately] Olin P, et al. **Lakartidningen** 1996 Feb 14;93(7):603–4 **(Swe)**

[A debate on pertussis vaccines. The monocomponent vaccine has many advantages] Taranger J, et al. **Lakartidningen** 1996 Feb 14;93(7):601–3 **(Swe)**

THERAPEUTIC USE

Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome. Li Volti S, et al. **Childs Nerv Syst** 1996 Feb;12(2):100–2

Acellular pertussis vaccines for infants [editorial; comment] [see comments] Edwards KM, et al. **N Engl J Med** 1996 Feb 8;334(6):391–2. Comment on: N Engl J Med 1996 Feb 8;334(6):341–8. Comment on: N Engl J Med 1996 Feb 8;334(6):349–55. Comment in: N Engl J Med 1996 Jun 6;334(23):1547; discussion 1547–8. Comment in: N Engl J Med 1996 Jun 6;334(23):1547–8.

A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group [see comments] Greco D, et al. **N Engl J Med** 1996 Feb 8;334(6):341–8. Comment in: N Engl J Med 1996 Feb 8;334(6):391–2.

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine [see comments] [published erratum appears in N Engl J Med 1996 May 2;334(18):1207] Gustafsson L, et al. **N Engl J Med** 1996 Feb 8;334(6):349–55. Comment in: N Engl J Med 1996 Feb 8;334(6):391–2.

Acellular pertussis vaccines [letter; comment] Poltera AA. **N Engl J Med** 1996 Jun 6;334(23):1547; discussion 1547–8. Comment on: N Engl J Med 1996 Feb 8;334(6):391–2.

Acellular pertussis vaccines [letter; comment] Tamburlini G, et al. **N Engl J Med** 1996 Jun 6;334(23):1547–8. Comment on: N Engl J Med 1996 Feb 8;334(6):391–2.

Control of pertussis [letter] Lennon D, et al. **N Z Med J** 1996 Jul 26;109(1026):283–4

Clinical course of pertussis in immunized children. Bortolussi R, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):870–4

New developments with pertussis vaccines. Halsey NA, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):970–1

[The effect on Coxsackie B3 viral infection of these different immunomodifiers: pertussis corpuscular vaccine, purified staphylococcal anatoxin and their combination] Semenova IB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):54–5 **(Rus)**

TOXICITY

Interaction between Bordetella pertussis vaccine and chlorpromazine in mouse experiments. Antmann K, et al. **Acta Microbiol Immunol Hung** 1995;42(4):395–401

Is the mouse weight gain test outdated as a model for the assessment of pertussis toxicity? Straaten-van der Kappelle IV, et al. **Dev Biol Stand** 1996;86:344

[Interaction between Bordetella pertussis vaccine and chlorpromazine in mice] Antmann K, et al. **Acta Pharm Hung** 1995 Sep;65(5):163–6 (Eng. Abstr.) **(Hun)**

PERVASIVE CHILD DEVELOPMENT DISORDERS see **CHILD DEVELOPMENT DISORDERS, PERVASIVE**

PERYLENE

ANALOGS & DERIVATIVES

N,N'-bis[3,3'-(dimethylamino)propylamine]-3,4,9, 10-perylenetetracarboxylic diimide, a dicationic perylene dye for rapid precipitation and quantitation of trace amounts of DNA. Liu ZR, et al. **Anal Biochem** 1996 Apr 5;236(1):139–45

Antitumour activity of photosensitized hypericin on A431 cell xenografts. Vandenbogaerde AL, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1619–25

Inhibition of neutrophil superoxide generation by hypericin, an antiretroviral agent. Nishiuchi T, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):335–42

A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Agostinis P, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):613–7

EPR-spin trapping kinetic studies of superoxide radicals produced by photosensitized hypocrellin A. A photodynamic therapeutic agent. Zang LY, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):685–91

Effects of anthralin and hypericin on growth factor signalling and cell proliferation in vitro. Richter A, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2039–45

Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Fehr MJ, et al. **Biochemistry** 1995 Dec 5;34(48):15845–8

St John's wort as an antidepressant [editorial; comment] De Smet PA, et al. **BMJ** 1996 Aug 3;313(7052):241–2. Comment on: BMJ 1996 Aug 3;313(7052):253–8.

St John's wort for depression—an overview and meta-analysis of randomised clinical trials [see comments] Linde K, et al. **BMJ** 1996 Aug 3;313(7052):253–8. Comment in: BMJ 1996 Aug 3;313(7052):241–2.

Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study. Estey EP, et al. **Cancer Chemother Pharmacol** 1996;37(4):343–50

Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Zhang W, et al. **Cancer Lett** 1995 Sep 4;96(1):31–5

Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C. Harris MS, et al. **Curr Eye Res** 1996 Mar; 15(3):255–62

Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Cohen PA, et al. **Experientia** 1996 Feb 15;52(2):181–3

High-performance liquid chromatographic determination of the biologically active principle hypericin in phytotherapeutic vegetable extracts and alcoholic beverages. Micali G, et al. **J Chromatogr A** 1996 Apr 19; 731(1–2):336–9

Hypericin: a new laser phototargeting agent for human cancer cells. VanderWerf QM, et al. **Laryngoscope** 1996 Apr;106(4):479–83

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Hadjur C, et al. **Photochem Photobiol** 1996 Aug;64(2):375–81

Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Miller GG, et al. **Photochem Photobiol** 1995 Jun;61(6):632–8

Subcellular distribution of hypericin in human cancer cells. Miskovsky P, et al. **Photochem Photobiol** 1995 Sep; 62(3):546–9

Hypericin-induced phototoxicity in cultured fibroblasts and swine erythrocytes. Yu H, et al. **Photochem Photobiol** 1996 Jul;64(1):168–73

Production of hypericin, pseudohypericin and flavonoids in cell cultures of various Hypericum species and their chemotypes. Kartnig T, et al. **Planta Med** 1996 Feb; 62(1):51–3

PES CAVUS see **FOOT DEFORMITIES**

PES PLANUS see **FLATFOOT**

PESSARIES

Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. **Magill PJ. Br J Gen Pract** 1995 Nov; 45(400):589–93

Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. **Baker ER, et al. J Assist Reprod Genet** 1995 Mar;12(3):205–9

The release of isoconazole nitrate from different suppository bases: in-vitro dissolution, physicochemical and microbiological studies. Asikoglu M, et al. **J Pharm Pharmacol** 1995 Sep;47(9):713–6

The release of isoconazole nitrate from different suppository bases: in-vivo release of drug labelled with 99mTc in rabbits. Asikoglu M, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):717–20

Vaginal prolapse: management with nonsurgical techniques. Davila GW. **Postgrad Med** 1996 Apr;99(4):171–6, 181, 184–5

STANDARDS

New disposable vaginal device (continence guard) in the treatment of female stress incontinence. Design, efficacy and short term safety. Thyssen H, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):170–3

PESSARIES, INTRACERVICAL see **INTRAUTERINE DEVICES**

PESSARIES, INTRAUTERINE see **INTRAUTERINE DEVICES**

PEST CONTROL

Morphological studies on Phlebotomus papatasi (Scopoli) in Riyadh City, Saudi Arabia. Abou el-Ela RG, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):631–48

Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631–42 (61 ref.)

METHODS

Screwworm eradication program in Central America. Galvin TJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:233–40

In vitro control of Phthirus pubis with four pediculocides: Eurax, Elimite, Licid and Benzanil. Ragheb DA, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):677–81

Farmers call for overhaul of badger control policy [news] **Vet Rec** 1995 Nov 4;137(19):475–6

[Input of DDT into the environment by forest pest control in 1983/84 in Brandenburg—assessment of the contamination level] Abbas B. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):452–7 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Central America Regional Screwworm Eradication Program (benefit/cost study). Wyss JH, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:241–7

STANDARDS

Swedish pesticide risk reduction 1981–1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119–47 (67 ref.)

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71–117 (202 ref.)

PEST CONTROL, BIOLOGICAL

see related

CHEMOSTERILANTS

The potential for malaria control with the biological larvicide Bacillus thuringiensis israelensis (Bti) in Peru and Ecuador. Kroeger A, et al. **Acta Trop** 1995 Sep;60(1):47–57

Aedes aegypti control in the Lao People's Democratic Republic, with reference to copepods. Jennings CD, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):324–30

Cross-resistance of the diamondback moth indicates altered interactions with domain II of Bacillus thuringiensis toxins. Tabashnik BE, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2839–44

Biological control of mosquito larvae by Guppy fish. Elias M, et al. **Bangladesh Med Res Counc Bull** 1995 Aug; 21(2):81–6

Bacillus thuringiensis crystal proteins CRY1Ab and CRY1Fa share a high affinity binding site in Plutella xylostella (L.). Granero F, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):779–83

Substitution of residues on the proximal side of Cry1A Bacillus thuringiensis delta-endotoxins affects irreversible binding to Manduca sexta midgut membrane. Hussain SR, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):8–14

Effect of two commercial formulations of Bacillus thuringiensis subsp. kurstaki (Dipel 8L and Dipel 8AF) on the Collembolan species Folsomia candida in a soil microcosm study. Addison JA, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):771–8

Influence of disease-suppressive strains of Streptomyces on the native Streptomyces community in soil as determined by the analysis of cellular fatty acids. Bowers JH, et al. **Can J Microbiol** 1996 Jan;42(1):27–37

Extraction and characterization of the insecticidal toxin hirsutellin A produced by Hirsutella thompsonii var. thompsonii. Liu WZ, et al. **Exp Mycol** 1995 Dec; 19(4):254–62

Biocontrol from a mosquito control director's point of view. Beidler EJ. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):258–9 (6 ref.)

The future of microbial insecticides as vector control agents. Federici BA. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):260–8 (32 ref.)

Effect of tadpole shrimp, Triops longicaudatus, (Notostraca: Triopsidae), on the efficacy of the microbial control agent Bacillus thuringiensis var. israelensis in experimental microcosms. Fry-O'Brien LL, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):33–8

Control of tsetse flies (Diptera: Glossinidae) with the aid of attractants. Jordan AM. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):249–55 (52 ref.)

The future of insect growth regulators in vector control. Mulla MS. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):269–73 (32 ref.)

Regulatory factors affecting larval mosquito populations in container and pool habitats: implications for biological control. Washburn JO. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):279–83 (13 ref.)

Keeping screwworms at bay [news] Kahler SC. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1003–4

The safety of Bacillus species as insect vector control agents. Drobniewski FA. **J Appl Bacteriol** 1994 Feb;76(2):101–9 (80 ref.)

Irreversible binding kinetics of Bacillus thuringiensis CryIA delta-endotoxins to gypsy moth brush border membrane vesicles is directly correlated to toxicity. Liang Y, et al. **J Biol Chem** 1995 Oct 20;270(42):24719–24

Isolation and curing of plasmid DNA from Bacillus thuringiensis israelensis strains showing variable insecticidal activities. Rady MH, et al. **J Egypt Soc Parasitol** 1996 Aug; 26(2):423–32

The susceptibility of different species of sciarid flies to entomopathogenic nematodes. Gouge DH, et al. **J Helminthol** 1995 Dec;69(4):313–8

Biocontrol potential of the entomogenous fungi Beauveria bassiana and Metarhizium anisopliae for tsetse flies (Glossina spp.) at developmental sites. Kaaya GP, et al. **J Invertebr Pathol** 1995 Nov;66(3):237–41

Release of Romanomermis iyengari (Nematoda:Mermithidae) to control Aedes taeniorhynchus (Diptera:Culicidae) in Punta del Este, Isla de la Juventud, Cuba. Santamarina Mijares A, et al. **J Med Entomol** 1996 Jul;33(4):680–2

Control of mosquito larvae by encapsulated pathogen Bacillus thuringiensis var. israelensis. Elçin YM. **J Microencapsul** 1995 Sep–Oct;12(5):515–23

Sarcocystis singaporensis: studies on host specificity, pathogenicity, and potential use as a biocontrol agent of wild rats. Jakel T, et al. **J Parasitol** 1996 Apr;82(2):280–7

Effects of the spore-endotoxin complex of a strain of Bacillus thuringiensis serovar morrisoni upon Triatoma vitticeps (Hemiptera: Reduviidae) under laboratory conditions. Lima MM, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep; 89(3):403–5

Vectors control importance on leishmaniasis transmission. Oliveira Filho AM, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):451–6

Rabbit virus threatens ecology after leaping the fence [news] Lawson M. **Nature** 1995 Dec 7;378(6557):531

Fate of biological control introductions: monitoring an Australian fungal pathogen of grasshoppers in North America. Bidochka MJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):918–21

Vip3A, a novel Bacillus thuringiensis vegetative insecticidal protein with a wide spectrum of activities against lepidopteran insects. Estruch JJ, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5389–94

Construction of an improved mycoinsecticide overexpressing a toxic protease. St Leger R, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6349–54

A harebrained scheme. Experimental rabbit-killing virus runs amok in Australia [news] Seife C. **Sci Am** 1996 Feb; 274(2):24, 26

Australia fends off critic of plan to eradicate rabbits [news] [see comments] Drollette D. **Science** 1996 Apr 12; 272(5259):191–2. Comment in: Science 1996 Jul 5;273(5271):16–7. Comment in: Science 1996 Jul 5;273(5271):17–8.

Release of RHD virus in Australia [letter; comment] Matson DO. **Science** 1996 Jul 5;273(5271):16–7. Comment on: Science 1996 Apr 12;272(5259):191–2.

Release of RHD virus in Australia [letter; comment] Smith AW. **Science** 1996 Jul 5;273(5271):17–8. Comment on: Science 1996 Apr 12;272(5259):191–2.

Baculovirus bounty. Volkman LE. **Science** 1995 Sep 29; 269(5232):1834 (12 ref.)

Effect of inorganic salts, soaps and detergents on dissolution and larvicidal activity of alginate formulation of Bacillus sphaericus. Vijayan V, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):183–7

Positive cooperativity among insecticidal scorpion neurotoxins. Herrmann R, et al. **Toxicon** 1995 Aug; 33(8):1099–102

Predacious activity of the nematode-trapping fungus Duddingtonia flagrans against cyathostome larvae in faeces after passage through the gastrointestinal tract of horses. Larsen M, et al. **Vet Parasitol** 1995 Dec;60(3–4):315–20

Biological control of trichostrongyles in calves by the fungus Duddingtonia flagrans fed to animals under natural grazing conditions. Larsen M, et al. **Vet Parasitol** 1995 Dec; 60(3–4):321–30

[Observation on the development of Coelomomyces indica in Culex tritaeniorhynchus larvae] Wang Z, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):104–6 (Eng. Abstr.) **(Chi)**

[Isolation and identification of a pathogen of grasshoppers] Liu S, et al. **Wei Sheng Wu Hsueh Pao** 1995 Apr;35(2):86–90 (Eng. Abstr.) **(Chi)**

[Characters and insecticidal polypeptide of a new strain of Bacillus thuringiensis subsp. kenyae in China] Ren G, et al. **Wei Sheng Wu Hsueh Pao** 1995 Aug;35(4):303–8 (Eng. Abstr.) **(Chi)**

METHODS

Optimization of blends of synthetic pheromone components for trapping male limabean pod borers (Etiella zinckenella Tr.) (Lepidoptera: Phycitidae): preliminary evidence on geographical differences. Tóth M, et al. **Bioorg Med Chem** 1996 Mar;4(3):495–7

Biological control program against simuliids in the State of São Paulo, Brazil. Araújo-Coutinho CJ. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):131–3

Bacillus thuringiensis: fermentation process and risk assessment. A short review. Capalbo DM. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):135–8 (27 ref.)

Cloning of a fragment of the gene cryIVB from Bacillus thuringiensis var. israelensis coding for the aminoterminal segment of a 130 kDa larvicidal endotoxin. Saar JH, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):139–40

[Laboratory examination of the effectiveness of new biological preparations for reducing populations of cockroaches (Blattella germanica L.)] Zukowski K. **Rocz Panstw Zaki Hig** 1995;46(3):293–7 (Eng. Abstr.) **(Pol)**

PESTE-DES-PETITS-RUMINANTS VIRUS

GENETICS

The nucleotide sequence of the fusion protein gene of the peste des petits ruminants virus: the long untranslated region in the 5'-end of the F-protein gene of morbilliviruses seems to be specific to each virus. Meyer G, et al. **Virus Res** 1995 Jun;37(1):23–35

PESTICIDE RESIDUES

Pesticides in baby food: a European issue. von Mühlendahl KE, et al. **Eur J Pediatr** 1996 May;155(5):417–8

Rapid decomposition of permethrin in the outer fly of an experimental tent in Pakistan. Bouma MJ, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):125–9

Residual activity of three slow-release temephos formulations against Aedes aegypti larvae. Cilek JE, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):358–9

Deposition of malathion and permethrin on sod grass after single, ultra-low volume applications in a suburban neighborhood in Michigan. Knepper RG, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):45–51

Airborne insecticide residues after broadcast application for cat flea (Siphonaptera: Pulicidae) control. Koehler PG, et al. **J Econ Entomol** 1995 Dec;88(6):1684–9

["Clean fruit and health": results of a consumer health protection program concerning risks of pesticide residues in apples] Villa L, et al. **Ann Ig** 1995 Nov–Dec;7(6):459–73 (Eng. Abstr.) **(Ita)**

[The residual effect of temephos on Aedes aegypti larvae] Macoris M de L, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):375–7 (Eng. Abstr.) **(Por)**

[Ecology or convention? No big differences between the different means in agriculture] **Lakartidningen** 1996 Feb 21;93(8):699 **(Swe)**

ADVERSE EFFECTS

Symptoms in forestry workers handling conifer plants treated with permethrin. Kolmodin-Hedman B, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):487–93

Pesticide residues in food. **Food Chem Toxicol** 1996 Mar; 34(3):317–8

[Statistical description of health complaints after pyrethroid exposure—a comparison of exposed groups] Weigelt E, et al. **Gesundheitswesen** 1995 Dec;57(12):792–7 (Eng. Abstr.) **(Ger)**

ANALYSIS

Pesticide analysis in food by MS. Cairns T, et al. **Anal Chem** 1995 Sep 1;67(17):552A–557A

Tandem mass spectrometry of herbicide residues in lipid-rich tissue. Headley JV, et al. **Anal Chem** 1995 Dec 1; 67(23):4349–53

Determination of carbosulfan in oranges by high-performance liquid chromatography with post-column fluorescence. Brooks MW, et al. **Analyst** 1995 Oct;120(10):2479–81

Simple and rapid method for simultaneous gas chromatographic determination of bitertanol, metalaxyl, oxadixyl, propiconazole, and triadimefon residues in cucumbers. Lee WO, et al. **Analyst** 1995 Oct;120(10):2475–8

Development and evaluation of a dipstick immunoassay format for the determination of atrazine residues on-site. Wittmann C, et al. **Analyst** 1996 Jun;121(6):863–9

Accumulation levels of organochlorine pesticides in human adipose tissue: a new sample survey in Abruzzo. Giuliani AR, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):539–44

Environmental impact of two molluscicides: niclosamide and metaldehyde in a rice paddy ecosystem. Calumpang SM, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):494–501

Organochlorine pesticide residues in cow's milk in Uganda. Ejobi F, et al. **Bull Environ Contam Toxicol** 1996 Apr; 56(4):551–7

Acaricide residue determination in honey. García MA, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):881–7

Monitoring of organophosphorus insecticides in the Guadalete River (southern Spain). Gómez-Gómez C, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):431–8

Validation of an immunoassay for methomyl in water and dislodgeable residues on grape leaves. Itak JA, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):270–7

DDT and its metabolites in Western gull eggs from southern California and northwestern Baja California. Jimenez-Castro C, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):374–81

Residues of dicloran in clingstone peaches after pre- and postharvest application. Lentza-Rizos C, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):231–9

Mercury contamination of golf courses due to pesticide use. Matthews SL, et al. **Bull Environ Contam Toxicol** 1995 Sep; 55(3):390–7

Analytical methods for the determination of isoproturon and diflufenican residues in runoff and soil. Patty L, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):802–9

Identification of a point source of chlordane contamination from a timber treatment facility. Simpson CD, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):289–95

Organochlorine pesticide residues in human breast milk from tropical areas in Mexico. Waliszewski SM, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):22–8

Dissipation of three s-triazine herbicides, atrazine, simazine, and ametryn, in subtropical soils. Wang YS, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):351–8

Assessment of chlorinated pesticide residues in cigarette tobacco based on supercritical fluid extraction and GC-ECD. Djordjevic MV, et al. **Carcinogenesis** 1995 Nov; 16(11):2627–32

Pesticides in household dust and soil: exposure pathways for children of agricultural families. Simcox NJ, et al. **Environ Health Perspect** 1995 Dec;103(12):1126–34

The effect of commercial processing on incurred residues of DDE in meat products. Ariño A, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):559–66

Reduction in phosalone residue levels during industrial dehydration of apples. Mergnat T, et al. **Food Addit Contam** 1995 Nov–Dec;12(6):759–67

Screening procedure for organochlorine and organophosphorus pesticide residues in milk using matrix solid phase dispersion (MSPD) extraction and gas chromatographic determination. Schenck FJ, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):535–41

Food and Drug Administration Pesticide Program: residue monitoring 1994. **J AOAC Int** 1995 Sep–Oct; 78(5):117A–142A

Passive diffusion through polymeric membranes: a novel

cleanup procedure for analysis of azinphos-methyl and azinphos-ethyl residues in fruits and vegetables. Ahmad N, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1450-4

Determination of thiabendazole residues in white and sweet potatoes by liquid chromatography with fluorescence detection. Arenas RV, et al. **J AOAC Int** 1995 Nov-Dec; 78(6):1455-8

Monitoring of pesticide residues in fresh vegetables, fruits, and other selected food items in Belgium, 1991-1993. Dejonckheere W, et al. **J AOAC Int** 1996 Jan-Feb; 79(1):97-110

Monitoring of pesticide residues in human milk, soil, water, and food samples collected from Kafr El-Zayat Governorate. Dogheim SM, et al. **J AOAC Int** 1996 Jan-Feb;79(1):111-6

Liquid chromatographic determination of simazine, atrazine, and propazine residues in catfish. Holland DC, et al. **J AOAC Int** 1995 Jul-Aug;78(4):1067-71

Analysis of 2,2,2-trifluoroethyl derivatives of carboxylic acid herbicides by gas chromatography with mass-selective and electron capture detection. Lee AS, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1459-64

Atomic emission detection for gas chromatographic analysis of nitrogen-containing herbicides in water. Olson NL, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1464-73

Multiresidue liquid chromatographic method for simultaneous determination of pyrethroid insecticides in fruits and vegetables. Pang GF, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1474-80

Modification of AOAC multiresidue method for determination of synthetic pyrethroid residues in fruits, vegetables, and grains. Part I: Acetonitrile extraction system and optimization of florisil cleanup and gas chromatography. Pang GF, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1481-8

Modification of AOAC multiresidue method for determination of synthetic pyrethroid residues in fruits, vegetables, and grains. Part II: Acetone extraction system. Pang GF, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1489-96

Multiresidue method for determination of organophosphorus insecticide residues in fatty processed foods by gel permeation chromatography. Sannino A, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1502-12

Levels of organochlorine pesticides in Mexican butter. Waliszewski SM, et al. **J AOAC Int** 1996 May-Jun; 79(3):784-6

Determination of imazalil residues in lemons by gas chromatography with nitrogen-phosphorus detection. Yamazaki Y, et al. **J AOAC Int** 1996 May-Jun;79(3):787-90

Determination of the pesticide diflubenzuron in mushrooms by high-performance liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry. Barnes KA, et al. **J Chromatogr A** 1995 Sep 29;712(1):85-93

Determination of imidacloprid in vegetables by high-performance liquid chromatography with diode-array detection. Fernandez-Alba AR, et al. **J Chromatogr A** 1996 Jan 15;721(1):97-105

Determination of organophosphorus pesticides and their transformation products in river waters by automated on-line solid-phase extraction followed by thermospray liquid chromatography-mass spectrometry. Lacorte S, et al. **J Chromatogr A** 1995 Sep 29;712(1):103-12

Trace determination of herbicides in estuarine waters by liquid chromatography-high-flow pneumatically assisted electrospray mass spectrometry. Molina C, et al. **J Chromatogr A** 1995 Sep 29;712(1):113-22

Gas chromatographic system equipped with a mass detector and a selective nitrogen-phosphorous detector operating simultaneously in the analysis of pesticide residues. Morello M, et al. **J Chromatogr A** 1996 Aug 2;740(2):263-71

Gel permeation chromatography-high performance liquid chromatography combination as an automated clean-up technique for the multiresidue analysis of fats. Rimkus GG, et al. **J Chromatogr A** 1996 Jun 14;737(1):9-14

Accreditation in the UK for pesticide residue analysis in foods. Thorpe SA, et al. **J Chromatogr A** 1996 Jun 14; 737(1):3-7 (4 ref.)

Matrix solid-phase dispersion extraction procedure for multiresidue pesticide analysis in oranges. Torres CM, et al. **J Chromatogr A** 1996 Jan 5;719(1):95-103

Organochlorine residues in human adipose and hepatic tissues from autopsy sources in northern Italy. Gallelli G, et al. **J Toxicol Environ Health** 1995 Nov;46(3):293-300

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1-44 (85 ref.)

Levels of DDT residues in human milk of Venezuelan women from various rural populations. Brunetto R, et al. **Sci Total Environ** 1996 Jul 30;186(3):203-7

Fenvalerate (alpha-cyano-m-phenoxy-benzyl alpha-isopropyl-p-chlorophenyl acetate) residues in and on okra fruits. Jain RK. **Sci Total Environ** 1996 Sep 9; 187(3):253-5

Solid phase extraction for the confirmation of results in polar pesticides residue analysis by HPTLC. Mouratidis S, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):327-30

[Research on the microbiological and chemical quality of the water from the river Idice with special reference to metals, volatile organic halogens and pesticides] De Luca G, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):881-93 (Eng. Abstr.) **(Ita)**

[The intake of dithiocarbamate fungicides with a total hypercaloric diet prepared in a large Roman hospital (1991-1992)] Rodolico S, et al. **Ann Ig** 1994 Jul-Dec; 6(4-6):771-80 (Eng. Abstr.) **(Ita)**

[Enzyme immunoassay of pesticide residues in foods] Nishijima M. **Nippon Rinsho** 1995 Sep;53(9):2310-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Congener specific analysis of toxaphene in serum using ECNI-MS. Gill US, et al. **Chemosphere** 1996 Sep; 33(6):1021-5

ISOLATION & PURIFICATION

Recovery of trace organic chemicals from a large mass of water using a newly developed liquid-liquid continuous extractor. Umano K, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):558-65

METABOLISM

Absorption, translocation, and accumulation of carbendazim in opium poppy (Papaver somniferum L.). Banerji R, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):283-8

Organochlorine compounds in three species of shellfish from Waikareao Estuary, Tauranga Harbour, New Zealand. Burggraaf S, et al. **Bull Environ Contam Toxicol** 1996 Jul; 57(1):111-7

Organochlorine pesticide residues in mothers' milk in Uganda. Ejobi F, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):873-80

Residues of malathion in stored grains. Gözek K. **Bull Environ Contam Toxicol** 1996 Oct;57(4):544-8

Distribution and dissipation of carbofuran in a paddy field in the Kano plains of Kenya. Lalah JO, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):584-93

Organochlorine residue levels and bioconcentration factors in otters (Lutra lutra L.) from northeast Spain. López-Martín JM, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):532-5

Dissipation of herbicide residues in the soil of a citrus orchard (Citrus sinensis L. Osbeck) after the ninth consecutive annual application. Machado-Neto JG, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):303-8

Runoff losses of surface-applied metribuzin as influenced by yard waste compost amendments, no-tillage, and conventional-tillage. Malone RW, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):536-43

Fungicide procymidone residue in agriculture land. Nagami H. **Bull Environ Contam Toxicol** 1996 Apr;56(4):594-8

Effect of Magnacide(R) H herbicide residuals on water quality within wildlife refuges of the Klamath Basin, CA. Nordone AJ, et al. **Bull Environ Contam Toxicol** 1996 Jun; 56(6):964-70

Dissipation of deltamethrin and fenvalerate residues in green gram (Vigna radiata (L.) Wilczek) under Indian climatic condition. Sukul P. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):562-7

Tetrachlorodibenzo-p-dioxin residue reduction by cooking/processing of fish fillets harvested from the Great Lakes. Zabik ME, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):264-9

Loss of pirimicarb residues from contaminated fabrics. Zhou K, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):29-33

Determination of PCB metabolites in Canadian human milk. Newsome WH, et al. **Chemosphere** 1996 Aug;33(3):559-65

Fate and impact of pesticides applied to potato cultures: the Nicolet River basin. Caux PY, et al. **Ecotoxicol Environ Saf** 1996 Mar;33(2):175-85

Metabolism of 2-chlorobenzoic acid in Pseudomonas stutzeri. Kozlovsky SA, et al. **Folia Microbiol (Praha)** 1995; 40(5):454-6

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71-117 (202 ref.)

Organochlorine residues in marine mammals from the northern hemisphere—a consideration of the composition of organochlorine residues in the blubber of marine mammals. Vetter W, et al. **Sci Total Environ** 1996 Jul 16; 186(1-2):29-39

PHARMACOKINETICS

Organochlorine pesticide accumulation and genotoxicity in Mexican free-tailed bats from Oklahoma and New Mexico. Thies ML, et al. **Arch Environ Contam Toxicol** 1996 Feb; 30(2):178-87

Activation of in vivo metabolism of malathion in male Tilapia nilotica. El-Dib MA, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):667-74

Bioavailability of bound pesticide residues and potential toxicologic consequences - an update. Kacew S, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):62-68 (73 ref.)

POISONING

Swedish pesticide risk reduction 1981-1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119-47 (67 ref.)

STANDARDS

Impact of the Delaney Clause in the EPA. Fenner-Crisp PA. **Exp Toxicol Pathol** 1996 Feb;48(2-3):199-200

TOXICITY

Chronic influence of pyrethroid supermethrin on some reproductive features in Japanese quail (140 days long avian reproduction test). Mlynarčiková H, et al. **Cent Eur J Public Health** 1995 Aug;3(3):132-3

Pesticides—the NAS report: how can the recommendations be implemented? Fenner-Crisp PA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:159-62

International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU—a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995-96; 15(6):313-37 (88 ref.)

[Effect of carbaryl and lead on phenols, chlorophyll and proteins of the microalga Ankistrodesmus falcatus] Martínez-Tabche L, et al. **Rev Latinoam Microbiol** 1995 Apr-Jun;37(2):93-9 (Eng. Abstr.) **(Spa)**

URINE

Determination of combined residues of metalaxyl and 2,6-dimethylaniline metabolites in urine by gas chromatography/mass spectrometry. Headley JV, et al. **J AOAC Int** 1996 Jan-Feb;79(1):117-23

PESTICIDE SYNERGISTS

Efficacy of a 1:1 and 1:5 mixture of technical permethrin and piperonyl butoxide against Anopheles quadrimaculatus and Psorophora columbiae. Groves RL, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):311-4

[Effect of water contamination with surface active substances and plant protecting agents on aquatic organisms] Ranke-Rybicka B, et al. **Rocz Panstw Zakl Hig** 1995; 46(2):175-81 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Biphasic responses in synergistic interactions. Hodgson E, et al. **Toxicology** 1995 Dec 28;105(2-3):211-6

Positive cooperativity among insecticidal scorpion neurotoxins. Herrmann R, et al. **Toxicon** 1995 Aug; 33(8):1099-102

TOXICITY

Developmental toxicity study of piperonyl butoxide in CD rats. Tanaka T, et al. **Toxicol Ind Health** 1995 Mar-Apr; 11(2):175-84

PESTICIDES

Histology of the skin and determination of blood and serum parameters during the recovery phase of sarcoptic manage in cattle after avermectin (Ivomec) treatment. Löwenstein M, et al. **Appl Parasitol** 1996 Jun;37(2):77-86

Assessment of human exposure to pesticides in greenhouses and effectiveness of personal protective devices. Iorizzo L, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):25-33

US pesticide use reaches new record [news] Roberts J. **BMJ** 1996 Jun 15;312(7045):1498-9

Humoral and cellular immunity rates in chemical plant workers employed in the production of liquid pesticides. Kluciński P, et al. **Int J Occup Med Environ Health** 1996; 9(2):103-10

[A new programme on safety evaluation of pesticides—the IPCS Joint Meeting on Pesticides (JMP)] Sekizawa J. **Eisei Shikenjo Hokoku** 1995;(113):84-90 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Reevaluating the evidence on pesticide safety [letter; comment] Bukowski JA, et al. **Am J Public Health** 1995 Nov;85(11):1586-7. Comment on: Am J Public Health 1995 Feb;85(2):249-52.

Developmental neurotoxicology in the neonate—effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81-8 (26 ref.)

US court case starts over eyeless babies [news] Dyer C. **BMJ** 1996 May 18;312(7041):1247

Pesticide appliers with mixed pesticide exposure: G-banded analysis and possible relationship to non-Hodgkin's lymphoma. Garry VF, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):11-6

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63-9 (85 ref.)

Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165-71 (85 ref.)

Pesticides: an important but underused model for the environmental health sciences. Hodgson E, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:97-106 (105 ref.)

Cytogenetic monitoring of occupational exposure to pesticides: characterization of GSTM1, GSTT1, and NAT2 genotypes. Scarpato R, et al. **Environ Mol Mutagen** 1996; 27(4):263-9

Chromosomal aberrations in human lymphocytes from two groups of workers occupationally exposed to pesticides in Syria. Mohammad O, et al. **Environ Res** 1995 Jul;70(1):24-9

Pesticides and birth defects [letter; comment] Czeizel AE. **Epidemiology** 1996 Jan;7(1):111. Comment on: Epidemiology 1995 Jan;6(1):6-7.

PESTICIDES

Soft tissue sarcoma and non-Hodgkin's lymphoma in workers exposed to phenoxy herbicides, chlorophenols, and dioxins: two nested case-control studies. Kogevinas M, et al. **Epidemiology** 1995 Jul;6(4):396–402

The domestic use of pesticides and childhood cancer; thoughts on the importance of the abstracts in environmental publications. von Mühlendahl KE. **Eur J Pediatr** 1995 Dec;154(12):991–2

Increased risk of suicide with exposure to pesticides in an intensive agricultural area. A 12-year retrospective study. Parrón T, et al. **Forensic Sci Int** 1996 May 17;79(1):53–63

Cancer in offspring of parents engaged in agricultural activities in Norway: incidence and risk factors in the farm environment. Kristensen P, et al. **Int J Cancer** 1996 Jan 3;65(1):39–50

An analysis of 190 cases of suspected pesticide illness. Lessenger JE, et al. **J Am Board Fam Pract** 1995 Jul–Aug; 8(4):278–82

Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935–40 (27 ref.)

'Provocative' report issued on use of pesticides [news] Marwick C. **JAMA** 1996 Mar 27;275(12):899–900

Temporary variations in chromosomal aberrations in a group of agricultural workers exposed to pesticides. Carbonell E, et al. **Mutat Res** 1995 Oct;344(3–4):127–34

Cytogenetic monitoring of a group of Italian floriculturists: no evidence of DNA damage related to pesticide exposure. Scarpato R, et al. **Mutat Res** 1996 Feb;367(2):73–82

Prevalence of dermatoses and skin sensitisation associated with use of pesticides in fruit farmers of southern Taiwan. Guo YL, et al. **Occup Environ Med** 1996 Jun;53(6):427–31

Bladder cancer among French farmers: does exposure to pesticides in vineyards play a part? Viel JF, et al. **Occup Environ Med** 1995 Sep;52(9):587–92

A review of the acceptable daily intakes of pesticides assessed by WHO. Lu FC. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):352–64 (9 ref.)

Testicular cancer in pesticide applicators in Swedish agriculture [letter] Dich J, et al. **Scand J Work Environ Health** 1996 Feb;22(1):66

Frequency of sister chromatid exchange and hematological effects in pesticide-exposed greenhouse sprayers. Lander F, et al. **Scand J Work Environ Health** 1995 Aug; 21(4):283–8

The cat, the flea, and pesticides. Logas DB. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):801–11 (60 ref.)

[Activity of PZ-peptidase in blood serum of workers from a pesticide dust production factory] Kossmann S, et al. **Pneumonol Pol** 1990 Sep–Oct;58(9–10):531–4 (Eng. Abstr.) **(Pol)**

[Symptoms related to the use of agricultural pesticides. The perspective from the primary care service] Subías Lorén PJ, et al. **Aten Primaria** 1995 Dec;16(10):615–7 (Eng. Abstr.) **(Spa)**

ANALYSIS

Pesticide analysis in food by MS. Cairns T, et al. **Anal Chem** 1995 Sep 1;67(17):552A–557A

Exposure to pesticides in ambient air. Beard J, et al. **Aust J Public Health** 1995 Aug;19(4):357–62

Exposure to pesticides in ambient air [letter] Beard J, et al. **Aust N Z J Public Health** 1996 Jun;20(3):325–6

Uniform System for the Evaluation of Substances. V. ESPE, risk assessment for pesticides. Linders JB, et al. **Chemosphere** 1995 Sep;31(5):3237–48

Pesticides in baby food [news] **Environ Health Perspect** 1995 Dec;103(12):1082–3

FDA Total Diet Study, July 1986–April 1991, dietary intakes of pesticides, selected elements, and other chemicals. Gunderson EL. **J AOAC Int** 1995 Nov–Dec;78(6):1353–63

Dietary intakes of pesticides, selected elements, and other chemicals: FDA Total Diet Study, June 1984–April 1986. Gunderson EL. **J AOAC Int** 1995 Jul–Aug;78(4):910–21

Immunoassay of pesticides: an update. Kaufman BM, et al. **J AOAC Int** 1995 Jul–Aug;78(4):1079–90 (111 ref.)

U.S. Food and Drug Administration pesticide program: incidence/level monitoring of domestic and imported pears and tomatoes. Roy RR, et al. **J AOAC Int** 1995 Jul–Aug; 78(4):930–40

Pesticide monitoring of drinking water with the help of solid-phase extraction and high-performance liquid chromatography. Junker-Buchheit A, et al. **J Chromatogr A** 1996 Jun 14;737(1):67–74

Determination of polar pesticides in ground water using liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. Spliid NH, et al. **J Chromatogr A** 1996 Jun 7;736(1–2):105–14

Pesticides in ground water in the United States: monitoring, modeling, and risks from the U.S. perspective. Cohen SZ. **J Environ Sci Health B** 1996 May;31(3):345–52

[Evaluation of wood preservative pollutants of indoor air] Liebl B, et al. **Gesundheitswesen** 1995 Aug–Sep; 57(8–9):476–88 (Eng. Abstr.) **(Ger)**

[The determination of toxic compounds with a dinitrophenol structure in biological fluids] Shormanov VK, et al. **Sud Med Ekspert** 1995 Jul–Sep;38(3):33–6 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Recovery of trace organic chemicals from a large mass of water using a newly developed liquid–liquid continuous extractor. Umano K, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):558–65

METABOLISM

Characterization of the expression of the thcB gene, coding for a pesticide-degrading cytochrome P-450 in Rhodococcus strains. Shao ZQ, et al. **Appl Environ Microbiol** 1996 Feb;62(2):403–7

Effect of corn plants and rhizosphere populations on pesticide degradation. Buyanovsky GA, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):689–96

Role of a laccase in the degradation of pentachlorophenol. Ricotta A, et al. **Bull Environ Contam Toxicol** 1996 Oct; 57(4):560–7

Determination of pesticide metabolites in human urine using an isotope dilution technique and tandem mass spectrometry. Hill RH Jr, et al. **J Anal Toxicol** 1995 Sep; 19(5):323–9

Estimating pesticide field half-lives from a backpropagation neural network. Domine D, et al. **SAR QSAR Environ Res** 1993;1(2–3):211–9

Pesticide-metabolizing enzymes. Hodgson E, et al. **Toxicol Lett** 1995 Dec;82–83:73–81 (41 ref.)

PHARMACOLOGY

Pesticidal impact on the protein metabolism of freshwater field crab, Oziotelphusa senex senex (Fabricius). Radhakrishnaiah K, et al. **Biomed Environ Sci** 1995 Jun; 8(2):137–48

Molecular biology and evolution of resistance of toxicants. Taylor M, et al. **Mol Biol Evol** 1996 Jul;13(6):719–34 (141 ref.)

The study of interactive effects of pollutants: a biomarker approach. Johnston G. **Sci Total Environ** 1995 Oct 27; 171(1–3):205–12 (18 ref.)

POISONING

Socio-economic, environmental and health aspects of farm workers engaged in mango plantations. Gupta BN, et al. **Biomed Environ Sci** 1995 Dec;8(4):301–9

Agrochemicals exposure and health implications in Githunguri location, Kenya. Kimani VN, et al. **East Afr Med J** 1995 Aug;72(8):531–5

Pesticides—how research has succeeded and failed to translate science into policy: endocrinological effects on wildlife. Colborn T. **Environ Health Perspect** 1995 Sep;103 Suppl 6:81–5 (55 ref.)

Disorders in metabolism and granulocyte function in acute intoxications with phosphororganic pesticides. Andonova S, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):36

Pesticide incidents reported to the Health and Safety Executive 1989/90- 1991/92. Thompson JP, et al. **Hum Exp Toxicol** 1995 Aug;14(8):630–3

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339–42 (17 ref.)

Lipid peroxidation in acute aluminium phosphide poisoning. Chugh SN, et al. **J Assoc Physicians India** 1995 Apr; 43(4):265–6

Cardiovascular manifestations in aluminium phosphide poisoning with special reference to echocardiographic changes. Gupta MS, et al. **J Assoc Physicians India** 1995 Nov;43(11):773–4, 779–80

Tissue magnesium content and histopathological changes in non-survivors of aluminium phosphide poisoning. Siwach SB, et al. **J Assoc Physicians India** 1995 Oct;43(10):676–8

Suspected triphenyltin poisoning [letter; comment] Cavanagh JB. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):661–2 . Comment on: J Neurol Neurosurg Psychiatry 1990 Apr;53(4):356–7.

Pesticide poisoning in the Asia-Pacific Region and the role of a regional information network. Fernando R. **J Toxicol Clin Toxicol** 1995;33(6):677–82

Pesticides and children. Reigart JR. **Pediatr Ann** 1995 Dec; 24(12):663–8 (18 ref.)

Swedish pesticide risk reduction 1981–1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119–47 (67 ref.)

Recent epidemics of poisoning by pesticides. Ferrer A, et al. **Toxicol Lett** 1995 Dec;82–83:55–63 (24 ref.)

Illegal poisoning [letter] Thompson D. **Vet Rec** 1996 Feb 24;138(8):192

[Toxicity of a flea pesticide (news)] Kamphuis A. **Tijdschr Diergeneeskd** 1995 Nov 15;120(22):647 **(Dut)**

[Ophthalmopathy due to environmental toxic substances especially intoxication by organophosphorus pesticides] Ishikawa S. **Nippon Ganka Gakkai Zasshi** 1996 Jun; 100(6):417–32 (Eng. Abstr.) **(Jpn)**

[Prognostication in chronic pesticide poisoning in agricultural workers: state of lipid metabolism] Dobzhanskii IS, et al. **Med Tr Prom Ekol** 1996;(1):20–2 (Eng. Abstr.) **(Rus)**

[A case of acute peroral poisoning by the preparation Nitrafen] Nikitin PV, et al. **Sud Med Ekspert** 1996 Jan–Mar; 39(1):33–5 (9 ref.) **(Rus)**

STANDARDS

U.S. EPA challenges and review—highlights of the Fiscal Year 1994 Inspection Program and EPA's laboratory accreditation considerations. Dull D. **Qual Assur** 1995 Mar; 4(1):20–8

TOXICITY

Chronic neurologic sequelae to cholinesterase inhibition among agricultural pesticide applicators. Ames RG, et al. **Arch Environ Health** 1995 Nov–Dec;50(6):440–4

The international validation study of the acute toxic class method (oral). Schlede E, et al. **Arch Toxicol** 1995; 69(10):659–70

Effects of agrochemicals on the immune systems of earthworms. Bunn KE, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):632–9

Cytogenetic effects of occupational exposure in the peripheral blood lymphocytes of pesticide sprayers. Kourakis A, et al. **Carcinogenesis** 1996 Jan;17(1):99–101

Pesticides and phytoseiid mites: strategies for risk assessment. Bakker FM, et al. **Ecotoxicol Environ Saf** 1995 Oct; 32(1):58–67

The Agricultural Health Study. Alavanja MC, et al. **Environ Health Perspect** 1996 Apr;104(4):362–9

Pesticide appliers, biocides, and birth defects in rural Minnesota. Garry VF, et al. **Environ Health Perspect** 1996 Apr;104(4):394–9

Delaney still the best protection [letter] Lester SU. **Environ Health Perspect** 1996 Apr;104(4):352

Pesticide-induced immunotoxicity: are Great Lakes residents at risk? Thomas PT. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:55–61 (78 ref.)

Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. Bohnen NI, et al. **J Neurol Sci** 1995 Oct;132(2):110–21 (93 ref.)

Role of decomposition products in sodium methyldithiocarbamate-induced immunotoxicity. Keil DE, et al. **J Toxicol Environ Health** 1996 Apr 5;47(5):479–92

Clinical immunotoxicity of pesticides. Vial T, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):215–29 (59 ref.)

Ameliorating effect of vitamin C on murine sperm toxicity induced by three pesticides (endosulfan, phosphamidon and mancozeb). Khan PK, et al. **Mutagenesis** 1996 Jan; 11(1):33–6

A review of the acceptable daily intakes of pesticides assessed by WHO. Lu FC. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):352–64 (9 ref.)

Lack of carcinogenicity of pesticide mixtures administered in the diet at acceptable daily intake (ADI) dose levels in rats. Ito N, et al. **Toxicol Lett** 1995 Dec;82–83:513–20

Pesticide exposure assessment. Krieger RI. **Toxicol Lett** 1995 Dec;82–83:65–72 (26 ref.)

In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Bagchi D, et al. **Toxicology** 1995 Dec 15;104(1–3):129–40

In vitro and in vivo induction of heat shock (stress) protein (Hsp) gene expression by selected pesticides. Bagchi D, et al. **Toxicology** 1996 Aug 1;112(1):57–68

Regulatory and research issues related to cholinesterase inhibition. Padilla S. **Toxicology** 1995 Sep 1;102(1–2):215–20 (29 ref.)

Experiences with an advanced screening procedure for the identification of chemicals with an immunotoxic potential in routine toxicology. Vohr HW. **Toxicology** 1995 Dec 15; 104(1–3):149–58

Mutagenicity of stable dust and drinking water on swine and cattle farms. Raszyk J, et al. **Vet Med (Praha)** 1995 Sep; 40(9):273–8

[An experimental study of the mechanism of the combined action on the body of ionizing radiation, pesticides, nitrates and lead and cadmium salts] Honcharuk IeH, et al. **Lik Sprava** 1995 May–Jun;(5–6):7–12 (Eng. Abstr.) **(Ukr)**

URINE

Determination of pesticide metabolites in human urine using an isotope dilution technique and tandem mass spectrometry. Hill RH Jr, et al. **J Anal Toxicol** 1995 Sep; 19(5):323–9

PESTIVIRUS

Monitoring vaccines, diagnostic reagents and biotherapeutics for contaminating viruses [editorial] Evermann JF. **Br Vet J** 1996 Mar;152(2):131–4

Ruminant pestiviruses. Nettleton PF, et al. **Br Vet J** 1995 Nov–Dec;151(6):615–42 (130 ref.)

Prevalence of cattle persistently infected with bovine viral diarrhea virus in 20 dairy herds in two counties in central Michigan and comparison of prevalence of antibody-positive cattle among herds with different infection and vaccination status. Houe H, et al. **J Vet Diagn Invest** 1995 Jul;7(3):321–6

CLASSIFICATION

Pestivirus diversity. Paton DJ. **J Comp Pathol** 1995 Apr; 112(3):215–36 (167 ref.)

Six antigenic groups within the genus pestivirus as identified by cross neutralization assays. Dekker A, et al. **Vet Microbiol** 1995 Dec;47(3–4):317–29

A nested polymerase chain reaction assay to differentiate pestiviruses. Sullivan DG, et al. **Virus Res** 1995 Oct; 38(2–3):231–9

GENETICS

Demonstration and genotyping of pestivirus RNA from mammalian cell lines. Harasawa R, et al. **Microbiol Immunol** 1995;39(12):979–85

Partial sequencing of hog cholera virus Alfort strain genome and its comparison with other pestivirus strains. Bakkali Kassimi L, et al. **Vet Res** 1995;26(4):300–9

IMMUNOLOGY

Application of antibody titers against bovine viral diarrhea virus (BVDV) as a measure to detect herds with cattle persistently infected with BVDV. Houe H, et al. **J Vet Diagn Invest** 1995 Jul;7(3):327–32

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563–77 (107 ref.)

ISOLATION & PURIFICATION

Failure to consider the antigenic diversity of porcine reproductive and respiratory syndrome (PRRS) virus isolates may lead to misdiagnosis. Yoon KJ, et al. **J Vet Diagn Invest** 1995 Jul;7(3):386–7

Isolation of bovine viral diarrhea virus–like pestiviruses from roe deer (Capreolus capreolus). Frölich K, et al. **J Wildl Dis** 1995 Apr;31(2):243–6

Demonstration and genotyping of pestivirus RNA from mammalian cell lines. Harasawa R, et al. **Microbiol Immunol** 1995;39(12):979–85

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

Experimentally induced "late–onset" mucosal disease--characterization of the cytopathogenic viruses isolated. Fritzemeier J, et al. **Vet Microbiol** 1995 Sep; 46(1–3):285–94

[Epidemiological characterization of a pestivirus isolate from a viremic pig out of a mixed pig–cattle herd] Frey HR, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May; 102(5):181–3 (Eng. Abstr.) **(Ger)**

[Simple detection of the contamination in animal cell cultures] Harasawa R, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2361–8 (15 ref.) **(Jpn)**

PATHOGENICITY

Effect of cytopathic bovine viral diarrhea virus (BVDV) superinfection on viral antigen association with platelets, viremia, and specific antibody levels in two heifers persistently infected with noncytopathic BVDV. Bezek DM, et al. **J Vet Diagn Invest** 1995 Jul;7(3):395–7

PHYSIOLOGY

Evolutionary relationship of hepatitis C, pesti–, flavi–, plantviruses, and newly discovered GB hepatitis agents. Ohba K, et al. **FEBS Lett** 1996 Jan 15;378(3):232–4

Swine and ruminant pestiviruses requîre the same cellular factor to enter bovine cells. Flores, EF, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1295–303

Enhanced replication of orbiviruses in bovine testicle cells infected with bovine viral diarrhoea virus. Nakamura S, et al. **J Vet Med Sci** 1995 Aug;57(4):677–81

PESTIVIRUS, BOVINE see **DIARRHEA VIRUS, BOVINE VIRAL**

PESTIVIRUS INFECTIONS

VETERINARY

Ruminant pestiviruses. Nettleton PF, et al. **Br Vet J** 1995 Nov–Dec;151(6):615–42 (130 ref.)

Isolation of bovine viral diarrhea virus–like pestiviruses from roe deer (Capreolus capreolus). Frölich K, et al. **J Wildl Dis** 1995 Apr;31(2):243–6

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563–77 (107 ref.)

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

Variation in neuropathogenicity in sheep fetuses transplacentally infected with non–cytopathogenic and cytopathogenic biotypes of bovine–virus diarrhoea virus. Hewicker–Trautwein M, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):557–67

[Epidemiological characterization of a pestivirus isolate from a viremic pig out of a mixed pig–cattle herd] Frey HR, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May; 102(5):181–3 (Eng. Abstr.) **(Ger)**

PET–HUMAN BONDING see **BONDING, HUMAN–PET**

PET SCAN see **TOMOGRAPHY, EMISSION–COMPUTED**

PETECHIAE see **PURPURA**

PETHIDINE see **MEPERIDINE**

PETIT MAL EPILEPSY see **EPILEPSY, ABSENCE**

PETIT MAL STATUS see **STATUS EPILEPTICUS**

PETRIELLIDIUM see **PSEUDALLESCHERIA**

PETROLATUM

Split–thickness skin graft donor site management. A randomized prospective trial comparing a hydrophilic polyurethane absorbent foam dressing with a petrolatum gauze dressing. Weber RS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1145–9

ADMINISTRATION & DOSAGE

Painless ESWL by cutaneous application of vaseline. Heidenreich A, et al. **Scand J Urol Nephrol** 1995 Jun; 29(2):155–60

ADVERSE EFFECTS

Sensitization to white petrolatum used as a vehicle for patch testing. Conti A, et al. **Contact Dermatitis** 1995 Sep; 33(3):201–2

THERAPEUTIC USE

Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. Smack DP, et al. **JAMA** 1996 Sep 25;276(12):972–7

PETROLATUM, LIQUID see **MINERAL OIL**

PETROLEUM

Effect of hydrocarbons and crude oil contamination on the sensitivity of French bean to alfalfa mosaic virus. Jurík M, et al. **Acta Virol** 1995 Dec;39(5–6):275–77

Long–term follow–up mortality study of petroleum refinery and chemical plant employees. Tsai SP, et al. **Am J Ind Med** 1996 Jan;29(1):75–87

Mortality among maintenance employees potentially exposed to asbestos in a refinery and petrochemical plant. Tsai SP, et al. **Am J Ind Med** 1996 Jan;29(1):89–98

Thermodesulforhabdus norvegicus gen. nov., sp. nov., a novel thermophilic sulfate–reducing bacterium from oil field water. Beeder J, et al. **Arch Microbiol** 1995 Nov; 164(5):331–6

Sequential enrichment of microbial populations exhibiting enhanced biodegradation of crude oil. Venkateswaran K, et al. **Can J Microbiol** 1995 Sep;41(9):767–75

Crude oil spill in sea water: an assessment of the risk for bathers correlated to benzo(a)pyrene exposure. Attias L, et al. **Cent Eur J Public Health** 1995 Aug;3(3):142–5

The Brent Spar saga [news] **Environ Health Perspect** 1995 Sep;103(9):786–7

A case–control study of leukemia among petroleum workers. Sathiakumar N, et al. **J Occup Environ Med** 1995 Nov; 37(11):1269–77

A 50–year mortality follow–up of a large cohort of oil refinery workers in Texas. Satin KP, et al. **J Occup Environ Med** 1996 May;38(5):492–506

An evaluation of unleaded petrol as a harm reduction strategy for petrol sniffers in an aboriginal community. Burns CB, et al. **J Toxicol Clin Toxicol** 1996;34(1):27–36

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

Extraction and purification of microbial DNA from petroleum–contaminated soils and detection of low numbers of toluene, octane and pesticide degraders by multiplex polymerase chain reaction and Southern analysis. Knaebel DB, et al. **Mol Ecol** 1995 Oct;4(5):579–91

Microbial densities and physicochemical quality of some crude oil flow stations' saver pit effluents in the Niger Delta areas of Nigeria. Okoh AI, et al. **Sci Total Environ** 1996 Aug 30;187(2):73–8

[Epidemiological studies on risk for adverse pregnancy outcomes in women neighboring a petrochemical works] Chen Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):209–12 (Eng. Abstr.) **(Chi)**

[Hygienic characteristics of the state of the environment and of the health of the population in areas with a developed petrochemical industry] Karamova LM, et al. **Gig Sanit** 1996 Jan–Feb;(1):37–9 **(Rus)**

[Biological effects of chemicals used in oil and gas extraction and purification of water bodies polluted with oil] Galiev MA, et al. **Med Tr Prom Ekol** 1996;(2):14–6 (Eng. Abstr.) **(Rus)**

[Conditions of waste fluid accumulation at petrochemical and oil processing enterprises and prevention of their harm to water bodies] Suleimanov RA. **Med Tr Prom Ekol** 1995; (12):31–6 (Eng. Abstr.) **(Rus)**

[The dynamics of the prevalence of IHD among men working by the field–watch method at an oil– and gas–producing complex in western Siberia] Gafarov VV, et al. **Ter Arkh** 1996;68(1):18–21 (Eng. Abstr.) **(Rus)**

[The working conditions of smokers and their assistants on drilling rigs during geological prospecting operations and the measures for their improvement] Makarenko NA, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):139–40 **(Rus)**

ADVERSE EFFECTS

Effect of the reduction of petrol lead on blood lead levels of the population of Barcelona (Spain). Rodamilans M, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):717–21

Supplemental tests in the evaluation of occupational hand dermatitis in soldiers. Wolf R, et al. **Int J Dermatol** 1996 Mar;35(3):173–6

Veterinarians join bird rescue effort after oil spill [news] Meehan SK. **J Am Vet Med Assoc** 1996 May 1;208(9):1375

No increase in micronuclei frequency in cultured blood lymphocytes from a group of filling station attendants. Pitarque M, et al. **Mutat Res** 1996 Mar 1;367(3):161–7

Parkinsonism secondary to petroleum exposure [letter; comment] McCrank E. **Neurology** 1995 Nov;45(11):2112. Comment on: Neurology 1994 Jun;44(6):1051–4.

Mesothelioma in oil refinery workers [letter; comment] Finkelstein M. **Scand J Work Environ Health** 1996 Feb; 22(1):67. Comment on: Scand J Work Environ Health 1995 Aug;21(4):301–9.

Clinical and clinical laboratory correlates in sea otters dying unexpectedly in rehabilitation centers following the Exxon Valdez oil spill. Rebar AH, et al. **Vet Pathol** 1995 Jul; 32(4):346–50

[Health status of female workers of oil–processing enterprises] Gainullina MK, et al. **Med Tr Prom Ekol** 1995; (12):20–4 (Eng. Abstr.) **(Rus)**

ANALYSIS

Determination of polynuclear aromatic hydrocarbons present in asphaltenes from Mexican oil. A possible environmental risk. Dieck T, et al. **Arch Med Res** 1995 Winter;26(4):445–7

Distribution of oil and grease and petroleum hydrocarbons in the Straits of Johor, peninsular Malaysia. Abdullah AR, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):155–62

MICROBIOLOGY

Thermotoga subterranea sp. nov., a new thermophilic bacterium isolated from a continental oil reservoir. Jeanthon C, et al. **Arch Microbiol** 1995 Aug;164(2):91–7

Microbial degradation of resins fractionated from Arabian light crude oil. Venkateswaran K, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):418–24

POISONING

The impact of the 1993 Braer oil spill on grey seals in Shetland. Hall AJ, et al. **Sci Total Environ** 1996 Jul 16; 186(1–2):119–25

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1–2):109–18 (54 ref.)

Toxicology of oil field pollutants in cattle: a review. Coppock RW, et al. **Vet Hum Toxicol** 1995 Dec;37(6):569–76 (59 ref.)

Milford Haven oil spill [letter] Cooke M. **Vet Rec** 1996 Apr 6;138(14):339–49

[Severe interstitial and mediastinal emphysema caused by petroleum poisoning] Ben Jaballah N, et al. **Cah Anesthesiol** 1995;43(4):377–80 **(Fre)**

TOXICITY

An evaluation of the environmental implications of petroleum refinery emissions by multielemental neutron activation analysis of rumen fluid ash of buffaloes. Garg AN, et al. **Appl Radiat Isot** 1996 May–Jun;47(5–6):581–6

Petroleum and chlorinated hydrocarbons in water from Lake Manzala and associated canals. Badawy MI, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):258–63

Acute toxicity studies with earthworms, Lumbricus terrestris. Ebere AG, et al. **Bull Environ Contam Toxicol** 1995 Nov; 55(5):766–70

Plastic bags for stable storage of the water–soluble fraction of crude petroleum used in aquatic environment toxicity and tainting studies. Heras H, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):597–602

Hazard evaluation of soil contaminants with aquatic animals and plant toxicity tests. Ramanathan A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):956–63

Protein biomarkers of phytotoxicity in hazard evaluation. Ramanathan A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):926–34

Biomarker assessment of the effects of petroleum refinery contamination on channel catfish. Martin LK Jr, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):81–7

Systemic and developmental toxicity of dermally applied distillate aromatic extract in rats. Feuston MH, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):276–84

Developmental toxicity study of clarified slurry oil (CSO) in the rat. Hoberman AM, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):34–40

Studies on the tumor initiation/promotion potential of six middle distillates (MDs) in mouse skin. Jungen H, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):114–20

Evaluation of coal liquids derived from the EDS process in carcinogenesis screening tests. McKee RH, et al. **J Appl Toxicol** 1995 May–Jun;15(3):159–65

Light catalytically cracked naphtha: subchronic toxicity of vapors in rats and mice and developmental toxicity screen in rats. Dalbey WE, et al. **J Toxicol Environ Health** 1996 Jan;47(1):77–91

PETROLEUM

Genetic effects of petroleum fuels: cytogenetic monitoring of gasoline station attendants. Carere A, et al. **Mutat Res** 1995 Nov;332(1-2):17-26

Induction of short-term biomarkers of tumor promotion in skin of CD-1 mice by petroleum middle distillates: preliminary observations. Skisak C, et al. **Prog Clin Biol Res** 1995;391:439-44

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145-55 (77 ref.)

Neutral endopeptidase (NEP) and its role in pathological pulmonary change with inhalation exposure to JP-8 jet fuel. Pfaff JK, et al. **Toxicol Ind Health** 1996 Jan-Feb; 12(1):93-103

[The effect of benzine and formaldehyde on the prenatal development of rats with induced iron trace-element disorder] Senichenkova IN, et al. **Ontogenez** 1996 Mar-Apr;27(2):108-13 (Eng. Abstr.) **(Rus)**

[Characteristics of lipid metabolism in workers of the petrochemical industry] Astakhova ZT. **Vopr Med Khim** 1995 Sep-Oct;41(5):53-6 (Eng. Abstr.) **(Rus)**

PETROLEUM JELLY see **PETROLATUM**

PETROSAL SINUS SAMPLING

Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas. Mamelak AN, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):475-81

Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. Kalogeras KT, et al. **J Clin Invest** 1996 May 1;97(9):2045-50

False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. Yamamoto Y, et al. **J Neurosurg** 1995 Dec;83(6):1087-91

Diagnosis of Cushing's disease in children: the role of inferior petrosal sinus sampling [letter; comment] Calzolari F, et al. **Pediatr Radiol** 1995;25(7):575. Comment on: Pediatr Radiol 1994;24(8):547-9.

[The limitations of catheterization of the inferior petrosal sinus in the differential diagnosis of Cushing's syndrome (letter)] Merino Torres JF, et al. **Rev Clin Esp** 1995 Dec; 195(12):882-3 **(Spa)**

PETROUS BONE

Suppurative petrous apicitis: osteitis or osteomyelitis? an imaging case report. Horn KL, et al. **Am J Otolaryngol** 1996 Jan-Feb;17(1):54-7

Case report: petrous internal carotid artery aneurysm: an unusual cause of eustachian tube dysfunction. Goodman TR, et al. **Clin Radiol** 1996 Sep;51(9):658-60

[Malignant tumors of the petrous bone. Apropos of 25 cases] Depondt J, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(7):309-16 (11 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

The temporal bone [corrected and republished in AJNR Am J Neuroradiol 1996 Jan;17(1):201-4] Swartz JD, et al. **AJNR Am J Neuroradiol** 1995 Nov-Dec;16(10):2081-4

BLOOD SUPPLY

Imaging quiz case 1. Ectopic internal carotid artery (ICA) within the petrous temporal bone. Saada AA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):792, 794 (10 ref.)

EMBRYOLOGY

[Developmental studies on the petrous part of the human temporal bone--special references to the morphogenesis of the facial nerve canal] Kida K. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):205-16 (Eng. Abstr.) **(Jpn)**

INJURIES

[High resolution computerized tomography of the petrous bones in a bone algorithm and 2D reconstruction for evaluation of the facial nerve canal] Marangos N, et al. **HNO** 1995 Dec;43(12):732-6 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Petrous bone extension of middle-ear acquired cholesteatoma. Robert Y, et al. **Acta Radiol** 1996 Mar; 37(2):166-70

Arterial encasement and cranial nerve displacement in a case of cholesterol granuloma of the petrous apex [letter] Hardjasudarma M, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):284-5

A case of acquired petrous cholesteatoma associated with insidious middle ear infection treated by staging the surgical procedures. Gyo K, et al. **Auris Nasus Larynx** 1995; 22(3):192-6

Cholesterol granuloma cyst of the petrous apex. Isaacson JE, et al. **Ear Nose Throat J** 1996 Jul;75(7):425-9

A petrous bone destructive acoustic neurinoma: a tumor of far-lateral origin? Sekiya T, et al. **Eur Arch Otorhinolaryngol** 1995;252(6):379-82

Magnetic resonance imaging of petrous carotid aneurysms. Patrick JT. **J Neuroimaging** 1996 Jul;6(3):177-9

Developmental patterns and characteristic symptoms of petroclival meningiomas. Kawase T, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):1-6

Petrous carotid canal stenosis in malignant osteopetrosis: CT documentation with MR angiographic correlation. Curé JK, et al. **Radiology** 1996 May;199(2):415-21

[Congenital cholesteatoma of the petrous process and mastoid: a report of two cases] Pérez Obón J, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):349-52 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Imaging quiz case 2. Bilateral osteomas of the petrous temporal bones. Hamilton MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):793, 795 (9 ref.)

Radiation dose to the lens from CT of petrous bones [letter; comment] Maclennan AC. **Br J Radiol** 1995 Oct; 68(814):1136. Comment on: Br J Radiol 1995 Jan;68(805):19-22. Comment on: Br J Radiol 1995 Feb;68(806):219.

[High resolution CT of the petrous bone for locating a foreign body in the middle ear] Becker C, et al. **Rontgenpraxis** 1995 Aug;48(8):245-6 **(Ger)**

SURGERY

Chordoma and chondrosarcoma: relationship to the internal carotid artery. Goel A. **Acta Neurochir (Wien)** 1995; 133(1-2):30-5

Middle fossa sub-Gasserian ganglion approach to clivus chordomas. Goel A. **Acta Neurochir (Wien)** 1995; 136(3-4):212-6

Extended middle fossa approach for petroclival lesions. Goel A. **Acta Neurochir (Wien)** 1995;135(1-2):78-83

Excision of petroclival tumors by a total petrosectomy approach. Cass SP, et al. **Am J Otol** 1994 Jul;15(4):474-84

Interconnecting the posterior and middle cranial fossae for tumors that traverse Meckel's cave. Cheung SW, et al. **Am J Otol** 1995 Mar;16(2):200-8

Impact of a restorative dentistry service on the prescription of apical surgery in a district general hospital. Beckett H. **Ann R Coll Surg Engl** 1996 Jul;78(4):369-71

A case of acquired petrous cholesteatoma associated with insidious middle ear infection treated by staging the surgical procedures. Gyo K, et al. **Auris Nasus Larynx** 1995; 22(3):192-6

Tension pneumocephalus: a case following petrousectomy. Robin N, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6; 55(1-2):65-6

En bloc petrosectomy for petroclival lesions [letter] Gormley WB, et al. **J Neurosurg** 1996 Mar;84(3):536

Flexible fiberoptic endoscopy and laser surgery in obliterated cochleas: human temporal bone studies. Kautzky M, et al. **Lasers Surg Med** 1996;18(3):271-7

Giant cholesterol cyst of the petrous bone: a case report. Gökalp HZ, et al. **Neurosurg Rev** 1995;18(3):205-8

Enhanced retrosigmoid exposure with posterior semicircular canal resection. Arriaga M, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):46-8

Transsphenoid endoscopic management of petrous apex cholesterol granuloma. Griffith AJ, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):91-4

[Removal of petrous bone cholesteatoma and obliteration with adipose tissue] Yu Z, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(4):243-5 (Eng. Abstr.) **(Chi)**

[Sub-temporal supra-petrous approach to the horizontal portion of the sub-petrous internal carotid artery. Technique, indications, incidents and accidents] Candon E, et al. **Neurochirurgie** 1996;42(1):6-16 (Eng. Abstr.) **(Fre)**

[Importance of catheterization of inferior petrous sinuses in surgical treatment of Cushing's in children and adolescents] Bonicki W, et al. **Neurol Neurochir Pol** 1995 Sep-Oct; 29(5):729-36 (Eng. Abstr.) **(Pol)**

[The modified transcochlear approach to the petroclival area and the prepontine cistern: indications, techniques and results] Sanna M, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):259-67 (Eng. Abstr.) **(Spa)**

PETROUS PYRAMID see **PETROUS BONE**

PETS see **ANIMALS, DOMESTIC**

PEUTZ-JEGHERS SYNDROME

Polyposis: the Peutz-Jeghers syndrome. Spigelman AD, et al. **Br J Surg** 1995 Oct;82(10):1311-4 (31 ref.)

[Peutz-Jeghers syndrome] Meozzi A, et al. **Pediatr Med Chir** 1995 Sep-Oct;17(5):479-82 (Eng. Abstr.) **(Ita)**

[Hamartomatous polyposis syndrome] Tamura K, et al. **Nippon Rinsho** 1995 Nov;53(11):2728-33 (24 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Q-switched ruby laser treatment of mucocutaneous melanosis associated with Peutz-Jeghers syndrome. Chang CJ, et al. **Ann Plast Surg** 1996 Apr;36(4):394-7

Polyposis: the Peutz-Jeghers syndrome [letter] Parker MC, et al. **Br J Surg** 1996 Jun;83(6):874-5

Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Defago MR, et al. **Endoscopy** 1996 Feb;28(2):267

Adenoma malignum of the uterine cervix associated with Peutz-Jeghers syndrome [letter] Fujiwaki R, et al. **Int J Gynaecol Obstet** 1996 May;53(2):171-2

[Peutz-Jeghers syndrome and adenocarcinoma. Report of a case] Castro RR, et al. **Arq Gastroenterol** 1994 Oct-Dec; 31(4):145-8 (Eng. Abstr.) **(Por)**

[Molecular changes in adenocarcinoma of the small intestine associated with Peutz-Jeghers syndrome] Hidalgo L, et al. **Rev Esp Enferm Dig** 1996 Feb;88(2):137-40 (Eng. Abstr.) **(Spa)**

[Deep cystic enteritis in Peutz-Jeghers syndrome (pseudoinfiltrating lesions in a patient with enteric polyps)] Ortiz J, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):587-9 (Eng. Abstr.) **(Spa)**

GENETICS

A pericentric inversion of chromosome six in a patient with Peutz-Jeghers' syndrome and the use of FISH to localise the breakpoints on a genetic map. Markie D, et al. **Hum Genet** 1996 Aug;98(2):125-8

[Peutz-Jeghers syndrome. Apropos a familial case at Hospital Arzobispo Loayza] Lozano A, et al. **Rev Gastroenterol Peru** 1996 Jan-Apr;16(1):72-6 (19 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

A solitary Peutz-Jeghers-type hamartomatous polyp of the rectum: report of a case and review of the literature. Nakayama H, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):273-6

PEYER'S PATCHES

ABNORMALITIES

Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. Neumann B, et al. **J Exp Med** 1996 Jul 1;184(1):259-64

ANATOMY & HISTOLOGY

Morphological characteristics of the ileal Peyer's patches in the rhesus macaque: a histological and ultrastructural study. Kuhn EM, et al. **Anat Histol Embryol** 1996 Mar;25(1):65-9

Expanding the role of Peyer's patches in B-cell ontogeny. Griebel PJ, et al. **Immunol Today** 1996 Jan;17(1):30-9 (76 ref.)

Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. Kelsall BL, et al. **J Exp Med** 1996 Jan 1; 183(1):237-47

CYTOLOGY

Microdissected domes from gut-associated lymphoid tissues: a model of M cell transepithelial transport in vitro. Kabok Z, et al. **Adv Exp Med Biol** 1995;371A:235-8

A dual origin for IgA plasma cells in the murine small intestine. Kroese FG, et al. **Adv Exp Med Biol** 1995; 371A:435-40

Substance P promotes Peyer's patch and splenic B cell differentiation. Pascual DW, et al. **Adv Exp Med Biol** 1995; 371A:55-9

Effect of corticosteroid on lymphocyte adhesion. Pearson D, et al. **Adv Exp Med Biol** 1995;371A:167-70

Evidence that membranous (M) cell genesis is immuno-regulated. Savidge TC, et al. **Adv Exp Med Biol** 1995;371A:239-41

Three-dimensional (3D-) reconstruction of M cells in rabbit Peyer's patches: definition of the intraepithelial compartment of the follicle-associated epithelium. Regoli M, et al. **Anat Rec** 1995 Sep;243(1):19-26

Lymphocyte traffic through lymph nodes and Peyer's patches of the rat: B- and T-cell-specific migration patterns within the tissue, and their dependence on splenic tissue. Blaschke V, et al. **Cell Tissue Res** 1995 Dec; 282(3):377-86

Distribution of alpha 4 beta 7 and alpha E beta 7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes. Andrew DP, et al. **Eur J Immunol** 1996 Apr;26(4):897-905

Phenotypic and functional characterization of CD11c+ dendritic cell population in mouse Peyer's patches. Ruedl C, et al. **Eur J Immunol** 1996 Aug;26(8):1801-6

Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Smith MW, et al. **Exp Physiol** 1995 Sep;80(5):735-43

Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches. Fujisawa H, et al. **Int J Immunopharmacol** 1995 Jul; 17(7):611-7

M cells in Peyer's patches of the intestine. Gebert A, et al. **Int Rev Cytol** 1996;167:91-159 (310 ref.)

CD28 is required for germinal center formation. Ferguson SE, et al. **J Immunol** 1996 Jun 15;156(12):4576-81

B cells selected for apoptosis in the sheep ileal Peyer's patch have enhanced mutational diversity in the Ig V lambda light chain. Maybaum TA, et al. **J Immunol** 1996 Aug 15;

157(4):1474–84

DRUG EFFECTS

Bombesin affects mucosal immunity and gut-associated lymphoid tissue in intravenously fed mice. Li J, et al. **Arch Surg** 1995 Nov;130(11):1164–9; discussion 1169–70

Oestrogen treatment depletes extrathymic T cells from intestinal lymphoid tissues. Boll G, et al. **Scand J Immunol** 1996 Mar;43(3):345–50

GROWTH & DEVELOPMENT

Postnatal development of lymphoid follicles in rat Peyer's patches, with special reference to increased follicle number. Chen D, et al. **Arch Histol Cytol** 1995 Aug;58(3):335–43

IMMUNOLOGY

Adherence of porcine Peyer's patch, peripheral blood and lymph node lymphocytes to Peyer's patch lamina propria. Kadioglu A, et al. **Adv Exp Med Biol** 1995;371A:81–3

Immune reaction of pigs following intra-gastric or ileal inoculation of attenuated Salmonella typhi. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:913–7

Immunohistochemical study of rat Peyer's patches in peptidoglycan-polysaccharide complex-induced chronic enteritis. Tanaka S, et al. **Adv Exp Med Biol** 1995; 371B:1395–8

Analysis of intraepithelial lymphocytes and Peyer's patch lymphoid tissue in TCR-alpha knockout mice. Viney J, et al. **Adv Exp Med Biol** 1995;371A:117–20

History of oral tolerance and mucosal immunity. Brandtzaeg P. **Ann N Y Acad Sci** 1996 Feb 13;778:1–27

The role of dendritic cells in antigen processing in the Peyer's patch. Kelsall BL, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:47–54

Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064. Yasui H, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):244–6

Reversible effects on B and T cells of the gut-associated lymphoid tissues in rats malnourished during suckling: impaired induction of the immune response to intra-Peyer patches immunization with cholera toxin. Fló J, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):147–54

Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474–8 (46 ref.)

Mucosa-associated (beta 7-integrinhigh) lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behavior. Hänninen A, et al. **Diabetes** 1996 Sep;45(9):1173–80

Phenotypic and functional characterization of CD11c+ dendritic cell population in mouse Peyer's patches. Ruedl C, et al. **Eur J Immunol** 1996 Aug;26(8):1801–6

Intravital demonstration of sequential migration process of lymphocyte subpopulations in rat Peyer's patches. Miura S, et al. **Gastroenterology** 1995 Oct;109(4):1113–23

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53–8 (6 ref.)

Protection against non-typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: role of specific antibody and phagocytes. Wallace FJ, et al. **Immunol Cell Biol** 1995 Jun;73(3):258–65

Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into ISCOMS. Estrada A, et al. **Immunol Invest** 1995 Aug;24(5):819–28

Induction of IgA B cell differentiation of bone marrow-derived B cells by Peyer's patch autoreactive helper T cells. Kihira T, et al. **Immunol Invest** 1995 Aug; 24(5):701–11

Defense mechanisms in Peyer's patches and mesenteric lymph nodes against Yersinia enterocolitica involve integrins and cytokines. Autenrieth IB, et al. **Infect Immun** 1996 Apr; 64(4):1357–68

Role of maternal antibody in the induction of virus specific and bystander IgA responses in Peyer's patches of suckling mice. Kramer DR, et al. **Int Immunol** 1995 Jun;7(6):911–8

alpha 4 integrin plays a critical role in early stages of T lymphocyte migration in Peyer's patches of rats. Tsuzuki Y, et al. **Int Immunol** 1996 Mar;8(3):287–95

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. Neurath MF, et al. **J Exp Med** 1996 Jun 1;183(6):2605–16

Reciprocal regulation of mucosal surface IgA+ B cells by Ig receptor cross-linking and CD40 ligand. Ehrhardt RO, et al. **J Immunol** 1996 Aug 15;157(4):1397–405

Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches. Nakagawa I, et al. **J Infect Dis** 1996 Jun;173(6):1428–36

IFN-alpha-mediated suppression of low-affinity FC(epsilon) receptors on Peyer's patch lymphocytes and augmentation of soluble CD23: implications for IgE responses. Miller H, et al. **J Leukoc Biol** 1996 May;59(5):725–7

Induction of humoral immune response to Salmonella typhimurium in mouse Peyer's patches. Camacho Villarreal NG, et al. **Rev Latinoam Microbiol** 1995 Apr-Jun; 37(2):153–60

Oestrogen treatment depletes extrathymic T cells from intestinal lymphoid tissues. Boll G, et al. **Scand J Immunol** 1996 Mar;43(3):345–50

Experimental mucosal disease in cattle: changes of lymphocyte subpopulations in Peyer's patches and in lymphoid nodules of large intestine. Liebler EM, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):233–48

[Intestinal immunology in digestive parasitoses] Gottstein B, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B85–90 (Fre)

METABOLISM

Selective binding and transcytosis of Ulex europaeus 1 lectin by mouse Peyer's patch M-cells in vivo. Clark MA, et al. **Cell Tissue Res** 1995 Dec;282(3):455–61

Cytosolic distribution of villin in M cells from mouse Peyer's patches correlates with the absence of a brush border. Kerneis S, et al. **Gastroenterology** 1996 Feb;110(2):515–21

Identification of M-cells in the rabbit tonsil by vimentin immunohistochemistry and in vivo protein transport. Gebert A. **Histochem Cell Biol** 1995 Sep;104(3):211–20

MICROBIOLOGY

Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474–8 (46 ref.)

Infection of rabbit Peyer's patches by Shigella flexneri: effect of adhesive or invasive bacterial phenotypes on follicle-associated epithelium. Sansonetti PJ, et al. **Infect Immun** 1996 Jul;64(7):2752–64

Penetration of M cells and destruction of Peyer's patches by Yersinia enterocolitica: an ultrastructural and histological study. Autenrieth IB, et al. **J Med Microbiol** 1996 Apr;44(4):285–94

The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Bäumler AJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):279–83

PARASITOLOGY

Eimeria coecicola Cheissin 1947: endogenous development in gut-associated lymphoid tissue. Pakandl M, et al. **Parasitol Res** 1996;82(4):347–51

PATHOLOGY

Lymphocyte subpopulations in gut-associated lymphoid tissue of cattle with experimental mucosal disease. Liebler EM, et al. **Adv Exp Med Biol** 1995;371B:825–7

Primary gastric lymphomas (MALTomas): a nuclear image analysis comparison with lymph node monocytoid B-cells and marginal zones of spleen and Peyer's patches. Spina D, et al. **Anal Cell Pathol** 1995 Jun;8(4):307–21

Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Powell JJ, et al. **Gut** 1996 Mar;38(3):390–5

PHYSIOLOGY

Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Smith MW, et al. **Exp Physiol** 1995 Sep;80(5):735–43

ULTRASTRUCTURE

Histology of the continuous Peyer's patches in the terminal ileum of pigs in the perinatal period. Halouzka R, et al. **Adv Exp Med Biol** 1995;371A:399–401

A confocal microscopical analysis of Peyer's patch membranous (M) cell and lymphocyte interactions in the scid mouse. Savidge TC, et al. **Adv Exp Med Biol** 1995; 371A:243–5

PEYOTE see **MESCALINE**

PEYRONIE'S DISEASE see **PENILE INDURATION**

PF1 PHAGE see **INOVIRUS**

PF 3 see **PLATELET FACTOR 3**

PF 4 see **PLATELET FACTOR 4**

PFAUNDLER-HURLER SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

PG ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PGA see **PROSTAGLANDINS A**

PGD see **PROSTAGLANDINS D**

PGD2 see **PROSTAGLANDIN D2**

PGE see **PROSTAGLANDINS E**

PGE RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGE SYNTHETIC see **PROSTAGLANDINS E, SYNTHETIC**

PGE1 see **ALPROSTADIL**

PGE2 see **DINOPROSTONE**

PGE2ALPHA see **DINOPROSTONE**

PGE2 RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGF see **PROSTAGLANDINS F**

PGF SYNETHETIC see **PROSTAGLANDINS F, SYNTHETIC**

PGF2 see **DINOPROST**

PGF2ALPHA see **DINOPROST**

PGH see **PROSTAGLANDINS H**

PGH SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PGI2 see **EPOPROSTENOL**

PGX see **EPOPROSTENOL**

PH see **HYDROGEN-ION CONCENTRATION**

PH1 CHROMOSOME see **PHILADELPHIA CHROMOSOME**

PHACOEMULSIFICATION

Prognostic factors in long-term intraocular pressure control following combined phacoemulsification and trabeculectomy. Stewart WC, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):145–50

Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255–7 (10 ref.). Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.

Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al. **Am J Ophthalmol** 1996 Aug;122(2):161–70 (24 ref.). Comment in: Am J Ophthalmol 1996 Aug;122(2):255–7.

Cataract extraction after silicone oil repair of retinal detachments due to necrotizing retinitis. Meldrum ML, et al. **Arch Ophthalmol** 1996 Jul;114(7):885–92

The mechanical properties of the human lens capsule following capsulorhexis or radiofrequency diathermy capsulotomy. Morgan JE, et al. **Arch Ophthalmol** 1996 Sep; 114(9):1110–5

Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. Bömer TG, et al. **Br J Ophthalmol** 1995 Sep;79(9):809–13

Anterior chamber aspirate cultures in small incision cataract surgery [see comments] Manners TD, et al. **Br J Ophthalmol** 1995 Oct;79(10):878–80. Comment in: Br J Ophthalmol 1995 Oct;79(10):873.

Cataract-operation with topical anesthesia and i.v. sedation. Huyghe P, et al. **Bull Soc Belge Ophtalmol** 1994;254:45–7

Topical anaesthesia for phacoemulsification surgery. Duguid IG, et al. **Eye** 1995;9 (Pt 4):456–9

Consultation Section. How would you manage an eye that developed inflammatory response after uncomplicated phacoemulsification with intraocular lens implantation? **J Cataract Refract Surg** 1995 Jul;21(4):366–70

Anterior chamber fluid contamination after uncomplicated phacoemulsification. Assalian A, et al. **J Cataract Refract Surg** 1995 Sep;21(5):539–42

Topical anesthesia in patients with communication deficits [letter] Bernstein RM. **J Cataract Refract Surg** 1995 Sep; 21(5):487–8

Pathology of silicone intraocular lenses in human eyes obtained postmortem. Blotnick CA, et al. **J Cataract Refract Surg** 1995 Jul;21(4):447–52

Calculating intraocular lens power in eyes with keratoconus using videokeratography. Celikkol L, et al. **J Cataract Refract Surg** 1996 May;22(4):497–500

Delivery of topical anesthesia [letter; comment] Claoué C. **J Cataract Refract Surg** 1996 Mar;22(2):155–6. Comment on: J Cataract Refract Surg 1995 Sep;21(5):499–503.

Visual significance of glistenings seen in the AcrySof intraocular lens. Dhaliwal DK, et al. **J Cataract Refract Surg** 1996 May;22(4):452–7

Intraocular pressure response to combined phacoemulsification and trabeculotomy ab externo versus phacoemulsification alone in primary open-angle glaucoma. Gimbel HV, et al. **J Cataract Refract Surg** 1995 Nov;21(6):653–60

Phacoemulsification and silicone foldable intraocular lens implantation in a patient with chronic sarcoid uveitis [letter] Kanellopoulos AJ, et al. **J Cataract Refract Surg** 1995 Jul; 21(4):364–5

Evaluation of intraocular pressure with Healon and Healon GV in sutureless cataract surgery with foldable lens implantation. Kohnen T, et al. **J Cataract Refract Surg** 1996 Mar;22(2):227–37

Phacoemulsification with intraocular lens implantation in high myopia. Lyle WA, et al. **J Cataract Refract Surg** 1996 Mar;22(2):238–42

Topical anesthesia for phacoemulsification: initial 20-case series with one month follow-up. Novak KD, et al.

J Cataract Refract Surg 1995 Nov;21(6):672–5

Batch–by–batch analysis of topographic changes induced by sutured and sutureless clear corneal incisions. Vass C, et al. **J Cataract Refract Surg** 1996 Apr;22(3):324–30

Intraocular lens implantation in severely mentally and physically handicapped patients. Goto S, et al. **Jpn J Ophthalmol** 1995;39(2):187–92

Combined phacoemulsification, endoscopic ciliary process photocoagulation, and intraocular lens implantation in glaucoma management. Uram M. **Ophthalmic Surg** 1995 Jul–Aug;26(4):346–52

Anterior chamber fluid cultures following phacoemulsification and posterior chamber lens implantation. Gimbel HV, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):121–6

Mitomycin C in glaucoma triple procedure [letter] Gelber EC. **Ophthalmology** 1996 Mar;103(3):347–8

Phacoemulsification after retinal detachment surgery. Kerrison JB, et al. **Ophthalmology** 1996 Feb;103(2):216–9

Combined cataract extraction with intraocular lens implant and mitomycin–augmented trabeculectomy. Lederer CM Jr. **Ophthalmology** 1996 Jul;103(7):1025–34

Effects of diclofenac eye drops on corneal epithelial structure and function after small–incision cataract surgery. Shimazaki J, et al. **Ophthalmology** 1996 Jan;103(1):50–7

Preliminary results with a new hydrogel intraocular lens. Stanley JA. **Surv Ophthalmol** 1995 Jul–Aug;40(1):82–3

[A preliminary report of small incision cataract surgery by phacoemulsification] Xie L, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Sep;31(5):330–2 (Eng. Abstr.) **(Chi)**

[Dynamic viscosity and corneal endothelial protection with Healonid, Healon GV, Provisc and Viscoat during phacoemulsification] Bresciani C, et al. **J Fr Ophtalmol** 1996;19(1):39–50 (Eng. Abstr.) **(Fre)**

[Phacoemulsification and topical anesthesia. Apropos of 40 cases] Roman S, et al. **J Fr Ophtalmol** 1996;19(1):32–8 (Eng. Abstr.) **(Fre)**

[Lowering intraocular pressure by phacoemulsification and posterior chamber lens implantation] Jahn CE. **Ophthalmologe** 1995 Aug;92(4):560–3 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Corneal astigmatism after phacoemulsification and lens implantation through unsutured scleral and corneal tunnel incisions. Gross RH, et al. **Am J Ophthalmol** 1996 Jan; 121(1):57–64

Aspergillus endophthalmitis after sutureless cataract surgery. Oxford KW, et al. **Am J Ophthalmol** 1995 Oct;120(4):534–5

Effects of posterior capsular disruption on the outcome of phacoemulsification surgery. Mulhern M, et al. **Br J Ophthalmol** 1995 Dec;79(12):1133–7

A case of Descemet's membrane detachment during phacoemulsification surgery [letter] Mulhern M, et al. **Br J Ophthalmol** 1996 Feb;80(2):185–6

First day follow up for routine phacoemulsification? Whitefield L, et al. **Br J Ophthalmol** 1996 Feb;80(2):148–50

Post–phaco endophthalmitis: on the increase? [letter] Staudenmaier C. **Can J Ophthalmol** 1995 Aug;30(5):274

Astigmatism and visual recovery after phacoemulsification and conventional extracapsular cataract extraction. Naus NC, et al. **Doc Ophthalmol** 1995;90(1):53–9

Intraocular deposition of metallic fragments during phacoemulsification: possible causes and effects. Dunbar CM, et al. **Eye** 1995;9 (Pt 4):434–6

Dislocated nuclear fragments after cataract surgery. Tommila P, et al. **Eye** 1995;9 (Pt 4):437–41

Update: metal fragments shed by Storz PREMIERE phacoemulsification units. **Health Devices** 1995 Jul; 24(7):290

Temperature measurements during phacoemulsification and erbium:YAG laser phacoablation in model systems. Berger JW, et al. **J Cataract Refract Surg** 1996 Apr;22(3):372–8

Astigmatic decay following small incision, self–sealing cataract surgery: one–year follow–up. Feil SH, et al. **J Cataract Refract Surg** 1995 Jul;21(4):433–6

Evaluating surgically induced astigmatism by Fourier analysis of corneal topography data. Olsen T, et al. **J Cataract Refract Surg** 1996 Apr;22(3):318–23

Long–term astigmatic changes after phacoemulsification with single–stitch, horizontal suture closure. Storr–Paulsen A, et al. **J Cataract Refract Surg** 1995 Jul;21(4):429–32

Complications and results of phacoemulsification performed by residents. Tarbet KJ, et al. **J Cataract Refract Surg** 1995 Nov;21(6):661–5

Cracking of acrylic intraocular lenses during capsular bag insertion. Carlson KH, et al. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):572–3

Effects of wound architecture and suture technique on postoperative astigmatism. Gimbel HV, et al. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):524–8

Corneal topographic changes and induced astigmatism resulting from superior and temporal scleral pocket incisions. Kohnen T, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):263–9

Outcomes of dropped nucleus during phacoemulsification. Kapusta MA, et al. **Ophthalmology** 1996 Aug;103(8):1184–7

Endophthalmitis in patients with retained lens fragments after phacoemulsification. Kim JE, et al. **Ophthalmology** 1996 Apr;103(4):575–8

Corneal curvature changes with corneal tunnel phacoemulsification [letter; comment] Leyland MD. **Ophthalmology** 1996 Jun;103(6):867–8. Comment on: Ophthalmology 1996 Feb;103(2):226–32.

A prospective evaluation of corneal curvature changes with 3.0– to 3.5–mm corneal tunnel phacoemulsification [see comments] Long DA, et al. **Ophthalmology** 1996 Feb; 103(2):226–32. Comment in: Ophthalmology 1996 Jun;103(6):867–8.

Enlargement of incision width during phacoemulsification and folded intraocular lens implant surgery. Steinert RF, et al. **Ophthalmology** 1996 Feb;103(2):220–5

INSTRUMENTATION

Update: metal fragments shed by Storz PREMIERE phacoemulsification units. **Health Devices** 1995 Jul; 24(7):290

Lid speculum for surgery without lid block [letter] Anderson CJ. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):4–5

Modified stretch technique for small pupil phacoemulsification with topical anesthesia. Dinsmore SC. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):27–30

Silicone sleeve defects [letter] Hunter LH. **J Cataract Refract Surg** 1996 Mar;22(2):158

[Anterior high–frequency capsulotomy: advantages and problems] Coester C. **Klin Monatsbl Augenheilkd** 1996 May; 208(5):268–9 (Eng. Abstr.) **(Ger)**

METHODS

Learning phaco: self–sealing incision in phaco. Uusitalo R. **Acta Ophthalmol Scand** 1995 Oct;73(5):475

Explantation of a foldable silicone intraocular lens. Batlan SJ, et al. **Am J Ophthalmol** 1996 Aug;122(2):270–2

The 'pupil snap' sign of posterior capsule rupture with hydrodissection in phacoemulsification [letter] Yeoh R. **Br J Ophthalmol** 1996 May;80(5):486

Primary posterior capsulorhexis in phacoemulsification: short term results. Smets RM, et al. **Bull Soc Belge Ophtalmol** 1994;254:25–8

No–stitch phacotrabeculectomy. Arnold PN. **J Cataract Refract Surg** 1996 Mar;22(2):253–60

Long–term endothelial cell loss following phacoemulsification through a temporal clear corneal incision. Dick HB, et al. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):63–71

Intraocular availability and pupillary effect of flurbiprofen and indomethacin during cataract surgery. Gimbel H, et al. **J Cataract Refract Surg** 1996 May;22(4):474–9

Phaco sweep. Gimbel HV, et al. **J Cataract Refract Surg** 1995 Sep;21(5):493–6

Combined endocapsular phacoemulsification, pars plana vitrectomy, and intraocular lens implantation. Hurley C, et al. **J Cataract Refract Surg** 1996 May;22(4):462–6

Corneal sensation after small incision, sutureless, one–handed phacoemulsification. John T. **J Cataract Refract Surg** 1995 Jul;21(4):425–8

First results of cataract surgery and implantation of negative power intraocular lenses in highly myopic eyes. Kohnen S, et al. **J Cataract Refract Surg** 1996 May;22(4):416–20

Comparison of the induced astigmatism after temporal clear corneal tunnel incisions of different sizes. Kohnen T, et al. **J Cataract Refract Surg** 1995 Jul;21(4):417–24

Phacoemulsification in a patient with torticollis [letter; comment] Liu C. **J Cataract Refract Surg** 1995 Jul;21(4):364 . Comment on: J Cataract Refract Surg 1994 May;20(3):353–4. Comment on: J Cataract Refract Surg 1995 Mar;21(2):111.

Combined phacoemulsification, intraocular lens implantation, and trabeculectomy. Mamalis N, et al. **J Cataract Refract Surg** 1996 May;22(4):467–73

Combined phacoemulsification, intraocular lens implantation, and trabeculectomy with a modified scleral tunnel and single–stitch closure. Shingleton BJ, et al. **J Cataract Refract Surg** 1995 Sep;21(5):528–32

Capsulotomy for phacoemulsification in hypermature cataracts. Vajpayee RB, et al. **J Cataract Refract Surg** 1995 Nov;21(6):612–5

Topical versus peribulbar anesthesia in clear corneal cataract surgery. Zehetmayer M, et al. **J Cataract Refract Surg** 1996 May;22(4):480–4

Phacoemulsification: small incision cataract surgery. Craig EA. **Scott Med J** 1995 Jun;40(3):72–3 (16 ref.)

[Small pupil and phacoemulsification] Lemagne JM, et al. **Bull Soc Belge Ophtalmol** 1995;255:147–9 (Eng. Abstr.) **(Fre)**

[Comparative prospective study of effects of Biovisc and Healonid on endothelial cell loss and intraocular pressure in cataract surgery] Colin J, et al. **J Fr Ophtalmol** 1995; 18(5):356–63 (Eng. Abstr.) **(Fre)**

[Phacoemulsification and clear cornea incision: review of 100 initial cases] Lendi B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):273–4 (Eng. Abstr.) **(Fre)**

[Endothelial cell loss after phacoemulsification and 3.5 vs. 5 mm corneal tunnel incision] Dick B, et al. **Ophthalmologe** 1995 Aug;92(4):476–83 (Eng. Abstr.) **(Ger)**

TRENDS

Phaco triples: are we crossing the limit? [editorial] Thomas R. **Indian J Ophthalmol** 1995 Dec;43(4):157–8

PHAGE ATTACHMENT SITES see **ATTACHMENT SITES (MICROBIOLOGY)**

PHAGE FD see **INOVIRUS**

PHAGE G4 see **MICROVIRUS**

PHAGE IKE see **INOVIRUS**

PHAGE LAMBDA see **BACTERIOPHAGE LAMBDA**

PHAGE M13 see **BACTERIOPHAGE M13**

PHAGE MS2 see **LEVIVIRUS**

PHAGE MU see **BACTERIOPHAGE MU**

PHAGE MU 1 see **BACTERIOPHAGE MU**

PHAGE MU 2 see **RNA PHAGES**

PHAGE N4 see **PODOVIRIDAE**

PHAGE P1 see **BACTERIOPHAGE P1**

PHAGE P2 see **BACTERIOPHAGE P2**

PHAGE P22 see **BACTERIOPHAGE P22**

PHAGE PF1 see **INOVIRUS**

PHAGE PHI X 174 see **BACTERIOPHAGE PHI X 174**

PHAGE PHI 6 see **BACTERIOPHAGE PHI 6**

PHAGE PHI 29 see **BACILLUS PHAGES**

PHAGE PHI 105 see **BACILLUS PHAGES**

PHAGE Q BETA see **ALLOLEVIVIRUS**

PHAGE RECEPTORS see **RECEPTORS, VIRUS**

PHAGE T2 see **MYOVIRIDAE**

PHAGE T3 see **BACTERIOPHAGE T3**

PHAGE T4 see **BACTERIOPHAGE T4**

PHAGE T7 see **BACTERIOPHAGE T7**

PHAGE TYPING see **BACTERIOPHAGE TYPING**

PHAGES see **BACTERIOPHAGES**

PHAGES, RNA see **RNA PHAGES**

PHAGES T see **T–PHAGES**

PHAGOCYTE BACTERICIDAL DYSFUNCTION

BLOOD

Application of a fluorochrome–lysostaphin assay to the detection of phagocytic and bactericidal disturbances in human neutrophils and monocytes. Bellinati–Pires R, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec; 5(6):337–42

DIAGNOSIS

Application of a fluorochrome–lysostaphin assay to the detection of phagocytic and bactericidal disturbances in human neutrophils and monocytes. Bellinati–Pires R, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec; 5(6):337–42

ETIOLOGY

Application of a fluorochrome–lysostaphin assay to the detection of phagocytic and bactericidal disturbances in human neutrophils and monocytes. Bellinati–Pires R, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec; 5(6):337–42

PHAGOCYTES

The mononuclear phagocyte–dendritic cell dichotomy: myths, facts, and a revised concept. Goerdt S, et al. **Clin Exp Immunol** 1996 Jul;105(1):1–9 (143 ref.)

CYTOLOGY

Mononuclear cells in salivary glands of normal and isoproterenol–treated rats. Cohen RE, et al. **Arch Oral Biol** 1995 Nov;40(11):1015–21

Effect of phagocytosis of pHEMA particles and of heat–killed Candida albicans on expression of carbohydrate–binding sites such as endogenous lectins in phagocytes. Smetana K Jr, et al. **Biomaterials** 1996 Apr; 17(7):741–4

A life stage of particle–laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph [see comments] Matsuno K, et al. **J Exp Med** 1996 Apr 1;183(4):1865–78 . Comment in: J Exp Med 1996 Apr 1;183(4):1287–92.

DRUG EFFECTS

Mineral fiber-induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236-47 (53 ref.)

In vitro effect of mercuric chloride and sodium selenite on chemiluminescent response of pronephros cells isolated from tilapia, Oreochromis aureus. Low KW, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):909-15

Uptake and intracellular activity of fleroxacin in phagocytic cells. Yamamoto T, et al. **Chemotherapy** 1995 Sep-Oct; 41(5):353-9

Evidence for the involvement of opioid peptides in phagocytosis, conformation, granulation and aggregation of immunocompetent Lumbricus terrestris amoebocytes. Renzelli-Cain R, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):205-11

Innate immune function as a bioindicator of pollution stress in fish. Rice CD, et al. **Ecotoxicol Environ Saf** 1996 Mar; 33(2):186-92

Effects of 3'-hydroxyfarrerol (IdB 1031), a novel flavonoid agent, on phagocyte products. Meloni F, et al. **Inflammation** 1995 Dec;19(6):689-99

Elevated superoxide generation in mononuclear phagocytes by treatment with 1 alpha hydroxyvitamin D3: changes in kinetics and in oxidase cytosolic factor p47. Deutsch A, et al. **J Am Soc Nephrol** 1995 Jul;6(1):102-9

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20-2 (7 ref.)

Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. Brock TG, et al. **J Immunol** 1996 Apr 1; 156(7):2522-7

Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. Roilides E, et al. **J Infect Dis** 1995 Oct;172(4):1028-34

PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Shi J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6014-8

Cadmium ions influence the chemiluminescence activity of murine splenocytes both in vitro and in vivo. Cíž M, et al. **Toxicol Lett** 1996 Jul;86(1):39-45

[Effect of fluoroquinolones on the interaction of phagocytic cells with pathogens, lymphocyte function and immune response] Iordanova AI, et al. **Antibiot Khimioter** 1995 Aug; 40(8):50-6 **(Rus)**

ENZYMOLOGY

Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Ridley AJ. **Curr Biol** 1995 Jul 1;5(7):710-2 (19 ref.)

The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view. Robinson JM, et al. **Histochem Cell Biol** 1995 Mar;103(3):163-80 (197 ref.)

Expression of rat cathepsin S in phagocytic cells. Petanceska S, et al. **J Biol Chem** 1996 Feb 23;271(8):4403-9

Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. Sumimoto H, et al. **J Biol Chem** 1996 Sep 6;271(36):22152-8

Elimination of false negative results in the two-hybrid system in the phagocyte NADPH oxidase. Hong YR, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):301-5

IMMUNOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239-76 (187 ref.)

Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Schlesinger LS. **Curr Top Microbiol Immunol** 1996;215:71-96 (150 ref.)

Protection against non-typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: role of specific antibody and phagocytes. Wallace FJ, et al. **Immunol Cell Biol** 1995 Jun;73(3):258-65

Parasite escape mechanisms: the role of Leishmania lipophosphoglycan on the human phagocyte functions. A review. Panaro MA, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):595-605 (50 ref.)

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **J Hematother** 1995 Oct;4(5):453-6

Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. Yang Y, et al. **J Immunol** 1996 Jun 1;156(11):4224-31

Fc gamma receptors of phagocytes. de Haas M, et al. **J Lab Clin Med** 1995 Oct;126(4):330-41 (128 ref.)

Standardization of a flow cytometric assay for phagocyte respiratory burst activity. Vuorte J, et al. **Scand J Immunol** 1996 Mar;43(3):329-34

Evaluation of the effect of experimental cow endometritis on bactericidal capability of phagocytizing cells isolated from the blood and uterine lumen. Kluciński W, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):461-6

[Increased activity of phagocytes in cigarette smokers--supposed connection with lung emphysema] Zięba M, et al. **Pneumonol Pol** 1990 Nov-Dec; 58(11-12):651-4 (23 ref.) **(Pol)**

[Reaction of pulmonary phagocytes after partial hepatectomy] Pliushch IV, et al. **Biull Eksp Biol Med** 1995 May;119(5):477-9 **(Rus)**

[Activation of phagocytes with anti-ICAM-3 monoclonal antibodies] Zemskov VM, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):447-9 **(Rus)**

[Molecular genetic aspects of invasive and antiphagocytic properties of pathogenic Yersinia] Kukleva LM, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan-Mar;(1):11-6 (95 ref.) **(Rus)**

METABOLISM

Stimulation of nitric oxide production in rat lung lavage cells by anti-Mac-1beta antibody: effects of ozone inhalation. Pendino KJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr; 14(4):327-33

Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes. Goebel C, et al. **Arch Toxicol** 1995;69(7):450-9

Characterization of P2Z purinergic receptors on phagocytic cells of the thymic reticulum in culture. Coutinho-Silva R, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):217-22

A cation non-selective channel induced by extracellular ATP in macrophages and phagocytic cells of the thymic reticulum. Coutinho-Silva R, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):125-30

Progesterone inhibits superoxide radical production by mononuclear phagocytes in pseudopregnant rats. Sugino N, et al. **Endocrinology** 1996 Feb;137(2):749-54

Receptor-induced translocation of activated guanine-nucleotide-binding protein alpha i subunits to the cytoskeleton in myeloid differentiated human leukemia (HL-60) cells. Wieland T, et al. **Eur J Biochem** 1996 Aug 1;239(3):752-8

Direct measurement of oscillatory generation of superoxide anions by single phagocytes. Isogai Y, et al. **FEBS Lett** 1996 Feb 19;380(3):263-6

An SH3 domain-mediated interaction between the phagocyte NADPH oxidase factors p40phox and p47phox. Ito T, et al. **FEBS Lett** 1996 May 6;385(3):229-32

Interleukin 8: cells of origin in inflammatory bowel disease. Grimm MC, et al. **Gut** 1996 Jan;38(1):90-8

The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells. Gibson FC 3rd, et al. **Infect Immun** 1996 Mar;64(3):1065-9

Effects of 3'-hydroxyfarrerol (IdB 1031), a novel flavonoid agent, on phagocyte products. Meloni F, et al. **Inflammation** 1995 Dec;19(6):689-99

Effects of trinitrotoluene (TNT) metabolites on chemiluminescence response of phagocytic cells. Thierfelder W, et al. **Int J Immunopharmacol** 1995 May; 17(5):453-6

Elevated superoxide generation in mononuclear phagocytes by treatment with 1 alpha hydroxyvitamin D3: changes in kinetics and in oxidase cytosolic factor p47. Deutsch A, et al. **J Am Soc Nephrol** 1995 Jul;6(1):102-9

p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. Hazen SL, et al. **J Biol Chem** 1996 Jan 26;271(4):1861-7

Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. Brock TG, et al. **J Immunol** 1996 Apr 1; 156(7):2522-7

Sea urchin genes expressed in activated coelomocytes are identified by expressed sequence tags. Complement homologues and other putative immune response genes suggest immune system homology within the deuterostomes. Smith LC, et al. **J Immunol** 1996 Jan 15; 156(2):593-602

Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. Giulian D, et al. **J Neurosci** 1996 May 15; 16(10):3139-53

Targeting of teniposide to the mononuclear phagocytic system (MPS) by incorporation in liposomes and submicron lipid particles; an autoradiographic study in mice. Liliemark E, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):113-8

Purification of Rac-GDP dissociation inhibitor complex from phagocyte cytosol. Abo A. **Methods Enzymol** 1995; 256:33-41

High levels of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells. Waschek JA, et al. **Regul Pept** 1995 Dec 14;60(2-3):149-57

MICROBIOLOGY

Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Kozel TR, et al. **Infect Immun** 1996 Jun;64(6):2336-8

Association of bacteria with human phagocytes. Rest RF. **Methods Enzymol** 1995;253:12-26 (22 ref.)

[The characteristics of the interaction of Bacillus anthracis with host phagocytes in relation to the plasmid spectrum of the causative agent] Popov SF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):13-6 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. MacLean JA, et al. **Am J Pathol** 1996 Feb;148(2):657-66

Flow-cytometric analysis of oxidative and proteolytical activities in tissue-associated phagocytes from normal and hypertrophic muscles. Löhrke B, et al. **Anal Cell Pathol** 1995 Dec;9(4):281-93

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Elsässer D, et al. **Blood** 1996 May 1;87(9):3803-12

PHYSIOLOGY

Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Anderson R, et al. **Bibl Nutr Dieta** 1995;(52):66-74 (34 ref.)

Recombinant human interleukin-3 enhances the in vitro survival of mononuclear phagocytes from the peripheral blood of very low birth weight premature infants at birth. Omar SA, et al. **Biol Neonate** 1996;69(1):1-11

Fc-receptor function after human splenic autotransplantation. Leemans R, et al. **Br J Surg** 1996 Apr; 83(4):543-6

Phagocytic cells in the rat olfactory epithelium after bulbectomy. Suzuki Y, et al. **Exp Neurol** 1995 Dec; 136(2):225-33

Survival to lipopolysaccharide, cytokine release and phagocyte functions in mice treated with different total parenteral nutrition regimens. Tufano MA, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):493-509

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20-2 (7 ref.)

Mononuclear phagocytes egress from an in vitro model of the vascular wall by migrating across endothelium in the basal to apical direction: role of intercellular adhesion molecule 1 and the CD11/CD18 integrins. Randolph GJ, et al. **J Exp Med** 1996 Feb 1;183(2):451-62

Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. Triggiani M, et al. **J Exp Med** 1995 Nov 1; 182(5):1181-90

Abnormal phagocytic function in children under one year of age. Kearns AM, et al. **J Infect** 1996 Mar;32(2):103-7

Role of mononuclear phagocytes in M tuberculosis pathogenesis. Schlesinger LS. **J Investig Med** 1996 Aug; 44(6):312-23 (161 ref.)

Transcription factor PU.1 mediates induction of c-fms in vascular smooth muscle cells: a mechanism for phenotypic change to phagocytic cells. Inaba T, et al. **Mol Cell Biol** 1996 May;16(5):2264-73

Leishmania donovani lipophosphoglycan (LPG) inhibits respiratory burst and chemotaxis of dog phagocytes. Panaro MA, et al. **New Microbiol** 1996 Apr;19(2):107-12

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97-106 (108 ref.)

[Role of hematopoietic factors in regulation of proliferation and function of phagocytes] Czygier M, et al. **Postepy Hig Med Dosw** 1995;49(4):563-79 (80 ref.) (Eng. Abstr.) **(Pol)**

[Effects of space flight factors on production of oxygen radicals by phagocytes in cosmonauts] Meshkov DO, et al. **Aviakosm Ekolog Med** 1995;29(6):18-21 (Eng. Abstr.) **(Rus)**

[Significance of the functional state of blood phagocytes in the choice of optimal regime of EHF therapy of patients with pulmonary tuberculosis] Novikova LN, et al. **Probl Tuberk** 1995;(6):17-20 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Impairment of phagocytic cell respiratory burst by UVA in the presence of fluoroquinolones: an oxygen-dependent phototoxic damage to cell surface microvilli. Saniabadi AR, et al. **J Photochem Photobiol B** 1996 Apr;33(2):137-42

SECRETION

Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma. Jansen PM, et al. **Blood** 1996 Jun 15;87(12):5144-51

Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes. Sitrin RG, et al. **J Leukoc Biol** 1996 Feb;59(2):302-11

ULTRASTRUCTURE

Human macrophage response to retrieved titanium alloy particles in vitro. Maloney WJ, et al. **Clin Orthop** 1996 Jan;(322):268-78

Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte. Giulian D, et al. **J Neurosci** 1995 Nov;15(11):7712-26

VIROLOGY

[Apoptosis in the African swine fever virus-swine mononuclear phagocyte system] Makarov VV. **Mol Gen Mikrobiol Virusol** 1995 Jul-Sep;(3):38-43 (Eng.

Abstr.) **(Rus)**

PHAGOCYTOSIS

Haemophagocytosis in bone marrow aspirate--a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182–91 (25 ref.)

Tuberculosis-associated haemophagocytic syndrome: a report of two cases and a review of the literature. Undar L, et al. **Acta Haematol** 1996;96(2):73–8 (36 ref.)

Antibody-dependent cellular cytotoxicity, ingestion and digestion in Dermatophagoides pteronyssinus-sensitive asthmatic children. Barić I, et al. **Acta Med Croatica** 1995; 49(4–5):177–80

Flow-cytometric studies of the phagocytic capacities of equine neutrophils. Johannisson A, et al. **Acta Vet Scand** 1995;36(4):553–62

Opsono-phagocytosis of non-encapsulated Haemophilus influenzae. Vogel L, et al. **Adv Exp Med Biol** 1995; 371A:695–8

Elevated serum ferritin levels: associated diseases and clinical significance [letter; comment] Koduri PR, et al. **Am J Med** 1996 Jul;101(1):121–2; discussion 122. Comment on: Am J Med 1995 Jun;98(6):566–71.

Inhibition of neutrophil oxidative burst and phagocytosis by meconium. Clark P, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1301–5

Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. MacLean JA, et al. **Am J Pathol** 1996 Feb;148(2):657–66

Microglia digest Staphylococcus aureus into low molecular weight biologically active compounds. Fincher EF 4th, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R149–56

Splenic preservation based on preserved histology and phagocytic function using upper short gastric vessels [letter] Petroianu A, et al. **Am J Surg** 1995 Dec;170(6):702

Intramammary defense against infections induced by Escherichia coli in cows. Paape MJ, et al. **Am J Vet Res** 1996 Apr;57(4):477–82

Morphological study of thymus stromal cells (TEL-2 cell) which play a role in the elimination of double positive immature thymocytes by phagocytosis. Kawabuchi M, et al. **Anat Rec** 1996 Mar;244(3):271–83

Evaluation of a method for measurement of intracellular killing of Staphylococcus aureus in human neutrophil granulocytes. Nielsen SL, et al. **APMIS** 1995 Jun; 103(6):460–8

Phagocytosis by rat liver: relationships between phagosomes and lysosomes. Wattiaux R, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):569–74

The functional role of the gamma-chain cysteine in Fc gamma RI-mediated phagocytosis using co-transfected COS-7 cells. Hutchinson MJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):114S

Degradation of chylomicron remnants by macrophages occurs via phagocytosis. Mamo JC, et al. **Biochemistry** 1996 Aug 6;35(31):10210–4

Phagocytosis-promoting factor in human colostrum. Straussberg R, et al. **Biol Neonate** 1995;68(1):15–8

Decrease in surface charge density of Klebsiella pneumoniae treated with cefodizime and enhancement of the phagocytic function of human polymorphonuclear leucocytes stimulated by the drug-treated bacteria. Muratsugu M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1259–63

Effect of phagocytosis of pHEMA particles and of heat-killed Candida albicans on expression of carbohydrate-binding sites such as endogenous lectins in phagocytes. Smetana K Jr, et al. **Biomaterials** 1996 Apr; 17(7):741–4

Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Maródi L, et al. **Blood** 1995 Dec 15;86(12):4645–9

A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Pascual E, et al. **Br J Rheumatol** 1995 Aug; 34(8):724–6

Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Hamel W, et al. **Cancer Res** 1996 Jun 15;56(12):2697–702

Changes in superoxide anion production and phagocytosis by circulating neutrophils during tumor progression in a rat model. Szucs S, et al. **Cell Immunol** 1996 Jun 15; 170(2):202–11

Antibody dependent cell mediated cytotoxicity and erythrophagocytosis assays in Rh haemolytic disease of the newborn. Patil JS, et al. **Ceylon Med J** 1996 Jun;41(2):46–50

Mechanism of enhancement of bactericidal activity of phagocytes against Klebsiella pneumoniae treated with subminimal inhibitory concentrations of cefodizime. Nomura S, et al. **Chemotherapy** 1995 Jul–Aug;41(4):267–75

Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Bennett MR, et al. **Circ Res** 1995 Dec; 77(6):1136–42

Pulmonary intravascular phagocytosis in liver disease. Chang SW, et al. **Clin Chest Med** 1996 Mar;17(1):137–50 (62 ref.)

Effects of extracellular matrix and Bruch's membrane on retinal outer segment phagocytosis by cultured human retinal pigment epithelium. Miceli MV, et al. **Curr Eye Res** 1996 Jan;15(1):17–26

Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Schlesinger LS. **Curr Top Microbiol Immunol** 1996;215:71–96 (150 ref.)

Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Roilides E, et al. **Cytokine** 1996 Jan;8(1):42–8

Increased phagocytic capacity of the blood, but decreased phagocytic activity per individual circulating neutrophil after an ultradistance run. Gabriel H, et al. **Eur J Appl Physiol** 1995;71(2–3):281–4

Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. de Chastellier C, et al. **Eur J Cell Biol** 1995 Oct;68(2):167–82

Bcl-2 delays macrophage engulfment of human B cells induced to undergo apoptosis. Flora PK, et al. **Eur J Immunol** 1996 Sep;26(9):2243–7

Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Burger JA, et al. **Eur J Surg** 1995 Sep;161(9):647–53

Direct measurement of oscillatory generation of superoxide anions by single phagocytes. Isogai Y, et al. **FEBS Lett** 1996 Feb 19;380(3):263–6

Mechanisms of opsonized HIV entry in normal B lymphocytes. Legendre C, et al. **FEBS Lett** 1996 Mar 4; 381(3):227–32

Effect of iC3b binding to immune complexes upon the phagocytic response of human neutrophils: synergistic functions between Fc gamma R and CR3. Ohkuro M, et al. **FEBS Lett** 1995 Oct 16;373(3):189–92

The cell biology of phagocytes. Edwards SW, et al. **Immunol Today** 1995 Nov;16(11):508–10

Nigella sativa: effect on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. Haq A, et al. **Immunopharmacology** 1995 Aug;30(2):147–55

Interaction of Legionella pneumophila with Acanthamoeba castellanii: uptake by coiling phagocytosis and inhibition of phagosome-lysosome fusion. Bozue JA, et al. **Infect Immun** 1996 Feb;64(2):668–73

Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Kozel TR, et al. **Infect Immun** 1996 Jun;64(6):2336–8

Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Mahenthiralingam E, et al. **Infect Immun** 1995 Nov;63(11):4519–23

Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing. Takahashi S, et al. **Infect Immun** 1995 Dec;63(12):4764–9

Ingestion of Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli by human peritoneal mesothelial cells. Visser CE, et al. **Infect Immun** 1996 Aug; 64(8):3425–8

Role of the capsular polysaccharide-like serotype-specific antigen in resistance of Actinobacillus actinomycetemcomitans to phagocytosis by human polymorphonuclear leukocytes. Yamaguchi N, et al. **Infect Immun** 1995 Dec;63(12):4589–94

Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Pericle F, et al. **Int J Cancer** 1996 May 3;66(3):367–73

Quantification of Staphylococcus aureus and Escherichia coli in the liquid medium by fluorimetry and its use in phagocytosis assay. Fang W. **J Appl Bacteriol** 1996 Jun; 80(6):577–82

The role of tyrosine phosphorylation and Ca2+ accumulation in Fc gamma-receptor-mediated phagocytosis of human neutrophils. Kobayashi K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1156–61

Stimulation of phagocytosis and phagosome-lysosome fusion by glycosphingolipids from Sphingomonas paucimobilis. Miyazaki Y, et al. **J Biochem (Tokyo)** 1995 Aug; 118(2):271–7

FcgammaRII-mediated adhesion and phagocytosis induce L-plastin phosphorylation in human neutrophils. Jones SL, et al. **J Biol Chem** 1996 Jun 14;271(24):14623–30

Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells. Nagarajan S, et al. **J Biol Chem** 1995 Oct 27; 270(43):25762–70

Identification of a domain (155–183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. Navazo MD, et al. **J Biol Chem** 1996 Jun 28;271(26):15381–5

Enumeration of phagocytosed Staphylococcus aureus inside cells of the mouse macrophage cell line J774 by bioluminescence, fluorescence and viable counting techniques. Sunderland J, et al. **J Biolumin Chemilumin** 1995 Sep–Oct;10(5):291–9

Different fates of phagocytosed particles after delivery into macrophage lysosomes. Oh YK, et al. **J Cell Biol** 1996 Feb;132(4):585–93

Role of integrins in regulation of collagen phagocytosis by human fibroblasts. Lee W, et al. **J Cell Physiol** 1996 Sep; 168(3):695–704

Involvement of CD44 and the cytoskeletal linker protein ankyrin in human neutrophil bacterial phagocytosis. Moffat FL Jr, et al. **J Cell Physiol** 1996 Sep;168(3):638–47

Tumour related cutaneous elastophagocytosis. Sweeney EC, et al. **J Clin Pathol** 1996 Jan;49(1):81–3

A novel opioid mechanism seems to modulate phagocytosis in Tetrahymena. Renaud FL, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):205–7

Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptor-mediated phagocytosis in macrophages. Allen LA, et al. **J Exp Med** 1996 Aug 1;184(2):627–37

New insights into the mobilization and phagocytic activity of dendritic cells [comment] Austyn JM. **J Exp Med** 1996 Apr 1;183(4):1287–92. Comment on: J Exp Med 1996 Apr 1;183(4):1865–78.

The inlAB locus mediates the entry of Listeria monocytogenes into hepatocytes in vivo. Gaillard JL, et al. **J Exp Med** 1996 Feb 1;183(2):359–69

Human monocytes are unable to bind to or phagocytize IgA and IgG immune complexes formed with influenza virus in vitro. Scott CB, et al. **J Immunol** 1996 Jul 1;157(1):351–9

Neutrophils undergo apoptosis following ingestion of Escherichia coli. Watson RW, et al. **J Immunol** 1996 May 15;156(10):3986–92

Assessment of in vivo attachment/phagocytosis by alveolar macrophages. Weaver T, et al. **J Immunol Methods** 1996 Jun 21;193(2):149–56

Cooperative between CR1 (CD35) and CR3 (CD 11b/CD18) in the binding of complement-opsonized particles. Sutterwala FS, et al. **J Leukoc Biol** 1996 Jun;59(6):883–90

Killing of phagocytosed Staphylococcus aureus by human neutrophils requires intracellular free calcium. Wilsson A, et al. **J Leukoc Biol** 1996 Jun;59(6):902–7

Platelets enhance Fc(gamma) receptor-mediated phagocytosis and respiratory burst in neutrophils: the role of purinergic modulation and actin polymerization. Zalavary S, et al. **J Leukoc Biol** 1996 Jul;60(1):58–68

The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)

Response to Leydig cell apoptosis in the absence of testicular macrophages. Gaytan F, et al. **J Reprod Immunol** 1995 May;29(1):81–94

Oxidative damage and enhanced erythrophagocytosis in canine erythrocytes infected with Babesia gibsoni. Murase T, et al. **J Vet Med Sci** 1996 Mar;58(3):259–61

Phagocytosis of splenetic neutrophils of mice enhanced by orally administered peptidoglycan from Bifidobacterium thermophilum. Sasaki T, et al. **J Vet Med Sci** 1996 Jan; 58(1):85–6

Temperature effects on Legionella pneumophila killing by and multiplication in phagocytes of guinea pigs. Miyamoto H, et al. **Microbiol Immunol** 1995;39(9):647–54

In vitro phagocytosis and survival of Streptococcus suis capsular type 2 inside murine macrophages. Brazeau C, et al. **Microbiology** 1996 May;142 (Pt 5):1231–7

Role of LPS length in clearance rate of bacteria from the bloodstream in mice. Ohno A, et al. **Microbiology** 1995 Oct;141 (Pt 10):2749–56

Oxygen-dependent leishmanicidal activity of stimulated macrophages. Chakraborty R, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):23–9

M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Podbielski A, et al. **Mol Microbiol** 1996 Feb; 19(3):429–41

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Falo LD Jr, et al. **Nat Med** 1995 Jul;1(7):649–53

Phagocytosis and killing of suspended and adhered bacteria by peritoneal cells after dialysis. Calame W, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):320–7

Determination of the surface tension of block copolymer micelles by phagocytosis. Rolland A, et al. **Pharm Res** 1995 Oct;12(10):1435–8

Clustered syk tyrosine kinase domains trigger phagocytosis. Greenberg S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1103–7

MR imaging of phagocytosis in experimental gliomas. Zimmer C, et al. **Radiology** 1995 Nov;197(2):533–8

Evaluation of the immune status in patients with primary and secondary Sjögren's syndrome. Slezák R, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1):11–2

Phagocytosis and oxidative burst of blood phagocytes in chronic obstructive airway disease. Müns G, et al. **Scand J Infect Dis** 1995;27(4):369–73

Enter Listeria, unruffled. Gallagher RB. **Science** 1996 Mar 29;271(5257):1825

Phagocytosis of fluorescent beads by rat thyroid follicular cells (FRTL-5): comparison with iodide trapping as an index of functional activity of thyrocytes in vitro. Sagartz JE, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):635–43

The influence of carbon particles on the concentration of acid phosphatase and lysozyme enzymes within alveolar macrophages during the killing and degradation of Mycobacterium bovis. Attwood EM, et al. **Tuber Lung Dis** 1996 Aug;77(4):341–7

Colorimetric assay using XTT for assessing virulence of avian Pasteurella multocida strains. Choi KH, et al. **Vet Microbiol** 1995 Jul;45(2–3):191–200

Stimulation of avian respiratory phagocytes by Pasteurella multocida: effects of the route of exposure, bacterial dosage and strain, and the age of chickens. Hassanin HH, et al. **Vet Microbiol** 1995 Oct;46(4):401–13

Influence of chondroitinase on indirect hemagglutination titers and phagocytosis of Pasteurella multocida serogroups A, D and F. Rimler RB, et al. **Vet Microbiol** 1995 Dec;

47(3–4):287–94

Characterization of camel leukocytes by flow cytometry and microscopic evaluation of granulocyte phagocytosis of fluorescent bacteria. Abdurahman OA, et al. **Zentralbl Veterinarmed A** 1996 Apr;43(2):111–7

[Effects of SL-probiotic preparation on the body weight and phagocytosis of white mice] Wang X, et al. **Wei Sheng Wu Hsueh Pao** 1995 Dec;35(6):455–9 (Eng. Abstr.) **(Chi)**

[Hemophagocytic syndromes. A series of 23 cases] Tiab M, et al. **Ann Med Interne (Paris)** 1996;147(3):138–44 (Eng. Abstr.) **(Fre)**

[The phagocytosis of polymorphonuclear neutrophilic granulocytes in progressive periodontitis] Konopka T, et al. **Schweiz Monatsschr Zahnmed** 1995;105(9):1129–33 (Eng. Abstr.) **(Ger)**

[Effects of intravascular latex injection on factors responsible for acute lung injury] Ishizaka A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep;33(9):930–5 (Eng. Abstr.) **(Jpn)**

[Determination of the absorption capacity of peripheral blood neutrophils and monocytes] Blindar' VN, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):18–20 (Eng. Abstr.) **(Rus)**

[Methodical bases of the use of erythrocytic diagnostic agents as phagocytosis objects] Kuznetsov VF, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):21–3 (Eng. Abstr.) **(Rus)**

[Effect of Yersinia pseudotuberculosis pVM82 on the activity of components of complement and phagocytosis by human blood neutrophils] Sever IS. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):23–6 (Eng. Abstr.) **(Rus)**

[A comparative evaluation of the use of bacterial and latex phagocytosis objects for the study of the phagocytic activity of peripheral blood neutrophils] Siuch NI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):70–1 **(Rus)**

[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):39–43 (88 ref.) (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

The effects of midazolam, droperidol, fentanyl, and alfentanil on phagocytosis and killing of bacteria by polymorphonuclear leukocytes in vitro. Krumholz W, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):624–7

Morphine stimulates phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a G protein–coupled opiate receptor. Peterson PK, et al. **Adv Neuroimmunol** 1995;5(3):299–309

Effect of cytochalasin D on the mechanical properties and morphology of passive human neutrophils. Ting-Beall HP, et al. **Ann Biomed Eng** 1995 Sep–Oct;23(5):666–71

Neutrophil and monocyte phagocytic functions in patients with colorectal adenocarcinoma during fluorouracil therapy. Lukač J, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2805–9

Ex vivo effect of azithromycin in human leukocyte bactericidal functions [letter] Tomažič J, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1906

The effect of zinc on bacterial phagocytosis, killing and cytoprotection in human polymorphonuclear leucocytes. Sunzel B, et al. **APMIS** 1995 Sep;103(9):635–44

Effect of hydrocortisone treatment on oxygen metabolism and phagocytosis of peripheral blood neutrophils in asthmatic patients, sensitive and resistant to glucocorticosteroid therapy. Jankowska R, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):383–6

Effects of salvianolic acid A on oxygen radicals released by rat neutrophils and on neutrophil function. Lin TJ, et al. **Biochem Pharmacol** 1996 May 3;51(9):1237–41

Pharmaceutical and biological properties of doxorubicin encapsulated in liposomes (L-ADM): the effect of repeated administration on the systemic phagocytic activity and pharmacokinetics. Yachi K, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):653–67

Influence of recombinant human erythropoietin therapy on in vivo chemotaxis and in vitro phagocytosis of polymorphonuclear cells of hemodialysis patients. Sperschneider H, et al. **Blood Purif** 1996;14(2):157–64

In vitro effect of mercuric chloride and sodium selenite on chemiluminescent response of pronephros cells isolated from tilapia, Oreochromis aureus. Low KW, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):909–15

Peroxisome proliferators activate Kupffer cells in vivo. Bojes HK, et al. **Cancer Res** 1996 Jan 1;56(1):1–4

Complement receptor type 3 mediates phagocytosis and killing of Listeria monocytogenes by a TNF-alpha- and IFN-gamma-stimulated macrophage precursor hybrid. Drevets DA, et al. **Cell Immunol** 1996 Apr 10;169(1):1–6

Effects of latrunculin A on immunological phagocytosis and macrophage spreading-associated changes in the F-actin/G-actin content of the cells. Oliveira CA, et al. **Chem Biol Interact** 1996 Mar 25;100(2):141–53

Influence of brodimoprim on polymorphonuclear leukocyte phagocytosis and oxidant radical production. Braga PC, et al. **Chemotherapy** 1995 Sep–Oct;41(5):360–7

Effects of artesunate on immune function in mice. Lin PY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):441–4

Granulocyte colony-stimulating factor does not enhance phagocytosis or microbicidal activity of human mature polymorphonuclear neutrophils in vitro. Shimono N, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):556–62

The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes. Spika S, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):224–8

Evidence for the involvement of opioid peptides in phagocytosis, conformation, granulation and aggregation of immunocompetent Lumbricus terrestris amoebocytes. Renzelli-Cain R, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):205–11

Effect of prolactin on the in vitro phagocytic capacity of macrophages. Ortega E, et al. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):139–46

Augmentation of endotoxin-induced pulmonary responses by mononuclear cell phagocytosis in the reticuloendothelial system. Ishizaka A, et al. **Crit Care Med** 1996 Jun; 24(6):1034–40

Effects of vitamin A on immunological deficiencies in rats with obstructive jaundice. Karan B, et al. **Eur J Surg** 1996 Mar;162(3):217–22

Natural, high-mannose glycoproteins inhibit ROS binding and ingestion by RPE cell cultures. Lutz DA, et al. **Exp Eye Res** 1995 Oct;61(4):487–93

Phagocytosis and chemotaxis of rat alveolar macrophages after a combined or separate exposure to ozone and carbon black. Creutzenberg O, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):202–6

Investigations of receptor-mediated phagocytosis by hormone-induced (imprinted) Tetrahymena pyriformis. Kovács P, et al. **Experientia** 1996 Aug 15;52(8):769–73

Modulation of phagocytosis by anisoosmolarity and betaine in rat liver macrophages (Kupffer cells) and RAW 264.7 mouse macrophages. Warskulat U, et al. **FEBS Lett** 1996 Aug 12;391(3):287–92

Enhancement of phagocytosis in mouse macrophages by pituitary adenylate cyclase activating polypeptide (PACAP) and related peptides. Ichinose M, et al. **Immunopharmacology** 1995 Sep;30(3):217–24

Evidences of 4-hydroxynonenal involvement in modulation of phagocyte activities. Di Mauro C, et al. **Int J Tissue React** 1995;17(2):61–72

Carbachol does not correct the defect in the phagocytosis of outer segments by Royal College of Surgeons rat retinal pigment epithelial cells. Hall MO, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1473–7

Biomaterial-induced dysfunction in the capacity of rabbit alveolar macrophages to kill Staphylococcus epidermidis RP12. Giridhar G, et al. **J Biomed Mater Res** 1995 Oct; 29(10):1179–83

Supplemental L-arginine HCl augments bacterial phagocytosis in human polymorphonuclear leukocytes. Moffat FL Jr, et al. **J Cell Physiol** 1996 Jul;168(1):26–33

Cytokines modulate phagocytosis and intracellular digestion of collagen fibrils by fibroblasts in rabbit periosteal explants. Inverse effects on procollagenase production and collagen phagocytosis. van der Zee E, et al. **J Cell Sci** 1995 Oct; 108 (Pt 10):3307–15

Effects of sub-minimal inhibitory concentrations of antimicrobial agents on the cell surface of Klebsiella pneumoniae and phagocytic killing activity. Nomura S, et al. **J Chemother** 1995 Oct;7(5):406–13

Macrophages have cell surface IL-10 that regulates macrophage bactericidal activity. Fleming SD, et al. **J Immunol** 1996 Feb 1;156(3):1143–50

Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis. Karimi K, et al. **J Immunol** 1995 Dec 15;155(12):5786–94

Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. Lefkowitz SS, et al. **J Infect Dis** 1996 May;173(5):1202–7

Beta-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage. Fradin C, et al. **J Leukoc Biol** 1996 Jul;60(1):81–7

Okadaic acid inhibits the signal responsible for activation of the NADPH-oxidase in neutrophils stimulated with serum-opsonized yeast. Harbecke O, et al. **J Leukoc Biol** 1996 May;59(5):754–62

Enhancing effects of chicken egg white derivatives on the phagocytic response in the dog. Hirota Y, et al. **J Vet Med Sci** 1995 Oct;57(5):825–9

Modulation of phagocytosis by P2-purinergic receptors in mouse peritoneal macrophages. Ichinose M. **Jpn J Physiol** 1995;45(5):707–21

Thymic nurse cells as the site of thymocyte apoptosis and apoptotic cell clearance in the thymus of cyclophosphamide-treated mice. Hiramine C, et al. **Lab Invest** 1996 Aug;75(2):185–201

Influence of deoxyspergualin on mononuclear phagocytic system in mice. Asano K, et al. **Life Sci** 1996;58(10):PL 171–5

Effects of benzodiazepines on immunodeficiency and resistance in mice. Galdiero F, et al. **Life Sci** 1995 Nov 17;57(26):2413–23

A flow cytometric assay reveals a suppression of phagocytosis by rabbit defensin NP-3A in mouse peritoneal macrophages. Ichinose M, et al. **Microbiol Immunol** 1995; 39(5):365–7

Resistance of glucose-6-phosphate dehydrogenase deficiency to malaria: effects of fava bean hydroxypyrimidine glucosides on Plasmodium falciparum growth in culture and on the phagocytosis of infected cells. Ginsburg H, et al. **Parasitology** 1996 Jul;113 (Pt 1):7–18

Studies of the organ distribution in mice of teniposide liposomes designed for treatment of diseases in the mononuclear phagocytic system. Liliemark E, et al. **Pediatr Res** 1995 Jul;38(1):7–10

1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Tokuda N, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):244–50

Immunobiological activities of mould products: functional impairment of human monocytes exposed to aflatoxin B1. Cusumano V, et al. **Res Microbiol** 1996 Jun;147(5):385–91

Heavy metal-specific inhibition of phagocytosis and different in vitro sensitivity of heterogeneous coelomocytes from Lumbricus terrestris (Oligochaeta). Fugère N, et al. **Toxicology** 1996 May 17;109(2–3):157–66

[Modification of phagocytic microbicide function by antifungal agents--measuring luminol enhanced chemoluminescence in full blood] Wilhelm L, et al. **Langenbecks Arch Chir** 1996;381(2):88–94 (Eng. Abstr.) **(Ger)**

[Effect of pidotimod on phagocytosis and intracellular killing of Staphylococcus aureus by human circulating polymorphonuclear neutrophils and alveolar macrophages] Oddera S, et al. **Drugs Exp Clin Res** 1993;19 Suppl:27–35 **(Ita)**

[Effect of clarithromycin on macrophage functions] Xu G, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):864–72 (Eng. Abstr.) **(Jpn)**

[The influence of local anesthetics on human leukocyte functions studied by micro whole blood collection and flowcytometry] Okuno S, et al. **Masui** 1996 Mar; 45(3):317–25 (Eng. Abstr.) **(Jpn)**

[Effect of contrast media used in hysterosalpingography (HSG) on phagocytosis of spermatozoa by peritoneal macrophages in female rats] Mikulska D. **Ann Acad Med Stetin** 1995;41:131–43 (Eng. Abstr.) **(Pol)**

[Comparative study of the effect of recombinant tumor necrosis factor and synthetic peptides, corresponding to its fragments, on phagocytosis,mediated by Fc- and MF-receptors] Koniaev IG, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):304–8 **(Rus)**

[Inhibition of phagolysis in a Bacillus thuringiensis culture by chitosan] Kochkina ZM, et al. **Prikl Biokhim Mikrobiol** 1996 Mar–Apr;32(2):247–50 (Eng. Abstr.) **(Rus)**

[Antiphagocytic activity of sera treated with organic solvents (chloroform, ether)] Stefanovič J, et al. **Bratisl Lek Listy** 1995 Jun;96(6):307–10 (Eng. Abstr.) **(Slo)**

[In vitro effect of disodium cromoglycate on phagocytic activity of polymorphonuclear cells of healthy asthmatic patients] Gómez Castillo CA, et al. **Rev Alerg Mex** 1995 Sep–Oct;42(5):89–95 (Eng. Abstr.) **(Spa)**

GENETICS

Detection and characterization by differential PCR of host eukaryotic cell genes differentially transcribed following uptake of intracellular bacteria. Schwan WR, et al. **Infect Immun** 1996 Jan;64(1):91–9

Correlations of neutrophil phagocytosis for proven bulls with traits of economic importance of their daughters. Dürr JW, et al. **J Dairy Sci** 1996 Jan;79(1):133–9

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19-induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Elsässer D, et al. **Blood** 1996 May 1;87(9):3803–12

Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Ely P, et al. **Blood** 1996 May 1;87(9):3813–21

Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry. Chaka W, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):753–9

Quantitative flow cytometric analysis of opsonophagocytosis and killing of nonencapsulated Haemophilus influenzae by human polymorphonuclear leukocytes. Vogel L, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):394–400

Abnormal complement-mediated immune clearance in MRL-lpr/+ heterozygote mice: dose-dependent effect of the Fas antigen mutation. Meryhew NL, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):236–44

Suppressive effects of Aspergillus fumigatus culture filtrates on human alveolar macrophages and polymorphonuclear leucocytes. Murayama T, et al. **Eur Respir J** 1996 Feb; 9(2):293–300

Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis. Fulton SA, et al. **Infect Immun** 1996 Jul;64(7):2523–31

Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. De Bruijn ML, et al. **J Immunol** 1996 Apr 15;156(8):2686–92

A study of the role of corticosterone as a mediator in

exercise-induced stimulation of murine macrophage phagocytosis. Forner MA, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):789-94

Phagocytosis of Streptococcus uberis by bovine mammary macrophages: opsonizing effect of bovine antiserum. Almeida RA, et al. **Zentralbl Veterinarmed [B]** 1995 Aug; 42(6):331-7

[Functional evaluation of erythrocytic antibodies by photometric detection of erythrophagocytosis in the monocyte monolayer assay] Cassens U, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):297-300 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Changes in neutrophil actin and shape during sequestration induced by complement fragments in rabbits. Motosugi H, et al. **Am J Pathol** 1996 Sep;149(3):963-73

Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Stern M, et al. **Am J Pathol** 1996 Sep;149(3):911-21

Secretion of Osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. McKee MD, et al. **Anat Rec** 1996 Jun;245(2):394-409

Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function [see comments] Alexiewicz JM, et al. **Ann Intern Med** 1995 Dec 15;123(12):919-24. Comment in: Ann Intern Med 1995 Dec 15;123(12):952-3.

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239-76 (187 ref.)

Construction of a cDNA library from human retinal pigment epithelial cells challenged with rod outer segments. Cavaney DM, et al. **Aust N Z J Ophthalmol** 1995 May; 23(2):139-44

Temperature-dependent changes in plasma-membrane lipid order and the phagocytotic activity of the amoeba Acanthamoeba castellanii are closely correlated. Avery SV, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):811-6

Influence of plasma membrane fluidity on phagocytotic activity in Acanthamoeba castellanii. Avery SV, et al. **Biochem Soc Trans** 1995 Aug;23(3):409S

Impaired neutrophil phagocytosis in preterm neonates: lack of correlation with expression of immunoglobulin or complement receptors. Falconer AE, et al. **Biol Neonate** 1995;68(4):264-9

Neutrophil chemotaxis, phagocytosis, and generation of reaction oxygen species show a hierarchy of responsiveness to increasing concentrations of N-formyl-Met-Leu-Phe. Iizawa O, et al. **Biol Signals** 1995 Jan-Feb;4(1):14-8

The molecular dissection of Fc gamma receptor mediated phagocytosis. Indik ZK, et al. **Blood** 1995 Dec 15; 86(12):4389-99 (85 ref.)

Interaction of cultured human keratinocytes with liposomes encapsulating silver sulphadiazine: proof of the uptake of intact vesicles. Schaller M, et al. **Br J Dermatol** 1996 Mar; 134(3):445-50

Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263-74 (50 ref.)

Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein Tag. Maniak M, et al. **Cell** 1995 Dec 15;83(6):915-24

Distribution of annexin I during non-pathogen or pathogen phagocytosis by confocal imaging and immunogold electron microscopy. Harricane MC, et al. **Cell Biol Int** 1996 Mar;20(3):193-203

The effect of fiber length on the dissolution by macrophages of rockwool and glasswool fibers. Luoto K, et al. **Environ Res** 1995 Jul;70(1):51-61

Human Kupffer cell recognition and phagocytosis of apoptotic peripheral blood lymphocytes. Falasca L, et al. **Exp Cell Res** 1996 Apr 10;224(1):152-62

A comparison of phagocytosis by the retinal pigment epithelium in normal and delayed amelanotic chickens. Lahiri D, et al. **Exp Eye Res** 1993 Jun;56(6):625-34

Nitric oxide-dependent killing of Candida albicans by murine peritoneal cells during an experimental infection. Rementeria A, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):157-62

Phagocytozing ameboid microglial cells studied in a mouse corpus callosum slice preparation. Brockhaus J, et al. **Glia** 1996 Jan;16(1):81-90

Membrane-bound glycoconjugates of fetal mouse erythropoietic cells with special reference to phagocytosis by hepatic macrophages. Iwatsuki H, et al. **Histochem Cell Biol** 1995 Oct;104(4):277-86

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243-6 (14 ref.)

Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells. Relationship to cell morphology. McLaren MJ. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1213-24

Lipopolysaccharide outer core is a ligand for corneal cell binding and ingestion of Pseudomonas aeruginosa. Zaidi TS, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):976-86

An ultrastructural study of the phagocytic activity of astrocytes in adult rat brain. al-Ali SY, et al. **J Anat** 1996 Apr;188 (Pt 2):257-62

Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties. Ayhan H, et al. **J Biomater Sci Polym Ed** 1995;7(4):329-42

Na+/H+ exchange activity during phagocytosis in human neutrophils: role of Fcgamma receptors and tyrosine kinases. Fukushima T, et al. **J Cell Biol** 1996 Mar; 132(6):1037-52

Phagosome-lysosome fusion is a calcium-independent event in macrophages. Zimmerli S, et al. **J Cell Biol** 1996 Jan; 132(1-2):49-61

Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. Verhoven B, et al. **J Exp Med** 1995 Nov 1;182(5):1597-601

Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. Gaynor CD, et al. **J Immunol** 1995 Dec 1;155(11):5343-51

J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. Mukherjee S, et al. **J Infect Dis** 1996 May; 173(5):1222-31

In vitro culture of murine peritoneal and alveolar macrophages modulates phagocytosis of Pseudomonas aeruginosa and glucose transport. Everett KD, et al. **J Leukoc Biol** 1996 Apr;59(4):539-44

Alveolar macrophage response to yeasts and inert particles. Nyberg K, et al. **J Med Vet Mycol** 1996 Jan-Feb;34(1):11-7

Cytokine-mediated human polymorphonuclear neutrophil phagocytosis: evidence of differential sensitivities to manipulation of intracellular mechanisms. Garner CV, et al. **J Surg Res** 1996 Jan;60(1):84-90

Measuring resistance to phagocytosis of group A and G streptococci: comparison of direct bactericidal assay and flow cytometry. Schnitzler N, et al. **Med Microbiol Immunol (Berl)** 1995 May;184(1):17-22

A non-linear mathematical model for the in vivo evaluation of the RES phagocytic function. Bondareva IB, et al. **Medinfo** 1995;8 Pt 2:1091

Tuberculosis-associated hemophagocytic syndrome in a hemodialysis patient: case report and review of the literature. Yang CW, et al. **Nephron** 1996;72(4):690-2

Cytoplasmic motility reflects phagocytic activity in alveolar macrophages from dog lungs. Yamaya M, et al. **Respir Physiol** 1995 Aug;101(2):199-205

Expression of MHC class II molecules on human monocytes is regulated independently from each other after phagocytosis of bacteria. Wuorela M, et al. **Scand J Immunol** 1996 Jan;43(1):39-46

Caco-2 and IEC-18 intestinal epithelial cells exert bactericidal activity through an oxidant-dependent pathway. Deitch EA, et al. **Shock** 1995 Nov;4(5):345-50

Effect of hemorrhagic shock and resuscitation upon hepatic phagocytic clearance and killing of circulating microorganisms. Kondo S, et al. **Shock** 1996 Feb; 5(2):106-11

Immune functions in beluga whales (Delphinapterus leucas): evaluation of phagocytosis and respiratory burst with peripheral blood leukocytes using flow cytometry. de Guise S, et al. **Vet Immunol Immunopathol** 1995 Aug; 47(3-4):351-62

Studies on the cell tropism of Listeria monocytogenes in ovine fetal brain cell cultures. Peters M, et al. **Vet Microbiol** 1996 Apr;49(3-4):169-79

Properties of a Streptococcus suis isolate of serotype 2 and two capsular mutants. Salasia SI, et al. **Vet Microbiol** 1995 Jul;45(2-3):151-6

Evaluation of the effect of experimental cow endometritis on bactericidal capability of phagocytizing cells isolated from the blood and uterine lumen. Kluciński W, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):461-6

[Oxidants and antioxidants. Biological effects and therapeutic perspectives] Urban T, et al. **Ann Chir** 1995;49(5):427-34 (55 ref.) (Eng. Abstr.) **(Fre)**

[Assessing the basic stages of the phagocytic process: current approaches to and prospects for research development] Khaitov RM, et al. **Patol Fiziol Eksp Ter** 1995 Jul-Sep; (3):3-10 (59 ref.) (Eng. Abstr.) **(Rus)**

PHAGOLYSOSOMES see **PHAGOSOMES**

PHAGOSOMES

see related
PHAGOCYTOSIS

ENZYMOLOGY

Redistribution and fate of colchicine-induced alkaline phosphatase in rat hepatocytes: possible formation of autophagosomes whose membrane is derived from excess plasma membrane. Araki N, et al. **Histochem Cell Biol** 1995 Oct;104(4):257-65

GENETICS

Sequestration of mitotic (M-phase) chromosomes in autophagosomes: mitotic programmed cell death in human Chang liver cells induced by an OH• burst from vanadyl(4). Sit KH, et al. **Anat Rec** 1996 May;245(1):1-8

IMMUNOLOGY

Salmonella typhi does not inhibit phagosome-lysosome fusion in human monocyte-derived macrophages. Ishibashi Y, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):55-61

METABOLISM

Translocation of annexin I to plasma membranes and phagosomes in human neutrophils upon stimulation with opsonized zymosan: possible role in phagosome function. Kaufman M, et al. **Biochem J** 1996 May 15;316 (Pt 1):35-42

Role of compartmentation in promoting toxicity of leukocyte-generated strong oxidants. Lymar SV, et al. **Chem Res Toxicol** 1995 Sep;8(6):833-40

Acidification of phagosomes containing Salmonella typhimurium in murine macrophages. Rathman M, et al. **Infect Immun** 1996 Jul;64(7):2765-73

Microtubule-associated protein-dependent binding of phagosomes to microtubules. Blocker A, et al. **J Biol Chem** 1996 Feb 16;271(7):3803-11

MICROBIOLOGY

The phagosome containing Legionella pneumophila within the protozoan Hartmannella vermiformis is surrounded by the rough endoplasmic reticulum. Abu Kwaik Y. **Appl Environ Microbiol** 1996 Jun;62(6):2022-8

Rapid and complete fusion of macrophage lysosomes with phagosomes containing Salmonella typhimurium. Oh YK, et al. **Infect Immun** 1996 Sep;64(9):3877-83

Acidification of phagosomes containing Salmonella typhimurium in murine macrophages. Rathman M, et al. **Infect Immun** 1996 Jul;64(7):2765-73

The effects of inhibitors of vacuolar acidification on the release of Listeria monocytogenes from phagosomes of Caco-2 cells. Conte MP, et al. **J Med Microbiol** 1996 Jun; 44(6):418-24

PHYSIOLOGY

A time-saving biological test to evaluate phagosome-lysosome fusion in cells. Le Pocher H, et al. **Anal Biochem** 1996 Jul 1;238(2):203-5

Phagocytosis by rat liver: relationships between phagosomes and lysosomes. Wattiaux R, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):569-74

Interaction of Legionella pneumophila with Acanthamoeba castellanii: uptake by coiling phagocytosis and inhibition of phagosome-lysosome fusion. Bozue JA, et al. **Infect Immun** 1996 Feb;64(2):668-73

Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosome-lysosome interaction. Oh YK, et al. **Infect Immun** 1996 Jan;64(1):319-25

Phagocytosed live Listeria monocytogenes influences Rab5-regulated in vitro phagosome-endosome fusion. Alvarez-Dominguez C, et al. **J Biol Chem** 1996 Jun 7; 271(23):13834-43

Phagosome-lysosome fusion is a calcium-independent event in macrophages. Zimmerli S, et al. **J Cell Biol** 1996 Jan; 132(1-2):49-61

ULTRASTRUCTURE

Thermal control of rod outer segment length and shedding in a fish, Fundulus zebrinus. Allen DM. **Exp Eye Res** 1995 Aug;61(2):165-71

Spacious phagosome formation within mouse macrophages correlates with Salmonella serotype pathogenicity and host susceptibility. Alpuche-Aranda CM, et al. **Infect Immun** 1995 Nov;63(11):4456-62

Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptor-mediated phagocytosis in macrophages. Allen LA, et al. **J Exp Med** 1996 Aug 1;184(2):627-37

PHALLIC STAGE

The phallic child: its emergence and meaning in a clinical setting. Hunter J. **Am J Psychother** 1995 Summer; 49(3):428-45

PHALLOIDINE

CHEMISTRY

Comparative study on the conformation of phalloidin, viroisin, and related derivatives in aqueous solution. Kobayashi N, et al. **Eur J Biochem** 1995 Sep 15; 232(3):726-36

[The effect of phalloidin on stability of F- and G-actin] Vedenkina NS, et al. **Mol Biol (Mosk)** 1995 May-Jun; 29(3):597-602 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effect of phalloidin on cholestasis, hemodynamics, and microcirculation in isolated perfused rat liver. Barriault C, et al. **Hepatology** 1996 Feb;23(2):294-302

Phalloidin unzips nebulin from thin filaments in skeletal myofibrils. Ao X, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3397-403

Bifunctional protein cross-linking reagents improve labeling of cytoskeletal proteins for qualitative and quantitative

fluorescence microscopy. Safiejko-Mroczka B, et al. **J Histochem Cytochem** 1996 Jun;44(6):641-56

TOXICITY

Thin filament activation by phalloidin in skinned cardiac muscle. Bukatina AE, et al. **J Mol Cell Cardiol** 1995 Jun; 27(6):1311-5

Effect of agents which modify reticuloendothelial system function on acute phalloidin-induced lethality and hepatotoxicity in mice [letter; comment] Calabrese EJ. **Toxicol Appl Pharmacol** 1996 Jan;136(1):208-9. Comment on: Toxicol Appl Pharmacol 1995 Apr;131(2):206-15.

Structural and functional alterations of hepatocytes during transient phalloidin-induced cholestasis in the rat. Loranger A, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):100-11

PHANER see **CHEIROGALEIDAE**

PHANTOM LIMB

Acute phantom limb pain controlled by ketamine. Knox DJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):620-2

Lignocaine for acute phantom limb pain reactivation by regional anaesthesia [letter] Lamacraft G. **Anaesthesia** 1996 Aug;51(8):800

Touching the phantom limb [letter] Ramachandran VS, et al. **Nature** 1995 Oct 12;377(6549):489-90

[Ketamine and phantom pain (letter)] Hansen G. **Ugeskr Laeger** 1995 Nov 27;157(48):6735-6 **(Dan)**

COMPLICATIONS

Regional anaesthesia for repeat Caesarean section in a patient with phantom limb pain. Uncles DR, et al. **Anaesthesia** 1996 Jan;51(1):69-70

DIAGNOSIS

[Phantom pain following leg amputation: retrospective study of incidence, therapy and the effect of preoperative analgesia] Zuurmond WW, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1080-3 (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Clonazepam for the treatment of lancinating phantom limb pain. Bartusch SL, et al. **Clin J Pain** 1996 Mar;12(1):59-62

ETIOLOGY

On the vagaries of bodies [comment] Desjarlais R. **Cult Med Psychiatry** 1995 Jun;19(2):207-15. Comment on: Cult Med Psychiatry 1995 Jun;19(2):141-82. Comment on: Cult Med Psychiatry 1995 Jun;19(2):183-205.

[The man with 6 arms. An analysis of supernumerary phantom limbs after right hemisphere stroke] Sellal F, et al. **Rev Neurol (Paris)** 1996 Mar;152(3):190-5 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Phantom limb pain and etiology of amputation in unilateral lower extremity amputees. Weiss SA, et al. **J Pain Symptom Manage** 1996 Jan;11(1):3-17

Phantom or central neuropathic pain? [letter] Vecht CJ, et al. **Pain** 1995 Dec;63(3):392-4

Synaesthesia in phantom limbs induced with mirrors. Ramachandran VS, et al. **Proc R Soc Lond B Biol Sci** 1996 Apr 22;263(1369):377-86

PREVENTION & CONTROL

Pre-emptive epidural analgesia may prevent phantom limb pain [letter; comment] Schug SA, et al. **Reg Anesth** 1995 May-Jun;20(3):256. Comment on: Reg Anesth 1993 Mar-Apr;18(2):121-7. Comment on: Reg Anesth 1994 May-Jun;19(3):217-8.

PSYCHOLOGY

The role of coping in adjustment to phantom limb pain. Hill A, et al. **Pain** 1995 Jul;62(1):79-86

Synaesthesia in phantom limbs induced with mirrors. Ramachandran VS, et al. **Proc R Soc Lond B Biol Sci** 1996 Apr 22;263(1369):377-86

PHANTOMS, IMAGING

Phantom study of chest radiography with storage phosphor, selenium, and film-screen systems. Kehler M, et al. **Acta Radiol** 1996 May;37(3 Pt 1):332-6

Phantom gastric mucosa for evaluating computed radiography in double-constrast upper gastrointestinal examinations. Murakami M, et al. **Acta Radiol** 1996 Mar; 37(2):204-7

Investigation of applicability of alanine and radiochromic detectors to dosimetry of proton clinical beams. Nichiporov D, et al. **Appl Radiat Isot** 1995 Dec;46(12):1355-62

A home-made phantom for learning ultrasound-guided invasive techniques. Gibson RN, et al. **Australas Radiol** 1995 Nov;39(4):356-7

Construction of an ultrasound biopsy phantom. Patel AS, et al. **Australas Radiol** 1996 May;40(2):185-6

Comparative study of bone mineral density estimated by various methods of single- and dual-energy quantitative computed tomography: the capability of the four-equation four-unknown method. Tanno M, et al. **Bone** 1996 Mar; 18(3):239-47

Comparisons of angiographic core laboratory analyses of phantom and clinical images: interlaboratory variability. Beauman GJ, et al. **Cathet Cardiovasc Diagn** 1996 Jan; 37(1):24-31

Optimal collimator choice for sequential iodine-123 and technetium-99m imaging. Geeter FD, et al. **Eur J Nucl Med** 1996 Jul;23(7):768-74

Scatter-to-primary ratio and absorption efficiency in screen-film and computed radiography systems. McLean D, et al. **Eur J Radiol** 1996 Feb;21(3):212-6

Laser transillumination of breast tissue phantoms using time-resolved techniques. Jarlman O, et al. **Eur Radiol** 1996;6(3):387-92

Comparison of the ANSI, RSD, KKH, and BRMD thyroid-neck phantoms for 125I thyroid monitoring. Kramer GH, et al. **Health Phys** 1996 Mar;70(3):425-9

The BRMD thyroid-neck phantom: design and construction. Kramer GH, et al. **Health Phys** 1996 Aug;71(2):211-4

Organ and effective doses in the male phantom ADAM exposed in AP direction to broad unidirectional beams of monoenergetic electrons. Schultz FW, et al. **Health Phys** 1996 Apr;70(4):498-504

FDTD simulations of Clini-Therm applicators on inhomogeneous planar tissue models. Chan KW, et al. **Int J Hyperthermia** 1995 Nov-Dec;11(6):809-20

Dual-beam imaging for online verification of radiotherapy field placement. Jaffray DA, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1273-80

Three-dimensional flow images by reconstruction from two-dimensional vector velocity maps. Bohs LN, et al. **J Am Soc Echocardiogr** 1995 Nov-Dec;8(6):915-23

Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results [letter] Genant HK. **J Bone Miner Res** 1995 Jun;10(6):997-8

A laboratory model for dental radiographic studies. Jenkins SM, et al. **J Oral Rehabil** 1995 Oct;22(10):753-8

Radiofrequency magnetic field gradient echoes have reduced sensitivity to susceptibility gradients. Karczmar G, et al. **Magn Reson Imaging** 1995;13(6):791-7

Depth dose flattening of electron beams using a wire mesh bolus. Alasti H, et al. **Med Phys** 1995 Oct;22(10):1675-83

The calibration and use of plane-parallel ionization chambers for dosimetry of electron beams. Almond PR, et al. **Med Phys** 1995 Aug;22(8):1307-14

Energy imparted and effective doses in computed tomography. Atherton JV, et al. **Med Phys** 1996 May; 23(5):735-41

Spatial mapping of the percentage cellularity in human bone marrow using magnetic resonance imaging. Ballon D, et al. **Med Phys** 1996 Feb;23(2):243-50

A simple method of obtaining off-axis half-value layers for megavoltage photon beams. Barish RJ. **Med Phys** 1995 Sep; 22(9):1467-8

Bayesian image estimation of digital chest radiography: interdependence of noise, resolution, and scatter fraction. Baydush AH, et al. **Med Phys** 1995 Aug;22(8):1255-61

Tissue-phantom ratios from percentage depth doses. Bjärngard BE, et al. **Med Phys** 1996 May;23(5):629-34

Radiation damage of amorphous silicon, thin-film, field-effect transistors. Boudry JM, et al. **Med Phys** 1996 May;23(5):743-54

Quantitative versus subjective evaluation of mammography accreditation phantom images. Chakraborty DP, et al. **Med Phys** 1995 Feb;22(2):133-43

Confirmation of target localization and dosimetry for 3D conformal radiotherapy treatment planning by MR imaging of a ferrous sulfate gel head phantom. Chan MF, et al. **Med Phys** 1995 Jul;22(7):1171-5

Systematic verification of a three-dimensional electron beam dose calculation algorithm. Cheng A, et al. **Med Phys** 1996 May;23(5):685-93

The spectrum and angular distribution of x rays scattered from a water phantom. Cheng CW, et al. **Med Phys** 1995 Aug;22(8):1235-45

White polystyrene as a substitute for water in high energy photon dosimetry. Christ G. **Med Phys** 1995 Dec; 22(12):2097-100

Electron-beam characteristics at extended treatment distances. Das IJ, et al. **Med Phys** 1995 Oct;22(10):1667-74

Measured electron energy and angular distributions from clinical accelerators. Deasy JO, et al. **Med Phys** 1996 May; 23(5):675-84

A fully automated algorithm for the segmentation of lung fields on digital chest radiographic images. Duryea J, et al. **Med Phys** 1995 Feb;22(2):183-91

Correcting for rf inhomogeneities in multiecho pulse sequence MRI dosimetry. Duzenli C, et al. **Med Phys** 1995 Oct;22(10):1645-50

A model for electron-beam applicator scatter. Ebert MA, et al. **Med Phys** 1995 Sep;22(9):1419-29

A Monte Carlo investigation of electron-beam applicator scatter. Ebert MA, et al. **Med Phys** 1995 Sep;22(9):1431-5

Intercomparison of normalized head-scatter factor measurement techniques. Frye DM, et al. **Med Phys** 1995 Feb;22(2):249-53

Radionuclide photon dose kernels for internal emitter dosimetry. Furhang EE, et al. **Med Phys** 1996 May; 23(5):759-64

Correction of motion artifacts in linogram and projection reconstruction MRI using geometry and consistency constraints. Gai N, et al. **Med Phys** 1996 Feb;23(2):251-62

The application of transit dosimetry to precision radiotherapy. Hansen VN, et al. **Med Phys** 1996 May; 23(5):713-21

Three-dimensional reconstruction of vascular trees: experimental evaluation. Henri CJ, et al. **Med Phys** 1996 May;23(5):617-27

Deconvolution of detector size effect for small field measurement. Higgins PD, et al. **Med Phys** 1995 Oct; 22(10):1663-6

Determination of 3D imaging geometry and object configurations from two biplane views: an enhancement of the Metz-Fencil technique. Hoffmann KR, et al. **Med Phys** 1995 Aug;22(8):1219-27

A general approach to the reconstruction of x-ray helical computed tomography. Hsieh J. **Med Phys** 1996 Feb; 23(2):221-9

Energy imparted in computed tomography. Huda W, et al. **Med Phys** 1995 Aug;22(8):1263-9

An evaluation of the recommendations of the TG-25 protocol for determination of depth dose curves for electron beams using ionization chambers. Huq MS, et al. **Med Phys** 1995 Aug;22(8):1333-7

Dosimetric characteristics of a commercial multileaf collimator. Huq MS, et al. **Med Phys** 1995 Feb;22(2):241-7

Design and optimization of an aperiodic ultrasound phased array for intracavitary prostate thermal therapies. Hutchinson EB, et al. **Med Phys** 1996 May;23(5):767-76

Optimization of conformal electron beam therapy using energy- and fluence-modulated beams. Hyödynmaa S, et al. **Med Phys** 1996 May;23(5):659-66

Transmission imaging of large attenuators using a slant hole collimator on a three-headed SPECT system. King MA, et al. **Med Phys** 1996 Feb;23(2):263-72

Evaluation of bremsstrahlung spectra generated by a 4-MeV linear accelerator. Krmar M, et al. **Med Phys** 1996 May; 23(5):651-4

Photoacoustic ultrasound (PAUS)--reconstruction tomography. Kruger RA, et al. **Med Phys** 1995 Oct; 22(10):1605-9

A fast and stable maximum a posteriori conjugate gradient reconstruction algorithm. Lalush DS, et al. **Med Phys** 1995 Aug;22(8):1273-84

Dual-slice spiral versus single-slice spiral scanning: comparison of the physical performance of two computed tomography scanners. Liang Y, et al. **Med Phys** 1996 Feb; 23(2):205-220

The evaluation of optimized implants for idealized implant geometries. Low DA, et al. **Med Phys** 1995 Sep; 22(9):1477-85

A direct approach for the determination of absorbed dose from electron beams using non-water phantoms. Lu XQ, et al. **Med Phys** 1995 Dec;22(12):2083-91

Calibration of the delayed-gamma neutron activation facility. Ma R, et al. **Med Phys** 1996 Feb;23(2):273-7

Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Macey DJ, et al. **Med Phys** 1995 Oct;22(10):1637-43

Evaluation of digitally reconstructed radiographs (DRRs) used for clinical radiotherapy: a phantom study. McGee KP, et al. **Med Phys** 1995 Nov;22(11 Pt 1):1815-27

Radiation therapy dosimetry using magnetic resonance imaging of polymer gels. Maryanski MJ, et al. **Med Phys** 1996 May;23(5):699-705

Physical characteristics of a clinical d(48.5)+Be neutron therapy beam produced by a superconducting cyclotron. Maughan RL, et al. **Med Phys** 1995 Sep;22(9):1459-65

Water calorimetry and ionization chamber dosimetry in an 85-MeV clinical proton beam. Palmans H, et al. **Med Phys** 1996 May;23(5):643-50

Optimization of MR pulse sequences for Bayesian image segmentation. Prince JL, et al. **Med Phys** 1995 Oct; 22(10):1651-6

A QA phantom for dynamic stereotactic radiosurgery: quantitative measurements. Ramani R, et al. **Med Phys** 1995 Aug;22(8):1343-6

Evaluation of electronic portal imaging device for missing tissue compensator design and verification. Roback DM, et al. **Med Phys** 1995 Dec;22(12):2029-34

Thermoluminescent dosimetry in electron beams: energy dependence. Robar V, et al. **Med Phys** 1996 May; 23(5):667-73

Calculation of dose distributions in the vicinity of high-Z interfaces for photon beams. Sauer OA. **Med Phys** 1995 Oct;22(10):1685-90

Calculation of x-ray spectra for radiosurgical beams. Sixel KE, et al. **Med Phys** 1995 Oct;22(10):1657-61

Considerations for superficial photon dosimetry. Stern RL, et al. **Med Phys** 1995 Sep;22(9):1469-70

Segmentation of mammograms using multiple linked self-organizing neural networks. Suckling J, et al. **Med Phys** 1995 Feb;22(2):145-52

How water equivalent are water-equivalent solid materials for output calibration of photon and electron beams? Tello VM, et al. **Med Phys** 1995 Jul;22(7):1177-89

Comment on "Intercomparison on normalized head-scatter factor measurement techniques" [Med. Phys. 22, 249-253 (1995)] [letter] Ten Haken RK. **Med Phys** 1995 Sep; 22(9):1471, 1475

Influence of shape on the accuracy of grid-based volume computations. van t' Veld AA, et al. **Med Phys** 1995 Sep;

22(9):1377–85
Quantitative mammography contrast threshold test tool. Wagner AJ, et al. **Med Phys** 1995 Feb;22(2):127–32
Quantitation of organ symmetry by diagnostic ultrasonic imaging: a group theoretical approach. Wang SL, et al. **Med Phys** 1995 Oct;22(10):1611–8
A transmission–map–based scatter correction technique for SPECT in inhomogeneous media. Welch A, et al. **Med Phys** 1995 Oct;22(10):1627–35
Comment on "Optimization of pencil beam width for electron–beam dose calculations" [Med. Phys. 22, 411–419 (1995)] [letter; comment] Werner BL. **Med Phys** 1995 Sep; 22(9):1441, 1443. Comment on: Med Phys 1995 Apr;22(4):411–9.
Angular–dependent coherent scatter measured with a diagnostic x–ray image intensifier–based imaging system. Westmore MS, et al. **Med Phys** 1996 May;23(5):723–33
Parametrization of head–scatter factors for rectangular photon fields using an equivalent square formalism. Yu MK, et al. **Med Phys** 1995 Aug;22(8):1329–32
A convolution–adapted ratio–TAR algorithm for 3D photon beam treatment planning. Zhu XR, et al. **Med Phys** 1995 Aug;22(8):1315–27
A computer simulation of motion in turbo FLASH imaging and echo–planar imaging. Suga M, et al. **Medinfo** 1995;8 Pt 1:706
Signal profile measurements for evaluation of the volume–selection performance of ISIS. Ljungberg M, et al. **NMR Biomed** 1995 Sep;8(6):271–7
The effect of phantom wall thickness on volume determination in SPET. Hillel PG, et al. **Nucl Med Commun** 1995 Dec;16(12):1034–40
Validation of a dual–isotope technique using 123I–MIBG and 201Tl in the assessment of sympathetic reinnervation following heart transplantation: phantom and patient studies. Krause BJ, et al. **Nucl Med Commun** 1995 Aug; 16(8):675–82
Quantitative whole body scintigraphy—a simplified approach. Marienhagen J, et al. **Nuklearmedizin** 1996 Feb; 35(1):20–4
The European spine phantom: reply to Dr Peter Tothill's letter [letter] Reeve J, et al. **Osteoporos Int** 1996;6(2):183–4
The effect of scattered radiation in dual–energy analysis. Baba–Hamed T, et al. **Phys Med Biol** 1995 Oct; 40(10):1619–32
Diffusion in Fe(II/III) radiation dosimetry gels measured by magnetic resonance imaging. Balcom BJ, et al. **Phys Med Biol** 1995 Oct;40(10):1665–76
Measurement of dynamic wedge angles and beam profiles by means of MRI ferrous sulphate gel dosimetry. Bengtsson M, et al. **Phys Med Biol** 1996 Feb;41(2):269–77
Filtered backprojection reconstruction of combined parallel beam and cone beam SPECT data. Defrise M, et al. **Phys Med Biol** 1995 Sep;40(9):1517–37
A portal image alignment and patient setup verification procedure using moments and correlation techniques. Dong L, et al. **Phys Med Biol** 1996 Apr;41(4):697–723
Anthropomorphic phantom measurements for the validation of a treatment planning system. Dunscombe P, et al. **Phys Med Biol** 1996 Mar;41(3):399–411
A study of various parameters of spherically curved phased arrays for noninvasive ultrasound surgery. Fan X, et al. **Phys Med Biol** 1996 Apr;41(4):591–608
An investigation of light transport through scattering bodies with non–scattering regions. Firbank M, et al. **Phys Med Biol** 1996 Apr;41(4):767–83
Characteristics of the absorbed dose to water standard at ENEA. Guerra AS, et al. **Phys Med Biol** 1996 Apr; 41(4):657–74
Experimental determination of the beam quality dependence factors, kQ, for ionization chambers used in photon and electron dosimetry. Guerra AS, et al. **Phys Med Biol** 1995 Jul;40(7):1177–90
10 MV x–ray SMRs obtained using zero–area S(p) correction factors derived by means of the Bjärngard–Petti method. Iwasaki A. **Phys Med Biol** 1996 Apr;41(4):625–36
K x–ray fluorescence measurements of bone lead concentration: the analysis of low–level data. Kim R, et al. **Phys Med Biol** 1995 Sep;40(9):1475–85
Limitations of a pencil beam approach to photon dose calculations in lung tissue. Knöös T, et al. **Phys Med Biol** 1995 Sep;40(9):1411–20
The influence of glucose concentration upon the transport of light in tissue–simulating phantoms. Kohl M, et al. **Phys Med Biol** 1995 Jul;40(7):1267–87
A dynamic phantom brain model for near–infrared spectroscopy. Kurth CD, et al. **Phys Med Biol** 1995 Dec; 40(12):2079–92
Transmission maximum–likelihood reconstruction with ordered subsets for cone beam CT. Manglos SH, et al. **Phys Med Biol** 1995 Jul;40(7):1225–41
Ionization chamber dosimetry of proton beams using cylindrical and plane parallel chambers. Nw versus Nk ion chamber calibrations. Medin J, et al. **Phys Med Biol** 1995 Jul;40(7):1161–76
Wall effects in plane–parallel ionization chambers. Nilsson B, et al. **Phys Med Biol** 1996 Apr;41(4):609–23
Proton dose monitoring with PET: quantitative studies in Lucite. Oelfke U, et al. **Phys Med Biol** 1996 Jan; 41(1):177–96
Model–based scatter correction for fully 3D PET. Ollinger JM. **Phys Med Biol** 1996 Jan;41(1):153–76
Application of a surface matching image registration technique to the correlation of cardiac studies in positron emission tomography (PET) by transmission images. Pallotta S, et al. **Phys Med Biol** 1995 Oct;40(10):1695–708
Limiting values of backscatter factors for low–energy x–ray beams. Patrocinio HJ, et al. **Phys Med Biol** 1996 Feb; 41(2):239–53
Initial assessment of a simple system for frequency domain diffuse optical tomography. Pogue BW, et al. **Phys Med Biol** 1995 Oct;40(10):1709–29
The physical performance of different x–ray contrast agents: calculations using a Monte Carlo model of the imaging chain. Sandborg M, et al. **Phys Med Biol** 1995 Jul; 40(7):1209–24
A model for ultrasonic scattering from tissues based on the K distribution. Shankar PM. **Phys Med Biol** 1995 Oct; 40(10):1633–49
An improved energy–range relationship for high–energy electron beams based on multiple accurate experimental and Monte Carlo data sets. Sorcini BB, et al. **Phys Med Biol** 1995 Jul;40(7):1135–59
Calculation of the absorbed dose distribution due to irregularly shaped photon beams using pencil beam kernels derived form basic beam data. Storchi P, et al. **Phys Med Biol** 1996 Apr;41(4):637–56
A table of phantom scatter factors of photon beams as a function of the quality index and field size. Storchi P, et al. **Phys Med Biol** 1996 Mar;41(3):563–71
Computer–aided design optimization with the use of a fast dose model for linear–accelerator–based stereotactic radiosurgery. Suh TS, et al. **Phys Med Biol** 1996 Apr; 41(4):675–96
An estimation of the relative biological effectiveness of 50 MV bremsstrahlung beams by microdosimetric techniques. Tilikidis A, et al. **Phys Med Biol** 1996 Jan;41(1):55–69
Monte Carlo calculations of epithermal boron neutron capture therapy with heavy water. Wallace SA, et al. **Phys Med Biol** 1995 Oct;40(10):1599–608
Intensity–modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Yu CX. **Phys Med Biol** 1995 Sep;40(9):1435–49
Single–photon transmission measurements in positron tomography using 137Cs. Yu SK, et al. **Phys Med Biol** 1995 Jul;40(7):1255–66
A Green's function method for heavy ion beam transport. Shinn JL, et al. **Radiat Environ Biophys** 1995 Aug; 34(3):155–9
Composition of mammographic phantom materials. Geise RA, et al. **Radiology** 1996 Feb;198(2):347–50
Mammographic phantom studies with synchrotron radiation. Johnston RE, et al. **Radiology** 1996 Sep;200(3):659–63
Stereotactic localization using magnetic resonance imaging. Walton L, et al. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:155–63
A method for estimating an overlying layer correction in quantitative ultrasound imaging. Lu ZF, et al. **Ultrason Imaging** 1995 Oct;17(4):269–90
Effects of shadowing on the time–intensity curves in contrast echocardiography: a phantom study. Bos LJ, et al. **Ultrasound Med Biol** 1996;22(2):217–27
A model based on dimensional analysis for noninvasive quantification of valvular regurgitation under confined and impinging conditions: in vitro pulsatile flow validation. Burleson AC, et al. **Ultrasound Med Biol** 1995; 21(7):899–911
[Evaluation of non–uniform attenuation correction using simultaneous transmission and emission computed tomography—basic analysis with myocardial phantom] Otake H, et al. **Kaku Igaku** 1996 Mar;33(3):273–7 (Eng. Abstr.) **(Jpn)**
[Computed radiography in X–ray examination of stomach: evaluation by phantom experiments and clinical studies] Murakami M. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug;55(9):651–8 (Eng. Abstr.) **(Jpn)**
[Estimation of effective dose from CT examination] Nishizawa K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):763–8 (Eng. Abstr.) **(Jpn)**
[Evaluation of data compression in gastrointestinal examinations using computed radiography] Uchida K. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun;56(7):482–9 (Eng. Abstr.) **(Jpn)**

PHANTOMS, RADIOGRAPHIC see **PHANTOMS, IMAGING**

PHANTOMS, RADIOLOGIC see **PHANTOMS, IMAGING**

PHARMACEUTIC AIDS

ADVERSE EFFECTS

Anaphylactic shock following povidone. Gonzalo Garijo MA, et al. **Ann Pharmacother** 1996 Jan;30(1):37–40

CHEMISTRY

A new drug delivery system using plasma–irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma–irradiated double–compressed tablet composed of water–soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192–5
Stability of drug additives to peritoneal dialysate. Bailie GR, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):328–35

PHARMACOLOGY

Percutaneous penetration of fluorescein isothiocyanate–dextrans and the mechanism for enhancement effect of enhancers on the intercellular penetration. Ogiso T, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1566–71
Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. Bai JP, et al. **J Pharm Sci** 1995 Nov;84(11):1291–4

POISONING

[Camphor poisoning: repeatedly? (letter)] Larchet M, et al. **Arch Pediatr** 1995 Nov;2(11):1121 **(Fre)**

RADIATION EFFECTS

A new drug delivery system using plasma–irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma–irradiated double–compressed tablet composed of water–soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192–5

PHARMACEUTIC AIDS (PRESERVATIVES) see **PRESERVATIVES, PHARMACEUTICAL**

PHARMACEUTICAL ECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACEUTICAL SERVICES

The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis. Malta E. **Adv Neurol** 1995; 68:263–9; discussion 271–5
It's about lives, not just numbers [editorial] Yarborough P. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2668
Consultant pharmacy as a career or practice–building option. Allen WO. **Am Pharm** 1995 Nov;NS35(11):55–60; quiz 60–1
Pharmaceutical (who) care(s)? Cohen MR. **Am Pharm** 1995 Nov;NS35(11):37–8; discussion 38–40
Winning payment for cognitive services: what works. Constantine LM, et al. **Am Pharm** 1995 Sep;NS35(9):14–9
Alaskan adventures in pharmacy. Keeney EM. **Am Pharm** 1995 Oct;NS35(10):24
Helping pharmacists provide disease–based pharmaceutical care. Meade V. **Am Pharm** 1995 Mar;NS35(3):45–8
An introduction to patient care outcomes: linking science with practice. Pathak DS, et al. **Am Pharm** 1995 Oct; NS35(10):36–7
Eight steps toward payment for cognitive services. Perri M 3rd. **Am Pharm** 1995 Sep;NS35(9):20–4
Standardizing documentation for filing pharmaceutical care claims. Rupp MT. **Am Pharm** 1995 Sep;NS35(9):26–30
The role of technology in patient care [comment] Beardsley RS. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):315. Comment on: J Am Pharm Assoc (Wash) 1996 May;NS36(5):309–14.
Clinical monitoring plans for the delivery of pharmaceutical care. Munroe WP. **J Am Pharm Assoc (Wash)** 1996 Jun; NS36(6):397–402; quiz 402–4
Compensation in Canada for resolving drug–related problems. Poirier S, et al. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):117–22
'Concept pharmacy': bringing pharmaceutical care to life. Stover KA. **J Am Pharm Assoc (Wash)** 1996 Feb; NS36(2):141–2
APhA House of Delegates adopts 13 new policies. Stover KA. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):394–6
Evolving role of the pharmacist in the critical care environment. Dasta JF. **J Clin Anesth** 1996 May;8(3 Suppl):99S–102S (31 ref.)
[Drug–to–drug interactions and pharmaceutical advice] Sáenz Calvo A, et al. **Aten Primaria** 1996 May 31; 17(9):559–63 (Eng. Abstr.) **(Spa)**

ECONOMICS

Understanding capitation and pharmaceutical care. Christensen DB, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):374–80,404
[The allocation of the pharmacy budget to health centers] Benavent Areu J, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):116–21 (Eng. Abstr.) **(Spa)**

HISTORY

[Pharmaceutical services at the beginning of the 19th century with reference to 1815 fees of Bern drugs] Ledermann F. **Gesnerus** 1996;53(1–2):34–48 (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

HMO pharmacy directors' opinions of acquisition of pharmacy benefit management companies. Lawrence DB, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1547–9
The asthma year in Swedish pharmacies: a nationwide information and pharmaceutical care program for patients with asthma. Lisper B, et al. **Ann Pharmacother** 1996 May; 30(5):455–60
Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies [see comments]

Hammarström B, et al. **J Clin Pharm Ther** 1995 Dec; 20(6):327–34. Comment in: J Clin Pharm Ther 1995 Dec;20(6):310–2.

Clinical radiopharmacy: principles and practices. Rhodes BA, et al. **Semin Nucl Med** 1996 Apr;26(2):77–84

[The new pharmacy practice: can pharmaceutical intervention improve therapeutical efficiency] Alvarez de Toledo F, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):277–82 (19 ref.) (Eng. Abstr.) **(Spa)**

[Save the effective monopoly of Apoteksbolaget! (letter)] Melander A, et al. **Lakartidningen** 1996 Jul 10; 93(28–29):2564–5 **(Swe)**

STANDARDS

ASHP guidelines on pharmaceutical services in correctional facilities. American Society of Health–System Pharmacists. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1810–3

Correctional facilities guidelines [letter] Cason D, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):320; discussion 320, 325

The challenge of postal medicine [letter] Rothschild BM. **Ann Intern Med** 1996 Feb 15;124(4):454–5

Consumer watch–dog criticises pharmacy staff [letter] Court C. **BMJ** 1996 Jan 13;312(7023):74

STATISTICS & NUMERICAL DATA

Small group intervention vs formal seminar for improving appropriate drug use. Santoso B. **Soc Sci Med** 1996 Apr; 42(8):1163–8

SUPPLY & DISTRIBUTION

Correctional facilities guidelines [letter] Babb J. **Am J Health Syst Pharm** 1996 Feb 1;53(3):315, 320; discussion 320, 325

TRENDS

The third strategic–planning conference for pharmacy practice. **Am J Health Syst Pharm** 1995 Oct 15; 52(20):2217–23

Pharmacy factors that influence the success of integrated health care systems. Penna PM. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S7–10

Liability and the changing role of pharmacists. Fink JL 3rd. **Am Pharm** 1995 Dec;NS35(12):34–5

Recent advances: ambulatory care and family medicine. Gums JG. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):716–8 (10 ref.)

Pharmaceutical care innovations in Japan. Akaho E, et al. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):123–7

Moving pharmacists toward providing pharmaceutical care. Stover KA. **J Am Pharm Assoc (Wash)** 1996 Feb; NS36(2):137–40

The role of commercial nuclear pharmacy in the future practice of nuclear medicine. Callahan RJ. **Semin Nucl Med** 1996 Apr;26(2):85–90

[The evolution of pharmaceutical services and drug consumption in Spain (letter)] del Río MC, et al. **Aten Primaria** 1996 Jul–Aug;18(3):148–9 **(Spa)**

PHARMACIES

Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales [see comments] Sheridan J, et al. **BMJ** 1996 Aug 3;313(7052):272–4. Comment in: BMJ 1996 Aug 3;313(7052):245–6.

Advertising health risk products: ethics vs. economics. Gupta S, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):381–2

Tobacco advertising in pharmacies [letter] Brenner SA. **J Fam Pract** 1996 Mar;42(3):308–9

Pharmacies and prevention of potentially fatal drug interactions [letter; comment] Cavuto NJ, et al. **JAMA** 1996 Apr 10;275(14):1086–7. Comment on: JAMA 1995 Jul 5;274(1):29–34. Comment on: JAMA 1995 Jul 5;274(1):35–43.

A community–based clinical pharmacy teaching, research, and service program in Zimbabwe. Maponga CC, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):614–20

[Mail order–pharmacies are a new and controversial phenomenon in the USA] Bergström L. **Lakartidningen** 1996 Aug 7;93(32–33):2718 **(Swe)**

[A comment to the discussion on drug utilization. Pharmacies owned by county councils should reduce drug costs] Lindvall IH. **Lakartidningen** 1996 Jun 19;93(25):2403–4 **(Swe)**

[Save the effective monopoly of Apoteksbolaget! (letter)] Melander A, et al. **Lakartidningen** 1996 Jul 10; 93(28–29):2564–5 **(Swe)**

ECONOMICS

Pharmaceuticals. Rural drugstore's bitter pill. MacPherson P. **Hosp Health Netw** 1996 May 5;70(9):58

LEGISLATION & JURISPRUDENCE

Corporate pharmacy's responsibility for a dispensing error. Brushwood DB, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):668–70

ORGANIZATION & ADMINISTRATION

Work activities at an ambulatory care pharmacy with an integrated model of pharmacy practice. Nickman NA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):397–402

STANDARDS

Professionalism in the community pharmacy setting [letter] Odedina FT. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1572

Dispensing errors and counseling in community practice. Allan EL, et al. **Am Pharm** 1995 Dec;NS35(12):25–33

STATISTICS & NUMERICAL DATA

Retail pharmacies in developing countries: a behavior and intervention framework. Goel P, et al. **Soc Sci Med** 1996 Apr;42(8):1155–61

PHARMACISTS

AIDS prevention training for pharmacy workers in Mexico City. Pick S, et al. **AIDS Care** 1996 Feb;8(1):55–69

Pharmacists as HIV/AIDS information resources: survey of Alabama pharmacists. Binkley D, et al. **AIDS Educ Prev** 1995 Oct;7(5):455–66

Handling the first dose of a questionable order. Aebi C. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2092–4

Liability insurance coverage for nontraditional services. Almquist DD. **Am J Health Syst Pharm** 1996 Mar 1; 53(5):510

Introduction to pharmacist participation in measuring and monitoring patients' health–related quality of life. Bungay KM, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S19–23

Creating patient care opportunities. Glover J. **Am J Health Syst Pharm** 1996 Mar 1;53(5):512–3

Drug reactions identified at resident physicians' morning report [letter] Kaufman MB. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2031

Computer–guided academic detailing as part of a drug benefit program. Keys PW, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2199–203; discussion 22034

Panelists describe collaborative drug therapy management efforts. Landis NT. **Am J Health Syst Pharm** 1996 Mar 1;53(5):501–2, 505–6

Using pharmacists' documentation of clinical activities to reclaim employees and reposition the department. McDaniel MR, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):285–8

What pharmacists should understand about homeopathic remedies. McDermott JH, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2442–5

Pharmaceutical aspects of mucositis mouthwash mixtures [letter] Mueller BA, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2596–7

Pharmacist–managed ticlopidine clinic [letter] Pecini M. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2030–1

Riding into battle without a pharm.D. degree. Roberts BL Jr. **Am J Health Syst Pharm** 1995 Sep 15;52(18):1981–2

Survey of board–certified pharmacotherapy specialists in Minnesota [letter] Shepherd MF, et al. **Am J Health Syst Pharm** 1996 Apr 15;53(8):942, 944–5

Patient advocacy and interests of the pharmacist's employer [letter] Sloan HS. **Am J Health Syst Pharm** 1996 Feb 1; 53(3):315

Lessons from the other literature [editorial] Talley CR. **Am J Health Syst Pharm** 1996 Mar 1;53(5):517

The Code of Ethics for pharmacists [editorial] Vottero LD. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2096

Pharmacists and stroke prevention [editorial] Wittkowsky AK. **Am J Health Syst Pharm** 1996 May 1;53(9):1009

Preventing medication errors. Wyman CM. **Am J Health Syst Pharm** 1996 Feb 1;53(3):257–8

Collaborative drug therapy management [see comments] Zellmer WA. **Am J Health Syst Pharm** 1995 Aug 1; 52(15):1732. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Consultant pharmacy as a career or practice–building option. Allen WO. **Am Pharm** 1995 Nov;NS35(11):55–60; quiz 60–1

Demystifying outcomes for the pharmacist. Cinque MP. **Am Pharm** 1995 Oct;NS35(10):38–9

Response to: 'a mother's perspective' [letter] Cooper MJ. **Am Pharm** 1995 Sep;NS35(9):4

Liability and the changing role of pharmacists. Fink JL 3rd. **Am Pharm** 1995 Dec;NS35(12):34–5

Advanced counseling techniques: integrating assessment and intervention. Foster SL, et al. **Am Pharm** 1995 Oct; NS35(10):40–8; quiz 48–50 (10 ref.)

Evaluating employee benefits: insurance and flexible spending. Goodyear JA. **Am Pharm** 1995 Sep; NS35(9):38–40

Avoiding liability problems. American Pharmaceutical Association. Lynn NJ, et al. **Am Pharm** 1995 Dec; NS35(12):14–22; quiz 23–4

Practical considerations in anticonvulsant therapy—Part 2. Meyer MC, et al. **Am Pharm** 1995 Sep;NS35(9):31–6, 40

The pharmacist's role on the hospital patient management team. Ronshagen J. **Am Pharm** 1995 Sep;NS35(9):54–9; quiz 59–60

Pharmacists are heroes, too. Sagraves R. **Am Pharm** 1995 Oct;NS35(10):33–4

Spotlighting working conditions, payment systems. Stover KA. **Am Pharm** 1995 Mar;NS35(3):49–52

HIV infection and AIDS: attitudes and knowledge of Arizona pharmacists. Katz MD, et al. **Ann Pharmacother** 1995 Dec;29(12):1218–23

Identifying inappropriate prescribing in the elderly: time to refocus [editorial] Plushner S, et al. **Ann Pharmacother** 1996 Jan;30(1):81–3

Urinary excretion of cyclophosphamide [letter; comment] Ehrsson H. **Arch Environ Health** 1995 Sep–Oct;50(5):396–7 . Comment on: Arch Environ Health 1994 May–Jun;49(3):165–9.

Evaluation of a primary care anticoagulant clinic. Issue of quality control was not addressed [letter; comment] Adlakha S, et al. **BMJ** 1996 Jun 22;312(7046):1609; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Over the counter drugs. The interface between the community pharmacist and patients [see comments] Bond CM, et al. **BMJ** 1996 Mar 23;312(7033):758–60. Comment in: BMJ 1996 Jul 13;313(7049):116.

Evaluation of a primary care anticoagulant clinic. Reporting of results should be standardised [letter; comment] Fitzmaurice DA, et al. **BMJ** 1996 Jun 22; 312(7046):1609–10; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Evaluation of a primary care anticoagulant clinic. Authors did not present enough data [letter; comment] Fowlie PW. **BMJ** 1996 Jun 22;312(7046):1609. Comment on: BMJ 1996 Mar 2;312(7030):560.

Evaluation of a primary care anticoagulant clinic managed by a pharmacist [see comments] Macgregor SH, et al. **BMJ** 1996 Mar 2;312(7030):560. Comment in: BMJ 1996 Jun 22;312(7046):1609. Comment in: BMJ 1996 Jun 22;312(7046):1609; discussion 1610. Comment in: BMJ 1996 Jun 22;312(7046):1609–10; discussion 1610.

Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485–508 (138 ref.)

Pharmacist counseling of older people [letter] Kimminau KS, et al. **J Am Geriatr Soc** 1996 Mar;44(3):335–6

Getting the most from your employee benefits: retirement plans. Goodyear JA. **J Am Pharm Assoc (Wash)** 1996 Jun; NS36(6):383–5

Advertising health risk products: ethics vs. economics. Gupta S, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):381–2

Compensation in Canada for resolving drug–related problems. Poirier S, et al. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):117–22

An atmosphere of mistrust. Ponte CD. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):322

The pharmacist as self–care advisor. Pray WS. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):329–40; quiz 340–2

APhA House of Delegates adopts 13 new policies. Stover KA. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):394–6

Moving pharmacists toward providing pharmaceutical care. Stover KA. **J Am Pharm Assoc (Wash)** 1996 Feb; NS36(2):137–40

The impact of clinical pharmacy intervention in a psychiatric hospital. Dorevitch A, et al. **J Clin Pharm Ther** 1996 Feb; 21(1):45–8

Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies [see comments] Hammarström B, et al. **J Clin Pharm Ther** 1995 Dec; 20(6):327–34. Comment in: J Clin Pharm Ther 1995 Dec;20(6):310–2.

Extended roles for pharmacists in caring for skin conditions: a welcome development which needs further evaluation [editorial; comment] Williams HC. **J Clin Pharm Ther** 1995 Dec;20(6):310–2. Comment on: J Clin Pharm Ther 1995 Dec;20(6):327–34.

Preoperative assessment and postoperative management of the elderly surgical patient [letter; comment] Gelb JJ. **Med J Aust** 1996 Mar 18;164(6):383–4. Comment on: Med J Aust 1995 Sep 18;163(6):328–30.

Impact of pharmacist counseling on medication knowledge and compliance. Williford SL, et al. **Mil Med** 1995 Nov; 160(11):561–4

The role of pharmacists in the recruitment of a cohort for postmarketing surveillance. A case study of acitretin in The Netherlands. Sturkenboom MC, et al. **Pharm World Sci** 1995 Jul 28;17(4):126–32

Outcome analysis of a pharmacist–managed anticoagulation service. Wilt VM, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):732–9

Doctor/pharmacist—a unique group practice [editorial] Dreyer AC, et al. **S Afr Med J** 1995 Oct;85(10):986–8

Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Torinuki W. **Tohoku J Exp Med** 1995 Aug;176(4):249–52

[Role of pharmacist in cancer pain management] Yoshida S, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:365–73 (Eng. Abstr.) **(Jpn)**

[Improved information on drugs to patients. A project with a pharmacist in the therapeutic team at a cardiology department] Veggeland T. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1901–3 (Eng. Abstr.) **(Nor)**

[Smoking cessation program using nicotine patch among physicians and pharmacists of Catalonia: results after 3–12 months] Pardell H, et al. **An Med Interna** 1996 Jan; 13(1):16–20 (Eng. Abstr.) **(Spa)**

[Physicians and pharmacists should cooperate more and

more! It is beneficial for independent drug information] Nilsson JL. **Lakartidningen** 1996 Apr 17;93(16):1507–8 **(Swe)**

EDUCATION see EDUCATION, PHARMACY

LEGISLATION & JURISPRUDENCE

Pharmacists' duty to refrain from dispensing potentially addictive medication if necessary. Mullan K, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):308–10

Unsafe activities of compounding pharmacists [letter] Perrin JH. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2827–8

Requirements for pharmacists dispensing ephedrine products. Stein GC. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1630

Pharmacist prescribing [editorial; comment] Talley CR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1635. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1616, 1620, 1623–4. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1693–5. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1699–701. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1732.

Obtaining prescribing authority for pharmacists: lessons learned [see comments] Wittenburg AS. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1616, 1620, 1623–4. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Update on state prescribing authority. Flanagan ME. **Am Pharm** 1995 Oct;NS35(10):12–8

ORGANIZATION & ADMINISTRATION

Do pharmacists need prescribing privileges to implement pharmaceutical care? [see comments] Carmichael JM. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1699–701. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

The key to pharmacist prescribing: collaboration. Galt KA. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1696–9

Prescribing medications: changing the paradigm for a changing health care system [see comments] Webb CE. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1693–5. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

PSYCHOLOGY

Sibling rivalry? [letter] DeNunzio D, et al. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1707

Ethical opinion in a formulary recommendation. DuChane J, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1564; discussion 1564–8

Predictors of organizational and career commitment among Illinois pharmacists. Kong SX. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2005–11

HMO pharmacy directors' opinions of acquisition of pharmacy benefit management companies. Lawrence DB, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1547–9

Relationship between hospital pharmacists' job satisfaction and involvement in clinical activities. Olson DS, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):281–4

Making a difference for patients, one pharmacist at a time. Raehl CL. **Am J Health Syst Pharm** 1995 Aug 1; 52(15):1663–6, 1675

Prescribing authority: an examination of Ohio pharmacists' opinions. Desikan R, et al. **Am Pharm** 1995 Oct; NS35(10):19–23

Secundum artem, or the sensory side of pharmacy. Glover MF. **Am Pharm** 1995 Oct;NS35(10):35, 50

Attitudes of Bolivian pharmacists in dealing with diarrhea cases. Zamora Gutiérrez AD, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):322–7

The role of the community pharmacist as a dental health adviser. Dickinson C, et al. **Community Dent Health** 1995 Dec;12(4):235–7

Chain pharmacists' attitudes on and awareness of domestic abuse. Ford J, et al. **J Am Pharm Assoc (Wash)** 1996 May; NS36(5):323–8

STANDARDS

Quality-assurance testing of staff pharmacists handling cytotoxic agents. Harrison BR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):402–7

Professionalism in the community pharmacy setting [letter] Odedina FT. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1572

Unsubstantiated maligning of pharmacists who compound [letter] Padron VA. **Am J Health Syst Pharm** 1996 May 1;53(9):1080

Asking a pharmacist to resign for making an error. Peterson AM, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):760–3

Meeting Joint Commission requirements for competence assessment. Rich DS. **Am J Health Syst Pharm** 1996 Apr 1;53(7):726, 729

Sterile cockpit. Davis NM, et al. **Am Pharm** 1995 Dec; NS35(12):11

Improving communication between general practitioners and pharmacists. Joint statement by the Royal Australian College of General Practitioners and the Pharmaceutical Society of Australia. Bollen M. **Aust Fam Physician** 1996 Jul;25(7):1011–3

Pill or people?—the choice is ours. Raleigh F. **J Clin Pharm Ther** 1996 Feb;21(1):1–2

SUPPLY & DISTRIBUTION

Bolstering requests for more personnel. Steffen WM, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1006–7

UTILIZATION

Advice about management of skin conditions in the community: who are the providers? Yeatman JM, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S46–7

PHARMACISTS' AIDES

EDUCATION

AIDS prevention training for pharmacy workers in Mexico City. Pick S, et al. **AIDS Care** 1996 Feb;8(1):55–69

STANDARDS

The national voluntary certification program for pharmacy technicians. Smith JE. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2026–9

UTILIZATION

Technician checking of pharmacists computerized order entry for parenteral nutrient solutions. Fields HS. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1801–2

PHARMACOECONOMICS see ECONOMICS, PHARMACEUTICAL

PHARMACOEPIDEMIOLOGY

A survey of population-based drug databases in Canada. Miller E, et al. **Can Med Assoc J** 1996 Jun 15; 154(12):1855–64

Pharmacoepidemiology in practice. Current status and future trends. Alvarez-Requejo A, et al. **Drug Saf** 1995 Jul; 13(1):1–7 (39 ref.)

Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Rossiter BJ, et al. **Drugs Aging** 1995 Aug;7(2):117–30 (131 ref.)

Drug Utilization Research and Pharmacoepidemiology meeting. Utrecht, the Netherlands, 19 May 1995. Abstracts. **Pharm World Sci** 1995 Sep 22;17(5 Suppl I):11–7

[Individual-based statistics on drug utilization] Hallas J, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):41–6 (Eng. Abstr.) **(Dan)**

EDUCATION

Pharmacoepidemiology graduate course [letter] Nguyen VX. **Ann Pharmacother** 1995 Nov;29(11):1169–70

METHODS

Comparing period prevalences with application to drug utilization. McFarland BH. **J Clin Epidemiol** 1996 Apr; 49(4):473–82 (21 ref.)

[Significance of pharmacoepidemiology for drug monitoring and quality of care: the pill] Stricker BH, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2541–3 **(Dut)**

STANDARDS

From the Food and Drug Administration. Nightingale SL. **JAMA** 1995 Oct 11;274(14):1109

TRENDS

[Future drug utilization] Højgaard L. **Ugeskr Laeger** 1995 Oct 2;157(40):5562 **(Dan)**

PHARMACOGENETICS

Mechanisms of drug eruptions: Part I. Breathnach SM. **Australas J Dermatol** 1995 Aug;36(3):121–7 (100 ref.)

Pharmacogenetic models of alcoholism. Li TK, et al. **Clin Neurosci** 1995;3(3):182–8 (62 ref.)

Genetic susceptibility in the occupational setting: introduction to the workshop. Caporaso N. **Med Lav** 1995 May-Jun;86(3):199–206

[Variability of drug effects and pharmacogenetics] Jacqz-Aigrain E. **Arch Pediatr** 1996;3 Suppl 1:226s–228s **(Fre)**

[Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica] Jorge LF, et al. **Rev Med Panama** 1995 Sep;20(3):98–107 (Eng. Abstr.) **(Spa)**

METHODS

[Gene therapy, gene pharmacology: concepts, fields of application, problems] Müller H. **Ther Umsch** 1995 Dec; 52(12):853–8 (Eng. Abstr.) **(Ger)**

TRENDS

Pharmacogenetics in the new patterns of healthcare delivery. Idle JR, et al. **Pharmacogenetics** 1995 Dec;5(6):347–50

PHARMACOGNOSY

Recent advances in pharmacognosy research in China. Wang ZT, et al. **Gen Pharmacol** 1995 Oct;26(6):1211–24 (186 ref.)

20th Belgian-Dutch LOF-Symposium on Pharmacognosy and Natural Products Chemistry. Paclitaxel and other taxanes as new anti-cancer drugs. Leiden, The Netherlands, 24 November 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl N):N1–14

[New theoretical study on the biological origins of Chinese medicinal herbs] Xie Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):259–61, 318 (Eng. Abstr.) **(Chi)**

HISTORY

[Departure of pharmacognosy from the Josephinum institute] Holubar K. **Wien Klin Wochenschr** 1995;107(17):532–3 **(Ger)**

PHARMACOKINETICS

Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Thomas RS, et al. **Am Ind Hyg Assoc J** 1996 Jan;57(1):23–32

Clarification of kinetic terminology [letter] Overdyk FJ, et al. **Anesthesiology** 1996 Aug;85(2):446–7

Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials. Ebling WF, et al. **Ann Pharmacother** 1996 Jan;30(1):12–9

A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. Ishii K, et al. **Biol Pharm Bull** 1995 Jun;18(6):882–6

The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism. Cheng H. **Biopharm Drug Dispos** 1995 Dec; 16(9):791–6

Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Iwatsubo T, et al. **Biopharm Drug Dispos** 1996 May;17(4):273–310 (123 ref.)

Methodology for using oral dose pharmacokinetic data to select drugs for prolonged release formulations and validation of the method using simulated data. Zhou M, et al. **Biopharm Drug Dispos** 1995 May;16(4):319–31

Effects of cellular pharmacology on drug distribution in tissues. Rippley RK, et al. **Biophys J** 1995 Sep;69(3):825–39

An in vitro technique for the rapid determination of drug entry into breast milk. Notarianni LJ, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):333–7

Drug removal in continuous haemofiltration and haemodialysis. Davies JG, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):524–8 (30 ref.)

Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain. de Lange EC, et al. **Br J Pharmacol** 1995 Nov;116(5):2538–44

Building a structured model of a complex pharmacokinetic system with time delays. Ďurišová M, et al. **Bull Math Biol** 1995 Nov;57(6):787–808

The 1994 G. Malcolm Brown Lecture. Biological barriers and medicine. Goresky CA. **Clin Invest Med** 1995 Dec; 18(6):484–501 (23 ref.)

The backpropagation neural network—a Bayesian classifier. Introduction and applicability to pharmacokinetics. Erb RJ. **Clin Pharmacokinet** 1995 Aug;29(2):69–79 (50 ref.)

Clinical pharmacokinetics of various topical ophthalmic delivery systems. Frangie JP. **Clin Pharmacokinet** 1995 Aug;29(2):130–8 (37 ref.)

Input from the deep south compartment. A personal viewpoint [editorial] Holford NH. **Clin Pharmacokinet** 1995 Sep;29(3):139–41

The target concentration approach to clinical drug development. Holford NH. **Clin Pharmacokinet** 1995 Nov; 29(5):287–91 (17 ref.)

A size standard for pharmacokinetics. Holford NH. **Clin Pharmacokinet** 1996 May;30(5):329–32

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Morgan DJ, et al. **Clin Pharmacokinet** 1995 Nov; 29(5):370–91 (145 ref.)

Estimating bioavailability when clearance changes in time: the effect of model misspecification [letter; comment] Fattinger KE, et al. **Clin Pharmacol Ther** 1995 Nov; 58(5):595–600. Comment on: Clin Pharmacol Ther 1994 Jun;55(6):623–37.

Analytical information is mandatory for pharmacokinetic papers [letter; comment] Klotz U. **Clin Pharmacol Ther** 1996 Apr;59(4):482. Comment on: Clin Pharmacol Ther 1994 Sep;56(3):279–85.

Effects of dietary fat on drug absorption. Zhi J, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):487–91 (47 ref.)

Species similarities and differences in pharmacokinetics. Lin JH. **Drug Metab Dispos** 1995 Oct;23(10):1008–21 (141 ref.)

Drug interactions of clinical importance. An updated guide. Quinn DI, et al. **Drug Saf** 1995 Jun;12(6):393–452 (14 ref.)

Gender effects in pharmacokinetics and pharmacodynamics. Harris RZ, et al. **Drugs** 1995 Aug;50(2):222–39 (170 ref.)

Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)

Limitations of the maximum entropy principle in devising drug input rate. Paintaud G, et al. **Eur J Clin Pharmacol** 1995;49(1–2):139–43

BIO-international '94 Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies and Pre-Conference Satellite on 'In Vivo/In Vitro Correlation'. Munich, Germany, June 14–17, 1994. Blume

HH, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan-Mar; 20(1):3-13

Pharmacokinetics during continuous renal replacement therapy. Keller E. **Int J Artif Organs** 1996 Feb;19(2):113-7 (8 ref.)

Unifying concept of pharmacokinetics derived from drug distribution and elimination in renal failure. Keller F, et al. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):546-9

Computation of the initial distribution of a drug by repetitive convolution with a circulatory transport function. Schröder T, et al. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):565-8

Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit. Tanswell P, et al. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):550-4

Analysis of errors due to assigned model constants in pharmacokinetic calculations based on functional optimization. Thomaseth K. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):555-9 (8 ref.)

Pharmacokinetics of continuous renal replacement therapy. Schetz M, et al. **Intensive Care Med** 1995 Jul;21(7):612-20 (33 ref.)

Directional decision for a two-tailed alternative [letter] Hauschke D, et al. **J Biopharm Stat** 1996 May;6(2):211-8

Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. Krewski D, et al. **J Biopharm Stat** 1995 Nov;5(3):245-71

A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. Mentré F, et al. **J Biopharm Stat** 1995 Jul;5(2):141-58

A model for estimating individualized valproate clearance values in children. Botha JH, et al. **J Clin Pharmacol** 1995 Oct;35(10):1020-4

Artificial neural netw[illegible] as a novel approach to integrated pharmacokinetic-[illegible]macodynamic analysis. Gobburu JV, et al. **J Pharm** [illegible]. 1996 May;85(5):505-10

A novel multivariate approach for estimating the degree of similarity in bioavailability between two pharmaceutical products. Hsu HC, et al. **J Pharm Sci** 1995 Jun;84(6):768-72

Pharmacokinetic parameter estimations by minimum relative entropy method. Amisaki T, et al. **J Pharmacokinet Biopharm** 1995 Oct;23(5):479-94

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development [see comments] Charnick SB, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):217-29 (70 ref.) . Comment in: J Pharmacokinet Biopharm 1995 Apr;23(2):231-5.

Simulation for population analysis of Michaelis-Menten elimination kinetics. Hashimoto Y, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):205-16

The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications. Hoffman A, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):449-68

Comparison of some control strategies for three-compartment PK/PD models. Hu C, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):525-50

Convergence of direct and indirect pharmacodynamic response models [comment] Jusko WJ, et al. **J Pharmacokinet Biopharm** 1995 Feb;23(1):5-8; discussion 9-10. Comment on: J Pharmacokinet Biopharm 1995 Feb;23(1):1-4.

Commentary on "Physiologically based pharmacokinetic modeling as a tool for drug development" [comment] Ludden TM, et al. **J Pharmacokinet Biopharm** 1995 Apr; 23(2):231-5. Comment on: J Pharmacokinet Biopharm 1995 Apr;23(2):217-30.

Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. Merlé Y, et al. **J Pharmacokinet Biopharm** 1995 Feb;23(1):101-25

Simple approximate formulas for calculating the time to clear drug and the time to accumulate drug when the plasma disposition curve of the drug is multiexponential [letter; comment] Noe DA. **J Pharmacokinet Biopharm** 1994 Dec; 22(6):565-7. Comment on: J Pharmacokinet Biopharm 1980 Jun;8(3):311-8.

A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data [see comments] Verotta D, et al. **J Pharmacokinet Biopharm** 1995 Feb; 23(1):1-4. Comment in: J Pharmacokinet Biopharm 1995 Feb;23(1):5-8; discussion 9-10.

New hepatocellular diffusion model for analysis of hepatobiliary transport processes of drugs. Yasui H, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):183-203

An interactive computer program for determining areas bounded by drug concentration curves using lagrange interpolation. Ediss C, et al. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):165-8

Estimation of oral drug absorption in man based on intestine permeability in rats. Levet-Trafit B, et al. **Life Sci** 1996; 58(24):PL359-63

Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Mahmood I, et al. **Life Sci** 1996;59(7):579-85

Partial identification of underdetermined compartmental models: a method based on positive linear Lyapunov functions. Eisenfeld J. **Math Biosci** 1996 Mar;132(2):111-40

A stochastic model for circulatory transport in pharmacokinetics. Lánský P. **Math Biosci** 1996 Mar; 132(2):141-67

On the correction for radioactive decay in pharmacokinetic modeling. Williams LE, et al. **Med Phys** 1995 Oct; 22(10):1619-26

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Smith DA, et al. **Med Res Rev** 1996 May;16(3):243-66 (54 ref.)

Application of neural networks for the prediction of human pharmacokinetic parameters. Ritschel WA, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):629-43

The pros and cons of drug 'trafficking'. Stokes CL. **Nat Med** 1995 Nov;1(11):1135-6

Membranes and Barriers: Targeted Drug Delivery. Proceedings from a technical review meeting. September 28-29, 1993. **NIDA Res Monogr** 1995;154:1-244

The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Chen ML, et al. **Pharm Res** 1995 May;12(5):700-8

Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Ette EI, et al. **Pharm Res** 1995 May;12(5):729-37

Non steady-state descriptions of drug permeation through stratum corneum. I. The biphasic brick-and-mortar model. Heisig M, et al. **Pharm Res** 1996 Mar;13(3):421-6

A cellular automata model of dissolution. Kier LB, et al. **Pharm Res** 1995 Oct;12(10):1521-5

Compressed donut-shaped tablets with zero-order release kinetics. Kim CJ. **Pharm Res** 1995 Jul;12(7):1045-8

Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs. Kwon Y, et al. **Pharm Res** 1996 Apr;13(4):566-9

Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Stewart BH, et al. **Pharm Res** 1995 May;12(5):693-9

Absorption rate vs. exposure: which is more useful for bioequivalence testing? Tozer TN, et al. **Pharm Res** 1996 Mar;13(3):453-6

MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Urien S. **Pharm Res** 1995 Aug;12(8):1225-30

Effect of nonionic surfactant on transport of model drugs in emulsions. Yoon KA, et al. **Pharm Res** 1996 Mar; 13(3):433-9

Drug release from semisolids: effect of membrane permeability on sensitivity to product parameters. Zatz JL. **Pharm Res** 1995 May;12(5):787-9

Calculating predictive performance: a user's note. Wu G. **Pharmacol Res** 1995 Jun;31(6):393-9

An in vitro perfusion model for the determination of absorption properties of drugs in isolated rat small intestine. Norta M, et al. **Pharmazie** 1996 Feb;51(2):101-3

Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Shigematsu A, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):122-42 (20 ref.)

Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics. Mager H, et al. **Stat Med** 1995 May 15-30; 14(9-10):1009-24

The impact of patient compliance on drug concentration profile in multiple doses. Wang W, et al. **Stat Med** 1996 Mar 30;15(6):659-69

A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Poulin P, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):126-30

Modifying toxicokinetics with antidotes. Baud FJ, et al. **Toxicol Lett** 1995 Dec;82-83:785-93 (20 ref.)

Toxicokinetic models for volatile industrial chemicals and reactive metabolites. Filser JG, et al. **Toxicol Lett** 1995 Dec;82-83:357-66 (28 ref.)

Extrapolation of physiological parameters for physiologically based simulation models. Fiserova-Bergerova V. **Toxicol Lett** 1995 Sep;79(1-3):77-86 (39 ref.)

A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Haddad S, et al. **Toxicol Lett** 1996 May; 85(2):113-26

Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. Hoang K. **Toxicol Lett** 1995 Sep;79(1-3):99-106 (20 ref.)

Development of partition coefficients, Vmax and Km values, and allometric relationships. Knaak JB, et al. **Toxicol Lett** 1995 Sep;79(1-3):87-98 (26 ref.)

Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. Suzuki H, et al. **Toxicol Lett** 1995 Dec;82-83:349-55 (31 ref.)

The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Dec; 82-83:497-504 (21 ref.)

Basic principles of pharmacokinetics. Benet LZ, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):115-23 (15 ref.)

Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies. Dahlem AM, et al. **Toxicol Pathol** 1995 Mar-Apr; 23(2):170-8 (9 ref.)

Food and Drug Administration viewpoints on toxicokinetics: the view from review. DeGeorge JJ. **Toxicol Pathol** 1995 Mar-Apr;23(2):220-5

Absorption, metabolism, and other factors that influence drug exposure in toxicology studies. Mayer PR. **Toxicol Pathol** 1995 Mar-Apr;23(2):165-9

Differences between pharmacokinetics and toxicokinetics. Welling PG. **Toxicol Pathol** 1995 Mar-Apr;23(2):143-7 (23 ref.)

Torsten Teorell, the father of pharmacokinetics. Paalzow LK. **Ups J Med Sci** 1995;100(1):41-6

[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328-34 (71 ref.) **(Fre)**

[Statistic determination of release limits of a finished product active principle compared to drug specification at peremption and eventually at the end of its after reconstitution] Nivet JM. **Ann Pharm Fr** 1996;54(3):131-9 (Eng. Abstr.) **(Fre)**

[Value of population approach in the study of pharmacokinetic variability in pediatrics] Burtin P, et al. **Arch Pediatr** 1996;3 Suppl 1:239s-241s **(Fre)**

[Circadian rhythm in the sensitivity of target systems to drugs: an underestimated phenomenon] Reinberg AE. **Bull Acad Natl Med** 1996 Mar;180(3):533-43; discussion 544-7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of computers to pharmacokinetics, Bayesian approach and population pharmacokinetics] Hecquet B. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:607s-611s (Eng. Abstr.) **(Fre)**

[The fundamentals of pharmacokinetics] Lauven PM, et al. **Anaesthesist** 1995 Sep;44(9):663-76 (14 ref.) **(Ger)**

[Pharmacologic principles of drug prescribing in pregnancy] Estler CJ. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):743-8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Age as a factor in dose-response relationship of drugs] Gundert-Remy U. **Z Gerontol Geriatr** 1995 Nov-Dec; 28(6):408-14 (68 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacokinetic and metabolic studies in the development of drugs] Vereczkey L. **Acta Pharm Hung** 1995 Jul; 65(4):105-11 (Eng. Abstr.) **(Hun)**

[Disease states and changes in drug pharmacokinetics] Ventresca GP, et al. **Clin Ter** 1996 Mar;147(3):131-44 (25 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacokinetics and its methods of investigation (editorial)] Araie M. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):487-8 **(Jpn)**

[Enzyme immunoassay of drug in blood (serum)] Nishihara K. **Nippon Rinsho** 1995 Sep;53(9):2301-9 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular pharmacological and toxicological studies of drug-metabolizing enzymes] Kato R. **Yakugaku Zasshi** 1995 Sep;115(9):661-80 (94 ref.) (Eng. Abstr.) **(Jpn)**

[Drug kinetics in soft contact lenses. I. In vitro studies] Rybakova EG, et al. **Vestn Oftalmol** 1995 Oct-Dec; 111(4):21-4 (Eng. Abstr.) **(Rus)**

[Drug forms for drug delivery into the gastrointestinal tract] Chalabala M, et al. **Ceska Slov Farm** 1995 Oct;44(5):242-5 (Eng. Abstr.) **(Slo)**

PHARMACOLOGY

see related
DRUGS

Drug-NSAID interactions. Small RE, et al. **Am Pharm** 1995 Mar;NS35(3):53-5

Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. Drews J. **Arzneimittelforschung** 1995 Aug;45(8):934-9 (24 ref.)

Pharmacoeconomics: a challenge for clinical pharmacologists. Walley T, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):199-202

Proceeding of the British Pharmacological Society Meeting. 6-8 September 1995. Abstracts. **Br J Pharmacol** 1995 Dec; 116 Suppl:274P-466P

Proceedings of the British Pharmacological Society meeting. 12-14 July 1995. Abstracts. **Br J Pharmacol** 1995 Oct;116 Suppl:1P-273P

Premature babies and pharmacology. Hamilton J. **Can Med Assoc J** 1995 Dec 15;153(12):1745-8

Interest and limits of human tissue and cell use in pharmacotoxicology. Potier M, et al. **Cell Biol Toxicol** 1995 Aug;11(3-4):133-9 (30 ref.)

Input from the deep south compartment. A personal viewpoint [editorial] Holford NH. **Clin Pharmacokinet** 1995 Sep;29(3):139-41

The target concentration approach to clinical drug development. Holford NH. **Clin Pharmacokinet** 1995 Nov; 29(5):287-91 (17 ref.)

Publication and proprietary information. Reidenberg MM. **Clin Pharmacol Ther** 1996 Apr;59(4):367-8

Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact** 1995;12(2):77-91 (38 ref.)

American Academy of Veterinary Pharmacology and Therapeutics: perspectives on the utility of flexible drug labeling. An AAVPT perspective: Part I. Koritz GD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):875-6

American Academy of Veterinary Pharmacology and Therapeutics: perspectives on the utility of flexible drug labeling. An AAVPT perspective: Part II. Riviere JE. **J Am Vet Med Assoc** 1995 Oct 1;207(7):876-8

Pharmacodynamics as a research tool. Bailey JM. **J Clin Anesth** 1996 May;8(3 Suppl):48S-52S (12 ref.)

British Pharmaceutical Conference 1995. Science Proceedings, 132nd meeting. Warwick, September 15-18,

1995. **J Pharm Pharmacol** 1995 Dec;47(12B):1055–133
XIX National Meeting of the Spanish Society of Pharmacology, Madrid, October 4–6, 1995. Abstracts. **Methods Find Exp Clin Pharmacol** 1995;17 Suppl A:1–159
German institute renews east–west unease [news] Abbott A. **Nature** 1996 Aug 8;382(6591):486
Joint meeting of the German and Dutch Pharmacological Societies. Maastricht, The Netherlands, 4–7 October 1995. Abstracts. **Naunyn Schmiedebergs Arch Pharmacol** 1995; 352(5 Suppl 1):R1–38
10th American Association of Pharmaceutical Scientists (AAPS) annual meeting. Miami Beach, Florida, November 5–9, 1995. Abstracts. **Pharm Res** 1995 Sep;12(9 Suppl):S1–471
Groningen Utrecht Institute for Drug Exploration (GUIDE) Autumn meeting. Groningen, The Netherlands, 3 November 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl O):O1–15
1st European Congress of Pharmacology. Milan, Italy, June 16–19, 1995. Abstracts. **Pharmacol Res** 1995;31 Suppl:1–385
XII Congress of the Polish Pharmacological Society. Bydgoszcz, September 17–20, 1995. Abstracts. **Pol J Pharmacol** 1995;47 Suppl:1–130
Drug discovery and development in academic institutions. Burks TF. **Proc West Pharmacol Soc** 1995;38:137–9
Choice and decisions in the development of pharmaceutical products. Proceedings of the 2nd International Meeting on Statistical Methods in Biopharmacy. Paris, 6–7 September 1993. **Stat Med** 1995 May 15–30;14(9–10):885–1143
[Abstracts of reports presented at the 45th Pharmacology Seminar in Brno (26–28 October 1995)] **Cesk Fysiol** 1996 Jun;45(2):70–98 **(Cze, Slo)**
[Statistic determination of release limits of a finished product active principle compared to drug specification at peremption and eventually at the end of its after reconstitution] Nivet JM. **Ann Pharm Fr** 1996;54(3):131–9 (Eng. Abstr.) **(Fre)**
[Variability of drug effect—age factors] Guignard JP, et al. **Arch Pediatr** 1996;3 Suppl 1:229s–231s **(Fre)**
[Variability of drug effects and pharmacogenetics] Jacqz-Aigrain E. **Arch Pediatr** 1996;3 Suppl 1:226s–228s **(Fre)**
[Nutritional factors and variability of drug effects] Mazouni MS, et al. **Arch Pediatr** 1996;3 Suppl 1:232s–235s **(Fre)**
[To the Interpharm in Stuttgart in April (editorial)] **Med Monatsschr Pharm** 1996 Apr;19(4):93 **(Ger)**
[Pharmacology and society] Habermann E. **Pharm Unserer Zeit** 1995 Sep;24(5):273–80 (26 ref.) **(Ger)**
[Homeopathy from the viewpoint of the clinical pharmacologist] Haustein KO. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):97–101 (Eng. Abstr.) **(Ger)**
[After the benzodiazepines] Cugurra F. **Clin Ter** 1995 Dec; 146(12):861–4 (Eng. Abstr.) **(Ita)**
[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135–45 (24 ref.) **(Jpn)**
[Application of the common marmoset to pharmacological studies] Nomoto M. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):11–8 (23 ref.) (Eng. Abstr.) **(Jpn)**
[XXVI Annual meeting of the Argentine Society of Experimental Pharmacology. Mar del Plata, 26–30 November 1994. Abstracts] **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):145–68 **(Spa)**

EDUCATION

Rational drug therapy as evaluated from student's clinical case reports. Kohli K, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):400–2
Using "literature" to evaluate new drugs. Felpel LP. **J Dent Educ** 1996 May;60(5):465–6
Integration of pharmacology into a problem-based learning curriculum for medical students. Sivam SP, et al. **Med Educ** 1995 Jul;29(4):289–96
Drug storage at home [letter] Natu MV, et al. **World Health Forum** 1995;16(4):401–3
[A new course on global medicine. From relief work to pharmacological front line research] Esscher A, et al. **Lakartidningen** 1996 Jun 5;93(23):2241–3 **(Swe)**

HISTORY

Professor Emil Starkenstein and the clinical pharmacology. Jezdinský J, et al. **Acta Univ Palacki Olomuc Fac Med** 1994; 138:75–6
A personal view of pharmacology. Black J. **Annu Rev Pharmacol Toxicol** 1996;36:1–33 (57 ref.)
Evolution of Mexican pharmacology. Hong E. **Arch Med Res** 1995;26 Spec No:S175–6
Second W.D.M. Paton Memorial Lecture. The evolution of experimental pharmacology as a biological science: the pioneering work of Buchheim and Schmiedeberg. Muscholl E. **Br J Pharmacol** 1995 Oct;116(4):2155–9
First W.D.M. Paton Memorial Lecture. An F4–vescent episode: Sir Henry Dale's laboratory 1919–1942. Tansey EM. **Br J Pharmacol** 1995 Aug;115(8):1339–45
Therapeutic nihilism? Herman J. **Isr J Med Sci** 1996 Mar–Apr;32(3–4):259–64
Autobiographical notes. Donald J. Jenden. Jenden DJ. **Life Sci** 1996;58(22):1909–15
Ocular pharmacology and toxicology. Flach AJ. **Ophthalmology** 1996 Aug;103(8 Suppl):S118–42
The legacies of Sir William Whitla. Shanks RG. **Ulster Med J** 1994 Apr;63(1):52–75
[Retrospect of a pharmacologist's life] Jiang MX. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):289–92 **(Chi)**
[50 years' of Czechoslovak pharmacology and celebrated pharmacologists (editorial)] Rašková H. **Cesk Fysiol** 1996 Jun;45(2):67–9 **(Cze)**
[History of the chapel of the Pharmacology Institute of the University of Milano] Montorsi W. **Minerva Chir** 1995 Sep; 50(9 Suppl):115–8 **(Ita)**
[The formation and development of pharmacological research in Russian aviation and space medicine (on the 60th anniversary of the Institute of Aviation and Space Medicine of the Ministry of Defense of the Russian Federation)] Vasil'ev PV, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):72–3 **(Rus)**

METHODS

Microdialysis sampling for pharmacological studies: HPLC and CE analysis. Lunte SM, et al. **Adv Chromatogr** 1996; 36:383–432 (73 ref.)
Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. Fullerton T, et al. **J Pharm Sci** 1996 Jun;85(6):600–7
Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. Gobburu JV, et al. **J Pharm Sci** 1996 May;85(5):505–10
Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions. Lutz MW, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):37–46
Isolation of syncytial microvillous membrane vesicles from human term placenta and their application in drug–nutrient interaction studies. van der Aa EM, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):47–56
Precision-cut tissue slices: applications in pharmacology and toxicology. Parrish AR, et al. **Life Sci** 1995;57(21):1887–901 (151 ref.)
Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Tallarida RJ, et al. **Life Sci** 1996;58(2):PL 23–8
Development and submission of a nonclinical (pharmacology/toxicology) CANDA. Coleman JB, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):46–53

TRENDS

Drug use and misuse: frontiers between biological science, bureaucracy and clinical pragmatism [editorial] Rossdale PD. **Equine Vet J** 1996 Jan;28(1):7–8
Strategies and recent technologies in drug discovery. Kubinyi H. **Pharmazie** 1995 Oct;50(10):647–62 (311 ref.)
Questions of the end of the century and millennium. Ecologic pharmacology. Dobrescu D. **Rom J Physiol** 1994 Jan–Dec; 31(1–4):19–24

PHARMACOLOGY, CLINICAL

A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Hanlon JT, et al. **Am J Med** 1996 Apr;100(4):428–37
Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials. Ebling WF, et al. **Ann Pharmacother** 1996 Jan;30(1):12–9
Science, medicine and clinical pharmacology. The Lilly Lecture 1994. Breckenridge A. **Br J Clin Pharmacol** 1995 Jul;40(1):1–9 (41 ref.)
97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Lake Buena Vista, Florida, March 20–22, 1996. Abstracts. **Clin Pharmacol Ther** 1996 Feb;59(2):129–224
Pharmaceutical biotechnology. **Curr Opin Biotechnol** 1995 Dec;6(6):719–75
The healthy volunteer in clinical pharmacology: personality and motivation. Meyer FP, et al. **Eur J Clin Pharmacol** 1995;48(2):91–6
AHI perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots. Apley MD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):901–2; discussion 902–4
AHI perspectives: flexible drug labeling and its impact on the drug development process. A clinical pharmacologist's perspective. Ter Hune TN. **J Am Vet Med Assoc** 1995 Oct 1;207(7):898; discussion 902–4
Effective half-life in clinical pharmacology. Boxenbaum H, et al. **J Clin Pharmacol** 1995 Aug;35(8):763–6
Effectiveness of pharmacist consultations [comment] Flynn CA, et al. **J Fam Pract** 1996 Jan;42(1):22–3. Comment on: J Fam Pract 1995 Nov;41(5):469–72.
The impact of a pharmacotherapy consultation on the cost and outcome of medical therapy [see comments] Jameson J, et al. **J Fam Pract** 1995 Nov;41(5):469–72. Comment in: J Fam Pract 1996 Jan;42(1):22–3.
Advanced Activities in Pharmaceutical Care, 24th European Symposium on Clinical Pharmacy. Prague, Czech Republic, 10–13 October 1995. Abstracts. **Pharm World Sci** 1995 Sep 22;17(5 Suppl J):J1–27
Clinical Pharmacological meeting. Utrecht, The Netherlands, 6 October 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl M):M1–9
Standard operating procedure (SOP) for the registration and computer-supported evaluation of pharmaco-EEG data. Working Team "EEG in Phase I" of CIPS. Versavel M, et al. **Pharmacopsychiatry** 1995 Nov;28(6):245–8 (8 ref.)
1st Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, 27–30 September 1995, and Synthelabo Symposium Alpha 1-blockers in BPH Uroselectivity and Quality of Life. Abstracts. **Therapie** 1995;Suppl:S1–191
[Cardiointervalography in the practice of experimental and clinical pharmacology] Arushanian EB. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):74–8 (18 ref.) (Eng. Abstr.) **(Rus)**
[Is clinical pharmacology important in primary health care? The Mallorca experience (letter)] Rodríguez Moreno C. **Aten Primaria** 1996 Jan;17(1):88, 90 **(Spa)**

EDUCATION

A new opportunity for training in clinical pharmacology. Baber NS, et al. **Br J Clin Pharmacol** 1996 May;41(5):365–8
Survey of clinical pharmacology training in the United States and Canada. Cantilena LR Jr, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):1–7

MANPOWER

Clinical pharmacology: present status and projections for the future. Vestal RE. **J Clin Pharmacol** 1996 Apr;36(4):286–91

METHODS

[Apropos of pooling biologic specimens before the measurement of a constituent or a property] Férard G, et al. **Ann Biol Clin (Paris)** 1995;53(1–2):49–50 **(Fre)**

STANDARDS

Who is responsible for clinical pharmacology? [editorial] Colburn WA, et al. **J Clin Pharmacol** 1996 May;36(5):383–5

TRENDS

Paediatric clinical pharmacology in the former Soviet Union: Ukraine. Rieder MJ. **Biol Neonate** 1995;68(4):276–81 (7 ref.)

PHARMACOPOEIAS

Safety of medications in lactation cessation [letter] O'Shea E. **Can Fam Physician** 1996 Apr;42:616
Improving prescribing through use of CPS [letter] Cowan S, et al. **Can Med Assoc J** 1996 Sep 1;155(5):512–3
Alternatives to animal testing: achievements and recent developments in the European Pharmacopoeia. Castle P. **Dev Biol Stand** 1996;86:21–9
Radiopharmaceuticals 1994. Nil desperandum. European Association of Nuclear Medicine Committees on Radiopharmaceuticals and Positron Emission Tomography. Cox PH, et al. **Eur J Nucl Med** 1995 Jun;22(6):563–70
The United States Pharmacopeia Veterinary Practitioners' Reporting Program. Meyer EK, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):361–3
A collaborative study of proposed European Pharmacopoeia reference preparations of low molecular mass heparin. Gray E, et al. **Thromb Haemost** 1995 Sep;74(3):893–9
[Farmacotherapeutisch Kompas 1995] Danz M, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):357–60 **(Dut)**
[Methods of thin layer chromatography in quality control (a comparison of the Hungarian and European pharmacopoeias)] Volford O, et al. **Acta Pharm Hung** 1995 Sep;65(5):167–73 (Eng. Abstr.) **(Hun)**
[Improving on the Japanese pharmacopeia—on assays and determinations] Ishibashi M. **Eisei Shikenjo Hokoku** 1995; (113):137–9 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Trust of primary care physicians in the reliability of the vade mecum] Nieto-Hernández T, et al. **Aten Primaria** 1996 Mar 15;17(4):247–50 (Eng. Abstr.) **(Spa)**

HISTORY

Pedanius Dioscorides (born about AD40, died about AD90). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):427

STANDARDS

USP monographs and tests of radiochemical purity [letter; comment] Briner WH. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1817–8. Comment on: Am J Health Syst Pharm 1995 Feb 1;52(3):310–3.

PHARMACOTHERAPY see **DRUG THERAPY**

PHARMACY

see related
COMMUNITY PHARMACY SERVICES
EDUCATION, PHARMACY
LEGISLATION, PHARMACY
PHARMACY SERVICE, HOSPITAL
PRESCRIPTIONS, DRUG
TECHNOLOGY, PHARMACEUTICAL

Women happier than men in pharmacy career [news] **Am J Health Syst Pharm** 1995 Sep 15;52(18):1970, 1977
Gloria Niemeyer Francke is fourth recipient of Donald E. Francke Medal [news] **Am J Health Syst Pharm** 1995 Aug 15;52(16):1743
Pharmacy and the Internet [editorial] Klein CN. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2095
Rainforest holds many lessons for pharmacy. Stover KA. **Am Pharm** 1995 Sep;NS35(9):13
Comment: selected topics in drug information access and practice: an update [letter; comment] Seaba HH. **Ann Pharmacother** 1995 Sep;29(9):941–2. Comment on: Ann Pharmacother 1994 Dec;28(12):1389–94.
Benefits of certification for pharmacy specialists. McArtor JP, et al. **J Am Pharm Assoc (Wash)** 1996 Feb; NS36(2):128–34
Public health in the United States. Moore SR. **J R Soc Health** 1995 Aug;115(4):261–2
International pharmacy. Bond CA, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):586–91
Women's health and the pharmacy profession—an alliance whose time has come [letter] Ponte CD. **Womens Health Issues** 1995 Fall;5(3):155–6
[Pharmaceutical care abroad and in the Czech Republic] Macešková B. **Ceska Slov Farm** 1996 Feb;45(1):4–7 (Eng. Abstr.) **(Cze)**
[Prof. Pijpers talks. Members benefit form expansion specialty pharmacy (interview by Jan Hulsen)] Pijpers A. **Tijdschr Diergeneeskd** 1996 Jun 15;121(12):370–2 **(Dut)**
[French language pharmaceutical publications in 1995. II. List and characteristics of French language pharmaceutical periodicals] Bador P, et al. **J Pharm Belg** 1996 May–Jun; 51(3):131–40 **(Fre)**
[French language pharmaceutical publications in 1995. I. Assessment and analysis of French language pharmaceutical periodicals] Bador P, et al. **J Pharm Belg** 1996 Mar–Apr;51(2):74–81 (Eng. Abstr.) **(Fre)**
[CD–ROM and pharmacy: a new means of accessing information. I. Characteristics and analysis of CD–ROMs of interest to pharmacy] Couvreux J, et al. **J Pharm Belg** 1995 Sep–Oct;50(5):461–9 (Eng. Abstr.) **(Fre)**
[CD–ROM and pharmacy: a new means of accessing information. II. Lists and characteristics of CD–ROMs of interest to pharmacy] Couvreux J, et al. **J Pharm Belg** 1995 Nov–Dec;50(6):502–47 **(Fre)**

ECONOMICS see ECONOMICS, PHARMACEUTICAL

EDUCATION see EDUCATION, PHARMACY

HISTORY

Antiques of the pharmacy. Part 2: Offering relief when cure is impossible. Weinberg F. **Can Fam Physician** 1995 Oct; 41:1754–8
["Pharmaco–theology"] Krafft F. **Pharmazie** 1996 Jun; 51(6):422–6 (Eng. Abstr.) **(Ger)**
[A quarter of a century for the College of Military Pharmacists] Zhatkin OA, et al. **Voen Med Zh** 1995 Jul; (7):75–6 **(Rus)**

LEGISLATION & JURISPRUDENCE see LEGISLATION, PHARMACY

ORGANIZATION & ADMINISTRATION

An essential ingredient. Finley RS. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1667–9

STANDARDS

Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Bradley CA, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):681–9
ASEAN GMP and pharmaceutical industries in Indonesia. Soesilo S, et al. **PDA J Pharm Sci Technol** 1995 Jul–Aug; 49(4):192–5
Analysis of the practice of nutrition support pharmacy specialists. Holcombe BJ, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):806–13

TRENDS

The third strategic–planning conference for pharmacy practice. **Am J Health Syst Pharm** 1995 Oct 15; 52(20):2217–23
Pharmacy's transition to a proactive practice mode. Poole TA. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2821–4
Re–engineering pharmacy [editorial; comment] Talley CR. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2667. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2671–5. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2676–80. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2681–5.
Characteristics, importance, and implications of comprehensive drug therapy management. Williard RL, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):623–32
Rho Chi Lecture Award. Is something broken that requires fixing? Bachmann KA. **Ann Pharmacother** 1995 Nov; 29(11):1156–9
Medicine, pharmacy, and industry—a fly's eye view of health care [editorial] Halperin JA. **Ann Pharmacother** 1995 Sep; 29(9):925–33
The future of pharmacy: Armageddon or Pollyanna? [editorial] [see comments] Stewart RB. **Ann Pharmacother** 1995 Dec;29(12):1292–6. Comment in: Ann Pharmacother 1995 Dec;29(12):1297–8.
Influencing the destiny of pharmacy [editorial; comment] Whitney HA Jr. **Ann Pharmacother** 1995 Dec;29(12):1297–8 . Comment on: Ann Pharmacother 1995 Dec;29(12):1292–6.
Technology and automation in pharmaceutical care [see comments] Felkey BG, et al. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):309–14. Comment in: J Am Pharm Assoc (Wash) 1996 May;NS36(5):315.
[Research at Brazilian universities. The post–graduate course for pharmacy at the State University Porto Alegre/Rio Grande do Sul as an example] Spitzer V. **Pharm Unserer Zeit** 1996 May;25(3):135–7 **(Ger)**

PHARMACY ADMINISTRATION

see related
FEES, PHARMACEUTICAL
INSURANCE, PHARMACEUTICAL SERVICES

Contributions of pharmacy management to systems' success: Fallon Healthcare System. Cano SB. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S23–7
Contributions of pharmacy management to systems' success: Abbott Northwestern hospital. Giese RM. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S18–22
Developing pharmacy's role in ambulatory care: Parkland Health and Hospital System. Hatwig CA. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S27–32
Contributions of pharmacy management to systems' success: Scott & White Hospital, Clinics & Health Plan. Woodward BW. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S13–8
Use of cost–consequence models in managed care. Blissenbach HF. **Pharmacotherapy** 1995 Sep–Oct;15(5 Pt 2):59S–61S

METHODS

Evaluating the performance of a pharmacy benefit management company. Stern CS. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1865–7

STANDARDS

Pharmacy without walls. Shane RR. **Am J Health Syst Pharm** 1996 Feb 15;53(4):418–25
APOM–project: an investigation of pharmacy organization and management [letter] Mobach MP, et al. **Pharm World Sci** 1996 Apr;18(2):83–4

PHARMACY AND THERAPEUTICS COMMITTEE

see related
FORMULARIES, HOSPITAL

Pharmacoeconomics and the quality of decision–making by pharmacy and therapeutics committees. Langley PC. **Am J Health Syst Pharm** 1995 Jul 15;52(14 Suppl 3):S24–6
[Lists presented by eight drug committees compared. The number of preparations varies. Similar views on the most expensive drugs] Bergman U, et al. **Lakartidningen** 1996 Apr 10;93(15):1459–60 **(Swe)**
[Towards a new drug management] Hoffmann M, et al. **Lakartidningen** 1995 Oct 11;92(41):3804, 3807 **(Swe)**
[A new model of drug committees' activities developed in Gothenburg (letter)] Iwarson S. **Lakartidningen** 1996 Jul 24;93(30–31):2649–50 **(Swe)**

STANDARDS

Hashing out a policy on conflicts of interest for a P&T committee. Fredrick DS, et al. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2791–2

PHARMACY EDUCATION see EDUCATION, PHARMACY

PHARMACY EDUCATION, CONTINUING see EDUCATION, PHARMACY, CONTINUING

PHARMACY EDUCATION, GRADUATE see EDUCATION, PHARMACY, GRADUATE

PHARMACY SCHOOLS see SCHOOLS, PHARMACY

PHARMACY SERVICE, CLINICAL see PHARMACY SERVICE, HOSPITAL

PHARMACY SERVICE, HOSPITAL

Pharmacist's impact on antimicrobial drug therapy. Cadle RM, et al. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1544–6
Improved detection of drug–related problems in intensive care unit patients [letter] Chen R, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):185–6
Oncology pharmacy as a specialty [editorial] Holcombe BJ. **Am J Health Syst Pharm** 1996 Apr 1;53(7):734
Influence of pharmaceutical sales representatives on the formulary system. Hoppe SA, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1549–51
Preventing chemotherapy errors [editorial; comment] Ignoffo RJ. **Am J Health Syst Pharm** 1996 Apr 1;53(7):733. Comment on: Am J Health Syst Pharm 1996 Apr 1;53(7):737–46. Comment on: Am J Health Syst Pharm 1996 Apr 1;53(7):752–6. Comment on: Am J Health Syst Pharm 1996 Apr 1;53(7):757–9.
Pharmacy preparation of total nutrient admixtures [letter] James JK, et al. **Am J Health Syst Pharm** 1995 Dec 1; 52(23):2727–8
Making decisions about drug repackaging [letter] Kostka MD, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):564–5
An iconoclastic perspective on progress in pharmacy practice. Pierpaoli PG. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1763–70
Riding into battle without a pharm.D. degree. Roberts BL Jr. **Am J Health Syst Pharm** 1995 Sep 15;52(18):1981–2
Computerized system for physician order entry. Schneider R, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2184–6
Spilled hazardous drugs: the need of an inactivation method [letter] Mateu J, et al. **Ann Pharmacother** 1996 Jan; 30(1):85–6
Avoiding drug errors. Pharmacists and computerised prescribing can help [letter; comment] [see comments] Cotter SM. **BMJ** 1995 Nov 18;311(7016):1367–8. Comment on: BMJ 1995 Aug 19;311(7003):463–4. Comment in: BMJ 1996 Mar 16;312(7032):707.
A survey of allopurinol dosage prescribing. McClintock AD, et al. **N Z Med J** 1995 Aug 25;108(1006):346–7
Roles and functions of the hospital pharmacist on the nutrition support team. Driscoll DF. **Nutrition** 1996 Feb; 12(2):138–9
Roles and functions of the hospital pharmacist on the nutrition support team. Lee HS. **Nutrition** 1996 Feb; 12(2):140
[Rational use of antibiotics at hospitals] Kolmos HJ. **Ugeskr Laeger** 1996 Jan 15;158(3):255–7 **(Dan)**
[The participation of hospital pharmacy services in enteral nutrition] Hidalgo FJ, et al. **Nutr Hosp** 1995 Nov–Dec; 10(6):358–63 (Eng. Abstr.) **(Spa)**
[A comment to the discussion on drug utilization. Pharmacies owned by county councils should reduce drug costs] Lindvall IH. **Lakartidningen** 1996 Jun 19;93(25):2403–4 **(Swe)**

ECONOMICS

Cost of providing pharmaceutical services to hospice patients. Haugtvedt CL, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2419–22
Communicating pharmaceutical outcomes to hospital administration. Mountzuris J. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S9–11
Cost of medication–related problems at a university hospital. Schneider PJ, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2415–8
Federal–discount prices still off–limits to public hospitals [news] Thompson CA. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2386, 2392, 2394
Measuring of impact of patient counseling in the outpatient pharmacy setting: development and implementation of the counseling models for the Kaiser Permanente/USC Patient Consultation Study. Johnson KA, et al. **Clin Ther** 1995 Sep–Oct;17(5):988–1002
Survey results from academic health center intensive care units: considerations for departments of pharmacy. Matuszewski KA, et al. **Clin Ther** 1995 May–Jun; 17(3):517–24; discussion 516
Switch therapy in community–acquired pneumonia. Ramirez JA. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):219–23
Therapeutic exchange of cefotaxime for ceftriaxone: evaluation, implementation, and subsequent cost savings at a 300–bed community hospital. Rawlings RD. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):235–7
Econotherapeutics. Roark MK, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):209–17
Decreased fluoroquinolone use with a pharmacy service–pharmaceutical company partnership. North DS. **Drugs** 1995;49 Suppl 2:501–3
Cost–evaluation model for clinical trials in a hospital pharmacy service. Idoate A, et al. **Pharm World Sci** 1995 Sep 22;17(5):172–6

LEGISLATION & JURISPRUDENCE

[Strategy of quality of the application of the Huriet law in hospitals] Hugues ML, et al. **Ann Pharm Fr** 1995; 53(5):230–4 (Eng. Abstr.) **(Fre)**

MANPOWER

Coping with the layoff of coworkers. Hoyt DB. **Am J Health Syst Pharm** 1996 Mar 1;53(5):514–5

ORGANIZATION & ADMINISTRATION

Computer software for pharmacy oncology services [see comments] Berard CM, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):752–6. Comment in: Am J Health Syst Pharm 1996 Apr 1;53(7):733.
Improved detection of drug–related problems in intensive

care unit patients [letter] Chen R, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):185–6

Offsite intravenous admixture center shared by health-system facilities. Fauber WS, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2550–5

Pharmacists' provision of continuity of care to patients with human immunodeficiency virus infection. Foisy MM, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1013–7

Contributions of pharmacy management to systems' success: Abbott Northwestern hospital. Giese RM. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S18–22

Safety of an extemporaneously prepared injection. Goldstein B, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):414, discussion 414–7

Paperless system of managing drug information requests [letter] Gora-Harper ML, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):678, 683

Work activities before and after implementation of an automated dispensing system. Guerrero RM, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):548–54

Re-engineering for dramatic improvement in the medication-use process [comment] [see comments] Ivey MF. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2681–5 . Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2671–5. Comment in: Am J Health Syst Pharm 1995 Dec 1;52(23):2667.

Implementing comprehensive pharmaceutical services at an academic tertiary care hospital. Janning SW, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):542–7

Computer-assisted antimicrobial surveillance in a community teaching hospital. Jozefiak ET, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1536–40

Comprehensive services in an ambulatory care pharmacy. Lewis RK, et al. **Am J Health Syst Pharm** 1995 Aug 15; 52(16):1793–7

Collaborating with re-engineering consultants: maintaining resources for the future [see comments] McAllister JC 3rd. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2676–80. Comment in: Am J Health Syst Pharm 1995 Dec 1;52(23):2667.

Using pharmacists' documentation of clinical activities to reclaim employees and reposition the department. McDaniel MR, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):285–8

Work activities at an ambulatory care pharmacy with an integrated model of pharmacy practice. Nickman NA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):397–402

Comparison of Department of Veterans Affairs pharmacy services in 1992 and 1994 with strategic-planning goals. Portner TS, et al. **Am J Health Syst Pharm** 1996 May 1; 53(9):1032–40

Re-engineering the hospital: a house without rooms [see comments] Schneider PJ. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2671–5. Comment in: Am J Health Syst Pharm 1995 Dec 1;52(23):2667. Comment in: Am J Health Syst Pharm 1995 Dec 1;52(23):2681–5.

Ordering out for a pharmacy newsletter. Scoggin JA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):362, 364

Using bar-code technology to capture clinical intervention data in a hospital with a stand-alone pharmacy computer system. Scott MG, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):651–4

Developing pharmacy's role in ambulatory care: Cedars-Sinai Medical Center. Shane R. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S32–6

Pharmacy without walls. Shane RR. **Am J Health Syst Pharm** 1996 Feb 15;53(4):418–25

Re-engineering pharmacy [editorial; comment] Talley CR. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2667. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2671–5. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2676–80. Comment on: Am J Health Syst Pharm 1995 Dec 1;52(23):2681–5.

Enforcing antimicrobial restrictions [letter; comment] White AC Jr, et al. **Am J Health Syst Pharm** 1996 Apr 1; 53(7):796–7. Comment on: Am J Health Syst Pharm 1995 Jul 1;52(13):1433–5.

Contributions of pharmacy management to systems' success: Scott & White Hospital, Clinics & Health Plan. Woodward BW. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S13–8

Detailed planning to upgrade the sterile-products preparation area to a cleanroom. Wright B. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1750, 1753–5

Pharmacist-managed intravenous to oral step-down program. Hunter KA, et al. **Clin Ther** 1995 May-Jun; 17(3):534–40; discussion 516

A team approach to hospital formulary replacement. Lee J, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1–2):239–42

Outcome analysis of a pharmacist-managed anticoagulation service. Wilt VM, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):732–9

STANDARDS

ASHP guidelines: minimum standard for pharmacies in hospitals. American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2711–7

Workshop synopses. **Am J Health Syst Pharm** 1995 Jul 15; 52(14 Suppl 3):S32–5

ASHP statement on the role of the pharmacist in patient-focused care. American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1995 Aug 15; 52(16):1808–10

Top-priority actions for preventing adverse drug events in hospitals. Recommendations of an expert panel. **Am J Health Syst Pharm** 1996 Apr 1;53(7):747–51

Bacteriologic survey of a cleanroom [letter] Beaupin CM, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2469–70

Preventing medication errors in cancer chemotherapy [see comments] Cohen MR, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):737–46. Comment in: Am J Health Syst Pharm 1996 Apr 1;53(7):733.

Technician checking of pharmacists computerized order entry for parenteral nutrient solutions. Fields HS. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1801–2

Quality-assurance testing of staff pharmacists handling cytotoxic agents. Harrison BR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):402–7

Quality-improvement processes in an oncology pharmacy service [see comments] Lunik MC, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):757–9. Comment in: Am J Health Syst Pharm 1996 Apr 1;53(7):733.

Policy to restrict use of i.v. bumetanide. Montgomery PA, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1802–4

Asking a pharmacist to resign for making an error. Peterson AM, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):760–3

Meeting Joint Commission requirements for competence assessment. Rich DS. **Am J Health Syst Pharm** 1996 Apr 1;53(7):726, 729

Process for preventing or identifying and resolving problems in drug therapy. Robertson KE. **Am J Health Syst Pharm** 1996 Mar 15;53(6):639–50

Total quality management in hospital pharmacy. Godwin HN, et al. **Am Pharm** 1995 Oct;NS35(10):51–9; quiz 59–60

Survey of antibiotic control policies in university-affiliated teaching institutions. Lesar TS, et al. **Ann Pharmacother** 1996 Jan;30(1):31–4

Quality patrol. Prescription for accuracy. Appleby C. **Hosp Health Netw** 1995 Nov 20;69(22):46

Practical guides. II: Hospital pharmacy quality control services. Sewell GJ. **J Clin Pharm Ther** 1995 Jun; 20(3):149–57 (36 ref.)

[Improved information on drugs to patients. A project with a pharmacist in the therapeutic team at a cardiology department] Veggeland T. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1901–3 (Eng. Abstr.) **(Nor)**

STATISTICS & NUMERICAL DATA

Pharmacy involvement in patient-focused care in Florida hospitals. Schultz DM, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2121–4

TRENDS

Rethinking hospital pharmaceutical marketing. Zellmer WA. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1590

Opportunity for pharmacy leadership in integrated health care systems. Zellmer WA. **Am J Health Syst Pharm** 1996 Feb 15;53(4 Suppl 1):S3–4

UTILIZATION

The impact of clinical pharmacy intervention in a psychiatric hospital. Dorevitch A, et al. **J Clin Pharm Ther** 1996 Feb; 21(1):45–8

PHARYNGEAL ARCHES see BRANCHIAL REGION

PHARYNGEAL DISEASES

CHEMICALLY INDUCED

[Upper airway obstruction. An unusual and life-threatening complication of Waran therapy] Engborg L, et al. **Lakartidningen** 1995 Oct 25;92(43):3997, 3999 **(Swe)**

COMPLICATIONS

Upper airway obstruction caused by acquired inhibitor to factor VIII. Joynt GM, et al. **Anaesthesia** 1996 Jul; 51(7):689–91

Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Barchiesi F, et al. **Clin Infect Dis** 1995 Sep;21(3):561–4

Recurrent suppurative thyroiditis due to pyriform sinus fistula: a case report. Schneider U, et al. **Eur J Pediatr** 1995 Aug;154(8):640–2

Recurrent cervical abscess due to piriform sinus fistula. Yamashita H, et al. **J Laryngol Otol** 1995 Sep;109(9):886–8

Postlaryngectomy dysphagia caused by an anterior neopharyngeal diverticulum. Deschler DG, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):167–9

Massive hematoma resulting in bilateral hypoglossal nerve paralysis. Vito KJ, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):491–4

Pharyngeal and swallowing disorders in infants. Jolley SG, et al. **Semin Pediatr Surg** 1995 Aug;4(3):157–65 (38 ref.)

CONGENITAL

Partial DiGeorge anomaly presenting as an enlarging third pharyngeal pouch cyst. DiNardo LJ, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):785–7

DIAGNOSIS

Diagnostic imaging in the evaluation of dysphagia. Barloon TJ, et al. **Am Fam Physician** 1996 Feb 1;53(2):535–46 (22 ref.)

Pharyngeal dysesthesia as an aura in temporal lobe epilepsy. Carmant L, et al. **Epilepsia** 1996 Sep;37(9):911–3

The modified Valsalva manoeuvre to improve visualization of the hypopharynx during flexible nasopharyngoscopy. Spraggs PD, et al. **J Laryngol Otol** 1995 Sep;109(9):863–4

The natural history of globus pharyngeus. Rowley H, et al. **Laryngoscope** 1995 Oct;105(10):1118–21

[Dystonia as the cause of pharyngolaryngeal motility disorders] Zwirner P, et al. **HNO** 1995 Aug;43(8):498–501 (Eng. Abstr.) **(Ger)**

[Clinical differential diagnosis of the mouth and oropharynx] Grevers G. **Radiologe** 1996 Mar;36(3):181–7 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Quereda C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):30–7

EPIDEMIOLOGY

Speech results and complications of near-total laryngectomy. Gavilán J, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):729–33

ETIOLOGY

Pulmonary barotrauma as the cause of pneumoretropharynx in pulmonary lymphangioleiomyomatosis. Crausman RS, et al. **Am J Emerg Med** 1996 May;14(3):297–9

Breast feeding and tonsillectomy. Pisacane A, et al. **BMJ** 1996 Mar 23;312(7033):746–7

The craniopharyngeal canal indicating the presence of pharyngeal adenopituitary tissue. Kjaer I, et al. **Eur J Radiol** 1995 Sep;20(3):212–4

Pharyngo-oesophageal fistula following iatrogenic perforation of a pharyngeal pouch. Martin-Hirsch DP, et al. **J Laryngol Otol** 1995 Dec;109(12):1215–6

Pseudoaneurysm of the carotid artery with haemorrhage into the hypopharynx. Tanaka S, et al. **J Laryngol Otol** 1995 Sep;109(9):889–91

Pharyngocutaneous fistula following laryngectomy. Udaipurwala IH, et al. **JPMA J Pak Med Assoc** 1995 May; 45(5):130–2

Role of gastroesophageal reflux disease in patients with cervical symptoms. Rival R, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):364–9

Traumatic retropharyngeal hematoma: a case report. Shaw CB, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):485–8

[Three cases of postoperative laryngopharyngeal edema following nonsimultaneous bilateral radical neck dissection] Haraguchi HH, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Dec;98(12):1903–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Relationship between birch pollen allergy and oral and pharyngeal hypersensitivity to fruit] Yamamoto T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1086–91 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Value of screening for oro-pharyngeal Chlamydia trachomatis infection. Jebakumar SP, et al. **J Clin Pathol** 1995 Jul;48(7):658–61

Parapharyngeal abscess from Pseudomonas aeruginosa infection in an HIV positive patient [letter] Sanderson RJ, et al. **J Infect** 1995 Sep;31(2):174

Progressive intractable actinomycosis in patients with AIDS. Manfredi R, et al. **Scand J Infect Dis** 1995;27(4):405–7

PARASITOLOGY

Anisakiasis of the tonsils. Bhargava D, et al. **J Laryngol Otol** 1996 Apr;110(4):387–8

PATHOLOGY

Maneuver to assist examination of the hypopharynx. Purser S, et al. **Head Neck** 1995 Sep-Oct;17(5):389–93

Neonatal cervical choristoma--a case report. Nayak S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S1

Heterotopia of the tonsil. Bhargava D, et al. **J Laryngol Otol** 1996 Jun;110(6):611–2

Thalamo-olivary degeneration in a patient with laryngopharyngeal dystonia. Yamamoto T, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):438–41

Large oral ulcers leading to the destruction of the tonsils in patients with AIDS. Chaudhry R, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):474–8

PHYSIOPATHOLOGY

Limb girdle muscular dystrophy: a radiologic and manometric study of the pharynx and esophagus [see comments] Stübgen JP. **Dysphagia** 1996 Winter;11(1):25–9 . Comment in: Dysphagia 1996 Winter;11(1):30–3.

Upper esophageal sphincter and pharyngeal function and

oropharyngeal (transfer) dysphagia. Castell JA, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):35–50

Mechanisms of oral–pharyngeal dysphagia in patients with Parkinson's disease. Ali GN, et al. **Gastroenterology** 1996 Feb;110(2):383–92

PREVENTION & CONTROL

Functional outcome after surgery for prevention of pharyngospasms in tracheoesophageal speakers. Part I: Speech characteristics. Blom ED, et al. **Laryngoscope** 1995 Oct;105(10):1093–103

Functional outcome after surgery for prevention of pharyngospasms in tracheoesophageal speakers. Part II: Swallow characteristics. Pauloski BR, et al. **Laryngoscope** 1995 Oct;105(10):1104–10

Gastroesophageal reflux prophylaxis decreases the incidence of pharyngocutaneous fistula after total laryngectomy. Seikaly H, et al. **Laryngoscope** 1995 Nov;105(11):1220–2

RADIOGRAPHY

Functional abnormalities of the pharynx: a prospective analysis of radiographic abnormalities relative to age and symptoms. Frederick MG, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):353–7

Helical (spiral) CT of the upper airway with three–dimensional imaging: technique and clinical assessment. Zeiberg AS, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):293–9

Globus sensation: value of static radiography combined with videofluoroscopy of the pharynx and oesophagus. Schima W, et al. **Clin Radiol** 1996 Mar;51(3):177–85

Limb girdle muscular dystrophy: a radiologic and manometric study of the pharynx and esophagus [see comments] Stübgen JP. **Dysphagia** 1996 Winter;11(1):25–9 . Comment in: Dysphagia 1996 Winter;11(1):30–3.

Multiple branchial cleft anomalies. White SA, et al. **Eur J Surg** 1995 Jun;161(6):443–5

Cervical thymic cysts: CT appearance of two cases including a persistent thymopharyngeal duct cyst. Burton EM, et al. **Pediatr Radiol** 1995;25(5):363–5

Dysphagia in a diabetic patient. Piédrola G, et al. **Postgrad Med J** 1995 Nov;71(841):683–4

SURGERY

Oropharyngeal dysphagia and disorders of the upper esopharyngeal sphincter. Duranceau A. **Ann Chir Gynaecol** 1995;84(2):225–33 (15 ref.)

Reconstruction of cutaneous–pharyngeal fistula in two layers using microvascular free flap (a preliminary report). Car M. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):324

Cervical necrotising fasciitis with pharyngeal perforation: treatment and reconstruction. Yii NW, et al. **Br J Plast Surg** 1996 Jun;49(4):237–41

Pharyngoesophageal swallowing disorders. Jamieson JR. **Curr Opin Gen Surg** 1993;:189–94 (33 ref.)

ULTRASONOGRAPHY

[Examination technique of ultrasound `follow–up of pharyngeal closure after laryngectomy] Eistert B, et al. **Laryngorhinootologie** 1995 Dec;74(12):756–60 (Eng. Abstr.) **(Ger)**

VETERINARY

Transendoscopic laser treatment of guttural pouch tympanites in eight foals. Tate LP Jr, et al. **Vet Surg** 1995 Sep–Oct;24(5):367–72

PHARYNGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNGEAL MUSCLES

Abnormalities of ABR and auditory perception test findings in acquired palatal myoclonus. Kurauchi T, et al. **Int J Neurosci** 1996 Apr;85(3–4):273–83

Oculopharyngeal myopathy with sensorineural hearing loss. Alusi GH, et al. **J Laryngol Otol** 1996 Jun;110(6):567–9

Oculopharyngeal muscular dystrophy in two unrelated Japanese families. Uyama E, et al. **Neurology** 1996 Mar; 46(3):773–8

CHEMISTRY

Neurotransmitters for the canine inferior pharyngeal constrictor muscle. Tadaki N, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):755–9

DRUG EFFECTS

The action of serotonin and the nematode neuropeptide KSAYMRFamide on the pharyngeal muscle of the parasitic nematode, Ascaris suum. Brownlee DJ, et al. **Parasitology** 1995 Sep;111 (Pt 3):379–84

Effects of naloxone on upper airway collapsibility in normal sleeping subjects. Meurice JC, et al. **Thorax** 1996 Aug; 51(8):851–2

INNERVATION

Transsynaptic localization of pharyngeal premotor neurons in rat. Bao X, et al. **Brain Res** 1995 Oct 23;696(1–2):246–9

PATHOLOGY

Intranuclear inclusions in oculopharyngeal muscular dystrophy among Bukhara Jews. Blumen SC, et al. **Neurology** 1996 May;46(5):1324–8

PHYSIOLOGY

Electrically–activated dilator muscles reduce pharyngeal resistance in anaesthetized dogs with upper airway obstruction. Bishara H, et al. **Eur Respir J** 1995 Sep; 8(9):1537–42

Mutations in the Caenorhabditis elegans Na,K–ATPase alpha–subunit gene, eat–6, disrupt excitable cell function. Davis MW, et al. **J Neurosci** 1995 Dec;15(12):8408–18

PHYSIOPATHOLOGY

Do palatal lift prostheses stimulate velopharyngeal neuromuscular activity? Witt PD, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):469–75

RADIOGRAPHY

[Cricopharyngeal dysfunction] **Rontgenpraxis** 1996 Jun; 49(6):152–3 **(Ger)**

SURGERY

Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Buchholz DW. **Dysphagia** 1995 Fall;10(4):255–8 (20 ref.)

Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Born LJ, et al. **Mov Disord** 1996 Jan;11(1):53–8

ULTRASTRUCTURE

[Oculopharyngeal muscular dystrophy specific intranuclear tubulofilamentous inclusions (letter)] Uyama E, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):817–8 **(Jpn)**

PHARYNGEAL NEOPLASMS

Carcinoma of the larynx and hypopharynx in the elderly. Thompson AC, et al. **Eur J Surg Oncol** 1996 Feb;22(1):65–8

Parapharyngeal space neoplasms. Hughes KV 3rd, et al. **Head Neck** 1995 Mar–Apr;17(2):124–30

Perinatal management of a lingual teratoma. McMahon MJ, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):848–51

COMPLICATIONS

Retropharyngeal lipoma causing symptoms of obstructive sleep apnea. Aland JW Jr. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):628–30

[Simultaneous screening of HPV–6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Recurrent rhabdomyoma of the parapharyngeal space. Goldfarb D, et al. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):58–60

The value of magnetic resonance imaging in the differential diagnosis of parapharyngeal space tumours. Leverstein H, et al. **Clin Otolaryngol** 1995 Oct;20(5):428–33

Highly aggressive behaviour of occult papillary thyroid carcinoma [letter] Hardingham M. **J Laryngol Otol** 1996 Jul;110(7):710

Retro– and para–pharyngeal ganglioneuroma. Walch C, et al. **J Laryngol Otol** 1996 Jan;110(1):87–90

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)

Parapharyngeal masses. Report de 4 cases. Dhillon RS, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):273–6

[Local evaluation of cancers of the piriform sinus] Laccourreye H. **Ann Otolaryngol Chir Cervicofac** 1995; 112(3):138–42 **(Fre)**

[Parapharyngeal tumors: apropos of 14 cases] Verhulst J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):327–33 (Eng. Abstr.) **(Fre)**

[Endoscopic diagnosis of multiple primary cancer of the upper airways] Belousova NV, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):33–5 (Eng. Abstr.) **(Rus)**

[Asymptomatic thoracic and abdominal tumors with lymph nodes metastasis as a reason for consultation] Pardal Refoyo JL, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):161–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Adenovirus–mediated gene therapy for head and neck squamous cell carcinomas. Goebel EA, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):562–7

Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. Sugimoto C, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):675–80

5–Fluorouracil metabolism and cytotoxicity after pre–treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F–nuclear magnetic resonance spectroscopy study in vivo. Tausch–Treml R, et al. **Cancer Chemother Pharmacol** 1996;37(3):259–65

Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Arias F, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):675–82

Survival after chemotherapy with cisplatin and infusion of bleomycin prior to local–regional treatment in pyriform sinus cancer. Grau JJ, et al. **Tumori** 1996 May–Jun; 82(3):221–4

[Cephalic cancer pain controlled by intraventricular administration of morphine and clonidine] Loriferne JF, et al. **Ann Fr Anesth Reanim** 1995;14(2):233–6 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

A follow–up study of determinants of second tumor and metastasis among subjects with cancer of the oral cavity, pharynx, and larynx. Barbone F, et al. **J Clin Epidemiol** 1996 Mar;49(3):367–72

Oral cavity and pharyngeal cancer among Department of Veterans Affairs hospital discharges. Fedele DJ, et al. **J Public Health Dent** 1995 Summer;55(3):143–7

ETIOLOGY

Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection. Singh B, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):639–43

Cancer of the lung, pleura, larynx and pharynx in an area with an asbestos–cement plant. Curin K, et al. **Arh Hig Rada Toksikol** 1995 Sep;46(3):289–300

HISTORY

[The illness of Sigmund Freud] Pucci V, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):233–4 **(Ita)**

MORTALITY

Trends in survival from cancers of the oral cavity and pharynx in Scotland: a clue as to why the disease is becoming more common? Macfarlane GJ, et al. **Br J Cancer** 1996 Mar;73(6):805–8

Outcome of pyriform sinus cancer: a retrospective institutional review. Marks SC, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):27–31

PATHOLOGY

Recurrent rhabdomyoma of the parapharyngeal space. Goldfarb D, et al. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):58–60

Retropharyngeal liposarcoma. Yueh B, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):331–40 (65 ref.)

Prognostic significance of skin involvement from mucosal tumors of the head and neck. Cole RD, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1246–8

Native cellular fluorescence of neoplastic upper aerodigestive mucosa. Kolli VR, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1287–92

Second cancers occurring after cancers of the mouth and pharynx: data from three population–based registries in Australia, Scotland and Slovenia. Macfarlane GJ, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):315–8

Micrometastases in carcinoma of the upper aerodigestive tract: detection, risk of metastasizing, and prognostic value of depth of invasion. Ambrosch P, et al. **Head Neck** 1995 Nov–Dec;17(6):473–9

Schwannoma of the posterior pharyngeal wall: a case report. Haraguchi H, et al. **J Laryngol Otol** 1996 Feb;110(2):170–1 (3 ref.)

Synovial sarcoma of the pharynx. Ramamurthy L, et al. **J Laryngol Otol** 1995 Dec;109(12):1207–10 (19 ref.)

Xenograft growth and histodifferentiation of squamous cell carcinomas of the pharynx and larynx. Chen J, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):197–202

Malignant meningioma of the parapharyngeal space: a case report. Dominguez–Malagon H, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):55–9

[Rhabdomyoma of the adult type. Apropos of a case of parapharyngeal site] Birtwisle–Peyrottes I, et al. **Arch Anat Cytol Pathol** 1996;44(2–3):117–21 (11 ref.) (Eng. Abstr.) **(Fre)**

[Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer] Brochet F, et al. **Bull Cancer Radiother** 1996;83(1):8–11 (34 ref.) (Eng. Abstr.) **(Fre)**

[Simultaneous screening of HPV–6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**

[Our experience in the management of parapharyngeal tumors] Povedano Rodríguez V, et al. **An Otorrinolaringol Ibero Am** 1995;22(4):393–403 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

The war on oral cavity and pharyngeal cancer. Slavkin HC. **J Am Dent Assoc** 1996 Apr;127(4):517–20

PHARYNGEAL NEOPLASMS

PSYCHOLOGY

Well-being and coping in oral and pharyngeal cancer patients. Langius A, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):242–9

RADIOGRAPHY

Schwannoma of the posterior pharyngeal wall. Singh B, et al. **J Laryngol Otol** 1995 Sep;109(9):883–5

RADIOTHERAPY

Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Arias F, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):675–82

Squamous cell carcinoma of the pharyngeal walls treated with radiotherapy. Chang L, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):477–83 (16 ref.)

[Radiotherapy and curietherapy of squamous cell carcinoma of the posterior pharyngeal wall (excluding the nasopharynx)] Chenal C, et al. **Bull Cancer Radiother** 1996; 83(1):54–9 (Eng. Abstr.) **(Fre)**

[Results of postoperative cervical node irradiation in carcinoma of the pharyngo-larynx. A study of the cooperative group of radiotherapists] Hoffstetter S, et al. **Bull Cancer Radiother** 1996;83(2):86–9 (Eng. Abstr.) **(Fre)**

REHABILITATION

Rehabilitation outcomes of long-term survivors treated for head and neck cancer. de Boer MF, et al. **Head Neck** 1995 Nov–Dec;17(6):503–15

SECONDARY

Occult thyroid carcinoma presenting as a parapharyngeal mass. Ferrario F, et al. **J Laryngol Otol** 1995 Dec; 109(12):1204–6

Metastatic melanoma to the pharynx and trachea. Gutfreund CA, et al. **Otolaryngol Head Neck Surg** 1995 Dec; 113(6):820–1

SURGERY

Mediastinal tracheostomy. Maipang T, et al. **Am J Surg** 1996 Jun;171(6):581–6

The galeo pericranial flap in oropharyngeal reconstruction. Ilankovan V, et al. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):47–50

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Free jejunal interposition reconstruction after pharyngolaryngectomy: 201 consecutive cases. Theile DR, et al. **Head Neck** 1995 Mar–Apr;17(2):83–8

Split, free, jejunal transfer for pharyngoesophageal and soft-tissue reconstruction. Li K, et al. **J Reconstr Microsurg** 1995 Jul;11(4):251–3

[Tactics of the surgeon in repeated removal of a large chemodectoma] Polishchuk NE, et al. **Klin Khir** 1995; (11–12):24–6 **(Rus)**

[Primary and delayed combined plastic repair of pharngoesophagostomies in patients with laryngopharyngeal cancer] Matiakin EG, et al. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):39–41 (Eng. Abstr.) **(Rus)**

[Initial experience in vascular plastic surgery in the surgical treatment of metastases of laryngopharyngeal cancer] Pogosov VS, et al. **Vestn Otorinolaringol** 1995 Nov–Dec; (6):25–7 (Eng. Abstr.) **(Rus)**

THERAPY

Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Goebel EA, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):562–7

A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Robbins KT, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):853–7

Outcome of pyriform sinus cancer: a retrospective institutional review. Marks SC, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):27–31

ULTRASTRUCTURE

Malignant meningioma of the parapharyngeal space: a case report. Dominguez-Malagon H, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):55–9

VETERINARY

Squamous cell carcinoma of the pharyngeal wall in a horse. Tuckey JC, et al. **Aust Vet J** 1995 Jun;72(6):227

PHARYNGECTOMY

Free jejunal interposition reconstruction after pharyngolaryngectomy: 201 consecutive cases. Theile DR, et al. **Head Neck** 1995 Mar–Apr;17(2):83–8

Acoustic parameters and speech analysis after supracricoid hemilaryngopharyngectomy. Laccourreye O, et al. **Laryngoscope** 1995 Nov;105(11):1223–6

[Surgery of the hypopharynx after radiotherapy] Rodriguez J, et al. **Bull Cancer Radiother** 1996;83(1):17–23 (Eng. Abstr.) **(Fre)**

METHODS

Primary closure of pharyngeal remnant after total laryngectomy and partial pharyngectomy: how much residual mucosa is sufficient? Hui Y, et al. **Laryngoscope** 1996 Apr;106(4):490–4

[Restoration of the mandible after trans-mandibular approach of invasive tumors of the oropharynx (43 cases)] Beauvillain C, et al. **Bull Cancer Radiother** 1996;83(1):31–3 (Eng. Abstr.) **(Fre)**

[Surgery of the oropharynx after radiotherapy] Rodriguez J, et al. **Bull Cancer Radiother** 1996;83(1):24–30 (Eng. Abstr.) **(Fre)**

[Suprahyoid pharyngotomy for surgical therapy of malignant and benign oral and hypopharyngeal tumors] Metternich FU, et al. **HNO** 1996 May;44(5):242–5 (Eng. Abstr.) **(Ger)**

PHARYNGITIS

Computer instruction in learning concepts of streptococcal pharyngitis. Hilger AE, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):629–31

Acute pharyngitis: etiology and diagnosis. Bisno AL. **Pediatrics** 1996 Jun;97(6 Pt 2):949–54 (76 ref.)

CLASSIFICATION

[Pharyngitis and its various clinical manifestations] Schroeder HG. **Ther Umsch** 1995 Nov;52(11):749–54 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Picture of the month. Polyarteritis nodosa with angioedema. Cron RQ, et al. **Arch Pediatr Adolesc Med** 1996 Aug; 150(8):875–6

Update on the status of Lyme borreliosis in British Columbia, Canada [letter] Banerjee S. **Clin Infect Dis** 1995 Sep; 21(3):704

Bacteremic group A streptococcal pharyngitis presenting as acute airway obstruction [letter] Gradon JD, et al. **Clin Infect Dis** 1995 Sep;21(3):704–5

Atypical PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis) in a young girl with Fanconi anemia. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):159–61

A young woman with hepatitis after a sore throat. Aceti A, et al. **Lancet** 1995 Dec 16;346(8990):1603

Diphtheritic neuropathy. Créange A, et al. **Muscle Nerve** 1995 Dec;18(12):1460–3

Jugular thrombophlebitis complicating bacterial pharyngitis (Lemierre's syndrome). De Sena S, et al. **Pediatr Radiol** 1996;26(2):141–4

DIAGNOSIS

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)

Value of new rapid tests for the diagnosis of group A streptococcal pharyngitis. Shulman ST. **Pediatr Infect Dis J** 1995 Oct;14(10):923–4

[Pharyngo-tonsillitis: Current clinical, bacteriological, serological and therapeutic aspects] Sternon J, et al. **Rev Med Brux** 1995 Nov;16(5):344–8 (12 ref.) (Eng. Abstr.) **(Fre)**

[Necrotizing fasciitis of soft tissues of the face and neck] Zbären P, et al. **HNO** 1995 Oct;43(10):619–23 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pacifico L, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1005–8

Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis. Brook I, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1405–9

Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. Davies HD, et al. **Clin Infect Dis** 1995 Nov;21(5):1294–9

A double-blind, multicenter comparative study of two regimens of clindamycin hydrochloride in the treatment of patients with acute streptococcal tonsillitis/pharyngitis. Gallegos B, et al. **Clin Ther** 1995 Jul–Aug;17(4):613–21

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)

Severe carbamazepine toxicity induced by concurrent erythromycin therapy [letter] Mota CR, et al. **Eur J Pediatr** 1996 Apr;155(4):345

5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Adam D, et al. **Infection** 1995;23 Suppl 2:S83–6

A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci. Carbon C, et al. **J Antimicrob Chemother** 1995 Jun;35(6):843–54

Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. Dykhuizen RS, et al. **J Antimicrob Chemother** 1996 Jan;37(1):133–8

Cefetamet pivoxil in the treatment of pharyngotonsillitis due to group A beta-hemolytic streptococci: preliminary report. Gervaix A, et al. **J Chemother** 1995 May;7 Suppl 1:21–4

Benzathine as a cause for a false-positive test result for amphetamines [letter; comment] Berthier M, et al. **J Pediatr** 1995 Oct;127(4):669–70. Comment on: J Pediatr 1995 Jan;126(1):135–40.

Clinical observation of qingjie liyan mixture in the treatment of 46 cases of chronic pharyngitis. Liu B, et al. **J Tradit Chin Med** 1995 Sep;15(3):180–2

Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group. Pichichero ME, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S102–7

A review of the rationale and advantages of various mixtures of benzathine penicillin G. Bass JW. **Pediatrics** 1996 Jun; 97(6 Pt 2):960–3

Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Dajani A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):758–64

Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Holm S, et al. **Scand J Infect Dis** 1995;27(3):221–8

Improving physician prescribing patterns to treat rhinopharyngitis. Intervention strategies in two health systems of Mexico. Pérez-Cuevas R, et al. **Soc Sci Med** 1996 Apr;42(8):1185–94

[Dirithromycin, a new antibiotic in the treatment of pharyngeal inflammation] Riazantsev SV, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):40–3 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Epidemiological observations on Streptococcus pyogenes serotype T1 in Uppsala county, Sweden 1989–1995. Osterlund A. **APMIS** 1996 Mar;104(3):168–70

Prevalence of streptococcal sorethroat in the school children of Dhaka. Faruq QO, et al. **Bangladesh Med Res Counc Bull** 1995 Dec;21(3):87–94

Incidence and pathogenicity of Arcanobacterium haemolyticum during a 2-year study in Ottawa. Mackenzie A, et al. **Clin Infect Dis** 1995 Jul;21(1):177–81

The effect of laryngeal mask cuff pressure on postoperative sore throat incidence. Burgard G, et al. **J Clin Anesth** 1996 May;8(3):198–201

ETIOLOGY

Differential diagnosis of common causes of pediatric pharyngitis. Ruppert SD. **Nurse Pract** 1996 Apr; 21(4):38–42, 44, 47–8 (21 ref.)

Role of gastroesophageal reflux disease in patients with cervical symptoms. Rival R, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):364–9

Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)

Cigarette smoking and sore throats in adults [letter] Murthy P, et al. **Postgrad Med J** 1995 Aug;71(838):510

[Effects of pathology of the gastrointestinal system on the state of the mucous membrane of the larynx and pharynx] Mashkova TA, et al. **Vestn Otorinolaringol** 1996 Mar–Apr; (2):31–3 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Salivary specific antibodies in relation to adhesion of Streptococcus pyogenes to pharyngeal cells of patients with rheumatic fever and rheumatic heart disease. Kumar KS, et al. **Adv Exp Med Biol** 1995;371A:677–9

Optical immunoassay for rapid detection of group A beta-hemolytic streptococci. Should culture be replaced? Schlager TA, et al. **Arch Pediatr Adolesc Med** 1996 Mar; 150(3):245–8

MICROBIOLOGY

Lemierre's syndrome: a case of postanginal septicemia and bilateral flank abscesses. Karanas YL, et al. **Ann Plast Surg** 1995 Nov;35(5):525–8

Arcanobacterium haemolyticum pharyngitis and exanthem. Three case reports and literature review. Gaston DA, et al. **Arch Dermatol** 1996 Jan;132(1):61–4

Proper evaluation of rapid antigen detection methods for diagnosing streptococcal pharyngitis [editorial] Wegner DL. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):241, 245–8

Recurrent Streptococcus pyogenes pharyngitis due to an inadequately cleaned orthodontic appliance [letter] Khatib R, et al. **Clin Infect Dis** 1995 Jul;21(1):230

Isolation of Arcanobacterium haemolyticum from throat culture samples in the Czech Republic [letter] Chalupa P, et al. **Infection** 1995 Nov–Dec;23(6):397

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)

Comparison of throat culture methods for the recovery of group A streptococci in a pediatric office setting. Roddey OF Jr, et al. **JAMA** 1995 Dec 20;274(23):1863–5

Therapeutic failure in group C streptococcal pharyngitis [letter] Hutchinson NA, et al. **Lancet** 1995 Nov 18; 346(8986):1367

Jugular thrombophlebitis complicating bacterial pharyngitis (Lemierre's syndrome). De Sena S, et al. **Pediatr Radiol** 1996;26(2):141–4

Rapid streptococcal tests [letter; comment] Gutman S. **Pediatrics** 1996 May;97(5):783–4. Comment on: Pediatrics 1996 Feb;97(2):288.

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

Should nurses in Israeli primary care clinics be expected to manage streptococcal throat infections? Kahan E, et al. **Public Health** 1995 Sep;109(5):347–51

Septicaemia caused by phenotypic variants of group A streptococci. Geslin P, et al. **Res Microbiol** 1996 May; 147(4):273–7

[Potential pathogenic throat bacterial flora in acute successive pharyngitis and tonsillitis in children] Chylak J. **Med Dosw Mikrobiol** 1995;47(1–2):25–33 (Eng. Abstr.) **(Pol)**

[Properties of S. aureus and H. influenzae strains residing in the throats of children] Chylak J. **Przegl Epidemiol** 1995; 49(3):275–83 (Eng. Abstr.) **(Pol)**

NURSING

Streptococcus "A" screens [letter] Cecchini JA. **Nurse Pract** 1996 Apr;21(4):152–3

PARASITOLOGY

The first human case of Clinostomum complanatum (Trematoda: Clinostomidae) infection in Korea. Chung DI, et al. **Korean J Parasitol** 1995 Sep;33(3):219–23

PHYSIOPATHOLOGY

[The level of volatile fatty acids in saliva as an indicator of the status of the human oropharyngeal epithelium—normal microflora] Babin VN, et al. **Biull Eksp Biol Med** 1995 May;119(5):494–6 **(Rus)**

SURGERY

[Abscess tonsillectomy in acute parapharyngitis] Bobrov VM. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):36–8 **(Rus)**

VETERINARY

[Veterinary dentistry (11). Feline gingivitis–stomatitis–pharyngitis complex. Chronic/recurrent stomatitis in cats] van Foreest A. **Tijdschr Diergeneeskd** 1995 Oct 1;120(19):558–62 (Eng. Abstr.) **(Dut)**

[Chronic pharyngitis in the horse] van Nieuwstadt RA. **Tijdschr Diergeneeskd** 1996 Feb 1;121(3):76 **(Dut)**

VIROLOGY

Enteroviral pharyngitis diagnosed by reverse transcriptase–polymerase chain reaction. Sharland M, et al. **Arch Dis Child** 1996 May;74(5):462–3

PHARYNGO–CONJUNCTIVAL FEVER see **ADENOVIRUS INFECTIONS, HUMAN**

PHARYNGOESOPHAGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNGOSTOMY

[Primary and delayed combined plastic repair of pharngoesophagostomies in patients with laryngopharyngeal cancer] Matiakin EG, et al. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):39–41 (Eng. Abstr.) **(Rus)**

PHARYNX

see related
PHARYNGECTOMY
PHARYNGOSTOMY

Aerodigestive tract foreign bodies in the older child and adolescent. Darrow DH, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):267–71

Traumatic epiglottis following blind finger sweep to remove a pharyngeal foreign body. Kabbani M, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):495–7

The effects of cold, touch, and chemical stimulation of the anterior faucial pillar on human swallowing [see comments] Kaatzke-McDonald MN, et al. **Dysphagia** 1996 Summer; 11(3):198–206. Comment in: Dysphagia 1996 Summer;11(3):207–8.

Comments on the effects of cold, touch, and chemical stimulation of the anterior faucial pillar on human swallowing [editorial; comment] Lazarus CL. **Dysphagia** 1996 Summer;11(3):207–8. Comment on: Dysphagia 1996 Summer;11(3):198–206.

The grandson of the Heimlich maneuver. Eschelbach MM. **J Fam Pract** 1995 Nov;41(5):505–6

ABNORMALITIES

The craniopharyngeal canal indicating the presence of pharyngeal adenopituitary tissue. Kjaer I, et al. **Eur J Radiol** 1995 Sep;20(3):212–4

ANATOMY & HISTOLOGY

Upper airway shape: Is it important in the pathogenesis of obstructive sleep apnea? Leiter JC. **Am J Respir Crit Care Med** 1996 Mar;153(3):894–8 (38 ref.)

Mallampati grade and laryngeal mask placement [letter; comment] Brimacombe JR, et al. **Anesth Analg** 1996 May; 82(5):1112–3. Comment on: Anesth Analg 1995 Nov;81(5):1001–4.

Laryngeal mask airway positioning is related to Mallampati grading in adults [see comments] McCrory CR, et al. **Anesth Analg** 1995 Nov;81(5):1001–4. Comment in: Anesth Analg 1996 May;82(5):1112–3.

Pharyngeal hypophysis. Fuller GN, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):671–2

Axial configuration of the velopharyngeal valve and its valving mechanism. Finkelstein Y, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):299–305

Myology of the pharyngoesophageal segment: gross anatomic and histologic characteristics. Kelly JH, et al. **Laryngoscope** 1996 Jun;106(6):713–20

A cascade impactor entry port for MDI sprays with collection characteristics imitating a physical model of the human throat. Miller NC, et al. **Pharm Res** 1996 Mar; 13(3):391–7

[The peripharyngeal space. Anatomy and normal imaging] Kahn JL, et al. **J Radiol** 1996 Feb;77(2):87–97 (10 ref.) (Eng. Abstr.) **(Fre)**

[The lymph vessel system of the mouth cavity and pharynx] Werner JA. **Laryngorhinootologie** 1995 Oct;74(10):622–8 (Eng. Abstr.) **(Ger)**

[Morphology and histochemistry of lymphatic vessels of the upper aerodigestive tract: a clinically oriented study] Werner JA. **Laryngorhinootologie** 1995 Sep;74(9):568–76 (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

The arterial basis of pharyngeal flaps. Mercer NS, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1026–37

[The "dangerous loop" of the internal carotid artery. An anatomic study] Tillmann B, et al. **HNO** 1995 Oct; 43(10):601–4 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Neuronal localization of serotonin in the nematode Ascaris suum. Johnson CD, et al. **J Comp Neurol** 1996 Apr 8; 367(3):352–60

DRUG EFFECTS

A phenomenological model describing pharyngeal pulsing in the nematode Caenorhabditis elegans anesthetized by alcohol. Biswas SN, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):233–44

EMBRYOLOGY

[Morphology of an additional (pharyngeal) adenohypophysis and its interrelationship with pharyngeal tonsils in the human fetus] Khlystova ZS, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):211–4 **(Rus)**

ENZYMOLOGY

Molecular cloning of cDNA and analysis of expression of the gene for alpha-glucosidase from the hypopharyngeal gland of the honeybee Apis mellifera L. Ohashi K, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):380–5

Inhibition studies on calf pregastric esterase: the enzyme has no functional thiol group. Timmermans MY, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):931–6

Purification and molecular characterization of lamb pregastric lipase. De Caro J, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):321–9

INJURIES

Surgical treatment for caustic ingestion injury of the pharynx, larynx, and esophagus. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:116–9

Pharyngo–esophageal perforation due to blunt trauma. Polsky S, et al. **Am Surg** 1995 Nov;61(11):994–6 (11 ref.)

Near–fatal aspiration of a child's dummy: design fault or deliberate injury? Barrett TG, et al. **J Accid Emerg Med** 1995 Jun;12(2):154–5

Pharyngeal perforation: an easily missed finding following intra–oral injury. Rowley H, et al. **J Accid Emerg Med** 1995 Jun;12(2):145–6

Pharyngeal trauma in children—accidental and otherwise. Tostevin PM, et al. **J Laryngol Otol** 1995 Dec; 109(12):1168–75

Traumatizing effects of blind oral intubation using the Augustine Guide. Kautzky M, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):156–61

Maladministration of anthelmintic boluses [letter] West HJ, et al. **Vet Rec** 1995 Jul 15;137(3):76

INNERVATION

Interacting genes required for pharyngeal excitation by motor neuron MC in Caenorhabditis elegans. Raizen DM, et al. **Genetics** 1995 Dec;141(4):1365–82

METABOLISM

Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Shaker R, et al. **Gastroenterology** 1995 Nov;109(5):1575–82

MICROBIOLOGY

Salivary specific antibodies in relation to adhesion of Streptococcus pyogenes to pharyngeal cells of patients with rheumatic fever and rheumatic heart disease. Kumar KS, et al. **Adv Exp Med Biol** 1995;371A:677–9

The prevalence of group A streptococcal throat carriage in Al Ain, United Arab Emirates. Dawson KP, et al. **Ann Trop Paediatr** 1996 Jun;16(2):123–7

Bacteriocins in Neisseria meningitidis. Screening of systemic patient strains and pharyngeal isolates from healthy carriers. Allunans J, et al. **APMIS** 1996 Mar;104(3):206–12

Single dose ofloxacin in the eradication of pharyngeal carriage of Neisseria meningitidis. Halstensen A, et al. **Drugs** 1995;49 Suppl 2:399–400

Attachment of Moraxella catarrhalis to pharyngeal epithelial cells is mediated by a glycosphingolipid receptor. Ahmed K, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):305–9

Corynebacterium argentoratense sp. nov., from the human throat. Riegel P, et al. **Int J Syst Bacteriol** 1995 Jul; 45(3):533–7

Genetic correlates of throat and skin isolates of group A streptococci. Bessen DE, et al. **J Infect Dis** 1996 Apr; 173(4):896–900

Comparison of throat culture methods for the recovery of group A streptococci in a pediatric office setting. Roddey OF Jr, et al. **JAMA** 1995 Dec 20;274(23):1863–5

Increased proportions of bacteria capable of cleaving IgA1 in the pharynx of infants with atopic disease. Kilian M, et al. **Pediatr Res** 1995 Aug;38(2):182–6

[Potential pathogenic throat bacterial flora in acute successive pharyngitis and tonsillitis in children] Chylak J. **Med Dosw Mikrobiol** 1995;47(1–2):25–33 (Eng. Abstr.) **(Pol)**

[Properties of S. aureus and H. influenzae strains residing in the throats of children] Chylak J. **Przegl Epidemiol** 1995; 49(3):275–83 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Sleep apnea syndrome. Examination of pharyngeal obstruction with high–speed MR and polysomnography. Suto Y, et al. **Acta Radiol** 1996 May;37(3 Pt 1):315–20

Associations among upper airway structure, body position, and obesity in skeletal Class I male patients with obstructive sleep apnea. Ono T, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):625–34

Recurrent rhabdomyoma of the parapharyngeal space. Goldfarb D, et al. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):58–60

Upper airway and soft tissue anatomy in normal subjects and patients with sleep–disordered breathing. Significance of the lateral pharyngeal walls. Schwab RJ, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1673–89

Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans [see comments] Mathru M, et al. **Anesthesiology** 1996 Feb;84(2):273–9. Comment in: Anesthesiology 1996 Feb;84(2):253–5.

Anterior approach for CT–guided biopsy of skull base and parapharyngeal space lesions. Esposito MB, et al. **J Comput Assist Tomogr** 1996 Sep–Oct;20(5):739–41

Parapharyngeal masses. Report de 4 cases. Dhillon RS, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):273–6

Effect of chronic continuous positive airway pressure (CPAP) therapy on upper airway size in patients with sleep apnoea/hypopnoea syndrome. Mortimore IL, et al. **Thorax** 1996 Feb;51(2):190–2

[Effects of pathology of the gastrointestinal system on the state of the mucous membrane of the larynx and pharynx] Mashkova TA, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;

(2):31–3 (Eng. Abstr.) **(Rus)**
[Simultaneous screening of HPV–6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**
[Our experience in the management of parapharyngeal tumors] Povedano Rodríguez V, et al. **An Otorrinolaringol Ibero Am** 1995;22(4):393–403 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Pharyngeal hypophysis. Fuller GN, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):671–2
Kinematic and dynamic characteristics of solid pellet movement during the pharyngeal phase of swallowing. Kern MK, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):716–23
Postural changes in respiratory airflow pressure and resistance in nasal, hypopharyngeal, and pharyngeal airway in normal subjects. Tvinnereim M, et al. **Ann Otol Rhinol Laryegol** 1996 Mar;105(3):218–21
Technical note: dynamic analysis of the pharynx during swallowing using Turbo-FLASH magnetic resonance imaging combined with an oral positive contrast agent—a preliminary study. Suto Y, et al. **Br J Radiol** 1995 Oct; 68(814):1099–102
Axial configuration of the velopharyngeal valve and its valving mechanism. Finkelstein Y, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):299–305
Relationships between integrated oral–nasal differential pressure and velopharyngeal closure. Hinton VA, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):306–10
Influence of cold stimulation on the normal pharyngeal swallow response [see comments] Ali GN, et al. **Dysphagia** 1996 Winter;11(1):2–8. Comment in: Dysphagia 1996 Winter;11(1):9–10.
Surface EMG measurements at the throat during dry and wet swallowing. Gupta V, et al. **Dysphagia** 1996 Summer; 11(3):173–9
Normal adult swallowing of liquid and viscous material: scintigraphic data on bolus transit and oropharyngeal residues. Hamlet S, et al. **Dysphagia** 1996 Winter;11(1):41–7
Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)
Characteristics of lower esophageal sphincter relaxation induced by pharyngeal stimulation with minute amounts of water. Mittal RK, et al. **Gastroenterology** 1996 Aug; 111(2):378–84
Inhibition of progressing primary esophageal peristalsis by pharyngeal water stimulation in humans. Trifan A, et al. **Gastroenterology** 1996 Feb;110(2):419–23
Palatal and pharyngeal reflexes in health and in motor neuron disease. Hughes TA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):96–8
The repeatability and variability of electrical impedance tomography indices of pharyngeal transit time in normal adults. Hughes TA, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A79–86
Medullary neuronal activities in gasping induced by pharyngeal stimulation and hypoxia. Fung ML, et al. **Respir Physiol** 1995 Jun;100(3):195–202

PHYSIOPATHOLOGY

Effect of blood transfusion on tumor recurrence and postoperative pharyngocutaneous fistula formation in patients subjected to total laryngectomy. Celikkanat S, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):566–8
Functional abnormalities of the pharynx: a prospective analysis of radiographic abnormalities relative to age and symptoms. Frederick MG, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):353–7
Mechanical properties of the velopharynx in obese patients with obstructive sleep apnea. Ryan CF, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):806–12
Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Shapiro J, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):331–5
Predominance and improvement of velopharyngeal function in patients without complete closure in blowing [letter; comment] Yamaoka M, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):353. Comment on: Cleft Palate Craniofac J 1994 Jul;31(4):271–9.
Solid-state computerized manometry improves diagnostic yield in pharyngeal dysphagia: simultaneous videoradiography and manometry in dysphagia patients with normal barium swallows. Buchholz D, et al. **Dysphagia** 1996 Summer;11(3):219–20
Prepharyngeal dysphagia in Parkinson's disease [see comments] Leopold NA, et al. **Dysphagia** 1996 Winter; 11(1):14–22. Comment in: Dysphagia 1996 Winter;11(1):23–4.
Pathological pharyngo–esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)
Upper esophageal sphincter and pharyngeal function and oropharyngeal (transfer) dysphagia. Castell JA, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):35–50
Advancement of the mandible improves velopharyngeal airway patency. Isono S, et al. **J Appl Physiol** 1995 Dec; 79(6):2132–8
Enlargement of the lateral pharyngeal fat pad space in pigs increases upper airway resistance. Winter WC, et al. **J Appl Physiol** 1995 Sep;79(3):726–31
Palatal and pharyngeal reflexes in health and in motor neuron disease. Hughes TA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):96–8
The case of the disappearing fish bone. Canbay E, et al. **J Otolaryngol** 1995 Dec;24(6):375–6
[The pharyngoesophageal segment] Ekberg O, et al. **Radiologe** 1995 Oct;35(10):689–92 (22 ref.) (Eng. Abstr.) **(Ger)**
[Functional MRI of the pharynx in obstructive sleep apnea using rapid 2D FLASH sequences] Jäger L, et al. **Radiologe** 1996 Mar;36(3):245–53 (Eng. Abstr.) **(Ger)**
[Temporal and spatial pattern analysis of pharyngeal swallowing in patients with abnormal sensation in the throat] Saito K. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul; 98(7):1154–63 (Eng. Abstr.) **(Jpn)**
[Retropharyngeal abscess] Crusat Braña S, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):169–78 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

An unusual foreign body migrating from pharynx to mediastinum. Sinha A, et al. **J Laryngol Otol** 1996 Mar; 110(3):279–80
[Computed tomography of the upper respiratory tract in patients with apnea] Obenberger J, et al. **Cas Lek Cesk** 1996 Mar 6;135(5):145–9 (Eng. Abstr.) **(Cze)**
[Videofluorography as a method of evaluating hypernasality] Haapanen ML, et al. **Duodecim** 1994;110(9):891–5 **(Fin)**

RADIONUCLIDE IMAGING

Normal adult swallowing of liquid and viscous material: scintigraphic data on bolus transit and oropharyngeal residues. Hamlet S, et al. **Dysphagia** 1996 Winter;11(1):41–7

SURGERY

Surgical treatment for caustic ingestion injury of the pharynx, larynx, and esophagus. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:116–9
Oropharyngeal reconstruction after ablative surgery of the head and neck—experience of 93 cases. Lim DT, et al. **Ann Acad Med Singapore** 1995 May;24(3):370–2
Anastomosis technique for high pharyngogastrostomy. Krasna MJ, et al. **Ann Thorac Surg** 1995 Dec;60(6):1821–3
An audit of velopharyngeal incompetence treated by the Orticochea pharyngoplasty. James NK, et al. **Br J Plast Surg** 1996 Jun;49(4):197–201
Patient selection for uvulopalatopharyngoplasty [letter] Carney AS, et al. **Chest** 1996 Sep;110(3):864
Acute obstructive sleep apnea as a complication of sphincter pharyngoplasty. Witt PD, et al. **Cleft Palate Craniofac J** 1996 May;33(3):183–9
Objective measurement of the results of uvulopalatopharyngoplasty. Prichard AJ, et al. **Clin Otolaryngol** 1995 Dec;20(6):495–8
Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)
Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)
Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery. Greenspun JC, et al. **J Clin Anesth** 1995 Aug; 7(5):398–402
The function of free jejunal autografts in the pharyngo–oesophageal segment. Wilson JA, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):363–6
Split, free, jejunal transfer for pharyngoesophageal and soft-tissue reconstruction. Li K, et al. **J Reconstr Microsurg** 1995 Jul;11(4):251–3
Primary closure of pharyngeal remnant after total laryngectomy and partial pharyngectomy: how much residual mucosa is sufficient? Hui Y, et al. **Laryngoscope** 1996 Apr;106(4):490–4
Previous tonsillectomy as prognostic indicator for success of uvulopalatopharyngoplasty. McGuirt WF Jr, et al. **Laryngoscope** 1995 Nov;105(11):1253–5
Transoral–transpharyngeal approach to the craniocervical junction. Kingdom TT, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):393–400
Upper airway resistance syndrome after uvulopalatopharyngoplasty for obstructive sleep apnea syndrome. Woodson BT. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):457–61
Reconstruction of the pharynx and overlying soft tissue by a partitioned free jejunal flap. Carlson GW, et al. **Plast Reconstr Surg** 1996 Feb;97(2):460–2
The arterial basis of pharyngeal flaps. Mercer NS, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1026–37
Sphincter pharyngoplasty [letter; comment] Moss AL. **Plast Reconstr Surg** 1995 Dec;96(7):1745–6. Comment on: Plast Reconstr Surg 1994 May;93(6):1154–68.
Morbidity and functional outcome of free jejunal transfer reconstruction for circumferential defects of the pharynx and cervical esophagus. Reece GP, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1307–16
Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)
[Uvulopalatopharyngoplasty: safety managements and causes of failure] Peng P, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):135–7 (Eng. Abstr.) **(Chi)**
[Treatment of velopharyngeal stenosis after pharyngotomy for chronic snoring. Apropos of 13 cases] Chabolle F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):324–9 (Eng. Abstr.) **(Fre)**
[The excision of branchial parapharyngeal cysts by transbuccal or l cervical approach] Chabot M, et al. **J Otolaryngol** 1996 Apr;25(2):108–12 (Eng. Abstr.) **(Fre)**
[Uvulo–palatopharyngioplasty: indication, technique and results in relation to ronchopathy and sleep apnea syndrome] Cseh A, et al. **Schweiz Rundsch Med Prax** 1996 May 21;85(21):684–8 (Eng. Abstr.) **(Ger)**
[Morphologic and ultrastructural changes of soft palate in patients who underwent palatopharyngoplasty] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):18–23 (Eng. Abstr.) **(Ita)**
[One–stage repair of the laryngopharynx and the cervical part of the esophagus with a free combined gastro–omental autograft using microsurgery technique] Antokhil NI, et al. **Khirurgiia (Mosk)** 1995;(6):58 **(Rus)**

ULTRASTRUCTURE

[Morphologic and ultrastructural changes of soft palate in patients who underwent palatopharyngoplasty] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):18–23 (Eng. Abstr.) **(Ita)**

VIROLOGY

Titration of varicella–zoster virus DNA in throat swabs from varicella patients by combined use of PCR and microplate hybridization. Hondo R, et al. **Jpn J Med Sci Biol** 1995 Oct–Dec;48(5–6):249–55
Isolation of influenza A and B viruses in HeLa cells. Yamanaka T, et al. **Microbiol Immunol** 1995;39(5):361–3
[Simultaneous screening of HPV–6b and 16 in pharyngolaryngeal cancer] Alvarez Alvarez I, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):93–6 (Eng. Abstr.) **(Spa)**

PHASE I CLINICAL TRIALS see **CLINICAL TRIALS, PHASE I**

PHASE II CLINICAL TRIALS see **CLINICAL TRIALS, PHASE II**

PHASE III CLINICAL TRIALS see **CLINICAL TRIALS, PHASE III**

PHASEOLUS see **LEGUMES**

PHASEOLUS VULGARIS LECTINS see **PHYTOHEMAGGLUTININS**

PHEMA see **POLYHYDROXYETHYL METHACRYLATE**

PHENACETIN

ADVERSE EFFECTS

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)
Clonal analysis of phenacetin–implicated urothelial carcinoma [letter] Rinaldi F, et al. **Int J Cancer** 1995 Dec 11;63(6):881–2

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Chronic interstitial nephritis in abuse of phenacetin–containing analgesics (Saridon etc.) 1953 (classical article)] Zollinger HU. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2253–4 **(Ger)**

TOXICITY

Thymosin fraction 5 does not influence urinary tract carcinogenesis by phenacetin and N–butyl–N–(4–hydroxybutyl)nitrosamine in NON/Shi mice. Murai T, et al. **Oncol Res** 1995;7(3–4):139–44

URINE

Studies on 13C–phenacetin metabolism. II. A combination of breath test and urine test of in vivo metabolites in the diagnosis of liver disease. Kajiwara M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1258–60

PHENADONE see **METHADONE**

PHENANTHRENES

ADVERSE EFFECTS

Cardiac effects of standard–dose halofantrine therapy. Matson PA, et al. **Am J Trop Med Hyg** 1996 Mar; 54(3):229–31
Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy.

Schmeiser HH, et al. **Cancer Res** 1996 May 1;56(9):2025–8
Contact urticaria from abietic acid. el Sayed F, et al. **Contact Dermatitis** 1995 Jun;32(6):361–2
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. Kano S, et al. **Kanseashogaku Zasshi** 1995 Dec;69(12):1408–12
Blackwater fever after halofantrine [letter] Orlando G, et al. **Lancet** 1996 May 18;347(9012):1408–9
Cardiac complications of halofantrine: a prospective study of 20 patients. Monlun E, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):430–3
[Electrocardiographic changes due to halofantrine in the treatment of malaria: therapeutic implications] Giudicelli CP, et al. **Bull Acad Natl Med** 1996 Jan;180(1):71–80; discussion 80–2 (Eng. Abstr.) **(Fre)**
[Prolonged QT interval and cardiac toxicity due to halofantrine (letter)] Fourcade L, et al. **Med Trop (Mars)** 1995;55(2):182–3 **(Fre)**
[Monitoring of long QT interval during treatment of malaria with halofantrine (letter)] Nicolas X, et al. **Med Trop (Mars)** 1995;55(4):394–5 **(Fre)**

BLOOD

New solid-phase extraction for an improved high-performance liquid chromatographic procedure for the quantitation of halofantrine and monodesbutylhalofantrine in blood or plasma. Gaillard Y, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):315–21
A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. Brocks DR, et al. **J Pharm Biomed Anal** 1995 Jun; 13(7):911–8

CHEMICAL SYNTHESIS

Direct synthesis and characterization of site-specific adenosyl adducts derived from the binding of a 3,4-dihydroxy-1,2-epoxybenzo[c]phenanthrene stereoisomer to an 11-mer oligodeoxyribonucleotide. Laryea A, et al. **Chem Res Toxicol** 1995 Apr–May; 8(3):444–54

CHEMISTRY

In vitro reaction with DNA of the fjord-region diol epoxides of benzo[g]chrysene and benzo[c]phenanthrene as studied by 32P-postlabeling. Giles AS, et al. **Chem Res Toxicol** 1995 Jun;8(4):591–9
Quantum mechanical studies of the structure and reactivities of the diol epoxides of benzo[c]phenanthrene. Lewis-Bevan L, et al. **Chem Res Toxicol** 1995 Jun;8(4):499–505
A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Humberstone AJ, et al. **J Pharm Sci** 1996 May;85(5):525–9

METABOLISM

Metabolism of phenanthrene by the white rot fungus Pleurotus ostreatus. Bezalel L, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2547–53
Quantifying the biodegradation of phenanthrene by Pseudomonas stutzeri P16 in the presence of a nonionic surfactant. Grimberg SJ, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2387–92
Regio- and stereospecific oxidation of 9,10-dihydroanthracene and 9,10-dihydrophenanthrene by naphthalene dioxygenase: structure and absolute stereochemistry of metabolites. Resnick SM, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3355–9
An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Halliday RC, et al. **Br J Clin Pharmacol** 1995 Oct; 40(4):369–78
Benzo[c]phenanthrene-DNA adducts in mouse epidermis in relation to the tumorigenicities of four configurationally isomeric 3,4-dihydrodiol 1,2-epoxides. Agarwal R, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):586–92
Crown gall culture and production of tanshinone in Salvia miltiorrhiza. Zhang Y, et al. **Chin J Biotechnol** 1995; 11(2):137–41

PHARMACOKINETICS

A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Humberstone AJ, et al. **J Pharm Sci** 1996 May;85(5):525–9

PHARMACOLOGY

Antimicrobial screening of zinc in the absence or presence of oleoresins and various resin acids. Johansson A, et al. **APMIS** 1995 Jun;103(6):419–27
Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Roberts ES, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):295–302
Mechanistic studies of 9-ethynylphenanthrene-inactivated cytochrome P450 2B1. Roberts ES, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):303–12
Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Chan MM, et al. **Cancer Lett** 1995 Sep 4;96(1):23–9
Rosemary extract and carnosol stimulate rat liver glutathione-S-transferase and quinone reductase activities. Singletary KW. **Cancer Lett** 1996 Feb 27;100(1–2):139–44
Effect of halofantrine and its desbutyl metabolite on lymphocyte proliferation dynamics. Fasanmade AA, et al. **Life Sci** 1995;57(14):PL175–80
Inhibitors of cAMP-dependent protein kinase impair long-term memory formation in day-old chicks. Zhao WQ, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):106–18
[The differentiation-inducing effect of tanshinone and retinoic acid on human cervical carcinoma cell line in vitro] Yuan S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov; 17(6):422–4 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Touze JE, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):225–8
Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Singletary K, et al. **Cancer Lett** 1996 Jun 24; 104(1):43–8
In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria. Ezedinachi E. **Cent Afr J Med** 1996 Apr;42(4):109–11
A case of dual chloroquine and halofantrine treatment failure in Zimbabwe. Mharakurwa S. **Cent Afr J Med** 1995 Oct; 41(10):327–9
Halofantrine in the treatment of malaria [letter; comment] Horton J. **Drug Saf** 1995 Oct;13(4):271–2. Comment on: Drug Saf 1995 Apr;12(4):264–73.
A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children. Anabwani GM, et al. **East Afr Med J** 1996 Mar;73(3):155–8
Efficacy of halofantrine in the treatment of uncomplicated falciparum malaria. Mbori-Ngacha DA, et al. **East Afr Med J** 1995 Dec;72(12):796–9
Halofantrine in the treatment of falciparum malaria. Patel KH, et al. **Indian J Malariol** 1995 Mar;32(1):1–5
[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**
[The halofantrine treatment of Plasmodium falciparum malaria. Clinical experience] Villota Arrieta J, et al. **An Esp Pediatr** 1996 Feb;44(2):117–20 (Eng. Abstr.) **(Spa)**

TOXICITY

Chronic toxicity of phenanthrene to the marine polychaete worm, Nereis (Neanthes) arenaceodentata. Emery VL Jr, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):265–70
Effect of site-specifically located aristolochic acid DNA adducts on in vitro DNA synthesis by human DNA polymerase alpha. Broschard TH, et al. **Cancer Lett** 1995 Nov 27;98(1):47–56
Lack of tumorigenicity of cholesterol epoxides and estrone-3,4-quinone in the rat mammary gland. el-Bayoumy K, et al. **Cancer Res** 1996 May 1;56(9):1970–3
Dose-dependent differences in the mutational profiles of (–)-(1R,2S,3S,4R)-3,4-dihydroxy-1, 2-epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene and its less carcinogenic enantiomer. Wei SJ, et al. **Cancer Res** 1996 Aug 15;56(16):3695–703
Benzo[c]phenanthrene 3,4-dihydrodiol 1,2-epoxide adducts in native and denatured DNA. Agarwal R, et al. **Carcinogenesis** 1996 Aug;17(8):1773–6
Malignant transformation of the liver tumour precursor cell line OC/CDE 22 by the four stereoisomeric fjord region 3,4-dihydrodiol 1,2-epoxides of benzo[c]phenanthrene. Seidel A, et al. **Carcinogenesis** 1995 Sep;16(9):2111–5
Expression of a 32 kDa protein in rat mammary tumors induced by anti-benzo[c]phenanthrene-3,4-diol-1,2-epoxide. Ronai Z, et al. **Int J Cancer** 1996 Jul 3;67(1):124–8
Influence of DT diaphorase on quinone-mediated genotoxicity in human and fish cell lines. Hasspieler BM, et al. **Mutat Res** 1996 May 17;360(1):43–9
Mutagenicity of nitrophenanthrene derivatives for Salmonella typhimurium: effects of nitroreductase and acetyltransferase. Sera N, et al. **Mutat Res** 1996 Jan 17; 349(1):137–44

PHENANTHRIDINES

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Walterová D, et al. **Acta Univ Palacki Olomuc Fac Med** 1995;139:7–16 (110 ref.)
Synthesis of novel phosphoramidite reagents for the attachment of antisense oligonucleotides to various regions of the benzophenanthridine ring system. Chen JK, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):473–82

BLOOD

A simple competitive enzyme immunoassay for the detection of the trypanocidal drug isometamidium. Eisler MC, et al. **Ther Drug Monit** 1996 Feb;18(1):73–9
Isometamidium concentrations in the sera of cattle maintained under a chemoprophylactic regime in a tsetse-infested area of Zimbabwe. Eisler MC, et al. **Trop Med Int Health** 1996 Aug;1(4):535–41

DIAGNOSTIC USE

Flow cytometric analysis of cell suspensions exposed to shock waves in the presence of the radical sensitive dye hydroethidine. Endl E, et al. **Ultrasound Med Biol** 1995; 21(4):569–77

METABOLISM

The accumulation and compartmentalization of isometamidium chloride in Trypanosoma congolense, monitored by its intrinsic fluorescence. Wilkes JM, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):319–27
Use of hydroethidine and flow cytometry to assess the effects of leukocytes on the malarial parasite Plasmodium falciparum. van der Heyde HC, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):417–25
Characterization and mechanism of the berberine bridge enzyme, a covalently flavinylated oxidase of benzophenanthridine alkaloid biosynthesis in plants. Kutchan TM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24475–81
Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. Bindokas VP, et al. **J Neurosci** 1996 Feb 15;16(4):1324–36

PHARMACOKINETICS

Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist. Elder CA, et al. **Drug Metab Dispos** 1995 Jul;23(7):776–8

PHARMACOLOGY

French Guyanan stock of Trypanosoma vivax resistant to diminazene aceturate but sensitive to isometamidium chloride. Desquesnes M, et al. **Acta Trop** 1995 Oct; 60(2):133–6
The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Steele TD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:427–30
Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy. Gakunju DM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2606–9
Protein kinase C inhibitor, chelerythrine, potentiates the adrenaline-mediated aggregation of human platelets through calcium influx. Shah BH, et al. **Biochem Mol Biol Int** 1996 May;38(6):1135–41
Stimulation by chelerythrine of the phosphorylation of the amino acid serine in an approximately 20 kDa protein present in the mitochondrial fraction of the rat retina. Lombardini JB. **Biochem Pharmacol** 1996 Jul 26;52(2):253–7
Effects of benzophenanthridine alkaloids on the phosphorylation of an approximately 44 kDa protein present in a mitochondrial fraction of the rat heart. Lombardini JB, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):151–7
The influence of linker chain length on the sequence specificity of DNA damage by n-bromoalkylphenanthridinium bromides in plasmid DNA and in intact human cells. Murray V, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):79–86
Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Chmura SJ, et al. **Cancer Res** 1996 Jun 15;56(12):2711–4
Inhibition of copper/quinoprotein amine oxidases from Aspergillus niger by benzophenanthridine alkaloids. Luhová L, et al. **J Enzym Inhib** 1995;9(4):295–302
Alpha-adrenergic preservation of myocardial pH during ischemia is PKC isoform dependent. Rehring TF, et al. **J Surg Res** 1996 Jun;63(1):324–7
Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Freemerman AJ, et al. **Mol Pharmacol** 1996 May; 49(5):788–95
Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Gagnon C, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):667–76

TOXICITY

Effect of quaternary benzo[c]phenanthridine alkaloids sanguinarine, chelerythrine and fagaronine on some mammalian cells. Vavrečková C, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:7–10

PHENANTHROLINES

Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)

ADVERSE EFFECTS

Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter] Tam LS, et al. **Aust N Z J Med** 1995 Jun;25(3):258

PHENANTHROLINES

CHEMISTRY

Formation and microscopical application of a fluorescent 1,10-phenanthroline derivative of ruthenium red. Bertolesi GE, et al. **Acta Histochem** 1995 Oct;97(4):401–8

Inhibitors of Escherichia coli RNA polymerase specific for the single-stranded DNA of transcription intermediates. Tetrahedral cuprous chelates of 1,10-phenanthrolines. Perrin DM, et al. **Biochemistry** 1996 Apr 23;35(16):5318–26

Chiral discrimination in the binding of tris(phenanthroline)ruthenium(II) to calf thymus DNA: an electrochemical study. Mahadevan S, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):138–43

Triplex-mediated cleavage of DNA by 1,10-phenanthroline-linked 2'-O-methyl RNA. Shimizu M, et al. **FEBS Lett** 1996 Apr 22;384(3):207–10

DNA-stacking interactions determine the sequence specificity of the deoxyribonuclease activity of 1,10-phenanthroline-copper ion. Schaeffer F, et al. **J Mol Biol** 1996 Jul 26;260(4):523–39

Drosophila engrailed-1,10-phenanthroline chimeras as probes of homeodomain-DNA complexes. Pan CQ, et al. **Protein Sci** 1995 Nov;4(11):2279–88

METABOLISM

Regions of 23 S ribosomal RNA proximal to transfer RNA bound at the P and E sites. Bullard JM, et al. **J Mol Biol** 1995 Oct 6;252(5):572–82

DNA-stacking interactions determine the sequence specificity of the deoxyribonuclease activity of 1,10-phenanthroline-copper ion. Schaeffer F, et al. **J Mol Biol** 1996 Jul 26;260(4):523–39

PHARMACOLOGY

Inhibition of hydroperoxide-induced DNA single-strand breakage by 1, 10-phenanthroline in HL-60 cells: implications for iron speciation. Byrnes RW. **Arch Biochem Biophys** 1996 Aug 1;332(1):70–8

Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+. Davis DA, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):127–34

Research communication copper-1,10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells, resulting from direct oxidation by the hydroxyl radical. Tsang SY, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):13–6

Effects of zinc and divalent cation chelators on ATP hydrolysis and Ca deposition by rachitic rat matrix vesicles. Hsu HH, et al. **Bone** 1995 Nov;17(5):473–7

Lethal interaction between hydrogen peroxide and o-phenanthroline in Escherichia coli. Asad NR, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2551–5

Induction of tumor necrosis by delta-aminolevulinic acid and 1,10-phenanthroline photodynamic therapy. Rebeiz N, et al. **Cancer Res** 1996 Jan 15;56(2):339–44

Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients. Einat M, et al. **Exp Hematol** 1995 Dec;23(14):1439–44

Depletion of cellular iron by bps and ascorbate: effect on toxicity of adriamycin. Nyayapati S, et al. **Free Radic Biol Med** 1996;20(3):319–29

Effect of 1,10-phenanthroline on DNA binding by 1,25-(OH)2 vitamin D receptor. Atkins KB, et al. **Horm Metab Res** 1995 Oct;27(10):455–60

Inhibition of OH radical-induced strand break formation of poly(U) by Ru(bpy)32+ or Ru(phen)32+ attached to the polynucleotide. Tossi AB, et al. **Int J Radiat Biol** 1995 Nov;68(5):525–33

Influence of 1,10-phenanthroline and its analogues, other chelators and transition metal ions on dipeptidase activity of the rumen bacterium, Prevotella ruminicola. Wallace RJ, et al. **J Appl Bacteriol** 1996 Jul;81(1):42–7

Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. Arribas J, et al. **J Biol Chem** 1996 May 10;271(19):11376–82

Translocation of loops regulates transport activity of mitochondrial ADP/ATP carrier deduced from formation of a specific intermolecular disulfide bridge catalyzed by copper-o-phenanthroline. Majima E, et al. **J Biol Chem** 1995 Dec 8;270(49):29548–54

Pharmacological induction of heat shock protein 68 synthesis in cultured rat astrocytes. Nishimura RN, et al. **J Biol Chem** 1995 Dec 15;270(50):29967–70

The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. Chan K, et al. **J Pharm Pharmacol** 1995 May;47(5):402–6

Study on the effects of "foshousan" plus danshen in preventing IUGR rats with passive smoking from peroxidation in erythrocyte lipid. Han QH, et al. **J Tongji Med Univ** 1995; 15(2):120–4

TOXICITY

1,10-Phenanthroline stimulates internucleosomal DNA fragmentation in isolated rat-liver nuclei by promoting the redox activity of endogenous copper ions. Burkitt MJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):163–9

Ortho-phenanthroline modulates enzymes of cellular energy metabolism. Gerber E, et al. **Toxicology** 1996 Jun 17; 110(1-3):85–93

PHENANTOIN see **PHENYTOIN**

PHENAZINE METHOSULFATE see **METHYLPHENAZONIUM METHOSULFATE**

PHENAZINES

Efficacy of the Ryu nonstaining KOH technique for rapidly determining gram reactions of food-borne and waterborne bacteria and yeasts. Powers EM. **Appl Environ Microbiol** 1995 Oct;61(10):3756–8

Pseudomeningitis again. Association with cytocentrifuge funnel and Gram-stain reagent contamination. Southern PM Jr, et al. **Arch Pathol Lab Med** 1996 May;120(5):456–8

Evaluation of dipstrips, direct gram stain and pyuria as screening tests for the detection of bacteriuria. Hussain R, et al. **JPMA J Pak Med Assoc** 1996 Feb;46(2):38–41

CHEMISTRY

Marked detergents effects on safranine T-mediated photo-induced electron transfer in cytochrome P-450 1A2. Nakano R, et al. **Biochim Biophys Acta** 1995 Oct 25; 1252(2):245–50

Base-pair exchange kinetics of the imino and amino protons of the 3'-phenazinium tethered DNA-RNA duplex, r(5'GAUUGAA3'):d(5'TCAATC3'-Pzn), and their comparison with those of B-DNA duplex. Maltseva TV, et al. **J Biochem Biophys Methods** 1995 Jun;30(2-3):163–77

ISOLATION & PURIFICATION

Isolation and structure determination of two novel phenazines from a Streptomyces with inhibitory activity against metallo-enzymes, including metallo-beta-lactamase. Gilpin ML, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1081–5

Novel neuronal cell protecting substances, aestivophoenins A and B, produced by Streptomyces purpeofuscus [letter] Shin-ya K, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1378–81

METABOLISM

Scavenging of neutrophil-derived superoxide anion by 1-hydroxyphenazine, a phenazine derivative associated with chronic Pseudomonas aeruginosa infection: relevance to cystic fibrosis. Muller M. **Biochim Biophys Acta** 1995 Dec 12;1272(3):185–9

Molecular analysis of genes encoding phenazine biosynthesis in the biological control bacterium. Pseudomonas aureofaciens 30-84. Pierson LS 3rd, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):299–307

Induction of phenazine biosynthesis in cultures of Pseudomonas aeruginosa by L-N-(3-oxohexanoyl)homoserine lactone. Stead P, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):15–22

The phzI gene of Pseudomonas aureofaciens 30-84 is responsible for the production of a diffusible signal required for phenazine antibiotic production. Wood DW, et al. **Gene** 1996 Feb 2;168(1):49–53

PHARMACOLOGY

Safranin O reduces loss of glycosaminoglycans from bovine articular cartilage during histological specimen preparation. Király K, et al. **Histochem J** 1996 Feb;28(2):99–107

Isolation and structure determination of two novel phenazines from a Streptomyces with inhibitory activity against metallo-enzymes, including metallo-beta-lactamase. Gilpin ML, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1081–5

Antitumor agents. 164. Podophenazine, 2",3"-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors. Cho SJ, et al. **J Med Chem** 1996 Mar 29;39(7):1396–402

TOXICITY

A novel antitumor compound, NC-190, induces topoisomerase II-dependent DNA cleavage and DNA fragmentation. Yamagishi T, et al. **Cancer Chemother Pharmacol** 1996;38(1):29–34

Genotoxicity in vivo of phenazine and aminophenazines assayed in the wing spot test and the DNA-repair test with Drosophila melanogaster. Watanabe T, et al. **Mutat Res** 1996 Jul 10;369(1-2):75–80

PHENAZOCINE

ANALOGS & DERIVATIVES

Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Matsuno K, et al. **Brain Res** 1995 Sep 4;690(2):200–6

Intrahippocampal administration of (+)-SKF 10,047, a sigma ligand, reverses MK-801-induced impairment of working memory in rats. Ohno M, et al. **Brain Res** 1995 Jul 3; 684(2):237–42

(+)-N-allylnormetazocine enhances N-acetyltransferase activity and melatonin synthesis: preliminary evidence for a functional role of sigma receptors in the rat pineal gland. Steardo L, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):845–9

Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. Volonté M, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):358–67

[Search for an endogenous ligand for sigma receptors] Samovilova NN, et al. **Vopr Med Khim** 1995 Sep–Oct; 41(5):9–13 (Eng. Abstr.) **(Rus)**

PHENAZONE see **ANTIPYRINE**

PHENAZOPYRIDINE

URINE

Urinary excretion of pyridinium cross-links of collagen in infancy. Tsukahara H, et al. **Metabolism** 1996 Apr; 45(4):510–4

PHENBENZORPHAN see **PHENAZOCINE**

PHENCYCLIDINE

see related
PHENCYCLIDINE ABUSE
RECEPTORS, PHENCYCLIDINE

ADVERSE EFFECTS

A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):82–93 (122 ref.)

[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Ethanol-induced inhibition of [3H]thienylcyclohexylpiperidine (TCP) binding to NMDA receptors in brain synaptic membranes and to a purified protein complex. Michaelis EK, et al. **J Neurochem** 1996 Jul;67(1):201–11

ANALYSIS

Simple and sensitive detection of phencyclidine in body fluids by gas chromatography with surface ionization detection. Ishii A, et al. **Int J Legal Med** 1996;108(5):244–7

ANTAGONISTS & INHIBITORS

DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Sharp JW, et al. **Brain Res** 1995 Jul 31;687(1-2):114–24

Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Maurel-Remy S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R9–11

Effect of repeated haloperidol administration on phencyclidine discrimination in rats. Wiley JL. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):699–711

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Bakshi VP, et al. **Psychopharmacology (Berl)** 1995 Nov; 122(2):198–201

ECONOMICS

Normalized demand for drugs and other reinforcers. Hursh SR, et al. **J Exp Anal Behav** 1995 Nov;64(3):373–84

METABOLISM

Phencyclidine metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11. Shelnutt SR, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):292–8

Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. Valentine JL, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):717–24

PHARMACOLOGY

Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Hertel P, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):103–14

Effects of calcium antagonists nifedipine and flunarizine on phencyclidine-induced changes in the regional dopaminergic metabolism of the rat brain. Etou K, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):83–6

Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Noda Y, et al. **Br J Pharmacol** 1995 Nov;116(5):2531–7

Role of nitric oxide in the development of tolerance and sensitization to behavioural effects of phencyclidine in mice. Noda Y, et al. **Br J Pharmacol** 1996 Apr; 117(7):1579–85

Chronic postnatal phencyclidine treatment on [3H](+) pentazocine binding in juvenile rat brain. Sircar R, et al.

Brain Res Dev Brain Res 1995 Sep 29;88(2):224–6
The phencyclidine–glutamate model of schizophrenia. Halberstadt AL. **Clin Neuropharmacol** 1995 Jun; 18(3):237–49 (108 ref.)
Involvement of dopamine D1 receptors in phencyclidine–induced behavioral stimulation in rats. Tsutsumi T, et al. **Clin Neuropharmacol** 1995 Feb; 18(1):64–71
Mechanism–based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Crowley JR, et al. **Drug Metab Dispos** 1995 Aug;23(8):786–93
Involvement of nitric oxide in phencyclidine–induced hyperlocomotion in mice. Noda Y, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):291–7
Potentiation of phencyclidine–induced dopamine release in the rat striatum by the blockade of dopamine D2 receptor. Yonezawa Y, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):305–8
Haloperidol prevents ketamine– and phencyclidine–induced HSP70 protein expression but not microglial activation. Nakki R, et al. **Exp Neurol** 1996 Feb;137(2):234–41
Normalized demand for drugs and other reinforcers. Hursh SR, et al. **J Exp Anal Behav** 1995 Nov;64(3):373–84
Phencyclidine–induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine. White IM, et al. **J Neural Transm Gen Sect** 1995;102(2):99–112
Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. Carlezon WA Jr, et al. **J Neurosci** 1996 May 1;16(9):3112–22
Automation of the social interaction test by a video–tracking system: behavioural effects of repeated phencyclidine treatment. Sams–Dodd F. **J Neurosci Methods** 1995 Jul; 59(2):157–67
Antiphencyclidine monoclonal Fab fragments reverse phencyclidine–induced behavioral effects and ataxia in rats. Valentine JL, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):709–16
Drug–induced circling preference in rats. Correlation with monoamine levels. Ali SF, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):145–54
WIN 63480, a hydrophilic TCP–site ligand, has reduced agonist–independent NMDA ion channel access compared to MK–801 and phencyclidine. Ault B, et al. **Neuropharmacology** 1995 Dec;34(12):1597–606
Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Frederick DL, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):789–97
Phencyclidine impairs temporal order memory for spatial locations in rats. Long JM, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):645–8
Phencyclidine injections into the dorsal hippocampus disrupt long– but not short–term memory within a spatial learning task. Kesner RP, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):203–8
The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats. Popoli P, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):156–61

PHENCYCLIDINE ABUSE

EPIDEMIOLOGY

Female PCP–using jail detainees: proneness to violence and gender differences. Fishbein DH. **Addict Behav** 1996 Mar–Apr;21(2):155–72

PHENCYCLIDINE RECEPTORS see **RECEPTORS, PHENCYCLIDINE**

PHENELZINE

ADVERSE EFFECTS

Phenelzine–induced fulminant hepatic failure [letter] Gómez–Gil E, et al. **Ann Intern Med** 1996 Apr 1; 124(7):692–3
Serotonin syndrome induced by administration of venlafaxine and phenelzine [letter] Heisler MA, et al. **Ann Pharmacother** 1996 Jan;30(1):84
Extreme suicidality following serotonin syndrome [letter; comment] Serfaty MA, et al. **Br J Psychiatry** 1995 Sep; 167(3):410. Comment on: Br J Psychiatry 1995 Mar;166(3):401–2.
[Abuse of the monoamine oxidase (MAOI) inhibitors as antidepressive drugs: a critical review] García–Campayo JJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):217–22 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Chemical and photochemical generated carbon–centered radical intermediate and its reaction with desoxyribonucleic acid. Justo GZ, et al. **Free Radic Biol Med** 1995 Oct; 19(4):431–40

PHARMACOLOGY

A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. Coupland NJ, et al. **Int Clin Psychopharmacol** 1995 Nov; 10(4):229–38
GABA–elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (–)–deprenyl and clorgyline. Todd KG, et al. **J Affect Disord** 1995 Dec 13;35(3):125–9
Prenatal stress prevents the desensitization of the corticosterone response to TFMPP by desmethylimipramine, but not by phenelzine, in adult male offspring. Poland RE, et al. **Life Sci** 1995;57(23):2163–70
Effects of the MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain. Paslawski TM, et al. **Prog Brain Res** 1995;106:181–6

POISONING

Two fatalities involving phenelzine. Lichtenwalner MR, et al. **J Anal Toxicol** 1995 Jul–Aug;19(4):265–6
"Ping–pong" gaze in severe monoamine oxidase inhibitor toxicity. Erich JL, et al. **J Emerg Med** 1995 Sep–Oct; 13(5):653–5

THERAPEUTIC USE

Combination monoamine oxidase inhibitor and beta–blocker treatment of migraine, with anxiety and depression. Merikangas KR, et al. **Biol Psychiatry** 1995 Nov 1; 38(9):603–10
Anaesthetic management of labour and delivery in a woman taking long–term MAOI. Pavy TJ, et al. **Can J Anaesth** 1995 Jul;42(7):618–20
[Abuse of the monoamine oxidase (MAOI) inhibitors as antidepressive drugs: a critical review] García–Campayo JJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):217–22 (Eng. Abstr.) **(Spa)**

PHENEMAL see **PHENOBARBITAL**

PHENETHANOLAMINE N–METHYLTRANSFERASE

ANALYSIS

SNAP–25 is differentially expressed by noradrenergic and adrenergic chromaffin cells. Kannan R, et al. **FEBS Lett** 1996 May 6;385(3):159–64

ANTAGONISTS & INHIBITORS

Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine–type inhibitors of phenylethanolamine N–methyltransferase. Grunewald GL, et al. **J Med Chem** 1996 Aug 30;39(18):3539–46

GENETICS

Alterations in catecholamine system enzymes. Nagatsu T, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:159–65
Genetic analysis of the relationships between behavioral and neuroendocrine traits in Roman High and Low Avoidance rat lines. Castanon N, et al. **Behav Genet** 1995 Jul; 25(4):371–84
Investigation of the phenylethanolamine N–methyltransferase gene as a candidate gene for hypertension. Koike G, et al. **Hypertension** 1995 Oct;26(4):595–601
Hormonal control of rat adrenal phenylethanolamine N–methyltransferase. Enzyme activity, the final critical pathway. Wong DL, et al. **Neuropsychopharmacology** 1995 Nov;13(3):223–34
Regulation of PNMT gene promoter constructs transfected into the TE 671 human medulloblastoma cell line. Hemmick LM, et al. **Neurosci Lett** 1995 Dec 1;201(1):77–80

METABOLISM

Simultaneous measurement of enzyme activity, protein, mRNA, and metabolites in small samples. Burke WJ, et al. **Anal Biochem** 1995 Sep 20;230(2):345–8
The adrenergic innervation of the rat central amygdaloid nucleus: a light and electron microscopic immunocytochemical study using phenylethanolamine N–methyltransferase as a marker. Asan E. **Anat Embryol (Berl)** 1995 Nov;192(5):471–81
Differential regulation of phenylethanolamine N–methyltransferase expression in two distinct subpopulations of bovine chromaffin cells. Cahill AL, et al. **J Neurochem** 1996 Sep;67(3):1217–24

ULTRASTRUCTURE

Ultrastructural study of phenylethanolamine–N–methyltransferase, corticotropin–releasing factor and neurotensin immunoreactive neurons in the external cuneate nucleus of the gerbil. Lan CT, et al. **Brain Res** 1996 Mar 4; 711(1–2):211–22

PHENETHYL ALCOHOL see **PHENYLETHYL ALCOHOL**

PHENETHYLAMINES

Dofetilide—medical and media information [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C112–3

ADMINISTRATION & DOSAGE

A randomized, double–blind, placebo–controlled, dose–ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. Echt DS, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):687–99
Use of intravenous dofetilide in atrial flutter with hemodynamic instability. Kuruma A, et al. **Jpn Circ J** 1996 Jan;60(1):67–9

ANALYSIS

Evaluation of ractopamine cross–reactivity in several commercially available beta–agonist enzyme immunoassay kits. Wicker AL, et al. **Analyst** 1995 Dec;120(12):2879–81
alpha–Phenylethylamine identified in judicial samples [letter] Meyer E, et al. **Forensic Sci Int** 1995 Dec 18;76(2):159–60
Determination of ractopamine hydrochloride in swine and turkey tissues by liquid chromatography with coulometric detection. Turberg MP, et al. **J AOAC Int** 1995 Nov–Dec; 78(6):1394–402

METABOLISM

High– and low–affinity sites for [3H]dofetilide binding to guinea pig myocytes. Duff HJ, et al. **Circ Res** 1995 Oct; 77(4):718–25
Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Walker DK, et al. **Drug Metab Dispos** 1996 Apr;24(4):447–55
Evidence for high–affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Cunha RA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):261–71
Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography. Johansson B, et al. **Neuropharmacology** 1995 Apr;34(4):393–403
Identification of ractopamine hydrochloride metabolites excreted in rat bile. Smith DJ, et al. **Xenobiotica** 1995 May; 25(5):511–20

PHARMACOKINETICS

Structural requirements for cocaine–sensitive and –insensitive uptake of phenethylamines into the adrenal chromaffin cell. Powers JL, et al. **J Neurochem** 1995 Nov;65(5):2031–42
The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):193–216 (125 ref.)

PHARMACOLOGY

The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK–801) on endogenous amino acid release from mouse cortex. Srinivasan J, et al. **Br J Pharmacol** 1995 Dec;116(8):3087–92
Effects of CGS 21680 in vivo on dopamine D2 agonist binding in the rat brain. Hillefors–Berglund M, et al. **Brain Res** 1995 Aug 28;690(1):34–40
Characterization of the vasorelaxant activity of tyramine and other phenylethylamines in rat aorta. Varma DR, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):742–6
Cloned human inward rectifier K+ channel as a target for class III methanesulfonanilides. Kiehn J, et al. **Circ Res** 1995 Dec;77(6):1151–5
Preconditioning of bovine endothelial cells. The protective effect is mediated by an adenosine A2 receptor through a protein kinase C signaling pathway. Zhou X, et al. **Circ Res** 1996 Jan;78(1):73–81
Action of beta–phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Barroso N, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):195–203
Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Popoli P, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):215–7
Cholecystokinin–B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase. Ding XQ, et al. **Gastroenterology** 1995 Oct;109(4):1181–7
Characterization of ocular hypertension induced by adenosine agonists. Crosson CE, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1833–9
Effect of ractopamine on growth performance, carcass composition, and cutting yields of pigs slaughtered at 107 and 125 kilograms. Crome PK, et al. **J Anim Sci** 1996 Apr; 74(4):709–16
Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D–sotalol and dofetilide. Montero M, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):571–7
SAR studies of fluorine–substituted benzylamines and substituted 2–phenylethylamines as substrates and inactivators of monoamine oxidase B. Silverman RB, et al. **J Enzym Inhib** 1995;9(3):203–15
Determination of tolerance to tear protein release following a twice a day topical application of N,N–dimethyl–2–phenylethylamine HCl. Shirolkar S, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):41–7
Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. Lee YW, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1642–8
Comparison of bidisomide, flecainide and dofetilide on action

potential duration in isolated canine atria: effect of isoproterenol. Martin CL, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):154–62

Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. Mathôt RA, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):245–53

Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. Subramaniam S, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):161–8

Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit. Tohse N, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):303–9

Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Knoll J, et al. **Life Sci** 1996;58(23):2101–14

Modulation of erythropoietin production by selective adenosine agonists and antagonists in normal and anemic rats. Nagashima K, et al. **Life Sci** 1996;59(9):761–71

Mapping the block of a cloned human inward rectifier potassium channel by dofetilide. Kiehn J, et al. **Mol Pharmacol** 1996 Aug;50(2):380–7

High affinity open channel block by dofetilide of HERG expressed in a human cell line. Snyders DJ, et al. **Mol Pharmacol** 1996 Jun;49(6):949–55

Effects of remacemide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. van Luijtelaar EL, et al. **Neuropharmacology** 1995 Apr;34(4):419–25

Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Morelli M, et al. **Neuroscience** 1995 Jul;67(1):49–55

Effect of gastrin receptor blockade on gastrin and histidine decarboxylase gene expression in rats during achlorhydria. Simon B, et al. **Scand J Gastroenterol** 1995 Jun;30(6):503–10

THERAPEUTIC USE

Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Bashir Y, et al. **Am J Cardiol** 1995 Nov 15;76(14):1040–4

Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs. D'Alonzo AJ, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):424–34

A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. Van Outryve M, et al. **J Clin Pharm Ther** 1995 Oct;20(5):277–82

A double-blind randomized placebo-controlled trial of sibutramine. Bray GA, et al. **Obes Res** 1996 May; 4(3):263–70

TOXICITY

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):193–216 (125 ref.)

Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Webster WS, et al. **Teratology** 1996 Mar;53(3):168–75

URINE

Urinary phenylethylamine and cortisol levels in the early puerperium. Taylor A, et al. **J Affect Disord** 1996 Apr 12;37(2-3):137–42

PHENETHYLAZOCINE see **PHENAZOCINE**

PHENFORMIN

ADVERSE EFFECTS

Phenformin-induced lactic acidosis: an almost forgotten complication of treatment with biguanides. Ko GT, et al. **Br J Hosp Med** 1995 Nov 1-14;54(9):469–70

PHENINDIONE

ANALOGS & DERIVATIVES

[Diffuse alveolar hemorrhage secondary to oral anticoagulant use] Léna H, et al. **Rev Mal Respir** 1995;12(5):496–8 (Eng. Abstr.) **(Fre)**

[Prolonged fever induced by fluindione (letter)] Grunenberger F, et al. **Rev Med Interne** 1995;16(12):973–4 **(Fre)**

THERAPEUTIC USE

[A clinico-morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Ratner MIa, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):32–5 (Eng. Abstr.) **(Rus)**

PHENIRAMINE

BLOOD

Determination of loratadine and pheniramine from human serum by gas chromatography-mass spectrometry. Martens J. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):183–8

PHENOBARBITAL

Low expression of the WAF1/CIP1 gene product, p21, in enzyme-altered foci induced in rat liver by diethylnitrosamine or phenobarbital. Martens U, et al. **Cancer Lett** 1996 Jun 24;104(1):21–6

Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Counts JL, et al. **Carcinogenesis** 1996 Jun;17(6):1251–7

Chemopreventive effects of taurine on diethylnitrosamine and phenobarbital-induced hepatocarcinogenesis in male F344 rats. Okamoto K, et al. **Jpn J Cancer Res** 1996 Jan; 87(1):30–6

Soybean isoflavone extract suppresses early but not later promotion of hepatocarcinogenesis by phenobarbital in female rat liver. Lee KW, et al. **Nutr Cancer** 1995; 24(3):267–78

ADMINISTRATION & DOSAGE

Drug discrimination under a concurrent schedule. Snodgrass SH, et al. **J Exp Anal Behav** 1996 May;65(3):495–512

ADVERSE EFFECTS

Stevens-Johnson syndrome resulting from whole-brain irradiation and phenytoin [letter; comment] Weltman E, et al. **Am J Clin Oncol** 1996 Aug;19(4):431. Comment on: Am J Clin Oncol 1996 Feb;19(1):32–4.

Anticonvulsant hypersensitivity syndrome. Vittorio CC, et al. **Arch Intern Med** 1995 Nov 27;155(21):2285–90

Effects of phenobarbital administration on results of serum biochemical analyses and adrenocortical function tests in epileptic dogs. Chauvet AE, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1305–7

In utero exposure to phenobarbital and intelligence deficits in adult men. Reinisch JM, et al. **JAMA** 1995 Nov 15; 274(19):1518–25

Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Riva D, et al. **Pediatr Neurol** 1996 Jan;14(1):36–40

[Atrium 300 hepatitis. A new case (letter)] Cayla JM, et al. **Presse Med** 1995 Nov 18;24(35):1665 **(Fre)**

[The anticonvulsant hypersensitivity syndrome caused by phenobarbital (letter)] Gorraiz A, et al. **An Med Interna** 1995 Dec;12(12):617 **(Spa)**

ANALOGS & DERIVATIVES

Influence of albumin concentration, albumin species, pH and temperature on the stereoselectively different binding of (S)-(+)- and (R)-(-)-1-methyl-5-phenyl-5-propyl-barbiturate to serum albumin. Büch HP, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1049–53

Characterization of p-hydroxyphenobarbital glucuronide generated from immobilized rat hepatic UDP-glucuronosyltransferase [letter] Studenberg SD, et al. **J Pharm Sci** 1995 Sep;84(9):1134–6

ANALYSIS

[Determination of phenobarbital by solid-phase immunoenzyme analysis. Choice of optimal strategy] Danilova NP, et al. **Bioorg Khim** 1995 Aug;21(8):632–5 (Eng. Abstr.) **(Rus)**

BLOOD

Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. Johansen K, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):281–8

[Phenobarbital] Kawasaki H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:921–3 (12 ref.) **(Jpn)**

CHEMISTRY

[Sorption properties of Polish sorbents of the 2nd generation in relation to phenobarbital] Jurkowski P, et al. **Polim Med** 1995;25(3-4):47–50 (Eng. Abstr.) **(Pol)**

METABOLISM

Altered aromatic amine metabolism in epileptic patients treated with phenobarbital. Wallin H, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):771–3

Calcium release in HSY cells conforms to a steady-state mechanism involving regulation of the inositol 1,4,5-trisphosphate receptor Ca2+ channel by luminal [Ca2+]. Tanimura A, et al. **J Cell Biol** 1996 Feb; 132(4):607–16

Lack of effect of histological lesions on the phenytoin and phenobarbital concentrations in the brain cortex of epileptic patients. Schnabel R, et al. **J Neurol Sci** 1995 Nov; 133(1-2):177–82

PHARMACOKINETICS

Effect of pregnancy on plasma phenobarbital concentrations in rats. Moriyama M, et al. **Acta Med Okayama** 1995 Oct; 49(5):237–40

Effects of ingesta on systemic availability of phenobarbitone in dogs. Watson AD, et al. **Aust Vet J** 1996 Mar;73(3):108–9

Effects of felbamate on the pharmacokinetics of phenobarbital. Reidenberg P, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):279–87

Determination of phenobarbitone population clearance values for South African children. Botha JH, et al. **Eur J Clin Pharmacol** 1995;48(5):381–3

Detection of codeine and phenobarbital in sweat collected with a sweat patch. Kintz P, et al. **J Anal Toxicol** 1996 May-Jun;20(3):197–201

Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. Frenia ML, et al. **J Toxicol Clin Toxicol** 1996; 34(2):169–75

[Sorption properties of Polish sorbents of the 2nd generation in relation to phenobarbital] Jurkowski P, et al. **Polim Med** 1995;25(3-4):47–50 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Phenobarbital-induced activation of CYP2H1 and 5-aminolevulinate synthase genes in chick embryo hepatocytes is blocked by an inhibitor of protein phosphorylation. Dogra SC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):271–8

Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. Murayama N, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):184–92

Involvement of synthesis and phosphorylation of nuclear protein factors that bind to the positive cis-acting element in the transcriptional activation of the CYP2B1/B2 gene by phenobarbitone in vivo. Nirodi CS, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):79–86

Purification of a phenobarbital-inducible UDP-glucuronosyltransferase isoform from dog liver which catalyzes morphine and testosterone glucuronidation. Oguri K, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):159–66

The liver-specific response to phenobarbital involves a transient increase in phosphorylation of a 34-kda nuclear protein in rat liver and in hepatocytes in culture. Baffet G, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):947–56

Nuclear matrix condensation and c-myc and c-fos expression are specifically altered in culture rat hepatocytes after exposure to cyproterone acetate and phenobarbital. Duivenvoorden WC, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):598–605

Phenobarbital induction of cytochrome P4501A1 is regulated by cAMP-dependent protein kinase-mediated signaling pathways in rainbow trout hepatocytes. Sadar MD, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):455–61

Genetic analysis of the phenobarbital regulation of the cytochrome P-450 2b-9 and aldehyde dehydrogenase type 2 mRNAs in mouse liver. Damon M, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):481–6

Effects of phenobarbital and interleukin-6 on cytochrome P4502B1 and 2B2 in cultured rat hepatocytes. Clark MA, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):701–6

Pentobarbitone modulation of NMDA receptors in neurones isolated from the rat olfactory brain. Charlesworth P, et al. **Br J Pharmacol** 1995 Dec;116(7):3005–13

Activation of in vivo metabolism of malathion in male Tilapia nilotica. El-Dib MA, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):667–74

Responsiveness of hepatocytes from dichloroacetic acid or phenobarbital treated mice to growth factors in primary culture. Tsai WH, et al. **Cancer Lett** 1996 Feb 6; 99(2):177–83

Glucuronidation of 4-((hydroxymethyl)nitrosamino)-1-(3-pyridyl)-1-butanone, a metabolically activated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by phenobarbital-treated rats. Murphy SE, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):772–9

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Goldberg MR, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):268–74

Induction of hepatic cytochrome P450 by phenobarbitone in rhesus monkey (Macacs mulatta). Ramana KV, et al. **Drug Chem Toxicol** 1996;19(1-2):97–107

In vitro hydroxylation and epoxidation of some isomeric lauric acid analogs by rat liver microsomes. Identification of metabolites and effects of clofibrate or phenobarbital pretreatment. Boucher JL, et al. **Drug Metab Dispos** 1996 Apr;24(4):462–8

Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Bullock P, et al. **Drug Metab Dispos** 1995 Jul;23(7):736–48

Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Klekotka PA, et al. **Drug Metab Dispos** 1995 Dec;23(12):1434–5

Effects of phenobarbital, dexamethasone, and 3-methylcholanthrene administration on the metabolism of 17 beta-estradiol by liver microsomes from female rats. Suchar LA, et al. **Endocrinology** 1996 Feb;137(2):663–76

Human liver S-9 metabolic activation: proficiency in cytogenetic assays and comparison with phenobarbital/beta-naphthoflavone or aroclor 1254 induced rat S-9. Johnson TE, et al. **Environ Mol Mutagen** 1996;28(1):51–9

Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Gasior

M, et al. **Epilepsia** 1996 Mar;37(3):262–8

The inhibition of phosphoenolpyruvate carboxykinase following in vivo chronic phenobarbital treatment in the rat is due to a post-translational event. Chauvin C, et al. **Eur J Biochem** 1996 May 15;238(1):207–13

Endoplasmic reticulum proliferates without an increase in cytochrome P-450 in hepatocytes of mice treated with phenobarbital and cobalt chloride. Amatsu T, et al. **Eur J Cell Biol** 1995 Nov;68(3):256–62

Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Fleishaker JC, et al. **Eur J Clin Pharmacol** 1996;50(1–2):139–45

Effects of phenobarbital on aniline metabolism in primary liver cell culture of rats with ethionine-induced liver disorder. Noguchi M, et al. **Exp Anim** 1996 Apr; 45(2):161–70

Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]anthracene--implications for cancer etiology [letter] Surh Y. **Experientia** 1995 Sep 29; 51(9–10):999

Effect of prenatal undernutrition and phenobarbitone administration on discrimination learning and passive avoidance behaviour in rats. Jaiswal AK, et al. **Indian J Exp Biol** 1996 Feb;34(2):118–23

Effect of phenobarbital and the peroxisome proliferator ciprofibrate on gamma-Glutamyltranspeptidase activity and leukotriene C4 concentration in cultured rat hepatocytes. Hong JT, et al. **J Biochem Toxicol** 1995 Oct; 10(5):239–243

A kinetic analysis of hepatic microsomal activation of parathion and chlorpyrifos in control and phenobarbital-treated rats. Ma T, et al. **J Biochem Toxicol** 1995 Apr;10(2):63–8

Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. Honkakoski P, et al. **J Biol Chem** 1996 Apr 19;271(16):9746–53

Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes. Sadar MD, et al. **J Biol Chem** 1996 Jul 26;271(30):17635–43

Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. Sewerynek E, et al. **J Cell Biochem** 1995 Aug;58(4):436–44

Suppressed expression of phenobarbital-inducible hepatic cytochrome P-450s in Eisai-hyperbilirubinuria rats (EHBR/Eis). Oguro T, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1676–84

Critical role of extracellular matrix on induction by phenobarbital of cytochrome P450 2B1/2 in primary cultures of adult rat hepatocytes. Brown SE, et al. **Lab Invest** 1995 Dec;73(6):818–27

Phenobarbital induction of hepatic CYP2B1 and CYP2B2: pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Agrawal AK, et al. **Mol Pharmacol** 1996 Mar;49(3):523–31

Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers. Kimmett SM, et al. **Mol Pharmacol** 1996 Apr;49(4):676–82

The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation. Thorp JA, et al. **Obstet Gynecol** 1995 Dec;86(6):982–9

Phenobarbital in the anticonvulsant dose range does not impair learning and memory or alter brain AChE activity or monoamine levels. Sudha S, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):633–8

The effects of phenobarbital pretreatment on the metabolism and toxicity of paraoxon in the mouse. Vitarius JA, et al. **Pharmacol Toxicol** 1995 Jul;77(1):16–22

Hepatic effects of dieldrin and phenobarbital in male B6C3F1 mice and Fisher 344 rats: species selective induction of DNA synthesis. Kolaja KL, et al. **Prog Clin Biol Res** 1995; 391:397–408

Alterations in hippocampal hemicholinium-3 binding and related behavioural and biochemical changes after prenatal phenobarbitone exposure. Zahalka EH, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):44–50

Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Finnell RH, et al. **Teratology** 1995 Dec;52(6):324–32

Phenobarbital induces the 2-hydroxylation of desipramine. Spina E, et al. **Ther Drug Monit** 1996 Feb;18(1):60–4

Effect of sulfamethazine on phenobarbital and benzo[a]pyrene induced hepatic microsomal mixed function oxidase system in rats. Kodam KM, et al. **Toxicol Lett** 1996 Sep;87(1):25–30

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82–83:655–62 (11 ref.)

Influence of Aroclor 1254, phenobarbital, beta-naphthoflavone, and ethanol pretreatment on the biotransformation of cyclophosphamide in male and female rats. Sessink PJ, et al. **Toxicology** 1996 Aug 16; 112(2):141–50

[The effects of phenobarbital, valproic acid and carbamazepine on the serum lipids and lipoproteins in a pediatric population] de Juan Frigola J, et al. **An Esp Pediatr** 1996 Feb;44(2):133–8 (Eng. Abstr.) **(Spa)**

[Vecuronium resistance induced by chronic phenobarbital treatment (letter)] Herrero E, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):113–4 **(Spa)**

THERAPEUTIC USE

GI cocktail [letter; comment] Rosenberg CA. **Ann Emerg Med** 1996 Jul;28(1):104–5. Comment on: Ann Emerg Med 1995 Dec;26(6):687–90.

Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Hermanns G, et al. **Epilepsia** 1996 Jul;37(7):675–9

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)

Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. de Silva M, et al. **Lancet** 1996 Mar 16;347(9003):709–13

Antenatal phenobarbital therapy and neonatal outcome. I: Effect on intracranial hemorrhage. Shankaran S, et al. **Pediatrics** 1996 May;97(5):644–8

Antenatal phenobarbital therapy and neonatal outcome. II: Neurodevelopmental outcome at 36 months. Shankaran S, et al. **Pediatrics** 1996 May;97(5):649–52

[Multidimensional psychometric assessment of preoperative mood. Effects of zolpidem compared to phenobarbital combined with promethazine as premedication] Uhlig T, et al. **Anaesthesist** 1995 Sep;44(9):634–42 (Eng. Abstr.) **(Ger)**

[Treatment of cholestatic liver diseases with phenobarbital and ursodeoxycholic acid] Stiehl A. **Z Gastroenterol** 1993 Feb;31 Suppl 2:129–30 (Eng. Abstr.) **(Ger)**

[Treatment of the partial epilepsy in the first two years of life. Experience in 26 cases] Martínez Bermejo A, et al. **Rev Neurol** 1995 Mar-Apr;23(120):290–2 (Eng. Abstr.) **(Spa)**

TOXICITY

Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Kolaja KL, et al. **Carcinogenesis** 1996 May;17(5):947–54

Reversibility of promoter induced hepatic focal lesion growth in mice. Kolaja KL, et al. **Carcinogenesis** 1996 Jul; 17(7):1403–9

Phenobarbital selectively promotes initiated cells with reduced TGF beta receptor levels. Mansbach JM, et al. **Carcinogenesis** 1996 Jan;17(1):171–4

Expression of growth factors and growth factor receptors in the liver of C57BL/10J mice following administration of phenobarbitone. Orton TC, et al. **Carcinogenesis** 1996 May;17(5):973–81

Phenobarbital promotes the development of adenocarcinomas in the accessory sex glands of MNU-inoculated L-W rats. Pollard M, et al. **Carcinogenesis** 1995 Oct;16(10):2419–21

Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model. Sherman CD, et al. **Carcinogenesis** 1995 Oct;16(10):2499–506

Subchronic effects of dieldrin and phenobarbital on hepatic DNA synthesis in mice and rats. Kolaja KL, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):219–28

The influence of aging on dimethylnitrosamine-demethylase enzyme kinetics in rat liver microsomes. Van Asten JG, et al. **Mech Ageing Dev** 1995 Aug 8;82(2–3):63–72

Expression of c-myc in altered hepatic foci induced in rats by various single doses of diethylnitrosamine and promotion by 0.05% phenobarbital. Deguchi T, et al. **Mol Carcinog** 1995 Nov;14(3):152–9

Evaluation of phenobarbital/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays. Callander RD, et al. **Mutagenesis** 1995 Nov;10(6):517–22

The effect of dieldrin and phenobarbital on preneoplastic hepatic lesion growth in male F344 rat and B6C3F1 mouse. Kolaja KL, et al. **Prog Clin Biol Res** 1995;391:409–23

Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. McClain RM. **Prog Clin Biol Res** 1995;391:325–36 (35 ref.)

The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment. Stevenson DE, et al. **Prog Clin Biol Res** 1995;391:337–45 (28 ref.)

Promoting effects of phenobarbital on the enzyme-altered foci induced by intrahepatic gamma-ray-irradiation in the rat liver. Ida K, et al. **Radiat Med** 1995 Sep-Oct; 13(5):227–33

Neonatal phenobarbital-induced persistent alterations in plasma testosterone profiles and testicular function. Wani JH, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):295–300

URINE

Identification of phenobarbital N-glucuronides as urinary metabolites of phenobarbital in mice. Neighbors SM, et al. **Drug Metab Dispos** 1995 May;23(5):548–52

PHENOBARBITONE see **PHENOBARBITAL**

PHENOL RED see **PHENOLSULFONPHTHALEIN**

PHENOL SULFOTRANSFERASE see **ARYLSULFOTRANSFERASE**

PHENOLOXIDASE see **MONOPHENOL MONOOXYGENASE**

PHENOLPHTHALEINS

Beeting (sic) a crimson retreat [letter; comment] Rosalki SB. **Lancet** 1996 Feb 17;347(8999):474. Comment on: Lancet 1996 Jan 6;347(8993):5–6.

ANALYSIS

Comparison of reversed-phase liquid chromatography with colorimetry for analysis of phenolphthalein preparations. Torrado S, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1167–72

PHARMACOKINETICS

Evidence for an UDP-glucuronic acid/phenol glucuronide antiport in rat liver microsomal vesicles. Bánhegyi G, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):171–6

TOXICITY

Phenolphthalein highlights NTP bioassay review [news] **Environ Health Perspect** 1996 Apr;104(4):377–8

PHENOLS

Phenol peeling: new standards of excellence. Edison RB. **Aesthetic Plast Surg** 1996 Winter;20(1):81–2

Oxidation of caffeine and related methylxanthines in ascorbate and polyphenol-driven Fenton-type oxidations. Stadler RH, et al. **Free Radic Res** 1996 Mar;24(3):225–10

Management of skin-grafted burn wounds with Xeroform and layers of dry coarse-mesh gauze dressing results in excellent graft take and minimal nursing time. Hansbrough W, et al. **J Burn Care Rehabil** 1995 Sep-Oct;16(5):531–4

Phenol lumbar sympathetic block in diabetic lower limb ischemia. Mashiah A, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):467–9

ADMINISTRATION & DOSAGE

Expression of cytochrome P450 17alpha-hydroxylase/C17-20 lyase in the fetal rat testis is reduced by maternal exposure to exogenous estrogens. Majdic G, et al. **Endocrinology** 1996 Mar;137(3):1063–70

Sclerotherapy of testicular hydroceles with 3% aqueous phenol. Ozdemir E. **Hinyokika Kiyo** 1996 Jun;42(6):427–32

Polyphenols in our diet: do they matter? [editorial] Ferro-Luzzi A, et al. **Nutrition** 1995 Jul-Aug;11(4):399–400

Disposition of phenol in rat after oral, dermal, intravenous, and intratracheal administration. Hughes MF, et al. **Xenobiotica** 1995 Aug;25(8):873–83

[The role of dietary plant polyphenols in health maintenance] Zloch Z. **Cas Lek Cesk** 1996 Jan 31;135(3):84–8 (Eng. Abstr.) **(Cze)**

[Intradiscal injection of hypertonic saline, phenol-glycerin and osmic acid for the treatment of lumbar disc herniation: an experimental study] Shioda M. **Nippon Seikeigeka Gakkai Zasshi** 1995 Oct;69(10):964–76 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Occupational allergic contact dermatitis caused by epoxy diacrylate in ultraviolet-light-cured paint, and bisphenol A in dental composite resin. Jolanki R, et al. **Contact Dermatitis** 1995 Aug;33(2):94–9

Dangerous dental sealants? [news] **Environ Health Perspect** 1996 Apr;104(4):373–4

The comparative tea staining potential of phenolic, chlorhexidine and anti-adhesive mouthrinses. Addy M, et al. **J Clin Periodontol** 1995 Dec;22(12):923–8

Is micropigmentation surgery an answer to stable bindi-induced depigmentation? [letter] Bose SK. **J Dermatol** 1995 Jul;22(7):533–4

[Comparison of nerve damage with alcohol and that with phenol in guinea pigs] Matsuda T, et al. **Masui** 1995 Nov; 44(11):1464–6 (Eng. Abstr.) **(Jpn)**

[Industrial hygiene of workers in diphenylolpropane production] Kogan OS, et al. **Med Tr Prom Ekol** 1995; (12):40–4 **(Rus)**

ANALYSIS

Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Birkett A, et al. **Am J Clin Nutr** 1996 May;63(5):766–72

Method to assay the concentrations of phenolic constituents of biological interest in wines. Goldberg D, et al. **Anal Chem** 1996 May 15;68(10):1688–94

Biosensor based on an enzyme modified electrode for highly-sensitive measurement of polyphenols. Eremenko A, et al. **Biosens Bioelectron** 1995 Fall;10(8):717–22

Antibacterial polyphenols from olive oil mill waste waters. Capasso R, et al. **J Appl Bacteriol** 1995 Oct;79(4):393–8

Levels of a terpenoid glycoside (blumenin) and cell

wall-bound phenolics in some cereal mycorrhizas. Maier W, et al. **Plant Physiol** 1995 Oct;109(2):465–70

Thermospray-LC-MS analysis of various groups of polyphenols in tea. II: Chlorogenic acids, theaflavins and thearubigins. Kiehne A, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):299–302

Natural fermentation of lentils. Influence of time, concentration and temperature on protein content, trypsin inhibitor activity and phenolic compound content. Tabera J, et al. **Z Lebensm Unters Forsch** 1995 Dec;201(6):587–91

[Determination of bakuchiol in the fruit of Psoralea corylifolia L.] Yao S, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):681–3, 704 (Eng. Abstr.) **(Chi)**

[A chromatographic method for determining diphenyloipropane in the air of a work area] Kogan OS, et al. **Gig Sanit** 1996 Jan–Feb;(1):48–9 **(Rus)**

[Effect of carbaryl and lead on phenols, chlorophyll and proteins of the microalga Ankistrodesmus falcatus] Martínez-Tabche L, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):93–9 (Eng. Abstr.) **(Spa)**

BLOOD

High-performance liquid chromatographic determination of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone in plasma. Rodgers AH, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):365–8

CHEMICAL SYNTHESIS

Stereoselective synthesis and thromboxane A2 (TXA2) receptor antagonistic activity of optically active phenol derivatives. Fukumoto S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):749–55

CHEMISTRY

Alterations in phospholipid bilayers caused by oxyethylenated nonylphenol surfactants. de la Maza A, et al. **Arch Biochem Biophys** 1996 May 1;329(1):1–8

Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Salah N, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):339–46

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)

X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agents, thiocyanate, methylparaben, and phenol. Whittingham JL, et al. **Biochemistry** 1995 Nov 28;34(47):15553–63

Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Kramer JB, et al. **Bioorg Med Chem** 1995 Apr;3(4):403–10

Structural functions of antimicrobial long-chain alcohols and phenols. Kubo I, et al. **Bioorg Med Chem** 1995 Jul; 3(7):873–80

Carbon-catalyzed oxidative coupling of phenolic compounds. Osei-Twum EY, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):513–9

Correlation of physicochemical properties of alkylphenols with their graph-theoretical epsilon parameter. Cash GG. **Chemosphere** 1995 Nov;31(10):4307–15

Hydrolyzable tannins and related polyphenols. Okuda T, et al. **Fortschr Chem Org Naturst** 1995;66:1–117 (266 ref.)

Structure of transient radicals from cytostatic-active p-alkoxyphenols by continuous-flow EPR. Lassmann G, et al. **Free Radic Biol Med** 1995 Nov;19(5):533–9

Marchantins and related polyphenols from liverwort: physico-chemical studies of their radical-scavenging properties. Schwartner C, et al. **Free Radic Biol Med** 1996; 20(2):237–44

Redox behaviour of phenolic porphyrins in basic solutions: a reappraisal. Milgrom LR, et al. **Free Radic Res** 1996 Jan; 24(1):19–29

Action of phenolic antioxidants on various active oxygen species. Cynshi O, et al. **J Biolumin Chemilumin** 1995 Sep–Oct;10(5):261–9

Detection of substances with alcoholic or phenolic hydroxyl groups by generation of hydrogen peroxide with imidazole and peroxyoxalate chemiluminescence. Nozaki O, et al. **J Biolumin Chemilumin** 1995 Nov–Dec;10(6):339–44

Neuroactive polyamine wasp toxins: nuclear magnetic resonance spectroscopic analysis of the protolytic properties of philanthotoxin-343. Jaroszewski JW, et al. **J Med Chem** 1996 Jan 19;39(2):515–21

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)

Quantitative relationships of structure-activity and volume fraction for selected nonpolar and polar narcotic chemicals. Jaworska JS, et al. **SAR QSAR Environ Res** 1993;1(1):3–19

Derivatives of 4-styrylpyridines: synthesis, estrogen receptor binding affinity, and photophysical properties. Haroutounian SA, et al. **Steroids** 1995 Sep;60(9):636–45

ISOLATION & PURIFICATION

Separation of the eleven priority pollutant phenols by capillary zone electrophoresis. Li G, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):93–102

Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. Fu X, et al. **J Nat Prod** 1995 Sep;58(9):1384–91

Isolation of E-1-(4'-Hydroxyphenyl)-but-1-en-3-one from Scutellaria barbata. Ducki S, et al. **Planta Med** 1996 Apr; 62(2):195–6

Antiperoxidative components in Thymus vulgaris. Haraguchi H, et al. **Planta Med** 1996 Jun;62(3):217–21

METABOLISM

Biodegradation of mixed wastes in continuously operated cyclic reactors. Wang KW, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:803–15

Use of starvation promoters to limit growth and selectively enrich expression of trichloroethylene- and phenol-transforming activity in recombinant Escherichia coli [corrected] [published erratum appears in Appl Environ Microbiol 1995 Nov;61(11):4140] Matin A, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3323–8

Application of reverse transcriptase PCR for monitoring expression of the catabolic dmpN gene in a phenol-degrading sequencing batch reactor. Selvaratnam S, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3981–5

Detection and characterization of the electron paramagnetic resonance-silent glutathionyl-5,5-dimethyl-1-pyrroline N-oxide adduct derived from redox cycling of phenoxyl radicals in model systems and HL-60 cells. Stoyanovosky DA, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):3–11

The nature of the transition state for enzyme-catalyzed phosphoryl transfer. Hydrolysis of O-aryl phosphorothioates by alkaline phosphatase. Hollfelder F, et al. **Biochemistry** 1995 Sep 26;34(38):12255–64

Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Chen H, et al. **Carcinogenesis** 1995 Oct;16(10):2301–7

o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Thompson DC, et al. **Chem Res Toxicol** 1995 Apr-May; 8(3):323–7

Estrogens in unexpected places: possible implications for researchers and consumers. Feldman D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:129–33

Substrate specificity of flavin-dependent vanillyl-alcohol oxidase from Penicillium simplicissimum. Evidence for the production of 4-hydroxycinnamyl alcohols from 4-allylphenols. Fraaije MW, et al. **Eur J Biochem** 1995 Nov 15;234(1):271–7

Possible common properties of dietary fibre constituents and polyphenols. Bravo L, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S211–4

Metabolism of phenols by Ochromonas danica. Semple KT, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):253–7

Lobular distribution of human liver phenol and bilirubin uridine 5'-diphosphate glucuronosyltransferase messenger RNAs. Chen F, et al. **Gastroenterology** 1996 Aug; 111(2):472–80

Effects of glycine and bovine serum albumin on inhibition of propionate metabolism in ovine hepatocytes caused by reduced phenolic monomers. Cremin JD Jr, et al. **J Anim Sci** 1995 Oct;73(10):3009–21

Isolation and characterization of a new bacterium carboxylating phenol to benzoic acid under anaerobic conditions. Li T, et al. **J Bacteriol** 1996 May;178(9):2551–8

Carbon catabolite repression of phenol degradation in Pseudomonas putida is mediated by the inhibition of the activator protein PhlR. Müller C, et al. **J Bacteriol** 1996 Apr;178(7):2030–6

Cometabolic degradation of o-cresol and 2,6-dimethylphenol by Penicillium frequentans Bi 7/2. Hofrichter M, et al. **J Basic Microbiol** 1995;35(5):303–13

Phenol degradation by Acinetobacter calcoaceticus NCIB 8250. Paller G, et al. **J Basic Microbiol** 1995;35(5):325–35

Genetic evidence for interdomain regulation of the phenol-responsive final sigma54-dependent activator DmpR. Ng LC, et al. **J Biol Chem** 1996 Jul 19; 271(29):17281–6

Preparation of phenolic paclitaxel metabolites. Park H, et al. **J Med Chem** 1996 Jul 5;39(14):2705–9

Use of micellar electrokinetic capillary chromatography in the study of in vitro metabolism of phenol by human liver microsomes. Davies MI, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):893–7

Simultaneous microdialysis sampling from multiple sites in the liver for the study of phenol metabolism. Davies MI, et al. **Life Sci** 1996;59(12):1001–13

The MarR repressor of the multiple antibiotic resistance (mar) operon in Escherichia coli: prototypic member of a family of bacterial regulatory proteins involved in sensing phenolic compounds. Sulavik MC, et al. **Mol Med** 1995 May;1(4):436–46

The relative effect of Azone and Transcutol on permeant diffusivity and solubility in human stratum corneum. Harrison JE, et al. **Pharm Res** 1996 Apr;13(4):542–6

Arabidopsis mutants lacking phenolic sunscreens exhibit enhanced ultraviolet-B injury and oxidative damage. Landry LG, et al. **Plant Physiol** 1995 Dec;109(4):1159–66

Derivatives of 4-styrylpyridines: synthesis, estrogen receptor binding affinity, and photophysical properties. Haroutounian SA, et al. **Steroids** 1995 Sep;60(9):636–45

1H and 19F-nmr spectroscopic studies on the metabolism and urinary excretion of mono- and disubstituted phenols in the rat. Bollard ME, et al. **Xenobiotica** 1996 Mar; 26(3):255–73

Species- and gender-related differences in amine, alcohol and phenol sulphoconjugations. Shiraga T, et al. **Xenobiotica** 1995 Nov;25(10):1063–71

PHARMACOKINETICS

Kinetics of phenols in body fluid compartments during hemodialysis. Erben J, et al. **Artif Organs** 1995 Jun; 19(6):544–6

Availability and mean transit times of phenol and its metabolites in the isolated perfused rat liver: normal and retrograde studies using tracer concentrations of phenol. Ballinger LN, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):949–56

Pharmacokinetics of wood creosote: glucuronic acid and sulfate conjugation of phenolic compounds. Ogata N, et al. **Pharmacology** 1995 Sep;51(3):195–204

Disposition of phenol in rat after oral, dermal, intravenous, and intratracheal administration. Hughes MF, et al. **Xenobiotica** 1995 Aug;25(8):873–83

PHARMACOLOGY

Inhibition of influenza virus protein synthesis by a plant preparation from Geranium sanguineum L. Serkedjieva J. **Acta Virol** 1995 Feb;39(1):5–10

White wine reduces the susceptibility of low-density lipoprotein to oxidation [letter; comment] Caldú P, et al. **Am J Clin Nutr** 1996 Mar;63(3):403–4. Comment on: Am J Clin Nutr 1995 Mar;61(3):549–54.

Genistein and tyrphostin 47 stimulate CFTR-mediated Cl-secretion in T84 cell monolayers. Sears CL, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G874–82

Inhibitory effects of phenolic carboxylic acid analogues on xanthine oxidase. Chang WS, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2097–100

Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits. Wiseman SA, et al. **Atherosclerosis** 1996 Feb;120(1–2):15–23

Effects of hydroquinone-type and phenolic antioxidants on calcium signals and degranulation of RBL-2H3 cells. Akasaka R, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1513–9

Inhibition of metmyoglobin/H2O2-dependent low density lipoprotein lipid peroxidation by naturally occurring phenolic acids. Laranjinha J, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):395–402

Interaction of nonylphenol and hepatic CYP1A in rats. Lee PC, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):885–9

Blockade of swelling-induced chloride channels by phenol derivatives. Gschwentner M, et al. **Br J Pharmacol** 1996 May;118(1):41–8

Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Chen H, et al. **Carcinogenesis** 1995 Oct;16(10):2301–7

Inhibition of 1,2,4-benzenetriol-generated active oxygen species and induction of phase II enzymes by green tea polyphenols. Lee SF, et al. **Chem Biol Interact** 1995 Dec 22;98(3):283–301

Effects of estrogen and nonylphenol on the post-transcriptional regulation of vitellogenin gene expression. Ren L, et al. **Chem Biol Interact** 1996 Mar 8; 100(1):67–76

Stereoselective synthesis and thromboxane A2 (TXA2) receptor antagonistic activity of optically active phenol derivatives. Fukumoto S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):749–55

Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice. Jurin M, et al. **Clin Exp Metastasis** 1996 Jan;14(1):55–60

Comparison of the effect of various chemical peeling agents in a mini-pig model. Moy LS, et al. **Dermatol Surg** 1996 May;22(5):429–32

The E-screen assay: a comparison of different MCF7 cell stocks. Villalobos M, et al. **Environ Health Perspect** 1995 Sep;103(9):844–50

Reduction of the tyrosyl radical and the iron center in protein R2 of ribonucleotide reductase from mouse, herpes simplex virus and E. coli by p-alkoxyphenols. Pötsch S, et al. **FEBS Lett** 1995 Oct 23;374(1):95–9

Reduction of ferrylmyoglobin by dietary phenolic acid derivatives of cinnamic acid. Laranjinha J, et al. **Free Radic Biol Med** 1995 Sep;19(3):329–37

Study of some biochemical changes among workers occupationally exposed to phenol, alone or in combination with other organic solvents. Shamy MY, et al. **Ind Health** 1994;32(4):207–14

Antimutagenic effects of polyphenols isolated from Terminalia bellerica myroblan in Salmonella typhimurium. Padam SK, et al. **Indian J Exp Biol** 1996 Feb;34(2):98–102

Hypoxic and posthypoxic neuronal injury in hippocampal cell culture: attenuation by lipophylic antioxidant U-18 and superoxide dismutase. Khaspekov LG, et al. **Int J Neurosci** 1995 May;82(1–2):33–45

Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. Vanichkin A, et al. **J Infect Dis** 1996 Apr; 173(4):927–33

Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol-6-yl)-phenols with improved delta opioid receptor selectivity. Bertha CM, et al.

J Med Chem 1996 May 10;39(10):2081–6
Synthetic and structure/activity studies on acid–substituted 2–arylphenols: discovery of 2–[2–propyl–3–[3–[2–ethyl–4–(4–fluorophenyl)–5–hydroxyphenoxy]–propoxy]phenoxy]benzoic acid, a high–affinity leukotriene B4 receptor antagonist. Sawyer JS, et al. **J Med Chem** 1995 Oct 27;38(22):4411–32
Time course of muscle atrophy and recovery following a phenol–induced nerve block. Bodine–Fowler SC, et al. **Muscle Nerve** 1996 Apr;19(4):497–504
Inhibition of 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP) mutagenicity by black and green tea extracts and polyphenols. Apostolides Z, et al. **Mutat Res** 1996 Apr 4;359(3):159–63
Modulation of the mutagenicity and metabolism of the tobacco–specific nitrosamine 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone (NNK) by phenolic compounds. Miller C, et al. **Mutat Res** 1996 Jul 5;368(3–4):221–33
Protection against ultraviolet–B radiation–induced local and systemic suppression of contact hypersensitivity and edema responses in C3H/HeN mice by green tea polyphenols. Katiyar SK, et al. **Photochem Photobiol** 1995 Nov; 62(5):855–61
Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Falch BS, et al. **Planta Med** 1995 Aug;61(4):321–8
Genetic evidence for direct sensing of phenolic compounds by the VirA protein of Agrobacterium tumefaciens. Lee YW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12245–9
[Inhibition of colorectal carcinoma induced by 1, 2–dimethylhydrazine in mice with tea polyphenols] Pan H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):356–9 (Eng. Abstr.) **(Chi)**
[Inhibitors of protein–tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin–Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**
[Regulation by an antioxidant of growth, composition, and physico–chemical features of lipids from Saccharomyces cerevisiae] Reshetnik OA, et al. **Dokl Akad Nauk** 1996 Feb; 346(5):705–7 **(Rus)**
[Mechanism of the radiation–protective effect of indralin] Vasin MV, et al. **Radiats Biol Radioecol** 1996 Jan–Feb; 36(1):36–46 (Eng. Abstr.) **(Rus)**
[Studies of the radiation–protective effects of indralin on the hematopoietic system of different species of animals] Vasin MV, et al. **Radiats Biol Radioecol** 1996 Mar–Apr; 36(2):168–89 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The treatment of the splitting nail with phenol alcohol partial nail matricectomy. Miller MA, et al. **Dermatol Surg** 1996 Apr;22(4):388–90
Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169–80 (87 ref.)
The comparative effects on plaque regrowth of phenolic chlorhexidine and anti–adhesive mouthrinses. Moran J, et al. **J Clin Periodontol** 1995 Dec;22(12):929–34
[Incidence of recurrence of aneurysmal bone cysts following surgical treatment and adjuvant therapy with phenol] Bitzan P, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct; 133(5):422–8 (Eng. Abstr.) **(Ger)**

TOXICITY

Model–based QSAR for ionizable compounds: toxicity of phenols against Tetrahymena pyriformis. Piršelová K, et al. **Arch Environ Contam Toxicol** 1996 Feb;30(2):170–7
Comparative sensitivity of three age classes of Artemia salina larvae to several phenolic compounds. Barahona MV, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):271–8
Cytotoxicity of phenolic compounds on Dicentrarchus labrax erythrocytes. Bogé G, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):171–8
Acute toxicity of selected metals and phenols on RTG–2 and CHSE–214 fish cell lines. Castaño A, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):222–9
Toxicity of phenolic compounds to sediment bacteria. Dean–Ross D, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):245–50
Toxicity of phenol and monochlorophenols to growth and metabolic activities of Pseudomonas. Huang DS, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):69–76
Applications of frontier molecular orbital energies in QSAR studies. Huang Q, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):758–65
Quantitative structure–activity relationships of organic acids and bases. Zhao YH, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):242–9
Correlation of physicochemical properties of alkylphenols with their graph–theoretical epsilon parameter. Cash GG. **Chemosphere** 1995 Nov;31(10):4307–15
Structure–toxicity relationships for phenols to Tetrahymena pyriformis. Cronin MT, et al. **Chemosphere** 1996 Apr; 32(8):1453–68 (36 ref.)
Environmental estrogenic effects of alkylphenol ethoxylates. Nimrod AC, et al. **Crit Rev Toxicol** 1996 May;26(3):335–64
Comparison of the toxicity of various lignin–related phenolic compounds toward selected fungi perfecti and fungi imperfecti. Guiraud P, et al. **Ecotoxicol Environ Saf** 1995 Oct;32(1):29–33
Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Sharpe RM, et al. **Environ Health Perspect** 1995 Dec; 103(12):1136–43
Evaluation of the micronucleus test in vitro using Chinese hamster cells: results of four chemicals weakly positive in the in vivo micronucleus test. Miller BM, et al. **Environ Mol Mutagen** 1995;26(3):240–7
In vivo estrogenic activity of nonylphenol in rainbow trout. Lech JJ, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):229–32
Investigations on acute hepato– and nephrotoxicity of pentabromophenol. Szymańska JA, et al. **Int J Occup Med Environ Health** 1995;8(3):245–54
Multiple actions of arylalkylamine arthropod toxins on the N–methyl–D–aspartate receptor. Donevan SD, et al. **Neuroscience** 1996 Jan;70(2):361–75
Histopathologic changes in primate spinal cord after single and repeated epidural phenol administration. Katz JA, et al. **Reg Anesth** 1995 Jul–Aug;20(4):283–90
A novel QSAR approach for estimating toxicity of phenols. Schultz TW, et al. **SAR QSAR Environ Res** 1996; 5(2):99–112

URINE

Habitual and genetic factors that affect urinary background levels of biomarkers for organic solvent exposure. Kawamoto T, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):114–20
1H and 19F–nmr spectroscopic studies on the metabolism and urinary excretion of mono– and disubstituted phenols in the rat. Bollard ME, et al. **Xenobiotica** 1996 Mar; 26(3):255–73
Prediction of urinary sulphate and glucuronide conjugate excretion for substituted phenols in the rat using quantitative structure–metabolism relationships. Holmes E, et al. **Xenobiotica** 1995 Dec;25(12):1269–81

PHENOLSULFONPHTHALEIN

ANALOGS & DERIVATIVES

Gender–differential liver plasma membrane affinities in hepatic tetrabromosulfonephthalein (TBS) uptake. Torres AM. **Biochem Pharmacol** 1996 May 3;51(9):1117–22

DIAGNOSTIC USE

Clinical usefulness of the dye–injection method for diagnosing premature rupture of the membranes in equivocal cases. Fujimoto S, et al. **J Obstet Gynaecol** 1995 Jun;21(3):215–20
[Phenolsulfonphthalein (PSP)] Tomita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1085–7 (5 ref.) **(Jpn)**

PHARMACOKINETICS

The secretory intestinal transport of some beta–lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. Saitoh H, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):205–11

PHENOPERIDINE

PHARMACOLOGY

Glycosylated and non–glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Priou A, et al. **Clin Endocrinol (Oxf)** 1995 Aug; 43(2):213–7

PHENOPROMIN see **AMPHETAMINE**

PHENOTHIAZINE ANTIPSYCHOTIC AGENTS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINE TRANQUILIZERS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINES

see related
ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

Fluorescent location of cells of cytological interest in cervical smears prestained with thionin. Steven FS, et al. **Anticancer Res** 1996 May–Jun;16(3A):1193–6
A thionin stain for visualizing bone cells, mineralizing fronts and cement lines in undecalcified bone sections. Derkx P, et al. **Biotech Histochem** 1995 Mar;70(2):70–4
Use of azure–D2 for the measurement of uric acid in serum. Lamb EJ, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep; 33(9):595–601

ADVERSE EFFECTS

In vivo study of the mutagenicity of biperidine, pipotiazine, chlorpromazine, and haloperidol [letter] Smith M de A, et al. **Am J Med Genet** 1996 Apr 9;67(2):238
Corneal endothelial changes in schizophrenic patients with long–term administration of major tranquilizers. Yasuhara T, et al. **Am J Ophthalmol** 1996 Jan;121(1):84–8
Fenoverine–induced rhabdomyolysis. Chariot P, et al. **Hum Exp Toxicol** 1995 Aug;14(8):654–6
Cardiac arrhythmia in a child receiving pericyazine [letter] Jaworowsky S, et al. **Isr J Psychiatry Relat Sci** 1995; 32(4):299–300
Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Torinuki W. **Tohoku J Exp Med** 1995 Aug;176(4):249–52
[Akathisia induced by low doses of neuroleptics after a pallidal infarction (letter)] Auzou P, et al. **Presse Med** 1996 Feb 17;25(6):260 **(Fre)**

CHEMICAL SYNTHESIS

Antitumor activity of phenothiazine–related compounds. Nagy S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1915–8

CHEMISTRY

Stability–indicating assay of mequitazine in bulk and pharmaceutical tablets. Bakry RS, et al. **Acta Pharm Hung** 1996 Mar;66(2):83–8
Development of a melanin–based high–performance liquid chromatography stationary phase and its use in the study of drug–melanin binding interactions. Ibrahim H, et al. **Anal Biochem** 1995 Aug 10;229(2):272–7

ISOLATION & PURIFICATION

Development of a melanin–based high–performance liquid chromatography stationary phase and its use in the study of drug–melanin binding interactions. Ibrahim H, et al. **Anal Biochem** 1995 Aug 10;229(2):272–7

PHARMACOLOGY

Effects of two benzo[a]phenothiazines on multi–drug resistance (mdr) and tumor antigen expression. Molnár J, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2013–6
Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10–[n–(phthalimido)alkyl–2–substituted–10H–phenothiazines and 1–(2–chloroethyl)–3–(2–substituted–10 H–phenothiazin–10–yl)alkyl–1–ureas. Petri IB, et al. **Anticancer Res** 1996 May–Jun;16(3A):1247–50
Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine–related compounds. Sakagami H, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2533–40
Effect of chlorpromazine and benzo[a]phenothiazines on heterotrophic auxin requiring and autotrophic auxin non–requiring tobacco tissue cultures. Szabó M, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2113–6
Structure–activity relationships of phenothiazines in inhibiting lymphocyte motility as determined by a novel flow cytometric assay. Matthews N, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1053–61
Ethmozine and ethacizine––new antiarrhythmic drugs with defibrillating properties. Varon D, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct–Dec;4(4):299–311
Electrographic studies of the effects of RP 60180, a novel kappa agonist, on the photosensitive baboon Papio papio. Stutzmann JM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):687–97
[Role of cholinergic mechanisms in the functioning of specific structures of the visual analyzer] Aleksandrov MV, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):64–8 **(Rus)**

THERAPEUTIC USE

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)
[Migraine in childhood and adolescence: a retrospective review of hospital cases] Castro–Gago M, et al. **Rev Neurol** 1995 Jul–Aug;23(122):769–72 (Eng. Abstr.) **(Spa)**

TOXICITY

Antitumor activity of phenothiazine–related compounds. Nagy S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1915–8

PHENOTYPE

see related
SOMATOTYPES

Familial facioscapulohumeral muscular dystrophy: phenotypic diversity and genetic abnormality. Nakagawa M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):189–92
Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14–linked early onset Alzheimer's disease. Egensperger R, et al. **Acta Neuropathol (Berl)** 1995;90(3):257–65
Clinical features and lung function in 18–year–old adolescents with alpha 1–antitrypsin deficiency. Sveger T, et al. **Acta Paediatr** 1995 Jul;84(7):815–6
Clinical evidence for genomic imprinting in bipolar I disorder. Grigoroiu–Serbanescu M, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):365–70
Biological phenotype of HIV–1 and transmission [letter] Albert J, et al. **AIDS** 1995 Jul;9(7):822–3
Lower prevalence and incidence of HIV–1 syncytium–inducing phenotype among injecting drug users compared with homosexual men. Spijkerman IJ, et al. **AIDS** 1995 Sep;9(9):1085–92
Chronic ethanol consumption alters effects of ethanol in vitro

on brain membrane structure of high alcohol sensitivity and low alcohol sensitivity rats. Avdulov NA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):886–91

Task persistence after alcohol consumption among children of alcoholics. Baer JS, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):955–60

A strategy for the identification of candidate genes for alcohol–related phenotypes and other human disorders using rapid polymerase chain reaction mapping of gene–based sequence–tagged sites. Berry R, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):821–3

Stage–dependent effects of ethanol on cranial neural crest cell development: partial basis for the phenotypic variations observed in fetal alcohol syndrome. Cartwright MM, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1454–62

Classical and neoclassical approaches to the genetic analysis of alcohol–related phenotypes. Dudek BC, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):802–10

Identifying alcoholism vulnerability alleles. Goldman D. **Alcohol Clin Exp Res** 1995 Aug;19(4):824–31 (71 ref.)

Apolipoprotein E phenotype modifies metabolic and hemodynamic abnormalities related to central obesity in women. Uusitupa MI, et al. **Am J Clin Nutr** 1996 Aug; 64(2):131–6

Segregation analysis of continuous phenotypes by using higher sample moments. Lee H, et al. **Am J Hum Genet** 1996 Jan;58(1):213–24

Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Rubinsztein DC, et al. **Am J Hum Genet** 1996 Jul;59(1):16–22

Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe. Kenworthy L, et al. **Am J Med Genet** 1995 Nov 20;59(3):283–90

Molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy. Parano E, et al. **Ann Neurol** 1996 Aug;40(2):247–51

Molecular basis of phenotypic variability in sporadic Creutzfeldt–Jakob disease. Parchi P, et al. **Ann Neurol** 1996 Jun;39(6):767–78

Major injury leads to predominance of the T helper–2 lymphocyte phenotype and diminished interleukin–12 production associated with decreased resistance to infection. O'Sullivan ST, et al. **Ann Surg** 1995 Oct; 222(4):482–90; discussion 490–2

Red cell 6–phosphogluconate dehydrogenase polymorphism in the Gadaba of Andhra Pradesh (India). Report of new variant phenotypes. Rao PM, et al. **Anthropol Anz** 1995 Dec;53(4):327–30

A study of leg–crossing in a German sample. Reiss M. **Anthropol Anz** 1995 Sep;53(3):263–8

Alpha–1–antitrypsin PLowell: a normally functioning variant present in low concentration. Cook L, et al. **Aust N Z J Med** 1995 Dec;25(6):695–7

The degree of lateralization of paw usage (handedness) in the mouse is defined by three major phenotypes. Biddle FG, et al. **Behav Genet** 1996 Jul;26(4):391–406

Genetic analysis of the relationships between behavioral and neuroendocrine traits in Roman High and Low Avoidance rat lines. Castanon N, et al. **Behav Genet** 1995 Jul; 25(4):371–84

Organization of motor and posture patterns in paradise fish (Macropodus opercularis): environmental and genetic components of phenotypical correlation structures. Gerlai R, et al. **Behav Genet** 1995 Jul;25(4):385–96

Changes in heritability across increasing levels of behavior problems in young twins. Gjone H, et al. **Behav Genet** 1996 Jul;26(4):419–26

Physical similarity and the equal–environment assumption in twin studies of psychiatric disorders. Hettema JM, et al. **Behav Genet** 1995 Jul;25(4):327–35

A gene–culture model of human handedness. Laland KN, et al. **Behav Genet** 1995 Sep;25(5):433–45

Genetic vs. environmental contributions to human handedness: insights gained from studying individuals with unilateral hand injuries. Porac C. **Behav Genet** 1995 Sep; 25(5):447–55

Developmental and genetic influences on the P50 sensory gating phenotype. Myles–Worsley M, et al. **Biol Psychiatry** 1996 Feb 15;39(4):289–95

Spectral analysis of EEG from families. Eischen SE, et al. **Biol Psychol** 1995 Aug;41(1):61–8

Mutator phenotype in a subset of chronic lymphocytic leukemia. Gartenhaus R, et al. **Blood** 1996 Jan 1;87(1):38–41

Gene expression and vascular smooth muscle cell phenotype. Weissberg PL, et al. **Blood Press Suppl** 1995;2:68–73 (19 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

The genetic dissection of multifactorial traits. Elston RC. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:103–6

The place of airway hyperresponsiveness in the asthma phenotype. Sterk PJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:8–11; discussion 17–8 (30 ref.)

Problems in the phenotypic assessment of asthma. Weiss ST. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:12–4; discussion 17–8 (4 ref.)

Is there a specific phenotype for asthma? Woolcock AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:3–7; discussion 17–8

Discordance between phenotype and genotype in malignant hyperthermia. MacLennan DH. **Curr Opin Neurol** 1995 Oct;8(5):397–401 (33 ref.)

Variability of clinical and immunological phenotype in immunodeficiency–centromeric instability–facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840–6 (21 ref.)

Phenotypic variability in van der Woude syndrome. Lacombe D, et al. **Genet Couns** 1995;6(3):221–6

Marden–Walker phenotype: a diagnostic dilemma. Soekarman D, et al. **Genet Couns** 1996;7(1):31–9

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 —> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)

Molecular basis for the CAT–2 null phenotype in maize. Bethards LA, et al. **Genetics** 1988 Jan;118(1):149–53

TGF beta promotes the basal phenotype of epidermal keratinocytes: transcriptional induction of K#5 and K#14 keratin genes. Jiang CK, et al. **Growth Factors** 1995; 12(2):87–97

Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B–100. Benlian P, et al. **Hum Mutat** 1996;7(4):340–5

Where phenotype does not match genotype. German J. **Hum Mutat** 1995;6(1):7–8

Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Summers KM. **Hum Mutat** 1996;7(4):283–93 (98 ref.)

A rare Rh phenotype in a north Indian family. Jolly JG, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S11–2

Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Kishimoto T, et al. **Int J Cancer** 1996 Aug 22;69(4):290–4

Phenotype differences of STRs in 7 human populations. Meyer E, et al. **Int J Legal Med** 1995;107(6):314–22

Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. Frank–Raue K, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1780–3

Mastitis of periparturient Holstein cattle: a phenotypic and genetic study. Detilleux JC, et al. **J Dairy Sci** 1995 Oct; 78(10):2285–93

Two retroviral infections of periparturient Holstein cattle: a phenotypic and genetic study. Detilleux JC, et al. **J Dairy Sci** 1995 Oct;78(10):2294–8

Phenotypic relationship of yield and type scores from first lactation with herd life and profitability. Norman HD, et al. **J Dairy Sci** 1996 Apr;79(4):689–701

Application of capillary electrophoresis in the identification of phenotypes containing the beta–lactoglobulin C variant. Paterson GR, et al. **J Dairy Sci** 1995 Dec;78(12):2637–44

Phenotype characterization and prevalence of rBAT M467T mutation in Italian cystinuric patients. de Sanctis L, et al. **J Inherit Metab Dis** 1996;19(2):243–5

Genetic versus phenotypic models of selection: can genetics be neglected in a long–term perspective? Weissing FJ. **J Math Biol** 1996;34(5–6):533–55

Homozygosity for Machado–Joseph disease gene enhances phenotypic severity [letter] Sobue G, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):354–6

Recurrent myoglobinuria due to carnitine palmitoyltransferase II deficiency: expression of the molecular phenotype in cultured muscle cells. Villard J, et al. **J Neurol Sci** 1996 Mar;136(1–2):178–81

Clinical heterogeneity in congenital sucrase–isomaltase deficiency [editorial; comment] Treem WR. **J Pediatr** 1996 Jun;128(6):727–9. Comment on: J Pediatr 1996 Jun;128(6):753–6.

3–Year–old phenotypic female with campomelic dysplasia and bilateral gonadoblastoma. Hong JR, et al. **J Pediatr Surg** 1995 Dec;30(12):1735–7

The consequences of phenotypic plasticity in cyclically varying environments: a genetic algorithm study. Behera N, et al. **J Theor Biol** 1996 Jan 21;178(2):135–44

The inheritance of phenotypes: an adaptation to fluctuating environments. Lachmann M, et al. **J Theor Biol** 1996 Jul 7;181(1):1–9

Observations on the normal distribution of quantitative traits. Xiao PT. **Med Hypotheses** 1995 Oct;45(4):386–8

Variable phenotype of rapid–onset dystonia–parkinsonism. Brashear A, et al. **Mov Disord** 1996 Mar;11(2):151–6

Dominantly inherited cerebello–olivary atrophy is not due to a mutation at the spinocerebellar ataxia–I, Machado–Joseph disease, or Dentato–Rubro–Pallido–Luysian atrophy locus. Subramony SH, et al. **Mov Disord** 1996 Mar;11(2):174–80

X–linked recessive bulbospinal neuronopathy: clinical phenotypes and CAG repeat size in androgen receptor gene. Shimada N, et al. **Muscle Nerve** 1995 Dec; 18(12):1378–84

Genetic control of the CD4/CD8 T–cell ratio in humans [see comments] Amadori A, et al. **Nat Med** 1995 Dec; 1(12):1279–83. Comment in: Nat Med 1995 Dec;1(12):1240–1.

The CD4/CD8 ratio: message in a bottle? [comment] Chakravarti A. **Nat Med** 1995 Dec;1(12):1240–1. Comment on: Nat Med 1995 Dec;1(12):1279–83.

Prepubertal castration alters the phenotypic profile of adult rat thymocytes. Leposavic G, et al. **Neuroimmunomodulation** 1995 Mar–Apr;2(2):100–7

Intrafamilial phenotypic heterogeneity of the Poland complex: a case report. Parano E, et al. **Neuropediatrics** 1995 Aug;26(4):217–9

Rett syndrome—distribution of phenotypes with special attention to the preserved speech variant. Skjeldal OH, et al. **Neuropediatrics** 1995 Apr;26(2):87

The adaptive advantage of phenotypic memory in changing environments. Jablonka E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1332):133–41

Arabidopsis in Madison: genes and phenotypes spread like weeds. Chasan R. **Plant Cell** 1995 Nov;7(11):1737–48 (34 ref.)

Further evidence for anticipation in schizophrenia. Thibaut F, et al. **Psychiatry Res** 1995 Nov 29;59(1–2):25–33

Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Korach KS, et al. **Recent Prog Horm Res** 1996;51:159–86; discussion 186–8 (50 ref.)

Transcriptional control of cell phenotypes in the neuroendocrine system. Rosenfeld MG, et al. **Recent Prog Horm Res** 1996;51:217–38; discussion 238–9 (98 ref.)

HLA A/B recombination in a white woman with the S–s–phenotype of the MNS system. Salaru NN. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):139–40

Characterization of the hybrid RHD gene leading to the partial D category IIIc phenotype. Beckers EA, et al. **Transfusion** 1996 Jun;36(6):567–74

Involvement of Ser103 of the Rh polypeptides in G epitope formation. Faas BH, et al. **Transfusion** 1996 Jun; 36(6):506–11

Molecular basis of the K:6,–7 [Js(a+b–)] phenotype in the Kell blood group system. Lee S, et al. **Transfusion** 1995 Oct;35(10):822–5

In vitro and in vivo phenotypes resulting from deletion of the high temperature requirement A (htrA) gene from the bovine vaccine strain Brucella abortus S19. Robertson GT, et al. **Vet Microbiol** 1996 Apr;49(3–4):197–207

Primary hepatic marginal zone B–cell lymphoma with mantle cell lymphoma phenotype. Ueda G, et al. **Virchows Arch** 1996 Jul;428(4–5):311–4

Phenotypic variation and its correlation with mutations in the low density lipoprotein (LDL) receptor gene in familial hypercholesterolemia. Sun XM, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:12–3

[Molecular analysis of the heterogeneity of hereditary monosymptomatic sensorineural hearing loss] Fiegert P, et al. **Laryngorhinootologie** 1996 Mar;75(3):141–7 (Eng. Abstr.) **(Ger)**

[Phenotype variability in adrenoleukodystrophy. Presentation of three new cases and a review of literature] Ara JR, et al. **Rev Neurol** 1996 Jul;24(131):843–7 (Eng. Abstr.) **(Spa)**

PHENOXAZOLE see **PEMOLINE**

PHENOXYACETATES

CHEMICAL SYNTHESIS

Structure–activity relationship study of TXA2 receptor antagonists. 4–[2–(4–substituted phenylsulfonylamino)ethylthio]phenoxyacetic acids and related compounds. Kawashima Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1132–6

METABOLISM

The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat beta 3–adrenoceptor. Mayers RM, et al. **Eur J Pharmacol** 1996 Jan 11;295(2–3):199–205

PHARMACOLOGY

Structure–activity relationship study of TXA2 receptor antagonists. 4–[2–(4–substituted phenylsulfonylamino)ethylthio]phenoxyacetic acids and related compounds. Kawashima Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1132–6

The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat beta 3–adrenoceptor. Mayers RM, et al. **Eur J Pharmacol** 1996 Jan 11;295(2–3):199–205

Effects on metabolic rate and fuel selection of a selective beta–3 agonist (ICI D7114) in healthy lean men. Goldberg GR, et al. **Int J Obes Relat Metab Disord** 1995 Sep; 19(9):625–31

The effect of a TXA2 receptor antagonist ON–579 on experimental allergic reactions. Nagai H, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):123–33

PHENOXYBENZAMINE

THERAPEUTIC USE

Influence of alpha–adrenergic blockade on ventricular arrhythmias, QTc interval and heart rate variability in phaeochromocytoma. Dąbrowska B, et al. **J Hum Hypertens** 1995 Nov;9(11):925–9

PHENPROCOUMALOL see **PHENPROCOUMON**

PHENPROCOUMAROL see PHENPROCOUMON

PHENPROCOUMON

ADMINISTRATION & DOSAGE

Randomized comparison of aspirin and phenprocoumon for prevention of right-sided thromboembolic complications associated with transvenous defibrillation leads. Jung W, et al. **Eur Heart J** 1995 Jul;16(7):986-92

[May (must?) in a for recurrent thrombophlebitis [with normal AT III/ protein C+S] fully "marcumarized" patient (with [otherwise?] negative contraindications) with acute posterior wall infarct (15 min "old") a brief lysis therapy be instituted?] Seitz R. **Internist (Berl)** 1995 Dec;36(12):1202 **(Ger)**

ADVERSE EFFECTS

[Phenprocoumon-induced necrotizing hepatitis (letter)] Ehrenforth S, et al. **Dtsch Med Wochenschr** 1995 Nov 3; 120(44):1529-30 **(Ger)**

[Pronounced phenprocoumon overdosage as a consequence of an unclear physician's order (letter)] Schaer B. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):887 **(Ger)**

[Phenprocoumon-induced cholestatic hepatitis] Woolley S, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1507-10 (Eng. Abstr.) **(Ger)**

METABOLISM

[Possible potentiation of phenprocoumon by clarithromycin and roxithromycin] Meyboom RH, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):375-7 (Eng. Abstr.) **(Dut)**

POISONING

Fatal cerebellar haemorrhage due to phenprocoumon poisoning. Höhler T, et al. **Int J Legal Med** 1996; 108(5):268-71

THERAPEUTIC USE

The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation. Bruhn HD, et al. **J Heart Valve Dis** 1995 Mar;4(2):138-40

PHENTANYL see FENTANYL

PHENTERMINE

ADVERSE EFFECTS

A toxic reaction from combining fluoxetine and phentermine [letter] Bostwick JM, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):189-90

THERAPEUTIC USE

Treatment of a 4-year-old boy with ADHD with the dopamine releaser phentermine [letter] Rothman RB. **J Clin Psychiatry** 1996 Jul;57(7):308-9

Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity [letter] Rothman RB. **J Clin Psychiatry** 1996 Feb;57(2):92-3

PHENTOLAMINE

ADMINISTRATION & DOSAGE

Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses [see comments] Bechara A, et al. **J Urol** 1996 Mar;155(3):913-4. Comment in: J Urol 1996 Mar;155(3):924-5.

Peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Preliminary report. Galer BS. **Reg Anesth** 1995 Sep-Oct;20(5):444-7

Oral phentolamine mesylate in the treatment of complex regional pain syndrome. McCleane GJ. **Ulster Med J** 1996 May;65(1):87-8

ADVERSE EFFECTS

Risks of self-injection therapy for impotence [letter] Millard RJ, et al. **Med J Aust** 1996 Jul 15;165(2):117-8

PHARMACOLOGY

Role of alpha-adrenoceptors in the maintenance of core temperature in humans. Frank SM, et al. **Clin Sci (Colch)** 1995 Sep;89(3):219-25

Alpha 1- and alpha 2-adrenoreceptor actions of phentolamine and prazosin on breathing movements in fetal sheep in utero. Giussani DA, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):249-55

Microwave-induced lethal heat stress: effects of phentolamine, prazosin and metoprolol. Jauchem JR, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):241-8

THERAPEUTIC USE

Phentolamine abolishes the pain of chronic pancreatitis. McCleane GJ. **Br J Hosp Med** 1996 Apr 17-30;55(8):521

Pharmacological management of erectile dysfunction. Montorsi F, et al. **Drugs** 1995 Sep;50(3):465-79 (59 ref.)

Correct treatment for accidental epinephrine auto-injector-induced digital ischemia [letter; comment] Brenner GM. **J Am Osteopath Assoc** 1995 Sep;95(9):510. Comment on: J Am Osteopath Assoc 1995 Jun;95(6):377-8.

PHENYL ETHERS

ANALYSIS

Tandem mass spectrometry of herbicide residues in lipid-rich tissue. Headley JV, et al. **Anal Chem** 1995 Dec 1; 67(23):4349-53

ISOLATION & PURIFICATION

Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. Fu X, et al. **J Nat Prod** 1995 Sep;58(9):1384-91

Barceloneic acid A, a new farnesyl-protein transferase inhibitor from a Phoma species. Jayasuriya H, et al. **J Nat Prod** 1995 Jul;58(7):986-91

Isolation and antibacterial activity of marchantin A, a cyclic bis(bibenzyl) constituent of Hungarian Marchantia polymorpha. Kámory E, et al. **Planta Med** 1995 Aug; 61(4):387-8

METABOLISM

Relationships between conformational behaviour and binding affinity towards beta 1 and beta 2 adrenoceptors of some chiral phenoxypropanolamines with bulky N-substituents. Villa L, et al. **Farmaco** 1995 Oct;50(10):643-58

[Biodegradation of herbicide chlornitrofen (CNP) and mutagenicity of its degradation products] Kitamori S. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):142-50 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The biological activity of cyclic bis(bibenzyls): a rational approach. Keseru GM, et al. **Bioorg Med Chem** 1995 Nov; 3(11):1511-7

RES-1214-1 and -2, novel non-peptidic endothelin type A receptor antagonists produced by Pestalotiopsis sp. Ogawa T, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1401-6

Comparative study of the cytostatic effects of Oliphen and Ukrain. Voltchek I, et al. **J Chemother** 1996 Apr;8(2):144-6

Beta subunit coexpression and the alpha1 subunit domain I-II linker affect piperidine block of neuronal calcium channels. Zamponi GW, et al. **J Neurosci** 1996 Apr 15;16(8):2430-43

Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Falch BS, et al. **Planta Med** 1995 Aug;61(4):321-8

Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Berg DT, et al. **Science** 1996 Sep 6;273(5280):1389-91

POISONING

[A case of acute peroral poisoning by the preparation Nitrafen] Nikitin PV, et al. **Sud Med Ekspert** 1996 Jan-Mar; 39(1):33-5 (9 ref.) **(Rus)**

TOXICITY

Lung hypoplasia and surfactant system immaturity induced in the fetal rat by prenatal exposure to nitrofen. Alfanso LF, et al. **Biol Neonate** 1996;69(2):94-100

Mutagenic activity of the amido derivatives and their hydroxamic acids of nitrobiphenyl ethers. Miyauchi M, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):446-52

Depletion of glutathione and hepato-toxicity caused by vinyl ethers in mice. Isobe M, et al. **J Toxicol Sci** 1995 May; 20(2):161-4

Genotoxicity of potential metabolites of nitroscanate--an antischistosomal drug. Gupta RL, et al. **Mutat Res** 1995 Dec;335(3):235-43

[Biodegradation of herbicide chlornitrofen (CNP) and mutagenicity of its degradation products] Kitamori S. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):142-50 (Eng. Abstr.) **(Jpn)**

PHENYL MERCURY COMPOUNDS see PHENYLMERCURY COMPOUNDS

PHENYLACETATES

ANALYSIS

Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. Tateishi T, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1921-4

BLOOD

Determination of 1,2,6-inositol trisphosphate (derivatives) in plasma using iron(III)-loaded adsorbents and capillary zone electrophoresis-(indirect) UV detection. Buscher BA, et al. **J Chromatogr A** 1995 Dec 22;718(2):413-9

The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. Lázníček M, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):823-8

IMMUNOLOGY

The development of peripheral TNP-tolerance and suppressor function in Xenopus laevis, the South African clawed toad. Ruben LN, et al. **Dev Comp Immunol** 1995 Sep-Oct;19(5):405-15

Three-dimensional structures of the Fab fragment of murine N1G9 antibody from the primary immune response and of its complex with (4-hydroxy-3-nitrophenyl)acetate. Mizutani R, et al. **J Mol Biol** 1995 Nov 24;254(2):208-22

METABOLISM

Properties of D-hydantoinase from Agrobacterium tumefaciens and its use for the preparation of N-carbamyl D-amino acids. Durham DR, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1095-100

Molecular characterization of the 4-hydroxyphenylacetate catabolic pathway of Escherichia coli W: engineering a mobile aromatic degradative cluster. Prieto MA, et al. **J Bacteriol** 1996 Jan;178(1):111-20

PHARMACOKINETICS

Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Castillo M, et al. **Drug Metab Dispos** 1995 May;23(5):566-72

PHARMACOLOGY

In vitro activities of the lichen secondary metabolites vulpinic acid, (+)-usnic acid, and (-)-usnic acid against aerobic and anaerobic microorganisms. Lauterwein M, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2541-3

Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Hudgins WR, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1273-9

Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Pineau T, et al. **Biochem Pharmacol** 1996 Aug 23; 52(4):659-67

Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Adam L, et al. **Cancer Res** 1995 Nov 15;55(22):5156-60

Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Liu L, et al. **Cytokine** 1995 Jul; 7(5):449-56

Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Shack S, et al. **Int J Cancer** 1995 Sep 27;63(1):124-9

Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches. Fujisawa H, et al. **Int J Immunopharmacol** 1995 Jul; 17(7):611-7

Thermorubin and 2-hydroxyphenyl acetic acid, aldose reductase inhibitors. Hayashi K, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1345-6

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. Prasanna P, et al. **J Neurochem** 1996 Feb;66(2):710-6

Phenylacetate is an inhibitor of prostatic growth and development in organ culture. Lipschutz JH, et al. **J Urol** 1996 May;155(5):1762-70

S-(-)-ET 126: a potent and selective M1 antagonist in vitro and in vivo. Ghelardini C, et al. **Life Sci** 1996; 58(12):991-1000

Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Danesi R, et al. **Mol Pharmacol** 1996 Jun;49(6):972-9

A patch clamp study of the effects of ciprofloxacin and biphenyl acetic acid on rat hippocampal neurone GABAA and ionotropic glutamate receptors. Halliwell RF, et al. **Neuropharmacology** 1995 Dec;34(12):1615-24

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Esquenet M, et al. **Prostate** 1996 Mar;28(3):182-94

THERAPEUTIC USE

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. Newmark HL, et al. **J Cell Biochem Suppl** 1995;22:247-53 (45 ref.)

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Sugita Y, et al. **Kurume Med J** 1995;42(3):133-40

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Tsuda H, et al. **Kurume Med J** 1996;43(2):137-47

Long-term treatment of girls with ornithine transcarbamylase deficiency. Maestri NE, et al. **N Engl J Med** 1996 Sep 19;335(12):855-9

TOXICITY

Multiple actions of arylalkylamine arthropod toxins on the

N-methyl-D-aspartate receptor. Donevan SD, et al. **Neuroscience** 1996 Jan;70(2):361-75

PHENYLALANINE

Involvement of Phe19 in the Mn(2+)-L-malate binding and the subunit interactions of pigeon liver malic enzyme. Chou WY, et al. **Biochemistry** 1996 Jul 30;35(30):9873-9

The role of Phe-92 in the Ca(2+)-induced conformational transition in the C-terminal domain of calmodulin. Meyer DF, et al. **J Biol Chem** 1996 May 10;271(19):11284-90

International database of tetrahydrobiopterin deficiencies. Blau N, et al. **J Inherit Metab Dis** 1996;19(1):8-14

Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. Yannicelli S, et al. **J Inherit Metab Dis** 1995;18(2):131-4

ADMINISTRATION & DOSAGE

The use of a low phenylalanine diet in response to the challenging behaviour of a man with untreated phenylketonuria and profound learning disabilities. Harvey EL, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):520-6

Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the day. van Spronsen FJ, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):839-44

ADVERSE EFFECTS

Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. Griffiths P, et al. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):365-72

ANALOGS & DERIVATIVES

Synthesis of p-phosphonomethyl-L-phenylalanine using camphor sultam or D-valine as chiral auxiliaries and its incorporation into integrin sequences. Larsson E, et al. **Acta Chem Scand** 1996 Jan;50(1):54-7

Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Brown PD. **Adv Enzyme Regul** 1995; 35:293-301

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967-74 (48 ref.)

Inactivation of cysteine proteases. Govardhan CP, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):110-4

Cloning of m-fluorophenylalanine-resistant gene and mutational analysis of feedback-resistant prephenate dehydratase from Corynebacterium glutamicum. Chan MS, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):537-42

Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Chen L, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):976-84

Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanin e (A-4166)receptor in HIT T-15 cells. Displacement of [3H]glibenclamide. Fujita T, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):407-11

The synthesis and characterisation of a glyoxal inhibitor of chymotrypsin. Murphy EA, et al. **Biochem Soc Trans** 1996 Feb;24(1):129S

Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Grams F, et al. **Biochemistry** 1995 Oct 31;34(43):14012-20

A mechanism for hydroxylation by tyrosine hydroxylase based on partitioning of substituted phenylalanines. Hillas PJ, et al. **Biochemistry** 1996 Jun 4;35(22):6968-75

Solution structure of dehydropeptides: a CD investigation. Pieroni O, et al. **Biopolymers** 1996 Jan;38(1):97-108

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281-7

Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Eccles SA, et al. **Cancer Res** 1996 Jun 15;56(12):2815-22

Hydroxylforms of p-boronophenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors. Takagaki M, et al. **Cancer Res** 1996 May 1;56(9):2017-20

Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Ogawa T, et al. **Eur J Nucl Med** 1996 Aug;23(8):889-95

Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Valverde O, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):79-93

Monamidocin, a novel fibrinogen receptor antagonist. II. Biological activity and structure-activity relationships. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1226-33

Monamidocin, a novel fibrinogen receptor antagonist. I. Production isolation, characterization and structural elucidation. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1221-5

Potent inhibitors of cysteine proteases from the marine fungus Microascus longirostris. Yu CM, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):395-7

Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1. Zhang ZY, et al. **J Biol Chem** 1996 Mar 8;271(10):5386-92

Characterization of dynamic state inhibitors of HIV-1 protease. Vaillancourt M, et al. **J Enzym Inhib** 1995; 9(3):217-33

Evaluation of the stability and animal biodistribution of gadolinium (III) benzylamine-derivatized diethylenetriaminepentaacetic acid. Deal KA, et al. **J Med Chem** 1996 Aug 2;39(16):3096-3106

Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine. Reissmann S, et al. **J Med Chem** 1996 Feb 16;39(4):929-36

Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. Sledge GW Jr, et al. **J Natl Cancer Inst** 1995 Oct 18; 87(20):1546-50

The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats. Daugé V, et al. **J Neurochem** 1996 Sep;67(3):1301-8

Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-L-methionine. Kubota K, et al. **J Nucl Med** 1996 Feb;37(2):320-5

The disposition, tissue distribution, and cellular transport of N-[[(trimethylamino)boryl]carbonyl]-L-phenylalanine methyl ester in CF1 mice. Miller MC 3rd, et al. **J Pharm Sci** 1995 Aug;84(8):933-6

Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Fujitani S, et al. **Metabolism** 1996 Feb;45(2):184-9

Interaction of glycyl-phenylalanine with carbohydrates as a model of N-terminal glycation of proteins. Argirov OK, et al. **Ophthalmic Res** 1996;28 Suppl 1:62-4

Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog. Tse FL, et al. **Pharm Res** 1996 Mar; 13(3):440-4

Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion. Seto Y, et al. **Pharmacology** 1995 Oct;51(4):245-53

Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Botos I, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2749-54

Ionophoretic properties of the non-sulfonylurea hypoglycemic agents A-4166 and KAD-1229. Bakkali-Nadi A, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun;88(3):339-47

Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions. Wanaka K, et al. **Thromb Res** 1996 Apr 1;82(1):79-86

ANALYSIS

Determination of isotopic ratios of L-leucine and L-phenylalanine and their stable isotope labeled analogues in biological samples by gas chromatography/triple-stage quadrupole mass spectrometry. Schweer H, et al. **J Mass Spectrom** 1996 Jul;31(7):727-34

BLOOD

No fine motor deficits in patients with untreated non-phenylketonuria hyperphenylalaninaemia. Weglage J, et al. **Acta Paediatr** 1996 Mar;85(3):320-3

Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. Stegink LD, et al. **Am J Clin Nutr** 1995 Dec;62(6):1206-11

Quantitation of L-amino acids by substrate recycling between an aminotransferase and a dehydrogenase: application to the determination of L-phenylalanine in human blood. Nakamura K, et al. **Anal Biochem** 1996 Feb 1;234(1):19-22

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. MacDonald A, et al. **Arch Dis Child** 1996 May;74(5):412-7

An automated enzymatic method on the Roche COBAS MIRA S for monitoring phenylalanine in dried blood spots of patients with phenylketonuria. Randell EW, et al. **Clin Biochem** 1996 Apr;29(2):133-8

Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. Hashem N, et al. **Hum Genet** 1996 Jul;98(1):3-6

Immune status of children with phenylketonuria. Gropper SS, et al. **J Am Coll Nutr** 1995 Jun;14(3):264-70

Structural and functional consequences of mutations in 6-pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. Oppliger T, et al. **J Biol Chem** 1995 Dec 8;270(49):29498-506

Molecular basis of non-PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. Desviat LR, et al. **J Inherit Metab Dis** 1996; 19(2):227-30

Transient neonatal hyperphenylalaninaemia is not related to mutations at the phenylalanine hydroxylase gene. Zschocke J, et al. **J Inherit Metab Dis** 1995;18(3):369-70

Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man. Moja EA, et al. **Life Sci** 1996 May 24;58(26):2389-95

In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Möller HE, et al. **Neuropediatrics** 1995 Aug; 26(4):199-202

Radiological assessment of the hand and wrist in phenylketonuria and hyperphenylalaninaemia. Greeves LG, et al. **Pediatr Radiol** 1995;25(5):353-5

Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the day. van Spronsen FJ, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):839-44

[Maternal hyperphenylalaninemia in a population of healty Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring] Hyánek J, et al. **Cas Lek Cesk** 1996 Jan 17;135(2):50-3 (Eng. Abstr.) **(Cze)**

[Malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency] Leroux B, et al. **Arch Pediatr** 1996;3 Suppl 1:163s-166s **(Fre)**

CHEMISTRY

Circular dichroism spectroscopy of three tyrosine-to-phenylalanine substitutions of fd gene 5 protein. Mark BL, et al. **Biochemistry** 1995 Oct 3; 34(39):12854-65

Elucidating the mechanism of nucleotide-dependent changes in the redox potential of the [4Fe-4S] cluster in nitrogenase iron protein: the role of phenylalanine 135. Ryle MJ, et al. **Biochemistry** 1996 Jul 23;35(29):9424-34

On the conformation of Phe78 of a chromoprotein antibiotic, neocarzinostatin. Imajo S, et al. **Bioorg Med Chem** 1995 Apr;3(4):429-36

Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side-chain topology. Tourwé D, et al. **Biopolymers** 1996 Jan;38(1):1-12

Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. Noda K, et al. **J Biol Chem** 1995 Dec 1;270(48):28511-4

Addition of side chain interactions to modified Lifson-Roig helix-coil theory: application to energetics of phenylalanine-methionine interactions. Stapley BJ, et al. **Protein Sci** 1995 Nov;4(11):2383-91

DEFICIENCY

Parenteral glycyl-L-tyrosine maintains tyrosine pools and supports growth and nitrogen balance in phenylalanine-deficient rats. Stehle P, et al. **J Nutr** 1996 Mar;126(3):663-7

DIAGNOSTIC USE

In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. Guldberg P, et al. **Eur J Pediatr** 1995 Jul;154(7):551-6

GENETICS

Replacement of the conserved tyrosine 1210 by phenylalanine in the insulin receptor affects insulin-induced dephosphorylation of focal adhesion kinase but leaves other responses intact. Van der Zon GC, et al. **Biochemistry** 1996 Aug 13;35(32):10377-82

Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 (stromelysin 1) obtained by site-directed mutation of phenylalanine 83. Benbow U, et al. **J Biol Chem** 1996 May 3;271(18):10715-22

Methotrexate resistance of mouse dihydrofolate reductase: effect of substitution of phenylalanine-31 by serine or tryptophan. Evenson DA, et al. **J Med Chem** 1996 Apr 26;39(9):1763-6

[Production and catalytic properties of point mutants Phe41-->His and Phe143-->Glu of horseradish peroxidase, expressed in Escherichia coli] Gazarian IG, et al. **Biokhimiia** 1995 Oct;60(10):1555-63 (Eng. Abstr.) **(Rus)**

METABOLISM

Twenty-four-hour intravenous and oral tracer studies with L-[1-13C]phenylalanine and L-[3,3-2H2]tyrosine at a tyrosine-free, generous phenylalanine intake in adults. Sanchez M, et al. **Am J Clin Nutr** 1996 Apr;63(4):532-45

Enteral glutamate is almost completely metabolized in first pass by the gastrointestinal tract of infant pigs. Reeds PJ, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E413-8

An active site phenylalanine of 3-oxo-delta 5-steroid isomerase is catalytically important for proton transfer. Brothers PN, et al. **Biochemistry** 1995 Nov 28; 34(47):15453-8

A mechanism for hydroxylation by tyrosine hydroxylase based on partitioning of substituted phenylalanines. Hillas PJ, et al. **Biochemistry** 1996 Jun 4;35(22):6968-75

Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance. McNulty PH, et al. **Circulation** 1995 Oct 15;92(8):2151-6

Attachment, invasion, chemotaxis, and proteinase expression of B16-BL6 melanoma cells exhibiting a low metastatic phenotype after exposure to dietary restriction of tyrosine and phenylalanine. Uhlenkott CE, et al.

Clin Exp Metastasis 1996 Mar;14(2):125–37

Inhibitors in tea of intestinal absorption of phenylalanine in rats. Kreydiyyeh SI.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Jan;113(1):67–71

Hyperglucagonemia stimulates phenylalanine oxidation in humans. Tessari P, et al. **Diabetes** 1996 Apr;45(4):463–70

Role of the conserved aspartate and phenylalanine residues in prokaryotic and mitochondrial elongation factor Ts in guanine nucleotide exchange. Zhang Y, et al.
FEBS Lett 1996 Aug 12;391(3):330–2

Response of phenylalanine and leucine kinetics to branched chain–enriched amino acids and insulin in patients with cirrhosis [see comments] Tessari P, et al.
Gastroenterology 1996 Jul;111(1):127–37. Comment in: Gastroenterology 1996 Jul;111(1):252–5.

Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. Denne SC, et al. **J Clin Invest** 1996 Feb 1; 97(3):746–54

Blood–brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. Knudsen GM, et al. **J Inherit Metab Dis** 1995;18(6):653–64

Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. Leuzzi V, et al. **J Inherit Metab Dis** 1995;18(5):624–34

PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. Romano V, et al.
J Inherit Metab Dis 1996;19(1):15–24

An RNA pocket for the planar aromatic side chains of phenylalanine and tryptophane. Zinnen S, et al.
Nucleic Acids Symp Ser 1995;(33):148–51

The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pietz J, et al. **Pediatr Res** 1995 Nov; 38(5):657–63

Biosynthesis of pseudoisoeugenols in tissue cultures of Pimpinella anisum. Phenylalanine ammonia lyase and cinnamic acid 4–hydroxylase activities. Reichling J, et al.
Pharm World Sci 1995 Jul 28;17(4):113–9

Characterization of the wild-type form of 4a–carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. Johnen G, et al.
Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12384–8

Cation–pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163–8 (66 ref.)

[Effect of ionizing radiation on membrane transport properties of small intestines] Khyzhnykh SV, et al.
Ukr Biokhim Zh 1995 Jul–Aug;67(4):53–7 (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

Uptake of phenylalanine by the rat brain after resuscitation from cardiac arrest. Kapuściński A. **Folia Neuropathol** 1995; 33(2):101–4

Phenylalanine kinetics in human adipose tissue. Coppack SW, et al. **J Clin Invest** 1996 Aug 1;98(3):692–7

Effect of zinc on D–galactose and L–phenylalanine uptake in rat intestine in vitro. Lugea A, et al. **Rev Esp Fisiol** 1995 Sep;51(3):139–46

PHARMACOLOGY

Changes in the ratio of branched–chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. Okuno M, et al.
Biochem Biophys Res Commun 1995 Sep 25;214(3):1045–50

PHENYLALANINE AMMONIA–LYASE

BIOSYNTHESIS

Biosynthesis of pseudoisoeugenols in tissue cultures of Pimpinella anisum. Phenylalanine ammonia lyase and cinnamic acid 4–hydroxylase activities. Reichling J, et al.
Pharm World Sci 1995 Jul 28;17(4):113–9

Cloning and properties of a rice gene encoding phenylalanine ammonia–lyase. Zhu Q, et al. **Plant Mol Biol** 1995 Nov; 29(3):535–50

GENETICS

Phenylalanine ammonia–lyase gene structure, expression, and evolution in Nicotiana. Fukasawa–Akada T, et al.
Plant Mol Biol 1996 Feb;30(4):711–22

Characterization of the structure and determination of mRNA levels of the phenylalanine ammonia–lyase gene family from Populus kitakamiensis. Osakabe Y, et al.
Plant Mol Biol 1995 Sep;28(6):1133–41

Cloning and properties of a rice gene encoding phenylalanine ammonia–lyase. Zhu Q, et al. **Plant Mol Biol** 1995 Nov; 29(3):535–50

THERAPEUTIC USE

Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia–lyase: a preliminary report. Safos S, et al.
Artif Cells Blood Substit Immobil Biotechnol 1995; 23(6):681–92

PHENYLALANINE HYDROXYLASE

BIOSYNTHESIS

Structure of the phenylalanine hydroxylase gene in Drosophila melanogaster and evidence of alternative promoter usage. Ruiz–Vázquez P, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):238–42

CHEMISTRY

Structure–function relationships of phenylalanine hydroxylase revealed by radiation target analysis. Davis MD, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):235–41

Tryptophan fluorescence of human phenylalanine hydroxylase produced in Escherichia coli. Knappskog PM, et al. **Biochemistry** 1995 Sep 19;34(37):11790–9

Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in Escherichia coli. Comparison of resting and activated states. Kappock TJ, et al. **J Biol Chem** 1995 Dec 22;270(51):30532–44

DEFICIENCY

Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. Hashem N, et al.
Hum Genet 1996 Jul;98(1):3–6

PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. Romano V, et al.
J Inherit Metab Dis 1996;19(1):15–24

GENETICS

Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. Guldberg P, et al. **Am J Hum Genet** 1996 Jul;59(1):84–94

Structure of the phenylalanine hydroxylase gene in Drosophila melanogaster and evidence of alternative promoter usage. Ruiz–Vázquez P, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):238–42

Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations. Kuzmin AI, et al. **Eur J Hum Genet** 1995;3(4):246–55

In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. Guldberg P, et al. **Eur J Pediatr** 1995 Jul;154(7):551–6

Localization of the human achaete–scute homolog gene (ASCL1) distal to phenylalanine hydroxylase (PAH) and proximal to tumor rejection antigen (TRA1) on chromosome 12q22–q23. Renault B, et al. **Genomics** 1995 Nov 1;30(1):81–3

Polymorphism in the 3' untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. Ramus SJ, et al. **Hum Genet** 1995 Dec;96(6):741–3

Novel missense mutation in the phenylalanine hydroxylase gene leading to complete loss of enzymatic activity. Dianzani I, et al. **Hum Mutat** 1995;6(3):247–9

PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Eiken HG, et al. **Hum Mutat** 1996;7(3):228–38

Mutations Ivs4nt1, 47delCT, and G148S identified in the phenylalanine hydroxylase gene by RT–PCR of illegitimate transcripts and chemical cleavage of mismatch. Ramus SJ, et al. **Hum Mutat** 1995;6(3):250–1

Molecular basis of non–PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. Desviat LR, et al. **J Inherit Metab Dis** 1996; 19(2):227–30

Phenylketonuria mutations in southern Chinese detected by denaturing gradient gel electrophoresis in exon 7 of PAH gene. Gu XF, et al. **J Inherit Metab Dis** 1995;18(6):753–4

Transient neonatal hyperphenylalaninaemia is not related to mutations at the phenylalanine hydroxylase gene. Zschocke J, et al. **J Inherit Metab Dis** 1995;18(3):369–70

The activity of the highly inducible mouse phenylalanine hydroxylase gene promoter is dependent upon a tissue–specific, hormone–inducible enhancer. Faust DM, et al. **Mol Cell Biol** 1996 Jun;16(6):3125–37

PAH Mutation Analysis Consortium Database: a database for disease–producing and other allelic variation at the human PAH locus. Hoang L, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):127–31

Newborn mass screening and molecular genetics of phenylketonuria in east Asia. Okano Y, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:123–9

[Advances in the diagnosis of phenylketonuria with the introduction of direct detection of PAH gene mutation] Kozák L, et al. **Cas Lek Cesk** 1995 Jun 14;134(12):385–7 (Eng. Abstr.) **(Cze)**

[Allele–specific sequencing] Kalinin VN, et al.
Dokl Akad Nauk 1995 Aug;343(5):692–4 **(Rus)**

METABOLISM

Phosphorylation of recombinant human phenylalanine hydroxylase: effect on catalytic activity, substrate activation and protection against non–specific cleavage of the fusion protein by restriction protease. Døskeland AP, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):409–14

PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Eiken HG, et al. **Hum Mutat** 1996;7(3):228–38

Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in Escherichia coli. Comparison of resting and activated states. Kappock TJ, et al. **J Biol Chem** 1995 Dec 22;270(51):30532–44

PHYSIOLOGY

Structure and function of the aromatic amino acid hydroxylases. Hufton SE, et al. **Biochem J** 1995 Oct 15; 311 (Pt 2):353–66 (223 ref.)

RADIATION EFFECTS

Structure–function relationships of phenylalanine hydroxylase revealed by radiation target analysis. Davis MD, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):235–41

PHENYLALANINE MUSTARD see **MELPHALAN**

PHENYLALANINE–SPECIFIC TRNA see **RNA, TRANSFER, PHE**

PHENYLALANYL T RNA SYNTHETASE

CHEMISTRY

Conservation in evolution for a small monomeric phenylalanyl–tRNA synthetase of the tRNA(Phe) recognition nucleotides and initial aminoacylation site. Aphasizhev R, et al. **Biochemistry** 1996 Jan 9;35(1):117–23

Structural similarities in the noncatalytic domains of phenylalanyl–tRNA and biotin synthetases. Safro M, et al.
Protein Sci 1995 Nov;4(11):2429–32

METABOLISM

Conservation in evolution for a small monomeric phenylalanyl–tRNA synthetase of the tRNA(Phe) recognition nucleotides and initial aminoacylation site. Aphasizhev R, et al. **Biochemistry** 1996 Jan 9;35(1):117–23

Recognition of tRNAPhe by phenylalanyl–tRNA synthetase of Thermus thermophilus. Moor NA, et al.
Eur J Biochem 1995 Dec 15;234(3):897–902

Rabbit translation elongation factor 1 alpha stimulates the activity of homologous aminoacyl–tRNA synthetase. Negrutskii BS, et al. **FEBS Lett** 1996 Mar 11;382(1–2):18–20

Footprinting of tRNA(Phe) transcripts from Thermus thermophilus HB8 with the homologous phenylalanyl–tRNA synthetase reveals a novel mode of interaction. Kreutzer R, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4598–602

PHENYLAMINES see **ANILINE COMPOUNDS**

PHENYLBARBITAL see **PHENOBARBITAL**

PHENYLBUTAZONE

ADMINISTRATION & DOSAGE

Ultrasonographic renal changes associated with phenylbutazone administration in three foals. Léveillé R, et al. **Can Vet J** 1996 Apr;37(4):235–6

ADVERSE EFFECTS

Nonsteroidal anti–inflammatory drug–induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035–8 (18 ref.)

Erythema–multiforme–like contact dermatitis due to phenylbutazone. Kerre S, et al. **Contact Dermatitis** 1995 Sep;33(3):213–4

ANALOGS & DERIVATIVES

Determination of some non–steroid anti–inflammatory drugs by capillary isotachophoresis. Pospíšilová M, et al.
J Pharm Biomed Anal 1995 Aug;13(9):1147–52

ANALYSIS

Determination of some non–steroid anti–inflammatory drugs by capillary isotachophoresis. Pospíšilová M, et al.
J Pharm Biomed Anal 1995 Aug;13(9):1147–52

PHARMACOKINETICS

Phenylbutazone in racing greyhounds: plasma and urinary residues 24 and 48 hours after a single intravenous administration. Mills PC, et al. **Aust Vet J** 1995 Aug; 72(8):304–8

[Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog] Kietzmann M, et al.
DTW Dtsch Tierarztl Wochenschr 1996 Jan;103(1):14–6 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Pharmacologic interaction of furosemide and phenylbutazone in horses. Hinchcliff KW, et al. **Am J Vet Res** 1995 Sep; 56(9):1206–12

The dose–related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo–Medrol) on

cultured explants of equine carpal articular cartilage. Jolly WT, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):429–37

THERAPEUTIC USE

Effect of phenylbutazone and flunixin meglumine on acute toxic mastitis in dairy cows. Dascanio JJ, et al. **Am J Vet Res** 1995 Sep;56(9):1213–8

Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Owens JG, et al. **Am J Vet Res** 1996 Jun;57(6):866–74

Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Owens JG, et al. **Equine Vet J** 1995 Jul;27(4):296–300

URINE

Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. Mills PC, et al. **Res Vet Sci** 1995 Nov;59(3):261–6

PHENYLBUTYRATES

Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. Baldwin ET, et al. **Adv Exp Med Biol** 1995;362:445–9

Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic. Kiso Y. **Adv Exp Med Biol** 1995;362:413–23

CHEMICAL SYNTHESIS

4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. Leone-Bay A, et al. **J Med Chem** 1996 Jun 21; 39(13):2571–8

CHEMISTRY

Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Baldwin ET, et al. **Structure** 1995 Jun 15;3(6):581–90

METABOLISM

Metabolism of fenbufen by cultured 3T3-L1 adipocytes: synthesis and metabolism of xenobiotic glycerolipids. Dodds PF, et al. **J Lipid Res** 1995 Dec;36(12):2493–503

PHARMACOKINETICS

4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. Leone-Bay A, et al. **J Med Chem** 1996 Jun 21; 39(13):2571–8

PHARMACOLOGY

Stereoselective anticonvulsant activity of the enantiomers of (+/-)-2-hydroxy-2-phenylbutyramide. Meza-Toledo SE, et al. **Arzneimittelforschung** 1995 Jul;45(7):756–9

Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Liu L, et al. **Cytokine** 1995 Jul; 7(5):449–56

Effect of fenbufen on the penetration of quinolone antibiotics into cerebrospinal fluid. Comparative study with 5 quinolones. Iwamoto K, et al. **Drugs** 1995;49 Suppl 2:349–51

Influence of butibufen on enzyme activity and lysosomal stabilization ex vivo: a comparative study with hydrocortisone and acetylsalicylic acid. Alamo C, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):303–10

Effects of short-term treatment with the thromboxane synthesis blocker indobufen on pressor and depressor humoral factors in healthy humans. Zacharieva S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):615–9

Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Kojo H, et al. **Mol Pharmacol** 1995 Sep;48(3):401–6

A prostacyclin-sparing effect of indobufen vs. aspirin. De Caterina R, et al. **Thromb Haemost** 1996 Mar;75(3):510–4

THERAPEUTIC USE

Long-term treatment of girls with ornithine transcarbamylase deficiency. Maestri NE, et al. **N Engl J Med** 1996 Sep 19;335(12):855–9

Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets. Dmoszyńska A, et al. **Thromb Res** 1995 Sep 15; 79(5–6):483–90

[The effect of indobufen on platelet function and dialyzer regeneration in patients on hemodialysis] Sokołowska B, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):475–82 (Eng. Abstr.) **(Pol)**

[The effect of indobufen on patency in femoro-popliteal/crural bypass using artificial grafts] Cernak I, et al. **Vojnosanit Pregl** 1994 May-Jun;51(3):214–9 (Eng. Abstr.) **(Scr)**

PHENYLCARBAMIDES see **PHENYLUREA COMPOUNDS**

PHENYLCARBINOLS see **BENZYL ALCOHOLS**

PHENYLENEDIAMINES

ADMINISTRATION & DOSAGE

Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Tangirala RK, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1625–30

ADVERSE EFFECTS

Occupational allergy to p-phenylenediamine in milk testers. Rebandel P, et al. **Contact Dermatitis** 1995 Aug;33(2):138

Water tester's dermatitis due to a para-phenylenediamine derivative. Weller R, et al. **Contact Dermatitis** 1996 Feb; 34(2):138

Allergic reactions to nonrubber products by testing with rubber mixes. Part III: The black rubber mix [news] Fisher AA. **Cutis** 1995 Nov;56(5):253–4

Contact urticaria to the M17 protective mask. Pope RW, et al. **Mil Med** 1995 Oct;160(10):536–7

CHEMICAL SYNTHESIS

New low-density lipoprotein receptor upregulators acting via a novel mechanism. Ashton MJ, et al. **J Med Chem** 1996 Aug 16;39(17):3343–56

CHEMISTRY

Dual functionalities of 4-aminodiphenylamine in enzymatic assay and mediated biosensor construction. Groom CA, et al. **Anal Biochem** 1995 Nov 1;231(2):393–9

Immunofluorescent artifacts due to the pH of antifading mounting media. Swartz DJ, et al. **Biotechniques** 1996 Mar; 20(3):398–400

Unusual reactivity of cisplatin analogs that bear o-phenylenediamine ligands: insights for the design of more effective cytotoxic agents. Köckerbauer R, et al. **J Inorg Biochem** 1996 Jun;62(4):281–98

METABOLISM

Antioxidant stoichiometry and the oxidative fate of vitamin E in peroxyl radical scavenging reactions. Liebler DC, et al. **Lipids** 1995 Sep;30(9):789–93

Plant activation and its role in environmental mutagenesis and antimutagenesis. Plewa MJ, et al. **Mutat Res** 1996 Feb 19;350(1):163–71

Toxicokinetics of 2,4- and 2,6-toluenediamine in hydrolysed urine and plasma after occupational exposure to 2,4- and 2,6- toluene diisocyanate. Lind P, et al. **Occup Environ Med** 1996 Feb;53(2):94–9

PHARMACOLOGY

Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro. Schaider H, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2501–9

Paraphenylene diamine, a contact allergen, induces oxidative stress in normal human keratinocytes in culture. Picardo M, et al. **Br J Dermatol** 1996 Apr;134(4):681–5

Sensitization of mice to paraphenylenediamine and structurally-related compounds: adjuvant effects of vitamin A supplementation. Kalish RS, et al. **Contact Dermatitis** 1995 Dec;33(6):407–13

Mutagenic synergy between paraoxon and plant-activated m-phenylenediamine or 2-acetoxyacetylaminofluorene. Gichner T, et al. **Environ Mol Mutagen** 1996;27(1):59–66

New low-density lipoprotein receptor upregulators acting via a novel mechanism. Ashton MJ, et al. **J Med Chem** 1996 Aug 16;39(17):3343–56

Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Dailey JW, et al. **Neurosci Lett** 1995 Aug 4;195(2):77–80

POISONING

Hair dye poisoning. Sood AK, et al. **J Assoc Physicians India** 1996 Jan;44(1):69

A woman who collapsed after painting her soles. Abdulla KA, et al. **Lancet** 1996 Sep 7;348(9028):658

Rhabdomyolysis in paraphenylenediamine intoxication. Shemesh IY, et al. **Vet Hum Toxicol** 1995 Jun;37(3):244–5

THERAPEUTIC USE

Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Schaider H, et al. **Eur J Nucl Med** 1996 Jan; 23(1):55–60

TOXICITY

Evaluation of cross-sensitization among dye-intermediate agents using a modified lymphocyte transformation test. Li Q, et al. **Arch Toxicol** 1996;70(7):414–9

Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Hayward JJ, et al. **Carcinogenesis** 1995 Oct;16(10):2429–33

Evaluation of the micronucleus test in vitro using Chinese hamster cells: results of four chemicals weakly positive in the in vivo micronucleus test. Miller BM, et al. **Environ Mol Mutagen** 1995;26(3):240–7

Genotoxicity of m-phenylenediamine and 2-aminofluorene in Salmonella typhimurium and human lymphocytes with and without plant activation. Plewa MJ, et al. **Environ Mol Mutagen** 1995;26(2):171–7

Non-carcinogenicity of 2,2'-(4-aminophenyl)imino-bisethanol sulfate in a long-term feeding study in Fischer 344 rats. Hagiwara A, et al. **Food Chem Toxicol** 1996 Jun;34(6):537–46

Assessment of DNA adducts and the frequency of 6-thioguanine resistant T-lymphocytes in F344 rats fed 2,4-toluenediamine or implanted with a toluenediisocyanate-containing polyester polyurethane foam. Delclos KB, et al. **Mutat Res** 1996 Apr 6;367(4):210–8

Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity. Cheung YL, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):203–11

Mutagenicity and toxicity studies of p-phenylenediamine and its derivatives. Chung KT, et al. **Toxicol Lett** 1995 Nov; 81(1):23–32

PHENYLEPHRINE

Local anaesthesia in flexible nasendoscopy. A comparison between cocaine and co-phenylcaine. Lennox P, et al. **J Laryngol Otol** 1996 Jun;110(6):540–2

ADMINISTRATION & DOSAGE

Randomized trial of bolus phenylephrine or ephedrine for maintenance of arterial pressure during spinal anaesthesia for Caesarean section. Thomas DG, et al. **Br J Anaesth** 1996 Jan;76(1):61–5

A pre-operative mydriatic regime using a single application of tropicamide Novel Ophthalmic Delivery System and guttae phenylephrine 10%. Patel CK, et al. **Eye** 1995;9 (Pt 3):337–40

Intracorporeal phenylephrine in the treatment of priapism [see comments] Muruve N, et al. **J Urol** 1996 Jan; 155(1):141–3. Comment in: J Urol 1996 Jan;155(1):147. Comment in: J Urol 1996 Aug;156(2 Pt 1):483.

ADVERSE EFFECTS

Postoperative anisocoria: neurogenic or phenylephrine induced? A rapid diagnostic test. Sitzman BT, et al. **Anesth Analg** 1996 Sep;83(3):633–5

Cocaine and phenylephrine [letter; comment] Noorily SH, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb; 122(2):207–8. Comment on: Arch Otolaryngol Head Neck Surg 1995 Jun;121(6):681–4.

BLOOD

High-performance liquid chromatographic determination of phenylephrine and its conjugates in human plasma using solid-phase extraction and electrochemical detection. Gumbhir K, et al. **J Pharm Biomed Anal** 1996 Mar; 14(5):623–30

DIAGNOSTIC USE

Cluster headache in two sisters. Pupillary response to phenylephrine and tyramine. Havelius U, et al. **Headache** 1996 Jul-Aug;36(7):448–51

Noninvasive assessment of baroreflex control in borderline hypertension. Comparison with the phenylephrine method. Watkins LL, et al. **Hypertension** 1996 Aug;28(2):238–43

PHARMACOKINETICS

Relative bioavailability of carbinoxamine and phenylephrine from a retard capsule after single and repeated dose administration in healthy subjects. Stockis A, et al. **Arzneimittelforschung** 1995 Sep;45(9):1009–12

PHARMACOLOGY

Infusions of pressor agents selectively attenuate depressor responses to ACh in anesthetized dogs. Nakahara T, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H273–81

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551–7

Phenylephrine increases cerebral blood flow during low-flow hypothermic cardiopulmonary bypass in baboons. Schwartz AE, et al. **Anesthesiology** 1996 Aug;85(2):380–4

Reactivity to alpha agonists is heightened in immature porcine pulmonary arteries. Kadletz M, et al. **Ann Thorac Surg** 1996 May;61(5):1359–62

alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):277–82

A role of asialoglycoproteins for plasma-membrane-induced inhibition of the switching from alpha 1 to beta subtypes in adrenergic response during primary culture of rat hepatocytes. Kajiyama Y, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):743–9

Effects of clonidine premedication on the pressor response to alpha-adrenergic agonists. Tanaka M, et al. **Br J Anaesth** 1995 Nov;75(5):593–7

Effect of isoproterenol, phenylephrine, and sodium nitroprusside on fundus pulsations in healthy volunteers. Schmetterer L, et al. **Br J Ophthalmol** 1996 Mar;

80(3):217–23

The role of capacitative Ca2+ influx in the alpha 1B–adrenoceptor–mediated contraction to phenylephrine of the rat spleen. Burt RP, et al. **Br J Pharmacol** 1995 Oct;116(4):2327–33

Effect of swimming on vascular reactivity to phenylephrine and KCl in male rats. Jansakul C. **Br J Pharmacol** 1995 Jun;115(4):587–94

Effects of 8–bromoguanosine 3':5'–cyclic monophosphate on phenylephrine–induced phosphatidylinositol hydrolysis and contraction in rat caudal artery. Lum Min SA, et al. **Br J Pharmacol** 1995 Sep;116(1):1697–703

Effect of sympathectomy on inotropic responsiveness to alpha–adrenoceptor stimulation in developing mouse myocardia. Tanaka H, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1285–8

Alpha–adrenergic agonist and endothelin–1 induced intracellular Ca2+ response in the presence of a Ca2+ entry blocker in cultured rat ventricular myocytes. De Jonge HW, et al. **Cell Calcium** 1995 Dec;18(6):515–25

Depletion of mitogen–activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine–induced hypertrophic response in rat cardiac myocytes. Glennon PE, et al. **Circ Res** 1996 Jun; 78(6):954–61

The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Chandler WL, et al. **Circulation** 1995 Nov 15;92(10):2984–94

Basic fibroblast growth factor restores endothelium–dependent responses after balloon injury of rabbit arteries. Meurice T, et al. **Circulation** 1996 Jan 1; 93(1):18–22

alpha 1–Adrenoceptors on rabbit aortic smooth muscle cells in culture and in experimental intimal thickening. Manderson JA, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):912–8

Elevated spontaneous activity of phenylephrine–excited neurons in the caudal ventrolateral medulla of spontaneously hypertensive rats. Wong TM, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S46–7

Effect of halothane on phenylephrine–induced vascular smooth muscle contractions in endotoxin–exposed rat aortic rings. Grissom TE, et al. **Crit Care Med** 1996 Feb; 24(2):287–93

Adrenergic effects on the corneal and intraretinal direct–current electroretinogram and on the standing potential of albino rabbit eyes. Jarkman S, et al. **Doc Ophthalmol** 1995;89(3):251–66

Alpha 1–adrenergic effects on dopamine neurons recorded intracellularly in the rat midbrain slice. Grenhoff J, et al. **Eur J Neurosci** 1995 Aug 1;7(8):1707–13

Identification of alpha 1–adrenoceptor subtypes involved in the antinatriuretic response to intrarenal infusion of phenylephrine. Chen C, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):1–6

Cyclic GMP potentiates phenylephrine but not cyclic ADP–ribose–evoked calcium release from rat lacrimal acinar cells. Jorgensen TD, et al. **FEBS Lett** 1996 Aug 5;391(1–2):117–20

Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone–salt hypertensive rats. White RM, et al. **Hypertension** 1996 Jun;27(6):1245–53

Regulation of protein synthesis by alpha 1–adrenergic receptor subtypes in cultured rabbit aortic vascular smooth muscle cells. Siwik DA, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):508–18

Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion? Newman TM, et al. **J Cell Physiol** 1996 Jul; 168(1):134–40

Stimulation of the Na+/Ca2+ exchanger by phenylephrine, angiotensin II and endothelin 1. Ballard C, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):11–7

Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. Huang YT, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):535–41

Adrenergic regulation of the heat shock response in brown adipose tissue. Matz JM, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1751–8

Effects of phenylephrine on the contractile tension and cytosolic Ca2+ level in rat anococcygeus muscle. Shimizu K, et al. **J Smooth Muscle Res** 1995 Aug;31(4):163–73

Alpha–adrenergic preservation of myocardial pH during ischemia is PKC isoform dependent. Rehring TF, et al. **J Surg Res** 1996 Jun;63(1):324–7

A modified method for quantitative measurements of cholinergic and adrenergic sialogogue–induced salivation in mice. Murai S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):601–8

A noninvasive evaluation of baroreceptor sensitivity with the Valsalva maneuver and phenylephrine methods. Richter JP, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul–Aug;17(6):423–8

Effect of phenylephrine and prazosin on the somatostatinergic system in the rat frontoparietal cortex. López–Sañudo S, et al. **Peptides** 1995;16(8):1453–9

Contrast medium induced renal vasoconstriction, role of alpha receptors. Drescher P, et al. **Scand J Urol Nephrol Suppl** 1995;172:103–8

[Excitatory effect of alpha–adrenoceptor on the transient inward current in sheep myocardium] Shi WB, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):387–93 (Eng. Abstr.) (Chi)

[The experimental evaluation of the difference in closing dynamics of internal urethral ostium on the urinary continence and on the ejaculation induced by an administration of phenylephrine] Morita T, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1761–9 (Eng. Abstr.) (Jpn)

THERAPEUTIC USE

Phenylephrine in treating maternal hypotension due to spinal anaesthesia for caesarean delivery: effects on neonatal catecholamine concentrations, acid base status and Apgar scores. LaPorta RF, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):901–5

Evaluation and management of hemoptysis in infants and children. A report of nine cases. Thompson JW, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):516–20

Phenylephrine and pilocarpine in the treatment of post–operative irido–corneal adhesion. Tabandeh H, et al. **Eye** 1995;9 (Pt 4):452–5

New directions in the treatment of heart failure: some paradoxical observations. Merin RG. **J Card Surg** 1995 Jul; 10(4 Suppl):509–13

Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. McKnight JA, et al. **J Hum Hypertens** 1995 Oct;9(10):855–8

Re: Intracorporeal phenylephrine in the treatment of priapism [letter; comment] Seftel AD. **J Urol** 1996 Aug;156(2 Pt 1):483. Comment on: J Urol 1996 Jan;155(1):141–3.

Treatment of supraventricular tachycardia under spinal anesthesia [letter] Gajraj NM, et al. **Reg Anesth** 1995 Jul–Aug;20(4):359

Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. Miller JA, et al. **Stroke** 1995 Dec;26(12):2260–6

PHENYLETHANOL see **PHENYLETHYL ALCOHOL**

PHENYLETHANOLAMINE N–METHYLTRANSFERASE see **PHENETHANOLAMINE N–METHYLTRANSFERASE**

PHENYLETHYL ALCOHOL

Analysis of position of trial sequence and type of diluent on the detection threshold for phenyl ethyl alcohol using a single staircase method. Pierce JD Jr, et al. **Percept Mot Skills** 1996 Apr;82(2):451–8

ANALOGS & DERIVATIVES

Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene–transformed rat embryo fibroblast cells. Su ZZ, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1841–8

Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12–O–tetradecanoylphorbol–13–acetate–induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Huang MT, et al. **Carcinogenesis** 1996 Apr;17(4):761–5

Hydroxylated aromatic inhibitors of HIV–1 integrase. Burke TR Jr, et al. **J Med Chem** 1995 Oct 13;38(21):4171–8

Formation of F2–isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol. Salami M, et al. **Pharmacol Res** 1995 May;31(5):275–9

Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Petroni A, et al. **Thromb Res** 1995 Apr 15;78(2):151–60

[Inhibition of penicillin acylase from Escherichia coli by benzylalkylketones and benzylalkylcarbinols] Tserniuk VN, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):29–32 (Eng. Abstr.) (Rus)

ANALYSIS

Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2–phenylethanol. Tateishi T, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1921–4

PHENYLETHYLAMINES see **PHENETHYLAMINES**

PHENYLGLYOXAL

CHEMISTRY

Evidence for essential arginine residues at the active sites of maize branching enzymes. Cao H, et al. **J Protein Chem** 1996 Apr;15(3):291–304

METABOLISM

Involvement of an arginyl residue in the nucleotide–binding site of Ca(2+)–ATPase from sarcoplasmic reticulum as seen by reaction with phenylglyoxal. Corbalán–García S, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):179–85

PHARMACOLOGY

Chemical modification of bacterial 4–aminobutyrate aminotransferase by phenylglyoxal. Tunnicliff G. **J Enzym Inhib** 1995;9(4):309–16

Characterization of a phenylglyoxal–sensitive passive Ca2+ permeability in human erythrocytes. Raess BU, et al. **J Membr Biol** 1996 May;151(1):45–51

PHENYLHYDRAZINES

Comparative determination of ascorbic acid in bass (Morone lebrax) liver by HPLC and DNPH methods. Otles S. **Int J Food Sci Nutr** 1995 Aug;46(3):229–32

Analysis of protein carbonyls with 2,4–dinitrophenyl hydrazine and its antibodies by immunoblot in two–dimensional gel electrophoresis. Nakamura A, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):768–74

CHEMISTRY

The copper–topaquinone–phenylhydrazine–adduct geometry in Escherichia coli amine oxidase derivatized with phenylhydrazines substituted with 19F–NMR relaxation measurements. Steinebach V, et al. **Eur J Biochem** 1996 Jun 15;238(3):683–9

METABOLISM

Metabolism of [ring–U–14C] agaritine by precision–cut rat, mouse and human liver and lung slices. Price RJ, et al. **Food Chem Toxicol** 1996 Jul;34(7):603–9

PHARMACOLOGY

Detection of free radical metabolite formation using in vivo EPR spectroscopy: evidence of rat hemoglobin thiyl radical formation following administration of phenylhydrazine. Jiang JJ, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):266–70

Reaction mechanism for the inactivation of the quinoprotein methylamine dehydrogenase by phenylhydrazine. Davidson VL, et al. **Biochim Biophys Acta** 1995 Sep 27; 1252(1):146–50

TOXICITY

Physiological response to experimentally induced anemia in rats: a comparative study. Redondo PA, et al. **Lab Anim Sci** 1995 Oct;45(5):578–83

PHENYLISOHYDANTOIN see **PEMOLINE**

PHENYLISOPROPYLADENOSINE

PHARMACOLOGY

Different effects of an adenosine A1 analogue and ischemic preconditioning in isolated rabbit hearts. Lasley RD, et al. **Ann Thorac Surg** 1995 Dec;60(6):1698–703

Sodium fluoride attenuates the negative inotropic effects of muscarinic M2 and adenosine receptor agonists. Neumann J, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):451–7

Characterization of ocular hypertension induced by adenosine agonists. Crosson CE, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1833–9

Age–related effects in rabbit hearts of N6–R–phenylisopropyladenosine, an adenosine A1 receptor agonist. Mudumbi RV, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B351–7

Interaction of beta–adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. Neumann J, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1655–67

Adaptive changes in adenosine receptors following long–term treatment with the adenosine receptor agonist R–phenylisopropyl adenosine. Fernandez M, et al. **Life Sci** 1996;58(9):769–76

Adenosine attenuation of isoproterenol–stimulated adenylyl cyclase activity is enhanced with aging in the adult heart. Romano FD, et al. **Life Sci** 1996;58(6):493–502

Habituation of exploratory activity in rats: action of N6phenylisopropyladenosine, caffeine and their combination. Molinengo L, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Nov; 19(7):1189–200

PHENYLKETONURIA

Editorial comment on phenylketonuria [editorial] Zetterström R. **Acta Paediatr** 1995 Jul;84(7):716–8

Birth weight in phenylketonuria [letter; comment] Woolf LI, et al. **Arch Dis Child** 1995 Sep;73(3):276. Comment on: Arch Dis Child 1994 Aug;71(2):114–8.

BLOOD

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. MacDonald A, et al. **Arch Dis Child** 1996 May;74(5):412–7

An automated enzymatic method on the Roche COBAS MIRA S for monitoring phenylalanine in dried blood spots of patients with phenylketonuria. Randell EW, et al. **Clin Biochem** 1996 Apr;29(2):133–8

Normal serum levels of vitamin B12 and folic acid in children with phenylketonuria [letter] Strisciuglio P, et al. **Eur J Pediatr** 1995 Oct;154(10):866

Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the

day. van Spronsen FJ, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):839–44

CHEMICALLY INDUCED

ATP diphosphohydrolase activity in synaptosomes from cerebral cortex of rats subjected to chemically induced phenylketonuria. Wyse AT, et al. **Braz J Med Biol Res** 1995 Jun;28(6):643–9

COMPLICATIONS

Late effects of phenylketonuria. Walter JH. **Arch Dis Child** 1995 Dec;73(6):485–6 (37 ref.)

PKU and diabetes: help requested [letter] Webster DR, et al. **J Inherit Metab Dis** 1995;18(5):649

DIAGNOSIS

Performance of neonatal screening programme must be monitored [letter; comment] Galloway A, et al. **BMJ** 1996 May 4;312(7039):1158. Comment on: BMJ 1996 Jan 20;312(7024):182.

No reduction in birth weight in phenylketonuria. Tillotson SL, et al. **Eur J Pediatr** 1995 Oct;154(10):847–9

Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. Griffiths P, et al. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):365–72

In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Möller HE, et al. **Neuropediatrics** 1995 Aug; 26(4):199–202

Newborn mass screening and molecular genetics of phenylketonuria in east Asia. Okano Y, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:123–9

[Advances in the diagnosis of phenylketonuria with the introduction of direct detection of PAH gene mutation] Kozák L, et al. **Cas Lek Cesk** 1995 Jun 14;134(12):385–7 (Eng. Abstr.) **(Cze)**

DIET THERAPY

Nutrient intake and food consumption of adolescents and young adults with phenylketonuria. Schulz B, et al. **Acta Paediatr** 1995 Jul;84(7):743–8

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. MacDonald A, et al. **Arch Dis Child** 1996 May;74(5):412–7

Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. Dotremont H, et al. **J Inherit Metab Dis** 1995;18(2):127–30

Phenylketonuric patients decades after diet. Fisch RO, et al. **J Inherit Metab Dis** 1995;18(3):347–53

PKU and diabetes: help requested [letter] Webster DR, et al. **J Inherit Metab Dis** 1995;18(5):649

Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. Yannicelli S, et al. **J Inherit Metab Dis** 1995;18(2):131–4

The use of a low phenylalanine diet in response to the challenging behaviour of a man with untreated phenylketonuria and profound learning disabilities. Harvey EL, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):520–6

Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the day. van Spronsen FJ, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):839–44

[Methodology of care for children with phenylketonuria and maple-syrup urine disease] Jiménez Soto Z. **Arch Latinoam Nutr** 1993 Sep;43(3):204–10 (22 ref.) (Eng. Abstr.) **(Spa)**

[Lists of food exchanges for use in phenylketonuria and maple-syrup urine disease] Jiménez Soto Z. **Arch Latinoam Nutr** 1993 Sep;43(3):211–6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. Safos S, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(6):681–92

Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. Pietz J, et al. **J Pediatr** 1995 Dec;127(6):936–43

ENZYMOLOGY

Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. Guldberg P, et al. **Am J Hum Genet** 1996 Jul;59(1):84–94

Biotinidase activity in patients with phenylketonuria. Schulpis KH, et al. **J Inherit Metab Dis** 1995;18(6):750–1

EPIDEMIOLOGY

Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. Velázquez A, et al. **Hum Genet** 1996 Jan;97(1):99–102

ETIOLOGY

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

GENETICS

Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. Guldberg P, et al. **Am J Hum Genet** 1996 Jul;59(1):84–94

Phenylketonuria mutation analysis in Northern Ireland: a rapid stepwise approach. Zschocke J, et al. **Am J Hum Genet** 1995 Dec;57(6):1311–7

Characterization of phenylketonuria alleles in the Italian population. Dianzani I, et al. **Eur J Hum Genet** 1995; 3(5):294–302

Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations. Kuzmin AI, et al. **Eur J Hum Genet** 1995;3(4):246–55

In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. Guldberg P, et al. **Eur J Pediatr** 1995 Jul;154(7):551–6

Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. Hashem N, et al. **Hum Genet** 1996 Jul;98(1):3–6

Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. Kozák L, et al. **Hum Genet** 1995 Oct;96(4):472–6

Identification of a common 6-pyruvoyl-tetrahydropterin synthase mutation at codon 87 in Chinese phenylketonuria caused by tetrahydrobiopterin synthesis deficiency. Liu TT, et al. **Hum Genet** 1996 Sep;98(3):313–6

Polymorphism in the 3' untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. Ramus SJ, et al. **Hum Genet** 1995 Dec;96(6):741–3

Novel missense mutation in the phenylalanine hydroxylase gene leading to complete loss of enzymatic activity. Dianzani I, et al. **Hum Mutat** 1995;6(3):247–9

PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Eiken HG, et al. **Hum Mutat** 1996;7(3):228–38

Mutation analysis of phenylketonuria in south and central Portugal: prevalence of V388M mutation. Leandro P, et al. **Hum Mutat** 1995;6(2):192–4

Molecular basis of non-PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. Desviat LR, et al. **J Inherit Metab Dis** 1996; 19(2):227–30

Phenylketonuria mutations in southern Chinese detected by denaturing gradient gel electrophoresis in exon 7 of PAH gene. Gu XF, et al. **J Inherit Metab Dis** 1995;18(6):753–4

Discordant phenylketonuria phenotypes in one family: the relationship between genotype and clinical outcome is a function of multiple effects. Tyfield LA, et al. **J Med Genet** 1995 Nov;32(11):867–70

Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. Levy HL, et al. **J Pediatr** 1996 Jun; 128(6):770–5

Molecular screening of genetic defects with RNA-SSCP analysis: the PKU and cystinuria model. Giannattasio S, et al. **Mol Cell Probes** 1995 Jun;9(3):201–5

A fluorescent multiplex ARMS method for rapid mutation analysis. Zschocke J, et al. **Mol Cell Probes** 1995 Dec; 9(6):447–51

Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population. Eisensmith RC, et al. **Pediatrics** 1996 Apr; 97(4):512–6

Newborn mass screening and molecular genetics of phenylketonuria in east Asia. Okano Y, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:123–9

IMMUNOLOGY

Immune status of children with phenylketonuria. Gropper SS, et al. **J Am Coll Nutr** 1995 Jun;14(3):264–70

METABOLISM

Volumetric bone mineral density—a potential role in paediatrics. Cowell CT, et al. **Acta Paediatr Suppl** 1995 Sep;411:12–6, discussion 17

Resting energy expenditure in children with phenylketonuria. Allen JR, et al. **Am J Clin Nutr** 1995 Oct;62(4):797–801

Lipid status and fatty acid metabolism in phenylketonuria. Giovannini M, et al. **J Inherit Metab Dis** 1995;18(3):265–72 (28 ref.)

Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. Knudsen GM, et al. **J Inherit Metab Dis** 1995;18(6):653–64

Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. Leuzzi V, et al. **J Inherit Metab Dis** 1995;18(5):624–34

The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pietz J, et al. **Pediatr Res** 1995 Nov; 38(5):657–63

PATHOLOGY

Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. Leuzzi V, et al. **J Inherit Metab Dis** 1995;18(5):624–34

PHYSIOPATHOLOGY

Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. Diamond A, et al. **Brain** 1996 Apr;119 (Pt 2):523–38

Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Pontoglio M, et al. **Cell** 1996 Feb 23;84(4):575–85

Body protein in prepubertal children with phenylketonuria. Allen JR, et al. **Eur J Clin Nutr** 1996 Mar;50(3):178–86

Thyroid function parameters during a selenium repletion/depletion study in phenylketonuric subjects. Calomme MR, et al. **Experientia** 1995 Dec 18; 51(12):1208–15

Physical growth in patients with phenylketonuria. Dhondt JL, et al. **J Inherit Metab Dis** 1995;18(2):135–7

Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. Pietz J, et al. **J Pediatr** 1995 Dec;127(6):936–43

PREVENTION & CONTROL

Phenylketonuria screening: effect of early newborn discharge. Sinai LN, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):605–8

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176–84 (54 ref.)

[20-year national screening for phenylketonuria in The Netherlands. National Guidance Commission PKU] Verkerk PH. **Ned Tijdschr Geneeskd** 1995 Nov 11; 139(45):2302–5 (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

Information processing in patients with early and continuously-treated phenylketonuria. Stemerdink BA, et al. **Eur J Pediatr** 1995 Sep;154(9):739–46

RADIOGRAPHY

Radiological assessment of the hand and wrist in phenylketonuria and hyperphenylalaninaemia. Greeves LG, et al. **Pediatr Radiol** 1995;25(5):353–5

THERAPY

Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Fang B, et al. **Gene Ther** 1994 Jul;1(4):247–54

PHENYLKETONURIA, MATERNAL

COMPLICATIONS

[Pregnancy and the child of a mother with phenylketonuria] Abadie V, et al. **Arch Pediatr** 1996 May;3(5):489–6 (38 ref.) (Eng. Abstr.) **(Fre)**

DIET THERAPY

Nutrition support of maternal phenylketonuria. Acosta PB. **Semin Perinatol** 1995 Jun;19(3):182–90 (46 ref.)

EPIDEMIOLOGY

[Maternal hyperphenylalaninemia in a population of healty Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring] Hyánek J, et al. **Cas Lek Cesk** 1996 Jan 17;135(2):50–3 (Eng. Abstr.) **(Cze)**

PSYCHOLOGY

Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. Waisbren SE, et al. **Am J Public Health** 1995 Dec;85(12):1636–41

PHENYLMERCURIALS see **PHENYLMERCURY COMPOUNDS**

PHENYLMERCURIC ACETATE

ADVERSE EFFECTS

Psychological and somatic subjective symptoms as a result of dermatological patch testing with metallic mercury and phenyl mercuric acetate. Marcusson JA. **Toxicol Lett** 1996 Feb;84(2):113–22

ANALOGS & DERIVATIVES

Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Santavicca M, et al. **Biochem J** 1996 May 1; 315 (Pt 3):953–8

APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. Galazka G, et al. **Biochemistry** 1996 Aug 27;35(34):11221–7

PHENYLMERCURY COMPOUNDS

PHARMACOLOGY

Effect of sulfhydryl oxidation on ionic and gating currents associated with L-type calcium channels in isolated guinea-pig ventricular myocytes. Lacampagne A, et al. **Cardiovasc Res** 1995 Nov;30(5):799-806

[In vitro changes induced by phenylmercury nitrate on fungi causing keratitis. Scanning electron microscopy study] Duhamel C, et al. **J Fr Ophtalmol** 1995;18(12):819-21 (Eng. Abstr.) **(Fre)**

PHENYLMETHANOLS see **BENZYL ALCOHOLS**

PHENYLMETHYLAMINE see **BENZYLAMINES**

PHENYLMETHYLSULFONYL FLUORIDE

CHEMISTRY

The 2 A crystal structure of subtilisin E with PMSF inhibitor. Chu NM, et al. **Protein Eng** 1995 Mar;8(3):211-5

PHARMACOLOGY

Amplification of arachidonic acid metabolism in rat liver cells (the C-9 cell-line) by tosyl-L-phenylalanine chloromethyl ketone and phenylmethyl-sulfonyl fluoride. Levine L. **Prostaglandins** 1995 Aug;50(2):89-101

TOXICITY

Selective promotion by phenylmethanesulfonyl fluoride of peripheral and spinal cord neuropathies initiated by diisopropyl phosphorofluoridate in the hen. Peraica M, et al. **Toxicol Lett** 1995 Oct;80(1-3):115-21

PHENYLPROPANOLAMINE

ADVERSE EFFECTS

Phenylpropanolamine and associated myocardial injury. Leo PJ, et al. **Ann Emerg Med** 1996 Sep;28(3):359-62

Psychotic episode related to phenylpropanolamine and amantadine in a healthy female [letter] Stroe AE, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):457-8

ANALYSIS

Determination of ephedrine, pseudoephedrine, and norephedrine in mixtures (bulk and dosage forms) by proton nuclear magnetic resonance spectroscopy. Hanna GM. **J AOAC Int** 1995 Jul-Aug;78(4):946-54

PHARMACOLOGY

Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. McMahon LR, et al. **Physiol Behav** 1996 Jan;59(1):63-9

POISONING

[Ventricular tachycardia secondary to phenylpropanolamine poisoning: apropos a case] Barriales Villa R, et al. **Rev Esp Cardiol** 1995 Nov;48(11):762-4 (Eng. Abstr.) **(Spa)**

PHENYLPROPIONATES

CHEMICAL SYNTHESIS

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. Almansa C, et al. **J Med Chem** 1996 May 24;39(11):2197-206

CHEMISTRY

Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. Bhattacharyya DK, et al. **J Biol Chem** 1996 Jan 26;271(4):2179-84

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. Almansa C, et al. **J Med Chem** 1996 May 24;39(11):2197-206

METABOLISM

Probing the substrate specificity for lipases. A CoMFA approach for predicting the hydrolysis rates of 2-arylpropionic esters catalyzed by Candida rugosa lipase. Botta M, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):121-6

Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite) of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in dogs. Asami M, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1584-9

PHARMACOKINETICS

Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats. Yoshida H, et al. **Chirality** 1996;8(3):258-63

PHARMACOLOGY

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al. **Drugs Exp Clin Res** 1995;21(3):85-8

Cytotoxic compounds from a two-sponge association. Jung JH, et al. **J Nat Prod** 1995 Nov;58(11):1722-6

TOXICITY

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al. **Drugs Exp Clin Res** 1995;21(3):85-8

URINE

Increased urinary excretion of dicarboxylic acids and 4-hydroxyphenyllactic acid in patients with Zellweger syndrome [letter] Mayatepek E, et al. **Eur J Pediatr** 1995 Sep;154(9):755-6

PHENYLPROPYLHYDROXYCUMARINUM see **PHENPROCOUMON**

PHENYLPYRUVIC ACIDS

CHEMISTRY

Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution. Chen Z, et al. **Arch Biochem Biophys** 1995 Sep 10; 322(1):198-203

N-PHENYLSALICYLAMIDES see **SALICYLANILIDES**

PHENYLSULFAPYRAZOLE see **SULFAPHENAZOLE**

PHENYLTHIOCARBAMIDE see **PHENYLTHIOUREA**

PHENYLTHIOHYDANTOIN

ANALYSIS

A simple method for differentiating Leu and Ile in peptides. The negative-ion mass spectra of [M-H]- ions of phenylthiohydantoin Leu and Ile. Ramsay SL, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1241-3

PHENYLTHIOUREA

Taste discrimination using alternative solvents for PTC and NaCl. Masuoka S, et al. **Chem Senses** 1995 Jun; 20(3):299-304

PHARMACOLOGY

[The use of phenylthiocarbamide for evaluating the degree of cAMP-dependent resistance to hypoxia in animals] Bolekhan EA, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):85-9 (Eng. Abstr.) **(Rus)**

PHENYLUREA COMPOUNDS

ANALYSIS

Development and evaluation of a chemiluminescent immunoassay for chlortoluron using a camera luminometer. Katmeh MF, et al. **Analyst** 1996 Mar;121(3):329-32

CHEMISTRY

Synthesis, azido-tetrazole equilibrium studies and biological activity of 1-(2-azido-6-chloropyrid-4-yl)-3-phenylurea, a photoaffinity labeling reagent for cytokinin-binding proteins. Dias M, et al. **Bioorg Med Chem** 1995 Apr; 3(4):361-6

METABOLISM

Metabolism of the herbicide chlortoluron by human cytochrome P450 3A4. Mehmood Z, et al. **Chemosphere** 1995 Dec;31(11-12):4515-29

PHARMACOKINETICS

The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA: Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Peck RW, et al. **Eur J Clin Pharmacol** 1995;49(3):243-9

PHARMACOLOGY

TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters. Sugiyama Y, et al. **Atherosclerosis** 1995 Nov;118(1):145-53

Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Matsuo M, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):254-60

Effect of E5324, a novel inhibitor of acyl-CoA:cholesterol acyltransferase, on cholesteryl ester synthesis and accumulation in macrophages. Kogushi M, et al. **Jpn J Pharmacol** 1995 Jun;68(2):191-9

Inhibition of cholesterol esterification in macrophages and vascular smooth muscle foam cells: evaluation of E5324, an acyl-CoA cholesterol acyltransferase inhibitor. Nicholson AC, et al. **Lipids** 1995 Aug;30(8):771-4

POISONING

Metobromuron/metolachlor ingestion with late onset methemoglobinemia in a pregnant woman successfully treated with methylene blue. Yang CC, et al. **J Toxicol Clin Toxicol** 1995;33(6):713-6

THERAPEUTIC USE

[Influence of KU-1257 on the recurrence and relapse of acetic acid-induced chronic gastric ulcers in rats] Sekiguchi H, et al. **Nippon Yakurigaku Zasshi** 1996 Feb;107(2):67-78 (Eng. Abstr.) **(Jpn)**

TOXICITY

Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines. Phelps PC, et al. **Cancer Lett** 1995 Oct 20;97(1):7-15

PHENYTOIN

Induction of cerebral thrombosis with phenytoin in rats. Tani S, et al. **Stroke** 1995 Nov;26(11):2081-6

ADMINISTRATION & DOSAGE

Adverse effects with administration of phenytoin: infusion pump vs manual infusion [letter] Schmidt H, et al. **Acad Emerg Med** 1995 Aug;2(8):758-9

Tacrolimus-phenytoin interaction [letter] Thompson PA, et al. **Ann Pharmacother** 1996 May;30(5):544

No interaction between dopamine and phenytoin [letter] Torres E, et al. **Ann Pharmacother** 1995 Dec;29(12):1300-1

Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ, et al. **Arch Neurol** 1996 Aug; 53(8):764-8

Analysis of anticonvulsant and neurotoxic responses to combination therapy with carbamazepine, felbamate and phenytoin by response-surface modeling. Gennings C, et al. **Arzneimittelforschung** 1995 Jul;45(7):739-48

Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Profeta LM, et al. **Mt Sinai J Med** 1995 Sep;62(4):312-4

ADVERSE EFFECTS

Stevens-Johnson syndrome resulting from whole-brain radiation and phenytoin [see comments] Cockey GH, et al. **Am J Clin Oncol** 1996 Feb;19(1):32-4. Comment in: Am J Clin Oncol 1996 Aug;19(4):431.

Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Hunt SJ. **Am J Dermatopathol** 1995 Aug;17(4):399-402

Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. Binder L, et al. **Am J Emerg Med** 1996 Jul;14(4):398-401

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238-44 (52 ref.)

Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410-2 (34 ref.)

Comment: leucovorin-phenytoin: a drug-drug interaction? [letter; comment] Tidwell BH, et al. **Ann Pharmacother** 1995 Dec;29(12):1303-4. Comment on: Ann Pharmacother 1995 Jul-Aug;29(7-8):726-35. Comment on: Ann Pharmacother 1995 Jul-Aug;29(7-8):760-8.

Phenytoin toxicity associated with ticlopidine administration [letter] Rindone JP, et al. **Arch Intern Med** 1996 May 27; 156(10):1113

Anticonvulsant hypersensitivity syndrome. Vittorio CC, et al. **Arch Intern Med** 1995 Nov 27;155(21):2285-90

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109-12 (19 ref.)

Phenytoin-induced toxic epidermal necrolysis: a case report. Creamer JD, et al. **Clin Exp Dermatol** 1996 Mar; 21(2):116-20

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195-7

Urinary retention related to phenytoin therapy. Nussinovitch M, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):382-3

Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223-6 (32 ref.)

Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. Jeng YM, et al. **Epilepsia** 1996 Jan;37(1):104-7

Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. Ruggian JC, et al. **J Am Soc Nephrol** 1996 Mar;7(3):397-402

Hydroxyproline and total protein levels in gingiva from patients treated with phenytoin and cyclosporine-A. Akalin FA, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):21-30

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241–3 (23 ref.)

Phenytoin–induced focal chorea [letter] Shulman LM, et al. **Mov Disord** 1996 Jan;11(1):111–4

Images in clinical medicine. Toxic epidermal necrolysis. Pion IA, et al. **N Engl J Med** 1995 Dec 14;333(24):1609

Phenytoin–associated vasculitis and ANCA positivity: a case report. Parry RG, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):357–9

A potentially fatal drug reaction. Patel D, et al. **Tenn Med** 1996 Aug;89(8):294–5

Phenytoin as a risk factor in gingival hyperplasia. Perlík F, et al. **Ther Drug Monit** 1995 Oct;17(5):445–8

A case of phenytoin–alcohol interaction [letter] Bellibas SE, et al. **Therapie** 1995 Sep–Oct;50(5):487–8

[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320–8 (44 ref.) **(Fin)**

[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):239–43 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Oligospermia improved by switching an anticonvulsant from phenytoin to valproate] Niwa K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):492–4 (Eng. Abstr.) **(Jpn)**

[Toxic cholestatic hepatitis due to phenytoin] de la Serna Higuera C, et al. **Gastroenterol Hepatol** 1995 Nov; 18(9):471–3 (11 ref.) (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

The comparison of anticonvulsant properties of commercial diphenylhydantoin (DPH) and its 3–amino–derivative (3–amino–DPH). Kozicka M. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:57–60

Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ, et al. **Arch Neurol** 1996 Aug; 53(8):764–8

Effect of 5–(p–hydroxyphenyl)–5–phenylhydantoin (p–HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic–gingival hyperplasia: in vivo and in vitro study. Ieiri I, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):51–6

Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3–7 (48 ref.)

Fosphenytoin use in children. Pellock JM. **Neurology** 1996 Jun;46(6 Suppl 1):S14–6 (8 ref.)

Intravenous administration of fosphenytoin: options for the management of seizures. Ramsay RE, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S17–9 (12 ref.)

Emergency treatment of status epilepticus. Runge JW, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S20–3 (25 ref.)

Intramuscular use of fosphenytoin: an overview. Uthman BM, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S24–8 (28 ref.)

Use of parenteral antiepileptic drugs and the role for fosphenytoin. Wilder BJ. **Neurology** 1996 Jun;46(6 Suppl 1):S1–2

Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. TenHoor CN, et al. **Pharm Res** 1995 Nov;12(11):1806–9

The effect of 5–(p–hydroxyphenyl)–5–phenylhydantoin (p–HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic side effects: in vivo and in vitro studies. Ieiri I, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S247–51

BLOOD

Renewable perfluorosulfonated ionomer carbon paste electrode for competitive homogeneous electrochemical immunoassays using a redox cationic labeled hapten. Rapicault S, et al. **Anal Chem** 1996 Mar 1;68(5):930–5

Estimating phenytoin concentrations by the Sheiner–Tozer method in adults with pronounced hypoalbuminemia. Dager WE, et al. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):667–70

Phenytoin serum concentration monitoring during pregnancy and puerperium in Mexican epileptic women. Rodriguez–Palomares C, et al. **Arch Med Res** 1995 Winter; 26(4):371–7

Near–patient rapid assay of phenytoin concentration. Scheyer RD, et al. **Epilepsia** 1995 Nov;36(11):1152–4

Phenytoin free fraction determination: comparison of an improved direct serum injection high–performance liquid chromatographic method to ultrafiltration coupled with fluorescence polarization immunoassay. Gurley BJ, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):358–64

Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on–line dialysis and high–performance liquid chromatography. Johansen K, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):281–8

Is routine measurement of free phenytoin concentrations rational? [letter; comment] Beringer PM, et al. **Ther Drug Monit** 1995 Aug;17(4):381–2. Comment on: Ther Drug Monit 1994 Apr;16(2):139–44.

In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Dasgupta A, et al. **Ther Drug Monit** 1996 Feb;18(1):97–9

Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acid. Ratnaraj N, et al. **Ther Drug Monit** 1995 Aug;17(4):327–32

[Phenytoin] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:924–7 (21 ref.) **(Jpn)**

CHEMISTRY

Dissolution of phenytoin precipitate with sodium bicarbonate in an occluded central venous access device. Akinwande KI, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):707–9

Effect of cogrinding with various kinds of surfactants on the dissolution behavior of phenytoin. Otsuka M, et al. **J Pharm Sci** 1995 Dec;84(12):1434–7

IMMUNOLOGY

[Study of an anti–serum against phenytoin with two organometallic tracers] Mfouara JC, et al. **Ann Pharm Fr** 1996;54(1):34–9 (Eng. Abstr.) **(Fre)**

METABOLISM

Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury. Markowsky SJ, et al. **Ann Pharmacother** 1996 May; 30(5):443–8

Cytochrome P450 isozymes and antiepileptic drug interactions. Levy RH. **Epilepsia** 1995;36 Suppl 5:S8–13 (13 ref.)

Lack of effect of histological lesions on the phenytoin and phenobarbital concentrations in the brain cortex of epileptic patients. Schnabel R, et al. **J Neurol Sci** 1995 Nov; 133(1–2):177–82

PHARMACOKINETICS

Effect of dexamethasone on the decrease of serum phenytoin concentrations [letter] Recuenco I, et al. **Ann Pharmacother** 1995 Sep;29(9):935

The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. Blum RA, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:35S–38S

Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Samara E, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:84–91

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)

Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex. Walker MC, et al. **Epilepsia** 1996 May;37(5):421–7

The pharmacokinetics of phenytoin in gingival crevicular fluid and plasma in relation to gingival overgrowth. McLaughlin WS, et al. **J Clin Periodontol** 1995 Dec; 22(12):942–5

Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Rapeport WG, et al. **J Clin Psychiatry** 1996;57 Suppl 1:24–8

Bioavailability of phenytoin following oral administration of phenytoin–lipid conjugates to rats. Scriba GK, et al. **J Pharm Pharmacol** 1995 Nov;47(11):945–8

Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Profeta LM, et al. **Mt Sinai J Med** 1995 Sep;62(4):312–4

Age–related changes in pharmacokinetic parameters of phenytoin after liver resection in rats. Nakashima E, et al. **Pharm Res** 1995 Oct;12(10):1530–4

Phenytoin malabsorption after jejunostomy tube delivery. Rodman DP, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):801–5

PHARMACOLOGY

Phenytoin–folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):726–35 (65 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

The comparison of anticonvulsant properties of commercial diphenylhydantoin (DPH) and its 3–amino–derivative (3–amino–DPH). Kozicka M. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:57–60

Induction of the male–specific cytochrome P450 3A2 in female rats by phenytoin. Ghosal A, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):153–62

Influence of the extracellular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models. Genever PG, et al. **Br J Dermatol** 1995 Aug; 133(2):231–5

Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Tasaki K, et al. **Brain Dev** 1995 May–Jun;17(3):182–5

Phenytoin inhibits expression of microtubule–associated protein 2 and influences cell–viability and neurite growth of cultured cerebellar granule cells. Kempermann G, et al. **Brain Res** 1995 Jul 31;687(1–2):194–8

Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Ducharme MP, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):617–24

Influence of D–cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice. Wlaź P, et al. **Epilepsia** 1996 Jul;37(7):610–7

Effects of 5, 5'–diphenylhydantoin on the thyroid status in rats. Schröder–van der Elst JP, et al. **Eur J Endocrinol** 1996 Feb;134(2):221–4

Effect of phenytoin on interleukin–1 beta production in human gingival fibroblasts challenged to tumor necrosis factor alpha in vitro. Brunius G, et al. **Eur J Oral Sci** 1996 Feb;104(1):27–33

Differential effects of phenytoin and sodium valproate on seizure–induced changes in gamma–aminobutyric acid and glutamate release in vivo. Rowley HL, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):541–6

Drug effects on triiodothyronine uptake by rat anterior pituitary cells in vitro. Lim CF, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):151–7

Phenytoin–induced glutathione depletion in rat peripheral nerve. Raya A, et al. **Free Radic Biol Med** 1995 Nov; 19(5):665–7

Effects of phenytoin on plasma high–density lipoprotein cholesterol levels in men with low levels of high–density lipoprotein cholesterol. Goerdt C, et al. **J Clin Pharmacol** 1995 Aug;35(8):767–75

Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. Magariños AM, et al. **J Neurosci** 1996 May 15; 16(10):3534–40

Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. Surks MI, et al. **JAMA** 1996 May 15; 275(19):1495–8

Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia–induced epilepsy. Edmonds HL Jr, et al. **Life Sci** 1996;59(10):PL127–31

Phenytoin–initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Kim PM, et al. **Mol Pharmacol** 1996 Jan;49(1):172–81

Effect of chronic administration of phenytoin on regional monoamine levels in rat brain. Meshkibaf MH, et al. **Neurochem Res** 1995 Jul;20(7):773–8

Phenytoin delays ischemic depolarization, but cannot block its long–term consequences, in the rat hippocampal slice. Watson GB, et al. **Neuropharmacology** 1995 May; 34(5):553–8

Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones. Chao TI, et al. **Neuroreport** 1995 Sep 11;6(13):1778–80

Influence of dilantin on the reactions of neurons of the sensorimotor cortex and hippocampus during learning. Shul'gina GI. **Neurosci Behav Physiol** 1995 Sep–Oct; 25(5):413–8

Chronic phenytoin induced impairment of learning and memory with associated changes in brain acetylcholine esterase activity and monoamine levels. Sudha S, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):119–24

Can phenytoin lower plasma fibrinogen concentrations? Goerdt C, et al. **Thromb Res** 1995 Aug 1;79(3):231–6

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin– and phenobarbital–inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82–83:655–62 (11 ref.)

[Effect of dilantin on retardation of cortex neuronal activity during interaction of extraneous stimuli and the dominant status of the defense reflex] Shul'gina GI, et al. **Dokl Akad Nauk** 1996 Apr;347(5):707–10 **(Rus)**

POISONING

Amiodarone and phenytoin: interaction [letter] Ahmad S. **J Am Geriatr Soc** 1995 Dec;43(12):1449–50

Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms [letter] Sanderson DR. **J Clin Psychiatry** 1996 Apr;57(4):177

Hypoglycemia associated with phenytoin intoxication. Manto M, et al. **J Toxicol Clin Toxicol** 1996;34(2):205–8

Phenytoin toxicity due to concomitant antituberculosis therapy. Walubo A, et al. **S Afr Med J** 1995 Nov; 85(11):1175–6

THERAPEUTIC USE

Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic–autonomic syndrome in patients with chronic alcoholism. Ilyuchina VA, et al. **Alcohol** 1995 Nov–Dec; 12(6):511–7

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)

Pneumothorax and wound dehiscence related to collagenase deregulation: treatment with diphenylhydantoin. O'Toole MJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1646–50

A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Miller M, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2151–6

Randomised study assessing the effect of phenytoin and magnesium sulphate on maternal cerebral circulation in eclampsia using transcranial Doppler ultrasound. Naidu S, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):111–6

Phenytoin in the treatment of cocaine abuse: a double–blind study. Crosby RD, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):458–68

Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Backman JT, et al. **Epilepsia** 1996 Mar; 37(3):253–7

Systematic testing of medical intractability for

carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Hermanns G, et al. **Epilepsia** 1996 Jul;37(7):675–9
Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Pulliainen V, et al. **Epilepsia** 1995 Dec; 36(12):1195–202
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)
Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis—a double blind study. Rao UR, et al. **J Rheumatol** 1995 Jul;22(7):1235–40
Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. de Silva M, et al. **Lancet** 1996 Mar 16;347(9003):709–13
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Duggan K, et al. **N Engl J Med** 1995 Dec 14;333(24):1638–9
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Friedman MN. **N Engl J Med** 1995 Dec 14;333(24):1638; discussion 1639
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Sankar R, et al. **N Engl J Med** 1995 Dec 14;333(24):1638; discussion 1639
Effective anticonvulsant therapy in a patient with limb shaking: a case report. Shimoda M, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):71–2
Concurrent use of phenytoin and furosemide: problems in a patient with congestive cardiac failure, chronic renal failure, liver cirrhosis and fluid overload. Bissoli F, et al. **Recenti Prog Med** 1996 May;87(5):227–8
Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis. Beech J, et al. **Res Vet Sci** 1995 Sep;59(2):95–101
Effect of phenytoin on smoke inhalation injury in sheep. Nishida K, et al. **Shock** 1995 Sep;4(3):211–5
Diaphragmatic myoclonus: diagnosis by fluoroscopy and electromyography with response to phenytoin. Young CR, et al. **South Med J** 1995 Dec;88(12):1270–3
Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acid. Ratnaraj N, et al. **Ther Drug Monit** 1995 Aug;17(4):327–32
[A change in the thyroid status of children with epilepsy being treated with diphenylhydantoin] Temin PA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):25–9 **(Rus)**

TOXICITY

Phenytoin covalent binding and embryopathy in mouse embryos co-cultured with maternal hepatocytes from mouse, rat, and rabbit. Ozolins TR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1831–40
Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)
Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds. Phillips NK, et al. **Epilepsia** 1996 Oct;37(10):991–9
DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Liu L, et al. **Free Radic Biol Med** 1995 Nov;19(5):639–48
Perspective on the carcinogenic potential of phenytoin based on rodent tumor bioassays and human epidemiological data. Dethloff LA, et al. **Hum Exp Toxicol** 1996 Apr; 15(4):335–48
Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)
Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice. Ozolins TR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):945–53
Prenatal exposure to sodium phenytoin in rats induces complex maze learning deficits comparable to those induced by exposure to phenytoin acid at half the dose. Vorhees CV, et al. **Neurotoxicol Teratol** 1995 Nov–Dec; 17(6):627–32
Effect of doxorubicin and phenytoin on sea urchin development. Sconzo G, et al. **Pharmazie** 1995 Sep; 50(9):616–9

PHEOCHROMOCYTOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

Phaeochromocytoma in pregnancy: a case report. Atan A, et al. **Int Urol Nephrol** 1996;28(1):11–3
Phaeochromocytoma in various disguises. Monkelbaan JF, et al. **Neth J Med** 1995 Aug;47(2):70–5
Extraadrenal pheochromocytoma. Baše J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1):47–9
[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[A case of adrenal neoplasm] Petrone U, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):185–8 (Eng. Abstr.) **(Ita)**
[Cutaneous vasculitis, mixed cryoglobulinemia in a patient with non-secreting monolateral pheochromocytoma. A likely paraneoplastic syndrome] Perrone A, et al. **Recenti Prog Med** 1995 Dec;86(12):499–502 (Eng. Abstr.) **(Ita)**

BLOOD

Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline. McClean DR, et al. **Blood Press** 1995 Jul;4(4):215–7
Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? Pruszczyk P, et al. **Clin Chim Acta** 1995 Dec 29;243(2):205–12
Selective venous catheterization and plasma catecholamine analysis in the diagnosis of phaeochromocytoma. Walker IA. **J R Soc Med** 1996 Apr;89(4):216P–8P

BLOOD SUPPLY

Intracardiac pheochromocytoma with dual coronary blood supply: case report and literature review. Fitzgerald PJ, et al. **Cardiovasc Surg** 1995 Oct;3(5):557–61 (20 ref.)

CHEMICALLY INDUCED

Pseudo-phaeochromocytoma and the serotonin syndrome [letter; comment] Brown TM, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):513. Comment on: Clin Endocrinol (Oxf) 1995 Jan;42(1):95–8; discussion 98–9.

CHEMISTRY

Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Gladson CL, et al. **Am J Pathol** 1996 May;148(5):1423–34
Detection of ret homodimers in MEN 2A-associated pheochromocytomas. Wada M, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):606–9

COMPLICATIONS

Pheochromocytoma with reversible focal cardiac dysfunction. Scott IU, et al. **Am Heart J** 1995 Oct; 130(4):909–11
Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937–9 (12 ref.)
Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment [letter] Choi KL, et al. **Aust N Z J Med** 1995 Jun;25(3):257
Hypertension secondary to adrenal tumors ten years experience. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Jul-Sep;87(7–9):124–5
Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. Huddle KR, et al. **Chest** 1996 May;109(5):1394–7
Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)
Coexistence of bilateral adrenal phaeochromocytoma and idiopathic hyperaldosteronism. Tan GH, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):603–9
Anaesthetic management of a patient with von Hippel-Lindau disease: a combination of bilateral phaeochromocytoma and spinal cord haemangioblastoma. Ercan M, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):81–3
Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43–50
Coexisting extraadrenal pheochromocytoma and renal artery stenosis: a case report and review of the pathophysiology. Pickard JL, et al. **J Pediatr Surg** 1995 Nov;30(11):1613–5
Pressor effect of metoclopramide in phaeochromocytoma [letter] Freestone S, et al. **Postgrad Med J** 1996 Mar; 72(845):188–9
Pheochromocytoma associated with polycythemia: case report. Rezkalla MA, et al. **S D J Med** 1995 Oct; 48(10):349–51
[Tumors outside of the central nervous system in Von Hippel-Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**
[Infrahepatic ectopic non-secreting chromaffin tumor] Pfister C, et al. **Ann Chir** 1995;49(10):963–7 (Eng. Abstr.) **(Fre)**
[Granulosis rubra nasi and pheochromocytoma] Heid E, et al. **Ann Dermatol Venereol** 1996;123(2):106–8 (Eng. Abstr.) **(Fre)**
[Pheochromocytoma in Von Hippel Lindau disease. 3 cases] Tourniaire J, et al. **Ann Endocrinol (Paris)** 1995; 56(6):609–12 (Eng. Abstr.) **(Fre)**
[Pheochromocytoma-induced multiorgan failure. An internal medicine and surgical emergency] Lamberts R, et al. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):479–84 (Eng. Abstr.) **(Ger)**
[Tachycardia and hypotension attacks as the main symptoms of pheochromocytoma—case report] Sayali E, et al. **Wien Med Wochenschr** 1995;145(14):333–6 (Eng. Abstr.) **(Ger)**
[Pheochromocytoma-gastric leiomyoblastoma association. A possible expression of Carney's triad. A case report] Amoroso A, et al. **Recenti Prog Med** 1995 Sep;86(9):348–52 (Eng. Abstr.) **(Ita)**
[Pheochromocytoma, acute myocardial infarction and silent postprandial ischemia] Juncal A, et al. **Rev Esp Cardiol** 1996 Jan;49(1):73–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

A clinical diagnosis of urinary bladder (extra-adrenal) phaeochromocytoma. Kyriakidis A, et al. **Acta Urol Belg** 1995 Sep;63(3):65–6
Hypertension and myocardial and cerebral infarctions. **Am J Med** 1996 Mar;100(3):357–64
Phaeochromocytoma diagnosis [letter] Tormey WP. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):595–7
Plasma or urinary metanephrines for the diagnosis of pheochromocytoma? That is the question [editorial; comment] Bravo EL. **Ann Intern Med** 1996 Aug 15; 125(4):331–2. Comment on: Ann Intern Med 1996 Aug 15;125(4):300–3.
Plasma metanephrines in the diagnosis of pheochromocytoma [letter] Elijovich F. **Ann Intern Med** 1996 Apr 1; 124(7):694–5
The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma [see comments] Héron E, et al. **Ann Intern Med** 1996 Aug 15;125(4):300–3. Comment in: Ann Intern Med 1996 Aug 16;125(4):331–2.
Phaeochromocytoma. Foo M, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):318–21
Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Boomsma F, et al. **Clin Chim Acta** 1995 Jul 31;239(1):57–63
Investigation of phaeochromocytoma. Bouloux PG, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):657–64 (31 ref.)
Primary hepatic pheochromocytoma. Rimmelin A, et al. **Eur Radiol** 1996;6(1):82–5
Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. Peaston RT, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1378–84
Paroxystic hypertension in a long-term hemodialyzed patient. Successful adrenalectomy for a dopamine-producing pheochromocytoma. Ferrante A, et al. **J Endocrinol Invest** 1995 Sep;18(8):656–62
MR demonstration of a cystic pheochromocytoma. Belden CJ, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):778–80
Diencephalic epilepsy resembling pheochromocytoma: a first reported case in Thailand. Charoenlarp K, et al. **J Med Assoc Thai** 1995 Jun;78(6):332–6
Pheochromocytoma in pregnancy: a case report. Kunthonkitidej K. **J Med Assoc Thai** 1996 Apr; 79(4):258–62
Death from phaeochromocytoma: lessons from a post-mortem survey. Platts JK, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):299–306
Pheochromocytoma and pseudovasculitis [letter] McColl GJ, et al. **J Rheumatol** 1995 Jul;22(7):1442–3
Dihydroxyphenylglycol in pheochromocytoma: its diagnostic use for norepinephrine dominant tumor. Nakada T, et al. **J Urol** 1996 Jan;155(1):14–8
Pheochromocytoma: on the verge of extinction under managed care. Gross JS, et al. **N J Med** 1996 Jul; 93(7):39–40
Abdominal tumours and neurofibromatosis. Martin AJ, et al. **Postgrad Med J** 1996 Jan;72(843):59–60
[Pheochromocytoma, pulmonary nodule and hypercalcemia (clinical conference)] Kauppinen-Mäkelin R, et al. **Duodecim** 1995;111(7):644–51 **(Fin)**
[Detection of patients with pheochromocytoma using a cybernetic analysis method of the signs and symptoms of the disease] Balažovjech I, et al. **Ann Urol (Paris)** 1996; 30(1):7–13 (Eng. Abstr.) **(Fre)**
[Problems posed by asymptomatic pheochromocytoma and malignant tumors of the adrenal medulla] Zvara V, et al. **Ann Urol (Paris)** 1996;30(1):14–9 (Eng. Abstr.) **(Fre)**
[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses] Aupetit-Faisant B, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1355–65; discussion 1365–7 (Eng. Abstr.) **(Fre)**
[Imaging of primary hepatic pheochromocytoma] Lewin M, et al. **J Radiol** 1996 Mar;77(3):191–5 (Eng. Abstr.) **(Fre)**
[Abdominal space-occupying lesion. Bilateral pheochromocytoma in MEN IIa and well differentiated retroperitoneal liposarcoma] Lohr F, et al. **Radiologe** 1995 Aug;35(8):543–5 **(Ger)**
[A case of asymptomatic extra-adrenal pheochromocytoma] Kobayashi K, et al. **Hinyokika Kiyo** 1996 Apr;42(4):295–7 (Eng. Abstr.) **(Jpn)**
[Atypical overgrowth of the left suprarenal gland imitating pheochromocytoma] Orzeł M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:133–6 (Eng. Abstr.) **(Pol)**
[Familial occurrence of pheochromocytoma] Feltynowski T, et al. **Pol Arch Med Wewn** 1995 May;93(5):427–32 (Eng. Abstr.) **(Pol)**
[A false diagnosis of hypertrophic myocardiopathy in pheochromocytoma] Lopes HF, et al. **Arq Bras Cardiol** 1995 Aug;65(2):167–9 (Eng. Abstr.) **(Por)**
[25 years' experience with diagnosis of pheochromocytoma] Balažovjech I. **Vnitr Lek** 1995 Aug;41(8):513–6 (Eng. Abstr.) **(Slo)**

[Pheochromocytoma: a review of our own cases] Blasco Alfonso JE, et al. **Actas Urol Esp** 1996 Jan;20(1):43–9 (Eng. Abstr.) **(Spa)**

[Pheochromocytoma in children: 2 cases] Fernández Córdoba MS, et al. **An Esp Pediatr** 1996 Mar;44(3):277–8 (6 ref.) **(Spa)**

[Laboratory contribution to the diagnosis of pheochromocytoma] Rivero Marcotegui A, et al. **An Med Interna** 1996 Jan;13(1):40–4 (60 ref.) **(Spa)**

DRUG THERAPY

Influence of alpha-adrenergic blockade on ventricular arrhythmias, QTc interval and heart rate variability in phaeochromocytoma. Dąbrowska B, et al. **J Hum Hypertens** 1995 Nov;9(11):925–9

ENZYMOLOGY

Isolation of a full-length cDNA clone for human GTP cyclohydrolase I type 1 from pheochromocytoma. Nomura T, et al. **J Neural Transm Gen Sect** 1995;101(1–3):237–42

ETIOLOGY

Pseudopheochromocytoma in a patient with Parkinson's disease [letter] Duarte J, et al. **Ann Pharmacother** 1996 May; 30(5):546

GENETICS

Monogenetic hypertension and pheochromocytoma. Neumann HP, et al. **Am J Kidney Dis** 1996 Sep; 28(3):329–33

RET proto-oncogene mutations and rearrangements in endocrine diseases [comment] Lloyd RV. **Am J Pathol** 1995 Dec;147(6):1539–44. Comment on: Am J Pathol 1995 Dec;147(6):1600–7.

Molecular and immunohistochemical analysis of P53 in phaeochromocytoma. Dahia PL, et al. **Br J Cancer** 1995 Nov;72(5):1211–3

Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Eng C, et al. **Br J Cancer** 1996 Aug;74(3):339–41

Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. Aguiar RC, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):93–6

Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma. Kimura T, et al. **Endocr J** 1995 Aug;42(4):517–25

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S, et al. **Endocr J** 1995 Aug;42(4):527–36

Complex congenital heart disease, microcephaly, pheochromocytoma and neurofibromatosis type I in a girl born from consanguineous parents. Stoll C, et al. **Genet Couns** 1995;6(3):217–20

RET mutation screening in sporadic pheochromocytoma [letter; comment] Arnold A. **J Clin Endocrinol Metab** 1996 Jan;81(1):430. Comment on: J Clin Endocrinol Metab 1995 Jul;80(7):2063–8.

Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. Gross DJ, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):147–9

Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. Modigliani E, et al. **J Intern Med** 1995 Oct;238(4):363–7

Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. Crossey PA, et al. **J Med Genet** 1995 Nov;32(11):885–6

Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II [see comments] Neumann HP, et al. **JAMA** 1995 Oct 11;274(14):1149–51. Comment in: JAMA 1996 Mar 20;275(11):839–40.

Von Hippel-Lindau disease and pheochromocytoma [letter; comment] Walther MM, et al. **JAMA** 1996 Mar 20; 275(11):839–40. Comment on: JAMA 1995 Oct 11;274(14):1149–51.

Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. **Verh Dtsch Ges Pathol** 1995;79:L-LV

[Multiple familial pheochromocytomas: sonographic demonstration of multiple adrenal, celiac and bladder localizations in a child] Arroja JM, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1231–4 (Eng. Abstr.) **(Fre)**

METABOLISM

Inhibition by Zn2+ of uridine 5'-triphosphate-induced Ca(2+)-influx but not Ca(2+)-mobilization in rat phaeochromocytoma cells. Koizumi S, et al. **Br J Pharmacol** 1995 Aug;115(8):1502–8

Double effect of ethanol on intracellular Ca2+ levels in undifferentiated PC12 cells. Belia S, et al. **Cell Signal** 1995 May;7(4):389–95

Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? Pruszczyk P, et al. **Clin Chim Acta** 1995 Dec 29;243(2):205–12

Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. deS Senanayake P, et al. **J Clin Invest** 1995 Nov;96(5):2503–9

ATP receptor-mediated increase of Ca ionophore-stimulated arachidonic acid release from PC12 pheochromocytoma cells. Murayama T, et al. **Jpn J Pharmacol** 1995 Sep; 69(1):43–51

Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway. Rockow S, et al. **Oncogene** 1996 Jun 6;12(11):2351–9

MORTALITY

Death from phaeochromocytoma: lessons from a post-mortem survey. Platts JK, et al. **J R Coll Physicians Lond** 1995 Jul-Aug;29(4):299–306

PATHOLOGY

Adrenal cortical tumors clinically mimicking pheochromocytoma. Alsabeh R, et al. **Am J Clin Pathol** 1995 Oct;104(4):382–90

A case of von Recklinghausen's disease with bilateral pheochromocytoma-malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Sakaguchi N, et al. **Am J Surg Pathol** 1996 Jul; 20(7):889–97

Pheochromocytomas with extension into central vascular structures. Rötker J, et al. **Ann Thorac Surg** 1996 Jan; 61(1):222–4

Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2. Cortazzo M, et al. **Cancer Res** 1996 Mar 15;56(6):1199–203

Primary malignant pheochromocytoma in the left forearm. Wang Y, et al. **Chin Med J (Engl)** 1996 Apr;109(4):331–3

Pheochromocytoma of the urinary bladder: a case report. Lee SP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr;57(4):297–300

Adrenal and extra-adrenal phaeochromocytomas. contribution of histology, immunochemistry and DNA flow cytometry in the diagnosis of malignancy [letter; comment] Gosset P, et al. **Eur J Surg** 1996 Jan;162(1):77 . Comment on: Eur J Surg 1994 Oct;160(10):547–52.

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine-neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683–7 (47 ref.)

[Characteristics of the morphological structure of malignant tumors of the adrenal medulla] Kalashnikov SA, et al. **Klin Khir** 1995;(5):26–8 **(Rus)**

[Insulin-dependent diabetes mellitus and a malignant pheochromocytoma with a long-term evolution (letter)] Catalina PF, et al. **Rev Clin Esp** 1995 Oct;195(10):737 **(Spa)**

PHYSIOPATHOLOGY

Heart rate variability in pheochromocytoma. Dabrowska B, et al. **Am J Cardiol** 1995 Dec 1;76(16):1202–4

Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43–50

Pheochromocytoma--the catecholamine dependent hypertension. Januszewicz W, et al. **J Physiol Pharmacol** 1995 Sep;46(3):285–95

Postural palpitations--a curious presentation of intrathoracic phaeochromocytoma. John LC, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):234–5

[Evaluation of blood rheology indices in patients with pheochromocytoma] Berent H, et al. **Pol Arch Med Wewn** 1996 Mar;95(3):190–7 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Bladder pheochromocytoma with ring calcification. Asbury WL Jr, et al. **Abdom Imaging** 1996 May-Jun;21(3):275–7

RADIONUCLIDE IMAGING

Pheochromocytoma with catecholamine-induced impairment of cardiac neuronal function. Agostini D, et al. **Am Heart J** 1995 Nov;130(5):1128–30

The usefulness of cardio-vascular visualization in the localization of mediastinal pheochromocytomas with I-131-MIBG. Başoğlu T, et al. **Ann Nucl Med** 1996 Feb; 10(1):135–8

Abnormal cardiac sympathetic nerve function in a patient with pheochromocytoma. An analysis using 123I metaiodobenzylguanidine scintigraphy. Izumi C, et al. **Int J Cardiol** 1995 Jun 30;50(2):189–92

Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. Neumann DR, et al. **J Comput Assist Tomogr** 1996 Mar-Apr;20(2):312–6

Iodine-123-MIBG imaging in pheochromocytoma with cardiomyopathy and pulmonary edema. Suga K, et al. **J Nucl Med** 1996 Aug;37(8):1361–4

RADIOTHERAPY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. Tristam M, et al. **J Nucl Med** 1996 Jun;37(6):1058–63

SECONDARY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

[Follow-up of malignant metastatic pheochromocytoma. Discussion of the therapeutic strategy] Fett W, et al. **Med Klin** 1995 Nov 15;90(11):661–4, 672 **(Ger)**

SECRETION

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)

Adrenocorticotropic hormone-secreting pheochromocytomas: the exception to the rule. Chen H, et al. **Surgery** 1995 Dec;118(6):988–94; discussion 994–5

SURGERY

Pre-operative management for surgery of pheochromocytoma. Májek M, et al. **Ann Urol (Paris)** 1996; 30(1):20–4

Initial experience with endoscopic retroperitoneal adrenalectomy. Parrilla P, et al. **Br J Surg** 1996 Jul; 83(7):987–8

Phaeochromocytoma and calcium channel block [letter; comment] Tobias JD. **Can J Anaesth** 1995 Sep;42(9):837–8 . Comment on: Can J Anaesth 1995 Mar;42(3):228–30.

A case of massive adrenal malignant pheochromocytoma: management of a large pheochromocytoma. Kondo T, et al. **Hinyokika Kiyo** 1995 Sep;41(9):669–73

Assessment of adrenal surgery on creatinine clearance in patients with phaeochromocytoma. Nakada T, et al. **Int Urol Nephrol** 1995;27(2):121–30

Surgical strategy for pheochromocytoma: emphasis on the pledge of flank extraperitoneal approach in selected patients. Obara T, et al. **Surgery** 1995 Dec;118(6):1083–9

[Role of laparoscopy in surgery of the adrenal glands] Henry JF, et al. **J Chir (Paris)** 1996 May;133(3):111–6 (Eng. Abstr.) **(Fre)**

[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery] Schüttler J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):341–9 (Eng. Abstr.) **(Ger)**

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

[123I-metaiodobenzylguanidine myocardial scintigraphy in a case of pheochromocytoma before and after resection of it] Matsumoto K, et al. **Kaku Igaku** 1995 Sep; 32(9):1023–8 (Eng. Abstr.) **(Jpn)**

[Anesthesia with transesophageal echocardiography for removal of pheochromocytoma] Matsuura T, et al. **Masui** 1995 Oct;44(10):1388–90 (Eng. Abstr.) **(Jpn)**

[Perioperative course of 17 cases of pheochromocytoma] González R, et al. **Rev Invest Clin** 1996 Mar-Apr; 48(2):97–103 (Eng. Abstr.) **(Spa)**

URINE

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542–5 (16 ref.)

PHEOCHROMOCYTOMA CELL LINE see PC12 CELLS

PHEOPHYTINS

ANALYSIS

Analysis of the absorption spectrum of photosystem II reaction centers: temperature dependence, pigment assignment, and inhomogeneous broadening. Konermann L, et al. **Biochemistry** 1996 Jan 23;35(3):829–42

Pigment content of D1-D2-cytochrome b559 reaction center preparations after removal of CP47 contamination: an immunological study. Pueyo JJ, et al. **Biochemistry** 1995 Nov 21;34(46):15214–8

CHEMISTRY

Effects of hydrogen bonding to a bacteriochlorophyll-bacteriopheophytin dimer in reaction centers from Rhodobacter sphaeroides. Allen JP, et al. **Biochemistry** 1996 May 28;35(21):6612–9

Spin-lattice relaxation of the pheophytin, Pheo-, radical of photosystem II. Deligiannakis Y, et al. **Biochemistry** 1996 Sep 3;35(35):11239–46

Long-time quantum simulation of the primary charge separation in bacterial photosynthesis. Makri N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3926–31

ISOLATION & PURIFICATION

Separation of mono- and divinyl chlorophyll species by high-performance liquid chromatography using an octadecyl polyvinyl alcohol polymer column. Shioi Y, et al. **Anal Biochem** 1995 Oct 10;231(1):225–9

PHERESIS see BLOOD COMPONENT REMOVAL

PHEROMONES

Efficacy of tail-tag decoys impregnated with pheromone and acaricide for control of bont ticks on cattle. Allan SA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:85-93

A model for pheromone discrimination in the insect antennal lobe: investigation of the role of neuronal response pattern complexity. Linster C, et al. **Chem Senses** 1996 Feb; 21(1):19-27

Physical mapping of the conjugative bacteriocin plasmid pPD1 of Enterococcus faecalis and identification of the determinant related to the pheromone response. Fujimoto S, et al. **J Bacteriol** 1995 Oct;177(19):5574-81

Comparison of carbon dioxide, octenol and a host-odour as mosquito attractants in the Upper Rhine Valley, Germany. Becker N, et al. **Med Vet Entomol** 1995 Oct;9(4):377-80

Kar4p, a karyogamy-specific component of the yeast pheromone response pathway. Kurihara LJ, et al. **Mol Cell Biol** 1996 Aug;16(8):3990-4002

ANALYSIS

Labial gland chemistry of three species of bumblebees (Hymenoptera: Apidae) from North America. Bergström G, et al. **Bioorg Med Chem** 1996 Mar;4(3):515-9

Quantitative analysis for pheromone inhibitor and pheromone shutdown in Enterococcus faecalis. Nakayama J, et al. **Dev Biol Stand** 1995;85:35-8

Origin and identification of bacteria which produce kairomones in the frass of Acrolepiopsis assectella (Lep., Hyponomeutoidea). Thibout E, et al. **Experientia** 1995 Nov 15;51(11):1073-5

ANTAGONISTS & INHIBITORS

Quantitative analysis for pheromone inhibitor and pheromone shutdown in Enterococcus faecalis. Nakayama J, et al. **Dev Biol Stand** 1995;85:35-8

CHEMICAL SYNTHESIS

A convenient synthesis of trans-sabinene hydrate from (-)-3-thujol via a highly selective ene reaction of singlet oxygen. Baeckström P, et al. **Bioorg Med Chem** 1996 Mar; 4(3):419-21

Asymmetric aldol condensation as a route to polypropionate derived pheromones. DiBattista JP, et al. **Bioorg Med Chem** 1996 Mar;4(3):423-8

A versatile and convenient protocol for the stereocontrolled synthesis of olefinic insect pheromones. Vasil'ev AA, et al. **Bioorg Med Chem** 1996 Mar;4(3):389-400

CHEMISTRY

Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):208-12 (30 ref.)

A cooperative model for receptor recognition and cell adhesion: evidence from the molecular packing in the 1.6-A crystal structure of the pheromone Er-1 from the ciliated protozoan Euplotes raikovi. Weiss MS, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10172-6

GENETICS

How is pheromone specificity encoded in proteins? Prestwich GD, et al. **Chem Senses** 1995 Aug;20(4):461-9 (36 ref.)

Differential amplification of pheromone genes of the ciliate Euplotes raikovi. La Terza A, et al. **Dev Genet** 1995; 17(3):272-9

The pheromone response factor coordinates filamentous growth and pathogenicity in Ustilago maydis. Hartmann HA, et al. **EMBO J** 1996 Apr 1;15(7):1632-41

Genetics of differences in pheromonal hydrocarbons between Drosophila melanogaster and D. simulans. Coyne JA. **Genetics** 1996 May;143(1):353-64

The biallelic a mating type locus of Ustilago maydis: remnants of an additional pheromone gene indicate evolution from a multiallelic ancestor. Urban M, et al. **Mol Gen Genet** 1996 Mar 7;250(4):414-20

METABOLISM

Transformation of presumptive precursors to frontalin and exo-brevicomin by bark beetles and west Indian sugarcane weevil (Coleoptera). Perez AL, et al. **Bioorg Med Chem** 1996 Mar;4(3):445-50

A novel family of genes encoding putative pheromone receptors in mammals. Dulac C, et al. **Cell** 1995 Oct 20; 83(2):195-206

Ligand specificity of pheromone-binding proteins of the processionary moth. Feixas J, et al. **Eur J Biochem** 1995 Dec 1;234(2):521-6

Redox-shift of the pheromone-binding protein in the silkmoth Antheraea polyphemus. Ziegelberger G. **Eur J Biochem** 1995 Sep 15;232(3):706-11

Mutation of RGA1, which encodes a putative GTPase-activating protein for the polarity-establishment protein Cdc42p, activates the pheromone-response pathway in the yeast Saccharomyces cerevisiae. Stevenson BJ, et al. **Genes Dev** 1995 Dec 1;9(23):2949-63

Mutations within the first LSGGQ motif of Ste6p cause defects in a-factor transport and mating in Saccharomyces cerevisiae. Browne BL, et al. **J Bacteriol** 1996 Mar; 178(6):1712-9

Pheromone signalling in Saccharomyces cerevisiae requires the small GTP-binding protein Cdc42p and its activator CDC24. Zhao ZS, et al. **Mol Cell Biol** 1995 Oct; 15(10):5246-57

Enterococcus faecalis pheromone binding protein, PrgZ, recruits a chromosomal oligopeptide permease system to import sex pheromone cCF10 for induction of conjugation. Leonard BA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):260-4

Role of yeast insulin-degrading enzyme homologs in propheromone processing and bud site selection. Adames N, et al. **Science** 1995 Oct 20;270(5235):464-7

PHARMACOLOGY

Vomeronasal organ removal blocks pheromonal induction of estrus in gray short-tailed opossums (Monodelphis domestica). Jackson LM, et al. **Biol Reprod** 1996 Feb; 54(2):506-12

Induction of phenazine biosynthesis in cultures of Pseudomonas aeruginosa by L-N-(3-oxohexanoyl)homoserine lactone. Stead P, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):15-22

Response of gravid Phlebotmus papatasi females to an oviposition attractant/stimulant associated with conspecific eggs. Srinivasan R, et al. **Indian J Exp Biol** 1995 Oct; 33(10):757-60

Ubiquitination of the yeast a-factor receptor. Roth AF, et al. **J Cell Biol** 1996 Aug;134(3):661-74

Interactions between the ankyrin repeat-containing protein Akr1p and the pheromone response pathway in Saccharomyces cerevisiae. Kao LR, et al. **Mol Cell Biol** 1996 Jan;16(1):168-78

Tetrodotoxin as a pheromone [letter] Matsumura K. **Nature** 1995 Dec 7;378(6557):563-4

Pheromone response in yeast: association of Bem1p with proteins of the MAP kinase cascade and actin. Leeuw T, et al. **Science** 1995 Nov 17;270(5239):1210-3

[Cytogenetic effect of volatile components of urine of sexually mature animals on bone marrow cells of young female house mice Mus musculus L.] Daev EV, et al. **Genetika** 1996 Mar;32(3):411-4 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Chemical cues are necessary but insufficient for reproductive activation of female pine vole (Microtus pinetorum). Solomon NG, et al. **Biol Reprod** 1996 May;54(5):1038-45

Proteins that smell: pheromone recognition and signal transduction. Prestwich GD. **Bioorg Med Chem** 1996 Mar; 4(3):505-13 (55 ref.)

Pheromone-inducible gene regulation and signalling for the control of aggregation substance expression in the conjugative plasmid pCF10. Leonard BA, et al. **Dev Biol Stand** 1995;85:27-34

The mating-type locus B alpha 1 of Schizophyllum commune contains a pheromone receptor gene and putative pheromone genes. Wendland J, et al. **EMBO J** 1995 Nov 1;14(21):5271-8

Sulfated 17,20 beta-dihydroxy-4-pregnen-3-one functions as a potent and specific olfactory stimulant with pheromonal actions in the goldfish. Sorensen PW, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):128-42

Genetic relationships between the G protein beta gamma complex, Ste5p, Ste20p and Cdc42p: investigation of effector roles in the yeast pheromone response pathway. Akada R, et al. **Genetics** 1996 May;143(1):103-17

FAR1 is required for oriented polarization of yeast cells in response to mating pheromones. Valtz N, et al. **J Cell Biol** 1995 Nov;131(4):863-73

Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):208-12 (30 ref.)

Field and laboratory responses of adult Ixodes scapularis (Acari: Ixodidae) to kairomones produced by white-tailed deer. Carroll JF, et al. **J Med Entomol** 1996 Jul;33(4):640-4

Sensory transduction in vomeronasal neurons: evidence for G alpha o, G alpha i2, and adenylyl cyclase II as major components of a pheromone signaling cascade. Berghard A, et al. **J Neurosci** 1996 Feb 1;16(3):909-18

Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406-22 (181 ref.)

Signaling in the yeast pheromone response pathway: specific and high-affinity interaction of the mitogen-activated protein (MAP) kinases Kss1 and Fus3 with the upstream MAP kinase kinase Ste7. Bardwell L, et al. **Mol Cell Biol** 1996 Jul;16(7):3637-50

AKR1 encodes a candidate effector of the G beta gamma complex in the Saccharomyces cerevisiae pheromone response pathway and contributes to control of both cell shape and signal transduction. Pryciak PM, et al. **Mol Cell Biol** 1996 Jun;16(6):2614-26

Identification of the pheromone response element in Ustilago maydis. Urban M, et al. **Mol Gen Genet** 1996 Apr 24; 251(1):31-7

Insect pheromone in elephants [letter] Rasmussen LE, et al. **Nature** 1996 Feb 22;379(6567):684

Identification and characterization of the genes of Enterococcus faecalis plasmid pCF10 involved in replication and in negative control of pheromone-inducible conjugation. Hedberg PJ, et al. **Plasmid** 1996 Jan; 35(1):46-57

An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Håvarstein LS, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11140-4

Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Ji G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12055-9

Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):125-41 (128 ref.)

Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al. **Semin Cell Biol** 1995 Apr;6(2):95-104 (105 ref.)

URINE

Twenty-four hour feline excretion patterns in entire and castrated cats. Hendriks WH, et al. **Physiol Behav** 1995 Sep;58(3):467-9

PHEROMONES, SEXUAL see **SEX ATTRACTANTS**

PHI PEPTIDE see **PEPTIDE PHI**

PHI X 174 PHAGE see **BACTERIOPHAGE PHI X 174**

PHI 6 PHAGE see **BACTERIOPHAGE PHI 6**

PHIALAPHORA JEANSELMEI see **EXOPHIALA**

PHIALOPHORA

First case of osteomyelitis due to Phialophora richardsiae in a patient with HIV infection [letter] Uberti-Foppa C, et al. **AIDS** 1995 Aug;9(8):975-6

Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Jha V, et al. **Am J Kidney Dis** 1996 Jul;28(1):137-9 (21 ref.)

Phialophora corneal ulcer. Hirst LW, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):223-5

Phialophora verrucosa infection in an AIDS patient. Duggan JM, et al. **Mycoses** 1995 May-Jun;38(5-6):215-8

ENZYMOLOGY

Use of the polymerase chain reaction to identify coding sequences for chitin synthase isozymes in Phialophora verrucosa. Peng M, et al. **Curr Genet** 1995 May; 27(6):517-23

GENETICS

Use of the polymerase chain reaction to identify coding sequences for chitin synthase isozymes in Phialophora verrucosa. Peng M, et al. **Curr Genet** 1995 May; 27(6):517-23

PHYSIOLOGY

Sex hormone effects on Phialophora verrucosa in vitro and characterization of progesterone receptors. Hernández-Hernández F, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):235-9

PHIALOPHORA GOUGEROTII see **EXOPHIALA**

PHILADELPHIA CHROMOSOME

see related
ONCOGENE PROTEINS, FUSION

Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myeloid leukemia (CML). Podestà M, et al. **Bone Marrow Transplant** 1995 Oct;16(4):549-55

Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Stockschläder M, et al. **Bone Marrow Transplant** 1995 Nov;16(5):663-7

BCR-ABL rearrangement and 'variant' Philadelphia chromosome in de novo acute myelogenous leukaemia FAB subtype M1. Cigudosa JC, et al. **Br J Haematol** 1995 Dec;91(4):932-4

New variant Ph translocation in chronic myeloid leukemia: t(Y;22)(p11;q11). Gallego MS, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):75-8

Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. Tosi S, et al. **Cancer Genet Cytogenet** 1996 Jul 15;89(2):153-6

Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Martin H, et al. **Exp Hematol** 1995 Dec;23(14):1612-8

Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia [letter] Oikawa H, et al. **Int J Hematol** 1995 Jun;61(4):229-30

Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). Estrov Z, et al. **J Cell Physiol** 1996 Mar;166(3):618-30

Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation. Sessarego M, et al. **Leuk Res** 1995 Dec; 19(12):921-5

Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in

lymphoid blast vs Ph+ acute lymphoblastic leukemia. Anastasi J, et al. **Leukemia** 1996 May;10(5):795–802

KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Andersson BS, et al. **Leukemia** 1995 Dec; 9(12):2100–8

Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha [letter] Henic N, et al. **Leukemia** 1996 Jan;10(1):185–6

Complete phenotypic and genotypic lineage switch in a Philadelphia chromosome-positive acute lymphoblastic leukemia. Pane F, et al. **Leukemia** 1996 Apr;10(4):741–5

A late-appearing Philadelphia chromosome in acute lymphoblastic leukemia confirmed by expression of BCR-ABL mRNA. Tsuchiya H, et al. **Leukemia** 1995 Oct; 9(10):1689–93

[Chronic myeloid leukemia, biological aspects] Costello R, et al. **Rev Med Interne** 1996;17(3):213–23 (139 ref.) (Eng. Abstr.) **(Fre)**

[Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia] Martinet D, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):855–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Unclassified chronic myeloproliferative disorder (Ph negative/bcr rearrangement negative CML) with late appearing Philadelphia like chromosome] Hamada K, et al. **Rinsho Ketsueki** 1996 Mar;37(3):221–7 (Eng. Abstr.) **(Jpn)**

[Diagnosis and follow-up in chronic myeloid leukemia. Detection and quantification of specific transcripts with the help of reverse transcriptase-polymerase chain reaction] Osland A, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):726–30 (Eng. Abstr.) **(Nor)**

[Unclassified chronic myeloproliferative Ph(–); i(17q); +8 syndrome with mixed myelo-megakaryoblastic crisis—case report] Mariańska B, et al. **Acta Haematol Pol** 1996; 27(1):85–8 (Eng. Abstr.) **(Pol)**

PHILANTHROPIC FUNDS see **FUND RAISING**

PHILATELY

100 years of x rays [letter] Caroe J. **BMJ** 1995 Sep 9; 311(7006):688–9

Stamps in cardiology [editorial] Davies MK, et al. **Heart** 1996 Jul;76(1):10

William Harvey (1578–1657). Davies MK, et al. **Heart** 1996 Jul;76(1):11–2

Ferdinand Ritter von Hebra—founder of modern dermatology. Pretterklieber ML. **Isr J Med Sci** 1996 Jul; 32(7):584

Julius Tandler—professor of anatomy, and social reformer. Pretterklieber ML. **Isr J Med Sci** 1995 Sep;31(9):590

Robert Barany—discoverer of the caloric nystagmus. Pretterklieber ML. **Isr J Med Sci** 1995 Oct;31(10):647–A

Pioneers in allergy and anaphylaxis. Shafrir E. **Isr J Med Sci** 1996 May;32(5):344

Jacques L. Monod, Francois J. Jacob and Andre M. Lwoff—introducers of new dimensions in cellular genetics and molecular biology. Shafrir E. **Isr J Med Sci** 1996 Feb; 32(2):162

Nurses—an integral part of the medical team. Shafrir E. **Isr J Med Sci** 1996 Jan;32(1):78

Hospitals on stamps. Shafrir E. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):269

Rosa canina (dog rose). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):470

Pedanius Dioscorides (born about AD40, died about AD90). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):427

Karl Rokitansky (1804–78). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):683

Joseph Hyrtl (1811–94). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):130

Thymus serpyllum (wild thyme). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):224

Mentha piperita (peppermint). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):607

Neurological stamp. Valeriana officinalis (garden heliotrope). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Mar; 60(3):255

St Apollonia (died about AD 249). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):558

Willow. Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):5

Convallari majalis (lily of the valley) (also known as Our Lady's tears, ladder to heaven). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):367

David Livingstone (1813–73). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):303

Romanian physician contributes to the control of diabetes. Dumitrascu DL, et al. **Mayo Clin Proc** 1996 May;71(5):522

Dumitru Bagdasar—father of Romanian neurosurgery. Dumitrascu DL, et al. **Mayo Clin Proc** 1996 Jan;71(1):31

Hans von Euler-Chelpin—Noble laureate. Kyle RA, et al. **Mayo Clin Proc** 1996 Jun;71(6):596

James D. Watson and DNA. Kyle RA, et al. **Mayo Clin Proc** 1996 Jul;71(7):658

Allan Cormack—codeveloper of computed tomographic scanner. Shampo MA, et al. **Mayo Clin Proc** 1996 Mar; 71(3):288

Werner Arber—Nobel laureate. Shampo MA, et al. **Mayo Clin Proc** 1995 Oct;70(10):945

Daniel Nathans—geneticist and microbiologist wins Nobel prize. Shampo MA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):360

Karl Theodore Dussik—pioneer in ultrasound. Shampo MA, et al. **Mayo Clin Proc** 1995 Dec;70(12):1136

David Hubel—Nobel Prize winner for investigations of brain function. Shampo MA, et al. **Mayo Clin Proc** 1996 Feb; 71(2):116

Phoebe Pember—confederate nurse during the Civil War. Shampo MA, et al. **Mayo Clin Proc** 1996 Sep;71(9):856

[The why of "Postal Radiations", a book of scientific and philatelic disclosure] Aquila N. **Radiol Med (Torino)** 1995 Nov;90(5):595–6 **(Ita)**

PHILOLOGY, ORIENTAL

The cosmobiological balance of the emotional and spiritual worlds: phenomenological structuralism in traditional Chinese medical thought. Davis S. **Cult Med Psychiatry** 1996 Mar;20(1):83–123

PHILOSOPHY

Postmodernism—feminism and the deconstruction of the feminine: Kristeva and Irigaray. Van Buren J. **Am J Psychoanal** 1995 Sep;55(3):231–43

Poststructuralism and other 'species' in public health—a 'Darwinian' view. Gaughwin M. **Aust J Public Health** 1995 Aug;19(4):430–3

"Philosophers will be busy" [letter] Needham CW. **Conn Med** 1996 Jun;60(6):368–9

At the juncture of theory and practice. Remarks on receiving the Henry Knowles Beecher Award. Bok S. **Hastings Cent Rep** 1996 May–Jun;26(3):5–8

The poverty of Popperian epidemiology. Karhausen LR. **Int J Epidemiol** 1995 Oct;24(5):869–74

Nursing's values from a Confucian perspective. Chao YM. **Int Nurs Rev** 1995 Sep–Oct;42(5):147–9

Spirituality as integrative energy': a philosophical analysis as requisite precursor to holistic nursing practice. Goddard NC. **J Adv Nurs** 1995 Oct;22(4):808–15 (40 ref.)

Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201–5 (28 ref.)

Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)

The phenomenological movement: implications for nursing research. Walters AJ. **J Adv Nurs** 1995 Oct;22(4):791–9 (23 ref.)

Poststructural psychoanalysis or wild analysis? Chessick RD. **J Am Acad Psychoanal** 1995 Spring;23(1):47–62; discussion 63–70

Reply to Whitehouse and Deal editorial [letter; comment] Dick EG. **J Am Geriatr Soc** 1996 Jun;44(6):734–7. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1314–5.

Clinical truth and contemporary relativism: meaning and narration in the psychoanalytic situation. Reed GS. **J Am Psychoanal Assoc** 1995;43(3):713–39

More thoughts on animal rights and animal liberation [letter] Hartwick JR. **J Am Vet Med Assoc** 1996 Jan 1;208(1):23–4

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209–14 (44 ref.)

Beyond determinism and materialism, or isn't it time we took consciousness seriously? [comment] Locke EA. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):265–73. Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

The elimination of morality. Harris J. **J Med Ethics** 1995 Aug;21(4):220–4

Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)

A good and peaceful death: a personal statement. Saunders DE Jr. **J S C Med Assoc** 1996 Feb;92(2):44–7

PAR Village for chemically dependent women. Philosophy and program elements. Coletti SD, et al. **J Subst Abuse Treat** 1995 Jul–Aug;12(4):289–96

The physician as general. Nie JB. **JAMA** 1996 Oct 2; 276(13):1099

The cranes and skyhooks of Daniel C Dennett [editorial] Gregory RL. **Perception** 1995;24(10):1101–4

Narrative and psychological understanding. Josselson R. **Psychiatry** 1995 Nov;58(4):330–43

Psychoanalytic neonate models and non-Cartesian frameworks. Berger LS. **Psychoanal Rev** 1996 Feb; 83(1):49–65

Lacanian perspectives on political and social controversies: a symposium. Friedlander S. **Psychoanal Rev** 1995 Oct; 82(5):651–4

Notes on Foucault. Stoller RJ. **Psychoanal Rev** 1996 Feb; 83(1):12–20; discussion 11–2

From a medical consultation to a written text. 2. Pragmatics and textlinguistics applied to medicine. Nessa J. **Scand J Prim Health Care** 1995 Jun;13(2):89–92

Epidemiology's role in the creation of a humane world: convergences and divergences among the schools [editorial] Breilh J. **Soc Sci Med** 1995 Oct;41(7):911–4

Health-related quality of life between naturalism and hermeneutics. Rosenberg R. **Soc Sci Med** 1995 Nov; 41(10):1411–5 (17 ref.)

A Kantian argument in favor of unimpeded access to health care [see comments] Heubel F. **Theor Med** 1995 Jun; 16(2):199–213. Comment in: Theor Med 1995 Jun;16(2):215–22.

Kant, health care and justification [comment] Loewy EH. **Theor Med** 1995 Jun;16(2):215–22. Comment on: Theor Med 1995 Jun;16(2):199–213.

Religious dimensions of dying and death. O'Connell LJ. **West J Med** 1995 Sep;163(3):231–5

Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)

[Is the mind located in the brain?] Louhiala P. **Duodecim** 1994;110(1):35–41 (22 ref.) **(Fin)**

[What is mental health?] Richard J. **Rev Med Suisse Romande** 1995 Jul;115(7):543–7 **(Fre)**

[2 basic problems of psychoanalytic psychotherapy and their philosophical revision] Bürgy M. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):389–94 (57 ref.) (Eng. Abstr.) **(Ger)**

[Processes of interpretation in psychiatry] Küchenhoff B. **Schweiz Arch Neurol Psychiatr** 1995;146(5):240–2 (Eng. Abstr.) **(Ger)**

[The concept of reification in psychiatry and sociology] Morozov VM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):112–4 (15 ref.) **(Rus)**

[The tradition of observing the laws of nature in making a judgement (comment)] Shulkin NN. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):202–4. Comment on: Zh Vyssh Nerv Deiat Im I P Pavlova 1994 Jul–Oct;44(4–5):888–92. **(Rus)**

HISTORY

Chinese Confucian culture and the medical ethical tradition. Guo Z. **J Med Ethics** 1995 Aug;21(4):239–46 (13 ref.)

Death and the internal milieu: Claude Bernard and the origins of experimental medicine. Wasserstein AG. **Perspect Biol Med** 1996 Spring;39(3):313–26

[Eccentric path and schizophrenic ego splitting. Friedrich Hölderlin's philosophical writing fragments in their relation to his life and illness] Frommer J. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):341–9 (Eng. Abstr.) **(Ger)**

[Ancient philosophy as a source of ideas for "borderline" psychiatry in the historical and epistemological aspect] Ovsiannikov SA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(2):76–83 **(Rus)**

PHILOSOPHY, MEDICAL

Outcomes, endpoints, and expectations [editorial] Bryan-Brown CW, et al. **Am J Crit Care** 1996 Mar; 5(2):87–9

The future of epidemiology: a humanist response [letter] Lawson J, et al. **Am J Public Health** 1996 Jul;86(7):1029–30

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

Constructivism in psychotherapy. Truth and consequences. Held BS. **Ann N Y Acad Sci** 1996 Jun 24;775:198–206 (43 ref.)

Jenner, romanticism, and research. Chiswick ML. **Arch Dis Child** 1996 Jan;74(1):1–2

Biological psychiatry and reductionism [letter] Daniel WF. **Br J Psychiatry** 1996 May;168(5):655

Biological psychiatry and reductionism. Empirical findings and philosophy [editorial] Karlsson H, et al. **Br J Psychiatry** 1995 Oct;167(4):434–8

Psychiatry and philosophy [editorial] Shepherd M. **Br J Psychiatry** 1995 Sep;167(3):287–8

Letting compassion open the door: battered women's disclosure to medical providers. Bauer HM, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):459–65

Physicians' duty of compassion. Dougherty CJ, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):426–33

Compassion, reason, and moral judgment. Loewy EH. **Camb Q Healthc Ethics** 1995 Fall;4(4):466–75

Love thy patient: justice, caring, and the doctor-patient relationship. Rhodes R. **Camb Q Healthc Ethics** 1995 Fall; 4(4):434–47

Richard Selzer on death, resurrection, and compassion [interview by Thomasine Kushner] Selzer R. **Camb Q Healthc Ethics** 1995 Fall;4(4):494–8

A dialogue on compassion and supererogation in medicine. Thomasma DC, et al. **Camb Q Healthc Ethics** 1995 Fall; 4(4):415–25

Sympathy as the basis of compassion. Welie JV. **Camb Q Healthc Ethics** 1995 Fall;4(4):476–87

Capitation method ruffles feathers [letter] Gibney P. **Can Fam Physician** 1996 Jul;42:1289–91; discussion 1291, 1293

Capitation method ruffles feathers [letter] Rubenstein W. **Can Fam Physician** 1996 Jul;42:1289; discussion 1291, 1293

The biopsychosocial paradigm and the future of psychiatry. Freedman AM. **Compr Psychiatry** 1995 Nov–Dec; 36(6):397–406 (44 ref.)

Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Cook DJ, et al. **Crit Care Med** 1996 Feb;24(2):334–7 (46 ref.)

The science of the humane and the humanism of science [see comments] Rorty AO. **Cult Med Psychiatry** 1995 Jun;

19(2):217–23. Comment in: Cult Med Psychiatry 1995 Jun;19(2):141–82. Comment in: Cult Med Psychiatry 1995 Jun;19(2):183–205.
Selected works of Hans Jonas available in English. **Hastings Cent Rep** 1995;25(7 Spec No):51
Where have all the primary care physicians gone? A Socratic discourse. Meighan SS. **Health Care Manage Rev** 1995 Summer;20(3):64–7
Twentieth century paradigms that threaten both scientific and humane medicine in the twenty-first century. Feinstein AR. **J Clin Epidemiol** 1996 Jun;49(6):615–7
Medical hubris and the public health: the ethical dimension. McCormick J. **J Clin Epidemiol** 1996 Jun;49(6):619–21
Purpose-straight chiropractic: not science, not health care. Keating JC Jr. **J Manipulative Physiol Ther** 1995 Jul–Aug; 18(6):416–8
Prenatal diagnosis: whose right? Heyd D. **J Med Ethics** 1995 Oct;21(5):292–7
Is disease a natural kind? [see comments] D'Amico R. **J Med Philos** 1995 Oct;20(5):551–69. Comment in: J Med Philos 1995 Oct;20(5):571–84.
Expanding the horizon of reflection on health and disease. Khushf G. **J Med Philos** 1995 Oct;20(5):461–73 (31 ref.)
Health as an objective value. Lennox JG. **J Med Philos** 1995 Oct;20(5):499–511
Health as an analogical concept. Mordacci R. **J Med Philos** 1995 Oct;20(5):475–97 (46 ref.)
Dis-ease about kinds: reply to D'Amico [comment] Reznek L. **J Med Philos** 1995 Oct;20(5):571–84. Comment on: J Med Philos 1995 Oct;20(5):551–69.
A theory of health and disease: the objectivist-subjectivist dichotomy. Sade RM. **J Med Philos** 1995 Oct;20(5):513–25
Human action and God's will: a problem of consistency in Jewish bioethics [see comments] Zohar NJ. **J Med Philos** 1995 Aug;20(4):387–402. Comment in: J Med Philos 1995 Aug;20(4):341–6.
Medicine—more than molecules and money [letter; comment] Hirsch EO. **JAMA** 1995 Nov 22–29;274(20):1587; discussion 1588. Comment on: JAMA 1995 Jul 26;274(4):331–4.
Medicine—more than molecules and money [letter; comment] Theodoropoulos DS. **JAMA** 1995 Nov 22–29;274(20):1588 . Comment on: JAMA 1995 Jul 26;274(4):331–4.
The future of outcomes research may benefit from the evolution of medical critical thinking. Kazandjian VA. **Jt Comm J Qual Improv** 1995 Oct;21(10):553–7
Essentialism and nominalism in medicine: logic of diagnosis in disease terminology. Scadding JG. **Lancet** 1996 Aug 31; 348(9027):594–6
Empowering physicians for the future. Zako LR. **Mich Med** 1995 Nov;94(11):18–23
May the balance be with you. Bell H. **Minn Med** 1995 Dec; 78(12):6–7, 53
Real futility. Historical beginnings and continuing debate about futile treatment. Stell LK. **N C Med J** 1995 Sep; 56(9):432–8
Euthanasia and the good life. Lemmens T. **Perspect Biol Med** 1995 Autumn;39(1):15–27 (25 ref.)
The philosophy of psychopathy. Stein DJ. **Perspect Biol Med** 1996 Summer;39(4):569–80 (26 ref.)
Bioethical concepts of health in medicine. Slabý A. **Sb Lek** 1995;96(3):195–8
Three stages of medical dialogue. Abramovitch H, et al. **Theor Med** 1996 Jun;17(2):175–87
The outlook of the Tekhne Iatrike and the Medical Act to the third millenium. Araya RF. **Theor Med** 1996 Jun; 17(2):163–73 (46 ref.)
Inclusion of psychosocial conditions in clinical practice and the problem of medicalization. Førde R. **Theor Med** 1996 Jun;17(2):151–61
The legitimacy of clinical knowledge: towards a medical epistemology embracing the art of medicine. Malterud K. **Theor Med** 1995 Jun;16(2):183–98
To test or not to test: a clinical dilemma. Resnik DB. **Theor Med** 1995 Jun;16(2):141–52
Doctors for the rural poor. Garg BS, et al. **World Health Forum** 1996;17(3):268–70
[Belle époque? (editorial)] Dunning AJ. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2705–6 **(Dut)**
[Medicine, urgent choices] Kouchner B. **Bull Mem Acad R Med Belg** 1995;150(12):469–79 **(Fre)**
[A structural approach to discourse ethics] Rusche T. **Diskussionsforum Med Ethik** 1994;(3–4):IX–XII (Eng. Abstr.) **(Ger)**
[Singer—and no end in sight? Or: can severely handicapped patients be "persons"?] Grüning J. **Rehabilitation (Stuttg)** 1996 May;35(2):126–8 (Eng. Abstr.) **(Ger)**
[Greatness and hazards of medicine] Nager F. **Schweiz Med Wochenschr** 1996 May 11;126(19):794–800 (Eng. Abstr.) **(Ger)**
[Is there a scientific alternative to alternative medicine?] Adler RH. **Schweiz Rundsch Med Prax** 1995 Dec 19; 84(51–52):1517–21 (Eng. Abstr.) **(Ger)**
[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**
[Praise for the clinic. The contribution of clinical medicine to the philosophy of science] Visioli O. **Ann Ital Med Int** 1996 Jan–Mar;11(1):62–5 **(Ita)**
[The normal and the pathological] Hofmann B. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3800–2 (Eng. Abstr.) **(Nor)**
[Incomprehensible about science and communication (letter)] Karterud S. **Tidsskr Nor Laegeforen** 1995 Nov 10; 115(27):3419 **(Nor)**
[The logical-gnoseologic sources of diagnosis (what was Niccolò Paganini's illness?)] Sharov BK. **Vestn Rentgenol Radiol** 1995 Sep–Oct;(5):42–8 **(Rus)**
[Sacred life. Common sense cannot explain all circumstances] Ringskog S. **Lakartidningen** 1996 Jul 24;93(30–31):2644–6 **(Swe)**

HISTORY

Rosicrucianism, Lutheran orthodoxy, and the rejection of Paracelsianism in early seventeenth-century Denmark. Shackelford J. **Bull Hist Med** 1996 Summer;70(2):181–204
The cosmobiological balance of the emotional and spiritual worlds: phenomenological structuralism in traditional Chinese medical thought. Davis S. **Cult Med Psychiatry** 1996 Mar;20(1):83–123
Rethinking responsibility. Bernstein RJ. **Hastings Cent Rep** 1995;25(7 Spec No):13–20
Appreciating The Phenomenon of Life. Kass LR. **Hastings Cent Rep** 1995;25(7 Spec No):3–12
Petr Skrabanek and the Lancet. Fox R. **J Clin Epidemiol** 1996 Jun;49(6):607–8
A brief history of medicine's war on responsibility. Szasz T. **J Clin Epidemiol** 1996 Jun;49(6):609–13
The neologism omicron nu tau omicron iota in Broussais's condemnation of medical ontology. Bole TJ 3rd. **J Med Philos** 1995 Oct;20(5):543–9
Medicine as metaphor in Plato. Lidz JW. **J Med Philos** 1995 Oct;20(5):527–41
"That puzleing problem": Isaac Newton and the political physiology of self. Iliffe R. **Med Hist** 1995 Oct;39(4):433–58
Sir William Osler's life and humanity. Sharma OP. **Natl Med J India** 1995 Nov–Dec;8(6):279–81
The Mammography Quality Standards Act of 1992. History and philosophy. Houn F, et al. **Radiol Clin North Am** 1995 Nov;33(6):1059–65
Reflections on the principle of life, medical theory and ethics, and the limitations of science. McGirr EM. **Scott Med J** 1994 Oct;39(5):150–1
Specialists without spirit: limitations of the mechanistic biomedical model. Hewa S, et al. **Theor Med** 1995 Jun; 16(2):129–39
[Is the mind in the brain? (letter)] Perret L. **Duodecim** 1994; 110(8):842–3 **(Fin)**
[Effect of major epidemics on cultural awareness] Spitzy KH. **Wien Med Wochenschr** 1995;145(23):627–32 (Eng. Abstr.) **(Ger)**
[Importance of the brain in body-soul discussion from the history of medicine perspective] Benedum J. **Zentralbl Neurochir** 1995;56(4):186–92 (Eng. Abstr.) **(Ger)**

PHILOSOPHY, NURSING

The illusion of strategic planning [editorial] Joel LA. **Am J Nurs** 1996 May;96(5):7
Environmental paradigms: moving toward an ecocentric perspective. Kleffel D. **ANS Adv Nurs Sci** 1996 Jun; 18(4):1–10 (38 ref.)
From Carper's patterns of knowing to ways of being: an ontological philosophical shift in nursing. Silva MC, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):1–13
Humanistic behaviors and primary nursing practice. Smith MJ. **Appl Nurs Res** 1996 Feb;9(1):33–6
Integrating esthetics into nursing: literature as a suggested modality. Mohr WK. **Arch Psychiatr Nurs** 1995 Dec; 9(6):365–72
Dialectical analysis concerning the rational aspect of the art of nursing. Johnson JL. **Image J Nurs Sch** 1996 Summer; 28(2):169–75 (106 ref.)
The proper focus of nursing: a critique of the "caring" ideology. Barker PJ, et al. **Int J Nurs Stud** 1995 Aug; 32(4):386–97 (44 ref.)
A classical view of the theory-practice gap in nursing. Allmark P. **J Adv Nurs** 1995 Jul;22(1):18–23 (23 ref.)
Hermeneutic phenomenology: philosophical perspectives and current use in nursing research. Annells M. **J Adv Nurs** 1996 Apr;23(4):705–13 (52 ref.)
A view from somewhere: the presence and function of religious commitment in nursing practice. Cusveller BS. **J Adv Nurs** 1995 Nov;22(5):973–8 (15 ref.)
A critical reflection on the personal impact of managerial hegemony within nurse education. Gordon NS, et al. **J Adv Nurs** 1996 Mar;23(3):479–86
A sharing in critical thought by nursing faculty. Hendricks-Thomas J, et al. **J Adv Nurs** 1995 Sep; 22(3):594–9 (35 ref.)
Nurse-physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)
The professional paradigm of qualified psychiatric nurses. Lindström UA. **J Adv Nurs** 1995 Oct;22(4):655–62
Intuition and expertise: comments on the Benner debate. Paley J. **J Adv Nurs** 1996 Apr;23(4):665–71 (38 ref.)
Humanism and positivism in nursing: contradictions and conflicts. Playle JF. **J Adv Nurs** 1995 Nov;22(5):979–84 (46 ref.)
Transcultural nursing: a perspective derived from Jean-Paul Sartre. Rajan MF. **J Adv Nurs** 1995 Sep;22(3):450–5 (20 ref.)
Technology and the lifeworld of critical care nursing. Walters AJ. **J Adv Nurs** 1995 Aug;22(2):338–46 (26 ref.)
Reflecting professional values in the philosophy of nursing. Schank MJ, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):55–60
Health promotion and the "ideology of choice". Lowenberg JS. **Public Health Nurs** 1995 Oct;12(5):319–23 (37 ref.)
The contrary ideals of individualism and nursing value of care. Katims I. **Sch Inq Nurs Pract** 1995 Fall;9(3):231–40; discussion 241–4 (30 ref.)

HISTORY

History. Care versus cure—examining the dichotomy through a historical lens. Keeling AW. **J Prof Nurs** 1996 May–Jun;12(3):131

PHIMOSIS

CONGENITAL

[Congenital phimosis] Solov'ev AE, et al. **Klin Khir** 1995; (6):52–3 **(Rus)**

PHYSIOPATHOLOGY

[Minor symptoms in family medicine: smegma and physiological phimosis (letter)] Drenth JJ. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2452–3 **(Dut)**
[Minor symptoms in family medicine; smegma and physiological phimosis] Koning M, et al. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1632–4 **(Dut)**
[Minor symptoms in family medicine: smegma and physiological phimosis (letter)] van der Zee DC, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2452 **(Dut)**

SURGERY

CO2 laser for therapeutic circumcision in adults. Aynaud O, et al. **Eur Urol** 1995;28(1):74–6
[Congenital phimosis] Solov'ev AE, et al. **Klin Khir** 1995; (6):52–3 **(Rus)**

PHLEBITIS

Studies in phlebitis. VII: In vitro and in vivo evaluation of pH-solubilized levemopamil. Myrdal PB, et al. **J Pharm Sci** 1995 Jul;84(7):849–52

COMPLICATIONS

Stroke—a rare presentation of Eales' disease. A case report. Misra UK, et al. **Angiology** 1996 Jan;47(1):73–6
Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328–31 (15 ref.)
Idiopathic colonic phlebitis with massive ascites. Matsunaga I, et al. **Intern Med** 1995 Aug;34(8):776–81

DIAGNOSIS

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

DRUG THERAPY

Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)

EPIDEMIOLOGY

[Incidence of phlebitis in patients with intestinal inflammatory disease undergoing peripheral parenteral nutrition] Romero Roger JA, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):63–5 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Portal pyelophlebitis identified by CT scan in a patient with ischemic bowel. Ghani A, et al. **Am Surg** 1995 Dec; 61(12):1039–40
Drug injection in jugular veins: a new risk factor for vascular diseases in HIV-infected patients? A case report. Maggi P, et al. **Angiology** 1995 Nov;46(11):1049–52
Thrombosis, phlebitis, and varicose veins [editorial] [see comments] Campbell B. **BMJ** 1996 Jan 27;312(7025):198–9 . Comment in: BMJ 1996 May 4;312(7039):1158.
Clinical-anamnestic and instrumental data in outpatients suffering from venous disease. Pinto A, et al. **Int Angiol** 1995 Dec;14(4):400–3
Infusion-related phlebitis. Danchaivijitr S, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S85–90
Infusion phlebitis in medical and surgical patients in Siriraj Hospital. Danchaivijitr S, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S91–4
Necrotizing venulitis and in situ saphenous vein bypass [letter] Cartier R, et al. **J Vasc Surg** 1996 Jul;24(1):179–81

PATHOLOGY

[Thrombosis and phlebitis of superficial veins. Differential histopathologic diagnosis] Leu HJ. **Pathologe** 1995 Nov; 16(6):386–90 (9 ref.) (Eng. Abstr.) **(Ger)**

PHLEBITIS

RADIONUCLIDE IMAGING

The detection of occult phlebitis with Tc-99m stannous fluoride colloid labeled white blood cell scintigraphy. Chan KW, et al. **Clin Nucl Med** 1995 Jul;20(7):645-6

PHLEBOGRAPHY

Iobitridol 250 vs iohexol 240 in phlebography of th lower limbs. A double-blind clinical trial. Chagnaud C, et al. **Acta Radiol Suppl** 1996;400:89-91

Prospective study of safety of lower extremity phlebography with nonionic contrast medium. AbuRahma AF, et al. **Am J Surg** 1996 Feb;171(2):255-60

Follow-up of patients with suspected venous thrombosis but negative radionuclide venography. Murphy JJ, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):232-4

Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Balestreri L, et al. **Eur J Radiol** 1995 Jul;20(2):108-11

Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis. Lausen I, et al. **Eur J Radiol** 1995 Sep;20(3):200-4

Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas. Mamelak AN, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):475-81

[Follow-up phlebography after the conservative treatment of a deep venous thrombosis of the leg?] Kriessmann A. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):148-9 **(Ger)**

[Diagnosis of floating venous thrombi by spiral CT phlebography] Gartenschläger M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):376-81 (Eng. Abstr.) **(Ger)**

ECONOMICS

Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Hull RD, et al. **Thromb Haemost** 1995 Jul;74(1):189-96

METHODS

Iodixanol in leg phlebography: a randomized, double-blind parallel group phase III trial comparing iodixanol to ioxaglate. Sapoval MR, et al. **Clin Radiol** 1996 Mar; 51(3):210-3

[Phlebography with MR in the study of deep venous thrombosis] Catalano C, et al. **Radiol Med (Torino)** 1995 Jul-Aug;90(1-2):38-43 (Eng. Abstr.) **(Ita)**

[MR venography using 3D-fast STIR sequence for lower extremities] Ohkawa S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):774-5 (Eng. Abstr.) **(Jpn)**

[Venography and percutaneous embolization of the spermatic vein with spring coil as treatment of the varicocele in childhood] Rivilla Parra F, et al. **Cir Pediatr** 1995 Jul; 8(3):123-7 (Eng. Abstr.) **(Spa)**

PHLEBOTOMUS

Experimental infection and transmission of Leishmania major by laboratory-reared Phlebotomus bergeroti parrot. Hanafi HA, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):644-6

Insecticide susceptibility of Phlebotomus papatasi to organochlorine, organophosphate & carbamate compounds in some arid areas of western Rajasthan. Singh KV, et al. **Indian J Med Res** 1996 Feb;103:91-3

Phlebotomine sand fly (Diptera: Psychodidae) control using a residual pyrethroid insecticide. Robert LL, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):195-9

Susceptibility status of Phlebotomus papatasi and Sergentomyia punjabaensis (Diptera:Psychodidae) to some insecticides in district Bikaner (Rajasthan). Bansal SK, et al. **J Commun Dis** 1996 Mar;28(1):28-32

Observation on host preference of Phlebotomus argentipes in district South-24-Parganas, West Bengal, India. Basak B, et al. **J Commun Dis** 1995 Jun;27(2):122-3

The seasonal and daily activities of Phlebotomus papatasi in Riyadh, Saudi Arabia. Morsy TA, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):699-711

Species composition of sand flies and population dynamics of Phlebotomus papatasi (Diptera: Psychodidae) in the southern Jordan Valley, an endemic focus of cutaneous leishmaniasis. Janini R, et al. **J Med Entomol** 1995 Nov; 32(6):822-6

Effect of minor engineering intervention in the control of breeding of Phlebotomus papatasi (Scopoli) sandflies. Dhiman RC. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):368-70

[Studies on the deltamethrin-medicated bath of domestic dogs for interrupting visceral leishmaniasis transmission] Xiong G, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):178-81 (Eng. Abstr.) **(Chi)**

[Survey of Phlebotomus neglectus Tonnoir, 1921 (=P. major s.l.) in a leishmaniasis focus in northern Italy (province of Verona)] Maroli M, et al. **Parassitologia** 1995 Dec; 37(2-3):241-4 (Eng. Abstr.) **(Ita)**

[Preliminary results of a project about the ecology of phlebotomus vectors of cutaneous leishmaniasis in the state of Bahia] Sherlock IA, et al. **Rev Soc Bras Med Trop** 1996 Mar-Apr;29(2):207-14 (Eng. Abstr.) **(Por)**

[Phlebotomus fauna (Diptera: Psychodidae) of 3 provinces of the northeastern region of Marañon, Peru] Cáceres AG, et al. **Rev Soc Bras Med Trop** 1995 Jul-Sep;28(3):215-21 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Morphological studies on Phlebotomus papatasi (Scopoli) in Riyadh City, Saudi Arabia. Abou el-Ela RG, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):631-48

DRUG EFFECTS

DDT resistance in P. Papatasi in Bihar. Das Gupta RK, et al. **J Commun Dis** 1995 Jun;27(2):124

GENETICS

Evolution of multiple families of non-LTR retrotransposons in phlebotomine sandflies. Booth DR, et al. **Genet Res** 1996 Jun;67(3):227-37

GROWTH & DEVELOPMENT

Use of weather data and remote sensing to predict the geographic and seasonal distribution of Phlebotomus papatasi in southwest Asia. Cross ER, et al. **Am J Trop Med Hyg** 1996 May;54(5):530-6

IMMUNOLOGY

The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on the fecundity and mortality of Phlebotomus duboscqi (Diptera: Psychodidae). Ingonga P, et al. **Acta Trop** 1996 Feb; 60(4):269-79

Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebotomus duboscqi gut antigens. Mbati PA, et al. **East Afr Med J** 1995 Aug;72(8):519-22

PARASITOLOGY

Is Phlebotomus (Larroussius) orientalis a vector of visceral leishmaniasis in south-west Ethiopia? Hailu A, et al. **Acta Trop** 1995 Sep;60(1):15-20

Leishmania major MON-26 isolated from naturally infected Phlebotomus papatasi (Diptera: Psychodidae) in Isfahan Province, Iran. Yaghoobi-Ershadi MR, et al. **Acta Trop** 1995 Aug;59(4):279-82

Phlebotomine sandflies (Diptera:, Psychodidae): their importance and some aspects of control. Mutinga MJ. **East Afr Med J** 1996 Jan;73(1):48-9 (9 ref.)

Deficiency in beta1,3-galactosyltransferase of a Leishmania major lipophosphoglycan mutant adversely influences the Leishmania-sand fly interaction. Butcher BA, et al. **J Biol Chem** 1996 Aug 23;271(34):20573-9

Changes in lipophosphoglycan and gene expression associated with the development of Leishmania major in Phlebotomus papatasi. Saraiva EM, et al. **Parasitology** 1995 Sep;111 (Pt 3):275-87

Presumed vectors of leishmaniasis in the principality of Monaco. Izri MA, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):114

[Evidence for the transmission of the causative agent of visceral leishmaniasis by the sandfly Phlebotomus (Adlerius) turanicus Artemiev, 1974 in Turkmenistan] Lesnikova EV, et al. **Med Parazitol (Mosk)** 1995 Jul-Sep; (3):24-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Response of gravid Phlebotmus papatasi females to an oviposition attractant/stimulant associated with conspecific eggs. Srinivasan R, et al. **Indian J Exp Biol** 1995 Oct; 33(10):757-60

Assessment of plant tissue feeding by sand flies (Diptera: Psychodidae) and mosquitoes (Diptera: Culicidae). Schlein Y, et al. **J Med Entomol** 1995 Nov;32(6):882-7

PHLEBOTOMUS FEVER

COMPLICATIONS

[Neurological symptoms after an infection by the sandfly fever virus] Pauli C, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1468-72 (22 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Sandfly fever viruses in Italy. Nicoletti L, et al. **Arch Virol Suppl** 1996;11:41-7 (42 ref.)

Prevalence of sand fly fever, West Nile, Crimean-Congo hemorrhagic fever, and leptospirosis antibodies in Pakistani military personnel. Bryan JP, et al. **Mil Med** 1996 Mar; 161(3):149-53

ETIOLOGY

Aseptic meningitis caused by sandfly fever virus, serotype Toscana. Schwarz TF, et al. **Clin Infect Dis** 1995 Sep; 21(3):669-71

TRANSMISSION

Travel-related vector-borne virus infections in Germany. Schwarz TF, et al. **Arch Virol Suppl** 1996;11:57-65

[Meningitis after travel in the Mediterranean region, caused by the sandfly fever virus] Schwarz TF, et al. **Nervenarzt** 1995 Oct;66(10):789-91 (Eng. Abstr.) **(Ger)**

VIROLOGY

Nested RT-PCR for detection of sandfly fever virus, serotype Toscana, in clinical specimens, with confirmation by nucleotide sequence analysis. Schwarz TF, et al. **Res Virol** 1995 Sep-Oct;146(5):355-62

PHLEBOTOMUS FEVER VIRUS see SANDFLY FEVER GROUP VIRUSES

PHLEBOTOMY

see related

BLOODLETTING

Evaluation of bedside blood glucose monitoring by the phlebotomy team in an acute general care hospital [see comments] Johnston JM, et al. **Acta Diabetol** 1995 Dec; 32(4):213-6. Comment in: Acta Diabetol 1995 Dec;32(4):211-2.

Review: selective filtration--a phlebotomy strategy for sickle cell therapy. Nusbaum NJ. **Am J Med Sci** 1995 Dec; 310(6):264-6 (12 ref.)

Is lidocaine-prilocaine cream (EMLA) always useful for venous puncture in preoperative autologous blood donation? Vivien B, et al. **Can J Anaesth** 1996 Mar; 43(3):232-7

Human recombinant erythropoietin and phlebotomy in the treatment of iron overload in uremic patients. Chen KS, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):248-53

Vibrio fluvialis wound infection associated with medicinal leech therapy. Varghese MR, et al. **Clin Infect Dis** 1996 Apr;22(4):709-10

Increased erythropoietin response to venesection in erythrocytosic renal transplant patients. Oymak O, et al. **Int Urol Nephrol** 1995;27(2):223-7

EMLA and venepuncture [letter; comment] Nott MR, et al. **J R Soc Med** 1995 Nov;88(11):664. Comment on: J R Soc Med 1995 May;88(5):264-7.

Confirmation of the safety of autologous blood donation by patients awaiting heart or lung transplantation. A controlled study using hemodynamic monitoring. Klapper E, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1594-9

New approach to subclavian venipuncture [letter] Magney JE, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):877

[Monthly question: how should porphyria cutanea tarda be treated?] Lacour JP. **Ann Dermatol Venereol** 1996; 123(4):292-4 **(Fre)**

ADVERSE EFFECTS

Topical ibuprofen for skin analgesia prior to venepuncture. Smith AJ, et al. **Anaesthesia** 1996 May;51(5):495-7

Keloid at the venipuncture site [letter] Yadav TP, et al. **Indian Pediatr** 1995 Nov;32(11):1243-4

Pain responses of hospitalized infants and children to venipuncture and intravenous cannulation. Van Cleve L, et al. **J Pediatr Nurs** 1996 Jun;11(3):161-8

Evaluation of a new topical anesthetic agent: a pilot study. Lander J, et al. **Nurs Res** 1996 Jan-Feb;45(1):50-3

Venepuncture: the medicolegal hazards. McConnell AA, et al. **Postgrad Med J** 1996 Jan;72(843):23-4

Blood donation-related neurologic needle injury: evaluation of 2 years' worth of data from a large blood center. Newman BH, et al. **Transfusion** 1996 Mar;36(3):213-5

[Efficacy of the EMLA cream in the reduction of pain caused by venipuncture in children premedicated with oral midazolam] Cassinello F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):360-3 (Eng. Abstr.) **(Spa)**

METHODS

Applied physiology for the frustrated phlebotomist [letter] Baruch A, et al. **Am J Med** 1996 Jan;100(1):121

Dilating peripheral veins [letter] Robbins PM. **Anaesth Intensive Care** 1995 Oct;23(5):654-5

Practice tip. Dilating veins. Murtagh J. **Aust Fam Physician** 1995 Sep;24(9):1699

Contamination of blood cultures by switch-needle and nonswitch-needle techniques in a paediatric ward. Pitaksiripan S, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S81-4

[A method for the puncture of the insufficiently developed and poorly delineated subcutaneous veins of the forearm] Popov SD, et al. **Vestn Khir Im I I Grek** 1992 Feb; 148(2):182-3 **(Rus)**

PSYCHOLOGY

Pain in infancy: individual differences. Axia G, et al. **Percept Mot Skills** 1995 Aug;81(1):142

STANDARDS

Prothrombin time: one tube or two. Yawn BP, et al. **Am J Clin Pathol** 1996 Jun;105(6):794-7

Guidelines of the National Heart, Lung, and Blood Institute Working Group on Blood Drawing, Processing, and Storage for Genetic Studies. Austin MA, et al. **Am J Epidemiol** 1996 Sep 1;144(5):437-41

VETERINARY

The response of various hematologic parameters in the young bovine subjected to multiple phlebotomies. Harper SB, et al. **ASAIO J** 1994 Jul-Sep;40(3):M816-25 (128 ref.)

PHLEGMASIA ALBA DOLENS see **THROMBOPHLEBITIS**

PHLEGMON see **CELLULITIS**

PHLEOMYCINS

Generation of small fusion genes carrying phleomycin resistance and Drosophila alcohol dehydrogenase reporter properties: their application in retroviral vectors. Gautier R, et al. **Exp Cell Res** 1996 May 1;224(2):291-301

Stable DNA transformation of Toxoplasma gondii using phleomycin selection. Messina M, et al. **Gene** 1995 Nov 20;165(2):213-7

PHARMACOLOGY

A mutant approach and molecular strategy to study fungal cell walls. Pramanik A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S73-81

Complementation of a Toxoplasma gondii ROP1 knock-out mutant using phleomycin selection. Soldati D, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):87-97

The bacterial phleomycin resistance gene ble as a dominant selectable marker in Chlamydomonas. Stevens DR, et al. **Mol Gen Genet** 1996 Apr 24;251(1):23-30

PHLORETIN-GLUCOSIDASE see **GLYCOSYLCERAMIDASE**

PHLORHIZIN

CHEMICAL SYNTHESIS

Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Tsujihara K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun; 44(6):1174-80

PHARMACOLOGY

Phlorizin or vanadate treatment reverses impaired expression of albumin and hepatocyte nuclear factor 1 in diabetic rats. Barrera-Hernandez G, et al. **Diabetes** 1996 Sep; 45(9):1217-22

Effect of proximal tubular glucose transport blockade on urinary enzyme excretions in hyperglycemic rats. Ishii N, et al. **Enzyme Protein** 1994-95;48(5-6):243-50

PHLORIZIN HYDROLASE see **GLYCOSYLCERAMIDASE**

PHLOROGLUCINOL

ANALOGS & DERIVATIVES

Anti-tumor promoting activity of Dryopteris phlorophenone derivatives. Kapadia GJ, et al. **Cancer Lett** 1996 Aug 2; 105(2):161-5

PHOBIA, SCHOOL see **PHOBIC DISORDERS**

PHOBIA, SOCIAL see **PHOBIC DISORDERS**

PHOBIAS see **PHOBIC DISORDERS**

PHOBIC DISORDERS

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1-2):30-3 (27 ref.)

On the road to recovery for emotional harm. Is the fear of AIDS a legally compensable injury? Bollinger RC. **J Leg Med** 1995 Sep;16(3):417-45

How shy is too shy? Stein MB. **Lancet** 1996 Apr 27; 347(9009):1131-2

Blood-injury-injection fears in medical practice [letter] Page AC. **Med J Aust** 1996 Feb 5;164(3):189

Phobic postural vertigo. Brandt T. **Neurology** 1996 Jun; 46(6):1515-9 (31 ref.)

[Social phobias: outlines of a new disease] **Fortschr Med Suppl** 1996;171:1-12 **(Ger)**

[Comments from the conference "Understanding social phobia". Oslo, September 15-16, 1995] Rybakowski J. **Psychiatr Pol** 1996 Jan-Feb;30(1):171 **(Pol)**

DIAGNOSIS

Social phobia in adults with stuttering. Stein MB, et al. **Am J Psychiatry** 1996 Feb;153(2):278-80

Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification. Stein MB, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):169-74

Gender and age differences in the prevalence of specific fears and phobias. Fredrikson M, et al. **Behav Res Ther** 1996 Jan;34(1):33-9

Social sensitivity: a shared feature of all phobias. Stravynski A, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):343-51

Confirmatory factor analysis of the Fear Questionnaire with social phobia patients. Cox BJ, et al. **Br J Psychiatry** 1996 Apr;168(4):497-9

Phobic and anxiety conditions--diagnosis and therapy. Vlahova-Nikolova V, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):84

Cognitive biases in generalized social phobia. Foa EB, et al. **J Abnorm Psychol** 1996 Aug;105(3):433-9

Disgust and spider phobia. Mulkens SA, et al. **J Abnorm Psychol** 1996 Aug;105(3):464-8

AIDS phobia [letter] Sood AK, et al. **J Assoc Physicians India** 1996 Jan;44(1):70-1

Personality traits in social phobia, I: Comparisons with healthy controls. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):560-8

Feared stimuli are expected in specific situations: the use of situationalism and fear expectancy in a self-report measurement of fears. Bixler RD, et al. **J Clin Psychol** 1995 Jul;51(4):544-7

Lay beliefs about phobia. Furnham A. **J Clin Psychol** 1995 Jul;51(4):518-25

Measurement and correlates of internalized homophobia: a factor analytic study. Ross MW, et al. **J Clin Psychol** 1996 Jan;52(1):15-21

Perspectives on needle phobia [letter; comment] McSherry J. **J Fam Pract** 1995 Nov;41(5):437, 512. Comment on: J Fam Pract 1995 Aug;41(2):169-75.

[Diagnosis of Taijin-Kyofu and social phobia] Kasahara T. **Seishin Shinkeigaku Zasshi** 1995;97(5):357-66 (47 ref.) **(Jpn)**

DRUG THERAPY

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Fahlén T, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):351-8

Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Miner CM, et al. **Biol Psychiatry** 1995 Nov 15;38(10):696-8

Personality traits in social phobia, II: Changes during drug treatment. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):569-73

Sertraline in social phobia [letter] Czepowicz VD, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):372-3

[Citalopram in the treatment of panic disorders and school phobia in children and adolescents] Lepola U, et al. **Duodecim** 1994;110(1):60-2 **(Fin)**

EPIDEMIOLOGY

Food and general neophobia in Swedish families: parent-child comparisons and relationships with serving specific foods. Koivisto UK, et al. **Appetite** 1996 Apr; 26(2):107-18

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Magee WJ, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):159-68

Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification. Stein MB, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):169-74

Frequency of phobic disorder in a community sample of young adolescents. Milne JM, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1202-11

ETIOLOGY

Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia. Sosis MB, et al. **J Clin Anesth** 1995 Aug;7(5):389-94

GENETICS

Autism, affective disorders, and social phobia. Smalley SL, et al. **Am J Med Genet** 1995 Feb 27;60(1):19-26

A twin-family study of self-report symptoms of panic-phobia and somatization. Kendler KS, et al. **Behav Genet** 1995 Nov;25(6):499-515

PHYSIOPATHOLOGY

Social phobia: everyone's disorder? Jefferson JW. **J Clin Psychiatry** 1996;57 Suppl 6:28-32 (28 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681-725 (152 ref.)

PSYCHOLOGY

Appearance, body image and distress in facial dysmorphophobia. Thomas CS, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):231-6

Effects of a model on food neophobia in humans. Hobden K, et al. **Appetite** 1995 Oct;25(2):101-13

Aetiology of spider phobia: classificatory differences between two origins instruments. Kirkby KC, et al. **Behav Res Ther** 1995 Nov;33(8):955-8

Social sensitivity: a shared feature of all phobias. Stravynski A, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):343-51

AIDS phobia--a case report. Latha KS. **Indian J Public Health** 1995 Jan-Mar;39(1):27-8

Is homophobia associated with homosexual arousal? Adams HE, et al. **J Abnorm Psychol** 1996 Aug;105(3):440-5

Effects of focus of attention on anxiety levels and social performance of individuals with social phobia. Woody SR. **J Abnorm Psychol** 1996 Feb;105(1):61-9

Case study: body dysmorphic disorder in adolescents. Phillips KA, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1216-20

Internalized homophobia in lesbian relationships. Downey JI, et al. **J Am Acad Psychoanal** 1995 Fall;23(3):435-47

Internalized homophobia and the negative therapeutic reaction. Friedman RC, et al. **J Am Acad Psychoanal** 1995 Spring;23(1):99-113

Perspectives on needle phobia [letter; comment] Daniels AJ. **J Fam Pract** 1995 Nov;41(5):437; discussion 512. Comment on: J Fam Pract 1995 Aug;41(2):169-75.

Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects. Cohen LJ, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):82-5

Social phobia and PTSD in Vietnam veterans. Orsillo SM, et al. **J Trauma Stress** 1996 Apr;9(2):235-52

Social fears in hypochondriasis. Schwenzer M. **Psychol Rep** 1996 Jun;78(3 Pt 1):971-5

[Social phobia] Oosterbaan DB, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2649-52 **(Dut)**

[Dysmorphophobia--a disorder of modern times?] Washeim HA, et al. **Fortschr Med** 1995 Sep 10;113(25):349-50 **(Ger)**

[Interactive production of resistance] Streeck U. **Z Psychosom Med Psychoanal** 1995;41(3):241-52 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

A brain single photon-emission computed tomography (SPECT) study of generalized social phobia. Stein MB, et al. **Biol Psychiatry** 1996 May 1;39(9):825-8

THERAPY

Flying therapy for flying phobia. McCarthy GW, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1179-84

Treatment of fear of blushing, sweating, or trembling. Results at long-term follow-up. Scholing A, et al. **Behav Modif** 1996 Jul;20(3):338-56

Prediction of outcome in the treatment of specific phobia. A cross validation study. Hellström K, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):403-11

One versus five sessions of applied tension in the treatment of blood phobia. Hellström K, et al. **Behav Res Ther** 1996 Feb;34(2):101-12

One-session therapist directed exposure vs two forms of manual directed self-exposure in the treatment of spider phobia. Hellström K, et al. **Behav Res Ther** 1995 Nov; 33(8):959-65

Homework compliance, perceptions of control, and outcome of cognitive-behavioral treatment of social phobia. Leung AW, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):423-32

Change in danger cognitions in agoraphobia and social phobia during treatment. Poulton RG, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):413-21

Virtual reality exposure therapy in the treatment of fear of flying: a case report. Rothbaum BO, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):477-81

Treatment of generalized social phobia: results at long-term follow-up. Scholing A, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):447-52

Coping strategies and phobias: the relationship between fears, phobias and methods of coping with stressors. Davey GC, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):423-34

Individual response patterns and treatment matching in the phobic disorders: a review. Menzies RG. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):1-10 (36 ref.)

Does rational role-play enhance the outcome of exposure therapy in dysmorphophobia? A case study. Cromarty P, et al. **Br J Psychiatry** 1995 Sep;167(3):399-402

The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years. O'Rourke D, et al. **Br J Psychiatry** 1996 Apr; 168(4):462-9

Phobic and anxiety conditions--diagnosis and therapy. Vlahova-Nikolova V, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):84

Eye movement desensitization of medical phobias: two case studies. Lohr JM, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):141-51

Computerized exposure and in vivo exposure treatments of spider fear in children: two case reports. Nelissen I, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):153-6

Cognitive-behavioral treatment of body dysmorphic disorder: a case report. Schmidt NB, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):161-7

Exposure therapy in the treatment of vaginal penetration phobia: a single-case evaluation. Vonk ME, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):359-63

Cognitive-behavioral group treatment for social phobia in adolescents. A preliminary study. Albano AM, et al. **J Nerv Ment Dis** 1995 Oct;183(10):649-56

Walkfree [letter] Cohen D, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):245

Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies. Juster HR, et al. **Prog Behav Modif** 1996;30:74-98 (90 ref.)

Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment. Juster HR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):821-42 (77 ref.)

Enactment and play following medical trauma. An analytic case study. Goldberger M. **Psychoanal Study Child** 1995; 50:252–71

Defence style and behaviour therapy outcome in a specific phobia. Muris P, et al. **Psychol Med** 1996 May;26(3):635–9

[Spider-phobia is treatable. Therapy changes cerebral activation patterns] Johanson A, et al. **Lakartidningen** 1996 Aug 28;93(34):2831–5 **(Swe)**

PHOBIC NEUROSES see **PHOBIC DISORDERS**

PHOBOS see **MARS**

PHOCINE DISTEMPER VIRUS see **DISTEMPER VIRUS, PHOCINE**

PHOCOMELIA see **ECTROMELIA**

PHODOPUS

GENETICS

Albino and pink-eyed dilution mutants in the Russian dwarf hamster Phodopus campbelli. Robinson R. **J Hered** 1996 Mar-Apr;87(2):155–6

GROWTH & DEVELOPMENT

Effects of photoperiod on testicular inhibin-alpha and androgen binding protein mRNA expression during postnatal development in Siberian hamsters, Phodopus sungorus. Rao JN, et al. **Life Sci** 1995;57(19):1761–70

PARASITOLOGY

[The first finding of a spontaneous gastric cryptosporidiosis infection in hamsters (Phodopus roborovskii Satunin, 1903)] Pavlásek I, et al. **Vet Med (Praha)** 1995 Aug;40(8):261–3 (Eng. Abstr.) **(Cze)**

PHYSIOLOGY

Control of secretory lipid droplets in the harderian gland by testosterone and the photoperiod: comparison of two species of hamsters. Buzzell GR, et al.
Gen Comp Endocrinol 1995 Aug;99(2):230–8

A short red light pulse during dark phase of LD-cycle perturbs the hamster's circadian clock. Klante G, et al. **J Comp Physiol [A]** 1995 Dec;177(6):775–80

PHODOPUS CAMPBELLI see **PHODOPUS**

PHODOPUS SUNGORUS see **PHODOPUS**

PHODOPUS SUNGORUS CAMPBELLI see **PHODOPUS**

PHOEBE see **SATURN**

PHONATION

Quantitative videostroboscopic measurement of glottal gap and vocal function: an analysis of thyroplasty type I. Omori K, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):280–5

Fo-perturbation and Fo/loudness dynamics in voices of normal children, with and without education in singing. Dejonckere PH, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):107–15

Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. Dromey C, et al. **J Speech Hear Res** 1995 Aug;38(4):751–64

Variations across time in acoustic and electroglottographic measures of phonatory function in women with and without vocal nodules. Hall KD. **J Speech Hear Res** 1995 Aug; 38(4):783–93

[Phonetic results after surgery of laryngotracheal stenoses in children] Pech C, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(5):199–204 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Variation in fold vibration during voiced obstruents in Russian. Barry SM. **Eur J Disord Commun** 1995; 30(2):124–31

Vocal load as measured by the voice accumulator. Buekers R, et al. **Folia Phoniatr Logop** 1995;47(5):252–61

Neural control of vocalization: respiratory and emotional influences. Davis PJ, et al. **J Voice** 1996 Mar;10(1):23–38 (107 ref.)

Objective measures of voice production in patients complaining of laryngeal fatigue. Eustace CS, et al.
J Voice 1996 Jun;10(2):146–54

Respiratory function during speaking and singing in professional country singers. Hoit JD, et al. **J Voice** 1996 Mar;10(1):39–49

Measures of vocal function during changes in vocal effort level. Huang DZ, et al. **J Voice** 1995 Dec;9(4):429–38

A physiological and acoustic study on voiced bilabial fricative/beta:/as a vocal exercise. Laukkanen AM, et al. **J Voice** 1996 Mar;10(1):67–77

Differences in voice quality between men and women: use of the long-term average spectrum (LTAS). Mendoza E, et al. **J Voice** 1996 Mar;10(1):59–66

External laryngeal frame function in voice production revisited: a review. Vilkman E, et al. **J Voice** 1996 Mar; 10(1):78–92 (90 ref.)

Early otitis media and phonological development at age 2 years. Abraham SS, et al. **Laryngoscope** 1996 Jun; 106(6):727–32

Characteristics of an in vivo canine model of phonation with a constant air pressure source. Nasri S, et al.
Laryngoscope 1996 Jun;106(6):745–51

Mechanical perturbation of jaw movements during speech: effects on articulation and phonation. Bauer A, et al.
Percept Mot Skills 1995 Jun;80(3 Pt 2):1108–12

PHONATION DISORDERS see **VOICE DISORDERS**

PHONETICS

Heredity and environment in phoneme articulation: hereditary and environmental contributions to articulation proficiency. Dixon WE Jr, et al.
Acta Genet Med Gemellol (Roma) 1995;44(2):63–73

Continuous versus discrete information processing in pattern recognition. Massaro DW, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):193–209

Consonant perception by users of Nucleus and Clarion multichannel cochlear implants. Doyle KJ, et al.
Am J Otol 1995 Sep;16(5):676–81

Alterations in functional neuroanatomical connectivity in Alzheimer's disease. Positron emission tomography of auditory verbal short-term memory. Becker JT, et al.
Ann N Y Acad Sci 1996 Jan 17;777:239–42

Diadochokinetic rate in persons with traumatic brain injury. Blumberger J, et al. **Brain Inj** 1995 Nov-Dec;9(8):797–804

Phonological and lexical coding in verbal short-term memory and learning. Trojano L, et al. **Brain Lang** 1995 Nov;51(2):336–54

Predominance and improvement of velopharyngeal function in patients without complete closure in blowing [letter; comment] Yamaoka M, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):353. Comment on: Cleft Palate Craniofac J 1994 Jul;31(4):271–9.

The role of the output phonological buffer in the control of speech timing: a single case study. Cohen L, et al.
Cortex 1995 Sep;31(3):469–86

Consonant harmony as a compensatory mechanism in fluent aphasic speech. Kohn SE, et al. **Cortex** 1995 Dec; 31(4):747–56

The effect of multichannel compression on vowel and stop-consonant discrimination in normal-hearing and hearing-impaired subjects. Crain TR, et al. **Ear Hear** 1995 Oct;16(5):529–43

The transmission of phoneme-level information by multichannel tactile speech perception aids. Weisenberger JM, et al. **Ear Hear** 1995 Aug;16(4):392–406

Temporal and spectral cue use for initial plosive voicing perception by hearing-impaired children and normal-hearing children and adults. Holden-Pitt LD, et al. **Eur J Disord Commun** 1995;30(4):417–34

Comparison of direct and indirect calculations of laryngeal airway resistance in various voicing conditions. McHenry M, et al. **Eur J Disord Commun** 1995;30(4):435–49

Results of systematic speech sound monitoring in children with cleft palate. Ainoda N, et al. **Folia Phoniatr Logop** 1996;48(2):86–91

Intelligibility and spectral differences in high-pitched vowels. Maurer D, et al. **Folia Phoniatr Logop** 1996;48(1):1–10

Event-related brain potentials elicited by rhyming and non-rhyming pictures differentiate subgroups of reading disabled adolescents. McPherson WB, et al.
Integr Physiol Behav Sci 1996 Jan-Mar;31(1):3–17

Modeling the perception of concurrent vowels: Role of formant transitions. Assmann PF. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1141–52

Acoustic characteristics of less-masculine-sounding male speech. Avery JD, et al. **J Acoust Soc Am** 1996 Jun; 99(6):3738–48

Consonant recognition for spectrally degraded speech as a function of consonant-vowel intensity ratio. Balakrishnan U, et al. **J Acoust Soc Am** 1996 Jun;99(6):3758–69

Perception of the place of articulation of French stop bursts. Bonneau A, et al. **J Acoust Soc Am** 1996 Jul;100(1):555–64

Acoustic parameters of nasalized vowels in hearing-impaired and normal-hearing speakers. Chen MY.
J Acoust Soc Am 1995 Nov;98(5 Pt 1):2443–53

Rate representation and discriminability of second formant frequencies for /epsilon/-like steady-state vowels in cat auditory nerve. Conley RA, et al. **J Acoust Soc Am** 1995 Dec;98(6):3223–34

Phonemic restoration and integration during dichotic listening. Eimas PD, et al. **J Acoust Soc Am** 1996 Feb; 99(2):1141–7

Some acoustic features of nasal and nasalized vowels: a target for vowel nasalization. Feng G, et al. **J Acoust Soc Am** 1996 Jun;99(6):3694–706

Lexical familiarity and English-language experience affect Japanese adults' perception of / / and /l/. Flege JE, et al. **J Acoust Soc Am** 1996 Feb;99(2):1161–73

On the externalization of sound images. Hartmann WM, et al. **J Acoust Soc Am** 1996 Jun;99(6):3678–88

Effect of relative and overall amplitude on perception of voiceless stop consonants by listeners with normal and impaired hearing. Hedrick MS, et al. **J Acoust Soc Am** 1995 Sep;98(3):1292–303

Vowel discrimination in cats: acquisition, effects of stimulus level, and performance in noise. Hienz RD, et al.
J Acoust Soc Am 1996 Jun;99(6):3656–68

Vowel discrimination in cats: thresholds for the detection of second formant changes in the vowel /epsilon/. Hienz RD, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1052–8

Influences of phonetic identification and category goodness on American listeners' perception of /r/ and /l/. Iverson P, et al. **J Acoust Soc Am** 1996 Feb;99(2):1130–40

Vowel-onset detection by vowel-strength measurement, cochlear-nucleus simulation, and multilayer perceptrons. Kortekaas RW, et al. **J Acoust Soc Am** 1996 Feb; 99(2):1185–99

Phonemic resetting versus postural adjustments in the speech of cochlear implant users: an exploration of voice-onset time. Lane H, et al. **J Acoust Soc Am** 1995 Dec; 98(6):3096–106

The time course of auditory segregation: concurrent vowels that vary in duration. McKeown JD, et al.
J Acoust Soc Am 1995 Oct;98(4):1866–77

Two cross-linguistic factors underlying tongue shapes for vowels. Nix DA, et al. **J Acoust Soc Am** 1996 Jun; 99(6):3707–17

Cross-language identification of consonants. Part 1. Korean perception of English. Schmidt AM. **J Acoust Soc Am** 1996 May;99(5):3201–11

Modeling formant frequency discrimination of female vowels. Sommers MS, et al. **J Acoust Soc Am** 1996 Jun; 99(6):3770–81

Three-dimensional tongue surface shapes of English consonants and vowels. Stone M, et al.
J Acoust Soc Am 1996 Jun;99(6):3728–37

Some effects of filtered contexts on the perception of vowels and fricatives. Watkins AJ, et al. **J Acoust Soc Am** 1996 Jan;99(1):588–94

Identification performance by right- and left-handed listeners on dichotic CV materials. Wilson RH, et al.
J Am Acad Audiol 1996 Jan;7(1):1–6

The development of phonological rules and visual strategies in average and poor spellers. Lennox C, et al.
J Exp Child Psychol 1996 Jun;62(1):60–83

Kindergarten letter knowledge, phonological skills, and memory processes: relative effects on early literacy. Näslund JC, et al. **J Exp Child Psychol** 1996 Jun;62(1):30–59

Children's sensitivity to syllables, onsets, rimes, and phonemes. Treiman R, et al. **J Exp Child Psychol** 1996 Apr;61(3):193–215

Children's sensitivity to syllables, onsets, rimes, and phonemes. Treiman R, et al. **J Exp Child Psychol** 1996 Aug;62(3):193–215

Lexical effects on phonetic categorization: the role of stimulus naturalness and stimulus quality. Burton MW, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):1230–5

Reliability of prosodic cues for resolving syntactic ambiguity. Allbritton DW, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):714–35

Pseudohomophone effects and models of word recognition. Seidenberg MS, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jan;22(1):48–62

Errors in short-term memory for speech: a developmental study. Treiman R. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1197–208

A finite element model of the human face. Stress distribution around the chin due to articulation of the five vowels in Japanese. Motoyoshi M, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):11–20

A phonologically based analysis of misspellings by third graders with disordered-phonology histories. Clarke-Klein S, et al. **J Speech Hear Res** 1995 Aug;38(4):839–49

Some spectral correlates of pathological breathy and rough voice quality for different types of vowel fragments. de Krom G. **J Speech Hear Res** 1995 Aug;38(4):794–811

Activation of lip motor units with variations in speech rate and phonetic structure. McClean MD, et al.
J Speech Hear Res 1995 Aug;38(4):772–82

How children learn to organize their speech gestures: further evidence from fricative-vowel syllables. Nittrouer S, et al. **J Speech Hear Res** 1996 Apr;39(2):379–89

Traditional and phonological treatment for teaching English fricatives and affricates to Koreans. Schmidt AM, et al. **J Speech Hear Res** 1995 Aug;38(4):828–38

Consonant-vowel interdependencies in babbling and early words: preliminary examination of a locus equation approach. Sussman HM, et al. **J Speech Hear Res** 1996 Apr;39(2):424–33

The influence of speaking rate on vowel space and speech intelligibility for individuals with amyotrophic lateral sclerosis. Turner GS, et al. **J Speech Hear Res** 1995 Oct; 38(5):1001–13

Perceived pitch of whispered vowels--relationship with formant frequencies: a preliminary study. Higashikawa M, et al. **J Voice** 1996 Jun;10(2):155–8

A physiological and acoustic study on voiced bilabial fricative/beta:/as a vocal exercise. Laukkanen AM, et al. **J Voice** 1996 Mar;10(1):67–77

Reliability of pitch discrimination of vowel and piano tones. Liu TA, et al. **J Voice** 1995 Dec;9(4):394–402

Comparison of neural network and k-NN classification methods in medical image and voice recognitions. Kim EK, et al. **Med J Osaka Univ** 1993 Sep;41–42(1–4):11–6

A developmental deficit in short-term phonological memory: implications for language and reading. Baddeley A, et al.

Memory 1993 Mar;1(1):65–78
The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)
The Children's Test of Nonword Repetition: a test of phonological working memory. Gathercole SE, et al. **Memory** 1994 Jun;2(2):103–27
Production of proper names: a clinical case study of the effects of phonemic cueing. Semenza C, et al. **Memory** 1993 Dec;1(4):265–80
Effects of practice on tip–of–the–tongue states. Smith SM, et al. **Memory** 1994 Mar;2(1):31–49
Selective preservation of place names in an aphasic patient: a short report. Warrington EK, et al. **Memory** 1993 Dec; 1(4):281–8
Category–specific difficulty naming with verbs in Alzheimer's disease. Robinson KM, et al. **Neurology** 1996 Jul;47(1):178–82
Speech timing in ataxic disorders: sentence production and rapid repetitive articulation. Ziegler W, et al. **Neurology** 1996 Jul;47(1):208–14
A dissociation between developmental surface and phonological dyslexia in two undergraduate students. Hanley JR, et al. **Neuropsychologia** 1995 Jul;33(7):909–14
Errors on cues for consonant identification on auditory and visual word–recognition tasks. Berryman L, et al. **Percept Mot Skills** 1996 Apr;82(2):702
An examination of error reductions in consonant recognition when vision and hearing are combined. Berryman L, et al. **Percept Mot Skills** 1996 Apr;82(2):558
Language production in younger and older adults. Drummond S, et al. **Percept Mot Skills** 1996 Apr;82(2):578
Use of the long vs short form of the speech sounds perception test in a school–age population. Gray RM, et al. **Percept Mot Skills** 1996 Apr;82(2):475–80
Relationships between measures of phonological performance in preterm children. Holdgrafer G. **Percept Mot Skills** 1995 Aug;81(1):41–2
Effect of fundamental frequency on medial [+voice]/[–voice] judgments. Diehl RL, et al. **Phonetica** 1995;52(3):188–95
Age of learning affects rate–dependent processing of stops in a second language. Flege JE, et al. **Phonetica** 1996; 53(3):143–61
Phonetic and phonological aspects of English affricate production in children with speech disorders. Hardcastle WJ, et al. **Phonetica** 1995;52(3):242–50
Explaining the dispersion of the single–vowel occurrences in an F1/F2 space. Iivonen A. **Phonetica** 1995;52(3):221–7
A probable case of clicks influencing the sound patterns of some European languages. Ohala JJ. **Phonetica** 1995; 52(3):160–70
Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)
Interactions of fundamental frequency contour and perceived duration in Norwegian. van Dommelen WA. **Phonetica** 1995;52(3):180–7
Understanding normal and impaired word reading: computational principles in quasi–regular domains. Plaut DC, et al. **Psychol Rev** 1996 Jan;103(1):56–115
Consonant perception with linear and compression amplification. Hickson L, et al. **Scand Audiol** 1995; 24(3):175–84
Spectral factors in the perception of vowel quantity in Icelandic. Pind J. **Scand J Psychol** 1996 Jun;37(2):121–31
[An analytical study on recognition confusion of vowels in patients with 22 channel cochlear implant] Momoi T. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1318–22 (Eng. Abstr.) **(Jpn)**
[Contingent negative variations associated with vocalization in humans] Ohsawa K, et al. **No To Shinkei** 1996 Apr; 48(4):357–61 (Eng. Abstr.) **(Jpn)**
[Sex differences in speech perception: effect of perceptive restoration of missing phonemes] Koroleva IV, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):77–82 **(Rus)**
[The perception of the tone and noise quality of a sound signal] Malinnikova TG, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):131–40 (Eng. Abstr.) **(Rus)**

PHONOCARDIOGRAPHY

Low frequency analysis of opening sound for detection of single leg separation of Björk–Shiley Convexo–Concave heart valves. Durand LG, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S32–7
[Left ventricular diastolic function: value of its study with mitral and pulmonary venous Doppler phonocardiography and apexography] Ormezzano O, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):703–11 (Eng. Abstr.) **(Fre)**

PHONOPHORESIS

Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. Kassan DG, et al. **J Am Acad Dermatol** 1996 Apr;34(4):657–66 (74 ref.)
Effect of phonophoresis with dexamethasone on adrenal function. Franklin ME, et al. **J Orthop Sports Phys Ther** 1995 Sep;22(3):103–7
Phonophoretic delivery of 10% hydrocortisone through the epidermis of humans as determined by serum cortisol concentrations. Bare AC, et al. **Phys Ther** 1996 Jul; 76(7):738–45; discussion 746–9
Phonophoretic permeation of procaine hydrochloride through an MDCK cell monolayer Hehn B, et al. **Pharmazie** 1996 May;51(5):341–5 (Eng. Abstr.) **(Ger)**
[A pharmacokinetic study of para–aminobenzoic acid administered into the rabbit eye by phonophoresis] Panova IG, et al. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug;(4):487–9 (Eng. Abstr.) **(Rus)**
[The use of ultraphonophoresis in the rehabilitation of myocardial infarct patients] Mikhno LE, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):5–7 (Eng. Abstr.) **(Rus)**

METHODS

[The effect of the ultraphonophoesis of deresinated naphthalan in patients with a history of exudative pleurisy] Insanov AB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):18–20 (Eng. Abstr.) **(Rus)**
[The characteristics of the mechanism of action in the electro– and ultraphonophoresis of brine and mud preparations] Levitskiĭ EF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):8–10 (Eng. Abstr.) **(Rus)**

PHORBOL 12,13–DIBUTYRATE

METABOLISM

Biological activity of 26–succinylbryostatin 1. Bignami GS, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):197–206
Learning–specific, time–dependent increase in [3H]phorbol dibutyrate binding to protein kinase C in selected regions of the rat brain. Bernabeu R, et al. **Brain Res** 1995 Jul 10;685(1–2):163–8
Molecular modeling and site–directed mutagenesis studies of a phorbol ester–binding site in protein kinase C. Wang S, et al. **J Med Chem** 1996 Jun 21;39(13):2541–53
Flow threshold for enhanced phorbol ester binding in the ischemic gerbil brain. Tanaka K, et al. **Neurochem Res** 1995 Sep;20(9):1007–12
[3H]phorbol 12,13–dibutyrate/PKC binding in thoracic spinal cord: no change in amyotrophic lateral sclerosis. Krieger C, et al. **Neuroreport** 1995 Jul 10;6(10):1381–4

PHARMACOLOGY

PKC mediates LPS– and phorbol–induced cardiac cell nitric oxide synthase activity and hypocontractility. McKenna TM, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1891–8
Relaxant effect of nicorandil on the tonic contraction of the canine large coronary artery induced by phorbol 12,13–dibutylate. Kuromaru O, et al. **Arch Int Pharmacodyn Ther** 1995 Jul–Aug;330(1):25–38
Contrasting effects of phorbol ester and agonist–mediated activation of protein kinase C on phosphoinositide and Ca2+ signalling in a human neuroblastoma. Willars GB, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):905–13
Peripheral vascular smooth muscle responsiveness to tumour–promoting phorbol esters in pacing–induced heart failure. Forster C. **Can J Physiol Pharmacol** 1995 May; 73(5):651–60
Protein kinase C isoforms in iris sphincter smooth muscle: differential effects of phorbol ester on contraction and cAMP accumulation are species specific. Husain S, et al. **Curr Eye Res** 1996 Mar;15(3):329–34
Modulation of L–type Ca2+ current by isoprenaline, carbachol and phorbol ester in cultured rat aortic vascular smooth muscle (A7r5) cells. Satoh H, et al. **Gen Pharmacol** 1995 Mar;26(2):369–79
Phorbol ester and diacylglycerol activation of native protein kinase C species from various tissues. Johnson MS, et al. **Mol Cell Biochem** 1995 May 24;146(2):127–37
Phorbol ester alters the electrophysiological responses to hypoxia and ischemic–like conditions in the rat hippocampal slice. Fowler JC. **Mol Chem Neuropathol** 1995 Sep;26(1):31–42
Suppression of two cloned smooth muscle–derived delayed rectifier potassium channels by cholinergic agonists and phorbol esters. Vogalis F, et al. **Mol Pharmacol** 1995 Dec; 48(6):1015–23
Defective phorbol ester–stimulated secretion of beta–amyloid precursor protein from Alzheimer's disease fibroblasts. Bergamaschi S, et al. **Neurosci Lett** 1995 Dec 1;201(1):1–5
Excitation and sensitization of the heat response induced by a phorbol ester in canine visceral polymodal receptors studied in vitro. Leng S, et al. **Neurosci Lett** 1996 Mar 8;206(1):13–6
Chloride secretion induced by phorbol dibutyrate and forskolin in the human colonic carcinoma cell line HT–29Cl.19A is regulated by different mechanisms. Bajnath RB, et al. **Pflugers Arch** 1995 Sep;430(5):705–12

PHORBOL ESTERS

CHEMICAL SYNTHESIS

Synthesis and evaluation of phorboid 20–homovanillates: discovery of a class of ligands binding to the vanilloid (capsaicin) receptor with different degrees of cooperativity. Appendino G, et al. **J Med Chem** 1996 Aug 2; 39(16):3123–31

CHEMISTRY

[Structural studies of phorbol ester–binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

METABOLISM

CD53 antigen and epidermal growth factor induce similar changes in the pattern of phorbol ester binding in a B cell lymphoma. Barcia R, et al. **Cell Immunol** 1996 Apr 10; 169(1):107–12
Mechanism of interaction of protein kinase C with phorbol esters. Reversibility and nature of membrane association. Mosior M, et al. **J Biol Chem** 1995 Oct 27;270(43):25526–33
Protein kinase Calpha contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities. Slater SJ, et al. **J Biol Chem** 1996 Mar 1; 271(9):4627–31

PHARMACOLOGY

Inhibitory action of in vitro ethanol and acetaldehyde exposure on LHRH–and phorbol ester–stimulated testosterone secretion by rat testicular interstitial cells. Wanderley MI, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):135–41
Phorbol ester and okadaic acid–resistant cells: the crossroads of signal transduction and drug resistance. Saijo N, et al. **Am J Med** 1995 Dec 29;99(6A):35S–39S
Relaxant effect of nicorandil on the tonic contraction of the canine large coronary artery induced by phorbol 12,13–dibutylate. Kuromaru O, et al. **Arch Int Pharmacodyn Ther** 1995 Jul–Aug;330(1):25–38
Phosphatidylserine synthesis in phorbol ester treated glioma C6 cells. Czarny M, et al. **Biochem Mol Biol Int** 1995 Jul; 36(3):659–67
Differential regulation of glucose transport and glucose transporter (GLUT–1) gene expression by vanadate, phorbol ester and okadaic acid in L6 skeletal muscle cells. Venkatesan N, et al. **Biochem Mol Biol Int** 1995 Nov; 37(4):773–83
Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P–glycoprotein by the protein kinase C inhibitor 1–(5–isoquinolinesulfonyl)–2–methylpiperazine (H7) in multidrug–resistant MCF–7/Dox human breast carcinoma cells. Ahn CH, et al. **Biochem Pharmacol** 1996 Aug 9; 52(3):393–9
Protein kinase C–alpha is multiply phosphorylated in response to phorbol ester stimulation of PC12 cells. Gatti A, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):111–8
Alterations in the action potential of Aplysia neurons evoked by a phorbolester are mediated by protein kinase C. Papp A, et al. **Brain Res** 1995 Jun 26;684(1):107–11
PKC–dependent reduction of the acetylcholine–evoked inward Na current in Aplysia D–neurons: effect of injected PKC and PKC activators. Papp A, et al. **Brain Res** 1996 Feb 5;708(1–2):123–7
Differential regulation of phospholipases C and D by phorbol esters and the physiological activators carbachol and glutamate in astrocytes from chicken embryo cerebrum and cerebellum. Mangoura D, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):1–11
Phorbol esters and PKC signaling regulate proliferation, vimentin cytoskeleton assembly and glutamine synthetase activity of chick embryo cerebrum astrocytes in culture. Mangoura D, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):1–11
Promoter activity of the gene encoding the beta–amyloid precursor protein is up–regulated by growth factors, phorbol ester, retinoic acid and interleukin–1. Lahiri DK, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):233–40
Peripheral vascular smooth muscle responsiveness to tumour–promoting phorbol esters in pacing–induced heart failure. Forster C. **Can J Physiol Pharmacol** 1995 May; 73(5):651–60
Phorbol ester and cyclic AMP–mediated regulation of the melanoma–associated cell adhesion molecule MUC18/MCAM. Rummel MM, et al. **Cancer Res** 1996 May 1;56(9):2218–23
Regulation of chicken vimentin gene expression by serum, phorbol ester, and growth factors: identification of a novel fibroblast growth factor–inducible element. Carey I, et al. **Cell Growth Differ** 1995 Jul;6(7):899–908
Superoxide anion is a natural inhibitor of FAS–mediated cell death. Clément MV, et al. **EMBO J** 1996 Jan 15; 15(2):216–25
Time course of phorbol ester–induced contraction and protein kinase C activation in rat aorta. Bazan E, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):253–7
Phorbol esters elicit Ca(2+)–dependent delayed contractions in diabetic rat aorta. Hattori Y, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):51–8
Phorbol ester activation of the rat vascular myocyte Na(+)–H(+) exchanger isoform 1. Siczkowski M, et al. **Hypertension** 1996 Apr;27(4):859–66
Circumvention of P–glycoprotein–mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. Smith CD, et al. **J Biol Chem** 1995 Nov 24;270(47):28145–52

PHORBOL ESTERS

Phorbol ester regulation of opioid peptide gene expression in myocardial cells. Role of nuclear protein kinase. Ventura C, et al. **J Biol Chem** 1995 Dec 15;270(50):30115–20

Adhesion–activating phorbol ester increases the mobility of leukocyte integrin LFA–1 in cultured lymphocytes. Kucik DF, et al. **J Clin Invest** 1996 May 1;97(9):2139–44

Synthesis and evaluation of phorboid 20–homovanillates: discovery of a class of ligands binding to the vanilloid (capsaicin) receptor with different degrees of cooperativity. Appendino G, et al. **J Med Chem** 1996 Aug 2; 39(16):3123–31

Phorbol ester–enhanced noradrenaline secretion correlates with the presence and activity of protein kinase C–alpha in human SH–SY5Y neuroblastoma cells. Turner NA, et al. **J Neurochem** 1996 Jun;66(6):2381–9

Involvement of a phorbol ester–insensitive protein kinase C in the alpha2–adrenergic inhibition of voltage–gated calcium current in chick sympathetic neurons. Boehm S, et al. **J Neurosci** 1996 Aug 1;16(15):4596–603

Gi–mediated stimulation of type II adenylyl cyclase is augmented by Gq–coupled receptor activation and phorbol ester treatment. Tsu RC, et al. **J Neurosci** 1996 Feb 15; 16(4):1317–23

Effects of phorbol 12,13–diacetate and its influence on spasmogenic responses in normal and sensitized guinea–pig trachea. De Diego A, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):750–6

Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2–dopamine release–modulatory receptors. Hoffmann IS, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):662–8

Effect of phorbol ester, 12–deoxyphorbol 13–isobutylate (DPB), on muscle tension and cytosolic Ca2+ in rat anococcygeus muscle. Kaneda T, et al. **Jpn J Pharmacol** 1995 Nov;69(3):195–204

Doppa induces cell death but not differentiation of U937 cells: evidence for the involvement of PKC–beta 1 in the regulation of apoptosis. Pongracz J, et al. **Leuk Res** 1996 Apr;20(4):319–26

A decrease in glucose 6–phosphate dehydrogenase activity and mRNA is an early event in phorbol ester–induced differentiation of thp–1 promonocytic leukemia cells. Bremner TA, et al. **Life Sci** 1996;58(12):1015–22

Suppression of two cloned smooth muscle–derived delayed rectifier potassium channels by cholinergic agonists and phorbol esters. Vogalis F, et al. **Mol Pharmacol** 1995 Dec; 48(6):1015–23

Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Mutat Res** 1995 Dec;333(1–2):153–60 (47 ref.)

Phorbol ester alters rat hippocampal neuronal response to hypoxia. Liu ZW, et al. **Neuroreport** 1995 Oct 23; 6(15):2069–72

Relationship between contractile responses and cytosolic free calcium levels in response to phorbol ester (PMA) in isolated rat aorta. Kamata K, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec;90(3):423–6

PHORBOL MYRISTATE ACETATE see **TETRADECANOYLPHORBOL ACETATE**

PHORBOLS

The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

PHORIAS see **STRABISMUS**

PHOSGENE

Intratracheal administration of DBcAMP attenuates edema formation in phosgene–induced acute lung injury. Sciuto AM, et al. **J Appl Physiol** 1996 Jan;80(1):149–57

ADVERSE EFFECTS

Tolerance to phosgene is associated with a neutrophilic influx into the rat lung. Ghio AJ, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1064–71

POISONING

Occupational phosgene poisoning: a case report and review. Wyatt JP, et al. **J Accid Emerg Med** 1995 Sep;12(3):212–3 (11 ref.)

PHOSPHAMIDE see **DIMETHOATE**

PHOSPHAMIDON

TOXICITY

Interaction of phosphamidon with neuropathy target esterase and acetylcholinesterase of hen brain. Jokanović M, et al. **Arch Toxicol** 1995;69(6):425–8

Sensitivity of selected zooplankton exposed to phosphamidon, fenitrothion, and fenthion. Kaur K, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):199–203

Comparative study on the synergistic and individual effects of dimecron and cuman L on oxygen uptake and haematological parameters of a freshwater edible fish, sarotherodon mossambicus (Peters). Ramaswamy M, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):796–802

PHOSPHATASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHATE ACETYLTRANSFERASE

BIOSYNTHESIS

Genetic manipulation of acid formation pathways by gene inactivation in Clostridium acetobutylicum ATCC 824. Green EM, et al. **Microbiology** 1996 Aug;142 (Pt 8):2079–86

GENETICS

Cloning, sequencing, and expression of genes encoding phosphotransacetylase and acetate kinase from Clostridium acetobutylicum ATCC 824. Boynton ZL, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2758–66

PHOSPHATE DIABETES see **HYPOPHOSPHATEMIA, FAMILIAL**

PHOSPHATE FLUORIDE, ACIDULATED see **ACIDULATED PHOSPHATE FLUORIDE**

PHOSPHATES

see related
HYPOPHOSPHATEMIA
PHOSPHORIC ACID ESTERS

Struvite stones: long term follow up under metaphylaxis. Jarrar K, et al. **Ann Urol (Paris)** 1996;30(3):112–7

Tensile bond strength of a composite resin cement for bonded prosthesis to various dental alloys. Rubo JH, et al. **J Prosthet Dent** 1995 Sep;74(3):230–4

Effect of new ET–Kyoto solution on 17–hour lung preservation in isolated rat lungs. Hirata T, et al. **Transplant Proc** 1996 Jun;28(3):1922–3

Ultrastructural changes of the pulmonary vasculature in canine lungs preserved for 20 hours in newly developed solutions. Kosaka S, et al. **Transplant Proc** 1996 Jun; 28(3):1839–40

New ET–Kyoto solution containing N–acetylcysteine, nitroglycerin, and dibutyryl cyclic AMP provides reliable 30–hour canine lung preservation. Liu CJ, et al. **Transplant Proc** 1996 Jun;28(3):1871–3

Newly developed preservation solution for the lung: 30–hour preservation with new ET–Kyoto solution. Wada H, et al. **Transplant Proc** 1996 Jun;28(3):1178–80

[Polyethylene glycol versus sodium phosphate: comparison of 2 preparations for colonoscopy] Pontone P, et al. **G Chir** 1996 Mar;17(3):128–31 (Eng. Abstr.) **(Ita)**

[Comparative study of the efficacy and tolerance of 2 types of colon cleansing] Fernández Seara J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):785–91 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Toothpaste Fluocaril bi–fluoré 250 in the therapy of cervical dentin hypersensitivity, plaque score influencing. Zapletalová Z. **Acta Univ Palacki Olomuc Fac Med** 1995; 139:39–41

Expression of the renal 25–hydroxyvitamin D–24–hydroxylase gene: regulation by dietary phosphate. Wu S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F203–8

Preparing the bowel for colonoscopy. Abubakar K, et al. **Arch Dis Child** 1995 Nov;73(5):459–61

Single–day, divided–dose oral sodium phosphate laxative versus intestinal lavage as preparation for colonoscopy: efficacy and patient tolerance. Henderson JM, et al. **Gastrointest Endosc** 1995 Sep;42(3):238–43

Effect of oral sodium phosphate colon preparation on serum electrolytes in patients with normal serum creatinine [see comments] Lieberman DA, et al. **Gastrointest Endosc** 1996 May;43(5):467–9. Comment in: Gastrointest Endosc 1996 May;43(5):524–8.

Effects of multibuffer supplementation on acid–base balance and 2,3–diphosphoglycerate following repetitive anaerobic exercise. Kraemer WJ, et al. **Int J Sport Nutr** 1995 Dec; 5(4):300–14

Hypocalcemia after an acute phosphate load is secondary to reduced calcium efflux from bone: studies in patients with minimal renal function and varying parathyroid activity. Kaye M. **J Am Soc Nephrol** 1995 Aug;6(2):273–80

Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. Naveh–Many T, et al. **J Clin Invest** 1995 Oct; 96(4):1786–93

Bowel preparation for colonoscopy: a randomized prospective trail comparing sodium phosphate and polyethylene glycol in a predominantly elderly population. Thomson A, et al. **J Gastroenterol Hepatol** 1996 Feb; 11(2):103–7

Role of oral sodium phosphate and its effectiveness in large bowel preparation for out–patient colonoscopy. Chia YW, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):374–6

Oral phosphate binders without aluminium and calcium – a pipe–dream? [editorial] Ritz E, et al. **Nephrol Dial Transplant** 1996 May;11(5):766–8 (20 ref.)

Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long–term calcium–controlled study. Gambacciani M, et al. **Osteoporos Int** 1995; 5(6):467–71

In corticosteroid–treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double–masked randomized study. Guaydier–Souquières G, et al. **Osteoporos Int** 1996;6(2):171–7

[Effect of orthograde intestinal irrigation with Prepacol and polyethyleneglycol solution on duration of postoperative ileus after colorectal resections] Gründel K, et al. **Langenbecks Arch Chir** 1996;381(3):160–4 (Eng. Abstr.) **(Ger)**

[Colonic preparation with sodium phosphate. Prospective, randomized, placebo–controlled double blind study with various antiemetics] Güller R, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31–32):1352–7 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Oral sodium phosphate catharsis and acute renal failure. Ahmed M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1261–2 (9 ref.)

Tertiary hyperparathyroidism after long–term phosphate supplementation in adult–onset hypophosphataemic osteomalacia. Narváez J, et al. **Br J Rheumatol** 1996 Jun; 35(6):598–600

Inhibition of Western–diet induced hyperproliferation and hyperplasia in mouse colon by two sources of calcium. Richter F, et al. **Carcinogenesis** 1995 Nov;16(11):2685–9

Biochemical effects of oral sodium phosphate. DiPalma JA, et al. **Dig Dis Sci** 1996 Apr;41(4):749–53

Colorectal ulcers associated with sodium phosphate catharsis [letter] Hixson LJ. **Gastrointest Endosc** 1995 Jul;42(1):101–2

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.). Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

Red ring sign versus aphthous ulcers of colonic mucosa? [letter] Stark ME, et al. **Gastrointest Endosc** 1996 May; 43(5):529–30

Colonic mucosal abnormalities associated with oral sodium phosphate solution [see comments] Zwas FR, et al. **Gastrointest Endosc** 1996 May;43(5):463–6. Comment in: Gastrointest Endosc 1996 May;43(5):524–8.

Fatal hypocalcemia from sodium phosphate enemas [letter] Selva O'Callaghan A, et al. **J Am Geriatr Soc** 1995 Dec; 43(12):1447–8

Nephrocalcinosis is associated with renal tubular acidosis in children with X–linked hypophosphatemia. Seikaly M, et al. **Pediatrics** 1996 Jan;97(1):91–3

ANALYSIS

Photometric microtiter assay of inorganic phosphate in the presence of acid–labile organic phosphates. Drueckes P, et al. **Anal Biochem** 1995 Sep 1;230(1):173–7

Hard tissue of teeth and their calcium and phosphate content in Ambystoma mexicanum (Urodela: Ambystomatidae). Bolte M, et al. **Anat Anz** 1996 Jan;178(1):71–80

Studies with pre–treatment of milk with calcium acetata to reduce the phosphate content [letter] Schröder CH, et al. **Eur J Pediatr** 1995 Aug;154(8):689

Carbonate in struvite stone detected in Raman spectra compared with infrared spectra and X–ray diffraction. Takasaki E. **Int J Urol** 1996 Jan;3(1):27–30

Epizootiologic evaluation of urolithiasis in cats: 3,498 cases (1982–1992). Thumchai R, et al. **J Am Vet Med Assoc** 1996 Feb 15;208(4):547–51

NMR studies of Pi–containing extracellular and cytoplasmic compartments in brain. Fitzpatrick JH Jr, et al. **J Neurochem** 1996 Jun;66(6):2612–20

ANTAGONISTS & INHIBITORS

P2 purinoceptor stimulation attenuates PTH inhibition of phosphate uptake by a G protein–dependent mechanism. Lederer ED, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F309–16

BLOOD

The role of serum phosphate level and acute ischemic bowel disease. Leo PJ, et al. **Am J Emerg Med** 1996 Jul; 14(4):377–9

Effect of aging on the metabolism of phosphorus and 1,25–dihydroxyvitamin D in healthy men. Portale AA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E483–90

Paraprotein interference causing pseudohyperphosphataemia: evaluation of an improved methodology. Savory DJ, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):498–501

Sodium glycerophosphate in the treatment of neonatal hypophosphataemia. Costello I, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F44–5

Serum alkaline phosphatase, calcium, and phosphate levels following clinical use of natural coral. Case reports. Alpaslan G, et al. **Aust Dent J** 1995 Oct;40(5):327–9

Effects of increased arterial epinephrine on insulin, glucose and phosphate. Kjeldsen SE, et al. **Blood Press** 1996 Jan; 5(1):27–31

Acute suppression of parathyroid activity during hemofiltration. Panichi V, et al. **Blood Purif** 1996;14(1):15–9

Metabolic effects of pamidronate in patients with metastatic bone disease. Vinholes J, et al. **Br J Cancer** 1996 May;

73(9):1089–95

Severe hypophosphataemia in autograft recipients during accelerated leucocyte recovery [letter] [see comments] Raanani P, et al. **Br J Haematol** 1995 Dec;91(4):1031–2. Comment in: Br J Haematol 1996 Apr;93(1):250.

Effect of aldrin on carbohydrate, protein, and ionic metabolism of a freshwater catfish, Heteropneustes fossilis. Singh NN, et al. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):204–10

Pseudohyperphosphatemia. Larner AJ. **Clin Biochem** 1995 Aug;28(4):391–3 (40 ref.)

Monoclonal immunoglobulin interferences in measurement of serum inorganic phosphate with a new modified reagent [letter] Poupon–Fleuret C, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1298–300

Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ, et al. **Clin Nephrol** 1996 Feb;45(2):111–9

Serum calcium, inorganic phosphate and alkaline phosphatase activity in lactating females. Onwuameze IC. **East Afr Med J** 1995 Jun;72(6):379–80

Effect of various vitamin D metabolites on serum calcium and inorganic phosphate in the freshwater snake Natrix piscator. Srivastav AK, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):49–52

Serum calcium, magnesium and inorganic phosphorous levels during various phases of menstrual cycle. Pandya AK, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):411–4

Hypophosphataemic versus hyperphosphataemic ARF [letter] Lazar AI. **J Assoc Physicians India** 1995 Oct; 43(10):730

Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH–related peptide levels. Kovacs CS, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3036–42

Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. Nowicki M, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):156–9

Alkali therapy, hyperphosphatemia, and acute tumor lysis syndrome [letter] Koduri PR. **Med Pediatr Oncol** 1996 Jan; 26(1):73

Influence of serum phosphate on the efficacy of oral 1,25–dihydroxyvitamin D3 pulse therapy. Shoji S, et al. **Miner Electrolyte Metab** 1995;21(1–3):223–8

Long–term treatment with calcium–alpha–ketoglutarate corrects secondary hyperparathyroidism. Zimmermann E, et al. **Miner Electrolyte Metab** 1996;22(1–3):196–9

Treatment of hyperparathyroidism—why is it crucial to control serum phosphate? [editorial] Brancaccio D, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):420–3 (23 ref.)

Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy? [letter] Ionova D, et al. **Nephrol Dial Transplant** 1995;10(9):1782

Serum phosphate control: what about calcium salts of keto–amino acids? [letter; comment] Macia M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2159–60. Comment on: Nephrol Dial Transplant 1994;9(10):1366–7.

Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Tan CC, et al. **Nephrol Dial Transplant** 1996 May;11(5):851–3

Determination of individual ultrafiltration time (APEX) and purification phosphate time by peritoneal equilibration test: application to individual peritoneal dialysis modality prescription in children. Fischbach M, et al. **Perit Dial Int** 1996;16 Suppl 1:S557–60

[Clinical observation and study of blood phosphate concentration changes in postoperative patients] Chen L, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):276–8 (Eng. Abstr.) **(Chi)**

[Interference of dysglobulinemia and lactescence on serum phosphate determination: an easy and efficient correction (letter)] Fleuret C, et al. **Ann Biol Clin (Paris)** 1995; 53(3):141–3 **(Fre)**

[Enema–induced hyperphosphatemia in ileus of the small and large intestine] Wilmanns C, et al. **Zentralbl Chir** 1995; 120(12):981–3 (Eng. Abstr.) **(Ger)**

[Inorganic phosphate in serum and urine] Nagata N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:772–5 (10 ref.) **(Jpn)**

[Abetalipoproteinemia and transient hyperphosphatemia of childhood (letter)] Diego Núñez MA, et al. **An Esp Pediatr** 1996 Jun;44(6):634–5 **(Spa)**

CHEMICAL SYNTHESIS

Selenophosphate. Glass RS, et al. **Methods Enzymol** 1995; 252:309–15

[Synthesis of oligodeoxyribonucleotides with modified internucleotide phosphate residues] Hayakawa Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1306–14 (33 ref.) **(Jpn)**

[Synthesis and properties of 2'–phosphorylated oligoribonucleotides] Sekine M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1315–22 (52 ref.) **(Jpn)**

CHEMISTRY

Mixed–mode retention of peptides on phosphate–modified polybutadiene–coated zirconia. Sun L, et al. **Anal Chem** 1995 Aug 1;67(15):2517–23

Distinct phosphate backbone contacts revealed by some mutant peptides of zinc finger protein Spl: effect of protein–induced bending on DNA recognition. Nagaoka M, et al. **Biochemistry** 1996 Jul 2;35(26):8761–8

Modulation of a salt link does not affect binding of phosphate to its specific active transport receptor. Yao N, et al. **Biochemistry** 1996 Feb 20;35(7):2079–85

The solubility of calcium and phosphate in two specialty amino acid solutions. MacKay MW, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):63–6

Phosphoryl migration during the chemical synthesis of RNA. Morgan MA, et al. **Nucleic Acids Res** 1995 Oct 11; 23(19):3949–53

Nuclear magnetic resonance study of a high–surface–area aluminum phosphate glass and its thermally reversible sol–gel precursor. Harmer MA, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):35–49

Nuclear magnetic resonance investigation of the structures of phosphate and phosphate–containing glasses: a review. Kirkpatrick RJ, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):9–21 (51 ref.)

Multi–nuclear and multi–dimensional nuclear magnetic resonance investigation of silver iodide–silver phosphate fast ion conducting glasses. Olsen KK, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):123–32

[The chemistry of phosphorus: pseudorotation] Taira K. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1323–32 (53 ref.) **(Jpn)**

[Calorimetric study of stable complexes of myosin subfragment I with adenosine diphosphate and phosphate analogs] Levitskii DI, et al. **Biofizika** 1996 Jan–Feb; 41(1):64–72 (29 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Aluminum tolerance of Pseudomonas fluorescens in a phosphate–deficient medium. Appanna VD, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):404–11

Regulation of opossum kidney (OK) cell Na/Pi cotransport by Pi deprivation involves mRNA stability. Markovich D, et al. **Pflugers Arch** 1995 Aug;430(4):459–63

DIAGNOSTIC USE

The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double–bind randomized study. Sudduth RH, et al. **Gastrointest Endosc** 1995 Nov;42(5):413–5

METABOLISM

The effect of sodium bicarbonate on CBF and intracellular pH in man: stable Xe–CT and 31P–MRS. Nakashima K, et al. **Acta Neurol Scand Suppl** 1996;166:96–8

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García–Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. Chati Z, et al. **Am Heart J** 1996 Mar; 131(3):560–6

The effect of simvastatin treatment on natural antioxidants in low–density lipoproteins and high–energy phosphates and ubiquinone in skeletal muscle. Laaksonen R, et al. **Am J Cardiol** 1996 Apr 15;77(10):851–4

Phosphate transport inhibition by KW–3902, an adenosine A1 receptor antagonist, is mediated by cyclic adenosine monophosphate. Cai H, et al. **Am J Kidney Dis** 1995 Nov; 26(5):825–30

Stability of high–energy phosphates in right ventricle: myocardial energetics during right coronary hypotension. Itoya M, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H320–8

Stimulation of proximal convoluted tubule phosphate transport by epidermal growth factor: signal transduction. Quigley R, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F339–44

Inorganic phosphate is transported into mitochondria in the absence of ATP biosynthesis: an in vivo 31P NMR study in the human skeletal muscle. Iotti S, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):191–4

Adaptation to phosphate depletion in opossum kidney cells. Saxena S, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):141–7

Metabolic evidence for the order of addition of individual phosphate esters in the myo–inositol moiety of inositol hexakisphosphate in the duckweed Spirodela polyrhiza L. Brearley CA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):227–33

Locally formed dopamine modulates renal Na–Pi co–transport through DA1 and DA2 receptors. Perrichot R, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):433–7

Stereospecificity of inositol hexakisphosphate dephosphorylation by Paramecium phytase. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):907–10

The inhibition of Na(+)–Pi cotransport and Pi self–exchange mechanisms in lactating rat mammary tissue. Shillingford JM, et al. **Biochem Soc Trans** 1995 Nov;23(4):559S

Kinetics of the phosphorylation of Na,K–ATPase by inorganic phosphate detected by a fluorescence method. Apell HJ, et al. **Biochemistry** 1996 Aug 20;35(33):10922–30

The transient kinetics of Escherichia coli chorismate synthase: substrate consumption, product formation, phosphate dissociation, and characterization of a flavin intermediate. Bornemann S, et al. **Biochemistry** 1996 Jul 30;35(30):9907–16

Crystal structure of glycosomal glyceraldehyde–3–phosphate dehydrogenase from Leishmania mexicana: implications for structure–based drug design and a new position for the inorganic phosphate binding site. Kim H, et al. **Biochemistry** 1995 Nov 21;34(46):14975–86

Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states. Mitchell EP, et al. **Biochemistry** 1996 Jun 11;35(23):7341–55

Kinetics of inorganic phosphate release during the interaction of p21ras with the GTPase–activating proteins, p120–GAP and neurofibromin. Nixon AE, et al. **Biochemistry** 1995 Nov 28;34(47):15592–8

Effect of substrates and pH on the intestinal Na+/phosphate cotransporter: evidence for an intervesicular divalent phosphate allosteric regulatory site. Peerce BE. **Biochim Biophys Acta** 1995 Oct 4;1239(1):1–10

Active site comparisons highlight structural similarities between myosin and other P–loop proteins. Smith CA, et al. **Biophys J** 1996 Apr;70(4):1590–602

Mechanisms of intestinal phosphate transport in small ruminants. Schröder B, et al. **Br J Nutr** 1995 Nov; 74(5):635–48

Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles. Merchant TE, et al. **Cancer** 1995 Nov 15;76(10):1715–23

Myocardial beta–adrenergic receptor function and high–energy phosphates in brain death—related cardiac dysfunction. Bittner HB, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II472–8

Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets. Patel L, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):687–96

Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH–deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass. Valk NK, et al. **Clin Endocrinol (Oxf)** 1995 Sep; 43(3):317–24

The transport of phosphate between the plasma and dialysate compartments in peritoneal dialysis is influenced by an electric potential difference. Graff J, et al. **Clin Physiol** 1996 May;16(3):291–300

Growth of a mutant defective in a putative phosphoinositide–specific phospholipase C of Schizosaccharomyces pombe is restored by low concentrations of phosphate and inositol. Fankhauser H, et al. **Curr Genet** 1995 Jul;28(2):199–203

Apparent nonnuclear regulation of intestinal phosphate transport: effects of 1,25–dihydroxyvitamin D3,24,25–dihydroxyvitamin D3, and 25–hydroxyvitamin D3. Nemere I. **Endocrinology** 1996 Jun;137(6):2254–61

Normal phosphate transport in cells from the S2 and S3 segments of Hyp–mouse proximal renal tubules. Nesbitt T, et al. **Endocrinology** 1996 Mar;137(3):943–8

X–ray structure of yeast inorganic pyrophosphatase complexed with manganese and phosphate. Harutyunyan EH, et al. **Eur J Biochem** 1996 Jul 1;239(1):220–8

A new method for the determination of specific 13C enrichment in phosphorylated [1–13C]glucose metabolites. 13C–coupled, 1H–decoupled 31P–NMR spectroscopy of tissue perchloric acid extracts. Lutz NW, et al. **Eur J Biochem** 1996 Jun 1;238(2):470–5

Phosphate–binding sites in phosphorylating glyceraldehyde–3–phosphate dehydrogenase from Bacillus stearothermophilus. Michels S, et al. **Eur J Biochem** 1996 Feb 1;235(3):641–7

Phosphate transport via Na+ –Pi cotransport and anion exchange in lactating rat mammary tissue. Shillingford JM, et al. **Exp Physiol** 1996 Mar;81(2):273–84

Non–physiological expression of UhpT does not lead to uncontrolled leakage of sugar phosphates out of Escherichia coli cells. van de Zee JR, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):21–6

Characterization of the genes encoding a phosphate–regulated two component sensory system in the marine cyanobacterium Synechococcus sp. WH7803. Watson GM, et al. **FEMS Microbiol Lett** 1996 Aug 15; 142(1):105–9

A putative new membrane protein, Pho86p, in the inorganic phosphate uptake system of Saccharomyces cerevisiae. Yompakdee C, et al. **Gene** 1996 May 24;171(1):41–7

A role for ATPase in the mechanisms of ATP–dependent Ca and phosphate deposition by isolated rachitic matrix vesicles. Hsu HH, et al. **Int J Biochem Cell Biol** 1995 Dec; 27(12):1349–56

Renal refractoriness to phosphaturic action of parathyroid hormone in a patient with hypomagnesemia [see comments] Mihara M, et al. **Intern Med** 1995 Jul;34(7):666–9. Comment in: Intern Med 1995 Jul;34(7):603–4.

A phosphate transport system is required for symbiotic nitrogen fixation by Rhizobium meliloti. Bardin S, et al. **J Bacteriol** 1996 Aug;178(15):4540–7

PstB protein of the phosphate–specific transport system of Escherichia coli is an ATPase. Chan FY, et al. **J Bacteriol** 1996 Jul;178(13):3974–7

Phosphate load as the evolutionary driving force for the development of a high filtration rate based excretory organ: a hypothesis. Ilani A. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):123–38 (32 ref.)

A method for in vivo [32P]phosphate labelling of testis proteins. Kundu TK, et al. **J Biochem Biophys Methods** 1995 Jun;30(2-3):185-9

Schizosaccharomyces pombe thiamine pyrophosphokinase is encoded by gene tmr3 and is a regulator of thiamine metabolism, phosphate metabolism, mating, and growth. Fankhauser H, et al. **J Biol Chem** 1995 Nov 24; 270(47):28457-62

The role of cytosolic calcium in chronic adaptation to phosphate depletion in opossum kidney cells. Saxena S, et al. **J Biol Chem** 1996 Feb 16;271(7):3902-6

Phosphorylation of the cytosolic domain of peptidylglycine alpha-amidating monooxygenase. Yun HY, et al. **J Biol Chem** 1995 Dec 15;270(50):30075-83

Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and Hyp mice: evidence that the HYP gene locus product is an extrarenal factor. Nesbitt T, et al. **J Bone Miner Res** 1995 Sep;10(9):1327-33

Fractional reabsorption of calcium, magnesium and phosphate in the kidneys of freshwater North American eels (Anguilla rostrata LeSueur) following removal of the corpuscles of Stannius. Butler DG, et al. **J Comp Physiol [B]** 1995;165(5):348-58

Mechanisms of phosphate uptake into brush-border membrane vesicles from goat jejunum. Schröder B, et al. **J Comp Physiol [B]** 1996;166(3):230-40

Effects of insulin-like growth factor I on phosphate transport in cultured proximal tubule cells. Hirschberg R, et al. **J Lab Clin Med** 1995 Nov;126(5):428-34

Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts. Kobara M, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):417-28

Impact acceleration-induced severe diffuse axonal injury in rats: characterization of phosphate metabolism and neurologic outcome. Heath DL, et al. **J Neurotrauma** 1995 Dec;12(6):1027-34

Maturation of rat renal phosphate transport: effect of triiodothyronine. Euzet S, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):449-57

Forefronts in Nephrology: Phosphates. Symposium proceedings. Seelisberg, Switzerland, September 24-27, 1995. **Kidney Int** 1996 Apr;49(4):937-1037

Renal Na/Pi-cotransporters. Biber J, et al. **Kidney Int** 1996 Apr;49(4):981-5 (33 ref.)

Endoplasmic reticulum phosphate transport. Burchell A. **Kidney Int** 1996 Apr;49(4):953-8 (40 ref.)

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975-80 (24 ref.)

Phosphate metabolism: contribution of different cellular compartments. Dennis VW. **Kidney Int** 1996 Apr; 49(4):938-42 (33 ref.)

Role of renal handling of extracellular nucleotides in modulation of phosphate transport. Friedlander G, et al. **Kidney Int** 1996 Apr;49(4):1019-22 (43 ref.)

Phosphate transport in osteoclasts: a functional and immunochemical characterization. Gupta A, et al. **Kidney Int** 1996 Apr;49(4):968-74

Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kavanaugh MP, et al. **Kidney Int** 1996 Apr;49(4):959-63 (23 ref.)

Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005-9 (52 ref.). Comment in: Kidney Int 1996 Apr;49(4):1010-1.

Structural and functional aspects of the phosphate carrier from mitochondria. Krämer R. **Kidney Int** 1996 Apr; 49(4):947-52 (55 ref.)

Simultaneous occlusion of Na+ and phosphate by the intestinal brush border membrane Na+/phosphate cotransporter. Peerce BE. **Kidney Int** 1996 Apr; 49(4):988-91

Atomic basis of the exquisite specificity of phosphate and sulfate transport receptors. Quiocho FA. **Kidney Int** 1996 Apr;49(4):943-6 (14 ref.)

Epithelial phosphate transport in ruminants, mechanisms and regulation. Shirazi-Beechey SP, et al. **Kidney Int** 1996 Apr; 49(4):992-6 (39 ref.)

Mechanism of renal phosphate retention during growth. Silverstein D, et al. **Kidney Int** 1996 Apr;49(4):1023-6

P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Ballinger JR, et al. **Magn Reson Imaging** 1995;13(6):877-83

Effect of melanin on phosphorus T1S in human melanoma xenografts studied by 31P MRS. Olsen DR, et al. **Magn Reson Imaging** 1995;13(6):847-52

Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211-30 (65 ref.)

Inhibition of phosphate-metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287-324 (169 ref.)

Selenophosphate. Glass RS, et al. **Methods Enzymol** 1995; 252:309-15

Structural requirements of parathyroid hormone/parathyroid hormone-related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida-Klein A, et al. **Miner Electrolyte Metab** 1995;21(1-3):177-9 (16 ref.)

Molecular analysis of the phosphate-specific transport (pst) operon of Pseudomonas aeruginosa. Nikata T, et al. **Mol Gen Genet** 1996 Apr 10;250(6):692-8

Structure and distribution of specific cis-elements for transcriptional regulation of PHO84 in Saccharomyces cerevisiae. Ogawa N, et al. **Mol Gen Genet** 1995 Dec 10; 249(4):406-16

A putative membrane protein, Pho88p, involved in inorganic phosphate transport in Saccharomyces cerevisiae. Yompakdee C, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):580-90

The signal-transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933-9 (27 ref.)

A phosphate transporter from the mycorrhizal fungus Glomus versiforme [see comments] Harrison MJ, et al. **Nature** 1995 Dec 7;378(6557):626-9. Comment in: Nature 1995 Dec 7;378(6557):560-1.

Plant biology. At the roots of nutrition [news; comment] Schroeder JI. **Nature** 1995 Dec 7;378(6557):560-1. Comment on: Nature 1995 Dec 7;378(6557):626-9.

Calcium balance and intact PTH variations during haemodiafiltration. Argilés A, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2083-9

Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Graziani G, et al. **Nephrol Dial Transplant** 1995;10(8):1376-80

Molecular mechanisms in renal phosphate reabsorption [editorial] Murer H, et al. **Nephrol Dial Transplant** 1995; 10(9):1501-4 (19 ref.)

Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Spengler K, et al. **Nephrol Dial Transplant** 1996 May;11(5):808-12

Effect of parathyroid hormone on rat skeletal muscle in vivo. Thompson CH, et al. **Nephron** 1996;72(2):253-6

Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Pettegrew JW, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):973-5

Effect of iron as a new type of phosphate binder in hemodialysis patients. Kuroda S, et al. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):468-73

Interaction of mRNA with the Escherichia coli ribosome: accessibility of phosphorothioate-containing mRNA bound to ribosomes for iodine cleavage. Alexeeva EV, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2228-35

The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299-301 (2 ref.)

The N-terminal hydrophobic region of the mature phosphate translocator is sufficient for targeting to the chloroplast inner envelope membrane. Knight JS, et al. **Plant Cell** 1995 Sep;7(9):1421-32

Chloroplast ribonucleoproteins (RNPs) as phosphate acceptors for casein kinase II: purification by ssDNA-cellulose column chromatography. Kanekatsu M, et al. **Plant Cell Physiol** 1995 Dec;36(8):1649-56

Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia. Kumar R, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):296-305

Indirect coupling of phosphate release to de novo tension generation during muscle contraction. Davis JS, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10482-6

Negative electrostatic surface potential of protein sites specific for anionic ligands. Ledvina PS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6786-91

Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Kato T, et al. **Psychiatry Res** 1995 Sep 29;61(3):151-60

Identification of phosphates involved in catalysis by the ribozyme RNase P RNA. Harris ME, et al. **RNA** 1995 Apr; 1(2):210-8

Depletion of high energy phosphate compouds in the tumor-bearing state and reversal after tumor resection. Hochwald SN, et al. **Surgery** 1996 Sep;120(3):534-41

Synthesis of high energy phosphates during cold ischemic rat liver preservation with gaseous oxygen insufflation. Minor T, et al. **Transplantation** 1996 Jan 15;61(1):20-2

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Modification of phosphate metabolism by administration of aluminum hydroxide. 1956 (classical article)] Baur H, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2305-7 **(Ger)**

PHARMACOKINETICS

Urea, creatinine and phosphate kinetic modeling during dialysis: application to pediatric hemodialysis. Maasrani M, et al. **Int J Artif Organs** 1995 Mar;18(3):122-9

Are calcitriol boli worth the return to aluminum hydroxide as a phosphate binder in severe secondary hyperparathyroidism? [letter] Calabrese G, et al. **Nephron** 1995;71(1):113-4

PHARMACOLOGY

Thiophosphate induces apoptosis in human leukemia cell lines. Jiang L, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):393-7

Effect of substrates and pH on the intestinal Na+/phosphate cotransporter: evidence for an intervesicular divalent phosphate allosteric regulatory site. Peerce BE. **Biochim Biophys Acta** 1995 Oct 4;1239(1):1-10

Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. Wada H, et al. **Biochim Biophys Acta** 1996 Jun 13; 1274(3):89-93

BDM compared with P(i) and low Ca2+ in the cross-bridge reaction initiated by flash photolysis of caged ATP. Kagawa K, et al. **Biophys J** 1995 Dec;69(6):2590-600

Effects of phosphate and ADP on shortening velocity during maximal and submaximal calcium activation of the thin filament in skeletal muscle fibers. Metzger JM. **Biophys J** 1996 Jan;70(1):409-17

Influence of inorganic phosphate and pH on ATP utilization in fast and slow skeletal muscle fibers. Potma EJ, et al. **Biophys J** 1995 Dec;69(6):2580-9

Glutamine- and phosphate-containing hypotonic storage media better maintain erythrocyte membrane physical properties. Dumaswala UJ, et al. **Blood** 1996 Jul 15; 88(2):697-704

Phosphate regulates the stability of skeletal alkaline phosphatase activity in human osteosarcoma (SaOS-2) cells without equivalent effects on the level of skeletal alkaline phosphatase immunoreactive protein. Farley JR. **Calcif Tissue Int** 1995 Nov;57(5):371-8

NMR studies and restrained-molecular-dynamics calculations of a long A+T-rich stretch in DNA. Effects of phosphate charge and solvent approximations. Leijon M, et al. **Eur J Biochem** 1995 Dec 15;234(3):832-42

Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial-generated reactive oxygen species. Kowaltowski AJ, et al. **FEBS Lett** 1996 Jan 8;378(2):150-2

Inhibitory effect of glucose and phosphate on the second cleavage division of hamster embryos: is it linked to metabolism? Barnett DK, et al. **Hum Reprod** 1996 Jan; 11(1):177-83

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111-9 (49 ref.)

Effects of substrates and phosphate on INT (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium chloride) and CTC (5-cyano-2,3-ditolyl tetrazolium chloride) reduction in Escherichia coli. Smith JJ, et al. **J Appl Bacteriol** 1996 Feb;80(2):209-15

Binding of phosphate, aluminum fluoride, or beryllium fluoride to F-actin inhibits severing by gelsolin. Allen PG, et al. **J Biol Chem** 1996 Mar 1;271(9):4665-70

Effect of inorganic phosphate concentration on the nature of inner mitochondrial membrane alterations mediated by Ca2+ ions. A proposed model for phosphate-stimulated lipid peroxidation. Kowaltowski AJ, et al. **J Biol Chem** 1996 Feb 9;271(6):2929-34

Response of rainbow trout (Oncorhynchus mykiss) growing from 50 to 200 g to supplements of dibasic sodium phosphate in a semipurified diet. Rodehutscord M. **J Nutr** 1996 Jan;126(1):324-31

Comparative effects of inorganic phosphate and oxalate on uptake and release of Ca2+ by the sarcoplasmic reticulum in saponin skinned rat cardiac trabeculae. Steele DS, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):565-76

Adaptive response of the archaeon Sulfolobus acidocaldarius BC65 to phosphate starvation. Osorio G, et al. **Microbiology** 1996 Jun;142 (Pt 6):1531-6

The orientation of phosphate activated glutaminase in the inner mitochondrial membrane of synaptic and non-synaptic rat brain mitochondria. Roberg B, et al. **Neurochem Int** 1995 Oct-Nov;27(4-5):367-76

Anionic properties of beta-lactam-enhancing factor on methicillin-resistant Staphylococcus aureus. Tajima Y, et al. **Res Microbiol** 1996 May;147(4):279-86

Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Huang RN, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):243-9

[Use of microbial phytase at different phosphorus supply levels in broiler fattening. 1. Effect on fattening performance and tibia stability] Richter G. **Arch Tierernahr** 1993;45(3):235-44 (Eng. Abstr.) **(Ger)**

[Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability] Suyama K, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):491-6 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Production of interleukin-6 by osteoblastic cells is independent of medium inorganic phosphate. Tran JM, et al. **Biochem Mol Med** 1995 Aug;55(2):90-5

Phosphate deprivation induces overexpression of two proteins related to the rat renal phosphate cotransporter NaPi-2. Boyer CJ, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):117-23

Signal transduction in the control of phosphate-regulated genes of Escherichia coli. Wanner BL. **Kidney Int** 1996 Apr;49(4):964-7 (24 ref.)

Hypothermic perfusion preservation of liver: the role of phosphate in stimulating ATP synthesis studied by 31P NMR. Lockett CJ, et al. **Transpl Int** 1995;8(6):440-5

THERAPEUTIC USE

Effect of sodium hexametaphosphate on dental calculus formation in dogs. Stookey GK, et al. **Am J Vet Res** 1995 Jul;56(7):913-8

Adjuvant treatment for early epithelial ovarian cancer: results

of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica [see comments] Bolis G, et al. **Ann Oncol** 1995 Nov;6(9):887–93. Comment in: Ann Oncol 1995 Nov;6(9):865–6.

Pleuroperitoneal migration of intraperitoneal phosphorus–32–chromic phosphate therapy for stage I ovarian carcinoma. Wilkinson RH Jr. **J Nucl Med** 1996 Apr;37(4):636–9

A newly developed solution enhances thirty–hour preservation in a canine lung transplantation model. Liu CJ, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):569–76

TOXICITY

Response of periphyton biomass to high phosphorus concentrations in laboratory experiments. Giorgi AD. **Bull Environ Contam Toxicol** 1995 Dec;55(6):825–32

Dexamethasone inhibits inorganic phosphate stimulated Ca(2+)–dependent damage of isolated rat liver and renal cortex mitochondria. Campbell PI, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):221–5

URINE

Phosphate excretion during 24 h of hypoxia in conscious rats. Mimura Y. **Acta Physiol Scand** 1995 Nov;155(3):283–9

22–Oxacalcitriol does not interfere with parathyroid hormone–induced phosphaturia or cyclic–AMP excretion. Friedlaender MM, et al. **Bone** 1995 Sep;17(3):301–6

Potassium depletion and salt–sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions. Wu X, et al. **Clin Exp Hypertens** 1995 Aug; 17(6):989–1008

Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat. Wu X, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1269–85

Role of dopamine in the exaggerated phosphaturic response to parathyroid hormone in the remnant kidney. Isaac J, et al. **J Lab Clin Med** 1995 Nov;126(5):470–3

Oncogenic osteomalacia associated with a meningeal phosphaturic mesenchymal tumor. Case report. David K, et al. **J Neurosurg** 1996 Feb;84(2):288–92

Effect of insulin on urinary phosphate excretion in type II diabetes mellitus with or without renal insufficiency. Ishimura E, et al. **Metabolism** 1996 Jun;45(6):782–6

Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Constantin A, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):493–500

PHOSPHATES, INORGANIC see **PHOSPHATES**

PHOSPHATES, ORGANIC see **PHOSPHORIC ACID ESTERS**

PHOSPHATIDAL COMPOUNDS see **PLASMALOGENS**

PHOSPHATIDATE PHOSPHATASE

GENETICS

Identification and cDNA cloning of 35–kDa phosphatidic acid phosphatase (type 2) bound to plasma membranes. Polymerase chain reaction amplification of mouse H2O2–inducible hic53 clone yielded the cDNA encoding phosphatidic acid phosphatase. Kai M, et al. **J Biol Chem** 1996 Aug 2;271(31):18931–8

ISOLATION & PURIFICATION

Identification of phosphatidate phosphohydrolase purified from rat liver membranes on SDS–polyacrylamide gel electrophoresis. Siess EA, et al. **FEBS Lett** 1996 Mar 4; 381(3):169–73

METABOLISM

Regulation of phosphatidate phosphatase activity from the yeast Saccharomyces cerevisiae by phospholipids. Wu WI, et al. **Biochemistry** 1996 Mar 26;35(12):3790–6

Identification of phosphatidate phosphohydrolase purified from rat liver membranes on SDS–polyacrylamide gel electrophoresis. Siess EA, et al. **FEBS Lett** 1996 Mar 4; 381(3):169–73

Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1–phosphate, lysophosphatidate, and sphingosine 1–phosphate. Waggoner DW, et al. **J Biol Chem** 1996 Jul 12;271(28):16506–9

PHYSIOLOGY

Phosphatidate phosphohydrolase and signal transduction. Brindley DN, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):45–57 (78 ref.)

PHOSPHATIDATE PHOSPHOHYDROLASE see **PHOSPHATIDATE PHOSPHATASE**

PHOSPHATIDES see **PHOSPHOLIPIDS**

PHOSPHATIDIC ACIDS

Impedance analysis of supported lipid bilayer membranes: a scrutiny of different preparation techniques. Steinem C, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):169–80

ANALYSIS

Age–associated changes in the content and fatty acid composition of brain glycerophospholipids. López GH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):331–43

High–performance liquid chromatography of phosphatidic acid. Abidi SL, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):281–97 (100 ref.)

BIOSYNTHESIS

ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)

Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. Gomez–Cambronero J. **J Interferon Cytokine Res** 1995 Oct;15(10):877–85

CHEMISTRY

Characteristics of phosphatidic acid–containing lipoproteins which selectively inhibit bitter taste: high affinity to frog tongue surface and hydrophobic model membranes. Katsuragi Y, et al. **Biochim Biophys Acta** 1996 Apr 17; 1289(3):322–8

Effects of pH and cholesterol on DMPA membranes: a solid state 2H– and 31P–NMR study. Pott T, et al. **Biophys J** 1995 Nov;69(5):1897–908

Tetraoleoylpyrophosphatidic acid: a four acyl–chain lipid which forms a hexagonal II phase with high curvature. Powell GL, et al. **Biophys J** 1996 Mar;70(3):1402–6

Structural and thermotropic properties of calcium–dimyristoylphosphatidic acid complexes at acidic and neutral pH conditions. Takahashi H, et al. **Biophys J** 1995 Oct;69(4):1464–72

Acyclic oligonucleotide analogues. Merle Y, et al. **Int J Biol Macromol** 1995 Oct;17(5):239–46

DEFICIENCY

Human platelet signaling defect characterized by impaired production of inositol–1,4,5–triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: evidence for defective phospholipase C activation. Yang X, et al. **Blood** 1996 Sep 1;88(5):1676–83

METABOLISM

Phosphatidic acid mobilized by phospholipase D is involved in the phorbol 12–myristate 13–acetate–induced G2 delay of A431 cells. Kaszkin M, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):129–38

Intralysosomal glycerophospholipid catabolism in liver: hydrolysis of amino alcohol–containing phospholipids and their metabolites. Kunze H. **Biochim Biophys Acta** 1993 Sep 8;1169(3):273–9

Ultrafast glycerophospholipid–selective transbilayer motion mediated by a protein in the endoplasmic reticulum membrane. Buton X, et al. **J Biol Chem** 1996 Mar 22; 271(12):6651–7

Phosphatidic acid generation through interleukin 2 (IL–2)–induced alpha–diacylglycerol kinase activation is an essential step in IL–2–mediated lymphocyte proliferation. Flores I, et al. **J Biol Chem** 1996 Apr 26; 271(17):10334–40

Raf–1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf–1 in 12–O–tetradecanoylphorbol–13–acetate–stimulated Madin–Darby canine kidney cells. Ghosh S, et al. **J Biol Chem** 1996 Apr 5;271(14):8472–80

Purification and properties of a phosphatidic acid–preferring phospholipase A1 from bovine testis. Examination of the molecular basis of its activation. Higgs HN, et al. **J Biol Chem** 1996 May 3;271(18):10874–83

Identification of diacylglycerol pyrophosphate as a novel metabolic product of phosphatidic acid during G–protein activation in plants. Munnik T, et al. **J Biol Chem** 1996 Jun 28;271(26):15708–15

Identification of the binding site for acidic phospholipids on the pH domain of dynamin: implications for stimulation of GTPase activity. Zheng J, et al. **J Mol Biol** 1996 Jan 12;255(1):14–21

Preparation and characterization of glucosylated aminoglycerophospholipids. Ravandi A, et al. **Lipids** 1995 Oct;30(10):885–91

Changes in glycerophospholipid profile in experimental nephrotic syndrome. Mimura K, et al. **Metabolism** 1996 Jul;45(7):822–6

Plasticity of cholinoreceptors of neurons of the common snail after effects on inositol–1,4,5–triphosphate– and CA(2+)–dependant mobilization of stored CA2+ and the level of phosphatidic acid. Pivovarov AS. **Neurosci Behav Physiol** 1995 Nov–Dec;25(6):474–82

Glycerophospholipid metabolism and human labour. Rice GE. **Reprod Fertil Dev** 1995;7(3):613–22 (118 ref.)

PHARMACOLOGY

Selective inhibition of phosphatidylinositol 3–kinase by phosphatidic acid and related lipids. Lauener R, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):8–14

Phosphatidic acid mobilized by phospholipase D is involved in the phorbol 12–myristate 13–acetate–induced G2 delay of A431 cells. Kaszkin M, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):129–38

Phosphatidylethanol stimulates the plasma–membrane calcium pump from human erythrocytes. Suju M, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):933–8

Characteristics of phosphatidic acid–containing lipoproteins which selectively inhibit bitter taste: high affinity to frog tongue surface and hydrophobic model membranes. Katsuragi Y, et al. **Biochim Biophys Acta** 1996 Apr 17; 1289(3):322–8

Activation of detergent–solubilized diacylglycerol acyltransferase by anionic phospholipids. Kamisaka Y, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):520–3

Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells. Williger BT, et al. **J Biol Chem** 1995 Dec 15;270(50):29656–9

Phosphatidic acid and lysophosphatidic acid induce haptotactic migration of human monocytes. Zhou D, et al. **J Biol Chem** 1995 Oct 27;270(43):25549–56

Inhibition of neuroblastoma cell phosphatidylinositol 3–kinase by CDP–diacylglycerol and phosphatidate. Lavie Y, et al. **J Neurochem** 1996 Feb;66(2):811–6

Phosphatidic acid activation of protein kinase C in LA–N–1 neuroblastoma cells. Lang D, et al. **Neurosci Lett** 1995 Dec 15;201(3):199–202

[Effect of sn–2–acetylated analogs of phosphatidalic acid on release and aggregation of human platelets] Muzia GI, et al. **Biokhimiia** 1996 Mar;61(3):455–60 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Messenger functions of phosphatidic acid. English D, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):117–32 (140 ref.)

PHOSPHATIDYLCHOLINES

The effect of cornea proteoglycans on liposome peroxidation. Albertini R, et al. **Arch Biochem Biophys** 1996 Mar 15; 327(2):209–14

Nitric oxide inhibits peroxynitrite–induced production of hydroxyeicosatetraenoic acids and F2–isoprostanes in phosphatidylcholine liposomes. Laskey RE, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):193–8

Effects of fumonisin B1 on oxygen transport in membranes. Yin JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5; 225(1):250–5

Effects of phospholipid fatty acyl chain length on phosphorylation and dephosphorylation of the Ca(2+)–ATPase. Starling AP, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):875–9

Effects of submicellar bile salt concentrations on biological membrane permeability to low molecular weight non–ionic solutes. Albalak A, et al. **Biochemistry** 1996 Jun 18; 35(24):7936–45

Structural requirements for the association of native and partially folded conformations of alpha–lactalbumin with model membranes. Bañuelos S, et al. **Biochemistry** 1996 Apr 2;35(13):3892–8

Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Billy D, et al. **Biochemistry** 1995 Oct 17; 34(41):13699–704

Gramicidin A aggregation in supported gel state phosphatidylcholine bilayers. Mou J, et al. **Biochemistry** 1996 Mar 12;35(10):3222–6

Study by infrared spectroscopy of the interdigitation of C26:0 cerebroside sulfate into phosphatidylcholine bilayers. Nabet A, et al. **Biochemistry** 1996 May 28;35(21):6674–83

Pyrene lipids as markers of peroxidative processes in different regions of low and high density lipoproteins. Viani P, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):78–86

Effects of pH conditions on Ca2+ transport catalyzed by ionophores A23187, 4–BrA23187, and ionomycin suggest problems with common applications of these compounds in biological systems. Erdahl WL, et al. **Biophys J** 1995 Dec;69(6):2350–63

Interaction of poly(ethylene–glycols) with air–water interfaces and lipid monolayers: investigations on surface pressure and surface potential. Winterhalter M, et al. **Biophys J** 1995 Oct;69(4):1372–81

Effect of lipid ozonation products on liposomal membranes detected by Laurdan fluorescence. Salgo MG, et al. **Free Radic Biol Med** 1995 Nov;19(5):609–16

Enhancement of lipid peroxidation by indole–3–acetic acid and derivatives: substituent effects. Candeias LP, et al. **Free Radic Res** 1995 Nov;23(5):403–18

Apolipoprotein A–I conformation in reconstituted discoidal lipoproteins varying in phospholipid and cholesterol content. Bergeron J, et al. **J Biol Chem** 1995 Nov 17; 270(46):27429–38

pH–dependent conformational properties of saposins and their interactions with phospholipid membranes. Vaccaro AM, et al. **J Biol Chem** 1995 Dec 22;270(51):30576–80

An evaluation of the safety of mixed micelles in healthy subjects. Ballinger AB, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):110–2

Imaging of single molecule diffusion. Schmidt T, et al.

PHOSPHATIDYLCHOLINES

Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2926–9

ADMINISTRATION & DOSAGE

Comparison of a new intravenous echo contrast agent (BY 963) with Albunex for opacification of left ventricular cavity. Leischik R, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):101–9

Phase I: transcranial echo contrast studies in healthy volunteers. Kaps M, et al. **Stroke** 1995 Nov;26(11):2048–52

ADVERSE EFFECTS

Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury [see comments] Lichtenberger LM, et al. **Nat Med** 1995 Feb; 1(2):154–8. Comment in: Nat Med 1995 Jul;1(7):602–3.

ANALYSIS

Evaluation of amniotic fluid elastolytic activity: can it be a method of fetal lung maturity assessment? A comparison with Gluck's L/S test. Bażowska G, et al. **Acta Genet Med Gemellol (Roma)** 1994;43(3–4):185–92

Prediction of fetal lung maturity in infants of diabetic mothers using the FLM S/A and disaturated phosphatidylcholine tests. Tanasijevic MJ, et al. **Am J Clin Pathol** 1996 Jan; 105(1):17–22

Fetal lung maturation in congenital diaphragmatic hernia. Moya FR, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1401–5

Identification and quantitation of choline glycerophospholipids that contain aldehyde residues by fluorometric high-performance liquid chromatography. Ou Z, et al. **Anal Biochem** 1995 May 20;227(2):289–94

Enzymatic determination of phosphatidylcholine, sphingomyelin and phosphatidylglycerol in lipid dispersions, blood cell membranes and rat pulmonary surfactant. Encinar JA, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):9–15

Phosphatidylcholine transfer protein from bovine liver contains highly unsaturated phosphatidylcholine species. Geijtenbeek TB, et al. **FEBS Lett** 1996 Aug 12;391(3):333–5

Comments on hydroperoxide detection [letter; comment] Yamamoto Y. **Free Radic Biol Med** 1995 Dec;19(6):943–4 . Comment on: Free Radic Biol Med 1995 Jan;18(1):1–10.

Direct measurement of lipid hydroperoxides in iron-dependent spinal neuronal injury. Zhang JR, et al. **J Neurochem** 1996 Jan;66(1):355–61

Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Piotrowski JJ, et al. **Life Sci** 1996;58(9):735–40

BIOSYNTHESIS

Incorporation of exogenous fatty acids into molecular species of rat hepatocyte phosphatidylcholine. Schmid PC, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):306–12

Expression of phosphatidylethanolamine N-methyltransferase-2 in McArdle-RH7777 hepatoma cells inhibits the CDP-choline pathway for phosphatidylcholine biosynthesis via decreased gene expression of CTP:phosphocholine cytidylyltransferase. Cui Z, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):939–45

Stimulation of phosphatidylcholine biosynthesis in mouse MLE-12 type-II cells by conditioned medium from cortisol-treated rat fetal lung fibroblasts. MacDonald JI, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):425–31

Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat sympathetic neurons and impair axonal extension. Posse de Chaves E, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):411–7

Two new sphingomyelin analogues inhibit phosphatidylcholine biosynthesis by decreasing membrane-bound CTP: phosphocholine cytidylyltransferase levels in HaCaT cells. Wieder T, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):873–9

Tight connection between choline transport and phosphatidylcholine synthesis in MDCK cells. Zlatkine P, et al. **Biochem J** 1996 May 1;315 (Pt 3):983–7

Lipid composition of the phosphatidylcholine-producing bacterium Hyphomicrobium vulgare NP-160. Batrakov SG, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):129–37

Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion. Fast DG, et al. **Biochim Biophys Acta** 1995 Sep 14; 1258(2):159–68

c-Ha-ras oncogene expression increases choline uptake, CTP: phosphocholine cytidylyltransferase activity and phosphatidylcholine biosynthesis in the immortalized human keratinocyte cell line HaCaT. Geilen CC, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):299–305

The enhancement of phosphatidylcholine biosynthesis by angiotensin II in H9c2 cells. Tran K, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):283–90

Partial liquid ventilation enhances surfactant phospholipid production. Steinhorn DM, et al. **Crit Care Med** 1996 Jul; 24(7):1252–6

Effect of 1-O-octadecyl-2-O-methyl-glycerophosphocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. Zhou X, et al. **Eur J Biochem** 1995 Sep 15;232(3):881–8

Phosphatidylcholine synthesis-related enzyme activities of bovine brain microvessels exhibit susceptibility to peroxidation. Sipione S, et al. **FEBS Lett** 1996 Apr 8; 384(1):19–24

A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. Cui Z, et al. **J Biol Chem** 1996 Jun 21;271(25):14668–71

Overexpression of MARCKS, but not protein kinase C-alpha, increases phorbol ester-stimulated synthesis of phosphatidylcholine in human SK-N-MC neuroblastoma cells. Rose SD, et al. **J Neurochem** 1996 Apr;66(4):1766–9

Phorbol ester stimulation of phosphatidylcholine synthesis in four cultured neural cell lines: correlations with expression of protein kinase C isoforms. Sproull SA, et al. **Neurochem Res** 1995 Dec;20(12):1397–407

BLOOD

Reaction of phosphatidylcholine hydroperoxide in human plasma: the role of peroxidase and lecithin:cholesterol acyltransferase. Nagata Y, et al. **Arch Biochem Biophys** 1996 May 1;329(1):24–30

Arachidonic acid status of human infants: influence of gestational age at birth and diets with very long chain n-3 and n-6 fatty acids. Carlson SE. **J Nutr** 1996 Apr;126(4 Suppl):1092S–8S

High phosphatidylcholine hydroperoxide level in plasma of guinea pigs with low and excess supplementation of ascorbic acid. Kinoshita M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb;42(1):35–46

[Five cases of hereditary high red cell membrane phosphatidylcholine hemolytic anemia in three families] Wakita M, et al. **Rinsho Ketsueki** 1996 Mar;37(3):265–70 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Microscale synthesis of phosphatidyl-[3H]choline from 1,2-diacylglycerol. Assessment of isomerization by reversed-phase high-performance liquid chromatography. Bugaut M, et al. **Lipids** 1995 Sep;30(9):875–81

CHEMISTRY

Phosphatidylcholine molecular species of calf lung surfactant. Kahn MC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L567–73

Interaction of anionic/nonionic surfactant mixtures with phosphatidylcholine liposomes. de la Maza A, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):167–73

Partial characterization of regulation of biliary lecithin hydrophobicity: association with organic anion-induced solute cholestasis in rats. Miura H, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):795–7

Lecithin hydrophobicity modulates the process of cholesterol crystal nucleation and growth in supersaturated model bile systems. Ochi H, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):139–44

Dimethylsulphoxide stabilizes gel phases of phosphatidylcholines. Yu ZW, et al. **Biochem Soc Trans** 1995 Aug;23(3):411S

Cardiotoxin II segregates phosphatidylglycerol from mixtures with phosphatidylcholine: (31)P and (2)H NMR spectroscopic evidence. Carbone MA, et al. **Biochemistry** 1996 Mar 19;35(11):3368–78

Induction of nonbilayer structures in diacylphosphatidylcholine model membranes by transmembrane alpha-helical peptides: importance of hydrophobic mismatch and proposed role of tryptophans. Killian JA, et al. **Biochemistry** 1996 Jan 23;35(3):1037–45

Effect of liposomal composition on photoactivated liposome fusion. Miller CR, et al. **Biochemistry** 1996 Sep 10; 35(36):11782–90

Gramicidin channel function does not depend on phospholipid chirality. Providence LL, et al. **Biochemistry** 1995 Dec 19;34(50):16404–11

Changes in phosphatidylcholine liposomes caused by a mixture of Triton X-100 and sodium dodecyl sulfate. de la Maza A, et al. **Biochim Biophys Acta** 1996 Apr 19; 1300(2):125–34

Temperature-controlled release property of phospholipid vesicles bearing a thermo-sensitive polymer. Hayashi H, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):127–34

Calorimetric detection of a sub-main transition in long-chain phosphatidylcholine lipid bilayers. Jørgensen K. **Biochim Biophys Acta** 1995 Dec 13;1240(2):111–4

Interaction between alpha-tocopherol and heteroacid phosphatidylcholines with different amounts of unsaturation. Sánchez-Migallón MP, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):251–8

Lateral domain heterogeneity in cholesterol/phosphatidylcholine monolayers as a function of cholesterol concentration and phosphatidylcholine acyl chain length. Slotte JP. **Biochim Biophys Acta** 1995 Sep 13;1238(2):118–26

Thermodynamics of transfer of cholesterol from gel to fluid phases of phospholipid bilayers. Spink CH, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):190–6

Anomalous phase behavior of long chain saturated lecithin bilayers. Sun WJ, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):17–24

Molecular order and dynamics of phosphatidylcholine bilayer membranes in the presence of cholesterol, ergosterol and lanosterol: a comparative study using 2H-, 13C- and 31P-NMR spectroscopy. Urbina JA, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):163–76

The effect of side-chain analogues of cholesterol on the thermotropic phase behavior of 1-stearoyl-2-oleoylphosphatidylcholine bilayers: a differential scanning calorimetric study. Vilchèze C, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):235–42

Effects of plant sterols on the hydration and phase behavior of DOPE/DOPC mixtures. Webb MS, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):226–38

Archaebacterial lipid models: stable liposomes from 1-alkyl-2-phytanyl-sn-glycero-3-phosphocholines. Yamauchi K, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):163–9

Hydrostatic pressure-induced conformational changes in phosphatidylcholine headgroups: a 2H NMR study. Bonev BB, et al. **Biophys J** 1995 Aug;69(2):518–23

Chiral discrimination in a monolayer of a triple-chain phosphatidylcholine. Bringezu F, et al. **Biophys J** 1996 Apr; 70(4):1789–95

The effect of increasing membrane curvature on the phase transition and mixing behavior of a dimyristoyl-sn-glycero-3-phosphatidylcholine/ distearoyl-sn-glycero-3-phosphatidylcholine lipid mixture as studied by Fourier transform infrared spectroscopy and differential scanning calorimetry. Brumm T, et al. **Biophys J** 1996 Mar;70(3):1373–9

The hemifusion intermediate and its conversion to complete fusion: regulation by membrane composition. Chernomordik L, et al. **Biophys J** 1995 Sep;69(3):922–9

Effects of diacylglycerols on conformation of phosphatidylcholine headgroups in phosphatidylcholine/phosphatidylserine bilayers. Goldberg EM, et al. **Biophys J** 1995 Sep;69(3):965–73

Definition of lipid membrane structural parameters from neutronographic experiments with the help of the strip function model. Gordeliy VI, et al. **Biophys J** 1995 Oct; 69(4):1424–8

Phase separation dynamics and lateral organization of two-component lipid membranes. Jørgensen K, et al. **Biophys J** 1995 Sep;69(3):942–54

IR spectroscopic determination of gel state miscibility in long-chain phosphatidylcholine mixtures. Mendelsohn R, et al. **Biophys J** 1995 Nov;69(5):1987–98

Glycosphingolipid headgroup orientation in fluid phospholipid/cholesterol membranes: similarity for a range of glycolipid fatty acids. Morrow MR, et al. **Biophys J** 1995 Sep;69(3):955–64

Lipid vesicle adsorption versus formation of planar bilayers on solid surfaces. Nollert P, et al. **Biophys J** 1995 Oct; 69(4):1447–55

Partition coefficient of a surfactant between aggregates and solution: application to the micelle-vesicle transition of egg phosphatidylcholine and octyl beta-D-glucopyranoside. Paternostre M, et al. **Biophys J** 1995 Dec;69(6):2476–88

Interdigitation does not affect translational diffusion of lipids in liquid crystalline bilayers. Schram V, et al. **Biophys J** 1995 Dec;69(6):2517–20

Site of action of the local anesthetic tetracaine in a phosphatidylcholine bilayer with incorporated cardiolipin. Shibata A, et al. **Biophys J** 1995 Aug;69(2):470–7

Temperature dependence of the repulsive pressure between phosphatidylcholine bilayers. Simon SA, et al. **Biophys J** 1995 Oct;69(4):1473–83

The interfacial elastic packing interactions of galactosylceramides, sphingomyelins, and phosphatidylcholines. Smaby JM, et al. **Biophys J** 1996 Feb; 70(2):868–77

Thermodynamics of interdigitated phases of phosphatidylcholine in glycerol. Swamy MJ, et al. **Biophys J** 1995 Oct;69(4):1402–8

Phase stability of phosphatidylcholines in dimethylsulfoxide solutions. Yu ZW, et al. **Biophys J** 1995 Oct;69(4):1456–63

The action of hypochlorous acid on phosphatidylcholine liposomes in dependence on the content of double bonds. Stoichiometry and NMR analysis. Arnhold J, et al. **Chem Phys Lipids** 1995 Oct 22;78(1):55–64

Solubilizing effects caused by alkyl pyridinium surfactants in phosphatidylcholine liposomes. de la Maza A, et al. **Chem Phys Lipids** 1995 Aug 1;77(1):79–87

Interaction of undecaprenyl phosphate with phospholipid bilayers. Janas T, et al. **Chem Phys Lipids** 1995 Aug 1; 77(1):89–97

The composition of individual molecular species of plasma phosphatidylcholine in human pregnancy. Postle AD, et al. **Early Hum Dev** 1995 Aug 30;43(1):47–58

The micelle to vesicle transition of lipids and detergents in the presence of a membrane protein: towards a rationale for 2D crystallization. Dolder M, et al. **FEBS Lett** 1996 Mar 11;382(1–2):203–8

Fast solute release from photosensitive liposomes: an alternative to 'caged' reagents for use in biological systems. Morgan CG, et al. **FEBS Lett** 1995 Nov 13;375(1–2):113–6

DNA initiates polymorphic structural transitions in lecithin. Tarahovsky TS, et al. **FEBS Lett** 1996 Jul 22;390(2):133–6

Effect of lipid ozonation products on liposomal membranes detected by Laurdan fluorescence. Salgo MG, et al. **Free Radic Biol Med** 1995 Nov;19(5):609–16

Local anesthetic [2-(decyloxy)phenyl]-2-(1-piperidinyl)ethyl ester of

carbamic acid perturbs phosphatidylcholine bilayer. Gallová J, et al. **Gen Physiol Biophys** 1995 Feb;14(1):61–5

Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes. Arab S, et al. **Glycoconj J** 1996 Apr;13(2):159–66

Lateral organization of pyrene-labeled lipids in bilayers as determined from the deviation from equilibrium between pyrene monomers and excimers. Barenholz Y, et al. **J Biol Chem** 1996 Feb 9;271(6):3085–90

Phosphatidylcholines with sn-1 saturated and sn-2 cis-monounsaturated acyl chains. Their melting behavior and structures. Wang G, et al. **J Biol Chem** 1995 Sep 29; 270(39):22738–46

Phospholipids with a short acyl chain modulate phospholipase and acyltransferase activities. Koumanov KS, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):59–76

Immobilized artificial membrane chromatography: a rapid and accurate HPLC method for predicting bile salt–membrane interactions. Cohen DE, et al. **J Lipid Res** 1995 Oct;36(10):2251–60

Susceptibility for hydroperoxide formation of phosphatidylcholine and phosphatidylethanolamine in liposomes. Wang JY, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):273–80

Analysis of micellar and vesicular lecithin and cholesterol in model bile using 1H- and 31P-NMR. de Graaf MP, et al. **MAGMA** 1995 Jul;3(2):67–75

Structure of the ripple phase in lecithin bilayers. Sun WJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7008–12

Antioxidant protection of egg lecithin liposomes during sonication. Gabrielska J, et al. **Z Naturforsch [C]** 1995 Jul–Aug;50(7–8):561–4

[Interaction of hypochlorite with hydroperoxides and other oxidation products of phosphatidylcholine liposomes] Panasenko OM, et al. **Biokhimiia** 1995 Sep;60(9):1419–28 (Eng. Abstr.) **(Rus)**

[Interactions of surfactants with model and biological membranes. XXII. Spectrophotometric determination of partition coefficient of heptacaine, a local anesthetic, between the phospholipid liposome and water phase] Hammel M, et al. **Ceska Slov Farm** 1996 Mar;45(2):58–66 (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

A prognostic role for anti-phosphatidyl choline antibodies in human cerebral malaria. Das BK, et al. **Clin Exp Immunol** 1996 Mar;103(3):442–5

Allergy to soy lecithin in a child. Renaud C, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):328–9

ISOLATION & PURIFICATION

[Determination of di-alpha-phosphatidylcholine in the seeds of Astragalus chinensis L. by TLC-scanning] Xu Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct;20(10):615–6, 640 (Eng. Abstr.) **(Chi)**

METABOLISM

The effect of betamethasone on phosphatidylcholine species composition in fetal rat lungs. Stettner S, et al. **Acta Vet Hung** 1995;43(2–3):297–302

Continuous, vesicle-based fluorimetric assays of 14- and 85-kDa phospholipases A2. Bayburt T, et al. **Anal Biochem** 1995 Nov 20;232(1):7–23

A chemiluminescence method to analyze phosphatidylcholine–phospholipase activity in plasma membrane preparations and in intact cells. Lucas M, et al. **Anal Biochem** 1995 Nov 1;231(2):277–81

Synthetic oligonucleotide does not bind to lipid emulsion resembling low-density lipoprotein. Bydlowski SP, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:252–4

Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Podo F, et al. **Anticancer Res** 1996 May-Jun;16(3B):1399–412

The fibril forming region of the beta-amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. Liang JS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):962–7

Methylamine decreases trafficking and packaging of newly synthesized phosphatidylcholine in lamellar bodies in alveolar type II cells. Chander A, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):271–8

Regulation of phosphatidylcholine synthesis in maturing type II cells: increased mRNA stability of CTP:phosphocholine cytidylyltransferase. Hogan M, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):799–803

Phosphatidylcholine increases the secretion of triacylglycerol-rich lipoproteins by CaCo-2 cells. Mathur SN, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):569–75

Bradykinin-stimulated phosphatidylcholine hydrolysis in airway smooth muscle: the role of Ca2+ and protein kinase C. Pyne S, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):637–42

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039–46

Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Gazit E, et al. **Biochemistry** 1995 Sep 12;34(36):11479–88

The hydrophobic nature of residue-5 of human protein C is a major determinant of its functional interactions with acidic phospholipid vesicles. Jalbert LR, et al. **Biochemistry** 1996 Jun 4;35(22):7093–9

Specific interaction of (R)-3-hydroxybutyrate dehydrogenase with membrane phosphatidylcholine as studied by ESR spectroscopy in oriented phospholipid multibilayers: coenzyme binding enhances the interaction with phosphatidylcholine. Klein K, et al. **Biochemistry** 1996 Mar 5;35(9):3044–9

Asymmetric and functional reconstitution of band 3 into pre-formed phosphatidylcholine vesicles. Boulter JM, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):265–71

Stability against temperature and external agents of vesicles composed of archael bolaform lipids and egg PC. Fan Q, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):83–8

Ethanol-enhanced permeation of phosphatidylcholine/phosphatidylethanolamine mixed liposomal membranes due to ethanol-induced lateral phase separation. Komatsu H, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):73–9

Incorporation of 12(S)-hydroxyeicosatetraenoic acid into the phosphatidylcholine signaling pathway. Legrand AB, et al. **Biochim Biophys Acta** 1996 May 31;1301(1–2):150–60

Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. Main LA, et al. **Biochim Biophys Acta** 1996 Mar 29;1300(1):17–24

EPR study of spermine interaction with multilamellar phosphatidylcholine liposomes. Momo F, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):89–94

Subcellular fractions of bovine brain degrade phosphatidylcholine by sequential deacylation of the sn-1 and sn-2 positions. Pete MJ, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):325–32

Mastoparan-induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells. Mizuno K, et al. **Br J Pharmacol** 1995 Oct;116(3):2090–6

Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. Vázquez M, et al. **Br J Pharmacol** 1995 Oct;116(3):2067–75

Phosphatidylcholine could be the source of 1,2-DAG which activates protein kinase C in EGF-stimulated colon carcinoma cells (HT29). Balogh A, et al. **Cell Signal** 1995 Nov;7(8):793–801

High-pressure proton NMR study of lateral self-diffusion of phosphatidylcholines in sonicated unilamellar vesicles. Lee BS, et al. **Chem Phys Lipids** 1995 Nov 17;78(2):103–17

Hydrophobicity and sorption of chlorophenolates to lipid membranes Smejtek P, et al. **Chemosphere** 1996 Jul; 33(1):177–201

Accumulation of phosphatydilcholine-hydroperoxide in dialysis patients with diabetic nephropathy. Sanaka T, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S33–7

Evolutionary comparison of enzyme activities of phosphatidylcholine metabolism in the nervous system of an invertebrate (Loligo pealei), lower vertebrate (Mustelus canis) and the rat. Anfuso CD, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):493–501

Pores formed in lipid bilayers and in native membranes by nodularin, a cyanobacterial toxin. Spassova M, et al. **Eur Biophys J** 1995;24(2):69–76

Comparative study of the metabolic pools of sphingomyelin and phosphatidylcholine sensitive to tumor necrosis factor. Andrieu N, et al. **Eur J Biochem** 1996 Mar 1;236(2):738–45

Expression of a rat liver phosphatidylcholine translocator in Xenopus laevis oocytes. Kullak-Ublick GA, et al. **Hepatology** 1996 May;23(5):1254–9

Synthesis and intracellular transport of aminoglycerophospholipids in permeabilized cells of the yeast, Saccharomyces cerevisiae. Achleitner G, et al. **J Biol Chem** 1995 Dec 15;270(50):29836–42

Transmembrane movement of phosphatidylcholine in mitochondrial outer membrane vesicles. Dolis D, et al. **J Biol Chem** 1996 May 17;271(20):11879–83

Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells. Li Q, et al. **J Biol Chem** 1995 Nov 3;270(44):26216–23

Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. Ruetz S, et al. **J Biol Chem** 1995 Oct 27;270(43):25388–95

Alpha-branched 1,2-diacyl phosphatidylcholines as effectors of activity of cytochrome P450SCC (CYP11A1). Modeling the structure of the fatty acyl chain region of cardiolipin. Schwarz D, et al. **J Biol Chem** 1996 May 31; 271(22):12840–6

Thrombin induces proliferation of osteoblast-like cells through phosphatidylcholine hydrolysis. Suzuki A, et al. **J Cell Physiol** 1996 Jul;168(1):209–16

Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. Sakai M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb;42(1):47–54

Intrinsic sterol- and phosphatidylcholine transfer activities of 17 beta-hydroxysteroid dehydrogenase type IV. Seedorf U, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):549–53

Staphylococcal enterotoxin-B (SEB) alters [14C]-choline transport and phosphatidylcholine metabolism in cultured human kidney proximal tubular cells. Khullar M, et al. **Mol Cell Biochem** 1995 May 24;146(2):115–20

Lipid peroxidation as an indicator of biocompatibility in haemodialysis. Sanaka T, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:34–8

Diffusivity of bile salt/phospholipid aggregates in mucin. Li CY, et al. **Pharm Res** 1996 Apr;13(4):535–41

Mutant rat phosphatidylinositol/phosphatidylcholine transfer proteins specifically defective in phosphatidylinositol transfer: implications for the regulation of phospholipid transfer activity. Alb JG Jr, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8826–30

Gastric mucosal phosphatidylcholine hydroperoxide increases during cold water-immersion restraint stress in rats. Shian WM, et al. **Tohoku J Exp Med** 1995 Jun; 176(2):127–30

Perfluorodecanoic acid, a peroxisome proliferator, activates phospholipase C, inhibits CTP:phosphocholine cytidylyltransferase, and elevates diacylglycerol in rat liver. Reo NV, et al. **Toxicol Lett** 1996 Jul;86(1):1–11

[Comparative study of the kinetics of phospholipid liposome peroxidation, induced by hypochlorite and in the Fe2+ + ascorbate system] Panasenko OM, et al. **Biofizika** 1996 Mar-Apr;41(2):334–41 (Eng. Abstr.) **(Rus)**

[Effect of specific activation of phosphatidylcholine metabolism in hamster fibroblasts transformed by Rous sarcoma virus] Krasil'nikov MA, et al. **Biokhimiia** 1996 Mar;61(3):525–31 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Uptake and distribution of the boron-containing ether lipid B-Et-11-OMe in tumor-bearing mice. Lemmen P, et al. **Anticancer Drugs** 1995 Dec;6(6):744–8

PHARMACOLOGY

Purification and characterization of a (R)-3-hydroxybutyrate dehydrogenase deletion mutant. Evidence for C-terminal involvement in enzyme activation by lecithin. Langston HP, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):45–52

Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Comoglio A, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1313–6

Iron-ascorbate-phospholipid mediated modification of low density lipoprotein. Greenspan P, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):242–8

Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dilauroylphosphatidylcholine-induced vesiculation. Diaz C, et al. **Blood** 1996 Apr 1;87(7):2956–61

Cholesterol-lowering effect of soyabean lecithin in normolipidaemic rats by stimulation of biliary lipid secretion. Polichetti E, et al. **Br J Nutr** 1996 Mar; 75(3):471–8

Modulation of mite antigen-induced immune responses by lecithin-bound iodine in peripheral blood lymphocytes from patients with bronchial asthma. Kawano Y, et al. **Br J Pharmacol** 1995 Aug;115(7):1141–8

Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan-induced diabetes. Buko V, et al. **Cell Biochem Funct** 1996 Jun; 14(2):131–7

Relationship of phosphatidylcholine to hydrophobic surfactant on rat intestinal chylomicron secretion. Rodgers JB, et al. **Experientia** 1996 Jul 15;52(7):671–6

Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Mourelle M, et al. **Gastroenterology** 1996 Apr;110(4):1093–7

Alkyl-PAF and acyl-PAF human neutrophil priming for enhanced fMLP- and rC5a-induced superoxide anion production. Pinckard RN, et al. **J Leukoc Biol** 1996 Feb; 59(2):219–28

Phospholipids with a short acyl chain modulate phospholipase and acyltransferase activities. Koumanov KS, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):59–76

Effects of dietary phosphatidylcholine on memory in memory deficient mice with low brain acetylcholine concentration. Moriyama T, et al. **Life Sci** 1996;58(6):PL111–8

Human skin irritation studies of a lecithin microemulsion gel and of lecithin liposomes. Dreher F, et al. **Skin Pharmacol** 1996;9(2):124–9

[Absorption of di-linoleoylphosphatidylcholine after oral administration] Oette K, et al. **Arzneimittelforschung** 1995 Aug;45(8):875–9 (Eng. Abstr.) **(Ger)**

[Accumulation of ATP in rat and human hepatocyte cell membranes exposed to certain growth factors and phosphatidylcholine] Globa AG, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):271–4 **(Rus)**

[The protective effect of phosphatidylcholine liposomes in hemorrhagic shock in cats] Kryzhanovskiĭ GN, et al. **Biull Eksp Biol Med** 1995 May;119(5):480–4 **(Rus)**

[Decrease in atherogenicity of blood serum in vitro under the effect of polyunsaturated phosphatidylcholine micelles] Nikitina NA, et al. **Biull Eksp Biol Med** 1995 May; 119(5):497–501 **(Rus)**

[The immunomodulating action of preparations possessing membrane-protective properties under intensive physical loading] Uteshev BS, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):47–50 (Eng. Abstr.) **(Rus)**

[The efficacy of the immunomodulating action of Essentiale and the modified animal erythrocytes] Uteshev BS, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):52–5 (Eng. Abstr.) **(Rus)**

[The immunomodulating action of polyunsaturated

phospholipids] Uteshev BS, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):49-52 (Eng. Abstr.) **(Rus)**

[Immunomodulating action of essentiale during prolonged intake of dietary cholesterol] Bart EV, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):15-8 (Eng. Abstr.) **(Rus)**

[Inhibition of formation of superoxide radicals in leukocytes of hypercholesteremic patients under the effect of a lipid platelet activation factor antagonist] Muzia GI, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):45-8 (Eng. Abstr.) **(Rus)**

[Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] Mancilla-Ramírez J, et al. **Gac Med Mex** 1995 Jan-Feb;131(1):14-22 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. Machleidt T, et al. **J Exp Med** 1996 Aug 1;184(2):725-33

SECRETION

Activated eosinophils stimulate phosphatidylcholine secretion in primary culture of rat type II pneumocytes. Okumura M, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):569-75

Developmental regulation of phospholipid secretion by fetal type II pneumocytes. Kresch MJ, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):39-46

Patterns of bile salts and biliary lipids early after liver transplantation differentiate patients with unfavorable graft outcome. Tisone G, et al. **Transplant Proc** 1996 Jun; 28(3):1655-6

THERAPEUTIC USE

Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Patterson TS, et al. **Clin Pediatr (Phila)** 1996 May;35(5):257-60

Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Lister J. **Eur J Haematol Suppl** 1996;57:18-23

[The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB] Zeman M, et al. **Sb Lek** 1995; 96(1):43-8 (Eng. Abstr.) **(Cze)**

[Effect of essentiale on the cardioprotective action of anapriline, nitroglycerin and their combinations in acute total myocardial ischemia] Bender KI, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):12-5 (Eng. Abstr.) **(Rus)**

TOXICITY

Expression of human phospholipid hydroperoxide glutathione peroxidase gene for protection of host cells from lipid hydroperoxide-mediated injury. Yagi K, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):486-91

PHOSPHATIDYLETHANOLAMINES

Conjugates of glycosylated steroids and polyamines as novel nonviral gene delivery systems. Longley C, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:268-70

Efficient gene transfer to dispersed human pancreatic islet cells in vitro using adenovirus-polylysine/DNA complexes or polycationic liposomes. Saldeen J, et al. **Diabetes** 1996 Sep;45(9):1197-203

In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Caplen NJ, et al. **Gene Ther** 1995 Nov;2(9):603-13

Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Cao L, et al. **Hum Gene Ther** 1995 Nov;6(11):1497-501

Imaging of single molecule diffusion. Schmidt T, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2926-9

ADMINISTRATION & DOSAGE

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927-38 (37 ref.)

Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. Dinney CP, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):585-92

Increased liposome extravasation in selected tissues: effect of substance P. Rosenecker J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7236-41

Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. ten Hagen TL, et al. **Transplantation** 1995 Dec 15;60(11):1211-4

ADVERSE EFFECTS

Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. Wang L, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2077-80

ANALYSIS

Direct measurement of lipid hydroperoxides in iron-dependent spinal neuronal injury. Zhang JR, et al. **J Neurochem** 1996 Jan;66(1):355-61

N-acylphosphatidylethanolamine in dry and imbibing cottonseeds. Amounts, molecular species, and enzymatic synthesis. Sandoval JA, et al. **Plant Physiol** 1995 Sep; 109(1):269-75

Mammalian phospholipase D: phosphatidylethanolamine as an essential component. Nakamura S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4300-4

BIOSYNTHESIS

Phosphatidylethanolamine synthesis in the normal and lymphomatous mouse liver; a 13C NMR study. Dixon RM. **Anticancer Res** 1996 May-Jun;16(3B):1351-6

Effect of 1-O-octadecyl-2-O-methyl-glycerophosphocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. Zhou X, et al. **Eur J Biochem** 1995 Sep 15;232(3):881-8

Nonenzymatically evoked and cytochrome P450-dependent lipid peroxidation inhibits synthesis of phosphatidylethanolaminevia the ethanolamine base exchange reaction in rat liver microsomes. Jasínka R, et al. **FEBS Lett** 1996 May 13;386(1):33-8

Ethanolamine analogues stimulate DNA synthesis by a mechanism not involving phosphatidylethanolamine synthesis. Kiss Z, et al. **FEBS Lett** 1996 Feb 26; 381(1-2):67-70

BLOOD

Isolation and identification of glycated aminophospholipids from red cells and plasma of diabetic blood. Ravandi A, et al. **FEBS Lett** 1996 Feb 26;381(1-2):77-81

Red blood cell membrane phosphatidylethanolamine fatty acid content in various forms of retinitis pigmentosa. Schaefer EJ, et al. **J Lipid Res** 1995 Jul;36(7):1427-33

Marked enrichment of the alkenylacyl subclass of plasma ethanolamine glycerophospholipid with eicosapentaenoic acid in human subjects consuming a fish oil concentrate. Wilkinson T, et al. **Lipids** 1996 Mar;31 Suppl:S211-5

CHEMICAL SYNTHESIS

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). Kirpotin D, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):115-8

CHEMISTRY

Thermotropic properties of dioleoylphosphatidylethanolamine in aqueous dimethyl sulfoxide solutions. Yu ZW, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):187-95

A modified spectroscopic method for the determination of the transbilayer distribution of phosphatidylethanolamine in soya-bean asolectin small unilamellar vesicles. Sarti P, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):643-8

Stabilization of the non-lamellar phase of dioleoylphosphatidylethanolamine by dimethylsulphoxide. Yu ZW, et al. **Biochem Soc Trans** 1995 Aug;23(3):412S

Molecular interactions of ether-linked phospholipids. Hing FS, et al. **Biochemistry** 1995 Sep 19;34(37):11904-9

Hydrophobic alkyl headgroups strongly promote membrane curvature and violate the headgroup volume correlation due to "headgroup" insertion. Lee YC, et al. **Biochemistry** 1996 Mar 26;35(12):3677-84

Effect of liposomal composition on photoactivated liposome fusion. Miller CR, et al. **Biochemistry** 1996 Sep 10; 35(36):11782-90

Temperature-controlled release property of phospholipid vesicles bearing a thermo-sensitive polymer. Hayashi H, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):127-34

Small concentrations of alamethicin induce a cubic phase in bulk phosphatidylethanolamine mixtures. Keller SL, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):241-6

A calorimetric study of binary mixtures of saturated and monounsaturated mixed-chain phosphatidylethanolamines. Lin HN, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):199-206

Components of the lateral pressure in lipid bilayers deduced from HII phase dimensions. Marsh D. **Biochim Biophys Acta** 1996 Mar 13;1279(2):119-23

The phosphorus-31 spectra of dielectrophoretically reoriented tubules in the HII phase of DOPE. Osman P, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):160-8

Metastability of dimiristoylphosphatidylethanolamine as studied by FT-IR and the effect of alpha-tocopherol. Salgado J, et al. **Biochim Biophys Acta** 1995 Nov 1; 1239(2):213-25

Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine. Takahashi H, et al. **Biochim Biophys Acta** 1996 Mar 15; 1289(2):209-16

Phosphatidylethanol as a 13C-NMR probe for reporting packing constraints in phospholipid membranes. Victorov AV, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):151-62

Effects of plant sterols on the hydration and phase behavior of DOPE/DOPC mixtures. Webb MS, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):226-38

Nuclear magnetic resonance studies of lipid hydration in monomethyldioleoylphosphatidylethanolamine dispersions. Chen ZJ, et al. **Biophys J** 1996 Mar;70(3):1412-8

The hemifusion intermediate and its conversion to complete fusion: regulation by membrane composition. Chernomordik L, et al. **Biophys J** 1995 Sep;69(3):922-9

Time-resolved fluorescence anisotropy of fluorescent-labeled lysophospholipid and taurodeoxycholate aggregates. DeLong LJ, et al. **Biophys J** 1996 Mar;70(3):1466-71

Molecular order and hydration property of amine group in phosphatidylethanolamine and its N-methyl derivatives at subzero temperatures. Hsieh CH, et al. **Biophys J** 1995 Dec; 69(6):2521-30

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). Kirpotin D, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):115-8

Susceptibility for hydroperoxide formation of phosphatidylcholine and phosphatidylethanolamine in liposomes. Wang JY, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):273-80

Role of lipid polymorphism in pulmonary surfactant. Perkins WR, et al. **Science** 1996 Jul 19;273(5273):330-2

Lamellar biogels: fluid-membrane-based hydrogels containing polymer lipids. Warriner HE, et al. **Science** 1996 Feb 16;271(5251):969-73

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G, et al. **Vaccine** 1995 Nov; 13(16):1557-62

Molecular interactions of quinidine with phospholipid bilayers. Suwalsky M, et al. **Z Naturforsch [C]** 1995 Jul-Aug;50(7-8):527-34

IMMUNOLOGY

Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Sugi T, et al. **Blood** 1995 Oct 15;86(8):3083-9

METABOLISM

Phosphatidylethanolamine methylation and hepatoma cell growth. Vance DE, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1413-6 (17 ref.)

Human erythrocyte band 7.2b is preferentially labeled by a photoreactive phospholipid. Desneves J, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):108-14

Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Sugiura T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):113-7

Evidence for receptor and G-protein regulation of a phosphatidylethanolamine-hydrolysing phospholipase A1 in guinea-pig heart microsomes: stimulation of phospholipase A1 activity by DL-isoprenaline and guanine nucleotides. Badiani K, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):805-9

Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Neuenschwander PF, et al. **Biochemistry** 1995 Oct 31;34(43):13988-93

Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Hansen HS, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):303-8

Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of Escherichia coli. Huijbregts RP, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):41-50

Compound D609 inhibits phorbol ester-stimulated phospholipase D activity and phospholipase C-mediated phosphatidylethanolamine hydrolysis. Kiss Z, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):105-8

Ethanol-enhanced permeation of phosphatidylcholine/phosphatidylethanolamine mixed liposomal membranes due to ethanol-induced lateral phase separation. Komatsu H, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):73-9

Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. Vázquez M, et al. **Br J Pharmacol** 1995 Oct;116(3):2067-75

Interaction of a fluorescent analog of N-deacetyl-N-methyl-colchicine (colcemid) with liver alcohol dehydrogenase. Sengupta S, et al. **Eur J Biochem** 1995 Sep 15;232(3):844-8

Characterization and localization of the rat, mouse and human testicular phosphatidylethanolamine binding protein. Seddiqi N, et al. **Experientia** 1996 Feb 15; 52(2):101-10

Synthesis and intracellular transport of aminoglycerophospholipids in permeabilized cells of the yeast, Saccharomyces cerevisiae. Achleitner G, et al. **J Biol Chem** 1995 Dec 15;270(50):29836-42

Import of phosphatidylethanolamine for the assembly of rat brain mitochondrial membranes. Camici O, et al. **J Membr Biol** 1995 Nov;148(2):169-76

Preferential esterification of arachidonic acid into

ethanolamine phospholipids in epithelial cells from ovine endometrium. Tamby JP, et al. **J Reprod Fertil** 1996 May; 107(1):23–30

Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine. Kawada M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):873–8

[The role of the phosphoinositide signal system and phosphatidylethanolamine methylation in the development of long-term posttetanic potentiation in rats] Pavlinova LI, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):45–50 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. Uster PS, et al. **FEBS Lett** 1996 May 20; 386(2–3):243–6

PHARMACOLOGY

Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes. Hara T, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):51–8

Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2. Breuer R, et al. **Life Sci** 1995;57(16):PL237–40

Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Asano T, et al. **Oncol Res** 1995;7(5):253–7

Role of phospholipids containing docosahexaenoyl chains in modulating the activity of protein kinase C. Giorgione J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9767–70

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G, et al. **Vaccine** 1995 Nov; 13(16):1557–62

PHYSIOLOGY

A phospholipid acts as a chaperone in assembly of a membrane transport protein. Bogdanov M, et al. **J Biol Chem** 1996 May 17;271(20):11615–8

THERAPEUTIC USE

Prevention of experimental endotoxin shock by a monocyte activator. Passlick B, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2535–40

TOXICITY

Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Konopka K, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):186–96

PHOSPHATIDYLGLYCEROLS

Structural requirements for the association of native and partially folded conformations of alpha-lactalbumin with model membranes. Bañuelos S, et al. **Biochemistry** 1996 Apr 2;35(13):3892–8

Partitioning of HIV-1 Gag and Gag-related proteins to membranes. Ehrlich LS, et al. **Biochemistry** 1996 Apr 2; 35(13):3933–43

ANALYSIS

Enzymatic determination of phosphatidylcholine, sphingomyelin and phosphatidylglycerol in lipid dispersions, blood cell membranes and rat pulmonary surfactant. Encinar JA, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):9–15

BIOSYNTHESIS

Isolation and expression of the Rhodobacter sphaeroides gene (pgsA) encoding phosphatidylglycerophosphate synthase. Dryden SC, et al. **J Bacteriol** 1996 Feb;178(4):1030–8

CHEMICAL SYNTHESIS

Stereospecific labeling of the glycerol moiety: synthesis of 1,2-dioleoyl-sn-[3-3H]glycero-3-phospho(1-rac-glycerol). Schmitt JD, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):131–7

CHEMISTRY

Cardiotoxin II segregates phosphatidylglycerol from mixtures with phosphatidylcholine: (31)P and (2)H NMR spectroscopic evidence. Carbone MA, et al. **Biochemistry** 1996 Mar 19;35(11):3368–78

Interaction of alpha-lactalbumin with phosphatidylglycerol. Influence of protein binding on the lipid phase transition and lipid acyl chain mobility. Montich GG, et al. **Biochemistry** 1995 Oct 10;34(40):13139–45

Insertion of diphtheria toxin in lipid bilayers studied by spin label ESR. Montich GG, et al. **Biochemistry** 1995 Sep 12; 34(36):11561–7

Interaction of dipyridamole with lipids in mixed Langmuir monolayers. Borissevitch GP, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):12–8

Rapid diffusion of the lipid phosphorus of phosphatidylglycerol liposomes through polycarbonate membranes is caused by the oxidation of the unsaturated fatty acids. Chow CY, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):168–76

Direct measurement of ion distributions between lipid membranes with X-ray diffraction. Kirchner S. **Biochim Biophys Acta** 1996 Mar 13;1279(2):181–9

METABOLISM

Comparison of lipid aggregation and self-aggregation activities of pulmonary surfactant-associated protein A. Ruano ML, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):683–9

Control by phosphatidylglycerol of expression of the flhD gene in Escherichia coli. Mizushima T, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):397–401

Kinetic analysis of cardiolipin synthase: a membrane enzyme with two glycerophospholipid substrates. Schlame M, et al. **Lipids** 1995 Jul;30(7):633–40

PHARMACOLOGY

Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. Shakiba S, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1383–5

The role of phosphatidylglycerol as a functional effector and membrane anchor of the D1-core peptide from photosystem II-particles of the cyanobacterium Oscillatoria chalybea. Kruse O, et al. **Z Naturforsch [C]** 1995 May-Jun;50(5–6):380–90

THERAPEUTIC USE

Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Patterson TS, et al. **Clin Pediatr (Phila)** 1996 May;35(5):257–60

Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Lister J. **Eur J Haematol Suppl** 1996;57:18–23

Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Revak SD, et al. **Pediatr Res** 1996 Apr; 39(4 Pt 1):715–24

PHOSPHATIDYLINOSITOL PHOSPHATES

BIOSYNTHESIS

Stimulation of nuclear polyphosphoinositide synthesis by GTP-gamma-S: a potential regulatory role for nuclear GTP-binding proteins. Martelli AM, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):182–6

Thrombin receptors modulate insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate accumulation in 1321N1 astrocytoma cells. Batty IH, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):347–51

Phorbol esters stimulate phosphatidylinositol 3,4,5-trisphosphate production in 3T3-L1 adipocytes: implications for stimulation of glucose transport. Navé BT, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):203–5

Phosphatidylinositol transfer protein dictates the rate of inositol trisphosphate production by promoting the synthesis of PIP2. Cunningham E, et al. **Curr Biol** 1995 Jul 1;5(7):775–83

Integrin-dependent control of inositol lipid synthesis in vascular endothelial cells and smooth muscle cells. McNamee HP, et al. **Exp Cell Res** 1996 Apr 10; 224(1):116–22

METABOLISM

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23–33 (31 ref.)

Decreased m3-muscarinic and alpha 1-adrenergic receptor stimulation of PIP2 hydrolysis in parotid gland membranes from aged rats: defect in activation of G alpha q/11. Sawaki K, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):319–26

Reducing PIP2 hydrolysis, Ins(1,4,5)P3 receptor availability, or calcium gradients inhibits progesterone-stimulated Xenopus oocyte maturation. Han JK, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):931–9

Evidence for substrate-cycling of 3-, 3,4-, 4-, and 4,5-phosphorylated phosphatidylinositols in plants. Brearley CA, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1001–7

Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. James SR, et al. **Biochem J** 1996 May 1;315 (Pt 3):709–13

Stimulation of signal transduction pathways by MCP-1 in human monocytes and THP-1 cells. Turner SJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):69S

Immunocytochemical detection of the intranuclear variations of phosphatidylinositol 4,5-bisphosphate amount associated with changes of activity and amount of phospholipase C beta 1 in cells exposed to mitogenic or differentiating agonists. Maraldi NM, et al. **Biol Cell** 1995;83(2-3):201–10

Spectroscopic studies of a phosphoinositide-binding peptide from gelsolin: behavior in solutions of mixed solvent and anionic micelles. Xian W, et al. **Biophys J** 1995 Dec; 69(6):2695–702

Activation of phosphatidylinositol bisphosphate signal transduction pathway after experimental brain injury: a lipid study. Dhillon HS, et al. **Brain Res** 1995 Nov 6; 698(1-2):100–6

Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Rameh LE, et al. **Cell** 1995 Dec 1;83(5):821–30

Defective CD4+ T cell signaling in murine AIDS: uncoupling of the T cell receptor complex from PIP2 hydrolysis. Fitzpatrick EA, et al. **Cell Immunol** 1996 Feb 1;167(2):176–87

Effect of carbachol on phospholipase C-mediated phosphatidylinositol 4,5-bisphosphate hydrolysis, and its modulation by isoproterenol in rabbit corneal epithelial cells. Zhang Y, et al. **Curr Eye Res** 1995 Jul;14(7):563–71

Follicle cell regulation of amino acid uptake and polyphosphoinositide metabolism in oocytes of the limpet Patella vulgata. Borg B, et al. **Dev Biol** 1995 Sep; 171(1):159–68

Phosphatidylinositol 3,4,5-trisphosphate is a substrate for the 75 kDa inositol polyphosphate 5-phosphatase and a novel 5-phosphatase which forms a complex with the p85/p110 form of phosphoinositide 3-kinase. Jackson SP, et al. **EMBO J** 1995 Sep 15;14(18):4490–500

alphaIIb beta 3-integrin mediated adhesion of human platelets to a fibrinogen matrix triggers phospholipase C activation and phosphatidylinositol 3',4'-biphosphate accumulation. Gironcel D, et al. **FEBS Lett** 1996 Jul 8; 389(3):253–6

Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. Niggli V, et al. **FEBS Lett** 1995 Dec 4;376(3):172–6

CD8-dependent CTL require co-engagement of CD8 and the TCR for phosphatidylinositol hydrolysis, but CD8-independent CTL do not and can kill in the absence of phosphatidylinositol hydrolysis. Knall C, et al. **Int Immunol** 1995 Jun;7(6):995–1004

Identification of a phosphatidylinositol 4,5-bisphosphate-binding site in chicken skeletal muscle alpha-actinin. Fukami K, et al. **J Biol Chem** 1996 Feb 2; 271(5):2646–50

A functional phosphatidylinositol 3,4,5-trisphosphate/phosphoinositide binding domain in the clathrin adaptor AP-2 alpha subunit. Implications for the endocytic pathway. Gaidarov I, et al. **J Biol Chem** 1996 Aug 23;271(34):20922–9

Identification and cloning of centaurin-alpha. A novel phosphatidylinositol 3,4,5-trisphosphate-binding protein from rat brain. Hammonds-Odie LP, et al. **J Biol Chem** 1996 Aug 2;271(31):18859–68

Stimulation of Fc(alpha) receptors induces tyrosine phosphorylation of phospholipase C-gamma(1), phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells. Gómez-Guerrero C, et al. **J Immunol** 1996 Jun 1; 156(11):4369–76

CCK-B receptor-mediated stimulation of polyphosphoinositide turnover in GH3 pituitary cells in response to cholecystokinin and pentagastrin. Smith AJ, et al. **Life Sci** 1996;58(11):883–95

An aldose reductase inhibitor but not myo-inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats. Berti-Mattera L, et al. **Metabolism** 1996 Mar;45(3):320–7

Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate. Gilmore AP, et al. **Nature** 1996 Jun 6;381(6582):531–5

In utero hypoxic ischemia decreases the cholinergic agonist-stimulated poly-phosphoinositide turnover in the developing rat brain. Hersey K, et al. **Neurochem Res** 1995 Dec;20(12):1477–82

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Damen JE, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1689–93

Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Abdel-Latif AA. **Proc Soc Exp Biol Med** 1996 Feb;211(2):163–77 (126 ref.)

Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Hilgemann DW, et al. **Science** 1996 Aug 16;273(5277):956–9

Inositol trisphosphate, polyphosphoinositide turnover, and high-energy metabolites in focal cerebral ischemia and reperfusion. Sun GY, et al. **Stroke** 1995 Oct; 26(10):1893–900

PHARMACOLOGY

Arachidonoyl-diacylglycerol kinase. Specific in vitro inhibition by polyphosphoinositides suggests a mechanism for regulation of phosphatidylinositol biosynthesis. Walsh JP, et al. **J Biol Chem** 1995 Dec 1;270(48):28647–53

Phosphatidylinositol (3,4,5)-trisphosphate stimulates phosphorylation of pleckstrin in human platelets. Zhang J, et al. **J Biol Chem** 1995 Sep 29;270(39):22807–10

Recombinant scinderin enhances exocytosis, an effect blocked by two scinderin-derived actin-binding peptides and PIP2. Zhang L, et al. **Neuron** 1996 Aug;17(2):287–96

PHOSPHATIDYLINOSITOL PHOSPHATES

PHYSIOLOGY

Phosphorylation of the platelet p47 phosphoprotein is mediated by the lipid products of phosphoinositide 3-kinase. Toker A, et al. **J Biol Chem** 1995 Dec 8; 270(49):29525-31

PHOSPHATIDYLINOSITOLS

Selective modifications of the phospholipid fatty acid composition in human platelet membranes using nonspecific and specific lipid transfer proteins. Bayon Y, et al. **Anal Biochem** 1995 Sep 1;230(1):75-84

Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331-6 (54 ref.)

Fluorescently labeled phosphatidylinositol transfer protein isoforms (alpha and beta), microinjected into fetal bovine heart endothelial cells, are targeted to distinct intracellular sites. De Vries KJ, et al. **Exp Cell Res** 1996 Aug 25; 227(1):33-9

ANALYSIS

Characterization of inositolphospholipids in Trypanosoma cruzi trypomastigote forms. Uhrig ML, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):233-9

Quantitative chromatographic analysis of inositol phospholipids and related compounds. Singh AK, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):255-80 (130 ref.)

[Changes in the contents of phosphoinositides in formed elements of blood and endometrial tissue in patients with hyperplastic processes and cancer of the endometrium] Damirov MM, et al. **Akush Ginekol (Mosk)** 1995;(4):43-6 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

The mechanism of muscarinic receptor-stimulated phosphatidylinositol resynthesis in 1321N1 astrocytoma cells and its inhibition by Li+. Batty IH, et al. **J Neurochem** 1995 Nov;65(5):2279-89

BIOSYNTHESIS

Anticholinesterase drugs stimulate phosphatidylinositol response in rat tracheal slices. Shibata O, et al. **Anesth Analg** 1996 Jun;82(6):1211-4

Light adaptation of bovine retinas in situ stimulates phosphatidylinositol synthesis in rod outer segments in vitro. Ghalayini AJ, et al. **Curr Eye Res** 1995 Nov; 14(11):1025-9

Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Sibelius U, et al. **Infect Immun** 1996 Feb; 64(2):674-6

Arachidonoyl-diacylglycerol kinase. Specific in vitro inhibition by polyphosphoinositides suggests a mechanism for regulation of phosphatidylinositol biosynthesis. Walsh JP, et al. **J Biol Chem** 1995 Dec 1;270(48):28647-53

The mechanism of muscarinic receptor-stimulated phosphatidylinositol resynthesis in 1321N1 astrocytoma cells and its inhibition by Li+. Batty IH, et al. **J Neurochem** 1995 Nov;65(5):2279-89

BLOOD

Platelet phosphoinositide signaling system: an overstimulated pathway in depression. Karege F, et al. **Biol Psychiatry** 1996 Apr 15;39(8):697-702

Phosphoinositide metabolism triggered by wheat germ agglutinin in human platelets. Yatomi Y, et al. **Int J Hematol** 1995 Oct;62(3):163-73

Bradykinin stimulates phosphoinositide turnover and phospholipase C but not phospholipase D and NADPH oxidase in human neutrophils. Catz SD, et al. **J Leukoc Biol** 1996 Apr;59(4):591-7

[Changes in the contents of phosphoinositides in formed elements of blood and endometrial tissue in patients with hyperplastic processes and cancer of the endometrium] Damirov MM, et al. **Akush Ginekol (Mosk)** 1995;(4):43-6 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Fetal bovine serum induces changes in fatty acid composition of Trypanosoma cruzi phosphoinositides. Racagni G, et al. **Can J Microbiol** 1995 Oct;41(10):951-4

Molecular dynamics study of an alpha-cyclodextrin-phosphatidylinositol inclusion complex. Göschl M, et al. **Eur Biophys J** 1996;24(5):300-10

Neutron diffraction reveals the orientation of the headgroup of inositol lipids in model membranes [letter] Bradshaw JP, et al. **Nat Struct Biol** 1996 Feb;3(2):125-7

HISTORY

History of phosphoinositide research. Hokin LE. **Subcell Biochem** 1996;26:1-41

ISOLATION & PURIFICATION

Isolation of phosphooligosaccharide/phosphoinositol glycan from caveolae and cytosol of insulin-stimulated cells. Parpal S, et al. **J Cell Biol** 1995 Oct;131(1):125-35

METABOLISM

The effect of vasopressin on the phosphoinositides of Tetrahymena pyriformis. Relationship with glycogen content. László V, et al. **Acta Microbiol Immunol Hung** 1995;42(2):209-13

ATP a potent regulator of inositol phospholipids-phospholipase C and lipid mediators in brain cortex. Strosznajder J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):527-34

Role of glucose metabolism and phosphoinositide hydrolysis in glucose-induced sensitization/desensitization of insulin secretion from mouse pancreatic islets. Thams P, et al. **Acta Physiol Scand** 1995 May;154(1):65-74

Regulation of signal transduction. Weber G, et al. **Adv Enzyme Regul** 1995;35:1-21

Signal transduction mechanisms in Alzheimer disease. Shimohama S, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:15-22

Epidermal growth factor increases phosphoinositide turnover and intracellular free calcium in an immortalized human myometrial cell line independent of the arachidonic acid metabolic pathway. Anwer K, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):676-81

Functional characterization of phosphoinositide-specific phospholipase C-beta 1 and -beta 3 in intestinal smooth muscle. Murthy KS, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C969-78

Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells. McHenry CR, et al. **Am J Surg** 1995 Nov;170(5):484-7

Cysteine-699, a possible palmitoylation site of the thyrotropin receptor, is not crucial for cAMP or phosphoinositide signaling but is necessary for full surface expression. Kosugi S, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):636-40

Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Bogoyevitch MA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):115-21

Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. Clerk A, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):109-18

Possible involvement of a tyrosine kinase-dependent pathway in the regulation of phosphoinositide metabolism by vanadate in normal mouse islets. Jonas JC, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):49-55

Thrombin stimulates wortmannin-inhibitable phosphoinositide 3-kinase and membrane blebbing in CHRF-288 cells. Vemuri GS, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):805-10

Contrasting effects of phorbol ester and agonist-mediated activation of protein kinase C on phosphoinositide and Ca2+ signalling in a human neuroblastoma. Willars GB, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):905-13

Inhibition of PDGF-induced phosphoinositide-turnover by glucopiericidin A. Ahn SC, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):125-32

Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Esqueda EE, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):643-58

Desensitization of neurotensin-induced phosphoinositide hydrolysis in transfected CHO cells. Hermans E, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1749-52

Nuclear Ca(2+)-fluxes and phosphoinositides in plants. Bunney TD, et al. **Biochem Soc Trans** 1995 Nov;23(4):581S

Mastoparan induces inositol phospholipid changes and plasmolysis in carrot cells. Galanopoulou D, et al. **Biochem Soc Trans** 1995 Nov;23(4):573S

Inositol lipid signal transduction in phytoalexin elicitation. Walton TJ. **Biochem Soc Trans** 1995 Nov;23(4):862-7 (38 ref.)

Crystal structure of phosphatidylinositol-specific phospholipase C from Bacillus cereus in complex with glucosaminyl(alpha 1-->6)-D-myo-inositol, an essential fragment of GPI anchors. Heinz DW, et al. **Biochemistry** 1996 Jul 23;35(29):9496-504

Cloning and expression of human cDNA encoding phosphatidylinositol transfer protein beta. Tanaka S, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):199-202

Parathyroid hormone-activated phosphoinositide degradation and calcium channels in human dermal fibroblasts. Pun KK, et al. **Biol Signals** 1995 Jan-Feb; 4(1):19-23

Hexachlorocyclohexanes affect the arachidonic acid release from phosphatidylinositol but not from other phospholipid classes in tubular cell cultures. Puente-Fraga JC, et al. **Biosci Rep** 1995 Aug;15(4):191-9

Effects of 8-bromoguanosine 3':5'-cyclic monophosphate on phenylephrine-induced phosphatidylinositol hydrolysis and contraction in rat caudal artery. Lum Min SA, et al. **Br J Pharmacol** 1995 Sep;116(1):1697-703

Coupling of metabotropic glutamate receptors to phosphoinositide mobilisation and inhibition of cyclic AMP generation in the guinea-pig cerebellum. Neil KE, et al. **Br J Pharmacol** 1996 May;118(2):311-6

Characterization of metabotropic glutamate receptor-stimulated phosphoinositide hydrolysis in rat cultured cerebellar granule cells. Toms NJ, et al. **Br J Pharmacol** 1995 Dec;116(7):2824-7

1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover. Periyasamy S, et al. **Brain Res** 1995 Sep 25;693(1-2):118-23

Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Israel A, et al. **Brain Res Bull** 1995;38(5):441-6

Molecular cloning of a phosphoinositide-specific phospholipase C from catfish olfactory rosettes. Abogadie FC, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):10-6

Phosphatidylinositol responses are involved in the vascular effects of thiamylal and fentanyl. Shibata O, et al. **Can J Anaesth** 1995 Dec;42(12):1164-70

Effects of fatigue of rat EDL in situ on metabolism of phosphoinositides. Oueslati H, et al. **Can J Appl Physiol** 1995 Sep;20(3):289-99

The induction of protrusion by neomycin in human glioma cells is correlated with a decrease followed by an increase in filamentous actin. Safiejko-Mroczka B, et al. **Cell Biol Int** 1995 Aug;19(8):655-74

Effect of cAMP elevating agents on carbachol-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. Yang CM, et al. **Cell Calcium** 1996 Mar;19(3):243-54

Oestradiol-17 beta modulates PAF-evoked phospholipase D activity but not inositide-lipid hydrolysis in human endometrial cell line, HEC-1B. Ahmed A, et al. **Cell Signal** 1995 May;7(4):403-9

Identification of PI-PLC beta 1, gamma 1, and delta 1 in rat liver: subcellular distribution and relationship to inositol lipid nuclear signalling. Bertagnolo V, et al. **Cell Signal** 1995 Sep;7(7):669-78

Inhibitory effect of phorbol ester on bradykinin-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. Luo SF, et al. **Cell Signal** 1995 Aug;7(6):571-81

Adenosine receptor activation potentiates phosphoinositide hydrolysis and arachidonic acid release in DDT1-MF2 cells: putative interrelations. Schachter JB, et al. **Cell Signal** 1995 Sep;7(7):659-68

Dual effect of formycin A upon the hydrolysis of phosphoinositides in perifused pancreatic islets. Ulusoy S, et al. **Cell Signal** 1995 Nov;7(8):821-6

Signal transduction mechanism in response to aflatoxin B1 exposure: phosphatidylinositol metabolism. Mistry KJ, et al. **Chem Biol Interact** 1995 Nov 17;98(2):145-52

Enhanced phosphoinositide turnover signalling stimulated by endothelin B-type receptor in endothelial cells from spontaneously hypertensive rats. Yokokawa K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S195-6

Phosphatidylinositol transfer protein dictates the rate of inositol trisphosphate production by promoting the synthesis of PIP2. Cunningham E, et al. **Curr Biol** 1995 Jul 1;5(7):775-83

Intracellular signalling. New directions for phosphatidylinositol transfer. Martin T. **Curr Biol** 1995 Sep 1;5(9):990-2 (13 ref.)

Stepwise transfer from high to low lithium concentrations increases the head-forming potential in Hydra vulgaris and possibly activates the PI cycle. Hassel M, et al. **Dev Biol** 1996 Aug 1;177(2):439-48

Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells. Baxter RM, et al. **Eur J Biochem** 1995 Nov 15;234(1):84-91

Endothelin-induced phosphoinositide hydrolysis in the muscular layer of stem villi vessels of human term placenta. Mondon F, et al. **Eur J Endocrinol** 1995 Nov;133(5):606-12

Exogenous human immunodeficiency virus type-1 Tat protein selectively stimulates a phosphatidylinositol-specific phospholipase C nuclear pathway in the Jurkat T cell line. Zauli G, et al. **Eur J Immunol** 1995 Sep;25(9):2695-700

PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover. Catalán RE, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):183-8

Effects of kappa-opioid receptor agonists on stimulated phosphoinositide hydrolysis in rat kidney. Mosaddeghi M, et al. **Eur J Pharmacol** 1995 May 26;289(3):411-7

Enhancement of 5-hydroxytryptamine-stimulated phosphoinositide hydrolysis in the rat cerebral cortex by repeated immobilization stress. Okuyama N, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):61-7

Effect of histamine on phosphoinositide turnover and intracellular calcium in human ciliary muscle cells. Markwardt KL, et al. **Exp Eye Res** 1996 May;62(5):511-20

A beta-subclass phosphatidylinositol-specific phospholipase C from squid (Loligo forbesi) photoreceptors exhibiting a truncated C-terminus. Carne A, et al. **FEBS Lett** 1995 Sep 25;372(2-3):243-8

Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889-95 (46 ref.)

Isolation and sequencing of the cDNA encoding phosphatidylinositol transfer protein from rabbit lung. Tsao FH, et al. **Gene** 1996 Jun 26;172(2):299-302

Visualization of receptor coupled phosphoinositide turnover in single neurons and a glial cell line in culture. Bevilacqua JA, et al. **Gene Ther** 1994;1 Suppl 1:S69

Phosphatidylinositol metabolism in lymphocytes of chronic

alcoholic patients after anti-CD3 stimulation. Hrelia S, et al. **Immunol Lett** 1995 May;46(1-2):63-6

Excitatory amino acid-, except 1S,3R-ACPD, induced transient high stimulation of phosphoinositide metabolism during hippocampal neuron development. Blanc EM, et al. **Int J Dev Neurosci** 1995 Nov;13(7):723-37

Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. Baek SH, et al. **J Biol Chem** 1996 Apr 5;271(14):8170-5

Phospholipid composition dependence of Ca2+-dependent phospholipid binding to the C2A domain of synaptotagmin IV. Fukuda M, et al. **J Biol Chem** 1996 Apr 5; 271(14):8430-4

A functional phosphatidylinositol 3,4,5-trisphosphate/phosphoinositide binding domain in the clathrin adaptor AP-2 alpha subunit. Implications for the endocytic pathway. Gaidarov I, et al. **J Biol Chem** 1996 Aug 23;271(34):20922-9

Regulation of profilin localization in Saccharomyces cerevisiae by phosphoinositide metabolism. Ostrander DB, et al. **J Biol Chem** 1995 Nov 10;270(45):27045-50

Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. Ryeom SW, et al. **J Biol Chem** 1996 Aug 23; 271(34):20536-9

Endothelins stimulate phosphoinositide breakdown in the rat spinal cord through ETA receptors. Poulat P, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S148-9

Ca2+ influx, phosphoinositide hydrolysis, and histamine release induced by lysophosphatidylserine in mast cells. Lloret S, et al. **J Cell Physiol** 1995 Oct;165(1):89-95

Thy-1-mediated phosphatidylinositol turnover in cultured rat glomerular mesangial cell. Narisawa-Saito M, et al. **J Cell Physiol** 1996 Sep;168(3):705-10

Stimulation of phosphatidylinositol turnover is a key event for Fas-dependent, activation-induced apoptosis in human T lymphocytes. Izquierdo M, et al. **J Immunol** 1996 Jul 1;157(1):21-8

Phosphatidylinositol hydrolysis in freshly isolated human T lymphocytes. Berney SM, et al. **J Immunol Methods** 1995 Oct 12;186(1):71-7

Pharmacological evidence for the existence of different subtypes of muscarinic acetylcholine receptors for phosphoinositide hydrolysis in neonatal versus adult rat atria. Camusso JJ, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):1-10

Characterization of the effects of lithium and inositol on phosphoinositide turnover in cerebellar granule cells in primary culture. del Rio E, et al. **J Neurochem** 1996 Feb; 66(2):517-24

Modulation by ionotropic excitatory amino acids and potassium of (+/-)-1-aminocyclopentane-trans-1,3-dicarboxylic acid-stimulated phosphoinositide hydrolysis in mouse cerebellar granule cells. Gorman AM, et al. **J Neurochem** 1995 Dec;65(6):2473-83

The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. Jope RS, et al. **J Neurochem** 1996 Jun;66(6):2402-9

Activation of adenosine A2 receptors stimulates phosphoinositide metabolism in rat peripheral nerve. Sheldon RL, et al. **J Neurochem** 1996 Feb;66(2):613-9

Inhibition of excitatory amino acid-induced phosphoinositide hydrolysis as a possible mechanism of nitroprusside neurotoxicity. Yu O, et al. **J Neurochem** 1996 Jan; 66(1):346-54

Transiently selective activation of phosphoinositide turnover in layer V pyramidal neurons after specific mGluRs stimulation in rat somatosensory cortex during early postnatal development. Bevilacqua JA, et al. **J Neurosci** 1995 Dec;15(12):7916-28

The positive inotropic effect and the hydrolysis of phosphoinositide induced by endothelin-3 in rabbit ventricular myocardium: inhibition by a selective antagonist of ET(A) receptors, FR139317. Endoh M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):61-70

The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. Kisielewska J, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):329-39

Interaction of ethanol and anoxia with muscarinic receptor--stimulated phosphoinositide metabolism during brain development. Balduini W, et al. **Life Sci** 1995; 57(18):1667-73

Effects of glucose and oxygen deprivation on phosphoinositide hydrolysis in cerebral cortex slices from neonatal rats. Cristòfol RM, et al. **Life Sci** 1996; 59(7):587-97

Inhibition of muscarinic stimulated phosphoinositide hydrolysis in the rat parotid gland by cAMP. Gerstin EH Jr, et al. **Life Sci** 1996;58(2):145-53

Alcohol exposure during brain development reduces 3H-MK-801 binding and enhances metabotropic-glutamate receptor-stimulated phosphoinositide hydrolysis in rat hippocampus. Vallés S, et al. **Life Sci** 1995 Mar 17;56(17):1373-83

Structural importance of the cis-5 ethylenic bond in the endogenous desaturation product of dietary elaidic acid, cis-5,trans-9 18:2 acid, for the acylation of rat mitochondria phosphatidylinositol. Wolff RL. **Lipids** 1995 Oct; 30(10):893-8

Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. Zawalich WS, et al. **Metabolism** 1996 Feb; 45(2):273-8

Transmembrane signaling and phosphoinositides. Cho MH, et al. **Methods Cell Biol** 1995;49:543-54 (50 ref.)

Enhancement of muscarinic receptor-coupled phosphatidyl inositol hydrolysis in diabetic bladder. Mimata H, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):71-6

Characterization of the phosphatidylinositol-specific phospholipase C-released form of rat osseous plate alkaline phosphatase and its possible significance on endochondral ossification. Pizauro JM, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):121-9

Phosphoinositide-generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):5-14 (88 ref.)

A role for phosphatidylinositol transfer protein in secretory vesicle formation. Ohashi M, et al. **Nature** 1995 Oct 12; 377(6549):544-7

Regulation of phosphoinositide hydrolysis and cytosolic free calcium induced by endothelin in human glomerular epithelial cells. Späth M, et al. **Nephrol Dial Transplant** 1995;10(8):1299-304

A neurochemical approach for studying response to acetylcholine in Alzheimer's disease. Alder JT, et al. **Neurochem Res** 1995 Jul;20(7):769-71

Ethanol inhibits muscarinic receptor-stimulated phosphoinositide metabolism and calcium mobilization in rat primary cortical cultures. Kovacs KA, et al. **Neurochem Res** 1995 Aug;20(8):939-49

Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Bruno V, et al. **Neuropharmacology** 1995 Aug;34(8):1089-98

Effects of quisqualic acid analogs on metabotropic glutamate receptors coupled to phosphoinositide hydrolysis in rat hippocampus. Littman L, et al. **Neuropharmacology** 1995 Aug;34(8):829-41

P2y purinergic receptors coupled to phosphoinositide hydrolysis in tissues of the cochlear lateral wall. Ogawa K, et al. **Neuroreport** 1995 Jul 31;6(11):1538-40

Developmental changes in carbachol-stimulated phosphoinositide turnover in synaptoneurosomes of the robust nucleus of the archistriatum in the zebra finch. Sakaguchi H. **Neuroreport** 1995 Oct 2;6(14):1901-4

Cyclic GMP inhibits phosphoinositide turnover in choroid plexus: evidence for interactions between second messengers concurrently triggered by 5-HT2C receptors. Kaufman MJ, et al. **Neurosci Lett** 1996 Mar 15; 206(2-3):153-6

Developmental changes in glutamate receptor stimulated inositol phospholipid metabolism and 45Ca(2+)-accumulation in posthatch chicken forebrain. Kavanagh JM, et al. **Neurosci Lett** 1995 Jul 21;194(3):161-4

Arginine vasopressin stimulates 32P labeling of phosphoinositides in rat pineal gland. Novotná R, et al. **Neurosci Lett** 1995 Sep 1;197(1):49-52

Acute and chronic effects of estrogenic compounds on glutamate-stimulated phosphatidylinositol metabolism in primary neuronal cultures. Yourick DL, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):145-8

Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Greenwood AF, et al. **Neuroscience** 1995 Nov;69(1):125-38

The 3-phosphorylated phosphoinositide response of 3T3-L1 preadipose cells exposed to insulin, insulin-like growth factor-1, or platelet-derived growth factor. Sorisky A, et al. **Obes Res** 1996 Jan;4(1):9-19

Pituitary adenylate cyclase-activating peptide stimulates neurite growth in PC12 cells. Hernandez A, et al. **Peptides** 1995;16(5):927-32

Involvement of septide-sensitive tachykinin receptors in inositol phospholipid hydrolysis in the rat urinary bladder. Torrens Y, et al. **Peptides** 1995;16(4):587-94

Mutant rat phosphatidylinositol/phosphatidylcholine transfer proteins specifically defective in phosphatidylinositol transfer: implications for the regulation of phospholipid transfer activity. Alb JG Jr, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8826-30

The yeast and mammalian isoforms of phosphatidylinositol transfer protein can all restore phospholipase C-mediated inositol lipid signaling in cytosol-depleted RBL-2H3 and HL-60 cells. Cunningham E, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6589-93

12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids [published erratum appears in Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11322] Liu B, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9323-7

5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine. Fiorella D, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):237-43

Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533-9 (74 ref.)

Phosphoinositide turnover and its role in plant signal transduction. Coté GG, et al. **Subcell Biochem** 1996; 26:317-43 (156 ref.)

Effects of excitatory amino acids on phosphoinositide metabolism in frog retina. Choe HG, et al. **Vision Res** 1996 Jul;36(13):1873-81

[Effect of plant polysaccharides on phosphatidylinositol turnover of sarcoma S180 cell membranes] Huang T, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):692-3, inside backcover (Eng. Abstr.) **(Chi)**

[Phosphoinositide response and change in free radical oxidation in catecholamine cardionecrosis in rats] Vishnevskiĭ AA, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):137-9 **(Rus)**

[Effect of estradiol on the rat brain synaptosomal phosphoinositide composition] Gevorkian ES, et al. **Vopr Med Khim** 1995 Sep-Oct;41(5):35-7 (Eng. Abstr.) **(Rus)**

[Phosphoinositide response and changes in the supraoptic-neurohypophyseal system in individual resistance of rats to hypoxia] Vishnevskiĭ AA, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):10-2 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Selective inhibition of DNA polymerase epsilon by phosphatidylinositol. Shoji-Kawaguchi M, et al. **J Biochem (Tokyo)** 1995 May;117(5):1095-9

Expression of the phosphoinositide-specific phospholipase Cbeta3 gene in the rat. Lagercrantz J, et al. **Neuroreport** 1995 Dec 15;6(18):2542-4

PHYSIOLOGY

Role of phosphatidylinositol-linked proteins in paroxysmal nocturnal hemoglobinuria pathogenesis. Kinoshita T, et al. **Annu Rev Med** 1996;47:1-10 (48 ref.)

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al. **Biochem Soc Trans** 1995 Nov;23(4):853-6 (28 ref.)

Abnormal phosphatidylinositol (PI)-signalling in bipolar disorder [letter; comment] Soares JC, et al. **Biol Psychiatry** 1996 Mar 15;39(6):461-4. Comment on: Biol Psychiatry 1995 Jun 1;37(11):761-3.

Phosphoinositide second messengers in olfaction. Bruch RC. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):451-9 (95 ref.)

Modulation of Xenopus embryo mesoderm-specific gene expression and dorsoanterior patterning by receptors that activate the phosphatidylinositol cycle signal transduction pathway. Ault KT, et al. **Development** 1996 Jul; 122(7):2033-41

Stimulation of phosphatidylinositol turnover is a key event for Fas-dependent, activation-induced apoptosis in human T lymphocytes. Izquierdo M, et al. **J Immunol** 1996 Jul 1;157(1):21-8

Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. Tigyi G, et al. **J Neurochem** 1996 Feb;66(2):537-48

Phosphoinositides and synaptic transmission. Hawthorne JN. **Subcell Biochem** 1996;26:43-57 (64 ref.)

[The role of the phosphoinositide signal system and phosphatidylethanolamine methylation in the development of long-term posttetanic potentiation in rats] Pavlinova LI, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):45-50 (Eng. Abstr.) **(Rus)**

SECRETION

Effects of short-term culturing on islet phosphoinositide and insulin secretory responses to glucose and carbachol. Zawalich WS, et al. **Acta Diabetol** 1995 Oct;32(3):158-64

PHOSPHATIDYLSERINE SYNTHASE see **CDP DIACYLGLYCEROL-SERINE O-PHOSPHATIDYLTRANSFERASE**

PHOSPHATIDYLSERINES

Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Billy D, et al. **Biochemistry** 1995 Oct 17; 34(41):13699-704

ANALYSIS

Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine. Bruckheimer EM, et al. **J Leukoc Biol** 1996 Jun;59(6):784-8 (58 ref.)

BIOSYNTHESIS

Phosphatidylserine synthesis in glioma C6 cells is inhibited by Ca2+ depletion from the endoplasmic reticulum: effects of 2,5-di-tert-butylhydroquinone and thimerosal. Wiktorek M, et al. **Biochem Biophys Res Commun** 1996 Jul 25; 224(3):645-50

Phosphatidylserine synthesis in phorbol ester treated glioma C6 cells. Czarny M, et al. **Biochem Mol Biol Int** 1995 Jul; 36(3):659-67

Ultrastructural detection of surface exposed phosphatidylserine on activated blood platelets. Stuart MC, et al. **Thromb Haemost** 1995 Oct;74(4):1145-51

PHOSPHATIDYLSERINES

BLOOD

Conformational order of phospholipids incorporated into human erythrocytes: an FTIR spectroscopy study. Moore DJ, et al. **Biochemistry** 1996 Jan 9;35(1):229–35

Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Wood BL, et al. **Blood** 1996 Sep 1; 88(5):1873–80

Isolation and identification of glycated aminophospholipids from red cells and plasma of diabetic blood. Ravandi A, et al. **FEBS Lett** 1996 Feb 26;381(1-2):77–81

CHEMISTRY

Conformational order of phospholipids incorporated into human erythrocytes: an FTIR spectroscopy study. Moore DJ, et al. **Biochemistry** 1996 Jan 9;35(1):229–35

Infrared spectroscopic study of the interaction of diacylglycerol with phosphatidylserine in the presence of calcium. López-García F, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):264–72

Effect of X31 influenza virus fusion on phosphatidylserine asymmetry in erythrocytes. Pak CC, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):98–104

Effects of diacylglycerols on conformation of phosphatidylcholine headgroups in phosphatidylcholine/phosphatidylserine bilayers. Goldberg EM, et al. **Biophys J** 1995 Sep;69(3):965–73

Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane. Taylor KD, et al. **Br J Cancer** 1995 Dec;72(6):1400–5

Effects of Ca2+ and Mg2+ on dynamics of the polar head group of phosphatidylserine bilayers. Araiso T, et al. **Jpn J Physiol** 1995;45(3):369–80

IMMUNOLOGY

A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Vogt E, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):700–7

Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies. Jansen NL, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):266–8

Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Adler RR, et al. **Biol Reprod** 1995 Oct;53(4):905–10

Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Silvestris F, et al. **Blood** 1996 Jun 15; 87(12):5185–95

Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. Matsuda J, et al. **Br J Rheumatol** 1996 Jun;35(6):589–91

The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Yodfat O, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):14–20

[ELISA in the determination of antiphosphatidylserine antibodies] Fialová L, et al. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):52–5 (Eng. Abstr.) **(Cze)**

METABOLISM

Intracellular trafficking of phospholipids: import of phosphatidylserine into mitochondria. Vance JE, et al. **Anticancer Res** 1996 May-Jun;16(3B):1333–9 (48 ref.)

Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Gazit E, et al. **Biochemistry** 1995 Sep 12;34(36):11479–88

Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Neuenschwander PF, et al. **Biochemistry** 1995 Oct 31;34(43):13988–93

The interaction of alpha-tocopherol with phosphatidylserine vesicles and calcium. Sánchez-Migallón MP, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):23–30

Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dilauroylphosphatidylcholine-induced vesiculation. Diaz C, et al. **Blood** 1996 Apr 1;87(7):2956–61

Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Toti F, et al. **Blood** 1996 Feb 15;87(4):1409–15

An improved assay for measuring the transverse redistribution of fluorescent phospholipids in plasma membranes. Pomorski T, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):139–46

Phosphatidylserine exposure on the platelet plasma membrane during A23187-induced activation is independent of cytoskeleton reorganization. Gaffet P, et al. **Eur J Cell Biol** 1995 Aug;67(4):336–45

Synthesis and intracellular transport of aminoglycerophospholipids in permeabilized cells of the yeast, Saccharomyces cerevisiae. Achleitner G, et al. **J Biol Chem** 1995 Dec 15;270(50):29836–42

Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. Billy D, et al. **J Biol Chem** 1995 Nov 10;270(45):26883–9

Phospholipid composition dependence of Ca2+-dependent phospholipid binding to the C2A domain of synaptotagmin IV. Fukuda M, et al. **J Biol Chem** 1996 Apr 5; 271(14):8430–4

Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. Ghosh S, et al. **J Biol Chem** 1996 Apr 5;271(14):8472–80

A novel phosphatidylserine-binding peptide motif defined by an anti-idiotypic monoclonal antibody. Localization of phosphatidylserine-specific binding sites on protein kinase C and phosphatidylserine decarboxylase. Igarashi K, et al. **J Biol Chem** 1995 Dec 8;270(49):29075–8

Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. Ryeom SW, et al. **J Biol Chem** 1996 Aug 23; 271(34):20536–9

The cysteine residue responsible for the release of fibroblast growth factor-1 residues in a domain independent of the domain for phosphatidylserine binding. Tarantini F, et al. **J Biol Chem** 1995 Dec 8;270(49):29039–42

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545–56

Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. Verhoven B, et al. **J Exp Med** 1995 Nov 1;182(5):1597–601

Autocrine/paracrine involvement of platelet-activating factor and transforming growth factor-beta in the induction of phosphatidylserine recognition by murine macrophages. Rose DM, et al. **J Immunol** 1995 Dec 15;155(12):5819–25

Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)

Ca(+2)-phosphatidylserine-dependent protein kinase C activity in fetal, neonatal and adult rabbit lung and isolated lamellar bodies. Samuels ER, et al. **Life Sci** 1995; 57(17):1557–68

Polyunsaturation in cell membranes and lipid bilayers and its effects on membrane proteins. Slater SJ, et al. **Lipids** 1996 Mar;31 Suppl:S189–92

Pepscan mapping and fusion-related properties of the major phosphatidylserine-binding domain of the glycoprotein of viral hemorrhagic septicemia virus, a salmonid rhabdovirus. Estepa A, et al. **Virology** 1996 Feb 1;216(1):60–70

PHARMACOLOGY

Phosphatidylserine-mediated adhesion of T-cells to endothelial cells. Qu J, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):343–6

Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Bennett MR, et al. **Circ Res** 1995 Dec; 77(6):1136–42

Inhibition by cholesterylphosphorylserine of T-cell-mediated immune responses in mice. Bruni A, et al. **Int J Immunopharmacol** 1995 Jun;17(6):517–21

Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. Gilbert GE, et al. **J Biol Chem** 1996 May 10;271(19):11120–5

Effect of acidic phospholipids on sphingosine kinase. Olivera A, et al. **J Cell Biochem** 1996 Mar 15;60(4):529–37

Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. Sakai M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb;42(1):47–54

PHYSIOLOGY

Increased vesicle endocytosis due to an increase in the plasma membrane phosphatidylserine concentration. Farge E. **Biophys J** 1995 Dec;69(6):2501–6

PHOSPHINES

Quantitation of hydrogen peroxide using tris(2-carboxyethyl)phosphine. Han J, et al. **Anal Biochem** 1996 Feb 1;234(1):107–9

POISONING

Zinc phosphide poisoning in a horse [see comments] Drolet R, et al. **Equine Vet J** 1996 Mar;28(2):161–2. Comment in: Equine Vet J 1996 Mar;28(2):89–91.

Sherlock Holmes and chemical poisons [editorial; comment] Frape DL. **Equine Vet J** 1996 Mar;28(2):89–91. Comment on: Equine Vet J 1996 Mar;28(2):161–2.

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339–42 (17 ref.)

Lipid peroxidation in acute aluminium phosphide poisoning. Chugh SN, et al. **J Assoc Physicians India** 1995 Apr; 43(4):265–6

Cardiovascular manifestations in aluminium phosphide poisoning with special reference to echocardiographic changes. Gupta MS, et al. **J Assoc Physicians India** 1995 Nov;43(11):773–4, 779–80

Tissue magnesium content and histopathological changes in non-survivors of aluminium phosphide poisoning. Siwach SB, et al. **J Assoc Physicians India** 1995 Oct;43(10):676–8

Acute pancreatitis due to zinc phosphide ingestion. Sarma PS, et al. **Postgrad Med J** 1996 Apr;72(846):237–8

TOXICITY

Chronic toxicity of indium arsenide and indium phosphide to the lungs of hamsters. Tanaka A, et al. **Fukuoka Igaku Zasshi** 1996 May;87(5):108–15

PHOSPHINIC ACIDS

CHEMISTRY

Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. Jirácek J, et al. **J Biol Chem** 1996 Aug 9; 271(32):19606–11

PHARMACOLOGY

The reduction of thymine residues in DNA by the combined action of UV light and hypophosphite. Yakovlev DY, et al. **J Photochem Photobiol B** 1995 Aug;29(2-3):119–23

PHOSPHITES

[A new method of fixing histological preparations using dimethylphosphite] Samusev RP, et al. **Morfologiia** 1994 Apr-Jun;106(4-6):169–70 **(Rus)**

TOXICITY

Triphenylphosphite neuropathy in hens. Fioroni F, et al. **Arch Toxicol** 1995;69(10):705–11

PHOSPHOACYLASE see **PHOSPHATE ACETYLTRANSFERASE**

PHOSPHOADENOSINE PHOSPHOSULFATE

METABOLISM

Kinetics of PAPS translocase: evidence for an antiport mechanism. Ozeran JD, et al. **Biochemistry** 1996 Mar 26; 35(12):3685–94

Identification and partial purification of PAPS translocase. Ozeran JD, et al. **Biochemistry** 1996 Mar 26; 35(12):3695–703

In vivo modification of 3'-phosphoadenosine 5'-phosphosulfate and sulfate by infusion of sodium sulfate, cysteine, and methionine. Kim HJ, et al. **Drug Metab Dispos** 1995 Aug;23(8):840–5

Acetaminophen does not decrease hepatic 3'-phosphoadenosine 5'-phosphosulfate in mice. Kim HJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1506–11

Depletion of hepatic 3'-phosphoadenosine 5'-phosphosulfate (PAPS) and sulfate in rats by xenobiotics that are sulfated. Kim HJ, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):654–8

Different mechanism of saturation of acetaminophen sulfate conjugation in mice and rats. Liu L, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):128–34

PHOSPHOCREATINE

St. Thomas' Hospital cardioplegia: enhanced protection with exogenous creatine phosphate. Chambers DJ, et al. **Ann Thorac Surg** 1996 Jan;61(1):67–75

ANALOGS & DERIVATIVES

The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. Schimmel L, et al. **Anticancer Res** 1996 Jan-Feb;16(1):375–80

Effects of high energy phosphates and L-arginine on the electrical parameters of ischemic-reperfused rat skeletal muscle fibers. Tricarico D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):17–25

Depletion of high energy phosphate compouds in the tumor-bearing state and reversal after tumor resection. Hochwald SN, et al. **Surgery** 1996 Sep;120(3):534–41

ANALYSIS

Applicability of small endomyocardial biopsies for evaluation of high energy phosphates and glycogen in the heart. Bøtker HE, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2081–9

BIOSYNTHESIS

Phosphocreatine synthesis by isolated rat skeletal muscle mitochondria is not dependent upon external ADP: a 31P NMR study. Kernec F, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):819–25

Control of the rate of phosphocreatine resynthesis after exercise in trained and untrained human quadriceps muscles. Takahashi H, et al. **Eur J Appl Physiol** 1995; 71(5):396–404

METABOLISM

Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Gordon A, et al. **Cardiovasc Res** 1995 Sep; 30(3):413–8

31P nuclear magnetic resonance spectroscopic imaging of regions of remodeled myocardium in the infarcted rat heart. Friedrich J, et al. **Circulation** 1995 Dec 15;92(12):3527–38

Phosphocreatine–dependent glutamate uptake by synaptic vesicles. A comparison with atp–dependent glutamate uptake. Xu CJ, et al. **J Biol Chem** 1996 Jun 7; 271(23):13435–40

Adaptation to chronic hypoxia alters cardiac metabolic response to beta stimulation: novel face of phosphocreatine overshoot phenomenon. Novel–Chaté V, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1679–87

P–31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Ballinger JR, et al. **Magn Reson Imaging** 1995;13(6):877–83

Human cardiac high–energy phosphate metabolite concentrations by 1D–resolved NMR spectroscopy. Bottomley PA, et al. **Magn Reson Med** 1996 May; 35(5):664–70

Creatine and nucleoside triphosphates in rat cerebral gray and white matter. Whittingham TS, et al. **Metab Brain Dis** 1995 Dec;10(4):347–52

Localised proton magnetic resonance spectroscopy in X–linked adrenoleukodystrophy. Confort–Gouny S, et al. **Neuroradiology** 1995 Oct;37(7):568–75

Diffusion coefficients of ATP and creatine phosphate in isolated muscle: pulsed gradient 31P NMR of small biological samples. Hubley MJ, et al. **NMR Biomed** 1995 Apr;8(2):72–8

Application of homonuclear decoupling to measures of diffusion in biological 31P spin echo spectra. Hubley MJ, et al. **NMR Biomed** 1995 May;8(3):113–7

31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1215–20

Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase–encoded 31P–MRS. Kato T, et al. **Psychol Med** 1995 May;25(3):557–66

Allopurinol improves postischemic skeletal muscle performance and endurance but not high–energy phosphate levels. Gürke L, et al. **Transplant Proc** 1995 Oct; 27(5):2840–1

[Effect of DL–butylphthalide (NBP) on mouse brain energy metabolism in complete brain ischemia induced by decapitation] Feng YP, et al. **Yao Hsueh Hsueh Pao** 1995; 30(10):741–4 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Effects of high energy phosphates and L–arginine on the electrical parameters of ischemic–reperfused rat skeletal muscle fibers. Tricarico D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):17–25

Effects of high–energy phosphates on carbachol–evoked cationic current in single smooth muscle cells from guinea–pig ileum. Bakhramov A. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):659–69

The effects of phosphocreatine introduced simultaneously into many cardiac cells. Tuganowski W. **Pflugers Arch** 1996 Feb;431(4):652–7

PHYSIOLOGY

The phosphocreatine overshoot occurs independent of myocardial work. Kaplan LJ, et al. **Biochimie** 1995; 77(4):245–8

THERAPEUTIC USE

[The antihypoxic action of the preparation Neoton in complicated spinal trauma] Stashkevich AT. **Lik Sprava** 1995 Jul–Aug;(7–8):104–6 (Eng. Abstr.) **(Rus)**

[The efficacy of emoxipin and neoton in unstable stenocardia] Golikov AP, et al. **Ter Arkh** 1996;68(1):31–3 (Eng. Abstr.) **(Rus)**

PHOSPHODIESTERASE ANTAGONISTS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHODIESTERASE INHIBITORS

Biotech shares fall as company halts asthma drug trials [news] Ward M. **Nature** 1996 Feb 8;379(6565):480

[Selective type III phosphodiesterase inhibitor as an antithrombotic agent] Kimura Y. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):205–16 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities] Kaneko M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1268–76 (23 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

The direct and interactive effects of phosphodiesterase inhibition and beta–adrenergic stimulation on myocyte contractile function after hypothermic cardioplegic arrest. Dorman BH, et al. **Anesth Analg** 1995 Nov;81(5):925–31

Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double–blinded, randomized, placebo–controlled, interventional study. Barton P, et al. **Chest** 1996 May;109(5):1302–12

Pharmacologic and hemodynamic effects of combined beta–agonist stimulation and phosphodiesterase inhibition in the failing human heart. Gilbert EM, et al. **Chest** 1995 Dec;108(6):1524–32

Effect of pentoxifylline on patch test response. Balato N, et al. **Contact Dermatitis** 1996 Feb;34(2):153

CHEMICAL SYNTHESIS

4–(4–Guanidinobenzoyl)–2–imidazolones and related compounds: phosphodiesterase inhibitors and novel cardiotonics with combined histamine H2 receptor agonist and PDE III inhibitor activity. Glass D, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):709–19

New indole and pyridazinoindole analogs—synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation. Monge A, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):689–98

Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Coste H, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1577–85

Design and synthesis of conformationally constrained analogues of 4–(3–butoxy–4–methoxybenzyl)imidazolidin–2–one (Ro 20–1724) as potent inhibitors of cAMP–specific phosphodiesterase. Brackeen MF, et al. **J Med Chem** 1995 Nov 24;38(24):4848–54

Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6–(4–(benzylamino)–7–quinazolinyl)–4,5–dihydro–5–methyl–3(2H)– pyridazinone (KF15232). Nomoto Y, et al. **J Med Chem** 1996 Jan 5;39(1):297–303

Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)–(+/–)–methyl 3–acetyl–4–[3–(cyclopentyloxy)–4–methoxyphenyl]–3–methyl–1–pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP–specific phosphodiesterase. Stafford JA, et al. **J Med Chem** 1995 Dec 22;38(26):4972–5

CHEMISTRY

Deconvolution of combinatorial libraries for drug discovery: experimental comparison of pooling strategies. Wilson–Lingardo L, et al. **J Med Chem** 1996 Jul 5; 39(14):2720–6

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)

METABOLISM

Protein kinase C in rod outer segments: effects of phosphorylation of the phosphodiesterase inhibitory subunit. Udovichenko IP, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):291–5

Interferon–gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor. Patrizio M, et al. **Glia** 1995 Jun;14(2):94–100

PHARMACOKINETICS

Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Prielipp RC, et al. **Chest** 1996 May; 109(5):1291–301

PHARMACOLOGY

Effect of different xanthines and phosphodiesterase inhibitors on c–fos expression in rat striatum. Svenningsson P, et al. **Acta Physiol Scand** 1995 May;154(1):17–24

Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV–1 replication. Angel JB, et al. **AIDS** 1995 Oct;9(10):1137–44

Milrinone: basic and clinical pharmacology and acute and chronic management. Shipley JB, et al. **Am J Med Sci** 1996 Jun;311(6):286–91 (36 ref.)

Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen–induced cytokine gene expression in peripheral blood mononuclear cells. Essayan DM, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):692–702

The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Thusu KG, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1605–10

Repletion of high energy phosphates in the postischemic neonatal heart. Pridjian AK, et al. **Am Surg** 1996 Jun; 62(6):494–8

The effects of pentoxifylline on the generation of reactive oxygen species and lipid peroxidation in human spermatozoa. McKinney KA, et al. **Andrologia** 1996 Jan–Feb;28(1):15–20

The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery. Salmenperä M, et al. **Anesth Analg** 1996 May;82(5):954–7

Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Polson JB, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:403–27 (87 ref.)

New indole and pyridazinoindole analogs—synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation. Monge A, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):689–98

Pentoxifylline attenuates pulmonary macromolecular leakage after intestinal ischemia–reperfusion. Carter MB, et al. **Arch Surg** 1995 Dec;130(12):1337–44

The effects of the phospholipase A2 inhibitor, manoalide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intraarticular injection of human recombinant interleukin–1 alpha in the rabbit. Schrier DJ, et al. **Arthritis Rheum** 1996 Aug;39(8):1292–9

Characterization of the phosphodiesterase inhibition by 2–(3–methoxy–5–methylsulfinyl–2–thienyl)–1H–imidazo–(4,5–c)–pyridine HCl and its sulfide– and sulfone derivatives in myocardial preparations from failing human hearts. Bethke T, et al. **Arzneimittelforschung** 1995 Jul; 45(7):771–6

Pharmacological activities of imidazo(1,2–alpha]pyrazine derivatives. Michel A, et al. **Arzneimittelforschung** 1995 Dec;45(12):1288–93

EMD 53998 acts as Ca(2+)–sensitizer and phosphodiesterase III–inhibitor in human myocardium. Uhlmann R, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):365–71

Acute administration of a permeant analog of cAMP and a phosphodiesterase inhibitor improve long–term habituation in the crab Chasmagnathus. Romano A, et al. **Behav Brain Res** 1996 Feb;75(1–2):119–25

Modulation of sperm membrane conformation by pentoxifylline in oligospermia: a biophysical investigation of sperm membrane in vitro. Nivsarkar M, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):791–5

Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Parker JC, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):916–23

Evidence for the presence of essential histidine and cysteine residues in platelet cGMP–inhibited phosphodiesterase. Ghazaleh FA, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):495–501

KS–505a, an isoform–selective inhibitor of calmodulin–dependent cyclic nucleotide phosphodiesterase. Ichimura M, et al. **Biochem J** 1996 May 15;316 (Pt 1):311–6

Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Coste H, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1577–85

Isoprenaline induction of cAMP–phosphodiesterase in guinea–pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Kochetkova M, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2033–8

Characterization of two recombinant PDE3 (cGMP–inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Leroy MJ, et al. **Biochemistry** 1996 Aug 6;35(31):10194–202

Compound D609 inhibits phorbol ester–stimulated phospholipase D activity and phospholipase C–mediated phosphatidylethanolamine hydrolysis. Kiss Z, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):105–8

Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes. Miyamoto K, et al. **Biol Pharm Bull** 1995 Mar; 18(3):431–4

Inhibition of platelet function by A02131–1, a novel inhibitor of cGMP–specific phosphodiesterase, in vitro and in vivo. Yu SM, et al. **Blood** 1996 May 1;87(9):3758–67

Effect of phosphodiesterase inhibitors on human arteries in vitro. Vroom MB, et al. **Br J Anaesth** 1996 Jan;76(1):122–9

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Banner KH, et al. **Br J Pharmacol** 1995 Dec;116(8):3169–74

Action of adenosine receptor antagonists on hypoxia–induced effects in the rat hippocampus in vitro. Croning MD, et al. **Br J Pharmacol** 1995 Oct;116(3):2113–9

Effects of theophylline and rolipram on antigen–induced airway responses in neonatally immunized rabbits. Gozzard N, et al. **Br J Pharmacol** 1996 Apr;117(7):1405–12

Effects of type–selective phosphodiesterase inhibitors on glucose–induced insulin secretion and islet phosphodiesterase activity. Shafiee–Nick R, et al. **Br J Pharmacol** 1995 Aug;115(8):1486–92

Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils. Polla B, et al. **Can J Physiol Pharmacol** 1995 May;73(5):661–4

Manipulation of bovine sperm metabolism and motility using anoxia and phosphodiesterase inhibitors. Schoff PK, et al. **Cell Motil Cytoskeleton** 1995;31(2):140–6

Rapid regulation of PDE–2 and PDE–4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro–9–(2–hydroxy–3–nonyl)–adenine (EHNA) and rolipram. Michie AM, et al. **Cell Signal** 1996 Feb;8(2):97–110

Interaction of phosphodiesterase inhibitor and isoproterenol in human and guinea–pig ventricular tissues and myocytes. Cheng PY, et al. **Chin J Physiol** 1995;38(3):185–91

Pentoxifylline ameliorates pulmonary damage caused by Streptococcus pneumoniae infection in mouse. Cui X, et al. **Chin Med J (Engl)** 1995 Nov;108(11):864–9

Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Hgashiyama A, et al. **Circulation** 1995

Nov 15;92(10):3094–104
Effects of selective phosphodiesterase type IV inhibitor, rolipram, on signal transducing phospholipases in neutrophil: inhibition of phospholipases A2, D but not C. Nakashima S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):137–43
Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Hagström-Toft E, et al. **Diabetes** 1995 Oct; 44(10):1170–5
Effect of cilostazol on experimental diabetic neuropathy in the rat. Kihara M, et al. **Diabetologia** 1995 Aug;38(8):914–8
Rolipram inhibition of phosphodiesterase-4 activation. DiSanto ME, et al. **Eur J Pharmacol** 1995 Jul 18; 290(2):169–72
Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Heaslip RJ, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):281–90
Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Kessler T, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):163–7
Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Klemm P, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):69–74
Effects of caffeine on Ca2+ fluxes and secretion in bovine chromaffin cells. Liu PS, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):265–72
Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Miyahara M, et al. **Eur J Pharmacol** 1995 Sep 15; 284(1–2):25–33
Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat. Wagner U, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):265–70
Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Yu SM, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):69–77
PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)
Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and beta-melanocyte-stimulating hormone. Cieszka KA, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):192–8
Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Palacios JM, et al. **Farmaco** 1995 Dec;50(12):819–27 (81 ref.)
Wortmannin inhibits store-mediated calcium entry and protein tyrosine phosphorylation in human platelets. Jenner S, et al. **FEBS Lett** 1996 Mar 4;381(3):249–51
Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.G4.1. Schmidt J, et al. **Immunopharmacology** 1995 Sep; 30(3):191–8
Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal anti-human IL-1 alpha antibody. Heyderman RS, et al. **Inflamm Res** 1995 Jul;44(7):275–80
Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Howell RE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S172–3
Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Van Wauwe J, et al. **Inflamm Res** 1995 Sep;44(9):400–5
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. Greten TF, et al. **Int J Immunopharmacol** 1995 Jul;17(7):605–10
The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity. Sullivan GW, et al. **Int J Immunopharmacol** 1995 Oct;17(10):793–803
Inhibition of cytotoxicity and cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline. Heinkelein M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):417–24
Sperm stimulants can improve fertilization rates in male-factor cases undergoing IVF to the same extent as micromanipulation by partial zona dissection (PZD) or subzonal sperm insemination (SUZI): a randomized controlled study. Edirisinghe WR, et al. **J Assist Reprod Genet** 1995 May;12(5):312–8
An evaluation of the effect of pentoxifylline on sperm function and treatment outcome of male-factor infertility: a preliminary study. Fountain S, et al. **J Assist Reprod Genet** 1995 Nov;12(10):704–9
Successful use of pentoxifylline in male-factor infertility and previous failure of in vitro fertilization: a prospective randomized study. Rizk B, et al. **J Assist Reprod Genet** 1995 Nov;12(10):710–4
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. Cross MJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25352–5
The phosphodiesterase inhibitor SQ 20006 selectively blocks mitogen activation of p70S6k and transition to S phase of the cell division cycle without affecting the steady state phosphorylation of eIF-4E. Frost V, et al. **J Biol Chem** 1995 Nov 3;270(44):26698–706
From Cyclic AMP to Cytokines. Pentoxifylline: Present and Future. Proceedings of an International Congress. Budapest, Hungary, July 7–9, 1994. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:v, S1–147
Effect of pentoxifylline on apoptosis of cultured cells. Belloc F, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S71–4
Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. Benbernou N, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S75–9
Pentoxifylline selectivity inhibits tumor necrosis factor synthesis in the arterial wall. Bernard C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S30–3
Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human endothelial cells: involvement of cyclic AMP. Franzini E, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S92–5
Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. Harkin CP, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):179–88
Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells. Leclerc NE, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S88–91
Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)
Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions. Seigneur M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S85–7
Effects of a new inotropic drug (DN-9693) on Ca2+ transients and contraction in ferret ventricular muscles. Tanaka T, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):227–32
Activated leukocytes, endothelial cells, and effects of pentoxifylline: observations by VEC-DIC microscopy. Tomita M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S34–9
Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes. Belhassen L, et al. **J Clin Invest** 1996 Apr 15;97(8):1908–15
Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. Kelley TJ, et al. **J Clin Invest** 1996 Jul 15;98(2):513–20
Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. Tsuboi Y, et al. **J Clin Invest** 1996 Jul 15;98(2):262–70
Comparison of venodilatory effect of amrinone and theophylline in human subjects. Harada K, et al. **J Clin Pharmacol** 1995 Nov;35(11):1067–70
Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. Kambayashi T, et al. **J Immunol** 1995 Nov 15;155(10):4909–16
Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase. Brackeen MF, et al. **J Med Chem** 1995 Nov 24;38(24):4848–54
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. Duplantier AJ, et al. **J Med Chem** 1996 Jan 5; 39(1):120–5
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. Iwasaki T, et al. **J Med Chem** 1996 Jul 5;39(14):2696–704
Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase. Stafford JA, et al. **J Med Chem** 1995 Dec 22;38(26):4972–5
Deconvolution of combinatorial libraries for drug discovery: experimental comparison of pooling strategies. Wilson-Lingardo L, et al. **J Med Chem** 1996 Jul 5; 39(14):2720–6
Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. Haikala H, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2155–65
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. Jung S, et al. **J Neuroimmunol** 1996 Aug; 68(1–2):1–11
Inotropic and chronotropic effects of 4-(4'-n-butylaniline)-7,8-dimethoxy-5H-pyrimido[5,4-b]indole in guinea-pig atria. Castiella E, et al. **J Pharm Pharmacol** 1995 Jul;47(7):601–7
Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram. Chiu N, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1073–7
Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion. Chiu T, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):793–9
Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. Howell RE, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):703–9
Comparison between the effects of a novel Ca++ sensitizer and a phosphodiesterase inhibitor on stunned myocardium. Korbmacher B, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1433–41
Negative inotropic action of denbufylline through interfering with the calcium channel independently of its PDE IV inhibitory activity in guinea pig ventricle papillary muscles. Sanae F, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):54–60
U-73122: a potent inhibitor of human polymorphonuclear neutrophil adhesion on biological surfaces and adhesion-related effector functions. Smith RJ, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):320–9
Radioimmunoassays for cyclic AMP cross-react with phosphodiesterase inhibitors and buffer components. Sinha B, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):29–36
A xanthine derivative denbufylline inhibits negative inotropic response to verapamil in guinea pig ventricular papillary muscles, independent of its phosphodiesterase inhibitory activity. Sanae F, et al. **Jpn J Pharmacol** 1995 Nov; 69(3):277–9
Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Matsumori A, et al. **Life Sci** 1996;59(10):PL121–5
Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability—effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Seeger W, et al. **Microvasc Res** 1995 Jul;50(1):1–17
Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):245–9 (21 ref.)
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Alvarez R, et al. **Mol Pharmacol** 1995 Oct;48(4):616–22
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Seldon PM, et al. **Mol Pharmacol** 1995 Oct;48(4):747–57
Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis [see comments] Sommer N, et al. **Nat Med** 1995 Mar;1(3):244–8 . Comment in: Nat Med 1995 Mar;1(3):211–4.
Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. Ortiz JL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):200–6
Effects of phosphodiesterase inhibitors and forskolin on cyclic GMP-activated channels in intact isolated cells of the chick pineal gland. D'Souza T, et al. **Neurochem Int** 1995 Dec;27(6):527–33
The effects of a selective cAMP phosphodiesterase inhibitor, rolipram, on methamphetamine-induced behavior. Iyo M, et al. **Neuropsychopharmacology** 1995 Aug;13(1):33–9
Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Truss MC, et al. **Neurourol Urodyn** 1996;15(1):59–70
Regulation of cyclic AMP levels in guinea pig pancreatic ducts and cultured duct epithelial monolayers. de Ondarza J, et al. **Pancreas** 1995 Oct;11(3):261–70
Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells. Graf K, et al. **Peptides** 1995;16(7):1273–8
3-Isobutyl-1-methylxanthine (IBMX) affects potassium permeability in rat sensory neurones via pathways that are sensitive and insensitive to [Ca2+]in. Usachev Y, et al. **Pflugers Arch** 1995 Jul;430(3):420–8
Effects of high doses of theophylline on memory acquisition. Zarrindast MR, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):307–11
The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Banner KH, et al. **Pulm Pharmacol** 1995 Feb;8(1):37–42
In vivo modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Oismüller C, et al. **Shock** 1995 Sep;4(3):161–5
Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)-mediated suppression of cell-mediated lymphocytotoxicity. Median-effect analysis for the drug dose reductions in PTX and CsA combination treatment. Khabar KS, et al. **Transplantation** 1996 Mar 15;61(5):838–41
Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro. Stief CG, et al. **Urol Int** 1995;55(4):183–9

[Effect of phosphodiesterase IV inhibitors on bone tissue: a possibility for its use as a new agent to treat osteoporosis] **Kasugai S, et al. Kokubyo Gakkai Zasshi** 1996 Jun;63(2):432 **(Jpn)**

[Hemodynamic effects of amrinone during emergence from cardiopulmonary bypass] Nakata F, et al. **Masui** 1995 Dec; 44(12):1632–8 (Eng. Abstr.) **(Jpn)**

[Amrinone administration exerts no deleterious effect on platelet counts and blood transfusion volume during CABG] Senami K, et al. **Masui** 1996 May;45(5):638–41 (Eng. Abstr.) **(Jpn)**

[Evaluation of selected parameters of lymphocyte activity in umbilical cord blood. III. Expression of receptors for SRCB susceptible and insusceptible to theophylline] Kamiński P, et al. **Ginekol Pol** 1996 Feb;67(2):60–4 (Eng. Abstr.) **(Pol)**

[Pentoxifylline] Paradowski PT, et al. **Postepy Hig Med Dosw** 1995;49(2):201–20 (112 ref.) (Eng. Abstr.) **(Pol)**

[Should coffee be classified as a doping agent? Caffeine is definitely effective when it comes to performance capacity (see comments)] Fredholm BB. **Lakartidningen** 1995 Nov 1;92(44):4079–80. Comment in: Lakartidningen 1995 Dec 20;92(51–52):4869. **(Swe)**

THERAPEUTIC USE

Pentoxifylline and oxygen consumption in severe sepsis—a preliminary report. Castañon-Gonzalez JA, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:219–22

Recurrent aphthous stomatitis: treatment with pentoxifylline [letter] Pizarro A, et al. **Acta Derm Venereol** 1996 Jan; 76(1):79–80

Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Prielipp RC, et al. **Chest** 1996 May; 109(5):1291–301

Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Chang AC, et al. **Crit Care Med** 1995 Nov;23(11):1907–14

Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Seino Y, et al. **Crit Care Med** 1996 Sep;24(9):1490–7

Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)

Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. Murakami R, et al. **Int J Cardiol** 1995 Aug;51(1):57–63

Is pentoxifylline effective in the treatment of psoriasis? [letter; comment] Omulecki A, et al. **J Am Acad Dermatol** 1996 Apr;34(4):714–5. Comment on: J Am Acad Dermatol 1994 Apr;30(4):603–21.

Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139–42 (29 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. Rieckmann P, et al. **J Neuroimmunol** 1996 Feb;64(2):193–200

Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia [letter] Binet JL, et al. **Leukemia** 1995 Dec; 9(12):2159–61

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)

Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211–4 (28 ref.). Comment on: Nat Med 1995 Mar;1(3):244–8.

Comparison of aminophylline and insulin infusions in treatment of hyperkalemia in patients with end-stage renal disease [letter] Duranay M, et al. **Nephron** 1996;73(1):105

Nephrotoxicity from contrast media: attenuation with theophylline [letter; comment] Drescher P, et al. **Radiology** 1995 Nov;197(2):547–8. Comment on: Radiology 1995 Apr;195(1):17–22.

Nephrotoxicity from contrast media: attenuation with theophylline [letter; comment] Morcos SK, et al. **Radiology** 1995 Nov;197(2):546–7; dicussion 248. Comment on: Radiology 1995 Apr;195(1):17–22.

The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative beta-blockade. Günnicker M, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):153–60

Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Dent G, et al. **Thorax** 1996 Jun; 51(6):647–9 (12 ref.)

[Therapy of acute coronary insufficiency with phosphodiesterase III inhibitors. Symposium. Hamburg, 13 February 1993] **Anaesthesist** 1993 Apr;42(4 Suppl):1–8 **(Ger)**

TOXICITY

Inhibitors in tea of intestinal absorption of phenylalanine in rats. Kreydiyyeh SI. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):67–71

Differential responses of human sperm to varying concentrations of pentoxyfylline with demonstration of toxicity. Centola GM, et al. **J Androl** 1995 Mar-Apr; 16(2):136–42

The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Larson JL, et al. **Pharmacol Toxicol** 1996 Jan;78(1):44–9

Inhibition of rat brain phosphatidylinositol-specific phospholipase C by aluminum: regional differences, interactions with aluminum salts, and mechanisms. Nostrandt AC, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):118–25

Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats. Whitehurst VE, et al. **Toxicology** 1996 Jun 17;110(1–3):113–21

PHOSPHODIESTERASES see PHOSPHORIC DIESTER HYDROLASES

PHOSPHOENOLPYRUVATE

Beneficial effects of combined use of phosphoenolpyruvate and gadolinium chloride on preservation-reperfusion liver injury in rats. Motoyama K, et al. **Transplant Proc** 1996 Apr;28(2):1101–2

ANALOGS & DERIVATIVES

An enzyme-substrate complex involved in bacterial cell wall biosynthesis. Benson TE, et al. **Nat Struct Biol** 1995 Aug; 2(8):644–53

ANALYSIS

Detection and quantitation of phosphorus metabolites in crude tissue extracts by 1H and 31P NMR: use of gradient assisted 1H-31P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. Pollesello P, et al. **NMR Biomed** 1995 Aug;8(5):190–6

CHEMISTRY

Influence of phosphoenolpyruvate and magnesium ions on the quaternary structure of enzyme I of the phosphotransferase system from gram-positive bacteria. Hübner G, et al. **Biochemistry** 1995 Dec 5;34(48):15700–3

The hard-soft acid-base principle in enzymatic catalysis: dual reactivity of phosphoenolpyruvate. Li Y, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4612–6

METABOLISM

Phosphoenolpyruvate mutase catalysis of phosphoryl transfer in phosphoenolpyruvate: kinetics and mechanism of phosphorus-carbon bond formation. Kim J, et al. **Biochemistry** 1996 Apr 9;35(14):4628–35

The hard-soft acid-base principle in enzymatic catalysis: dual reactivity of phosphoenolpyruvate. Li Y, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4612–6

THERAPEUTIC USE

Phosphoenolpyruvate/adenosine triphosphate enhances post-ischemic survival of skeletal muscle. Hickey MJ, et al. **J Reconstr Microsurg** 1995 Nov;11(6):415–22

PHOSPHOENOLPYRUVATE CARBOXYKINASES

ANTAGONISTS & INHIBITORS

The inhibition of phosphoenolpyruvate carboxykinase following in vivo chronic phenobarbital treatment in the rat is due to a post-translational event. Chauvin C, et al. **Eur J Biochem** 1996 May 15;238(1):207–13

BIOSYNTHESIS

Developmental changes in the phospho(enol)pyruvate carboxykinase gene expression in small intestine and liver of suckling rats. Asins G, et al. **Arch Biochem Biophys** 1996 May 1;329(1):82–6

The role of the TATA box in the hormonal regulation of phosphoenolpyruvate carboxykinase gene expression. Tebbey PW, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1006–13

A rapeseed cold-inducible transcript encodes a phosphoenolpyruvate carboxykinase. Sáez-Vásquez J, et al. **Plant Physiol** 1995 Oct;109(2):611–8

Persistent expression of genes transferred in the fetal rat liver via retroviruses. Hatzoglou M, et al. **Somat Cell Mol Genet** 1995 Jul;21(4):265–78

CHEMISTRY

Circular dichroism and Fourier transform infrared spectroscopic studies on the secondary structure of Saccharomyces cerevisiae and Escherichia coli phospho enolpyruvate carboxykinases. Encinas MV, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):23–7

Crystal structure of Escherichia coli phosphoenolpyruvate carboxykinase: a new structural family with the P-loop nucleoside triphosphate hydrolase fold. Matte A, et al. **J Mol Biol** 1996 Feb 16;256(1):126–43

Familiar jaws with new twists [news; comment] Pai EF. **Nat Struct Biol** 1996 Apr;3(4):307–9. Comment on: Nat Struct Biol 1996 Apr;3(4):355–63.

Snapshot of an enzyme reaction intermediate in the structure of the ATP-Mg2+-oxalate ternary complex of Escherichia coli PEP carboxykinase [see comments] Tari LW, et al. **Nat Struct Biol** 1996 Apr;3(4):355–63. Comment in: Nat Struct Biol 1996 Apr;3(4):307–9.

GENETICS

Sepsis-induced attenuation of glucagon and 8-BrcAMP modulation of the phosphoenolpyruvate carboxykinase gene. Deutschman CS, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R584–91

The phosphorylation state of the cAMP response element binding protein is decreased in diabetic rat liver. Davies GF, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):477–83

Effects of hyperthyroidism on expression of a phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice. Xu C, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):473–9

Molecular cloning, sequencing and expression of the cDNA of the mitochondrial form of phosphoenolpyruvate carboxykinase from human liver. Modaressi S, et al. **Biochem J** 1996 May 1;315 (Pt 3):807–14

Structural and functional analysis of the human phosphoenolpyruvate carboxykinase gene promoter. O'Brien RM, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):284–8

Fatty acids and fibrates are potent inducers of transcription of the phosphenolpyruvate carboxykinase gene in adipocytes. Antras-Ferry J, et al. **Eur J Biochem** 1995 Dec 1;234(2):390–6

The inhibition of phosphoenolpyruvate carboxykinase following in vivo chronic phenobarbital treatment in the rat is due to a post-translational event. Chauvin C, et al. **Eur J Biochem** 1996 May 15;238(1):207–13

Regulation of the gluconeogenic phosphoenolpyruvate carboxykinase and glycolytic aldolase A gene expression by O2 in rat hepatocyte cultures. Involvement of hydrogen peroxide as mediator in the response to O2. Kietzmann T, et al. **FEBS Lett** 1996 Jun 17;388(2–3):228–32

Identification and characterization of the pckA gene from Staphylococcus aureus. Scovill WH, et al. **J Bacteriol** 1996 Jun;178(11):3362–4

Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. Gabbay RA, et al. **J Biol Chem** 1996 Jan 26;271(4):1890–7

Adenovirus E1A proteins regulate phosphoenolpyruvate carboxykinase gene transcription through multiple mechanisms. Klemm DJ, et al. **J Biol Chem** 1996 Apr 5; 271(14):8082–8

The alpha-isoform of the CCAAT/enhancer-binding protein is required for mediating cAMP responsiveness of the phosphoenolpyruvate carboxykinase promoter in hepatoma cells. Roesler WJ, et al. **J Biol Chem** 1996 Apr 5; 271(14):8068–74

Identification and charaterization of the second retoinoic acid response element in the phosphoenolpyruvate carboxkinase gene promoter. Scott DK, et al. **J Biol Chem** 1996 Mar 15;271(11):6260–4

Examination of the phosphoenolpyruvate carboxykinase gene promoter in patients with noninsulin-dependent diabetes mellitus. Ludwig DS, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):503–6

Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Rosella G, et al. **Mol Endocrinol** 1995 Oct;9(10):1396–404

New connections in the regulation of PEPCK gene expression by insulin. Sutherland C, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):191–9 (100 ref.)

ISOLATION & PURIFICATION

Phosphoenolpyruvate carboxykinase from Trypanosoma cruzi. Purification and physicochemical and kinetic properties. Cymeryng C, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):91–101

METABOLISM

Measurement of metabolic fluxes through pyruvate kinase, phosphoenolpyruvate carboxykinase, pyruvate dehydrogenase, and pyruvate carboxylate in hepatocytes of different acinar origin. Jones CG, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):202–6

Reaction of wild-type C365S, and C458S saccharomyces cerevisiae phosphoenolpyruvate carboxykinases with fluorescent iodoacetamide derivatives. Krautwurst H, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):123–30

Phosphorylation of phosphoenolpyruvate carboxykinase in plants. Studies in plants with C4 photosynthesis and Crassulacean acid metabolism and in germinating seeds. Walker RP, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):653–8

Effects of divalent cations and nucleotides on the 14CO2-oxaloacetate exchange catalyzed by the phosphoenol pyruvate carboxykinase from the moderate halophile, Vibrio costicola. Salvarrey MS, et al.

Biochem Mol Biol Int 1995 Aug;36(6):1225–34
Trypanosoma cruzi phospho enol pyruvate carboxykinase (ATP–dependent): transition metal ion requirement for activity and sulfhydryl group reactivity. Jurado LA, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):188–96
Tissue–specific effects of
2,3,7,8–Tetrachlorodibenzo–p–dioxin (TCDD) on the activity of phosphoenolpyruvate carboxykinase (PEPCK) in rats. Viluksela M, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):308–15
2,3,7,8–Tetrachlorodibenzo–p–dioxin blocks the physiological regulation of hepatic phosphoenolpyruvate carboxykinase activity in primary rat hepatocytes. Stahl BU. **Toxicology** 1995 Nov 20;103(1):45–52

PHOSPHOENOLPYRUVATE CARBOXYLASE

BIOSYNTHESIS

Enhanced production of succinic acid by overexpression of phosphoenolpyruvate carboxylase in Escherichia coli. Millard CS, et al. **Appl Environ Microbiol** 1996 May; 62(5):1808–10

CHEMISTRY

Catalytic role of an arginine residue in the highly conserved and unique sequence of phosphoenolpyruvate carboxylase. Yano M, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1196–200

GENETICS

Site–directed mutagenesis of Flaveria trinervia phosphoenolpyruvate carboxylase: Arg450 and Arg767 are essential for catalytic activity and Lys829 affects substrate binding. Gao Y, et al. **FEBS Lett** 1996 Sep 2;392(3):285–8
Identification of multiple PEPC isogenes in leaves of the facultative Crassulacean acid metabolism (CAM) plant Kalanchoe blossfeldiana Poelln. cv. Tom Thumb. Gehrig H, et al. **FEBS Lett** 1995 Dec 27;377(3):399–402
Cloning and sequence analysis of the gene for phosphoenolpyruvate carboxylase from an extreme thermophile, Thermus sp. Nakamura T, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):319–24

ISOLATION & PURIFICATION

Purification and properties of four phosphoenolpyruvate carboxylase isoforms from the green alga Selenastrum minutum: evidence that association of the 102–kDa catalytic subunit with unrelated polypeptides may modify the physical and kinetic properties of the enzyme. Rivoal J, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):47–57
Purification and characterization of phosphoenolpyruvate carboxylase from the hyperthermophilic archaeon Methanothermus sociabilis. Sako Y, et al. **FEBS Lett** 1996 Aug 26;392(2):148–52

METABOLISM

Regulation of the supply of cytosolic oxaloacetate for mitochondrial metabolism via phosphoenolpyruvate carboxylase in barley leaf protoplasts. I. The effect of covalent modification on PEPC activity, pH response, and kinetic properties. Krömer S, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):343–50
Regulation of the supply of oxaloacetate for mitochondrial metabolism via phosphoenolpyruvate carboxylase in barley leaf protoplasts. II. Effects of metabolites on PEPC activity at different activation states of the protein. Krömer S, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):351–61
Site–directed mutagenesis of Lys600 in phosphoenolpyruvate carboxylase of Flaveria trinervia: its roles in catalytic and regulatory functions. Gao Y, et al. **FEBS Lett** 1995 Nov 13;375(1–2):95–8
Site–directed mutagenesis of Flaveria trinervia phosphoenolpyruvate carboxylase: Arg450 and Arg767 are essential for catalytic activity and Lys829 affects substrate binding. Gao Y, et al. **FEBS Lett** 1996 Sep 2;392(3):285–8
Purification and characterization of phosphoenolpyruvate carboxylase from the hyperthermophilic archaeon Methanothermus sociabilis. Sako Y, et al. **FEBS Lett** 1996 Aug 26;392(2):148–52

PHYSIOLOGY

C3–carboxylation as an anaplerotic reaction in phosphoenolpyruvate carboxylase–deficient Corynebacterium glutamicum. Peters–Wendisch PG, et al. **Arch Microbiol** 1996 Jun;165(6):387–96

PHOSPHOENOLPYRUVATE HEXOSE PHOSPHOTRANSFERASES see **PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM**

PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM

Regulation of sugar uptake via the phosphoenolpyruvate–dependent phosphotransferase systems in Bacillus subtilis and Lactococcus lactis is mediated by ATP–dependent phosphorylation of seryl residue 46 in HPr. Ye JJ, et al. **J Bacteriol** 1996 Jun; 178(12):3557–63
Regulation of the lactose phosphotransferase system of Streptococcus bovis by glucose: independence of inducer exclusion and expulsion mechanisms. Cook GM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2261–9

BIOSYNTHESIS

Purification by Ni2+ affinity chromatography, and functional reconstitution of the transporter for N–acetylglucosamine of Escherichia coli. Mukhija S, et al. **J Biol Chem** 1996 Jun 21;271(25):14819–24
Regulation of the lactose phosphotransferase system of Streptococcus bovis by glucose: independence of inducer exclusion and expulsion mechanisms. Cook GM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2261–9

CHEMISTRY

A fluorescence study of single tryptophan–containing mutants of enzyme IImtl of the Escherichia coli phosphoenolpyruvate–dependent mannitol transport system. Dijkstra DS, et al. **Biochemistry** 1996 May 28; 35(21):6628–34
Influence of phosphoenolpyruvate and magnesium ions on the quaternary structure of enzyme I of the phosphotransferase system from gram–positive bacteria. Hübner G, et al. **Biochemistry** 1995 Dec 5;34(48):15700–3
Interdomain interactions between the hydrophilic domains of the mannitol transporter of Escherichia coli in the unphosphorylated and phosphorylated states. Meijberg W, et al. **Biochemistry** 1996 Feb 27;35(8):2759–66
Conformational stability of the Escherichia coli HPr protein: test of the linear extrapolation method and a thermodynamic characterization of cold denaturation. Nicholson EM, et al. **Biochemistry** 1996 Sep 3; 35(35):11369–78
Importance of the region around glycine–338 for the activity of enzyme I of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system. Seok YJ, et al. **Biochemistry** 1996 Jan 9;35(1):236–42
Influence of N–cap mutations on the structure and stability of Escherichia coli HPr. Thapar R, et al. **Biochemistry** 1996 Sep 3;35(35):11268–77
Membrane topology of the mannose transporter of Escherichia coli K12. Huber F, et al. **Eur J Biochem** 1996 Aug 1;239(3):810–7
Function of the duplicated IIB domain and oligomeric structure of the fructose permease of Escherichia coli. Charbit A, et al. **J Biol Chem** 1996 Apr 26; 271(17):9997–10003
Structure of the IIA domain of the mannose transporter from Escherichia coli at 1.7 angstroms resolution. Nunn RS, et al. **J Mol Biol** 1996 Jun 14;259(3):502–11
The N–terminal domain of Escherichia coli enzyme I of the phosphoenolpyruvate/glycose phosphotransferase system: molecular cloning and characterization. Chauvin F, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7028–31
Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)
Importance of the carboxyl–terminal domain of enzyme I of the Escherichia coli phosphoenolpyruvate: sugar phosphotransferase system for phosphoryl donor specificity. Seok YJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):347–51
Homology modeling of histidine–containing phosphocarrier protein and eosinophil–derived neurotoxin: construction of models and comparison with experiment. Church WB, et al. **Proteins** 1995 Nov;23(3):422–30
Confronting the problem of interconnected structural changes in the comparative modeling of proteins. Samudrala R, et al. **Proteins** 1995 Nov;23(3):327–36
Phylogenetic analysis of the putative phosphorylation domain in the pyruvate kinase of Bacillus stearothermophilus. Nguyen CC, et al. **Res Microbiol** 1995 Nov–Dec; 146(9):713–9
Structural evidence for the evolutionary divergence of mycoplasma from gram–positive bacteria: the histidine–containing phosphocarrier protein. Pieper U, et al. **Structure** 1995 Aug 15;3(8):781–90

GENETICS

Transcriptional regulation of the pts operon in Streptococcus salivarius ATCC 25975. Gagnon G, et al. **Dev Biol Stand** 1995;85:357–62
Analysis of the promoter region of the Streptococcus mutans mannitol PTS operon. Honeyman AL, et al. **Dev Biol Stand** 1995;85:383–6
Expression, purification and characterization of the enzyme II mannitol–specific domain from Staphylococcus carnosus and determination of the active–site cysteine residue. Pogge von Strandmann R, et al. **Eur J Biochem** 1995 Oct 1; 233(1):116–22
Transcriptional analysis of bglPH expression in Bacillus subtilis: evidence for two distinct pathways mediating carbon catabolite repression. Krüger S, et al. **J Bacteriol** 1996 May;178(9):2637–44
Regulation of the putative bglPH operon for aryl–beta–glucoside utilization in Bacillus subtilis. Krüger S, et al. **J Bacteriol** 1995 Oct;177(19):5590–7
The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411–7 (46 ref.)
Characterization of the celB gene coding for beta–glucosidase from the hyperthermophilic archaeon Pyrococcus furiosus and its expression and site–directed mutation in Escherichia coli. Voorhorst WG, et al. **J Bacteriol** 1995 Dec; 177(24):7105–11
Fructose phosphotransferase system of Xanthomonas campestris pv. campestris: characterization of the fruB gene. de Crécy–Lagard V, et al. **Microbiology** 1995 Sep; 141 (Pt 9):2253–60
Cloning and sequencing of two genes from Staphylococcus carnosus coding for glucose–specific PTS and their expression in Escherichia coli K–12. Christiansen I, et al. **Mol Gen Genet** 1996 Feb 25;250(3):375–9
Molecular analysis of the scrA and scrB genes from Klebsiella pneumoniae and plasmid pUR400, which encode the sucrose transport protein Enzyme II Scr of the phosphotransferase system and a sucrose–6–phosphate invertase. Titgemeyer F, et al. **Mol Gen Genet** 1996 Feb 5;250(2):197–206
Regulation of ptsH and ptsI gene expression in Streptococcus salivarius ATCC 25975. Gagnon G, et al. **Mol Microbiol** 1995 Jun;16(6):1111–21
Molecular cloning of the Golgi apparatus uridine diphosphate–N–acetylglucosamine transporter from Kluyveromyces lactis. Abeijon C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5963–8
sigma54–dependent transcription of the Pseudomonas putida xylS operon is influenced by the IIANtr protein of the phosphotransferase system in Escherichia coli. Du Y, et al. **Res Microbiol** 1996 Mar–Apr;147(3):129–32
Novel PTS proteins revealed by bacterial genome sequencing: a unique fructose–specific phosphoryl transfer protein with two HPr–like domains in Haemophilus influenzae. Reizer J, et al. **Res Microbiol** 1996 May; 147(4):209–15 (29 ref.)
Structural evidence for the evolutionary divergence of mycoplasma from gram–positive bacteria: the histidine–containing phosphocarrier protein. Pieper U, et al. **Structure** 1995 Aug 15;3(8):781–90

ISOLATION & PURIFICATION

Purification by Ni2+ affinity chromatography, and functional reconstitution of the transporter for N–acetylglucosamine of Escherichia coli. Mukhija S, et al. **J Biol Chem** 1996 Jun 21;271(25):14819–24

METABOLISM

HPr: a model protein. Anderson JW. **Biochem Cell Biol** 1995 May–Jun;73(5–6):219–22 (15 ref.)
A fluorescence study of single tryptophan–containing mutants of enzyme IImtl of the Escherichia coli phosphoenolpyruvate–dependent mannitol transport system. Dijkstra DS, et al. **Biochemistry** 1996 May 28; 35(21):6628–34
Interdomain interactions between the hydrophilic domains of the mannitol transporter of Escherichia coli in the unphosphorylated and phosphorylated states. Meijberg W, et al. **Biochemistry** 1996 Feb 27;35(8):2759–66
Mutation of serine–46 to aspartate in the histidine–containing protein of Escherichia coli mimics the inactivation by phosphorylation of serine–46 in HPrs from gram–positive bacteria. Napper S, et al. **Biochemistry** 1996 Sep 3; 35(35):11260–7
Importance of the region around glycine–338 for the activity of enzyme I of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system. Seok YJ, et al. **Biochemistry** 1996 Jan 9;35(1):236–42
Regulation of sugar uptake via the multiple sugar metabolism operon by the phosphoenolpyruvate–dependent sugar phosphotransferase transport system of Streptococcus mutans. Cvitkovitch DG, et al. **Dev Biol Stand** 1995; 85:351–6
Changes in the cellular energy state affect the activity of the bacterial phosphotransferase system. Rohwer JM, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):225–30
Investigation of transphosphorylation between chemotaxis proteins and the phosphoenolpyruvate:sugar phosphotransferase system. Johnson MS, et al. **FEBS Lett** 1995 Oct 30;374(2):161–4
Isolation and characterization of a mutation that alters the substrate specificity of the Escherichia coli glucose permease. Begley GS, et al. **J Bacteriol** 1996 Feb; 178(3):940–2
Identification of a site in the phosphocarrier protein, HPr, which influences its interactions with sugar permeases of the bacterial phosphotransferase system: kinetic analyses employing site–specific mutants. Koch S, et al. **J Bacteriol** 1996 Feb;178(4):1126–33
Identification of an anaerobically induced phosphoenolpyruvate–dependent fructose–specific phosphotransferase system and evidence for the Embden–Meyerhof glycolytic pathway in the heterofermentative bacterium Lactobacillus brevis. Saier MH Jr, et al. **J Bacteriol** 1996 Jan;178(1):314–6
The HPr protein of the phosphotransferase system links induction and catabolite repression of the Bacillus subtilis levanase operon. Stülke J, et al. **J Bacteriol** 1995 Dec; 177(23):6928–36
Regulation of sugar uptake via the

phosphoenolpyruvate-dependent phosphotransferase systems in Bacillus subtilis and Lactococcus lactis is mediated by ATP-dependent phosphorylation of seryl residue 46 in HPr. Ye JJ, et al. **J Bacteriol** 1996 Jun; 178(12):3557–63

Active site phosphorylation of enzyme I of the bacterial phosphotransferase system by an ATP-dependent kinase. Dannelly HK, et al. **J Biol Chem** 1996 Jun 21; 271(25):15285–91

Specific recognition of the Bacillus subtilis gnt cis-acting catabolite-responsive element by a protein complex formed between CcpA and seryl-phosphorylated HPr. Fujita Y, et al. **Mol Microbiol** 1995 Sep;17(5):953–60

The N-terminal domain of Escherichia coli enzyme I of the phosphoenolpyruvate/glycose phosphotransferase system: molecular cloning and characterization. Chauvin F, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7028–31

Coupling the phosphotransferase system and the methyl-accepting chemotaxis protein-dependent chemotaxis signaling pathways of Escherichia coli. Lux R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11583–7

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525–30 (41 ref.)

PHYSIOLOGY

Regulation of sugar transport via the multiple sugar metabolism operon of Streptococcus mutans by the phosphoenolpyruvate phosphotransferase system. Cvitkovitch DG, et al. **J Bacteriol** 1995 Oct;177(19):5704–6

6-PHOSPHOFRUCTOKINASE

see related
GLYCOGEN STORAGE DISEASE TYPE VII

ANALYSIS

Isozyme analysis of human normal polymorphonuclear leukocyte phosphofructokinase. Durante P, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):898–905

[Phosphofructokinase (PFK)] Kono N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:438–41 (20 ref.) **(Jpn)**

BLOOD

Isozyme analysis of human polymorphonuclear leukocyte phosphofructokinase from insulin resistant individuals. Durante P, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):975–82

Inherited phosphofructokinase deficiency associated with hemolysis and exertional myopathy [letter] Rudolphi O, et al. **Eur J Haematol** 1995 Oct;55(4):279–81

CHEMISTRY

Rabbit liver phosphofructokinase: rapid purification and phosphorylation site identification. Zhao Z, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):410–5

Phosphofructo-1-kinase: role of charge neutralization in the active site. Zheng RL, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):765–70

Tetramer-dimer equilibrium of phosphofructokinase and formation of hybrid tetramers. Le Bras G, et al. **Biochemistry** 1995 Oct 10;34(40):13203–10

DEFICIENCY

Inherited phosphofructokinase deficiency associated with hemolysis and exertional myopathy [letter] Rudolphi O, et al. **Eur J Haematol** 1995 Oct;55(4):279–81

Improvement of hemolysis in muscle phosphofructokinase deficiency by restriction of exercise. Toyoda H, et al. **Intern Med** 1996 Mar;35(3):222–6

Molecular basis of canine muscle type phosphofructokinase deficiency. Smith BF, et al. **J Biol Chem** 1996 Aug 16; 271(33):20070–4

Late-onset muscle weakness in partial phosphofructokinase deficiency: a unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation. Sivakumar K, et al. **Neurology** 1996 May;46(5):1337–42

GENETICS

Glycogenosis type VII (Tarui disease) in a Swedish family: two novel mutations in muscle phosphofructokinase gene (PFK-M) resulting in intron retentions. Nichols RC, et al. **Am J Hum Genet** 1996 Jul;59(1):59–65

Common promoter features in human and mouse liver type phosphofructokinase gene. Levanon D, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):929–36

Characterization of expression of phosphofructokinase isoforms in isolated rat pancreatic islets and purified beta cells and cloning and expression of the rat phosphofructokinase-A isoform. Ma Z, et al. **Biochim Biophys Acta** 1996 Aug 14;1308(2):151–63

Functional complementation of yeast phosphofructokinase mutants by the non-allosteric enzyme from Dictyostelium discoideum. Estévez AM, et al. **FEBS Lett** 1995 Oct 23; 374(1):100–4

Cloning, sequence and expression in Escherichia coli of the gene encoding phosphofructokinase from Bacillus macquariensis. Rouwendal GJ, et al. **Gene** 1996 May 24; 171(1):59–63

A cDNA encoding canine muscle-type phosphofructokinase. Smith BF, et al. **Gene** 1996 Feb 12;168(2):275–6

Mutations in muscle phosphofructokinase gene. Raben N, et al. **Hum Mutat** 1995;6(1):1–6 (37 ref.)

The genes for phosphofructokinase and pyruvate kinase of Lactobacillus delbrueckii subsp. bulgaricus constitute an operon. Branny P, et al. **J Bacteriol** 1996 Aug; 178(15):4727–30

Localization of the Pfkfb 2 gene on rat chromosome 13. Pape MR, et al. **Mamm Genome** 1996 Jul;7(7):559

Late-onset muscle weakness in partial phosphofructokinase deficiency: a unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation. Sivakumar K, et al. **Neurology** 1996 May;46(5):1337–42

An E2F-dependent late-serum-response promoter in a gene that controls glycolysis. Darville MI, et al. **Oncogene** 1995 Oct 19;11(8):1509–17

Nonsense mutation in the phosphofructokinase muscle subunit gene associated with retention of intron 10 in one of the isolated transcripts in Ashkenazi Jewish patients with Tarui disease. Vasconcelos O, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10322–6

ISOLATION & PURIFICATION

Rabbit liver phosphofructokinase: rapid purification and phosphorylation site identification. Zhao Z, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):410–5

METABOLISM

A pH-dependent allosteric transition in Ascaris suum phosphofructokinase distinct from that observed with fructose 2,6-bisphosphate. Rao GS, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):410–6

Phosphofructo-1-kinase: role of charge neutralization in the active site. Zheng RL, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):765–70

Activation by phosphorylation of phosphofructokinase from the annelid Lumbricus terrestris and comparison of phosphorylated sites in invertebrate phosphofructokinases. Schaloske R, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):377–83

Isotope partitioning with Ascaris suum phosphofructokinase is consistent with an ordered kinetic mechanism. Gibson GE, et al. **Biochemistry** 1996 Apr 30;35(17):5451–7

Evidence for association of an ATP-stimulatable Ca(2+)-independent phospholipase A2 from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein. Ramanadham S, et al. **Biochemistry** 1996 Apr 30;35(17):5464–71

Control of frequency and amplitudes is shared by all enzymes in three models for yeast glycolytic oscillations. Teusink B, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):204–12

Phosphofructokinase isozymes in pancreatic islets and clonal beta-cells (INS-1). Yaney GC, et al. **Diabetes** 1995 Nov; 44(11):1285–9

A two-hybrid system analysis shows interactions between 6-phosphofructo-1-kinase and 6-phosphofructo-2-kinase but not between other glycolytic enzymes of the yeast Saccharomyces cerevisiae. Müller S, et al. **Eur J Biochem** 1996 Mar 1;236(2):626–31

Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449–54 (27 ref.)

Specific characteristics of phosphofructokinase-microtubule interaction. Vértessy BG, et al. **FEBS Lett** 1996 Jan 29; 379(2):191–5

A yeast phosphofructokinase insensitive to the allosteric activator fructose 2,6-bisphosphate. Glycolysis/metabolic regulation/allosteric control. Heinisch JJ, et al. **J Biol Chem** 1996 Jul 5;271(27):15928–33

Changes of activity and isozyme pattern of phosphofructokinase in the brains of patients with Alzheimer's disease. Bigl M, et al. **J Neurochem** 1996 Sep; 67(3):1164–71

The effect of pH on glycolysis and phosphofructokinase activity in cultured cells and synaptosomes. Erecińska M, et al. **J Neurochem** 1995 Dec;65(6):2765–72

The phosphofructokinase-uncharged tRNA interaction in metabolic and cell cycle control: an interpretive review. Rabinovitz M. **Nucleic Acids Symp Ser** 1995;(33):182–9 (53 ref.)

[Structural changes in actin filaments during binding with phosphofructokinase (F-protein), detected using an optical diffraction method] Podlubnaia ZA, et al. **Biofizika** 1996 Jan-Feb;41(1):73–7 (Eng. Abstr.) **(Rus)**

PHOSPHOGALACTOSE URIDYL TRANSFERASE see **HEXOSEPHOSPHATE URIDYLYLTRANSFERASE**

PHOSPHOGLUCOMUTASE

ANALYSIS

Identification of membrane-bound phosphoglucomutase and glucose-6 phosphatase by 32P-labeling of rat liver microsomal membrane proteins with 32P-glucose-6 phosphate. Mithieux G, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):908–14

GENETICS

PGM1 subtypes in Cantabria (middle N Spain). Calvet R, et al. **Gene Geogr** 1995 Apr;9(1):59–63

Polymorphism of phosphoglucomutase 1 (PGM1) in five Han subpopulations in China. Hu J, et al. **Gene Geogr** 1995 Apr; 9(1):1–4

Distribution of PGM1 and GC subtypes in the four Sardinian provinces. Vona G, et al. **Gene Geogr** 1995 Apr;9(1):41–52

A novel human phosphoglucomutase (PGM5) maps to the centromeric region of chromosome 9. Edwards YH, et al. **Genomics** 1995 Nov 20;30(2):350–3

Characterization of the essential gene glmM encoding phosphoglucosamine mutase in Escherichia coli. Mengin-Lecreulx D, et al. **J Biol Chem** 1996 Jan 5; 271(1):32–9

ISOLATION & PURIFICATION

[Phosphoglucomutase (PGM)] Takahashi N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:210–4 (19 ref.) **(Jpn)**

METABOLISM

A novel dystrophin/utrophin-associated protein is an enzymatically inactive member of the phosphoglucomutase superfamily. Moiseeva EP, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):103–13

PHYSIOLOGY

Avirulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection. Goldberg JB, et al. **Infect Immun** 1995 Oct;63(10):4166–9

PHOSPHOGLUCONATE DEHYDROGENASE

ANTAGONISTS & INHIBITORS

Polyethylene sulfonate: a tight-binding inhibitor of 6-phosphogluconate dehydrogenase of Cryptococcus neoformans. Niehaus WG, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):325–30

BLOOD

Inhibition of 6-phosphogluconate dehydrogenase by carbamylation and protection by alpha-crystallin, a chaperone-like protein. Ganea E, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):626–31

CHEMISTRY

Bromopyruvate for the affinity labelling of a single cysteine residue near the carboxylate binding site of lamb liver 6-phosphogluconate dehydrogenase. Hanau S, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):785–93

Structural and mechanistic similarities of 6-phosphogluconate and 3-hydroxyisobutyrate dehydrogenases reveal a new enzyme family, the 3-hydroxyacid dehydrogenases. Hawes JW, et al. **FEBS Lett** 1996 Jul 8;389(3):263–7

GENETICS

Red cell 6-phosphogluconate dehydrogenase polymorphism in the Gadaba of Andhra Pradesh (India). Report of new variant phenotypes. Rao PM, et al. **Anthropol Anz** 1995 Dec;53(4):327–30

Nucleotide sequence and features of the Bacillus licheniformis gnt operon. Yoshida K, et al. **DNA Res** 1994; 1(4):157–62

Inhibition of translation initiation on Escherichia coli gnd mRNA by formation of a long-range secondary structure involving the ribosome binding site and the internal complementary sequence. Chang JT, et al. **J Bacteriol** 1995 Nov;177(22):6560–7

The molecular mechanism underlying the "rare allele phenomenon" in a subspecific hybrid zone of the California field mouse, Peromyscus californicus. Hoffman SM, et al. **J Mol Evol** 1995 Dec;41(6):1165–9

METABOLISM

[Negative cooperativity of 6-phosphogluconate dehydrogenase in rat liver] Volnova NE, et al. **Biokhimiia** 1996 Mar;61(3):451–4 (Eng. Abstr.) **(Rus)**

PHOSPHOGLUCOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

3-PHOSPHOGLYCERALDEHYDE see **GLYCERALDEHYDE 3-PHOSPHATE**

PHOSPHOGLYCERALDEHYDE DEHYDROGENASE see **GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE**

PHOSPHOGLYCERATE KINASE

ANTAGONISTS & INHIBITORS

Novel inhibitors of 3-phosphoglycerate kinase. Hickey MJ, et al. **Biochem Soc Trans** 1995 Nov;23(4):607S

PHOSPHOGLYCERATE KINASE

Specific inhibitors for the glycolytic enzymes of Trypanosoma brucei. Trinquier M, et al. **Bioorg Med Chem** 1995 Nov;3(11):1423–7

BIOSYNTHESIS

Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Ookawara T, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):35–40

Differential appearance of DNase I–hypersensitive sites correlates with differential transcription of Pgk genes during spermatogenesis in the mouse. Kumari M, et al. **J Biol Chem** 1996 Jun 14;271(24):14390–7

CHEMISTRY

Sequential domain unfolding in phosphoglycerate kinase: fluorescence intensity and anisotropy stopped–flow kinetics of several tryptophan mutants. Beechem JM, et al. **Biochemistry** 1995 Oct 24;34(42):13943–8

Structure of the R65Q mutant of yeast 3–phosphoglycerate kinase complexed with Mg–AMP–PNP and 3–phospho–D–glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

Folding and functional complementation of engineered fragments from yeast phosphoglycerate kinase. Pecorari F, et al. **Biochemistry** 1996 Mar 19;35(11):3465–76

Is the continuity of the domains required for the correct folding of a two–domain protein? Ritco–Vonsovici M, et al. **Biochemistry** 1995 Dec 26;34(51):16543–51

Probing intradomain and interdomain conformational changes during equilibrium unfolding of phosphoglycerate kinase: fluorescence and circular dichroism study of tryptophan mutants. Sherman MA, et al. **Biochemistry** 1995 Oct 24;34(42):13934–42

Sucrose reduces the efficiency of protein denaturation by a chaotropic agent. Taylor LS, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):39–46

The role of the C–terminal lysine in the hinge bending mechanism of yeast phosphoglycerate kinase. Adams B, et al. **FEBS Lett** 1996 Apr 29;385(1–2):101–4

Occurrence of transient multimeric species during the refolding of a monomeric protein. Pecorari F, et al. **J Biol Chem** 1996 Mar 1;271(9):5270–6

An integrated kinetic analysis of intermediates and transition states in protein folding reactions. Parker MJ, et al. **J Mol Biol** 1995 Nov 10;253(5):771–86

2.0 A resolution structure of a ternary complex of pig muscle phosphoglycerate kinase containing 3–phospho–D–glycerate and the nucleotide Mn adenylylimidodiphosphate. May A, et al. **Proteins** 1996 Mar;24(3):292–303

DEFICIENCY

Molecular defect of a phosphoglycerate kinase variant associated with haemolytic anaemia and neurological disorders in a large kindred. Turner G, et al. **Br J Haematol** 1995 Sep;91(1):60–5

GENETICS

Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Ookawara T, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):35–40

Molecular abnormality of a phosphoglycerate kinase variant (PGK–Alabama). Yoshida A, et al. **Blood Cells Mol Dis** 1995;21(3):179–81

The 3–phosphoglycerate kinase gene of the yeast Yarrowia lipolytica de–represses on gluconeogenic substrates. Le Dall M, et al. **Curr Genet** 1996 Apr;29(5):446–5

Complementation of a pgk deletion mutation in Saccharomyces cerevisiae with expression of the phosphoglycerate–kinase gene from the hyperthermophilic Archaeon Sulfolobus solfataricus. Piper PW, et al. **Curr Genet** 1996 May;29(6):594–6

Analysis of clonality by polymerase chain reaction for phosphoglycerate kinase–1. Heteroduplex generator. Doherty T, et al. **Diagn Mol Pathol** 1995 Sep;4(3):182–90

Dimeric 3–phosphoglycerate kinases from hyperthermophilic Archaea. Cloning, sequencing and expression of the 3–phosphoglycerate kinase gene of Pyrococcus woesei in Escherichia coli and characterization of the protein. Structural and functional comparison with the 3–phosphoglycerate kinase of Methanothermus fervidus. Hess D, et al. **Eur J Biochem** 1995 Oct 1;233(1):227–37

The phosphoglycerate kinase and glyceraldehyde–3–phosphate dehydrogenase genes from the thermophilic archaeon Sulfolobus solfataricus overlap by 8–bp. Isolation, sequencing of the genes and expression in Escherichia coli. Jones CE, et al. **Eur J Biochem** 1995 Nov 1;233(3):800–8

The 3'–untranslated regions from the Trypanosoma brucei phosphoglycerate kinase–encoding genes mediate developmental regulation. Blattner J, et al. **Gene** 1995 Aug 30;162(1):153–6

The 3–phosphoglycerate kinase of the hyperthermophilic archaeum Pyrococcus woesei produced in Escherichia coli: loss of heat resistance due to internal translation initiation and its restoration by site–directed mutagenesis. Hess D, et al. **Gene** 1996 Jun 12;172(1):121–4

Lack of a BglII site at the 5' region of the PGK 1 locus: a new variant discovered in two Chibchan Amerindian groups from Costa Rica. Azofeifa J, et al. **Hum Genet** 1995 Nov;96(5):626–7

Induction of the gap–pgk operon encoding glyceraldehyde–3–phosphate dehydrogenase and 3–phosphoglycerate kinase of Xanthobacter flavus requires the LysR–type transcriptional activator CbbR. Meijer WG, et al. **J Bacteriol** 1996 Feb;178(3):881–7

Differential appearance of DNase I–hypersensitive sites correlates with differential transcription of Pgk genes during spermatogenesis in the mouse. Kumari M, et al. **J Biol Chem** 1996 Jun 14;271(24):14390–7

Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. Li H, et al. **J Biol Chem** 1996 Aug 30;271(35):21262–7

The bacteriophage 434 operator/repressor system in yeast. Webster CI, et al. **Microbiology** 1995 Sep;141 (Pt 9):2191–200

Cloning of the gene for phosphoglycerate kinase from Schistosoma mansoni and characterization of its gene product. Lee KW, et al. **Mol Biochem Parasitol** 1995 May; 71(2):221–31

The multifunctional transcription factors Abf1p, Rap1p and Reb1p are required for full transcriptional activation of the chromosomal PGK gene in Saccharomyces cerevisiae. Packham EA, et al. **Mol Gen Genet** 1996 Feb 25; 250(3):348–56

Differential gene expression of chloroplast and cytosolic phosphoglycerate kinase in tobacco. Bringloe DH, et al. **Plant Mol Biol** 1996 Feb;30(3):637–40

Higher–plant chloroplast and cytosolic 3–phosphoglycerate kinases: a case of endosymbiotic gene replacement. Brinkmann H, et al. **Plant Mol Biol** 1996 Jan;30(1):65–75

[Clonal analysis of hepatocellular carcinoma] Ochiai T, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:182–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immune response to Schistosoma mansoni phosphoglycerate kinase during natural and experimental infection: identification of a schistosome–specific B–cell epitope. Lee KW, et al. **Infect Immun** 1995 Nov;63(11):4307–11

METABOLISM

Structure of the R65Q mutant of yeast 3–phosphoglycerate kinase complexed with Mg–AMP–PNP and 3–phospho–D–glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

The hyperthermophilic bacterium Thermotoga neapolitana possesses two isozymes of the 3–phosphoglycerate kinase/triosephosphate isomerase fusion protein. Yu JS, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):307–12

Occurrence of transient multimeric species during the refolding of a monomeric protein. Pecorari F, et al. **J Biol Chem** 1996 Mar 1;271(9):5270–6

Import of a DHFR hybrid protein into glycosomes in vivo is not inhibited by the folate–analogue aminopterin. Häusler T, et al. **J Cell Biol** 1996 Feb;132(3):311–24

PHOSPHOGLYCERATE MUTASE

CHEMISTRY

Phosphoglycerate mutase from Schizosaccharomyces pombe: development of an expression system and characterisation of three histidine mutants of the enzyme. Nairn J, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):69–75

GENETICS

Phosphoglycerate mutase from Schizosaccharomyces pombe: development of an expression system and characterisation of three histidine mutants of the enzyme. Nairn J, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):69–75

2,3–Bisphosphoglycerate–independent phosphoglycerate mutase is conserved among different phylogenic kingdoms. Graña X, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):287–93

A precise localization of a mouse gene encoding increased phosphoglycerate mutase activity (Pgam1e1) on chromosome 19. Pretsch W, et al. **Mamm Genome** 1996 Aug;7(8):619

A salinity–induced gene from the halophyte M. crystallinum encodes a glycolytic enzyme, cofactor–independent phosphoglyceromutase. Forsthoefel NR, et al. **Plant Mol Biol** 1995 Oct;29(2):213–26

PHOSPHOGLYCERIDES see **GLYCEROPHOSPHATES**

PHOSPHOGLYCEROMUTASE see **PHOSPHOGLYCERATE MUTASE**

PHOSPHOHEXOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

PHOSPHOHYDROLASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOLS**

PHOSPHO–2–KETO–3–DEOXYHEPTONATE ALDOLASE

CHEMISTRY

Identical amino acid sequence of the aroA(G) gene products of Bacillus subtilis 168 and B. subtilis Marburg strain. Bolotin A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2219–22

Evidence for a novel class of microbial 3–deoxy–D–arabino–heptulosonate–7–phosphate synthase in Streptomyces coelicolor A3(2), Streptomyces rimosus and Neurospora crassa. Walker GE, et al. **Microbiology** 1996 Aug;142 (Pt 8):1973–82

GENETICS

Aromatic amino–acid biosynthesis in Candida albicans: identification of the ARO4 gene encoding a second DAHP synthase. Pereira SA, et al. **Curr Genet** 1996 Apr; 29(5):441–5

ISOLATION & PURIFICATION

Purification, crystallization, and preliminary crystallographic analysis of 3–deoxy–D–arabino–heptulosonate–7–phosphate synthase from Escherichia coli. Shumilin IA, et al. **Proteins** 1996 Mar;24(3):404–6

METABOLISM

Chorismate mutase and 3–deoxy–D–arabino–heptulosonate 7–phosphate synthase of the methylotrophic actinomycete Amycolatopsis methanolica. Euverink GJ, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3796–803

Evidence for a novel class of microbial 3–deoxy–D–arabino–heptulosonate–7–phosphate synthase in Streptomyces coelicolor A3(2), Streptomyces rimosus and Neurospora crassa. Walker GE, et al. **Microbiology** 1996 Aug;142 (Pt 8):1973–82

PHOSPHOLIPASE A1 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE A2 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE B see **LYSOPHOSPHOLIPASE**

PHOSPHOLIPASE C

ANALYSIS

Chromogenic assay for phospholipase C from Bacillus cereus. Hergenrother PJ, et al. **Anal Biochem** 1995 Aug 10; 229(2):313–6

ANTAGONISTS & INHIBITORS

Influence of PLC and MLCK inhibitors and the role of L–calcium channels in the cat pulmonary vascular bed. Kaye AD, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L507–13

Effects of phospholipase C inhibitors on Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by alpha 1A– and alpha 2A–adrenoceptors in rat portal vein myocytes. Macrez–Leprêtre N, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):30–4

Inhibition of demecolcin–induced DNA synthesis by inhibitors of phospholipase C and protein kinase C. Suzuki K, et al. **Biochem Biophys Res Commun** 1996 Feb 6; 219(1):163–7

EJ–Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet–derived growth factor–BB via phosphatidylinositol 3–kinase. Heldman AW, et al. **Circ Res** 1996 Feb;78(2):312–21

Effects of an aminosteroid inhibitor of phospholipase C–dependent processes on the TCR–mediated signal transduction pathway in human T cells. Vassilopoulos D, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):59–68

Inhibition by gangliosides of Bacillus cereus phospholipase C activity against monolayers, micelles and bilayer vesicles. Daniele JJ, et al. **Eur J Biochem** 1996 Jul 1;239(1):105–10

Effect of the aminosteroid, U73122, on Ca2+ uptake and release properties of rat liver microsomes. De Moel MP, et al. **Eur J Biochem** 1995 Dec 1;234(2):626–31

Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor–differentiated PC12 cells. Li X, et al. **J Neurochem** 1995 Dec;65(6):2500–8

D609, a phosphatidylcholine–specific phospholipase C inhibitor, blocks interleukin–1 beta–induced vascular cell adhesion molecule 1 gene expression in human endothelial cells. Cobb RR, et al. **Mol Pharmacol** 1996 Jun; 49(6):998–1004

BIOSYNTHESIS

Liposomal incorporation changes the effect of 1.25–dihydroxyvitamin D3 on the phospholipase C signal transduction pathway and the eicosanoid cascade on keratinocytes in vitro. Prüfer K, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):247–52

Age–related loss of cholinergic–muscarinic coupling to PLC: comparison with changes in brain regional PLC subtypes mRNA distribution. Narang N, et al. **Brain Res** 1996 Feb 5;708(1–2):143–52

A new phospholipase C delta 4 is induced at S–phase of the cell cycle and appears in the nucleus. Liu N, et al.

J Biol Chem 1996 Jan 5;271(1):355–60

Immunohistochemical expression of phospholipase C in global and focal ischemic encephalopathy in gerbil: relationship with morphological changes. Koo H. **J Korean Med Sci** 1996 Feb;11(1):44–54

Biochemical analysis of SH2 domain-mediated protein interactions. Gish G, et al. **Methods Enzymol** 1995; 254:503–23

Transcriptional activation of virulence genes in wild-type strains of Listeria monocytogenes in response to a change in the extracellular medium composition. Ripio MT, et al. **Res Microbiol** 1996 Jun;147(5):371–84

[The effect of subinhibitory concentrations of quinolone and macrolide antibiotics on production of thermolabile hemolysins in Pseudomonas aeruginosa] Hybenová D, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):169–70 (Eng. Abstr.) (Czs)

BLOOD

A chemiluminescence method to analyze phosphatidylcholine–phospholipase activity in plasma membrane preparations and in intact cells. Lucas M, et al. **Anal Biochem** 1995 Nov 1;231(2):277–81

Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin-stimulated human platelets. Banno Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14989–94

Bradykinin stimulates phosphoinositide turnover and phospholipase C but not phospholipase D and NADPH oxidase in human neutrophils. Catz SD, et al. **J Leukoc Biol** 1996 Apr;59(4):591–7

CHEMISTRY

Phospholipase C in mouse oocytes: characterization of beta and gamma isoforms and their possible involvement in sperm-induced Ca2+ spiking. Dupont G, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):583–91

Phospholipase C delta 1 requires a pleckstrin homology domain for interaction with the plasma membrane. Paterson HF, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):661–6

Molecular cloning, expression and regulatory activity of G alpha 11- and beta gamma-subunit-stimulated phospholipase C-beta from avian erythrocytes. Waldo GL, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):559–68

The pleckstrin homology domain of phospholipase C-delta 1 binds with high affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. Garcia P, et al. **Biochemistry** 1995 Dec 12;34(49):16228–34

Crystal structure of phosphatidylinositol-specific phospholipase C from Bacillus cereus in complex with glucosaminyl(alpha 1—>6)-D-myo-inositol, an essential fragment of GPI anchors. Heinz DW, et al. **Biochemistry** 1996 Jul 23;35(29):9496–504

Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Ferguson KM, et al. **Cell** 1995 Dec 15; 83(6):1037–46

A beta-subclass phosphatidylinositol-specific phospholipase C from squid (Loligo forbesi) photoreceptors exhibiting a truncated C-terminus. Carne A, et al. **FEBS Lett** 1995 Sep 25;372(2-3):243–8

C2 domain conformational changes in phospholipase C-delta 1. Grobler JA, et al. **Nat Struct Biol** 1996 Sep;3(9):788–95

Phospholipid signalling. Taking stock of PI-PLC [news; comment] Irvine R. **Nature** 1996 Apr 18;380(6575):581–3 . Comment on: Nature 1996 Apr 18;380(6575):595–602.

Identification of a phospholipase C beta2 region that interacts with Gbeta-gamma. Kuang Y, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2964–8

DEFICIENCY

Genomic organization of the hamster phospholipase C-delta 1 gene: differential loss of separate alleles of the phospholipase C-delta 1 gene in two fibroblast mutants lacking phospholipase C-delta 1. Leonis MA, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):382–90

Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Lee SB, et al. **Blood** 1996 Sep 1;88(5):1684–91

DRUG EFFECTS

Activation of phospholipase C in SH-SY5Y neuroblastoma cells by potassium-induced calcium entry. Smart D, et al. **Br J Pharmacol** 1995 Sep;116(2):1797–800

Hepatocyte growth factor induces activation of Nck and phospholipase C-gamma in lung carcinoma cells. Kochhar KS, et al. **Cancer Lett** 1996 Jul 12;104(2):163–9

Stimulatory effects of sucralfate on secretion and synthesis of mucus by rabbit gastric mucosal cells. Involvement of phospholipase C. Takahashi S, et al. **Dig Dis Sci** 1996 Mar; 41(3):498–504

Ceramide inhibits IgE-mediated activation of phospholipase D, but not of phospholipase C, in rat basophilic leukemia (RBL-2H3) cells. Nakamura Y, et al. **J Immunol** 1996 Jan 1;156(1):256–62

Glutamate-induced antigenic changes of phospholipase C-delta in cultured cortical neurons. Shimohama S, et al. **J Neurosci Res** 1995 Jun 15;41(3):418–26

Perfluorodecanoic acid, a peroxisome proliferator, activates phospholipase C, inhibits CTP:phosphocholine cytidylyltransferase, and elevates diacylglycerol in rat liver. Reo NV, et al. **Toxicol Lett** 1996 Jul;86(1):1–11

GENETICS

Genomic organization of the hamster phospholipase C-delta 1 gene: differential loss of separate alleles of the phospholipase C-delta 1 gene in two fibroblast mutants lacking phospholipase C-delta 1. Leonis MA, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):382–90

Purification and characterization of phospholipase C-beta 1 mutants expressed in E. coli. Meij JT, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):705–11

A new inositol 1,4,5-trisphosphate binding protein similar to phospholipase C-delta 1. Kanematsu T, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):319–25

Molecular cloning of a phosphoinositide-specific phospholipase C from catfish olfactory rosettes. Abogadie FC, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):10–6

Assignment of the mouse homologue of a human MEN1 candidate gene, phospholipase C-beta 3 (Plcb3), to chromosome region 19B by FISH. Gobl AE, et al. **Cytogenet Cell Genet** 1995;71(3):257–9

Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. Johansen KA, et al. **Infect Immun** 1996 Aug;64(8):3259–66

A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli. Leão SC, et al. **Infect Immun** 1995 Nov;63(11):4301–6

Phylogenetic analysis of phospholipase C genes from Clostridium perfringens types A to E and Clostridium novyi. Tsutsui K, et al. **J Bacteriol** 1995 Dec; 177(24):7164–70

Molecular cloning, splice variants, expression, and purification of phospholipase C-delta 4. Lee SB, et al. **J Biol Chem** 1996 Jan 5;271(1):25–31

Chromosome mapping of the rat phospholipase C beta 1 gene. Calabrese G, et al. **Mamm Genome** 1995 Aug;6(8):549–50

Genetic mapping of the human and mouse phospholipase C genes. Lyu MS, et al. **Mamm Genome** 1996 Jul;7(7):501–4

Analysis of the phospholipase C gene of Clostridium perfringens KZ1340 isolated from Antarctic soil. Kameyama K, et al. **Microbiol Immunol** 1996;40(4):255–63

Expression of the phosphoinositide-specific phospholipase Cbeta3 gene in the rat. Lagercrantz J, et al. **Neuroreport** 1995 Dec 15;6(18):2542–4

The rat phospholipase C beta 4 gene is expressed at high abundance in cerebellar Purkinje cells. Roustan P, et al. **Neuroreport** 1995 Oct 2;6(14):1837–41

Hyperparathyroidism of multiple endocrine neoplasia type 1: candidate gene and parathyroid calcium sensing protein expression. Carling T, et al. **Surgery** 1995 Dec; 118(6):924–30; discussion 930–1

IMMUNOLOGY

Expression of a 118 Kd protein in colon carcinoma cells that is immunologically related to PLC-gamma 1 and is augmented by serum-free conditions. Fry DW, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):265–78

A recombinant insect-specific alpha-toxin of Buthus occitanus tunetanus scorpion confers protection against homologous mammal toxins. Bouhaouala-Zahar B, et al. **Eur J Biochem** 1996 Jun 15;238(3):653–60

ISOLATION & PURIFICATION

Purification and characterization of phospholipase C-beta 1 mutants expressed in E. coli. Meij JT, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):705–11

METABOLISM

ATP a potent regulator of inositol phospholipids–phospholipase C and lipid mediators in brain cortex. Stroszнajder J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):527–34

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23–33 (31 ref.)

Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium. Sanborn BM, et al. **Adv Exp Med Biol** 1995;395:469–79 (54 ref.)

Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Matsushima H, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):213–7

ANG II-induced tyrosine phosphorylation stimulates phospholipase C-gamma 1 and Cl-channels in mesangial cells. Marrero MB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1834–42

Functional characterization of phosphoinositide-specific phospholipase C-beta 1 and -beta 3 in intestinal smooth muscle. Murthy KS, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C969–78

Chromogenic assay for phospholipase C from Bacillus cereus. Hergenrother PJ, et al. **Anal Biochem** 1995 Aug 10; 229(2):313–6

A comparative study of unpassaged and animal passaged cultures of Listeria monocytogenes in rabbits. Vahidy R, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):139–42

Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Podo F, et al. **Anticancer Res** 1996 May-Jun;16(3B):1399–412

Effect of chronic ethanol on phospholipase A2- and C-activity in chick embryo brain, heart and liver. Natsuki R. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):348–57

Galanin increases cytoplasmic calcium in insulin-producing RINm5F cells by activating phospholipase C. Ahrén B. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):89–94

Et-1 and Et-3 actions mediated by cloned ETA endothelin receptors exhibit different sensitivities to BQ-123. Gresser O, et al. **Biochem Biophys Res Commun** 1996 Jul 5; 224(1):169–71

P2-purigenic receptors regulate phospholipase C and adenylate cyclase activities in immortalized Schwann cells. Berti-Mattera LN, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):555–61

Mutation of an EF-hand Ca(2+)-binding motif in phospholipase C of Dictyostelium discoideum: inhibition of activity but no effect on Ca(2+)-dependence. Drayer AL, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):505–10

Phospholipase C in mouse oocytes: characterization of beta and gamma isoforms and their possible involvement in sperm-induced Ca2+ spiking. Dupont G, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):583–91

Ca2+ signalling mechanisms of the beta 2 integrin on neutrophils: involvement of phospholipase C gamma 2 and Ins(1,4,5)P3. Hellberg C, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):403–9

Time-dependent inhibition of phospholipase C beta-catalysed phosphoinositide hydrolysis: a comparison of different assays. James SR, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):917–21

A new inositol 1,4,5-trisphosphate binding protein similar to phospholipase C-delta 1. Kanematsu T, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):319–25

Asymmetric signal transduction in polarized ileal Na(+)-absorbing cells: carbachol activates brush-border but not basolateral-membrane PIP2-PLC and translocates PLC-gamma 1 only to the brush border. Khurana S, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):509–18

Phospholipase C delta 1 requires a pleckstrin homology domain for interaction with the plasma membrane. Paterson HF, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):661–6

Early signalling events implicated in leukotriene B4-induced activation of the NADPH oxidase in eosinophils: role of Ca2+, protein kinase C and phospholipases C and D. Perkins RS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):795–806

The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Si-Tahar M, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):401–8

Molecular cloning, expression and regulatory activity of G alpha 11- and beta gamma-subunit-stimulated phospholipase C-beta from avian erythrocytes. Waldo GL, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):559–68

Early signalling mechanism in colonic epithelial cell response to gastrin. Yassin RR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):945–50

Inhibition of PDGF-induced phosphoinositide-turnover by glucopiericidin A. Ahn SC, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):125–32

Evidence suggesting a role for phospholipase C isozyme, PLC-delta 1 in corticomedullary osmotic gradients in rat kidneys. Lee KH, et al. **Biochem Mol Biol Int** 1995 Sep; 37(1):25–31

Mu-opioid activation of phospholipase C in SH-SY5Y cells rapidly desensitizes: mechanistic studies. Smart D, et al. **Biochem Soc Trans** 1995 Aug;23(3):419S

Dual inhibitory effect of gangliosides on phospholipase C-promoted fusion of lipidic vesicles. Basáñez G, et al. **Biochemistry** 1996 Jun 11;35(23):7506–13

The pleckstrin homology domain of phospholipase C-delta 1 binds with high affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. Garcia P, et al. **Biochemistry** 1995 Dec 12;34(49):16228–34

Structural and dynamic characterization of the phosphotyrosine binding region of a Src homology 2 domain—phosphopeptide complex by NMR relaxation, proton exchange, and chemical shift approaches. Pascal SM, et al. **Biochemistry** 1995 Sep 12;34(36):11353–62

Regulation of bradykinin-stimulated phospholipase C and arachidonic acid release by protein kinase A in MDCK-D1 cells. Kennedy CR, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):206–14

Inhibition of PDGF-induced phospholipase C activation by herbimycin A. Kim BY, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):33–6

Compound D609 inhibits phorbol ester-stimulated phospholipase D activity and phospholipase C-mediated phosphatidylethanolamine hydrolysis. Kiss Z, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):105–8

Gastric chief cells possess NK1 receptors which mediate pepsinogen secretion and are regulated by agents that increase cAMP and phospholipase C. Kitsukawa Y, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):105–16

Diadenosine polyphosphates regulate cytosolic calcium in human fibroblast cells by interaction with P2x purinoceptors coupled to phospholipase C. Tepel M, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):145–50

Immunocytochemical detection of the intranuclear variations of phosphatidylinositol 4,5-bisphosphate amount associated with changes of activity and amount of phospholipase C

beta 1 in cells exposed to mitogenic or differentiating agonists. Maraldi NM, et al. **Biol Cell** 1995;83(2-3):201-10

Desensitization of the mu-opioid activation of phospholipase C in SH-SY5Y cells: the role of protein kinases C and A and Ca(2+)-activated K+ currents. Smart D, et al. **Br J Pharmacol** 1995 Nov;116(6):2655-60

Endogenous nitric oxide signalling system and the cardiac muscarinic acetylcholine receptor-inotropic response. Sterin-Borda L, et al. **Br J Pharmacol** 1995 Aug; 115(8):1525-31

Relationship between opioids and activation of phospholipase C and protein kinase C in brain injury induced pial artery vasoconstriction. Armstead WM. **Brain Res** 1995 Aug 21; 689(2):183-8

Opioid mu- and kappa-receptor mediate phospholipase C activation through Gi1 in Xenopus oocytes. Ueda H, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):166-70

Relationship of growth stimulated by lithium, estradiol, and EGF to phospholipase C activity in MCF-7 human breast cancer cells. Taylor JA, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):265-77

Identification of PI-PLC beta 1, gamma 1, and delta 1 in rat liver: subcellular distribution and relationship to inositol lipid nuclear signalling. Bertagnolo V, et al. **Cell Signal** 1995 Sep;7(7):669-78

Differential regulation of phospholipase D and phospholipase C by protein kinase C-beta and -delta in liver macrophages. Dieter P, et al. **Cell Signal** 1995 Sep;7(7):687-94

High-density lipoprotein and low-density lipoprotein-mediated signal transduction in cultured human skin fibroblasts. Möllers C, et al. **Cell Signal** 1995 Sep; 7(7):695-707

Concentration of enzyme-dependent activation of PLC-beta 1 and PLC-beta 2 by G alpha 11 and beta gamma-subunits. Paterson A, et al. **Cell Signal** 1995 Sep;7(7):709-20

Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331-6 (54 ref.)

Coincidence detection at the level of phospholipase C activation mediated by the m4 muscarinic acetylcholine receptor. Carroll RC, et al. **Curr Biol** 1995 May 1; 5(5):536-44

Effect of carbachol on phospholipase C-mediated phosphatidylinositol 4,5-bisphosphate hydrolysis, and its modulation by isoproterenol in rabbit corneal epithelial cells. Zhang Y, et al. **Curr Eye Res** 1995 Jul;14(7):563-71

Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. Cifone MG, et al. **EMBO J** 1995 Dec 1; 14(23):5859-68

Transforming potentials of epidermal growth factor and nerve growth factor receptors inversely correlate with their phospholipase C gamma affinity and signal activation. Obermeier A, et al. **EMBO J** 1996 Jan 2;15(1):73-82

Prostaglandin E2 activates phospholipase C and elevates intracellular calcium in cultured myometrial cells: involvement of EP1 and EP3 receptor subtypes. Asbóth G, et al. **Endocrinology** 1996 Jun;137(6):2572-9

Regulation of insulin release by phospholipase C activation in mouse islets: differential effects of glucose and neurohumoral stimulation. Zawalich WS, et al. **Endocrinology** 1995 Nov;136(11):4903-9

Activators of protein kinase C but not of phospholipase C modulate adenylate cyclase-responses of normal pig epidermis. Iizuka H, et al. **Epithelial Cell Biol** 1995; 4(1):35-41

The intranuclear amount of phospholipase C beta 1 decreases following cell differentiation in Friend cells, whereas gamma 1 isoform is not affected. Zini N, et al. **Eur J Cell Biol** 1995 Sep;68(1):25-34

Exogenous human immunodeficiency virus type-1 Tat protein selectively stimulates a phosphatidylinositol-specific phospholipase C nuclear pathway in the Jurkat T cell line. Zauli G, et al. **Eur J Immunol** 1995 Sep;25(9):2695-700

Receptor-induced heterologous desensitization of receptor-regulated phospholipase C. Galas MC, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):175-82

Thrombin and melittin activate phospholipase C in human HaCaT keratinocytes. Haase I, et al. **Exp Dermatol** 1996 Apr;5(2):84-8

alphaIIb beta 3-integrin mediated adhesion of human platelets to a fibrinogen matrix triggers phospholipase C activation and phosphatidylinositol 3',4'-biphosphate accumulation. Gironcel D, et al. **FEBS Lett** 1996 Jul 8; 389(3):253-6

Silencing of the epidermal growth factor receptor in the absence of the ligand requires phospholipase C activity. Langgut W, et al. **FEBS Lett** 1995 Sep 25;372(2-3):173-6

Involvement of pertussis toxin-sensitive GTP-binding proteins in sphingosine 1-phosphate-induced activation of phospholipase C-Ca2+ system in HL60 leukemia cells. Okajima F, et al. **FEBS Lett** 1996 Feb 5;379(3):260-4

Squid photoreceptor phospholipase C is stimulated by membrane Gq alpha but not by soluble Gq alpha. Suzuki T, et al. **FEBS Lett** 1995 Dec 27;377(3):333-7

Dopamine D1 receptor regulation of phospholipase C. Jose PA, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S39-42 (45 ref.)

AIDS-associated mycoplasmas possess phospholipases C in the membrane. Shibata K, et al. **Infect Immun** 1995 Oct; 63(10):4174-7

The two distinct phospholipases C of Listeria monocytogenes have overlapping roles in escape from a vacuole and cell-to-cell spread. Smith GA, et al. **Infect Immun** 1995 Nov;63(11):4231-7

Regulation of phospholipase C-beta1 by Gq and m1 muscarinic cholinergic receptor. Steady-state balance of receptor-mediated activation and GTPase-activating protein-promoted deactivation. Biddlecome GH, et al. **J Biol Chem** 1996 Apr 5;271(14):7999-8007

An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. Derman MP, et al. **J Biol Chem** 1996 Feb 23;271(8):4251-5

Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling. Feng JF, et al. **J Biol Chem** 1996 Jul 12;271(28):16451-4

Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. Herrlich A, et al. **J Biol Chem** 1996 Jul 12;271(28):16764-72

Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C. Hwang KC, et al. **J Biol Chem** 1995 Nov 10;270(45):27058-62

Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid. Hwang SC, et al. **J Biol Chem** 1996 Aug 2;271(31):18342-9

Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors. Jiang H, et al. **J Biol Chem** 1996 Jun 7;271(23):13430-4

The role of carboxyl-terminal basic amino acids in Gqalpha-dependent activation, particulate association, and nuclear localization of phospholipase C-beta1. Kim CG, et al. **J Biol Chem** 1996 Aug 30;271(35):21187-92

Pertussis toxin inhibits phospholipase C activation and Ca2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids. Okajima F, et al. **J Biol Chem** 1995 Nov 3;270(44):26332-40

Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. Pantaloni C, et al. **J Biol Chem** 1996 Sep 6;271(36):22146-51

Molecular, biochemical, and electrophysiological characterization of Drosophila norpA mutants. Pearn MT, et al. **J Biol Chem** 1996 Mar 1;271(9):4937-45

Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. Pisegna JR, et al. **J Biol Chem** 1996 Jul 19;271(29):17267-74

Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. Rao GN, et al. **J Biol Chem** 1995 Nov 17; 270(46):27871-5

Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. Richardson RM, et al. **J Biol Chem** 1995 Nov 17;270(46):27829-33

Negative signaling via FcgammaRIIB1 in B cells blocks phospholipase Cgamma2 tyrosine phosphorylation but not Syk or Lyn activation. Sarkar S, et al. **J Biol Chem** 1996 Aug 16;271(33):20182-6

The G protein beta gamma subunit transduces the muscarinic receptor signal for Ca2+ release in Xenopus oocytes. Stehno-Bittel L, et al. **J Biol Chem** 1995 Dec 15; 270(50):30068-74

Identification of a novel receptor kinase that phosphorylates a phospholipase C-linked muscarinic receptor. Tobin AB, et al. **J Biol Chem** 1996 Feb 16;271(7):3907-16

Dopamine D1A receptor regulation of phospholipase C isoform. Yu PY, et al. **J Biol Chem** 1996 Aug 9; 271(32):19503-8

A C-terminal mutant of the G protein beta subunit deficient in the activation of phospholipase C-beta. Zhang S, et al. **J Biol Chem** 1996 Aug 16;271(33):20208-12

ETA receptors mediate activation of phospholipases C and D in rat myometrium. Dokhac L, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S307-9

Secretin potentiates cholecystokinin-stimulated amylase release by AR4-2J cells via a stimulation of phospholipase C. Bold RJ, et al. **J Cell Physiol** 1995 Oct;165(1):172-6

A role for phospholipase C activity but not ryanodine receptors in the initiation and propagation of intercellular calcium waves. Hansen M, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2583-90

Phospholipase C and adenylate cyclase signalling systems in the action of hCG on porcine myometrial smooth muscle cells. Kisielewska J, et al. **J Endocrinol** 1996 Jan; 148(1):175-80

CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. Law CL, et al. **J Exp Med** 1996 Feb 1;183(2):547-60

A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. Takata M, et al. **J Exp Med** 1996 Jul 1;184(1):31-40

Requirement of phospholipase C-gamma 2 activation in surface immunoglobulin M-induced B cell apoptosis [see comments] Takata M, et al. **J Exp Med** 1995 Oct 1; 182(4):907-14. Comment in: J Exp Med 1995 Oct 1;182(4):903-6.

Differential activation of phospholipase C-gamma 1 and mitogen-activated protein kinase in naive and antigen-primed CD4 T cells by the peptide/MHC ligand. Ericsson PO, et al. **J Immunol** 1996 Mar 15;156(6):2045-53

Stimulation of Fc(alpha) receptors induces tyrosine phosphorylation of phospholipase C-gamma(1), phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells. Gómez-Guerrero C, et al. **J Immunol** 1996 Jun 1; 156(11):4369-76

CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase. Silvennoinen O, et al. **J Immunol** 1996 Jan 1;156(1):100-7

Low conductance states of a single ion channel are not 'closed'. Korchev YE, et al. **J Membr Biol** 1995 Oct; 147(3):233-9

Cloning and characterization of two related serotonergic receptors from the brain and the reproductive system of Aplysia that activate phospholipase C. Li XC, et al. **J Neurosci** 1995 Nov;15(11):7585-91

Protein kinase C involvement in homologous desensitization of delta-opioid receptor coupled to Gi1-phospholipase C activation in Xenopus oocytes. Ueda H, et al. **J Neurosci** 1995 Nov;15(11):7485-99

Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism. Khac LD, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):130-6

Altered oxygen tension modulates cytokine-induced signal transduction in polymorphonuclear leukocytes: regulation of the G PLC pathway. Derevianko A, et al. **J Surg Res** 1996 Apr;62(1):32-40

Structural requirements of parathyroid hormone/parathyroid hormone-related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida-Klein A, et al. **Miner Electrolyte Metab** 1995;21(1-3):177-9 (16 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)

ATP-dependent activation of phospholipase C by antigen, NECA, Na3VO4, and GTP-gamma-S in permeabilized RBL cell ghosts: differential augmentation by ATP, phosphoenolpyruvate and phosphocreatine. Dreskin SC. **Mol Cell Biochem** 1995 May 24;146(2):165-70

Characterization of the phosphatidylinositol-specific phospholipase C-released form of rat osseous plate alkaline phosphatase and its possible significance on endochondral ossification. Pizauro JM, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):121-9

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Borrello MG, et al. **Mol Cell Biol** 1996 May;16(5):2151-63

Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Law CL, et al. **Mol Cell Biol** 1996 Apr;16(4):1305-15

Tyrosine phosphorylation of Grb2-associated proteins correlates with phospholipase C gamma 1 activation in T cells. Motto DG, et al. **Mol Cell Biol** 1996 Jun;16(6):2823-9

G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells. Offermanns S, et al. **Mol Endocrinol** 1996 May;10(5):566-74

G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Abbracchio MP, et al. **Mol Pharmacol** 1995 Dec;48(6):1038-45

Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside. Azula FJ, et al. **Mol Pharmacol** 1996 Aug;50(2):367-79

Alpha 2-adrenergic receptors activate phospholipase C in renal epithelial cells. Gesek FA. **Mol Pharmacol** 1996 Aug; 50(2):407-14

Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization. Hermans E, et al. **Mol Pharmacol** 1996 Feb;49(2):365-72

Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Nicholas RA, et al. **Mol Pharmacol** 1996 Aug;50(2):224-9

Inhibition of the phosphorylation of a myristoylated alanine-rich C kinase substrate by methyl methanesulfonate in cultured NIH 3T3 cells. Shin I, et al. **Mutat Res** 1996 Apr 13;351(2):163-71

Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C. Liu M, et al. **Nature** 1996 Jul 4;382(6586):83-7

Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl

cyclase. Burde R, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Jan; 353(2):123–9

Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Matsushima H, et al.
Neurobiol Aging 1995 Nov–Dec;16(6):895–900

Transfected rat mu opioid receptors (rMOR1 and rMOR1B) stimulate phospholipase C and Ca2+ mobilization. Zimprich A, et al. **Neuroreport** 1995 Dec 29;7(1):54–6

Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Greenwood AF, et al. **Neuroscience** 1995 Nov;69(1):125–38

Characterisation of a phospholipase C produced by Pseudomonas fluorescens. Ivanov A, et al.
New Microbiol 1996 Apr;19(2):113–21

The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125FAK and paxillin and cell proliferation. Charlesworth A, et al. **Oncogene** 1996 Mar 21;12(6):1337–45

Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC–gamma 1 but excludes P130CAS. Torres M, et al. **Oncogene** 1996 Jan 4;12(1):77–86

The yeast and mammalian isoforms of phosphatidylinositol transfer protein can all restore phospholipase C–mediated inositol lipid signaling in cytosol–depleted RBL–2H3 and HL–60 cells. Cunningham E, et al.
Proc Natl Acad Sci U S A 1996 Jun 25;93(13):6589–93

A heterotrimeric G protein complex couples the muscarinic m1 receptor to phospholipase C–beta. Dippel E, et al.
Proc Natl Acad Sci U S A 1996 Feb 20;93(4):1391–6

Cloning and characterization of Lnk, a signal transduction protein that links T–cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3–kinase. Huang X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11618–22

Identification of a phospholipase C beta2 region that interacts with Gbeta–gamma. Kuang Y, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2964–8

Specific and high–affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Lemmon MA, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10472–6

Platelet–derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3–kinase. Moriya S, et al.
Proc Natl Acad Sci U S A 1996 Jan 9;93(1):151–5

G protein subunits and the stimulation of phospholipase C by Gs–and Gi–coupled receptors: Lack of receptor selectivity of Galpha(16) and evidence for a synergic interaction between Gbeta gamma and the alpha subunit of a receptor activated G protein. Zhu X, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2827–31

Tyrosine phosphorylation of phospholipase C–gamma 1 by vaccinia virus growth factor. Kim HS, et al. **Virology** 1995 Dec 1;214(1):21–8

PHARMACOLOGY

A recombinant insect–specific alpha–toxin of Buthus occitanus tunetanus scorpion confers protection against homologous mammal toxins. Bouhaouala–Zahar B, et al. **Eur J Biochem** 1996 Jun 15;238(3):653–60

Stimulation of Ca(2+)–activated non–specific cationic channels by phospholipase C–linked glutamate receptors in synaptoneurosomes? Vignes M, et al. **Eur J Neurosci** 1995 Aug 1;7(8):1791–802

Role of phospholipase C and phospholipase A2 in the nitric oxide–independent vasodilator effect of bradykinin in the rat perfused heart. Fulton D, et al.
J Pharmacol Exp Ther 1996 Aug;278(2):518–26

Effect of pH on myofilament Ca(2+)–sensitivity in alpha–toxin permeabilized guinea pig detrusor muscle. Wu C, et al. **J Urol** 1995 Nov;154(5):1921–4

Force–inhibiting effect of okadaic acid on skinned rat uterus permeabilized with alpha–toxin. Watanabe M, et al.
Pflugers Arch 1995 Sep;430(5):754–6

PHYSIOLOGY

PLC gamma 1 Src homology domain induces mitogenesis in quiescent NIH 3T3 fibroblasts. Smith MR, et al.
Biochem Biophys Res Commun 1996 May 6;222(1):186–93

Phosphoinositide–specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99–113 (143 ref.)

Differential regulation of phospholipases C and D by phorbol esters and the physiological activators carbachol and glutamate in astrocytes from chicken embryo cerebrum and cerebellum. Mangoura D, et al.
Brain Res Dev Brain Res 1995 Jun 27;87(1):12–21

Differential involvement of phospholipase C isozymes in Alzheimer's disease. Shimohama S, et al. **Gerontology** 1995; 41 Suppl 1:13–9

The broad–range phospholipase C and a metalloprotease mediate listeriolysin O–independent escape of Listeria monocytogenes from a primary vacuole in human epithelial cells. Marquis H, et al. **Infect Immun** 1995 Nov; 63(11):4531–4

Neuropeptide YY1 receptors–mediated increase in intracellular Ca2+ concentration via phospholipase C–dependent pathway in porcine aortic smooth muscle cells. Shigeri Y, et al. **J Biochem (Tokyo)** 1995 Sep; 118(3):515–20

Morphogen–induced decline in Gialpha2 triggers F9 teratocarcinoma stem cell progression via phospholipase C and mitogen–activated protein kinase. Gao P, et al.
J Biol Chem 1996 Apr 12;271(15):9002–8

Endothelin–1–induced phospholipase C–beta and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. Lamers JM, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 3:S100–3

Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine–specific phospholipase C. Machleidt T, et al. **J Exp Med** 1996 Aug 1;184(2):725–33

Enteric glia exhibit P2U receptors that increase cytosolic calcium by a phospholipase C–dependent mechanism. Kimball BC, et al. **J Neurochem** 1996 Feb;66(2):604–12

Prostaglandin E2 production by endotoxin–stimulated alveolar macrophages is regulated by phospholipase C pathways. Lo CJ, et al. **J Trauma** 1996 Apr;40(4):557–62; discussion 563

[Regulation of phospholipase C–delta 1] Hirata M, et al.
Seikagaku 1995 Sep;67(9):1128–32 (15 ref.) **(Jpn)**

TOXICITY

Effects of Clostridium perfringens recombinant and crude phospholipase C and theta–toxin on rabbit hemodynamic parameters. Asmuth DM, et al. **J Infect Dis** 1995 Nov; 172(5):1317–23

PHOSPHOLIPASE D

[Multiplicity and purification of animal phospholipase D] Okamura S, et al. **Seikagaku** 1995 Nov;67(11):1290–5 (15 ref.) **(Jpn)**

AGONISTS

Evidence for Rho–mediated agonist stimulation of phospholipase D in rat1 fibroblasts. Effects of Clostridium botulinum C3 exoenzyme. Malcolm KC, et al.
J Biol Chem 1996 May 31;271(22):13135–9

Bradykinin stimulates phospholipase D in PC12 cells by a mechanism which is independent of increases in intracellular Ca2+. Horwitz J, et al. **Neurochem Res** 1995 Sep;20(9):1041–8

ANTAGONISTS & INHIBITORS

Acidic phospholipids inhibit the phospholipase D activity of rat brain neuronal nuclei. Kanfer JN, et al.
FEBS Lett 1996 Mar 25;383(1–2):6–8

Multiple forms of phospholipase D inhibitor from rat brain cytosol. Purification and characterization of heat–labile form. Han JS, et al. **J Biol Chem** 1996 May 10; 271(19):11163–9

Ceramide inhibits IgE–mediated activation of phospholipase D, but not of phospholipase C, in rat basophilic leukemia (RBL–2H3) cells. Nakamura Y, et al. **J Immunol** 1996 Jan 1;156(1):256–62

Phospholipase D inhibitors from a Myrsine species. Hegde VR, et al. **J Nat Prod** 1995 Oct;58(10):1492–7

BIOSYNTHESIS

Expressed sequence tags identify human isologs of the ARF–dependent phospholipase D. Ribbes G, et al.
Biochem Biophys Res Commun 1996 Jul 5;224(1):206–11

BLOOD

A chemiluminescence method to analyze phosphatidylcholine–phospholipase activity in plasma membrane preparations and in intact cells. Lucas M, et al. **Anal Biochem** 1995 Nov 1;231(2):277–81

GTPgammaS–stimulated phospholipase D activation in human neutrophils occurs by protein kinase C–dependent and –independent pathways but not tyrosine kinases. Lowe GM, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):484–90

Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):21–6 (18 ref.)

Bradykinin stimulates phosphoinositide turnover and phospholipase C but not phospholipase D and NADPH oxidase in human neutrophils. Catz SD, et al.
J Leukoc Biol 1996 Apr;59(4):591–7

Impaired activation of phospholipase D in polycythaemia vera–implications for the pathogenesis of the disease? Samuelsson J. **Leuk Lymphoma** 1995 Sep;19(1–2):21–6 (60 ref.)

Neutrophil phospholipase D: inhibition by Rho–GDP dissociation inhibitor and stimulation by small GTPase GDP dissociation stimulator. Bowman EP, et al.
Methods Enzymol 1995;256:246–56

CHEMISTRY

Structural heterogeneity of phospholipase D in 10 dicots. Dyer JH, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):31–6

Expressed sequence tags identify human isologs of the ARF–dependent phospholipase D. Ribbes G, et al.
Biochem Biophys Res Commun 1996 Jul 5;224(1):206–11

Evidence for an essential lysyl residue in phospholipase D from Streptomyces sp. by modification with diethyl pyrocarbonate and pyridoxal 5–phosphate. Secundo F, et al. **Biochemistry** 1996 Jul 30;35(30):9631–6

Mammalian phospholipase D: phosphatidylethanolamine as an essential component. Nakamura S, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4300–4

Structure and regulation of phospholipase D. Morris AJ, et al. **Trends Pharmacol Sci** 1996 May;17(5):182–5 (29 ref.)

DRUG EFFECTS

Augmentation by calmodulin of ADP–ribosylation factor–stimulated phospholipase D activity in permeabilized rabbit peritoneal neutrophils. Takahashi K, et al. **J Immunol** 1996 Feb 1;156(3):1229–34

Inhibition of phospholipase D and superoxide generation by glucose in diabetic neutrophils. Ortmeyer J, et al.
Life Sci 1996;59(3):255–62

GENETICS

Differential mRNA expression of phospholipase D (PLD) isozymes during cAMP–induced differentiation in C6 glioma cells. Yoshimura S, et al.
Biochem Biophys Res Commun 1996 Aug 14;225(2):494–9

Characterization of Saccharomyces cerevisiae deficient in expression of phospholipase D. Ella KM, et al.
Biochem J 1996 Feb 15;314 (Pt 1):15–9

Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. Johansen KA, et al. **Infect Immun** 1996 Aug;64(8):3259–66

Human ADP–ribosylation factor–activated phosphatidylcholine–specific phospholipase D defines a new and highly conserved gene family. Hammond SM, et al. **J Biol Chem** 1995 Dec 15;270(50):29640–3

Identification and characterization of a gene encoding phospholipase D activity in yeast. Waksman M, et al.
J Biol Chem 1996 Feb 2;271(5):2361–4

Purification and characterization of phospholipase D (PLD) from rice (Oryza sativa L.) and cloning of cDNA for PLD from rice and maize (Zea mays L.). Ueki J, et al.
Plant Cell Physiol 1995 Jul;36(5):903–14

Caseous lymphadenitis vaccine development: site–specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Tachedjian M, et al. **Vaccine** 1995 Dec;13(18):1785–92

IMMUNOLOGY

Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. Gomez–Cambronero J.
J Interferon Cytokine Res 1995 Oct;15(10):877–85

ISOLATION & PURIFICATION

Characterization and partial purification of phospholipase D from human placenta. Vinggaard AM, et al.
Biochim Biophys Acta 1995 Sep 14;1258(2):169–76

Stimulation of phospholipase D by ADP–ribosylation factor. Brown HA, et al. **Methods Enzymol** 1995;257:313–24

Phospholipase D from soybean (Glycine max L.) suspension–cultured cells: purification, structural and enzymatic properties. Abousalham A, et al.
Plant Cell Physiol 1995 Sep;36(6):989–96

METABOLISM

ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)

Angiotensins differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar–Kyoto rats. Freeman EJ, et al. **Am J Hypertens** 1995 Nov;8(11):1105–11

Thromboxane A2–stimulated phospholipase D in osteoblast–like cells: possible involvement of PKC. Shinoda J, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E524–9

Glycosylphosphatidylinositol–alkaline phosphatase from calf intestine as substrate for glycosylphosphatidylinositol–specific phospholipases—microassay using hydrophobic chromatography in pipet tips. Rhode H, et al.
Anal Biochem 1995 Oct 10;231(1):99–108

Tyrosine kinase is involved in angiotensin II–stimulated phospholipase D activation in aortic smooth muscle cells: function of Ca2+ influx. Suzuki A, et al.
Atherosclerosis 1996 Mar;121(1):119–27

The mechanism of sphingosine enhancement of phorbol ester–mediated phospholipase D activation in lymphocytes. Cao YZ, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):908–15

Effect of insulin on the phospholipase–D activity of untreated and insulin–pretreated (hormonally imprinted) Tetrahymena. Kovács P, et al.
Biochem Biophys Res Commun 1996 May 15;222(2):359–61

Differential phospholipid–labeling suggests two subtypes of phospholipase D in rat Leydig cells. Lauritzen L, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):747–54

Enhanced phospholipase D activity and altered morphology in RhoA–overexpressing RAT1 fibroblasts. Malcolm KC, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):514–9

Activation of phospholipase D in human fibroblasts by

ceramide and sphingosine: evaluation of their modulatory role in bradykinin stimulation of phospholipase D. Meacci E, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):392–9

Effect of Clostridium difficile toxin B on IgE receptor–mediated signal transduction in rat basophilic leukemia cells: inhibition of phospholipase D activation. Ojio K, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):591–6

Involvement of vicinal dithiols in differential regulation of fMLP and phorbol ester–activated phospholipase D in stimulated human neutrophils. Planat V, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):847–53

Vasopressin activates phospholipase D through pertussis toxin–insensitive GTP–binding protein in aortic smooth muscle cells: function of Ca2+/calmodulin. Miwa M, et al. **Biochem Cell Biol** 1995 Mar–Apr;73(3–4):191–9

Erythropoietin stimulates G–protein–coupled phospholipase D in haematopoietic target cells. Clejan S, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):853–60

Phospholipase D activation by P2Z–purinoceptor agonists in human lymphocytes is dependent on bivalent cation influx. Gargett CE, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):529–35

Phosphatidic acid mobilized by phospholipase D is involved in the phorbol 12–myristate 13–acetate–induced G2 delay of A431 cells. Kaszkin M, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):129–38

Potentiated bradykinin–induced increase of 1,2–diacylglycerol generation and phospholipase D activity in human senescent fibroblasts. Meacci E, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):799–803

Early signalling events implicated in leukotriene B4–induced activation of the NADPH oxidase in eosinophils: role of Ca2+, protein kinase C and phospholipases C and D. Perkins RS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):795–806

Tyrosine phosphorylation, MAPK and PLD in AII stimulated mitogenesis. Morton C, et al. **Biochem Soc Trans** 1995 Aug;23(3):426S

Activation of phospholipase D in SH–SY5Y neuroblastoma cells: dependence on Ca2+ and protein kinase C. Purkiss JR. **Biochem Soc Trans** 1995 Aug;23(3):427S

Evidence for an essential lysyl residue in phospholipase D from Streptomyces sp. by modification with diethyl pyrocarbonate and pyridoxal 5–phosphate. Secundo F, et al. **Biochemistry** 1996 Jul 30;35(30):9631–6

Phospholipase D regulation by a physical interaction with the actin–binding protein gelsolin. Steed PM, et al. **Biochemistry** 1996 Apr 23;35(16):5229–37

Compound D609 inhibits phorbol ester–stimulated phospholipase D activity and phospholipase C–mediated phosphatidylethanolamine hydrolysis. Kiss Z, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):105–8

Antigen–mediated phospholipase D activation in rat basophilic leukemia (RBL–2H3) cells: possible involvement of calcium/calmodulin. Kumada T, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):107–14

Mastoparan–induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells. Mizuno K, et al. **Br J Pharmacol** 1995 Oct;116(3):2090–6

The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Wieder T, et al. **Cancer Lett** 1996 Feb 27;100(1–2):71–9

Oestradiol–17 beta modulates PAF–evoked phospholipase D activity but not inositide–lipid hydrolysis in human endometrial cell line, HEC–1B. Ahmed A, et al. **Cell Signal** 1995 May;7(4):403–9

Activation of human endometrial phospholipase D by bradykinin. Ahmed A, et al. **Cell Signal** 1995 Aug; 7(6):599–609

Interferon beta mediated intracellular signalling traffic in human lymphocytes. Cataldi A, et al. **Cell Signal** 1995 Aug; 7(6):627–33

Differential regulation of phospholipase D and phospholipase C by protein kinase C–beta and –delta in liver macrophages. Dieter P, et al. **Cell Signal** 1995 Sep;7(7):687–94

ARF–regulated phospholipase D: a potential role in membrane traffic. Cockcroft S. **Chem Phys Lipids** 1996 May 24;80(1–2):59–80 (165 ref.)

Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):21–6 (18 ref.)

Enzymology of mammalian phospholipases D: in vitro studies. Liscovitch M, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):37–44 (82 ref.)

The N–acylation–phosphodiesterase pathway and cell signalling. Schmid HH, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):133–42 (64 ref.)

Sphingoid bases and phospholipase D activation. Spiegel S, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):27–36 (87 ref.)

Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331–6 (54 ref.)

Insulin stimulates phospholipase D–dependent phosphatidylcholine hydrolysis, Rho translocation, de novo phospholipid synthesis, and diacylglycerol/protein kinase C signaling in L6 myotubes. Standaert ML, et al. **Endocrinology** 1996 Jul;137(7):3014–20

Triggering of a phospholipase D pathway upon mitogenic stimulation of human peripheral blood mononuclear cells enriched with 12(S)–hydroxyicosatetraenoic acid. Meskini N, et al. **Eur J Biochem** 1995 Nov 1;233(3):907–15

Evidence for ADP–ribosylation–factor–mediated activation of phospholipase D by m3 muscarinic acetylcholine receptor. Rümenapp U, et al. **Eur J Biochem** 1995 Nov 15;234(1):240–4

Reconstitution of GTP–gamma–S–dependent phospholipase D activity with ARF, RhoA, and a soluble 36–kDa protein. Shimooku K, et al. **FEBS Lett** 1996 Jun 3;387(2–3):141–4

Localisation of bradykinin–like immunoreactivity and modulation of bradykinin–evoked phospholipase D activity by 17 beta–oestradiol in human endometrium. Li XF, et al. **Growth Factors** 1995;12(3):203–9

Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentration. Yasunari K, et al. **Hypertension** 1996 Aug; 28(2):159–68

Nuclear phospholipase D in Madin–Darby canine kidney cells. Guanosine 5'–O–(thiotriphosphate)–stimulated activation is mediated by RhoA and is downstream of protein kinase C. Balboa MA, et al. **J Biol Chem** 1995 Dec 15;270(50):29843–7

Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. Friedman P, et al. **J Biol Chem** 1996 Jan 12;271(2):953–7

Interaction of ceramides, sphingosine, and sphingosine 1–phosphate in regulating DNA synthesis and phospholipase D activity. Gómez–Muñoz A, et al. **J Biol Chem** 1995 Nov 3;270(44):26318–25

ADP–ribosylation factor translocation correlates with potentiation of GTP gamma S–stimulated phospholipase D activity in membrane fractions of HL–60 cells. Houle MG, et al. **J Biol Chem** 1995 Sep 29;270(39):22795–800

Synergistic activation of rat brain phospholipase D by ADP–ribosylation factor and rhoA p21, and its inhibition by Clostridium botulinum C3 exoenzyme. Kuribara H, et al. **J Biol Chem** 1995 Oct 27;270(43):25667–71

RhoA and a cytosolic 50–kDa factor reconstitute GTP gamma S–dependent phospholipase D activity in human neutrophil subcellular fractions. Kwak JY, et al. **J Biol Chem** 1995 Nov 10;270(45):27093–8

Activation of phospholipase D and phosphatidylinositol 4–phosphate 5–kinase in HL60 membranes is mediated by endogenous Arf but not Rho. Martin A, et al. **J Biol Chem** 1996 Jul 19;271(29):17397–403

Regulation of membrane–bound phospholipase D by protein kinase C in HL60 cells. Synergistic action of small GTP–binding protein RhoA. Ohguchi K, et al. **J Biol Chem** 1996 Feb 23;271(8):4366–72

Inhibition of receptor signaling to phospholipase D by Clostridium difficile toxin B. Role of Rho proteins. Schmidt M, et al. **J Biol Chem** 1996 Feb 2;271(5):2422–6

Phospholipase D–derived products in the regulation of 12–O–tetradecanoylphorbol–13–acetate–stimulated prostaglandin synthesis in madin–darby canine kidney cells. Sciorra VA, et al. **J Biol Chem** 1996 Jun 14; 271(24):14226–32

Regulation of phospholipase D by protein kinase C is synergistic with ADP–ribosylation factor and independent of protein kinase activity. Singer WD, et al. **J Biol Chem** 1996 Feb 23;271(8):4504–10

Effect of prostaglandin E2 on phospholipase D activity in osteoblast–like MC3T3–E1 cells. Oiso Y, et al. **J Bone Miner Res** 1995 Aug;10(8):1185–90

ETA receptors mediate activation of phospholipases C and D in rat myometrium. Dokhac L, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S307–9

Evidence that phospholipase D mediates ADP ribosylation factor–dependent formation of Golgi coated vesicles. Ktistakis NT, et al. **J Cell Biol** 1996 Jul;134(2):295–306

Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. Kusner DJ, et al. **J Exp Med** 1996 Aug 1;184(2):585–95

IL–1 beta primes IL–8–activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. Brandolini L, et al. **J Leukoc Biol** 1996 Mar;59(3):427–34

Oxidized low density lipoprotein–mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. Natarajan V, et al. **J Lipid Res** 1995 Sep;36(9):2005–16

Phospholipase D activity of rat brain neuronal nuclei. Kanfer JN, et al. **J Neurochem** 1996 Aug;67(2):760–6

Role of phospholipase D activation in nervous system physiology and pathophysiology. Klein J, et al. **J Neurochem** 1995 Oct;65(4):1445–55 (83 ref.)

Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen– and Ca(2+)–ionophore–induced secretion in a rat mast cell line. Ali H, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):837–45

Stimulation of phospholipase D by ADP–ribosylation factor. Brown HA, et al. **Methods Enzymol** 1995;257:313–24

Regulation and functional significance of phospholipase D in myocardium. Eskildsen–Helmond YE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):39–48 (72 ref.)

The transphosphatidylation activity of phospholipase D. Yu CH, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):101–5 (40 ref.)

Involvement of Ral GTPase in v–Src–induced phospholipase D activation. Jiang H, et al. **Nature** 1995 Nov 23; 378(6555):409–12

Different functions for the interleukin 8 receptors (IL–8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL–8R1 but not IL–8R2. Jones SA, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6682–6

Mammalian phospholipase D: activation by ammonium sulfate and nucleotides. Nakamura S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12319–22

Mammalian phospholipase D: phosphatidylethanolamine as an essential component. Nakamura S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4300–4

Phospholipase D signaling is essential for meiosis. Rose K, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12151–5

Activation of phospholipase D by prostaglandin F2 alpha in rat luteal cells and effects of inhibitors of arachidonic acid metabolism. Yamamoto H, et al. **Prostaglandins** 1995 Oct;50(4):201–11

Activation of phospholipase D in cultured human amnion cells. Inamori K, et al. **Reprod Fertil Dev** 1995;7(6):1591–4

PHARMACOLOGY

Phospholipase D activity regulates the binding of leukotriene B4 to human polymorphonuclear leukocytes. Kiel D, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):645–53

PHYSIOLOGY

Differential regulation of phospholipases C and D by phorbol esters and the physiological activators carbachol and glutamate in astrocytes from chicken embryo cerebrum and cerebellum. Mangoura D, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):12–21

Regulation of phospholipase D by protein kinase C. Kiss Z. **Chem Phys Lipids** 1996 May 24;80(1–2):81–102 (243 ref.)

Phospholipase D and signal transduction in mammalian cells. Natarajan V. **Chem Phys Lipids** 1996 May 24;80(1–2):1–2

Regulation of phospholipase D by tyrosine kinases. Natarajan V, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):103–16 (156 ref.)

Biochemistry and cell biology of phospholipase D in human neutrophils. Olson SC, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):3–19 (124 ref.)

Endothelin–1–induced phospholipase C–beta and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. Lamers JM, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S100–3

Stimulation of protein and DNA synthesis in mouse C2C12 satellite cells: evidence for phospholipase D–dependent and –independent pathways. Morrison KS, et al. **J Cell Physiol** 1995 Nov;165(2):273–83

Dependence of stimulus–transcription coupling on phospholipase D in agonist–stimulated pituitary cells. Cesnjaj M, et al. **Mol Biol Cell** 1995 Aug;6(8):1037–47

Structure and regulation of phospholipase D. Morris AJ, et al. **Trends Pharmacol Sci** 1996 May;17(5):182–5 (29 ref.)

[Phospholipase D. New pathways of signal transduction] Höer A, et al. **Med Monatsschr Pharm** 1996 May; 19(5):122–31 (81 ref.) **(Ger)**

PHOSPHOLIPASES

ANTAGONISTS & INHIBITORS

Effects of selective phosphodiesterase type IV inhibitor, rolipram, on signal transducing phospholipases in neutrophil: inhibition of phospholipases A2, D but not C. Nakashima S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):137–43

Cerebroprotective action of the phospholipase inhibitor quinacrine in the ischemia/reperfused gerbil hippocampus. Phillis JW. **Life Sci** 1996;58(6):PL97–101

CHEMISTRY

In vitro folding of Escherichia coli outer–membrane phospholipase A. Dekker N, et al. **Eur J Biochem** 1995 Aug 15;232(1):214–9

Phospholipases: structural and functional motifs for working at an interface. Roberts MF. **FASEB J** 1996 Aug; 10(10):1159–72 (41 ref.)

Extending the C2 domain family: C2s in PKCs delta, epsilon, eta, theta, phospholipases, GAPs, and perforin. Ponting CP, et al. **Protein Sci** 1996 Jan;5(1):162–6

GENETICS

Rat GP–3 is a pancreatic lipase with kinetic properties that differ from colipase–dependent pancreatic lipase. Jennens ML, et al. **J Lipid Res** 1995 Nov;36(11):2374–82

METABOLISM

Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Broekemeier KM, et al. **Biochemistry** 1995 Dec 19;34(50):16440–9

Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Birch M, et al. **Infect Immun** 1996 Mar;64(3):751–5

Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase–mediated calpain activation. Arora AS, et al. **J Cell Physiol** 1996 Jun;167(3):434–42

Activation of the phospholipase/cyclooxygenase cascade in

the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

Phospholipases induce melanogenesis in organ-cultured skin. Maeda K, et al. **Photochem Photobiol** 1996 Jul;64(1):220–3

Structure of beta 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. Kwong PD, et al. **Structure** 1995 Oct 15;3(10):1109–19

Ammodytoxin A acceptor in bovine brain synaptic membranes. Križaj I, et al. **Toxicon** 1995 Apr;33(4):437–49

PHYSIOLOGY

Phospholipases: structural and functional motifs for working at an interface. Roberts MF. **FASEB J** 1996 Aug; 10(10):1159–72 (41 ref.)

THERAPEUTIC USE

Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. Applebaum-Bowden D, et al. **J Clin Invest** 1996 Feb 1;97(3):799–805

PHOSPHOLIPASES A

A quick procedure for the isolation of dimeric piratoxins-I and II, two myotoxins from Bothrops pirajai snake venom. N-terminal sequencing. Toyama MH, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1047–55

Mammalian calcium-independent phospholipase A2. Ackermann EJ, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):125–36 (102 ref.)

Mammalian platelet-activating factor acetylhydrolases. Stafforini DM, et al. **Biochim Biophys Acta** 1996 Jun 11; 1301(3):161–73 (138 ref.)

ADMINISTRATION & DOSAGE

Targeting of porcine pancreatic phospholipase A2 to human platelets: introduction of an RGD sequence by genetic engineering. Bekkers AC, et al. **Thromb Haemost** 1995 Oct; 74(4):1138–44

ANALYSIS

Continuous, vesicle-based fluorimetric assays of 14- and 85-kDa phospholipases A2. Bayburt T, et al. **Anal Biochem** 1995 Nov 20;232(1):7–23

Continuous measurement of phospholipase A2 activity using the fluorescent probe ADIFAB. Richieri GV, et al. **Anal Biochem** 1995 Aug 10;229(2):256–63

Secretory group II phospholipase A2 in human atherosclerotic plaques. Menschikowski M, et al. **Atherosclerosis** 1995 Dec;118(2):173–81

Colocalization of cytosolic phospholipase A2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils. Pouliot M, et al. **Eur J Biochem** 1996 May 15;238(1):250–8

A high efficiency method for purification and assay of bee venom phospholipase A2. Ameratunga RV, et al. **Pathology** 1995 Apr;27(2):157–60

Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Clemens JA, et al. **Stroke** 1996 Mar;27(3):527–35

ANTAGONISTS & INHIBITORS

The effects of the phospholipase A2 inhibitor, manoalide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intraarticular injection of human recombinant interleukin-1 alpha in the rabbit. Schrier DJ, et al. **Arthritis Rheum** 1996 Aug;39(8):1292–9

A specific inhibitor of cytosolic phospholipase A2 activity, AACOCF3, inhibits glucose-induced insulin secretion from isolated rat islets. Loweth AC, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):423–7

4-Alkoxybenzamidines as new potent phospholipase A2 inhibitors. Aitdafoun M, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):737–42

Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation. Croxtall JD, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):351–6

Lipidic mimetics as inhibitors of pancreatic phospholipase A2. Nicolaou A, et al. **Biochem Soc Trans** 1995 Nov; 23(4):614S

Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Dentan C, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):353–7

Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2. Emadi S, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):226–32

Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Lio YC, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):55–60

Arbutin inhibits PLA2 in partially hydrated model systems. Oliver AE, et al. **Biochim Biophys Acta** 1996 Jul 12; 1302(1):69–78

Effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) and related benzoquinones on porcine pancreas phospholipase A2 activity. Amano T, et al. **Biol Pharm Bull** 1995 May;18(5):779–81

New phospholipase A2 inhibitor: synthesis and inhibition mechanism of oxazolidinone phospholipid analog. Iwama S, et al. **Bioorg Med Chem** 1995 Oct;3(10):1397–403

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Endoh T, et al. **Carcinogenesis** 1996 Mar; 17(3):467–75

Synthesis and antipancreatitis activities of novel N-(2-sulfonylamino-5-trifluoromethyl-3-pyridyl) carboxamide derivatives as phospholipase A2 inhibitors. Kimura H, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct; 43(10):1696–700

Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A2 activity and some inflammatory responses. Gil B, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):281–8

Effect of thielocin A1 beta on bee venom phospholipase A2-induced edema in mouse paw. Tanaka K, et al. **Eur J Pharmacol** 1995 Jun 12;279(2-3):143–8

Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Jorens PG, et al. **Eur Respir J** 1995 Oct;8(10):1647–53

Protein 1 (Clara cell protein) serum levels in lung cancer patients receiving chemotherapy. Nomori H, et al. **Eur Respir J** 1995 Oct;8(10):1654–7

Effects of chlorpromazine on the enzymatic and toxic properties of the most basic phospholipase A2 from Vipera russelli snake venom. Babu AS, et al. **Inflamm Res** 1995 Aug;44(8):340–4

Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. Cross MJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25352–5

Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. Locati M, et al. **J Biol Chem** 1996 Mar 15;271(11):6010–6

Influence of alkyl chain lengths in dialkylglycerophosphocholines towards phospholipase A2 inhibition in macrophages. Letourneux Y, et al. **J Enzym Inhib** 1995;9(2):135–45

Deconvolution of combinatorial libraries for drug discovery: experimental comparison of pooling strategies. Wilson-Lingardo L, et al. **J Med Chem** 1996 Jul 5; 39(14):2720–6

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. Marshall LA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1254–62

Reducing ischemia-reperfusion injury in rat island groin flaps by dexamethasone and BW755C. Dolan RW, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1322–5

Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2. Breuer R, et al. **Life Sci** 1995;57(16):PL237–40

Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409–14 (45 ref.)

Cellular and topical in vivo inflammatory murine models in the evaluation of inhibitors of phospholipase A2. Glaser KB, et al. **Skin Pharmacol** 1995;8(6):300–8

Bovine serum albumin does not completely block synaptosomal cholinergic activities of presynaptically acting snake venom phospholipase A2 enzymes. Fletcher JE, et al. **Toxicon** 1995 Aug;33(8):1051–60

5-hydroxy-3-vinyl-2(5H)-furanone—a new inhibitor of human synovial phospholipase A2 and platelet aggregation from fermentations of a Calyptella species (basidiomycetes). Lorenzen K, et al. **Z Naturforsch [C]** 1995 May-Jun; 50(5-6):403–9

BIOSYNTHESIS

The concerted regulation of cPLA2, COX2, and lipocortin 1 expression by IL-1beta in A549 cells. Croxtal JD, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):491–5

Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2. Hayakawa M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):681–6

Oxidative stress mediates synthesis of cytosolic phospholipase A2 after UVB injury. Chen X, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):23–33

Identification of calcium-dependent phospholipase A2 isoforms in human and rat pancreatic islets and insulin secreting beta-cell lines. Chen M, et al. **Endocrinology** 1996 Jul;137(7):2901–9

Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands. Aho HJ, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1826–32

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. Vishwanath BS, et al. **J Clin Invest** 1996 Jul 15;98(2):365–71

Stimulation of group II phospholipase A2 mRNA expression and release in an immortalized astrocyte cell line (DITNC) by LPS, TNF alpha, and IL-1 beta. Interactive effects. Tong W, et al. **Mol Chem Neuropathol** 1995 May;25(1):1–17

Discordance between macrophage arachidonate metabolic phenotype and the expression of cytosolic phospholipase A2 and cyclooxygenase. Dolecki GJ, et al. **Prostaglandins** 1995 Jun;49(6):397–414

Induction of both cytosolic phospholipase A2 and prostaglandin H synthase-2 by interleukin-1 beta in WISH cells in inhibited by dexamethasone. Xue S, et al. **Prostaglandins** 1996 Feb;51(2):107–24

BLOOD

Effects of estrogen and progesterone on platelet-activating factor acetylhydrolase activity in ovariectomised rats. Ohshige A, et al. **Artery** 1994;21(4):234–42

Influence of a cigarette smoke extract on the hormonal regulation of platelet-activating factor acetylhydrolase in rats. Yasuda K, et al. **Biol Reprod** 1995 Aug;53(2):244–52

Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Styles LA, et al. **Blood** 1996 Mar 15; 87(6):2573–8

Plasma concentrations of type II phospholipase A2, cytokines and eicosanoids in patients with burns. Nakae H, et al. **Burns** 1995 Sep;21(6):422–6

Phospholipases A2 in the serum of patients after coronary artery bypass surgery. Grönroos JM, et al. **Crit Care Med** 1996 Feb;24(2):259–62

Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease [see comments] Goudevenos J, et al. **Eur Heart J** 1995 Aug; 16(8):1036–43. Comment in: Eur Heart J 1995 Aug;16(8):1017–9.

Serum phospholipases A2 after aortobifemoral reconstruction. Grönroos JM, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):271–4

Differences in phospholipase A2 activity between males and females and Asian Indians and Caucasians. Kuslys T, et al. **Eur J Clin Invest** 1996 Apr;26(4):310–5

Protein kinase C inhibitors enhance G-protein induced phospholipase A2 activation in intact human platelets. Iorio P, et al. **FEBS Lett** 1996 Mar 4;381(3):244–8

Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells. Laine VJ, et al. **Gut** 1996 May;38(5):747–52

Phospholipid degradation in rat calcium ionophore-activated platelets is catalyzed mainly by two discrete secretory phospholipase As. Yokoyama K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1280–7

5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. Wijkander J, et al. **J Biol Chem** 1995 Nov 3;270(44):26543–9

Serum phospholipase A2 in patients with multiple organ failure. Nyman KM, et al. **J Surg Res** 1996 Jan;60(1):7–14

Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver. Nevalainen TJ, et al. **Lab Invest** 1996 Mar;74(3):585–91

Haemodialysis activates phospholipase A2 enzyme. Vishwanath BS, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):109–16

Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Iatrou C, et al. **Nephron** 1996;72(4):611–6

Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis. Endo S, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec;90(3):413–21

Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock. Nakae H, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):131–9

[Phospholipase A2 in schizophrenia] Rípová D, et al. **Ceska Slov Psychiatr** 1995 Nov;91(5):259–64 (Eng. Abstr.) **(Cze)**

[Serum phospholipase A2 activity in patients with aspirin-induced asthma] Toyoshima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):691–4 (Eng. Abstr.) **(Jpn)**

[Pancreatic phospholipase A2] Ogawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:333–7 (5 ref.) **(Jpn)**

[Phospholipase A] Tsujita T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:678–80 (8 ref.) **(Jpn)**

CHEMISTRY

Complete primary structure of the subunits of heterodimeric phospholipase A2 from Vipera a. zinnikeri venom. Komori Y, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):303–7

Molecular cloning and characterization of a neurotoxic phospholipase A2 from the venom of Taiwan habu (Trimeresurus mucrosquamatus). Tsai IH, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):895–900

The structural elements of phospholipase A2 affecting the enhancement of 8-anilinonaphthalene-1-sulfonate fluorescence. Chang LS, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):617–23

Active site of bee venom phospholipase A2: the role of histidine-34, aspartate-64 and tyrosine-87. Annand RR, et al. **Biochemistry** 1996 Apr 9;35(14):4591–601

Escherichia coli outer membrane phospholipase A: role of two serines in enzymatic activity. Brok RG, et al. **Biochemistry** 1996 Jun 18;35(24):7787–93

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2. Huang Z, et al. **Biochemistry** 1996 Mar 26;35(12):3712–21

Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A2. Lee BI, et al. **Biochemistry** 1996 Apr 2;35(13):4231–40

Phospholipase A2 engineering. The roles of disulfide bonds

in structure, conformational stability, and catalytic function. Zhu H, et al. **Biochemistry** 1995 Nov 21; 34(46):15307–14

Solution structure of porcine pancreatic phospholipase A2. van den Berg B, et al. **EMBO J** 1995 Sep 1;14(17):4123–31

Targeting of porcine pancreatic phospholipase A2 to human platelets. Introduction of an RGD sequence and acyl-group by chemical modification. Bekkers AC, et al. **Eur J Biochem** 1996 May 15;238(1):70–6

A conserved histidine residue of Escherichia coli outer-membrane phospholipase A is important for activity. Brok RG, et al. **Eur J Biochem** 1995 Dec 15;234(3):934–8

Characterization of alpha-neurotoxin and phospholipase A2 activities from Micrurus venoms. Determination of the amino acid sequence and receptor-binding ability of the major alpha-neurotoxin from Micrurus nigrocinctus nigrocinctus. Rosso JP, et al. **Eur J Biochem** 1996 May 15;238(1):231–9

Properties of phospholipase A2 activity from bovine retinal rod outer segments. Castagnet PI, et al. **Exp Eye Res** 1993 Jun;56(6):709–19

Crystallization and preliminary X-ray analysis of outer membrane phospholipase A from Escherichia coli. Blaauw M, et al. **FEBS Lett** 1995 Oct 2;373(1):10–2

Crystal structure analysis of phospholipase A2 from trimeresurus flavoviridis (Habu snake) venom at 1.5 A resolution. Suzuki A, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):730–40

1H, 15N and 13C resonance assignments and secondary structure of group II phospholipase A2 from Agkistrodon piscivorus piscivorus: presence of an amino-terminal helix in solution. Jerala R, et al. **J Biomol NMR** 1996 Mar; 7(2):107–20

Cytosolic phospholipase A2. Clark JD, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):83–117 (139 ref.)

Crystal structure of an acidic phospholipase A2 from the venom of Agkistrodon halys pallas at 2.0 A resolution. Wang XQ, et al. **J Mol Biol** 1996 Feb 9;255(5):669–76

The essentiality of His-47 and the N-terminal region for the binding of 8-anilinonaphthalene-1-sulfonate with Taiwan cobra phospholipase A2. Chang LS, et al. **J Protein Chem** 1996 Apr;15(3):255–60

Phospholipase A2-evoked destabilization of planar lipid membranes. O'Regan MH, et al. **Neurosci Lett** 1996 Jan 5;202(3):201–3

DRUG EFFECTS

Phospholipase A2-mediated inflammation induces regression of malignant gliomas. Goddard DH, et al. **Cancer Lett** 1996 Apr 19;102(1–2):1–6

Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)

Effect of hormones and antihormones on phospholipase A2 activity in human endometrial stromal cells. Periwal SB, et al. **Prostaglandins** 1996 Mar;51(3):191–201

GENETICS

cDNA cloning and sequence analysis of a lysine-49 phospholipase A2 myotoxin from Agkistrodon contortrix laticinctus snake venom. Selistre de Araujo HS, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):21–30

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Tew DG, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):591–9

Expression of Taiwan banded krait phospholipase A2 in Escherichia coli, a fully active enzyme generated by hydrolyzing with aminopeptidase. Chang LS, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):990–6

Effects of dexamethasone and transforming growth factor-beta 2 on group II phospholipase A2 mRNA and activity levels in interleukin 1 beta- and forskolin-stimulated mesangial cells. Vervoordeldonk MJ, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):435–41

Site-directed mutagenesis of Cys324 and Cys331 in human cytosolic phospholipase A2: locus of action of thiol modification reagents leading to inactiviation of cPLA2. Li B, et al. **Biochemistry** 1996 Mar 12;35(10):3156–61

Tumor necrosis factor-alpha induces the 85-kDa cytosolic phospholipase A2 gene expression in human bronchial epithelial cells. Wu T, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):175–84

The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. Yoshimi N, et al. **Cancer Lett** 1995 Oct 20;97(1):75–82

Human homologue of a candidate for the Mom1 locus, the secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199. Praml C, et al. **Cancer Res** 1995 Dec 1;55(23):5504–6

Absence of secretory phospholipase A2 gene alterations in human colorectal cancer. Riggins GJ, et al. **Cancer Res** 1995 Nov 15;55(22):5184–6

Three secretory phospholipase A(2) genes that map to human chromosome 1P35–36 are not mutated in individuals with attenuated adenomatous polyposis coli. Spirio LN, et al. **Cancer Res** 1996 Mar 1;56(5):955–8

A phospholipase A2-like pseudogene retaining the highly conserved introns of Mojave toxin and other snake venom group II PLA2s, but having different exons. John TR, et al. **DNA Cell Biol** 1996 Aug;15(8):661–8

Cloning and expression of cystolic phospholipase A2 (cPLA2) and a naturally occurring variant. Phosphorylation of Ser505 of recombinant cPLA2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Gordon RD, et al. **Eur J Biochem** 1996 Jun 15;238(3):690–7

Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells. Vadas P, et al. **Eur J Biochem** 1996 Feb 1; 235(3):557–63

Accelerated evolution of Trimeresurus okinavensis venom gland phospholipase A2 isozyme-encoding genes. Nobuhisa I, et al. **Gene** 1996 Jun 26;172(2):267–72

Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis. Lilja I, et al. **Gut** 1995 Sep;37(3):380–5

Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis. Dobbie Z, et al. **Hum Genet** 1996 Sep; 98(3):386–90

Cloning and expression of a cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase. Hattori M, et al. **J Biol Chem** 1995 Dec 29;270(52):31345–52

Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states [editorial; comment] Nadel JA. **J Clin Invest** 1996 Jun 15; 97(12):2689–90. Comment on: J Clin Invest 1996 Jun 15;97(12):2784–91.

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase [see comments] Stafforini DM, et al. **J Clin Invest** 1996 Jun 15;97(12):2784–91. Comment in: J Clin Invest 1996 Jun 15;97(12):2689–90.

Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes. Tan XD, et al. **J Immunol** 1996 Apr 15;156(8):2985–90

Molecular evolution of group II phospholipases A2. Ogawa T, et al. **J Mol Evol** 1995 Dec;41(6):867–77

Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Dawson E, et al. **Psychiatr Genet** 1995 Winter;5(4):177–80

Targeting of porcine pancreatic phospholipase A2 to human platelets: introduction of an RGD sequence by genetic engineering. Bekkers AC, et al. **Thromb Haemost** 1995 Oct; 74(4):1138–44

IMMUNOLOGY

Immunological responses to phospholipase-A of Salmonella typhi. Punj V, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):237–46

Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. Müller UR, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):395–402

Study of the acrosome reaction and the fertilizing ability of hamster epididymal cauda spermatozoa treated with antibodies against phospholipase A2 and/or lysophosphatidylcholine. Riffo MS, et al. **J Exp Zool** 1996 Aug 15;275(6):459–68

ISOLATION & PURIFICATION

Purification and characterization of Ca(2+)-dependent phospholipases A2 from rat kidney. Aarsman AJ, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):95–103

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Tew DG, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):591–9

Purification and some properties of two phospholipases and a toxin from the venom of desert cobra (Walterinnesia aegyptia). Duhaiman AS, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):1011–20

A quick procedure for the isolation of dimeric piratoxins-I and II, two myotoxins from Bothrops pirajai snake venom. N-terminal sequencing. Toyama MH, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1047–55

Characterization of multiple nicotinic acetylcholine receptor-binding proteins and phospholipases A2 from the venom of the coral snake Micrurus nigrocinctus. Alape-Girón A, et al. **FEBS Lett** 1996 Feb 12; 380(1–2):29–32

Purification of a novel calcium-independent phospholipase A2 from rabbit kidney. Portilla D, et al. **J Biol Chem** 1996 Jun 28;271(26):15451–7

Affinity purification of phospholipase A2 on immobilized artificial membranes containing and lacking the glycerol backbone. Bernal C, et al. **J Chromatogr A** 1996 Apr 19; 731(1–2):139–51

Mobile phase effects on membrane protein elution during immobilized artificial membrane chromatography. Pidgeon C, et al. **J Chromatogr A** 1996 Jan 19;721(2):213–30

Purification and characterization of a novel phospholipase A2 from king cobra (Ophiophagus hannah) venom. Chiou JY, et al. **J Protein Chem** 1995 Aug;14(6):451–6

A high efficiency method for purification and assay of bee venom phospholipase A2. Ameratunga RV, et al. **Pathology** 1995 Apr;27(2):157–60

A cytosolic phospholipase A2 from potato tissues appears to be patatin. Senda K, et al. **Plant Cell Physiol** 1996 Apr; 37(3):347–53

METABOLISM

Hypoxia induces changes in phospholipase A2 in rat proximal tubules: evidence for multiple forms. Choi KH, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F846–53

Complement C5b-9 activates cytosolic phospholipase A2 in glomerular epithelial cells. Cybulsky AV, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F739–49

Phospholipase A2 activity is increased in guinea pig uterine cervix in late pregnancy and at parturition. Rajabi MR, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E940–7

High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion. Tsunoda Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G435–44

Continuous measurement of phospholipase A2 activity using the fluorescent probe ADIFAB. Richieri GV, et al. **Anal Biochem** 1995 Aug 10;229(2):256–63

Phospholipase A2 regulation in neural function and injury. Verity MA. **Ann N Y Acad Sci** 1995 Sep 15;765:341

Alpha-tocopherol and phospholipase A2 in liver and brain of chicks posthatching: the influence of dietary fat and vitamin E. Fuhrmann H, et al. **Ann Nutr Metab** 1995; 39(5):302–9

Interfacial enzymology of glycerolipid hydrolases: lessons from secreted phospholipases A2. Gelb MH, et al. **Annu Rev Biochem** 1995;64:653–88 (208 ref.)

Phospholipases A2 in ras-transfected fibroblasts. Guthridge CJ, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1957–62

Influence of calcium on arachidonic acid mobilization by murine resident peritoneal macrophages. Lloret S, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):251–7

Bee venom phospholipase A2 is recognized by the macrophage mannose receptor. Mukhopadhyay A, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):78–84

Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. Svetlov SI, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):113–22

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Tselepis AD, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1764–73

Effect of chronic ethanol on phospholipase A2- and C-activity in chick embryo brain, heart and liver. Natsuki R. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):348–57

Expression of Taiwan banded krait phospholipase A2 in Escherichia coli, a fully active enzyme generated by hydrolyzing with aminopeptidase. Chang LS, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):990–6

Phospholipase A2 is activated by tumor necrosis factor-alpha in primary hepatocytes stimulated by a deleted form of hepatocyte growth factor. Georgakopoulos E, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1263–70

Ceramide induces structural defects into phosphatidylcholine bilayers and activates phospholipase A2. Huang HW, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):834–8

Activation of phospholipase A2 by the human endothelin receptor in Chinese hamster ovary cells involves Gi protein-mediated calcium influx. Kruger H, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):52–8

Increase of mitochondrial PLA2-released fatty acids is an early event in tumor necrosis factor alpha-treated WEHI-164 cells. Levrat C, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):531–8

Shear stress activates cytosolic phospholipase A2 (cPLA2) and MAP kinase in human endothelial cells. Pearce MJ, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):500–4

Increased activity of porcine pancreatic phospholipase A2 by designed long-range electrostatic stabilisation of the transition state. Sheffield PJ, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):778–84

Phospholipase A2-activating peptide-induced contraction of smooth muscle is mediated by protein kinase C--MAP kinase cascade. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):203–10

Role of cytosolic phospholipase A2 in arachidonic acid release of rat-liver macrophages: regulation by Ca2+ and phosphorylation. Ambs P, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):189–95

Evidence for receptor and G-protein regulation of a phosphatidylethanolamine-hydrolysing phospholipase A1 in guinea-pig heart microsomes: stimulation of phospholipase A1 activity by DL-isoprenaline and guanine nucleotides. Badiani K, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):805–9

A novel phospholipase A2 from human placenta. Buhl WJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):147–53

Characterization of a platelet-activating factor acetylhydrolase secreted by the nematode parasite Nippostrongylus brasiliensis. Grigg ME, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):541–7

Degradation of pyrene-labelled phospholipids by lysosomal

phospholipases in vitro. Dependence of degradation on the length and position of the labelled and unlabelled acyl chains. Lusa S, et al. **Biochem J** 1996 May 1;315 (Pt 3):947–52

Entry of polyunsaturated fatty acids into the brain: evidence that high-density lipoprotein-induced methylation of phosphatidylethanolamine and phospholipase A2 are involved. Magret V, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):805–11

Granulocyte-macrophage colony-stimulating factor (GM-CSF) promotes phosphorylation and an increase in the activity of cytosolic phospholipase A2 in human neutrophils. Nahas N, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):503–8

Binding and internalization of extracellular type-I phospholipase A2 in uterine stromal cells. Rossini GP, et al. **Biochem J** 1996 May 1;315 (Pt 3):1007–14

Maximal epidermal growth-factor-induced cytosolic phospholipase A2 activation in vivo requires phosphorylation followed by an increased intracellular calcium concentration. Schalkwijk CG, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):91–6

Effects of dexamethasone and transforming growth factor-beta 2 on group II phospholipase A2 mRNA and activity levels in interleukin 1 beta- and forskolin-stimulated mesangial cells. Vervoordeldonk MJ, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):435–41

Evidence for the activation of the signal-responsive phospholipase A2 by exogenous hydrogen peroxide. Boyer CS, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):753–61

Characterisation of cytosolic phospholipase A2 as mediator of the enhanced arachidonic acid release from dimethyl sulphoxide differentiated U937 cells. Withnall MT, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1893–902

The effect of dioleoylglycerol on cytosolic phospholipase A2 activity using a continuous fluorescence displacement assay. Creaney A, et al. **Biochem Soc Trans** 1995 Nov; 23(4):569S

The effect of anions on interfacial binding and activation of secretory phospholipase A2. Kinkaid AR, et al. **Biochem Soc Trans** 1995 Nov;23(4):556S

Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. Ancian P, et al. **Biochemistry** 1995 Oct 10;34(40):13146–51

Relationships between bilayer structure and phospholipase A2 activity: interactions among temperature, diacylglycerol, lysolecithin, palmitic acid, and dipalmitoylphosphatidylcholine. Bell JD, et al. **Biochemistry** 1996 Apr 16;35(15):4945–55

Effects of temperature and glycerides on the enhancement of Agkistrodon piscivorus piscivorus phospholipase A2 activity by lysolecithin and palmitic acid. Bell JD, et al. **Biochemistry** 1995 Sep 12;34(36):11551–60

Escherichia coli outer membrane phospholipase A: role of two serines in enzymatic activity. Brok RG, et al. **Biochemistry** 1996 Jun 18;35(24):7787–93

Modulation of phospholipase A2: identification of an inactive membrane-bound state. Burack WR, et al. **Biochemistry** 1995 Nov 14;34(45):14819–28

Cooperativity and binding in the mechanism of cytosolic phospholipase A2. Burke JR, et al. **Biochemistry** 1995 Nov 21;34(46):15165–74

Systematic relationship between phospholipase A2 activity and dynamic lipid bilayer microheterogeneity. Høngер T, et al. **Biochemistry** 1996 Jul 16;35(28):9003–6

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2. Huang Z, et al. **Biochemistry** 1996 Mar 26;35(12):3712–21

Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A2. Lee BI, et al. **Biochemistry** 1996 Apr 2;35(13):4231–40

Activation of phospholipase A2 by amyloid beta-peptides in vitro. Lehtonen JY, et al. **Biochemistry** 1996 Jul 23; 35(29):9407–14

Site-directed mutagenesis of Cys324 and Cys331 in human cytosolic phospholipase A2: locus of action of thiol modification reagents leading to inactiviation of cPLA2. Li B, et al. **Biochemistry** 1996 Mar 12;35(10):3156–61

Evidence for association of an ATP-stimulatable Ca(2+)-independent phospholipase A2 from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein. Ramanadham S, et al. **Biochemistry** 1996 Apr 30;35(17):5464–71

Kinetic basis for the substrate specificity during hydrolysis of phospholipids by secreted phospholipase A2. Rogers J, et al. **Biochemistry** 1996 Jul 23;35(29):9375–84

Phospholipase A2 engineering. The roles of disulfide bonds in structure, conformational stability, and catalytic function. Zhu H, et al. **Biochemistry** 1995 Nov 21; 34(46):15307–14

Activation of cytosolic phospholipase A2 in permeabilized human neutrophils. Bauldry SA, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):223–34

PAF and haematopoiesis. X. Macrophage colony-stimulating factor and granulocyte macrophage colony-stimulating factor enhance platelet-activating factor acetylhydrolase production by human blood-derived macrophages. Dupuis F, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):27–32

Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study. Gorshkova IN, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):103–13

Phospholipase A stimulation in tumor cells by subtoxic concentration of tert-butyl hydroperoxide. Kondakova IV, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):297–302

Human group II phospholipase A2 in normal and diseased intervertebral discs. Miyahara K, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):183–90

Thioesterase and protein deacylase activities of porcine pancreatic phospholipase A2. Nocito M, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):17–22

Subcellular fractions of bovine brain degrade phosphatidylcholine by sequential deacylation of the sn-1 and sn-2 positions. Pete MJ, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):325–32

Phospholipase A(2) activity in non-glycated and glycated low density lipoproteins. Sakurai T, et al. **Biochim Biophys Acta** 1996 May 31;1301(1-2):85–9

Regulation of prostaglandin synthesis in Madin Darby canine kidney cells: role of prostaglandin G/H synthase and secreted phospholipase A2. Schaefers HJ, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):197–202

Phospholipase A2-induced stimulation of A549 lung adenocarcinoma cell line proliferation. Tokumoto H, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):236–42

The regulation of neutrophil phospholipase A2 by granulocyte-macrophage colony-stimulating factor and its role in priming superoxide production. Roberts PJ, et al. **Br J Haematol** 1996 Mar;92(4):804–14

Phospholipase A2-mediated inflammation induces regression of malignant gliomas. Goddard DH, et al. **Cancer Lett** 1996 Apr 19;102(1-2):1–6

Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Rao CV, et al. **Cancer Res** 1996 Feb 1;56(3):532–7

Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit hearts. Vesterqvist O, et al. **Cardiovasc Res** 1996 Jun;31(6):932–40

Phospholipase A2 activity and calpactin I levels in rat lymphokine-activated killer cells: correlation with the cytotoxic activity. Cifone MG, et al. **Cell Immunol** 1996 Jun 15;170(2):274–82

Signal transduction pathways leading to arachidonic acid release from neutrophilic HL-60 cells. The involvement of G protein, protein kinase C and phospholipase A2. Buhl WJ, et al. **Cell Signal** 1995 May;7(4):351–64

Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Byron KL. **Circ Res** 1996 May; 78(5):813–20

Enhanced phospholipase A2 activity in cultured cardiomyocytes from newborn spontaneously hypertensive rat. Millanvoye-Van Brussel E, et al. **Clin Sci (Colch)** 1996 May;90(5):403–7

Immunohistochemical localization of phospholipase A2 in human and bovine male reproductive organs. Rönkkö S. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):503–9

Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Hurst JS, et al. **Curr Eye Res** 1995 Sep;14(9):769–75

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Guimbaud R, et al. **Dig Dis Sci** 1995 Dec;40(12):2635–40

Lysophosphatidylcholine-stimulated protein and glycoprotein production by human gallbladder mucosal cells. Nag MK, et al. **Dig Dis Sci** 1995 Sep;40(9):1990–6

Interferon-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 is required for the formation of interferon-stimulated gene factor three. Flati V, et al. **EMBO J** 1996 Apr 1;15(7):1566–71

ACTH-dependent proteolytic activity of a novel phosphoprotein (p43) intermediary in the activation of phospholipase A2 and steroidogenesis. Cymeryng CB, et al. **Endocr Res** 1995 Feb-May;21(1-2):281–8

Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Gattaz WF, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):129–31

Targeting of porcine pancreatic phospholipase A2 to human platelets. Introduction of an RGD sequence and acyl-group by chemical modification. Bekkers AC, et al. **Eur J Biochem** 1996 May 15;238(1):70–6

Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis. Enari M, et al. **Eur J Biochem** 1996 Mar 1;236(2):533–8

Cloning and expression of cystolic phospholipase A2 (cPLA2) and a naturally occurring variant. Phosphorylation of Ser505 of recombinant cPLA2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Gordon RD, et al. **Eur J Biochem** 1996 Jun 15;238(3):690–7

Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets. Akiba S, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):343–50

Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation. Berenbaum F, et al. **Exp Cell Res** 1996 Feb 1;222(2):379–84

H2O2 renders cells accessible to lysis by exogenous phospholipase A2: a novel mechanism for cell damage in inflammatory processes. Dan P, et al. **FEBS Lett** 1996 Mar 25;383(1-2):75–8

rab 3-peptide stimulates exocytosis of the ram sperm acrosome via interaction with cyclic AMP and phospholipase A2 metabolites. Garde J, et al. **FEBS Lett** 1996 Aug 12;391(3):263–8

Elevated cPLA2 levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis. MacEwan DJ. **FEBS Lett** 1996 Jan 22;379(1):77–81

Activation of bee venom phospholipase A2 through a peptide-enzyme complex. Mingarro I, et al. **FEBS Lett** 1995 Sep 18;372(1):131–4

The level of pancreatic PLA2 receptor is closely associated with the proliferative state of rat uterine stromal cells. Tessier C, et al. **FEBS Lett** 1996 Jul 29;390(3):311–4

Long-term potentiation requires activation of calcium-independent phospholipase A2. Wolf MJ, et al. **FEBS Lett** 1995 Dec 27;377(3):358–62

Platelet-activating factor-acetylhydrolase activity in follicular fluid of patients undergoing in vitro fertilization and embryo transfer. Narahara H, et al. **Fertil Steril** 1995 Dec;64(6):1172–6

PHGPx and phospholipase A2/GPx: comparative importance on the reduction of hydroperoxides in rat liver mitochondria. Antunes F, et al. **Free Radic Biol Med** 1995 Nov;19(5):669–77

Platelet-activating factor acetylhydrolases in Caco-2 cells and epithelium of normal and ulcerative colitis patients. Riehl TE, et al. **Gastroenterology** 1995 Dec;109(6):1826–34

Phospholipase A2 and cobra venom cytotoxin Vc5 interactions and membrane structure. Gasanov SE, et al. **Gen Physiol Biophys** 1995 Apr;14(2):107–23

Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Madsen LM, et al. **Infect Immun** 1996 Jul;64(7):2425–30

Cholera toxin induces synthesis of phospholipase A2-activating protein. Peterson JW, et al. **Infect Immun** 1996 Jun;64(6):2137–43

Differential involvement of protein kinase C in activating cytosolic phospholipase A2 in alveolar macrophages and monocyte differentiated U937 cells. Withnall MT, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S139–40

Mammalian secreted and cytosolic phospholipase A2 show different specificities for phospholipid molecular species. Burdge GC, et al. **Int J Biochem Cell Biol** 1995 Oct; 27(10):1027–32

Glucose-induced phosphorylation and activation of a high molecular weight cytosolic phospholipase A2 in neonatal rat pancreatic islets. Dunlop M, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1191–9

Phospholipid composition, phospholipase A2 and sphingomyelinase activities in rat liver nuclear membrane and matrix. Neitcheva T, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):995–1001

Hyperosmolality stimulates phospholipase A2 activity in rabbit renal medulla and in Madin-Darby canine kidney (MDCK) cells. Zabłocki K. **Int J Biochem Cell Biol** 1995 Oct;27(10):1055–63

Enhanced glomerular phospholipase activity in the obstructed kidney. Fukuzaki A, et al. **Int Urol Nephrol** 1995;27(6):783–90

Modulation by dexamethasone of phospholipase A2 activities in endotoxemic guinea pigs. De Castro CM, et al. **J Appl Physiol** 1995 Oct;79(4):1271–7

Activation of phospholipase A2 and acylation of lysophospholipids: the major regulators for platelet activating factor production in rat neutrophils. Naraba H, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):442–7

Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. Balsinde J, et al. **J Biol Chem** 1996 Mar 22; 271(12):6758–65

Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. Blencowe C, et al. **J Biol Chem** 1995 Dec 29;270(52):31151–7

Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. Börsch-Haubold AG, et al. **J Biol Chem** 1995 Oct 27; 270(43):25885–92

Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A2 but not for cytoskeletal organization. Clark EA, et al. **J Biol Chem** 1996 Jun 21;271(25):14814–8

Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A2 expressed in insect cells and present in human monocytes. de Carvalho MG, et al. **J Biol Chem** 1996 Mar 22;271(12):6987–97

Purification and properties of a phosphatidic acid-preferring phospholipase A1 from bovine testis. Examination of the molecular basis of its activation. Higgs HN, et al. **J Biol Chem** 1996 May 3;271(18):10874–83

Presence of a light-independent phospholipase A2 in bovine retina but not in rod outer segments. Jacob M, et al. **J Biol Chem** 1996 Aug 9;271(32):19209–18

Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2. Kohn EC, et al. **J Biol Chem** 1996 Jul 19;271(29):17476–84

Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor. Nicolas JP, et al. **J Biol Chem** 1995 Dec 1; 270(48):28869-73

Identification of essential residues for the catalytic function of 85-kDa cytosolic phospholipase A2. Probing the role of histidine, aspartic acid, cysteine, and arginine. Pickard RT, et al. **J Biol Chem** 1996 Aug 9;271(32):19225-31

Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. Reddy ST, et al. **J Biol Chem** 1996 Jan 5;271(1):186-91

Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. Sapirstein A, et al. **J Biol Chem** 1996 Aug 30;271(35):21505-13

Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. Schievella AR, et al. **J Biol Chem** 1995 Dec 22; 270(51):30749-54

Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. Tjoelker LW, et al. **J Biol Chem** 1995 Oct 27;270(43):25481-7

The calcium-dependent association and functional coupling of calmodulin with myocardial phospholipase A2. Implications for cardiac cycle-dependent alterations in phospholipolysis. Wolf MJ, et al. **J Biol Chem** 1996 Aug 30;271(35):20989-92

Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2. Zvaritch E, et al. **J Biol Chem** 1996 Jan 5;271(1):250-7

Arachidonic acid release from NIH 3T3 cells by group-I phospholipase A2: involvement of a receptor-mediated mechanism. Xing M, et al. **J Cell Physiol** 1995 Dec; 165(3):566-75

Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by alpha 1-adrenergic receptors in Madin-Darby canine kidney cells. Xing M, et al. **J Clin Invest** 1996 Mar 1; 97(5):1302-10

Antigen receptors on immature, but not mature, B and T cells are coupled to cytosolic phospholipase A2 activation: expression and activation of cytosolic phospholipase A2 correlate with lymphocyte maturation. Gilbert JJ, et al. **J Immunol** 1996 Mar 15;156(6):2054-61

Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. Voelkel-Johnson C, et al. **J Immunol** 1996 Jan 1; 156(1):201-7

Secretory phospholipase A2 activity is required for permeability barrier homeostasis. Mao-Qiang M, et al. **J Invest Dermatol** 1996 Jan;106(1):57-63

Cytosolic phospholipase A2. Clark JD, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):83-117 (139 ref.)

PAF and haematopoiesis: V. Platelet-activating factor and acetylhydrolase in human femoral bone marrow. Denizot Y, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):45-7

Inhibition of platelet type II phospholipase A2 by an acylamino phospholipid does not alter arachidonate liberation. Gaigé B, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):281-93

Myocardial phospholipase A2. Gross RW. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):131-7 (25 ref.)

Phospholipids with a short acyl chain modulate phospholipase and acyltransferase activities. Koumanov KS, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):59-76

Phospholipase A2 activity in vitro cultured cells--influence of ascorbate supplementation. Stoll KE, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):261-6

Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitor. Fleisch JH, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):252-7

Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. Pruzanski W, et al. **J Rheumatol** 1995 Nov;22(11):2114-9

Is phospholipase in vinegared oysters a casual agent for human poisoning? Sajiki J. **J Toxicol Environ Health** 1996 Feb 23;47(3):221-32

Arachidonic acid protects against hypoxic injury in rat proximal tubules. Alkhunaizi AM, et al. **Kidney Int** 1996 Mar;49(3):620-5

Effect of high glucose concentration on phospholipase A2 activity in mesangial cells. Choi K. **Kidney Int Suppl** 1995 Sep;51:S22-7 (48 ref.)

"Cytosolic" phospholipase A2 is in the nucleus of subconfluent endothelial cells but confined to the cytoplasm of confluent endothelial cells and redistributes to the nuclear envelope and cell junctions upon histamine stimulation. Sierra-Honigmann MR, et al. **Lab Invest** 1996 Mar;74(3):684-95

The synovial-like membrane at the bone interface in loose total hip replacements contains high levels of extracellular group II phospholipase A2. Cirino G, et al. **Life Sci** 1996; 59(7):PL81-6

PAF-acetylhydrolase activity and PAF levels in pancreas and plasma of well-fed, diabetic and fasted rat. Trapali M, et al. **Life Sci** 1996;59(10):849-57

Specificity of polyunsaturated fatty acid release from rat brain synaptosomes. Kim HY, et al. **Lipids** 1996 Mar;31 Suppl:S229-33

Critical analysis of phospholipid hydrolyzing activities in ripening tomato fruits. Study by spectrofluorimetry and high-performance liquid chromatography. Rouet-Mayer MA, et al. **Lipids** 1995 Aug;30(8):739-46

Metastatic intraperitoneal spread is initiated by phospholipase A2. Snoj M. **Med Hypotheses** 1995 May;44(5):392-4

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)

Phospholipase A2 expression in human and rodent insulin-secreting cells. Loweth AC, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):177-83

Tumor necrosis factor-alpha and interleukin-1 alpha enhance glucose utilization by astrocytes: involvement of phospholipase A2. Yu N, et al. **Mol Pharmacol** 1995 Sep; 48(3):550-8

Alterations in the activity of phospholipases A2 in postmortem white matter from patients with multiple sclerosis. Huterer SJ, et al. **Neurochem Res** 1995 Nov; 20(11):1335-43

The regulation of phospholipase-A2 (PLA-2) by cytokines expressing hematopoietic growth-stimulating properties. DellaPuca R, et al. **Proc Soc Exp Biol Med** 1996 Jun; 212(2):174-84

Interleukin-1 beta induces the synthesis and activity of cytosolic phospholipase A2 and the release of prostaglandin E2 in human amnion-derived WISH cells. Xue S, et al. **Prostaglandins** 1995 Jun;49(6):351-69

Eicosanoid production and phospholipase A2 activity in uterine tissue from castrated rats with non-insulin dependent diabetes mellitus. Jawerbaum A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):341-5

Incorporation of an unnatural amino acid in the active site of porcine pancreatic phospholipase A2. Substitution of histidine by 1,2,4-triazole-3-alanine yields an enzyme with high activity at acidic pH. Beiboer SH, et al. **Protein Eng** 1996 Apr;9(4):345-52

Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407). Gustafson-Svärd C, et al. **Scand J Gastroenterol** 1995 Oct;30(10):1000-7

Increased platelet phospholipase A2 activity in schizophrenia. Gattaz WF, et al. **Schizophr Res** 1995 Jul;16(1):1-6

Lipopolysaccharide induces time-dependent increases in prostaglandin H synthase-2 and cytosolic phospholipase A2 mRNA in cultured human microvessel-derived endothelial cells. Flynn JT, et al. **Shock** 1995 Dec; 4(6):433-40

Synaptosomal binding of 125I-labelled daboiatoxin, a new PLA2 neurotoxin from the venom of Daboia russelli siamensis. Maung-Maung-Thwin, et al. **Toxicon** 1996 Feb; 34(2):183-99

Binding proteins on synaptic membranes for crotoxin and taipoxin, two phospholipases A2 with neurotoxicity. Tzeng MC, et al. **Toxicon** 1995 Apr;33(4):451-7

Pancreaticobiliary maljunction-associated pancreatitis: an experimental study on the activation of pancreatic phospholipase A2. Nakamura T, et al. **World J Surg** 1996 Jun;20(5):543-50

[Intestinal ischemia and type II phospholipase A2: preliminary report] Koike K, et al. **Nippon Geka Gakkai Zasshi** 1995 Dec;96(12):823 **(Jpn)**

[The phospholipase A2 hydrolysis of irradiated lipid membranes] Kisel' MA, et al. **Radiats Biol Radioecol** 1995 Nov-Dec;35(6):873-9 (Eng. Abstr.) **(Rus)**

[Lipid composition and phospholipase A2 activity in rat placental cell membranes in hypoxic states] Pogorelova TN, et al. **Vopr Med Khim** 1995 Nov-Dec;41(6):30-3 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Phospholipase A2 from Naja naja sputatrix venom is a muscarinic acetylcholine receptor inhibitor. Miyoshi S, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):17-25

Changes in epitope exposition of apolipoprotein A-I on the surface of high density lipoproteins after phospholipase A2 treatment. Menschikowski M, et al. **Atherosclerosis** 1995 Oct;117(2):159-67

Molecular cloning and characterization of a neurotoxic phospholipase A2 from the venom of Taiwan habu (Trimeresurus mucrosquamatus). Tsai IH, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):895-900

Differential effects of glycero- and sphingo-phospholipolysis on human high-density lipoprotein fluidity. Lottin H, et al. **Biochim Biophys Acta** 1996 May 31;1301(1-2):127-32

Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia. Brunner J, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;246(1):13-6

The anticoagulant effect of the human secretory phospholipase A2 on blood plasma and on a cell-free system is due to a phospholipid-independent mechanism of action involving the inhibition of factor Va. Mounier C, et al. **Eur J Biochem** 1996 May 1;237(3):778-85

Human pancreatic phospholipase A2 stimulates the growth of human pancreatic cancer cell line. Hanada K, et al. **FEBS Lett** 1995 Oct 2;373(1):85-7

Effects of type I and type II phospholipase A2 on rat peritoneal mast cells. Roche CM, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S5-6

The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. Weinrauch Y, et al. **J Clin Invest** 1996 Jan 1;97(1):250-7

Phospholipase A2 triggers the first phase of the thermal stress response and exhibits cell-type specificity. Jurivich DA, et al. **J Immunol** 1996 Aug 15;157(4):1669-77

Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis. Karimi K, et al. **J Immunol** 1995 Dec 15;155(12):5786-94

Human type II phospholipase A2-induced Mac-1 expression on human neutrophils. Takasaki J, et al. **J Leukoc Biol** 1996 Aug;60(2):174-80

Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart. Fulton D, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):518-26

Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. Reid MS, et al. **J Pharmacol Exp Ther** 1996 Mar; 276(3):1244-56

Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Brunner J, et al. **Psychiatry Res** 1995 Sep 29;58(2):165-9

Phospholipase A2-induced electrophysiologic and histologic changes in rabbit dorsal lumbar spine tissues. Ozaktay AC, et al. **Spine** 1995 Dec 15;20(24):2659-68

No role for enzymatic activity or dantrolene-sensitive Ca2+ stores in the muscular effects of bothropstoxin, a Lys49 phospholipase A2 myotoxin. Rodrigues-Simioni L, et al. **Toxicon** 1995 Nov;33(11):1479-89

PHYSIOLOGY

Exposure of macrophages to PLA2-modified lipoproteins leads to cellular lipid accumulations. Menschikowski M, et al. **Anal Cell Pathol** 1995 Sep;9(2):113-21

Lysophosphatidylcholine inhibits NMDA-induced currents by a mechanism independent of phospholipase A2-mediated protein kinase C activation in hippocampal glial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):811-6

Phospholipase-A2-dependent signalling in the heart. Van Bilsen M, et al. **Cardiovasc Res** 1995 Oct;30(4):518-29 (125 ref.)

Role of interferon-gamma against invasion by Toxoplasma gondii in a human monocytic cell line (THP1): involvement of the parasite's secretory phospholipase A2. Gómez Marín JE, et al. **Cell Immunol** 1996 May 1;169(2):218-25

Properties of phospholipase A2 activity from bovine retinal rod outer segments. Castagnet PI, et al. **Exp Eye Res** 1993 Jun;56(6):709-19

Would the real role(s) for secretory PLA2s please stand up [editorial; comment] Chilton F. **J Clin Invest** 1996 May 15;97(10):2161-2. Comment on: J Clin Invest 1996 May 15;97(10):2233-41.

Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate [see comments] Grass DS, et al. **J Clin Invest** 1996 May 15;97(10):2233-41. Comment in: J Clin Invest 1996 May 15;97(10):2161-2.

PLA2 promotes fusion between PMN-specific granules and complex liposomes. Blackwood RA, et al. **J Leukoc Biol** 1996 May;59(5):663-70

Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. Adams J, et al. **J Neurochem** 1996 Jan;66(1):6-13

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435-41 (72 ref.)

Phospholipase A2 controls the induction of short-term versus long-term depression in the cerebellar Purkinje neuron in culture. Linden DJ. **Neuron** 1995 Dec;15(6):1393-401

SECRETION

An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Yuan Y, et al. **Blood** 1995 Dec 1;86(11):4166-74

Prostaglandin E2 requirement for transforming growth factor beta 1 inhibition of elicited macrophage 14 kDa phospholipase A2 release. McCord M, et al. **Br J Pharmacol** 1995 Nov;116(6):2575-81

Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Wolbink GJ, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):287-92

The inhibitory effect of 1,25-dihydroxyvitamin D3 on the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. Narahara H, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3121-6

Secretory phospholipases A2. Murakami M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):119-30 (64 ref.)

Secretory type II phospholipase A2 and the generation of intrauterine signals. Rice GE. **Reprod Fertil Dev** 1995; 7(6):1471-9 (99 ref.)

TOXICITY

Phospholipase A2-induced neurotoxicity in vitro and in vivo in rats. Clapp LE, et al. **Brain Res** 1995 Sep 25; 693(1-2):101-11

Inhibition of ACh release at an Aplysia synapse by neurotoxic

phospholipases A2: specific receptors and mechanisms of action. Fossier P, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):29–40

Phospholipase A2 myotoxins from Bothrops snake venoms. Gutiérrez JM, et al. **Toxicon** 1995 Nov;33(11):1405–24 (129 ref.)

Pathological changes induced by an acidic phospholipase A2 from Ophiophagus hannah venom on heart and skeletal muscle of mice after systemic injection. Huang MZ, et al. **Toxicon** 1996 Feb;34(2):201–11

Purification and primary structure of a myotoxic lysine–49 phospholipase A2 with low lipolytic activity from Trimeresurus gramineus venom. Nakai M, et al. **Toxicon** 1995 Nov;33(11):1469–78

PHOSPHOLIPID ETHERS

ADMINISTRATION & DOSAGE

Phase I trial of ilmofosine as a 24 hour infusion weekly. von Mehren M, et al. **Invest New Drugs** 1995;13(3):205–10

CHEMICAL SYNTHESIS

Synthesis and growth inhibitory properties of glycosides of 1–O–hexadecyl–2–O–methyl–sn–glycerol, analogs of the antitumor ether lipid ET–18–OCH3 (edelfosine). Marino–Albernas JR, et al. **J Med Chem** 1996 Aug 16; 39(17):3241–7

Synthesis and biological evaluation of radioiodinated phospholipid ether analogs. Rampy MA, et al. **Nucl Med Biol** 1995 May;22(4):505–12

CHEMISTRY

Molecular interactions of ether–linked phospholipids. Hing FS, et al. **Biochemistry** 1995 Sep 19;34(37):11904–9

Interdigitation of bilayers from ether lipid analogs: (R)–PAF, (R)–Lyso–PAF and the antineoplastic (R)–ET–18–OMe. Xie X, et al. **Biochim Biophys Acta** 1996 Aug 14; 1283(1):111–8

DIAGNOSTIC USE

Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer. Rampy MA, et al. **J Nucl Med** 1996 Sep;37(9):1540–5

METABOLISM

Subcellular fractions of bovine brain degrade phosphatidylcholine by sequential deacylation of the sn–1 and sn–2 positions. Pete MJ, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):325–32

Reconstitution of bacteriorhodopsin and ATP synthase from Micrococcus luteus into liposomes of the purified main tetraether lipid from Thermoplasma acidophilum: proton conductance and light–driven ATP synthesis. Freisleben HJ, et al. **Chem Phys Lipids** 1995 Nov 17;78(2):137–47

1–O–octadecyl–2–O–methyl–glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF–7 cells. Zhou X, et al. **J Clin Invest** 1996 Aug 15;98(4):937–44

PHARMACOLOGY

Inhibition of Na+/H+ exchanger activity by an alkyl–lysophospholipid analogue in a human breast cancer cell line. Besson P, et al. **Biochem Pharmacol** 1996 May 3;51(9):1153–8

Differentiation of HL–60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET–18–OCH3. Civoli F, et al. **Cancer Chemother Pharmacol** 1996;38(3):269–72

ET–18–OCH3 inhibits nuclear factor–kappa B activation by 12–O–tetradecanoylphorbol–13–acetate but not by tumor necrosis factor–alpha or interleukin 1 alpha. Daniel LW, et al. **Cancer Res** 1995 Nov 1;55(21):4844–9

Effect of 1–O–octadecyl–2–O–methyl–glycerophosphocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF–7 and A549 cells and its relationship to inhibition of cell proliferation. Zhou X, et al. **Eur J Biochem** 1995 Sep 15;232(3):881–8

Response of human multiple myeloma–derived cell lines to alkyl–lysophospholipid. Glasser L, et al. **Exp Hematol** 1996 Feb;24(2):253–7

Noncytotoxic alkyl–lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Botzler C, et al. **Int J Cancer** 1996 Mar 1; 65(5):633–8

The association of lipid activators with the amphipathic helical domain of CTP:phosphocholine cytidylyltransferase accelerates catalysis by increasing the affinity of the enzyme for CTP. Yang W, et al. **J Biol Chem** 1995 Oct 13;270(41):23951–7

Antitumor activity of the R– and S–enantiomers of RS–2–[[hydroxy[[2–[(octadecyloxy)methyl]tetrahydrofuran–2–yl]methoxy]–phosphinyl]oxy]–N, N,N,–trimethylethylaminium hydroxide inner salt. Houlihan WJ, et al. **J Med Chem** 1996 Jan 19;39(2):605–8

Effect of platelet activating factor antagonist (TCV–309) on lung injury in dogs with experimentally endotoxin–induced shock. Okano S, et al. **J Vet Med Sci** 1995 Aug;57(4):751–3

Selective inhibition of adhesion molecule expression by edelfosine (ET–18–OCH3) on human umbilical vein or microvascular endothelium. Bosse DC, et al. **Pathobiology** 1995;63(2):109–14

Synthetic peptides derived from the steroid binding domain block modulator and molybdate action toward the rat glucocorticoid receptor. Bodine PV, et al. **Receptor** 1995 Summer;5(2):117–22

TOXICITY

Synthesis and growth inhibitory properties of glycosides of 1–O–hexadecyl–2–O–methyl–sn–glycerol, analogs of the antitumor ether lipid ET–18–OCH3 (edelfosine). Marino–Albernas JR, et al. **J Med Chem** 1996 Aug 16; 39(17):3241–7

PHOSPHOLIPIDS

see related
ANTIBODIES, ANTIPHOSPHOLIPID
ANTIPHOSPHOLIPID SYNDROME

Pro–oxidant effects of cross–linked haemoglobins explored using liposome and cytochrome c oxidase vesicle model membranes. Rogers MS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):827–33

Release of lipid vesicle contents by an antibacterial cecropin A–melittin hybrid peptide. Mancheño JM, et al. **Biochemistry** 1996 Jul 30;35(30):9892–9

Aerobic and anaerobic functioning of superoxide–producing cytochrome b–559 reconstituted with phospholipids. Koshkin V. **Biochim Biophys Acta** 1995 Dec 12; 1232(3):225–9

Phospholipid membrane permeability of peptide nucleic acid [corrected and republished with original paging, article originally printed in FEBS Lett 1995 May 22;365(1):27–9] Wittung P, et al. **FEBS Lett** 1995 Nov 20;375(3):27–9

[Diagnostic value of soybean reagent for determination of activated partial thromboplastin time] Shanskaia AI, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):41–3 **(Rus)**

ANALYSIS

Phospholipid composition and organization in model beta–thalassemic erythrocytes. Kuypers FA, et al. **Am J Hematol** 1996 Jan;51(1):45–54

Sensitive method for the determination of pulmonary surfactant phospholipid/sphingomyelin ratio in human amniotic fluids for the diagnosis of respiratory distress syndrome by thin–layer chromatography–immunostaining. Iwamori M, et al. **Anal Biochem** 1996 Jun 15;238(1):29–33

Structural characterization of phospholipids by matrix–assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry. Marto JA, et al. **Anal Chem** 1995 Nov 1;67(21):3979–84

Combined extraction techniques of tumour cells and lipid/phospholipid assignment by two dimensional NMR spectroscopy. Henke J, et al. **Anticancer Res** 1996 May–Jun; 16(3B):1417–27

Abnormal lipoprotein phospholipid composition in patients with essential hypertension. Bagdade JD, et al. **Atherosclerosis** 1995 Oct;117(2):209–15

The phospholipid composition of enveloped viruses depends on the intracellular membrane through which they bud. van Genderen IL, et al. **Biochem Soc Trans** 1995 Aug; 23(3):523–6

Correlation between level of (n – 3) polyunsaturated fatty acids in brain phospholipids and learning ability in rats. A multiple generation study. Jensen MM, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):203–9

Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Kuypers FA, et al. **Blood** 1996 Feb 1; 87(3):1179–87

Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea–pigs. Vázquez M, et al. **Br J Pharmacol** 1995 Dec;116(8):3337–43

Fourier–transform infrared spectroscopic analysis of rabbit lung surfactant: subfraction–associated phospholipid and protein profiles. Knells G, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):193–201

Sequential microenzymatic assay of cholesterol, triglycerides, and phospholipids in a single aliquot. Nanjee MN, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):915–26

Interspecies comparisons of lens phospholipids. Iwata JL, et al. **Curr Eye Res** 1995 Oct;14(10):937–41

Age–dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328–33 (34 ref.)

Effect of age on the fatty acid composition of phospholipids in human lymphocytes. Ponnappan U, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):125–33

The spatial distribution of phospholipids and glycolipids in the membrane of the bacterium Micrococcus luteus varies during the cell cycle. Welby M, et al. **FEBS Lett** 1996 Apr 15;384(2):107–11

Correlations of Na+–Li+ exchange activity with Na+ and Li+ binding and phospholipid composition in erythrocyte membranes of white hypertensive and normotensive individuals. A nuclear magnetic resonance investigation. Chi Y, et al. **Hypertension** 1996 Mar;27(3 Pt 1):456–64

Fatty acid composition of the major phospholipids of Pneumocystic carinii: comparison with those in the lungs of normal and methylprednisolone–immunosuppressed rats. Guo Z, et al. **Infect Immun** 1996 Apr;64(4):1407–12

Cholesterol, phospholipids and markers of the function of the accessory sex glands in the semen of men with hypercholesterolaemia. Grizard G, et al. **Int J Androl** 1995 Jun;18(3):151–6

A comparison of three tests for determining fetal pulmonary maturity. Rodriguez–Macias KA. **Int J Gynaecol Obstet** 1995 Oct;51(1):39–42

Polar lipids of Staphylococcus strains analysed by fast atom bombardment mass spectrometry. Drucker DB, et al. **J Appl Bacteriol** 1995 Aug;79(2):219–24

Microbial biomass in a shallow, urban aquifer contaminated with aromatic hydrocarbons: analysis by phospholipid fatty acid content and composition. Franzmann PD, et al. **J Appl Bacteriol** 1996 Jun;80(6):617–25

Phospholipids of Lactobacillus spp. Drucker DB, et al. **J Bacteriol** 1995 Nov;177(21):6304–8

Determination of lipid ester ozonides and core aldehydes by high–performance liquid chromatography with on–line mass spectrometry. Ravandi A, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):271–85

Plasma lipopolysaccharide–binding protein is found associated with a particle containing apolipoprotein A–I, phospholipid, and factor H–related proteins. Park CT, et al. **J Biol Chem** 1996 Jul 26;271(30):18054–60

Quantitative analysis of pulmonary surfactant phospholipids by high–performance liquid chromatography and light–scattering detection. Bünger H, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):25–31

Skeletal muscle membrane lipid composition is related to adiposity and insulin action. Pan DA, et al. **J Clin Invest** 1995 Dec;96(6):2802–8

EPR linewidth (T2) method to measure oxygen permeability of phospholipid bilayers and its use to study the effect of low ethanol concentrations. Smirnov AI, et al. **J Magn Reson B** 1996 May;111(2):149–57

Dietary fatty acid profile influences the composition of skeletal muscle phospholipids in rats. Ayre KJ, et al. **J Nutr** 1996 Mar;126(3):653–62

Composition of phospholipids of white muscle of six tuna species. Medina I, et al. **Lipids** 1995 Dec;30(12):1127–35

Simultaneous extraction of cellular lipids and water–soluble metabolites: evaluation by NMR spectroscopy. Tyagi RK, et al. **Magn Reson Med** 1996 Feb;35(2):194–200

Changes in phospholipid composition of blood cell membranes (erythrocyte, platelet, and polymorphonuclear) in different types of diabetes—clinical and biological correlations. Labrouche S et al. **Metabolism** 1996 Jan; 45(1):57–71

Phospholipid degradation is induced by heat in alpha–tocopherol–enriched eggs. Nemecz G, et al. **Poult Sci** 1995 Sep;74(9):1520–6

Distribution of arachidonic, eicosapentaenoic, docosahexaenoic and related fatty acids in ovine endometrial phospholipids in late gestation and labor. Zhang Q, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):201–9

Amniotic fluid phospholipids. New predictive values of L/S and PG/S ratios. Ruiz–Budría J, et al. **Rev Esp Fisiol** 1995 Mar;51(1):17–21

31P nuclear magnetic resonance study of phospholipids in ischemia/reperfusion injury in a rat fatty liver model. Reddy MC, et al. **Transplantation** 1996 Apr 27;61(8):1151–5

[Evaluation of platelet membrane structure in patients with chronic glomerulonephritis (CGN)] Zdrojewski Z, et al. **Przegl Lek** 1996;53(5):431–3 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2–glycoprotein I and anti–beta 2–glycoprotein I. Schousboe I, et al. **Thromb Haemost** 1995 May;73(5):798–804

BIOSYNTHESIS

Eukaryotic phospholipid biosynthesis. Kent C. **Annu Rev Biochem** 1995;64:315–43 (221 ref.)

Effect of haloperidol on phospholipid biosynthesis in rat brain. Singh SP, et al. **Indian J Exp Biol** 1996 Feb; 34(2):111–4

Functional characterization of an inositol–sensitive upstream activation sequence in yeast. A cis–regulatory element responsible for inositol–choline mediated regulation of phospholipid biosynthesis. Bachhawat N, et al. **J Biol Chem** 1995 Oct 20;270(42):25087–95

Regulation of phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Carman GM, et al. **J Biol Chem** 1996 Jun 7;271(23):13293–6 (105 ref.)

Effects of CoA–independent transacylase inhibitors on the production of lipid inflammatory mediators. Winkler JD, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1338–47

Unusual effect of myo–inositol on phospholipid biosynthesis in Cryptococcus neoformans. Vincent VL, et al. **Microbiology** 1995 Aug;141 (Pt 8):1829–37

Role of axons in membrane phospholipid synthesis in rat sympathetic neurons. Vance JE, et al. **Neurobiol Aging** 1995 May–Jun;16(3):493–8; discussion 498–9

The yeast UME6 gene is required for both negative and

positive transcriptional regulation of phospholipid biosynthetic gene expression. Jackson JC, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1322–9

Effect of chlorpromazine on the synthesis of neutral lipids and phospholipids from [3H]glycerol in the primordial human placenta. Heiczman A, et al. **Placenta** 1995 Jun; 16(4):347–58

Regulation of yeast phospholipid biosynthetic gene expression in response to inositol involves two superimposed mechanisms. Ashburner BP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9722–6

[Relationship between the synthesis of a new stress response component and bacterial cell metabolism] Lysak EI, et al. **Mikrobiologiia** 1995 Jul–Aug;64(4):437–41 (Eng. Abstr.) **(Rus)**

BLOOD

Effect of n–3 polyunsaturated fatty acid intake on phospholipid fatty acid composition in plasma and erythrocytes. Prisco D, et al. **Am J Clin Nutr** 1996 Jun; 63(6):925–32

Serum phospholipid fatty acids in severely injured patients on total parenteral nutrition with medium chain/long chain triglyceride emulsions. Adolph M, et al. **Ann Nutr Metab** 1995;39(4):251–60

Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non–haematological cancers. Kuliszkiewicz–Janus M, et al. **Anticancer Res** 1996 May–Jun;16(3B):1587–94

Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low– and high–density lipoprotein to human platelets. Engelmann B, et al. **Biochem J** 1996 May 1;315 (Pt 3):781–9

Alterations in individual molecular species of human platelet phospholipids during thrombin stimulation: electrospray ionization mass spectrometry–facilitated identification of the boundary conditions for the magnitude and selectivity of thrombin–induced platelet phospholipid hydrolysis. Han X, et al. **Biochemistry** 1996 May 7;35(18):5822–32

Phospholipid asymmetry in red blood cells and spectrin–free vesicles during prolonged storage. de Jong K, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):101–10

Changes in arachidonic acid metabolism and the aggregation of polymorphonuclear leukocytes in rats with streptozotocin–induced diabetes. Nakagawa Y, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):145–51

Pathways for flip–flop of mono– and di–anionic phospholipids in the erythrocyte membrane. Serra MV, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):263–73

Effects of silica on serum phospholipid, lipid peroxide and morphological characteristics of rat lung. Guo WX, et al. **Biomed Environ Sci** 1995 Jun;8(2):169–75

Cholesterol–loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl–CoA:1–palmitoyl–sn–glycero–3–phosphocholine acyl transferase. A model of spur cell anemia. Allen DW, et al. **Blood** 1996 Apr 15;87(8):3489–93

Sensitivity of the activated partial thromboplastin time, the dilute Russell's viper venom time, and the kaolin clotting time for the detection of the lupus anticoagulant: a direct comparison using plasma dilutions. Martin BA, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):31–8

Plasma phospholipid fatty acids in X–linked adrenoleukodystrophy. Aveldaño MI, et al. **Clin Chem** 1996 Mar;42(3):454–61

Effects of membrane incorporation of short–chain phospholipids on sodium pump function in human erthrocytes. Dwight JF, et al. **Clin Chim Acta** 1995 Dec 15;243(1):73–85

Phospholipid composition of erythrocyte membranes and plasma of mammalian blood including Australian marsupials; quantitative 31P NMR analysis using detergent. Nouri–Sorkhabi MH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):221–7

Chemotactic 5–oxo–icosatetraenoic acids activate a unique pattern of neutrophil responses. Analysis of phospholipid metabolism, intracellular Ca2+ transients, actin reorganization, superoxide–anion production and receptor up–regulation. Norgauer J, et al. **Eur J Biochem** 1996 Mar 15;236(3):1003–9

Docosahexaenoic and arachidonic acid content of serum and red blood cell membrane phospholipids of preterm infants fed breast milk, standard formula or formula supplemented with n–3 and n–6 long–chain polyunsaturated fatty acids. Boehm G, et al. **Eur J Pediatr** 1996 May;155(5):410–6

Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients. Krawczyk W, et al. **Exp Nephrol** 1995 Jul–Aug; 3(4):265–6

Phospholipid metabolism induced by Clostridium perfringens alpha–toxin elicits a hot–cold type of hemolysis in rabbit erythrocytes. Ochi S, et al. **Infect Immun** 1996 Sep; 64(9):3930–3

Does serum albumin/phospholipid index better reflect overall protein status in man? Ogunkeye OO, et al. **Int J Food Sci Nutr** 1996 May;47(3):209–11

Isolation of an erythrocyte membrane protein that mediates Ca2+–dependent transbilayer movement of phospholipid. Bassé F, et al. **J Biol Chem** 1996 Jul 19;271(29):17205–10

Short–term diabetic ketosis alters n–6 polyunsaturated fatty acid content in plasma phospholipids. Bassi A, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1650–3

Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. Bottger A, et al. **J Clin Invest** 1996 Aug 1;98(3):856–62

Short–term diets rich in arachidonic acid influence plasma phospholipid polyunsaturated fatty acid levels and prostacyclin and thromboxane production in humans. Sinclair AJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1110S–4S

n–3 and n–6 fatty acid intake and serum phospholipid fatty acid composition in middle–aged women living in rural and urban areas in Okayama Prefecture. Okita M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):313–23

Effect of goitre on phospholipid fatty–acid metabolism in children [letter] Tichelaar HY, et al. **Lancet** 1995 Dec 9; 346(8989):1564

Effect of dietary alpha–linolenic acid intake on incorporation of docosahexaenoic and arachidonic acids into plasma phospholipids of term infants. Sauerwald TU, et al. **Lipids** 1996 Mar;31 Suppl:S131–5

Relation between plasma phospholipid saturated fatty acids and hyperinsulinemia. Folsom AR, et al. **Metabolism** 1996 Feb;45(2):223–8

Influence of cholesterol–lowering on plasma membrane lipids and function. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):123–36

Chemotherapy–associated changes in 31P MRS spectra of sera from patients with multiple myeloma. Kuliszkiewicz–Janus M, et al. **NMR Biomed** 1995 May; 8(3):127–32

Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets. Dmoszyńska A, et al. **Thromb Res** 1995 Sep 15; 79(5–6):483–90

[Phospholipid levels in exploration of cerebral atherosclerosis in African Senegalese population] Sall ND, et al. **Dakar Med** 1994;39(1):77–80 (Eng. Abstr.) **(Fre)**

[Experimental study on effects of a high–sugar diet and physical exercise on serum phospholipids in young adults] Imaki M, et al. **Nippon Eiseigaku Zasshi** 1995 Dec; 50(5):947–51 (Eng. Abstr.) **(Jpn)**

[Phospholipids and its fractions] Suzuki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:623–6 (15 ref.) **(Jpn)**

[The effect of human recombinant erythropoietin on levels of plasma phospholipids in patients chronically treated with hemodialysis] Krawczyk W, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):21–5 (Eng. Abstr.) **(Pol)**

[The fatty acid composition of the phospholipids of the erythrocyte membranes, thrombocytes and alpha–lipoproteins in schizophrenia patients] Iusupova IU. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):58–62 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion–resistant properties. Ishihara K, et al. **Biomaterials** 1995 Jul; 16(11):873–9

Nucleoside conjugates. 15. Synthesis and biological activity of anti–HIV nucleoside conjugates of ether and thioether phospholipids. Hong CI, et al. **J Med Chem** 1996 Apr 26; 39(9):1771–7

Studies on the synthesis of dehydroepiandrosterone (DHEA) phosphatide. Williams JR, et al. **Steroids** 1995 Apr; 60(4):333–6

CHEMISTRY

Selective modifications of the phospholipid fatty acid composition in human platelet membranes using nonspecific and specific lipid transfer proteins. Bayon Y, et al. **Anal Biochem** 1995 Sep 1;230(1):75–84

31P nuclear magnetic resonance analysis of phospholipids in a ternary homogeneous system. Branca M, et al. **Anal Biochem** 1995 Nov 20;232(1):1–6

Direct measurement by single photon counting of lipid hydroperoxides in human plasma and lipoproteins. Zamburlini A, et al. **Anal Biochem** 1995 Nov 20; 232(1):107–13

Phospholipid solubilization during detergent extraction of rhodopsin from photoreceptor disk membranes. Aveldaño MI. **Arch Biochem Biophys** 1995 Dec 20;324(2):331–43

Alterations in phospholipid bilayers caused by oxyethylenated nonylphenol surfactants. de la Maza A, et al. **Arch Biochem Biophys** 1996 May 1;329(1):1–8

Fluorescence polarization study on the dynamics and location of peroxidized fluorescent phospholipids in liposomes. Wang JY, et al. **Arch Biochem Biophys** 1996 Jun 15; 330(2):387–94

Liver microsomal phospholipid fatty acids behavior and its relationship to bilirubin UDP–glucuronyltransferase activity in bile duct ligated rats. Ouviña CB, et al. **Arch Physiol Biochem** 1995 Aug;103(4):442–4

Identification of phosphatidate nonlamellar phases on liposomes by flow cytometry. Baeza I, et al. **Biochem Cell Biol** 1995 May–Jun;73(5–6):289–97

A modified spectroscopic method for the determination of the transbilayer distribution of phosphatidylethanolamine in soya–bean asolectin small unilamellar vesicles. Sarti P, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):643–8

Aggregation of phospholipid vesicles induced by the ribosome inactivating protein saporin. Hao Q, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):701–9

Molecular species of phospholipids of interleukin–2–dependent murine cytotoxic T lymphocytes. Nishihira J, et al. **Biochem Mol Biol Int** 1995 Apr; 35(5):1017–27

Interaction of a signal peptide with phospholipid vesicles: the kinetics of binding, insertion and structural changes. Golding C, et al. **Biochem Soc Trans** 1995 Nov;23(4):554S

The interaction of the neurodegenerative fragment of the beta–amyloid peptide with phospholipid membranes. van Veen M, et al. **Biochem Soc Trans** 1995 Nov;23(4):547S

Control of the depth of molecules within membranes by polar groups: determination of the location of anthracene–labeled probes in model membranes by parallax analysis of nitroxide–labeled phospholipid induced fluorescence quenching. Asuncion–Punzalan E, et al. **Biochemistry** 1995 Sep 12;34(36):11460–6

Inhibition of trypsin and thrombin by amino(4–amidinophenyl)methanephosphonate diphenyl ester derivatives: X–ray structures and molecular models. Bertrand JA, et al. **Biochemistry** 1996 Mar 12; 35(10):3147–55

Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts. Cajal Y, et al. **Biochemistry** 1996 May 7;35(18):5684–95

Ripple phase in asymmetric unilamellar bilayers with saturated and unsaturated phospholipids. Czajkowsky DM, et al. **Biochemistry** 1995 Oct 3;34(39):12501–5

Interaction of brain spectrin (fodrin) with phospholipids. Diakowski W, et al. **Biochemistry** 1995 Oct 10; 34(40):13252–8

Quantitation of the phase preferences of the major lipids of the Acholeplasma laidlawii B membrane. Foht PJ, et al. **Biochemistry** 1995 Oct 24;34(42):13811–7

Interaction of fusogenic synthetic peptide with phospholipid bilayers: orientation of the peptide alpha–helix and binding isotherm. Ishiguro R, et al. **Biochemistry** 1996 Apr 16; 35(15):4976–83

Aggregation of acidic lipid vesicles by myelin basic protein: dependence on potassium concentration. Jo E, et al. **Biochemistry** 1995 Oct 17;34(41):13705–16

Effect of liposomal composition on photoactivated liposome fusion. Miller CR, et al. **Biochemistry** 1996 Sep 10; 35(36):11782–90

Stabilization of granulocyte colony–stimulating factor and structurally analogous growth factors by anionic phospholipids. Rourke AM, et al. **Biochemistry** 1996 Sep 10;35(36):11913–7

Temperature dependence of polypeptide partitioning between water and phospholipid bilayers. Russell CJ, et al. **Biochemistry** 1996 Jul 23;35(29):9526–32

Tetrahymena thermophila: analysis of phospholipids and phosphonolipids by high–field 1H–NMR. Adosraku RK, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):167–74

Conformational disorder in unsaturated phospholipids by FTIR spectroscopy. Chia NC, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):141–50

n–6 and n–3 fatty acid accumulation in thp–1 cell phospholipids. Galella G, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):280–90

Thermal unfolding of the cytotoxin alpha–sarcin: phospholipid binding induces destabilization of the protein structure. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):126–34

Vesicles made of glycophospholipids with homogeneous (two fluorocarbon or two hydrocarbon) or heterogeneous (one fluorocarbon and one hydrocarbon) hydrophobic double chains. Guillod F, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):283–92

Critical pressures in multicomponent lipid monolayers. Hagen JP, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):169–72

The water adsorption characteristics of charged phospholipids. Jendrasiak GL, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):63–9

Membrane–damaging action of Clostridium perfringens alpha–toxin on phospholipid liposomes. Nagahama M, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):120–6

Model of a sub–main transition in phospholipid bilayers. Nielsen M, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):170–6 (20 ref.)

Arbutin inhibits PLA2 in partially hydrated model systems. Oliver AE, et al. **Biochim Biophys Acta** 1996 Jul 12; 1302(1):69–78

The interaction of the anti–cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Speelmans G, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):60–6

Phosphatidylethanol as a 13C–NMR probe for reporting packing constraints in phospholipid membranes. Victorov AV, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):151–62

Gamma–irradiation of liposomes composed of saturated phospholipids: effect of bilayer composition, size, concentration and absorbed dose on chemical degradation and physical destabilization of liposomes. Zuidam NJ, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):135–48

5'–linked lipid–oligodeoxyridonucleotide derivatives as inhibitors of human immunodeficiency virus replication.

Kim SG, et al. **Bioorg Med Chem** 1996 Apr;4(4):603–8

Stopped–flow fluorometric study of the interaction of melittin with phospholipid bilayers: importance of the physical state of the bilayer and the acyl chain length. Bradrick TD, et al. **Biophys J** 1995 Nov;69(5):1999–2010

In situ study by polarization modulated Fourier transform infrared spectroscopy of the structure and orientation of lipids and amphipathic peptides at the air–water interface. Cornut I, et al. **Biophys J** 1996 Jan;70(1):305–12

Infrared reflection–absorption of melittin interaction with phospholipid monolayers at the air/water interface. Flach CR, et al. **Biophys J** 1996 Jan;70(1):539–46

Study of phospholipid structure by 1H, 13C, and 31P dipolar couplings from two–dimensional NMR. Hong M, et al. **Biophys J** 1995 Nov;69(5):1939–50

Evidence for the formation of microdomains in liquid crystalline large unilamellar vesicles caused by hydrophobic mismatch of the constituent phospholipids. Lehtonen JY, et al. **Biophys J** 1996 Apr;70(4):1753–60

Lipid vesicle adsorption versus formation of planar bilayers on solid surfaces. Nollert P, et al. **Biophys J** 1995 Oct; 69(4):1447–55

Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness. Paula S, et al. **Biophys J** 1996 Jan; 70(1):339–48

Interaction of a nonspecific wheat lipid transfer protein with phospholipid monolayers imaged by fluorescence microscopy and studied by infrared spectroscopy. Subirade M, et al. **Biophys J** 1995 Sep;69(3):974–88

Planar asymmetric lipid bilayers of glycosphingolipid or lipopolysaccharide on one side and phospholipids on the other: membrane potential, porin function, and complement activation. Wiese A, et al. **Biophys J** 1996 Jan;70(1):321–9

Aggregates of saturated phospholipids at the air–water interface. Evans RW. **Chem Phys Lipids** 1995 Nov 17; 78(2):163–75

Fatty acids in the triglycerides and phospholipids of the common shrew (Sorex araneus) and the water shrew (Neomys fodiens). Käkelä R, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):71–81

Interactions of inorganic mercury with phospholipid micelles and model membranes. A 31P–NMR study. Girault L, et al. **Eur Biophys J** 1996;24(6):413–21

Calcium induced alterations in structural and functional role of phospholipids in Microsporum gypseum. Giri S, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):166–9

Phospholipid composition, phospholipase A2 and sphingomyelinase activities in rat liver nuclear membrane and matrix. Neitcheva T, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):995–1001

Role of the N– and C–terminal domains of bovine beta 2–glycoprotein I in its interaction with cardiolipin. Hagihara Y, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):129–36

Wild–type Escherichia coli cells regulate the membrane lipid composition in a "window" between gel and non–lamellar structures. Morein S, et al. **J Biol Chem** 1996 Mar 22; 271(12):6801–9

Acylation of pulmonary surfactant protein–C is required for its optimal surface active interactions with phospholipids. Wang Z, et al. **J Biol Chem** 1996 Aug 9;271(32):19104–9

Two processes responsible for chemiluminescence development in the course of iron–mediated lipid peroxidation. Sharov VS, et al. **J Biolumin Chemilumin** 1996 Mar–Apr;11(2):91–8

Thin–layer chromatography and high–performance liquid chromatography for the assay of fatty acid compositions of individual phospholipids in platelets from non–insulin–dependent diabetes mellitus patients: effect of eicosapentaenoic acid ethyl ester administration. Miwa H, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3; 677(2):217–23

High–resolution solid–state NMR spectra of integral membrane proteins reconstituted into magnetically oriented phospholipid bilayers. Howard KP, et al. **J Magn Reson B** 1996 Jul;112(1):91–4

Atomic force microscopy observations of acyl chains in phospholipids. Muscatello U, et al. **J Microsc** 1996 Jun;182 (Pt 3):200–7

Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. Gazit E, et al. **J Mol Biol** 1996 May 24;258(5):860–70

Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. Grynberg A, et al. **J Mol Cell Cardiol** 1995 Nov;27(11):2507–20

A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men. Gooderham MH, et al. **J Nutr** 1996 Aug;126(8):2000–6

Chemical hydrolysis of phospholipids. Zuidam NJ, et al. **J Pharm Sci** 1995 Sep;84(9):1113–9

Molecular architecture and biophysical properties of phospholipids during thermal adaptation in fish: an experimental and model study. Fodor E, et al. **Lipids** 1995 Dec;30(12):1119–26

Nuclear magnetic resonance investigation of hydrocarbon chain packing in bilayers of polyunsaturated phospholipids. Holte LL, et al. **Lipids** 1996 Mar;31 Suppl:S199–203

Hydrocarbon chain distribution of ether phospholipids of the ascidian Halocynthia roretzi and the sea urchin Strongylocentrotus intermedius. Jeong BY, et al. **Lipids** 1996 Jan;31(1):9–18

A role for phospholipid polyunsaturation in modulating membrane protein function. Litman BJ, et al. **Lipids** 1996 Mar;31 Suppl:S193–7

Dietary modulation of phospholipid fatty acid composition and lipoxygenase products in mouse lung homogenates. Zhang H, et al. **Lipids** 1996 Jan;31(1):19–25

Ca(2+)–bridging mechanism and phospholipid head group recognition in the membrane–binding protein annexin V. Swairjo MA, et al. **Nat Struct Biol** 1995 Nov;2(11):968–74

Effects of bezafibrate on erythrocyte membrane phospholipids in alcohol–treated rats. Fujioka S, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):67–80

Fatty acid composition of membrane phospholipids of cataractous human lenses. Simonelli F, et al. **Ophthalmic Res** 1996;28 Suppl 1:101–4

Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Li Y, et al. **Pharm Res** 1996 Jan;13(1):76–9

Electrostatic force microscope for probing surface charges in aqueous solutions. Xu S, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10384–8

Phospholipid molecular species with eicosapentaenoic acid (20:5(n–3)) are less stable than species with arachidonic acid (20:4(n–6)) in isolated rat liver cells. Woldseth B, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):513–22

Nanoscale complexity of phospholipid monolayers investigated by near–field scanning optical microscopy. Hwang J, et al. **Science** 1995 Oct 27;270(5236):610–4

Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb–IIIa. Holme PA, et al. **Thromb Haemost** 1995 Dec; 74(6):1533–40

[Dietary plant phospholipids as stabilizers of oil solutions of beta–carotene] Karagodina ZV, et al. **Vopr Pitan** 1995; (4):37–9 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

[Use of fractionated soy phospholipids in a test of activated partial thromboplastin time] Staritsyna NN, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):36–8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Vinik AI, et al. **Diabetes Care** 1995 Sep;18(9):1225–32

Immunogenicity of immunoliposomes: reactivity against species–specific IgG and liposomal phospholipids. Phillips NC, et al. **Immunol Lett** 1995 Mar;45(3):149–52

Phospholipid–dependent anti–beta 2–glycoprotein I (beta 2–GPI) antibodies and antiphospholipid syndrome. Kaburaki J, et al. **Intern Med** 1996 Feb;35(2):105–10

Anesthesia with antiphospholipid antibodies: anesthetic management of a parturient with lupus anticoagulant and anticardiolipin antibody. Fahy BG, et al. **J Clin Anesth** 1996 Feb;8(1):49–53

Role of beta 2–glycoprotein I in the anticardiolipin antibody affinity for phospholipid in autoimmune disease. Dueymes M, et al. **Lupus** 1995 Dec;4(6):477–81

[Clinical subsets and phospholipid–dependent anti–beta 2–glycoprotein I antibodies in antiphospholipid syndrome] Kaburaki J, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1170–4 (Eng. Abstr.) **(Jpn)**

METABOLISM

Acute hypoxia modulates arachidonic acid metabolism in cat carotid bodies. Role of dopamine. Strosznajder RP. **Acta Neurobiol Exp (Warsz)** 1996;56(2):535–43

The effect of Ambroxol on bleomycin–induced changes in phospholipid composition of rat lung surfactant. Stettner S, et al. **Acta Physiol Hung** 1995;83(2):181–7

Betamethasone and adult rat lung surfactant lipids. Stettner S, et al. **Acta Vet Hung** 1995;43(2–3):291–6

Exposure of macrophages to PLA2–modified lipoproteins leads to cellular lipid accumulations. Menschikowski M, et al. **Anal Cell Pathol** 1995 Sep;9(2):113–21

In vitro 31P–magnetic resonance spectroscopy of muscle extracts in malignant hyperthermia–susceptible patients. Payen JF, et al. **Anesthesiology** 1996 May;84(5):1077–82

31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. Franks SE, et al. **Anticancer Res** 1996 May–Jun; 16(3B):1365–74

Phospholipid metabolites in 1H–decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Negendank W, et al. **Anticancer Res** 1996 May–Jun;16(3B):1539–44 (32 ref.)

Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Podo F, et al. **Anticancer Res** 1996 May–Jun;16(3B):1305–15 (57 ref.)

Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Ting YL, et al. **Anticancer Res** 1996 May–Jun;16(3B):1381–8

Effect of linoleic acid hydroperoxide on endothelial cell calcium homeostasis and phospholipid hydrolysis. Sweetman LL, et al. **Arch Biochem Biophys** 1995 Oct 20; 323(1):97–107

Aluminum facilitation of iron–mediated lipid peroxidation is dependent on substrate, pH and aluminum and iron concentrations. Xie CX, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):222–6

HDL3 stimulates multiple signaling pathways in human skin fibroblasts. Walter M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1975–86

Differential labelings suggest two specific phospholipid subclass hydrolysis promoted by PDGF–BB in vascular smooth muscle cells. Comminges C, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1008–13

Differential phospholipid–labeling suggests two subtypes of phospholipase D in rat Leydig cells. Lauritzen L, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):747–54

Molecular species of phospholipids in a murine stem–cell line responsive to erythropoietin. Beckman BS, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):861–7

Degradation of pyrene–labelled phospholipids by lysosomal phospholipases in vitro. Dependence of degradation on the length and position of the labelled and unlabelled acyl chains. Lusa S, et al. **Biochem J** 1996 May 1;315 (Pt 3):947–52

Anionic phospholipids bind to L–selectin (but not E–selectin) at a site distinct from the carbohydrate–binding site. Malhotra R, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):297–303

Active synthesis of C24:5, n–3 fatty acid in retina. Rotstein NP, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):859–64

Effects of chain length and sulphur position of thia fatty acids on their incorporation into phospholipids in 7800 C1 hepatoma cells and isolated rat hepatocytes, and their effects on fatty acid composition of phospholipids. Wu P, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):751–8

Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+–ATPase inhibitors. Dachary–Prigent J, et al. **Biochemistry** 1995 Sep 12;34(36):11625–34

Binding of hisactophilin I and II to lipid membranes is controlled by a pH–dependent myristoyl–histidine switch. Hanakam F, et al. **Biochemistry** 1996 Aug 27; 35(34):11036–44

Role of portal region lysine residues in electrostatic interactions between heart fatty acid binding protein and phospholipid membranes. Herr FM, et al. **Biochemistry** 1996 Jan 30;35(4):1296–303

Phospholipid binding and lecithin–cholesterol acyltransferase activation properties of apolipoprotein A–I mutants. Holvoet P, et al. **Biochemistry** 1995 Oct 17;34(41):13334–42

Fatty acid flip–flop in phospholipid bilayers is extremely fast. Kamp F, et al. **Biochemistry** 1995 Sep 19;34(37):11928–37

Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: implications for protein––membrane contact. Lu Y, et al. **Biochemistry** 1996 Jun 25;35(25):8193–200

An antimicrobial peptide, magainin 2, induced rapid flip–flop of phospholipids coupled with pore formation and peptide translocation. Matsuzaki K, et al. **Biochemistry** 1996 Sep 3;35(35):11361–8

Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Matsuzaki K, et al. **Biochemistry** 1995 Oct 3;34(39):12553–9

Hemoglobin oxidation products extract phospholipids from the membrane of human erythrocytes. Moxness MS, et al. **Biochemistry** 1996 Jun 4;35(22):7181–7

Phospholipid binding, phosphorylation by protein kinase C, and filament assembly of the COOH terminal heavy chain fragments of nonmuscle myosin II isoforms MIIA and MIIB. Murakami N, et al. **Biochemistry** 1995 Dec 12; 34(49):16046–55

Kinetic basis for the substrate specificity during hydrolysis of phospholipids by secreted phospholipase A2. Rogers J, et al. **Biochemistry** 1996 Jul 23;35(29):9375–84

Relationship between arachidonate––phospholipid remodeling and apoptosis. Surette ME, et al. **Biochemistry** 1996 Jul 16;35(28):9187–96

Preparation and characterization of a disulfide–linked bioconjugate of annexin V with the B–chain of urokinase: an improved fibrinolytic agent targeted to phospholipid–containing thrombi. Tanaka K, et al. **Biochemistry** 1996 Jan 23;35(3):922–9

V92A mutation altered the folding propensity of chicken apocytochrome c and its interaction with phospholipids. Tong JC, et al. **Biochemistry** 1996 Jul 23;35(29):9460–8

Investigation of the interaction of m–calpain with phospholipids: calpain–phospholipid interactions. Arthur JS, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):201–6

n–6 and n–3 fatty acid accumulation in thp–1 cell phospholipids. Galella G, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):280–90

Phospholipid vesicles and other cholesterol carriers in bile. Gilat T, et al. **Biochim Biophys Acta** 1996 Jun 10; 1286(2):95–115 (108 ref.)

Interaction of phospholipid liposomes with plasma membrane isolated from alveolar type II cells: effect of pulmonary surfactant protein A. Kuroki Y, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):53–9

The transfer of docosahexaenoic acid from the yolk to the tissues of the chick embryo. Maldjian A, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):81–9

Interactions of annexin V with phospholipid monolayers. Mukhopadhyay S, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):58–62

20S human proteasomes bind with a specific orientation to lipid monolayers in vitro. Newman RH, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):111–6

Mobilization of acyl chains from endogenous cellular phospholipids into cholesteryl esters during foam-cell formation in mouse peritoneal macrophages. Nishikawa K, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):257–63

Acetylated low density lipoprotein inhibits the incorporation of arachidonic acid in phospholipids with a concomitant increase of cholesterol arachidonate in rat peritoneal macrophages. Pollaud C, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):211–9

Kinetics of phospholipid membrane fusion induced by surfactant apoproteins A and B. Poulain FR, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):169–75

H+, K+, and Na+ transport across phospholipid vesicular membrane by the combined action of protein uncoupler 2,4-dinitrophenol and valinomycin. Prabhananda BS, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):193–9

Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cis-parinaric acid. Ritov VB, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):127–40

Effect of 17 beta-estradiol on chondrocyte membrane fluidity and phospholipid metabolism is membrane-specific, sex-specific, and cell maturation-dependent. Schwartz Z, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):1–10

The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Speelmans G, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):60–6

Verapamil competes with doxorubicin for binding to anionic phospholipids resulting in increased internal concentrations and rates of passive transport of doxorubicin. Speelmans G, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):137–46

Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids. Subbaiah PV, et al. **Biochim Biophys Acta** 1996 May 31; 1301(1–2):115–26

Altered regulation of surfactant phospholipid and protein A during acute pulmonary inflammation. Viviano CJ, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):235–44

Osmotic stress sensitizes sterol-free phospholipid bilayers to the action of Amphotericin B. Wolf BD, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):156–62

Antitumorigenic activities of chalcones. I. Inhibitory effects of chalcone derivatives on 32Pi-incorporation into phospholipids of HeLa cells promoted by 12-O-tetradecanoyl-phorbol 13-acetate (TPA). Iwata S, et al. **Biol Pharm Bull** 1995 Dec;18(12):1710–13

Inhibitory effects of steroidal saponins on 12-O-tetradecanoylphorbol-13-acetate (TPA)-enhanced 32P-incorporation into phospholipids of HeLa cells and proliferation of human malignant tumor cells. Mimaki Y, et al. **Biol Pharm Bull** 1995 Mar;18(3):467–9

The effect of ethanol and diazepam on the fatty acid composition of plasma and liver phospholipids in the rat. Ristić V, et al. **Biol Pharm Bull** 1995 Jun;18(6):842–5

Biospecific interactions of Vitamin K-dependent factors with phospholipid-like polystyrene derivatives. Part I: Factor II. Migonney V, et al. **Biomaterials** 1996 Apr;17(8):823–9

Interaction of mastoparan-B from venom of a hornet in Taiwan with phospholipid bilayers and its antimicrobial activity. Park NG, et al. **Biopolymers** 1995 Dec; 36(6):793–801

Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening. Luddington R, et al. **Br J Haematol** 1996 Mar;92(3):744–6

Phospholipid fatty acids of brain and liver are modified by alpha-tocopherol and dietary fat in growing chicks. Fuhrmann H, et al. **Br J Nutr** 1996 Jul;76(1):109–22

Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles. Merchant TE, et al. **Cancer** 1995 Nov 15;76(10):1715–23

Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter-induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190–6

An improved assay for measuring the transverse redistribution of fluorescent phospholipids in plasma membranes. Pomorski T, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):139–46

Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct. Cravedi JP, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):642–8

Metabolism, bioaccumulation, and incorporation of diethanolamine into phospholipids. Mathews JM, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):625–33

Phospholipids and reactive nitrogen intermediates collaborate in expression of the T cell mitogenesis-inhibitory activity of immunosuppressive macrophages induced in mycobacterial infection. Tomioka H, et al. **Clin Exp Immunol** 1996 Feb;103(2):219–25

Phospholipids and glycosphingolipids in cultured skin fibroblasts from patients with progressive systemic sclerosis (scleroderma). Komleva AV, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):581–8

Insulin inhibits changes in the phospholipid profiles in sciatic nerves from streptozocin-induced diabetic rats: a phosphorus-31 magnetic resonance study. Driscoll DM, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):11–6

Inspired oxygen concentration alters the phospholipids and protein content in the bronchoalveolar lavage-accessible space. Godinez MH, et al. **Crit Care Med** 1996 May; 24(5):862–9

Meibomian gland phospholipids. Greiner JV, et al. **Curr Eye Res** 1996 Apr;15(4):371–5

Phospholipid metabolism and membrane dynamics. Alb JG, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):534–41 (46 ref.)

Dietary omega-3 fatty acids and cholesterol modify desaturase activities and fatty acyl constituents of rat intestinal brush border and microsomal membranes of diabetic rats. Keelan M, et al. **Diabetes Res** 1994;26(2):47–66

Insulin stimulates phospholipase D-dependent phosphatidylcholine hydrolysis, Rho translocation, de novo phospholipid synthesis, and diacylglycerol/protein kinase C signaling in L6 myotubes. Standaert ML, et al. **Endocrinology** 1996 Jul;137(7):3014–20

Diradylglycerol formation in cholecystokinin-stimulated rabbit pancreatic acini. Assessment of precursor phospholipids by means of molecular species analysis. Hermans SW, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):73–81

Influence of the signal sequence and chaperone SecB on the interaction between precursor protein prePhoE and phospholipids. Van Raalte AL, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):207–14

Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Berkovic D, et al. **Eur J Cancer** 1995 Nov;31A(12):2080–5

Effects of ageing and adrenergic stimulation on alpha 1- and beta-adrenoceptors and phospholipid fatty acids in rat heart. Benediktsdóttir VE, et al. **Eur J Pharmacol** 1995 May 26;289(3):419–27

Effect of high glucose on fetal lung maturation at different times in gestation. Gewolb IH. **Exp Lung Res** 1996 Mar-Apr;22(2):201–11

In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. McCloud CM, et al. **Exp Mol Pathol** 1995 Feb;62(1):12–21

H2O2 renders cells accessible to lysis by exogenous phospholipase A2: a novel mechanism for cell damage in inflammatory processes. Dan P, et al. **FEBS Lett** 1996 Mar 25;383(1–2):75–8

Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection. Huang RT, et al. **FEBS Lett** 1996 Aug 19;392(1):59–62

Calcium-dependent binding of uteroglobin (PCB-BP/CCSP) to negatively charged phospholipid liposomes. Nord M, et al. **FEBS Lett** 1995 Nov 6;374(3):403–6

Cholesterol protects the phospholipid bilayer from oxidative damage. Parasassi T, et al. **Free Radic Biol Med** 1995 Oct; 19(4):511–6

Molecular association of trinitrobenzenesulfonic acid and surface phospholipids in the development of colitis in rats. Tatsumi Y, et al. **Gastroenterology** 1996 Mar;110(3):780–9

Pulmonary phospholipid changes induced by butylated hydroxy toluene, an antioxidant, in rats. Tamizhselvi R, et al. **Indian J Exp Biol** 1995 Oct;33(10):796–7

Pathogenesis of corneal infection: binding of Pseudomonas aeruginosa to specific phospholipids. Panjwani N, et al. **Infect Immun** 1996 May;64(5):1819–25

Mammalian secreted and cytosolic phospholipase A2 show different specificities for phospholipid molecular species. Burdge GC, et al. **Int J Biochem Cell Biol** 1995 Oct; 27(10):1027–32

The effect of spermine on calcium requirement for protein kinase C association with phospholipid vesicles. Moruzzi MS, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):783–8

Differential effects of interferon-gamma and -beta on fatty acid turnover, lipid bilayer fluidity and TNF-alpha release in murine macrophage J774.2 cells. Darmani H, et al. **Int J Exp Pathol** 1995 Oct;76(5):331–7

Phosphatidylserine-specific transbilayer lipid translocation in synaptosomal plasma membranes from Narke japonica. Anzai K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1232–7

Interaction of calponin with phospholipids. Fujii T, et al. **J Biochem (Tokyo)** 1995 May;117(5):999–1003

Phospholipid degradation in rat calcium ionophore-activated platelets is catalyzed mainly by two discrete secretory phospholipase As. Yokoyama K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1280–7

Myristoylation-facilitated binding of the G protein ARF1GDP to membrane phospholipids is required for its activation by a soluble nucleotide exchange factor. Franco M, et al. **J Biol Chem** 1996 Jan 19;271(3):1573–8

Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. Freedman SJ, et al. **J Biol Chem** 1996 Jul 5; 271(27):16227–36

Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. Hailman E, et al. **J Biol Chem** 1996 May 24;271(21):12172–8

Acylglycerol recycling from triacylglycerol to phospholipid, not lipase activity, is defective in neutral lipid storage disease fibroblasts. Igal RA, et al. **J Biol Chem** 1996 Jul 12;271(28):16644–51

Cell cycle regulation of membrane phospholipid metabolism. Jackowski S. **J Biol Chem** 1996 Aug 23;271(34):20219–22 (69 ref.)

Characterization of carbohydrate-binding protein p33/41: relation with annexin IV, molecular basis of the doublet forms (p33 and p41), and modulation of the carbohydrate binding activity by phospholipids. Kojima K, et al. **J Biol Chem** 1996 Mar 29;271(13):7679–85

Primary alcohols modulate the activation of the G protein-coupled receptor rhodopsin by a lipid-mediated mechanism. Mitchell DC, et al. **J Biol Chem** 1996 Aug 9;271(32):19033–6

Influence of cluster formation of acidic phospholipids on decrease in the affinity for ATP of DnaA protein. Mizushima T, et al. **J Biol Chem** 1996 Feb 16;271(7):3633–8

Identification of diacylglycerol pyrophosphate as a novel metabolic product of phosphatidic acid during G-protein activation in plants. Munnik T, et al. **J Biol Chem** 1996 Jun 28;271(26):15708–15

Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids. Oldenburg KR, et al. **J Biol Chem** 1996 Jul 19;271(29):17582–91

Limited proteolysis of rat phosphatidylinositol transfer protein by trypsin cleaves the C terminus, enhances binding to lipid vesicles, and reduces phospholipid transfer activity. Tremblay JM, et al. **J Biol Chem** 1996 Aug 30; 271(35):21075–80

Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. VanRollins M, et al. **J Biol Chem** 1996 Jun 14;271(24):14001–9

Evidence of oxidative stress in erythrocyte phospholipid composition in the pathogenesis of familial Mediterranean fever (periodical disease). Karaguezyan KG, et al. **J Clin Pathol** 1996 Jun;49(6):453–5

Regulatory effect of 1,25-dihydroxyvitamin D3 on insulin release and calcium handling via the phospholipid pathway in islets from vitamin D-deficient rats. Billaudel BJ, et al. **J Endocrinol Invest** 1995 Oct;18(9):673–82

Topographical distribution of phospholipids in boar sperm plasma and intracellular membranes as revealed by freeze-fracture cytochemistry. Kan FW, et al. **J Histochem Cytochem** 1996 Jul;44(7):687–701

Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis. Ahmed HA, et al. **J Lipid Res** 1995 Dec;36(12):2562–73

Extracellular processing of phospholipids is required for permeability barrier homeostasis. Mao-Qiang M, et al. **J Lipid Res** 1995 Sep;36(9):1925–35

Association of synthetic peptide fragments of human apolipoprotein A-I with phospholipids. Vanloo B, et al. **J Lipid Res** 1995 Aug;36(8):1686–96

Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)

Specific activity of brain palmitoyl-CoA pool provides rates of incorporation of palmitate in brain phospholipids in awake rats. Grange E, et al. **J Neurochem** 1995 Nov; 65(5):2290–8

Modulation of fetal rat brain and liver phospholipid content by intraamniotic ethyl docosahexaenoate administration. Green P, et al. **J Neurochem** 1995 Dec;65(6):2555–60

Docosahexaenoate turnover in brain phospholipids [letter] Rapoport SI. **J Neurochem** 1995 Oct;65(4):1903–5

Brain neutral lipids and phospholipids are modified by long-term feeding of beef tallow vs. corn oil diets. MacDonald RS, et al. **J Nutr** 1996 Jun;126(6):1554–62

The effect of lysine, a water-structure breaker, on the stability of phospholipid-stabilized emulsions. Lutz O, et al. **J Pharm Pharmacol** 1995 Jul;47(7):566–70

Stimulation of arachidonic acid release from thyroid phospholipids. Stelmach H, et al. **J Physiol Pharmacol** 1995 Dec;46(4):439–46

Glutathione and phospholipid depletion of liver tumors after arterial ischemia. Wang LQ, et al. **J Surg Oncol** 1996 Apr; 61(4):284–9

Effects of Ca++ and glycine on lipid breakdown and death of ATP-depleted MDCK cells. Venkatachalam MA, et al. **Kidney Int** 1995 Jul;48(1):118–28

Significantly different fatty acid profiles in various phospholipid head groups of neuroblastoma cell lines. Dasgupta A, et al. **Life Sci** 1996;58(15):1285–90

Phospholipid molecular species composition of developing fetal guinea pig brain. Burdge GC, et al. **Lipids** 1995 Aug; 30(8):719–24

Molecular architecture and biophysical properties of phospholipids during thermal adaptation in fish: an experimental and model study. Fodor E, et al. **Lipids** 1995 Dec;30(12):1119–26

Synergistic induction of phospholipid metabolism by granulocyte-macrophage colony stimulating factor and steel factor in human growth factor-dependent cell line, M07e. Mantel C, et al. **Lipids** 1995 Jul;30(7):641–7

Thyroid hormone is required for dietary fish oil to induce hypersecretion of biliary cholesterol in the rat. Prigge WF, et al. **Lipids** 1995 Sep;30(9):833–8

Effect of tumor necrosis factor-alpha on triglyceride and phospholipid content and fatty acid composition of liver

and carcass in rats. Raina N, et al. **Lipids** 1995 Aug; 30(8):713–8

In vivo labeling of brain phospholipids by long-chain fatty acids: relation to turnover and function. Rapoport SI. **Lipids** 1996 Mar;31 Suppl:S97–101

Critical analysis of phospholipid hydrolyzing activities in ripening tomato fruits. Study by spectrofluorimetry and high-performance liquid chromatography. Rouet-Mayer MA, et al. **Lipids** 1995 Aug;30(8):739–46

Infected erythrocyte choline carrier inhibitors: exploring some potentialities inside Plasmodium phospholipid metabolism for eventual resistance acquisition. Vial HJ, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:91–7

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients. Guerci B, et al. **Metabolism** 1996 Apr;45(4):430–4

Effect of 3-amino-1-propanol, indomethacin and 4-bromophenacyl bromide on the hormone binding of insulin pretreated Tetrahymena: influence of phospholipid metabolism disturbances on hormonal imprinting. Kovács P, et al. **Microbios** 1995;84(341):255–61

Effect of propionyl-L-carnitine treatment on membrane phospholipid fatty acid turnover in diabetic rat erythrocytes. Arduini A, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):31–7

Enhancement of phospholipid hydrolysis in vasopressin-stimulated BHK-21 and H9c2 cells. Tran K, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):69–76

Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun-Aug; 25(2–3):155–73 (94 ref.)

Differential incorporation of fatty acids into and peroxidative loss of fatty acids from phospholipids of human spermatozoa. Alvarez JG, et al. **Mol Reprod Dev** 1995 Nov; 42(3):334–46

Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Pettegrew JW, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):973–5

Effects of exogenous linoleic acid on fatty acid composition, receptor-mediated cAMP formation, and transport functions in rat astrocytes in primary culture. Murphy MG. **Neurochem Res** 1995 Nov;20(11):1365–75

Neural membrane phospholipids in Alzheimer disease. Wells K, et al. **Neurochem Res** 1995 Nov;20(11):1329–33

1H and 31P magnetic resonance spectroscopic imaging of white matter signal hyperintensity areas in elderly subjects. Constans JM, et al. **Neuroradiology** 1995 Nov;37(8):615–23

31P NMR spectroscopy studies of phospholipid metabolism in human melanoma xenograft lines differing in rate of tumour cell proliferation. Lyng H, et al. **NMR Biomed** 1995 Apr;8(2):65–71

Distribution of membrane phospholipids in the rabbit uvea. Greiner JV, et al. **Ophthalmic Res** 1995;27(5):277–85

A novel method for incorporation of ion channels into a planar phospholipid bilayer which allows solution changes on a millisecond timescale. Sitsapesan R, et al. **Pflugers Arch** 1995 Aug;430(4):584–9

Tomato annexins p34 and p35 bind to F-actin and display nucleotide phosphodiesterase activity inhibited by phospholipid binding. Calvert CM, et al. **Plant Cell** 1996 Feb;8(2):333–42

Insertion of pea lectin into a phospholipid monolayer. Booij P, et al. **Plant Mol Biol** 1996 Apr;31(1):169–73

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold-regulated) genes of Arabidopsis thaliana on dehydration-induced phase transitions of phospholipid membranes. Webb MS, et al. **Plant Physiol** 1996 May; 111(1):301–12

Mutant rat phosphatidylinositol/phosphatidylcholine transfer proteins specifically defective in phosphatidylinositol transfer: implications for the regulation of phospholipid transfer activity. Alb JG Jr, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8826–30

An inhalational anesthetic binding domain in the nicotinic acetylcholine receptor. Eckenhoff RG. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2807–10

Role of the C2A domain of synaptotagmin in transmitter release as determined by specific antibody injection into the squid giant synapse preterminal. Mikoshiba K, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10703–7

Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):346–52

A family of phospholipid autacoids: occurrence, metabolism and bioactions. Tokumura A. **Prog Lipid Res** 1995; 34(2):151–84 (240 ref.)

Diets rich in eicosapentaenoic acid and gamma-linolenic acid affect phospholipid fatty acid composition and production of prostaglandins E1, E2 and E3 in turbot (Scophthalmus maximus), a species deficient in delta 5 fatty acid desaturase. Bell JG, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct;53(4):279–86

A subfamily of P-type ATPases with aminophospholipid transporting activity. Tang X, et al. **Science** 1996 Jun 7; 272(5267):1495–7

Age-dependent neurotoxicity in rats chronically exposed to low level lead ingestion: phospholipid metabolism in synaptosomes and microvessels. Singh AK. **Toxicol Ind Health** 1994 Jan-Apr;10(1-2):89–101

Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Reasor MJ, et al. **Toxicology** 1996 Jan 8;106(1-3):139–47

Synthetic peptides reveal a phospholipid binding domain in the glycoprotein of VHSV, a salmonid rhabdovirus. Coll JM. **Vet Res** 1995;26(5-6):399–407

[Sidedness of biomembrane: asymmetrical distribution and flip-flop of phospholipids across lipid bilayer] Anzai K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2418–26 (93 ref.) **(Jpn)**

[Flippases—phospholipid transporting proteins] Pulaski L. **Postepy Biochem** 1995;41(2):131–8 (78 ref.) **(Pol)**

[Disruption of processing of alkaline phosphatase as a result of single amino acid changes affects the composition and metabolism of phospholipids from Escherichia coli, secreting mutant proteins] Kalinin AE, et al. **Biokhimiia** 1996 Jan;61(1):100–9 (Eng. Abstr.) **(Rus)**

[Changes in phospholipid composition in mitochondria of the medulla oblongata and frontal lobe of the cerebrum in hemorrhagic shock in cats] Kryzhanovskiĭ GN, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):387–91 **(Rus)**

[Phospholipid spectrum in target organs in chronic stress] Atadzhanov MA, et al. **Patol Fiziol Eksp Ter** 1995 Jul-Sep; (3):46–8 (Eng. Abstr.) **(Rus)**

[Changes in the lipid composition of salmon liver and eye lens in cataracts] Toĭvonen LV, et al. **Prikl Biokhim Mikrobiol** 1995 Sep-Oct;31(5):571–5 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

[A comparative study of fat emulsions clearance test using long chain triglycerides and medium chain triglycerides in volunteers] He G, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):379–82 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody. Krugner-Higby L, et al. **AIDS Res Hum Retroviruses** 1995 Jun;11(6):705–12

Influence of sonographic contrast media on microcirculation in rats. Jung F, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1138–41

Selective inhibition of phosphatidylinositol 3-kinase by phosphatidic acid and related lipids. Lauener R, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):8–14

Short-chain phospholipids enhance amphipathic peptide-mediated gene transfer. Legendre JY, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):179–85

Acidic phospholipids inhibit the intramolecular association between the N- and C-terminal regions of vinculin, exposing actin-binding and protein kinase C phosphorylation sites. Weekes J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):827–32

Lipid regulation of CTP: phosphocholine cytidylyltransferase: electrostatic, hydrophobic, and synergistic interactions of anionic phospholipids and diacylglycerol. Arnold RS, et al. **Biochemistry** 1996 Jul 30;35(30):9917–24

Fatty acids and anionic phospholipids alter the palmitoyl coenzyme A kinetics of hepatic monoacylglycerol acyltransferase in Triton X-100 mixed micelles. Coleman RA, et al. **Biochemistry** 1996 Jul 23;35(29):9576–83

Soluble phospholipids enhance factor Xa-catalyzed prothrombin activation in solution. Koppaka V, et al. **Biochemistry** 1996 Jun 11;35(23):7482–91

Regulation of phosphatidate phosphatase activity from the yeast Saccharomyces cerevisiae by phospholipids. Wu WI, et al. **Biochemistry** 1996 Mar 26;35(12):3790–6

Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells. DiSanto ME, et al. **Cell Signal** 1995 Nov;7(8):827–35

Acidic phospholipids inhibit the phospholipase D activity of rat brain neuronal nuclei. Kanfer JN, et al. **FEBS Lett** 1996 Mar 25;383(1-2):6–8

Different effects of various phospholipids on Ki-Ras-, Ha-Ras-, and Rap1B-induced B-Raf activation. Kuroda S, et al. **J Biol Chem** 1996 Jun 21;271(25):14680–3

Effect of acidic phospholipids on sphingosine kinase. Olivera A, et al. **J Cell Biochem** 1996 Mar 15;60(4):529–37

Modulation of murine macrophage nitric oxide synthesis by liposomal phospholipids: correlation with liposome immune adjuvant activity. Phillips NC, et al. **J Drug Target** 1995; 3(2):137–47

Inhibition of platelet type II phospholipase A2 by an acylamino phospholipid does not alter arachidonate liberation. Gaigé B, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):281–93

Alkyl and alkoxyethyl antineoplastic phospholipids. Koufaki M, et al. **J Med Chem** 1996 Jun 21;39(13):2609–14

GTPase-activating protein activity of n(alpha 1)-Chimaerin and effect of lipids. Ahmed S, et al. **Methods Enzymol** 1995; 256:114–25

Effect of phospholipids on the reconstitution and thermal stability of delipidated rat ovarian luteinizing hormone/human chorionic gonadotropin receptors in proteoliposomes. Kolena J, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):53–60

Phospholipids inhibit proteolysis of protein kinase C alpha by mM calcium-requiring calpain. Lang D, et al. **Neurochem Res** 1995 Nov;20(11):1361–4

Effect of phospholipids and organic solvents on the formation of 5,16-androstadien-3 beta-ol from pregnenolone in adrenal and testicular microsomes. Meadus WJ, et al. **Steroids** 1995 May;60(5):395–400

Inhibition by phospholipids, lysophospholipids and gangliosides of melittin-induced phosphorylation in bovine mammary gland. Katoh N. **Toxicology** 1995 Dec 15; 104(1-3):73–81

PHYSIOLOGY

The cotranslational integration of membrane proteins into the phospholipid bilayer is a multistep process. Do H, et al. **Cell** 1996 May 3;85(3):369–78

Tyrosine kinase but not phospholipid/Ca2+ signaling pathway is involved in interferon-gamma stimulation of Ia expression in macrophages. Chakrabarti R, et al. **J Cell Biochem** 1996 Feb;60(2):235–45

Regulation of neutral cholesterol esterase activity by phospholipids containing negative charges in substrate liposome. Ishii I, et al. **J Lipid Res** 1995 Nov;36(11):2303–10

Membrane phospholipids and adrenergic receptor function. Williams S, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149-150:217–21 (47 ref.)

Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Xu N, et al. **Thromb Res** 1995 Oct 1; 80(1):35–46

RADIATION EFFECTS

Gamma-irradiation of liposomes composed of saturated phospholipids: effect of bilayer composition, size, concentration and absorbed dose on chemical degradation and physical destabilization of liposomes. Zuidam NJ, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):135–48

SECRETION

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Chianale J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):781–6

THERAPEUTIC USE

Aspirin, salicylate and gastrointestinal injury [letter; comment] Fernández AG, et al. **Nat Med** 1995 Jul; 1(7):602–3. Comment on: Nat Med 1995 Feb;1(2):154–8.

URINE

Increased urinary excretion of lipids by patients with kidney stones. Khan SR, et al. **Br J Urol** 1996 Apr;77(4):506–11

PHOSPHOMANNOSE ISOMERASE see **MANNOSEPHOSPHATE ISOMERASE**

PHOSPHOMONOESTERASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHONIC ACIDS

CHEMICAL SYNTHESIS

Total synthesis of (+/-)-phosphonothrixin, a novel herbicidal antibiotic containing C-P bond. Nakamura K, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1134–7

Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase. Beauchamp LM, et al. **J Med Chem** 1996 Feb 16;39(4):949–56

Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents. Dvořáková H, et al. **J Med Chem** 1996 Aug 16;39(17):3263–8

Synthesis and biological evaluation of1',2'-seconucleo-5'-phosphonates. Racha S, et al. **J Med Chem** 1996 Mar 1; 39(5):1130–5

A plausibly prebiotic synthesis of phosphonic acids. de Graaf RM, et al. **Nature** 1995 Nov 30;378(6556):474–7

CHEMISTRY

Inhibition of herpes simplex virus replication by antisense oligo-2'-O-methylribonucleoside methylphosphonates. Kean JM, et al. **Biochemistry** 1995 Nov 14;34(45):14617–20

The chemical synthesis of Leishmania donovani phosphoglycan via polycondensation of a glycobiosyl hydrogenphosphonate monomer. Nikolaev AV, et al. **Carbohydr Res** 1995 Aug 11;272(2):179–89

Phosphonothrixin, a novel herbicidal antibiotic produced by Saccharothrix sp. ST-888. II. Structure determination. Kimura T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1130–3

Palladium(II) complexes of dialkyl alpha-Anilinobenzylphosphonates. Synthesis, characterization, and cytostatic activity. Curić M, et al. **J Inorg Biochem** 1996 Aug 1;63(2):125–42

Steroidal alkenylphosphonates via palladium-catalyzed coupling reactions. Skoda-Földes R, et al. **Steroids** 1995 Dec;60(12):791–5

IMMUNOLOGY

Reactive immunization [comment] Wirsching P, et al.

Science 1995 Dec 15;270(5243):1775–82. Comment on: Science 1995 Dec 15;270(5243):1797–800.

ISOLATION & PURIFICATION

Phosphonothrixin, a novel herbicidal antibiotic produced by Saccharothrix sp. ST–888. I. Taxonomy, fermentation, isolation and biological properties. Takahashi E, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1124–9

Capillary electrophoresis analysis of chemical warfare agent breakdown products. I. Counterelectroosmotic separation of alkylphosphonic acids and their monoester derivatives. Mercier JP, et al. **J Chromatogr A** 1996 Aug 16; 741(2):279–85

METABOLISM

Three–dimensional structure of the zinc–containing phosphotriesterase with the bound substrate analog diethyl 4–methylbenzylphosphonate. Vanhooke JL, et al. **Biochemistry** 1996 May 14;35(19):6020–5

PHARMACOLOGY

Phosphonate inhibitors of protein–tyrosine and serine/threonine phosphatases. Kole HK, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1025–31

Phosphonate analogues of triacylglycerols are potent inhibitors of lipase. Mannesse ML, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):56–64

In vitro inhibition of membrane–mediated calcification by novel phosphonates. Skrtic D, et al. **Calcif Tissue Int** 1996 May;58(5):347–54

Succinyl phosphonate inhibits alpha–ketoglutarate oxidative decarboxylation, catalyzed by alpha–ketoglutarate dehydrogenase complexes from E. coli and pigeon breast muscle. Biryukov AI, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):167–70

S 17162 is a novel selective inhibitor of big ET–1 responses in the rat. Descombes JJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S61–4

Inhibition of big ET–1–induced pressor response by an orally active dual inhibitor of endothelin–converting enzyme and neutral endopeptidase 24.11. Trapani AJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S69–71

Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin. Deadman J, et al. **J Enzym Inhib** 1995;9(1):29–41

alpha–Hydroxy phosphinyl–based inhibitors of human renin. Patel DV, et al. **J Med Chem** 1995 Oct 27;38(22):4557–69

Concurrent blockade of hippocampal metabotropic glutamate and N–methyl–D–aspartate receptors disrupts working memory in the rat. Ohno M, et al. **Neuroscience** 1996 Jan; 70(2):303–11

[Features of inhibiting butyrylcholinesterase and carboxylesterase hydrolysis with fluoranhydride esters of beta,beta–diphenylethylphosphonic acid] Brestkin AP, et al. **Biokhimiia** 1996 Mar;61(3):472–9 (Eng. Abstr.) **(Rus)**

[Phosphorus–containing inhibitors of penicillin acylase. 4. Irreversible inhibition of penicillin acylase from Escherichia coli by monoaryl esters of benzylphosphonic acid] Solodenko VA, et al. **Ukr Biokhim Zh** 1995 Sep–Oct; 67(5):32–42 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Radiation doses of yttrium–90 citrate and yttrium–90 EDTMP as determined via analogous yttrium–86 complexes and positron emission tomography. Rösch F, et al. **Eur J Nucl Med** 1996 Aug;23(8):958–66

TOXICITY

Ancillary approaches to toxicokinetic evaluations. Takacs AR. **Toxicol Pathol** 1995 Mar–Apr;23(2):179–86

PHOSPHONOACETATE see **PHOSPHONOACETIC ACID**

PHOSPHONOACETIC ACID

ANALOGS & DERIVATIVES

Evaluation of the antiviral activity of N–(phosphonoacetyl)–L–aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Wyde PR, et al. **Antiviral Res** 1995 May;27(1–2):59–69

Tumorigenicity and gene amplification potentials of cyclin D1–overexpressing NIH3T3 cells. Asano K, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1169–76

Phase I trial of fluorouracil modulation by N–phosphonacetyl–L–aspartate and 6–methylmercaptopurine ribonucleoside. Hageboutros A, et al. **Cancer Chemother Pharmacol** 1996;37(3):229–34

Separate pathways for p53 induction by ionizing radiation and N–(phosphonoacetyl)–L–aspartate. Chen CY, et al. **Cancer Res** 1996 Aug 15;56(16):3659–62

PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1073–9

Cytosine deaminase gene as a positive selection marker. Wei K, et al. **J Biol Chem** 1996 Feb 16;271(7):3812–6

Modulation of metabolism and cytotoxicity of cytosine arabinoside with N–(phosphon)–acetyl–L–aspartate in human leukemic blast cells and cell lines. Noordhuis P, et al. **Leuk Res** 1996 Feb;20(2):127–34

PHARMACOLOGY

Selection of bacteriophage T4 antimutator DNA polymerases: a link between proofreading and sensitivity to phosphonoacetic acid. Reha–Krantz LJ, et al. **Mutat Res** 1996 Feb 19;350(1):9–16

Functional and molecular characterization of African swine fever virus mutants resistant to phosphonoacetic acid. Marques MI, et al. **Virology** 1995 Dec 1;214(1):72–81

PHOSPHONOFORMATE see **FOSCARNET**

PHOSPHONOFORMIC ACID see **FOSCARNET**

PHOSPHONOMYCIN see **FOSFOMYCIN**

PHOSPHOPEPTIDES

Ability of a beta–casein phosphopeptide to modulate the precipitation of calcium phosphate by forming amorphous dicalcium phosphate nanoclusters. Holt C, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1035–9

ANALYSIS

High performance capillary electrophoresis of casein phosphopeptides containing 2–5 phosphoseryl residues: relationship between absolute electrophoretic mobility and peptide charge and size. Adamson NJ, et al. **Electrophoresis** 1995 Apr;16(4):525–8

A modified procedure for caseinophosphopeptide analysis. Lin JH, et al. **J Chromatogr Sci** 1996 Aug;34(8):358–61

CHEMICAL SYNTHESIS

Solid phase synthesis of pp60src–related phosphopeptides via 'global' phosphorylation and their use as substrates for enzymatic phosphorylation by casein kinase–2. Perich JW, et al. **Bioorg Med Chem** 1996 Feb;4(2):143–50

Structure–activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3–kinase with PDGF–beta receptor. Ramalingam K, et al. **Bioorg Med Chem** 1995 Sep;3(9):1263–72

Chemical synthesis of phosphopeptides using the arylthio group for protection of phosphate: application to identification of cdc2 kinase phosphorylation sites. Ueno Y, et al. **Int J Pept Protein Res** 1995 Aug;46(2):106–12

SH2 domain specificity determination using oriented phosphopeptide library. Zhou S, et al. **Methods Enzymol** 1995;254:523–35

The synthesis and compositional analysis of phosphopeptides. Sanderson SD, et al. **Mol Biotechnol** 1995 Oct;4(2):139–49 (70 ref.)

CHEMISTRY

Structural and dynamic characterization of an SH2 domain–phosphopeptide complex by NMR approaches. Pascal SM, et al. **Biochem Soc Trans** 1995 Nov;23(4):729–33

Structure of the phosphopeptidomannans from flocculent and non–flocculent yeast Kluyveromyces lactis. Bilang M, et al. **Carbohydr Res** 1996 Jan 11;280(2):303–13

Conformational effects of serine phosphorylation in phospholamban peptides. Quirk PG, et al. **Eur J Biochem** 1996 Feb 15;236(1):85–91

Identification of residues within the SHC phosphotyrosine binding/phosphotyrosine interaction domain crucial for phosphopeptide interaction. Yajnik V, et al. **J Biol Chem** 1996 Jan 26;271(4):1813–6

The synthesis and compositional analysis of phosphopeptides. Sanderson SD, et al. **Mol Biotechnol** 1995 Oct;4(2):139–49 (70 ref.)

Crystal structure of the PI 3–kinase p85 amino–terminal SH2 domain and its phosphopeptide complexes. Nolte RT, et al. **Nat Struct Biol** 1996 Apr;3(4):364–74

Structural basis for IL–4 receptor phosphopeptide recognition by the IRS–1 PTB domain. Zhou MM, et al. **Nat Struct Biol** 1996 Apr;3(4):388–93

Amino acid sequence determination of phosphoenkephalins using liquid secondary ionization mass spectrometry. Dass C, et al. **Rapid Commun Mass Spectrom** 1995;9(12):1148–54

Solution structure of the C–terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide. Narula SS, et al. **Structure** 1995 Oct 15;3(10):1061–73

IMMUNOLOGY

Primary structure of light and heavy chain variable regions of antibodies recognizing phosphorylated vimentins. Tsujino S, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):633–7

The effects of post–translational side–chain modifications on the stimulatory activity, serum stability and conformation of synthetic peptides carrying T helper cell epitopes. Otvos L Jr, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):11–9

Characterization of mAb AP422, a novel phosphorylation–dependent monoclonal antibody against tau protein. Hasegawa M, et al. **FEBS Lett** 1996 Apr 8; 384(1):25–30

ISOLATION & PURIFICATION

Characterization of trypsin immobilized on oxirane–acrylic beads for obtaining phosphopeptides from casein. Lorenzen PC, et al. **Z Ernahrungswiss** 1995 Jun;34(2):118–30

METABOLISM

Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: implications for regulation of tyrosine kinase activity. Ladbury JE, et al. **Biochemistry** 1996 Aug 27;35(34):11062–9

Structural and dynamic characterization of the phosphotyrosine binding region of a Src homology 2 domain—phosphopeptide complex by NMR relaxation, proton exchange, and chemical shift approaches. Pascal SM, et al. **Biochemistry** 1995 Sep 12;34(36):11353–62

Phosphoinositide 3–kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine–based activation motif. Reconstitution with synthetic phosphopeptides. Chacko GW, et al. **J Biol Chem** 1996 May 3;271(18):10775–81

Rapid identification of phosphopeptide ligands for SH2 domains. Screening of peptide libraries by fluorescence–activated bead sorting. Müller K, et al. **J Biol Chem** 1996 Jul 12;271(28):16500–5

Functional comparison of native and recombinant human salivary histatin 1. Driscoll J, et al. **J Dent Res** 1995 Dec; 74(12):1837–44

SH2 domain specificity determination using oriented phosphopeptide library. Zhou S, et al. **Methods Enzymol** 1995;254:523–35

Prediction and analysis of SH2 domain–phosphopeptide interactions. Zvelebil MJ, et al. **Protein Eng** 1995 Jun; 8(6):527–33

PHARMACOLOGY

Synergistic activation of PtdIns 3–kinase by tyrosine–phosphorylated peptide and beta gamma–subunits of GTP–binding proteins. Okada T, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):475–80

Structure–activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3–kinase with PDGF–beta receptor. Ramalingam K, et al. **Bioorg Med Chem** 1995 Sep;3(9):1263–72

Functional comparison of native and recombinant human salivary histatin 1. Driscoll J, et al. **J Dent Res** 1995 Dec; 74(12):1837–44

Dietary casein phosphopeptides prevent bone loss in aged ovariectomized rats. Tsuchita H, et al. **J Nutr** 1996 Jan; 126(1):86–93

PHOSPHOPROTEIN PHOSPHATASE

Serine/threonine protein phosphatases. Wera S, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):17–29 (170 ref.)

AGONISTS

Activation of protein phosphatase–1 isoforms and glycogen synthase kinase–3 beta in muscle from mdx mice. Villa–Moruzzi E, et al. **Int J Biochem Cell Biol** 1996 Jan; 28(1):13–22

ANALYSIS

A continuous spectrophotometric assay for phosphorylase kinase. Wang ZX, et al. **Anal Biochem** 1995 Sep 1; 230(1):55–61

Cytosolic and nuclear localization of protein phosphatase 2C beta 1 in COS and BHK cells. Wenk J, et al. **Eur J Cell Biol** 1995 Dec;68(4):377–86

Quantitation of protein phosphatase 1 and 2A in extracts of the budding yeast and fission yeast. Farkas I, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):767–73

Differential subcellular localization of neural isoforms of the catalytic subunit of calmodulin–dependent protein phosphatase (calcineurin) in central nervous system neurons: immunohistochemistry on formalin–fixed paraffin sections employing antigen retrieval by microwave irradiation. Usuda N, et al. **J Histochem Cytochem** 1996 Jan;44(1):13–8

Assaying protein phosphatases in sperm and flagella. Bracho GE, et al. **Methods Cell Biol** 1995;47:447–58

ANTAGONISTS & INHIBITORS

Endothall thioanhydride inhibits protein phosphatases–1 and –2A in vivo. Erdödi F, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1176–84

Polyamines inhibit myosin phosphatase and increase LC20 phosphorylation and force in smooth muscle. Swärd K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C563–71

Inhibition of protein serine/threonine phosphatases by fumonisin B1, a mycotoxin. Fukuda H, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):160–5

Multiple structural domains within I kappa B alpha are required for its inducible degradation by both cytokines and phosphatase inhibitors. Good LF, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):123–8

Protein phosphatase inhibitors potentiate Ca2+/calmodulin–dependent protein kinase II activity in rat pancreatic acinar cells. Hwang J, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):520–4

The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):72–6

Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. Tanaka H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):291–7

Inhibition of asialoglycoprotein endocytosis and degradation in rat hepatocytes by protein phosphatase inhibitors. Holen I, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):317–26

The protein phosphatase inhibitor calyculin A stimulates chemokine production by human synovial cells. Jordan NJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):89–95

Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases. Kole HK, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1025–31

Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Endo S, et al. **Biochemistry** 1996 Apr 23; 35(16):5220–8

Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Li M, et al. **Biochemistry** 1996 Jun 4;35(22):6998–7002

Conformational studies of microcystin-LR using NMR spectroscopy and molecular dynamics calculations. Trogen GB, et al. **Biochemistry** 1996 Mar 12;35(10):3197–205

Tyrosine-272 is involved in the inhibition of protein phosphatase-1 by multiple toxins. Zhang L, et al. **Biochemistry** 1996 Feb 6;35(5):1606–11

Inhibition of microsomal cholesterol ester hydrolase by okadaic acid in isolated rat hepatocytes. Martinez MJ, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):90–4

Inhibitors of protein phosphatases (okadaic acid and tautomycin) block sea urchin development. Troll W, et al. **Biol Bull** 1995 Oct-Nov;189(2):201

FK506 in bone marrow transplantation [letter] Hemenway C. **Blood** 1995 Nov 1;86(9):3611–2

Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Kawamura KI, et al. **Br J Cancer** 1996 Jan;73(2):183–8

Ability of okadaic acid and other protein phosphatase inhibitors to mimic the stimulatory effects of 12-O-tetradecanoylphorbol-13-acetate on hydroperoxide production in mouse epidermis in vivo. Newell SW, et al. **Cancer Lett** 1996 Jan 2;98(2):241–51

Control of 1,25-dihydroxyvitamin D3 receptor-mediated enhancement of osteocalcin gene transcription: effects of perturbing phosphorylation pathways by okadaic acid and staurosporine. Desai RK, et al. **Endocrinology** 1995 Dec; 136(12):5685–93

Characterization of a ribosomal inhibitory polypeptide of protein phosphatase-1 from rat liver. Beullens M, et al. **Eur J Biochem** 1996 Jul 1;239(1):183–9

The protein phosphatase inhibitor calyculin-A affects catecholamine secretion and granular distribution in cultured adrenomedullary chromaffin cells. Gutierrez LM, et al. **Eur J Cell Biol** 1995 Sep;68(1):88–95

T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Weller M, et al. **Exp Cell Res** 1995 Dec;221(2):395–403

RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. Hamaguchi T, et al. **FEBS Lett** 1995 Sep 18;372(1):54–8

Phosphatase inhibition in human neuroblastoma cells alters tau antigenicity and renders it incompetent to associate with exogenous microtubules. Shea TB, et al. **FEBS Lett** 1996 Feb 12;380(1-2):63–7

Factors responsible for the Ca(2+)-dependent inactivation of calcineurin in brain. Stemmer PM, et al. **FEBS Lett** 1995 Oct 30;374(2):237–40

Protein phosphatase-1 inhibition induces high SCEs in normal whole blood cultures. Mann RK, et al. **Indian J Exp Biol** 1995 Sep;33(9):710–1

Dibefurin, a novel fungal metabolite inhibiting calcineurin phosphatase activity. Brill GM, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):124–8

A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. Eto M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1104–7

Solution structure of nodularin. An inhibitor of serine/threonine-specific protein phosphatases. Annila A, et al. **J Biol Chem** 1996 Jul 12;271(28):16695–702

Calcineurin feedback inhibition of agonist-evoked cAMP formation. Antoni FA, et al. **J Biol Chem** 1995 Nov 24; 270(47):28055–61

4-(Fluoromethyl)phenyl phosphate acts as a mechanism-based inhibitor of calcineurin. Born TL, et al. **J Biol Chem** 1995 Oct 27;270(43):25651–5

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. Li M, et al. **J Biol Chem** 1996 May 10;271(19):11059–62

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. Inomata M, et al. **J Cancer Res Clin Oncol** 1995;121(12):729–38

Tautomycin: an inhibitor of protein phosphatases 1 and 2A but not a tumor promoter on mouse skin and in rat glandular stomach. Suganuma M, et al. **J Cancer Res Clin Oncol** 1995;121(9-10):621–7

Inhibition of constitutive serine phosphatase activity in T lymphoma cells results in phosphorylation of pp19/cofilin and induces apoptosis. Samstag Y, et al. **J Immunol** 1996 Jun 1;156(11):4167–73

Okadaic acid inhibits the signal responsible for activation of the NADPH-oxidase in neutrophils stimulated with serum-opsonized yeast. Harbecke O, et al. **J Leukoc Biol** 1996 May;59(5):754–62

Stimulation of motility and respiration of intact fowl spermatozoa by calyculin A, a specific inhibitor of protein phosphatase-1 and -2A, via a Ca2+-dependent mechanism. Ashizawa K, et al. **J Reprod Fertil** 1995 Sep; 105(1):109–14

Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes. Matsushima-Nishiwaki R, et al. **Lipids** 1995 Nov; 30(11):1029–34

Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. da Cruz e Silva EF, et al. **Mol Med** 1995 Jul;1(5):535–41

Protein serine/threonine phosphatases as binding proteins for okadaic acid. Nagao M, et al. **Mutat Res** 1995 Dec; 333(1-2):173–9 (33 ref.)

Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Ariza RR, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):433–40

Force-inhibiting effect of okadaic acid on skinned rat uterus permeabilized with alpha-toxin. Watanabe M, et al. **Pflugers Arch** 1995 Sep;430(5):754–6

Okadaic acid, a protein phosphatase inhibitor, blocks calcium changes, gene expression, and cell death induced by gibberellin in wheat aleurone cells. Kuo A, et al. **Plant Cell** 1996 Feb;8(2):259–69

Inhibitors of serine/threonine phosphoprotein phosphatases alter circadian properties in Gonyaulax polyedra. Comolli J, et al. **Plant Physiol** 1996 May;111(1):285–91

Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Andjelković M, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5699–704

Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [see comments] Kimura K, et al. **Science** 1996 Jul 12;273(5272):245–8. Comment in: Science 1996 Jul 12;273(5272):203.

Protein phosphatase regulation by endogenous inhibitors. Shenolikar S. **Semin Cancer Biol** 1995 Aug;6(4):219–27 (60 ref.)

Microcystin uptake and inhibition of protein phosphatases: effects of chemoprotectants and self-inhibition in relation to known hepatic transporters. Runnegar M, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):264–72

Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. Koprak S, et al. **Transplantation** 1996 Mar 27;61(6):926–32

BIOSYNTHESIS

1 alpha,25-dihydroxyvitamin D3-induced upregulation of calcineurin during leukemic HL-60 cell differentiation. Omay SB, et al. **Blood** 1996 Apr 1;87(7):2947–55

Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. Doherty MJ, et al. **FEBS Lett** 1995 Nov 20;375(3):294–8

Up-regulation of protein serine/threonine phosphatase type 2C during 1 alpha,25-dihydroxyvitamin D3-induced monocytic differentiation of leukemic HL-60 cells. Nishikawa M, et al. **FEBS Lett** 1995 Nov 20;375(3):299–303

Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Yong WH, et al. **Genomics** 1995 Sep 20;29(2):533–6

Identification of a novel protein phosphatase 2A regulatory subunit highly expressed in muscle. Tehrani MA, et al. **J Biol Chem** 1996 Mar 1;271(9):5164–70

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Tiefenbrun N, et al. **Mol Cell Biol** 1996 Jul;16(7):3934–44

Enhanced UV sensitivity of yeast cells induced by overexpression of Mg(2+)-dependent protein phosphatase alpha (type 2C alpha). Kobayashi T, et al. **Mutat Res** 1996 Apr 2;362(3):213–7

Expression of the cell cycle control protein cdc25 in cleavage stage bovine embryos. Jones JM, et al. **Zygote** 1995 May; 3(2):133–9

BLOOD

Type 1 phosphatase inhibitors reduce the restoration of guanine nucleotide exchange activity of eukaryotic initiation factor 2B inhibited reticulocyte lysates rescued by hemin. Babu SV, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):201–8

Calcineurin protein phosphatase activity in peripheral blood lymphocytes. Rusnak F, et al. **Bone Marrow Transplant** 1996 Mar;17(3):309–13

Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. Revan S, et al. **J Biol Chem** 1996 Jul 19;271(29):17114–8

Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Piccinni G, et al. **Transplantation** 1996 May 27;61(10):1526–31

CHEMISTRY

Only in the presence of immunophilins can cyclosporin and FK506 disrupt in vivo binding of calcineurin A to its autoinhibitory domain yet strengthen interaction between calcineurin A and B subunits. Chaudhuri B, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):781–90

Interactions and properties of smooth muscle myosin phosphatase. Ichikawa K, et al. **Biochemistry** 1996 May 21;35(20):6313–20

Mutational analysis of the catalytic subunit of muscle protein phosphatase-1. Zhang J, et al. **Biochemistry** 1996 May 21; 35(20):6276–82

Protein serine/threonine phosphatases. Villafranca JE, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):397–402 (42 ref.)

Primary structure, expression and developmental regulation of a Dictyostelium calcineurin A homologue. Dammann H, et al. **Eur J Biochem** 1996 Jun 1;238(2):391–9

Regions of the 110-kDa regulatory subunit M110 required for regulation of myosin-light-chain-phosphatase activity in smooth muscle. Gailly P, et al. **Eur J Biochem** 1996 Jul 15;239(2):326–32

Identification of protein-phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Johnson DF, et al. **Eur J Biochem** 1996 Jul 15;239(2):317–25

Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. Doherty MJ, et al. **FEBS Lett** 1995 Nov 20;375(3):294–8

Molecular cloning of a 74-kDa regulatory subunit (B" or delta) of human protein phosphatase 2A. Tanabe O, et al. **FEBS Lett** 1996 Jan 22;379(1):107–11

Phosphorylation of the large subunit of myosin phosphatase and inhibition of phosphatase activity. Ichikawa K, et al. **J Biol Chem** 1996 Mar 1;271(9):4733–40

Identification of a new family of protein phosphatase 2A regulatory subunits. McCright B, et al. **J Biol Chem** 1995 Nov 3;270(44):26123–8

Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). Wesselborg S, et al. **J Biol Chem** 1996 Jan 19;271(3):1274–7

Roles of active site residues and the NH2-terminal domain in the catalysis and substrate binding of human Cdc25. Xu X, et al. **J Biol Chem** 1996 Mar 1;271(9):5118–24

Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. Egloff MP, et al. **J Mol Biol** 1995 Dec 15;254(5):942–59

Preliminary crystallization studies of calmodulin-dependent protein phosphatase (calcineurin) from bovine brain. Balendiran K, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149-150:127–30

Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Kissinger CR, et al. **Nature** 1995 Dec 7;378(6557):641–4

Identification of an essential acidic residue in Cdc25 protein phosphatase and a general three-dimensional model for a core region in protein phosphatases. Eckstein JW, et al. **Protein Sci** 1996 Jan;5(1):5–12

Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. Lohse DL, et al. **Structure** 1995 Oct 15;3(10):987–90 (24 ref.)

[The structure of smooth muscle myosin phosphatase] Ito M, et al. **Seikagaku** 1996 Feb;68(2):147–51 (15 ref.) **(Jpn)**

DEFICIENCY

T cell responses in calcineurin A alpha-deficient mice. Zhang BW, et al. **J Exp Med** 1996 Feb 1;183(2):413–20

GENETICS

Chromosomal localization and 5' sequence of the human protein serine/threonine phosphatase 5' gene. Xu X, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):514–7

The variable subunit associated with protein phosphatase 2A0 defines a novel multimember family of regulatory subunits. Zolnierowicz S, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):187–94

Protein phosphatase type-1 mRNA levels in response to starvation-refeeding and streptozotocin-diabetes. Drake PG, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):971–9

Mutational analysis of the catalytic subunit of muscle protein phosphatase-1. Zhang J, et al. **Biochemistry** 1996 May 21; 35(20):6276–82

Protein phosphatase mRNA expression in Purkinje cells of staggerer and reeler mutant mice. Guo H, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):121–6

The role of cdc2, cdc25 and cyclin A genes in the maintenance of immortalization and growth arrest in a rat embryonic fibroblast conditional cell line. Gonos ES, et al. **Cell Biol Int** 1996 Mar;20(3):159–67

Inactivation of a single-2A phosphoprotein phosphatase is lethal in Neurospora crassa. Yatzkan E, et al. **Curr Genet** 1995 Oct;28(5):458–66

Expression of the cell cycle control gene, cdc25, is constitutive in the segmental founder cells but is cell-cycle-regulated in the micromeres of leech embryos. Bissen ST. **Development** 1995 Sep;121(9):3035–43

A mutation in protein phosphatase 2A regulatory subunit A affects auxin transport in Arabidopsis. Garbers C, et al. **EMBO J** 1996 May 1;15(9):2115–24

Escherichia coli isocitrate dehydrogenase kinase/phosphatase. Overproduction and kinetics of interaction with its substrates by using intrinsic fluorescence and fluorescent nucleotide analogues. Rittinger K, et al. **Eur J Biochem** 1996 Apr 1;237(1):247–54

Molecular cloning of a 74-kDa regulatory subunit (B" or delta) of human protein phosphatase 2A. Tanabe O, et al. **FEBS Lett** 1996 Jan 22;379(1):107–11

Zygotic degradation of two maternal Cdc25 mRNAs terminates Drosophila's early cell cycle program. Edgar BA, et al. **Genes Dev** 1996 Aug 1;10(15):1966–77

Genetic interactions between REG1/HEX2 and GLC7, the gene encoding the protein phosphatase type 1 catalytic subunit in Saccharomyces cerevisiae. Huang D, et al. **Genetics** 1996 May;143(1):119–27

Suppressors of a Saccharomyces cerevisiae pkc1 mutation identify alleles of the phosphatase gene PTC1 and of a novel gene encoding a putative basic leucine zipper protein. Huang KN, et al. **Genetics** 1995 Dec;141(4):1275–85

Localization of the mouse protein serine/threonine phosphatase 2C beta gene to chromosome 17E 4–5. Ohnishi M, et al. **Genomics** 1996 Feb 15;32(1):134–6

The mouse protein phosphatase 2Cbeta (Ppm1b) gene maps to the distal part of mouse chromosome 17. Watanabe T, et al. **Genomics** 1996 Apr 1;33(1):147–9

Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Yong WH, et al. **Genomics** 1995 Sep 20;29(2):533–6

A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hansen L, et al. **Hum Mol Genet** 1995 Aug;4(8):1313–20

Isolation and cloning of a protein-serine/threonine phosphatase from an archaeon. Leng J, et al. **J Bacteriol** 1995 Nov;177(22):6510–7

High complexity in the expression of the B' subunit of protein phosphatase 2A0. Evidence for the existence of at least seven novel isoforms. Csortos C, et al. **J Biol Chem** 1996 Feb 2;271(5):2578–88

Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast. Lippuner V, et al. **J Biol Chem** 1996 May 31;271(22):12859–66

The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. McCright B, et al. **J Biol Chem** 1996 Sep 6;271(36):22081–9

Identification of a new family of protein phosphatase 2A regulatory subunits. McCright B, et al. **J Biol Chem** 1995 Nov 3;270(44):26123–8

Regulation of calcineurin gene expression in Schizosaccharomyces pombe. Dependence on the ste11 transcription factor. Plochocka-Zulinska D, et al. **J Biol Chem** 1995 Oct 20;270(42):24794–9

Degradation of maternal string mRNA is controlled by proteins encoded on maternally contributed transcripts. Myers FA, et al. **Mech Dev** 1995 Jun;51(2–3):217–26

Cdc25 cell-cycle phosphatase as a target of c-myc. Galaktionov K, et al. **Nature** 1996 Aug 8;382(6591):511–7

Cell cycle regulation of cdc25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. Zwicker J, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3822–30

Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Santoro M, et al. **Oncogene** 1996 Apr 18; 12(8):1821–6

Characterization of DNA sequences encoding a novel isoform of the 55 kDa B regulatory subunit of the type 2A protein serine/threonine phosphatase of Arabidopsis thaliana. Corum JW 3rd, et al. **Plant Mol Biol** 1996 May; 31(2):419–27

Sensitivity to abscisic acid of guard-cell K+ channels is suppressed by abi1-1, a mutant Arabidopsis gene encoding a putative protein phosphatase. Armstrong F, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9520–4

Reconstitution of active human calcineurin from recombinant subunits expressed in bacteria. Rokosz LL, et al. **Protein Expr Purif** 1995 Oct;6(5):655–64

ISOLATION & PURIFICATION

Purification and characterization of protein phosphatase 2C in rat parotid acinar cells: two forms of Mg(2+)-activated histone phosphatase and phosphorylation by cAMP-dependent protein kinase. Yokoyama N, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):1–8

Affinity chromatography of regulatory subunits of protein phosphatase-1. Zhao S, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):82–90

Purification and characterization of a protein phosphatase that dephosphorylates pyruvate kinase in an anoxia tolerant animal. Brooks SP, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1223–34

Isolation and characterization of the catalytic subunit of protein phosphatase 2A from Neurospora crassa. Szöör B, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov;112(3):515–22

Partial purification and characterization of two phosvitin phosphatases from rat brain. Geladopoulos TP, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):97–106

Isolation and cloning of a protein-serine/threonine phosphatase from an archaeon. Leng J, et al. **J Bacteriol** 1995 Nov;177(22):6510–7

Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Nishimura M, et al. **J Biol Chem** 1995 Nov 3;270(44):26341–6

Immunolocalization of protein phosphatase type 1 in Paramecium cells using antibodies against recombinant protein and peptides. Momayezi M, et al. **J Histochem Cytochem** 1996 Aug;44(8):891–905

Partial purification and characterization of a soluble protein phosphatase from Leishmania donovani promastigotes. Nandi S, et al. **Mol Cell Biochem** 1995 Jul 19;148(2):191–8

Purification and characterization of multiple S6 phosphatases from the rat parotid gland. Yokoyama N. **Mol Cell Biochem** 1995 Jul 19;148(2):123–32

Reconstitution of active human calcineurin from recombinant subunits expressed in bacteria. Rokosz LL, et al. **Protein Expr Purif** 1995 Oct;6(5):655–64

METABOLISM

Regulation of ATP-sensitive K+ channel by membrane-bound protein phosphatases in rat principal tubule cell. Kubokawa M, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):F355–62

Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. Tumlin JA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F558–63

The dephosphorylation of 22-kDa phosphoprotein by type 2B protein phosphatase in rat parotid acinar cells. Sugiya H, et al. **Arch Oral Biol** 1995 Aug;40(8):713–6

Role of protein phosphatase 2A in the regulation of mitogen-activated protein kinase activity in ventricular cardiomyocytes. Braconi Quintaje SB, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):539–47

Only in the presence of immunophilins can cyclosporin and FK506 disrupt in vivo binding of calcineurin A to its autoinhibitory domain yet strengthen interaction between calcineurin A and B subunits. Chaudhuri B, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):781–90

Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Fuhrer DK, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):289–96

Protein kinase C increases force and slows relaxation in smooth muscle: evidence for regulation of the myosin light chain phosphatase. Ikebe M, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):370–6

Alpha-subunit of farnesyltransferase is phosphorylated in vivo: effect of protein phosphatase-1 on enzymatic activity. Kumar A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):445–52

Control of a novel adenylyl cyclase by calcineurin. Paterson JM, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1000–8

In vivo and in vitro binding of microcystin to protein phosphatases 1 and 2A. Runnegar M, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):162–9

Phosphorylation of phosphatase-1alpha in cells expressing v-src. Villa-Moruzzi E, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):863–7

Cyclic GMP-dependent stimulation reverses G-protein-coupled inhibition of smooth muscle myosin light chain phosphate. Wu X, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):658–63

Activation of hepatic acetyl-CoA carboxylase by glutamate and Mg2+ is mediated by protein phosphatase-2A. Gaussin V, et al. **Biochem J** 1996 May 15;316 (Pt 1):217–24

Protein phosphatase and kinase activities possibly involved in exocytosis regulation in Paramecium tetraurelia. Kissmehl R, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):65–76

The activity of calmodulin is altered by phosphorylation: modulation of calmodulin function by the site of phosphate incorporation. Sacks DB, et al. **Biochem J** 1995 Nov 15; 312 (Pt 1):197–204

Thapsigargin activates univalent- and bivalent-cation entry in human neutrophils by a SK&F 13 96365- and Gd3+-sensitive pathway and is a partial secretagogue: involvement of pertussis-toxin-sensitive G-proteins and protein phosphatases 1/2A and 2B in the signal-transduction pathway. Wenzel-Seifert K, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):679–86

Time-dependent pseudo-activation of hepatic glycogen synthase b by glucose 6-phosphate without involvement of protein phosphatases. Wera S, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):91–6

Purification and characterization of a protein phosphatase that dephosphorylates pyruvate kinase in an anoxia tolerant animal. Brooks SP, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1223–34

Protein phosphatase type-1 mRNA levels in response to starvation-refeeding and streptozotocin-diabetes. Drake PG, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):971–9

PP2C phosphatase activity is coupled to cAMP-mediated pathway in rat parotid acinar cells. Yokoyama N, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):845–53

Developmental expression of FK506 binding proteins and calcineurin in rat brain. Charters AR, et al. **Biochem Soc Trans** 1995 Aug;23(3):422S

A Drosophila early embryonic ventral transcript encoding a protein phosphatase-1 binding protein. Hawcroft G, et al. **Biochem Soc Trans** 1995 Nov;23(4):631S

Effects of insulin secretagogues on phosphoprotein phosphatase 1 and 2A activities in rat islets of Langerhans. Murphy LI, et al. **Biochem Soc Trans** 1995 Nov;23(4):593S

Interactions and properties of smooth muscle myosin phosphatase. Ichikawa K, et al. **Biochemistry** 1996 May 21;35(20):6313–20

Characterization of mammalian C-CDC25Mm exchange factor and kinetic properties of the exchange reaction intermediate p21.C-CDC25Mm. Jacquet E, et al. **Biochemistry** 1995 Sep 26;34(38):12347–54

Activation of calcineurin A subunit phosphatase activity by its calcium-binding B subunit. Watanabe Y, et al. **Biochemistry** 1996 Jan 16;35(2):562–6

Reversible phosphorylation as a controlling factor for sustaining calcium oscillations in HeLa cells: Involvement of calmodulin-dependent kinase II and a calyculin A-inhibitable phosphatase. Zhu DM, et al. **Biochemistry** 1996 Jun 4;35(22):7214–23

Effects of protein kinase C and phosphoprotein phosphatase modulators on Ehrlich cell plasma membrane redox system activity. del Castillo-Olivares A, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):157–60

Phosphatase 2A regulates the responsiveness of olfactory cilia. Kroner C, et al. **Biochim Biophys Acta** 1996 Jun 13; 1312(2):169–75

Modulation of queuine uptake and incorporation into tRNA by protein kinase C and protein phosphatase. Morris RC, et al. **Biochim Biophys Acta** 1996 Apr 24;1311(2):124–32

Phosphatase 2A participates in interferon-gamma's induced upregulation of C1 inhibitor mRNA expression. Heda GD, et al. **Blood** 1996 Apr 1;87(7):2831–8

Calcium/calmodulin-dependent protein kinase II and protein phosphatase 2B (calcineurin) immunoreactivity in the rat hippocampus long after ischemia. Onodera H, et al. **Brain Res** 1995 Jun 26;684(1):95–8

Postnatal changes in serine/threonine protein phosphatases and their association with the microtubules. Dudek SM, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):54–61

Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factor (MPF) and cdc25-C in HeLa cells. Barth H, et al. **Cancer Res** 1996 May 15; 56(10):2268–72

Involvement of protein kinase C and of protein phosphatases 1 and/or 2A in p47 phox phosphorylation in formylmet-Leu-Phe stimulated neutrophils: studies with selective inhibitors RO 31-8220 and calyculin A. Bengis-Garber C, et al. **Cell Signal** 1995 Sep;7(7):721–32

Stress causes induction of MAP kinase-specific phosphatase and rapid repression of MAP kinase activity in Drosophila. Cornelius G, et al. **Cell Signal** 1995 Aug;7(6):611–5

The effect of acute (60 minute) insulin stimulation upon human skeletal muscle glycogen synthase and protein phosphatase-1 in non-insulin-dependent diabetic patients and control subjects. Barriocanal LA, et al. **Diabet Med** 1995 Dec;12(12):1110–5

Regulation of glycogen synthase and protein phosphatase-1 by hexosamines. Crook ED, et al. **Diabetes** 1996 Mar; 45(3):322–7

Pub1 acts as an E6-AP-like protein ubiquitiin ligase in the degradation of cdc25. Nefsky B, et al. **EMBO J** 1996 Mar 15;15(6):1301–12

REG1 binds to protein phosphatase type 1 and regulates glucose repression in Saccharomyces cerevisiae. Tu J, et al. **EMBO J** 1995 Dec 1;14(23):5939–46

Effect of tumor necrosis factor-alpha on insulin action in cultured rat skeletal muscle cells. Begum N, et al. **Endocrinology** 1996 Jun;137(6):2441–6

Carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting cells: evidence for functional consequences on enzyme activity and insulin secretion. Kowluru A, et al. **Endocrinology** 1996 Jun; 137(6):2315–23

A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn. Agostinis P, et al. **Eur J Biochem** 1996 Mar 1; 236(2):548–57

Characterization of a ribosomal inhibitory polypeptide of protein phosphatase-1 from rat liver. Beullens M, et al. **Eur J Biochem** 1996 Jul 1;239(1):183–9

Regulation of p42 mitogen-activated-protein kinase activity by protein phosphatase 2A under conditions of growth inhibition by epidermal growth factor in A431 cells. Chajry N, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):97–102

Primary structure, expression and developmental regulation of a Dictyostelium calcineurin A homologue. Dammann H, et al. **Eur J Biochem** 1996 Jun 1;238(2):391–9

Regions of the 110-kDa regulatory subunit M110 required for regulation of myosin-light-chain-phosphatase activity in smooth muscle. Gailly P, et al. **Eur J Biochem** 1996 Jul 15;239(2):326–32

Identification of protein-phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Johnson DF, et al. **Eur J Biochem** 1996 Jul 15;239(2):317–25

Calcium-activated opsin phosphatase activity in retinal rod outer segments. Kutuzov MA, et al. **Eur J Biochem** 1996 Jun 15;238(3):613–22

Association of Lyn tyrosine kinase with the nuclear matrix

and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity. Radha V, et al. **Eur J Biochem** 1996 Mar 1;236(2):352-9

Ba2+ replaces Ca2+/calmodulin in the activation of protein phosphatases and in exocytosis of all major transmitters. Verhage M, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):387-98

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570-6 (77 ref.)

NMR identification of calcineurin B residues affected by binding of a calcineurin A peptide. Anglister J, et al. **FEBS Lett** 1995 Nov 13;375(1-2):108-12

5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. Davies SP, et al. **FEBS Lett** 1995 Dec 27;377(3):421-5

Molecular cloning and functional expression of a recombinant 72.5 kDa fragment of the 110 kDa regulatory subunit of smooth muscle protein phosphatase 1M. Haystead CM, et al. **FEBS Lett** 1995 Dec 18;377(2):123-7

Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. Helps NR, et al. **FEBS Lett** 1995 Dec 27;377(3):295-300

Interaction of protein phosphatase type 1 with a splicing factor. Hirano K, et al. **FEBS Lett** 1996 Jul 1;389(2):191-4

The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. MacKintosh RW, et al. **FEBS Lett** 1995 Sep 11;371(3):236-40

Binding of vanadium (IV) to the phosphatase calcineurin. Parra-Diaz D, et al. **FEBS Lett** 1995 Nov 27; 376(1-2):58-60

Molecular cloning of a human polypeptide related to yeast sds22, a regulator of protein phosphatase-1. Renouf S, et al. **FEBS Lett** 1995 Nov 13;375(1-2):75-8

In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. Saito T, et al. **FEBS Lett** 1995 Dec 4;376(3):238-42

Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. Tanida I, et al. **FEBS Lett** 1996 Jan 22;379(1):38-42

Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Di Como CJ, et al. **Genes Dev** 1996 Aug 1;10(15):1904-16

Bifunctional protein required for asymmetric cell division and cell-specific transcription in Bacillus subtilis. Feucht A, et al. **Genes Dev** 1996 Apr 1;10(7):794-803

A ceramide-activated protein phosphatase mediates ceramide-induced G1 arrest of Saccharomyces cerevisiae. Nickels JT, et al. **Genes Dev** 1996 Feb 15;10(4):382-94

Phosphorylated sites of M(r) 25,000 protein, a putative protein phosphatase 2A modulator, and phosphorylation of the synthetic peptide containing these sites by protein kinase C. Hashimoto E, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):626-32

Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. Yamamoto H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1224-31

Activation of protein phosphatase 1. Formation of a metalloenzyme. Chu Y, et al. **J Biol Chem** 1996 Feb 2; 271(5):2574-7

Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene. Daniel S, et al. **J Biol Chem** 1996 Jun 21;271(25):14692-7

Reverse phosphotransfer from OmpR to EnvZ in a kinase-/phosphatase+ mutant of EnvZ (EnvZ.N347D), a bifunctional signal transducer of Escherichia coli. Dutta R, et al. **J Biol Chem** 1996 Jan 19;271(3):1424-9

Phosphorylation of the large subunit of myosin phosphatase and inhibition of phosphatase activity. Ichikawa K, et al. **J Biol Chem** 1996 Mar 1;271(9):4733-40

Positive regulation of cdc2 gene activity by protein phosphates type 2A. Jaramillo-Babb VL, et al. **J Biol Chem** 1996 Mar 15;271(11):5988-92

Dephosphorylation of catalytic subunit of cAMP-dependent protein kinase at Thr-197 by a cellular protein phosphatase and by purified protein phosphatase-2A. Liauw S, et al. **J Biol Chem** 1996 Jan 5;271(1):258-63

Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. Loh C, et al. **J Biol Chem** 1996 May 3;271(18):10884-91

Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. Merrick SE, et al. **J Biol Chem** 1996 Mar 8;271(10):5589-94

TAG-1/axonin-1 is a high-affinity ligand of neurocan, phosphacan/protein-tyrosine phosphatase-zeta/beta, and N-CAM. Milev P, et al. **J Biol Chem** 1996 Jun 28; 271(26):15716-23

Isocitrate dehydrogenase kinase/phosphatase. Kinetic characteristics of the wild-type and two mutant proteins. Miller SP, et al. **J Biol Chem** 1996 Aug 9;271(32):19124-8

The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. Morana SJ, et al. **J Biol Chem** 1996 Jul 26;271(30):18263-71

Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Nishimura M, et al. **J Biol Chem** 1995 Nov 3;270(44):26341-6

Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. Quilliam LA, et al. **J Biol Chem** 1996 May 10;271(19):11076-82

c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells. Reyes JG, et al. **J Biol Chem** 1996 Aug 30;271(35):21375-80

Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin. Schaefer A, et al. **J Biol Chem** 1996 Jun 7;271(23):13484-90

Characterization of a phosphoprotein phosphatase for the phosphorylated form of nucleoside-diphosphate kinase from Pseudomonas aeruginosa. Shankar S, et al. **J Biol Chem** 1995 Nov 24;270(47):28246-50

A Mg(2+)-dependent, Ca(2+)-inhibitable serine/threonine protein phosphatase from bovine brain. Wang Y, et al. **J Biol Chem** 1995 Oct 27;270(43):25607-12

Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). Wesselborg S, et al. **J Biol Chem** 1996 Jan 19;271(3):1274-7

Roles of active site residues and the NH2-terminal domain in the catalysis and substrate binding of human Cdc25. Xu X, et al. **J Biol Chem** 1996 Mar 1;271(9):5118-24

Protein phosphatase 2A is essential for the activation of Ca2+-activated K+ currents by cGMP-dependent protein kinase in tracheal smooth muscle and Chinese hamster ovary cells. Zhou XB, et al. **J Biol Chem** 1996 Aug 16;271(33):19760-7

Involvement of protein phosphatase-1 in cytoskeletal organization of cultured endothelial cells. Shinoki N, et al. **J Cell Biochem** 1995 Nov;59(3):368-75

Role of cdc25-C phosphatase in the immediate G2 delay induced by the exogenous factors epidermal growth factor and phorbolester. Barth H, et al. **J Cell Physiol** 1996 Sep; 168(3):589-99

Drosophila PPY, a novel male specific protein serine/threonine phosphatase localised in somatic cells of the testis. Armstrong CG, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3367-75

Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. Goedert M, et al. **J Neurochem** 1995 Dec; 65(6):2804-7

Angiotensin II type 2 receptor-mediated stimulation of protein phosphatase 2A in rat hypothalamic/brainstem neuronal cocultures. Huang XC, et al. **J Neurochem** 1995 Nov;65(5):2131-7

Human cytomegalovirus carries serine/threonine protein phosphatases PP1 and a host-cell derived PP2A. Michelson S, et al. **J Virol** 1996 Mar;70(3):1415-23

Ras-Cdc25 and Rho-Dbl binding assays: complex formation in vitro. Hart M, et al. **Methods Enzymol** 1995;255:129-35

Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements. Lenzen C, et al. **Methods Enzymol** 1995;255:95-109

Analysis of interaction between Ras and CDC25 guanine nucleotide exchange factor using yeast GAL4 two-hybrid system. Mosteller RD, et al. **Methods Enzymol** 1995; 255:135-48

The Cdc25 protein of Saccharomyces cerevisiae is required for normal glucose transport. Silljé HH, et al. **Microbiology** 1996 Jul;142 (Pt 7):1765-73

The REG2 gene of Saccharomyces cerevisiae encodes a type 1 protein phosphatase-binding protein that functions with Reg1p and the Snf1 protein kinase to regulate growth. Frederick DL, et al. **Mol Cell Biol** 1996 Jun;16(6):2922-31

The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase. Luke MM, et al. **Mol Cell Biol** 1996 Jun;16(6):2744-55

Protein phosphatase type 1 interacts with proteins required for meiosis and other cellular processes in Saccharomyces cerevisiae. Tu J, et al. **Mol Cell Biol** 1996 Aug; 16(8):4199-206

Regulation of chromosome segregation by Glc8p, a structural homolog of mammalian inhibitor 2 that functions as both an activator and an inhibitor of yeast protein phosphatase 1. Tung HY, et al. **Mol Cell Biol** 1995 Nov;15(11):6064-74

Adaptation to high-salt stress in Saccharomyces cerevisiae is regulated by Ca2+/calmodulin-dependent phosphoprotein phosphatase (calcineurin) and cAMP-dependent protein kinase. Hirata D, et al. **Mol Gen Genet** 1995 Nov 27;249(3):257-64

Aspartyl-phosphate phosphatases deactivate the response regulator components of the sporulation signal transduction system in Bacillus subtilis. Perego M, et al. **Mol Microbiol** 1996 Mar;19(6):1151-7 (25 ref.)

Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Shibasaki F, et al. **Nature** 1996 Jul 25;382(6589):370-3

Cytoskeletal-associated protein kinase and phosphatase activities from cerebral cortex of young rats. de Freitas MS, et al. **Neurochem Res** 1995 Aug;20(8):951-6

Mosaic organization of calcineurin immunoreactivity in the adult cat striatum. Goto S, et al. **Neurosci Lett** 1995 Sep 22;198(1):25-8

Dephosphorylation studies of SKNSH-SY 5Y cell Tau proteins by endogenous phosphatase activity. Soulié C, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):189-92

S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Spitkovsky D, et al. **Oncogene** 1996 Jun 20;12(12):2549-54

The brain specific Ras exchange factor CDC25 Mm: modulation of its activity through Gi-protein-mediated signals. Zippel R, et al. **Oncogene** 1996 Jun 20; 12(12):2697-703

A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Lee J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6043-7

ESR study on calcineurin. Wei Q, et al. **Sci China B** 1995 Sep;38(9):1117-22

Activation of cell-specific transcription by a serine phosphatase at the site of asymmetric division [see comments] Duncan L, et al. **Science** 1995 Oct 27; 270(5236):641-4. Comment in: Science 1995 Oct 27;270(5236):578-9.

Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Klauck TM, et al. **Science** 1996 Mar 15;271(5255):1589-92

Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Kumagai A, et al. **Science** 1996 Sep 6;273(5280):1377-80

Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Poon RY, et al. **Science** 1995 Oct 6;270(5233):90-3

Flicking the switches: phosphorylation of serine/threonine protein phosphatases. Brautigan DL. **Semin Cancer Biol** 1995 Aug;6(4):211-7 (37 ref.)

Glucocorticoid receptor phosphorylation in v-mos-transformed cells. Borror KC, et al. **Steroids** 1995 May;60(5):375-82

Activity of smooth muscle phosphatases 1 and 2A in rabbit basilar artery in vasospasm. Fukami M, et al. **Stroke** 1995 Dec;26(12):2321-7

Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Batiuk TD, et al. **Transplantation** 1996 Jan 15;61(1):158-61

[Alteration of phospholamban phosphatase activity associated with cardiac sarcoplasmic reticulum during sepsis in rats] Yang Q, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):357-65 (Eng. Abstr.) **(Chi)**

[Alterations of protein phosphatases, PP2A and PP1, during retinoic acid-induced differentiation of HL-60 cells] Zhu T. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):173-86 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Reconstitution of calyculin-inhibited K-Cl cotransport in dog erythrocyte ghosts by exogenous PP-1. Krarup T, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C898-902

Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin. Mata M, et al. **J Biol Chem** 1996 Jul 12;271(28):16888-96

Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion. Raufman JP, et al. **J Biol Chem** 1996 Aug 16;271(33):19877-82

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323-50 (154 ref.)

PHYSIOLOGY

Protein phosphatase-1 in the kidney: evidence for a role in the regulation of medullary Na(+)-K(+)-ATPase. Li D, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F673-80

Regulation of human sperm motility and hyperactivation components by calcium, calmodulin, and protein phosphatases. Ahmad K, et al. **Arch Androl** 1995 Nov-Dec; 35(3):187-208

Inhibition of NF-AT signal transduction events by a dominant-negative form of calcineurin. Muramatsu T, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):466-72

Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. Tomono M, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):675-80

Okadaic acid inhibits alkaline phosphatase activity in MC3T3-E1 cells. Choi JY, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):943-7

Intracellular calcium and calcineurin regulate neutrophil motility on vitronectin through a receptor identified by antibodies to integrins alphav and beta3. Hendey B, et al. **Blood** 1996 Mar 1;87(5):2038-48

Mg2+-dependent phosphatase as an inhibitory mediator of the nonselective cation current induced by aluminum fluoride in guinea-pig chromaffin cells. Inoue M, et al. **Brain Res** 1995 Jul 31;687(1-2):199-204

Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux.

Cameron AM, et al. **Cell** 1995 Nov 3;83(3):463–72
Roles of protein phosphatase 1 and 2A in an IL–6–mediated autocrine growth loop of human myeloma cells. Kang HS, et al. **Cell Immunol** 1996 Mar 15;168(2):174–83
Regulation of dynein–driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Protein serine/threonine phosphatases. Villafranca JE, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):397–402 (42 ref.)
Protein phosphatase 2B of Saccharomyces cerevisiae is required for tolerance to manganese, in blocking the entry of ions into the cells. Farcasanu IC, et al. **Eur J Biochem** 1995 Sep 15;232(3):712–7
Protein phosphatase 2A positively and negatively regulates Ras1–mediated photoreceptor development in Drosophila. Wassarman DA, et al. **Genes Dev** 1996 Feb 1;10(3):272–8
vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)–ATPase assembly. Hemenway CS, et al. **Genetics** 1995 Nov;141(3):833–44
The role of calcineurin in immune system responses. Kincaid RL. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1170–7 (40 ref.)
Thrombin–mediated ET–1 gene regulation involves CaM kinases and calcineurin in human endothelial cells. Marsen TA, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S1–4
Involvement of protein phosphatase 2A in PKC–independent pathway of neutrophil superoxide generation by fMLP. Okuyama M, et al. **J Cell Biochem** 1996 Feb;60(2):279–88
Calcineurin functions in Ca(2+)–activated cell death in mammalian cells. Shibasaki F, et al. **J Cell Biol** 1995 Nov; 131(3):735–43
Activation of inducible nitric oxide synthase gene in murine macrophages requires protein phosphatases 1 and 2A activities. Dong Z, et al. **J Leukoc Biol** 1995 Dec; 58(6):725–32
Glutamate induces a calcineurin–mediated dephosphorylation of Na+,K(+)–ATPase that results in its activation in cerebellar neurons in culture. Marcaida G, et al. **J Neurochem** 1996 Jan;66(1):99–104
Evidence for a role of protein phosphatases 1 and 2A during early nephrogenesis. Svennilson J, et al. **Kidney Int** 1995 Jul;48(1):103–10
Regulation of phospholamban and troponin–I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)
Ca2+–calmodulin promotes survival of pheromone–induced growth arrest by activation of calcineurin and Ca2+–calmodulin–dependent protein kinase. Moser MJ, et al. **Mol Cell Biol** 1996 Sep;16(9):4824–31
Genetic evidence for the functional redundancy of the calcineurin– and Mpk1–mediated pathways in the regulation of cellular events important for growth in Saccharomyces cerevisiae. Nakamura T, et al. **Mol Gen Genet** 1996 May 23;251(2):211–9
Effects of different kinases and phosphatases on nuclear and cytoplasmic maturation of bovine oocytes. Lévesque JT, et al. **Mol Reprod Dev** 1995 Sep;42(1):114–21
Calcineurin regulates M channel modal gating in sympathetic neurons. Marrion NV. **Neuron** 1996 Jan;16(1):163–73
Cell–cell communication regulates the effects of protein aspartate phosphatases on the phosphorelay controlling development in Bacillus subtilis. Perego M, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1549–53
The role of protein phosphatase type–2A in the Xenopus cell cycle: initiation of the G2/M transition. Lee TH. **Semin Cancer Biol** 1995 Aug;6(4):203–9 (39 ref.)
Control and activity of type–1 serine/threonine protein phosphatase during the cell cycle. Ludlow JW, et al. **Semin Cancer Biol** 1995 Aug;6(4):195–202 (42 ref.)
Role of protein phosphatase 2A in Drosophila development. Mayer–Jaekel RE, et al. **Semin Cancer Biol** 1995 Aug; 6(4):249–56
Regulation by tumour antigens defines a role for PP2A in signal transduction. Mumby M. **Semin Cancer Biol** 1995 Aug;6(4):229–37 (59 ref.)
Regulation of gene expression by serine/threonine protein phosphatases. Schönthal AH. **Semin Cancer Biol** 1995 Aug; 6(4):239–48 (102 ref.)

PHOSPHOPROTEIN PHOSPHOHYDROLASE see **PHOSPHOPROTEIN PHOSPHATASE**

PHOSPHOPROTEIN PP53 see **PROTEIN P53**

PHOSPHOPROTEINS

ADMINISTRATION & DOSAGE

Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. Harnish DC, et al. **J Biol Chem** 1996 Jun 7; 271(23):13621–8

ANALYSIS

Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumors. Böhling T, et al. **Am J Pathol** 1996 Feb; 148(2):367–73
Stoichiometry of p22–phox and gp91–phox in phagocyte cytochrome b558. Huang J, et al. **Biochemistry** 1995 Dec 26;34(51):16753–7
Plant and human neutrophil oxidative burst complexes contain immunologically related proteins. Dwyer SC, et al. **Biochim Biophys Acta** 1996 Mar 15;1289(2):231–7
The identification of the phosphorylated 150/160–kDa proteins of sarcoplasmic reticulum, their kinase and their association with the ryanodine receptor. Shoshan–Barmatz V, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):89–100
Trophic and protective actions of brain–derived neurotrophic factor on striatal DARPP–32–containing neurons in vitro. Nakao N, et al. **Brain Res Dev Brain Res** 1995 Dec 21; 90(1–2):92–101
Prognostic value of cadherin–associated molecules (alpha–, beta–, and gamma–catenins and p120cas) in bladder tumors. Shimazui T, et al. **Cancer Res** 1996 Sep 15;56(18):4154–8
Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Belmont LD, et al. **Cell** 1996 Feb 23;84(4):623–31
Molecular environment of ZO–1 in epithelial and non–epithelial cells. Howarth AG, et al. **Cell Motil Cytoskeleton** 1995;31(4):323–32
Antibody against phosphorylated proteins (MPM–2) recognizes mitotic microtubules in endosperm cells of higher plant Haemanthus. Smirnova EA, et al. **Cell Motil Cytoskeleton** 1995;31(1):34–44
Immunocytochemical study of microvilli in a gastric carcinoma–derived cell line. Kasami M, et al. **Cell Struct Funct** 1995 Aug;20(4):245–52
In situ hybridization shows Dmp1 (AG1) to be a developmentally regulated dentin–specific protein produced by mature odontoblasts. George A, et al. **Connect Tissue Res** 1995;33(1–3):67–72
Differential expression of nucleophosmin and stathmin in human T lymphoblastic cell lines, CCRF–CEM and JURKAT analyzed by two–dimensional gel electrophoresis. Nakamura K, et al. **Electrophoresis** 1995 Aug;16(8):1530–5
Mammalian homologue of the calcium–sensitive phosphoglycoprotein, parafusin. Wyroba E, et al. **Eur J Cell Biol** 1995 Dec;68(4):419–26
Subcellular distribution and phosphorylation of the nuclear localization signal binding protein, NBP60. Kawahire S, et al. **Exp Cell Res** 1996 Feb 1;222(2):385–94
Components of the nucleolar processing complex (Pre–rRNA, fibrillarin, and nucleolin) colocalize during mitosis and are incorporated to daughter cell nucleoli. Medina FJ, et al. **Exp Cell Res** 1995 Nov;221(1):111–25
In situ localization of nucleolin in the plant nucleolar matrix. Minguez A, et al. **Exp Cell Res** 1996 Jan 10;222(1):171–8
Localization of 7H6 tight junction–associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. Satoh H, et al. **Exp Cell Res** 1996 Feb 1;222(2):269–74
Localization and expression of zonula occludens–1 tight junction–associated protein in baboon (Papio anubis) corpora lutea. Khan–Dawood FS, et al. **Hum Reprod** 1996 Jun;11(6):1262–7
Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. McKee MD, et al. **J Bone Miner Res** 1995 Dec; 10(12):1913–29
The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Derenzini M, et al. **Lab Invest** 1995 Oct;73(4):497–502
Identification of influenza C virus phosphoproteins. Nishimura H, et al. **Microbiol Immunol** 1995;39(9):737–40

ANTAGONISTS & INHIBITORS

Inhibition of cyclic GMP–dependent protein kinase–mediated effects by (Rp)–8–bromo–PET–cyclic GMPS. Butt E, et al. **Br J Pharmacol** 1995 Dec;116(8):3110–6
Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor–beta in mouse mammary epithelial cells. Woo PL, et al. **J Biol Chem** 1996 Jan 5;271(1):404–12
CD45 monoclonal antibodies inhibit TCR–mediated calcium signals, calmodulin–kinase IV/Gr activation, and oncoprotein 18 phosphorylation. Shivnan E, et al. **J Immunol** 1996 Jul 1;157(1):101–9

BIOSYNTHESIS

Nicotinamide inhibits IRF–1 mRNA induction and prevents IL–1 beta–induced nitric oxide synthase expression in pancreatic beta cells. Akabane A, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):524–30
Increased expression of insulin receptor substrate–1 in human pancreatic cancer. Bergmann U, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):886–90
The interferon–inducible growth–inhibitory p202 protein: DNA binding properties and identification of a DNA binding domain. Choubey D, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):396–401
Molecular cloning and in vivo expression of the bovine steroidogenic acute regulatory protein. Hartung S, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):646–53
Regulation of expression of the steroidogenic acute regulatory (StAR) protein by ACTH in bovine adrenal fasciculata cells. Nishikawa T, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):12–8
Cloning of a cDNA encoding a 190–kDa insulin receptor substrate–1–like protein of simian COS cells. Wang L, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):321–8
Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187–99 (309 ref.)
Stathmin gene expression in mammary gland and in Nb2 cells. Puissant C, et al. **Biol Cell** 1995;85(2–3):109–15
Steel factor induces serine phosphorylation of Stat3 in human growth factor–dependent myeloid cell lines. Gotoh A, et al. **Blood** 1996 Jul 1;88(1):138–45
Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Manie SN, et al. **Blood** 1996 Mar 1;87(5):1855–61
Retinoic acid activates interferon regulatory factor–1 gene expression in myeloid cells. Matikainen S, et al. **Blood** 1996 Jul 1;88(1):114–23
GAP–43 expression in the medulla of macaque monkeys: changes during postnatal development and the effects of early median nerve repair. Jain N, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):24–34
SCG10 expresses growth–associated manner in developing rat brain, but shows a different pattern to p19/stathmin or GAP–43. Sugiura Y, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):73–91
Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1–induced apoptosis. Tanaka S, et al. **Cancer Res** 1996 Aug 1;56(15):3391–4
Induction of stathmin expression during erythropoietic differentiation. Rabilloud T, et al. **Cell Growth Differ** 1995 Oct;6(10):1307–14
A skeleton in the atherosclerosis closet [editorial; comment] Demer LL. **Circulation** 1995 Oct 15;92(8):2029–32. Comment on: Circulation 1995 Oct 15;92(8):2163–8.
Osteopontin is expressed in human aortic valvular lesions [see comments] O'Brien KD, et al. **Circulation** 1995 Oct 15;92(8):2163–8. Comment in: Circulation 1995 Oct 15;92(8):2029–32.
Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. de Bri E, et al. **Clin Orthop** 1996 Sep;(330):251–60
Ezrin becomes restricted to outer cells following asymmetrical division in the preimplantation mouse embryo. Louvet S, et al. **Dev Biol** 1996 Aug 1;177(2):568–79
Expression of insulin receptor mRNA and insulin receptor substrate 1 in pancreatic islet beta–cells. Harbeck MC, et al. **Diabetes** 1996 Jun;45(6):711–7
Identification and characterization of three members of the human SR family of pre–mRNA splicing factors. Screaton GR, et al. **EMBO J** 1995 Sep 1;14(17):4336–49
Expression of the steroidogenic acute regulatory (StAR) protein: a novel LH–induced mitochondrial protein required for the acute regulation of steroidogenesis in mouse Leydig tumor cells. Clark BJ, et al. **Endocr Res** 1995 Feb–May;21(1–2):243–57
Diethylumbelliferyl phosphate inhibits steroidogenesis by interfering with a long–lived factor acting between protein kinase A activation and induction of the steroidogenic acute regulatory protein (StAR). Choi YS, et al. **Eur J Biochem** 1995 Dec 1;234(2):680–5
Growth and cell density–dependent expression of stathmin in C2 myoblasts in culture. Balogh A, et al. **Exp Cell Res** 1996 Apr 10;224(1):8–15
Suppression of superoxide anion production by interleukin–10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. Kuga S, et al. **Exp Hematol** 1996 Feb;24(2):151–7
Characterization of proteins phosphorylated by the cAMP–dependent protein kinase of bovine heart mitochondria. Sardanelli AM, et al. **FEBS Lett** 1995 Dec 27;377(3):470–4
Osteopontin expression detected in adult cochleae and inner ear fluids. Lopez CA, et al. **Hear Res** 1995 May; 85(1–2):210–22
Induction of heat shock protein 70 and nucleolin and their intracellular distribution during early stage of liver regeneration. Konishi T, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1170–7
Molecular cloning and developmental expression of mouse p130, a member of the retinoblastoma gene family. Chen G, et al. **J Biol Chem** 1996 Apr 19;271(16):9567–72
The major astrocytic phosphoprotein PEA–15 is encoded by two mRNAs conserved on their full length in mouse and human. Estellés A, et al. **J Biol Chem** 1996 Jun 21; 271(25):14800–6
Formation of STAT1–STAT2 heterodimers and their role in the activation of IRF–1 gene transcription by interferon–alpha. Li X, et al. **J Biol Chem** 1996 Mar 8; 271(10):5790–4
The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation–induced phosphoproteins that target PP2A to both nucleus and cytoplasm. McCright B, et al. **J Biol Chem** 1996 Sep 6;271(36):22081–9
Neoplastic transformation induced by insulin receptor substrate–1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. Tanaka S, et al. **J Biol Chem** 1996 Jun 14;271(24):14610–6
Regulation of the herpesvirus saimiri oncogene stpC, similar to that of T–cell activation genes, in growth–transformed human T lymphocytes. Fickenscher H, et al. **J Virol** 1996

Sep;70(9):6012–9
Inducible expression of the P, V, and NP genes of the paramyxovirus simian virus 5 in cell lines and an examination of NP–P and NP–V interactions. Precious B, et al. **J Virol** 1995 Dec;69(12):8001–10
Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Ito T, et al. **Mol Cell Biol** 1996 Mar;16(3):943–51
E2F–4 switches from p130 to p107 and pRB in response to cell cycle reentry. Moberg K, et al. **Mol Cell Biol** 1996 Apr;16(4):1436–49
Re-emergence of GAP–43 in cochlear nucleus and superior olive following cochlear ablation in the rat. Illing RB, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):9–12
B–50 (GAP–43) in the rat spinal cord caudal to hemisection: lack of intraspinal sprouting by dorsal root axons. Nacimiento W, et al. **Neurosci Lett** 1995 Jul 14; 194(1–2):13–6
Distribution of messenger RNAs for D1 dopamine receptors and DARPP–32 in striatum and cerebral cortex of the cynomolgus monkey: relationship to D1 dopamine receptors. Brené S, et al. **Neuroscience** 1995 Jul;67(1):37–48
Cold calcium signaling in Arabidopsis involves two cellular pools and a change in calcium signature after acclimation. Knight H, et al. **Plant Cell** 1996 Mar;8(3):489–503
Multiple serine phosphorylation sites on the 30 kDa TMV cell–to–cell movement protein synthesized in tobacco protoplasts. Haley A, et al. **Plant J** 1995 Nov;8(5):715–24
Histamine, ZO–1 and increased blood–retinal barrier permeability in diabetic retinopathy. Gardner TW. **Trans Am Ophthalmol Soc** 1995;93:583–621
Spot synthesis of overlapping peptides on paper membrane supports enables the identification of linear monoclonal antibody binding determinants on morbillivirus phosphoproteins. Martens W, et al. **Vet Microbiol** 1995 May;44(2–4):289–98
293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein. Langer SJ, et al. **Virology** 1996 Jul 1;221(1):172–9

BLOOD

Hyperphosphorylated p47–phox lost the ability to activate NADPH oxidase in guinea pig neutrophils. Yamaguchi M, et al. **Biochem Biophys Res Commun** 1995 Nov 2; 216(1):203–8
Wortmannin inhibits store–mediated calcium entry and protein tyrosine phosphorylation in human platelets. Jenner S, et al. **FEBS Lett** 1996 Mar 4;381(3):249–51
Lymphocyte isoforms of mouse p50 LSP1, which are phosphorylated in mitogen–activated T cells, are formed through alternative splicing and phosphorylation. Matsumoto N, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):237–43
Assembly of the human neutrophil NADPH oxidase involves binding of p67phox and flavocytochrome b to a common functional domain in p47phox. De Leo FR, et al. **J Biol Chem** 1996 Jul 19;271(29):17013–20
FcgammaRII–mediated adhesion and phagocytosis induce L–plastin phosphorylation in human neutrophils. Jones SL, et al. **J Biol Chem** 1996 Jun 14;271(24):14623–30
A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase. Kawakatsu H, et al. **J Biol Chem** 1996 Mar 8;271(10):5680–5
Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. Chao W, et al. **J Clin Invest** 1995 Dec;96(6):2654–60
Detection of human cytomegalovirus myocardial involvement by polymerase chain reaction during systemic infection and correlation with pp65 antigenemia and DNAemia in infected heart recipients. Ghisetti V, et al. **Transplantation** 1996 Apr 15;61(7):1072–5
Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus–free recipients of livers from seropositive donors. Grossi P, et al. **Transplantation** 1996 Jun 15; 61(11):1659–60
CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation. Iberer F, et al. **Wien Klin Wochenschr** 1995;107(23):718–22

CHEMICAL SYNTHESIS

Synthetic Tyr–phospho and non–hydrolyzable phosphonopeptides as PTKs and TC–PTP inhibitors. Ruzza P, et al. **Int J Pept Protein Res** 1995 Dec; 46(6):535–46

CHEMISTRY

Calcium destabilises Drosophila cactus protein and dephosphorylates the dorsal transcription factor. Kubota K, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1191–6
Alpha endosulfine is a novel molecule, structurally related to a family of phosphoproteins. Peyrollier K, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):583–6
Stimulation by chelerythrine of the phosphorylation of the amino acid serine in an approximately 20 kDa protein present in the mitochondrial fraction of the rat retina. Lombardini JB. **Biochem Pharmacol** 1996 Jul 26;52(2):253–7
Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C–terminal ezrin–radixin–moesin association domains. Bretscher A, et al. **Biochemistry** 1995 Dec 26;34(51):16830–7
Structure of the IRS–1 PTB domain bound to the juxtamembrane region of the insulin receptor. Eck MJ, et al. **Cell** 1996 May 31;85(5):695–705
A new family of regulators of G–protein–coupled receptors? Siderovski DP, et al. **Curr Biol** 1996 Feb 1;6(2):211–2
Novel topology of a zinc–binding domain from a protein involved in regulating early Xenopus development. Borden KL, et al. **EMBO J** 1995 Dec 1;14(23):5947–56
Identification and characterization of three members of the human SR family of pre–mRNA splicing factors. Screaton GR, et al. **EMBO J** 1995 Sep 1;14(17):4336–49
Conformational effects of serine phosphorylation in phospholamban peptides. Quirk PG, et al. **Eur J Biochem** 1996 Feb 15;236(1):85–91
Identification of a nucleolin binding site in human topoisomerase I. Bharti AK, et al. **J Biol Chem** 1996 Jan 26;271(4):1993–7
A major tyrosine–phosphorylated protein of Trypanosoma brucei is a nucleolar RNA–binding protein. Das A, et al. **J Biol Chem** 1996 Jun 28;271(26):15675–81
A functional phosphatidylinositol 3,4,5–trisphosphate/phosphoinositide binding domain in the clathrin adaptor AP–2 alpha subunit. Implications for the endocytic pathway. Gaidarov I, et al. **J Biol Chem** 1996 Aug 23;271(34):20922–9
Identification of p90, a prominent tyrosine–phosphorylated protein in fibroblast growth factor–stimulated cells, as 80K–H. Goh KC, et al. **J Biol Chem** 1996 Mar 8; 271(10):5832–8
The alpha chain of the AP–2 adaptor is a clathrin binding subunit. Goodman OB Jr, et al. **J Biol Chem** 1995 Oct 6;270(40):23768–73
Interaction of insulin receptor substrate–2 (IRS–2) with the insulin and insulin–like growth factor I receptors. Evidence for two distinct phosphotyrosine–dependent interaction domains within IRS–2. He W, et al. **J Biol Chem** 1996 May 17;271(20):11641–5
A novel 55–kDa regulatory subunit for phosphatidylinositol 3–kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. Inukai K, et al. **J Biol Chem** 1996 Mar 8;271(10):5317–20
The physical association of casein kinase 2 with nucleolin. Li D, et al. **J Biol Chem** 1996 Jun 28;271(26):15662–8
Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin. Maciejewski PM, et al. **J Biol Chem** 1995 Nov 17;270(46):27661–5
CD45 protein–tyrosine phosphatase associates with the WW domain–containing protein, CD45AP, through the transmembrane region. MCFarland ED, et al. **J Biol Chem** 1995 Nov 24;270(47):28103–7
Purification of a new clathrin assembly protein from bovine brain coated vesicles and its identification as myelin basic protein. Prasad K, et al. **J Biol Chem** 1995 Dec 22; 270(51):30551–6
PTB domains of IRS–1 and Shc have distinct but overlapping binding specificities. Wolf G, et al. **J Biol Chem** 1995 Nov 17;270(46):27407–10
Mapping and functional role of phosphorylation sites in the thyroid transcription factor–1 (TTF–1). Zannini M, et al. **J Biol Chem** 1996 Jan 26;271(4):2249–54
Characterization of multiply phosphorylated peptides selectively precipitated from a pancreatic casein digest. Adamson NJ, et al. **J Dairy Sci** 1995 Dec;78(12):2653–9
Characterization and purification of a protein kinase C substrate in human B cells. Identification as lymphocyte–specific protein 1 (LSP1). Carballo E, et al. **J Immunol** 1996 Mar 1;156(5):1709–13
The C–terminal SH3 domain of p67phox binds its natural ligand in a reverse orientation. Finan P, et al. **J Mol Biol** 1996 Aug 16;261(2):173–80
Use of tyrosine–phosphorylated proteins to screen bacterial expression libraries for SH2 domains. Margolis B, et al. **Methods Enzymol** 1995;255:360–9
Ezrin self–association involves binding of an N–terminal domain to a normally masked C–terminal domain that includes the F–actin binding site. Gary R, et al. **Mol Biol Cell** 1995 Aug;6(8):1061–75
Structural basis of cyclin–dependent kinase activation by phosphorylation. Russo AA, et al. **Nat Struct Biol** 1996 Aug;3(8):696–700
Structural basis for IL–4 receptor phosphopeptide recognition by the IRS–1 PTB domain. Zhou MM, et al. **Nat Struct Biol** 1996 Apr;3(4):388–93
Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH–PTP2. Eck MJ, et al. **Nature** 1996 Jan 18;379(6562):277–80
Structure of the WW domain of a kinase–associated protein complexed with a proline–rich peptide. Macias MJ, et al. **Nature** 1996 Aug 15;382(6592):646–9
The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac–specific and rho–specific guanine nucleotide exchange factor domains. Debant A, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5466–71
Phosphorylation–dependent conformational changes in OmpR, an osmoregulatory DNA–binding protein of Escherichia coli. Kenney LJ, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8866–70
Inhibition of G–protein betagamma–subunit functions by phosducin–like protein. Schröder S, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2100–4
Paramyxovirus phosphoproteins form homotrimers as determined by an epitope dilution assay, via predicted coiled coils. Curran J, et al. **Virology** 1995 Dec 1; 214(1):139–49
Biochemical characterization and localization of JC virus large T antigen phosphorylation domains. Swenson JJ, et al. **Virology** 1995 Oct 1;212(2):295–308

DEFICIENCY

Ornithine decarboxylase induction during liver regeneration in IRS–1–deficient mice. Furusaka A, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):284–90
Protein phosphorylation in neutrophils from patients with p67–phox–deficient chronic granulomatous disease. Heyworth PG, et al. **Blood** 1996 May 15;87(10):4404–10
Hypoxic induction of gene expression in chronic granulomatous disease–derived B–cell lines: oxygen sensing is independent of the cytochrome b558–containing nicotinamide adenine dinucleotide phosphate oxidase. Wenger RH, et al. **Blood** 1996 Jan 15;87(2):756–61
A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Taylor GA, et al. **Immunity** 1996 May;4(5):445–54
4PS/insulin receptor substrate (IRS)–2 is the alternative substrate of the insulin receptor in IRS–1–deficient mice. Patti ME, et al. **J Biol Chem** 1995 Oct 20;270(42):24670–3
Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation. Schubart UK, et al. **J Biol Chem** 1996 Jun 14; 271(24):14062–6
Insulin signalling and insulin actions in the muscles and livers of insulin–resistant, insulin receptor substrate 1–deficient mice. Yamauchi T, et al. **Mol Cell Biol** 1996 Jun; 16(6):3074–84

DRUG EFFECTS

Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA–1 cells treated with modified citrus pectin. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):833–41

GENETICS

Cell proliferation–dependent expression of two isoforms of the nucleolar phosphoprotein p130. Pai CY, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):581–7
Molecular cloning of a novel macrophage maturation–associated transcript encoding a protein with several potential transmembrane domains. Rehli M, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):661–7
Chicken acidic ribosomal phosphoprotein PO: isolation and molecular characterization of cDNA clones. Wang H, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):595–604
Structure of the human steroidogenic acute regulatory protein (StAR) gene: StAR stimulates mitochondrial cholesterol 27–hydroxylase activity. Sugawara T, et al. **Biochemistry** 1995 Oct 3;34(39):12506–12
Steroidogenic factor 1–dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene. Sugawara T, et al. **Biochemistry** 1996 Jul 16;35(28):9052–9
The human steroidogenic acute regulatory (StAR) gene is expressed in the urogenital system and encodes a mitochondrial polypeptide. Gradi A, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):228–33
Two–exon skipping due to a point mutation in p67–phox–deficient chronic granulomatous disease. Aoshima M, et al. **Blood** 1996 Sep 1;88(5):1841–5
Mutations in the X–linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)
Functional analysis of pRb2/p130 interaction with cyclins. Claudio PP, et al. **Cancer Res** 1996 May 1;56(9):2003–8
MADR2 maps to 18q21 and encodes a TGFbeta–regulated MAD–related protein that is functionally mutated in colorectal carcinoma. Eppert K, et al. **Cell** 1996 Aug 23; 86(4):543–52
The human p62 cDNA encodes Sam68 and not the RasGAP–associated p62 protein. Lock P, et al. **Cell** 1996 Jan 12;84(1):23–4
Transcriptional regulation of phosphoprotein p18 during monocytic differentiation of U937 leukemic cells. Mistry S, et al. **Cell Mol Biol Res** 1995;41(2):103–10
Fine mapping of the autosomal recessive retinitis pigmentosa locus (RP12) on chromosome 1q; exclusion of the phosducin gene (PDC). van Soest S, et al. **Cytogenet Cell Genet** 1996;73(1–2):81–5
Human insulin receptor substrate–1: variant sequences in familial non–insulin–dependent diabetes mellitus. Armstrong M, et al. **Diabet Med** 1996 Feb;13(2):133–8
No association between the Gly971Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population. Chuang LM, et al. **Diabetes Care** 1996 May; 19(5):446–9
Molecular scanning of the insulin receptor substrate–1 (IRS–1) gene in Japanese patients with NIDDM: identification of five novel polymorphisms. Ura S, et al. **Diabetologia** 1996 May;39(5):600–8
The conserved amino–terminal domain of hSRP1 alpha is

essential for nuclear protein import. Weis K, et al. **EMBO J** 1996 Apr 15;15(8):1818–25

Functional dissection of the mouse Hox-a5 gene. Zhao JJ, et al. **EMBO J** 1996 Mar 15;15(6):1313–22

Decreased stathmin expression does not affect the actions of human choriogonadotropin or epidermal growth factor in Leydig tumor cells. Hoelscher SR, et al. **Endocrinology** 1995 Nov;136(11):5004–13

Hormonal regulation of messenger ribonucleic acid encoding steroidogenic acute regulatory protein in ovine corpora lutea. Juengel JL, et al. **Endocrinology** 1995 Dec; 136(12):5423–9

Steroid production after in vitro transcription, translation, and mitochondrial processing of protein products of complementary deoxyribonucleic acid for steroidogenic acute regulatory protein. King SR, et al. **Endocrinology** 1995 Nov;136(11):5165–76

The Drosophila tamou gene, a component of the activating pathway of extramacrochaetae expression, encodes a protein homologous to mammalian cell–cell junction–associated protein ZO–1. Takahisa M, et al. **Genes Dev** 1996 Jul 15;10(14):1783–95

Mapping of the human dentin matrix acidic phosphoprotein gene (DMP1) to the dentinogenesis imperfecta type II critical region at chromosome 4q21. Aplin HM, et al. **Genomics** 1995 Nov 20;30(2):347–9

Chromosome localization of human genes for clathrin adaptor polypeptides AP2 beta and AP50 and the clathrin–binding protein, VCP. Druck T, et al. **Genomics** 1995 Nov 1;30(1):94–7

The gene encoding p120cas, a novel catenin, localizes on human chromosome 11q11 (CTNND) and mouse chromosome 2 (Catns). Reynolds AB, et al. **Genomics** 1996 Jan 1;31(1):127–9

Polymorphism in and localization of the gene LCP2 (SLP–76) to chromosome 5q33.1–qter. Sunden SLF, et al. **Genomics** 1996 Jul 1;35(1):269–70

Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post–synaptic membrane. Sadoulet–Puccio HM, et al. **Hum Mol Genet** 1996 Apr;5(4):489–96

T–>A transversion 11 bp from a splice acceptor site in the human gene for steroidogenic acute regulatory protein causes congenial lipoid adrenal hyperplasia. Tee MK, et al. **Hum Mol Genet** 1995 Dec;4(12):2299–305

Deletion of Gly723 in the insulin receptor substrate–1 of a patient with noninsulin–dependent diabetes mellitus. Esposito DL, et al. **Hum Mutat** 1996;7(4):364–6

Identification of a donor splice site mutation leading to loss of p22–phox exon 5 in autosomal chronic granulomatous disease. Porter CD, et al. **Hum Mutat** 1996;7(4):374

p150TSP, a conserved nuclear phosphoprotein that contains multiple tetratricopeptide repeats and binds specifically to SH2 domains. Malek SN, et al. **J Biol Chem** 1996 Mar 22;271(12):6952–62

Comparison of the rat nucleolar protein nopp140 with its yeast homolog SRP40. Differential phosphorylation in vertebrates and yeast. Meier UT. **J Biol Chem** 1996 Aug 9;271(32):19376–84

Purification, cloning, and expression of a novel, endogenous, calcium–sensitive, 28–kDa phosphoprotein. Parente JA, et al. **J Biol Chem** 1996 Aug 16;271(33):20096–101

Sequence determination of an extremely acidic rat dentin phosphoprotein. Ritchie HH, et al. **J Biol Chem** 1996 Sep 6;271(36):21695–8

Insulin receptor substrate–2 binds to the insulin receptor through its phosphotyrosine–binding domain and through a newly identified domain comprising amino acids 591–786. Sawka–Verhelle D, et al. **J Biol Chem** 1996 Mar 15; 271(11):5980–3

Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation. Schubart UK, et al. **J Biol Chem** 1996 Jun 14; 271(24):14062–6

Xenopus laevis actin–depolymerizing factor/cofilin: a phosphorylation–regulated protein essential for development. Abe H, et al. **J Cell Biol** 1996 Mar; 132(5):871–85

Mad1p, a phosphoprotein component of the spindle assembly checkpoint in budding yeast. Hardwick KG, et al. **J Cell Biol** 1995 Nov;131(3):709–20

Identification and cDNA cloning of a Xenopus nucleolar phosphoprotein, xNopp180, that is the homolog of the rat nucleolar protein Nopp140. Cairns C, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3339–47

Codon 972 polymorphism in the insulin receptor substrate–1 gene, obesity, and risk of noninsulin–dependent diabetes mellitus. Sigal RJ, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1657–9

A common amino acid polymorphism in insulin receptor substrate–1 causes impaired insulin signaling. Evidence from transfection studies. Almind K, et al. **J Clin Invest** 1996 Jun 1;97(11):2569–75

Expression of the steroidogenic acute regulatory protein mRNA in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Endocrinol** 1996 Jul;150(1):43–50

The phosphoprotein gene of a dolphin morbillivirus isolate exhibits genomic variation at the editing site. Bolt G, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3051–8

Identification and characterization of BICP27, an early protein of bovine herpesvirus 1 which may stimulate mRNA 3' processing. Singh M, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):615–25

Differential dysregulation of nitric oxide production in macrophages with targeted disruptions in IFN regulatory factor–1 and –2 genes. Salkowski CA, et al. **J Immunol** 1996 May 1;156(9):3107–10

Differential–display polymerase chain reaction identifies nucleophosmin as an estrogen–regulated gene in human vascular smooth muscle cells. Koike H, et al. **J Vasc Surg** 1996 Mar;23(3):477–82

Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC–MSB1 MDV–transformed lymphoblastoid cells. Xie Q, et al. **J Virol** 1996 Feb;70(2):1125–31

Two forms of Xenopus nuclear factor 7 have overlapping spatial but different temporal patterns of expression during development. Gong SG, et al. **Mech Dev** 1995 Aug; 52(2–3):305–18

Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Drewes T, et al. **Mol Cell Biol** 1996 Mar;16(3):925–31

Growth factor–induced tyrosine phosphorylation of Hrs, a novel 115–kilodalton protein with a structurally conserved putative zinc finger domain. Komada M, et al. **Mol Cell Biol** 1995 Nov;15(11):6213–21

TFIIB–directed transcriptional activation by the orphan nuclear receptor hepatocyte nuclear factor 4. Malik S, et al. **Mol Cell Biol** 1996 Apr;16(4):1824–31

Inhibition of cell proliferation by the Mad1 transcriptional repressor. Roussel MF, et al. **Mol Cell Biol** 1996 Jun; 16(6):2796–801

Characterization and regulation of the mouse insulin receptor substrate gene promoter. Araki E, et al. **Mol Endocrinol** 1995 Oct;9(10):1367–79

Characterization of a dominant negative mutant form of the HNF–4 orphan receptor. Taylor DG, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):2930–5

Expression of the receptor tyrosine kinase substrate genes eps8 and eps15 during mouse development. Avantaggiato V, et al. **Oncogene** 1995 Sep 21;11(6):1191–8

Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Ishino M, et al. **Oncogene** 1995 Dec 7;11(11):2331–8

Cloning and expression of the Rb–related mouse p130 mRNA. LeCouter JE, et al. **Oncogene** 1996 Apr 4; 12(7):1433–40

Analysis of phosducin as a candidate gene for retinopathies. Ara–Iwata F, et al. **Ophthalmic Genet** 1996 Mar;17(1):3–14

Characterization of a maize ribosomal P2 protein cDNA and phylogenetic analysis of the P1/P2 family of ribosomal proteins. Goddemeier ML, et al. **Plant Mol Biol** 1996 Feb; 30(3):655–8

Genomic structure of the human retinoblastoma–related Rb2/p130 gene. Baldi A, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4629–32

GAIP, a protein that specifically interacts with the trimeric G protein G alpha i3, is a member of a protein family with a highly conserved core domain. De Vries L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11916–20

Molecular cloning of a protein kinase whose phosphorylation is regulated by genetic adhesion during Chlamydomonas fertilization. Kurvari V, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):39–43

Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Pande H, et al. **Scand J Infect Dis Suppl** 1995;99:117–20

Editing of morbillivirus P gene transcripts in infected animals. Haas L, et al. **Vet Microbiol** 1995 May;44(2–4):299–306

Synthesis of leader RNA and editing of P mRNA during transcription by rinderpest virus. Ghosh A, et al. **Virus Res** 1996 Mar;41(1):69–76

IMMUNOLOGY

The expression of acidic ribosomal phosphoproteins on the surface membrane of different tissues in autoimmune and normal mice which are the target molecules for anti–double–stranded DNA antibodies. Sun KH, et al. **Immunology** 1996 Mar;87(3):362–71

High–level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow–up. Bek B, et al. **J Clin Microbiol** 1996 Feb;34(2):457–9

Identification of an 85 kDa phosphoprotein as an immunodominant protein specific for human herpesvirus 7–infected cells. Foà–Tomasi L, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):511–8

Recombinant ribosomal P2 protein can unmask anti–ribosomal P autoantibodies from healthy adults. Pan ZJ, et al. **J Lab Clin Med** 1996 Apr;127(4):333–9

Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. Yoshio T, et al. **J Rheumatol** 1995 Sep;22(9):1681–7

Application of a monoclonal antibody recognizing protein p30 to detect African swine fever virus–infected cells in peripheral blood. Ramiro–Ibáñez F, et al. **J Virol Methods** 1995 Nov;55(3):339–45

Immunodominant RNA recognition motifs of human nucleolin/C23. Valdez BC, et al. **Mol Immunol** 1995 Nov; 32(16):1207–13

ISOLATION & PURIFICATION

Chicken acidic ribosomal phosphoprotein PO: isolation and molecular characterization of cDNA clones. Wang H, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):595–604

Characterization and identification of a human dentin phosphophoryn. Chang SR, et al. **Calcif Tissue Int** 1996 Sep;59(3):149–53

Rice gibberellin–binding phosphoprotein structurally related to ribulose–1,5–bisphosphate carboxylase/oxygenase activase. Komatsu S, et al. **FEBS Lett** 1996 Apr 15; 384(2):167–71

Purification of a new clathrin assembly protein from bovine brain coated vesicles and its identification as myelin basic protein. Prasad K, et al. **J Biol Chem** 1995 Dec 22; 270(51):30551–6

A highly specific and sensitive monoclonal antibody detecting histidine–tagged recombinant proteins. Pogge von Strandmann E, et al. **Protein Eng** 1995 Jul;8(7):733–5

METABOLISM

Nitroprusside inhibits serotonin–induced mitogenesis and tyrosine phosphorylation of smooth muscle cells. Lee SL, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L362–7

Differential whole–cell extract preparation and electrophoretic mobility shift assay to evaluate the effect of tyrosine phosphatases on DNA binding activity of transcription factors. Nakshatri H, et al. **Anal Biochem** 1996 Apr 5;236(1):178–81

Agents that promote protein phosphorylation increase catecholamine secretion and inhibit the activity of the Na(+)–Ca2+ exchanger in bovine chromaffin cells. Lin LF, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:395–6

A 115 kDa tyrosine phosphorylated protein associates with Grb–2 in activated Jurkat cells. Meisner H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:204–5

Common and distinct elements in insulin and PDGF signaling. Myers MG Jr, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:369–87

Cytokine regulation of ezrin expression in the human colon cancer cell line HT29. Jiang WG, et al. **Anticancer Res** 1996 Mar–Apr;16(2):861–5

Extracellular zinc ions induces mitogen–activated protein kinase activity and protein tyrosine phosphorylation in bombesin–sensitive Swiss 3T3 fibroblasts. Hansson A. **Arch Biochem Biophys** 1996 Apr 15;328(2):233–8

Molecular cloning and characterization of a novel casein kinase II substrate, HASPP28, from rat brain. Shen L, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):131–41

Respiratory burst and tyrosine phosphorylation by vanadate. Yamaguchi M, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):382–6

Dephosphorylation of a 30–kDa protein of fowl spermatozoa by the addition of myosin light chain kinase substrate peptide inhibits the flagellar motility. Ashizawa K, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):706–12

The liver–specific response to phenobarbital involves a transient increase in phosphorylation of a 34–kda nuclear protein in rat liver and in hepatocytes in culture. Baffet G, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):947–56

Cell cycle phase–dependent changes of localization and oligomerization states of nucleophosmin / B23. Chou YH, et al. **Biochem Biophys Res Commun** 1995 Dec 5; 217(1):313–25

G–protein and tyrosine kinase receptor cross–talk in rat aortic smooth muscle cells: thrombin– and angiotensin II–induced tyrosine phosphorylation of insulin receptor substrate–1 and insulin–like growth factor 1 receptor. Du J, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):934–9

Translocation of p190rho guanosine triphosphatase–activating protein from cytosol to the membrane in human neutrophils stimulated with different agonists. Dusi S, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):859–62

Src kinase plays an essential role in integrin–mediated tyrosine phosphorylation of Crk–associated substrate p130Cas. Hamasaki K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):338–43

Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor/scatter factor. Jiang WG, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1062–9

Induction of CD38/NADase and its monoclonal antibody–induced tyrosine phosphorylation in human leukemia cell lines. Kontani K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):466–71

Calcium destabilises Drosophila cactus protein and dephosphorylates the dorsal transcription factor. Kubota K, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1191–6

Identification of a rapidly dephosphorylating 95–kDa protein as elongation factor 2 during 8–Br–cAMP treatment of N1E115 neuroblastoma cells. Li H, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):131–7

Differential regulation of insulin–stimulated tyrosine phosphorylation of IRS–1 and SHC by Wortmannin in intact cells. Li PM, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):80–4

Suc1–associated neurotrophic factor target (SNT) protein is

a major FGF-stimulated tyrosine phosphorylated 90-kDa protein which binds to the SH2 domain of GRB2. Ong SH, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):1021-6

Attenuation of p47phox and p67phox membrane translocation as the inhibitory mechanism of S-nitrosothiol on the respiratory burst oxidase in human neutrophils. Park JW. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):31-5

MEKA/phosducin attenuates hydrophobicity of transducin beta gamma subunits without binding to farnesyl moiety. Tanaka H, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):587-91

GTP, a nonsubstrate of ATP citrate lyase, is a phosphodonor for the enzyme histidine autophosphorylation. Tuháčková Z, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):61-6

Involvement of several protein kinases in the phosphorylation of p47-phox. Yamaguchi M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):891-5

Both rapamycin-sensitive and -insensitive pathways are involved in the phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in response to insulin in rat epididymal fat-cells. Diggle TA, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):447-53

Mechanisms of NADPH oxidase activation: translocation of p40phox, Rac1 and Rac2 from the cytosol to the membranes in human neutrophils lacking p47phox or p67phox. Dusi S, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):409-12

Protein phosphatase and kinase activities possibly involved in exocytosis regulation in Paramecium tetraurelia. Kissmehl R, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):65-76

Insulin and insulin-like growth factor-1 stimulate dephosphorylation of paxillin in parallel with focal adhesion kinase. Konstantopoulos N, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):387-90

Binding of the proline-rich region of the epithelial Na+ channel to SH3 domains and its association with specific cellular proteins. McDonald FJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):491-7

Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Saad MJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):741-4

Focal adhesion kinase (p125FAK) and paxillin are substrates for sphingomyelinase-induced tyrosine phosphorylation in Swiss 3T3 fibroblasts. Sasaki T, et al. **Biochem J** 1996 May 1;315 (Pt 3):1035-40

Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. Schnyder B, et al. **Biochem J** 1996 May 1;315 (Pt 3):767-74

Interactions between cytosolic components of the NADPH oxidase: p40phox interacts with both p67phox and p47phox. Wientjes FB, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):919-24

Correlation of altered tyrosine phosphorylation with methotrexate resistance in a cisplatin-resistant subline of L1210 cells. Bhushan A, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):477-82

The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35-8 (26 ref.)

Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. Londos C, et al. **Biochem Soc Trans** 1995 Aug;23(3):611-5 (16 ref.)

Phosphorylation mechanism of nucleoside diphosphate kinase: 31P-nuclear magnetic resonance studies. Lecroisey A, et al. **Biochemistry** 1995 Sep 26;34(38):12445-50

Melanoma growth stimulatory activity signaling through the class II interleukin-8 receptor enhances the tyrosine phosphorylation of Crk-associated substrate, p130, and a 70-kilodalton protein. Schraw W, et al. **Biochemistry** 1995 Oct 24;34(42):13760-7

Cyclic AMP-dependent phosphoprotein components I and II interact with beta gamma subunits of transducin in frog rod outer segments. Suh KH, et al. **Biochemistry** 1996 Jan 9;35(1):290-8

Recovery from acute challenge with noradrenaline, vasopressin and angiotensin II in isolated rat hepatocytes. Aggarwal SR, et al. **Biochim Biophys Acta** 1996 Feb 29; 1310(3):284-92

Topological organization of the cytosolic activating complex of the superoxide-generating NADPH-oxidase. Pinpointing the sites of interaction between p47phox, p67phox and p40phox using the two-hybrid system. Fuchs A, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):39-47

Modulation of the skeletal muscle ryanodine receptor by endogenous phosphorylation of 160/150-kDa proteins of the sarcoplasmic reticulum. Orr I, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):80-8

The identification of the phosphorylated 150/160-kDa proteins of sarcoplasmic reticulum, their kinase and their association with the ryanodine receptor. Shoshan-Barmatz V, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):89-100

In isolated human centrosomes, the associated kinases phosphorylate a specific subset of centrosomal proteins. Keryer G, et al. **Biol Cell** 1995;84(3):155-65

Protein phosphorylation in neutrophils from patients with p67-phox-deficient chronic granulomatous disease. Heyworth PG, et al. **Blood** 1996 May 15;87(10):4404-10

The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R gamma chain is involved in interleukin-13-mediated signal transduction. Wang LM, et al. **Blood** 1995 Dec 1;86(11):4218-27

Tyrosine phosphorylation of 100-130 kDa proteins in lung cancer correlates with poor prognosis. Nishimura M, et al. **Br J Cancer** 1996 Sep;74(5):780-7

Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Fischer T, et al. **Br J Haematol** 1996 Mar;92(3):595-603

Extracellular processing of dentin matrix protein in the mineralizing odontoblast culture. Satoyoshi M, et al. **Calcif Tissue Int** 1995 Sep;57(3):237-41

Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Sel S, et al. **Cancer Lett** 1996 Mar 29;101(2):205-10

BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Chen Y, et al. **Cancer Res** 1996 Jul 15; 56(14):3168-72

Characterization of the M(r) 65,000 lymphokine-activated killer proteins phosphorylated after tumor target binding: evidence that pp65a and pp65b are phosphorylated forms of L-plastin. Frederick MJ, et al. **Cancer Res** 1996 Jan 1;56(1):138-44

Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Jeha S, et al. **Cancer Res** 1996 Mar 15;56(6):1445-50

Identification of murine p120 isoforms and heterogeneous expression of p120cas isoforms in human tumor cell lines. Mo YY, et al. **Cancer Res** 1996 Jun 1;56(11):2633-40

GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits. Berman DM, et al. **Cell** 1996 Aug 9;86(3):445-52

Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Eck MJ, et al. **Cell** 1996 May 31;85(5):695-705

Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Rameh LE, et al. **Cell** 1995 Dec 1;83(5):821-30

Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Kiess M, et al. **Cell Growth Differ** 1995 Oct; 6(10):1287-98

A kinase/phosphatase system involving the protooncogene Lck is necessary for inducible modulation of Sob 1 during T cell activation. Benson BA, et al. **Cell Immunol** 1996 Jun 15;170(2):245-50

A 56,000 Mr phosphoseryl protein in PC12 cell lysates strongly associates with protein-A sepharose beads and was observed in immune complex kinase assays for PP60c-src. Buensuceso C, et al. **Cell Signal** 1995 Nov;7(8):765-71

Comparison between the distribution of 7H6 tight junction-associated antigen and occludin during the development of chick intestine. Kimura M, et al. **Cell Struct Funct** 1996 Feb;21(1):91-6

Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. Draijer R, et al. **Circ Res** 1995 Nov;77(5):897-905

Role of the regulatory domain of the EGF-receptor cytoplasmic tail in selective binding of the clathrin-associated complex AP-2. Boll W, et al. **Curr Biol** 1995 Oct 1;5(10):1168-78

Insulin-like growth factor-I promotes cell proliferation in the absence of modulation of collagen phenotypes and utilizes IRS-1, not PLC-gamma 1, in corneal endothelial cells. Choi SH, et al. **Curr Eye Res** 1995 Aug;14(8):669-76

Novel adapter proteins that link the human GM-CSF receptor to the phosphatidylino-sitol 3-kinase and Shc/Grb2/ras signaling pathways. Jücker M, et al. **Curr Top Microbiol Immunol** 1996;211:67-75

Mesoderm and endoderm differentiation in animal cap explants: identification of the HNF4-binding site as an activin A responsive element in the Xenopus HNF1alpha promoter. Weber H, et al. **Development** 1996 Jun; 122(6):1975-84

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Beretta L, et al. **EMBO J** 1996 Feb 1;15(3):658-64

Multiple SH3 domain interactions regulate NADPH oxidase assembly in whole cells. de Mendez I, et al. **EMBO J** 1996 Mar 15;15(6):1211-20

A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains. Goppelt A, et al. **EMBO J** 1996 Jun 17;15(12):3105-16

Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. Haghighat A, et al. **EMBO J** 1995 Nov 15;14(22):5701-9

A pathogenic bacterium triggers epithelial signals to form a functional bacterial receptor that mediates actin pseudopod formation. Rosenshine I, et al. **EMBO J** 1996 Jun 3;15(11):2613-24

The conserved amino-terminal domain of hSRP1 alpha is essential for nuclear protein import. Weis K, et al. **EMBO J** 1996 Apr 15;15(8):1818-25

Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Carvalho CR, et al. **Endocrinology** 1996 Jan;137(1):151-9

Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Chow JC, et al. **Endocrinology** 1996 Jul; 137(7):2880-6

Identification by mutation of the tyrosine residues in the insulin receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinase. Rocchi S, et al. **Endocrinology** 1995 Dec;136(12):5291-7

A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn. Agostinis P, et al. **Eur J Biochem** 1996 Mar 1; 236(2):548-57

CTBP1/RBP1, a Saccharomyces cerevisiae protein which binds to T-rich single-stranded DNA containing the 11-bp core sequence of autonomously replicating sequence, is a poly(deoxypyrimidine)-binding protein. Ikeda M, et al. **Eur J Biochem** 1996 May 15;238(1):38-47

Depolarization-induced tyrosine phosphorylation of paxillin in PC12h cells. Khan MA, et al. **Eur J Biochem** 1996 Feb 1;235(3):579-84

Calcium-activated opsin phosphatase activity in retinal rod outer segments. Kutuzov MA, et al. **Eur J Biochem** 1996 Jun 15;238(3):613-22

C23 interacts with B23, a putative nucleolar-localization-signal-binding protein. Li YP, et al. **Eur J Biochem** 1996 Apr 1;237(1):153-8

Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Bouillie S, et al. **Eur J Immunol** 1995 Sep;25(9):2661-7

Fertilization in Dictyostelium: pharmacological analyses and the presence of a substrate protein suggest protein kinase C is essential for gamete fusion. Gunther KE, et al. **Exp Cell Res** 1995 Oct;220(2):325-331

Tissue-specific posttranslational modification of the small heat shock protein HSP27 in Drosophila. Marin R, et al. **Exp Cell Res** 1996 Feb 25;223(1):1-8

Development of the blood-retinal barrier in vitro: formation of tight junctions as revealed by occludin and ZO-1 correlates with the barrier function of chick retinal pigment epithelial cells. Konari K, et al. **Exp Eye Res** 1995 Jul; 61(1):99-108

Erythropoietin stimulates phosphorylation of eIF-4E and identification of a 37-kD phosphoprotein that binds mRNA caps in erythroblasts. Bu X, et al. **Exp Hematol** 1996 Feb; 24(3):423-8

Partial reconstitution of the respiratory burst oxidase in lymphoblastoid B cell lines lacking p67-phox after transfection with an expression vector containing wild-type and mutant p67 -phox cDNAs: Deletions of the carboxy and amino terminal residues of p67-phox are not required for activity. Chanock SJ, et al. **Exp Hematol** 1996 Mar; 24(4):531-6

p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Salgia R, et al. **Exp Hematol** 1996 Feb; 24(2):310-3

An SH3 domain-mediated interaction between the phagocyte NADPH oxidase factors p40phox and p47phox. Ito T, et al. **FEBS Lett** 1996 May 6;385(3):229-32

Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. Niggli V, et al. **FEBS Lett** 1995 Dec 4;376(3):172-6

Glucose- and insulin-induced phosphorylation of the insulin receptor and its primary substrates IRS-1 and IRS-2 in rat pancreatic islets. Velloso LA, et al. **FEBS Lett** 1995 Dec 27;377(3):353-7

Mammalian DNA cytosine-5 methyltransferase interacts with p23 protein. Zhang X, et al. **FEBS Lett** 1996 Aug 26;392(2):179-83

Rapid inhibition of protein histidine phosphorylation by UV-irradiation in Xanthomonas oryzae pv. oryzae. Huang HJ, et al. **FEMS Microbiol Lett** 1995 Dec 15; 134(2-3):189-94

Tyrosine protein phosphorylation in murine B lymphocytes by stimulation with lipopolysaccharide from Porphyromonas gingivalis. Kimura S, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):1-6

A U6 snRNA:pre-mRNA interaction can be rate-limiting for U1-independent splicing. Crispino JD, et al. **Genes Dev** 1995 Sep 15;9(18):2314-23

Requirement of a corepressor for Dr1-mediated repression of transcription. Mermelstein F, et al. **Genes Dev** 1996 Apr 15;10(8):1033-48

Functional interactions between the pelle kinase, Toll receptor, and tube suggest a mechanism for activation of dorsal. Norris JL, et al. **Genes Dev** 1996 Apr 1;10(7):862-72

Human TAFII250 interacts with RAP74: implications for RNA polymerase II initiation. Ruppert S, et al. **Genes Dev** 1995 Nov 15;9(22):2747-55

Stem cell factor induces phosphorylation of a 200 kDa protein which associates with c-kit. Linnekin D, et al. **Growth Factors** 1995;12(1):57-67

Vav and SLP-76 interact and functionally cooperate in IL-2

gene activation. Wu J, et al. **Immunity** 1996 Jun; 4(6):593–602

Tyrosine–phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of Syk. Wienands J, et al. **Int Immunol** 1995 Nov;7(11):1701–8

Elevated superoxide generation in mononuclear phagocytes by treatment with 1 alpha hydroxyvitamin D3: changes in kinetics and in oxidase cytosolic factor p47. Deutsch A, et al. **J Am Soc Nephrol** 1995 Jul;6(1):102–9

Phosphorylated sites of M(r) 25,000 protein, a putative protein phosphatase 2A modulator, and phosphorylation of the synthetic peptide containing these sites by protein kinase C. Hashimoto E, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):626–32

Phosphorylation of HS1, GAP–associated p190 and a novel GAP–associated p60 protein by cross–linking of Fc gamma RIIIA. Zeng H, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1166–74

Regulation of both glycogen synthase and PHAS–I by insulin in rat skeletal muscle involves mitogen–activated protein kinase–independent and rapamycin–sensitive pathways. Azpiazu I, et al. **J Biol Chem** 1996 Mar 1;271(9):5033–9

The proto–oncogene product c–Crk associates with insulin receptor substrate–1 and 4PS. Modulation by insulin growth factor–I (IGF) and enhanced IGF–I signaling Beitner–Johnson D, et al. **J Biol Chem** 1996 Apr 19; 271(16):9287–90

The ear of alpha–adaptin interacts with the COOH–terminal domain of the Eps 15 protein. Benmerah A, et al. **J Biol Chem** 1996 May 17;271(20):12111–6

Phosphorylation of the respiratory burst oxidase subunit p47phox as determined by two–dimensional phosphopeptide mapping. Phosphorylation by protein kinase C, Protein kinase A, and a mitogen–activated protein kinase. El Benna J, et al. **J Biol Chem** 1996 Mar 15; 271(11):6374–8

1,25–Dihydroxyvitamin D3 stimulates expression and translocation of protein kinase Calpha and Cdelta via a nongenomic mechanism and rapidly induces phosphorylation of a 33–kDa protein in acute promyelocytic NB4 cells. Berry DM, et al. **J Biol Chem** 1996 Jul 5;271(27):16090–6

Identification of the sites of interaction between lymphocyte phosphatase–associated phosphoprotein (LPAP) and CD45. Bruyns E, et al. **J Biol Chem** 1995 Dec 29; 270(52):31372–6

p190–B, a new member of the Rho GAP family, and Rho are induced to cluster after integrin cross–linking. Burbelo PD, et al. **J Biol Chem** 1995 Dec 29;270(52):30919–26

Csk is constitutively associated with a 60–kDa tyrosine–phosphorylated protein in human T cells. Catipovic B, et al. **J Biol Chem** 1996 Apr 19; 271(16):9698–703

Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon–gamma–inducible expression of human indoleamine 2,3–dioxygenase gene. Chon SY, et al. **J Biol Chem** 1996 Jul 19;271(29):17247–52

Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose–mediated activation of the acetyl–CoA carboxylase gene. Daniel S, et al. **J Biol Chem** 1996 Jun 21;271(25):14692–7

Role of cellular casein kinase II in the function of the phosphoprotein (P) subunit of RNA polymerase of vesicular stomatitis virus. Das T, et al. **J Biol Chem** 1995 Oct 13;270(41):24100–7

A domain of p47phox that interacts with human neutrophil flavocytochrome b558. DeLeo FR, et al. **J Biol Chem** 1995 Nov 3;270(44):26246–51

Integrin alpha v beta 5–dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin. De Nichilo MO, et al. **J Biol Chem** 1996 May 3;271(18):11016–22

The Rac target NADPH oxidase p67phox interacts preferentially with Rac2 rather than Rac1. Dorseuil O, et al. **J Biol Chem** 1996 Jan 5;271(1):83–8

Platelet–derived growth factor induction of the immediate–early gene MCP–1 is mediated by NF–kappaB and a 90–kDa phosphoprotein coactivator. Freter RR, et al. **J Biol Chem** 1996 Jul 19;271(29):17417–24

Identification of p90, a prominent tyrosine–phosphorylated protein in fibroblast growth factor–stimulated cells, as 80K–H. Goh KC, et al. **J Biol Chem** 1996 Mar 8; 271(10):5832–8

Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3–kinase in 3T3–L1 adipocytes. Guo D, et al. **J Biol Chem** 1996 Jan 12;271(2):615–8

p130Cas, a substrate associated with v–Src and v–Crk, localizes to focal adhesions and binds to focal adhesion kinase. Harte MT, et al. **J Biol Chem** 1996 Jun 7; 271(23):13649–55

Distinct modes of interaction of SHC and insulin receptor substrate–1 with the insulin receptor NPEY region via non–SH2 domains. He W, et al. **J Biol Chem** 1995 Oct 6;270(40):23258–62

Insulin regulation of membrane–associated insulin receptor substrate 1. Heller–Harrison RA, et al. **J Biol Chem** 1995 Oct 13;270(41):24442–50

A novel 55–kDa regulatory subunit for phosphatidylinositol 3–kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. Inukai K, et al. **J Biol Chem** 1996 Mar 8;271(10):5317–20

Interaction between the phosphotyrosine binding domain of Shc and the insulin receptor is required for Shc phosphorylation by insulin in vivo. Isakoff SJ, et al. **J Biol Chem** 1996 Feb 23;271(8):3959–62

Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. Johnston JA, et al. **J Biol Chem** 1995 Dec 1;270(48):28527–30

Identification of a new adapter protein that may link the common beta subunit of the receptor for granulocyte/macrophage colony–stimulating factor, interleukin (IL)–3, and IL–5 to phosphatidylinositol 3–kinase. Jücker M, et al. **J Biol Chem** 1995 Nov 17; 270(46):27817–22

Sphingomyelinase and ceramide suppress insulin–induced tyrosine phosphorylation of the insulin receptor substrate–1. Kanety H, et al. **J Biol Chem** 1996 Apr 26; 271(17):9895–7

Tumor necrosis factor alpha–induced phosphorylation of insulin receptor substrate–1 (IRS–1). Possible mechanism for suppression of insulin–stimulated tyrosine phosphorylation of IRS–1. Kanety H, et al. **J Biol Chem** 1995 Oct 6;270(40):23780–4

Adapter function of protein–tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate–1 interaction. Kharitonenkov A, et al. **J Biol Chem** 1995 Dec 8; 270(49):29189–93

A negative cofactor containing Dr1/p19 modulates transcription with TFIIA in a promoter–specific fashion. Kim J, et al. **J Biol Chem** 1996 Aug 2;271(31):18405–12

Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate–1 (IRS–1) but fail to mediate the biological effects of insulin. Evidence that IRS–1 phosphorylation is not sufficient for normal insulin action. Krook A, et al. **J Biol Chem** 1996 Mar 22; 271(12):7134–40

The transmembrane protein–tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. Kulas DT, et al. **J Biol Chem** 1996 Jan 12;271(2):748–54

The transmembrane protein–tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling. Kulas DT, et al. **J Biol Chem** 1996 Jan 12;271(2):755–60

Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. Lacerda HM, et al. **J Biol Chem** 1996 Jan 5;271(1):439–45

Mannose 6–phosphate receptors and ADP–ribosylation factors cooperate for high affinity interaction of the AP–1 Golgi assembly proteins with membranes. Le Borgne R, et al. **J Biol Chem** 1996 Jan 26;271(4):2162–70

Sp1 is phosphorylated and its DNA binding activity down–regulated upon terminal differentiation of the liver. Leggett RW, et al. **J Biol Chem** 1995 Oct 27; 270(43):25879–84

Tyrosine phosphorylation and enhanced expression of paxillin during neuronal differentiation in vitro. Leventhal PS, et al. **J Biol Chem** 1996 Mar 15;271(11):5957–60

Insulin–induced activation of phosphatidylinositol (PI) 3–kinase. Insulin–induced phosphorylation of insulin receptors and insulin receptor substrate–1 displaces phosphorylated platelet–derived growth factor receptors from binding sites on PI 3–kinase. Levy–Toledano R, et al. **J Biol Chem** 1995 Dec 15;270(50):30018–22

Role of MacMARCKS in integrin–dependent macrophage spreading and tyrosine phosphorylation of paxillin. Li J, et al. **J Biol Chem** 1996 May 31;271(22):12985–90

p150TSP, a conserved nuclear phosphoprotein that contains multiple tetratricopeptide repeats and binds specifically to SH2 domains. Malek SN, et al. **J Biol Chem** 1996 Mar 22;271(12):6952–62

Interaction between the amino–terminal SH3 domain of CRK and its natural target proteins. Matsuda M, et al. **J Biol Chem** 1996 Jun 14;271(24):14468–72

A casein kinase II phosphorylation site in the cytoplasmic domain of the cation–dependent mannose 6–phosphate receptor determines the high affinity interaction of the AP–1 Golgi assembly proteins with membranes. Mauxion F, et al. **J Biol Chem** 1996 Jan 26;271(4):2171–8

CD45 protein–tyrosine phosphatase associates with the WW domain–containing protein, CD45AP, through the transmembrane region. MCFarland ED, et al. **J Biol Chem** 1995 Nov 24;270(47):28103–7

Phosphorylation of insulin receptor substrate–1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. Mothe I, et al. **J Biol Chem** 1996 May 10; 271(19):11222–7

Interactions of phosducin with defined G protein beta gamma–subunits. Müller S, et al. **J Biol Chem** 1996 May 17;271(20):11781–6

Direct binding of C–terminal region of p130Cas to SH2 and SH3 domains of Src kinase. Nakamoto T, et al. **J Biol Chem** 1996 Apr 12;271(15):8959–65

Differential regulation of activation–induced tyrosine phosphorylation and recruitment of SLP–76 to Vav by distinct isoforms of the CD45 protein–tyrosine phosphatase. Onodera H, et al. **J Biol Chem** 1996 Sep 6;271(36):22225–30

4PS/insulin receptor substrate (IRS)–2 is the alternative substrate of the insulin receptor in IRS–1–deficient mice. Patti ME, et al. **J Biol Chem** 1995 Oct 20;270(42):24670–3

Adhesion through the interaction of lymphocyte function–associated antigen–1 with intracellular adhesion molecule–1 induces tyrosine phosphorylation of p130cas and its association with c–CrkII. Petruzzelli L, et al. **J Biol Chem** 1996 Mar 29;271(13):7796–801

The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. Platanias LC, et al. **J Biol Chem** 1996 Jan 5;271(1):278–82

Requirement for phosphatidylinositol 3'–kinase activity in platelet–derived growth factor–stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin. Rankin S, et al. **J Biol Chem** 1996 Mar 29;271(13):7829–34

Thrombin stimulates phosphorylation of insulin–like growth factor–1 receptor, insulin receptor substrate–1, and phospholipase C–gamma 1 in rat aortic smooth muscle cells. Rao GN, et al. **J Biol Chem** 1995 Nov 17; 270(46):27871–5

Nerve growth factor stimulates the tyrosine phosphorylation of endogenous Crk–II and augments its association with p130Cas in PC–12 cells. Ribon V, et al. **J Biol Chem** 1996 Mar 29;271(13):7375–80

CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. Salgia R, et al. **J Biol Chem** 1995 Dec 8;270(49):29145–50

Triggering of the human interleukin–6 gene by interferon–gamma and tumor necrosis factor–alpha in monocytic cells involves cooperation between interferon regulatory factor–1, NF kappa B, and Sp1 transcription factors. Sanceau J, et al. **J Biol Chem** 1995 Nov 17; 270(46):27920–31

Insulin receptor substrate–2 binds to the insulin receptor through its phosphotyrosine–binding domain and through a newly identified domain comprising amino acids 591–786. Sawka–Verhelle D, et al. **J Biol Chem** 1996 Mar 15; 271(11):5980–3

Sphingosylphosphorylcholine rapidly induces tyrosine phosphorylation of p125FAK and paxillin, rearrangement of the actin cytoskeleton and focal contact assembly. Requirement of p21rho in the signaling pathway. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24343–51

The alpha 6A beta 1 and alpha 6B beta 1 integrin variants signal differences in the tyrosine phosphorylation of paxillin and other proteins. Shaw LM, et al. **J Biol Chem** 1995 Oct 6;270(40):23648–52

A clathrin–binding site in the hinge of the beta 2 chain of mammalian AP–2 complexes. Shih W, et al. **J Biol Chem** 1995 Dec 29;270(52):31083–90

Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974–containing internalization motif. Sorkin A, et al. **J Biol Chem** 1996 Jun 7;271(23):13377–84

Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N–terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. Sumimoto H, et al. **J Biol Chem** 1996 Sep 6;271(36):22152–8

The Fyn tyrosine kinase binds Irs–1 and forms a distinct signaling complex during insulin stimulation. Sun XJ, et al. **J Biol Chem** 1996 May 3;271(18):10583–7

Evidence for a differential interaction of SHC and the insulin receptor substrate–1 (IRS–1) with the insulin–like growth factor–I (IGF–I) receptor in the yeast two–hybrid system. Tartare–Deckert S, et al. **J Biol Chem** 1995 Oct 6; 270(40):23456–60

Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'–kinase activity via modulation of phosphorylation of insulin receptor substrate–1. Ugi S, et al. **J Biol Chem** 1996 May 24;271(21):12595–602

Systematic mapping of potential binding sites for Shc and Grb2 SH2 domains on insulin receptor substrate–1 and the receptors for insulin, epidermal growth factor, platelet–derived growth factor, and fibroblast growth factor. Ward CW, et al. **J Biol Chem** 1996 Mar 8; 271(10):5603–9

Phosphorylation of SLP–76 by the ZAP–70 protein–tyrosine kinase is required for T–cell receptor function. Wardenburg JB, et al. **J Biol Chem** 1996 Aug 16;271(33):19641–4

Selective activation of T cell kinase p56lck by Herpesvirus saimiri protein tip. Wiese N, et al. **J Biol Chem** 1996 Jan 12;271(2):847–52

Regulation of the kinetics of phosducin phosphorylation in retinal rods. Wilkins JF, et al. **J Biol Chem** 1996 Aug 9; 271(32):19232–7

PTB domains of IRS–1 and Shc have distinct but overlapping binding specificities. Wolf G, et al. **J Biol Chem** 1995 Nov 17;270(46):27407–10

Substrate specificities of the insulin and insulin–like growth factor 1 receptor tyrosine kinase catalytic domains. Xu B, et al. **J Biol Chem** 1995 Dec 15;270(50):29825–30

Biochemical characterization of ezrin–actin interaction. Yao X, et al. **J Biol Chem** 1996 Mar 22;271(12):7224–9

Characterization and cloning of a 58/53–kDa substrate of the insulin receptor tyrosine kinase. Yeh TC, et al. **J Biol Chem** 1996 Feb 9;271(6):2921–8

Characterization of the in vivo phosphorylation sites of the mRNA.cap–binding complex proteins eukaryotic initiation factor–4E and p20 in Saccharomyces cerevisiae. Zanchin NI, et al. **J Biol Chem** 1995 Nov 3;270(44):26505–10

The RB2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. Baldi A, et al. **J Cell Biochem** 1995 Nov;59(3):402–8

Combination of insulinomimetic agents H2O2 and vanadate enhances insulin receptor mediated tyrosine

phosphorylation of IRS-1 leading to IRS-1 association with the phosphatidylinositol 3-kinase. Wilden PA, et al. **J Cell Biochem** 1995 Jul;58(3):279–91

Human myeloid cell nuclear differentiation antigen binds specifically to nucleolin. Xie J, et al. **J Cell Biochem** 1995 Dec;59(4):529–36

The tyrosine kinase substrate eps:5 is constitutively associated with the plasma membrane adaptor AP-2. Benmerah A, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1831–8

The 110-kD spindle pole body component of Saccharomyces cerevisiae is a phosphoprotein that is modified in a cell cycle-dependent manner. Friedman DB, et al. **J Cell Biol** 1996 Mar;132(5):903–14

Na+/H+ exchange activity during phagocytosis in human neutrophils: role of Fcgamma receptors and tyrosine kinases. Fukushima T, et al. **J Cell Biol** 1996 Mar; 132(6):1037–52

A novel adaptor-related protein complex. Simpson F, et al. **J Cell Biol** 1996 May;133(4):749–60

Mitotic mechanisms in Alzheimer's disease? Vincent I, et al. **J Cell Biol** 1996 Feb;132(3):413–25

Fluoride at mitogenic concentrations increases the steady state phosphotyrosyl phosphorylation level of cellular proteins in human bone cells. Thomas AB, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2570–8

A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. Almind K, et al. **J Clin Invest** 1996 Jun 1;97(11):2569–75

The cytosolic subunit p67phox contains an NADPH-binding site that participates in catalysis by the leukocyte NADPH oxidase. Smith RM, et al. **J Clin Invest** 1996 Aug 15; 98(4):977–83

Electrophoretic gels of dentin matrix proteins as diffusion media for in vitro mineralization. Wada Y, et al. **J Dent Res** 1996 Jun;75(6):1381–7

Deciliation induces phosphorylation of a 90-kDa cortical protein in Tetrahymena thermophila. Gitz DL, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):742–8

Proteolysis of a 34 kDa phosphoprotein coincident with a decrease in protein kinase activity during the erythrocytic schizont stage of the malaria parasite. Wiser MF. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):659–64

Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells. Mizuno K, et al. **J Exp Med** 1996 Aug 1;184(2):457–63

Implication of the GRB2-associated phosphoprotein SLP-76 in T cell receptor-mediated interleukin 2 production. Motto DG, et al. **J Exp Med** 1996 Apr 1;183(4):1937–43

Direct association of pp125FAK with paxillin, the focal adhesion-targeting mechanism of pp125FAK. Tachibana K, et al. **J Exp Med** 1995 Oct 1;182(4):1089–99

Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. Gallina A, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1151–7

Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system. Mallipeddi SK, et al. **J Gen Virol** 1996 May;77 (Pt 5):1019–23

CD45 monoclonal antibodies inhibit TCR-mediated calcium signals, calmodulin-kinase IV/Gr activation, and oncoprotein 18 phosphorylation. Shivnan E, et al. **J Immunol** 1996 Jul 1;157(1):101–9

A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. Labadia ME, et al. **J Leukoc Biol** 1996 Jan; 59(1):116–24

Tumor necrosis factor triggers redistribution to a Triton X-100-insoluble, cytoskeletal fraction of beta 2 integrins, NADPH oxidase components, tyrosine phosphorylated proteins, and the protein tyrosine kinase p58fgr in human neutrophils adherent to fibrinogen. Yan SR, et al. **J Leukoc Biol** 1995 Nov;58(5):595–606

The C-terminal SH3 domain of p67phox binds its natural ligand in a reverse orientation. Finan P, et al. **J Mol Biol** 1996 Aug 16;261(2):173–80

Nucleolin is a sequence-specific RNA-binding protein: characterization of targets on pre-ribosomal RNA. Ghisolfi-Nieto L, et al. **J Mol Biol** 1996 Jul 5;260(1):34–53

Interaction of beta-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. Neumann J, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1655–67

Insulin-induced differentiation and modulation of neuronal thread protein expression in primitive neuroectodermal tumor cells is linked to phosphorylation of insulin receptor substrate-1. Xu YY, et al. **J Mol Neurosci** 1995;6(2):91–108

Phosphorylation of the conditioning-associated GTP-binding protein cp20 by protein kinase C. Nelson TJ, et al. **J Neurochem** 1995 Nov;65(5):2350–7

NMDA receptor activation-responsive phosphoproteins in the developing optic tectum. Scheetz AJ, et al. **J Neurosci** 1996 Feb 15;16(4):1460–9

A 110-kD nuclear shuttling protein, nucleolin, binds to the neurite-promoting IKVAV site of laminin-1. Kibbey MC, et al. **J Neurosci Res** 1995 Oct 15;42(3):314–22

The involvement of p23, hsp90, and immunophilins in the assembly of progesterone receptor complexes. Johnson J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):31–7

Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. Watts SW, et al. **J Vasc Res** 1996 Jul-Aug;33(4):288–98

Tyrosine kinase-dependent release of an adenovirus preterminal protein complex from the nuclear matrix. Angeletti PC, et al. **J Virol** 1996 May;70(5):3060–7

Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication. Dal Monte P, et al. **J Virol** 1996 Apr;70(4):2086–94

Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions. García-Barreno B, et al. **J Virol** 1996 Feb;70(2):801–8

Downregulation of Lck-mediated signal transduction by tip of herpesvirus saimiri. Jung JU, et al. **J Virol** 1995 Dec; 69(12):7814–22

SR protein splicing factors interact with the Rous sarcoma virus negative regulator of splicing element. McNally LM, et al. **J Virol** 1996 Feb;70(2):1163–72

Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II. Ueda K, et al. **J Virol** 1996 Jul;70(7):4714–23

Formation of focal adhesion and spreading of polarized human colon cancer cells in association with tyrosine phosphorylation of paxillin in response to phorbol ester. Sakamoto M, et al. **Lab Invest** 1996 Jan;74(1):199–208

Phosphorylation-dependent complexes of p120 Ras-specific GTPase-activating protein with p62 and p190. Ellis C, et al. **Methods Enzymol** 1995;255:179–92

Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Gary R, et al. **Mol Biol Cell** 1995 Aug;6(8):1061–75

Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase. Hildebrand JD, et al. **Mol Biol Cell** 1995 Jun;6(6):637–47

Gap-junction disassembly and connexin 43 dephosphorylation induced by 18 beta-glycyrrhetinic acid. Guan X, et al. **Mol Carcinog** 1996 Jul;16(3):157–64

Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Bartel S, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):171–9

Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Antonetti DA, et al. **Mol Cell Biol** 1996 May;16(5):2195–203

Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS. Auvinen M, et al. **Mol Cell Biol** 1995 Dec;15(12):6513–25

Regulated nuclear import of the Drosophila rel protein dorsal: structure-function analysis. Govind S, et al. **Mol Cell Biol** 1996 Mar;16(3):1103–14

SIN3-dependent transcriptional repression by interaction with the Mad1 DNA-binding protein. Kasten MM, et al. **Mol Cell Biol** 1996 Aug;16(8):4215–21

Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Law SF, et al. **Mol Cell Biol** 1996 Jul; 16(7):3327–37

Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mèndez R, et al. **Mol Cell Biol** 1996 Jun;16(6):2857–64

The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-kappa B, c-Fos, and c-Jun activities. Min W, et al. **Mol Cell Biol** 1996 Jan;16(1):359–68

YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites. Myers MG Jr, et al. **Mol Cell Biol** 1996 Aug;16(8):4147–55

p21 Disrupts the interaction between cdk2 and the E2F-p130 complex. Shiyanov P, et al. **Mol Cell Biol** 1996 Mar; 16(3):737–44

Finely tuned regulation of cytoplasmic retention of Xenopus nuclear factor 7 by phosphorylation of individual threonine residues. Shou W, et al. **Mol Cell Biol** 1996 Mar;16(3):990–7

Csk enhances insulin-stimulated dephosphorylation of focal adhesion proteins. Tobe K, et al. **Mol Cell Biol** 1996 Sep; 16(9):4765–72

In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Tommasi S, et al. **Mol Cell Biol** 1995 Dec;15(12):6901–13

Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation. Zalvide J, et al. **Mol Cell Biol** 1995 Oct;15(10):5800–10

Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes. Smith LK, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):73–81

Biological activity of phosphorylated and dephosphorylated bovine prolactin. Wicks JR, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):223–9

Binding of p23 and hsp90 during assembly with the progesterone receptor. Johnson JL, et al. **Mol Endocrinol** 1995 Jun;9(6):670–8

Effects of different kinases and phosphatases on nuclear and cytoplasmic maturation of bovine oocytes. Lévesque JT, et al. **Mol Reprod Dev** 1995 Sep;42(1):114–21

A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Holgado-Madruga M, et al. **Nature** 1996 Feb 8;379(6565):560–4

Unitary anion currents through phospholemman channel molecules. Moorman JR, et al. **Nature** 1995 Oct 26; 377(6551):737–40

Complementary distribution of the phosphoproteins DARPP-32 and I-1 in the cerebellar system. Alder R, et al. **Neuroreport** 1995 Nov 27;6(17):2368–72

B-50 (GAP-43) in the rat spinal cord caudal to hemisection: lack of intraspinal sprouting by dorsal root axons. Nacimiento W, et al. **Neurosci Lett** 1995 Jul 14; 194(1-2):13–6

Studies of Schizosaccharomyces pombe DNA polymerase alpha at different stages of the cell cycle. Park H, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4337–44

The CtBP binding domain in the adenovirus E1A protein controls CR1-dependent transactivation. Sollerbrant K, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2578–84

The identification of p130cas-binding proteins and their role in cellular transformation. Burnham MR, et al. **Oncogene** 1996 Jun 6;12(11):2467–72

The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125FAK and paxillin and cell proliferation. Charlesworth A, et al. **Oncogene** 1996 Mar 21;12(6):1337–45

Tyrosine phosphorylation of murine Crkl. de Jong R, et al. **Oncogene** 1995 Oct 19;11(8):1469–74

Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Johnson DG. **Oncogene** 1995 Nov 2;11(9):1685–92

Networks of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins. Khwaja A, et al. **Oncogene** 1996 Jun 20;12(12):2491–8

Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein. Lovrić J, et al. **Oncogene** 1996 Mar 7; 12(5):1145–51

G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4. Mayol X, et al. **Oncogene** 1996 Jul 18;13(2):237–46

Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Muthuswamy SK, et al. **Oncogene** 1995 Nov 2;11(9):1801–10

Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC-gamma 1 but excludes P130CAS. Torres M, et al. **Oncogene** 1996 Jan 4;12(1):77–86

Calcium induces rapid changes in protein phosphorylation in permeabilized pancreatic acini. Wagner AC, et al. **Pancreas** 1995 Oct;11(3):236–40

Developmental and cell cycle regulation of alfalfa nucMs1, a plant homolog of the yeast Nsr1 and mammalian nucleolin. Bögre L, et al. **Plant Cell** 1996 Mar;8(3):417–28

Functional characteristics of the maize RNA-binding protein MA16. Freire MA, et al. **Plant Mol Biol** 1995 Nov; 29(4):797–807

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Chou J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10516–20

The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Debant A, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5466–71

GAIP, a protein that specifically interacts with the trimeric G protein G alpha i3, is a member of a protein family with a highly conserved core domain. De Vries L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11916–20

Activation of the translational suppressor 4E-BP1 following infection with encephalomyocarditis virus and poliovirus. Gingras AC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5578–83

Recruitment of hepatocyte nuclear factor 4 into specific intranuclear compartments depends on tyrosine phosphorylation that affects its DNA-binding and transactivation potential. Ktistaki E, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9876–80

Interactions of a Rel protein with its inhibitor. Lehming N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10242–6

Human protein Sam68 relocalization and interaction with poliovirus RNA polymerase in infected cells. McBride AE, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2296–301

Evidence for an insulin receptor substrate 1 independent insulin signaling pathway that mediates insulin-responsive glucose transporter (GLUT4) translocation. Morris AJ, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8401–6

Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Polte TR, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10678–82

The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Pulido R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11686–90

Molecular cloning and characterization of a cellular

phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Schaeper U, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10467-71

Helicobacter pylori attachment to gastric cells induces cytoskeletal rearrangements and tyrosine phosphorylation of host cell proteins. Segal ED, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1259-64

PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Shi J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6014-8

4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. von Manteuffel SR, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4076-80

Regulation of phosducin phosphorylation in retinal rods by Ca2+/calmodulin-dependent adenylyl cyclase. Willardson BM, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1475-9

A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. Wong WT, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9530-4

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Zhang LH, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10619-23

Growth hormone (GH)-induced tyrosine-phosphorylated proteins in cells that express GH receptors. Harding PA, et al. **Receptor** 1995 Summer;5(2):81-92

Characterization of growth hormone-induced tyrosine-phosphorylated proteins in mouse cells that express GH receptors. Xu BC, et al. **Receptor** 1995 Summer;5(2):105-16

Regulation of alternative 3' splice site selection by constitutive splicing factors. Lin CH, et al. **RNA** 1995 May; 1(3):234-45

SR proteins escort the U4/U6.U5 tri-snRNP to the spliceosome. Roscigno RF, et al. **RNA** 1995 Sep; 1(7):692-706

Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption. Hardwick KG, et al. **Science** 1996 Aug 16;273(5277):953-6

Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Ohno H, et al. **Science** 1995 Sep 29;269(5232):1872-5

Sendai virus P protein is constitutively phosphorylated at serine249: high phosphorylation potential of the P protein. Byrappa S, et al. **Virology** 1996 Feb 1;216(1):228-34

Mutations in conserved domain I of the Sendai virus L polymerase protein uncouple transcription and replication. Chandrika R, et al. **Virology** 1995 Nov 10;213(2):352-63

Localization of the Us protein kinase of equine herpesvirus type 1 is affected by the cytoplasmic structures formed by the noval IR6 protein. Colle CF, et al. **Virology** 1996 Jun 15;220(2):424-35

Reexamination of the Sendai virus P protein domains required for RNA synthesis: a possible supplemental role for the P protein. Curran J. **Virology** 1996 Jul 1; 221(1):130-40

Protein interactions entered into by the measles virus P, V, and C proteins. Liston P, et al. **Virus Res** 1995 Oct; 38(2-3):241-59

[Tyrosine phosphorylation of focal adhesion kinase (p125FAK) and paxillin in glomeruli from diabetic rats] Shikano T, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb; 38(2):57-64 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Hunter GK, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):59-64

Synergistic activation of PtdIns 3-kinase by tyrosine-phosphorylated peptide and beta gamma-subunits of GTP-binding proteins. Okada T, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):475-80

Cytokine regulation of the liver transcription factor hepatocyte nuclear factor-3 beta is mediated by the C/EBP family and interferon regulatory factor 1. Samadani U, et al. **Cell Growth Differ** 1995 Jul;6(7):879-90

A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. Labadia ME, et al. **J Leukoc Biol** 1996 Jan; 59(1):116-24

The Drosophila insulin receptor activates multiple signaling pathways but requires insulin receptor substrate proteins for DNA synthesis. Yenush L, et al. **Mol Cell Biol** 1996 May;16(5):2509-17

PHYSIOLOGY

Role of the steroidogenic acute regulatory protein (StAR) in steroidogenesis. Stocco DM, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):197-205 (125 ref.)

Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Anderson JM, et al. **Biochem Soc Trans** 1995 Aug; 23(3):470-5 (45 ref.)

Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. de Koning JP, et al. **Blood** 1996 Jan 1;87(1):132-40

Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Sato T, et al. **Blood** 1995 Nov 1;86(9):3373-80

Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Tan RS, et al. **Cancer Res** 1996 May 15;56(10):2417-21

Actin cytoskeleton. Missing link for intracellular bacterial motility? Pollard TD. **Curr Biol** 1995 Aug 1;5(8):837-40

CCAAT/enhancer-binding protein beta (C/EBP beta) binds and activates while hepatocyte nuclear factor-4 (HNF-4) does not bind but represses the liver-type arginase promoter. Chowdhury S, et al. **Eur J Biochem** 1996 Mar 1;236(2):500-9

The novel catenin p120cas binds classical cadherins and induces an unusual morphological phenotype in NIH3T3 fibroblasts. Reynolds AB, et al. **Exp Cell Res** 1996 Jun 15; 225(2):328-37

Biochemical evidence for adhesion-promoting role of major intrinsic protein isolated from both normal and cataractous human lenses. Michea LF, et al. **Exp Eye Res** 1995 Sep; 61(3):293-301

Shared role of the pRB-related p130 and p107 proteins in limb development. Cobrinik D, et al. **Genes Dev** 1996 Jul 1;10(13):1633-44

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97-101 (13 ref.)

Cloning and characterization of an ovarian-specific protein that associates with the short form of the prolactin receptor. Duan WR, et al. **J Biol Chem** 1996 Jun 28;271(26):15602-7

Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. Hung HL, et al. **J Biol Chem** 1996 Jan 26;271(4):2323-31

Characterization of a nuclear protein conferring brefeldin A resistance in Schizosaccharomyces pombe. Turi TG, et al. **J Biol Chem** 1996 Apr 12;271(15):9166-71

Hepatocyte nuclear factor-4 is responsible for the liver-specific expression of the gene coding for hepatocyte growth factor-like protein. Waltz SE, et al. **J Biol Chem** 1996 Apr 12;271(15):9024-32

Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al. **J Cancer Res Clin Oncol** 1995;121(9-10):516-20 (34 ref.)

Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis. Berryman M, et al. **J Cell Biol** 1995 Dec;131(5):1231-42

The phosphoprotein stathmin is essential for nerve growth factor-stimulated differentiation. Di Paolo G, et al. **J Cell Biol** 1996 Jun;133(6):1383-90

Spc42p: a phosphorylated component of the S. cerevisiae spindle pole body (SPD) with an essential function during SPB duplication. Donaldson AD, et al. **J Cell Biol** 1996 Mar;132(5):887-901

Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. Rajasekaran AK, et al. **J Cell Biol** 1996 Feb;132(3):451-63

Production of nitric oxide (NO) is not essential for protection against acute Toxoplasma gondii infection in IRF-1-/- mice. Khan IA, et al. **J Immunol** 1996 Jan 15;156(2):636-43

Interferon regulatory factor element and interferon regulatory factor 1 in the induction of major histocompatibility complex class I genes in neural cells. Massa PT, et al. **J Interferon Cytokine Res** 1995 Sep; 15(9):799-810

Phosducin and PP33 are in vivo targets of PKA and type 1 or 2A phosphatases, regulators of cell elongation in teleost rod inner-outer segments. Pagh-Roehl K, et al. **J Neurosci** 1995 Oct;15(10):6475-88

Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression. Caswell R, et al. **J Virol** 1996 Jun;70(6):4028-37

Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. Vuori K, et al. **Mol Cell Biol** 1996 Jun; 16(6):2606-13

WW domains and retrovirus budding [letter] Garnier L, et al. **Nature** 1996 Jun 27;381(6585):744-5

Role of auxilin in uncoating clathrin-coated vesicles. Ungewickell E, et al. **Nature** 1995 Dec 7;378(6557):632-5

Drosophila immunity: a comparative analysis of the Rel proteins dorsal and Dif in the induction of the genes encoding diptericin and cecropin. Gross I, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1238-45

Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Beretta L, et al. **Oncogene** 1996 Apr 4;12(7):1593-6

UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. Gu J, et al. **Oncogene** 1995 Nov 16; 11(10):2175-8

The IRS-signalling system in insulin and cytokine action. White MF. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):181-9 (80 ref.)

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Hotamisligil GS, et al. **Science** 1996 Feb 2; 271(5249):665-8

Regulating G protein signaling [news]. Roush W. **Science** 1996 Feb 23;271(5252):1056-8

SECRETION

Gene expression of TGF-beta 1 and elaboration of extracellular matrix using in situ hybridization and EM radioautography during dentinogenesis. Inage T, et al. **Anat Rec** 1996 Jun;245(2):250-66

ULTRASTRUCTURE

Extracellular matrix in tooth cementum and mantle dentin: localization of osteopontin and other noncollagenous proteins, plasma proteins, and glycoconjugates by electron microscopy. McKee MD, et al. **Anat Rec** 1996 Jun; 245(2):293-312

PHOSPHOPYRUVATE DIKINASE see **PYRUVATE, ORTHOPHOSPHATE DIKINASE**

PHOSPHOPYRUVATE HYDRATASE

ANALYSIS

Creatine kinase BB and neuron-specific enolase in cerebrospinal fluid in the diagnosis of brain insult. Vázquez MD, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):210-4

High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging. Dowlati A, et al. **Cancer** 1996 May 15;77(10):2039-43

A novel strategy to identify maternal and paternal inheritance in the mouse. Römer I, et al. **Electrophoresis** 1995 May; 16(5):823-30

Neuroendocrine differentiation in colorectal carcinomas. Syversen U, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):667-74

Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. Paone G, et al. **J Cancer Res Clin Oncol** 1996;122(8):499-503

Purification and properties of pig liver and muscle enolases. Farrar WW, et al. **J Protein Chem** 1995 Aug;14(6):487-97

Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Nyberg P, et al. **Thorax** 1996 Jan;51(1):92-4

Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells. Paus E, et al. **Tumour Biol** 1996;17(5):271-80

Clinical implication of neuroendocrine differentiation in prostatic adenocarcinomas. Constantinides C, et al. **Urol Int** 1995;55(3):134-6

[Value of neuron specific enolase levels and squamous cell carcinoma antigen in bronchial lavage fluid in patients with lung cancer] Zaltęska J, et al. **Pneumonol Alergol Pol** 1996; 64(1-2):11-8 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Assay for in vivo yeast invertase activity using NaF. Silveira MC, et al. **Anal Biochem** 1996 Jun 15;238(1):26-8

BIOSYNTHESIS

Non-neuronal enolase is an endothelial hypoxic stress protein. Aaronson RM, et al. **J Biol Chem** 1995 Nov 17; 270(46):27752-7

Transcriptional up-regulation of the mouse gene for the muscle-specific subunit of enolase during terminal differentiation of myogenic cells. Lamandé N, et al. **Mol Reprod Dev** 1995 Jul;41(3):306-13

Identification and gene expression of anaerobically induced enolase in Echinochloa phyllopogon and Echinochloa crus-pavonis. Fox TC, et al. **Plant Physiol** 1995 Oct; 109(2):433-43

BLOOD

Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Jørgensen LG, et al. **Br J Cancer** 1996 Aug;74(3):463-7

Increased serum levels of neuron-specific enolase in epileptic patients and after electroconvulsive therapy--a preliminary report. Greffe J, et al. **Clin Chim Acta** 1996 Jan 31; 244(2):199-208

Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. DeGiorgio CM, et al. **Epilepsia** 1996 Jul;37(7):606-9

Neuron-specific enolase is increased after single seizures during inpatient video/EEG monitoring. Rabinowicz AL, et al. **Epilepsia** 1996 Feb;37(2):122-5

Clinical significance of serum S100 in metastatic malignant melanoma [corrected and republished article originally printed in Eur J Cancer 1995 Jun;31A(6):924-8] Guo HB, et al. **Eur J Cancer** 1995 Oct;31A(11):1898-902

Serum neurone-specific enolase as an indicator of stroke volume. Cunningham RT, et al. **Eur J Clin Invest** 1996 Apr;26(4):298-303

Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Paone G, et al. **Eur Respir J** 1995 Jul;8(7):1136-40

Evaluation of the serum markers CEA, NSE, TPS and

CYFRA 21.1 in lung cancer. Giovanella L, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):156-60

Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. Johnsson P, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):694-9

Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K, et al. **Jpn J Cancer Res** 1995 Jul;86(7):698-705

Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Nitta T, et al. **Jpn J Clin Oncol** 1995 Oct;25(5):179-83

Serum NSE in status epilepticus [letter; comment] Schmitt B, et al. **Neurology** 1996 Jun;46(6):1780-1. Comment on: Neurology 1994 Jun;44(6):1167-9. Comment on: Neurology 1995 Jun;45(6):1134-7.

[The "neuron-specific enolase" tumor marker as a prognostic indicator in small cell bronchial carcinoma] Hoster M, et al. **Pneumologie** 1995 Aug;49(8):470-4 (Eng. Abstr.) **(Ger)**

[Prognostic value of neuron enolase levels in serum of patients with lung neoplasms] Jassem E, et al. **Pneumonol Alergol Pol** 1995;63(7-8):415-20 (Eng. Abstr.) **(Pol)**

[The value of determining neuron specific enolase for diagnosis of complete remission during treatment of small cell lung cancer] Rowińska-Zakrzewska E, et al. **Pneumonol Alergol Pol** 1996;64(1-2):19-23 (Eng. Abstr.) **(Pol)**

[Comparison of the degree of regression of small cell lung neoplasm in clinical-radiologic evaluation with levels of neuron specific enolase (NSE) in serum] Rowińska-Zakrzewska E, et al. **Pneumonol Alergol Pol** 1995;63(11-12):601-8 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

The significance of neuron specific enolase levels in cerebrospinal fluid and serum after experimental traumatic brain damage. Uzan M, et al. **Acta Neurochir (Wien)** 1995; 135(3-4):141-3

Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Lamers KJ, et al. **Acta Neurol Scand** 1995 Sep;92(3):247-51

Cerebrospinal fluid levels of S-100b protein and neuron-specific enolase in chronic inflammatory demyelinating polyneuropathy. Nagamatsu M, et al. **Acta Neurol Scand** 1995 Jun;91(6):483-7

Clinico-pathophysiological features of acute autonomic and sensory neuropathy: a long-term follow-up study. Yasuda T, et al. **J Neurol** 1995 Oct;242(10):623-8

CHEMISTRY

X-ray structure and catalytic mechanism of lobster enolase. Duquerroy S, et al. **Biochemistry** 1995 Oct 3; 34(39):12513-23

A carboxylate oxygen of the substrate bridges the magnesium ions at the active site of enolase: structure of the yeast enzyme complexed with the equilibrium mixture of 2-phosphoglycerate and phosphoenolpyruvate at 1.8 A resolution. Larsen TM, et al. **Biochemistry** 1996 Apr 9; 35(14):4349-58

DRUG EFFECTS

The effects of sodium perchlorate on rabbit muscle enolase--Spectral characterization of the monomer. Kornblatt MJ, et al. **Eur J Biochem** 1996 Feb 15; 236(1):78-84

Glutamate-induced efflux of protein, neuron-specific enolase and lactate dehydrogenase from a mesencephalic cell culture. Gross J, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):305-10

GENETICS

Differential expression of alpha- and beta-enolase genes during rat heart development and hypertrophy. Keller A, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1843-51

Dbl expression driven by the neuron specific enolase promoter induces tumor formation in transgenic mice with a p53(+/-) genetic background. Colucci-D'Amato GL, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):762-70

Microwave induced alteration in the neuron specific enolase gene expression. Verma M, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):239-44

Characterization of the "promoter region" of the enolase-encoding gene enol from the anaerobic fungus Neocallimastix frontalis: sequence and promoter analysis. Fischer M, et al. **Curr Genet** 1995 Jun;28(1):80-6

Conserved alternative splicing in the 5'-untranslated region of the muscle-specific enolase gene. Primary structure of mRNAs, expression and influence of secondary structure on the translation efficiency. Oliva D, et al. **Eur J Biochem** 1995 Aug 15;232(1):141-9

Transcription of the human beta enolase gene (ENO-3) is regulated by an intronic muscle-specific enhancer that binds myocyte-specific enhancer factor 2 proteins and ubiquitous G-rich-box binding factors. Feo S, et al. **Mol Cell Biol** 1995 Nov;15(11):5991-6002

Sucrose synthase and enolase expression in actinorhizal nodules of Alnus glutinosa: comparison with legume nodules. van Ghelue M, et al. **Mol Gen Genet** 1996 Mar 7;250(4):437-46

Characterization of squid enolase mRNA: sequence analysis, tissue distribution, and axonal localization. Chun JT, et al. **Neurochem Res** 1995 Aug;20(8):923-30

Transcriptional regulation by an upstream repression sequence from the yeast enolase gene ENO1. Carmen AA, et al. **Yeast** 1995 Sep 15;11(11):1031-43

IMMUNOLOGY

The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Adamus G, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):120-9

ISOLATION & PURIFICATION

Purification and properties of pig liver and muscle enolases. Farrar WW, et al. **J Protein Chem** 1995 Aug;14(6):487-97

METABOLISM

Mechanism of rabbit muscle enolase: identification of the rate-limiting steps and the site of Li+ inhibition. Kornblatt MJ. **Arch Biochem Biophys** 1996 Jun 1;330(1):12-18

Study of second messenger levels and of sugar catabolism enzyme activities in transformed cells resistant to ionizing radiations. Pacini S, et al. **Biochem Mol Biol Int** 1995 Sep; 37(1):81-8

Toward identification of acid/base catalysts in the active site of enolase: comparison of the properties of K345A, E168Q, and E211Q variants. Poyner RR, et al. **Biochemistry** 1996 Feb 6;35(5):1692-9

Neuron specific enolase and status epilepticus-induced neuronal injury [editorial] Treiman DM. **Epilepsia** 1996 Jul; 37(7):595-7

Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. Angiolella L, et al. **J Infect Dis** 1996 Mar;173(3):684-90

Enolase activity and isoenzyme distribution in human brain regions and tumors. Joseph J, et al. **J Neurochem** 1996 Jun; 66(6):2484-90

A new approach for multiple sampling of cisternal cerebrospinal fluid in rodents with minimal trauma and inflammation. Huang YL, et al. **J Neurosci Methods** 1995 Dec;63(1-2):13-22

Immunoreactive neuron-specific enolase (NSE) is expressed in testicular carcinoma-in-situ. Kang JL, et al. **J Pathol** 1996 Feb;178(2):161-5

A DEAD-box RNA helicase in the Escherichia coli RNA degradosome. Py B, et al. **Nature** 1996 May 9; 381(6578):169-72

PHARMACOLOGY

Inhibition of neutral cholesteryl ester hydrolase by the glycolytic enzyme enolase. Is this a secondary function of enolase? Shand JH, et al. **Lipids** 1995 Aug;30(8):763-70

PHYSIOLOGY

Neuronal overmaturation in dysraphism: ontogenic expression of neuropeptides in the fetal brain and developmental anomalies in exencephaly. Oi S, et al. **Childs Nerv Syst** 1995 Sep;11(9):504-10

SECRETION

Establishment of a human cell line secreting neuron-specific enolase from a primitive neuroectodermal tumor of the retroperitoneal cavity. Nakashima J, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1172-8

PHOSPHORAMIDE MUSTARDS

CHEMICAL SYNTHESIS

Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. Roth T, et al. **Anticancer Drug Des** 1995 Dec; 10(8):655-66

CHEMISTRY

A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC). Dong Q, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12170-4

METABOLISM

Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. Bunting KD, et al. **J Biol Chem** 1996 May 17;271(20):11891-6

PHARMACOLOGY

Metabolism of cyclophosphamide by aldehyde dehydrogenases. Agarwal DP, et al. **Adv Exp Med Biol** 1995;372:115-22

Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Andersson BS, et al. **Cancer Chemother Pharmacol** 1996;38(5):406-16

A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC). Dong Q, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12170-4

PHOSPHORANES

CHEMISTRY

Solid-state nuclear magnetic resonance investigations on chlorocyclophosphazenes. Paasch S, et al. **Solid State Nucl Magn Reson** 1995 Jul;4(5):267-80

PHOSPHORESCENCE see **LUMINESCENCE**

PHOSPHORIBOSYL PYROPHOSPHATE

METABOLISM

The IMP dehydrogenase inhibitor mycophenolic acid antagonizes the CTP synthetase inhibitor 3-deazauridine in MOLT-3 human leukemia cells: a central role for phosphoribosyl pyrophosphate. van Berg AA, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1095-8

Role of cellular ribose-5-phosphate content in the regulation of 5-phosphoribosyl-1-pyrophosphate and de novo purine synthesis in a human hepatoma cell line. Boer P, et al. **Metabolism** 1995 Nov;44(11):1469-74

Effect of methotrexate on the intracellular phosphoribosyl pyrophosphate level and glucose transport of Ehrlich ascites tumor cells in vitro. Fung KP, et al. **Oncology** 1996 Jan-Feb;53(1):27-30

PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE see **AMIDOPHOSPHORIBOSYLTRANSFERASE**

PHOSPHORIBOSYL PYROPHOSPHATE SYNTHETASE see **RIBOSE-PHOSPHATE PYROPHOSPHOKINASE**

PHOSPHORIBOSYLANTHRANILATE PYROPHOSPHORYLASE see **ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE**

PHOSPHORIC ACID ESTERS

ADMINISTRATION & DOSAGE

[Long-term consequences of the effects of single inhalation of Pu-239 in association with tributyl phosphate and hexachlorobutadiene in rats] Kalmykova ZI, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):88-93 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Long-term consequences of the effects of single inhalation of Pu-239 in association with tributyl phosphate and hexachlorobutadiene in rats] Kalmykova ZI, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):88-93 (Eng. Abstr.) **(Rus)**

ANALYSIS

Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Drueckes P, et al. **Anal Biochem** 1995 Sep 1;230(1):173-7

CHEMISTRY

Influence of membrane components on the stability and drug release properties of reverse phase evaporation vesicles (REVs): light sensitive all-trans retinal, negatively charged phospholipid dicetylphosphate and cholesterol. Gürsel M, et al. **J Microencapsul** 1995 Nov-Dec;12(6):661-9

Evidence for DNA phosphate backbone alkylation and cleavage by pyrrolo[1,2-a]benzimidazoles: small molecules capable of causing base-pair-specific phosphodiester bond hydrolysis. Schulz WG, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11854-8

METABOLISM

Biosynthesis of cyclic diterpene hydrocarbons in rice cell suspensions: conversion of 9,10-syn-labda-8(17),13-dienyl diphosphate to 9beta-pimara-7,15-diene and stemar-13-ene. Mohan RS, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):33-47

Biochemical evidence for the formation of a covalent acyl-phosphate linkage between UDP-N-acetylmuramate and ATP in the Escherichia coli UDP-N-acetylmuramate:L-alanine ligase-catalyzed reaction. Falk PJ, et al. **Biochemistry** 1996 Feb 6; 35(5):1417-22

4-Phospho-hydroxy-L-threonine is an obligatory intermediate in pyridoxal 5'-phosphate coenzyme biosynthesis in Escherichia coli K-12. Zhao G, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):275-80

Deuterium isotope effect on the metabolism of the flame retardant tris(2,3-dibromopropyl) phosphate in the isolated perfused rat liver. Van Beerendonk GJ, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):111-7

Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by

phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Kato T, et al. **Psychiatry Res** 1995 Sep 29;61(3):151-60

Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Yaida Y, et al. **Regul Pept** 1995 Oct 20; 59(2):193-9

[The enzymes of glutamate and organic phosphate metabolism in the saliva in fluorosis (clinical and experimental research)] Petrovich UA, et al. **Stomatologiia (Mosk)** 1995;74(2):26-8 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Screening for apoptosis inducers in microbial products and induction of apoptosis by cytostatin. Yamazaki K, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1138-40

Biochemical characterization of liver microsomal, Golgi, lysosomal, and serum beta-glucuronidases in dibutyl phosphate-treated rats. Nishimura Y, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):56-66

Intracellular sorting of lysosomal beta-glucuronidase is altered due to administration of dibutyl phosphate. Nishimura Y, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):46-55

POISONING

Effect of pyridostigmine pretreatment on cardiorespiratory function in tabun poisoning. Worek F, et al. **Hum Exp Toxicol** 1995 Aug;14(8):634-42

TOXICITY

Toxic effects of butylated triphenyl phosphate-based hydraulic fluid and tricresyl phosphate in female F344 rats. Latendresse JR, et al. **Vet Pathol** 1995 Jul;32(4):394-402

[A comparative study of the interaction of phosphoric acid dichlorovinyl esters with a neurotoxic esterase from the brain of hens and rats] Makhaeva GF, et al. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug;31(4):396-403 (Eng. Abstr.) **(Rus)**

URINE

Urinary excretion of alkylphosphates in the general population (Italy). Aprea C, et al. **Sci Total Environ** 1996 Jan 5;177(1-3):37-41

PHOSPHORIC ACIDS

Synthesis of novel phosphoramidite reagents for the attachment of antisense oligonucleotides to various regions of the benzophenanthridine ring system. Chen JK, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):473-82

Effect of mobile phase additives on peptide retention in reversed-phase chromatography with pellicular and totally porous sorbents. Corradini D, et al. **J Chromatogr A** 1996 Mar 29;728(1-2):225-33

The synthesis of blocked triplet-phosphoramidites and their use in mutagenesis. Ono A, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4677-82

[Hygienic assessment of dust and gas factors at the enterprises using phosphoric acid production wastes] Rumiantsev GI, et al. **Gig Sanit** 1996 Mar-Apr;(2):13-5 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Scanning electron microscopic study and shear bond strength measurement with 5% and 37% phosphoric acid. Bhad WA, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct; 108(4):410-4

Comment on concentration and etch time for phosphoric acid [letter] Unruh MD. **Am J Orthod Dentofacial Orthop** 1996 Jul;110(1):15A-16A

ADVERSE EFFECTS

Long-time etching at low pH jeopardizes periodontal healing. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun; 22(6):459-63

Periodontal tissue-vitality after different etching modalities. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun;22(6):464-8

CHEMICAL SYNTHESIS

Synthesis of novel phosphoramidite reagents for the attachment of antisense oligonucleotides to various regions of the benzophenanthridine ring system. Chen JK, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):473-82

Oligodeoxynucleoside phosphoramidates (P-NH2): synthesis and thermal stability of duplexes with DNA and RNA targets. Peyrottes S, et al. **Nucleic Acids Res** 1996 May 15;24(10):1841-8

CHEMISTRY

Computational studies of crystalline H3PO4. Moss GR, et al. **Acta Crystallogr B** 1995 Oct 1;51 (Pt 5):650-60

Experimental electron density in crystalline H3PO4. Souhassou M, et al. **Acta Crystallogr B** 1995 Oct 1;51 (Pt 5):661-8

Reversible structural changes of octacalcium phosphate and labile acid phosphate. Suzuki O, et al. **J Dent Res** 1995 Nov;74(11):1764-9

PHOSPHORIC DIESTER HYDROLASE INHIBITORS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHORIC DIESTER HYDROLASES

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179-83 (18 ref.)

Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. Iwasaki T, et al. **J Med Chem** 1996 Jul 5;39(14):2696-704

ANALYSIS

Determination of phosphodiesterase activity in rat mast cells using the fluorescent cAMP analogue anthraniloyl cAMP. Alfonso A, et al. **Cell Signal** 1995 Jul;7(5):513-8

Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro. Stief CG, et al. **Urol Int** 1995;55(4):183-9

[Phosphatidylinositol specific phospholipase C (PI-PLC) in differentiation of Listeria monocytogenes and Listeria innocua] Pachelska M, et al. **Med Dosw Mikrobiol** 1995; 47(1-2):17-23 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS see PHOSPHODIESTERASE INHIBITORS

BIOSYNTHESIS

Receptor-mediated induction of human glomerular epithelial cell alkaline phosphodiesterase I by glucocorticoids. Stefanović V, et al. **Arch Physiol Biochem** 1995 Aug; 103(4):427-30

Identification of a Bacillus thuringiensis gene that positively regulates transcription of the phosphatidylinositol-specific phospholipase C gene at the onset of the stationary phase. Lereclus D, et al. **J Bacteriol** 1996 May;178(10):2749-56

Characterization of a plasma membrane-associated phosphoinositide-specific phospholipase C from soybean. Shi J, et al. **Plant J** 1995 Sep;8(3):381-90

BLOOD

Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Tenor H, et al. **Clin Exp Allergy** 1995 Jul;25(7):616-24

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Seldon PM, et al. **Mol Pharmacol** 1995 Oct;48(4):747-57

CHEMISTRY

Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta [see comments] Essen LO, et al. **Nature** 1996 Apr 18;380(6575):595-602. Comment in: Nature 1996 Apr 18;380(6575):581-3.

Characterization of a plasma membrane-associated phosphoinositide-specific phospholipase C from soybean. Shi J, et al. **Plant J** 1995 Sep;8(3):381-90

Expression, characterization, and crystallization of the catalytic core of rat phosphatidylinositide-specific phospholipase C delta 1. Grobler JA, et al. **Protein Sci** 1996 Apr;5(4):680-6

DRUG EFFECTS

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Barnette MS, et al. **Biochem Pharmacol** 1996 Apr 12;51(7):949-56

Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Madelian V, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1739-47

Nitric oxide, an enteric nonadrenergic-noncholinergic relaxant transmitter: evidence using phosphodiesterase V and nitric oxide synthase inhibition. Williams SJ, et al. **Br J Pharmacol** 1995 Sep;116(2):1789-96

Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Hulley P, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2431-40

Rolipram inhibition of phosphodiesterase-4 activation. DiSanto ME, et al. **Eur J Pharmacol** 1995 Jul 18; 290(2):169-72

Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. Begany DP, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):37-41

GENETICS

Growth of a mutant defective in a putative phosphoinositide-specific phospholipase C of Schizosaccharomyces pombe is restored by low concentrations of phosphate and inositol. Fankhauser H, et al. **Curr Genet** 1995 Jul;28(2):199-203

cDNA sequence and gene locus of the human retinal phosphoinositide-specific phospholipase-C beta 4 (PLCB4). Alvarez RA, et al. **Genomics** 1995 Sep 1; 29(1):53-61

Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Kawagoe H, et al. **Genomics** 1995 Nov 20;30(2):380-4

A Bacillus subtilis secreted phosphodiesterase/alkaline phosphatase is the product of a Pho regulon gene, phoD. Eder S, et al. **Microbiology** 1996 Aug;142 (Pt 8):2041-7

Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Bennett J, et al. **Nat Med** 1996 Jun;2(6):649-54

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257-85 (161 ref.)

METABOLISM

Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Houslay MD. **Adv Enzyme Regul** 1995;35:303-38 (68 ref.)

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3-6 (27 ref.)

Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Suttorp N, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C778-85

Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP [editorial] Zeidel ML. **Am J Physiol** 1996 Jul; 271(1 Pt 2):F1

Glycosylphosphatidylinositol-alkaline phosphatase from calf intestine as substrate for glycosylphosphatidylinositol-specific phospholipases--microassay using hydrophobic chromatography in pipet tips. Rhode H, et al. **Anal Biochem** 1995 Oct 10;231(1):99-108

Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Exton JH. **Annu Rev Pharmacol Toxicol** 1996;36:481-509 (170 ref.)

Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Polson JB, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:403-27 (87 ref.)

Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Sugiura T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):113-7

Effect of deoxycholate on guanine-nucleotide-dependent carbachol stimulation of phosphoinositidase C in mouse brain cortical membranes. Bas N, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):445-9

Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gs alpha and is not a consequence of phosphoinositidase C activation. Burford NT, et al. **Biochem J** 1996 May 1;315 (Pt 3):883-8

Changes in the components of a nuclear inositide cycle during differentiation in murine erythroleukaemia cells. Divecha N, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):63-7

Cyclic GMP regulates activation of phosphoinositidase C by bradykinin in sensory neurons. Harvey JS, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):539-44

KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase. Ichimura M, et al. **Biochem J** 1996 May 15;316 (Pt 1):311-6

Asymmetric signal transduction in polarized ileal Na(+)-absorbing cells: carbachol activates brush-border but not basolateral-membrane PIP2-PLC and translocates PLC-gamma 1 only to the brush border. Khurana S, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):509-18

Thyroid-stimulating hormone rapidly stimulates inositol polyphosphate formation in FRTL-5 thyrocytes without activating phosphoinositidase C. Singh J, et al. **Biochem J** 1996 May 15;316 (Pt 1):175-82

Effect of lithium on muscarinic cholinoceptor-stimulated phosphoinositide-specific phospholipase C substrate selectivity in CHO-m1 cells. Godwin M, et al. **Biochem Soc Trans** 1995 Aug;23(3):421S

Protein kinase C modulation of phosphoinositidase C in 1321N1 human astrocytoma cells. Purkiss JR. **Biochem Soc Trans** 1996 Feb;24(1):54S

Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"-P1,P3-triphosphate hydrolase. Barnes LD, et al. **Biochemistry** 1996 Sep 10;35(36):11529-35

Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: evidence for defective phospholipase C activation. Yang X, et al. **Blood** 1996 Sep 1;88(5):1676-83

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Banner KH, et al. **Br J Pharmacol** 1995 Dec;116(8):3169-74

Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Shafiee-Nick R, et al. **Br J Pharmacol** 1995 Aug;115(8):1486-92

Hydrolysis of cyclic guanosine monophosphate and cyclic

adenosine monophosphate by the penis and aorta of the diabetic rat. Miller MA, et al. **Br J Urol** 1996 Aug; 78(2):252–6

Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Rao CV, et al. **Cancer Res** 1996 Feb 1;56(3):532–7

Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Reddy BS, et al. **Cancer Res** 1996 May 15;56(10):2314–20

Interferon beta mediated intracellular signalling traffic in human lymphocytes. Cataldi A, et al. **Cell Signal** 1995 Aug; 7(6):627–33

Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells. DiSanto ME, et al. **Cell Signal** 1995 Nov;7(8):827–35

Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Hichami A, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):91–7

Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Howell RE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S172–3

Unilateral ureteral obstruction increases glomerular soluble guanylyl cyclase activity. McDowell KA, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1498–503

Phosphatidylinositol hydrolysis by Trypanosoma brucei glycosylphosphatidylinositol phospholipase C. Bütikofer P, et al. **J Biol Chem** 1996 Jun 28;271(26):15533–41

Phosphatidylinositol phospholipase C is activated allosterically by the aminoglycoside G418. 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecylphosphonate and its analogs inhibit glycosylphosphatidylinositol phospholipase C. Morris JC, et al. **J Biol Chem** 1996 Jun 28;271(26):15468–77

Simultaneous but independent activation of adenylate cyclase and glycosylphosphatidylinositol-phospholipase C under stress conditions in Trypanosoma brucei. Rolin S, et al. **J Biol Chem** 1996 May 3;271(18):10844–52

Dissociation of cyclic inositol phosphohydrolase activity from annexin III. Sekar MC, et al. **J Biol Chem** 1996 Apr 5;271(14):8295–9

Identification of determinants in the alpha-subunit of Gq required for phospholipase C activation. Venkatakrishnan G, et al. **J Biol Chem** 1996 Mar 1;271(9):5066–72

Growth-promoting effects of Ca(2+)-mobilizing agents in hepatocytes: lack of correlation between the acute activation of phosphoinositide-specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2 alpha. Dajani OF, et al. **J Cell Physiol** 1996 Sep;168(3):608–17

Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. Duplantier AJ, et al. **J Med Chem** 1996 Jan 5; 39(1):120–5

Light adaptation and the rising phase of the flash photocurrent of salamander retinal rods. Jones GJ. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):441–51

Multiple forms of the enzyme glycerophosphodiesterase are present in human brain. Ross BM, et al. **Lipids** 1995 Dec; 30(12):1075–81

Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Alvarez R, et al. **Mol Pharmacol** 1995 Oct;48(4):616–22

The effects of the ring fragmentation product of thymidine C5-hydrate on phosphodiesterases and klenow (exo-) fragment. Matray TJ, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4642–8

Comparison of features of the RNase activity of 5'-exonuclease-1 and 5'-exonuclease-2 of Saccharomyces cerevisiae. Poole TL, et al. **Nucleic Acids Symp Ser** 1995; (33):79–81

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Beavo JA. **Physiol Rev** 1995 Oct; 75(4):725–48 (179 ref.)

Tomato annexins p34 and p35 bind to F-actin and display nucleotide phosphodiesterase activity inhibited by phospholipid binding. Calvert CM, et al. **Plant Cell** 1996 Feb;8(2):333–42

Involvement of guanylate cyclase and phosphodiesterases in the functional heterogeneity of human blood platelet subpopulations. Opper C, et al. **Thromb Res** 1995 Dec 15; 80(6):461–70

Inhibition of rat brain phosphatidylinositol-specific phospholipase C by aluminum: regional differences, interactions with aluminum salts, and mechanisms. Nostrandt AC, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):118–25

Daily variations in cGMP, guanylate cyclase and phosphodiesterase in the golden hamster retina. Faillace MP, et al. **Vision Res** 1996 May;36(10):1365–9

[Effect of phosphodiesterase IV inhibitors on bone tissue: a possibility for its use as a new agent to treat osteoporosis] Kasugai S, et al. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):432 **(Jpn)**

PHARMACOLOGY

Acetylcholinesterase in Dendrobaena veneta (Oligochaeta: Opisthopora) is present with forms sensitive and insensitive to phosphatidylinositol phospholipase C. Biochemical characterization and histochemical localization in the nervous system. Talesa V, et al. **Eur J Biochem** 1996 Jun 1;238(2):538–48

High efficiency of glycerol 2-phosphate and sn-glycerol 3-phosphate as nucleotidyl acceptors in snake venom phosphodiesterase esterifications. Formation of primary and secondary AMP-O-glyceryl and AMP-O-glycerophosphoryl esters and evidence for an acceptor-binding enzyme site. Vergeles JM, et al. **Eur J Biochem** 1995 Oct 15;233(2):442–7

Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Hulley P, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2431–40

PHYSIOLOGY

CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Kelley TJ, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):657–64

Phosphoinositide-specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99–113 (143 ref.)

Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Spina D, et al. **Br J Pharmacol** 1995 Oct;116(4):2334–40

Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Suttorp N, et al. **Lung** 1996;174(3):181–94

PHOSPHORIC MONOESTER HYDROLASES

ANALYSIS

Identification and subcellular localization of sphinganine-phosphatases in rat liver. De Ceuster P, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):139–46

Identification of a glycosylphosphatidylinositol-anchored glycoprotein with nucleoside phosphatase activity on the membrane of pig pancreatic zymogen granules. Soriani M, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):683–95

A fluorogenic assay of endogenous phosphatase for assessment of cell adhesion. Tolosa E, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):165–72

Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Vinitha R, et al. **Jpn J Med Sci Biol** 1995 Jun;48(3):145–56

ANTAGONISTS & INHIBITORS

Phosphatase inhibitors promote ICAM-1 and LFA-1 mediated homotypic aggregation of Jurkat and U937 cells. Weeks BS, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):82–7

Inhibition of phosphate-metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287–324 (169 ref.)

Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Arendt T, et al. **Neuroscience** 1995 Dec;69(3):691–8

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

BIOSYNTHESIS

Cloning and expression of a human placenta inositol 1,3,4,5-tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Drayer AL, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):243–9

Production of recombinant human brain type I inositol-1,4,5-trisphosphate 5-phosphatase in Escherichia coli. Lack of phosphorylation by protein kinase C. Erneux C, et al. **Eur J Biochem** 1995 Dec 1;234(2):598–602

Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels. Argaud D, et al. **J Biol Chem** 1995 Oct 13;270(41):24229–36

[Regulation of biosynthesis of intracellular enzymes in Bacillus intermedius 3S-19] Znamenskaia LV, et al. **Prikl Biokhim Mikrobiol** 1995 Jul-Aug;31(4):412–6 (Eng. Abstr.) **(Rus)**

BLOOD

[Alkaline phosphatase isoenzymes in a case of transient hyperphosphatasemia] Botti C, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):587–9 (Eng. Abstr.) **(Ita)**

[Benign transient hyperphosphatasemia: the contribution of 20 new cases] Garrote de Marcos JM, et al. **An Esp Pediatr** 1996 Feb;44(2):112–6 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Solution structure of the MutT enzyme, a nucleoside triphosphate pyrophosphohydrolase. Abeygunawardana C, et al. **Biochemistry** 1995 Nov 21;34(46):14997–5005

Mutation of the conserved domains of two inositol polyphosphate 5-phosphatases. Jefferson AB, et al. **Biochemistry** 1996 Jun 18;35(24):7890–4

Crystal structure of the rat liver fructose-2,6-bisphosphatase based on selenomethionine multiwavelength anomalous dispersion phases. Lee YH, et al. **Biochemistry** 1996 May 14;35(19):6010–9

The role of Glu 57 in the mechanism of the Escherichia coli MutT enzyme by mutagenesis and heteronuclear NMR. Lin J, et al. **Biochemistry** 1996 May 28;35(21):6715–26

Identity of zinc ion-dependent acid phosphatase from bovine brain and myo-inositol 1-phosphatase. Caselli A, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):241–9

Spectroscopic studies of myo-inositol monophosphatase with a novel fluorescent substrate. Pineda T, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):259–64

A novel GDP-mannose mannosyl hydrolase shares homology with the MutT family of enzymes. Frick DN, et al. **J Biol Chem** 1995 Oct 13;270(41):24086–91

Crystallization and preliminary X-ray analysis of fructose 6-phosphate, 2-kinase:fructose 2,6-bisphosphatase. Istvan ES, et al. **Protein Sci** 1995 Nov;4(11):2439–41

DEFICIENCY

Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus. Suchy SF, et al. **Hum Mol Genet** 1995 Dec;4(12):2245–50

3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. Jaeken J, et al. **J Inherit Metab Dis** 1996;19(2):223–6

GENETICS

Polymorphisms and probable lack of mutation in a human mutT homolog, hMTH1, in hereditary nonpoliposis colorectal cancer. Wu C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1239–45

Hepatocyte growth factor and transforming growth factor beta regulate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatocyte primary cultures. Joaquin M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):235–40

cDNA and genomic sequences for rat 8-oxo-dGTPase that prevents occurrence of spontaneous mutations due to oxidation of guanine nucleotides. Cai JP, et al. **Carcinogenesis** 1995 Oct;16(10):2343–50

Isolation and mapping of a human gene (DIFF6) homologous to yeast CDC3, CDC10, CDC11, and CDC12, and mouse Diff6. Mori T, et al. **Cytogenet Cell Genet** 1996;73(3):224–7

Cloning and characterization of a human cDNA (INPPL1) sharing homology with inositol polyphosphate phosphatases. Hejna JA, et al. **Genomics** 1995 Sep 1; 29(1):285–7

Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. Jänne PA, et al. **Genomics** 1995 Jul 20; 28(2):280–5

Chromosomal mapping of the gene (INPP5A) encoding the 43-kDa membrane-associated inositol polyphosphate 5-phosphatase to 10q26.3 by fluorescence in situ hybridization. Mitchell CA, et al. **Genomics** 1996 Jan 1; 31(1):139–40

Identification and chromosomal mapping of the mouse inositol polyphosphate 1-phosphatase gene. Okabe I, et al. **Genomics** 1995 Nov 20;30(2):358–60

Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Okamoto K, et al. **Int J Cancer** 1996 Feb 8;65(4):437–41

Elevated mutation rate in mutT bacteria during starvation: evidence for DNA turnover? Bridges BA. **J Bacteriol** 1996 May;178(9):2709–11

Identification and characterization of phoN-Sf, a gene on the large plasmid of Shigella flexneri 2a encoding a nonspecific phosphatase. Uchiya KI, et al. **J Bacteriol** 1996 Aug;178(15):4548–54

Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-kinase/fructose 2,6-bisphosphatase from human placenta. Sakai A, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):506–11

Mouse MTH1 protein with 8-oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphatase activity that prevents transversion mutation. cDNA cloning and tissue distribution. Kakuma T, et al. **J Biol Chem** 1995 Oct 27;270(43):25942–8

Purification and characterization of two isoenzymes of DL-glycerol-3-phosphatase from Saccharomyces cerevisiae. Identification of the corresponding GPP1 and GPP2 genes and evidence for osmotic regulation of Gpp2p expression by the osmosensing mitogen-activated protein kinase signal transduction pathway. Norbeck J, et al. **J Biol Chem** 1996 Jun 7;271(23):13875–81

Suppressors of Escherichia coli mutT: anitimutators for DNA replication errors. Schaaper RM. **Mutat Res** 1996 Feb 19; 350(1):17–23

Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Steen VM, et al.

Pharmacogenetics 1996 Feb;6(1):113–6
Genetics of myo–inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

IMMUNOLOGY

Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer. Nielsen JT, et al. **Clin Physiol** 1995 Sep;15(5):467–81

ISOLATION & PURIFICATION

The purification and properties of phosphonoacetate hydrolase, a novel carbon–phosphorus bond–cleavage enzyme from Pseudomonas fluorescens 23F. McGrath JW, et al. **Eur J Biochem** 1995 Nov 15;234(1):225–30
Purification and characterization of two isoenzymes of DL–glycerol–3–phosphatase from Saccharomyces cerevisiae. Identification of the corresponding GPP1 and GPP2 genes and evidence for osmotic regulation of Gpp2p expression by the osmosensing mitogen–activated protein kinase signal transduction pathway. Norbeck J, et al. **J Biol Chem** 1996 Jun 7;271(23):13875–81
Purification and biochemical characterization of a mammalian phosphatidylinositol 3,4,5–trisphosphate 5–phosphatase. Woscholski R, et al. **J Biol Chem** 1995 Dec 29;270(52):31001–7
The 145–kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5–triphosphate 5–phosphatase. Damen JE, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1689–93

METABOLISM

H2O2 activates red blood cell K–Cl cotransport via stimulation of a phosphatase. Bize I, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C849–55
6–Phosphofructo–2–kinase/fructose–2,6–bisphosphatase: a metabolic signaling enzyme. Pilkis SJ, et al. **Annu Rev Biochem** 1995;64:799–835 (221 ref.)
Effects of ultraviolet light irradiation in biotreatment of organophosphates. Hung SC, et al. **Appl Biochem Biotechnol** 1996 Jan;56(1):37–47
Islet fructose 6–phosphate, 2–kinase:fructose 2,6–bisphosphatase: isozymic form, expression, and characterization. Sakurai T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):159–63
2–Carboxyarabinitol 1–phosphate (CA1P) formation through a phosphate exchange reaction catalysed by the CA1P phosphatase from French bean (Phaseolus vulgaris L.). Andralojc PJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):389–93
Structure–activity relationship of cytoplasmic 5'–nucleotidase substrate sites. Skladanowski AC, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1001–7
Bovine inositol monophosphatase: enzyme–metal–ion interactions studied by pre–equilibrium fluorescence spectroscopy. Thorne MR, et al. **Biochem J** 1996 May 1; 315 (Pt 3):989–94
Dictyostelium discoideum contains three inositol monophosphatase activities with different substrate specificities and sensitivities to lithium. Van Dijken P, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):491–5
Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592–6 (40 ref.)
Catalytic activity of the SH2 domain of human pp60c–src; evidence from NMR, mass spectrometry, site–directed mutagenesis and kinetic studies for an inherent phosphatase activity. Boerner RJ, et al. **Biochemistry** 1995 Nov 21; 34(46):15351–8
The contribution of lysine–36 to catalysis by human myo–inositol monophosphatase. Ganzhorn AJ, et al. **Biochemistry** 1996 Aug 20;35(33):10957–66
Mutation of the conserved domains of two inositol polyphosphate 5–phosphatases. Jefferson AB, et al. **Biochemistry** 1996 Jun 18;35(24):7890–4
The role of Glu 57 in the mechanism of the Escherichia coli MutT enzyme by mutagenesis and heteronuclear NMR. Lin J, et al. **Biochemistry** 1996 May 28;35(21):6715–26
Spectroscopic studies of myo–inositol monophosphatase with a novel fluorescent substrate. Pineda T, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):259–64
Lethal double–stranded RNA processing activity of ribonuclease III in the absence of suhB protein of Escherichia coli. Inada T, et al. **Biochimie** 1995; 77(4):294–302
Role of phosphatases during transport and energy metabolism in Labeo rohita after exposure to cypermethrin. Philip GH, et al. **Biomed Environ Sci** 1996 Mar;9(1):52–9
cDNA and genomic sequences for rat 8–oxo–dGTPase that prevents occurrence of spontaneous mutations due to oxidation of guanine nucleotides. Cai JP, et al. **Carcinogenesis** 1995 Oct;16(10):2343–50
The expression of a specific 2–deoxyglucose–6P phosphatase prevents catabolite repression mediated by 2–deoxyglucose in yeast. Randez–Gil F, et al. **Curr Genet** 1995 Jul; 28(2):101–7
Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798–805 (79 ref.)
Phosphatidylinositol 3,4,5–trisphosphate is a substrate for the 75 kDa inositol polyphosphate 5–phosphatase and a novel 5–phosphatase which forms a complex with the p85/p110 form of phosphoinositide 3–kinase. Jackson SP, et al. **EMBO J** 1995 Sep 15;14(18):4490–500
Purification and characterization of the phosphatidylinositol–3,4,5–trisphosphate phosphatase in bovine thymus. Kabuyama Y, et al. **Eur J Biochem** 1996 Jun 1;238(2):350–6
Tissue distribution and intracellular localisation of the 75–kDa inositol polyphosphate 5–phosphatase. Speed CJ, et al. **Eur J Biochem** 1995 Nov 15;234(1):216–24
p150Ship, a signal transduction molecule with inositol polyphosphate–5–phosphatase activity. Lioubin MN, et al. **Genes Dev** 1996 May 1;10(9):1084–95
Inositols do it all. Majerus PW. **Genes Dev** 1996 May 1; 10(9):1051–3 (11 ref.)
Reflectance enzyme histochemistry (REH): visualization of cerium–based and DAB primary reaction products of phosphatases and oxidases in cryostat sections by confocal laser scanning microscopy. Halbhuber KJ, et al. **Histochem Cell Biol** 1996 Mar;105(3):239–49
Rapid enzymatic method for biotyping and control of lactic acid bacteria used in the production of yogurt and some cheeses. Bianchi–Salvadori B, et al. **Int J Food Microbiol** 1995 Oct;27(2–3):253–61
Properties of two sugar phosphate phosphatases from Streptococcus bovis and their potential involvement in inducer expulsion. Cook GM, et al. **J Bacteriol** 1995 Dec; 177(23):7007–9
Fructosebisphosphatase isoenzymes of the chemoautotroph Xanthobacter flavus. van den Bergh ER, et al. **J Bacteriol** 1995 Oct;177(20):5860–4
Arginine 343 and 350 are two active residues involved in substrate binding by human Type I D–myo–inositol 1,4,5,–trisphosphate 5–phosphatase. Communi D, et al. **J Biol Chem** 1996 May 17;271(20):11676–83
Post–translational modification of human brain type I inositol–1,4,5–trisphosphate 5–phosphatase by farnesylation. De Smedt F, et al. **J Biol Chem** 1996 Apr 26;271(17):10419–24
Purification and characterization of a novel xylulose 5–phosphate–activated protein phosphatase catalyzing dephosphorylation of fructose–6–phosphate,2–kinase:fructose–2,6–bisphosphatase. Nishimura M, et al. **J Biol Chem** 1995 Nov 3;270(44):26341–6
The ATP–binding site in the 2–kinase domain of liver 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase. Study of the role of Lys–54 and Thr–55 by site–directed mutagenesis. Vertommen D, et al. **J Biol Chem** 1996 Jul 26;271(30):17875–80
Purification and biochemical characterization of a mammalian phosphatidylinositol 3,4,5–trisphosphate 5–phosphatase. Woscholski R, et al. **J Biol Chem** 1995 Dec 29;270(52):31001–7
Purification and characterization of diacylglycerol pyrophosphate phosphatase from Saccharomyces cerevisiae. Wu WI, et al. **J Biol Chem** 1996 Jan 26; 271(4):1868–76
Ecto–alkaline phosphatase considered as levamisole–sensitive phosphohydrolase at physiological pH range during mineralization in cultured fetal calvaria cells. Anagnostou F, et al. **J Cell Biochem** 1996 Mar 15;60(4):484–94
Differential regulation of the expression of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase and pyruvate kinase by cyclic adenosine 3',5'–monophosphate in fetal and adult hepatocytes. Casado M, et al. **J Cell Physiol** 1995 Dec;165(3):630–8
Protein kinases and phosphatases during the developmental cycle of myxobacteria. Muñoz Dorado J, et al. **Microbiologia** 1995 Sep;11(3):376–8
Unusual inositol triphosphate metabolism in yeast [letter] Robinson KS, et al. **Microbiology** 1996 Jun;142 (Pt 6):1333–4
A presynaptic inositol–5–phosphatase. McPherson PS, et al. **Nature** 1996 Jan 25;379(6563):353–7
Myo–inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate. Vadnal R, et al. **Neuropsychopharmacology** 1995 Jul;12(4):277–85
The SAL1 gene of Arabidopsis, encoding an enzyme with 3'(2'),5'–bisphosphate nucleotidase and inositol polyphosphate 1–phosphatase activities, increases salt tolerance in yeast. Quintero FJ, et al. **Plant Cell** 1996 Mar; 8(3):529–37
Covalent control of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)
Inhibition of glycolysis in boar spermatozoa by alpha–chlorohydrin phosphate appears to be mediated by phosphatase activity. Jones AR, et al. **Reprod Fertil Dev** 1995;7(5):1089–94

PHYSIOLOGY

Angiotensin II–mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)
A prospective view on phosphatases and replicative senescence. Bernier L, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):13–9 (30 ref.)
Phosducin and PP33 are in vivo targets of PKA and type 1 or 2A phosphatases, regulators of cell elongation in teleost rod inner–outer segments. Pagh–Roehl K, et al. **J Neurosci** 1995 Oct;15(10):6475–88
Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Ono M, et al. **Nature** 1996 Sep 19;383(6597):263–6

PHOSPHORUS

see related
ORGANOPHOSPHORUS COMPOUNDS
ORGANOTHIOPHOSPHORUS COMPOUNDS

Investigation of the impurities found in methamphetamine synthesised from pseudoephedrine by reduction with hydriodic acid and red phosphorus. Windahl KL, et al. **Forensic Sci Int** 1995 Dec 18;76(2):97–114
Calcium and phosphorus nutrition in infants. Demarini S, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):367–73 (85 ref.)

ADMINISTRATION & DOSAGE

Response of broilers to graded levels of microbial phytase added to maize–soyabean–meal–based diets containing three levels of non–phytate phosphorus. Kornegay ET, et al. **Br J Nutr** 1996 Jun;75(6):839–52
Absorption and endogenous excretion of phosphorus in growing broiler chicks, as influenced by calcium and phosphorus ratios in feed. al–Masri MR. **Br J Nutr** 1995 Sep;74(3):407–15
Effects of supplemental phytase and phosphorus on histological, mechanical and chemical traits of tibia and performance of turkeys fed on soyabean–meal–based semi–purified diets high in phytate phosphorus. Qian H, et al. **Br J Nutr** 1996 Aug;76(2):263–72
Effect of three levels of vitamin D intake in preterm infants receiving high mineral–containing milk. Koo WW, et al. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):182–9
Long–term control of hyperparathyroidism in advanced renal failure by low–phosphorus low–protein diet supplemented with calcium (without changes in plasma calcitriol). Combe C, et al. **Nephron** 1995;70(3):287–95
Phosphorus equivalence of microbial phytase in turkey diets as influenced by calcium to phosphorus ratios and phosphorus levels. Qian H, et al. **Poult Sci** 1996 Jan; 75(1):69–81
Effects of supplemental phytase and phosphorus on histological and other tibial bone characteristics and performances of broilers fed semi–purified diets. Qian H, et al. **Poult Sci** 1996 May;75(5):618–26
[Supplementation of premature infant nutrition with calcium and phosphor for improving mineral supply of premature and small–for–gestational age newborn infants] Hettrich B, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):334–40 (Eng. Abstr.) **(Ger)**

ANALYSIS

Presence of phosphorus in Nephila clavipes dragline silk. Michal CA, et al. **Biophys J** 1996 Jan;70(1):489–93
Radon emanation coefficients for phosphogypsum. Rutherford PM, et al. **Health Phys** 1995 Oct;69(4):513–20
Changes in tissue calcium and phosphorus content and plasma concentrations of parathyroid hormone and calcitonin after long–term magnesium deficiency in rats. Planells E, et al. **J Am Coll Nutr** 1995 Jun;14(3):292–8
Effects of citric acid treatment on the Ca, P and Mg contents of human dental roots. Hennequin M, et al. **J Clin Periodontol** 1995 Jul;22(7):550–7
Phosphorus J coupling constants of ATP in human myocardium and calf muscle. Jung WI, et al. **J Magn Reson B** 1996 Jan;110(1):39–46
Effects of voltage clamping on epithelial cell composition in toad urinary bladder studied with x–ray microanalysis. Bowler JM, et al. **J Membr Biol** 1995 May;145(2):175–85
In vivo phosphorus spectroscopy of human skin. Bohning DE, et al. **Magn Reson Med** 1996 Feb;35(2):186–93
Detection and quantitation of phosphorus metabolites in crude tissue extracts by 1H and 31P NMR: use of gradient assisted 1H–31P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. Pollesello P, et al. **NMR Biomed** 1995 Aug;8(5):190–6
Immunohistochemical study on collagenous proteins and biophysical analysis of crystals in extraskeletal chondroma. Ota M, et al. **Pathol Int** 1995 Aug;45(8):596–601
[Phosphorus–containing inhibitors of penicillin acylase. 4. Irreversible inhibition of penicillin acylase from Escherichia coli by monoaryl esters of benzylphosphonic acid] Solodenko VA, et al. **Ukr Biokhim Zh** 1995 Sep–Oct; 67(5):32–42 (Eng. Abstr.) **(Rus)**

BLOOD

Decreasing the complications of renal osteodystrophy secondary to high phosphorus levels by using an innovative self–monitoring educational program. Zagaroli AM, et al. **Adv Perit Dial** 1995;11:254–7
Pseudohyperphosphatemia in multiple myeloma [letter] Mavrikakis M, et al. **Am J Hematol** 1996 Feb;51(2):178–9
Review of the literature: severe hyperphosphatemia. Thatte L, et al. **Am J Med Sci** 1995 Oct;310(4):167–74
The effect of intravenous loading with glucose on inorganic

phosphorus and lipids-bound phosphorus in the patients with subarachnoid haemorrhages (SAH). Pilarczyk M. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:137-9

The effect of intravenous loading with glucose on inorganic phosphorus and lipids-bound phosphorus content in the patients with transient brain ischaemia. Pilarczyk M. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:133-6

Postparturient hypocalcemia of dairy cows: a model for the study of the interdependence of Ca, Pi, and Mg homeostasis. Riond JL, et al. **Bone** 1995 Oct;17(4 Suppl):429S-434S

Bilirubin interference with determination of creatinine, lactate, phosphorus, and uric acid on Beckman Synchron CX7 [letter] Beyne P, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):988-90

Biochemical effects of oral sodium phosphate. DiPalma JA, et al. **Dig Dis Sci** 1996 Apr;41(4):749-53

Normalization of mineral homeostasis after reversal of osteopetrosis. Nesbitt T, et al. **J Bone Miner Res** 1995 Jul; 10(7):1116-21

Short- and long-term effects of calcitonin and calcium administration on blood calcium, magnesium and inorganic phosphorus in post menopausal osteoporosis. Casao E, et al. **J Trace Elem Med Biol** 1995 Oct;9(3):181-4

Correction of chronic metabolic acidosis in haemodialysed patients by acetate-free biofiltration does not influence parathyroid function. de Précigout V, et al. **Nephrol Dial Transplant** 1995;10(6):821-4

Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease. Lippuner K, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):70-4

Divergent selection for body weight and yolk precursor in Coturnix coturnix japonica. 11. Correlated responses over thirty generations. Nestor KE, et al. **Poult Sci** 1996 Apr; 75(4):472-7

Divergent selection for body weight and yolk precursor in Coturnix coturnix japonica. 10. Response to selection over thirty generations. Nestor KE, et al. **Poult Sci** 1996 Mar; 75(3):303-10

Reduction of dietary phosphorus absorption by oral phoshorus binders. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec; 90(3):389-401

[Effect of low-phosphorus milk for infants on blood and urine calcium and phosphorus parameters in neonates (letter)] Lapillonne A, et al. **Arch Pediatr** 1996 Feb;3(2):192-3 **(Fre)**

CHEMISTRY

Transmission electron microscopy observations at the interface of bone and four types of calcium phosphate ceramics with different calcium/phosphorus molar ratios. Kitsugi T, et al. **Biomaterials** 1995 Sep;16(14):1101-7

Amino acid grafting of beta-lactoglobulin mediated by phosphorus oxychloride. Sitohy M, et al. **Int J Biol Macromol** 1995 Oct;17(5):269-72

Mechanical and histological investigation of hydrothermally treated and untreated anodic titanium oxide films containing Ca and P. Ishizawa H, et al. **J Biomed Mater Res** 1995 Nov;29(11):1459-68

Identification of multiple transition structures on the potential energy hypersurface for [2+2] electrocyclization of the pentadienyl cation bearing a phosphorus in the 3-position. Smith DA, et al. **J Mol Graph** 1995 Oct;13(5):283-6, 301-2

Phosphorus 31 solid state NMR characterization of oligonucleotides covalently bound to a solid support. Macdonald PM, et al. **Nucleic Acids Res** 1996 Aug 1; 24(15):2868-76

A method to determine and factors that influence in vivo solubilization of phosphates in commercial Leghorn hens. Rao SK, et al. **Poult Sci** 1995 Oct;74(10):1644-9

Magic-angle spinning nuclear magnetic resonance study of the structure of some PbO-Al2O3-P2O5 glasses. Lockyer MW, et al. **Solid State Nucl Magn Reson** 1995 Oct; 5(1):23-34

DEFICIENCY

Acute recumbency and marginal phosphorus deficiency in dairy cattle. Gerloff BJ, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):716-9

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. Slatopolsky E, et al. **J Clin Invest** 1996 Jun 1; 97(11):2534-40

Binding properties of goat intestinal vitamin D receptors as affected by dietary calcium and/or phosphorus depletion. Schröder B, et al. **Zentralbl Veterinarmed A** 1995 Aug; 42(6):411-7

METABOLISM

Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Meyerhoff DJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):685-92

25-Hydroxyvitamin D3 reverses alteration of the vitamin D-endocrine system in blacks. Bell NH. **Am J Med** 1995 Dec;99(6):597-9

Inhibitory effects of steroidal saponins on 12-O-tetradecanoylphorbol-13-acetate (TPA)-enhanced 32P-incorporation into phospholipids of HeLa cells and proliferation of human malignant tumor cells. Mimaki Y, et al. **Biol Pharm Bull** 1995 Mar;18(3):467-9

Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: a 31phosphorous magnetic resonance spectroscopic imaging study. Deicken RF, et al. **Biol Psychiatry** 1995 Sep 1;38(5):279-86

Absorption and endogenous excretion of phosphorus in growing broiler chicks, as influenced by calcium and phosphorus ratios in feed. al-Masri MR. **Br J Nutr** 1995 Sep;74(3):407-15

An in vitro procedure for studying enzymic dephosphorylation of phytate in maize-soyabean feeds for turkey poults. Zyla K, et al. **Br J Nutr** 1995 Jul;74(1):3-17

The effect of estrogen deficiency on bone mineral density, renal calcium and phosphorus handling and calcitropic hormones in the rat. Dick IM, et al. **Calcif Tissue Int** 1996 Sep;59(3):174-8

The purification and properties of phosphonoacetate hydrolase, a novel carbon-phosphorus bond-cleavage enzyme from Pseudomonas fluorescens 23F. McGrath JW, et al. **Eur J Biochem** 1995 Nov 15;234(1):225-30

Influence of different fasting periods on P-31-MR-spectroscopy of the liver in normals and patients with liver metastases. Brinkmann G, et al. **Eur Radiol** 1996; 6(1):62-5

Effect of chronic high protein intake on magnesium, calcium, and phosphorus balance in growing cats. Hashimoto M, et al. **Exp Anim** 1996 Jan;45(1):63-70

Renal disorders and calcium phosphorus tubular dysfunctions in multiple myeloma. Goranov S. **Folia Med (Plovdiv)** 1995; 37(4A Suppl):46

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55-63 (86 ref.)

Global analysis of proteins synthesized during phosphorus restriction in Escherichia coli. VanBogelen RA, et al. **J Bacteriol** 1996 Aug;178(15):4344-66

Uneven hepatic iron and phosphorus distribution in beta-thalassemia. Ambu R, et al. **J Hepatol** 1995 Nov; 23(5):544-9

Quantitation of phosphorus metabolites in newborn human brain using internal water as reference standard. Cady EB, et al. **Magn Reson Imaging** 1996;14(3):293-304

The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Cross HR, et al. **Magn Reson Med** 1995 Nov;34(5):673-85

Simultaneous 3D NMR spectroscopy of fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Li CW, et al. **Magn Reson Med** 1996 Jun; 35(6):841-7

Responses of mouse fast and slow skeletal muscle to streptozotocin diabetes: myosin isoenzymes and phosphorous metabolites. Fewell JG, et al. **Mol Cell Biochem** 1995 Jul 19;148(2):147-54

Additive effects of 1,25-dihydroxycholecalciferol and phytase on phytate phosphorus utilization and related parameters in broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):111-9

A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Sep; 89(3):373-88

Use of sheep maintained by intragastric infusion as a model for studying the endogenous loss of phosphorus in ruminants. Rajaratne AA, et al. **Res Vet Sci** 1996 Jan; 60(1):92-3

[Physiology of intestinal absorption of phosphorus in animals] Barlet JP, et al. **Reprod Nutr Dev** 1995;35(5):475-89 (128 ref.) (Eng. Abstr.) **(Fre)**

[Effect of a supplemental Aspergillus niger phytase on the utilization of plant phosphorus by rainbow trout (Oncorhynchus mykiss)] Rodehutscord M, et al. **Arch Tierernahr** 1995;48(1-2):211-9 (Eng. Abstr.) **(Ger)**

[Calcium-phosphorus metabolism in celiac disease in children] Praticò G, et al. **Pediatr Med Chir** 1995 Sep-Oct; 17(5):403-6 (Eng. Abstr.) **(Ita)**

[Experimental study on brain phosphorus energy metabolism during retrograde cerebral perfusion using 31-P magnetic resonance spectroscopy] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):740-1 **(Jpn)**

PHARMACOKINETICS

Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. Serfaty-Lacrosniere C, et al. **J Am Coll Nutr** 1995 Aug; 14(4):364-8

An evaluation of various response criteria in assessing biological availability of phosphorus for broilers. Ravindran V, et al. **Poult Sci** 1995 Nov;74(11):1820-30

PHARMACOLOGY

The effect of HA, TCP and ALCAP bioceramic capsules on the viability of human monocyte and monocyte derived macrophages. Ross L, et al. **Biomed Sci Instrum** 1996; 32:71-9

Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: effect on neurotensin degradation in vitro and in vivo. Vincent B, et al. **Br J Pharmacol** 1995 Jul;115(6):1053-63

POISONING

Acute hepatotoxicity from ingestion of yellow phosphorus-containing fireworks. Fernandez OU, et al. **J Clin Gastroenterol** 1995 Sep;21(2):139-42

THERAPEUTIC USE

High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Zazzo JF, et al. **Intensive Care Med** 1995 Oct; 21(10):826-31

Use of a phosphorus-enriched dialysate in a hypercatabolic renal failure patient receiving intensive hemodialysis therapy. Zabaneh RI, et al. **Nephron** 1996;72(4):696-8

TOXICITY

Response of periphyton biomass to high phosphorus concentrations in laboratory experiments. Giorgi AD. **Bull Environ Contam Toxicol** 1995 Dec;55(6):825-32

URINE

Effects of recombinant human insulin-like growth factor I on renal handling of phosphorus, calcium, and sodium in normal humans. Kopple JD, et al. **Am J Kidney Dis** 1995 Nov;26(5):818-24

Effect of dietary magnesium level on urinary and faecal excretion of calcium, magnesium and phosphorus in adult, ovariectomized cats. Pastoor FJ, et al. **Br J Nutr** 1995 Jul; 74(1):77-84

Re-evaluation of the "week-end effect" data: possible role of urinary copper and phosphorus in the pathogenesis of renal calculi. Rodgers AL, et al. **J Trace Elem Med Biol** 1995 Oct;9(3):150-5

[Effect of low-phosphorus milk for infants on blood and urine calcium and phosphorus parameters in neonates (letter)] Lapillonne A, et al. **Arch Pediatr** 1996 Feb;3(2):192-3 **(Fre)**

PHOSPHORUS, DIETARY

Chemical and physical evaluations of commercial dicalcium phosphates as sources of phosphorus in animal nutrition. Lima FR, et al. **Poult Sci** 1995 Oct;74(10):1659-70

ADMINISTRATION & DOSAGE

Effects of varying dietary calcium and phosphorus on growth and on composition of empty bodies and isolated bones of male kids. Pfeffer E, et al. **Arch Tierernahr** 1996; 49(3):243-52

Dietary phosphorus restriction to half the minimum required amount slightly reduces weight gain and length of tibia, but sustains femur mineralization and prevents nephrocalcinosis in female kittens. Pastoor FJ, et al. **Br J Nutr** 1995 Jul;74(1):85-100

The relationship between calcium, phosphorus, and sodium intake, race, and blood pressure in children with renal insufficiency: a report of the Growth Failure in Children with Renal Diseases (GFRD) Study. Trachtman H, et al. **J Am Soc Nephrol** 1995 Jul;6(1):126-31

Calcium, phosphorus and human bone development. Anderson JJ. **J Nutr** 1996 Apr;126(4 Suppl):1153S-8S (32 ref.)

Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Yi H, et al. **Nephron** 1995; 70(2):242-8

Effects of phytase and 1,25-dihydroxycholecalciferol on phytate utilization and the quantitative requirement for calcium and phosphorus in young broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):95-110

Response of turkey poults to tiered levels of Natuphos phytase added to soybean meal-based semi-purified diets containing three levels of nonphytate phosphorus. Ravindran V, et al. **Poult Sci** 1995 Nov;74(11):1843-54

ADVERSE EFFECTS

Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. Calvo MS, et al. **J Nutr** 1996 Apr; 126(4 Suppl):1168S-80S (72 ref.)

Diet-induced nephrocalcinosis in female rats is irreversible and is induced primarily before the completion of adolescence. Peterson CA, et al. **J Nutr** 1996 Jan; 126(1):259-65

CHEMISTRY see PHOSPHORUS/chemistry

DEFICIENCY see PHOSPHORUS/deficiency

ISOLATION & PURIFICATION

A method to determine and factors that influence in vivo solubilization of phosphates in commercial Leghorn hens. Rao SK, et al. **Poult Sci** 1995 Oct;74(10):1644-9

METABOLISM

New aspects of adaptation of rat renal Na-Pi cotransporter to alterations in dietary phosphate. Lötscher M, et al. **Kidney Int** 1996 Apr;49(4):1012-8

Reduction of dietary phosphorus absorption by oral phoshorus binders. Graff L, et al.

PHOSPHORUS, DIETARY

Res Commun Mol Pathol Pharmacol 1995 Dec; 90(3):389–401

PHARMACOKINETICS

Mineral bioavailability and bone mineral contents in pigs given calcium carbonate postprandially. Pointillart A, et al. **Bone** 1995 Oct;17(4):357–62

Efficacy of a recombinant-derived phytase in improving the bioavailability of phosphorus in corn–soybean meal diets for pigs. Cromwell GL, et al. **J Anim Sci** 1995 Jul; 73(7):2000–8

Improving phosphorus availability in soybean meal for broilers by supplemental phytase. Denbow DM, et al. **Poult Sci** 1995 Nov;74(11):1831–42

A method to determine and factors that influence in vivo solubilization of phosphates in commercial Leghorn hens. Rao SK, et al. **Poult Sci** 1995 Oct;74(10):1644–9

PHARMACOLOGY

Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439–47 (102 ref.)

Response of rainbow trout (Oncorhynchus mykiss) growing from 50 to 200 g to supplements of dibasic sodium phosphate in a semipurified diet. Rodehutscord M. **J Nutr** 1996 Jan;126(1):324–31

Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Tallon S, et al. **Kidney Int** 1996 May;49(5):1441–6

Effects of dietary calcium and phosphorus on vitamin D metabolism and calcium absorption in hamster. Schedl HP, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):281–6

[Effect of low-phosphorus milk for infants on blood and urine calcium and phosphorus parameters in neonates (letter)] Lapillonne A, et al. **Arch Pediatr** 1996 Feb;3(2):192–3 **(Fre)**

THERAPEUTIC USE

Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: a French case–control study. Boutron MC, et al. **Br J Cancer** 1996 Jul;74(1):145–51

The use of high-phosphorus supplements to inhibit dental enamel demineralisation by ice lollies. Grenby TH, et al. **Int J Food Sci Nutr** 1995 Aug;46(3):275–9

PHOSPHORUS RADIOISOTOPES

32P and beta emitting radionuclides in microbiology and cell biology. Rees B. **Health Phys** 1996 May;70(5):639–42 (20 ref.)

Security at MIT [letter] Campbell KD. **Nature** 1995 Dec 14;378(6558):658

Contamination [letter; comment] Dricks V. **Nature** 1995 Nov 2;378(6552):10. Comment on: Nature 1995 Oct 19;377(6550):563.

Accidental contamination 'unlikely' [news] Macilwain C. **Nature** 1995 Nov 2;378(6552):9

Establishment of two rat osteosarcoma cell lines (YROS-1 and YROS-2) induced by radioactive phosphorus. Machida J, et al. **Pathol Res Pract** 1995 Jun;191(5):478–85

ADMINISTRATION & DOSAGE

The beta-particle-emitting radioisotope stent (isostent): animal studies and planned clinical trials. Fischell TA, et al. **Am J Cardiol** 1996 Aug 14;78(3A):45–50

Analytic representation of the dose from a 32P-coated stent. Prestwich WV. **Med Phys** 1996 Jan;23(1):9–13

ADVERSE EFFECTS

Nobel lab subject of radiation probe. **Immunol Today** 1996 Jan;17(1):3

BLOOD

[The kinetics of radionuclide distribution between the plasma and formed elements of the blood in dogs] Kolosov IV, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):417–20 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

31P nuclear magnetic resonance evidence of skeletal muscle metabolic abnormalities in mitral stenosis. Lee CW, et al. **Am J Cardiol** 1996 Sep 1;78(5):588–91

A method for in vivo [32P]phosphate labelling of testis proteins. Kundu TK, et al. **J Biochem Biophys Methods** 1995 Jun;30(2–3):185–9

Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. Osaka G, et al. **J Pharm Sci** 1996 Jun;85(6):612–8

POISONING

FBI investigates radiation exposure claims [news] Appel A. **Nature** 1995 Oct 19;377(6550):568

Nuclear regulators to investigate 'contamination' incident at MIT [news] [see comments] Macilwain C. **Nature** 1995 Oct 19;377(6550):563. Comment in: Nature 1995 Nov 2;378(6552):10. Comment in: Nature 1995 Nov 9;378(6553):124.

NIH denies blame for radiation poisoning but tightens rules [news] Macilwain C. **Nature** 1995 Dec 21–28;378(6559):757

THERAPEUTIC USE

Stereotactic intratumour irradiation with nuclide for craniopharyngiomas. Liu Z, et al. **Chin Med J (Engl)** 1996 Mar;109(3):219–22

Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma. Wilkinson RH Jr. **J Nucl Med** 1996 Apr;37(4):636–9

[Treatment of distant iodine-negative metastases of thyroid cancer with 32P] Drozdovskiĭ BI, et al. **Vopr Onkol** 1996; 42(3):71–2 (Eng. Abstr.) **(Rus)**

PHOSPHORYLASE A

DRUG EFFECTS

Differences between rapid and longer-term actions of angiotensin II in isolated rat hepatocytes. Effects on phosphorylase a activity and c-fos expression. García-Sáinz JA, et al. **Arch Med Res** 1995;26 Spec No:S189–93

METABOLISM

Allosteric regulation of liver phosphorylase a: revisited under approximated physiological conditions. Ercan N, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):255–64

Modification of kinetic parameters of glycogen phosphorylase from mantle tissue of Mytilus galloprovincialis by a phosphorylation mechanism. San Juan Serrano F, et al. **Int J Biochem Cell Biol** 1995 Sep; 27(9):917–22

Evidence for essential arginine residues at the active sites of maize branching enzymes. Cao H, et al. **J Protein Chem** 1996 Apr;15(3):291–304

PHOSPHORYLASE B

DEFICIENCY

Phosphorylase b kinase deficiency glycogenosis with cirrhosis of the liver. Kagalwalla AF, et al. **J Pediatr** 1995 Oct;127(4):602–5

ISOLATION & PURIFICATION

Purification and isoenzymic composition of glycogen phosphorylase b from normal and abnormal (PSE) muscles. Lopez Buesa P, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):30–4

METABOLISM

A calorimetric study of the binding of AMP to liver glycogen phosphorylase b. García-Fuentes L, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):83–8

Modification of kinetic parameters of glycogen phosphorylase from mantle tissue of Mytilus galloprovincialis by a phosphorylation mechanism. San Juan Serrano F, et al. **Int J Biochem Cell Biol** 1995 Sep; 27(9):917–22

Purification and isoenzymic composition of glycogen phosphorylase b from normal and abnormal (PSE) muscles. Lopez Buesa P, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):30–4

[Reconstruction of muscle glycogen phosphorylase b from an apoenzyme and pyridoxal-5'-phosphate and its analogs. Interaction of apophosphorylase and the reconstructed enzyme with specific ligands] Chebotareva NA, et al. **Biokhimiia** 1995 Dec;60(12):2030–9 (Eng. Abstr.) **(Rus)**

PHOSPHORYLASE KINASE

ANALYSIS

A continuous spectrophotometric assay for phosphorylase kinase. Wang ZX, et al. **Anal Biochem** 1995 Sep 1; 230(1):55–61

Subcellular distribution of phosphorylase kinase in rat brain. Association of the enzyme with mitochondria and membranes. Psarra AM, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):29–42

ANTAGONISTS & INHIBITORS

Involvement of phosphorylase kinase inhibition in the effect of resorcinol and proglycosyn on glycogen metabolism in the liver. Van Schaftingen E. **Eur J Biochem** 1995 Nov 15;234(1):301–7

Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma-subunit. Wangsgard WP, et al. **J Biol Chem** 1996 Aug 30;271(35):21126–33

CHEMISTRY

A comparison of the properties of the binary and ternary complexes formed by calmodulin and troponin C with two regulatory peptides of phosphorylase kinase. Steiner RF, et al. **Biophys Chem** 1996 Apr 16;59(3):277–88

Structure of the human gene encoding the phosphorylase kinase beta subunit (PHKB). Wüllrich-Schmoll A, et al. **Eur J Biochem** 1996 Jun 1;238(2):374–80

DEFICIENCY

Neonatal-onset severe recurrent hypoglycaemia in an infant with hepatic phosphorylase kinase deficiency with normal enzyme activity in erythrocytes. Fiçicioğlu C, et al. **J Inherit Metab Dis** 1996;19(1):84–5

Phosphorylase b kinase deficiency glycogenosis with cirrhosis of the liver. Kagalwalla AF, et al. **J Pediatr** 1995 Oct;127(4):602–5

GENETICS

Isolation of cDNA encoding the human liver phosphorylase kinase alpha subunit (PHKA2) and identification of a missense mutation of the PHKA2 gene in a family with liver phosphorylase kinase deficiency. Hirono H, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):505–11

Structure of the human gene encoding the phosphorylase kinase beta subunit (PHKB). Wüllrich-Schmoll A, et al. **Eur J Biochem** 1996 Jun 1;238(2):374–80

Human cDNA encoding the muscle isoform of the phosphorylase kinase gamma subunit (PHKG1). Wehner M, et al. **Hum Genet** 1995 Nov;96(5):616–8

METABOLISM

Divalent cations but not other activators enhance phosphorylase kinase's affinity for glycogen phosphorylase. Xu YH, et al. **Biochemistry** 1996 Apr 16;35(15):5014–21

Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma-subunit. Wangsgard WP, et al. **J Biol Chem** 1996 Aug 30;271(35):21126–33

Effect of Mg2+ concentrations on phosphorylation/activation of phosphorylase b kinase by cAMP/Ca(2+)-independent, autophosphorylation-dependent protein kinase. Yu JS, et al. **J Protein Chem** 1995 Nov;14(8):747–52

The association of phosphorylase kinase with membranes of rat liver smooth endoplasmic reticulum. Maridakis GA, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):153–63

[Kinetics of action of phosphorylase kinase in a cascade enzymatic system. III. Hysteretic properties of phosphorylase kinase from skeletal muscles] Andreeva IE, et al. **Biokhimiia** 1995 Aug;60(8):1326–35 (Eng. Abstr.) **(Rus)**

[Association of rabbit skeletal muscle phosphorylase kinase with sarcoplasmic reticulum membranes] Zemskova MA, et al. **Biokhimiia** 1995 Nov;60(11):1903–10 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The testis isoform of the phosphorylase kinase catalytic subunit (PhK-gammaT) plays a critical role in regulation of glycogen mobilization in developing lung. Liu L, et al. **J Biol Chem** 1996 May 17;271(20):11761–6

PHOSPHORYLATION

Mechanisms of phosphoryl and acyl transfer. Cleland WW, et al. **FASEB J** 1995 Dec;9(15):1585–94 (50 ref.)

PHOSPHORYLCHOLINE

ADMINISTRATION & DOSAGE

Choline phosphate and phorbol ester potentiate the mitogenic effect of insulin by competitive mechanisms in NIH 3T3 fibroblasts. Kiss Z, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):505–9

ANALOGS & DERIVATIVES

Modulation of smooth muscle contraction by sphingosylphosphorylcholine. Bitar KN, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G370–7

Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Engelmann J, et al. **Anticancer Res** 1996 May–Jun;16(3B):1429–39

Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. Campbell EJ, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M853–7

Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat sympathetic neurons and impair axonal extension. Posse de Chaves E, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):411–7

Conformation of human serum apolipoprotein A-I(166–185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR and CD. Evidence for specific peptide-SDS interactions. Wang G, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):174–84

Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation. Zeisig R, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):177–84

The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Wieder T, et al. **Cancer Lett** 1996 Feb 27;100(1–2):71–9

Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Berkovic

D, et al. **Eur J Cancer** 1995 Nov;31A(12):2080-5
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Fleer EA, et al. **Eur J Cancer** 1996 Mar;32A(3):506-11
The biological activity of acetylated sphingosylphosphorylcholine derivatives. Zanglis A, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):63-74
Solution conformation of mu-selective dermorphin and delta-selective deltorphin-I in phospholipid micelles, studied by NMR spectroscopy and molecular dynamics simulations. Segawa M, et al. **Int J Pept Protein Res** 1995 Jul;46(1):37-46
Pertussis toxin inhibits phospholipase C activation and Ca2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids. Okajima F, et al. **J Biol Chem** 1995 Nov 3;270(44):26332-40
Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24334-42
Sphingosylphosphorylcholine rapidly induces tyrosine phosphorylation of p125FAK and paxillin, rearrangement of the actin cytoskeleton and focal contact assembly. Requirement of p21rho in the signaling pathway. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24343-51
A new wound healing agent--sphingosylphosphorylcholine. Sun L, et al. **J Invest Dermatol** 1996 Feb;106(2):232-7
Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. Himber J, et al. **J Lipid Res** 1995 Jul;36(7):1567-85
The use of dodecylphosphocholine micelles in solution NMR. Kallick DA, et al. **J Magn Reson B** 1995 Oct;109(1):60-5
Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate. Nishida K, et al. **Med Prog Technol** 1995 May;21(2):91-103
A distinct G(i) protein-coupled receptor for sphingosylphosphorylcholine in human leukemia HL-60 cells and human neutrophils. Van Koppen CJ, et al. **Mol Pharmacol** 1996 Jun;49(6):956-61

ANALYSIS

Phosphocholine and choline content of rat sarcoma cells grown in the presence and absence of serum. Smith TA, et al. **Anticancer Res** 1996 May-Jun;16(3B):1389-92
Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Singer S, et al. **Cancer Res** 1995 Nov 15;55(22):5140-5
Phosphorylcholine-containing antigens in bacteria from the mouth and respiratory tract. Gillespie SH, et al. **J Med Microbiol** 1996 Jan;44(1):35-40
Identification of phosphocholine-containing glycoglycerolipids purified from Mycoplasma fermentans-infected human helper T-cell culture as components of M. fermentans. Matsuda K, et al. **Microbiol Immunol** 1995;39(5):307-13
Ultrastructural colocalization of phosphorylcholine and a phosphorylcholine-associated epitope in first-stage larvae of Trichinella spiralis. Hernández S, et al. **Parasitol Res** 1995;81(8):643-50

IMMUNOLOGY

Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Nicoletti C. **Exp Mol Pathol** 1995 Apr;62(2):99-108
In vivo and in vitro study of the primary and secondary antibody response to a bacterial antigen in aged mice. Borghesi C, et al. **Int J Exp Pathol** 1995 Dec;76(6):419-24
Alteration in the reactivity of sphingomyelin in mitogen-stimulated lymphocytes. Hirota K, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):4-8
Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity. Pewzner-Jung Y, et al. **J Immunol** 1996 Apr 15; 156(8):3065-73
Interference between Neisseria meningitidis and PC-KLH induced anti-phosphorylcholine PFC responses in NZB/W autoimmune mice. Seoane R, et al. **Microbiol Immunol** 1995;39(7):491-7
[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57-63 (37 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Aiken NR, et al. **Anticancer Res** 1996 May-Jun;16(3B):1393-7
Prevention of attachment of phosphorylcholine to a major excretory-secretory product of Acanthocheilonema viteae using tunicamycin. Houston KM, et al. **J Parasitol** 1996 Apr;82(2):320-4

PHARMACOLOGY

Phosphocholine reverses inhibition of pulmonary surfactant adsorption caused by C-reactive protein. McEachren TM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L492-7

PHOSPHORYLCHOLINE, ACETYL GLYCERYL ETHER see **PLATELET ACTIVATING FACTOR**

PHOSPHORYLCHOLINE CHLORIDE see **PHOSPHORYLCHOLINE**

PHOSPHORYLCHOLINE-GLYCERIDE TRANSFERASE see **DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE**

PHOSPHOSERINE

Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation. Evidence for a multistep pathway of regulation. Cotto JJ, et al. **J Biol Chem** 1996 Feb 16;271(7):3355-8
Phosphorylation of both serine residues in cardiac troponin I is required to decrease the Ca2+ affinity of cardiac troponin C. Zhang R, et al. **J Biol Chem** 1995 Dec 22; 270(51):30773-80

ANALOGS & DERIVATIVES

Inhibition by cholesterylphosphorylserine of T-cell-mediated immune responses in mice. Bruni A, et al. **Int J Immunopharmacol** 1995 Jun;17(6):517-21

ANALYSIS

Intramolecular interactions regulate serine/threonine phosphorylation of vinculin. Schwienbacher C, et al. **FEBS Lett** 1996 Apr 8;384(1):71-4
Separation and quantification of D- and L-phosphoserine in rat brain using N alpha-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (Marfey's reagent) by high-performance liquid chromatography with ultraviolet detection. Goodnough DB, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20; 672(2):290-4
Multiple serine phosphorylation sites on the 30 kDa TMV cell-to-cell movement protein synthesized in tobacco protoplasts. Haley A, et al. **Plant J** 1995 Nov;8(5):715-24

CHEMISTRY

O-phospho-DL-threonine and O-phospho-L-threonine compared with their serine analogs. Maniukiewicz W, et al. **Acta Crystallogr C** 1996 Jul 15;52 (Pt 7):1736-41
Chemical synthesis of phosphopeptides using the arylthio group for protection of phosphate: application to identification of cdc2 kinase phosphorylation sites. Ueno Y, et al. **Int J Pept Protein Res** 1995 Aug;46(2):106-12

ISOLATION & PURIFICATION

Effects of cooling temperature on the separation of phosphoamino acids. Lombardini JB, et al. **Anal Biochem** 1995 May 20;227(2):399-400

METABOLISM

O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115-23 (45 ref.)
Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. Gotoh A, et al. **Blood** 1996 Jul 1;88(1):138-45
Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Muslin AJ, et al. **Cell** 1996 Mar 22;84(6):889-97
Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Joel PB, et al. **Mol Endocrinol** 1995 Aug;9(8):1041-52
Membrane interactions of a phosphomonoester elevated early in Alzheimer's disease. Mason RP, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):531-9
Transient and persistent phosphorylation of AMPA-type glutamate receptor subunits in cerebellar Purkinje cells. Nakazawa K, et al. **Neuron** 1995 Sep;15(3):697-709
Phosphorylation of serine-46 in HPr, a key regulatory protein in bacteria, results in stabilization of its solution structure. Pullen K, et al. **Protein Sci** 1995 Dec;4(12):2478-86

PHARMACOLOGY

Molecular membrane interactions of a phospholipid metabolite. Implications for Alzheimer's disease pathophysiology. Mason RP, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:368-73
The effects of L-AP4 and L-serine-O-phosphate on inhibition in primary somatosensory cortex of the adult rat in vivo. Wan H, et al. **Neuropharmacology** 1995 Aug; 34(8):1053-62

PHOSPHOTHREONINE

ANALYSIS

Intramolecular interactions regulate serine/threonine phosphorylation of vinculin. Schwienbacher C, et al. **FEBS Lett** 1996 Apr 8;384(1):71-4

CHEMISTRY

O-phospho-DL-threonine and O-phospho-L-threonine compared with their serine analogs. Maniukiewicz W, et al. **Acta Crystallogr C** 1996 Jul 15;52 (Pt 7):1736-41
Chemical synthesis of phosphopeptides using the arylthio group for protection of phosphate: application to identification of cdc2 kinase phosphorylation sites. Ueno Y, et al. **Int J Pept Protein Res** 1995 Aug;46(2):106-12

ISOLATION & PURIFICATION

Effects of cooling temperature on the separation of phosphoamino acids. Lombardini JB, et al. **Anal Biochem** 1995 May 20;227(2):399-400

METABOLISM

O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115-23 (45 ref.)

PHOSPHOTRANSACETYLASE see **PHOSPHATE ACETYLTRANSFERASE**

PHOSPHOTRANSFERASES

ANTAGONISTS & INHIBITORS

Differential biological effects of K252 kinase inhibitors are related to membrane solubility but not to permeability. Ross AH, et al. **J Neurochem** 1995 Dec;65(6):2748-56
Inhibition of phosphate-metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287-324 (169 ref.)
Differential effects of kinase inhibitors on erythropoietin and vascular endothelial growth factor gene expression in rat hepatocytes. Gess B, et al. **Pflugers Arch** 1996 Jul; 432(3):426-32

BIOSYNTHESIS

Pyrophosphate-dependent phosphofructokinase of Entamoeba histolytica: molecular cloning, recombinant expression and inhibition by pyrophosphate analogues. Bruchhaus I, et al. **Biochem J** 1996 May 15;316 (Pt 1):57-63
Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels. Argaud D, et al. **J Biol Chem** 1995 Oct 13;270(41):24229-36

CHEMISTRY

Crystallization and preliminary X-ray analysis of fructose 6-phosphate, 2-kinase:fructose 2,6-bisphosphatase. Istvan ES, et al. **Protein Sci** 1995 Nov;4(11):2439-41

DEFICIENCY

Multiple transport protein defects in a patient with glycogen storage disease type 1: GSD 1b/1c beta. Hawkins RA, et al. **J Inherit Metab Dis** 1995;18(5):558-66

DRUG EFFECTS

Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Takashima A, et al. **Neurosci Lett** 1996 Jan 12;203(1):33-6

GENETICS

Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in Escherichia coli. Noguchi N, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2359-63
Hepatocyte growth factor and transforming growth factor beta regulate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatocyte primary cultures. Joaquin M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):235-40
Characterization and phylogeny of the pfp gene of Amycolatopsis methanolica encoding PPi-dependent phosphofructokinase. Alves AM, et al. **J Bacteriol** 1996 Jan;178(1):149-55
Role of an upstream open reading frame in mediating arginine-specific translational control in Neurospora crassa. Luo Z, et al. **J Bacteriol** 1996 Apr;178(8):2172-7
[Resistance of cytomegalovirus to ganciclovir: rapid detection of the mutations 460 of the UL97 phosphotransferase] Alain S, et al. **Pathol Biol (Paris)** 1996 May;44(5):456-60 (Eng. Abstr.) **(Fre)**

METABOLISM

A novel serine-specific kinase activity associated with exocrine secretory granules. Tang LH, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G481-9
A new method for quantitative determination of tritium-labeled nucleoside kinase products adsorbed on

DEAE-cellulose. Gerber S, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):263-7

Islet fructose 6-phosphate, 2-kinase:fructose 2,6-bisphosphatase: isozymic form, expression, and characterization. Sakurai T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):159-63

2-Carboxyarabinitol 1-phosphate (CA1P) formation through a phosphate exchange reaction catalysed by the CA1P phosphatase from French bean (Phaseolus vulgaris L.). Andralojc PJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):389-93

Mechanism of the reaction catalysed by cytosolic 5'-nucleotidase/phosphotransferase: formation of a phosphorylated intermediate. Baiocchi C, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):797-801

An altered T2 beta translocase of the glucose-6-phosphatase system in the membrane of the endoplasmic reticulum from livers of Ehrlich-ascites-tumour-bearing mice. Lucius RW, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):537-40

An investigation of the kinase activity of aurochs heart pyruvate dehydrogenase complex. Czygier M, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):313-7

Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592-6 (40 ref.)

Kinetic mechanisms of polyphosphate glucokinase from Mycobacterium tuberculosis. Hsieh PC, et al. **Biochemistry** 1996 Jul 30;35(30):9772-81

Initial rate and equilibrium isotope exchange studies on the ATP-dependent activity of polyphosphate Glucokinase from Propionibacterium shermanii. Kowalczyk TH, et al. **Biochemistry** 1996 May 28;35(21):6777-85

A phosphotransferase activity of the Bacillus subtilis sporulation protein Spo0F that employs phosphoramidate substrates. Zapf JW, et al. **Biochemistry** 1996 Mar 5; 35(9):2926-33

A novel serine/threonine-specific protein phosphotransferase activity of Nm23/nucleoside-diphosphate kinase. Engel M, et al. **Eur J Biochem** 1995 Nov 15;234(1):200-7

Reverse phosphotransfer from OmpR to EnvZ in a kinase-/phosphatase+ mutant of EnvZ (EnvZ.N347D), a bifunctional signal transducer of Escherichia coli. Dutta R, et al. **J Biol Chem** 1996 Jan 19;271(3):1424-9

Cloning, expression, and characterization of polyphosphate glucokinase from Mycobacterium tuberculosis. Hsieh PC, et al. **J Biol Chem** 1996 Mar 1;271(9):4909-15

Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Nishimura M, et al. **J Biol Chem** 1995 Nov 3;270(44):26341-6

Induction of a nerve growth factor-sensitive kinase that phosphorylates the DNA-binding domain of the orphan nuclear receptor NGFI-B. Hirata Y, et al. **J Neurochem** 1995 Oct;65(4):1780-8

Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53-85 (113 ref.)

Kinetic mechanism of pyrophosphate-dependent phosphofructokinase from Giardia lamblia. Phillips NF, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):43-51

Phosphotransfer reactions as a means of G protein activation. Piacentini L, et al. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):59-63 (45 ref.)

PHARMACOLOGY

Activation of p44 and p42 MAP kinases is not essential for the survival of rat sympathetic neurons. Virdee K, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2159-69

PHYSIOLOGY

PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50-1 (22 ref.)

PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR)

Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382-3 (22 ref.)

AGONISTS

Effect of acidic phospholipids on sphingosine kinase. Olivera A, et al. **J Cell Biochem** 1996 Mar 15;60(4):529-37

ANALYSIS

NPTII assays for measuring gene expression and enzyme activity in transgenic plants. Curtis IS, et al. **Methods Mol Biol** 1995;49:149-59 (20 ref.)

The detection of neomycin phosphotransferase activity in plant extracts. Scheid OM, et al. **Methods Mol Biol** 1995; 44:201-6

ANTAGONISTS & INHIBITORS

Selective inhibition of phosphatidylinositol 3-kinase by phosphatidic acid and related lipids. Lauener R, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):8-14

Different pathways of inhibitory effects of wortmannin on exocytosis are revealed by video-enhanced light microscope. Ozawa K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):243-8

Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Scheid MP, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):159-62

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039-46

Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Downing GJ, et al. **Biochemistry** 1996 Mar 19;35(11):3587-94

Modulation of the substrate specificity of the mammalian phosphatidylinositol 3-kinase by cholesterol sulfate and sulfatide. Woscholski R, et al. **Biochemistry** 1995 Sep 12; 34(36):11489-93

N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Yatomi Y, et al. **Biochemistry** 1996 Jan 16;35(2):626-33

The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Price BD, et al. **Cancer Res** 1996 Jan 15; 56(2):246-50

The effects of wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, on insulin-stimulated glucose transport, GLUT4 translocation, antilipolysis, and DNA synthesis. Evans JL, et al. **Cell Signal** 1995 May; 7(4):365-76

Wortmannin inhibits insulin secretion in pancreatic islets and beta-TC3 cells independent of its inhibition of phosphatidylinositol 3-kinase. Gao Z, et al. **Diabetes** 1996 Jul;45(7):854-62

Effects of wortmannin on glucose uptake and protein kinase C activity in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):143-52

Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Miwa I, et al. **Enzyme Protein** 1994-95;48(3):135-42

Inhibition of phosphatidylinositol 3-kinase blocks T cell antigen receptor/CD3-induced activation of the mitogen-activated kinase Erk2. Von Willebrand M, et al. **Eur J Biochem** 1996 Feb 1;235(3):828-35

Wortmannin inhibits transcytosis of dimeric IgA by the polymeric immunoglobulin receptor. Cardone M, et al. **FEBS Lett** 1995 Nov 27;376(1-2):74-6

Cochlioquinone A, an inhibitor of diacylglycerol kinase. Machida T, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1076-80

Cyclic AMP-increasing agents interfere with chemoattractant-induced respiratory burst in neutrophils as a result of the inhibition of phosphatidylinositol 3-kinase rather than receptor-operated Ca2+ influx. Ahmed MU, et al. **J Biol Chem** 1995 Oct 6;270(40):23816-22

Wortmannin, an inhibitor of phosphoinositide 3-kinase, inhibits transcytosis in polarized epithelial cells. Hansen SH, et al. **J Biol Chem** 1995 Nov 24;270(47):28425-32

Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. Kaliman P, et al. **J Biol Chem** 1996 Aug 9;271(32):19146-51

Arachidonoyl-diacylglycerol kinase. Specific in vitro inhibition by polyphosphoinositides suggests a mechanism for regulation of phosphatidylinositol biosynthesis. Walsh JP, et al. **J Biol Chem** 1995 Dec 1;270(48):28647-53

Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. Zeng G, et al. **J Clin Invest** 1996 Aug 15;98(4):894-8

Analysis of R59022 actions in Xenopus laevis oocytes. Sadler SE, et al. **J Exp Zool** 1996 Apr 1;274(5):317-25

The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. Marquardt DL, et al. **J Immunol** 1996 Mar 1;156(5):1942-5

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. Norman BH, et al. **J Med Chem** 1996 Mar 1;39(5):1106-11

Inhibition of neuroblastoma cell phosphatidylinositol 3-kinase by CDP-diacylglycerol and phosphatidate. Lavie Y, et al. **J Neurochem** 1996 Feb;66(2):811-6

Effects of wortmannin analogs on bone in vitro and in vivo. Sato M, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):543-50

Inhibition of phosphatidylinositol-3'-kinase prevents induction of endotoxin tolerance in vitro. Bowling WM, et al. **J Surg Res** 1996 Jun;63(1):287-92

Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells. Kubota Y, et al. **Leukemia** 1996 Apr;10(4):720-6

Wortmannin blocks lipid and protein kinase activities associated with PI 3-kinase and inhibits a subset of responses induced by Fc epsilon R1 cross-linking. Barker SA, et al. **Mol Biol Cell** 1995 Sep;6(9):1145-58

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Wymann MP, et al. **Mol Cell Biol** 1996 Apr;16(4):1722-33

Phosphatidylinositol phosphate 5-kinase: purification and inhibition studies. Kwok F, et al. **Prep Biochem Biotechnol** 1996 Feb;26(1):1-19

Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells. Bonnefoy-Bérard N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10142-6

Phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits 5-hydroxytryptamine-mediated potentiation of platelet aggregation induced by epinephrine. Shah BH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):157-64

[Thermoinactivation of NAD-kinase from rabbit liver] Afanas'eva GV, et al. **Biokhimiia** 1995 Jul;60(7):1082-8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Controlled overexpression of selected domains of the P85 subunit of phosphatidylinositol 3-kinase reverts v-Ha-Ras transformation. Zhang QX, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):207-14

Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Ueda Y, et al. **Int Immunol** 1995 Jun;7(6):957-66

BLOOD

Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets. Relative sctivation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alphaIIbbeta3 integrin. Zhang J, et al. **J Biol Chem** 1996 Mar 15; 271(11):6265-72

Assay for Rho-dependent phosphoinositide 3-kinase activity in platelet cytosol. Rittenhouse SE. **Methods Enzymol** 1995; 256:241-6

CHEMISTRY

Functional group characterization of homoserine kinase from Escherichia coli. Huo X, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):373-9

Radiolabeling of catalytic subunits of PI 3-kinases with 17 beta-hydroxy-16 alpha(-)[125I]iodowortmannin: identification of the G beta gamma-sensitive isoform as a complex composed of 46-kDa and 100-kDa subunits. Kurosu H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):655-61

Comparative analysis of the QUTR transcription repressor protein and the three C-terminal domains of the pentafunctional AROM enzyme. Lamb HK, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):941-50

Characterization of SH2-ligand interactions via library affinity selection with mass spectrometric detection. Kelly MA, et al. **Biochemistry** 1996 Sep 10;35(36):11747-55

Utility of a novel spin-labeled nucleotide in investigation of the substrate and effector sites of phosphoribulokinase. Koteiche HA, et al. **Biochemistry** 1995 Nov 21; 34(46):15068-74

Escherichia coli diacylglycerol kinase is an alpha-helical polytopic membrane protein and can spontaneously insert into preformed lipid vesicles. Sanders CR 2nd, et al. **Biochemistry** 1996 Jul 2;35(26):8610-8

Identification of a 200 kDa polypeptide as type 3 phosphatidylinositol 4-kinase from bovine brain by partial protein and cDNA sequencing. Gehrmann T, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):53-63

Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase. Barchi JJ Jr, et al. **Biopolymers** 1996 Feb;38(2):191-208

When is a lipid kinase not a lipid kinase? When it is a protein kinase. Hunter T. **Cell** 1995 Oct 6;83(1):1-4 (19 ref.)

Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase. Breeze AL, et al. **EMBO J** 1996 Jul 15;15(14):3579-89

Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. Wang L, et al. **FEBS Lett** 1996 Jul 15;390(1):39-43

Kinetic mechanism and end-product regulation of deoxyguanosine kinase from beef liver mitochondria. Park I, et al. **J Biochem (Tokyo)** 1995 May;117(5):1058-61

A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. Inukai K, et al. **J Biol Chem** 1996 Mar 8;271(10):5317-20

Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain. Molz L, et al. **J Biol Chem** 1996 Jun 7; 271(23):13892-9

A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. Songyang Z, et al. **J Biol Chem** 1995 Nov 3; 270(44):26029-32

Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. Virbasius JV, et al. **J Biol Chem** 1996 Jun 7;271(23):13304-7

Crystal structure of P13K SH3 domain at 20 angstroms resolution. Liang J, et al. **J Mol Biol** 1996 Apr 5; 257(3):632-43

Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nolte RT, et

al. **Nat Struct Biol** 1996 Apr;3(4):364–74

Exploring the allowed sequence space of a membrane protein. Wen J, et al. **Nat Struct Biol** 1996 Feb;3(2):141–8

Structural and functional diversity of phosphoinositide 3-kinases. Zvelebil MJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):217–23 (60 ref.)

Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Spychala J, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1232–7

Crystallization and preliminary X-ray crystallographic analysis of phosphoribulokinase from Rhodobacter sphaeroides. Roberts DL, et al. **Protein Sci** 1995 Nov; 4(11):2442–3

Developmentally expressed myosin heavy-chain kinase possesses a diacylglycerol kinase domain. Thanos CD, et al. **Protein Sci** 1996 Apr;5(4):782–5

[Heterogenity of diacylglycerol Kinase—Structure, biochemical characteristics and gene expression in the brain] Goto K. **Kaibogaku Zasshi** 1995 Dec;70(6):509–11 (4 ref.) **(Jpn)**

CLASSIFICATION

Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain. Molz L, et al. **J Biol Chem** 1996 Jun 7; 271(23):13892–9

DEFICIENCY

Segregation of the N301T mutation in the family of the index patient with mevalonate kinase deficiency. Goebel-Schreiner B, et al. **J Inherit Metab Dis** 1995; 18(2):197–200

Cholesterol biosynthesis in Zellweger syndrome: normal activity of mevalonate kinase, mevalonate-5'-pyrophosphate decarboxylase and IPP-isomerase in patients' fibroblasts but deficient mevalonate kinase activity in liver. Wanders RJ, et al. **J Inherit Metab Dis** 1996;19(2):193–6

DRUG EFFECTS

Different effects of insulin and platelet-derived growth factor on phosphatidylinositol 3-kinase at the subcellular level in 3T3-L1 adipocytes. A possible explanation for their specific effects on glucose transport. Ricort JM, et al. **Eur J Biochem** 1996 Jul 1;239(1):17–22

Association of phosphatidylinositol 3 kinase to protein kinase C zeta during interleukin-2 stimulation. Gómez J, et al. **Eur J Immunol** 1996 Aug;26(8):1781–7

Bacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. Herrera-Velit P, et al. **J Immunol** 1996 Feb 1; 156(3):1157–65

GENETICS

Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in Escherichia coli. Noguchi N, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2359–63

Localisation of the gene encoding diacylglycerol kinase 3 (DAGK3) to human chromosome 3q27–28 and mouse chromosome 16. Fitzgibbon J, et al. **Curr Eye Res** 1995 Nov;14(11):1041–3

Integrative and replicative genetic transformation of Aureobasidium pullulans. Thornewell SJ, et al. **Curr Genet** 1995 Dec;29(1):66–72

Nucleotide sequence and features of the Bacillus licheniformis gnt operon. Yoshida K, et al. **DNA Res** 1994; 1(4):157–62

Molecular cloning of the hom-thrC-thrB cluster from Bacillus sp. ULM1: expression of the thrC gene in Escherichia coli and corynebacteria, and evolutionary relationships of the threonine genes. Malumbres M, et al. **Folia Microbiol (Praha)** 1995;40(6):595–606

Analysis of two capreomycin-resistance determinants from Streptomyces capreolus and characterization of the action of their products. Thiara AS, et al. **Gene** 1995 Dec 29; 167(1-2):121–6

Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Di Como CJ, et al. **Genes Dev** 1996 Aug 1;10(15):1904–16

Assignment of the human diacylglycerol kinase 4 (DAGK4) gene to chromosome 4p16.3. Endele S, et al. **Genomics** 1996 Apr 1;33(1):145–6

Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Hashimoto K, et al. **Gynecol Obstet Invest** 1995;40(3):204–8

Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector. Nash MA, et al. **Hum Gene Ther** 1995 Nov;6(11):1379–89

Cloning and transcriptional analysis of two threonine biosynthetic genes from Lactococcus lactis MG1614. Madsen SM, et al. **J Bacteriol** 1996 Jul;178(13):3689–94

Cloning and molecular genetic characterization of the Escherichia coli gntR, gntK, and gntU genes of GntI, the main system for gluconate metabolism. Tong S, et al. **J Bacteriol** 1996 Jun;178(11):3260–9

Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-kinase/fructose 2,6-bisphosphatase from human placenta. Sakai A, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):506–11

Efficient expression of the gene for spinach phosphoribulokinase in Pichia pastoris and utilization ofthe recombinant enzyme to explore the role of regulatory cysteinyl residues by site-directed mutagenesis. Brandes HK, et al. **J Biol Chem** 1996 Mar 15;271(11):6490–6

Molecular cloning and characterization of a novel human diacylglycerol kinase zeta. Bunting M, et al. **J Biol Chem** 1996 Apr 26;271(17):10230–6

Cloning and characterization of a glucocorticoid-induced diacylglycerol kinase. Klauck TM, et al. **J Biol Chem** 1996 Aug 16;271(33):19781–8

The isolation and characterization of cDNA encoding the mouse bifunctional ATP sulfurylase-adenosine 5'-phosphosulfate kinase. Li H, et al. **J Biol Chem** 1995 Dec 8;270(49):29453–9

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. Lorenz MC, et al. **J Biol Chem** 1995 Nov 17;270(46):27531–7

Cloning, expression, and localization of 230-kDa phosphatidylinositol 4-kinase. Nakagawa T, et al. **J Biol Chem** 1996 May 17;271(20):12088–94

Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those of the EPH family of protein-tyrosine kinases. Sakane F, et al. **J Biol Chem** 1996 Apr 5; 271(14):8394–401

A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. Songyang Z, et al. **J Biol Chem** 1995 Nov 3; 270(44):26029–32

Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates. Tang W, et al. **J Biol Chem** 1996 Apr 26;271(17):10237–41

Identification of new members of a carbohydrate kinase-encoding gene family. Worley KC, et al. **J Comput Biol** 1995 Fall;2(3):451–8

Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases. Poltoratsky VP, et al. **J Immunol** 1995 Nov 15;155(10):4529–33

Depression of streptomycin production by Streptomyces griseus at elevated growth temperature: studies using gene fusions. Deeble VJ, et al. **Microbiology** 1995 Oct;141 (Pt 10):2511–8

The regulator of streptomycin gene expression, StrR, of Streptomyces griseus is a DNA binding activator protein with multiple recognition sites. Retzlaff L, et al. **Mol Microbiol** 1995 Oct;18(1):151–62

A novel positive detection system of in vivo mutations in rpsL (strA) transgenic mice. Gondo Y, et al. **Mutat Res** 1996 May 17;360(1):1–14

Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. Smih F, et al. **Nucleic Acids Res** 1995 Dec 25;23(24):5012–9

Molecular cloning of a cDNA encoding diacylglycerol kinase (DGK) in Arabidopsis thaliana. Katagiri T, et al. **Plant Mol Biol** 1996 Feb;30(3):647–53

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

The ataxia-telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375–7 (23 ref.)

[Change in expression and inheritance of the marker gene nptII in progeny of Nicotiana tabacum L transgenic plants] Deineko EV, et al. **Dokl Akad Nauk** 1995 Sep; 344(3):407–11 **(Rus)**

IMMUNOLOGY

Inhibition of protein synthesis in frog (Xenopus laevis) egg extracts by an antibody against phosphatidylinositol 4,5-bisphosphate. Keating TJ, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):643–6

Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Cai YC, et al. **Immunity** 1995 Oct; 3(4):417–26

ISOLATION & PURIFICATION

Affinity purification of 5-methylthioadenosine kinase and 5-methylthioribose/S-adenosylhomocysteine nucleosidase from Klebsiella pneumoniae. Cornell KA, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):285–90

Purification, characterization, and investigation of the mechanism of aminoglycoside 3'-phosphotransferase type Ia. Siregar JJ, et al. **Biochemistry** 1995 Oct 3;34(39):12681–8

Identification of a 200 kDa polypeptide as type 3 phosphatidylinositol 4-kinase from bovine brain by partial protein and cDNA sequencing. Gehrmann T, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):53–63

Identification and characterization of geranylgeraniol kinase and geranylgeranyl phosphate kinase from the Archaebacterium Sulfolobus acidocaldarius. Ohnuma S, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):541–7

Isolation of inositol 1,3,4-trisphosphate 5/6-kinase, cDNA cloning and expression of the recombinant enzyme. Wilson MP, et al. **J Biol Chem** 1996 May 17;271(20):11904–10

Partial purification of two forms of choline kinase and separation of choline kinase from sphingosine kinase of rat brain. Cao ZM, et al. **Neurochem Res** 1995 Jun;20(6):643–9

Purification and characterization of phosphoribulokinase from the cyanobacterium Synechococcus PCC7942. Wadano A, et al. **Plant Cell Physiol** 1995 Oct;36(7):1381–5

Phosphatidylinositol phosphate 5-kinase: purification and inhibition studies. Kwok F, et al. **Prep Biochem Biotechnol** 1996 Feb;26(1):1–19

METABOLISM

Regulation of signal transduction. Weber G, et al. **Adv Enzyme Regul** 1995;35:1–21

Fc receptor stimulation of PI 3-kinase in NK cells is associated with protein kinase C-independent granule release and cell-mediated cytotoxicity. Bonnema JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:209–13

Common and distinct elements in insulin and PDGF signaling. Myers MG Jr, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:369–87

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a metabolic signaling enzyme. Pilkis SJ, et al. **Annu Rev Biochem** 1995;64:799–835 (221 ref.)

Anomeric specificity of rat hepatic 6-phosphofructo-2-kinase: an NMR study. Lee YH, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):357–60

Differential stimulation of NAD kinase and binding of peptide substrates by wild-type and mutant plant calmodulin isoforms. Liao B, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):53–60

Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Fuhrer DK, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):289–96

Radiolabeling of catalytic subunits of PI 3-kinases with 17 beta-hydroxy-16 alpha(-)[125I]iodowortmannin: identification of the G beta gamma-sensitive isoform as a complex composed of 46-kDa and 100-kDa subunits. Kurosu H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):655–61

Phosphatidylinositol 3-kinase is involved in TRE-dependent gene expression in response to arginine vasopressin. Nishioka N, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1037–42

Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Saito Y, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):23–6

Activation of phosphatidylinositol 3-kinase by prolactin in Nb2 cells. al-Sakkaf KA, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):779–84

Hepatocyte growth factor-induced proliferation of primary hepatocytes is mediated by activation of phosphatidylinositol 3-kinase. Skouteris GG, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):229–33

Differences in binding of PI 3-kinase to the src-homology domains 2 and 3 of p56 lck and p59 fyn tyrosine kinases. Sušа M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):729–34

PI 3-kinase-dependent and independent chemotaxis of human neutrophil leukocytes. Thelen M, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1255–62

Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Bokoch GM, et al. **Biochem J** 1996 May 1;315 (Pt 3):775–9

Phosphatidylinositol 3-kinase activity is required for early endosome fusion. Jones AT, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):31–4

Disruption of GLUT1 glucose carrier trafficking in L6E9 and Sol8 myoblasts by the phosphatidylinositol 3-kinase inhibitor wortmannin. Kaliman P, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):471–7

Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways. Kilgour E, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):517–22

Activation of phosphatidylinositol 3-kinase by concanavalin A through dual signaling pathways, G-protein-coupled and phosphotyrosine-related, and an essential role of the G-protein-coupled signals for the lectin-induced respiratory burst in human monocytic THP-1 cells. Matsuo T, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):505–12

Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. Navé BT, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):55–60

Synergistic activation of PtdIns 3-kinase by tyrosine-phosphorylated peptide and beta gamma-subunits of GTP-binding proteins. Okada T, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):475–80

Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Saad MJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):741–4

Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and

granulocyte–macrophage colony stimulating factor. Scheid MP, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):159–62

The biosynthesis of GDP–D–arabinopyranose in Crithidia fasciculata: characterization of a D–arabino–1–kinase activity and its use in the synthesis of GDP–[5–3H]D–arabinopyranose. Schneider P, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):307–15

Insulin–mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3–kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Sparks JD, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):567–74

Lysophosphatidic acid stimulates glucose transport in Xenopus oocytes via a phosphatidylinositol 3'–kinase with distinct properties. Thomson FJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):161–6

Thrombin stimulates wortmannin–inhibitable phosphoinositide 3–kinase and membrane blebbing in CHRF–288 cells. Vemuri GS, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):805–10

Phosphatidylinositol 3–kinase acts at an intracellular membrane site to enhance GLUT4 exocytosis in 3T3–L1 cells. Yang J, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):125–31

Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3–kinase in Fc epsilon RI–mediated signal transduction. Yano H, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):145–50

Involvement of phosphatidylinositol 3–kinase in stimulation of glucose transport by growth factors in 3T3–L1 adipocytes. Conricode KM. **Biochem Mol Biol Int** 1995 Jul;36(4):835–43

The TOR signalling pathway and growth control in yeast. Hall MN. **Biochem Soc Trans** 1996 Feb;24(1):234–9 (42 ref.)

Lack of inhibition of phosphoinositide 3–kinase enzyme activity by FKBP12/rapamycin. Hollis CM, et al. **Biochem Soc Trans** 1996 Feb;24(1):66S

Involvement of phosphatidylinositol 3–kinase in the activation of p70 S6 kinase by the T cell costimulatory molecule CD28. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):88S

Phosphoinositide 3–kinase and CD28–mediated T–cell co–stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240–5 (50 ref.)

Diacylglycerol– and phosphatidic acid–kinase studies in plant cell suspension cultures. Wissing JB, et al. **Biochem Soc Trans** 1995 Nov;23(4):867–71

Interfacial catalysis by phosphoinositide 3'–hydroxykinase. Barnett SF, et al. **Biochemistry** 1995 Oct 31;34(43):14254–62

The pleckstrin homology domain of phospholipase C–delta 1 binds with high affinity to phosphatidylinositol 4,5–bisphosphate in bilayer membranes. Garcia P, et al. **Biochemistry** 1995 Dec 12;34(49):16228–34

Catalytic mechanism of enterococcal kanamycin kinase (APH(3')–IIIa): viscosity, thio, and solvent isotope effects support a Theorell–Chance mechanism. McKay GA, et al. **Biochemistry** 1996 Jul 2;35(26):8680–5

Regiospecificity of aminoglycoside phosphotransferase from Enterococci and Staphylococci (APH(3')–IIIa). Thompson PR, et al. **Biochemistry** 1996 Jul 2;35(26):8686–95

Association of phosphatidylinositol 3–kinase, via the SH2 domains of p85, with focal adhesion kinase in polyoma middle t–transformed fibroblasts. Bachelot C, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):45–52

The different effects of sphingosine on diacylglycerol kinase isozymes in Jurkat cells, a human T–cell line. Yamada K, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):211–6

Sphingosine activates cellular diacylglycerol kinase in intact Jurkat cells, a human T–cell line. Yamada K, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):217–24

Structure–activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3–kinase with PDGF–beta receptor. Ramalingam K, et al. **Bioorg Med Chem** 1995 Sep;3(9):1263–72

PI 3–kinase activation in BCR/abl–transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Jain SK, et al. **Blood** 1996 Sep 1;88(5):1542–50

CD38–mediated growth suppression of B–cell progenitors requires activation of phosphatidylinositol 3–kinase and involves its association with the protein product of the c–cbl proto–oncogene. Kitanaka A, et al. **Blood** 1996 Jul 15;88(2):590–8

Effect of amount and types of dietary fat on intestinal bacterial 7 alpha–dehydroxylase and phosphatidylinositol–specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Reddy BS, et al. **Cancer Res** 1996 May 15;56(10):2314–20

Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3–kinase association with tyrosine–phosphorylated proteins. Rameh LE, et al. **Cell** 1995 Dec 1;83(5):821–30

Molecular study and regulation of D–myo–inositol 1,4,5–trisphosphate 3–kinase. Communi D, et al. **Cell Signal** 1995 Sep;7(7):643–50 (52 ref.)

EJ–Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet–derived growth factor–BB via phosphatidylinositol 3–kinase. Heldman AW, et al. **Circ Res** 1996 Feb;78(2):312–21

Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3–kinase activity stimulated with PDGF. Iwama A, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S318–20

The GTP–binding protein Rac does not couple PI 3–kinase to insulin–stimulated glucose transport in adipocytes. Marcusohn J, et al. **Curr Biol** 1995 Nov 1;5(11):1296–302

Phosphoinositide kinases. Carpenter CL, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):153–8 (53 ref.)

Novel adapter proteins that link the human GM–CSF receptor to the phosphatidylino–sitol 3–kinase and Shc/Grb2/ras signaling pathways. Jücker M, et al. **Curr Top Microbiol Immunol** 1996;211:67–75

Oligodendrocytes and their precursors require phosphatidylinositol 3–kinase signaling for survival. Vemuri GS, et al. **Development** 1996 Aug;122(8):2529–37

Effect of IGF–I on phosphatidylinositol 3–kinase in soleus muscle of lean and insulin–resistant obese mice. Jullien D, et al. **Diabetes** 1996 Jul;45(7):869–75

Insulin–induced activation of phosphoinositide 3–kinase in Fao cells. Hayashi T, et al. **Diabetologia** 1996 May; 39(5):515–22

EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3–kinase. Akimoto K, et al. **EMBO J** 1996 Feb 15;15(4):788–98

FKBP12–rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol–4 kinase activity. Cardenas ME, et al. **EMBO J** 1995 Dec 1;14(23):5892–907

Phosphatidylinositol 3,4,5–trisphosphate is a substrate for the 75 kDa inositol polyphosphate 5–phosphatase and a novel 5–phosphatase which forms a complex with the p85/p110 form of phosphoinositide 3–kinase. Jackson SP, et al. **EMBO J** 1995 Sep 15;14(18):4490–500

Activation of phosphoinositide 3–kinase by interaction with Ras and by point mutation. Rodriguez–Viciana P, et al. **EMBO J** 1996 May 15;15(10):2442–51

Chromaffin granule–associated phosphatidylinositol 4–kinase activity is required for stimulated secretion. Wiedemann C, et al. **EMBO J** 1996 May 1;15(9):2094–101

Effect of aging on insulin receptor, insulin receptor substrate–1, and phosphatidylinositol 3–kinase in liver and muscle of rats. Carvalho CR, et al. **Endocrinology** 1996 Jan;137(1):151–9

Identification by mutation of the tyrosine residues in the insulin receptor substrate–1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3–kinase. Rocchi S, et al. **Endocrinology** 1995 Dec;136(12):5291–7

Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3–kinase with the insulin receptor and the insulin–like growth factor–1 (IGF– I) receptor: comparative study using the yeast two–hybrid system. Tartare–Deckert S, et al. **Endocrinology** 1996 Mar; 137(3):1019–24

A 60–kilodalton protein in rat hepatoma cells overexpressing insulin receptor was tyrosine phosphorylated and associated with Syp, phophatidylinositol 3–kinase, and Grb2 in an insulin–dependent manner [see comments] Zhang–Sun G, et al. **Endocrinology** 1996 Jul;137(7):2649–58 . Comment in: Endocrinology 1996 Jul;137(7):2647–8.

Relationship between type II phosphatidylinositol 4–kinase activity and protein tyrosine phosphorylation in membranes from normal and sickle red cells. De Neef RS, et al. **Eur J Biochem** 1996 Feb 1;235(3):549–56

A two–hybrid system analysis shows interactions between 6–phosphofructo–1–kinase and 6–phosphofructo–2–kinase but not between other glycolytic enzymes of the yeast Saccharomyces cerevisiae. Müller S, et al. **Eur J Biochem** 1996 Mar 1;236(2):626–31

Specific binding of Fyn and phosphatidylinositol 3–kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Chalupny NJ, et al. **Eur J Immunol** 1995 Oct;25(10):2978–84

Comparison of CD28–B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3–kinase association to CD28 and cytokine production. Ghiotto–Ragueneau M, et al. **Eur J Immunol** 1996 Jan; 26(1):34–41

Association of phosphatidylinositol 3 kinase to protein kinase C zeta during interleukin–2 stimulation. Gómez J, et al. **Eur J Immunol** 1996 Aug;26(8):1781–7

HIV induces activation of phosphatidylinositol 4–kinase and mitogen–activated protein kinase by interacting with T cell CD4 surface molecules. Schmid–Antomarchi H, et al. **Eur J Immunol** 1996 Mar;26(3):717–20

Insulin leads to a parallel translocation of PI–3–kinase and protein kinase C zeta [see comments] Mosthaf L, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):19–24. Comment in: Exp Clin Endocrinol Diabetes 1996;104(1):17–8.

Activation of Src–family protein tyrosine kinases and phosphatidylinositol 3–kinase in 3T3–L1 mouse preadipocytes by interleukin–11. Fuhrer DK, et al. **Exp Hematol** 1996 Feb;24(2):195–203

Maltokinase (ATP:maltose 1–phosphotransferase) from Actinoplanes sp.: demonstration of enzyme activity and characterization of the reaction product. Drepper A, et al. **FEBS Lett** 1996 Jun 17;388(2–3):177–9

Interaction of p85 subunit of PI 3–kinase with insulin and IGF–1 receptors analysed by using the two–hybrid system. Lamothe B, et al. **FEBS Lett** 1995 Oct 2;373(1):51–5

Involvement of phosphatidylinositol 3–kinase in the activation of extracellular signal–regulated kinase by PDGF in hepatic stellate cells. Marra F, et al. **FEBS Lett** 1995 Dec 4;376(3):141–5

Specific association of phosphatidylinositol 3–kinase with the protooncogene product Cbl in Fc gamma receptor signaling. Matsuo T, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):11–4

Effects of phorbol esters on insulin–induced activation of phosphatidylinositol 3–kinase, glucose transport, and glycogen synthase in rat adipocytes. Standaert ML, et al. **FEBS Lett** 1996 Jun 10;388(1):26–8

Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. Wang L, et al. **FEBS Lett** 1996 Jul 15;390(1):39–43

Missense mutations at the FKBP12–rapamycin–binding site of TOR1. Freeman K, et al. **Gene** 1996 Jun 12;172(1):143–7

A multifunctional Urechis caupo protein, PAPS synthetase, has both ATP sulfurylase and APS kinase activities. Rosenthal E, et al. **Gene** 1995 Nov 20;165(2):243–8

In vitro association of the phosphatidylinositol 3–kinase regulatory subunit (p85) with the human insulin receptor. Ottinger EA, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):346–53

Mecillinam resistance in Escherichia coli is conferred by loss of a second activity of the AroK protein. Vinella D, et al. **J Bacteriol** 1996 Jul;178(13):3818–28

Phosphatidylinositol–3'kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase. Beslu N, et al. **J Biol Chem** 1996 Aug 16;271(33):20075–81

The molecular pathway for the regulation of phosphoribulokinase by thioredoxin f. Brandes HK, et al. **J Biol Chem** 1996 Feb 16;271(7):3333–5

Phosphoinositide 3–kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine–based activation motif. Reconstitution with synthetic phosphopeptides. Chacko GW, et al. **J Biol Chem** 1996 May 3;271(18):10775–81

Interleukin–10 stimulation of phosphatidylinositol 3–kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. Crawley JB, et al. **J Biol Chem** 1996 Jul 5;271(27):16357–62

Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3–kinase and for EpR–associated PI 3–kinase activity. Damen JE, et al. **J Biol Chem** 1995 Oct 6;270(40):23402–8

An 11–amino acid sequence from c–met initiates epithelial chemotaxis via phosphatidylinositol 3–kinase and phospholipase C. Derman MP, et al. **J Biol Chem** 1996 Feb 23;271(8):4251–5

Binding to the platelet–derived growth factor receptor transiently activates the p85alpha–p110alpha phosphoinositide 3–kinase complex in vivo. Domin J, et al. **J Biol Chem** 1996 Aug 30;271(35):21614–21

Protein kinase C delta specifically associates with phosphatidylinositol 3–kinase following cytokine stimulation. Ettinger SL, et al. **J Biol Chem** 1996 Jun 14; 271(24):14514–8

Phosphatidic acid generation through interleukin 2 (IL–2)–induced alpha–diacylglycerol kinase activation is an essential step in IL–2–mediated lymphocyte proliferation. Flores I, et al. **J Biol Chem** 1996 Apr 26; 271(17):10334–40

Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen–activated protein kinase signaling pathway. Gabbay RA, et al. **J Biol Chem** 1996 Jan 26;271(4):1890–7

The HIV–1 nef protein interferes with phosphatidylinositol 3–kinase activation 1. Graziani A, et al. **J Biol Chem** 1996 Mar 22;271(12):6590–3

Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3–kinase in 3T3–L1 adipocytes. Guo D, et al. **J Biol Chem** 1996 Jan 12;271(2):615–8

Formation of c–Cbl.phosphatidylinositol 3–kinase complexes on lymphocyte membranes by a p56lck–independent mechanism. Hartley D, et al. **J Biol Chem** 1996 Sep 6; 271(36):21939–43

Phosphatidylinositol 3–kinase is an early intermediate in the G beta gamma–mediated mitogen–activated protein kinase signaling pathway. Hawes BE, et al. **J Biol Chem** 1996 May 24;271(21):12133–6

Insulin–mediated targeting of phosphatidylinositol 3–kinase to GLUT4–containing vesicles. Heller–Harrison RA, et al. **J Biol Chem** 1996 Apr 26;271(17):10200–4

Effect of the activation of phosphatidylinositol 3–kinase by a thiophosphotyrosine peptide on glucose transport in 3T3–L1 adipocytes. Herbst JJ, et al. **J Biol Chem** 1995 Oct 27;270(43):26000–5

Alpha1 adrenergic receptors activate phosphatidylinositol 3–kinase in human vascular smooth muscle cells. Role in mitogenesis. Hu ZW, et al. **J Biol Chem** 1996 Apr 12; 271(15):8977–82

A novel 55–kDa regulatory subunit for phosphatidylinositol 3–kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. Inukai K, et al. **J Biol Chem** 1996 Mar 8;271(10):5317–20

Identification of a new adapter protein that may link the common beta subunit of the receptor for granulocyte/macrophage colony–stimulating factor, interleukin (IL)–3, and IL–5 to phosphatidylinositol 3–kinase. Jücker M, et al. **J Biol Chem** 1995 Nov 17; 270(46):27817–22

Phosphoinositide 3–kinase binds constitutively to alpha/beta–tubulin and binds to gamma–tubulin in response

to insulin. Kapeller R, et al. **J Biol Chem** 1995 Oct 27; 270(43):25985–91

Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3–kinase increases glucose transport activity with translocation of glucose transporters in 3T3–L1 adipocytes. Katagiri H, et al. **J Biol Chem** 1996 Jul 19;271(29):16987–90

Brush border phosphatidylinositol 3–kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na+/H+ exchange. Khurana S, et al. **J Biol Chem** 1996 Apr 26;271(17):9919–27

Association of activated phosphatidylinositol 3–kinase with p120cbl in antigen receptor–ligated B cells. Kim TJ, et al. **J Biol Chem** 1995 Nov 17;270(46):27504–9

Insulin–induced activation of phosphatidylinositol (PI) 3–kinase. Insulin–induced phosphorylation of insulin receptors and insulin receptor substrate–1 displaces phosphorylated platelet–derived growth factor receptors from binding sites on PI 3–kinase. Levy–Toledano R, et al. **J Biol Chem** 1995 Dec 15;270(50):30018–22

Kinetic mechanism of aminoglycoside phosphotransferase type IIIa. Evidence for a Theorell–Chance mechanism. McKay GA, et al. **J Biol Chem** 1995 Oct 20; 270(42):24686–92

Activation of phospholipase D and phosphatidylinositol 4–phosphate 5–kinase in HL60 membranes is mediated by endogenous Arf but not Rho. Martin A, et al. **J Biol Chem** 1996 Jul 19;271(29):17397–403

Activated phosphatidylinositol 3–kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3–L1 adipocytes. Martin SS, et al. **J Biol Chem** 1996 Jul 26;271(30):17605–8

Phosphorylation of insulin receptor substrate–1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. Mothe I, et al. **J Biol Chem** 1996 May 10; 271(19):11222–7

Two distinct intracytoplasmic regions of the T–cell adhesion molecule CD28 participate in phosphatidylinositol 3–kinase association. Pagès F, et al. **J Biol Chem** 1996 Apr 19; 271(16):9403–9

p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3–kinase. Panchamoorthy G, et al. **J Biol Chem** 1996 Feb 9; 271(6):3187–94

Kidney N–acetylgalactosamine (GalNAc)–1–phosphate kinase, a new pathway of GalNAc activation. Pastuszak I, et al. **J Biol Chem** 1996 Aug 23;271(34):20776–82

Requirement for phosphatidylinositol 3'-kinase activity in platelet–derived growth factor–stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin. Rankin S, et al. **J Biol Chem** 1996 Mar 29;271(13):7829–34

Hepatocyte growth factor–induced scatter of Madin–Darby canine kidney cells requires phosphatidylinositol 3–kinase. Royal I, et al. **J Biol Chem** 1995 Nov 17;270(46):27780–7

Phosphatidylinositol 3–OH kinase activity is not required for activation of mitogen–activated protein kinase by cytokines. Scheid MP, et al. **J Biol Chem** 1996 Jul 26; 271(30):18134–9

p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3–kinase in response to epidermal growth factor in PC12 and other cells. Soltoff SP, et al. **J Biol Chem** 1996 Jan 5;271(1):563–7

Insulin activates a p21–activated kinase in muscle cells via phosphatidylinositol 3–kinase. Tsakiridis T, et al. **J Biol Chem** 1996 Aug 16;271(33):19664–7

Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'-kinase activity via modulation of phosphorylation of insulin receptor substrate–1. Ugi S, et al. **J Biol Chem** 1996 May 24;271(21):12595–602

A novel, phospholipase C–independent pathway of inositol 1,4,5–trisphosphate formation in Dictyostelium and rat liver. Van Dijken P, et al. **J Biol Chem** 1995 Dec 15; 270(50):29724–31

The ATP–binding site in the 2–kinase domain of liver 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase. Study of the role of Lys–54 and Thr–55 by site–directed mutagenesis. Vertommen D, et al. **J Biol Chem** 1996 Jul 26;271(30):17875–80

Combination of insulinomimetic agents H2O2 and vanadate enhances insulin receptor mediated tyrosine phosphorylation of IRS–1 leading to IRS–1 association with the phosphatidylinositol 3–kinase. Wilden PA, et al. **J Cell Biochem** 1995 Jul;58(3):279–91

ARIA/HRG regulates AChR epsilon subunit gene expression at the neuromuscular synapse via activation of phosphatidylinositol 3–kinase and Ras/MAPK pathway. Tansey MG, et al. **J Cell Biol** 1996 Jul;134(2):465–76

Differential regulation of the expression of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase and pyruvate kinase by cyclic adenosine 3',5'–monophosphate in fetal and adult hepatocytes. Casado M, et al. **J Cell Physiol** 1995 Dec;165(3):630–8

Phosphatidylinositol 3–kinase activation in normal human B lymphocytes. Aagaard–Tillery KM, et al. **J Immunol** 1996 Jun 15;156(12):4543–54

Signaling through CD28/CTLA–4 family receptors: puzzling participation of phosphatidylinositol–3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071–4 (69 ref.)

CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C–gamma and phosphatidylinositol 3–kinase. Silvennoinen O, et al. **J Immunol** 1996 Jan 1;156(1):100–7

CD28–mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3–kinase, and protein kinase C. Teng JM, et al. **J Immunol** 1996 May 1;156(9):3222–32

CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3–kinase. Truitt KE, et al. **J Immunol** 1995 Nov 15;155(10):4702–10

Carbachol inhibits insulin–stimulated phosphatidylinositol 3–kinase activity in SH–SY5Y neuroblastoma cells. Lavie Y, et al. **J Neurochem** 1996 Sep;67(3):1245–51

Physiologic levels of beta–amyloid activate phosphatidylinositol 3–kinase with the involvement of tyrosine phosphorylation. Luo Y, et al. **J Neurochem** 1996 Sep;67(3):978–87

The UL97 gene product of human cytomegalovirus is an early–late protein with a nuclear localization but is not a nucleoside kinase. Michel D, et al. **J Virol** 1996 Sep; 70(9):6340–6

Unusual inositol triphosphate metabolism in yeast [letter] Robinson KS, et al. **Microbiology** 1996 Jun;142 (Pt 6):1333–4

Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3–kinase in muscle and brain. Antonetti DA, et al. **Mol Cell Biol** 1996 May;16(5):2195–203

CD28–mediated costimulation in the absence of phosphatidylinositol 3–kinase association and activation. Crooks ME, et al. **Mol Cell Biol** 1995 Dec;15(12):6820–8

Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3–kinase in activation of pp70 S6 kinase. Dahl J, et al. **Mol Cell Biol** 1996 Jun;16(6):2728–35

Functional interactions of phosphatidylinositol 3–kinase with GTPase–activating protein in 3T3–L1 adipocytes. DePaolo D, et al. **Mol Cell Biol** 1996 Apr;16(4):1450–7

Membrane localization of phosphatidylinositol 3–kinase is sufficient to activate multiple signal–transducing kinase pathways. Klippel A, et al. **Mol Cell Biol** 1996 Aug; 16(8):4117–27

Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS–I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3–kinase. Mèndez R, et al. **Mol Cell Biol** 1996 Jun;16(6):2857–64

Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Choi OH, et al. **Nature** 1996 Apr 18;380(6575):634–6

The proto–oncogene product p120CBL and the adaptor proteins CRKL and c–CRK link c–ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol–3' kinase pathway. Sattler M, et al. **Oncogene** 1996 Feb 15; 12(4):839–46

Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)

A heterotrimeric GTPase–regulated isoform of PI3K and the regulation of its potential effectors. Stephens L, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):211–5 (40 ref.)

Cloning and characterization of Lnk, a signal transduction protein that links T–cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3–kinase. Huang X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11618–22

Phorbol ester treatment inhibits phosphatidylinositol 3–kinase activation by, and association with, CD28, a T–lymphocyte surface receptor. Hutchcroft JE, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8808–12

The inability of phosphatidylinositol 3–kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin–stimulated glucose uptake. Isakoff SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10247–51

Cloning and expression of human deoxyguanosine kinase cDNA. Johansson M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7258–62

Evidence for phosphatidylinositol 3–kinase as a regulator of endocytosis via activation of Rab5. Li G, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10207–11

Platelet–derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3–kinase. Moriya S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):151–5

Embryonic mesoderm cells spread in response to platelet–derived growth factor and signaling by phosphatidylinositol 3–kinase. Symes K, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9641–4

Phosphatidylinositol 3–kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter. Young AT, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11613–7

Covalent control of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)

A target for phosphoinositide 3–kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441–2 (11 ref.)

PHARMACOLOGY

Recombinant scinderin, an F–actin severing protein, increases calcium–induced release of serotonin from permeabilized platelets, an effect blocked by two scinderin–derived actin–binding peptides and phosphatidylinositol 4,5–bisphosphate. Marcu MG, et al. **Blood** 1996 Jan 1; 87(1):20–4

Requirement for phosphatidylinositol 3'-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. Minshall C, et al. **J Immunol** 1996 Feb 1;156(3):939–47

PHYSIOLOGY

Phosphoinositide 3–kinase and the regulation of cell growth. Carpenter CL, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):M11–6 (65 ref.)

Phosphatidylinositol–3–kinase activity is required for the anti–ig–mediated growth inhibition of a human B–lymphoma cell line. Beckwith M, et al. **Blood** 1996 Jan 1;87(1):202–10

Evidence for a role of phosphatidylinositol 3–kinase in IL–4–induced germline C epsilon transcription. Ikizawa K, et al. **Cell Immunol** 1996 May 25;170(1):134–40

Novel functions of phosphatidylinositol 3–kinase in terminally differentiated cells. Nakanishi S, et al. **Cell Signal** 1995 Aug;7(6):545–57 (127 ref.)

Intracellular signalling. PI 3–kinase puts GTP on the Rac. Parker PJ. **Curr Biol** 1995 Jun 1;5(6):577–9

CD28–dependent killing by human YT cells requires phosphatidylinositol 3–kinase activation. Lu Y, et al. **Eur J Immunol** 1996 Jun;26(6):1278–84

Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol–3 kinase in signal transduction via the human B lymphocyte antigen CD22. Tuscano JM, et al. **Eur J Immunol** 1996 Jun;26(6):1246–52

Mammalian RAFT1 kinase domain provides rapamycin–sensitive TOR function in yeast. Alarcon CM, et al. **Genes Dev** 1996 Feb 1;10(3):279–88

Wortmannin inhibits mitogen–activated protein kinase activation by platelet–activating factor through a mechanism independent of p85/p110–type phosphatidylinositol 3–kinase. Ferby IM, et al. **J Biol Chem** 1996 May 17;271(20):11684–8

Phosphorylation of the platelet p47 phosphoprotein is mediated by the lipid products of phosphoinositide 3–kinase. Toker A, et al. **J Biol Chem** 1995 Dec 8; 270(49):29525–31

Activation and nuclear translocation of mitogen–activated protein kinases by polyomavirus middle–T or serum depend on phosphatidylinositol 3–kinase. Urich M, et al. **J Biol Chem** 1995 Dec 8;270(49):29286–92

Different sensitivity to wortmannin of two vacuolar sorting signals indicates the presence of distinct sorting machineries in tobacco cells. Matsuoka K, et al. **J Cell Biol** 1995 Sep; 130(6):1307–18

A role for phosphatidylinositol 3–kinase in the regulation of beta 1 integrin activity by the CD2 antigen. Shimizu Y, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1867–80

Potential sites of PI–3 kinase function in the endocytic pathway revealed by the PI–3 kinase inhibitor, wortmannin. Shpetner H, et al. **J Cell Biol** 1996 Feb;132(4):595–605

CD28–mediated up–regulation of beta 1–integrin adhesion involves phosphatidylinositol 3–kinase. Zell T, et al. **J Immunol** 1996 Feb 1;156(3):883–6

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow–growth phenotype, while mutations in the UL97–encoded phosphotransferase confer ganciclovir resistance in three double–resistant human cytomegalovirus strains recovered from patients with AIDS. Baldanti F, et al. **J Virol** 1996 Mar;70(3):1390–5

TOR controls translation initiation and early G1 progression in yeast. Barbet NC, et al. **Mol Biol Cell** 1996 Jan;7(1):25–42

Roles of 1–phosphatidylinositol 3–kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Quon MJ, et al. **Mol Cell Biol** 1995 Oct;15(10):5403–11

A phosphatidylinositol (PI) kinase gene family in Dictyostelium discoideum: biological roles of putative mammalian p110 and yeast Vps34p PI 3–kinase homologs during growth and development. Zhou K, et al. **Mol Cell Biol** 1995 Oct;15(10):5645–56

Regulation of phosphoinositide–3–kinase by G protein beta gamma subunits in a rat osteosarcoma cell line. Morris AJ, et al. **Mol Pharmacol** 1995 Sep;48(3):532–9

A phosphatidylinositol–3–OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Morris JZ, et al. **Nature** 1996 Aug 8; 382(6591):536–9

Growth factor–dependent survival of rodent fibroblasts requires phosphatidylinositol 3–kinase but is independent of pp70S6K activity. Yao R, et al. **Oncogene** 1996 Jul 18; 13(2):343–51

Phosphatidylinositol 3' kinase: one of the effectors of Ras. Rodriguez–Viciana P, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):225–31; discussion 231–2 (50 ref.)

PIK–related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50–1 (22 ref.)

PHOSPHOTRANSFERASES, ATP see **PHOSPHOTRANSFERASES**

PHOSPHOTRANSFERASES (CARBOXYL GROUP ACCEPTOR)

BIOSYNTHESIS

Genetic manipulation of acid formation pathways by gene inactivation in Clostridium acetobutylicum ATCC 824. Green EM, et al. **Microbiology** 1996 Aug;142 (Pt 8):2079–86

GENETICS

Increase in osmotolerance of Rhizobium fredii soybean isolate BD32 by the proB proA operon of Escherichia coli. Neumivakin LV, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):796–801

Transcription of Bacillus subtilis degR is sigma D dependent and suppressed by multicopy proB through sigma D. Ogura M, et al. **J Bacteriol** 1996 Jan;178(1):216–22

METABOLISM

The carbamoyl-phosphate synthase family and carbamate kinase: structure–function studies. Rubio V, et al. **Biochem Soc Trans** 1995 Nov;23(4):879–83 (33 ref.)

PHOSPHOTRANSFERASES (NITROGENOUS GROUP ACCEPTOR)

CHEMISTRY

Influence of phosphoenolpyruvate and magnesium ions on the quaternary structure of enzyme I of the phosphotransferase system from gram-positive bacteria. Hübner G, et al. **Biochemistry** 1995 Dec 5;34(48):15700–3

Importance of the region around glycine–338 for the activity of enzyme I of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system. Seok YJ, et al. **Biochemistry** 1996 Jan 9;35(1):236–42

The N-terminal domain of Escherichia coli enzyme I of the phosphoenolpyruvate/glycose phosphotransferase system: molecular cloning and characterization. Chauvin F, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7028–31

Importance of the carboxyl-terminal domain of enzyme I of the Escherichia coli phosphoenolpyruvate: sugar phosphotransferase system for phosphoryl donor specificity. Seok YJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):347–51

GENETICS

Regulation of ptsH and ptsI gene expression in Streptococcus salivarius ATCC 25975. Gagnon G, et al. **Mol Microbiol** 1995 Jun;16(6):1111–21

METABOLISM

Importance of the region around glycine–338 for the activity of enzyme I of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system. Seok YJ, et al. **Biochemistry** 1996 Jan 9;35(1):236–42

The N-terminal domain of Escherichia coli enzyme I of the phosphoenolpyruvate/glycose phosphotransferase system: molecular cloning and characterization. Chauvin F, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7028–31

Coupling the phosphotransferase system and the methyl-accepting chemotaxis protein-dependent chemotaxis signaling pathways of Escherichia coli. Lux R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11583–7

PHOSPHOTRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS) see **TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS)**

PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR)

BIOSYNTHESIS

Molecular cloning of human phosphomevalonate kinase and identification of a consensus peroxisomal targeting sequence. Chambliss KL, et al. **J Biol Chem** 1996 Jul 19; 271(29):17330–4

CHEMISTRY

Crystal structure of bacteriophage T4 deoxynucleotide kinase with its substrates dGMP and ATP. Teplyakov A, et al. **EMBO J** 1996 Jul 15;15(14):3487–97

ISOLATION & PURIFICATION

Identification and characterization of geranylgeraniol kinase and geranylgeranyl phosphate kinase from the Archaebacterium Sulfolobus acidocaldarius. Ohnuma S, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):541–7

Purified inositol hexakisphosphate kinase is an ATP synthase: diphosphoinositol pentakisphosphate as a high-energy phosphate donor. Voglmaier SM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4305–10

METABOLISM

Diacylglycerol- and phosphatidic acid-kinase studies in plant cell suspension cultures. Wissing JB, et al. **Biochem Soc Trans** 1995 Nov;23(4):867–71

ATP synthase subunit C storage in the polymorphonucleocytes of late infantile and juvenile batten patients. Ansari NH, et al. **Int J Dev Neurosci** 1995 Aug; 13(5):455–62

Inorganic polyphosphate supports resistance and survival of stationary-phase Escherichia coli. Rao NN, et al. **J Bacteriol** 1996 Mar;178(5):1394–400

Purified inositol hexakisphosphate kinase is an ATP synthase: diphosphoinositol pentakisphosphate as a high-energy phosphate donor. Voglmaier SM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4305–10

[Batten disease (Neuronal ceroid lipofuscinoses)—accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation] Ezaki J, et al. **Nippon Rinsho** 1995 Dec;53(12):3055–61 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHOSPHOTRANSFERASES (PHOSPHOMUTASES)

DEFICIENCY

Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. Van Schaftingen E, et al. **FEBS Lett** 1995 Dec 27;377(3):318–20

GENETICS

Cloning and functional analysis of the pmmA gene encoding phosphomannomutase from the photosynthetic prokaryote Prochlorothrix hollandica. Dwivedi K, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):210–4

Cloning and nucleotide sequence of fosfomycin biosynthetic genes of Streptomyces wedmorensis. Hidaka T, et al. **Mol Gen Genet** 1995 Nov 27;249(3):274–80

METABOLISM

Phosphoenolpyruvate mutase catalysis of phosphoryl transfer in phosphoenolpyruvate: kinetics and mechanism of phosphorus–carbon bond formation. Kim J, et al. **Biochemistry** 1996 Apr 9;35(14):4628–35

PHYSIOLOGY

Avirulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection. Goldberg JB, et al. **Infect Immun** 1995 Oct;63(10):4166–9

PHOSPHOTRIOSE ISOMERASE see **TRIOSEPHOSPHATE ISOMERASE**

PHOSPHOTUNGSTIC ACID

ANALYSIS

Chromatin defects in normal and malformed human ejaculated and epididymal spermatozoa: a cytochemical ultrastructural study. Francavilla S, et al. **J Reprod Fertil** 1996 Mar;106(2):259–68

PHOSPHOTYROSINE

Thermodynamic studies of SHC phosphotyrosine interaction domain recognition of the NPXpY motif. Mandiyan V, et al. **J Biol Chem** 1996 Mar 1;271(9):4770–5

Persistence of tyrosine-phosphorylated FcepsilonRI in deactivated cells. Paolini R, et al. **J Biol Chem** 1996 Jul 5;271(27):15987–92

A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. O'Bryan JP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2729–34

Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites. van der Geer P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):963–8

ANALYSIS

Phosphotyrosine phosphatase associated with band 3 protein in the human erythrocyte membrane. Zipser Y, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):881–7

Tyrosine phosphorylation in inflammatory neutrophils. Lloyds D, et al. **Biochem Soc Trans** 1996 Feb;24(1):79S

Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis. Lower EE, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):277–82

Expression of immunoreactivities to 75 kDa nerve growth factor receptor, trk gene product and phosphotyrosine in granular cell tumors. Hoshi N, et al. **Pathol Int** 1995 Oct; 45(10):748–56

Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736–42

BIOSYNTHESIS

Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Manie SN, et al. **Blood** 1996 Mar 1;87(5):1855–61

Expression of phosphotyrosine in squamous cell carcinoma of the oral mucosa. Preliminary study. Maiorano E, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun;71(5–6):157–62

BLOOD

Effect of cAMP and cGMP on endothelin-stimulated tyrosine phosphorylation in rabbit platelets. Catalán RE, et al. **Biochem Biophys Res Commun** 1995 Oct 4; 215(1):219–26

CHEMISTRY

Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. He W, et al. **J Biol Chem** 1996 May 17;271(20):11641–5

Identification of residues within the SHC phosphotyrosine binding/phosphotyrosine interaction domain crucial for phosphopeptide interaction. Yajnik V, et al. **J Biol Chem** 1996 Jan 26;271(4):1813–6

Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. Tong L, et al. **J Mol Biol** 1996 Mar 1;256(3):601–10

Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function. Kong G, et al. **Mol Cell Biol** 1996 Sep; 16(9):5026–35

IMMUNOLOGY

Lysis buffer composition dramatically affects extraction of phosphotyrosine-containing proteins. Ignatoski KM, et al. **Biotechniques** 1996 May;20(5):794–6

A cell-free Salmonella typhimurium extract induces inhibition of tyrosine phosphorylation in murine splenic T-lymphocytes. Matsui K, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):51–3

Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. Gomez-Cambronero J. **J Interferon Cytokine Res** 1995 Oct;15(10):877–85

Association of beta 1 integrin with phosphotyrosine in growth cone filopodia. Wu DY, et al. **J Neurosci** 1996 Feb 15;16(4):1470–8

Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. Landry F, et al. **J Urol** 1996 Jan;155(1):386–90

ISOLATION & PURIFICATION

Effects of cooling temperature on the separation of phosphoamino acids. Lombardini JB, et al. **Anal Biochem** 1995 May 20;227(2):399–400

Tyrosine phosphorylation in Myxococcus xanthus, a multicellular prokaryote. Frasch SC, et al. **J Bacteriol** 1996 Jul;178(14):4084–8

METABOLISM

Interleukin-11 induces tyrosine phosphorylation, and c-jun and c-fos mRNA expression in human K562 and U937 cells. Adunyah SE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:296–9

Protein kinase C mediates short- and long-term effects on receptor tyrosine kinases. Regulation of tyrosine phosphorylation and degradation. Seedorf K, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:459–62

Respiratory burst and tyrosine phosphorylation by vanadate. Yamaguchi M, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):382–6

Tumor necrosis factor alpha increases tyrosine phosphorylation of a 23-kDa nuclear protein in U937 cells through ceramide signaling pathway. Ji L, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):489–96

Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor/scatter factor. Jiang WG, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1062–9

Integrin stimulation decreases tyrosine phosphorylation and activity of focal adhesion kinase in thymocytes. Kanazawa S, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):438–45

Tyrosine phosphorylation of inducible nitric oxide synthase: implications for potential post-translational regulation. Pan J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):889–94

Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Saad MJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):741–4

Correlation of altered tyrosine phosphorylation with methotrexate resistance in a cisplatin-resistant subline of L1210 cells. Bhushan A, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):477–82

Structural and dynamic characterization of the phosphotyrosine binding region of a Src homology 2 domain—phosphopeptide complex by NMR relaxation, proton exchange, and chemical shift approaches. Pascal SM, et al. **Biochemistry** 1995 Sep 12;34(36):11353–62

Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Tallett A, et al. **Cancer Res** 1996 Sep 15;56(18):4255-63

HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Gallay P, et al. **Cell** 1995 Nov 17; 83(4):569-76

Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Rameh LE, et al. **Cell** 1995 Dec 1;83(5):821-30

An examination of focal adhesion formation and tyrosine phosphorylation in fibroblasts isolated from src-, fyn-, and yes- mice. Bockholt SM, et al. **Cell Adhes Commun** 1995 May;3(2):91-100

Divergent phosphotyrosine signaling via Fc gamma RIIIA on human NK cells. Manciulea M, et al. **Cell Immunol** 1996 Jan 10;167(1):63-71

Thyroid stimulating hormone and N6-2'-O-dibutyryladenosine 3'-5'-cyclic monophosphate decrease 110,000-130,000 M(r) tyrosine-phosphorylated substrate in rat thyroid cells. Takano T, et al. **Cell Signal** 1995 Jul;7(5):519-25

Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Chow JC, et al. **Endocrinology** 1996 Jul; 137(7):2880-6

Tyrosine phosphorylation of the growth hormone (GH) receptor and Janus tyrosine kinase-2 is involved in the insulin-like actions of GH in primary rat adipocytes. Eriksson H, et al. **Endocrinology** 1995 Nov; 136(11):5093-101

A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn. Agostinis P, et al. **Eur J Biochem** 1996 Mar 1; 236(2):548-57

Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells. Baxter RM, et al. **Eur J Biochem** 1995 Nov 15;234(1):84-91

Bradykinin induces tyrosine phosphorylation in human foreskin fibroblasts and 293 cells transfected with rat B2 kinin receptor. Tippmer S, et al. **Eur J Biochem** 1996 Mar 15;236(3):953-9

Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Chalupny NJ, et al. **Eur J Immunol** 1995 Oct;25(10):2978-84

Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product. Uddin S, et al. **Exp Hematol** 1996 Apr;24(5):622-7

Homodimerization and intermolecular tyrosine phosphorylation of the Tyk-2 tyrosine kinase. Domanski P, et al. **FEBS Lett** 1995 Nov 6;374(3):317-22

Gastrin induces tyrosine phosphorylation of Shc proteins and their association with the Grb2/Sos complex. Seva C, et al. **FEBS Lett** 1996 Jan 2;378(1):74-8

A cell-free Salmonella typhimurium extract induces inhibition of tyrosine phosphorylation in murine splenic T-lymphocytes. Matsui K, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):51-3

rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Imamura F, et al. **Int J Cancer** 1996 Mar 1;65(5):627-32

Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta. Denning MF, et al. **J Biol Chem** 1996 Mar 8;271(10):5325-31

The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. Fiore F, et al. **J Biol Chem** 1995 Dec 29;270(52):30853-6

Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase. Fournier E, et al. **J Biol Chem** 1996 May 31;271(22):12956-63

Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. Gerhartz C, et al. **J Biol Chem** 1996 May 31; 271(22):12991-8

Interaction between the phosphotyrosine binding domain of Shc and the insulin receptor is required for Shc phosphorylation by insulin in vivo. Isakoff SJ, et al. **J Biol Chem** 1996 Feb 23;271(8):3959-62

Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells. Kontani K, et al. **J Biol Chem** 1996 Jan 19; 271(3):1534-7

Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagine-X-X-phosphotyrosine motifs of growth factor receptors. Laminet AA, et al. **J Biol Chem** 1996 Jan 5; 271(1):264-9

Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC. O'Bryan JP, et al. **J Biol Chem** 1996 May 17;271(20):11787-91

Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha-tubulin on tyrosine. Peters JD, et al. **J Biol Chem** 1996 Mar 1;271(9):4755-62

Intracluster restriction of Fc receptor gamma-chain tyrosine phosphorylation subverted by a protein-tyrosine phosphatase inhibitor. Pfefferkorn LC, et al. **J Biol Chem** 1996 May 10;271(19):11099-105

Ectopic expression of human and feline CD9 in a human B cell line confers beta 1 integrin-dependent motility on fibronectin and laminin substrates and enhanced tyrosine phosphorylation. Shaw AR, et al. **J Biol Chem** 1995 Oct 13;270(41):24092-9

Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. Szabò I, et al. **J Biol Chem** 1996 Aug 23; 271(34):20465-9

Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of shc in human keratinocytes. Wery S, et al. **J Biol Chem** 1996 Apr 12;271(15):8529-32

A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. Wishart MJ, et al. **J Biol Chem** 1995 Nov 10;270(45):26782-5

Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc. Zhou MM, et al. **J Biol Chem** 1995 Dec 29;270(52):31119-23

Fluoride at mitogenic concentrations increases the steady state phosphotyrosyl phosphorylation level of cellular proteins in human bone cells. Thomas AB, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2570-8

Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. Campbell KS, et al. **J Exp Med** 1996 Jul 1;184(1):93-100

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. Carlesso N, et al. **J Exp Med** 1996 Mar 1;183(3):811-20

Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data. Mikol V, et al. **J Mol Biol** 1995 Nov 17; 254(1):86-95

Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. Watts SW, et al. **J Vasc Res** 1996 Jul-Aug;33(4):288-98

c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Wisniewski D, et al. **Leukemia** 1996 Feb;10(2):229-37

Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Zhou MM, et al. **Nature** 1995 Dec 7;378(6557):584-92

The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation. Milia E, et al. **Oncogene** 1996 Aug 15; 13(4):767-75

Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation. Tian M, et al. **Oncogene** 1996 Feb 15;12(4):727-34

Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Joung I, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5991-5

Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling. Ravichandran KS, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5275-80

Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Bu R, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):257-64

Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation. Jayaraman T, et al. **Science** 1996 Jun 7;272(5267):1492-4

[Detection of phosphotyrosine-containing proteins in the nuclear matrix of certain tumors] Filatova LS, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):279-81 **(Rus)**

PHARMACOLOGY

Association of inhibition of cell growth by O-phospho-L-tyrosine with decreased tyrosine phosphorylation. Mishra S, et al. **Cancer Lett** 1996 Apr 19;102(1-2):65-71

4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. Burke TR Jr, et al. **J Med Chem** 1996 Mar 1; 39(5):1021-7

L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. Ye B, et al. **J Med Chem** 1995 Oct 13; 38(21):4270-5

PHYSIOLOGY

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119-31 (113 ref.)

Detachment of cultured cells from the substratum induced by the neutrophil-derived oxidant NH2Cl: synergistic role of phosphotyrosine and intracellular Ca2+ concentration. Nakamura TY, et al. **J Cell Biol** 1995 Oct;131(2):509-24

Modulation of biological tyrosine reactions by tyrosine phosphorylation. Gmeiner BM, et al. **Wien Klin Wochenschr** 1995;107(22):687-9 (12 ref.)

PHOSPHOTYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

PHOSVITIN

GENETICS

Isolation and characterization of a vitellogenin cDNA from rainbow trout (Oncorhynchus mykiss) and the complete sequence of a phosvitin coding segment. Goulas A, et al. **DNA Cell Biol** 1996 Jul;15(7):605-16

PHOTIC STIMULATION

Role of the neuronal activity of nucleus prepositus hypoglossi in optokinetic stimulation in the cat. Sato S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:53-6

Alternations of eye movements induced by visual stimulation in a patient with acute cerebellar infarction. Watanabe S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:47-52

Detection of visual dysfunction in optic atrophy by functional magnetic resonance imaging during monocular visual stimulation. Miki A, et al. **Am J Ophthalmol** 1996 Sep; 122(3):404-15

Habituation of female sexual arousal to slides and film. Laan E, et al. **Arch Sex Behav** 1995 Oct;24(5):517-41

Integral bias in the cognitive processing of emotionally linked pictures. Martin M, et al. **Br J Psychol** 1995 Aug;86 (Pt 3):419-35

The effects of lesions of the thalamic intergeniculate leaflet on the pineal metabolism. Cipolla-Neto J, et al. **Brain Res** 1995 Sep 11;691(1-2):133-41

Efferent projections of the olivary pretectal nucleus in the albino rat subserving the pupillary light reflex and related reflexes. A light microscopic tracing study. Klooster J, et al. **Brain Res** 1995 Aug 7;688(1-2):34-46

Changes in neuronal activity related to the repetition and relative familiarity of visual stimuli in rhinal and adjacent cortex of the anaesthetised rat. Zhu XO, et al. **Brain Res** 1995 Aug 14;689(1):101-10

Effects of adenosine on chick retinal pigment epithelium: membrane potentials and light-evoked responses. Maruiwa F, et al. **Curr Eye Res** 1995 Aug;14(8):685-91

Age-related changes in the electrophysiological response to visual stimulus novelty: a topographical approach. Thomas KM, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 98(4):294-308

Photic-induced epileptic negative myoclonus: a case report. Gambardella A, et al. **Epilepsia** 1996 May;37(5):492-4

Wavelength specificity of photoparoxysmal responses in idiopathic generalized epilepsy. Takahashi Y, et al. **Epilepsia** 1995 Nov;36(11):1084-8

Self-induced photogenic seizures in a child with severe myoclonic epilepsy in infancy: optical investigations and treatments. Takahashi Y, et al. **Epilepsia** 1995 Jul; 36(7):728-32

Latency variability of responses to visual stimuli in cells of the cat's lateral geniculate nucleus. Lu SM, et al. **Exp Brain Res** 1995;105(1):7-17

Interactions between two different visual stimuli in the receptive fields of inferior temporal neurons in macaques during matching behaviors. Sato T. **Exp Brain Res** 1995; 105(2):209-19

Visual evoked potentials after photostress in newly diagnosed insulin-dependent diabetes patients. Parisi V, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Oct;233(10):601-4

Increase of REM duration and decrease of REM latency after a prolonged test of visual attention. De Gennaro L, et al. **Int J Neurosci** 1995 Jun;82(3-4):163-8

Frequency and luminance-dependent blood flow and K+ ion changes during flicker stimuli in cat optic nerve head. Buerk DG, et al. **Invest Ophthalmol Vis Sci** 1995 Oct; 36(11):2216-27

Differential distribution of CaM kinases and induction of c-fos expression by flashing and sustained light in rat retinal cells. Yoshida K, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):174-9

Voice development under training with and without the influence of real-time visually presented biofeedback [letter] Rossiter D, et al. **J Acoust Soc Am** 1996 May; 99(5):3253-6

Postural adjustments produced by moving visual (horizontal optokinetic) patterns. Blanks RH, et al. **J Am Acad Audiol** 1996 Jan;7(1):39-48

Different neural pathways coordinate Drosophila flight initiations evoked by visual and olfactory stimuli. Trimarchi JR, et al. **J Exp Biol** 1995 May;198 (Pt 5):1099-104

The effect of repeated reactivations on memory specificity in infancy. Hitchcock DF, et al. **J Exp Child Psychol** 1996 Aug;62(3):378-400

Does bright light suppress nocturnal melatonin secretion more in women than men? Monteleone P, et al. **J Neural Transm Gen Sect** 1995;102(1):75-80

Red-light-induced suppression of melatonin synthesis is mediated by N-methyl-D-aspartate receptor activation in retinally normal and retinally degenerate rats. Poeggeler

BH, et al. **J Neurobiol** 1995 Sep;28(1):1–8

Magnetic and electrical responses of the human brain to texture-defined form and to textons. Regan D, et al. **J Neurophysiol** 1995 Sep;74(3):1167–78

The emergence of the capacity to name left visual field stimuli in a callosotomy patient: implications for functional plasticity. Baynes K, et al. **Neuropsychologia** 1995 Oct; 33(10):1225–42

Contingent and non-contingent auditory cueing in Parkinson's disease. Kritikos A, et al. **Neuropsychologia** 1995 Oct;33(10):1193–203

Visually-triggered oscillations in the cat lateral posterior-pulvinar complex. Shumikhina S, et al. **Neuroreport** 1995 Nov 27;6(17):2341–7

Effects of different patterns of light adaptation on cellular and synaptic plasticity in teleost retina: comparison of flickering and steady lights. Haamedi SN, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):93–6

The reaction of Helix photosensitive neurons to light and cyclic GMP. Pasic M, et al. **Neuroscience** 1995 Nov; 69(2):557–65

Small amounts of chromatic aberration influence dynamic accommodation. Kruger PB, et al. **Optom Vis Sci** 1995 Sep; 72(9):656–66

P3(00) habituation from auditory and visual stimuli. Romero R, et al. **Physiol Behav** 1996 Mar;59(3):517–22

Antagonizing correlation between periodic synchronous discharges and photically induced giant evoked responses in Creutzfeldt--Jakob disease (Heidenhain type): a case study. Jibiki I, et al. **Psychiatry Clin Neurosci** 1995 Mar; 49(1):87–90

Shades of gray matter: noninvasive optical images of human brain responses during visual stimulation. Gratton G, et al. **Psychophysiology** 1995 Sep;32(5):505–9

Visually evoked cerebral blood flow velocity changes in different states of brain dysfunction. Becker VU, et al. **Stroke** 1996 Mar;27(3):446–9

Photoreactive flow changes in the posterior cerebral artery in control subjects and patients with occipital lobe infarction. Urban PP, et al. **Stroke** 1995 Oct;26(10):1817–9

Infant color vision: motion nulls for red/green vs luminance-modulated stimuli in infants and adults. Teller DY, et al. **Vision Res** 1996 Apr;36(7):955–74

[Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations] Azulay JP, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):128–34 (Eng. Abstr.) **(Fre)**

[The effect of stimulus-driven factor on attentional capture: evidence from visual search paradigm containing static and dynamic stimuli] Kawahara J. **Shinrigaku Kenkyu** 1996 Apr; 67(1):25–32 (Eng. Abstr.) **(Jpn)**

[Formation of a visual information trace. Analysis of evoked potentials] Beteleva TG. **Fiziol Cheloveka** 1996 May-Jun; 22(3):45–51 **(Rus)**

[Evaluation of the integrity of visual objects as a function of their dimensions] Bondarko VM, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):65–70 **(Rus)**

[Disorders in the perception of spatially oriented visual stimuli and Parkinsonism: role of the dopaminergic system] Iakimovskii AF, et al. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):69–72 **(Rus)**

[Hemispheric asymmetry while learning of visual stimulus classifications under conditions of hindrance] Udalova GP. **Fiziol Cheloveka** 1995 Jul-Aug;21(4):5–12 **(Rus)**

ADVERSE EFFECTS

Self induced photosensitive epilepsy. Das K, et al. **J Assoc Physicians India** 1995 Oct;43(10):723

Visually induced paroxysmal nausea and vomiting as presenting manifestations of multiple sclerosis [letter; comment] Bronstein AM. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):703. Comment on: J Neurol Neurosurg Psychiatry 1995 Sep;59(3):342–3.

Photosensitive temporal lobe epilepsy. Benbadis SR, et al. **Neurology** 1996 Jun;46(6):1540–2 (10 ref.)

Electrographic studies of the effects of RP 60180, a novel kappa agonist, on the photosensitive baboon Papio papio. Stutzmann JM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):687–97

Photic injury triggers apoptosis of photoreceptor cells. Abler AS, et al. **Res Commun Mol Pathol Pharmacol** 1996 May; 92(2):177–89

"Sonic, tonic, clonic": three cases of video game epilepsy. Allen A, et al. **Ulster Med J** 1994 Apr;63(1):99–102

INSTRUMENTATION

Phase locking of neuronal responses to the vertical refresh of computer display monitors in cat lateral geniculate nucleus and striate cortex. Wollman DE, et al. **J Neurosci Methods** 1995 Aug;60(1–2):107–13

METHODS

Effects of stimulus velocity and acceleration on smooth pursuit in motor neuron disease. Abel LA, et al. **J Neurol** 1995 Jul;242(7):419–24

Sensitivity to cross-like figures in the cat striate neurons. Shevelev IA, et al. **Neuroscience** 1995 Nov;69(1):51–7

Colorimetric analyses of various light sources for the D-15 color vision test. Hovis JK, et al. **Optom Vis Sci** 1995 Sep; 72(9):667–78

Influence of the luminance signal and red-green and yellow-blue opponent chromatic signals in figural-stimuli stereograms. Jiménez JR, et al. **Optom Vis Sci** 1995 Sep; 72(9):649–55

[New methods of stimulation of evoked visual potentials] Sóth J, et al. **Cesk Slov Oftalmol** 1995 Apr;51(2):111–4 (Eng. Abstr.) **(Slo)**

PHOTOAGING OF SKIN see **SKIN AGING**

PHOTOALLERGY see **DERMATITIS, PHOTOALLERGIC**

PHOTOBACTERIUM

DRUG EFFECTS

Toxicity of methyl tertiary butyl ether to Daphnia magna and Photobacterium phosphoreum. Gupta G, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):618–20

Quantitative structure-activity relationships of organic acids and bases. Zhao YH, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):242–9

ENZYMOLOGY

The lumQ gene is linked to the lumP gene and the lux operon in Photobacterium leiognathi. Lin JW, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):684–95

Methylenetetrahydrofolate dehydrogenase-cyclohydrolase from Photobacterium phosphoreum shares properties with a mammalian mitochondrial homologue. Pawelek PD, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):47–54

Three-dimensional model of the alpha-subunit of bacterial luciferase. Sandalova T, et al. **Proteins** 1995 Oct; 23(2):241–55

GENETICS

Regulatory region with putA gene of proline dehydrogenase that links to the lum and the lux operons in Photobacterium leiognathi. Lin JW, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):868–75

Isolation and characterization of the structural gene for OmpL, a pressure-regulated porin-like protein from the deep-sea bacterium Photobacterium species strain SS9. Welch TJ, et al. **J Bacteriol** 1996 Aug;178(16):5027–31

An rpoE-like locus controls outer membrane protein synthesis and growth at cold temperatures and high pressures in the deep-sea bacterium Photobacterium sp. strain SS9. Chi E, et al. **Mol Microbiol** 1995 Aug; 17(4):713–26

GROWTH & DEVELOPMENT

Modelling of microbial activity and prediction of shelf life for packed fresh fish. Dalgaard P. **Int J Food Microbiol** 1995 Aug;26(3):305–17

ISOLATION & PURIFICATION

Qualitative and quantitative characterization of spoilage bacteria from packed fish. Dalgaard P. **Int J Food Microbiol** 1995 Aug;26(3):319–33

METABOLISM

Isolation and characterization of the structural gene for OmpL, a pressure-regulated porin-like protein from the deep-sea bacterium Photobacterium species strain SS9. Welch TJ, et al. **J Bacteriol** 1996 Aug;178(16):5027–31

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

PHOTOBIOLOGY

see related
LIGHT
PHOTOCHEMISTRY
PHOTOSYNTHESIS

Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191–200 (82 ref.)

Biologic Effects of Light. Atlanta, Georgia, October 9–11, 1995. Abstracts. **Photodermatol Photoimmunol Photomed** 1995 Apr;11(2):59–89

PHOTOCHEMICAL REACTION CENTER, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

PHOTOCHEMICAL REACTION CENTER, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOCHEMISTRY

Tandem reflectron time-of-flight mass spectrometer utilizing photodissociation. Beussman DJ, et al. **Anal Chem** 1995 Nov 1;67(21):3952–7

Calcium modulates the photoassembly of photosystem II (Mn)4-clusters by preventing ligation of nonfunctional high-valency states of manganese. Chen C, et al. **Biochemistry** 1995 Oct 17;34(41):13511–26

Two-dimensional domain shape transitions in photosensitive monolayer assemblies. Yoneyama M, et al. **Biosystems** 1995; 35(2–3):113–6

Photochemical formation of singlet molecular oxygen in illuminated aqueous solutions of several commercially available sunscreen active ingredients. Allen JM, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):605–9

Laser pulse-induced photochemical strand cleavage of site-specifically and covalently modified (+)-anti-benzo[a]pyrene diol epoxide-oligonucleotide adducts. Li B, et al. **Chem Res Toxicol** 1995 Apr-May; 8(3):396–402

Diffusion and binding measurements within oral biofilms using fluorescence photobleaching recovery methods. Birmingham JJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Dec 29; 350(1334):325–43

INSTRUMENTATION

Photodegradation of fluoroquinolones using a continuous-flow photochemical reaction unit [letter] McMullin CM, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):392–4

PHOTOCHEMOTHERAPY

UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Kokelj F, et al. **Acta Derm Venereol** 1995 Sep;75(5):386–7

Influence of activation and differentiation of cells on the effectiveness of photodynamic therapy. Schick E, et al. **Acta Derm Venereol** 1995 Jul;75(4):276–9

Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Jeanmougin M, et al. **Ann Hematol** 1996 Aug;73(2):91–3

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV. **Ann R Coll Surg Engl** 1995 Jul;77(4):308–12 (25 ref.)

Photodamaging effects of tetraphenylporphycene in a human carcinoma cell line. Villanueva A, et al. **Anticancer Drug Des** 1996 Mar;11(2):89–99

Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow. Chan WS, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1887–92

Antitumour activity of photosensitized hypericin on A431 cell xenografts. Vandenbogaerde AL, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1619–25

Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Martin A, et al. **Arch Dermatol Res** 1995; 287(7):665–74

Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures. Koechli OR, et al. **Arch Gynecol Obstet** 1995;256(4):167–76

Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Husain D, et al. **Arch Ophthalmol** 1996 Aug;114(8):978–85

Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Young LH, et al. **Arch Ophthalmol** 1996 Feb;114(2):186–92

Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Fromm D, et al. **Arch Surg** 1996 Jun;131(6):667–9

Photodynamic therapy for psoriasis? Fergin P. **Australas J Dermatol** 1996 May;37(2):87–8 (17 ref.)

Physico-chemical modeling of the role of free radicals in photodynamic therapy. III. Interactions of stable free radicals with excited photosensitizers studied by kinetic ESR spectroscopy. Kriska T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):192–8

In vivo experimental studies on the role of free radicals in photodynamic therapy. II. Photodynamic effect on free radical concentration in mice tumors measured by ESR spectroscopy. Kriska T, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):136–40

The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):72–6

Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Baas P, et al. **Br J Cancer** 1996 Apr;73(8):945–51

Hexadecafluorinated zinc phthalocyanine: photodynamic properties against the EMT-6 tumour in mice and pharmacokinetics using 65Zn as a radiotracer. Boyle RW, et al. **Br J Cancer** 1996 Jan;73(1):49–53

Photodynamic treatment of human endothelial cells promotes the adherence of neutrophils in vitro. de Vree WJ, et al. **Br J Cancer** 1996 Jun;73(11):1335–40

Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light. Foster TH, et al. **Br J Cancer** 1996 Apr;73(8):933–6

Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. Karagianis G, et al. **Br J Cancer** 1996 Feb;73(4):514–21

Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Kick G, et al. **Br J Cancer** 1996 Jul;74(1):30–6

Photodynamic therapy on the normal rabbit larynx with phthalocyanine and 5-aminolaevulinic acid induced

protoporphyrin IX photosensitisation. Kleemann D, et al. **Br J Cancer** 1996 Jul;74(1):49–58

The effect of aminolaevulinic acid–induced, protoporphyrin IX–mediated photodynamic therapy on the cremaster muscle microcirculation in vivo. Leveckis J, et al. **Br J Cancer** 1995 Nov;72(5):1113–9

Efficacy of intravenous delta–aminolaevulinic acid photodynamic therapy on rabbit papillomas. Lofgren LA, et al. **Br J Cancer** 1995 Oct;72(4):857–64

Distribution and photodynamic effects of meso–tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Mlkvy P, et al. **Br J Cancer** 1996 Jun;73(12):1473–9

Apoptosis and necrosis induced with light and 5–aminolaevulinic acid–derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22–9

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA–induced protoporphyrin IX in a colon carcinoma model. Orenstein A, et al. **Br J Cancer** 1996 Apr; 73(8):937–44

Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Veenhuizen RB, et al. **Br J Cancer** 1996 Jun;73(11):1387–92

Photodynamic therapy of epithelial skin tumours using delta–aminolaevulinic acid and desferrioxamine. Fijan S, et al. **Br J Dermatol** 1995 Aug;133(2):282–8

Photodynamic therapy of primary skin cancer: a review. Roberts DJ, et al. **Br J Plast Surg** 1995 Sep;48(6):360–70 (71 ref.)

Photothermal effects on murine mammary tumors using indocyanine green and an 808–nm diode laser: an in vivo efficacy study. Chen WR, et al. **Cancer Lett** 1996 Jan 2; 98(2):169–73

Accumulation of benzoporphyrin derivative in malignant and host cell populations of the murine RIF tumor [published erratum appears in Cancer Lett 1996 Jan 19;99(1):133] Korbelik M, et al. **Cancer Lett** 1995 Nov 6;97(2):249–54

Cytotoxic, nuclear, and growth inhibitory effects of photodynamic drugs on pancreatic carcinoma cells. Ward AJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):39–47

Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. de Vree WJ, et al. **Cancer Res** 1996 Jul 1;56(13):2908–11

Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Molpus KL, et al. **Cancer Res** 1996 Mar 1;56(5):1075–82

Combination chemotherapy and photodynamic therapy with N–(2–hydroxypropyl) methacrylamide copolymer–bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Peterson CM, et al. **Cancer Res** 1996 Sep 1;56(17):3980–5

Induction of tumor necrosis by delta–aminolevulinic acid and 1,10–phenanthroline photodynamic therapy. Rebeiz N, et al. **Cancer Res** 1996 Jan 15;56(2):339–44

Photodynamic therapy. Stables GI, et al. **Cancer Treat Rev** 1995 Jul;21(4):311–23 (98 ref.)

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

Topical photodynamic therapy in verrucae. A pilot study. Ammann R, et al. **Dermatology** 1995;191(4):346–7

Photodynamic therapy: a safe and effective treatment for tumor overgrowth in patients with oesophageal cancer and metal stents. Messmann H, et al. **Endoscopy** 1995 Oct; 27(8):629

Photodynamic therapy for polyps in familial adenomatous polyposis—a pilot study. Mlkvy P, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1160–5

Photodynamic effects of 5–aminolevulinic acid–induced porphyrin on human bladder carcinoma cells in vitro. Riesenberg R, et al. **Eur J Cancer** 1996 Feb;32A(2):328–34

Photodynamic therapy and lip vermilion dysplasia: a pilot study. Gregory GF, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):346–7

The role of photodynamic therapy in the management of oral cancer and precancer. Hopper C. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):71–2 (7 ref.)

Intra–operative laser–induced photodynamic therapy in the treatment of experimental hepatic tumours. Liu DL, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1073–80

Inhibition of intimal hyperplasia in balloon injured arteries with adjunctive phthalocyanine sensitised photodynamic therapy. Nyamekye I, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):19–28

Photoimmunotherapy of human uveal melanoma cells. Hu LK, et al. **Exp Eye Res** 1995 Oct;61(4):385–91

Photodynamic therapy for early esophageal cancer [letter; comment] Chan AW. **Gastroenterology** 1995 Oct; 109(4):1406–7. Comment on: Gastroenterology 1995 Feb;108(2):337–44.

Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser. van Gool CA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):435–40

Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach. Loh CS, et al. **Gut** 1996 Jan;38(1):71–8

Structural alterations induced by photodynamic action of hematoporphyrin derivative (HpD) in plasma membrane of glioblastoma (U–87MG) cells: time dependent fluorescence spectroscopic study. Joshi K, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):200–6

Effect of hematoporphyrin derivative and light on sulfhydryl groups in brain tumour cells. Joshi PG, et al. **Indian J Exp Biol** 1995 Oct;33(10):721–4

Photodynamic therapy of tumours with hexadecafluoro zinc phthalocynine formulated in PEG–coated poly(lactic acid) nanoparticles. Allémann E, et al. **Int J Cancer** 1996 Jun 11;66(6):821–4

Photodynamic therapy in dermatology. Frazier CC. **Int J Dermatol** 1996 May;35(5):312–6 (50 ref.)

Photodynamic therapy of ocular melanoma with bis silicon 2,3–naphthalocyanine in a rabbit model. Hill RA, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2476–81

T–cell responses in photoimmune therapy. Heald PW, et al. **J Clin Apheresis** 1995;10(3):144–9 (26 ref.)

Treatment of head and neck cancer with photodynamic therapy: results after one year. Dilkes MG, et al. **J Laryngol Otol** 1995 Nov;109(11):1072–6

Photodynamic therapy in the treatment of head and neck cancers: a two–year experience. Kulapaditharom B, et al. **J Med Assoc Thai** 1996 Apr;79(4):229–35

Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer–aided studies. Rodighiero P, et al. **J Med Chem** 1996 Mar 15;39(6):1293–302

PEG–coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT–6 mouse mammary tumours. Allémann E, et al. **J Pharm Pharmacol** 1995 May;47(5):382–7

Repetitive photodynamic therapy with topical delta–aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non–melanoma skin tumours. Calzavara–Pinton PG. **J Photochem Photobiol B** 1995 Jul;29(1):53–7

In vivo damage to chorioallantoic membrane blood vessels by porphycene–induced photodynamic therapy. Gottfried V, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):115–21

On the role of protoporphyrin IX photoproducts in photodynamic therapy [news] Gudgin Dickson EF, et al. **J Photochem Photobiol B** 1995 Jul;29(1):91–3

Effects of sonodynamic and photodynamic treatment on cellular thiol levels. Kessel D, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):103–6

Apoptosis of mouse MS–2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)–phthalocyanine. Zhou C, et al. **J Photochem Photobiol B** 1996 May;33(3):219–23

Histological evaluation of phthalocyanine mediated photodynamic occlusion of corneal neovascularization enhanced by hyperbaric oxygenation. Pallikaris IG, et al. **J Refract Surg** 1996 Feb;12(2):S313–6

Differential modulation of vascular endothelial and smooth muscle cell function by photodynamic therapy of extracellular matrix: novel insights into radical–mediated prevention of intimal hyperplasia. Adili F, et al. **J Vasc Surg** 1996 Apr;23(4):698–705

Management of Barrett's oesophagus [comment] Kelley DJ, et al. **Lancet** 1996 Aug 31;348(9027):561–2. Comment on: Lancet 1996 Aug 31;348(9027):584–5.

Laser photochemotherapy with anthracyclines on cultured human squamous carcinoma cells. Paiva MB, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):257–62

Clinical and preclinical photodynamic therapy. Fisher AM, et al. **Lasers Surg Med** 1995;17(1):2–31 (241 ref.)

Pharmacokinetics of pyropheophorbide–a–hexyl ether in the dog. Payne JT, et al. **Lasers Surg Med** 1996;18(4):406–9

Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro. Soukos NS, et al. **Lasers Surg Med** 1996; 18(3):253–9

Photosensitization of the rat endometrium following 5–aminolevulinic acid induced photodynamic therapy. Steiner RA, et al. **Lasers Surg Med** 1996;18(3):301–8

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Kramer M, et al. **Ophthalmology** 1996 Mar;103(3):427–38

The validation of a new vascular damage assay for photodynamic therapy agents. Bellnier DA, et al. **Photochem Photobiol** 1995 Nov;62(5):896–905

Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Bezdetnaya L, et al. **Photochem Photobiol** 1996 Aug;64(2):382–6

Photodynamic activities and skin photosensitivity of the bis(dimethylthexylsiloxy)silicon 2,3–naphthalocyanine in mice. Brasseur N, et al. **Photochem Photobiol** 1995 Dec; 62(6):1058–65

Flow cytometric technique for quantitating cytotoxic response to photodynamic therapy. Campbell DL, et al. **Photochem Photobiol** 1996 Jan;63(1):111–6

Tumor oxygenation changes post–photodynamic therapy. Chen Q, et al. **Photochem Photobiol** 1996 Jan;63(1):128–31

Octa–alkyl zinc phthalocyanines: potential photosensitizers for use in the photodynamic therapy of cancer. Cook MJ, et al. **Photochem Photobiol** 1995 Sep;62(3):542–5

Psoralen photobiology: recent advances. Gasparro FP. **Photochem Photobiol** 1996 May;63(5):553–7 (36 ref.)

Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a Psoralen and Ultraviolet A light. Gottlieb P, et al. **Photochem Photobiol** 1996 May; 63(5):562–5

Inactivation of Trypanosoma cruzi trypomastigote forms in blood components by photodynamic treatment with phthalocyanines. Gottlieb P, et al. **Photochem Photobiol** 1995 Nov;62(5):869–74

Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Hadjur C, et al. **Photochem Photobiol** 1996 Aug;64(2):375–81

Photosensitization of murine tumor, vasculature and skin by 5–aminolevulinic acid–induced porphyrin. Henderson BW, et al. **Photochem Photobiol** 1995 Oct;62(4):780–9

PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T–lymphocytes. Johnson R, et al. **Photochem Photobiol** 1996 May;63(5):566–71

Stimulatory and inhibitory effects of iron on photodynamic inactivation of leukemia cells. Lin F, et al. **Photochem Photobiol** 1995 Sep;62(3):528–34

Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Miller GG, et al. **Photochem Photobiol** 1995 Jun;61(6):632–8

The effect of photodynamic treatment of yeast with the sensitizer chloroaluminum phthalocyanine on various cellular parameters. Paardekooper M, et al. **Photochem Photobiol** 1995 Sep;62(3):561–7

Alkyl ether analogs of chlorophyll–a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy. Pandey RK, et al. **Photochem Photobiol** 1996 Jul; 64(1):194–204

Serine conjugates of chlorophyll and bacteriochlorophyll: photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Rosenbach–Belkin V, et al. **Photochem Photobiol** 1996 Jul;64(1):174–81

Potentiation of merocyanine 540–mediated photodynamic therapy by salicylate and related drugs. Traul DL, et al. **Photochem Photobiol** 1995 Oct;62(4):790–9

A mathematical model for light dosimetry in photodynamic destruction of human endometrium. Tromberg BJ, et al. **Phys Med Biol** 1996 Feb;41(2):223–37

Integrating sphere effect in whole–bladder wall photodynamic therapy: III. Fluence multiplication, optical penetration and light distribution with an eccentric source for human bladder optical properties. van Staveren HJ, et al. **Phys Med Biol** 1996 Apr;41(4):579–90

Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Hill JS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12126–30

Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. van Geel IP, et al. **Radiat Res** 1996 May;145(5):602–9

The influence of intravesical photodynamic therapy on subsequent bladder irradiation tolerance. Post JG, et al. **Radiother Oncol** 1995 Nov;37(2):124–30

The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose–rate effects? Veenhuizen RB, et al. **Radiother Oncol** 1995 Nov; 37(2):131–5

Photodynamic therapy of head and neck cancers. Biel MA. **Semin Surg Oncol** 1995 Sep–Oct;11(5):355–9

Photodynamic therapy: Part II. Dougherty TJ. **Semin Surg Oncol** 1995 Sep–Oct;11(5):333–4

Photodynamic therapy for recurrent supratentorial gliomas. Muller PJ, et al. **Semin Surg Oncol** 1995 Sep–Oct; 11(5):346–54

Photodynamic therapy in Barrett's esophagus: reduction of specialized mucosa, ablation of dysplasia, and treatment of superficial esophageal cancer. Overholt BF, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):372–6

Use of photodynamic therapy for the management of pleural malignancies. Pass HI, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):360–7 (21 ref.)

Photodynamic therapy of brain tumors. Popovic EA, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):335–45 (31 ref.)

Laser photochemotherapy: a less invasive approach for treatment of cancer. Saxton RE, et al. **Semin Surg Oncol** 1995 Jul–Aug;11(4):283–9 (76 ref.)

Endoscopic treatment of gastrointestinal tumors: indications and results of laser photocoagulation and photodynamic therapy. Spinelli P, et al. **Semin Surg Oncol** 1995 Jul–Aug; 11(4):307–18

Laser–induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Pomer S, et al. **Urol Int** 1995;55(4):197–201

Photodynamic efficiency of liposome–administered tetramethyl hematoporphyrin in two human bladder cancer cell lines. Bachor R, et al. **Urol Res** 1995;23(3):151–6

[Photodynamic therapy of malignant tumors] Jirsa M. **Sb Lek** 1996;97(1):115–34 (98 ref.) **(Cze)**

[Photodynamic therapy of centrally located early–stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27–30 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for gastric cancer] Mimura S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):41–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy (PDT) for early cervical cancer] Muroya T, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):47–56 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36–40 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro] Kabuto M, et al. **No To Shinkei** 1995 Oct;47(10):969–73 (Eng. Abstr.) **(Jpn)**

[Inappropriate public relation drive concerning the treatment of basalioma at the Norwegian Radium Hospital (letter)] Moan J. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):112–3 **(Nor)**

[Clinical fluorescent diagnosis of tumors using photosensitizer photogem] Chissov VI, et al. **Khirurgiia (Mosk)** 1995; (5):37–41 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Skin burn associated with pulse oximetry during perioperative photodynamic therapy. Farber NE, et al. **Anesthesiology** 1996 Apr;84(4):983–5

Photodynamic therapy. Cytotoxicity of aluminum phthalocyanine on intimal hyperplasia. Eton D, et al. **Arch Surg** 1995 Oct;130(10):1098–103

Photodynamic therapy–mediated oxidative stress can induce expression of heat shock proteins. Gomer CJ, et al. **Cancer Res** 1996 May 15;56(10):2355–60

Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. Chang SC, et al. **J Urol** 1996 May;155(5):1749–53

Transperineal photodynamic ablation of the canine prostate. Selman SH, et al. **J Urol** 1996 Jul;156(1):258–60

Damage threshold of normal rat brain in photodynamic therapy. Chen Q, et al. **Photochem Photobiol** 1996 Jul; 64(1):163–7

Problems associated with the use of broad-band illumination sources for photodynamic therapy [letter] Stringer MR. **Phys Med Biol** 1995 Oct;40(10):1733–5

Bladder calcifications after photodynamic therapy: analysis of a rare complication. Walther MM, et al. **Urology** 1996 Jun;47(6):831–5

INSTRUMENTATION

A diffusing sphere which delivers homogeneous laser light for use in photodynamic therapy. Bernstein EF, et al. **J Dermatol Sci** 1995 May;9(3):195–202

Photodynamic laser cyclodestruction with chloroaluminum sulfonated phthalocyanine (CASPc) or Photofrin (PII) vs. Nd:YAG laser cyclodestruction in a pigmented rabbit model. Hill RA, et al. **Lasers Surg Med** 1995;17(2):166–71

Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size. Overholt BF, et al. **Lasers Surg Med** 1996;18(3):248–52

[Computer-controlled laser irradiation unit for studies of light-induced processes in cell cultures] Knappe A, et al. **Biomed Tech (Berl)** 1995 Oct;40(10):272–5 (Eng. Abstr.) **(Ger)**

[Photodynamic therapy of dysplasia and early cancer of the esophagus] Gossner L, et al. **Leber Magen Darm** 1996 May; 26(3):132, 135–7 (Eng. Abstr.) **(Ger)**

METHODS

The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. Lilge L, et al. **Br J Cancer** 1996 Feb;73(3):332–43

Extracorporeal photochemotherapy in a patient with Ki-1–positive anaplastic large-cell lymphoma. Schwartz J, et al. **Br J Dermatol** 1996 Feb;134(2):332–5

Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells. Malham GM, et al. **Br J Neurosurg** 1996 Feb;10(1):51–7

Feasibility of laser targeted photo-occlusion of ocular vessels. Asrani S, et al. **Br J Ophthalmol** 1995 Aug;79(8):766–70

Use of photodynamic therapy for the treatment of squamous cell carcinoma of the soft palate. Poate TW, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):66–8

Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Kriegmair M, et al. **Br J Urol** 1996 May;77(5):667–71

Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study. Estey EP, et al. **Cancer Chemother Pharmacol** 1996;37(4):343–50

Potentiation of photodynamic therapy–elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Krosl G, et al. **Cancer Res** 1996 Jul 15;56(14):3281–6

Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. Schmidt-Erfurth U, et al. **Exp Eye Res** 1996 Jan;62(1):1–10

Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Frank RG, et al. **Genitourin Med** 1996 Feb;72(1):70–1

Intrauterine light delivery for photodynamic therapy of the human endometrium. Fehr MK, et al. **Hum Reprod** 1995 Nov;10(11):3067–72

Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Chang SC, et al. **Int J Cancer** 1996 Aug 7; 67(4):555–62

Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. Szeimies RM, et al. **J Invest Dermatol** 1995 Nov; 105(5):672–7

Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX [see comments] Barr H, et al. **Lancet** 1996 Aug 31;348(9027):584–5. Comment in: Lancet 1996 Aug 31;348(9027):561–2.

Effect of photosensitizer delivery system and irradiation parameters on the efficiency of photodynamic therapy of B16 pigmented melanoma in mice. Biolo R, et al. **Photochem Photobiol** 1996 Feb;63(2):224–8

In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Lee LK, et al. **Photochem Photobiol** 1995 Nov;62(5):882–6

Ex vivo light dosimetry and Monte Carlo simulations for endobronchial photodynamic therapy. Murrer LH, et al. **Phys Med Biol** 1995 Nov;40(11):1807–17

Integrating sphere effect in whole-bladder-wall photodynamic therapy: II. The influence of urine at 458, 488, 514 and 630 nm optical irradiation. van Staveren HJ, et al. **Phys Med Biol** 1995 Aug;40(8):1307–15

Intracavitary photodynamic therapy for malignant pleural mesothelioma. Takita H, et al. **Semin Surg Oncol** 1995 Sep-Oct;11(5):368–71

5,20-bis(4-sulphophenyl)-10,15-bis (2-methoxy-4-sulphophenyl)-21-thiaporphyrin as a new potent sensitizer in photodynamic therapy. Ziółkowski P, et al. **Tumori** 1995 Sep-Oct;81(5):364–9

[Photodynamic therapy of small adenocarcinomas with methylene blue] Orth K, et al. **Chirurg** 1995 Dec; 66(12):1254–7 (Eng. Abstr.) **(Ger)**

[Photodynamic therapy and breast-plasty of a extensive superficial trunk skin basalioma of the breast. An effective combination therapy with photodynamic diagnosis] Fritsch C, et al. **Hautarzt** 1996 Jun;47(6):438–42 (Eng. Abstr.) **(Ger)**

[Experimental bases for photodynamic laser therapy in chronic polyarthritis] Hendrich C, et al. **Orthopade** 1996 Feb;25(1):30–6 (Eng. Abstr.) **(Ger)**

[The combined use of photodynamic therapy with ionizing radiation on breast carcinoma cells in vitro] Dobler-Girdziunaite D, et al. **Strahlenther Onkol** 1995 Nov;171(11):622–9 (Eng. Abstr.) **(Ger)**

[The photodynamic therapy of malignant tumors in basic sites with the preparations photohem and photosens (the results of 3 years of observations)] Sokolov VV, et al. **Vopr Onkol** 1995;41(2):134–8 **(Rus)**

TRENDS

[History of photodynamic therapy—past, present and future] Kato H. **Gan To Kagaku Ryoho** 1996 Jan;23(1):8–15 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHOTOCHEMOTHERAPY, EXTRACORPOREAL see **PHOTOPHERESIS**

PHOTOCHEMOTHERAPY, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTOCOAGULATION see **LIGHT COAGULATION**

PHOTODENSITOMETRY see **DENSITOMETRY, X-RAY**

PHOTODERMATITIS see **PHOTOSENSITIVITY DISORDERS**

PHOTODYNAMIC THERAPY see **PHOTOCHEMOTHERAPY**

PHOTOGRAMMETRY

Classification of colorectal adenomas with quantitative pathology. Evaluation of morphometry, stereology, mitotic counts and syntactic structure analysis. Meijer GA, et al. **Anal Cell Pathol** 1995 Dec;9(4):311–23

Computerized morphometric analysis of the femoral diaphyseal canal. Toni A, et al. **Chir Organi Mov** 1995 Apr-Jun;80(2):207–19 **(Eng, Ita)**

Subsidence of tibial components in knee arthroplasty. A comparison between conventional radiography and roentgen stereophotogrammetry. Ryd L, et al. **Invest Radiol** 1995 Jul;30(7):396–400

Roentgen stereophotogrammetric analysis for assessing migration of total hip replacement femoral components. Kiss J, et al. **Proc Inst Mech Eng [H]** 1995;209(3):169–75

INSTRUMENTATION

Application of recent stereological tools for unbiased three-dimensional estimation of number and size of nuclei in renal cell carcinoma samples. Artacho-Pérula E, et al. **Anal Cell Pathol** 1995 Dec;9(4):295–309

Comparison of stereo optic disc photographs from the Nidek 3-Dx and Zeiss retinal cameras. Barry CJ, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):203–5

METHODS

NLT and extrapolated DLT:3-D cinematography alternatives for enlarging the volume of calibration. Hinrichs RN, et al. **J Biomech** 1995 Oct;28(10):1219–23

Measurement of upper extremity orientation by video stereometry system. Peterson B, et al. **Med Biol Eng Comput** 1996 Mar;34(2):149–54

PAR Corneal Topography System (PAR CTS): the clinical application of close-range photogrammetry. Belin MW, et al. **Optom Vis Sci** 1995 Nov;72(11):828–37 (16 ref.)

Mechanics of the external fixation test in the lumbar spine. A roentgen stereophotogrammetric analysis. Axelsson P, et al. **Spine** 1996 Feb 1;21(3):330–3

PHOTOGRAPHY

see related
MOTION PICTURES

Emergency department photography [letter; comment] Birinyi F. **Acad Emerg Med** 1995 Sep;2(9):850. Comment on: Acad Emerg Med 1994 Sep-Oct;1(5):454–62.

Retinal blood vessel width measured on color fundus photographs by image analysis. Wu DC, et al. **Acta Ophthalmol Scand Suppl** 1995;(215):33–40

Using the photo CD in academic radiology. Older RA. **AJR Am J Roentgenol** 1996 Feb;166(2):453–6

Comparison between tomographic scanning evaluation and photographic measurement of the neuroretinal rim. Dichtl A, et al. **Am J Ophthalmol** 1996 May;121(5):494–501

Retinal nerve fiber layer assessment by scanning laser polarimetry and standardized photography. Niessen AG, et al. **Am J Ophthalmol** 1996 May;121(5):484–93

Changes in facial dimensions assessed from lateral and frontal photographs. Part I—Methodology. Bishara SE, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):389–93

Chemical pollutants in X-ray film processing departments. Scobbie E, et al. **Ann Occup Hyg** 1996 Aug;40(4):423–35

Guidance after twin and singleton death [letter; comment] Bryan E, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F123. Comment on: Arch Dis Child Fetal Neonatal Ed 1995 Mar;72(2):F125–6.

The use of cervicography in the follow-up of cervical intraepithelial neoplasia treated by CO2 laser. Allen DG, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):349–50

Digital photography for the light microscope: results with a gated, video-rate CCD camera and NIH-image software. Shaw SL, et al. **Biotechniques** 1995 Dec;19(6):946–55

Adding retinal photography to screening for diabetic retinopathy: a prospective study in primary care [see comments] O'Hare JP, et al. **BMJ** 1996 Mar 16; 312(7032):679–82. Comment in: BMJ 1996 Jun 29;312(7047):1670; discussion 1670–1.

Food photography II: use of food photographs for estimating portion size and the nutrient content of meals. Nelson M, et al. **Br J Nutr** 1996 Jul;76(1):31–49

Contact dermatitis and asthma from sodium metabisulfite in a photographic technician. Jacobs MC, et al. **Contact Dermatitis** 1995 Jul;33(1):65–6

The accurate assessment of changes in retinal vessel diameter using multiple frame electrocardiograph synchronised fundus photography. Dumskyj MJ, et al. **Curr Eye Res** 1996 Jun;15(6):625–32

Constructing retinal fundus photomontages. A new computer-based method. Mahurkar AA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1675–83

Polarized light photography in the evaluation of photoaging. Muccini JA, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):765–9

Digital image databasing. Brown S, et al. **J Audiov Media Med** 1995 Dec;18(4):157–62

Intraoral and intranasal photography using a retinal fundus camera. Merin LM, et al. **J Audiov Media Med** 1995 Mar; 18(1):23–5

Photography in the operating room, a primer: Part 1—The environment and equipment. Morris MA. **J Biol Photogr** 1995 Oct;63(4):77–83

Flow visualization with air and smoke in a bypass graft model under steady flow conditions. Johnson LR, et al. **J Biomech** 1995 Oct;28(10):1237–41

A technique for calibrating measurements from photographs of sliced specimens. Han J, et al. **J Biomech Eng** 1995 Nov; 117(4):495–7

Clinical photographs as teaching aids: how reliable are they? McCombe A, et al. **J Laryngol Otol** 1995 Aug;109(8):741–3

Exploring the concept of health among adolescents with diabetes using photography. Hanna KM, et al. **J Pediatr Nurs** 1995 Oct;10(5):321–7

Photoscreening for amblyogenic factors. Ottar WL, et al. **J Pediatr Ophthalmol Strabismus** 1995 Sep–Oct; 32(5):289–95

Anterior chamber angle biometry: a comparison of Scheimpflug photography and ultrasound biomicroscopy. Böker T, et al. **Ophthalmic Res** 1995;27 Suppl 1:104–9

Recording eye movements using coaxial cameras—applications for visual ergonomics and reading studies. Hazel CA, et al. **Optom Vis Sci** 1995 Sep; 72(9):679–83

The value of Polaroid photography in a burn unit [letter] Ghosh SJ, et al. **Plast Reconstr Surg** 1996 Feb;97(2):481–2

Blow up: the "I" of the camera. Kirley JP. **Psychoanal Rev** 1995 Jun;82(3):443–53

The hidden world of surgery. Aguilera-Hellweg M. **Sci Am** 1996 Jul;275(1):66–71

A schlieren study of the interaction between a lithotripter

shock wave and a simulated kidney stone. Carnell MT, et al. **Ultrasound Med Biol** 1995;21(5):721–4

[Cervicographic screening of women in early pregnancy] Zlatkov V. **Akush Ginekol (Sofiia)** 1995;34(3):35–8 (Eng. Abstr.) **(Bul)**

[Validity of photographical dietary assessment; a preliminary analysis] Kawamura T, et al. **Nippon Koshu Eisei Zasshi** 1995 Nov;42(11):992–8 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Screening for diabetic retinopathy. True costs are different from those given in paper [letter; comment] Waugh NR. **BMJ** 1996 Jun 29;312(7047):1670; discussion 1670–1. Comment on: BMJ 1996 Mar 16;312(7032):679–82.

HISTORY

An appreciation of the life and work of John Arthur Fairfax Fozzard MA Hon FRPS 1905–1993. Beard L. **J Audiov Media Med** 1995 Dec;18(4):167–70

The nude in medical photography: a historical perspective, with modern legal ramifications. Burns SB. **J Biol Photogr** 1996 Jan;64(1):15–26

Kodachrome—a brief history and introduction to the film and process. Young WH. **J Biol Photogr** 1995 Oct; 63(4):87–90

Hay Bilharzia!, by Klock, Ildefonso, and Mateo–Serrano: medical images of poverty and development in Puerto Rico in the 1950s. Rigau–Pérez JG, et al. **P R Health Sci J** 1996 Mar;15(1):33–44

INSTRUMENTATION

Crash pulse recorder—validation in full scale crash tests. Kullgren A, et al. **Accid Anal Prev** 1995 Oct;27(5):717–27

Field trial of the Otago photoscreener. Kennedy R, et al. **Can J Ophthalmol** 1995 Jun;30(4):193–7

Flow cytometer and imaging device used in combination. Kubota F, et al. **Cytometry** 1995 Oct 1;21(2):129–32

Self–assessment of angles of strabismus with photographic Purkinje I and IV reflection pattern evaluation. Effert R, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug; 233(8):494–506

A comparative study of digital images versus 35–millimeter images. Wilcox LA, et al. **Mil Med** 1995 Sep;160(9):470–2

METHODS

Re: making black–and–white slides of radiographs using Kodak Ektachrome film and a custom–made view box [letter; comment] Kircher K. **AJR Am J Roentgenol** 1996 May;166(5):1230. Comment on: AJR Am J Roentgenol 1995 May;164(5):1297.

Making slides from radiographs [letter; comment] Lewis TT. **AJR Am J Roentgenol** 1996 Jan;166(1):214. Comment on: AJR Am J Roentgenol 1995 May;164(5):1297.

Grading of retinal nerve fiber layer with a photographic reference set [see comments] Niessen AG, et al. **Am J Ophthalmol** 1995 Nov;120(5):577–86. Comment in: Am J Ophthalmol 1995 Nov;120(5):665–7.

Retinal nerve fiber layer [editorial; comment] Sommer A. **Am J Ophthalmol** 1995 Nov;120(5):665–7 (20 ref.). Comment on: Am J Ophthalmol 1995 Nov;120(5):577–86.

Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet–Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul;114(7):848–55

Assessment of cytomegalovirus retinitis. Clinical evaluation vs centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul; 114(7):791–805

A longitudinal study of cortical cataracts using retroillumination photographs. Datiles MB 3rd, et al. **Curr Eye Res** 1996 Jan;15(1):53–61

Improvements of Littmann's theoretical method [letter; comment] Sanchez A, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug;233(8):535. Comment on: Graefes Arch Clin Exp Ophthalmol 1994 Jun;232(6):361–7.

Computerized digital photography in auditory research: a comparison of publication–quality digital printers with traditional darkroom methods. Trune DR, et al. **Hear Res** 1995 Jun;86(1–2):163–70

Fluorescence photography in the evaluation of acne. Lucchina LC, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):58–63

The reliability of interpretation of photoscreening results with the off PS–100 in Headstart preschool children. Lewis RC, et al. **J Am Optom Assoc** 1995 Jul;66(7):429–34

'Funnel light' photography of metallic objects (designed by Leon J. LeBeau). Wesche H. **J Audiov Media Med** 1995 Dec;18(4):163–4

Scheimpflug anterior segment photography assessment of wound healing after myopic excimer laser photorefractive keratectomy. Binder PS, et al. **J Cataract Refract Surg** 1996 Mar;22(2):205–12

Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. Joannou J, et al. **J Intern Med** 1996 Jan;239(1):43–7

Life–size photograph transparencies: a method for the photographic detection and documentation of recovery from facial paralysis. el–Naggar M, et al. **J Laryngol Otol** 1995 Aug;109(8):748–50

Evaluation of lens transparency changes through photographed images during a 13–month observation period. Asano K, et al. **Ophthalmic Res** 1995;27 Suppl 1:86–93

Changes in light scattering intensity of the transparent lenses of subjects selected from population–based surveys depending on age: analysis through Scheimpflug images. Fujisawa K, et al. **Ophthalmic Res** 1995 Mar–Apr; 27(2):89–101

Usefulness of Scheimpflug photography to follow up Wilson's disease. Obara H, et al. **Ophthalmic Res** 1995;27 Suppl 1:100–3

The use of Scheimpflug photography in the documentation of clinical states and in the biometry of the anterior eye segment. Olbert D. **Ophthalmic Res** 1995;27 Suppl 1:20–4

Computed tomographic images and three–dimensional expression of crystalline lens findings from multiple slices of Scheimpflug slit images. Sakamoto Y, et al. **Ophthalmic Res** 1995;27 Suppl 1:94–9

Theoretical basis for camera control in teleoperating. Danis J. **Surg Endosc** 1996 Aug;10(8):804–8

[Personal–likeness identification based on the corpse and intravital photography. Methodological recommendations No. 94/266. Approved by the Ministry of Health and the Medical Industry of Russia 3 July 95] Zviagin VN, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):39–42 **(Rus)**

STANDARDS

Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study [see comments] Harding SP, et al. **BMJ** 1995 Oct 28;311(7013):1131–5. Comment in: BMJ 1996 Jun 29;312(7047):1670; discussion 1670–1.

Nudity in clinical photography: a literature review and the quest for standardization. Peres M, et al. **J Biol Photogr** 1996 Jan;64(1):3–13 (25 ref.)

PHOTOKERATECTOMY see KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER

PHOTOLYSIS

Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. Wada H, et al. **Biochim Biophys Acta** 1996 Jun 13; 1274(3):89–93

Photodegradation of 2,2',5,5'–tetrachlorobiphenyl in hexane. Miao XS, et al. **Bull Environ Contam Toxicol** 1996 Apr; 56(4):571–4

Kinetics and photophysical mechanism of sunlight photolysis of unstable resmethrin and phenothrin in aerosols and thin films. Samsonov YN, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):903–10

Photolysis of caged compounds characterized by ratiometric confocal microscopy: a new approach to homogeneously control and measure the calcium concentration in cardiac myocytes. Lipp P, et al. **Cell Calcium** 1996 Mar; 19(3):255–66

Photodecomposition of 1,2,3,4– and 2,3,7,8–tetrachlorodibenzo–p–dioxin (TCDD) in water–alcohol media on a solid support. Hosoya K, et al. **Chemosphere** 1995 Oct;31(7):3687–98

Cardiac sarcoplasmic reticulum phosphorylation increases Ca2+ release induced by flash photolysis of nitr–5. Patel JR, et al. **Circ Res** 1995 Nov;77(5):943–9

Measurement of nucleotide exchange kinetics with isolated synthetic myosin filaments using flash photolysis. Conibear PB, et al. **FEBS Lett** 1996 Feb 12;380(1–2):13–6

Electrical currents generated by a partially purified Na/Ca exchanger from lobster muscle reconstituted into liposomes and adsorbed on black lipid membranes: activation by photolysis of Ca2+. Eisenrauch A, et al. **J Membr Biol** 1995 May;145(2):151–64

Two–photon scanning microphotolysis for three–dimensional data storage and biological transport measurements. Kubitscheck U, et al. **J Microsc** 1996 Jun;182 (Pt 3):225–33

Evaluation of ketoprofen (R,S and R/S) phototoxicity by a battery of in vitro assays. Boscá F, et al. **J Photochem Photobiol B** 1995 Dec;31(3):133–8

Calcium current reactivation after flash photolysis of nifedipine in skeletal muscle fibres of the frog. Feldmeyer D, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):51–6

Control of hypertrophic scar growth using antibody–targeted photolysis. Wolfort SF, et al. **J Surg Res** 1996 Apr; 62(1):17–22

Use of vanadate–induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)

Vanadate–mediated photolysis of dynein heavy chains. King SM. **Methods Cell Biol** 1995;47:503–6

Photochemical production of double–strand breaks in cellular DNA. Limoli CL, et al. **Mutagenesis** 1995 Sep;10(5):453–6

The influence of ionic strength upon relaxation from rigor induced by flash photolysis of caged–ATP in skinned murine skeletal muscle fibres. Veigel C, et al. **Pflugers Arch** 1995 Oct;430(6):994–1003

[Studies on structure of light degradation products of (–)–(S)–10–(1–aminocyclopropyl)–9–fluoro–3–methyl–7–oxo–2,3–dihyd ro–7H–pyrido[1,2,3–de][1,4]benzoxazine–6–carboxylic acid (T–3761) in aqueous solution and solid state] Demachi K, et al. **Yakugaku Zasshi** 1995 Sep;115(9):716–31 (Eng. Abstr.) **(Jpn)**

PHOTOMETRY

Notes on the apparent discordance of pulse oximetry and multi–wavelength haemoglobin photometry. Nijland R, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:49–52

Correlation study of two methods for evaluating corneal endothelial damage in vitro: the Janus green photometry technique versus cell counting. Pharmakakis N, et al. **Ophthalmic Res** 1995 Mar–Apr;27(2):67–73

INSTRUMENTATION

Comparison of two reflectance photometers in the assessment of neonatal hypoglycaemia. Kirkham P, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F170–3

Pattern recognition for automated DNA sequencing: I. On–line signal conditioning and feature extraction for basecalling. Golden JB 3rd, et al. **Ismb** 1993;1:136–44

A new luminometer for sensitive quantification by chemiluminescence of specific proteins in microtitre plates and on blot membranes. Vesterberg O. **J Biochem Biophys Methods** 1995 Nov;30(4):301–14

METHODS

Measurements of sodium and potassium in newborns and prematures by ion–selective electrodes and flame photometry: influence of lipid and protein content of blood. Kau N, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:107–11

Prediction and non–invasive assessment of neonatal jaundice in the term healthy newborn infant. Knudsen A. **Acta Paediatr** 1996 Apr;85(4):393–7 (32 ref.)

Microscopic photometric quantification of stiffness and relaxation time of red blood cells in a flow chamber. Artmann GM. **Biorheology** 1995 Sep–Oct;32(5):553–70

A new laser photometric technique for the measurement of erythrocyte aggregation and sedimentation kinetics. Muralidharan E, et al. **Biorheology** 1994 May–Jun; 31(3):277–85

On–line laser–photometric monitoring of aerosol deposition in ventilated rabbit lungs. Schmehl T, et al. **J Appl Physiol** 1996 Jan;80(1):351–6

Electroretinogram flicker photometry and its applications. Jacobs GH, et al. **J Opt Soc Am A** 1996 Mar;13(3):641–8 (42 ref.)

STATISTICS & NUMERICAL DATA

Detection of false lithium readings in whole–blood specimens from cadavers by flame photometry [letter] Green TR, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1302

PHOTOMICROGRAPHY

Optical recording from cerebellar Purkinje cells using intracellularly injected voltage–sensitive dyes. Kogan A, et al. **Brain Res** 1995 Nov 27;700(1–2):235–9

Comparative genomic hybridization imaging by the one–chip true–color CCD camera kappa CF 15 MC. Bornfleth H, et al. **Cytometry** 1996 May 1;24(1):1–13

Time–lapse cinephotomicrography, videography, and videomicrography of the avian blastoderm. Bortier H, et al. **Methods Cell Biol** 1996;51:331–54 (18 ref.)

METHODS

Evaluating the accuracy of different sperm counting chambers by performing strict counts of photographed beads. Shiran E, et al. **J Assist Reprod Genet** 1995 Aug; 12(7):434–42

A non–invasive photographic modification for recording early vascular development in the chick. Giles JJ, et al. **J Microsc** 1995 Sep;179 (Pt 3):282–5

Stereoscopic and biplanar microphotography of Golgi–impregnated neurons: a correlative study using conventional and real–time, direct–image confocal microscopies. Freire M, et al. **J Neurosci Methods** 1995 May;58(1–2):109–16

PHOTONS

MCML—Monte Carlo modeling of light transport in multi–layered tissues. Wang L, et al. **Comput Methods Programs Biomed** 1995 Jul;47(2):131–46

Evaluation of Monte Carlo simulation of photon counting efficiency for germanium detectors. Kamboj S, et al. **Health Phys** 1996 Apr;70(4):512–9

Neutron–photon treatment: modern day Pyrrhic victory? Regarding Haraf et al. IJROBP 33(1): 3–14; 1995 [letter; comment] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):757. Comment on: Int J Radiat Oncol Biol Phys 1995 Aug 30;33(1):3–14.

A study on 3D Monte Carlo modeling of photon propagation through tissue. Kiymik MK. **J Med Syst** 1995 Aug; 19(4):313–22

Accounting for the variation in collision kerma–to–terma ratio in polyenergetic photon beam convolution. Hoban

PW. **Med Phys** 1995 Dec;22(12):2035–44

A Monte Carlo model of photon beams used in radiation therapy. Lovelock DM, et al. **Med Phys** 1995 Sep; 22(9):1387–94

Considerations for superficial photon dosimetry. Stern RL, et al. **Med Phys** 1995 Sep;22(9):1469–70

How water equivalent are water–equivalent solid materials for output calibration of photon and electron beams? Tello VM, et al. **Med Phys** 1995 Jul;22(7):1177–89

Photon dose calculation incorporating explicit electron transport. Yu CX, et al. **Med Phys** 1995 Jul;22(7):1157–65

A table of phantom scatter factors of photon beams as a function of the quality index and field size. Storchi P, et al. **Phys Med Biol** 1996 Mar;41(3):563–71

How photons start vision. Baylor D.
Proc Natl Acad Sci U S A 1996 Jan 23;93(2):560–5 (44 ref.)

Does the photon beam quality factor depend on the type of ionization chamber? Christ G, et al. **Radiother Oncol** 1995 Aug;36(2):153–5

ADVERSE EFFECTS

Hip stiffness following mixed conformal neutron and photon radiotherapy: a dose–volume relationship. Chuba PJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):693–9

THERAPEUTIC USE

Short communication: Total craniofacial photon shell technique for radiotherapy of extensive angiosarcomas of the head. Kinard JD, et al. **Br J Radiol** 1996 Apr; 69(820):351–5

Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Forman JD, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):259–66

Conformal radiation treatment of prostate cancer using inversely–planned intensity–modulated photon beams produced with dynamic multileaf collimation [see comments] Ling CC, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):721–30. Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):845–6.

Relationship of wedge isodose angle to percent depth–dose curves. Saw CB, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1147–52

A simple and generally applicable method to estimate the peripheral dose in radiation teletherapy with high energy x–rays or gamma radiation. Van der Giessen PH.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1059–68

Comparison of dose homogeneity effects due to electron equilibrium loss in lung for 6 MV and 18 MV photons. White PJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1141–6

Modeling transmission and scatter for photon beam attenuators. Ahnesjö A, et al. **Med Phys** 1995 Nov;22(11 Pt 1):1711–20

Calorimetric determination of the absorbed dose–to–water beam quality correction factor kQ for high–energy photon beams. Vatnitsky SM, et al. **Med Phys** 1995 Nov;22(11 Pt 1):1749–52

PHOTOPERIOD

Effects of photoperiod and androgen on pituitary function and neuropeptide staining in Siberian hamsters. Bittman EL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R64–72

Varying photoperiod in the laboratory rat: profound effect on 24–h sleep pattern but no effect on sleep homeostasis. Franken P, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R691–701

Testicular regression and recrudescence without subsequent photorefractoriness in Siberian hamsters. Gorman MR, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R800–6

Hypothalamic NPY and prepro–NPY mRNA in Djungarian hamsters: effects of food deprivation and photoperiod. Mercer JG, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1099–106

Lighting conditions alter Candida albicans–induced sleep responses in rabbits. Toth LA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1441–7

Defeminization of the reproductive response to photoperiod occurs early in prenatal development in the sheep. Herbosa CG, et al. **Biol Reprod** 1996 Feb;54(2):420–8

Gonadotropins in lactating sows exposed to long or short days during pregnancy and lactation: serum concentrations and ovarian receptors. Kermabon AY, et al.
Biol Reprod 1995 Nov;53(5):1095–102

Spontaneous recrudescence of spermatogenesis in the photoinhibited male Djungarian hamster, Phodopus sungorus. Schlatt S, et al. **Biol Reprod** 1995 Nov; 53(5):1169–77

Gonadal responses of the male tau mutant Syrian hamster to short–day–like programmed infusions of melatonin. Stirland JA, et al. **Biol Reprod** 1995 Aug;53(2):361–7

Effect of photoperiod before and after birth on puberty in ewe lambs. Sunderland SJ, et al. **Biol Reprod** 1995 Nov; 53(5):1178–82

New intermittent lighting programme (the Reading system) for laying pullets. Morris TR, et al. **Br Poult Sci** 1995 Sep; 36(4):531–5

Differential testicular responses to short daylength in deer mice are reflected by regional and morphological differences in the GnRH neuronal system. Korytko AI, et al. **Brain Res** 1995 Jul 10;685(1–2):135–42

Short–photoperiod exposure reduces L–aromatic–amino–acid decarboxylase immunostaining in the arcuate nucleus and median eminence of male Syrian hamsters. Krajnak K, et al. **Brain Res** 1996 Mar 11;712(1):95–101

Photoperiod affects the expression of neural cell adhesion molecule and polysialic acid in the hypothalamus of the Siberian hamster. Lee W, et al. **Brain Res** 1995 Aug 28; 690(1):64–72

Seasonal variation in blood pressure in normotensive women studied by home measurements. Imai Y, et al.
Clin Sci (Colch) 1996 Jan;90(1):55–60

Photoperiodic elevation of testicular zinc protects seminiferous tubules against fluoride toxicity in the bank vole (Clethrionomys glareolus). Krasowska A, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Jan;113(1):81–4

Screening of RAPD markers linked to the photoperiod–sensitivity gene in rice chromosome 6 using bulked segregant analysis. Monna L, et al. **DNA Res** 1995 Jun 30;2(3):101–6

Changes in plasma luteinizing hormone concentration in turkey hens after switching from short–day to long–day photoperiods. Bacon WL, et al.
Domest Anim Endocrinol 1995 Jul;12(3):257–67

Short photoperiod–dependent down–regulation of thyrotropin–alpha and –beta in hamster pars tuberalis–specific cells is prevented by pinealectomy. Bockmann J, et al. **Endocrinology** 1996 May;137(5):1804–13

The tau mutation in the Syrian hamster alters the photoperiodic responsiveness of the gonadal axis to melatonin signal frequency. Stirland JA, et al.
Endocrinology 1996 May;137(5):2183–6

Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat. Gaytan O, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):1–8

Photoperiod regulation of plasma growth hormone levels during parr–smolt transformation of Atlantic salmon: implications for hypoosmoregulatory ability and growth. Björnsson BT, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):73–82

Control of secretory lipid droplets in the harderian gland by testosterone and the photoperiod: comparison of two species of hamsters. Buzzell GR, et al.
Gen Comp Endocrinol 1995 Aug;99(2):230–8

Plasma prolactin and luteinizing hormone during termination and onset of photorefractoriness in intact and pinealectomized European starlings (Sturnus vulgaris). Chakraborty S. **Gen Comp Endocrinol** 1995 Aug; 99(2):185–91

Influence of photoperiod, time, and sex on hormone concentrations in collared lemmings (Dicrostonyx groenlandicus). Gower BA, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):53–62

Changes in brain GnRH associated with photorefractoriness in house sparrows (Passer domesticus). Hahn TP, et al.
Gen Comp Endocrinol 1995 Sep;99(3):349–63

Photoperiodic effects on steroid negative feedback in female prairie voles (Microtus ochrogaster). Moffatt CA, et al.
Gen Comp Endocrinol 1995 Oct;100(1):92–5

Circadian rhythm of catecholamine excretion in rats after phase shift of light–dark cycle. Sudo A, et al.
Ind Health 1995;33(2):57–66

Seasonal variation in human illumination exposure at two different latitudes. Cole RJ, et al. **J Biol Rhythms** 1995 Dec;10(4):324–34

Is a critical interval of the circadian pacemaker at dusk responsive to light and melatonin responsible for the timing of estrus in the Romney Marsh ewe? Matthews CD, et al. **J Biol Rhythms** 1995 Dec;10(4):308–18

Circadian aspect of photoperiodic time measurement in a female house sparrow, Passer domesticus. Ravikumar G, et al. **J Biol Rhythms** 1995 Dec;10(4):319–23

Unexpected c–fos gene expression in the suprachiasmatic nucleus of mice entrained to a skeleton photoperiod. Schwartz WJ, et al. **J Biol Rhythms** 1996 Mar;11(1):35–44

The effects of anterior hypothalamic lesions on short–day responses in Siberian hamsters given timed melatonin infusions. Song CK, et al. **J Biol Rhythms** 1996 Mar; 11(1):14–26

A short red light pulse during dark phase of LD–cycle perturbs the hamster's circadian clock. Klante G, et al.
J Comp Physiol [A] 1995 Dec;177(6):775–80

Inhibitory effect of increased photoperiod on wool follicle growth. Pearson AJ, et al. **J Endocrinol** 1996 Jan; 148(1):157–66

Effect of changing from a short–day to long–day photoperiod on the breeding season of the brushtail possum (Trichosurus vulpecula). Gemmell RT, et al. **J Exp Zool** 1995 Oct 15; 273(3):242–6

Egg production and emergence of adult cat fleas (Siphonaptera: Pulicidae) exposed to different photoperiods. Metzger ME, et al. **J Med Entomol** 1996 Jul;33(4):651–5

Seasonal changes in song nuclei and song behavior in Gambel's white–crowned sparrows. Smith GT, et al.
J Neurobiol 1995 Sep;28(1):114–25

Daily melatonin injections induce cytological changes in pars tuberalis–specific cells similar to short photoperiod. Böckers TM, et al. **J Neuroendocrinol** 1995 Aug;7(8):607–13

Regulation of melatonin secretion by light in the isolated pineal organ of the white sucker (Catostomus commersoni). Bolliet V, et al. **J Neuroendocrinol** 1995 Jul;7(7):535–42

Effects of N–methyl–D–aspartate (NMDA) on seasonal cycles of reproduction, body weight and pelage colour in the male Siberian hamster. Ebling FJ, et al.
J Neuroendocrinol 1995 Jul;7(7):555–66

Photoperiod regulates the LH response to central glutamatergic stimulation in the male Syrian hamster. Ebling FJ, et al. **J Neuroendocrinol** 1993 Dec;5(6):609–18

Evidence that melatonin acts in the pituitary gland through a dopamine–independent mechanism to mediate effects of daylength on the secretion of prolactin in the ram. Lincoln GA, et al. **J Neuroendocrinol** 1995 Aug;7(8):637–43

The effect of photoperiod on plasma levels of melanin–concentrating hormone in the trout. Lyon VE, et al. **J Neuroendocrinol** 1993 Oct;5(5):493–9

Light and dark cause a shift in the spatial expression of a neuropeptide–processing enzyme in the rat retina. Schlamp CL, et al. **J Neurosci** 1996 Apr 1;16(7):2164–71

Effects of photoperiod on pineal melatonin in the marsh rice rat (Oryzomys palustris). Edmonds KE, et al.
J Pineal Res 1995 Apr;18(3):148–53

Daily variation in the content of indoleamines, catecholamines and related compounds in the pineal gland of Syrian hamsters kept under long and short photoperiods. Miguez JM, et al. **J Pineal Res** 1995 Oct;19(3):139–48

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149–65 (209 ref.)

Influences of season and of temperature, photoperiod, and subcutaneous melatonin infusion on the glomerular filtration rate of ewes. Tsuda T, et al. **J Pineal Res** 1995 Nov;19(4):166–72

The effect of duration of exposure to short days on the gonadal response to long days in male starlings (Sturnus vulgaris). Boulakoud MS, et al. **J Reprod Fertil** 1995 Jul; 104(2):215–7

Response of prolactin to different photoperiods after surgical disconnection of the hypothalamus and pituitary in sheep fetuses. Houghton DC, et al. **J Reprod Fertil** 1995 Jul; 104(2):199–206

Effects of photoperiod on testicular inhibin–alpha and androgen binding protein mRNA expression during postnatal development in Siberian hamsters, Phodopus sungorus. Rao JN, et al. **Life Sci** 1995;57(19):1761–70

per mRNA cycling is locked to lights–off under photoperiodic conditions that support circadian feedback loop function. Qiu J, et al. **Mol Cell Biol** 1996 Aug; 16(8):4182–8

Adaptive inducibility of CREM as transcriptional memory of circadian rhythms. Foulkes NS, et al. **Nature** 1996 May 2;381(6577):83–5

Effects of photoperiod on food–storing and the hippocampus in birds. Krebs JR, et al. **Neuroreport** 1995 Aug 21; 6(12):1701–4

Differences of somatostatin mRNA in the rat suprachiasmatic nucleus under light–dark and constant dark conditions: an analysis by in situ hybridization. Nishiwaki T, et al.
Neurosci Lett 1995 Sep 15;197(3):231–4

In Syrian and European hamsters, the duration of sensitive phase to light of the suprachiasmatic nuclei depends on the photoperiod. Vuillez P, et al. **Neurosci Lett** 1996 Apr 12;208(1):37–40

NPY stimulation of food intake in Siberian hamsters is not photoperiod dependent. Boss–Williams KA, et al.
Physiol Behav 1996 Jan;59(1):157–64

Effects of the light—dark cycle on a water tank social interaction test in mice. Nejdi A, et al. **Physiol Behav** 1996 Jan;59(1):45–7

Phase relationship between ocular and behavioral circadian rhythms in Bulla gouldiana exposed to different photoperiods. Roberts MH, et al. **Physiol Behav** 1996 Apr–May;59(4–5):703–8

The use of intermittent lighting in broiler raising. 1. Effect on broiler performance and efficiency of nitrogen retention. Buyse J, et al. **Poult Sci** 1996 May;75(5):589–94

Responses of laying hens to forced molt procedures of variable length with or without light restriction. Hurwitz S, et al. **Poult Sci** 1995 Nov;74(11):1745–53

The use of intermittent lighting in broiler raising. 2. Effects on the somatotrophic and thyroid axes and on plasma testosterone levels. Kühn ER, et al. **Poult Sci** 1996 May; 75(5):595–600

Effect of short photoperiodic cycles on male genital tract and testicular parameters in male goats (Capra hircus). Delgadillo JA, et al. **Reprod Nutr Dev** 1995;35(5):549–58

[The effect of the duration of daylight on human hormonal and biochemical indices in the north] Boĭko ER, et al.
Fiziol Zh Im I M Sechenova 1995 Jul;81(7):86–92 (Eng. Abstr.) **(Rus)**

[The photoperiodic regulation of the development and diapause of the nymphs of the taiga tick Ixodes persulcatus (Ixodidae)] Belozerov VN. **Parazitologiia** 1995 Mar–Apr; 29(2):101–4 (Eng. Abstr.) **(Rus)**

[The correlation of light and hygrothermal factors in the determination of the morphogenetic diapause of the larvae and nymphs of the taiga tick in the northwestern spurs of the eastern Sayan] Korotkov IuS, et al.
Parazitologiia 1995 May–Jun;29(3):145–53 (Eng. Abstr.) **(Rus)**

[The effect of epiphysectomy and destruction of the lateral

septal nucleus of the brain on the genital system in juvenile rats under different light regimens (the interaction of gonadostat+ + and photoperiodic mechanisms in the regulation of ovarian functions)] Slaetna OV, et al. **Fiziol Zh** 1995 Jan-Apr;41(1-2):67-73 (Eng. Abstr.) **(Ukr)**

PHOTOPHERESIS

Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience. Prinz B, et al. **Arch Dermatol Res** 1995;287(7):621-6

Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Cribier B, et al. **Dermatology** 1995; 191(1):25-31

Photopheresis for the treatment of cutaneous T-cell lymphoma. Lim HW, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1117-26 (25 ref.)

Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5-methoxypsoralen and UVA, interferon alfa-2b, and extracorporeal photopheresis. Wolf P, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):291-4

Cytolytic response to HIV in patients with HIV disease treated with extracorporeal photochemotherapy: preliminary study. Gonzalez J, et al. **Photochem Photobiol** 1996 May;63(5):558-61

The lack of efficacy of 4,6,6'-trimethylangelicin to induce immune suppression in an animal model for photopheresis: a comparison with 8-MOP. van Iperen HP, et al. **Photochem Photobiol** 1996 May;63(5):577-82

ADVERSE EFFECTS

Aggressive squamous cell carcinomas in patients treated with extracorporeal photopheresis for cutaneous T-cell lymphoma [letter] Nehal KS, et al. **Arch Dermatol** 1995 Oct;131(10):1211-2

METHODS

Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. Miller JL, et al. **Br J Dermatol** 1995 Sep;133(3):467-71

PHOTOPLETHYSMOGRAPHY

Blood pressure evaluation by noninvasive and traditional methods. Consistencies and discrepancies among photoplethysmomanometry, office sphygmomanometry, and ambulatory monitoring. Effects of blood pressure measurement. Musso NR, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):293-9

[Hemodynamics in the periodontium and gingiva] Charvát P, et al. **Cesk Fysiol** 1995 Dec;44(4):204-5 (Eng. Abstr.) **(Cze)**

INSTRUMENTATION

A microprocessor based photoplethysmograph for use in clinical practice. Wright IP, et al. **Anaesthesia** 1995 Oct; 50(10):875-8

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37-43 (77 ref.) **(Ger)**

METHODS

A rapid noninvasive blood pressure measurement method for discrete value and full waveform determination. Schnall RP, et al. **J Appl Physiol** 1996 Jan;80(1):307-14

The time-variable photoplethysmographic signal; dependence of the heart synchronous signal on wavelength and sample volume. Ugnell H, et al. **Med Eng Phys** 1995 Dec;17(8):571-8

PHOTOPROTEINS see **LUMINESCENT PROTEINS**

PHOTORADIATION see **LIGHT**

PHOTORADIATION, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTORADIATION THERAPY see **PHOTOTHERAPY**

PHOTOREACTIVATING ENZYME see **DNA PHOTOLYASE**

PHOTORECEPTORS

CHEMISTRY

Visual pigment types and quantum-catch ratios: implications from three marine teleosts. Hárosi FI. **Biol Bull** 1996 Apr; 190(2):203-12

Centrin in the photoreceptor cells of mammalian retinae. Wolfrum U. **Cell Motil Cytoskeleton** 1995;32(1):55-64

The sequence of arrestins from rod and cone photoreceptors in the frogs Rana catesbeiana and Rana pipiens. Localization of gene transcripts by reverse-transcription polymerase chain reaction on isolated photoreceptors. Abdulaeva G, et al. **Eur J Biochem** 1995 Dec 1; 234(2):437-42

Simplified ganglioside composition of photoreceptors compared to other retinal neurons. Dreyfus H, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):574-85

Dystrophin localization at synapse [letter; comment] Stell WK. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):255. Comment on: Invest Ophthalmol Vis Sci 1995 Oct;36(11):2318-22.

An interface of interaction between photoreceptor cGMP phosphodiesterase catalytic subunits and inhibitory gamma subunits. Natochin M, et al. **J Biol Chem** 1996 Aug 16; 271(33):19964-9

Vitronectin receptor expression and distribution at the photoreceptor-retinal pigment epithelial interface. Anderson DH, et al. **J Comp Neurol** 1995 Sep 11; 360(1):1-16

Identification of pigment epithelium-derived factor in the interphotoreceptor matrix of bovine eyes. Wu YQ, et al. **Protein Expr Purif** 1995 Aug;6(4):447-56

Lectin cytochemical analysis of glycoconjugates in photoreceptor cell membranes of Lampetra japonica. Ishikawa M, et al. **Vision Res** 1996 Jun;36(11):1513-20

CYTOLOGY

Development and maintenance of outer segments by isolated chick embryo photoreceptor cells in culture. Saga T, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):561-73

DRUG EFFECTS

Retinal photoreceptor dystrophies: LI. Edward Jackson Memorial Lecture [letter; comment] Berson EL. **Am J Ophthalmol** 1995 Nov;120(5):683-4. Comment on: Am J Ophthalmol 1995 May;119(5):543-62.

The effects of bFGF on RCS rat eyes. Perry J, et al. **Curr Eye Res** 1995 Jul;14(7):585-92

Permeation and block by internal and external divalent cations of the catfish cone photoreceptor cGMP-gated channel. Haynes LW. **J Gen Physiol** 1995 Sep; 106(3):507-23

Diverse current and voltage responses to baclofen in an identified molluscan photoreceptor. Matzel LD, et al. **J Neurophysiol** 1995 Aug;74(2):506-18

Protein kinase and G-protein regulation of Ca2+ currents in Hermissenda photoreceptors by 5-HT and GABA. Yamoah EN, et al. **J Neurosci** 1996 Aug 1;16(15):4799-809

Effects of prenatal cocaine exposure in the photoreceptor cells of the rat retina. Silva-Araújo A, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):77-86

EMBRYOLOGY

Polyamines and ripening of photoreceptor outer segments in chicken embryos. Taibi G, et al. **Int J Dev Neurosci** 1995 Nov;13(7):759-66

ENZYMOLOGY

Calcium modulation of bovine photoreceptor guanylate cyclase. Duda T, et al. **Biochemistry** 1996 Jul 2; 35(26):8478-82

Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina. Zhang SR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1793-9

Inactivation of EF-hands makes GCAP-2 (p24) a constitutive activator of photoreceptor guanylyl cyclase by preventing a Ca2+-induced "activator-to-inhibitor" transition. Dizhoor AM, et al. **J Biol Chem** 1996 Aug 9; 271(32):19346-50

Tryptophan hydroxylase is expressed by photoreceptors in Xenopus laevis retina. Green CB, et al. **Vis Neurosci** 1995 Jul-Aug;12(4):663-70

[Organization of the gene for the beta-subunit of human photoreceptor cyclic GMP phosphodiesterase] Suslova VA, et al. **Bioorg Khim** 1996 Apr;22(4):256-63 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Development of the pattern of photoreceptors in the chick retina. Bruhn SL, et al. **J Neurosci** 1996 Feb 15;16(4):1430-9

METABOLISM

Turnover rate and number of Na(+)-Ca2+, K+ exchange sites in retinal photoreceptors. Rispoli G, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:346-55 (26 ref.)

Heterologous expression of photoreceptor peripherin/rds and Rom-1 in COS-1 cells: assembly, interactions, and localization of multisubunit complexes. Goldberg AF, et al. **Biochemistry** 1995 Oct 31;34(43):14213-9

Noise analysis of the glutamate-activated current in photoreceptors. Larsson HP, et al. **Biophys J** 1996 Feb; 70(2):733-42

Truncation of IGF-I yields two mitogens for retinal Müller glial cells. Ikeda T, et al. **Brain Res** 1995 Jul 17;686(1):87-92

Study on the aging changes of DNA and protein synthesis of bipolar and photoreceptor cells of mouse retina by light and electron microscopic radioautography. Toriyama K. **Cell Mol Biol (Noisy-le-grand)** 1995 Jun;41(4):593-601

Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina. Little CW, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):204-11

Biosynthesis of the unsaturated 14-carbon fatty acids found on the N termini of photoreceptor-specific proteins. DeMar JC Jr, et al. **J Biol Chem** 1996 Mar 1;271(9):5007-16

Cloning, sequencing, and expression of a 24-kDa Ca(2+)-binding protein activating photoreceptor guanylyl cyclase. Dizhoor AM, et al. **J Biol Chem** 1995 Oct 20; 270(42):25200-6

Cloning of the cDNA for a novel photoreceptor protein. Higashide T, et al. **J Biol Chem** 1996 Jan 19;271(3):1797-804

Permeation of internal and external monovalent cations through the catfish cone photoreceptor cGMP-gated channel. Haynes LW. **J Gen Physiol** 1995 Sep; 106(3):485-505

Removal of extracellular chloride suppresses transmitter release from photoreceptor terminals in the mudpuppy retina. Thoreson WB, et al. **J Gen Physiol** 1996 May; 107(5):631-42

The dihydropyridine-sensitive calcium channel subtype in cone photoreceptors. Wilkinson MF, et al. **J Gen Physiol** 1996 May;107(5):621-30

Relationship between dietary supply of long-chain fatty acids and membrane composition of long- and very long chain essential fatty acids in developing rat photoreceptors. Suh M, et al. **Lipids** 1996 Jan;31(1):61-4

bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7042-7

PATHOLOGY

Apoptotic photoreceptor cell death after traumatic retinal detachment in humans [letter] Sebag J, et al. **Arch Ophthalmol** 1996 Sep;114(9):1158-9

Photoreceptor loss in age-related macular degeneration. Curcio CA, et al. **Invest Ophthalmol Vis Sci** 1996 Jun; 37(7):1236-49

Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Naash ML, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):775-82

Microglial cells invade the outer retina as photoreceptors degenerate in Royal College of Surgeons rats. Roque RS, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):196-203

Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina. Zhang SR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1793-9

bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7042-7

PHYSIOLOGY

Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Adler R. **Arch Ophthalmol** 1996 Jan; 114(1):79-83 (43 ref.)

Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245-7 (24 ref.)

Müller cell changes precede photoreceptor cell degeneration in the age-related retinal degeneration of the Fischer 344 rat. DiLoreto DA Jr, et al. **Brain Res** 1995 Nov 6; 698(1-2):1-14

Control of photoreceptor proteins by Ca2+. Koch KW. **Cell Calcium** 1995 Oct;18(4):314-21 (72 ref.)

The spatio-temporal pattern of photoreceptor degeneration in the aged rd/rd mouse retina. Jiménez AJ, et al. **Cell Tissue Res** 1996 May;284(2):193-202

Photoreceptor recovery in retinoid-deprived rats after vitamin A replenishment. Katz ML, et al. **Exp Eye Res** 1993 Jun;56(6):671-82

Systemic hypoxia dehydrates the space surrounding photoreceptors in the cat retina. Cao W, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):586-96

The effect of light history on the aspartate-isolated fast-PIII responses of the albino rat retina. Reiser MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):221-9

Photoreceptor cells in the vitiligo mouse die by apoptosis. TRPM-2/clusterin expression is increased in the neural retina and in the retinal pigment epithelium. Smith SB, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2193-201

Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (rd/rd) and normal CBA/N (+/+)mice. Yoshimura T, et al. **J Comp Physiol [A]** 1996 Jun;178(6):797-802

Response dynamics and receptive-field organization of catfish ganglion cells. Sakai HM, et al. **J Gen Physiol** 1995 Jun;105(6):795-814

Light responses from one type of ON-OFF amacrine cells in the rabbit retina. Dacheux RF, et al. **J Neurophysiol** 1995 Dec;74(6):2460-8

Magnesium-dependent block of the light-activated and trp-dependent conductance in Drosophila photoreceptors. Hardie RC, et al. **J Neurophysiol** 1995 Dec;74(6):2590-9

Evidence for a contribution of ICa to serotonergic modulation of IK,Ca in Hermissenda photoreceptors. Yamoah EN, et al. **J Neurophysiol** 1995 Sep;74(3):1349-54

Antagonists of cyclic nucleotide-gated channels and molecular mapping of their site of action. Kramer RH, et al. **J Neurosci** 1996 Feb 15;16(4):1285-93

Photopigment transmittance imaging of the primate photoreceptor mosaic. Packer OS, et al. **J Neurosci** 1996 Apr 1;16(7):2251-60

Blue-cone horizontal cells in the retinae of horses and other

equidae. Sandmann D, et al. **J Neurosci** 1996 May 15; 16(10):3381–96

A digital feedback controller application for studying photoreceptor adaptation by 'voltage clamp by light'. Djupsund K, et al. **J Neurosci Methods** 1995 Nov; 62(1–2):29–36

Direct measurement of human–cone–photoreceptor alignment. Burns SA, et al. **J Opt Soc Am A** 1995 Oct; 12(10):2329–38

Incoherent spatial impulse response in variable–cross–section photoreceptors and frequency–domain analysis. Lakshminarayanan V, et al. **J Opt Soc Am A** 1995 Oct; 12(10):2339–47

Rod transduction parameters from the a wave of local receptor populations. Nusinowitz S, et al. **J Opt Soc Am A** 1995 Oct;12(10):2259–66

Photoreceptor and bipolar cell contributions to the cat electroretinogram: a kinetic model for the early part of the flash response. Robson JG, et al. **J Opt Soc Am A** 1996 Mar;13(3):613–22

On the filling in of the visual blind spot: some rules of thumb. Durgin FH, et al. **Perception** 1995;24(7):827–40

Dermal photoreceptors regulate basking behavior in the lizard Podarcis muralis. Tosini G, et al. **Physiol Behav** 1996 Jan;59(1):195–8

Gain and kinetics of activation in the G–protein cascade of phototransduction. Lamb TD. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):566–70

The differences in the expressions of visual pigments and transducin in photoreceptor cell differentiation. Ohguro H, et al. **Tohoku J Exp Med** 1996 Mar;178(3):233–40

Shifting relationships between photoreceptors and pigment epithelial cells in monkey retina: implications for the development of retinal topography. Robinson SR, et al. **Vis Neurosci** 1995 Jul–Aug;12(4):767–78

[Quantitative characteristics of recycling tissue corneal receptors] Sotnikov OS, et al. **Biull Eksp Biol Med** 1995 May;119(5):544–8 **(Rus)**

PHYSIOPATHOLOGY

Mechanisms of photoreceptor death in retinal degenerations: from the cell biology of the 1990s to the ophthalmology of the 21st century? [letter] Crane WG. **Arch Ophthalmol** 1996 Sep;114(9):1158

Photoreceptor function in heterozygotes with insertion or deletion mutations in the RDS gene. Jacobson SG, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1662–74

Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. Fulton AB, et al. **J Opt Soc Am A** 1996 Mar;13(3):566–71

RADIATION EFFECTS

Photoreceptor sensitivity and the shot noise of chemical processes. Petracchi D, et al. **Biophys J** 1996 Jan; 70(1):111–20

Parallel suppression of retinal and pineal melatonin synthesis by retinally mediated light. Morgan IG, et al. **Neuroreport** 1995 Jul 31;6(11):1530–2

[X–ray structural study of the effect of light on isolated bovine photoreceptor membranes] Krivandin AV, et al. **Biofizika** 1995 Mar–Apr;40(2):354–60 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Ultrastructural features of retinal dystrophy in mutant vitiligo mice. Nir I, et al. **Exp Eye Res** 1995 Sep;61(3):363–77

Fine structure of the retinal photoreceptors of the barred owl (Strix varia). Braekevelt CR, et al. **Histol Histopathol** 1996 Jan;11(1):79–88

Mechanisms of opsin activation. Buczylko J, et al. **J Biol Chem** 1996 Aug 23;271(34):20621–30

The ultrastructural study of ribosomes in photoreceptor inner segments of the pcd cerebellar mutant mouse. Okubo A, et al. **Jpn J Ophthalmol** 1995;39(2):152–61

PHOTORECEPTORS, CONE see **CONES (RETINA)**

PHOTORECEPTORS, INVERTEBRATE

CHEMISTRY

Similarity among the Drosophila (6–4)photolyase, a human photolyase homolog, and the DNA photolyase–blue–light photoreceptor family [see comments] Todo T, et al. **Science** 1996 Apr 5;272(5258):109–12. Comment in: Science 1996 Apr 5;272(5258):48–9.

CYTOLOGY

JUN cooperates with the ETS domain protein pointed to induce photoreceptor R7 fate in the Drosophila eye. Treier M, et al. **Cell** 1995 Dec 1;83(5):753–60

Phosphorylation of Drosophila Jun by the MAP kinase rolled regulates photoreceptor differentiation. Peverali FA, et al. **EMBO J** 1996 Aug 1;15(15):3943–50

Mutations in the Drosophila hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. Krämer H, et al. **J Cell Biol** 1996 Jun;133(6):1205–15

Uncoupling cell fate determination from patterned cell division in the Drosophila eye [see comments] de Nooij JC, et al. **Science** 1995 Nov 10;270(5238):983–5. Comment in: Science 1995 Nov 10;270(5238):916–7.

Sifting mitosis, cell fate in fly eyes [news; comment] Roush W. **Science** 1995 Nov 10;270(5238):916–7. Comment on: Science 1995 Nov 10;270(5238):983–5.

Genes seen turning imaginal fly eyes into reality [news] Roush W. **Science** 1996 Jun 21;272(5269):1739

DRUG EFFECTS

G–protein mediated responses to localized serotonin application in an invertebrate photoreceptor. Rogers RF, et al. **Neuroreport** 1995 Nov 13;6(16):2161–5

EMBRYOLOGY

Hedgehog, transmitted along retinal axons, triggers neurogenesis in the developing visual centers of the Drosophila brain. Huang Z, et al. **Cell** 1996 Aug 9; 86(3):411–22

Early decisions in Drosophila eye morphogenesis. Bonini NM, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):507–15 (73 ref.)

orthodenticle is required for photoreceptor cell development in the Drosophila eye. Vandendries ER, et al. **Dev Biol** 1996 Jan 10;173(1):243–55

Drosophila nonmuscle myosin II has multiple essential roles in imaginal disc and egg chamber morphogenesis. Edwards KA, et al. **Development** 1996 May;122(5):1499–511

wingless inhibits morphogenetic furrow movement in the Drosophila eye disc. Treisman JE, et al. **Development** 1995 Nov;121(11):3519–27

frizzled regulates mirror–symmetric pattern formation in the Drosophila eye. Zheng L, et al. **Development** 1995 Sep; 121(9):3045–55

Identification and characterization of autosomal genes that interact with glass in the developing Drosophila eye. Ma C, et al. **Genetics** 1996 Apr;142(4):1199–213

ENZYMOLOGY

Squid photoreceptor phospholipase C is stimulated by membrane Gq alpha but not by soluble Gq alpha. Suzuki T, et al. **FEBS Lett** 1995 Dec 27;377(3):333–7

GROWTH & DEVELOPMENT

Daughter of sevenless is a substrate of the phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling. Herbst R, et al. **Cell** 1996 Jun 14;85(6):899–909

pipsqueak encodes a novel nuclear protein required downstream of seven–up for the development of photoreceptors R3 and R4. Weber U, et al. **EMBO J** 1995 Dec 15;14(24):6247–57

Regulation of cell–cell contacts in developing Drosophila eyes by Dsrc41, a new, close relative of vertebrate c–src. Takahashi F, et al. **Genes Dev** 1996 Jul 1;10(13):1645–56

Protein phosphatase 2A positively and negatively regulates Ras1–mediated photoreceptor development in Drosophila. Wassarman DA, et al. **Genes Dev** 1996 Feb 1;10(3):272–8

Morphogenesis of the photoreceptive site and development of the electrical responses in the butterfly genital photoreceptors during the pupal period. Miyako Y, et al. **J Comp Neurol** 1995 Dec 11;363(2):296–306

METABOLISM

Ca2+ induces an increase in cGMP–phosphodiesterase activity in squid retinal photoreceptors. Brown JE, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):684–9

TRP: its role in phototransduction and store–operated Ca2+ entry. Friel DD. **Cell** 1996 May 31;85(5):617–9 (20 ref.)

Drosophila photoreceptor axon guidance and targeting requires the dreadlocks SH2/SH3 adapter protein. Garrity PA, et al. **Cell** 1996 May 31;85(5):639–50

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

A beta–subclass phosphatidylinositol–specific phospholipase C from squid (Loligo forbesi) photoreceptors exhibiting a truncated C–terminus. Carne A, et al. **FEBS Lett** 1995 Sep 25;372(2–3):243–8

Effects of intracellular Ca2+ chelation on the light response in Drosophila photoreceptors. Hardie RC. **J Comp Physiol [A]** 1995 Dec;177(6):707–21

INDO–1 measurements of absolute resting and light–induced Ca2+ concentration in Drosophila photoreceptors. Hardie RC. **J Neurosci** 1996 May 1;16(9):2924–33

Selective, activity–dependent uptake of histamine into an arthropod photoreceptor. Stuart AE, et al. **J Neurosci** 1996 May 15;16(10):3178–88

PATHOLOGY

Subunit–destabilizing mutations in Drosophila copper/zinc superoxide dismutase: neuropathology and a model of dimer dysequilibrium [see comments] Phillips JP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8574–8. Comment in: Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8533–4.

PHYSIOLOGY

Phosphoinositide–mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256–74 (125 ref.)

Distinguishing between roles for calcium in Limulus photoreceptor excitation. Richard EA, et al. **Cell Calcium** 1995 Oct;18(4):331–41 (45 ref.)

Light activated calcium release in Limulus ventral photoreceptors as revealed by laser confocal microscopy. Ukhanov K, et al. **Cell Calcium** 1995 Oct;18(4):301–13

Structure and cellular physiology of Ca2+ stores in invertebrate photoreceptors. Walz B, et al. **Cell Calcium** 1995 Oct;18(4):342–51 (52 ref.)

Rhodopsin plays an essential structural role in Drosophila photoreceptor development. Kumar JP, et al. **Development** 1995 Dec;121(12):4359–70

Is there evidence for a cGMP–gated cation channel in the photosensory membrane of Sepia? Re publication: 'Evidence for a cGMP gated cation channel in photoreceptor cell membranes of Sepia officinalis'. Stieve H. **FEBS Lett** 1995 Oct 9;373(2):187, discussion 188

Drosophila TFIIA–S is up–regulated and required during Ras–mediated photoreceptor determination. Zeidler MP, et al. **Genes Dev** 1996 Jan 1;10(1):50–9

Molecular, biochemical, and electrophysiological characterization of Drosophila norpA mutants. Pearn MT, et al. **J Biol Chem** 1996 Mar 1;271(9):4937–45

Characterisation of columnar neurons and visual signal processing in the medulla of the locust optic lobe by system identification techniques. James AC, et al. **J Comp Physiol [A]** 1996 Feb;178(2):183–99

Establishment of neuronal connectivity during development of the Drosophila larval visual system. Campos AR, et al. **J Neurobiol** 1995 Nov;28(3):313–29

Cyclic–GMP enhances light–induced excitation and induces membrane currents in Drosophila retinal photoreceptors. Bacigalupo J, et al. **J Neurosci** 1995 Nov;15(11):7196–200

Inhibitors of cyclic–GMP phosphodiesterase alter excitation of Limulus ventral photoreceptors in Ca(2+)–dependent fashion. Johnson EC, et al. **J Neurosci** 1995 Oct; 15(10):6586–91

Light removes inactivation of the A–type potassium channels in scallop hyperpolarizing photoreceptors. Shimatani Y, et al. **J Neurosci** 1995 Oct;15(10):6489–97

Characterization of low–dimensional dynamics in the crayfish caudal photoreceptor. Pei X, et al. **Nature** 1996 Feb 15; 379(6566):618–21

Activation of light–dependent K+ channels in ciliary invertebrate photoreceptors involves cGMP but not the IP3/Ca2+ cascade. del Pilar Gomez M, et al. **Neuron** 1995 Sep;15(3):607–18

Gq alpha protein function in vivo: genetic dissection of its role in photoreceptor cell physiology. Scott K, et al. **Neuron** 1995 Oct;15(4):919–27

Regulation of the TRP Ca2+ channel by INAD in Drosophila photoreceptors. Shieh BH, et al. **Neuron** 1996 May;16(5):991–8

Current components stimulated by different G–proteins in Limulus ventral photoreceptor. Contzen K, et al. **Neuroreport** 1995 Oct 2;6(14):1905–8

The biology of vision of Drosophila. Zuker CS. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):571–6 (52 ref.)

Matched filtering by a photoreceptor membrane. Laughlin SB. **Vision Res** 1996 Jun;36(11):1529–41

RADIATION EFFECTS

Effects of intracellular Ca2+ chelation on the light response in Drosophila photoreceptors. Hardie RC. **J Comp Physiol [A]** 1995 Dec;177(6):707–21

INDO–1 measurements of absolute resting and light–induced Ca2+ concentration in Drosophila photoreceptors. Hardie RC. **J Neurosci** 1996 May 1;16(9):2924–33

ULTRASTRUCTURE

Studies on the structure of ocellar photoreceptor cells of Drosophila melanogaster with special reference to subrhabdomeric cisternae. Yoon CS, et al. **Cell Tissue Res** 1996 Apr;284(1):77–85

PHOTORECEPTORS, RETINAL see **RODS AND CONES**

PHOTORECEPTORS, ROD see **RODS (RETINA)**

PHOTORECEPTORS, VERTEBRATE see **RODS AND CONES**

PHOTOSENSITIVITY DISORDERS

Burns induced by plants. Lagey K, et al. **Burns** 1995 Nov; 21(7):542–3

Erythropoietic protoporphyria without cutaneous photosensitivity and with ringed sideroblasts in an atomic bomb survivor [letter] Takeda Y, et al. **Lancet** 1996 Feb 10;347(8998):395–6

Photosensitivity. Baker CS. **Med J Aust** 1996 Jul 15; 165(2):96–101 (17 ref.)

[Light–induced eruptions and their photoprotection] Jeanmougin M. **Rev Med Interne** 1995;16 Suppl 3:348S–353s (27 ref.) **(Fre)**

BLOOD

The diagnostic value of morphometry on blood lymphocytes in erythrodermic actinic reticuloid. Preesman AH, et al. **Arch Dermatol** 1995 Nov;131(11):1298–303

Photodynamic DNA–breaking activity of serum from patients with various photosensitivity dermatoses.

Hashizume H, et al. **Arch Dermatol Res** 1995;287(6):586–90

CHEMICALLY INDUCED

Chrysiasis revisited: a clinical and pathological study. Smith RW, et al. **Br J Dermatol** 1995 Nov;133(5):671–8
Photosensitivity induced by fleroxacin. Kimura M, et al. **Clin Exp Dermatol** 1996 Jan;21(1):46–7
Ampiroxicam–induced photosensitivity. Kurumaji Y. **Contact Dermatitis** 1996 Apr;34(4):298–9
Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)
Photosensitivity skin reactions to calcium channel blockers. Seggev JS, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):852–5
Photosensitivity from pyridoxine hydrochloride (vitamin B6). Morimoto K, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):304–5
Photosensitivity reaction to fluoxetine [letter] Gaufberg E, et al. **J Clin Psychiatry** 1995 Oct;56(10):486
Photosensitivity to clozapine [letter] Howanitz E, et al. **J Clin Psychiatry** 1995 Dec;56(12):589
Skin side–effects of amiodarone therapy. Ettler K, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4–5):305–15
[Hydroxychloroquine–puvatherapy photoinduced acute generalized exanthematous pustulosis] Bonnetblanc JM, et al. **Ann Dermatol Venereol** 1995;122(9):604–5 (Eng. Abstr.) **(Fre)**
[Contact photoallergic eczema caused by ketoprofen] Jeanmougin M, et al. **Ann Dermatol Venereol** 1996; 123(4):251–5 (Eng. Abstr.) **(Fre)**
[Photosensitization induced by quinine used in the treatment of idiopathic nocturnal cramps (letter)] Delmas A, et al. **Presse Med** 1995 Nov 25;24(36):1707 **(Fre)**
[Drug–induced photodermatoses: how are they to be diagnosed and interpreted?] Beani JC. **Rev Med Interne** 1995;16 Suppl 3:337s–341s **(Fre)**
[Dermatotoxicity studies of calcipotriol (MC903) ointment—primary skin irritation, skin sensitization, phototoxicity and skin photosensitization] Suzuki T, et al. **J Toxicol Sci** 1996 Jul;21 Suppl 2:475–84 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Zalla MJ, et al. **Acta Derm Venereol Suppl (Stockh)** 1996;195:1–15 (103 ref.)
Skin response to ultraviolet B light in patients infected with human immunodeficiency virus. Kaporis A, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct–Dec; 11(5–6):188–91

DIAGNOSIS

The diagnostic value of morphometry on blood lymphocytes in erythrodermic actinic reticuloid. Preesman AH, et al. **Arch Dermatol** 1995 Nov;131(11):1298–303
A young woman with a photosensitive pruritic rash on her face and upper trunk. Zuber M, et al. **Arthritis Rheum** 1996 Aug;39(8):1419–22
[Photobiological study of lupus erythematosus] Bensaid P, et al. **Ann Dermatol Venereol** 1995;122(3):84–9 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of actinic prurigo in Chimila Indians. Durán MM, et al. **Int J Dermatol** 1996 Jun;35(6):413–6
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. Berger TG, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):837–8

EPIDEMIOLOGY

Actinic keratoses: the bald facts [letter] Long CC, et al. **Arch Dermatol** 1996 Sep;132(9):1132–3
Juvenile spring eruption: a prevalence study. Tan E, et al. **N Z Med J** 1996 Aug 9;109(1027):293–5

ETIOLOGY

Solar pruritus. Bech–Thomsen N, et al. **Acta Derm Venereol** 1995 Nov;75(6):488–9
Photosensitivity associated with combined UV–B and calcipotriene therapy [see comments] McKenna KE, et al. **Arch Dermatol** 1995 Nov;131(11):1305–7. Comment in: Arch Dermatol 1995 Nov;131(11):1323–4.
Photolocalized eruption associated with acute hepatitis B virus infection. Hayakawa K, et al. **Br J Dermatol** 1996 Jan;134(1):167–9
Solar urticaria: a case report. Tsien A, et al. **Cutis** 1996 Feb; 57(2):87–90; quiz 94
Erythropoietic protoporphyria presenting in an adult. Henderson CA, et al. **J R Soc Med** 1995 Aug; 88(8):476P–477P (8 ref.)
The action spectrum for induction of chronic actinic dermatitis is similar to that for sunburn inflammation. Menagé HD, et al. **Photochem Photobiol** 1995 Dec; 62(6):976–9
[Photosensitivity] Granlund H. **Duodecim** 1995;111(5):457–65 (19 ref.) **(Fin)**
[Heliodermatitis or photo–induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720–8 (89 ref.) **(Fre)**

GENETICS

Clinical characteristics of three patients with UVs syndrome, a photosensitive disorder with defective DNA repair. Itoh T, et al. **Br J Dermatol** 1996 Jun;134(6):1147–50
Hereditary polymorphic light eruption of American Indians: occurrence in non–Indians with polymorphic light eruption. Fusaro RM, et al. **J Am Acad Dermatol** 1996 Apr; 34(4):612–7

IMMUNOLOGY

Polymorphic light eruption—an immunopathological study of provoked lesions. Verheyen AM, et al. **Clin Exp Dermatol** 1995 Jul;20(4):297–303
HLA–DR4 may determine expression of actinic prurigo in British patients. Menagé H duP, et al. **J Invest Dermatol** 1996 Feb;106(2):362–7

METABOLISM

A study of the kinetics and pattern of E–selectin, VCAM–1 and ICAM–1 expression in chronic actinic dermatitis. Menagé H du P, et al. **Br J Dermatol** 1996 Feb;134(2):262–8

PATHOLOGY

Annular elastolytic giant cell granuloma—actinic granuloma? Revenga F, et al. **Clin Exp Dermatol** 1996 Jan;21(1):51–3
Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5–methoxypsoralen and UVA, interferon alfa–2b, and extracorporeal photopheresis. Wolf P, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):291–4

THERAPY

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)

VETERINARY

Narthecium ossifragum associated photosensitization in sheep in the Faroe Islands. Flåøyen A, et al. **Acta Vet Scand** 1995; 36(2):277–8
Photosensitivity in South Africa. VIII. Ovine metabolism of Tribulus terrestris saponins during experimentally induced geeldikkop. Miles CO, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):351–9
Recovery of hepatic function and latent mortalities in sheep exposed to the blue–green alga Microcystis aeruginosa. Carbis CR, et al. **Vet Rec** 1995 Jul 1;137(1):12–5

PHOTOSENSITIZERS see **PHOTOSENSITIZING AGENTS**

PHOTOSENSITIZING AGENTS

see related
HEMATOPORPHYRIN PHOTORADIATION
PHOTOCHEMOTHERAPY
PUVA THERAPY

Fluorescence and photosensitization of experimental endometriosis in the rat after systemic 5–aminolevulinic acid administration: a potential new approach to the diagnosis and treatment of endometriosis. Yang JZ, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):154–60
Biophysical and biological evaluation of porphyrin–bisacridine conjugates. Karagianis G, et al. **Anticancer Drug Des** 1996 Apr;11(3):205–20
Likely photosensitizing agents available in the United Kingdom—an update. Bellaney GJ, et al. **Clin Exp Dermatol** 1996 Jan;21(1):14–16
Severe phototoxic reaction secondary to the application of a fig leaves' decoction used as a tanning agent. Micali G, et al. **Contact Dermatitis** 1995 Sep;33(3):212–3
On the role of protoporphyrin IX photoproducts in photodynamic therapy [news] Gudgin Dickson EF, et al. **J Photochem Photobiol B** 1995 Jul;29(1):91–3
Effect of haematoporphyrin–induced photosensitization on lipid membranes. Lakos Z, et al. **J Photochem Photobiol B** 1995 Aug;29(2–3):185–91
Photodynamic laser cyclodestruction with chloroaluminum sulfonated phthalocyanine (CASPc) or Photofrin (PII) vs. Nd:YAG laser cyclodestruction in a pigmented rabbit model. Hill RA, et al. **Lasers Surg Med** 1995;17(2):166–71
Psoralen photobiology: recent advances. Gasparro FP. **Photochem Photobiol** 1996 May;63(5):553–7 (36 ref.)
Photosensitization of murine tumor, vasculature and skin by 5–aminolevulinic acid–induced porphyrin. Henderson BW, et al. **Photochem Photobiol** 1995 Oct;62(4):780–9
The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Ben–Hur E, et al. **Transfus Med Rev** 1996 Jan; 10(1):15–22 (71 ref.)
[Clinical fluorescent diagnosis of tumors using photosensitizer photogem] Chissov VI, et al. **Khirurgiia (Mosk)** 1995; (5):37–41 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Comparison of local intravascular drug–delivery catheter systems. Gonschior P, et al. **Am Heart J** 1995 Dec; 130(6):1174–81
Structural and functional effects of endometrial photodynamic therapy in a rat model. Fehr MK, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):115–21
Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Husain D, et al. **Arch Ophthalmol** 1996 Aug;114(8):978–85
The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. Lilge L, et al. **Br J Cancer** 1996 Feb;73(3):332–43
Calculation of 8–methoxypsoralen dose according to body surface area in PUVA treatment. Sakuntabhai A, et al. **Br J Dermatol** 1995 Dec;133(6):919–23
Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Molpus KL, et al. **Cancer Res** 1996 Mar 1;56(5):1075–82
Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Kramer M, et al. **Ophthalmology** 1996 Mar;103(3):427–38
Effect of photosensitizer delivery system and irradiation parameters on the efficiency of photodynamic therapy of B16 pigmented melanoma in mice. Biolo R, et al. **Photochem Photobiol** 1996 Feb;63(2):224–8
Liposome–mediated delivery of photosensitizers: localization of zinc (II)–phthalocyanine within implanted tumors after intravenous administration. Love WG, et al. **Photochem Photobiol** 1996 May;63(5):656–61

ADVERSE EFFECTS

Lack of photosensitising potential of tenidap, a novel anti–rheumatic agent. Ferguson J, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:63S–66S

BLOOD

Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Fromm D, et al. **Arch Surg** 1996 Jun;131(6):667–9
The effect of different liposomal formulations on the interaction of Zn(II)–phthalocyanine with isolated low and high density lipoproteins. Polo L, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1249–55
High–performance liquid chromatographic determination of the silicon phthalocyanine Pc 4 in human blood. Zuk MM, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17; 673(2):320–4
Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638–42
Biodistribution and virus inactivation efficacy of a silicon phthalocyanine in red blood cell concentrates as a function of delivery vehicle. Ben–Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):575–9

CHEMICAL SYNTHESIS

Synthesis and photobiological properties of 3–acylangelicins, 3–alkoxycarbonylangelicins and related derivatives. Iester M, et al. **Farmaco** 1995 Oct;50(10):669–78
Octa–alkyl zinc phthalocyanines: potential photosensitizers for use in the photodynamic therapy of cancer. Cook MJ, et al. **Photochem Photobiol** 1995 Sep;62(3):542–5
Phototoxicity of some bromine–substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers. Pal P, et al. **Photochem Photobiol** 1996 Feb;63(2):161–8
Alkyl ether analogs of chlorophyll–a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy. Pandey RK, et al. **Photochem Photobiol** 1996 Jul; 64(1):194–204

CHEMISTRY

Photoinactivation of trypanothione reductase and glutathione reductase by Al–phthalocyanine tetrasulfonate and hematoporphyrin. Kliukienė R, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):629–32
Physico–chemical modeling of the role of free radicals in photodynamic therapy. III. Interactions of stable free radicals with excited photosensitizers studied by kinetic ESR spectroscopy. Kriska T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):192–8
EPR–spin trapping kinetic studies of superoxide radicals produced by photosensitized hypocrellin A. A photodynamic therapeutic agent. Zang LY, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):685–91
Measurement of 1268 nm emission for comparison of singlet oxygen (1 delta g) production efficiency of various dyes. Arakane K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):1–4
Type I benzophenone–mediated nucleophilic reaction of 5'–amino–2',5'–dideoxyguanosine. A model system for the investigation of photosensitized formation of DNA–protein cross–links. Morin B, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):792–9
Isolation and photodynamic effects of hematoporphyrin derivative components: a chromatographic analysis of the starting materials. Owens JW, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):295–309
Visible light–sensitized oxidation of arachidonic acid in the

presence of inperatorin. Fukui Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):387–93

The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). Aveline BM, et al. **J Photochem Photobiol B** 1995 Oct; 30(2–3):161–9

Characteristics of triplex-directed photoadduct formation by psoralen-linked oligodeoxynucleotides. Bates PJ, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4283–9

Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Bezdetnaya L, et al. **Photochem Photobiol** 1996 Aug;64(2):382–6

Study of photoinduced energy and electron transfer in alpha–terthienyl–bovine serum albumin conjugates: a laser flash photolysis study. Boch R, et al. **Photochem Photobiol** 1996 Jul;64(1):92–9

Interactions between N-aspartyl chlorin e6, detergent micelles and plasma lipoproteins. Kessel D. **Photochem Photobiol** 1995 Jun;61(6):646–9

In vivo excitation of photosensitizers by infrared light. Lenz P. **Photochem Photobiol** 1995 Aug;62(2):333–8

Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Steinbach P, et al. **Photochem Photobiol** 1995 Nov; 62(5):887–95

Bilirubin ditaurate—a sensitive compound for examination of photosensitizers. Jirsa M, et al. **Sb Lek** 1995;96(1):1–6

[Formation and photosensitizing activity of protein tryptophanile photochemical breakdown products in isolated erythrocyte membranes] Vorobei AV, et al. **Biofizika** 1995 Mar–Apr;40(2):342–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Antigenicity of poly(dA–dT) . poly(dA–dT) photocrosslinked with 8–methoxypsoralen. Arif Z, et al. **Arch Biochem Biophys** 1996 May 15;329(2):191–8

Specific targeting of phototoxic haptenated liposomes to a hapten–specific B cell lymphoma. Avrilionis K, et al. **Cell Immunol** 1996 Feb 25;168(1):13–23

METABOLISM

Photosensitization of the endometrium with topical 5–aminolevulinic acid. Gannon MJ, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1826–8

The influence of iron chelators on the accumulation of protoporphyrin IX in 5–aminolaevulinic acid–treated cells. Berg K, et al. **Br J Cancer** 1996 Sep;74(5):688–97

Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB–treated mice. van der Veen N, et al. **Br J Cancer** 1996 Apr;73(7):925–30

Uptake by cells and photosensitizing effectiveness of novel pheophorbide derivatives in vitro. Dagan A, et al. **Int J Cancer** 1995 Dec 11;63(6):831–9

Biodistribution of a Zn(II) phthalocyanine to plasma lipoproteins. Kessel D. **J Photochem Photobiol B** 1996 May; 33(3):273–4

Formation of cyclobutane thymine dimers from UVA photosensitization of pyridopsoralen monoadducted DNA. Guillo LA, et al. **Photochem Photobiol** 1996 Aug; 64(2):349–55

Ascorbic acid glycation of lens proteins produces UVA sensitizers similar to those in human lens. Ortwerth BJ, et al. **Photochem Photobiol** 1995 Sep;62(3):454–62

Subcellular damage kinetics within co–cultivated WI38 and VA13–transformed WI38 human fibroblasts following 5–aminolevulinic acid–induced protoporphyrin IX formation. Uberriegler KP, et al. **Photochem Photobiol** 1995 Dec;62(6):1052–7

PHARMACOKINETICS

Interaction of hydro– or lipophilic phthalocyanines with cells of different metastatic potential. Valduga G, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):585–90

Hexadecafluorinated zinc phthalocyanine: photodynamic properties against the EMT–6 tumour in mice and pharmacokinetics using 65Zn as a radiotracer. Boyle RW, et al. **Br J Cancer** 1996 Jan;73(1):49–53

Novel asymmetric photosensitizers: an in vitro study. Haylett AK, et al. **Cancer Lett** 1996 Aug 2;105(2):187–93

Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638–42

Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5–aminolevulinic acid. Chang SC, et al. **J Urol** 1996 May;155(5):1744–8

Pharmacokinetics of pyropheophorbide–a–hexyl ether in the dog. Payne JT, et al. **Lasers Surg Med** 1996;18(4):406–9

In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Schmidt–Erfurth U, et al. **Lasers Surg Med** 1995;17(2):178–88

Structure–photodynamic activity relationships of a series of 4–substituted zinc phthalocyanines. Margaron P, et al. **Photochem Photobiol** 1996 Feb;63(2):217–23

Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Miller GG, et al. **Photochem Photobiol** 1995 Jun;61(6):632–8

Evaluation of new benzoporphyrin derivatives with enhanced PDT efficacy. Pandey RK, et al. **Photochem Photobiol** 1995 Oct;62(4):764–8

Effect of delivery system on the pharmacokinetics and tissue distribution of bis(di–isobutyl octadecylsiloxy)silicon 2,3–naphthalocyanine (isoBOSINC), a photosensitizer for tumor therapy. Zuk MM, et al. **Photochem Photobiol** 1996 Jan;63(1):132–40

[Dynamics of photosensitizer in the cell] Aizawa K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):22–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5–aminolevulinic acid. Fehr MK, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):951–7

Photodamaging effects of tetraphenylporphycene in a human carcinoma cell line. Villanueva A, et al. **Anticancer Drug Des** 1996 Mar;11(2):89–99

Photodynamic therapy. Cytotoxicity of aluminum phthalocyanine on intimal hyperplasia. Eton D, et al. **Arch Surg** 1995 Oct;130(10):1098–103

A comparative analysis of the photosensitized inhibition of growth–factor regulated protein kinases by hypericin–derivatives. Agostinis P, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):613–7

Free radical induced biophysical modification of membrane lipids: a novel mechanism proposed for a haemorheological alteration induced by 4,5′8–trimethyl psoralen. Nivsarkar M, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):625–33

The influence of merocyanine 540 and protoporphyrin on physicochemical properties of the erythrocyte membrane. Lagerberg JW, et al. **Biochim Biophys Acta** 1996 Jan 31; 1278(2):247–53

Mitochondria are the functional intracellular target for a photosensitizing boronated porphyrin. Munday AD, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):1–4

Novel cytotoxic DNA sequence and minor groove targeted photosensitizers: conjugates of pyrene and netropsin analogues. Hartley JA, et al. **Bioorg Med Chem** 1995 Jun; 3(6):623–9

Hexadecafluorinated zinc phthalocyanine: photodynamic properties against the EMT–6 tumour in mice and pharmacokinetics using 65Zn as a radiotracer. Boyle RW, et al. **Br J Cancer** 1996 Jan;73(1):49–53

Strong and prolonged induction of c–jun and c–fos proto–oncogenes by photodynamic therapy. Kick G, et al. **Br J Cancer** 1996 Jul;74(1):30–6

Photodynamic therapy on the normal rabbit larynx with phthalocyanine and 5–aminolaevulinic acid induced protoporphyrin IX photosensitisation. Kleemann D, et al. **Br J Cancer** 1996 Jul;74(1):49–58

The effect of aminolaevulinic acid–induced, protoporphyrin IX–mediated photodynamic therapy on the cremaster muscle microcirculation in vivo. Leveckis J, et al. **Br J Cancer** 1995 Nov;72(5):1113–9

Apoptosis and necrosis induced with light and 5–aminolaevulinic acid–derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22–9

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA–induced protoporphyrin IX in a colon carcinoma model. Orenstein A, et al. **Br J Cancer** 1996 Apr; 73(8):937–44

Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells. Malham GM, et al. **Br J Neurosurg** 1996 Feb;10(1):51–7

Photosensitization of oesophageal smooth muscle by 3–NO2–1, 4–dihydropyridines: evidence for two cyclic GMP–dependent effector pathways. Martin–Caraballo M, et al. **Br J Pharmacol** 1995 Dec;116(8):3293–301

Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study. Estey EP, et al. **Cancer Chemother Pharmacol** 1996;37(4):343–50

Photothermal effects on murine mammary tumors using indocyanine green and an 808–nm diode laser: an in vivo efficacy study. Chen WR, et al. **Cancer Lett** 1996 Jan 2; 98(2):169–73

Photodynamic therapy–mediated oxidative stress can induce expression of heat shock proteins. Gomer CJ, et al. **Cancer Res** 1996 May 15;56(10):2355–60

Riboflavin–mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Granzow C, et al. **Cancer Res** 1995 Nov 1;55(21):4837–43

Induction of tumor necrosis by delta–aminolevulinic acid and 1,10–phenanthroline photodynamic therapy. Rebeiz N, et al. **Cancer Res** 1996 Jan 15;56(2):339–44

DNA photocleavage by novel intercalating 6–(2–pyridinium)phenanthridinium viologens. Colmenarejo G, et al. **FEBS Lett** 1995 Nov 6;374(3):426–8

Effects of hydroxyl radical scavengers on relaxation of supercoiled DNA by aminomethyl–trimethyl–psoralen and monochromatic UVA photons. Oroskar AA, et al. **Free Radic Biol Med** 1996;20(5):751–6

Growth inhibitory effects of pMC540 and merodantoin on established MCF–7 human breast tumor xenografts. Sharma R, et al. **In Vivo** 1995 Mar–Apr;9(2):103–8

Inhibition of OH radical–induced strand break formation of poly(U) by Ru(bpy)32+ or Ru(phen)32+ attached to the polynucleotide. Tossi AB, et al. **Int J Radiat Biol** 1995 Nov;68(5):525–33

Killing of Streptococcus sanguis in biofilms using a light–activated antimicrobial agent. Wilson M, et al. **J Antimicrob Chemother** 1996 Feb;37(2):377–81

Assessment of the cytotoxicity of the photosensitizing drug BPD verteporfin using human vascular smooth muscle cells in culture. Labow RS, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):728–36

Wavelength dependency of photodynamic effects after sensitization with 5–aminolevulinic acid in vitro and in vivo. Szeimies RM, et al. **J Invest Dermatol** 1995 Nov; 105(5):672–7

The killing of Helicobacter pylori by low–power laser light in the presence of a photosensitiser. Millson CE, et al. **J Med Microbiol** 1996 Apr;44(4):245–52

Studies on photoinactivation by various phthalocyanines of a free or replicating non–enveloped virus. Gaspard S, et al. **J Photochem Photobiol B** 1995 Dec;31(3):159–62

Molecular mechanism of drug photosensitization. Part 6. Photohaemolysis sensitized by tolmetin. Giuffrida S, et al. **J Photochem Photobiol B** 1995 Aug;29(2–3):125–33

In vivo damage to chorioallantoic membrane blood vessels by porphycene–induced photodynamic therapy. Gottfried V, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):115–21

Photodynamic inactivation of cell–free HIV strains by a red–absorbing chlorin–type photosensitizer. Grandadam M, et al. **J Photochem Photobiol B** 1995 Dec;31(3):171–7

Effects of sonodynamic and photodynamic treatment on cellular thiol levels. Kessel D, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):103–6

Meso–substituted cationic porphyrins as efficient photosensitizers of gram–positive and gram–negative bacteria. Merchat M, et al. **J Photochem Photobiol B** 1996 Feb;32(3):153–7

Ex–vivo treatment of gastric Helicobacter infection by photodynamic therapy. Millson CE, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):59–65

Photoinactivation of bacteria. Use of a cationic water–soluble zinc phthalocyanine to photoinactivate both gram–negative and gram–positive bacteria. Minnock A, et al. **J Photochem Photobiol B** 1996 Feb;32(3):159–64

Treatment with 8–MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results. Moor AC, et al. **J Photochem Photobiol B** 1995 Aug;29(2–3):193–8

Tris(2,2′–bipyridyl)ruthenium(II)–mediated photoinduced electron transfer of engineered cytochrome P450 1A2. Nakano R, et al. **J Photochem Photobiol B** 1996 Feb; 32(3):171–6

Light scattering of human skin: a comparison between zinc (II)–phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1–2):3–9 (23 ref.)

HepG2 human hepatocarcinoma cells: an experimental model for photosensitization by endogenous porphyrins. Vonarx–Coinsman V, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):201–8

The UVR wavelength dependence for lomefloxacin photosensitization of human skin. Young AR, et al. **J Photochem Photobiol B** 1996 Feb;32(3):165–70

Ultraviolet light and 8–methoxypsoralen inhibit expression of endothelial adhesion molecules. Laing TJ, et al. **J Rheumatol** 1995 Nov;22(11):2126–31

Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long–wave UV light. Tsung K, et al. **J Virol** 1996 Jan;70(1):165–71

Enhancement of the antitumor effect by combined use of high–energy shock waves and ATX–70. Maruyama M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):800–1

Cure of prophage in Staphylococcus aureus by furocoumarin photoadditions. Cavalcanti SM, et al. **Microbios** 1995; 81(327):85–91

Photochemical production of double–strand breaks in cellular DNA. Limoli CL, et al. **Mutagenesis** 1995 Sep;10(5):453–6

Preferential repair in Saccharomyces cerevisiae rad mutants after induction of interstrand cross–links by 8–methoxypsoralen plus UVA. Meniel V, et al. **Mutagenesis** 1995 Nov;10(6):543–8

Alterations in erythrocyte band 3 organization induced by the photosensitizer, hematoporphyrin derivative. Beaton S, et al. **Photochem Photobiol** 1995 Aug;62(2):353–5

Biodistribution and virus inactivation efficacy of a silicon phthalocyanine in red blood cell concentrates as a function of delivery vehicle. Ben–Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):575–9

Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Bezdetnaya L, et al. **Photochem Photobiol** 1996 Aug;64(2):382–6

Photodynamic activities and skin photosensitivity of the bis(dimethylthexylsiloxy)silicon 2,3–naphthalocyanine in mice. Brasseur N, et al. **Photochem Photobiol** 1995 Dec; 62(6):1058–65

Effect of glucose on photodynamic action of methylene blue in Escherichia coli cells. Capella M, et al. **Photochem Photobiol** 1996 Jul;64(1):205–10

Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Cincotta L, et al. **Photochem Photobiol** 1996 Feb;63(2):229–37

Octa–alkyl zinc phthalocyanines: potential photosensitizers for use in the photodynamic therapy of cancer. Cook MJ, et al. **Photochem Photobiol** 1995 Sep;62(3):542–5

Apoptosis or necrosis following Photofrin photosensitization: influence of the incubation protocol. Dellinger M.

Photochem Photobiol 1996 Jul;64(1):182–7

Role of calcium in photodynamically induced cell damage of human fibroblasts. Hubmer A, et al. **Photochem Photobiol** 1996 Jul;64(1):211–5

PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Johnson R, et al. **Photochem Photobiol** 1996 May;63(5):566–71

Sites of photodamage in vivo and in vitro by a cationic porphyrin. Kessel D, et al. **Photochem Photobiol** 1995 Nov; 62(5):875–81

Intensity-dependent enzyme photosensitization using 532 nm nanosecond laser pulses. Lambert CR, et al. **Photochem Photobiol** 1996 Feb;63(2):154–60

Structure-photodynamic activity relationships of a series of 4-substituted zinc phthalocyanines. Margaron P, et al. **Photochem Photobiol** 1996 Feb;63(2):217–23

The effect of photodynamic treatment of yeast with the sensitizer chloroaluminum phthalocyanine on various cellular parameters. Paardekooper M, et al. **Photochem Photobiol** 1995 Sep;62(3):561–7

Phototoxicity of some bromine-substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers. Pal P, et al. **Photochem Photobiol** 1996 Feb;63(2):161–8

The lack of efficacy of 4,6,6'-trimethylangelicin to induce immune suppression in an animal model for photopheresis: a comparison with 8-MOP. van Iperen HP, et al. **Photochem Photobiol** 1996 May;63(5):577–82

8-Methoxypsoralen photoadduct formation in complementary oligonucleotides containing a cross-linkable site. Park J, et al. **Photodermatol Photoimmunol Photomed** 1995 Jun; 11(3):102–6

Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates. Margolis-Nunno H, et al. **Transfusion** 1996 Aug;36(8):743–50

5,20-bis(4-sulphophenyl)-10,15-bis (2-methoxy-4-sulphophenyl)-21-thiaporphyrin as a new potent sensitizer in photodynamic therapy. Ziółkowski P, et al. **Tumori** 1995 Sep-Oct;81(5):364–9

[Photodynamic effect of HPD on DNA functions] Qi Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct;17(5):390–4 (Eng. Abstr.) **(Chi)**

[Tissue autofluorescence damping mechanisms, sensitized by tumorotrophic dyes] Oganesian VA, et al. **Biofizika** 1995 Nov-Dec;40(6):1308–12 (Eng. Abstr.) **(Rus)**

[The anticlastogenic effect of ascorbic acid in relation to the damages induced in human lymphocytes by the photomutagenic action of 8-methoxypsoralen and by ammonium molybdate] Makedonov GP, et al. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):726–9 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Electron paramagnetic resonance evidence of the generation of superoxide ($O_2^{\cdot-}$) and hydroxyl ($^{\cdot}OH$) radicals by irradiation of a new photodynamic therapy photosensitizer, Victoria Blue BO. Viola A, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):49–58

Study of photoinduced energy and electron transfer in alpha-terthienyl-bovine serum albumin conjugates: a laser flash photolysis study. Boch R, et al. **Photochem Photobiol** 1996 Jul;64(1):92–9

Ultraviolet A-induced photodegradation of 5-methoxypsoralen, 8-methoxypsoralen and psoralen reduces the biological effectiveness of the furocoumarins in vivo. Knudsen EA, et al. **Photodermatol Photoimmunol Photomed** 1995 Jun; 11(3):131–3

THERAPEUTIC USE

Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Jeanmougin M, et al. **Ann Hematol** 1996 Aug;73(2):91–3

Biological activities of phthalocyanines. XVII histopathologic evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. Margaron P, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):613–20

Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Young LH, et al. **Arch Ophthalmol** 1996 Feb;114(2):186–92

Effects of photodynamic therapy on leucocyte-endothelium interaction: differences between normal and tumour tissue. Dellian M, et al. **Br J Cancer** 1995 Nov;72(5):1125–30

Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light. Foster TH, et al. **Br J Cancer** 1996 Apr;73(8):933–6

Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. Karagianis G, et al. **Br J Cancer** 1996 Feb;73(4):514–21

Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Veenhuizen RB, et al. **Br J Cancer** 1996 Jun;73(11):1387–92

Use of photodynamic therapy for the treatment of squamous cell carcinoma of the soft palate. Poate TW, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):66–8

Current treatment of vitiligo in China. Shao C, et al. **Chin Med J (Engl)** 1995 Sep;108(9):647–9 (10 ref.)

Topical photodynamic therapy in verrucae. A pilot study. Ammann R, et al. **Dermatology** 1995;191(4):346–7

Intra-operative laser-induced photodynamic therapy in the treatment of experimental hepatic tumours. Liu DL, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1073–80

Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus [see comments] Laukka MA, et al. **Gastrointest Endosc** 1995 Jul;42(1):59–63. Comment in: Gastrointest Endosc 1995 Jul;42(1):96–8.

Photodynamic therapy: a new light on Barrett's esophagus [editorial; comment] Lightdale CJ. **Gastrointest Endosc** 1995 Jul;42(1):96–8. Comment on: Gastrointest Endosc 1995 Jul;42(1):59–63. Comment on: Gastrointest Endosc 1995 Jul;42(1):64–70.

Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer [see comments] Overholt BF, et al. **Gastrointest Endosc** 1995 Jul;42(1):64–70. Comment in: Gastrointest Endosc 1995 Jul;42(1):96–8.

Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser. van Gool CA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):435–40

Structural alterations induced by photodynamic action of hematoporphyrin derivative (HpD) in plasma membrane of glioblastoma (U-87MG) cells: time dependent fluorescence spectroscopic study. Joshi K, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):200–6

Photodynamic therapy of ocular melanoma with bis silicon 2,3-naphthalocyanine in a rabbit model. Hill RA, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2476–81

Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)-phthalocyanine. Zhou C, et al. **J Photochem Photobiol B** 1996 May;33(3):219–23

Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. Chang SC, et al. **J Urol** 1996 May;155(5):1749–53

Laser photochemotherapy with anthracyclines on cultured human squamous carcinoma cells. Paiva MB, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):257–62

Potentiation of merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. Traul DL, et al. **Photochem Photobiol** 1995 Oct;62(4):790–9

Problems associated with the use of broad-band illumination sources for photodynamic therapy [letter] Stringer MR. **Phys Med Biol** 1995 Oct;40(10):1733–5

Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Hill JS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12126–30

Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. van Geel IP, et al. **Radiat Res** 1996 May;145(5):602–9

Laser-induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Pomer S, et al. **Urol Int** 1995;55(4):197–201

[Photodynamic therapy (PDT) for early cervical cancer] Muroya T, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):47–56 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**

[The photodynamic therapy of malignant tumors in basic sites with the preparations photohem and photosens (the results of 3 years of observations)] Sokolov VV, et al. **Vopr Onkol** 1995;41(2):134–8 **(Rus)**

TOXICITY

Metal binding and resultant loss of phototoxicity of alpha-terthienyl: metal detoxification versus alpha-terthienyl inactivation. Nivsarkar M, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):183–9

Merocyanine 540 mediated photoirradiation of leukemic cells. In vitro inference on cell survival. Lydaki E, et al. **J Photochem Photobiol B** 1996 Jan;32(1–2):27–32

Effects of beta-carotene and alpha-tocopherol on photogenotoxicity induced by 8-methoxypsoralen: the role of oxygen. Bianchi L, et al. **Mutat Res** 1996 Aug 12; 369(3–4):183–94

Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a Psoralen and Ultraviolet A light. Gottlieb P, et al. **Photochem Photobiol** 1996 May; 63(5):562–5

Evaluation of new benzoporphyrin derivatives with enhanced PDT efficacy. Pandey RK, et al. **Photochem Photobiol** 1995 Oct;62(4):764–8

Hypericin-induced phototoxicity in cultured fibroblasts and swine erythrocytes. Yu H, et al. **Photochem Photobiol** 1996 Jul;64(1):168–73

Meso-tetra-(4-sulfonatophenyl)-porphine of low neurotoxicity. Střelečková E, et al. **Sb Lek** 1995;96(1):7–13

PHOTOSYNTHESIS

Feasibility studies for a photosynthetic artificial lung. Optimization of parameters affecting photosynthesis. Basu S, et al. **ASAIO J** 1994 Jul-Sep;40(3):M743–6

Protochlorophyllide reductase in photosynthetic prokaryotes and its role in chlorophyll synthesis. Rowe JD, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):417–24

Phosphorylation of phosphoenolpyruvate carboxykinase in plants. Studies in plants with C4 photosynthesis and Crassulacean acid metabolism and in germinating seeds. Walker RP, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):653–8

Assembly of the tetra-Mn site of photosynthetic water oxidation by photoactivation: Mn stoichiometry and detection of a new intermediate. Ananyev GM, et al. **Biochemistry** 1996 Apr 2;35(13):4102–9

Role of PufX protein in photosynthetic growth of Rhodobacter sphaeroides. 1. PufX is required for efficient light-driven electron transfer and photophosphorylation under anaerobic conditions. Barz WP, et al. **Biochemistry** 1995 Nov 21;34(46):15235–47

Dynamic properties of the minor chlorophyll a/b binding proteins of photosystem II, an in vitro model for photoprotective energy dissipation in the photosynthetic membrane of green plants. Ruban AV, et al. **Biochemistry** 1996 Jan 23;35(3):674–8

Axial heme ligation in the cytochrome bc1 complexes of mitochondrial and photosynthetic membranes. A near-infrared magnetic circular dichroism and electron paramagnetic resonance study. Finnegan MG, et al. **Biochim Biophys Acta** 1996 May 20;1274(1–2):9–20

Molecular cloning, DNA sequence and transcriptional analysis of the Rhodospirillum molischianum B800/850 light-harvesting genes. Germeroth L, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):145–50

115th, 117th, 118th and 120th Conference of the Gesellschaft für Biologische Chemie. 1994, 1995. Abstracts. **Biol Chem Hoppe Seyler** 1995 Sep;376 Suppl:S17–186

Nonlinear annihilation of excitations in photosynthetic systems. Valkunas L, et al. **Biophys J** 1995 Sep; 69(3):1117–29

Study of heme Fe(III) ligated by OH- in cytochrome b-559 and its low temperature photochemistry in intact chloroplasts. Fiege R, et al. **FEBS Lett** 1995 Dec 27; 377(3):325–9

Unassembled subunits of the photosynthetic oxygen-evolving complex present in the thylakoid lumen are long-lived and assembly-competent. Hashimoto A, et al. **FEBS Lett** 1996 Aug 5;391(1–2):29–34

Effects of hydrogen/deuterium exchange on photosynthetic water cleavage in PS II core complexes from spinach. Karge M, et al. **FEBS Lett** 1996 Jan 8;378(2):140–4

Chloroflexus aggregans sp. nov., a filamentous phototrophic bacterium which forms dense cell aggregates by active gliding movement. Hanada S, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):676–81

The heat shock protein ClpB mediates the development of thermotolerance in the cyanobacterium Synechococcus sp. strain PCC 7942. Eriksson MJ, et al. **J Bacteriol** 1996 Aug; 178(16):4839–46

Sequence of the bchG gene from Chloroflexus aurantiacus: relationship between chlorophyll synthase and other polyprenyltransferases. Lopez JC, et al. **J Bacteriol** 1996 Jun;178(11):3369–73

The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):415–21 (53 ref.)

Consequences for the organization of reaction center-light harvesting antenna of 1 (LH1) core complexes of Rhodobacter sphaeroides arising from deletion of amino acid residues from the C terminus of the LH1 alpha polypeptide. McGlynn P, et al. **J Biol Chem** 1996 Feb 9; 271(6):3285–92

Photosynthetic oxidation of MnS and FeS by Chlorobium spp. Borrego C, et al. **Microbiologia** 1995 Sep;11(3):351–8

Growth and photosynthetic activities of acclimated cyanobacteria in sewage effluents. Sallal AK. **Microbios** 1995;84(339):97–103

Reduction of the cytosolic fructose-1,6-bisphosphatase in transgenic potato plants limits photosynthetic sucrose biosynthesis with no impact on plant growth and tuber yield. Zrenner R, et al. **Plant J** 1996 May;9(5):671–81

Molecular comparison of carbonic anhydrase from Flaveria species demonstrating different photosynthetic pathways. Ludwig M, et al. **Plant Mol Biol** 1995 Oct;29(2):353–65

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661–9 (35 ref.)

Kinetics of photo-induced electron transfer from high-potential iron-sulfur protein to the photosynthetic reaction center of the purple phototroph Rhodoferax fermentans. Hochkoeppler A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6998–7002

Evolution of chlorophyll and bacteriochlorophyll: the problem of invariant sites in sequence analysis. Lockhart PJ, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1930–4

Long-time quantum simulation of the primary charge separation in bacterial photosynthesis. Makri N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3926–31

[Bacterial processes of photosynthesis and dark assimilation of carbon dioxide in the lakes of Bunger Hills Oasis in Eastern Antarctica] Gal'chenko VF, et al. **Mikrobiologiia** 1995 Nov-Dec;64(6):833–44 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Alterations in cell pigmentation, protein expression, and photosynthetic capacity of the cyanobacterium Oscillatoria tenuis grown under low iron conditions. Trick CG, et al. **Can J Microbiol** 1995 Dec;41(12):1117–23

The association of different detergents with the photosynthetic reaction center protein of Rhodobacter

sphaeroides R26 and the effects on its photochemistry. Gast P, et al. **Eur J Biochem** 1996 Aug 1;239(3):805–9

GENETICS

Asymmetry requirements in the photosynthetic reaction center of Rhodobacter capsulatus. Taguchi AK, et al. **Biochemistry** 1996 Mar 12;35(10):3175–86

Regulatory circuits controlling photosynthesis gene expression. Bauer CE, et al. **Cell** 1996 Apr 5;85(1):5–8 (19 ref.)

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron–sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Identification of multiple PEPC isogenes in leaves of the facultative Crassulacean acid metabolism (CAM) plant Kalanchoe blossfeldiana Poelln. cv. Tom Thumb. Gehrig H, et al. **FEBS Lett** 1995 Dec 27;377(3):399–402

Cloning and characterization of senC, a gene involved in both aerobic respiration and photosynthesis gene expression in Rhodobacter capsulatus. Buggy J, et al. **J Bacteriol** 1995 Dec;177(23):6958–65

Control of hemA expression in Rhodobacter sphaeroides 2.4.1: regulation through alterations in the cellular redox state. Zeilstra-Ryalls JH, et al. **J Bacteriol** 1996 Feb; 178(4):985–93

Manipulating photosynthesis in transgenic plants. Knight JS, et al. **Methods Mol Biol** 1995;44:263–80

Directed inactivation of the psbI gene does not affect photosystem II in the cyanobacterium Synechocystis sp. PCC 6803. Ikeuchi M, et al. **Mol Gen Genet** 1995 Dec 20;249(6):622–8

Evolution and expression of C4 photosynthesis genes. Ku MS, et al. **Plant Physiol** 1996 Aug;111(4):949–57 (48 ref.)

PHYSIOLOGY

A perturbed two-level model for exciton trapping in small photosynthetic systems. Somsen OJ, et al. **Biophys J** 1996 Feb;70(2):669–83

WIMOVAC: a software package for modelling the dynamics of plant leaf and canopy photosynthesis. Humphries SW, et al. **Comput Appl Biosci** 1995 Aug;11(4):361–71

Photosynthesis. Regulation by redox signalling. Allen JF, et al. **Curr Biol** 1995 Aug 1;5(8):869–72 (14 ref.)

Oxygenic photosynthesis. Electron transfer in photosystem I and photosystem II. Nugent JH. **Eur J Biochem** 1996 May 1;237(3):519–31 (122 ref.)

Functional effects of structural changes in photosystem II as measured by chlorophyll fluorescence kinetics. Vermaas WF. **Methods Cell Biol** 1995;50:15–30

Photosynthesis: the Z-scheme revised. Prince RC. **Trends Biochem Sci** 1996 Apr;21(4):121–2

RADIATION EFFECTS

Overexpression of glutathione reductase but not glutathione synthetase leads to increases in antioxidant capacity and resistance to photoinhibition in poplar trees. Foyer CH, et al. **Plant Physiol** 1995 Nov;109(3):1047–57

PHOTOSYNTHETIC REACTION CENTER, BACTERIAL

Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191–200 (82 ref.)

BIOSYNTHESIS

Formation of the light-harvesting complex I (B870) of anoxygenic phototrophic purple bacteria. Drews G. **Arch Microbiol** 1996 Sep;166(3):151–9

Heterologous assembly and rescue of stranded phycocyanin subunits by expression of a foreign cpcBA operon in Synechocystis sp. strain 6803. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6804–9

Control of hemA expression in Rhodobacter sphaeroides 2.4.1: regulation through alterations in the cellular redox state. Zeilstra-Ryalls JH, et al. **J Bacteriol** 1996 Feb; 178(4):985–93

The synthesis and assembly of functional high and low light LH2 antenna complexes from Rhodopseudomonas palustris in Rhodobacter sphaeroides. Fowler GJS, et al. **J Biol Chem** 1996 Jun 7;271(23):13356–61

Translational control of puf operon expression in Rhodobacter sphaeroides 2.4.1. Gong L, et al. **Microbiology** 1996 Aug;142 (Pt 8):2057–69

Absence of PsaC subunit allows assembly of photosystem I core but prevents the binding of PsaD and PsaE in Synechocystis sp. PCC6803. Yu J, et al. **Plant Mol Biol** 1995 Oct;29(2):331–42

CHEMISTRY

Isolation, characterization, and functional role of the high-potential iron-sulfur protein (HiPIP) from Rhodoferax fermentans. Hochkoeppler A, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):313–8

Effects of hydrogen bonding to a bacteriochlorophyll-bacteriopheophytin dimer in reaction centers from Rhodobacter sphaeroides. Allen JP, et al. **Biochemistry** 1996 May 28;35(21):6612–9

Time-resolved and steady-state spectroscopic analysis of membrane-bound reaction centers from Rhodobacter sphaeroides: comparisons with detergent-solubilized complexes. Beekman LM, et al. **Biochemistry** 1995 Nov 14;34(45):14712–21

Comparison of the structural requirements for bacteriochlorophyll binding in the core light-harvesting complexes of Rhodospirillum rubrum and Rhodospirillum sphaeroides using reconstitution methodology with bacteriochlorophyll analogs. Davis CM, et al. **Biochemistry** 1996 Mar 5;35(9):3072–84

Electron transfer from the tetraheme cytochrome to the special pair in the Rhodopseudomonas viridis reaction center: effect of mutations of tyrosine L162. Dohse B, et al. **Biochemistry** 1995 Sep 12;34(36):11335–43

Mg coordination by amino acid side chains is not required for assembly and function of the special pair in bacterial photosynthetic reaction centers. Goldsmith JO, et al. **Biochemistry** 1996 Feb 20;35(7):2421–8

Laser-flash kinetic analysis of the fast electron transfer from plastocyanin and cytochrome c6 to photosystem I. Experimental evidence on the evolution of the reaction mechanism. Hervás M, et al. **Biochemistry** 1995 Sep 12; 34(36):11321–6

A comparative thermodynamic analysis by laser-flash absorption spectroscopy of photosystem I reduction by plastocyanin and cytochrome c6 in Anabaena PCC 7119, Synechocystis PCC 6803 and Spinach. Hervás M, et al. **Biochemistry** 1996 Feb 27;35(8):2693–8

Structure and protein binding interactions of the primary donor of the Chloroflexus aurantiacus reaction center. Ivancich A, et al. **Biochemistry** 1996 May 14;35(19):6126–35

Shift of the special pair redox potential: electrostatic energy computations of mutants of the reaction center from Rhodobacter sphaeroides. Muegge I, et al. **Biochemistry** 1996 Jun 25;35(25):8359–70

Highly purified photosynthetic reaction center (PscA/cytochrome c551)2 complex of the green sulfur bacterium Chlorobium limicola. Oh-oka H, et al. **Biochemistry** 1995 Oct 10;34(40):13091–7

The asymmetry of P+ in bacterial reaction centers revealed by circular dichroism spectroscopy. Olson JM, et al. **Biochemistry** 1995 Nov 21;34(46):15230–4

In vivo participation of a high potential iron–sulfur protein as electron donor to the photochemical reaction center of Rubrivivax gelatinosus. Schoepp B, et al. **Biochemistry** 1995 Sep 19;34(37):11736–42

Investigation of the differences in the local protein environments surrounding tyrosine radicals YZ. and YD. in photosystem II using wild-type and the D2-Tyr160Phe mutant of Synechocystis 6803. Tang XS, et al. **Biochemistry** 1996 Feb 6;35(5):1475–84

Time-resolved electrochromism associated with the formation of quinone anions in the Rhodobacter sphaeroides R26 reaction center. Tiede DM, et al. **Biochemistry** 1996 Aug 20;35(33):10763–75

Vibrational dephasing of long- and short-lived primary donor excited states in mutant reaction centers of Rhodobacter sphaeroides. Vos MH, et al. **Biochemistry** 1996 Feb 27;35(8):2687–92

The conformation of the isoprenyl chain relative to the semiquinone head in the primary electron acceptor (QA) of higher plant PSII (plastosemiquinone) differs from that in bacterial reaction centers (ubisemiquinone or menasemiquinone) by ca. 90 degrees. Zheng M, et al. **Biochemistry** 1996 Jul 9;35(27):8955–63

Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)

Excited state dynamics in photosystem I: effects of detergent and excitation wavelength. Hastings G, et al. **Biophys J** 1995 Nov;69(5):2044–55

Energy transfer in spectrally inhomogeneous light-harvesting pigment-protein complexes of purple bacteria. Hess S, et al. **Biophys J** 1995 Dec;69(6):2211–25

Electronic structure of Q-A in reaction centers from Rhodobacter sphaeroides. I. Electron paramagnetic resonance in single crystals. Isaacson RA, et al. **Biophys J** 1995 Aug;69(2):311–22

Femtosecond probe of structural analogies between chlorosomes and bacteriochlorophyll c aggregates. Savikhin S, et al. **Biophys J** 1995 Sep;69(3):1100–4

A mixed-ligand iron-sulfur cluster (C556SPaB or C565SPsaB) in the Fx-binding site leads to a decreased quantum efficiency of electron transfer in photosystem I. Vassiliev IR, et al. **Biophys J** 1995 Oct;69(4):1544–53

Direct observation of sub-picosecond equilibration of excitation energy in the light-harvesting antenna of Rhodospirillum rubrum. Visser HM, et al. **Biophys J** 1995 Sep;69(3):1083–99

Light-harvesting complex. Rings of light. Hunter CN. **Curr Biol** 1995 Aug 1;5(8):826–8

Structure and function of photosystem I. Fromme P. **Curr Opin Struct Biol** 1996 Aug;6(4):473–84 (73 ref.)

Purple bacterial antenna complexes. Fyfe PK, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):467–72 (41 ref.)

Characterization of a redox-active cross-linked complex between cyanobacterial photosystem I and its physiological acceptor flavodoxin. Mühlenhoff U, et al. **EMBO J** 1996 Feb 1;15(3):488–97

Topological analysis of the Rhodobacter capsulatus PucC protein and effects of C-terminal deletions on light-harvesting complex II. LeBlanc HN, et al. **J Bacteriol** 1996 Aug;178(16):4801–6

Subunit interactions and protein stability in the cyanobacterial light-harvesting proteins. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6798–803

Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):275–83 (50 ref.)

Proline in a transmembrane helix compensates for cavities in the photosynthetic reaction center. Schiffer M, et al. **J Mol Biol** 1995 Sep 29;252(4):472–82

Long-range electrostatic interaction in the bacterial photosynthetic reaction centre [letter] Maróti P, et al. **Nat Struct Biol** 1995 Dec;2(12):1057–9

Long-time quantum simulation of the primary charge separation in bacterial photosynthesis. Makri N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3926–31

Potentiation of proton transfer function by electrostatic interactions in photosynthetic reaction centers from Rhodobacter sphaeroides: First results from site-directed mutation of the H subunit. Takahashi E, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2640–5

Context dependence of phenotype prediction and diversity in combinatorial mutagenesis. Delagrave S, et al. **Protein Eng** 1995 Mar;8(3):237–42

Structural model of the photosynthetic reaction center of Rhodobacter capsulatus. Foloppe N, et al. **Proteins** 1995 Jul;22(3):226–44

Similarity of a chromatic adaptation sensor to phytochrome and ethylene receptors. Kehoe DM, et al. **Science** 1996 Sep 6;273(5280):1409–12

Structure and function of bacterial light-harvesting complexes. Kühlbrandt W. **Structure** 1995 Jun 15;3(6):521–5 (17 ref.)

DRUG EFFECTS

The association of different detergents with the photosynthetic reaction center protein of Rhodobacter sphaeroides R26 and the effects on its photochemistry. Gast P, et al. **Eur J Biochem** 1996 Aug 1;239(3):805–9

GENETICS

Deletion of a B800–850 light-harvesting complex in Rhodospirillum molischianum DSM119 leads to "revertants" expressing a B800–820 complex: insights into pigment binding. Sauer PR, et al. **Biochemistry** 1996 May 21;35(20):6500–7

Molecular cloning, DNA sequence and transcriptional analysis of the Rhodospirillum molischianum B800/850 light-harvesting genes. Germeroth L, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):145–50

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron-sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Gene duplication and the evolution of photosynthetic reaction center proteins. Lockhart PJ, et al. **FEBS Lett** 1996 May 6;385(3):193–6

A new mutation in the pufL gene responsible for the terbutryn resistance phenotype in Rubrivivax gelatinosus. Ouchane S, et al. **FEBS Lett** 1995 Oct 23;374(1):130–4

A global signal transduction system regulates aerobic and anaerobic CO2 fixation in Rhodobacter sphaeroides. Qian Y, et al. **J Bacteriol** 1996 Jan;178(1):12–8

Directed mutagenesis of the Rhodobacter capsulatus puhA gene and orf 214: pleiotropic effects on photosynthetic reaction center and light-harvesting 1 complexes. Wong DK, et al. **J Bacteriol** 1996 Apr;178(8):2334–42

Heterologous expression of genes encoding bacterial light-harvesting complexes in Rhodobacter sphaeroides. Fowler GJ, et al. **J Biol Chem** 1995 Oct 6;270(40):23875–82

Directed inactivation of the psbI gene does not affect photosystem II in the cyanobacterium Synechocystis sp. PCC 6803. Ikeuchi M, et al. **Mol Gen Genet** 1995 Dec 20;249(6):622–8

Characterization of psaI and psaL mutants of Synechococcus sp. strain PCC 7002: a new model for state transitions in cyanobacteria. Schluchter WM, et al. **Photochem Photobiol** 1996 Jul;64(1):53–66

Identification of a sequence-specific DNA binding factor required for transcription of the barley chloroplast blue light-responsive psbD-psbC promoter. Kim M, et al. **Plant Cell** 1995 Sep;7(9):1445–57

Targeted inactivation of the gene psaI encoding a subunit of photosystem I of the cyanobacterium Synechocystis sp. PCC 6803. Nakamoto H. **Plant Cell Physiol** 1995 Dec; 36(8):1579–87

Expression of the puf operon in an aerobic photosynthetic bacterium, Roseobacter denitrificans. Nishimura K, et al. **Plant Cell Physiol** 1996 Mar;37(2):153–9

Random chemical mutagenesis of a specific psbDI region coding for a lumenal loop of the D2 protein of photosystem II in Synechocystis sp. PCC 6803. Ermakova-Gerdes S, et al. **Plant Mol Biol** 1996 Jan;30(2):243–54

Over-production of the D1:2 protein makes Synechococcus cells more tolerant to photoinhibition of photosystem II. Soitamo AJ, et al. **Plant Mol Biol** 1996 Feb;30(3):467–78

Light-dependent chlorophyll a biosynthesis upon chlL deletion in wild-type and photosystem I-less strains of the cyanobacterium Synechocystis sp. PCC 6803. Wu Q, et

al. **Plant Mol Biol** 1995 Dec;29(5):933–45
Context dependence of phenotype prediction and diversity in combinatorial mutagenesis. Delagrave S, et al. **Protein Eng** 1995 Mar;8(3):237–42

ISOLATION & PURIFICATION

Co-crystallization and characterization of the photosynthetic reaction center-cytochrome c2 complex from Rhodobacter sphaeroides. Adir N, et al. **Biochemistry** 1996 Feb 27; 35(8):2535–47
Pigment-protein complexes from the photosynthetic membrane of the cyanobacterium Synechocystis sp. PCC 6803. Barbato R, et al. **Eur J Biochem** 1995 Dec 1; 234(2):459–65

METABOLISM

Electron transfer dynamics of Rhodopseudomonas viridis reaction centers with a modified binding site for the accessory bacteriochlorophyll. Arlt T, et al. **Biochemistry** 1996 Jul 16;35(28):9235–44
Role of the PufX protein in photosynthetic growth of Rhodobacter sphaeroides. 2. PufX is required for efficient ubiquinone/ubiquinol exchange between the reaction center QB site and the cytochrome bc1 complex. Barz WP, et al. **Biochemistry** 1995 Nov 21;34(46):15248–58
Binding sites of quinones in photosynthetic bacterial reaction centers investigated by light-induced FTIR difference spectroscopy: symmetry of the carbonyl interactions and close equivalence of the QB vibrations in Rhodobacter sphaeroides and Rhodopseudomonas viridis probed by isotope labeling. Breton J, et al. **Biochemistry** 1995 Sep 12;34(36):11606–16
Comparison of the structural requirements for bacteriochlorophyll binding in the core light-harvesting complexes of Rhodospirillum rubrum and Rhodospirillum sphaeroides using reconstitution methodology with bacteriochlorophyll analogs. Davis CM, et al. **Biochemistry** 1996 Mar 5;35(9):3072–84
Energetics and kinetics of radical pairs in reaction centers from Rhodobacter sphaeroides. A femtosecond transient absorption study. Holzwarth AR, et al. **Biochemistry** 1996 Sep 10;35(36):11820–31
Low-temperature femtosecond-resolution transient absorption spectroscopy of large-scale symmetry mutants of bacterial reaction centers. Lin S, et al. **Biochemistry** 1996 Mar 12;35(10):3187–96
Laser flash absorption spectroscopy study of flavodoxin reduction by photosystem I in Synechococcus sp. PCC 7002. Mühlenhoff U, et al. **Biochemistry** 1996 Feb 6; 35(5):1367–74
Fourier transforms infrared difference spectroscopy of secondary quinone acceptor photoreduction in proton transfer mutants of Rhodobacter sphaeroides. Nabedryk E, et al. **Biochemistry** 1995 Nov 14;34(45):14722–32
Membrane-bound c-type cytochromes in Heliobacillus mobilis. In vivo study of the hemes involved in electron donation to the photosynthetic reaction center. Nitschke W, et al. **Biochemistry** 1995 Sep 19;34(37):11831–9
Pathway of proton transfer in bacterial reaction centers: further investigations on the role of Ser-L223 studied by site-directed mutagenesis. Paddock ML, et al. **Biochemistry** 1995 Dec 5;34(48):15742–50
Site-directed mutagenesis of the CP 47 protein of photosystem II: alteration of conserved charged residues in the domain 364E–444R. Putnam-Evans C, et al. **Biochemistry** 1996 Apr 2;35(13):4046–53
Deletion of a B800–850 light-harvesting complex in Rhodospirillum molischianum DSM119 leads to "revertants" expressing a B800–820 complex: insights into pigment binding. Sauer PR, et al. **Biochemistry** 1996 May 21;35(20):6500–7
Asymmetry requirements in the photosynthetic reaction center of Rhodobacter capsulatus. Taguchi AK, et al. **Biochemistry** 1996 Mar 12;35(10):3175–86
The membrane-bound cytochrome cy of Rhodobacter capsulatus can serve as an electron donor to the photosynthetic reaction of Rhodobacter sphaeroides. Jenney FE Jr, et al. **Biochim Biophys Acta** 1996 Feb 15; 1273(2):159–64
Energy transfer in spectrally inhomogeneous light-harvesting pigment-protein complexes of purple bacteria. Hess S, et al. **Biophys J** 1995 Dec;69(6):2211–25
Nonlinear annihilation of excitations in photosynthetic systems. Valkunas L, et al. **Biophys J** 1995 Sep; 69(3):1117–29
A mixed-ligand iron-sulfur cluster (C556SPaB or C565SPsaB) in the Fx-binding site leads to a decreased quantum efficiency of electron transfer in photosystem I. Vassiliev IR, et al. **Biophys J** 1995 Oct;69(4):1544–53
Direct observation of sub-picosecond equilibration of excitation energy in the light-harvesting antenna of Rhodospirillum rubrum. Visser HM, et al. **Biophys J** 1995 Sep;69(3):1083–99
Electron transport regulates exchange of two forms of photosystem II D1 protein in the cyanobacterium Synechococcus. Campbell D, et al. **EMBO J** 1995 Nov 15;14(22):5457–66
Characterization of a redox active cross-linked complex between cyanobacterial photosystem I and soluble ferredoxin. Lelong C, et al. **EMBO J** 1996 May 1; 15(9):2160–8
Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron-sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33
Characterization of a redox-active cross-linked complex between cyanobacterial photosystem I and its physiological acceptor flavodoxin. Mühlenhoff U, et al. **EMBO J** 1996 Feb 1;15(3):488–97
Stereoselectivity of pigment exchange with 13(2)-hydroxylated tetrapyrroles in reaction centers of Rhodobacter sphaeroides R26. Storch KF, et al. **Eur J Biochem** 1996 May 15;238(1):280–6
Effect of the PufQ protein on early steps in the pathway of bacteriochlorophyll biosynthesis in Rhodobacter capsulatus. Fidai S, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):264–8
Shortcut of the photosynthetic electron transfer in a mutant lacking the reaction center-bound cytochrome subunit by gene disruption in a purple bacterium, Rubrivivax gelatinosus. Nagashima KV, et al. **FEBS Lett** 1996 May 6;385(3):209–13
Femtosecond kinetics of electron transfer in the bacteriochlorophyll(M)-modified reaction centers from Rhodobacter sphaeroides (R-26). Streltsov AM, et al. **FEBS Lett** 1996 Mar 25;383(1–2):129–32
Topological analysis of the Rhodobacter capsulatus PucC protein and effects of C-terminal deletions on light-harvesting complex II. LeBlanc HN, et al. **J Bacteriol** 1996 Aug;178(16):4801–6
Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):275–83 (50 ref.)
Consequences for the organization of reaction center-light harvesting antenna 1 (LH1) core complexes of Rhodobacter sphaeroides arising from deletion of amino acid residues from the C terminus of the LH1 alpha polypeptide. McGlynn P, et al. **J Biol Chem** 1996 Feb 9; 271(6):3285–92
RNase P from a photosynthetic organelle contains an RNA homologous to the cyanobacterial counterpart. Baum M, et al. **J Mol Biol** 1996 Mar 22;257(1):43–52
Kinetics of photo-induced electron transfer from high-potential iron-sulfur protein to the photosynthetic reaction center of the purple phototroph Rhodoferax fermentans. Hochkoeppler A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6998–7002
Potentiation of proton transfer function by electrostatic interactions in photosynthetic reaction centers from Rhodobacter sphaeroides: First results from site-directed mutation of the H subunit. Takahashi E, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2640–5
Structure and function of bacterial light-harvesting complexes. Kühlbrandt W. **Structure** 1995 Jun 15;3(6):521–5 (17 ref.)

PHOTOSYNTHETIC REACTION CENTER, PLANT

Temperature-induced functional and structural transformations of the photosystem II oxygen-evolving complex in spinach subchloroplast preparations. Shutilova N, et al. **Biochem Mol Biol Int** 1995 May;35(6):1233–43
Photosynthesis: the Z-scheme revised. Prince RC. **Trends Biochem Sci** 1996 Apr;21(4):121–2

ANALYSIS

Pigment content of D1-D2-cytochrome b559 reaction center preparations after removal of CP47 contamination: an immunological study. Pueyo JJ, et al. **Biochemistry** 1995 Nov 21;34(46):15214–8

ANTAGONISTS & INHIBITORS

Formation and decay of the S3 EPR signal species in acetate-inhibited photosystem II. Szalai VA, et al. **Biochemistry** 1996 Feb 13;35(6):1946–53
Cu(II)-inhibitory effect on photosystem II from higher plants. A picosecond time-resolved fluorescence study. Yruela I, et al. **Biochemistry** 1996 Jul 23;35(29):9469–74

BIOSYNTHESIS

Light is required for efficient translation elongation and subsequent integration of the D1-protein into photosystem II. van Wijk KJ, et al. **FEBS Lett** 1996 Jun 17; 388(2–3):89–93
The nuclear-encoded chlorophyll-binding photosystem II-S protein is stable in the absence of pigments. Funk C, et al. **J Biol Chem** 1995 Dec 15;270(50):30141–7
In vitro synthesis and assembly of photosystem II core proteins. The D1 protein can be incorporated into photosystem II in isolated chloroplasts and thylakoids. van Wijk KJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25685–95
Altered mRNA binding activity and decreased translational initiation in a nuclear mutant lacking translation of the chloroplast psbA mRNA. Yohn CB, et al. **Mol Cell Biol** 1996 Jul;16(7):3560–6
A nuclear mutant of Arabidopsis with impaired stability on distinct transcripts of the plastid psbB, psbD/C, ndhH, and ndhC operons. Meurer J, et al. **Plant Cell** 1996 Jul; 8(7):1193–207
Absence of PsaC subunit allows assembly of photosystem I core but prevents the binding of PsaD and PsaE in Synechocystis sp. PCC6803. Yu J, et al. **Plant Mol Biol** 1995 Oct;29(2):331–42
Light intensity regulation of cab gene transcription is signaled by the redox state of the plastoquinone pool. Escoubas JM, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10237–41

CHEMISTRY

Light-induced charge separation between plastocyanin and the iron-sulfur clusters FA and FB in the complex of plastocyanin and photosystem I. Hippler M, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):414–8
Structure of photosystem II in spinach thylakoid membranes: comparison of detergent-solubilized and native complexes by electron microscopy. Nicholson WV, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):543–7
Assembly of the tetra-Mn site of photosynthetic water oxidation by photoactivation: Mn stoichiometry and detection of a new intermediate. Ananyev GM, et al. **Biochemistry** 1996 Apr 2;35(13):4102–9
Structural flexibility of chiral macroaggregates of light-harvesting chlorophyll a/b pigment-protein complexes. Light-induced reversible structural changes associated with energy dissipation. Barzda V, et al. **Biochemistry** 1996 Jul 9;35(27):8981–5
Cold-sensitive assembly of a mutant manganese-stabilizing protein caused by a Val to Ala replacement. Betts SD, et al. **Biochemistry** 1996 May 21;35(20):6302–7
Conformational changes induced by phosphorylation in the CP29 subunit of photosystem II. Croce R, et al. **Biochemistry** 1996 Aug 27;35(34):11142–8
Excited state equilibration in the photosystem I-light-harvesting I complex: P700 is almost isoenergetic with its antenna. Croce R, et al. **Biochemistry** 1996 Jul 2; 35(26):8572–9
ESEEM study of the plastoquinone anion radical ($QA.^-$) in 14N- and 15N-labeled photosystem II treated with CN. Deligiannakis Y, et al. **Biochemistry** 1995 Dec 12; 34(49):16030–8
Spin-lattice relaxation of the pheophytin, Pheo-, radical of photosystem II. Deligiannakis Y, et al. **Biochemistry** 1996 Sep 3;35(35):11239–46
Interactions between diphenylcarbazide, zinc, cobalt, and manganese on the oxidizing side of photosystem II. Ghirardi ML, et al. **Biochemistry** 1996 Feb 13;35(6):1820–8
Mutagenesis of photosystem I in the region of the ferredoxin cross-linking site: modifications of positively charged amino acids. Hanley J, et al. **Biochemistry** 1996 Jul 2; 35(26):8563–71
A comparative thermodynamic analysis by laser-flash absorption spectroscopy of photosystem I reduction by plastocyanin and cytochrome c6 in Anabaena PCC 7119, Synechocystis PCC 6803 and Spinach. Hervás M, et al. **Biochemistry** 1996 Feb 27;35(8):2693–8
Spectroscopic characterization of intermediate steps involved in donor-side-induced photoinhibition of photosystem II. Jegerschöld C, et al. **Biochemistry** 1996 Jun 18; 35(24):7794–801
Analysis of the absorption spectrum of photosystem II reaction centers: temperature dependence, pigment assignment, and inhomogeneous broadening. Konermann L, et al. **Biochemistry** 1996 Jan 23;35(3):829–42
Interaction of the 33 kDa extrinsic protein with photosystem II: rebinding of the 33 kDa extrinsic protein to photosystem II membranes which contain four, two, or zero manganese per photosystem II reaction center. Leuschner C, et al. **Biochemistry** 1996 Apr 9;35(14):4551–7
Photosystem II of green plants: topology of core pigments and redox cofactors as inferred from electrochromic difference spectra. Mulkidjanian AY, et al. **Biochemistry** 1996 Mar 5;35(9):3093–107
Pigment quantitation and analysis by HPLC reverse phase chromatography: a characterization of antenna size in oxygen-evolving photosystem II preparations from cyanobacteria and plants. Patzlaff JS, et al. **Biochemistry** 1996 Jun 18;35(24):7802–11
Induction of luminol chemiluminescence by the manganese cluster of the photosystem II water-oxidizing complex to the S0, S1, S2, and S3 states. Putrenko II. **Biochemistry** 1996 Mar 5;35(9):2865–71
ENDOR and special TRIPLE resonance spectroscopy of QA.- of photosystem 2. Rigby SE, et al. **Biochemistry** 1995 Sep 19;34(37):12075–81
ENDOR and special triple resonance spectroscopy of A1.- of photosystem 1. Rigby SE, et al. **Biochemistry** 1996 May 28;35(21):6651–6
Site-directed mutagenesis of the subunit PsaC establishes a surface-exposed domain interacting with the photosystem I core binding site. Rodday SM, et al. **Biochemistry** 1996 Sep 10;35(36):11832–8
Formation and decay of the S3 EPR signal species in acetate-inhibited photosystem II. Szalai VA, et al. **Biochemistry** 1996 Feb 13;35(6):1946–53
Investigation of the differences in the local protein environments surrounding tyrosine radicals YZ. and YD. in photosystem II using wild-type and the D2-Tyr160Phe mutant of Synechocystis 6803. Tang XS, et al. **Biochemistry** 1996 Feb 6;35(5):1475–84
245 GHz high-field EPR study of tyrosine-D zero and tyrosine-Z zero in mutants of photosystem II. Un S, et

al. **Biochemistry** 1996 Jan 23;35(3):679–84

Properties of the chloride-depleted oxygen-evolving complex of photosystem II studied by electron paramagnetic resonance. van Vliet P, et al. **Biochemistry** 1996 Feb 13;35(6):1829–39

The conformation of the isoprenyl chain relative to the semiquinone head in the primary electron acceptor (QA) of higher plant PSII (plastosemiquinone) differs from that in bacterial reaction centers (ubisemiquinone or menasemiquinone) by ca. 90 degrees. Zheng M, et al. **Biochemistry** 1996 Jul 9;35(27):8955–63

Functional reconstitution of photosystem II with recombinant manganese-stabilizing proteins containing mutations that remove the disulfide bridge. Betts SD, et al. **Biochim Biophys Acta** 1996 Jun 13;1274(3):135–42

Chemical platinization and its effect on excitation transfer dynamics and P700 photooxidation kinetics in isolated photosystem I. Lee JW, et al. **Biophys J** 1995 Aug; 69(2):652–9

Nonlinear polarization spectroscopy in the frequency domain of light-harvesting complex II: absorption band substructure and exciton dynamics. Lokstein H, et al. **Biophys J** 1995 Oct;69(4):1536–43

Chlorophyll a and carotenoid triplet states in light-harvesting complex II of higher plants. Peterman EJ, et al. **Biophys J** 1995 Dec;69(6):2670–8

Structure and function of photosystem I. Fromme P. **Curr Opin Struct Biol** 1996 Aug;6(4):473–84 (73 ref.)

Exciton delocalization in the antenna of purple bacteria: exciton spectrum calculations using Z-ray data and experimental site inhomogeneity. Dracheva TV, et al. **FEBS Lett** 1996 May 27;387(1):81–4

Correlated behavior of the EPR signal of cytochrome b-559 heme Fe(III) ligated by OH- and the multiline signal of the Mn cluster in PS-II membrane fragments. Fiege R, et al. **FEBS Lett** 1996 May 27;387(1):33–5

High-specific binding of Fe(II) at the Mn-binding site in Mn-depleted PSII membranes from spinach. Semin BK, et al. **FEBS Lett** 1995 Nov 20;375(3):223–6

Identification of Fourier transform infrared signals from the non-heme iron in photosystem II. Noguchi T, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):9–12

Characterization of the light-induced cross-linking of the alpha-subunit of cytochrome b559 and the D1 protein in isolated photosystem II reaction centers. Barbato R, et al. **J Biol Chem** 1995 Oct 13;270(41):24032–7

Mutational analysis of photosystem I polypeptides. Role of PsaD and the lysyl 106 residue in the reductase activity of the photosystem I. Chitnis VP, et al. **J Biol Chem** 1996 May 17;271(20):11772–80

Comparison of primary charge separation in the photosystem II reaction center complex isolated from wild-type and D1-130 mutants of the cyanobacterium Synechocystis PCC 6803. Giorgi LB, et al. **J Biol Chem** 1996 Jan 26; 271(4):2093–101

Reconstitution of barley photosystem I with modified PSI-C allows identification of domains interacting with PSI-D and PSI-A/B. Naver H, et al. **J Biol Chem** 1996 Apr 12; 271(15):8996–9001

Two-dimensional crystals of photosystem II: biochemical characterization, cryoelectron microscopy and localization of the D1 and cytochrome b559 polypeptides. Marr KM, et al. **J Cell Biol** 1996 Mar;132(5):823–33

Two-dimensional crystallization and cryo-electron microscopy of photosystem II. Nakazato K, et al. **J Mol Biol** 1996 Mar 29;257(2):225–32

Tyrosyl radicals in photosystem II. Barry BA. **Methods Enzymol** 1995;258:303–19

Picture story. Jellyroll boat. Riddihough G. **Nat Struct Biol** 1996 Aug;3(8):675

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661–9 (35 ref.)

Light-harvesting chlorophyll a/b-binding protein inserted into isolated thylakoids binds pigments and is assembled into trimeric light-harvesting complex. Kuttkat A, et al. **Plant Physiol** 1995 Dec;109(4):1267–76

Proximity of the manganese cluster of photosystem II to the redox-active tyrosine YZ. Gilchrist ML Jr, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9545–9

Predicting the structure of the light-harvesting complex II of Rhodospirillum molischianum. Hu X, et al. **Protein Sci** 1995 Sep;4(9):1670–82

Comparative immunological detection of lipids and carotenoids on peptides of photosystem I from higher plants and cyanobacteria. Makewicz A, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5–6):319–28

DRUG EFFECTS

Changes in the levels of photosynthetic pigments in Phaseolus aureus Roxb. exposed to Hg and Cd at two stages of development: a comparative study. Shaw BP. **Bull Environ Contam Toxicol** 1995 Oct;55(4):574–80

GENETICS

Cold-sensitive assembly of a mutant manganese-stabilizing protein caused by a Val to Ala replacement. Betts SD, et al. **Biochemistry** 1996 May 21;35(20):6302–7

An independent role of cytochrome c-550 in cyanobacterial photosystem II as revealed by double-deletion mutagenesis of the psbO and psbV genes in Synechocystis sp. PCC 6803. Shen JR, et al. **Biochemistry** 1995 Oct 3; 34(39):12661–8

Isolation of a psaF-deficient mutant of Chlamydomonas reinhardtii: efficient interaction of plastocyanin with the photosystem I reaction center is mediated by the PsaF subunit. Farah J, et al. **EMBO J** 1995 Oct 16;14(20):4976–84

Cis-acting elements and trans-acting factors for accurate translation of chloroplast psbA mRNAs: development of an in vitro translation system from tobacco chloroplasts. Hirose T, et al. **EMBO J** 1996 Apr 1;15(7):1687–95

Reconstitution and pigment-binding properties of recombinant CP29. Giuffra E, et al. **Eur J Biochem** 1996 May 15;238(1):112–20

An Arabidopsis thaliana cDNA encoding PS II-X, a 4.1 kDa component of photosystem II: a bipartite presequence mediates SecA/delta pH-independent targeting into thylakoids. Kim SJ, et al. **FEBS Lett** 1996 Jul 22; 390(2):175–8

Gene duplication and the evolution of photosynthetic reaction center proteins. Lockhart PJ, et al. **FEBS Lett** 1996 May 6;385(3):193–6

Molecular studies of CtpA, the carboxyl-terminal processing protease for the D1 protein of the photosystem II reaction center in higher plants. Oelmüller R, et al. **J Biol Chem** 1996 Sep 6;271(36):21848–52

Selection on the codon bias of Chlamydomonas reinhardtii chloroplast genes and the plant psbA gene. Morton BR. **J Mol Evol** 1996 Jul;43(1):28–31

A generalized epistasis analysis as a method of reconstruction of developmental process and its application to Drosophila dorso-ventral axis formation. Takeda Y. **J Theor Biol** 1995 Sep 7;176(1):47–58

Alterations in chlorophyll a/b binding proteins in Solanaceae cybrids. Babiychuk E, et al. **Mol Gen Genet** 1995 Dec 20; 249(6):648–54

Detection of point mutations in chloroplast genes of Antirrhinum majus L. I. Identification of a point mutation in the psaB gene of a photosystem I plastome mutant. Schaffner C, et al. **Mol Gen Genet** 1995 Dec 15; 249(5):533–44

Site-directed mutagenesis and analysis of second-site revertants indicates a requirement for C-terminal amino acids of PsaB for stable assembly of the photosystem I reaction center complex in Chlamydomonas reinhardtii. Lee H, et al. **Photochem Photobiol** 1996 Jul;64(1):46–52

Characterization of psaI and psaL mutants of Synechococcus sp. strain PCC 7002: a new model for state transitions in cyanobacteria. Schluchter WM, et al. **Photochem Photobiol** 1996 Jul;64(1):53–66

A DNA binding activity for one of two closely defined phytochrome regulatory elements in an Lhcb promoter is more abundant in etiolated than in green plants. Degenhardt J, et al. **Plant Cell** 1996 Jan;8(1):31–41

Identification of a sequence-specific DNA binding factor required for transcription of the barley chloroplast blue light-responsive psbD-psbC promoter. Kim M, et al. **Plant Cell** 1995 Sep;7(9):1445–57

A nuclear mutant of Arabidopsis with impaired stability on distinct transcripts of the plastid psbB, psbD/C, ndhH, and ndhC operons. Meurer J, et al. **Plant Cell** 1996 Jul; 8(7):1193–207

Tobacco nuclear genes for Photosystem I subunits, psaD, psaE and psaH share an octamer motif bound with nuclear proteins. Nakamura M, et al. **Plant Cell Physiol** 1995 Oct; 36(7):1393–7

Genetic engineering of the processing site of D1 precursor protein of photosystem II reaction center in Chlamydomonas reinhardtii. Takahashi Y, et al. **Plant Cell Physiol** 1996 Mar;37(2):161–8

Characterization of a cDNA clone encoding 23 kDa polypeptide of the oxygen-evolving complex of photosystem II in rice. Yoshiba Y, et al. **Plant Cell Physiol** 1995 Dec;36(8):1677–82

Random chemical mutagenesis of a specific psbDI region coding for a lumenal loop of the D2 protein of photosystem II in Synechocystis sp. PCC 6803. Ermakova-Gerdes S, et al. **Plant Mol Biol** 1996 Jan;30(2):243–54

RNA-binding proteins of 37/38 kDa bind specifically to the barley chloroplast psbA 3'-end untranslated RNA. Memon AR, et al. **Plant Mol Biol** 1996 Mar;30(6):1195–205

Molecular study of a light-harvesting apoprotein of Giraudyopsis stellifer (Chrysophyceae). Passaquet C, et al. **Plant Mol Biol** 1995 Oct;29(1):135–48

Over-production of the D1:2 protein makes Synechococcus cells more tolerant to photoinhibition of photosystem II. Soitamo AJ, et al. **Plant Mol Biol** 1996 Feb;30(3):467–78

Developmental and light-regulated expression of individual members of the light-harvesting complex b gene family in Pinus palustris. Peer W, et al. **Plant Physiol** 1996 Jun; 111(2):627–34

ISOLATION & PURIFICATION

Pigment content of D1-D2-cytochrome b559 reaction center preparations after removal of CP47 contamination: an immunological study. Pueyo JJ, et al. **Biochemistry** 1995 Nov 21;34(46):15214–8

Isolation and characterization of a Photosystem II complex from the red alga Cyanidium caldarium: association of cytochrome c-550 and a 12 kDa protein with the complex. Enami I, et al. **Biochim Biophys Acta** 1995 Dec 12; 1232(3):208–16

Two-dimensional crystals of photosystem II: biochemical characterization, cryoelectron microscopy and localization of the D1 and cytochrome b559 polypeptides. Marr KM, et al. **J Cell Biol** 1996 Mar;132(5):823–33

METABOLISM

Electron donation to photosystem II by diphenylcarbazide is inhibited both by the endogenous manganese complex and by exogenous manganese ions. Rashid A, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):241–5

Assembly of the tetra-Mn site of photosynthetic water oxidation by photoactivation: Mn stoichiometry and detection of a new intermediate. Ananyev GM, et al. **Biochemistry** 1996 Apr 2;35(13):4102–9

Assembly of light-harvesting chlorophyll a/b complex in vitro. Time-resolved fluorescence measurements. Booth PJ, et al. **Biochemistry** 1996 Apr 23;35(16):5103–8

Conversion of the spin state of the manganese complex in photosystem II induced by near-infrared light. Boussac A, et al. **Biochemistry** 1996 Jun 4;35(22):6984–9

Calcium modulates the photoassembly of photosystem II (Mn)4-clusters by preventing ligation of nonfunctional high-valency states of manganese. Chen C, et al. **Biochemistry** 1995 Oct 17;34(41):13511–26

Conformational changes induced by phosphorylation in the CP29 subunit of photosystem II. Croce R, et al. **Biochemistry** 1996 Aug 27;35(34):11142–8

ESEEM study of the plastoquinone anion radical (QA.--) in 14N- and 15N-labeled photosystem II treated with CN. Deligiannakis Y, et al. **Biochemistry** 1995 Dec 12; 34(49):16030–8

State transitions or delta pH-dependent quenching of photosystem II fluorescence in red algae. Delphin E, et al. **Biochemistry** 1996 Jul 23;35(29):9435–45

Binding dynamics and electron transfer between plastocyanin and photosystem I. Drepper F, et al. **Biochemistry** 1996 Jan 30;35(4):1282–95

Universality of energy and electron transfer processes in photosystem I. Hastings G, et al. **Biochemistry** 1995 Nov 28;34(47):15512–22

Photoaccumulation in photosystem I does produce a phylloquinone (A1.-) radical. Heathcote P, et al. **Biochemistry** 1996 May 28;35(21):6644–50

Bicarbonate binding to the non-heme iron of photosystem II investigated by Fourier transform infrared difference spectroscopy and 13C-labeled bicarbonate. Hienerwadel R, et al. **Biochemistry** 1995 Dec 19;34(50):16288–97

Copper(II) inhibition of electron transfer through photosystem II studied by EPR spectroscopy. Jegerschöld C, et al. **Biochemistry** 1995 Oct 3;34(39):12747–54

Degradation of the D1- and D2-proteins of photosystem II in higher plants is regulated by reversible phosphorylation. Koivuniemi A, et al. **Biochemistry** 1995 Dec 12;34(49):16022–9

Reconstitution of the endogenous plastoquinone pool in photosystem II (PS II) membrane fragments, inside-out-vesicles, and PS II core complexes from spinach. Kurreck J, et al. **Biochemistry** 1995 Dec 5; 34(48):15721–31

Interaction of the 33 kDa extrinsic protein with photosystem II: rebinding of the 33 kDa extrinsic protein to photosystem II membranes which contain four, two, or zero manganese per photosystem II reaction center. Leuschner C, et al. **Biochemistry** 1996 Apr 9;35(14):4551–7

Laser flash absorption spectroscopy study of flavodoxin reduction by photosystem I in Synechococcus sp. PCC 7002. Mühlenhoff U, et al. **Biochemistry** 1996 Feb 6; 35(5):1367–74

Induction of luminol chemiluminescence by the manganese cluster of the photosystem II water-oxidizing complex to the S0, S1, S2, and S3 states. Putrenko II. **Biochemistry** 1996 Mar 5;35(9):2865–71

ENDOR and special triple resonance spectroscopy of A1.- of photosystem 1. Rigby SE, et al. **Biochemistry** 1996 May 28;35(21):6651–6

Dynamic properties of the minor chlorophyll a/b binding proteins of photosystem II, an in vitro model for photoprotective energy dissipation in the photosynthetic membrane of green plants. Ruban AV, et al. **Biochemistry** 1996 Jan 23;35(3):674–8

Structural dynamics in the plastocyanin-photosystem 1 electron-transfer complex as revealed by mutant studies. Sigfridsson K, et al. **Biochemistry** 1996 Jan 30;35(4):1249–57

Nonlinear annihilation of excitations in photosynthetic systems. Valkunas L, et al. **Biophys J** 1995 Sep; 69(3):1117–29

Electron transport regulates exchange of two forms of photosystem II D1 protein in the cyanobacterium Synechococcus. Campbell D, et al. **EMBO J** 1995 Nov 15;14(22):5457–66

Isolation of a psaF-deficient mutant of Chlamydomonas reinhardtii: efficient interaction of plastocyanin with the photosystem I reaction center is mediated by the PsaF subunit. Farah J, et al. **EMBO J** 1995 Oct 16;14(20):4976–84

Biochemical and functional properties of photosystem II in agranal membranes from maize mesophyll and bundle sheath chloroplasts. Bassi R, et al. **Eur J Biochem** 1995 Nov 1;233(3):709–19

Reconstitution and pigment-binding properties of recombinant CP29. Giuffra E, et al. **Eur J Biochem** 1996 May 15;238(1):112–20

Interaction between photosystem I and flavodoxin from the cyanobacterium Synechococcus sp. PCC 7002 as revealed by chemical cross-linking. Mühlenhoff U, et al.

Eur J Biochem 1996 Jan 15;235(1-2):324-31

Carotene desaturation is linked to a respiratory redox pathway in Narcissus pseudonarcissus chromoplast membranes. Involvement of a 23-kDa oxygen-evolving-complex-like protein. Nievelstein V, et al. **Eur J Biochem** 1995 Nov 1;233(3):864-72

Impaired photosystem II in a mutant of Chlamydomonas reinhardtii defective in sulfoquinovosyl diacylglycerol. Sato N, et al. **Eur J Biochem** 1995 Nov 15;234(1):16-23

Unassembled subunits of the photosynthetic oxygen-evolving complex present in the thylakoid lumen are long-lived and assembly-competent. Hashimoto A, et al. **FEBS Lett** 1996 Aug 5;391(1-2):29-34

Effects of hydrogen/deuterium exchange on photosynthetic water cleavage in PS II core complexes from spinach. Karge M, et al. **FEBS Lett** 1996 Jan 8;378(2):140-4

An Arabidopsis thaliana cDNA encoding PS II-X, a 4.1 kDa component of photosystem II: a bipartite presequence mediates SecA/delta pH-independent targeting into thylakoids. Kim SJ, et al. **FEBS Lett** 1996 Jul 22; 390(2):175-8

Isolation and properties of PS II membrane fragments depleted of the non heme iron center. Kurreck J, et al. **FEBS Lett** 1996 Feb 26;381(1-2):53-7

Donor-side photoinhibition in photosystem II from Chlamydomonas reinhardtii upon mutation of tyrosine-Z in the D1 polypeptide to phenylalanine. Minagawa J, et al. **FEBS Lett** 1996 Jul 1;389(2):199-202

Novel amplification of non-photochemical chlorophyll fluorescence quenching following viral infection in Chlorella. Seaton GG, et al. **FEBS Lett** 1996 Jul 8; 389(3):319-23

High-specific binding of Fe(II) at the Mn-binding site in Mn-depleted PSII membranes from spinach. Semin BK, et al. **FEBS Lett** 1995 Nov 20;375(3):223-6

Site-directed mutagenetic study on the role of negative patches on silene plastocyanin in the interactions with cytochrome f and photosystem I. Lee BH, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1209-17

Characterization of the light-induced cross-linking of the alpha-subunit of cytochrome b559 and the D1 protein in isolated photosystem II reaction centers. Barbato R, et al. **J Biol Chem** 1995 Oct 13;270(41):24032-7

Role of the RCII-D1 protein in the reversible association of the oxygen-evolving complex proteins with the lumenal side of photosystem II. Eisenberg-Domovich Y, et al. **J Biol Chem** 1995 Dec 15;270(50):30181-6

Occupation of the QB-binding pocket by a photosystem II inhibitor triggers dark cleavage of the D1 protein subjected to brief preillumination. Nakajima Y, et al. **J Biol Chem** 1996 Jul 19;271(29):17383-9

Molecular studies of CtpA, the carboxyl-terminal processing protease for the D1 protein of the photosystem II reaction center in higher plants. Oelmüller R, et al. **J Biol Chem** 1996 Sep 6;271(36):21848-52

Differential D1 dephosphorylation in functional and photodamaged photosystem II centers. Dephosphorylation is a prerequisite for degradation of damaged D1. Rintamäki E, et al. **J Biol Chem** 1996 Jun 21;271(25):14870-5

Kinetic resolution of the incorporation of the D1 protein into photosystem II and localization of assembly intermediates in thylakoid membranes of spinach chloroplasts. van Wijk KJ, et al. **J Biol Chem** 1996 Apr 19;271(16):9627-36

In vitro synthesis and assembly of photosystem II core proteins. The D1 protein can be incorporated into photosystem II in isolated chloroplasts and thylakoids. van Wijk KJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25685-95

A new chloroplast protein import intermediate reveals distinct translocation machineries in the two envelope membranes: energetics and mechanistic implications. Scott SV, et al. **J Cell Biol** 1996 Jan;132(1-2):63-75

RNase P from a photosynthetic organelle contains an RNA homologous to the cyanobacterial counterpart. Baum M, et al. **J Mol Biol** 1996 Mar 22;257(1):43-52

Tyrosyl radicals in photosystem II. Barry BA. **Methods Enzymol** 1995;258:303-19

Carboxyl-terminal processing protease for the D1 precursor protein: cloning and sequencing of the spinach cDNA. Inagaki N, et al. **Plant Mol Biol** 1996 Jan;30(1):39-50

On the role of the N-terminus of the extrinsic 33 kDa protein of Photosystem II. Seidler A, et al. **Plant Mol Biol** 1996 Apr;31(1):183-8

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661-9 (35 ref.)

Degradation pattern of photosystem II reaction center protein D1 in intact leaves. The major photoinhibition-induced cleavage site in D1 polypeptide is located amino terminally of the DE loop. Kettunen R, et al. **Plant Physiol** 1996 Aug;111(4):1183-90

Light-harvesting chlorophyll a/b-binding protein inserted into isolated thylakoids binds pigments and is assembled into trimeric light-harvesting complex. Kuttkat A, et al. **Plant Physiol** 1995 Dec;109(4):1267-76

The precursor of PsaD assembles into the photosystem I complex in two steps. Minai L, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6338-42

The role of phosphatidylglycerol as a functional effector and membrane anchor of the D1-core peptide from photosystem II-particles of the cyanobacterium Oscillatoria chalybea. Kruse O, et al. **Z Naturforsch [C]** 1995 May-Jun;50(5-6):380-90

RADIATION EFFECTS

Light-induced charge separation between plastocyanin and the iron-sulfur clusters FA and FB in the complex of plastocyanin and photosystem I. Hippler M, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):414-8

Structural flexibility of chiral macroaggregates of light-harvesting chlorophyll a/b pigment-protein complexes. Light-induced reversible structural changes associated with energy dissipation. Barzda V, et al. **Biochemistry** 1996 Jul 9;35(27):8981-5

Spectroscopic characterization of intermediate steps involved in donor-side-induced photoinhibition of photosystem II. Jegerschöld C, et al. **Biochemistry** 1996 Jun 18; 35(24):7794-801

UV-B-induced inhibition of photosystem II electron transport studied by EPR and chlorophyll fluorescence. Impairment of donor and acceptor side components. Vass I, et al. **Biochemistry** 1996 Jul 9;35(27):8964-73

Functional and structural changes of the photosystem II complex induced by high irradiance in cyanobacterial cells. Komenda J, et al. **Eur J Biochem** 1995 Oct 15;233(2):677-82

ULTRASTRUCTURE

Structure of photosystem II in spinach thylakoid membranes: comparison of detergent-solubilized and native complexes by electron microscopy. Nicholson WV, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):543-7

Tubular crystals of a photosystem II core complex. Tsiotis G, et al. **J Mol Biol** 1996 Jun 7;259(2):241-8

PHOTOSYSTEM I REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOSYSTEM II REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOTHERAPY

Fibreoptic phototherapy in the management of jaundice in low birthweight neonates. Donzelli GP, et al. **Acta Paediatr** 1996 Mar;85(3):366-70

Phototherapy for neonatal jaundice. Tan KL. **Acta Paediatr** 1996 Mar;85(3):277-9

The impact of phototherapy in the management of neonatal hyperbilirubinemia: comparison of historical cohorts. Valaes T, et al. **Acta Paediatr** 1996 Mar;85(3):273-6

Melatonin in light treatment of patients with seasonal and nonseasonal depression. Thalén BE, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):274-84

Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Lam RW, et al. **Arch Gen Psychiatry** 1996 Jan;53(1):41-4

Predicting the need for phototherapy in healthy mature neonates using transcutaneous bilirubinometry on the first postnatal day. Knudsen A. **Biol Neonate** 1995;68(6):398-403

Influence of phototherapy treatment duration for seasonal affective disorder: outcome at one vs. two weeks. Labbate LA, et al. **Biol Psychiatry** 1995 Dec 1;38(11):747-50

Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Neumeister A, et al. **Biol Psychiatry** 1996 Jan 1;39(1):16-21

Clinical and chronobiological effects of light therapy on nonseasonal affective disorders. Yamada N, et al. **Biol Psychiatry** 1995 Jun 15;37(12):866-73

Light treatment for NASA shiftworkers. Stewart KT, et al. **Chronobiol Int** 1995 Apr;12(2):141-51

Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma. Tong MC, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):189-92

Influence of photoisomers in bilirubin determinations on Kodak Ektachem and Hitachi analysers in neonatal specimens study of the contribution of structural and configurational isomers. Gulian JM, et al. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):503-12

Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers. Dellian M, et al. **Int J Cancer** 1996 Jan 17;65(2):246-8

Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. Alster TS, et al. **J Am Acad Dermatol** 1996 Jul;35(1):79-81

The effects of bright light treatment on the symptoms of fibromyalgia. Pearl SJ, et al. **J Rheumatol** 1996 May; 23(5):896-902

Double-blind, placebo-controlled investigation of the effect of combined phototherapy/low intensity laser therapy upon experimental ischaemic pain in humans. Mokhtar B, et al. **Lasers Surg Med** 1995;17(1):74-81

Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Constantinescu CS. **Med Hypotheses** 1995 Nov;45(5):455-8 (38 ref.)

A mechanism of action underlying the antidepressant effect of light. Partonen T. **Med Hypotheses** 1995 Jul;45(1):33-4

Use of eyepatches in phototherapy: effects on conjunctival bacterial pathogens and conjunctivitis. Fok TF, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1091-4

Why use homeopathic doses of phototherapy? Maisels MJ. **Pediatrics** 1996 Aug;98(2 Pt 1):283-7

Is phototherapy safe for HIV-infected individuals? Adams ML, et al. **Photochem Photobiol** 1996 Aug;64(2):234-7 (41 ref.)

PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267-8 (11 ref.)

A new optimal wavelength for treatment of port wine stains? Kienle A, et al. **Phys Med Biol** 1995 Oct;40(10):1559-76

Observed behavior of patients with seasonal affective disorder and an interviewer predicts response to light treatment. Geerts E, et al. **Psychiatry Res** 1995 Aug 28; 57(3):223-30

Effect of bright light treatment on agitated behavior in institutionalized elderly subjects. Lovell BB, et al. **Psychiatry Res** 1995 Jun 29;57(1):7-12

Effect of light therapy on salivary melatonin in seasonal affective disorder. Rice J, et al. **Psychiatry Res** 1995 Apr 28;56(3):221-8

The influence of comorbid disorders and of continuation light treatment on remission and recurrence in winter depression. Partonen T, et al. **Psychopathology** 1995;28(5):256-62

[Phototherapy of atopic dermatitis] Marguery MC, et al. **Ann Dermatol Venereol** 1995;122(10):729-34 (27 ref.) **(Fre)**

[Phototherapy in psychiatry: clinical update and review of indications] Gross F, et al. **Encephale** 1996 Mar-Apr; 22(2):143-8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Seasonal affective syndrome and phototherapy: theoretical concepts and clinical applications] Sartori S, et al. **Encephale** 1996 Jan-Feb;22(1):7-16 (59 ref.) (Eng. Abstr.) **(Fre)**

[Case report: treatment of a patient with sleep phase advance disorder with phototherapy] Voderholzer U, et al. **Wien Med Wochenschr** 1995;145(17-18):470-2 (Eng. Abstr.) **(Ger)**

[The action of high-intensity light on catecholamine excretion in depressive patients] Bozhko GKh, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):58-60 (Eng. Abstr.) **(Rus)**

[Light therapy is effective against seasonal depression] Nystrand A. **Lakartidningen** 1996 Sep 4;93(36):3049 **(Swe)**

ADVERSE EFFECTS

Localized chrysiasis induced by laser therapy. Trotter MJ, et al. **Arch Dermatol** 1995 Dec;131(12):1411-4

Malignant melanoma in situ in a Japanese psoriatic patient treated with phototherapy [letter] Kikuchi-Numagami K, et al. **Int J Dermatol** 1996 Mar;35(3):225-6

Bilirubin phototoxicity to human cells by green light phototherapy in vitro. Böhm F, et al. **Photochem Photobiol** 1995 Dec;62(6):980-3

[Bullous eruptions induced by phototherapy] Jeanmougin M. **Ann Dermatol Venereol** 1995;122(3):124-8 (36 ref.) **(Fre)**

CONTRAINDICATIONS

[Lupus and sunlight] Lacour JP. **Rev Med Interne** 1995;16 Suppl 3:342s-3s **(Fre)**

INSTRUMENTATION

Fiberoptic phototherapy systems. **Health Devices** 1995 Dec; 24(12):496-8

METHODS

Effectiveness of the light visor [letter; comment] Wallace G. **Am J Psychiatry** 1996 Aug;153(8):1110-1. Comment on: Am J Psychiatry 1995 Aug;152(8):1197-202.

'Natural' light treatment of seasonal affective disorder. Wirz-Justice A, et al. **J Affect Disord** 1996 Apr 12; 37(2-3):109-20

Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. Zelickson BD, et al. **J Am Acad Dermatol** 1996 Jul;35(1):64-8

A controlled comparison of light box and head-mounted units in the treatment of seasonal depression. Levitt AJ, et al. **J Clin Psychiatry** 1996 Mar;57(3):105-10

[Light therapy in 3 children with winter depression] Meesters Y. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2664-6 (Eng. Abstr.) **(Dut)**

[Light therapy can restore a disturbed sleep/wake rhythm in dementia: but what is the basis of its efficacy?] Beullens J. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):264-9 (40 ref.) (Eng. Abstr.) **(Dut)**

[Melatonin excretion in patients with depression under the action of light of increased intensity] Bozhko GKh, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):51-3 (Eng. Abstr.) **(Rus)**

[Lateral photo-color therapy in the combined ambulatory treatment of mental disorders] Marstenkovs'kyĭ IA. **Lik Sprava** 1995 Jul-Aug;(7-8):111-3, 193 (Eng. Abstr.) **(Ukr)**

STANDARDS

Phototherapy units in Brazil: are they effective? De Carvalho M, et al. **J Perinat Med** 1995;23(4):315-9

PHOTOTOXICITY see **DERMATITIS, PHOTOTOXIC**

PHOTOTROPHIC BACTERIA

CHEMISTRY

Isolation, characterization, and functional role of the

high-potential iron-sulfur protein (HiPIP) from Rhodoferax fermentans. Hochkoeppler A, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):313-8

CP-MAS 13C-NMR dipolar correlation spectroscopy of 13C-enriched chlorosomes and isolated bacteriochlorophyll c aggregates of Chlorobium tepidum: the self-organization of pigments is the main structural feature of chlorosomes. Balaban TS, et al. **Biochemistry** 1995 Nov 21;34(46):15259-66

Influence of charge and polarity on the redox potentials of high-potential iron-sulfur proteins: evidence for the existence of two groups. Heering HA, et al. **Biochemistry** 1995 Nov 14;34(45):14675-86

Structure and protein binding interactions of the primary donor of the Chloroflexus aurantiacus reaction center. Ivancich A, et al. **Biochemistry** 1996 May 14;35(19):6126-35

The asymmetry of P+ in bacterial reaction centers revealed by circular dichroism spectroscopy. Olson JM, et al. **Biochemistry** 1995 Nov 21;34(46):15230-4

Origin of the two carbonyl oxygens of bacteriochlorophyll a. Demonstration of two different pathways for the formation of ring E in Rhodobacter sphaeroides and Roseobacter denitrificans, and a common hydratase mechanism for 3-acetyl group formation. Porra RJ, et al. **Eur J Biochem** 1996 Jul 1;239(1):85-92

CLASSIFICATION

The phylogenetic relationship among Ectothiorhodospiraceae: a reevaluation of their taxonomy on the basis of 16S rDNA analyses. Imhoff JF, et al. **Arch Microbiol** 1996 Feb;165(2):106-13

Lipopolysaccharide and porin of Roseobacter denitrificans, confirming its phylogenetic relationship to the alpha-3 subgroup of Proteobacteria. Neumann U, et al. **Microbiology** 1995 Aug;141 (Pt 8):2013-7

ENZYMOLOGY

Malate dehydrogenase from the green gliding bacterium Chloroflexus aurantiacus is phylogenetically related to lactic dehydrogenases. Synstad B, et al. **Arch Microbiol** 1996 May;165(5):346-53

Highly purified photosynthetic reaction center (PscA/cytochrome c551)2 complex of the green sulfur bacterium Chlorobium limicola. Oh-oka H, et al. **Biochemistry** 1995 Oct 10;34(40):13091-7

Synthesis of 1',6'-disubstituted sucroses and their behavior as glucosyl donors for a microbial alpha-glucosyltransferase. Kakinuma H, et al. **Carbohydr Res** 1996 Apr 18;284(1):61-72

GENETICS

Genomic heterogeneity in Chlorobium limicola: chromosomic and plasmidic differences among strains. Méndez-Alvarez S, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):279-85

Physical map of the genome of the green phototrophic bacterium Chlorobium tepidum. Naterstad K, et al. **J Bacteriol** 1995 Oct;177(19):5480-4

Structure and expression of the Chlorobium vibrioforme hemB gene and characterization of its encoded enzyme, porphobilinogen synthase. Rhie G, et al. **J Biol Chem** 1996 Apr 5;271(14):8176-82

Expression of the puf operon in an aerobic photosynthetic bacterium, Roseobacter denitrificans. Nishimura K, et al. **Plant Cell Physiol** 1996 Mar;37(2):153-9

Activity and thermostability of the small self-splicing group I intron in the pre-tRNA(Ile) of the purple bacterium Azoarcus. Tanner M, et al. **RNA** 1996 Jan;2(1):74-83

IMMUNOLOGY

Polyclonal antibodies to chlorosome proteins as probes for green sulfur bacteria. Cahill AD, et al. **Appl Environ Microbiol** 1995 Feb;61(2):784-7

METABOLISM

Biotechnological potentials of anoxygenic phototrophic bacteria. I. Production of single-cell protein, vitamins, ubiquinones, hormones, and enzymes and use in waste treatment. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:173-226 (311 ref.)

Biotechnological potentials of anoxygenic phototrophic bacteria. II. Biopolyesters, biopesticide, biofuel, and biofertilizer. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:227-78 (327 ref.)

Formation of the light-harvesting complex I (B870) of anoxygenic phototrophic purple bacteria. Drews G. **Arch Microbiol** 1996 Sep;166(3):151-9

The porins from the halophilic species Ectothiorhodospira shaposhnikovii and Ectothiorhodospira vacuolata. Wolf E, et al. **Arch Microbiol** 1996 Sep;166(3):169-75

Energy and electron transfer upon selective femtosecond excitation of pigments in membranes of Heliobacillus mobilis. Liebl U, et al. **Biochemistry** 1996 Jul 30; 35(30):9925-34

Secondary electron transfer processes in membranes of Heliobacillus mobilis. Lin S, et al. **Biochemistry** 1995 Oct 3;34(39):12761-7

Femtosecond probe of structural analogies between chlorosomes and bacteriochlorophyll c aggregates. Savikhin S, et al. **Biophys J** 1995 Sep;69(3):1100-4

Anaerobic protoporphyrin biosynthesis does not require incorporation of methyl groups from methionine. Bollivar DW, et al. **J Bacteriol** 1995 Oct;177(20):5778-83

Photosynthetic oxidation of MnS and FeS by Chlorobium spp. Borrego C, et al. **Microbiologia** 1995 Sep;11(3):351-8

PHYSIOLOGY

[Bacterial processes of photosynthesis and dark assimilation of carbon dioxide in the lakes of Bunger Hills Oasis in Eastern Antarctica] Gal'chenko VF, et al. **Mikrobiologiia** 1995 Nov-Dec;64(6):833-44 (Eng. Abstr.) **(Rus)**

PHOTOTROPISM

Phytochrome A regulates red-light induction of phototropic enhancement in Arabidopsis. Parks BM, et al. **Plant Physiol** 1996 Jan;110(1):155-62

PHRENIC NERVE

Thoracoscopic release of tracheopexy stitch causing phrenic nerve paralysis in an infant. Oyarzun R, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):188-90

Partial unilateral phrenic nerve paralysis caused by a large intrathoracic goitre. van Doorn LG, et al. **Neth J Med** 1996 Jun;48(6):216-9 (3 ref.)

Transdiaphragmatic pressure in quadriplegic individuals ventilated by diaphragmatic pacemaker. Garrido-García H, et al. **Thorax** 1996 Apr;51(4):420-3

CHEMISTRY

Mechanical ventilation increases substance P concentration in the vagus, sympathetic, and phrenic nerves. Balzamo E, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):153-7

CYTOLOGY

Thyrotropin-releasing hormone-immunoreactive varicosities synapse on rat phrenic motoneurons. Murphy SM, et al. **J Comp Neurol** 1995 Aug 21;359(2):310-22

DRUG EFFECTS

The effect of halothane on phrenic and chemoreceptor responses to hypoxia in anesthetized kittens. Morray JP, et al. **Anesth Analg** 1996 Aug;83(2):329-35

Vecuronium-induced depression of phrenic nerve activity during hypoxia in the rabbit. Wyon N, et al. **Anesth Analg** 1996 Jun;82(6):1252-6

Potentiating effects of beta-eudesmol-related cyclohexylidene derivatives on succinylcholine-induced neuromuscular block in isolated phrenic nerve-diaphragm muscles of normal and alloxan-diabetic mice. Kimura M, et al. **Biol Pharm Bull** 1995 Mar;18(3):407-10

Depolarizing neuromuscular blocking action of coryneine derived from aconite root in isolated mouse phrenic nerve-diaphragm muscles. Kimura M, et al. **Biol Pharm Bull** 1995 May;18(5):691-5

Actions of systemic theophylline on hemidiaphragmatic recovery in rats following cervical spinal cord hemisection. Nantwi KD, et al. **Exp Neurol** 1996 Jul;140(1):53-9

Effects of triclosan on the rat phrenic nerve-diaphragm preparation. Kjaerheim V, et al. **J Clin Periodontol** 1995 Jun;22(6):488-93

Action of reactive oxygen species and their antagonists on twitch tension of the rat phrenic nerve-diaphragm. Crosland RD. **Pharmacol Toxicol** 1995;77:231-7

INJURIES

Combined left-sided recurrent laryngeal and phrenic nerve palsy after coronary artery operation. Tewari P, et al. **Ann Thorac Surg** 1996 Jun;61(6):1721-2; discussion 1722-3

Incidence of phrenic neuropathy after isolated lung transplantation. The Loyola University Lung Transplant Group. Sheridan PH Jr, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):684-91

Diaphragmatic paralysis following scalenotomy for thoracic outlet syndrome. Heine M, et al. **J Ky Med Assoc** 1996 Jan;94(1):13-5

Bilateral phrenic nerve injury after neck dissection: an uncommon cause of respiratory failure. Yaddanapudi S, et al. **J Laryngol Otol** 1996 Mar;110(3):281-3

Diaphragmatic paresis in newborns due to phrenic nerve injury. Zifko U, et al. **Neuropediatrics** 1995 Oct;26(5):281-4

PHYSIOLOGY

The presence of coherence in sympathetic and phrenic activities in a developing mammal. Gootman PM, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):137-45

Comparison of cervical magnetic and transcutaneous phrenic nerve stimulation before and after threshold loading. Mador MJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):448-53

Effects of ventilator resistance and compliance on phrenic nerve activity in spontaneously breathing cats. Schulze A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):671-6

Phrenic nerve activity during artificial ventilation at different body temperatures and its relationships with carotid chemosensory activity. Iturriaga R, et al. **Biol Res** 1994; 27(2):145-57

A comparative study of pre-sympathetic and Bötzinger neurons in the rostral ventrolateral medulla (RVLM) of the rat. Kanjhan R, et al. **Brain Res** 1995 Nov 13; 699(1):19-32

Short-latency excitation of phrenic motor output mediated by non-NMDA receptors. Karius DR, et al. **Brain Res** 1995 Jun 5;682(1-2):235-8

Intraoperative phrenic nerve monitoring in cardiac surgery. Mazzoni M, et al. **Chest** 1996 Jun;109(6):1455-60

Application of a cervical stimulating apparatus for bilateral transcutaneous phrenic nerve stimulation. Eastwood PR, et al. **J Appl Physiol** 1995 Aug;79(2):632-7

Neurochemical control of tissue resistance in piglets. Martin RJ, et al. **J Appl Physiol** 1995 Sep;79(3):812-7

Myoneural interactions affect diaphragm muscle adaptations to inactivity. Miyata H, et al. **J Appl Physiol** 1995 Nov; 79(5):1640-9

Phrenic motoneuron firing rates during brief inspiratory resistive loads. Road J, et al. **J Appl Physiol** 1995 Nov; 79(5):1540-5

Recruitment order and dendritic morphology of rat phrenic motoneurons. Torikai H, et al. **J Comp Neurol** 1996 Mar 4;366(2):231-43

Transvenous phrenic nerve stimulation during prolonged mechanical ventilation in awake, nonparalyzed ewes. Ferrigno M, et al. **Lab Anim Sci** 1995 Dec;45(6):690-3

Somatosensory evoked potentials of the phrenic nerve. Zifko UA, et al. **Muscle Nerve** 1995 Dec;18(12):1487-9

Inspiratory activity responses to lung inflation and ventral medullary surface cooling of glossopharyngeal nerve (stylopharyngeal muscle branch) and its motoneuron distribution in the rat. Fukuda Y, et al. **Neurosci Res** 1995 Aug;23(1):103-14

Phrenic afferent input excites C1-C2 spinal neurons in rats. Razook JC, et al. **Pain** 1995 Oct;63(1):117-25

Unilateral magnetic stimulation of the phrenic nerve. Mills GH, et al. **Thorax** 1995 Nov;50(11):1162-72

[Phrenic stimulation] Similowski T, et al. **Rev Mal Respir** 1995;12(5):503-4 **(Fre)**

[Implantation of a phrenic stimulator in central respiratory paralysis] Fritz U, et al. **Anaesthesist** 1995 Dec;44(12):880-3 (Eng. Abstr.) **(Ger)**

[Effects of calcium channel blockers on electrical and mechanical responses of rat phrenic nerve-diaphragm preparations] Zupko I, et al. **Acta Pharm Hung** 1995 Jul; 65(4):127-31 (Eng. Abstr.) **(Hun)**

PHYSIOPATHOLOGY

Effects of sevoflurane on respiratory activities in the phrenic nerve of decerebrate cats. Masuda A, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):774-81

Phrenic nerve stimulation during transesophageal atrial pacing may cause apnea in spontaneously breathing patients [letter] Roth JV. **Anesth Analg** 1996 Sep;83(3):661

The role of the phrenic nerves in stress response in upper abdominal surgery. Segawa H, et al. **Anesth Analg** 1996 Jun;82(6):1215-24

Percutaneous magnetic coil stimulation of the phrenic nerve roots and trunk. Chokoverty S, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):369-74

Phrenic nerve conduction in amyotrophic lateral sclerosis. Evangelista T, et al. **J Neurol Sci** 1995 May;129 Suppl:35-7

Phrenic nerve conduction studies in the intensive care unit [letter] Saadeh PB, et al. **Muscle Nerve** 1996 Aug; 19(8):1057-8

Phrenic neuropathy in chronic renal failure. Zifko U, et al. **Thorax** 1995 Jul;50(7):793-4

SURGERY

The superimposed effects of chronic phrenicotomy and cervical spinal cord hemisection on glial cytoarchitecture in the rat phrenic nucleus. Liou WW, et al. **J Spinal Cord Med** 1996 Apr;19(2):58-70

TRANSPLANTATION

Use of the phrenic nerve for brachial plexus reconstruction. Gu YD, et al. **Clin Orthop** 1996 Feb;(323):119-21

PHRENOLOGY

HISTORY

Phrenology. Weinberg F. **Can Fam Physician** 1996 Apr; 42:717-20

The role of gender, phrenology, discrimination and nervous prostration in Clara Barton's career. Spiegel AD. **J Community Health** 1995 Dec;20(6):501-26

Phrenology in the science and culture of the 19th century. Greenblatt SH. **Neurosurgery** 1995 Oct;37(4):790-804; discussion 804-5

O-PHTHALALDEHYDE

Fluorimetric determination of monobromobimane and o-phthalaldehyde adducts of gamma-glutamylcysteine and glutathione: application to assay of gamma-glutamylcysteinyl synthetase activity and glutathione concentration in liver. Yan CC, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):217-24

ANALYSIS

Liquid chromatographic determination of D- and L-amino acids by derivatization with o-phthaldialdehyde and N-isobutyryl-L-cysteine. Applications with reference to the analysis of peptidic antibiotics, toxins, drugs and pharmaceutically used amino acids. Brückner H, et al. **J Chromatogr A** 1995 Sep 8;711(1):201-15

CHEMISTRY

Labelling the Ca(2+)-ATPase of skeletal-muscle sarcoplasmic reticulum with the cross-linker o-phthalaldehyde. Khan YM, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):433-7

Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. Fekkes D, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):177-86

METABOLISM

Identification of cysteine and lysine residues present at the active site of beef liver glutamate dehydrogenase by o-phthalaldehyde. Pandey A, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):122-8

PHARMACOLOGY

The mechanism of inhibition of the Ca(2+)-ATPase of skeletal-muscle sarcoplasmic reticulum by the cross-linker o-phthalaldehyde. Khan YM, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):439-45

Involvement of a lysine residue in the inactivation of Leuconostoc mesenteroides NRRL B-512F dextransucrase by o-phthalaldehyde. Goyal A, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):579-85

Kinetics of irreversible inhibition of yeast alcohol dehydrogenase during modification by o-phthaldehyde. Le WP, et al. **Enzyme Protein** 1994-95;48(3):183-90

Inactivation of an NADPH-dependent succinic semialdehyde reductase by o-phthalaldehyde. Cho SW, et al. **FEBS Lett** 1996 Mar 11;382(1-2):179-82

Reactivity of essential cysteine and lysine residues present at the catalytic domain of pig heart mitochondrial malate dehydrogenase. Sheikh S, et al. **J Enzym Inhib** 1995; 9(3):235-42

PHTHALAMUDINE see **CHLORTHALIDONE**

PHTHALAZINES

ADMINISTRATION & DOSAGE

Investigation on the efficacy and tolerance of azelastine (HCL) nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis. Conde Hernández J, et al. **Allergol Immunopathol (Madr)** 1995 Mar-Apr;23(2):51-7

Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Conde Hernández DJ, et al. **Curr Med Res Opin** 1995;13(6):299-304

Duration of action of a single dose of azelastine in patients with chronic asthma. Chervinsky P, et al. **J Asthma** 1995; 32(2):141-5

CHEMISTRY

Autoencapsulation through intermolecular forces: a synthetic self-assembling spherical complex. Meissner RS, et al. **Science** 1995 Dec 1;270(5241):1485-8

ISOLATION & PURIFICATION

An investigation of the properties of a "shielded" phase for the solid phase extraction of acidic and basic compounds. Martin P, et al. **J Pharm Biomed Anal** 1996 Feb; 14(4):419-27

PHARMACOLOGY

Inhibition of leukotriene synthesis by azelastine. Hamasaki Y, et al. **Ann Allergy Asthma Immunol** 1996 May; 76(5):469-75

Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Nakano T, et al. **Biochemistry** 1996 Aug 27;35(34):11196-202

Effects of glucose and an aldose reductase inhibitor on albumin permeation through a layer of cultured bovine vascular endothelial cells. Mimura K, et al. **Horm Metab Res** 1995 Oct;27(10):442-6

Electrophysiological effects of azelastine in isolated guinea pig atrial and ventricular fibers. Kecskeméti V. **Inflamm Res** 1995 Apr;44 Suppl 1:S98-9

Topical active H1-antihistamines and their effect on nasal airway resistance. van Houten RJ, et al. **J Laryngol Otol** 1995 Sep;109(9):841-3

Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. Pelletier JC, et al. **J Med Chem** 1996 Jan 19;39(2):343-6

Inhibitory effects of azelastine and tranilast on leukotriene B4 and leukotriene C4 generation by rat colonic mucosa. Shimizu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):355-8

Number and ultrastructure of epithelial cells in crypts and villi along the streptozotocin-diabetic small intestine: a quantitative study on the effects of insulin and aldose reductase inhibition. Zoubi SA, et al. **Virchows Arch** 1995; 427(2):187-93

THERAPEUTIC USE

Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):122-7

Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. LaForce C, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):181-8

Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice. Girard J, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):43-9

Effect of azelastine on endotoxin-induced airway hyperresponsiveness in mice. Konno S, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):292-7

An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. **J Allergy Clin Immunol** 1996 Jun;97(6):1218-24

PHTHALEIN DYES

PHARMACOLOGY

Effect of cholephilic dyes on hepatic tight junctional permeability in the rat. Roma MG, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1079-86

PHTHALIC ACIDS

CHEMISTRY

A 1H NMR analysis of the interaction between terephthalamide derivatives and the oligonucleotide duplex d(GGTAATTACC)2. Pavlopoulos S, et al. **Anticancer Drug Des** 1995 Dec;10(8):623-39

METABOLISM

Plasmid-mediated degradation of o-phthalate and salicylate by a Moraxella sp. Rani M, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):377-81

Molecular analysis of isophthalate and terephthalate degradation by Comamonas testosteroni YZW-D. Wang YZ, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:9-12

PHARMACOLOGY

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91-8

THERAPEUTIC USE

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91-8

TOXICITY

Quantitative structure-activity relationships of organic acids and bases. Zhao YH, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):242-9

Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Sharpe RM, et al. **Environ Health Perspect** 1995 Dec; 103(12):1136-43

Subchronic 90-day oral toxicology of di(2-ethylhexyl) terephthalate in the rat. Barber ED, et al. **Food Chem Toxicol** 1995 Nov;33(11):971-8

UK panics over phthalates in babymilk formulae [news] Bradbury J. **Lancet** 1996 Jun 1;347(9014):1541

Developmental toxicity of mono-n-benzyl phthalate, one of the major metabolites of the plasticizer n-butyl benzyl phthalate, in rats. Ema M, et al. **Toxicol Lett** 1996 Jul; 86(1):19-25

PHTHALIC ANHYDRIDES

ADVERSE EFFECTS

Study of employees with anhydride-induced respiratory disease after removal from exposure. Grammer LC, et al. **J Occup Environ Med** 1995 Jul;37(7):820-5

IMMUNOLOGY

Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens. Dearman RJ, et al. **Immunology** 1995 Dec;86(4):545-50

Airway responses following intradermal sensitization to different types of allergens: ovalbumin, trimellitic anhydride and Dermatophagoides farinae. Arakawa H, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):274-80

METABOLISM

Lysine adducts between methyltetrahydrophthalic anhydride and collagen in guinea pig lung. Jönsson BA, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):156-62

PHARMACOLOGY

The structure-activity relationship between synthetic butylidenephthalide derivatives regarding the competence and progression of inhibition in primary cultures proliferation of mouse aorta smooth muscle cells. Mimura Y, et al. **Biol Pharm Bull** 1995 Sep;18(9):1203-6

Anti-competence effects of synthetic phthalide derivatives on platelet-derived growth factor-induced DNA synthesis in primary cultures of rat aorta smooth muscle cells. Mimura Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1660-4

Competence effect of PDGF on Ki-67 antigen and DNA contents, and its inhibition by trichostatin-A and a butylydene phthalide BP-421 in primary smooth muscle cells of rat aorta by flow cytometry. Okabe M, et al. **Biol Pharm Bull** 1995 Dec;18(12):1665-70

TOXICITY

Local lymph node activation in rats after dermal application of the sensitizers 2,4-dinitrochlorobenzene and trimellitic anhydride. Arts JH, et al. **Food Chem Toxicol** 1996 Jan; 34(1):55-62

PHTHALIMIDES

CHEMICAL SYNTHESIS

Phenylphthalimides with tumor necrosis factor alpha production-enhancing activity. Shibata Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):156-62

Search for new anticonvulsant compounds. Part 1: Synthesis, physicochemical and anticonvulsant properties of new derivatives of alpha-amino-gamma-phthalimidobutyric acid. Malawska B, et al. **Pharmazie** 1995 Nov;50(11):722-5

CHEMISTRY

The cytotoxicity of N-Pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide. Hall IH, et al. **Biomed Pharmacother** 1995;49(5):251-8

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. Furet P, et al. **J Comput Aided Mol Des** 1995 Dec; 9(6):465-72

[Interaction of synthetic ligands containing N,4-disubstituted mono- and diphthalimides with DNA] Salmanova DV, et al. **Mol Biol (Mosk)** 1995 Jul-Aug;29(4):848-61 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence. Miyachi H, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):439-44

Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor alpha. Sasaki K, et al. **Biol Pharm Bull** 1995 Sep;18(9):1228-33

Phenylphthalimides with tumor necrosis factor alpha production-enhancing activity. Shibata Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):156-62

Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Bailleux V, et al. **Epilepsia** 1995 Jun;36(6):559-65

Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Yen A, et al. **Eur J Cell Biol** 1996 Apr; 69(4):327-34

Effect of three novel polyamine oxa-analogues (MTR-OSPD, DIP-SPN and APPO-TFA) on the growth and proliferation of Swiss 3T3 cells. Bardocz S, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):697-704

Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives. Norman MH, et al. **J Med Chem** 1996 Jan 5;39(1):149-57

Transformation of BALB/c 3T3 cells in vitro by the fungicides captan, captafol and folpet. Perocco P, et al. **Jpn J Cancer Res** 1995 Oct;86(10):941-7

TOXICITY

The cytotoxicity of N-Pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide. Hall IH, et al. **Biomed Pharmacother** 1995;49(5):251-8

[Twenty-eight days repeated dose toxicity test of N-(fluorodichloromethylthio)phthalimide in rats] Matsushima Y, et al. **Eisei Shikenjo Hokoku** 1995; (113):19-30 (Eng. Abstr.) **(Jpn)**

URINE

Urinary excretion of tetrahydrophtalimide in fruit growers with dermal exposure to captan. de Cock J, et al. **Am J Ind Med** 1995 Aug;28(2):245-56

PHTHIRAPTERA see **LICE**

PHYCOCYANIN

BIOSYNTHESIS

Heterologous assembly and rescue of stranded phycocyanin subunits by expression of a foreign cpcBA operon in Synechocystis sp. strain 6803. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6804–9

CHEMISTRY

Subunit interactions and protein stability in the cyanobacterial light-harvesting proteins. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6798–803

Pressure-induced dissociation and denaturation of allophycocyanin at subzero temperatures. Foguel D, et al. **J Biol Chem** 1995 Dec 1;270(48):28759–66

Studies on the dissociation of cryptomonad biliproteins. MacColl R, et al. **J Biol Chem** 1995 Nov 17; 270(46):27555–61

GENETICS

Genetic diversity and phylogeny of toxic cyanobacteria determined by DNA polymorphisms within the phycocyanin locus. Neilan BA, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3875–83

Expression of genes involved in phycocyanin biosynthesis following recovery of Synechococcus PCC 6301 from nitrogen starvation, and the effect of gabaculine on cpcBa transcript levels. Gilbert SM, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):93–8

PHYCODNAVIRIDAE

ENZYMOLOGY

Molecular cloning of the three base restriction endonuclease R.CviJI from eukaryotic Chlorella virus IL-3A. Swaminathan N, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2463–9

Evolutionary relationships among large double-stranded DNA viruses that infect microalgae and other organisms as inferred from DNA polymerase genes. Chen F, et al. **Virology** 1996 May 1;219(1):170–8

An early gene of the Chlorella virus PBCV-1 encodes a functional aspartate transcarbamylase. Landstein D, et al. **Virology** 1996 Jul 1;221(1):151–8

GENETICS

Molecular cloning of the three base restriction endonuclease R.CviJI from eukaryotic Chlorella virus IL-3A. Swaminathan N, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2463–9

A Feldmannia algal virus has two genome size-classes. Ivey RG, et al. **Virology** 1996 Jun 15;220(2):267–73

A brown algal virus genome contains a "RING" zinc finger motif. Krueger SK, et al. **Virology** 1996 May 1;219(1):301–3

Large deletions in antigenic variants of the chlorella virus PBCV-1. Landstein D, et al. **Virology** 1995 Dec 20; 214(2):413–20

Characterization of a repetitive DNA element in a brown algal virus. Lee AM, et al. **Virology** 1995 Oct 1; 212(2):474–80

Analysis of 94 kb of the chlorella virus PBCV-1 330-kb genome: map positions 88 to 182. Lu Z, et al. **Virology** 1996 Feb 1;216(1):102–23

Large deletions in the genome of Chlorella virus CVK1. Songsri P, et al. **Virology** 1995 Dec 20;214(2):405–12

GROWTH & DEVELOPMENT

Infectivity of algal viruses studied by chlorophyll fluorescence. Rohozinski J, et al. **J Gen Virol** 1995 Nov; 76 (Pt 11):2859–62

METABOLISM

Characterization of DNA-binding proteins and protein kinase activities in Chlorella virus CVK2. Yamada T, et al. **Virology** 1996 May 15;219(2):395–406

PHYSIOLOGY

Novel amplification of non-photochemical chlorophyll fluorescence quenching following viral infection in Chlorella. Seaton GG, et al. **FEBS Lett** 1996 Jul 8; 389(3):319–23

PHYCOERYTHRIN

CHEMISTRY

Binding of PE-CY5 conjugates to the human high-affinity receptor for IgG (CD64) [letter] van Vugt MJ, et al. **Blood** 1996 Sep 15;88(6):2358–61

Studies on the dissociation of cryptomonad biliproteins. MacColl R, et al. **J Biol Chem** 1995 Nov 17; 270(46):27555–61

The discovery of a novel R-phycoerythrin from an antarctic red alga. MacColl R, et al. **J Biol Chem** 1996 Jul 19; 271(29):17157–60

PHYCOMYCES

ENZYMOLOGY

Two NAD+-isocitrate dehydrogenase forms in Phycomyces blakesleeanus. Induction in response to acetate growth and characterization, kinetics, and regulation of both enzyme forms. Alvarez-Villafañe E, et al. **Biochemistry** 1996 Apr 16;35(15):4741–52

The pH dependence and modification by diethyl pyrocarbonate of isocitrate lyase from Phycomyces blakesleeanus. Rúa J, et al. **Eur J Biochem** 1995 Sep 1; 232(2):381–90

GENETICS

Genetic characterization of two phototropism mutants of Phycomyces with defects in the genes madI and madJ. Campuzano V, et al. **Curr Genet** 1995 May;27(6):524–7

PkpA, a novel Phycomyces blakesleeanus serine/threonine protein kinase. Ruiz-Pérez VL, et al. **Curr Genet** 1995 Sep; 28(4):309–16

PHYSIOLOGY

The GTP-binding protein G alpha s is present in dormant spores and expressed differentially during spore germination of the fungus Phycomyces blakesleeanus. Martínez-Cadena G, et al. **Microbiology** 1995 Dec;141 (Pt 12):3149–54

Blue-light receptor requirement for gravitropism, autochemotropism and ethylene response in Phycomyces. Campuzano V, et al. **Photochem Photobiol** 1996 May; 63(5):686–94

PHYCOMYCETES

ISOLATION & PURIFICATION

Isozyme and morphological characteristics of the anaerobic fungus Piromyces mae isolated from the duodenum, rumen and faeces of sheep. Wong MV, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):9–14

METABOLISM

Effect of the fluorescent brightener Rylux BSU on the cell wall chitin content in Basidiobolus ranarum. Raclavský V, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:19–20

PHYLLODES TUMOR

DIAGNOSIS

Benign phyllodes tumor of the breast: MR imaging features. Farria DM, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):187–9

Phyllodes type of atypical prostatic hyperplasia. Fujita K, et al. **Int J Urol** 1996 Mar;3(2):158–60

[Phyllodes tumor: diagnosis and treatment] Uribe A, et al. **Rev Chil Obstet Ginecol** 1995;60(1):17–22 (Eng. Abstr.) **(Spa)**

GENETICS

Additional copies of 1q in sequential samples from a phyllodes tumor of the breast [see comments] Birdsall SH, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):111–4. Comment in: Cancer Genet Cytogenet 1995 Sep;83(2):174–5.

No rearrangement of the CHOP and TLS/FUS genes in two cases of phyllodes tumor of the breast [letter] Birdsall SH, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):90–1

Is i(1)(q10) a chromosome marker in phyllodes tumor of the breast? [letter; comment] Dal Cin P, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):174–5. Comment on: Cancer Genet Cytogenet 1995 Sep;83(2):111–4.

PATHOLOGY

Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Noguchi S, et al. **Cancer** 1995 Nov 15;76(10):1779–85

The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Reinfuss M, et al. **Cancer** 1996 Mar 1;77(5):910–6

Malignant phyllodes tumour: report of two cases. Muthuphei MN. **East Afr Med J** 1995 Dec;72(12):818–20

Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Moffat CJ, et al. **Histopathology** 1995 Sep;27(3):205–18 (38 ref.)

Cystosarcoma phylloides: heterogeneity in a rare tumour type. Bissett D, et al. **J R Coll Surg Edinb** 1996 Aug; 41(4):244–5

RADIOGRAPHY

Benign and malignant phyllodes tumors: mammographic and sonographic findings. Liberman L, et al. **Radiology** 1996 Jan;198(1):121–4

[Diagnostic imaging of phyllodes tumors: preliminary observations] Draghi F, et al. **Radiol Med (Torino)** 1996 May;91(5):585–9 (Eng. Abstr.) **(Ita)**

SURGERY

The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Reinfuss M, et al. **Cancer** 1996 Mar 1;77(5):910–6

[Phyllodes breast tumors: apropos 2 cases] Bruzzese A, et al. **G Chir** 1995 Aug-Sep;16(8-9):366–8 (9 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Benign and malignant phyllodes tumors: mammographic and sonographic findings. Liberman L, et al. **Radiology** 1996 Jan;198(1):121–4

[Diagnostic imaging of phyllodes tumors: preliminary observations] Draghi F, et al. **Radiol Med (Torino)** 1996 May;91(5):585–9 (Eng. Abstr.) **(Ita)**

PHYLLOQUINONE see **PHYTONADIONE**

PHYLLOQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

PHYLOGENY

Some prerequisites for a study of the evolution of cognition in the animal kingdom. Gervet J, et al. **Acta Biotheor** 1996 Mar;44(1):37–57

Atavisms in homo sapiens: a Bolkian heterodoxy revisited. Verhulst J. **Acta Biotheor** 1996 Mar;44(1):59–73

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73–120 (138 ref.)

Aspartic proteinases (cyprosins) from Cynara cardunculus spp. Flavescens cv. cardoon; purification, characterisation, and tissue-specific expression. Brodelius PE, et al. **Adv Exp Med Biol** 1995;362:255–66

Candida albicans aspartic proteinase: cDNA cloning and comparison among strains. Murayama SY, et al. **Adv Exp Med Biol** 1995;362:573–6

Phylogeny of the immunoglobulin joining (J) chain. Takahashi T, et al. **Adv Exp Med Biol** 1995;371A:353–6

Sequence and phylogenetic analysis of glycoprotein 120 of an HIV type 1 variant (GWGR) prevalent in Brazil. da Costa SM, et al. **AIDS Res Hum Retroviruses** 1995 Sep; 11(9):1143–5

Topiary pruning of the HIV and SIV phylogenetic tree. Wills C. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1417–9

Lack of ancient Polynesian-Amerindian contact [letter; comment] Bonatto SL, et al. **Am J Hum Genet** 1996 Jul; 59(1):253–8. Comment on: Am J Hum Genet 1993 Sep;53(3):549–62. Comment on: Am J Hum Genet 1994 Jul;55(1):7–11.

The genetic relationship between the Finns and the Finnish Saami (Lapps): analysis of nuclear DNA and mtDNA. Lahermo P, et al. **Am J Hum Genet** 1996 Jun;58(6):1309–22

The involucrin gene and hominoid relationships. Green H, et al. **Am J Phys Anthropol** 1995 Oct;98(2):213–6; discussion 228–32

Learning to live with a trichotomy. Marks J. **Am J Phys Anthropol** 1995 Oct;98(2):211–3; discussion 218–24

A simulation test of Smith's "Degrees of freedom" correction for comparative studies. Nunn CL. **Am J Phys Anthropol** 1995 Nov;98(3):355–67

When is ancient polymorphism a potential problem for molecular phylogenetics? Rogers J, et al. **Am J Phys Anthropol** 1995 Oct;98(2):216–8; discussion 224–8

Unconventional myosins. Mooseker MS, et al. **Ann Rev Cell Dev Biol** 1995;11:633–75 (159 ref.)

Phylogenetic analysis of ten black yeast species using nuclear small subunit rRNA gene sequences. Haase G, et al. **Antonie Van Leeuwenhoek** 1995 Jul;68(1):19–33

Phylogenetic diversity of subsurface marine microbial communities from the Atlantic and Pacific oceans. Fuhrman JA, et al. **Appl Environ Microbiol** 1995 Dec; 61(12):4517

Phylogenetic comparison of two polycyclic aromatic hydrocarbon-degrading mycobacteria. Govindaswami M, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3221–6

Phylogenetic probes for analyzing abundance and spatial organization of nitrifying bacteria. Mobarry BK, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2156–62

Phylogenetic position of yeastlike endosymbionts of anobiid beetles. Noda H, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):162–7

Phylogenetic diversity of the intestinal bacterial community in the termite Reticulitermes speratus. Ohkuma M, et al. **Appl Environ Microbiol** 1996 Feb;62(2):461–8

Phylogeny of not-yet-cultured spirochetes from termite guts. Paster BJ, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):347–52

Molecular Phylogenetic classification of fungi. Taylor JW. **Arch Med Res** 1995 Autumn;26(3):307–14 (72 ref.)

Purification, primary structure, and evolution of cytochrome c-550 from the magnetic bacterium, Magnetospirillum magnetotacticum. Yoshimatsu K, et al. **Arch Microbiol** 1995 Jun;163(6):400–6

Sequence analyses and a unifying system of virus taxonomy: consensus via consent [news] Calisher CH, et al. **Arch Virol** 1995;140(11):2093–9

Molecular evidence that the whitefly-transmitted sweetpotato mild mottle virus belongs to a distinct genus of the Potyviridae. Colinet D, et al. **Arch Virol** 1996; 141(1):125–35

Sequence comparison and classification of beet luteovirus isolates. de Miranda JR, et al. **Arch Virol** 1995; 140(12):2183–200

Species-specific and interspecies relatedness of NSP1 sequences in human, porcine, bovine, feline, and equine rotavirus strains. Kojima K, et al. **Arch Virol** 1996; 141(1):1–12

Envelope gene sequences of human T-lymphotropic virus type 1 in Taiwan. Lin MT, et al. **Arch Virol** 1996; 141(2):219–29

Host dependent variation of hepatitis C virus: phylogenetic analyses. Maekawa S, et al. **Arch Virol** 1995; 140(12):2123–33

Peanut bud necrosis tospovirus S RNA: complete nucleotide sequence, genome organization and homology to other tospoviruses. Satyanarayana T, et al. **Arch Virol** 1996; 141(1):85–98

Phylogeny and the function of REM sleep. Siegel JM. **Behav Brain Res** 1995 Jul-Aug;69(1-2):29–34 (42 ref.)

Cloning and characterization of a ribosomal P protein from Taenia solium, the aetiological agent of human cysticercosis. Kalinna BH, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):231–7

Sequence analysis of four acidic beta-crystallin subunits of amphibian lenses: phylogenetic comparison between beta- and gamma-crystallins. Lu SF, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):219–28

The deduced primary structure of subunit I from cytochrome c oxidase suggests that the genus Polytomella shares a common mitochondrial origin with Chlamydomonas. Antaramian A, et al. **Biochim Biophys Acta** 1996 Mar 28; 1273(3):198–202

Analysis of biological function of poly(ADP-ribosyl)ation in Drosophila melanogaster. Miwa M, et al. **Biochimie** 1995; 77(6):466–71 (32 ref.)

Regeneration in the vertebrate central nervous system: phylogeny, ontogeny, and mechanisms. Larner AJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):597–619 (159 ref.)

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789–92 (20 ref.)

The tympanal hearing organ of a fly: phylogenetic analysis of its morphological origins. Edgecomb RS, et al. **Cell Tissue Res** 1995 Nov;282(2):251–68

Divergence of human and nonhuman primate lymphocyte responses to bacterial superantigens. Bavari S, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):248–54

A weighting system and algorithm for aligning many phylogenetically related sequences. Gotoh O. **Comput Appl Biosci** 1995 Oct;11(5):543–51

Comparative analysis by independent contrasts (CAIC): an Apple Macintosh application for analysing comparative data. Purvis A, et al. **Comput Appl Biosci** 1995 Jun; 11(3):247–51

Pattern of ecological shifts in the diversification of Hawaiian Drosophila inferred from a molecular phylogeny. Kambysellis MP, et al. **Curr Biol** 1995 Oct 1;5(10):1129–39

Human immunodeficiency virus type 2: human biology of the other AIDS virus. D'Aquila RT. **Curr Clin Top Infect Dis** 1996;16:84–101 (86 ref.)

Mitochondrial DNA sequences reveal close relationships between social parasitic ants and their host species. Baur A, et al. **Curr Genet** 1995 Aug;28(3):242–7

Structural features and phylogeny of the actin gene of Chondrus crispus (Gigartinales, Rhodophyta). Bouget FY, et al. **Curr Genet** 1995 Jul;28(2):164–72

Phylogenetic affinities of the grasses to other monocots as revealed by molecular analysis of chloroplast DNA. Katayama H, et al. **Curr Genet** 1996 May;29(6):572–81

Phylogeny of Alternaria fungi known to produce host-specific toxins on the basis of variation in internal transcribed spacers of ribosomal DNA. Kusaba M, et al. **Curr Genet** 1995 Oct;28(5):491–8

Phylogenetic position of the Chromista plastids based on small subunit rRNA coding regions. Medlin LK, et al. **Curr Genet** 1995 Nov;28(6):560–5

Coadaptation and immunodeficiency virus: lessons from the Felidae. Carpenter MA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):739–45 (53 ref.)

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798–806 (28 ref.)

MADS-box genes in plant ontogeny and phylogeny: Haeckel's 'biogenetic law' revisited. Theissen G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):628–39 (97 ref.)

Chromosomal relationships and phylogenetic and clustering analyses on genes Callithrix group argentata (Callitrichidae, Primates). Nagamachi CY, et al. **Cytogenet Cell Genet** 1996; 72(4):331–8

Fish major histocompatibility complex genes: an expansion. Dixon B, et al. **Dev Comp Immunol** 1995 Mar-Apr; 19(2):109–33 (77 ref.)

Molecular cloning of prohormone convertase 1 from the atrial gland of Aplysia. Gorham EL, et al. **DNA Cell Biol** 1996 Apr;15(4):339–45

Why ontogeny recapitulates phylogeny. Ohno S. **Electrophoresis** 1995 Sep;16(9):1782–6

Arbitrarily amplified DNA in systematics and phylogenetics. Schierwater B. **Electrophoresis** 1995 Sep;16(9):1643–7 (45 ref.)

At least four MHC class I genes are transcribed in the horse: phylogenetic analysis suggests an unusual evolutionary history for the MHC in this species. Ellis SA, et al. **Eur J Immunogenet** 1995 Jun;22(3):249–60

Phylogenetic resolution of Morchella, Verpa, and Disciotis [Pezizales: Morchellaceae] based on restriction enzyme analysis of the 28S ribosomal RNA gene. Bunyard BA, et al. **Exp Mycol** 1995 Sep;19(3):223–33

Phylogenetic ordinal placement based on rDNA sequences of the freshwater genera Ophioceras and Pseudohalonectria. Chen W, et al. **Exp Mycol** 1995 Sep; 19(3):191–201

Ancient divergence of long and short isoforms of adenylate kinase: molecular evolution of the nucleoside monophosphate kinase family. Fukami-Kobayashi K, et al. **FEBS Lett** 1996 May 6;385(3):214–20

Phylogenetic position of the menaquinone-containing acidophilic chemo-organotroph Acidobacterium capsulatum. Hiraishi A, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):91–4

Chitin synthase homologs in three ectomycorrhizal truffles. Lanfranco L, et al. **FEMS Microbiol Lett** 1995 Dec 1; 134(1):109–14

Phylogeny of symbiotic methanogens in the gut of the termite Reticulitermes speratus. Ohkuma M, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):45–50

Reevaluating the classification of Halobacteroides and Haloanaerobacter species based on sequence comparisons of the 16S ribosomal RNA gene. Patel BK, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):115–9

A new root-nodulating symbiont of the tropical legume Sesbania, Rhizobium sp. SIN-1, is closely related to R. galegae, a species that nodulates temperate legumes. Rana D, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):19–25

Phylogenetic analysis of polycyclic aromatic hydrocarbon degrading mycobacteria by 16S rRNA sequencing. Wang RF, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):75–80

Emissary canals in the hominoidea and their phylogenetic significance. Braga J. **Folia Primatol (Basel)** 1995; 65(3):144–53

The anterior dentition of adapids and anthropoid origins. Greenfield LO. **Folia Primatol (Basel)** 1995;65(2):59–84

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

Phylogenetic relationships among two species of golden monkey and three species of leaf monkey inferred from rDNA variation. Wang W, et al. **Folia Primatol (Basel)** 1995;65(3):138–43

Canine brain glucose transporter 3: gene sequence, phylogenetic comparisons and analysis of functional sites. Borson ND, et al. **Gene** 1996 Feb 12;168(2):251–6

The rhodopsin-encoding gene of bony fish lacks introns. Fitzgibbon J, et al. **Gene** 1995 Oct 27;164(2):273–7

Phylogeny based on elongation factor Tu reflects the phenotypic features of mycoplasmas better than that based on 16S rRNA. Kamla V, et al. **Gene** 1996 May 24; 171(1):83–7

The secondary structure and phylogenetic relationship deduced from complete nucleotide sequence of mitochondrial small subunit rRNA in yeast Hansenula wingei. Okamoto K, et al. **Genes Genet Syst** 1996 Apr; 71(2):69–74

Repeated horizontal transfer of P transposons between Scaptomyza pallida and Drosophila bifasciata. Hagemann S, et al. **Genetica** 1996 Jul;98(1):43–51

Mitochondrial portraits of human populations using median networks. Bandelt HJ, et al. **Genetics** 1995 Oct; 141(2):743–53

Evolutionary origin of nonuniversal CUGSer codon in some Candida species as inferred from a molecular phylogeny. Pesole G, et al. **Genetics** 1995 Nov;141(3):903–7

Nucleotide variation at the Gpdh locus in the genus Drosophila. Wells RS. **Genetics** 1996 May;143(1):375–84

A new method of inference of ancestral nucleotide and amino acid sequences. Yang Z, et al. **Genetics** 1995 Dec; 141(4):1641–50

Pattern of X-Y chromosome pairing in microtine rodents. Borodin PM, et al. **Hereditas** 1995;123(1):17–23

Drosophila lactate dehydrogenase. Functional and evolutionary aspects. Karvountzi E, et al. **Hereditas** 1995; 123(1):61–7

Extreme genetic differences among populations of Gazella granti, Grant's gazelle in Kenya. Arctander P, et al. **Heredity** 1996 May;76 (Pt 5):465–75

RAPD analysis of systematic relationships among the Cervidae. Comincini S, et al. **Heredity** 1996 Mar;76 (Pt 3):215–21

Phylogeny of the genus Hegeter (Tenebrionidae, Coleoptera) and its colonization of the Canary Islands deduced from Cytochrome Oxidase I mitochondrial DNA sequences. Juan C, et al. **Heredity** 1996 Apr;76 (Pt 4):392–403

Evidence for sibling species in Cryptocercus punctulatus, the wood roach, from variation in mitochondrial DNA and karyotype. Kambhampati S, et al. **Heredity** 1996 May;76 (Pt 5):485–96

A population genetic analysis of chloroplast DNA in Phacelia. Levy F, et al. **Heredity** 1996 Feb;76 (Pt 2):143–55

Mitochondrial DNA differentiation among geographical populations of Pronolagus rupestris, Smith's red rock rabbit (Mammalia: Lagomorpha). Matthee CA, et al. **Heredity** 1996 May;76 (Pt 5):514–23

Biogeography and taxonomy of Apodemus sylvaticus (the woodmouse) in the Tyrrhenian region: enzymatic variations and mitochondrial DNA restriction pattern analysis. Michaux JR, et al. **Heredity** 1996 Mar;76 (Pt 3):267–77

Vermiforms. Morowitz HJ. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):33–4

Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes. Ogasawara K, et al. **Hum Genet** 1996 Jun; 97(6):777–83

Phylogenetic analysis of Leber's hereditary optic neuropathy mitochondrial DNA's indicates multiple independent occurrences of the common mutations. Brown MD, et al. **Hum Mutat** 1995;6(4):311–25

Janus' faces of DNA sequence evolution. **Immunol Rev** 1995 Apr;144:315–8

The week in phylogeny and ontogeny: opportunities for oncology. Halberg F. **In Vivo** 1995 Jul-Aug;9(4):269–78 (92 ref.)

Analysis of the human gene encoding latent transforming growth factor-beta-binding protein-2. Bashir MM, et al. **Int J Biochem Cell Biol** 1996 May;28(5):531–42

An organelle-like small subunit ribosomal RNA gene from Babesia bovis: nucleotide sequence, secondary structure of the transcript and preliminary phylogenetic analysis. Gozar MM, et al. **Int J Parasitol** 1995 Aug;25(8):929–38

Intraspecific variation in small-subunit rRNA sequences in GenBank: why single sequences may not adequately represent prokaryotic taxa. Clayton RA, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):595–9

Molecular phylogeny of the genus Frankia and related genera and emendation of the family Frankiaceae. Normand P, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):1–9

Phylogenetic relationships of the filamentous sulfur bacterium Thiothrix ramosa based on 16S rRNA sequence analysis. Polz MF, et al. **Int J Syst Bacteriol** 1996 Jan; 46(1):94–7

The phylogeny of Methanopyrus kandleri. Rivera MC, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):348–51

Phylogeny of the Sphaerotilus-Leptothrix group inferred from morphological comparisons, genomic fingerprinting, and 16S ribosomal DNA sequence analyses. Siering PL, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):173–82

Analysis of the phylogenetic relationships of strains of Burkholderia solanacearum, Pseudomonas syzygii, and the blood disease bacterium of banana based on 16S rRNA gene sequences. Taghavi M, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):10–5

Phylogenetic relationships among Rhizobium species nodulating the common bean (Phaseolus vulgaris L.). van Berkum P, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):240–4

Phylogenetic analysis of Fusobacterium prausnitzii based upon the 16S rRNA gene sequence and PCR confirmation. Wang RF, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):341–3

Phylogenetic evidence for the transfer of Pseudomonas cocovenenans (van Damme et al. 1960) to the genus Burkholderia as Burkholderia cocovenenans (van Damme et al. 1960) comb. nov. Zhao N, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):600–3

Sequence variation and subtyping of human and simian T-cell lymphotropic virus type I strains from South Africa. Englebrecht S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):298–302

Characterization and phylogeny of the pfp gene of Amycolatopsis methanolica encoding PPi-dependent phosphofructokinase. Alves AM, et al. **J Bacteriol** 1996 Jan;178(1):149–55

Cloning, functional organization, transcript studies, and phylogenetic analysis of the complete nitrogenase structural genes (nifHDK2) and associated genes in the archaeon Methanosarcina barkeri 227. Chien YT, et al. **J Bacteriol** 1996 Jan;178(1):143–8

Molecular and phylogenetic characterization of pyruvate and 2-ketoisovalerate ferredoxin oxidoreductases from Pyrococcus furiosus and pyruvate ferredoxin oxidoreductase from Thermotoga maritima. Kletzin A, et al. **J Bacteriol** 1996 Jan;178(1):248–57

Isolation of an ftsZ homolog from the archaebacterium Halobacterium salinarium: implications for the evolution of FtsZ and tubulin. Margolin W, et al. **J Bacteriol** 1996 Mar;178(5):1320–7

Phylogenetic analysis of phospholipase C genes from Clostridium perfringens types A to E and Clostridium novyi. Tsutsui K, et al. **J Bacteriol** 1995 Dec; 177(24):7164–70

Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. Becker MM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24496–501

DNA "fossils" and phylogenetic analysis. Using L1 (LINE-1, long interspersed repeated) DNA to determine the evolutionary history of mammals. Furano AV, et al. **J Biol Chem** 1995 Oct 27;270(43):25301–4 (66 ref.)

Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. Gillen CM, et al. **J Biol Chem** 1996 Jul 5;271(27):16237–44

The phylogenetically conserved histidines of Escherichia coli

porphobilinogen synthase are not required for catalysis. Mitchell LW, et al. **J Biol Chem** 1995 Oct 13; 270(41):24054–9

Modular organization of T4 DNA polymerase. Evidence from phylogenetics. Wang CC, et al. **J Biol Chem** 1995 Nov 3;270(44):26558–64

Periventricular morphology in the diencephalon of antarctic notothenioid teleosts. Lannoo MJ, et al. **J Comp Neurol** 1995 Oct 9;361(1):95–107

Hen's teeth and whale's feet: generalized characters and their compatibility. Benham C, et al. **J Comput Biol** 1995 Winter; 2(4):515–25

Toward a characterization of landscapes of combinatorial optimization problems, with special attention to the phylogeny problem. Charleston MA. **J Comput Biol** 1995 Fall;2(3):439–50

The effects of sequence length, tree topology, and number of taxa on the performance of phylogenetic methods. Charleston MA, et al. **J Comput Biol** 1994 Summer; 1(2):133–51

Skewed base compositions, asymmetric transition matrices, and phylogenetic invariants. Ferretti V, et al. **J Comput Biol** 1994 Spring;1(1):77–92

A biologically consistent model for comparing molecular phylogenies. Mirkin B, et al. **J Comput Biol** 1995 Winter; 2(4):493–507

Reconstructing trees when sequence sites evolve at variable rates. Steel MA, et al. **J Comput Biol** 1994 Summer; 1(2):153–63

Classifying and counting linear phylogenetic invariants for the Jukes–Cantor model. Steel MA, et al. **J Comput Biol** 1995 Spring;2(1):39–47

Small subunit ribosomal DNA phylogeny of various microsporidia with emphasis on AIDS related forms. Baker MD, et al. **J Eukaryot Microbiol** 1995 Sep–Oct; 42(5):564–70

Phylogeny of the large extrachromosomal DNA of organisms in the phylum Apicomplexa. Egea N, et al. **J Eukaryot Microbiol** 1995 Nov–Dec;42(6):679–84

Preliminary characterisation of chlorarachniophyte mitochondrial DNA. Gilson P, et al. **J Eukaryot Microbiol** 1995 Nov–Dec;42(6):696–701

Primary structure of the hydrogenosomal malic enzyme of Trichomonas vaginalis and its relationship to homologous enzymes. Hrdý I, et al. **J Eukaryot Microbiol** 1995 Sep–Oct; 42(5):593–603

Characterization, sequencing and phylogeny of the ecdysteroid UDP-glucosyltransferase gene from two distinct nuclear polyhedrosis viruses isolated from Choristoneura fumiferana. Barrett JW, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2447–56

Persistence of a 1930 swine influenza A (H1N1) virus in Quebec. Bikour MH, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2539–47

Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the midwestern United States. Kapur V, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1271–6

Complete nucleotide sequence of the Italian human T-cell lymphotropic virus type II isolate Gu and phylogenetic identification of a possible origin of South European epidemics. Salemi M, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1193–201

Molecular phylogeny of the red panda (Ailurus fulgens). Slattery JP, et al. **J Hered** 1995 Nov–Dec;86(6):413–22

RAPD variation within and among natural populations of trembling aspen (Populus tremuloides Michx.) from Alberta. Yeh FC, et al. **J Hered** 1995 Nov–Dec; 86(6):454–60

The actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. Cox GM, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):261–6

The 5S rRNA and the rRNA intergenic spacer of the two varieties of Cryptococcus neoformans. Fan M, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):215–21

Phylogeny and dating of some pathogenic keratinophilic fungi using small subunit ribosomal RNA. Harmsen D, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):299–303

Random amplified polymorphic DNA for strain delineation within Candida tropicalis. Lin D, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):241–6

Phylogenetic relationships of human–pathogenic Cladosporium (Xylohypha) species inferred from partial LS rRNA sequences. Masclaux F, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):327–38

Genetic homogeneity of Trichophyton mentagrophytes var. interdigitale isolated from geographically distant regions. Mochizuki T, et al. **J Med Vet Mycol** 1996 Mar–Apr; 34(2):139–43

The adenylosuccinate synthetase from the hyperthermophilic archaeon Pyrococcus species displays unusual structural features. Bouyoub A, et al. **J Mol Biol** 1996 Aug 16; 261(2):144–54

Protein sequences indicate that turtles branched off from the amniote tree after mammals. Caspers GJ, et al. **J Mol Evol** 1996 May;42(5):580–6

Evolution according to large ribosomal subunit RNA. De Rijk P, et al. **J Mol Evol** 1995 Sep;41(3):366–75

The beta-tubulin gene family evolution in the Drosophila montium subgroup of the melanogaster species group. Drosopoulou E, et al. **J Mol Evol** 1995 Sep;41(3):293–8

Geosiphon pyriforme, a fungus forming endocytobiosis with Nostoc (cyanobacteria), is an ancestral member of the Glomales: evidence by SSU rRNA analysis. Gehrig H, et al. **J Mol Evol** 1996 Jul;43(1):71–81

Molecular phylogeny of gibbons inferred from mitochondrial DNA sequences: preliminary report. Hayashi S, et al. **J Mol Evol** 1995 Sep;41(3):359–65

Primary structure and eubacterial relationships of the pyruvate:ferredoxin oxidoreductase of the amitochondriate eukaryote Trichomonas vaginalis. Hrdý I, et al. **J Mol Evol** 1995 Sep;41(3):388–96

Gene duplication and recombination in the evolution of mammalian Fc receptors. Hughes AL. **J Mol Evol** 1996 Jul;43(1):4–10

Evolution of the bovine lysozyme gene family: changes in gene expression and reversion of function. Irwin DM. **J Mol Evol** 1995 Sep;41(3):299–312

Evolution and recombination of bovine DNA repeats. Jobse C, et al. **J Mol Evol** 1995 Sep;41(3):277–83

Divergence of the phytochrome gene family predates angiosperm evolution and suggests that Selaginella and Equisetum arose prior to Psilotum. Kolukisaoglu HU, et al. **J Mol Evol** 1995 Sep;41(3):329–37

18S rRNA suggests that Entoprocta are protostomes, unrelated to Ectoprocta. Mackey LY, et al. **J Mol Evol** 1996 May;42(5):552–9

Anomalous phylogenies based on bacterial catalase gene sequences [letter] Mayfield JE, et al. **J Mol Evol** 1996 Apr; 42(4):469–71

Gorilla and orangutan c-myc nucleotide sequences: inference on hominoid phylogeny. Mohammad-Ali K, et al. **J Mol Evol** 1995 Sep;41(3):262–76

Molecular and phylogenetic analysis of PCR-amplified cyclin-dependent kinase (CDK) family sequences from representatives of the earliest available lineages of eukaryotes. Riley DE, et al. **J Mol Evol** 1995 Oct; 41(4):407–13

Phylogeny reconstruction for protein sequences based on amino acid properties. Schmidt W. **J Mol Evol** 1995 Oct; 41(4):522–30

What can 18S rDNA do for bivalve phylogeny? Steiner G, et al. **J Mol Evol** 1996 Jul;43(1):58–70

T-DNA integrations in a new family of repetitive elements of Nicotiana tabacum. Suter-Crazzolara C, et al. **J Mol Evol** 1995 Oct;41(4):498–504

Molecular evolutionary analysis of the YWVZ/7B globin gene cluster of the insect Chironomus thummi. Trewitt PM, et al. **J Mol Evol** 1995 Sep;41(3):313–28

On transition bias in mitochondrial genes of pocket gophers. Xia X, et al. **J Mol Evol** 1996 Jul;43(1):32–40

Molecular phylogeny of Schistosoma species supports traditional groupings within the genus. Barker SC, et al. **J Parasitol** 1996 Apr;82(2):292–8

Phylogeny of the Haplosporidia (Eukaryota: Alveolata) based on small subunit ribosomal RNA gene sequence. Flores BS, et al. **J Parasitol** 1996 Aug;82(4):616–23

Phylogenetic analysis of the 16S–23S rRNA intergenic spacer regions of the genus Ureaplasma. Harasawa R, et al. **J Vet Med Sci** 1996 Mar;58(3):191–5

Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian–Ugandan Cooperation AIDS Program. Buonaguro L, et al. **J Virol** 1995 Dec;69(12):7971–81

Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. Carr JK, et al. **J Virol** 1996 Sep;70(9):5935–43

Complete genetic characterization and analysis of isolation of Sin Nombre virus. Chizhikov VE, et al. **J Virol** 1995 Dec;69(12):8132–6

Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, Peromyscus leucopus: genetic characterization of the M genome of New York virus. Hjelle B, et al. **J Virol** 1995 Dec;69(12):8137–41

Isolation and characterization of a new simian T-cell leukemia virus type 1 from naturally infected celebes macaques (Macaca tonkeana): complete nucleotide sequence and phylogenetic relationship with the Australo-Melanesian human T-cell leukemia virus type 1. Ibrahim F, et al. **J Virol** 1995 Nov;69(11):6980–93

Regulatory genes of simian immunodeficiency viruses from west African green monkeys (Cercopithecus aethiops sabaeus). Jubier-Maurin V, et al. **J Virol** 1995 Nov; 69(11):7349–53

Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. Picard FJ, et al. **J Virol** 1995 Nov;69(11):7248–56

Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. Poss M, et al. **J Virol** 1995 Dec;69(12):8118–22

Intratype variation in 12 human papillomavirus types: a worldwide perspective. Stewart AC, et al. **J Virol** 1996 May;70(5):3127–36

Distribution of baboon endogenous virus among species of African monkeys suggests multiple ancient cross-species transmissions in shared habitats. van der Kuyl AC, et al. **J Virol** 1995 Dec;69(12):7877–87

Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. Yamada T, et al. **J Virol** 1995 Dec;69(12):7743–53

A reevaluation of the higher taxonomy of viruses based on RNA polymerases. Zanotto PM, et al. **J Virol** 1996 Sep; 70(9):6083–96

Phylogenetic analysis of hepatitis C virus isolates from hemodialysis patients. Zeuzem S, et al. **Kidney Int** 1996 Mar;49(3):896–902

Minimum description principle applied to construction of molecular phylogenetic tree. Ren FR, et al. **Medinfo** 1995; 8 Pt 2:899–903

Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods. Felsenstein J. **Methods Enzymol** 1996;266:418–27

Progressive alignment of amino acid sequences and construction of phylogenetic trees from them. Feng DF, et al. **Methods Enzymol** 1996;266:368–82

Using CLUSTAL for multiple sequence alignments. Higgins DG, et al. **Methods Enzymol** 1996;266:383–402

Reconstruction of gene trees from sequence data. Saitou N. **Methods Enzymol** 1996;266:427–49

Phylogenetic analyses of the homologous transmembrane channel-forming proteins of the F0F1-ATPases of bacteria, chloroplasts and mitochondria. Blair A, et al. **Microbiology** 1996 Jan;142 (Pt 1):17–32

Bacillus subtilis mutS mutL operon: identification, nucleotide sequence and mutagenesis. Ginetti F, et al. **Microbiology** 1996 Aug;142 (Pt 8):2021–9

Lipopolysaccharide and porin of Roseobacter denitrificans, confirming its phylogenetic relationship to the alpha-3 subgroup of Proteobacteria. Neumann U, et al. **Microbiology** 1995 Aug;141 (Pt 8):2013–7

16S–23S rDNA intergenic sequences indicate that Leuconostoc oenos is phylogenetically homogeneous. Zavaleta AI, et al. **Microbiology** 1996 Aug;142 (Pt 8):2105–14

Phylogenetic relationships between Old World Leishmania strains revealed by analysis of a repetitive DNA sequence. Piarroux R, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):249–52

Cytochrome b nucleotide sequences and the identification of five primary lineages of extant cetaceans. Arnason U, et al. **Mol Biol Evol** 1996 Feb;13(2):407–17

Arbitrarily primed DNA fingerprinting for phylogenetic reconstruction in vertebrates: the Xiphophorus model. Borowsky RL, et al. **Mol Biol Evol** 1995 Nov;12(6):1022–32

Sequence heterogeneities among 16S ribosomal RNA sequences, and their effect on phylogenetic analyses at the species level. Cilia V, et al. **Mol Biol Evol** 1996 Mar; 13(3):451–61

Length variation and secondary structure of introns in the Mlc1 gene in six species of Drosophila. Clark AG, et al. **Mol Biol Evol** 1996 Mar;13(3):471–82

Molecular evolution of P transposable elements in the genus Drosophila. I. The saltans and willistoni species groups. Clark JB, et al. **Mol Biol Evol** 1995 Sep;12(5):902–13

Sampling properties of DNA sequence data in phylogenetic analysis. Cummings MP, et al. **Mol Biol Evol** 1995 Sep; 12(5):814–22

Nucleotide sequence of a marsupial LINE-1 element and the evolution of placental mammals. Dörner M, et al. **Mol Biol Evol** 1995 Sep;12(5):944–8

Phylogenetic relationships within the Alcidae (Charadriiformes: Aves) inferred from total molecular evidence. Friesen VL, et al. **Mol Biol Evol** 1996 Feb; 13(2):359–67

First molecular evidence for the existence of a Tardigrada + Arthropoda clade. Giribet G, et al. **Mol Biol Evol** 1996 Jan;13(1):76–84

Phylogenetic analysis of the 90 kD heat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species. Gupta RS. **Mol Biol Evol** 1995 Nov;12(6):1063–73

Phylogenetic position of cetaceans relative to artiodactyls: reanalysis of mitochondrial and nuclear sequences. Hasegawa M, et al. **Mol Biol Evol** 1996 May;13(5):710–7

Phylogenetic place of mitochondrion-lacking protozoan, Giardia lamblia, inferred from amino acid sequences of elongation factor 2. Hashimoto T, et al. **Mol Biol Evol** 1995 Sep;12(5):782–93

Phylogenetic relationships of amphibian families inferred from DNA sequences of mitochondrial 12S and 16S ribosomal RNA genes. Hay JM, et al. **Mol Biol Evol** 1995 Sep;12(5):928–37

The robustness of two phylogenetic methods: four-taxon simulations reveal a slight superiority of maximum likelihood over neighbor joining. Huelsenbeck JP. **Mol Biol Evol** 1995 Sep;12(5):843–9

Variations in mitochondrial tRNA gene organization of reptiles as phylogenetic markers. Kumazawa Y, et al. **Mol Biol Evol** 1995 Sep;12(5):759–72

Relative apparent synapomorphy analysis (RASA). I: The statistical measurement of phylogenetic signal. Lyons-Weiler J, et al. **Mol Biol Evol** 1996 Jul;13(6):749–57

Mitochondrial DNA phylogeny and the reconstruction of the population history of a species: the case of the European anchovy (Engraulis encrasicolus). Magoulas A, et al. **Mol Biol Evol** 1996 Jan;13(1):178–90

Mitochondrial DNA sequence evolution in sharks: rates, patterns, and phylogenetic inferences. Martin AP. **Mol Biol Evol** 1995 Nov;12(6):1114–23

Phylogenetic history of LINE-1 among arvicolid rodents. Modi WS. **Mol Biol Evol** 1996 May;13(5):633–41

Molecular phylogeny of annexins and identification of a primitive homologue in Giardia lamblia. Morgan RO, et al. **Mol Biol Evol** 1995 Nov;12(6):967–79

Phylogenetic relationships within the aplocheiloid fish genus Rivulus (Cyprinodontiformes, Rivulidae): implications for Caribbean and Central American biogeography. Murphy WJ, et al. **Mol Biol Evol** 1996 May;13(5):642–9

The root of the phylogenetic tree of human populations. Nei M, et al. **Mol Biol Evol** 1996 Jan;13(1):170–7

Early origin of foraminifera suggested by SSU rRNA gene sequences. Pawlowski J, et al. **Mol Biol Evol** 1996 Mar; 13(3):445–50

Interchromosomal exchange of genetic information between gene arrangements on the third chromosome of Drosophila pseudoobscura. Popadić A, et al. **Mol Biol Evol** 1995 Sep; 12(5):938–43

Recent horizontal transfer of a mariner transposable element among and between Diptera and Neuroptera. Robertson HM, et al. **Mol Biol Evol** 1995 Sep;12(5):850–62

Efficiencies of different genes and different tree-building methods in recovering a known vertebrate phylogeny. Russo CA, et al. **Mol Biol Evol** 1996 Mar;13(3):525–36

Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV–1). Seibert SA, et al. **Mol Biol Evol** 1995 Sep;12(5):803–13

A novel measure of genetic distance for highly polymorphic tandem repeat loci. Shriver MD, et al. **Mol Biol Evol** 1995 Sep;12(5):914–20

Among–site rate variation and phylogenetic analysis of 12S rRNA in sigmodontine rodents. Sullivan J, et al. **Mol Biol Evol** 1995 Nov;12(6):988–1001

Phylogenetic analysis of cichlid fishes using nuclear DNA markers. Sültmann H, et al. **Mol Biol Evol** 1995 Nov; 12(6):1033–47

Phylogenetic test of the molecular clock and linearized trees. Takezaki N, et al. **Mol Biol Evol** 1995 Sep;12(5):823–33

Majority–rule reduced consensus trees and their use in bootstrapping. Wilkinson M. **Mol Biol Evol** 1996 Mar; 13(3):437–44

Recognizing the forest for the trees: testing temporal patterns of cladogenesis using a null model of stochastic diversification. Wollenberg K, et al. **Mol Biol Evol** 1996 Jul;13(6):833–49

Testing models of female reproductive migratory behaviour and population structure in the Caribbean hawksbill turtle, Eretmochelys imbricata, with mtDNA sequences. Bass AL, et al. **Mol Ecol** 1996 Jun;5(3):321–8

Genetic diversity within mer genes directly amplified from communities of noncultivated soil and sediment bacteria. Bruce KD, et al. **Mol Ecol** 1995 Oct;4(5):605–12

Phylogeography and population structure of the Atlantic and Mediterranean green turtle Chelonia mydas: a mitochondrial DNA control region sequence assessment. Encalada SE, et al. **Mol Ecol** 1996 Aug;5(4):473–83

Widespread geographical distribution of mitochondrial haplotypes in rock–dwelling cichlid fishes from Lake Tanganyika. Meyer A, et al. **Mol Ecol** 1996 Jun;5(3):341–50

Chloroplast DNA phylogeography of the argan tree of Morocco. el Mousadik A, et al. **Mol Ecol** 1996 Aug; 5(4):547–55

The phylogenetic distribution of a transposable dioxygenase from the Niagara River watershed. Nakatsu CH, et al. **Mol Ecol** 1995 Oct;4(5):593–603

Gene transfer from a bacterium injected into an aquifer to an indigenous bacterium. Zhou JZ, et al. **Mol Ecol** 1995 Oct;4(5):613–8

Molecular characterization of the lysosomal acid phosphatase from Drosophila melanogaster. Chung HJ, et al. **Mol Gen Genet** 1996 Mar 20;250(5):635–46

Structure and expression of three genes encoding ACC oxidase homologs from melon (Cucumis melo L.). Lasserre E, et al. **Mol Gen Genet** 1996 Apr 24;251(1):81–90

Easel, a gypsy LTR–retrotransposon in the Salmonidae. Tristem M, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):229–36

The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825–34 (59 ref.)

GroEL (Hsp60)–based eubacterial and organellar phylogenies [letter; comment] Viale A. **Mol Microbiol** 1995 Sep;17(5):1013. Comment on: Mol Microbiol 1995 Jan;15(1):1–11.

The analysis of protein coding genes suggests monophyly of Trypanosoma. Alvarez F, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):333–43

Molecular phylogeny of Azteca ants (Hymenoptera:Formicidae) and the colonization of Cecropia trees. Ayala FJ, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):423–8

Phylogeny of the Chlamydomonadales (Chlorophyceae): a comparison of ribosomal RNA gene sequences from the nucleus and the chloroplast. Buchheim MA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):391–402

Re: Molecular systematics of hystricognath rodents: the contribution of sciurognath mitochondrial 12S rRNA sequences [letter] Catzeflis FM, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):357–60

Hominoid phylogeny estimated by model selection using goodness of fit significance tests. Czelusniak J, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):283–90

Complete sequence of the mitochondrial DNA in the sea urchin Arbacia lixula: conserved features of the echinoid mitochondrial genome. De Giorgi C, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):323–32

Phylogenetic analysis of Pacific salmon (genus Oncorhynchus) based on mitochondrial DNA sequence data. Domanico MJ, et al. **Mol Phylogenet Evol** 1995 Dec; 4(4):366–71

The distribution and phylogenetic significance of a 50–kb chloroplast DNA inversion in the flowering plant family Leguminosae. Doyle JJ, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):429–38

Molecular phylogenetics of Poaceae: an expanded analysis of rbcL sequence data. Duvall MR, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):352–8

Phylogenetic analysis of beta–tubulin sequences from amitochondrial protozoa. Edlind TD, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):359–67

Phylogenetic relationships of the Prodontria (Coleoptera; Scarabaeidae; subfamily Melolonthinae), derived from sequence variation in the mitochondrial cytochrome oxidase II gene. Emerson BC, et al. **Mol Phylogenet Evol** 1995 Dec;4(4):433–47

Epilogue: a personal account of the origins of a new paradigm. Goodman M. **Mol Phylogenet Evol** 1996 Feb; 5(1):269–85

Molecular phylogenetics and biogeography of tanagers in the genus Ramphocelus (Aves). Hackett SJ. **Mol Phylogenet Evol** 1996 Apr;5(2):368–82

Re: A commentary on the use of sequence data for phylogeny reconstruction [letter] Hackett SJ, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):350–6

DNA evidence on the phylogenetic systematics of New World monkeys: support for the sister–grouping of Cebus and Saimiri from two unlinked nuclear genes. Harada ML, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):331–49

Systematics of New World monkeys (Platyrrhini, Primates) based on 16S mitochondrial DNA sequences: a comparative analysis of different weighting methods in cladistic analysis. Horovitz I, et al. **Mol Phylogenet Evol** 1995 Dec; 4(4):448–56

Use of rRNA secondary structure in phylogenetic studies to identify homologous positions: an example of alignment and data presentation from the frogs. Kjer KM. **Mol Phylogenet Evol** 1995 Sep;4(3):314–30

Early evolution of the Metazoa and phylogenetic status of diploblasts as inferred from amino acid sequence of elongation factor–1 alpha. Kobayashi M, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):414–22

The simultaneous diversification of South American echimyid rodents (Hystricognathi) based on complete cytochrome b sequences. Lara MC, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):403–13

A hierarchical molecular phylogeny within the genus Daphnia. Lehman N, et al. **Mol Phylogenet Evol** 1995 Dec; 4(4):395–407

Hominoid phylogeny and taxonomy: a consideration of the molecular and fossil evidence in an historical perspective. Mann A, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):169–81

Molecular phylogenetics of oryzomyine rodents: the genus Oligoryzomys. Myers P, et al. **Mol Phylogenet Evol** 1995 Dec;4(4):372–82

A phylogenetic analysis of monocotyledons based on the chloroplast gene rps4, using parsimony and a new numerical phenetics method. Nadot S, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):257–82

A phylogenetic analysis of cuckoo bumblebees (Psithyrus, Lepeletier) and bumblebees (Bombus, Latreille) inferred from sequences of the mitochondrial gene cytochrome oxidase I. Pedersen BV. **Mol Phylogenet Evol** 1996 Apr; 5(2):289–97

Evidence on mammalian phylogeny from sequences of exon 28 of the von Willebrand factor gene. Porter CA, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):89–101

Mitochondrial phylogeny of trematomid fishes (Notothenioidae, Perciformes) and the evolution of Antarctic fish. Ritchie PA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):383–90

Phylogenetic relationships among the true porpoises (Cetacea:Phocoenidae). Rosel PE, et al. **Mol Phylogenet Evol** 1995 Dec;4(4):463–74

Re: The questionable implications of the dopamine D4 receptor (DRD4) gene tree for primate phylogeny [letter] Ruvolo M, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):439–40

Phylogenetic relationships inferred from the sequence and secondary structure of ITS1 rRNA in Albinaria and putative Isabellaria species (Gastropoda, Pulmonata, Clausiliidae). Schilthuizen M, et al. **Mol Phylogenet Evol** 1995 Dec;4(4):457–62

Phylogenetic relationship of silkmoths inferred from sequence data of the arylphorin gene. Shimada T, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):223–34

Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)

Mhc–DRB genes and the origin of New World monkeys. Trtkova K, et al. **Mol Phylogenet Evol** 1995 Dec; 4(4):408–19

Phylogeny of Eucalyptus and Angophora based on 5S rDNA spacer sequence data. Udovicic F, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):247–56

In search of butterfly origins. Weller SJ, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):235–46

An unusual ribosomal DNA sequence from Gossypium gossypioides reveals ancient, cryptic, intergenomic introgression. Wendel JF, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):298–313

Phylogenetic relationships of the soybean sudden death syndrome pathogen Fusarium solani f. sp. phaseoli inferred from rDNA sequence data and PCR primers for its identification. O'Donnell K, et al. **Mol Plant Microbe Interact** 1995 Sep–Oct;8(5):709–16

Phylogenetic position of the order Lagomorpha (rabbits, hares and allies) [see comments] Graur D, et al. **Nature** 1996 Jan 25;379(6563):333–5. Comment in: Nature 1996 Jan 25;379(6563):299–300.

Inferring complex phylogenies [letter] Hillis DM. **Nature** 1996 Sep 12;383(6596):130–1

Phylogenesis of prion protein [letter] [see comments] Krakauer DC, et al. **Nature** 1996 Apr 25;380(6576):675. Comment in: Nature 1996 Jul 4;382(6586):32–3.

Mitochondrial DNA sequence relationships of the extinct blue antelope Hippotragus leucophaeus. Robinson TJ, et al. **Naturwissenschaften** 1996 Apr;83(4):178–82

R4, a non–LTR retrotransposon specific to the large subunit rRNA genes of nematodes. Burke WD, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4628–34

A cholinesterase genes server (ESTHER): a database of cholinesterase–related sequences for multiple alignments, phylogenetic relationships, mutations and structural data retrieval. Cousin X, et al. **Nucleic Acids Res** 1996 Jan 1; 24(1):132–6

Conservation patterns in angiosperm rDNA ITS2 sequences. Hershkovitz MA, et al. **Nucleic Acids Res** 1996 Aug 1; 24(15):2857–67

The phylogeny of tRNAs seems to confirm the predictions of the coevolution theory of the origin of the genetic code. Di Giulio M. **Orig Life Evol Biosph** 1995 Dec;25(6):549–64

Effects of sequence alignment on the phylogeny of Sarcocystis deduced from 18S rDNA sequences. Ellis J, et al. **Parasitol Res** 1995;81(8):696–9

Phylogenetic relationships within Taenia taeniaeformis variants and other taeniid cestodes inferred from the nucleotide sequence of the cytochrome c oxidase subunit I gene. Okamoto M, et al. **Parasitol Res** 1995;81(6):451–8

The possible role of long–chain, omega–3 fatty acids in human brain phylogeny. Chamberlain JG. **Perspect Biol Med** 1996 Spring;39(3):436–45

The systematics of North American Daphnia (Crustacea: Anomopoda): a molecular phylogenetic approach. Colbourne JK, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1337):349–60

Molecular phylogenies and host–parasite cospeciation: gophers and lice as a model system. Hafner MS, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Jul 29; 349(1327):77–83

Revealing the history of infectious disease epidemics through phylogenetic trees. Holmes EC, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Jul 29; 349(1327):33–40

Phylogenies and comparative data, a microevolutionary perspective. Martins EP. **Philos Trans R Soc Lond B Biol Sci** 1995 Jul 29; 349(1327):85–91

Inferring population history from molecular phylogenies. Nee S, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Jul 29; 349(1327):25–31

A composite estimate of primate phylogeny. Purvis A. **Philos Trans R Soc Lond B Biol Sci** 1995 Jun 29; 348(1326):405–21

Ovule development: identification of stage–specific and tissue–specific cDNAs. Nadeau JA, et al. **Plant Cell** 1996 Feb;8(2):213–39

Origin of allelic diversity in antirrhinum S locus RNases. Xue Y, et al. **Plant Cell** 1996 May;8(5):805–14

A non–photosynthetic ferredoxin gene is induced by ethylene in Citrus organs. Alonso JM, et al. **Plant Mol Biol** 1995 Dec;29(6):1211–21

Molecular comparison of carbonic anhydrase from Flaveria species demonstrating different photosynthetic pathways. Ludwig M, et al. **Plant Mol Biol** 1995 Oct;29(2):353–65

Differential accumulation of the transcripts of 22 novel protein kinase genes in Arabidopsis thaliana. Thümmler F, et al. **Plant Mol Biol** 1995 Nov;29(3):551–65

A lectin and a lectin–related protein are the two most prominent proteins in the bark of yellow wood (Cladrastis lutea). Van Damme EJ, et al. **Plant Mol Biol** 1995 Nov; 29(3):579–98

Two divergent xyloglucan endotransglycosylases exhibit mutually exclusive patterns of expression in nasturtium. Rose JK, et al. **Plant Physiol** 1996 Feb;110(2):493–9

Use of randomly amplified polymorphic DNA markers for the genetic analysis of relatedness and diversity in chickens and turkeys. Smith EJ, et al. **Poult Sci** 1996 May; 75(5):579–84

Myc and Max: molecular evolution of a family of proto–oncogene products and their dimerization partner. Atchley WR, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10217–21

Comparative analysis of ribonuclease P RNA using gene sequences from natural microbial populations reveals tertiary structural elements. Brown JW, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3001–6

cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Cimprich KA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2850–5

Bootstrap confidence levels for phylogenetic trees. Efron B, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7085–90

Monophyletic origin and unique dispersal patterns of

domestic fowls. Fumihito A, et al.
Proc Natl Acad Sci U S A 1996 Jun 25;93(13):6792–5

Inferring phylogenies from DNA sequences of unequal base compositions. Galtier N, et al.
Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11317–21

Chloroplast DNA variation and the recent radiation of the giant senecios (Asteraceae) on the tall mountains of eastern Africa. Knox EB, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10349–53

Calculating the probability of multitaxon evolutionary trees: bootstrappers Gambit. Lake JA.
Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9662–6

Does behavior reflect phylogeny in swiftlets (Aves: Apodidae)? A test using cytochrome b mitochondrial DNA sequences. Lee PL, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7091–6

Equine rhinovirus 1 is more closely related to foot-and-mouth disease virus than to other picornaviruses. Li F, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):990–5

Archaeal-eubacterial mergers in the origin of Eukarya: phylogenetic classification of life. Margulis L.
Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1071–6

Pea formaldehyde-active class III alcohol dehydrogenase: common derivation of the plant and animal forms but not of the corresponding ethanol-active forms (classes I and P). Shafqat J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5595–9

Molecular cloning and sequence analysis of expansins—a highly conserved, multigene family of proteins that mediate cell wall extension in plants. Shcherban TY, et al.
Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9245–9

Unexpected beta2-microglobulin sequence diversity in individual rainbow trout. Shum BP, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2779–84

Plant members of a family of sulfate transporters reveal functional subtypes. Smith FW, et al.
Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9373–7

Phylogenetic resolution within the Elephantidae using fossil DNA sequence from the American mastodon (Mammut americanum) as an outgroup. Yang H, et al.
Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1190–4

Long, polymorphic microsatellites in simple organisms. Field D, et al. **Proc R Soc Lond B Biol Sci** 1996 Feb 22; 263(1367):209–15

Mitochondrial DNA phylogeny and sequential colonization of Canary Islands by darkling beetles of the genus Pimelia (Tenebrionidae). Juan C, et al.
Proc R Soc Lond B Biol Sci 1995 Aug 22;261(1361):173–80

The English debate on taxonomy and phylogeny, 1937–1940. Winsor MP. **Pubbl Stn Zool Napoli II** 1995;17(2):227–52

Phylogeny of Serpulina based on sequence analyses of the 16S rRNA gene and comparison with a scheme involving biochemical classification. Fellström C, et al.
Res Vet Sci 1995 Jul;59(1):5–9

Lophophorate phylogeny [letter; comment] Morris SC, et al. **Science** 1996 Apr 12;272(5259):282–3. Comment on: Science 1995 Mar 17;267(5204):1641–3.

An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al.
Trends Pharmacol Sci 1995 Nov;16(11):375–81 (56 ref.)

The phylogeny of Mycobacterium tuberculosis [letter] Frieden TR. **Tuber Lung Dis** 1996 Jun;77(3):291

Morbillivirus infections of aquatic mammals: newly identified members of the genus. Osterhaus AD, et al.
Vet Microbiol 1995 May;44(2–4):219–27

Genetic diversity and phylogenetic classification of viral hemorrhagic septicemia virus (VHSV). Basurco B, et al.
Vet Res 1995;26(5–6):460–3

The phylogeny of New World (Tacaribe complex) arenaviruses. Bowen MD, et al. **Virology** 1996 May 1; 219(1):285–90

Variability and phylogeny of the L1 capsid protein gene of human papillomavirus type 5: contribution of clusters of nonsynonymous mutations and of a 30-nucleotide duplication. Kawase M, et al. **Virology** 1996 Jul 1; 221(1):189–98

Molecular characterization of the Japanese encephalitis serocomplex of the flavivirus genus. Poidinger M, et al.
Virology 1996 Apr 15;218(2):417–21

Phylogeny of Old and New World vultures (Aves: Accipitridae and Cathartidae) inferred from nucleotide sequences of the mitochondrial cytochrome b gene. Wink M. **Z Naturforsch [C]** 1995 Nov–Dec;50(11–12):868–82

[Comparative biochemistry of the triune brain] Bureau M, et al. **Acta Psychiatr Belg** 1994;94(4–6):225–47 (63 ref.) (Eng. Abstr.) **(Fre)**

[Phylogenetic origin of symptoms in psychopathology. Exemplified by hysteria] Demaret A.
Acta Psychiatr Belg 1994;94(4–6):280–98 (Eng. Abstr.) **(Fre)**

[Phylogeny of sleep stages] Jouvet M.
Acta Psychiatr Belg 1994;94(4–6):256–67 (Eng. Abstr.) **(Fre)**

[The long progress of neurohypophyseal peptides] Legros JJ. **Acta Psychiatr Belg** 1994;94(4–6):248–55 (Eng. Abstr.) **(Fre)**

[Phylogeny of myelin and myelin forming cells] Zalc B. **C R Seances Soc Biol Fil** 1995;189(2):239–44 (11 ref.) (Eng. Abstr.) **(Fre)**

[A comparison of the morphology of mammalian and bird ear ossicles and reflections on the asymmetrical form of the human stapes arch] Hüttenbrink KB.
Laryngorhinootologie 1996 Mar;75(3):123–8 (Eng. Abstr.) **(Ger)**

[Phylogenetic elements in Goethe's theory of colors] Solch R. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29–30):911–6 (Eng. Abstr.) **(Ger)**

[Mites (Cheliceromorpha, Arachnida: Acari) remarks on phylogeny and evolution] Błaszak C. **Wiad Parazytol** 1995; 41(3):245–51 **(Pol)**

[Evolution of gypsy-group retrotransposons: phylogenetic analysis of domains included in the pol-polyprotein] Makarova KS, et al. **Genetika** 1995 Dec;31(12):1614–29 (Eng. Abstr.) **(Rus)**

[Comparison of 18S ribosomal RNA genes in invertebrate phylogeny] Aleshin VV, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1408–26 (58 ref.) **(Rus)**

[Phylogenetic relationships between 16 species of Lake Baikal sculpin fish based on a nucleotide sequence analysis of a mitochondrial DNA fragment of the cytochrome b gene] Kiril'chik SV, et al. **Mol Biol (Mosk)** 1995 Jul–Aug; 29(4):817–25 (Eng. Abstr.) **(Rus)**

[Distribution and phylogenetic analysis of HTLV-I isolates, persisting in the Russian Far East] Yamashita M, et al.
Mol Biol (Mosk) 1995 Sep–Oct;29(5):1172–82 **(Rus)**

[The development of the active sleep phase in phylogeny and ontogeny] Aristakesian EA, et al.
Zh Evol Biokhim Fiziol 1995 May–Jun;31(3):346–65 (85 ref.) **(Rus)**

[Phylogeny of lice (Insecta: Anoplura) of the Old World Monkey (Catarrhina)] Retana Salazar AP.
Rev Biol Trop 1994 Dec;42(3):633–8 (Eng. Abstr.) **(Spa)**

PHYSALAEMIN

ANALOGS & DERIVATIVES

Pharmacological characterization of GR82334, a tachykinin NK1 receptor antagonist, in the isolated spinal cord of the neonatal rat. Guo JZ, et al. **Eur J Pharmacol** 1995 Jul 25; 281(1):49–54

Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists. Conte B, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):212–8

PHYSALOPTERA see **SPIRUROIDEA**

PHYSARUM

METABOLISM

Fragmin, a microfilament regulatory protein from Physarum polycephalum, is phosphorylated by casein kinase II-type enzymes. De Corte V, et al. **Biochemistry** 1996 Apr 30; 35(17):5472–80

PHYSARUM POLYCEPHALUM

CHEMISTRY

Large complexes of beta-poly(L-malate) with DNA polymerase alpha, histones, and other proteins in nuclei of growing plasmodia of Physarum polycephalum. Angerer B, et al. **Biochemistry** 1995 Nov 14;34(45):14741–51

Purification and some properties of hemagglutinin from the Myxomycete, Physarum polycephalum. Yokota M, et al.
Experientia 1996 Jun 15;52(6):544–8

ENZYMOLOGY

A novel intracellular acid proteinase from the plasmodia of a true slime mold, Physarum polycephalum.
Murakami-Murofushi K, et al. **Adv Exp Med Biol** 1995; 362:565–8

A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Lechner T, et al.
Biochim Biophys Acta 1996 Sep 5;1296(2):181–8

DNA polymerase delta of Physarum polycephalum. Achhammer G, et al. **Curr Genet** 1995 Nov;28(6):534–45

GENETICS

Identification and sequence analysis of a rap gene from the true slime mold Physarum polycephalum. Kozlowski P, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):29–33

The two alleles of the hapP gene in Physarum polycephalum code for different proteins. Lépine G, et al.
Biochim Biophys Acta 1995 Dec 27;1264(3):271–4

Rearrangements of mitochondrial DNA and the mitochondrial fusion-promoting plasmid (mF) are associated with defective mitochondrial fusion in Physarum polycephalum. Takano H, et al. **Curr Genet** 1996 Feb; 29(3):257–64

Cloning and genomic sequence of the Physarum polycephalum Ppras1 gene, a homologue of the ras protooncogene. Trzcinska-Danielewicz J, et al. **Gene** 1996 Feb 22;169(1):143–4

Electroporation of Physarum polycephalum. Burland TG, et al. **Methods Mol Biol** 1995;47:303–20

Mapping of a replication origin within the promoter region of two unlinked, abundantly transcribed actin genes of Physarum polycephalum. Bénard M, et al.
Mol Cell Biol 1996 Mar;16(3):968–76

Enhanced self-splicing of Physarum polycephalum intron 3 by a second group I intron. Rocheleau GA, et al.
RNA 1995 Apr;1(2):183–93

Accurate and efficient insertional RNA editing in isolated Physarum mitochondria. Visomirski-Robic LM, et al.
RNA 1995 Sep;1(7):681–91

GROWTH & DEVELOPMENT

Plasmodium development in the myxomycete Physarum polycephalum: genetic control and cellular events. Bailey J. **Microbiology** 1995 Oct;141 (Pt 10):2355–65 (80 ref.)

METABOLISM

In vivo topoisomerase II cleavage sites in the ribosomal DNA of Physarum polycephalum. Borde V, et al.
Biochemistry 1996 May 7;35(18):5787–95

Physarum polycephalum haemagglutinins: effect of nutrition on synthesis, and their possible role in nature. Morita M, et al. **Microbiology** 1995 Sep;141 (Pt 9):2315–22

PHYSIOLOGY

Phase switching of oscillatory contraction in relation to the regulation of amoeboid behavior by the plasmodium of Physarum polycephalum. Nakagaki T, et al.
J Theor Biol 1996 Apr 7;179(3):261–7

Functional mapping of the branched signal transduction pathway that controls sporulation in Physarum polycephalum. Starostzik C, et al. **Photochem Photobiol** 1995 Nov;62(5):930–3

RADIATION EFFECTS

Functional mapping of the branched signal transduction pathway that controls sporulation in Physarum polycephalum. Starostzik C, et al. **Photochem Photobiol** 1995 Nov;62(5):930–3

PHYSCOMITRELLA see **MOSSES**

PHYSIATRY see **PHYSICAL MEDICINE**

PHYSICAL CONDITIONING, ANIMAL

Effects of streptozotocin-induced diabetes, physical training and their combination on collagen biosynthesis in rat skeletal muscle. Han X, et al. **Acta Physiol Scand** 1995 Sep; 155(1):9–16

A transtracheal catheter for recording the static tracheal pressure in the exercising horse. Roethlisberger-Holm K, et al. **Acta Vet Scand** 1995;36(4):461–73

Relationships between muscle membrane lipids, fiber type, and enzyme activities in sedentary and exercised rats. Kriketos AD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1154–62

SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise-trained old rats. Tate CA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H68–72

Blood ionized calcium concentrations in horses before and after the cross-country phase of three-day event competition. Geiser DR, et al. **Am J Vet Res** 1995 Nov; 56(11):1502–5

Site-specific proteoglycan characteristics of third carpal articular cartilage in exercised and nonexercised horses. Palmer JL, et al. **Am J Vet Res** 1995 Dec;56(12):1570–6

Responses of blood and plasma lactate and plasma purine concentrations to maximal exercise and their relation to performance in standardbred trotters. Räsänen LA, et al.
Am J Vet Res 1995 Dec;56(12):1651–6

Effect of acute treadmill exercise on LFA-1 antigen expression in murine splenocytes. Hoffman-Goetz L.
Anticancer Res 1995 Sep–Oct;15(5B):1981–4

Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Venditti P, et al.
Arch Biochem Biophys 1996 Jul 1;331(1):63–8

Exercise induces the translocation of GLUT4 to transverse tubules from an intracellular pool in rat skeletal muscle. Roy D, et al. **Biochem Biophys Res Commun** 1996 Jun 5; 223(1):147–52

Exercise during adolescence and its effects on mammary gland development, proliferation, and nitrosomethylurea (NMU) induced tumorigenesis in rats. Whittal KS, et al.
Breast Cancer Res Treat 1996;37(1):21–7

Effects of treadmill exercise and high-fat feeding on muscle degeneration in mdx mice at the time of weaning. Mokhtarian A, et al. **Clin Sci (Colch)** 1995 Oct;89(4):447–52

The influence of isotonic exercise on cardiac hypertrophy in arterial hypertension: impact on cardiac function and on the capacity for aerobic work. Moreno Júnior H, et al. **Comp Biochem Physiol A Physiol** 1995 Oct; 112(2):313–20

Effects of an endurance training programme on the passive and noradrenaline-activated compliances of rat aorta. Koutsis G, et al. **Eur J Appl Physiol** 1995;71(2–3):173–9

Physical conditioning in rats influences the central and peripheral catecholamine responses to sustained exercise. Pagliari R, et al. **Eur J Appl Physiol** 1995;71(1):41–52

Tumour purine nucleotides and cell proliferation in response to exercise in rats. Daneryd P, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2309–12

Effect of exercise and 2-deoxyglucose on the K+ channel

opener action of CGRP in the guinea pig ureter. Maggi CA, et al. **Gen Pharmacol** 1996 Jan;27(1):95–100

Exercise training generates ascorbate free radical in rat heart. Somani SM, et al. **Indian J Physiol Pharmacol** 1995 Oct; 39(4):323–9

Antioxidant enzyme activities and lipid peroxidation levels in exercised and hypertensive rat tissues. Hong H, et al. **Int J Biochem Cell Biol** 1995 Sep;27(9):923–31

The effects of different treadmill running programs on the muscle morphology of adult rats. Deschenes MR, et al. **Int J Sports Med** 1995 Jul;16(5):273–7

Training-induced protection and effect of terminated training on exercise-induced damage and water content in mouse skeletal muscles. Komulainen J, et al. **Int J Sports Med** 1995 Jul;16(5):293–7

Effects of jump training on bone hypertrophy in young and old rats. Umemura Y, et al. **Int J Sports Med** 1995 Aug; 16(6):364–7

Factors associated with finishing status for dogs competing in a long-distance sled race. Constable PD, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):879–82

Tibial stress fractures in racing standardbreds: 13 cases (1989–1993). Ruggles AJ, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):634–7

Prognosis for return to racing after recovery from infectious pleuropneumonia in thoroughbred racehorses: 70 cases (1984–1989). Seltzer KL, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1300–1

Exercise training-induced changes in anterior pituitary gonadotrope of the female rat. Caston AL, et al. **J Appl Physiol** 1995 Jul;79(1):194–201

Metabolic responses of rat respiratory muscles to voluntary exercise training. Halseth AE, et al. **J Appl Physiol** 1995 Sep;79(3):902–7

Effects of exercise training on responses of peripheral and visceral arteries in swine. McAllister RM, et al. **J Appl Physiol** 1996 Jan;80(1):216–25

Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle. Torgan CE, et al. **J Appl Physiol** 1995 Jul;79(1):163–7

Mechanical and metabolic performance of the rat heart: effects of combined stress of heat acclimation and swimming training. Horowitz M, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun; 4(1–2):139–56

Effect of physical training on bone adaptation in three zones of the rat tibia. Bourrin S, et al. **J Bone Miner Res** 1995 Nov;10(11):1745–52

A mobile cage facilitates periodic social contact and exercise for singly caged adult Vervet monkeys. Seier JV, et al. **J Med Primatol** 1996 Jan;25(1):64–8

The influence of strength training, swim training and ageing on the Achilles tendon and m. soleus of the rat. Simonsen EB, et al. **J Sports Sci** 1995 Aug;13(4):291–5

Comparative hematological study of two breeds of foals (Andalusian and Arab) subjected to exercise of progressive intensity. Rubio MD, et al. **J Vet Med Sci** 1995 Apr; 57(2):311–5

Acute or chronic exercise alters angiotensin II-induced contraction of rat aorta. Izawa T, et al. **Jpn J Physiol** 1995; 45(6):1093–100

Effect of a training session of endurance running on anserine and carnosine contents in fast and slow muscles of young rats. Tanaka M. **Jpn J Physiol** 1995;45(4):659–66

Prolonged recovery and reduced adaptation in aged rat muscle following eccentric exercise. McBride TA, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):185–200

A neural network confirms that physical exercise reverses EEG changes in depressed rats. Sarbadhikari SN. **Med Eng Phys** 1995 Dec;17(8):579–82

A chronically instrumented rat model to assess the altered baroreflex due to exercise. Hyek MF, et al. **Med Sci Sports Exerc** 1995 Sep;27(9):1339–44

Effects of exercise training and feeding on lipoprotein lipase gene expression in adipose tissue, heart, and skeletal muscle of the rat. Ong JM, et al. **Metabolism** 1995 Dec; 44(12):1596–605

Regional changes in capillary supply in skeletal muscle of interval-sprint and low-intensity, endurance-trained rats. Gute D, et al. **Microcirculation** 1994 Oct;1(3):183–93

Effects of training, early handling, and perinatal flumazenil on shuttle box acquisition in Roman low-avoidance rats: toward overcoming a genetic deficit. Escorihuela RM, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):353–67

Cold acclimation and endurance training in guinea pigs: changes in lung, muscle and brown fat tissue. Hoppeler H, et al. **Respir Physiol** 1995 Aug;101(2):189–98

Cold acclimation and endurance training in guinea pigs: changes in daily and maximal metabolism. Turner DL, et al. **Respir Physiol** 1995 Aug;101(2):183–8

HDL-cholesterol increase associated to triglycerides degradation in vitro. Jimeno B, et al. **Rev Esp Fisiol** 1995 Jun;51(2):101–4

The prevalence of abnormal behaviours in dressage, eventing and endurance horses in relation to stabling. McGreevy PD, et al. **Vet Rec** 1995 Jul 8;137(2):36–7

[Cardiodepressive effects of muscular exercise in spontaneously hypertensive rats] Raimondi G, et al. **Cardiologia** 1995 Apr;40(4):253–9 (Eng. Abstr.) **(Ita)**

[Role of the hypophysis, hormonal growth inducers and physical exercises in the regulation of function of thyrocytes, C-cells and parathyrocytes in rats during simulated weightlessness] Kaplanskiĭ AS, et al. **Aviakosm Ekolog Med** 1995;29(4):47–52 (Eng. Abstr.) **(Rus)**

[Hypoxic training stimulates new growth of pancreatic beta cells and slows development of diabetes mellitus in rats] Kolesnik IuM, et al. **Dokl Akad Nauk** 1995 Jul;343(1):127–9 **(Rus)**

[Study of biological activity of nidus vespae infusions during physical exercise] Kostiuchenkov VN, et al. **Kosm Biol Aviakosm Med** 1991 Nov-Dec;25(6):58–9 **(Rus)**

ADVERSE EFFECTS

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.). Comment on: Equine Vet J 1995 Jul;27(4):275–9.

Fatal musculoskeletal injuries incurred during racing and training in thoroughbreds. Estberg L, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):92–6

METHODS

Training increases the in vivo fracture strength in osteoporotic bone. Protection by muscle contraction examined in rat tibiae. Kaastad TS, et al. **Acta Orthop Scand** 1996 Aug;67(4):371–6

PHYSIOLOGY

Rat skeletal muscle metabolism in experimental heart failure: effects of physical training. Brunotte F, et al. **Acta Physiol Scand** 1995 Aug;154(4):439–47

Effects of endurance training on left ventricular performance: a study in anaesthetized rabbits. Hexeberg E, et al. **Acta Physiol Scand** 1995 Aug;154(4):479–88

Effects of exercise-training on hypoxia and angiotensin II-induced pulmonary vasoconstrictions. Kashimura O, et al. **Acta Physiol Scand** 1995 Nov;155(3):291–5

Plasma atrial natriuretic peptide in standardbred and Finnhorse trotters during and after exercise. Kokkonen UM, et al. **Acta Physiol Scand** 1995 May;154(1):51–8

Effects of swimming training on the lysosomal enzyme system in brown adipose tissue of rats: an analogy between swimming exercise and cold acclimation. Ohno H, et al. **Acta Physiol Scand** 1995 Nov;155(3):333–4

Influence of methylprednisolone acetate on osteochondral healing in exercised tarsocrural joints of horses. Carter BG, et al. **Am J Vet Res** 1996 Jun;57(6):914–22

Effects of furosemide on hemorheologic alterations induced by incremental treadmill exercise in thoroughbreds. Weiss DJ, et al. **Am J Vet Res** 1996 Jun;57(6):891–5

Decreased birefringence of the superficial zone collagen network in the canine knee (stifle) articular cartilage after long distance running training, detected by quantitative polarised light microscopy. Arokoski JP, et al. **Ann Rheum Dis** 1996 Apr;55(4):253–64

Effect of endurance training under hypoxic condition on oxidative enzyme activity in rat skeletal muscle. Takahashi H, et al. **Appl Human Sci** 1996 May;15(3):111–4

Bronchoalveolar lavage in horses: effect of exercise and repeated sampling on cytology. Clark CK, et al. **Aust Vet J** 1995 Jul;72(7):249–52

Exercise training alters kinetics of antioxidant enzymes in rat tissues. Somani SM, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):587–95

The response of the skeleton to physical training: a biochemical study in horses. Price JS, et al. **Bone** 1995 Sep; 17(3):221–7

Effect of swimming on vascular reactivity to phenylephrine and KC1 in male rats. Jansakul C. **Br J Pharmacol** 1995 Jun;115(4):587–94

Pulmonary artery pressure during exercise in the horse after inhibition of nitric oxide synthase. Mills PC, et al. **Br Vet J** 1996 Mar;152(2):119–22

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep-Oct; 151(5):473–5 (6 ref.). Comment on: Br Vet J 1995 Sep-Oct;151(5):523–45.

Cyclooxygenase blockade limits blood flow to collateral-dependent myocardium during exercise. Altman JD, et al. **Cardiovasc Res** 1995 Nov;30(5):697–704

Endurance training effects on the contractile activation characteristics of single muscle fibres from the rat diaphragm. Lynch GS, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6–7):430–7

Effects of prerace exercise, frusemide, sex and ambient temperature on blood sodium, bicarbonate and pH values in standardbred horses. Frey LP, et al. **Equine Vet J** 1995 May;27(3):170–3

Progression and association with lameness and racing performance of radiographic changes in the proximal sesamoid bones of young standardbred trotters. Grøndahl AM, et al. **Equine Vet J** 1994 Mar;26(2):152–5

Cardiorespiratory and metabolic responses to exercise in horses with various abnormalities of the upper respiratory tract. King CM, et al. **Equine Vet J** 1994 May;26(3):220–5

Skeletal muscle characteristics in red blood cell normovolaemic and hypervolaemic standardbred racehorses. Ronéus M, et al. **Equine Vet J** 1994 Jul; 26(4):319–22

Plasma lactate response to submaximal and maximal exercise tests with training, and its relationship to performance and muscle characteristics in standardbred trotters. Ronéus N, et al. **Equine Vet J** 1994 Mar;26(2):117–21

Effect of a warm-up on energy supply during high intensity exercise in horses. Tyler CM, et al. **Equine Vet J** 1996 Mar; 28(2):117–20

Effect of exercise and adrenal insufficiency on urea production in rats. Litvinova L, et al. **Eur J Appl Physiol** 1995;70(6):536–40

Acceleration of aerobic adaptation by inclusion of appropriate additives in the diet of rats subjected to submaximal physical exercises. Boyadjiev N. **Folia Med (Plovdiv)** 1994;36(4):5–12

Training influence on age-dependent changes in the gait of rats. Dorner H, et al. **Gerontology** 1996;42(1):7–13

Preventive effect of long-term aerobic exercise on thrombus formation in rat cerebral vessels. Sasaki Y, et al. **Haemostasis** 1995 Sep-Oct;25(5):212–7

Proper nutrition a concern for ultimate athlete. Energy expenditure and nutrition top themes in proceedings available from the International Sled Dog VMA [news] **J Am Vet Med Assoc** 1996 Jun 15;208(12):1955–6

Feed deprivation of mares: plasma metabolite and hormonal concentrations and responses to exercise. Sticker LS, et al. **J Anim Sci** 1995 Dec;73(12):3696–704

Acid-base variables during incremental exercise in sprint-trained horses fed a high-fat diet. Taylor LE, et al. **J Anim Sci** 1995 Jul;73(7):2009–18

Running performance and cardiovascular capacity are not impaired in creatine-depleted rats. Adams GR, et al. **J Appl Physiol** 1995 Sep;79(3):1002–7

Invited editorial on "Selective brain cooling in the horse during exercise and environmental heat stress" [editorial; comment] Baker MA. **J Appl Physiol** 1995 Dec; 79(6):1847–8. Comment on: J Appl Physiol 1995 Dec;79(6):1849–54.

Effect of treadmill incline and speed on metabolic rate during exercise in thoroughbred horses. Eaton MD, et al. **J Appl Physiol** 1995 Sep;79(3):951–7

Effects of acute exercise on hepatic lipogenic enzymes in fasted and refed rats. Griffiths MA, et al. **J Appl Physiol** 1995 Sep;79(3):879–85

Metabolic responses of rat respiratory muscles to voluntary exercise training. Halseth AE, et al. **J Appl Physiol** 1995 Sep;79(3):902–7

Augmented mesenteric and renal vasoconstriction during exercise in senescent Fischer 344 rats. Kregel KC. **J Appl Physiol** 1995 Sep;79(3):706–12

Selective brain cooling in the horse during exercise and environmental heat stress [see comments] McConaghy FF, et al. **J Appl Physiol** 1995 Dec;79(6):1849–54. Comment in: J Appl Physiol 1995 Dec;79(6):1847–8.

Effect of diet and training on muscle glycogen storage and utilization in sled dogs. Reynolds AJ, et al. **J Appl Physiol** 1995 Nov;79(5):1601–7

Enhanced hepatic gluconeogenic capacity for selected precursors after endurance training. Sumida KD, et al. **J Appl Physiol** 1995 Dec;79(6):1883–8

Influence of simulated microgravity on cardiac output and blood flow distribution during exercise. Woodman CR, et al. **J Appl Physiol** 1995 Nov;79(5):1762–8

Effect of prior exercise on the partitioning of an intestinal glucose load between splanchnic bed and skeletal muscle. Hamilton KS, et al. **J Clin Invest** 1996 Jul 1;98(1):125–35

The effect of exercise training on cold tolerance in adult and old C57BL/6J mice. Schaefer VI, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B38–42

In vivo evidence of abnormal mechanical and oxidative functions in the exercised muscle of dystrophic hamsters by 31P-NMR. Le Rumeur E, et al. **J Neurol Sci** 1995 Nov; 133(1–2):16–23

Exercise down-regulates hepatic lipogenic enzymes in food-deprived and refed rats. Griffiths MA, et al. **J Nutr** 1996 Aug;126(8):1959–71

Chronic nonpulsatile blood flow. II. Hemodynamic responses to progressive exercise in calves with chronic nonpulsatile biventricular bypass. Tominaga R, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):857–62

Chronic nonpulsatile blood flow. III. Effects of pump flow rate on oxygen transport and utilization in chronic nonpulsatile biventricular bypass. Tominaga R, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):863–72

Changes in skeletal muscle composition in response to swimming training for young horses. Misumi K, et al. **J Vet Med Sci** 1995 Oct;57(5):959–61

Lung cyclic nucleotides in exercise-trained rats attenuate hypoxic pulmonary vasoconstriction. Kashimura O, et al. **Lung** 1995;173(6):363–72

Effects of age and endurance training on beta-adrenergic receptor characteristics in Fischer 344 rats. Mazzeo RS, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):157–69

Diabetic nephropathy in an aerobically trained rat model of diabetes. Albright AL, et al. **Med Sci Sports Exerc** 1995 Sep;27(9):1270–7

Effect of endurance exercise on ovulation in the rat. Chatterton RT Jr, et al. **Med Sci Sports Exerc** 1995 Nov; 27(11):1509–15

Effects of exercise training on endothelium-dependent peripheral vascular responsiveness. Delp MD. **Med Sci Sports Exerc** 1995 Aug;27(8):1152–7 (38 ref.)

Cardiac adrenergic responses and electrophysiology during ischemia: effect of exercise. Hamra M, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):993–1002

Endothelium-mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135-44 (34 ref.)

Contribution of endothelium-derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. McAllister RM, et al. **Med Sci Sports Exerc** 1995 Aug; 27(8):1145-51 (49 ref.)

Hemodynamic and regional blood flow responses to nicotine at rest and during exercise. Symons JD, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):457-67

Adaptations of immature trabecular bone to exercise and augmented dietary protein. Zernicke RF, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1486-93

Metabolic and hormonal responses to adrenoceptor antagonists in 48-hour-starved exercising rats. Benthem L, et al. **Metabolism** 1995 Oct;44(10):1332-9

Effect of physical training on mitochondrial function in skeletal muscle of normal and diabetic rats. el Midaoui A, et al. **Metabolism** 1996 Jul;45(7):810-6

Exercise training has a long-lasting effect on prevention of non-insulin-dependent diabetes mellitus in Otsuka-Long-Evans-Tokushima Fatty rats. Shima K, et al. **Metabolism** 1996 Apr;45(4):475-80

The effects of blood CO2 reaction rates on CO2 removal from muscle in exercised trout. Currie S, et al. **Respir Physiol** 1995 Jun;100(3):261-9

Blood parameter and heart rate response to training in Andalusian horses. Agüera EI, et al. **Rev Esp Fisiol** 1995 Jun;51(2):55-64

Effects of function and weight-bearing on the healing of full-thickness cartilage defects in rats. Grundnes O, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):297-301

Ascent rate, post-dive exercise, and decompression sickness in the rat. Pollard GW, et al. **Undersea Hyperb Med** 1995 Dec;22(4):367-76

Continuous monitoring of ECG in horses at rest and during exercise. Scheffer CW, et al. **Vet Rec** 1995 Oct 7; 137(15):371-4

Comparison of the workload of Dutch warmblood horses ridden normally and on a treadmill. Sloet van Oldruitenborgh-Oosterbaan MM, et al. **Vet Rec** 1995 Aug 5;137(6):136-9

Training-induced modifications in some biochemical defences against free radicals in equine erythrocytes. Avellini L, et al. **Vet Res Commun** 1995;19(3):179-84

Cardiovascular, respiratory and metabolic effects of interval training at VLA4. Gottlieb-Vedi M, et al. **Zentralbl Veterinarmed A** 1995 May;42(3):165-75

Effect of exercise on enzymatic activity in tracheal fluid and on intrapleural pressure difference in horses. Maisi P, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):315-24

Exercise-induced changes in the activities of beta-glucuronidase and N-acetyl-beta-D-glucosaminidase in plasma and muscle of standardbred trotters. Raulo SM, et al. **Zentralbl Veterinarmed A** 1996 Apr;43(2):119-26

[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143-50 (15 ref.) **(Rus)**

PHYSICAL CONDITIONING, HUMAN see **EXERCISE THERAPY**

PHYSICAL EDUCATION AND TRAINING

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335-46 (68 ref.)

Prognostic value of training-induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery. Vanhees L, et al. **Am J Cardiol** 1995 Nov 15;76(14):1014-9

Analysis of body-composition techniques and models for detecting change in soft tissue with strength training. Nelson ME, et al. **Am J Clin Nutr** 1996 May;63(5):678-86

Effect of training on epinephrine-stimulated lipolysis determined by microdialysis in human adipose tissue. Stallknecht B, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1059-66

Impact of aerobic training on fitness and quality of life in multiple sclerosis [see comments] Petajan JH, et al. **Ann Neurol** 1996 Apr;39(4):432-41. Comment in: Ann Neurol 1996 Apr;39(4):422-3.

Effect of daily hyperhydration on fluid-electrolyte changes in endurance-trained volunteers during prolonged restriction of muscular activity. Zorbas YG, et al. **Biol Trace Elem Res** 1995 Oct;50(1):57-78

Development of scales to measure perceived physical education class climate: a cross-national project. Biddle S, et al. **Br J Educ Psychol** 1995 Sep;65 (Pt 3):341-58

Physical training improves endothelial function in patients with chronic heart failure. Hornig B, et al. **Circulation** 1996 Jan 15;93(2):210-4

Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Piepoli M, et al. **Circulation** 1996 Mar 1;93(5):940-52

The effect on immunity of long-term intensive training in elite swimmers. Gleeson M, et al. **Clin Exp Immunol** 1995 Oct;102(1):210-6

Assessment of nutrition and physical activity education programmes in children. Burke V, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):212-6 (33 ref.)

Electromyographic validation of basic exercises for physical conditioning programmes. I. Analysis of the deltoid muscle (anterior portion) and pectoralis major muscle (clavicular portion) in rowing exercises with middle grip. Ferreira MI, et al. **Electromyogr Clin Neurophysiol** 1995 Jun-Jul; 35(4):239-45

Kinetics of plasma potassium concentrations during exhausting exercise in trained and untrained men. Marcos E, et al. **Eur J Appl Physiol** 1995;71(2-3):207-14

The role of metabolites in strength training. II. Short versus long isometric contractions. Schott J, et al. **Eur J Appl Physiol** 1995;71(4):337-41

The role of metabolites in strength training. I. A comparison of eccentric and concentric contractions. Smith RC, et al. **Eur J Appl Physiol** 1995;71(4):332-6

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52-7 (38 ref.)

Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. Taaffe DR, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):421-5

Exertional rhabdomyolysis as a result of strenuous military training. Aizawa H, et al. **J Neurol Sci** 1995 Oct; 132(2):239-40

Outcomes of a field trial to improve children's dietary patterns and physical activity. The Child and Adolescent Trial for Cardiovascular Health. CATCH collaborative group [see comments] Luepker RV, et al. **JAMA** 1996 Mar 13;275(10):768-76. Comment in: JAMA 1996 Jul 17;276(3):195.

Assessment of training-induced autonomic adaptations in athletes with spectral analysis of cardiovascular variability signals. Shin K, et al. **Jpn J Physiol** 1995;45(6):1053-69

Exercise, wellbeing, and endogenous molecules of mood [letter] Armstrong N, et al. **Lancet** 1996 Aug 17; 348(9025):477

Team spirit. Moriarity JM. **Minn Med** 1996 Jul;79(7):12-8

The best athletes are better [letter] Maffuli N. **Nature** 1996 Jul 25;382(6589):294

Science tracks down the training dangers [news] Surridge C. **Nature** 1996 Jul 4;382(6586):14-5

Effect of instruction on perceived physical ability and exercise adherence. Cain RE. **Percept Mot Skills** 1996 Apr; 82(2):494

Influence of British national curriculum physical education on teachers' behaviours associated with pupils' psychosocial development: a case study in one English town. Curtner-Smith MD, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):967-76

Development of content: influences on girls' junior high school volleyball success in practice and achievement. Pellett TL, et al. **Percept Mot Skills** 1996 Feb;82(1):219-24

Perceptions of childhood obesity of undergraduate students in physical education. Savage MP. **Psychol Rep** 1995 Jun; 76(3 Pt 2):1251-9

Comparison of attitudes of teachers of physical and musical education toward inclusion of children with disabilities. Sideridis GD, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):768-70

Fair Play for Kids: effects on the moral development of children in physical education. Gibbons SL, et al. **Res Q Exerc Sport** 1995 Sep;66(3):247-55

Practice schedule effects on the performance and learning of low- and high-skilled students: an applied study. Hebert EP, et al. **Res Q Exerc Sport** 1996 Mar;67(1):52-8

Children's activity levels and lesson context during third-grade physical education. McKenzie TL, et al. **Res Q Exerc Sport** 1995 Sep;66(3):184-93

Value orientations of preservice teachers. Solmon MA, et al. **Res Q Exerc Sport** 1995 Sep;66(3):219-30

Athletic performance in relation to training load. Foster C, et al. **Wis Med J** 1996 Jun;95(6):370-4

[Contraindications for physical training (editorial)] Näveri H. **Duodecim** 1994;110(12):1181-3 (16 ref.) **(Fin)**

[Physical activity in childhood may have advantages even in older age (editorial)] Taimela S. **Duodecim** 1995; 111(3):216-8 **(Fin)**

[Physical exercise and the heart: benefits, indications, intensity, modalities] Letac B. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):459-64 **(Fre)**

[Role of sports in Army-Nation relations] Auclair J. **Bull Acad Natl Med** 1995 Oct;179(7):1441-7 (Eng. Abstr.) **(Fre)**

[Physical training and blood pressure] Bertrand E, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1471-80; discussion 1481 (Eng. Abstr.) **(Fre)**

[Hormonal response and adaptation to short-term exercise and training] Guézennec CY. **Bull Acad Natl Med** 1995 Oct;179(7):1449-57; discussion 1458-9 (Eng. Abstr.) **(Fre)**

[Introduction to the session on the subject: physical activities and health] Pène P. **Bull Acad Natl Med** 1995 Oct; 179(7):1415-6 **(Fre)**

[Physical activity and cardiorespiratory equilibrium] Préfaut C. **Bull Acad Natl Med** 1995 Oct;179(7):1461-9; discussion 1469-70 (Eng. Abstr.) **(Fre)**

[Training counseling in general practice] Held T. **Schweiz Rundsch Med Prax** 1995 Aug 29;84(35):920-7 (Eng. Abstr.) **(Ger)**

[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953-62 (38 ref.) (Eng. Abstr.) **(Ger)**

[Isokinetic training in the elderly] Hopf T, et al. **Sportverletz Sportschaden** 1995 Dec;9(4):129-30 **(Ger)**

[Environmental hygiene characteristics of gymnasia in the city of Pescara] Romano F, et al. **Ann Ig** 1995 Jul-Aug; 7(4):283-90 (Eng. Abstr.) **(Ita)**

[Macro- and microrheologic properties of blood in people with varying levels of training] Murav'ev AV, et al. **Fiziol Cheloveka** 1995 Jul-Aug;21(4):137-42 **(Rus)**

[Personality features of patients with hypertension and low-intensity physical training] Vecherinin OK, et al. **Klin Med (Mosk)** 1995;73(5):73-4 **(Rus)**

[Functional properties of blood proteins in highly trained athletes] Tolkacheva NV, et al. **Kosm Biol Aviakosm Med** 1991 Sep-Oct;25(5):15-7 (Eng. Abstr.) **(Rus)**

[Ultrastructural changes in the skeletal muscles during local endurance training (a morphometric study)] Sukhova ZI, et al. **Morfologiia** 1994 Jul-Dec;107(7-12):75-82 (Eng. Abstr.) **(Rus)**

HISTORY

Thomas K. Cureton, Jr.: pioneer researcher, proselytizer, and proponent for physical fitness. Berryman JW. **Res Q Exerc Sport** 1996 Mar;67(1):1-12

METHODS

Weight training improves walking endurance in healthy elderly persons. Ades PA, et al. **Ann Intern Med** 1996 Mar 15;124(6):568-72

Short-term training, muscle glycogen, and cycle endurance. Green HJ, et al. **Can J Appl Physiol** 1995 Sep;20(3):315-24

Effects of a one-year high-intensity versus low-intensity resistance training program on bone mineral density in older women. Pruitt LA, et al. **J Bone Miner Res** 1995 Nov;10(11):1788-95

ORGANIZATION & ADMINISTRATION

Nutrition and physical activity program to attenuate obesity and promote physical and metabolic fitness in elementary school children. Donnelly JE, et al. **Obes Res** 1996 May; 4(3):229-43

Characteristics of elementary school principals and their support for the physical education program. Lock RS, et al. **Percept Mot Skills** 1995 Aug;81(1):307-15

STANDARDS

School physical education. Pate RR, et al. **J Sch Health** 1995 Oct;65(8):312-8

Physical training improves body composition of black obese 7- to 11-year-old girls. Gutin B, et al. **Obes Res** 1995 Jul; 3(4):305-12

Inadequate pre-season preparation of schoolboy rugby players—a survey of players at 25 Cape Province high schools. Upton PA, et al. **S Afr Med J** 1996 May; 86(5):531-3

TRENDS

The play approach to learning in the context of families and schools: an alternative paradigm for nutrition and fitness education in the 21st century. Rickard KA, et al. **J Am Diet Assoc** 1995 Oct;95(10):1121-6

PHYSICAL EFFORT see **EXERTION**

PHYSICAL ENDURANCE

Modelling the effect of taper on performance, maximal oxygen uptake, and the anaerobic threshold in endurance triathletes. Zarkadas PC, et al. **Adv Exp Med Biol** 1995; 393:179-86

Exercise capacity and skeletal muscle structure and function before and after balloon mitral valvuloplasty. Barlow CW, et al. **Am J Cardiol** 1995 Oct 1;76(10):684-8

A single bout of exhaustive exercise affects integrated baroreflex function after 16 days of head-down tilt. Engelke KA, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R614-20

Lymphocytes and NK cell activity during repeated bouts of maximal exercise. Nielsen HB, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R222-7

Increments in skeletal muscle GLUT-1 and GLUT-4 after endurance training in humans. Phillips SM, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E456-62

mRNAs of enzymes involved in energy metabolism and mtDNA are increased in endurance-trained athletes. Puntschart A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C619-25

Skeletal muscle pyruvate dehydrogenase activity during maximal exercise in humans. Putman CT, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E458-68

Weight training improves walking endurance in healthy elderly persons. Ades PA, et al. **Ann Intern Med** 1996 Mar 15;124(6):568-72

Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Venditti P, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):63-8

Metabolic response of forearm muscle to graded exercise in type II diabetes mellitus: effect of endurance training. DeVries DA, et al. **Can J Appl Physiol** 1996 Apr; 21(2):120–33

Anaerobic and aerobic peak power output and the force–velocity relationship in endurance–trained athletes: effects of aging. Chamari K, et al. **Eur J Appl Physiol** 1995; 71(2–3):230–4

Increased phagocytic capacity of the blood, but decreased phagocytic activity per individual circulating neutrophil after an ultradistance run. Gabriel H, et al. **Eur J Appl Physiol** 1995;71(2–3):281–4

Effects of an endurance training programme on the passive and noradrenaline–activated compliances of rat aorta. Koutsis G, et al. **Eur J Appl Physiol** 1995;71(2–3):173–9

Kinetics of plasma potassium concentrations during exhausting exercise in trained and untrained men. Marcos E, et al. **Eur J Appl Physiol** 1995;71(2–3):207–14

Endurance time characteristics of human ankle dorsiflexors and plantarflexors. Shahidi AV, et al. **Eur J Appl Physiol** 1995;71(2–3):124–30

Control of the rate of phosphocreatine resynthesis after exercise in trained and untrained human quadriceps muscles. Takahashi H, et al. **Eur J Appl Physiol** 1995; 71(5):396–404

Physical work load, physical capacity and strain among elderly female aides in home–care service. Torgén M, et al. **Eur J Appl Physiol** 1995;71(5):444–52

Critical power test for ramp exercise [letter; comment] [see comments] Vandewalle H. **Eur J Appl Physiol** 1995; 71(2–3):285–6. Comment on: Eur J Appl Physiol 1994;69(5):435–8. Comment in: Eur J Appl Physiol 1995;71(4):379–80.

Integration of the physiological factors determining endurance performance ability. Coyle EF. **Exerc Sport Sci Rev** 1995;23:25–63 (67 ref.)

Effect of a composite Indian herbal preparation, CIHP(III) on avoidance learning during endurance performance of rats. Bhardwaj SK, et al. **Indian J Exp Biol** 1995 Aug; 33(8):580–4

Effects of carbohydrate supplementation on performance during 1 hour of high–intensity exercise. Anantaraman R, et al. **Int J Sports Med** 1995 Oct;16(7):461–5

Loss of muscle oxidative capacity after an extreme endurance run: the Paris–Dakar foot–race. Höchli D, et al. **Int J Sports Med** 1995 Aug;16(6):343–6

A walking program for nursing home residents: effects on walk endurance, physical activity, mobility, and quality of life. MacRae PG, et al. **J Am Geriatr Soc** 1996 Feb; 44(2):175–80

Progressive effect of endurance training on VO2 kinetics at the onset of submaximal exercise. Phillips SM, et al. **J Appl Physiol** 1995 Dec;79(6):1914–20

Superoxide dismutase derivative reduces oxidative damage in skeletal muscle of rats during exhaustive exercise. Radák Z, et al. **J Appl Physiol** 1995 Jul;79(1):129–35

Intrinsic myocardial function and oxidative stress after exhaustive exercise. Seward SW, et al. **J Appl Physiol** 1995 Jul;79(1):251–5

Muscle torque in young and older untrained and endurance–trained men. Alway SE, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):B195–201

How fast do we age? Exercise performance over time as a biomarker. Bortz WM 4th, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M223–5

Gender–related differences in left ventricular filling dynamics in older subjects after endurance exercise training. Spina RJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):B232–7

Effects of wearing two different clothing ensembles on endurance performance of handgrip exercise. Jeong YO, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):25–31

Reproducibility of isometric trunk extension torque, trunk extensor endurance, and related electromyographic parameters in the context of their clinical applicability. van Dieën JH, et al. **J Orthop Res** 1996 Jan;14(1):139–43

Muscular endurance repetitions to predict bench press strength in men of different training levels. Mayhew JL, et al. **J Sports Med Phys Fitness** 1995 Jun;35(2):108–13

Effect of a training session of endurance running on anserine and carnosine contents in fast and slow muscles of young rats. Tanaka M. **Jpn J Physiol** 1995;45(4):659–66

Post–swim orthostatic intolerance in a marathon swimmer. Finlay JB, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1231–7

Estimation of critical power with nonlinear and linear models. Gaesser GA, et al. **Med Sci Sports Exerc** 1995 Oct;27(10):1430–8

Autonomic nervous system control of the heart: endurance exercise training. Shi X, et al. **Med Sci Sports Exerc** 1995 Oct;27(10):1406–13

Effect of endurance training on glycerol kinetics during strenuous exercise in humans. Klein S, et al. **Metabolism** 1996 Mar;45(3):357–61

Simple indicators of physical working capacity. Hassmén P. **Percept Mot Skills** 1995 Oct;81(2):383–94

[Hemodynamics in arterial hypertension treated with running endurance training or nifedipine therapy] Winterfeld HJ, et al. **Z Kardiol** 1996 Mar;85(3):171–7 (Eng. Abstr.) **(Ger)**

[Hemodynamics, endurance and psychomotor parameters in residents of various latitudes in contrasting seasons] Solonin IuG. **Fiziol Cheloveka** 1996 May–Jun;22(3):113–7 **(Rus)**

[Ultrastructural changes in the skeletal muscles during local endurance training (a morphometric study)] Sukhova ZI, et al. **Morfologiia** 1994 Jul–Dec;107(7–12):75–82 (Eng. Abstr.) **(Rus)**

[The effect of iodobromide baths on the physical work capacity and extrasystole in patients with ischemic heart disease and stable stenocardia] Klemenko SV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):11–4 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Gordon A, et al. **Cardiovasc Res** 1995 Sep; 30(3):413–8

The antiserotonin agent pizotifen does not increase endurance performance in humans. Pannier JL, et al. **Eur J Appl Physiol** 1995;72(1–2):175–8

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111–9 (49 ref.)

Effects of carbohydrate feeding before and during prolonged exercise on subsequent maximal exercise performance capacity. el–Sayed MS, et al. **Int J Sport Nutr** 1995 Sep; 5(3):215–24

Caffeine and performance. Spriet LL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S84–99 (56 ref.)

Influence of ingesting a carbohydrate–electrolyte solution on endurance capacity during intermittent, high–intensity shuttle running. Nicholas CW, et al. **J Sports Sci** 1995 Aug; 13(4):283–90

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)

Anabolic–androgenic steroid increases running endurance in rats. Van Zyl CG, et al. **Med Sci Sports Exerc** 1995 Oct; 27(10):1385–9

Decreased endurance to cold water swimming and delayed sexual maturity in the rat following neonatal lead exposure. Yu SY, et al. **Toxicol Lett** 1996 Jun;85(3):135–41

[Effect of 1–alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men] Tomten SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):37–40 (Eng. Abstr.) **(Nor)**

[Should coffee be classified as a doping agent? Caffeine is definitely effective when it comes to performance capacity (see comments)] Fredholm BB. **Lakartidningen** 1995 Nov 1;92(44):4079–80. Comment in: Lakartidningen 1995 Dec 20;92(51–52):4869. **(Swe)**

IMMUNOLOGY

The impact of exercise on the immune system: NK cells, interleukins 1 and 2, and related responses. Shephard RJ, et al. **Exerc Sport Sci Rev** 1995;23:215–41 (233 ref.)

PHYSIOLOGY

Mitochondrial ATP production rate in 55 to 73–year–old men: effect of endurance training. Berthon P, et al. **Acta Physiol Scand** 1995 Jun;154(2):269–74

Evidence of myocardial injury during prolonged strenuous exercise. Laslett L, et al. **Am J Cardiol** 1996 Aug 15; 78(4):488–90

Validity of total body water assessment for determining changes of body composition during endurance training in distance runners. Mitsuzono R, et al. **Appl Human Sci** 1995 Nov;14(6):303–4

Effect of endurance training under hypoxic condition on oxidative enzyme activity in rat skeletal muscle. Takahashi H, et al. **Appl Human Sci** 1996 May;15(3):111–4

Endurance training effect on individuals with postpoliomyelitis. Ernstoff B, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):843–8

Reliability of electromyographic power spectral analysis of back muscle endurance in healthy subjects. Ng JK, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):259–64

Physical performance and heat tolerance after chronic water loading and heat acclimation. Kristal–Boneh E, et al. **Aviat Space Environ Med** 1995 Aug;66(8):733–8

Effect of daily hyperhydration on fluid–electrolyte changes in endurance–trained volunteers during prolonged restriction of muscular activity. Zorbas YG, et al. **Biol Trace Elem Res** 1995 Oct;50(1):57–78

Protein turnover rates of two human subjects during an unassisted crossing of Antarctica. Stroud MA, et al. **Br J Nutr** 1996 Aug;76(2):165–74

The relationship between carbon dioxide sensitivity and sprint or endurance performance in young swimmers. McGurk SP, et al. **Br J Sports Med** 1995 Jun;29(2):129–33

Effects of sodium bicarbonate on fluid, electrolyte and acid–base balance in racehorses [see comments] Lloyd DR, et al. **Br Vet J** 1995 Sep–Oct;151(5):523–45. Comment in: Br Vet J 1995 Sep–Oct;151(5):473–5.

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep–Oct; 151(5):473–5 (6 ref.). Comment on: Br Vet J 1995 Sep–Oct;151(5):523–45.

Short–term training, muscle glycogen, and cycle endurance. Green HJ, et al. **Can J Appl Physiol** 1995 Sep;20(3):315–24

Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested. MacLaren DP, et al. **Clin Sci (Colch)** 1995 Aug;89(2):137–43

Predicting endurance limits in arm cranking exercise with a subjectively based method. Capodaglio P, et al. **Ergonomics** 1996 Jul;39(7):924–32

The influence of recovery duration between periods of exercise on the critical power function. Bishop D, et al. **Eur J Appl Physiol** 1995;72(1–2):115–20

Thermal tolerance following artificially induced polycythaemia. Patterson MJ, et al. **Eur J Appl Physiol** 1995;71(5):416–23

The relationship between voluntary electromyogram, endurance time and intensity of effort in isometric handgrip exercise. West W, et al. **Eur J Appl Physiol** 1995;71(4):301–5

Alterations in atrial natriuretic peptide gene expression during endurance training in rats. Azizi C, et al. **Eur J Endocrinol** 1995 Sep;133(3):361–5

Calcitonin gene–related peptide during exercise and training. Schifter S, et al. **Horm Metab Res** 1995 Oct;27(10):473–5

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52–7 (38 ref.)

Proceedings of the Gatorade Sports Science Institute Conference on Nutrition Ergogenic aids. November 1994. **Int J Sport Nutr** 1995 Jun;5 Suppl:Siii–iv, S1–131

Carbohydrates, branched–chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29–38 (42 ref.)

The influence of ingesting a carbohydrate–electrolyte beverage during 4 hours of recovery on subsequent endurance capacity. Fallowfield JL, et al. **Int J Sport Nutr** 1995 Dec;5(4):285–99

Effect of carbohydrate ingestion subsequent to carbohydrate supercompensation on endurance performance. Kang J, et al. **Int J Sport Nutr** 1995 Dec;5(4):329–43

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39–61 (91 ref.)

Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Lukaski HC. **Int J Sport Nutr** 1995 Jun;5 Suppl:S74–83 (37 ref.)

Fat loading: the next magic bullet? Sherman WM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S1–12 (29 ref.)

An assessment of carbohydrate intake in collegiate distance runners. Tanaka JA, et al. **Int J Sport Nutr** 1995 Sep; 5(3):206–14

Unaccustomed high–mileage vs intensity training–related changes in performance and serum amino acid levels. Lehmann M, et al. **Int J Sports Med** 1996 Apr;17(3):187–92

Circulating gastrointestinal hormone changes in marathon running. O'Connor AM, et al. **Int J Sports Med** 1995 Jul; 16(5):283–7

Effects of exhaustive endurance exercise and its one–week daily repetition on neutrophil count and functional status in untrained men. Suzuki K, et al. **Int J Sports Med** 1996 Apr;17(3):205–12

Effect of prolonged exercise at 65 and 80% of VO2max on running economy. Xu F, et al. **Int J Sports Med** 1995 Jul; 16(5):309–13

Predicted and measured resting metabolic rate of male and female endurance athletes. Thompson J, et al. **J Am Diet Assoc** 1996 Jan;96(1):30–4

Computerized tomography and pulmonary diffusing capacity in highly trained athletes after performing a triathlon. Caillaud C, et al. **J Appl Physiol** 1995 Oct;79(4):1226–32

Aging among elite distance runners: a 22–yr longitudinal study. Trappe SW, et al. **J Appl Physiol** 1996 Jan; 80(1):285–90

Changes in insulin action and GLUT–4 with 6 days of inactivity in endurance runners. Vukovich MD, et al. **J Appl Physiol** 1996 Jan;80(1):240–4

Dynamic optimization analysis for equipment setup problems in endurance cycling. Kautz SA, et al. **J Biomech** 1995 Nov;28(11):1391–401

The relationship between critical power and running performance. Kolbe T, et al. **J Sports Sci** 1995 Jun; 13(3):265–9

Effects of a single bout of ultraendurance exercise on lipid levels and susceptibility of lipids to peroxidation in triathletes. Ginsburg GS, et al. **JAMA** 1996 Jul 17; 276(3):221–5

Assessment of training–induced autonomic adaptations in athletes with spectral analysis of cardiovascular variability signals. Shin K, et al. **Jpn J Physiol** 1995;45(6):1053–69

Prediction of maximal oxygen uptake by squat test in men and women. Inoue Y, et al. **Kobe J Med Sci** 1996 Apr; 42(2):119–29

Effects of age and endurance training on beta–adrenergic receptor characteristics in Fischer 344 rats. Mazzeo RS, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):157–69

Effect of endurance exercise on ovulation in the rat. Chatterton RT Jr, et al. **Med Sci Sports Exerc** 1995 Nov; 27(11):1509–15

A chronically instrumented rat model to assess the altered baroreflex due to exercise. Hyek MF, et al. **Med Sci Sports Exerc** 1995 Sep;27(9):1339–44

Immune function in marathon runners versus sedentary controls. Nieman DC, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):986–92

Cardiovascular responses to exercise in sprinters and distance runners. Torok DJ, et al. **Med Sci Sports Exerc** 1995 Jul;

27(7):1050–6
Regional changes in capillary supply in skeletal muscle of interval–sprint and low–intensity, endurance–trained rats. Gute D, et al. **Microcirculation** 1994 Oct;1(3):183–93
Effect of carbohydrate substrate availability on ratings of perceived exertion during prolonged exercise of moderate intensity. Kang J, et al. **Percept Mot Skills** 1996 Apr; 82(2):495–506
Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)
Prevalence of asthma in young cross–country skiers in central Scandinavia: differences between Norway and Sweden. Sue–Chu M, et al. **Respir Med** 1996 Feb;90(2):99–105
The relation between the PST1 restriction fragment length polymorphism at the APO–AI locus and plasma APO–AI concentrations in marathon runners. Ziman MR, et al. **S Afr Med J** 1995 Oct;85(10):1013–6
Biochemical markers of bone metabolism during distance running in healthy, regularly exercising men and women. Brahm H, et al. **Scand J Med Sci Sports** 1996 Feb;6(1):26–30
The influence of training intensity, airway infections and environmental conditions on seasonal variations in bronchial responsiveness in cross–country skiers. Heir T, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):152–9
Salivary and blood lactate after supramaximal exercise in sprinters and long–distance runners. Ohkuwa T, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):285–90
Mild overcooling increases energy expenditure during endurance exercise. Sjödin A, et al. **Scand J Med Sci Sports** 1996 Feb;6(1):22–5
Activities of selected aerobic and anaerobic enzymes in the gluteus medius muscle of endurance horses with different performance records. Rivero JL, et al. **Vet Rec** 1995 Aug 19;137(8):187–92
[Changes in body height and weight during ultra–long marathon running] Raschka C. **Sportverletz Sportschaden** 1995 Dec;9(4):123–5 **(Ger)**
[Longitudinal analysis of change in sports performance of women between ages 30 and 75: a comparison between peak and leisure sports participation] Okonek CC. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):127–35 (Eng. Abstr.) **(Ger)**
[The dynamics of the physical work capacity of women during pregnancy] Osipov VG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):33–4 **(Rus)**

PHYSICAL EXAMINATION

Value of the cardiovascular physical examination for detecting valvular heart disease in asymptomatic subjects. Roldan CA, et al. **Am J Cardiol** 1996 Jun 15;77(15):1327–31
Case–control study of digital–rectal screening in relation to mortality from cancer of the distal rectum. Herrinton LJ, et al. **Am J Epidemiol** 1995 Nov 1;142(9):961–4
Ectopic pregnancy: prospective study with improved diagnostic accuracy. Kaplan BC, et al. **Ann Emerg Med** 1996 Jul;28(1):10–7
The examination. Epstein N. **Ann Intern Med** 1996 Aug 1; 125(3):250–1
Guarding paediatricians against allegations of assault. Chambers TL, et al. **Arch Dis Child** 1996 Jul;75(1):82–5
Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. **Arthritis Rheum** 1996 Jan;39(1):1–8
Degenerative lumbar spinal stenosis. Diagnostic value of the history and physical examination. Katz JN, et al. **Arthritis Rheum** 1995 Sep;38(9):1236–41
Health checks and coronary risk: further evidence from a randomised controlled trial [see comments] Hanlon P, et al. **BMJ** 1995 Dec 16;311(7020):1609–13. Comment in: BMJ 1996 Apr 13;312(7036):974.
Extrapyramidal signs should be sought more often in Alzheimer's disease [letter; comment] Lowenthal MN. **BMJ** 1996 Jul 6;313(7048):45. Comment on: BMJ 1996 Mar 23;312(7033):724.
Using clinical signs to diagnose anaemia in African children. Luby SP, et al. **Bull World Health Organ** 1995;73(4):477–82
The relative diagnostic impact of screening mammography and physical examination. Taves DH, et al. **Can Assoc Radiol J** 1996 Aug;47(4):257–9
Patient consent to observation. Responses to requests for written consent in an academic family practice unit [see comments] Shafir MS, et al. **Can Fam Physician** 1995 Aug; 41:1367–72. Comment in: Can Fam Physician 1995 Nov;41:1850, 1852.
Madeleine's death [letter; comment] Ogborn M. **Can Med Assoc J** 1996 Apr 15;154(8):1144. Comment on: Can Med Assoc J 1996 Jan 15;154(2):246–9.
Interdisciplinary training in the evaluation of child sexual abuse. Palusci VJ, et al. **Child Abuse Negl** 1995 Sep; 19(9):1031–8
The physical after–effects of torture. Forrest D. **Forensic Sci Int** 1995 Nov 30;76(1):77–84
Clearing athletes for sports participation [see comments] Scarpinato L. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):120–2 . Comment in: Hosp Pract (Off Ed) 1996 Jul 15;31(7):44.
Sports participation [letter; comment] Weinstock FJ. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):44. Comment on: Hosp Pract (Off Ed) 1996 Apr 15;31(4):120–2.
Rectal examination in hospital patients. Reardon M, et al. **Ir Med J** 1995 Nov–Dec;88(6):220–1
Client views on periodic health examinations: opinions and personal experience. Nupponen R. **J Adv Nurs** 1996 Mar; 23(3):521–7
Self–administered examination versus conventional medical examination of the musculoskeletal system in the neck, shoulders, and upper limbs. The Stockholm MUSIC I Study Group. Toomingas A, et al. **J Clin Epidemiol** 1995 Dec;48(12):1473–83
Rectal examination: a potential hazard to physicians [letter] Golan G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):173
More than a sports exam [letter; comment] [see comments] Beasley JW. **J Fam Pract** 1995 Nov;41(5):433, 437. Comment on: J Fam Pract 1995 Jul;41(1):42–50. Comment in: J Fam Pract 1996 Mar;42(3):306.
Complete physical [letter; comment] Feldman J. **J Fam Pract** 1995 Nov;41(5):431–2. Comment on: J Fam Pract 1995 Jun;40(6):543–5.
Preparticipation physical examination [letter; comment] McKeag DB. **J Fam Pract** 1996 Mar;42(3):306. Comment on: J Fam Pract 1995 Nov;41(5):433, 437.
Physical exams [letter; comment] Weitz BC. **J Fam Pract** 1995 Oct;41(4):327–8. Comment on: J Fam Pract 1995 Jun;40(6):547–54.
Incidence of previously undetected disease in routine paediatric otolaryngology admissions. Zeitoun H, et al. **J Laryngol Otol** 1996 Jun;110(6):557–8
Murphy's sign, acute cholecystitis and elderly people. Adedeji OA, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):88–9
The use of objective structured clinical examination (OSCE) for evaluation and instruction in graduate medical education. Sloan DA, et al. **J Surg Res** 1996 Jun; 63(1):225–30
Is computed tomography a useful adjunct to the clinical examination for the diagnosis of pediatric gastrointestinal perforation from blunt abdominal trauma in children? Albanese CT, et al. **J Trauma** 1996 Mar;40(3):417–21
The Rational Clinical Examination. Does this patient have abnormal central venous pressure? Cook DJ, et al. **JAMA** 1996 Feb 28;275(8):630–4
Examination room design for the pediatric otolaryngology practice. Cook SP. **Laryngoscope** 1996 Aug;106(8):1049–50
The interactive patient: a multimedia interactive educational tool on the World Wide Web. Hayes KA, et al. **MD Comput** 1996 Jul–Aug;13(4):330–4
Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. McGuire D, et al. **Neurology** 1996 May; 46(5):1442–4
Blood pressure variability at annual periodic health examination for employees and cardiovascular risk factors. Inoue M, et al. **Occup Med (Oxf)** 1996 Jun;46(3):228–30
Child sexual abuse. Hymel KP, et al. **Pediatr Rev** 1996 Jul; 17(7):236–49; quiz 249–50
The preparticipation sports physical: are we dropping the ball? Cavanaugh RM Jr, et al. **Pediatrics** 1995 Dec; 96(6):1151–3 (25 ref.)
Medical examination of the internationally adopted child: screening for infectious diseases and developmental delay. Hostetter MK, et al. **Postgrad Med** 1996 Apr;99(4):70–2, 75–7, 81–2
Health risks in young athletes [letter; comment] Weinstock FJ. **Postgrad Med** 1995 Nov;98(5):14. Comment on: Postgrad Med 1995 Aug;98(2):123–6, 129–32.
Comparison between scintigraphy with polyclonal immunoglobulin (99Tcm–HIG) and physical examination in polyarthritic disease. Vesterskiöld L, et al. **Scand J Rheumatol** 1996;25(3):159–63
Rectal examinations and appendicitis malpractice claims [letter] Fink S. **South Med J** 1995 Dec;88(12):1279
The value of naked eye examination of biopsied lymph nodes in the diagnosis of tuberculous lymphadenitis. Bem C. **Trop Doct** 1996 Jan;26(1):10–3
[Effects of digital rectal examination on serum prostate specific antigen] Nord MP, et al. **Presse Med** 1996 Apr 6;25(12):577–80 (Eng. Abstr.) **(Fre)**
[Deficits in gynecologic education in patient examination for suspected sex offenses (letter)] Kremling H, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):XXXIII–XXXIV **(Ger)**
[Prostate cancer screening in total health care check—using serum PSA and AUA score] Komeda Y, et al. **Hinyokika Kiyo** 1996 Apr;42(4):275–8 (Eng. Abstr.) **(Jpn)**
[Investigation of gastric cancers detected at a medical check–up center] Kura T, et al. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):202–14 (Eng. Abstr.) **(Jpn)**
[Public health nurse staffing requirements for health examination of infants and children in municipalities of Japan] Hoshi T, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr; 43(4):267–75 (Eng. Abstr.) **(Jpn)**
[Personnel requirements for health examination for 6 month and 9 mont–old children in municipalities in Japan] Hoshi T, et al. **Nippon Koshu Eisei Zasshi** 1995 Jul;42(7):511–20 (Eng. Abstr.) **(Jpn)**
[Comparison of life habits and health examination data between smokers and ex–smokers] Kawada T, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):403–8 (Eng. Abstr.) **(Jpn)**
[Relationship between participation in annual health examinations and mortality rate over a 5–year period] Shirasaki S. **Nippon Koshu Eisei Zasshi** 1996 Apr; 43(4):286–98 (Eng. Abstr.) **(Jpn)**
[Health personnel staffing requirements for health examination for the age of 1 1/2 in municipalities in Japan] Tanaka H, et al. **Nippon Koshu Eisei Zasshi** 1995 Oct; 42(10):843–57 (Eng. Abstr.) **(Jpn)**
[Comparison of activities of daily living (ADL), medical treatment and blood pressure of elderly participants and non–participants in health examinations] Yamakawa M, et al. **Nippon Koshu Eisei Zasshi** 1995 Sep;42(9):769–76 (Eng. Abstr.) **(Jpn)**
[Gaucher disease type 1, incidentally found on a periodic physical examination] Yoshida K, et al. **Rinsho Ketsueki** 1996 Jan;37(1):82–5 (Eng. Abstr.) **(Jpn)**
[Health check ups—good to have? (letter)] Wessel–Holst CF. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2353 **(Nor)**
[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4–9 (60 ref.) (Eng. Abstr.) **(Rus)**
[The medical examination of draftees and servicemen with surgical diseases] Chetvertak AM. **Voen Med Zh** 1992 Feb; (2):30–4, 79 (Eng. Abstr.) **(Rus)**
[The control checkup and medical examination of servicemen in the work practice of staff military medical commissions] Likhodiĭ IV, et al. **Voen Med Zh** 1992 Feb;(2):34–7 **(Rus)**
[The medical examination of citizens who are subject to the military service draft] Liufing AA, et al. **Voen Med Zh** 1996 May;317(5):19–21 **(Rus)**
[The importance of a medical evaluation in adolescence within the field of vocational guidance] Mustać M, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):35–40 (Eng. Abstr.) **(Scr)**
[Examinations and referrals at a health center: a study of associated factors] Gómez–Calcerrada Berrocal D, et al. **Aten Primaria** 1996 Mar 31;17(5):353–7 (Eng. Abstr.) **(Spa)**
[Occupational medical tests in the past (letter; comment)] Johansson B. **Lakartidningen** 1996 Apr 10;93(15):1406. Comment on: Lakartidningen 1995 Dec 13;92(50):4778–9. Comment on: Lakartidningen 1996 Feb 7;93(6):444–5. **(Swe)**

ADVERSE EFFECTS

The association of urinary tract infection with a recent pelvic examination in women [editorial] Reed BD. **Arch Fam Med** 1996 Jun;5(6):361–2
The association of urinary tract infection with a recent pelvic examination in women. Tiemstra JD, et al. **Arch Fam Med** 1996 Jun;5(6):357–60 (18 ref.)
Systemic effects of screening for retinopathy of prematurity. Laws DE, et al. **Br J Ophthalmol** 1996 May;80(5):425–8

METHODS

Physical diagnosis skills of physicians in training: a focused assessment [see comments] Mangione S, et al. **Acad Emerg Med** 1995 Jul;2(7):622–9. Comment in: Acad Emerg Med 1995 Jul;2(7):576–7. Comment in: Acad Emerg Med 1995 Jul;2(7):578–9.
Method of checking nasal patency in newborns [letter] Wernecke W. **Am Fam Physician** 1996 Sep 1;54(3):872
Can prehospital personnel detect hypoxemia without the aid of pulse oximeters? Brown LH, et al. **Am J Emerg Med** 1996 Jan;14(1):43–4
The Pemberton sign. Wallace C, et al. **Ann Intern Med** 1996 Oct 1;125(7):568–9
Assessment of peritonism in appendicitis. Golledge J, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):11–4
Total skin examination during screening for malignant melanoma does not increase the detection rate. De Rooij MJ, et al. **Br J Dermatol** 1996 Jul;135(1):42–5
A combined approach for the early detection of ovarian cancer in asymptomatic women. Adonakis GL, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):221–5
Physical examination of the adult patient with respiratory diseases: inspection and palpation. Maitre B, et al. **Eur Respir J** 1995 Sep;8(9):1584–93 (64 ref.)
A guide to writing medical reports on survivors of torture. Forrest D, et al. **Forensic Sci Int** 1995 Nov 30;76(1):69–75
Usefulness of digital rectal examination, serum prostate–specific antigen, transrectal ultrasonography and systematic prostate biopsy for the detection of organ–confined prostate cancer. Gohji K, et al. **Int J Urol** 1995 May;2(2):116–20
New sign to confirm the presence of groin hernia in infants and small children [letter] Donald GR. **Ir Med J** 1996 Mar–Apr;89(2):50
The significance of an absent ankle reflex. Bowditch MG, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):276–9
Examining separated symphysis pubis. Davidson MR. **J Nurse Midwifery** 1996 May–Jun;41(3):259–62 (15 ref.)
Adult cancer detection screening by physical examination. **Nurse Pract** 1996 Mar;21(3):85–6, 89–90, 92–6 passim (0 ref.)
Speculoscopy: a tool to enhance the detection of abnormal vaginal and cervical cells [letter] Carrico DJ. **Nurse Pract** 1996 May;21(5):14, 156
Examination findings in legally confirmed child sexual abuse: it's normal to be normal [letter; comment] Hobbs CJ, et

al. **Pediatrics** 1996 Jan;97(1):148–50. Comment on: Pediatrics 1994 Sep;94(3):310–7.
Nonorganic signs of significance in low back pain. Kummel BM. **Spine** 1996 May 1;21(9):1077–81
Clinical breast examination. Goodson WH 3d.
West J Med 1996 Apr;164(4):355–8
[The study of muscle strength in clinical practice (letter)] Tepper M. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2588 **(Dut)**
[Clinical examination of the shoulder] Jessner A.
Orthopade 1995 Nov;24(6):475–82 (Eng. Abstr.) **(Ger)**
[Shoulder problems in leisure athletes: physical examination, diagnosis and therapy. Sensible procedures in daily practice] Vaeckenstedt J, et al.
Schweiz Med Wochenschr 1996 Mar 16;126(11):447–56 (21 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Using interactive video to add physical assessment data to computer-based patient simulations in nursing. White JE.
Comput Nurs 1995 Sep–Oct;13(5):233–5

PSYCHOLOGY

Comparing survey results [letter] Dean MM.
Can Fam Physician 1996 May;42:846
Digital rectal examinations and prostate cancer screening: attitudes of African American men. Gelfand DE, et al.
Oncol Nurs Forum 1995 Sep;22(8):1253–5

STANDARDS

The accurate diagnosis of oral lesions in human immunodeficiency virus infection. Impact on medical staging. Cruz GD, et al.
Arch Otolaryngol Head Neck Surg 1996 Jan;122(1):68–73
Determining the approximate area of a burn: an inconsistency investigated and re-evaluated. Perry RJ, et al. **BMJ** 1996 May 25;312(7042):1338
Residents' breast examination performance. How often? How well? Covar RA, et al. **Md Med J** 1995 Sep;44(9):694–8
More on the President's checkup [letter] Alper PR.
N Engl J Med 1995 Dec 14;333(24):1645–6

TRENDS

Recapturing expertise in the physical examination: is it too late? [editorial; comment] Thomas H Jr.
Acad Emerg Med 1995 Jul;2(7):578–9. Comment on: Acad Emerg Med 1995 Jul;2(7):622–9.

UTILIZATION

Breast screening by African-American women: insights from a household survey and focus groups. Danigelis NL, et al. **Am J Prev Med** 1995 Sep–Oct;11(5):311–7
As mammography use increases, are some providers omitting clinical breast examination? Burns RB, et al.
Arch Intern Med 1996 Apr 8;156(7):741–4
Impact of a mailed intervention on annual mammography and physician breast examinations among women at high risk of breast cancer. Richardson JL, et al.
Cancer Epidemiol Biomarkers Prev 1996 Jan;5(1):71–6

PHYSICAL EXAMINATION, PREADMISSION see **DIAGNOSTIC TESTS, ROUTINE**

PHYSICAL FITNESS

see related
EXERCISE

Alcohol consumption and physical fitness among young adults. Braun BL, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1048–54
NIH develops consensus statement on the role of physical activity for cardiovascular health. **Am Fam Physician** 1996 Aug;54(2):763–4, 767
Analysis of change in self-reported physical function among older persons in four population studies. Beckett LA, et al. **Am J Epidemiol** 1996 Apr 15;143(8):766–78
Amount and intensity of physical activity, physical fitness, and serum lipids in men. The MARATHOM Investigators. Marrugat J, et al. **Am J Epidemiol** 1996 Mar 15;143(6):562–9
Physical exercise and reduced risk of nonfatal myocardial infarction. O'Connor GT, et al. **Am J Epidemiol** 1995 Dec 1;142(11):1147–56
A multisite field test of the acceptability of physical activity counseling in primary care: project PACE. Long BJ, et al. **Am J Prev Med** 1996 Mar–Apr;12(2):73–81
Aerobic fitness, blood lipids, and body fat in children. Hager RL, et al. **Am J Public Health** 1995 Dec;85(12):1702–6
Impact of aerobic training on fitness and quality of life in multiple sclerosis [see comments] Petajan JH, et al.
Ann Neurol 1996 Apr;39(4):432–41. Comment in: Ann Neurol 1996 Apr;39(4):422–3.
Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men [see comments] Lynch J, et al. **Arch Intern Med** 1996 Jun 24;156(12):1307–14. Comment in: Arch Intern Med 1996 Jun 24;156(12):1258.
Health-related fitness test battery for adults: aspects of reliability. Suni JH, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):399–405
Breaking Olympic records [editorial] Newsholme EA.
BMJ 1996 Aug 3;313(7052):246
Bone mass, muscle strength, and different body constitutional parameters in adolescent boys with a low or moderate exercise level. Nordström P, et al. **Bone** 1995 Oct; 17(4):351–6
Sport specific fitness testing of elite badminton players. Chin MK, et al. **Br J Sports Med** 1995 Sep;29(3):153–7
Physiological profiles and sport specific fitness of Asian elite squash players. Chin MK, et al. **Br J Sports Med** 1995 Sep;29(3):158–64
Reasons why the dockers lost their fitness for work—a retrospective survey. Waśkiewicz J.
Bull Inst Marit Trop Med Gdynia 1993–94;44–45(1–4):25–31
The power spectral analysis of heart rate variability in athletes during dynamic exercise—Part I. Shin K, et al. **Clin Cardiol** 1995 Oct;18(10):583–6
Relationships between field fitness test and basal serum testosterone and cortisol levels in soccer players. Bosco C, et al. **Clin Physiol** 1996 May;16(3):317–22
Physical activity assessment: a review of methods. Melanson EL Jr, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):385–96 (91 ref.)
Poor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middle-aged Swedish men. Eriksson KF, et al.
Diabetologia 1996 May;39(5):573–9
Body mass and physical activity are important predictors of serum androgen concentrations in young healthy men. Mantzoros CS, et al. **Epidemiology** 1995 Jul;6(4):432–5
Physical work load, physical capacity and strain among elderly female aides in home-care service. Torgén M, et al. **Eur J Appl Physiol** 1995;71(5):444–52
Do physical activity and physical fitness avert premature mortality? Lee IM, et al. **Exerc Sport Sci Rev** 1996; 24:135–71 (113 ref.)
Physical activity and health-related quality of life. Rejeski WJ, et al. **Exerc Sport Sci Rev** 1996;24:71–108 (102 ref.)
Consumers ... Americans more fat than fit [news]
Hosp Health Netw 1996 Aug 20;70(16):9
Conditioning leisure time physical activity and cardiorespiratory fitness in sociodemographic groups of middle-ages men in eastern Finland. Lakka TA, et al.
Int J Epidemiol 1996 Feb;25(1):86–93
Perceptions of physical fitness and exercise activity among older adults. Melillo KD, et al. **J Adv Nurs** 1996 Mar; 23(3):542–7
Blood lipids, cardiovascular fitness, obesity, and blood pressure: the presence of potential coronary heart disease risk factors in adolescents. Anding JD, et al.
J Am Diet Assoc 1996 Mar;96(3):238–42
Fitness and function at the end of life [editorial; comment] Fiatarone MA. **J Am Geriatr Soc** 1995 Dec;43(12):1439–40 . Comment on: J Am Geriatr Soc 1995 Dec;43(12):1356–62.
Epidemiology of physical activity, physical fitness and coronary heart disease. Whaley MH, et al.
J Cardiovasc Risk 1995 Aug;2(4):289–95 (38 ref.)
Association of physical fitness and transient myocardial ischemia in patients with coronary artery disease. Jiang W, et al. **J Cardpulm Rehabil** 1995 Nov–Dec;15(6):431–8
Effects of 2,000 kcal per week of walking and stair climbing on physical fitness and risk factors for coronary heart disease. Leon AS, et al. **J Cardpulm Rehabil** 1996 May–Jun; 16(3):183–92
Ability of the Caltrac accelerometer to assess daily physical activity levels. Richardson MT, et al.
J Cardpulm Rehabil 1995 Mar–Apr;15(2):107–13
Physical-strength tests and mortality among visitors to health-promotion centers in Japan. Fujita Y, et al.
J Clin Epidemiol 1995 Nov;48(11):1349–59
Limitations in upper-body strength associated with breast cancer: a comparison of black and white women. Satariano WA, et al. **J Clin Epidemiol** 1996 May;49(5):535–44
Muscle torque in young and older untrained and endurance-trained men. Alway SE, et al.
J Gerontol A Biol Sci Med Sci 1996 May;51(3):B195–201
Interrelationships of peak expiratory flow rate with physical and cognitive function in the elderly: MacArthur Foundation studies of aging. Cook NR, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50(6):M317–23
Effects of training on potassium homeostasis during exercise. McKenna MJ. **J Mol Cell Cardiol** 1995 Apr;27(4):941–9 (52 ref.)
Physical fitness testing in children operated on for tracheoesophageal fistula. Zaccara A, et al.
J Pediatr Surg 1995 Sep;30(9):1334–7
Potential recruits referred for cardiac opinion review of 100 consecutive cases—a waste of time or an investment? Ineson N, et al. **J R Army Med Corps** 1995 Oct; 141(3):129–33
Gender differences in physical activity and determinants of physical activity in rural fifth grade children. Trost SG, et al. **J Sch Health** 1996 Apr;66(4):145–50
Recreational exercise participation and aerobic fitness in men and women: analysis of data from a national survey. Bonen A, et al. **J Sports Sci** 1995 Aug;13(4):297–303
From the Centers for Disease Control and Prevention. State-specific changes in physical activity among persons aged > or = 65 years—United States, 1987–1992.
JAMA 1995 Nov 15;274(19):1500–1
From the Centers for Disease Control and Prevention. Prevalence of physical inactivity during leisure time among overweight persons—1994. **JAMA** 1996 Mar 27;275(12):905
Surgeon General's report on physical activity and health. From the Centers for Disease Control and Prevention.
JAMA 1996 Aug 21;276(7):522
From the Centers for Disease Control and Prevention. State-specific prevalence of participation in physical activity—1994. **JAMA** 1996 Sep 11;276(10):775
Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. **JAMA** 1996 Jul 17;276(3):241–6 (0 ref.)
Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. Blair SN, et al. **JAMA** 1996 Jul 17; 276(3):205–10
Evaluation of the revised physical activity readiness questionnaire in older adults. Cardinal BJ, et al.
Med Sci Sports Exerc 1996 Apr;28(4):468–72
The validity of non-exercise cardiorespiratory fitness prediction models [letter; comment] Jackson AS, et al.
Med Sci Sports Exerc 1995 Jul;27(7):1096–8. Comment on: Med Sci Sports Exerc 1995 Jan;27(1):85–91.
Ethnicity affects aerobic fitness in US adolescent girls. Pivarnik JM, et al. **Med Sci Sports Exerc** 1995 Dec; 27(12):1635–8
Sports medicine's top performers [editorial] Meyer CR.
Minn Med 1996 Jul;79(7):5
State-specific prevalence of participation in physical activity—Behavioral Risk Factor Surveillance System, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Aug 9; 45(31):673–5
Proceedings of conference on nutrition and physical activity to optimize performance and well-being. Atlanta, Georgia, April 5–7, 1995. **Nutr Rev** 1996 Apr;54(4 Pt 2):S1–183
Measuring nutrition status, physical activity, and fitness, with special emphasis on populations at nutritional risk. Rodrigues Matsudo VK. **Nutr Rev** 1996 Apr;54(4 Pt 2):S79–96 (171 ref.)
Nutrition and physical activity program to attenuate obesity and promote physical and metabolic fitness in elementary school children. Donnelly JE, et al. **Obes Res** 1996 May; 4(3):229–43
The association among fat distribution, physical fitness, and the risk factors of cardiovascular disease in obese women. Tanaka H, et al. **Obes Res** 1995 Dec;3 Suppl 5:649S–653S
Physical fitness in children with juvenile rheumatoid arthritis and other chronic pediatric illnesses. Singsen BH.
Pediatr Clin North Am 1995 Oct;42(5):1035–50 (61 ref.)
Cluster analysis of levels of body fatness in children. Zhu W, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):803–8
Starting participation in an employee fitness program: attitudes, social influence, and self-efficacy. Lechner L, et al. **Prev Med** 1995 Nov;24(6):627–33
Reliability of the prudential FITNESSGRAM trunk lift test in young adults. Jackson AW, et al. **Res Q Exerc Sport** 1996 Mar;67(1):115–7
Age, physical fitness and health. Astrand PO. **Sb Lek** 1994; 95(2):59–63
Physical fitness and CHD risk factors in operators and managers of nuclear and thermal power plants situated in environmentally different regions of the Czech Republic. Brandejský P, et al. **Sb Lek** 1994;95(2):127–38
A healthy lifestyle, physical fitness and prevention of disease. Hebbelinck M. **Sb Lek** 1994;95(2):65–73
Physical performance, physical activity and quality of life in elderly people [editorial; comment] Grimby G.
Scand J Med Sci Sports 1995 Jun;5(3):127–8. Comment on: Scand J Med Sci Sports 1995 Jun;5(3):129–42. Comment on: Scand J Med Sci Sports 1995 Jun;5(3):147–51.
Patterns of intense physical activity among 15- to 30-year-old Finns. The Cardiovascular Risk in Young Finns Study. Raitakari OT, et al.
Scand J Med Sci Sports 1996 Feb;6(1):36–9
Exercise-induced asthma and cardiovascular fitness in asthmatic children. Thio BJ, et al. **Thorax** 1996 Feb; 51(2):207–9
The effect of minimal exercise on fitness in elderly women after hip surgery. Patterson AJ, et al. **Ulster Med J** 1995 Oct;64(2):118–25
Comments on Maine urchin divers [letter; comment] Daugherty CG. **Undersea Hyperb Med** 1996 Mar;23(1):56–7 . Comment on: Undersea Hyperb Med 1995 Sep;22(3):307–13.
Sea-level physical activity and acute mountain sickness at moderate altitude. Honigman B, et al. **West J Med** 1995 Aug;163(2):117–21
[Changes in physical activity are not reflected in physical fitness of older teenagers. A 2-year follow-up study] Andersen LB. **Ugeskr Laeger** 1996 Apr 8;158(15):2113–7 (Eng. Abstr.) **(Dan)**
[Physical fitness in children and adolescents: how can it be measured? A review of the literature] Michaud PA, et al.
Arch Pediatr 1996 May;3(5):497–504 (45 ref.) (Eng. Abstr.) **(Fre)**
[Role of physical activities in a public health policy] Rieu M. **Bull Acad Natl Med** 1995 Oct;179(7):1417–26; discussion 1426–8 (Eng. Abstr.) **(Fre)**
[Physical activities and health: results of a national survey of workers] Simon-Rigaud ML. **Bull Acad Natl Med** 1995 Oct;179(7):1429–36; discussion 1436–9 (Eng. Abstr.) **(Fre)**
[Driving of a motor vehicle after implantation of a

cardioverter-defibrillator in malignant heart rhythm disorders. Criteria for the medical assessment of driving fitness in Europe] Lüderitz B, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):119–23 (Eng. Abstr.) **(Ger)**

[Effect of physical activity on physical fitness among workers] Sasaki C, et al. **Nippon Eiseigaku Zasshi** 1995 Oct; 50(4):876–85 (Eng. Abstr.) **(Jpn)**

[A study on physique, exercise frequency and physical strength of middle-aged forestry workers] Sasaki H, et al. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):976–85 (Eng. Abstr.) **(Jpn)**

[Effect of physical exercise in fibromyalgia] Mengshoel AM. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):746–8 (31 ref.) (Eng. Abstr.) **(Nor)**

[The characteristics of their free time and the physical work capacity of adolescents] Sukharev AG, et al. **Gig Sanit** 1995 Nov–Dec;(6):29–31 (Eng. Abstr.) **(Rus)**

[The dynamics of the risk factors for IHD and the physical work capacity of the workers on locomotive teams based on the results of prospective observations] Prazdnov AS. **Ter Arkh** 1996;68(1):22–4 (Eng. Abstr.) **(Rus)**

[Improvement in the system of checking and assessing the physical fitness of military physicians] Dergachev VB, et al. **Voen Med Zh** 1995 Sep;(9):4–7, 80 (Eng. Abstr.) **(Rus)**

[Should the physical development of servicemen be evaluated and what is the necessity for the collection of health information] Kuvakin VI. **Voen Med Zh** 1995 Feb;(2):50–4 **(Rus)**

[The use of balneological factors to accelerate the recovery of physical work capacity in athletes] Gigineishvili GR, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug; (4):22–5 (Eng. Abstr.) **(Rus)**

[The use of an electrosleep method for restoring the performance capacity and relieving the psychoemotional stress of athletes in cyclic sports] Liubimskaia II, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):29–30 (Eng. Abstr.) **(Rus)**

[Evaluation of physical fitness in military personnel using the 1600 meter running test] Životić-Vanović M, et al. **Vojnosanit Pregl** 1995 Sep–Oct;52(5):443–9 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

"Lifestyle" interventions for promoting physical activity: a kilocalorie expenditure–based home feasibility study. Leaf DA, et al. **Am J Med Sci** 1996 Aug;312(2):68–75

Aerobic fitness of prepubescent children. Armstrong N, et al. **Ann Hum Biol** 1995 Sep–Oct;22(5):427–41

Physical fitness and cardiopulmonary baroreflex to passive head–up tilt. Hayashi H, et al. **Appl Human Sci** 1995 Jul; 14(4):167–76

The relative utility of health–related fitness tests and skilled motor performance tests as measures of biological age in Japanese men. Lee MS, et al. **Appl Human Sci** 1996 May; 15(3):97–104

Serum 25–hydroxyvitamin D3 is related to physical activity and ethnicity but not obesity in a multicultural workforce. Scragg R, et al. **Aust N Z J Med** 1995 Jun;25(3):218–23

Long term effects of smoking on physical fitness and lung function: a longitudinal study of 1393 middle aged Norwegian men for seven years. Sandvik L, et al. **BMJ** 1995 Sep 16;311(7007):715–8

Bone mass at lumbar spine and tibia in young males—impact of physical fitness, exercise, and anthropometric parameters: a prospective study in a cohort of military recruits. Casez JP, et al. **Bone** 1995 Sep;17(3):211–9

Prevention of falls in the elderly. Myers AH, et al. **Bone** 1996 Jan;18(1 Suppl):87S–101S

Smoking habits and long–term decline in physical fitness and lung function in men. Pipe A. **Clin J Sport Med** 1996 Apr; 6(2):139

Relationship between habitual physical activity and insulin area among individuals with impaired glucose tolerance. The San Luis Valley Diabetes Study. Regensteiner JG, et al. **Diabetes Care** 1995 Apr;18(4):490–7

Fitness in the fit: does physical conditioning affect cardiovascular risk factors in middle–aged marathon runners? Ketelhut RG, et al. **Eur Heart J** 1996 Feb; 17(2):199–203

Unbalanced haemostatic changes following strenuous physical exercise. A study in young sedentary males. van den Burg PJ, et al. **Eur Heart J** 1995 Dec;16(12):1995–2001

Physical fitness, mortality and obesity. Barlow CE, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S41–4 (14 ref.)

Fat, friendless and unhealthy: 9–year old children's perception of body shape stereotypes. Hill AJ, et al. **Int J Obes Relat Metab Disord** 1995 Jun;19(6):423–30

Exercise intensity increased by addition of handheld weights to rebounding exercise. Smith JF, et al. **J Cardpulm Rehabil** 1995 Jan–Feb;15(1):34–8

Physical fitness, physical activity, and fatness in relation to blood pressure and lipids in preadolescent children. Results from the FRESH Study. Stewart KJ, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):122–9

Hormonal responses to maximal and submaximal exercise in trained and untrained men of various ages. Silverman HG, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B30–7

The measurement and interpretation of aerobic fitness in children: current issues. Welsman JR, et al. **J R Soc Med** 1996 May;89(5):281P–5P (57 ref.)

Examining warm–up decrement as a function of interpolated open and closed motor tasks: implications for practice strategies. Anshel MH. **J Sports Sci** 1995 Jun;13(3):247–56

Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. Pelliccia A, et al. **JAMA** 1996 Jul 17;276(3):211–5

Physical and motor fitness in twins. Chatterjee S, et al. **Jpn J Physiol** 1995;45(3):519–34

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83–102 (85 ref.)

Aerobic response to endurance exercise training in children. Rowland TW, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):654–8

Relationships between mobility of axial structures and physical performance. Schenkman M, et al. **Phys Ther** 1996 Mar;76(3):276–85

Total radical trapping antioxidant potential (TRAP) and exercise. Sharpe PC, et al. **QJM** 1996 Mar;89(3):223–8

Metabolic and cardiorespiratory reactions in tennis–players in laboratory testing and under sport–specific conditions. Smekal G, et al. **Wien Med Wochenschr** 1995;145(22):611–5

[Longitudinal analysis of change in sports performance of women between ages 30 and 75: a comparison between peak and leisure sports participation] Okonek CC. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):127–35 (Eng. Abstr.) **(Ger)**

[Effects of prolonged administration of branched–chain amino acids on body composition and physical fitness] Candeloro N, et al. **Minerva Endocrinol** 1995 Dec; 20(4):217–23 (Eng. Abstr.) **(Ita)**

[Bone mineral density of the lumbar spine and its relation to biological and lifestyle factors in middle–aged and aged Japanese women (Part 3). Relationships of physical fitness and lifestyle factors to bone mineral density in premenopausal and postmenopausal women] Kajita E, et al. **Nippon Eiseigaku Zasshi** 1995 Oct;50(4):893–900 (Eng. Abstr.) **(Jpn)**

[The effects of fitness–type exercise on iron status and hematological status for female college students] Kondo S, et al. **Rinsho Byori** 1995 Sep;43(9):953–9 (Eng. Abstr.) **(Jpn)**

[Significance of chronotropic exertion effects on the heart in diagnosing physical fitness in children practising swimming] Walat S. **Ann Acad Med Stetin** 1995;41:109–29 (Eng. Abstr.) **(Pol)**

[Physical practicing of athletes. Methodology and training] Yazbek Júnior P. **Arq Bras Cardiol** 1995 Feb;64(2):167–9 **(Por)**

[The functional status of sailors from different job groups] Shatalov AI, et al. **Voen Med Zh** 1995 Jun;(6):61–4, 80 (Eng. Abstr.) **(Rus)**

[The use of apparatus–supported physiotherapy for the accelerated recovery and enhancement of sports performance] Gigineishvili GR, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct; (5):25–30 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Current and ideal physique choices in exercising and nonexercising college women from a pilot athletic image scale. Lenart EB, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):831–48

Perceived vulnerability and control of martial arts and physical fitness students. Madden ME. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):899–910

Perceived exertion during physical exercise among individuals high and low in fitness. Travlos AK, et al. **Percept Mot Skills** 1996 Apr;82(2):419–24

Physical fitness and perceived stress. Relationships with coronary artery disease risk factors. Labbate LA, et al. **Psychosomatics** 1995 Nov–Dec;36(6):555–60

PHYSICAL MEDICINE

see related

BIOMECHANICS

The compleat physiatrist [editorial] Johnson EW. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):83

Residency interviewing [editorial] Johnson EW. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):251

The 45th annual John Stanley Coulter Lecture. Post–polio sequelae and the paradigms of the 50s: Newtie, Ozzie, and Harriet versus paradigms of caring and a future for rehabilitation in America. Bruno RL. **Arch Phys Med Rehabil** 1995 Dec;76(12):1093–6

Volumetric determinations with CAD/CAM in prosthetics and orthotics: errors of measurement. Lilja M, et al. **J Rehabil Res Dev** 1995 May;32(2):141–8

Rehabilitation research and development in physical medicine in Japan: a historical and state–of–the–art review [editorial] Ueda S. **J Rehabil Res Dev** 1995 May;32(2):ix–xi

ECONOMICS

Case–mix measurement in medical rehabilitation. Stineman MG. **Arch Phys Med Rehabil** 1995 Dec;76(12):1163–70 (40 ref.)

EDUCATION

Interest in manual medicine among residents in physical medicine and rehabilitation. The need for increased instruction. Atchison JW, et al. **Am J Phys Med Rehabil** 1995 Nov–Dec;74(6):439–43

Integration of physical medicine and rehabilitation into the undergraduate medical curriculum. The Undergraduate Education Committee of the Association of Academic Physiatrists Workgroup. Bloch RM, et al. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):242–3

Analyzing the National Resident Match data. Are there too many physical medicine and rehabilitation training positions? A commentary. DeLisa JA, et al. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):141–3

Managed care and its effect on residency training in physical medicine and rehabilitation. A commentary. DeLisa JA, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):380–2

Factors influencing the specialty choice of the PM&R graduating class of 1994 and the entering class of 1995 [letter; comment] Massagli TL. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):244. Comment on: Am J Phys Med Rehabil 1995 Jul–Aug;74(4):262–70.

Educational goals and objectives in physical medicine and rehabilitation for the medical school graduate. Association of Academic Physiatrists Undergraduate Education Committee Workgroup. Tuel SM, et al. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):149–51

Chief residency in PM&R. A balance of education and administration. Young MA, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):257–62

HISTORY

The historical role of the physiatrist in the management of Duchenne muscular dystrophy. A commentary. Bach JR. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):239–41

INSTRUMENTATION

[A computerized endurance test: efficacy of pelvic floor rehabilitation treatment in patients with stress incontinence] Guarnaschelli C, et al. **Minerva Urol Nefrol** 1995 Mar; 47(1):19–23 (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Physiatric implications of Medicare's final rule. A commentary. Braddom RL. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):317–9

MANPOWER

Physical medicine and rehabilitation workforce study: the supply of and demand for physiatrists. Hogan PF, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):95–9

METHODS

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S45–51 (58 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 3. Cancer rehabilitation. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S52–8 (38 ref.)

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. Hertanu JS, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S38–44 (92 ref.)

Focused review: physiatric management of HIV–related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

Assessment methods for rehabilitation. Biefang S, et al. **Int J Rehabil Res** 1995 Sep;18(3):201–13 (47 ref.)

ORGANIZATION & ADMINISTRATION

American Academy of Physical Medicine and Rehabilitation presidential address. Facing new realities: strategies for change. Grabois M. **Arch Phys Med Rehabil** 1996 Mar; 77(3):215–8

STANDARDS

ISB recommendations for standardization in the reporting of kinematic data. Wu G, et al. **J Biomech** 1995 Oct; 28(10):1257–61

TRENDS

The 28th Walter J. Zeiter lecture. Facing new realities: back to the future. Reinstein L. **Arch Phys Med Rehabil** 1996 Mar;77(3):219–22

Physical medicine and rehabilitation. Brandstater ME, et al. **JAMA** 1996 Jun 19;275(23):1843–4

PHYSICAL STIMULATION

Responses of neurons in the caudal intralaminar thalamic complex of the rat to stimulation of the uterus, vagina, cervix, colon and skin. Berkley KJ, et al. **Brain Res** 1995 Oct 9;695(1):92–5

Stimulus–sensitive seizures in postanoxic coma. Van Cott AC, et al. **Epilepsia** 1996 Sep;37(9):868–74

Effect of labor analgesia with nalbuphine hydrochloride on fetal response to vibroacoustic stimulation. Poehlmann S, et al. **J Reprod Med** 1995 Oct;40(10):707–10

Initiation and frequency of breast expression in breastfeeding mothers of LBW and VLBW infants. Hill PD, et al. **Nurs Res** 1995 Nov–Dec;44(6):352–5

Quality of semen obtained by penile vibratory stimulation in men with spinal cord injuries: observations and predictors. Sønksen J, et al. **Urology** 1996 Sep;48(3):453–7

[Reliability of magnetic stimulation in the diagnosis of peripheral facial paralysis of idiopathic origin] Schrader M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(2):123–7 (Eng. Abstr.) **(Fre)**

[A study on effect of mechanical irritation in development and progression of tongue cancer] Sato T. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):532–50 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

A feedback controlled silicon microprobe for quantitative mechanical stimulation of nerve and tissue. Jackson D, et al. **J Neurosci Methods** 1995 Aug;60(1–2):157–63

An electromechanical stimulator system for neurophysiological and psychophysical studies of pain. Schneider W, et al. **J Neurosci Methods** 1995 Aug; 60(1–2):61–8

Vibratory stimulation and rectal probe electroejaculation as therapy for patients with spinal cord injury: semen parameters and pregnancy rates. Nehra A, et al. **J Urol** 1996 Feb;155(2):554–9

METHODS

The silent period induced by transcranial magnetic stimulation in muscles supplied by cranial nerves: normal data and changes in patients. Werhahn KJ, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):586–96

Comfortable zone of the mandible evaluated by the constant stimuli method. Abekura H, et al. **J Oral Rehabil** 1996 May; 23(5):330–5

The effect of intracorporeal injection plus genital and audiovisual sexual stimulation versus second injection on penile color Doppler sonography parameters. Montorsi F, et al. **J Urol** 1996 Feb;155(2):536–40

[Responses of ligamentous fibroblasts to mechanical stimulation] Desrosiers EA, et al. **Ann Chir** 1995; 49(8):768–74 (Eng. Abstr.) **(Fre)**

PHYSICAL THERAPY

see related
NATUROPATHY

Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients. Dam M, et al. **Adv Neurol** 1996;69:551–5

Burnout in occupational therapists and physical therapists working in head injury rehabilitation. Schlenz KC, et al. **Am J Occup Ther** 1995 Nov–Dec;49(10):986–93

Effectiveness of an intensive outpatient rehabilitation program for postacute stroke patients. Werner RA, et al. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):114–20

Nocturnal saturation improves by target-flow inspiratory muscle training in patients with COPD. Heijdra YF, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):260–5

Knee hyperextension gait abnormalities in unstable knees. Recognition and preoperative gait retraining. Noyes FR, et al. **Am J Sports Med** 1996 Jan–Feb;24(1):35–45

Who should see orthopaedic outpatients—physiotherapists or surgeons? Weale AE, et al. **Ann R Coll Surg Engl** 1995 Mar;77(2 Suppl):71–3

Mood improvement in elderly women after in-hospital physical rehabilitation. Barbisoni P, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):346–9

Gait training efficacy using a home-based practice model in chronic hemiplegia. Rodriquez AA, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):801–5

Relax sympathetic dystrophy in children. Active early physiotherapy is the key to prevention [letter; comment] Beattie TF. **BMJ** 1995 Dec 2;311(7018):1503–4. Comment on: BMJ 1995 Jun 24;310(6995):1648–9.

Comparison between primary care physiotherapy education/advice clinics and traditional hospital based physiotherapy treatment: a randomized trial. Worsfold C, et al. **Br J Gen Pract** 1996 Mar;46(404):165–8

High-intensity physical training in adults with asthma. A 10-week rehabilitation program. Emtner M, et al. **Chest** 1996 Feb;109(2):323–30

The effect of physical therapy on respiratory complications following cardiac valve surgery. Johnson D, et al. **Chest** 1996 Mar;109(3):638–44

Fifteen months' follow-up of intensive inpatient physiotherapy and exercise in ankylosing spondylitis. Viitanen JV, et al. **Clin Rheumatol** 1995 Jul;14(4):413–9

Outcome of treatment of chronic low back pain in inpatients. Effect of individual physiotherapy including intensive dynamic training in inpatients with chronic low back trouble, evaluated by means of low back pain rating scale. Laursen SO, et al. **Dan Med Bull** 1995 Jun;42(3):290–3

A randomised controlled trial of different intensities of physiotherapy and different goal-setting procedures in 44 children with cerebral palsy. Bower E, et al. **Dev Med Child Neurol** 1996 Mar;38(3):226–37

Correlates of physicians' decisions to refer children with cerebral palsy for physical therapy. Campbell SK, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1062–74

Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. 15 year follow-up study. Hämäläinen H, et al. **Eur Heart J** 1995 Dec;16(12):1839–44

Effects of early motion on healing of musculoskeletal tissues. Buckwalter JA. **Hand Clin** 1996 Feb;12(1):13–24 (81 ref.)

Early motion protocols in hand and wrist rehabilitation. Crosby CA, et al. **Hand Clin** 1996 Feb;12(1):31–41

Early motion after extensor tendon surgery. Crosby CA, et al. **Hand Clin** 1996 Feb;12(1):57–64 (37 ref.)

Early motion after arthroplasty. Kirkpatrick WH, et al. **Hand Clin** 1996 Feb;12(1):73–86 (45 ref.)

Early motion in the treatment of fractures and dislocations in the hand and wrist. Margles SW. **Hand Clin** 1996 Feb; 12(1):65–72

Early motion after replantation. Silverman PM, et al. **Hand Clin** 1996 Feb;12(1):97–107

Early motion after wrist surgery. Thompson ST, et al. **Hand Clin** 1996 Feb;12(1):87–96

Early motion after flexor tendon surgery. Wang AW, et al. **Hand Clin** 1996 Feb;12(1):43–55 (47 ref.)

Early motion after hand and wrist reconstruction. Wehbé MA. **Hand Clin** 1996 Feb;12(1):25–9

Outcome following conservative management of thoracic outlet syndrome. Novak CB, et al. **J Hand Surg [Am]** 1995 Jul;20(4):542–8

Outcome study of ulnar nerve compression at the elbow treated with simple decompression and an early programme of physical therapy. Nathan PA, et al. **J Hand Surg [Br]** 1995 Oct;20(5):628–37

Early active mobilization after tendon transfers using mesh reinforced suture techniques. Silfverskiöld KL, et al. **J Hand Surg [Br]** 1995 Jun;20(3):291–300

Early active mobilization of tendon grafts using mesh reinforced suture techniques. Silfverskiöld KL, et al. **J Hand Surg [Br]** 1995 Jun;20(3):301–7

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):3–11 (20 ref.)

Recovery of muscle strength following arthroscopic meniscectomy. Matthews P, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):18–26

Video views [letter] Merrick C. **J Orthop Sports Phys Ther** 1995 Jul;22(1):39–40

Differential diagnosis in physical therapy evaluation of thigh pain in an adolescent boy. Pellecchia GL, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):51–5

Effects of aquatic therapy on joint flexibility and functional ability in subjects with rheumatic disease. Templeton MS, et al. **J Orthop Sports Phys Ther** 1996 Jun;23(6):376–81

Managing acute low back pain [letter] Laslett M, et al. **N Z Med J** 1996 Jul 26;109(1026):284

Sudeck's atrophy of the left tibiotarsal joint in a renal transplant patient: effects of medical and physical therapy [letter] Campieri C, et al. **Nephron** 1995;71(1):122–3

Conservative management of mechanical neck disorders. A systematic overview and meta-analysis. Gross AR, et al. **Online J Curr Clin Trials** 1996 Jul 30;Doc No 200–201:[34457 words; 185 paragraphs]

Comparison of the canalith repositioning procedure and vestibular habituation training in forty patients with benign paroxysmal positional vertigo. Steenerson RL, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):61–4

The role of the pediatrician in prescribing therapy services for children with motor disabilities. American Academy of Pediatrics Committee on Children With Disabilities. **Pediatrics** 1996 Aug;98(2 Pt 1):308–10

Physical Therapy '96: scientific meeting and exposition. June 14–18, 1996. Abstracts. **Phys Ther** 1996 May;76(5):S1–128

Defining the PTA's roles. Amborse-Walsh L. **Phys Ther** 1996 Apr;76(4):410–3

Work-related musculoskeletal disorders among physical therapists. Bork BE, et al. **Phys Ther** 1996 Aug;76(8):827–35

Heart failure. Cahalin LP. **Phys Ther** 1996 May;76(5):516–33 (84 ref.)

Early family experiences and helping behaviors of physical therapists. Curtis KA, et al. **Phys Ther** 1995 Dec; 75(12):1089–100

Physical therapy in lung transplantation. Downs AM. **Phys Ther** 1996 Jun;76(6):626–42 (102 ref.)

Physician referral to physical therapy in a cohort of workers compensated for low back pain. Ehrmann-Feldman D, et al. **Phys Ther** 1996 Feb;76(2):150–6; discussion 156–7

Be not content to "sleep and feed" [letter] Holmes JA. **Phys Ther** 1996 Jun;76(6):664–6

The influence of subject and test design on dynamometric measurements of extremity muscles. Keating JL, et al. **Phys Ther** 1996 Aug;76(8):866–89 (224 ref.)

Is the clinical concept of spinal stiffness multidimensional? Maher C, et al. **Phys Ther** 1995 Oct;75(10):854–60; discussion 861–4

Outcomes research [letter; comment] Michels E. **Phys Ther** 1996 Feb;76(2):194–6. Comment on: Phys Ther 1995 Nov;75(11):965–70.

Initial health status of patients at outpatient physical therapy clinics. Mossberg KA, et al. **Phys Ther** 1995 Dec; 75(12):1043–51; discussion 1051–3

Validity of the Peabody Developmental Gross Motor Scale as an evaluative measure of infants receiving physical therapy. Palisano RJ, et al. **Phys Ther** 1995 Nov; 75(11):939–48; discussion 948–51

Physical therapist assistants' perceptions of the documented roles of the physical therapist assistant. Robinson AJ, et al. **Phys Ther** 1995 Dec;75(12):1054–64; discussion 1064–6

Specialization, certification, turf, and society [editorial] Rothstein JM. **Phys Ther** 1995 Nov;75(11):936–8

Outcomes and survival [editorial] Rothstein JM. **Phys Ther** 1996 Feb;76(2):126–7

Romance, reality, and managed care [editorial] Rothstein JM. **Phys Ther** 1996 Jun;76(6):574–5

Objective versus subjective: kudzu terminology [editorial] Rothstein JM. **Phys Ther** 1996 Aug;76(8):814–6

The Denny-Brown collection: useful resource for physical therapy practitioners and educators. Vilensky JA, et al. **Phys Ther** 1996 Aug;76(8):890–3

The knowledge and attitudes of occupational therapy, physiotherapy and speech-language therapy students, regarding the speech-language therapist's role in the hospital stroke rehabilitation team. Felsher L, et al. **S Afr J Commun Disord** 1994;41:49–63

Penetrating stab wounds of the chest—when should chest physiotherapy commence? A comparative study. Senekal M, et al. **S Afr J Surg** 1995 Jun;33(2):61–6

Restoration of gait by combined treadmill training and multichannel electrical stimulation in non-ambulatory hemiparetic patients. Hesse S, et al. **Scand J Rehabil Med** 1995 Dec;27(4):199–204

The effect of pain reduction on perceived tension and EMG-recorded trapezius muscle activity in workers with shoulder and neck pain. Vasseljen O Jr, et al. **Scand J Rehabil Med** 1995 Dec;27(4):243–52

Spine update. Functional restoration. Hazard RG. **Spine** 1995 Nov 1;20(21):2345–8 (20 ref.)

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Dam M, et al. **Stroke** 1996 Jul;27(7):1211–4

Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Walker-Batson D, et al. **Stroke** 1995 Dec;26(12):2254–9

Physiotherapy as an aid to treatment of bilateral femoral paralysis in a calf. White AJ, et al. **Vet Rec** 1995 Nov 4; 137(19):489–91

[Results obtained by a mobile handicap-prevention unit at the Institut de Léprologie de Dakar] Hirzel C, et al. **Acta Leprol** 1995;9(4):183–6 (Eng. Abstr.) **(Fre)**

[Kinesitherapy for mucoviscidosis] Wils J, et al. **Rev Pneumol Clin** 1995;51(3):164–74 (71 ref.) (Eng. Abstr.) **(Fre)**

[Annual meeting of the Swiss Society of Rheumatology and The Swiss Society of Physical Medicine and Rehabilitation. Loeche-les-Bains, 7–9 September 1995. Abstracts] **Schweiz Med Wochenschr Suppl** 1995;72:3S–14S **(Fre, Ger)**

[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563–7 (12 ref.) **(Ger)**

[Rupture of lateral ligaments of the ankle joint: MR imaging before and after functional therapy] Grebe P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):225–9 (Eng. Abstr.) **(Ger)**

[Neurorehabilitation/geriatric rehabilitation—goals achieved and aims from the viewpoint of the so-called "Vorarlberg Model"] Barolin GS. **Wien Med Wochenschr** 1995; 145(19–20):568–76 (Eng. Abstr.) **(Ger)**

[Sequelae of manipulation of the postmastectomy arm] Klimaschewski H. **Z Lymphol** 1996 Jun;20(1):43–5 **(Ger)**

[Interference of anticonvulsants in the rehabilitation treatment] Pisaturo C, et al. **Minerva Pediatr** 1996 Apr; 48(4):135–41 (Eng. Abstr.) **(Ita)**

[Acute effect of use of the Flutter on expectoration of sputum in patients with chronic respiratory diseases] Nakamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):180–5 (Eng. Abstr.) **(Jpn)**

[Physical therapy without physicians' referral (letter)] Lexow AL. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1717; discussion 1718 **(Nor)**

[Mobility and group discussions. Treatment of chronic muscle pain in women in general practice] Steihaug S, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1335–8 (Eng. Abstr.) **(Nor)**

[Physical therapy without referral (letter)] Stokke O. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1259–60 **(Nor)**

[Effect of physical therapy and chiropractic (letter)] Torstensen TA. **Tidsskr Nor Laegeforen** 1996 May 30; 116(14):1717; discussion 1718 **(Nor)**

[Results of kinesis therapy in patients with diabetic macroangiopathy of the lower extremities] Ponikowska I, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):16–8 (Eng. Abstr.) **(Pol)**

[Early rehabilitative physiotherapy after surgical laparoscopy in gynecology. Answers to the questions of practicing physicians] Strugatskiĭ VM, et al. **Akush Ginekol (Mosk)** 1995;(5):46–9 **(Rus)**

[Effectiveness of local magnetic field of the acoustic frequency in the treatment of patients with acute inflammatory diseases of the larynx] Tarasov DI, et al. **Vestn Otorinolaringol** 1995 Nov–Dec;(6):11–5 (Eng. Abstr.)

(Rus)
[The manual therapy of newborn infants and young children] Biedermann H. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):48–9 (Rus)
[The use of physical factors in the combined treatment of traumatic damages to the nerve trunks of the extremities] Danda VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):21–5 (Eng. Abstr.) (Rus)
[The therapeutic use of physical factors in the combined therapy of patients with psoriatic arthritis] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):48–52 (51 ref.) (Rus)
[Physical factors in the treatment and rehabilitation of sexual disorders in men] Karpukhin IV. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):38–41 (Rus)
[The role of chronotherapy in optimizing the treatment of patients living under ecologically adverse conditions] Oranskii IE, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun;(3):3–5 (Eng. Abstr.) (Rus)
[Measurement of motor strength of the hand using the Martin Vigorometer in evaluating the success of physical therapy in arthritis of the thumb (see comments)] Culjak M, et al. **Reumatizam** 1993;40(1):21–3 (Eng. Abstr.). Comment in: Reumatizam 1993;40(1):25–8. (Scr)
[Comparative study on the influence of health education on perceived recurrences after physiotherapy] Medina Mirapeix F, et al. **Aten Primaria** 1995 Nov 15;16(8):464–8 (Eng. Abstr.) (Spa)

ADVERSE EFFECTS

[Accessory nerve injury as a complication of therapeutic stretching of the shoulder] Halonen E, et al. **Duodecim** 1994;110(9):889–90 (Fin)

ECONOMICS

Charges for outpatient rehabilitation: growth and differences in provider types. Buchanan JL, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):320–8
[The role and tasks of health–resort medicine under the current socioeconomic conditions] Korolenko ES, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):3–6 (Rus)

EDUCATION

Academic productivity [letter] LaBan MM. **Arch Phys Med Rehabil** 1995 Oct;76(10):977
Interrater reliability of auscultation of breath sounds among physical therapists. Brooks D, et al. **Phys Ther** 1995 Dec;75(12):1082–8
The future of PT education [letter] Domholdt E. **Phys Ther** 1996 May;76(5):538–40; discussion 540–1, 544–5
Conceptual learning processes in physical therapy students. Graham CL. **Phys Ther** 1996 Aug;76(8):856–65
Benefits of the collaborative model [letter; comment] Miller T, et al. **Phys Ther** 1995 Dec;75(12):1137–9. Comment on: Phys Ther 1995 Jun;75(6):503–10.
Physical therapy clinical education in a 2:1 student–instructor education model. Triggs Nemshick M, et al. **Phys Ther** 1996 Sep;76(9):968–81; discussion 982–4
Commitment to clinical education [letter; comment] White DM. **Phys Ther** 1995 Dec;75(12):1139–40. Comment on: Phys Ther 1995 Sep;75(9):784–5.

HISTORY

Orthopaedia: or, the art of correcting and preventing deformities. 1743 [classical article] Andry M. **Hand Clin** 1996 Feb;12(1):153–65
The treatment of fractures by mobilization and massage. 1908 [classical article] Lucas–Championnière J. **Hand Clin** 1996 Feb;12(1):167–71

INSTRUMENTATION

Active traction splinting for proximal interphalangeal joint injuries. Murray KA, et al. **Ann Plast Surg** 1995 Jul;35(1):15–8
Clinical and financial outcomes of lateral rotation low air–loss therapy in patients in the intensive care unit. Takiguchi SA, et al. **Heart Lung** 1995 Jul–Aug;24(4):315–20
A novel electric design for electromagnetic stimulation—the Slinky coil. Ren C, et al. **IEEE Trans Biomed Eng** 1995 Sep;42(9):918–25
Balance abilities of professional dancers on select balance tests. Crotts D, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):12–7
The lennie test for measuring scapular position in healthy young adult females: a reliability and validity study. Sobush DC, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):39–50
Wobble board training after partial sprains of the lateral ligaments of the ankle: a prospective randomized study. Wester JU, et al. **J Orthop Sports Phys Ther** 1996 May;23(5):332–6
Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis [letter; comment] Mahesh VK, et al. **J Pediatr** 1996 Jan;128(1):165–6. Comment on: J Pediatr 1994 May;124(5 Pt 1):689–93.
Influence of examiner experience and gender on interrater reliability of KT–1000 arthrometer measurements. Ballantyne BT, et al. **Phys Ther** 1995 Oct;75(10):898–906
Evaluation of a new device for measuring responses to posteroanterior forces in a patient population, Part 1: Reliability testing. Latimer J, et al. **Phys Ther** 1996 Feb;76(2):158–65
Identifying patients with diabetes mellitus who are at risk for lower–extremity complications: use of Semmes–Weinstein monofilaments. Mueller MJ. **Phys Ther** 1996 Jan;76(1):68–71 (15 ref.)
[A comprehensive approach to designing of magnetotherapy techniques based on the Atos device] Raigorodskii IuM, et al. **Med Tekh** 1995 Jul–Aug;(4):32–5 (Eng. Abstr.) (Rus)
[The use of apparatus–supported physiotherapy for the accelerated recovery and enhancement of sports performance] Gigineishvili GR, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):25–30 (Eng. Abstr.) (Rus)

MANPOWER

Test–retest reliability of a psychometric instrument designed to measure physical therapy students' burnout. Balogun JA, et al. **Percept Mot Skills** 1995 Oct;81(2):667–72

METHODS

A tool to assess biomechanical gait efficiency; a preliminary clinical study. Kerrigan DC, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):3–8
Effects of an accelerated rehabilitation program after anterior cruciate ligament reconstruction with combined semitendinosus–gracilis autograft and a ligament augmentation device. MacDonald PB, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):588–92
Ligament stability two to six years after anterior cruciate ligament reconstruction with autogenous patellar tendon graft and participation in accelerated rehabilitation program. Shelbourne KD, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):575–9
Lumbar trunk muscle endurance testing: an inexpensive alternative to a machine for evaluation. Ito T, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):75–9
Standing balance during internally produced perturbations in subjects with hemiplegia: validation of the balance scale. Stevenson TJ, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):656–62
Multidisciplinary intensive treatment for chronic low back pain: a randomized, prospective study. Bendix AF, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):62–9
Long–term follow up to patients with frozen shoulder after mobilization under anesthesia, with special reference to the rotator cuff. Weber M, et al. **Clin Rheumatol** 1995 Nov;14(6):686–91
Motor rehabilitation: evolution of functional markers in trained hemiparetic patients and effectiveness of synchronous techniques. Zelaschi F, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):203–7
Early mobilization in the treatment of Colles' fracture: a 3 year prospective study. Millet PJ, et al. **Injury** 1995 Dec;26(10):671–5
Clinical screening for congenital dislocation of the hip. Darmonov AV, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):383–8
Intertester reliability of the cyriax evaluation in assessing patients with shoulder pain. Pellecchia GL, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):34–8
Therapy methods for cerebral palsy [letter] Bourne RJ. **J Paediatr Child Health** 1995 Aug;31(4):364–5
Therapy methods for cerebral palsy [letter] Flett PJ. **J Paediatr Child Health** 1995 Aug;31(4):366–7
Therapy methods for cerebral palsy [letter] McCoy A, et al. **J Paediatr Child Health** 1995 Aug;31(4):365–6; discussion 367
Therapy methods for cerebral palsy [letter] Mounzouris N. **J Paediatr Child Health** 1995 Aug;31(4):365; discussion 367
Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Riedler J, et al. **J Paediatr Child Health** 1996 Feb;32(1):48–50
Physical therapy management of the subluxated wrist in children with arthritis. Barden W, et al. **Phys Ther** 1995 Oct;75(10):879–85
Interrater reliability of auscultation of breath sounds among physical therapists. Brooks D, et al. **Phys Ther** 1995 Dec;75(12):1082–8
Clinical decision making by experienced and inexperienced pediatric physical therapists for children with diplegic cerebral palsy. Embrey DG, et al. **Phys Ther** 1996 Jan;76(1):20–33
The effects of neurodevelopmental treatment versus practice on the reaching of children with spastic cerebral palsy. Fetters L, et al. **Phys Ther** 1996 Apr;76(4):346–58
Management of a patient with lacerations of the tendons of the extensor digitorum and extensor indicis muscles to the index finger. Flowers KR, et al. **Phys Ther** 1996 Jan;76(1):61–6
Standardizing low back management [letter; comment] Glinn JE. **Phys Ther** 1995 Oct;75(10):922–4. Comment on: Phys Ther 1995 Jun;75(6):470–85; discussion 485–9.
How should treatments be critiqued for scientific merit? [see comments] Harris SR. **Phys Ther** 1996 Feb;76(2):175–81 (37 ref.). Comment in: Phys Ther 1996 Jun;76(6):667–8. Comment in: Phys Ther 1996 Jul;76(7):786–7.
Physical therapy and health outcomes in patients with spinal impairments. Jette DU, et al. **Phys Ther** 1996 Sep;76(9):930–41; discussion 942–5
A comparison of pisiform and thumb grips in stiffness assessment. Maher C, et al. **Phys Ther** 1996 Jan;76(1):41–8
Temporal stability of gait in Parkinson's disease. Morris ME, et al. **Phys Ther** 1996 Jul;76(7):763–77; discussion 778–80
Low–load, prolonged stretch in the treatment of knee flexion contractures in nursing home residents. Steffen TM, et al. **Phys Ther** 1995 Oct;75(10):886–95; discussion 895–7
Work hardening: evidence for success of a program. Ricke SA, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1077–8
Chest physiotherapy in cystic fibrosis [letter; comment] Webber BA. **Thorax** 1995 Oct;50(10):1123–4. Comment on: Thorax 1995 Feb;50(2):165–9.
[Manual fragmentation of deep vein thrombosis] Richaud C, et al. **J Mal Vasc** 1995;20(3):166–71 (Eng. Abstr.) (Fre)
[Conservative therapy and rehabilitation following surgery of the rotator cuff] Jessner–Kaplans M, et al. **Orthopade** 1995 Nov;24(6):541–7 (Eng. Abstr.) (Ger)
[Effectiveness, indications and contraindications of manual lymph drainage therapy in painful edema] Asdonk J. **Z Lymphol** 1995 Aug;19(1):16–22 (22 ref.) (Ger)
[Adjuvant therapy in lymphedema] Brenke R, et al. **Z Lymphol** 1996 Jun;20(1):31–5 (10 ref.) (Eng. Abstr.) (Ger)
[Outcome of various inpatient lymph drainage procedures] Herpertz U. **Z Lymphol** 1996 Jun;20(1):27–30 (Eng. Abstr.) (Ger)
[Isokinetic muscle training with high motion speeds in the rehabilitation following surgical treatment of fresh anterior cruciate rupture] Hehl G, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):306–10 (Eng. Abstr.) (Ger)
[Is physiotherapy useful following surgery for carpal tunnel syndrome?] Weitbrecht WU, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):429–31 (Eng. Abstr.) (Ger)
[Therapeutic effect of "Ueda" method for a case of spastic paraplegia as a sequela of transverse myelitis] Tojo M. **No To Hattatsu** 1996 May;28(3):251–6 (Eng. Abstr.) (Jpn)
[Physical and pharmacological methods in the rehabilitative treatment of patients with combined cardiocerebral vascular pathology] Ezhova LV. **Lik Sprava** 1995 Jul–Aug;(7–8):21–4 (Eng. Abstr.) (Rus)
[The efficacy of physiotherapeutic methods in the combined treatment of duodenal peptic ulcer] Mal'kuta MA, et al. **Voen Med Zh** 1995 Jun;(6):42–3 (Rus)
[Anesthesia by physiotherapy methods] Ushakov AA. **Voen Med Zh** 1992 Feb;(2):47–50 (Rus)
[The combined exposure to physical factors at the sanatorium–health resort stage of patient rehabilitation in ischemic heart disease] Bobrov LL, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):6–9 (Rus)
[Experience with physiotherapy in a posttraumatic neurodystrophic syndrome of the extremities] Landa VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):21–4 (Eng. Abstr.) (Rus)
[Physiotherapeutic methods in the postoperative period in acute pancreatitis patients] Larionov KS, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun;(3):16–8 (Eng. Abstr.) (Rus)
[Physical treatment methods in dysplastic scoliosis in children] Nenasheva TV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):44–6 (58 ref.) (Rus)
[The characteristics of rehabilitating the disabled and the means for realizing a rehabilitation program using sanatorium and health–resort treatment methods] Sorokina EI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):35–8 (Rus)
[Demyelinating diseases and physical treatment methods] Strelkova NI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):41–4 (24 ref.) (Rus)
[Physical factors in the treatment of patients with osteoarthrosis and venous insufficiency] Tereshina LG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):20–2 (Eng. Abstr.) (Rus)
[The therapeutic and prophylactic use of physical factors in the postpartum period: methods and technological features] Zheleznova EB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):41–3 (Rus)
[Speleotherapy in chronic obstructive bronchitis] Zunnunov ZR, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):34–6 (Rus)
[Better treatment relieves lymphedema. Intensive self–care is effective] Henriksson TG. **Lakartidningen** 1996 Sep 11;93(37):3127–31 (Swe)

ORGANIZATION & ADMINISTRATION

Back school in a first episode of compensated acute low back pain: a clinical trial to assess efficacy and prevent relapse. Leclaire R, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):673–9
The American society of hand therapists: a part of the solution. Donnell M. **J Hand Ther** 1995 Oct–Dec;8(4):237–9

PSYCHOLOGY

Psychiatric evaluation of physical rehabilitation patients.

Aoki T, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):440–3

STANDARDS

Manipulative physiotherapy for spinal problems in primary care: outcomes of care. Bradshaw C, et al. **Br J Rheumatol** 1995 Nov;34(11):1070–3

Clinical competency guidelines for pulmonary rehabilitation professionals. American Association of Cardiovascular and Pulmonary Rehabilitation Position Statement. **J Cardpulm Rehabil** 1995 May–Jun;15(3):173–8

"What constitutes evidence?" [letter] Berger D, et al. **Phys Ther** 1996 Sep;76(9):1011–2; 1014–5

Evaluating scientific merit [letter; comment] Danoff J. **Phys Ther** 1996 Jul;76(7):786–7. Comment on: Phys Ther 1996 Feb;76(2):175–81.

Outcomes research: shifting the dominant research paradigm in physical therapy [see comments] Jette AM. **Phys Ther** 1995 Nov;75(11):965–70. Comment in: Phys Ther 1996 Feb;76(2):194–6.

Critiquing treatment for scientific merit [letter; comment] Michels E. **Phys Ther** 1996 Jun;76(6):667–8. Comment on: Phys Ther 1996 Feb;76(2):175–81.

Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)

When thoughtfulness dies [editorial] Rothstein JM. **Phys Ther** 1996 Apr;76(4):342–3

Defining the minimum level of detectable change for the Roland–Morris questionnaire. Stratford PW, et al. **Phys Ther** 1996 Apr;76(4):359–65; discussion 366–8

STATISTICS & NUMERICAL DATA

Physical therapists' recognition of battered women in clinical settings. Clark TJ, et al. **Phys Ther** 1996 Jan;76(1):12–8; discussion 18–9

TRENDS

The impact of managed care on musculoskeletal physical treatment. Mooney V. **Orthopedics** 1995 Nov;18(11):1063–4

[Manual lymph drainage in new federal Germany] Klimaschewski H. **Z Lymphol** 1995 Dec;19(2):48–50 (Eng. Abstr.) **(Ger)**

[The role and tasks of health-resort medicine under the current socioeconomic conditions] Korolenko ES, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):3–6 **(Rus)**

[The problems of physical therapy] Maliavin AG. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):38–41 **(Rus)**

[The problems and prospects of a climatotherapy health resort under current conditions] Soldatchenko SS, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun;(3):5–7 (Eng. Abstr.) **(Rus)**

[Physiotherapy in the rehabilitative treatment following gynecological operations in children and adolescents: the current trends] Strugatskiĭ VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):41–3 **(Rus)**

UTILIZATION

Conflict of interest, physicians and physiotherapy. Waldman M. **Can Med Assoc J** 1996 Jun 1;154(11):1737–9

PHYSICAL THERAPY DEPARTMENT, HOSPITAL

Comparison between primary care physiotherapy education/advice clinics and traditional hospital based physiotherapy treatment: a randomized trial. Worsfold C, et al. **Br J Gen Pract** 1996 Mar;46(404):165–8

A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months [see comments] Strijbos JH, et al. **Chest** 1996 Feb;109(2):366–72. Comment in: Chest 1996 Feb;109(2):299–300.

Pulmonary rehabilitation. Does the site matter? [editorial; comment] Thomas HM 3rd. **Chest** 1996 Feb;109(2):299–300 . Comment on: Chest 1996 Feb;109(2):366–72.

ORGANIZATION & ADMINISTRATION

The value of accident and emergency based physiotherapy services. Morris CD, et al. **J Accid Emerg Med** 1996 Mar;13(2):111–3

UTILIZATION

Rehabilitation after hip fracture—equal opportunity for all? Hoenig H, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):58–63

PHYSICALLY CHALLENGED see **DISABLED**

PHYSICALLY HANDICAPPED see **DISABLED**

PHYSICIAN ASSIGNMENT ACCEPTANCE see **MEDICARE ASSIGNMENT**

PHYSICIAN ASSISTANTS

Transition from housestaff in the neonatal intensive care unit: a time to review, revise, and reconfirm [editorial; comment] Little GA, et al. **Am J Perinatol** 1996 Feb;13(2):127–9. Comment on: Am J Perinatol 1995 Nov;12(6):442–6.

A comparative study of caesarean deliveries by assistant medical officers and obstetricians in Mozambique. Pereira C, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):508–12

Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study. Verver S, et al. **Fam Pract** 1996 Feb;13(1):35–40

The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)

Physician assistant impairment. A peer review program for North Carolina. Mattingly DE, et al. **N C Med J** 1996 Jul–Aug;57(4):233–5

Nurse practitioners and physician assistants: do they have a role in your practice? Stone EL. **Pediatrics** 1995 Oct;96(4 Pt 2):844–50; discussion 850–1

[Preoperative assessment in an area without continuous medical anesthesia service] Scharplatz D. **Swiss Surg** 1995;(3):162–4 (Eng. Abstr.) **(Ger)**

ECONOMICS

Transition from housestaff to nonphysicians as neonatal intensive care providers: cost, impact on revenue, and quality of care [see comments] Schulman M, et al. **Am J Perinatol** 1995 Nov;12(6):442–6. Comment in: Am J Perinatol 1996 Feb;13(2):127–9.

Balancing the health care workforce [letter] Caton LE. **Health Aff (Millwood)** 1995 Fall;14(3):281–2

EDUCATION

Universal precautions training of preclinical students: impact on knowledge, attitudes, and compliance. Diekema DJ, et al. **Prev Med** 1995 Nov;24(6):580–5

Effect of training on the clinical management of malaria by medical assistants in Ghana. Ofori-Adjei D, et al. **Soc Sci Med** 1996 Apr;42(8):1169–76

HISTORY

[Soldiers of mercy (the exhibition in the Military Medical Museum of the Ministry of Defense of the Russian Federation)] Krutov VS, et al. **Voen Med Zh** 1995 Dec;(12):51–3 **(Rus)**

LEGISLATION & JURISPRUDENCE

Working together. Physicians, midlevel practitioners reach compromise on scope-of-practice issues. Ortolon K. **Tex Med** 1995 Oct;91(10):16–8

[Administering injections—legal questions. Areas of responsibilities for the physician—patient education responsibility—case report: injections by the physicians assistant] Binder G. **Fortschr Med** 1996 Jun 20;114(17):221–2 **(Ger)**

PSYCHOLOGY

Physician assistants in control: ED mayhem [letter] Hall GJ. **Am J Emerg Med** 1996 May;14(3):338–9

Satisfaction of physician assistants and other nonphysician providers in a managed care setting. Freeborn DK, et al. **Public Health Rep** 1995 Nov–Dec;110(6):714–9

STANDARDS

Guidelines on the role of physician assistants in emergency departments. American College of Emergency Physicians. **Ann Emerg Med** 1995 Dec;26(6):773

Another go at the experiment [see comments] Howard LW, et al. **Public Health Rep** 1995 Nov–Dec;110(6):668–73. Comment in: Public Health Rep 1995 Nov–Dec;110(6):667.

Beware of medical quick fixes [comment] Mullan F. **Public Health Rep** 1995 Nov–Dec;110(6):667. Comment on: Public Health Rep 1995 Nov–Dec;110(6):668–73.

UTILIZATION

Emergency department uses of physician assistants and nurse practitioners: a national survey. Hooker RS, et al. **Am J Emerg Med** 1996 May;14(3):245–9

Utilization of advanced practice nurses in healthcare systems and multispecialty group practice. Schaffner JW, et al. **J Nurs Adm** 1995 Dec;25(12):37–43

PHYSICIAN-ASSISTED SUICIDE see **SUICIDE, ASSISTED**

PHYSICIAN-HOSPITAL ORGANIZATIONS see **HOSPITAL-PHYSICIAN JOINT VENTURES**

PHYSICIAN-HOSPITAL RELATIONS see **HOSPITAL-PHYSICIAN RELATIONS**

PHYSICIAN IMPAIRMENT

Quality improvement and substance abuse: rethinking impaired provider policies. Corsino BV, et al. **Am J Med Qual** 1996 Summer;11(2):94–9 (21 ref.)

Helping sick doctors. Confidential voluntary scheme has been set up in Britain [letter; comment] Brown RM. **BMJ** 1996 Jun 29;312(7047):1675. Comment on: BMJ 1996 Mar 23;312(7033):722–3.

Helping sick doctors [editorial] [see comments] Chambers R, et al. **BMJ** 1996 Mar 23;312(7033):722–3. Comment in: BMJ 1996 Jun 29;312(7047):1675.

Helping sick doctors. Stress management interventions need to be evaluated [letter; comment] Sims J, et al. **BMJ** 1996 Jun 29;312(7047):1675. Comment on: BMJ 1996 Mar 23;312(7033):722–3.

Another task for harrassed doctors [news] Smith J. **BMJ** 1996 Mar 30;312(7034):800

Allow physicians who commit sex offences to work, but away from patients [letter; comment] [see comments] Dunn RW. **Can Med Assoc J** 1995 Nov 1;153(9):1228. Comment on: Can Med Assoc J 1995 Jul 15;153(2):169–76. Comment in: Can Med Assoc J 1996 Feb 15;154(4):443. Comment in: Can Med Assoc J 1996 Feb 15;154(4):443; discussion 443–4.

Anesthetists taking drugs: is overwork the cause? [letter; comment] Nauth-Misir RC. **Can Med Assoc J** 1995 Dec 1;153(11):1567. Comment on: Can Med Assoc J 1995 Aug 15;153(4):449–52.

The incompetent doctor: behind closed doors. Essay review. Cassell J. **J Health Polit Policy Law** 1995 Winter;20(4):1084–8

Medical advice for sick physicians [letter; comment] Brandon S. **Lancet** 1996 Jun 1;347(9014):1559. Comment on: Lancet 1996 Apr 20;347(9008):1059.

Physicians can't heal themselves [see comments] Scally G. **Lancet** 1996 Apr 20;347(9008):1059. Comment in: Lancet 1996 Jun 1;347(9014):1558–9. Comment in: Lancet 1996 Jun 1;347(9014):1559.

Medical advice for sick physicians [letter; comment] Waldron HA. **Lancet** 1996 Jun 1;347(9014):1558–9. Comment on: Lancet 1996 Apr 20;347(9008):1059.

The riddle of the chemically dependent physician. Heartbreak or joy? **N C Med J** 1996 Jul–Aug;57(4):204–6

Psychiatric diagnoses in North Carolina Physicians Health Program participants. Betts WC. **N C Med J** 1996 Jul–Aug;57(4):214–5

Into the next century. A strategic plan for the North Carolina Physicians Health Program. Keith JF Jr. **N C Med J** 1996 Jul–Aug;57(4):243–5

Our brothers' keepers. A history of the North Carolina Physicians Health Program. McLeod JH. **N C Med J** 1996 Jul–Aug;57(4):201–2

Physician assistant impairment. A peer review program for North Carolina. Mattingly DE, et al. **N C Med J** 1996 Jul–Aug;57(4):233–5

The contrast between physicians seen by the medical board and those seen in private practice. Stratas NE. **N C Med J** 1996 Jul–Aug;57(4):218–22

A North Carolina Medical Board member looks at the North Carolina Physicians Health Program. Trado CE. **N C Med J** 1996 Jul–Aug;57(4):230–2

Positioning a safety net for physicians and their patients. Vanderberry RC. **N C Med J** 1996 Jul–Aug;57(4):196–8

The impaired physician. The Ethics Committee of the American Academy of Otolaryngology-Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):213–9

Questioning patient care: when closed mouths must speak [editorial] Smoot EC 3rd. **Plast Reconstr Surg** 1996 Jun;97(7):1455–60

A Hungarian physician's views on alcoholism [letter] Hargitai Z. **Postgrad Med** 1996 Jun;99(6):46–7

Confidential help for impaired physicians [letter; comment] Patternac ST. **Postgrad Med** 1995 Nov;98(5):14. Comment on: Postgrad Med 1995 Sep;98(3):15–6, 26–7.

Statewide physician health program. **Wis Med J** 1996 Jul;95(7):471–2

The disruptive-abusive physician: a new look at an old problem. Benzer DG, et al. **Wis Med J** 1995;94(8):455–60

[Scientifically valid material of facts is needed (letter)] Andersson S. **Lakartidningen** 1996 Jul 10;93(28–29):2566 **(Swe)**

[Rehabilitation of physicians with cooperation problems (letter)] Nyström S. **Lakartidningen** 1995 Nov 1;92(44):4078 **(Swe)**

LEGISLATION & JURISPRUDENCE

Physicians & AIDS: discrimination and the Rehabilitation Act—Doe v. Attorney General. **Am J Law Med** 1995;21(1):167–9

Must physicians reveal their wounds? Furrow BR. **Camb Q Healthc Ethics** 1996 Spring;5(2):204–13

Drugs, alcohol and liability [editorial] Harty-Golder B. **J Fla Med Assoc** 1996 Jun–Jul;83(6):425–8

When the board comes a'callin'. Johnston ME. **J Tenn Med Assoc** 1996 Feb;89(2):54–5

MMA objects to sexual misconduct report [news] **Minn Med** 1995 Sep;78(9):33

Report to BMP assails right to due process. Smith AJ. **Minn Med** 1995 Sep;78(9):34

Professional liability. **N J Med** 1995 Dec;92(12):771–2

The road to recovery. New law removes one barrier to rehabilitation for impaired physicians. Jones TL. **Tex Med** 1995 Aug;91(8):22–4

PSYCHOLOGY

The ultimate curse. Crisci C. **J Med Ethics** 1995 Oct;21(5):277; discussion 278–80

PHYSICIAN IMPAIRMENT

The psychosocial work environment of physicians. The impact of demands and resources on job dissatisfaction and psychiatric distress in a longitudinal study of Johns Hopkins Medical School graduates. Johnson JV, et al. **J Occup Environ Med** 1995 Sep;37(9):1151–9

Running on empty. Colón K. **Minn Med** 1996 Apr; 79(4):12–20

PHYSICIAN INCENTIVE PLANS

Function-based payment model for inpatient medical rehabilitation: an evaluation. Sutton JP, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):693–701

A prescribing incentive scheme for non-fundholding general practices: an observational study. Bateman DN, et al. **BMJ** 1996 Aug 31;313(7056):535–8

Incentives. A payoff to get with the program. Morrall K. **Hosp Health Netw** 1996 Jan 20;70(2):50–2

Recruitment to rural practice. Macleod JA. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):43–5

Have we got a deal for you, doc. Small towns recruiting big time to lure physicians to rural Texas. BeSaw L. **Tex Med** 1995 Aug;91(8):13–6

[Proposal of incentives for a fee-for-service medical practice] Gérvas J, et al. **Gac Sanit** 1996 Jan-Feb;10(52):34–9; discussion 40–3 **(Spa)**

LEGISLATION & JURISPRUDENCE

Policy. HCFA's new take on physician incentives. Meyer H. **Hosp Health Netw** 1996 May 5;70(9):62–3, 66

ORGANIZATION & ADMINISTRATION

Bonus/incentive programs to increase physician productivity in academic emergency medicine [letter] Zun LS, et al. **Am J Emerg Med** 1996 May;14(3):334–6

PHYSICIAN-PATIENT RELATIONS

see related

TRUTH DISCLOSURE

Physician-patient partnership in managing chronic illness. Clark NM, et al. **Acad Med** 1995 Nov;70(11):957–9

Psychometric properties of a standardized-patient checklist and rating-scale form used to assess interpersonal and communication skills. Cohen DS, et al. **Acad Med** 1996 Jan;71(1 Suppl):S87–9

Medicine and the arts [comment] Dittrich L. **Acad Med** 1996 Mar;71(3):256. Comment on: Acad Med 1996 Mar;71(3):257.

Crossing the cultural doctor-patient barrier. Greengold NL, et al. **Acad Med** 1996 Feb;71(2):112–4

Mentality and behaviour of a Mediterranean neurosurgeon. Foroglou G. **Acta Neurochir (Wien)** 1995;132(4):202–5

Mentality and behaviour of the central European. van der Werf D. **Acta Neurochir (Wien)** 1995;132(4):206–11

Mentality and behaviour of neurosurgeons and patients in China. Wang CC. **Acta Neurochir (Wien)** 1995;132(4):196–8

Physicians as agents. Canup CN. **Ala Med** 1995 Jul;65(1):4–5

The care-giving relationship: paradoxical and transcendent aspects. Montgomery CL. **Altern Ther Health Med** 1996 Mar;2(2):52–7

Telling patients about their somatoform disorders [letter; comment] Gillette RD. **Am Fam Physician** 1996 Feb 15; 53(3):865–6. Comment on: Am Fam Physician 1995 Jul;52(1):193–204.

Treating patients from other cultures. Orr RD. **Am Fam Physician** 1996 May 1;53(6):2004–6 (22 ref.)

Cautious history-taking with potentially violent patients [letter; comment] Solomon G. **Am Fam Physician** 1996 May 1;53(6):1987. Comment on: Am Fam Physician 1995 Sep 15;52(4):1169–74.

Going fishing. Adams ND. **Am J Med** 1996 Apr;100(4):475–6

Physician implementation of and patient adherence to recommendations from comprehensive geriatric assessment [see comments] Reuben DB, et al. **Am J Med** 1996 Apr; 100(4):444–51. Comment in: Am J Med 1996 Apr;100(4):383–5.

Clarification of source [letter] Brucker MC. **Am J Obstet Gynecol** 1995 Dec;173(6):1899–900

Conflicts between physicians and patients in non-elective cesarean delivery: incidence and the adequacy of informed consent. Lescale KB, et al. **Am J Perinatol** 1996 Apr; 13(3):171–6

The borderline patient's intolerance of aloneness: insecure attachments and therapist availability. Gunderson JG. **Am J Psychiatry** 1996 Jun;153(6):752–8

Analytic asymmetries and their discontents. Hadar U. **Am J Psychoanal** 1995 Sep;55(3):215–30

Recognition of the anaesthetists: a Spanish view [letter; comment] Garcia MA, et al. **Anaesthesia** 1995 Oct; 50(10):923. Comment on: Anaesthesia 1995 May;50(5):381–2.

How much do they really want to know? Preoperative patient interviews and the anesthesiologist [editorial; comment] Roizen MF, et al. **Anesth Analg** 1996 Mar; 82(3):443–4. Comment on: Anesth Analg 1996 Mar;82(3):445–51.

Wayne and his bipap babushka. Wright LD. **Ann Emerg Med** 1996 Feb;27(2):267–8

Violence in intimate relationships [letter; comment] Bates CK. **Ann Intern Med** 1996 Sep 1;125(5):426; discussion 426–7. Comment on: Ann Intern Med 1995 Nov 15;123(10):774–81. Comment on: Ann Intern Med 1995 Nov 15;123(10):782–94.

The patient-physician convenant: an affirmation of asklepios [editorial] Cassel CK. **Ann Intern Med** 1996 Mar 15; 124(6):604–6

On being a patient [editorial] Davidoff F. **Ann Intern Med** 1996 Jan 15;124(2):269–70

The examination. Epstein N. **Ann Intern Med** 1996 Aug 1; 125(3):250–1

On being a doctor. Umaña. Gianakos D. **Ann Intern Med** 1995 Nov 1;123(9):730

Whose death is it, anyway? [comment] Gilligan T, et al. **Ann Intern Med** 1996 Jul 15;125(2):137–41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149–51.

The gift. Kennedy AL. **Ann Intern Med** 1996 Sep 15; 125(6):513

Sisyphus or Pegasus? The physician interviewer in the era of corporatization of care [editorial; comment] Lipkin M Jr. **Ann Intern Med** 1996 Mar 1;124(5):511–3. Comment on: Ann Intern Med 1996 Mar 1;124(5):497–504.

Insight. Moore ME. **Ann Intern Med** 1996 Mar 15; 124(6):609–10

The bet. Novack DH. **Ann Intern Med** 1996 Oct 15; 125(8):692–3

Atonement. Paltiel O. **Ann Intern Med** 1996 Sep 1; 125(5):416–7

Peak of the season. Pate MA. **Ann Intern Med** 1996 Jan 1; 124(1 Pt 1):69

The breakthrough [see comments] Pisetsky DS. **Ann Intern Med** 1996 Feb 1;124(3):345–7. Comment in: Ann Intern Med 1996 Jun 1;124(11):1016–7.

Domestic violence and physician intervention [letter; comment] Rixey S. **Ann Intern Med** 1996 Sep 1;125(5):427 . Comment on: Ann Intern Med 1995 Nov 15;123(10):804–5.

Doctor's orders. Rodowski MF. **Ann Intern Med** 1996 Sep 15;125(6):512

Outpatient clinic. Schwaber MJ. **Ann Intern Med** 1996 Jun 1;124(11):1012–3

CPR-not-indicated and futility [letter; comment] Shorr AF. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):76; discussion 77 . Comment on: Ann Intern Med 1995 Feb 15;122(4):304–8.

Marrying medicine. Van Peenen HJ. **Ann Intern Med** 1995 Dec 15;123(12):957–9

Communion [see comments] Weinberg RB. **Ann Intern Med** 1995 Nov 15;123(10):804–5. Comment in: Ann Intern Med 1995 Nov 15;123(10):774–81. Comment in: Ann Intern Med 1996 Sep 1;125(5):427.

Post-midnight reverie. Wrenn K. **Ann Intern Med** 1995 Dec 1;123(11):890

The art of communication with children [letter] Srivatsa KM. **Arch Dis Child** 1995 Sep;73(3):277–8

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)

Interruption in the medical interaction. Realini T, et al. **Arch Fam Med** 1995 Dec;4(12):1028–33

Maintaining communication in a time of uncertainty. Segal ES. **Arch Fam Med** 1995 Dec;4(12):1066–7

What role do patients wish to play in treatment decision making? Deber RB, et al. **Arch Intern Med** 1996 Jul 8; 156(13):1414–20

Empathy revisited [see comments] Gianakos D. **Arch Intern Med** 1996 Jan 22;156(2):135–6. Comment in: Arch Intern Med 1996 Jul 22;156(14):1582, 1586.

Understanding patient values requires communication, not empathy [letter; comment] Kutner JS. **Arch Intern Med** 1996 Jul 22;156(14):1582, 1586. Comment on: Arch Intern Med 1996 Jan 22;156(2):135–6.

Cancer screening and informed patient discussions. Truth and consequences. Wolf AM, et al. **Arch Intern Med** 1996 May 27;156(10):1069–72

Teaching residents about patient and practice termination in community-based continuity settings. DeWitt TG, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1367–70

Communication between adolescents and physicians about sexual behavior and risk prevention. Schuster MA, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):906–13

Objects, contradictions and collaboration in medical cognition: an activity-theoretical perspective. Engeström Y. **Artif Intell Med** 1995 Oct;7(5):395–412

A matter of balance. Hogan C. **Aust Fam Physician** 1995 Sep;24(9):1766–9

The dilemma of the unexpected result. Vafiadis P. **Aust Fam Physician** 1996 Jun;25(6):971–3; 975

Relationships between doctors and patients in obstetrics and gynaecology. Daniels KR, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):286–9

To tell or not to tell: the psychiatrist and child abuse. Adler R. **Aust N Z J Psychiatry** 1995 Jun;29(2):190–8

Factors associated with Pap smear taking in general practice: focusing public health initiatives. Heywood A, et al. **Aust N Z J Public Health** 1996 Jun;20(3):260–6

Being on first name terms may signify greater respect [letter] Ellis CJ. **BMJ** 1995 Sep 23;311(7008):813

Telling patients there is nothing wrong [editorial; comment] Fitzpatrick R. **BMJ** 1996 Aug 10;313(7053):311–2. Comment on: BMJ 1996 Aug 10;313(7053):329–32.

White coat effects. Gordon PM, et al. **BMJ** 1995 Dec 23–30; 311(7021):1704

Asking patients to write lists. Randomised controlled trials support it [letter; comment] Jadad AR. **BMJ** 1995 Sep 16; 311(7007):746. Comment on: BMJ 1995 Jul 1;311(6996):34.

Patients' prerogatives and perceptions of benefit. Kee F. **BMJ** 1996 Apr 13;312(7036):958–60

Asking patients to write lists. Clinic audit supports it [letter] Lambert H. **BMJ** 1995 Sep 16;311(7007):746

Shackling prisoners in hospital. Causes problems for doctors [letter; comment] Pearce SJ. **BMJ** 1996 May 11; 312(7040):1228. Comment on: BMJ 1996 Jan 27;312(7025):200.

US doctors reject patients' wishes [news] Rutter TL. **BMJ** 1995 Dec 2;311(7018):1455

Australian doctors in confidentiality controversy [news] Zinn C. **BMJ** 1995 Oct 14;311(7011):971–2

Management of opiate dependence [letter] Gabbay MB. **Br J Gen Pract** 1996 Jan;46(402):50

Characteristics of drug misusers and their perceptions of general practitioner care. Hindler C, et al. **Br J Gen Pract** 1996 Mar;46(404):149–52

Fear of aggression at work among general practitioners who have suffered a previous episode of aggression. Hobbs FD. **Br J Gen Pract** 1994 Sep;44(386):390–4

Factors that influence the patient centredness of a consultation. Law SA, et al. **Br J Gen Pract** 1995 Oct; 45(399):520–4

Counselling in general practice [letter] McDonald PS. **Br J Gen Pract** 1994 Sep;44(386):426–7

Use of the consultation satisfaction questionnaire to examine patients' satisfaction with general practitioners and community nurses: reliability, replicability and discriminant validity. Poulton BC. **Br J Gen Pract** 1996 Jan; 46(402):26–31

Domestic violence: a hidden problem for general practice. Richardson J, et al. **Br J Gen Pract** 1996 Apr; 46(405):239–42 (43 ref.)

Erotic transference and a threatened sense of self. Kotze B, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):21–31

Patients' views towards care received from psychiatrists. Barker DA, et al. **Br J Psychiatry** 1996 May;168(5):641–6

Accepting voices [letter] Blades P. **Br J Psychiatry** 1996 May; 168(5):657

Letting compassion open the door: battered women's disclosure to medical providers. Bauer HM, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):459–65

Physicians' duty of compassion. Dougherty CJ, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):426–33

Must physicians reveal their wounds? Furrow BR. **Camb Q Healthc Ethics** 1996 Spring;5(2):204–13

Compassion, reason, and moral judgment. Loewy EH. **Camb Q Healthc Ethics** 1995 Fall;4(4):466–75

Why it was hard for me to learn compassion as a third-year medical student. Lu MC. **Camb Q Healthc Ethics** 1995 Fall; 4(4):454–8

Illness and compassion: AIDS in an American Zen community. Nakasone RY. **Camb Q Healthc Ethics** 1995 Fall;4(4):488–93

Love thy patient: justice, caring, and the doctor-patient relationship. Rhodes R. **Camb Q Healthc Ethics** 1995 Fall; 4(4):434–47

The relationship of empathy to moral reasoning in first-year medical students. Self DJ, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):448–53

Richard Selzer on death, resurrection, and compassion [interview by Thomasine Kushner] Selzer R. **Camb Q Healthc Ethics** 1995 Fall;4(4):494–8

A dialogue on compassion and supererogation in medicine. Thomasma DC, et al. **Camb Q Healthc Ethics** 1995 Fall; 4(4):415–25

Sympathy as the basis of compassion. Welie JV. **Camb Q Healthc Ethics** 1995 Fall;4(4):476–87

Physicians and immigrant patients. Cross-cultural communication. Cave A, et al. **Can Fam Physician** 1995 Oct;41:1685–90

Chronic unhappiness. Investigating the phenomenon in family practice. Ellis CG. **Can Fam Physician** 1996 Apr; 42:645–51

Respectful treatment of the elderly [editorial] Nixon M. **Can Fam Physician** 1996 Mar;42:385–6, 395–7 **(Eng, Fre)**

Intimacy in the patient-physician relationship. Committee on Ethics of the College of Family Physicians of Canada. Yeo M, et al. **Can Fam Physician** 1996 Aug;42:1505–8 (4 ref.)

The practitioner, the patient and resistance to change: recent ideas on compliance. Butler C, et al. **Can Med Assoc J** 1996 May 1;154(9):1357–62

Allow physicians who commit sex offences to work, but away from patients [letter; comment] [see comments] Dunn RW. **Can Med Assoc J** 1995 Nov 1;153(9):1228. Comment on: Can Med Assoc J 1995 Jul 15;153(2):169–76. Comment in: Can Med Assoc J 1996 Feb 15;154(4):443. Comment in: Can Med Assoc J 1996 Feb 15;154(4):443; discussion 443–4.

What to do with physicians who commit sexual abuse [letter; comment] Emson H. **Can Med Assoc J** 1996 Feb 15; 154(4):443; discussion 443–4. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1228.

Communications research [letter; comment] Entwistle V, et al. **Can Med Assoc J** 1995 Oct 15;153(8):1064–5. Comment on: Can Med Assoc J 1995 May 1;152(9):1423–33.

Managing erotic feelings in the physician-patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.). Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.

Multicultural health care requires adjustments by doctors and patients. Hamilton J. **Can Med Assoc J** 1996 Sep 1; 155(5):585–7

New college data may shed light on issue of sexual abuse by physicians. Johnston C. **Can Med Assoc J** 1996 May 15;154(10):1553–5

Physician–patient privilege: the legal assault continues. McPhedran M. **Can Med Assoc J** 1996 Jun 1;154(11):1760–3

Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)

Helping patients stop smoking: confrontation or caring? [letter; comment] Panton WD. **Can Med Assoc J** 1996 Jun 15;154(12):1834. Comment on: Can Med Assoc J 1996 Jan 15;154(2):159–64.

Physician–patient relationships: patients as friends and patients who harass [letter; comment] Phillips S. **Can Med Assoc J** 1996 Apr 15;154(8):1149–50. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1241–5.

A curriculum on physician–patient sexual misconduct and teacher–learner mistreatment. Part 1: content. Robinson GE, et al. **Can Med Assoc J** 1996 Mar 1;154(5):643–9

A curriculum on physician–patient sexual misconduct and teacher–learner mistreatment. Part 2: Teaching method. Robinson GE, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1021–5

Physician–patient relationships: patients as friends and patients who harass [letter; comment] Rourke J, et al. **Can Med Assoc J** 1996 Apr 15;154(8):1149; discussion 1150 . Comment on: Can Med Assoc J 1995 Nov 1;153(9):1241–5.

Counselling patients before death: support for their decisions [letter; comment] Waugh D. **Can Med Assoc J** 1995 Nov 15;153(10):1417. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1340–2.

What to do with physicians who commit sexual abuse [letter; comment] Wood RH. **Can Med Assoc J** 1996 Feb 15; 154(4):443. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1228.

The influence of personal message with music on anxiety and side effects associated with chemotherapy. Sabo CE, et al. **Cancer Nurs** 1996 Aug;19(4):283–9

End-of-life discussions with patients. Timing and truth-telling [editorial; comment] Gilligan T, et al. **Chest** 1996 Jan;109(1):11–2. Comment on: Chest 1996 Jan;109(1):258–64.

What do physicians tell patients with end-stage COPD about intubation and mechanical ventilation? [see comments] Sullivan KE, et al. **Chest** 1996 Jan;109(1):258–64. Comment in: Chest 1996 Jan;109(1):11–2.

A training guideline of cultural competence for child and adolescent psychiatric residencies. Kim WJ. **Child Psychiatry Hum Dev** 1995 Winter;26(2):125–36

Inaccurate medical student introductions: frequency and motivation. Beatty ME, et al. **Conn Med** 1995 Aug; 59(8):455–60

White coat hypertension. Pickering TG. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):192–8 (36 ref.)

Caring for HIV-infected drug users: a provider's perspective [editorial] Selwyn PA. **Cutis** 1995 Nov;56(5):250–2

Why should physicians worry about patient satisfaction? Applying some of the principles used in the emergency department to hospital and office-based practices. Sutherland SF, et al. **Del Med J** 1996 Jan;68(1):19–22

The crux [letter; comment] Harper DC. **Dev Med Child Neurol** 1995 Sep;37(9):840–1. Comment on: Dev Med Child Neurol 1995 Jun;37(6):471–2.

Differences in preferences between diabetic patients and diabetologists regarding quality of care: a matter of continuity and efficiency of care? Casparie AF, et al. **Diabet Med** 1995 Sep;12(9):828–32

Patient empowerment and the traditional medical model. A case of irreconcilable differences? Anderson RM. **Diabetes Care** 1995 Mar;18(3):412–5

Patients' experiences of and satisfaction with care for their epilepsy. Buck D, et al. **Epilepsia** 1996 Sep;37(9):841–9

Logic, hermeneutics, and informed consent. Little JM, et al. **Eur J Surg** 1996 Jan;162(1):3–10 (31 ref.)

Patient management or patient care? [letter; comment] Brown RL. **Fam Med** 1995 Nov-Dec;27(10):632–3. Comment on: Fam Med 1995 Jul-Aug;27(7):460–2.

One of our teachers is missing [editorial] Curtis P. **Fam Med** 1995 Oct;27(9):605–6

The doctor, the patient: a first-year course for personal and professional growth. Davies SM, et al. **Fam Med** 1995 Jul-Aug;27(7):444–8

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10–23 (86 ref.). Comment in: Fam Med 1996 Jan;28(1):57–8.

Managing patients [editorial] [see comments] Johnson TM. **Fam Med** 1995 Jul-Aug;27(7):460–2. Comment in: Fam Med 1995 Nov-Dec;27(10):632–3.

Teaching professional boundaries in the physician–patient relationship [letter] Miser WF, et al. **Fam Med** 1996 Apr; 28(4):243

Family medicine in a culturally diverse world: a solution-oriented approach to common cross-cultural problems in medical encounters. Shapiro J, et al. **Fam Med** 1996 Apr;28(4):249–55

Patients' predispositions to discuss health issues affecting quality of life. Street RL Jr, et al. **Fam Med** 1995 Nov-Dec; 27(10):663–70

Situational disease. Gannik DE. **Fam Pract** 1995 Jun; 12(2):202–6 (14 ref.)

Surviving the 'heartsink' experience. Mathers NJ, et al. **Fam Pract** 1995 Jun;12(2):176–83

Patient expectations: what do primary care patients want from the GP and how far does meeting expectations affect patient satisfaction? Williams S, et al. **Fam Pract** 1995 Jun; 12(2):193–201

Irritable bowel: it helps to have a friendly physician—or so it would seem. Kapadia CR. **Gastroenterology** 1995 Nov; 109(5):1711–3

How we lie. Annas GJ. **Hastings Cent Rep** 1995 Nov-Dec; 25(6):S12–14

The best system in the world. Brody H. **Hastings Cent Rep** 1995 Nov-Dec;25(6):S18–21

The SUPPORT Study. Who's talking? Marshall PA. **Hastings Cent Rep** 1995 Nov-Dec;25(6):S9–11

Effects of market reforms on doctors and their patients. Blumenthal D. **Health Aff (Millwood)** 1996 Summer; 15(2):170–84

The patient/physician relationship: one doctor's view. Wade JC. **Health Aff (Millwood)** 1995 Winter;14(4):209–12

Physicians. To each his own [news] **Hosp Health Netw** 1996 Jul 20;70(14):14

Consumers. The feminine mystique [news] **Hosp Health Netw** 1995 Dec 5;69(23):14

Customer service. Timeliness is next to godliness. Appleby C. **Hosp Health Netw** 1996 Aug 5;70(15):40

Working smarter, not harder. Lumsdon K. **Hosp Health Netw** 1995 Nov 5;69(21):26–31

Delivery channels. Call in for a consult. McPherson P. **Hosp Health Netw** 1996 Feb 20;70(4):70

Artwork. Capturing healers on canvas. Montague J. **Hosp Health Netw** 1995 Nov 20;69(22):48

Gag clauses in managed care. Brunton SA. **Hosp Pract (Off Ed)** 1996 May 15;31(5):118–9

Primary care of the adolescent patient. Faigel HC. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):127–33, 137–8, 144–8 (10 ref.)

Primary care of the somatizing patient: a collaborative model. Lipsitt DR. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):77–80, 83, 87–8

The elderly patient with multiple complaints. McCahill ME, et al. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):49–54, 57; discussion 57–8

Caring for the terminally ill [letter] Zimmerman SJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):28

Should gamete donation between family members be restricted? The case of a 16-year-old donor. Pierce J, et al. **Hum Reprod** 1995 Jun;10(6):1330–2; discussion 1334–7

Seven ways to avoid frivolous malpractice claims. Muller J. **Indiana Med** 1996 Jan-Feb;89(1):22–4

Elder abuse reporting and ethical dilemmas. Williams G. **Iowa Med** 1996 Jan;86(1):20–2

Trials and tribulations of country doctors: a qualitative study of doctor–patient relationships in rural Israel. Monnickendam SM, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):239–45; discussion 245–7

Deception/trust. Sobel R. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):256–9 (15 ref.)

Strategies for health education for adolescent patients: a preliminary investigation. Schubiner H, et al. **J Adolesc Health** 1995 Jul;17(1):37–41

Intersubjectivity, creative uncertainty, and systems theory—an approach to the clinical use of empathy. Anshin RN. **J Am Acad Psychoanal** 1995 Fall;23(3):369–78

Fusion states, collective countertransference, and mutual dependence. Giovacchini PL. **J Am Acad Psychoanal** 1995 Fall;23(3):411–23

Nonsexual exploitation of patients—an ethical perspective. Gruenberg PB. **J Am Acad Psychoanal** 1995 Fall; 23(3):425–34

Psychoanalysis and its vicissitudes: the doctor's dilemma. Kestenbaum CJ. **J Am Acad Psychoanal** 1995 Fall; 23(3):501–14

Patients' posttermination representations of their psychotherapists. Wzontek N, et al. **J Am Acad Psychoanal** 1995 Fall;23(3):395–410

Relationship-centered care: beyond the finishing school [editorial] Brody H. **J Am Board Fam Pract** 1995 Sep–Oct; 8(5):416–8

What's in a name? [editorial] Parmley WW. **J Am Coll Cardiol** 1995 Dec;26(7):1755

Communicating with older patients: a challenge for researchers and clinicians. Hodes RJ, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1167–8

Two panels on interaction: an introduction. Panel report. **J Am Psychoanal Assoc** 1995;43(2):517–20

Toward a definition of the term and concept of interaction. Panel report. **J Am Psychoanal Assoc** 1995;43(2):521–37

Interpretive perspectives on interaction. Panel report. **J Am Psychoanal Assoc** 1995;43(2):539–51

Medical deresponsibilization. Sureau C. **J Assist Reprod Genet** 1995 Sep;12(8):552–8

Evaluating telephone T.A.L.K. Kosower E, et al. **J Biocommun** 1996;23(1):27–31

Telephone T.A.L.K.: a teaching/assessment tool for medical training. Kosower E, et al. **J Biocommun** 1996;23(1):22–6

Is refusal of futile treatment unjustified paternalism? [comment] Jecker NS. **J Clin Ethics** 1995 Summer; 6(2):133–7. Comment on: J Clin Ethics 1995 Summer;6(2):112–27.

Partiality and the pediatrician. Ladd RE. **J Clin Ethics** 1996 Spring;7(1):29–34

Comments on the AMA report "Ethical issues in managed care [see comments] Miles SH, et al. **J Clin Ethics** 1995 Winter;6(4):306–11. Comment in: J Clin Ethics 1995 Winter;6(4):312–7. Comment in: J Clin Ethics 1995 Winter;6(4):318–9.

Knowledge at the bedside: a feminist view of what's happening with this patient. Nelson HL. **J Clin Ethics** 1996 Spring;7(1):20–8

Interests, obligations, and justice: some notes toward an ethic of managed care [comment] Pellegrino ED. **J Clin Ethics** 1995 Winter;6(4):312–7. Comment on: J Clin Ethics 1995 Winter;6(4):306–11.

Memo [see comments] Keeler ML. **J Emerg Med** 1996 Jan-Feb;14(1):105–6. Comment in: J Emerg Med 1996 Jan-Feb;14(1):92–5. Comment in: J Emerg Med 1996 Jan-Feb;14(1):95–6.

Laughter in the temple of pain and illness [editorial; comment] Ratzan RM. **J Emerg Med** 1996 Jan-Feb; 14(1):92–5. Comment on: J Emerg Med 1996 Jan-Feb;14(1):105–6.

Laughter and loyalty [editorial; comment] Rosen P. **J Emerg Med** 1996 Jan-Feb;14(1):95–6. Comment on: J Emerg Med 1996 Jan-Feb;14(1):105–6.

Using humor in the office setting: a pediatric perspective [editorial] Bennett HJ. **J Fam Pract** 1996 May;42(5):462–4

Managed care in the house of God [letter; comment] Cullinane K. **J Fam Pract** 1996 Apr;42(4):417–8. Comment on: J Fam Pract 1995 Nov;41(5):441–2.

Managed care in the house of God [letter; comment] Gillette RD. **J Fam Pract** 1996 Apr;42(4):343, 417–8. Comment on: J Fam Pract 1995 Nov;41(5):441–2.

Antibiotics and respiratory infections: are patients more satisfied when expectations are met? Hamm RM, et al. **J Fam Pract** 1996 Jul;43(1):56–62

The curse. Hudgings DW. **J Fam Pract** 1995 Oct;41(4):408

What are the sciences of relationship-centered primary care. Inui TS. **J Fam Pract** 1996 Feb;42(2):171–7

Managed care in the house of God [letter; comment] Kohan WM. **J Fam Pract** 1996 Apr;42(4):417–8. Comment on: J Fam Pract 1995 Nov;41(5):441–2.

Sustained partnership in primary care [see comments] Leopold N, et al. **J Fam Pract** 1996 Feb;42(2):129–37. Comment in: J Fam Pract 1996 Jul;43(1):13.

Health education and patient satisfaction. Schauffler HH, et al. **J Fam Pract** 1996 Jan;42(1):62–8

A patient's guide to managed care in the House of God: the best care is less care [editorial] [see comments] Slomka J. **J Fam Pract** 1995 Nov;41(5):441–2. Comment in: J Fam Pract 1996 Apr;42(4):343, 417; discussion 417–8. Comment in: J Fam Pract 1996 Apr;42(4):417; discussion 417–8.

Another pearl [letter; comment] Strouse WS. **J Fam Pract** 1995 Nov;41(5):433. Comment on: J Fam Pract 1995 Jan;40(1):19–20.

Sustained partnerships [letter; comment] Thom D. **J Fam Pract** 1996 Jul;43(1):13. Comment on: J Fam Pract 1996 Feb;42(2):129–37.

Sweetheart. Wilkinson J. **J Fam Pract** 1996 May;42(5):535–6

Another courtroom assault on the confidentiality of the psychotherapist–patient relationship. Leong GB, et al. **J Forensic Sci** 1995 Sep;40(5):862–4

Commentary on "Another courtroom assault on the confidentiality of the psychotherapist–patient relationship", Leong et al J Forensic Sci 1995;40(5):862–4 [letter] Slovenko R. **J Forensic Sci** 1996 Jul;41(4):551–2; discussion 551–2

The primary care pathway to mammography: a long and winding road [editorial; comment] Burack RC. **J Gen Intern Med** 1995 Jun;10(6):349–50. Comment on: J Gen Intern Med 1995 Jun;10(6):299–306.

Things that ring in the night [letter; comment] Casanova JE. **J Gen Intern Med** 1995 Jul;10(7):412–3. Comment on: J Gen Intern Med 1994 Oct;9(10):554–7.

Discrimination and abuse experienced by general internists in Canada. Cook DJ, et al. **J Gen Intern Med** 1995 Oct; 10(10):565–72

The difficult patient: prevalence, psychopathology, and functional impairment [see comments] Hahn SR, et al. **J Gen Intern Med** 1996 Jan;11(1):1–8. Comment in: J Gen Intern Med 1996 Jan;11(1):56–7.

Effects of a physician communication intervention on patient care outcomes [see comments] Joos SK, et al. **J Gen Intern Med** 1996 Mar;11(3):147–55. Comment in: J Gen Intern Med 1996 Mar;11(3):187–8.

When the patient abuses the physician [editorial] Justice AC, et al. **J Gen Intern Med** 1995 Oct;10(10):588–9

Maximizing the quality of the physician–patient encounter [editorial; comment] Kaplan SH, et al. **J Gen Intern Med** 1996 Mar;11(3):187–8. Comment on: J Gen Intern Med 1996 Mar;11(3):147–55.

Physicians' psychosocial beliefs correlate with their patient communication skills [see comments] Levinson W, et al. **J Gen Intern Med** 1995 Jul;10(7):375–9. Comment in: J Gen Intern Med 1995 Jul;10(7):411.

"Reverse" cross-cultural medicine [letter] Paola F, et al. **J Gen Intern Med** 1995 Sep;10(9):532

How important is context in teaching interviewing? [editorial; comment] Pomerantz A. **J Gen Intern Med** 1995 Jul; 10(7):411. Comment on: J Gen Intern Med 1995 Jul;10(7):375–9.

Improving patient quality of life with feedback to physicians about functional status. Rubenstein LV, et al. **J Gen Intern Med** 1995 Nov;10(11):607–14

Improving residents' confidence in using psychosocial skills. Smith RC, et al. **J Gen Intern Med** 1995 Jun;10(6):315–20

How do medical residents discuss resuscitation with patients? Tulsky JA, et al. **J Gen Intern Med** 1995 Aug;10(8):436–42

Not quite like buying a refrigerator [editorial] Miller MF. **J Ky Med Assoc** 1996 Jun;94(6):243

Privacy and autonomy in the physician–patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

The white coats are coming, the white coats are coming. Mahkorn SK. **J Med Assoc Ga** 1996 Apr;85(2):85–7

Re: A barrier to physician/patient communication [letter] Morfesis FA. **J Med Assoc Ga** 1996 Jan;85(1):4

Rational non-interventional paternalism: why doctors ought to make judgments of what is best for their patients. Savulescu J. **J Med Ethics** 1995 Dec;21(6):327–31

Old Dan Tucker syndrome [editorial] South D. **J Miss State Med Assoc** 1996 Aug;37(8):711–2

Cultural gaps leave patients angry, doctors confused [news] Vanchieri C. **J Natl Cancer Inst** 1995 Nov 1;87(21):1576–7

Patient–provider relationship in the context of genetic testing for hereditary cancers. Carter MA. **J Natl Cancer Inst Monogr** 1995;(17):119–21

How patients stress, con, and intimidate physicians to file dubious disability reports. Brooks TR. **J Natl Med Assoc** 1996 May;88(5):300–4

Marketing one, two, three. Maguire PJ. **J Okla State Med Assoc** 1995 Oct;88(10):425–6

Communication with cancer patients: does it matter? Butow PN, et al. **J Palliat Care** 1995 Winter;11(4):34–8 (50 ref.)

The Patient Requests Form: a way of measuring what patients want from their general practitioner. Valori R, et al. **J Psychosom Res** 1996 Jan;40(1):87–94

The psychological care of medical patients [letter; comment] Daggett P. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):368. Comment on: J R Coll Physicians Lond 1995 May–Jun;29(3):192–3.

Why do people go to their doctors? Calnan M. **J R Soc Med** 1995 Dec;88(12):702p–3p

Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69–72 (38 ref.)

Patient factors influencing variation in the use of preventive interventions for alcohol abuse by primary care physicians. Volk RJ, et al. **J Stud Alcohol** 1996 Mar;57(2):203–9

Congruence in personality between clinician and client: relationship to ratings of voice treatment. Andrews ML, et al. **J Voice** 1995 Sep;9(3):261–9

A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators [see comments] **JAMA** 1995 Nov 22–29;274(20):1591–8. Comment in: JAMA 1995 Nov 22–29;274(20):1634–6. Comment in: JAMA 1996 Apr 24;275(16):1227; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1227–8; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228–9; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229–30; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1230–1. Comment in: JAMA 1996 Apr 24;275(16):1231–2.

Regaining the initiative. Forging a new model of the patient–physician relationship [see comments] Balint J, et al. **JAMA** 1996 Mar 20;275(11):887–91. Comment in: JAMA 1996 Jul 3;276(1):27.

A piece of my mind. A jack of all trades. Brown JT. **JAMA** 1996 Jul 24–31;276(4):264

The SUPPORT project and improving care for seriously ill patients [letter; comment] Donnelly WJ. **JAMA** 1996 Apr 24;275(16):1228; discussion 1230–1. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

Boundaries in the physician–patient relationship [letter; comment] Fay A. **JAMA** 1995 Nov 1;274(17):1345–6. Comment on: JAMA 1995 May 10;273(18):1445–9.

Patient–physician communication: respect for culture, religion, and autonomy [letter; comment] Fenyvesi T. **JAMA** 1996 Jan 10;275(2):107; discussion 109–10. Comment on: JAMA 1995 Sep 13;274(10):820–5. Comment on: JAMA 1995 Sep 13;274(10):826–9. Comment on: JAMA 1995 Sep 13;274(10):844–5.

Patient–physician communication: respect for culture, religion and autonomy [letter; comment] Fitzgibbons S. **JAMA** 1996 Jan 10;275(2):108; discussion 109–10. Comment on: JAMA 1995 Sep 13;274(10):826–9.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Frank RR. **JAMA** 1996 Apr 24;275(16):1228–9; discussion 1230–1. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

The patient's perspective. Garfein JL. **JAMA** 1996 May 1; 275(17):1371

A piece of my mind. Do you have a minute? Gilsdorf JR. **JAMA** 1996 Feb 7;275(5):343

The patient–physician relationship. JAMA focuses on the center of medicine [editorial; comment] Glass RM. **JAMA** 1996 Jan 10;275(2):147–8. Comment on: JAMA 1996 Jan 10;275(2):152–6.

Computer-based medical translator system helps bridge language gap between physician, patient [news] Gunby P. **JAMA** 1995 Oct 4;274(13):1002–4

The patient–physician relationship: time to reimburse what we preach [letter; comment] Hensel WA. **JAMA** 1996 Jul 3;276(1):27. Comment on: JAMA 1996 Mar 20;275(11):887–91.

Speak no evil: physician silence in the face of professional impropriety. Jones TR. **JAMA** 1996 Sep 4;276(9):753–4

A piece of my mind. Managed care and mandatory movies. Kapp MB. **JAMA** 1996 Oct 2;276(13):1023

Patient–physician communication: respect for culture, religion, and autonomy [letter; comment] Kazal LA Jr. **JAMA** 1996 Jan 10;275(2):108; discussion 109–10. Comment on: JAMA 1995 Sep 13;274(10):826–9.

Patient-centered medicine. A professional evolution [see comments] Laine C, et al. **JAMA** 1996 Jan 10;275(2):152–6 . Comment in: JAMA 1996 Jan 10;275(2):147–8. Comment in: JAMA 1996 Apr 17;275(15):1156; discussion 1157. Comment in: JAMA 1996 Apr 17;275(15):1156–7.

Don't ignore patients' threats, psychiatrists told [news] Lamberg L. **JAMA** 1996 Jun 12;275(22):1715–6

Boundaries in the physician–patient relationship [letter; comment] Lazarus AA. **JAMA** 1995 Nov 1;274(17):1346. Comment on: JAMA 1995 May 10;273(18):1445–9.

Improving care near the end of life. Why is it so hard? [editorial; comment] Lo B. **JAMA** 1995 Nov 22–29; 274(20):1634–6. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

A piece of my mind. Friday afternoon. Lynn JT 3rd. **JAMA** 1996 May 8;275(18):1382

Physician–assisted suicide and euthanasia [letter; comment] Masdeu JC. **JAMA** 1996 Jul 17;276(3):196–7. Comment on: JAMA 1996 Mar 27;275(12):919–25.

A piece of my mind. Ashes, ashes. Massad S. **JAMA** 1995 Oct 11;274(14):1102

The impact of managed care on patients' trust in medical care and their physicians. Mechanic D, et al. **JAMA** 1996 Jun 5;275(21):1693–7

The physician as general. Nie JB. **JAMA** 1996 Oct 2; 276(13):1099

Patient–physician communication: respect for culture, religion, and autonomy [letter; comment] Pantilat SZ. **JAMA** 1996 Jan 10;275(2):107; discussion 109–10. Comment on: JAMA 1995 Sep 13;274(10):820–5.

Patient–physician communication: respect for culture, religion, and autonomy [letter; comment] Pastorek JG 2nd. **JAMA** 1996 Jan 10;275(2):108–9; discussion 109–10. Comment on: JAMA 1995 Sep 13;274(10):826–9.

Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)

Patient-centered medicine [letter; comment] Reyes-Ortiz CA. **JAMA** 1996 Apr 17;275(15):1156; discussion 1157. Comment on: JAMA 1996 Jan 10;275(2):152–6.

The patient–physician covenant [letter; comment] Ring JJ. **JAMA** 1995 Oct 25;274(16):1265–6. Comment on: JAMA 1995 May 17;273(19):1553.

A piece of my mind. When you come into my room. Schmidt SA. **JAMA** 1996 Aug 21;276(7):512

A piece of my mind. Haying. Squier HA. **JAMA** 1996 Jan 10;275(2):99

The SUPPORT project and improving care for seriously ill patients [letter; comment] Strong MS. **JAMA** 1996 Apr 24;275(16):1231–2. Comment on: JAMA 1995 Nov 22–29;274(20):1591–8.

Geriatric ethics: responsibilities and conspiracies, Part I. Ainslie N, et al. **Kans Med** 1996 Spring;97(1):13, 15

Israeli Ministry sets down confidentiality rules [news] Fishman RH. **Lancet** 1996 Apr 27;347(9009):1180

White-coat hypertension as a cause of cardiovascular dysfunction [see comments] Glen SK, et al. **Lancet** 1996 Sep 7;348(9028):654–7. Comment in: Lancet 1996 Sep 7;348(9028):630.

Is white-coat hypertension innocent? [comment] McGrath BP. **Lancet** 1996 Sep 7;348(9028):630. Comment on: Lancet 1996 Sep 7;348(9028):654–7.

Evidence-based medicine and compassion [letter] Newton J, et al. **Lancet** 1996 Jun 29;347(9018):1839

Euthanasia, physician-assisted suicide, and persistent vegetative state [letter] Soothill JF. **Lancet** 1996 Aug 24; 348(9026):548

Playing doctors: refiguring the doctor–patient relationship in Hervé Guibert's AIDS novels. Caron D. **Lit Med** 1995 Fall;14(2):237–49

Tenderness and steadiness: emotions in medical practice. Coulehan JL. **Lit Med** 1995 Fall;14(2):222–36

The patient–physician relationship: covenant or contract? Li JT. **Mayo Clin Proc** 1996 Sep;71(9):917–8

Where are we going and why? [letter] Bonsack RM. **Md Med J** 1995 Dec;44(12):1024

Mohawk English in the medical interview. Woolfson P, et al. **Med Anthropol Q** 1995 Dec;9(4):503–9

Attitudes of medical students and primary care physicians regarding input of older and younger patients in medical decisions. Beisecker AE, et al. **Med Care** 1996 Feb; 34(2):126–37

Eliminating language barriers for non-English-speaking patients. Hornberger JC, et al. **Med Care** 1996 Aug; 34(8):845–56

Patient and visit characteristics related to physicians' participatory decision-making style. Results from the Medical Outcomes Study. Kaplan SH, et al. **Med Care** 1995 Dec;33(12):1176–87

The effects of having a regular doctor on access to primary care. Lambrew JM, et al. **Med Care** 1996 Feb;34(2):138–51

Patient–doctor communication in cross-national perspective. A study in Mexico. Waitzkin H, et al. **Med Care** 1996 Jul; 34(7):641–71

The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145–51 (10 ref.)

The Calgary–Cambridge Referenced Observation Guides: an aid to defining the curriculum and organizing the teaching in communication training programmes. Kurtz SM, et al. **Med Educ** 1996 Mar;30(2):83–9

Managing HIV. Part 7: Professional issues. 7.7 HIV care: the impact on the doctor. Kelly BJ, et al. **Med J Aust** 1996 Aug 5;165(3):150

Managing HIV. Part 7: Professional issues. 7.3 What do people with HIV, their carers and families want of their medical carers? Scott M, et al. **Med J Aust** 1996 Jul 15; 165(2):92–3

Changing medical organization and the erosion of trust. Mechanic D. **Milbank Q** 1996;74(2):171–89

Physician detection of family violence. Do buttons worn by doctors generate conversations about domestic abuse? Bolin L, et al. **Minn Med** 1996 Jun;79(6):42–5

Strangers in a strange land. Clement D. **Minn Med** 1996 May; 79(5):11–4, 17–9

Trading places. Clement D. **Minn Med** 1996 May;79(5):6–7, 10

Providing culturally competent health care to Hmong patients. Gervais KG. **Minn Med** 1996 May;79(5):49–51

Some good sources on cross-cultural medicine [letter] Richards HN. **Minn Med** 1996 Jul;79(7):2

More than medicine: caring for the AIDS patient. Simpson M, et al. **Minn Med** 1995 Nov;78(11):6–7, 62–3

Patients are diverse; truth is not [letter] Slater CB. **Minn Med** 1996 Jul;79(7):2–3

Minding your manners [editorial] Thomas JR. **Mo Med** 1995 Oct;92(10):613

A case of professional sexual misconduct. **N C Med J** 1996 Jul–Aug;57(4):208–12

An open letter to the North Carolina Medical Board [letter] Grove DD. **N C Med J** 1996 Jul–Aug;57(4):192–3

Physician–assisted suicide [letter; comment] Hamilton NG, et al. **N Engl J Med** 1996 Aug 15;335(7):519; discussion 519–20. Comment on: N Engl J Med 1996 Feb 1;334(5):310–5.

A trial of increased access to primary care [letter] Magill MK, et al. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

Not perfectly formed. **N Z Med J** 1996 May 24;109(1022):194

Sexual activity between doctors and patients [letter; comment] Briant RH, et al. **N Z Med J** 1996 Apr 12; 109(1019):127–8. Comment on: N Z Med J 1995 Nov 24;108(1012):481–3. Comment on: N Z Med J 1996 Jan 26;109(1014):17. Comment on: N Z Med J 1996 Apr 26;109(1020):150.

Fathers of children with disabilities comment on health services. Clarkson JE, et al. **N Z Med J** 1996 Jul 26; 109(1026):274–6

Medical discipline and sexual activity between doctors and patients [letter; comment] Cullen R. **N Z Med J** 1996 Apr 26;109(1020):150. Comment on: N Z Med J 1996 Apr 12;109(1019):127–8.

Medical discipline and sexual activity between doctors and patients [see comments] Cullen RM, et al. **N Z Med J** 1995 Nov 24;108(1012):481–3. Comment in: N Z Med J 1996 Jan 26;109(1014):17. Comment in: N Z Med J 1996 Apr 12;109(1019):127–8.

The gatekeeper controversy: why it exists and how it can be resolved. Glasgow N. **N Z Med J** 1996 May 10; 109(1021):168–70

Sexual contacts between doctors and patients [letter; comment] [see comments] Goodyear-Smith F. **N Z Med J** 1996 Jan 26;109(1014):17. Comment on: N Z Med J 1995 Nov 24;108(1012):481–3. Comment in: N Z Med J 1996 Apr 12;109(1019):127–8.

Medical discipline and sexual activity between doctors and patients [letter; comment] Northwood B. **N Z Med J** 1996 Apr 26;109(1020):150. Comment on: N Z Med J 1996 Apr 12;109(1019):127–8.

Sexual activity between doctors and patients [letter] White G. **N Z Med J** 1996 Apr 12;109(1019):128

Physician–patient interaction in reproductive counseling. Lipkin M Jr. **Obstet Gynecol** 1996 Sep;88(3 Suppl):31S–40S (51 ref.)

Wrong answers [editorial] Carroll-Johnson RM. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):9

Physicians urged to address quality of life after breast cancer treatment [news] **Oncology (Huntingt)** 1995 Nov; 9(11):1123–4

Many patients said to leave their MD's office without understanding what they've been told [news] **Oncology (Huntingt)** 1995 Nov;9(11):1134

Compensation. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):224–7

Patients equate quality with service. Lance MP. **Pa Med** 1995 Jun;98(6):16–7

Spreading us thinner and thinner...[editorial] Mills JW. **Pa Med** 1995 Jun;98(6):6

A new approach to health system reform: seizing the moral high ground. Silverman JS. **Pa Med** 1995 Jun;98(6):28–30

Enhancing patient compliance in pediatrics. Liptak GS. **Pediatr Rev** 1996 Apr;17(4):128–34

Restoring the therapeutic effects of the patient–physician relationship [editorial] Oreopoulos DG. **Perit Dial Int** 1996 Jan–Feb;16(1):5–9

Rituals and roles in medical practice. Elks ML. **Perspect Biol Med** 1996 Summer;39(4):601–9 (28 ref.)

A time to heal. Field RJ Jr. **Pharos** 1996 Spring;59(2):11–3

Read Don Quixote. King CR. **Pharos** 1995 Summer; 58(3):24–8

A patient in the teaching hospital: balancing privacy and education [see comments] Sargeant RR. **Pharos** 1995 Summer;58(3):29–34. Comment in: Pharos 1995 Summer;58(3):43.

Race and culture in medical education [letter; comment] Vaughn S. **Pharos** 1995 Summer;58(3):49. Comment on: Pharos 1995 Spring;58(2):39–42.

Where have all the old patients gone? [editorial] Goldwyn RM. **Plast Reconstr Surg** 1996 Apr;97(5):1023

Two by two. Anderson EG. **Postgrad Med** 1996 Jan; 99(1):25–6

A new malpractice defense: common sense. Anderson EG. **Postgrad Med** 1996 Jul;100(1):29–30

Through the looking glass: how do patients view us? [editorial] Howard RB. **Postgrad Med** 1996 Apr;99(4):21–3

Discussing the diagnosis and prognosis with cancer patients. Bennett M, et al. **Postgrad Med J** 1996 Jan;72(843):25–9 (14 ref.)

Dealing with the difficult patient. Smith S. **Postgrad Med J** 1995 Nov;71(841):653–7

Overcoming culture and language barriers. Baylav A. **Practitioner** 1996 Jun;240(1563):403–6

A surgeon with HIV. Cembrowicz S, et al. **Practitioner** 1996 Jan;240(1558):9–12 (2 ref.)

Motivating change in health behavior. Implications for health promotion and disease prevention. Botelho RJ, et al. **Prim Care** 1995 Dec;22(4):565–89 (52 ref.)

Consumer vs. patient [letter] Bosley W. **Psychiatr Serv** 1995 Jul;46(7):732

Boundaries in psychotherapy: model guidelines. Hundert EM, et al. **Psychiatry** 1995 Nov;58(4):345–56

Touching limits in the analytic dyad. McLaughlin JT. **Psychoanal Q** 1995 Jul;64(3):433–65

The ideal of the anonymous analyst and the problem of self-disclosure. Renik O. **Psychoanal Q** 1995 Jul; 64(3):466–95

Aloneness in the countertransference. Schafer R. **Psychoanal Q** 1995 Jul;64(3):496–516

Ulysses and I: a brief memoir of a long analysis. Adams B. **Psychoanal Rev** 1995 Oct;82(5):727–40

Doctor-dependent changes in complaint-related cognitions and anxiety during medical consultations in functional abdominal complaints. Van Dulmen AM, et al. **Psychol Med** 1995 Sep;25(5):1011–8

Access, expectations and communication: Japanese mothers' interaction with GPs in a pilot study in North London. Arai Y, et al. **Public Health** 1995 Sep;109(5):353–61

Beta interferon and multiple sclerosis: why the fuss? [editorial] Mumford CJ. **QJM** 1996 Jan;89(1):1–3

Student innovations in the training of physicians at Brown: the whole patient and the whole physician programs. Blitz A. **R I Med** 1995 Oct;78(10):298–9

Student as patient: perspectives from the other side. Hsiao AL. **R I Med** 1995 Oct;78(10):297–8

Clinic. Wilkinson J. **R I Med** 1995 Oct;78(10):295–6

The crisis in medicine -- a response [editorial] Kolbe RJ. **S Afr Med J** 1996 Mar;86(3):234–5

Treating family members [letter] Pantanowitz L. **S Afr Med J** 1996 Apr;86(4):386

Avoiding—and defending—allegations of inappropriate physician conduct. Midwest Medical Insurance Company Risk Management Committee. **S D J Med** 1995 Nov; 48(11):389–91

On metaphor [editorial] Freeman JW. **S D J Med** 1996 Jun; 49(6):183–4

From a medical consultation to a written text. 2. Pragmatics and textlinguistics applied to medicine. Nessa J. **Scand J Prim Health Care** 1995 Jun;13(2):89–92

From a medical consultation to a written text. 1. Transcribing the doctor–patient dialogue. Nessa J. **Scand J Prim Health Care** 1995 Jun;13(2):83–8

A change in expectations [editorial] Miller WT. **Semin Roentgenol** 1995 Oct;30(4):307

Medication decision-making and management: a client-centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)

Interruptive patterns in medical visits: the effects of role, status and gender. Irish JT, et al. **Soc Sci Med** 1995 Sep; 41(6):873–81

Health promotion in primary care: physician–patient communication and decision making about prescription medications. Makoul G, et al. **Soc Sci Med** 1995 Nov; 41(9):1241–54

Process and outcomes in general practice consultations: problems in defining high quality care. Winefield HR, et al. **Soc Sci Med** 1995 Oct;41(7):969–75

Physician religious beliefs and the physician–patient relationship: a study of devout physicians. Olive KE. **South Med J** 1995 Dec;88(12):1249–55

Physicians' attitudes and retention of patients in their methadone maintenance programs. Caplehorn JR, et al. **Subst Use Misuse** 1996 May;31(6):663–77

Doctors also suffer when giving bad news to cancer patients. Espinosa E, et al. **Support Care Cancer** 1996 Jan;4(1):61–3

Communication in cancer care: is there enough to talk about? [editorial; comment] Guex P, et al. **Support Care Cancer** 1996 Mar;4(2):73–4. Comment on: Support Care Cancer 1996 Mar;4(2):82–96. Comment on: Support Care Cancer 1996 Mar;4(2):97–101. Comment on: Support Care Cancer 1996 Mar;4(2):102–9. Comment on: Support Care Cancer 1996 Mar;4(2):110–7. Comment on: Support Care Cancer 1996 Mar;4(2):118–28.

The patient's contract with the doctor [editorial] Ausman JI. **Surg Neurol** 1995 Jun;43(6):612

Physicians should tell patients about plan limits [letter] Huebner M. **Tex Med** 1996 Jun;92(6):7

Three stages of medical dialogue. Abramovitch H, et al. **Theor Med** 1996 Jun;17(2):175–87

Philip Roth's Patrimony: narrative and ethics in a case study. Erde EL. **Theor Med** 1995 Sep;16(3):239–52

The dying patient—teaching doctors to care. Branday JM. **West Indian Med J** 1996 Jun;45(2):45–7

Physician–patient communication in managed care. Gordon GH, et al. **West J Med** 1995 Dec;163(6):527–31

Patients' perspectives on dying and on the care of dying patients. McCormick TR, et al. **West J Med** 1995 Sep; 163(3):236–43

Patients from Japan and physician–patient communication [letter; comment] Uyeda RY. **West J Med** 1995 Nov; 163(5):487. Comment on: West J Med 1995 Jul;163(1):36–9.

Informing breast surgery patients about treatment options. Gold JA. **Wis Med J** 1995;94(7):403–4

Women's narratives in primary care medical encounters. Borges S, et al. **Women Health** 1995;23(1):29–56

What do people expect from their doctors? Boland M. **World Health Forum** 1995;16(3):221–7; discussion 227–47

[Ethical and psychological aspects in gynecologic oncology] Macku J. **Cas Lek Cesk** 1996 Mar 20;135(6):188–90 (Eng. Abstr.) **(Cze)**

[Motivation for preventive care] Honzák R, et al. **Sb Lek** 1995;96(2):131–6 (Eng. Abstr.) **(Cze)**

[The meeting between patients and professionals who treat them (editorial)] Mabeck CE. **Ugeskr Laeger** 1996 Mar 25; 158(13):1804 **(Dan)**

[The meeting between patients and professionals who treat them. Qualitative interview of patients with amyotrophic lateral sclerosis and their closest relatives] Timm HU. **Ugeskr Laeger** 1996 Mar 25;158(13):1812–7 (Eng. Abstr.) **(Dan)**

[Patients' right and physicians' power] Lindqvist M. **Duodecim** 1995;111(1):96–9 **(Fin)**

[What is quality care?] Niinistö L. **Duodecim** 1995;111(1):51–5 **(Fin)**

[Doctor–patient relationship in rehabilitation] Salminen JK, et al. **Duodecim** 1994;110(15):1468–72 **(Fin)**

[The patient–doctor relationship and metabolic control in patients with diabetes mellitus] Viinamäki H, et al. **Duodecim** 1994;110(16):1524–8 **(Fin)**

[Ethical implications in the psychotherapeutic relationship] Szafran AW. **Acta Psychiatr Belg** 1995;95(6):320–5 (Eng. Abstr.) **(Fre)**

[Patient transfer between 2 hospital services: informing patients] Huber P, et al. **Ann Med Interne (Paris)** 1996; 147(1):5–9 (Eng. Abstr.) **(Fre)**

[The new patient] Imbert C. **Bull Acad Natl Med** 1996 Jan; 180(1):33–40 **(Fre)**

[Standards, options and recommendations for a successful practice in psycho-oncology. National Federation of Centers for the fight against cancer] Saltel P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):847–64 (55 ref.) **(Fre)**

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

[Physician–patient relationship in oncologic ultrasonography. The right way to inform the patient] Leclère J, et al. **J Radiol** 1996 Jun;77(6):405–9 (Eng. Abstr.) **(Fre)**

[Radiologists: moods and questions] Mériot P, et al. **J Radiol** 1995 Aug;76(8):487–9 **(Fre)**

[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**

[What should one tell the patient?] Loizeau E. **Rev Med Suisse Romande** 1996 Jul;116(7):545–7 **(Fre)**

[Psychosocial aspects of chronic lumbago: the physicians and patients' behavior] Vannotti M, et al. **Rev Med Suisse Romande** 1995 Dec;115(12):951–4 **(Fre)**

[Oncogenetic consultation: various relational, psychological and ethical aspects] Guex P, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1023–6 (Eng. Abstr.) **(Fre)**

[Psychosocial stresses of gynecologists and their effects] Heckenhausen D. **Arch Gynecol Obstet** 1995; 257(1–4):592–602 **(Ger)**

[Woman physician in general practice] Leifels-Fischer B. **Arch Gynecol Obstet** 1995;257(1–4):709–12 **(Ger)**

[Women see—women physicians—see women] Riegl GF. **Arch Gynecol Obstet** 1995;257(1–4):583–92 **(Ger)**

[Oncologic after-care and rehabilitation—physician–patient interaction in gynecologic oncology] Schünemann H, et al. **Arch Gynecol Obstet** 1995;257(1–4):277–83 (14 ref.) **(Ger)**

[Neurolinguistic programming in physician–patient communication. Basic principles of the procedure—examples for application in surgery] Graf U. **Fortschr Med** 1995 Sep 20;113(26):368–71 (Eng. Abstr.) **(Ger)**

[Motivation for smoking cessation by the general practitioner] Käse E. **Fortschr Med** 1996 Mar 20; 114(8):87–8 **(Ger)**

[General practice and patient-oriented medical education. Practicum for "Introduction to clinical medicine (with patient examination)"] Langhorst J. **Fortschr Med** 1995 Oct 30;113(30):433–4 **(Ger)**

[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ. **Fortschr Med** 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Needs and expectations of cancer patients from their physicians: what do patients expect?] Haasche A, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):M39–41 **(Ger)**

[Help or hinderniss? The effect of legal norms on the physician–patient relationship] Ulsenheimer K. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M110–9 (113 ref.) **(Ger)**

[Positions and perspectives. Opening address by the chairman of the 102nd Congress of the German Society of Internal Medicine, Wiesbaden, 14 April 1996] Greten H. **Med Klin** 1996 May 15;91(5):257–61 **(Ger)**

[Talking medicine contra alternative medicine? (letter; comment)] Heimpel H. **Med Klin** 1995 Sep 15;90(9):554. Comment on: Med Klin 1995 Jun 15;90(6):372–3. **(Ger)**

[Dichotomy and duplicity—revisited] Haag A, et al. **Psychother Psychosom Med Psychol** 1996 Jun;46(6):241–4 (Eng. Abstr.) **(Ger)**

[The Patient Satisfaction Questionnaire: a suitable tool for quality control in the physician–patient relationship?] Langewitz W, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):351–7 (Eng. Abstr.) **(Ger)**

[The physician–patient relationship and sophisticated modern technology] Wenz W. **Rontgenpraxis** 1995 Aug; 48(8):238–44 (21 ref.) **(Ger)**

[Physician–patient relations and stress caused by coloscopy in patients with chronic inflammatory bowel disease] Frenzer A, et al. **Schweiz Med Wochenschr Suppl** 1996; 79:94S–96S (Eng. Abstr.) **(Ger)**

[Bad news and the successful life] Baumann-Hölzle R. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):445–50 (Eng. Abstr.) **(Ger)**

[Interview in medicine] Laemmel K. **Schweiz Rundsch Med Prax** 1996 Jul 2;85(27–28):863–9 (Eng. Abstr.) **(Ger)**

[Truth disclosure in physicians' dialogue: compassionate lie or merciless statistics?] Oelz O. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):440–4 (Eng. Abstr.) **(Ger)**

[What does the patient expect from the physician?] Schipperges H. **Schweiz Rundsch Med Prax** 1996 Jul 2; 85(27–28):857–62 (Eng. Abstr.) **(Ger)**

[Difficult patients—difficult physicians?] Schläpfer A. **Schweiz Rundsch Med Prax** 1996 Jul 2;85(27–28):870–6 (Eng. Abstr.) **(Ger)**

[How much truth can the patient endure?] Uchtenhagen A. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):451–3 (Eng. Abstr.) **(Ger)**

[Truth at the bedside in a historical overview] von Engelhardt D. **Schweiz Rundsch Med Prax** 1996 Apr 2; 85(14):432–9 (Eng. Abstr.) **(Ger)**

[Not about life or death, but about interpersonal understanding (interview by Dr. Klaus Reinhardt)] Ludwig H. **Ther Umsch** 1996 Jun;53(6):426–8 **(Ger)**

[Free from tobacco. Counseling of smokers in medical practice—experiences from the Swiss campaign] Burkhalter AK. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):531–6 (Eng. Abstr.) **(Ger)**

[The "Patient Anxiety Seminar" as a graduate education program—effectiveness and use in general practice] Perkonigg A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):370–7 (Eng. Abstr.) **(Ger)**

[Patient counseling by the physician in smoking cessation—conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

[Individual therapy goals: on outcome documentation of inpatient psychotherapy from the patient and therapist viewpoint] Heuft G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):186–99 (Eng. Abstr.) **(Ger)**

[The human transparent and the human veiled: the therapeutic relationship with the heterocultural patient] Diasio N. **Ann Ig** 1995 May–Jun;7(3):209–16 (Eng. Abstr.) **(Ita)**

[Physician–patient relations in cardiology (letter)] Fiorista F. **G Ital Cardiol** 1995 Dec;25(12):1682 **(Ita)**

[The family physician and the clinician (editorial)] Bonati B. **Recenti Prog Med** 1996 Apr;87(4):167–71 **(Ita)**

[Communication with the patient: a duty useful to physicians, a benefit to patients] Bonomo L. **Recenti Prog Med** 1995 Sep;86(9):331 **(Ita)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

[Communication of bad information: general indications and

guidelines] Saltini A, et al. **Recenti Prog Med** 1995 Oct; 86(10):409–17 (12 ref.) (Eng. Abstr.) **(Ita)**

[When a patient does not hear (letter)] Berg RE, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3421 **(Nor)**

[How to make quality assurance of the meeting between two people?] Hjortdahl P. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3115–6 **(Nor)**

[Communication between cancer patients and their physicians. Knowledge and attitudes] Kaasa S, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1065–6 **(Nor)**

[When the patient does not hear (letter)] Ranhoff AH. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):111–2 **(Nor)**

[Cognitive therapy of subjective somatic symptoms (see comments)] Wilhelmsen I, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):861–4 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1996 May 20;116(13):1615. **(Nor)**

[What do adolescents think about their physician: a comparison between pediatricians and physicians for adults] Surís i Granell JC, et al. **An Esp Pediatr** 1996 Apr; 44(4):326–8 (Eng. Abstr.) **(Spa)**

[Opinion of asymptomatic HIV-positive patients about their primary care physicians] Belda Ibáñez J, et al. **Aten Primaria** 1995 Sep 15;16(4):215–9 (Eng. Abstr.) **(Spa)**

[User satisfaction with primary care teams: related to doctor's training in the field of physician-patient relations] Iragüen Eguskiza P, et al. **Aten Primaria** 1995 Nov 15;16(8):485–90 (Eng. Abstr.) **(Spa)**

[Additional question ("is there anything else...?") in primary health care] Peláez Fernández C, et al. **Aten Primaria** 1996 Jan;17(1):12–6 (Eng. Abstr.) **(Spa)**

[Therapeutic relations between health professionals and patients. Experience of a work group] Ramírez Hidalgo A, et al. **Aten Primaria** 1995 Sep 15;16(4):221–8 **(Spa)**

[Causes of non-compliance and associated factors in non-attendance of scheduled consultation] Sánchez Muñoz C, et al. **Aten Primaria** 1996 Jan;17(1):34–8 (Eng. Abstr.) **(Spa)**

[From paternalism to democracy: beneficence—person and current bioethics in Puerto Rico] Lugo E. **Bol Asoc Med P R** 1995 Mar-Apr;87(3–4):67–71 **(Spa)**

[Difficult to talk about psychosocial problems. A video shows how easily may the physician-patient dialogue be blocked] Arborelius E, et al. **Lakartidningen** 1995 Nov 15; 92(46):4325–9 **(Swe)**

[Patients are pleased to be answer questions (letter)] Ehrenpreis J. **Lakartidningen** 1995 Dec 6;92(49):4674 **(Swe)**

[Are you a professional physician? Consult a professional interpreter!] Feigenberg E. **Lakartidningen** 1995 Sep 27; 92(39):3600–1 **(Swe)**

[Meeting patients and help them find themselves (letter)] Hellström O. **Lakartidningen** 1996 Jun 26;93(26–27):2488 **(Swe)**

[Soften punishment in malpractive cases! Prevent occurrence of a culture of dissatisfaction and revenge!] Jacobsson L. **Lakartidningen** 1995 Nov 29;92(48):4534, 4539 **(Swe)**

[How to get rid of a doctor. A noble story (letter)] Lantz ET. **Lakartidningen** 1996 Jan 31;93(5):341–2 **(Swe)**

[Supervisory groups for better treatment of patients] Lind J. **Lakartidningen** 1996 Jun 19;93(25):2398–402 **(Swe)**

[Participation in a Balint group is good for the patient-physician relation (letter)] Malmquist A. **Lakartidningen** 1996 Jan 17;93(3):123 **(Swe)**

[Difficulties in facing cancer patients: learn of each others experiences to improve communication with the patient] Orn P. **Lakartidningen** 1996 Mar 13;93(11):979 **(Swe)**

[The male patient in general medicine] Hallberg H. **Nord Med** 1995;110(8–9):228–9, 231 **(Swe)**

PHYSICIAN REFUSAL TO TREAT see **REFUSAL TO TREAT**

PHYSICIAN SELF-REFERRAL

Conflict of interest, physicians and physiotherapy. Waldman M. **Can Med Assoc J** 1996 Jun 1;154(11):1737–9

LEGISLATION & JURISPRUDENCE

Issue of fraud raised as MD self-referral comes under spotlight in Ontario. Cohen L. **Can Med Assoc J** 1996 Jun 1;154(11):1744–6

Stark self-referral law. Beck S, et al. **Iowa Med** 1995 Dec; 85(12):484–7

Update on physician self-referral and medical malpractice arbitration. Weber RD. **Mich Med** 1995 Nov;94(11):7

Laws prohibiting physician self-referrals. The impact on health care integration in Minnesota. Struthers MS, et al. **Minn Med** 1996 Jan;79(1):29–32

Tax-exempt integrated delivery systems: Part 2, Stark I and Stark II. Vogel PL, et al. **Mo Med** 1995 Sep;92(9):572–3

Stark self-referral rules burdened with complexities. Barratt K, et al. **Wis Med J** 1995 Dec;94(12):697–701

PHYSICIAN SHORTAGE AREA see **MEDICALLY UNDERSERVED AREA**

PHYSICIANS

Physician transformation from hero to lover. Edlich RF, et al. **Acad Emerg Med** 1995 Sep;2(9):845–7

New opportunities to improve physicians' lifelong learning. Anderson MC. **Acad Med** 1996 Feb;71(2):115–6

Professional competencies in the changing health care system: physicians' views on the importance and adequacy of formal training in medical school. Finocchio LJ, et al. **Acad Med** 1995 Nov;70(11):1023–8

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)

Physicians' children are treated differently in the emergency department. Diekema DS, et al. **Am J Emerg Med** 1996 Jan;14(1):6–9

Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis [see comments] Bernstein CN, et al. **Am J Gastroenterol** 1995 Dec;90(12):2106–14. Comment in: Am J Gastroenterol 1995 Dec;90(12):2090–2. Comment in: Am J Gastroenterol 1996 Jul;91(7):1472–3.

The quality of consent [editorial] LaCombe MA. **Am J Med** 1996 Mar;100(3):258–60

Art and the science of medicine. LaCombe MA. **Am J Med** 1995 Oct;99(4):427–31

Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. Canadian Collaborative Study for Predictive Testing for Huntington Disease. Copley TT, et al. **Am J Med Genet** 1995 Jul 31; 58(1):59–69

Physician attitudes toward human immunodeficiency virus testing in pregnancy. Segal AI. **Am J Obstet Gynecol** 1996 Jun;174(6):1750–5; discussion 1755–6

Asklepios: ancient hero of medical caring [see comments] Bailey JE. **Ann Intern Med** 1996 Jan 15;124(2):257–63. Comment in: Ann Intern Med 1996 Aug 1;125(3):253; discussion 254. Comment in: Ann Intern Med 1996 Aug 1;125(3):254.

Physician compliance with guidelines [letter; comment] Jung BC. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):77–8. Comment on: Ann Intern Med 1995 Feb 15;122(4):277–82.

Identifying adverse events caused by medical care: degree of physician agreement in a retrospective chart review. Localio AR, et al. **Ann Intern Med** 1996 Sep 15; 125(6):457–64

Physicians' attitudes about the care of patients in the persistent vegetative state: a national survey [see comments] Payne K, et al. **Ann Intern Med** 1996 Jul 15;125(2):104–10 . Comment in: Ann Intern Med 1996 Jul 15;125(2):146–7.

Sickness in the medical profession. Waldron HA. **Ann Occup Hyg** 1996 Aug;40(4):391–6

Attitudes and opinions toward surgical research. A survey of surgical residents and their chairpersons. Souba WW, et al. **Ann Surg** 1996 Apr;223(4):377–83

Who decides? Physicians' willingness to use life-sustaining treatment. Hanson LC, et al. **Arch Intern Med** 1996 Apr 8;156(7):785–9

A randomized study of the efficacy of the PROPATH Program for patients with Parkinson disease [see comments] Mercer BS. **Arch Neurol** 1996 Sep;53(9):881–4. Comment in: Arch Neurol 1996 Sep;53(9):848.

Reverse gullibility and scientific evidence. Riffenburgh RH. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):600–1

Only doing my duty? [editorial] Adshead G. **BMJ** 1995 Oct 14;311(7011):965–6

Career preferences of doctors [editorial; comment] Allen I. **BMJ** 1996 Jul 6;313(7048):2. Comment on: BMJ 1996 Jul 6;313(7048):19–24.

Careers advice for doctors [editorial] Carnall D, et al. **BMJ** 1996 Jul 6;313(7048):3

Bovine spongiform encephalopathy. Doctors are less likely than patients to have stopped eating beef [letter; comment] Cohen H. **BMJ** 1996 Jul 20;313(7050):171–2. Comment on: BMJ 1995 Nov 25;311(7017):1415–21. Comment on: BMJ 1996 Jan 20;312(7024):180–1. Comment on: BMJ 1996 Mar 30;312(7034):790–1.

Working in a developing country. Which is good experience [letter] Connolly AM, et al. **BMJ** 1995 Oct 7;311(7010):946

Doctors in Britain urged to practise effectively [news] Dillner L. **BMJ** 1996 Jan 20;312(7024):143–4

Israeli Medical Association and torture. Association tries to ensure that no doctors participate in acts of torture [letter] Dolev E, et al. **BMJ** 1996 Sep 7;313(7057):630

Amnesty highlights doctors' duty to report torture [news] Dyer O. **BMJ** 1996 Jun 1;312(7043):1377

Doctors who smoke. Zealotry is counter productive [letter; comment] Ebdy MJ. **BMJ** 1995 Oct 7;311(7010):945. Comment on: BMJ 1995 Jul 15;311(6998):142–3.

The rights of HIV infected healthcare workers [editorial; comment] Erridge P. **BMJ** 1996 Jun 29;312(7047):1625–6 . Comment on: BMJ 1996 Jun 29;312(7047):1679.

Project has been set up to explore ways of preventing wastage of doctors [letter] Harvey J, et al. **BMJ** 1996 Aug 24;313(7055):491

Doctors who smoke. Little progress has been made over 20 years [letter; comment] Hedley AJ. **BMJ** 1995 Oct 7; 311(7010):945. Comment on: BMJ 1995 Jul 15;311(6998):142–3.

Surgeons will not want jobs in hospitals that do not do emergency surgery [letter] Hopkins R. **BMJ** 1996 Jun 29; 312(7047):1672

German doctor donates kidney [news] Karcher H. **BMJ** 1996 Aug 24;313(7055):443

Work in the European Union. Klemperer F. **BMJ** 1996 Mar 2;312(7030):567–70

Career destinations in 1994 of United Kingdom medical graduates of 1983: results of a questionnaire survey. Lambert TW, et al. **BMJ** 1996 Apr 6;312(7035):893–7

"Coming out"—a personal dilemma [see comments] Logie S. **BMJ** 1996 Jun 29;312(7047):1679. Comment in: BMJ 1996 Jun 29;312(7047):1625–6.

Doctors who smoke. Doctors should advise but do not have to lead by example [letter; comment] O'Brien P, et al. **BMJ** 1995 Oct 7;311(7010):945. Comment on: BMJ 1995 Jul 15;311(6998):142–3.

Myths in medicine. Story that early retirement is associated with longevity is often quoted [letter] Padfield A. **BMJ** 1996 Jun 22;312(7046):1611

Egyptian doctors held as prisoners of conscience [letter] Phillipson H. **BMJ** 1996 May 11;312(7040):1231

Doctors who smoke. Why not exclude doctors with other unhealthy habits too? [letter; comment] Sudbury P. **BMJ** 1995 Oct 7;311(7010):945. Comment on: BMJ 1995 Jul 15;311(6998):142–3.

Australian doctors put in firing line [news] Zinn C. **BMJ** 1996 Jun 1;312(7043):1378

Attitudes to adverse drug reaction reporting [letter] Inman WH. **Br J Clin Pharmacol** 1996 May;41(5):434–5

Finance in the NHS for doctors. Mickelsen P. **Br J Hosp Med** 1995 Oct 4–17;54(7):351–2

Pass the Royal College examinations. MCQ technique. Williams C, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):479–81

How physicians and biomedical scientists in India learn information-seeking skills. Schwartz DG. **Bull Med Libr Assoc** 1995 Jul;83(3):360–2

HIV-infected health care workers. The personal impact. Scoles P. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):226–39

Facing ethical issues [editorial] Burditt AM. **Can Fam Physician** 1995 Nov;41:1836–7, 1846–7 **(Eng, Fre)**

Doctors, nurses, and primary care [editorial] Flook N. **Can Fam Physician** 1995 Sep;41:1441–3, 1455–8 **(Eng, Fre)**

Physician mobility: individual rights [letter; comment] Goodwin DM. **Can Med Assoc J** 1995 Nov 1;153(9):1228–9 . Comment on: Can Med Assoc J 1995 Aug 15;153(4):397–8.

US report on violence in the medical workplace may hold lessons for Canadian MDs. Grant D. **Can Med Assoc J** 1995 Dec 1;153(11):1651–2

Global physician budgets as common-property resources: some implications for physicians and medical associations. Hurley J, et al. **Can Med Assoc J** 1996 Apr 15;154(8):1161–8

Computers a cornerstone of evidence-based care, conference told. Lowry F. **Can Med Assoc J** 1995 Dec 1; 153(11):1636–9

Factors influencing the emigration of physicians from Canada to the United States. McKendry RJ, et al. **Can Med Assoc J** 1996 Jan 15;154(2):171–81

Improving physician prescribing practices: bridge over troubled waters [editorial] MacLeod SM. **Can Med Assoc J** 1996 Mar 1;154(5):675–7 (10 ref.)

Physician-assessment and physician-enhancement programs in Canada. Page GG, et al. **Can Med Assoc J** 1995 Dec 15;153(12):1723–8

Physicians should keep an open mind on complementary health care, Congress says. Spencer MH. **Can Med Assoc J** 1995 Dec 15;153(12):1796–7

US not the only country luring Canadian MDs. Wharry S. **Can Med Assoc J** 1996 Jun 1;154(11):1742

Business and management training for physicians. CME or the third degree. Alberts WM. **Chest** 1995 Dec; 108(6):1711–7

Coping and learning with data systems in the information age. Brandstetter RW, et al. **Chest** 1996 Jan;109(1):238–40

Get real, Dr. Stobo [letter] Carlen R. **Chest** 1996 Mar; 109(3):853–4

Operator-specific outcomes. A call to professional responsibility [editorial] Califf RM, et al. **Circulation** 1996 Feb 1;93(3):403–6

Assisted suicide: opinions of Alberta physicians. Kinsella TD, et al. **Clin Invest Med** 1995 Oct;18(5):406–12

The responsive workbench: a virtual working environment for physicians. Fröhlich B, et al. **Comput Biol Med** 1995 Mar;25(2):301–8

Improving clinician's coded data entry through the use of an electronic patient record system: 3.5 years experience with a semiautomatic browsing and encoding tool in clinical routine. Hohnloser JH, et al. **Comput Biomed Res** 1996 Feb;29(1):41–7

Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Martin TL, et al. **Diabetes Care** 1995 Aug;18(8):1124–32

Who shall decide? [editorial; comment] Coates A. **Eur J Cancer** 1995 Nov;31A(12):1917–8. Comment on: Eur J Cancer 1995 Nov;31A(12):1955–9.

Doctor Net: Physicians can create their own free home page on the Web [letter] Cykiert R. **Geriatrics** 1996 Aug; 51(8):11–2

Physicians' approach to the management of hypertension in a developing community. Olubodun JO. **Int J Cardiol** 1995 Sep;51(2):193–7

Public health in Jewish lore Medicus Judaicus: the physician in Jewish lore rights and duties. Kottek SS.

Isr J Med Sci 1996 Feb;32(2):159–60

Public policy statement on inquiring into physicians' health on applications for licensure, examination and privileges. **J Addict Dis** 1995;14(2):97–9

Public policy statement on mutually accepted sanctions by State Boards of Medical Examiners. **J Addict Dis** 1995; 14(2):98–9

Chemically dependent physicians and informed consent disclosure. Ackerman TF. **J Addict Dis** 1996;15(2):25–42

Four years experience of a hospital's impaired physician committee. Schwartz RP, et al. **J Addict Dis** 1995; 14(2):13–21

Nurse–physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)

Patients' attitudes about gifts to physicians from pharmaceutical companies. Blake RL Jr, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):457–64

Relationship of diet, abdominal obesity, and physical activity to plasma lipoprotein levels in Asian Indian physicians residing in the United States. Yagalla MV, et al. **J Am Diet Assoc** 1996 Mar;96(3):257–61

Physicians, ethics, advance directives, and long-term care [letter] Gordon M, et al. **J Am Geriatr Soc** 1996 Apr; 44(4):471–2

Physicians' prevention-related practice behaviors in treating adult patients with asthma: results of a national survey [corrected and republished in J Asthma 1995;32(4):309–18] Wolle JM, et al. **J Asthma** 1995;32(2):131–40

Physician and nurse considerations for receiving a "fast-track" patient in the intensive care unit. Papadakos PJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):21–3

Physicians' attitudes regarding Down syndrome. Hermann R, et al. **J Child Neurol** 1996 Jan;11(1):66–70

Rectal examination: a potential hazard to physicians [letter] Golan G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):173

Blue collar doctor. Brouillette JN. **J Fla Med Assoc** 1995 Oct;82(10):701–2

The medical information superhighway. Duetsch H. **J Fla Med Assoc** 1995 Aug;82(8):545–8

Failure to communicate. Harty-Golder B. **J Fla Med Assoc** 1995 Sep;82(9):617–9

Attitudes of Florida Academic Physicians toward the Florida Medical Association. Herold AE. **J Fla Med Assoc** 1996 May;83(5):321–6

The Human Genome Project and the clinician. Makowski DR. **J Fla Med Assoc** 1996 May;83(5):307–14

Who are we? We are only young once, make the best of it or get out of the way, here come the young 'uns [editorial] Shea D. **J Fla Med Assoc** 1995 Dec;82(12):797–8

Who are we? We are one big family with big problems [editorial] Shea JD. **J Fla Med Assoc** 1996 May; 83(5):299–300

Who are we? We are against violence [editorial] Shea JD. **J Fla Med Assoc** 1995 Oct;82(10):661–2

Who are we? We are international [editorial] Shea JD. **J Fla Med Assoc** 1995 Sep;82(9):593–4

Physician visit frequency in Alzheimer's disease [letter; comment] Murden RA. **J Gen Intern Med** 1995 Sep; 10(9):533. Comment on: J Gen Intern Med 1995 Apr;10(4):187–93.

A study of physicians, hospitals, and payers in the Atlanta health care market. Minyard K, et al. **J Med Assoc Ga** 1996 Apr;85(2):71–5, 77–9

Opting out of Medicare. One physician takes a stand. Schlitt M. **J Med Assoc Ga** 1996 Apr;85(2):89–90

Universal precautions: knowledge, compliance and attitudes of doctors and nurses in Thailand. Danchaivijitr S, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S112–7

NCI survey explores the M.D.'s perspective on ABMT trials [news] Mathews J. **J Natl Cancer Inst** 1995 Oct 18; 87(20):1510–1

A survey of physician knowledge of drug costs. Hoffman J, et al. **J Pain Symptom Manage** 1995 Aug;10(6):432–5

Salt and solution: physician heal thyself. Kappel DA. **J Trauma** 1995 Sep;39(3):401–3

Usefulness of physicians functioning as emergency medical technicians [editorial; comment] McSwain NE Jr. **J Trauma** 1995 Dec;39(6):1027–8. Comment on: J Trauma 1995 Dec;39(6):1029–35.

Preventable death evaluation of the appropriateness of the on-site trauma care provided by Urgences-Santé physicians [see comments] Sampalis JS, et al. **J Trauma** 1995 Dec;39(6):1029–35. Comment in: J Trauma 1995 Dec;39(6):1027–8.

Physicians accessing the Internet, the PAI Project. An educational initiative [editorial] Chi-Lum BI, et al. **JAMA** 1996 May 1;275(17):1361–2

Physicians and pharmaceutical sales representatives [letter; comment] Perry RF. **JAMA** 1995 Oct 25;274(16):1267; discussion 1268. Comment on: JAMA 1995 Apr 26;273(16):1296–8.

Physicians and pharmaceutical sales representatives [letter; comment] Price G. **JAMA** 1995 Oct 25;274(16):1267–8. Comment on: JAMA 1995 Apr 26;273(16):1296–8.

Alleged role of medical personnel in genocide in Rwanda [letter] Hall P. **Lancet** 1996 May 4;347(9010):1265

Doctors implicated in Tutsi genocide [news] Harris MC. **Lancet** 1996 Mar 9;347(9002):684

Poor recall performance of journal-browsing doctors [letter] Kellett CF, et al. **Lancet** 1996 Aug 17;348(9025):479

Release of Syrian doctors [letter; comment] Phillipson H. **Lancet** 1995 Dec 23–30;346(8991–8992):1711. Comment on: Lancet 1995 Nov 4;346(8984):1232.

Forgotten imprisoned Syrian doctors [letter] [see comments] Phillipson H. **Lancet** 1995 Nov 4;346(8984):1232. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1711.

Television entertainment and the US health-care debate [see comments] Turow J. **Lancet** 1996 May 4;347(9010):1240–3 . Comment in: Lancet 1996 Jul 6;348(9019):62.

The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. Tangalos EG, et al. **Mayo Clin Proc** 1996 Sep;71(9):829–37

Knowledge, power and experience: variation in physicians' perceptions of breast cancer risk factors. McMullin JM, et al. **Med Anthropol** 1996 Mar;16(4):295–317

Physicians' response to length-of-stay profiling. Evans JH 3rd, et al. **Med Care** 1995 Nov;33(11):1106–19

Evaluation of physician intervention letters. Rascati KL, et al. **Med Care** 1996 Aug;34(8):760–6

Hospitals, doctors and telephones [letter] Ashley D, et al. **Med J Aust** 1996 Apr 1;164(7):444–5

Hospitals, doctors and telephones [letter] Pheils MT. **Med J Aust** 1996 Apr 1;164(7):444

Doctors and handwashing: instilling Semmelweis' message [editorial; comment] Pritchard RC, et al. **Med J Aust** 1996 Apr 1;164(7):389–90. Comment on: Med J Aust 1996 Apr 1;164(7):395–8.

Suspension of the hospital doctor [editorial] Samuel A. **Med Leg J** 1996;64 (Pt 2):45–7

Physician wellness target of MSMS Committee. Miller JJ. **Mich Med** 1995 Sep;94(9):24–5

A physician's view of managed care contracting. McIntire T. **Mo Med** 1996 Jun;93(6):284–5

Providers, insurors & payors how do they interact? [editorial] O'Sullivan D. **Mo Med** 1995 Dec;92(12):720–2

Informed consent: an evolution from battery/medical negligence to potential invasion of physician privacy. Reid D. **Mo Med** 1996 Jun;93(6):275–7

The dangers of being a doctor [letter; comment] Gollberg HR. **N C Med J** 1995 Aug;56(8):348–9. Comment on: N C Med J 1995 May;56(5):189–95. Comment on: N C Med J 1995 May;56(5):228–33.

Physician-assisted suicide [letter; comment] Wilson KG, et al. **N Engl J Med** 1996 Aug 15;335(7):518–9; discussion 519–20. Comment on: N Engl J Med 1994 Jul 14;331(2):89–94. Comment on: N Engl J Med 1996 Feb 1;334(5):303–9. Comment on: N Engl J Med 1996 Feb 1;334(5):310–5.

Physicians and nurse practitioners: can they work together? Weiss CA, et al. **N J Med** 1996 Apr;93(4):57–8

Medical discipline and sexual activity between doctors and patients [see comments] Cullen RM, et al. **N Z Med J** 1995 Nov 24;108(1012):481–3. Comment in: N Z Med J 1996 Jan 26;109(1014):17. Comment in: N Z Med J 1996 Apr 12;109(1019):127–8.

Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. Leversha AM, et al. **N Z Med J** 1995 Oct 27;108(1010):428–30

One doctor against managed care. Duvall CP. **Nat Med** 1996 Jul;2(7):735–6

The CPA and doctors: little cause for cheer [letter] George T. **Natl Med J India** 1996 May–Jun;9(3):141–2

Confirmation of self-reported cataract in the Physicians' Health Study [see comments] Christen WG, et al. **Ophthalmic Epidemiol** 1994 Jun;1(2):85–91. Comment in: Ophthalmic Epidemiol 1994 Jun;1(2):63–5.

Obligations to patient, profession, society, family, and self—an integrating resolution. The Ethics Committee of the American Academy of Otolaryngology-Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):241–9

The National Association of Physicians for the Environment: an introduction. Grupenhoff JT. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):199–200

Why are we here? Balshi JD. **Pa Med** 1995 Nov;98(11):44

What POs mean for PA physicians. Lance MP. **Pa Med** 1995 Dec;98(12):24–5

Palmtop computers and the physician. Zweibel SL. **Pacing Clin Electrophysiol** 1996 May;19(5):854–7

Do parents and professionals agree on the developmental status of high-risk infants? Kim MM, et al. **Pediatrics** 1996 May;97(5):676–81

Doctor in-between [editorial] Goldwyn RM. **Plast Reconstr Surg** 1996 Mar;97(3):635–6

Consultation is a two-way street [editorial] [see comments] Setness PA. **Postgrad Med** 1995 Oct;98(4):15–8. Comment in: Postgrad Med 1996 Jan;99(1):44.

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147–50 (8 ref.)

Beyond medicine: the doctor as a member of the corporate business team. Goldstone RL. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995;:61–8

Contextual inquiry: discovering physicians' true needs. Coble JM, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :469–73

A survey of Japanese physicians' attitudes and practice in caring for terminally ill cancer patients. Uchitomi Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):53–7

Capital punishment and the physician: the views of six Rhode Island physicians [see comments] Crowley JP, et al. **R I Med** 1995 Aug;78(8):215–21. Comment in: R I Med 1995 Oct;78(10):277.

Physician-assisted suicide, a symposium. Death made too easy or an act of profound compassion? Martin E, et al. **R I Med** 1995 Aug;78(8):222–30

Cost shifting—insurance company style [editorial] Heilman RS. **Radiographics** 1995 Nov;15(6):1298

The MASA and the doctor in full-time public service [letter] Fatti C. **S Afr Med J** 1996 Feb;86(2):178

Alternative medicine—a doctor's perspective [letter] Levin S. **S Afr Med J** 1996 Feb;86(2):183–4

Alternative medicine—a doctor's perspective [letter] Pantanowitz D. **S Afr Med J** 1996 Feb;86(2):184

Alternative medicine—a doctor's perspective [letter] Richards A. **S Afr Med J** 1996 Feb;86(2):184

Overtime in the public health sector [letter] Rosochachi Z. **S Afr Med J** 1995 Oct;85(10):1036–7

The doctor glut. Experts debate predictions of a physician surplus [news] Schneider D. **Sci Am** 1996 Feb;274(2):20–1

Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311–6 (24 ref.)

Is tenure irrelevant for academic clinicians? Halperin EC. **South Med J** 1995 Nov;88(11):1099–106

Physician religious beliefs and the physician-patient relationship: a study of devout physicians. Olive KE. **South Med J** 1995 Dec;88(12):1249–55

Physician reporting of and referral for patient complaints about sleep disorders. Rubinstein I, et al. **South Med J** 1996 May;89(5):483–6

Malpractice litigation fear and risk management beliefs among teaching hospital physicians. Schumacher JE, et al. **South Med J** 1995 Dec;88(12):1204–11

Interobserver agreement in the classification of stroke in the physicians' health study. Berger K, et al. **Stroke** 1996 Feb; 27(2):238–42

US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Carotid endarterectomy. Goldstein LB, et al. **Stroke** 1996 May; 27(5):801–6

Will increased awareness among physicians of the significance of sudden agonizing headache affect the outcome of subarachnoid hemorrhage? Coventry and Warwickshire Study: audit of subarachnoid hemorrhage (establishing historical controls), hypothesis, campaign layout, and cost estimation. Tolias CM, et al. **Stroke** 1996 May;27(5):807–12

"The strike that failed" Canadian physician strike, 1987 [letter] Carney AL. **Surg Neurol** 1996 Aug;46(2):191

Changing careers [letter] Kushner J. **Surg Neurol** 1995 Jun; 43(6):613

MBAs for MDs. Besaw L. **Tex Med** 1996 Jun;92(6):49–52

A matter of concern. BeSaw L. **Tex Med** 1996 Jul;92(7):22–7

Physicians should temper managed care rhetoric [letter] Gessler DJ. **Tex Med** 1996 Jun;92(6):7–8

Physician strategies for the 21st century. Sloane RW Jr. **Tex Med** 1995 Sep;91(9):44–7

Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician. Abbott J, et al. **Thorax** 1995 Jul;50(7):794–6

Role of physicians in an awareness campaign concerning organ sharing. Jacob F, et al. **Transplant Proc** 1996 Feb; 28(1):370

Defining and evaluating physician competence in end-of-life patient care. A matter of awareness and emphasis. Blank LL. **West J Med** 1995 Sep;163(3):297–301

Statewide Physician Health Program. **Wis Med J** 1995; 94(7):384–5

Seven reasons for Wisconsin physicians to oppose proposed legislation to legalize physician-assisted suicide. Green MJ, et al. **Wis Med J** 1995 Dec;94(12):693–5

[Clinical medicine and nursing. Therapy or care?] Pacovský V. **Sb Lek** 1995;96(4):395–8 **(Cze)**

[Emergency ambulances manned by physicians] Hansen TB, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):425–7 **(Dan)**

[Physician and language] Balk-Smit Duyzentkunst F. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2749–51 **(Dut)**

[Between two levels—chief physician and young doctor discuss the stumbling blocks of intercollegiality (interview by Hannu Sariola)] Tuominen J, et al. **Duodecim** 1995; 111(1):100–5 **(Fin)**

[Representations, discourses and practices about drug substitution with opiates. Apropos of a survey conducted in cooperation with 97 French physicians] André P, et al. **Ann Med Interne (Paris)** 1996;147(1):20–30 (Eng. Abstr.) **(Fre)**

[Burundi: knowledge and practices of physicians and nursing personnel about acute respiratory infections in children] Baribwira C, et al. **Med Trop (Mars)** 1996;56(1):95–8 (Eng. Abstr.) **(Fre)**

[Does the physician need religion?] Rohr K. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29–30):893–8 (Eng. Abstr.) **(Ger)**

[Physician as patient (editorial)] Modan B. **Harefuah** 1995 Nov 15;129(10):395–6 **(Heb)**

[Hebrew knowledge of new immigrant physicians] Notzer N, et al. **Harefuah** 1995 Jun 1;128(11):694–6, 743 (Eng. Abstr.) **(Heb)**

[Relationship between physicians and art] Hankiss J. **Orv Hetil** 1996 Feb 11;137(6):306–10 **(Hun)**

[The evaluation of the currency of the knowledge on viral hepatitis in a group of primary physicians of Rome] Patti AM, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):621–4 (Eng. Abstr.)

(Ita)
[Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster] Terada K, et al. **Kansenshogaku Zasshi** 1995 Aug; 69(8):908–12 (Eng. Abstr.) (Jpn)
[Hepatocellular carcinoma and physicians of internal medicine (discussion)] **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2043–55 (Jpn)
[Should a physician always be a physician? (letter)] Argren B. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1504 (Nor)
[Cultural differences between leaders and clinicians—the example of Haukeland Sykehus (letter)] Farstad M. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2354 (Nor)
[Health service for physicians—what do physicians want? (letter)] Flottorp S, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):893 (Nor)
[Health services for physicians—what do physicians wish for themselves? (letter)] Flottorp S, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):533; discussion 534 (Nor)
[Physicians are no longer always at work... (letter)] Fyrand O. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):300–1 (Nor)
[Physicians' own control of their working situation—a myth?] Gjerberg E, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10; 116(15):1800–4 (Eng. Abstr.) (Nor)
[Obligations of employment agreements (letter)] Jakobsen A. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1260–1 (Nor)
[Turnover of positions as the medically responsible physician in Norwegian municipalities 1988–91] Kolstrup N, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2671–4 (Eng. Abstr.) (Nor)
[Health services for physicians—what do physicians wish for themselves? (letter)] Krog T, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):533; discussion 534 (Nor)
[Health and work conditions of physicians. Experiences and visions 35 years after certification] Noer K. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3642–3 (Nor)
[Medicine, physicians and mass media—dissatisfaction and misunderstandings] Nylenna M. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):215–6 (Nor)
[Physicians too protest against nuclear weapon testing (letter)] Osen K. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3071 (Nor)
[Physicians liable for military service for sale (letter)] Smeland E. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3072 (Nor)
[Frustration and confidence failure (letter)] Smith P. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3418 (Nor)
[Hospitals misuse employments of trainee physicians (letter)] Solheim K. **Tidsskr Nor Laegeforen** 1995 Oct 20; 115(25):3183 (Nor)
[The elderly physicians] Svabø HM. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1064 (Nor)
[Health service for physicians. What do physicians want—form and substance?] Thorsen O, et al. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3788–90 (Eng. Abstr.) (Nor)
[The scientific information culture of the physician] Uvarenko AR. **Vrach Delo** 1995 Jan–Feb;(1–2):3–5 (Rus)
[Smoking cessation program using nicotine patch among physicians and pharmacists of Catalonia: results after 3–12 months] Pardell H, et al. **An Med Interna** 1996 Jan; 13(1):16–20 (Eng. Abstr.) (Spa)
[Spanish exile and Mexican medicine] Vilar P. **An R Acad Nac Med (Madr)** 1996;Spec No:65–77 (Spa)
[Human rights of the physician] García-Romero H. **Gac Med Mex** 1995 Mar–Apr;131(2):245–50 (Eng. Abstr.) (Spa)
[Self esteem, clinical protocols, and protocollized dissent. Task Force of Care Quality (letter; comment)] Alvarez Gil R. **Med Clin (Barc)** 1995 Nov 18;105(17):678. Comment on: Med Clin (Barc) 1994 Oct 8;103(11):421–2. (Spa)
[Medical student traits associated with future success as physicians (see comments)] Garduño-Espinosa J, et al. **Rev Invest Clin** 1995 Sep–Oct;47(5):355–64 (Eng. Abstr.) . Comment in: Rev Invest Clin 1996 Mar–Apr;48(2):165–7. (Spa)
[Medical students' future success as physicians (letter; comment)] López-Jiménez F, et al. **Rev Invest Clin** 1996 Mar–Apr;48(2):165–7. Comment on: Rev Invest Clin 1995 Sep–Oct;47(5):355–64. (Spa)
[The physician that the country needs. 1966 (classical article)] Martínez García PD. **Salud Publica Mex** 1995 Sep–Oct; 37(5):473–6 (Spa)
[Salaries of American physicians are decreasing for the first time] Bergström L. **Lakartidningen** 1996 Jan 31;93(5):323 (Swe)
[The Tule-test is a good test of physicians' clinical competence. Low unemployment among those who passed the examination] Fagrell B, et al. **Lakartidningen** 1996 Feb 7;93(6):475–6 (Swe)
[The physician and the computer] Fällman H. **Lakartidningen** 1996 Jun 26;93(26–27):2482–6 (Swe)
[The physician and the computer] Fällman H. **Lakartidningen** 1996 May 1;93(18):1701–9 (Swe)
[Death of two elderly physicians. Is euthanasia an expression of diminishing humanism?] Jersild PC. **Lakartidningen** 1996 May 22;93(21):2035–6 (Swe)
[A guideline program for physicians' leadership. The chief must have time for his task, recruitment must be stimulated] Johnson K. **Lakartidningen** 1996 Mar 27;93(13):1181 (Swe)
[Increased salaries don't signify increased quality of health care (letter)] Jonson T. **Lakartidningen** 1995 Oct 25; 92(43):3977, 3979 (Swe)
[The physician as patient. A resource for better health care] Katz G. **Lakartidningen** 1996 Mar 6;93(10):901–2 (Swe)
[Lars Jakt, anesthesiologist, Treliske Hospital, Truro, Cornwall: "nomadizing" physicians will probably remain in England] Lind J. **Lakartidningen** 1996 Mar 27; 93(13):1186–8 (Swe)
[Working in the EEC? Moving around is free—but certification is required] Lind J. **Lakartidningen** 1996 Mar 13;93(11):982–6 (Swe)
[Physicians and pharmacists should cooperate more and more! It is beneficial for independent drug information] Nilsson JL. **Lakartidningen** 1996 Apr 17;93(16):1507–8 (Swe)
[Patients' rights are too physician-oriented] Orn P. **Lakartidningen** 1996 May 22;93(21):2012 (Swe)
[Physicians of the world now in Sweden, too. They work without profit for people in exposed positions] Orn P. **Lakartidningen** 1996 Aug 7;93(32–33):2717 (Swe)
[Loyal to the physician or to ethics? (letter)] Palmgren L. **Lakartidningen** 1996 Mar 20;93(12):1102, 1107 (Swe)
[What benefit for the patients are high-class physicians? (letter)] Palmgren L. **Lakartidningen** 1996 Apr 10; 93(15):1413 (Swe)
[Disclosure of X-ray results by the radiologist? Yes, say the patients. May be, say the physicians] Storby G. **Lakartidningen** 1996 Mar 6;93(10):927–30 (Eng. Abstr.) (Swe)
[French citizens irritated by reform plans. Street-protest of physicians against impaired working conditions] Trenning-Himmelsbach A. **Lakartidningen** 1996 Jan 31; 93(5):324–6, 331 (Swe)
[Regulated working time and guaranteed leisure time for Finnish physicians? (interview by Eva Oldinger)] Eklund B. **Nord Med** 1996 May;111(5):152–3, 155 (Swe)
[Abolition 2000. A physicians' action against nuclear weapons] Engstedt L. **Nord Med** 1995;110(8–9):230–1 (Swe)

ECONOMICS

Will competition change the physician workforce? Early signals from the market. Schwartz AL. **Acad Med** 1996 Jan;71(1):15–22
New physicians, unlike new mechanics, find pay and location restricted [letter] MacDonald P. **Can Med Assoc J** 1996 May 1;154(9):1315–6
Physicians pay for health-card fraud [letter] Troup W. **Can Med Assoc J** 1996 Aug 15;155(4):368–9
Physician remuneration methods: the need for change and flexibility [editorial] Wright CJ. **Can Med Assoc J** 1996 Mar 1;154(5):678–80 (12 ref.)
Agency theory: a framework for analyzing physician services. Pontes MC. **Health Care Manage Rev** 1995 Fall; 20(4):57–67
Doctor pay hikes slow in 1994 for some specialties [news] **Hosp Health Netw** 1995 Oct 5;69(19):32
Public health, medical care, and mortality rates [editorial] Shi L. **J Health Care Poor Underserved** 1995;6(3):307–21
Facts. Kentucky physicians, Medicaid, and the provider tax [news] **J Ky Med Assoc** 1995 Aug;93(8):325–6
Earnings of male and female physicians [letter; comment] Bohlmann BJ. **N Engl J Med** 1996 Aug 15;335(7):525. Comment on: N Engl J Med 1996 Apr 11;334(15):960–4.
A national survey of the arrangements managed-care plans make with physicians [see comments] Gold MR, et al. **N Engl J Med** 1995 Dec 21;333(25):1678–83. Comment in: N Engl J Med 1995 Dec 21;333(25):1706–8.
Earnings of male and female physicians [letter; comment] Hauswald M, et al. **N Engl J Med** 1996 Aug 15; 335(7):524–5; discussion 525. Comment on: N Engl J Med 1996 Apr 11;334(15):960–4.
The shifting healthcare marketplace: purchasers, not MCOs, are the powers that be [editorial] Coulter CH. **Postgrad Med** 1996 Jun;99(6):15–6, 21–4
Speaking out on working conditions [letter] Fatti C. **S Afr Med J** 1994 Dec;84(12):876
Speaking out on working conditions [letter] Jackson JH. **S Afr Med J** 1994 Dec;84(12):876–7
Making the cap fit. What you need to know about capitation. BeSaw L. **Tex Med** 1996 Jan;92(1):24–9
The workers' comp monolith. Despite improvements, problems still remain. BeSaw L. **Tex Med** 1995 Dec; 91(12):16–9
[No additional 10% tax for chief physicians with old contracts based on the Health Care Law. Ruling of the Baden-Wurttemberg District Labor Court of 12 April 1995] Rieger HJ. **Dtsch Med Wochenschr** 1995 Oct 6; 120(40):1374–6 (Ger)

EDUCATION see EDUCATION, MEDICAL

HISTORY

Killing in the name of healing: the active role of the German medical profession during the Third Reich. Ernst E. **Am J Med** 1996 May;100(5):579–81
Jews and medicine in the USA. Brown TM. **Isr J Med Sci** 1996 Jul;32(7):597–9
Sarmento, Schomberg and Scotland: Jewish physicians in the period of emancipation, 1739–1839. Collins KE. **Isr J Med Sci** 1996 Jul;32(7):589–91
Jews and medicine: a temporal overview. Introduction. Glick S. **Isr J Med Sci** 1996 Jul;32(7):586
Jewish social medicine. Contracts between physicians and Jewish communities (17th and 18th centuries). Kottek SS. **Isr J Med Sci** 1996 Mar–Apr;32(3–4):265–8
Jewish physicians during the Holocaust. Nadav DS. **Isr J Med Sci** 1996 Jul;32(7):594–6
The physician automobilist. Dumesic DA. **J Hist Med Allied Sci** 1996 Apr;51(2):208–22
Neurology in literature. Some of Trollope's doctors. Perkin GD. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):288
More doctors. Perkin GD. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):447
Some Proustian doctors [letter] Perkin GD. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):90
Images of physicians in literature: medical Bildungsromans. Jones AH. **Lancet** 1996 Sep 14;348(9029):734–6
Images of physicians in literature: from quacks to heroes. McLellan MF. **Lancet** 1996 Aug 17;348(9025):458–60
Einstein's medical friends and their influence on his life. Kantha SS. **Med Hypotheses** 1996 Mar;46(3):257–60
Presidents who have caused a stir. First general meeting; Monday, 11th October 1993. Philipp E. **Trans Med Soc Lond** 1993–94;110:1–13
[Physicians on current coins] Bouvy LA. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2681–8 (Dut)
[Mikhail Bulgakov—a colleague and cult figure] Olsen B. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3784–7 (Eng. Abstr.) (Nor)
[Creative longevity of scientist physicians] Maiat VS. **Klin Med (Mosk)** 1995;73(6):66–8 (Rus)
[The scientific and public activities of physicians in ancient Ostrog] Shpizel' RS, et al. **Lik Sprava** 1995 May–Jun; (5–6):198–203 (Rus)
[The graduates of '45] Antipin GM, et al. **Voen Med Zh** 1995 Dec;(12):53–4 (Rus)
[The medical service officers on the front lines in World War II] Chizh IM, et al. **Voen Med Zh** 1995 Oct;(10):4–12 (Rus)
[Soldiers of mercy (the exhibition in the Military Medical Museum of the Ministry of Defense of the Russian Federation)] Krutov VS, et al. **Voen Med Zh** 1995 Dec; (12):51–3 (Rus)
[Johannes Chesnecopherus. Sweden's first professor of medicine] Wiman LG. **Lakartidningen** 1995 Dec 20; 92(51–52):4907–9 (Swe)

LEGISLATION & JURISPRUDENCE

When patient care is shared, who is the most responsible physician? Capen K. **Can Med Assoc J** 1996 Mar 15; 154(6):885–6
New Medicaid laws bring regulatory relief. Abrams M. **Indiana Med** 1996 May–Jun;89(3):256–8
Howe v. Hull. Kidd TW Jr. **Issues Law Med** 1995 Fall; 11(2):193–5
Physician liability for health-care fraud. Thrasher JE. **J Fla Med Assoc** 1996 May;83(5):332–3
Physician malpractice: does the past predict the future? Taragin MI, et al. **J Gen Intern Med** 1995 Oct;10(10):550–6
Physician liability in managed care. A review of four major areas of exposure [see comments] Bean RV. **J Med Assoc Ga** 1995 Sep;84(7):313–5. Comment in: J Med Assoc Ga 1996 Apr;85(2):60.
Managed care and physician liability [letter; comment] Uzych L. **J Med Assoc Ga** 1996 Apr;85(2):60. Comment on: J Med Assoc Ga 1995 Sep;84(7):313–5.
Medical care and the criminal law. Stratton WT. **Kans Med** 1996 Spring;97(1):8–9
More on death and dying [editorial] Culliton BJ. **Nat Med** 1996 Jun;2(6):607
Intensive care treatment decisions: the roots of our confusion [letter; comment] De Ville K, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):795–6. Comment on: Pediatrics 1994 Jul;94(1):98–101.
What do you know about the NPDB? [editorial] Setness PA. **Postgrad Med** 1996 Jul;100(1):15–6, 21–2
Hope for antitrust relief. Besaw L. **Tex Med** 1996 Jun; 92(6):26–9
Who's the boss? Ortolon K. **Tex Med** 1996 Jun;92(6):30–2
[No additional 10% tax for chief physicians with old contracts based on the Health Care Law. Ruling of the Baden-Wurttemberg District Labor Court of 12 April 1995] Rieger HJ. **Dtsch Med Wochenschr** 1995 Oct 6; 120(40):1374–6 (Ger)
[The provisos for substitutes in formulaic elective performance agreements (comment)] Rieger HJ. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1603–4. Comment on: Dtsch Med Wochenschr 1995 Nov 17;120(46):1603–4. (Ger)
[Honorarium sharing between the radiologists and transit physicians. Decision of the Higher Regional Court, Hamm, January 16, 1995] Rieger HJ. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1524–6 (Ger)
[Once more: the duty of fee reduction according to Article 6 a of the Schedule of Charges for Physicians] Rieger HJ.

Dtsch Med Wochenschr 1995 Dec 8;120(49):1714–5 **(Ger)**

[The provisos for substitutes in formulaic elective performance agreements. The problems due to the new Schedule of Charges for Physicians] Rieger HJ. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):926 **(Ger)**

[Large equipment: precedent for autonomy? (editorial)] Montgomery FU. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):195–6 **(Ger)**

[A code of ethics for qualified physicians (letter)] Pianosi G. **Med Lav** 1995 Jul–Aug;86(4):362–4 **(Ita)**

ORGANIZATION & ADMINISTRATION

The business side of healthcare [letter; comment] Halick J. **Postgrad Med** 1996 May;99(5):43; discussion 44, 46. Comment on: Postgrad Med 1996 Feb;99(2):21–5.

Healthcare—whose business is it? [editorial] [see comments] Larsen RR. **Postgrad Med** 1996 Feb;99(2):21–5. Comment in: Postgrad Med 1996 May;99(5):43; discussion 44, 46.

PSYCHOLOGY

How doctors learn: the role of clinical problems across the medical school–to–practice continuum. Slotnick HB. **Acad Med** 1996 Jan;71(1):28–34

Physicians' opinions on the delivery of mammographic screening services: immediate interpretation versus double reading. Slanetz PJ, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):377–9

When a doctor is a patient. Kirsch M. **Am J Gastroenterol** 1996 Jul;91(7):1299–300

Physician feedback on pharmacy–edited pharmacotherapy bulletin [letter] Berod T. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2340–1

Patterns of hospital care and physician perspectives from an Italian, Japanese, and USA hospital. Louis CZ, et al. **Am J Med Qual** 1996 Fall;11(3):123–34

Clinical incoherence about persons: the problem of the persistent vegetative state [editorial; comment] Cassell EJ. **Ann Intern Med** 1996 Jul 15;125(2):146–7. Comment on: Ann Intern Med 1996 Jul 15;125(2):104–10.

Whose death is it, anyway? [comment] Gilligan T, et al. **Ann Intern Med** 1996 Jul 15;125(2):137–41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149–51.

Characteristics of physicians with participatory decision–making styles [see comments] Kaplan SH, et al. **Ann Intern Med** 1996 Mar 1;124(5):497–504. Comment in: Ann Intern Med 1996 Mar 1;124(5):511–3.

Annual meeting: perspectives. Wrenn K. **Ann Intern Med** 1996 May 15;124(10):924

The greed of dermatologists [letter] Burr RD. **Arch Dermatol** 1995 Oct;131(10):1205–6

The role of intuitive thinking in the diagnostic process. Peters RM. **Arch Fam Med** 1995 Nov;4(11):939–41

I treated; now I want to prevent. Waltman RE. **Arch Fam Med** 1995 Oct;4(10):831

The relativity of alternative medicine [editorial; comment] Alpert JS. **Arch Intern Med** 1995 Dec 11–25;155(22):2385 . Comment on: Arch Intern Med 1995 Dec 11–25;155(22):2405–8.

Complementary medicine. What physicians think of it: a meta–analysis [see comments] Ernst E, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2405–8. Comment in: Arch Intern Med 1995 Dec 11–25;155(22):2385.

Empathy revisited [see comments] Gianakos D. **Arch Intern Med** 1996 Jan 22;156(2):135–6. Comment in: Arch Intern Med 1996 Jul 22;156(14):1582, 1586.

In the eye of the beholder. Hux JE, et al. **Arch Intern Med** 1995 Nov 27;155(21):2277–80

Cindy's death. Michael PR. **Arch Intern Med** 1996 Jan 22; 156(2):133–4

Undying care for terminal patients [letter; comment] Wright JD. **Arch Intern Med** 1995 Nov 27;155(21):2356. Comment on: Arch Intern Med 1995 Jun 26;155(12):1265–9.

Content analysis of prime–time television medical news. A pediatric perspective. Prabhu NP, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):46–9

Stress and the doctor's health. Lawrence JM. **Aust Fam Physician** 1996 Aug;25(8):1249–53, 1256

Doctors and medical politics [editorial] Carnall D. **BMJ** 1995 Dec 9;311(7019):1519–20

Half of physicians are unaware of surveillance system for Creutzfeldt–Jakob disease [letter] Franks A, et al. **BMJ** 1996 May 25;312(7042):1358

Career preferences of doctors who qualified in the United Kingdom in 1993 compared with those of doctors qualifying in 1974, 1977, 1980, and 1983 [see comments] Lambert TW, et al. **BMJ** 1996 Jul 6;313(7048):19–24. Comment in: BMJ 1996 Jul 6;313(7048):2.

Medical practitioners' knowledge of dysentery treatment in Bangladesh [see comments] Ronsmans C, et al. **BMJ** 1996 Jul 27;313(7051):205–6. Comment in: BMJ 1996 Jul 27;313(7051):181–2.

Scare over oral contraceptives. Doctors should take warning seriously [letter] Watson C. **BMJ** 1995 Dec 16; 311(7020):1638

Prescribing habits of Peruvian physicians and factors influencing them. Zárate Cárdenas E, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):328–37

Female and male leaderships: lesson from Norwegian doctors. Hofoss D, et al. **Cah Sociol Demogr Med** 1995 Jan–Mar;35(1):53–71

Debating benzodiazepine use [letter; comment] [see comments] Lexchin J. **Can Fam Physician** 1995 Aug; 41:1293, 1295. Comment on: Can Fam Physician 1995 May;41:760, 763–5, 772–6. Comment in: Can Fam Physician 1995 Nov;41:1848.

What breast cancer self–help groups want you to know [editorial] Phillips C, et al. **Can Fam Physician** 1996 Aug; 42:1447–9, 1455–7 **(Eng, Fre)**

Cancer in remission. Challenge in collaboration for family physicians and oncologists. Wood ML, et al. **Can Fam Physician** 1996 May;42:899–904; 907–10

Presidential address, 1995. Surgery 2000: a look back to the future. Heughan C. **Can J Surg** 1996 Jun;39(3):188–92

Pros and cons of capitation [letter] Bowering D. **Can Med Assoc J** 1996 Jul 15;155(2):159

Madeleine's death [letter; comment] Dutchyn SL. **Can Med Assoc J** 1996 Apr 15;154(8):1144. Comment on: Can Med Assoc J 1996 Jan 15;154(2):246–9.

Madeleine's death [letter; comment] Goertzen J. **Can Med Assoc J** 1996 Apr 15;154(8):1144. Comment on: Can Med Assoc J 1996 Jan 15;154(2):246–9.

Managing erotic feelings in the physician–patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.). Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.

Mixed reaction to suicide of terminally ill woman [letter] Gugliotta D. **Can Med Assoc J** 1995 Nov 1;153(9):1225–6

Mixed reaction to suicide of terminally ill woman [letter] Harding SR. **Can Med Assoc J** 1995 Nov 1;153(9):1226

Suicide totals for MDs sad reminder of stresses facing medicine, conference told. Johnston C. **Can Med Assoc J** 1996 Jul 1;155(1):109–11

Would you recommend a medical career to your children? Johnston C. **Can Med Assoc J** 1996 Jun 1;154(11):1757–9

Gun control [letter] [see comments] Kane BJ. **Can Med Assoc J** 1995 Oct 1;153(7):880. Comment in: Can Med Assoc J 1996 Jan 1;154(1):11; discussion 12–3.

Physicians say government–approved love affair with gambling sure bet to cause problems. Kezwer G. **Can Med Assoc J** 1996 Jan 1;154(1):84–8

The politics of despair: AIDS and the failure of treatment [see comments] Mackie ID. **Can Med Assoc J** 1995 Oct 1;153(7):967–8. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139; discussion 140. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139–40. Comment in: Can Med Assoc J 1996 Jan 15;154(2):140.

Gun control [letter; comment] Sobrian J. **Can Med Assoc J** 1996 Jan 1;154(1):11; discussion 12–3. Comment on: Can Med Assoc J 1995 Oct 1;153(7):879. Comment on: Can Med Assoc J 1995 Oct 1;153(7):879–80. Comment on: Can Med Assoc J 1995 Oct 1;153(7):880.

Physician job satisfaction: reversing the decline. Suchman AL. **Cleve Clin J Med** 1996 May–Jun;63(3):137–8

Canadian attitudes toward use of primary repair in management of colon trauma. A survey of 317 members of the Canadian Association of General Surgeons. Pezim ME, et al. **Dis Colon Rectum** 1996 Jan;39(1):40–4

Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy [see comments] Bremnes RM, et al. **Eur J Cancer** 1995 Nov;31A(12):1955–9 . Comment in: Eur J Cancer 1995 Nov;31A(12):1917–8.

Personal surgical experience. The impact of malignant disease on the life and practice of surgeons. Malignant myeloma and stem cell transplantation. Dunn DC. **Eur J Surg Oncol** 1995 Oct;21(5):558–60

Reactions of salaried physicians to hospital decline. Lachman R, et al. **Health Serv Res** 1996 Jun;31(2):171–90

How solo physicians view their practices. Carlson B. **Indiana Med** 1996 May–Jun;89(3):250–4

Psychological adjustment among Soviet immigrant physicians: distress and self–assessments of its sources. Factourovich A, et al. **Isr J Psychiatry Relat Sci** 1996; 33(1):32–9

The reactions of patients and doctors in the united arab emirates towards smoking. Harrison A, et al. **J Addict Dis** 1996;15(1):75–92

The nurse–doctor relationship: a selective literature review. Sweet SJ, et al. **J Adv Nurs** 1995 Jul;22(1):165–70 (41 ref.)

Do dentists and physicians advise tobacco users to quit? Tomar SL, et al. **J Am Dent Assoc** 1996 Feb;127(2):259–65

Rewards of entering podiatric medicine and attitudes toward older adults. Chumbler NR, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):288–94

Getting to GRIP with a problem [letter] Grainger C, et al. **J Epidemiol Community Health** 1996 Feb;50(1):108

Physicians' psychosocial beliefs correlate with their patient communication skills [see comments] Levinson W, et al. **J Gen Intern Med** 1995 Jul;10(7):375–9. Comment in: J Gen Intern Med 1995 Jul;10(7):411.

Triage decisions for emergency department patients with chest pain: do physicians' risk attitudes make the difference? Pearson SD, et al. **J Gen Intern Med** 1995 Oct; 10(10):557–64

Teaching an old dog new tricks [editorial; comment] Schwartz JS, et al. **J Gen Intern Med** 1995 Jun;10(6):353–4 . Comment on: J Gen Intern Med 1995 Jun;10(6):342–5.

How do medical residents discuss resuscitation with patients? Tulsky JA, et al. **J Gen Intern Med** 1995 Aug;10(8):436–42

Physicians' personal malpractice experiences are not related to defensive clinical practices [see comments] Glassman PA, et al. **J Health Polit Policy Law** 1996 Summer; 21(2):219–41. Comment in: J Health Polit Policy Law 1996 Summer;21(2):267–88.

Attitudes of referring physicians regarding total joint replacement: a preliminary report. Rankin EA, et al. **J Natl Med Assoc** 1996 Aug;88(8):506–8

The experience of psychiatric residents with disaster support: a descriptive report. Sansone RA, et al. **J Okla State Med Assoc** 1996 Jul;89(7):238–41

A piece of my mind. Do you have a minute? Gilsdorf JR. **JAMA** 1996 Feb 7;275(5):343

A piece of my mind. Haying. Squier HA. **JAMA** 1996 Jan 10;275(2):99

Attitudes of Japanese physicians towards life–sustaining treatment [letter; comment] Fair D. **Lancet** 1995 Oct 7; 346(8980):971. Comment on: Lancet 1995 Aug 5;346(8971):356–9.

I believe therefore I practise. Graham I. **Lancet** 1996 Jan 6;347(8993):4–5

Influence of physician perceptions on putting knowledge into practice. Nobel J. **Lancet** 1996 Jun 8;347(9015):1571

Attitudes of Japanese physicians towards life–sustaining treatment [letter; comment] Tanida N. **Lancet** 1995 Oct 7;346(8980):970–1. Comment on: Lancet 1995 Aug 5;346(8971):327–8. Comment on: Lancet 1995 Aug 5;346(8971):356–9.

The relationship between resource constraints and physician problem solving. Implications for improving the process of care. Lescoe–Long MA, et al. **Med Care** 1996 Sep; 34(9):931–53

Physician satisfaction with human immunodeficiency virus type 1 and hepatitis B virus testing in San Diego County. Rau J, et al. **Med Care** 1996 Jan;34(1):1–10

Physicians and grief: a paradigm shift. Dunstone DC. **Mich Med** 1995 Nov;94(11):15–7

Attitudes of physicians regarding physician–assisted suicide. Reisner M, et al. **N J Med** 1995 Oct;92(10):663–6

The best of health to you doctor. O'Hagan J. **N Z Med J** 1996 Jul 26;109(1026):280–2

AIDS physicians find support in the trenches [news] Kedar I. **Nat Med** 1996 Feb;2(2):140

Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Krauss GL, et al. **Neurology** 1996 Jun;46(6):1534–9

A pediatrician's view: anyone for a game of bridge? [letter] Austin G. **Pediatr Ann** 1995 Oct;24(10):503, 518, 530

An initial evaluation of work fatigue and circadian changes as assessed by multiplate posturography. Kohen–Raz R, et al. **Percept Mot Skills** 1996 Apr;82(2):547–57

A reason to choose medicine [letter; comment] McKinley RA. **Pharos** 1995 Fall;58(4):36. Comment on: Pharos 1995 Summer;58(3):38–42.

The silent observer [letter] [published erratum appears in Plast Reconstr Surg 1996 Feb;97(2):501] Gonzales K. **Plast Reconstr Surg** 1995 Oct;96(5):1232–3

Narrowing the gray zone. How clinical practice guidelines can improve the decision–making process [editorial] Larsen RR. **Postgrad Med** 1996 Aug;100(2):17–8, 23–4

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.). Comment on: Prev Med 1995 Nov;24(6):546–2.

Death anxiety, locus of control, and purpose in life of physicians. Their relationship to patient death notification. Viswanathan R. **Psychosomatics** 1996 Jul–Aug;37(4):339–45

Doctors also suffer when giving bad news to cancer patients. Espinosa E, et al. **Support Care Cancer** 1996 Jan;4(1):61–3

The development of a successful neurosurgical practice. Maroon JC. **Surg Neurol** 1995 Oct;44(4):402

Comparative medicine [letter] Thurston DW. **Vet Rec** 1995 Jul 15;137(3):76

The disruptive–abusive physician: a new look at an old problem. Benzer DG, et al. **Wis Med J** 1995;94(8):455–60

Florida physician and nurse education and practice related to domestic violence. Carbonell JL, et al. **Womens Health Issues** 1995 Winter;5(4):203–7

[How physicians evaluate the activity of Czech health insurance companies (editorial)] Hájek M. **Rozhl Chir** 1996 Jan;75(1):3–4 **(Cze)**

[Motivation for preventive care] Honzák R, et al. **Sb Lek** 1995;96(2):131–6 (Eng. Abstr.) **(Cze)**

[Active euthanasia in newborn infants with spina bifida? (letter)] Molenaar JC. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):801–2 **(Dut)**

[Attitudes of French cardiologists towards smoking] Tessier JF, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):341–7 (Eng. Abstr.) **(Fre)**

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

[Fellowship among physicians] Mumenthaler M. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29–30):899–903 (Eng. Abstr.) **(Ger)**

[Can we determine attitudes towards "right to die" among Israeli doctors?] Ishay R. **Harefuah** 1996 Feb 15; 130(4):288–91 **(Heb)**

[Physicians and the mass media. Opinion of physicians on the coverage of medicine, health policy and the medical profession by the mass media] Hofoss D, et al.

Tidsskr Nor Laegeforen 1996 Jan 20;116(2):270–4 (Eng. Abstr.) **(Nor)**

[Attitude of Norwegian physicians to homeopathy] Nessa J. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2149–50 **(Nor)**

[Attitudes of Norwegian physicians to homeopathy. A questionnaire among 2 019 physicians on their cooperation with homeopathy specialists] Pedersen EJ, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2186–9 (Eng. Abstr.) **(Nor)**

[Physicians' view on drug therapy for hypertension. A questionnaire in the county of Hordaland] Smiseth OA, et al. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1588–90 (Eng. Abstr.) **(Nor)**

[Evolution in consumption of and attitude towards tobacco towards physicians at the regional hospital "Reina Sofia," Córdoba] Mengual Luque P, et al. **Gac Sanit** 1996 Jan–Feb; 10(52):18–24 (32 ref.) (Eng. Abstr.) **(Spa)**

[Anesthesia preferences among the medical population (letter)] Isla–Baranda A, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):117 **(Spa)**

[Facing death requires maturity and courage (letter)] Bring G. **Lakartidningen** 1996 Jan 31;93(5):339 **(Swe)**

[Physician—cure thyself! (letter)] Häggblom H. **Lakartidningen** 1995 Nov 22;92(47):4405 **(Swe)**

[A better life for physicians is desirable (letter)] Hasselgren G. **Lakartidningen** 1996 Apr 3;93(14):1315 **(Swe)**

[Disagreement among physicians about active euthanasia. 245 answers from a Swedish questionnaire reflect uncertainty] Nilstun T, et al. **Lakartidningen** 1996 Apr 3;93(14):1350–1 **(Swe)**

[Rehabilitation of physicians with cooperation problems (letter)] Nyström S. **Lakartidningen** 1995 Nov 1;92(44):4078 **(Swe)**

[Physicians at the top security criminal institution in the country. Feeling of safety may rapidly turn to fear] Orn P. **Lakartidningen** 1996 Mar 20;93(12):1084–6 **(Swe)**

[4000 physicians answered a health status questionnaire. Physicians' mental health is worse compared to general population] Orn P. **Lakartidningen** 1996 Jan 31;93(5):317 **(Swe)**

STANDARDS

Reporting poorly performing doctors may seem an expensive waste of time [letter] **BMJ** 1996 Jan 20;312(7024):187

Seriously deficient professional performance [editorial] Brearley S. **BMJ** 1996 May 11;312(7040):1180–1

Choosing tomorrow's doctors [editorial] Goldbeck–Wood S. **BMJ** 1996 Aug 10;313(7053):313

Performance procedures for seriously deficient professional performance are flawed [letter] Simanowitz A. **BMJ** 1996 Aug 31;313(7056):562

Physicians. Public Citizen names names [news] **Hosp Health Netw** 1996 May 5;70(9):11

Physicians ... California has taken a step to eliminate credentialing application hassles for its doctors [news] **Hosp Health Netw** 1996 Jul 20;70(14):13

Physician–drug company conflict of interest. Patterson WB, et al. **J Clin Oncol** 1996 Jan;14(1):316–20

Living up to our responsibility: the minority physician in the underserved community. Veal YS. **J Natl Med Assoc** 1996 Jun;88(6):338–40

Dealing with duffers [letter; comment] Campbell LM, et al. **Lancet** 1995 Oct 28;346(8983):1164. Comment on: Lancet 1995 Sep 16;346(8977):720.

GMC revises guidelines [news] Clark S. **Lancet** 1995 Oct 21;346(8982):1092

Dealing with duffers [letter; comment] Goodman NW. **Lancet** 1995 Nov 25;346(8987):1431–2. Comment on: Lancet 1995 Sep 16;346(8977):720.

The incompetent doctor: the remedy. Medical (Professional Performance) Act 1995. Samuels A. **Med Leg J** 1996;64 (Pt 2):83–90

A meta–analysis of nurse practitioners and nurse midwives in primary care. Brown SA, et al. **Nurs Res** 1995 Nov–Dec; 44(6):332–9

Preferences of parents for pediatric emergency physicians' attire. Gonzalez Del Rey JA, et al. **Pediatr Emerg Care** 1995 Dec;11(6):361–4

[Improvement in the system of checking and assessing the physical fitness of military physicians] Dergachev VB, et al. **Voen Med Zh** 1995 Sep;(9):4–7, 80 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Belgium: an overview of physician manpower policy issues. De Graeve D, et al. **Cah Sociol Demogr Med** 1995 Oct–Dec; 35(3–4):209–20

Denmark: demography of doctors. Hansen MK. **Cah Sociol Demogr Med** 1995 Oct–Dec;35(3–4):221–6

Comparison of activity level and service intensity of male and female physicians in five fields of medicine in Ontario [see comments] Woodward CA, et al. **Can Med Assoc J** 1995 Oct 15;153(8):1097–106. Comment in: Can Med Assoc J 1996 Feb 1;154(3):303. Comment in: Can Med Assoc J 1996 Feb 15;154(4):446; discussion 446, 448.

Recognition and management of teething diarrhea among Florida pediatricians. Coreil J, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):591–8

Physician attitudes toward pharmaceutical sales representatives. Andaleeb SS, et al. **Health Care Manage Rev** 1995 Summer;20(3):68–76

New York City physicians serving high volumes of Medicaid children: who are they and how do they practice? Fairbrother G, et al. **Inquiry** 1995 Fall;32(3):345–52

Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. Lieberman JR, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):835–8

The perceptions of African–American physicians concerning their treatment by managed care organizations [editorial] Lavizzo–Mourey R, et al. **J Natl Med Assoc** 1996 Apr; 88(4):210–4

Aggression against doctors [letter] Stark MM, et al. **J R Soc Med** 1996 May;89(5):300

Retirement of senior physicians in rural Minnesota. Factors influencing physicians' plans to retire. Lee J, et al. **Minn Med** 1995 Dec;78(12):21–5

Life after medical practice. A retirement profile of Minnesota physicians. Seim HC, et al. **Minn Med** 1995 Dec; 78(12):27–30

Attitudes of Michigan physicians and the public toward legalizing physician–assisted suicide and voluntary euthanasia [see comments] Bachman JG, et al. **N Engl J Med** 1996 Feb 1;334(5):303–9. Comment in: N Engl J Med 1996 Aug 15;335(7):518; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):518–9; discussion 519–20.

Legalizing assisted suicide—views of physicians in Oregon [see comments] Lee MA, et al. **N Engl J Med** 1996 Feb 1;334(5):310–5. Comment in: N Engl J Med 1996 Aug 15;335(7):518; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):518–9; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):519; discussion 519–20.

A report card on the physician work force in the United States [see comments] Rivo ML, et al. **N Engl J Med** 1996 Apr 4;334(14):892–6. Comment in: N Engl J Med 1996 Apr 4;334(14):916–7. Comment in: N Engl J Med 1996 Aug 22;335(8):598; discussion 598–9.

Enough already? The training of new EP and pacing physicians. Nickelson DE, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2094–5

[France: the spirit of laws or the uncertain number of physicians] Ha Doan BD. **Cah Sociol Demogr Med** 1995 Oct–Dec;35(3–4):269–78 **(Fre)**

[Adverse drug effect notifications by nurses and comparison with cases reported by physicians] Sacilotto K, et al. **Therapie** 1995 Sep–Oct;50(5):455–8 (Eng. Abstr.) **(Fre)**

[Endangering health by smoking. Results of an English long–term study] Vogel S. **Med Monatsschr Pharm** 1996 Jun;19(6):164–7 **(Ger)**

[The number of physicians in Hungary 1841–1989] Kapronczay K. **Orv Hetil** 1996 Feb 25;137(8):422–4 **(Hun)**

[Factors associated with medical productivity] Arredondo A. **Educ Med Salud** 1995 Apr–Jun;29(2):174–88 **(Spa)**

SUPPLY & DISTRIBUTION

Mandatory national health service in the United States: no panacea for improving physician mix and distribution. Gellert GA. **Acad Med** 1996 Jan;71(1):10–2

Will competition change the physician workforce? Early signals from the market. Schwartz AL. **Acad Med** 1996 Jan;71(1):15–22

Rural health care [letter; comment] Howe RK. **Arch Fam Med** 1995 Nov;4(11):917–8. Comment on: Arch Fam Med 1994 Feb;3(2):119–21.

US physician manpower needs. Generalists and specialists: achieving the balance [see comments] Dalen JE. **Arch Intern Med** 1996 Jan 8;156(1):21–4. Comment in: Arch Intern Med 1996 Jun 24;156(12):1354.

uS has oversupply of doctors [news] Charatan FB. **BMJ** 1996 Feb 3;312(7026):269

Too many doctors, and more on the way [news] Roberts J. **BMJ** 1996 Apr 6;312(7035):868

More doctors needed at scene of emergencies [news] Warden J. **BMJ** 1996 Aug 31;313(7056):509

Sweden: recent developments in physician manpower. Calltorp J. **Cah Sociol Demogr Med** 1995 Oct–Dec; 35(3–4):379–87

Canadian physicians considering a move to US can face complicated immigration process. Chang HJ. **Can Med Assoc J** 1995 Oct 15;153(8):1167–8

Sex differences among physicians in rural practice [letter; comment] Peloso PM. **Can Med Assoc J** 1996 Feb 1; 154(3):303. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

In Italy, a medical degree often means unemployment or underemployment. Thorne S. **Can Med Assoc J** 1996 Mar 15;154(6):889–90

Pathologists: supply and demand [letter; comment] West R. **Can Med Assoc J** 1995 Dec 15;153(12):1710–1. Comment on: Can Med Assoc J 1995 Sep 15;153(6):805–8.

Physician supply for the next generation: deluge or deprivation? [letter] Eleff M. **Health Aff (Millwood)** 1995 Fall;14(3):280

Managing the physician workforce: hands off, the market is working. Foreman S. **Health Aff (Millwood)** 1996 Summer;15(2):243–9

The physician workforce delusion [letter] Woolhandler S, et al. **Health Aff (Millwood)** 1995 Fall;14(3):279

Provision of health care services in Austria. A time series approach. Radosch U. **Health Econ** 1995 Nov–Dec; 4(6):479–83

Physician impact on hospital admission and on mortality rates in the Medicare population. Krakauer H, et al. **Health Serv Res** 1996 Jun;31(2):191–211

Are doctors a dime a dozen? [news] **Hosp Health Netw** 1995 Nov 20;69(22):15

Physicians. Help wanted. **Hosp Health Netw** 1996 Jun 20; 70(12):62

Who's going to suffer? MacPherson P. **Hosp Health Netw** 1996 Jan 5;70(1):25

Statewide medical education in Indiana. Lukemeyer GT, et al. **Indiana Med** 1996 May–Jun;89(3):264–70

Physician service to the underserved: implications for affirmative action in medical education. Cantor JC, et al. **Inquiry** 1996 Summer;33(2):167–80

Matching physician supply and requirements: testing policy recommendations. Politzer RM, et al. **Inquiry** 1996 Summer;33(2):181–94

Physician–scientists as missing persons. Association of Subspecialty Professors. Neilson EG, et al. **J Investig Med** 1995 Dec;43(6):534–42

Unemployed doctors: a challenge to the medical profession? Riska E. **J R Soc Med** 1996 Jul;89(7):382–4

Canadian physician supply. Watanabe M. **J R Soc Med** 1995; 88 Suppl 26:49–51; discussion 52–5

Perspectives on the physician workforce to the year 2020 [see comments] Cooper RA. **JAMA** 1995 Nov 15; 274(19):1534–43. Comment in: JAMA 1995 Nov 15;274(19):1558–60. Comment in: JAMA 1996 Mar 6;275(9):685–6.

The shifting sands of graduate medical education. Dunn MR, et al. **JAMA** 1996 Sep 4;276(9):710–3

Domestic production vs international immigration: Options for the US physician workforce. Kindig DA, et al. **JAMA** 1996 Sep 25;276(12):978–82

Migrating docs: studying physician practice location [letter; comment] Konrad TR, et al. **JAMA** 1995 Dec 27; 274(24):1914. Comment on: JAMA 1995 Sep 6;274(9):685–91.

From the Institute of Medicine. Lohr KN, et al. **JAMA** 1996 Mar 13;275(10):748

Gastroenterology workforce modeling. Meyer GS, et al. **JAMA** 1996 Sep 4;276(9):689–94

Employment status of physicians completing training [letter] Pendergrass HP. **JAMA** 1996 Jul 24–31;276(4):281–2

Physician workforce projections: too many or just right? [letter; comment] Politzer RM, et al. **JAMA** 1996 Mar 6; 275(9):685–6. Comment on: JAMA 1995 Nov 15;274(19):1534–43.

Graduate medical education and physician supply in New York State. Salsberg ES, et al. **JAMA** 1996 Sep 4; 276(9):683–8

Changes in marketplace demand for physicians: a study of medical journal recruitment advertisements. Seifer SD, et al. **JAMA** 1996 Sep 4;276(9):695–9

The evolution of divergences in physician supply policy in Canada and the United States. Sullivan RB, et al. **JAMA** 1996 Sep 4;276(9):704–9

Employment status of physicians completing training [letter] Sunshine JH, et al. **JAMA** 1996 Jul 24–31;276(4):281–2

Estimating physician workforce requirements. The devil is in the assumptions [editorial; comment] Tarlov AR. **JAMA** 1995 Nov 15;274(19):1558–60. Comment on: JAMA 1995 Nov 15;274(19):1534–43.

Cuban doctors in South Africa [letter] Pick WM. **Lancet** 1996 May 25;347(9013):1488

Cuban doctors in South Africa [letter] Shisana O. **Lancet** 1996 May 25;347(9013):1488

Minority physicians serving in rural National Health Service Corps sites. Pathman DE, et al. **Med Care** 1996 May; 34(5):439–54

Doctors in health care: can we determine the right numbers? Douglas RM. **Med J Aust** 1995 Sep 18;163(6):322–3

Australian medical schools intake: threats to student numbers. Leeder SR. **Med J Aust** 1995 Sep 18;163(6):324–5

Forecasting physician workforce requirements in Minnesota. Priester R, et al. **Minn Med** 1995 Oct;78(10):21–8

Unemployed physicians [letter; comment] Cooper RA. **N Engl J Med** 1996 Feb 22;334(8):541–2. Comment on: N Engl J Med 1995 Oct 12;333(15):979–83. Comment on: N Engl J Med 1995 Oct 19;333(16):1086–7.

The physician work force in the United States [letter; comment] Knapp RM. **N Engl J Med** 1996 Aug 22; 335(8):598; discussion 598–9. Comment on: N Engl J Med 1996 Apr 4;334(14):916–7.

The role of black and Hispanic physicians in providing health care for underserved populations [see comments] Komaromy M, et al. **N Engl J Med** 1996 May 16; 334(20):1305–10. Comment in: N Engl J Med 1996 May 16;334(20):1327–8.

The physician work force in the United States [letter; comment] Martz EW. **N Engl J Med** 1996 Aug 22; 335(8):598; discussion 598–9. Comment on: N Engl J Med 1996 Apr 4;334(14):892–6.

Graduate medical education and water in the soup [editorial; comment] [see comments] Mullan F. **N Engl J Med** 1996 Apr 4;334(14):916–7. Comment on: N Engl J Med 1996 Apr 4;334(14):892–6. Comment in: N Engl J Med 1996 Aug 22;335(8):598; discussion 598–9.

A report card on the physician work force in the United States [see comments] Rivo ML, et al. **N Engl J Med** 1996

Apr 4;334(14):892–6. Comment in: N Engl J Med 1996 Apr 4;334(14):916–7. Comment in: N Engl J Med 1996 Aug 22;335(8):598; discussion 598–9.

Diversity in medicine [editorial; comment] Steinbrook R. **N Engl J Med** 1996 May 16;334(20):1327–8. Comment on: N Engl J Med 1996 May 16;334(20):1305–10.

Loss of specialists hurts research [editorial] Culliton BJ. **Nat Med** 1996 Jul;2(7):721

Supply and demand. Caudill CC. **Nebr Med J** 1996 Jul; 81(7):181–2

Surplus of physicians [letter] Chouinard J. **Postgrad Med** 1996 Aug;100(2):54

Surplus of physicians [letter] Edmunds WP. **Postgrad Med** 1996 Aug;100(2):53–4

Do we really have a doctor glut? Or is it a question of guiding students to where they're needed? [editorial] Setness PA. **Postgrad Med** 1996 May;99(5):15–7, 20–1

Future physician requirements: generalists and specialists—shortage or surplus. Friedenberg RM. **Radiology** 1996 Jul;200(1):45A–47A

Too many radiologists? Update. Janower ML, et al. **Radiology** 1996 Aug;200(2):545–9

From a Bill to a Sir: Sir Raymond Hoffenberg [interview by Ina van der Linde] Hoffenberg R. **S Afr Med J** 1996 Mar;86(3):283–4

Coming the Cubans [news] van der Linde I. **S Afr Med J** 1996 Jan;86(1):15–6

The overprotection of neurosurgeons jeopardizes future neurosurgical care. Stranjalis G. **Surg Neurol** 1996 Apr; 45(4):314–9

Physician work force in Texas: planning for the future. Guckian JC, et al. **Tex Med** 1995 Nov;91(11):50–7

Strategies to achieve balance in the physician workforce. Cooper RA. **Trans Am Clin Climatol Assoc** 1994; 106:188–200; discussion 200–2

[Geographical distribution of physicians in Chile] Goic A. **Rev Med Chil** 1995 Mar;123(3):306–11 (Eng. Abstr.) **(Spa)**

[Development of traditional careers at new universities. The case of medicine] Goic A. **Rev Med Chil** 1995 Jan; 123(1):99–107 (Eng. Abstr.) **(Spa)**

[How many neurologists should work in a district hospital?] Fossas P. **Rev Neurol** 1995 Jan–Feb;23(119):230 **(Spa)**

[How many neurologists should work in a district hospital?] Goberna E. **Rev Neurol** 1995 Jan–Feb;23(119):231 **(Spa)**

[How many neurologists should work in a district hospital?] Morera Guitart J. **Rev Neurol** 1995 Jan–Feb;23(119):229–30 **(Spa)**

[How many neurologists should work in a district hospital?] Parajuá JL. **Rev Neurol** 1995 Jan–Feb;23(119):228–9 **(Spa)**

[How many neurologists should work in a district hospital?] Vilar V. **Rev Neurol** 1995 Jan–Feb;23(119):231–2 **(Spa)**

TRENDS

Changes in career plans during medical training and practice: it's time to look ahead and act [editorial; comment] Dauphinee WD. **Can Med Assoc J** 1996 Apr 1; 154(7):1049–52. Comment on: Can Med Assoc J 1996 Apr 1;154(7):1035–8.

Career changes among Saskatchewan physicians [see comments] Shaw S, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1035–8. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1049–52.

The white coats are coming, the white coats are coming. Mahkorn SK. **J Med Assoc Ga** 1996 Apr;85(2):85–7

Commodity trading and PC [editorial] Asher RL. **Nebr Med J** 1996 Apr;81(4):106

["I have read about the dinosaur". How does the Italian physician keep up with the times?] Bausano G. **Recenti Prog Med** 1995 Oct;86(10):375–7 **(Ita)**

UTILIZATION

Physician use in Ontario and the United States: The impact of socioeconomic status and health status. Katz SJ, et al. **Am J Public Health** 1996 Apr;86(4):520–4

Utilization of physician resources for ambulatory care. Tataryn DJ, et al. **Med Care** 1995 Dec;33(12 Suppl):DS84–99

PHYSICIANS' ASSISTANTS see **PHYSICIAN ASSISTANTS**

PHYSICIANS' EXTENDERS see **PHYSICIAN ASSISTANTS**

PHYSICIANS, FAMILY

Diagnostic ultrasound skills for family physicians [letter; comment] Deutchman M. **Am Fam Physician** 1995 Oct; 52(5):1284, 1286. Comment on: Am Fam Physician 1995 May 1;51(6):1401, 1404.

The role of the family physician in the day care setting. Olsen CG, et al. **Am Fam Physician** 1996 Sep 15;54(4):1257–65, 1267–8 (32 ref.)

Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)

Involving family physicians in education programs for cervical cancer screening. McGregor SE, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:289–91

Maximizing the referral of older women for screening mammography. Lemkau JP, et al. **Arch Fam Med** 1996 Mar;5(3):174–8

Helping sick doctors. Stress management interventions need to be evaluated [letter; comment] Sims J, et al. **BMJ** 1996 Jun 29;312(7047):1675. Comment on: BMJ 1996 Mar 23;312(7033):722–3.

GPs' low morale [letter] Kernick D. **Br J Gen Pract** 1995 Aug;45(397):445

The role of the primary care physician in tobacco use prevention and cessation. Bal DG, et al. **CA Cancer J Clin** 1995 Nov–Dec;45(6):369–74

Meeting the challenge: providing anesthesia services in rural hospitals [editorial] [see comments] Barry AW. **Can Med Assoc J** 1995 Nov 15;153(10):1455–6. Comment in: Can Med Assoc J 1996 Feb 1;154(3):300.

Role of the general practitioner in the delivery of surgical and anesthesia services in rural western Canada [see comments] Chiasson PM, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1447–52. Comment in: Can Med Assoc J 1996 Mar 1;154(5):631–2.

Do physician–payment mechanisms affect hospital utilization? A study of Health Service Organizations in Ontario. Hutchison B, et al. **Can Med Assoc J** 1996 Mar 1;154(5):653–61

McGill–trained MD, experiment give June 20 shuttle flight strong Canadian flavour. Thirsk R. **Can Med Assoc J** 1996 Jun 15;154(12):1884–8

Nutrition guidance by primary–care physicians: perceived barriers and low involvement. Hiddink GJ, et al. **Eur J Clin Nutr** 1995 Nov;49(11):842–51

Medical students' and private family physicians' perceptions of family practice. Miller KE, et al. **Fam Med** 1996 Jan; 28(1):33–8

Reducing systematic bias in studies of general practitioners: the use of a medical peer in the recruitment of general practitioners in research. Heywood A, et al. **Fam Pract** 1995 Jun;12(2):227–31

A controlled trial of general practitioners' attitudes to patients with schizophrenia. Lawrie SM, et al. **Health Bull (Edinb)** 1996 May;54(3):201–3

Science, empathy, and the disappearing resident [letter] Dean CE. **J Clin Psychiatry** 1996 Apr;57(4):178–9

Answering clinical questions. Chambliss ML, et al. **J Fam Pract** 1996 Aug;43(2):140–4

Family medicine research in the community setting: what can we learn from successful researchers? Hueston WJ, et al. **J Fam Pract** 1996 Aug;43(2):171–6

"Window of opportunity" in managed care [letter] Pontious JM. **J Fam Pract** 1996 May;42(5):532

Questions asked by family physicians who want to serve as medical student preceptors. Sheets KJ, et al. **J Fam Pract** 1996 May;42(5):503–11

Primary care physicians' medical decision making for late–life depression. Callahan CM, et al. **J Gen Intern Med** 1996 Apr;11(4):218–25

Dividing up the turf. Generalists versus specialists [editorial] Greenfield S. **J Gen Intern Med** 1996 Apr;11(4):245–6

Improving communication between housestaff and primary care physicians [editorial; comment] Morrison J, et al. **J Gen Intern Med** 1995 Dec;10(12):702–3. Comment on: J Gen Intern Med 1995 Dec;10(12):688–90.

When does a generalist need a specialist? [editorial] Neilson EG. **J Gen Intern Med** 1996 Apr;11(4):247–8

Depression, guidelines, and reality [editorial; comment] Siegler EL. **J Gen Intern Med** 1995 Dec;10(12):699–700. Comment on: J Gen Intern Med 1995 Dec;10(2):663–70.

Frequency and impact of housestaff contact with primary care physicians [see comments] Ways M, et al. **J Gen Intern Med** 1995 Dec;10(12):688–90. Comment in: J Gen Intern Med 1996 Dec;10(12):702–3.

Delivery of care for hypertension. McInnes GT, et al. **J Hum Hypertens** 1995 Jun;9(6):429–33

General practitioners and changing scenario in drug abuse. Chowdhury JR, et al. **J Indian Med Assoc** 1995 Apr; 93(4):155–6

Chiropractic referral: the views of a group of conventional medical practitioners with an interest in unconventional therapies. Jamison JR. **J Manipulative Physiol Ther** 1995 Oct;18(8):512–8

Do general practitioners influence the uptake of breast cancer screening? Majeed FA, et al. **J Med Screen** 1995; 2(3):119–24

A piece of my mind. Ashes, ashes. Massad S. **JAMA** 1995 Oct 11;274(14):1102

Medical advice for sick physicians [letter; comment] Brandon S. **Lancet** 1996 Jun 1;347(9014):1559. Comment on: Lancet 1996 Apr 20;347(9008):1059.

Death of the personal doctor. McCormick J. **Lancet** 1996 Sep 7;348(9028):667–8

Medical advice for sick physicians [letter; comment] Waldron HA. **Lancet** 1996 Jun 1;347(9014):1558–9. Comment on: Lancet 1996 Apr 20;347(9008):1059.

Army family physician satisfaction. Blount BW, et al. **Mil Med** 1995 Oct;160(10):501–5

The role of general practitioners in mental health care: a survey of needs and problems. Falloon IR, et al. **N Z Med J** 1996 Feb 9;109(1015):34–6

The value of a family physician [letter] Treu BW. **Nat Med** 1995 Nov;1(11):1102

Can academic health centers survive health care reform? [letter] Koehing GH. **Neurosurgery** 1995 Jul;37(1):161–2

A model for connecting doctors to university based medical resources through the Internet. Vanzyl AJ, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:517–21

Doctor/pharmacist—a unique group practice [editorial] Dreyer AC, et al. **S Afr Med J** 1995 Oct;85(10):986–8

Transformation of the image of the general practitioner in the new South Africa [letter; comment] Hellenberg D. **S Afr Med J** 1995 Jul;85(7):682. Comment on: S Afr Med J 1994 Nov;84(11):718–9.

Relationships between general practitioners and specialists [letter] Rainier–Pope CR. **S Afr Med J** 1995 Aug;85(8):794

Alzheimer's disease patients and their caregivers: medical care issues for the primary care physician. Barrett JJ, et al. **South Med J** 1996 Jan;89(1):1–9

Variation in recommendations for breast and cervical cancer screening among primary care physicians in North Carolina, 1991. Herman CJ, et al. **South Med J** 1996 Jun; 89(6):583–90

An overview of internal medicine manpower: impact of the increased need for primary care physicians. Levey GS, et al. **Trans Am Clin Climatol Assoc** 1994;106:203–11; discussion 212

Survey of knowledge, attitudes and practices for tuberculosis among general practitioners. Hong YP, et al. **Tuber Lung Dis** 1995 Oct;76(5):431–5

[Diagnosis and treatment of bacterial vaginosis by general practitioners] Schmidt H, et al. **Ugeskr Laeger** 1995 Aug 7;157(32):4459–62 (Eng. Abstr.) **(Dan)**

[Should the function of general hospital physicians be standardized? (letter; comment)] Bergen JF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):106. Comment on: Ned Tijdschr Geneeskd 1995 Aug 19;139(33):1676–7. Comment on: Ned Tijdschr Geneeskd 1995 Aug 19;139(33):1697–9. **(Dut)**

[The role of general practitioners in post–occupational health care in an industrial area] Chau N, et al. **Cah Sociol Demogr Med** 1995 Jan–Mar;35(1):33–51 **(Fre)**

[The competence of family physicians in caring for dementia patients. A survey of general practitioners in Quebec] Poulin de Courval L, et al. **Can Fam Physician** 1996 Aug; 42:1496–502 (Eng. Abstr.) **(Fre)**

[Consultations with practitioners of alternative medicine] Bernstein JH, et al. **Harefuah** 1996 Jan 15;130(2):83–5, 144, 143 (Eng. Abstr.) **(Heb)**

[Improvement of communication between consultants and family practitioners: a controlled trial] Grafstein Y, et al. **Harefuah** 1995 Jul;129(1–2):20–4, 79 (Eng. Abstr.) **(Heb)**

[The family physician and the clinician (editorial)] Bonati B. **Recenti Prog Med** 1996 Apr;87(4):167–71 **(Ita)**

[Changing market for Oslo physicians. Justification for and consequences of changes in agreements] Bjørndal A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2794–7 (Eng. Abstr.) **(Nor)**

[Does the general practitioner have a place in future medicine?] Hjortdahl P. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2319–21 (Eng. Abstr.) **(Nor)**

[What does the primary care physician now about his deceased patients? A study of deaths in a group practice] Kristoffersen JE. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):869–71 (Eng. Abstr.) **(Nor)**

[The rise and fall of permanently employed physicians in primary health care (1970–2000) (letter)] Malterud K. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3182 **(Nor)**

[Is there a role for general practitioners in future medicine?] Sletnes KE. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2322–4 (Eng. Abstr.) **(Nor)**

[Rise and fall of primary care physicians with fixed salaries (1970–2000)] Strand S. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2755–6 **(Nor)**

[The role of the general practitioner in the prevention and control of modern diseases] Planojević M. **Med Pregl** 1995; 48(7–8):213–5 **(Scr)**

[What do adolescents think about their physician: a comparison between pediatricians and physicians for adults] Suris i Granell JC, et al. **An Esp Pediatr** 1996 Apr; 44(4):326–8 (Eng. Abstr.) **(Spa)**

[Primary care physicians' referrals to a mental health unit] Gamero Samino MJ, et al. **Aten Primaria** 1996 Apr 30; 17(7):445–8 (Eng. Abstr.) **(Spa)**

[Characterization of the assistance work of the general/family physician] Gérvas J, et al. **Aten Primaria** 1995 Nov 15; 16(8):501–6 **(Spa)**

[Factors conditioning absenteeism among primary care physicians] Nebot Adell C, et al. **Aten Primaria** 1996 Mar 15;17(4):257–60 (Eng. Abstr.) **(Spa)**

[Trust of primary care physicians in the reliability of the vade mecum] Nieto–Hernández T, et al. **Aten Primaria** 1996 Mar 15;17(4):247–50 (Eng. Abstr.) **(Spa)**

[Family physician's role in anorexia nervosa (letter)] Pardo Alvarez J, et al. **Aten Primaria** 1995 Sep 15;16(4):234 **(Spa)**

[Primary care research: attitude of family physicians trained at the Córdoba Teaching Unit] Ruiz Moral R, et al. **Aten Primaria** 1995 Oct 15;16(6):360–3 (Eng. Abstr.) **(Spa)**

[Concerning the denomination "family physician" (letter)] Villar Gil J. **Aten Primaria** 1996 Mar 15;17(4):303 **(Spa)**

[Treatment of hyperlipemia: opinions of primary care physicians of the La Rioja region] Brea Hernando AJ, et al. **Med Clin (Barc)** 1996 Mar 23;106(11):409–13 (Eng. Abstr.) **(Spa)**

[The primary care physician, the specialist and the internist?

Keys to a crisis. Possible answers (letter; comment)] Puras A. **Med Clin (Barc)** 1996 Mar 16;106(10):395. Comment on: Med Clin (Barc) 1995 Sep 30;105(10):374–6. **(Spa)**

ECONOMICS

Proposals for primary care remuneration: consultation or window-dressing? [letter] Yeates G. **Can Med Assoc J** 1996 Jun 1;154(11):1623–4

Physicians. Primary care paying off more [news] **Hosp Health Netw** 1996 Apr 20;70(8):16

Physicians ... primary care physicians in managed care practices still earn more than those in nonmanaged care practices [news] **Hosp Health Netw** 1995 Dec 5;69(23):13

The Multifund and outcome research. D'Souza MF. **Int J Epidemiol** 1995;24 Suppl 1:S113–8

EDUCATION

Family practice, internal medicine, and pediatrics as partners in the education of generalists. Schatz IJ, et al. **Acad Med** 1996 Jan;71(1):35–9

Genetic testing: are family physicians ready? [editorial; comment] Weber R. **Am Fam Physician** 1996 May 1; 53(6):1976, 1978. Comment on: Am Fam Physician 1996 May 1;53(6):2077–84.

Increasing the abilities of family doctors [letter] Livingston M. **Can Fam Physician** 1996 Jul;42:1293, 1295

Needs for CME in geriatrics. Part 1: Perceptions of patients and community informants. Pereles L, et al. **Can Fam Physician** 1996 Mar;42:437–45

Physicians' perceptions of and approaches to woman abuse. Does certification in family medicine make a difference? Tudiver F, et al. **Can Fam Physician** 1996 Aug;42:1475–80

Surgical care in rural Canada: training and planning for the future [editorial] Inglis FG. **Can Med Assoc J** 1995 Nov 15;153(10):1453–4

Surviving the 'heartsink' experience. Mathers NJ, et al. **Fam Pract** 1995 Jun;12(2):176–83

Change in knowledge of general practitioners during their professional careers. van Leeuwen YD, et al. **Fam Pract** 1995 Sep;12(3):313–7

An educational needs assessment of rural family physicians. Norris TE, et al. **J Am Board Fam Pract** 1996 Mar–Apr; 9(2):86–93

General practitioners and treatment of malaria–need for continuing medical education [letter] Garg M, et al. **J Assoc Physicians India** 1995 Aug;43(8):584–5

Improving residents' confidence in using psychosocial skills. Smith RC, et al. **J Gen Intern Med** 1995 Jun;10(6):315–20

An assessment of the needs of family physicians for a rheumatology Continuing Medical Educational program: results of a pilot project. Davis P, et al. **J Rheumatol** 1995 Sep;22(9):1762–5

Primary care neurologists [letter; comment] Fiedler KJ. **Neurology** 1996 Jun;46(6):1782; discussion 1783–4. Comment on: Neurology 1995 Jun;45(6):1052–61.

Physician training for patient-centered nutrition counseling in a lipid intervention trial. Ockene JK, et al. **Prev Med** 1995 Nov;24(6):563–70

Physician education and management of hypercholesterolemia and compliance issues. Drown DJ. **Prog Cardiovasc Nurs** 1995 Summer;10(3):42

Education program for general practitioners on breast and cervical cancer screening: a randomized trial. PRE.SA.GF Collaborative Group. Boissel JP, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):541–7

Continuing medical education—is it necessary for general practitioners? [letter; comment] Fehrsen GS. **S Afr Med J** 1995 Oct;85(10):1034. Comment on: S Afr Med J 1995 Jun;85(6):497–8.

Recertification for general practitioners [letter; comment] Parr GW. **S Afr Med J** 1995 Aug;85(8):785. Comment on: S Afr Med J 1995 May;85(5):392.

[Level of knowledge on neurology among primary care general physicians] Casabella B, et al. **Med Clin (Barc)** 1995 Sep 30;105(10):367–9 (Eng. Abstr.) **(Spa)**

HISTORY

[About physicians as characters in Norwegian literature] Nørstebø E. **Tidsskr Nor Laegeforen** 1995 Dec 10; 115(30):3778–83 (Eng. Abstr.) **(Nor)**

[Publicly employed physicians—war years and post-war judicial process] Schiøtz A. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3757–64 (Eng. Abstr.) **(Nor)**

[Einar Wallquist was born 100 years ago. A physician of Lapland who became king in his county] Ohman L. **Lakartidningen** 1996 Jun 19;93(25):2431–4 **(Swe)**

LEGISLATION & JURISPRUDENCE

Managed care contracting for physicians [editorial] Askanas A. **J Fam Pract** 1996 Aug;43(2):133–8

Healing the healer [letter] **Postgrad Med** 1996 Mar;99(3):70

ORGANIZATION & ADMINISTRATION

Medical student teaching and family physicians' use of time [letter] Guazzo E. **J Fam Pract** 1996 Aug;43(2):112; discussion 113

Medical student teaching and family physicians' use of time [letter] Scherger JE, et al. **J Fam Pract** 1996 Aug;43(2):112; discussion 113

Impact of medical student teaching [comment] Schwartz K. **J Fam Pract** 1996 Mar;42(3):228–9. Comment on: J Fam Pract 1996 Mar;42(3):243–9.

Impact of medical student teaching on family physicians' use of time [see comments] Vinson DC, et al. **J Fam Pract** 1996 Mar;42(3):243–9. Comment in: J Fam Pract 1996 Mar;42(3):228–9.

PSYCHOLOGY

Physicians' fears about treating anxiety disorders [letter] Carswell TW Jr. **Am Fam Physician** 1996 Apr;53(5):1521

A survey in Puglia: the attitudes and opinions of specialists, general physicians and patients on follow-up practice. G.S.Bio.Ca.M. Paradiso A, et al. **Ann Oncol** 1995;6 Suppl 2:53–6

Attitudes of Dutch general practitioners and nursing home physicians to active voluntary euthanasia and physician-assisted suicide. Onwuteaka-Philipsen BD, et al. **Arch Fam Med** 1995 Nov;4(11):951–5

New York State primary care physicians' attitudes to community pharmacists' clinical services. Bailie GR, et al. **Arch Intern Med** 1996 Jul 8;156(13):1437–41

Continuing rise in emergency admissions. GPs' low morale is contributing factor [letter] Chambers R. **BMJ** 1996 Aug 3;313(7052):302

Responding to out of hours requests for visits: a survey of general practitioner opinion. Court BV, et al. **BMJ** 1996 Jun 1;312(7043):1401–2

General practitioners' views on over the counter sales by community pharmacists [see comments] Erwin J, et al. **BMJ** 1996 Mar 9;312(7031):617–8. Comment in: BMJ 1996 Mar 9;312(7031):593–4. Comment in: BMJ 1996 Jul 13;313(7049):116.

GPs in Glasgow are in favour of primary care emergency centres [letter; comment] [see comments] O'Neil J. **BMJ** 1996 Jun 22;312(7046):1610. Comment on: BMJ 1996 Feb 10;312(7027):352–6. Comment in: BMJ 1996 Jun 22;312(7046):1553–4.

What do general practitioners want from a dermatology department? Harlow ED, et al. **Br J Dermatol** 1996 Feb; 134(2):313–8

The views of general practitioners on community carrier screening for cystic fibrosis. Boulton M, et al. **Br J Gen Pract** 1996 May;46(406):299–301

Gender differences in general practitioners at work. Chambers R, et al. **Br J Gen Pract** 1996 May; 46(406):291–93

Fear of aggression at work among general practitioners who have suffered a previous episode of aggression. Hobbs FD. **Br J Gen Pract** 1994 Sep;44(386):390–4

Epilepsy monitoring and advice recorded: general practitioners' views, current practice and patients' preferences. Ridsdale L, et al. **Br J Gen Pract** 1996 Jan; 46(402):11–4

Stress among general practitioners and their spouses: a qualitative study. Rout U. **Br J Gen Pract** 1996 Mar; 46(404):157–60

Clinical guidelines in primary care: a survey of general practitioners' attitudes and behaviour. Siriwardena AN. **Br J Gen Pract** 1995 Dec;45(401):643–7

How family influences practice of obstetrics. Do married women family physicians make different choices? Brown JB, et al. **Can Fam Physician** 1996 Jul;42:1319–26

Chronic unhappiness. Investigating the phenomenon in family practice. Ellis CG. **Can Fam Physician** 1996 Apr; 42:645–51

Clinical practice guidelines. New-to-practice family physicians' attitudes. Ferrier BM, et al. **Can Fam Physician** 1996 Mar;42:463–8

Normal people with special needs [editorial] Gibson GA. **Can Fam Physician** 1996 May;42:831–3; 839–42 **(Eng, Fre)**

Needs for CME in geriatrics. Part 2: Physician priorities and perceptions of community representatives. Pereles I, et al. **Can Fam Physician** 1996 Apr;42:632–40

Qualitative research. A personal journey [editorial] Reid AJ. **Can Fam Physician** 1996 Mar;42:389, 400 **(Eng, Fre)**

Physicians' perceptions of and approaches to woman abuse. Does certification in family medicine make a difference? Tudiver F, et al. **Can Fam Physician** 1996 Aug;42:1475–80

Current health policy initiatives and options. New-to-practice family physicians' attitudes. Woodward CA, et al. **Can Fam Physician** 1995 Dec;41:2104–11

Intimacy in the patient-physician relationship. Committee on Ethics of the College of Family Physicians of Canada. Yeo M, et al. **Can Fam Physician** 1996 Aug;42:1505–8 (4 ref.)

Female family physicians in obstetrics: achieving personal balance. Carroll JC, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1283–9

Triviality and frequency of night calls irk British GPs. Richmond C. **Can Med Assoc J** 1996 Jan 1;154(1):82–3

Anxiety and depression in general practitioners: associations with type of practice, fundholding, gender and other personal characteristics. Chambers R, et al. **Fam Pract** 1996 Apr;13(2):170–3

Constipation: a different entity for patients and doctors. Herz MJ, et al. **Fam Pract** 1996 Apr;13(2):156–9

"I know what to do, but it's not possible to do it"—general practitioners' perceptions of their ability to detect psychological distress. Howe A. **Fam Pract** 1996 Apr; 13(2):127–32

Not another questionnaire!: eliciting the views of general practitioners. MacPherson I, et al. **Fam Pract** 1995 Sep; 12(3):335–8

Surviving the 'heartsink' experience. Mathers NJ, et al. **Fam Pract** 1995 Jun;12(2):176–83

Neonatal examination and screening—survey of GP practice and opinion. Glazener CM, et al. **Health Bull (Edinb)** 1996 Jul;54(4):355–60

Trials and tribulations of country doctors: a qualitative study of doctor-patient relationships in rural Israel. Monnickendam SM, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):239–45; discussion 245–7

Physicians' attitudes toward complementary or alternative medicine: a regional survey. Berman BM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):361–6

Happy residents, happy people, or both? [editorial; comment] Frey JJ 2nd. **J Am Board Fam Pract** 1995 Sep–Oct; 8(5):418–20. Comment on: J Am Board Fam Pract 1995 Sep–Oct;8(5):367–75.

Dimensions of happiness: a qualitative study of family practice residents [see comments] Manusov EG, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):367–75. Comment in: J Am Board Fam Pract 1995 Sep–Oct;8(5):418–20.

The primary care pathway to mammography: a long and winding road [editorial; comment] Burack RC. **J Gen Intern Med** 1995 Jun;10(6):349–50. Comment on: J Gen Intern Med 1995 Jun;10(6):299–306.

Things that ring in the night [letter; comment] Casanova JE. **J Gen Intern Med** 1995 Jul;10(7):412–3. Comment on: J Gen Intern Med 1994 Oct;9(10):554–7.

Attitudes of medical students and primary care physicians regarding input of older and younger patients in medical decisions. Beisecker AE, et al. **Med Care** 1996 Feb; 34(2):126–37

Are differences in practitioners' acceptance of a quality assurance intervention related to their performance? Hargraves JL, et al. **Med Care** 1996 Sep;34(9 Suppl):SS77–86

Consistency in performance among primary care practitioners. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS52–66

The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Pathman DE, et al. **Med Care** 1996 Sep; 34(9):873–89

A comparison of US and Canadian family physician attitudes toward their respective health-care systems. Scanlan A, et al. **Med Care** 1996 Aug;34(8):837–44

General practitioner attitudes to recall systems for cervical screening [see comments] Beilby JJ, et al. **Med J Aust** 1995 Sep 4;163(5):245–8. Comment in: Med J Aust 1996 Jan 1;164(1):55.

Young physicians: taking charge in an era of change [interview by Karen Bouffard] Edelmann K. **Mich Med** 1996 May;95(5):26–9

Healing the healer [letter] **Postgrad Med** 1996 Mar;99(3):70

The cost of caring: who heals the healer? [editorial] Setness PA. **Postgrad Med** 1996 Jan;99(1):15–6, 22, 24

Barriers to providing nutrition counseling by physicians: a survey of primary care practitioners [see comments] Kushner RF. **Prev Med** 1995 Nov;24(6):546–52. Comment in: Prev Med 1995 Nov;24(6):543–5.

Access, expectations and communication: Japanese mothers' interaction with GPs in a pilot study in North London. Arai Y, et al. **Public Health** 1995 Sep;109(5):353–61

Acceptability to general practitioners of national health insurance and capitation as a reimbursement mechanism. Blecher MS, et al. **S Afr Med J** 1995 Sep;85(9):847–51

[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands (see comments)] van Riemsdijk MM, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2306–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2759. **(Dut)**

[Development in primary care does not preclude the personal physician approach] Saarelma O. **Duodecim** 1995; 111(1):26–31 **(Fin)**

[Assessment by the primary care physician of his influence on the patient's hospital choice and of his own ability to evaluate hospital quality] Gross R, et al. **Harefuah** 1995 Aug;129(3–4):90–5, 159 (Eng. Abstr.) **(Heb)**

[Job satisfaction in physicians with a career in general clinical medicine] Vieira D, et al. **Acta Med Port** 1995 Oct; 8(10):531–5 (Eng. Abstr.) **(Por)**

[The opinions of family medicine residents in Andalucía on some aspects related to their specialty (letter)] Ruiz Moral R, et al. **Aten Primaria** 1996 May 31;17(9):595–6 **(Spa)**

STANDARDS

Standardized patients as a measure of change in the ability of family physicians to detect and manage alcohol abuse. Lockyer J, et al. **Acad Med** 1996 Jan;71(1 Suppl):S1–3

Health reform and family physicians' skills. Grand'Maison P. **Can Fam Physician** 1995 Sep;41:1561–3 **(Eng, Fre)**

Ability of primary care physicians to diagnose and manage Pneumocystis carinii pneumonia. Curtis JR, et al. **J Gen Intern Med** 1995 Jul;10(7):395–9

The need for a transformation of the image of the general practitioner in the new South Africa [editorial] [see comments] Mankazana M, et al. **S Afr Med J** 1994 Nov; 84(11):718–9. Comment in: S Afr Med J 1995 Jul;85(7):682.

[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996

Jan;17(1):24–32 (21 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Primary care physician productivity: the physician factor. Smith DM, et al. **J Gen Intern Med** 1995 Sep;10(9):495–503

[Diuretics in the treatment of hypertension: critical analysis of opinions of general practitioners and cardiologists] Charansonney OL, et al. **Therapie** 1996 Jan–Feb; 51(1):49–55 (Eng. Abstr.) **(Fre)**

SUPPLY & DISTRIBUTION

The effect of a medical school's admission and curriculum policies on increasing the number of physicians in primary care specialties. Barnhart J, et al. **Acad Med** 1996 Mar; 71(3):293–5

Special article: increasing the number of generalist physicians—a new regulatory paradigm. Mirvis DM. **Am J Med Sci** 1995 Dec;310(6):247–51

The challenge of defining and counting generalist physicians: an analysis of Physician Masterfile data. Grumbach K, et al. **Am J Public Health** 1995 Oct;85(10):1402–7

A physician workforce for the 21st century. Cooper RA. **Ann Thorac Surg** 1995 Nov;60(5):1541–6 (10 ref.)

Crisis in recruitment [letter] Thistlewaite JE, et al. **Br J Gen Pract** 1996 Apr;46(405):254–5

Need for GP anesthetists [letter; comment] Kearney RA, et al. **Can Med Assoc J** 1996 Feb 1;154(3):300. Comment on: Can Med Assoc J 1995 Nov 15;153(10):1455–6.

Where have all the primary care physicians gone? A Socratic discourse. Meighan SS. **Health Care Manage Rev** 1995 Summer;20(3):64–7

Factors influencing retention of rural Pennsylvania family physicians [see comments] Forti EM, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):469–74. Comment in: J Am Board Fam Pract 1995 Nov–Dec;8(6):496–9.

Recruitment and retention of rural physicians: how much progress have we made? [editorial; comment] Rabinowitz H. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):496–9. Comment on: J Am Board Fam Pract 1995 Nov–Dec;8(6):469–74.

Quality of the family physician component of AMA Masterfile. Williams PT, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):94–9

Projections of the future supply of family physicians in Connecticut: a basis for regional planning. Douglass AB. **J Fam Pract** 1995 Nov;41(5):451–5

Medicare costs in urban areas and the supply of primary care physicians [see comments] Mark DH, et al. **J Fam Pract** 1996 Jul;43(1):33–9. Comment in: J Fam Pract 1996 Jul;43(1):30–2.

Balancing primary versus specialty care [see comments] Shi L. **J R Soc Med** 1995 Aug;88(8):428–32 (62 ref.). Comment in: J R Soc Med 1995 Aug;88(8):425.

Counting generalist physicians [letter; comment] Bennett MD. **JAMA** 1996 May 22–29;275(20):1544–5. Comment on: JAMA 1994 May 18;271(19):1505–7. Comment on: JAMA 1994 Sep 7;272(9):680–7.

Projections for the generalist physician workforce [letter; comment] Kindig DA. **JAMA** 1995 Dec 20;274(23):1833; discussion 1834. Comment on: JAMA 1995 Sep 6;274(9):692–5.

Projections for the generalist physician workforce [letter; comment] Petersdorf RG. **JAMA** 1995 Dec 20; 274(23):1833–4. Comment on: JAMA 1995 Sep 6;274(9):692–5.

Competition, professional synergism, and the geographic distribution of rural physicians. Connor RA, et al. **Med Care** 1995 Nov;33(11):1067–78

Lessons from Pogo. McCabe WP. **Mich Med** 1996 May; 95(5):64

UTILIZATION

Consumer use of multiple general practitioners: an Australian epidemiological study. Veale BM, et al. **Fam Pract** 1995 Sep;12(3):303–8

The sex of the general practitioner: a comparison of characteristics, patients, and medical conditions managed. Britt H, et al. **Med Care** 1996 May;34(5):403–15

Primary care physicians in underserved areas. Family physicians dominate. Burnett WH, et al. **West J Med** 1995 Dec;163(6):532–6

PHYSICIANS' OFFICES

Computer-based patient education: observations on effective communication in the clinical setting. Sechrest RC, et al. **J Biocommun** 1996;23(1):8–12

LEGISLATION & JURISPRUDENCE

Cutting red tape on clinical labs: why Congress should deregulate doctors. Mahkorn S. **J Ark Med Soc** 1995 Nov; 92(6):283–91

Consider implications of handgun prohibition [letter] Restrepo R. **Tex Med** 1996 Jun;92(6):7

ADA is changing the way physicians practice medicine. Barratt K, et al. **Wis Med J** 1996 Jan;95(1):54–6

UTILIZATION

Patient's choice of hospital or office for Medicaid ambulatory care in Alabama. Bronstein JM, et al. **Med Care** 1996 Apr; 34(4):348–60

PHYSICIAN'S PRACTICE PATTERNS

Obtaining previous mammograms for comparison [letter; comment] Logan-Young WW, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):989. Comment on: AJR Am J Roentgenol 1995 Aug;165(2):488.

The sex ratio of American radiologists: comparison and implications by age, subspecialty, and type of practice. Owen JB, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1337–41

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)

Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). Zuanetti G, et al. **Am J Cardiol** 1996 Jul 15;78(2):153–7

Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Fendrick AM, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1544–8

Breast cancer surveillance: ambulatory care focus in residency may influence practice patterns. Borum ML. **Am J Med Sci** 1996 Sep;312(3):123–5

Getting physicians to change their practices. Wallace KG. **Am J Nurs** 1996 Feb;96(2):20

Evidence-based practice in obstetrics and gynecology: its time has come [letter; comment] King JC, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):232–3. Comment on: Am J Obstet Gynecol 1995 Nov;173(5):1452–60.

Differences in practice patterns between obstetricians and family physicians: use of serum screening. Yankowitz J, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1361–5

Physician recognition of hypercholesterolemia in patients undergoing peripheral and carotid artery revascularization. Aspry KE, et al. **Am J Prev Med** 1995 Sep–Oct; 11(5):336–41

Reported treatment of hypercholesterolemia by family physicians in Sweden and Minnesota. Troein M, et al. **Am J Prev Med** 1995 Sep–Oct;11(5):324–8

Prevalence and detection of HIV risk behavior in primary care: implications for clinical preventive services. Ward J, et al. **Am J Prev Med** 1995 Jul–Aug;11(4):224–30

Breast cancer evaluation and follow-up: a survey of The Ohio Chapter of The American College of Surgeons. Stark ME, et al. **Am Surg** 1996 Jun;62(6):458–60

Changing anesthesiologists' practice patterns. Can it be done? Cohen MM, et al. **Anesthesiology** 1996 Aug;85(2):260–9

Electrocardiogram ordering practices among anesthesiologists [letter] McKinley AC, et al. **Anesthesiology** 1996 Jan;84(1):240–1

Do physicians' beliefs about coronary risk factors account for poor screening and treatment rates? Meyers DG, et al. **Angiology** 1996 Aug;47(8):783–7

The impact of managed care formularies on the practice of allergy-immunology [editorial] Storms WW. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):4–5

Emergency medicine clinical guidelines: we can make them, but will we use them? [editorial; comment] Schriger DL. **Ann Emerg Med** 1996 May;27(5):655–7. Comment on: Ann Emerg Med 1996 May;27(5):606–9.

ACEP chest pain policy: emergency physician awareness [see comments] Wigder HN, et al. **Ann Emerg Med** 1996 May; 27(5):606–9. Comment in: Ann Emerg Med 1996 May;27(5):655–7.

Characteristics of physicians with participatory decision-making styles [see comments] Kaplan SH, et al. **Ann Intern Med** 1996 Mar 1;124(5):497–504. Comment in: Ann Intern Med 1996 Mar 1;124(5):511–3.

Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes [see comments] Krumholz HM, et al. **Ann Intern Med** 1996 Feb 1;124(3):292–8. Comment in: Ann Intern Med 1996 Feb 1;124(3):335–8.

Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)

Drug use in the nursing home [letter] Tolle SW, et al. **Ann Intern Med** 1996 Mar 15;124(6):616

Changing physician behavior in ordering digoxin assays. Fraser GL, et al. **Ann Pharmacother** 1996 May;30(5):449–54

National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Janes RH Jr, et al. **Ann Surg** 1996 Mar;223(3):261–72

Post-treatment management options for patients with lung cancer. Virgo KS, et al. **Ann Surg** 1995 Dec;222(6):700–10

Surveillance after curative colon cancer resection: practice patterns of surgical subspecialists [see comments] Virgo KS, et al. **Ann Surg Oncol** 1995 Nov;2(6):472–82. Comment in: Ann Surg Oncol 1995 Nov;2(6):467–8.

Lack of correlation between internists' ability in dermatology and their patterns of treating patients with skin disease. Kirsner RS, et al. **Arch Dermatol** 1996 Sep;132(9):1043–6

Dermatologists in Kaiser Permanente-northern California. Satisfaction, perceived constrains, and policy options. Weinberg DJ, et al. **Arch Dermatol** 1996 Sep;132(9):1057–63

What influences physician practice behavior? [editorial; comment] Jogerst GJ, et al. **Arch Fam Med** 1996 Sep; 5(9):455–6. Comment on: Arch Fam Med 1996 Sep;5(9):448–54.

Medical decision making and perceived socioeconomic class. Kikano GE, et al. **Arch Fam Med** 1996 May;5(5):267–70

Bronchodilators and antibiotics in the treatment of acute bronchitis [editorial; comment] King DE. **Arch Fam Med** 1996 Feb;5(2):86. Comment on: Arch Fam Med 1996 Feb;5(2):79–83.

Current management of acute bronchitis in ambulatory care: The use of antibiotics and bronchodilators [see comments] Mainous AG 3rd, et al. **Arch Fam Med** 1996 Feb;5(2):79–83 . Comment in: Arch Fam Med 1996 Feb;5(2):84–5. Comment in: Arch Fam Med 1996 Feb;5(2):86.

Treatment of acute bronchitis: there's much work to be done [editorial; comment] Williamson HA Jr. **Arch Fam Med** 1996 Feb;5(2):84–5. Comment on: Arch Fam Med 1996 Feb;5(2):79–83.

As mammography use increases, are some providers omitting clinical breast examination? Burns RB, et al. **Arch Intern Med** 1996 Apr 8;156(7):741–4

Response to DCCT: how sweet is it? [letter; comment] Maher JC. **Arch Intern Med** 1995 Dec 11–25;155(22):2481, 2485 . Comment on: Arch Intern Med 1995 Apr 10;155(7):665–7.

Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Schlicht JR, et al. **Arch Intern Med** 1996 Feb 12;156(3):290–4

From research to public health interventions. I. Impact of an educational strategy for physicians to improve treatment practices of common diseases. Guiscafre H, et al. **Arch Med Res** 1995;26 Spec No:S31–9

Tuberculosis testing. Physician attitudes and practice. Cheng TL, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):682–5

Impact of maternal group B streptococcal screening on pediatric management in full-term newborns. Peralta-Carcelen M, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):802–8

Removable prosthodontics: a survey of practices and attitudes among South Australian dentists. Coates AJ, et al. **Aust Dent J** 1996 Jun;41(3):151–8

The provision of orthodontic services by general dental practitioners. 2. Factors influencing variation in service provision. Lawrence AJ, et al. **Aust Dent J** 1995 Dec; 40(6):360–4

Teaching rational prescribing. Black F. **Aust Fam Physician** 1996 Jul;25(7):1097–9

Compliance issues in adolescence: practical strategies. Blair S, et al. **Aust Fam Physician** 1995 Nov;24(11):2037–40

The index theory and the magic of medicine. Colquhoun JP. **Aust Fam Physician** 1996 Jun;25(6):978–9

Change in zidovudine prescribing practices in Australia, 1991–1993. McNulty AM, et al. **Aust N Z J Med** 1995 Jun;25(3):239–40

A study of general practitioners' reasons for changing their prescribing behaviour. Armstrong D, et al. **BMJ** 1996 Apr 13;312(7036):949–52

Use of performance indicators for general practice [letter; comment] Baker SJ. **BMJ** 1996 Jan 6;312(7022):58. Comment on: BMJ 1995 Jul 22;311(6999):209–10.

A prescribing incentive scheme for non-fundholding general practices: an observational study. Bateman DN, et al. **BMJ** 1996 Aug 31;313(7056):535–8

Over the counter drugs. GPs' rate of recommending over the counter drugs varies [letter; comment] Bradley C, et al. **BMJ** 1996 Jul 13;313(7049):115–6. Comment on: BMJ 1996 Mar 9;312(7031):629–32. Comment on: BMJ 1996 Mar 16;312(7032):688–91.

Inappropriate treatment for dysentery [editorial; comment] Cash R. **BMJ** 1996 Jul 27;313(7051):181–2. Comment on: BMJ 1996 Jul 27;313(7051):205–6.

GPs' prescribing behaviour may be affected by drug promotion [letter] Gill PS, et al. **BMJ** 1996 Aug 10; 313(7053):367

General practitioners' management of acute back pain: a survey of reported practice compared with clinical guidelines [see comments] Little P, et al. **BMJ** 1996 Feb 24;312(7029):485–8. Comment in: BMJ 1996 Jun 8;312(7044):1480. Comment in: BMJ 1996 Jun 8;312(7044):1481.

India's consumer groups call for more rational prescribing [news] Mudur G. **BMJ** 1996 Jan 13;312(7023):76

The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme [see comments] Stewart-Brown S, et al. **BMJ** 1995 Dec 9; 311(7019):1543–7. Comment in: BMJ 1996 Mar 30;312(7034):848. Comment in: BMJ 1996 Mar 30;312(7034):848–9.

Routine surgical follow up: do surgeons agree? [see comments] Waghorn A, et al. **BMJ** 1995 Nov 18; 311(7016):1344–5. Comment in: BMJ 1995 Nov 18;311(7016):1315–6.

Effects of fundholding on prescribing habits. Results of similar study in Mersey were different [letter; comment] Wilson R, et al. **BMJ** 1996 Mar 30;312(7034):848. Comment on: BMJ 1995 Dec 9;311(7019):1543–7.

Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study. Wilson RP, et al. **BMJ** 1996 Sep 7; 313(7057):595–9

Alterations in prescribing by general practitioner fundholders: an observational study [see comments] Wilson RP, et al. **BMJ** 1995 Nov 18;311(7016):1347–50. Comment in: BMJ 1996 Mar 30;312(7034):848–9. Comment in: BMJ 1996 Mar 30;312(7034):849.

Referral patterns within Scotland to specialist oncology

centres for patients with testicular germ cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists. Clarke K, et al. **Br J Cancer** 1995 Nov;72(5):1300–2

What factors influence general practitioners' commencement of hormone replacement in perimenopausal women? Larcos G. **Br J Clin Pract** 1996 Jan–Feb;50(1):6–8

Influence of sex of general practitioner on management of menorrhagia. Coulter A, et al. **Br J Gen Pract** 1995 Sep; 45(398):471–5

Influences on prescribing in non-fundholding general practices. Eccles MP, et al. **Br J Gen Pract** 1996 May; 46(406):287–90

Sharing resources to create a district drug formulary: a countywide controlled trial. Hill-Smith I. **Br J Gen Pract** 1996 May;46(406):271–75

Referral patterns and diagnosis in presenile Alzheimer's disease: implications for general practice. Newens AJ, et al. **Br J Gen Pract** 1994 Sep;44(386):405–7

Patients with urinary tract infection: proposed management strategies of general practitioners, microbiologists and urologists. Olesen F, et al. **Br J Gen Pract** 1995 Nov; 45(400):611–3

Epilepsy monitoring and advice recorded: general practitioners' views, current practice and patients' preferences. Ridsdale L, et al. **Br J Gen Pract** 1996 Jan; 46(402):11–4

Attitudes of Bolivian pharmacists in dealing with diarrhea cases. Zamora Gutiérrez AD, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):322–7

Prescribing habits of Peruvian physicians and factors influencing them. Zárate Cárdenas E, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):328–37

Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed. Godwin M, et al. **Can Fam Physician** 1996 Jul; 42:1309–16

Homeopathy's potential for enriching the medical interview. Looking beyond the tiny white pill [editorial] Lépine P. **Can Fam Physician** 1995 Oct;41:1649–51, 1658–60 **(Eng, Fre)**

Sex vs gender [letter; comment] Lewans R. **Can Fam Physician** 1996 Apr;42:619–20. Comment on: Can Fam Physician 1995 Dec;41:2060–5, 2076–80.

Comparing obstetric practice patterns [letter; comment] McMurray SJ. **Can Fam Physician** 1995 Sep;41:1470, 1472 . Comment on: Can Fam Physician 1995 Apr;41:601–7.

Who provides follow-up care for patients with early breast cancer? Worster A, et al. **Can Fam Physician** 1995 Aug; 41:1314–20

Infant feeding practices: are CPS guidelines followed? Carceller A, et al. **Can J Public Health** 1995 Sep–Oct; 86(5):301–4

Geographic differences in the attitudes, knowledge and infection control practices of Ontario dentists. McCarthy GM, et al. **Can J Public Health** 1996 Mar–Apr;87(2):119–24

HIV testing practices of primary care physicians: an Ontario survey. Skotniski EM, et al. **Can J Public Health** 1996 May–Jun;87(3):172–5

Strategies for improving prescribing practice [see comments] Anderson GM, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1013–7 (38 ref.). Comment in: Can Med Assoc J 1996 Jun 1;154(11):1620.

Mobilizing physicians to conduct clinical intervention in tobacco use through a medical-association program: 5 years' experience in British Columbia [see comments] Bass F. **Can Med Assoc J** 1996 Jan 15;154(2):159–64. Comment in: Can Med Assoc J 1996 Jun 15;154(12):1834.

Do consensus conferences influence their participants? Clarfield AM, et al. **Can Med Assoc J** 1996 Feb 1; 154(3):331–6

Modifying prescribing of regulated analgesics [letter; comment] Hux JE. **Can Med Assoc J** 1996 Apr 1; 154(7):1005–6; discussion 1006–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Episiotomy results stand despite lack of compliance [letter; comment] Klein MC. **Can Med Assoc J** 1995 Dec 15; 153(12):1708–10. Comment on: Can Med Assoc J 1995 Sep 15;153(6):783–6.

Modifying prescribing of regulated analgesics [letter; comment] Murray M. **Can Med Assoc J** 1996 Apr 1; 154(7):1006; discussion 1006–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Modifying prescribing of regulated analgesics [letter] Panton WD. **Can Med Assoc J** 1996 Apr 1;154(7):1006; discussion 1006–7

Declaring pediatric brain death: current practice in a Canadian pediatric critical care unit. Parker BL, et al. **Can Med Assoc J** 1995 Oct 1;153(7):909–16

How tumor stage affects surgeons' surveillance strategies after colon cancer surgery. Johnson FE, et al. **Cancer** 1995 Oct 15;76(8):1325–9

Cervical carcinoma and pregnancy. A national patterns of care study of the American College of Surgeons. Jones WB, et al. **Cancer** 1996 Apr 15;77(8):1479–88

Oncologists and primary care physicians' attitudes toward pain control and morphine prescribing in France [see comments] Larue F, et al. **Cancer** 1995 Dec 1; 76(11):2375–82. Comment in: Cancer 1995 Dec 1;76(11):2181–5.

Survey of asthma practice among emergency physicians [see comments] Emerman CL, et al. **Chest** 1996 Mar; 109(3):708–12. Comment in: Chest 1996 Mar;109(3):594–5.

Effect of routine emergency department triage pulse oximetry screening on medical management. Mower WR, et al. **Chest** 1995 Nov;108(5):1297–302

Guidelines in need of guidance [editorial; comment] Sarwar A, et al. **Chest** 1996 Mar;109(3):594–5. Comment on: Chest 1996 Mar;109(3):708–12.

The clinical interface—a British physician's view. Neuberger J, et al. **Clin Chim Acta** 1996 Apr 15;248(1):11–8 (9 ref.)

Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S138–41 (0 ref.)

How should excess admission laboratory test utilization be curtailed? —paediatricians' preferences. Feldman BM, et al. **Clin Invest Med** 1995 Dec;18(6):502–9

The clinical use of antenatal corticosteroids. Gardner MO, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):746–54 (39 ref.)

Head injury management in the United States [letter] Cruz J. **Crit Care Med** 1996 May;24(5):897–8

A dermatologic diary. Portrait of a practice. Shelley WB, et al. **Cutis** 1995 Aug;56(2):85–92

My experience with 33 patients infected with HIV. Hadjipanayis CG, et al. **Del Med J** 1996 Feb;68(2):143–5

Practical procedures [editorial] Bax M. **Dev Med Child Neurol** 1996 May;38(5):377–8

Perioperative steroid use in colorectal patients. Results of a survey. Beck DE, et al. **Dis Colon Rectum** 1996 Sep; 39(9):995–9

Drugs for the doctor's bag—you respond [comment] **Drug Ther Bull** 1995 Jul;33(7):56. Comment on: Drug Ther Bull 1995 Jan 19;33(1):3–5.

Drugs for the doctor's bag [see comments] **Drug Ther Bull** 1995 Jan 19;33(1):3–5 (8 ref.). Comment in: Drug Ther Bull 1995 Jul;33(7):56.

Current management of breast cancer [editorial; comment] Adwok JA. **East Afr Med J** 1996 Feb;73(2):81–2. Comment on: East Afr Med J 1996 Feb;73(2):83–7.

Nutrition guidance by primary-care physicians: perceived barriers and low involvement. Hiddink GJ, et al. **Eur J Clin Nutr** 1995 Nov;49(11):842–51

Attitudes of European urologists to early prostatic carcinoma. I. Diagnostic work-up on suspected prostatic cancer cases. Hansen MV, et al. **Eur Urol** 1995;28(3):189–95

Attitudes of European urologists to early prostatic carcinoma, II. Attitude to therapy and to screening examinations. Hansen MV, et al. **Eur Urol** 1995; 28(3):196–201

A survey of corneal graft practice in the United Kingdom. Burdon MA, et al. **Eye** 1995;9 (Pt 6 Su):6–12

Managing patients [editorial] [see comments] Johnson TM. **Fam Med** 1995 Jul–Aug;27(7):460–2. Comment in: Fam Med 1995 Nov–Dec;27(10):632–3.

The validity of urine examination for urinary tract infections in daily practice. Winkens RA, et al. **Fam Pract** 1995 Sep; 12(3):290–3

Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom. Milne R, et al. **Gut** 1995 Sep;37(3):314–8

A survey of blood transfusion practices of gynecologic oncologists. Price FV, et al. **Gynecol Oncol** 1995 Oct; 59(1):45–50

A decision analysis of practice patterns used in evaluating and treating abnormal Pap smears. Roland PY, et al. **Gynecol Oncol** 1995 Oct;59(1):75–80

Effects of market reforms on doctors and their patients. Blumenthal D. **Health Aff (Millwood)** 1996 Summer; 15(2):170–84

Post-mortem rates and junior doctors in Tayside—three years after the Joint Working Party report. Inglis FG, et al. **Health Bull (Edinb)** 1995 Nov;53(6):379–85

Physician variation in the management of patients with atrial fibrillation. Lip GY, et al. **Heart** 1996 Feb;75(2):200–5

Prescribing patterns in primary health care in Taiwan. Lai MS, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):437–41

Oxytocics in developing countries. Dujardin B, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):243–51

The Dutch obstetric intervention study—variations in practice patterns. Heres MH, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):145–50

The prescription as final common pathway. Avorn J. **Int J Technol Assess Health Care** 1995 Summer; 11(3):384–90

Factors affecting pediatric residents' intentions to screen for high risk behaviors. Middleman AB, et al. **J Adolesc Health** 1995 Aug;17(2):106–12

Complementary or alternative medicine [letter] Barrett S. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):71

Effect of physician specialty on use of necessary coronary angiography [see comments] Borowsky SJ, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1484–91. Comment in: J Am Coll Cardiol 1995 Nov 15;26(6):1437–9.

Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction [see comments] Brand DA, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1432–6. Comment in: J Am Coll Cardiol 1995 Nov 15;26(6):1437–9.

Care of acute myocardial infarction by noninvasive and invasive cardiologists: procedure use, cost and outcome. Di Salvo TT, et al. **J Am Coll Cardiol** 1996 Feb;27(2):262–9

Are beta-blockers really underutilized in postinfarction patients? [editorial; comment] O'Rourke RA. **J Am Coll Cardiol** 1995 Nov 15;26(6):1437–9. Comment on: J Am Coll Cardiol 1995 Nov 15;26(6):1432–6.

Clinical decision making: what is the evidence? [editorial; comment] Parmley WW. **J Am Coll Cardiol** 1996 Mar 1; 27(3):736. Comment on: J Am Coll Cardiol 1996 Mar 1;27(3):737–50.

Physician response to dietary recommendations in long-term-care facilities. Ellis JR, et al. **J Am Diet Assoc** 1995 Dec;95(12):1424–5

Missed opportunities for intervening in the lives of pregnant women addicted to alcohol or other drugs. Gehshan S. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):160–3

Practicing refractive surgery with Food and Drug Administration restraints [editorial] Koch DD. **J Cataract Refract Surg** 1995 Nov;21(6):595

Physician coverage of therapeutic apheresis. Woll JE. **J Clin Apheresis** 1995;10(4):183–7

Predictors of chronic benzodiazepine use in a health maintenance organization sample. Simon GE, et al. **J Clin Epidemiol** 1996 Sep;49(9):1067–73

Continued prescribing of inappropriate drugs in general practice. Britten N, et al. **J Clin Pharm Ther** 1995 Aug; 20(4):199–205

Influencing the prescribing behaviour of physicians: a metaevaluation. Pippalla RS, et al. **J Clin Pharm Ther** 1995 Aug;20(4):189–98

Knowledge, attitude, practice, and prescribing pattern of oral rehydration therapy among private practitioners in Nigeria. Okeke TA, et al. **J Diarrhoeal Dis Res** 1996 Mar;14(1):33–6

Pediatrician and family physician agreement with and adoption of universal hepatitis B immunization. Freed GL, et al. **J Fam Pract** 1996 Jun;42(6):587–92

Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold? Mainous AG 3rd, et al. **J Fam Pract** 1996 Apr;42(4):357–61

Medicating the elderly [letter; comment] Schneider AP 2nd. **J Fam Pract** 1996 Apr;42(4):341–2. Comment on: J Fam Pract 1995 Oct;41(4):331–6.

Impact of medical student teaching [comment] Schwartz K. **J Fam Pract** 1996 Mar;42(3):228–9. Comment on: J Fam Pract 1996 Mar;42(3):243–9.

Impact of medical student teaching on family physicians' use of time [see comments] Vinson DC, et al. **J Fam Pract** 1996 Mar;42(3):243–9. Comment in: J Fam Pract 1996 Mar;42(3):228–9.

Using the biopsychosocial model in practice. Improving the care of patients with late-life depression [editorial] Covinsky KE, et al. **J Gen Intern Med** 1996 Apr; 11(4):249–50

When you've seen how one doctor works, you've not seen how all doctors work [editorial] Lipscomb J. **J Gen Intern Med** 1995 Sep;10(9):526–7

Announcing "from research to practice" [editorial] O'Keefe M, et al. **J Gen Intern Med** 1996 Apr;11(4):251

Teaching an old dog new tricks [editorial; comment] Schwartz JS, et al. **J Gen Intern Med** 1995 Jun;10(6):353–4 . Comment on: J Gen Intern Med 1995 Jun;10(6):342–5.

Community patterns of transdermal nicotine use and provider counseling [see comments] Swartz SH, et al. **J Gen Intern Med** 1995 Dec;10(12):656–62. Comment in: J Gen Intern Med 1995 Dec;10(12):697–9.

Management of hypertension in general practice: agreements with and variations from the British Hypertension Society guidelines. Dickerson JE, et al. **J Hum Hypertens** 1995 Oct;9(10):835–9

Experiences in case management of diarrhoea in large hospitals. Patwari AK. **J Indian Med Assoc** 1995 Jun; 93(6):243–4, 236, 242

Managed health care: fast track to the morgue. Fightlin ML. **J Med Assoc Ga** 1996 Jan;85(1):19–21

AMA and USP seek physician assistance in preventing medication errors. **J Miss State Med Assoc** 1995 Dec; 36(11):383–5

Physician responsibility in conducting genetic testing. Reilly P. **J Natl Cancer Inst Monogr** 1995;(17):59–61

Past quit smoking assistance and doctors' advice for white and African-American smokers. Hymowitz N, et al. **J Natl Med Assoc** 1996 Apr;88(4):249–52

Obesity and hypertension among African Americans: do African-American primary care providers address these conditions when secondary to primary illness? Johnson EH, et al. **J Natl Med Assoc** 1996 Apr;88(4):225–9

Treatment orientation and associated characteristics of North American academic psychiatrists. Bodkin JA, et al. **J Nerv Ment Dis** 1995 Dec;183(12):729–35

The effect of managed care on nuclear cardiology. Michnich ME, et al. **J Nucl Cardiol** 1996 Jan–Feb;3(1):65–71

Is the practice of medicine getting harder? Or am I just getting older? Jordan ML. **J Okla State Med Assoc** 1995 Sep;88(9):405–6

Pediatric pain practices: a national survey of health professionals. Broome ME, et al. **J Pain Symptom Manage** 1996 May;11(5):312–20

Cryptorchidism, pediatricians, and family practitioners: patterns of practice and referral. Steckler RE, et al. **J Pediatr** 1995 Dec;127(6):948–51

On the need for evidence-based medicine. Sackett DL, et al. **J Public Health Med** 1995 Sep;17(3):330–4 (22 ref.)

Acute stroke treatment in UK hospitals: the Stroke Association survey of consultant opinion. Lindley RI, et al. **J R Coll Physicians Lond** 1995 Nov–Dec;29(6):479–84

The growth of medical science: the lessons of Malthus. Swales JD. **J R Coll Physicians Lond** 1995 Nov-Dec; 29(6):490-501

What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? Criswell LA, et al. **J Rheumatol** 1995 May;22(5):829-35

Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. Suarez-Almazor ME, et al. **J Rheumatol** 1995 May;22(5):836-43

Reporting HIV infection in children: physician practices and perceptions. Meyer PA, et al. **J S C Med Assoc** 1995 Nov; 91(11):451-5

Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer [see comments] Plawker MW, et al. **J Urol** 1996 Feb;155(2):601-4. Comment in: J Urol 1996 Feb;155(2):610-1.

Adapting practice patterns to a managed care environment: carotid endarterectomy--a case example. Brook RH. **J Vasc Surg** 1996 May;23(5):913-7

The growing conundrum. Growth hormone treatment of the non-growth hormone deficient child [editorial; comment] Bercu BB. **JAMA** 1996 Aug 21;276(7):567-8. Comment on: JAMA 1996 Aug 21;276(7):531-7.

Quality of outpatient care: diabetes [letter; comment] Bowman MA, et al. **JAMA** 1995 Nov 22-29;274(20):1584; discussion 1585. Comment on: JAMA 1995 May 17;273(19):1503-8. Comment on: JAMA 1995 May 17;273(19):1534-7.

Quality of outpatient care: diabetes [letter; comment] Clemenson N. **JAMA** 1995 Nov 22-29;274(20):1584; discussion 1585. Comment on: JAMA 1995 May 17;273(19):1503-8. Comment on: JAMA 1995 May 17;273(19):1534-7.

Short stature and growth hormone therapy. A national study of physician recommendation patterns [see comments] Cuttler L, et al. **JAMA** 1996 Aug 21;276(7):531-7. Comment in: JAMA 1996 Aug 21;276(7):567-8.

Patients who drink alcohol: pain, pleasure, and paradox [editorial; comment] Delbanco TL. **JAMA** 1996 Mar 13; 275(10):803-4. Comment on: JAMA 1996 Mar 13;275(10):761-7. Comment on: JAMA 1996 Mar 13;797-801.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Donnelly WJ. **JAMA** 1996 Apr 24;275(16):1228; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Dougherty PJ. **JAMA** 1996 Apr 24;275(16):1227-8; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Frank RR. **JAMA** 1996 Apr 24;275(16):1228-9; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

A 47-year-old man with chronic depression [see comments] Goodwin F. **JAMA** 1996 Feb 14;275(6):479-85. Comment in: JAMA 1996 Jun 26;275(24):1883; discussion 1884. Comment in: JAMA 1996 Jun 26;275(24):1883-4. Comment in: JAMA 1996 Jun 26;275(24):1884.

Preferences for CPR and life-sustaining treatment among nursing home residents [letter; comment] Hilberman M. **JAMA** 1996 May 1;275(17):1309; discussion 1310. Comment on: JAMA 1995 Dec 13;274(22):1775-9.

What is adequate and appropriate pain treatment? [letter; comment] Jacobson L, et al. **JAMA** 1996 May 1; 275(17):1310-1. Comment on: JAMA 1995 Dec 20;274(23):1881-2.

Quality of outpatient care: diabetes [letter; comment] Joergens V, et al. **JAMA** 1995 Nov 22-29;274(20):1584-5 . Comment on: JAMA 1995 May 17;273(19):1503-8.

Choice of initial therapy for hypertension [see comments] Kaplan NM, et al. **JAMA** 1996 May 22-29;275(20):1577-80 . Comment in: JAMA 1996 May 22-29;275(20):1604-6.

Prediction of violence both art and science [news] Lamberg L. **JAMA** 1996 Jun 12;275(22):1712

Improving care near the end of life. Why is it so hard? [editorial; comment] Lo B. **JAMA** 1995 Nov 22-29; 274(20):1634-6. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

Physician-assisted suicide and euthanasia [letter; comment] Masdeu JC. **JAMA** 1996 Jul 17;276(3):196-7. Comment on: JAMA 1996 Mar 27;275(12):919-25.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Parrillo JE. **JAMA** 1996 Apr 24;275(16):1229; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

Preferences for CPR and life-sustaining treatment among nursing home residents [letter; comment] Phipps E. **JAMA** 1996 May 1;275(17):1309; discussion 1310. Comment on: JAMA 1995 Dec 13;274(22):1775-9.

Dear doctor ... regarding calcium channel blockers [letter; comment] Stryer DB, et al. **JAMA** 1996 Feb 21; 275(7):517-9. Comment on: JAMA 1995 Aug 23-30;274(8):620-5.

When physicians ask, women tell about domestic abuse and violence [news] Titus K. **JAMA** 1996 Jun 26;275(24):1863-5

Putting knowledge about change into practice. Proceedings of a conference. Kansas City, Missouri, September 26-27, 1994 [see comments] **Jt Comm J Qual Improv** 1995 Jul; 21(7):317-68. Comment in: Jt Comm J Qual Improv 1995 Oct;21(10):508-11.

Integrating behavioral and systems strategies to change clinical practice. Backer TE. **Jt Comm J Qual Improv** 1995 Jul;21(7):351-3

Involving physicians in clinical pathways: an example for perioperative knee arthroplasty. Horne M. **Jt Comm J Qual Improv** 1996 Feb;22(2):115-24

The community clinical oncology program: its effect on clinical practice [comment] Warnecke RB, et al. **Jt Comm J Qual Improv** 1995 Jul;21(7):336-9. Comment on: Jt Comm J Qual Improv 1995 Jul;21(7):347-51.

Influence of physician perceptions on putting knowledge into practice. Nobel J. **Lancet** 1996 Jun 8;347(9015):1571

Will the real Dr Doublit please stand up? [letter; comment] Wolff G. **Lancet** 1995 Sep 30;346(8979):906-7. Comment on: Lancet 1995 Aug 5;346(8971):323.

Variations in processes and structures of cardiac surgery practice. Tobler HG, et al. **Med Care** 1995 Oct;33(10 Suppl):OS43-58

Differences in work activities between private and community health centre GPs [letter; comment] Lake PB, et al. **Med J Aust** 1996 Jan 1;164(1):53-4. Comment on: Med J Aust 1995 Aug 21;163(4):187-90.

Amoxycillin-clavulanic acid prescribing remains high in the elderly despite warnings of drug-associated jaundice [letter] Parkes AJ. **Med J Aust** 1995 Oct 16;163(8):446

Helicobacter pylori: how often are eradication therapies prescribed? [letter] Parkes AJ. **Med J Aust** 1995 Sep 18; 163(6):334

Screening recommendations in general practice: a survey of graduates from different medical schools. Rolfe IE, et al. **Med J Aust** 1996 Jul 1;165(1):14-7

The practitioner, the patient, the resident, and the pharmaceutical "gift" [letter] Harlass FE, et al. **Mil Med** 1995 Sep;160(9):A10

Knowledge, attitudes, and practices of physicians regarding urinary incontinence in persons aged > or = 65 years--Massachusetts and Oklahoma, 1993. **MMWR Morb Mortal Wkly Rep** 1995 Oct 13;44(40):747, 753-4

Compliance with guidelines results in appropriate ondansetron prescribing at Christchurch Hospital. Busch AF, et al. **N Z Med J** 1996 Apr 26;109(1020):142-4

The role of general practitioners in mental health care: a survey of needs and problems. Falloon IR, et al. **N Z Med J** 1996 Feb 9;109(1015):34-6

Balancing proactive and reactive care. Gillies JC, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):15-8

Qualitative differences between urban and rural practice. Mungall IJ. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):10-2

Differential care of corneal ulcers in the community based on apparent severity. McLeod SD, et al. **Ophthalmology** 1996 Mar;103(3):479-84

A survey of the radiographic practices of general dentists for edentulous patients. Kogon S, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):365-8

Processing of adenoid and tonsil specimens in children: a national survey of standard practices and a five-year review of the experience at the Children's Hospital of Pittsburgh. Dohar JE, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):94-7

To sign, or not to sign: evaluating networks from Timbuktu. Orlowski SR. **Pa Med** 1996 Mar;99(3):10-1

Preoperative evaluation of the cervical spine in children with trisomy-21: results of a questionnaire study. Litman RS, et al. **Paediatr Anaesth** 1995;5(6):355-61

Treatment of terminal cancer pain in France: a questionnaire study. Vainio A. **Pain** 1995 Aug;62(2):155-62

Children with asthma in the emergency department: spectrum of disease, variation with ethnicity, and approach to treatment. Horowitz I, et al. **Pediatr Emerg Care** 1995 Aug; 11(4):240-2

Barriers to prevention of perinatal group B streptococcal disease. Jafari HS, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):662-7

Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs [see comments] **Pediatrics** 1996 Jul; 98(1):143-5 (00 ref.). Comment in: Pediatrics 1996 Jul;98(1):118-23.

Patterns of care received by Medicaid recipients with urinary tract infections. Fargason CA Jr, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):638-42

Practice variations by population: training significance. Feigin RD, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):186-90

The critical role of provider practices in undervaccination. Grabowsky M, et al. **Pediatrics** 1996 May;97(5):735-7

The language of acupuncture: should Western physicians learn it? Erickson JK. **Pharos** 1995 Fall;58(4):21-5 (14 ref.)

Prudence: the guide for perplexed physicians in the third millennium [see comments] Geppert CM. **Pharos** 1995 Summer;58(3):2-7. Comment in: Pharos 1995 Fall;58(4):36.

Narrowing the gray zone. How clinical practice guidelines can improve the decision-making process [editorial] Larsen RR. **Postgrad Med** 1996 Aug;100(2):17-8, 23-4

Evaluating the efficacy of the National Cholesterol Education Program adult treatment guidelines: cholesterol lowering intervention program. Caggiula AW, et al. **Prev Med** 1995 Sep;24(5):485-91

Practice patterns in the diagnosis and treatment of anxiety and depression in the medically ill. A survey of psychiatrists. Epstein SA, et al. **Psychosomatics** 1996 Jul-Aug;37(4):356-67

Problems encountered using nebulized medications in hospitals [letter; comment] Beach JR, et al. **Respir Med** 1995 Nov;89(10):711-2. Comment on: Respir Med 1995 Jan;89(1):57-9.

How is sputum microbiology used in general practice? Johnson PH, et al. **Respir Med** 1996 Feb;90(2):87-8

Management of acute asthma attacks associated with respiratory tract infection: a postal survey of general practitioners in the U.K. Jones K, et al. **Respir Med** 1996 Aug;90(7):419-25

Informed consent--a survey of doctors' practices in South Africa. Henley L, et al. **S Afr Med J** 1995 Dec; 85(12):1273-8

Analysis of paediatric prescribing profiles in two health-funding systems. Rothberg AD, et al. **S Afr Med J** 1996 Jun;86(6):672-4

Informed consent--a survey of doctors' practices in South Africa [letter] Youngleson JH. **S Afr Med J** 1996 May; 86(5):566-7

The concept of individualized hypertension care in general practice and outpatient clinics. The general practitioner hypertension practice study (III). Ribacke M. **Scand J Prim Health Care** 1995 Jun;13(2):112-7

Antidepressant treatment in general practice--an interview study. Rosholm JU, et al. **Scand J Prim Health Care** 1995 Dec;13(4):281-6

General practitioners' management of female urinary incontinence. Medical records do not reflect patients' recall. Sandvik H, et al. **Scand J Prim Health Care** 1995 Sep;13(3):168-74

General practice consultations in central and northern Finland. Vehviläinen AT, et al. **Scand J Prim Health Care** 1995 Sep;13(3):197-204

How do we follow patients with Ta grade 1-111 bladder tumors in Denmark? Nielsen KT, et al. **Scand J Urol Nephrol Suppl** 1995;172:27-31

Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Olsen LH, et al. **Scand J Urol Nephrol Suppl** 1995;172:33-6

The management of operable breast cancer in Scotland surgeons' opinions. The Scottish Cancer Trials Breast Group. Robinson SM, et al. **Scott Med J** 1994 Apr; 39(2):45-9

Variation in recommendations for breast and cervical cancer screening among primary care physicians in North Carolina, 1991. Herman CJ, et al. **South Med J** 1996 Jun; 89(6):583-90

Screening for prostate cancer: a comparison of urologists and primary care physicians. McKnight JT, et al. **South Med J** 1996 Sep;89(9):885-8

The mandibular third molar. Dentists' judgment in the removal of asymptomatic molars. Knutsson K. **Swed Dent J Suppl** 1996;114:1-48

Quality assurance of clinical transfusion practice by implementation of the privilege of blood prescription and computerized prospective audit of blood requests. Marconi M, et al. **Transfus Med** 1996 Mar;6(1):11-9

Folic acid prescription in pregnancy. Cupples ME, et al. **Ulster Med J** 1995 Apr;64(1):31-3

[Psychiatric therapeutic programs--practical design] Lauritsen BJ. **Ugeskr Laeger** 1996 Sep 9;158(37):5148-9 (Eng. Abstr.) **(Dan)**

[Hearing problems--what do general practitioners do?] Parving A. **Ugeskr Laeger** 1996 Sep 9;158(37):5145-7 (Eng. Abstr.) **(Dan)**

[Evaluation of professional practice and health care organization in anesthesia and intensive care: a strategic approach (editorial)] Petit J. **Ann Fr Anesth Reanim** 1996; 15(1):9-12 **(Fre)**

[Study on insomnia treatment by family physicians] Baillargeon L, et al. **Can Fam Physician** 1996 Mar; 42:426-32 (Eng. Abstr.) **(Fre)**

[General practitioners' approach to urination disorders in men over the age of 50. A survey of 250 physicians in Brittany] Coeurdacier P, et al. **Prog Urol** 1996 Feb; 6(1):52-9 (Eng. Abstr.) **(Fre)**

[What influence should clinical studies have on the physician's practice? Reflections on the example of acute dialysis] Schaefer K, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):77-9 **(Ger)**

[Factors influencing the prescribing of nootropic drugs. Results of a representative inquiry in Lower Saxony] Stoppe G, et al. **Dtsch Med Wochenschr** 1995 Nov 24; 120(47):1614-9 (Eng. Abstr.) **(Ger)**

[Self-assessment of prescribing behavior of psychotropic drugs for children and adolescence. Results of a survey of established physicians] Trott GE, et al. **Psychiatr Prax** 1995 Nov;22(6):235-9 (Eng. Abstr.) **(Ger)**

[Acting and thinking in medicine (editorial)] Montesi A. **Radiol Med (Torino)** 1996 Mar;91(3):169-73 **(Ita)**

[Administrative handling of gastrointestinal hemorrhage in Norway] Aabakken L, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1688-91 (Eng. Abstr.) **(Nor)**

[Knowledge, professional practice and health policy] Bjørndal A, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):829-30 **(Nor)**

[Patient listing system--grouping of patients and workload of physicians. Patterns in general practice in the

municipality of Trondheim] Paulsen B. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2797–800 (Eng. Abstr.) **(Nor)**

[Functional disturbances of the nervous system in the practice of occupational health] Polakowska B. **Med Pr** 1995; 46(4):341–6 (Eng. Abstr.) **(Pol)**

[Self esteem, clinical protocols, and protocollized dissent. Task Force of Care Quality (letter; comment)] Alvarez Gil R. **Med Clin (Barc)** 1995 Nov 18;105(17):678. Comment on: Med Clin (Barc) 1994 Oct 8;103(11):421–2. **(Spa)**

[The pattern of visits at an emergency psychiatric department. The emergency group is not needed around the clock] Day MH, et al. **Lakartidningen** 1996 Sep 11; 93(37):3132–6, 3139–40 **(Swe)**

[Too varying practices in the care of Chlamydia infections. Is a care program a solution?] Ramstedt K, et al. **Lakartidningen** 1996 Jun 19;93(25):2440–3 **(Swe)**

CLASSIFICATION

Nursing interventions classification: a content analysis of nursing activities in public schools. Sigsby LM, et al. **J Community Health Nurs** 1995;12(4):229–37

ECONOMICS

Outside financial interests in radiology offices: prevalence, payment, and practice patterns in involved offices. Deitch C, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1331–5

Impact of the operating physician on costs of percutaneous transluminal coronary angioplasty. Heidenreich PA, et al. **Am J Cardiol** 1996 Jun 1;77(14):1169–73

Cost and appropriateness of radionuclide exercise stress testing by cardiologists and non-cardiologists. Stein JH, et al. **Am J Cardiol** 1996 Jan 15;77(2):139–42

The "business" of medicine: hippocratic or hypocritical? Schuller DE. **Ann Allergy Asthma Immunol** 1996 Jul; 77(1):28–32

Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors. Bloor K, et al. **BMJ** 1996 Jun 15;312(7045):1525–7

Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501–6 (44 ref.)

Relative fees and the utilization of physicians' services in Canada. Hurley J, et al. **Health Econ** 1995 Nov–Dec; 4(6):419–38

Using physician practice cost functions in payment policy: the problem of endogeneity bias. Escarce JJ. **Inquiry** 1996 Spring;33(1):66–78

The availability of health care information for consumer use. Mowll CA. **J Health Care Finance** 1995 Summer; 21(4):31–44

GP fundholding and the costs of prescribing. Whynes DK, et al. **J Public Health Med** 1995 Sep;17(3):323–9

Prescribing patterns and costs [letter; comment] Sturdy P, et al. **J R Soc Med** 1996 Apr;89(4):238. Comment on: J R Soc Med 1995 Oct;88(10):570–5.

The patient-physician relationship: time to reimburse what we preach [letter; comment] Hensel WA. **JAMA** 1996 Jul 3;276(1):27. Comment on: JAMA 1996 Mar 20;275(11):887–91.

Changes in clinical practice in response to reductions in reimbursement: physician autonomy and resistance to bureaucratization. Posner KL, et al. **Med Anthropol Q** 1995 Dec;9(4):476–92

Poststroke rehabilitation in older Americans. The Medicare experience. Lee AJ, et al. **Med Care** 1996 Aug;34(8):811–25

The relationship between resource constraints and physician problem solving. Implications for improving the process of care. Lescoe-Long MA, et al. **Med Care** 1996 Sep; 34(9):931–53

Physician response to patient insurance status in ambulatory care clinical decision-making. Implications for quality of care. Mort EA, et al. **Med Care** 1996 Aug;34(8):783–97

A national survey of the arrangements managed-care plans make with physicians [see comments] Gold MR, et al. **N Engl J Med** 1995 Dec 21;333(25):1678–83. Comment in: N Engl J Med 1995 Dec 21;333(25):1706–8.

Extreme risk—the new corporate proposition for physicians [editorial; comment] Woolhandler S, et al. **N Engl J Med** 1995 Dec 21;333(25):1706–8. Comment on: N Engl J Med 1995 Dec 21;333(25):1678–83. Comment on: ,N Engl J Med 1995 Dec 21;333(25):1684–7.

The effect of capitated and fee-for-service remuneration on physician decision making in gynecology. Ransom SB, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):707–10

The effect of capitated and fee-for-service remuneration on physician decision making in gynecology [letter] Redwine DB. **Obstet Gynecol** 1996 Sep;88(3):482

Prompting for cost-effective test ordering: a randomized controlled trial. Hollingworth GR, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:635–9

[The established rheumatologist in the tension field between health care deficits and cost control in public health] Stroehmann I, et al. **Z Rheumatol** 1995 Jul–Aug; 54(4):198–201 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Allergists, antitrust, and managed care. Miles JJ. **Allergy Proc** 1995 Nov–Dec;16(6):305–9

Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)

Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)

Effects of the German 1993 health reform law upon primary care practitioners' individual performance: results from an empirical study in sentinel practices. Hoopmann M, et al. **J Epidemiol Community Health** 1995 Aug;49 Suppl 1:33–6

Recent medical-legal proceedings and their effect on the practice of medicine in Chicago. Heim SE, et al. **J Spinal Disord** 1995 Oct;8(5):419–21 (13 ref.)

Rocky Mountain spotted fever: legal duty to warn for noncontagious disease [letter] Getfand MS, et al. **JAMA** 1995 Nov 22–29;274(20):1586–7

A dilemma for clinicians [letter] Logan RL. **N Z Med J** 1996 Jan 26;109(1014):18

The antitrust question: a new perspective. Orlowski SR. **Pa Med** 1996 Jun;99(6):16–7

Internet listservers and pediatrics: newly emerging legal and clinical practice issues. II. De Ville KA. **Pediatrics** 1996 Sep;98(3 Pt 1):453–4

Internet list servers and pediatrics: newly emerging legal and clinical practice issues. Elliott SJ, et al. **Pediatrics** 1996 Mar;97(3):399–400

Doctor, your file is open [editorial] Pretorius R. **S Afr Med J** 1996 Apr;86(4):330–2

Physician practice mergers. Part II: The antitrust implications of a merger. Sinclair SE. **Va Med Q** 1995 Fall;122(4):284–9

ORGANIZATION & ADMINISTRATION

Physician's skills needed for today's complex medical practice [letter] Tibbitts GM. **Acad Med** 1996 Jan;71(1):1

Allergists, antitrust, and managed care. Miles JJ. **Allergy Proc** 1995 Nov–Dec;16(6):305–9

Physicians' perceptions of and approaches to woman abuse. Does certification in family medicine make a difference? Tudiver F, et al. **Can Fam Physician** 1996 Aug;42:1475–80

Who provides follow-up care for patients with early breast cancer? Worster A, et al. **Can Fam Physician** 1995 Aug; 41:1314–20

Explaining variations in the frequency of night visits in general practice. Whynes DK, et al. **Fam Pract** 1996 Apr; 13(2):174–8

The enormity of the task. SUPPORT and changing practice. Solomon MZ. **Hastings Cent Rep** 1995 Nov–Dec; 25(6):S28–32

When to perform the final HIV antibody test following possible exposure. The British Co-operative Clinical Group. **Int J STD AIDS** 1995 Sep–Oct;6(5):332–5

Responsibility taking and role definition in family practice: effect of training and practice setting [see comments] Biderman A, et al. **Isr J Med Sci** 1996 Jul;32(7):545–50. Comment in: Isr J Med Sci 1996 Jul;32(7):570–2.

Processes of care. Comparisons of certified nurse-midwives and obstetricians. Oakley D, et al. **J Nurse Midwifery** 1995 Sep–Oct;40(5):399–409

Are differences in practitioners' acceptance of a quality assurance intervention related to their performance? Hargraves JL, et al. **Med Care** 1996 Sep;34(9 Suppl):SS77–86

STANDARDS

Effectiveness of notification and group education in modifying prescribing of regulated analgesics [see comments] Anderson JF, et al. **Can Med Assoc J** 1996 Jan 1;154(1):31–9. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1005–6; discussion 1006–7. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1006; discussion 1006–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1470, 1472. Comment in: Can Med Assoc J 1996 May 15;154(10):1472, 1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1476; discussion 1476–7.

Improving prescribing through use of CPS [letter] Cowan S, et al. **Can Med Assoc J** 1996 Sep 1;155(5):512–3

Evaluation of vision screening practices of Illinois pediatricians. Marcinak JF, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):353–7

Consistency and variation in fertility investigations in Europe. Helmerhorst FM, et al. **Hum Reprod** 1995 Aug; 10(8):2027–30

Identifying the characteristics of optimum practice: findings from a survey of practice experts in nursing, midwifery and health visiting. Butterworth T, et al. **J Adv Nurs** 1995 Jul;22(1):24–32

Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes [letter; comment] Lynn CK. **J Am Coll Cardiol** 1996 Mar 1; 27(3):754–5. Comment on: J Am Coll Cardiol 1995 Sep;26(3):577–82.

Are "nonsignificant differences" significant? [letter; comment] Ong JJ, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):753–4. Comment on: J Am Coll Cardiol 1995 Sep;26(3):577–82.

Cardiologists versus internists in the care of unstable angina [letter; comment] Soloman NA. **J Am Coll Cardiol** 1996 Mar 1;27(3):753. Comment on: J Am Coll Cardiol 1995 Sep;26(3):577–82.

A piece of my mind. Standards of Care. Argy O. **JAMA** 1996 May 1;275(17):1296

Another standard of care—the patient [letter] Kellerman R. **JAMA** 1996 Aug 14;276(6):450

Partnering with physicians to achieve quality improvement. Conway AC, et al. **Jt Comm J Qual Improv** 1995 Nov; 21(11):619–26

Uncertainty in clinical practice: implications for quality and costs of health care. Logan RL, et al. **Lancet** 1996 Mar 2;347(9001):595–8

Consistency in performance among primary care practitioners. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS52–66

Doctors should note reason for prescription [letter] Goldstein AO. **N C Med J** 1995 Dec;56(12):596

Guidelines for the use of granulocyte colony stimulating factor (G-CSF) [letter; comment] Black P, et al. **N Z Med J** 1995 Aug 25;108(1006):350. Comment on: N Z Med J 1995 Jul 14;108(1003):279.

Guidelines for the use of granulocyte colony stimulating factor (G-CSF) [letter; comment] Forgeson G. **N Z Med J** 1995 Aug 25;108(1006):349. Comment on: N Z Med J 1995 May 10;108(999):177–8. Comment on: N Z Med J 1995 Jul 14;108(1003):279.

Guidelines for the use of granulocyte colony stimulating factor (G-CSF) [letter; comment] Harvey V, et al. **N Z Med J** 1995 Aug 25;108(1006):349. Comment on: N Z Med J 1995 Jul 14;108(1003):279.

Failure of implementation of the National Heart Foundation of New Zealand guidelines for the management of dyslipidaemia. Patel H, et al. **N Z Med J** 1996 Feb 9; 109(1015):24–6

Glaucoma care and conformance with preferred practice patterns. Examination of the private, community-based ophthalmologist. Hertzog LH, et al. **Ophthalmology** 1996 Jul;103(7):1009–13

The use of desk-top cholesterol analysers in general practice. Summerton AM, et al. **Public Health** 1995 Sep;109(5):363–7

On chance and compromise [editorial] Freeman JW. **S D J Med** 1995 Oct;48(10):341

[How to develop recommendations for clinical practice?] Matillon Y, et al. **Arch Pediatr** 1996;3 Suppl 1:257s–260s **(Fre)**

STATISTICS & NUMERICAL DATA

Practices styles and preference of Danish cataract surgeons—1995 survey. Hansen TE. **Acta Ophthalmol Scand** 1996 Feb;74(1):56–9

Variations in practice patterns: antiviral drug use in hospitalized patients with herpes infections. DesHarnais S, et al. **Am J Med Qual** 1996 Spring;11(1):33–42

Patterns of hospital care and physician perspectives from an Italian, Japanese, and USA hospital. Louis CZ, et al. **Am J Med Qual** 1996 Fall;11(3):123–34

The decision to extract: Part 1—Interclinician agreement. Baumrind S, et al. **Am J Orthod Dentofacial Orthop** 1996 Mar;109(3):297–309

Functional ACL bracing. A survey of current opinion and practice. Decoster LC, et al. **Am J Orthop** 1995 Nov; 24(11):838–43

Current status of cochlear implants in Latin America. Chiossone E. **Am J Otol** 1995 Mar;16(2):183–5

Patient report of HIV risk screening by primary care physicians. Wenrich MD, et al. **Am J Prev Med** 1996 Mar–Apr;12(2):116–22

Abortions in rural Idaho: physicians' attitudes and practices. Rosenblatt RA, et al. **Am J Public Health** 1995 Oct; 85(10):1423–5

Superficial fine needle aspiration by clinicians: a survey of utilization. Fitzpatrick BT, et al. **Am Surg** 1996 Sep; 62(9):719–23

Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty. Unwin AJ, et al. **Ann R Coll Surg Engl** 1995 Sep; 77(5):351–4

What influences physician practice behavior? An interview study of physicians who received consultative geriatric assessment recommendations [see comments] Maly RC, et al. **Arch Fam Med** 1996 Sep;5(9):448–54. Comment in: Arch Fam Med 1996 Sep;5(9):455–6.

Referral for dialysis in Ontario. Mendelssohn DC, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2473–8

Albumin and nonprotein colloid solution use in US academic health centers. Yim JM, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2450–5

Do ophthalmologists, anesthesiologists, and internists agree about preoperative testing in healthy patients undergoing cataract surgery? [see comments] Bass EB, et al. **Arch Ophthalmol** 1995 Oct;113(10):1248–56. Comment in: Arch Ophthalmol 1995 Oct;113(10):1241–2.

Specific therapeutic group age-sex related prescribing units (STAR-PUs): weightings for analysing general practices' prescribing in England [see comments] Lloyd DC, et al. **BMJ** 1995 Oct 14;311(7011):991–4. Comment in: BMJ 1996 Feb 10;312(7027):378.

A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1303–6 (17 ref.)

Differences between general practices in hospital admission rates for self-inflicted injury and self-poisoning: influence of socioeconomic factors. Smith T. **Br J Gen Pract** 1995 Sep;45(398):458–62

Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons. Marley JJ, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):28–36

Community resources for psychiatric and psychosocial problems. Family physicians' referral patterns in urban Ontario. Craven MA, et al. **Can Fam Physician** 1995 Aug; 41:1325–35

Survey of cardiac pacing in Canada (1993). Goldman BS, et al. **Can J Cardiol** 1996 Jun;12(6):573–8

Has laparoscopic cholecystectomy changed patterns of practice and patient outcome in Ontario? Cohen MM, et al. **Can Med Assoc J** 1996 Feb 15;154(4):491–500

Did continuous quality improvement lead to lower episiotomy rate? [letter; comment] Fellows GF. **Can Med Assoc J** 1995 Dec 1;153(11):1568. Comment on: Can Med Assoc J 1995 Aug 1;153(3):275–82.

Neurosurgery workforce in Canada, 1996 to 2011. Canadian Neurosurgical Society. Hugenholtz H. **Can Med Assoc J** 1996 Jul 1;155(1):39–48

Sex differences in physicians' activity level [letter; comment] McCall J. **Can Med Assoc J** 1996 Feb 15;154(4):446; discussion 446, 448. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

Education, practice reviews needed to reduce surgical intervention, Quebec report says. Rafuse J. **Can Med Assoc J** 1996 Aug 15;155(4):463–4

Sex differences in physicians' activity level [letter; comment] Rieder MJ. **Can Med Assoc J** 1996 Feb 15;154(4):446; discussion 446, 448. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

Concerns of patients, MDs are transforming transfusion medicine. Robb N. **Can Med Assoc J** 1996 Feb 1; 154(3):391–6

Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cherny NJ, et al. **Cancer** 1995 Oct 1;76(7):1283–93

Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation to published recommendations. Shepherd J, et al. **Cardiology** 1996 Jan–Feb;87(1):1–5

Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Krumholz HM, et al. **Circulation** 1995 Nov 15; 92(10):2841–7

Swimming with the current [editorial] Asbell PA. **CLAO J** 1995 Jul;21(3):152

Pediatricians' preferences for anticipatory guidance topics compared with parental anxieties. Stickler GB, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):384–7

The use of antibiotic prophylaxis in radiology departments for patients at high-risk of infective endocarditis. Howlett DC, et al. **Clin Radiol** 1996 Sep;51(9):649–50

Dentists' variability in restorative decisions, microscopic and radiographic caries depth. Lewis DW, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):106–11

Protocols used by UK general practitioners, what is expected of them and what solutions are provided. Young A, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):85–90

Pediatric urology and the daily medical practice: way apart? Feitz WF, et al. **Eur Urol** 1995;28(2):158–60

Patterns of integration and clinical value of voiding cystourethrography in the work-up of urinary tract infection in children. Mussurakis S, et al. **Eur Urol** 1995; 28(2):165–70

Paracetamol prescribing—an epidemic? Dawson KP, et al. **Fam Pract** 1996 Apr;13(2):179–81

Variability in GPs' referral rates in Spain. García Olmos L, et al. **Fam Pract** 1995 Jun;12(2):159–62

Use of X-rays in family practice. A multicentre study. Njalsson T, et al. **Fam Pract** 1995 Jun;12(2):143–8

Neonatal examination and screening—survey of GP practice and opinion. Glazener CM, et al. **Health Bull (Edinb)** 1996 Jul;54(4):355–60

Wide variation in the use of thrombolytic therapy among junior doctors in south and central Scotland. Hood S, et al. **Health Bull (Edinb)** 1996 Mar;54(2):131–9

The impact of nonclinical factors on practice variations: the case of hysterectomies. Geller SE, et al. **Health Serv Res** 1996 Feb;30(6):729–50

The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Gurwitz JH, et al. **Health Serv Res** 1995 Dec;30(5):672–85

Demographic variation in the rate of knee replacement: a multi-year analysis. Katz BP, et al. **Health Serv Res** 1996 Jun;31(2):125–40

Physician impact on hospital admission and on mortality rates in the Medicare population. Krakauer H, et al. **Health Serv Res** 1996 Jun;31(2):191–211

Practice setting and physician influences on judgments of colon cancer treatment by community physicians. McFall SL, et al. **Health Serv Res** 1996 Apr;31(1):5–19

Ambulatory care practice variation within a Medicaid program. Weiner JP, et al. **Health Serv Res** 1996 Feb; 30(6):751–70

Publications. Health care atlas reveals inequities [news] **Hosp Health Netw** 1996 Mar 5;70(5):11

Pharmaceuticals ... a run on brand X -news- **Hosp Health Netw** 1996 Sep 5;70(17):16

Mirror, mirror ... on the wall, who are the healthiest Americans of all? Hudson T. **Hosp Health Netw** 1996 Apr 5;70(7):24–6, 28, 30

New York City physicians serving high volumes of Medicaid children: who are they and how do they practice? Fairbrother G, et al. **Inquiry** 1995 Fall;32(3):345–52

Rational prescribing and interpractitioner variation. A multilevel approach. Davis P, et al. **Int J Technol Assess Health Care** 1995 Summer; 11(3):428–42

Pharmaceutical prescriptions in Italy. Garattini S. **Int J Technol Assess Health Care** 1995 Summer; 11(3):417–27

Variation in use of breast-conserving surgery in Lombardia, Italy. Grilli R, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):733–40

Perioperative use of total parenteral nutrition. Variations in guidelines and practice in three Norwegian hospitals. Mjaaland M, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):741–9

Artificial nutrition support in intensive care units in Spain. Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units (SEMIUC). Planas M. **Intensive Care Med** 1995 Oct; 21(10):842–6

Vaginal birth after cesarean: a 5-year experience in a family practice residency program. Miller ES, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):357–60

An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations. Ciol MA, et al. **J Am Geriatr Soc** 1996 Mar;44(3):285–90

Physician-reported determinants of screening mammography in older women: the impact of physician and practice characteristics. Roetzheim RG, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1398–402

Practice styles and preferences of ASCRS members—1994 survey. Leaming DV. **J Cataract Refract Surg** 1995 Jul; 21(4):378–85

Geographic variation in patient surveillance after colon cancer surgery. Johnson FE, et al. **J Clin Oncol** 1996 Jan; 14(1):183–7

Practice patterns of rural family physicians based on the American Diabetes Association standards of care. Zoorob RJ, et al. **J Community Health** 1996 Jun;21(3):175–82

Patterns of practice in emergency department management of chest pain of suspected cardiac origin: clinical utility of single stat creatine kinase (CK) [see comments] Tsang T, et al. **J Emerg Med** 1995 Jul–Aug;13(4):471–80. Comment in: J Emerg Med 1995 Jul–aug;13(4):533–5.

Who gets repeat screening mammography: the role of the physician. Burns RB, et al. **J Gen Intern Med** 1995 Sep; 10(9):520–2

Medical specialists prefer to withdraw familiar technologies when discontinuing life support. Christakis NA, et al. **J Gen Intern Med** 1995 Sep;10(9):491–4

Do primary care physicians screen patients about alcohol intake using the CAGE questions? Wenrich MD, et al. **J Gen Intern Med** 1995 Nov;10(11):631–4

Physicians' personal malpractice experiences are not related to defensive clinical practices [see comments] Glassman PA, et al. **J Health Polit Policy Law** 1996 Summer; 21(2):219–41. Comment in: J Health Polit Policy Law 1996 Summer;21(2):267–88.

The use of low-osmolar contrast agents: technological change and defensive medicine [see comments] Jacobson PD, et al. **J Health Polit Policy Law** 1996 Summer; 21(2):243–66. Comment in: J Health Polit Policy Law 1996 Summer;21(2):267–88.

Measuring defensive medicine using clinical scenario surveys [see comments] Klingman D, et al. **J Health Polit Policy Law** 1996 Summer;21(2):185–217. Comment in: J Health Polit Policy Law 1996 Summer;(21(2):267–88.

Variation in dentists' clinical decisions. Bader JD, et al. **J Public Health Dent** 1995 Summer;55(3):181–8 (67 ref.)

A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators [see comments] **JAMA** 1995 Nov 22–29;274(20):1591–8. Comment in: JAMA 1995 Nov 22–29;274(20):1634–6. Comment in: JAMA 1996 Apr 24;275(16):1227; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1227–8; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1228–9; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1229–30; discussion 1230–1. Comment in: JAMA 1996 Apr 24;275(16):1230–1. Comment in: JAMA 1996 Apr 24;275(16):1231–2.

Defensive medicine and obstetrics. Baldwin LM, et al. **JAMA** 1995 Nov 22–29;274(20):1606–10

The impact of diagnostic testing on therapeutic interventions [see comments] Verrilli D, et al. **JAMA** 1996 Apr 17; 275(15):1189–91. Comment in: JAMA 1996 Apr 17;275(15):1197–8. Comment in: JAMA 1996 Aug 21;276(7):528–9.

Why do physicians prefer to withdraw some forms of life support over others? Intrinsic attributes of life-sustaining treatments are associated with physicians' preferences. Asch DA, et al. **Med Care** 1996 Feb;34(2):103–11

Treatment differences between blacks and whites with colorectal cancer. Ball JK, et al. **Med Care** 1996 Sep; 34(9):970–84

Factors that determine the treatment for local and regional prostate cancer. Desch CE, et al. **Med Care** 1996 Feb; 34(2):152–62

Variations by specialty in physician ratings of the appropriateness and necessity of indications for procedures. Kahan JP, et al. **Med Care** 1996 Jun;34(6):512–23

Comparing the use of diagnostic tests in Canadian and US hospitals. Katz SJ, et al. **Med Care** 1996 Feb;34(2):117–25

Physician practice style and rates of hospitalization for chronic medical conditions. Komaromy M, et al. **Med Care** 1996 Jun;34(6):594–609

The impact of practicing in multiple hospitals on physician profiles. Miller ME, et al. **Med Care** 1996 May;34(5):455–62

Does publishing the parameters that trigger review of Medicare claims change provider behavior? Results of the parameter release study. Nyman JA, et al. **Med Care** 1995 Oct;33(10):1022–34

Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Simons LA, et al. **Med J Aust** 1996 Feb 19;164(4):208–11

Effect of utilization review in a fee-for-service health insurance plan [see comments] Rosenberg SN, et al. **N Engl J Med** 1995 Nov 16;333(20):1326–30. Comment in: N Engl J Med 1995 Nov 16;333(20):1353–4. Comment in: N Engl J Med 1996 Mar 14;334(11):737.

Caesarean section incidence [letter; comment] Dunn HP. **N Z Med J** 1996 Feb 9;109(1015):39. Comment on: N Z Med J 1995 Dec 8;108(1013):511–2.

Patterns of referral and examination for retinopathy in pregnant women with diabetes by primary care physicians [see comments] Marrero DG, et al. **Ophthalmic Epidemiol** 1995 Jun;2(2):93–8. Comment in: Ophthalmic Epidemiol 1995 Jun;2(2):57–8.

Patterns of diabetic eye care by primary care physicians in the state of Indiana [see comments] Yung CW, et al. **Ophthalmic Epidemiol** 1995 Jun;2(2):85–91. Comment in: Ophthalmic Epidemiol 1995 Jun;2(2):57–8.

Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey. Askew GL, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):889–92

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.). Comment on: Prev Med 1995 Nov;24(6):546–2.

Lowering physician hospital resource consumption using low-cost low-technology computing. Johnson CC, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:661–5

Effectiveness of a physician education program in reducing consumption of hospital resources in elective total hip replacement. Johnson CC, et al. **South Med J** 1996 Mar; 89(3):282–9

Radiosurgery patterns of practice. Larson DA, et al. **Surg Neurol** 1995 Nov;44(5):414–9; discussion 419–20

Office abortion services for women: private physician providers. Wyatt L Jr, et al. **Women Health** 1995; 23(2):47–65

[Management of myocardial infarction in the Rhone-Alps area. Are there many variations in practice?] Colin C, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):307–13 (Eng. Abstr.) **(Fre)**

[Use of radionuclide isotopes by cardiologists. Results of a French survey. Study group: "Nuclear Cardiology" of the French Society of Cardiology and the Society of Nuclear Medicine and Biophysics] Pézard P, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):299–305 (Eng. Abstr.) **(Fre)**

TRENDS

A survey of the practice of prophylactic oophorectomy by gynecologists in the state of Alaska. Conklin BH, et al. **Alaska Med** 1996 Apr–Jun;38(2):71–4

Putting prevention into practice. Impact of a multifaceted physician education program on preventive services in the inner city. Gemson DH, et al. **Arch Intern Med** 1995 Nov 13;155(20):2210–6

Trends in diagnostic testing following a national guideline for evaluation of dyspepsia. Schwartz LM, et al. **Arch Intern Med** 1996 Apr 22;156(8):873–5

Physician performance of preventive care for women. Gill JM. **Del Med J** 1996 Jul;68(7):349–55

A change in practice: current urologic practice in response to reports concerning vasectomy and prostate cancer. Sandlow JI, et al. **Fertil Steril** 1996 Aug;66(2):281–4

Trends in pacemaker mode prescription 1984–1994: a single centre study of 3710 patients. Aggarwal RK, et al. **Heart** 1996 May;75(5):518–21

What do family medicine residency graduates do? [editorial] Green LA, et al. **J Am Board Fam Pract** 1996 Mar–Apr; 9(2):149–51

The geographic and temporal patterns of residency-trained family physicians: University of Washington Family Practice Residency Network. West PA, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):100–8

Does continuity of care increase HMO patients' satisfaction with physician performance? Weyrauch KF. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):31–6

Where are we going and why? [letter] Bonsack RM. **Md Med J** 1995 Dec;44(12):1024

Minimal increase in use of breast-conserving surgery from 1986 to 1990. Nattinger AB, et al. **Med Care** 1996 May;

34(5):479–89
Changes in medical practice raise ethical questions. Murray MJ. **Minn Med** 1995 Nov;78(11):50
Reinventing the house of medicine: the study of the federation. Bohigian GM. **Mo Med** 1995 Sep;92(9):566–7
Survival of the fittest [letter] Crowley WJ Jr. **Mo Med** 1995 Sep;92(9):562
Physician prescribing of controlled drugs. Perspectives of the North Carolina Medical Board and the State Bureau of Investigation. Pittman D, et al. **N C Med J** 1996 Jul–Aug; 57(4):236–40
Change in prescribing patterns of general practitioners in Italy before and after the Reform Drug Act. A case study of changes in the city of Turin. Rolle C, et al. **Pharm World Sci** 1995 Sep 22;17(5):158–62
Graduates comment on issues related to the decline of Wisconsin family physicians providing maternity care. Turkal N, et al. **Wis Med J** 1996 Jan;95(1):17–21
[Cesarean section trends at the Toulouse University Hospital, from 1983 to 1993. Determinants and consequences] Baille MF, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):763–71 (Eng. Abstr.) **(Fre)**

UTILIZATION

Whose guidelines are they, anyway? Mammography utilization in Ontario. Goel V. **Can J Public Health** 1996 May–Jun;87(3):181–2

PHYSICIAN'S ROLE

Medicine and the arts [comment] Dittrich L. **Acad Med** 1996 Mar;71(3):256. Comment on: Acad Med 1996 Mar;71(3):257.
Sexual abstinence counseling of adolescents by physicians. Patton D, et al. **Adolescence** 1995 Winter;30(120):963–9
Incorporating gun safety into clinical practice. Camosy PA. **Am Fam Physician** 1996 Sep 1;54(3):971–5, 977–8 (16 ref.)
AAFP's role in public education about antibiotic resistance [letter] Comstock LK. **Am Fam Physician** 1996 May 15; 53(7):2283
Chemically dependent patients in recovery: roles for the family physician. Del Toro IM, et al. **Am Fam Physician** 1996 Apr;53(5):1667–81 (19 ref.)
The family physician's role in adolescent idiopathic scoliosis [editorial; comment] DiGuiseppi CG, et al. **Am Fam Physician** 1996 May 15;53(7):2268–72. Comment on: Am Fam Physician 1996 May 15;53(7):2327–34.
Care at the twilight: ethics and end–of–life care. Doukas DJ, et al. **Am Fam Physician** 1995 Oct;52(5):1294–6, 1299 (12 ref.)
SAFE questions: overcoming barriers to the detection of domestic violence. Neufeld B. **Am Fam Physician** 1996 Jun; 53(8):2575–80, 2582 (32 ref.)
The role of the family physician in the day care setting. Olsen CG, et al. **Am Fam Physician** 1996 Sep 15;54(4):1257–65, 1267–8 (32 ref.)
10 steps to keep the children in your practice nonsmokers [editorial] Thomas RE. **Am Fam Physician** 1996 Aug; 54(2):450–2
Physician involvement and assessment in the development of hospital oncology programs. Konski AA. **Am J Clin Oncol** 1996 Jun;19(3):311–6
The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798–801 (12 ref.)
Carbon monoxide detectors and emergency physicians [editorial] Leikin JB. **Am J Emerg Med** 1996 Jan;14(1):90–4
Decreasing the organ donor shortage [letter; comment] Kramer JL. **Am J Forensic Med Pathol** 1995 Sep;16(3):257; discussion 259–60. Comment on: Am J Forensic Med Pathol 1994 Jun;15(2):156–9.
The surgeon's role in the treatment of chronic intestinal pseudoobstruction. Murr MM, et al. **Am J Gastroenterol** 1995 Dec;90(12):2147–51
Medical futility and implications for physician autonomy. Daar JF. **Am J Law Med** 1995;21(2–3):221–40 (117 ref.)
Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)
The power of physicians: autonomy and balance in a changing system. Friedman E. **Am J Med** 1995 Dec; 99(6):579–86
Quality of life: who can make the judgment? [letter] Materson RS. **Am J Med** 1996 Aug;101(2):236
The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)
The preventive medicine manager: a new role for preventive medicine specialists in managed care. Bokor A, et al. **Am J Prev Med** 1996 May–Jun;12(3):143–4
Role of emergency physicians in the care of children. American College of Emergency Physicians. **Ann Emerg Med** 1996 Sep;28(3):383
Emergency medicine's role in organ and tissue donation. American College of Emergency Physicians. **Ann Emerg Med** 1996 Sep;28(3):384
Pediatric emergency physician interpretation of plain radiographs: Is routine review by a radiologist necessary and cost–effective? Simon HK, et al. **Ann Emerg Med** 1996 Mar;27(3):295–8
Physician–run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)
Violence in intimate relationships and the practicing internist: new "disease" or new agenda? [comment] [see comments] Alpert EJ. **Ann Intern Med** 1995 Nov 15;123(10):774–81 (33 ref.). Comment on: Ann Intern Med 1995 Nov 15;123(10):737–46. Comment on: Ann Intern Med 1995 Nov 15;123(10):782–94. Comment on: Ann Intern Med 1995 Nov 15;123(10):800–2. Comment on: Ann Intern Med 1995 Nov 15;123(10):804–5. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.
Can physicians diagnose strengths and weaknesses in health plans? [editorial] Borowsky SJ, et al. **Ann Intern Med** 1996 Aug 1;125(3):239–41
Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)
Capitated payment for medical care and the role of the physician [editorial; comment] Selker HP. **Ann Intern Med** 1996 Feb 15;124(4):449–51. Comment on: Ann Intern Med 1996 Feb 15;124(4):442–8.
Physician–controlled utilization management [letter] Temianka D. **Ann Intern Med** 1996 May 1;124(9):856
Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):163–7 (29 ref.)
Roles of the general practitioner in different contexts. Van Dormael M. **Ann Soc Belg Med Trop** 1995;75 Suppl 1:79–88
The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)
Maximizing the referral of older women for screening mammography. Lemkau JP, et al. **Arch Fam Med** 1996 Mar;5(3):174–8
Elder abuse: what can physicians do? Rosenblatt DE. **Arch Fam Med** 1996 Feb;5(2):88–90
The internist's role in addressing violence. A review of current recommendations and a model for intervention. Conway T. **Arch Intern Med** 1996 May 13;156(9):951–6
Promoting completion of health care proxies following hospitalization. A randomized controlled trial in a community hospital. Reilly BM, et al. **Arch Intern Med** 1995 Nov 13;155(20):2202–6
Just say no ... welfare [letter; comment] Auten RL Jr. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1177; discussion 1178. Comment on: Arch Pediatr Adolesc Med 1995 Mar;149(3):235–6.
Role of the primary care provider in expediting care of children with acute appendicitis. Chande VT, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):703–6
The pediatrician and cancer prevention [letter; comment] Donnelly BW. **Arch Pediatr Adolesc Med** 1995 Dec; 149(12):1399–400. Comment on: Arch Pediatr Adolesc Med 1995 Feb;149(2):133–4.
Just say no ... welfare [letter; comment] Kwasman A. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1177–8. Comment on: Arch Pediatr Adolesc Med 1995 Mar;149(3):235–6.
Just say no ... welfare [letter; comment] Moyer RP. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1177; discussion 1178. Comment on: Arch Pediatr Adolesc Med 1995 Mar;149(3):235–6.
The role of the rehabilitation physician in the postacute continuum. Frederickson M, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC5–9
Heartsink revisited. Colquhoun JP. **Aust Fam Physician** 1995 Oct;24(10):1964–5
Family therapy skills for general practitioners. Jackson L, et al. **Aust Fam Physician** 1996 Aug;25(8):1265–7, 1269–71
Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
Doctors who smoke. Medical students should be educated about their exemplary role [letter; comment] Chada N. **BMJ** 1995 Oct 7;311(7010):945. Comment on: BMJ 1995 Jul 15;311(6998):142–3.
The role of an anaesthetist in a field hospital during the cholera epidemic among Rwandan refugees in Goma. Ginosar Y, et al. **Br J Anaesth** 1995 Dec;75(6):810–6
Should general practitioners have any role in maternity care in the future? Smith LF. **Br J Gen Pract** 1996 Apr; 46(405):243–7
Pathways to suicide prevention. Murphy BM, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):11–4 (18 ref.)
Section 9 police statement and junior doctors [letter; comment] Scott CC. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):175. Comment on: Br J Hosp Med 1995 Mar 15–Apr 4;53(6):283–7.
Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)
The role of the primary care physician in tobacco use prevention and cessation. Bal DG, et al. **CA Cancer J Clin** 1995 Nov–Dec;45(6):369–74
Medical ethics during genocide. Blair L. **Can Fam Physician** 1996 Jul;42:1415–9
A dying child. Dawson SA. **Can Fam Physician** 1995 Sep; 41:1534–40 (27 ref.)
Chronic unhappiness. Investigating the phenomenon in family practice. Ellis CG. **Can Fam Physician** 1996 Apr; 42:645–51
Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913–22 (85 ref.)
Tuberculosis. A widespread health issue [editorial; comment] Holton D. **Can Fam Physician** 1995 Sep;41:1447–9, 1462–4 . Comment on: Can Fam Physician 1995 Jun;41:1014–23. Comment on: Can Fam Physician 1995 Jun;41:1025–9. Comment on: Can Fam Physician 1995 Jun;41:1030–6. **(Eng, Fre)**
Going political. Family physicians can promote child health in Canada [editorial] Levitt C. **Can Fam Physician** 1995 Sep;41:1436–8, 1452–5 **(Eng, Fre)**
Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)
Uncovering hidden stories about abuse [editorial] Radomsky N. **Can Fam Physician** 1996 Aug;42:1445–7, 1452–4 **(Eng, Fre)**
Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)
The disempowerment of psychiatrists [letter] Mai FM. **Can J Psychiatry** 1995 Nov;40(9):568–9
Refusal to police breast–feeding [letter; comment] Abdurrahman MB. **Can Med Assoc J** 1995 Dec 1; 153(11):1568–9. Comment on: Can Med Assoc J 1995 May 15;152(10):1587–8.
Acknowledging the weather–health link. Bart JL, et al. **Can Med Assoc J** 1995 Oct 1;153(7):941–4 (30 ref.)
Physicians and the minefield surrounding informed consent. Capen K. **Can Med Assoc J** 1996 Aug 15;155(4):458–60
Role of the general practitioner in the delivery of surgical and anesthesia services in rural western Canada [see comments] Chiasson PM, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1447–52. Comment in: Can Med Assoc J 1996 Mar 1;154(5):631–2.
Sustaining development [letter; comment] Dubé JM. **Can Med Assoc J** 1996 Mar 15;154(6):758, 760. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1117–20.
Bioethics for clinicians: 1. Consent [see comments] Etchells E, et al. **Can Med Assoc J** 1996 Jul 15;155(2):177–80 (31 ref.). Comment in: Can Med Assoc J 1996 Jul 15;155(2):189–90.
FPs can play important role in treatment of infertile patients, counsellors say. Michaels E. **Can Med Assoc J** 1996 May 15;154(10):1559–61
Helping patients stop smoking: confrontation or caring? [letter; comment] Panton WD. **Can Med Assoc J** 1996 Jun 15;154(12):1834. Comment on: Can Med Assoc J 1996 Jan 15;154(2):159–64.
Changes in Canada pension plan disability rules hold implications for physicians. Romaniuk A. **Can Med Assoc J** 1995 Dec 15;153(12):1777–8
Lead, follow or get out of the way: what is the physician's role in a changing society [editorial] Rose M. **Can Med Assoc J** 1996 Jul 15;155(2):209–11
Bioethics for clinicians [editorial; comment] Singer PA. **Can Med Assoc J** 1996 Jul 15;155(2):189–90. Comment on: Can Med Assoc J 1996 Jul 15;155(2):177–80.
The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)
Yes, minister, Canadians need strong tobacco–control legislation now! [editorial] Walters DJ, et al. **Can Med Assoc J** 1996 Jan 15;154(2):191–2
Ecosystem and population health: the role of Canadian physicians at home and abroad [editorial] [see comments] Woollard RF. **Can Med Assoc J** 1995 Oct 15;153(8):1117–20 . Comment in: Can Med Assoc J 1996 Mar 15;154(6):758, 760.
Smoking and health: physician responsibility. A statement of the Joint Committee on Smoking and Health. American College of Chest Physicians. American Thoracic Society. Asia Pacific Society of Respirology. Canadian Thoracic Society. European Respiratory Society, and International Union Against Tuberculosis and Lung Disease. **Chest** 1995 Oct;108(4):1118–21
Tough love and the pulmonologist [editorial] Smith DD. **Chest** 1996 Mar;109(3):599–600
Child sexual abuse continues to present many dilemmas for the practicing pediatrician [letter] Finkel MA. **Child Abuse Negl** 1996 Jan;20(1):93–4
Battered women: how the primary care practitioner can help. Henry CA, et al. **Cleve Clin J Med** 1996 Jul–Aug; 63(4):199–201
The medical director in the multi–level long–term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug; 11(3):359–72 (4 ref.)
The medical director in non–institutional long–term care programs. Finucane TE, et al. **Clin Geriatr Med** 1995 Aug; 11(3):391–402 (15 ref.)
The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403–17 (10 ref.)
Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449–65 (8 ref.)
Current role of the medical director in community–based nursing facilities. Levinson MJ, et al. **Clin Geriatr Med** 1995 Aug;11(3):343–58 (10 ref.)
The role of the primary care physician in the care of the terminally ill. Ogle KS, et al. **Clin Geriatr Med** 1996 May; 12(2):267–78
History and evolution of the role of the medical director.

Pattee JJ. **Clin Geriatr Med** 1995 Aug;11(3):331–41
The medical director in hospital–based transitional care units. Smith RL, et al. **Clin Geriatr Med** 1995 Aug;11(3):373–89 (11 ref.)
The future of long–term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531–45 (10 ref.)
Physician factors affecting patient willingness to comply with exercise recommendations. Harsha DM, et al. **Clin J Sport Med** 1996 Apr;6(2):112–8
Home healthcare: the role of the primary care physician. Goldberg AI. **Compr Ther** 1995 Nov;21(11):633–8 (20 ref.)
Medicine and Mephistopheles [editorial] Bone RC. **Crit Care Med** 1996 Jul;24(7):1099–100
How decisive are physician values in end–of–life decision–making? [editorial; comment] Silverman HJ. **Crit Care Med** 1996 Jun;24(6):909–11. Comment on: Crit Care Med 1996 Jun;24(6):968–75.
Plaintiffs are patients too [letter; comment] Levinson JM. **Del Med J** 1996 Feb;68(2):149–50. Comment on: Del Med J 1995 Dec;67(12):630–1.
Polyps and polypectomy surveillance––role of the histopathologist. Riddell RH. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1138–40 (6 ref.)
Doctors against smoking [editorial] Hill MJ. **Eur J Cancer Prev** 1996 Apr;5(2):91–2
Provider–associated factors in obstetric interventions. Pel M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug; 61(2):129–34
Adults with congenital heart disease––the important role and obligation of the paediatric cardiologist and the general paediatrician. Stocker FP. **Eur J Pediatr** 1995;154(9 Suppl 4):S82–4
Smoking and health: a physician's responsibility. A statement of the joint committee on smoking and health. American College of Chest Physicians, American Thoracic Society, Asia Pacific Society of Respirology, Canadian Thoracic Society, European Respiratory Society, International Union Against Tuberculosis and Lung Disease. **Eur Respir J** 1995 Oct;8(10):1808–11
Smoking and smoking cessation: a major role for the respiratory physician [editorial] Yernault JC. **Eur Respir J** 1995 Oct;8(10):1633
Treating an HIV–positive male patient. Goldschmidt RH, et al. **Fam Med** 1995 Jul–Aug;27(7):422–3
"I know what to do, but it's not possible to do it"––general practitioners' perceptions of their ability to detect psychological distress. Howe A. **Fam Pract** 1996 Apr; 13(2):127–32
Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214–20 (14 ref.)
Suffering at the end of life [editorial] [see comments] Butler RN. **Geriatrics** 1996 May;51(5):8. Comment in: Geriatrics 1996 Jul;51(7):16.
A matter of law? [letter] Cachecho R, et al. **Hastings Cent Rep** 1996 May–Jun;26(3):2
The second–hand suicide threat. Doukas D, et al. **Hastings Cent Rep** 1995 Nov–Dec;25(6):20; discussion 20–2
Preservation of life or property? [letter; comment] Welsh F. **Hastings Cent Rep** 1995 Nov–Dec;25(6):2. Comment on: Hastings Cent Rep 1994 Nov–Dec;24(6):S1.
How to become the positively perfect physician. Lee CA. **Hawaii Med J** 1996 Jun;55(6):98–9, 105
Survey of Hawaii physicians' attitudes on health care reform. Sunderland P. **Hawaii Med J** 1995 Oct;54(10):740–5
Managed care and the role and training of psychiatrists. Meyer RE, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):65–77 (23 ref.)
Infection, infidelity, and informed patients. Kuritzky L. **Hosp Pract (Off Ed)** 1996 May 15;31(5):117–8
Domestic violence: the physician's role [see comments] Melvin SY. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):45–52; discussion 52–3. Comment in: Hosp Pract (Off Ed) 1995 Dec 15;30(12):18.
Domestic violence [letter; comment] Uzych L. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):18. Comment on: Hosp Pract (Off Ed) 1995 Oct 15;30(10):45–52; discussion 52–3.
Caring for the terminally ill [letter] Zimmerman SJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):28
Managed care needs proactive physicians [interview by Bob Carlson] Hochstetler M. **Indiana Med** 1996 May–Jun; 89(3):242–8
Medical ethics under managed care. Schwartz P. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):124–8 (16 ref.)
Managed care: the decline and fall of a physician meritocracy? [editorial] Burke G. **Internist (Bert)** 1996 Feb; 37(2):26–7
Elder abuse. Haugland S. **Iowa Med** 1996 Jan;86(1):18–9
Diagnosing and managing elder abuse. Jogerst G. **Iowa Med** 1996 Jan;86(1):29–31 (9 ref.)
Detached concern doesn't cut it [editorial] McMillan W. **Iowa Med** 1996 Jul–Aug;86(6):223
Responsibility taking and role definition in family practice: effect of training and practice setting [see comments] Biderman A, et al. **Isr J Med Sci** 1996 Jul;32(7):545–50. Comment in: Isr J Med Sci 1996 Jul;32(7):570–2.
Power and structure in primary care [editorial; comment] Weingarten MA. **Isr J Med Sci** 1996 Jul;32(7):570–2. Comment on: Isr J Med Sci 1996 Jul;32(7):545–50. Comment on: Isr J Med Sci 1996 Jul;32(7):551–4. Comment on: Isr J Med Sci 1996 Jul;32(7):555–60.
Deputed power of medical control: the hidden message in the ritual of oral shift reports. Ekman I, et al. **J Adv Nurs** 1995 Nov;22(5):1006–11
Rhett Butler and the superior physician [editorial] Marcuse EK. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):335–7
The face of death––grim reaper or rite of passage? [editorial] Parmley WW. **J Am Coll Cardiol** 1996 Jan;27(1):234–5
The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)
Assisted suicide and euthanasia [letter] Finucane TE. **J Am Geriatr Soc** 1996 Jun;44(6):733
From advocacy to tenacity: finding the limits [editorial; comment] Morreim EH. **J Am Geriatr Soc** 1995 Oct; 43(10):1170–2. Comment on: J Am Geriatr Soc 1995 Oct;43(10):1174.
Advance directives and older adults: a critical care perspective [letter] Nuckton TJ. **J Am Geriatr Soc** 1996 Jun;44(6):733–4
Reporting mistreatment of older adults: the role of physicians. Rosenblatt DE, et al. **J Am Geriatr Soc** 1996 Jan; 44(1):65–70
Preoperative assessment of older adults [letter; comment] Rosenthal RA. **J Am Geriatr Soc** 1996 Feb;44(2):213–4. Comment on: J Am Geriatr Soc 1995 Jul;43(7):811–21.
The process of dying [letter] Rousseau P. **J Am Geriatr Soc** 1996 May;44(5):612–3
Making a difference for children: the medical community's role in improving child care. Reisman B. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):170–4 (21 ref.)
Domestic violence: changing theory, changing practice. Warshaw C. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):87–91, 100 (70 ref.)
Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)
Reducing risk of zoonotic parasitic diseases––a shared responsibility. Roundtable: veterinarians, physicians jointly responsible [news] Allert C. **J Am Vet Med Assoc** 1995 Aug 15;207(4):403–4
You and the law. The Domestic Abuse Act: the physician's role. Mixon D. **J Ark Med Soc** 1995 Oct;92(5):218–20
The physician's responsibility and domestic violence [editorial] Seguin–Calderon R. **J Ark Med Soc** 1995 Oct; 92(5):209–10
The role of a physician in the composition of the Star Spangled Banner. Spiegel AD. **J Community Health** 1995 Aug;20(4):367–78
Breast screening: a randomised controlled trial in UK general practice of three interventions designed to increase uptake. Sharp DJ, et al. **J Epidemiol Community Health** 1996 Feb; 50(1):72–6
Values and roles in primary care. Lamberts H, et al. **J Fam Pract** 1996 Feb;42(2):178–80
Effect of physician gender on the prescription of estrogen replacement therapy. Seto TB, et al. **J Gen Intern Med** 1996 Apr;11(4):197–203
Depression, guidelines, and reality [editorial; comment] Siegler EL. **J Gen Intern Med** 1995 Dec;10(12):699–700. Comment on: J Gen Intern Med 1995 Dec;10(2):663–70.
Suicidal ideation among urban medical outpatients. Zimmerman M, et al. **J Gen Intern Med** 1995 Oct; 10(10):573–6
Physicians' discourses on malpractice and the meaning of medical malpractice. Marjoribanks T, et al. **J Health Soc Behav** 1996 Jun;37(2):163–78
Role and responsibility of paediatricians in diarrhoea case management. Amdekar YK. **J Indian Med Assoc** 1995 Jun; 93(6):233–4
General practitioners and changing scenario in drug abuse. Chowdhury JR, et al. **J Indian Med Assoc** 1995 Apr; 93(4):155–6
Role of physicians in preventing diarrhoea. Suresh K, et al. **J Indian Med Assoc** 1995 Jun;93(6):245–7
The physician's role in the treatment of obesity [editorial; comment] Hirsch J. **J Intern Med** 1995 Oct;238(4):295–7 . Comment on: J Intern Med 1995 Oct;238(4):299–306.
The patient's last advocate [editorial] Stulc JP. **J Ky Med Assoc** 1996 Apr;94(4):161
Physicians, smoking and hospitals. Committee on Chronic Diseases. **J La State Med Soc** 1995 Dec;147(12):531–2
Quality time [editorial] England LE. **J Miss State Med Assoc** 1995 Aug;36(8):245
Physicians and domestic violence. Can we make a difference? [editorial] McAfee RE. **J Miss State Med Assoc** 1995 Oct–Nov;36(10):347–8
Television viewing and violence in children: pediatrician as agent for change. Sege R, et al. **J Miss State Med Assoc** 1995 Oct–Nov;36(10):318–27
Why patients enroll in clinical trials: physicians play a key role [news] McNeil C. **J Natl Cancer Inst** 1996 Jun 5; 88(11):709–11
Serving those for whom cure is no longer feasible (2) [news] Randal J. **J Natl Cancer Inst** 1996 Aug 7;88(15):1018–20
Today's physician, tomorrow's world [editorial] Walton TM Jr. **J Natl Med Assoc** 1995 Oct;87(10):739
Communicating risk: nuclear physicians as patient advocate [news] Steuer J. **J Nucl Med** 1996 Feb;37(2):11N–12N, 15N
Internalization of biopsychosocial values by medical students: a test of self–determination theory. Williams GC, et al. **J Pers Soc Psychol** 1996 Apr;70(4):767–79
Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Alderslade R. **J Public Health Med** 1995 Sep; 17(3):335–42 (7 ref.)
A call for physicians to help end the cycle of domestic violence. Barton N. **J S C Med Assoc** 1995 Oct;91(10):417–9
Euthanasia: a personal perspective. Salter RB. **J S C Med Assoc** 1996 Jun;92(6):275–9
Ramblings from an AMA ex–delegate [editorial] Thomison JB. **J Tenn Med Assoc** 1996 Feb;89(2):60–2
A prospective study of surgeon–performed ultrasound as the primary adjuvant modality for injured patient assessment. Rozycki GS, et al. **J Trauma** 1995 Sep;39(3):492–8; discussion 498–500
Trauma surgeons on violence prevention: ready, willing, and able? [editorial; comment] Schwab CW, et al. **J Trauma** 1996 Apr;40(4):671–2. Comment on: J Trauma 1996 Apr;40(4):602–6.
Violence prevention involvement among trauma surgeons: description and preliminary evaluation [see comments] Tellez ML, et al. **J Trauma** 1996 Apr;40(4):602–6. Comment in: J Trauma 1996 Apr;40(4):671–2.
The Kobe earthquake: a chance to serve. Fujiwara M. **JAMA** 1996 Jan 3;275(1):79, 81
Physician complicity in misrepresentation and omission of evidence of torture in postdetention medical examinations in Turkey [see comments] Iacopino V, et al. **JAMA** 1996 Aug 7;276(5):396–402. Comment in: JAMA 1996 Aug 7;276(5):416–7.
Older drivers and physicians [editorial; comment] Martinez R. **JAMA** 1995 Oct 4;274(13):1060. Comment on: JAMA 1995 Oct 4;274(13):1026–30.
The physician as general. Nie JB. **JAMA** 1996 Oct 2; 276(13):1099
The physician's role in helping smoke–sensitive patients to use the Americans with Disabilities Act to secure smoke–free workplaces and public spaces. Parmet WE, et al. **JAMA** 1996 Sep 18;276(11):909–13
Compromise, complicity, and torture [editorial; comment] Westermeyer J. **JAMA** 1996 Aug 7;276(5):416–7. Comment on: JAMA 1996 Aug 7;276(5):375–81. Comment on: JAMA 1996 Aug 7;276(5):396–402.
A model for practice guideline adaptation and implementation: empowerment of the physician [see comments] Wise CG, et al. **Jt Comm J Qual Improv** 1995 Sep;21(9):465–76. Comment in: Jt Comm J Qual Improv 1996 Feb;22(2):83–4.
HIV and the paediatrician as the child's advocate. Duke C, et al. **Lancet** 1996 Jul 27;348(9022):247–9
Pathologist or laboratory physician? [letter; comment] al–Jubouri MA. **Lancet** 1995 Sep 30;346(8979):903. Comment on: Lancet 1995 Jul 22;346(8969):258.
Pathologist or laboratory physician [letter; comment] Zanetto U. **Lancet** 1995 Sep 30;346(8979):903–4. Comment on: Lancet 1995 Jul 22;346(8969):258.
Smoking cessation counseling in adults and children: the clinician's role. Adams JA. **Md Med J** 1995 Oct; 44(10):779–87 (26 ref.)
"Managing" to redefine psychiatry. Cohen IH. **Md Med J** 1995 Dec;44(12):1019–23
Bonesetters and curers in a Mexican community: conceptual models, status, and gender. Huber BR, et al. **Med Anthropol** 1996 May;17(1):23–38
Leadership for quality improvement in group practices. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS40–51
Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337–74 (113 ref.)
Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43–9 (23 ref.). Comment in: Med J Aust 1996 Jun 17;164(12):759–60.
Workers' compensation––what role the doctor? [letter] Brown P. **Med J Aust** 1996 Jun 17;164(12):757–8
Workers' compensation––what role the doctor? [see comments] Cameron SJ. **Med J Aust** 1996 Jan 1;164(1):26–7 . Comment in: Med J Aust 1996 May 6;164(9):572.
Is a general practitioner legally bound to render assistance to a stranger? Gerber P. **Med J Aust** 1996 Aug 5; 165(3):159–61
Compensation, stress and the "V" code [letter; comment] Kaplan R. **Med J Aust** 1996 May 6;164(9):572. Comment on: Med J Aust 1996 Jan 1;164(1):26–7.
Workers' compensation––what role the doctor? [letter] Lark A. **Med J Aust** 1996 Jun 17;164(12):757; discussion 758
Managing HIV. Part 8: Controlling an epidemic. 8.1 HIV and the doctor's role in public health. Penny R, et al. **Med J Aust** 1996 Aug 19;165(4):209
Clinicians and management. Van der Weyden MB. **Med J Aust** 1995 Sep 18;163(6):320–1
Physician involvement in hospital information system selection: a success story. Rosenal T, et al. **Medinfo** 1995; 8 Pt 1:554–8
What effect are women physicians having on the practice of medicine in Michigan? It depends on who you ask. Ward RD. **Mich Med** 1995 Sep;94(9):18–21
Sports medicine's top performers [editorial] Meyer CR. **Minn Med** 1996 Jul;79(7):5
Taking the helm in turbulent times. Miller JP. **Minn Med** 1995 Sep;78(9):6–7, 58
Reporting obligations under the Vulnerable Adults Act. Sanders SJ. **Minn Med** 1995 Sep;78(9):43–6

Cutting school absenteeism [letter] Vinson CL. **Minn Med** 1996 Jun;79(6):58–9

What can physicians do to help victims of domestic violence? **Mo Med** 1995 Nov;92(11):688–91

The answer is, "no! chess for fun". **Hahn F. Mo Med** 1995 Sep;92(9):564–5

Smoking and health: a physician's responsibility. A statement of the Joint Committee on Smoking and Health. American College of Chest Physicians, American Thoracic Society, Asia Pacific Society of Respirology, Canadian Thoracic Society, European Respiratory Society, International Union Against Tuberculosis and Lung Disease. **Monaldi Arch Chest Dis** 1995 Oct;50(5):394–7

When you don't know what to say, don't say anything [letter] Lucey DT. **N C Med J** 1995 Sep;56(9):414

Doctor as witness, doctor as juror. Going to court in a non–defendant, non–adversarial role. Summerlin HH Jr. **N C Med J** 1995 Oct;56(10):510–2

Primary care physicians and health promotion [letter; comment] Alper PR. **N Engl J Med** 1996 Aug 22; 335(8):599–600; discussion 600. Comment on: N Engl J Med 1996 Apr 11;334(15):996–8.

Management of acute mesenteric ischemia [letter; comment] Donnelly WJ. **N Engl J Med** 1996 Aug 22;335(8):595–6; discussion 596. Comment on: N Engl J Med 1996 Apr 4;334(14):908–11.

Managed care [letter; comment] Lewis RJ. **N Engl J Med** 1995 Nov 2;333(18):1220; discussion 1221 . Comment on: N Engl J Med 1995 Jul 6;333(1):50–2.

Managed care [letter; comment] Millard F. **N Engl J Med** 1995 Nov 2;333(18):1221. Comment on: N Engl J Med 1995 Jul 6;333(1):50–2.

Primary care physicians and health promotion [letter; comment] Poland GA. **N Engl J Med** 1996 Aug 22; 335(8):599; discussion 600. Comment on: N Engl J Med 1996 Apr 11;334(15):996–8.

The physician's role in health promotion revisited—a survey of primary care practitioners [see comments] Wechsler H, et al. **N Engl J Med** 1996 Apr 11;334(15):996–8. Comment in: N Engl J Med 1996 Aug 22;335(8):599; discussion 600. Comment in: N Engl J Med 1996 Aug 22;335(8):599–600; discussion 600.

A survey of pediatric office–based interventions on smoking. Hymowitz N. **N J Med** 1995 Oct;92(10):657–60

"Unavailable" and death certificates [letter] Clarke B. **N Z Med J** 1996 Jan 26;109(1014):18

The role of general practitioners in mental health care: a survey of needs and problems. Falloon IR, et al. **N Z Med J** 1996 Feb 9;109(1015):34–6

The patient and the public good. Hellman S. **Nat Med** 1995 May;1(5):400–2

Adverse drug reactions: the role of the internist [editorial] Kerremans AL, et al. **Neth J Med** 1995 Dec;47(6):261–4

The neurologist and the dying patient [editorial; comment] Bernat JL, et al. **Neurology** 1996 Mar;46(3):598–9. Comment on: Neurology 1996 Mar;46(3):870–2.

Why oncologists should get involved in practice guideline development. ASCO Health Services Committee Program. **Oncology (Huntingt)** 1995 May;9(5):412, 415 (0 ref.)

Physicians should beware of Medicare secondary payer laws. **Pa Med** 1995 Sep;98(9):23

Hold harmless, due process resolutions supported by AMA House of Delegates [news] **Pa Med** 1995 Sep;98(9):40–1

Medical savings accounts: physicians are key. Fisher GR 3rd. **Pa Med** 1996 Mar;99(3):44

Managed care: physicians can build it better. Mecum RF. **Pa Med** 1995 Oct;98(10):1a–2a

Spreading us thinner and thinner...[editorial] Mills JW. **Pa Med** 1995 Jun;98(6):6

Coping with kaleidoscopic change. Montesano MT. **Pa Med** 1995 Jun;98(6):12–5

Orthopaedic trauma in children less than three years old: the orthopaedist's and pediatrician's problem. Novkov HV, et al. **Pediatr Emerg Care** 1996 Feb;12(1):21–2

Physicians and schools: a matter of communication. Adams RM. **Pediatr Infect Dis J** 1996 Jan;15(1):98–9

The role of the pediatric infectious disease subspecialist in a large health maintenance organization. Marcy SM. **Pediatr Infect Dis J** 1995 Nov;14(11):1030–3

The pediatric infectious disease physician: current roles and importance of the specialty in the care of children. Strategic Development and Long–Range Planning Committee, Pediatric Infectious Diseases Society. Peter G. **Pediatr Infect Dis J** 1995 Oct;14(10):900–3

The role of the pediatrician in prescribing therapy services for children with motor disabilities. American Academy of Pediatrics Committee on Children With Disabilities. **Pediatrics** 1996 Aug;98(2 Pt 1):308–10

Physician's role in coordinating care of hospitalized children. American Academy of Pediatrics. Committee on Hospital Care. **Pediatrics** 1996 Sep;98(3 Pt 1):509–10

The role of the pediatrician in implementing the Americans with Disabilities Act: subject review. American Academy of Pediatrics Committee on Children with Disabilities. **Pediatrics** 1996 Jul;98(1):146–8 (09 ref.)

The critical role of provider practices in undervaccination. Grabowsky M, et al. **Pediatrics** 1996 May;97(5):735–7

Assuring quality of care for children with special needs in managed care organizations: roles for pediatricians. Ireys HT, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):178–85

Pediatric office–based smoking intervention: impact on maternal smoking and relapse. Wall MA, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):622–8

Mental health of medical students: the culture of objectivity in medicine. Gordon LE. **Pharos** 1996 Spring;59(2):2–10

Managed care: now you see it, now you don't [editorial] [see comments] Goldwyn RM. **Plast Reconstr Surg** 1995 Dec;96(7):1697. Comment in: Plast Reconstr Surg 1996 Sep;98(3):570. Comment in: Plast Reconstr Surg 1996 Sep;98(3):570–1.

Domestic violence. Do you know when and how to intervene? Steiner RP, et al. **Postgrad Med** 1996 Jul; 100(1):103–6, 111–4, 116 (19 ref.)

Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)

Payers, players, and providers: the new lexicon [editorial] Lazarus A. **Psychiatr Serv** 1995 Oct;46(10):977

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

Domestic violence: a guide for health care providers. Hazen A, et al. **R I Med** 1995 Oct;78(10):290–2

Capital punishment and the physician [letter; comment] Settipane GA. **R I Med** 1995 Oct;78(10):277. Comment on: R I Med 1995 Aug;78(8):215–21.

Smoking cessation: professional problem or public policy? [editorial] Calverley PM. **Respir Med** 1996 Mar;90(3):123–5

The ophthalmologist's role in Chlamydia trachomatis infection. Mancino R, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1994;71:79–83

Anti–life mentality in medical circles [editorial] de Muelenaere CW. **S Afr Med J** 1995 Nov;85(11):1147–50

Role of Danish general practitioners in AIDS prevention. Sandbaek A, et al. **Scand J Prim Health Care** 1995 Dec; 13(4):307–15

Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67–9 (41 ref.)

Patient rights and physician responsibility: four problems in AIDS care. Cooke M. **Semin Dermatol** 1995 Sep; 14(3):252–8

Medical humanitarianism and human rights: reflections on doctors without borders and doctors of the world. Fox RC. **Soc Sci Med** 1995 Dec;41(12):1607–16; discussion 1617–26

Interruptive patterns in medical visits: the effects of role, status and gender. Irish JT, et al. **Soc Sci Med** 1995 Sep; 41(6):873–81

Non–medical influences on medical decision–making. McKinlay JB, et al. **Soc Sci Med** 1996 Mar;42(5):769–76

Patients' and doctors' perception of long–term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study [see comments] Fossá SD, et al. **Support Care Cancer** 1996 Mar;4(2):118–28. Comment in: Support Care Cancer 1996 Mar;4(2):73–4.

The physician's role in curing social ills. Carson B. **Surg Neurol** 1996 May;45(5):497–503

Heri, Hodie, Cras ... yesterday, today, and tomorrow. Cancellaro LA. **Tenn Med** 1996 Aug;89(8):284–5

The ultimate lottery. Life, death, and transplant surgeons. BeSaw L. **Tex Med** 1996 Jan;92(1):30–5

Health–care outcomes research. Texas Medical Association Council on Scientific Affairs. Burnside JW. **Tex Med** 1996 Jul;92(7):61–71

When less is more. Physicians turn to hospice care to help dying patients. Jones TL. **Tex Med** 1996 Jan;92(1):42–6

Order in the court. TEXPAC effort to reform state's highest court paying dividends. Ortolon K. **Tex Med** 1995 Nov; 91(11):31–3

Physicians need to know disabled parking guidelines. Pietrobono J. **Tex Med** 1995 Dec;91(12):39–40

The role of doctors in influencing infant feeding practices in South India. Fidler K, et al. **Trop Doct** 1995 Oct; 25(4):178–80

Colorado pediatricians' involvement in community activities. Brown J, et al. **West J Med** 1995 Nov;163(5):451–3

A picture is worth a thousand words [editorial] Clever LH. **West J Med** 1995 Nov;163(5):485

Preserving our noble heritage. Kassirer JP. **West J Med** 1996 Jun;164(6):535–6

WIC update: the physician's role in helping families, pregnant women obtain good nutrition. Huber C. **Wis Med J** 1995; 94(8):462–3

Domestic violence: the physician as patient advocate. LaCrosse L. **Wis Med J** 1996 Jun;95(6):392–3

Doctor, you're needed away from the bedside. Richards MJ. **Wis Med J** 1995;94(7):329–30

Differences and diversity: shall it be confrontation or creativity? Richards MJ. **Wis Med J** 1995 Nov;94(11):595–6

Family violence: practical recommendations for physicians and the medical community. Buel SM, et al. **Womens Health Issues** 1995 Winter;5(4):158–72 (24 ref.)

Project SAFE: domestic violence education for practicing physicians. Flitcraft A. **Womens Health Issues** 1995 Winter; 5(4):183–8

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)

Physicians can reduce the incidence of domestic violence. Jones RF 3rd. **Womens Health Issues** 1995 Winter;5(4):157

What do people expect from their doctors? Boland M. **World Health Forum** 1995;16(3):221–7; discussion 227–47

[Physician's role as a rehabilitation worker (editorial)] Alaranta H, et al. **Duodecim** 1994;110(15):1373–4 **(Fin)**

[Challenges for medical education at the beginning of the new millennium] Pasternack A. **Duodecim** 1995; 111(1):85–90 **(Fin)**

[Surgeon's role in the screening of breast cancer (editorial)] Brémond A. **Ann Chir** 1996;50(2):103–5 **(Fre)**

[Absent pediatrician or pediatrician as conductor of an orchestra] Farriaux JP. **Arch Pediatr** 1996;3 Suppl 1:32s–33s **(Fre)**

[Role and strategy of the pediatrician facing school difficulties] Vallée L, et al. **Arch Pediatr** 1996;3 Suppl 1:61s–64s **(Fre)**

[Individual screening of breast cancer: the gynecologists's point of view] Gorins A. **Contracept Fertil Sex** 1996 Mar; 24(3):191–3 **(Fre)**

[Ethical problems with the current French practice in therapeutic abortions. Part 3: resolving moral dilemmas in fetal medicine] Gold F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):727–32 (Eng. Abstr.) **(Fre)**

[Missions of medicine and the foundation of medical morals] Daher M. **J Med Liban** 1995;43(1):33–5 **(Fre)**

[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

[Identification of victims of violence and torture: the practitioner's role] Subilia L, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1291–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Brief definitions of concepts in medical ethics. 32. The Geneva Declaration] Meran JG. **Diskussionsforum Med Ethik** 1994;(3–4):XIV **(Ger)**

[Physicians and politics] Schärli AF. **Schweiz Rundsch Med Prax** 1996 Jun 18;85(25–26):832–9 (Eng. Abstr.) **(Ger)**

[Necessity of psychiatrist's support for critical care medicine] Tedo I. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):151–8 (Eng. Abstr.) **(Jpn)**

[Evaluation of visual functions and ophthalmologists in future] [editorial] Saishin M. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):3–4 **(Jpn)**

[Abortion legislation and physician's role (see comments)] Bergsjø P. **Tidsskr Nor Laegeforen** 1996 Apr 20; 116(10):1207–8. Comment in: Tidsskr Nor Laegeforen 1996 May 20;116(13):1616–7. **(Nor)**

[Physicians' responsibility in the violation of human rights] Dramsdahl M, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10; 116(18):2198 **(Nor)**

[Physicians from all countries—unite! Growth and return of severe infections] Haug C. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):353–4 **(Nor)**

[Head physicians should prioritize clinical research (letter)] Jensen P. **Tidsskr Nor Laegeforen** 1996 Jun 20; 116(16):1934–5 **(Nor)**

[Physician's role in Norwegian art of painting] Larsen IF. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3790–3 (Eng. Abstr.) **(Nor)**

[German medicine during the Nazi regime—cooperation and resistance] Lavik NJ. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3794–9 (Eng. Abstr.) **(Nor)**

[Jehovah's Witnesses—blood transfusion or not? Are physicians all–time losers?] Oian P. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):646–7 **(Nor)**

[Educating future physicians for Ontario—eight roles of physicians] Ostbye T. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):995–6 **(Nor)**

[Is there a role for general practitioners in future medicine?] Sletnes KE. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2322–4 (Eng. Abstr.) **(Nor)**

[Role of the clinician in modern cardiology (editorial)] da Luz PL. **Arq Bras Cardiol** 1995 Apr;64(4):297–8 **(Por)**

[The role of the primary care physician in AIDS (editorial)] da Pena Alvarez JM. **Aten Primaria** 1996 Jul–Aug; 18(3):103–4 **(Spa)**

[Irresponsible physicians! (letter)] Brinkeback D. **Lakartidningen** 1995 Nov 8;92(45):4161 **(Swe)**

[Preventive medical work is important but difficult. Shortage of time and information is main obstacle] Himmelmann L, et al. **Lakartidningen** 1996 Feb 21;93(8):694–9 **(Swe)**

[Physician in the cyberspace. Internet is cheap and convenient for communication as well as training] Holmquist C. **Lakartidningen** 1996 Feb 7;93(6):471–4 **(Swe)**

[What is the role of physicians employed by insurance companies? (letter)] Hultman PA. **Lakartidningen** 1996 Apr 10;93(15):1408 **(Swe)**

[War and peace in Yugoslavia—what role can the Swedish medical community play?] Jacobsson L, et al. **Lakartidningen** 1996 Aug 7;93(32–33):2721–2 **(Swe)**

[The physician–in–chief must follow the rules of the game (letter)] Jacobsson L. **Lakartidningen** 1996 May 22; 93(21):2042 **(Swe)**

[More physicians should be engaged in standardization procedures] Johnson K. **Lakartidningen** 1996 Feb 21; 93(8):652–4 **(Swe)**

[Correct thinking but incorrect handlings. Confusing reality of emergency care physicians doesn't fit in the responsibility pattern] Kesek M. **Lakartidningen** 1995 Nov 29;92(48):4572–6 **(Swe)**

[What is the value of well–tried experience of general practitioners?] Krakau I, et al. **Lakartidningen** 1996 Apr 17;93(16):1544–6 **(Swe)**

[Expanded rehabilitation responsibility for insurance authorities. A new role of physicians employed by insurance authorities requires education] Lidbeck J. **Lakartidningen** 1996 Jun 5;93(23):2258–60 **(Swe)**

[The Mälarhospital in Eskilstuna: personal and professional development as part of internship] Lind J. **Lakartidningen** 1995 Nov 1;92(44):4061–2, 4067–9 **(Swe)**

[Expert physicians are important in insurance claim processing. Medical assessment is the basis for correct compensation] Lysell E. **Lakartidningen** 1996 Feb 14; 93(7):589–92 **(Swe)**

[The physician must not put himself before his patient (letter)] Mandahl A. **Lakartidningen** 1996 Jun 5;93(23):2222 **(Swe)**

[Hospital physicians—general practitioners and continuity of health care (letter)] Nordlander NB. **Lakartidningen** 1996 May 22;93(21):2042 **(Swe)**

[The role in the society of physicians employed by insurance authorities. Extended information as a basis for assessment] Rydell N. **Lakartidningen** 1996 Jun 26;93(26–27):2487 **(Swe)**

[Preventive work requires more engagement (letter)] Swartz ME. **Lakartidningen** 1996 May 1;93(18):1710–1 **(Swe)**

[Is the head of a clinic a common civil servant?] Szamosi A. **Lakartidningen** 1996 May 29;93(22):2118, 2123 **(Swe)**

[A "loyal" chief physician is not very popular among the public (letter)] Szamosi A. **Lakartidningen** 1996 Jun 5; 93(23):2222 **(Swe)**

[A French physician is at risk to be suspended because of a book about Mitterand's disease] Trenning-Himmelsbach A. **Lakartidningen** 1996 Feb 7;93(6):435 **(Swe)**

PHYSICIANS, WOMEN

Applicant pool for emergency medicine residencies [editorial; comment] Granger NA, et al. **Ann Emerg Med** 1996 Mar; 27(3):363–4. Comment on: Ann Emerg Med 1996 Mar;27(3):331–8.

Underrepresentation in the applicant pool for emergency medicine residencies [editorial; comment] Strayhorn G. **Ann Emerg Med** 1996 Mar;27(3):364–6. Comment on: Ann Emerg Med 1996 Mar;27(3):331–8.

Balancing family and career: advice from the trenches. Carnes M. **Ann Intern Med** 1996 Oct 1;125(7):618–20

Whither WIST? Women in Surgical Training Scheme. Makin CA. **Ann R Coll Surg Engl** 1995 Jul;77(4 Suppl):197

Obstetric experience of female medical practitioners as patients. Evans S. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):282–5

Boosting women consultants [letter] Cockburn J, et al. **BMJ** 1996 May 11;312(7040):1230

Do patients prefer women doctors? Cockburn J, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):2–3

Isolation, excessive time demands and sexism face female MDs, CMA workshop told. MacLeod K. **Can Med Assoc J** 1996 Mar 1;154(5):708–9

Women physicians in Delaware. Walters D. **Del Med J** 1996 Jul;68(7):365–6

Gender concordance between family practice residents and diagnoses in an ambulatory setting. Orzano AJ, et al. **Fam Med** 1995 Jul–Aug;27(7):440–3

Consumers. The feminine mystique [news] **Hosp Health Netw** 1995 Dec 5;69(23):14

In the OR. The humane touch. Sandrick KM. **Hosp Health Netw** 1996 Jun 5;70(11):64

Women in dermatology: a personal view. XII. Rogers S. **Int J Dermatol** 1995 Aug;34(8):531–2

Harassment of women physicians. Schiffman M, et al. **J Am Med Womens Assoc** 1995 Nov–Dec;50(6):207–11 (36 ref.)

Effect of physician gender on the prescription of estrogen replacement therapy. Seto TB, et al. **J Gen Intern Med** 1996 Apr;11(4):197–203

Women physicians leading change. **J Ky Med Assoc** 1995 Sep;93(9):406–13

Training women for surgical leadership. Wilson JA. **J R Coll Surg Edinb** 1996 Jun;41(3):212–4

Women doctors—a review [letter] Crome P, et al. **J R Soc Med** 1995 Dec;88(12):724

Promotion of women physicians in academic medicine [letter; comment] Nickerson KG, et al. **JAMA** 1995 Oct 11; 274(14):1133; discussion 1134. Comment on: JAMA 1995 Apr 5;273(13):1022–5.

Promotion of women physicians in academic medicine [letter] Ruffin MT 4th, et al. **JAMA** 1995 Oct 11;274(14):1133–4

Would I rather be doing anything else?: Kansas women in medicine. Ward S. **Kans Med** 1995 Fall;96(3):140–5

The feminization of the medical profession in Israel. Notzer N, et al. **Med Educ** 1995 Sep;29(5):377–81

Women consultants, their background and training: some myths explored. Tait A, et al. **Med Educ** 1995 Sep; 29(5):372–6

What effect are women physicians having on the practice of medicine in Michigan? It depends on who you ask. Ward RD. **Mich Med** 1995 Sep;94(9):18–21

MSMA women physicians leading change. Starnes LR. **Mo Med** 1995 Sep;92(9):584–7

Is registrarship a different experience for women? Saloojee H, et al. **S Afr Med J** 1996 Mar;86(3):253–7

Women in medicine. Franke J. **Tex Med** 1995 Sep;91(9):36–9

[Characteristics of career and life planning by women physicians] Jensen U. **Arch Gynecol Obstet** 1995; 257(1–4):694–9 **(Ger)**

[Women see—women physicians—see women] Riegl GF. **Arch Gynecol Obstet** 1995;257(1–4):583–92 **(Ger)**

[Health and work conditions of physicians. Experiences and visions 35 years after certification] Noer K. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3642–3 **(Nor)**

[Instruction and equality in medical research. Sex-related obstacles after equal education] Hultman CM, et al. **Lakartidningen** 1995 Nov 22;92(47):4452, 4455–6, 4461 **(Swe)**

ECONOMICS

Salary inequities and health care costs [letter] Mutha S, et al. **Acad Med** 1995 Oct;70(10):853–4

Kinder, gentler, and lower-paid women physicians. Braus P. **Minn Med** 1995 Sep;78(9):8–9, 60

Differences in earnings between male and female physicians [see comments] Baker LC. **N Engl J Med** 1996 Apr 11; 334(15):960–4. Comment in: N Engl J Med 1996 Apr 11;334(15):982–3. Comment in: N Engl J Med 1996 Aug 15;335(7):524–5; discussion 525. Comment in: N Engl J Med 1996 Aug 15;335(7):525.

EDUCATION see EDUCATION, MEDICAL

HISTORY

1995 Inaugural address [editorial] Fourcroy JL. **J Am Med Womens Assoc** 1995 Nov–Dec;50(6):198

"Pioneer work on all sides": the first generations of women physicians in The Netherlands, 1879–1930. Marland H. **J Hist Med Allied Sci** 1995 Oct;50(4):441–77

Women doctors—a review [letter] Bewley BR. **J R Soc Med** 1996 Jun;89(6):359

A celebration of women in anaesthesia 1894–1994. Clarke RS, et al. **J R Soc Med** 1995 Sep;88(9):519P–521P

More on women in organized medicine [letter; comment] Miller JM. **Md Med J** 1996 Jan;45(1):23. Comment on: Md Med J 1995 Sep;44(9):709–10.

A brief history of women and organized medicine [see comments] Short JH. **Md Med J** 1995 Sep;44(9):709–10. Comment in: Md Med J 1996 Jan;45(1):23.

Wisconsin women have a long history in medicine. Campbell G. **Wis Med J** 1995 Dec;94(12):708–9

[Medical education of women in Germany—progress in our century] Wilmanns JC. **Arch Gynecol Obstet** 1995; 257(1–4):712–9 **(Ger)**

[About physicians as characters in Norwegian literature] Nørstebø E. **Tidsskr Nor Laegeforen** 1995 Dec 10; 115(30):3778–83 (Eng. Abstr.) **(Nor)**

[The first dissertations by women physicians defended at the Military Medical Academy] Shabunin AV. **Voen Med Zh** 1995 Oct;(10):78–9 **(Rus)**

PSYCHOLOGY

Marrying medicine. Van Peenen HJ. **Ann Intern Med** 1995 Dec 15;123(12):957–9

Gender differences in general practitioners at work. Chambers R, et al. **Br J Gen Pract** 1996 May; 46(406):291–93

How family influences practice of obstetrics. Do married women family physicians make different choices? Brown JB, et al. **Can Fam Physician** 1996 Jul;42:1319–26

Female family physicians in obstetrics: achieving personal balance. Carroll JC, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1283–9

Do Canadian female surgeons feel discriminated against as women? Ferris LE, et al. **Can Med Assoc J** 1996 Jan 1; 154(1):21–7

Physician-patient relationships: patients as friends and patients who harass [letter; comment] Phillips S. **Can Med Assoc J** 1996 Apr 15;154(8):1149–50. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1241–5.

Contrasting experiences and perceptions of women and men physician graduates of Stanford University School of Medicine. Gray GM, et al. **Trans Am Clin Climatol Assoc** 1995;107:159–71; discussion 172–4

[Psychological and social career blocks in the career path of the woman physician] Sieverding M. **Arch Gynecol Obstet** 1995;257(1–4):699–704 **(Ger)**

[4000 physicians answered a health status questionnaire. Physicians' mental health is worse compared to general population] Orn P. **Lakartidningen** 1996 Jan 31;93(5):317 **(Swe)**

STATISTICS & NUMERICAL DATA

Applicant pool for emergency medicine residency programs: information on minority and female applicants [see comments] Martin ML. **Ann Emerg Med** 1996 Mar; 27(3):331–8. Comment in: Ann Emerg Med 1996 Mar;27(3):363–4. Comment in: Ann Emerg Med 1996 Mar;27(3):364–6.

Utilisation of hormone replacement therapy by women doctors [see comments] Isaacs AJ, et al. **BMJ** 1995 Nov 25;311(7017):1399–401. Comment in: BMJ 1996 May 18;312(7041):1301.

Doctors and their careers: the future [letter; comment] Bynoe AG. **Br J Hosp Med** 1995 Sep 6–19;54(5):235. Comment on: Br J Hosp Med 1995 Jun 7–20;53(11):545–6.

Sex differences in physicians' activity level [letter; comment] McCall J. **Can Med Assoc J** 1996 Feb 15;154(4):446; discussion 446, 448. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

Sex differences in physicians' activity level [letter; comment] Rieder MJ. **Can Med Assoc J** 1996 Feb 15;154(4):446; discussion 446, 448. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

Female enrollment in colleges of osteopathic medicine: five years and five percentage points behind. Baker HH. **J Am Osteopath Assoc** 1995 Oct;95(10):604–6

Women doctors—a review. Bewley BR. **J R Soc Med** 1995 Jul;88(7):399P–405P (37 ref.)

Women physicians—good news and bad news [editorial; comment] Kirchstein RL. **N Engl J Med** 1996 Apr 11; 334(15):982–3. Comment on: N Engl J Med 1996 Apr 11;334(15):960–4.

Breastfeeding practices among resident physicians. Miller NH, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):434–7

Woman, M.D.: issues, perceptions and choices. Johns CJ. **Trans Am Clin Climatol Assoc** 1995;107:1–19

Female medical students outnumbering men; medical schools seeking more female faculty, mentors. Campbell G. **Wis Med J** 1995 Dec;94(12):703–6

[Women physicians and academic careers] Höss C. **Arch Gynecol Obstet** 1995;257(1–4):704–9 **(Ger)**

[Woman physician in general practice] Leifels-Fischer B. **Arch Gynecol Obstet** 1995;257(1–4):709–12 **(Ger)**

[Women in dermatology. German and other European clinics in a comparison] Hermes B, et al. **Hautarzt** 1996 May; 47(5):351–4 (Eng. Abstr.) **(Ger)**

[Women in the medical profession in Israel] Notzer N, et al. **Harefuah** 1995 Dec 1;129(11):449–51, 536 (Eng. Abstr.) **(Heb)**

SUPPLY & DISTRIBUTION

Women family physicians and rural medicine. Can the grass be greener in the country [editorial] Rourke LL, et al. **Can Fam Physician** 1996 Jun;42:1063–7, 1077–82 **(Eng, Fre)**

Growing number of female physicians changing the face of Canadian medicine. Birenbaum R. **Can Med Assoc J** 1995 Oct 15;153(8):1164–6

TRENDS

Career changes among Saskatchewan physicians [see comments] Shaw S, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1035–8. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1049–52.

UTILIZATION

The sex of the general practitioner: a comparison of characteristics, patients, and medical conditions managed. Britt H, et al. **Med Care** 1996 May;34(5):403–15

PHYSICS

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209–14 (44 ref.)

Commentary on Rosenbluth W, Hicks L. Evaluating low-speed rear-end impact severity and resultant occupant stress parameters J Forensic Sci, 1994;39 (6, Nov): 1393–1424 [letter] Bailey M. **J Forensic Sci** 1996 Jul; 41(4):551

Physicists advance into biology [news] Glanz J. **Science** 1996 May 3;272(5262):646–8

EDUCATION

Effect of integration of injury control information into a high school physics course. Martinez R, et al. **Ann Emerg Med** 1996 Feb;27(2):216–24

HISTORY

Einstein's medical friends and their influence on his life. Kantha SS. **Med Hypotheses** 1996 Mar;46(3):257–60

Pierre and Marie Curie-Sklodowska. Chavaudra J. **Med Phys** 1995 Nov;22(11 Pt 2):1877–87

Rutherford's curriculum vitae, 1894–1907. Cohen M. **Med Phys** 1995 Jun;22(6):841–59

Henri Becquerel (1852–1908). Dutreix J, et al. **Med Phys** 1995 Nov;22(11 Pt 2):1869–75 (47 ref.)

Origins of the science of radiation physics and of the field of radiology. Laughlin JS. **Med Phys** 1995 Nov;22(11 Pt 2):A7–9

Notes on the legacy of the Röntgen rays. Rosenow UF. **Med Phys** 1995 Nov;22(11 Pt 2):1855–67

The quest for the laws governing radiations and the search for beneficial innovations. Laughlin JS. **Radiat Res** 1995 Nov;144(2):129–40 (59 ref.)

Roentgen. Rossi HH, et al. **Radiat Res** 1995 Nov;144(2):124–8

Lightening. Goldblatt D. **Semin Neurol** 1995 Dec; 15(4):397–400

[From X-rays to radioactivity and radium. The discovery and works of Henri Becquerel (1851–1908)] Dutreix J. **Bull Acad Natl Med** 1996 Jan;180(1):109–18 (Eng. Abstr.) **(Fre)**

[Bertha Röntgen or the transparency of the hand] Picard JD. **Bull Acad Natl Med** 1996 Jan;180(1):119–29 (Eng.

PHYSICS

Abstr.) **(Fre)**
[Wilhelm Conrad Röntgen and the discovery of X-rays] Tubiana M. **Bull Acad Natl Med** 1996 Jan;180(1):97–108 (Eng. Abstr.) **(Fre)**
[The discovery of x-rays] Vlasov PV.
Vestn Rentgenol Radiol 1995 Sep–Oct;(5):55–7 **(Rus)**

PHYSIOGNOMY

see related
FACIAL EXPRESSION

PHYSIOLOGIC AVAILABILITY see **BIOLOGICAL AVAILABILITY**

PHYSIOLOGY

Toward modeling the human physionome. Bassingthwaighte JB. **Adv Exp Med Biol** 1995;382:331–9
SSR Research Award. David Garbers. **Biol Reprod** 1996 Feb; 54(2):313
Distinguished Service Award. Rupert P. Amann.
Biol Reprod 1996 Feb;54(2):313–5
3rd Congress of Federation of Asian and Oceanian Physiological Societies. Shanghai, China, 7–10 November 1994. Abstracts. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):A1–61
Bibliography of Comparative Biochemistry and Physiology A. Generated from the Current Awareness in Biological Sciences database. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):I–III
Bibliography for Comparative Biochemistry and Physiology B generated from the Current Awareness in Biological Sciences database.
Comp Biochem Physiol B Biochem Mol Biol 1996 May; 114(1):I–VI
Physiologic variables in nursing research: progress, yes ... but more work is needed [letter; comment] Sigmon HD, et al. **Image J Nurs Sch** 1996 Summer;28(2):94. Comment on: Image J Nurs Sch 1995 Winter;27(4):273–6.
Proceedings of the scientific meetings of the Physiological Society. University College Cork, 19–22 September 1995. Abstracts. **J Physiol (Lond)** 1995 Nov;489:1P–185P
Proceedings of the scientific meeting of the Physiological Society. Oxford, 11–14 July 1995. Abstracts.
J Physiol (Lond) 1995 Sep;487:1P–226P, 1S–13S
The Proceedings of the 72nd Annual Meeting of the Physiological Society of Japan. Nagoya, March 30–31, 1995. Abstracts. **Jpn J Physiol** 1995;45 Suppl 1:S1–283
A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)
1st Congress of the Federation of European Physiological Societies. Maastricht, The Netherlands, 9–12 September 1995. Abstracts. **Pflugers Arch** 1995;430(4 Suppl):i–xii, R9–170
Physiology on the World-Wide Web. Gardner D.
Physiologist 1995 Oct;38(5):187, 193–4
[Quo vadis pathophysiology? (letter)] Rokyta R.
Cas Lek Cesk 1995 Sep 20;134(18):595 **(Cze)**
[Biocybernetics and physiology yesterday and today] Wünsch Z, et al. **Cesk Fysiol** 1996 Mar;45(1):42–6 (Eng. Abstr.) **(Cze)**
[63rd Congress of the Society of Physiology. Strasbourg, 20–22 December 1995. Abstracts] **Arch Physiol Biochem** 1995 Nov;103(5):D1–160 **(Fre)**
[The problems of human ecological physiology] Sultanov FF. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):129–34 **(Rus)**
[Mathematical approach to the evaluation of accuracy of physiological measurements by different methods] Pravetskii NV, et al. **Kosm Biol Aviakosm Med** 1991 Nov–Dec;25(6):53–5 **(Rus)**
[Theses of papers presented at the 3rd (XVI) meeting of the Physiologic Society of the Russian Academy of Sciences] **Usp Fiziol Nauk** 1994 Jul–Sep;25(3):1–127 **(Rus)**
[The information principle in physiology: an analysis from the position of the general theory of functional systems] Sudakov KV. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):3–27 (79 ref.) (Eng. Abstr.) **(Rus)**

EDUCATION

Conference on teaching physiology. **Am J Physiol** 1995 Dec; 269(6 Pt 3):S80–4
Directed case study method for teaching human anatomy and physiology. Cliff WH, et al. **Am J Physiol** 1996 Jun; 270(6 Pt 3):S19–28
An educational tool for understanding the cardiovascular changes associated with diabetes. Collins HL, et al.
Am J Physiol 1995 Dec;269(6 Pt 3):S4–31
Integrative physiology: some texts and methods of integrative study. Engelberg J. **Am J Physiol** 1995 Dec;269(6 Pt 3):S55–60
Preparing students to participate in an active learning environment. Modell HI. **Am J Physiol** 1996 Jun;270(6 Pt 3):S69–77
Resting membrane potentials: a student test of alternate hypotheses. Thurman CL. **Am J Physiol** 1995 Dec;269(6 Pt 3):S37–41
Understanding physiology by acting out concepts. Yucha CB.
Am J Physiol 1995 Dec;269(6 Pt 3):S50–4
Instructing the animal physiology graduate student in human assisted reproductive technology. Boone WR, et al.
J Anim Sci 1995 Aug;73(8):2503–6
The training of physiologists for the 21st century. Williams JA. **Physiologist** 1995 Oct;38(5):189–91
[Should there be something new in the teaching of physiology in medical schools?] Herget J. **Cesk Fysiol** 1995 Sep; 44(3):158–9 **(Cze)**
[Should there be something new in the teaching of physiology in medical schools? (letter)] Trojan S. **Cesk Fysiol** 1995 Dec;44(4):206 **(Cze)**

HISTORY

An unrecognized renal physiologist: Friedrich Wöhler. Richet G. **Am J Nephrol** 1995;15(6):528–32
Our debt to Peter Stewart. Jones NL.
Can J Appl Physiol 1995 Sep;20(3):326–32
Carl Arthur Goresky. August 25, 1932 to March 21, 1996. Goldsmith HL, et al. **Clin Invest Med** 1996 Jun;19(3):144–8
Homer Smith: his contribution to physiology. Berliner RW.
J Am Soc Nephrol 1995 Jun;5(12):1988–92
William Harvey and the circulation of the blood. Chapman A. **J Lab Clin Med** 1995 Nov;126(5):423–7
Cellular aspects of transvascular exchange: a 40-year perspective. Renkin EM. **Microcirculation** 1994 Oct; 1(3):157–67
Reflections of a "senior physiologist": bridge over the Pacific ocean. Koizumi K. **Neurobiology (Bp)** 1995;3(3–4):381–92
Death and the internal milieu: Claude Bernard and the origins of experimental medicine. Wasserstein AG.
Perspect Biol Med 1996 Spring;39(3):313–26
A short survey of the scientific work of Torsten Teorell. Obrink KJ. **Ups J Med Sci** 1995;100(1):11–8
Torsten Teorell, the father of pharmacokinetics. Paalzow LK. **Ups J Med Sci** 1995;100(1):41–6
[One more league on the windy and rainy journey] Chen MQ. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):193–8 **(Chi)**
[History of the Physiological Society] **Cesk Fysiol** 1995 Dec; 44(4):208–11 **(Cze)**
[History of physiology journals] Hník P. **Cesk Fysiol** 1996 Mar;45(1):47–9 (Eng. Abstr.) **(Cze)**
[History of the Physiology Society] Trojan S.
Cesk Fysiol 1995 Dec;44(4):208–11 **(Cze)**
[100 years with Starling's hypothesis] Henriksen JH.
Ugeskr Laeger 1996 May 13;158(20):2843–4 **(Dan)**
[Eulogy of Professor Corneille Heymans, Nobel Prize in Medicine and Physiology in 1938] Godfraind T.
Bull Mem Acad R Med Belg 1994;149(12):456–64 **(Fre)**
[Friedrich Hoffmann and Georg Ernst Stahl, classic representatives of baroque medicine] Győzö B.
Orv Hetil 1996 Mar 10;137(10):531–3 **(Hun)**
[The pedagogical activities of an academic and scientific complex (on the 20th anniversary of the creation of the P. K. Anokhin Research Institute of Normal Physiology of the Russian Academy of Medical Sciences)] Makarov VA. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):109–12 **(Rus)**
[I. P. Pavlov's Nobel Prize speech] Samoĭlov VO.
Fiziol Zh Im I M Sechenova 1995 Nov;81(11):157–65 **(Rus)**
[Their memory should be preserved by grateful descendents (Ivan Mikhallovich Sechenov, Ivan Petrovich Pavlov)] Makarov VA, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1995 Nov–Dec; 45(6):1219–24 **(Rus)**
[The man behind the rod: John Auer. A broad-minded physiologist] Billström R, et al. **Lakartidningen** 1995 Sep 27;92(39):3577–9 **(Swe)**

INSTRUMENTATION

A new instrument for the measurement of rib cage and abdomen circumference variation in respiration at rest and during exercise. Lafortuna CL, et al.
Eur J Appl Physiol 1995;71(2–3):259–65
Gravitational artefact in frequency spectra of movement acceleration: implications for actigraphy in young and elderly subjects. Van Someren EJ, et al.
J Neurosci Methods 1996 Mar;65(1):55–62
[An audio monitor for physiological research] Bud'ko DIu, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):133–5 **(Rus)**

METHODS

A comparison of intersegmental joint dynamics to isokinetic dynamometer measurements. Kaufman KR, et al.
J Biomech 1995 Oct;28(10):1243–56
[A tensometric method for the quantitative assessment of tremor] Romanov SP, et al.
Fiziol Zh Im I M Sechenova 1996 Feb;82(2):118–23 **(Rus)**

TRENDS

Beyond discipline: creating a culture for interdisciplinary research. Bruhn JG. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):331–41
Integrative study in physiology and medicine: obstacles on the road to integration. Engelberg J.
Integr Physiol Behav Sci 1995 Sep–Dec;30(4):265–72

PHYSIOLOGY, COMPARATIVE

Bibliography of Comparative Biochemistry and Physiology A generated from the Current Awareness in Biological Sciences database. **Comp Biochem Physiol A Physiol** 1995 Oct;112(2):I–III

HISTORY

A tribute to Charles Richard Taylor. Charles P. Lyman professor of biology at Harvard University. 8 September 1939 to 10 September 1995. Weibel ER. **J Exp Biol** 1996 Aug;199 (Pt 8):i–iv

PHYSIOTHERAPY see **PHYSICAL THERAPY**

PHYSOSTIGMINE

ADMINISTRATION & DOSAGE

Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Peskind ER, et al. **Biol Psychiatry** 1995 Oct 15; 38(8):532–8
Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs. Meshulam Y, et al. **J Appl Toxicol** 1995 Jul–Aug; 15(4):263–6
[Physostigmine in treatment of cerebellar ataxia] Aschoff JC, et al. **Nervenarzt** 1996 Apr;67(4):311–8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Observations on the physostigmine syndrome in patients with Alzheimer's disease. Wirkowski E, et al.
J Neuropsychiatry Clin Neurosci 1991 Winter;3(1):73–5

ANALOGS & DERIVATIVES

Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. Cuadra G, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):228–36

PHARMACOKINETICS

Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Asthana S, et al.
Clin Pharmacol Ther 1995 Sep;58(3):299–309

PHARMACOLOGY

Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats. Ally A, et al. **Brain Res** 1995 Apr 24;677(2):268–76
Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Storch A, et al.
Eur J Pharmacol 1995 Aug 15;290(3):207–19
Enhancement by nifedipine of cholinergic-induced depression of locomotor activity in mice. Sansone M, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):163–7
Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse. Ukai M, et al. **Gen Pharmacol** 1995 Nov; 26(7):1529–32
The effect of physostigmine on acid–base status in arterial and venous blood of anaesthetized rabbits following hypovolemic shock. Zunić G, et al. **Gen Pharmacol** 1995 Mar;26(2):291–5
Metabolic response to tacrine (THA) and physostigmine in the aged rat brain. Bassant MH, et al.
J Cereb Blood Flow Metab 1995 Nov;15(6):1093–102
Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. Cuadra G, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):228–36
Enhancement of the post-training cholinergic tone antagonizes the impairment of retention induced by a nitric oxide synthase inhibitor in mice. Kopf SR, et al.
Neurobiol Learn Mem 1996 May;65(3):207–12
Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Protais P, et al.
Psychopharmacology (Berl) 1995 Aug;120(4):376–83

THERAPEUTIC USE

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Asthana S, et al.
Alzheimer Dis Assoc Disord 1995 Winter;9(4):223–32
Protracted post-traumatic confusional state treated with physostigmine. Eames P, et al. **Brain Inj** 1995 Oct; 9(7):729–34
L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Marin DB, et al. **Psychiatry Res** 1995 Oct 16;58(3):181–9

TOXICITY

Method for screening drug and chemical effects in laboratory rats using computerized quantitative electroencephalography. Jones RD, et al.
Vet Hum Toxicol 1995 Dec;37(6):521–7

PHYTAGGLUTININS see LECTINS

PHYTANIC ACID

ANALOGS & DERIVATIVES

Phytanic acid alpha-oxidation in rat liver peroxisomes. Production of alpha-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors. Mihalik SJ, et al. **Eur J Biochem** 1995 Sep 1;232(2):545-51

Phytanic acid oxidation in man: identification of a new enzyme catalysing the formation of 2-ketophytanic acid from 2-hydroxyphytanic acid and its deficiency in the Zellweger syndrome. Wanders RJ, et al. **J Inherit Metab Dis** 1995;18(2):201-3

ANTAGONISTS & INHIBITORS

Ketoconazole and other imidazole derivatives are potent inhibitors of peroxisomal phytanic acid alpha-oxidation. Pahan K, et al. **FEBS Lett** 1995 Dec 18;377(2):213-6

BLOOD

Mild retinal changes in a 47-year-old patient with phytanic acid storage disease. Yamamoto S, et al. **Ophthalmologica** 1995;209(5):251-5

METABOLISM

Phytanic acid is a retinoid X receptor ligand. Lemotte PK, et al. **Eur J Biochem** 1996 Feb 15;236(1):328-33

Phytanic acid alpha-oxidation in rat liver peroxisomes. Production of alpha-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors. Mihalik SJ, et al. **Eur J Biochem** 1995 Sep 1;232(2):545-51

Phytanic acid oxidation in man: identification of a new enzyme catalysing the formation of 2-ketophytanic acid from 2-hydroxyphytanic acid and its deficiency in the Zellweger syndrome. Wanders RJ, et al. **J Inherit Metab Dis** 1995;18(2):201-3

Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders. Kase BF, et al. **Scand J Clin Lab Invest** 1996 May;56(3):211-7

6-PHYTASE

[Effect of a supplemental Aspergillus niger phytase on the utilization of plant phosphorus by rainbow trout (Oncorhynchus mykiss)] Rodehutscord M, et al. **Arch Tierernahr** 1995;48(1-2):211-9 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Response of broilers to graded levels of microbial phytase added to maize-soyabean-meal-based diets containing three levels of non-phytate phosphorus. Kornegay ET, et al. **Br J Nutr** 1996 Jun;75(6):839-52

Effects of supplemental phytase and phosphorus on histological, mechanical and chemical traits of tibia and performance of turkeys fed on soyabean-meal-based semi-purified diets high in phytate phosphorus. Qian H, et al. **Br J Nutr** 1996 Aug;76(2):263-72

Improving phosphorus availability in soybean meal for broilers by supplemental phytase. Denbow DM, et al. **Poult Sci** 1995 Nov;74(11):1831-42

Effects of supplemental phytase and phosphorus on histological and other tibial bone characteristics and performances of broilers fed semi-purified diets. Qian H, et al. **Poult Sci** 1996 May;75(5):618-26

Response of turkey poults to tiered levels of Natuphos phytase added to soybean meal-based semi-purified diets containing three levels of nonphytate phosphorus. Ravindran V, et al. **Poult Sci** 1995 Nov;74(11):1843-54

BIOSYNTHESIS

Phytase from Aspergillus niger. Volfová O, et al. **Folia Microbiol (Praha)** 1994;39(6):481-4

Stable accumulation of Aspergillus niger phytase in transgenic tobacco leaves. Verwoerd TC, et al. **Plant Physiol** 1995 Dec;109(4):1199-205

GENETICS

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257-85 (161 ref.)

METABOLISM

Inositol phosphates in barley (Hordeum vulgare L.) aleurone tissue are stereochemically similar to the products of breakdown of InsP6 in vitro by wheat-bran phytase. Brearley CA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):279-86

Stereospecificity of inositol hexakisphosphate dephosphorylation by Paramecium phytase. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):907-10

Interaction of myoinositoltrisphosphate-phytase complex with the receptor for intercellular Ca2+ mobilization in plants. Dasgupta S, et al. **Biochemistry** 1996 Apr 16; 35(15):4994-5001

Dietary Aspergillus niger phytase increases iron absorption in humans. Sandberg AS, et al. **J Nutr** 1996 Feb; 126(2):476-80

The efficacy of an enzymic cocktail and a fungal mycelium in dephosphorylating corn-soybean meal-based feeds fed to growing turkeys. Zyla K, et al. **Poult Sci** 1996 Mar; 75(3):381-7

PHARMACOKINETICS

Phosphorus equivalence of microbial phytase in turkey diets as influenced by calcium to phosphorus ratios and phosphorus levels. Qian H, et al. **Poult Sci** 1996 Jan; 75(1):69-81

PHARMACOLOGY

Effect of phytic acid and microbial phytase on Cd accumulation, Zn status, and apparent absorption of Ca, P, Mg, Fe, Zn, Cu, and Mn in growing rats. Rimbach G, et al. **Ann Nutr Metab** 1995;39(6):361-70

Phytase-induced changes in mineral utilization in zinc-supplemented diets for pigs. Adeola O, et al. **J Anim Sci** 1995 Nov;73(11):3384-91

Additive effects of 1,25-dihydroxycholecalciferol and phytase on phytate phosphorus utilization and related parameters in broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):111-9

Effects of phytase and 1,25-dihydroxycholecalciferol on phytate utilization and the quantitative requirement for calcium and phosphorus in young broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):95-110

Supplemental microbial phytase improves zinc utilization in broilers. Yi Z, et al. **Poult Sci** 1996 Apr;75(4):540-6

[Use of microbial phytase at different phosphorus supply levels in broiler fattening. 1. Effect on fattening performance and tibia stability] Richter G. **Arch Tierernahr** 1993;45(3):235-44 (Eng. Abstr.) **(Ger)**

STANDARDS

Efficacy of a recombinant-derived phytase in improving the bioavailability of phosphorus in corn-soybean meal diets for pigs. Cromwell GL, et al. **J Anim Sci** 1995 Jul; 73(7):2000-8

PHYTIC ACID

Phytic acid in health and disease. Zhou JR, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):495-508 (171 ref.)

ANALYSIS

Faecal phytic acid and its relation to other putative markers of risk for colorectal cancer. Owen RW, et al. **Gut** 1996 Apr;38(4):591-7

Fermentation of rice-bengal gram dhal blends with whey: changes in phytic acid content and in vitro digestibility of starch and protein. Sharma A, et al. **Nahrung** 1995; 39(4):282-7

Effect of blanching on the content of antinutritional factors in selected vegetables. Mosha TC, et al. **Plant Foods Hum Nutr** 1995 Jun;47(4):361-7

BLOOD

Internalization and distribution of inositol hexakisphosphate in red blood cells. Boucher L, et al. **Biotechnol Appl Biochem** 1996 Aug;24 (Pt 1):73-8

CHEMISTRY

Enhanced resolution in the fingerprinting of short-chain oligonucleotides using the dodecasodium salt of phytic acid in capillary electrophoresis. Okafo G, et al. **Anal Chem** 1996 Jun 1;68(11):1982-6

Stereospecificity of inositol hexakisphosphate dephosphorylation by Paramecium phytase. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):907-10

DIAGNOSTIC USE

A scintigraphic study on gastric emptying in petients with non-ulcer dyspepsia. Wang S, et al. **J Tongji Med Univ** 1996;16(1):41-4

Discrepant pattern of solid and liquid gastric emptying in Chinese patients with type II diabetes mellitus. Chang CS, et al. **Nucl Med Commun** 1996 Jan;17(1):60-5

Effects of oral erythromycin on upper gastrointestinal motility in patients with non-insulin-dependent diabetes mellitus. Kao CH, et al. **Nucl Med Commun** 1995 Sep; 16(9):790-3

METABOLISM

Inositol phosphates in barley (Hordeum vulgare L.) aleurone tissue are stereochemically similar to the products of breakdown of InsP6 in vitro by wheat-bran phytase. Brearley CA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):279-86

Metabolic evidence for the order of addition of individual phosphate esters in the myo-inositol moiety of inositol hexakisphosphate in the duckweed Spirodela polyrhiza L. Brearley CA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):227-33

Isolation of InsP4 and InsP6 binding proteins from human platelets: InsP4 promotes Ca2+ efflux from inside-out plasma membrane vesicles containing 104 kDa GAP1IP4BP protein. O'Rourke F, et al. **Biochem J** 1996 May 1;315 (Pt 3):1027-34

Stereospecificity of inositol hexakisphosphate dephosphorylation by Paramecium phytase. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):907-10

Nucleus-associated phosphorylation of Ins(1,4,5)P3 to InsP6 in Dictyostelium. Van der Kaay J, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):911-7

Interaction of myoinositoltrisphosphate-phytase complex with the receptor for intercellular Ca2+ mobilization in plants. Dasgupta S, et al. **Biochemistry** 1996 Apr 16; 35(15):4994-5001

An in vitro procedure for studying enzymic dephosphorylation of phytate in maize-soyabean feeds for turkey poults. Zyla K, et al. **Br J Nutr** 1995 Jul;74(1):3-17

Membrane-associated inositol hexakisphosphate binding in bovine retina. Day NS, et al. **Curr Eye Res** 1995 Sep; 14(9):851-5

The degradation of phytic acid in legumes prepared by different methods. Schlemmer U, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S207-10

Inositolpolyphosphates and their binding proteins--a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):229-32 (29 ref.)

Effects of phytase and 1,25-dihydroxycholecalciferol on phytate utilization and the quantitative requirement for calcium and phosphorus in young broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):95-110

Additive effects of 1,25-dihydroxycholecalciferol and phytase on phytate phosphorus utilization and related parameters in broiler chickens. Mitchell RD, et al. **Poult Sci** 1996 Jan;75(1):111-9

The efficacy of an enzymic cocktail and a fungal mycelium in dephosphorylating corn-soybean meal-based feeds fed to growing turkeys. Zyla K, et al. **Poult Sci** 1996 Mar; 75(3):381-7

Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187-226 (181 ref.)

PHARMACOKINETICS

Distribution volume of three 99mTc-labeled compounds in the rat liver with time after intraportal and intravenous injections. Nishigaki J, et al. **Biol Pharm Bull** 1995 Dec; 18(12):1705-9

PHARMACOLOGY

Manganese absorption in humans: the effect of phytic acid and ascorbic acid in soy formula. Davidsson L, et al. **Am J Clin Nutr** 1995 Nov;62(5):984-7

The influence of different protein sources on phytate inhibition of nonheme-iron absorption in humans. Reddy MB, et al. **Am J Clin Nutr** 1996 Feb;63(2):203-7

Effect of phytic acid and microbial phytase on Cd accumulation, Zn status, and apparent absorption of Ca, P, Mg, Fe, Zn, Cu, and Mn in growing rats. Rimbach G, et al. **Ann Nutr Metab** 1995;39(6):361-70

IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. Yang GY, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2479-87

The effect of inositol hexaphosphate in the high-affinity hemoglobin of the Andean chicken (Gallus gallus). Mejía O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov;109(2-3):437-41

THERAPEUTIC USE

A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. Shivapurkar N, et al. **Cancer Lett** 1996 Feb 27; 100(1-2):169-79

Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Kamp DW, et al. **Toxicol Pathol** 1995 Nov-Dec;23(6):689-95

PHYTIN see PHYTIC ACID

PHYTOCHROME

CHEMISTRY

Mechanism of native oat phytochrome photoreversion: a time-resolved absorption investigation. Chen E, et al. **Biochemistry** 1996 Jan 23;35(3):843-50

Fourier-transform infrared spectroscopy of phytochrome: difference spectra of the intermediates of the photoreactions. Foerstendorf H, et al. **Biochemistry** 1996 Aug 20;35(33):10793-9

Protein kinase A-catalyzed phosphorylation and its effect on conformation in phytochrome A. Lapko VN, et al. **Biochemistry** 1996 May 28;35(21):6585-94

Influence of expression system on chromophore binding and preservation of spectral properties in recombinant phytochrome A. Gärtner W, et al. **Eur J Biochem** 1996 Mar 15;236(3):978-83

Similarity of a chromatic adaptation sensor to phytochrome and ethylene receptors. Kehoe DM, et al. **Science** 1996 Sep 6;273(5280):1409-12

[Phytochrome--structure and properties] Tretyn A, et al. **Postepy Biochem** 1996;42(1):57-64 (25 ref.) **(Pol)**

PHYTOCHROME

GENETICS

Divergence of the phytochrome gene family predates angiosperm evolution and suggests that Selaginella and Equisetum arose prior to Psilotum. Kolukisaoglu HU, et al. **J Mol Evol** 1995 Sep;41(3):329–37

Phytochrome signal-transduction: characterization of pathways and isolation of mutants. Barnes SA, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):67–74 (20 ref.)

GT-2: in vivo transcriptional activation activity and definition of novel twin DNA binding domains with reciprocal target sequence selectivity. Ni M, et al. **Plant Cell** 1996 Jun;8(6):1041–59

Missense mutations define a restricted segment in the C-terminal domain of phytochrome A critical to its regulatory activity. Xu Y, et al. **Plant Cell** 1995 Sep; 7(9):1433–43

Effects of gibberellins on seed germination of phytochrome-deficient mutants of Arabidopsis thaliana. Yang YY, et al. **Plant Cell Physiol** 1995 Oct;36(7):1205–11

Transcription of tobacco phytochrome-A genes initiates at multiple start sites and requires multiple cis-acting regulatory elements. Adam E, et al. **Plant Mol Biol** 1995 Dec;29(5):983–93

The phytochrome gene family in tomato includes a novel subfamily. Hauser BA, et al. **Plant Mol Biol** 1995 Dec; 29(6):1143–55

Abundance and half-life of the distinct oat phytochrome A3 and A4 mRNAs. Higgs DC, et al. **Plant Mol Biol** 1995 Oct;29(2):367–77

Atypical phytochrome gene structure in the green alga Mesotaenium caldariorum. Lagarias DM, et al. **Plant Mol Biol** 1995 Dec;29(6):1127–42

Evidence for some common signal transduction events for opposite regulation of nitrate reductase and phytochrome-I gene expression by light. Raghuram N, et al. **Plant Mol Biol** 1995 Oct;29(1):25–35

Function of phytochrome A in potato plants as revealed through the study of transgenic plants. Heyer AG, et al. **Plant Physiol** 1995 Sep;109(1):53–61

Mutational analysis of phytochrome B identifies a small COOH-terminal-domain region critical for regulatory activity. Wagner D, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8596–600

METABOLISM

Protein kinase A-catalyzed phosphorylation and its effect on conformation in phytochrome A. Lapko VN, et al. **Biochemistry** 1996 May 28;35(21):6585–94

Influence of expression system on chromophore binding and preservation of spectral properties in recombinant phytochrome A. Gärtner W, et al. **Eur J Biochem** 1996 Mar 15;236(3):978–83

Light signal transduction mediated by phytochromes: preliminary studies and possible approaches. Song PS, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):1–19 (131 ref.)

Phytochrome regulates phosphorylation of a protein with characteristics of a nucleoside diphosphate kinase in the crude membrane fraction from stem sections of etiolated pea seedlings. Hamada T, et al. **J Photochem Photobiol B** 1996 Apr;33(2):143–51

Phosphorylation/dephosphorylation steps are key events in the phytochrome-mediated enhancement of nitrate reductase mRNA levels and enzyme activity in maize. Chandok MR, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):599–608

A DNA binding activity for one of two closely defined phytochrome regulatory elements in an Lhcb promoter is more abundant in etiolated than in green plants. Degenhardt J, et al. **Plant Cell** 1996 Jan;8(1):31–41

A microtubule-associated protein in maize is expressed during phytochrome-induced cell elongation. Nick P, et al. **Plant J** 1995 Dec;8(6):835–44

Expression of functional oat phytochrome A in transgenic rice. Clough RC, et al. **Plant Physiol** 1995 Nov; 109(3):1039–45

Function of phytochrome A in potato plants as revealed through the study of transgenic plants. Heyer AG, et al. **Plant Physiol** 1995 Sep;109(1):53–61

Phytochrome A regulates red-light induction of phototropic enhancement in Arabidopsis. Parks BM, et al. **Plant Physiol** 1996 Jan;110(1):155–62

Chromophore-bearing NH2-terminal domains of phytochromes A and B determine their photosensory specificity and differential light lability. Wagner D, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4011–5

[Phytochrome--structure and properties] Tretyn A, et al. **Postepy Biochem** 1996;42(1):57–64 (25 ref.) **(Pol)**

PHYTOHEMAGGLUTININS

ADMINISTRATION & DOSAGE

Dietary phytohaemagglutinin slows down the proliferation of a mouse plasmacytoma (MPC-11) tumour in Balb/c mice. Pryme IF, et al. **Cancer Lett** 1996 Jun 5;103(2):151–5

BIOSYNTHESIS

Targeting and release of phytohemagglutinin from the roots of bean seedlings. Kjemtrup S, et al. **Plant Physiol** 1995 Oct;109(2):603–10

CHEMISTRY

Absorbance- and light-based solid-phase assays for CMPNeuAc:Galbeta1-4GlcNAc-R alpha-2,3-sialyltransferase. Yeh JC, et al. **Anal Biochem** 1996 Apr 5;236(1):126–33

Crystallization of glycosylated and nonglycosylated phytohemagglutinin-L. Dao-Thi MH, et al. **Proteins** 1996 Jan;24(1):134–7

GENETICS

Molecular cloning of two different mannose-binding lectins from tulip bulbs. Van Damme EJ, et al. **Eur J Biochem** 1996 Mar 1;236(2):419–27

PvAlf, an embryo-specific acidic transcriptional activator enhances gene expression from phaseolin and phytohemagglutinin promoters. Bobb AJ, et al. **Plant J** 1995 Sep;8(3):331–43

IMMUNOLOGY

Intestinal and systemic immune responses in rats to dietary lectins. Gómez E, et al. **Adv Exp Med Biol** 1995;371A:533–6

The phytohaemagglutinin (PHA) skin test as an indicator of stress-induced changes in immune reactivity in pigs. Ekkel ED, et al. **Vet Q** 1995 Dec;17(4):143–6

ISOLATION & PURIFICATION

Isolation of the lectin and an L4 isolectin from Phaseolus vulgaris by affinity chromatography on insoluble ovomucoid. Gonçalves RB, et al. **Braz J Med Biol Res** 1995 Feb;28(2):191–4

METABOLISM

Interaction of lectins with their ligand carbohydrate of alpha-fetoprotein: analysis by mixed-lectin affinity electrophoresis. Taketa K, et al. **Electrophoresis** 1996 Mar; 17(3):483–8

Effect of early dietary deficiency in polyunsaturated fatty acids on two lectin binding sites in the small intestine of postweanling rats. Alessandri JM, et al. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):165–76

Crystallization of glycosylated and nonglycosylated phytohemagglutinin-L. Dao-Thi MH, et al. **Proteins** 1996 Jan;24(1):134–7

PHARMACOLOGY

An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Baricordi OR, et al. **Blood** 1996 Jan 15;87(2):682–90

Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex. Whisler RL, et al. **Cell Immunol** 1996 Mar 15;168(2):201–10

Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients. Crucian B, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):766–9

Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes. Haga Y, et al. **Dig Dis Sci** 1996 Jul;41(7):1468–74

Expression of c-fos and c-jun proteins and AP-1 binding activity during cell cycle progression of HL60 cells and phytohemagglutinin-stimulated lymphocytes. Tay DL, et al. **Exp Hematol** 1996 Feb;24(2):277–84

Reversible effect of phytohaemagglutinin on the growth and metabolism of rat gastrointestinal tract. Bardocz S, et al. **Gut** 1995 Sep;37(3):353–60

Polyamine metabolism of enterocyte-like Caco-2 cells after exposure to Phaseolus vulgaris lectin. Koninkx JF, et al. **Gut** 1996 Jan;38(1):47–52

Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Van Wauwe J, et al. **Inflamm Res** 1995 Sep;44(9):400–5

The effect of organic acids on phytohaemagglutinin-activated proliferation of human lymphocytes in vitro. Schlottfeldt J, et al. **Int J Immunopharmacol** 1995 Mar;17(3):175–82

Influence of mitogenic activators on the structure of leukocytes. Frąckowiak D, et al. **J Photochem Photobiol B** 1996 Mar;33(1):45–50

The effect of PHA stimulation on lymphocyte sub-populations in whole-blood cultures. O'Donovan MR, et al. **Mutagenesis** 1995 Jul;10(4):371–4

[The effect of streptococcal group A polysaccharide on PHA-induced T-cell proliferation] Bazanova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):71–3 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

The crystallographic structure of phytohemagglutinin-L. Hamelryck TW, et al. **J Biol Chem** 1996 Aug 23; 271(34):20479–85

PHYTOHORMONES see **PLANT GROWTH REGULATORS**

PHYTOMENADIONE see **PHYTONADIONE**

PHYTOMITOGENS see **LECTINS**

PHYTONADIONE

ADMINISTRATION & DOSAGE

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)

Intravenous vitamin K1 injections: dangerous prophylaxis [letter; comment] O'Reilly RA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2127–8. Comment on: Arch Intern Med 1995 Jan 23;155(2):149–61.

Changes of K vitamins in portal and femoral venous plasma of rats after oral administration of phylloquinone and menaquinone-4. Sakamoto N, et al. **Int J Vitam Nutr Res** 1995;65(2):105–10

Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. Booth SL, et al. **J Am Diet Assoc** 1996 Feb;96(2):149–54

[Syringes for oral administration of vitamin K1 lipid emulsion (letter)] Le Guévello P, et al. **Arch Pediatr** 1995 Oct; 2(10):1022–3 **(Fre)**

ADVERSE EFFECTS

Intravenous vitamin K1 injections: dangerous prophylaxis [letter; comment] O'Reilly RA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2127–8. Comment on: Arch Intern Med 1995 Jan 23;155(2):149–61.

[Cutaneous hypersensitivity at the site of injection of vitamin K1] Moreau-Cabarrot A, et al. **Ann Dermatol Venereol** 1996;123(3):177–9 (22 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Thijssen HH, et al. **Br J Nutr** 1996 Jan;75(1):121–7

Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. Thijssen HH, et al. **J Nutr** 1996 Feb; 126(2):537–43

BLOOD

Serial changes in serum vitamin K1, triglyceride, cholesterol, osteocalcin and 25-hydroxyvitamin D3 in patients after hip replacement for fractured neck of femur or osteoarthritis. Roberts NB, et al. **Eur J Clin Invest** 1996 Jan;26(1):24–9

Determination of vitamin K1 in serum using catalytic-reduction liquid chromatography with fluorescence detection. MacCrehan WA, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):209–17

Variation of phylloquinone (vitamin K1) concentrations in hemodialysis patients. Kohlmeier M, et al. **Thromb Haemost** 1995 Nov;74(5):1252–4

METABOLISM

Bioavailability of phylloquinone and menaquinones after oral and colorectal administration in vitamin K-deficient rats. Groenen-van Dooren MM, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):797–801

Photoaccumulation in photosystem I does produce a phylloquinone (A1.-) radical. Heathcote P, et al. **Biochemistry** 1996 May 28;35(21):6644–50

PHARMACOKINETICS

The pharmacokinetics and lipoprotein fraction distribution of intramuscular vs. oral vitamin K1 supplementation in women of childbearing age: effects on hemostasis. Hagstrom JN, et al. **Thromb Haemost** 1995 Dec; 74(6):1486–90

PHYSIOLOGY

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

THERAPEUTIC USE

Transfusion medicine issues in the practice of anesthesiology [letter; comment] Alparin JB. **Transfus Med Rev** 1995 Oct; 9(4):339. Comment on: Transfus Med Rev 1995 Jan;9(1):60–78.

[Prophylaxis of late hemorrhagic disease in newborn infants with vitamin K1 at birth (letter)] Besson-Leaud M, et al. **Arch Pediatr** 1996 Jan;3(1):89–90 discussion 90 **(Fre)**

PHYTOPHAGINEAE see **PLANT VIRUSES**

PHYTOPHTHORA

Suppression of the hypersensitive response in potato by acetyl salicylic acid. Lee M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):309–11

A new elicitor of the hypersensitive response in tobacco: a fungal glycoprotein elicits cell death, expression of defence genes, production of salicylic acid, and induction of systemic acquired resistance. Baillieul F, et al. **Plant J** 1995 Oct;8(4):551–60

CHEMISTRY

Investigation of the conformational properties of a beta-(1-->3) branched beta-(1-->6) heptasaccharide elicitor and its analogues by internal coordinate stochastic dynamics. Petukhov MG, et al. **Carbohydr Res** 1995 Dec 27;279:41-57

A structural model for the mechanisms of elicitor release from fungal cell walls by plant beta-1,3-endoglucanase. Okinaka Y, et al. **Plant Physiol** 1995 Nov;109(3):839-45

GENETICS

Inactivation of transgenes in Phytophthora infestans is not associated with their deletion, methylation, or mutation. Judelson HS, et al. **Curr Genet** 1995 Nov;28(6):571-9

The Phytophthora sojae genome contains tandem repeat sequences which vary from strain to strain. Mao Y, et al. **Fungal Genet Biol** 1996 Mar;20(1):43-51

Genetic mapping and non-Mendelian segregation of mating type loci in the oomycete, Phytophthora infestans. Judelson HS, et al. **Genetics** 1995 Oct;141(2):503-12

Characterization of a gene cluster of Phytophthora cryptogea which codes for elicitins, proteins inducing a hypersensitive-like response in tobacco. Panabières F, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec; 8(6):996-1003

Presence of Ty1-copia group retrotransposon sequences in the potato late blight pathogen Phytophthora infestans. Tooley PW, et al. **Mol Plant Microbe Interact** 1996 May; 9(4):305-9

Phytophthora sojae avirulence genes, RAPD, and RFLP markers used to construct a detailed genetic linkage map. Whisson SC, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec;8(6):988-95

ISOLATION & PURIFICATION

Application of the PCR technique to detect Phytophthora infestans in potato tubers and leaves. Niepold F, et al. **Microbiol Res** 1995 Nov;150(4):379-85

PATHOGENICITY

Phytophthora sojae avirulence genes, RAPD, and RFLP markers used to construct a detailed genetic linkage map. Whisson SC, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec;8(6):988-95

PHYSIOLOGY

Gene activation by UV light, fungal elicitor or fungal infection in Petroselinum crispum is correlated with repression of cell cycle-related genes. Logemann E, et al. **Plant J** 1995 Dec;8(6):865-76

PHYTOPLANKTON

CLASSIFICATION

A comparison of some neural and non-neural methods for identification of phytoplankton from flow cytometry data. Wilkins MF, et al. **Comput Appl Biosci** 1996 Feb;12(1):9-18

DRUG EFFECTS

Effect of organic four solvents on natural phytoplankton assemblages: consequences for ecotoxicological experiments on herbicides. Bérard A. **Bull Environ Contam Toxicol** 1996 Aug;57(2):183-90

Replacement of the medium for a natural phytoplankton community by tangential-flow filtration, with special emphasis on toxicity tests. Petersen S, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):603-9

Effects of thiobencarb on the growth of three species of phytoplankton. Sabater C, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):977-84

METABOLISM

Ataxonomic assessment of phytoplankton integrity by means of flow cytometry. Steinberg CE, et al. **Arch Toxicol Suppl** 1996;18:417-34

PHYTOREOVIRUS see **REOVIRIDAE**

PHYTOSTEROLS

ADMINISTRATION & DOSAGE

A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Pelletier X, et al. **Ann Nutr Metab** 1995; 39(5):291-5

A marked and sustained reduction in LDL sterols by diet and cholestyramine in beta-sitosterolemia. Parsons HG, et al. **Clin Invest Med** 1995 Oct;18(5):389-400

BIOSYNTHESIS

Sterol biosynthesis: strong inhibition of maize delta 5,7-sterol delta 7-reductase by novel 6-aza-B-homosteroids and other analogs of a presumptive carbocationic intermediate of the reduction reaction. Rahier A, et al. **Biochemistry** 1996 Jun 4;35(22):7069-76

BLOOD

Serum cholesterol, cholesterol precursors and plant sterols in different inflammatory bowel diseases. Hakala K, et al. **Digestion** 1996;57(2):83-9

Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. Lütjohann D, et al. **J Lipid Res** 1995 Aug; 36(8):1763-73

Phytosterolaemia in a Norwegian family: diagnosis and characterization of the first Scandinavian case. Lütjohann D, et al. **Scand J Clin Lab Invest** 1996 May;56(3):229-40

CHEMISTRY

Effects of plant sterols on the hydration and phase behavior of DOPE/DOPC mixtures. Webb MS, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):226-38

METABOLISM

Novel sterol transformations promoted by Saccharomyces cerevisiae strain GL7: evidence for 9 beta, 19-cyclopropyl to 9(11)-isomerization and for 14-demethylation to 8(14)-sterols. Venkatramesh M, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):189-99

PHARMACOLOGY

Enhanced efficacy of sitostanol-containing versus sitostanol-free phytosterol mixtures in altering lipoprotein cholesterol levels and synthesis in rats. Ling WH, et al. **Atherosclerosis** 1995 Dec;118(2):319-31

Inhibitory effect of some oxygenated stigmastane-type sterols on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Kimura Y, et al. **Biol Pharm Bull** 1995 Nov;18(11):1617-9

Effects of orally administered liposomes with soybean-derived sterols and their glucosides on rat body weight. Maitani Y, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1551-5

Phytosterols as growth regulators. Eugster C, et al. **Panminerva Med** 1995 Dec;37(4):228-37

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Weisser H, et al. **Prostate** 1996 May; 28(5):300-6

TOXICITY

Wood-derived estrogens: studies in vitro with breast cancer cell lines and in vivo in trout. Mellanen P, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):381-8

PHYTOTHERAPY see **MEDICINE, HERBAL**

PI-MESONS see **MESONS**

PIA MATER

Treatment of epilepsy with multiple subpial transections: an acute histologic analysis in human subjects. Kaufmann WE, et al. **Epilepsia** 1996 Apr;37(4):342-52

MR of leptomeningeal melanosis in children. Byrd SE, et al. **Eur J Radiol** 1995 Jul;20(2):93-9

BLOOD SUPPLY

cGMP and cAMP in prostaglandin-induced pial artery dilation and increased CSF opioid concentration. Armstead WM. **Am J Physiol** 1996 Jul;271(1 Pt 2):H166-72

Opioids contribute to hypoxia-induced pial artery dilation through activation of ATP-sensitive K+ channels. Shankar V, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H997-1002

Influence of brain injury on opioid-induced pial artery vasodilation. Thorogood MC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1776-83

Role of nitric oxide, adenosine, N-methyl-D-aspartate receptors, and neuronal activation in hypoxia-induced pial arteriolar dilation in rats. Pelligrino DA, et al. **Brain Res** 1995 Dec 15;704(1):61-70

Effects of increased pulse pressure on cerebral arterioles. Baumbach GL. **Hypertension** 1996 Feb;27(2):159-67

Anesthetic-dependent pial arteriolar response to ethanol. Gordon EL, et al. **J Neurosurg** 1995 Nov;83(5):875-7

Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels. Prior R, et al. **Neuroreport** 1995 Sep 11;6(13):1747-51

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820-4; discussion 824-5 (14 ref.)

Relationship between opioids and prostaglandins in hypoxia-induced vasodilation of pial arteries in the newborn pig. Armstead WM. **Proc Soc Exp Biol Med** 1996 Jun;212(2):135-41

Impaired pial arteriolar reactivity to hypercapnia during hyperammonemia depends on glutamine synthesis. Hirata T, et al. **Stroke** 1996 Apr;27(4):729-36

Glutamate-induced disruption of the blood-brain barrier in rats. Role of nitric oxide. Mayhan WG, et al. **Stroke** 1996 May;27(5):965-9; discussion 970

[Experimental study on hypertensive crises in epileptic seizures--changes in pial artery diameter, intracranial pressure and regional cerebral blood flow] Eguchi T, et al. **No To Shinkei** 1995 Dec;47(12):1143-8 (Eng. Abstr.) **(Jpn)**

[Microcirculatory disorders in cerebral ischemia in rats and their correction by using leu-enkephalin] Aleksandrov PN, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):87-94 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Postcontrast MRI of cranial meninges: leptomeningitis versus pachymeningitis. Kioumehr F, et al. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):713-20

Magnetic resonance imaging of syrinx associated with intramedullary metastases and leptomeningeal disease. Phuphanich S, et al. **J Neuroimaging** 1996 Apr;6(2):115-7

RADIATION EFFECTS

Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates. Kemshead JT, et al. **Recent Results Cancer Res** 1996; 141:145-58

SURGERY

Multiple subpial transections for partial seizures in sensorimotor cortex. Wyler AR, et al. **Neurosurgery** 1995 Dec;37(6):1122-7; discussion 1127-8

Pial synangiosis for moyamoya syndrome in children. Adelson PD, et al. **Pediatr Neurosurg** 1995;23(1):26-33

ULTRASTRUCTURE

Scanning electron microscopy of human cerebral meningeal stomata. Li J, et al. **Anat Anz** 1996 Jun;178(3):259-61

PIAL VEIN see **CEREBRAL VEINS**

PICA

CLASSIFICATION

Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. Takeda N, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):589-90

COMPLICATIONS

Case study: hypersomnolence and precocious puberty in a child with pica and chronic lead intoxication. Boris NW, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1050-4

Toxic 'sock' syndrome bezoar formation and pancreatitis associated with iron deficiency and pica. Adler AI, et al. **West J Med** 1995 Nov;163(5):480-2

EPIDEMIOLOGY

Pica in a rural obstetric population. Smulian JC, et al. **South Med J** 1995 Dec;88(12):1236-40

RADIOGRAPHY

Retained foreign body: associations with elevated lead levels, pica, and duodenal anomaly. Sprinkle JD Jr, et al. **Pediatr Radiol** 1995;25(7):528-9

VETERINARY

Treatment of gastrointestinal tract impaction of a 2-year-old Asian elephant (Elephas maximus). Warren K, et al. **Aust Vet J** 1996 Jan;73(1):37-8

PICHIA

ENZYMOLOGY

Redox balances in recombinant Saccharomyces cerevisiae. Hahn-Hägerdal B, et al. **Ann N Y Acad Sci** 1996 May 15; 782:286-96

An inducible acid phosphatase from the yeast Pichia pastoris: characterization of the gene and its product. Payne WE, et al. **Gene** 1995 Sep 22;163(1):19-26

Mannosyltransferase activities in membranes from various yeast strains. Verostek MF, et al. **Glycobiology** 1995 Oct; 5(7):671-81

A short-chain dehydrogenase gene from Pichia stipitis having D-arabinitol dehydrogenase activity. Hallborn J, et al. **Yeast** 1995 Jul;11(9):839-47

Molecular cloning of the GTP-cyclohydrolase structural gene RIB1 of Pichia guilliermondii involved in riboflavin biosynthesis. Liauta-Teglivets O, et al. **Yeast** 1995 Aug; 11(10):945-52

Cloning and characterization of the Pichia pastoris PRC1 gene encoding carboxypeptidase Y. Ohi H, et al. **Yeast** 1996 Jan;12(1):31-40

[Ferrireductase from Pichia guilliermondii: properties and regulation of activity and synthesis] Fedorovych DV, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):32-7 (Eng. Abstr.) **(Ukr)**

GENETICS

Rapid screening and mapping of conformational epitopes expressed in the secretion expression system Pichia pastoris. Kocken CHM, et al. **Anal Biochem** 1996 Jul 15;239(1):111-2

PICHIA

Increased xylose reductase activity in the xylose-fermenting yeast Pichia stipitis by overexpression of XYL1. Dahn KM, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:267-76

Functional expression of recombinant spiny dogfish shark (Squalus acanthias) cytochrome P450c17 (17 alpha-hydroxylase/C17,20-lyase) in yeast (Pichia pastoris). Trant JM. **Arch Biochem Biophys** 1996 Feb 1;326(1):8-14

Inhibition of Aspergillus serine proteinase by Streptomyces subtilisin inhibitor and high-level expression of this inhibitor in Pichia pastoris. Markaryan A, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):372-6

Cloning and sequence analysis of the invertase gene INV 1 from the yeast Pichia anomala. Pérez JA, et al. **Curr Genet** 1996 Feb;29(3):234-40

Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. Weiss HM, et al. **FEBS Lett** 1995 Dec 27;377(3):451-6

High-level production of spinach glycolate oxidase in the methylotrophic yeast Pichia pastoris: engineering a biocatalyst. Payne MS, et al. **Gene** 1995 Dec 29; 167(1-2):215-9

An inducible acid phosphatase from the yeast Pichia pastoris: characterization of the gene and its product. Payne WE, et al. **Gene** 1995 Sep 22;163(1):19-26

Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen. Smith PM, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):331-43

Cloning of a novel constitutively expressed pectate lyase gene pelB from Fusarium solani f. sp. pisi (Nectria haematococca, mating type VI) and characterization of the gene product expressed in Pichia pastoris. Guo W, et al. **J Bacteriol** 1995 Dec;177(24):7070-7

Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions. Luo D, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):825-31

Efficient expression of the gene for spinach phosphoribulokinase in Pichia pastoris and utilization ofthe recombinant enzyme to explore the role of regulatory cysteinyl residues by site-directed mutagenesis. Brandes HK, et al. **J Biol Chem** 1996 Mar 15;271(11):6490-6

A short-chain dehydrogenase gene from Pichia stipitis having D-arabinitol dehydrogenase activity. Hallborn J, et al. **Yeast** 1995 Jul;11(9):839-47

Molecular cloning of the GTP-cyclohydrolase structural gene RIB1 of Pichia guilliermondii involved in riboflavin biosynthesis. Liauta-Teglivets O, et al. **Yeast** 1995 Aug; 11(10):945-52

Cloning and characterization of the Pichia pastoris PRC1 gene encoding carboxypeptidase Y. Ohi H, et al. **Yeast** 1996 Jan;12(1):31-40

IMMUNOLOGY

Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen. Smith PM, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):331-43

Human natural yeast killer toxin-like candidacidal antibodies. Polonelli L, et al. **J Immunol** 1996 Mar 1;156(5):1880-5

METABOLISM

Peculiarities of the regulation of fermentation and respiration in the crabtree-negative, xylose-fermenting yeast Pichia stipitis. Passoth V, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:201-12

Phosphorus-31 and carbon-13 nuclear magnetic resonance studies of glucose and xylose metabolism in cell suspensions and agarose-immobilized cultures of Pichia stipitis and Saccharomyces cerevisiae. Lohmeier-Vogel EM, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2832-8

Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris. Sun J, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):28-34

Isolation and characterization of Pas2p, a peroxisomal membrane protein essential for peroxisome biogenesis in the methylotrophic yeast Pichia pastoris. Wiemer EAC, et al. **J Biol Chem** 1996 Aug 2;271(31):18973-80

Labeling of peroxisomes with green fluorescent protein in living P. pastoris cells. Monosov EZ, et al. **J Histochem Cytochem** 1996 Jun;44(6):581-9

Production and purification of N-terminal half-transferrin in Pichia pastoris. Steinlein LM, et al. **Protein Expr Purif** 1995 Oct;6(5):619-24

PHYSIOLOGY

The Pichia pastoris PER6 gene product is a peroxisomal integral membrane protein essential for peroxisome biogenesis and has sequence similarity to the Zellweger syndrome protein PAF-1. Waterham HR, et al. **Mol Cell Biol** 1996 May;16(5):2527-36

ULTRASTRUCTURE

Formation of the peroxisome lumen is abolished by loss of Pichia pastoris Pas7p, a zinc-binding integral membrane protein of the peroxisome. Kalish JE, et al. **Mol Cell Biol** 1995 Nov;15(11):6406-19

PICHINDE VIRUS

Role of atrial natriuretic peptide in disturbed water and electrolyte metabolism of guinea pigs infected with Pichinde virus. Guo ZM, et al. **Lab Anim Sci** 1995 Oct; 45(5):484-92

Persistent infection of mice with Pichinde virus associated with failure to thrive. Wright KE, et al. **Microb Pathog** 1995 Aug;19(2):73-82

IMMUNOLOGY

Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. Selin LK, et al. **J Exp Med** 1996 Jun 1; 183(6):2489-99

PICIBANIL

ADMINISTRATION & DOSAGE

Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Yamaguchi Y, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2201-6

Potential advantages in therapeutic index of OK-432 ointment to abdominal skin over systemic applied in a mouse model. Matsuoka H, et al. **Cancer Lett** 1996 Mar 19;101(1):15-20

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. Kitahara S, et al. **J Laryngol Otol** 1996 May; 110(5):449-53

OK-432 therapy for lymphangioma in children: why and how does it work? Ogita S, et al. **J Pediatr Surg** 1996 Apr; 31(4):477-80

[The efficacy of transarterial immuno-embolization therapy in patients with unresectable hepatocellular carcinoma] Kishi K, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1590-3 (Eng. Abstr.) **(Jpn)**

[Influence of intratumor administration of OK-432 on the tumor selectivity of 5'-DFUR] Ogawa K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2095-100 (Eng. Abstr.) **(Jpn)**

[A case report: complete remission of stage IV uterine cervix carcinoma by immuno-chemotherapy with intraarterial infusion using implantable reservoir system] Shimizu A, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1706-10 (Eng. Abstr.) **(Jpn)**

[Oral administration of OK-432 is an effective immunotherapy against colon cancer—a study in a murine mesenteric lymphnode metastasis model] Nukata Y, et al. **Nippon Geka Gakkai Zasshi** 1995 Oct;96(10):671-9 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. Katsumoto Y, et al. **Br J Cancer** 1996 Jan;73(1):110-6

Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line. Asai K, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):275-9

The immuno-stimulant OK-432 enhances liver regeneration after 70% hepatectomy. Kato K, et al. **J Hepatol** 1995 Jul; 23(1):87-94

The preventive effects of OK432 on endotoxin-induced liver injury: liver protection by the modulation of hepatic macrophage function. Fujita S, et al. **Surg Today** 1996; 26(1):29-35

[Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin] Matsuoka H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1644-6 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Kitsuki H, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):283-90

Successful treatment of a recurrent large cystic hygroma in a child with intracystic injection of OK-432 [letter] Hase T, et al. **Eur J Pediatr** 1996 May;155(5):424

Sclerosing of recurrent lymphangioma using OK-432. Mikhail M, et al. **J Pediatr Surg** 1995 Aug;30(8):1159-60

[T cell receptor V beta repertoire of locoregional lymphocytes in malignant effusions] Miyahara E, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1622-5 (Eng. Abstr.) **(Jpn)**

[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283-90 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Successful treatment of hemopneumothorax with intrapleural OK432 in pulmonary metastases of cutaneous angiosarcoma] Takizawa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1334-7 (Eng. Abstr.) **(Jpn)**

PICK'S DISEASE OF BRAIN see **DEMENTIA, PRESENILE**

PICK'S DISEASE OF HEART see **PERICARDITIS, CONSTRICTIVE**

PICKWICKIAN SYNDROME

COMPLICATIONS

Ischemic hepatitis due to obstructive sleep apnea. Mathurin P, et al. **Gastroenterology** 1995 Nov;109(5):1682-4

DIAGNOSIS

Pickwickian syndrome and indications for surgically induced weight loss [letter; comment] Sugerman HJ, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):87-8. Comment on: Surv Ophthalmol 1995 Jan-Feb;39(4):307-14.

[Excessive diurnal fatigue with psychotic symptoms in Pickwickian syndrome] Pankow W, et al. **Med Klin** 1995 Aug 15;90(8):490-4 **(Ger)**

HISTORY

[The Pickwick syndrome. From literary speculations to sleep research] Tjørstad K. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3768-72 (Eng. Abstr.) **(Nor)**

PICOBIRNAVIRUS

ISOLATION & PURIFICATION

Identification of picobirnavirus, viruses with bisegmented double stranded RNA, in rabbit faeces. Ludert JE, et al. **Res Vet Sci** 1995 Nov;59(3):222-5

PICODNAVIRUSES see **PARVOVIRIDAE**

PICOLINES

A blinded clinical trial comparing conventional cleansing enema, Pico-salax and Golytely for barium enema bowel preparation. Lai AK, et al. **Clin Radiol** 1996 Aug; 51(8):566-9

ADMINISTRATION & DOSAGE

The quest for a more acceptable bowel preparation: comparison of a polyethylene glycol/electrolyte solution and a mannitol/Picolax mixture for colonoscopy. Saunders BP, et al. **Postgrad Med J** 1995 Aug;71(838):476-9

ADVERSE EFFECTS

Delayed hypersensitivity reaction to the preservative myristyl picolinium chloride. Goulden V, et al. **Contact Dermatitis** 1995 Sep;33(3):209-10

PHARMACOLOGY

Myocardial protection with potassium-channel openers is as effective as St. Thomas' solution in the rabbit heart. Lawton JS, et al. **Ann Thorac Surg** 1996 Jul;62(1):31-8; discussion 38-9

Biochemical pharmacology of penclomedine (NSC-338720). Benvenuto JA, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1157-64

G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Altavilla D, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):31-9

Cromakalim- and RP 49356-induced 42K+ and 86Rb+ efflux in rat myometrium. Piper IT, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):1-8

Protective effects of the K+ ATP channel opener, aprikalim, against free radicals in isolated rabbit hearts. Pignac J, et al. **Free Radic Biol Med** 1996;20(3):383-9

Hyperpolarized cardiac arrest with a potassium-channel opener, aprikalim. Maskal SL, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1083-95

[The mutagenic and modifying properties of emoxipin studied by micronucleus assay in liver cells] Uryvaeva IV, et al. **Izv Akad Nauk Ser Biol** 1996 Jan-Feb;(1):5-9 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[The effect of oxypine on tissue edema in allergic rabbits] Bazanov GA. **Biull Eksp Biol Med** 1995 Jul;120(7):84-6 **(Rus)**

[The efficacy of emoxipin and neoton in unstable stenocardia] Golikov AP, et al. **Ter Arkh** 1996;68(1):31-3 (Eng. Abstr.) **(Rus)**

PICOLINIC ACIDS

ADMINISTRATION & DOSAGE

A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. Melillo G, et al. **J Exp Med** 1995 Dec 1;182(6):1683-93

ANALYSIS

A rapid approach for the detection of dipicolinic acid in bacterial spores using pyrolysis/mass spectrometry. Beverly MB, et al. **Rapid Commun Mass Spectrom** 1996; 10(4):455-8

CHEMICAL SYNTHESIS

Chemical synthesis of allysine ethylene acetal and conversion in situ into 1-piperideine-6-carboxylic acid: key intermediate of the alpha-aminoadipic acid for beta-lactam antibiotics biosynthesis. Rumbero A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1237-40

123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Beer HF, et al. **Nucl Med Biol** 1995 Oct;22(7):929-936

ISOLATION & PURIFICATION

Halopicolinic acids, novel products arising through the degradation of chloro- and bromo-biphenyl by Sphingomonas paucimobilis BPSI-3. Davison AD, et al. **Can J Microbiol** 1996 Jan;42(1):66-71

METABOLISM

Finding of a homarine-synthesizing enzyme in turban shell and some properties of the enzyme. Nishitani H, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):327-32

Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Cesura AM, et al. **Eur J Biochem** 1996 Mar 15;236(3):996-1002

Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. Galva MD, et al. **J Neural Transm Gen Sect** 1995; 101(1-3):83-94

PHARMACOKINETICS

123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Beer HF, et al. **Nucl Med Biol** 1995 Oct;22(7):929-936

PHARMACOLOGY

Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV). Sakurai H, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1095-101

Effect of chromium picolinate on growth, body composition, and tissue accretion in pigs. Boleman SL, et al. **J Anim Sci** 1995 Jul;73(7):2033-42

Influence of chromium tripicolinate on glucose metabolism and nutrient partitioning in growing lambs. Kitchalong L, et al. **J Anim Sci** 1995 Sep;73(9):2694-705

Effects of dietary chromium picolinate supplementation on growth, carcass characteristics, and accretion rates of carcass tissues in growing-finishing swine. Mooney KW, et al. **J Anim Sci** 1995 Nov;73(11):3351-7

[The effect of chromium picolinate on the liver levels of trace elements] Aguilar MV, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):373-6 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. **Ann Neurol** 1996 Jul;40(1):99-107

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241-6 (69 ref.)

[Therapeutic efficacy of zinc picolinate in patients with taste disorders] Sakai F, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1135-9 (Eng. Abstr.) **(Jpn)**

TOXICITY

Chromium(III) picolinate [letter] McCarty MF. **FASEB J** 1996 Feb;10(2):365-9

Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. Stearns DM, et al. **FASEB J** 1995 Dec;9(15):1643-8

PICORNAVIRIDAE

CLASSIFICATION

Equine rhinovirus 1 is more closely related to foot-and-mouth disease virus than to other picornaviruses. Li F, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):990-5

DRUG EFFECTS

[Susceptibility of picornaviruses + + to an antiviral of plant origin (meliacin)] Wachsman MB, et al. **Rev Argent Microbiol** 1995 Jan-Mar;27(1):33-7 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA. **Protein Sci** 1995 Aug; 4(8):1439-45 (65 ref.)

GENETICS

The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Girard M, et al. **Biologicals** 1995 Jun;23(2):165-9 (32 ref.)

The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85-98 (57 ref.)

The 3' untranslated region of picornavirus RNA: features required for efficient genome replication. Rohll JB, et al. **J Virol** 1995 Dec;69(12):7835-44

Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Borman AM, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3656-63

Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. Jackson RJ, et al. **RNA** 1995 Dec;1(10):985-1000 (104 ref.)

IMMUNOLOGY

Antibody recognition of picornaviruses and escape from neutralization: a structural view. Mateu MG. **Virus Res** 1995 Sep;38(1):1-24 (161 ref.)

ISOLATION & PURIFICATION

Search for picornaviruses at onset of inflammatory myopathy. Behan WM, et al. **J Clin Pathol** 1996 Jul; 49(7):592-4

METABOLISM

Internal initiation of translation directed by the 5'-untranslated region of the mRNA for eIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation. Gan W, et al. **J Biol Chem** 1996 Jan 12;271(2):623-6

PHYSIOLOGY

Drosophila-host genetic control of susceptibility to Drosophila C virus. Thomas-Orillard M, et al. **Genetics** 1995 Aug;140(4):1289-95

Analysis of picornavirus 2A(pro) proteins: separation of proteinase from translation and replication functions. Lu HH, et al. **J Virol** 1995 Dec;69(12):7445-52

The 3' untranslated region of picornavirus RNA: features required for efficient genome replication. Rohll JB, et al. **J Virol** 1995 Dec;69(12):7835-44

PICORNAVIRIDAE INFECTIONS

COMPLICATIONS

Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Smyth AR, et al. **Arch Dis Child** 1995 Aug;73(2):117-20

DIAGNOSIS

Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel. Gilbert LL, et al. **J Clin Microbiol** 1996 Jan;34(1):140-3

DRUG THERAPY

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175-87 (93 ref.)

IMMUNOLOGY

Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation. Zhu Z, et al. **J Clin Invest** 1996 Jan 15;97(2):421-30

VIROLOGY

Natural and experimental rhinovirus infections of the lower respiratory tract. Johnston SL. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S46-52 (71 ref.)

PICORNAVIRUS INFECTIONS see **PICORNAVIRIDAE INFECTIONS**

PICRATES

The importance of tissue fixation for light microscopic immunohistochemical localization of peroxisomal proteins: the superiority of Carnoy's fixative over Baker's formalin and Bouin's solution. Lehmann T, et al. **Histochem Cell Biol** 1995 Mar;103(3):187-95

PICROTOXIN

ANALOGS & DERIVATIVES

A single point mutation decreases picrotoxinin sensitivity of the human GABA receptor rho 1 subunit. Enz R, et al. **Neuroreport** 1995 Jul 31;6(11):1569-72

Cloning of a gamma-aminobutyric acid type C receptor subunit in rat retina with a methionine residue critical for picrotoxinin channel block. Zhang D, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11756-60

METABOLISM

Interaction of picrotoxin with GABAA receptor channel-lining residues probed in cysteine mutants. Xu M, et al. **Biophys J** 1995 Nov;69(5):1858-67

PHARMACOLOGY

Picrotoxin is a CYP1A1 inducer in rainbow trout hepatocytes. Sadar MD, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1060-6

Interaction of picrotoxin with GABAA receptor channel-lining residues probed in cysteine mutants. Xu M, et al. **Biophys J** 1995 Nov;69(5):1858-67

Enhancement by GABA of the association rate of picrotoxin and tert-butylbicyclophosphorothionate to the rat cloned alpha 1 beta 2 gamma 2 GABAA receptor subtype. Dillon GH, et al. **Br J Pharmacol** 1995 Jun;115(3):539-45

Distribution of Fos-positive neurons in cortical and subcortical structures after picrotoxin-induced convulsions varies with seizure type. Willoughby JO, et al. **Brain Res** 1995 Jun 12;683(1):73-87

Is perinatal picrotoxin anxiogenic? Silva MR, et al. **Braz J Med Biol Res** 1995 Jun;28(6):663-6

Effects of propofol and thiopentone on picrotoxin convulsive threshold in the rabbit. Hasan Z, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):714-7

Neural connection from hippocampus to nucleus accumbens and the subpallidal area and their contribution to locomotor activity. Shen AY, et al. **Chin J Physiol** 1995;38(2):111-6

Pentobarbitone induces Fos in astrocytes: increased expression following picrotoxin and seizures. Hiscock JJ, et al. **Exp Neurol** 1996 May;139(1):115-20

Circuit reorganization in Ara-C-treated cerebellar cultures chronically exposed to picrotoxin. Seil FJ, et al. **Int J Dev Neurosci** 1996 Feb;14(1):45-54

Neural computation of motion in the fly visual system: quadratic nonlinearity of responses induced by picrotoxin in the HS and CH cells. Kondoh Y, et al. **J Neurophysiol** 1995 Dec;74(6):2665-84

Role of metabotropic glutamate receptor subtypes in the patterning of epileptiform activities in vitro. Merlin LR, et al. **J Neurophysiol** 1995 Aug;74(2):896-900

Subunit composition determines picrotoxin and bicuculline sensitivity of Drosophila gamma-aminobutyric acid receptors. Zhang HG, et al. **Mol Pharmacol** 1995 Nov; 48(5):835-40

High level of footshock during inhibitory avoidance training prevents amnesia induced by intranigral injection of GABA antagonists. Cobos-Zapiain GG, et al. **Neurobiol Learn Mem** 1996 May;65(3):202-6

A single amino acid in gamma-aminobutyric acid rho 1 receptors affects competitive and noncompetitive components of picrotoxin inhibition. Wang TL, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11751-5

Effect of intracerebroventricular and intrahypothalamic administrations of picrotoxin on basal and stimulated gastric acid secretion. Lin WC, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):143-56

Effects of iontophoretically applied naloxone, picrotoxin and strychnine on dorsal horn neuron activities treated with high frequency conditioning stimulation in cats. Jeong Y, et al. **Yonsei Med J** 1995 Sep;36(4):336-47

TOXICITY

[The effect of salicylates on the toxicity of GABAlytics for mice] Golovko AI, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):619-20 **(Rus)**

PICRYL CHLORIDE

IMMUNOLOGY

Regulation of chemokine gene expression by contact hypersensitivity and by oral tolerance. Yuan YS, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:434-7

Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone. Shornick LP, et al. **J Exp Med** 1996 Apr 1;183(4):1427-36

alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. Grabbe S, et al. **J Immunol** 1996 Jan 15;156(2):473-8

PHARMACOLOGY

Suppressive effects of central opioids on delayed type hypersensitivity to trinitrochlorobenzene: comparative study with morphine and electroacupuncture. Kasahara T, et al. **In Vivo** 1995 May-Jun;9(3):177-81

PICRYLSULFONIC ACID see **TRINITROBENZENESULFONIC ACID**

PICTURE ARCHIVING AND COMMUNICATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

PICTURE ARCHIVING, RADIOLOGIC see **RADIOLOGY INFORMATION SYSTEMS**

PIEBALDISM

see related
WAARDENBURG'S SYNDROME

COMPLICATIONS

Graft-versus-host reaction affecting lesional skin but not normal skin in a patient with piebaldism. Chow RK, et

PIEBALDISM

al. **Br J Dermatol** 1996 Jan;134(1):134–7

ETIOLOGY

White forelock could be early sign of tuberous sclerosis [letter; comment] Desch LW.
Arch Pediatr Adolesc Med 1996 Jun;150(6):651–2. Comment on: Arch Pediatr Adolesc Med 1995 Sep;149(9):1031–2.

GENETICS

A 12–bp deletion (7818del12) in the c–kit protooncogene in a large Italian kindred with piebaldism. Riva P, et al. **Hum Mutat** 1995;6(4):343–5

PATHOLOGY

Griscelli syndrome: report of three cases. Göğüş S, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):309–19

SURGERY

Surgical combination therapy for vitiligo and piebaldism. Falabella R, et al. **Dermatol Surg** 1995 Oct;21(10):852–7

PIEDRA

DIAGNOSIS

Guidelines of care for superficial mycotic infections of the skin: Piedra. Guidelines/Outcomes Committee. American Academy of Dermatology. **J Am Acad Dermatol** 1996 Jan; 34(1):122–4

PATHOLOGY

New findings in black piedra infection [letter] Figueras MJ, et al. **Br J Dermatol** 1996 Jul;135(1):157–8

THERAPY

Guidelines of care for superficial mycotic infections of the skin: Piedra. Guidelines/Outcomes Committee. American Academy of Dermatology. **J Am Acad Dermatol** 1996 Jan; 34(1):122–4

PIERRE ROBIN SYNDROME

COMPLICATIONS

Pierre Robin anomalad, maculopathy, and autolytic cataract. Rogers NK, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov–Dec;32(6):391–2
Airway obstruction in the Pierre Robin sequence. Tomaski SM, et al. **Laryngoscope** 1995 Feb;105(2):111–4

GENETICS

Cerebro–costo–mandibular syndrome: a follow–up study with 6 patients [letter] Schrander–Stumpel C, et al. **Genet Couns** 1996;7(1):71–2

THERAPY

Nasogastric intubation for nutrition and airway protection in infants with Robin sequence. Prodoehl DC, et al. **J Perinatol** 1995 Sep–Oct;15(5):395–7

PIG SKIN DRESSINGS see **BIOLOGICAL DRESSINGS**

PIG–TAILED MONKEY see **MACACA NEMESTRINA**

PIGEON BREEDER'S LUNG see **BIRD FANCIER'S LUNG**

PIGEONS

Orientation invariant pattern recognition by pigeons (Columba livia) and humans (Homo sapiens). Delius JD, et al. **J Comp Psychol** 1995 Sep;109(3):278–90
Pigeons' preference for variable–interval water reinforcement under widely varied water budgets. Case DA, et al. **J Exp Anal Behav** 1995 Nov;64(3):299–311
The what and the where of the pigeon's processing of complex visual stimuli. Kirkpatrick–Steger K, et al. **J Exp Psychol Anim Behav Process** 1996 Jan;22(1):60–7
Peripheral neuropathy of dietary riboflavin deficiency in racing pigeons. Wada Y, et al. **J Vet Med Sci** 1996 Feb; 58(2):161–3
Intracellular survival and multiplication of virulent and less virulent strains of Streptococcus bovis in pigeon macrophages. De Herdt P, et al. **Vet Microbiol** 1995 Jul; 45(2–3):157–69
Diazinon poisoning in pigeons [letter] Pennycott TW. **Vet Rec** 1996 Jan 27;138(4):96
[The influence of experimental hemispherectomy and hemicerebellectomy on the acquisition and retention of habituation in pigeon] Kaźmierczak H. **Otolaryngol Pol** 1995;49(4):339–45 (Eng. Abstr.) **(Pol)**
[Urban ecology of Triatoma infestans in Argentina. Association between Triatoma infestans and pigeon cotes] Vallvé SL, et al. **Rev Saude Publica** 1995 Jun;29(3):192–8 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Immunohistochemical characteristics of cutaneous Herbst corpuscles from beak and rictus in domestic pigeon. Germaná G, et al. **Eur J Morphol** 1995 Jul;33(3):279–86
Thalamostriatal projection neurons in birds utilize LANT6 and neurotensin: a light and electron microscopic double–labeling study. Veenman CL, et al. **J Chem Neuroanat** 1995 Jul;9(1):1–16
Projection of the nucleus pretectalis to a retinorecipient tectal layer in the pigeon (Columba livia). Gamlin PD, et al. **J Comp Neurol** 1996 May 6;368(3):424–38
Central projections and somatotopic organisation of trigeminal primary afferents in pigeon (Columba livia). Wild JM, et al. **J Comp Neurol** 1996 Apr 22;368(1):136–52
Centrifugal projections upon the retina: an anterograde tracing study in the pigeon (Columba livia). Woodson W, et al. **J Comp Neurol** 1995 Nov 27;362(4):489–509
Anatomical evidence of a retino–thalamo–hippocampal pathway in the pigeon (Columba livia). Trottier C, et al. **J Hirnforsch** 1995;36(4):489–500
Distribution within the choroid of cholinergic nerve fibers from the ciliary ganglion in pigeons. Cuthbertson S, et al. **Vision Res** 1996 Mar;36(6):775–86

BLOOD

Serum levels of prolactin and alpha–melanotrophin and structure of the ovary during the reproductive cycle of Columba livia (domestic pigeon). Castagnino RA, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):5–10

IMMUNOLOGY

Detection of salivary and seric IgG and IgA antipooled pigeon sera activities in patients with pigeon breeder's disease. Mendoza F, et al. **J Clin Lab Anal** 1996; 10(3):149–54
Cellular immune response to fractionated avian antigens by peripheral blood mononuclear cells from patients with pigeon breeder's disease [see comments] Mendoza F, et al. **J Lab Clin Med** 1996 Jan;127(1):23–8. Comment in: J Lab Clin Med 1996 Jan;127(1):10–2.

METABOLISM

Calcium–binding proteins in avian herbst and grandry sensory corpuscles. Del Valle ME, et al. **Anat Rec** 1995 Oct;243(2):272–81
Effect of chemical sympathectomy on serum levels of thyroid hormones and the biochemical profile of domestic pigeons. Parikh R, et al. **J Auton Nerv Syst** 1995 Jun 25; 53(2–3):87–94
Laminar distribution and sources of catecholaminergic input to the optic tectum of the pigeon (Columbia livia). Rodman HR, et al. **J Comp Neurol** 1995 Aug 28;359(3):424–42
Immunocytochemical demonstration of taurine in the retina and pineal organ of the pigeon. Ueck M, et al. **Neurochem Int** 1995 Dec;27(6):509–17
Species specific pharmacokinetics of rolitetracycline. Lashev L, et al. **Zentralbl Veterinarmed A** 1995 May;42(3):201–8

MICROBIOLOGY

Borrelia in pigeons: no serological evidence of Borrelia burgdorferi infection. Fabbi M, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):503–7

PARASITOLOGY

Lysis of erythrocytes by Trichomonas gallinae. De Carli GA, et al. **Avian Dis** 1996 Jan–Mar;40(1):228–30
Trichomoniasis as a factor in mourning dove population decline in Fillmore, Utah. Ostrand WD, et al. **J Wildl Dis** 1995 Jan;31(1):87–9

PHYSIOLOGY

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213–38 (130 ref.)
Exposure to oscillating magnetic fields influences sensitivity to electrical stimuli. I. Experiments on pigeons. Del Seppia C, et al. **Bioelectromagnetics** 1995;16(5):290–4
Time course of reinnervation of the olfactory bulb after transection of the primary olfactory nerve in the pigeon. Jennings RA, et al. **Brain Res** 1995 Jun 19;683(2):159–63
Inhibitor of protein synthesis phase–shifts the circadian oscillator and inhibits the light induced–phase shift of the melatonin rhythm in pigeon pineal cells. Murakami N, et al. **Brain Res** 1995 Sep 25;693(1–2):1–7
Operant discrimination learning in detelencephalated pigeons (Columba livia). Cerutti SM, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1089–95
A functional map of the pigeon basilar papilla: correlation of the properties of single auditory nerve fibres and their peripheral origin. Smolders JW, et al. **Hear Res** 1995 Dec; 92(1–2):151–69
Preoptic area lesions disrupt prolactin–induced parental feeding behavior in ring doves. Slawski BA, et al. **Horm Behav** 1995 Jun;29(2):248–66
Intratelencephalic projections of the visual wulst in pigeons (Columba livia). Shimizu T, et al. **J Comp Neurol** 1995 Sep 4;359(4):551–72
Convergence of somatosensory and auditory projections in the avian torus semicircularis, including the central auditory nucleus. Wild JM. **J Comp Neurol** 1995 Aug 7; 358(4):465–86
Disorientation of animals in microgravity. Mori S. **Nagoya J Med Sci** 1995 Dec;58(3–4):71–81
Horizontal optokinetic nystagmus in the pigeon during static tilts in the frontal plane. Zolotilina EG, et al. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):300–6
[The capacity for transitive inference in birds: the solving of the Gillan test by Corvidae and pigeons] Zorina ZA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):716–22 (Eng. Abstr.) **(Rus)**

VIROLOGY

Circovirus–like particles in the bursae of young racing pigeons [letter] Gough RE, et al. **Vet Rec** 1996 Feb 17; 138(7):167
Circovirus in pigeons [letter] Smyth JA. **Vet Rec** 1995 Dec 9;137(24):623

PIGMENT EPITHELIUM OF EYE

Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Polak BC, et al. **Br J Ophthalmol** 1995 Oct;79(10):922–5
[Periarteritis nodosa with initial ocular involvement] Pinto Ferreira F, et al. **J Fr Ophtalmol** 1995;18(12):788–93 (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Mutation of PAX2 in two siblings with renal–coloboma syndrome. Sanyanusin P, et al. **Hum Mol Genet** 1995 Nov; 4(11):2183–4

BLOOD SUPPLY

Lymphocyte migration across the anterior and posterior blood–retinal barrier in vitro. Devine L, et al. **Cell Immunol** 1996 Mar 15;168(2):267–75

CHEMISTRY

Blue and ultraviolet light–absorbing opsin from the retinal pigment epithelium. Hao W, et al. **Biochemistry** 1996 May 21;35(20):6251–6
Characterization of the 3' UTR sequence encoded by the AQP–1 gene in human retinal pigment epithelium. Ruiz A, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):174–8
Expression of kinesin heavy chain isoforms in retinal pigment epithelial cells. King–Smith C, et al. **Cell Motil Cytoskeleton** 1995;31(1):66–81
Isolation of a cDNA encoding a taurine transporter in the human retinal pigment epithelium. Miyamoto Y, et al. **Curr Eye Res** 1996 Mar;15(3):345–9
Vitamin E, retinyl palmitate, and protein in rhesus monkey retina and retinal pigment epithelium–choroid. Crabtree DV, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):47–60
In vivo measurement of lipofuscin in Stargardt's disease—Fundus flavimaculatus. Delori FC, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2327–31
Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age–related macular degeneration–related choroidal neovascular membranes. Lopez PF, et al. **Invest Ophthalmol Vis Sci** 1996 Apr; 37(5):855–68
The distribution of Na+,K(+)–ATPase and 5A11 antigen in apical microvilli of the retinal pigment epithelium is unrelated to alpha–spectrin. Rizzolo LJ, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3623–33
Vitronectin receptor expression and distribution at the photoreceptor–retinal pigment epithelial interface. Anderson DH, et al. **J Comp Neurol** 1995 Sep 11; 360(1):1–16
The photochemistry of human retinal lipofuscin as studied by EPR. Reszka K, et al. **Photochem Photobiol** 1995 Dec; 62(6):1005–8

CYTOLOGY

Retinal pigment epithelial cell count, distribution, and correlations in normal human eyes. Panda–Jonas S, et al. **Am J Ophthalmol** 1996 Feb;121(2):181–9
An improved method of isolating fetal human retinal pigment epithelium. Castillo BV Jr, et al. **Curr Eye Res** 1995 Aug; 14(8):677–83
Stimulation of retinal pigment epithelial cell growth by neuropeptides in vitro. Kishi H, et al. **Curr Eye Res** 1996 Jul;15(7):708–13
Additive effects of extra cellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Smith–Thomas L, et al. **Curr Eye Res** 1996 Jul;15(7):739–48
An apical tension–sensitive microfilament system in retinal pigment epithelial cells. Nagai H, et al. **Exp Cell Res** 1996 Feb 25;223(1):63–71
Phenotypic heterogeneity of retinal pigment epithelial cells in vitro and in situ. Burke JM, et al. **Exp Eye Res** 1996 Jan;62(1):63–73
ARPE–19, a human retinal pigment epithelial cell line with differentiated properties. Dunn KC, et al. **Exp Eye Res** 1996 Feb;62(2):155–69
Retinal pigment epithelium topography in the mature quokka, Setonix brachyurus. Fleming PA, et al. **Exp Eye Res** 1996 Jan;62(1):85–93
Natural, high–mannose glycoproteins inhibit ROS binding and ingestion by RPE cell cultures. Lutz DA, et al.

Exp Eye Res 1995 Oct;61(4):487–93

Retroviral gene transfer into retinal pigment epithelial cells followed by transplantation into rat retina. Dunaief JL, et al. **Hum Gene Ther** 1995 Sep;6(9):1225–9

A rapid method for isolation of retinal pigment epithelial cells from rat eyeballs. Sakagami K, et al. **Ophthalmic Res** 1995;27(5):262–7

In vivo and in vitro morphological analysis of melanocytes homozygous for the misp allele at the murine microphthalmia locus. Boissy RE, et al. **Pigment Cell Res** 1995 Dec;8(6):294–301

From lens regeneration in the newt to in–vitro transdifferentiation of vertebrate pigmented epithelial cells. Kodama R, et al. **Semin Cell Biol** 1995 Jun;6(3):143–9 (39 ref.)

DRUG EFFECTS

Hyalocytes synthesize and secrete inhibitors of retinal pigment epithelial cell proliferation in vitro. Lazarus HS, et al. **Arch Ophthalmol** 1996 Jun;114(6):731–6

Vascular endothelial growth factor is induced by long–term high glucose concentration and up–regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Sone H, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):193–8

Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C. Harris MS, et al. **Curr Eye Res** 1996 Mar; 15(3):255–62

Stimulation of retinal pigment epithelial cell growth by neuropeptides in vitro. Kishi H, et al. **Curr Eye Res** 1996 Jul;15(7):708–13

Additive effects of extra cellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Smith–Thomas L, et al. **Curr Eye Res** 1996 Jul;15(7):739–48

A cyclic adenosine monophosphate agonist elevates the b– and c–waves of the rabbit direct–current electroretinogram. Bragadóttir R, et al. **Doc Ophthalmol** 1995;90(3):291–303

Influence of oxygen free radicals and free radical scavengers on the growth behaviour and oxidative tissue damage of bovine retinal pigment epithelium cells in vitro. Augustin AJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan; 234(1):58–63

Vitamin E succinate inhibits proliferation and migration of retinal pigment epithelial cells in vitro: therapeutic implication for proliferative vitreoretinopathy. Sakamoto T, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Mar; 234(3):186–92

Shiva–1: in vitro and in vivo tests of the effects of a novel, synthetic, lytic peptide on ocular cells. Shahsavari M, et al. **Int Ophthalmol** 1995;19(1):29–34

Activation of Cl– currents in cultured rat retinal pigment epithelial cells by intracellular applications of inositol–1,4,5–triphosphate: differences between rats with retinal dystrophy (RCS) and normal rats. Strauss O, et al. **J Membr Biol** 1996 May;151(2):189–200

Epidermal dipeptide: a new regulatory factor in proliferative vitreoretinopathy. Rezai KA, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):65–71

Vitamin A incorporation into lipofuscin–like inclusions in the retinal pigment epithelium. Katz ML, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):29–38

Glycine stimulation of glutamate binding to chick retinal pigment epithelium. López Colomé AM, et al. **Neurochem Res** 1995 Aug;20(8):887–94

Effects of vitamin E on the retina and retinal pigment epithelium of IRCS rats. el–Hifnawi el–S, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):576–81

Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Toimela T, et al. **Ophthalmic Res** 1995;27 Suppl 1:150–3

[Electron microscopic studies of retinal pigment epithelial cells incubated with L–dopa in 10% and 20% oxygen] Muraki Y, et al. **Nippon Ganka Gakkai Zasshi** 1995 Nov; 99(11):1203–8 (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

In vitro transdifferentiation of embryonic rat retinal pigment epithelium to neural retina. Zhao S, et al. **Brain Res** 1995 Apr 24;677(2):300–10

The retinal pigmented epithelium is required for development and maintenance of the mouse neural retina. Raymond SM, et al. **Curr Biol** 1995 Nov 1;5(11):1286–95

An improved method of isolating fetal human retinal pigment epithelium. Castillo BV Jr, et al. **Curr Eye Res** 1995 Aug; 14(8):677–83

Genesis of the retinal pigment epithelium in the macaque monkey. Rapaport DH, et al. **J Comp Neurol** 1995 Dec 18;363(3):359–76

ENZYMOLOGY

Transforming growth factor–beta inhibits the cytokine–mediated expression of the inducible nitric oxide synthase mRNA in human retinal pigment epithelial cells. Kutty RK, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):386–93

Age–related changes of glycosidases in human retinal pigment epithelium. Cingle KA, et al. **Curr Eye Res** 1996 Apr;15(4):433–8

The influence of thapsigargin on Na,K–ATPase activity in cultured nonpigmented ciliary epithelial cells. Mito T, et al. **Curr Eye Res** 1995 Aug;14(8):651–7

Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine platinum (cp) mutation. Beermann F, et al. **Exp Eye Res** 1995 Nov;61(5):599–607

Cloning and expression of a bovine adenylyl cyclase type VII specific to the retinal pigment epithelium. Völkel H, et al. **FEBS Lett** 1996 Jan 15;378(3):245–9

Adenovirus–mediated gene transfer of ornithine aminotransferase in cultured human retinal pigment epithelium. Sullivan DM, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):766–74

Acetyl– and butyrylcholinesterase activities in the rat retina and retinal pigment epithelium. Sánchez–Chávez G, et al. **J Neurosci Res** 1995 Aug 1;41(5):655–62

GROWTH & DEVELOPMENT

Development and ageing of the RPE in a marsupial, the quokka. Fleming PA, et al. **Exp Eye Res** 1996 May; 62(5):457–69

IMMUNOLOGY

Synergistic effects of gamma interferon on inflammatory mediators that induce interleukin–6 gene expression and secretion by human retinal pigment epithelial cells. Nagineni CN, et al. **Clin Diagn Lab Immunol** 1994 Sep; 1(5):569–77

Macrophage subpopulations and RPE elimination in the pathogenesis of experimental autoimmune pigment epithelial protein–induced uveitis (EAPU). Broekhuyse RM, et al. **Exp Eye Res** 1996 May;62(5):471–80

Cross–matches on donor cadaver retinal pigment epithelial cells in corneal risk patients. Zavazava N, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Mar;234(3):164–70

Role of LFA–1, ICAM–1, VLA–4 and VCAM–1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro. Devine L, et al. **Immunology** 1996 Jul;88(3):456–62

INJURIES

A new wound healing model of retinal pigment epithelial cells in sheet culture. Kamei M, et al. **Curr Eye Res** 1996 Jul;15(7):714–8

METABOLISM

Formation of lipofuscin in cultured retinal pigment epithelial cells exposed to pre–oxidized photoreceptor outer segments. Wihlmark U, et al. **APMIS** 1996 Apr; 104(4):272–9

Lipofuscin formation in cultured retinal pigment epithelial cells exposed to photoreceptor outer segment material under different oxygen concentrations. Wihlmark U, et al. **APMIS** 1996 Apr;104(4):265–71

Hypoxic regulation of vascular endothelial growth factor in retinal cells. Aiello LP, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1538–44

TIMP–3 is expressed in the human retinal pigment epithelium. Ruiz A, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):467–74

Truncation of IGF–1 yields two mitogens for retinal Müller glial cells. Ikeda T, et al. **Brain Res** 1995 Jul 17;686(1):87–92

Nitric oxide induces c–fos gene expression via cyclic AMP response element binding protein (CREB) phosphorylation in rat retinal pigment epithelium. Ohki K, et al. **Brain Res** 1995 Oct 23;696(1–2):140–4

Müller and retinal pigment epithelial (RPE) cell expression of NGFI–A and c–fos mRNA in response to medium conditioned by the RPE. Jaynes CD, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):329–37

Effect of retinoic acid on expression of transforming growth factor–beta by retinal pigment epithelial cells in culture. MacDonald IM, et al. **Can J Ophthalmol** 1995 Oct; 30(6):301–5

Vitamin E in macular and peripheral tissues of the human eye. Friedrichson T, et al. **Curr Eye Res** 1995 Aug; 14(8):693–701

Cyclic AMP–dependent up–regulation of the taurine transporter in a human retinal pigment epithelial cell line. Ganapathy V, et al. **Curr Eye Res** 1995 Sep;14(9):843–50

Evidence of a functional VIP receptor in cultured human retinal pigment epithelium. Koh SW, et al. **Curr Eye Res** 1995 Nov;14(11):1009–14

Cholera toxin enhances taurine uptake in cultures of human retinal pigment epithelial cells. Miyamoto Y, et al. **Curr Eye Res** 1996 Mar;15(3):229–36

Immunodetection of an arrestin–like protein in human retinal pigment epithelium. Reising CA, et al. **Curr Eye Res** 1996 Jan;15(1):9–15

Calcium–activated potassium current in cultured rabbit retinal pigment epithelial cells. Tao Q, et al. **Curr Eye Res** 1996 Mar;15(3):237–46

Drug–dependent Ca2+ mobilization in organ–cultured rabbit ciliary processes. Yoshimura N, et al. **Curr Eye Res** 1995 Aug;14(8):629–35

Neurothelin: amino acid sequence, cell surface dynamics and actin colocalization. Schlosshauer B, et al. **Eur J Cell Biol** 1995 Oct;68(2):159–66

Chloride transport in cultured fetal human retinal pigment epithelium. Hu JG, et al. **Exp Eye Res** 1996 Apr;62(4):443–8

Development of the blood–retinal barrier in vitro: formation of tight junctions as revealed by occludin and ZO–1 correlates with the barrier function of chick retinal pigment epithelial cells. Konari K, et al. **Exp Eye Res** 1995 Jul; 61(1):99–108

Differential expression of the cellular retinaldehyde–binding protein in bovine ciliary epithelium. Martin–Alonso JM, et al. **Exp Eye Res** 1993 Jun;56(6):659–69

Characterisation of melatonin binding sites in the eye of the Japanese quail (Coturnix japonica). James K, et al. **Gen Comp Endocrinol** 1995 Nov;100(2):188–96

Radial distribution of tocopherols in rhesus monkey retina and retinal pigment epithelium–choroid. Crabtree DV, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):61–76

Beta–adrenergic stimulation of Na+, K+, Cl– cotransport in fetal nonpigmented ciliary epithelial cells. Crook RB, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1047–57

Localization of TIMP–3 mRNA expression to the retinal pigment epithelium. Della NG, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1921–4

Regulation and bioelectrical effects of cyclic adenosine monophosphate production in the ciliary epithelial bilayer. Horio B, et al. **Invest Ophthalmol Vis Sci** 1996 Mar; 37(4):607–12

Oxygen modulates the response of the retinal pigment epithelium to basic fibroblast growth factor and epidermal growth factor by receptor regulation. Khaliq A, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):436–43

Bidirectional glutathione transport by cultured human retinal pigment epithelial cells. Lu SC, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2523–30

Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Platts KE, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2262–9

Comparative adrenocholinergic control of intracellular Ca2+ in the layers of the ciliary body epithelium. Schütte M, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):212–20

Adreno–cholinergic modulation of junctional communications between the pigmented and nonpigmented layers of the ciliary body epithelium. Shi XP, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1037–46

Induction of intercellular adhesion molecule–1 by tumor necrosis factor–alpha through the 55–kDa receptor is dependent on protein kinase C in human retinal pigment epithelial cells. Sippy BD, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):597–606

Photoreceptor cells in the vitiligo mouse die by apoptosis. TRPM–2/clusterin expression is increased in the neural retina and in the retinal pigment epithelium. Smith SB, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2193–201

Inhibition of retinal pigment epithelial cell–induced tractional retinal detachment by disintegrins, a group of Arg–Gly–Asp–containing peptides from viper venom. Yang CH, et al. **Invest Ophthalmol Vis Sci** 1996 Apr; 37(5):843–54

Thrombin increases expression of urokinase receptor by activation of the thrombin receptor. Yang Z, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2254–61

Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. Ryeom SW, et al. **J Biol Chem** 1996 Aug 23; 271(34):20536–9

Constitutive and cytokine–induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF–kappa B and novel constitutive factors. Wood LD, et al. **J Biol Chem** 1995 Dec 22; 270(51):30619–26

Heme–mediated reactive oxygen species toxicity to retinal pigment epithelial cells is reduced by hemopexin. Hunt RC, et al. **J Cell Physiol** 1996 Jul;168(1):81–6

CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2–mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696–703

Control of nitric oxide production by endogenous TGF–beta1 and systemic nitric oxide in retinal pigment epithelial cells and peritoneal macrophages. Vodovotz Y, et al. **J Leukoc Biol** 1996 Aug;60(2):261–70

Agonist–induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat. Nash MS, et al. **Neurochem Int** 1995 Sep; 27(3):253–62

Centripetal transport of herpes simplex virus in human retinal pigment epithelial cells in vitro. Topp KS, et al. **Neuroscience** 1996 Apr;71(4):1133–44

Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell–cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Pereira L, et al. **Scand J Infect Dis Suppl** 1995;99:82–7 (42 ref.)

[Cultured human retinal pigment epithelial cell produced and secreted epidermal growth factor: its bioactivity and clinical significance] Cao J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):609–10, 639 (Eng. Abstr.) **(Chi)**

[The effects of dopa and oxygen on RNA concentrations in cultured chick embryonal retinal pigment epithelial cells] Kanda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Oct; 99(10):1123–6 (Eng. Abstr.) **(Jpn)**

[Production and metabolism of prostaglandin D2 by cultured chick retinal pigment epithelial cells] Shiroma T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):501–6 (Eng. Abstr.) **(Jpn)**

[An experimental in-vitro study of the effect of paraorbital mesenchyme with the Mi wh/Mi wh mutant genotype on the melanogenesis of the retinal pigment epithelium in mouse embryos] Sazhina MV, et al. **Izv Akad Nauk Ser Biol** 1995 Jul-Aug;(4):441-6 (Eng. Abstr.) **(Rus)**

[An analysis of keratin expression in the cells of the retinal pigment epithelium during transdifferentiation in newts] Grigorian EN, et al. **Ontogenez** 1995 Jul-Aug;26(4):310-23 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Pattern dystrophies of the retinal pigment epithelium. Daniele S, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):51-5

Frequency of congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Olea JL, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):48-50

A pigmented adenoma of the ciliary epithelium examined by magnetic resonance imaging. Greenberg PB, et al. **Am J Ophthalmol** 1995 Nov;120(5):679-81

Acute posterior multifocal placoid pigment epitheliopathy after acute group A streptococcal infection. Lowder CY, et al. **Am J Ophthalmol** 1996 Jul;122(1):115-7

Reduced vision secondary to pigmented cellular membranes on silicone intraocular lenses [letter] Schuster BL. **Am J Ophthalmol** 1996 Sep;122(3):452-3

Pigment dispersion secondary to cysts of the iris pigment epithelium. Alward WL, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1574-5

Choroidopathy in multiple evanescent white dot syndrome [letter] Borruat FX, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1569-71

Retinal pigment epithelial wound healing in vivo. Lopez PF, et al. **Arch Ophthalmol** 1995 Nov;113(11):1437-46

Ocular lymphoma diagnosed by internal subretinal pigment epithelium biopsy [letter] Pavan PR, et al. **Arch Ophthalmol** 1995 Oct;113(10):1233-4

Non-retinovascular leakage in diabetic maculopathy. Weinberger D, et al. **Br J Ophthalmol** 1995 Aug; 79(8):728-31

Granulomatous anterior uveitis presenting with acute posterior multifocal placoid pigment epitheliopathy. Alvi NP, et al. **Doc Ophthalmol** 1995;89(4):347-53

Retinal pigment epithelium tear following toxemia of pregnancy. Menchini U, et al. **Eur J Ophthalmol** 1995 Apr-Jun;5(2):139-41

Ophthalmoscopy for congenital hypertrophy of the retinal pigment epithelium (CHRPE) in patients with sporadic colorectal carcinoma. Hartvigsen A, et al. **Int J Colorectal Dis** 1995;10(3):138-9

Acute posterior multifocal placoid pigment epitheliopathy. Heath JD, et al. **Int Ophthalmol Clin** 1995 Spring; 35(2):93-105 (43 ref.)

Sub-retinal pigment epithelial deposits in a dominant late-onset retinal degeneration. Kuntz CA, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1772-82

Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells. Relationship to cell morphology. McLaren MJ. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1213-24

A mouse model of gyrate atrophy of the choroid and retina. Early retinal pigment epithelium damage and progressive retinal degeneration. Wang T, et al. **J Clin Invest** 1996 Jun 15;97(12):2753-62

A novel deletion at codon 441 of the APC gene associated with ophthalmic lesions (CHRPE) in a South African family. Grobbelaar JJ, et al. **J Med Genet** 1996 May; 33(5):384-6

Necrosis and apoptosis in neuroretina and pigment epithelium after diffuse photodynamic action in rats: a light and electron microscopic study. Büchi ER, et al. **Jpn J Ophthalmol** 1996;40(1):1-11

ICG and AMPPPE [letter] Howe L. **Ophthalmology** 1996 Jun;103(6):863

The variable expressivity of a family with central areolar pigment epithelial dystrophy. Keithahn MA, et al. **Ophthalmology** 1996 Mar;103(3):406-15

Fundus pigmentation in retinopathy of prematurity. Monos T, et al. **Pediatrics** 1996 Mar;97(3):343-8

Retinal pigment epithelial dystrophy in Briard dogs. Lightfoot RM, et al. **Res Vet Sci** 1996 Jan;60(1):17-23

Acute multifocal posterior placoid pigment epitheliopathy: a theory of pathogenesis. Park D, et al. **Retina** 1995; 15(4):351-2

[Contribution of the ophthalmologist to presymptomatic diagnosis of familial adenomatous polyposis (FAP)] Sommer E, et al. **Ophthalmologe** 1995 Dec;92(6):809-16 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Influence of chromosomal position and copy number of a white-directed ribozyme gene on the suppression of eye pigmentation in Drosophila melanogaster. Heinrich JC, et al. **Antisense Res Dev** 1995 Summer;5(2):155-60

Construction of a cDNA library from human retinal pigment epithelial cells challenged with rod outer segments. Cavaney DM, et al. **Aust N Z J Ophthalmol** 1995 May; 23(2):139-44

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):709-22 (97 ref.)

Effects of adenosine on chick retinal pigment epithelium: membrane potentials and light-evoked responses. Maruiwa F, et al. **Curr Eye Res** 1995 Aug;14(8):685-91

Effects of extracellular matrix and Bruch's membrane on retinal outer segment phagocytosis by cultured human retinal pigment epithelium. Miceli MV, et al. **Curr Eye Res** 1996 Jan;15(1):17-26

Influence of zinc on selected cellular functions of cultured human retinal pigment epithelium. Tate DJ, et al. **Curr Eye Res** 1995 Oct;14(10):897-903

Development of the blood-retinal barrier in vitro: formation of tight junctions as revealed by occludin and ZO-1 correlates with the barrier function of chick retinal pigment epithelial cells. Konari K, et al. **Exp Eye Res** 1995 Jul; 61(1):99-108

Reorganization of actin microfilaments and microtubules in regenerating retinal pigment epithelium. Korte GE, et al. **Exp Eye Res** 1995 Aug;61(2):189-203

A comparison of phagocytosis by the retinal pigment epithelium in normal and delayed amelanotic chickens. Lahiri D, et al. **Exp Eye Res** 1993 Jun;56(6):625-34

Normally occurring loss of single cells and repair of resulting defects in retinal pigment epithelium in situ. Nagai H, et al. **Exp Eye Res** 1996 Jan;62(1):55-61

Inhibition of fibroblast proliferation by human iris pigment epithelial cells in vitro: preliminary results. Fan ZJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):64-6

Carbachol does not correct the defect in the phagocytosis of outer segments by Royal College of Surgeons rat retinal pigment epithelial cells. Hall MO, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1473-7

Inwardly rectifying K+ currents in isolated human retinal pigment epithelial cells. Hughes BA, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1125-39

Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells. Relationship to cell morphology. McLaren MJ. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1213-24

The involvement of polyamines in the proliferation of cultured retinal pigment epithelial cells. Yanagihara N, et al. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):1975-83

Retinal pigmented epithelium does not transdifferentiate in adult goldfish. Knight JK, et al. **J Neurobiol** 1995 Aug; 27(4):447-56

Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Shima DT, et al. **Mol Med** 1995 Jan;1(2):182-93

Shifting relationships between photoreceptors and pigment epithelial cells in monkey retina: implications for the development of retinal topography. Robinson SR, et al. **Vis Neurosci** 1995 Jul-Aug;12(4):767-78

[The magnetic susceptibility of the melanin in the eyes of representatives of different vertebrate classes] Zagal'skaia EO. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug;31(4):416-22 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Pattern dystrophy of the retinal pigment epithelium and geographic atrophy of the macula. Marmor MF, et al. **Am J Ophthalmol** 1996 Sep;122(3):382-92

Effects of prolonged uniocular dark adaptation on the direct-current electroretinogram of pigmented and albino rabbits. Textorius O, et al. **Doc Ophthalmol** 1995; 90(3):305-17

RADIATION EFFECTS

Blue and ultraviolet light-absorbing opsin from the retinal pigment epithelium. Hao W, et al. **Biochemistry** 1996 May 21;35(20):6251-6

SURGERY

Laser synechialysis to prevent membrane recurrence on silicone intraocular lenses. Flynn WJ, et al. **Am J Ophthalmol** 1996 Sep;122(3):426-8

TRANSPLANTATION

Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina. Little CW, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):204-11

[Transplantation of retinal cells in man] Ehinger B. **Lakartidningen** 1996 Jan 31;93(5):364 **(Swe)**

ULTRASONOGRAPHY

Echographic evaluation of primary cysts of the iris pigment epithelium [letter; comment] Kozart DM. **Am J Ophthalmol** 1996 Jan;121(1):100-1. Comment on: Am J Ophthalmol 1995 Aug;120(2):161-7.

Location of the iris insertion in pigment dispersion syndrome. Sokol J, et al. **Ophthalmology** 1996 Feb;103(2):289-93

ULTRASTRUCTURE

Ultrastructural features of retinal dystrophy in mutant vitiligo mice. Nir I, et al. **Exp Eye Res** 1995 Sep;61(3):363-77

Fine structure of the retinal pigment epithelium of the barred owl (Strix varia). Brackevelt CR, et al. **Histol Histopathol** 1996 Jan;11(1):71-7

Fine structure of the retina and pigment epithelium in the creek chub, Semotilus atromaculatus (Cyprinidae, Teleostei). Collin SP, et al. **Histol Histopathol** 1996 Jan; 11(1):41-53

Ultrastructure and organisation of the retina and pigment epithelium in the cutlips minnow, Exoglossum maxillingua (Cyprinidae, Teleostei). Collin SP, et al. **Histol Histopathol** 1996 Jan;11(1):55-69

Intercellular junctions of the ciliary epithelium in anterior uveitis. Freddo TF. **Invest Ophthalmol Vis Sci** 1987 Feb; 28(2):320-9

Pigment epithelial and retinal phenotypes in the vitiligo mivit, mutant mouse. Sidman RL, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1097-115

Increased cell genesis in retinal pigment epithelium of perinatal vitiligo mutant mice. Tang M, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1116-24

Ultrastructural study of basal lamina of retinal pigment epithelium. Ou B, et al. **Ophthalmic Res** 1995;27(3):158-62

A model for the formation of ring mitochondria in retinal pigment epithelium. Liang H, et al. **Yen Ko Hsueh Pao** 1995 Mar;11(1):9-15

VIROLOGY

Susceptibility of human retinal pigment epithelial cells to different viruses. Huemer HP, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Mar;234(3):177-85

Retroviral gene transfer into retinal pigment epithelial cells followed by transplantation into rat retina. Dunaief JL, et al. **Hum Gene Ther** 1995 Sep;6(9):1225-9

Cytomegalovirus replication in human retinal pigment epithelial cells. Altered expression of viral early proteins. Detrick B, et al. **Invest Ophthalmol Vis Sci** 1996 Apr; 37(5):814-25

Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells. Tugizov S, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):61-74

Centripetal transport of herpes simplex virus in human retinal pigment epithelial cells in vitro. Topp KS, et al. **Neuroscience** 1996 Apr;71(4):1133-44

PIGMENTARY RETINOPATHY see **RETINITIS PIGMENTOSA**

PIGMENTATION

see related

SKIN PIGMENTATION

The amount of lens exfoliation and chamber-angle pigmentation in exfoliative syndrome with or without glaucoma [letter] Moreno-Montañés J, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):202-4

Pigmentation: a clue to hyperplastic right and transverse colon polyps [letter] Langdon DE. **Am J Gastroenterol** 1996 Aug;91(8):1679-80

Estimation of the age of bruising. Stephenson T, et al. **Arch Dis Child** 1996 Jan;74(1):53-5

Benign fleck retina [letter] Isaacs TW, et al. **Br J Ophthalmol** 1996 Mar;80(3):267-8

Pigmented eccrine porocarcinoma: a mimic of malignant melanoma. Hara K, et al. **Histopathology** 1995 Jul; 27(1):86-8

Spleen pigmentation in young C57BL mice is caused by accumulation of melanin. van der Heijden A, et al. **Lab Anim** 1995 Oct;29(4):459-63

6th meeting of the European Society for Pigment Cell Research. Lausanne, Switzerland, 19-21 October 1995. Abstracts. **Melanoma Res** 1995 Sep;5 Suppl 2:1-54

Pigmentation of the posterior lens capsule central to Wieger's ligament and the Scheie line: a possible indication of the pigment dispersion syndrome. Roberts DK, et al. **Optom Vis Sci** 1995 Oct;72(10):756-62

Effect of feed and water withdrawal on green liver discoloration, serum triglycerides, and hemoconcentration in turkeys. Huff WE, et al. **Poult Sci** 1996 Jan;75(1):59-61

The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Cone RD, et al. **Recent Prog Horm Res** 1996;51:287-317; discussion 318 (102 ref.)

Black hair follicular dysplasia [letter; comment] Dunn KA, et al. **Vet Rec** 1995 Oct 14;137(16):412. Comment on: Vet Rec 1994 Dec 17;135(25):607-8. Comment on: Vet Rec 1995 Jan 21;136(3):79-80.

DRUG EFFECTS

Effect of semduramicin, salinomycin, and monensin on performance, shank pigmentation, and coccidial lesions in broiler chickens in floor pens. McDougald LR, et al. **Avian Dis** 1996 Jan-Mar;40(1):68-71

Color coordinates for assessment of dietary vitamin E effects on beef color stability. Liu Q, et al. **J Anim Sci** 1996 Jan; 74(1):106-16

Titration of fresh meat color stability and malondialdehyde development with Holstein steers fed vitamin E-supplemented diets. Liu Q, et al. **J Anim Sci** 1996 Jan; 74(1):117-26

Agouti protein can act independently of melanocyte-stimulating hormone to inhibit melanogenesis. Hunt G, et al. **J Endocrinol** 1995 Nov;147(2):R1-4

Arbutin: mechanism of its depigmenting action in human melanocyte culture. Maeda K, et al.

J Pharmacol Exp Ther 1996 Feb;276(2):765–9

GENETICS

Nonrandom mating in the two-spot ladybird (Adalia bipunctata): the influence of weight on mating success. Tomlinson IP, et al. **Behav Genet** 1995 Sep;25(5):467–74
Molecular organization and germinal instability of R-stippled maize. Eggleston WB, et al. **Genetics** 1995 Sep; 141(1):347–60
Organization of paramutagenicity in R-stippled maize. Kermicle JL, et al. **Genetics** 1995 Sep;141(1):361–72
Transgene inactivation in Petunia hybrida is influenced by the properties of the foreign gene. Elomaa P, et al. **Mol Gen Genet** 1995 Oct 25;248(6):649–56

PHYSIOLOGY

Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits. Perkins RJ, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1493–8
A possible involvement of melanocortin 1-receptor in regulating feather color pigmentation in the chicken. Takeuchi S, et al. **Biochim Biophys Acta** 1996 Aug 14; 1308(2):164–8
Incorporation of codeine and metabolites into hair. Role of pigmentation. Gygi SP, et al. **Drug Metab Dispos** 1996 Apr; 24(4):495–501
Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Park HY, et al. **Exp Cell Res** 1996 Aug 25;227(1):70–9
Retrograde fluorescent microsphere tracing of retinal and central afferents to the nucleus of the optic tract in pigmented and albino rats. Aarnoutse EJ, et al. **Neurosci Lett** 1995 Dec 8;201(2):143–6

RADIATION EFFECTS

Mechanisms of ultraviolet light-induced pigmentation. Gilchrest BA, et al. **Photochem Photobiol** 1996 Jan; 63(1):1–10 (110 ref.)

PIGMENTATION DISORDERS

Circumscribed pigmented lesions. Hogan P. **Aust Fam Physician** 1995 Oct;24(10):1873–6, 1878
Long-term follow-up of cutaneous changes in siblings with mandibuloacral dysplasia who were originally considered to have hereditary sclerosing poikiloderma. Fryburg JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):900–2
Schamberg's disease: a case report. Bethea L. **J S C Med Assoc** 1995 Nov;91(11):469–70
Common disorders of pigmentation: when are more than cosmetic cover-ups required? Hacker SM. **Postgrad Med** 1996 Jun;99(6):177–86 (14 ref.)

CHEMICALLY INDUCED

Skin depigmentation related to transdermal clonidine therapy [letter] Doe N, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2129
Black breast milk due to minocycline therapy. Hunt MJ, et al. **Br J Dermatol** 1996 May;134(5):943–4
Chrysiasis revisited: a clinical and pathological study. Smith RW, et al. **Br J Dermatol** 1995 Nov;133(5):671–8
Striae from DEPO-PROVERA injections [letter] Harris D, et al. **Clin Exp Dermatol** 1996 Mar;21(2):172
Green hair. Mascaró JM Jr, et al. **Cutis** 1995 Jul;56(1):37–40
Canities--reversal with chemotherapy. Babu KG, et al. **J Assoc Physicians India** 1995 Aug;43(8):577
Redman syndrome [letter] Dayavathi, et al. **J Assoc Physicians India** 1995 Oct;43(10):724
Is micropigmentation surgery an answer to stable bindi-induced depigmentation? [letter] Bose SK. **J Dermatol** 1995 Jul;22(7):533–4
Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Delmas-Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(3):205–10 (17 ref.)
An unusual complication following intralesional triamcinolone injections [letter] Gahankari D, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1076
[Minor symptoms in family medicine; chloasma or 'pregnancy mask' (letter; comment)] Menke HE, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2698. Comment on: Ned Tijdschr Geneeskd 1995 Sep 30;139(39):1971–4. **(Dut)**

COMPLICATIONS

Congenital heart block due to pigment deposition in the conduction system. Ray R, et al. **Indian Heart J** 1995 Mar-Apr;47(2):141–2
Hemifacial hypoplasia and hypomelanosis of Ito. Tan ST, et al. **J Craniomaxillofac Surg** 1995 Oct;23(5):274–9
Hypomelanosis of Ito associated with neuroblastoma. Oguma E, et al. **Pediatr Radiol** 1996;26(4):273–5
[Neurocutaneous disorders with achromic spots. Tuberous sclerosis of Bourneville. Diagnostic criteria and follow-up protocol] Prats-Viñas JM. **Rev Neurol** 1996 Sep; 24(133):1056–9 (7 ref.) **(Spa)**

CONGENITAL

The incidence of birthmarks in Israeli neonates. Kahana M, et al. **Int J Dermatol** 1995 Oct;34(10):704–6
A theoretical study of the thermal response of skin to cryogen spray cooling and pulsed laser irradiation: implications for treatment of port wine stain birthmarks. Anvari B, et al. **Phys Med Biol** 1995 Sep;40(9):1451–65

DIAGNOSIS

Multiple pigmented spots on the face. Levine N. **Geriatrics** 1996 Apr;51(4):52
Hypomelanosis of Ito. Kulkarni ML, et al. **Indian Pediatr** 1996 Mar;33(3):243–5
Skin cancer detection in a clinical practice examination with standardized patients. Robinson JK, et al. **J Am Acad Dermatol** 1996 Apr;34(4):709–11
[Yellow discoloration of the lens in the diabetic patient] Menon SR, et al. **Klin Monatsbl Augenheilkd** 1996 May; 208(5):275–8 (Eng. Abstr.) **(Ger)**
[Ito's hypomelanosis] Averianov IuN, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):84–6 (8 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Purpura pigmentosa chronica successfully treated with oral cyclosporin A [letter] Okada K, et al. **Br J Dermatol** 1996 Jan;134(1):180–1

EPIDEMIOLOGY

The incidence of birthmarks in Israeli neonates. Kahana M, et al. **Int J Dermatol** 1995 Oct;34(10):704–6

ETIOLOGY

The continuing threat of retinopathy of prematurity [editorial] Palmer EA. **Am J Ophthalmol** 1996 Sep; 122(3):420–3
Macular coloboma-like lesions and pigment abnormalities as complications of cryotherapy for retinopathy of prematurity in very low birth-weight infants. Saito Y, et al. **Am J Ophthalmol** 1996 Sep;122(3):299–308
Localized chrysiasis induced by laser therapy. Trotter MJ, et al. **Arch Dermatol** 1995 Dec;131(12):1411–4
Prurigo pigmentosa associated with ketosis [letter] Murao K, et al. **Br J Dermatol** 1996 Feb;134(2):379–81
Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. Nagler A, et al. **Br J Dermatol** 1996 Apr;134(4):780–3
Blue nails and acquired immunodeficiency syndrome: not always associated with azidothymidine use. Glaser DA, et al. **Cutis** 1996 Apr;57(4):243–4
Ocular findings in Japanese women with nevus of Ota. Kono T, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov; 233(11):667–71
Localized green pigmentation in a patient with hyperbilirubinemia. Allegue F, et al. **J Am Acad Dermatol** 1996 Jul;35(1):108–9

GENETICS

Pigmentation, pleiotropy, and genetic pathways in humans and mice [editorial; comment] Barsh GS. **Am J Hum Genet** 1995 Oct;57(4):743–7. Comment on: Am J Hum Genet 1995 Oct;57(4):755–65.
Keratoderma, hypotrichosis and leukonychia totalis: a new syndrome? Başaran E, et al. **Br J Dermatol** 1995 Oct; 133(4):636–8
Dyskeratosis congenita: an inherited bone marrow failure syndrome. Dokal I. **Br J Haematol** 1996 Mar;92(4):775–9 (52 ref.)
Defective expression of early activation genes in cartilage-hair hypoplasia (CHH) with severe combined immunodeficiency (SCID). Castigli E, et al. **Clin Exp Immunol** 1995 Oct;102(1):6–10
Mosaic loss of 15q11q13 in a patient with hypomelanosis of Ito: is there a role for the P gene? Pellegrino JE, et al. **Hum Genet** 1995 Oct;96(4):485–9
Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)
X inactivation analysis in a female with hypomelanosis of Ito associated with a balanced X;17 translocation: evidence for functional disomy of Xp. Hatchwell E, et al. **J Med Genet** 1996 Mar;33(3):216–20
A translocation interrupts the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Toriello HV, et al. **Nat Genet** 1996 Jul;13(3):361–5

IMMUNOLOGY

Reticular acropigmentation of Kitamura: a study of HLA antigen typing [letter] Bocanegra OC, et al. **Br J Dermatol** 1995 Nov;133(5):819–20

METABOLISM

A case of atrophoderma of Pasini and Pierini: analysis of glycosaminoglycan of the lesional skin. Tajima S, et al. **J Dermatol** 1995 Oct;22(10):767–9

PATHOLOGY

Fractal and integer-dimensional geometric analysis of pigmented skin lesions. Cross SS, et al. **Am J Dermatopathol** 1995 Aug;17(4):374–8
Benzidine stain for the histochemical detection of hemoglobin in splinter hemorrhage (subungual hematoma) and black heel. Hafner J, et al. **Am J Dermatopathol** 1995 Aug; 17(4):362–7
Pigmented longitudinal bands of the nail. A clinicopathologic study. Molina D, et al. **Am J Dermatopathol** 1995 Dec; 17(6):539–41
Multiple pigmented follicular cysts: a subtype of multiple pilosebaceous cysts. Salopek TG, et al. **Br J Dermatol** 1996 Apr;134(4):758–62
Pigmented conjunctival epithelial dysplasia in an HIV positive African: detection of human papillomavirus type 16 [letter] Loeffler KU, et al. **Br J Ophthalmol** 1995 Dec; 79(12):1138–40
Clinico-neuropathological study of incontinentia pigmenti achromians--an autopsy case. Fujino O, et al. **Brain Dev** 1995 Nov-Dec;17(6):425–7
Reliability of computer image analysis of pigmented skin lesions of Australian adolescents. Aitken JF, et al. **Cancer** 1996 Jul 15;78(2):252–7
An histological and ultrastructural study of the 'dirty neck' appearance in atopic eczema. Humphreys F, et al. **Clin Exp Dermatol** 1996 Jan;21(1):17–19
Reticular pigmented genodermatosis with milia--a special form of Naegeli-Franceschetti-Jadassohn syndrome or a new entity? Tzermias C, et al. **Clin Exp Dermatol** 1995 Jul;20(4):331–5
Congenital heart block due to pigment deposition in the conduction system. Ray R, et al. **Indian Heart J** 1995 Mar-Apr;47(2):141–2
Cell infiltrate in progressive pigmented purpura (Schamberg's disease): immunophenotype, adhesion receptors, and intercellular relationships. Ghersetich I, et al. **Int J Dermatol** 1995 Dec;34(12):846–50
Multiple pigmented eccrine hidrocystomas. Bourke JF, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):480–2
Pigmentation abnormalities in systemic scleroderma examined by using a colorimeter (Choromo Meter CR-200). Maeda M, et al. **J Dermatol Sci** 1996 Mar; 11(3):228–33
Artefacts in electron microscopy: ultrastructural features of chrysiasis. Culora GA, et al. **J Pathol** 1995 Aug; 176(4):421–5
Involvement of the white matter in hypomelanosis of Ito (incontinentia pigmenti achromiens). Ruggieri M, et al. **Neurology** 1996 Feb;46(2):485–92
Pigment dispersal syndrome [letter; comment] Libre PE. **Ophthalmic Surg** 1995 Jul-Aug;26(4):290. Comment on: Ophthalmic Surg 1994 May;25(5):307–10.

PHYSIOPATHOLOGY

Lymphatic function in the yellow nail syndrome. Bull RH, et al. **Br J Dermatol** 1996 Feb;134(2):307–12
A comparison of phagocytosis by the retinal pigment epithelium in normal and delayed amelanotic chickens. Lahiri D, et al. **Exp Eye Res** 1993 Jun;56(6):625–34
Involvement of the white matter in hypomelanosis of Ito (incontinentia pigmenti achromiens). Ruggieri M, et al. **Neurology** 1996 Feb;46(2):485–92
Cerebellar involvement in hypomelanosis of Ito. Pini G, et al. **Neuropediatrics** 1995 Aug;26(4):208–10

RADIOGRAPHY

Ito hypomelanosis and moyamoya disease. Echenne BP, et al. **Pediatr Neurol** 1995 Sep;13(2):169–71

RADIOTHERAPY

A theoretical study of the thermal response of skin to cryogen spray cooling and pulsed laser irradiation: implications for treatment of port wine stain birthmarks. Anvari B, et al. **Phys Med Biol** 1995 Sep;40(9):1451–65

SURGERY

Longitudinal melanonychia in children. A study of eight cases. Léauté-Labrèze C, et al. **Arch Dermatol** 1996 Feb; 132(2):167–9
[The ruby laser: can removal of pigmented skin changes with the ruby laser be done by non-physician personnel?] Michel S, et al. **Gesundheitswesen** 1996 Jun;58(6):319–21 (Eng. Abstr.) **(Ger)**
[Removal of amateur and dirt tattooing with the Q-switched ruby laser] Raulin C, et al. **Hautarzt** 1995 Oct;46(10):711–3 (Eng. Abstr.) **(Ger)**
[Treatment of vascular malformations and pigment disorders of the face and neck by pulsed dye laser, Photoderm VL and Q-switched ruby laser] Hellwig S, et al. **Laryngorhinootologie** 1995 Oct;74(10):635–41 (Eng. Abstr.) **(Ger)**

THERAPY

The role of pulsed laser in the management of cosmetically significant pigmented lesions. Bekhor PS. **Australas J Dermatol** 1995 Nov;36(4):221–3 (5 ref.)

VETERINARY

Protoporphyric disorder in livers of broiler chickens. Shiozawa M, et al. **J Vet Med Sci** 1995 Jun;57(3):549–51
Black hair follicular dysplasia in a tricolour Jack Russell terrier. Knottenbelt CM, et al. **Vet Rec** 1996 May 11; 138(19):475–6

PIGMENTS

[Fiber optic chemical gas sensors based on environmental chromism] Sadaoka Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2355–60 (14 ref.) **(Jpn)**

ANALYSIS

Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Powell JJ, et al. **Gut** 1996 Mar;38(3):390–5

Distribution of lipochrome pigment in the prostate gland: biological and diagnostic implications. Leung CS, et al. **Hum Pathol** 1995 Dec;26(12):1302–7

[Daily intake of carotenoids (carotenes and xanthophylls) from total diet and the carotenoid content of selected vegetables and fuit] Müller H. **Z Ernahrungswiss** 1996 Mar; 35(1):45–50 (Eng. Abstr.) **(Ger)**

[Dipyrrole bile pigments] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:895–8 (9 ref.) **(Jpn)**

BIOSYNTHESIS

Effects of some heavy metals on growth, pigment and antibiotic production by Streptomyces galbus. Raytapadar S, et al. **Acta Microbiol Immunol Hung** 1995;42(2):171–7

Assay for tyrosine hydroxylation activity of tyrosinase from betalain–forming plants and cell cultures. Steiner U, et al. **Anal Biochem** 1996 Jun 15;238(1):72–5

Diversified shunt to the production of different proportions of secondary metabolites (polyketides and terpenes) induced by varying immobilization constraints on Gibberella fujikuroi. Roisin C, et al. **Ann N Y Acad Sci** 1996 May 15;782:61–9

An insertion element prevents phycobilisome synthesis in N2–fixing Synechocystis sp. strain BO 8402. Brass S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1964–8

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)

High–molecular–mass, iron–repressed cytoplasmic proteins in fluorescent Pseudomonas: potential peptide–synthetases for pyoverdine biosynthesis. Georges C, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):9–15

Structure and characterization of isopyoverdin from Pseudomonas putida BTP1 and its relation to the biogenetic pathway leading to pyoverdins. Jacques P, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):622–9

Brown–red pigment formation by the mycelial phase of a clinical isolate of Histoplasma capsulatum on Staib agar. A preliminary report. Staib F, et al. **Zentralbl Bakteriol** 1996 Apr;283(4):515–21

CHEMISTRY

The chemical mechanism of beta–haematin formation studied by Mössbauer spectroscopy. Adams PA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):25–7

Chemical reactivity and spectroscopy of the thiol ester–linked p–coumaric acid chromophore in the photoactive yellow protein from Ectothiorhodospira halophila. Hoff WD, et al. **Biochemistry** 1996 Jan 30; 35(4):1274–81

Reactions between tunichrome Mm–1, a tunicate blood pigment, and vanadium ions in acidic and neutral media. Ryan DE, et al. **Biochemistry** 1996 Jul 2;35(26):8640–50

Reactions between vanadium ions and biogenic reductants of tunicates: spectroscopic probing for complexation and redox products in vitro. Ryan DE, et al. **Biochemistry** 1996 Jul 2;35(26):8651–61

Stereoselectivity of pigment exchange with 13(2)–hydroxylated tetrapyrroles in reaction centers of Rhodobacter sphaeroides R26. Storch KF, et al. **Eur J Biochem** 1996 May 15;238(1):280–6

(all trans)–2,4,6,8,10,12–tetradecahexene–1,14–dial, a new pigment from Conidiobolus paulus. Vesonder RF. **J Nat Prod** 1996 Apr;59(4):441–2

Vanadium in ascidians and the chemistry of tunichromes. Smith MJ, et al. **Met Ions Biol Syst** 1995;31:423–90 (361 ref.)

Study of a melanic pigment of Proteus mirabilis. Agodi A, et al. **Res Microbiol** 1996 Mar–Apr;147(3):167–74

Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):213–9 (36 ref.)

GENETICS

Novel pyoverdine biosynthesis gene(s) of Pseudomonas aeruginosa PAO. Stintzi A, et al. **Microbiology** 1996 May; 142 (Pt 5):1181–90

Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Orlow SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10152–6

[Demonstration of transposition in Portulaca grandiflora (HOOK)] Rossi–Hassani BD, et al. **Ann Genet** 1995; 38(2):90–6 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

One–step extraction and concentration of pigments and acyl lipids by sec–butanol from in vitro and in vivo samples. Martinson TA, et al. **Anal Biochem** 1995 Jun 10; 228(1):123–30

METABOLISM

Endothelial lipopigment as an indicator of alpha–tocopherol deficiency in two equine neurodegenerative diseases. Cummings JF, et al. **Acta Neuropathol (Berl)** 1995; 90(3):266–72

Changes in the levels of photosynthetic pigments in Phaseolus aureus Roxb. exposed to Hg and Cd at two stages of development: a comparative study. Shaw BP. **Bull Environ Contam Toxicol** 1995 Oct;55(4):574–80

Alterations in cell pigmentation, protein expression, and photosynthetic capacity of the cyanobacterium Oscillatoria tenuis grown under low iron conditions. Trick CG, et al. **Can J Microbiol** 1995 Dec;41(12):1117–23

Alzheimer's disease: distribution of changes in intraneuronal lipopigment in the frontal cortex. Dowson JH, et al. **Dementia** 1995 Nov–Dec;6(6):334–42

Reconstitution and pigment–binding properties of recombinant CP29. Giuffra E, et al. **Eur J Biochem** 1996 May 15;238(1):112–20

Stereoselectivity of pigment exchange with 13(2)–hydroxylated tetrapyrroles in reaction centers of Rhodobacter sphaeroides R26. Storch KF, et al. **Eur J Biochem** 1996 May 15;238(1):280–6

Increased levels of 4–hydroxynonenal in human monocytes fed with malarial pigment hemozoin. A possible clue for hemozoin toxicity. Schwarzer E, et al. **FEBS Lett** 1996 Jun 17;388(2–3):119–22

Production of actinorhodin–related "blue pigments" by Streptomyces coelicolor A3(2). Bystrykh LV, et al. **J Bacteriol** 1996 Apr;178(8):2238–44

Yellow marking and pteridine contents in the integument of albino Armadillidium vulgare. Negishi S, et al. **Pigment Cell Res** 1996 Feb;9(1):35–41

Malaria pigment in leucocytes. Metzger WG, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):637–8

PHARMACOLOGY

Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells. Malham GM, et al. **Br J Neurosurg** 1996 Feb;10(1):51–7

Identification of antimutagenic substances in an extract of edible red alga, Porphyra tenera (asakusa–nori). Okai Y, et al. **Cancer Lett** 1996 Feb 27;100(1–2):235–40

Bleached pigment activates transduction in salamander cones. Cornwall MC, et al. **J Gen Physiol** 1995 Sep;106(3):543–57

Inhibitory effect of hemin, chlorophyllin and related pyrrole pigments on the mutagenicity of benzo[a]pyrene and its metabolites. Arimoto S, et al. **Mutat Res** 1995 Dec; 345(3–4):127–35

PHYSIOLOGY

Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Meyer JM, et al. **Infect Immun** 1996 Feb; 64(2):518–23

THERAPEUTIC USE

Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Oncology** 1996 May–Jun; 53(3):247–9

URINE

Beeting (sic) a crimson retreat [letter; comment] Mitchell SC. **Lancet** 1996 Feb 17;347(8999):474–5. Comment on: Lancet 1996 Jan 6;347(8993):5–6.

Beeting (sic) a crimson retreat [letter; comment] Rosalki SB. **Lancet** 1996 Feb 17;347(8999):474. Comment on: Lancet 1996 Jan 6;347(8993):5–6.

Things that go red in the urine; and others that don't [see comments] Thompson WG. **Lancet** 1996 Jan 6; 347(8993):5–6. Comment in: Lancet 1996 Feb 17;347(8999):474. Comment in: Lancet 1996 Feb 17;347(8999):474–5.

Beeturia and colonic oxalic acid. Eastwood MA, et al. **QJM** 1995 Oct;88(10):711–7

PIGS see **SWINE**

PIKE see **ESOCIDAE**

PILAR CYST see **EPIDERMAL CYST**

PILI, BACTERIAL see **FIMBRIAE, BACTERIAL**

PILI, COMMON see **FIMBRIAE, BACTERIAL**

PILI, CONJUGATIVE see **PILI, SEX**

PILI, SEX

see related
CONJUGATION, GENETIC

Regulation of tcp genes in classical and El Tor strains of Vibrio cholerae O1. Thomas S, et al. **Gene** 1995 Dec 1; 166(1):43–8

Rapid identification of colonization factor antigens I & II of enterotoxigenic Escherichia coli by coagglutination test. Ram S, et al. **Indian J Med Res** 1995 Oct;102:156–8

Functional implications of the expression of PilC proteins in meningococci. Virji M, et al. **Mol Microbiol** 1995 Jun; 16(6):1087–97

GENETICS

Relative significance of mannose–sensitive hemagglutinin and toxin–coregulated pili in colonization of infant mice by Vibrio cholerae El Tor. Attridge SR, et al. **Infect Immun** 1996 Aug;64(8):3369–73

Pilus biogenesis gene, pilC, of Neisseria gonorrhoeae: pilC1 and pilC2 are each part of a larger duplication of the gonococcal genome and share upstream and downstream homologous sequences with opa and pil loci. Jonsson AB, et al. **Microbiology** 1995 Oct;141 (Pt 10):2367–77

METABOLISM

Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Connell I, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9827–32

PHYSIOLOGY

Salmonella typhimurium fimbrial phase variation and FimA expression. Clegg S, et al. **J Bacteriol** 1996 Jan;178(2):542–5

PILOCARPINE

The pilocarpine model of epilepsy in mice. Cavalheiro EA, et al. **Epilepsia** 1996 Oct;37(10):1015–9

Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine. Mudò G, et al. **Epilepsia** 1996 Feb;37(2):198–207

Decrease of neurotrophin–3 mRNA in adult rat hippocampus after pilocarpine seizures. Schmidt–Kastner R, et al. **Exp Neurol** 1995 Dec;136(2):199–204

Extracellular potassium elevations in the hippocampus of rats with long–term pilocarpine seizures. Köhling R, et al. **Neurosci Lett** 1995 Dec 1;201(1):87–91

ADMINISTRATION & DOSAGE

Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Mishima HK, et al. **Am J Ophthalmol** 1996 Mar;121(3):319–21

Pharmacodynamic effects of pilocarpine eye drop enhanced by decreasing its volume of instillation. Lal A, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):267–70

Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Hamlar DD, et al. **Laryngoscope** 1996 Aug; 106(8):972–6

[Mydriasis and mydriatics (letter)] Olesen JM. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1385 **(Nor)**

ANALYSIS

Sensitive high–performance liquid chromatographic assay for pilocarpine in biological fluids using fluorescence derivatisation. Aromdee C, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):313–8

ANTAGONISTS & INHIBITORS

A comparison of the ability of myo–inositol and epi–inositol to attenuate lithium–pilocarpine seizures in rats. Patishi Y, et al. **Biol Psychiatry** 1996 May 1;39(9):829–32

CHEMISTRY

Hydroxypropyl–beta–cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Jarho P, et al. **Pharm Res** 1995 Sep;12(9):1371–5

DIAGNOSTIC USE

Postoperative anisocoria: neurogenic or phenylephrine induced? A rapid diagnostic test. Sitzman BT, et al. **Anesth Analg** 1996 Sep;83(3):633–5

Pilocarpine iontophoresis test: an index of physiological sweat secretion? Hjortskov N, et al. **Clin Physiol** 1995 Jul; 15(4):409–14

PHARMACOKINETICS

Sulfobutyl ether beta–cyclodextrin (SBE–beta–CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. Järvinen T, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):95–106

PHARMACOLOGY

Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Croft MA, et al. **Arch Ophthalmol** 1996 May;114(5):586–92

Potentiating effects on pilocarpine–induced saliva secretion, by extracts and N–containing sugars derived from mulberry leaves, in streptozocin–diabetic mice. Chen F, et al. **Biol Pharm Bull** 1995 Dec;18(12):1676–80

Competitive inhibition of coumarin 7–hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Kinonen T, et al. **Br J Pharmacol** 1995 Nov;116(6):2625–30

Short–term effects of secretagogues on the mouse parotid and sublingual gland tissular water. Materazzi S, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Mar;42(2):179–88

Relationship between muscarinic receptor subtypes and cyclic nucleotides in pons-medulla oblongata. Ge XQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):408–11

7-Nitro indazole, an inhibitor of neuronal nitric oxide synthase, attenuates pilocarpine-induced seizures. Van Leeuwen R, et al. **Eur J Pharmacol** 1995 Dec 12; 287(2):211–3

PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys. Millar JC, et al. **Exp Eye Res** 1995 Dec;61(6):677–83

The effect of topical cholinergic medications on human Tenon's capsule fibroblasts in tissue culture. Cunlife IA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug; 233(8):507–12

The additive miotic effects of dapiprazole and pilocarpine. Geyer O, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):448–51

Pharmacodynamic effects of pilocarpine eye drop enhanced by decreasing its volume of instillation. Lal A, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):267–70

Cholinergic drugs alter ciliary muscle response and receptor content. Erickson-Lamy KA, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):375–83

A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. Tanzer JM, et al. **J Dent Res** 1995 Dec;74(12):1845–9

Effect of pilocarpine on anterior chamber angles. Hung L, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):221–6

A modified method for quantitative measurements of cholinergic and adrenergic sialogogue-induced salivation in mice. Murai S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):601–8

Reversal of tropicamide mydriasis with single instillations of pilocarpine can induce substantial pseudo-myopia in young adults. Gilmartin B, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):475–9

Pergolide interactions with nicotine and pilocarpine in rats on the radial-arm maze. Levin ED. **Pharmacol Biochem Behav** 1995 Dec;52(4):837–40

Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats. Lobo LL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):485–8

Effect of nifedipine on lithium-pilocarpine-induced seizures in the rats. Wielosz M, et al. **Pol J Pharmacol** 1995 Jul–Aug; 47(4):279–84

Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Williams MB, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(4):363–8

Cyclosporin A-induced functional and morphological changes in pilocarpine treated rat submandibular glands. Dehpour AR, et al. **Toxicology** 1996 Apr 15;108(1–2):65–71

THERAPEUTIC USE

Cardiac failure aggravated by timolol eye drops: preoperative improvement by changing to pilocarpine. Bäcklund M, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):379–81

Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Bergeå B, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):207–15

Primary argon laser trabeculoplasty vs pilocarpine. IV. Long-term effects on optic nerve head. Bergeå B, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):216–21

Pilocarpine for anticholinergic adverse effects associated with desipramine treatment [letter] Salah RS, et al. **Am J Psychiatry** 1996 Apr;153(4):579

Phenylephrine and pilocarpine in the treatment of post-operative irido-corneal adhesion. Tabandeh H, et al. **Eye** 1995;9 (Pt 4):452–5

Pilocarpine in the management of overcorrection after radial keratotomy. Laranjeira E, et al. **J Refract Surg** 1996 Mar–Apr;12(3):382–90

A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Jacobs CD, et al. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):16–20

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Strahlman ER, et al. **Ophthalmology** 1996 Aug;103(8):1283–93

[Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension] Sirbat D, et al. **J Fr Ophtalmol** 1995;18(10):589–96 (Eng. Abstr.) **(Fre)**

TOXICITY

Comments on the pathogenesis of muscarinic agonist-induced corneal opacities in rats [letter] Durand-Cavagna G, et al. **Food Chem Toxicol** 1996 Jul; 34(7):661

Lithium-pilocarpine neurotoxicity: a potential model of status epilepticus. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):551–67 (195 ref.)

In-vivo genotoxicity of the alkaloid drug pilocarpine nitrate in bone marrow cells and male germ cells of mice. Hegde MJ, et al. **Mutat Res** 1995 Oct;344(3–4):103–8

Epileptiform activity induced by pilocarpine in the rat hippocampal-entorhinal slice preparation. Nagao T, et al. **Neuroscience** 1996 May;72(2):399–408

PILOMATRIXOMA

COMPLICATIONS

Multiple pilomatricomas and myotonic dystrophy in a patient with AIDS. Farrell AM, et al. **Clin Exp Dermatol** 1995 Sep;20(5):423–4

DIAGNOSIS

Hyperkeratotic nodule. Keratoacanthomalike pilomatricoma. Faust HB, et al. **Arch Dermatol** 1996 May;132(5):573, 576

Magnetic resonance imaging of pilomatricoma. De Beuckeleer LH, et al. **Eur Radiol** 1996;6(1):72–5

GENETICS

Multiple familial pilomatricomas: a cutaneous marker for Gardner syndrome? Pujol RM, et al. **Pediatr Dermatol** 1995 Dec;12(4):331–5

PATHOLOGY

Extramedullary hematopoiesis in pilomatricomas. Kaddu S, et al. **Am J Dermatopathol** 1995 Apr;17(2):126–30

Pilomatrix carcinoma and multiple pilomatrixomas. McCulloch TA, et al. **Br J Dermatol** 1996 Feb; 134(2):368–71

An unusual impediment to spectacle wear: pilomatrixoma [letter] Chapman FM, et al. **Br J Ophthalmol** 1995 Dec; 79(12):1143–4

Pilomatrix carcinoma with multiple visceral metastases. Report of a case. Niedermeyer HP, et al. **Cancer** 1996 Apr 1;77(7):1311–4

Fine-needle aspiration of pilomatrixoma [letter; comment] Chen KT. **Diagn Cytopathol** 1995 Oct;13(3):275–6. Comment on: Diagn Cytopathol 1994;10(4):365–9; discussion 369–70.

Pilomatricoma-like endometrioid adenosquamous carcinoma of the ovary with neuroendocrine differentiation. Fang J, et al. **Gynecol Oncol** 1996 May;61(2):291–3

Pilomatrix carcinoma--calcifying epitheliocarcinoma of Malherbe (a case report). Sabharwal BD, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S45–6

Perforating pilomatricoma. Alli N, et al. **J Am Acad Dermatol** 1996 Jul;35(1):116–8 (11 ref.)

Pilomatrixoma of the cheek: report of case. Strobl H, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1355–7

Pilomatrixoma of the eyelid. Shields JA, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug;32(4):260–1

Malignant pilomatrixoma of the scalp. Monchy D, et al. **Pathology** 1995 Apr;27(2):201–3

PHYSIOPATHOLOGY

EMH in pilomatricomas [letter] Falk S. **Am J Dermatopathol** 1996 Apr;18(2):218–9

SECONDARY

Pilomatrix carcinoma with multiple visceral metastases. Report of a case. Niedermeyer HP, et al. **Cancer** 1996 Apr 1;77(7):1311–4

SURGERY

Multiple occurrence of pilomatrixoma. Aslan G, et al. **Plast Reconstr Surg** 1996 Sep;98(3):510–3

VETERINARY

Metastatic pilomatrixoma associated with neurological signs in a dog. Rodríguez F, et al. **Vet Rec** 1995 Sep 2; 137(10):247–8

PILONIDAL CYST

DIAGNOSIS

[Eruptive vellus hair cysts] Jansen T, et al. **Hautarzt** 1996 May;47(5):378–81 (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Pilonidal sinus] Berger A, et al. **Ann Chir** 1995; 49(10):889–901 (27 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Bacteriology and complications of chronic pilonidal sinus treated with excision and primary suture. Søndenaa K, et al. **Int J Colorectal Dis** 1995;10(3):161–6

PATHOLOGY

The origin of pilonidal sinus: a case report. Yabe T, et al. **J Dermatol** 1995 Sep;22(9):696–9

SURGERY

Excision and primary suture of pilonidal sinus. Khaira HS, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):242–4

Reverse transcription-polymerase chain reaction detection of collagen transcripts in healing human wounds. Hopkinson I, et al. **Eur J Clin Invest** 1995 Jul;25(7):539–42

Pilonidal care: anaerobes as invisible villains [letter] Bascom JU. **Eur J Surg** 1996 Apr;162(4):351

Recurrent pilonidal sinus after excision with closed or open treatment: final result of a randomised trial. Søndenaa K, et al. **Eur J Surg** 1996 Mar;162(3):237–40

Bacteriology and complications of chronic pilonidal sinus treated with excision and primary suture. Søndenaa K, et al. **Int J Colorectal Dis** 1995;10(3):161–6

[Excision and immediate suture technic in the treatment of pilonidal fistula. Our experience] Calcina G, et al. **Minerva Chir** 1995 Sep;50(9):815–9 (Eng. Abstr.) **(Ita)**

[Pilonidal cysts and fistulas: radical excision "en bloc" and closure "per primam"] Mecchia P, et al. **Minerva Chir** 1995 Jun;50(6):553–6 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Early sonographic findings suggestive of the human fetal tail. Zimmer EZ, et al. **Prenat Diagn** 1996 Apr;16(4):360–2

PILONIDAL SINUS see PILONIDAL CYST

PILOT PROJECTS

What difference does it make to be treated in a clinical trial? A pilot study. Weijer C, et al. **Clin Invest Med** 1996 Jun; 19(3):179–83

Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. Fullerton T, et al. **J Pharm Sci** 1996 Jun;85(6):600–7

PIMARICIN see NATAMYCIN

PIMELIC ACIDS

METABOLISM

To be free or not: the fate of pimelate in Bacillus sphaericus and in Escherichia coli [letter] Lemoine Y, et al. **Mol Microbiol** 1996 Feb;19(3):645–7

PIMOZIDE

Pimozide and the Pharmaceutical Benefits Scheme [letter; comment] Norton DY. **Med J Aust** 1996 Mar 18;164(6):384 . Comment on: Med J Aust 1996 Jan 1;164(1):52.

ADVERSE EFFECTS

Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. Antkiewicz-Michaluk L, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):459–67

PHARMACOLOGY

Lack of effect of dopamine D2 blockade on ethanol intake in selected and unselected strains of rats. Goodwin FL, et al. **Alcohol** 1996 May-Jun;13(3):273–9

Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Brauer LH, et al. **Biol Psychiatry** 1996 Jan 1;39(1):26–32

Effect of pimozide on the increase of muscarinic receptors caused by mazindol and apomorphine in the rat cerebral motor cortex. de-Sousa FC, et al. **Braz J Med Biol Res** 1995 Jan;28(1):113–9

Complex response competition and dopamine blocking: choosing of high cost sucrose solution versus low cost water in rats. Hsiao S, et al. **Chin J Physiol** 1995; 38(2):99–109

PINDOLOL

ANALOGS & DERIVATIVES

Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. Hosohata Y, et al. **Biol Pharm Bull** 1995 Aug;18(8):1066–71

Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Hoey A, et al. **Br J Pharmacol** 1996 Feb;117(4):712–6

Multiple mechanisms of heterologous beta-adrenoceptor regulation in rat uterus. Nimmo AJ, et al. **J Endocrinol** 1995 Nov;147(2):303–9

Antioxidative action of the beta-adrenoceptor antagonist bopindolol and its metabolite 18-502. Aniya Y, et al. **Jpn J Pharmacol** 1995 Jul;68(3):323–9

[Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)] Widimský J, et al. **Vnitr Lek** 1996 Apr;42(4):223–8 (Eng. Abstr.) **(Cze)**

[Relation between cell proliferation and beta adrenergic receptor expression in activated T lymphocytes] Cazaux C, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(1):43–8 (Eng. Abstr.) **(Spa)**

ANALYSIS

High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. Zhang H, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):309–13

BLOOD

Selective extraction of beta-blockers from biological fluids by column-switching high-performance liquid

chromatography using an internal-surface phenylboronic acid precolumn. Ohta T, et al.
J Chromatogr B Biomed Appl 1996 Jan 12;675(1):168–73

ISOLATION & PURIFICATION

Comparison of two extraction methods for determination of propranolol and furosemide in human plasma by mixed-mode chromatography. Walshe M, et al.
J Pharm Biomed Anal 1996 Feb;14(4):475–81

PHARMACOKINETICS

Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner. Ujhelyi MR, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):683–9

PHARMACOLOGY

Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Meltzer HY, et al. **Biol Psychiatry** 1995 Sep 1;38(5):310–8

Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Hoey A, et al. **Br J Pharmacol** 1996 Feb;117(4):712–6

Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Blier P, et al.
Int Clin Psychopharmacol 1996 Mar;11(1):37–44

Different actions between pindolol and propranolol on the ionic currents in spontaneously beating rabbit sino-atrial node cells. Satoh H. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):967–72

Sleep and waking in 5,7-DHT-lesioned or (-)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone. Monti JM, et al.
Pharmacol Biochem Behav 1995 Oct;52(2):305–12

Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Meltzer HY, et al.
Psychiatry Res 1995 Sep 29;58(2):89–98

Effect of pindolol on the prolactin response to d-fenfluramine. Park SB, et al.
Psychopharmacology (Berl) 1995 Apr;118(4):471–4

THERAPEUTIC USE

Efficacy of pindolol for treatment of vasovagal syncope. Cohen MB, et al. **Am Heart J** 1995 Oct;130(4):786–90

Pindolol, 5-hydroxytryptamine, and antidepressant augmentation [letter; comment] Artigas F.
Arch Gen Psychiatry 1995 Nov;52(11):969–71. Comment on: Arch Gen Psychiatry 1995 Feb;52(2):156.

URINE

Selective extraction of beta-blockers from biological fluids by column-switching high-performance liquid chromatography using an internal-surface phenylboronic acid precolumn. Ohta T, et al.
J Chromatogr B Biomed Appl 1996 Jan 12;675(1):168–73

PINEAL BODY

Tinnitus and hearing loss in pineal region tumours. Missori P, et al. **Acta Neurochir (Wien)** 1995;135(3–4):154–8

Suprasellar embryonal carcinoma: report of one case. Wang JN, et al. **Acta Paediatr Sin** 1995 Nov-Dec;36(6):438–41

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2751–4 (17 ref.)

Intraventricular neurocytoma. Ng P, et al.
Australas Radiol 1996 May;40(2):125–33 (27 ref.)

Imaging of pineal apoplexy. Koenigsberg RA, et al.
Clin Imaging 1996 Apr-Jun;20(2):91–4

Intracranial primary leiomyosarcoma arising in a teratoma of the pineal area. Skullerud K, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):245–8

Pineoblastoma imaged during bone scintigraphy. McCormack S, et al. **Clin Nucl Med** 1995 Nov; 20(11):1023–4

Incidental pineal cysts in a prospectively ascertained normal cohort. Bodensteiner JB, et al. **Clin Pediatr (Phila)** 1996 May;35(5):277–9

Reverse Parinaud's syndrome due to pineal tumour. Menon V, et al. **Indian J Ophthalmol** 1995 Mar;43(1):31–2

Sudden death due to a glial cyst of the pineal gland. Milroy CM, et al. **J Clin Pathol** 1996 Mar;49(3):267–9

Magnetic resonance images reveal a high incidence of asymptomatic pineal cysts in young women. Sawamura Y, et al. **Neurosurgery** 1995 Jul;37(1):11–5; discussion 15–6

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ.
Pediatr Radiol 1996;26(8):537–41 (30 ref.)

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)

Tumors of the pineal region. Piovan E, et al. **Rays** 1996 Jan-Mar;21(1):87–100 (19 ref.) **(Eng, Ita)**

Spinal malignant lymphoma appearing after radiation and chemotherapy of a pineal region tumor. Amagasa M, et al. **Surg Neurol** 1996 Feb;45(2):167–9; discussion 169–71

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Radiotherapy and/or chemotherapy in children with primitive neuroectodermal tumor (PNET) of the pineal region] Dunst J. **Strahlenther Onkol** 1996 Feb;172(2):108–9 **(Ger)**

[Progress in pineal research] Shiotani Y.
Nippon Naibunpi Gakkai Zasshi 1995 Jul 20;71(5):647–50 (17 ref.) **(Jpn)**

[A case of pineoblastoma successfully treated with surgery, combined chemotherapy of cisplatin and etoposide, and radiotherapy] Akiyama Y, et al. **No Shinkei Geka** 1995 Oct; 23(10):921–5 (Eng. Abstr.) **(Jpn)**

[Usefulness of neoadjuvant brachytherapy in the treatment of pineoblastoma: a case report] Tada E, et al.
No Shinkei Geka 1996 May;24(5):481–5 (Eng. Abstr.) **(Jpn)**

[Use of epithalamin in climacteric myocardiopathy] Komarov FI, et al. **Klin Med (Mosk)** 1995;73(4):40–2 **(Rus)**

ANATOMY & HISTOLOGY

Central projections of the parapineal organ of the adult rainbow trout (Oncorhynchus mykiss). Yáñez J, et al.
Cell Tissue Res 1996 Jul;285(1):69–74

The pineal gland: structural and functional diversity. Shedpure M, et al. **Indian J Exp Biol** 1995 Sep;33(9):625–40 (80 ref.)

Melatonin rhythms and pineal structure in a tropical bat, Anoura geoffroyi, that does not use photoperiod to regulate seasonal reproduction. Heideman PD, et al.
J Pineal Res 1996 Mar;20(2):90–7

The pineal gland: a comparative MR imaging study in children and adults with respect to normal anatomical variations and pineal cysts. Sener RN. **Pediatr Radiol** 1995; 25(4):245–8

BLOOD SUPPLY

Microvascularization of the pineal gland in the freshwater turtle, Pseudemys scripta elegans (Reptilia): a scanning electron microscopic study of vascular corrosion casts. Kleiter N, et al. **J Pineal Res** 1995 Sep;19(2):93–102

CHEMISTRY

Polyunsaturated fatty acid composition of the salmon (Salmo salar L.) pineal organ: modification by diet and effect on prostaglandin production. Henderson RJ, et al.
Biochim Biophys Acta 1996 Feb 16;1299(3):289–98

Synaptotagmin I, synaptobrevin II, and syntaxin I are coexpressed in rat and gerbil pinealocytes. Redecker P.
Cell Tissue Res 1996 Mar;283(3):443–54

Simultaneous determination of serotonin, N-acetylserotonin and melatonin in the pineal gland of the juvenile golden hamster by high-performance liquid chromatography with electrochemical detection. Harumi T, et al.
J Chromatogr B Biomed Appl 1996 Jan 12;675(1):152–6

Effects of pineal indoles on ovarian response to gonadotropin-induced ovulation in mice. Chan WY, et al.
J Neural Transm Gen Sect 1995;100(3):239–46

Characterization of gonadotropin-releasing hormone (GnRH)-immunoreactive protein in the rat pineal gland. Park MK, et al. **J Neurosci Res** 1995 Jun 15;41(3):386–93

Electron probe X-ray microanalysis of the elemental composition of the pineal gland of young adults and aged rats. Humbert W, et al. **J Pineal Res** 1996 Jan;20(1):39–44

The chemical neuroanatomy of the mammalian pineal gland: neuropeptides. Møller M, et al. **Neurochem Int** 1996 Jan; 28(1):23–33 (72 ref.)

Immunocytochemical demonstration of taurine in the retina and pineal organ of the pigeon. Ueck M, et al.
Neurochem Int 1995 Dec;27(6):509–17

Localization of N-ethylmaleimide-sensitive fusion protein in pinealocytes. Moriyama Y, et al. **Neuroreport** 1995 Sep 11; 6(13):1757–60

[Melatonin and epithalamin inhibit the process of free radical oxidation in rats] Anisimov VN, et al. **Dokl Akad Nauk** 1995 Aug;343(4):557–9 **(Rus)**

CYTOLOGY

Inhibitor of protein synthesis phase-shifts the circadian oscillator and inhibits the light induced-phase shift of the melatonin rhythm in pigeon pineal cells. Murakami N, et al. **Brain Res** 1995 Sep 25;693(1–2):1–7

Synaptotagmin I, synaptobrevin II, and syntaxin I are coexpressed in rat and gerbil pinealocytes. Redecker P.
Cell Tissue Res 1996 Mar;283(3):443–54

Norepinephrine-induced phosphorylation of the transcription factor CREB in isolated rat pinealocytes: an immunocytochemical study. Tamotsu S, et al.
Cell Tissue Res 1995 Nov;282(2):219–26

Regulation of tryptophan hydroxylase by cyclic AMP, calcium, norepinephrine, and light in cultured chick pineal cells. Florez JC, et al. **J Neurochem** 1996 Jul;67(1):242–50

Sprouting of non-sympathetic myelinated and unmyelinated fibres in response to chronic sympathetic denervation in the pineal gland of the Chinese hamster, Cricetulus griseus. Matsushima S, et al. **J Neurocytol** 1995 Jul;24(7):519–31

[The epiphysis of relatively wild and domesticated foxes: the morphofunctional changes over the course of 24 hours] Kolesnikova LA. **Fiziol Zh Im I M Sechenova** 1996 Feb; 82(2):91–7 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Expression of class II MHC molecules in the rat pineal gland during development and effects of treatment with carbon tetrachloride. Sato T, et al. **Cell Tissue Res** 1996 Apr; 284(1):65–76

Effects of phosphodiesterase inhibitors and forskolin on cyclic GMP-activated channels in intact isolated cells of the chick pineal gland. D'Souza T, et al.
Neurochem Int 1995 Dec;27(6):527–33

Does histamine stimulate cyclic AMP formation in the avian pineal gland via a novel (non-H1, non-H2, non-H3) histamine receptor subtype. Nowak JZ, et al.
Neurochem Int 1995 Dec;27(6):519–26

Calcium responses of isolated, immunocytochemically identified rat pinealocytes to noradrenergic, cholinergic and vasopressinergic stimulations. Schomerus C, et al.
Neurochem Int 1995 Aug;27(2):163–75

Effects of sex hormones on the pineal response to isoproterenol and on pineal beta-adrenergic receptors. Yie SM, et al. **Neuroendocrinology** 1995 Jul;62(1):93–100

Diazepam increases melatonin secretion of photosensitive pineal organs of trout in the photopic and mesopic range of illumination. Meissl H, et al. **Neurosci Lett** 1996 Mar 22;207(1):37–40

Vasopressin potentiation of the melatonin synthetic pathway via specific V1a receptors in the rat pineal gland. Simonneaux V, et al. **Regul Pept** 1996 Jan 16;61(1):63–9

Endocrine effects of granulocyte colony-stimulating factor in cancer patients. Rovelli F, et al. **Tumori** 1995 Nov-Dec; 81(6):438–9

[The effect of reserpine on epiphysial-adrenocortical relations] Arushanian EB, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):17–8 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Development of regulation of melatonin release in pineal cells in chick embryo. Akasaka K, et al. **Brain Res** 1995 Sep 18;692(1–2):283–6

Hydroxyindole-O-methyltransferase gene expression in the pineal gland of chicken embryo: development of messenger RNA levels and regulation by serum. Grechez-Cassiau A, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):204–11

ENZYMOLOGY

Human hydroxyindole-O-methyltransferase in pineal gland, retina and Y79 retinoblastoma cells. Bernard M, et al.
Brain Res 1995 Oct 23;696(1–2):37–48

Melatonin synthesis: analysis of the more than 150-fold nocturnal increase in serotonin N-acetyltransferase messenger ribonucleic acid in the rat pineal gland. Roseboom PH, et al. **Endocrinology** 1996 Jul;137(7):3033–45

Sigma receptor modulation of noradrenergic-stimulated pineal melatonin biosynthesis in rats. Steardo L, et al.
J Neurochem 1996 Jul;67(1):287–93

Light-induced suppression of nocturnal serotonin N-acetyltransferase activity in chick pineal gland and retina: a wavelength comparison. Zawilska JB, et al.
J Pineal Res 1995 Sep;19(2):87–92

Arylamine and arylalkylamine N-acetyltransferases in retina, pineal gland, brain and liver of chicks: a comparative study. Nowak JZ, et al. **Neurochem Int** 1995 Sep;27(3):285–97

Presence of nitric oxide synthase in the sheep pineal gland: an experimental immunohistochemical study.
López-Figueroa MO, et al. **Neuroendocrinology** 1996 Apr; 63(4):384–92

A bizarre receptor mediating stimulatory effect of histamine on cyclic AMP formation in duck pineal gland. Nowak JZ, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):65–8

Partial characterization of serotonin N – acetyltransferases from northern pike (Esox lucius, L.) pineal organ and retina: effects of temperature. Falcón J, et al.
Pflugers Arch 1996 Jul;432(3):386–93

Pineal serotonin N-acetyltransferase: expression cloning and molecular analysis. Coon SL, et al. **Science** 1995 Dec 8; 270(5242):1681–3

GROWTH & DEVELOPMENT

Calbindin-D28k, calretinin, and S-100 immunoreactivities in rat pineal gland during postnatal development. Bastianelli E, et al. **J Pineal Res** 1995 Apr;18(3):127–34

Effects of the chemical denervation on the glial cells of the rat pineal gland: an immunocytochemical study during postnatal development. López-Muñoz F, et al.
J Pineal Res 1995 May;18(4):197–206

Developmental maturation of pineal gland function: synchronized CREM inducibility and adrenergic stimulation. Stehle JH, et al. **Mol Endocrinol** 1995 Jun; 9(6):706–16

IMMUNOLOGY

Expression of class II MHC molecules in the rat pineal gland during development and effects of treatment with carbon tetrachloride. Sato T, et al. **Cell Tissue Res** 1996 Apr; 284(1):65–76

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149–65 (209 ref.)

INNERVATION

Central projections from the goldfish pineal organ traced by HRP-immunocytochemistry. Jiménez AJ, et al. **Histol Histopathol** 1995 Oct;10(4):847–52

METABOLISM

Similar localization of immunoreactive glutamate and aspartate in the pineal organ and retina of various nonmammalian vertebrates. Vigh B, et al. **Acta Biol Hung** 1995;46(1):99–106

Orphan nuclear receptor RZRbeta: cyclic AMP regulates expression in the pineal gland. Baler R, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):975–8

Development of regulation of melatonin release in pineal cells in chick embryo. Akasaka K, et al. **Brain Res** 1995 Sep 18;692(1–2):283–6

The effects of lesions of the thalamic intergeniculate leaflet on the pineal metabolism. Cipolla-Neto J, et al. **Brain Res** 1995 Sep 11;691(1–2):133–41

Cells expressing preproenkephalin mRNA in the rat pineal gland are not serotonin-producing pinealocytes: evidence using in situ hybridization combined with immunocytochemistry for serotonin. Wang XT, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):73–84

Development of rhythmic melatonin synthesis in cultured pineal glands and pineal cells isolated from chick embryo. Lamošová D, et al. **Experientia** 1995 Sep 29;51(9–10):970–5

Development of post-hatching melatonin rhythm in zebra finches (Poephila guttata). Van't Hof TJ, et al. **Experientia** 1996 Mar 15;52(3):249–52

Secretion of the methoxyindoles melatonin, 5-methoxytryptophol, 5-methoxyindoleacetic acid, and 5-methoxytryptamine from trout pineal organs in superfusion culture: effects of light intensity. Yáñez J, et al. **Gen Comp Endocrinol** 1996 Feb;101(2):165–72

Changes induced by pineal indoles in post-implantation mouse embryos. Chan WY, et al. **Gen Pharmacol** 1995 Sep; 26(5):1113–8

Toward a chronome of superfused pike pineals: about-weekly (circaseptan) modulation of circadian melatonin release. Cornélissen G, et al. **In Vivo** 1995 Jul-Aug;9(4):323–9

Circadian expression of transcription factor Fra-2 in the rat pineal gland. Baler R, et al. **J Biol Chem** 1995 Nov 10; 270(45):27319–25

Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat. Puy H, et al. **J Clin Invest** 1996 Jan 1;97(1):104–10

Norepinephrine release in the rat pineal gland: the input from the biological clock measured by in vivo microdialysis. Drijfhout WJ, et al. **J Neurochem** 1996 Feb;66(2):748–55

Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. Ho AK, et al. **J Neurochem** 1995 Oct;65(4):1597–603

Expression of C-type natriuretic peptide in the bovine pineal gland. Middendorff R, et al. **J Neurochem** 1996 Aug; 67(2):517–24

Nyctohemeral rhythm in the levels of S-adenosylmethionine in the rat pineal gland and its relationship to melatonin biosynthesis. Sitaram BR, et al. **J Neurochem** 1995 Oct; 65(4):1887–94

The zinc pool is involved in the immune-reconstituting effect of melatonin in pinealectomized mice. Mocchegiani E, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1200–8

Exogenous melatonin entrains rhythm and reduces amplitude of endogenous melatonin: an in vivo microdialysis study. Drijfhout WJ, et al. **J Pineal Res** 1996 Jan;20(1):24–32

Effects of photoperiod on pineal melatonin in the marsh rice rat (Oryzomys palustris). Edmonds KE, et al. **J Pineal Res** 1995 Apr;18(3):148–53

Adenosine A2 receptor-mediated stimulation of cyclic AMP in cultured chicken pineal cells. Falcón J, et al. **J Pineal Res** 1995 Sep;19(2):72–8

Daytime dark exposure increases pineal melatonin in rat pups. Laakso ML, et al. **J Pineal Res** 1995 Aug;19(1):23–30

Beta-adrenergic receptor subtypes in human pineal gland. Little KY, et al. **J Pineal Res** 1996 Jan;20(1):15–20

Effects of the chemical denervation on the glial cells of the rat pineal gland: an immunocytochemical study during postnatal development. López-Muñoz F, et al. **J Pineal Res** 1995 May;18(4):197–206

Daily variation in the content of indoleamines, catecholamines and related compounds in the pineal gland of Syrian hamsters kept under long and short photoperiods. Miguez JM, et al. **J Pineal Res** 1995 Oct;19(3):139–48

Pineal gene expression: dawn in a dark matter. Stehle JH. **J Pineal Res** 1995 May;18(4):179–90 (90 ref.)

Sinusoidal 50-Hz magnetic fields depress rat pineal NAT activity and serum melatonin. Role of duration and intensity of exposure. Selmaoui B, et al. **Life Sci** 1995; 57(14):1351–8

Thapsigargin modulates agonist-stimulated cyclic AMP responses through cytosolic calcium-dependent and -independent mechanisms in rat pinealocytes. Ho AK, et al. **Mol Pharmacol** 1996 Jun;49(6):1104–12

Diurnal variation in mRNA encoding serotonin N-acetyltransferase in pineal gland. Borjigin J, et al. **Nature** 1995 Dec 21–28;378(6559):783–5

Melatonin synthesis in the retina and pineal gland of Djungarian hamsters at different times of the year. Steinlechner S, et al. **Neurochem Int** 1995 Sep;27(3):245–51

In vivo and in vitro flow cytometry comparative analysis of somatostatin-positive cells in the pineal gland of the neonatal rat. Viader M, et al. **Neuroendocrinology** 1995 Jul; 62(1):87–92

Sustained response of pineal melatonin synthesis to a single one-minute light pulse during night in Djungarian hamsters (Phodopus sungorus). Lerchl A. **Neurosci Lett** 1995 Sep 22;198(1):65–7

Arginine vasopressin stimulates 32P labeling of phosphoinositides in rat pineal gland. Novotná R, et al. **Neurosci Lett** 1995 Sep 1;197(1):49–52

[Study of control of the production of melatonin by perifusion of pineal bodies in rats] Zhao ZY, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):157–64 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Enhancing meningeal blood vessels masquerading as leptomeningeal spread of tumor in obstructive hydrocephalus. LeBlang SD, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1742–4

A choroid plexus papilloma arising from an incidental pineal cyst. Steven DA, et al. **AJNR Am J Neuroradiol** 1996 May; 17(5):939–42

Pineal ganglioglioma with premature thelarche. Report of a case and review of the literature. Chang YL, et al. **Childs Nerv Syst** 1996 Feb;12(2):103–6

Pineal and suprasellar metastasis of lung cancer: case report and review of the literature. Izumihara A, et al. **Comput Med Imaging Graph** 1995 Sep-Oct;19(5):435–7 (14 ref.)

Trilateral tumors in four different lines of transgenic mice expressing SV40 T-antigen. Marcus DM, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):392–6

Pineal parenchymal tumors: "oncogeny" recapitulates ontogeny. Min KW. **J Child Neurol** 1995 Nov;10(6):490

The midline pineal "eye": MR and CT characteristics of the pineal gland with and without benign cyst formation. Jinkins JR, et al. **J Pineal Res** 1995 Sep;19(2):64–71

Treatment of patients with pineoblastoma with high dose cyclophosphamide. Ashley DM, et al. **Med Pediatr Oncol** 1996 Jun;26(6):387–92

MRI of pineal region tumours: relationship between tumours and adjacent structures. Satoh H, et al. **Neuroradiology** 1995 Nov;37(8):624–30

[Germinoma of the pineal area. Long-term follow-up after stereotaxic biopsy] Lippitz B. **Nervenarzt** 1996 Apr; 67(4):294–300 (Eng. Abstr.) **(Ger)**

[Metastasis of the pineal gland] Jiménez Sáenz JM, et al. **Neurologia** 1996 Feb;11(2):86–7 **(Spa)**

PHYSIOLOGY

Functional connections between the pineal gland and immune system. Skwarło-Sońta K. **Acta Neurobiol Exp (Warsz)** 1996;56(1):341–57 (111 ref.)

Melatonin as a chronobiotic: PROS and CONS. Steinlechner S. **Acta Neurobiol Exp (Warsz)** 1996;56(1):363–72 (64 ref.)

The mammalian pineal gland and reproduction. Controversies and strategies for future research. Olcese J. **Adv Exp Med Biol** 1995;377:1–14 (97 ref.)

Maternal pineal gland participates in prepubertal rats' ovarian oocyte development. Fernández B, et al. **Anat Rec** 1995 Dec;243(4):461–5

The pineal gland and cancer. Ronco AL, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2033–9 (68 ref.)

Patterns of melatonin secretion during sexual maturation in female ferrets. Ryan KD, et al. **Biol Reprod** 1995 Dec; 53(6):1251–8

Regional and diurnal studies of melatonin and melatonin binding sites in the duck gastro-intestinal tract. Lee PP, et al. **Biol Signals** 1995 Jul-Aug;4(4):212–24

Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease. Nir I. **Biomed Environ Sci** 1995 Jun;8(2):90–105 (54 ref.)

Circadian regulation of melatonin production in cultured zebrafish pineal and retina. Cahill GM. **Brain Res** 1996 Feb 5;708(1–2):177–81

Rat pineal cell aggregates: ultrastructural and functional characteristics. Shacoori V, et al. **Brain Res Bull** 1995; 38(3):215–20

Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177–92 (72 ref.)

Regulation of synaptic ribbons in rat pineal gland explants by norepinephrine and sympathetic neurons in a co-culture model. McNulty JA, et al. **Cell Tissue Res** 1996 Jan; 283(1):59–66

Effect of pineal body and melatonin on chemiluminescence of peritoneal macrophages via hypothalamus in rats. Wei W, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):435–7

Melatonin suppresses the pinealectomy-induced elevation of collagen content in a wound. Drobnik J, et al. **Cytobios** 1996;85(340):51–8

Short photoperiod-dependent down-regulation of thyrotropin-alpha and -beta in hamster pars tuberalis-specific cells is prevented by pinealectomy. Bockmann J, et al. **Endocrinology** 1996 May;137(5):1804–13

Functional diversity of the pineal hormone melatonin: its role as an antioxidant. Reiter RJ. **Exp Clin Endocrinol Diabetes** 1996;104(1):10–6 (52 ref.)

The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Reiter RJ. **Exp Gerontol** 1995 May-Aug;30(3–4):199–212 (73 ref.)

Plasma prolactin and luteinizing hormone during termination and onset of photorefractoriness in intact and pinealectomized European starlings (Sturnus vulgaris). Chakraborty S. **Gen Comp Endocrinol** 1995 Aug; 99(2):185–91

Pineal gland and melatonin affect testicular status in the adult marsh rice rat (Oryzomys palustris). Edmonds KE, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):265–74

The pineal gland: structural and functional diversity. Shedpure M, et al. **Indian J Exp Biol** 1995 Sep;33(9):625–40 (80 ref.)

Pinealectomy, melatonin, and courtship behavior in male red-sided garter snakes (Thamnophis sirtalis parietalis). Mendonça MT, et al. **J Exp Zool** 1996 Jan 1;274(1):63–74

The effect of the pineal gland on liver regeneration in rats. Abbasoglu O, et al. **J Hepatol** 1995 Nov;23(5):578–81

Sprouting of non-sympathetic myelinated and unmyelinated fibres in response to chronic sympathetic denervation in the pineal gland of the Chinese hamster, Cricetulus griseus. Matsushima S, et al. **J Neurocytol** 1995 Jul;24(7):519–31

(+)-N-allylnormetazocine enhances N-acetyltransferase activity and melatonin synthesis: preliminary evidence for a functional role of sigma receptors in the rat pineal gland. Steardo L, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):845–9

The long-term effect of pinealectomy on the crypts of the rat gastrointestinal tract. Callaghan BD. **J Pineal Res** 1995 May;18(4):191–6

Age-related changes of neuronal responsiveness to melatonin in the striatum of sham-operated and pinealectomized rats. Castillo-Romero JL, et al. **J Pineal Res** 1995 Sep; 19(2):79–86

The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)

Thirty years of human pineal research: do we know its clinical relevance? García-Patterson A, et al. **J Pineal Res** 1996 Jan;20(1):1–6 (66 ref.)

Neurotrophic effects of the pineal gland: role of non-neuronal cells in co-cultures of the pineal gland and superior cervical ganglia. McNulty JA, et al. **J Pineal Res** 1995 Aug;19(1):40–50

Specific binding of 2-[125I]iodomelatonin by rat spleen crude membranes: day-night variations and effect of pinealectomy and continuous light exposure. Rafii-El-Idrissi M, et al. **J Pineal Res** 1996 Jan;20(1):33–8

Study on pineal function and DMBA-induced breast cancer formation in rats during exposure to a 100-mG, 50 Hz magnetic field. Mevissen M, et al. **J Toxicol Environ Health** 1996 Jun 7;48(2):169–85

Chronic lateral ventricle infusion of a pineal gland-derived decapeptide alters pulsatile secretion of LH in rats. Benson B, et al. **Life Sci** 1996;58(13):1083–90

Magnetic fields and pineal function in humans: evaluation of nocturnal acute exposure to extremely low frequency magnetic fields on serum melatonin and urinary 6-sulfatoxymelatonin circadian rhythms. Selmaoui B, et al. **Life Sci** 1996;58(18):1539–49

Signal transmission in the photosensitive pineal organ of the rainbow trout: modulation of ganglion cell activity by intrinsic dopamine. Brandstätter R, et al. **Neurochem Int** 1995 Dec;27(6):473–9

Acetylcholine modulates ganglion cell activity in the trout pineal organ. Brandstätter R, et al. **Neuroreport** 1995 Jul 31;6(11):1553–6

Effects of pinealectomy and constant light exposure on day-night changes of melatonin binding sites in the goldfish brain. Iigo M, et al. **Neurosci Lett** 1995 Sep 1;197(1):61–4

Daily melatonin infusions entrain the locomotor activity of pinealectomized lizards. Hyde LL, et al. **Physiol Behav** 1995 Nov;58(5):943–51

Reduced sympathetic innervation after alteration of target cell neurotransmitter phenotype in transgenic mice. Cho S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2862–6

[Pineal gland and melatonin] Masuzawa T, et al. **No Shinkei Geka** 1995 Oct;23(10):857–68 (74 ref.) **(Jpn)**

[Changes in the infradian rhythm of the dehydrogenases in the blood lymphocytes of rats due to epiphysectomy and the action of weak alternating magnetic fields] Temur'iants NA, et al. **Aviakosm Ekolog Med** 1995;29(3):39–43 (Eng. Abstr.) **(Rus)**

[The effect of epiphysectomy on the circadian dynamics of the cardiointervalogram indices of rats] Arushanian EB, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):64–8 (Eng. Abstr.) **(Rus)**

[The epiphysis of relatively wild and domesticated foxes: the morphofunctional changes over the course of 24 hours] Kolesnikova LA. **Fiziol Zh Im I M Sechenova** 1996 Feb; 82(2):91–7 (Eng. Abstr.) **(Rus)**

[The epiphysis in the visual analyzer system] Arushanian EB, et al. **Usp Fiziol Nauk** 1995 Jul-Sep;26(3):25–40 (98 ref.) (Eng. Abstr.) **(Rus)**

[The effect of epiphysectomy and melatonin administration on the catecholamine content of rat hypothalamic and adrenal tissue] Arushanian EB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):173–5 **(Rus)**

[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum--a functionally unified system for regulating

circadian behavioral fluctuations] Arushanian EB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):15–22 (44 ref.) (Eng. Abstr.) **(Rus)**

[Pineal functioning (melatonin levels) in healthy children of different ages. An update and the value of pineal gland study in pediatrics] Molina Carballo A, et al. **An Esp Pediatr** 1996 Jul;45(1):33–44 (124 ref.) (Eng. Abstr.) **(Spa)**

[The epiphysis in reproduction (the diapause and the sexual cycle)] Pérez Pérez F. **An R Acad Nac Med (Madr)** 1995; 112(2):383–406 (27 ref.) **(Spa)**

[The effect of epiphysectomy and destruction of the lateral septal nucleus of the brain on the genital system in juvenile rats under different light regimens (the interaction of gonadostat++ and photoperiodic mechanisms in the regulation of ovarian functions)] Slaetna OV, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):67–73 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

The pineal gland and cancer. Ronco AL, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2033–9 (68 ref.)

Melatonin replacement corrects sleep disturbances in a child with pineal tumor. Etzioni A, et al. **Neurology** 1996 Jan; 46(1):261–3

RADIATION EFFECTS

Pineal region tumours treated with interstitial brachytherapy with low activity sources (192–iridium). Matsumoto K, et al. **Acta Neurochir (Wien)** 1995;136(1–2):21–8

Regulation of melatonin secretion by light in the isolated pineal organ of the white sucker (Catostomus commersoni). Bolliet V, et al. **J Neuroendocrinol** 1995 Jul;7(7):535–42

Parallel suppression of retinal and pineal melatonin synthesis by retinally mediated light. Morgan IG, et al. **Neuroreport** 1995 Jul 31;6(11):1530–2

RADIOGRAPHY

Trilateral retinoblastoma: CT evaluation. Nunna SV, et al. **Indian J Ophthalmol** 1995 Mar;43(1):27–9

SECRETION

Low and high melatonin excretors among healthy individuals. Bergiannaki JD, et al. **J Pineal Res** 1995 Apr; 18(3):159–64

Distinct modes of melatonin secretion in normal men. Follenius M, et al. **J Pineal Res** 1995 Apr;18(3):135–40

Secretion of methoxyindoles from trout pineal organs in vitro: indication for a paracrine melatonin feedback. Yáñez J, et al. **Neurochem Int** 1995 Aug;27(2):195–200

Diazepam increases melatonin secretion of photosensitive pineal organs of trout in the photopic and mesopic range of illumination. Meissl H, et al. **Neurosci Lett** 1996 Mar 22;207(1):37–40

SURGERY

Surgical management of pineal region tumors. Bruce JN, et al. **Acta Neurochir (Wien)** 1995;134(3–4):130–5

Somnolence associated with melatonin deficiency after pinealectomy [letter; comment] Lehmann ED, et al. **Lancet** 1996 Feb 3;347(8997):323. Comment on: Lancet 1995 Dec 2;346(8988):1491.

Surgical pitfalls in pinealoma surgery. Kanno T. **Minim Invasive Neurosurg** 1995 Dec;38(4):153–7

Surgical removal of pineal region meningioma—three case reports. Matsuda Y, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):594–7

Pineoblastoma in adults. Chang SM, et al. **Neurosurgery** 1995 Sep;37(3):383–90; discussion 390–1

Endoscopic treatment of a symptomatic pineal cyst: technical case report. Turtz AR, et al. **Neurosurgery** 1995 Nov; 37(5):1013–4; discussion 1014–5

Successful removal of large pineal region meningiomas: two case reports. Mallucci CL, et al. **Surg Neurol** 1995 Dec; 44(6):562–6

ULTRASTRUCTURE

Effect of exogenous prolactin on ultrastructure of pinealocyte in female pigs during puberty. Przybylska B, et al. **Arch Vet Pol** 1994;34(1–2):91–8

Rat pineal cell aggregates: ultrastructural and functional characteristics. Shacoori V, et al. **Brain Res Bull** 1995; 38(3):215–20

Three dimensional culture of pineal cell aggregates: a model of cell–cell co–operation. Khan NA, et al. **J Neuroendocrinol** 1995 May;7(5):353–9

PINEAL GLAND see **PINEAL BODY**

PINEALOCYTOMA see **PINEALOMA**

PINEALOMA

COMPLICATIONS

Tinnitus and hearing loss in pineal region tumours. Missori P, et al. **Acta Neurochir (Wien)** 1995;135(3–4):154–8

DIAGNOSIS

Enhancing meningeal blood vessels masquerading as leptomeningeal spread of tumor in obstructive hydrocephalus. LeBlang SD, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1742–4

DRUG THERAPY

Treatment of patients with pineoblastoma with high dose cyclophosphamide. Ashley DM, et al. **Med Pediatr Oncol** 1996 Jun;26(6):387–92

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

[A case of pineoblastoma successfully treated with surgery, combined chemotherapy of cisplatin and etoposide, and radiotherapy] Akiyama Y, et al. **No Shinkei Geka** 1995 Oct; 23(10):921–5 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pineal parenchymal tumors: "oncogeny" recapitulates ontogeny. Min KW. **J Child Neurol** 1995 Nov;10(6):490

[Germinoma of the pineal area. Long–term follow–up after stereotaxic biopsy] Lippitz B. **Nervenarzt** 1996 Apr; 67(4):294–300 (Eng. Abstr.) **(Ger)**

[Pineocytoma associated with a cyst: report of a case] Nakajima M, et al. **No Shinkei Geka** 1995 Oct;23(10):911–5 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Pineoblastoma imaged during bone scintigraphy. McCormack S, et al. **Clin Nucl Med** 1995 Nov; 20(11):1023–4

RADIOTHERAPY

Pineal region tumours treated with interstitial brachytherapy with low activity sources (192–iridium). Matsumoto K, et al. **Acta Neurochir (Wien)** 1995;136(1–2):21–8

Radiation–induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

SURGERY

Surgical management of pineal region tumors. Bruce JN, et al. **Acta Neurochir (Wien)** 1995;134(3–4):130–5

Surgical pitfalls in pinealoma surgery. Kanno T. **Minim Invasive Neurosurg** 1995 Dec;38(4):153–7

Pineoblastoma in adults. Chang SM, et al. **Neurosurgery** 1995 Sep;37(3):383–90; discussion 390–1

THERAPY

[Usefulness of neoadjuvant brachytherapy in the treatment of pineoblastoma: a case report] Tada E, et al. **No Shinkei Geka** 1996 May;24(5):481–5 (Eng. Abstr.) **(Jpn)**

PINEOBLASTOMA see **PINEALOMA**

PINEOCYTOMA see **PINEALOMA**

PINK DISEASE see **ACRODYNIA**

PINNIPEDIA

VIROLOGY

Characterization of phocid herpesvirus–1 and –2 as putative alpha– and gammaherpesviruses of North American and European pinnipeds. Harder TC, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):27–35

PINOCYTOSIS

Mononuclear cell line THP–1 internalizes bactericidal/permeability–increasing protein by a non–receptor–mediated mechanism consistent with pinocytosis. Burnett RJ, et al. **Arch Surg** 1996 Feb; 131(2):200–5; discussion 206

DRUG EFFECTS

Contact sensitizers modulate mechanisms of receptor–mediated endocytosis but not fluid–phase endocytosis in murine epidermal Langerhans cells. Becker D, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):211–7

PHYSIOLOGY

An alpha 2 beta 1 integrin–dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three–dimensional collagen matrix. Davis GE, et al. **Exp Cell Res** 1996 Apr 10;224(1):39–51

Clathrin–independent pinocytosis is induced in cells overexpressing a temperature–sensitive mutant of dynamin. Damke H, et al. **J Cell Biol** 1995 Oct;131(1):69–80

Dictyostelium myosin I double mutants exhibit conditional defects in pinocytosis. Novak KD, et al. **J Cell Biol** 1995 Dec;131(5):1205–21

Organelle formation from pinocytotic elements in neurites of cultured sympathetic ganglia. Birks RI, et al. **J Neurocytol** 1972 Dec;1(4):311–40

Low–efficiency (macro–)pinocytic internalization of non–pathogenic Escherichia coli into HEp–2 cells. Sinai AP, et al. **Res Microbiol** 1995 Oct;146(8):617–31

PINWORMS see **ENTEROBIUS**

PIONS see **MESONS**

PIPECOLIC ACIDS

ADMINISTRATION & DOSAGE

Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leukocyte elastase level. Suzuki S, et al. **Thromb Res** 1995 Oct 1;80(1):93–8

BLOOD

Localization of Refsum disease with increased pipecolic acidaemia to chromosome 10p by homozygosity mapping and carrier testing in a single nuclear family. Nadal N, et al. **Hum Mol Genet** 1995 Oct;4(10):1963–6

ISOLATION & PURIFICATION

GABAA agonists: resolution and pharmacology of (+)– and (–)–isoguvacine oxide. Frølund B, et al. **Chirality** 1995; 7(6):434–8

METABOLISM

[Change in argatroban concentration within the vessel wall after local administration using hydrogel–coated balloon catheter] Imanishi T, et al. **J Cardiol** 1996 May;27(5):267–71 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Additional anticoagulant strategies for managing heparin–induced thrombocytopenia [letter] Nawarskas JJ, et al. **Am J Health Syst Pharm** 1996 Apr 15;53(8):945

Competitive NMDA–receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock–induced seizures in mice. Borowicz KK, et al. **Epilepsia** 1996 Jul; 37(7):618–24

Mechanism–based inhibition of L–pipecolate oxidase by 4,5–dehydro–L–pipecolic acid. Zabriskie TM. **J Med Chem** 1996 Aug 2;39(16):3046–8

Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. Kawai H, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):780–5

Antithrombotic effects of TAK–029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. Kawamura M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):502–10

Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Kawai H, et al. **Jpn J Pharmacol** 1995 Oct;69(2):143–8

Inhibitory effect of argatroban on thrombin–antithrombin III complex after percutaneous transluminal coronary angioplasty [letter] Sakamoto S, et al. **Thromb Haemost** 1995 Aug;74(2):801–2

[Effect of argatroban on flap survival length] Yamamoto T. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):351–9 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)

Thrombin inhibition in the acute phase of ischaemic stroke using argatroban. Kario K, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):423–7

The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. Kawai H, et al. **Thromb Res** 1995 Dec 1;80(5):429–34

PIPECURIUM see **PIPECURONIUM**

PIPECURONIUM

Comparison of neuromuscular, cardiovascular, and histamine–releasing properties of doxacurium and pipecuronium. Denman WT, et al. **J Clin Anesth** 1996 Mar; 8(2):113–8

Effect of plasma anticonvulsant level on pipecuronium–induced neuromuscular blockade: preliminary results. Hans P, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):254–8

ADMINISTRATION & DOSAGE

Left ventricular regional wall motion and haemodynamic changes following bolus administration of pipecuronium or pancuronium to adult patients undergoing coronary artery bypass grafting. Shorten GD, et al.

Can J Anaesth 1995 Aug;42(8):695–700

Pipecuronium bromide: a new steroid muscle relaxant--a clinical study. Jasser MT. **Middle East J Anesthesiol** 1995 Jun;13(2):181–95

[A new instrument for neuromuscular transmission monitoring: the accelerometer Tofguard. Comparative study of isometric force transduction in the assessment of pipecuronium dose–response relationship] Melloni C. **Minerva Anestesiol** 1995 Nov;61(11):471–82 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

[Evaluation of the hemodynamic effects of pipecuronium bromide. Absence of adverse hemodynamic effects] Ardigò M, et al. **Minerva Anestesiol** 1995 Jun;61(6):271–6 (Eng. Abstr.) **(Ita)**

PHARMACOKINETICS

Pharmacokinetics of pipecuronium in infants, children and adults. Tassonyi E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep;20(3):203–8

PIPEMIDIC ACID

TOXICITY

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Linseman DA, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):59–64

PIPERACILLIN

ADVERSE EFFECTS

Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Gerber L, et al. **Clin Infect Dis** 1995 Oct;21(4):1047–8

BLOOD

Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents. Dan M, et al. **Chemotherapy** 1995 Sep–Oct;41(5):323–9

CHEMISTRY

Compatibility of ondansetron hydrochloride and piperacillin sodium–tazobactam sodium during simulated Y-site administration. Chung KC, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1554–6

Stability of piperacillin sodium–tazobactam sodium in peritoneal dialysis solutions. Park TW, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2022–4

PHARMACOKINETICS

Disposition kinetics and bioavailability of piperacillin and cephapirin in mares. el-Komy AA. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):244–8

Pharmacokinetic–pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Nolting A, et al. **Pharm Res** 1996 Jan;13(1):91–6

PHARMACOLOGY

In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals. Verbist L, et al. **Acta Clin Belg** 1995;50(5):274–81

Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Traub WH, et al. **Chemotherapy** 1995 Sep–Oct;41(5):345–52

Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group. Verbist L, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):285–93

A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone. Wootton M, et al. **J Antimicrob Chemother** 1995 May;35(5):569–76

[Prevalence of pertussis in Fukuoka: incidence and MICs of antibiotics for Bordetella pertussis isolate] Horikawa K, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):878–83 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. van den Hazel SJ, et al. **Ann Intern Med** 1996 Sep 15;125(6):442–7

A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Böhme A, et al. **Infection** 1995 Nov–Dec;23(6):349–55

[Piperacillin in prevention and therapy in gynecological surgery] Giannone R, et al. **Minerva Ginecol** 1995 Jul–Aug; 47(7–8):335–9 (Eng. Abstr.) **(Ita)**

[Ruptured mycotic aneurysm of the middle cerebral artery: a case report] Suzuki K, et al. **No Shinkei Geka** 1995 Nov; 23(11):981–4 (Eng. Abstr.) **(Jpn)**

PIPERAMIC ACID see PIPEMIDIC ACID

PIPERAZINES

ADMINISTRATION & DOSAGE

Sildenafil, a novel effective oral therapy for male erectile dysfunction. Boolell M, et al. **Br J Urol** 1996 Aug; 78(2):257–61

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. Kleinbloesem CH, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):675–85

Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Rongen GA, et al. **Hypertension** 1996 Apr;27(4):933–8

ADVERSE EFFECTS

Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Dehlin O, et al. **Curr Med Res Opin** 1995;13(6):317–24

[Acute pseudo-angiocholitic hepatitis caused by oxatomide (letter)] Mohib S, et al. **Gastroenterol Clin Biol** 1996 Feb; 20(1):122–3 **(Fre)**

ANALYSIS

The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry [published erratum appears in Rapid Commun Mass Spectrom 1996;10(1):150] Penman AD, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1418–30

ANTAGONISTS & INHIBITORS

Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Meltzer HY, et al. **Psychiatry Res** 1995 Sep 29;58(2):89–98

BLOOD

Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Ishida M, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):143–6

Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring. Herron WJ, et al. **J Chromatogr A** 1995 Sep 29;712(1):55–60

Automated high-performance liquid chromatographic assay for lesopitron, a novel anxiolytic, in human plasma using on-line solid-phase extraction. García-Encina G, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):103–10

Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. Janiszewski JS, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):133–9

Rapid and sensitive detection of benzodiazepines and zopiclone in serum using high-performance thin-layer chromatography. Otsubo K, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):408–12

Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. Stanke F, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12; 675(1):43–51

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. Staton BA, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9; 668(1):99–106

CHEMICAL SYNTHESIS

Synthesis of [18F]NNC 12-0817 and [18F]NNC 12-0818; two potential radioligands for the dopamine transporter. Müller L, et al. **Appl Radiat Isot** 1995 May;46(5):323–8

Amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines: inhibitors of acylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Dugar S, et al. **Bioorg Med Chem** 1995 Sep;3(9):1231–6

Studies on pyridonecarboxylic acids. IV. Synthesis and antibacterial activity evaluation of S-(–)- and R-(+)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acids. Segawa J, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1238–40

Structure-activity relationships of dermorphin analogues containing chiral piperazin-2-one and piperazine derivatives. Yamashita T, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):856–9

Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Capasso S, et al. **Int J Pept Protein Res** 1995 Jun;45(6):567–73

Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents. Norman MH, et al. **J Med Chem** 1996 Mar 1;39(5):1172–88

1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3. Perrone R, et al. **J Med Chem** 1996 Aug 2;39(16):3195–202

N-aryl-N'-benzylpiperazines as potential antipsychotic agents. Reitz AB, et al. **J Med Chem** 1995 Oct 13; 38(21):4211–22

(S)-(–)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. TenBrink RE, et al. **J Med Chem** 1996 Jun 21;39(13):2435–7

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. Williams TM, et al. **J Med Chem** 1996 Mar 29;39(7):1345–8

Synthesis of N,N'-substituted piperazine and homopiperazine derivatives with polyamine-like actions at N-methyl-D-aspartate receptors. Zhou LM, et al. **J Med Chem** 1995 Dec 8;38(25):4891–6

Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system. Müller L, et al. **Nucl Med Biol** 1995 Aug;22(6):711–7

Structure-activity relationship studies of CNS agents. Part 24: New analogs of N-tert.-butyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-phenylpropanamide (WAY-100135). Boksa J, et al. **Pharmazie** 1996 Feb;51(2):72–6

Synthesis of new 1-(3-(4-phenylpiperazinyl-1)-imidazolidine derivatives. Kulinski T, et al. **Pharmazie** 1995 Dec; 50(12):821–2

[Synthesis and positive inotropic activity of 3,4-dimethoxybenzoyl-piperazine derivatives] Xu M, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):283–6 (Eng. Abstr.) **(Chi)**

[Preparation of aryloxyaminopropanol derivatives with potential effects on the cardiovascular system] Hlaváčová H, et al. **Ceska Slov Farm** 1995 Oct;44(5):261–4 (Eng. Abstr.) **(Cze)**

CHEMISTRY

Effects of H/D substitution on thermal vibrations in piperazinium hexanoate-h11, d11. Luo JQ, et al. **Acta Crystallogr B** 1996 Apr 1;52 (Pt 2):357–68

Structure-activity relationship studies of CNS agents, Part 23: N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-tetrahydroisoquinoline mimic 1-phenylpiperazine at 5-HT1A receptors. Mokrosz JL, et al. **Arch Pharm (Weinheim)** 1995 Jul–Aug;328(7–8):604–8

Inhibition of topoisomerase II by ICRF-193, the meso isomer of 2,3-bis(2,6-dioxopiperazin-4-yl)butane. Critical dependence on 2,3-butanediyl linker absolute configuration. Snapka RM, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):543–9

Solution and solid-state structure of the diketopiperazine of tyrosyl-tetrahydroisoquinoline-3-carboxylic acid. Ciajolo MR, et al. **Int J Pept Protein Res** 1995 Aug;46(2):134–8

Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures. Cui CB, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):534–40

Piperazinylalkyl heterocycles as potential antipsychotic agents. Scott MK, et al. **J Med Chem** 1995 Oct 13; 38(21):4198–210

A series of N4-imidoethyl derivatives of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine as 5-HT1A receptor ligands: synthesis and structure-affinity relationships. van Steen BJ, et al. **J Med Chem** 1995 Oct 13;38(21):4303–8

Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. Oren DA, et al. **J Mol Biol** 1996 May 31;259(1):120–34

Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. Knapp RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1284–91

Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pop E, et al. **Pharm Res** 1996 Mar;13(3):469–75

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Cutfield SM, et al. **Structure** 1995 Nov 15;3(11):1261–71

DIAGNOSTIC USE

Responses to mCPP stimulation in depressed patients [letter; comment] Pitchot W, et al. **Am J Psychiatry** 1995 Dec; 152(12):1834; discussion 1834–5. Comment on: Am J Psychiatry 1994 Nov;151(11):1626–30.

Responses to mCPP stimulation in depressed patients [letter; comment] Thakore JH. **Am J Psychiatry** 1995 Dec; 152(12):1833–4; discussion 1834–5. Comment on: Am J Psychiatry 1994 Nov;151(11):1626–30.

m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Goodman WK, et al. **Biol Psychiatry** 1995 Aug 1;38(3):138–49

Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder. Hollander E, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):485–90

The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pitchot W, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:91–2

Induction of depersonalization by the serotonin agonist

meta-chlorophenylpiperazine. Simeon D, et al. **Psychiatry Res** 1995 Sep 29;58(2):161-4

IMMUNOLOGY

[Antigenicity studies of prulifloxacin (NM441)] Tateda C, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:231-9 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures. Cui CB, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):534-40

Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties. Cui CB, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):527-33

METABOLISM

Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Campa MJ, et al. **Cancer Res** 1996 Apr 1;56(7):1695-701

Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116). Morita S, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2246-52

Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. de Groot MJ, et al. **Drug Metab Dispos** 1995 Jun; 23(6):667-9

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Barbhaiya RH, et al. **Eur J Clin Pharmacol** 1995;49(3):221-8

Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Barbhaiya RH, et al. **Eur J Clin Pharmacol** 1995;49(3):229-35

Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Ishida M, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):143-6

New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives. Berardi F, et al. **J Med Chem** 1996 Jan 5;39(1):176-82

Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. Gaillard P, et al. **J Med Chem** 1996 Jan 5;39(1):126-34

2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series. Meltzer PC, et al. **J Med Chem** 1996 Jan 19;39(2):371-9

1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3. Perrone R, et al. **J Med Chem** 1996 Aug 2;39(16):3195-202

Peroxidation of synaptosomes alters the dopamine uptake complex but spares the exocytotic release of dopamine. Ramassamy C, et al. **Neurodegeneration** 1995 Jun; 4(2):155-60

Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system. Müller L, et al. **Nucl Med Biol** 1995 Aug;22(6):711-7

PHARMACOKINETICS

Development of a fluorescence polarization immunoassay for the routine detection of N-desmethylzopiclone in urine samples. Mannaert E, et al. **Analyst** 1996 Jun;121(6):857-61

The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers. Mercer AJ, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:324-6

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Nakashima M, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2635-40

Clinical pharmacokinetics of zopiclone. Fernandez C, et al. **Clin Pharmacokinet** 1995 Dec;29(6):431-41 (38 ref.)

Pharmacokinetic study of a new quinolone, DW-116. Lee DK. **Drugs** 1995;49 Suppl 2:323-5

Clinical experience with OPC-17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC-17116 in Gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:395-8

NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Mikamo H, et al. **Drugs** 1995;49 Suppl 2:326-30

Penetration of NM441, a new quinolone, into human bile and gallbladder tissue. Tanimura H, et al. **Drugs** 1995;49 Suppl 2:337-40

Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116. Tanimura H, et al. **Drugs** 1995;49 Suppl 2:341-3

The bioactive peptide cyclo(His-Pro) may be absorbed following ingestion of nutritional supplements that contain it. Mizuma H, et al. **J Am Coll Nutr** 1996 Apr;15(2):175-9

Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Kaul S, et al. **J Clin Pharmacol** 1995 Aug;35(8):830-9

The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry [published erratum appears in Rapid Commun Mass Spectrom 1996;10(1):150] Penman AD, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1418-30

PHARMACOLOGY

ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Tanimoto C, et al. **Acta Med Okayama** 1995 Dec;49(6):281-6

Effect of dotarizine on CO2-dependent cerebrovascular reactivity. Chomicki J, et al. **Acta Neurochir (Wien)** 1995; 136(3-4):186-8

Effect of oxatomide on otitis media with effusion--an experimental study. Tanaka T, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):532-8

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279-89 (42 ref.)

Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Krystal JH, et al. **Am J Psychiatry** 1996 Jan; 153(1):83-92

Ketanserin and urapidil during myocardial revascularisation [letter; comment] Innes PA. **Anaesthesia** 1995 Dec; 50(12):1100. Comment on: Anaesthesia 1995 Apr;50(4):312-6.

Alkaloid delta agonist BW373U86 increases hypoxic tolerance. Bofetiado DM, et al. **Anesth Analg** 1996 Jun; 82(6):1237-41

The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers. Mercer AJ, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:324-6

Evaluation of the novel neuroprotective agent BW619C89 in the middle cerebral artery occlusion model of focal ischemia in the spontaneously hypertensive rat and normotensive Fischer 344 rat. Swan JH, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:39-46; discussion 59-61

Antimicrobial activity of CS-940, a new trifluorinated quinolone. Biedenbach DJ, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2325-30

Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram. Neckelmann D, et al. **Behav Brain Res** 1996 Feb;75(1-2):159-68

The Ca++/calmodulin-dependent protein kinase II inhibitors KN62 and KN93, and their inactive analogues KN04 and KN92, inhibit nicotinic activation of tyrosine hydroxylase in bovine chromaffin cells. Marley PD, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):15-8

Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells. Obata NH, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):566-71

Separation of H7-resistant protein kinase C isoforms from gonadotroph-derived alpha T3-1 cells. Simpson J, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):720-5

Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Ahn CH, et al. **Biochem Pharmacol** 1996 Aug 9; 52(3):393-9

Inhibition of oxidative insult in cultured cells by a novel 6-chromanol-containing antioxidant. Decker DE, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1063-70

Differential effect of 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) on alpha B-crystallin and hsp70 gene expression in murine cell lines. Lee YJ, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1149-55

Inhibition of topoisomerase II by ICRF-193, the meso isomer of 2,3-bis(2,6-dioxopiperazin-4-yl)butane. Critical dependence on 2,3-butanediyl linker absolute configuration. Snapka RM, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):543-9

Inhibition of voltage-gated Ca2+ channel activity in small cell lung carcinoma by the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz ine) . Williams CL, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1979-85

Expression of Ca2+/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma. Williams CL, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):707-15

The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Wyatt KM, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1599-606

KN-62, a calcium/calmodulin-dependent protein kinase II inhibitor, inhibits high potassium-stimulated prolactin secretion and intracellular calcium increases in anterior pituitary cells. Cui ZJ, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):343-7

Parthenogenic activation of pig oocytes by protein kinase inhibition. Mayes MA, et al. **Biol Reprod** 1995 Aug; 53(2):270-5

Amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines: inhibitors of acylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Dugar S, et al. **Bioorg Med Chem** 1995 Sep;3(9):1231-6

Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. van der Stroom JG, et al. **Br J Anaesth** 1996 May; 76(5):645-51

Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Allen TJ, et al. **Br J Pharmacol** 1996 May;118(2):249-54

Reduction by lifarizine of the neuronal damage induced by cerebral ischaemia in rodents. Alps BJ, et al. **Br J Pharmacol** 1995 Aug;115(8):1439-46

Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones. Budd DC, et al. **Br J Pharmacol** 1996 May;118(1):162-6

Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist. De Vries P, et al. **Br J Pharmacol** 1996 May;118(1):85-92

NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Dijk SN, et al. **Br J Pharmacol** 1995 Aug;115(7):1169-74

Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion. McBean DE, et al. **Br J Pharmacol** 1995 Dec;116(8):3093-8

[3H]-lifarizine, a high affinity probe for inactivated sodium channels. MacKinnon AC, et al. **Br J Pharmacol** 1995 Jul; 115(6):1103-9

Effects of 8-OHDPAT and 5-HT1A antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing. Mundey MK, et al. **Br J Pharmacol** 1996 Feb;117(4):750-6

Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Shimazawa M, et al. **Br J Pharmacol** 1995 Aug;115(8):1359-68

Meta-chlorophenylpiperazine attenuates formalin-induced nociceptive responses through 5-HT1/2 receptors in both normal and diabetic mice. Takeshita N, et al. **Br J Pharmacol** 1995 Dec;116(8):3133-8

The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain. Shapiro LA, et al. **Brain Res** 1995 Apr 24;677(2):250-6

GBR-12909-induced self-injurious behavior: role of dopamine. Sivam SP. **Brain Res** 1995 Sep 4;690(2):259-63

The effects of cocaine on cerebral metabolic function in periweanling rats: the roles of serotonergic and dopaminergic uptake blockade. Frick GS, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):158-70

Dopaminergic regulation of striatonigral tachykinin and dynorphin gene expression: a study with the dopamine uptake inhibitor GBR-12909. Sivam SP. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):197-210

Studies on pyridonecarboxylic acids. IV. Synthesis and antibacterial activity evaluation of S-(-)- and R-(+)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acids. Segawa J, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1238-40

Mechanism of action of OPC-8490 in human ventricular myocardium. Focaccio A, et al. **Circulation** 1996 Feb 15; 93(4):817-25

Effects of a novel 5-HT1A receptor agonist, E4424, on gastric adherent mucus levels following restraint stress in rats. Glavin GB, et al. **Dig Dis Sci** 1995 Nov;40(11):2317-20

NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Mikamo H, et al. **Drugs** 1995;49 Suppl 2:326-30

The effects of KN62, a Ca2+/calmodulin-dependent protein kinase II inhibitor, on adrenocortical cell aldosterone production. Clyne CD, et al. **Endocr Res** 1995 Feb-May; 21(1-2):259-65

Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV, et al. **Eur J Clin Pharmacol** 1995; 49(3):183-91

Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. Aulakh CS, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):65-70

BW373U86, a delta-opioid receptor agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys. Butelman ER, et al. **Eur J Pharmacol** 1995 Apr 24; 277(2-3):285-7

(S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by

intrahippocampal scopolamine. Carli M, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):133–9

A pharmacological profile of the selective silent 5–HT1A receptor antagonist, WAY–100635. Forster EA, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):81–8

Discriminative stimulus properties of flesinoxan: effects of enantiomers, (S)–UH301 and WAY–100635. Gommans J, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):135–40

The anxiolytic effects of flesinoxan, a 5–HT1A receptor agonist, are not related to its neuroendocrine effects. Groenink L, et al. **Eur J Pharmacol** 1995 Jul 4; 280(2):185–93

Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE–10064). Herzer T, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):205–8

Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Matsumoto RR, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):301–10

Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Nakachi N, et al. **Eur J Pharmacol** 1995 Aug 4; 281(2):195–203

Functional effects of the 5–HT1D receptor antagonist GR 127,935 at human 5–HT1D alpha, 5–HT1D beta, 5–HT1A and opossum 5–HT1B receptors. Pauwels PJ, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):95–103

Selective antagonism of human 5–HT1D and 5–HT1B receptor–mediated responses in stably transfected C6–glial cells by ketanserin and GR 127,935. Pauwels PJ, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):141–5

Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro. Pettersson E. **Eur J Pharmacol** 1995 Aug 25;282(1–3):131–5

First delineation of 5–HT1A receptors in human brain with PET and [11C]WAY–100635. Pike VW, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):R1–3

Differences in the effects of ketanserin and GR127935 on 5–HT–receptor mediated responses in rabbit saphenous vein and guinea–pig jugular vein. Razzaque Z, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):199–206

Effects of combined block of alpha 1–adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats. Riekkinen M, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):9–16

GR127935 is a potent antagonist of the 5–HT1–like receptor mediating contraction in the canine coronary artery. Terrón JA. **Eur J Pharmacol** 1996 Apr 4;300(1–2):109–12

Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H–7 and H–8. Tokuyama S, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):101–7

The activity of 5–HT1D receptor ligands at cloned human 5–HT1D alpha and 5–HT1D beta receptors. Walsh DM, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):79–84

21–aminosteroid and 2–(aminomethyl)chromans inhibition of arachidonic acid–induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Shi F, et al. **Free Radic Biol Med** 1995 Sep;19(3):349–57

H–7, a protein kinase C inhibitor, inhibits spontaneous tone and spasmogenic responses in normal and sensitized guinea pig trachea. de Diego A, et al. **Gen Pharmacol** 1995 Dec; 26(8):1747–55

Effects of piperazine derivatives on the activity of frog skeletal muscle fibers. Radicheva N, et al. **Gen Pharmacol** 1995 Oct;26(6):1431–9

Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Tanaka H, et al. **Gen Pharmacol** 1995 Dec;26(8):1765–72

Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations. Honda A, et al. **Hepatology** 1996 Aug;24(2):435–9

Blocking late cholesterol biosynthesis inhibits the growth of transplanted Morris hepatomas (7288CTC) in rats. Xu G, et al. **Hepatology** 1996 Aug;24(2):440–5

Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. Patella V, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):23–9

Influence of urapidil on cerebrospinal fluid pressure in humans with uncompromised intracranial compliance. Hörmann C, et al. **Intensive Care Med** 1995 Oct; 21(10):853–5

Antibacterial properties of AM–1155, a new 8–methoxy quinolone. Hosaka M, et al. **J Antimicrob Chemother** 1995 Aug;36(2):293–301

Tentative interpretive criteria and quality control parameters for in–vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)). Sewell DL, et al. **J Antimicrob Chemother** 1996 Jan;37(1):139–43

Use–dependent effects of the class III antiarrhythmic agent NE–10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L–type calcium currents. Fermini B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):259–71

Inhibition of regulated catecholamine secretion from PC12 cells by the Ca2+/calmodulin kinase II inhibitor KN–62. Schweitzer ES, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2619–28

Inhibition of agonist–mediated calcium entry by calmodulin antagonists and by the Ca2+/calmodulin kinase II inhibitor KN–62. Studies with thyroid FRTL–5 cells. Törnquist K, et al. **J Endocrinol** 1996 Jan;148(1):131–8

Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhibitor. Faltynek CR, et al. **J Enzym Inhib** 1995;9(2):111–22

New antihistamines: substituted piperazine and piperidine derivatives as novel H1–antagonists. Abou–Gharbia M, et al. **J Med Chem** 1995 Sep 29;38(20):4026–32

Enhanced D1 affinity in a series of piperazine ring substituted 1–piperazino–3–arylindans with potential atypical antipsychotic activity. Bøgesø KP, et al. **J Med Chem** 1995 Oct 27;38(22):4380–92

3–Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. Howard HR, et al. **J Med Chem** 1996 Jan 5;39(1):143–8

2–Carbomethoxy–3–(diarylmethoxy)–1 alpha H, 5 alpha H–tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series. Meltzer PC, et al. **J Med Chem** 1996 Jan 19;39(2):371–9

Characterization of potent and selective antagonists at postsynaptic 5–HT1A receptors in a series of N4–substituted arylpiperazines. Peglion JL, et al. **J Med Chem** 1995 Sep 29;38(20):4044–55

2–substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. Williams TM, et al. **J Med Chem** 1996 Mar 29;39(7):1345–8

Synthesis of N,N'–substituted piperazine and homopiperazine derivatives with polyamine–like actions at N–methyl–D–aspartate receptors. Zhou LM, et al. **J Med Chem** 1995 Dec 8;38(25):4891–6

Synthesis and activity of piperazine–containing antirhinoviral agents and crystal structure of SDZ 880–061 bound to human rhinovirus 14. Oren DA, et al. **J Mol Biol** 1996 May 31;259(1):120–34

Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. Clarke B, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):341–50

Flesinoxan dose–dependently reduces extracellular 5–hydroxytryptamine (5–HT) in rat median raphe and dorsal hippocampus through activation of 5–HT1A receptors. Bosker FJ, et al. **J Neurochem** 1996 Jun; 66(6):2546–55

Effects of protein kinase inhibitors on morphology and function of cultured bovine adrenal chromaffin cells: KN–62 inhibits secretory function by blocking stimulated Ca2+ entry. Maurer JA, et al. **J Neurochem** 1996 Jan; 66(1):105–13

Ca(2+)/calmodulin–dependent protein kinase II inhibitor KN–62 inhibits adrenal medullary chromaffin cell functions independent of its action on the kinase Tsutsui M, et al. **J Neurochem** 1996 Jun;66(6):2517–22

A use–dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat. Tsuchida E, et al. **J Neurosurg** 1996 Jul;85(1):104–11

Continuous intravenous infusion of iodine–123–IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ–37796. Seibyl JP, et al. **J Nucl Med** 1996 Jan;37(1):11–5

Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1–[2–(diphenylmethoxy)ethyl]–4–(3–phenyl–propyl)–piperazine. Acri JB, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):198–206

Effects of naloxone and D–Phe–Cys–Tyr–D–Trp–Arg–Thr–Pen–Thr–NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):484–90

Locomotor sensitization and decrease in [3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine. Boulay D, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):330–7

Potent and selective inactivation of human liver microsomal cytochrome P–450 isoforms by L–754,394, an investigational human immune deficiency virus protease inhibitor. Chiba M, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1527–34

Electrophysiological effects of N–(2–(4–(2–methoxyphenyl)–1–piperazinyl)ethyl)–N–(2–pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro. Corradetti R, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):679–88

Dual actions of the novel class III antiarrhythmic drug NE–10064 on delayed potassium channel currents in guinea pig ventricular and sinoatrial node cells. Davies MP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1149–54

WAY–100635, a potent and selective 5–hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)–WAY–100135. Fornal CA, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):752–62

Effects of the novel antipsychotic agent 7–(4–[4–(2,3–dichlorophenyl)–1–piperazinyl]butyloxy)–3,4–dihydro –2(1H)–quinolinone (OPC–14597) on prolactin release from the rat anterior pituitary gland. Inoue T, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):137–43

Structure–activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. Knapp RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1284–91

Alterations in locomotor activity after microinjections of GBR–12909, selective dopamine antagonists or neurotensin into the medial prefrontal cortex. Radcliffe RA, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1467–76

Ziprasidone (CP–88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):101–13

4–(2'–Methoxyphenyl)–1–[2'–[N–(2"–pyridinyl)–p–iodobenzamido]ethyl] piperazine and 4–(2'–methoxyphenyl)–1–[2'–[N–(2"–pyridinyl)–p–fluorobenzamido]ethyl]piperazine, two new antagonists at pre– and postsynaptic serotonin–1A receptors. Thielen RJ, et al. **J Pharmacol Exp Ther** 1996 May;277(2):661–70

Inhibition of topoisomerase II by ICRF–193 prevents efficient replication of herpes simplex virus type 1. Hammarsten O, et al. **J Virol** 1996 Jul;70(7):4523–9

Involvement of raphe–hippocampal serotonergic and septo–hippocampal cholinergic mechanisms in the penile erection induced by FR121196, a putative cognitive enhancer. Maeda N, et al. **Jpn J Pharmacol** 1995 May; 68(1):85–94

Protective action of isoquinolinesulfonamides in in vitro models of neuronal apoptosis. Cagnoli CM, et al. **Life Sci** 1996;58(19):PL295–301

The interaction of clozapine with the meta–chlorophenylpiperazine (mCPP) discriminative stimulus. Fiorella D, et al. **Life Sci** 1996;58(24):PL353–8

Prenatal stress prevents the desensitization of the corticosterone response to TFMPP by desmethylimipramine, but not by phenelzine, in adult male offspring. Poland RE, et al. **Life Sci** 1995;57(23):2163–70

Induction of early growth response–1 gene by interleukin–1 beta and tumor necrosis factor–alpha in normal human bone marrow stromal an osteoblastic cells: regulation by a protein kinase C inhibitor. Chaudhary LR, et al. **Mol Cell Biochem** 1996 Mar 9;156(1):69–77

Selective inhibition of topoisomerase II by ICRF–193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Beere HM, et al. **Mol Pharmacol** 1996 May; 49(5):842–51

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Druker BJ, et al. **Nat Med** 1996 May;2(5):561–6

Treatment with NMDA receptor antagonists does not affect developmental changes in NMDA receptor properties in vivo. Van Lookeren Campagne M, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):355–66

Attenuation of CCK–induced aversion in rats on the elevated x–maze by the selective 5–HT1A receptor antagonists (+) WAY100135 and WAY100635. Bickerdike MJ, et al. **Neuropharmacology** 1995 Jul;34(7):805–11

Characterization of 5–hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Hadrava V, et al. **Neuropharmacology** 1995 Oct; 34(10):1311–26

Studies on the role of 5–HT1A autoreceptors and alpha 1–adrenoceptors in the inhibition of 5–HT release—I. BMY7378 and prazosin. Hjorth S, et al. **Neuropharmacology** 1995 Jun;34(6):615–20

The effects of GR127935, a putative 5–HT1D receptor antagonist, on brain 5–HT metabolism, extracellular 5–HT concentration and behaviour in the guinea pig. Hutson PH, et al. **Neuropharmacology** 1995 Apr;34(4):383–92

Behavioural and neurochemical effects of OPC–14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Semba J, et al. **Neuropharmacology** 1995 Jul; 34(7):785–91

Ca/calmodulin–dependent kinase II inhibitor KN62 attenuates glutamate release by inhibiting voltage–dependent Ca(2+)–channels. Sihra TS, et al. **Neuropharmacology** 1995 Jul;34(7):731–41

Effects of the 5–HT1D receptor antagonist GR127935 on extracellular levels of 5–HT in the guinea–pig frontal cortex as measured by microdialysis. Skingle M, et al. **Neuropharmacology** 1995 Apr;34(4):377–82

Lack of cross–tolerance for hypophagia induced by DOI versus m–CPP suggests separate mediation by 5–HT2A and 5–HT2C receptors, respectively. Aulakh CS, et al. **Neuropsychopharmacology** 1995 Aug;13(1):1–8

Serotonin and thermoregulation. Physiologic and pharmacologic aspects of control revealed by intravenous m–CPP in normal human subjects. Schwartz PJ, et al. **Neuropsychopharmacology** 1995 Oct;13(2):105–15

Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Seletti B, et al. **Neuropsychopharmacology** 1995 Oct;13(2):93–104

Locomotor sensitization to [D–Trp(11)]neurotensin after repeated injections of the dopamine uptake inhibitor GBR12783 in rats. Boulay D, et al. **Neurosci Lett** 1996 Apr 12;208(1):5–8

Lazaroids protect isolated rat pancreatic acinar cells against damage induced by free radicals. Niederau C, et al. **Pancreas** 1995 Aug;11(2):107–21

Effects of the 5–HT1A antagonist (+)–WAY–100135 on

murine social and agonistic behavior. Bell R, et al. **Pharmacol Biochem Behav** 1996 May;54(1):159–67

Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine. Bourson A, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):107–14

Complementary memory storage sites in mice: their development as affected by the competitive NMDA receptor antagonist, CPP. Church AC, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):237–40

Cocaine cross-sensitization to dopamine uptake inhibitors: unique effects of GBR12909. Elmer GI, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):911–8

Partial agonistic effects of OPC–14597, a potential antipsychotic agent, on yawning behavior in rats. Fujikawa M, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):903–9

Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia test in mice. Groenink L, et al. **Pharmacol Biochem Behav** 1996 May;54(1):249–54

A dose–response analysis of the behavioral effects of (+)MK–801 in guinea pig: comparison with CPP. Jerram AH, et al. **Pharmacol Biochem Behav** 1996 Apr; 53(4):799–807

Alcohol intake in high alcohol drinking (HAD) rats is suppressed by FG5865, a novel 5–HT1A agonist/5–HT2 antagonist. Long TA, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):33–40

Synthesis of dopamine and 5–HT in anatomical regions of the rat's brain is unaffected by sustained infusion of amperozide. Adell A, et al. **Pharmacol Toxicol** 1995 Nov; 77(5):341–5

Structure–activity relationship studies of CNS agents. Part 24: New analogs of N–tert.–butyl–3–[4–(2–methoxyphenyl)–1–piperazinyl]–2–phenylpropanamide (WAY–100135). Boksa J, et al. **Pharmazie** 1996 Feb;51(2):72–6

Traumatic brain damage prevented by the non–N–methyl–D–aspartate antagonist 2,3–dihydroxy–6–nitro–7–sulfamoylbenzo[f] quinoxaline. Bernert H, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5235–40

A selective Ascaris acetylcholine receptor antagonist: 1,1–dimethyl–4–(2–quinolyl)–piperazinium iodide. Navarrete A, et al. **Proc West Pharmacol Soc** 1995;38:35–6

5–HT2C receptor–mediated phosphoinositide turnover and the stimulus effects of m–chlorophenylpiperazine. Fiorella D, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):237–43

Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. Little JT, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):280–8

Enhanced oral activity responses to intrastriatal SKF 38393 and m–CPP are attenuated by intrastriatal mianserin in neonatal 6–OHDA–lesioned rats. Plech A, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):466–73

Selectivity of the neuroprotective agent lifarizine [letter; comment] Sheridan RD. **Trends Pharmacol Sci** 1995 Sep; 16(9):292. Comment on: Trends Pharmacol Sci 1995 Apr;16(4):139–42.

[4–Arylpiperazine derivatives: a seedbed of drugs for various therapeutic indications] Coudert P, et al. **J Pharm Belg** 1995 Sep–Oct;50(5):445–54 (67 ref.) (Eng. Abstr.) **(Fre)**

[In vitro activity of a new quinolone, NM 394, against Chlamydia trachomatis] Poutiers F, et al. **Pathol Biol (Paris)** 1996 May;44(5):351–4 (Eng. Abstr.) **(Fre)**

[Study of zopiclone with quantitative EEG analysis and topography] Yamadera H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug; 15(4):355–61 (Eng. Abstr.) **(Jpn)**

[Effects of 5–HT1A receptor agonist and 5–HT1B receptor agonist on single and paired rats' behavior] Kumasegawa T, et al. **No To Shinkei** 1995 Sep;47(9):875–9 (Eng. Abstr.) **(Jpn)**

[The effect of urapidil on blood pressure, renal hemodynamics, lipid and glucose metabolism] Sanjuliani AF, et al. **Arq Bras Cardiol** 1995 Jul;65(1):59–63 (Eng. Abstr.) **(Por)**

[The effect of the NMDA–receptor antagonist (+/–)–CPP on the conditioned–reflex activation of an operant reaction in the brain electrical self–stimulation test in rats] Bespalov AIu, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb;46(1):117–21 (Eng. Abstr.) **(Rus)**

POISONING

Fatal zipeprol and dextromethorphan poisonings in Korea. Yoo Y, et al. **J Anal Toxicol** 1996 May–Jun;20(3):155–8

THERAPEUTIC USE

Effect of oxatomide on otitis media with effusion—an experimental study. Tanaka T, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):532–8

Oxatomide reduces inflammatory events induced by allergen–specific conjunctival challenge. Ciprandi G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):446–52

Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group. Squire IB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:317–8

Protective effect of the novel cerebrovascular–selective calcium antagonist (+/–)–(E)–1–(3–fluoro–6, 11–dihydrodibenz[b,e]–oxepine–11–yl)–4–(3–phenyl–2–propenyl)–piperazine dimaleate on ischemic brain damage after permanent middle cerebral artery occlusion in rats. Minato H, et al. **Arzneimittelforschung** 1996 Jun; 46(6):567–71

A biochemical study on combined treatment of experimental silicosis with tetradrine–PVNO and tetradrine–QOHP in rats. Yu L, et al. **Biomed Environ Sci** 1995 Sep;8(3):265–8

Adaptation of antihypertensive drug treatment with increasing age: from the young to the elderly. Focus on urapidil. **Blood Press** 1995;Suppl 3:1–73

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press** 1995;Suppl 3:47–57 (43 ref.)

Hemorheology of arterial hypertension: influence of urapidil. Delamaire M, et al. **Blood Press** 1995;Suppl 3:58–61

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press** 1995;Suppl 3:62–7 (49 ref.)

Addition of urapidil or metoprolol to the treatment of hypertensive non–responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Zanchetti A. **Blood Press** 1995;Suppl 3:38–46

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press Suppl** 1995;3:47–57

Hemorheology of arterial hypertension: influence of urapidil. Delamaire M, et al. **Blood Press Suppl** 1995;3:58–61

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press Suppl** 1995;3:62–7

Addition of urapidil or metoprolol to the treatment of hypertensive non–responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Zanchetti A. **Blood Press Suppl** 1995;3:38–46

Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment. Cooper PJ, et al. **Br J Ophthalmol** 1996 Apr;80(4):337–42

Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Brown CM, et al. **Br J Pharmacol** 1995 Aug; 115(8):1425–32

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. McCormack JG, et al. **Circulation** 1996 Jan 1;93(1):135–42

Clinical experience with OPC–17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC–17116 in Gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:395–8

Study of the effects of AM–1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa. Sato A, et al. **Drugs** 1995;49 Suppl 2:253–5

MDL 74,180 reduces cerebral infarction and free radical concentrations in rats subjected to ischaemia and reperfusion. Cowley DJ, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):227–33

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

Polymerase chain reaction–based assessment after macrofilaricidal therapy in Onchocerca volvulus infection. Nutman TB, et al. **J Infect Dis** 1996 Mar;173(3):773–6

Lazaroid therapy (methylaminochroman: U83836E) reduces vein graft intimal hyperplasia. Davies MG, et al. **J Surg Res** 1996 Jun;63(1):128–36

U83836E reduces secondary brain injury in a rabbit model of cryogenic trauma. Wilson JT, et al. **J Trauma** 1995 Sep; 39(3):473–7; discussion 477–9

The effect of urapidil on neurogenic bladder: a placebo controlled double–blind study. Yasuda K, et al. **J Urol** 1996 Sep;156(3):1125–30

A review of the effects of dopaminergic agents on humans, animals, and drug–seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):1–19 (130 ref.)

Effects of MCI–727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models. Tachibana I, et al. **Pancreas** 1996 Mar;12(2):165–72

Content of some microelements in chickens with ascaridiasis under combined drug treatment. Damyanova A, et al. **Parasitol Res** 1995;81(7):549–52

Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Brooks RR, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):84–93

[Course of ischemic risk in treated atheromatous hypertensive patients. The PRIHAM study] Godeau P, et al. **Ann Med Interne (Paris)** 1995;146(8):530–5 (Eng. Abstr.) **(Fre)**

[New non–benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197–207 (45 ref.) **(Ita)**

[Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies] Blaszyk K, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):512–7 (Eng. Abstr.) **(Pol)**

[Anesthesiological care in removal of jugular glomus tumor. First experience with the use of urapidil] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):50–3 **(Rus)**

TOXICITY

A randomized, double–blind, placebo–controlled ascending dose tolerance study of 619C89 in acute stroke. Muir KW, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:328–9

Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group. Squire IB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:317–8

Lipidosis of the dorsal root ganglia in rats treated with an almitrine metabolite. Yamanaka Y, et al. **Arch Toxicol** 1995; 69(6):391–6

NMDA receptors are involved at the ventrolateral nucleus tractus solitarii for termination of inspiration. Berger I, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):195–208

Some pharmacological properties and cumulative, subchronic and chronic toxicity of 9–methyl–2–[3–(4–phenyl–1–piperazinylpropyl)] –1,2,3,4–tetrahydro–beta–carbolin–1–one (B–193). Sieklucka–Dziuba M, et al. **Pol J Pharmacol** 1995 Jul–Aug; 47(4):305–11

Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. Kato I, et al. **Reprod Toxicol** 1996 May–Jun;10(3):209–14

[Single and 4–week oral toxicity studies of prulifloxacin (NM441) in aged dogs] Ihara T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:149–69 (Eng. Abstr.) **(Jpn)**

[A 13–week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5–week recovery test] Ishibashi S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:89–111 (Eng. Abstr.) **(Jpn)**

[A 4–week intravenous toxicity study of the active metabolite (NM394) of prulifloxacin (NM441) in rats followed by a 4–week recovery test] Ishida S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:131–48 (Eng. Abstr.) **(Jpn)**

[Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)] Iwakura K, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:241–57 (Eng. Abstr.) **(Jpn)**

[A photoallergenicity study of prulifloxacin (NM441) in guinea pigs] Kamata K, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:259–65 (Eng. Abstr.) **(Jpn)**

[Renal toxicity of prulifloxacin (NM441) in rats] Kawaminami A, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:267–76 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(1)—A fertility study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun; 21 Suppl 1:171–85 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2)—A teratogenicity study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:187–206 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3)—A teratogenicity study in rabbits by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:207–17 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(4)—A perinatal and postnatal study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:219–30 (Eng. Abstr.) **(Jpn)**

[A 4–week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4–week recovery test] Nishimura N, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:45–70 (Eng. Abstr.) **(Jpn)**

[A 4–week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4–week recovery test] Oda S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:71–88 (Eng. Abstr.) **(Jpn)**

[Single–dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats] Shimazu H, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:33–44 (Eng. Abstr.) **(Jpn)**

[A 13–week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5–week recovery test] Yoshida M, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:113–29 (Eng. Abstr.) **(Jpn)**

URINE

Development of a fluorescence polarization immunoassay for the routine detection of N–desmethylzopiclone in urine samples. Mannaert E, et al. **Analyst** 1996 Jun;121(6):857–61

Enantioselective determination of zopiclone and its metabolites in urine by capillary electrophoresis. Hempel G, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12; 675(1):139–46

PIPERIDINES

Remifentanil: a novel, short–acting, mu–opioid. Bürkle H, et al. **Anesth Analg** 1996 Sep;83(3):646–51 (52 ref.)

Remifentanil—an opioid for the 21st century [editorial] Thompson JP, et al. **Br J Anaesth** 1996 Mar;76(3):341–3

Cisapride [see comments] Washabau RJ, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1285–8 (33 ref.) . Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184.

Remifentanil: a new opioid. Glass PS. **J Clin Anesth** 1995 Nov;7(7):558–63 (24 ref.)
Laboratory and field evaluation of deet, CIC–4, and AI3–37220 against Anopheles dirus (Diptera: Culicidae) in Thailand. Frances SP, et al. **J Med Entomol** 1996 Jul; 33(4):511–5
Field evaluation of deet and a piperidine repellent (AI3–37220) against Amblyomma americanum (Acari: Ixodidae). Solberg VB, et al. **J Med Entomol** 1995 Nov; 32(6):870–5

ADMINISTRATION & DOSAGE

Twenty–four–hour intragastric acidity following early evening or bedtime administration of roxatidine in duodenal ulcer patients. Lazzaroni M, et al.
Aliment Pharmacol Ther 1996 Apr;10(2):187–91
Investigation on the efficacy and tolerance of azelastine (HCL) nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis. Conde Hernández J, et al.
Allergol Immunopathol (Madr) 1995 Mar–Apr;23(2):51–7
A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Hogue CW Jr, et al. **Anesth Analg** 1996 Aug;83(2):279–85
Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat. Buerkle H, et al. **Anesthesiology** 1996 Apr;84(4):926–35
Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Conde Hernández DJ, et al. **Curr Med Res Opin** 1995;13(6):299–304
Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. McKenna CJ, et al.
Eur J Gastroenterol Hepatol 1995 Sep;7(9):817–22
Dosage consideration for cisapride [letter; comment] McCauley MD. **J Am Vet Med Assoc** 1996 Jan 15; 208(2):184. Comment on: J Am Vet Med Assoc 1995 Nov 15;207(10):1285–8.
Technique of small intestinal biopsy: use of a pediatric Watson intestinal biopsy capsule combined with administration of cisapride [letter] Hjelt K.
J Pediatr Gastroenterol Nutr 1996 Feb;22(2):229–30
[Influence on glycemic control of improved diabetic gastroparesis by long–term cisapride therapy] Ishii K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1724–33 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects [letter] Hey JA, et al.
Ann Allergy Asthma Immunol 1996 May;76(5):476
Bronchospasm associated with cisapride. Pillans P. **BMJ** 1995 Dec 2;311(7018):1472
Aggravation of parkinsonian tremor by cisapride. Sempere AP, et al. **Clin Neuropharmacol** 1995 Feb;18(1):76–8
Cisapride–induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Pettignano R, et al. **Crit Care Med** 1996 Jul;24(7):1268–71
Lichenoid eruptions due to the H2–receptor antagonists roxatidine and ranitidine [letter] Horiuchi Y, et al.
J Dermatol 1996 Jul;23(7):510–2
Cisapride–induced long QT interval. Lewin MB, et al.
J Pediatr 1996 Feb;128(2):279–81
Torticollis as a side effect of cisapride treatment in an infant [letter] Dieckmann K, et al.
J Pediatr Gastroenterol Nutr 1996 Apr;22(3):336
Cisapride and fatal arrhythmia [letter] Wysowski DK, et al. **N Engl J Med** 1996 Jul 25;335(4):290–1

ANALYSIS

Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Yumibe N, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):165–72
The development and cross–validation of methods based on radioimmunoassay and LC/MS–MS for the quantification of the class III antiarrhythmic agent, MK–0499, in human plasma and urine. Gilbert JD, et al.
J Pharm Biomed Anal 1995 Jul;13(8):937–50

BLOOD

Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes. Urien S, et al.
Invest New Drugs 1995;13(1):37–41
Picogram determination of iloperidone in human plasma by solid–phase extraction and by high–performance liquid chromatography–selected–ion monitoring electrospray mass spectrometry. Mutlib AE, et al.
J Chromatogr B Biomed Appl 1995 Jul 21;669(2):237–46
Analysis of cisapride in neonatal plasma using high–performance liquid chromatography with a base–stable column and fluorescence detection. Preechagoon Y, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):139–43
[HPLC method for determination of lorcainide hydrochloride in human serum] Luo X, et al.
Yao Hsueh Hsueh Pao 1995;30(8):605–9 (Eng. Abstr.) **(Chi)**

CHEMICAL SYNTHESIS

4–(1–Naphthylamino)–piperidines as inhibitors of lipid peroxidation. Domány G, et al. **Arzneimittelforschung** 1996 Jun;46(6):553–6
Amides of piperidine, morpholine and piperazine substituted 1–phenylethylamines: inhibitors of acylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Dugar S, et al. **Bioorg Med Chem** 1995 Sep;3(9):1231–6
Synthesis and activity of 1–N–iminosugar inhibitors, siastatin B analogues for alpha–N–acetylgalactosaminidase and beta–N–acetylglucosaminidase. Nishimura Y, et al.
Bioorg Med Chem 1996 Jan;4(1):91–6
Structure–activity relationships of non–peptide vasopressin V1a antagonists: 1–(1–multi–substituted benzoyl 4–piperidyl)–3,4–dihydro–2(1H)–quinolinones. Kondo K, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):725–33
Synthesis and antimicrobial activity of some new piperidinyl benzimidazoles. Kuş C, et al. **Farmaco** 1996 Jun;51(6):413–7
Synthesis and antimetastatic activity of 6–trichloroacetamido and 6–guanidino analogues of siastatin B. Satoh T, et al.
J Antibiot (Tokyo) 1996 Mar;49(3):321–5
N–heteroaryl–2–phenyl–3–(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. Ladduwahetty T, et al. **J Med Chem** 1996 Jul 19; 39(15):2907–14
Structure–antigastrin activity relationships of new spiroglumide amido acid derivatives. Makovec F, et al.
J Med Chem 1996 Jan 5;39(1):135–42
New spiropiperidines as potent and selective non–peptide tachykinin NK2 receptor antagonists. Smith PW, et al.
J Med Chem 1995 Sep 15;38(19):3772–9
Synthesis and structure–activity relationships of acetylcholinesterase inhibitors: 1–benzyl–4–[(5,6–dimethoxy–1–oxoindan–2–yl) methyl]piperidine hydrochloride and related compounds. Sugimoto H, et al. **J Med Chem** 1995 Nov 24;38(24):4821–9
[11C]MDL 100907, a radioligland for selective imaging of 5–HT(2A) receptors with positron emission tomography. Lundkvist C, et al. **Life Sci** 1996;58(10):PL 187–92
Preparation and preliminary evaluation of 4–[211At]astato–N–piperidinoethyl benzamide. Garg PK, et al. **Nucl Med Biol** 1995 May;22(4):467–73
Effect of local anesthetic [2–(alkyloxy)phenyl]–2–(¡–piperidinyl)ethyl esters of carbamic acid on the activity of purified sarcoplasmic reticulum (Ca–Mg)ATPase. Andriamainty F, et al.
Pharmazie 1996 Apr;51(4):242–5

CHEMISTRY

An amino acid derived from aldol crosslink of elastin and collagen: structure, distribution, aging, and two models of hyperglycemia. Nakamura F, et al.
Arch Biochem Biophys 1996 Jan 15;325(2):167–73
(2E,4E)–N–(4–(1H–indol–3–yl)piperidin–1–yl)alkyl–5–(substituted phenyl)–2,4–pentadienamides as antiallergic agents with antihistaminic and anti slow–reacting substance (SRS) activities. Shigenaga S, et al.
Arch Pharm (Weinheim) 1996 Jan;329(1):3–10
The specificity and product of quenching singlet oxygen by 2,2,6,6–tetramethylpiperidine. Zang LY, et al.
Biochem Mol Biol Int 1995 Oct;37(2):283–93
Syntheses, activity and modeling studies of 3– and 4–(sulfo– and sulfonamidoalkyl)pyridine and piperidine–2–carboxylic acid derivatives as analogs of NMDA receptor antagonists. el Hadri A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1183–201
Synthesis and activity of 1–N–iminosugar inhibitors, siastatin B analogues for alpha–N–acetylgalactosaminidase and beta–N–acetylglucosaminidase. Nishimura Y, et al.
Bioorg Med Chem 1996 Jan;4(1):91–6
Formation of N2–tetrahydrofuranyl and N2–tetrahydropyranyl adducts in the reactions of alpha–acetoxy–N–nitrosopyrrolidine and alpha–acetoxy–N–nitrosopiperidine with DNA. Wang M, et al. **Chem Res Toxicol** 1995 Jun;8(4):617–24
Reactions of alpha–acetoxy–N–nitrosopyrrolidine and alpha–acetoxy–N–nitrosopiperidine with deoxyguanosine: formation of N2–tetrahydrofuranyl and N2–tetrahydropyranyl adducts. Young–Sciame R, et al.
Chem Res Toxicol 1995 Jun;8(4):607–16
Absolute configurations and conformations of the opioid agonist and antagonist enantiomers of picenadol. Froimowitz M, et al. **Chirality** 1995;7(7):518–25
A steric approach for the design of antihistamines with low muscarinic receptor antagonism. Zhang MQ, et al.
Inflamm Res 1995 Apr;44 Suppl 1:S90–1
The X–ray crystal structure of thrombin in complex with N alpha–2–naphthylsulfonyl–L–3–amidino–phenylalanyl–4–methylpiperidide: the beneficial effect of filling out an empty cavity. Bergner A, et al. **J Enzym Inhib** 1995; 9(1):101–10
Structure–activity relationships of inhibitors derived from 3–amidinophenylalanine. Stürzebecher J, et al.
J Enzym Inhib 1995;9(1):87–99
Structure–activity relationship studies of novel 4–[2–[bis(4–fluorophenyl)methoxy]ethyl]–1–(3–phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites. Dutta AK, et al. **J Med Chem** 1996 Feb 2;39(3):749–56
A comparative molecular field analysis study of N–benzylpiperidines as acetylcholinesterase inhibitors. Tong W, et al. **J Med Chem** 1996 Jan 19;39(2):380–7
Preparation of oligoribonucleotides containing 4–thiouridine using Fpmp chemistry. Photo–crosslinking to RNA binding proteins using 350 nm irradiation. McGregor A, et al.
Nucleic Acids Res 1996 Aug 15;24(16):3173–80
The kinetics of alkaline hydrolysis of the new potential antiarrhythmic, substance H + B, in the presence of beta–cyclodextrin. Stankovičová M, et al. **Pharmazie** 1995 Oct;50(10):705
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2735–40
[The biomimetic oxidation of propiverine hydrochloride and 1–methyl–4–piperidylbenzilate] Fröhlich L, et al.
Pharmazie 1995 Nov;50(11):736–40 (Eng. Abstr.) **(Ger)**
[Interactions of surfactants with model and biological membranes. XXII. Spectrophotometric determination of partition coefficient of heptacaine, a local anesthetic, between the phospholipid liposome and water phase] Hammel M, et al. **Ceska Slov Farm** 1996 Mar;45(2):58–66 (Eng. Abstr.) **(Slo)**

DIAGNOSTIC USE

Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Irie T, et al.
J Nucl Med 1996 Apr;37(4):649–55

ISOLATION & PURIFICATION

A–72363 A–1, A–2 and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192. I. Taxonomy of producing organism, fermentation, isolation and structure elucidation. Takatsu T, et al. **J Antibiot (Tokyo)** 1996 Jan; 49(1):54–60

METABOLISM

The peptide–based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion–transporting polypeptide. Eckhardt U, et al.
Hepatology 1996 Aug;24(2):380–4
Interactions between ifenprodil and the NR2B subunit of the N–methyl–D–aspartate receptor. Gallagher MJ, et al.
J Biol Chem 1996 Apr 19;271(16):9603–11
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. Shire D, et al. **J Biol Chem** 1996 Mar 22; 271(12):6941–6
Determination of diphenylpyraline in plasma and urine by high–performance liquid chromatography. Ebete KO, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):319–23
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine–labeled positional isomers of benzovesamicol. Jung YW, et al. **J Med Chem** 1996 Aug 16;39(17):3331–42
The quaternary transformation products of N–(3–chloropropyl)–4–piperidinyl diphenylacetate and N–(2–chloroethyl)–4–piperidinyl diphenylacetate (4–DAMP mustard) have differential affinity for subtypes of the muscarinic receptor. Ehlert FJ, et al.
J Pharmacol Exp Ther 1996 Feb;276(2):405–10
The vesamicol receptor ligand (+)–meta–[125I]iodobenzyltrozamicol [(+)–[125I]–MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6–hydroxydopamine (6–OHDA)–lesioned rat: possible implications for Parkinson's disease. Efange SM, et al. **Life Sci** 1996; 58(16):1367–74
[11C]MDL 100907, a radioligland for selective imaging of 5–HT(2A) receptors with positron emission tomography. Lundkvist C, et al. **Life Sci** 1996;58(10):PL 187–92
Characterization and distribution of binding sites for [3H]–SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Rinaldi–Carmona M, et al.
Life Sci 1996;58(15):1239–47
In vitro characterization of radioiodinated (–)–m–iodovesamicol in rat cerebral membranes. Shiba K, et al. **Life Sci** 1996;59(13):1039–45
In vivo characterization of radioiodinated 2–(4–phenylpiperidino)cyclohexanol (vesamicol) analogs: potential radioligand for mapping presynaptic cholinergic neurons. Shiba K, et al. **Nucl Med Biol** 1995 Aug; 22(6):823–8
Metabolism of a novel antiarrhythmic agent, bidisomide, in man: use of high resolution mass spectrometry to distinguish desisopropyl bidisomide from desacetyl bidisomide. Cook CS, et al. **Xenobiotica** 1995 Sep; 25(9):981–91
[Cisapride, a gastroprokinetic agent, binds to 5–HT4 receptors] Katayama K, et al.
Nippon Yakurigaku Zasshi 1995 Jun;105(6):461–8 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Distribution and elimination of RGH–5002 in rats. Terjéki E, et al. **Acta Physiol Hung** 1995;83(2):143–50
Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Dershwitz M, et al. **Anesthesiology** 1996 Apr;84(4):812–20
Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.

Egan TD, et al. **Anesthesiology** 1996 Apr;84(4):821–33
Measured context-sensitive half-times of remifentanil and alfentanil. Kapila A, et al. **Anesthesiology** 1995 Nov; 83(5):968–75
First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems. Eckhardt U, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):85–96
Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)
The pharmacokinetic properties of topical levocabastine. A review. Heykants J, et al. **Clin Pharmacokinet** 1995 Oct; 29(4):221–30 (39 ref.)
Pharmacokinetics and presystemic hepatic first-pass elimination of a novel sigma receptor antagonist, DuP 734, in the rat. Kapil RP, et al. **Drug Metab Dispos** 1995 May; 23(5):603–6
Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Mutlib AE, et al. **Drug Metab Dispos** 1995 Sep;23(9):951–64
Disposition of the opioid antagonist, LY255582, in rats and dogs. Swanson SP, et al. **Drug Metab Dispos** 1995 Sep; 23(9):916–21
Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride. Atarashi H, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):556–62
Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. Sainati SM, et al. **J Clin Pharmacol** 1995 Jul;35(7):713–20
Influence of the rate of intravenous administration of eliprodil (SL 82.0715), a new anti-ischaemic agent, on its distribution in rat plasma and tissues. Garrigou-Gadenne D, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):147–61
Comparative tissue distribution of conformationally restricted radioiodinated vesamicol receptor ligands. Efange SM, et al. **Nucl Med Biol** 1995 May;22(4):437–44
Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Cook CS, et al. **Pharm Res** 1995 Aug; 12(8):1158–64
In vivo disposition and in vitro metabolism of an anxiolytic compound, BMS-184111, in rats. Yeleswaram K, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):27–44

PHARMACOLOGY

An oxonol dye is the most potent known inhibitor of band 3-mediated anion exchange. Knauf PA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1073–7
The tachykinin NK2 receptor antagonist SR 48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs. Girard V, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1496–502
Effects of cisapride on feline colonic smooth muscle function. Washabau RJ, et al. **Am J Vet Res** 1996 Apr;57(4):541–6
Anesthetic potency of remifentanil in dogs. Michelsen LG, et al. **Anesthesiology** 1996 Apr;84(4):865–72
Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis. de Graaf-in 't Veld T, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):261–6
Selective effect of levocabastine on histamine receptor and histamine release from human leukocytes and guinea pig isolated tissue. Garrelds IM, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):327–34
Central cardiovascular effects of CPU-23, a substituted tetrahydroisoquinoline, in rats. Dong H, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):245–54
(2E,4E)-N-(4-(1H-indol-3-yl)piperidin-1-yl)alkyl-5-(substituted phenyl)-2,4-pentadienamides as antiallergic agents with antihistaminic and anti slow-reacting substance (SRS) activities. Shigenaga S, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):3–10
Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. D'Hooge R, et al. **Arzneimittelforschung** 1996 Jun;46(6):557–60
Piperine impairs cytochrome P4501A1 activity by direct interaction with the enzyme and not by down regulation of CYP1A1 gene expression in the rat hepatoma 5L cell line. Reen RK, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):562–9
Inhibition of insulin-induced chondrogenic differentiation of embryonic carcinoma cells by a teratogenic compound YM9429. Shibata M, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):593–9
Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Shivachar AC, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):669–76
Evaluation of isofagomine and its derivatives as potent glycosidase inhibitors. Dong W, et al. **Biochemistry** 1996 Feb 27;35(8):2788–95
Drug interactions between theophylline and H2-antagonists, roxatidine acetate hydrochloride and cimetidine: pharmacokinetic analysis in rats in vivo. Nagai N, et al. **Biol Pharm Bull** 1995 Nov;18(11):1610–3
Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Nochi S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1145–7
Amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines: inhibitors of acylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Dugar S, et al. **Bioorg Med Chem** 1995 Sep;3(9):1231–6
Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Gast A, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):553–60
Remifentanil reduces auditory and somatosensory evoked responses during isoflurane anaesthesia in a dose-dependent manner. Crabb I, et al. **Br J Anaesth** 1996 Jun;76(6):795–801
The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. Fairweather DB, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):119–25
Selective blockade of M2 and M3 muscarinic receptors by hexahydrobenzyl-fourdapine and a comparison with zamifenacin. Barlow RB, et al. **Br J Pharmacol** 1995 Dec; 116(7):2897–902
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Beattie DT, et al. **Br J Pharmacol** 1995 Dec;116(8):3149–57
Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Collins DR, et al. **Br J Pharmacol** 1995 Jul;115(6):869–70
The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Gardner CJ, et al. **Br J Pharmacol** 1995 Dec; 116(8):3158–63
Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance. Kaumann AJ, et al. **Br J Pharmacol** 1995 Jul;115(6):933–6
Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed. Leurs R, et al. **Br J Pharmacol** 1995 Oct;116(4):2315–21
The effect of a tachykinin NK1 receptor antagonist, SR140333, on oedema formation induced in rat skin by venom from the Phoneutria nigriventer spider. Palframan RT, et al. **Br J Pharmacol** 1996 May;118(2):295–8
Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Puisieux FL, et al. **Br J Pharmacol** 1996 Apr;117(7):1377–9
Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils. Rupniak NM, et al. **Br J Pharmacol** 1995 Sep;116(2):1937–43
Computerized planimetry in the objective assessment of the antispasmodic effect of Zamifenacin in double contrast barium enemas. Hughes T, et al. **Br J Radiol** 1996 Apr; 69(820):301–5
Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists. Advenier C. **Can J Physiol Pharmacol** 1995 Jul;73(7):878–84 (73 ref.)
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Buchdunger E, et al. **Cancer Res** 1996 Jan 1;56(1):100–4
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA, et al. **Cancer Res** 1996 Jul 1;56(13):2973–8
R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. Scheufler E, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):545–53
Effects of toquipidine on ionic channels of cultured embryonic Xenopus laevis myoblasts and neurons. Zheng P, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):427–39
Two components of delayed rectifier current in canine atrium and ventricle. Does IKs play a role in the reverse rate dependence of class III agents? Gintant GA. **Circ Res** 1996 Jan;78(1):26–37
Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Spector PS, et al. **Circ Res** 1996 Mar;78(3):499–503
Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)
Unique response of human arteries to endothelin B receptor agonist and antagonist. Liu JJ, et al. **Clin Sci (Colch)** 1996 Feb;90(2):91–6
Excitation and inhibition by cisapride of spontaneous and evoked electrical responses in smooth muscles of guinea-pig stomach. Ohno N, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):145–52
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Merlin JL, et al. **Cytometry** 1995 Aug 1;20(4):315–23
Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Gromada J, et al. **Diabetologia** 1995 Sep; 38(9):1025–32
Histamine H2-receptor antagonists stimulate proliferation but not migration of human gastric mucosal cells in vitro. Ciacci C, et al. **Dig Dis Sci** 1996 May;41(5):972–8
Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests. Duan LP, et al. **Dig Dis Sci** 1995 Oct;40(10):2200–6
Effect of cisapride on gallbladder emptying and plasma CCK in normal and vagotomized human subjects. Patankar R, et al. **Dig Dis Sci** 1996 Mar;41(3):543–8
Effects of cisapride on salivary production in normal subjects. Patel R, et al. **Dig Dis Sci** 1996 Mar;41(3):480–4
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)
Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)
Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Yang NN, et al. **Endocrinology** 1996 May; 137(5):2075–84
An NK1 receptor-dependent component of the slow excitation recorded intracellularly from rat motoneurons following dorsal root stimulation. Baranauskas G, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2409–17
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Aceto MD, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):R1–2
Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium. Atke A, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):63–8
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Maurel-Remy S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R9–11
Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Miyahara M, et al. **Eur J Pharmacol** 1995 Sep 15; 284(1-2):25–33
Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Novakova M, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):19–30
K+ channel openers produce epithelium-dependent relaxation of the guinea-pig trachea. Shikada K, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):193–7
In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]acetylcholine in the rabbit urinary bladder. Tobin G, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):1–8
Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Tsou K, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):R13–5
Characterization of the interaction of zamifenacin at muscarinic receptors in vitro. Watson N, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):135–42
Negative chronotropic and dromotropic effects of E-4031, an IKr blocker, on the atrioventricular node in anesthetized dog hearts. Yamazaki K, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):233–9
Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea pig. Girard V, et al. **Eur Respir J** 1995 Jul;8(7):1110–4
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. Sato M, et al. **FASEB J** 1996 Jun; 10(8):905–12
Molecular cloning of a levocabastine-sensitive neurotensin binding site. Chalon P, et al. **FEBS Lett** 1996 May 20; 386(2-3):91–4
Local anesthetic [2-(decyloxy)phenyl]-2-(1-piperidinyl)ethyl ester of carbamic acid perturbs phosphatidylcholine bilayer. Gallová J, et al. **Gen Physiol Biophys** 1995 Feb;14(1):61–5
Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Jones KL, et al. **Gut** 1996 Mar;38(3):310–5
The effects of roxatidine on neuromuscular transmission. Bossa R, et al. **In Vivo** 1995 Mar-Apr;9(2):113–5
Portocaval shunt, an H3-antagonist and plasma hormone levels. Fogel WA, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S52–3
Psychological effects of a drug that facilitates brain AMPA receptors. Lynch G, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):13–9
Endocrine and metabolic response to muscarinic stimulation and inhibition in the ruminant: effects of slaframine. Chapa AM, et al. **J Anim Sci** 1995 Dec;73(12):3673–80
A-72363 A-1, A-2, and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192, II. Biological activities. Kawase Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):61–4
Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B. Satoh T, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):321–5
Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. Bishop WR, et al. **J Biol Chem** 1995 Dec 22;270(51):30611–8
Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. Park DS, et al. **J Biol Chem** 1996 Apr 5;271(14):8161–9
Selective inhibition of Abeta fibril formation. Wood SJ, et

al. **J Biol Chem** 1996 Feb 23;271(8):4086–92

Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946]. Grover GJ, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):289–94

Effects of vasopressin V1 and V2 receptor antagonists on the development of salt-induced hypertension in Dahl rats. Hashimoto J, et al. **J Cardiovasc Pharmacol** 1995 Oct; 26(4):548–54

K+ channel-opening properties of a novel compound, NIP-121, in guinea pig myocardium as compared with those of cromakalim. Matsuda T, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):608–13

Effect of endothelin antagonists with or without BQ 788 on ET-1 responses in pithed rats. Sargent CA, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S216–8

Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. Yamada A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):159–66

Effects of 1-tetradecylperhydroazepine and 1-pentadecylpiperidine N-oxides on Ehrlich ascites mitochondria. Miko M, et al. **J Chemother** 1995 Oct; 7(5):446–8

The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction. Dershwitz M, et al. **J Clin Anesth** 1996 May;8(3 Suppl):88S–90S

Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor. Yamada K, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):326–9

Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. Reers M, et al. **J Enzym Inhib** 1995;9(1):61–72

Antiamoebic activity of Piper longum fruits against Entamoeba histolytica in vitro and in vivo. Ghoshal S, et al. **J Ethnopharmacol** 1996 Mar;50(3):167–70

Single oral dose of cisapride accelerates gastric antral emptying in healthy humans: an ultrasonographic study. Takeda T, et al. **J Gastroenterol** 1996 Jun;31(3):323–8

New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists. Abou-Gharbia M, et al. **J Med Chem** 1995 Sep 29;38(20):4026–32

Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites. Dutta AK, et al. **J Med Chem** 1996 Feb 2;39(3):749–56

N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity. Gaster LM, et al. **J Med Chem** 1995 Nov 24;38(24):4760–3

Alkyl and alkoxyethyl antineoplastic phospholipids. Koufaki M, et al. **J Med Chem** 1996 Jun 21;39(13):2609–14

Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. Makovec F, et al. **J Med Chem** 1996 Jan 5;39(1):135–42

2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. Moore WM, et al. **J Med Chem** 1996 Feb 2;39(3):669–72

A structure-activity relationship study of novel phenylacetamides which are sodium channel blockers. Roufos I, et al. **J Med Chem** 1996 Mar 29;39(7):1514–20

5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl) piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. Rowley M, et al. **J Med Chem** 1996 May 10;39(10):1943–5

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl) methyl]piperidine hydrochloride and related compounds. Sugimoto H, et al. **J Med Chem** 1995 Nov 24;38(24):4821–9

A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors. Tong W, et al. **J Med Chem** 1996 Jan 19;39(2):380–7

Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. Ward P, et al. **J Med Chem** 1995 Dec 22;38(26):4985–92

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Weller T, et al. **J Med Chem** 1996 Aug 2;39(16):3139–47

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. Williams PD, et al. **J Med Chem** 1995 Nov 10;38(23):4634–6

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis. Carlsson ML. **J Neural Transm Gen Sect** 1995;100(3):225–37

Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. Poncelet M, et al. **J Neural Transm Gen Sect** 1995;102(2):83–90

Facilitation of olfactory learning by a modulator of AMPA receptors. Larson J, et al. **J Neurosci** 1995 Dec; 15(12):8023–30

Beta subunit coexpression and the alpha1 subunit domain I-II linker affect piperidine block of neuronal calcium channels. Zamponi GW, et al. **J Neurosci** 1996 Apr 15;16(8):2430–43

Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. Arai A, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):627–38

Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. Chen L, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1276–83

LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. Cohen ML, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):97–104

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. Compton DR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):586–94

Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists. Conte B, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):212–8

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. Cook JJ, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):62–73

Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. Gifford AN, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1431–6

Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. Gitter BD, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):737–44

Selective inhibition by a class III antiarrhythmic agent, E-4031, of the negative chronotropic response to parasympathetic stimulation in anesthetized dogs. Imamura H, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):467–72

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. Kehne JH, et al. **J Pharmacol Exp Ther** 1996 May;277(2):968–81

In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist. Kudlacz EM, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):840–51

Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes. McLarnon JG, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):389–96

Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. McLean S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):900–8

Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol. Martin CL, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):154–62

Effects of repeated administration of N-[1-(2-benzo(b)-thiophenyl)cyclohexy]piperidine and cocaine on locomotor activity in C57BL/6 mice. Prinssen EP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):904–11

Intracellular [Mg++] determines specificity of K+ channel block by a class III antiarrhythmic drug. Sudo GZ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):951–7

Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity. Szczepanik AM, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):913–20

The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Szewczak MR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1404–13

Involvement of endothelins in immediate and late asthmatic responses of guinea pigs. Uchida Y, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1622–9

Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. Wiley JL, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):1–6

Evidence for a selective effect of ethanol on N-methyl-d-aspartate responses: ethanol affects a subtype of the ifenprodil-sensitive N-methyl-d-aspartate receptors. Yang X, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):114–24

A histamine H2 receptor antagonist, roxatidine, stimulates mucus secretion and synthesis by cultured rabbit gastric mucosal cells. Takahashi S, et al. **J Physiol Pharmacol** 1995 Dec;46(4):503–11

Antifertility potential of 2-[piperdinoethoxyphenyl]-3-[4-methoxyphenyl]-2H benzopyran: a potent anti-oestrogenic compound in rats. Singh R. **J Reprod Fertil** 1996 Jan; 106(1):49–53

OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog. Chihara T, et al. **Jpn J Pharmacol** 1995 Jul;68(3):345–7

Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Onodera S, et al. **Jpn J Pharmacol** 1995 Jun;68(2):161–73

Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats. Yamashita T, et al. **Jpn J Pharmacol** 1995 Jun; 68(2):145–52

Neuronal NK3-receptors in guinea-pig ileum and taenia caeci: in vitro characterization by their first non-peptide antagonist, SR142801. Croci T, et al. **Life Sci** 1995; 57(23):PL361–6

The interaction of 4-DAMP mustard with subtypes of the muscarinic receptor. Ehlert FJ. **Life Sci** 1996;58(22):1971–8 (39 ref.)

S-(-)-ET 126: a potent and selective M1 antagonist in vitro and in vivo. Ghelardini C, et al. **Life Sci** 1996; 58(12):991–1000

Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice. Miyazaki S, et al. **Life Sci** 1995; 57(23):2137–44

Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Santucci V, et al. **Life Sci** 1996;58(6):PL103–10

Effects of the histamine H3 agonist (R)-alpha-methylhistamine and the antagonist thioperamide in vitro on monoamine oxidase activity in the rat brain. Sakurai E, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:46–50

Pharmacology of endothelins: vascular preparations for studying ETA and ETB receptors. Caló G, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):31–7

The non-peptide NK1 receptor antagonist SR140333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo- or thermonociception in rats. Amann R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):201–5

Effect of SR 142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor agonists in isolated guinea-pig colon. Giuliani S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):512–9

5-HT4 receptor antagonist affinities of SB207710, SB205008, and SB203186 in the human colon, rat oesophagus, and guinea-pig ileum peristaltic reflex. McLean PG, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):132–40

Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Terranova JP, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):576–9

Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. McCool BA, et al. **Neuropharmacology** 1995 Jun; 34(6):621–9

Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin1 (NK1) receptor antagonist CP-99,994. Tattersall FD, et al. **Neuropharmacology** 1995 Dec;34(12):1697–9

The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. Gueudet C, et al. **Neuroreport** 1995 Jul 10;6(10):1421–5

Physiological and regenerative acetylcholine release from motor nerve: differential inhibitions by vesamicol and omega-agatoxin IVA. Hong SJ, et al. **Neuroscience** 1995 Jul;67(1):169–75

Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Layer RT, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):621–7

Analogues of sabeluzole with gastric acid secretion inhibitory effect. Domány G, et al. **Pharmazie** 1996 Jun;51(6):427–8

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2735–40

Effects of transient global ischemia and a monoamine oxidase inhibitor ifenprodil on rat brain monoamine metabolism. Tadano T, et al. **Prog Brain Res** 1995;106:173–80

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Neubauer BL, et al. **Prostate** 1995 Oct;27(4):220–9

Vesamicol, an acetylcholine uptake blocker in presynaptic vesicles, suppresses rapid eye movement (REM) sleep in the rat. Salin-Pascual RJ, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):485–7

Effect of (-)-DS 121 and (+)-UH 232 on cocaine self-administration in rats. Smith A, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):93–8

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Walsh DM, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):186–91

Effects of endothelin receptor selective antagonists, BQ-123 and BQ-788, on IRL 1620 and endothelin-1 responses of airway and vascular preparations from rats. O'Donnell SR, et al. **Pulm Pharmacol** 1995 Feb;8(1):11–9

Gastric antral motility in functional dyspepsia. Effect of mental stress and cisapride. Hveem K, et al. **Scand J Gastroenterol** 1996 May;31(5):452–7

Effects of the anti-gastric secretory drugs IT-066 and omeprazole mitogenic activities in the gastric juice of the

rat. Kasugai K, et al. **Scand J Gastroenterol** 1996 Feb; 31(2):111–7

Drug's link to genes reveals estrogen's many sides [news; comment] Pennisi E. **Science** 1996 Aug 30;273(5279):1171 . Comment on: Science 1996 Aug 30;273(5279):1222–5.

Identification of an estrogen response element activated by metabolites of 17beta–estradiol and raloxifene [see comments] Yang NN, et al. **Science** 1996 Aug 30; 273(5279):1222–5. Comment in: Science 1996 Aug 30;273(5279):1171.

Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording. Sugiyama A, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):109–14

Heat stabilized, infectious poliovirus. Ofori–Anyinam O, et al. **Vaccine** 1995 Aug;13(11):983–6

[Effect of FRG–8813, a new histamine H2–receptor antagonist, on gastric mucus production in rats] Kagoshima M, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):385–92 (Eng. Abstr.) **(Jpn)**

[A perfluorocarbon emulsion inhibits neutrophil activation] Obraztsov VV, et al. **Dokl Akad Nauk** 1995 Jun; 342(6):819–22 **(Rus)**

POISONING

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

THERAPEUTIC USE

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase –A and serotonin uptake inhibitor brofaromine. A double–blind placebo–controlled study. Fahlén T, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):351–8

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)

Double–blind, randomized trial of roxatidine 150 mg in the early evening versus bedtime administration in the short–term treatment of duodenal ulcer. Lazzaroni M, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):425–31

Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children. Cucchiara S, et al. **Am J Gastroenterol** 1996 Apr;91(4):680–5

A clinical study on the significance of platelet–activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Ono S, et al. **Am J Surg** 1996 Apr;171(4):409–15

The effect of oral cisapride premedication on fasting gastric volumes. Kluger MT, et al. **Anaesth Intensive Care** 1995 Dec;23(6):687–90

Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Warner DS, et al. **Anesth Analg** 1996 Aug;83(2):348–53

Improved skin blood flow and cutaneous temperature in the foot of a patient with arteriosclerosis obliterans by vasopressin V1 antagonist (OPC21268). A case report. Toba K, et al. **Angiology** 1995 Nov;46(11):1027–33

Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Gehanno P, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):507–12

Cisapride for the treatment of chronic idiopathic constipation. Gardner VY, et al. **Ann Pharmacother** 1995 Nov;29(11):1161–3 (12 ref.)

Effects of inogatran, a new low–molecular–weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Gustafsson D, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):69–79

Use of cisapride in the resolution of pelvic flexure impaction in a horse. Steinebach MA, et al. **Can Vet J** 1995 Oct; 36(10):624–5

Tremorlytic activity of budipine: a quantitative study with long–term tremor recordings. Spieker S, et al. **Clin Neuropharmacol** 1995 Jun;18(3):266–72

A multicenter, randomized, double–blind comparison of roxatidine with ranitidine in the treatment of patients with uncomplicated benign gastric ulcer disease. The Multicenter Roxatidine Cooperative Study Group. Brandstätter G, et al. **Clin Ther** 1995 May–Jun;17(3):467–78

Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Cutts TF, et al. **Dig Dis Sci** 1996 Jul;41(7):1369–78

Cisapride in neurologically impaired children with chronic constipation. Staiano A, et al. **Dig Dis Sci** 1996 May; 41(5):870–4

Placebo–controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Vaezi MF, et al. **Dig Dis Sci** 1996 Apr;41(4):754–63

A risk–benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384–92 (103 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

Attenuation of genetic hypertension after short–term vasopressin V1A receptor antagonism. Burrell LM, et al. **Hypertension** 1995 Nov;26(5):828–34

Rumination–treatment with cisapride [letter] Sood AK, et al. **J Assoc Physicians India** 1995 Apr;43(4):304–5

Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride. Atarashi H, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):556–62

Quality of peptic ulcer healing induced by lansoprazole and roxatidine. Fujino MA, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S44–6

Personality traits in social phobia, II: Changes during drug treatment. Fahlén T. **J Clin Psychiatry** 1995 Dec; 56(12):569–73

Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double–blind controlled multicentre study in Singapore. Fock KM, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):379–82

Comparison of roxatidine and famotidine on nocturnal gastric juice secretion. Tanioka H, et al. **J Int Med Res** 1996 Jan–Feb;24(1):88–91

Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study [news] Ziegler J. **J Natl Cancer Inst** 1996 Aug 21;88(16):1100–2

Prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by the platelet–activating factor antagonist, E5880. Hirashima Y, et al. **J Neurosurg** 1996 May;84(5):826–30

Cisapride therapy for gastrointestinal disease. Cucchiara S. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):259–69 (90 ref.)

Cisapride for children with intractable constipation: an interim verdict! [editorial; comment] Loening–Baucke V. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):3–5. Comment on: J Pediatr Gastroenterol Nutr 1996 Jan;22(1):38–44.

Treatment of intractable constipation in children: experience with cisapride [see comments] Nurko S, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):38–44. Comment in: J Pediatr Gastroenterol Nutr 1996 Jan;22(1):3–5.

Differential efficacy of the class III agent MK–499 against programmed stimulation–induced and ischemic–induced ventricular arrhythmias in a canine model of previous myocardial infarction. Lynch JJ Jr, et al. **J Pharmacol Exp Ther** 1996 May;277(2):671–8

Effects of napsagatran (Ro 46–6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. Roux S, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):71–8

Cisapride for constipation in spinal cord injured patients: a preliminary report. Longo WE, et al. **J Spinal Cord Med** 1995 Oct;18(4):240–4

Gastroparesis with multiple sclerosis [letter] Read SJ, et al. **Lancet** 1995 Nov 4;346(8984):1228

A comparison of five maintenance therapies for reflux esophagitis [see comments] Vigneri S, et al. **N Engl J Med** 1995 Oct 26;333(17):1106–10. Comment in: N Engl J Med 1995 Oct 26;333(17):1148–50. Comment in: N Engl J Med 1996 Feb 29;334(9):600–1.

Effect of sabeluzole (R 58,735) on memory functions in patients with epilepsy. Aldenkamp AP, et al. **Neuropsychobiology** 1995;32(1):37–44

Are there any differences in the safety and efficacy of brofaromine and imipramine between non–elderly and elderly patients with major depression? Volz HP, et al. **Neuropsychobiology** 1995;32(1):23–30

Insulin normalization as an approach to the pharmacological treatment of obesity. Campfield LA, et al. **Obes Res** 1995 Nov;3 Suppl 4:591S–603S

In vivo effects of a novel calcium antagonist (R56865) against induced epoxyscillirosidin and tulp poisoning in sheep. Swan GE, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):163–6

The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double–blind, placebo controlled study. Wyndaele JJ, et al. **Paraplegia** 1995 Nov;33(11):625–7

Efficacy and safety of an opiate sigma–receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose–range study. Modell S, et al. **Pharmacopsychiatry** 1996 Mar;29(2):63–6

Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks. Volz HP, et al. **Psychiatry Res** 1995 Sep 29;58(2):107–15

A double–blind, randomized, placebo–controlled, multi–center study of brofaromine in the treatment of post–traumatic stress disorder. Baker DG, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):386–9

Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double–blind, placebo–controlled trial. Dahl R, et al. **Rhinology** 1995 Sep;33(3):121–5

A double–blind, randomized, placebo–controlled trial of cisapride in Saudi Arabs with functional dyspepsia. al–Quorain A, et al. **Scand J Gastroenterol** 1995 Jun; 30(6):531–4

Gastro–oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride. Olafsdottir E. **Scand J Gastroenterol Suppl** 1995;211:32–4

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

The clinical use of cisapride in gastro–oesophageal reflux disease, with particular focus on the long–term treatment aspects. Tytgat GN. **Scand J Gastroenterol Suppl** 1995; 211:39–43

Cisapride as a successful treatment for acute intestinal pseudo–obstruction. Mazloum BW, et al. **South Med J** 1996 Aug;89(8):828–30

Lubeluzole in acute ischemic stroke. A double–blind, placebo–controlled phase II trial. Lubeluzole International Study Group. Diener HC, et al. **Stroke** 1996 Jan;27(1):76–81

Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride. Barr J, et al. **Thorax** 1996 Jan; 51(1):82–6

[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis] Lips P, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1215–7 (31 ref.) **(Dut)**

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Effective prevention of indomethacin–induced gastroduodenal mucosal lesions with roxatidine acetate] Dammann HG, et al. **Arzneimittelforschung** 1995 Aug; 45(8):880–2 (Eng. Abstr.) **(Ger)**

[Roxatidine acetate in therapy of reflux esophagitis] Friedrich P, et al. **Fortschr Med** 1996 Jun 10;114(16):213–6 (Eng. Abstr.) **(Ger)**

[A clinical–pharmacological case (I). Action of cisapride (Prepulsid) on bladder function] Meier C, et al. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):62–4 (Eng. Abstr.) **(Ger)**

[The evaluation of the time of gastric radio–isotopic emptying in subjects with non–insulin dependent diabetes mellitus] Allegra G, et al. **Clin Ter** 1996 Mar;147(3):93–8 (Eng. Abstr.) **(Ita)**

[Influence of KU–1257 on the recurrence and relapse of acetic acid–induced chronic gastric ulcers in rats] Sekiguchi H, et al. **Nippon Yakurigaku Zasshi** 1996 Feb;107(2):67–78 (Eng. Abstr.) **(Jpn)**

[Agonists–antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44–47):41–2 (16 ref.) (Eng. Abstr.) **(Pol)**

[Chronic constipation. Use of cisapride] Uzcategui Arauz A, et al. **G E N** 1995 Jul–Sep;49(3):218–23 (Eng. Abstr.) **(Spa)**

[Effects levocabastine ophthalmic solution (H1 receptor antagonist) on symptoms of vernal conjunctivitis. A prospective, randomized double–blind study] Graue E. **Gac Med Mex** 1994 Nov–Dec;130(6):481–6 (Eng. Abstr.) **(Spa)**

TOXICITY

Potentiation of carbon tetrachloride hepatotoxicity by piperine. Piyachaturawat P, et al. **Drug Chem Toxicol** 1995 Nov;18(4):333–44

Effect of folate supplementation on clinical chemistry and hematologic changes related to bidisomide administration in the rat. Vandenberghe Y, et al. **Drug Chem Toxicol** 1995 Nov;18(4):235–70

URINE

Study of local anesthetics. Part 128. HPLC study of the degradation of heptacaine and carbisocaine in urine, human and rabbit serums. Lehotay J, et al. **Acta Pharm Hung** 1995 May;65(3):95–6

PIPERIDONES

CHEMICAL SYNTHESIS

N–aryl–N'–benzylpiperazines as potential antipsychotic agents. Reitz AB, et al. **J Med Chem** 1995 Oct 13; 38(21):4211–22

CHEMISTRY

Preparation of optically active epiderstatin and its stereoisomers—epiderstatin is not a real inhibitor of the mitogenic activity induced by epidermal growth factor. Ubukata M, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1176–8

Piperazinylalkyl heterocycles as potential antipsychotic agents. Scott MK, et al. **J Med Chem** 1995 Oct 13; 38(21):4198–210

PHARMACOLOGY

Effects of BRL55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide–resistant, ATP–sensitive potassium current. Edwards G, et al. **Br J Pharmacol** 1995 Jul;115(6):1027–37

Imidazole derivatives of pyrrolidonic and piperidonic as potential inhibitors of human placental aromatase in vitro. Baroudi M, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):73–7

THERAPEUTIC USE

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Sugita Y, et al. **Kurume Med J** 1995;42(3):133–40

Inhibitory effect of antineoplaston A10 and AS2–1 on human hepatocellular carcinoma. Tsuda H, et al. **Kurume Med J** 1996;43(2):137–47

TOXICITY

Cytotoxic evaluation of some N-acyl and N-acyloxy analogues of 3,5-bis(arylidene)-4-piperidones. Dimmock JR, et al. **Drug Des Discov** 1994 Jul;12(1):19-28

Nephrotoxic potential of N-(3,5-dichlorophenyl)glutarimide and N-(3,5-dichlorophenyl)glutaramic acid in Fischer 344 rats. Kellner-Weibel GL, et al. **Toxicol Lett** 1995 Oct; 80(1-3):123-9

PIPERONYL BUTOXIDE

Efficacy of a 1:1 and 1:5 mixture of technical permethrin and piperonyl butoxide against Anopheles quadrimaculatus and Psorophora columbiae. Groves RL, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):311-4

In vitro control of Phthirus pubis with four peliculocides: Eurax, Elimite, Licid and Benzanil. Ragheb DA, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):677-81

TOXICITY

Piperonyl butoxide mutagenicity in human RSa cells. Suzuki H, et al. **Mutat Res** 1995 Aug;344(1-2):27-30

Cytogenetic effects of piperonyl butoxide and safrole in CHO-K1 cells. Tayama S. **Mutat Res** 1996 Jul 5; 368(3-4):249-60

Developmental toxicity study of piperonyl butoxide in CD rats. Tanaka T, et al. **Toxicol Ind Health** 1995 Mar-Apr; 11(2):175-84

PIPEROXAN

PHARMACOLOGY

Influence of the alpha 2 noradrenergic antagonist piperoxane on longevity in the Fischer-344 rat: a preliminary report. Compton DM, et al. **Psychol Rep** 1995 Aug;77(1):139-42

PIPIDAE

EMBRYOLOGY

Dorsal mesoderm has a dual origin and forms by a novel mechanism in Hymenochirus, a relative of Xenopus. Minsuk SB, et al. **Dev Biol** 1996 Feb 25;174(1):92-103

PIRACETAM

ANALOGS & DERIVATIVES

ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Margineanu DG, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):321-5

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Noyer M, et al. **Eur J Pharmacol** 1995 Nov 14; 286(2):137-46

A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ratnaraj N, et al. **Ther Drug Monit** 1996 Apr;18(2):154-7

PHARMACOLOGY

Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Brandão F, et al. **Alcohol** 1996 May-Jun;13(3):239-49

Explorative and drinking behavior after prolonged access to alcohol and following chronic piracetam administration in mice. Salimov R, et al. **Alcohol** 1995 Nov-Dec; 12(6):485-9

On the possible role of nootropica in geriatric prevention and therapy. Nagy IZ. **Ann N Y Acad Sci** 1996 Jun 15; 786:444-52 (45 ref.)

Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Peuvot J, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1129-34

Piracetam and aniracetam antagonism of centrally active drug-induced antinociception. Galeotti N, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):943-50

Effect of chronic piracetam on age-related changes of cross-maze exploration in mice. Salimov R, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):637-40

[Antagonism of piracetam on the amnestic effect of diazepam in mice] Pan JC, et al. **Yao Hsueh Hsueh Pao** 1996; 31(2):91-4 (Eng. Abstr.) **(Chi)**

[In vitro effects of piracetam on the radiosensitivity of hypoxic cells (adaptation of MTT assay to hypoxic conditions)] Lagarde P, et al. **Bull Cancer (Paris)** 1995 Nov; 82(11):929-38 (Eng. Abstr.) **(Fre)**

[Effect of low doses of piracetam on conditional reflex memory in rats] Tushmalova NA, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):60-1 **(Rus)**

[Effects of piracetam on occupationally significant functions of patients with arterial hypertension working under conditions of psychoemotional stress] Dasaeva LA. **Med Tr Prom Ekol** 1995;(10):26-8 (Eng. Abstr.) **(Rus)**

[Changes in the reaction to damage to the case in caddisfly larvae under the influence of piracetam] Inozemtsev AN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov-Dec; 45(6):1211-3 **(Rus)**

[Changes in the indices of neuronal functional activity under the action of piracetam as a possible basis for realizing the effects of nootropic agents] Vernyi IaI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul-Aug; 45(4):791-801 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[Piracetam as a corrector of long-term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy] Trofimov SS, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):435-7 **(Rus)**

[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam] Mendzheritskiĭ AM, et al. **Vopr Med Khim** 1995 Sep-Oct;41(5):16-9 (Eng. Abstr.) **(Rus)**

PIRENZEPINE

ADMINISTRATION & DOSAGE

Dose-dependent effects of intravitreal pirenzepine on deprivation myopia and lens-induced refractive errors in chickens [letter] Rickers M, et al. **Exp Eye Res** 1995 Oct; 61(4):509-16

ANALOGS & DERIVATIVES

First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Baldwin DS, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):239-44

Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Catlow JT, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):85-90

Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Chiu JA, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):609-15

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Ring BJ, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):658-66

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Bakshi VP, et al. **Psychopharmacology (Berl)** 1995 Nov; 122(2):198-201

The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Cools AR, et al. **Psychopharmacology (Berl)** 1995 Jun; 119(4):428-39

ANTAGONISTS & INHIBITORS

Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse. Ukai M, et al. **Gen Pharmacol** 1995 Nov; 26(7):1529-32

BLOOD

Determination of pirenzepine in human plasma using liquid chromatography with tandem mass spectrometric detection. Chavez CM, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1179-84

PHARMACOLOGY

5-HT1A, GABAB, and pirenzepine-insensitive muscarinic receptors are functionally coupled to distinct pools of the same kind of G proteins in rat hippocampus. Odagaki Y, et al. **Brain Res** 1995 Aug 14;689(1):129-35

Effect of selective and non-selective muscarinic blockade on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Tatsuta M, et al. **Carcinogenesis** 1996 Feb;17(2):293-6

Selective and unselective blockade of sympathicus and parasympathicus and vagal enhancement by pirenzepine: effects on heart rate and heart rate variability in healthy subjects. Wilhelmy R, et al. **Clin Sci (Colch)** 1996;91 Suppl:124

Effects of pirenzepine on omeprazole-induced gastrin gene expression in rat antral tissues. Tari A, et al. **Dig Dis Sci** 1996 Jun;41(6):1150-6

kappa-Opioid receptor agonists improve pirenzepine-induced disturbance of spontaneous alternation performance in the mouse. Ukai M, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):173-8

Pirenzepine-sensitive component of forelimb vascular resistance and heart rate in cats. Stein R, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):49-58

In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. Maccario M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3774-8

[Effect of resection of the proximal part of the small intestine on inhibition of gastric secretion as affected by pituitrin, gastrozepin and histodil] Trefilov AB. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):29-32 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Pirenzepine versus scopolamine methyl bromide in double-contrast barium enema study of large bowel. Marraccini P, et al. **Abdom Imaging** 1996 Jul-Aug; 21(4):304-8

The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Cottriall CL, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1368-79

Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. Tari A, et al. **J Gastroenterol** 1996 Apr; 31(2):167-70

Pirenzepine for clozapine-induced hypersalivation [letter] Fritze J, et al. **Lancet** 1995 Oct 14;346(8981):1034

Pirenzepine prevents form deprivation myopia in a dose dependent manner. Leech EM, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):351-6

[The efficacy of gastrotsepin in functional diseases of the large intestine] Golovenko OV, et al. **Klin Med (Mosk)** 1995;73(3):52-4 **(Rus)**

[The histoenzymological and ultrastructural changes in the gastric mucosa in peptic ulcer after treatment with pirenzepine and histamine H2-receptor blockaders] Degtiareva II, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):48-51 (Eng. Abstr.) **(Rus)**

PIRIBEDIL

PHARMACOKINETICS

Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. Pagliari R, et al. **J Neural Transm Gen Sect** 1995;101(1-3):13-26

PHARMACOLOGY

Restoration of brain protein synthesis in mature and aged rats by a DA agonist, piribedil. Bustany P, et al. **Fundam Clin Pharmacol** 1995;9(5):458-68

Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. Pagliari R, et al. **J Neural Transm Gen Sect** 1995;101(1-3):13-26

Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Delbarre B, et al. **Mol Chem Neuropathol** 1995 Sep;26(1):43-52

Different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry. Jardon B, et al. **Vision Res** 1995 Oct; 35(19):2665-73

TOXICITY

An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Smith L, et al. **Mov Disord** 1996 Mar; 11(2):125-35

PIRIBENDYL see **PIRIBEDIL**

PIRINITRAMIDE

ADMINISTRATION & DOSAGE

[Patient-controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134-8 (Eng. Abstr.) **(Ger)**

[Combination of intravenous patient-controlled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69-75 (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia with clonidine and piritramide] Sümpelmann R, et al. **Anaesthesist** 1996 Jan;45(1):88-94 (Eng. Abstr.) **(Ger)**

PIRITRAMID see **PIRINITRAMIDE**

PIRITRAMIDE see **PIRINITRAMIDE**

PIROPLASMA see **BABESIA**

PIROPLASMOSIS see **BABESIOSIS**

PIROXICAM

ADMINISTRATION & DOSAGE

Systemic piroxicam as an adjunct to patient-controlled analgesia with alfentanil for postoperative pain relief. Van Lancker P, et al. **Anaesthesia** 1996 Jul;51(7):658-62

Postoperative analgesia in dental day case surgery. A comparison between Feldene 'Melt' (piroxicam) and diclofenac suppositories. Wakeling HG, et al. **Anaesthesia** 1996 Aug;51(8):784-6

Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone [see comments] Blackburn WD Jr, et al. **Arthritis Rheum** 1995 Oct;38(10):1447-56. Comment in: Arthritis Rheum 1996 Jul;39(7):1263-4.

Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic

monitoring device. de Klerk E, et al. **Br J Rheumatol** 1996 Jan;35(1):60–5

Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Ghozlan PR, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:51–5

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Lindén B, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:35–8

A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Carrabba M, et al. **Curr Med Res Opin** 1995; 13(6):343–55

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on postoperative pain following laparoscopy. O'Hanlon JJ, et al. **Ulster Med J** 1996 May; 65(1):51–4

ADVERSE EFFECTS

Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy. Rawson NS. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):676–80

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Patoia L, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:61–7

Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. Tubert-Bitter P, et al. **J Clin Epidemiol** 1996 Jan; 49(1):121–3

Piroxicam induced Stevens-Johnson syndrome. Katoh N, et al. **J Dermatol** 1995 Sep;22(9):677–80

ANALOGS & DERIVATIVES

Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Burssens A, et al. **Acta Orthop Belg** 1995;61(3):205–11

Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips. Gebuhr P, et al. **Acta Orthop Scand** 1996 Feb;67(1):29–32

Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aabakken L, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):151–6

The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Jones NC, et al. **Anaesthesia** 1996 May;51(5):446–8

Peritonsillar infiltration with low-dose tenoxicam after tonsillectomy. Knudsen KE, et al. **Br J Anaesth** 1995 Sep; 75(3):286–8

Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Ilias W, et al. **Br J Clin Pract** 1996 Jun;50(4):197–202

Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. de Klerk E, et al. **Br J Rheumatol** 1996 Jan;35(1):60–5

Intramuscular tenoxicam to treat acute renal colic. Al-Waili NS. **Br J Urol** 1996 Jan;77(1):15–6

Effect of nonionic surfactants on the percutaneous absorption tenoxicam. Endo M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):865–7

Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639–57 (76 ref.)

Zwitterionic nature of tenoxicam: crystal structures and thermal analyses of a polymorph of tenoxicam and a 1:1 tenoxicam:acetonitrile solvate. Caira MR, et al. **J Pharm Sci** 1995 Jul;84(7):884–8

Tenoxicam pharmacokinetics in rats: a population model. Troconiz IF, et al. **J Pharm Sci** 1995 Dec;84(12):1482–7

[Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study] Bestetti F. **Minerva Med** 1996 Mar;87(3):117–22 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial] Peretti G. **Minerva Med** 1996 Apr;87(4):155–60 (Eng. Abstr.) **(Ita)**

PHARMACOKINETICS

In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Santoyo S, et al. **Pharm Acta Helv** 1996 Jul;71(2):141–6

PHARMACOLOGY

Determining selectivity of drugs by quantitative two-dimensional gel analysis. A study of tenidap, piroxicam, and dexamethasone. Otterness IG, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):917–25

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Jacoby RF, et al. **Cancer Res** 1996 Feb 15;56(4):710–4

Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Thürmann P, et al. **Eur J Clin Pharmacol** 1995;48(3–4):241–6

Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. Buritova J, et al. **Neuroreport** 1995 Jul 10;6(10):1385–8

Effects of piroxicam and esculetin on the MDA-MB-231 human breast cancer cell line. Noguchi M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):325–9

THERAPEUTIC USE

Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Pereira MA, et al. **Carcinogenesis** 1996 Feb;17(2):373–6

Complete regression of villous adenomas of the colon using piroxicam, a nonsteroidal anti-inflammatory drug. Gowen GF. **Dis Colon Rectum** 1996 Jan;39(1):101–2

A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Sjaastad O, et al. **Headache** 1995 Oct;35(9):549–50

[Peripheral arthritis in family practice] de Bock GH. **Tijdschr Gerontol Geriatr** 1996 Apr;27(2):67–72 (Eng. Abstr.) **(Dut)**

[Evaluation of the effectiveness and tolerability of MED 15 vs. piroxicam in patients with acute epicondylitis] Meloni P, et al. **Clin Ter** 1995 Jun–Jul;146(6–7):453–6 (Eng. Abstr.) **(Ita)**

TOXICITY

Effects of the nonsteroidal anti-inflammatory drug piroxicam on rat liver mitochondria. Salgueiro-Pagadigorria CL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):85–91

Effects of the nonsteroidal anti-inflammatory drug piroxicam on energy metabolism in the perfused rat liver. Salgueiro-Pagadigorria CL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):93–8

Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Santucci L, et al. **Dig Dis Sci** 1995 Sep;40(9):2074–80

[Experimental data on bases of MAC of piroxicam in the air of workplace] Bogachuk GP, et al. **Med Tr Prom Ekol** 1996;(4):26–8 (Eng. Abstr.) **(Rus)**

PISUM SATIVUM see **PEAS**

PIT AND FISSURE SEALANTS

Restoring interproximal caries [letter; comment] Aslani MB. **Pediatr Dent** 1995 Jul–Aug;17(4):256. Comment on: Pediatr Dent 1995 May–Jun;17(3):230.

ADVERSE EFFECTS

Dangerous dental sealants? [news] **Environ Health Perspect** 1996 Apr;104(4):373–4

CHEMISTRY

Split-mouth study of sealant retention with carbon dioxide laser versus acid etch conditioning. Walsh LJ. **Aust Dent J** 1996 Apr;41(2):124–7

A comparative study of fluoride-releasing composite resin and glass ionomer materials used as fissure sealants. Rock WP, et al. **J Dent** 1996 Jul;24(4):275–80

A comparison of six enamel treatment procedures for sealant bonding. Brown JR, et al. **Pediatr Dent** 1996 Jan–Feb; 18(1):29–31

DIAGNOSTIC USE

The effect of placing a clear pit and fissure sealant on the validity and reproducibility of occlusal caries diagnosis. Deery C, et al. **Caries Res** 1995;29(5):377–81

HISTORY

Michael Buonocore and the Eastman Dental Center: a historic perspective on sealants. Handelman SL, et al. **J Dent Res** 1996 Jan;75(1):529–34

THERAPEUTIC USE

Sealant use and dental utilization in U.S. children. Cherry-Peppers G, et al. **ASDC J Dent Child** 1995 Jul–Aug;62(4):250–5

Sealant status and factors associated with sealant presence among children in Milwaukee, WI. Gonzalez CD, et al. **ASDC J Dent Child** 1995 Sep–Oct;62(5):335–41

Fissure sealants: a 4-year clinical trial comparing an experimental glass polyalkenoate cement with a bis glycidyl methacrylate resin used as fissure sealants. Williams B, et al. **Br Dent J** 1996 Feb 10;180(3):104–8

Retention and caries preventive effects of a GIC and a resin-based fissure sealant. Arrow P, et al. **Community Dent Oral Epidemiol** 1995 Oct;23(5):282–5

A study into the prevention of fissure caries using an antimicrobial varnish. Bratthall D, et al. **Int Dent J** 1995 Aug;45(4):245–54

The influence of dft index on sealant success: a 48-month survival analysis. Bravo M, et al. **J Dent Res** 1996 Feb; 75(2):768–74

A longitudinal evaluation of fissure sealants applied in dental practices. Ismail AI, et al. **J Dent Res** 1995 Sep; 74(9):1583–90

The prevalence of dental sealants in the US population: findings from NHANES III, 1988–1991. Selwitz RH, et al. **J Dent Res** 1996 Feb;75 Spec No:652–60

Longitudinal evaluation of sealing molars with and without incipient dental caries in a public health program. Heller KE, et al. **J Public Health Dent** 1995 Summer;55(3):148–53

The use of dental sealants by Ohio dentists. Siegal MD, et al. **J Public Health Dent** 1996 Winter;56(1):12–21

Survey of pediatric dentists concerning dental sealants. Halterman CW, et al. **Pediatr Dent** 1995 Nov–Dec; 17(7):455–6

PIT VIPER VENOMS see **CROTALID VENOMS**

PITCH DISCRIMINATION

Auditory sensory ("echoic") memory dysfunction in schizophrenia. Strous RD, et al. **Am J Psychiatry** 1995 Oct; 152(10):1517–9

The Doppler illusion: the influence of dynamic intensity change on perceived pitch. Neuhoff JG, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):970–85

Spectral regularity as a factor distinct from harmonic relations in auditory grouping. Roberts B, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):604–14

Tone discrimination performance in schizophrenic patients and normal volunteers: impact of stimulus presentation levels and frequency differences. Holcomb HH, et al. **Psychiatry Res** 1995 Jun 29;57(1):75–82

Categorical perception of sound frequency by crickets. Wyttenbach RA, et al. **Science** 1996 Sep 13; 273(5281):1542–4

PHYSIOLOGY

Gaba mediated long-term depression (LTD) in the rat medial vestibular nuclei. Grassi S, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:164–9

Ontogeny of eyeblink conditioning in the rat: auditory frequency and discrimination learning effects. Andrews SJ, et al. **Dev Psychobiol** 1995 Sep;28(6):307–20

[Reaction times at auditory threshold: a comparison of normal hearing probands and patients with hearing damage] Hustert B, et al. **Laryngorhinootologie** 1996 Mar; 75(3):135–40 (Eng. Abstr.) **(Ger)**

[Diagnosis of auditory threshold with frequency-specific recording of auditory evoked potentials: personal results and methodological aspects] Schönweiler R, et al. **Laryngorhinootologie** 1995 Sep;74(9):531–8 (Eng. Abstr.) **(Ger)**

PITCH PERCEPTION

Synesthesia-like mappings of lightness, pitch, and melodic interval. Hubbard TL. **Am J Psychol** 1996 Summer; 109(2):219–38

Encoding the fundamental frequency of a complex tone in the presence of a spectrally overlapping masker. Carlyon RP. **J Acoust Soc Am** 1996 Jan;99(1):517–24

Infants' pitch perception: inharmonic tonal complexes. Clarkson MG, et al. **J Acoust Soc Am** 1995 Sep; 98(3):1372–9

On the pitches of the components of a complex tone. Hartmann WM, et al. **J Acoust Soc Am** 1996 Jan; 99(1):567–78

Electrode ranking of "place pitch" and speech recognition in electrical hearing. Nelson DA, et al. **J Acoust Soc Am** 1995 Oct;98(4):1987–99

Prominence lent by rising and falling pitch movements: Testing two models. Rump HH, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1122–31

Speech versus nonspeech in pitch memory. Semal C, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1132–40

Pitch of iterated rippled noise. Yost WA. **J Acoust Soc Am** 1996 Jul;100(1):511–8

A time domain description for the pitch strength of iterated rippled noise. Yost WA, et al. **J Acoust Soc Am** 1996 Feb; 99(2):1066–78

Separating the effects of alertness from the effects of encoding in a pitch-imagery task. Sullivan C, et al. **J Gen Psychol** 1996 Apr;123(2):105–14

Perceived pitch of whispered vowels--relationship with formant frequencies: a preliminary study. Higashikawa M, et al. **J Voice** 1996 Jun;10(2):155–8

Measures of vocal function during changes in vocal effort level. Huang DZ, et al. **J Voice** 1995 Dec;9(4):429–38

Reliability of pitch discrimination of vowel and piano tones. Liu TA, et al. **J Voice** 1995 Dec;9(4):394–402

Annoyance and discomfort during exposure to high-frequency noise from an ultrasonic washer. Holmberg K, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):819–27

Acceptable levels of tonal and broad-band repetitive and continuous sounds during the performance of nonauditory tasks. Landström U, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):803–16

PHYSIOLOGY

Intonation of musical intervals by musical intervals by deaf subjects stimulated with single bipolar cochlear implant electrodes. Pijl S, et al. **Hear Res** 1995 Sep;89(1-2):203-11

Detection of frequency modulation in the FM-bat Phyllostomus discolor. Esser KH, et al. **J Comp Physiol [A]** 1996 Jun;178(6):787-96

[Diagnosis of endolymphatic hydrops with low tone masked otoacoustic emissions] Nubel K, et al. **Laryngorhinootologie** 1995 Nov;74(11):651-6 (Eng. Abstr.) **(Ger)**

PITHECINAE see **CEBIDAE**

PITUITARY ADENOMA, PROLACTIN-SECRETING see **PROLACTINOMA**

PITUITARY-ADRENAL FUNCTION TESTS

A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Ammari F, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):473-6

A comparison of pituitary-adrenal responses to corticotropin-releasing hormone, hypoglycaemia and metyrapone in children with brain tumours and growth hormone deficiency. Fujiwara I, et al. **Eur J Pediatr** 1995 Sep;154(9):717-22

PITUITARY-ADRENAL SYSTEM

Influences of blood sampling procedures on basal hypothalamic-pituitary-adrenal hormone levels and leukocyte values in rhesus macaques (Macaca mulatta). Capitanio JP, et al. **J Med Primatol** 1996 Jan;25(1):26-33

DRUG EFFECTS

Gender difference in alcohol-evoked hypothalamic-pituitary-adrenal activity in the rat: ontogeny and role of neonatal steroids. Ogilvie KM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):255-61

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240-54 (207 ref.)

Reduction of cortisol levels after single intra-articular and intramuscular steroid injection. Lazarevic MB, et al. **Am J Med** 1995 Oct;99(4):370-3

Cortisol levels after single local steroid injection [letter] Maillefert JF, et al. **Am J Med** 1996 May;100(5):586-7

Induction of adrenal suppression by megestrol acetate [letter] Khoo SH, et al. **Ann Intern Med** 1996 Mar 15;124(6):613

Induction of adrenal suppression by megestrol acetate [letter] Loprinzi CL, et al. **Ann Intern Med** 1996 Mar 15;124(6):613

Induction of adrenal suppression by megestrol acetate [letter] Stoffer SS, et al. **Ann Intern Med** 1996 Mar 15;124(6):613-4

Down-regulation of the hypothalamo-pituitary-adrenal axis reduces brain damage and number of seizures following hypoxia/ischaemia in rats. Krugers HJ, et al. **Brain Res** 1995 Aug 28;690(1):41-7

A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man. Inder WJ, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):425-31

Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. Lanzone A, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):73-7

Effect of fenfluramine on episodic ACTH and cortisol secretion. Schürmeyer TH, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):39-45

Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Brannan MD, et al. **Clin Ther** 1995 Jul-Aug;17(4):637-47

Effects of neurokinin-A on the rat hypothalamo-pituitary-adrenal axis. Malendowicz LK, et al. **Endocr Res** 1995 Nov;21(4):757-67

Effect of androstenedione administration on the maternal hypothalamo-pituitary-adreno-placental axis in the pregnant rhesus monkey. Giussani DA, et al. **Endocrinology** 1996 Feb;137(2):608-14

Degranulation and decrease in histamine levels of thalamic mast cells coincides with corticosterone secretion induced by compound 48/80. Bugajski AJ, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S50-1

The hypothalamic-pituitary-thyroid axis in patients maintained on lithium prophylaxis for years: high triiodothyronine serum concentrations are correlated to the prophylactic efficacy. Baumgartner A, et al. **J Affect Disord** 1995 Jun 8;34(3):211-8

Effects of cocaine on pulsatile activity of hypothalamic-pituitary-adrenal axis in male rhesus monkeys: neuroendocrine and behavioral correlates. Sarnyai Z, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):225-34

kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor. Taylor CC, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):877-84

Effect of indomethacin on the CRH- and VP-induced pituitary-adrenocortical response during social stress. Bugajski J, et al. **Life Sci** 1996;58(5):PL 67-72

Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Castelo-Branco C, et al. **Metabolism** 1996 Jan;45(1):24-7

Evidence that activation of the hypothalamo-pituitary-adrenal axis by electrical stimulation of the noradrenergic A1 group is not mediated by noradrenaline. Gartside SE, et al. **Neuroendocrinology** 1995 Jul;62(1):2-12

Immunoneutralization of lipocortin 1 reverses the acute inhibitory effects of dexamethasone on the hypothalamo-pituitary-adrenocortical responses to cytokines in the rat in vitro and in vivo. Taylor AD, et al. **Neuroendocrinology** 1995 Jul;62(1):19-31

Suppression of HPA-axis activity by haloperidol after experimentally induced heat stress. Hennig J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):603-14

Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. Maes M, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):67-81

Ontogenetic studies of tolerance development: effects of chronic morphine on the hypothalamic-pituitary-adrenal axis. Little PJ, et al. **Psychopharmacology (Berl)** 1995 Nov; 122(1):78-84

Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. McIntyre HD, et al. **Thorax** 1995 Dec; 50(12):1280-4

[Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure] Trembecki J, et al. **Pol Arch Med Wewn** 1995 Aug; 94(2):144-52 (Eng. Abstr.) **(Pol)**

[The long-term depression of the function of the hypothalamo-hypophyseal-adrenocortical system in rats] Filaretova LP, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):24-31 (Eng. Abstr.) **(Rus)**

[Evaluation of the hormonal status of patients with bronchial asthma by using various drug doses] Kakhnovskiĭ IM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):16-22 (Eng. Abstr.) **(Rus)**

[The effect of adenosine on the hypothalamo-hypophyseal-adrenal system] Kononenko VIa, et al. **Fiziol Zh** 1994 Sep-Dec;40(5-6):20-3 (Eng. Abstr.) **(Ukr)**

IMMUNOLOGY

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285-98 (138 ref.)

[Changes of specific and non-specific immunological functions before and after transsphenoidal tumor excision--a case of Cushing disease] Tomizawa Y, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Jul 20;71(5):673-8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Alcohol, corticosteroids, energy utilization, and hippocampal endangerment. Eskay RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:105-14

Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Pacák K, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:115-30

Long-term effects of prenatal stress and handling on metabolic parameters: relationship to corticosterone secretion response. Vallée M, et al. **Brain Res** 1996 Mar 18;712(2):287-92

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Stokes PE. **Eur Neuropsychopharmacol** 1995;5 Suppl:77-82 (48 ref.)

Time course of the early pituitary-adrenal and metabolic responses to accidental injury. Barton RN, et al. **J Trauma** 1995 Nov;39(5):888-94

PHYSIOLOGY

The hypothalamic-pituitary-adrenocortical system and sleep in man. Friess E, et al. **Adv Neuroimmunol** 1995;5(2):111-25 (63 ref.)

Adrenocorticoid hormones and the development and expression of mammalian monogamy. Carter CS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:82-91

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491-511 (68 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730-42 (43 ref.)

Molecular aspects of the regulation of the hypothalamo-pituitary-adrenal axis during development in the rat. Grino M, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:339-51

Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system. Kvetňanský R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:131-58 (158 ref.)

Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Muglia L, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:49-59 (36 ref.)

Receptors for melanocortin peptides in the hypothalamic-pituitary-adrenal axis and skin. Tsigos C, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:352-63

The maternal hypothalamic-pituitary-adrenal axis in the third trimester of human pregnancy. Magiakou MA, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):419-28

The role of gonadal steroids in hypothalamic-pituitary-adrenal axis regulation. Young EA. **Crit Rev Neurobiol** 1995;9(4):371-81 (78 ref.)

Interactions of the endocrine and immune systems in children and young adults. Papanicolaou DA, et al. **Curr Opin Pediatr** 1995 Aug;7(4):440-4 (27 ref.)

Plasma neurotensin levels in humans: relation to hormone levels in diseases involving the hypothalamo-pituitary-thyroid axis. Schimpff RM, et al. **Eur J Endocrinol** 1995 Nov;133(5):534-8

Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):229-51 (125 ref.)

Social effects and circadian rhythms in squirrel monkey pituitary-adrenal activity. Lyons DM, et al. **Horm Behav** 1995 Jun;29(2):177-90

Differences in the hypothalamic-pituitary-adrenal axis of black and white men. Yanovski JA, et al. **Horm Res** 1995; 44(5):208-12

Alteration of the hypothalamus-pituitary-testis axis in oligozoospermic men with normal gonadotropin levels. Fujisawa M, et al. **Int J Urol** 1995 Sep;2(4):273-6

Behavioral and pituitary adrenal-axis responses of dairy cows to social isolation and deprivation of lying down. Munksgaard L, et al. **J Anim Sci** 1996 Apr;74(4):769-78

Suppression of hypothalmic-pituitary-adrenal axis responses to stress in lactating women. Altemus M, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2954-9

The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. Streeten DH, et al. **J Clin Endocrinol Metab** 1996 Jan; 81(1):285-90

Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function. Schmider J, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):250-8

Role of the hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice. Effect of stress and inhibition of endogenous glucocorticoids. Fantuzzi G, et al. **J Immunol** 1995 Oct 1;155(7):3552-5

Facilitation and feedback in the hypothalamo-pituitary-adrenal axis during food restriction in rats. García-Belenguer S, et al. **J Neuroendocrinol** 1993 Dec;5(6):663-8

Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)--neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. Schmidt ED, et al. **J Neurosci** 1995 Nov;15(11):7417-26

Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. Fecho K, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):633-45

Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577-81 (19 ref.). Comment on: J Rheumatol 1996 Apr;23(4):596-602.

Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-1 beta production in the brain without affecting the activation of the hypothalamus-pituitary-adrenal axis. Di Santo E, et al. **Neuroimmunomodulation** 1995 May-Jun;2(3):149-54

The hypothalamic-pituitary-adrenal axis in obesity. Chalew S, et al. **Obes Res** 1995 Jul;3(4):371-82 (136 ref.)

Relationship between hypothalamic-pituitary-adrenal activity and blockade of tolerance to morphine analgesia by pain: a strain comparison. Vaccarino AL, et al. **Pain** 1995 Dec;63(3):385-9

The role of pituitary-adrenal counterregulation of inflammation in cerulein-induced pancreatitis: a comparison between Fischer and Lewis rats. Abe R, et al. **Pancreas** 1996 Apr;12(3):280-5

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285-98 (138 ref.)

The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. McNaughton N, et al. **Pharmacol Biochem Behav** 1996 May;54(1):51-6

Intermittent stress in pigs: effects on behavior, pituitary-adrenocortical axis, growth, and gastric ulceration. Jensen KH, et al. **Physiol Behav** 1996 Apr-May; 59(4-5):741-8

Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481-502 (98 ref.)

PITUITARY-ADRENAL SYSTEM

Corticosterone, brain mineralocorticoid receptors (MRs) and the activity of the hypothalamic-pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis. Oitzl MS, et al. **Psychoneuroendocrinology** 1995;20(6):655-75

The effects of normal aging on cortisol and adrenocorticotropin responses to hypertonic saline infusion. Raskind MA, et al. **Psychoneuroendocrinology** 1995; 20(6):637-44

Gender differences in patterns of HPA axis response to challenge: Macarthur studies of successful aging. Seeman TE, et al. **Psychoneuroendocrinology** 1995;20(7):711-25

High self-esteem, hardiness and affective stability are associated with higher basal pituitary-adrenal hormone levels. Zorrilla EP, et al. **Psychoneuroendocrinology** 1995; 20(6):591-601

The impact of long-term hemodialysis on pituitary-adrenocortical function. Vigna L, et al. **Ren Fail** 1995 Sep;17(5):629-37

Endogenous opioids may modulate the activity of the hypothalamus-pituitary-adrenocortical axis in domestic fowl. Pierzchala-Koziec K, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):139-46

[Status of the hypophyseal-adrenal system in inhabitants of a large industrial city in Siberia] Fedina RG, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):47-54 **(Rus)**

[Effect of environmental factors and social habits on the state of the hypophyseal-adrenal system and plasma insulin in healthy people] Krivoshchekov SG, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):126-30 **(Rus)**

[Stress-induced analgesia. The role of the hormones of the hypophyseal-adrenocortical system] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):40-6 (Eng. Abstr.) **(Rus)**

[The function of the hypophyseal-adrenocortical system and the orienting-exploratory behavior of rat pups] Vataeva LA, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):83-7 **(Rus)**

[Aging and the morphofunctional changes in the hypothalamo-hypophyseal-adrenal cortical system] Bazhanova ED. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb; 31(1):92-102 (74 ref.) **(Rus)**

PHYSIOPATHOLOGY

Fetal ethanol exposure: hypothalamic-pituitary-adrenal and beta-endorphin responses to repeated stress. Weinberg J, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):122-31

Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):557-60

The use of the short tetracosactrin test for the investigation of suspected pituitary hypofunction. Wang TW, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):112-8

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419-37 (87 ref.)

Effects of the immune/inflammatory reaction on the hypothalamic-pituitary-adrenal axis. Mastorakos G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:438-48 (34 ref.)

Sensitization to stress and psychostimulants. Involvement of dopamine transmission versus the HPA axis. Prasad BM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:617-25

HPA axis function and temperament in depression: a negative report. Roy A. **Biol Psychiatry** 1996 Mar 1;39(5):364-6

Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Chowdrey HS, et al. **Br J Pharmacol** 1995 Nov; 116(5):2417-24

Hormonal control of rheumatoid inflammation. Panayi GS. **Br Med Bull** 1995 Apr;51(2):462-71 (34 ref.)

Crowding stress impairs the pituitary-adrenocortical responsiveness to the vasopressin but not corticotropin-releasing hormone stimulation. Bugajski J, et al. **Brain Res** 1995 May 29;681(1-2):223-8

The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides. Inder WJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):283-90

The impact of liver transplantation on endocrine status in men. Madersbacher S, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):461-6

Corticotropin-releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic-pituitary-adrenal response to acute local inflammation in the rat. Turnbull AV, et al. **Endocrinology** 1996 Feb;137(2):455-63

Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. Grasser A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):31-7

Adrenal function following high-dose steroids in ovarian cancer patients. Del Priore G, et al. **Gynecol Oncol** 1995 Oct;59(1):102-4

Pituitary-adrenocortical function in abdominal obesity of males: evidence for decreased 21-hydroxylase activity. Hautanen A, et al. **J Steroid Biochem Mol Biol** 1996 Apr; 58(1):123-33

Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5-6):259-63 (68 ref.)

Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Pasquali R, et al. **Metabolism** 1996 Mar; 45(3):351-6

Impaired hypothalamo-pituitary-adrenal axis function in Swiss nude athymic mice. Daneva T, et al. **Neuroendocrinology** 1995 Jul;62(1):79-86

Hypothalamic-pituitary-adrenal response to chronic stress in five inbred rat strains: differential responses are mainly located at the adrenocortical level. Gómez F, et al. **Neuroendocrinology** 1996 Apr;63(4):327-37

Intermediate glucocorticoid feedback of corticotropin secretion in patients with major depression. Kellner M, et al. **Psychiatry Res** 1995 Nov 29;59(1-2):157-60

Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer's disease. O'Brien JT, et al. **Psychol Med** 1996 Jan;26(1):7-14

Increased pituitary activation following metyrapone administration in post-traumatic stress disorder. Yehuda R, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):1-16

Serotonin, Cushing's disease, and depression [editorial] Sonino N, et al. **Psychother Psychosom** 1996 Mar-Apr; 65(2):63-5

-Effect of endogenous opioids on adrenal cortex activity in women with hypothalamic amenorrhea- Krause BT, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):194-8 (Eng. Abstr.) **(Ger)**

[Endocrinology update--I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24-32 (112 ref.) **(Ger)**

[Hypothalamic-adenohypophysial function of corticotropin releasing hormone (CRH)-ACTH system in hypoxic coma] Nishioka H, et al. **No To Shinkei** 1996 Jan;48(1):53-7 (Eng. Abstr.) **(Jpn)**

[Hypothalamic-adenohypophysial function of corticotropin releasing hormone (CRH)-ACTH system in brain death] Nishioka H, et al. **No To Shinkei** 1995 Dec;47(12):1159-63 (Eng. Abstr.) **(Jpn)**

[Stimulus of the hypophyseal-adrenocortical axis with corticotropin releasing hormone (CRH) in acquired immunodeficiency syndrome. Evidence for activation of the immune-neuroendocrine system] Lewi DS, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):109-18 (Eng. Abstr.) **(Por)**

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50-60 (80 ref.) (Eng. Abstr.) **(Rus)**

[Apitherapy in the combined treatment of patients with pulmonary tuberculosis taking into account the hypophyseal-adrenal system indices] Masterov GD. **Vrach Delo** 1995 Jan-Feb;(1-2):120-2 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[The functional status of the hypophyseal-thyroid and hypophyseal-adrenal systems in breast cancer patients taking into account their exposure to the factors of the accident at the Chernobyl Atomic Electric Power Station] Maevskaia LP. **Lik Sprava** 1995 May-Jun;(5-6):29-31 (Eng. Abstr.) **(Rus)**

PITUITARY APOPLEXY

CHEMICALLY INDUCED

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Morsi A, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):121-4

Clomiphene-induced pituitary apoplexy in a patient with acromegaly. Walker AB, et al. **Postgrad Med J** 1996 Mar; 72(845):172-3

DIAGNOSIS

MR of nonhemorrhagic postpartum pituitary apoplexy. Lavallée G, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1939-41

Pituitary apoplexy in adolescence: case report. Shah SA, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S26-7

ETIOLOGY

Ischaemic stroke leading to left hemiparesis and autohypophysectomy in a case of pituitary macroadenoma. Mukherjee S, et al. **J Assoc Physicians India** 1995 Nov; 43(11):801-2

[Stress-induced pituitary apoplexy in 2 phases] Proust F, et al. **Neurochirurgie** 1995;41(5):372-6 (Eng. Abstr.) **(Fre)**

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Hypophyseal apoplexy] Sánchez Valiente S. **Neurologia** 1995 Jun-Jul;10(6):252-3 **(Spa)**

PITUITARY DISEASES

BLOOD

A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency. Reutens AT, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1591-7

COMPLICATIONS

Isolated adrenocorticotropin deficiency as a rare cause of hypoglycaemia in children. Further studies and report of an additional case. al Jurayyan NA. **Horm Res** 1995; 44(5):238-40

Hypopituitarism associated with transient diabetes insipidus followed by an episode of painless thyroiditis in a young man. Mizokami T, et al. **Intern Med** 1996 Feb;35(2):135-41

Central hypothyroidism resulting from pituitary suppression and peripheral thyrotoxicosis in a premature infant born to a mother with Graves disease. Hashimoto H, et al. **J Pediatr** 1995 Nov;127(5):809-11

Pituitary abscess: an unusual presentation of "aseptic meningitis". Schwartz ID, et al. **J Pediatr Endocrinol Metab** 1995 Apr-Jun;8(2):141-6

[Premenopausal hyperprolactinemia revealing pseudotumoral hypophysitis (letter)] Garcin JM, et al. **Presse Med** 1995 Jul 1-8;24(24):1134 **(Fre)**

[Diabetes insipidus and panhypopituitarism in an 8-year-old girl due to probable lymphocytic hypophysitis] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Apr;44(4):402-4 (20 ref.) **(Spa)**

CONGENITAL

MRI of congenital pituitary insufficiency. Magalhães AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul-Aug; 50(4):182-4

DIAGNOSIS

Primary empty sella: differences and similarities between children and adults. Zucchini S, et al. **Acta Paediatr** 1995 Dec;84(12):1382-5

Role of magnetic resonance imaging in hypothalamic-pituitary disorders. Zucchini S, et al. **Horm Res** 1995;44 Suppl 3:8-14 (42 ref.)

Current concepts of imaging in patients with pituitary/hypothalamic dysfunction. Korogi Y, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):270-8 (36 ref.)

Unusual presentation of a pituitary abscess. Har-El G, et al. **Surg Neurol** 1996 Apr;45(4):351-3

Two cases of lymphocytic hypophysitis presenting with diabetes insipidus: a variant of lymphocytic infundibulo-neurohypophysitis. Nishioka H, et al. **Surg Neurol** 1996 Sep;46(3):285-90; discussion 290-1

Lymphocytic infundibulohypophysitis presenting in the postpartum period: case report. Van Havenbergh T, et al. **Surg Neurol** 1996 Sep;46(3):280-4

[Imaging in hypothalamo-hypophyseal diseases] Vézina JL. **Ann Endocrinol (Paris)** 1995;56(5):511-2 (5 ref.) **(Fre)**

[Lymphocytic hypophysitis: a reality] Virally-Monod ML, et al. **Presse Med** 1996 Jun 8;25(20):933-8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging and hypothalamo-hypophyseal disorders in children: morpho-functional and etiologic aspects] Zucchini S, et al. **Pediatr Med Chir** 1995 Sep-Oct; 17(5):397-401 (33 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Lymphocytic hypophysitis [letter] Cohen R, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):769

Growth hormone replacement treatment in adult patients [letter] Shalet SM. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):737

ETIOLOGY

Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. Citron JT, et al. **J Urol** 1996 Feb;155(2):529-33

[A case of pituitary abscess caused by infection of Rathke's cleft cyst] Sato M, et al. **No Shinkei Geka** 1995 Nov; 23(11):991-5 (Eng. Abstr.) **(Jpn)**

GENETICS

A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. Rutishauser J, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):192-8

METABOLISM

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805-37 (285 ref.)

PATHOLOGY

Hypophysitis in surgical and autoptical specimens. Sautner D, et al. **Acta Neuropathol (Berl)** 1995;90(6):637-44

Interstitial amyloid deposits in the pituitary gland. Morphometry, immunohistology, and correlation to diseases. Röcken C, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1055–60

Sinus histiocytosis with massive lymphadenopathy localized to the sella. Ng HK, et al. **Br J Neurosurg** 1995;9(4):551–5

Pituitary enlargement. von Werder K. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):299–303

Rathke cleft cyst: CT, MR, and pathology of 23 cases [published erratum appears in J Comput Assist Tomogr 1996 Jan–Feb;20(1):171] Naylor MF, et al. **J Comput Assist Tomogr** 1995 Nov–Dec;19(6):853–9

Thickening of the pituitary stalk: suggestive of intrasellar tuberculoma [letter; comment] Chandy MJ. **Neurosurgery** 1995 Dec;37(6):1232–3. Comment on: Neurosurgery 1995 May;36(5):1013–5; discussion 1015–6.

MRI of congenital pituitary insufficiency. Magalhães AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):182–4

The pathologic, surgical, and MR spectrum of Rathke cleft cysts. Kleinschmidt–DeMasters BK, et al. **Surg Neurol** 1995 Jul;44(1):19–26; discussion 26–7

Pituitary choristoma composed of corticotrophs and adrenocortical cells in the sella turcica. Oka H, et al. **Virchows Arch** 1996 Mar;427(6):613–7

PHYSIOPATHOLOGY

A comparison between short ACTH and insulin stress tests for assessing hypothalamo–pituitary–adrenal function. Ammari F, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):473–6

RADIOGRAPHY

Rathke cleft cyst: CT, MR, and pathology of 23 cases [published erratum appears in J Comput Assist Tomogr 1996 Jan–Feb;20(1):171] Naylor MF, et al. **J Comput Assist Tomogr** 1995 Nov–Dec;19(6):853–9

SURGERY

The pathologic, surgical, and MR spectrum of Rathke cleft cysts. Kleinschmidt–DeMasters BK, et al. **Surg Neurol** 1995 Jul;44(1):19–26; discussion 26–7

PITUITARY FUNCTION TESTS

UTILIZATION

A survey of the current methods used in the UK to assess pituitary function. Davies MJ, et al. **J R Soc Med** 1996 Mar;89(3):159P–64P

PITUITARY GLAND

consider also terms at HYPOPHYS–

see related

HYPOPHYSECTOMY

Human keratinocyte culture using porcine pituitary extract in serum–free medium. Wang HJ, et al. **Burns** 1995 Nov; 21(7):503–6

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100–2 (32 ref.). Comment on: Acta Paediatr 1995 Oct;84(10):1201–3.

ANATOMY & HISTOLOGY

Pharyngeal hypophysis. Fuller GN, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):671–2

BLOOD SUPPLY

Basic fibroblast growth factor within endothelial cells during vascularization of the anterior pituitary. Schechter J, et al. **Anat Rec** 1996 May;245(1):46–52

Growth hormone–releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone–releasing peptide–6. Fletcher TP, et al. **Domest Anim Endocrinol** 1996 May;13(3):251–8

Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)

CHEMISTRY

Immunohistochemical demonstration of tenascin in human pituitary glands and adenomas. Ikeda H, et al. **Acta Histochem** 1995 Jul;97(3):273–80

Preparative and analytical capillary zone electrophoresis analysis of native endorphins and enkephalins extracted from the bovine pituitary: mass spectrometric confirmation of the molecular mass of leucine enkephalin. Lee HG, et al. **Anal Biochem** 1995 Aug 10;229(2):188–97

Calcium oxalate crystals in human pathology. Molecular analysis with the laser Raman microprobe. Pestaner JP, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):537–40

Interstitial amyloid deposits in the pituitary gland. Morphometry, immunohistology, and correlation to diseases. Röcken C, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1055–60

Identification of two prolactin cDNA sequences from a goldfish pituitary cDNA library. Chan YH, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):8–12

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)

Acute effect of thyroxine on pituitary neuromedin B content of hypothyroid rats and its correlation with TSH secretion. Ortiga–Carvalho TM, et al. **Braz J Med Biol Res** 1995 Jun;28(6):715–9

Angiotensin II–binding sites in chicken brain and pituitary: autoradiographic localization. Natke C, et al. **Cell Tissue Res** 1996 Feb;283(2):297–303

Isolation and characterization of human pituitary chorionic gonadotropin. Birken S, et al. **Endocrinology** 1996 Apr; 137(4):1402–11

Molecular cloning and functional characterization of a rat pituitary G protein–coupled adenosine triphosphate (ATP) receptor. Chen ZP, et al. **Endocrinology** 1996 May; 137(5):1833–40

Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Day R, et al. **Endocrinology** 1995 Nov;136(11):5232–5

Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. O'Carroll AM, et al. **Endocrinology** 1995 Nov;136(11):5224–7

The appearance of proopiomelanocortin early in vertebrate evolution: cloning and sequencing of POMC from a Lamprey pituitary cDNA library. Heinig JA, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):137–44

Isolation and characterization of melanotropins from lamprey pituitary glands. Takahashi A, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):197–204

Levels of pro–opiomelanocortin and prolactin mRNA in the fetal sheep pituitary following hypoxaemia and glucocorticoid treatment in late gestation. Matthews SG, et al. **J Endocrinol** 1995 Oct;147(1):139–46

Molecular forms of GnRH in three model fishes: rockfish, medaka and zebrafish. Powell JF, et al. **J Endocrinol** 1996 Jul;150(1):17–23

Heterogeneity of human luteinizing hormone in pituitary tumor homogenates and cell incubates. van Ginkel LA, et al. **J Endocrinol Invest** 1995 Apr;18(4):258–64

Effects of intracerebroventricular administration of 6–hydroxydopamine on ouabain–like immunoreactivity in plasma and the hypothalamo–pituitary axis in rats. Komiyama Y, et al. **J Hypertens** 1996 Apr;14(4):447–52

Bovine pituitary membrane glycoproteins contain beta–N–acetylgalactosaminylated N–linked sugar chains. Taka J, et al. **J Neurochem** 1996 Feb;66(2):852–9

Relationship between the number of immunostaining gonadotropes and the plasma concentrations of gonadotrophins in ewes with and without the FecBB gene. Heath DA, et al. **J Reprod Fertil** 1996 Jan;106(1):73–8

Melatonin–binding sites in the gonadotroph–enriched zona tuberalis of ewes. Skinner DC, et al. **J Reprod Fertil** 1995 Jul;104(2):243–50

Splicing variants of the human growth hormone mRNA: detection in pituitary, mononuclear cells and dermal fibroblasts. Palmetshofer A, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):225–34

Size and charge heterogeneity of pituitary and plasma prolactin in the male rat. Briski KP, et al. **Neuroendocrinology** 1996 May;63(5):437–45

Immunocytochemical localization of basic fibroblast growth factor in the human pituitary gland. Marin F, et al. **Neuroendocrinology** 1995 Nov;62(5):523–9

ELISA measurements of vasotocin and isotocin in plasma and pituitary of the rainbow trout: effect of salinity. Pierson PM, et al. **Peptides** 1995;16(5):859–65

Characterization and distribution of bombesin binding sites in the goldfish hypothalamic feeding center and pituitary. Himick BA, et al. **Regul Pept** 1995 Dec 14;60(2–3):167–76

CYTOLOGY

Direct projection from the suprachiasmatic nucleus to hypophysiotrophic corticotropin–releasing factor immunoreactive cells in the paraventricular nucleus of the hypothalamus demonstrated by means of Phaseolus vulgaris–leucoagglutinin tract tracing. Vrang N, et al. **Brain Res** 1995 Jun 26;684(1):61–9

Immunohistochemical identification and morphometric study of ACTH cells of mink (Mustela vison) during growth and different stages of sexual activity in the adult. Vidal S, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):18–26

Tissue culture of dwarf embryonic pituitary glands [letter] Wilson DB, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):741–3

Immunocytochemical distribution of catecholamine–synthesizing neurons in the hypothalamus and pituitary gland of pigs: tyrosine hydroxylase and dopamine–beta–hydroxylase. Leshin LS, et al. **J Comp Neurol** 1996 Jan 1;364(1):151–68

Effects of TRH, prolactin and TSH on cell proliferation in the intermediate lobe of the rat pituitary gland. Pawelczyk T, et al. **J Endocrinol** 1996 Feb;148(2):193–6

Localization of GnRH molecular forms in the brain, pituitary, and testis of the frog, Rana esculenta. Di Matteo L, et al. **J Exp Zool** 1996 Jan 1;274(1):33–40

Mapping of corticotropic cells in the normal human pituitary. Trouillas J, et al. **J Histochem Cytochem** 1996 May; 44(5):473–9

Immunohistochemical studies on the development of TSH cells in the pituitary of Xenopus laevis larvae. Ogawa K, et al. **J Vet Med Sci** 1995 Jun;57(3):539–42

Electroporation of rat pituitary cells. Paulssen RH, et al. **Methods Mol Biol** 1995;48:123–31

Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L–type Ca2+ current in the pituitary cell line AtT–20. Tallent M, et al. **Neuroscience** 1996 Apr; 71(4):1073–81

Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Sheng HZ, et al. **Science** 1996 May 17; 272(5264):1004–7

Depression of the somatotropic cells in the bovine pituitary gland due to application of recombinant bovine somatotropin––an immunohistochemical and morphometric study. Schmidt P, et al. **Zentralbl Veterinarmed A** 1996 Jun; 43(4):233–41

DRUG EFFECTS

Development of pituitary lesions in ND4 Swiss Webster mice when estimating the sensory irritancy of airborne chemicals using ASTM method E981–84. Werley MS, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):712–6

The effect of unkei–to on pituitary gonadotropin secretion and ovulation in anovulatory cycles of young women. Ushiroyama T, et al. **Am J Chin Med** 1995;23(3–4):223–30

Effects of photoperiod and androgen on pituitary function and neuropeptide staining in Siberian hamsters. Bittman EL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R64–72

Maitotoxin–elevated cytosolic free calcium in GH4C1 rat pituitary cells nimodipine–sensitive and –insensitive mechanisms. Xi D, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):759–69

Activation of the baboon fetal pituitary–adrenocortical axis at midgestation by estrogen: responsivity of the fetal adrenal gland to adrenocorticotropic hormone in vitro. Berghorn KA, et al. **Biol Reprod** 1995 Nov;53(5):996–1002

Effects of indirect selection for pituitary responsiveness to gonadotropin–releasing hormone on the storage and release of luteinizing hormone and follicle–stimulating hormone in prepubertal male lambs. Evans NP, et al. **Biol Reprod** 1995 Aug;53(2):237–43

Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1–27) in guinea–pigs in vivo. Lindén A, et al. **Br J Pharmacol** 1995 Jul;115(6):913–6

Corticotropin–releasing factor treatment upregulates interleukin–1 receptors in the mouse pituitary: reversal by dexamethasone. Takao T, et al. **Brain Res** 1995 Aug 7; 688(1–2):219–22

Acute effect of thyroxine on pituitary neuromedin B content of hypothyroid rats and its correlation with TSH secretion. Ortiga–Carvalho TM, et al. **Braz J Med Biol Res** 1995 Jun;28(6):715–9

The GnRH challenge test: a quantitative measure of pituitary desensitization during GnRH agonist administration. Scheele F, et al. **Clin Endocrinol (Oxf)** 1996 May; 44(5):581–6

Desensitization of gonadotropin–releasing hormone action in the gonadotrope–derived alpha T3–1 cell line. McArdle CA, et al. **Endocrinology** 1995 Nov;136(11):4864–71

Sphingosine derivatives inhibit depolarization–evoked calcium entry in rat GH4C1 cells. Törnquist K, et al. **Endocrinology** 1995 Nov;136(11):4894–902

Protein kinase–C mediates chicken vasoactive intestinal peptide stimulated prolactin secretion and gene expression in turkey primary pituitary cells. Sun S, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):289–97

Effect of corticotropin–releasing factor on the pituitary–ovary axis in human luteal phase. Apa R, et al. **Gynecol Endocrinol** 1995 Dec;9(4):271–6

Short term pituitary desensitization: effects of different doses of the gonadotrophin–releasing hormone agonist triptorelin. Broekmans FJ, et al. **Hum Reprod** 1996 Jan; 11(1):55–60

Pharmacokinetics of two human menopausal gonadotrophin preparations after single intravenous administration during pituitary suppression. Duijkers IJ, et al. **Hum Reprod** 1995 Jun;10(6):1367–72

Dietary sodium intake modulates pituitary proopiomelanocortin mRNA abundance. Mayan H, et al. **Hypertension** 1996 Aug;28(2):244–9

Effects of a long acting somatostatin analog on pituitary, adrenal, and testicular function during rest and acute exercise: unexpected stimulation of testosterone secretion. Vasankari T, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3298–303

Inverse control of growth hormone and prolactin secretion in clonidine–stimulated dairy cattle. Borromeo V, et al. **J Endocrinol** 1995 Aug;146(2):271–7

Mechanisms of altered LH secretion in neonatally oestrogenized male rats. Pinilla L, et al. **J Endocrinol** 1995 Oct;147(1):43–50

Nicotine acts directly on pituitary GH3 cells to inhibit prolactin promoter activity. Coleman DT, et al. **J Neuroendocrinol** 1995 Oct;7(10):785–9

Mechanism of action of pituitary adenylate cyclase-activating polypeptide (PACAP) in human nonfunctioning pituitary tumors. Lania A, et al. **J Neuroendocrinol** 1995 Sep;7(9):695-702

Novel aspects of GnRH-induced intracellular signaling and secretion in pituitary gonadotrophs. Stojilkovic SS, et al. **J Neuroendocrinol** 1995 Oct;7(10):739-57 (110 ref.)

Selective inhibition of high voltage-activated L-type and Q-type Ca2+ currents by serotonin in rat melanotrophs. Ciranna L, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):595-609

Vasoactive intestinal peptide increases the liberation of arachidonate from anterior pituitary cells in vitro. Judd AM. **Life Sci** 1995;57(18):1641-6

CCK-B receptor-mediated stimulation of polyphosphoinositide turnover in GH3 pituitary cells in response to cholecystokinin and pentagastrin. Smith AJ, et al. **Life Sci** 1996;58(11):883-95

Differential desensitization response of the neonatal and adult rat somatotroph to growth hormone-releasing hormone and phorbol ester. Collins BJ, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):75-81

Functional properties of a mutant T3 receptor beta (R338W) identified in a subject with pituitary resistance to thyroid hormone. Sasaki S, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):109-17

Ethanol increases the activity of large conductance, Ca(2+)-activated K+ channels in isolated neurohypophysial terminals. Dopico AM, et al. **Mol Pharmacol** 1996 Jan;49(1):40-8

Maitotoxin increases voltage independent chloride and sodium currents in GH4C1 rat pituitary cells. Young RC, et al. **Nat Toxins** 1995;3(6):419-27

Age-related changes in brain and pituitary 5 alpha-reductase with finasteride (Proscar) treatment. Lephart ED. **Neurobiol Aging** 1995 Jul-Aug;16(4):647-50

In vitro morphometric and proliferative variations in VIP-immunoreactive pituitary cells induced by estradiol. Carretero J, et al. **Neuroendocrinology** 1995 Sep; 62(3):277-82

A transient effect of estrogen on calcium currents and electrophysiological responses to gonadotropin-releasing hormone in ovine gonadotropes. Heyward PM, et al. **Neuroendocrinology** 1995 Dec;62(6):543-52

Effects of perinatal administration of haloperidol on GH pituitary contents and serum levels during the first postnatal month. Iñiguez C, et al. **Neuroendocrinology** 1995 Sep; 62(3):308-12

Effect of histamine on gene expression and release of proopiomelanocortin-derived peptides from the anterior and intermediate pituitary lobes in conscious male rats. Knigge U, et al. **Neuroendocrinology** 1995 Oct;62(4):319-25

Melatonin inhibits oxytocin and vasopressin release from the neurointermediate lobe of the hamster pituitary. Juszczak M, et al. **Neuroreport** 1995 Dec 15;6(18):2453-6

Monosodium glutamate increases NGF and NPY concentrations in rat hypothalamus and pituitary. Tirassa P, et al. **Neuroreport** 1995 Dec 15;6(18):2450-2

Activation of the thyrotropin-releasing hormone (TRH) receptor by a direct precursor of TRH, TRH-Gly. Yamada M, et al. **Neurosci Lett** 1995 Aug 18;196(1-2):109-12

The effect of haloperidol on met-enkephalin, beta-endorphin, cholecystokinin and substance P in the pituitary, the hypothalamus and the striatum of rats during aging. Lau SM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Nov;19(7):1163-75

Acute and short-term actions of serotonin administration on the pituitary-testicular axis in the adult rat. Hedger MP, et al. **Reprod Fertil Dev** 1995;7(5):1101-9

Endocrine effects of granulocyte colony-stimulating factor in cancer patients. Rovelli F, et al. **Tumori** 1995 Nov-Dec; 81(6):438-9

EMBRYOLOGY

Thyrotropin-releasing hormone: does two hundred micrograms provide effective stimulation to the preterm fetal pituitary gland compared with four hundred micrograms? Crowther C, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):719-23

Activation of the baboon fetal pituitary-adrenocortical axis at midgestation by estrogen: responsivity of the fetal adrenal gland to adrenocorticotropic hormone in vitro. Berghorn KA, et al. **Biol Reprod** 1995 Nov;53(5):996-1002

The Ames dwarf gene is required for Pit-1 gene activation. Andersen B, et al. **Dev Biol** 1995 Dec;172(2):495-503

Ontogeny of basal and regulated proopiomelanocortin-derived peptide secretion from fetal and neonatal pituitary intermediate lobe cells: melanotrophs exhibit transient glucocorticoid responses during development. Lugo DI, et al. **Dev Biol** 1996 Jan 10; 173(1):110-8

Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. Shinoda K, et al. **Dev Dyn** 1995 Sep;204(1):22-9

Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep. Young IR, et al. **Endocrinology** 1996 Jun;137(6):2424-31

The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Kimura S, et al. **Genes Dev** 1996 Jan 1;10(1):60-9

Human fetal pituitary gland in holoprosencephaly and anencephaly. Kjaer I, et al. **J Craniofac Genet Dev Biol** 1995 Oct-Dec;15(4):222-9

Response of prolactin to different photoperiods after surgical disconnection of the hypothalamus and pituitary in sheep fetuses. Houghton DC, et al. **J Reprod Fertil** 1995 Jul; 104(2):199-206

The ontogeny of pit-1 expression in the human fetal pituitary gland. Puy LA, et al. **Neuroendocrinology** 1996 Apr; 63(4):349-55

Molecular aspects of the ontogeny of the pituitary-gonadal axis. Huhtaniemi I. **Reprod Fertil Dev** 1995;7(5):1025-35 (57 ref.)

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509-16 (52 ref.)

[Morphology of an additional (pharyngeal) adenohypophysis and its interrelationship with pharyngeal tonsils in the human fetus] Khlystova ZS, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):211-4 **(Rus)**

ENZYMOLOGY

Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule. Galanopoulou AS, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):111-8

Arachidonic acid and lipoxygenase products stimulate protein kinase C beta mRNA levels in pituitary alpha T3-1 cell line: role in gonadotropin-releasing hormone action. Shraga-Levine Z, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):667-70

Heterogeneity of rat type I 5 alpha-reductase cDNA: cloning, expression and regulation by pituitary implants and dihydrotestosterone. Lopez-Solache I, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):139-44

The role of the calpain-calpastatin system in thyrotropin-releasing hormone-induced selective down-regulation of a protein kinase C isozyme, nPKC epsilon, in rat pituitary GH4C1 cells. Eto A, et al. **J Biol Chem** 1995 Oct 20;270(42):25115-20

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Figueiredo-Pereira ME, et al. **J Biol Chem** 1996 Jul 12;271(28):16455-9

Purification and characterization of carboxypeptidase D, a novel carboxypeptidase E-like enzyme, from bovine pituitary. Song L, et al. **J Biol Chem** 1995 Oct 20; 270(42):25007-13

Carbonic anhydrase isoenzyme II is located in corticotrophs of the human pituitary gland. Parkkila AK, et al. **J Histochem Cytochem** 1996 Mar;44(3):245-50

Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. Böckers TM, et al. **J Neuroendocrinol** 1995 Jun;7(6):445-53

Effects of lipopolysaccharide and glucocorticoids on expression of interleukin-1 beta converting enzyme in the pituitary and brain of mice. Layé S, et al. **J Neuroimmunol** 1996 Aug;68(1-2):61-6

Age-related increase in peptidylarginine deiminase in the male rat pituitary. Akiyama K, et al. **Mech Ageing Dev** 1995 Jul 14;81(2-3):119-29

[Activity of soluble and membrane-bound forms of carboxypeptidase H in regions of the rat brain in emotional stress] Vernigora AN, et al. **Ukr Biokhim Zh** 1995 Jan-Feb; 67(1):52-6 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Normal MR appearance of the pituitary gland in the first 2 years of life. Dietrich RB, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1413-9

Neuropeptide Y: localization in the brain and pituitary of the developing frog (Rana esculenta). D'Aniello B, et al. **Cell Tissue Res** 1996 Aug;285(2):253-9

Melanotrope dopamine D2 receptor isoform expression in the developing rat pituitary. Chronwall BM, et al. **Int J Dev Neurosci** 1996 Apr;14(2):77-86

Immunohistochemical studies on the development of TSH cells in the pituitary of Xenopus laevis larvae. Ogawa K, et al. **J Vet Med Sci** 1995 Jun;57(3):539-42

INJURIES

Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. Pombo M, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3180-4

INNERVATION

Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. Nikitin AYu, et al. **Genes Dev** 1996 Aug 1;10(15):1870-9

METABOLISM

Toxin of the marine alga Prymnesium patelliferum enhances voltage dependent Ca(2+)-currents, elevates the cytosolic Ca(2+)-concentration and facilitates hormone release in clonal rat pituitary cells. Kolderup J, et al. **Acta Physiol Scand** 1995 Jul;154(3):321-7

Ca2+ uptake in GH3 cells during hypotonic swelling: the sensory role of stretch-activated ion channels. Chen Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1790-8

Characterization of cholecystokinin binding sites in goldfish brain and pituitary. Himick BA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R137-43

Modulatory actions of corticotropin-releasing factor-binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81-95 (55 ref.)

Isolation and characterization of two distinct growth hormone cDNAs from the goldfish, Carassius auratus. Law MS, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):19-23

Expression of human Pit-1 product in the human pituitary and pituitary adenomas. Immunohistochemical studies using an antibody against synthetic human Pit-1 product. Sanno N, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):73-7

Regulation of pituitary growth hormone-releasing factor (GRF) receptor gene expression by GRF. Miki N, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):586-90

Identification and localization of gene expression of a low M(r) GTP-binding protein, ram p25 in pituitary gland. Nagata K, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1223-30

Sexually dimorphic expression of pituitary growth hormone-releasing factor receptor in the rat. Ono M, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1060-6

Translocon-associated protein TRAP delta and a novel TRAP-like protein are coordinately expressed with pro-opiomelanocortin in Xenopus intermediate pituitary. Holthuis JC, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):205-13

DNA elements with AT-rich core sequences direct pituitary cell-specific expression of the pro-opiomelanocortin gene in transgenic mice. Liu B, et al. **Biochem J** 1995 Dec 15; 312 (Pt 3):827-32

Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis. Guo W, et al. **Biochem Mol Med** 1995 Oct;56(1):8-13

Maitotoxin-elevated cytosolic free calcium in GH4C1 rat pituitary cells nimodipine-sensitive and -insensitive mechanisms. Xi D, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):759-69

Cloning and expression of a myc family member from the pituitary gland of the Rainbow trout, Oncorhynchus mykiss. Panno JP, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):7-11

Effects of indirect selection for pituitary responsiveness to gonadotropin-releasing hormone on the storage and release of luteinizing hormone and follicle-stimulating hormone in prepubertal male lambs. Evans NP, et al. **Biol Reprod** 1995 Aug;53(2):237-43

Pituitary contents of beta-endorphin, dynorphin, substance P, cholecystokinin and somatostatin in rats with streptozotocin-induced diabetes. Tang F, et al. **Biol Signals** 1996 Jan-Feb;5(1):44-50

Endocrine interaction between zinc and prolactin. An interpretative review. Brandão-Neto J, et al. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):139-49 (57 ref.)

Expression of platelet-derived growth factor B-chain in the mature rat brain and pituitary gland. Sasahara M, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):63-74

Spatial and temporal aspects of Ca2+ oscillations in Xenopus laevis melanotrope cells. Scheenen WJ, et al. **Cell Calcium** 1996 Mar;19(3):219-27

Presence of interleukin-10 transcripts in human pituitary and hypothalamus. Rady PL, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):289-96

Neuropeptide Y: localization in the brain and pituitary of the developing frog (Rana esculenta). D'Aniello B, et al. **Cell Tissue Res** 1996 Aug;285(2):253-9

Regulation of somatostatin receptor mRNA expression. Berelowitz M, et al. **Ciba Found Symp** 1995;190:111-22; discussion 122-6

Somatostatin modulates voltage-dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant. Kleuss C. **Ciba Found Symp** 1995;190:171-82; discussion 182-6 (38 ref.)

Hypergastrinaemia in Cushing's syndrome: pituitary origin or glucocorticoid-induced? López-Guzmán A, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):335-9

Corticotropin-releasing factor (CRF) receptors in infant rhesus monkey brain and pituitary gland: biochemical characterization and autoradiographic localization. Grigoriadis DE, et al. **Dev Neurosci** 1995;17(5-6):357-67

GABAergic inhibition of the pituitary release of adrenocorticotropin and alpha-melanotropin is impaired in dogs with hepatic encephalopathy. Rothuizen J, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):59-68

Interaction of cyclic AMP- and calcium-dependent mechanisms in the regulation of growth hormone-releasing hormone-stimulated growth hormone release from ovine pituitary cells. Sartin JL, et al. **Domest Anim Endocrinol** 1996 May;13(3):229-38

Effect of GnRH antagonists on phorbol ester-induced LH release from rat pituitary gonadotrophs. Saito S, et al. **Endocr J** 1994 Aug;41(4):415-9

Regulation and function of the fetal adrenal gland in sheep. Wintour EM, et al. **Endocr Res** 1995 Feb-May;21(1-2):81-9

A PCR-derived, non-isotopic labeled prolactin cRNA probe

suitable for in situ hybridization. Wu H, et al. **Endocr Res** 1995 Nov;21(4):793–802

Gonadotropin–releasing hormone–induced desensitization may account for the decrease in pituitary responsiveness after the preovulatory luteinizing hormone surge. Cassina MP, et al. **Endocrinology** 1996 Mar;137(3):1057–62

Effects of extracellular nucleotides in the pituitary: adenosine triphosphate receptor–mediated intracellular responses in gonadotrope–derived alpha T3–1 cells. Chen ZP, et al. **Endocrinology** 1996 Jan;137(1):248–56

Pituitary activin receptor subtypes and follistatin gene expression in female rats: differential regulation by activin and follistatin. Dalkin AC, et al. **Endocrinology** 1996 Feb; 137(2):548–54

Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH–releasing hormone in the rat. Murao K, et al. **Endocrinology** 1996 Mar;137(3):1118–22

Retinoic acid induces expression of the transcription factor GHF–1/Pit–1 in pituitary prolactin– and growth hormone–producing cell lines. Sánchez–Pacheco A, et al. **Endocrinology** 1995 Dec;136(12):5391–8

Sphingosine derivatives inhibit depolarization–evoked calcium entry in rat GH4C1 cells. Törnquist K, et al. **Endocrinology** 1995 Nov;136(11):4894–902

Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin–inducible neuro–endocrine interface. Wang Z, et al. **Endocrinology** 1996 Jul;137(7):2947–53

Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Xu Y, et al. **Endocrinology** 1995 Nov; 136(11):5070–5

Dissociation of the complex between the neuroendocrine chaperone 7B2 and prohormone convertase PC2 is not associated with proPC2 maturation. Braks JA, et al. **Eur J Biochem** 1996 Jun 1;238(2):505–10

Progesterone together with estradiol promotes luteinizing hormone beta–subunit mRNA stability in rat pituitary cells cultured in vitro. Park D, et al. **Eur J Endocrinol** 1996 Feb;134(2):236–42

Dihydropyridine–like effects of amiodarone and desethylamiodarone on thyrotropin secretion and intracellular calcium concentration in rat pituitary. Roussel JP, et al. **Eur J Endocrinol** 1995 Oct;133(4):489–98

Expression and characterization of the substance P (NK1) receptor in the rat pituitary and AtT20 mouse pituitary tumor cells. Winkler A, et al. **Eur J Pharmacol** 1995 Sep 15;291(1):51–5

The brain histamine (HA) and pituitary luteinizing hormone (LH) levels in female rats anesthetized with ether on proestrus. Kim CY, et al. **Exp Anim** 1996 Apr;45(2):175–7

Immunoreactive human chorionic gonadotropin beta core fragment in human pituitary. Hoermann R, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):324–31

A rainbow trout SRY–type gene expressed in pituitary glands. Ito M, et al. **FEBS Lett** 1995 Dec 11;377(1):37–40

Cloning of a melatonin–related receptor from human pituitary. Reppert SM, et al. **FEBS Lett** 1996 May 20; 386(2–3):219–24

Identification of POMC processing products in single melanotrope cells by matrix–assisted laser desorption/ionization mass spectrometry. van Strien FJ, et al. **FEBS Lett** 1996 Jan 29;379(2):165–70

Calcium store depletion potentiates a phosphodiesterase inhibitor– and dibutyryl cGMP–evoked calcium influx in rat pituitary GH3 cells. Willmott NJ, et al. **FEBS Lett** 1996 May 13;386(1):39–42

Somatotropin release–inhibiting factor and galanin innervation in the hypothalamus and pituitary of seabream (Sparus aurata). Power DM, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):264–74

Elevations of somatolactin in plasma and pituitaries and increased alpha–MSH cell activity in red drum exposed to black background and decreased illumination. Zhu Y, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):21–31

Changes in the ultrastructural distribution of prolactin and growth hormone mRNAs in pituitary cells of female rats after estrogen and bromocriptine treatment, studied using in situ hybridization with biotinylated oligonucleotide probes. Matsuno A, et al. **Histochem Cell Biol** 1995 Jul; 104(1):37–45

Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol–treated ovariectomized rats. Spritzer PM, et al. **Horm Metab Res** 1996 Apr;28(4):171–6

Melanotrope dopamine D2 receptor isoform expression in the developing rat pituitary. Chronwall BM, et al. **Int J Dev Neurosci** 1996 Apr;14(2):77–86

Glial–like cells of the rat pituitary intermediate lobe change morphology and shift from vimentin to GFAP expression during development. Gary KA, et al. **Int J Dev Neurosci** 1995 Oct;13(6):555–65

Transient expression of S–100 by melanotropes of the rat pituitary intermediate lobe during development. Sands SA, et al. **Int J Dev Neurosci** 1995 Oct;13(6):567–76

Prosomatostatin processing in permeabilized cells. Calcium is required for prohormone cleavage but not formation of nascent secretory vesicles. Austin CD, et al. **J Biol Chem** 1996 Jan 12;271(2):1194–9

A protease processing site is essential for prorenin sorting to the regulated secretory pathway. Brechler V, et al. **J Biol Chem** 1996 Aug 23;271(34):20636–40

The c–Jun delta–domain inhibits neuroendocrine promoter activity in a DNA sequence– and pituitary–specific manner. Farrow KN, et al. **J Biol Chem** 1996 Jul 19; 271(29):17139–46

Activin increases phosphorylation and decreases stability of the transcription factor Pit–1 in MtTW15 somatotrope cells. Gaddy–Kurten D, et al. **J Biol Chem** 1995 Dec 1; 270(48):28733–9

Different composite regulatory elements direct expression of the human alpha subunit gene to pituitary and placenta. Heckert LL, et al. **J Biol Chem** 1995 Nov 3; 270(44):26497–504

Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. Holthuis JCM, et al. **J Biol Chem** 1996 Jul 26;271(30):17755–60

A novel family of Cys–Cys, His–Cys zinc finger transcription factors expressed in developing nervous system and pituitary gland. Jiang Y, et al. **J Biol Chem** 1996 May 3; 271(18):10723–30

Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. Pisegna JR, et al. **J Biol Chem** 1996 Jul 19;271(29):17267–74

CCAAT/enhancer–binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GHFT1–5 cells. Schaufele F. **J Biol Chem** 1996 Aug 30; 271(35):21484–9

Expression of purinergic receptor channels and their role in calcium signaling and hormone release in pituitary gonadotrophs. Integration of P2 channels in plasma membrane– and endoplasmic reticulum–derived calcium oscillations. Tomić M, et al. **J Biol Chem** 1996 Aug 30; 271(35):21200–8

Gonadotropin–releasing hormone messenger RNA expression in gonadotroph tumors and normal human pituitary. Miller GM, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):80–3

Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. Eskeland NL, et al. **J Clin Invest** 1996 Jul 1;98(1):148–56

Characterization of the hypothalamo–pituitary–IGF–I axis in rats made obese by overfeeding. Cattaneo L, et al. **J Endocrinol** 1996 Feb;148(2):347–53

A possible role for D8/PSF–A–like sequences in lactotroph versus somatotroph expression of the human prolactin gene. Leite V, et al. **J Endocrinol** 1996 Jun;149(3):473–83

Ca2+ entry in gonadotrophs and alpha T3–1 cells: does store–dependent Ca2+ influx mediate gonadotrophin–releasing hormone action? McArdle CA, et al. **J Endocrinol** 1996 Apr;149(1):155–69

Pituitary and plasma levels of growth hormone in Booroola sheep that are either homozygous carriers or non–carriers of the FecBB fecundity gene. Moore LG, et al. **J Endocrinol** 1995 Nov;147(2):217–23

Median charge of gonadotrophin isoforms in the pituitary gland and in the circulation of sheep fetuses from mid– to late gestation. Phillips DJ, et al. **J Endocrinol** 1996 Apr; 149(1):29–39

Neural expression of the pituitary GH gene. Render CL, et al. **J Endocrinol** 1995 Dec;147(3):413–22

Effects of pituitary adenylate cyclase–activating polypeptide and vasoactive intestinal polypeptide on cyclic AMP accumulation in sheep pituitary cells in vitro. Sawangjaroen K, et al. **J Endocrinol** 1996 Mar;148(3):545–52

Differential acetylation of pro–opiomelanocortin–derived peptides in the pituitary gland of Xenopus laevis in relation to background adaptation. van Strien FJ, et al. **J Endocrinol** 1995 Jul;146(1):159–67

Bioactivity and immunoreactivity of rat pituitary prolactin submitted to various extraction procedures. Prada MI, et al. **J Endocrinol Invest** 1995 May;18(5):341–5

Differential distribution of S–100 protein and vimentin in the hypophyseal pars tuberalis of the guinea pig. Kameda Y. **J Histochem Cytochem** 1996 May;44(5):501–10

Ultrastructural immunogold localization of vimentin and S–100 protein in guinea pig pars tuberalis. Kameda Y. **J Histochem Cytochem** 1996 May;44(5):511–8

An inactivating inward–rectifying K current present in prolactin cells from the pituitary of lactating rats. Corrette BJ, et al. **J Membr Biol** 1996 Mar;150(2):185–95

Cloning and analysis of the cDNA for the common alpha–subunit of the donkey pituitary glycoprotein hormones. Chopineau M, et al. **J Mol Endocrinol** 1996 Feb; 16(1):9–13

Cloning of rabbit prolactin cDNA and prolactin gene expression in the rabbit mammary gland. Gabou L, et al. **J Mol Endocrinol** 1996 Feb;16(1):27–37

Transcriptional down–regulation by epidermal growth factor of TRH receptor mRNA in rat pituitary cells. Monden T, et al. **J Mol Endocrinol** 1995 Aug;15(1):73–9

Molecular cloning and characterization of the yellowtail GH gene and its promoter: a consensus sequence for teleost and avian Pit–1/GHF–1 binding sites. Ohkubo T, et al. **J Mol Endocrinol** 1996 Feb;16(1):63–72

Effects of morphine and naloxone on prolactin and growth hormone gene expression in the male rat pituitary gland. Dobado–Berrios PM, et al. **J Neuroendocrinol** 1993 Oct; 5(5):553–6

Effects of dehydroepiandrosterone (DHEA) on pituitary prolactin and arcuate nucleus neuron tyrosine hydroxylase mRNA levels in the rat. Garcia de Yebenes E, et al. **J Neuroendocrinol** 1995 Aug;7(8):589–95

Antidopaminergic–induced hypothalamic LHRH release and pituitary gonadotrophin secretion in 12 day–old female and male rats. Lacau–Mengido IM, et al. **J Neuroendocrinol** 1993 Dec;5(6):705–9

Melatonin receptors couple through a cholera toxin–sensitive mechanism to inhibit cyclic AMP in the ovine pituitary. Morgan PJ, et al. **J Neuroendocrinol** 1995 May;7(5):361–9

Sex–steroid control of galanin in the rat hypothalamic–pituitary axis. Selvais PL, et al. **J Neuroendocrinol** 1995 May;7(5):401–7

Multiple tyrosine hydroxylase transcripts and immunoreactive forms in the rat: differential expression in the anterior pituitary and adrenal gland. Schussler N, et al. **J Neurosci Res** 1995 Dec 15;42(6):846–54

Ca2+ current expression in pituitary melanotrophs of neonatal rats and its regulation by D2 dopamine receptors. Gomora JC, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):763–73

Distribution and characterization of the melatonin receptors in the hypothalamus and pituitary gland of three domestic ungulates. Nonno R, et al. **J Pineal Res** 1995 May; 18(4):207–16

Melatonin receptors in the rat brain and pituitary. Williams LM, et al. **J Pineal Res** 1995 Nov;19(4):173–7

Fetal antigen 1 and growth hormone in pituitary somatotroph cells [letter] Larsen JB, et al. **Lancet** 1996 Jan 20; 347(8995):191

Inhibition of alpha–MSH secretion is associated with increased cyclic–AMP egress from the neurointermediate lobe of Xenopus laevis. Leenders HJ, et al. **Life Sci** 1995 Nov 17;57(26):2447–53

Stress–induced upregulation of pituitary interleukin–1 receptors is mediated by corticotropin releasing factor. Takao T, et al. **Life Sci** 1996;59(11):PL165–8

The human growth hormone gene is regulated by a multicomponent locus control region. Jones BK, et al. **Mol Cell Biol** 1995 Dec;15(12):7010–21

The D2 receptor: blocked transcription in GH3 cells and cellular pathways employed by D2A to regulate prolactin promoter activity. Fischberg DJ, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):129–37

Influence of Hepes– and CO2/HCO(3–)–buffer on Ca2+ transients induced by TRH and elevated K+ in rat pituitary GH4C1 cells. Törnquist K, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):77–82

Repression of glycoprotein hormone alpha–subunit gene expression and secretion by activin in alpha T3–1 cells. Attardi B, et al. **Mol Endocrinol** 1995 Dec;9(12):1737–49

Calcium–sensing receptor expression and regulation by extracellular calcium in the AtT–20 pituitary cell line. Emanuel RL, et al. **Mol Endocrinol** 1996 May;10(5):555–65

Alteration of opioid peptide concentrations in the rat pituitary following survivable closed head injury. Grigoriants OO, et al. **Neurochem Res** 1995 Jul; 20(7):827–31

Glutamate receptor agonists modulate $[Ca2+]_i$ in isolated rat melanotropes. Giovannucci DR, et al. **Neuroendocrinology** 1995 Aug;62(2):111–22

Rat interleukin–1 beta binding sites in rat hypothalamus and pituitary gland. Marquette C, et al. **Neuroendocrinology** 1995 Oct;62(4):362–9

Cellular trafficking of exogenous growth hormone in dwarf rat pituitary. Mertani HC, et al. **Neuroendocrinology** 1996 Mar;63(3):257–68

The ontogeny of pit–1 expression in the human fetal pituitary gland. Puy LA, et al. **Neuroendocrinology** 1996 Apr; 63(4):349–55

Docked granules, the exocytic burst, and the need for ATP hydrolysis in endocrine cells. Parsons TD, et al. **Neuron** 1995 Nov;15(5):1085–96

Effects of aging on the expression of neurotrophins and their receptors in the rat pituitary gland. Kononen J, et al. **Neuroreport** 1995 Nov 27;6(17):2429–34

Altered expression of dopamine D2 receptor mRNA splice variants in brain and pituitary of spontaneously hypertensive rats. Autelitano DJ, et al. **Neurosci Lett** 1995 Jul 28;195(1):1–4

Distribution of neurofilament proteins and peripherin in the rat pituitary gland. Bäck N, et al. **Neurosci Res** 1995 Jun; 22(3):267–75

Release of false transmitter serotonin from the dopaminergic nerve terminals of the rat pituitary intermediate lobe. Vanhatalo S, et al. **Neurosci Res** 1995 Jul;22(4):367–74

Pituitary–specific chromatin structure of the rat prolactin distal enhancer element. Willis SD, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1065–72

Effect of hypophysectomy on pituitary adenylate cyclase–activating polypeptide gene expression in the rat testis. Shuto Y, et al. **Peptides** 1995;16(6):1039–44

Modulation of Ca2+ oscillation and apamin–sensitive, Ca2+–activated K+ current in rat gonadotropes. Tse A, et al. **Pflugers Arch** 1995 Sep;430(5):645–52

Ontogeny of pituitary and serum growth hormone in growing turkeys as measured by radioimmunoassay and radioreceptor assay. Proudman JA, et al. **Poult Sci** 1995 Jul;74(7):1201–8

Vasoactive intestinal peptide stimulates prolactin mRNA expression in turkey pituitary cells: effects of dopaminergic drugs. Xu M, et al. **Proc Soc Exp Biol Med** 1996 May;

212(1):52–62
IGF-I receptor signalling: lessons from the somatotroph. Melmed S, et al. **Recent Prog Horm Res** 1996;51:189–215; discussion 215–6 (65 ref.)
[Additional groups of nonapeptidergic neurosecretory cells in secretory cells of the hypothalamus and adjacent brain areas in dehydrated rats] Grinevich VV, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):268–70 **(Rus)**
[The effect of controllable and uncontrollable stressor actions on dexamethasone receptor binding in the hypophysis and hippocampus of rats with different behavioral strategies] Ordian NE, et al. **Fiziol Zh Im I M Sechenova** 1996 Feb; 82(2):50–4 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Visual disturbances in patients with pituitary adenoma. Ikeda H, et al. **Acta Neurol Scand** 1995 Aug;92(2):157–60
Pituitary enlargement on magnetic resonance imaging in congenital hypothyroidism. Desai MP, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):623–8
Hyperprolactinaemia in patients with pituitary adenomas. The pituitary stalk compression syndrome. Kruse A, et al. **Br J Neurosurg** 1995;9(4):453–7
Role of magnetic resonance imaging in the diagnosis and prognosis of growth hormone deficiency. Bozzola M, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):21–6
Pituitary enlargement. von Werder K. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):299–303
Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/– mice. Nikitin AYu, et al. **Genes Dev** 1996 Aug 1;10(15):1870–9
Dehydration–induced proliferation of identified pituicytes in fully adult rats. Murugaiyan P, et al. **Glia** 1995 Sep; 15(1):65–76
Failure of steroid replacement to consistently normalize pituitary function in congenital adrenal hyperplasia: hormonal and MRI data. Speiser PW, et al. **Horm Res** 1995; 44(6):241–6
The "pituitary pseudoaneurysm" artefact with 3D TOF MRA of the circle of Willis. Uberoi R, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):822–3
Dural invasion and proliferative potential of pituitary adenomas. Daita G, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):211–4
Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):234–6
MRI of pituitary hyperplasia in hypothyroidism. Wolansky LJ, et al. **Neuroradiology** 1996 Jan;38(1):50–2
Precocious puberty with pituitary gland hyperplasia: two cases in one family. Gupta R, et al. **Pediatr Radiol** 1996; 26(6):418–20
MR of the pituitary in patients with Prader–Willi syndrome: size determination and imaging findings. Miller L, et al. **Pediatr Radiol** 1996;26(1):43–7
Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31
[Anterior pituitary failure in the post–partum period and autoimmune thyroiditis: pituitary necrosis or hypophysitis? (letter)] Morange I, et al. **Presse Med** 1995 Jul 1–8; 24(24):1133 **(Fre)**
[MRI of the pituitary adenomas with reference to the hormonal activity] Masunaga S, et al. **No To Shinkei** 1995 Dec;47(12):1165–9 (Eng. Abstr.) **(Jpn)**
[Trans–septo–sphenoidal transnasal approach for microsurgery of hypophyseal tumors] Gras Albert JR, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):201–12 (Eng. Abstr.) **(Spa)**
[Hypophyseal apoplexy] Sánchez Valiente S. **Neurologia** 1995 Jun–Jul;10(6):252–3 **(Spa)**

PHYSIOLOGY

Effects of photoperiod and androgen on pituitary function and neuropeptide staining in Siberian hamsters. Bittman EL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R64–72
Characterization of corticotropin–releasing factor receptor subtypes. Grigoriadis DE, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:60–80 (60 ref.)
Pharyngeal hypophysis. Fuller GN, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):671–2
Hypothyroidism affects pulsatile LH secretion in pubertal orchiectomized rats. Maia AL, et al. **Arch Physiol Biochem** 1995 Aug;103(4):516–20
Influence of hypothalamus and ovary on pituitary function in transgenic mice expressing the bovine growth hormone gene and in growth hormone–deficient Ames dwarf mice. Chandrashekar V, et al. **Biol Reprod** 1996 May;54(5):1002–8
Pubertal development of male African catfish (Clarias gariepinus). Pituitary ultrastructure and responsiveness to gonadotropin–releasing hormone. Schulz RW, et al. **Biol Reprod** 1995 Oct;53(4):940–50
Follicular and luteal progesterone play different roles synchronizing pituitary and ovarian events in the 4–day cyclic rat. Tébar M, et al. **Biol Reprod** 1995 Nov; 53(5):1183–9
GnRH–induced cytosolic calcium oscillations in pituitary gonadotrophs: phase resetting by membrane depolarization. Vergara LA, et al. **Biophys J** 1995 Oct;69(4):1606–14
Specific [3H]spiperone binding sites in the pituitary of rainbow trout (Oncorhynchus mykiss) and goldfish (Carassius auratus). Omeljaniuk RJ. **Can J Physiol Pharmacol** 1995 May;73(5):585–93
The 1994 Stevenson Award Lecture. Follicle–stimulating hormone and luteinizing hormone: a tale of two gonadotropins. Schwartz NB. **Can J Physiol Pharmacol** 1995 Jun;73(6):675–84
Simultaneous measurement of [Ca2+]i and secretion–coupled membrane turnover, by single cell fluorescence microscopy. Shorte SL, et al. **Cell Calcium** 1995 Nov; 18(5):440–54
Diurnal variation of corticotropin–releasing factor binding sites in the rat brain and pituitary. Fuchs E, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):21–37
The tilapia prolactin I gene: evolutionary conservation of the regulatory elements directing pituitary–specific expression. Poncelet AC, et al. **DNA Cell Biol** 1996 Aug; 15(8):679–92
Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. Akita S, et al. **Endocrinology** 1996 Jul; 137(7):3140–3
Calcium currents in a pituitary cell line (AtT–20): differential roles in stimulus–secretion coupling. Loechner KJ, et al. **Endocrinology** 1996 Apr;137(4):1429–37
Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary–testicular axis and growth hormone and insulin–like growth factor I secretion in intact adult male rats. Pierroz DD, et al. **Endocrinology** 1996 Jan;137(1):3–12
Involvement of extracellular sodium in agonist–induced gonadotropin release from goldfish (Carassius auratus) gonadotrophs. Van Goor F, et al. **Endocrinology** 1996 Jul; 137(7):2859–71
Electron microscopic observation of substance P–like immunoreactive nerve fibres and innervation in the anterior pituitary of macaques. Liu S. **Eur J Neurosci** 1995 Aug 1;7(8):1664–73
Seasonal changes in pituitary function: amplification of midfollicular luteinizing hormone secretion during the dark season. Martikainen H, et al. **Fertil Steril** 1996 Apr; 65(4):718–20
Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)
Steroid activation of the brain–pituitary complex gonadotropic function in the triploid rainbow trout Oncorhynchus mykiss. Breton B, et al. **Gen Comp Endocrinol** 1996 Feb;101(2):155–64
Brain–pituitary–gonadal axis during early development and sexual differentiation in the rainbow trout, Oncorhynchus mykiss. Feist G, et al. **Gen Comp Endocrinol** 1996 Jun; 102(3):394–409
Transdermal estrogen replacement therapy in normal perimenopausal women: effects on pituitary–ovarian function. De Leo V, et al. **Gynecol Endocrinol** 1996 Feb; 10(1):49–53
Kinetics of the pituitary–thyroid axis and the peripheral thyroid hormones in 2 children with thyroxine intoxication. Kaiserman I, et al. **Horm Res** 1995;44(5):229–37
Pituitary down–regulation in IVF cycles: is it necessary to use strict criteria? Calhaz–Jorge C, et al. **J Assist Reprod Genet** 1995 Oct;12(9):615–9
Comparison between nafarelin acetate and D–Trp6–LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: a prospective crossover study. Tanos V, et al. **J Assist Reprod Genet** 1995 Nov;12(10):715–9
Reaction of pituitary–adrenal and autonomic nervous systems to stress in trained and untrained elderly people. Korkushko OV, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):27–32
Effect of ovariectomy on cancellous bone in the hypophysectomized rat. Chen MM, et al. **J Bone Miner Res** 1995 Sep;10(9):1334–42
Mobilization of LH secretory granules in gonadotrophs in relation to gene expression, synthesis and secretion of LH during the preovulatory phase of the sheep oestrous cycle. Currie RJ, et al. **J Endocrinol** 1995 Nov;147(2):259–70
The neonatal period: a critical interval in male primate development. Mann DR, et al. **J Endocrinol** 1996 May; 149(2):191–7
The role of excitatory amino acid pathways in the control of pituitary function in neonatally oestrogenized male rats. Pinilla L, et al. **J Endocrinol** 1995 Oct;147(1):51–7
IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action? [editorial] Ceda GP. **J Endocrinol Invest** 1995 Oct;18(9):734–7 (26 ref.)
Acute stimulation of the hypothalamic–pituitary–adrenal axis by IL–1 beta, TNF alpha and IL–6: a dose response study. van der Meer MJ, et al. **J Endocrinol Invest** 1996 Mar; 19(3):175–82
The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary. Holthuis JC, et al. **J Neurochem** 1996 Jun;66(6):2248–56
Contribution of the ventral subiculum to inhibitory regulation of the hypothalamo–pituitary–adrenocortical axis. Herman JP, et al. **J Neuroendocrinol** 1995 Jun;7(6):475–82
Evidence that melatonin acts in the pituitary gland through a dopamine–independent mechanism to mediate effects of daylength on the secretion of prolactin in the ram. Lincoln GA, et al. **J Neuroendocrinol** 1995 Aug;7(8):637–43
A 5–day estradiol therapy, in amounts reproducing concentrations of the early–mid follicular phase, prevents the activation of the hypothalamo–pituitary–adrenal axis by interleukin–1 alpha in the ovariectomized rhesus monkey. Xia–Zhang L, et al. **J Neuroendocrinol** 1995 May; 7(5):387–92
Effects of lipopolysaccharide and glucocorticoids on expression of interleukin–1 beta converting enzyme in the pituitary and brain of mice. Layé S, et al. **J Neuroimmunol** 1996 Aug;68(1–2):61–6
Maternal protein restriction influences the programming of the rat hypothalamic–pituitary–adrenal axis. Langley–Evans SC, et al. **J Nutr** 1996 Jun;126(6):1578–85
A–type potassium current modulated by A1 adenosine receptor in frog melanotrophs. Mei YA, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):431–42
The peptide ACTH(1–39), adrenal growth and steroidogenesis in the sheep fetus after disconnection of the hypothalamus and pituitary. Phillips ID, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):871–9
Autonomous testicular hormonal control of fetal gubernaculum development in rabbits: a re–examination of histological slides in the legacy of the late Professor Alfred Jost. van der Schoot P. **J Reprod Fertil** 1996 Jan; 106(1):153–9
A phorbol ester that activates protein kinase C mimics the action of estradiol or epidermal growth factor for initiating embryo implantation in the delayed implanting hypophysectomized rat. Johnson DC. **Life Sci** 1996; 58(10):861–7
Gonadotroph function in 3–week–old gilts reared in a warm or cool thermal environment. Matteri RL, et al. **Life Sci** 1996;59(1):27–32
The endocrinology of the menopause. Burger HG. **Maturitas** 1996 Mar;23(2):129–36 (44 ref.)
Targeted ablation of pituitary pre–proopiomelanocortin cells by herpes simplex virus–1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Allen RG, et al. **Mol Endocrinol** 1995 Aug; 9(8):1005–16
The nitric oxide synthase (NOS)–like immunoreactive extrahypophysial projections of the neurosecretory preoptic nucleus of the electric ray (elasmobranchs) suggest a neuroregulatory role for this nucleus. Pérez SE, et al. **Neurosci Lett** 1995 Aug 4;195(2):85–8
Neuropeptide Y inhibits Ca2+ oscillations, cyclic AMP, and secretion in melanotrope cells of Xenopus laevis via a Y1 receptor. Scheenen WJ, et al. **Peptides** 1995;16(5):889–95
Prolactin increases CD4/CD8 cell ratio in thymus–grafted congenitally athymic nude mice. Gaufo GO, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4165–9
Localization of vasopressin mRNA and immunoreactivity in pituicytes of pituitary stalk–transected rats after osmotic stimulation. Pu LP, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10653–7
Effect of estrogen on hyperprolactinemia–induced glucose intolerance in SHN mice. Matsuda M, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):243–7
Regulation of insulin–like growth factor–binding proteins in rats with insulin–dependent diabetes mellitus. Rodgers BD, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):234–41
Thyroid axis function during the menstrual cycle in women with premenstrual syndrome. Girdler SS, et al. **Psychoneuroendocrinology** 1995;20(4):395–403
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)
Acute and short–term actions of serotonin administration on the pituitary–testicular axis in the adult rat. Hedger MP, et al. **Reprod Fertil Dev** 1995;7(5):1101–9
[Effects of lesion or stimulation of pituitary gland and hypothalamic arcuate nucleus on pain modulation in rats] Chen QL, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):505–9 (Eng. Abstr.) **(Chi)**
[Role of the hypophysis, hormonal growth inducers and physical exercises in the regulation of function of thyrocytes, C–cells and parathyrocytes in rats during simulated weightlessness] Kaplanskiĭ AS, et al. **Aviakosm Ekolog Med** 1995;29(4):47–52 (Eng. Abstr.) **(Rus)**
[Functional activity of the hypophyseal–thyroid system in pregnant women under conditions of the town of Khabarovska] Uchakina RV, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):85–91 **(Rus)**
[Accessory groups of nonapeptidergic cells in the diencephalon of intact and hypophysectomized rats] Grinevich VV, et al. **Morfologiia** 1994 Apr–Jun; 106(4–6):38–46 (Eng. Abstr.) **(Rus)**
[The nuclei of the follicular cells regulate steroidogenesis stimulated by a pituitary suspension in the follicles of the common frog in vitro] Skoblina MN, et al. **Ontogenez** 1995 Nov–Dec;26(6):446–52 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Relationship between thyroid–pituitary function and response to therapy in patients with recurrent breast cancer. Yokoe T, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2069–72
Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness. Rots NY, et al. **Endocrinology** 1996 May;137(5):1678–86

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Felberbaum RE, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):151–5

Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ghizzoni L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):601–6

Evidence for a hypothalamic-pituitary versus adrenal cortical effect of glycemic control on counterregulatory hormone responses to hypoglycemia in insulin-dependent diabetes mellitus. Kinsley BT, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):684–91

Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome. Leese G, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1867–70

Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. Lortholary O, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):791–6

Effect of hypothyroidism on the pituitary-gonadal axis in the adult female rat. Mattheij JA, et al. **J Endocrinol** 1995 Jul;146(1):87–94

Stress-induced inhibition of the hypothalamic-pituitary-thyroid axis is attenuated in the aged Fischer 344/N male rat. Cizza G, et al. **Neuroendocrinology** 1995 Nov;62(5):506–13

Interleukin 6 modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats. Zhou D, et al. **Neuroendocrinology** 1996 Mar; 63(3):227–36

Canine pituitary-dependent hyperadrenocorticism: a spontancous animal model for neurodegenerative disorders and their treatment with 1-deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207–15 (30 ref.)

Serotonin, Cushing's disease, and depression [editorial] Sonino N, et al. **Psychother Psychosom** 1996 Mar-Apr; 65(2):63–5

[Hypophyseal-thyroid function following partial thyroid resections for euthyroid struma nodosa] Todorov G, et al. **Khirurgiia (Sofiia)** 1995;48(2):13–5 (Eng. Abstr.) **(Bul)**

[Pituitary function in hemochromatosis] Pedersen-Bjergaard U, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1818–22 (35 ref.) (Eng. Abstr.) **(Dan)**

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316–9 (13 ref.) **(Jpn)**

[Effect of hemodialysis on the pituitary adrenocortical axis in patients with diabetic nephropathy] Moczulski D, et al. **Pol Arch Med Wewn** 1996 May;95(5):433–42 (Eng. Abstr.) **(Pol)**

[Preservation of gonadotrophic function and pregnancy in Sheehan's syndrome: a case report and review of the literature] Vieira HB, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):135–8 (17 ref.) (Eng. Abstr.) **(Por)**

RADIATION EFFECTS

[The functional status of the hypophyseal-thyroid and hypophyseal-adrenal systems in breast cancer patients taking into account their exposure to the factors of the accident at the Chernobyl Atomic Electric Power Station] Maevskaia LP. **Lik Sprava** 1995 May-Jun;(5-6):29–31 (Eng. Abstr.) **(Rus)**

[Several indicators of lipids, blood hormones and T-cell unit of the immune system in mice with increased body mass at distant periods after local irradiation of the thymus, hypothalamus-hypophysis and gonads] Savina NP, et al. **Radiats Biol Radioecol** 1996 Mar-Apr;36(2):278–83 (Eng. Abstr.) **(Rus)**

[The effect of the local irradiation of areas of the thymus, hypothalamus/hypophysis and gonads in mice on the cellularity of the autologous and transplanted thymus] Savina NP, et al. **Radiats Biol Radioecol** 1995 Jul-Aug; 35(4):486–93 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. van Royen EA, et al. **J Nucl Med** 1996 Sep;37(9):1449–51

SECRETION

Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Aström C. **Acta Neurol Scand** 1995 Oct; 92(4):281–96 (103 ref.)

Electrochemical detection of exocytosis at single rat melanotrophs. Paras CD, et al. **Anal Chem** 1995 Oct 15; 67(20):3633–7

Inhibition of regulated neuropeptide secretion from mouse pituitary cells by propofol. YaDeau JT. **Anesth Analg** 1996 Sep;83(3):611–7

D2-like dopamine receptor mediates dopaminergic or gamma-aminobutyric acidergic inhibition of melanotropin-releasing hormone release from the pars intermedia in frogs (Rana nigromaculata). Tonosaki Y, et al. **Endocrinology** 1995 Dec;136(12):5260–5

Influence of thyroid hormones on the regulation of growth hormone secretion. Giustina A, et al. **Eur J Endocrinol** 1995 Dec;133(6):646–53 (52 ref.)

Regulation of mouse placental lactogen secretion by factors secreted from the pituitary in vitro. Yamaguchi M, et al. **Eur J Endocrinol** 1996 Jan;134(1):123–7

Paracrine cell to cell interactions determine the effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vitro prolactin release from rat pituitary cells. Benter S, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(6):386–90

Interactions between signaling pathways in mediating GnRH-stimulated GTH release from goldfish pituitary cells: protein kinase C, but not cyclic AMP is an important mediator of GnRH-stimulated gonadotropin secretion in goldfish. Jobin RM, et al. **Gen Comp Endocrinol** 1996 Jun; 102(3):327–41

Roles of calcium and calmodulin in the mediation of acute and sustained GnRH-stimulated gonadotropin secretion from dispersed goldfish pituitary cells. Jobin RM, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):91–106

Role of gonadotrophin releasing hormone baseline concentrations in the control of pituitary gonadotrophin and ovarian steroid secretion in the pseudopregnant rat. Schuiling GA, et al. **Hum Reprod** 1996 Jan;11(1):13–8

A V1-type receptor for mediating the neurohypophysial hormone-induced ACTH release in trout pituitary. Pierson PM, et al. **J Endocrinol** 1996 Apr;149(1):109–15

In vitro pituitary GH secretion after GHRH, forskolin, dibutyryl cyclic-adenosine 3',5'-monophosphate and phorbol 12-myristate 13-acetate stimulation in long-term orchidectomized rats. Tena-Sempere M, et al. **J Mol Endocrinol** 1996 Feb;16(1):81–8

Dopaminergic regulation of secretory granule-associated proteins in rat intermediate pituitary. Oyarce AM, et al. **J Neurochem** 1996 Jul;67(1):229–41

A technique for sorting rat gonadotropes using anti-LH or anti-FSH antibodies covalently attached to magnetic beads. Valenti S, et al. **J Neuroendocrinol** 1995 Sep;7(9):673–9

Evidence that secretory products of the reticuloepithelial cells of the rat thymus modulate the secretion of gonadotrophins by rat pituitary cells in culture. Mendoza ME, et al. **J Reprod Immunol** 1995 Mar;28(3):203–15

Regulation of pituitary beta-endorphin secretion in aging rats: in vitro responsiveness to dopamine. Saland LC, et al. **Life Sci** 1995 Mar 17;56(17):1415–25

Biphasic effect of MCH on alpha-MSH release from the tilapia (Oreochromis mossambicus) pituitary. Gröneveld D, et al. **Peptides** 1995;16(5):945–9

SURGERY

Transnasal-transsphenoidal endoscopic surgery of the pituitary gland. Carrau RL, et al. **Laryngoscope** 1996 Jul; 106(7):914–8

Herniation of the third ventricle into empty sella caused by surgery for pituitary apoplexy--case report. Kobayashi S, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):451–4

Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Massoud F, et al. **Surg Neurol** 1996 Apr;45(4):341–6

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32–6

[Hypophyseal surgery: experience in Paris] Derome P. **Ann Endocrinol (Paris)** 1995;56(6):627–9 **(Fre)**

[Hypophyseal surgery: experience in Montreal] Hardy J. **Ann Endocrinol (Paris)** 1995;56(6):625–6 **(Fre)**

[Trans-septo-sphenoidal transnasal approach for microsurgery of hypophyseal tumors] Gras Albert JR, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):201–12 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

The laryngeal mask airway for stereotactic implantation of fetal hypophysis [letter] Silva LC, et al. **Anesth Analg** 1996 Feb;82(2):430–1

Study of microencapsulation for pituitary transplantation: capsule preparation and in vitro study. Chen ZP, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(5):597–604

Heterogeneity of rat type I 5 alpha-reductase cDNA: cloning, expression and regulation by pituitary implants and dihydrotestosterone. Lopez-Solache I, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):139–44

Ultrastructural study on the plical epithelium of the bursa of Fabricius in chick embryos: influence of partial decerebration and hypophyseal allografts. Romano N, et al. **J Anat** 1996 Feb;188 (Pt 1):29–41

Prolactin increases CD4/CD8 cell ratio in thymus-grafted congenitally athymic nude mice. Gaufo GO, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4165–9

ULTRASTRUCTURE

Pubertal development of male African catfish (Clarias gariepinus). Pituitary ultrastructure and responsiveness to gonadotropin-releasing hormone. Schulz RW, et al. **Biol Reprod** 1995 Oct;53(4):940–50

Changes in the ultrastructural distribution of prolactin and growth hormone mRNAs in pituitary cells of female rats after estrogen and bromocriptine treatment, studied using in situ hybridization with biotinylated oligonucleotide probes. Matsuno A, et al. **Histochem Cell Biol** 1995 Jul; 104(1):37–45

Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Goudreau JL, et al. **Neuroendocrinology** 1995 Aug; 62(2):147–54

VIROLOGY

Detection of polyomaviral DNA sequences in normal and adenomatous human pituitary tissues using the polymerase chain reaction. Woloschak M, et al. **Cancer** 1995 Aug 1; 76(3):490–6

PITUITARY GLAND, ANTERIOR

The craniopharyngeal canal indicating the presence of pharyngeal adenopituitary tissue. Kjaer I, et al. **Eur J Radiol** 1995 Sep;20(3):212–4

ABNORMALITIES

Congenital hypopituitarism with hypoplasia of the anterior pituitary gland and a normal posterior pituitary lobe [see comments] Kato F, et al. **Acta Paediatr** 1995 Oct; 84(10):1201–3. Comment in: Acta Paediatr 1995 Oct;84(10):1100–2.

Anterior pituitary cells defective in the cell-autonomous factor, df, undergo cell lineage specification but not expansion. Gage PJ, et al. **Development** 1996 Jan; 122(1):151–60

Nasal pyriform aperture stenosis and absence of the anterior pituitary gland: report of two cases. Beregszàszi M, et al. **J Pediatr** 1996 Jun;128(6):858–61

ANATOMY & HISTOLOGY

The population of GnRH-containing neurons showing socially mediated size changes project to the pituitary in a teleost, Haplochromis burtoni. Bushnik TL, et al. **Brain Behav Evol** 1995;46(6):371–7

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

Primary low cerebrospinal fluid pressure syndrome with galactorrhea: findings at MR imaging. Sawada A, et al. **Cephalalgia** 1996 Apr;16(2):124–6

CHEMISTRY

Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Farnoud MR, et al. **Int J Cancer** 1996 Jul 3;67(1):45–53

Relationship between the number of immunostaining gonadotropes and the plasma concentrations of gonadotrophins in ewes with and without the FecBB gene. Heath DA, et al. **J Reprod Fertil** 1996 Jan;106(1):73–8

Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Nishino T, et al. **Mol Med** 1995 Nov;1(7):781–8

Localization of the N-methyl-D-aspartate R1 receptor subunit in specific anterior pituitary hormone cell types of the female rat. Bhat GK, et al. **Neuroendocrinology** 1995 Aug;62(2):178–86

Differential distribution of synaptotagmin I and rab3 in the anterior pituitary of four mammalian species. Redecker P, et al. **Neuroendocrinology** 1995 Aug;62(2):101–10

All prepro-VIP-derived peptides, except PHI/PHV, are expressed in the female rat anterior pituitary and increased by estrogen. Skakkebaek ML, et al. **Peptides** 1995; 16(7):1287–94

CYTOLOGY

Study of ACTH-immunoreactive cells after transplantation of neonatal adrenal glands into adult adrenalectomized rats. Sarria R, et al. **Anat Histol Embryol** 1995 Sep;24(3):185–90

Intercellular communication within the rat anterior pituitary gland: VI. Development of gap junctions between folliculo-stellate cells under the influence of ovariectomy and sex steroids in the female rat. Kurono C. **Anat Rec** 1996 Mar;244(3):366–73

A differential staining method for adenohypophyseal cells. Kikui Y, et al. **Arch Histol Cytol** 1995 Aug;58(3):375–8

Simultaneous measurements of exocytosis and intracellular calcium concentration with fluorescent indicators in single pituitary gonadotropes. Masumoto N, et al. **Cell Calcium** 1995 Sep;18(3):223–31

The effect of extracellular polyvalent cations on bovine anterior pituitary cells. Evidence for a Ca(2+)-sensing receptor coupled to release of intracellular calcium stores. Shorte SL, et al. **Cell Calcium** 1996 Jan;19(1):43–57

Immunocytochemical and morphometric study on the changes of TSH, PRL, GH and ACTH cells during the development of Bufo arenarum. Miranda LA, et al. **Cell Tissue Res** 1996 Jan;283(1):125–32

The pars tuberalis of the ewe: no effect of season or ovariectomy on the distribution, density or presence of immunoreactive cells. Skinner DC, et al. **Cell Tissue Res** 1996 Apr;284(1):117–23

Structural and functional differences between prolactin cells from the inner and outer zones of the male rat anterior pituitary. Vila-Porcile E, et al. **Cell Tissue Res** 1996 May;

284(2):247–59

Anterior pituitary cells defective in the cell–autonomous factor, df, undergo cell lineage specification but not expansion. Gage PJ, et al. **Development** 1996 Jan; 122(1):151–60

Functional glutamate receptors in a subpopulation of anterior pituitary cells. Villalobos C, et al. **FASEB J** 1996 Apr; 10(5):654–60

Uneven regional distributions of prolactin– and growth hormone–secreting cells and sexually dimorphic proportions of prolactin secretors in the adenohypophysis of adult chickens. Lopez ME, et al. **Gen Comp Endocrinol** 1995 Nov;100(2):246–54

Hypotonic lysis of red blood cell contamination from human anterior pituitary adenoma cell preparations [letter] Atkin SL, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):657–8

Identification of epidermal growth factor–secreting cells in the anterior pituitary of lactating female rats. Mouihate A, et al. **J Endocrinol** 1996 Feb;148(2):319–24

Age–related changes in the numbers of mammotrophs, somatotrophs and mammosomatotrophs in the anterior pituitary gland of female rats: a flow cytometric study. Shinkai T, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):125–31

The application of in vitro models of anterior pituitary function in toxicity testing. Gillies GE, et al. **Methods Mol Biol** 1995;43:81–93

Anterior pituitary cells: getting to know their neighbors. Perez FM, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):C1–6 (41 ref.)

In situ recordings of presumed folliculo–stellate cells in the intermediate lobe of the pituitary gland of Xenopus laevis. Borst JG, et al. **Neurosci Lett** 1996 May 3;209(1):61–4

Caffeine–induced oscillations of cytosolic Ca2+ in GH3 pituitary cells are not due to Ca2+ release from intracellular stores but to enhanced Ca2+ influx through voltage–gated Ca2+ channels. Villalobos C, et al. **Pflugers Arch** 1996 Jan;431(3):371–8

Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine–regulated mechanism. Missale C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4240–5

Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Sheng HZ, et al. **Science** 1996 May 17; 272(5264):1004–7

DRUG EFFECTS

Testosterone inhibits the basal and gonadotropin–releasing hormone–stimulated synthesis and release of newly synthesized alpha– and lutropin (LH) beta–subunit but not release of stored LH in cultured rat pituitary cells. Starzec AB, et al. **Biochim Biophys Acta** 1996 Feb 29; 1310(3):348–54

Effects of mastoparan upon the late stages of the ACTH secretory pathway of AtT–20 cells. McFerran BW, et al. **Br J Pharmacol** 1995 Jun;115(4):696–72

Triiodothyronine attenuates estradiol–induced increases in dopamine D–2 receptor number in rat anterior pituitary. Nedvídková J, et al. **Brain Res** 1996 Mar 11;712(1):148–52

Reduction in the expression and action of transforming growth factor beta 1 on lactotropes during estrogen–induced tumorigenesis in the anterior pituitary. Pastorcic M, et al. **Cancer Res** 1995 Nov 1;55(21):4892–8

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

Pituitary response to thyrotropin, corticotropin, and gonadotropin–releasing hormones in lactating cows treated with sometribove for a fourth consecutive lactation. Adriaens FA, et al. **Domest Anim Endocrinol** 1995 Oct; 12(4):301–16

The interactive effects of VIP, PHI, GHRH, and SRIF on the release of growth hormone from cultured adenohypophysial cells in cattle. Soliman EB, et al. **Endocr J** 1995 Oct;42(5):717–22

An increase in the blood thyroxine level after methylene blue in rats: the interaction with carbimazole. Nedvídková J, et al. **Endocr Res** 1995 Nov;21(4):709–17

Failure of ethanol metabolites to alter gonadotropin secretion or luteinizing hormone synthesis in vitro. Uddin S, et al. **Endocr Res** 1995 Aug;21(3):653–70

Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Wera S, et al. **Endocr Res** 1995 Aug;21(3):623–33

Preprothyrotropin–releasing hormone–(178–199) does not inhibit corticotropin release. Nicholson WE, et al. **Endocrinology** 1996 May;137(5):2171–4

Comparison between depot leuprorelin and daily buserelin in IVF. Porcu E, et al. **J Assist Reprod Genet** 1995 Jan; 12(1):15–9

Melanin–concentrating hormone gene–related peptide stimulates ACTH, but not alpha–MSH, release from the tilapia pituitary. Gröneveld D, et al. **J Endocrinol** 1996 Jan;148(1):R1–4

The effects of GH–releasing peptide–6 (GHRP–6) and GHRP–2 on intracellular adenosine 3',5'–monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. Wu D, et al. **J Endocrinol** 1996 Feb; 148(2):197–205

Daily melatonin injections induce cytological changes in pars tuberalis–specific cells similar to short photoperiod. Böckers TM, et al. **J Neuroendocrinol** 1995 Aug;7(8):607–13

Cyclosporine effects on in vitro responsiveness of anterior pituitary hormone release to dopamine and thyrotropin–releasing hormone in young female rats. Moreno ML, et al. **J Neuroendocrinol** 1995 Oct; 7(10):765–74

Induction of cellular follicle–stimulating hormone in the hamster adenohypophysis requires intermittent stimulation by luteinizing hormone releasing hormone. Woller MJ, et al. **J Neuroendocrinol** 1995 May;7(5):393–400

Effects of the novel antipsychotic agent 7–(4–[4–(2,3–dichlorophenyl)–1–piperazinyl]butyloxy)–3,4–dihydro –2(1H)–quinolinone (OPC–14597) on prolactin release from the rat anterior pituitary gland. Inoue T, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):137–43

Translocation of protein kinase C isozymes in rat pituitary lactotroph–enriched cell cultures by substance P: effects of sex and age. Mau SE, et al. **J Recept Signal Transduct Res** 1995 Jul;15(6):801–9

EGF release by rat gonadotroph cells: characteristics and effects of LHRH. Mouite A, et al. **Life Sci** 1996; 58(2):107–14

Baclofen, a gamma–aminobutyric acid B agonist, modifies hormonal secretion in pituitary cells from infantile female rats. Rey–Roldan EB, et al. **Life Sci** 1996;58(13):1059–65

Altered regulation of pituitary luteinizing hormone secretion by GnRH and inhibin in the aged persistent–estrous female rat. Jih MH, et al. **Mech Ageing Dev** 1995 Sep 29; 84(1):15–27

Effect of cAMP on GnRH stimulated LH secretion from individual pituitary gonadotropes. Cassina P, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):127–35

Heterogeneous response of porcine gonadotrope subpopulations to gonadotropin releasing hormone (GnRH) during postnatal development. Torronteras R, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):203–13

Arachidonic acid–induced hormone release in somatotropes: involvement of calcium. Roudbaraki MM, et al. **Neuroendocrinology** 1996 Mar;63(3):244–56

Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Taylor AD, et al. **Neuroendocrinology** 1995 Nov;62(5):530–42

An interleukin–1–alpha–like neuronal system in the preoptic–hypothalamic region and its induction by bacterial lipopolysaccharide in concentrations which alter pituitary hormone release. Rettori V, et al. **Neuroimmunomodulation** 1994 Jul–Aug;1(4):251–8

All prepro–VIP–derived peptides, except PHI/PHV, are expressed in the female rat anterior pituitary and increased by estrogen. Skakkebaek ML, et al. **Peptides** 1995; 16(7):1287–94

Capacitative Ca2+ entry contributes to the Ca2+ influx induced by thyrotropin–releasing hormone (TRH) in GH3 pituitary cells. Villalobos C, et al. **Pflugers Arch** 1995 Oct; 430(6):923–35

Methylene blue––an endocrine modulator. Haluzík M, et al. **Sb Lek** 1995;96(4):319–22

EMBRYOLOGY

The fine structure of dexamethasone–induced growth hormone cells in the anterior pituitary gland of the rat fetus. Nogami H, et al. **Arch Histol Cytol** 1995 Dec;58(5):581–9

Ontogeny of basal and regulated secretion from POMC cells of the developing anterior lobe of the rat pituitary gland. Lugo DI, et al. **Dev Biol** 1996 Jan 10;173(1):95–109

Gsh–1, an orphan Hox gene, is required for normal pituitary development. Li H, et al. **EMBO J** 1996 Feb 15; 15(4):714–24

The adenohypophysis and the cranial base in early human development. Kjaer I, et al. **J Craniofac Genet Dev Biol** 1995 Jul–Sep;15(3):157–61

ENZYMOLOGY

Separation of H7–resistant protein kinase C isoforms from gonadotroph–derived alpha T3–1 cells. Simpson J, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):720–5

Arachidonate 12–lipoxygenase in porcine anterior pituitary cells: its localization and possible function in gonadotrophs. Ikawa H, et al. **J Endocrinol** 1996 Jan;148(1):33–41

Translocation of protein kinase C isozymes in rat pituitary lactotroph–enriched cell cultures by substance P: effects of sex and age. Mau SE, et al. **J Recept Signal Transduct Res** 1995 Jul;15(6):801–9

Dependence of stimulus–transcription coupling on phospholipase D in agonist–stimulated pituitary cells. Cesnjaj M, et al. **Mol Biol Cell** 1995 Aug;6(8):1037–47

Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin–sensitive G protein. Sim PJ, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):257–63

Heterogeneous distribution of ecto–Ca–ATPases in primary cultures of human adenohypophyseal cells. Kittel A, et al. **Scanning Microsc** 1995 Jun;9(2):485–90; discussion 490–2

GROWTH & DEVELOPMENT

Heterogeneous response of porcine gonadotrope subpopulations to gonadotropin releasing hormone (GnRH) during postnatal development. Torronteras R, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):203–13

INNERVATION

Evidence for axonal sprouting in the anterior pituitary following adrenalectomy in the rat. Lu CR, et al. **J Endocrinol** 1995 Oct;147(1):161–6

METABOLISM

Effect of S(–)– and R(+)–salsolinol on the POMC gene expression and ACTH release of an anterior pituitary cell line. Putscher I, et al. **Alcohol** 1995 Sep–Oct;12(5):447–52

Tumor–related selection of calcium signals in vasopressin–stimulated human adenomatous corticotrophs. Corcuff JB, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E451–7

Recording of a large–conductance chloride channel in normal rat lactotrophs. Fahmi M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E969–76

Solubilization and characterization of a growth hormone secretagogue receptor from porcine anterior pituitary membranes. Pomés A, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):939–45

G–protein modulation of neuronal class E (alpha 1E) calcium channel expressed in GH3 cells. Yassin M, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):453–8

Concentrations of gonadotropin–releasing hormone (GnRH) receptor messenger ribonucleic acid in pituitary tissue of orchidectomized sheep: effect of estradiol and GnRH. Adams BM, et al. **Biol Reprod** 1996 Feb;54(2):407–12

Pulsatile gonadotropin–releasing hormone (GnRH) increases concentrations of GnRH receptor messenger ribonucleic acid and numbers of GnRH receptors during luteolysis in the ewe. Turzillo AM, et al. **Biol Reprod** 1995 Aug; 53(2):418–23

Angiotensin II changes inositol–1,4,5–trisphosphate content in the pituitary and hypothalamus but not in cerebral cortex of the rat brain. Lachowicz A, et al. **Biol Signals** 1995 Jul–Aug;4(4):206–11

Reduction in the expression and action of transforming growth factor beta 1 on lactotropes during estrogen–induced tumorigenesis in the anterior pituitary. Pastorcic M, et al. **Cancer Res** 1995 Nov 1;55(21):4892–8

Synaptic relationship of substance P–like–immunoreactive nerve fibers with gland cells of the anterior pituitary in the rat. Liu Y, et al. **Cell Tissue Res** 1996 Aug;285(2):227–34

Dynamics of secretory granules in somatotrophs of rats after stimulation with growth hormone–releasing factor: a stereological analysis. Nakagawa J, et al. **Cell Tissue Res** 1995 Dec;282(3):493–501

Effects of corticotropin–releasing hormone, lysine vasopressin, oxytocin, and angiotensin II on adrenocorticotropin secretion from porcine anterior pituitary cells. Abraham EJ, et al. **Domest Anim Endocrinol** 1996 May;13(3):259–68

Control of growth hormone synthesis. Tuggle CK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):1–33 (256 ref.)

Failure of ethanol metabolites to alter gonadotropin secretion or luteinizing hormone synthesis in vitro. Uddin S, et al. **Endocr Res** 1995 Aug;21(3):653–70

Autocrine and/or paracrine action of vasoactive intestinal peptide on thyrotropin–releasing hormone induced prolactin release. Balsa JA, et al. **Endocrinology** 1996 Jan; 137(1):144–50

Gonadotropin–releasing hormone regulation of pituitary follistatin gene expression during the primary follicle–stimulating hormone surge. Bauer–Dantoin AC, et al. **Endocrinology** 1996 May;137(5):1634–9

Short photoperiod–dependent down–regulation of thyrotropin–alpha and –beta in hamster pars tuberalis–specific cells is prevented by pinealectomy. Bockmann J, et al. **Endocrinology** 1996 May;137(5):1804–13

Differential regulation of proopiomelanocortin messenger ribonucleic acid in the pars distalis and pars intermedia of the pituitary gland after prolonged hypoxemia in fetal sheep. Braems GA, et al. **Endocrinology** 1996 Jul; 137(7):2731–8

Regulation of mitogen–activated protein kinase in the pars tuberalis of the ovine pituitary: interactions between melatonin, insulin–like growth factor–1, and forskolin. Hazlerigg DG, et al. **Endocrinology** 1996 Jan;137(1):210–8

Corticotropin–releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures. Pozzoli G, et al. **Endocrinology** 1996 Jan;137(1):65–71

Transforming growth factor–beta and p27 expression in pituitary cells. Qian X, et al. **Endocrinology** 1996 Jul; 137(7):3051–60

Regulation of corticotropin–releasing factor receptor messenger ribonucleic acid in rat anterior pituitary. Sakai K, et al. **Endocrinology** 1996 May;137(5):1758–63

Gene expression of hypothalamic somatostatin, growth hormone releasing factor, and their pituitary receptors in hypothyroidism. Tam SP, et al. **Endocrinology** 1996 Feb; 137(2):418–24

Effects of interleukin–1 beta on thyrotropin secretion and thyroid hormone uptake in cultured rat anterior pituitary cells. Wassen FW, et al. **Endocrinology** 1996 May; 137(5):1591–8

Expression of synaptosomal–associated protein SNAP–25 in endocrine anterior pituitary cells. Aguado F, et al. **Eur J Cell Biol** 1996 Apr;69(4):351–9

Cysteine proteinases in GH4C1 cells, a rat pituitary tumor cell line, are secreted by the constitutive and regulated

secretory pathways. Waguri S, et al. **Eur J Cell Biol** 1995 Aug;67(4):308–18

Drug effects on triiodothyronine uptake by rat anterior pituitary cells in vitro. Lim CF, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):151–7

Functional glutamate receptors in a subpopulation of anterior pituitary cells. Villalobos C, et al. **FASEB J** 1996 Apr; 10(5):654–60

Uneven regional distributions of prolactin- and growth hormone-secreting cells and sexually dimorphic proportions of prolactin secretors in the adenohypophysis of adult chickens. Lopez ME, et al. **Gen Comp Endocrinol** 1995 Nov;100(2):246–54

Cellular basis for gender-dependent differences in growth hormone secretion in young chickens: analysis using reverse hemolytic plaque assays. Morpurgo B, et al. **Growth Dev Aging** 1995 Spring-Summer;59(1–2):25–30

Ontogeny of 17B-estradiol (E2)- and estrogen receptor (ER)- immunostained cells in the hypothalamus and adenohyophyseal pars distalis of the chick embryo. Woods JE, et al. **Growth Dev Aging** 1995 Fall;59(3):93–105

Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. Haugen BR, et al. **J Biol Chem** 1996 Jan 5; 271(1):385–9

Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. Hashimoto K, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2933–9

Cellular localization of the growth hormone receptor/binding protein in the human anterior pituitary gland. Mertani HC, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3361–7

Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. Zafar M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3621–7

Fertilization-promoting peptide: a novel peptide, structurally similar to TRH, with potent physiological activity. Cockle SM. **J Endocrinol** 1995 Jul;146(1):3–8

Pituitary lactotrope expresses transforming growth factor beta (TGF beta) type II receptor mRNA and protein and contains 125I-TGF beta 1 binding sites. De A, et al. **J Endocrinol** 1996 Apr;149(1):19–27

Role of guanine nucleotide-binding proteins, Gi alpha 3 and Gs alpha, in dopamine and thyrotropin-releasing hormone signal transduction: evidence for competition and commonality. Kineman RD, et al. **J Endocrinol** 1996 Mar; 148(3):447–55

Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cells. Lee SC, et al. **J Endocrinol** 1996 Jan;148(1):69–76

Estrogen increases the release of epidermal growth factor from individual pituitary cells in female rats. Mouihate A, et al. **J Endocrinol** 1995 Sep;146(3):495–500

Further studies on the regulation, localization and function of the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in the rat anterior pituitary gland. Rondeel JM, et al. **J Endocrinol** 1995 Aug; 146(2):293–300

Effects of acute administration of growth hormone-releasing hormone (GHRH) and oxytocin on somatotroph cells in sheep: morphometric study and growth hormone (GH) secretion. Rico M, et al. **J Endocrinol Invest** 1995 Jun; 18(6):442–9

GnRH receptor site increase on the surface of cultured gonadotropes of senescent C57BL/6NNia mice. Parkening TA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov; 50(6):B342–50

Expression of the pituitary transcription factor GHF-1/PIT-1 in cell types of the adult porcine adenohypophysis. Malagon MM, et al. **J Histochem Cytochem** 1996 Jun;44(6):621–7

The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha-subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)

Identification and localization of 23,000 and glycosylated rat prolactin in subcellular fractions of rat anterior pituitary and purified secretory granules. Bollengier F, et al. **J Neuroendocrinol** 1993 Dec;5(6):669–76

Leukaemia inhibitory factor expression in cultured rat anterior pituitary is regulated by glucocorticoids. Carter DA. **J Neuroendocrinol** 1995 Aug;7(8):623–8

Differential seasonal regulation of melatonin receptor density in the pars tuberalis and the suprachiasmatic nuclei: a study in the hedgehog (Erinaceus europaeus, L.). Gauer F, et al. **J Neuroendocrinol** 1993 Dec;5(6):685–90

Neuropeptide Y and luteinizing hormone releasing hormone synergize to stimulate the development of cellular follicle-stimulating hormone in the hamster adenohypophysis. Woller MJ, et al. **J Neuroendocrinol** 1995 Sep;7(9):733–6

Induction of cellular follicle-stimulating hormone in the hamster adenohypophysis requires intermittent stimulation by luteinizing hormone releasing hormone. Woller MJ, et al. **J Neuroendocrinol** 1995 May;7(5):393–400

Control of Ca2+ entry into rat lactotrophs by thyrotrophin-releasing hormone. Carew MA, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):349–60

Reduced ability of hypothalamic and pituitary extracts from old mice to stimulate thymulin secretion in vitro. Goya RG, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):143–54

Ionic milieu controls the compartment-specific activation of pro-opiomelanocortin processing in AtT-20 cells. Schmidt WK, et al. **Mol Biol Cell** 1995 Oct;6(10):1271–85

Site-specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression. Ngô V, et al. **Mol Cell Biol** 1996 Jul;16(7):3245–54

Immortalized anterior pituitary alpha T3 gonadotropes contain functional luteinizing hormone/human chorionic gonadotropin receptors. Huang ZH, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):217–22

Multifactorial regulation of pituitary adenylate cyclase-activating polypeptide (PACAP)-induced production of cyclic AMP in ATT-20 corticotrophs: major involvement of Rolipram-sensitive and insensitive phosphodiesterases. Koch B, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):27–34

Production and secretion of N-terminal secretogranin II derived peptides in GH3B6 prolactin cells. Muller L, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):101–12

Regulation of alpha-subunit mRNA transcripts by pituitary adenylate cyclase-activating polypeptide (PACAP) in pituitary cell cultures and alpha T3-1 cells. Tsujii T, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):123–30

Differential alternative splicing of PACAP receptor in pituitary cell subpopulations. Vertongen P, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):131–5

A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Heinflink M, et al. **Mol Endocrinol** 1995 Nov;9(11):1455–60

Modulation of regulatory and catalytic subunit levels of cAMP-dependent protein kinase A in anterior pituitary cells in response to direct activation of protein kinases A and C or after GnRH stimulation. Garrel G, et al. **Neuroendocrinology** 1995 Nov;62(5):514–22

Epidermal growth factor: a potential paracrine and autocrine system within the pituitary. Mouihate A, et al. **Neuroreport** 1995 Jul 10;6(10):1401–4

Developmental changes of tachykinins in the hypothalamus and anterior pituitary of female Siberian hamsters from prepuberty to adulthood. Debeljuk L, et al. **Peptides** 1995; 16(5):827–31

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Halmos G, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2398–402

PATHOLOGY

Hypophysitis in surgical and autoptical specimens. Sautner D, et al. **Acta Neuropathol (Berl)** 1995;90(6):637–44

Altered thyrotropic and somatotropic responses to environmental challenges in congenitally athymic mice. Goya RG, et al. **Brain Behav Immun** 1995 Jun;9(2):79–86

Dynamic enhancement MRI of anterior lobe in pituitary dwarfism. Liu HM, et al. **Neuroradiology** 1995 Aug; 37(6):486–90

PHYSIOLOGY

Oxytocin and the anterior pituitary gland. Samson WK, et al. **Adv Exp Med Biol** 1995;395:355–64 (63 ref.)

The role of GTP binding proteins in the release of gonadotrophin by alpha T3-1 cells. Betteridge A. **Biochem Soc Trans** 1996 Feb;24(1):146S

KN-62, a calcium/calmodulin-dependent protein kinase II inhibitor, inhibits high potassium-stimulated prolactin secretion and intracellular calcium increases in anterior pituitary cells. Cui ZJ, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):343–7

Spontaneous electrical and calcium oscillations in unstimulated pituitary gonadotrophs. Li YX, et al. **Biophys J** 1995 Sep;69(3):785–95

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

Molecular diversity of GABA-gated chloride channels in the rat anterior pituitary. Boué-Grabot E, et al. **Brain Res** 1995 Dec 15;704(1):125–9

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

Assessment of a combined anterior pituitary function test in beagle dogs: rapid sequential intravenous administration of four hypothalamic releasing hormones. Meij BP, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):161–70

Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Rawlings SR, et al. **Endocr Rev** 1996 Feb;17(1):4–29 (170 ref.)

Effects of extracellular nucleotides in the pituitary: adenosine triphosphate receptor-mediated intracellular responses in gonadotrope-derived alpha T3-1 cells. Chen ZP, et al. **Endocrinology** 1996 Jan;137(1):248–56

Corticotropin-releasing hormone stimulates Ca2+ entry through L- and P-type Ca2+ channels in rat corticotropes. Kuryshev YA, et al. **Endocrinology** 1996 Jun; 137(6):2269–77

Testosterone regulates gonadotropin-releasing hormone-induced calcium signals in male rat gonadotrophs. Tobin VA, et al. **Endocrinology** 1996 Apr; 137(4):1299–305

The long-term effect of low protein diet on the somatostatin hypothalamic neuronal system and the pituitary growth hormone cells in growing ewe. Polkowska J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):59–66

Exercise training-induced changes in anterior pituitary gonadotrope of the female rat. Caston AL, et al. **J Appl Physiol** 1995 Jul;79(1):194–201

Effect of cAMP on GnRH stimulated LH secretion from individual pituitary gonadotropes. Cassina P, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):127–35

Anterior pituitary cells: getting to know their neighbors. Perez FM, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):C1–6 (41 ref.)

Targeted ablation of pituitary pre-proopiomelanocortin cells by herpes simplex virus-1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Allen RG, et al. **Mol Endocrinol** 1995 Aug; 9(8):1005–16

Mechanism of melatonin signal transduction in the neonatal rat pituitary. Vanecek J, et al. **Neurochem Int** 1995 Sep; 27(3):273–8

Electrophysiological characterization of GABAA receptors in anterior pituitary cells of newborn rats. Zemková H, et al. **Neuroendocrinology** 1995 Aug;62(2):123–9

The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):201–16 (182 ref.)

The estrous cycle and pituitary-ovarian function in Lewis and Fischer rats. Smith CC, et al. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):231–5

Ultrastructural modifications and changes in the expression of hormonal genes produced by indomethacin in the anterior pituitary gland of the rat. Romano LA, et al. **Neurol Res** 1995 Oct;17(5):389–92

In situ recordings of presumed folliculo-stellate cells in the intermediate lobe of the pituitary gland of Xenopus laevis. Borst JG, et al. **Neurosci Lett** 1996 May 3;209(1):61–4

Caffeine enhancement of electrical activity through direct blockade of inward rectifying K+ currents in GH3 rat anterior pituitary cells. Barros F, et al. **Pflugers Arch** 1996 Jan;431(3):443–51

Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Missale C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4240–5

[Inhibitory effects of hypothalamic arcuate nucleus or anterior pituitary stimulation on the nociceptive responses of thalamic parafascicular neurons] Jiao YY, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):423–8 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Templ E, et al. **Br J Rheumatol** 1996 Apr;35(4):350–6

Anterior pitutiary and pituitary-dependent target organ function in men infected with the human immunodeficiency virus. Wilson LD, et al. **Metabolism** 1996 Jun;45(6):738–46

SECRETION

Individual lactotropes release prolactin in a temporally divergent and sexually dimorphic pattern. Castaño JP, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E814–9

Effects of short-term cortisol infusion on growth hormone-releasing hormone stimulation of growth hormone release in sheep. Thompson K, et al. **Am J Vet Res** 1995 Sep;56(9):1228–31

Cyclic GMP stimulates growth hormone release in rat anterior pituitary cells. Hartt DJ, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):918–26

Hormonal changes in male subjects over-ninety. Ravaglia G, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun; 71(5–6):133–9

Regulation of adrenocorticotropin secretion in vitro by anterior pituitary corticotrophs from fallow deer (Dama dama). Willard ST, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):283–92

Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Wera S, et al. **Endocr Res** 1995 Aug;21(3):623–33

Use of newly designed microperifusion system with amperometric sensors for near-continuous on-line monitoring of hormone secretion. I. correlation with the luteinizing hormone secretory response to gonadotropin-releasing hormone. Cantor HC, et al. **Endocrinology** 1996 Jul;137(7):2782–90

Somatostatin increases growth hormone (GH) secretion in a subpopulation of porcine somatotropes: evidence for functional and morphological heterogeneity among porcine GH-producing cells. Castaño JP, et al. **Endocrinology** 1996 Jan;137(1):129–36

Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. Goth MI, et al. **Endocrinology** 1996 Jan;137(1):274–80

Preprothyrotropin-releasing hormone-(178–199) does not inhibit corticotropin release. Nicholson WE, et al. **Endocrinology** 1996 May;137(5):2171–4

The L beta T2 clonal gonadotrope: a model for single cell

studies of endocrine cell secretion. Thomas P, et al. **Endocrinology** 1996 Jul;137(7):2979–89

Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for interactions with dopamine through inhibitory coupling to calcium entry. Wang J, et al. **Endocrinology** 1996 Feb;137(2):587–94

Role of inositol trisphosphate–sensitive calcium stores in the regulation of adrenocorticotropin secretion by perifused rat anterior pituitary cells. Won JG, et al. **Endocrinology** 1995 Dec;136(12):5399–408

Involvement of pituitary adenylate cyclase–activating polypeptide in growth hormone secretion induced by serotoninergic mechanisms in the rat. Yamauchi K, et al. **Endocrinology** 1996 May;137(5):1693–7

Role of leukotriene C4 in follicle–stimulating hormone (FSH) secretion in female rat pituitary. Przylipiak A, et al. **Gynecol Endocrinol** 1996 Apr;10(2):95–100

Growth–associated protein–43 (GAP–43) facilitates peptide hormone secretion in mouse anterior pituitary AtT–20 cells. Gamby C, et al. **J Biol Chem** 1996 Apr 26;271(17):10023–8

Role of progesterone and nonsteroidal ovarian factors in regulating gonadotropin–releasing hormone self–priming in vitro. Byrne B, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1454–9

In obesity the somatotrope response to either growth hormone–releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. Maccario M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3774–8

The integrative control of adrenocorticotrophin secretion: a critical role for corticotrophin–releasing hormone. Evans MJ, et al. **J Endocrinol** 1996 Mar;148(3):475–83

Prolactin release from subpopulations of rat lactotrophs in the presence and absence of dopamine. Hu L, et al. **J Endocrinol** 1996 Jan;148(1):113–20

Identification of epidermal growth factor–secreting cells in the anterior pituitary of lactating female rats. Mouihate A, et al. **J Endocrinol** 1996 Feb;148(2):319–24

A quantitative analysis of testosterone action on FSH secretion from individual pituitary cells using the cell immunoblot assay. Noguchi K, et al. **J Endocrinol** 1996 Mar;148(3):427–33

Dexamethasone inhibits the release of TSH from the rat anterior pituitary gland in vitro by mechanisms dependent on de novo protein synthesis and lipocortin 1. Taylor AD, et al. **J Endocrinol** 1995 Dec;147(3):533–44

Oxytocin augmentation of gonadotropin–releasing hormone–stimulated luteinizing hormone release is modulated by cyclic AMP. Hurd SJ, et al. **Life Sci** 1996; 59(9):713–7

Lactotroph and somatotroph function in piglets reared in a constant hot environment. Matteri RL, et al. **Life Sci** 1996;58(8):711–7

EGF release by rat gonadotroph cells: characteristics and effects of LHRH. Mouite A, et al. **Life Sci** 1996; 58(2):107–14

Pituitary PRL secretion induced by tetraethylammonium is inhibited by dopamine through D2 receptors. Wang X, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):153–7

Adenylate–cyclase–dependent pituitary adrenocorticotropin secretion is defective in the inflammatory–disease–susceptible Lewis rat. Bernardini R, et al. **Neuroendocrinology** 1996 May;63(5):468–74

Adenohypophysial allografts releasing prolactin decrease prolactin mRNA concentration in the host hamster's adenohypophysis in situ. Campbell GT, et al. **Neuroendocrinology** 1996 May;63(5):430–6

Arachidonic acid–induced hormone release in somatotropes: involvement of calcium. Roudbaraki MM, et al. **Neuroendocrinology** 1996 Mar;63(3):244–56

Inhibition of nitric oxide synthase in the hypothalamus blocks the increase in plasma prolactin induced by intraventricular injection of interleukin–1 alpha in the rat. Rettori V, et al. **Neuroimmunomodulation** 1994 Mar–Apr;1(2):116–20

Role of neuromedin B in the in vitro thyrotropin release in response to thyrotropin–releasing hormone from anterior pituitaries of eu–, hypo–, and hyperthyroid rats. Pazos–Moura CC, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):353–8

Hypophysis–thyroid axis disturbances in human brain–dead donors. Colpart JJ, et al. **Transplant Proc** 1996 Feb; 28(1):171–2

[Prolactin and female gonadal endocrine regulation] Takeya U. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):824–32 (28 ref.) **(Jpn)**

SURGERY

[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

N–Ethyl–N–nitrosourea induces mammary cancers in the pituitary–isografted mouse which are histologically and genotypically distinct from those induced by N–methyl–N–nitrosourea. Swanson SM, et al. **Cancer Lett** 1996 Apr 19;102(1–2):159–65

Cell proliferation and apoptosis during mammary carcinogenesis in pituitary isografted mice. Christov KT, et al. **Carcinogenesis** 1996 Aug;17(8):1741–6

Adenohypophysial allografts releasing prolactin decrease prolactin mRNA concentration in the host hamster's adenohypophysis in situ. Campbell GT, et al. **Neuroendocrinology** 1996 May;63(5):430–6

ULTRASTRUCTURE

The fine structure of dexamethasone–induced growth hormone cells in the anterior pituitary gland of the rat fetus. Nogami H, et al. **Arch Histol Cytol** 1995 Dec;58(5):581–9

Development of a radioimmunoassay for European eel growth hormone and application to the study of silvering and experimental fasting. Marchelidon J, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):360–9

[The morphological state of the adenohypophyseal somatotrophs during body development under conditions of protein–energy insufficiency] Medvedev DI, et al. **Aviakosm Ekolog Med** 1995;29(3):28–31 (Eng. Abstr.) **(Rus)**

PITUITARY GLAND, POSTERIOR

ABNORMALITIES

Posterior pituitary ectopia and hypopituitarism—magnetic resonance appearances of four cases and a review of the literature. Denton ER, et al. **Br J Radiol** 1996 May; 69(821):402–6 (31 ref.)

Aberrant craniopharyngeal structures within the neurohypophysis of rats. Schaetti P, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):129–37

CHEMISTRY

Identification of specific binding sites for glucagon–like peptide–1 on the posterior lobe of the rat pituitary. Göke R, et al. **Neuroendocrinology** 1995 Aug;62(2):130–4

CYTOLOGY

Serum modulates cyclic AMP–dependent morphological changes in cultured neurohypophysial astrocytes. Ramsell KD, et al. **Brain Res Bull** 1996;39(2):109–14

Efferent projections from the retrochiasmatic area to the median eminence and to the pars nervosa of the hypophysis with special reference to the A15 dopaminergic cell group in the sheep. Gayrard V, et al. **Cell Tissue Res** 1995 Sep; 281(3):561–7

DRUG EFFECTS

Ba2+ ions evoke two kinetically distinct patterns of exocytosis in chromaffin cells, but not in neurohypophysial nerve terminals. Seward EP, et al. **J Neurosci** 1996 Feb 15;16(4):1370–9

ENZYMOLOGY

Cytochemical localization of ecto–ATPases in rat neurohypophysis. Thirion S, et al. **J Histochem Cytochem** 1996 Feb;44(2):103–11

METABOLISM

Vesicular monoamine transporter in microvesicles from bovine posterior pituitaries is immunologically similar to but distinct from the chromaffin granule counterpart in its sensitivities to 1–methyl–4–phenylpyridinium and histamine. Moriyama Y, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):790–4

Effect of hypothyroidism on vasoactive intestinal polypeptide–immunoreactive neurons in forebrain–neurohypophysial nuclei of the rat brain. Toni R, et al. **Brain Res** 1995 Jun 5;682(1–2):101–15

Dopaminergic periventriculo–hypophyseal nerves show tryptophan–hydroxylase immunoreactivity but lack serotonin synthesis. Vanhatalo S, et al. **Brain Res** 1995 Jul 31;687(1–2):205–10

Diurnal variation in the effect of melatonin on neurohypophysial hormone release from the rat hypothalamus. Yasin SA, et al. **Brain Res Bull** 1996; 39(1):1–5

BC1 RNA and vasopressin mRNA in rat neurohypophysis: axonal compartmentalization and differential regulation during dehydration and rehydration. Trembleau A, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2249–60

Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn–2. Schonemann MD, et al. **Genes Dev** 1995 Dec 15;9(24):3122–35

Dynorphin 1–17 delays the vasopressin induced mobilization of intracellular calcium in cultured astrocytes from the rat neural lobe. Boersma CJ, et al. **J Neuroendocrinol** 1993 Oct;5(5):583–90

Effect of centrally administered neuropeptide Y on hypothalamic and hypophyseal proopiomelanocortin–derived peptides in the rat. Blasquez C, et al. **Neuroscience** 1995 Sep;68(1):221–7

Immunocytochemical evidence for the presence of vasopressin in intermediate sized neurosecretory granules of solitary neurohypophyseal terminals in the homozygous Brattleboro rat. Sonnemans MS, et al. **Neuroscience** 1996 May;72(1):225–31

[Phosphoinositide response and changes in the supraoptic–neurohypophyseal system in individual resistance of rats to hypoxia] Vishnevskiĭ AA, et al. **Vopr Med Khim** 1995 Jul–Aug;41(4):10–2 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Loss of visibility of the neurohypophysis as a sign of central diabetes insipidus. Lee YJ, et al. **Eur J Radiol** 1996 Feb; 21(3):233–5

Aberrant craniopharyngeal structures within the neurohypophysis of rats. Schaetti P, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):129–37

Origin of posterior pituitary high intensity on T1–weighted magnetic resonance imaging. Immunohistochemical, electron microscopic, and magnetic resonance studies of posterior pituitary lobe of dehydrated rabbits. Sato N, et al. **Invest Radiol** 1995 Oct;30(10):567–71

Two cases of lymphocytic hypophysitis presenting with diabetes insipidus: a variant of lymphocytic infundibulo–neurohypophysitis. Nishioka H, et al. **Surg Neurol** 1996 Sep;46(3):285–90; discussion 290–1

Lymphocytic infundibulohypophysitis presenting in the postpartum period: case report. Van Havenbergh T, et al. **Surg Neurol** 1996 Sep;46(3):280–4

PHYSIOLOGY

Cholecystokinin octapeptide and the daily rhythm of vasopressin and oxytocin release. Morawska–Barszczewska J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):164–71

The neurohypophysial endocrine regulatory cascade: precursors, mediators, receptors, and effectors. Acher R, et al. **Front Neuroendocrinol** 1995 Jul;16(3):237–89 (236 ref.)

PHYSIOPATHOLOGY

[Water–electrolyte imbalance and posterior pituitary gland hormone] Yoshida S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1388–95 (20 ref.) **(Jpn)**

RADIOGRAPHY

Granular cell tumour of the neurohypophysis. Ji CH, et al. **Neuroradiology** 1995 Aug;37(6):451–2

[Granular cell tumors. Rare tumors of the neurohypophysis] Barrande G, et al. **Presse Med** 1995 Oct 14;24(30):1376–80 (Eng. Abstr.) **(Fre)**

SECRETION

A 14–kilodalton prolactin–like fragment is secreted by the hypothalamo–neurohypophyseal system of the rat. Torner L, et al. **Endocrinology** 1995 Dec;136(12):5454–60

ULTRASTRUCTURE

Ultrastructure of the hypothalamo–neurohypophysial system in rats exposed to lead. II. Neurohypophysis. Gałasińska–Pomykoł I, et al. **Rocz Akad Med Bialymst** 1994;39:111–6

PITUITARY GLYCOPROTEIN HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

PITUITARY GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

PITUITARY GROWTH HORMONE see **SOMATOTROPIN**

PITUITARY HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE**

PITUITARY HORMONE–REGULATING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE**

PITUITARY HORMONE RELEASE INHIBITING HORMONES

see related
RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE

PITUITARY HORMONE–RELEASING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE**

PITUITARY HORMONE–RELEASING HORMONES

see related
RECEPTORS, PITUITARY HORMONE–REGULATING HORMONE

CHEMISTRY

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)

PITUITARY HORMONES

see related
HYPOPITUITARISM
RECEPTORS, PITUITARY HORMONE

ANALYSIS

Identification, cellular localization and in vitro release of a novel teleost melanin-concentrating hormone gene-related peptide. Gröneveld D, et al. **Neuroendocrinology** 1995 Nov; 62(5):498-505

BIOSYNTHESIS

Impaired processing of brain proneurotensin and promelanin-concentrating hormone in obese fat/fat mice. Rovere C, et al. **Endocrinology** 1996 Jul;137(7):2954-8

BLOOD

Vital exhaustion, anger expression, and pituitary and adrenocortical hormones. Implications for the insulin resistance syndrome. Keltikangas-Järvinen L, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):275-80

A simple device for serial blood collection in human subjects and animals. Sir-Petermann T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):398-401

Red drum somatolactin: development of a homologous radioimmunoassay and plasma levels after exposure to stressors or various backgrounds. Zhu Y, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):275-88

Pronounced seasonal rhythms in plasma somatolactin levels in rainbow trout. Rand-Weaver M, et al. **J Endocrinol** 1995 Jul;146(1):113-9

The effect of photoperiod on plasma levels of melanin-concentrating hormone in the trout. Lyon VE, et al. **J Neuroendocrinol** 1993 Oct;5(5):493-9

Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Young WF Jr, et al. **Mayo Clin Proc** 1996 Jul;71(7):649-56

[Effect of ovariectomy and natural menopause on levels of selected pituitary hormones, 17-beta estradiol and lipid profile in blood serum] Halerz-Nowakowska B. **Ginekol Pol** 1995 Oct;66(10):553-60 (Eng. Abstr.) **(Pol)**

DEFICIENCY

Elevation of serum creatine phosphokinase during growth hormone treatment in patients with multiple pituitary hormone deficiency. Momoi T, et al. **Eur J Pediatr** 1995 Nov;154(11):886-9

Gonadal function and response to growth hormone (GH) in boys with isolated GH deficiency and to GH and gonadotropins in boys with multiple pituitary hormone deficiencies. Tatò L, et al. **Fertil Steril** 1996 Apr; 65(4):830-4

GENETICS

The molecular pathology of pituitary hormone deficiency and resistance. Woods KA, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):453-87 (140 ref.)

Structural organization of the gene encoding the neuroendocrine chaperone 7B2. Braks JA, et al. **Eur J Biochem** 1996 Feb 15;236(1):60-7

Differential melanin-concentrating hormone gene expression in two hypothalamic nuclei of the teleost tilapia in response to environmental changes. Gröneveld D, et al. **J Neuroendocrinol** 1995 Jul;7(7):527-33

METABOLISM

Purification and enzymatic characterization of recombinant prohormone convertase 2: stabilization of activity by 21 kDa 7B2 Lamango NS, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):238-50

The neuroendocrine protein 7B2 contains unusually potent transcriptional activating sequences. Chaudhuri B, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):1-10

Development of melanin-concentrating hormone-immunoreactive elements in the brain of gilthead seabream (Sparus auratus). Mancera JM, et al. **Cell Tissue Res** 1995 Dec;282(3):523-6

Dissociation of the complex between the neuroendocrine chaperone 7B2 and prohormone convertase PC2 is not associated with proPC2 maturation. Braks JA, et al. **Eur J Biochem** 1996 Jun 1;238(2):505-10

Cyclo-oxygenase mediation of endotoxin-induced fever, anterior and posterior pituitary hormone release, and hypothalamic c-Fos expression in the prepubertal pig. Parrott RF, et al. **Exp Physiol** 1995 Jul;80(4):663-74

Elevations of somatolactin in plasma and pituitaries and increased alpha-MSH cell activity in red drum exposed to black background and decreased illumination. Zhu Y, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):21-31

Quantification of immunohistochemistry using an image analyser: correlation with hormone concentrations in pituitary adenomas. Matsuo T, et al. **Histochem J** 1995 Dec; 27(12):989-96

Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: a potential mechanism for its inactivation. Zhu X, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4919-24

PHARMACOLOGY

Depolarizing action of secretory granule protein 7B2 on rat supraoptic neurosecretory neurons. Senatorov VV, et al. **J Neuroendocrinol** 1993 Oct;5(5):533-6

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167-72 (61 ref.)

A visuospatial dysfunction following posterior cortex injury is attenuated by postinjury administration of the ACTH4-9 analog ORG 2766. Wells DL, et al. **Neurobiol Learn Mem** 1995 Jul;64(1):97-102

Biphasic effect of MCH on alpha-MSH release from the tilapia (Oreochromis mossambicus) pituitary. Gröneveld D, et al. **Peptides** 1995;16(5):945-9

PHYSIOLOGY

Similarities in cellular expression and functions of melanin-concentrating hormone and atrial natriuretic factor in the rat digestive tract. Hervieu G, et al. **Endocrinology** 1996 Feb;137(2):561-71

Acute effects of spinal cord injury on the pituitary-testicular hormone axis and Sertoli cell functions: a time course study. Huang HF, et al. **J Androl** 1995 Mar-Apr;16(2):148-57

Calcium-induced aggregation of neuroendocrine protein 7B2 in vitro and its modulation by ATP. Linard CG, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):39-47

A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Qu D, et al. **Nature** 1996 Mar 21;380(6571):243-7

[An isohormone-inhibitor of biological activity of gonadotropin activity in Baltic salmon] Zenkevich GA, et al. **Dokl Akad Nauk** 1996 Apr;347(6):818-20 **(Rus)**

[Stress-induced analgesia. The role of the hormones of the hypophyseal-adrenocortical system] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):40-6 (Eng. Abstr.) **(Rus)**

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50-60 (80 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Pituitary dysfunctions in uremic patients undergoing peritoneal dialysis: a cross sectional descriptive study. Díez JJ, et al. **Adv Perit Dial** 1995;11:218-24

Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:386-95 (29 ref.)

Induction by cytokines of the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Neuroimmunomodulation** 1994 Jan;1(1):2-13 (50 ref.)

[Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy] Grabenbauer GG, et al. **Strahlenther Onkol** 1996 Apr;172(4):193-7 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

The treatment of infantile spasms by paediatric neurologists in the UK and Ireland [letter] Appleton RE. **Dev Med Child Neurol** 1996 Mar;38(3):278-9

Current strategies for hormone replacement therapy for the hypopituitary patient. Cuneo RC. **Med J Aust** 1995 Nov 20;163(10):539-41

PITUITARY HORMONES, ANTERIOR

ANALYSIS

Immunocytochemical and morphometric study on the changes of TSH, PRL, GH and ACTH cells during the development of Bufo arenarum. Miranda LA, et al. **Cell Tissue Res** 1996 Jan;283(1):125-32

BLOOD

Hormonal changes in male subjects over-ninety. Ravaglia G, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun; 71(5-6):133-9

Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Templ E, et al. **Br J Rheumatol** 1996 Apr;35(4):350-6

The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Korbonits M, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):365-71

Effect of endothelin-1 in man--impact on basal and stimulated concentrations of luteinizing hormone, follicle-stimulating hormone, thyrotropin, growth hormone, corticotropin, and prolactin with and without pretreatment with nifedipine. Vierhapper H. **Metabolism** 1996 May;45(5):658-61

METABOLISM

Changes in anterior pituitary response in patients with idiopathic hypothalamic hypogonadism caused by pulsatile GnRH therapy and testosterone replacement. Schopohl J, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):184-90

Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. Tepavčević D, et al. **J Endocrinol Invest** 1995 Jun; 18(6):427-30

[Interrelationship of prolactin concentration with levels of other hormones and with testicular ultrastructural morphometric indicators in the human fetus] Sukhorukov VS, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):654-6 **(Rus)**

PHARMACOLOGY

Effects of TRH, prolactin and TSH on cell proliferation in the intermediate lobe of the rat pituitary gland. Pawelczyk T, et al. **J Endocrinol** 1996 Feb;148(2):193-6

SECRETION

Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. Ramirez G, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):167-74

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325-34 (63 ref.)

Cyclosporine effects on in vitro responsiveness of anterior pituitary hormone release to dopamine and thyrotropin-releasing hormone in young female rats. Moreno ML, et al. **J Neuroendocrinol** 1995 Oct; 7(10):765-74

Hyperprolactinaemia and cyclosporine treatment on secretion of adenohypophyseal hormones. Lafuente A, et al. **Life Sci** 1996;59(12):993-1000

An interleukin-1-alpha-like neuronal system in the preoptic-hypothalamic region and its induction by bacterial lipopolysaccharide in concentrations which alter pituitary hormone release. Rettori V, et al. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):251-8

PITUITARY HORMONES, POSTERIOR

see related
NEUROPHYSINS

METABOLISM

[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199-214 (59 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

A V1-type receptor for mediating the neurohypophysial hormone-induced ACTH release in trout pituitary. Pierson PM, et al. **J Endocrinol** 1996 Apr;149(1):109-15

[Effect of resection of the proximal part of the small intestine on inhibition of gastric secretion as affected by pituitrin, gastrozepin and histodil] Trefilov AB. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):29-32 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The neurohypophysial endocrine regulatory cascade: precursors, mediators, receptors, and effectors. Acher R, et al. **Front Neuroendocrinol** 1995 Jul;16(3):237-89 (236 ref.)

PITUITARY IRRADIATION

The need for adjunctive focused radiation therapy in pituitary adenomas. Knosp E, et al. **Acta Neurochir Suppl (Wien)** 1995;63:81-4

Progressive late delayed postirradiation encephalopathy with Klüver-Bucy syndrome. Serial MRI and clinico-pathological studies. Thajeb P. **Clin Neurol Neurosurg** 1995 Aug;97(3):264-8

Radiosurgical pituitary ablation for cancer pain. Sloan PA, et al. **J Palliat Care** 1996 Summer;12(2):51-3

INSTRUMENTATION

Intracavitary treatment of intrasellar cystic craniopharyngeomas with 90-Yttrium by trans-sphenoidal approach--a technical note. Lange M, et al. **Acta Neurochir (Wien)** 1995;135(3-4):206-9

PITUITARY NEOPLASMS

Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Young WF Jr, et al. **Mayo Clin Proc** 1996 Jul;71(7):649-56

[Clinical neuroendocrinology] Marek J. **Sb Lek** 1995; 96(4):333-8 (Eng. Abstr.) **(Cze)**

BLOOD

Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. Kovacs CS, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3036-42

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331-46 (103 ref.)

CHEMICALLY INDUCED

Development of pituitary lesions in ND4 Swiss Webster mice when estimating the sensory irritancy of airborne chemicals using ASTM method E981-84. Werley MS, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):712-6

Reduction in the expression and action of transforming growth factor beta 1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Pastorcic M, et al. **Cancer Res** 1995 Nov 1;55(21):4892–8

Lactotroph hyperplasia in an estrogen treated male–to–female transsexual patient. Serri O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3177–9 (12 ref.)

Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. Garcia MM, et al. **J Endocrinol Invest** 1995 Jun;18(6):450–5

CHEMISTRY

Immunohistochemical demonstration of tenascin in human pituitary glands and adenomas. Ikeda H, et al. **Acta Histochem** 1995 Jul;97(3):273–80

Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Sanno N, et al. **Am J Clin Pathol** 1996 Jul;106(1):16–21

Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Farnoud MR, et al. **Int J Cancer** 1996 Jul 3;67(1):45–53

Heterogeneity of human luteinizing hormone in pituitary tumor homogenates and cell incubates. van Ginkel LA, et al. **J Endocrinol Invest** 1995 Apr;18(4):258–64

Neural cell adhesion molecule expression in human pituitary adenomas. Kleinschmidt–DeMasters BK, et al. **J Neurooncol** 1995;25(3):205–13

CLASSIFICATION

The World Health Organization classification of adenohypophysial neoplasms. A proposed five–tier scheme. Kovacs K, et al. **Cancer** 1996 Aug 1;78(3):502–10

COMPLICATIONS

MR features of pituitary metastases in two patients with central diabetes insipidus. De Merlier Y, et al. **Acta Neurol Belg** 1996 Jun;96(2):141–2

Visual disturbances in patients with pituitary adenoma. Ikeda H, et al. **Acta Neurol Scand** 1995 Aug;92(2):157–60

Verapamil–induced hyperprolactinemia complicated by a pituitary incidentaloma. Dombrowski RC, et al. **Ann Pharmacother** 1995 Oct;29(10):999–1001

Patterns of visual loss associated with pituitary macroadenomas. Poon A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):107–15

Pituitary microadenoma in Turner's syndrome. Pejaver RK, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):223–4

Hyperprolactinaemia in patients with pituitary adenomas. The pituitary stalk compression syndrome. Kruse A, et al. **Br J Neurosurg** 1995;9(4):453–7

Cushing's disease due to female gonadotroph adenoma of the pituitary. Ikeda H, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):383–6

Autonomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Sturrock ND, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):753–8

Proptosis precipitated by retinal detachment repair in a patient with occult pituitary tumour [letter] Nischal KK, et al. **Eye** 1995;9 (Pt 5):647–9

Hyperprolactinemia and reproductive disorders—a profile from north east. Choudhury SD, et al. **J Assoc Physicians India** 1995 Sep;43(9):617–8

Ischaemic stroke leading to left hemiparesis and autohypophysectomy in a case of pituitary macroadenoma. Mukherjee S, et al. **J Assoc Physicians India** 1995 Nov; 43(11):801–2

Suprasellar craniopharyngioma. Serrien B, et al. **J Belge Radiol** 1995 Aug;78(4):238

Clinical case seminar: Cushing's syndrome in an elderly woman with large thyroid and pituitary masses. Wallace EA, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):453–6

Pituitary macroadenoma in Addison's disease. Akçay G, et al. **J Int Med Res** 1996 Mar–Apr;24(2):221–7

Pituitary tumor and low gonadotropins in a patient with Turner's syndrome. Mermilliod JA, et al. **J La State Med Soc** 1995 Dec;147(12):540–3

Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. Phillip M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar; 8(1):47–50

Depressive disorder due to craniopharyngioma. Spence SA, et al. **J R Soc Med** 1995 Nov;88(11):637–8

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):234–6

Increased prolactin level and pituitary adenoma as a cause of headache in two patients with sickle cell disease. Sabbagh R, et al. **Pediatr Hematol Oncol** 1996 Jan–Feb; 13(1):101–5

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32–6

Persistent or recurrent hyperparathyroidism in patients with double adenomas. Tezelman S, et al. **Surgery** 1995 Dec; 118(6):1115–22; discussion 1122–4

[State of shock and bilateral paralysis of the III cranial nerve revealing necrotic pituitary macroadenoma (letter; comment)] Dupont C, et al. **Presse Med** 1995 Oct 21; 24(31):1447. Comment on: Presse Med 1995 Mar 11;24(10):501–3. **(Fre)**

[Nonobstructive urinary tract dilatation due to diabetes insipidus in a patient with craniopharyngioma] Ichiyanagi N, et al. **Hinyokika Kiyo** 1995 Aug;41(8):609–12 (Eng. Abstr.) **(Jpn)**

[A case of oligozoospermia with marginal hyperprolactinemia due to pituitary microadenoma] Kawano M, et al. **Hinyokika Kiyo** 1996 Apr;42(4):319–21 (Eng. Abstr.) **(Jpn)**

[A case of pituitary abscess caused by infection of Rathke's cleft cyst] Sato M, et al. **No Shinkei Geka** 1995 Nov; 23(11):991–5 (Eng. Abstr.) **(Jpn)**

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of Rathke's cleft cyst in association with anterior communicating artery aneurysm presenting a rare visual field defect] Yuki K, et al. **No To Shinkei** 1996 May; 48(5):482–5 (Eng. Abstr.) **(Jpn)**

[Penile erectile dysfunction secondary to hypophyseal adenoma] Franco Miranda E, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):805–7 (Eng. Abstr.) **(Spa)**

[Thymus carcinoid associated with type 1 multiple endocrine neoplasm syndrome] Martínez Cerezo FJ, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):21–3 (Eng. Abstr.) **(Spa)**

CONGENITAL

Antenatally diagnosed neonatal craniopharyngioma. Kültürsay N, et al. **J Perinatol** 1995 Sep–Oct;15(5):426–8

DIAGNOSIS

Are intra– and suprasellar masses detected by CT and MR really tumours? Tóth S, et al. **Acta Neurochir (Wien)** 1995; 137(1–2):54–7

Rathke's cleft cyst. Two cases with uncommon MR signals. Skjødt K, et al. **Acta Radiol** 1996 Jul;37(4):596–8

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597–603 (69 ref.)

Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95–106 (51 ref.)

High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. St–Jean E, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):305–9

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

Differential diagnosis and treatment of steroid–induced affective syndromes. Pies R. **Gen Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)

Pituitary adenoma presenting as sinonasal tumor: pitfalls in diagnosis. Luk IS, et al. **Hum Pathol** 1996 Jun;27(6):605–9

Antenatally diagnosed neonatal craniopharyngioma. Kültürsay N, et al. **J Perinatol** 1995 Sep–Oct;15(5):426–8

Intrasellar meningiomas. Wang CJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):486–90

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):234–6

MRI of a pituitary cryptococcoma simulating an adenoma. Yu YQ, et al. **Neuroradiology** 1995 Aug:37(6):449–50

Cushing's disease due to a giant pituitary adenoma in early infancy: CT and MRI features. Maeder P, et al. **Pediatr Radiol** 1996;26(1):48–50

Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Hayashi S, et al. **Radiat Med** 1995 Jul–Aug;13(4):167–70

MR imaging of macroadenomas. Mohammad–Zadeh L. **Radiol Technol** 1995 Sep–Oct;67(1):29–36; quiz 37–8

Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31

Aspergillosis of the sphenoid sinus: presentation as a pituitary mass and postoperative gallium–67 imaging. Parker KM, et al. **Surg Neurol** 1996 Apr;45(4):354–8

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9 (53 ref.) **(Dut)**

[Clinical imaging in psychiatry] Jabourian AP, et al. **Ann Med Psychol (Paris)** 1996 Jan;154(1):74–7 (Eng. Abstr.) **(Fre)**

[Granular cell tumors. Rare tumors of the neurohypophysis] Barrande G, et al. **Presse Med** 1995 Oct 14;24(30):1376–80 (Eng. Abstr.) **(Fre)**

[Macroprolactinoma] von Werder K. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):962 **(Ger)**

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

[MRI of the pituitary adenomas with reference to the hormonal activity] Masunaga S, et al. **No To Shinkei** 1995 Dec;47(12):1165–9 (Eng. Abstr.) **(Jpn)**

[The alpha subunit of glycoprotein hormones as a biochemical marker of pituitary tumors] Bulatov AA, et al. **Vopr Med Khim** 1995 Sep–Oct;41(5):19–23 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV. **Ann R Coll Surg Engl** 1995 Jul;77(4):308–12 (25 ref.)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine–resistant prolactinomas. Missale C, et al. **Br J Cancer** 1995 Dec;72(6):1397–9

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma. Kamel N, et al. **Endocr J** 1995 Aug;42(4):581–6

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Delgrange E, et al. **Eur J Endocrinol** 1996 Apr;134(4):454–6

In vivo responsiveness of morphological variants of growth hormone–producing pituitary adenomas to octreotide [see comments] Ezzat S, et al. **Eur J Endocrinol** 1995 Dec; 133(6):686–90. Comment in: Eur J Endocrinol 1995 Dec;133(6):675–7.

Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy. Shanis BS, et al. **Gynecol Endocrinol** 1996 Apr;10(2):91–4

Comparison among different dopamine–agonists of new formulation in the clinical management of macroprolactinomas. Colao A, et al. **Horm Res** 1995; 44(5):222–8

The effects of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone–deficient adults. Riedl M, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1434–8

The individual responsiveness to growth hormone (GH) treatment in GH–deficient adults is dependent on the level of GH–binding protein, body mass index, age, and gender. Johannsson G, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1575–81

Inhibitory effects of fumagillin and its analogue TNP–470 on the function, morphology and angiogenesis of an oestrogen–induced prolactinoma in Fischer 344 rats. Stępień H, et al. **J Endocrinol** 1996 Jul;150(1):99–106

Bleomycin for cystic craniopharyngioma [letter] Broggi G, et al. **J Neurosurg** 1996 Jun;84(6):1080–1

Use of bleomycin in intratumoral chemotherapy for cystic craniopharyngioma. Case report. Cavalheiro S, et al. **J Neurosurg** 1996 Jan;84(1):124–6

Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells. Newton CJ. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):327–36

[The therapy of a macroprolactinoma with the intramuscular application of a long–acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865–8 (10 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Cost analysis of intermediate care versus intensive care for the neurosurgery patient. Cohen L, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):3, 18

EPIDEMIOLOGY

Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of Japan. Kuratsu J, et al. **J Neurosurg** 1996 Jun; 84(6):946–50

Pituitary adenomas in childhood and adolescence. Mindermann T, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):79–83 (39 ref.)

GENETICS

The classification and molecular biology of pituitary adenomas. Thapar K, et al. **Adv Tech Stand Neurosurg** 1995; 22:3–53 (130 ref.)

Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin–like growth factor–1 levels in a large multiple endocrine neoplasia type 1 kindred. Burgess JR, et al. **Am J Med** 1996 May; 100(5):544–7

DNA measurement in pituitary adenomas assessed on imprints by image analysis. Kontogeorgos G, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):144–50

Chromosomal abnormalities in tumor and lymphocyte cultures from patients with pituitary adenomas [letter] Capra E, et al. **Cancer Genet Cytogenet** 1995 Oct 1;84(1):89

Antisense inhibition of parathyroid hormone–related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat. Akino K, et al. **Cancer Res** 1996 Jan 1;56(1):77–86

Frequent loss of the P16INK4a gene product in human pituitary tumors. Woloschak M, et al. **Cancer Res** 1996 Jun 1;56(11):2493–6

A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)–deficient mice. Fero ML, et al. **Cell** 1996 May 31;85(5):733–44

Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Nakayama K, et al. **Cell** 1996 May 31;85(5):707–20

Clinical and genetic changes in a case of a Cushing's carcinoma [letter; comment] Ball SG. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):125–6. Comment on: Clin Endocrinol (Oxf) 1995 Jun;42(6):663–70; discussion 671–2.

Structure of the thyrotrophin–releasing hormone receptor in human pituitary adenomas. Faccenda E, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):341–7

Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. Nikitin AYu, et al. **Genes Dev** 1996 Aug 1;10(15):1870–9

Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. Burgess JR, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1841–5

Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. Burgess JR, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2642–6

Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. Dahia PL, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1768–71

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon I, et al. **J Clin Invest** 1996 Jan 1; 97(1):187–95

Allelic loss at the tuberous sclerosis (Tsc2) gene locus in spontaneous uterine leiomyosarcomas and pituitary adenomas in the Eker rat model. Kubo Y, et al. **Jpn J Cancer Res** 1995 Sep;86(9):828–32

[Familial pituitary tumors] Yoshimoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2691–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

Acromegaly and pituitary tumors: early anatomoclinical observations. Brunori A, et al. **Surg Neurol** 1995 Jul; 44(1):83–7

METABOLISM

Immunohistochemical demonstration of TGF-beta-receptor type II in human pituitary adenomas. Fujiwara K, et al. **Acta Histochem** 1995 Oct;97(4):445–54

Tumor-related selection of calcium signals in vasopressin-stimulated human adenomatous corticotrophs. Corcuff JB, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E451–7

Expression of human Pit-1 product in the human pituitary and pituitary adenomas. Immunohistochemical studies using an antibody against synthetic human Pit-1 product. Sanno N, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):73–7

G-protein modulation of alpha 1A (P/Q) type calcium channel expressed in GH3 cells. Zong S, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):302–8

The prognostic importance of fibronectin and sialic acid levels in human pituitary adenomas. Ozyurt E, et al. **Cancer Lett** 1996 Feb 27;100(1-2):151–4

Reduction in the expression and action of transforming growth factor beta 1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Pastorcic M, et al. **Cancer Res** 1995 Nov 1;55(21):4892–8

Expression of the transferrin receptor in human anterior pituitary adenomas is confined to gonadotrophinomas. Atkin SL, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):467–71

Expression and characterization of the substance P (NK1) receptor in the rat pituitary and AtT20 mouse pituitary tumor cells. Winkler A, et al. **Eur J Pharmacol** 1995 Sep 15;291(1):51–5

Quantification of immunohistochemistry using an image analyser: correlation with hormone concentrations in pituitary adenomas. Matsuo T, et al. **Histochem J** 1995 Dec; 27(12):989–96

Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Woloschak M, et al. **Int J Cancer** 1996 Jul 3;67(1):16–9

Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. Alexander JM, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):783–90

Impaired processing of proopiomelanocortin in corticotroph macroadenomas. Gibson S, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):497–502

Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. Hashimoto K, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2933–9

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. LeRiche VK, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):656–62

Gonadotropin-releasing hormone messenger RNA expression in gonadotroph tumors and normal human pituitary. Miller GM, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):80–3

Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. Pellegrini-Bouiller I, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3390–6

Decreased follistatin gene expression in gonadotroph adenomas. Penabad JL, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3397–403

Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. Zafar M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3621–7

1,25-Dihydroxyvitamin D3-induced upregulation of the thyrotropin-releasing hormone receptor in clonal rat pituitary GH3 cells. Atley LM, et al. **J Endocrinol** 1995 Dec;147(3):397–404

Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas. Lania A, et al. **J Endocrinol Invest** 1995 Apr;18(4):265–70

Mechanism of action of pituitary adenylate cyclase-activating polypeptide (PACAP) in human nonfunctioning pituitary tumors. Lania A, et al. **J Neuroendocrinol** 1995 Sep;7(9):695–702

S-100 antigen-positive folliculostellate cells are not the source of IL-6 gene expression in human pituitary adenomas. Ueta Y, et al. **J Neuroendocrinol** 1995 Jun; 7(6):467–74

The human growth hormone gene is regulated by a multicomponent locus control region. Jones BK, et al. **Mol Cell Biol** 1995 Dec;15(12):7010–21

Protein kinase C-dependent growth hormone releasing peptides stimulate cyclic adenosine 3',5'-monophosphate production by human pituitary somatotropinomas expressing gsp oncogenes: evidence for crosstalk between transduction pathways. Adams EF, et al. **Mol Endocrinol** 1996 Apr;10(4):432–8

The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Bertherat J, et al. **Mol Endocrinol** 1995 Jul; 9(7):777–83

Effect of thyrotropin-releasing hormone on microtubules in GH3 cells. Ravindra R, et al. **Neuroreport** 1995 Jul 10; 6(10):1405–8

Opioid and tachykinin neuropeptides in prolactin-secreting human pituitary adenomas. Zhu X, et al. **Peptides** 1995; 16(6):1097–107

MORTALITY

[Analysis of causes of fatal outcome in children in the intensive care unit after removal of craniopharyngiomas] Savin IA, et al. **Anesteziol Reanimatol** 1996 Mar-Apr; (2):70–4 (Eng. Abstr.) **(Rus)**

NURSING

Cost analysis of intermediate care versus intensive care for the neurosurgery patient. Cohen L, et al. **J Nurs Adm** 1996 Jul-Aug;26(7-8):3, 18

PATHOLOGY

Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Pegolo G, et al. **Acta Cytol** 1995 Sep-Oct;39(5):887–92

Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Kawamoto H, et al. **Acta Neurochir (Wien)** 1995;136(1-2):37–43

Intracranial dissemination of a pituitary adenoma: presentation as an unusual mass in the cerebellopontine angle [letter] Depper MH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1500–1

Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Sanno N, et al. **Am J Clin Pathol** 1996 Jul;106(1):16–21

Ganglion cell-containing tumors of the pituitary gland. Towfighi J, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):369–77 (44 ref.)

Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814–20 (43 ref.)

Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81–92 (83 ref.)

Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. Feigenbaum SL, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1711–9

Ectopic nonfunctioning pituitary adenoma in the sphenoid sinus [letter; comment] Siegert B, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):430–1. Comment on: J Clin Endocrinol Metab 1995 Jun;80(6):1774–7.

MR volumetry for monitoring intramuscular bromocriptine treatment in macroprolactinomas. Benesch H, et al. **J Comput Assist Tomogr** 1995 Nov-Dec;19(6):866–70

Calcified cystic pituitary prolactinoma. Kasantikul V, et al. **J Med Assoc Thai** 1995 Sep;78(9):497–501

Symptomatic Rathke's cleft cysts in identical twins. Case illustration. Hayashi Y, et al. **J Neurosurg** 1996 Apr; 84(4):710

Ectopic pituitary adenoma occurring in the interpeduncular cistern. Case report. Takahata T, et al. **J Neurosurg** 1995 Dec;83(6):1092–4

Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells. Newton CJ. **J Steroid Biochem Mol Biol** 1995 Dec;55(3-4):327–36

Dural invasion and proliferative potential of pituitary adenomas. Daita G, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):211–4

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):234–6

p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Thapar K, et al. **Neurosurgery** 1996 Apr;38(4):763–70; discussion 770–1

Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Thapar K, et al. **Neurosurgery** 1996 Jan; 38(1):99–106; discussion 106–7

Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Capella C, et al. **Pathol Res Pract** 1995 May;191(4):345–7 (27 ref.)

Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)

Radiologic-Pathologic Conference of Children's Hospital Boston: scalp mass in a child following treatment for craniopharyngioma. Robson CD, et al. **Pediatr Radiol** 1996; 26(3):236–8

Craniopharyngioma: treatment in the CT and MR imaging era. Mark RJ, et al. **Radiology** 1995 Oct;197(1):195–8

Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31

Rapid recurrence of craniopharyngioma during pregnancy with recovery of vision: a case report. Maniker AH, et al. **Surg Neurol** 1996 Apr;45(4):324–7

Effects of gonadal steroids on the growth of human pituitary adenomas in vitro. Caronti B, et al. **Tumour Biol** 1995; 16(6):353–64

[Retrospect and prospect of endocrinological pathology] Tan Y. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):239–41 (21 ref.) **(Chi)**

[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Trans-septo-sphenoidal transnasal approach for microsurgery of hypophyseal tumors] Gras Albert JR, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):201–12 (Eng. Abstr.) **(Spa)**

[Hypophyseal apoplexy] Sánchez Valiente S. **Neurologia** 1995 Jun-Jul;10(6):252–3 **(Spa)**

PHYSIOPATHOLOGY

Frontal intermittent rhythmic delta activity (FIRDA) in pituitary adenoma. Kameda K, et al. **Clin Electroencephalogr** 1995 Jul;26(3):173–9

Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. Burgess JR, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2642–6

Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line. Turgeon JL, et al. **Mol Endocrinol** 1996 Apr;10(4):439–50

Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Leslie WD, et al. **Nucl Med Commun** 1995 Aug;16(8):698–702

Hot flushes in men with pituitary adenoma. McReynolds SM, et al. **Surg Neurol** 1995 Jul;44(1):14–7; discussion 17–8

PREVENTION & CONTROL

[Screening of multiple endocrine neoplasias type 1. Reflexions of the Study Group on Multiple Endocrine Neoplasias type 1] Cougard P, et al. **Ann Chir** 1995; 49(6):500–6 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Familial prolactinoma [letter; comment] Sobrinho LG. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):511. Comment on: Clin Endocrinol (Oxf) 1995 May;42(5):483–6.

RADIOGRAPHY

Granular cell tumour of the neurohypophysis. Ji CH, et al. **Neuroradiology** 1995 Aug;37(6):451–2

Radiologic-Pathologic Conference of Children's Hospital Boston: scalp mass in a child following treatment for craniopharyngioma. Robson CD, et al. **Pediatr Radiol** 1996; 26(3):236–8

Craniopharyngioma: treatment in the CT and MR imaging era. Mark RJ, et al. **Radiology** 1995 Oct;197(1):195–8

[Classical roentgenology and computerized tomography in the diagnosis of pituitary adenomas] Portnoĭ LM, et al. **Vestn Rentgenol Radiol** 1996 Jan-Feb;(1):5–9 (Eng. Abstr.) **(Rus)**

[Experience with using mobile x-ray computed tomography in the diagnosis of hypophyseal adenomas] Portnoĭ LM, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul-Sep; (3):28–30 **(Rus)**

RADIONUCLIDE IMAGING

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. van Royen EA, et al. **J Nucl Med** 1996 Sep;37(9):1449–51

RADIOTHERAPY

The need for adjunctive focused radiation therapy in pituitary adenomas. Knosp E, et al. **Acta Neurochir Suppl (Wien)**

1995;63:81–4

Intracavitary treatment of intrasellar cystic craniopharyngeomas with 90–Yttrium by trans–sphenoidal approach—a technical note. Lange M, et al. **Acta Neurochir (Wien)** 1995;135(3–4):206–9

Radiation therapy for pituitary adenomas. A retrospective study of the University of Louisville experience. Cornett MS, et al. **Am J Clin Oncol** 1996 Jun;19(3):292–5

Stereotactic intratumour irradiation with nuclide for craniopharyngiomas. Liu Z, et al. **Chin Med J (Engl)** 1996 Mar;109(3):219–22

Stereotactic radiosurgery of anterior skull base tumors. Lunsford LD, et al. **Clin Neurosurg** 1995;42:99–118

High efficacy without visual damage: the current status of pituitary radiotherapy [editorial; comment] Goldsmith BJ, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):765–7 . Comment on: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):599–605.

Long–term visual changes following pituitary irradiation [see comments] Movsas B, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):599–605 . Comment in: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):765–7.

[Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy] Grabenbauer GG, et al. **Strahlenther Onkol** 1996 Apr;172(4):193–7 (Eng. Abstr.) **(Ger)**

SECONDARY

Pituitary gland metastases. Sioutos P, et al. **Ann Surg Oncol** 1996 Jan;3(1):94–9 (31 ref.)

Radiograph of the month. Small cell lung carcinoma with metastasis to the pituitary. Dross P, et al. **Del Med J** 1996 Jun;68(6):313–5

Central diabetes insipidus caused by pituitary metastasis of lung cancer. Matsuda R, et al. **Intern Med** 1995 Sep; 34(9):913–8

SECRETION

Thyrotropin–secreting pituitary tumors in hyper– and hypothyroidism. Beck–Peccoz P, et al. **Acta Med Austriaca** 1996;23(1–2):41–6 (45 ref.)

Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Jin L, et al. **Am J Pathol** 1996 Jun;148(6):2057–66

Patients with TSH–secreting pituitary tumor possess different TSH molecular isoforms. Mason M, et al. **Arch Med Res** 1995 Autumn;26(3):239–43

A case of hyperthyroidism due to pituitary resistance to thyroid hormone. Hidaka Y, et al. **Endocr J** 1994 Aug; 41(4):339–43

Analysis of the in vitro secretory activity of human pituitary adenomas: modification of corticotropin release from adenoma tissue explant cultures by addition of a human plasma ultrafiltrate bioactive fraction. Zarković N, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):23–30

No difference between micro– and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration. Maraschini C, et al. **Gynecol Endocrinol** 1996 Feb;10(1):7–15

Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. Arafah BM, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3507–12

Vasopressin receptor expression and mutation analysis in corticotropin–secreting tumors. Dahia PL, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1768–71

Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin–secreting adenomas. Mamelak AN, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):475–81

Lack of effect of a gonadotropin–releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma [letter] Schuval BJ, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):864

Prolactin and growth hormone mRNA and protein characterization in SMtTW rat pituitary tumours. Delhase M, et al. **J Mol Endocrinol** 1995 Dec;15(3):233–43

Effects of chronic octreotide treatment on GH secretory dynamics and tumor growth in rats bearing an ectopic somatotroph (GC) tumor. Mounier F, et al. **J Neuroendocrinol** 1995 Aug;7(8):645–51

Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. Phillip M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar; 8(1):47–50

Elevated serum growth hormone accelerates gastric tumorigenesis in F344 rats after treatment with N–methyl–N–nitrosourea in their drinking water. Watanabe H, et al. **Jpn J Cancer Res** 1995 Jul;86(7):631–7

Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH–secreting adenomatous cells (GH1) in culture. Giustina A, et al. **Life Sci** 1996;58(1):83–90

Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Ishizuka T, et al. **Metabolism** 1996 Feb; 45(2):206–10

Mammosomatotroph adenoma cells secrete both growth hormone and prolactin. Kojima Y, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):791–6

Opioid and tachykinin neuropeptides in prolactin–secreting human pituitary adenomas. Zhu X, et al. **Peptides** 1995; 16(6):1097–107

Dynamics of prolactin secretion from diethylstilbestrol–induced rat prolactinoma tissue in vitro. Maas DL, et al. **Proc Soc Exp Biol Med** 1995 Nov; 210(2):150–5

[Problems in thyroid function screening using thyroid stimulating hormone. A case of thyrotoxicosis caused by a thyroid stimulating hormone–secreting pituitary tumor] Nygaard B. **Ugeskr Laeger** 1995 Oct 9;157(41):5728–9 (Eng. Abstr.) **(Dan)**

[The relationship between cell proliferation activity and secretory activity in pituitary adenoma—a review of 63 cases] Asano K, et al. **No To Shinkei** 1996 Jun;48(6):543–9 (Eng. Abstr.) **(Jpn)**

[Molecular forms of human growth hormone and prolactin, secreted by cultured pituitary tumor cells] Bulatov AA, et al. **Biokhimiia** 1995 Oct;60(10):1637–46 (Eng. Abstr.) **(Rus)**

SURGERY

The pretemporal approach to the interpeduncular and petroclival regions. de Oliveira E, et al. **Acta Neurochir (Wien)** 1995;136(3–4):204–11

Extended subgaleal fascia–pericranial temporalis flap for skull base reconstruction. Goel A, et al. **Acta Neurochir (Wien)** 1995;135(3–4):203–5

Do the suprasellar neurenteric cyst, the Rathke cleft cyst and the colloid cyst constitute a same entity? Graziani N, et al. **Acta Neurochir (Wien)** 1995;133(3–4):174–80

Outcomes analysis in cranial base surgery – preliminary results. Holmes B, et al. **Acta Neurochir (Wien)** 1995; 134(3–4):136–8

The transzygomatic approach: a long–term clinical review. Honeybul S, et al. **Acta Neurochir (Wien)** 1995; 136(3–4):111–6

Tension pneumocephalus after transsphenoidal surgery: two case reports. Yüceer N, et al. **Acta Neurochir (Wien)** 1995; 137(1–2):58–61

Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367–73 (7 ref.)

Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Dayan C, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):597–602

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Soule SG, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):711–6

Stereotactic radiosurgery of anterior skull base tumors. Lunsford LD, et al. **Clin Neurosurg** 1995;42:99–118

Obesity in childhood craniopharyngioma: relation to post–operative hypothalamic damage shown by magnetic resonance imaging. de Vile CJ, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2734–7

Transsphenoidal pituitary resection for preoperative diagnosis of prolactin–secreting pituitary adenoma in women: long term follow–up. Feigenbaum SL, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1711–9

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone–secreting metastasis detected by 111–indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long–term follow–up [editorial; comment] Lamberts SW, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3111–3. Comment on: J Clin Endocrinol Metab 1995 Nov;80(11):3114–20.

Risk factors and long–term outcome in pituitary–dependent Cushing's disease. Sonino N, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2647–52

Microprolactinomas: why requiem for surgery? Liuzzi A, et al. **J Endocrinol Invest** 1996 Mar;19(3):196–8

Endoscopic management of lesions of the sella turcica. Sethi DS, et al. **J Laryngol Otol** 1995 Oct;109(10):956–62

Delayed hyponatremia [letter; comment] Landolt AM. **J Neurosurg** 1996 Jan;84(1):150–1. Comment on: J Neurosurg 1995 Aug;83(2):363–7.

Bifrontal basal interhemispheric approach to craniopharyngioma resection with or without division of the anterior communicating artery. Shibuya M, et al. **J Neurosurg** 1996 Jun;84(6):951–6

Endoscopic management of craniopharyngiomas: a review of 3 cases. Abdullah J, et al. **Minim Invasive Neurosurg** 1995 Jun;38(2):79–84

Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas. Black PM. **Neurol Clin** 1995 Nov; 13(4):927–52 (115 ref.)

Resection of giant invasive pituitary tumors through a transfacial approach: technical case report. Anson JA, et al. **Neurosurgery** 1995 Sep;37(3):541–5; discussion 545–6

Gonadotropic pituitary carcinoma: case report. Beauchesne P, et al. **Neurosurgery** 1995 Oct;37(4):810–5; discussion 815–6

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)

Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807–8; discussion 808–9 (2 ref.)

Nonhemorrhagic pituitary macroadenoma producing reversible internal carotid artery occlusion: case report. Yaghmai R, et al. **Neurosurgery** 1996 Jun;38(6):1245–8

Intraoperative monitoring with pulse Doppler ultrasonography in transsphenoidal surgery: technique application. Yamasaki T, et al. **Neurosurgery** 1996 Jan; 38(1):95–7; discussion 97–8

MR and CT diagnosis of carotid pseudoaneurysm in children following surgical resection of craniopharyngioma. Lakhanpal SK, et al. **Pediatr Radiol** 1995;25(4):249–51

The triple–phase response—problems of water balance after pituitary surgery. Lindsay RS, et al. **Postgrad Med J** 1995 Jul;71(837):439–41

Gamma Knife treatment of pituitary adenomas. Ganz JC. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:3–10 (38 ref.)

Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow–up. Massoud F, et al. **Surg Neurol** 1996 Apr;45(4):341–6

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32–6

[Transsphenoidal microsurgical removal of GH–secreting pituitary adenoma in: a report of 200 cases] Su C, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):333–7 (Eng. Abstr.) **(Chi)**

[Initial experience of an endocrinologist with the treatment of hypophyseal adenomas with the Leksell gamma knife] Marek J, et al. **Cas Lek Cesk** 1995 Sep 6;134(17):543–6 (Eng. Abstr.) **(Cze)**

[Use of the radiosurgery knife in the treatment of hypophyseal adenomas] Vladyka V, et al. **Cas Lek Cesk** 1995 Sep 6;134(17):539–42 (Eng. Abstr.) **(Cze)**

[Cushing's disease: successful surgery through improved preoperative tumor localization] van Aken MO, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1455–9 (Eng. Abstr.) **(Dut)**

[Pituitary adenoma secreting prolactin. Results of their surgical treatment] Otten P, et al. **Neurochirurgie** 1996; 42(1):44–53 (Eng. Abstr.) **(Fre)**

[Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy] Grabenbauer GG, et al. **Strahlenther Onkol** 1996 Apr;172(4):193–7 (Eng. Abstr.) **(Ger)**

[Analysis of causes of fatal outcome in children in the intensive care unit after removal of craniopharyngiomas] Savin IA, et al. **Anesteziol Reanimatol** 1996 Mar–Apr; (2):70–4 (Eng. Abstr.) **(Rus)**

[Trans–septo–sphenoidal transnasal approach for microsurgery of hypophyseal tumors] Gras Albert JR, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):201–12 (Eng. Abstr.) **(Spa)**

[Surgery of hypophyseal tumors via lateral rhinotomy. Reduced risk of recurrence and the impact on vision] Petruson B, et al. **Lakartidningen** 1996 Jun 12; 93(24):2337–40 **(Swe)**

THERAPY

Failure in management of pituitary tumors discussion of 3 cases. Sutter B, et al. **Acta Neurochir (Wien)** 1995; 134(3–4):159–66

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Tsukamoto N, et al. **Endocr J** 1994 Aug;41(4):437–44

Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). Berezin M, et al. **J Endocrinol Invest** 1995 Jun;18(6):436–41

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9 (53 ref.) **(Dut)**

[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):174–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) **(Ger)**

[Normalization of the prolactin values during alfa–interferon therapy: the considerations with a female patient with anti–HCV–positive chronic hepatitis and prolactin–secreting hypophyseal microadenoma] Zennaro R, et al. **Clin Ter** 1996 Apr;147(4):169–71 (Eng. Abstr.) **(Ita)**

[Treatment of hypothalamic–pituitary tumors—experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

One–year follow–up evaluation of magnetic resonance imaging of the brain in dogs with pituitary–dependent hyperadrenocorticism. Bertoy EH, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1268–73

Central diabetes insipidus in a dog with a pro–opiomelanocortin–producing pituitary tumor not causing hyperadrenocorticism. Goossens MM, et al. **J Vet Intern Med** 1995 Sep–Oct;9(5):361–5

VIROLOGY

Detection of polyomaviral DNA sequences in normal and adenomatous human pituitary tissues using the polymerase

chain reaction. Woloschak M, et al. **Cancer** 1995 Aug 1; 76(3):490–6

PITUITRIN see **PITUITARY HORMONES, POSTERIOR**

PITYRIASIS LICHENOIDES

Pityriasis lichenoides in a family [letter] Dupont C. **Br J Dermatol** 1995 Aug;133(2):338–9

IMMUNOLOGY

Pityriasis lichenoides of childhood with atypical CD30-positive cells and clonal T-cell receptor gene rearrangements. Panhans A, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):489–90

MICROBIOLOGY

Pityriasis lichenoides et varioliformis acuta and group-A beta hemolytic streptococcal infection. English JC 3rd, et al. **Int J Dermatol** 1995 Sep;34(9):642–4

PITYRIASIS LICHENOIDES CHRONICA see **PITYRIASIS LICHENOIDES**

PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA see **PITYRIASIS LICHENOIDES**

PITYRIASIS ROSEA

Pityriasis rosea. Allen RA, et al. **Cutis** 1995 Oct;56(4):198–202 (70 ref.)

MICROBIOLOGY

Pityriasis rosea Gibert: detection of Legionella micdadei antibodies in patients. Gjenero-Margan I, et al. **Eur J Epidemiol** 1995 Aug;11(4):459–62

RADIOTHERAPY

UVB phototherapy for pityriasis rosea: a bilateral comparison study. Leenutaphong V, et al. **J Am Acad Dermatol** 1995 Dec;33(6):996–9

PITYRIASIS RUBRA PILARIS

Clinical picture. Darmstadt GL, et al. **Arch Fam Med** 1996 Sep;5(9):437

COMPLICATIONS

Arthropathic pityriasis rubra pilaris [letter] Fiallo P, et al. **Br J Dermatol** 1996 Jun;134(6):1154–5

Pityriasis rubra pilaris and human immunodeficiency virus infection. Miralles ES, et al. **Br J Dermatol** 1995 Dec; 133(6):990–3 (14 ref.)

Pityriasis rubra pilaris and HIV infection: a part of the spectrum of HIV-associated follicular syndrome [letter] Sánchez-Regaña M, et al. **Br J Dermatol** 1995 Nov; 133(5):818–9

ETIOLOGY

Pityriasis rubra pilaris as the initial manifestation of internal neoplasia. Sánchez-Regaña M, et al. **Clin Exp Dermatol** 1995 Sep;20(5):436–8

PITYRIASIS VERSICOLOR see **TINEA VERSICOLOR**

PITYROSPORUM see **MALASSEZIA**

PIVAMPICILLIN

ADVERSE EFFECTS

Side effects of oral antimicrobial agents in the horse: a comparison of pivampicillin and trimethoprim/sulphadiazine. Ensink JM, et al. **Vet Rec** 1996 Mar 16;138(11):253–6

ANALYSIS

Survey of airborne antibiotics. Møller NE, et al. **Contact Dermatitis** 1996 Apr;34(4):300–1

PIVMECILLINAM see **AMDINOCILLIN PIVOXIL**

PIXE see **SPECTROMETRY, X-RAY EMISSION**

PIZOTIFEN see **PIZOTYLINE**

PIZOTYLINE

PHARMACOLOGY

The antiserotonin agent pizotifen does not increase endurance performance in humans. Pannier JL, et al. **Eur J Appl Physiol** 1995;72(1–2):175–8

THERAPEUTIC USE

Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine [letter; comment] Christensen MF. **Arch Dis Child** 1995 Aug;73(2):183. Comment on: Arch Dis Child 1995 Jan;72(1):48–50.

Hemifacial spasm: treatment with pizotifen [letter] Gross ML. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):118

PLACEBO EFFECT

Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al. **Annu Rev Med** 1996;47:193–9 (18 ref.)

Placebo effects. Concept of placebo should be discarded [letter; comment] Gotzsche PC. **BMJ** 1995 Dec 16; 311(7020):1640–1. Comment on: BMJ 1995 Aug 26;311(7004):551–3.

Placebo effects. Placebos used not to be used in studies [letter; comment] Hart FD. **BMJ** 1995 Dec 16;311(7020):1641. Comment on: BMJ 1995 Aug 26;311(7004):551–3.

Placebo effects. Psychological, sociological, and general practice research may elucidate effects [letter; comment] Paterson C. **BMJ** 1995 Dec 16;311(7020):1640. Comment on: BMJ 1995 Aug 26;311(7004):551–3.

Placebo effects and antidepressant medication: implications for research and clinical care. Lurie SN. **Bull Menninger Clin** 1996 Winter;60(1):94–101

Rules of evidence and clinical recommendations [letter; comment] Tyers GF. **Can J Cardiol** 1995 Nov;11(10):967 . Comment on: Can J Cardiol 1993 Jul-Aug;9(6):487–9.

The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Harden RN, et al. **Headache** 1996 Jun;36(6):352–6

Potentiation of placebo analgesia by proglumide [letter] Benedetti F, et al. **Lancet** 1995 Nov 4;346(8984):1231

The measurement of caring [letter; comment] White KL. **Lancet** 1996 Aug 3;348(9023):338. Comment on: Lancet 1996 Jun 8;347(9015):1606–8.

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. McQuay H, et al. **Pain** 1996 Feb;64(2):331–5

Clinical and acoustic measures of the negative syndrome. Alpert M, et al. **Psychopharmacol Bull** 1995;31(2):321–6

Pattern of placebo response in panic disorder. Shear MK, et al. **Psychopharmacol Bull** 1995;31(2):273–8

Conditioned reinforcing effects of capsules associated with high versus low monetary payoff. Johanson CE, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):42–8

Placebo effects. Issues for clinical practice in psychiatry and medicine. Straus JL, et al. **Psychosomatics** 1996 Jul-Aug; 37(4):315–26 (121 ref.)

Placebo effect and randomized clinical trials. Elander G, et al. **Theor Med** 1995 Jun;16(2):171–82

PLACEBOS

Is "alcohol-free" beer a placebo? [letter; comment] Roeggla M, et al. **Ann Emerg Med** 1995 Dec;26(6):762–3. Comment on: Ann Emerg Med 1995 May;25(5):636–41.

Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials [see comments] Aspinall RL, et al. **BMJ** 1995 Sep 30;311(7009):844–6. Comment in: BMJ 1995 Sep 30;311(7009):821–2. Comment in: BMJ 1996 Jan 20;312(7024):183.

Confusion over use of placebos in clinical trials [editorial; comment] Collier J. **BMJ** 1995 Sep 30;311(7009):821–2. Comment on: BMJ 1995 Sep 30;311(7009):844–6.

N of 1 trials. Placebos should be abandoned [letter] Treasure W. **BMJ** 1996 Aug 17;313(7054):427–8

Placebo effects and antidepressant medication: implications for research and clinical care. Lurie SN. **Bull Menninger Clin** 1996 Winter;60(1):94–101

Vitamin C as placebo [letter; comment] Ball DR. **Can J Anaesth** 1995 Aug;42(8):750–1. Comment on: Can J Anaesth 1994 Dec;41(12):1166–71.

Ethical use of placebos in clinical trials [letter; comment] Orr RD. **J Fam Pract** 1996 Jan;42(1):85–6. Comment on: J Fam Pract 1995 Aug;41(2):126–36.

The use of placebos in psychiatry: a response to the draft document prepared by the Tri-Council Working Group. Young SN, et al. **J Psychiatry Neurosci** 1996 Jul; 21(4):235–8

Clozapine for treatment of schizophrenia [letter; comment] Orr RD. **JAMA** 1996 Jan 17;275(3):186–7. Comment on: JAMA 1995 Sep 27;274(12):981–3.

Placebo and EU guidelines [letter; comment] Agostoni A. **Lancet** 1995 Dec 23–30;346(8991–8992):1710. Comment on: Lancet 1995 Oct 14;346(8981):981.

Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Weinshenker BG, et al. **Neurology** 1996 Jun;46(6):1613–9

Placebo for depression? [letter] Balon R. **Neuropsychopharmacology** 1995 Jul;12(4):355

Placebo washout is not a meaningful part of antidepressant drug trials. Greenberg RP, et al. **Percept Mot Skills** 1995 Oct;81(2):688–90

[Unethical administration of placebos] Horák P. **Cas Lek Cesk** 1995 Aug 23;134(16):525 **(Cze)**

[Placebo in in medicine—treatment and research facets [editorial)] Witztum E, et al. **Harefuah** 1996 Feb 1; 130(3):178–80 **(Heb)**

[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases] Delfino M, et al. **Clin Ter** 1996 Mar; 147(3):113–6 (Eng. Abstr.) **(Ita)**

DIAGNOSTIC USE

The utility of comparative local anesthetic blocks versus placebo-controlled blocks for the diagnosis of cervical zygapophysial joint pain. Lord SM, et al. **Clin J Pain** 1995 Sep;11(3):208–13

Diagnostic placebo—another oxymoron? [editorial] Wilson PR. **Clin J Pain** 1995 Sep;11(3):167–8

PHARMACOLOGY

Using placebos [letter] Golomb BA. **Nature** 1996 Feb 29; 379(6568):765

THERAPEUTIC USE

Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Lockey RF, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):448–54

Placebo reconsidered [letter; comment] Volavka J. **Can J Psychiatry** 1995 Sep;40(7):426–7. Comment on: Can J Psychiatry 1995 May;40(4):171–6.

Re: The use of placebos in clinical trials for acute schizophrenia [letter; comment] Zipursky RB. **Can J Psychiatry** 1995 Sep;40(7):425–6. Comment on: Can J Psychiatry 1995 May;40(4):171–6.

Prediction of positive placebo response among chronic schizophrenic outpatients. Taiminen T, et al. **J Nerv Ment Dis** 1996 Feb;184(2):109–13

Benefits of placebos [letter; comment] Lyons D. **Nature** 1995 Nov 9;378(6553):125. Comment on: Nature 1995 Jun 15;375(6532):530. Comment on: Nature 1995 Sep 14;377(6545):98.

Benefits of placebos [letter; comment] Sannita WG. **Nature** 1995 Nov 9;378(6553):125. Comment on: Nature 1995 Jun 15;375(6532):530.

Placebo effects. Issues for clinical practice in psychiatry and medicine. Straus JL, et al. **Psychosomatics** 1996 Jul-Aug; 37(4):315–26 (121 ref.)

PLACENTA

see related
MATERNAL-FETAL EXCHANGE
UTEROPLACENTAL CIRCULATION

Ballantyne syndrome caused by a large placental chorioangioma. Dorman SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1632–3

Human placenta radioreceptor assay with digoxin and ouabain to detect endogenous digitalis-like factor(s) in human plasma and urine. Paci A, et al. **Clin Chem** 1996 Feb;42(2):270–8

Placental site trophoblastic tumor: three case reports and literature review. Denny LA, et al. **Gynecol Oncol** 1995 Nov;59(2):300–3 (15 ref.)

Applications of minisatellite variant repeat (MVR) mapping for maternal identification from remains of an infant and placenta. Tamaki K, et al. **J Forensic Sci** 1995 Jul; 40(4):695–700

The effect of manual removal of the placenta on post-cesarean endometritis [see comments] Atkinson MW, et al. **Obstet Gynecol** 1996 Jan;87(1):99–102. Comment in: Obstet Gynecol 1996 May;87(5 Pt 1):799–800.

The effect of manual removal of the placenta on post-cesarean endometritis [letter; comment] Baxi LV. **Obstet Gynecol** 1996 May;87(5 Pt 1):799–800. Comment on: Obstet Gynecol 1996 Jan;87(1):99–102.

The association between manual removal of the placenta and postpartum endometritis following vaginal delivery. Ely JW, et al. **Obstet Gynecol** 1995 Dec;86(6):1002–6

Confined placental mosaicism in term placentae: analysis of 125 cases. Artan S, et al. **Prenat Diagn** 1995 Dec; 15(12):1135–42

Blood contamination of amniotic fluid after amniocentesis in relation to placental location. Giorlandino C, et al. **Prenat Diagn** 1996 Feb;16(2):180–2

A case of maternal uniparental disomy of chromosome 9 in association with confined placental mosaicism for trisomy 9. Wilkinson TA, et al. **Prenat Diagn** 1996 Apr;16(4):371–4

Proceedings of the 1st International Meeting of World Placenta Associations. Sydney, New South Wales, Australia, 24–28 October 1994. **Reprod Fertil Dev** 1995; 7(6):1395–609

Predicting placental location—the pattern of decidual blood flow in early pregnancy using the gray-scale technique [letter] Applebaum M. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):299–300

ABNORMALITIES

Mouse embryos with paternal duplication of an imprinted chromosome 7 region die at midgestation and lack placental spongiotrophoblast. McLaughlin KJ, et al. **Development** 1996 Jan;122(1):265–70

Zonary placenta. Steemers NY, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):251–3 (3 ref.)

An X-chromosome linked locus contributes to abnormal placental development in mouse interspecific hybrid. Zechner U, et al. **Nat Genet** 1996 Apr;12(4):398–403

ANATOMY & HISTOLOGY

Placental weight, birth measurements, and blood pressure at age 8 years. Moore VM, et al. **Arch Dis Child** 1996 Jun;

74(6):538–41
Sonographic, stereological and Doppler flow velocimetric assessments of placental maturity. Burton GJ, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):818–25
Can placental surface area and neonatal weight be predicted from placental surface measurements? Preliminary observations on normal-term pregnancies. Blickstein I, et al. **Gynecol Obstet Invest** 1995;40(4):253–6
Anthropometric indices, cord length and placental weight in newborns. Jaya DS, et al. **Indian Pediatr** 1995 Nov; 32(11):1183–8
Effects of recombinant porcine somatotropin on placental size, fetal growth, and IGF-I and IGF-II concentrations in pigs. Sterle JA, et al. **J Anim Sci** 1995 Oct;73(10):2980–5
[The location of the placenta in pregnant women with one or more past cesarean sections] Filipov E, et al. **Akush Ginekol (Sofiia)** 1995;34(3):7–8 (Eng. Abstr.) **(Bul)**

BLOOD SUPPLY

Correlations of placental vascular anatomy and clinical outcomes in 69 monochorionic twin pregnancies. Machin G, et al. **Am J Med Genet** 1996 Jan 22;61(3):229–36
Absence of relaxation to lactate in human placental vessels of pregnancies with severe preeclampsia. Figueroa R, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1800–6
Acute maternal hydration in third-trimester oligohydramnios: effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output [see comments] Flack NJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1186–91. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):237.
Fetal placental embolization in the late-gestation ovine fetus: alterations in umbilical blood flow and fetal heart rate patterns. Gagnon R, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):63–72
Nitric oxide is involved in flow-induced dilation of isolated human small fetoplacental arteries. Learmont JG, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):583–8
Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Lyall F, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):714–8
Placental vascular anatomy and twin transfusion syndrome [letter; comment] Machin GA. **Am J Obstet Gynecol** 1996 Feb;174(2):799–800. Comment on: Am J Obstet Gynecol 1995 Mar;172(3):856–63.
The effects of atrial natriuretic factor and angiotensin II on fetal-placental perfusion pressure in the ex vivo cotyledon model. Markenson GR, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1143–7
Uteroplacental and luteal circulation in normal first-trimester pregnancies: Doppler ultrasonographic and morphologic study. Valentin L, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):768–75
Shear stress may stimulate release and action of nitric oxide in the human fetal-placental vasculature. Wieczorek KM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):708–13
Morphometry of the placental villous vasculature: data correction to account for post partal vessel collapse. Sciarrone A, et al. **Boll Soc Ital Biol Sper** 1995 Nov-Dec; 71(11–12):293–9
Vasa praevia: second trimester diagnosis using colour flow imaging. Daly-Jones E, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):284–6
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Rai RS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):842–4
Contractile actions of thrombin receptor-derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems. Tay-Uyboco J, et al. **Br J Pharmacol** 1995 Jun;115(4):569–78
A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intra-uterine growth retardation. Wang Z, et al. **Chin Med J (Engl)** 1996 Mar; 109(3):238–42
Studies on pregnancy hypertension and IUGR-SFD: effects of drugs on the blood vessels in the placenta of pregnant SHRSP. Fuchi I, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S286–7
Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611–29 (73 ref.)
The value of placental pathology in studies of spontaneous prematurity. Salafia CM, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):89–98
Endothelin-induced phosphoinositide hydrolysis in the muscular layer of stem villi vessels of human term placenta. Mondon F, et al. **Eur J Endocrinol** 1995 Nov;133(5):606–12
Lack of positive correlation between placental blood flow and mean arterial pressure in the non-anaesthetised guinea pig near term; an indication for autoregulation? Verkeste CM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug; 61(2):161–5
A new method for sampling maternal blood in the placental intervillous space. Camelo Júnior JS, et al. **Fetal Diagn Ther** 1995 Sep-Oct;10(5):322–5
Effect of Ca2+ agonist Bay K 8644 in human placental arteries. Barrús MT, et al. **Gen Pharmacol** 1995 Sep; 26(5):989–96
Endothelial modulation of vascular tone and 5-hydroxytryptamine-induced responses in human chorionic arteries and veins. Cruz MA, et al. **Gen Pharmacol** 1995 Nov;26(7):1571–7
Correlation between umbilical arterial flow and placental morphology. Kreczy A, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):306–9
Fetal endoscopic ('Fetendo') surgery: the relationship between insufflating pressure and the fetoplacental circulation. Skarsgard ED, et al. **J Pediatr Surg** 1995 Aug; 30(8):1165–8
Hemorrhagic endovasculitis of the placenta. A clinical-pathological study in Brazil. Altemani AM, et al. **J Perinat Med** 1995;23(5):359–63
Color Doppler sonographic assessment of placental circulation in the first trimester of normal pregnancy. Mercé LT, et al. **J Ultrasound Med** 1996 Feb;15(2):135–42
Membrane potential of smooth muscle cells of human placental chorionic vessels. Comparative effects of MgCl2 and MgSO4. Ibrahim B, et al. **Magnes Res** 1995 Jun; 8(2):127–35
Effect of histamine on endothelial permeability and structure and adhesion molecules of the paracellular junctions of perfused human placental microvessels. Leach L, et al. **Microvasc Res** 1995 Nov;50(3):323–37
Blood gas analysis of placental and uterine blood during cesarean delivery. Fujikura T, et al. **Obstet Gynecol** 1996 Jan;87(1):133–6
Stereological evaluation of vascular adaptations in human placental villi to differing forms of hypoxic stress. Burton GJ, et al. **Placenta** 1996 Jan;17(1):49–55
Short communication: the effect of mode of delivery on contractile function of placental arteries in vitro. George PR, et al. **Placenta** 1995 Dec;16(8):743–7
Role of thromboxane A2 in the vasoconstrictor response to endothelin-1, angiotensin II and 5-hydroxytryptamine in human placental vessels. Howarth SR, et al. **Placenta** 1995 Dec;16(8):679–89
Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.) . Comment in: Placenta 1995 Jun;16(4):333–4.
Effects of variation in oxygen tension on responses of the human fetoplacental vasculature to vasoactive agents in vitro. Read MA, et al. **Placenta** 1995 Dec;16(8):667–78
Interrelationships between the renin angiotensin system and uteroplacental blood flow—a recent perspective. Binder ND, et al. **Reprod Fertil Dev** 1995;7(6):1437–42 (55 ref.)
Control of placental blood flow: workshop report. Carter AM, et al. **Reprod Fertil Dev** 1995;7(6):1401–6
Regulation of human placental fetal vessel tone: role of nitric oxide. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1407–11 (56 ref.)
Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)
Vascular responses to sodium nitroprusside in the human fetal-placental circulation. Read MA, et al. **Reprod Fertil Dev** 1995;7(6):1557–61
Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Soma H, et al. **Reprod Fertil Dev** 1995;7(6):1533–8
[The ananlysis of relationship between fetal stress and blood dynamics in fetal vessels and placental bed vessels] Chang C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan; 31(1):15–7 (Eng. Abstr.) **(Chi)**
[Autologous placental blood for therapy of anemia in premature infants] Nickel S. **Fortschr Med** 1995 Dec 20; 113(35–36):509 **(Ger)**
[Effect of ritodrine hydrochloride on fetal perfusion pressure in dually perfused human placenta] Ohashi M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1237–42 (Eng. Abstr.) **(Jpn)**
[Asymmetry phenomenon of the placenta. The role of Doppler examination] Gąsior W, et al. **Ginekol Pol** 1995 May;66(5):302–4 (Eng. Abstr.) **(Pol)**
[Comparison of Doppler examination results for utero-placental blood flow and plate-villous index—morphologic determinant of placental barrier in pregnant patients with diabetes] Preis K, et al. **Ginekol Pol** 1995 Jul;66(7):386–90 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Plasma and placental calcitonin gene-related peptide in pregnancies complicated by severe preeclampsia. Schiff E, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1405–9
Placental tissue from human miscarriages expresses class II HLA-DR antigens. Athanassakis I, et al. **Am J Reprod Immunol** 1995 Nov;34(5):281–7
Immunohistochemical localization of endothelin-1 in placenta and fetal membranes in term and preterm human pregnancy. Marinoni E, et al. **Am J Reprod Immunol** 1995 Oct;34(4):213–8
The vascular endothelial cell specific membrane antigen HECMA 112 is immunochemically indistinguishable from vascular VE-cadherin. Schütz M, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):419–21
Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ezrin-radixin-moesin association domains. Bretscher A, et al. **Biochemistry** 1995 Dec 26;34(51):16830–7
Purification and characterization of folate binding proteins from rat placenta. da Costa M, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):23–30
Characterisation of the copper uptake mechanism and isolation of the ceruloplasmin receptor/copper transporter in human placental vesicles. Hilton M, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):153–60
Purification and characterization of high molecular weight hCG from human first trimester placenta. Shimojo M, et al. **Biol Pharm Bull** 1995 Dec;18(12):1637–42
Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Kalenga MK, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):429–33
Identification and characterization of a corticotrophin-releasing hormone receptor in human placenta. Clifton VL, et al. **Eur J Endocrinol** 1995 Nov; 133(5):591–7
Placental heat shock proteins: no immunohistochemical evidence for a differential stress response in preterm labour. Divers MJ, et al. **Gynecol Obstet Invest** 1995;40(4):236–43
Renin-like immunoreactivity in human placenta and fetal membranes. Hanssens M, et al. **Histochem Cell Biol** 1995 Dec;104(6):435–42
Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Clark DE, et al. **Hum Reprod** 1996 May;11(5):1090–8
Placental isoferritin patterns during normal first trimester and tubal gestations. Maymon R, et al. **Hum Reprod** 1995 Sep; 10(9):2445–7
Cellular distribution of proteasome subunit Lmp7 mRNA and protein in human placentas. Roby KF, et al. **Immunology** 1995 Nov;86(3):469–74
Expression of the vascular endothelial growth factor receptor, KDR, in human placenta. Vuckovic M, et al. **J Anat** 1996 Apr;188 (Pt 2):361–6
Characterization of an upstream regulatory element of the human apolipoprotein E gene, and purification of its binding protein from the human placenta. Jo DW, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):915–22
Characterization of the Ah receptor from human placental tissue. Nakai JS, et al. **J Biochem Toxicol** 1995 Jun; 10(3):151–9
The human prolactin receptor in the fetal membranes, decidua, and placenta. Maaskant RA, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):396–405
Purification and characterization of 1,25(OH)2D3 receptor from human placenta. Tanamura A, et al. **J Obstet Gynaecol** 1995 Dec;21(6):631–9
Localization of vascular endothelial growth factor and its receptor, flt, in human placenta and decidua by immunohistochemistry. Cooper JC, et al. **J Reprod Fertil** 1995 Nov;105(2):205–13
An inhibitor of the sodium pump obtained from human placenta. Hilton PJ, et al. **Lancet** 1996 Aug 3; 348(9023):303–5
Immunolocalization of eicosanoid enzymes and growth factors in human myometrium and fetoplacental tissues in failed labor inductions. Faber BM, et al. **Obstet Gynecol** 1996 Aug;88(2):174–9
Immunolocalization of 91 kDa ascitic protein in the human placenta. Kami K, et al. **Okajimas Folia Anat Jpn** 1995 Oct;72(4):227–34
Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Lyall F, et al. **Placenta** 1995 Oct; 16(7):579–87
Localization of amphiregulin in the human placenta and decidua throughout gestation: role in trophoblast growth. Lysiak JJ, et al. **Placenta** 1995 Jun;16(4):359–66
High densities of angiotensin II subtype 2 (AT2) receptors in the porcine placenta and fetal membranes. Nielsen AH, et al. **Placenta** 1996 Mar-Apr;17(2-3):147–53
Immunohistochemical localization of vascular endothelial growth factor in the human placenta. Shiraishi S, et al. **Placenta** 1996 Mar-Apr;17(2-3):111–21
Distribution of annexin I and II in term human fetal membranes, decidua and placenta. Sun M, et al. **Placenta** 1996 Mar-Apr;17(2-3):181–4
Cellular localization of glucose transporter messenger RNA in human placenta. Jansson T, et al. **Reprod Fertil Dev** 1995; 7(6):1425–30
Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Brackmann HH, et al. **Thromb Haemost** 1995 Aug;74(2):622–5
Effects of human placental extract on brain monoamines and monoamine oxidase activity in rats. Banerjee KK, et al. **Tohoku J Exp Med** 1995 May;176(1):17–24
[Molecules of the family of aspartic proteinases in the placenta of ruminants: hormones or proteins?] Beckers JF, et al. **Bull Mem Acad R Med Belg** 1994;149(8–11):355–64; discussion 364–7 (Eng. Abstr.) **(Fre)**
[The content of Na, K, Ca, Mg, total P, Fe, Cu and Zn in different tissues and in the placenta of sheep fetuses and newborn lambs] Leo M, et al. **Berl Munch Tierarztl Wochenschr** 1995 May;108(5):179–84 (Eng. Abstr.) **(Ger)**
[Mineral components of the human placenta, birth weight and infant head circumference] Jendryczko A, et al. **Ginekol Pol** 1995 May;66(5):267–71 (Eng. Abstr.) **(Pol)**

CYTOLOGY

Production of interferons in human placental trophoblast

subpopulations and their possible roles in pregnancy. Aboagye-Mathiesen G, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):650-9

Distribution of mosaicism in human placentae. Henderson KG, et al. **Hum Genet** 1996 May;97(5):650-4

Establishment and characterization of a cytotrophoblast cell line from normal placenta of human origin. Rong-Hao L, et al. **Hum Reprod** 1996 Jun;11(6):1328-33

Morphologic characteristics of the interaction between normal cytotrophoblasts and their malignant counterpart in the development of trophoblastic neoplasia. Goshen R, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):209-15

Effect of physiologic perfusion-fixation on the morphometrically evaluated dimensions of the term placental cotyledon. Luckhardt M, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):166-71

Placental blood transplant: who will benefit? Brenner M. **Nat Med** 1996 Sep;2(9):969-70

DRUG EFFECTS

Human placental monoamine transporters as targets for amphetamines. Ramamoorthy JD, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1782-7

Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Cusick W, et al. **Am J Reprod Immunol** 1995 Sep;34(3):141-7

Histopathology of postpartum placental sites in mink (Mustela vison) exposed to polychlorinated biphenyls or fractions thereof. Bäcklin BM, et al. **APMIS** 1995 Dec; 103(12):843-54

Placental and lactational transfer of lead in rats: a study on the lactational process and effects on offspring. Hallén IP, et al. **Arch Toxicol** 1995;69(9):596-602

Modulation by benzo[a]pyrene of epidermal growth factor receptors, cell proliferation, and secretion of human chorionic gonadotropin in human placental cell lines. Zhang L, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1171-80

The effects of the antihormones RU486 and tamoxifen on fetoplacental development and placental bed vascularisation in the rat: a model for intrauterine fetal growth retardation. Sadek S, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):630-41

Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries. Sabry S, et al. **Br J Pharmacol** 1995 Jul;115(6):1038-42

Comparative study of sodium nitroprusside induced vasodilation of human placental veins from premature and full-term normotensive and preeclamptic pregnancy. Bobier HS, et al. **Can J Physiol Pharmacol** 1995 Aug; 73(8):1118-22

Effect of androstenedione administration on the maternal hypothalamo-pituitary-adreno-placental axis in the pregnant rhesus monkey. Giussani DA, et al. **Endocrinology** 1996 Feb;137(2):608-14

In vitro human growth hormone increases human chorionic gonadotropin and progesterone secretion by human placenta at term: evidence of a modulatory role by opioids. Di Simone N, et al. **Gynecol Endocrinol** 1995 Jun; 9(2):157-64

Nitric oxide and prostaglandin systems inhibition on the isolated perfused human placenta from normal and preeclamptic pregnancies. González C, et al. **Gynecol Obstet Invest** 1995;40(4):244-8

In-vivo and in-vitro assessment of the influence of ritodrine and oxytocin on the placental secretion of human chorionic gonadotrophin and placental lactogen. Meuris S, et al. **Hum Reprod** 1996 Mar;11(3):664-7

Nitric oxide regulation of corticotropin-releasing hormone release from the human perfused placenta in vitro. Roe CM, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):763-9

The effect of C5a and U46619 on the isolated, perfused human placental lobule: development of a method for the online estimation of tissue fluid accumulation. Finch AM, et al. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):133-41

Impact of cocaine on human placental function using an in vitro perfusion system. Malek A, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):213-9

Interleukin-1 beta and tumor necrosis factor-alpha stimulate granulocyte colony-stimulating factor production by placental villous core mesenchymal cells. Vandermolen DT, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):172-8

The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. Kudoh M, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5-6):265-71

Influence of magnesium salts on the membrane potential of human endothelial placental vessel cells. Ibrahim B, et al. **Magnes Res** 1995 Sep;8(3):233-6

Calcium-dependent nitric oxide synthesis is potently stimulated by tetrahydrobiopterin in human primordial placenta. Kukor Z, et al. **Placenta** 1996 Jan;17(1):69-73

Developmentally regulated expression of IGF binding protein-3 (IGFBP-3) in human placental fibroblasts: effect of exogenous IGFBP-3 on IGF-1 action. Rogers J, et al. **Regul Pept** 1996 Mar 22;61(3):189-95

Lack of effect of cocaine on lysine and alanine uptake in human placental villi or transfer in perfused human placenta. Krishna RB, et al. **Reprod Fertil Dev** 1995; 7(6):1495-7

Decidua and placenta in mice after treatment with a synthetic glucocorticoid. Matejevic D, et al. **Reprod Fertil Dev** 1995; 7(6):1551-5

The effect of selenium compounds (selenite, selenate, ebselen) on the production of thromboxane and prostacyclin by the human term placenta in vitro. Eisenmann CJ, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):18-24

ENZYMOLOGY

Glycoproteins of the aspartyl proteinase gene family secreted by the developing placenta. Roberts RM, et al. **Adv Exp Med Biol** 1995;362:231-40

Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Sato S, et al. **Adv Exp Med Biol** 1995; 372:259-68

Expression of human and rat carbonyl reductase in E. coli. Comparison of the recombinant enzymes. Wermuth B. **Adv Exp Med Biol** 1995;372:203-9

Immunohistochemical characterization of placental nitric oxide synthase expression in preeclampsia. Ghabour MS, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):687-94

Oxidized aldose reductase: in vivo factor not in vitro artifact. Grimshaw CE, et al. **Arch Biochem Biophys** 1996 Mar 1; 327(1):89-97

Polycyclic aromatic hydrocarbon quinone-mediated oxidation reduction cycling catalysed by a human placental 17beta-hydroxysteroid dehydrogenase. Jarabak R, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):174-80

Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Johnson JL, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):26-34

Cloning and expression of a human placenta inositol 1,3,4,5-tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Drayer AL, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):243-9

Site-directed mutagenesis of the conserved serine 138 of human placental NAD+-dependent 15-hydroxyprostaglandin dehydrogenase to an alanine results in an inactive enzyme. Ensor CM, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):330-3

cDNA sequences of variant forms of human placenta diamine oxidase. Zhang X, et al. **Biochem Genet** 1995 Aug; 33(7-8):261-8

Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Brown RW, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1007-17

Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Brown RW, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):997-1005

A novel phospholipase A2 from human placenta. Buhl WJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):147-53

Human placental 17 beta-hydroxysteroid dehydrogenase: secondary structure and circular dichroism demonstration of conformational changes upon NADP binding. Mendoza-Hernández G, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):551-60

Characterization of gelatinases in human placenta. Shimamori Y, et al. **Biochem Mol Med** 1995 Oct;56(1):84-6

Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Hakkola J, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):379-83

Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Hakkola J, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):403-11

Differential expression and butyrate response of human alkaline phosphatase genes are mediated by upstream DNA elements. Park C, et al. **Biochemistry** 1996 Jul 30; 35(30):9807-14

Human placental ATP diphosphohydrolase is a highly N-glycosylated plasma membrane enzyme. Christoforidis S, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):257-62

Characterization and partial purification of phospholipase D from human placenta. Vinggaard AM, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):169-76

Highly selective affinity labeling of DNA polymerase alpha-primase from human placenta by reactive analogs of ATP. Zakharova OD, et al. **Biochimie** 1995; 77(9):699-702

Demonstration of tissue-specific promoters in nonprimate species that express aromatase P450 in placentae. Hinshelwood MM, et al. **Biol Reprod** 1995 Nov; 53(5):1151-9

Nitric oxide synthase activities in placental tissue from normotensive, pre-eclamptic and growth retarded pregnancies. Morris NH, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):711-4

Messenger RNA encoding thiol protein disulphide isomerase in amnion, chorion and placenta in human term and preterm labour. Morrison JJ, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):873-8

Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies. Rutherford RA, et al. **Br J Pharmacol** 1995 Dec;116(8):3099-109

Placental Na+, K+ activated ATP-ase activity in SHRSP in connection with pregnancy induced hypertension and intra-uterine growth retardation. Fuchi I, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S283-5

Modulation of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in the equine placenta by pregnenolone and progesterone metabolites [see comments] Chavatte PM, et al. **Equine Vet J** 1995 Sep;27(5):342-7. Comment in: Equine Vet J 1995 Sep;27(5):324-5.

Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta [see comments] Han X, et al. **Equine Vet J** 1995 Sep; 27(5):334-9. Comment in: Equine Vet J 1995 Sep;27(5):324-5.

Purification and properties of human placental ATP diphosphohydrolase. Christoforidis S, et al. **Eur J Biochem** 1995 Nov 15;234(1):66-74

Expression of inducible nitric oxide synthase in placenta of women with gestational diabetes. Schönfelder G, et al. **FASEB J** 1996 May;10(7):777-84

Cloning and sequencing of a human thioredoxin reductase. Gasdaska PY, et al. **FEBS Lett** 1995 Oct 2;373(1):5-9

Localization of tartrate-resistant acid phosphatase in human placenta. Janckila AJ, et al. **Histochem J** 1996 Mar; 28(3):195-200

Gestational development of human placental 17 beta-hydroxysteroid oxidoreductase types 1 and 2. Blomquist CH, et al. **Hum Reprod** 1995 Oct;10(10):2685-9

Cloning, expression and genomic organization of human placental protein disulfide isomerase (previously identified as phospholipase C alpha). Charnock-Jones DS, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):81-9

Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-kinase/fructose 2,6-bisphosphatase from human placenta. Sakai A, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):506-11

Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. Blackburn MR, et al. **J Biol Chem** 1995 Oct 13; 270(41):23891-4

Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. Rogi T, et al. **J Biol Chem** 1996 Jan 5;271(1):56-61

UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. Identification and separation of two distinct transferase activities. Sørensen T, et al. **J Biol Chem** 1995 Oct 13;270(41):24166-73

Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. Takino T, et al. **J Biol Chem** 1995 Sep 29;270(39):23013-20

Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. White T, et al. **J Biol Chem** 1995 Oct 13;270(41):24156-65

Regulation of placenta-specific expression of the aromatase cytochrome P-450 gene. Involvement of the trophoblast-specific element binding protein. Yamada K, et al. **J Biol Chem** 1995 Oct 20;270(42):25064-9

Isolation and characterization of a folate receptor-directed metalloprotease from human placenta. Yang XY, et al. **J Biol Chem** 1996 May 10;271(19):11493-9

Type 3 Iodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme. Salvatore D, et al. **J Clin Invest** 1995 Nov;96(5):2421-30

Why so much oestriol? A comparison of the aromatisation of androstenedione and 16 alpha-hydroxyandrostenedione when incubated alone or together with human placental microsomes. Othman YS, et al. **J Endocrinol** 1996 Mar; 148(3):399-407

Characterisation of acyltransferase activity in ovine placental tissue during pregnancy and at the time of labour. Wong MH, et al. **J Endocrinol** 1996 Feb;148(2):241-7

Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes. Sam KM, et al. **J Med Chem** 1995 Oct 27;38(22):4518-28

Detection of different adenosine triphosphatases in human placental brush border membranes. Brunette MG, et al. **J Membr Biol** 1995 Jun;145(3):285-93

Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. Wang Y, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):179-84

Imidazole derivatives of pyrrolidonic and piperidonic as potential inhibitors of human placental aromatase in vitro. Baroudi M, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):73-7

Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension. Seckl JR, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):447-55 (104 ref.)

Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life. Stewart PM, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):465-71

Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. Woo LW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1-2):79-88

Ginsenosides activate DNA polymerase delta from bovine placenta. Cho SW, et al. **Life Sci** 1995;57(14):1359-65

Functional ovarian and placental isoforms of porcine aromatase. Corbin CJ, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):29-37

Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum. Naruki M, et al. **Peptides** 1996;17(2):257-61

Nitric oxide synthase activity in placentae from women with pre-eclampsia. Conrad KP, et al. **Placenta** 1995 Dec;

16(8):691–9
Increased immunohistochemical expression of neutral metalloendopeptidase (enkephalinase; EC 3.4.24.11) in villi of the human placenta with pre-eclampsia. Li XM, et al. **Placenta** 1995 Jul;16(5):435–45
Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Gladyshev VN, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6146–51
Cytoplasmic and periplasmic production of human placental glutathione transferase in Escherichia coli. Battistoni A, et al. **Protein Expr Purif** 1995 Oct;6(5):579–87
Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Mizutani S, et al. **Regul Pept** 1995 Nov 10;59(3):371–8
Human placental cytochrome P450 and quinone reductase enzyme induction in relation to maternal smoking. Boden AG, et al. **Reprod Fertil Dev** 1995;7(6):1521–4
Human placental and fetal membrane nitric oxide synthase activity before, during and after labour at term. Di Iulio JL, et al. **Reprod Fertil Dev** 1995;7(6):1505–8
Effect of asymmetric dimethyl arginine on nitric oxide synthase activity in normal and pre-eclamptic placentae. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1581–4
Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al. **Reprod Fertil Dev** 1995;7(6):1431–6 (26 ref.)
2-Aminofluorene bioactivation by human term placental peroxidase. Murthy KR, et al. **Teratog Carcinog Mutagen** 1995;15(3):115–26
[Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values] Kolben M, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:126–31 (Eng. Abstr.) **(Ger)**
[Polymorphism of placental alkaline phosphatase on the level of DNA and protein in the Mordovian population] Bekman G, et al. **Genetika** 1996 Mar;32(3):420–4 (Eng. Abstr.) **(Rus)**
[Apurine/apyrimidine endonuclease from human placenta. Recognition of apurinized DNA by the enzyme] Beloglazova NG, et al. **Mol Biol (Mosk)** 1996 Jan–Feb; 30(1):220–30 **(Rus)**
[Interaction of uracil-DNA-glycosylase from human placenta with single-stranded deoxy- and oligoribonucleotides and their complexes] Vinogradova NL, et al. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):209–19 **(Rus)**
[The small Alu-like RNA from the A-431 cell line specifically regulates the activity of the RNA polymerase III from human placental nuclei] Sedova VM, et al. **Tsitologiia** 1995;37(8):820–3 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Maternal nutrition in early and late pregnancy in relation to placental and fetal growth. Godfrey K, et al. **BMJ** 1996 Feb 17;312(7028):410–4
Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)
Effect of restriction of placental growth on expression of IGFs in fetal sheep: relationship to fetal growth, circulating IGFs and binding proteins. Kind KL, et al. **J Endocrinol** 1995 Jul;146(1):23–34
Expression of granulocyte-colony stimulating factor and its receptor is regulated during the development of the human placenta. McCracken S, et al. **J Endocrinol** 1996 May; 149(2):249–58
Growth and metabolism of the ovine placenta during mid-gestation. Ehrhardt RA, et al. **Placenta** 1995 Dec; 16(8):727–41
Ontogenic changes in the nutritive function of the placenta. Schneider H. **Placenta** 1996 Jan;17(1):15–26 (135 ref.)
Amniotic fluid composition and fetal and placental growth rates in genetically hypertensive and normotensive rats. Erkadius E, et al. **Reprod Fertil Dev** 1995;7(6):1563–7
Placental and fetal hepatic growth are selectively inhibited by prolonged reductions of uterine blood flow in pregnant sheep. McLellan KC, et al. **Reprod Fertil Dev** 1995; 7(3):405–10

IMMUNOLOGY

Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta. Malek A, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):760–7
The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Peaceman AM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1391–6
Placental tissue from human miscarriages expresses class II HLA-DR antigens. Athanassakis I, et al. **Am J Reprod Immunol** 1995 Nov;34(5):281–7
Embryo-associated immunosuppressor factor is produced at the maternal-fetal interface in human pregnancy. Bose R, et al. **Am J Reprod Immunol** 1995 May;33(5):373–80
An 80-kDa syncytiotrophoblast alloantigen bound to maternal alloantibody in term placenta. Jalali GR, et al. **Am J Reprod Immunol** 1995 Mar;33(3):213–20
Seminal fluid and the expression of MHC class I antigens in the placenta of the rat. Kanbour-Shakir A, et al. **Am J Reprod Immunol** 1995 May;33(5):367–72
Fc gamma-receptor activity in the developing human placenta. Jensen TS, et al. **APMIS** 1995 Jun;103(6):433–8
Placental transfer of immunoglobulin G subclasses. Garty BZ, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):667–9
Trophoblast antigen levels in the first trimester of a trisomy 22 pregnancy. Wheeler DM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):197–9
Quantitative analysis of intraepithelial large granular lymphocyte distribution and maternofetal cellular interactions in the synepitheliochorial placenta of the deer. Lee CS, et al. **J Anat** 1995 Oct;187 (Pt 2):445–60
Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Katano K, et al. **Lupus** 1995 Aug;4(4):304–8
Immunosuppressive properties of plasma and lymphocytes from the human retroplacental blood. Xiao L, et al. **Scand J Immunol** 1996 Sep;44(3):299–304
[Deficiency of maternal recognition of fetal-placental antigens in pregnancy complicated by idiopathic growth retardation] Dudarewicz L, et al. **Ginekol Pol** 1995 Sep; 66(9):498–501 (Eng. Abstr.) **(Pol)**
[Comparison of Doppler examination results for utero-placental blood flow and plate-villous index--morphologic determinant of placental barrier in pregnant patients with diabetes] Preis K, et al. **Ginekol Pol** 1995 Jul;66(7):386–90 (Eng. Abstr.) **(Pol)**
[Immunologic function of the placenta and endothelium in virus infection; non-specific immunity] Paradowska E. **Postepy Hig Med Dosw** 1995;49(1):137–45 (Eng. Abstr.) **(Pol)**

INJURIES

Growth retardation in pregnancy: experimental model in the rabbit employing electrically induced thermal placental injury. Rosati P, et al. **Int J Exp Pathol** 1995 Jun; 76(3):179–81

METABOLISM

Effects of chlorpromazine on the rate of synthesis of various glycerolipids from [3H]glucose in the human primordial placenta. Gimes G, et al. **Acta Physiol Hung** 1995; 83(2):151–62
Regulation of utero-placental prorenin. Poisner AM. **Adv Exp Med Biol** 1995;377:411–26 (96 ref.)
Feto-maternal transfer of zidovudine: study on the perfused human placental cotyledon system [letter] Giroux M, et al. **AIDS** 1995 Jul;9(7):816–7
Placental transfer of milrinone in the nonhuman primate (baboon). Atkinson BD, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):895–6
Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery. Calhoun DA, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1306–11
Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes. Cheung CY, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):753–9
The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Peaceman AM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1391–6
Immunolocalization of progesterone-induced uterine protein-1 in human endometrium during the menstrual cycle and in the placenta throughout gestation. Sharpe-Timms KL, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1569–78
Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. Tuntland T, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):856–63
Contribution of fructose and lactate produced in placenta to calculation of fetal glucose oxidation rate. McGowan JE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E834–9
Placental transport and fetal utilization of leucine in a model of fetal growth retardation. Ross, JC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E491–503
Regulation of placental corticotropin-releasing hormone by steroids. Possible implications in labor initiation. Karalis K, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:551–5
Metallothionein expression in placental tissue in Menkes' disease. An immunohistochemical study. Haerslev T, et al. **APMIS** 1995 Jul–Aug;103(7–8):568–73
Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Communi D, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):303–8
Polymorphic functional imprinting of the human IGF2 gene among individuals, in blood cells, is associated with H19 expression. Giannoukakis N, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1014–9
Reconstitution and characterization of ATP-dependent bile acid transport in human and rat placenta. Bravo P, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):479–85
Tumour growth results in changes in placental amino acid transport in the rat: a tumour necrosis factor alpha-mediated effect. Carbó N, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):77–82
Isolation of ERp72 from guinea pig term placentae using heparin Sepharose affinity chromatography. Bonifacio MD, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1143–52
Detection of a high molecular weight heparin binding acidic growth factor in human placenta. Triantos A, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):737–45
Placental copper transport in the rat: role of low-molecular-weight ligands. Gyasi I, et al. **Biochem Mol Med** 1995 Oct;56(1):70–5
Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human placental microsomes. Collazo NR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1933–41
Inhibition of choline uptake in syncytial microvillus membrane vesicles of human term placenta. Specificity and nature of interaction. Van der Aa EM, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1873–8
Investigation of fusion complex assembly from placental clathrin coated vesicle membranes. Steel GJ, et al. **Biochem Soc Trans** 1995 Nov;23(4):555S
Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like protein. Richardson B, et al. **Biochemistry** 1996 Jun 11;35(23):7580–5
Characterisation of the copper uptake mechanism and isolation of the ceruloplasmin receptor/copper transporter in human placental vesicles. Hilton M, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):153–60
Effect of subadequate maternal vitamin-A status on placental transfer of retinol and beta-carotene to the human fetus. Dimenstein R, et al. **Biol Neonate** 1996;69(4):230–4
Expression of SQ10 (a preprorelaxin-like gene) in the pregnant rabbit placenta and uterus. Fields P, et al. **Biol Reprod** 1995 Nov;53(5):1139–45
Expression of vav proto-oncogene by nonhematopoietic trophoblast cells at the human uteroplacental interface. Higuchi T, et al. **Biol Reprod** 1995 Oct;53(4):840–6
Placental metabolism of cortisol at mid- and late gestation in swine. Klemcke HG. **Biol Reprod** 1995 Dec; 53(6):1293–301
Placental steroid hormone synthesis: unique features and unanswered questions. Strauss JF 3rd, et al. **Biol Reprod** 1996 Feb;54(2):303–11 (73 ref.)
Placental isoferritin: a new biomarker from conception to delivery. Maymon R, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):301–5 (29 ref.)
Simultaneous measurement of 45Ca outflow and human placental lactogen release from placental explants. Lebrun P, et al. **Cell Calcium** 1995 May;17(5):384–92
Codistribution of basic fibroblast growth factor and heparan sulfate proteoglycan in the growth zones of the human placenta. Mühlhauser J, et al. **Cell Tissue Res** 1996 Jul; 285(1):101–7
Immunolocalization of GLUT1 and connexin 26 in the rat placenta. Shin BC, et al. **Cell Tissue Res** 1996 Jul; 285(1):83–9
Production of interferons in human placental trophoblast subpopulations and their possible roles in pregnancy. Aboagye-Mathiesen G, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):650–9
Placental transfer of immunoglobulin G subclasses. Garty BZ, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):667–9
The synthesis of 19-norandrostenedione from dehydroepiandrosterone in equine placenta is inhibited by aromatase inhibitors 4-hydroxyandrostenedione and fadrozole. Moslemi S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):613–8
Cloning and sequence of bone morphogenetic protein 4 (BMP-4) from a human placental cDNA library. Oida S, et al. **DNA Seq** 1995;5(5):273–5
A cDNA encoding a new member of the rat placental lactogen family, PL-I mosaic (PL-Im). Hirosawa M, et al. **Endocr J** 1994 Aug;41(4):387–97
Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)
Inhibin and activin production in human placenta. Qu J, et al. **Endocr Rev** 1995 Aug;16(4):485–507 (258 ref.)
Analysis of messenger ribonucleic acid and protein for the ligands and receptors of the platelet-derived growth factor signaling pathway in the placenta, extraembryonic membranes, and uterus during the latter half of murine gestation. Bidwell MC, et al. **Endocrinology** 1995 Nov; 136(11):5189–201
The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. Cameron VA, et al. **Endocrinology** 1996 Mar;137(3):817–24
Insulin-like growth factor II affects the appearance and glycogen content of glycogen cells in the murine placenta. Lopez MF, et al. **Endocrinology** 1996 May;137(5):2100–8
Trans-acting factors dictate the species-specific placental expression of corticotropin-releasing factor genes in choriocarcinoma cell lines. Scatena CD, et al. **Endocrinology** 1996 Jul;137(7):3000–8
Two subtypes of endothelin receptors and endothelin peptides are expressed in differential cell types of the rat placenta: in vitro receptor autoradiographic and in situ hybridization studies. Shigematsu K, et al. **Endocrinology** 1996 Feb;137(2):738–48
Analyses of cis-acting and trans-acting elements that are crucial to sustain pregnancy-specific glycoprotein gene expression in different cell types. Koritschoner NP, et al. **Eur J Biochem** 1996 Mar 1;236(2):365–72
Therapeutic monitoring of nalbuphine: transplacental transfer

and estimated pharmacokinetics in the neonate. Nicolle E, et al. **Eur J Clin Pharmacol** 1996;49(6):485–9
Immunoreactive parathyroid hormone–related protein: its association with preterm labor. Ramirez MM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):21–6
The transport of vitamin C in the isolated human near–term placenta. Rybakowski C, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):107–14
Comparative aspects of placental exchange functions. Schröder HJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov; 63(1):81–90 (25 ref.)
Expression of erythropoietin by the human placenta. Conrad KP, et al. **FASEB J** 1996 May;10(7):760–8
Plasma membrane fatty acid–binding protein (FABPpm) is exclusively located in the maternal facing membranes of the human placenta. Campbell FM, et al. **FEBS Lett** 1995 Nov 20;375(3):227–30
Molecular cloning of the cDNA encoding a novel protein disulfide isomerase–related protein (PDIR). Hayano T, et al. **FEBS Lett** 1995 Sep 25;372(2–3):210–4
Toxicokinetics of 2,3,7,8–tetrachlorodibenzo–p–dioxin in female Sprague–Dawley rats including placental and lactational transfer to fetuses and neonates. Li X, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):70–6
Cloning of a new member of the insulin gene superfamily (INSL4) expressed in human placenta. Chassin D, et al. **Genomics** 1995 Sep 20;29(2):465–70
Colocalisation of vascular endothelial growth factor and its Flt–1 receptor in human placenta. Ahmed A, et al. **Growth Factors** 1995;12(3):235–43
Are estradiol–producing cells incompletely endowed? A chronicle of the emergence of certitude from conjecture. Lieberman S. **Gynecol Obstet Invest** 1996;41(3):147–72 (152 ref.)
Anti–adhesive glycosylation of fibronectin–like molecules in human placental matrix–type fibrinoid. Frank HG, et al. **Histochem Cell Biol** 1995 Oct;104(4):317–29
Calbindin–D9k expression in the pregnant cow uterus and placenta. Reiswig JD, et al. **Histochem Cell Biol** 1995 Aug; 104(2):169–74
Polycyclic aromatic hydrocarbons in placenta, maternal blood, umbilical cord blood and milk of Indian women. Madhavan ND, et al. **Hum Exp Toxicol** 1995 Jun; 14(6):503–6
Placental expression of alpha and beta subunits of human chorionic gonadotrophin in early pregnancies with Down's syndrome. Brizot ML, et al. **Hum Reprod** 1995 Sep; 10(9):2506–9
Epidermal growth factor receptors in placentae and fetal membranes from hypertension–complicated pregnancies. Ferrandina G, et al. **Hum Reprod** 1995 Jul;10(7):1845–9
Expression of leukaemia inhibitory factor (LIF) receptor in human placenta: a possible role for LIF in the growth and differentiation of trophoblasts. Kojima K, et al. **Hum Reprod** 1995 Jul;10(7):1907–11
Different composite regulatory elements direct expression of the human alpha subunit gene to pituitary and placenta. Heckert LL, et al. **J Biol Chem** 1995 Nov 3; 270(44):26497–504
Cell cycle–dependent regulation of the cyclin B1 promoter. Hwang A, et al. **J Biol Chem** 1995 Nov 24;270(47):28419–24
Na+ transport by human placental brush border membranes: are there several mechanisms? Brunette MG, et al. **J Cell Physiol** 1996 Apr;167(1):72–80
Opposing actions of transforming growth factor–beta and glucocorticoids in the regulation of fibronectin expression in the human placenta. Guller S, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3273–8
The expression of insulin–like growth factor (IGF) and IGF–binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF–IGFBP interactions at the feto–maternal interface. Han VK, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2680–93
Atrial natriuretic factor production by the human placenta. Lim AT, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3091–3
Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. Brownbill P, et al. **J Clin Invest** 1995 Nov;96(5):2220–6
Different molecular and messenger ribonucleic acid forms of insulin–like growth factor–binding protein–3 in the pregnant baboon (Papio anubis). Gargosky SE, et al. **J Endocrinol** 1995 Dec;147(3):449–61
Placental corticotrophin–releasing hormone: there by accident or design? Perkins AV, et al. **J Endocrinol** 1995 Dec;147(3):377–81
Inhibition of mouse placental lactogen–II release from placental cells by interleukin–1 after mid–pregnancy. Yamaguchi M, et al. **J Endocrinol** 1995 Dec;147(3):423–9
Hyperglycemia induced activation of type–1 protein phosphatase activator (kinase FA) in perfused human placenta. Hsieh TT, et al. **J Formos Med Assoc** 1996 Jan; 95(1):41–4
Calcium dependence of alpha–aminoisobutyric acid transfer in human bilaterally perfused placental lobules. Krishna BR, et al. **J Perinat Med** 1995;23(5):343–51
Determinants of placental drug transfer: studies in the isolated perfused human placenta. Bassily M, et al. **J Pharm Sci** 1995 Sep;84(9):1054–60
Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. Barzago MM, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):79–86
Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta. van der Aa EM, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):219–22
Isolation of syncytial microvillous membrane vesicles from human term placenta and their application in drug–nutrient interaction studies. van der Aa EM, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):47–56
Concentrations of Na+ and Cl– in transplacental ultrafiltrate in sheep. Faber JJ, et al. **J Physiol (Lond)** 1995 Aug 15; 487 (Pt 1):159–67
Ovine fetal–placental cocaine pharmacokinetics during continuous cocaine infusion. Downs T, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):185–90
Insulin–like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies. Roth S, et al. **J Soc Gynecol Investig** 1996 Mar–Apr; 3(2):78–84
Increased placental antifibrinolytic potential and fibrin deposits in pregnancy–induced hypertension and preeclampsia. Kanfer A, et al. **Lab Invest** 1996 Jan; 74(1):253–8
Angiotensin II receptor in human placental syncytiotrophoblast plasma membranes. Jiménez E, et al. **Life Sci** 1996;58(11):877–82
Insulin receptor binding from mid–term and full–term placentas of patients with gestational diabetes mellitus and normal pregnant women. al–Attas OS. **Mol Cell Biochem** 1995 Oct 4;151(1):27–31
Placental permeability for drugs of abuse and their metabolites. Olsen GD. **NIDA Res Monogr** 1995;154:152–62 (45 ref.)
Pharmacodynamics in the maternal–fetal–placental unit. Rudolph AM. **NIDA Res Monogr** 1995;154:163–74 (15 ref.)
The transfer of interleukin–8 across the human placenta perfused in vitro. Reisenberger K, et al. **Obstet Gynecol** 1996 Apr;87(4):613–6
Decreased expression of placental growth hormone in intrauterine growth retardation. Chowen JA, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):736–9
Relationship between bile acid transplacental gradients and transport across the fetal–facing plasma membrane of the human trophoblast. Monte MJ, et al. **Pediatr Res** 1995 Aug; 38(2):156–63
Effect on placental transfer of exogenous lipid administered to the pregnant rabbit. Stammers J, et al. **Pediatr Res** 1995 Dec;38(6):1026–31
Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Ala–Kokko TI, et al. **Pharmacol Toxicol** 1995 Aug;77(2):142–8
Transplacental and lactational exposure to mercury in hamster pups after maternal administration of methyl mercury in late gestation. Nordenhäll K, et al. **Pharmacol Toxicol** 1995 Aug;77(2):130–5
Transport and metabolism of adenosine in the perfused human placenta. Acevedo CG, et al. **Placenta** 1995 Oct; 16(7):611–22
Gene expression of human pregnancy–associated plasma protein–A in placenta from trisomic pregnancies. Brizot ML, et al. **Placenta** 1996 Jan;17(1):33–6
Current topic: the placental corticotrophin–releasing hormone–adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)
Growth and metabolism of the ovine placenta during mid–gestation. Ehrhardt RA, et al. **Placenta** 1995 Dec; 16(8):727–41
Transplacental clearances of inert hydrophilic tracers in rabbits of 18 days gestation. Faber JJ. **Placenta** 1995 Jul; 16(5):403–12
The effect of pre–eclampsia on human placental corticotrophin–releasing hormone content and processing [published erratum appears in Placenta 1995 Sep;16(6):567] Goland RS, et al. **Placenta** 1995 Jun;16(4):375–82
Effect of chlorpromazine on the synthesis of neutral lipids and phospholipids from [3H]glycerol in the primordial human placenta. Heiczman A, et al. **Placenta** 1995 Jun; 16(4):347–58
Calcium–dependent nitric oxide synthesis is potently stimulated by tetrahydrobiopterin in human primordial placenta. Kukor Z, et al. **Placenta** 1996 Jan;17(1):69–73
The study of mitochondrial gene modifications in human placenta. Kurauchi O, et al. **Placenta** 1995 Jul;16(5):461–7
Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat. Langley–Evans SC, et al. **Placenta** 1996 Mar–Apr; 17(2–3):169–72
Placental isoferritin levels during first trimester of normal and complete molar gestations. Maymon R, et al. **Placenta** 1995 Jul;16(5):455–60
Long–term dual perfusion of isolated human placental lobules with improved oxygenation for infectious diseases research. Polliotti BM, et al. **Placenta** 1996 Jan;17(1):57–68
Volume–activated release of D–aspartate from human placental tissue [letter] Shennan DB, et al. **Placenta** 1996 Mar–Apr;17(2–3):189–90
Birthweight and sodium/proton exchanger activity in the term human placenta [letter] Sibley C, et al. **Placenta** 1995 Jul;16(5):469–70
Placental prostanoid release in severe intrauterine growth retardation. Sorem KA, et al. **Placenta** 1995 Sep; 16(6):503–15
Fetal fluid acquisition [letter] Stulc J. **Placenta** 1995 Dec; 16(8):759–60
Short communication: selective placental transport of maternal IgG to the fetus. Williams PJ, et al. **Placenta** 1995 Dec;16(8):749–56
4–Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Liehr JG, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9220–4
Sumatriptan (Imitrex) transport by the human placenta. Schenker S, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):213–20
Alterations of intrauterine eicosanoid production in pregnancy–induced hypertension: decreased production of 12–hydroxyeicosatetraenoic acid in the placenta. Arbogast E, et al. **Prostaglandins** 1996 Feb;51(2):125–37
Transfer of immunoglobulin G across the isolated perfused human placental lobule. Duncan JI, et al. **Reprod Fertil Dev** 1995;7(6):1547–50
Endothelin receptors in the human amnion, chorion laeve, decidua vera and placenta. Hasegawa M, et al. **Reprod Fertil Dev** 1995;7(6):1585–9
Regulation of placental metabolism by glucose supply. Hay WW Jr. **Reprod Fertil Dev** 1995;7(3):365–75 (45 ref.)
Transport and metabolism of adenosine in diabetic human placenta. Osses N, et al. **Reprod Fertil Dev** 1995; 7(6):1499–503
Placental nitric oxide metabolism. Sooranna SR, et al. **Reprod Fertil Dev** 1995;7(6):1525–31 (38 ref.)
Cadmium and glutathione: effect on human placental thromboxane and prostacyclin production. Eisenmann CJ, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):41–8
Placental transfer and developmental effects of 9–cis retinoic acid in mice. Kochhar DM, et al. **Teratology** 1995 Apr; 51(4):257–65
Complement activation and tissue factor expression on the feto–placental allograft [letter] Cheng HM. **Thromb Haemost** 1995 Oct;74(4):1204
The effect of selenium compounds (selenite, selenate, ebselen) on the production of thromboxane and prostacyclin by the human term placenta in vitro. Eisenmann CJ, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):18–24
Alanine transport across the human placental brush border membrane and the role of SH groups in carrier function. Scholl A, et al. **Z Ernahrungswiss** 1995 Dec;34(4):285–92
[The studies of the estrogen and progesterone receptor levels in the placenta, fetal membrane, uteroplacental bed and myometrium in patients with prolonged pregnancy] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep; 30(9):536–8 (Eng. Abstr.) **(Chi)**
[Changes in levels of human placenta lactogen (hPL), progesterone, and estriol in blood serum and estrogens in urine during gestational diabetes mellitus] Olszewski J, et al. **Ginekol Pol** 1995 Mar;66(3):145–50 (Eng. Abstr.) **(Pol)**
[The transplacental transport and effect of morphine administered in the prenatal period on its level in adult rats] Bolko SS, et al. **Eksp Klin Farmakol** 1995 Nov–Dec; 58(6):42–4 (Eng. Abstr.) **(Rus)**
[Lipid composition and phospholipase A2 activity in rat placental cell membranes in hypoxic states] Pogorelova TN, et al. **Vopr Med Khim** 1995 Nov–Dec;41(6):30–3 (Eng. Abstr.) **(Rus)**
[Free radical oxidation in placental tissues in preterm delivery] Prokopenko VM, et al. **Vopr Med Khim** 1995 May–Jun;41(3):53–6 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Chronic Q fever of pregnancy presenting as Coxiella burnetii placentitis: successful outcome following therapy with erythromycin and rifampin. Bental T, et al. **Clin Infect Dis** 1995 Nov;21(5):1318–21
Diagnosis of congenital syphilis from placental examination: comparison of histopathology, Steiner stain, and polymerase chain reaction for Treponema pallidum DNA. Genest DR, et al. **Hum Pathol** 1996 Apr;27(4):366–72
Ureaplasma urealyticum infection of the placenta in pregnancies that ended prematurely. Kundsin RB, et al. **Obstet Gynecol** 1996 Jan;87(1):122–7

PARASITOLOGY

A histological and immunohistological study of malarial placentas. Moshi EZ, et al. **APMIS** 1995 Oct; 103(10):737–43
Images in clinical medicine. Placental malaria. Miller IJ, et al. **N Engl J Med** 1996 Jul 11;335(2):98
Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta [see comments] Fried M, et al. **Science** 1996 Jun 7;272(5267):1502–4. Comment in: Science 1996 Jun 7;272(5267):1416–7.
Malaria hideout found in new mothers [news; comment] Williams N. **Science** 1996 Jun 7;272(5267):1416–7. Comment on: Science 1996 Jun 7;272(5267):1502–4.

PATHOLOGY

The efficacy of the placental biopsy. Kliman HJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1084–8
Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):850–5 (24 ref.)
Placental histomorphometry and morphometric diffusing capacity of the villous membrane in pregnancies

complicated by maternal iron-deficiency anemia. Reshetnikova OS, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):724–7

Relationship between placental histologic features and umbilical cord blood gases in preterm gestations. Salafia CM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1058–64

Placental pathologic features of preterm preeclampsia. Salafia CM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1097–105

Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Cusick W, et al. **Am J Reprod Immunol** 1995 Sep;34(3):141–7

Mechanism of visceral damage in fetofetal transfusion syndrome. Rehan VK, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F48–50 (32 ref.)

Placental bed lesions and infant birth weight in hypertensive pregnant women. Ramos JG, et al. **Braz J Med Biol Res** 1995 Apr;28(4):447–55

Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611–29 (73 ref.)

Insulin-like growth factor II affects the appearance and glycogen content of glycogen cells in the murine placenta. Lopez MF, et al. **Endocrinology** 1996 May;137(5):2100–8

Distribution of mosaicism in human placentae. Henderson KG, et al. **Hum Genet** 1996 May;97(5):650–4

Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)

Maternal varicella during pregnancy: correlation of maternal history and fetal outcome with placental histopathology. Qureshi F, et al. **Hum Pathol** 1996 Feb;27(2):191–5

Correlation between umbilical arterial flow and placental morphology. Kreczy A, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):306–9

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al. **J Perinatol** 1995 Nov-Dec;15(6):510–3 (7 ref.)

The effects of anaemia on heart, placenta and body weight, and blood pressure in fetal and neonatal rats. Crowe C, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):515–9

The epidemiology of placental features: associations with gestational age and neonatal outcome. Beebe LA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):771–8

Placental basal plate myometrial fibers: clinical correlations of abnormally deep trophoblast invasion. Sherer DM, et al. **Obstet Gynecol** 1996 Mar;87(3):444–9

Twin transfusion: pathological studies of the monochorionic placenta in liveborn twins and of the perinatal autopsy in monochorionic twin pairs. Bendon RW. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):363–76

Fetal growth retardation and increased placental weight in the spontaneously hypertensive rat. Johnston BM. **Reprod Fertil Dev** 1995;7(3):639–45

Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66–89 (39 ref.)

[Present status in the study of placenta (editorial)] Liu B. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):323–5 **(Chi)**

[Placental tissue histomorphometry in hydrops fetalis] Lou X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun; 30(6):330–2 (Eng. Abstr.) **(Chi)**

[Stereoptical study of the microvilli in intrauterine growth retardation placenta with different ponderal indexes] Tao W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun; 30(6):326–9 (Eng. Abstr.) **(Chi)**

[Correlation of fetal umbilical artery velocity waveforms with placental pathology and biochemistry] Zheng X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):333–6 (Eng. Abstr.) **(Chi)**

[Benign placental trophoblast nodule. Case report with overview of proliferative diseases of the intermediate stage trophoblast] Buettner R, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):257–61 (Eng. Abstr.) **(Ger)**

[Morphologic features of immune interrelationships in the feto-placental system in development of a large fetus and in retardation of intrauterine fetal development] Iakovtsova AF, et al. **Arkh Patol** 1995 Jul-Aug;57(4):76–80 (Eng. Abstr.) **(Rus)**

[Human chagasic placenta: structural and cytochemical changes of blood vessels] Fretes RE, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):11–5 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Hepatocyte growth factor and placental development [letter; comment] Kilby M, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1946. Comment on: Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):937–42.

Maternal prepregnant weight and weight gain: relationship to placental microstructure and morphometric oxygen diffusion capacity. Stevens-Simon C, et al. **Am J Perinatol** 1995 Nov;12(6):407–12

Fetal cardiac bypass using an in-line axial flow pump to minimize extracorporeal surface and avoid priming volume. Reddy VM, et al. **Ann Thorac Surg** 1996 Aug;62(2):393–400

Secretion is a stimulus for the synthesis of human chorionic gonadotrophin by first trimester human placenta. Sharma SC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1235–41

Expression of Cdx-2 in the mouse embryo and placenta: possible role in patterning of the extra-embryonic membranes. Beck F, et al. **Dev Dyn** 1995 Nov;204(3):219–27

Suboptimal protein nutrition in early life later influences insulin action in pregnant rats. Holness MJ, et al. **Diabetologia** 1996 Jan;39(1):12–21

Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156–86 (431 ref.)

The fetal and infant origins of disease. Barker DJ. **Eur J Clin Invest** 1995 Jul;25(7):457–63 (51 ref.)

The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. Docherty SM, et al. **Hum Reprod** 1996 Jun;11(6):1157–61 (38 ref.)

Molecular characterization and in vitro biological activity of placentin, a new member of the insulin gene family. Koman A, et al. **J Biol Chem** 1996 Aug 23;271(34):20238–41

Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. Clifton VL, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2888–93

Amniotic fluid alpha fetoprotein (AFAFP) and maternal serum alpha fetoprotein (MSAFP) in abdominal pregnancies: correlation with extent and site of placental implantation and clinical implications. Shumway JB, et al. **J Matern Fetal Med** 1996 May-Jun;5(3):120–3

Effect of physiologic perfusion-fixation on the morphometrically evaluated dimensions of the term placental cotyledon. Luckhardt M, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):166–71

CRH, a placental clock and preterm labour [comment] Challis JR. **Nat Med** 1995 May;1(5):416. Comment on: Nat Med 1995 May;1(5):460–3.

Frequent ectopic expression of a placenta-specific gene at high levels in BALB/c mouse mammary carcinomas. VanHouten JN, et al. **Oncogene** 1996 May 16;12(10):2241–5

Conference report: placental growth and function. Challis JR, et al. **Placenta** 1995 Jul;16(5):471–5 (1 ref.)

Conference report: 1st international meeting of world placenta associations, Australia, 24–28 October 1994. Hunt JS. **Placenta** 1995 Jun;16(4):397–9

Keratinocyte growth factor and its receptor in the rhesus macaque placenta during the course of gestation. Izumi S, et al. **Placenta** 1996 Mar-Apr;17(2-3):123–35

Dipeptide transport in brush-border membrane vesicles (BBMV) prepared from human full-term placentae. Meredith D, et al. **Placenta** 1996 Mar-Apr;17(2-3):173–9

Hepatocyte growth factor/scatter factor and the placenta. Uehara Y, et al. **Placenta** 1996 Mar-Apr;17(2-3):97–101 (64 ref.)

Functional specialization in the ruminant placenta: evidence for two populations of fetal binucleate cells of different selective synthetic capacity. Wooding FB, et al. **Placenta** 1996 Jan;17(1):75–86

Gestational drive and the green-bearded placenta. Haig D. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6547–51

Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Kundu GC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2915–9

Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. Maruo T, et al. **Reprod Fertil Dev** 1995;7(6):1465–70 (15 ref.)

Recent advances in placental peptide research: workshop report. Mizutani S, et al. **Reprod Fertil Dev** 1995; 7(6):1443–50

Placental control of fetal growth. Robinson J, et al. **Reprod Fertil Dev** 1995;7(3):333–44 (133 ref.)

The placenta and the control of fetal breathing movements. Thorburn GD. **Reprod Fertil Dev** 1995;7(3):577–94 (107 ref.)

Course of pregnancy, steroid hormone levels and maturation process of placentomes after oestrone infusion in cows near term. Janowski T, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):345–50

[Effect of the beta receptor blockader carazolol on the dropping and retention of the placenta in the camel (C. dromedarius)] Nasr MT, et al. **Tierarztl Prax** 1996 Jun; 24(3):319–21 (Eng. Abstr.) **(Ger)**

[Maternal placenta] Botella Llusiá J. **An R Acad Nac Med (Madr)** 1995;112(4):833–45 **(Spa)**

PHYSIOPATHOLOGY

The placental cause of fetal growth retardation in twin gestations. Bleker OP, et al. **Acta Genet Med Gemellol (Roma)** 1995;44(2):103–6

Coincident expression of Menkes gene with copper efflux in human placental cells. Qian Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1880–4

The physiology of pre-eclampsia. Brown MA. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):781–91 (85 ref.)

SECRETION

Mouse growth hormone-releasing factor secretion is activated by inhibin and inhibited by activin in placenta. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):368–72

Secretion of colony stimulating factor-1 by human first trimester placental and decidual cell populations and the effect of this cytokine on trophoblast thymidine uptake in vitro. Jokhi PP, et al. **Hum Reprod** 1995 Oct;10(10):2800–7

In-vivo and in-vitro assessment of the influence of ritodrine and oxytocin on the placental secretion of human chorionic gonadotrophin and placental lactogen. Meuris S, et al. **Hum Reprod** 1996 Mar;11(3):664–7

Human chorionic gonadotrophin release and tissue viability in placental organ culture. Watson AL, et al. **Hum Reprod** 1995 Aug;10(8):2159–64

Nitric oxide regulation of corticotropin-releasing hormone release from the human perfused placenta in vitro. Roe CM, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):763–9

Differential release of interleukin-6 from human gestational tissues in association with labour and in vitro endotoxin treatment. Laham N, et al. **J Endocrinol** 1996 Jun; 149(3):431–9

T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells. Krishnan L, et al. **J Immunol** 1996 Jan 15;156(2):653–62

Cocaine inhibits hCG secretion by the human term placental cotyledon perfused in vitro. Simone C, et al. **Life Sci** 1996; 58(5):PL 63–6

[Corticotropin-releasing hormone in pregnancy] Sun G. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):270–2 (10 ref.) **(Chi)**

ULTRASONOGRAPHY

Early first-trimester ultrasound provides a window through which the chorionicity of twins can be diagnosed in an in vitro fertilization (IVF) population. Copperman AB, et al. **J Assist Reprod Genet** 1995 Nov;12(10):693–7

The relationship of sonographic placental grading, biochemical pulmonary maturity and neonatal outcome in pregnancy-induced hypertension. Jana N, et al. **J Indian Med Assoc** 1995 Jul;93(7):262–5

Translabial ultrasonography and placenta previa: does measurement of the os-placenta distance predict outcome? Dawson WB, et al. **J Ultrasound Med** 1996 Jun;15(6):441–6

Color Doppler sonographic assessment of placental circulation in the first trimester of normal pregnancy. Mercé LT, et al. **J Ultrasound Med** 1996 Feb;15(2):135–42

[Color Doppler of the utero placental territory and its relationship with the placental localization: normal and elevated resistance groups] Leible S, et al. **Rev Chil Obstet Ginecol** 1994;59(6):457–61; discussion 461–2 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

A chloride channel from human placenta reconstituted into giant liposomes. Riquelme G, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):733–8

Sulfate transport in human placental brush-border membrane vesicles. Grassl SM. **Biochim Biophys Acta** 1996 Jun 13; 1282(1):115–23

Sodium-dependent high-affinity binding of carnitine to human placental brush border membranes. Roque AS, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):274–82

Elastic fibres are an essential component of human placental stem villous stroma and an integrated part of the perivascular contractile sheath. Graf R, et al. **Cell Tissue Res** 1996 Jan;283(1):133–41

A new approach to the areolar structures in the pig placenta: histochemistry and development of mucous areolae. Bielańska-Osuchowska Z, et al. **Folia Histochem Cytobiol** 1995;33(2):95–101

Ultrastructure of mucous areolae in the pig placenta. Bielańska-Osuchowska Z. **Folia Histochem Cytobiol** 1995; 33(2):103–110

Twin pregnancies with complete hydatidiform mole and coexisting fetus: use of fluorescent in situ hybridization to evaluate placental X- and Y-chromosomal content. Choi-Hong SR, et al. **Hum Pathol** 1995 Nov; 26(11):1175–80

The effect of osmolarity on human placental mitochondria function. Martínez F, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):795–803

Uptake of cimetidine into syncytial microvillus membrane vesicles of human term placenta. van der Aa EM, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):219–22

Isolation of syncytial microvillous membrane vesicles from human term placenta and their application in drug-nutrient interaction studies. van der Aa EM, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):47–56

Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. Macara L, et al. **Placenta** 1996 Jan;17(1):37–48

Elevated alpha-fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester? Zimmermann R, et al. **Prenat Diagn** 1995 Dec;15(12):1121–4

The distribution of microvilli over the villous surface of the normal human term placenta is homogenous. Karimu AL, et al. **Reprod Fertil Dev** 1995;7(5):1269–73

[The ultrastructure of intermediate type trophoblast cell] Zhang R, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct;24(5):315–7 (Eng. Abstr.) **(Chi)**

VIROLOGY

Simian immunodeficiency virus infection of macaque primary

placental cells. Bui T, et al.
AIDS Res Hum Retroviruses 1995 Aug;11(8):955–61

Bidirectional enhancing activities between human T cell leukemia–lymphoma virus type I and human cytomegalovirus in human term syncytiotrophoblast cells cultured in vitro. Tóth FD, et al.
AIDS Res Hum Retroviruses 1995 Dec;11(12):1495–1507

Tissue macrophages are infected by human cytomegalovirus in vivo. Sinzger C, et al. **J Infect Dis** 1996 Jan;173(1):240–5

Investigation of the pathogenesis of transplacental transmission of Aleutian mink disease parvovirus in experimentally infected mink. Broll S, et al. **J Virol** 1996 Mar;70(3):1455–66

Cytomegalovirus in the perfused human term placenta in vitro. Mühlemann K, et al. **Placenta** 1995 Jun;16(4):367–73

[Comparative study of the placenta from HIV+ mothers. Ultrastructural analysis] Villegas-Castrejon H, et al.
Ginecol Obstet Mex 1996 Apr;64:167–76 (Eng. Abstr.) **(Spa)**

PLACENTA ACCRETA

The outcome of placenta accreta in Kuwait (1981–1993). Makhseed M, et al. **Int J Gynaecol Obstet** 1995 Aug; 50(2):139–44

[Placenta accreta. Ten cases] Benzineb N, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):751–5 (24 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Abdominal pain and hemoperitoneum in the gravid patient: a case report of placenta percreta. Smith L, et al.
Am J Emerg Med 1996 Jan;14(1):45–7

Placenta percreta involving urinary bladder. Teo RE, et al.
Br J Urol 1996 Jul;78(1):140

Post partum intra-abdominal hemorrhage due to placenta percreta. Veenstra MJ, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Oct;62(2):253–6

Spontaneous rupture of the uterus due to placenta percreta at 25-weeks' gestation: a case report. Kinoshita T, et al.
J Obstet Gynaecol Res 1996 Apr;22(2):125–8

[A rare cause of uterine rupture during pregnancy] Poli M, et al. **Minerva Ginecol** 1995 Sep;47(9):391–2 **(Ita)**

DIAGNOSIS

Retained placenta accreta: MRI and pathologic correlation. Amoh Y, et al. **J Comput Assist Tomogr** 1995 Sep–Oct; 19(5):827–9

Placenta percreta post evacuation: an unusual uterine mass on MRI. Neish AS, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):824–7

ETIOLOGY

Placenta previa and previous cesarean section. To WW, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):25–31

Placenta percreta post evacuation: an unusual uterine mass on MRI. Neish AS, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):824–7

PATHOLOGY

Retained placenta accreta: MRI and pathologic correlation. Amoh Y, et al. **J Comput Assist Tomogr** 1995 Sep–Oct; 19(5):827–9

Placenta increta occurring in a blighted ovum. Gist RS, et al. **South Med J** 1996 May;89(5):545–7

SURGERY

Successful conservative management of placenta percreta with rectal involvement in a primigravida. Lee LC, et al.
Acta Obstet Gynecol Scand 1995 Nov;74(10):839–41

Balloon occlusion of the abdominal aorta during caesarean hysterectomy for placenta percreta. Paull JD, et al.
Anaesth Intensive Care 1995 Dec;23(6):731–4

Anaesthesia for caesarean hysterectomy in a patient with a preoperative diagnosis of placenta percreta with invasion of the urinary bladder. Hunter T, et al. **Can J Anaesth** 1996 Mar;43(3):246–8; discussion 249–51

Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. Cirisano FD, et al. **J Reprod Med** 1996 Mar; 41(3):191–4

THERAPY

Two cases of placenta accreta managed conservatively. Komulainen MH, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Sep;62(1):135–7

ULTRASONOGRAPHY

Placenta previa increta diagnosed at 18 weeks' gestation. Report of a case with sonographic and pathologic correlation. Wheeler TC, et al. **J Reprod Med** 1996 Mar; 41(3):198–200

PLACENTA DISEASES

Proceedings of the 1st International Meeting of World Placenta Associations. Sydney, New South Wales, Australia, 24–28 October 1994. **Reprod Fertil Dev** 1995; 7(6):1395–609

[Placental chorioangioma. Two cases and review of the literature] Rousseau O, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(5):529–33 (27 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Salafia CM, et al.
Am J Obstet Gynecol 1995 Oct;173(4):1049–57

Maternal, placental, and neonatal associations with early germinal matrix/intraventricular hemorrhage in infants born before 32 weeks' gestation. Salafia CM, et al.
Am J Perinatol 1995 Nov;12(6):429–36

Primary causes of fetal deaths in Athens a clinicopathological study. Agapitos E, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):338–41

Asphyxia. Mac Donald D.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):579–94 (65 ref.)

Massive chronic intervillositis associated with recurrent abortions. Doss BJ, et al. **Hum Pathol** 1995 Nov; 26(11):1245–51

Fetal and neonatal haemodilution associated with multiple placental chorioangioma: case report. Montan S, et al.
J Obstet Gynaecol Res 1996 Feb;22(1):43–6

Advanced triploid pregnancy and preeclampsia. Sorem KA, et al. **South Med J** 1995 Nov;88(11):1144–5

[Complicated placental chorioangioma: infrequent cause of premature labor] Enriquez R, et al.
Rev Chil Obstet Ginecol 1994;59(5):390–2 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Case report. Antenatal diagnosis of chorioangioma of the placenta: MR features. Mochizuki T, et al.
J Comput Assist Tomogr 1996 May–Jun;20(3):413–6

EPIDEMIOLOGY

Increased incidence of placental chorioangioma in high-altitude pregnancies: hypobaric hypoxia as a possible etiologic factor. Reshetnikova OS, et al.
Am J Obstet Gynecol 1996 Feb;174(2):557–61

The effect of placental malaria infection on perinatal mortality in rural Malawi. McDermott JM, et al.
Am J Trop Med Hyg 1996;55(1 Suppl):61–5

Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Steketee RW, et al.
Am J Trop Med Hyg 1996;55(1 Suppl):24–32

Hemorrhagic endovasculitis of the placenta. A clinical-pathological study in Brazil. Altemani AM, et al.
J Perinat Med 1995;23(5):359–63

The epidemiology of placental features: associations with gestational age and neonatal outcome. Beebe LA, et al.
Obstet Gynecol 1996 May;87(5 Pt 1):771–8

Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Soma H, et al.
Reprod Fertil Dev 1995;7(6):1533–8

ETIOLOGY

Sex ratios of offspring and the causes of placental pathology. James WH. **Hum Reprod** 1995 Jun;10(6):1403–6

GENETICS

[Intrauterine growth retardation associated with a mosaic trisomy 20 limited to the placenta. A case report] Lacoste-Jugnet N, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(6):606–9 (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Placental ureaplasma urealyticum infection and low birth weight] Sun H, et al.
Chung Hua Fu Chan Ko Tsa Chih 1995 Jun;30(6):340–1 (Eng. Abstr.) **(Chi)**

PARASITOLOGY

Images in clinical medicine. Placental malaria. Miller IJ, et al. **N Engl J Med** 1996 Jul 11;335(2):98

PATHOLOGY

The efficacy of the placental biopsy. Kliman HJ, et al.
Am J Obstet Gynecol 1995 Oct;173(4):1084–8

Placental ratio and intrauterine growth retardation. Lao TT, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):924–6

Selected vascular lesions of the placenta. Gersell DJ.
Clin Lab Med 1995 Sep;15(3):611–29 (73 ref.)

Gestational trophoblastic disease. New approaches to diagnosis. Lage JM, et al. **Clin Lab Med** 1995 Sep; 15(3):631–64 (50 ref.)

Massive chronic intervillositis associated with recurrent abortions. Doss BJ, et al. **Hum Pathol** 1995 Nov; 26(11):1245–51

Teratoma of the placenta. Jaswal TS, et al.
J Indian Med Assoc 1995 Sep;93(9):362, 345

Placental nevus cells associated with giant congenital pigmented nevi. Antaya RJ, et al. **Pediatr Dermatol** 1995 Sep;12(3):260–2

Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66–89 (39 ref.)

[Non-trophoblastic tumors of the placenta] Dukovski A.
Akush Ginekol (Sofiia) 1994;33(2):40–3 (28 ref.) **(Bul)**

THERAPY

Placental-site trophoblastic tumor. Principles of diagnosis, clinical behaviour and treatment. Vardar MA, et al.
Eur J Gynaecol Oncol 1995;16(4):290–5

ULTRASONOGRAPHY

Early fetal circulation in pregnancies complicated by retroplacental hematoma. Rizzo G, et al.
J Clin Ultrasound 1995 Nov–Dec;23(9):525–9

Subchorionic placental cyst: a cause of fetal growth retardation—ultrasound and color-flow Doppler diagnosis and follow-up. Raga F, et al. **J Natl Med Assoc** 1996 May; 88(5):285–8

Large placental hemangioma diagnosed by ultrasonography—a case report. Lisboa Bittencourt A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1033–5

Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66–89 (39 ref.)

VIROLOGY

Cytomegalovirus in the perfused human term placenta in vitro. Mühlemann K, et al. **Placenta** 1995 Jun;16(4):367–73

PLACENTA PRAEVIA

The anaesthetic management of Caesarean section for placenta praevia: a questionnaire survey [see comments] Bonner SM, et al. **Anaesthesia** 1995 Nov;50(11):992–4. Comment in: Anaesthesia 1996 Apr;51(4):403.

Anaesthetic management of placenta praevia [letter; comment] Howard J, et al. **Anaesthesia** 1996 Apr;51(4):403 . Comment on: Anaesthesia 1995 Nov;50(11):992–4.

ETHNOLOGY

Increased risk of placenta previa among women of Asian origin. Taylor VM, et al. **Obstet Gynecol** 1995 Nov; 86(5):805–8

ETIOLOGY

One or multiple previous cesarean sections are associated with similar increased frequency of placenta previa. Hershkowitz R, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Oct;62(2):185–8

Placenta previa and previous cesarean section. To WW, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):25–31

Maternal cigarette smoking and placenta previa. Chelmow D, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):703–6

Antepartum haemorrhage: the influence of first trimester uterine bleeding. Obed JY, et al. **West Afr J Med** 1996 Jan–Mar;15(1):61–3

THERAPY

Autologous blood donation with placenta previa: is it feasible? Dinsmoor MJ, et al. **Am J Perinatol** 1995 Nov; 12(6):382–4

Pregnancies complicated by placenta praevia: what is appropriate management? Love CD, et al.
Br J Obstet Gynaecol 1996 Sep;103(9):864–7

ULTRASONOGRAPHY

Translabial ultrasonography and placenta previa: does measurement of the os-placenta distance predict outcome? Dawson WB, et al. **J Ultrasound Med** 1996 Jun;15(6):441–6

Transvaginal visualization of the cervix after instillation of water in the vaginal canal [letter; comment] Debevec C, et al. **J Ultrasound Med** 1995 Nov;14(11):804. Comment on: J Ultrasound Med 1995 Jan;14(1):73–5.

Diagnosis of vasa previa with ultrasound and color flow Doppler: a case report. Fleming AD, et al.
Nebr Med J 1996 Jul;81(7):191–3

PLACENTA, RETAINED

DIAGNOSIS

Placental polyp: MR imaging findings [letter; comment] Suzuki N, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1554. Comment on: AJR Am J Roentgenol 1993 Aug;161(2):345–6.

Retained placenta accreta: MRI and pathologic correlation. Amoh Y, et al. **J Comput Assist Tomogr** 1995 Sep–Oct; 19(5):827–9

Placenta percreta post evacuation: an unusual uterine mass on MRI. Neish AS, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):824–7

DRUG THERAPY

Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Bider D, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Jan;64(1):59–61 (13 ref.)

PLACENTA, RETAINED

ETIOLOGY

Placenta percreta post evacuation: an unusual uterine mass on MRI. Neish AS, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):824–7

PATHOLOGY

Retained placenta accreta: MRI and pathologic correlation. Amoh Y, et al. **J Comput Assist Tomogr** 1995 Sep–Oct; 19(5):827–9

ULTRASONOGRAPHY

Sonographic follow–up of a placenta left in situ after delivery of the fetus in an abdominal pregnancy. Bajo JM, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):285–8

VETERINARY

Prostaglandin F2 alpha metabolite and progesterone profiles in post–partum cows with retained foetal membranes. Bekana M, et al. **Acta Vet Scand** 1996;37(2):171–85

Evaluation of injections of collagenase and oxytetracycline via the umbilical artery as treatment for retained placenta in cattle. Fecteau KA, et al. **Am J Vet Res** 1996 Apr; 57(4):522–5

Evaluation of the use of intrauterine infusions of oxytetracycline, subcutaneous injections of fenprostalene, or a combination of both, for the treatment of retained fetal membranes in dairy cows. Stevens RD, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1612–5

Effects of fenprostalene and estradiol–17 beta benzoate on parturition and retained placenta in dairy cows and heifers. Rasmussen FE, et al. **J Dairy Sci** 1996 Feb;79(2):227–34

[Metabolic profile in cows in the peripartum period with and without retained placenta] Kudláč E, et al. **Vet Med (Praha)** 1995 Jul;40(7):201–7 (Eng. Abstr.) **(Cze)**

[Effectiveness of local treatment using a PVP–iodine compound for retained placenta in cows] Geiser S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):264–8 (Eng. Abstr.) **(Ger)**

[Caruncle removal in cattle—subsequent treatment and use of a new cervix dilator] Glock H. **Tierarztl Prax** 1996 Apr; 24(2):103–7 (Eng. Abstr.) **(Ger)**

[Effect of the beta receptor blockader carazolol on the dropping and retention of the placenta in the camel (C. dromedarius)] Nasr MT, et al. **Tierarztl Prax** 1996 Jun; 24(3):319–21 (Eng. Abstr.) **(Ger)**

PLACENTAL ANTICOAGULANT PROTEIN I see **ANNEXIN V**

PLACENTAL ANTICOAGULANT PROTEIN II see **ANNEXIN IV**

PLACENTAL ANTICOAGULANT PROTEIN III see **ANNEXIN III**

PLACENTAL ANTICOAGULANT PROTEINS see **ANNEXINS**

PLACENTAL EXTRACTS

THERAPEUTIC USE

[Experience in introducing the method of placental therapy in vitiligo in Ukraine] Mal'tsev VI, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):123–5 (Eng. Abstr.) **(Rus)**

PLACENTAL FUNCTION TESTS

[Use of a mathematical model to establish normal serum parameters characterizing the function of the fetoplacental complex] Shmagel' KV. **Klin Lab Diagn** 1995 May–Jun; (3):28–32 (Eng. Abstr.) **(Rus)**

METHODS

Assessment of hepatobiliary function and placental barrier integrity in pregnant rats by combination of bromosulphophthalein and fluorescein isothiocyanate plasma disappearance tests. Villaneuva GR, et al. **Int J Exp Pathol** 1995 Jun;76(3):183–90

PLACENTAL HORMONES

BIOSYNTHESIS

Decreased expression of placental growth hormone in intrauterine growth retardation. Chowen JA, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):736–9

BLOOD

Isolation of a bovine uterotropic placental factor and development of an enzyme immunoassay in peripheral serum. Iñiguez GM, et al. **Biol Reprod** 1995 Dec; 53(6):1324–9

PHARMACOLOGY

Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase. Murthy BS, et al. **Biochemistry** 1996 Apr 2;35(13):3880–5

Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. Boix E, et al. **J Mol Biol** 1996 Apr 19; 257(5):992–1007

PLACENTAL INSUFFICIENCY

COMPLICATIONS

Early ultrasonographic detection of fetal growth retardation in an ovine model of placental insufficiency. Barbera A, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1071–4

ETIOLOGY

[Basic pathogenetic mechanisms of chronic placental insufficiency] Milovanov AP, et al. **Arkh Patol** 1995 Jul–Aug;57(4):11–6 (54 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al. **J Perinatol** 1995 Nov–Dec;15(6):510–3 (7 ref.)

VETERINARY

Theriogenology question of the month. Placental insufficiency, probably the result of twin fetuses. Wolfsdorf K. **J Am Vet Med Assoc** 1996 Jan 15;208(2):201–2

PLACENTAL LACTOGEN

see related
RECEPTORS, SOMATOTROPIN

ANALYSIS

The expression of trophoblastic cell markers by lung carcinomas. Boucher LD, et al. **Hum Pathol** 1995 Nov; 26(11):1201–6

ANTAGONISTS & INHIBITORS

Posttranscriptional inhibition of mouse placental lactogen–II secretion by transforming growth factor beta 1: synergistic effects with epidermal growth factor and interleukin–6. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):373–9

Cytokines that use gp130 as a signal transducer stimulate mouse placental lactogen–I (mPL–I) but inhibit mPL–II production in vitro. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):399–406

BIOSYNTHESIS

Cytokines that use gp130 as a signal transducer stimulate mouse placental lactogen–I (mPL–I) but inhibit mPL–II production in vitro. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):399–406

Apolipoprotein A–I stimulates placental lactogen expression by human trophoblast cells. Handwerger S, et al. **Endocrinology** 1995 Dec;136(12):5555–60

BLOOD

[Estriol and human placental lactogen as risk indicators in pregnancies of diabetic and hypertensive patients] Günter HH, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug; 199(4):142–7 (Eng. Abstr.) **(Ger)**

[Human placental lactogen (hPL)] Mochizuki M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:600–3 (8 ref.) **(Jpn)**

CHEMISTRY

Identification of a tyrosine residue in ovine placental lactogen as essential for its binding to receptors. Cymes GD, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):31–6

Selective modification of recombinant bovine placental lactogen by site–directed mutagenesis at its C terminus. Vashdi–Elberg D, et al. **J Biol Chem** 1996 Mar 8; 271(10):5558–64

GENETICS

Identification of a composite steroid hormone response element on the human placental lactogen promoter. Stephanou A, et al. **Mol Cell Endocrinol** 1995 Jul; 112(1):123–9

[Modification of DNA with 4–aminooxybutylamine as a method for obtaining highly–sensitive hybridization probes. Mapping of the gene for human chorionic somatomammotropin hormone] Adarichev VA, et al. **Mol Biol (Mosk)** 1995 May–Jun;29(3):538–45 (Eng. Abstr.) **(Rus)**

METABOLISM

Identification of a tyrosine residue in ovine placental lactogen as essential for its binding to receptors. Cymes GD, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):31–6

Ontogeny of a specific high–affinity binding site for ovine placental lactogen in fetal and postnatal liver. Pratt SL, et al. **Domest Anim Endocrinol** 1995 Oct;12(4):337–47

A cDNA encoding a new member of the rat placental lactogen family, PL–I mosaic (PL–Im). Hirosawa M, et al. **Endocr J** 1994 Aug;41(4):387–97

Selective modification of recombinant bovine placental lactogen by site–directed mutagenesis at its C terminus. Vashdi–Elberg D, et al. **J Biol Chem** 1996 Mar 8; 271(10):5558–64

PHARMACOLOGY

Insulin–like growth factors–I and –II, somatotropin, prolactin, and placental lactogen are not acute effectors of lipolysis in ruminants. Houseknecht KL, et al. **Domest Anim Endocrinol** 1996 May;13(3):239–49

Human placental lactogen infusions into the medial preoptic area stimulate maternal behavior in steroid–primed, nulliparous female rats. Bridges RS, et al. **Horm Behav** 1995 Jun;29(2):216–26

In vitro contraction of the canine corpus cavernosum penis by direct perfusion with prolactin or growth hormone. Ra S, et al. **J Urol** 1996 Aug;156(2 Pt 1):522–5

PHYSIOLOGY

Hormonal influences on beta–lactoglobulin transgene expression inferred from chromatin structure. Whitelaw CB. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):121–5

SECRETION

Posttranscriptional inhibition of mouse placental lactogen–II secretion by transforming growth factor beta 1: synergistic effects with epidermal growth factor and interleukin–6. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):373–9

Simultaneous measurement of 45Ca outflow and human placental lactogen release from placental explants. Lebrun P, et al. **Cell Calcium** 1995 May;17(5):384–92

Regulation of rat placental lactogen (rPL)–II secretion: cAMP inhibits rPL–II secretion in vitro. Yamaguchi M, et al. **Eur J Endocrinol** 1995 Sep;133(3):342–6

Regulation of mouse placental lactogen secretion by factors secreted from the pituitary in vitro. Yamaguchi M, et al. **Eur J Endocrinol** 1996 Jan;134(1):123–7

Endometrial stromal cell decidualization inhibits human chorionic gonadotrophin and human placental lactogen secretion by co–cultured trophoblasts. Katsuragawa H, et al. **Hum Reprod** 1995 Nov;10(11):3028–34

In–vivo and in–vitro assessment of the influence of ritodrine and oxytocin on the placental secretion of human chorionic gonadotrophin and placental lactogen. Meuris S, et al. **Hum Reprod** 1996 Mar;11(3):664–7

Activin inhibits but inhibin activates mouse placental lactogen–II secretion. Yamaguchi M, et al. **J Endocrinol** 1995 Sep;146(3):469–74

Inhibition of mouse placental lactogen–II release from placental cells by interleukin–1 after mid–pregnancy. Yamaguchi M, et al. **J Endocrinol** 1995 Dec;147(3):423–9

Transforming growth factor–alpha regulates subpopulation of giant cells which secrete mouse placental lactogen–I (mPL–I) and/or mPL–II at midpregnancy. Yamaguchi M, et al. **J Endocrinol Invest** 1996 Mar;19(3):146–53

PLACENTAL PROTEINS see **PREGNANCY PROTEINS**

PLACENTAL–SITE TROPHOBLASTIC TUMOR see **TROPHOBLASTIC TUMOR, PLACENTAL SITE**

PLACENTAL VILLI see **CHORIONIC VILLI**

PLACENTATION

GENETICS

Manual performance and laterality in twins of known chorion type. Carlier M, et al. **Behav Genet** 1996 Jul;26(4):409–7

Handedness in twins according to zygosity and chorion type: a preliminary report. Derom C, et al. **Behav Genet** 1996 Jul;26(4):407–8

Transforming growth factor beta 1 expression in the endometrium of the mare during placentation. Lennard SN, et al. **Mol Reprod Dev** 1995 Oct;42(2):131–40

IMMUNOLOGY

[Regulation by maternally derived cytokines of pre–implantation development and uterine receptiveness] Stewart CL, et al. **Contracept Fertil Sex** 1995 Sep; 23(9):555–61 (37 ref.) (Eng. Abstr.) **(Fre)**

[Functional significance of CD56 large granular lymphocytes in the decidua in early pregnancy in the human] Marzusch K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:88–92 (Eng. Abstr.) **(Ger)**

PLACENTOMA, NORMAL see **PLACENTA**

PLACENTOME see **PLACENTA**

PLAGIARISM

Plagiarism, attribution, and other acts of negligent self–indulgence [editorial] Lutter LD. **Foot Ankle Int** 1996 May;17(5):245–6

Concept of grief. Cowles KV, et al. **J Adv Nurs** 1996 May; 23(5):1055–7

Quis custodiet ipsos custodes? [letter; comment] [see comments] Appleton BL. **Nature** 1995 Nov 30; 378(6556):432. Comment on: Nature 1995 Aug 31;376(6543):721. Comment on: Nature 1995 Sep 28;377(6547):282. Comment in: Nature 1996 Jan 4;379(6560):11.

Brazilian researcher protests against 'plagiarism' fine [news] [see comments] Bonalume Neto R. **Nature** 1996 Apr 4; 380(6573):371. Comment in: Nature 1996 Jun 6;381(6582):467.
ORI's unhappy lot [letter; comment] [see comments] McCutchen CW. **Nature** 1995 Sep 28;377(6547):282. Comment on: Nature 1995 Aug 31;376(6543):721. Comment in: Nature 1995 Nov 30;378(6556):432.
Quis custodiet ipsos custodes [letter; comment] Mishkin B. **Nature** 1995 Nov 30;378(6556):432. Comment on: Nature 1995 Aug 31;376(6543):721.
Questionable judgement [letter; comment] Schaufele F. **Nature** 1996 Jun 6;381(6582):467. Comment on: Nature 1996 Apr 4;380(6573):371.
Authorship disputes [letter; comment] McCutchen CW. **Science** 1995 Dec 8;270(5242):1557. Comment on: Science 1995 Sep 29;269(5232):1811.

PLAGUE

[In the footsteps of plague-carrying fleas in the old empire of Genghis Khan--report from a Mongolian city] Evengård B. **Lakartidningen** 1995 Dec 20;92(51-52):4910-1 **(Swe)**

DIAGNOSIS

[The clinical, diagnostic and treatment characteristics of plague today (editorial)] Pokrovskiĭ VI, et al. **Ter Arkh** 1995;67(11):3-5 **(Rus)**

DRUG THERAPY

Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. Russell P, et al. **J Antimicrob Chemother** 1996 Apr; 37(4):769-74
[Comparative effectiveness of rifampicin for parenteral administration and internal dose in the treatment of experimental plague in albino mice] Makarovskaia LN, et al. **Antibiot Khimioter** 1995 Jun;40(6):37-9 (Eng. Abstr.) **(Rus)**
[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun;40(6):23-30 (Eng. Abstr.) **(Rus)**
[Methods for rapid evaluation of the effectiveness of drugs showing promise for urgent prevention and treatment of plague] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun; 40(6):31-6 (Eng. Abstr.) **(Rus)**
[The clinical, diagnostic and treatment characteristics of plague today (editorial)] Pokrovskiĭ VI, et al. **Ter Arkh** 1995;67(11):3-5 **(Rus)**

EPIDEMIOLOGY

India's pneumonic plague outbreak continues to baffle [news] Mudur G. **BMJ** 1995 Sep 16;311(7007):706
An outbreak of plague in northwestern province, Zambia. McClean KL. **Clin Infect Dis** 1995 Sep;21(3):650-2
The power of plague. Wilson ME. **Epidemiology** 1995 Jul; 6(4):458-60
Indian 'plague' epidemic: unanswered questions and key lessons. Mavalankar DV. **J R Soc Med** 1995 Oct; 88(10):547-51
Plague in Majunga, Madagascar [letter] Rasolomaharo M, et al. **Lancet** 1995 Nov 4;346(8984):1234
Plague in India. Ramalingaswami V. **Nat Med** 1995 Dec; 1(12):1237-9
The plague [letter] Nagoba BS, et al. **Natl Med J India** 1995 Nov-Dec;8(6):296
Human plague in 1994. **Wkly Epidemiol Rec** 1996 May 31; 71(22):165-8 **(Eng, Fre)**

HISTORY

The plague in Penrith, Cumbria, 1597/8: its causes, biology and consequences. Scott S, et al. **Ann Hum Biol** 1996 Jan-Feb;23(1):1-21
Climatic changes, mycotoxins, plagues, and genius. Schoental R. **J R Soc Med** 1995 Oct;88(10):560-1
A Scottish doctor's association with the discovery of the plague bacillus. Yule WL. **Scott Med J** 1995 Dec; 40(6):184-6

IMMUNOLOGY

[A comparative study by immunoblotting of the serological response in white mice and guinea pigs inoculated against plague] Nekliaev VN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):75-6 **(Rus)**

MICROBIOLOGY

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178-81 (28 ref.)
Burkholderia pseudomallei and Indian plague-like illness [letter; comment] [published erratum appears in Lancet 1995 Oct 28;346(8983):1172] Bharadwaj R, et al. **Lancet** 1995 Oct 7;346(8980):975. Comment on: Lancet 1995 Sep 30;346(8979):904-5.
Burkholderia pseudomallei and Indian plague-like illness [letter; comment] [see comments] Dance DA, et al. **Lancet** 1995 Sep 30;346(8979):904-5. Comment on: Lancet 1994 Dec 3;344(8936):1574. Comment in: Lancet 1995 Oct 7;346(8980):975.
[Shibasaburo Kitasato's discovery of plague bacillus and its historical background--on the occasion of the centennial anniversary] Nakase Y. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):637-50 (53 ref.) **(Jpn)**
[The problem of natural foci of plague: the search for ways for its resolution (editorial)] Lomaradskiĭ IV, et al. **Med Parazitol (Mosk)** 1995 Oct-Dec;(4):3-9 (46 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Andrews GP, et al. **Infect Immun** 1996 Jun;64(6):2180-7
[Methods for rapid evaluation of the effectiveness of drugs showing promise for urgent prevention and treatment of plague] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun; 40(6):31-6 (Eng. Abstr.) **(Rus)**

TRANSMISSION

Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas. Hinnebusch BJ, et al. **Science** 1996 Jul 19;273(5273):367-70
[An experimental study of the ability of the hybrid crosses of Citellophillus tesquorum fleas of 2 subspecies to transmit the causative agent of plague] Nikitin AIa, et al. **Med Parazitol (Mosk)** 1995 Oct-Dec;(4):14-7 (Eng. Abstr.) **(Rus)**

VETERINARY

Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Davis KJ, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):156-63

PLAGUE VACCINE

IMMUNOLOGY

[A comparative study by immunoblotting of the serological response in white mice and guinea pigs inoculated against plague] Nekliaev VN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):75-6 **(Rus)**

THERAPEUTIC USE

A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Russell P, et al. **Vaccine** 1995 Nov;13(16):1551-6

PLAICE see **FLATFISHES**

PLANARIANS

CHEMISTRY

Parvalbumin-immunoreactive proteins in the nervous system of planarians. Hutticher A, et al. **Cell Mol Neurobiol** 1995 Aug;15(4):401-10

CYTOLOGY

Fixation and staining of planaria for histological study. DiCiaula LL, et al. **Biotech Histochem** 1995 May; 70(3):119-23

DRUG EFFECTS

Effects of 3-iodo-L-tyrosine, a tyrosine hydroxylase inhibitor, on eye pigmentation and biogenic amines in the planarian, Dugesia dorotocephala. Ness DK, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):153-61

GENETICS

Identification of members of several homeobox genes in a planarian using a ligation-mediated polymerase chain reaction technique. Balavoine G. **Nucleic Acids Res** 1996 Apr 15;24(8):1547-53

METABOLISM

Electrical responses and K+ activity changes to light in the ocellus of the planarian Dugesia japonica. Azuma K, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):593-9

PLANETS

see related
EXTRATERRESTRIAL ENVIRONMENT

Circumstellar disks and the search for neighbouring planetary systems. Beckwith SV, et al. **Nature** 1996 Sep 12; 383(6596):139-44
Looking for the twilight zone [news] Black D. **Nature** 1996 Jun 6;381(6582):474
NASA panel draws up 'road map' to hunt earth-like planets in space [news] Reichhardt T. **Nature** 1995 Dec 14; 378(6558):650
Condensation of methane, ammonia, and water and the inhibition of convection in giant planets. Guillot T. **Science** 1995 Sep 22;269(5231):1697-9
[The biological effects of heavy charged particles. The main results and prospective research in the context of interplanetary flights] Fedorenko BS. **Aviakosm Ekolog Med** 1995;29(2):16-21 (Eng. Abstr.) **(Rus)**
[Is there a correlation between cosmophysical factors and emergence of manic-depressive psychosis?] Lucatelli FJ, et al. **Biofizika** 1995 Sep-Oct;40(5):1020-4 (Eng. Abstr.) **(Rus)**
[Frequency and phase matching changes in dihydroorotate dehydrogenase activity rhythm in rat peripheral blood lymphocytes with changes in the rhythm of solar activity and planet periods] Strigun LM, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):294-8 **(Rus)**

PLANIGRAPHY, X-RAY see **TOMOGRAPHY, X-RAY**

PLANKTON

see related
DIATOMS

CLASSIFICATION

Ribosomal RNA-based oligonucleotide probes to identify marine green ultraphytoplankton. Knauber DC, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):89-94
Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

ENZYMOLOGY

Ribulose-1,5-bisphosphate carboxylase/oxygenase gene expression and diversity of Lake Erie planktonic microorganisms. Xu HH, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1913-21

GENETICS

Phylogenetic compositions of bacterioplankton from two California estuaries compared by denaturing gradient gel electrophoresis of 16S rDNA fragments. Murray AE, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2676-80
Ribulose-1,5-bisphosphate carboxylase/oxygenase gene expression and diversity of Lake Erie planktonic microorganisms. Xu HH, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1913-21
Characterization of uncultivated prokaryotes: isolation and analysis of a 40-kilobase-pair genome fragment from a planktonic marine archaeon. Stein JL, et al. **J Bacteriol** 1996 Feb;178(3):591-9
Ribosomal RNA-based oligonucleotide probes to identify marine green ultraphytoplankton. Knauber DC, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):89-94
Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

MICROBIOLOGY

A simple filtration method to remove plankton-associated Vibrio cholerae in raw water supplies in developing countries. Huo A, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2508-12
Phylogenetic compositions of bacterioplankton from two California estuaries compared by denaturing gradient gel electrophoresis of 16S rDNA fragments. Murray AE, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2676-80

PLANNED PARENTHOOD see **FAMILY PLANNING**

PLANNING, HEALTH AND WELFARE see **HEALTH PLANNING**

PLANNING, HEALTH FACILITY see **HEALTH FACILITY PLANNING**

PLANNING TECHNIQUES

see related
HEALTH PLANNING

Information systems and strategic management. Austin CJ, et al. **Health Care Manage Rev** 1995 Summer;20(3):26-33; discussion 34-42 (17 ref.)
Strategic planning in hospitals: a review and proposal. Bruton GD, et al. **Health Care Manage Rev** 1995 Summer; 20(3):16-25 (45 ref.)
Strategic planning for information management: what are the deliverables? Olsen AJ, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:785-9

PLANNING THEORIES see **PLANNING TECHNIQUES**

PLANT AGGLUTININS see **LECTINS**

PLANT DISEASES

First report of the inhibition of arbuscular mycorrhizal infection of Pisum sativum by specific and irreversible

inhibition of polyamine biosynthesis or by gibberellic acid treatment. El Ghachtouli N, et al. **FEBS Lett** 1996 May 6;385(3):189–92

Systemic acquired resistance in Arabidopsis requires salicylic acid but not ethylene. Lawton K, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):863–70

Cell cycle. Why don't plants get cancer? [news; comment] Doonan J, et al. **Nature** 1996 Apr 11;380(6574):481–2. Comment on: Nature 1996 Apr 11;380(6574):520–3.

Patents and indigenous lore [letter; comment] Miller H. **Nature** 1995 Dec 7;378(6557):532. Comment on: Nature 1995 Sep 14;377(6545):89–90.

Genetic and biochemical dissection of transgenic RNA–mediated virus resistance. Goodwin J, et al.
Plant Cell 1996 Jan;8(1):95–105

Expression of the Pseudomonas syringae avirulence protein AvrB in plant cells alleviates its dependence on the hypersensitive response and pathogenicity (Hrp) secretion system in eliciting genotype–specific hypersensitive cell death [see comments] Gopalan S, et al. **Plant Cell** 1996 Jul;8(7):1095–105. Comment in: Plant Cell 1996 Jul;8(7):1091–3.

Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091–3 (22 ref.). Comment on: Plant Cell 1996 Jul;8(7):1095–105.

High–affinity RNA–binding domains of alfalfa mosaic virus coat protein are not required for coat protein–mediated resistance. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8980–4

GENETICS

The tomato Cf–2 disease resistance locus comprises two functional genes encoding leucine–rich repeat proteins. Dixon MS, et al. **Cell** 1996 Feb 9;84(3):451–9

Molecular analysis of irradiation–induced and spontaneous deletion mutants at a disease resistance locus in Lactuca sativa. Anderson PA, et al. **Mol Gen Genet** 1996 Jun 12; 251(3):316–25

Identification of a new Arabidopsis disease resistance locus, RPs4, and cloning of the corresponding avirulence gene, avrRps4, from Pseudomonas syringae pv. pisi. Hinsch M, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):55–61

Infections with various types of organisms stimulate transcription from a short promoter fragment of the potato gst1 gene. Strittmatter G, et al.
Mol Plant Microbe Interact 1996 Jan;9(1):68–73

The L6 gene for flax rust resistance is related to the Arabidopsis bacterial resistance gene RPS2 and the tobacco viral resistance gene N. Lawrence GJ, et al. **Plant Cell** 1995 Aug;7(8):1195–206

Isolation of Arabidopsis genes that differentiate between resistance responses mediated by the RPS2 and RPM1 disease resistance genes. Reuber TL, et al. **Plant Cell** 1996 Feb;8(2):241–9

Identification, cloning, and characterization of PWL2, a gene for host species specificity in the rice blast fungus. Sweigard JA, et al. **Plant Cell** 1995 Aug;7(8):1221–33

The regulatory functions of the rolB and rolC genes of Agrobacterium rhizogenes are conserved in the homologous genes (Ngrol) of Nicotiana glauca in tobacco genetic tumors. Nagata N, et al. **Plant Cell Physiol** 1995 Sep;36(6):1003–12

Identification of amplified restriction fragment polymorphism (AFLP) markers tightly linked to the tomato Cf–9 gene for resistance to Cladosporium fulvum. Thomas CM, et al. **Plant J** 1995 Nov;8(5):785–94

Characterization of hsr201 and hsr515, two tobacco genes preferentially expressed during the hypersensitive reaction provoked by phytopathogenic bacteria. Czernic P, et al. **Plant Mol Biol** 1996 May;31(2):255–65

Mexican papita viroid: putative ancestor of crop viroids. Martinez–Soriano JP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9397–401

Detection of a major gene for resistance to fusiform rust disease in loblolly pine by genomic mapping. Wilcox PL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3859–64

MICROBIOLOGY

Xanthomonas campestris pv. parthenii pathovar nov. incitant of leaf blight of parthenium. Chand R, et al.
Antonie Van Leeuwenhoek 1995 Aug;68(2):161–4

Current status of the plasmodiophorids. Braselton JP.
Crit Rev Microbiol 1995;21(4):263–75 (50 ref.)

Mechanisms of fungicide resistance in phytopathogenic fungi. Steffens JJ, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):348–55 (77 ref.)

Biological control of plant root pathogens. Thomashow LS. **Curr Opin Biotechnol** 1996 Jun;7(3):343–7 (53 ref.)

Beauvericin and fumonisin B1 in preharvest Fusarium moniliforme maize ear rot in Sardinia. Bottalico A, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):599–607

Genetic differentiation in the rice blast fungus revealed by the distribution of the Fosbury retrotransposon. Shull V, et al. **Fungal Genet Biol** 1996 Mar;20(1):59–69

Genomic diversity and differentiation among phytoplasma strains in 16S rRNA groups I (aster yellows and related phytoplasmas) and III (X–disease and related phytoplasmas). Gundersen DE, et al.
Int J Syst Bacteriol 1996 Jan;46(1):64–75

Characterization of the mycoplasmalike organism associated with witches'–broom disease of lime and proposition of a Candidatus taxon for the organism, "Candidatus phytoplasma aurantifolia". Zreik L, et al.
Int J Syst Bacteriol 1995 Jul;45(3):449–53

Agroinfection. Grimsley N. **Methods Mol Biol** 1995; 44:325–42

PCR detection of the two 'Candidatus' Liberobacter species associated with greening disease of citrus. Jagoueix S, et al. **Mol Cell Probes** 1996 Feb;10(1):43–50

Erwinia chrysanthemi harpinEch: an elicitor of the hypersensitive response that contributes to soft–rot pathogenesis. Bauer DW, et al.
Mol Plant Microbe Interact 1995 Jul–Aug;8(4):484–91

Fusarium solani DNase is a signal for increasing expression of nonhost disease resistance response genes, hypersensitivity, and pisatin production. Hadwiger LA, et al. **Mol Plant Microbe Interact** 1995 Nov–Dec;8(6):871–9

Purification and characterization of an acidic beta–1,3–glucanase from cucumber and its relationship to systemic disease resistance induced by Colletotrichum lagenarium and tobacco necrosis virus. Ji C, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):899–905

The PWL host specificity gene family in the blast fungus Magnaporthe grisea. Kang S, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):939–48

Do plant pathogens produce inhibitors of the resistance reaction in plants? [letter; comment] Lawrence G.
Trends Microbiol 1995 Dec;3(12):475–6. Comment on: Trends Microbiol 1995 Dec;3(12):483–5.

[A preliminary study on essential oils for the control of Ustilago coicis] Zhang G, et al.
Chung Kuo Chung Yao Tsa Chih 1995 Nov;20(11):657–9, 702 (Eng. Abstr.) **(Chi)**

VIROLOGY

An appraisal of the banded and paracrystalline cytoplasmic inclusions induced in cymbidium mosaic potexvirus– and odontoglossum ringspot tobamovirus infected orchid cells using confocal laser scanning microscopy. Wong SM, et al. **Arch Virol** 1996;141(2):231–42

Viral RNA as a potential target for two independent mechanisms of replicase–mediated resistance against cucumber mosaic virus. Hellwald KH, et al. **Cell** 1995 Dec 15;83(6):937–46

Pear blister canker viroid: sequence variability and causal role in pear blister canker disease. Ambrós S, et al.
J Gen Virol 1995 Oct;76 (Pt 10):2625–9

Studies of coat protein–mediated resistance to tobacco mosaic virus (TMV). II. Challenge by a mutant with altered virion surface does not overcome resistance conferred by TMV coat protein. Clark WG, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2613–7

Transmission by aphids of a naturally non–transmissible plum pox virus isolate with the aid of potato virus Y helper component. López–Moya JJ, et al. **J Gen Virol** 1995 Sep; 76 (Pt 9):2293–7

Mapping of the seed transmission determinants of barley stripe mosaic virus. Edwards MC.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):906–15

RNA–mediated resistance with nonstructural genes from the tobacco etch virus genome. Swaney S, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):1004–11

Immunotherapy of plant viral diseases. Benvenuto E, et al.
Trends Microbiol 1995 Jul;3(7):272–5 (33 ref.)

PLANT DNA see **DNA, PLANT**

PLANT EMBRYOS see **SEEDS**

PLANT EXTRACTS

Natural–product inhibitors of human DNA ligase I. Tan GT, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):993–1000

Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. McRae S. **Can Med Assoc J** 1996 Aug 1;155(3):293–5

Determination of structure–activity relationships of Annonaceous acetogenins by inhibition of oxygen uptake in rat liver mitochondria. Landolt JL, et al.
Chem Biol Interact 1995 Oct 20;98(1):1–13

Unusual antimicrobial compounds from Aeollanthus buchnerianus. Dellar JE, et al. **Experientia** 1996 Feb 15; 52(2):175–9

Deleterious effects of khat addiction on semen parameters and sperm ultrastructure. el–Shoura SM, et al.
Hum Reprod 1995 Sep;10(9):2295–300

Larvicidal activity of a few plant extracts against Culex quinquefasciatus and Anopheles stephensi. Pushpalatha E, et al. **Indian J Malariol** 1995 Mar;32(1):14–23

Plant sources of acid stable lipases [letter; comment] Tursi JM, et al. **J Paediatr Child Health** 1995 Aug;31(4):364. Comment on: J Paediatr Child Health 1994 Dec;30(6):539–43.

Effect of Niclosamide (Bayluscide WP 70), Anacardium occidentale hexane extract and Euphorbia splendens latex on behavior of Biomphalaria glabrata (Say, 1818), under laboratory conditions. Jurberg P, et al.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):191–4

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

Spasmolytic flavonols from Artemisia abrotanum [letter] Bergendorff O, et al. **Planta Med** 1995 Aug;61(4):370–1

Mode of antibacterial action of totarol, a diterpene from Podocarpus nagi. Haraguchi H, et al. **Planta Med** 1996 Apr; 62(2):122–5

Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata.
Martínez–Vázquez M, et al. **Planta Med** 1996 Apr; 62(2):137–40

Antifungal principles of Baccharis pedunculata [letter] Rahalison L, et al. **Planta Med** 1995 Aug;61(4):360–2

An antifungal naphthoquinone, xanthones and secoiridoids from Swertia calycina [letter] Rodriguez S, et al.
Planta Med 1995 Aug;61(4):362–4

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha–reductase activity in human benign prostatic hyperplasia. Weisser H, et al. **Prostate** 1996 May; 28(5):300–6

Prevention of snail miracidia interactions using Phytolacca dodecandra (L'Herit) (endod) as a miracidiacide: an alternative approach to the focal control of schistosomiasis. Madhina D, et al. **Trop Med Int Health** 1996 Apr;1(2):221–6

Aspects of the cell growth of Candida guilliermondii in sugar cane bagasse hydrolysate. Molwitz M, et al.
Z Naturforsch [C] 1996 May–Jun;51(5–6):404–8

[The national drug control agency approves of a humbug drug (letter)] Jacobsen CD. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1384 **(Nor)**

[The national agency of drug control approves of a "humbug" drug. Approval of natural drugs (letter)] Westbye O.
Tidsskr Nor Laegeforen 1996 May 10;116(12):1504 **(Nor)**

ADMINISTRATION & DOSAGE

Structure–function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin. Pillion DJ, et al. **J Pharm Sci** 1996 May;85(5):518–24

[Garlic (Allium sativum)—a potent medicinal plant] Resch KL, et al. **Fortschr Med** 1995 Jul 20;113(20–21):311–5 (43 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo–controlled double–blind study] Witte B, et al.
Fortschr Med 1995 Oct 10;113(28):404–8 (Eng. Abstr.) **(Ger)**

[Phytoperfusion of the bladder after adenomectomy] Davidov MI, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct; (5):19–20 (Eng. Abstr.) **(Rus)**

[The use of pilastin for treating patients with chronic suppurative otitis media] Popova AE, et al.
Vestn Otorinolaringol 1996 Jan–Feb;(1):42–3 (Eng. Abstr.) **(Rus)**

[False safety with homeopathic agents. Swedes became ill with malaria in spite of prophylaxis] Carlsson T, et al.
Lakartidningen 1995 Nov 22;92(47):4467–8 **(Swe)**

[Ginseng extracts: on the importance of significance (letter)] Mårtens S. **Lakartidningen** 1995 Nov 15;92(46):4316 **(Swe)**

ADVERSE EFFECTS

Allergic contact dermatitis due to Centella asiatica: a new case. Gonzalo Garijo MA, et al.
Allergol Immunopathol (Madr) 1996 May–Jun;24(3):132–4

Contact dermatitis due to a massage liniment containing Inula helenium extract. Pazzaglia M, et al. **Contact Dermatitis** 1995 Oct;33(4):267

Allergic contact dermatitis from plant extracts in a cosmetic. Wilkinson SM, et al. **Contact Dermatitis** 1995 Jul;33(1):58–9

The association between oral leukoplakia and use of tobacco, alcohol and khat based on relative risks assessment in Kenya. Macigo FG, et al. **Eur J Oral Sci** 1995 Oct; 103(5):268–73

Occupational asthma caused by grass juice. Subiza J, et al.
J Allergy Clin Immunol 1995 Nov;96(5 Pt 1):693–5

Multiple cutaneous B–cell pseudolymphomas after allergen injections. Goerdt S, et al. **J Am Acad Dermatol** 1996 Jun; 34(6):1072–4

Budd–Chiari syndrome likely related to a slimming drug preparation [letter] Coche JC, et al. **J Hepatol** 1995 Nov; 23(5):626–7

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 May 22–29;275(20):1534

Clinical testing of "amole" (Agave lecheguilla): phase 1–A. Segura JJ, et al. **Proc West Pharmacol Soc** 1995;38:71–2

[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract] Süss R, et al.
Hautarzt 1996 Jun;47(6):459–61 (Eng. Abstr.) **(Ger)**

[Reduced number of reported cases. Natural products caused eczema] **Lakartidningen** 1996 Jul 10;93(28–29):2604–5 **(Swe)**

[Adverse effects of ginseng. No cure in breast cancer] Albertsson M, et al. **Lakartidningen** 1996 Jul 24; 93(30–31):2670–2 **(Swe)**

ANALYSIS

HPLC analysis of tonka bean extracts. Ehlers D, et al.
Z Lebensm Unters Forsch 1995 Sep;201(3):278–82

BIOSYNTHESIS

Cloning, expression, and characterization of (+)–delta–cadinene synthase: a catalyst for cotton phytoalexin biosynthesis. Chen XY, et al.
Arch Biochem Biophys 1995 Dec 20;324(2):255–66

Effect of NADPH–associated keto–reducing domain on

substrate entry into 6-hydroxymellein synthase, a multifunctional polyketide synthetic enzyme involved in phytoalexin biosynthesis in carrot. Kurosaki F. **Arch Biochem Biophys** 1996 Apr 1;328(1):213-7

A methyltransferase for synthesis of the flavanone phytoalexin sakuranetin in rice leaves. Rakwal R, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):732-5

Inositol lipid signal transduction in phytoalexin elicitation. Walton TJ. **Biochem Soc Trans** 1995 Nov;23(4):862-7 (38 ref.)

Two novel genes rapidly and transiently activated in suspension-cultured rice cells by treatment with N-acetylchitoheptaose, a biotic elicitor for phytoalexin production. Minami E, et al. **Plant Cell Physiol** 1996 Jun; 37(4):563-7

A structural model for the mechanisms of elicitor release from fungal cell walls by plant beta-1,3-endoglucanase. Okinaka Y, et al. **Plant Physiol** 1995 Nov;109(3):839-45

CHEMICAL SYNTHESIS

Construction of the tetracyclic skeleton of leucothol A. 1,2,4a,5,6,7,8,9,10,10a,11,11a-dodecahydro-11-hydroxy-11-methyl-7-phenylthiomethyl-5aH-5a,8-methano-cyclohepta[b] naphthalen-10-one. Kraus GA, et al. **Acta Crystallogr C** 1995 Jul 15;51 (Pt 7):1366-8

CHEMISTRY

High-performance liquid chromatographic resolution of NADP+ after induction of fluorescence and its application to assay for an NADPH-dependent enzyme: application to the determination of glutathione reductase activity in plant leaf extracts. Norman HA, et al. **Anal Biochem** 1996 May 15;237(1):30-6

Meliavolkenin, a new bioactive triterpenoid from Melia volkensii (Meliaceae). Zeng L, et al. **Bioorg Med Chem** 1995 Apr;3(4):383-90

Selective activation of heparin cofactor II by a sulfated polysaccharide isolated from the leaves of Artemisia princeps. Hayakawa Y, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):643-9

Characterisation of the endo-polygalacturonase-resistant region of the pectin from Bupleurum falcatum L.--a polysaccharide with an active function in clearance of immune complexes. Matsumoto T, et al. **Carbohydr Res** 1995 Apr 30;270(2):221-9

Camelliatannin D, a new inhibitor of bone resorption, from Camellia japonica. Hatano T, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):2033-5

Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter-induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190-6

Novel antioxidants from roasted perilla seed. Nagatsu A, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):887-9

Alangionosides G-M: glycosides of megastigmane derivatives from the leaves of Alangium premnifolium. Otsuka H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):754-9

Liquid chromatography combined with thermospray and continuous-flow fast atom bombardment mass spectrometry of glycosides in crude plant extracts. Wolfender JL, et al. **J Chromatogr A** 1995 Sep 29; 712(1):155-68

Alkaloids of Datura ferox from Argentina. Vitale AA, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):81-9

Comparative studies of allergenic extracts prepared from freshly collected, dried, or dried and defatted pollen. González Romano ML, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):142-7

HISTORY

Mentha piperita (peppermint). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):607

IMMUNOLOGY

Pityrosporum ovale extracts increase interleukin-4, interleukin-10 and IgE synthesis in patients with atopic eczema. Kröger S, et al. **Acta Derm Venereol** 1995 Sep; 75(5):357-60

Investigation of the stability of apple allergen extracts. Rudeschko O, et al. **Allergy** 1995 Jul;50(7):575-80

Use of monoclonal antibodies in the standardization of Parietaria judaica allergenic extracts. Afferni C, et al. **Biologicals** 1995 Sep;23(3):239-47

In vitro complement activation by ragweed allergen extract in the sera of ragweed allergic and non-allergic persons. Hidvégi T, et al. **Immunol Lett** 1995 Nov;48(1):65-71

Nitric oxide production by chicken macrophages activated by Acemannan, a complex carbohydrate extracted from Aloe vera. Karaca K, et al. **Int J Immunopharmacol** 1995 Mar;17(3):183-8

Comparative studies of allergenic extracts prepared from freshly collected, dried, or dried and defatted pollen. González Romano ML, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):142-7

ISOLATION & PURIFICATION

Influence of the pH of the extraction medium on the composition of birch (Betula verrucosa) pollen extracts. Cadot P, et al. **Allergy** 1995 May;50(5):431-7

Cytotoxic limonoids and tetranortriterpenoids from Melia azedarach. Itokawa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1171-5

Isolation of anti-leukemia compounds from Citrus reticulata. Mak NK, et al. **Life Sci** 1996;58(15):1269-76

Solasodine glycosides of Solanum unguiculatum (A.) Rich. Sarg TM, et al. **Pharm World Sci** 1995 Nov 24;17(6):191-4

Novel Saponins from Zizyphus spina-christi growing in Egypt. el-Din Hussein Mahran G, et al. **Planta Med** 1996 Apr;62(2):163-5

METABOLISM

Continuous ethanol production from nonsterilized carob pod extract by immobilized Saccharomyces cerevisiae on mineral kissiris using a two-reactor system. Roukas T. **Appl Biochem Biotechnol** 1996 Jun;59(3):299-307

Analysis of the components of Lycopus europaeus L. in body fluids during metabolism studies. Comparison of capillary electrophoresis and high-performance liquid chromatography. Wojciechowski H, et al. **J Chromatogr A** 1995 Nov 24;717(1-2):261-70

Plasma cathinone levels following chewing khat leaves (Catha edulis Forsk.). Halket JM, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):111-3

PHARMACOKINETICS

Gastrointestinal absorption characteristics of glycyrrhizin from glycyrrhiza extract. Wang Z, et al. **Biol Pharm Bull** 1995 Sep;18(9):1238-41

PHARMACOLOGY

Studies on the agronomic characteristics, yield, and saikosaponin content of two Bupleurum species in Taiwan. Liu SY, et al. **Am J Chin Med** 1995;23(2):181-94

Termination of pregnancy in rodents by oral administration of praneem, a purified neem seed extract. Mukherjee S, et al. **Am J Reprod Immunol** 1996 Jan;35(1):51-6

In vitro antimalarial activity of vegetal extracts used in West African traditional medicine. Benoit F, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):67-71

Activity of maitake D-fraction to inhibit carcinogenesis and metastasis. Nanba H. **Ann N Y Acad Sci** 1995 Sep 30; 768:243-5

Induction of programmed cell death (apoptosis) in human lymphoid leukemia cells by catechin compounds. Hibasami H, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1943-6

IL-12-mediated activation of MHC-unrestricted cytotoxicity of human PBMC subpopulations: synergic action of a plant rhamnogalacturonan. Klein-Franke A, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2511-6

Effects of coffee cherry on the immune system in SHN mice. Kobayashi T, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1827-30

Suppression by coffee cherry of the growth of spontaneous mammary tumours in SHN mice. Nagasawa H, et al. **Anticancer Res** 1996 Jan-Feb;16(1):151-3

Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Riou D, et al. **Anticancer Res** 1996 May-Jun;16(3A):1213-8

Antimicrobial screening of zinc in the absence or presence of oleoresins and various resin acids. Johansson A, et al. **APMIS** 1995 Jun;103(6):419-27

Immunotropic activity of lupin seeds extracts and fractions from Lupinus angustifolius and Lupinus albus. Błaszczyk B, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):147-53

In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Cavadas C, et al. **Arzneimittelforschung** 1995 Jul; 45(7):753-5

Stimulation of cytokine production via a special standardized mistletoe preparation in an in vitro human skin bioassay. Joller PW, et al. **Arzneimittelforschung** 1996 Jun; 46(6):649-53

Ex-vivo in-vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha and interleukin-1 beta secretion in human whole blood by extractum urticae dioicae foliorum. Obertreis B, et al. **Arzneimittelforschung** 1996 Apr;46(4):389-94

Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. Stein GM, et al. **Arzneimittelforschung** 1996 Jun;46(6):635-9

Undetected neuropsychophysiological sequelae of khat chewing in standard aviation medical examination. Khattab NY, et al. **Aviat Space Environ Med** 1995 Aug;66(8):739-44

Antioxidant effects of Ilex paraguariensis: induction of decreased oxidability of human LDL in vivo. Gugliucci A. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):338-44

Antiviral effect of Sanicula europaea L. leaves extract on influenza virus-infected cells. Turan K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):22-6

Scavenging activity of "beta catechin" on reactive oxygen species generated by photosensitization of riboflavin. Kumari MV, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1163-70

Antioxidant effects of "beta catechin". Yoneda T, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):995-1008

Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Janssens D, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):991-9

A novel diterpenoid labdane from Sideritis javalambrensis inhibits eicosanoid generation from stimulated macrophages but enhances arachidonate release. Pang L, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):863-8

Effect of Cleome arabica leaves extract on inflammatory cells response in rat. Selloum L, et al. **Biochem Soc Trans** 1995 Nov;23(4):609S

Studies of cuticle drugs from natural sources. III. Inhibitory effect of Myrica rubra on melanin biosynthesis. Matsuda H, et al. **Biol Pharm Bull** 1995 Aug;18(8):1148-50

Panax ginseng extract improves the performance of aged Fischer 344 rats in radial maze task but not in operant brightness discrimination task. Nitta H, et al. **Biol Pharm Bull** 1995 Sep;18(9):1286-8

Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Valenzuela A, et al. **Biol Res** 1994;27(2):105-12

The so-called phyto-estrogenic action of Pygeum africanum extract. Mathé G, et al. **Biomed Pharmacother** 1995; 49(7-8):339-40

A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Mathé G, et al. **Biomed Pharmacother** 1995;49(7-8):341-3

Meliavolkenin, a new bioactive triterpenoid from Melia volkensii (Meliaceae). Zeng L, et al. **Bioorg Med Chem** 1995 Apr;3(4):383-90

Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Oyama Y, et al. **Brain Res** 1996 Mar 18;712(2):349-52

Suppression of tumor cell growth by anthocyanins in vitro. Kamei H, et al. **Cancer Invest** 1995;13(6):590-4

Anti-tumor promoting activity of Dryopteris phlorophenone derivatives. Kapadia GJ, et al. **Cancer Lett** 1996 Aug 2; 105(2):161-5

Anti-tumor activity of the crude saponins obtained from asparagus. Shao Y, et al. **Cancer Lett** 1996 Jun 24; 104(1):31-6

Rosemary extract and carnosol stimulate rat liver glutathione-S-transferase and quinone reductase activities. Singletary KW. **Cancer Lett** 1996 Feb 27;100(1-2):139-44

The antagonistic effects of khellactones on platelet-activating factor, histamine, and leukotriene D4. Aida Y, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):859-67

A novel 16,23-epoxy-5 beta-cholestane glycoside with potent inhibitory activity on proliferation of human peripheral blood lymphocytes from Ornithogalum saundersiae bulbs. Kuroda M, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1257-9

Assay for antiviral activity of herbal extracts using their absorbed sera. Kurokawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1270-2

Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter-induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190-6

A novel hexahydrodibenzofuran derivative with potent inhibitory activity on melanin biosynthesis of cultured B-16 melanoma cells from Lindera umbellata bark. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):893-5

The inhibitory effect of the crude extract from a seaweed of Dygenea simplex C. Agardh on the in vitro cytopathic activity of HIV-1 and it's antigen production. Sekine H, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1580-4

Effects of garlic extract on platelet aggregation [letter; comment] Myers SP, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):888-9. Comment on: Clin Exp Pharmacol Physiol 1995 Jun-Jul;22(6-7):414-7.

Age and sex dependence of the effects of an aqueous extract of Physalis alkekengi fruits on rat hepatic glucose 6-P dehydrogenase activity. Vessal M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Aug; 111(4):675-80

Comparison of the effects of an aqueous extract of Physalis alkekengi fruits and/or various doses of 17-beta-estradiol on rat estrous cycle and uterine glucose 6-phosphate dehydrogenase activity. Vessal M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):229-36

"In vitro" effect of Egyptian tannin-containing plants and their extracts on the survival of pathogenic bacteria. Sotohy SA, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Sep; 102(9):344-8

Alterations in protein synthesis in the cyanobacterium Synechococcus sp. strain PCC 6301 in response to Calendula micrantha extract with molluscicidal activity. Hammouda O, et al. **Ecotoxicol Environ Saf** 1995 Aug; 31(3):201-4

An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Aruoma OI, et al. **Food Chem Toxicol** 1996 May;34(5):449-56

Effects of repeated treatments with an extract of Ginkgo biloba (EGb 761) on cerebral glucose utilization in the rat: an autoradiographic study. Duverger D, et al. **Gen Pharmacol** 1995 Oct;26(6):1375-83

Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gutierrez M, et al. **Gen Pharmacol** 1996 Jan;27(1):171-6

Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus Phyllanthus. Santos AR, et al. **Gen Pharmacol** 1995 Nov;26(7):1499-1506

Functional and antiischaemic effects of Monoacetyl-vitexinrhamnoside in different in vitro models. Schüssler M, et al. **Gen Pharmacol** 1995 Nov;26(7):1565–70

Antioxidant and anti-inflammatory property of Sandhika: a compound herbal drug. Chaurasia S, et al. **Indian J Exp Biol** 1995 Jun;33(6):428–32

Effect of leaf extract of Aegle marmelose (L.) Correa ex Roxb. on histological and ultrastructural changes in tissues of streptozotocin induced diabetic rats. Das AV, et al. **Indian J Exp Biol** 1996 Apr;34(4):341–5

Antinociceptive action of Azadirachta indica (neem) in mice: possible mechanisms involved. Khanna N, et al. **Indian J Exp Biol** 1995 Nov;33(11):848–50

Pentylenetetrazol-induced kindling in animals: protective effect of BR-16A. Kulkarni SK, et al. **Indian J Exp Biol** 1995 Jun;33(6):424–7

Effect of D-400, a herbomineral preparation on lipid profile, glycated haemoglobin and glucose tolerance in streptozotocin induced diabetes in rats. Mitra SK, et al. **Indian J Exp Biol** 1995 Oct;33(10):798–800

Effects of S-allyl cysteine sulfoxide isolated from Allium sativum Linn and gugulipid on some enzymes and fecal excretions of bile acids and sterols in cholesterol fed rats. Sheela CG, et al. **Indian J Exp Biol** 1995 Oct;33(10):749–51

Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn and gugulipid in cholesterol diet fed rats. Sheela CG, et al. **Indian J Exp Biol** 1995 May; 33(5):337–41

In vitro and in vivo therapeutic activity of Parthenium hysterophorus against Trypanosoma evansi. Talakal TS, et al. **Indian J Exp Biol** 1995 Nov;33(11):894–6

Assessment of endocrine response of Inula racemosa in relation to glucose homeostasis in rats. Tripathi YB, et al. **Indian J Exp Biol** 1995 Sep;33(9):686–9

In vitro anti human immunodeficiency virus activity of mangrove plants. Premanathan M, et al. **Indian J Med Res** 1996 May;103:278–81

Timely administration of extract of Ferula jaeschkeana causes luteolysis in the ovary of cyclic guineapig. Pathak S, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):395–9

The effect of the extract of the miswak (chewing sticks) used in Jordan and the Middle East on oral bacteria. Al lafi T, et al. **Int Dent J** 1995 Jun;45(3):218–22

In vitro inhibition of Helicobacter pylori by extracts of thyme. Tabak M, et al. **J Appl Bacteriol** 1996 Jun; 80(6):667–72

Endothelium-dependent vasorelaxation caused by various plant extracts. Fitzpatrick DF, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):90–5

The inhibiting effect of aqueous Azadirachta indica (Neem) extract upon bacterial properties influencing in vitro plaque formation. Wolinsky LE, et al. **J Dent Res** 1996 Feb; 75(2):816–22

Vibriocidal activities of some local herbs. Akinsinde KA, et al. **J Diarrhoeal Dis Res** 1995 Jun;13(2):127–9

Maternity and medicinal plants in Vanuatu. II. Pharmacological screening of five selected species. Bourdy G, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):139–43

Antimicrobial activity of Paliurus spina-christi Mill. (Christ's thorn). Brantner A, et al. **J Ethnopharmacol** 1996 Jun; 52(2):119–22

Antiulcer activity of Pteleopsis suberosa. De Pasquale R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):55–8

Xanthine oxidase inhibitory activity of some Panamanian plants from Celastraceae and Lamiaceae. González AG, et al. **J Ethnopharmacol** 1995 Apr;46(1):25–9

Antibacterial activity and phytochemical analysis of Vochysia divergens (Vochysiaceae). Hess SC, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):97–100

Evaluation of the protective potential of Artemisia maritima extract on acetaminophen- and CCl4-induced liver damage. Janbaz KH, et al. **J Ethnopharmacol** 1995 Jun 23; 47(1):43–7

Presence of aromatase inhibitors in cycads. Kowalska MT, et al. **J Ethnopharmacol** 1995 Jul 28;47(3):113–6

Scavenging effects of Mallotus repandus on active oxygen species. Lin JM, et al. **J Ethnopharmacol** 1995 Jun; 46(3):175–81

Anti-microbial activity and anti-complement activity of extracts obtained from selected Hawaiian medicinal plants. Locher CP, et al. **J Ethnopharmacol** 1995 Nov 17; 49(1):23–32

Antiviral screening of British Columbian medicinal plants. McCutcheon AR, et al. **J Ethnopharmacol** 1995 Dec 1; 49(2):101–10

Pharmacology of Casimiroa edulis; III. Relaxant and contractile effects in rat aortic rings. Magos GA, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):1–8

Some pharmacological studies on Artemisia herba-alba (Asso.) in rabbits and mice. Marrif HI, et al. **J Ethnopharmacol** 1995 Nov 17;49(1):51–5

Screening of some Cuban medicinal plants for antimicrobial activity. Martínez MJ, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):171–4

Chronic administration of aqueous extract of Stevia rebaudiana in rats: renal effects. Melis MS. **J Ethnopharmacol** 1995 Jul 28;47(3):129–34

Antibacterial activity of Helichrysum aureonitens (Asteraceae). Meyer JJ, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):109–11

Effects of Celastrus paniculatus on passive avoidance performance and biogenic amine turnover in albino rats. Nalini K, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):101–8

Effects of an ethanolic extract of Desmodium adscendens on central nervous system in rodents. N'gouemo P, et al. **J Ethnopharmacol** 1996 Jun;52(2):77–83

Cardioactive effects of Eremophila alternifolia extracts. Pennacchio M, et al. **J Ethnopharmacol** 1995 Jul 7; 47(2):91–5

Vasoactive effects of aqueous extracts from five Mexican medicinal plants on isolated rat aorta. Perusquía M, et al. **J Ethnopharmacol** 1995 Apr;46(1):63–9

Carrier herbal medicine: traditional and contemporary plant use. Ritch-Krc EM, et al. **J Ethnopharmacol** 1996 Jun; 52(2):85–94

Inhibitory effects of Cistus populifolius on contractile responses in the isolated rat duodenum. Sánchez de Rojas VR, et al. **J Ethnopharmacol** 1995 Apr;46(1):59–62

Ayurvedic herbal drugs with possible cytostatic activity. Smit HF, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):75–84 (53 ref.)

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131–9 (62 ref.)

Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9–26 (109 ref.)

Screening of selected medicinal plants of Nepal for antimicrobial activities. Taylor RS, et al. **J Ethnopharmacol** 1995 Jun;46(3):153–9

Antiviral activities of Nepalese medicinal plants. Taylor RS, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):157–63

Protective effects of Osbeckia octandra against galactosamine and tert-butyl hydroperoxide induced hepatocyte damage. Thabrew MI, et al. **J Ethnopharmacol** 1995 Dec 1; 49(2):69–76

Antimicrobial activity of extracts of three major plants from the Chihuahuan desert. Verástegui MA, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):175–7

Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Vlietinck AJ, et al. **J Ethnopharmacol** 1995 Apr;46(1):31–47

Studies on the constituents of the leaves of Nerium oleander on behavior pattern in mice. Zia A, et al. **J Ethnopharmacol** 1995 Nov 17;49(1):33–9

Effect of smokeless tobacco extract on human gingival keratinocyte levels of prostaglandin E2 and interleukin-1. Johnson GK, et al. **J Periodontol** 1996 Feb;67(2):116–24

Analysis of the mechanisms underlying the contractile response induced by the hydroalcoholic extract of Phyllanthus urinaria in the guinea-pig urinary bladder in-vitro. Dias MA, et al. **J Pharm Pharmacol** 1995 Oct; 47(10):846–51

Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. Levin RM, et al. **J Urol** 1996 Apr;155(4):1466–70

Effect of M-711 on experimental asthma in rats. Shichinohe K, et al. **J Vet Med Sci** 1996 Jan;58(1):55–9

Effects of yew alkaloids and related compounds on guinea-pig isolated perfused heart and papillary muscle. Alloatti G, et al. **Life Sci** 1996;58(10):845–54

Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. White HL, et al. **Life Sci** 1996;58(16):1315–21

Synergistic effects of ajoene and the microwave power density memories of water on germination inhibition of fungal spores. Rai S, et al. **Med Biol Eng Comput** 1995 May;33(3):313–6

Therapeutic actions of garlic constituents. Agarwal KC. **Med Res Rev** 1996 Jan;16(1):111–24 (132 ref.)

Evaluation of hydroxyl radical-scavenging property of garlic. Prasad K, et al. **Mol Cell Biochem** 1996 Jan 12; 154(1):55–63

Study on the antimutagenic effect of pine needle extract. Kong Z, et al. **Mutat Res** 1995 Aug;347(3–4):101–4

Natural antimutagenic agents. Mitscher LA, et al. **Mutat Res** 1996 Feb 19;350(1):143–52 (38 ref.)

Lack of micronucleus induction by 'Sobatum' in bone marrow erythrocytes of Swiss mice. Mohanan PV, et al. **Mutat Res** 1996 Sep 26;361(1):23–7

Chlorophyll and chromosome breakage. Sarkar D, et al. **Mutat Res** 1996 Aug 8;360(3):187–91

In vivo radioprotection with garlic extract. Singh SP, et al. **Mutat Res** 1995 Dec;345(3–4):147–53

Fungistatic and fungicidal activity of east African medicinal plants. Fabry W, et al. **Mycoses** 1996 Jan–Feb;39(1–2):67–70

In vitro antifungal activity of Polyporaceae against yeasts and dermatophytes. Steinmetz MD, et al. **Mycoses** 1995 Jul–Aug;38(7–8):305–9

Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. Bagnis C, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):507–13

Modulatory influence of alcoholic extract of Ocimum leaves on carcinogen-metabolizing enzyme activities and reduced glutathione levels in mouse. Banerjee S, et al. **Nutr Cancer** 1996;25(2):205–17

EGb 761 and the recovery of ion imbalance in ischemic reperfused diabetic rat retina. Szabo ME, et al. **Ophthalmic Res** 1995 Mar–Apr;27(2):102–9

Effect of root-tuber extract of Flemingia vestita, a leguminous plant, on Artyfechinostomum sufrartyfex and Fasciolopsis buski: a scanning electron microscopy study. Roy B, et al. **Parasitol Res** 1996;82(3):248–52

Catha edulis, a plant that has amphetamine effects. Kalix P. **Pharm World Sci** 1996 Apr;18(2):69–73

Interaction between oxytocin and 'sidaverin' on the gravid and non-gravid rat uterus. Lutterodt GD. **Pharmacol Res** 1995 Jul–Aug;32(1–2):89–94

Vasodilator effects of liriodenine and norushinsunine, two aporphine alkaloids isolated from Annona cherimolia, in rat aorta. Chuliá S, et al. **Pharmacology** 1995 Jun; 50(6):380–7

Influence of insecticidal plant materials used during storage on sensory attributes and instrumental hardness of dry edible beans (Phaseolus vulgaris L.). Dunkel FV, et al. **Plant Foods Hum Nutr** 1995 Jul;48(1):1–16

Characterization of the hypoglycemic effects of Trigonella foenum graecum seed [letter] Ali L, et al. **Planta Med** 1995 Aug;61(4):358–60

Reduction of ACh-induced contraction of rat isolated ileum by coptisine, (+)-caffeoylmalic acid, Chelidonium majus, and Corydalis lutea extracts. Boegge SC, et al. **Planta Med** 1996 Apr;62(2):173–4

In vitro anticancer activity of fruit extracts from Vaccinium species. Bomser J, et al. **Planta Med** 1996 Jun;62(3):212–6

Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Erdelmeier CA, et al. **Planta Med** 1996 Jun;62(3):241–5

Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Falch BS, et al. **Planta Med** 1995 Aug;61(4):321–8

Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. François G, et al. **Planta Med** 1996 Apr;62(2):126–9

Chelidonium majus L.: components with in vitro affinity for the GABAA receptor. Positive cooperation of alkaloids. Häberlein H, et al. **Planta Med** 1996 Jun;62(3):227–31

Effect of crude fractions of psoralea corylifolia seed extract on bone calcification. Miura H, et al. **Planta Med** 1996 Apr;62(2):150–3

Effect of jinkoh-eremol and agarospirol from agarwood on the central nervous system in mice. Okugawa H, et al. **Planta Med** 1996 Feb;62(1):2–6

The effect of purified extract of Fagopyrum esculentum (buckwheat) on protein kinases involved in signal transduction pathways. Samel D, et al. **Planta Med** 1996 Apr;62(2):106–10

Mayteine and 6-benzoyl-6-deacetylmayteine from Maytenus krukovii. Sekar KV, et al. **Planta Med** 1995 Aug;61(4):390

Anti-complementary activity of Crataegus sinaica. Shahat AA, et al. **Planta Med** 1996 Feb;62(1):10–3

Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Keung WM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4284–8

Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24–37 (189 ref.)

Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Emerit I, et al. **Radiat Res** 1995 Nov;144(2):198–205

A study of the pharmacological actions of Dioclea grandiflora Martius ex Bentham. Mattei R, et al. **Rev Paul Med** 1995 Jan–Feb;113(1):687–92

Protective effect of EGb 761 on ischemia-reperfusion damage in the rat retina. Droy-Lefaix MT, et al. **Transplant Proc** 1995 Oct;27(5):2861–2

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Rönnberg B, et al. **Vaccine** 1995 Oct;13(14):1375–82

Enhancement of human NK and LAK cytotoxicity against HCMV-infected cells by rhamnogalacturonan: specificity of reaction. Steinmassl M, et al. **Viral Immunol** 1996; 9(1):27–34

Protective effects of Osbeckia octandra against paracetamol-induced liver injury. Thabrew MI, et al. **Xenobiotica** 1995 Sep;25(9):1009–17

Inhibitory effect of spices on in vitro histamine production and histidine decarboxylase activity of Morganella morganii and on the biogenic amine formation in mackerel stored at 30 degrees C. Shakila RJ, et al. **Z Lebensm Unters Forsch** 1996 Jul;203(1):71–6

[The effect of an extract of sea buckthorn (Hippophae rhamnoides L.) on the healing of experimental skin wounds in rats] Ianev E, et al. **Khirurgiia (Sofiia)** 1995;48(3):30–3 (Eng. Abstr.) **(Bul)**

[An experimental study of the effect of an artichoke preparation on the activity of the sympathetic-adrenal system in carbon disulfide exposure] Khalkova Zh, et al. **Probl Khig** 1995;20:162–71 (Eng. Abstr.) **(Bul)**

[Use of cell culture for the research of cytotoxic and antiviral effects of a natural extract of Amaryllidaceae] Husson GP, et al. **C R Seances Soc Biol Fil** 1995;189(4):679–92 (Eng. Abstr.) **(Fre)**

[Purgative activity of Cassia italica] Assane M, et al. **Dakar Med** 1994;39(2):125–8 (Eng. Abstr.) **(Fre)**

[Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart] Joseph G, et al. **Arzneimittelforschung** 1995 Dec;45(12):1261–5 (Eng. Abstr.) **(Ger)**

[In vitro activity of Mercurius cyanatus complex against relevant pathogenic bacterial isolates] Vestweber AM, et al. **Arzneimittelforschung** 1995 Sep;45(9):1018–20 (Eng. Abstr.) **(Ger)**

[Comparison of the bioavailability of beta-aescin after single oral administration of two different drug formulations containing an extract of horse-chestnut seeds] Schrader

E, et al. **Pharmazie** 1995 Sep;50(9):623–7 (Eng. Abstr.) **(Ger)**

[Vigilance–decreasing effects of 2 plant–derived sedatives] Gerhard U, et al. **Schweiz Rundsch Med Prax** 1996 Apr 9;85(15):473–81 (Eng. Abstr.) **(Ger)**

[Effect of a Rhodiolae rosea extract on the level of inducible HSP–70 in the myocardium under stress] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):256–8 **(Rus)**

[The immunotropic properties of biologically active products obtained from Klamath weed (Hypericum perforatum L.)] Evstifeeva TA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):51–4 (Eng. Abstr.) **(Rus)**

[The pharmacological properties of a direct–action anticoagulant from the herb Nonea poulla (L.) D. C.] Gubaev AG, et al. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):40–2 (Eng. Abstr.) **(Rus)**

[The ecdysteroid fraction of the above–ground portion of Serratula coronata L. in the spontaneous E–rosette formation reaction and the agar migration test in vitro] Trenin DS, et al. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):55–7 (Eng. Abstr.) **(Rus)**

[The effect of increased muscular activity on the physical development and morphofunctional indices of cardiac endurance in sexually immature rats with the use of plant preparations] Sudzilovskii FV, et al. **Morfologiia** 1996; 109(1):32–5 (Eng. Abstr.) **(Rus)**

[Use of an activated chemiluminescence method for studying the pharmacologic properties of medicinal substances] Nanaeva MT, et al. **Vopr Med Khim** 1995 Sep–Oct; 41(5):48–50 (Eng. Abstr.) **(Rus)**

[Cardiovascular effects of aqueous extracts of the leaves of Clusia coclensis (Guttiferae)] García González M, et al. **Rev Biol Trop** 1996 Apr;44(1):87–91 (Eng. Abstr.) **(Spa)**

[Diuretic effect of Cecropia obtusifolia (Moraceae) on albino rats] Vargas Howell R, et al. **Rev Biol Trop** 1996 Apr; 44(1):93–6 (Eng. Abstr.) **(Spa)**

[Effect of a dry boldo extract on oro–cecal intestinal transit in healthy volunteers] Gotteland M, et al. **Rev Med Chil** 1995 Aug;123(8):955–60 (Eng. Abstr.) **(Spa)**

POISONING

Retrospective study of mistletoe ingestion. Spiller HA, et al. **J Toxicol Clin Toxicol** 1996;34(4):405–8

THERAPEUTIC USE

EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Roncin JP, et al. **Aviat Space Environ Med** 1996 May;67(5):445–52

Anti–tumor–promoting activities of euglobals from Eucalyptus plants. Takasaki M, et al. **Biol Pharm Bull** 1995 Mar;18(3):435–8

Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Yamane T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1662–7

Inhibitory effect of iridoids on Epstein–Barr virus activation by a short–term in vitro assay for anti–tumor promoters. Kapadia GJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):223–6

Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract. Kapadia GJ, et al. **Cancer Lett** 1996 Feb 27;100(1–2):211–4

The influence of flaxseed and lignans on colon carcinogenesis and beta–glucuronidase activity. Jenab M, et al. **Carcinogenesis** 1996 Jun;17(6):1343–8

Prevention of 20–methylcholanthrene–induced sarcoma by a mistletoe extract, Iscador. Kuttan G, et al. **Carcinogenesis** 1996 May;17(5):1107–9

Rosemary components inhibit benzo[a]pyrene–induced genotoxicity in human bronchial cells. Offord EA, et al. **Carcinogenesis** 1995 Sep;16(9):2057–62

Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane–induced colon cancer and 7,12–dimethylbenz[a]anthracene–induced mammary cancer in rats. Pereira MA, et al. **Carcinogenesis** 1996 Jun; 17(6):1305–11

Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Andri L, et al. **Clin Exp Allergy** 1995 Nov;25(11):1092–9

Anti–inflammatory efficacy of Melothria madraspatana in active rheumatoid arthritis [letter] Ramakrishanamacharya CH, et al. **Clin Rheumatol** 1996 Mar;15(2):214–5

Possibilities of scar treatment after thoracic surgery. Maragakis M, et al. **Drugs Exp Clin Res** 1995;21(5):199–206

Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Korting HC, et al. **Eur J Clin Pharmacol** 1995;48(6):461–5

Preventive and curative effects of Artemisia absinthium on acetaminophen and CCl4–induced hepatotoxicity. Gilani AH, et al. **Gen Pharmacol** 1995 Mar;26(2):309–15

Effect of Teucrium stocksianum on paracetamol–induced hepatotoxicity in mice. Rasheed RA, et al. **Gen Pharmacol** 1995 Mar;26(2):297–301

Hypocholesterolemic activity of nut shell extract of Semecarpus anacardium (Bhilawa) in cholesterol fed rabbits. Sharma A, et al. **Indian J Exp Biol** 1995 Jun; 33(6):444–8

Some pharmacological properties of Synclisia scabrida II. Orisakwe OE, et al. **Indian J Med Res** 1996 May;103:282–4

Hot water extracts of Chlorella vulgaris reduce opportunistic infection with Listeria monocytogenes in C57BL/6 mice infected with LP–BM5 murine leukemia viruses. Hasegawa T, et al. **Int J Immunopharmacol** 1995 Jun;17(6):505–12

Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Dutkiewicz S. **Int Urol Nephrol** 1996; 28(1):49–53

A double blind placebo controlled trial of ginkgo biloba extract in acute cerebral ischaemia. Garg RK, et al. **J Assoc Physicians India** 1995 Nov;43(11):760–3

The efficacy of a herbal–based toothpaste on the control of plaque and gingivitis. Mullally BH, et al. **J Clin Periodontol** 1995 Sep;22(9):686–9

Anti–ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants of Pakistan in aspirin–ulcerated rats. Akhtar AH, et al. **J Ethnopharmacol** 1995 Apr;46(1):1–6

Medical ethnobotany of the Siddis of Uttara Kannada district, Karnataka, India. Bhandary MJ, et al. **J Ethnopharmacol** 1995 Jul 28;47(3):149–58 (15 ref.)

Anti–giardial activity of gastrointestinal remedies of the Luo of east Africa. Johns T, et al. **J Ethnopharmacol** 1995 Apr; 46(1):17–23

Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: III. Kweifio–Okai G, et al. **J Ethnopharmacol** 1995 Apr;46(1):7–15

Anti–ulcer effect of the hot water extract of black tea (Camellia sinensis). Maity S, et al. **J Ethnopharmacol** 1995 Jun;46(3):167–74

Anti–inflammatory activity of the bark of Hippocratea excelsa. Perez RM, et al. **J Ethnopharmacol** 1995 Jul 7; 47(2):85–90

Natural premedication for mast cell proliferative disorders [letter] Yaniv R, et al. **J Ethnopharmacol** 1995 Apr; 46(1):71–2

Comparison of leg compression stocking and oral horse–chestnut seed extract therapy in patients with chronic venous insufficiency [see comments] Diehm C, et al. **Lancet** 1996 Feb 3;347(8997):292–4. Comment in: Lancet 1996 Apr 27;347(9009):1182; discussion 1183. Comment in: Lancet 1996 Apr 27;347(9009):1182–3.

Horse–chestnut seed extract for chronic venous insufficiency [letter; comment] Simini B. **Lancet** 1996 Apr 27; 347(9009):1182–3. Comment on: Lancet 1996 Feb 3;347(8997):292–4.

Horse–chestnut seed extract for chronic venous insufficiency [letter; comment] Vayssairat M, et al. **Lancet** 1996 Apr 27; 347(9009):1182; discussion 1183. Comment on: Lancet 1996 Feb 3;347(8997):292–4.

Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Cluzan RV, et al. **Lymphology** 1996 Mar; 29(1):29–35

Inhibitory effects of lanostane–type triterpene acids, the components of Poria cocos, on tumor promotion by 12–O–tetradecanoylphorbol–13–acetate in two–stage carcinogenesis in mouse skin. Kaminaga T, et al. **Oncology** 1996 Sep–Oct;53(5):382–5

Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Oncology** 1996 May–Jun; 53(3):247–9

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi–infarct dementia. Kanowski S, et al. **Pharmacopsychiatry** 1996 Mar;29(2):47–56

Extractum Fagopyri reduces atherosclerosis in high–fat diet fed rabbits. Wójcicki J, et al. **Pharmazie** 1995 Aug; 50(8):560–2

Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo–controlled, double–blind study. Syed TA, et al. **Trop Med Int Health** 1996 Aug; 1(4):505–9

Therapeutic utility, constituents and toxicity of some medicinal plants: a review. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Jun;37(3):255–8 (76 ref.)

[Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy] Purmová J, et al. **Ceska Slov Farm** 1995 Oct;44(5):246–51 (53 ref.) (Eng. Abstr.) **(Cze)**

[A clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension] Cherif S, et al. **J Pharm Belg** 1996 Mar–Apr;51(2):69–71 (Eng. Abstr.) **(Fre)**

[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[St. John's wort as antidepressive therapy] Ernst E. **Fortschr Med** 1995 Sep 10;113(25):354–5 (13 ref.) (Eng. Abstr.) **(Ger)**

[Horse chestnut seed extract—an effective therapy principle in general practice. Drug therapy of chronic venous insufficiency] Greeske K, et al. **Fortschr Med** 1996 May 30;114(15):196–200 (Eng. Abstr.) **(Ger)**

[Combined plant extract preparations—questionable "purification"] Wiesenauer M. **Fortschr Med** 1995 Oct 30; 113(30):425–6 **(Ger)**

[Phytopharmaceutic drugs in treatment of sleep disorders] Nachtmann A, et al. **Internist (Berl)** 1996 Jul;37(7):743–9 (50 ref.) **(Ger)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161–4 (12 ref.) (Eng. Abstr.) **(Ger)**

[Echinacea drugs—effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**

[The mistletoe myth—claims, reality and provable perspectives] Gabius HJ, et al. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):103–10 (Eng. Abstr.) **(Ger)**

[Efficacy and tolerance of allergenic extracts Allergovit and Novo–Helisen depot in immunotherapy of allergic diseases] Chyrek–Borowska S, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:32–41 (Eng. Abstr.) **(Pol)**

[Permixon in the treatment of benign prostatic hyperplasia] Gorilovskii LM. **Ter Arkh** 1995;67(8):62–4 **(Rus)**

[The use of a decoction of the rhizome of Leuzea carthamoides for the treatment of alcoholics with depressive states] Ibatov AN. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):78–9 (Eng. Abstr.) **(Rus)**

[The effect of gingko biloba on cochleovestibulary++ pathology of vascular origin] Cano Cuenca B, et al. **An Otorrinolaringol Ibero Am** 1995;22(6):619–29 (Eng. Abstr.) **(Spa)**

[Use of lipochromin in the treatment of trophic ulcers and wounds not healing for protracted time] Genik SM, et al. **Klin Khir** 1995;(7–8):40–1 **(Ukr)**

TOXICITY

Metal binding and resultant loss of phototoxicity of alpha–terthienyl: metal detoxification versus alpha–terthienyl inactivation. Nivsarkar M, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):183–9

Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Yamane T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1662–7

Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Büssing A, et al. **Cancer Lett** 1996 Jan 19;99(1):59–72

Cytotoxic limonoids and tetranortriterpenoids from Melia azedarach. Itokawa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1171–5

Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton–associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Lekehal M, et al. **Hepatology** 1996 Jul;24(1):212–8

Effects of decoctions prepared from Aconitum carmichaeli, Aconitum kusnezoffii and Tripterygium wilfordii on serum lactate dehydrogenase activity and histology of liver, kidney, heart and gonad in mice. Chan WY, et al. **Hum Exp Toxicol** 1995 Jun;14(6):489–93

Toxic effect of ethanolic extract of Nerium oleander (Apocynaceae) leaves against different developmental stages of Muscina stabulans (Diptera–Muscidae). el–Shazly MM, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):461–73

The ethnopharmacology and toxicology of Urginea sanguinea in the Pretoria area. Foukaridis GN, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):77–9

Effects of Hemerocallis flava on motor activity and the concentration of central monoamines and its metabolites in rats. Hsieh MT, et al. **J Ethnopharmacol** 1996 Jun; 52(2):71–6

Effects of Dalbergia subcymosa Ducke decoction on rats and their offspring during pregnancy. Peters VM, et al. **J Ethnopharmacol** 1995 Jun;46(3):161–5

Screening of medicinal plants for induction of somatic segregation activity in Aspergillus nidulans. Ramos Ruiz A, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):123–7

Mutagenic potential of Indian tobacco products. Niphadkar MP, et al. **Mutagenesis** 1996 Mar;11(2):151–4

Isolation of a compound from Eupatorium adenophorum (Spreng.) [Ageratina adenophora (Spreng.)] causing hepatotoxicity in mice. Oelrichs PB, et al. **Nat Toxins** 1995; 3(5):350–4

The acute toxicity of Riedeliella graciflora in laboratory animals. Dagli ML, et al. **Vet Hum Toxicol** 1995 Dec; 37(6):544–6

Behavioral effects of acute and long–term administration of catnip (Nepeta cataria) in mice. Massoco CO, et al. **Vet Hum Toxicol** 1995 Dec;37(6):530–3

[Toxicity of the Extreme East fir ointment] Karpukhina EA, et al. **Med Tr Prom Ekol** 1995;(7):45–6 **(Rus)**

PLANT EXTRACTS, CHINESE see **DRUGS, CHINESE HERBAL**

PLANT GALLS see **PLANT TUMORS**

PLANT GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, PLANT**

PLANT GENES see **GENES, PLANT**

PLANT GENOME see **GENOME, PLANT**

PLANT GROWTH REGULATORS

Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. Cassidy A, et al. **Br J Nutr** 1995 Oct;74(4):587–601

Brassinosteroids rescue the deficiency of CYP90, a

cytochrome P450, controlling cell elongation and de-etiolation in Arabidopsis. Szekeres M, et al. **Cell** 1996 Apr 19;85(2):171-82

ANALYSIS

Quantifying phytohormones in transformed plants. Priasen E, et al. **Methods Mol Biol** 1995;44:245-62

BIOSYNTHESIS

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1-18 (169 ref.)

CHEMISTRY

[Ethylene--its role in fruit ripening and senescence of blossoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65-72 (70 ref.) **(Pol)**

GENETICS

HOOKLESS1, an ethylene response gene, is required for differential cell elongation in the Arabidopsis hypocotyl. Lehman A, et al. **Cell** 1996 Apr 19;85(2):183-94

ISOLATION & PURIFICATION

Rotihibins, novel plant growth regulators from Streptomyces graminofaciens. Fukuchi N, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1004-10

Pironetin, a novel plant growth regulator produced by Streptomyces sp. NK10958. III. Biosynthesis. Kobayashi S, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):893-5

METABOLISM

Plant hormones: more than one way to detect ethylene. Theologis A. **Curr Biol** 1996 Feb 1;6(2):144-5 (14 ref.)

Catabolism of indole-3-acetic acid and 4- and 5-chloroindole-3-acetic acid in Bradyrhizobium japonicum. Jensen JB, et al. **J Bacteriol** 1995 Oct; 177(20):5762-6

Hormonal regulation of S-adenosylmethionine synthase transcripts in pea ovaries. Gómez-Gómez L, et al. **Plant Mol Biol** 1996 Feb;30(4):821-32

A role for brassinosteroids in light-dependent development of Arabidopsis [see comments] Li J, et al. **Science** 1996 Apr 19;272(5260):398-401. Comment in: Science 1996 Apr 19;272(5260):370-1.

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370-1 (7 ref.). Comment on: Science 1996 Apr 19;272(5260):398-401.

[Ethylene--its role in fruit ripening and senescence of biosoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65-72 (70 ref.) **(Pol)**

PHARMACOLOGY

Inhibitory effects of plant growth regulators on xanthine oxidase. Sheu SY, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):311-5

Active fragments and analogs of the plant growth factor, phytosulfokine: structure-activity relationships. Matsubayashi Y, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):209-14

Plant growth hormone kinetin delays ageing, prolongs the lifespan and slows down development of the fruitfly Zaprionus paravittiger. Sharma SP, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1067-71

A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Mathé G, et al. **Biomed Pharmacother** 1995;49(7-8):341-3

The so-called phyto-estrogenic action of Pygeum africanum extract. Mathé G, et al. **Biomed Pharmacother** 1995; 49(7-8):339-40

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103-12 (133 ref.)

Phytoestrogens are partial estrogen agonists in the adult male mouse. Mäkelä S, et al. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:123-7

Induction of a novel cytochrome P450 (CYP93 family) by methyl jasmonate in soybean suspension-cultured cells. Suzuki G, et al. **FEBS Lett** 1996 Mar 25;383(1-2):83-6

Brassinolide is a selective ribosomal cistron regulator in onion leaf base tissue. Karagiannis CS, et al. **Mech Ageing Dev** 1995 Apr 21;80(1):35-42

The plant growth regulator methyl jasmonate inhibits aflatoxin production by Aspergillus flavus. Goodrich-Tanrikulu M, et al. **Microbiology** 1995 Nov;141 (Pt 11):2831-7

Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75-81 (48 ref.)

Cytokinin induces a rapid decrease in the levels of mRNAs for catalase, 3-hydroxy-3-methylglutaryl CoA reductase, lectin and other unidentified proteins in etiolated cotyledons of cucumber. Toyama T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1349-59

Differential ethylene-inducible expression of cellulase in pepper plants. Ferrarese L, et al. **Plant Mol Biol** 1995 Nov; 29(4):735-47

Phytohormone control of the tobacco anionic peroxidase promoter. Klotz KL, et al. **Plant Mol Biol** 1996 Jun; 31(3):565-73

Uridine, a cell division factor in pea roots. Smit G, et al. **Plant Mol Biol** 1995 Nov;29(4):869-73

A brassinosteroid-insensitive mutant in Arabidopsis thaliana exhibits multiple defects in growth and development. Clouse SD, et al. **Plant Physiol** 1996 Jul;111(3):671-8

Uncoupled defense gene expression and antimicrobial alkaloid accumulation in elicited opium poppy cell cultures. Facchini PJ, et al. **Plant Physiol** 1996 Jul;111(3):687-97

The arabidopsis ACT7 actin gene is expressed in rapidly developing tissues and responds to several external stimuli. McDowell JM, et al. **Plant Physiol** 1996 Jul;111(3):699-711

A wound- and methyl jasmonate-inducible transcript coding for a myrosinase-associated protein with similarities to an early nodulin. Taipalensuu J, et al. **Plant Physiol** 1996 Feb; 110(2):483-91

[Tissue culture and rapid propagation of Pinellia ternata (Thunb) Breit] Wan M, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep;20(9):526-9, 574 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Hormonal and environmental regulation of a plant PDR5-like ABC transporter. Smart CC, et al. **J Biol Chem** 1996 Aug 9;271(32):19351-7

Molecular genetic studies confirm the role of brassinosteroids in plant growth and development. Clouse SD. **Plant J** 1996 Jul;10(1):1-8 (61 ref.)

The Arabidopsis XET-related gene family: environmental and hormonal regulation of expression. Xu W, et al. **Plant J** 1996 Jun;9(6):879-89

Post-termination-induced and hormonally dependent expression of low-molecular-weight heat shock protein genes in Douglas fir. Kaukinen KH, et al. **Plant Mol Biol** 1996 Mar;30(6):1115-28

[Mechanism of action of the plant hormone jasmonate. 1. Jasomonate-interacting proteins that regulate transcription of the p. pinII potato gene] Gurevich AI, et al. **Bioorg Khim** 1996 Feb;22(2):101-7 (Eng. Abstr.) **(Rus)**

PLANT HORMONES see **PLANT GROWTH REGULATORS**

PLANT LEAVES

Khat chewing as a cause of psychosis. Yousef G, et al. **Br J Hosp Med** 1995 Oct 4-17;54(7):322-6

Severe phototoxic reaction secondary to the application of a fig leaves' decoction used as a tanning agent. Micali G, et al. **Contact Dermatitis** 1995 Sep;33(3):212-3

Anticonvulsant activity of Albizzia lebbeck leaves. Kasture VS, et al. **Indian J Exp Biol** 1996 Jan;34(1):78-80

Leaf disk transformation. Curtis IS, et al. **Methods Mol Biol** 1995;44:59-70

CHEMISTRY

Differential display from plant leaves using oligo(dT) magnetic bead mRNA isolation and hot air PCR. McKendree WL Jr, et al. **Biotechniques** 1995 Nov; 19(5):715-6, 719

Chemical and biological demonstration of the presence of monofluoroacetate in the leaves of Palicourea marcgravii St. Hil. de-Moraes-Moreau RL, et al. **Braz J Med Biol Res** 1995 Jun;28(6):685-92

Validation of an immunoassay for methomyl in water and dislodgeable residues on grape leaves. Itak JA, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):270-7

Structural investigation of the polysaccharide fraction from the mucilage of Diceroaryum zanguebaricum Merr. Barone G, et al. **Carbohydr Res** 1996 Jan 4;280(1):111-9

Effect of leaf extract of Aegle marmelose (L.) Correa ex Roxb. on histological and ultrastructural changes in tissues of streptozotocin induced diabetic rats. Das AV, et al. **Indian J Exp Biol** 1996 Apr;34(4):341-5

Haematological & histological studies after curry leaf (Murraya koenigii) & mustard (Brassica juncea) feeding in rats. Khan BA, et al. **Indian J Med Res** 1995 Oct;102:184-6

Gummiferol, a cytotoxic polyacetylene from the leaves of Adenia gummifera. Fullas F, et al. **J Nat Prod** 1995 Oct; 58(10):1625-8

Coromandelin, a new isoflavone apioglucoside from the leaves of Dalbergia coromandeliana. Ramesh P, et al. **J Nat Prod** 1995 Aug;58(8):1240-1

Rollinecins A and B: two new bioactive annonaceous acetogenins from Rollinia mucosa. Shi G, et al. **J Nat Prod** 1996 May;59(5):548-51

Water-soluble viscous substance of Jew's mellow leaves lowers serum and liver cholesterol concentrations and increases fecal steroid excretion in rats fed a high cholesterol diet. Innami S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):465-75

Isolation and identification of a compound from avocado (Persea americana) leaves which causes necrosis of the acinar epithelium of the lactating mammary gland and the myocardium. Oelrichs PB, et al. **Nat Toxins** 1995;3(5):344-9

Evidence that spinach leaves express calreticulin but not calsequestrin. Navazio L, et al. **Plant Physiol** 1995 Nov; 109(3):983-90

Anti-complementary activity of Crataegus sinaica. Shahat AA, et al. **Planta Med** 1996 Feb;62(1):10-3

CYTOLOGY

Studies on selection and characterization of a stress-tolerant sugarcane cell line. Chen H, et al. **Chin J Biotechnol** 1995; 11(2):93-9

DRUG EFFECTS

Increased polycyclic aromatic hydrocarbon toxicity following their photomodification in natural sunlight: impacts on the duckweed Lemna gibba L. G-3. Huang XD, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):194-200

ENZYMOLOGY

Protein biotinylation in higher plants: characterization of biotin holocarboxylase synthetase activity from pea (Pisum sativum) leaves. Tissot G, et al. **Biochem J** 1996 Mar 1; 314 (Pt 2):391-5

Direct evidence for the different roles of the N- and C-terminal regulatory disulfides of sorghum leaf NADP-malate dehydrogenase in its activation by reduced thioredoxin. Issakidis E, et al. **FEBS Lett** 1996 Aug 26; 392(2):121-4

An active-site cysteine of sorghum leaf NADP-malate dehydrogenase studied by site-directed mutagenesis. Lemaire M, et al. **FEBS Lett** 1996 Mar 11;382(1-2):137-40

Chloroplast pentose-5-phosphate 3-epimerase from potato: cloning, cDNA sequence, and tissue-specific enzyme accumulation. Teige M, et al. **FEBS Lett** 1995 Dec 27; 377(3):349-52

Isolation of cDNA for a plasma membrane H(+)-ATPase from guard cells of Vicia faba L. Nakajima N, et al. **Plant Cell Physiol** 1995 Jul;36(5):919-24

A novel isoenzyme of ascorbate peroxidase localized on glyoxysomal and leaf peroxisomal membranes in pumpkin. Yamaguchi K, et al. **Plant Cell Physiol** 1995 Sep; 36(6):1157-62

beta-1,3-Glucanase is highly-expressed in laticifers of Hevea brasiliensis. Chye ML, et al. **Plant Mol Biol** 1995 Oct; 29(2):397-402

The differential expression of wound-inducible lipoxygenase genes in soybean leaves. Saravitz DM, et al. **Plant Physiol** 1996 Jan;110(1):287-99

Modelling the three-dimensional structure and the electrostatic potential field of two Cu,Zn superoxide dismutase variants from tomato leaves. Marino M, et al. **Protein Eng** 1995 Jun;8(6):551-6

GENETICS

Genetic analysis of mutations that alter cell fates in maize leaves: dominant Liguleless mutations. Fowler JE, et al. **Dev Genet** 1996;18(3):198-222

The REVOLUTA gene is necessary for apical meristem development and for limiting cell divisions in the leaves and stems of Arabidopsis thaliana. Talbert PB, et al. **Development** 1995 Sep;121(9):2723-35

GROWTH & DEVELOPMENT

Two independent and polarized processes of cell elongation regulate leaf blade expansion in Arabidopsis thaliana (L.) Heynh. Tsuge T, et al. **Development** 1996 May; 122(5):1589-600

Ectopic expression of the knox homeo box gene rough sheath1 alters cell fate in the maize leaf [published erratum appears in Genes Dev 1995 Nov 15;9(22):2870] Schneeberger RG, et al. **Genes Dev** 1995 Sep 15; 9(18):2292-304

Isolation and analysis of cDNAs encoding tomato cysteine proteases expressed during leaf senescence. Drake R, et al. **Plant Mol Biol** 1996 Feb;30(4):755-67

A senescence-associated gene of Arabidopsis thaliana is distinctively regulated during natural and artificially induced leaf senescence. Oh SA, et al. **Plant Mol Biol** 1996 Feb;30(4):739-54

Inhibition of leaf senescence by autoregulated production of cytokinin. Gan S, et al. **Science** 1995 Dec 22; 270(5244):1986-8

METABOLISM

Induction of volatile biosynthesis in the lima bean (Phaseolus lunatus) by leucine- and isoleucine conjugates of 1-oxo- and 1-hydroxyindan-4-carboxylic acid: evidence for amino acid conjugates of jasmonic acid as intermediates in the octadecanoid signalling pathway. Krumm T, et al. **FEBS Lett** 1995 Dec 27;377(3):523-9

Distinct roles for light-dependent NADPH:protochlorophyllide oxidoreductases (POR) A and B during greening in higher plants. Runge S, et al. **Plant J** 1996 Apr;9(4):513-23

Degradation pattern of photosystem II reaction center protein D1 in intact leaves. The major photoinhibition-induced cleavage site in D1 polypeptide is located amino terminally of the DE loop. Kettunen R, et al. **Plant Physiol** 1996 Aug;111(4):1183-90

Accumulation of a sulphur-rich seed albumin from sunflower in the leaves of transgenic subterranean clover (Trifolium subterraneum L.). Khan MR, et al. **Transgenic Res** 1996 May;5(3):179-85

Behavioral effects of acute and long-term administration of

catnip (Nepeta cataria) in mice. Massoco CO, et al. **Vet Hum Toxicol** 1995 Dec;37(6):530–3

[Cell cultured of Macleaya cordata—a producer of antimicrobial benzo[c]phenanthridine alkaloids] Fonin VS, et al. **Antibiot Khimioter** 1995 Aug;40(8):17–22 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Nuclear magnetic resonance study of spin relaxation and magnetic field gradients in maple leaves. McCain DC. **Biophys J** 1995 Sep;69(3):1111–6

RADIATION EFFECTS

Red/far-red and blue light-responsive regions of maize rbcS-m3 are active in bundle sheath and mesophyll cells, respectively. Purcell M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11504–8

PLANT LICE see **APHIDS**

PLANT OILS

The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Caughey GE, et al. **Am J Clin Nutr** 1996 Jan;63(1):116–22

Lipoprotein concentrations in normolipidemic males consuming oleic acid-rich diets from two different sources: olive oil and oleic acid-rich sunflower oil. Perez-Jimenez F, et al. **Am J Clin Nutr** 1995 Oct;62(4):769–75

Metabolic fate of an oral long-chain triglyceride load in humans. Binnert C, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E445–50

Effect of aerobic pretreatment with Aspergillus terreus on the anaerobic digestion of olive-mill wastewater. Borja R, et al. **Biotechnol Appl Biochem** 1995 Oct;22 (Pt 2):233–46

Is evening primrose oil of value in the treatment of premenstrual syndrome? Budeiri D, et al. **Control Clin Trials** 1996 Feb;17(1):60–8

Essential oil analysis and field evaluation of the citrosa plant "Pelargonium citrosum" as a repellent against populations of Aedes mosquitoes. Matsuda BM, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):69–74

Determination of shell content in palm kernel cake. Siew WL. **J AOAC Int** 1996 Jan-Feb;79(1):80–2

Antibacterial polyphenols from olive oil mill waste waters. Capasso R, et al. **J Appl Bacteriol** 1995 Oct;79(4):393–8

Differential effects of chylomicron remnants derived from corn oil or palm oil on bile acid synthesis and very low density lipoprotein secretion in cultured rat hepatocytes. Bravo E, et al. **Life Sci** 1996;59(4):331–7

Effect of microwave heating on the migration of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil and water. Badeka AB, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):313–7

Effect of gamma-radiation on migration behaviour of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil. Goulas AE, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):74–8

[Thermogenesis and energy utilization of olive oil and fish oil in a model study with sows] Müller HL, et al. **Z Ernahrungswiss** 1995 Jun;34(2):143–50 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Serum fatty acid composition in normal Japanese and its relationship with dietary fish and vegetable oil contents and blood lipid levels. Nakamura T, et al. **Ann Nutr Metab** 1995;39(5):261–70

Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Visioli F, et al. **Atherosclerosis** 1995 Sep;117(1):25–32

Olive oil, other dietary fats, and the risk of breast cancer (Italy). la Vecchia C, et al. **Cancer Causes Control** 1995 Nov;6(6):545–50

Olive oil and breast cancer [editorial; comment] Trichopoulou A. **Cancer Causes Control** 1995 Nov; 6(6):475–6. Comment on: Cancer Causes Control 1995 Nov;6(6):545–50.

Repellent action of neem cream against mosquitoes. Dua VK, et al. **Indian J Malariol** 1995 Jun;32(2):47–53

Oil of bitter orange: new topical antifungal agent. Ramadan W, et al. **Int J Dermatol** 1996 Jun;35(6):448–9

Effect of supplementation of milk fat with peanut oil on blood lipids and lipoproteins in infants. Hariharan K, et al. **Int J Food Sci Nutr** 1995 Nov;46(4):309–17

Influence of method of administration of rapeseed oil in dairy cows. 2. Status of divalent cations. Ferlay A, et al. **J Dairy Sci** 1995 Oct;78(10):2239–46

Fish oil supplementation in patients with heterozygous familial hypercholesterolemia. Balestrieri GP, et al. **Recenti Prog Med** 1996 Mar;87(3):102–5

ADVERSE EFFECTS

Morphologic examination of rabbit nasal mucosa after the nasal administration of insulin peanut oil suspension and a powder dosage form with soybean-derived sterylglucoside. Yamamoto T, et al. **Biol Pharm Bull** 1995 Jun;18(6):887–90

Allergic contact dermatitis from butoxyethyl nicotinic acid and Centella asiatica extract. Bilbao I, et al. **Contact Dermatitis** 1995 Dec;33(6):435–6

Occupational allergic contact dermatitis caused by ylang-ylang oil. Kenerva L, et al. **Contact Dermatitis** 1995 Sep;33(3):198–9

Coconut oil affects lipoprotein composition and structure of neonatal chicks. Castillo M, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):610–6

ANALYSIS

Genetic analysis of essential oil variants in Perilla frutescens. Yuba A, et al. **Biochem Genet** 1995 Oct;33(9–10):341–8

Effect of co-fractionation technique in the preparation of palm oil and sal fat based cocoa butter equivalent. Md. Ali AR. **Int J Food Sci Nutr** 1996 Jan;47(1):15–22

Blending of palm oil, palm stearin and palm kernel oil in the preparation of table and pastry margarine. Norlida HM, et al. **Int J Food Sci Nutr** 1996 Jan;47(1):71–4

Peanut oil in medications [letter] Weeks R. **Lancet** 1996 Sep 14;348(9029):759–60

Organochlorine pesticide analysis in oil seeds and vegetable oil: simplification of silica gel clean-up and elimination of chlorinated solvents. Filek G, et al. **Z Lebensm Unters Forsch** 1996 Jan;202(1):19–23

[Quality of semen Hydnocarpi anthelminiticae introduced to various places] Lin L, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):81–4, 126 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Trans fatty acids in hardened vegetable oils [letter; comment] Holmqvist O. **Atherosclerosis** 1996 Feb;120(1–2):245–7. Comment on: Atherosclerosis 1995 May;115(1):129–34.

Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits. Wiseman SA, et al. **Atherosclerosis** 1996 Feb;120(1–2):15–23

Purification and characterization of oil-bodies (oleosomes) and oil-body boundary proteins (oleosins) from the developing cotyledons of sunflower (Helianthus annuus L.). Millichip M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):333–7

Oleosins and oil bodies in plant seeds have postulated structures [letter] Ratnayake C, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):956–8

Similar distribution of trans fatty acid isomers in partially hydrogenated vegetable oils and adipose tissue of Canadians. Chen ZY, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):718–23

Effect of deep-fat frying on fat oxidation in soybean oil. Goburdhun D, et al. **Int J Food Sci Nutr** 1995 Nov; 46(4):363–71

Chemiluminescence detection of mono-, bis-, and tris-hydroperoxy triacylglycerols present in vegetable oils. Miyazawa T, et al. **Lipids** 1995 Nov;30(11):1001–6

Relative effects of high saturated fatty acid levels in meat, dairy products, and tropical oils on serum lipoprotein and low-density lipoprotein degradation by mononuclear cells in healthy males. Park S, et al. **Metabolism** 1996 May; 45(5):550–8

Healthful new oil from macadamia nuts. Ako H, et al. **Nutrition** 1995 May-Jun;11(3):286–8

Two novel thioesterases are key determinants of the bimodal distribution of acyl chain length of Cuphea palustris seed oil. Dehesh K, et al. **Plant Physiol** 1996 Jan;110(1):203–10

Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Petroni A, et al. **Thromb Res** 1995 Apr 15;78(2):151–60

[Effects of dietary fats of vegetable and animal origin on lipid synthesis in pigs] Mourot J, et al. **C R Acad Sci III** 1995 Sep;318(9):965–70 (Eng. Abstr.) **(Fre)**

[Dietary plant phospholipids as stabilizers of oil solutions of beta-carotene] Karagodina ZV, et al. **Vopr Pitan** 1995; (4):37–9 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Vegetable oil as an MR contrast agent for rectal applications. Pokieser P, et al. **Magn Reson Imaging** 1995;13(7):979–84

ECONOMICS

Note: vegetable oils. **Nutr Health** 1995;10(2):177–80

ISOLATION & PURIFICATION

Oil-bodies from sunflower (Helianthus annuus L.) seeds [letter] Beisson F, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):955–6

METABOLISM

Nutritional attributes of dietary flaxseed oil [letter; comment] Mantzioris E, et al. **Am J Clin Nutr** 1995 Oct;62(4):841–2 . Comment on: Am J Clin Nutr 1995 Jan;61(1):62–8.

Immobilization of lipases on polyethylene and application to perilla oil hydrolysis for production of alpha-linolenic acid. Watanabe T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):307–12

Lysophosphatidic acid acyltransferase from meadowfoam mediates insertion of erucic acid at the sn-2 position of triacylglycerol in transgenic rapeseed oil. Lassner MW, et al. **Plant Physiol** 1995 Dec;109(4):1389–94

Metabolizable energy and amino acid availability of full-fat seeds, meals, and oils of flax and canola. Lee KH, et al. **Poult Sci** 1995 Aug;74(8):1341–8

PHARMACOLOGY

Palmolein, olive oil, and serum lipids [letter; comment] Hegsted DM. **Am J Clin Nutr** 1995 Nov;62(5):1021–2. Comment on: Am J Clin Nutr 1995 May;61(5):1043–51.

Immunologic effects of marine- and plant-derived n-3 polyunsaturated fatty acids in nonhuman primates. Wu D, et al. **Am J Clin Nutr** 1996 Feb;63(2):273–80

Enhanced efficacy of sitostanol-containing versus sitostanol-free phytosterol mixtures in altering lipoprotein cholesterol levels and synthesis in rats. Ling WH, et al. **Atherosclerosis** 1995 Dec;118(2):319–31

Postprandial changes in platelet function and coagulation factors after high-fat meals with different fatty acid compositions. Freese R, et al. **Eur J Clin Nutr** 1995 Sep; 49(9):658–64

Effects of fish oil and sunflower oil supplementations on gentamicin-induced nephrotoxicity in rat. Abdel-Gayoum AA, et al. **Hum Exp Toxicol** 1995 Nov;14(11):884–8

Biochemical effects of garlic protein diet and garlic oil on glycosaminoglycan metabolism in cholesterol fed rats. Mathew BC, et al. **Indian J Exp Biol** 1996 Apr;34(4):346–50

Hypolipidemic effect of garlic protein substituted for casein in diet of rats compared to those of garlic oil. Mathew BC, et al. **Indian J Exp Biol** 1996 Apr;34(4):337–40

Duodenal infusion of oil in midlactation cows. 7. Interaction with niacin on responses to glucose, insulin, and beta-agonist challenges. Chilliard Y, et al. **J Dairy Sci** 1995 Nov;78(11):2452–63

The anti-oxidant activity of turmeric (Curcuma longa). Selvam R, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):59–67

Amaranth and its oil inhibit cholesterol biosynthesis in 6-week-old female chickens. Qureshi AA, et al. **J Nutr** 1996 Aug;126(8):1972–8

The essential oil from Tagetes minuta L. modulates the binding of [3H]flunitrazepam to crude membranes from chick brain. García DA, et al. **Lipids** 1995 Dec; 30(12):1105–10

Palmolein and groundnut oil have comparable effects on blood lipids and platelet aggregation in healthy Indian subjects. Ghafoorunissa, et al. **Lipids** 1995 Dec; 30(12):1163–9

Diets rich in eicosapentaenoic acid and gamma-linolenic acid affect phospholipid fatty acid composition and production of prostaglandins E1, E2 and E3 in turbot (Scophthalmus maximus), a species deficient in delta 5 fatty acid desaturase. Bell JG, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct;53(4):279–86

Field studies on the mosquito repellent action of neem oil. Sharma SK, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):180–2

[Effect of feeding rapeseed oil to dairy cows on the fatty acid composition of butterfat] Jahreis G, et al. **Z Ernahrungswiss** 1996 Jun;35(2):185–90 (Eng. Abstr.) **(Ger)**

[Thermogenesis in overfeeding with administration of olive oil and fish oil in a swine model study] Kirchgessner M, et al. **Z Ernahrungswiss** 1995 Sep;34(3):206–13 (Eng. Abstr.) **(Ger)**

[Effect of olive oil and fish oil on parameters of lipids and antioxidants in hyperlipoproteinemia] Reuter W, et al. **Z Ernahrungswiss** 1995 Jun;34(2):151–9 (Eng. Abstr.) **(Ger)**

POISONING

Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Mayeno AN, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):911–6

Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Kaufman LD, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):560–7 (89 ref.)

Chronic myeloid leukaemia and allogenic bone marrow transplantation in a patient with toxic oil syndrome [letter] Llamas-Sillero P, et al. **Postgrad Med J** 1995 Jul; 71(837):444–5

Melaleuca oil poisoning in a 17-month-old. Del Beccaro MA. **Vet Hum Toxicol** 1995 Dec;37(6):557–8

STANDARDS

Nutrition & health implications of palm oil in Indian diets. Ghafoorunissa. **Indian J Med Res** 1995 Nov;102:233–40

Nutritional significance of rice bran oil. Raghuram TC, et al. **Indian J Med Res** 1995 Nov;102:241–4

Effect of Japanese mint (Mentha arvensis) oil as fumigant on stored sorghum: physical characteristics, sensory quality and germination. Singh M, et al. **Int J Food Sci Nutr** 1995 Aug;46(3):225–8

Coconut oil and beef tallow, but not tricaprylin, can replace menhaden oil in the diet of red drum (Sciaenops ocellatus) without adversely affecting growth or fatty acid composition. Craig SR, et al. **J Nutr** 1995 Dec; 125(12):3041–8

PLANT OILS

THERAPEUTIC USE

Where next for prophylaxis against pre-eclampsia? [see comments] Pipkin FB, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):603–7. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Similar effects of rapeseed oil (canola oil) and olive oil in a lipid-lowering diet for patients with hyperlipoproteinemia. Nydahl M, et al. **J Am Coll Nutr** 1995 Dec;14(6):643–51

Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. Sundaram SG, et al. **J Nutr** 1996 May;126(5):1355–61

Peppermint oil and colon spasm. Kingham JG. **Lancet** 1995 Oct 14;346(8981):986

Response of hypercholesterolemic subjects to administration of tocotrienols. Qureshi AA, et al. **Lipids** 1995 Dec; 30(12):1171–7

Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Tomeo AC, et al. **Lipids** 1995 Dec;30(12):1179–83

Protective capability of dietary Zizyphus mistol seed oil, rich in 18:3, n-3, on the development of two murine mammary gland adenocarcinomas with high or low metastatic potential. Muñoz SF, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):135–8

Effects of dietary n-3, n-6 and n-9 polyunsaturated fatty acids on benzo(a)pyrene-induced forestomach tumorigenesis in C57BL6J mice. Silva RA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):273–7

Protective effect of coconut oil on renal necrosis occurring in rats fed a methyl-deficient diet. Monserrat AJ, et al. **Ren Fail** 1995 Sep;17(5):525–37

Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759–77 (91 ref.)

Efficacy of a phyto-aromatic gel against auricular manage in rabbits and carnivores. Mignon BR, et al. **Vet Rec** 1996 Apr 6;138(14):329–32

[Effects of coconut juice on the formation of hyperlipidemia and atherosclerosis] Zhao G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):216–8 (Eng. Abstr.) **(Chi)**

TOXICITY

Genotoxicity of the natural cercaricides "sucupira" oil and eremanthine in mammalian cells in vitro and in vivo. Dias F da L, et al. **Environ Mol Mutagen** 1995;26(4):338–44

Dietary effects of corn oil, oleic acid, perilla oil, and primrose oil on plasma and hepatic lipid level and atherosclerosis in Japanese quail. Sadi AM, et al. **Exp Anim** 1996 Jan; 45(1):55–62

Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid. Boswell K, et al. **Food Chem Toxicol** 1996 Jul;34(7):585–93

Toxic oil syndrome: traceback of the toxic oil and evidence for a point source epidemic. Posada de la Paz M, et al. **Food Chem Toxicol** 1996 Mar;34(3):251–7

Ultrastructure of liver from piglets fed Tower rapeseed oil. Cullen C, et al. **Histol Histopathol** 1996 Jan;11(1):27–33

1995 Bailey K. Ashford lecture. Public health lessons from two catastrophic epidemics: the toxic oil syndrome and the eosinophilia-myalgia syndrome. James TN. **P R Health Sci J** 1996 Mar;15(1):45–8

Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells. Söderberg TA, et al. **Toxicology** 1996 Feb 22;107(2):99–109

PLANT PHOTOSYNTHETIC PROTEIN COMPLEXES see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT PHOTOSYNTHETIC REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PLANT POISONING

Haemorrhagic colitis induced by Citrullus colocynthis. Al Faraj S. **Ann Trop Med Parasitol** 1995 Dec;89(6):695–6

Transitory complete atrioventricular block associated to ingestion of Nerium oleander. Nishioka S de A, et al. **Rev Assoc Med Bras** 1995 Jan-Feb;41(1):60–2

Ingestion of angel's trumpet: an increasingly common source of toxicity. Greene GS, et al. **South Med J** 1996 Apr; 89(4):365–9

Toxicity of field bindweed (Convolvulus arvensis) to mice. Schultheiss PC, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):452–4

Ingestion of poison hemlock (Conium maculatum). Frank BS, et al. **West J Med** 1995 Dec;163(6):573–4

[Veno-occlusive disease of small hepatic vein (Bush tea disease)] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):176–9 (24 ref.) **(Jpn)**

BLOOD

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson IB, et al. **Ann Intern Med** 1996 Apr 15;124(8):726–34 (46 ref.)

Plasma and urine concentrations of atropine after the ingestion of cooked deadly nightshade berries. Schneider F, et al. **J Toxicol Clin Toxicol** 1996;34(1):113–7

COMPLICATIONS

Constrictive bronchiolitis obliterans in Sauropus androgynus poisoning [letter] Roggli VL, et al. **J Toxicol Clin Toxicol** 1996;34(5):525–8

[Colocynth poisoning, a rare cause of acute diarrhea syndrome (letter)] Gálvez Contreras M del C, et al. **Med Clin (Barc)** 1996 Apr 20;106(15):599 **(Spa)**

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

EPIDEMIOLOGY

Two outbreaks of acute Tung Nut (Aleurites fordii) poisoning. Lin TJ, et al. **J Toxicol Clin Toxicol** 1996; 34(1):87–92

[Serious plant poisonings in Switzerland 1966–1994. Case analysis from the Swiss Toxicology Information Center] Jaspersen-Schib R, et al. **Schweiz Med Wochenschr** 1996 Jun 22;126(25):1085–98 (Eng. Abstr.) **(Ger)**

[New data on heliotropic dystrophy of the liver] Mansurov KK. **Klin Med (Mosk)** 1995;73(6):15–8 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Anticholinergic poisoning associated with herbal tea. Hsu CK, et al. **Arch Intern Med** 1995 Nov 13;155(20):2245–8

Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

PHYSIOPATHOLOGY

[Hemlock poisoning: an occasionally benign course (letter)] Brenet O, et al. **Presse Med** 1996 Jan 20;25(2):82 **(Fre)**

PREVENTION & CONTROL

Effects on reproduction in female offspring from Sprague-Dawley rats fed 10% snakeweed (Gutierrezia microcephala) throughout pregnancy and concurrent treatment with safflower oil. Staley EC, et al. **Vet Hum Toxicol** 1995 Oct;37(5):440–2

THERAPY

Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Safadi R, et al. **Arch Intern Med** 1995 Oct 23;155(19):2121–5

URINE

Plasma and urine concentrations of atropine after the ingestion of cooked deadly nightshade berries. Schneider F, et al. **J Toxicol Clin Toxicol** 1996;34(1):113–7

VETERINARY

Increased tolerance to annual ryegrass toxicity in sheep given a supplement of cobalt. Davies SC, et al. **Aust Vet J** 1995 Jun;72(6):221–4

The characteristics and causes of sheep losses in the Victorian Mallee. Harris DJ, et al. **Aust Vet J** 1995 Sep;72(9):331–40

Poisoning of cattle attributed to Cucumis melo ssp agrestis (Ulcardo melon). Jubb TF, et al. **Aust Vet J** 1995 Jul; 72(7):274–5

Reducing the effects of clover disease by strategic grazing of pastures. Little DL. **Aust Vet J** 1996 May;73(5):192–3

Macrozamia toxicosis in a dog. Mills JN, et al. **Aust Vet J** 1996 Feb;73(2):69–72

Evaluation of clinicopathological parameters in cattle grazing timber milkvetch. Maricle B, et al. **Can Vet J** 1996 Mar; 37(3):153–6

Yew poisoning in sheep. Rae CA, et al. **Can Vet J** 1995 Jul; 36(7):446

Anaranthus retroflexus (redroot pigweed) poisoning in lambs. Rae CA, et al. **Can Vet J** 1995 Jul;36(7):446

Effects of previous grazing treatment and consumption of locoweed on liver mineral concentrations in beef steers. Galyean ML, et al. **J Anim Sci** 1996 Apr;74(4):827–33

Plant poisonings and mycotoxicoses as constraints in livestock production in east Africa: the southern African experience. Naudé TW, et al. **J S Afr Vet Assoc** 1996 Mar; 67(1):8–11 (18 ref.)

Isolation of the toxin responsible for gousiekte, a plant-induced cardiomyopathy of ruminants in southern Africa. Fourie N, et al. **Onderstepoort J Vet Res** 1995 Jun; 62(2):77–87

In vivo effects of a novel calcium antagonist (R56865) against induced epoxysciliirosidin and tulp poisoning in sheep. Swan GE, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):163–6

Liver disease in cattle induced by consumption of moldy hay. Casteel SW, et al. **Vet Hum Toxicol** 1995 Jun; 37(3):248–51

Poisonous plant identification: a comparison of databases designed for veterinary use. Cornell J, et al. **Vet Hum Toxicol** 1995 Oct;37(5):482–5

The acute toxicity of Riedeliella graciflora in laboratory animals. Dagli ML, et al. **Vet Hum Toxicol** 1995 Dec; 37(6):544–6

The acute toxicity of Riedeliella graciflora in calves. Gorniak SL, et al. **Vet Hum Toxicol** 1995 Oct;37(5):447–8

Mescalbean (Sophora secundiflora) toxicity in a dog. Knauer KW, et al. **Vet Hum Toxicol** 1995 Jun;37(3):237–9

Intoxication due to Achyrantes aspera L. Sanchez Perere LM, et al. **Vet Hum Toxicol** 1995 Dec;37(6):582

Intoxication of Albanian cattle after ingestion of Senecio subalpinus. Smith RA, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):478–9

Nephrotoxicity of Narthecium ossifragum in cattle in Norway. Flåøyen A, et al. **Vet Rec** 1995 Sep 9; 137(11):259–63

Field diagnosis of nitrite poisoning in cattle by testing aqueous humour samples with urine test strips. Montgomery JF, et al. **Vet Rec** 1995 Dec 2;137(23):593–4

Prunus padus (bird cherry) poisoning in cattle. Sargison ND, et al. **Vet Rec** 1996 Feb 24;138(8):188

Suspected annual mercury (Mercurialis annua) poisoning of lambs grazing fallow arable land. Welchman DB, et al. **Vet Rec** 1995 Dec 2;137(23):592–3

[Ryegrass cramps in horses] van Essen GJ, et al. **Tijdschr Diergeneeskd** 1995 Dec 15;120(24):710–1 (Eng. Abstr.) **(Dut)**

PLANT PROTEINS

Plant transcription factors. Meshi T, et al. **Plant Cell Physiol** 1995 Dec;36(8):1405–20

[Role of soybean proteins in human nutrition (review)] Vysotskiĭ VG, et al. **Vopr Pitan** 1995;(5):20–7 (45 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):74–80

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. Pauli G, et al. **J Allergy Clin Immunol** 1996 May;97(5):1100–9

Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S, et al. **J Hematother** 1995 Oct; 4(5):429–32

Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. Troise C, et al. **J Investig Allergol Clin Immunol** 1995 Jan-Feb;5(1):25–30

ADVERSE EFFECTS

Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosis. Hashimoto M, et al. **Clin Exp Allergy** 1995 Sep; 25(9):848–52

ANALYSIS

Measurement of protein in natural rubber latex. Siler DJ, et al. **Anal Biochem** 1995 Aug 10;229(2):278–81

Measurement of natural rubber proteins in latex glove extracts: comparison of the methods. Beezhold D, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):520–6

Mountain cedar allergens found in nonpollen tree parts. Goetz DW, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):256–60

Di-isodityrosine, a novel tetrametric derivative of tyrosine in plant cell wall proteins: a new potential cross-link. Brady JD, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):323–7

A non-toxic two-chain ribosome-inactivating protein co-exists with a structure-related monomeric lectin (SNA III) in elder (Sambucus nigra) fruits. Girbés T, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):343

Isolation and characterization of a Photosystem II complex from the red alga Cyanidium caldarium: association of cytochrome c-550 and a 12 kDa protein with the complex. Enami I, et al. **Biochim Biophys Acta** 1995 Dec 12; 1232(3):208–16

Antibody against phosphorylated proteins (MPM-2) recognizes mitotic microtubules in endosperm cells of higher plant Haemanthus. Smirnova EA, et al. **Cell Motil Cytoskeleton** 1995;31(1):34–44

Direct detection of beta-1,3-glucanase in plant extracts by polyacrylamide gel electrophoresis. Kalix S, et al. **Electrophoresis** 1995 Jun;16(6):1016–8

Identification of glycosylated forms of wheat storage proteins using two-dimensional electrophoresis and blotting. Laurière M, et al. **Electrophoresis** 1996 Mar;17(3):497–501

Visualization of barley beta-glucan degrading isozymes after gel isoelectric focusing. Menteur S, et al. **Electrophoresis** 1995 Jun;16(6):1019–23

A silver stain protocol for proteins yielding high resolution and transparent background in sodium dodecyl sulfate-polyacrylamide gels. Swain M, et al. **Electrophoresis** 1995 Jun;16(6):948–51

Characterizing allelic proteins for genome mapping in maize. Touzet P, et al. **Electrophoresis** 1995 Jul;16(7):1289–94

Immunological detection of proteins similar to bacterial proteases in higher plant chloroplasts. Ostersetzer O, et al. **Eur J Biochem** 1996 Mar 15;236(3):932–6

In situ localization of nucleolin in the plant nucleolar matrix. Minguez A, et al. **Exp Cell Res** 1996 Jan 10;222(1):171–8

Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. Blaher B, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):124–32

Light and electron microscopic immunocytochemical localization of two major proteins in garlic bulb. Wen GY, et al. **J Cell Biochem** 1995 Aug;58(4):481–9

Immunogold probes for light and electron microscopic localization of Ole e I in several Oleaceae pollens. Fernandez MC, et al. **J Histochem Cytochem** 1996 Feb; 44(2):151–8

Water–soluble viscous substance of Jew's mellow leaves lowers serum and liver cholesterol concentrations and increases fecal steroid excretion in rats fed a high cholesterol diet. Innami S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):465–75

Identification of gliadin presence in pharmaceutical products: appropriateness of polyclonal antibodies for detection of gliadin and other toxic prolamins [letter; comment] Miletic ID, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov; 21(4):482–3. Comment on: J Pediatr Gastroenterol Nutr 1994 Jul;19(1):27–33.

Amino acid sequence of a Bowman–Birk proteinase inhibitor from pea seeds. Ferrasson E, et al. **J Protein Chem** 1995 Aug;14(6):467–75

Immunocytochemical localization of receptor protein kinases in plants. Counihan VP, et al. **Methods Cell Biol** 1995; 49:515–29 (25 ref.)

Nonradioactive method for ATPase assays. Kagami O, et al. **Methods Cell Biol** 1995;47:147–50

Measurement of ATPase activity using [gamma–32P]ATP. King SM. **Methods Cell Biol** 1995;47:141–5

Analysis of flagellar calcium–binding proteins. Otter T. **Methods Cell Biol** 1995;47:113–9

Detection of flagellar protein kinases on polyvinylidene difluoride membranes following sodium dodecyl sulfate–polyacrylamide gel electrophoresis. San Agustin JT, et al. **Methods Cell Biol** 1995;47:135–40

Analysis of the H(+)–ATPase and other proteins of the Arabidopsis plasma membrane. Schaller GE, et al. **Methods Cell Biol** 1995;50:129–48

Flagellar adenylyl cyclases in Chlamydomonas. Zhang Y, et al. **Methods Cell Biol** 1995;47:459–65

Immunocytochemical localization of proteins. Davies J. **Methods Mol Biol** 1995;49:453–62

Western blotting analysis. Fido RJ, et al. **Methods Mol Biol** 1995;49:423–37 (24 ref.)

ELISA detection of foreign proteins. Mills EN, et al. **Methods Mol Biol** 1995;49:439–51

Qid3 protein links plant bimodular proteins with fungal hydrophobins [letter] Lora JM, et al. **Mol Microbiol** 1995 Oct;18(2):380–2

Identification of a Brazil–nut allergen in transgenic soybeans [see comments] Nordlee JA, et al. **N Engl J Med** 1996 Mar 14;334(11):688–92. Comment in: N Engl J Med 1996 Mar 14;334(11):726–8.

Localization and characterization of a novel 20 kDa polypeptide in the chloroplast of the green alga Dunaliella salina. Andreasson E, et al. **Plant Cell Physiol** 1995 Dec; 36(8):1483–92

Immunolocalization of freezing–tolerance–associated proteins in the cytoplasm and nucleoplasm of wheat crown tissues. Houde M, et al. **Plant J** 1995 Oct;8(4):583–93

Elongation factor 1 alpha concentration is highly correlated with the lysine content of maize endosperm. Habben JE, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8640–4

A chemical study of the protein fractions of Tarragona hazelnuts (Corylus avellana). Bonvehí JS. **Z Lebensm Unters Forsch** 1995 Oct;201(4):371–4

Natural fermentation of lentils. Influence of time, concentration and temperature on protein content, trypsin inhibitor activity and phenolic compound content. Tabera J, et al. **Z Lebensm Unters Forsch** 1995 Dec;201(6):587–91

[Protein analysis of 6 crude drugs and their processed products by polyacrylamide gel electrophoresis technique] Shi J, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):533–5, 574 (Eng. Abstr.) **(Chi)**

[The dot–blot technic for quantitative determination of wheat protein in sausage] Marcin A, et al. **Vet Med (Praha)** 1995 Jul;40(7):227–31 (Eng. Abstr.) **(Slo)**

[Effect of carbaryl and lead on phenols, chlorophyll and proteins of the microalga Ankistrodesmus falcatus] Martínez–Tabche L, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):93–9 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Molecular cloning and immunocytochemical localization of jasmonic acid inducible cathepsin D inhibitors from potato. Strukelj B, et al. **Adv Exp Med Biol** 1995;362:293–8

An insertion element prevents phycobilisome synthesis in N2–fixing Synechocystis sp. strain BO 8402. Brass S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1964–8

Sequence and expression of the mRNA encoding HSP22, the mitochondrial small heat–shock protein in pea leaves. Lenne C, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):805–13

Synthesis and structure determination by NMR of a putative vacuolar targeting peptide and model of a proteinase inhibitor from Nicotiana alata. Nielsen KJ, et al. **Biochemistry** 1996 Jan 16;35(2):369–78

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455–66 (44 ref.)

Maize seedlings show cell–specific responses to heat shock as revealed by expression of RNA and protein. Greyson RI, et al. **Dev Genet** 1996;18(3):244–53

Pathways for inflorescence and floral induction in Antirrhinum. Bradley D, et al. **Development** 1996 May; 122(5):1535–44

Cholera toxin elevates pathogen resistance and induces pathogenesis–related gene expression in tobacco. Beffa R, et al. **EMBO J** 1995 Dec 1;14(23):5753–61

Bean ribonuclease–like pathogenesis–related protein genes (Ypr10) display complex patterns of developmental, dark–induced and exogenous–stimulus–dependent expression. Walter MH, et al. **Eur J Biochem** 1996 Jul 15; 239(2):281–93

Expression of Zm13, a pollen specific maize protein, in Escherichia coli reveals IgE–binding capacity and allergenic potential. Heiss S, et al. **FEBS Lett** 1996 Mar 4;381(3):217–21

A novel myb–related gene from Arabidopsis thaliana. Li SF, et al. **FEBS Lett** 1996 Jan 29;379(2):117–21

Promoter and expression studies on an Arabidopsis thaliana dehydrin gene. Rouse DT, et al. **FEBS Lett** 1996 Mar 4; 381(3):252–6

Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen. Smith PM, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):331–43

Heterologous assembly and rescue of stranded phycocyanin subunits by expression of a foreign cpcBA operon in Synechocystis sp. strain 6803. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6804–9

Translational regulation of chloroplast genes. Proteins binding to the 5'–untranslated regions of chloroplast mRNAs in Chlamydomonas reinhardtii. Hauser CR, et al. **J Biol Chem** 1996 Jan 19;271(3):1486–97

The use of protoplasts to study protein synthesis and transport by the plant endomembrane system. Denecke J, et al. **Methods Cell Biol** 1995;50:335–48

Synthesis of plant proteins in heterologous systems: Xenopus laevis oocytes. Galili G, et al. **Methods Cell Biol** 1995; 50:497–517

Heterologous expression of higher plant transport proteins and repression of endogenous ion currents in Xenopus oocytes. Schroeder JI. **Methods Cell Biol** 1995;50:519–33

Protein import into plant mitochondria. Winning BM, et al. **Methods Enzymol** 1995;260:293–302

In organello protein synthesis. Grohmann L. **Methods Mol Biol** 1995;49:391–7

Abnormal cell divisions in leaf primordia caused by the expression of the rice homeobox gene OSH1 lead to altered morphology of leaves in transgenic tobacco. Sato Y, et al. **Mol Gen Genet** 1996 Apr 24;251(1):13–22

Nuclear genes required for post–translational steps in the biogenesis of the chloroplast cytochrome b6f complex in maize. Voelker R, et al. **Mol Gen Genet** 1995 Dec 15; 249(5):507–14

Ectopic expression of the Arabidopsis transcriptional activator Athb–1 alters leaf cell fate in tobacco. Aoyama T, et al. **Plant Cell** 1995 Nov;7(11):1773–85

Alleles of the maize P gene with distinct tissue specificities encode Myb–homologous proteins with C–terminal replacements. Chopra S, et al. **Plant Cell** 1996 Jul; 8(7):1149–58

Ovule development: identification of stage–specific and tissue–specific cDNAs. Nadeau JA, et al. **Plant Cell** 1996 Feb;8(2):213–39

Induction of wound response genes in tomato leaves by bestatin, an inhibitor of aminopeptidases. Schaller A, et al. **Plant Cell** 1995 Nov;7(11):1893–8

Modular nature of abscisic acid (ABA) response complexes: composite promoter units that are necessary and sufficient for ABA induction of gene expression in barley. Shen Q, et al. **Plant Cell** 1996 Jul;8(7):1107–19

Ectopic expression of the maize homeobox genes ZmHox1a or ZmHox1b causes pleiotropic alterations in the vegetative and floral development of transgenic tobacco. Uberlacker B, et al. **Plant Cell** 1996 Mar;8(3):349–62

Identification of the product of ndhA gene as a thylakoid protein synthesized in response to photooxidative treatment. Martín M, et al. **Plant Cell Physiol** 1996 Apr; 37(3):293–8

Cloning and characterization of a probenazole–inducible gene for an intracellular pathogenesis–related protein in rice. Midoh N, et al. **Plant Cell Physiol** 1996 Jan;37(1):9–18

Visualization of differential gene expression using a novel method of RNA fingerprinting based on AFLP: analysis of gene expression during potato tuber development. Bachem CW, et al. **Plant J** 1996 May;9(5):745–53

The S locus receptor kinase gene encodes a soluble glycoprotein corresponding to the SKR extracellular domain in Brassica oleracea. Giranton JL, et al. **Plant J** 1995 Dec;8(6):827–34

CLA1, a novel gene required for chloroplast development, is highly conserved in evolution. Mandel MA, et al. **Plant J** 1996 May;9(5):649–58

O–glycosylation of a precursor to a sweet potato vacuolar protein, sporamin, expressed in tobacco cells. Matsuoka K, et al. **Plant J** 1995 Dec;8(6):877–89

Expression and cellular localization of rab28 mRNA and Rab28 protein during maize embryogenesis. Niogret MF, et al. **Plant J** 1996 Apr;9(4):549–57

Characterization of anther–expressed genes encoding a major class of extracellular oleosin–like proteins in the pollen coat of Brassicaceae. Ross JH, et al. **Plant J** 1996 May; 9(5):625–37

The macrophage–specific membrane protein Nramp controlling natural resistance to infections in mice has homologues expressed in the root system of plants. Belouchi A, et al. **Plant Mol Biol** 1995 Dec;29(6):1181–96

The in vitro assembly of the NADPH–protochlorophyllide oxidoreductase in pea chloroplasts. Dahlin C, et al. **Plant Mol Biol** 1995 Oct;29(2):317–30

Characterization and expression of metallothionein–like genes in cotton. Hudspeth RL, et al. **Plant Mol Biol** 1996 Jun; 31(3):701–5

New antifungal proteins from sugar beet (Beta vulgaris L.) showing homology to non–specific lipid transfer proteins. Nielsen KK, et al. **Plant Mol Biol** 1996 Jun;31(3):539–52

Production of biologically active hirudin in plant seeds using oleosin partitioning. Parmenter DL, et al. **Plant Mol Biol** 1995 Dec;29(6):1167–80

A wound–inducible gene from Salix viminalis coding for a trypsin inhibitor. Saarikoski P, et al. **Plant Mol Biol** 1996 Jun;31(3):465–78

Identification of three cDNA clones expressed in the leaf extension zone and with altered patterns of expression in the slender mutant of barley: a tonoplast intrinsic protein, a putative structural protein and protochlorophyllide oxidoreductase. Schünmann PH, et al. **Plant Mol Biol** 1996 Jun;31(3):529–37

Isolation and characterization of a cDNA encoding a plant defensin–like protein from roots of Norway spruce. Sharma P, et al. **Plant Mol Biol** 1996 Jun;31(3):707–12

A lectin and a lectin–related protein are the two most prominent proteins in the bark of yellow wood (Cladrastis lutea). Van Damme EJ, et al. **Plant Mol Biol** 1995 Nov; 29(3):579–98

A potato cDNA encoding a homologue of mammalian multidrug resistant P–glycoprotein. Wang W, et al. **Plant Mol Biol** 1996 Jun;31(3):683–7

A promiscuous chloroplast DNA fragment is transcribed in plant mitochondria but the encoded RNA is not edited. Zeltz P, et al. **Plant Mol Biol** 1996 Jun;31(3):647–56

Coi1–dependent expression of an Arabidopsis vegetative storage protein in flowers and siliques and in response to coronatine or methyl jasmonate. Benedetti CE, et al. **Plant Physiol** 1995 Oct;109(2):567–72

A potent antimicrobial protein from onion seeds showing sequence homology to plant lipid transfer proteins. Cammue BP, et al. **Plant Physiol** 1995 Oct;109(2):445–55

Characterization and gene expression of nodulin Npv30 from common bean. Campos F, et al. **Plant Physiol** 1995 Oct; 109(2):363–70

Polyembryony in Citrus. Accumulation of seed storage proteins in seeds and in embryos cultured in vitro. Koltunow AM, et al. **Plant Physiol** 1996 Feb; 110(2):599–609

Expression of an Arabidopsis potassium channel gene in guard cells. Nakamura RL, et al. **Plant Physiol** 1995 Oct; 109(2):371–4

Lupinus albus L. pathogenesis–related proteins that show similarity to PR–10 proteins. Pinto MP, et al. **Plant Physiol** 1995 Dec;109(4):1345–51

The correlation between heat–shock protein accumulation and persistence and chilling tolerance in tomato fruit. Sabehat A, et al. **Plant Physiol** 1996 Feb;110(2):531–7

A wound– and methyl jasmonate–inducible transcript coding for a myrosinase–associated protein with similarities to an early nodulin. Taipalensuu J, et al. **Plant Physiol** 1996 Feb; 110(2):483–91

Organ–specific and Agamous–regulated expression and glycosylation of a pollen tube growth–promoting protein. Cheung AY, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3853–8

Molecular cloning and sequence analysis of expansins—a highly conserved, multigene family of proteins that mediate cell wall extension in plants. Shcherban TY, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9245–9

Purification of a maize dehydrin protein expressed in Escherichia coli. Jepson SG, et al. **Protein Expr Purif** 1995 Oct;6(5):632–6

Resistance to geminivirus infection by virus–induced expression of dianthin in transgenic plants. Hong Y, et al. **Virology** 1996 Jun 1;220(1):119–27

CHEMICAL SYNTHESIS

Synthesis and characterization of the sweetness–suppressing polypeptide gurmarin and ent–gurmarin. Ota M, et al. **Biopolymers** 1996 Aug;39(2):199–205

CHEMISTRY

Isolation and characterization of the 18–kDa major apple allergen and comparison with the major birch pollen allergen (Bet v I). Vieths S, et al. **Allergy** 1995 May; 50(5):421–30

Evidence for an alpha helical T cell epitope in the C–terminus of the main birch pollen allergen Bet V 1. Kungl AJ, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):187–92

Chain length–dependent Pb(II)–coordination in phytochelatins. Mehra RK, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):730–6

A single amino acid determines the specificity for the target sequence of two zinc–finger proteins in plants. Takatsuji H. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):219–23

Variation in the primary structure of waxy proteins (granule–bound starch synthase) in diploid cereals. Taira

T, et al. **Biochem Genet** 1995 Aug;33(7-8):269-81

Secondary structure of NADPH: protochlorophyllide oxidoreductase examined by circular dichroism and prediction methods. Birve SJ, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):549-55

Determination of the three-dimensional structure of hordothionin-alpha by nuclear magnetic resonance. Han KH, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):885-92

Purification and characterization of oil-bodies (oleosomes) and oil-body boundary proteins (oleosins) from the developing cotyledons of sunflower (Helianthus annuus L.). Millichip M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):333-7

Oleosins and oil bodies in plant seeds have postulated structures [letter] Ratnayake C, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):956-8

Aggregation of phospholipid vesicles induced by the ribosome inactivating protein saporin. Hao Q, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):701-9

Differential modulation of binding loop flexibility and stability by Arg50 and Arg52 in Cucurbita maxima trypsin inhibitor-V deduced by trypsin-catalyzed hydrolysis and NMR spectroscopy. Cai M, et al. **Biochemistry** 1996 Apr 16;35(15):4784-94

Interaction of the 33 kDa extrinsic protein with photosystem II: rebinding of the 33 kDa extrinsic protein to photosystem II membranes which contain four, two, or zero manganese per photosystem II reaction center. Leuschner C, et al. **Biochemistry** 1996 Apr 9;35(14):4551-7

Solution structure and backbone dynamics of recombinant Cucurbita maxima trypsin inhibitor-V determined by NMR spectroscopy. Liu J, et al. **Biochemistry** 1996 Feb 6; 35(5):1516-24

Purification and sequencing of multiple forms of Brassica napus seed napin small chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):23-33

Purification and sequencing of multiple forms of Brassica napus seed napin large chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):34-43

In vivo endoproteolytically cleaved phaseolin is stable and accumulates in developing Phaseolus lunatus L. seeds. Sparvoli F, et al. **Biochim Biophys Acta** 1996 Jan 4; 1292(1):15-22

1H-nmr studies on the structure of a new thionin from barley endosperm. Bruix M, et al. **Biopolymers** 1995 Dec; 36(6):751-63

Structural analysis of the carbohydrate moiety of arabinogalactan-proteins from stigmas and styles of Nicotiana alata. Gane AM, et al. **Carbohydr Res** 1995 Nov 7;277(1):67-85

Protein chemotaxonomy of genus Datura. IV. Amino acid sequence of Datura ferredoxins depends not on the species but the section of Datura plants from which it comes. Mino Y. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1186-9

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225-55 (102 ref.)

Studies on the carbohydrate moieties of the timothy grass pollen allergen Phl p I. Petersen A, et al. **Electrophoresis** 1995 May;16(5):869-75

Sequence analysis of wheat grain allergens separated by two-dimensional electrophoresis with immobilized pH gradients. Posch A, et al. **Electrophoresis** 1995 Jul; 16(7):1115-9

From image processing to classification: III. Matching patterns by shifting and stretching. Skovgaard IM, et al. **Electrophoresis** 1995 Aug;16(8):1385-9

Molecular characterization of Api g 1, the major allergen of celery (Apium graveolens), and its immunological and structural relationships to a group of 17-kDa tree pollen allergens. Breiteneder H, et al. **Eur J Biochem** 1995 Oct 15;233(2):484-9

Synthesis and characterization of a homogeneous chemical conjugate between basic fibroblast growth factor and saporin. Buechler YJ, et al. **Eur J Biochem** 1995 Dec 15; 234(3):706-13

Analysis of the oxidation-reduction potentials of recombinant ferredoxin-NADP+ reductase from spinach chloroplasts. Corrado ME, et al. **Eur J Biochem** 1996 Aug 1;239(3):662-7

Isolation, characterization and electron microscopy analysis of a hemidiscoidal phycobilisome type from the cyanobacterium Anabaena sp. PCC 7120. Ducret A, et al. **Eur J Biochem** 1996 Mar 15;236(3):1010-24

Primary structure, sequence-specific 1H-NMR assignments and secondary structure in solution of bromelain inhibitor VI from pineapple stem. Hatano K, et al. **Eur J Biochem** 1995 Sep 1;232(2):335-43

Frustulins: domain conservation in a protein family associated with diatom cell walls. Kröger N, et al. **Eur J Biochem** 1996 Jul 15;239(2):259-64

Expression, lipoylation and structure determination of recombinant pea H-protein in Escherichia coli. Macherel D, et al. **Eur J Biochem** 1996 Feb 15;236(1):27-33

Primary structure of omega-hordothionin, a member of a novel family of thionins from barley endosperm, and its inhibition of protein synthesis in eukaryotic and prokaryotic cell-free systems. Méndez E, et al. **Eur J Biochem** 1996 Jul 1;239(1):67-73

Characterization and molecular cloning of Sambucus nigra agglutinin V (nigrin b), a GalNAc-specific type-2 ribosome-inactivating protein from the bark of elderberry (Sambucus nigra). Van Damme EJ, et al. **Eur J Biochem** 1996 Apr 15;237(2):505-13

Immunological evidence that HMG-CoA reductase kinase-A is the cauliflower homologue of the RKIN1 subfamily of plant protein kinases. Ball KL, et al. **FEBS Lett** 1995 Dec 18;377(2):189-92

Complete amino acid sequence of the protease inhibitor from buckwheat seeds. Belozersky MA, et al. **FEBS Lett** 1995 Sep 11;371(3):264-6

Modified 2S albumins with improved tryptophan content are correctly expressed in transgenic tobacco plants. Marcellino LH, et al. **FEBS Lett** 1996 May 6;385(3):154-8

Cloning and sequencing of winged bean (Psophocarpus tetragonolobus) basic agglutinin (WBA I): presence of second glycosylation site and its implications in quaternary structure. Sharma V, et al. **FEBS Lett** 1996 Jul 8; 389(3):289-92

Calcium in pollen-pistil interaction in Petunia hybrida Hort. III. Localization of Ca2+ ions and Ca(2+)-ATPase in pollinated pistil. Bednarska E, et al. **Folia Histochem Cytobiol** 1995;33(2):125-32

Variations in glutelin and high molecular weight endosperm proteins among subspecies of rice (Oryza sativa L.) detected by two-dimensional gel electrophoresis. Abe T, et al. **Genes Genet Syst** 1996 Apr;71(2):63-8

Characterization of carbohydrate structural features recognized by anti-arabinogalactan-protein monoclonal antibodies. Yates EA, et al. **Glycobiology** 1996 Mar; 6(2):131-9

Unique structural features of red kidney bean purple acid phosphatase. Cashikar AG, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):130-6

Deduced amino acid sequence of 2S storage protein from Brassica species and their conserved structural features. Dasgupta J, et al. **Indian J Biochem Biophys** 1995 Dec; 32(6):378-84

Characterization of Phl p 4, a major timothy grass (Phleum pratense) pollen allergen. Fischer S, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):189-98

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99-106

Subunit interactions and protein stability in the cyanobacterial light-harvesting proteins. Plank T, et al. **J Bacteriol** 1995 Dec;177(23):6798-803

Amino acid sequences of trypsin inhibitors from the melon Cucumis melo. Lee CF, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):18-22

Secondary structure and tertiary fold of the birch pollen allergen Bet v 1 in solution. Faber C, et al. **J Biol Chem** 1996 Aug 9;271(32):19243-50

Molecular characterization of a putative Arabidopsis thaliana copper transporter and its yeast homologue. Kampfenkel K, et al. **J Biol Chem** 1995 Nov 24;270(47):28479-86

Phosphorylation of nodulin 26 on serine 262 affects its voltage-sensitive channel activity in planar lipid bilayers. Lee JW, et al. **J Biol Chem** 1995 Nov 10;270(45):27051-7

Reconstitution of barley photosystem I with modified PSI-C allows identification of domains interacting with PSI-D and PSI-A/B. Naver H, et al. **J Biol Chem** 1996 Apr 12; 271(15):8996-9001

Do NOE distances contain enough information to assess the relative populations of multi-conformer structures? Bonvin AM, et al. **J Biomol NMR** 1996 Jan;7(1):72-6

Prediction of protein degradation of forages from solubility fractions. Kohn RA, et al. **J Dairy Sci** 1995 Aug; 78(8):1774-88

Ag(I)-binding to phytochelatins. Mehra RK, et al. **J Inorg Biochem** 1996 Feb;61(2):125-42

Crystal structure of concanavalin B at 1.65 A resolution. An "inactivated" chitinase from seeds of Canavalia ensiformis. Hennig M, et al. **J Mol Biol** 1995 Nov 24;254(2):237-46

The structure of the transition state for folding of chymotrypsin inhibitor 2 analysed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):260-88

Search for nucleation sites in smaller fragments of chymotrypsin inhibitor 2. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):289-304

Mechanism of Fe(III)-Zn(II) purple acid phosphatase based on crystal structures. Klabunde T, et al. **J Mol Biol** 1996 Jun 21;259(4):737-48

H NMR study of the solution structure of Ac-AMP2, a sugar binding antimicrobial protein isolated from Amaranthus caudatus. Martins JC, et al. **J Mol Biol** 1996 May 3; 258(2):322-33

Evolution of seed storage protein genes: legumin genes of Ginkgo biloba. Häger KP, et al. **J Mol Evol** 1995 Oct; 41(4):457-66

Extensive modifications for methionine enhancement in the beta-barrels do not alter the structural stability of the bean seed storage protein phaseolin. Dyer JM, et al. **J Protein Chem** 1995 Nov;14(8):665-78

Mechanism of the activation of proteinase inhibitor synthesis by systemin involves beta-sheet structure, a specific DNA-binding protein domain. Slósarek G, et al. **J Struct Biol** 1995 Jul-Aug;115(1):30-6

Reconstitution of dynein arms in vitro. Smith EF. **Methods Cell Biol** 1995;47:491-6

Thioredoxin and seed proteins. Wong JH, et al. **Methods Enzymol** 1995;252:228-40

Effect of various types of fermentation on in vitro protein and starch digestibility of differently processed pearl millet. Sharma A, et al. **Nahrung** 1996 May;40(3):142-5

The crystal structure of the antifungal protein zeamatin, a member of the thaumatin-like, PR-5 protein family [letter] Batalia MA, et al. **Nat Struct Biol** 1996 Jan;3(1):19-23

A novel DNA-binding domain that may form a single zinc finger motif. Yanagisawa S. **Nucleic Acids Res** 1995 Sep 11;23(17):3403-10

Factors affecting activation of the 'cloaked' Zea maize ribosome inactivating protein (RIP) zymogen. 1. 'LID' peptide hydrophobicities and oxidative structural changes. Hardin CC, et al. **Nucleic Acids Symp Ser** 1995;(33):249-53

Plant nuclear pore complex proteins are modified by novel oligosaccharides with terminal N-acetylglucosamine. Heese-Peck A, et al. **Plant Cell** 1995 Sep;7(9):1459-71

A galactose-rich, cell-wall glycoprotein from styles of Nicotiana alata. Sommer-Knudsen J, et al. **Plant J** 1996 Jan;9(1):71-83

Characterization and expression of metallothionein-like genes in cotton. Hudspeth RL, et al. **Plant Mol Biol** 1996 Jun; 31(3):701-5

Characterization of two integral membrane proteins located in the protein bodies of pumpkin seeds. Inoue K, et al. **Plant Mol Biol** 1995 Sep;28(6):1089-101

New antifungal proteins from sugar beet (Beta vulgaris L.) showing homology to non-specific lipid transfer proteins. Nielsen KK, et al. **Plant Mol Biol** 1996 Jun;31(3):539-52

Antifreeze proteins in winter rye are similar to pathogenesis-related proteins. Hon WC, et al. **Plant Physiol** 1995 Nov;109(3):879-89

Lupinus albus L. pathogenesis-related proteins that show similarity to PR-10 proteins. Pinto MP, et al. **Plant Physiol** 1995 Dec;109(4):1345-51

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141-9 (36 ref.)

Study of the intercellular fluid of healthy Lupinus albus organs. Presence of a chitinase and a thaumatin-like protein. Regalado AP, et al. **Plant Physiol** 1996 Jan; 110(1):227-32

A wound- and methyl jasmonate-inducible transcript coding for a myrosinase-associated protein with similarities to an early nodulin. Taipalensuu J, et al. **Plant Physiol** 1996 Feb; 110(2):483-91

Purification of a Zn-binding phloem protein with sequence identity to chitin-binding proteins. Taylor KC, et al. **Plant Physiol** 1996 Feb;110(2):657-64

Mass spectrometric amino acid sequencing of a mixture of seed storage proteins (napin) from Brassica napus, products of a multigene family. Gehrig PM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3647-52

Dimerization specificity of Arabidopsis MADS domain homeotic proteins APETALA1, APETALA3, PISTILLATA, and AGAMOUS. Riechmann JL, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4793-8

Similarity among the Drosophila (6-4)photolyase, a human photolyase homolog, and the DNA photolyase-blue-light photoreceptor family [see comments] Todo T, et al. **Science** 1996 Apr 5;272(5258):109-12. Comment in: Science 1996 Apr 5;272(5258):48-9.

Ab initio determination of the crystal structure of cytochrome c6 and comparison with plastocyanin. Frazão C, et al. **Structure** 1995 Nov 15;3(11):1159-69

Differential scanning calorimetry of lupin and soy proteins. Sousa IM, et al. **Z Lebensm Unters Forsch** 1995 Dec; 201(6):566-9

CLASSIFICATION

From image processing to classification: III. Matching patterns by shifting and stretching. Skovgaard IM, et al. **Electrophoresis** 1995 Aug;16(8):1385-9

DRUG EFFECTS

Protein biomarkers of phytotoxicity in hazard evaluation. Ramanathan A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):926-34

GENETICS

Purification and characterization of recombinant cytochrome P450TYR expressed at high levels in Escherichia coli. Halkier BA, et al. **Arch Biochem Biophys** 1995 Oct 1; 322(2):369-77

Ribosomal protein RL44 is encoded by two subfamilies in upland cotton (Gossypium hirsutum L.). Hood G, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):32-6

Two transcripts with different sizes derived from a rice homeobox gene, OSH1. Tamaoki M, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):408-13

High-level expression in Escherichia coli and purification of recombinant plant profilins: comparison of IgE-binding capacity and allergenic activity. Vrtala S, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):42-50

S-related protein can be recombined with self-compatibility in interspecific derivatives of Lycopersicon. Bernatzky R, et al. **Biochem Genet** 1995 Aug;33(7-8):215-25

Biotin carboxyl carrier protein and carboxyltransferase subunits of the multi-subunit form of acetyl-CoA carboxylase from Brassica napus: cloning and analysis of

expression during oilseed rape embryogenesis. Elborough KM, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):103–12

A single gene encodes two different transcripts for the ADP–glucose pyrophosphorylase small subunit from barley (Hordeum vulgare). Thorbjørnsen T, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):149–54

A novel multigene family that the gene for a maize DNA–binding protein, MNB1a belongs to: isolation of genomic clones from this family and some aspects of its molecular evolution. Yanagisawa S. **Biochem Mol Biol Int** 1996 Apr;38(4):665–73

Prohevein is poorly processed but shows enhanced resistance to a chitin–binding fungus in transgenic tomato plants. Lee HI, et al. **Braz J Med Biol Res** 1995 Jul;28(7):743–50

The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch. Chamovitz DA, et al. **Cell** 1996 Jul 12;86(1):115–21

The tomato Cf–2 disease resistance locus comprises two functional genes encoding leucine–rich repeat proteins. Dixon MS, et al. **Cell** 1996 Feb 9;84(3):451–9

Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de–etiolation in Arabidopsis. Szekeres M, et al. **Cell** 1996 Apr 19;85(2):171–82

Plant mitosis promoting factor disassembles the microtubule preprophase band and accelerates prophase progression in Tradescantia. Hush J, et al. **Cell Biol Int** 1996 Apr; 20(4):275–87

Cloning novel alfalfa cyclin sequences--a RACE–PCR approach. Russinova E, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):703–14

Cloning, sequencing and expression in Escherichia coli of Pha a 1 and four isoforms of Pha a 5, the major allergens of canary grass pollen. Suphioglu C, et al. **Clin Exp Allergy** 1995 Sep;25(9):853–65

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus daniellii. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455–66 (44 ref.)

The atpF group–II intron–containing gene from spinach chloroplasts is not spliced in transgenic Chlamydomonas chloroplasts. Deshpande NN, et al. **Curr Genet** 1995 Jul; 28(2):122–7

Characterization of the mitochondrial orfB gene and its derivative, orf224, a chimeric open reading frame specific to one mitochondrial genome of the "Polima" male–sterile cytoplasm in rapeseed (Brassica napus L.). Handa H, et al. **Curr Genet** 1995 Nov;28(6):546–52

The gene for ribosomal protein S10 is present in mitochondria of pea and potato but absent from those of Arabidopsis and Oenothera. Knoop V, et al. **Curr Genet** 1995 May; 27(6):559–64

Identification and characterization of the Arabidopsis thaliana chloroplast DNA region containing the genes psbA, trnH and rps19'. Liere K, et al. **Curr Genet** 1995 Jul;28(2):128–30

Sorghum mitochondrial orf25 and a related chimeric configuration of a male–sterile cytoplasm. Van Tang H, et al. **Curr Genet** 1996 Feb;29(3):265–74

Splicing and editing of rps10 transcripts in potato mitochondria. Zanlungo S, et al. **Curr Genet** 1995 May; 27(6):565–71

Co–suppression of beta–1,3–glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

Developmental regulation of co–suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

The homeobox gene GLABRA2 is required for position–dependent cell differentiation in the root epidermis of Arabidopsis thaliana. Masucci JD, et al. **Development** 1996 Apr;122(4):1253–60

Characterization of cDNAs induced in meiotic prophase in lily microsporocytes. Kobayashi T, et al. **DNA Res** 1994; 1(1):15–26

Organ–specific and auxin–inducible expression of two tobacco par A–related genes in transgenic plants. Niwa Y, et al. **DNA Res** 1994;1(5):213–21

Structural analysis of a recA–like gene in the genome of Arabidopsis thaliana. Sato S, et al. **DNA Res** 1995; 2(2):89–93

A novel expression vector for the cyanobacterium, Synechococcus PCC 6301. Takeshima Y, et al. **DNA Res** 1994;1(4):181–9

Association of protein polymorphism among pepper (Capsicum annuum L.) inbred lines with agronomic performance of their crosses. Posch A, et al. **Electrophoresis** 1995 May;16(5):860–4

Genetic variability of carrot seed proteins analyzed by one– and two–dimensional electrophoresis with immobilized pH gradients. Posch A, et al. **Electrophoresis** 1995 Jul; 16(7):1312–6

The higher plant Arabidopsis thaliana encodes a functional CDC48 homologue which is highly expressed in dividing and expanding cells. Feiler HS, et al. **EMBO J** 1995 Nov 15;14(22):5626–37

A mutation in protein phosphatase 2A regulatory subunit A affects auxin transport in Arabidopsis. Garbers C, et al. **EMBO J** 1996 May 1;15(9):2115–24

Multiple regions of the Arabidopsis SAUR–AC1 gene control transcript abundance: the 3' untranslated region functions as an mRNA instability determinant. Gil P, et al. **EMBO J** 1996 Apr 1;15(7):1678–86

Molecular identification of zeaxanthin epoxidase of Nicotiana plumbaginifolia, a gene involved in abscisic acid biosynthesis and corresponding to the ABA locus of Arabidopsis thaliana. Marin E, et al. **EMBO J** 1996 May 15;15(10):2331–42

The reduced expression of endogenous duplications (REED) in the maize R gene family is mediated by DNA methylation. Ronchi A, et al. **EMBO J** 1995 Nov 1; 14(21):5318–28

Transfer of rps19 to the nucleus involves the gain of an RNP–binding motif which may functionally replace RPS13 in Arabidopsis mitochondria. Sánchez H, et al. **EMBO J** 1996 May 1;15(9):2138–49

Human and plant proliferating–cell nuclear antigen have a highly conserved binding site for the p53–inducible gene product p21WAF1. Ball KL, et al. **Eur J Biochem** 1996 May 1;237(3):854–61

Structure and expression analysis of the gdcsPA and gdcsPB genes encoding two P–isoproteins of the glycine–cleavage system from Flaveria pringlei. Bauwe H, et al. **Eur J Biochem** 1995 Nov 15;234(1):116–24

Major structural differences between pokeweed antiviral protein and ricin A–chain do not account for their differing ribosome specificity. Chaddock JA, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):159–66

Expression in Escherichia coli of Sin a 1, the major allergen from mustard. González De La Peña MA, et al. **Eur J Biochem** 1996 May 1;237(3):827–32

Characterization and molecular cloning of Sambucus nigra agglutinin V (nigrin b), a GalNAc–specific type–2 ribosome–inactivating protein from the bark of elderberry (Sambucus nigra). Van Damme EJ, et al. **Eur J Biochem** 1996 Apr 15;237(2):505–13

Molecular cloning of two different mannose–binding lectins from tulip bulbs. Van Damme EJ, et al. **Eur J Biochem** 1996 Mar 1;236(2):419–27

Synthesis, cloning and expression in Escherichia coli of a gene coding for the Met8-->Leu CMTI I--a representative of the squash inhibitors of serine proteinases. Bolewska K, et al. **FEBS Lett** 1995 Dec 18;377(2):172–4

Evolution of legumin genes: loss of an ancestral intron at the beginning of angiosperm diversification. Häger KP, et al. **FEBS Lett** 1996 May 27;387(1):94–8

Stable expression of maize auxin–binding protein in insect cell lines. Henderson J, et al. **FEBS Lett** 1995 Sep 11; 371(3):293–6

Functional expression of the plant K+ channel KAT1 in insect cells. Marten I, et al. **FEBS Lett** 1996 Feb 19; 380(3):229–32

Both action potentials and variation potentials induce proteinase inhibitor gene expression in tomato. Stanković B, et al. **FEBS Lett** 1996 Jul 29;390(3):275–9

Induction of a novel cytochrome P450 (CYP93 family) by methyl jasmonate in soybean suspension–cultured cells. Suzuki G, et al. **FEBS Lett** 1996 Mar 25;383(1–2):83–6

Legumin encoding sequences from the redwood family (Taxodiaceae) reveal precursors lacking the conserved Asn–Gly processing site. Wind C, et al. **FEBS Lett** 1996 Mar 25;383(1–2):46–50

Transfer of rps10 from the mitochondrion to the nucleus in Arabidopsis thaliana: evidence for RNA–mediated transfer and exon shuffling at the integration site. Wischmann C, et al. **FEBS Lett** 1995 Oct 30;374(2):152–6

Restriction enzyme buffers and 5–azacytidine induce loss of protein and banding in plant metaphase chromosomes. Olszewska MJ, et al. **Folia Histochem Cytobiol** 1995; 33(3):201–8

The first intron of the Arabidopsis thaliana gene coding for elongation factor 1 beta contains an enhancer–like element. Gidekel M, et al. **Gene** 1996 May 8;170(2):201–6

Structure of the gene encoding nitrilase 1 from Arabidopsis thaliana. Hillebrand H, et al. **Gene** 1996 May 8; 170(2):197–200

Cloning of a cDNA encoding a new ribosome–inactivating protein from Beta vulgaris vulgaris (mangold). Hornung E, et al. **Gene** 1996 May 8;170(2):233–6

Nucleotide sequences of novel potato (Solanum tuberosum L.) MADS–box cDNAs and their expression in vegetative organs. Kang SG, et al. **Gene** 1995 Dec 12;166(2):329–30

A 14–kDa Arabidopsis thaliana RNA polymerase III subunit contains two alpha–motifs flanked by a highly charged C terminus. Larkin RM, et al. **Gene** 1996 Jun 26;172(2):211–5

Cloning and characterization of a cDNA encoding an 18.0–kDa class–I low–molecular–weight heat–shock protein from rice. Lee YL, et al. **Gene** 1995 Nov 20; 165(2):223–7

Cloning of the rice seed alpha–globulin–encoding gene: sequence similarity of the 5'–flanking region to those of the genes encoding wheat high–molecular–weight glutenin and barley D hordein. Nakase M, et al. **Gene** 1996 May 8;170(2):223–6

The structure and expression of an hsc70 gene from Lycopersicon esculentum. Sun SW, et al. **Gene** 1996 May 8;170(2):237–41

Structure and expression of a developmentally regulated cDNA encoding a cysteine protease (pseudotzain) from Douglas fir. Tranbarger TJ, et al. **Gene** 1996 Jun 26; 172(2):221–6

Nucleotide sequences of four pathogen–induced alfalfa peroxidase–encoding cDNAs. el–Turk J, et al. **Gene** 1996 May 8;170(2):213–6

Cloning, expression and immunological characterization of Ory s 1, the major allergen of rice pollen. Xu H, et al. **Gene** 1995 Oct 27;164(2):255–9

Integrated control of seed maturation and germination programs by activator and repressor functions of Viviparous–1 of maize. Hoecker U, et al. **Genes Dev** 1995 Oct 15;9(20):2459–69

Variations in glutelin and high molecular weight endosperm proteins among subspecies of rice (Oryza sativa L.) detected by two–dimensional gel electrophoresis. Abe T, et al. **Genes Genet Syst** 1996 Apr;71(2):63–8

Soybean resistance genes specific for different Pseudomonas syringae avirulence genes are allelic, or closely linked, at the RPG1 locus. Ashfield T, et al. **Genetics** 1995 Dec; 141(4):1597–604

Environmental programming of heritable epigenetic changes in paramutant r–gene expression using temperature and light at a specific stage of early development in maize seedlings. Mikula BC. **Genetics** 1995 Aug;140(4):1379–87

Sequences required for paramutation of the maize b gene map to a region containing the promoter and upstream sequences. Patterson GI, et al. **Genetics** 1995 Aug; 140(4):1389–406

Genetic analysis of the functions of the transposable element En in Zea mays: limited transposase elicits a differential response on reporter alleles. Peterson PA. **Genetics** 1995 Nov;141(3):1135–45

The molecular evolution of the small heat–shock proteins in plants. Waters ER. **Genetics** 1995 Oct;141(2):785–95

Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen. Smith PM, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):331–43

Construction of a plasmid used for the expression of a sevenfold–mutant barley beta–amylase with increased thermostability in Escherichia coli and properties of the sevenfold–mutant beta–amylase. Yoshigi N, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):562–7

A cell wall–associated, receptor–like protein kinase. He ZH, et al. **J Biol Chem** 1996 Aug 16;271(33):19789–93

Isolation and characterization of a cDNA clone encoding a member of the Com44/Cim44 envelope components of the chloroplast protein import apparatus. Ko K, et al. **J Biol Chem** 1995 Dec 1;270(48):28601–8

Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild–type yeast. Lippuner V, et al. **J Biol Chem** 1996 May 31;271(22):12859–66

A novel plant calmodulin–binding protein with a kinesin heavy chain motor domain. Reddy AS, et al. **J Biol Chem** 1996 Mar 22;271(12):7052–60

Hormonal and environmental regulation of a plant PDR5–like ABC transporter. Smart CC, et al. **J Biol Chem** 1996 Aug 9;271(32):19351–7

Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. Rosenblum MG, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):547–55

Characterization of an Arabidopsis thaliana gene that defines a new class of putative plant receptor kinases with an extracellular lectin–like domain. Hervé C, et al. **J Mol Biol** 1996 May 24;258(5):778–88

Seed storage proteins of spermatophytes share a common ancestor with desiccation proteins of fungi. Bäumlein H, et al. **J Mol Evol** 1995 Dec;41(6):1070–5

Molecular evolution of maize catalases and their relationship to other eukaryotic and prokaryotic catalases. Guan L, et al. **J Mol Evol** 1996 May;42(5):570–9

Evolution of seed storage protein genes: legumin genes of Ginkgo biloba. Häger KP, et al. **J Mol Evol** 1995 Oct; 41(4):457–66

Divergence of the phytochrome gene family predates angiosperm evolution and suggests that Selaginella and Equisetum arose prior to Psilotum. Kolukisaoglu HU, et al. **J Mol Evol** 1995 Sep;41(3):329–37

Legumin–like and vicilin–like seed storage proteins: evidence for a common single–domain ancestral gene. Shutov AD, et al. **J Mol Evol** 1995 Dec;41(6):1057–69

Synthesis of plant proteins in heterologous systems: Xenopus laevis oocytes. Galili G, et al. **Methods Cell Biol** 1995; 50:497–517

Enrichment of mRNA encoding flagellar proteins. Keller LR. **Methods Cell Biol** 1995;47:551–7

Expression of plant proteins in baculoviral and bacterial systems. Kunze R, et al. **Methods Cell Biol** 1995;50:461–79

Heterologous expression of higher plant transport proteins and repression of endogenous ion currents in Xenopus oocytes. Schroeder JI. **Methods Cell Biol** 1995;50:519–33

Expression and localization of plant membrane proteins in Saccharomyces. Serrano R, et al. **Methods Cell Biol** 1995; 50:481–96

Molecular mapping of genes for flagellar proteins in Chlamydomonas. Silflow CD, et al. **Methods Cell Biol** 1995;47:525–30

The plant oncogenes rolA, B, and C from Agrobacterium rhizogenes. Effects on morphology, development, and hormone metabolism. Michael T, et al. **Methods Mol Biol** 1995;44:207–22

Xenopus oocytes as a heterologous expression system. Theodoulou FL, et al. **Methods Mol Biol** 1995;49:317–40 (48 ref.)

Heterologous expression in yeast. Trueman LJ. **Methods Mol Biol** 1995;49:341–54 (18 ref.)

Rampant horizontal transfer and duplication of rubisco genes in eubacteria and plastids. Delwiche CF, et al. **Mol Biol Evol** 1996 Jul;13(6):873–82

Phylogenetic analysis of the 90 kD heat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species. Gupta RS. **Mol Biol Evol** 1995 Nov;12(6):1063–73

Intra- and interspecific variation of the alcohol dehydrogenase locus region in wild plants Arabis gemmifera and Arabidopsis thaliana [letter] Miyashita NT, et al. **Mol Biol Evol** 1996 Feb;13(2):433–6

Molecular analysis of the Arabidopsis pattern formation of gene GNOM: gene structure and intragenic complementation. Busch M, et al. **Mol Gen Genet** 1996 Apr 10;250(6):681–91

The promoter of the gene Itr1 from barley confers a different tissue specificity in transgenic tobacco. Diaz I, et al. **Mol Gen Genet** 1995 Sep 20;248(5):592–8

The transcriptional regulator CPRF1: expression analysis and gene structure. Feldbrügge M, et al. **Mol Gen Genet** 1996 Jul 26;251(6):619–27

Characterisation of a new allele of pale cress and its role in greening in Arabidopsis thaliana. Grevelding C, et al. **Mol Gen Genet** 1996 Jul 19;251(5):532–41

Zeon–1, a member of a new maize retrotransposon family. Hu W, et al. **Mol Gen Genet** 1995 Aug 30;248(4):471–80

A new family of DNA binding proteins includes putative transcriptional regulators of the Antirrhinum majus floral meristem identity gene SQUAMOSA. Klein J, et al. **Mol Gen Genet** 1996 Jan 15;250(1):7–16

Horizontal gene transfer: regulated expression of a tobacco homologue of the Agrobacterium rhizogenes rolC gene. Meyer AD, et al. **Mol Gen Genet** 1995 Nov 27; 249(3):265–73

Developmental and tissue–specific regulation of the gene for the wheat basic/leucine zipper protein HBP–1a(17) in transgenic Arabidopsis plants. Mikami K, et al. **Mol Gen Genet** 1995 Sep 20;248(5):573–82

Production of waxy (amylose–free) wheats. Nakamura T, et al. **Mol Gen Genet** 1995 Aug 21;248(3):253–9

Detection of point mutations in chloroplast genes of Antirrhinum majus L. I. Identification of a point mutation in the psaB gene of a photosystem I plastome mutant. Schaffner C, et al. **Mol Gen Genet** 1995 Dec 15; 249(5):533–44

Hordein promoter methylation and transcriptional activity in wild–type and mutant barley endosperm. Sørensen MB, et al. **Mol Gen Genet** 1996 Apr 10;250(6):750–60

Identification and isolation of the FEEBLY gene from tomato by transposon tagging. van der Biezen EA, et al. **Mol Gen Genet** 1996 Jun 12;251(3):267–80

Molecular cloning and functional characterization of a cDNA encoding nucleosome assembly protein 1 (NAP–1) from soybean. Yoon HW, et al. **Mol Gen Genet** 1995 Dec 15;249(5):465–73

Cloning and characterization of a bradyzoite–specifically expressed gene (hsp30/bag1) of Toxoplasma gondii, related to genes encoding small heat–shock proteins of plants. Bohne W, et al. **Mol Microbiol** 1995 Jun;16(6):1221–30

A phylogenetic analysis of monocotyledons based on the chloroplast gene rps4, using parsimony and a new numerical phenetics method. Nadot S, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):257–82

Molecular characterization of the Pseudomonas syringae pv. pisi plasmid–borne avirulence gene avrPpiB which matches the R3 resistance locus in pea. Cournoyer B, et al. **Mol Plant Microbe Interact** 1995 Sep–Oct;8(5):700–8

Use of a subtractive hybridization approach to identify new Medicago truncatula genes induced during root nodule development. Gamas P, et al. **Mol Plant Microbe Interact** 1996 May;9(4):233–42

Isolation and expression of a host response gene family encoding thaumatin–like proteins in incompatible oat–stem rust fungus interactions. Lin KC, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):511–22

Four Arabidopsis RPP loci controlling resistance to the Noco2 isolate of Peronospora parasitica map to regions known to contain other RPP recognition specificities. Reignault P, et al. **Mol Plant Microbe Interact** 1996 Aug; 9(6):464–73

Infections with various types of organisms stimulate transcription from a short promoter fragment of the potato gst1 gene. Strittmatter G, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):68–73

Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS–M. Plass C, et al. **Nat Genet** 1996 Sep;14(1):106–9

Control of inflorescence architecture in Antirrhinum. Bradley D, et al. **Nature** 1996 Feb 29;379(6568):791–7

A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis. Long JA, et al. **Nature** 1996 Jan 4;379(6560):66–9

A gene triggering flower formation in Arabidopsis [see comments] Mandel MA, et al. **Nature** 1995 Oct 12; 377(6549):522–4. Comment in: Nature 1995 Oct 12;377(6549):482.

Role of SUPERMAN in maintaining Arabidopsis floral whorl boundaries. Sakai H, et al. **Nature** 1995 Nov 9; 378(6553):199–203

Fully edited and partially edited nad9 transcripts differ in size and both are associated with polysomes in potato mitochondria. Lu B, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1369–74

Conserved expression of the Arabidopsis ACT1 and ACT 3 actin subclass in organ primordia and mature pollen. An YQ, et al. **Plant Cell** 1996 Jan;8(1):15–30

An anther–specific gene encoded by an S locus haplotype of Brassica produces complementary and differentially regulated transcripts. Boyes DC, et al. **Plant Cell** 1995 Aug; 7(8):1283–94

Sink limitation induces the expression of multiple soybean vegetative lipoxygenase mRNAs while the endogenous jasmonic acid level remains low. Bunker TW, et al. **Plant Cell** 1995 Aug;7(8):1319–31

Alleles of the maize P gene with distinct tissue specificities encode Myb–homologous proteins with C–terminal replacements. Chopra S, et al. **Plant Cell** 1996 Jul; 8(7):1149–58

AINTEGUMENTA, an APETALA2–like gene of Arabidopsis with pleiotropic roles in ovule development and floral organ growth. Elliott RC, et al. **Plant Cell** 1996 Feb;8(2):155–68

AGL15, a MADS domain protein expressed in developing embryos. Heck GR, et al. **Plant Cell** 1995 Aug;7(8):1271–82

Parallels between UNUSUAL FLORAL ORGANS and FIMBRIATA, genes controlling flower development in Arabidopsis and Antirrhinum. Ingram GC, et al. **Plant Cell** 1995 Sep;7(9):1501–10

The AINTEGUMENTA gene of Arabidopsis required for ovule and female gametophyte development is related to the floral homeotic gene APETALA2. Klucher KM, et al. **Plant Cell** 1996 Feb;8(2):137–53

The L6 gene for flax rust resistance is related to the Arabidopsis bacterial resistance gene RPS2 and the tobacco viral resistance gene N. Lawrence GJ, et al. **Plant Cell** 1995 Aug;7(8):1195–206

A maize gene encoding an NADPH binding enzyme highly homologous to isoflavone reductases is activated in response to sulfur starvation. Petrucco S, et al. **Plant Cell** 1996 Jan;8(1):69–80

Genetic separation of third and fourth whorl functions of AGAMOUS. Sieburth LE, et al. **Plant Cell** 1995 Aug; 7(8):1249–58

Overlap of Viviparous1 (VP1) and abscisic acid response elements in the Em promoter: G–box elements are sufficient but not necessary for VP1 transactivation. Vasil V, et al. **Plant Cell** 1995 Sep;7(9):1511–8

The maize Dwarf3 gene encodes a cytochrome P450–mediated early step in Gibberellin biosynthesis. Winkler RG, et al. **Plant Cell** 1995 Aug;7(8):1307–17

A family of transcripts encoding water channel proteins: tissue–specific expression in the common ice plant. Yamada S, et al. **Plant Cell** 1995 Aug;7(8):1129–42

The 5' flanking sequences of two S alleles in Lycopersicon peruvianum are highly heterologous but contain short blocks of homologous sequences. Chung IK, et al. **Plant Cell Physiol** 1995 Dec;36(8):1621–7

Identification of the chlB gene and the gene product essential for the light–independent chlorophyll biosynthesis in the cyanobacterium Plectonema boryanum. Fujita Y, et al. **Plant Cell Physiol** 1996 Apr;37(3):313–23

Specific expression of the chloroplast gene for RNA polymerase (rpoB) at an early stage of leaf development in rice. Inada H, et al. **Plant Cell Physiol** 1996 Mar; 37(2):229–32

Touch–inducible genes for calmodulin and a calmodulin–related protein are located in tandem on a chromosome of Arabidopsis thaliana. Ito T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1369–73

The sequence and expression of the gamma–VPE gene, one member of a family of three genes for vacuolar processing enzymes in Arabidopsis thaliana. Kinoshita T, et al. **Plant Cell Physiol** 1995 Dec;36(8):1555–62

Identification of the product of ndhA gene as a thylakoid protein synthesized in response to photooxidative treatment. Martín M, et al. **Plant Cell Physiol** 1996 Apr; 37(3):293–8

Potential transcription regulatory sequences in a promoter region of the wheat basic/leucine zipper protein HBP–1b(c38) gene. Mikami K, et al. **Plant Cell Physiol** 1995 Oct;36(7):1375–9

The seed–specific transcription factor VP1 (OSVP1) is expressed in rice suspension–cultured cells. Nakagawa H, et al. **Plant Cell Physiol** 1996 Apr;37(3):355–62

Structure of a gene subunit 9 of NADH dehydrogenase (nad9) in rice mitochondria and RNA editing of its transcript. Nishiwaki S, et al. **Plant Cell Physiol** 1995 Sep; 36(6):1135–8

Ethylene–induced gene expression of osmotin–like protein, a neutral isoform of tobacco PR–5, is mediated by the AGCCGCC cis–sequence. Sato F, et al. **Plant Cell Physiol** 1996 Apr;37(3):249–55

Molecular cloning of members of the S–multigene family in self–incompatible Brassica campestris L. Suzuki G, et al. **Plant Cell Physiol** 1995 Oct;36(7):1273–80

Cytokinin induces a rapid decrease in the levels of mRNAs for catalase, 3–hydroxy–3–methylglutaryl CoA reductase, lectin and other unidentified proteins in etiolated cotyledons of cucumber. Toyama T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1349–59

Isolation and characterization of two cDNAs encoding 4–coumarate:CoA ligase in Lithospermum cell cultures. Yazaki K, et al. **Plant Cell Physiol** 1995 Oct;36(7):1319–29

A recombinant rice 16.9–kDa heat shock protein can provide thermoprotection in vitro. Yeh CH, et al. **Plant Cell Physiol** 1995 Oct;36(7):1341–8

Mutations throughout an Arabidopsis blue–light photoreceptor impair blue–light–responsive anthocyanin accumulation and inhibition of hypocotyl elongation. Ahmad M, et al. **Plant J** 1995 Nov;8(5):653–8

Expression of the PmSUC1 sucrose carrier gene from Plantago major L. is induced during seed development. Gahrtz M, et al. **Plant J** 1996 Jan;9(1):93–100

A characterization of the MADS–box gene family in maize. Mena M, et al. **Plant J** 1995 Dec;8(6):845–54

Expression of the early nodulin, ENOD40, in soybean roots in response to various lipo–chitin signal molecules. Minami E, et al. **Plant J** 1996 Jul;10(1):23–32

Molybdenum co–factor biosynthesis: the Arabidopsis thaliana cDNA cnx1 encodes a multifunctional two–domain protein homologous to a mammalian neuroprotein, the insect protein Cinnamon and three Escherichia coli proteins. Stallmeyer B, et al. **Plant J** 1995 Nov;8(5):751–62

Transposon tagging of the maize Glossy2 locus with the transposable element En/Spm. Tacke E, et al. **Plant J** 1995 Dec;8(6):907–17

A molecular study of root–knot nematode–induced feeding sites. Van der Eycken W, et al. **Plant J** 1996 Jan;9(1):45–54

The Tokumasu radish mitochondrial genome contains two complete atp9 reading frames. Albaum M, et al. **Plant Mol Biol** 1995 Oct;29(1):179–85

Isolation and characterization of the Adh2 5' region from Petunia hybrida. Atkinson EF, et al. **Plant Mol Biol** 1996 Jan;30(2):367–71

Organization and expression of the gene coding for the potassium transport system AKT1 of Arabidopsis thaliana. Basset M, et al. **Plant Mol Biol** 1995 Dec;29(5):947–58

A vicilin–like seed protein of cycads: similarity to sucrose–binding proteins. Braun H, et al. **Plant Mol Biol** 1996 Apr;31(1):35–44

The PR–1a promoter contains a number of elements that bind GT–1–like nuclear factors with different affinity. Buchel AS, et al. **Plant Mol Biol** 1996 Feb;30(3):493–504

Isolation of cDNA clones of genes induced upon transfer of Chlamydomonas reinhardtii cells to low CO2. Burow MD, et al. **Plant Mol Biol** 1996 May;31(2):443–8

An unusual group 2 LEA gene family in citrus responsive to low temperature. Cai Q, et al. **Plant Mol Biol** 1995 Oct; 29(1):11–23

Identification of tissue–specific, dehydration–responsive elements in the Trg–31 promoter. Chaudhary S, et al. **Plant Mol Biol** 1996 Mar;30(6):1247–57

A gibberellin–stimulated ubiquitin–conjugating enzyme gene is involved in alpha–amylase gene expression in rice aleurone. Chen X, et al. **Plant Mol Biol** 1995 Nov; 29(4):787–95

Expression of DC8 is associated with, but not dependent on embryogenesis. Cheng JC, et al. **Plant Mol Biol** 1996 Apr; 31(1):127–41

Isolation of a root–specific cDNA encoding a ns–LTP–like protein from the roots of bean (Phaseolus vulgaris L.) seedlings. Choi DW, et al. **Plant Mol Biol** 1996 Mar; 30(5):1059–66

Characterization of a cDNA encoding a proline–rich 14 kDa protein in developing cortical cells of the roots of bean (Phaseolus vulgaris) seedlings. Choi DW, et al. **Plant Mol Biol** 1996 Mar;30(5):973–82

Characterization of hsr201 and hsr515, two tobacco genes preferentially expressed during the hypersensitive reaction provoked by phytopathogenic bacteria. Czernic P, et al. **Plant Mol Biol** 1996 May;31(2):255–65

A low–temperature–responsive gene from barley encodes a protein with single–stranded nucleic acid–binding activity which is phosphorylated in vitro. Dunn MA, et al. **Plant Mol Biol** 1996 Mar;30(5):947–59

A novel phloem–specific gene is expressed preferentially in aerial portions of Vicia faba. Foley RC, et al. **Plant Mol Biol** 1996 Feb;30(4):687–95

Editing of the chloroplast ndhB encoded transcript shows divergence between closely related members of the grass family (Poaceae). Freyer R, et al. **Plant Mol Biol** 1995 Nov; 29(4):679–84

Differential regulation of two ABA–inducible genes from Craterostigma plantagineum in transgenic Arabidopsis plants. Furini A, et al. **Plant Mol Biol** 1996 Jan;30(2):343–9

Characterization of a maize ribosomal P2 protein cDNA and phylogenetic analysis of the P1/P2 family of ribosomal proteins. Goddemeier ML, et al. **Plant Mol Biol** 1996 Feb; 30(3):655–8

Isolation of an Arabidopsis homologue of the maize homeobox Knotted–1 gene. Granger CL, et al. **Plant Mol Biol** 1996 May;31(2):373–8

cDNA encoding a wheat (Triticum aestivum cv. Chinese spring) glycine–rich RNA–binding protein. Guiltinan MJ, et al. **Plant Mol Biol** 1996 Mar;30(6):1301–6

Isolation of a novel RNA–binding protein and its association with a large ribonucleoprotein particle present in the nucleoplasm of tobacco cells. Hanano S, et al. **Plant Mol Biol** 1996 Apr;31(1):57–68

Leaf senescence in Brassica napus: expression of genes encoding pathogenesis–related proteins. Hanfrey C, et al.

Plant Mol Biol 1996 Feb;30(3):597–609

Gibberellin–repressible gene expression in the barley aleurone layer. Heck GR, et al. **Plant Mol Biol** 1996 Feb; 30(3):611–23

A simplified procedure for the subtractive cDNA cloning of photoassimilate–responding genes: isolation of cDNAs encoding a new class of pathogenesis–related proteins. Herbers K, et al. **Plant Mol Biol** 1995 Dec;29(5):1027–38

Isolation and characterization of two cDNA clones for mRNAs that are abundantly expressed in immature anthers of rice (Oryza sativa L.). Hihara Y, et al. **Plant Mol Biol** 1996 Mar;30(6):1181–93

Transcripts of the two NADPH protochlorophyllide oxidereductase genes PorA and PorB are differentially degraded in etiolated barley seedlings. Holtorf H, et al. **Plant Mol Biol** 1996 May;31(2):387–92

The CMS–associated 16 kDa protein encoded by orfH522 in the PET1 cytoplasm is also present in other male–sterile cytoplasms of sunflower. Horn R, et al. **Plant Mol Biol** 1996 Feb;30(3):523–38

Unusual sequences of group 3 LEA mRNA inducible by maturation or drying in soybean seeds. Hsing YC, et al. **Plant Mol Biol** 1995 Nov;29(4):863–8

Structural characterization of genes corresponding to cotton fiber mRNA, E6: reduced E6 protein in transgenic plants by antisense gene. John ME. **Plant Mol Biol** 1996 Jan; 30(2):297–306

A salt– and dehydration–inducible pea gene, Cyp15a, encodes a cell–wall protein with sequence similarity to cysteine proteases. Jones JT, et al. **Plant Mol Biol** 1995 Sep; 28(6):1055–65

Developmental expression of a turgor–responsive gene that encodes an intrinsic membrane protein. Jones JT, et al. **Plant Mol Biol** 1995 Sep;28(6):983–96

Application of modified differential display technique for cloning and sequencing of the 3' region from three putative members of wheat HSP70 gene family. Joshi CP, et al. **Plant Mol Biol** 1996 Feb;30(3):641–6

Phenotypic alterations of petal and sepal by ectopic expression of a rice MADS box gene in tobacco. Kang HG, et al. **Plant Mol Biol** 1995 Oct;29(1):1–10

Molecular cloning of a cDNA encoding diacylglycerol kinase (DGK) in Arabidopsis thaliana. Katagiri T, et al. **Plant Mol Biol** 1996 Feb;30(3):647–53

cDNA cloning and gene expression of ascorbate oxidase in tobacco. Kato N, et al. **Plant Mol Biol** 1996 Feb;30(4):833–7

Characterization of two class II chitinase genes from peanut and expression studies in transgenic tobacco plants. Kellmann JW, et al. **Plant Mol Biol** 1996 Jan;30(2):351–8

Two new oleosin isoforms with altered expression patterns in seeds of the Arabidopsis mutant fus3. Kirik V, et al. **Plant Mol Biol** 1996 May;31(2):413–7

The pea early nodulin gene PsENOD7 maps in the region of linkage group I containing sym2 and leghaemoglobin. Kozik A, et al. **Plant Mol Biol** 1996 Apr;31(1):149–56

A second and differentially expressed glutamyl–tRNA reductase gene from Arabidopsis thaliana. Kumar AM, et al. **Plant Mol Biol** 1996 Feb;30(3):419–26

The promoter of the Vicia faba L. VfENOD–GRP3 gene encoding a glycine–rich early nodulin mediates a predominant gene expression in the interzone II–III region of transgenic Vicia hirsuta root nodules. Küster H, et al. **Plant Mol Biol** 1995 Nov;29(4):759–72

Characterization of a strawberry gene for auxin–binding protein, and its expression in insect cells. Lazarus CM, et al. **Plant Mol Biol** 1996 May;31(2):267–77

Molecular cloning, characterization and expression analysis of isoforms encoding tonoplast–bound proton–translocating inorganic pyrophosphatase in tobacco. Lerchl J, et al. **Plant Mol Biol** 1995 Nov;29(4):833–40

Cloning and characterization of differentially expressed genes in imbibed dormant and afterripened Avena fatua embryos. Li B, et al. **Plant Mol Biol** 1995 Nov;29(4):823–31

Characterization of a cDNA encoding cysteine proteinase inhibitor from Chinese cabbage (Brassica campestris L. ssp. pekinensis) flower buds. Lim CO, et al. **Plant Mol Biol** 1996 Jan;30(2):373–9

Fine structure and function of the osmotin gene promoter. Liu D, et al. **Plant Mol Biol** 1995 Dec;29(5):1015–26

Elongation factor 1 alpha genes of the red alga Porphyra purpurea include a novel, developmentally specialized variant. Liu QY, et al. **Plant Mol Biol** 1996 Apr;31(1):77–85

Microsequencing and cDNA cloning of the Calvin cycle/OPPP enzyme ribose–5–phosphate isomerase (EC 5.3.1.6) from spinach chloroplasts. Martin W, et al. **Plant Mol Biol** 1996 Feb;30(4):795–805

Molecular characterization of the gene coding for GPRP, a class of proteins rich in glycine and proline interacting with membranes in Arabidopsis thaliana. Marty I, et al. **Plant Mol Biol** 1996 Feb;30(3):625–36

A cDNA from pea petals with sequence similarity to pollen allergen, cytokinin–induced and genetic tumour–specific genes: identification of a new family of related sequences. Michael AJ. **Plant Mol Biol** 1996 Jan;30(1):219–24

Isolation by PCR of a cDNA clone from pea petals with similarity to petunia and wheat zinc finger proteins. Michael AJ, et al. **Plant Mol Biol** 1996 Mar;30(5):1051–8

A senescence–associated gene of Arabidopsis thaliana is distinctively regulated during natural and artificially induced leaf senescence. Oh SA, et al. **Plant Mol Biol** 1996 Feb;30(4):739–54

Isolation and characterization of a microspore–specific gene from tobacco. Oldenhof MT, et al. **Plant Mol Biol** 1996 May;31(2):213–25

A novel wound–inducible extensin gene is expressed early in newly isolated protoplasts of Nicotiana sylvestris. Parmentier Y, et al. **Plant Mol Biol** 1995 Oct;29(2):279–92

Cloning and characterization of the cDNA for lycopene beta–cyclase from tomato reveals decrease in its expression during fruit ripening. Pecker I, et al. **Plant Mol Biol** 1996 Feb;30(4):807–19

Characterization of a family of genes encoding a fruit–specific wound–stimulated protein of bell pepper (Capsicum annuum): identification of a new family of transposable elements. Pozueta–Romero J, et al. **Plant Mol Biol** 1995 Sep;28(6):1011–25

A recombinant wheat serpin with inhibitory activity. Rasmussen SK, et al. **Plant Mol Biol** 1996 Feb;30(3):673–7

A wound–inducible gene from Salix viminalis coding for a trypsin inhibitor. Saarikoski P, et al. **Plant Mol Biol** 1996 Jun;31(3):465–78

Characterization of a plastid–specific HSP90 homologue: identification of a cDNA sequence, phylogenetic descendence and analysis of its mRNA and protein expression. Schmitz G, et al. **Plant Mol Biol** 1996 Feb; 30(3):479–92

Evidence for the expression of the triosephosphate translocator gene in green and non–green tissue of tomato and potato. Schünemann D, et al. **Plant Mol Biol** 1996 Apr;31(1):101–11

Isolation of a novel Arabidopsis ozone–induced cDNA by differential display. Sharma YK, et al. **Plant Mol Biol** 1995 Oct;29(1):91–8

A gene for Brassica napus extensin is differentially expressed on wounding. Shirsat AH, et al. **Plant Mol Biol** 1996 Mar; 30(6):1291–300

Characterisation of HEVER, a novel stress–induced gene from Hevea brasiliensis. Sivasubramaniam S, et al. **Plant Mol Biol** 1995 Oct;29(1):173–8

Evolution of the Group 1 late embryogenesis abundant (Lea) genes: analysis of the Lea B19 gene family in barley. Stacy RA, et al. **Plant Mol Biol** 1995 Sep;28(6):1039–54

Expression of nodulin genes in plant–determined ineffective nodules of pea. Suganuma N, et al. **Plant Mol Biol** 1995 Sep;28(6):1027–38

Isolation, characterization and expression of cDNA clones encoding a mitochondrial malate translocator from Panicum miliaceum L. Taniguchi M, et al. **Plant Mol Biol** 1996 Jan;30(1):51–64

Expression and in vitro targeting of a sunflower oleosin. Thoyts PJ, et al. **Plant Mol Biol** 1995 Oct;29(2):403–10

Analysis of Arabidopsis cDNA that shows homology to the tomato E8 cDNA. Trentmann SM, et al. **Plant Mol Biol** 1995 Oct;29(1):161–6

Isolation and characterization of an auxin–inducible glutathione S–transferase gene of Arabidopsis thaliana. van der Kop DA, et al. **Plant Mol Biol** 1996 Feb;30(4):839–44

Molecular analysis of a pistil–specific gene expressed in the stigma and cortex of Solanum tuberosum. Van Eldik GJ, et al. **Plant Mol Biol** 1996 Jan;30(1):171–6

A 200 bp region of the pea ENOD12 promoter is sufficient for nodule–specific and nod factor induced expression. Vijn I, et al. **Plant Mol Biol** 1995 Sep;28(6):1103–10

VsENOD5, VsENOD12 and VsENOD40 expression during Rhizobium–induced nodule formation on Vicia sativa roots. Vijn I, et al. **Plant Mol Biol** 1995 Sep;28(6):1111–9

Molecular analysis of two functional homologues of the S3 allele of the Papaver rhoeas self–incompatibility gene isolated from different populations. Walker EA, et al. **Plant Mol Biol** 1996 Mar;30(5):983–94

A novel kinesin–like protein with a calmodulin–binding domain. Wang W, et al. **Plant Mol Biol** 1996 Apr; 31(1):87–100

Structure and organization of two closely related low–temperature–induced dhn/lea/rab–like genes in Arabidopsis thaliana L. Heynh. Welin BV, et al. **Plant Mol Biol** 1995 Oct;29(2):391–5

Molecular cloning and expression of mRNAs encoding H1 histone and an H1 histone–like sequences in root tips of pea (Psium sativum L.). Woo HH, et al. **Plant Mol Biol** 1995 Sep;28(6):1143–7

The mRNA for an ETR1 homologue in tomato is constitutively expressed in vegetative and reproductive tissues. Zhou D, et al. **Plant Mol Biol** 1996 Mar; 30(6):1331–8

Cloning of a cDNA encoding the 21.2 kDa oleosin isoform from Arabidopsis thaliana and a study of its expression in a mutant defective in diacylglycerol acyltransferase activity. Zou J, et al. **Plant Mol Biol** 1996 May;31(2):429–33

Multiple genes, tissue specificity, and expression–dependent modulationcontribute to the functional diversity of potassium channels in Arabidopsis thaliana. Cao Y, et al. **Plant Physiol** 1995 Nov;109(3):1093–106

An Arabidopsis thaliana thionin gene is inducible via a signal transduction pathway different from that for pathogenesis–related proteins. Epple P, et al. **Plant Physiol** 1995 Nov;109(3):813–20

A cherry protein and its gene, abundantly expressed in ripening fruit, have been identified as thaumatin–like. Fils–Lycaon BR, et al. **Plant Physiol** 1996 May; 111(1):269–73

Tissue–specific expression of the gene for a putative plasma membrane H(+)–ATPase in a seagrass. Fukuhara T, et al. **Plant Physiol** 1996 Jan;110(1):35–42

Developmental and growth temperature regulation of two different microsomal omega–6 desaturase genes in soybeans. Heppard EP, et al. **Plant Physiol** 1996 Jan; 110(1):311–9

Genetic modification of respiratory capacity in potato. Hiser C, et al. **Plant Physiol** 1996 Jan;110(1):277–86

Transgenic analysis of a hybrid poplar wound–inducible promoter reveals developmental patterns of expression similar to that of storage protein genes. Hollick JB, et al. **Plant Physiol** 1995 Sep;109(1):73–85

Identification of a new pea gene, PsNlec1, encoding a lectin–like glycoprotein isolated from the symbiosomes of root nodules. Kardailsky IV, et al. **Plant Physiol** 1996 May; 111(1):49–60

Interaction of a potential vacuolar targeting receptor with amino– and carboxyl–terminal targeting determinants. Kirsch T, et al. **Plant Physiol** 1996 Jun;111(2):469–74

A multiple–stimuli–responsive as–1–related element of parA gene confers responsiveness to cadmium but not to copper. Kusaba M, et al. **Plant Physiol** 1996 Aug;111(4):1161–7

Molecular analysis of a new member of the opium poppy tyrosine/3,4–dihydroxyphenylalanine decarboxylase gene family. Maldonado–Mendoza IE, et al. **Plant Physiol** 1996 Jan;110(1):43–9

The broad bean gene VfNOD32 encodes a nodulin with sequence similarities to chitinases that is homologous to (alpha/beta)8–barrel–type seed proteins. Perlick AM, et al. **Plant Physiol** 1996 Jan;110(1):147–54

Cold–shock regulation of the Arabidopsis TCH genes and the effects of modulating intracellular calcium levels. Polisensky DH, et al. **Plant Physiol** 1996 Aug;111(4):1271–9

Cloning of a second Arabidopsis peptide transport gene. Song W, et al. **Plant Physiol** 1996 Jan;110(1):171–8

A thiol protease and an anionic peroxidase are induced by lowering cytokinins during callus growth in Petunia. Tournaire C, et al. **Plant Physiol** 1996 May;111(1):159–68

Structural requirements of oleosin domains for subcellular targeting to the oil body. van Rooijen GJ, et al. **Plant Physiol** 1995 Dec;109(4):1353–61

Stress activation of a bean hydroxyproline–rich glycoprotein promoter is superimposed on a pattern of tissue–specific developmental expression. Wycoff KL, et al. **Plant Physiol** 1995 Sep;109(1):41–52

Mass spectrometric amino acid sequencing of a mixture of seed storage proteins (napin) from Brassica napus, products of a multigene family. Gehrig PM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3647–52

Mutagenesis of the potato ADPglucose pyrophosphorylase and characterization of an allosteric mutant defective in 3–phosphoglycerate activation. Greene TW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1509–13

CAX1, an H+/Ca2+ antiporter from Arabidopsis. Hirschi KD, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8782–6

Molecular cloning and sequence analysis of expansins—a highly conserved, multigene family of proteins that mediate cell wall extension in plants. Shcherban TY, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9245–9

The PR5K receptor protein kinase from Arabidopsis thaliana is structurally related to a family of plant defense proteins. Wang X, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2598–602

The N gene of tobacco confers resistance to tobacco mosaic virus in transgenic tomato. Whitham S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8776–81

Arabidopsis AUX1 gene: a permease–like regulator of root gravitropism. Bennett MJ, et al. **Science** 1996 Aug 16; 273(5277):948–50

Ethylene insensitivity conferred by Arabidopsis ERS gene. Hua J, et al. **Science** 1995 Sep 22;269(5231):1712–4

A role for brassinosteroids in light–dependent development of Arabidopsis [see comments] Li J, et al. **Science** 1996 Apr 19;272(5260):398–401. Comment in: Science 1996 Apr 19;272(5260):370–1.

Allelic diversity and gene genealogy at the self–incompatibility locus in the Solanaceae. Richman AD, et al. **Science** 1996 Aug 30;273(5279):1212–6

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370–1 (7 ref.). Comment on: Science 1996 Apr 19;272(5260):398–401.

A receptor kinase–like protein encoded by the rice disease resistance gene, Xa21 [see comments] Song WY, et al. **Science** 1995 Dec 15;270(5243):1804–6. Comment in: Science 1995 Dec 15;270(5243):1772–3. Comment in: Science 1995 Dec 15;270(5243):1774.

Modification of phytohormone response by a peptide encoded by ENOD40 of legumes and a nonlegume. van de Sande K, et al. **Science** 1996 Jul 19;273(5273):370–3

An ethylene–inducible component of signal transduction encoded by never–ripe [see comments] Wilkinson JQ, et al. **Science** 1995 Dec 15;270(5243):1807–9. Comment in: Science 1995 Dec 15;270(5243):1774.

Accumulation of a sulphur–rich seed albumin from sunflower in the leaves of transgenic subterranean clover (Trifolium subterraneum L.). Khan MR, et al. **Transgenic Res** 1996 May;5(3):179–85

Intercellular induction of homeotic gene expression in flower development. Becraft PW. **Trends Genet** 1995 Jul; 11(7):253–5

Cf9 and Avr9, two major players in the gene–for–gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

PLANT PROTEINS

IMMUNOLOGY

Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. Baur X, et al. **Allergy** 1995 Jul;50(7):604–9

In vitro release of soluble CD23 by human lymphocytes in ragweed-sensitive versus nonatopic patients following stimulation with ragweed antigen E. Batterman J, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):359–62

Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Dockhorn RJ, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):204–8

Characterization of latex and chestnut antigens by immunoblotting. Moneo I, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):440–4

Coeliac disease. Pathogenesis and clinical aspects. Friis SU. **APMIS Suppl** 1996;61:1–48

Identification of major rye secalins as coeliac immunoreactive proteins. Rocher A, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):13–22

Prohevein from the rubber tree (Hevea brasiliensis) is a major latex allergen. Alenius H, et al. **Clin Exp Allergy** 1995 Jul; 25(7):659–65

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Menz G, et al. **Clin Exp Allergy** 1996 Jan;26(1):50–60

The allergenic properties of fresh and preserved Hevea brasiliensis latex protein preparations. Kekwick R, et al. **Clin Exp Immunol** 1996 May;104(2):337–42

Expression in Escherichia coli of Sin a 1, the major allergen from mustard. González De La Peña MA, et al. **Eur J Biochem** 1996 May 1;237(3):827–32

Expression of Zm13, a pollen specific maize protein, in Escherichia coli reveals IgE-binding capacity and allergenic potential. Heiss S, et al. **FEBS Lett** 1996 Mar 4;381(3):217–21

Production and characterization of monoclonal antibodies against the ribosome-inactivating protein PAP from Phytolacca americana. Desvoyes B, et al. **Hybridoma** 1995 Dec;14(6):571–5

Birch pollen allergens fail to evoke IgG1 responses in non-atopic individuals. Härfast B, et al. **Immunol Lett** 1995 Mar;45(3):223–4

Cocos nucifera pollen inducing allergy: sensitivity test and immunological study. Karmakar PR, et al. **Indian J Exp Biol** 1995 Jul;33(7):489–96

Shared IgE-binding sites among separated components of natural rubber latex. Aamir R, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):48–54

Purification and characterization of the major allergen from apple and its allergenic cross-reactivity with Bet v 1. Fahlbusch B, et al. **Int Arch Allergy Immunol** 1995 Oct; 108(2):119–26

Heterogeneity of pollen proteins within individual Betula pendula trees. Hjelmroos M, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):368–76

IgA and IgG binding components of wheat, rye, barley and oats recognized by immunoblotting analysis with sera from adult atopic dermatitis patients. Varjonen E, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):55–63

Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. Blaher B, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):124–32

Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. Ferreira FD, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):95–103

Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. Ikagawa S, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):53–64

T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens. Schenk S, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):986–96

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99–106

Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. Steinberger P, et al. **J Biol Chem** 1996 May 3; 271(18):10967–72

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. Ferreira F, et al. **J Exp Med** 1996 Feb 1;183(2):599–609

The main IgE-binding epitope of a major latex allergen, prohevein, is present in its N-terminal 43-amino acid fragment, hevein. Alenius H, et al. **J Immunol** 1996 Feb 15;156(4):1618–25

T cell epitope mapping of ragweed pollen allergen Ambrosia artemisiifolia (Amb a 5) and Ambrosia trifida (Amb t 5) and the role of free sulfhydryl groups in T cell recognition. Zhu X, et al. **J Immunol** 1995 Nov 15;155(10):5064–73

Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50

Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group 1 grass pollen isoallergens. Laffer S, et al. **Mol Immunol** 1996 Mar-Apr;33(4–5):417–26

Allergies to transgenic foods—questions of policy [editorial; comment] Nestle M. **N Engl J Med** 1996 Mar 14; 334(11):726–8. Comment on: N Engl J Med 1996 Mar 14;334(11):688–92.

ISOLATION & PURIFICATION

Isolation and characterization of the 18-kDa major apple allergen and comparison with the major birch pollen allergen (Bet v I). Vieths S, et al. **Allergy** 1995 May; 50(5):421–30

Isolation and characterization of a 30 kDa protein with antifungal activity from leaves of Engelmannia pinnatifida. Huynh QK, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):723–7

Inducible UDP-glucose dehydrogenase from French bean (Phaseolus vulgaris L.) locates to vascular tissue and has alcohol dehydrogenase activity. Robertson D, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):311–7

Simultaneous existence of two types of ribosome-inactivating proteins in the seeds of Cinnamonum camphora—characterization of the enzymatic activities of these cytotoxic proteins. Ling J, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):15–22

Purification and sequencing of multiple forms of Brassica napus seed napin large chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):34–43

Purification and sequencing of multiple forms of Brassica napus seed napin small chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):23–33

Identification of major rye secalins as coeliac immunoreactive proteins. Rocher A, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):13–22

The multiplicity of enzymatic DNA reduction: a new purification procedure for a DHA reducing protein from potato tubers. De Tullio MC, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun;71(5–6):163–70

Purification and properties of storage proteins (vicilins) from cowpea (Vigna unguiculata) seeds which are susceptible or resistant to the bruchid beetle Callosobruchus maculatus. Macedo ML, et al. **Braz J Med Biol Res** 1995 Feb; 28(2):183–90

Two-dimensional electrophoresis of acidic proteins isolated from ozone-stressed Norway spruce needles (Picea abies L. Karst): separation method and image processing. Davidsen NB. **Electrophoresis** 1995 Jul;16(7):1305–11

Two-dimensional electrophoresis of thylakoid protein patterns in two wheat cultivars with different sensitivity to sulfur dioxide. Ranieri A, et al. **Electrophoresis** 1995 Jul; 16(7):1301–4

Purification, characterization and partial amino acid sequencing of two new aspartic proteinases from fresh flowers of Cynara cardunculus L. Veríssimo P, et al. **Eur J Biochem** 1996 Feb 1;235(3):762–8

Molecular cloning and functional expression in E. coli of a novel plant enzyme mediating zeta-carotene desaturation. Albrecht M, et al. **FEBS Lett** 1995 Sep 25;372(2–3):199–202

Rapid purification of malate synthase from cotyledons of Brassica napus L. Hoppe A, et al. **FEBS Lett** 1995 Oct 30;374(2):225–7

Molecular chaperones are present in the thylakoid lumen of pea chloroplasts. Schlicher T, et al. **FEBS Lett** 1996 Feb 5;379(3):302–4

Purification and partial characterization of acyl carrier proteins from developing oil seeds of pisa (Actinodaphne hookeri) and ground nut (Arachis hypogaea). Sreenivas A, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):137–46

Shared IgE-binding sites among separated components of natural rubber latex. Aamir R, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):48–54

Identification and characterization of the major allergens of velvet grass (Holcus lanatus), Hol l 1 and Hol l 5. Schramm G, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):354–63

Characterization of Phl p 4, a major timothy grass (Phleum pratense) pollen allergen. Fischer S, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):189–98

Characterization of the allergen(s) in latex protein extracts. Tomazic VJ, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):635–42

A highly efficient procedure for purifying the ribosome-inactivating proteins alpha- and beta-momorcharins from Momordica charantia seeds, N-terminal sequence comparison and establishment of their N-glycosidase activity. Fong WP, et al. **Life Sci** 1996; 59(11):901–9

Purification of SF-assemblin. Bremerich A, et al. **Methods Cell Biol** 1995;47:315–21

Photoaffinity labeling and strategies for plasma membrane protein purification. Feldwisch J, et al. **Methods Cell Biol** 1995;50:51–60

Isolation of inner- and outer-arm dyneins. Howard DR, et al. **Methods Cell Biol** 1995;47:481–6

Separation of dynein species by high-pressure liquid chromatography. Kagami O, et al. **Methods Cell Biol** 1995; 47:487–9

Extraction and assay of protein from single plant cells. Outlaw WH Jr. **Methods Cell Biol** 1995;50:41–9

Electrophoretic separation of dynein heavy chains. Piperno G. **Methods Cell Biol** 1995;47:101–5

Two-dimensional separation of axonemal proteins. Piperno G. **Methods Cell Biol** 1995;47:107–12

Ferredoxin: thioredoxin system. Schürmann P. **Methods Enzymol** 1995;252:274–83

Separation of plant proteins by electrophoresis. Shewry PR, et al. **Methods Mol Biol** 1995;49:399–422 (26 ref.)

Actin-related proteins in Anabaena spp. and Escherichia coli. Guerrero-Barrera AL, et al. **Microbiology** 1996 May;142 (Pt 5):1133–40

Isolation and expression of a host response gene family encoding thaumatin-like proteins in incompatible oat-stem rust fungus interactions. Lin KC, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):511–22

Identification of a 67 kDa protein that binds specifically to the pre-rRNA primary processing site in a higher plant. Echeverria M, et al. **Nucleic Acids Res** 1995 Dec 25; 23(24):4963–70

Purification and properties of the first specific 5S rRNA binding protein from plants which shows transcription factor IIIA activity. Wyszko E, et al. **Nucleic Acids Symp Ser** 1995;(33):53–5

A kinesin-like protein, KatAp, in the cells of arabidopsis and other plants. Liu B, et al. **Plant Cell** 1996 Jan;8(1):119–132

Isolation and characterization of hardening-induced proteins in Chlorella vulgaris C-27: identification of late embryogenesis abundant proteins. Honjoh K, et al. **Plant Cell Physiol** 1995 Dec;36(8):1421–30

A cytosolic phospholipase A2 from potato tissues appears to be patatin. Senda K, et al. **Plant Cell Physiol** 1996 Apr; 37(3):347–53

Cellular localization of the Ca2+ binding TCH3 protein of Arabidopsis. Antosiewicz DM, et al. **Plant J** 1995 Nov; 8(5):623–36

Seeing blue: the discovery of cryptochrome. Ahmad M, et al. **Plant Mol Biol** 1996 Mar;30(5):851–61 (84 ref.)

Isolation of a new mitotic-like cyclin from Arabidopsis: complementation of a yeast cyclin mutant with a plant cyclin. Day IS, et al. **Plant Mol Biol** 1996 Feb;30(3):565–75

Cell cycle-dependent accumulation of a kinesin-like protein, KatB/C in synchronized tobacco BY-2 cells. Mitsui H, et al. **Plant Mol Biol** 1996 Jan;30(1):177–81

Immunological evidence for accumulation of two high-molecular-weight (104 and 90 kDa) HSPs in response to different stresses in rice and in response to high temperature stress in diverse plant genera. Pareek A, et al. **Plant Mol Biol** 1995 Oct;29(2):293–301

Purification and properties of Arabidopsis thaliana COR (cold-regulated) gene polypeptides COR15am and COR6.6 expressed in Escherichia coli. Gilmour SJ, et al. **Plant Physiol** 1996 May;111(1):293–9

Purification of a Zn-binding phloem protein with sequence identity to chitin-binding proteins. Taylor KC, et al. **Plant Physiol** 1996 Feb;110(2):657–64

Purification of a maize dehydrin protein expressed in Escherichia coli. Jepson SG, et al. **Protein Expr Purif** 1995 Oct;6(5):632–6

METABOLISM

Cardosin A and B, aspartic proteases from the flowers of cardoon. Faro C, et al. **Adv Exp Med Biol** 1995;362:373–7

Cry j 2, a major allergen of Japanese cedar pollen, shows polymethylgalacturonase activity. Ohtsuki T, et al. **Allergy** 1995 Jun;50(6):483–8

Chain length-dependent Pb(II)-coordination in phytochelatins. Mehra RK, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):730–6

A single amino acid determines the specificity for the target sequence of two zinc-finger proteins in plants. Takatsuji H. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):219–23

S-related protein can be recombined with self-compatibility in interspecific derivatives of Lycopersicon. Bernatzky R, et al. **Biochem Genet** 1995 Aug;33(7–8):215–25

Glycine decarboxylase and pyruvate dehydrogenase complexes share the same dihydrolipoamide dehydrogenase in pea leaf mitochondria: evidence from mass spectrometry and primary-structure analysis. Bourguignon J, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):229–34

Optical spectroscopic and reverse-phase HPLC analyses of Hg(II) binding to phytochelatins. Mehra RK, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):73–82

Inducible UDP-glucose dehydrogenase from French bean (Phaseolus vulgaris L.) locates to vascular tissue and has alcohol dehydrogenase activity. Robertson D, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):311–7

A characterisation of the peptide transport system in barley seeds. Waterworth WM, et al. **Biochem Soc Trans** 1995 Nov;23(4):558S

Reactive-site hydrolyzed Cucurbita maxima trypsin inhibitor-V: function, thermodynamic stability, and NMR solution structure. Cai M, et al. **Biochemistry** 1995 Sep 26; 34(38):12087–94

Interaction of the 33 kDa extrinsic protein with photosystem II: rebinding of the 33 kDa extrinsic protein to photosystem II membranes which contain four, two, or zero manganese per photosystem II reaction center. Leuschner C, et al. **Biochemistry** 1996 Apr 9;35(14):4551–7

A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Lechner T, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):181–8

C-terminal truncation of spinach chloroplast NAD(P)-dependent glyceraldehyde-3-phosphate dehydrogenase prevents inactivation and reaggregation.

Scheibe R, et al. **Biochim Biophys Acta** 1996 Sep 5; 1296(2):228–34

Evidence for a link between translocation and processing during protein import into soybean mitochondria. Whelan J, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):48–54

Suicide retrograde transport of volkensin in cerebellar afferents: direct evidence, neuronal lesions and comparison with ricin. Cevolani D, et al. **Brain Res** 1995 Aug 21; 689(2):163–71

Prohevein is poorly processed but shows enhanced resistance to a chitin-binding fungus in transgenic tomato plants. Lee HI, et al. **Braz J Med Biol Res** 1995 Jul;28(7):743–50

Shedding light on the chloroplast protein import machinery. Schnell DJ. **Cell** 1995 Nov 17;83(4):521–4 (14 ref.)

Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)

Polarography as a tool in peptide and protein analysis: studies on metal–chelating substances induced by cadmium in the algae Pheodactylum tricornutum and the graminae Agrostis capillaris. Nyberg S, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):147–53

Chloroplast mRNA 3'-end processing by a high molecular weight protein complex is regulated by nuclear encoded RNA binding proteins. Hayes R, et al. **EMBO J** 1996 Mar 1;15(5):1132–41

Degradation of the light–stress protein is mediated by an ATP–independent, serine–type protease under low–light conditions. Adamska I, et al. **Eur J Biochem** 1996 Mar 1; 236(2):591–9

Mutational studies of the amino acid residues in the combining site of Erythrina corallodendron lectin. Adar R, et al. **Eur J Biochem** 1996 Aug 1;239(3):668–74

Human and plant proliferating–cell nuclear antigen have a highly conserved binding site for the p53–inducible gene product p21WAF1. Ball KL, et al. **Eur J Biochem** 1996 May 1;237(3):854–61

Elicitors and suppressors of hydroxyproline–rich glycoprotein accumulation are solubilized from plant cell walls by endopolygalacturonase. Boudart G, et al. **Eur J Biochem** 1995 Sep 1;232(2):449–57

Alpha 2–macroglobulin receptor mediates binding and cytotoxicity of plant ribosome–inactivating proteins. Cavallaro U, et al. **Eur J Biochem** 1995 Aug 15; 232(1):165–71

Major structural differences between pokeweed antiviral protein and ricin A–chain do not account for their differing ribosome specificity. Chaddock JA, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):159–66

Phosphorylation of plant proteins and the identification of protein–tyrosine kinase activity in maize seedlings. Trojanek J, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):338–44

The NeuAc(alpha–2,6)–Gal/GalNAc–binding lectin from elderberry (Sambucus nigra) bark, a type–2 ribosome–inactivating protein with an unusual specificity and structure. Van Damme EJ, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):128–37

A role for ADP–ribosylation factor 1, but not COP I, in secretory vesicle biogenesis from the trans–Golgi network. Barr FA, et al. **FEBS Lett** 1996 Apr 8;384(1):65–70

Rice gibberellin–binding phosphoprotein structurally related to ribulose–1,5–bisphosphate carboxylase/oxygenase activase. Komatsu S, et al. **FEBS Lett** 1996 Apr 15; 384(2):167–71

DNA–nuclease activity of the single–chain ribosome–inactivating proteins dianthin 30, saporin 6 and gelonin. Roncuzzi L, et al. **FEBS Lett** 1996 Aug 19; 392(1):16–20

Evidence against specific binding of salicylic acid to plant catalase. Rüffer M, et al. **FEBS Lett** 1995 Dec 18; 377(2):175–80

Activities associated with the presence of ribosome–inactivating proteins increase in senescent and stressed leaves. Stirpe F, et al. **FEBS Lett** 1996 Mar 18; 382(3):309–12

Rapid purification of a functionally active plant sucrose carrier from transgenic yeast using a bacterial biotin acceptor domain. Stolz J, et al. **FEBS Lett** 1995 Dec 18; 377(2):167–71

Calcium in pollen–pistil interaction in Petunia hybrida Hort. II. Localization of Ca2+ ions and Ca(2+)–ATPase in unpollinated pistil. Bednarska E, et al. **Folia Histochem Cytobiol** 1995;33(1):43–52

The influence of the disappearance of plasmodesmal connections between antheridia and thallus on 3H–GA3 transport. Kwiatkowska M, et al. **Folia Histochem Cytobiol** 1995;33(1):53–5

Nuclear localization of the Arabidopsis APETALA3 and PISTILLATA homeotic gene products depends on their simultaneous expression. McGonigle B, et al. **Genes Dev** 1996 Jul 15;10(14):1812–21

Microheterogeneity of N–glycosylation on a stylar self–incompatibility glycoprotein of Nicotiana alata. Oxley D, et al. **Glycobiology** 1995 Jul;5(5):517–23

Changes in wall–bound polysaccharidase activities during the culture cycle of a Rubus fruticosus cell suspension. Faïk A, et al. **Int J Biol Macromol** 1995 Dec;17(6):381–6

Construction of a plasmid used for the expression of a sevenfold–mutant barley beta–amylase with increased thermostability in Escherichia coli and properties of the sevenfold–mutant beta–amylase. Yoshigi N, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):562–7

URF13, a ligand–gated, pore–forming receptor for T–toxin in the inner membrane of cms–T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437–45 (52 ref.)

The Ste20–like protein kinase, Mst1, dimerizes and contains an inhibitory domain. Creasy CL, et al. **J Biol Chem** 1996 Aug 30;271(35):21049–53

A conserved domain of the viviparous–1 gene product enhances the DNA binding activity of the bZIP protein EmBP–1 and other transcription factors. Hill A, et al. **J Biol Chem** 1996 Feb 16;271(7):3366–74

Molecular characterization of a putative Arabidopsis thaliana copper transporter and its yeast homologue. Kampfenkel K, et al. **J Biol Chem** 1995 Nov 24;270(47):28479–86

Sec–dependent thylakoid protein translocation. Delta pH requirement is dictated by passenger protein and ATP concentration. Mant A, et al. **J Biol Chem** 1995 Oct 6; 270(40):23275–81

Auxin–binding protein 1 does not bind auxin within the endoplasmic reticulum despite this being the predominant subcellular location for this hormone receptor. Tian H, et al. **J Biol Chem** 1995 Nov 10;270(45):26962–9

Phosphorylation of the transit sequence of chloroplast precursor proteins. Waegemann K, et al. **J Biol Chem** 1996 Mar 15;271(11):6545–54

Ricin A chain fused to a chloroplast–targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes. Walker D, et al. **J Biol Chem** 1996 Feb 23;271(8):4082–5

Effect of plant maturity and preservation method on in vitro protein degradation of forages. Kohn RA, et al. **J Dairy Sci** 1995 Jul;78(7):1544–51

Prediction of protein degradation of forages from solubility fractions. Kohn RA, et al. **J Dairy Sci** 1995 Aug; 78(8):1774–88

Ag(I)–binding to phytochelatins. Mehra RK, et al. **J Inorg Biochem** 1996 Feb;61(2):125–42

Hodgkin–Huxley analysis of a GCAC1 anion channel in the plasma membrane of guard cells. Kolb HA, et al. **J Membr Biol** 1995 Aug;146(3):273–82

The permeation of ammonium through a voltage–independent K+ channel in the plasma membrane of rye roots. White PJ. **J Membr Biol** 1996 Jul;152(1):89–99

Vanadium–dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

Phosphorylation of Chlamydomonas flagellar proteins. Bloodgood RA, et al. **Methods Cell Biol** 1995;47:121–7

Targeting of proteins to the nucleus. Carrington JC. **Methods Cell Biol** 1995;50:283–94

Import into the endoplasmic reticulum. Ceriotti A, et al. **Methods Cell Biol** 1995;50:295–308

The use of protoplasts to study protein synthesis and transport by the plant endomembrane system. Denecke J, et al. **Methods Cell Biol** 1995;50:335–48

Reactivation of Chlamydomonas cell models. Horst CJ, et al. **Methods Cell Biol** 1995;47:207–10

Production of recombinant plant calmodulin and its use to detect calmodulin–binding proteins. Liao B, et al. **Methods Cell Biol** 1995;49:487–500

Characterization and isolation of the chloroplast protein import machinery. Waegemann K, et al. **Methods Cell Biol** 1995;50:255–67

Determination of protein isoprenylation in vitro and in vivo. Zhu JK, et al. **Methods Cell Biol** 1995;50:31–9

In vitro protein import by isolated chloroplasts. Napier JA. **Methods Mol Biol** 1995;49:361–7

Targeting of foreign proteins to the chloroplast. Napier JA. **Methods Mol Biol** 1995;49:369–76 (20 ref.)

A light–induced protease from barley plastids degrades NADPH:protochlorophyllide oxidoreductase complexed with chlorophyllide. Reinbothe C, et al. **Mol Cell Biol** 1995 Nov;15(11):6206–12

Binding site requirements and differential representation of TGF factors in nuclear ASF–1 activity. Lam E, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3778–85

DNA–binding properties of Arabidopsis MADS domain homeotic proteins APETALA1, APETALA3, PISTILLATA and AGAMOUS. Riechmann JL, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3134–41

Factors affecting activation of the 'cloaked' Zea maize ribosome inactivating protein (RIP) zymogen. 1. 'LID' peptide hydrophobicities and oxidative structural changes. Hardin CC, et al. **Nucleic Acids Symp Ser** 1995;(33):249–53

The 41 kDa protein component of the spinach chloroplast petD mRNA 3' stem–loop:protein complex is a nuclear encoded chloroplast RNA–binding protein. Yang J, et al. **Nucleic Acids Symp Ser** 1995;(33):237–9

Indications for the occurrence of nitric oxide synthases in fungi and plants and the involvement in photoconidiation of Neurospora crassa. Ninnemann H, et al. **Photochem Photobiol** 1996 Aug;64(2):393–8

Developmental and cell cycle regulation of alfalfa nucMs1, a plant homolog of the yeast Nsr1 and mammalian nucleolin. Bögre L, et al. **Plant Cell** 1996 Mar;8(3):417–28

The regulator of MAT2 (ROM2) protein binds to early maturation promoters and represses PvALF–activated transcription. Chern MS, et al. **Plant Cell** 1996 Feb; 8(2):305–21

Characterization of a new vacuolar membrane aquaporin sensitive to mercury at a unique site. Daniels MJ, et al. **Plant Cell** 1996 Apr;8(4):587–99

DNA binding properties of two Arabidopsis MADS domain proteins: binding consensus and dimer formation. Huang H, et al. **Plant Cell** 1996 Jan;8(1):81–94

Localization and interaction of the cis–acting elements for abscisic acid, VIVIPAROUS1, and light activation of the C1 gene of maize. Kao CY, et al. **Plant Cell** 1996 Jul; 8(7):1171–9

The lysine–dependent stimulation of lysine catabolism in tobacco seed requires calcium and protein phosphorylation. Karchi H, et al. **Plant Cell** 1995 Nov;7(11):1963–70

A soybean sucrose binding protein independently mediates nonsaturable sucrose uptake in yeast. Overvoorde PJ, et al. **Plant Cell** 1996 Feb;8(2):271–80

Leaf permease1 gene of maize is required for chloroplast development. Schultes NP, et al. **Plant Cell** 1996 Mar; 8(3):463–75

Seasonal variation of western white pine (Pinus monticola D. Don) foliage proteins. Ekramoddoullah AK, et al. **Plant Cell Physiol** 1996 Mar;37(2):189–99

Chloroplast ribonucleoproteins (RNPs) as phosphate acceptors for casein kinase II: purification by ssDNA–cellulose column chromatography. Kanekatsu M, et al. **Plant Cell Physiol** 1995 Dec;36(8):1649–56

Transient and specific expression of a cysteine endopeptidase associated with autolysis during differentiation of Zinnia mesophyll cells into tracheary elements. Minami A, et al. **Plant Cell Physiol** 1995 Dec;36(8):1599–606

Three protein fractions that bind to a narrow region of the promoter of the ribosomal RNA gene in Vicia faba. Suzuki A, et al. **Plant Cell Physiol** 1995 Sep;36(6):1051–8

Emergence of proteases in germinating cucumber cotyledons and their roles in the two–step degradation of storage protein. Yamauchi Y, et al. **Plant Cell Physiol** 1996 Apr; 37(3):279–84

A receptor for protein import into potato mitochondria. Heins L, et al. **Plant J** 1996 Jun;9(6):829–39

A plant kinesin heavy chain–like protein is a calmodulin–binding protein. Reddy AS, et al. **Plant J** 1996 Jul;10(1):9–21

Isolation of pI 4.6 extensin peroxidase from tomato cell suspension cultures and identification of Val–Tyr–Lys as putative intermolecular cross–link site. Schnabelrauch LS, et al. **Plant J** 1996 Apr;9(4):477–89

MYB.Ph3 transcription factor from Petunia hybrida induces similar DNA–bending/distortions on its two types of binding site. Solano R, et al. **Plant J** 1995 Nov;8(5):673–82

Common occurrence of homologues of petunia glycine–rich protein–1 among plants. Cheng SH, et al. **Plant Mol Biol** 1996 Apr;31(1):163–8

Mitochondrial and chloroplast targeting sequences in tandem modify protein import specificity in plant organelles. de Castro Silva Filho M, et al. **Plant Mol Biol** 1996 Feb; 30(4):769–80

Functional characteristics of the maize RNA–binding protein MA16. Freire MA, et al. **Plant Mol Biol** 1995 Nov; 29(4):797–807

Degradation of mistargeted OEE33 in the chloroplast stroma. Halperin T, et al. **Plant Mol Biol** 1996 Mar;30(5):925–33

Binding site on pea chloroplast fructose–1,6–bisphosphatase involved in the interaction with thioredoxin. Hermoso R, et al. **Plant Mol Biol** 1996 Feb;30(3):455–65

Novel members of a family of AT hook–containing DNA–binding proteins from rice are identified through their in vitro interaction with consensus target sites of plant and animal homeodomain proteins. Meijer AH, et al. **Plant Mol Biol** 1996 Jun;31(3):607–18

The conserved ELK–homeodomain of KNOTTED–1 contains two regions that signal nuclear localization. Meisel L, et al. **Plant Mol Biol** 1996 Jan;30(1):1–14

A distinctly regulated protein repair L–isoaspartylmethyltransferase from Arabidopsis thaliana. Mudgett MB, et al. **Plant Mol Biol** 1996 Feb;30(4):723–37

Specificity in the immobilisation of cell wall proteins in response to different elicitor molecules in suspension–cultured cells of French bean (Phaseolus vulgaris L.). Wojtaszek P, et al. **Plant Mol Biol** 1995 Sep; 28(6):1075–87

Iron and copper nutrition–dependent changes in protein expression in a tomato wild type and the nicotianamine–free mutant chloronerva. Herbik A, et al. **Plant Physiol** 1996 Jun;111(2):533–40

Protective mechanism of the Mexican bean weevil against high levels of alpha–amylase inhibitor in the common bean. Ishimoto M, et al. **Plant Physiol** 1996 Jun;111(2):393–401

Interaction of a potential vacuolar targeting receptor with amino– and carboxyl–terminal targeting determinants. Kirsch T, et al. **Plant Physiol** 1996 Jun;111(2):469–74

Examination of the contribution of vacuolar proteases to intracellular protein degradation in Chara corallina. Moriyasu Y. **Plant Physiol** 1995 Dec;109(4):1309–15

Structural requirements of oleosin domains for subcellular targeting to the oil body. van Rooijen GJ, et al. **Plant Physiol** 1995 Dec;109(4):1353–61

A novel iron–regulated metal transporter from plants identified by functional expression in yeast. Eide D, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5624–8

Pre–mRNA splicing in plants: characterization of Ser/Arg splicing factors. Lopato S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3074–9

The precursor of PsaD assembles into the photosystem I complex in two steps. Minai L, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6338–42

Selective trafficking of KNOTTED1 homeodomain protein and its mRNA through plasmodesmata [see comments] Lucas WJ, et al. **Science** 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1943–4.

Sodium–driven potassium uptake by the plant potassium transporter HKT1 and mutations conferring salt tolerance [see comments] Rubio F, et al. **Science** 1995 Dec 8; 270(5242):1660–3. Comment in: Science 1996 Aug 16;273(5277):977–9.

Ethylene–binding sites generated in yeast expressing the Arabidopsis ETR1 gene [see comments] Schaller GE, et al. **Science** 1995 Dec 15;270(5243):1809–11. Comment in: Science 1995 Dec 15;270(5243):1774.

Targeting plant toxins to the urokinase and alpha 2–macroglobulin receptors. Cavallaro U, et al. **Semin Cancer Biol** 1995 Oct;6(5):269–78 (60 ref.)

The product of maize streak virus ORF V1 is associated with secondary plasmodesmata and is first detected with the onset of viral lesions. Dickinson VJ, et al. **Virology** 1996 Jun 1;220(1):51–9

Interaction of host proteins with the plus–strand promoter of brome mosaic virus RNA–2. Duggal R, et al. **Virology** 1995 Dec 20;214(2):638–41

PHARMACOKINETICS

Pharmacokinetics, metabolism and toxicity of the plant–derived photoxin alpha–terthienyl. Marles R, et al. **Pharmacol Toxicol** 1995;77:164–8

PHARMACOLOGY

In vitro release of soluble CD23 by human lymphocytes in ragweed–sensitive versus nonatopic patients following stimulation with ragweed antigen E. Batterman J, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):359–62

Selective cytotoxicity towards cytomegalovirus–infected cells by immunotoxins consisting of gelonin linked to anti–cytomegalovirus antibody. Barnett BB, et al. **Antiviral Res** 1995 Sep;28(1):93–100

The activity of plant–derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro. Bourinbaiar AS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):923–9

Active fragments and analogs of the plant growth factor, phytosulfokine: structure–activity relationships. Matsubayashi Y, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):209–14

Isolation and characterization of a 30 kDa protein with antifungal activity from leaves of Engelmannia pinnatifida. Huynh QK, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):723–7

Synthesis and characterization of the sweetness–suppressing polypeptide gurmarin and ent–gurmarin. Ota M, et al. **Biopolymers** 1996 Aug;39(2):199–205

In vitro and in vivo antileukemic activity of B43–pokeweed antiviral protein against radiation–resistant human B–cell precursor leukemia cells. Waddick KG, et al. **Blood** 1995 Dec 1;86(11):4228–33

Preclinical studies with the anti–CD19–saporin immunotoxin BU12–SAPORIN for the treatment of human–B–cell tumours. Flavell DJ, et al. **Br J Cancer** 1995 Dec; 72(6):1373–9

Saporin, a ribosome–inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Bergamaschi G, et al. **Br J Haematol** 1996 Jun 2; 93(4):789–94

Anti–CD30 (BER = H2) immunotoxins containing the type–1 ribosome–inactivating proteins momordin and PAP–S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Terenzi A, et al. **Br J Haematol** 1996 Mar;92(4):872–9

Behavioral and neurobiological alterations induced by the immunotoxin 192–IgG–saporin: cholinergic and non–cholinergic effects following i.c.v. injection. Walsh TJ, et al. **Brain Res** 1995 Dec 8;702(1–2):233–45

Cellular resistance to the antimelanoma immunotoxin ZME–gelonin and strategies to target resistant cells. Rosenblum MG, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):115–21

Regulation of cytokine production by sugi allergen–pullulan conjugate. Kohno K, et al. **Cell Immunol** 1996 Mar 15; 168(2):211–9

Sensitivity of ribosomes from Agrobacterium tumefaciens to the ribosome–inactivating protein crotin 2 depending on the translocational state. Alegre C, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Mar;42(2):151–8

Possible active site of the sweet–tasting protein thaumatin. Slootstra JW, et al. **Chem Senses** 1995 Oct;20(5):535–43

Activity and stability of a new sweet protein with taste–modifying action, curculin. Yamashita H, et al. **Chem Senses** 1995 Apr;20(2):239–43

Reduced level of serum cholesterol in low protein–fed Wistar rats administered gossypol and chloroquine. Nwoha PU, et al. **Contraception** 1995 Oct;52(4):261–5

The inhibitor protein of phosphorylated nitrate reductase from spinach (Spinacia oleracea) leaves is a 14–3–3 protein. Bachmann M, et al. **FEBS Lett** 1996 Jun 3;387(2–3):127–31

Differential up–regulation by tRNAs of ribosome–inactivating proteins. Brigotti M, et al. **FEBS Lett** 1995 Oct 9;373(2):115–8

Comparison of the performance of anti–CD7 and anti–CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T–cell acute lymphoblastic leukemia cell line. Flavell DJ, et al. **Hematol Oncol** 1995 Jul–Aug; 13(4):185–200

New lymphocyte stimulating monocot lectins from family Araceae. Kamboj SS, et al. **Immunol Invest** 1995 Aug; 24(5):845–55

Hypolipidemic effect of garlic protein substituted for casein in diet of rats compared to those of garlic oil. Mathew BC, et al. **Indian J Exp Biol** 1996 Apr;34(4):337–40

Biochemical effects of garlic protein diet and garlic oil on glycosaminoglycan metabolism in cholesterol fed rats. Mathew BC, et al. **Indian J Exp Biol** 1996 Apr;34(4):346–50

Toxicity of ribosome–inactivating proteins–containing immunotoxins to a human bladder carcinoma cell line. Battelli MG, et al. **Int J Cancer** 1996 Feb 8;65(4):485–90

In vivo inhibition of lens regrowth by fibroblast growth factor 2–saporin. Behar–Cohen FF, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2434–48

Specific depletion of the house dust mite allergen Der p 1 cereal flour prolamins. Barber D, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):963–5

Fungal membrane responses induced by plant defensins and thionins. Thevissen K, et al. **J Biol Chem** 1996 Jun 21; 271(25):15018–25

The inhibition of human salivary alpha–amylase by type II alpha–amylase inhibitor from Triticum aestivum is competitive, slow and tight–binding. Goff DJ, et al. **J Enzym Inhib** 1995;9(2):163–70

The anti–oxidant activity of turmeric (Curcuma longa). Selvam R, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):59–67

Potentiation of antiproliferative effects of monoclonal antibody Lym–1 and immunoconjugate Lym–1–gelonin on human Burkitt's lymphoma cells with gamma–interferon and tumor necrosis factor. O'Boyle KP, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):221–30

Depurination of A4256 in 28 S rRNA by the ribosome–inactivating proteins from barley and ricin results in different ribosome conformations. Holmberg L, et al. **J Mol Biol** 1996 May 31;259(1):81–94

The action of pokeweed antiviral protein and ricin A–chain on mutants in the alpha–sarcin loop of Escherichia coli 23S ribosomal RNA. Marchant A, et al. **J Mol Biol** 1995 Dec 15;254(5):848–55

1921gG–saporin immunotoxin–induced loss of cholinergic cells differentially activates microglia in rat basal forebrain nuclei. Rossner S, et al. **J Neurosci Res** 1995 Jun 15; 41(3):335–46

Water–soluble viscous substance of Jew's mellow leaves lowers serum and liver cholesterol concentrations and increases fecal steroid excretion in rats fed a high cholesterol diet. Innami S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):465–75

Effects of spinach leaf protein concentrate on the serum cholesterol and amino acid concentrations in rats fed a cholesterol–free diet. Satoh A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):563–73

Local infusion of FGF–saporin reduces intimal hyperplasia. Mattar SG, et al. **J Surg Res** 1996 Feb 1;60(2):339–44

Antiproliferative effect of basic fibroblast growth factor–saporin mitotoxin on keratocytes in culture. Wee WR, et al. **Korean J Ophthalmol** 1996 Jun;10(1):1–7

An anti–CD72 immunotoxin against therapy–refractory B–lineage acute lymphoblastic leukemia. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):119–22

Favorable pharmacodynamic features and superior anti–leukemic activity of B43 (anti–CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):93–102

Assaying proteins for molecular chaperone activity. Lee GJ. **Methods Cell Biol** 1995;50:325–34

Field bean protease inhibitor mitigates the sister–chromatid exchanges induced by bromoform and depresses the spontaneous sister–chromatid exchange frequency of human lymphocytes in vitro. Banerji AP, et al. **Mutat Res** 1996 May 17;360(1):29–35

Effect of proteolytic and glycolytic enzymes on a factor in Sorghum bicolor that induces mycelial growth in the smut fungus, Sporisorium reilianum. Bhaskaran S, et al. **Mycopathologia** 1995 May;130(2):95–101

Soy protein and serum lipids [letter; comment] Krauss RM, et al. **N Engl J Med** 1995 Dec 21;333(25):1715–6. Comment on: N Engl J Med 1995 Aug 3;333(5):276–82.

Loss of p75 nerve growth factor receptor mRNA containing neurons in rat forebrain after intraventricular IgG 192–saporin administration. Singh V, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):117–20

A potent antimicrobial protein from onion seeds showing sequence homology to plant lipid transfer proteins. Cammue BP, et al. **Plant Physiol** 1995 Oct;109(2):445–55

Protective mechanism of the Mexican bean weevil against high levels of alpha–amylase inhibitor in the common bean. Ishimoto M, et al. **Plant Physiol** 1996 Jun;111(2):393–401

Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti–HIV plant proteins MAP30 and GAP31. Lee–Huang S, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8818–22

PHYSIOLOGY

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

Actomyosin–based motility of endoplasmic reticulum and chloroplasts in Vallisneria mesophyll cells. Liebe S, et al. **Biol Cell** 1995;85(2–3):207–22

Protein targeting to the plant vacuole—a historical perspective. Dombrowski JE, et al. **Braz J Med Biol Res** 1996 Apr;29(4):413–30 (221 ref.)

The SCARECROW gene regulates an asymmetric cell division that is essential for generating the radial organization of the Arabidopsis root. Di Laurenzio L, et al. **Cell** 1996 Aug 9;86(3):423–33

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125–8 (27 ref.)

Regulation of dynein–driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98–102 (34 ref.)

Regulation of dynein activity within Chlamydomonas flagella. Piperno G. **Cell Motil Cytoskeleton** 1995; 32(2):103–5

Photomorphogenesis. Seeing the light in plant development. Terzaghi WB, et al. **Curr Biol** 1995 May 1;5(5):466–8 (11 ref.)

Phragmoplastin, a dynamin–like protein associated with cell plate formation in plants. Gu X, et al. **EMBO J** 1996 Feb 15;15(4):695–704

Inward and outward rectifying potassium currents in Saccharomyces cerevisiae mediated by endogenous and heterelogously expressed ion channels. Bertl A, et al. **Folia Microbiol (Praha)** 1994;39(6):507–9

A lea–class gene of tomato confers salt and freezing tolerance when expressed in Saccharomyces cerevisiae. Imai R, et al. **Gene** 1996 May 8;170(2):243–8

Loss of spatial control of the mitotic spindle apparatus in a Chlamydomonas reinhardtii mutant strain lacking basal bodies. Ehler LL, et al. **Genetics** 1995 Nov;141(3):945–60

Mutational analysis of photosystem I polypeptides. Role of PsaD and the lysyl 106 residue in the reductase activity of the photosystem I. Chitnis VP, et al. **J Biol Chem** 1996 May 17;271(20):11772–80

Characterization of a new vacuolar membrane aquaporin sensitive to mercury at a unique site. Daniels MJ, et al. **Plant Cell** 1996 Apr;8(4):587–99

Phaseolus ENOD40 is involved in symbiotic and non–symbiotic organogenetic processes: expression during nodule and lateral root development. Papadopoulou K, et al. **Plant Mol Biol** 1996 Feb;30(3):403–17

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold–regulated) genes of Arabidopsis thaliana on the freeze–induced fusion and leakage of liposomes. Uemura M, et al. **Plant Physiol** 1996 May;111(1):313–27

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold–regulated) genes of Arabidopsis thaliana on dehydration–induced phase transitions of phospholipid membranes. Webb MS, et al. **Plant Physiol** 1996 May; 111(1):301–12

Plants, like animals, may make use of peptide signals [news; comment] Marx J. **Science** 1996 Sep 6;273(5280):1338–9. Comment on: Science 1996 Sep 6;273(5280):1406–9.

Modification of phytohormone response by a peptide encoded by ENOD40 of legumes and a nonlegume. van de Sande K, et al. **Science** 1996 Jul 19;273(5273):370–3

RADIATION EFFECTS

Disintegration of phycobilisomes in a rice field cyanobacterium Nostoc sp. following UV irradiation. Sinha RP, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):697–706

Peroxidase changes in barley induced by ionizing and thermal radiation. Sah NK, et al. **Int J Radiat Biol** 1996 Jan; 69(1):107–11

Ultraviolet–B photodestruction of a light–harvesting complex. Lao K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5258–63

THERAPEUTIC USE

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):74–80

Anti–CD30 (BER = H2) immunotoxins containing the type–1 ribosome–inactivating proteins momordin and PAP–S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Terenzi A, et al. **Br J Haematol** 1996 Mar;92(4):872–9

Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Davol P, et al. **Cancer** 1995 Jul 1; 76(1):79–85

The blood constituents of gossypol–treated, protein–malnourished Wistar rats. Nwoha PU.

Contraception 1995 Oct;52(4):249–54

In vivo treatment of Heymann's Nephritis using a cytotoxic protein–toxin conjugate. Misquith S, et al. **FEBS Lett** 1995 Oct 9;373(2):151–4

The mitotoxin, basic fibroblast growth factor–saporin, effectively targets human prostatic carcinoma in an animal model. Davol P, et al. **J Urol** 1996 Sep;156(3):1174–9

Response of B–cell lymphoma to a combination of bispecific antibodies and saporin. French RR, et al. **Leuk Res** 1996 Jul;20(7):607–17

Antileukemic activity of recombinant humanized M195–gelonin immunotoxin in nude mice. Xu Y, et al. **Leukemia** 1996 Feb;10(2):321–6

TOXICITY

Preclinical evaluation of the ribosome–inactivating proteins PAP–1, PAP–S and RTA in mice. Benigni F, et al. **Int J Immunopharmacol** 1995 Oct;17(10):829–39

Cytotoxic effects of FGF2–saporin on bovine epithelial lens cells in vitro. Behar–Cohen FF, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2425–33

Isolation of a compound from Eupatorium adenophorum (Spreng.) [Ageratina adenophora (Spreng.)] causing hepatotoxicity in mice. Oelrichs PB, et al. **Nat Toxins** 1995; 3(5):350–4

Isolation and identification of a compound from avocado (Persea americana) leaves which causes necrosis of the acinar epithelium of the lactating mammary gland and the myocardium. Oelrichs PB, et al. **Nat Toxins** 1995;3(5):344–9

Changes in cortical nicotinic acetylcholine receptor numbers following unilateral destruction of pyramidal neurones by intrastriatal volkensin injection. Chessell IP, et al. **Neurodegeneration** 1995 Dec;4(4):415–24

Hepatoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum. Battelli MG, et al. **Virchows Arch** 1996 Feb;427(5):529–35

ULTRASTRUCTURE

Investigation of the structure of thylakoid membranes (spinach) by means of small–angle neutron scattering. Gordeliy VI, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):485–91

Solution structure of bromelain inhibitor IV from pineapple stem: structural similarity with Bowman–Birk trypsin/chymotrypsin inhibitor from soybean. Hatano K, et al. **Biochemistry** 1996 Apr 30;35(17):5379–84

Isolation, characterization and electron microscopy analysis of a hemidiscoidal phycobilisome type from the cyanobacterium Anabaena sp. PCC 7120. Ducret A, et al. **Eur J Biochem** 1996 Mar 15;236(3):1010–24

PLANT RNA see **RNA, PLANT**

PLANT ROOTS

CHEMISTRY

Hypoglycemic effect of the rhizomes of ophiopogonis tuber in normal and diabetic mice. Kako M, et al. **Biol Pharm Bull** 1995 May;18(5):785–7

Depolarizing neuromuscular blocking action of coryneine derived from aconite root in isolated mouse phrenic nerve–diaphragm muscles. Kimura M, et al. **Biol Pharm Bull** 1995 May;18(5):691–5

Cytotoxic activity of bryonolic acid isolated from transformed hairy roots of Trichosanthes kirilowii var. japonica. Kondo T, et al. **Biol Pharm Bull** 1995 May; 18(5):726–9

Inhibitory effects of methanolic extract from corydalis tuber against types I–IV allergic models. Matsuda H, et al. **Biol Pharm Bull** 1995 Jul;18(7):963–7

The difference in hypoglycemic action between polygonati rhizoma and polygonati officinalis rhizoma. Miura T, et al. **Biol Pharm Bull** 1995 Nov;18(11):1605–6

Meliavolkenin, a new bioactive triterpenoid from Melia volkensii (Meliaceae). Zeng L, et al. **Bioorg Med Chem** 1995 Apr;3(4):383–90

Studies on the constituents of Clematis species. VI. The constituents of Clematis stans Sieb. et Zucc. Kizu H, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2187–94

Cholestane glycosides from Solanum abutiloides. Tian RH, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1119–21

Chemical constituents of Chinese natural medicine, morindae radix, the dried roots of morinda officinalis how.: structures of morindolide and morofficinaloside. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1462–5

Medicinal foodstuff. III. Sugar beet. (1): Hypoglycemic oleanolic acid oligoglycosides, betavulgarosides I, II, III, and IV, from the root of Beta vulgaris L. (Chenopodiaceae). Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1212–7

Five new triterpene saponins, polygalasaponins XXVIII–XXXII from the root of Polygala japonica Houtt. Zhang D, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr; 44(4):810–5

Biologically active principles isolated from Salacia oblonga wall. Augusti KT, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):415–7

Agastaquinone, a new cytotoxic diterpenoid quinone from Agastache rugosa. Lee HK, et al. **J Nat Prod** 1995 Nov; 58(11):1718–21

Puqiedinone, a novel 5 alpha–cevanine alkaloid from the bulbs of Fritillaria puqiensis, an antitussive traditional Chinese medicine. Lin G, et al. **J Nat Prod** 1995 Nov; 58(11):1662–7

Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Ahn KS, et al. **Planta Med** 1996 Feb;62(1):7–9

In vitro biological activities of alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **Planta Med** 1996 Feb; 62(1):22–7

Pectic polysaccharides from roots of Glycyrrhiza uralensis: possible contribution of neutral oligosaccharides in the galacturonase–resistant region to anti–complementary and mitogenic activities. Kiyohara H, et al. **Planta Med** 1996 Feb;62(1):14–9

Inhibitory effects of protoberberine alkaloids from the roots of Coptis japonica on catecholamine biosynthesis in PC12 cells. Lee MK, et al. **Planta Med** 1996 Feb;62(1):31–4

In vitro cytotoxicity of chaparrin from Castela texana. Calzado–Flores C, et al. **Proc West Pharmacol Soc** 1995; 38:49–50

CYTOLOGY

Immunohistochemical assessment of cell proliferation in plant tissues using formaldehyde–fixed paraffin–embedded material. Schumacher U. **Acta Histochem** 1995 Jul; 97(3):291–4

The SCARECROW gene regulates an asymmetric cell division that is essential for generating the radial organization of the Arabidopsis root. Di Laurenzio L, et al. **Cell** 1996 Aug 9;86(3):423–33

The homeobox gene GLABRA2 is required for position–dependent cell differentiation in the root epidermis of Arabidopsis thaliana. Masucci JD, et al. **Development** 1996 Apr;122(4):1253–60

Root border cells as tools in plant cell studies. Brigham LA, et al. **Methods Cell Biol** 1995;49:377–87 (20 ref.)

The development of cell pattern in the root epidermis. Dolan L, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30;350(1331):95–9 (42 ref.)

DRUG EFFECTS

Effects of Mg2+, Co2+, and Hg2+ on the nucleus and nucleolus in root tip cells of Allium cepa. Liu D, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):779–87

Influence of soil characteristics on the clastogenic activity of maleic hydrazide in root tips of Vicia faba. De Marco A, et al. **Mutat Res** 1995 Aug;344(1–2):5–12

ENZYMOLOGY

Topography of the 27– and 31–kDa electron transport proteins in the onion root plasma membrane. Córdoba MC, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1054–9

Purification and properties of a plant beta–D–glucuronidase form Scutellaria root. Ikegami F, et al. **Biol Pharm Bull** 1995 Nov;18(11):1531–4

High–level tuber expression and sucrose inducibility of a potato Sus4 sucrose synthase gene require 5'and 3'flanking sequences and the leader intron. Fu H, et al. **Plant Cell** 1995 Sep;7(9):1387–94

GENETICS

arc6, an extreme chloroplast division mutant of Arabidopsis also alters proplastid proliferation and morphology in shoot and root apices. Robertson EJ, et al. **J Cell Sci** 1995 Sep; 108 (Pt 9):2937–44

Vicia faba root tip micronucleus test on the mutagenicity of water–soluble contents of cigarette smoke. Ji Q, et al. **Mutat Res** 1996 Jan 16;359(1):1–6

The promoter of the Vicia faba L. VfENOD–GRP3 gene encoding a glycine–rich early nodulin mediates a predominant gene expression in the interzone II–III region of transgenic Vicia hirsuta root nodules. Küster H, et al. **Plant Mol Biol** 1995 Nov;29(4):759–72

GROWTH & DEVELOPMENT

Plant development: pulled up by the roots. Dolan L, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):432–8 (37 ref.)

The plant oncogenes rolA, B, and C from Agrobacterium rhizogenes. Effects on morphology, development, and hormone metabolism. Michael T, et al. **Methods Mol Biol** 1995;44:207–22

Use of a subtractive hybridization approach to identify new Medicago truncatula genes induced during root nodule development. Gamas P, et al. **Mol Plant Microbe Interact** 1996 May;9(4):233–42

Control of root growth and development by cyclin expression [see comments] Doerner P, et al. **Nature** 1996 Apr 11;380(6574):520–3. Comment in: Nature 1996 Apr 11;380(6574):481–2.

Uridine, a cell division factor in pea roots. Smit G, et al. **Plant Mol Biol** 1995 Nov;29(4):869–73

Arabidopsis thaliana sku mutant seedlings show exaggerated surface–dependent alteration in root growth vector. Rutherford R, et al. **Plant Physiol** 1996 Aug;111(4):987–98

Arabidopsis AUX1 gene: a permease–like regulator of root gravitropism. Bennett MJ, et al. **Science** 1996 Aug 16; 273(5277):948–50

METABOLISM

Assessing cadmium partitioning in transgenic plants. Wagner GJ. **Methods Mol Biol** 1995;44:295–308

Plant biology. At the roots of nutrition [news; comment] Schroeder JI. **Nature** 1995 Dec 7;378(6557):560–1. Comment on: Nature 1995 Dec 7;378(6557):626–9.

Metabolic regulation of asparagine synthetase gene expression in maize (Zea mays L.) root tips. Chevalier C, et al. **Plant J** 1996 Jan;9(1):1–11

A sugar transporter from Medicago truncatula: altered expression pattern in roots during vesicular–arbuscular (VA) mycorrhizal associations. Harrison MJ. **Plant J** 1996 Apr;9(4):491–503

Characterization of a cDNA encoding a proline–rich 14 kDa protein in developing cortical cells of the roots of bean (Phaseolus vulgaris) seedlings. Choi DW, et al. **Plant Mol Biol** 1996 Mar;30(5):973–82

High–affinity potassium uptake in plants [letter; comment] Walker NA, et al. **Science** 1996 Aug 16;273(5277):977–9. Comment on: Science 1995 Dec 8;270(5242):1660–3.

Improved metabolic action of a bacterial lysine decarboxylase gene in tobacco hairy root cultures by its fusion to a rbcS transit peptide coding sequence. Herminghaus S, et al. **Transgenic Res** 1996 May;5(3):193–201

MICROBIOLOGY

Douglas–fir root–associated microorganisms with inhibitory activity towards fungal plant pathogens and human bacterial pathogens. Axelrood PE, et al. **Can J Microbiol** 1996 Jul;42(7):690–700

Construction of a modified mini–Tn5 lacZY non–antibiotic marker cassette: ecological evaluation of a lacZY marked Pseudomonas strain in the sugarbeet rhizosphere. Fedi S, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):251–7

A new root–nodulating symbiont of the tropical legume Sesbania, Rhizobium sp. SIN–1, is closely related to R. galegae, a species that nodulates temperate legumes. Rana D, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):19–25

In vitro sulfotransferase activity of NodH, a nodulation protein of Rhizobium meliloti required for host–specific nodulation. Ehrhardt DW, et al. **J Bacteriol** 1995 Nov; 177(21):6237–45

Effect of some fungicides on extracellular enzymes of Sclerotium rolfsii sacc. Ohazurike NC. **Nahrung** 1996 May; 40(3):150–3

Identification of a new pea gene, PsNlec1, encoding a lectin–like glycoprotein isolated from the symbiosomes of root nodules. Kardailsky IV, et al. **Plant Physiol** 1996 May; 111(1):49–60

Proteolytic processing of class IV chitinase in the compatible interaction of bean roots with Fusarium solani. Lange J, et al. **Plant Physiol** 1996 Aug;111(4):1135–44

Nodulating strains of Rhizobium loti arise through chromosomal symbiotic gene transfer in the environment. Sullivan JT, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8985–9

2,4–Dichlorophenoxyacetic acid affects the attachment of Azospirillum brasilense Cd to maize roots. Jofré E, et al. **Toxicology** 1996 Jan 22;107(1):9–15

PARASITOLOGY

A molecular study of root–knot nematode–induced feeding sites. Van der Eycken W, et al. **Plant J** 1996 Jan;9(1):45–54

PHYSIOLOGY

Nod factors produced by Rhizobium leguminosarum biovar viciae induce ethylene–related changes in root cortical cells of Vicia sativa ssp. nigra. van Spronsen PC, et al. **Eur J Cell Biol** 1995 Dec;68(4):463–9

PLANT SHOOTS

ANATOMY & HISTOLOGY

Confocal microscopy of the shoot apex. Running MP, et al. **Methods Cell Biol** 1995;49:217–29

CHEMISTRY

A galactose–rich, cell–wall glycoprotein from styles of Nicotiana alata. Sommer–Knudsen J, et al. **Plant J** 1996 Jan;9(1):71–83

A novel phloem–specific gene is expressed preferentially in aerial portions of Vicia faba. Foley RC, et al. **Plant Mol Biol** 1996 Feb;30(4):687–95

Molecular analysis of a pistil–specific gene expressed in the stigma and cortex of Solanum tuberosum. Van Eldik GJ, et al. **Plant Mol Biol** 1996 Jan;30(1):171–6

CYTOLOGY

Epidermal fate map of the Arabidopsis shoot meristem. Schnittger A, et al. **Dev Biol** 1996 May 1;175(2):248–55

DRUG EFFECTS

Characterization of an endo–beta–1,4–glucanase gene induced by auxin in elongating pea epicotyls. Wu SC, et al. **Plant Physiol** 1996 Jan;110(1):163–70

GENETICS

arc6, an extreme chloroplast division mutant of Arabidopsis

also alters proplastid proliferation and morphology in shoot and root apices. Robertson EJ, et al. **J Cell Sci** 1995 Sep; 108 (Pt 9):2937–44

Genetic separation of third and fourth whorl functions of AGAMOUS. Sieburth LE, et al. **Plant Cell** 1995 Aug; 7(8):1249–58

GROWTH & DEVELOPMENT

Specification of chimeric flowering shoots in wild-type Arabidopsis. Hempel FD, et al. **Plant J** 1995 Nov; 8(5):725–31

Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)

PHYSIOLOGY

Distinct classes of mitotic cyclins are differentially expressed in the soybean shoot apex during the cell cycle. Kouchi H, et al. **Plant Cell** 1995 Aug;7(8):1143–55

PLANT STEMS

Dependence of water conductivity on pressure and temperature in plant stems. Yamamoto R. **Biorheology** 1995 Jul–Aug;32(4):421–30

Agrobacterium–mediated transformation of stem disks from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:79–85

CHEMISTRY

Antiallergic constituents from oolong tea stem. Ohmori Y, et al. **Biol Pharm Bull** 1995 May;18(5):683–6

Inhibitory effect of alkaloids extracted from the stem bark of Hunteria zeylanica on 5–lipoxygenase activity in vitro. Reanmongkol W, et al. **Biol Pharm Bull** 1995 Jun; 18(6):910–2

Steam explosion of woody hemp chènevotte. Vignon MR, et al. **Int J Biol Macromol** 1995 Dec;17(6):395–404

Two new taxoids from the stem bark of Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Dec;58(12):1906–12

ENZYMOLOGY

Purification and characterization of taxa–4(5),11(12)–diene synthase from Pacific yew (Taxus brevifolia) that catalyzes the first committed step of taxol biosynthesis. Hezari M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):437–44

GENETICS

The REVOLUTA gene is necessary for apical meristem development and for limiting cell divisions in the leaves and stems of Arabidopsis thaliana. Talbert PB, et al. **Development** 1995 Sep;121(9):2723–35

GROWTH & DEVELOPMENT

Cell cycle regulation during growth–dormancy cycles in pea axillary buds. Devitt ML, et al. **Plant Mol Biol** 1995 Oct; 29(2):255–65

PLANT STEROLS see **PHYTOSTEROLS**

PLANT STRUCTURAL GENES see **GENES, STRUCTURAL, PLANT**

PLANT TUMORS

Ti plasmid–encoded genes responsible for catabolism of the crown gall opine mannopine by Agrobacterium tumefaciens are homologs of the T–region genes responsible for synthesis of this opine by the plant tumor. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3275–84

A Ti plasmid–encoded enzyme required for degradation of mannopine is functionally homologous to the T–region–encoded enzyme required for synthesis of this opine in crown gall tumors. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3285–92

Cell cycle. Why don't plants get cancer? [news; comment] Doonan J, et al. **Nature** 1996 Apr 11;380(6574):481–2. Comment on: Nature 1996 Apr 11;380(6574):520–3.

CHEMISTRY

Crown gall culture and production of tanshinone in Salvia miltiorrhiza. Zhang Y, et al. **Chin J Biotechnol** 1995; 11(2):137–41

Overexpression of a tryptophan decarboxylase cDNA in Catharanthus roseus crown gall calluses results in increased tryptamine levels but not in increased terpenoid indole alkaloid production. Goddijn OJ, et al. **Transgenic Res** 1995 Sep;4(5):315–23

MICROBIOLOGY

Is Hodgkin's disease a human counterpart of bacterially induced crown–gall tumours? [letter] [see comments] Sauter C. **Lancet** 1995 Nov 25;346(8987):1433. Comment in: Lancet 1996 Mar 30;347(9005):901–2.

Effect of acetosyringone on growth and oncogenic potential of Agrobacterium tumefaciens. Dion P, et al. **Methods Mol Biol** 1995;44:37–45

A plant oncogene as a phosphatase [letter] Filippini F, et al. **Nature** 1996 Feb 8;379(6565):499–500

PLANT VIRUSES

Optimum conditions for the storage of potato virus S. Ceřovská N, et al. **Acta Virol** 1995 Feb;39(1):51–2

Seed transmission of plant viruses: a lesson in biological complexity. Maule AJ, et al. **Trends Microbiol** 1996 Apr; 4(4):153–8 (24 ref.)

[Micro–morphology of the ovipositor in Hymenoptera and evolution from phytophagous Symphyta to parasitoid Apocrita] Nénon JP, et al. **C R Acad Sci III** 1995 Oct; 318(10):1045–51 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Beet necrotic yellow vein virus 42 kDa triple gene block protein binds nucleic acid in vitro. Bleykasten C, et al. **J Gen Virol** 1996 May;77 (Pt 5):889–97

Features on the surface of the tobacco rattle tobravirus particle that are antigenic and sensitive to proteolytic digestion. Legorburu FJ, et al. **J Gen Virol** 1996 May;77 (Pt 5):855–9

Rapid, small scale purification of rice hoja blanca and Echinochloa hoja blanca tenuivirus ribonucleoprotein. de Miranda JR, et al. **J Virol Methods** 1996 Jan;56(1):109–13

Structural comparison of the plant satellite viruses. Ban N, et al. **Virology** 1995 Dec 20;214(2):571–83

ENZYMOLOGY

Extraction of nuclei from sonchus yellow net rhabdovirus–infected plants yields a polymerase that synthesizes viral mRNAs and polyadenylated plus–strand leader RNA. Wagner JD, et al. **J Virol** 1996 Jan; 70(1):468–77

GENETICS

Use of plant viruses for delivery of vaccine epitopes. Beachy RN, et al. **Ann N Y Acad Sci** 1996 May 25;792:43–9 (16 ref.)

Nucleotide sequence of the genome of a citrus isolate of olive latent virus 1. Grieco F, et al. **Arch Virol** 1996; 141(5):825–38

Conservation of coat protein sequence among isolates of potato mop–top virus from Scotland and Peru. Mayo MA, et al. **Arch Virol** 1996;141(6):1115–21

Catalytic properties of hairpin ribozymes derived from Chicory yellow mottle virus and arabis mosaic virus satellite RNAs. DeYoung M, et al. **Biochemistry** 1995 Dec 5;34(48):15785–91

Early events in virus–plant interactions. Maia IG, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2521–32 (54 ref.)

PCR and non–isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):639–52 (94 ref.)

cDNA cloning and sequencing of 54kDa fragment of the 75kDa readthrough protein gene from beet necrotic yellow vein virus. Yu J, et al. **Chin J Biotechnol** 1995;11(2):119–23

Construction and expression of 75kDa readthrough protein gene from beet necrotic yellow vein virus. Yu J, et al. **Chin J Biotechnol** 1995;11(1):9–15

Variation in the genome of rice tungro bacilliform virus: molecular characterization of six isolates. Fan Z, et al. **J Gen Virol** 1996 May;77 (Pt 5):847–54

Sequence of RNA 2 of a nematode–transmissible isolate of tobacco rattle virus. Hernández C, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2847–51

Nucleotide sequence analysis of RNA–5 of five isolates of beet necrotic yellow vein virus and the identity of a deletion mutant. Kiguchi T, et al. **J Gen Virol** 1996 Apr; 77 (Pt 4):575–80

Complete sequence of an infectious full–length cDNA clone of citrus tatter leaf capillovirus: comparative sequence analysis of capillovirus genomes. Ohira K, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2305–9

Variation of viroid profiles in individual grapevine plants: novel grapevine yellow speckle viroid 1 mutants show alterations of hairpin I. Polivka H, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):155–61

Sequence analysis of pothos latent virus genomic RNA. Rubino L, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2835–9

Non–viral sequences at the 5' termini of mRNAs derived from virus–sense and virus–complementary sequences of the ambisense RNA segments of rice stripe tenuivirus. Shimizu T, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):541–6

The nucleotide sequence of cowpea mottle virus and its assignment to the genus Carmovirus. You XJ, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2841–5

In vivo restoration of biologically active 3' ends of virus–associated RNAs by nonhomologous RNA recombination and replacement of a terminal motif. Carpenter CD, et al. **J Virol** 1996 Jan;70(1):478–86

Detection of beet necrotic yellow vein virus using reverse transcription and polymerase chain reaction. Henry CM, et al. **J Virol Methods** 1995 Jul;54(1):15–28

Rapid cloning of uncharacterised tobacco rattle virus isolates using long template (LT) PCR. MacFarlane SA. **J Virol Methods** 1996 Jan;56(1):91–8

Agroinfection. Grimsley N. **Methods Mol Biol** 1995; 44:325–42

Genetic elements of plant viruses as tools for genetic engineering. Mushegian AR, et al. **Microbiol Rev** 1995 Dec; 59(4):548–78 (375 ref.)

A new method for designing PCR primers specific for groups of sequences and its application to plant viruses. Antoniw J. **Mol Biotechnol** 1995 Oct;4(2):111–9

Open reading frames of turnip crinkle virus involved in satellite symptom expression and incompatibility with Arabidopsis thaliana ecotype Dijon. Oh JW, et al. **Mol Plant Microbe Interact** 1995 Nov–Dec;8(6):979–87

Engineered RNA–mediated resistance to tomato spotted wilt virus is sequence specific. Prins M, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):416–8

Mexican papita viroid: putative ancestor of crop viroids. Martínez–Soriano JP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9397–401

Beet soil–borne virus RNA 3'–a further example of the heterogeneity of the gene content of furovirus genomes and of triple gene block–carrying RNAs. Koenig R, et al. **Virology** 1996 Feb 1;216(1):202–7

Multiple virus genes involved in the nematode transmission of pea early browning virus. MacFarlane SA, et al. **Virology** 1996 May 15;219(2):417–22

Specificity in the association of tomato black ring virus satellite RNA with helper virus. Oncino C, et al. **Virology** 1995 Oct 20;213(1):87–96

Comparisons of the genomic cis–elements and coding regions in RNA beta components of the hordeiviruses barley stripe mosaic virus, lychnis ringspot virus, and poa semilatent virus. Solovyev AG, et al. **Virology** 1996 May 1;219(1):9–18

Sequence of the PV2 gene of rice hoja blanca tenuivirus RNA–2. De Miranda JR, et al. **Virus Genes** 1995; 10(3):205–9

Cloning and sequence analysis of RNA–2 of a mechanically transmitted UK isolate of barley mild mosaic bymovirus (BaMMV). Jacobi V, et al. **Virus Res** 1995 Jul;37(2):99–111

[Analysis of the 3'–terminal region of the tick–borne filament–like virus substantiates its affiliation with the shallot X–virus group] Riabov EV, et al. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):104–10 **(Rus)**

IMMUNOLOGY

Immunological characterization of rice tungro spherical virus coat proteins and differentiation of isolates from the Philippines and India. Druka A, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1975–83

Immunotherapy of plant viral diseases. Benvenuto E, et al. **Trends Microbiol** 1995 Jul;3(7):272–5 (33 ref.)

ISOLATION & PURIFICATION

Single–step immunocapture RT–PCR in the detection of raspberry bushy dwarf virus. Kokko HI, et al. **Biotechniques** 1996 May;20(5):842–6

PCR and non–isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):639–52 (94 ref.)

A citrus exocortis viroid variant from broad bean (Vicia faba L.): infectivity and pathogenesis. Fagoaga C, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2271–7

Rapid differentiation of closely related isolates of two plant viruses by polymerase chain reaction and restriction fragment length polymorphism analysis. Barbara DJ, et al. **J Virol Methods** 1995 Sep;55(1):121–31

A rapid and sensitive dot–blot hybridization assay for the detection of citrus exocortis viroid in Citrus medica with digoxigenin–labelled RNA probes. Fonseca ME, et al. **J Virol Methods** 1996 Apr 5;57(2):203–7

Localization of fruit tree viruses by immuno–tissue printing in infected shoots of Malus sp. and Prunus sp. Knapp E, et al. **J Virol Methods** 1995 Oct;55(2):157–73

A simple imprint–hybridization method for detection of viroids. Romero–Durbán J, et al. **J Virol Methods** 1995 Sep;55(1):37–47

Detection of DNA and RNA plant viruses by PCR and RT–PCR using a rapid virus release protocol without tissue homogenization. Thomson D, et al. **J Virol Methods** 1995 Aug;54(2–3):85–95

Molecular identification of phytopathogenic viruses. Gallitelli D, et al. **Methods Mol Biol** 1996;50:57–79

Improved PCR methods for identification of phytopathogenic viruses. Minafra A, et al. **Methods Mol Biol** 1996;50:81–91

METABOLISM

High resolution analysis of the readthrough domain of beet necrotic yellow vein virus readthrough protein: a KTER motif is important for efficient transmission of the virus by Polymyxa betae. Tamada T, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1359–67

Novel NTP binding property of rice dwarf phytoreovirus minor core protein P5. Suzuki N, et al. **Virology** 1996 May 15;219(2):471–4

PATHOGENICITY

Engineered RNA–mediated resistance to tomato spotted wilt virus is sequence specific. Prins M, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):416–8

PHYSIOLOGY

Movement and transmission of banana bunchy top virus DNA component one in bananas. Hafner GJ, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2279–85

Vascular movement of plant viruses. Séron K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):435–42 (59 ref.)
Role of the variable domain in modulating potato spindle tuber viroid replication. Hu Y, et al. **Virology** 1996 May 1;219(1):45–56

PLANTAGO

see related
PSYLLIUM

CHEMISTRY

Rapid purification of a functionally active plant sucrose carrier from transgenic yeast using a bacterial biotin acceptor domain. Stolz J, et al. **FEBS Lett** 1995 Dec 18; 377(2):167–71
Phenylethanoids in the herb of Plantago lanceolata and inhibitory effect on arachidonic acid–induced mouse ear edema [letter] Murai M, et al. **Planta Med** 1995 Oct; 61(5):479–80

GENETICS

Expression of the PmSUC1 sucrose carrier gene from Plantago major L. is induced during seed development. Gahrtz M, et al. **Plant J** 1996 Jan;9(1):93–100

IMMUNOLOGY

English plantain and psyllium: lack of cross–allergenicity by crossed immunoelectrophoresis. Morgan MS, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):351–9

PHYSIOLOGY

Kinetic analysis of two simultaneously activated K+ currents in root cell protoplasts of Plantago media L. Vogelzang SA, et al. **J Membr Biol** 1995 Jul;146(1):59–71

PLANTAIN see **PLANTAGO**

PLANTAR PRINTS see **DERMATOGLYPHICS**

PLANTAR ULCER see **FOOT ULCER**

PLANTARIS MUSCLE see **MUSCLE, SKELETAL**

PLANTS

see related
HERBICIDES
POLLEN
SEEDS

Unusual plant cell contamination in a vaginal smear [letter] Demirezen S, et al. **Acta Cytol** 1996 Jul–Aug;40(4):841–2
Occupational asthma in horticulture caused by Lathyrus odoratus. Jansen A, et al. **Allergy Proc** 1995 May–Jun; 16(3):135–9
Detection of specific IgE antibodies to Japanese cypress pollen in patients with nasal allergy: a comparative study with Japanese cedar. Ganbo T, et al. **Auris Nasus Larynx** 1995;22(3):158–64
An infection from a penetrating plant wound. Golledge C. **Aust Fam Physician** 1995 Nov;24(11):2099
Plant growth hormone kinetin delays ageing, prolongs the lifespan and slows down development of the fruitfly Zaprionus paravittiger. Sharma SP, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1067–71
Isolation and characterization of a 30 kDa protein with antifungal activity from leaves of Engelmannia pinnatifida. Huynh QK, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):723–7
Phytoestrogens, body composition, and breast cancer. Horn–Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567–73 (59 ref.)
Allergic contact dermatitis from Hedera helix L. García M, et al. **Contact Dermatitis** 1995 Aug;33(2):133–4
Photocontact dermatitis from rue (Ruta montana L.). Ortiz–Frutos FJ, et al. **Contact Dermatitis** 1995 Oct; 33(4):284
Hand dermatitis in florists. Pereira F. **Contact Dermatitis** 1996 Feb;34(2):144–5
Immediate and delayed contact hypersensitivity to verbena plants. Potter PC, et al. **Contact Dermatitis** 1995 Nov; 33(5):343–6
Occupational contact dermatitis from lichens and Frullania. Quirino AP, et al. **Contact Dermatitis** 1995 Jul;33(1):68–9
Feeding on a marsh–living herbaceous plant by black howler monkeys (Alouatta caraya) in central Brazil. Rodrigues FH, et al. **Folia Primatol (Basel)** 1995;65(2):115–7
Marchantins and related polyphenols from liverwort: physico–chemical studies of their radical–scavenging properties. Schwartner C, et al. **Free Radic Biol Med** 1996; 20(2):237–44
Candida parapsilosis infection in a rose thorn wound. Turkal NW, et al. **J Am Board Fam Pract** 1995 Nov–Dec; 8(6):484–5
The Florida environment. Important outdoor aeroallergens. Jelks ML. **J Fla Med Assoc** 1996 Jun–Jul;83(6):406–10
Urinary calculus caused by plant material in a cynomolgus monkey. Lees CJ, et al. **Lab Anim Sci** 1995 Aug;45(4):441–2
Implication of flowers and weeds in fibrosing alveolitis [letter; comment] Hodges NG, et al. **Lancet** 1996 Apr 6; 347(9006):966. Comment on: Lancet 1996 Feb 3;347(8997):276–7. Comment on: Lancet 1996 Feb 3;347(8997):284–9.
Coexistence of multiple food chains in a heterogeneous environment: interactions among community structure, ecosystem functioning, and nutrient dynamics. Loreau M. **Math Biosci** 1996 Jun;134(2):153–88
Reporter genes and transient assays for plants. Matthews BF, et al. **Methods Mol Biol** 1995;55:147–62
Utilization of water hyacinth cellulose for production of cellobiase–rich preparation by Aspergillus niger 1. Ismail AM, et al. **Microbios** 1995;83(336):191–8
Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)
A review of the clinical effects of phytoestrogens. Knight DC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):897–904 (90 ref.)
Inhibitory effects of some steroidal saponins on human spermatozoa in vitro. Wang YF, et al. **Planta Med** 1996 Apr;62(2):130–2
Programmed cell death [letter] Fulton AB. **Science** 1996 Oct 4;274(5284):20–1
Antibacterial diterpenic acids from Brazilian propolis. Bankova V, et al. **Z Naturforsch [C]** 1996 May–Jun; 51(5–6):277–80
[Natural substances causing allergies and dermatitis] Tumová L, et al. **Ceska Slov Farm** 1995 Dec;44(6):293–300 (Eng. Abstr.) **(Cze)**
[Compositae dermatitis caused by contact allergy to sesquiterpene lactones] Bossuyt LE, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2572–4 (Eng. Abstr.) **(Dut)**
[Anti–ragweed campaign projects in the Drôme district] Couturier P. **Allerg Immunol (Paris)** 1995 Nov;27(9):340 (Eng. Abstr.) **(Fre)**
[The campaign against the spread of ragweed: the Quebec model] Déchamp C. **Allerg Immunol (Paris)** 1995 Nov; 27(9):332–4 (Eng. Abstr.) **(Fre)**
[The role of the environmental lawyer in the campaign against ragweed: practical approach] Desvignes–Morin AC. **Allerg Immunol (Paris)** 1995 Nov;27(9):350–1 (Eng. Abstr.) **(Fre)**
[Ragweed and public utilities] Deviller S. **Allerg Immunol (Paris)** 1995 Nov;27(9):335–6 (Eng. Abstr.) **(Fre)**
["Ambroisie, la Fleur du Mal." A 13–minute video program on ragweed] Luquet M. **Allerg Immunol (Paris)** 1995 Nov; 27(9):344 (Eng. Abstr.) **(Fre)**
[Ragweed alert from the Drôme physicians] Osterberger M. **Allerg Immunol (Paris)** 1995 Nov;27(9):343–4 (Eng. Abstr.) **(Fre)**
[New legislation from the Politique Agricole Commune passed in 1994 and its impact on the spread of ragweed. The public health laws are the responsibility of the mayor, the health department, the General Council and the State Council. Riotte–Flandrois F, et al. **Allerg Immunol (Paris)** 1995 Nov;27(9):345–6, 349 (Eng. Abstr.) **(Fre)**
[The anti–ragweed campaign experience in Saint–Fons (Rhône)] Vottero R. **Allerg Immunol (Paris)** 1995 Nov; 27(9):337–8 (Eng. Abstr.) **(Fre)**
[Effect of a supplemental Aspergillus niger phytase on the utilization of plant phosphorus by rainbow trout (Oncorhynchus mykiss)] Rodehutscord M, et al. **Arch Tierernahr** 1995;48(1–2):211–9 (Eng. Abstr.) **(Ger)**
[Thermal–spring parks within the ambit of protected areas: general trends in morphology and botany] Grossi F, et al. **Clin Ter** 1996 Apr;147(4):161–7 (Eng. Abstr.) **(Ita)**
[Human poisoning caused by chemicals for plant protection in 1994] Przybylska A. **Przegl Epidemiol** 1996;50(1–2):151–8 **(Pol)**

ANATOMY & HISTOLOGY

Improvements for observing Anthurium (Araceae) floral structures by light microscopy. Matsumoto TK, et al. **Biotech Histochem** 1995 Jul;70(4):205–10
Vascular movement of plant viruses. Séron K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):435–42 (59 ref.)
[The relationship of the lifespan of eukaryotes (animals and plants) to their physical characteristics] Metel'skiĭ ST. **Zh Obshch Biol** 1995 Nov–Dec;56(6):723–35 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)
Analysis of ascorbate in plant tissues by high–performance capillary zone electrophoresis. Davey MW, et al. **Anal Biochem** 1996 Jul 15;239(1):8–19
The occurrence of hsp70 in the outer membrane of plant mitochondria. Mooney B, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):309–13
Inositol phosphates in the duckweed Spirodela polyrhiza L. Brearley CA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):215–25
Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117–26 (47 ref.)
Plant polyphenols: free radical scavengers or chain–breaking antioxidants? Rice–Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)
Microinjection of fluorescence dye in a plant cell and its intercellular translocation using a multi–channel microelectrode system. Saito M, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):1–4
RNA isolation from plant tissues recalcitrant to extraction in guanidine. Bugos RC, et al. **Biotechniques** 1995 Nov; 19(5):734–7
Characterization of a monoclonal antibody that recognizes an arabinosylated (1—>6)–beta–D–galactan epitope in plant complex carbohydrates. Steffan W, et al. **Carbohydr Res** 1995 Oct 2;275(2):295–307
Cell–cycle specific cytotoxicity mediated by rearranged ent–kaurene diterpenoids isolated from Parinari curatellifolia. Lee IS, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):193–204
Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter–induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190–6
Cyclic peptides from higher plants. XXVIII. Antitumor activity and hepatic microsomal biotransformation of cyclic pentapeptides, astins, from Aster tataricus. Morita H, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1026–32
Chemical and chemotaxonomical studies on Dicranopteris species. Raja DP, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1800–3
Steroidal glycosides from roots of Cynanchum caudatum M. II. Warashina T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct; 43(10):1734–7
Acute irritant contact dermatitis from Agave americana L. Brazzelli V, et al. **Contact Dermatitis** 1995 Jul;33(1):60–1
Isolation and quantification of a new tuliposide (tuliposide D) by HPLC in Alstroemeria. Christensen LP, et al. **Contact Dermatitis** 1995 Sep;33(3):188–92
2–methoxy–6–pentyl–1,4–dihydroxybenzene (miconidin) from Primula obconica: a possible allergen? Krebs M, et al. **Contact Dermatitis** 1995 Aug;33(2):90–3
Heavy metals in aquatic plants and sediments from water systems in Macedonia, Greece. Sawidis T, et al. **Ecotoxicol Environ Saf** 1995 Oct;32(1):73–80
Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes. Haraguchi H, et al. **Experientia** 1996 Jun 15;52(6):564–7
Insect hormones in vertebrates: anabolic effects of 20–hydroxyecdysone in Japanese quail. Sláma K, et al. **Experientia** 1996 Jul 15;52(7):702–6
Isolation, characterization and pharmacological activity of Magydaris pastinacea (Lam) Paol. glucosides. Cerri R, et al. **Farmaco** 1995 Dec;50(12):841–8
An evaluation of ratio systems in radioecological studies. McGee EJ, et al. **Health Phys** 1996 Feb;70(2):215–21
New lymphocyte stimulating monocot lectins from family Araceae. Kamboj SS, et al. **Immunol Invest** 1995 Aug; 24(5):845–55
H NMR study of the solution structure of Ac–AMP2, a sugar binding antimicrobial protein isolated from Amaranthus caudatus. Martins JC, et al. **J Mol Biol** 1996 May 3; 258(2):322–33
Cis–clerodane diterpene lactones from Amphiachyris dracunculoides. 3. Harraz FM, et al. **J Nat Prod** 1996 May; 59(5):463–8
Phospholipase D inhibitors from a Myrsine species. Hegde VR, et al. **J Nat Prod** 1995 Oct;58(10):1492–7
Amoenolide K and amoenolide K 19–acetate, two grindelane peroxides from Amphiachyris amoena. Isolation, structure determination, and preparation of amoenolide K from amoenolide A by photochemical oxygenation. O'Mathúna DP, et al. **J Nat Prod** 1995 Sep;58(9):1407–18
C–geranyl compounds from Mimulus clevelandii. Phillips WR, et al. **J Nat Prod** 1996 May;59(5):495–7
13–O–acetylvakhmatine, a new diterpenoid alkaloid from the seeds of Consolida ambigua. Venkateswarlu V, et al. **J Nat Prod** 1995 Oct;58(10):1527–32
A highly efficient procedure for purifying the ribosome–inactivating proteins alpha– and beta–momorcharins from Momordica charantia seeds, N–terminal sequence comparison and establishment of their N–glycosidase activity. Fong WP, et al. **Life Sci** 1996; 59(11):901–9
Methods for isolation and analysis of the cytoskeleton. Abe S, et al. **Methods Cell Biol** 1995;50:223–36
Methods for isolation and analysis of polyribosomes. Davies E, et al. **Methods Cell Biol** 1995;50:209–22
Extraction and assay of protein from single plant cells. Outlaw WH Jr. **Methods Cell Biol** 1995;50:41–9
High–resolution NMR methods for study of higher plants. Roberts JK, et al. **Methods Cell Biol** 1995;49:245–58
Quantifying polyamines in Agrobacterium rhizogenes strains and in Ri plasmid transformed cells. Bagni N, et al. **Methods Mol Biol** 1995;44:223–36
Evaluation of the mutagenicity of the molluscicidal latex of Christ's Crown (Euphorbia milii var. hislopii) in mammalian cells in vitro and in vivo. Zamith HP, et al. **Mutat Res** 1996 May;368(1):15–20
Rapid analysis of small samples containing forskolin using monoclonal antibodies. Yanagihara H, et al. **Planta Med** 1996 Apr;62(2):169–72
On heavy metals in soil; rationalization of extractions by dilute salt solutions, comparison of the extracted concentrations with uptake by ryegrass and lettuce, and the possible influence of pyrophosphate on plant uptake. Aten CF, et al. **Sci Total Environ** 1996 Jan 19;

178(1-3):45-53
Vascular plants as sensitive indicators of lead and PCB transport from local sources in the Canadian Arctic. Dushenko WT, et al. **Sci Total Environ** 1996 Sep 20; 188(1):29-38
GFP in plants. Haseloff J, et al. **Trends Genet** 1995 Aug; 11(8):328-9

CLASSIFICATION

Phylogenetic affinities of the grasses to other monocots as revealed by molecular analysis of chloroplast DNA. Katayama H, et al. **Curr Genet** 1996 May;29(6):572-81
RNA editing in bryophytes and a molecular phylogeny of land plants. Malek O, et al. **EMBO J** 1996 Mar 15; 15(6):1403-11
Molecular phylogenetics of Poaceae: an expanded analysis of rbcL sequence data. Duvall MR, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):352-8
ndhF sequence evolution and the major clades in the sunflower family. Kim KJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10379-83

CYTOLOGY

Enhanced protoplast growth at the interface between oxygenated fluorocarbon liquid and aqueous culture medium supplemented with pluronic F-68. Lowe KC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):417-22
Actomyosin-based motility of endoplasmic reticulum and chloroplasts in Vallisneria mesophyll cells. Liebe S, et al. **Biol Cell** 1995;85(2-3):207-22
Changes in the rheological properties of the cell wall of plant seedlings under simulated microgravity conditions. Masuda Y, et al. **Biorheology** 1994 Mar-Apr;31(2):171-7
Cytokinesis in higher plants. Staehelin LA, et al. **Cell** 1996 Mar 22;84(6):821-4 (20 ref.)
Plant mitosis promoting factor disassembles the microtubule preprophase band and accelerates prophase progression in Tradescantia. Hush J, et al. **Cell Biol Int** 1996 Apr; 20(4):275-87
Effects of biological factors on cell growth and anthocyanin formation by suspended cultures of Perilla frutescens cells. Zhong J, et al. **Chin J Biotechnol** 1995;11(2):143-7
Microwave irradiation improvements in the silver staining of the nucleolar organizer (Ag-NOR) technique. Medina FJ, et al. **Histochem Cell Biol** 1995 Jun;103(6):403-13
The force for poleward chromosome motion in Haemanthus cells acts along the length of the chromosome during metaphase but only at the kinetochore during anaphase. Khodjakov A, et al. **J Cell Biol** 1996 Mar;132(6):1093-104
Phragmoplast of the green alga Spirogyra is functionally distinct from the higher plant phragmoplast. Sawitzky H, et al. **J Cell Biol** 1995 Sep;130(6):1359-71
Measurements of wall stress relaxation in growing plant cells. Cosgrove DJ. **Methods Cell Biol** 1995;49:231-43
Confocal epipolarization microscopy of gold probes in plant cells and protoplasts. Griffing LR, et al. **Methods Cell Biol** 1995;49:109-21 (40 ref.)
Synchronization of cell cultures of higher plants. Kodama H, et al. **Methods Cell Biol** 1995;49:315-29
Cell cycle synchronization, chromosome isolation, and flow-sorting in plants. Lucretti S, et al. **Methods Cell Biol** 1995;50:61-83
Patch-clamping plant cells. Maathuis FJ, et al. **Methods Cell Biol** 1995;49:293-302
Extraction and assay of protein from single plant cells. Outlaw WH Jr. **Methods Cell Biol** 1995;50:41-9
Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123-41 (61 ref.)
Genetic tagging of cells and cell layers for studies of plant development. Spena A, et al. **Methods Cell Biol** 1995; 49:331-54 (110 ref.)
Cell-specific ablation in plants. Thorsness MK, et al. **Methods Cell Biol** 1995;50:439-48
The isolation of intact chloroplasts. Napier JA, et al. **Methods Mol Biol** 1995;49:355-60
Cell-context signalling. Pennell RI, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):87-93 (48 ref.)
In and out of the plant cell cycle. Hirt H. **Plant Mol Biol** 1996 Jun;31(3):459-64 (29 ref.)

DRUG EFFECTS

Lethal effects of the consumption of field levels of paraquat-contaminated plants on frog tadpoles. Bauer Dial CA, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):870-7
Growth responses of Typha latifolia and Scirpus acutus to atrazine contamination. Langan MM, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):307-14
Uptake of lead by Lemna gibba L.: influence on specific growth rate and basic biochemical changes. Miranda MG, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):1000-7
The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1-24 (109 ref.)
In situ monitoring with the Tradescantia bioassays on the genotoxicity of gaseous emissions from a closed landfill site and an incinerator. Ma TH, et al. **Mutat Res** 1996 Jan 16;359(1):39-52

EMBRYOLOGY

Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344-8 (52 ref.)
[Molecular cloning of differentially expressed genes during plant somatic embryogenesis] Kayano T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):721-6 (32 ref.) **(Jpn)**

ENZYMOLOGY

Aspartic proteinases (cyprosins) from Cynara cardunculus spp. Flavescens cv. cardoon; purification, characterisation, and tissue-specific expression. Brodelius PE, et al. **Adv Exp Med Biol** 1995;362:255-66
Plant aspartic proteinases from Cynara cardunculus spp. flavescens cv. cardoon; nucleotide sequence of a cDNA encoding cyprosin and its organ-specific expression. Cordeiro MC, et al. **Adv Exp Med Biol** 1995;362:367-72
Cardosin A and B, aspartic proteases from the flowers of cardoon. Faro C, et al. **Adv Exp Med Biol** 1995;362:373-7
Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241-54 (72 ref.)
The primary sequence of cytochrome P450tyr, the multifunctional N-hydroxylase catalyzing the conversion of L-tyrosine to p-hydroxyphenylacetaldehyde oxime in the biosynthesis of the cyanogenic glucoside dhurrin in Sorghum bicolor (L.) Moench. Koch BM, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):177-86
Cloning, characterization, and heterologous expression of cDNAs for farnesyl diphosphate synthase from the guayule rubber plant reveals that this prenyltransferase occurs in rubber particles. Pan Z, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):196-204
Purification and characterization of an NADPH-cytochrome P450 (cytochrome c) reductase from spearmint (Mentha spicata) glandular trichomes. Ponnamperuma K, et al. **Arch Biochem Biophys** 1996 May 1;329(1):9-16
Characterization of IMT1, myo-inositol O-methyltransferase, from Mesembryanthemum crystallinum. Rammesmayer G, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):183-8
Covalent dimerization of ribulose bisphosphate carboxylase subunits by UV radiation. Ferreira RM, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):227-34
Kinetic analysis of the mitochondrial quinol-oxidizing enzymes during development of thermogenesis in Arum maculatum L. Leach GR, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):313-9
Phosphorylation of phosphoenolpyruvate carboxykinase in plants. Studies in plants with C4 photosynthesis and Crassulacean acid metabolism and in germinating seeds. Walker RP, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):653-8
Enzymic hydrolysis of raffinose and stachyose in soymilk by alpha-galactosidase from Gibberella fujikuroi. Mulimani VH, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):897-905
Diacylglycerol- and phosphatidic acid-kinase studies in plant cell suspension cultures. Wissing JB, et al. **Biochem Soc Trans** 1995 Nov;23(4):867-71
Crystal structure of glycyl endopeptidase from Carica papaya: a cysteine endopeptidase of unusual substrate specificity. O'Hara BP, et al. **Biochemistry** 1995 Oct 10; 34(40):13190-5
Stereochemistry of chitin hydrolysis by a plant chitinase/lysozyme and X-ray structure of a complex with allosamidin: evidence for substrate assisted catalysis. Terwisscha van Scheltinga AC, et al. **Biochemistry** 1995 Dec 5;34(48):15619-23
cDNA sequence and expression of subunit E of the vacuolar H(+)-ATPase in the inducible Crassulacean acid metabolism plant Mesembryanthemum crystallinum. Dietz KJ, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):134-8
Plant glyoxysomal but not mitochondrial malate dehydrogenase can fold without chaperone assistance. Gietl C, et al. **Biochim Biophys Acta** 1996 May 20; 1274(1-2):48-58
Evidence for a glycosylinositolphospholipid-anchored alkaline phosphatase in the aquatic plant Spirodela oligorrhiza. Morita N, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):53-62
Transcriptional and post-translational control of the plant plasma membrane H(+)-ATPase by mechanical treatments. Noubhani AM, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):213-9
Substrate specificity and transglucosylation catalyzed by cycad beta-glucosidase. Yagi F, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):315-21
Do de-N-glycosylation enzymes have an important role in plant cells? Berger S, et al. **Biochimie** 1995;77(9):751-60 (98 ref.)
A biochemical comparison between latex from Carica candamarcensis and C. papaya. Bravo LM, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2831-42
Comparative studies on animal and plant apyrases (ATP diphosphohydrolase EC 3.6.1.5) with application of immunological techniques and various ATPase inhibitors. Komoszyński MA. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):581-91
Codon usage in plant peroxidase genes. Tyson H, et al. **DNA Seq** 1995;5(6):339-51
Molecular characterisation of plant endoplasmic reticulum. Identification of protein disulfide-isomerase as the major reticuloplasmin. Coughlan SJ, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):215-24
A plant acyltransferase involved in triacylglycerol biosynthesis complements an Escherichia coli sn-1-acylglycerol-3-phosphate acyltransferase mutant. Hanke C, et al. **Eur J Biochem** 1995 Sep 15;232(3):806-10
New inhibitors of the ubiquinol oxidase of higher plant mitochondria. Hoefnagel MH, et al. **Eur J Biochem** 1995 Oct 15;233(2):531-7
The catalytic site of chloroplastic NADP-dependent malate dehydrogenase contains a His/Asp pair. Lemaire M, et al. **Eur J Biochem** 1996 Mar 15;236(3):947-52
Immunological detection of proteins similar to bacterial proteases in higher plant chloroplasts. Ostersetzer O, et al. **Eur J Biochem** 1996 Mar 15;236(3):932-6
The regulation of enzymes involved in chlorophyll biosynthesis. Reinbothe S, et al. **Eur J Biochem** 1996 Apr 15;237(2):323-43 (312 ref.)
Purification and properties of NAD(P)H: (quinone-acceptor) oxidoreductase of sugarbeet cells. Trost P, et al. **Eur J Biochem** 1995 Dec 1;234(2):452-8
IgE-binding trypsin inhibitors in plant pollen extracts. Berrens L, et al. **Experientia** 1995 Sep 29;51(9-10):953-5
Plant lysozymes. Beintema JJ, et al. **EXS** 1996;75:75-86 (52 ref.)
Molecular cloning and functional expression in E. coli of a novel plant enzyme mediating zeta-carotene desaturation. Albrecht M, et al. **FEBS Lett** 1995 Sep 25;372(2-3):199-202
A new family of lipolytic plant enzymes with members in rice, arabidopsis and maize. Brick DJ, et al. **FEBS Lett** 1995 Dec 27;377(3):475-80
Site-directed mutagenesis of Flaveria trinervia phosphoenolpyruvate carboxylase: Arg450 and Arg767 are essential for catalytic activity and Lys829 affects substrate binding. Gao Y, et al. **FEBS Lett** 1996 Sep 2;392(3):285-8
Site-directed mutagenesis of Lys600 in phosphoenolpyruvate carboxylase of Flaveria trinervia: its roles in catalytic and regulatory functions. Gao Y, et al. **FEBS Lett** 1995 Nov 13;375(1-2):95-8
Cinnamate 4-hydroxylase from Catharanthus roseus, and a strategy for the functional expression of plant cytochrome P450 proteins as translational fusions with P450 reductase in Escherichia coli. Hotze M, et al. **FEBS Lett** 1995 Nov 6;374(3):345-50
Purification and characterization of furostanol glycoside 26-O-beta-glucosidase from Costus speciosus rhizomes. Inoue K, et al. **FEBS Lett** 1996 Jan 8;378(2):157-60
Ascorbate is the natural substrate for plant peroxidases. Mehlhorn H, et al. **FEBS Lett** 1996 Jan 15;378(3):203-6
The 32 kDa tonoplast polypeptide Di associated with the V-type H+-ATPase of Mesembryanthemum crystallinum L. in the CAM state: A proteolytically processed subunit B? Zhigang A, et al. **FEBS Lett** 1996 Jul 8;389(3):314-8
Regulation of alternative oxidase activity in higher plants. Day DA, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):379-85 (41 ref.)
Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367-77 (70 ref.)
Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407-14 (57 ref.)
Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397-406 (64 ref.)
Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration. Albury MS, et al. **J Biol Chem** 1996 Jul 19;271(29):17062-6
The molecular pathway for the regulation of phosphoribulokinase by thioredoxin f. Brandes HK, et al. **J Biol Chem** 1996 Feb 16;271(7):3333-5
Characterization and mechanism of the berberine bridge enzyme, a covalently flavinylated oxidase of benzophenanthridine alkaloid biosynthesis in plants. Kutchan TM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24475-81
Acetyl coenzyme A:salutaridinol-7-O-acetyltransferase from papaver somniferum plant cell cultures. The enzyme catalyzing the formation of thebaine in morphine biosynthesis. Lenz R, et al. **J Biol Chem** 1995 Dec 29; 270(52):31091-6
Activation of a recombinant petunia glutamate decarboxylase by calcium/calmodulin or by a monoclonal antibody which recognizes the calmodulin binding domain. Snedden WA, et al. **J Biol Chem** 1996 Feb 23;271(8):4148-53
The catalytic cysteine and histidine in the plant acyl-acyl carrier protein thioesterases. Yuan L, et al. **J Biol Chem** 1996 Feb 16;271(7):3417-9
Plant lipoxygenases. Shibata D, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):213-28 (80 ref.)
In situ enzyme histochemistry on plastic-embedded plant material. De Block M. **Methods Cell Biol** 1995;49:153-63
Isolation and functional reconstruction of the vacuolar H(+)-ATPase. Ward JM, et al. **Methods Cell Biol** 1995; 50:149-60

Genotypic diversity revealed by allozymes and oligonucleotide DNA fingerprinting in French populations of the aquatic macrophyte Sparganium erectum. Piquot Y, et al. **Mol Ecol** 1996 Apr;5(2):251–8

H-protein of glycine decarboxylase is encoded by multigene families in Flaveria pringlei and F. cronquistii (Asteraceae). Kopriva S, et al. **Mol Gen Genet** 1995 Nov 1;249(1):111–6

Sucrose synthase and enolase expression in actinorhizal nodules of Alnus glutinosa: comparison with legume nodules. van Ghelue M, et al. **Mol Gen Genet** 1996 Mar 7;250(4):437–46

Evolution of floral scent in Clarkia: novel patterns of S-linalool synthase gene expression in the C. breweri flower. Dudareva N, et al. **Plant Cell** 1996 Jul;8(7):1137–48

A jojoba beta-Ketoacyl-CoA synthase cDNA complements the canola fatty acid elongation mutation in transgenic plants. Lassner MW, et al. **Plant Cell** 1996 Feb;8(2):281–92

C-terminal deletion analysis of plant plasma membrane H(+)-ATPase: yeast as a model system for solute transport across the plant plasma membrane. Regenberg B, et al. **Plant Cell** 1995 Oct;7(10):1655–66

The stroma of higher plant plastids contain ClpP and ClpC, functional homologs of Escherichia coli ClpP and ClpA: an archetypal two-component ATP-dependent protease. Shanklin J, et al. **Plant Cell** 1995 Oct;7(10):1713–22

Origin of allelic diversity in antirrhinum S locus RNases. Xue Y, et al. **Plant Cell** 1996 May;8(5):805–14

Acetyl-CoA carboxylase in higher plants: most plants other than gramineae have both the prokaryotic and the eukaryotic forms of this enzyme. Konishi T, et al. **Plant Cell Physiol** 1996 Mar;37(2):117–22

Transient and specific expression of a cysteine endopeptidase associated with autolysis during differentiation of Zinnia mesophyll cells into tracheary elements. Minami A, et al. **Plant Cell Physiol** 1995 Dec;36(8):1599–606

Plant homologues of components of MAPK (mitogen-activated protein kinase) signal pathways in yeast and animal cells. Nishihama R, et al. **Plant Cell Physiol** 1995 Jul;36(5):749–57 (100 ref.)

Purification of the cytosolic CuZn-superoxide dismutase (CuZn-SOD) of Marchantia paleacea var. diptera and its resemblance to CuZn-SOD from chloroplasts. Tanaka K, et al. **Plant Cell Physiol** 1996 Jun;37(4):523–9

A novel, soluble form of phytoene desaturase from Narcissus pseudonarcissus chromoplasts is Hsp70-complexed and competent for flavinylation, membrane association and enzymatic activation. Al-Babili S, et al. **Plant J** 1996 May; 9(5):601–12

Primary structure and expression of plant homologues of animal and fungal thioredoxin-dependent peroxide reductases and bacterial alkyl hydroperoxide reductases. Baier M, et al. **Plant Mol Biol** 1996 Jun;31(3):553–64

Higher-plant chloroplast and cytosolic 3-phosphoglycerate kinases: a case of endosymbiotic gene replacement. Brinkmann H, et al. **Plant Mol Biol** 1996 Jan;30(1):65–75

Molecular cloning and characterisation of asparagine synthetase from Lotus japonicus: dynamics of asparagine synthesis in N-sufficient conditions. Waterhouse RN, et al. **Plant Mol Biol** 1996 Mar;30(5):883–97

Cloning and characterization of a glutathione S-transferase that can be photolabeled with 5-azido-indole-3-acetic acid. Bilang J, et al. **Plant Physiol** 1995 Sep;109(1):253–60

Anthranilate synthase from Ruta graveolens. Duplicated AS alpha genes encode tryptophan-sensitive and tryptophan-insensitive isoenzymes specific to amino acid and alkaloid biosynthesis. Bohlmann J, et al. **Plant Physiol** 1996 Jun;111(2):507–14

Identification and gene expression of anaerobically induced enolase in Echinochloa phyllopogon and Echinochloa crus-pavonis. Fox TC, et al. **Plant Physiol** 1995 Oct; 109(2):433–43

Lysophosphatidic acid acyltransferase from meadowfoam mediates insertion of erucic acid at the sn-2 position of triacylglycerol in transgenic rapeseed oil. Lassner MW, et al. **Plant Physiol** 1995 Dec;109(4):1389–94

Two divergent xyloglucan endotransglycosylases exhibit mutually exclusive patterns of expression in nasturtium. Rose JK, et al. **Plant Physiol** 1996 Feb;110(2):493–9

A thiol protease and an anionic peroxidase are induced by lowering cytokinins during callus growth in Petunia. Tournaire C, et al. **Plant Physiol** 1996 May;111(1):159–68

Identification and characterization of a phloem-specific beta-amylase. Wang Q, et al. **Plant Physiol** 1995 Nov; 109(3):743–50

Identification and characterization of cDNAs encoding ethylene biosynthetic enzymes from Pelargonium x hortorum cv Snow Mass leaves. Wang TW, et al. **Plant Physiol** 1995 Oct;109(2):627–36

Modification of the substrate specificity of an acyl-acyl carrier protein thioesterase by protein engineering. Yuan L, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10639–43

Overexpression of a tryptophan decarboxylase cDNA in Catharanthus roseus crown gall calluses results in increased tryptamine levels but not in increased terpenoid indole alkaloid production. Goddijn OJ, et al. **Transgenic Res** 1995 Sep;4(5):315–23

[Specific segments of the amino acid sequence of plant peroxidase] Kazachenko KIu. **Biokhimiia** 1996 Jan; 61(1):82–4 (Eng. Abstr.) **(Rus)**

GENETICS

An efficient method of genomic DNA isolation from plant tissues. Stróżycki PM, et al. **Acta Biochim Pol** 1995; 42(3):329–31

High efficiency callus induction and plant regeneration in petiole culture of four poplar genotypes. Jafari MA, et al. **Acta Biol Hung** 1995;46(1):51–9

Expression of cholera toxin subunits in plants. Hein MB, et al. **Ann N Y Acad Sci** 1996 May 25;792:50–6

Antibody production and engineering in plants. Ma JK, et al. **Ann N Y Acad Sci** 1996 May 25;792:72–81 (35 ref.)

Cloning, characterization, and heterologous expression of cDNAs for farnesyl diphosphate synthase from the guayule rubber plant reveals that this prenyltransferase occurs in rubber particles. Pan Z, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):196–204

Genetic analysis of essential oil variants in Perilla frutescens. Yuba A, et al. **Biochem Genet** 1995 Oct;33(9-10):341–8

A duplicated sequence in sugarbeet mitochondrial transcripts is differentially edited: analysis of orfB and its derivative orf324 mRNAs. Kubo T, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):259–62

RNA editing in the cox3 mRNA of Magnolia is more extensive than in other dicot or monocot plants. Perrotta G, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):254–8

Universality of mitochondrial RNA editing in cytochrome-c oxidase subunit I (coxI) among the land plants. Sper-Whitis GL, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):301–8

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

Preparation of high molecular weight genomic DNA from nuclei of woody plants. Luro F, et al. **Biotechniques** 1995 Sep;19(3):388–92

Single-step protocol for preparation of plant tissue for analysis by PCR. Thomson D, et al. **Biotechniques** 1995 Sep;19(3):394–7, 400

Molecular cloning and structural analysis of cDNAs that encode 3 small GTP-binding proteins from sugar beet. Dallery E, et al. **C R Acad Sci III** 1996 Feb;319(2):91–7

An unstable minichromosome generates variegated oil yellow maize seedlings. Brock RD, et al. **Chromosoma** 1996 Jun; 104(8):575–84

Chromosome 'painting' in plants – a feasible technique? Fuchs J, et al. **Chromosoma** 1996;104(5):315–20

Characterisation of repeated sequences from microdissected B chromosomes of Crepis capillaris. Jamilena M, et al. **Chromosoma** 1995 Nov;104(2):113–20

Nucleolar organizer expression in Allium cepa L. chromosomes. Panzera F, et al. **Chromosoma** 1996 Jul; 105(1):12–9

The perinuclear microtubule-organizing center and the synaptonemal complex of higher plants share a common antigen: its putative transfer and role in meiotic chromosomal ordering. Schmit AC, et al. **Chromosoma** 1996 Mar;104(6):405–13

Distribution of 5-methylcytosine-rich regions in the metaphase chromosomes of Vicia faba. Frediani M, et al. **Chromosome Res** 1996 Feb;4(2):141–6

Stable chromosome fission associated with rDNA mobility. Hall KJ, et al. **Chromosome Res** 1995 Nov;3(7):417–22

Detection of rDNA sites in sugarcane by FISH. Jenkin MJ, et al. **Chromosome Res** 1995 Nov;3(7):444–5

Analysis and chromosomal localization of retrotransposons in sugar beet (Beta vulgaris L.): LINEs and Ty1-copia-like elements as major components of the genome. Schmidt T, et al. **Chromosome Res** 1995 Sep;3(6):335–45

Imaging of DNA in human and plant chromosomes by high-resolution scanning electron microscopy. Wanner G, et al. **Chromosome Res** 1995 Sep;3(6):368–74

Plant genetics: fast flowering. Smyth DR. **Curr Biol** 1996 Feb 1;6(2):122–4 (10 ref.)

Electron microscopic investigation of mitochondrial DNA from Chenopodium album (L.). Backert S, et al. **Curr Genet** 1996 Apr;29(5):427–36

Investigation of plant organellar DNAs by pulsed-field gel electrophoresis. Backert S, et al. **Curr Genet** 1995 Sep; 28(4):390–9

Intramolecular recombination of a mitochondrial minicircular plasmid-like DNA of date-palm mediated by a set of short direct-repeat sequences. Benslimane AA, et al. **Curr Genet** 1996 May;29(6):591–3

Structural and functional analysis of plastid genomes from parasitic plants: loss of an intron within the genus Cuscuta. Freyer R, et al. **Curr Genet** 1995 May;27(6):530–6

Phylogenetic affinities of the grasses to other monocots as revealed by molecular analysis of chloroplast DNA. Katayama H, et al. **Curr Genet** 1996 May;29(6):572–81

The gene for ribosomal protein S10 is present in mitochondria of pea and potato but absent from those of Arabidopsis and Oenothera. Knoop V, et al. **Curr Genet** 1995 May; 27(6):559–64

An intron loss in the chloroplast gene rpoC1 supports a monophyletic origin for the subfamily Cactoideae of the Cactaceae. Wallace RS, et al. **Curr Genet** 1996 Feb; 29(3):275–81

Molecular responses to drought and cold stress. Shinozaki K, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):161–7 (64 ref.)

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)

Functional analysis of the Antirrhinum floral homeotic DEFICIENS gene in vivo and in vitro by using a temperature-sensitive mutant. Zachgo S, et al. **Development** 1995 Sep;121(9):2861–75

Characterization of cDNAs induced in meiotic prophase in lily microsporocytes. Kobayashi T, et al. **DNA Res** 1994; 1(1):15–26

Codon usage in plant peroxidase genes. Tyson H, et al. **DNA Seq** 1995;5(6):339–51

Polymerase chain reaction-based assays for the characterisation of plant genetic resources. Powell W, et al. **Electrophoresis** 1995 Sep;16(9):1726–30 (36 ref.)

RNA editing in bryophytes and a molecular phylogeny of land plants. Malek O, et al. **EMBO J** 1996 Mar 15; 15(6):1403–11

Cucumber T-complex protein. Molecular cloning, bacterial expression and characterization within a 22-S cytosolic complex in cotyledons and hypocotyls. Ahnert V, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):114–9

Identification of multiple PEPC isogenes in leaves of the facultative Crassulacean acid metabolism (CAM) plant Kalanchoe blossfeldiana Poelln. cv. Tom Thumb. Gehrig H, et al. **FEBS Lett** 1995 Dec 27;377(3):399–402

Molecular cloning and bacterial expression of a cDNA encoding furostanol glycoside 26-O-beta-glucosidase of Costus speciosus. Inoue K, et al. **FEBS Lett** 1996 Jul 8; 389(3):273–7

Localization of highly repetitive, species-specific EcoRI elements from Lupinus luteus L. Sakowicz T, et al. **Folia Histochem Cytobiol** 1995;33(3):209–13

Population structure of morphological traits in Clarkia dudleyana. I. Comparison of FST between allozymes and morphological traits. Podolsky RH, et al. **Genetics** 1995 Jun;140(2):733–44

A functional mitochondrial ATP synthase proteolipid gene produced by recombination of parental genes in a petunia somatic hybrid. Rothenberg M, et al. **Genetics** 1988 Jan; 118(1):155–61

The molecular evolution of the small heat-shock proteins in plants. Waters ER. **Genetics** 1995 Oct;141(2):785–95

S-allele sequence diversity in natural populations of Solanum carolinense (Horsenettle). Richman AD, et al. **Heredity** 1995 Oct;75 (Pt 4):405–15

S-allele diversity in a natural population of Physalis crassifolia (Solanaceae) (ground cherry) assessed by RT-PCR. Richman AD, et al. **Heredity** 1996 May;76 (Pt 5):497–505

Hormonal and environmental regulation of a plant PDR5-like ABC transporter. Smart CC, et al. **J Biol Chem** 1996 Aug 9;271(32):19351–7

Phylogeny of the large extrachromosomal DNA of organisms in the phylum Apicomplexa. Egea N, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):679–84

Fungal cytochrome c genes from plants. Hudson A. **J Mol Evol** 1995 Dec;41(6):1170–1; discussion 1172

Differential homogenization and amplification of two satellite DNAs in the genus Cucurbita (Cucurbitaceae). King K, et al. **J Mol Evol** 1995 Dec;41(6):996–1005

Divergence of the phytochrome gene family predates angiosperm evolution and suggests that Selaginella and Equisetum arose prior to Psilotum. Kolukisaoglu HU, et al. **J Mol Evol** 1995 Sep;41(3):329–37

Comparison of the evolution of ribulose-1, 5-biphosphate carboxylase (rbcL) and atpB-rbcL noncoding spacer sequences in a recent plant group, the tribe Rubieae (Rubiaceae). Manen JF, et al. **J Mol Evol** 1995 Dec; 41(6):920–7

Intron position as an evolutionary marker of thioredoxins and thioredoxin domains. Sahrawy M, et al. **J Mol Evol** 1996 Apr;42(4):422–31

Fungal origin by horizontal transfer of a plant mitochondrial group I intron in the chimeric CoxI gene of Peperomia. Vaughn JC, et al. **J Mol Evol** 1995 Nov;41(5):563–72

Electroporation of plant protoplasts and tissues. Bates GW. **Methods Cell Biol** 1995;50:363–73

Particle bombardment. Christou P. **Methods Cell Biol** 1995; 50:375–82

Isolation of nuclei suitable for in vitro transcriptional studies. Cushman JC. **Methods Cell Biol** 1995;50:113–28

Preparation and transformation of monocot protoplasts. Maas C, et al. **Methods Cell Biol** 1995;50:383–99

Ribozymes. Steinecke P, et al. **Methods Cell Biol** 1995; 50:449–60

Reporter genes. Suter-Crazzolara C, et al. **Methods Cell Biol** 1995;50:425–38

Cell-specific ablation in plants. Thorsness MK, et al. **Methods Cell Biol** 1995;50:439–48

Assessment of translational regulation by run-off translation of polysomes in vitro. Vayda ME. **Methods Cell Biol** 1995; 50:349–59

Binary Ti plasmid vectors. An G. **Methods Mol Biol** 1995; 44:47–58

Agrobacterium-mediated transfer of geminiviruses to plant tissues. Boulton MI. **Methods Mol Biol** 1995;49:77–93 (47 ref.)

In situ hybridization to plant tissue sections. Burgess SR. **Methods Mol Biol** 1995;49:301–16

In vitro transcription of class II promoters in higher plants. Cooke R, et al. **Methods Mol Biol** 1995;49:271–89 (19 ref.)

Leaf disk transformation. Curtis IS, et al. **Methods Mol Biol** 1995;44:59–70

Chloramphenicol acetyl transferase assay. Davey MR, et al. **Methods Mol Biol** 1995;49:143–8 (11 ref.)

Regulation of Agrobacterium gene manipulation. Dewhurst

F. **Methods Mol Biol** 1995;44:369–91 (33 ref.)
Fluorometric GUS analysis for transformed plant material. Gartland KM, et al. **Methods Mol Biol** 1995;44:195–9
Nuclear "run-on" transcription assays. Gatehouse J, et al. **Methods Mol Biol** 1995;49:229–38
Tools for expressing foreign genes in plants. Guerineau F. **Methods Mol Biol** 1995;49:1–32 (82 ref.)
Gene transfer into plant protoplasts by electroporation. Jones H. **Methods Mol Biol** 1995;49:107–12 (10 ref.)
Use of cosmid libraries in plant transformations. Ma H. **Methods Mol Biol** 1995;44:351–67
Isolation and characterization of plant genomic DNA sequences via (inverse) PCR amplification. Offringa R, et al. **Methods Mol Biol** 1995;49:181–95 (38 ref.)
Northern analysis and nucleic acid probes. Sabelli PA, et al. **Methods Mol Biol** 1995;49:213–28 (32 ref.)
Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)
The detection of neomycin phosphotransferase activity in plant extracts. Scheid OM, et al. **Methods Mol Biol** 1995; 44:201–6
Isolation of whole cell (total) RNA. Scott RJ. **Methods Mol Biol** 1995;49:197–202
Poly(A)+ RNA isolation. Scott RJ. **Methods Mol Biol** 1995; 49:203–6
RNase A/T1 protection assay. Simpson CG, et al. **Methods Mol Biol** 1995;49:239–47
Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49–61 (18 ref.)
Noncoding sequences from the slowly evolving chloroplast inverted repeat in addition to rbcL data do not support gnetalean affinities of angiosperms. Goremykin V, et al. **Mol Biol Evol** 1996 Feb;13(2):383–96
Phylogenetic analysis of the 90 kD heat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species. Gupta RS. **Mol Biol Evol** 1995 Nov;12(6):1063–73
Intra- and interspecific variation of the alcohol dehydrogenase locus region in wild plants Arabis gemmifera and Arabidopsis thaliana [letter] Miyashita NT, et al. **Mol Biol Evol** 1996 Feb;13(2):433–6
A common group I intron between a plant parasitic fungus and its host. Nishida H, et al. **Mol Biol Evol** 1995 Sep; 12(5):883–6
Proliferation of direct repeats near the Oenothera chloroplast DNA origin of replication. Sears BB, et al. **Mol Biol Evol** 1996 Jul;13(6):850–63
Rapid optimization of electroporation conditions for plant cells, protoplasts, and pollen. Saunders JA, et al. **Mol Biotechnol** 1995 Jun;3(3):181–90
Protein polymorphism generated by differential RNA editing of a plant mitochondrial rps12 gene. Lu B, et al. **Mol Cell Biol** 1996 Apr;16(4):1543–9
Genotypic diversity revealed by allozymes and oligonucleotide DNA fingerprinting in French populations of the aquatic macrophyte Sparganium erectum. Piquot Y, et al. **Mol Ecol** 1996 Apr;5(2):251–8
Alterations in chlorophyll a/b binding proteins in Solanaceae cybrids. Babiychuk E, et al. **Mol Gen Genet** 1995 Dec 20; 249(6):648–54
Characterisation of the double genome structure of modern sugarcane cultivars (Saccharum spp.) by molecular cytogenetics. D'Hont A, et al. **Mol Gen Genet** 1996 Mar 7;250(4):405–13
Sequence variation in the putative replication origins of the five genetically distinct basic Euoenothera plastid chromosomes (plastomes). Hornung S, et al. **Mol Gen Genet** 1996 Jul 19;251(5):609–12
Epigenetic control of sexual phenotype in a dioecious plant, Melandrium album. Janoušek B, et al. **Mol Gen Genet** 1996 Mar 7;250(4):483–90
A new family of DNA binding proteins includes putative transcriptional regulators of the Antirrhinum majus floral meristem identity gene SQUAMOSA. Klein J, et al. **Mol Gen Genet** 1996 Jan 15;250(1):7–16
H-protein of glycine decarboxylase is encoded by multigene families in Flaveria pringlei and F. cronquistii (Asteraceae). Kopriva S, et al. **Mol Gen Genet** 1995 Nov 1;249(1):111–6
The Ty1–copia group retrotransposons in Vicia species: copy number, sequence heterogeneity and chromosomal localisation. Pearce SR, et al. **Mol Gen Genet** 1996 Feb 25;250(3):305–15
Conservation of the organization of the mitochondrial nad3 and rps12 genes in evolutionarily distant angiosperms. Perrotta G, et al. **Mol Gen Genet** 1996 Jun 12;251(3):326–37
Self-incompatibility (S) alleles of the Rosaceae encode members of a distinct class of the T2/S ribonuclease superfamily. Sassa H, et al. **Mol Gen Genet** 1996 Mar 20; 250(5):547–57
Involvement of two different urf-s related mitochondrial sequences in the molecular evolution of the CMS-specific S-Pcf locus in petunia. Yesodi V, et al. **Mol Gen Genet** 1995 Sep 20;248(5):540–6
Molecular phylogenetics of Poaceae: an expanded analysis of rbcL sequence data. Duvall MR, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):352–8
A phylogenetic analysis of monocotyledons based on the chloroplast gene rps4, using parsimony and a new numerical phenetics method. Nadot S, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):257–82
Hairy root nodulation of Casuarina glauca: a system for the study of symbiotic gene expression in an actinorhizal tree. Diouf D, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug; 8(4):532–7
Yearly variation of spontaneous somatic mutation frequency in the stamen hairs of Tradescantia clone KU 9 grown outdoors, which showed a significant increase after the Chernobyl accident. Ichikawa S, et al. **Mutat Res** 1996 Feb 1;349(2):249–59
Control of inflorescence architecture in Antirrhinum. Bradley D, et al. **Nature** 1996 Feb 29;379(6568):791–7
Conservation patterns in angiosperm rDNA ITS2 sequences. Hershkovitz MA, et al. **Nucleic Acids Res** 1996 Aug 1; 24(15):2857–67
Extensive RNA editing of U to C in addition to C to U substitution in the rbcL transcripts of hornwort chloroplasts and the origin of RNA editing in green plants. Yoshinaga K, et al. **Nucleic Acids Res** 1996 Mar 15; 24(6):1008–14
Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)
Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75–81 (48 ref.)
Male and female flowers of the dioecious plant sorrel show different patterns of MADS box gene expression. Ainsworth C, et al. **Plant Cell** 1995 Oct;7(10):1583–98
A novel class of MADS box genes is involved in ovule development in petunia. Angenent GC, et al. **Plant Cell** 1995 Oct;7(10):1569–82
The petunia MADS box gene FBP11 determines ovule identity. Colombo L, et al. **Plant Cell** 1995 Nov; 7(11):1859–68
A DNA binding activity for one of two closely defined phytochrome regulatory elements in an Lhcb promoter is more abundant in etiolated than in green plants. Degenhardt J, et al. **Plant Cell** 1996 Jan;8(1):31–41
AGL15, a MADS domain protein expressed in developing embryos. Heck GR, et al. **Plant Cell** 1995 Aug;7(8):1271–82
Conservation of floral homeotic gene function between Arabidopsis and antirrhinum. Irish VF, et al. **Plant Cell** 1995 Oct;7(10):1635–44
The L6 gene for flax rust resistance is related to the Arabidopsis bacterial resistance gene RPS2 and the tobacco viral resistance gene N. Lawrence GJ, et al. **Plant Cell** 1995 Aug;7(8):1195–206
C-terminal deletion analysis of plant plasma membrane H(+)-ATPase: yeast as a model system for solute transport across the plant plasma membrane. Regenberg B, et al. **Plant Cell** 1995 Oct;7(10):1655–66
The stroma of higher plant plastids contain ClpP and ClpC, functional homologs of Escherichia coli ClpP and ClpA: an archetypal two-component ATP-dependent protease. Shanklin J, et al. **Plant Cell** 1995 Oct;7(10):1713–22
Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091–3 (22 ref.). Comment on: Plant Cell 1996 Jul;8(7):1095–105.
Origin of allelic diversity in antirrhinum S locus RNases. Xue Y, et al. **Plant Cell** 1996 May;8(5):805–14
A family of transcripts encoding water channel proteins: tissue-specific expression in the common ice plant. Yamada S, et al. **Plant Cell** 1995 Aug;7(8):1129–42
Three protein fractions that bind to a narrow region of the promoter of the ribosomal RNA gene in Vicia faba. Suzuki A, et al. **Plant Cell Physiol** 1995 Sep;36(6):1051–8
mCCG methylation in angiosperms. Jeddeloh JA, et al. **Plant J** 1996 May;9(5):579–86
A repetitive DNA fragment carrying a hot spot for de novo DNA methylation enhances expression variegation in tobacco and petunia. ten Lohuis M, et al. **Plant J** 1995 Dec;8(6):919–32
Constitutive expression of small heat shock proteins in vegetative tissues of the resurrection plant Craterostigma plantagineum. Alamillo J, et al. **Plant Mol Biol** 1995 Dec; 29(5):1093–9
Isolation and characterization of the Adh2 5' region from Petunia hybrida. Atkinson EF, et al. **Plant Mol Biol** 1996 Jan;30(2):367–71
Isolation and sequence analysis of a cDNA encoding the c subunit of a vacuolar-type H(+)-ATPase from the CAM plant Kalanchoë daigremontiana. Bartholomew DM, et al. **Plant Mol Biol** 1996 May;31(2):435–42
The macrophage-specific membrane protein Nramp controlling natural resistance to infections in mice has homologues expressed in the root system of plants. Belouchi A, et al. **Plant Mol Biol** 1995 Dec;29(6):1181–96
A vicilin-like seed protein of cycads: similarity to sucrose-binding proteins. Braun H, et al. **Plant Mol Biol** 1996 Apr;31(1):35–44
Identification of a cDNA that encodes a 1-acyl-sn-glycerol-3-phosphate acyltransferase from Limnanthes douglasii. Brown AP, et al. **Plant Mol Biol** 1995 Oct;29(2):267–78
Divergent evolution of two plastid genes, rbcL and atpB, in a non-photosynthetic parasitic plant. Delavault P, et al. **Plant Mol Biol** 1995 Dec;29(5):1071–9
Intron length variation of the Adh gene in Brachyscome (Asteraceae). Denda T, et al. **Plant Mol Biol** 1995 Sep; 28(6):1067–73
Isolation and characterization of a Tritordeum cDNA encoding S-adenosylmethionine decarboxylase that is circadian-clock-regulated. Dresselhaus T, et al. **Plant Mol Biol** 1996 Mar;30(5):1021–33
Transcription, splicing and editing of plastid RNAs in the nonphotosynthetic plant Epifagus virginiana. Ems SC, et al. **Plant Mol Biol** 1995 Nov;29(4):721–33
A salinity-induced gene from the halophyte M. crystallinum encodes a glycolytic enzyme, cofactor-independent phosphoglyceromutase. Forsthoefel NR, et al. **Plant Mol Biol** 1995 Oct;29(2):213–26
Senescence-induced expression of a homologue of delta 9 desaturase in rose petals. Fukuchi-Mizutani M, et al. **Plant Mol Biol** 1995 Nov;29(4):627–35
Differential regulation of two ABA-inducible genes from Craterostigma plantagineum in transgenic Arabidopsis plants. Furini A, et al. **Plant Mol Biol** 1996 Jan;30(2):343–9
Molecular comparison of carbonic anhydrase from Flaveria species demonstrating different photosynthetic pathways. Ludwig M, et al. **Plant Mol Biol** 1995 Oct;29(2):353–65
Isolation and characterization of full-length cDNA clones of the giant taro (Alocasia macrorrhiza) trypsin/chymotrypsin inhibitor. Mathews A, et al. **Plant Mol Biol** 1996 Mar;30(5):1035–9
Characterization of a family of genes encoding a fruit-specific wound-stimulated protein of bell pepper (Capsicum annuum): identification of a new family of transposable elements. Pozueta-Romero J, et al. **Plant Mol Biol** 1995 Sep;28(6):1011–25
Genomic structure and expression of the pyruvate, orthophosphate dikinase gene of the dicotyledonous C4 plant Flaveria trinervia (Asteraceae). Rosche E, et al. **Plant Mol Biol** 1995 Nov;29(4):663–78
A wound-inducible gene from Salix viminalis coding for a trypsin inhibitor. Saarikoski P, et al. **Plant Mol Biol** 1996 Jun;31(3):465–78
High-resolution mapping of repetitive DNA by in situ hybridization: molecular and chromosomal features of prominent dispersed and discretely localized DNA families from the wild beet species Beta procumbens. Schmidt T, et al. **Plant Mol Biol** 1996 Mar;30(6):1099–113
Isolation and characterization of cDNAs encoding xylogenesis-associated and wounding-induced ribonucleases in Zinnia elegans. Ye ZH, et al. **Plant Mol Biol** 1996 Feb;30(4):697–709
Cloning and characterization of a glutathione S-transferase that can be photolabeled with 5-azido-indole-3-acetic acid. Bilang J, et al. **Plant Physiol** 1995 Sep;109(1):253–60
Anthranilate synthase from Ruta graveolens. Duplicated AS alpha genes encode tryptophan-sensitive and tryptophan-insensitive isoenzymes specific to amino acid and alkaloid biosynthesis. Bohlmann J, et al. **Plant Physiol** 1996 Jun;111(2):507–14
Two novel thioesterases are key determinants of the bimodal distribution of acyl chain length of Cuphea palustris seed oil. Dehesh K, et al. **Plant Physiol** 1996 Jan;110(1):203–10
Tissue-specific expression of the gene for a putative plasma membrane H(+)-ATPase in a seagrass. Fukuhara T, et al. **Plant Physiol** 1996 Jan;110(1):35–42
Early salt stress effects on the differential expression of vacuolar H(+)-ATPase genes in roots and leaves of Mesembryanthemum crystallinum. Löw R, et al. **Plant Physiol** 1996 Jan;110(1):259–65
Two genes encode highly similar chloroplastic NADP-malic enzymes in Flaveria. Implications for the evolution of C4 photosynthesis. Marshall JS, et al. **Plant Physiol** 1996 Aug; 111(4):1251–61
The interaction of light and abscisic acid in the regulation of plant gene expression. Weatherwax SC, et al. **Plant Physiol** 1996 Jun;111(2):363–70
RNA editing in plant organelles: a fertile field. Gray MW. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8157–9 (53 ref.)
A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)
Methylation of coding region alone inhibits gene expression in plant protoplasts. Hohn T, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8334–9
ndhF sequence evolution and the major clades in the sunflower family. Kim KJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10379–83
Identification and characterization of putative transposable DNA elements in solanaceous plants and Caenorhabditis elegans. Oosumi T, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8886–90
Two different but related mechanisms are used in plants for the repair of genomic double-strand breaks by homologous recombination. Puchta H, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5055–60
Enhanced green fluorescence by the expression of an Aequorea victoria green fluorescent protein mutant in mono- and dicotyledonous plant cells. Reichel C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5888–93
Allelic diversity and gene genealogy at the self-incompatibility locus in the Solanaceae. Richman AD, et al. **Science** 1996 Aug 30;273(5279):1212–6
Adenine methylation at dam sites increases transient gene expression in plant cells. Graham MW, et al. **Transgenic Res** 1995 Sep;4(5):324–31
Accumulation of a sulphur-rich seed albumin from sunflower in the leaves of transgenic subterranean clover (Trifolium subterraneum L.). Khan MR, et al. **Transgenic Res** 1996

May;5(3):179–85

The G-box: a ubiquitous regulatory DNA element in plants bound by the GBF family of bZIP proteins. Menkens AE, et al. **Trends Biochem Sci** 1995 Dec;20(12):506–10 (39 ref.)

Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)

Plant–parasite interactions: has the gene-for-gene model become outdated? [see comments] Innes RW. **Trends Microbiol** 1995 Dec;3(12):483–5. Comment in: Trends Microbiol 1995 Dec;3(12):475.

[Demonstration of transposition in Portulaca grandiflora (HOOK)] Rossi-Hassani BD, et al. **Ann Genet** 1995; 38(2):90–6 (Eng. Abstr.) **(Fre)**

[Loop-domain organization of genes in eukaryotic chromosomes] Glazkov MV. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):965–82 (118 ref.) **(Rus)**

[Molecular biological research on the origin of the angiosperms] Bobrova VK, et al. **Zh Obshch Biol** 1995 Nov–Dec;56(6):645–61 (51 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Kinetic analysis of the mitochondrial quinol-oxidizing enzymes during development of thermogenesis in Arum maculatum L. Leach GR, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):313–9

Analysis of tomato root initiation using a normal mixture distribution. Gutierrez RG, et al. **Biometrics** 1995 Dec; 51(4):1461–8

Pathways for inflorescence and floral induction in Antirrhinum. Bradley D, et al. **Development** 1996 May; 122(5):1535–44

Cattle grazing a riparian mountain meadow: effects of low and moderate stocking density on nutrition, behavior, diet selection, and plant growth response. Huber SA, et al. **J Anim Sci** 1995 Dec;73(12):3752–65

Characterization of type II protein secretion (xcp) genes in the plant growth-stimulating Pseudomonas putida, strain WCS358. de Groot A, et al. **Mol Gen Genet** 1996 Mar 7;250(4):491–504

Flower development. LEAFY blooms in aspen [news; comment] Coupland G. **Nature** 1995 Oct 12; 377(6549):482–3. Comment on: Nature 1995 Oct 12;377(6549):495–500. Comment on: Nature 1995 Oct 12;377(6549):522–4.

Male and female flowers of the dioecious plant sorrel show different patterns of MADS box gene expression. Ainsworth C, et al. **Plant Cell** 1995 Oct;7(10):1583–98

A novel class of MADS box genes is involved in ovule development in petunia. Angenent GC, et al. **Plant Cell** 1995 Oct;7(10):1569–82

Parallels between UNUSUAL FLORAL ORGANS and FIMBRIATA, genes controlling flower development in Arabidopsis and Antirrhinum. Ingram GC, et al. **Plant Cell** 1995 Sep;7(9):1501–10

Molecular genetic studies confirm the role of brassinosteroids in plant growth and development. Clouse SD. **Plant J** 1996 Jul;10(1):1–8 (61 ref.)

Arabinogalactan proteins and plant differentiation. Kreuger M, et al. **Plant Mol Biol** 1996 Mar;30(6):1077–86 (66 ref.)

Intercellular induction of homeotic gene expression in flower development. Becraft PW. **Trends Genet** 1995 Jul; 11(7):253–5

Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)

IMMUNOLOGY

Occupational contact urticaria syndrome caused by globe artichoke (Cynara scolymus). Quirce S, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):710–1

METABOLISM

Energy metabolism in plants under water deficits. Zagdańska B. **Acta Biochim Pol** 1995;42(3):281–9 (45 ref.)

Assay for tyrosine hydroxylation activity of tyrosinase from betalain-forming plants and cell cultures. Steiner U, et al. **Anal Biochem** 1996 Jun 15;238(1):72–5

Plant sterol biosynthesis: identification and characterization of higher plant delta 7-sterol C5(6)-desaturase. Taton M, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):279–88

A single amino acid determines the specificity for the target sequence of two zinc-finger proteins in plants. Takatsuji H. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):219–23

Metabolic evidence for the order of addition of individual phosphate esters in the myo-inositol moiety of inositol hexakisphosphate in the duckweed Spirodela polyrhiza L. Brearley CA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):227–33

Evidence for substrate-cycling of 3-, 3,4-, 4-, and 4,5-phosphorylated phosphatidylinositols in plants. Brearley CA, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1001–7

Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent. Caris C, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):879–85

Mechanism of indole-3-acetic acid oxidation by plant peroxidases: anaerobic stopped-flow spectrophotometric studies on horseradish and tobacco peroxidases. Gazaryan IG, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):841–7

Optical spectroscopic and reverse-phase HPLC analyses of Hg(II) binding to phytochelatins. Mehra RK, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):73–82

Nuclear Ca(2+)-fluxes and phosphoinositides in plants. Bunney TD, et al. **Biochem Soc Trans** 1995 Nov;23(4):581S

A novel inositol-lipid in plant-bacteria symbiosis. Hernandez LE, et al. **Biochem Soc Trans** 1995 Nov;23(4):582S

Characterisation of inositol 1,4,5-trisphosphate receptors from Chenopodium rubrum. Scanlon CH, et al. **Biochem Soc Trans** 1995 Nov;23(4):574S

The functional relationship of plant lipid-derived second messengers and plant lipid-activated protein kinase. Scherer GF. **Biochem Soc Trans** 1995 Nov;23(4):871–5 (48 ref.)

Diacylglycerol- and phosphatidic acid-kinase studies in plant cell suspension cultures. Wissing JB, et al. **Biochem Soc Trans** 1995 Nov;23(4):867–71

Interaction of myoinositoltrisphosphate-phytase complex with the receptor for intercellular Ca2+ mobilization in plants. Dasgupta S, et al. **Biochemistry** 1996 Apr 16; 35(15):4994–5001

Dynamic properties of the minor chlorophyll a/b binding proteins of photosystem II, an in vitro model for photoprotective energy dissipation in the photosynthetic membrane of green plants. Ruban AV, et al. **Biochemistry** 1996 Jan 23;35(3):674–8

Animal and plant cell lysates share a conserved chaperone system that assembles the glucocorticoid receptor into a functional heterocomplex with hsp90. Stancato LF, et al. **Biochemistry** 1996 Jan 16;35(2):554–61

Plant and human neutrophil oxidative burst complexes contain immunologically related proteins. Dwyer SC, et al. **Biochim Biophys Acta** 1996 Mar 15;1289(2):231–7

Recent advances in the biosynthesis of plant fatty acids. Harwood JL. **Biochim Biophys Acta** 1996 May 31; 1301(1–2):7–56 (588 ref.)

ADP-ribosylation reactions in plants. O'Farrell M. **Biochimie** 1995;77(6):486–91 (54 ref.)

Biosynthesis of acetylenic compounds in cultured cells of Asparagus officinalis from [1-13C]- and [U-13C] Glucose. Terada K, et al. **Biol Pharm Bull** 1995 Nov;18(11):1472–5

Role of certain environmental factors on cadmium uptake and toxicity in Spirodela polyrhiza (L.) Schleid. and Azolla pinnata R. Br. Gaur JP, et al. **Biomed Environ Sci** 1995 Sep;8(3):202–10

Adsorption and uptake of cadmium by Azolla pinnata: kinetics of inhibition by cations. Gaur JP, et al. **Biomed Environ Sci** 1995 Jun;8(2):149–57

Bioaccumulation and physiological changes in Hydrilla verticillata (l.f.) royle in response to mercury. Gupta M, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):319–26

Bioremediation of tannery effluent by aquatic macrophytes. Vajpayee P, et al. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):546–53

Evolution of chlorophyll biosynthesis--the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703–5 (14 ref.)

Transport proteins of the plant plasma membrane. Assmann SM, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):458–67

Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)

Polarography as a tool in peptide and protein analysis: studies on metal-chelating substances induced by cadmium in the algae Pheodactylum tricornutum and the graminae Agrostis capillaris. Nyberg S, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):147–53

Isoprene synthesis by plants and animals. Sharkey TD. **Endeavour** 1996;20(2):74–8 (45 ref.)

Sister chromatid exchange in human lymphocytes induced by propoxur following plant activation by Vicia faba. Gómez-Arroyo S, et al. **Environ Mol Mutagen** 1995; 26(4):324–30

Degradation of the light-stress protein is mediated by an ATP-independent, serine-type protease under low-light conditions. Adamska I, et al. **Eur J Biochem** 1996 Mar 1; 236(2):591–9

Structure and expression analysis of the gdcsPA and gdcsPB genes encoding two P-isoproteins of the glycine-cleavage system from Flaveria pringlei. Bauwe H, et al. **Eur J Biochem** 1995 Nov 15;234(1):116–24

On the mechanism of selenium tolerance in selenium-accumulating plants. Purification and characterization of a specific selenocysteine methyltransferase from cultured cells of Astragalus bisculatus. Neuhierl B, et al. **Eur J Biochem** 1996 Jul 1; 239(1):235–8

Carotene desaturation is linked to a respiratory redox pathway in Narcissus pseudonarcissus chromoplast membranes. Involvement of a 23-kDa oxygen-evolving-complex-like protein. Nievelstein V, et al. **Eur J Biochem** 1995 Nov 1;233(3):864–72

The regulation of enzymes involved in chlorophyll biosynthesis. Reinbothe S, et al. **Eur J Biochem** 1996 Apr 15;237(2):323–43 (312 ref.)

The NeuAc(alpha-2,6)-Gal/GalNAc-binding lectin from elderberry (Sambucus nigra) bark, a type-2 ribosome-inactivating protein with an unusual specificity and structure. Van Damme EJ, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):128–37

Purification, characterization and partial amino acid sequencing of two new aspartic proteinases from fresh flowers of Cynara cardunculus L. Verissimo P, et al. **Eur J Biochem** 1996 Feb 1;235(3):762–8

Carotenoids 3: in vivo function of carotenoids in higher plants. Demmig-Adams B, et al. **FASEB J** 1996 Mar; 10(4):403–12 (57 ref.)

UV-B- and oxidative stress-induced increase in nicotinamide and trigonelline and inhibition of defensive metabolism induction by poly(ADP-ribose)polymerase inhibitor in plant tissue. Berglund T, et al. **FEBS Lett** 1996 Feb 12; 380(1-2):188–93

Activities associated with the presence of ribosome-inactivating proteins increase in senescent and stressed leaves. Stirpe F, et al. **FEBS Lett** 1996 Mar 18; 382(3):309–12

Glutamate transfer RNA: a cofactor for heme and chlorophyll biosynthesis. Madan Kumar A, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):30–4 (31 ref.)

Modification of the fatty acid composition of Escherichia coli by coexpression of a plant acyl-acyl carrier protein desaturase and ferredoxin. Cahoon EB, et al. **J Bacteriol** 1996 Feb;178(3):936–9

The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):415–21 (53 ref.)

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387–96 (47 ref.)

Identification of diacylglycerol pyrophosphate as a novel metabolic product of phosphatidic acid during G-protein activation in plants. Munnik T, et al. **J Biol Chem** 1996 Jun 28;271(26):15708–15

1,4-Dihydropyridine binding sites in moss plasma membranes. Properties of receptors for a calcium channel antagonist. Schumaker KS, et al. **J Biol Chem** 1995 Oct 6;270(40):23461–7

Pervasive migration of organellar DNA to the nucleus in plants. Blanchard JL, et al. **J Mol Evol** 1995 Oct; 41(4):397–406

Targeting of proteins to the nucleus. Carrington JC. **Methods Cell Biol** 1995;50:283–94

Import into the endoplasmic reticulum. Ceriotti A, et al. **Methods Cell Biol** 1995;50:295–308

Transmembrane signaling and phosphoinositides. Cho MH, et al. **Methods Cell Biol** 1995;49:543–54 (50 ref.)

The use of protoplasts to study protein synthesis and transport by the plant endomembrane system. Denecke J, et al. **Methods Cell Biol** 1995;50:335–48

Protein--protein interactions within the endoplasmic reticulum. Gillikin JW, et al. **Methods Cell Biol** 1995; 50:309–23

Macromolecular movement into mitochondria. Glaser E, et al. **Methods Cell Biol** 1995;50:269–81

Chromoplasts. Price CA, et al. **Methods Cell Biol** 1995; 50:189–207

Assessment of translational regulation by run-off translation of polysomes in vitro. Vayda ME. **Methods Cell Biol** 1995; 50:349–59

Transfer RNA import into plant mitochondria. Marechal-Drouard L, et al. **Methods Enzymol** 1995; 260:310–27

Protein import into plant mitochondria. Winning BM, et al. **Methods Enzymol** 1995;260:293–302

Mitochondrial nucleic acid purification and analysis. Binder S. **Methods Mol Biol** 1995;49:383–9

Immunocytochemical localization of proteins. Davies J. **Methods Mol Biol** 1995;49:453–62

In organello protein synthesis. Grohmann L. **Methods Mol Biol** 1995;49:391–7

ELISA detection of foreign proteins. Mills EN, et al. **Methods Mol Biol** 1995;49:439–51

Translocation and exudation of tumor metabolites in crown galled plants. Savka MA, et al. **Mol Plant Microbe Interact** 1996 May;9(4):310–3

Extensive RNA editing of U to C in addition to C to U substitution in the rbcL transcripts of hornwort chloroplasts and the origin of RNA editing in green plants. Yoshinaga K, et al. **Nucleic Acids Res** 1996 Mar 15; 24(6):1008–14

Biosynthesis of pseudoisoeugenols in tissue cultures of Pimpinella anisum. Phenylalanine ammonia lyase and cinnamic acid 4-hydroxylase activities. Reichling J, et al. **Pharm World Sci** 1995 Jul 28;17(4):113–9

Protochlorophyllide reduction: a key step in the greening of plants. Fujita Y. **Plant Cell Physiol** 1996 Jun;37(4):411–21

Alternative splicing results in two different transcripts for H-protein of the glycine cleavage system in the C4 species Flaveria trinervia. Kopriva S, et al. **Plant J** 1995 Sep; 8(3):435–41

A plant kinesin heavy chain-like protein is a calmodulin-binding protein. Reddy AS, et al. **Plant J** 1996 Jul;10(1):9–21

The formation of mRNA 3'-ends in plants. Wu L, et al. **Plant J** 1995 Sep;8(3):323–9 (35 ref.)

The macrophage-specific membrane protein Nramp controlling natural resistance to infections in mice has homologues expressed in the root system of plants. Belouchi A, et al. **Plant Mol Biol** 1995 Dec;29(6):1181–96

Molecular cloning of the lectin and a lectin-related protein from common Solomon's seal (Polygonatum multiflorum). Van Damme EJ, et al. **Plant Mol Biol** 1996 Jun; 31(3):657–72

Induction of cysteine and serine proteases during xylogenesis in Zinnia elegans. Ye ZH, et al. **Plant Mol Biol** 1996 Mar; 30(6):1233–46

Purification and characterization of chaperonin 60 and

heat-shock protein 70 from chromoplasts of Narcissus pseudonarcissus. Bonk M, et al. **Plant Physiol** 1996 Jul; 111(3):931–9

Examination of the contribution of vacuolar proteases to intracellular protein degradation in Chara corallina. Moriyasu Y. **Plant Physiol** 1995 Dec;109(4):1309–15

Production of hypericin, pseudohypericin and flavonoids in cell cultures of various Hypericum species and their chemotypes. Kartnig T, et al. **Planta Med** 1996 Feb; 62(1):51–3

Pre-mRNA splicing in plants: characterization of Ser/Arg splicing factors. Lopato S, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):3074–9

Expression of a delta 9 14:0-acyl carrier protein fatty acid desaturase gene is necessary for the production of omega 5 anacardic acids found in pest-resistant geranium (Pelargonium xhortorum). Schultz DJ, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8771–5

The form and bioavailability of non-ionic organic chemicals in sewage sludge-amended agricultural soils. Beck AJ, et al. **Sci Total Environ** 1996 Jun 21;185(1–3):125–49

Screening the environmental fate of organic contaminants in sewage sludges applied to agricultural soils: II. The potential for transfers to plants and grazing animals. Duarte-Davidson R, et al. **Sci Total Environ** 1996 Jun 21; 185(1–3):59–70

Organic compounds in sludge-amended soils and their potential for uptake by crop plants. O'Connor GA.
Sci Total Environ 1996 Jun 21;185(1–3):71–81

Selective trafficking of KNOTTED1 homeodomain protein and its mRNA through plasmodesmata [see comments] Lucas WJ, et al. **Science** 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1943–4.

Ethylene sensors: how perceptive! [comment] Theologis A. **Science** 1995 Dec 15;270(5243):1774 (10 ref.). Comment on: Science 1995 Dec 15;270(5243):1804. Comment on: Science 1995 Dec 15;270(5243):1807–9. Comment on: Science 1995 Dec 15;270(5243):1809–11.

Plasmodesmata: plant channels for molecules on the move [see comments] Zambryski P. **Science** 1995 Dec 22; 270(5244):1943–4 (15 ref.). Comment in: Science 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1983–5.

Metabolism of myo-inositol phosphates and the alternative pathway in generation of myo-inositol trisphosphate involved in calcium mobilization in plants. Biswas S, et al. **Subcell Biochem** 1996;26:287–316 (203 ref.)

Phosphoinositide turnover and its role in plant signal transduction. Coté GG, et al. **Subcell Biochem** 1996; 26:317–43 (156 ref.)

Inositol phosphates and their metabolism in plants. Murthy PP. **Subcell Biochem** 1996;26:227–55 (90 ref.)

Adenine methylation at dam sites increases transient gene expression in plant cells. Graham MW, et al.
Transgenic Res 1995 Sep;4(5):324–31

Cyclic AMP, the reluctant messenger in plants. Bolwell GP.
Trends Biochem Sci 1995 Dec;20(12):492–5 (43 ref.)

[Chlorophyll biogenesis] Tanaka A, et al.
Tanpakushitsu Kakusan Koso 1996 Feb;41(2):136–45 (82 ref.) **(Jpn)**

[Interaction of 2Fe-2S-ferredoxins from plants and adrenal cortex with detergents] Mardanian SS, et al. **Biokhimiia** 1995 Jul;60(7):1055–61 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Xanthomonas campestris pv. parthenii pathovar nov. incitant of leaf blight of parthenium. Chand R, et al.
Antonie Van Leeuwenhoek 1995 Aug;68(2):161–4

Ballistosporous yeasts found on the surface of plant materials collected in New Zealand. The genera Bensingtonia and Bullera with descriptions of five new species. Hamamoto M, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):279–91

Amplification of 16S rRNA genes from Frankia strains in root nodules of Ceanothus griseus, Coriaria arborea, Coriaria plumosa, Discaria toumatou, and Purshia tridentata. Benson DR, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2904–9

Polymorphic restriction patterns of ribosomal internal transcribed spacers in the biocontrol fungus Puccinia carduorum correlate with weed host origin. Berthier YT, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3037–41

Analysis of partial sequences of genes coding for 16S rRNA of actinomycetes isolated from Casuarina equisetifolia nodules in Mexico. Niner BM, et al.
Appl Environ Microbiol 1996 Aug;62(8):3034–6

Phytoplasma-specific PCR primers based on sequences of the 16S–23S rRNA spacer region. Smart CD, et al.
Appl Environ Microbiol 1996 Aug;62(8):2988–93

In vitro analysis of the role of glucose oxidase from Talaromyces flavus in biocontrol of the plant pathogen Verticillium dahliae. Stosz SK, et al.
Appl Environ Microbiol 1996 Sep;62(9):3183–6

Four unnamed species of nonsymbiotic rhizobia isolated from the rhizosphere of Lotus corniculatus. Sullivan JT, et al.
Appl Environ Microbiol 1996 Aug;62(8):2818–25

Characterization of a highly repeated DNA sequence (SC1) from the arbuscular mycorrhizal fungus Scutellospora castanea and its detection in planta. Zeze A, et al.
Appl Environ Microbiol 1996 Jul;62(7):2443–8

A novel inositol-lipid in plant-bacteria symbiosis. Hernandez LE, et al. **Biochem Soc Trans** 1995 Nov;23(4):582S

A novel method for cloning DNA of plant-pathogenic mycoplasmalike organisms. Chen KH, et al.
Can J Microbiol 1995 Aug;41(8):753–7

The use of digoxigenin-labelled probes to detect DNA sequences specific for plant pathogenic bacteria. Dessaux Y, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov; 41(7):933–43

Current status of the plasmodiophorids. Braselton JP.
Crit Rev Microbiol 1995;21(4):263–75 (50 ref.)

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

Attachment of non-culturable toxigenic Vibrio cholerae O1 and non-O1 and Aeromonas spp. to the aquatic arthropod Gerris spinolae and plants in the River Ganga, Varanasi. Shukla BN, et al. **FEMS Immunol Med Microbiol** 1995 Oct; 12(2):113–20

VirE1 protein mediates export of the single-stranded DNA-binding protein VirE2 from Agrobacterium tumefaciens into plant cells. Sundberg C, et al.
J Bacteriol 1996 Feb;178(4):1207–12

Plant bacterial spores, active systemically as a separate entity, play a significant role in human illnesses such as cancer, granulomas, AIDS, and milky white abdominal ascites that currently defies recognition. White MW.
Med Hypotheses 1995 Jun;44(6):493–503

Agroinfection. Grimsley N. **Methods Mol Biol** 1995; 44:325–42

Tagging pathogenicity genes in Ustilago maydis by restriction enzyme-mediated integration (REMI). Bölker M, et al. **Mol Gen Genet** 1995 Sep 20;248(5):547–52

Hairy root nodulation of Casuarina glauca: a system for the study of symbiotic gene expression in an actinorhizal tree. Diouf D, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug; 8(4):532–7

Role of biosurfactant and ion channel-forming activities of syringomycin in transmembrane ion flux: a model for the mechanism of action in the plant-pathogen interaction. Hutchison ML, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug;8(4):610–20

Xanthomonas avirulence/pathogenicity gene family encodes functional plant nuclear targeting signals. Yang Y, et al.
Mol Plant Microbe Interact 1995 Jul–Aug;8(4):627–31

Identification, cloning, and characterization of PWL2, a gene for host species specificity in the rice blast fungus. Sweigard JA, et al. **Plant Cell** 1995 Aug;7(8):1221–33

Do plant pathogens produce inhibitors of the resistance reaction in plants? [letter; comment] Lawrence G.
Trends Microbiol 1995 Dec;3(12):475–6. Comment on: Trends Microbiol 1995 Dec;3(12):483–5.

What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370–2 (24 ref.)

Antifungal compounds induced in the dual culture with Phytolacca americana callus and Botrytis fabae. Kobayashi A, et al. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):398–402

[Pathogenic bacteria common to man and plants: the problem and the facts] Litvin VIu, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Mar–Apr; (2):101–4 (45 ref.) **(Rus)**

PARASITOLOGY

Response of periphyton biomass to high phosphorus concentrations in laboratory experiments. Giorgi AD.
Bull Environ Contam Toxicol 1995 Dec;55(6):825–32

A common group I intron between a plant parasitic fungus and its host. Nishida H, et al. **Mol Biol Evol** 1995 Sep; 12(5):883–6

PHYSIOLOGY

High efficiency callus induction and plant regeneration in petiole culture of four poplar genotypes. Jafari MA, et al.
Acta Biol Hung 1995;46(1):51–9

Stochastic behavior of organelle motion in Nitella internodal cells. Nemoto T, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1102–7

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al.
Biochem Soc Trans 1995 Nov;23(4):853–6 (28 ref.)

Systemin--a polypeptide defense signal in plants. Schaller A, et al. **Bioessays** 1996 Jan;18(1):27–33 (69 ref.)

Changes in the rheological properties of the cell wall of plant seedlings under simulated microgravity conditions. Masuda Y, et al. **Biorheology** 1994 Mar–Apr;31(2):171–7

Adaptive determinism during salt-adaptation in Sorghum bicolr. Seligmann H, et al. **Biosystems** 1995;36(1):71–7

Talking through walls: signaling in plant development. Dangl JL, et al. **Cell** 1995 Dec 29;83(7):1071–7 (35 ref.)

Self-incompatibility in flowering plants. Golz JF, et al.
Curr Opin Genet Dev 1995 Oct;5(5):640–5 (38 ref.)

MADS-box genes in plant ontogeny and phylogeny: Haeckel's 'biogenetic law' revisited. Theissen G, et al.
Curr Opin Genet Dev 1995 Oct;5(5):628–39 (97 ref.)

Tip-localized calcium entry fluctuates during pollen tube growth. Pierson ES, et al. **Dev Biol** 1996 Feb 25; 174(1):160–73

Absorbing possibilities: phytoremediation. Black H.
Environ Health Perspect 1995 Dec;103(12):1106–8

The role of plants and plant/microbial systems in the reduction of exposure. Shann JR.
Environ Health Perspect 1995 Jun;103 Suppl 5:13–5

Inward rectifier potassium channels in plants differ from their animal counterparts in response to voltage and channel modulators. Hedrich R, et al. **Eur Biophys J** 1995; 24(2):107–15

Is membrane potential involved in calmodulin gene expression after external stimulation in plants? Vian A, et al. **FEBS Lett** 1996 Feb 12;380(1–2):93–6

Calcium in pollen–pistil interaction in Petunia hybrida Hort. II. Localization of Ca2+ ions and Ca(2+)-ATPase in unpollinated pistil. Bednarska E, et al.
Folia Histochem Cytobiol 1995;33(1):43–52

The influence of the disappearance of plasmodesmal connections between antheridia and thallus on 3H-GA3 transport. Kwiatkowska M, et al.
Folia Histochem Cytobiol 1995;33(1):53–5

Plant defense metabolism is increased by the free radical-generating compound AAPH. Ohlsson AB, et al.
Free Radic Biol Med 1995 Sep;19(3):319–27

The origin of the oxidative burst in plants. Bolwell GP, et al. **Free Radic Res** 1995 Dec;23(6):517–32 (49 ref.)

Do EPR spectra show the presence of a unique and ubiquitous quinone-derived free radical that is associated with senescence in plants? [letter; comment] Goodman BA, et al. **Free Radic Res** 1995 Aug;23(2):187–92. Comment on: Free Radic Res Commun 1993;19(5):297–301.

Light signal transduction mediated by phytochromes: preliminary studies and possible approaches. Song PS, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):1–19 (131 ref.)

Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al.
J Anim Sci 1995 Sep;73(9):2774–90 (147 ref.)

How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al.
J Bioenerg Biomembr 1995 Aug;27(4):447–57 (78 ref.)

Calcium-sensitivity of the plasmalemmal delayed rectifier potassium current suggests that calcium influx in pulvinar protoplasts from Mimosa pudica L. can be revealed by hyperpolarization. Stoeckel H, et al. **J Membr Biol** 1995 Jul;146(2):201–9

Ion-selective microelectrodes for measurement of intracellular ion concentrations. Miller AJ.
Methods Cell Biol 1995;49:275–91

Analysis of the light signaling pathway in stomatal guard cells. Shimazaki K, et al. **Methods Cell Biol** 1995;49:501–13

Electrophysiology. Thain JF. **Methods Cell Biol** 1995; 49:259–74

Calcium and the generation of plant form. Knight MR, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):83–6 (23 ref.)

The petunia MADS box gene FBP11 determines ovule identity. Colombo L, et al. **Plant Cell** 1995 Nov; 7(11):1859–68

Light control of seedling morphogenetic pattern. McNellis TW, et al. **Plant Cell** 1995 Nov;7(11):1749–61 (94 ref.)

Ovule development: identification of stage-specific and tissue-specific cDNAs. Nadeau JA, et al. **Plant Cell** 1996 Feb;8(2):213–39

Coordinate transcriptional induction of myo-inositol metabolism during environmental stress. Ishitani M, et al.
Plant J 1996 Apr;9(4):537–48

Salt regulation of transcript levels for the c subunit of a leaf vacuolar H(+)-ATPase in the halophyte Mesembryanthemum crystallinum. Tsiantis MS, et al.
Plant J 1996 May;9(5):729–36

Immunological evidence for accumulation of two high-molecular-weight (104 and 90 kDa) HSPs in response to different stresses in rice and in response to high temperature stress in diverse plant genera. Pareek A, et al. **Plant Mol Biol** 1995 Oct;29(2):293–301

Annexins of plant cells. Clark GB, et al. **Plant Physiol** 1995 Dec;109(4):1133–9 (53 ref.)

Lectins as plant defense proteins. Peumans WJ, et al.
Plant Physiol 1995 Oct;109(2):347–52 (27 ref.)

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

Plants, like animals, may make use of peptide signals [news; comment] Marx J. **Science** 1996 Sep 6;273(5280):1338–9. Comment on: Science 1996 Sep 6;273(5280):1406–9.

Light-induced signal transduction pathway involving inositol phosphates. Sopory SK, et al. **Subcell Biochem** 1996; 26:345–70 (117 ref.)

Lipoxygenases in plants--their role in development and stress response. Rosahl S. **Z Naturforsch [C]** 1996 Mar–Apr; 51(3–4):123–38 (139 ref.)

RADIATION EFFECTS

[Biological effect of cosmic rays induced in embryo tissues of Arabidopsis seeds exposed in Cosmos-2044 (Bion-9)] Shchevchenko VV. **Aviakosm Ekolog Med** 1995; 29(5):46–51 (Eng. Abstr.) **(Rus)**

[Estimation of absorbed doses by dominant species of the ecosystem in Polesski state radio-ecological reserve] Kravchenko VA, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):163–7 (Eng. Abstr.) **(Rus)**

[The monitoring of natural populations of Dactylis glomerata L. in the area of the accident at the Chernobyl Atomic Electric Power Station] Shershunova VI, et al.
Radiats Biol Radioecol 1995 Sep–Oct;35(5):690–5 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Visualization of plant cell walls by atomic force microscopy.

Kirby AR, et al. **Biophys J** 1996 Mar;70(3):1138–43

Novel fixation of plant tissue, staining through paraffin with alcian blue and hematoxylin, and improved slide preparation. Graham ET, et al. **Biotech Histochem** 1995 Sep;70(5):263–6

Nuclear matrix isolated from plant cells. Moreno Díaz de la Espina SM. **Int Rev Cytol** 1995;162B:75–139 (172 ref.)

Methods for isolation and analysis of the cytoskeleton. Abe S, et al. **Methods Cell Biol** 1995;50:223–36

Isolation of nuclei suitable for in vitro transcriptional studies. Cushman JC. **Methods Cell Biol** 1995;50:113–28

Methods for isolation and analysis of polyribosomes. Davies E, et al. **Methods Cell Biol** 1995;50:209–22

Isolation and characterization of plasmodesmata. Epel BL, et al. **Methods Cell Biol** 1995;50:237–53

Isolation and fractionation of plant mitochondria and chloroplasts: specific examples. Gualberto JM, et al. **Methods Cell Biol** 1995;50:161–75

Isolation and characterization of plant nuclei. Guilfoyle TJ. **Methods Cell Biol** 1995;50:101–12

Preparation and transformation of monocot protoplasts. Maas C, et al. **Methods Cell Biol** 1995;50:383–99

Chromoplasts. Price CA, et al. **Methods Cell Biol** 1995; 50:189–207

Isolation of mitochondria. Binder S, et al. **Methods Mol Biol** 1995;49:377–81

VIROLOGY

An appraisal of the banded and paracrystalline cytoplasmic inclusions induced in cymbidium mosaic potexvirus– and odontoglossum ringspot tobamovirus infected orchid cells using confocal laser scanning microscropy. Wong SM, et al. **Arch Virol** 1996;141(2):231–42

Resistance against multiple plant viruses in plants mediated by a double stranded–RNA specific ribonuclease. Watanabe Y, et al. **FEBS Lett** 1995 Sep 25;372(2–3):165–8

Genome organization of ageratum yellow vein virus, a monopartite whitefly–transmitted geminivirus isolated from a common weed. Tan PH, et al. **J Gen Virol** 1995 Dec; 76 (Pt 12):2915–22

A simple imprint–hybridization method for detection of viroids. Romero–Durbán J, et al. **J Virol Methods** 1995 Sep;55(1):37–47

Print–capture PCR: a simple and highly sensitive method for the detection of plum pox virus (PPV) in plant tissues. Olmos A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2192–3

Tomato bushy stunt virus spread is regulated by two nested genes that function in cell–to–cell movement and host–dependent systemic invasion. Scholthof HB, et al. **Virology** 1995 Nov 10;213(2):425–38

Reason for non–aphid transmissibility in a strain of Kalanchoë mosaic potyvirus. Husted K. **Virus Genes** 1995;11(1):59–61

PLANTS, EDIBLE

Antioxidant effects of Ilex paraguariensis: induction of decreased oxidability of human LDL in vivo. Gugliucci A. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):338–44

Peanut and nut allergy. Sesame allergy is also a problem [letter] Perkins MS. **BMJ** 1996 Aug 3;313(7052):300

Use of sugarcane molasses for culture of Clostridium chauvoei. Micalizzi B, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S382–3

The diet as a source of dietary fibre. Southgate DA. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S22–6 (20 ref.)

Sapal: a traditional fermented taro [Colocasia esculenta (L.) Schott] corm and coconut cream mixture from Papua New Guinea. Gubag R, et al. **Int J Food Microbiol** 1996 Jan; 28(3):361–7

Feeding of potato, tomato and eggplant alkaloids affects food consumption and body and liver weights in mice. Friedman M, et al. **J Nutr** 1996 Apr;126(4):989–99

Grain dusts and grain plant components vary in their ability to recruit neutrophils. Von Essen SG, et al. **J Toxicol Environ Health** 1995 Dec;46(4):425–41

CHEMISTRY

Measurement of resistant starch in vitro and in vivo. Englyst HN, et al. **Br J Nutr** 1996 May;75(5):749–55

Measurement of rapidly available glucose (RAG) in plant foods: a potential in vitro predictor of the glycaemic response. Englyst HN, et al. **Br J Nutr** 1996 Mar; 75(3):327–37

Crocin, safranal and picrocrocin from saffron (Crocus sativus L.) inhibit the growth of human cancer cells in vitro. Escribano J, et al. **Cancer Lett** 1996 Feb 27;100(1–2):23–30

Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract. Kapadia GJ, et al. **Cancer Lett** 1996 Feb 27;100(1–2):211–4

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225–55 (102 ref.)

A comparison of commercial fibre sources: barley bran, corn bran, orange fibre and sugar beet fibre. Olson B. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S226–8

Cell–wall chemistry and architecture in relation to sources of dietary fibre. Selvendran RR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S27–41 (40 ref.)

Purification and partial characterization of acyl carrier proteins from developing oil seeds of pisa (Actinodaphne hookeri) and ground nut (Arachis hypogaea). Sreenivas A, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):137–46

Mineral values of selected plant foods common to southern Burkina Faso and to Niamey, Niger, west Africa. Smith GC, et al. **Int J Food Sci Nutr** 1996 Jan;47(1):41–53

Plant compositional constituents affecting between–plant and animal species prediction of forage intake. Meissner HH, et al. **J Anim Sci** 1995 Aug;73(8):2447–57

Identification of fatty acids in edible wild plants by gas chromatography. Guil JL, et al. **J Chromatogr A** 1996 Jan 5;719(1):229–35

Anti–hyperglycemic effect of some edible plants. Roman–Ramos R, et al. **J Ethnopharmacol** 1995 Aug 11; 48(1):25–32

Effect of blanching on the content of antinutritional factors in selected vegetables. Mosha TC, et al. **Plant Foods Hum Nutr** 1995 Jun;47(4):361–7

[The role of dietary plant polyphenols in health maintenance] Zloch Z. **Cas Lek Cesk** 1996 Jan 31;135(3):84–8 (Eng. Abstr.) **(Cze)**

[Mineral properties of roots and rhizomes of Sanguisorba oficinalis] Popov AI, et al. **Vopr Pitan** 1995;(2):30–2 (Eng. Abstr.) **(Rus)**

[Chemical composition of 6 unconventional plants from Oaxaca State, Mexico, as potential resources for animal feed] Arellano ML, et al. **Arch Latinoam Nutr** 1993 Sep; 43(3):264–8 (Eng. Abstr.) **(Spa)**

CYTOLOGY

Studies on selection and characterization of a stress–tolerant sugarcane cell line. Chen H, et al. **Chin J Biotechnol** 1995; 11(2):93–9

DRUG EFFECTS

Modification of the lipid component modulates nuclear matrix nucleolytic activity. Lubocka J, et al. **Acta Biochim Pol** 1995;42(2):211–5

Modulation of some nuclear matrix enzymatic activities by free fatty acids. Lubocka J, et al. **Acta Biochim Pol** 1995; 42(2):217–20

ENZYMOLOGY

Is proteolysis in the rumen of grazing animals mediated by plant enzymes? [letter] Theodorou MK, et al. **Br J Nutr** 1996 Mar;75(3):507–8

Structure and expression of two seed–specific cDNA clones encoding stearoyl–acyl carrier protein desaturase from sesame, Sesamum indicum L. Yukawa Y, et al. **Plant Cell Physiol** 1996 Mar;37(2):201–5

GENETICS

Identification of the proteins responsible for SAR DNA binding in nuclear matrix of Cucurbita pepo. Rzepecki R, et al. **Acta Biochim Pol** 1995;42(2):171–6

Expression analysis of a Cucurbita cDNA encoding endonuclease. Szopa J. **Acta Biochim Pol** 1995;42(2):183–9

Physical and gene organization of mitochondrial DNA from the fertile cytoplasm of sugarbeet (Beta vulgaris L.). Kubo T, et al. **Curr Genet** 1995 Aug;28(3):235–41

Transgenic plants on trial in the USA. Giddings LV. **Curr Opin Biotechnol** 1996 Jun;7(3):275–80

Inhibition of cysteine proteinases by Carica papaya cystatin produced in Escherichia coli. Song I, et al. **Gene** 1995 Sep 11;162(2):221–4

Chromosomal and genic barriers to introgression in Helianthus. Rieseberg LH, et al. **Genetics** 1995 Nov; 141(3):1163–71

IMMUNOLOGY

Immunoglobulins anti–endonuclease 32 kDa from Cucurbita pepo var patissonina affect process of DNA synthesis. Rzepecki R, et al. **Acta Biochim Pol** 1995;42(2):177–82

Type 1 allergic reactions to plant–derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893–5 (29 ref.)

METABOLISM

Pretreatment of sugar cane bagasse for enhanced ruminal digestion. Deschamps FC, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:171–82

Pretreatment of sugar cane bagasse hemicellulose hydrolysate for xylitol production by yeast. Dominguez JM, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:49–56

Dissipation of deltamethrin and fenvalerate residues in green gram (Vigna radiata (L.) Wilczek) under Indian climatic condition. Sukul P. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):562–7

Accumulation and physiological and biochemical effects of cadmium in a simple aquatic food chain. Devi M, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):38–43

Molecular cloning, immunochemical localization to the vacuole, and expression in transgenic yeast and tobacco of a putative sugar transporter from sugar beet. Chiou TJ, et al. **Plant Physiol** 1996 Feb;110(2):511–20

Transfer of radionuclides to vegetable and other crops grown on land reclaimed from the sea. Green N, et al. **Sci Total Environ** 1995 Dec 1;173–174:385–92

MICROBIOLOGY

Production and characterization of enterocin 900, a bacteriocin produced by Enterococcus faecium BFE 900 from black olives. Franz CM, et al. **Int J Food Microbiol** 1996 Apr;29(2–3):255–70

Microbiology of mesu, a traditional fermented bamboo shoot product. Tamang JP, et al. **Int J Food Microbiol** 1996 Feb; 29(1):49–58

Consistent striatal damage in rats induced by 3–nitropropionic acid and cultures of arthrinium fungus. Fu Y, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):413–8

[Infectivity and effectiveness of different strains of Frankia spp. on Atriplex cordobensis plants] Fabri S, et al. **Rev Argent Microbiol** 1996 Jan–Mar;28(1):31–8 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Adjusting hydration water volume to decrease preparation time in seed germination studies. Pillard DA. **Bull Environ Contam Toxicol** 1996 Apr;56(4):599–603

New antifungal proteins from sugar beet (Beta vulgaris L.) showing homology to non–specific lipid transfer proteins. Nielsen KK, et al. **Plant Mol Biol** 1996 Jun;31(3):539–52

VIROLOGY

Coding changes in the 3a cell–to–cell movement gene can extend the host range of brome mosaic virus systemic infection. De Jong W, et al. **Virology** 1995 Dec 20; 214(2):464–74

PLANTS, MEDICINAL

see related
ALKALOIDS
PHARMACOGNOSY
PLANT EXTRACTS

Clearing up confusion over yams and progesterone [letter] Dentali S. **Altern Ther Health Med** 1996 Jul;2(4):19–20

The efficacy, history, and politics of medicinal plants. Lipp FJ. **Altern Ther Health Med** 1996 Jul;2(4):36–41 (40 ref.)

The campothecin tree: harvesting a Chinese anticancer compound in the US [news] Petterson M. **Altern Ther Health Med** 1996 Mar;2(2):23–4

Mark Plotkin, PhD: in search of plants that heal [interview by Bonnie Horrigan] Plotkin M. **Altern Ther Health Med** 1996 Mar;2(2):66–75

Rainforest holds many lessons for pharmacy. Stover KA. **Am Pharm** 1995 Sep;NS35(9):13

Concern regarding herbal toxicities: case reports and counseling tips. Anderson LA. **Ann Pharmacother** 1996 Jan; 30(1):79–80

Haemorrhagic colitis induced by Citrullus colocynthis. Al Faraj S. **Ann Trop Med Parasitol** 1995 Dec;89(6):695–6

Antiviral effect of Sanicula europaea L. leaves extract on influenza virus–infected cells. Turan K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):22–6

Specific inhibition of Na+,K(+)–ATPase activity by atractylon, a major component of byaku–jutsu, by interaction with enzyme in the E2 state. Satoh K, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):339–43

Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata [letter; comment] Hollman A. **BMJ** 1996 Apr 6; 312(7035):912. Comment on: BMJ 1995 Dec 16;311(7020):1631–4.

Herbal products begin to attract the attention of brand–name drug companies. Cottrell K. **Can Med Assoc J** 1996 Jul 15;155(2):216–9

Hepatitis after the use of germander, a herbal remedy. Laliberté L, et al. **Can Med Assoc J** 1996 Jun 1; 154(11):1689–92

Cytotoxic effects of sinococuline. Liu WK, et al. **Cancer Lett** 1996 Feb 6;99(2):217–24

Anti–inflammatory efficacy of Melothria madraspatana in active rheumatoid arthritis [letter] Ramakrishanamacharya CH, et al. **Clin Rheumatol** 1996 Mar;15(2):214–5

Allergic contact dermatitis due to burdock (Arctium lappa). Rodriguez P, et al. **Contact Dermatitis** 1995 Aug; 33(2):134–5

Cryopreservation of transformed (hairy) roots of Artemisia annua. Teoh KH, et al. **Cryobiology** 1996 Feb;33(1):106–17

Health risks of herbal remedies. De Smet PA. **Drug Saf** 1995 Aug;13(2):81–93 (137 ref.)

"In vitro" effect of Egyptian tannin–containing plants and their extracts on the survival of pathogenic bacteria. Sotohy SA, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Sep; 102(9):344–8

Nature's medicine cabinet [news] **Environ Health Perspect** 1995 Jun;103(6):543–4

Genotoxicity of the natural cercaricides "sucupira" oil and eremanthine in mammalian cells in vitro and in vivo. Dias F da L, et al. **Environ Mol Mutagen** 1995;26(4):338–44

Nigella sativa: effect on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. Haq A, et al. **Immunopharmacology** 1995 Aug;30(2):147–55

Hepatoprotective studies on Phyllanthus emblica Linn. and quercetin [published erratum appears in Indian J Exp Biol 1995 Aug;33(8):preceding table of contents] Gulati RK, et al. **Indian J Exp Biol** 1995 Apr;33(4):261–8

Anticonvulsant activity of Albizzia lebbeck leaves. Kasture VS, et al. **Indian J Exp Biol** 1996 Jan;34(1):78–80

Hypocholesterolemic activity of nut shell extract of

Semecarpus anacardium (Bhilawa) in cholesterol fed rabbits. Sharma A, et al. **Indian J Exp Biol** 1995 Jun; 33(6):444–8

Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus. Srividya N, et al. **Indian J Exp Biol** 1995 Nov;33(11):861–4

The efficacy of a herbal-based toothpaste on the control of plaque and gingivitis. Mullally BH, et al. **J Clin Periodontol** 1995 Sep;22(9):686–9

Herbal knowledge on Nicaragua's Atlantic Coast: consensus within diversity. Barrett B. **J Community Health** 1995 Oct; 20(5):403–21

The inhibiting effect of aqueous Azadirachta indica (Neem) extract upon bacterial properties influencing in vitro plaque formation. Wolinsky LE, et al. **J Dent Res** 1996 Feb; 75(2):816–22

Vibriocidal activities of some local herbs. Akinsinde KA, et al. **J Diarrhoeal Dis Res** 1995 Jun;13(2):127–9

Drug leads from the Kallawaya herbalists of Bolivia. I. Background, rationale, protocol and anti-HIV activity. Abdel-Malek S, et al. **J Ethnopharmacol** 1996 Mar; 50(3):157–66

Anti-ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants of Pakistan in aspirin-ulcerated rats. Akhtar AH, et al. **J Ethnopharmacol** 1995 Apr;46(1):1–6

Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. Béjar E. **J Ethnopharmacol** 1996 Jan;50(1):1–12

Traditional herbal medicine in Transkei. Bhat RB, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):7–12

Anthelmintic usage of extracts of Embelia schimperi from Tanzania. Bøgh HO, et al. **J Ethnopharmacol** 1996 Jan; 50(1):35–42

Maternity and medicinal plants in Vanuatu. II. Pharmacological screening of five selected species. Bourdy G, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):139–43

Antigonorrhoeal activity of plants used in Guatemala for the treatment of sexually transmitted diseases. Cáceres A, et al. **J Ethnopharmacol** 1995 Oct;48(2):85–8

Some ethnopharmacological notes on African hallucinogens. De Smet PA. **J Ethnopharmacol** 1996 Mar;50(3):141–6 (50 ref.)

Effect of Luffa aegyptiaca (seeds) and Carissa edulis (leaves) extracts on blood glucose level of normal and streptozotocin diabetic rats. El-Fiky FK, et al. **J Ethnopharmacol** 1996 Jan;50(1):43–7

Chemical constituents of essential oils of muña, Bolivian plants traditionally used as pesticides, and their insecticidal properties against Chagas' disease vectors. Fournet A, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):145–9

Traditional healers in Tanzania: the treatment of malaria with plant remedies. Gessler MC, et al. **J Ethnopharmacol** 1995 Nov 3;48(3):131–44

Xanthine oxidase inhibitory activity of some Panamanian plants from Celastraceae and Lamiaceae. González AG, et al. **J Ethnopharmacol** 1995 Apr;46(1):25–9

Screening of Zulu medicinal plants for prostaglandin-synthesis inhibitors. Jäger AK, et al. **J Ethnopharmacol** 1996 Jun;52(2):95–100

Anti-giardial activity of gastrointestinal remedies of the Luo of east Africa. Johns T, et al. **J Ethnopharmacol** 1995 Apr; 46(1):17–23

The ethnopharmacopoeia of Rotuma. McClatchey W. **J Ethnopharmacol** 1996 Mar;50(3):147–56 (9 ref.)

A survey of medicinal plants of Jajarkot district, Nepal. Manandhar NP. **J Ethnopharmacol** 1995 Aug 11;48(1):1–6

Screening of some Cuban medicinal plants for antimicrobial activity. Martínez MJ, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):171–4

Protective effect of UL-409, a herbal formulation against physical and chemical factor induced gastric and duodenal ulcers in experimental animals. Mitra SK, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):165–9

Bioactivity of certain medicinal latexes used by the Ese'ejas. Mongelli E, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):159–63

Vasoactive effects of aqueous extracts from five Mexican medicinal plants on isolated rat aorta. Perusquía M, et al. **J Ethnopharmacol** 1995 Apr;46(1):63–9

Screening of medicinal plants for induction of somatic segregation activity in Aspergillus nidulans. Ramos Ruiz A, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):123–7

Carrier herbal medicine: an evaluation of the antimicrobial and anticancer activity in some frequently used remedies. Ritch-Krc EM, et al. **J Ethnopharmacol** 1996 Jul 5; 52(3):151–6

Carrier herbal medicine: traditional and contemporary plant use. Ritch-Krc EM, et al. **J Ethnopharmacol** 1996 Jun; 52(2):85–94

Anthelmintic activity of papaya latex against patent Heligmosomoides polygyrus infections in mice. Satrija F, et al. **J Ethnopharmacol** 1995 Nov 3;48(3):161–4

Antimicrobial activity of Guinea-Bissau traditional remedies. Silva O, et al. **J Ethnopharmacol** 1996 Jan;50(1):55–9

Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119–30 (67 ref.)

Effects of Artemisia pallens Wall. on blood glucose levels in normal and alloxan-induced diabetic rats. Subramoniam A, et al. **J Ethnopharmacol** 1996 Jan;50(1):13–7

Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9–26 (109 ref.)

Screening of selected medicinal plants of Nepal for antimicrobial activities. Taylor RS, et al. **J Ethnopharmacol** 1995 Jun;46(3):153–9

Antiviral activities of Nepalese medicinal plants. Taylor RS, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):157–63

Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Vlietinck AJ, et al. **J Ethnopharmacol** 1995 Apr;46(1):31–47

Budd-Chiari syndrome likely related to a slimming drug preparation [letter] Coche JC, et al. **J Hepatol** 1995 Nov; 23(5):626–7

Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. Wang M, et al. **J Lab Clin Med** 1995 Oct;126(4):350–2

Are drugs from the jungle cheaper to develop? [news] Randal J. **J Natl Cancer Inst** 1995 May 17;87(10):715

Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study [news] Ziegler J. **J Natl Cancer Inst** 1996 Aug 21;88(16):1100–2

Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Grob CS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):86–94

Mentha piperita (peppermint). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):607

Rosa canina (dog rose). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):470

Thymus serpyllum (wild thyme). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):224

Pedanius Dioscorides (born about AD40, died about AD90). Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):427

Convallari majalis (lily of the valley) (also known as Our Lady's tears, ladder to heaven). Haas LF. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):367

Willow. Haas LF. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):5

Medicinal plants of Seychelles. Grainger CR. **J R Soc Health** 1996 Apr;116(2):107–9

Fungistatic and fungicidal activity of east African medicinal plants. Fabry W, et al. **Mycoses** 1996 Jan-Feb;39(1-2):67–70

Toxicity of herbal products. Pillans PI. **N Z Med J** 1995 Nov 24;108(1012):469–71

Effect of dietary intake of freeze dried bitter gourd (Momordica charantia) in streptozotocin induced diabetic rats. Platel K, et al. **Nahrung** 1995;39(4):262–8

Plants and AIDS [letter] Atta-ur-Rahman. **Nature** 1996 Sep 26;383(6598):294

'Indian ginseng' brings royalties for tribe [news] Jayaraman KS. **Nature** 1996 May 16;381(6579):182

Patents and indigenous lore [letter; comment] Miller H. **Nature** 1995 Dec 7;378(6557):532. Comment on: Nature 1995 Sep 14;377(6545):89–90.

Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Pena JM, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1359–60

Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Rowin J, et al. **Neurology** 1996 Jun;46(6):1775–6

Modulatory influence of alcoholic extract of Ocimum leaves on carcinogen-metabolizing enzyme activities and reduced glutathione levels in mouse. Banerjee S, et al. **Nutr Cancer** 1996;25(2):205–17

20th Belgian-Dutch LOF-Symposium on Pharmacognosy and Natural Products Chemistry. Paclitaxel and other taxanes as new anti-cancer drugs. Leiden, The Netherlands, 24 November 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl N):N1–14

Spasmolytic flavonols from Artemisia abrotanum [letter] Bergendorff O, et al. **Planta Med** 1995 Aug;61(4):370–1

Reduction of ACh-induced contraction of rat isolated ileum by coptisine, (+)-caffeoylmalic acid, Chelidonium majus, and Corydalis lutea extracts. Boegge SC, et al. **Planta Med** 1996 Apr;62(2):173–4

Sesquiterpene lactones and other constituents of Centaurea napifolia [letter] Bruno M, et al. **Planta Med** 1995 Aug; 61(4):374–5

Antimicrobial activity of tannins from Terminalia citrina [letter] Burapadaja S, et al. **Planta Med** 1995 Aug; 61(4):365–6

Antiplatelet and vasorelaxing actions of some aporphinoids. Chen KS, et al. **Planta Med** 1996 Apr;62(2):133–6

Non-phenolic linear diarylheptanoids from Curcuma xanthorrhiza: a novel type of topical anti-inflammatory agents: structure-activity relationship. Claeson P, et al. **Planta Med** 1996 Jun;62(3):236–40

Isolation of E-1-(4'-Hydroxyphenyl)-but-1-en-3-one from Scutellaria barbata. Ducki S, et al. **Planta Med** 1996 Apr; 62(2):185–6

Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Erdelmeier CA, et al. **Planta Med** 1996 Jun;62(3):241–5

Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. François G, et al. **Planta Med** 1996 Apr;62(2):126–9

The effect of some 2-substituted quinolines isolated from Galipea longiflora on Plasmodium vinckei petteri infected mice. Gantier JC, et al. **Planta Med** 1996 Jun;62(3):285–6

Anti-inflammatory and analgesic activity of Baccharis trimera: identification of its active constituents. Gené RM, et al. **Planta Med** 1996 Jun;62(3):232–5

Chelidonium majus L.: components with in vitro affinity for the GABAA receptor. Positive cooperation of alkaloids. Häberlein H, et al. **Planta Med** 1996 Jun;62(3):227–31

Cytotoxicity of diterpenes from Premna schimperi and Premna oligotricha [letter] Habtemariam S. **Planta Med** 1995 Aug;61(4):368–9

Marine natural products research: current directions and future potential. König GM, et al. **Planta Med** 1996 Jun; 62(3):193–211 (160 ref.)

Potent antiplatelet, anti-inflammatory and antiallergic isoflavanquinones from the roots of Abrus precatorius. Kuo SC, et al. **Planta Med** 1995 Aug;61(4):307–12

Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata. Martínez-Vázquez M, et al. **Planta Med** 1996 Apr; 62(2):137–40

Ineupatorolides from Carpesium glossophyllum. Maruyama M, et al. **Planta Med** 1995 Aug;61(4):388–9

Antibacterial and antifungal polyine compounds from Glehnia littoralis ssp. leiocarpa. Matsuura H, et al. **Planta Med** 1996 Jun;62(3):256–9

Chemical and preliminary analgesic evaluation of geraniin and furosin isolated from Phyllanthus sellowianus. Miguel OG, et al. **Planta Med** 1996 Apr;62(2):146–9

Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium [letter] Mišik V, et al. **Planta Med** 1995 Aug;61(4):372–3

Effect of crude fractions of psoralea corylifolia seed extract on bone calcification. Miura H, et al. **Planta Med** 1996 Apr;62(2):150–3

Anthelmintic properties of alpha-sanshool from Zanthoxylum liebmannianum. Navarrete A, et al. **Planta Med** 1996 Jun;62(3):250–1

Isorhamnetin sulphate from the leaves and stems of Oenanthe javanica in Korea [letter] Park JC, et al. **Planta Med** 1995 Aug;61(4):377–8

Picroliv protects against alcohol-induced chronic hepatotoxicity in rats. Rastogi R, et al. **Planta Med** 1996 Jun;62(3):283–5

Smooth muscle relaxing compounds from Dodonaea viscosa. Rojas A, et al. **Planta Med** 1996 Apr;62(2):154–9

Biological activities of pyrrolidinoindoline alkaloids from Calycodendron milnei. Saad HE, et al. **Planta Med** 1995 Aug;61(4):313–6

Isolation of vasodilatory active flavonoids from the traditional remedy Satureja obovata. Sánchez de Rojas VR, et al. **Planta Med** 1996 Jun;62(3):272–4

Antinociceptive properties of steroids isolated from Phyllanthus corcovadensis in mice. Santos AR, et al. **Planta Med** 1995 Aug;61(4):329–32

Plant metabolites active against Trypanosoma cruzi. Sepúlveda-Boza S, et al. **Planta Med** 1996 Apr;62(2):98–105 (63 ref.)

Indolopyridoquinazoline alkaloids with antiplatelet aggregation activity from Zanthoxylum integrifoliolum. Sheen WS, et al. **Planta Med** 1996 Apr;62(2):175–6

Cytotoxicity and NMR spectral assignments of ergolide and bigelovin. Wang Q, et al. **Planta Med** 1996 Apr;62(2):166–8

Rearranged taxoids from Taxus yunnanensis [letter] Yue Q, et al. **Planta Med** 1995 Aug;61(4):375–7

Two flavones from Artemisia giraldii and their antimicrobial activity. Zheng WF, et al. **Planta Med** 1996 Apr; 62(2):160–2

Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Keung WM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4284–8

Plants used in the treatment of leishmanial ulcers due to Leishmania (Viannia) braziliensis in an endemic area of Bahia, Brazil. França F, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):229–32

Study of genotoxic effects of antidiarrheal medicinal herbs on human cells in vitro. Settheetham W, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:306–10

Acute intravascular haemolysis in glucose-6-phosphate dehydrogenase deficient patients following ingestion of herbal broth containing Acalypha indica. Senanayake N, et al. **Trop Doct** 1996 Jan;26(1):32

An estimation of Citrullus colocynthis toxicity for chicks. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Aug;37(4):356–8

Behavioral effects of acute and long-term administration of catnip (Nepeta cataria) in mice. Massoco CO, et al. **Vet Hum Toxicol** 1995 Dec;37(6):530–3

Protective effects of Osbeckia octandra against paracetamol-induced liver injury. Thabrew MI, et al. **Xenobiotica** 1995 Sep;25(9):1009–17

[Prospects for application of molecular biotechnique to pharmacognosy] Huang L. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):643–5, 702 (23 ref.) **(Chi)**

[Effect of plant polysaccharides on phosphatidylinositol turnover of sarcoma S180 cell membranes] Huang T, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):692–3, inside backcover (Eng. Abstr.) **(Chi)**

[Progress in the research of plant polysaccharides] Tian G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):441–4 (31 ref.) **(Chi)**

[New theoretical study on the biological origins of Chinese medicinal herbs] Xie Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):259–61, 318 (Eng. Abstr.) **(Chi)**

[A preliminary study on essential oils for the control of Ustilago coicis] Zhang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):657–9, 702 (Eng. Abstr.) **(Chi)**

[Therapeutic effectiveness of Crataegus] Weihmayr T, et al. **Fortschr Med** 1996 Jan 20;114(1–2):27–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Phytopharmaceutic drugs in treatment of sleep disorders] Nachtmann A, et al. **Internist (Berl)** 1996 Jul;37(7):743–9 (50 ref.) **(Ger)**

[Improving bladder function by pumpkin seeds?] Schilcher H. **Med Monatsschr Pharm** 1996 Jun;19(6):178–9 **(Ger)**

[Echinacea drugs—effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**

[Opium, mandrake and henbane. Control of surgical pain in the pre–anesthesiological era of surgery] Bauer AW. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):Oa7–9 **(Ger)**

[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al. **Mikrobiol Z** 1995 Jul–Aug;57(4):73–82 (29 ref.) (Eng. Abstr.) **(Rus)**

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

[Treatment of epilepsy among the Guarine (Palenque) tribes] Carod Artal FJ, et al. **Neurologia** 1995 Nov;10(9):394–5 **(Spa)**

[Hepatic veno–occlusive disease associated with ingestion of Senecio tephrosioides] Tomioka M, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec;15(3):299–302 (Eng. Abstr.) **(Spa)**

[Effect of a dry boldo extract on oro–cecal intestinal transit in healthy volunteers] Gotteland M, et al. **Rev Med Chil** 1995 Aug;123(8):955–60 (Eng. Abstr.) **(Spa)**

[A transcultural view of neurological and mental pathology in a Tzeltal Maya community of the Altos Chiapas] Carod FJ, et al. **Rev Neurol** 1996 Jul;24(131):848–54 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

[Medicinal plant resources of Berberis L. in Guizhou province] He S, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):646–9, 702 (Eng. Abstr.) **(Chi)**

[Development and utilization of medicinal plant resources of Salvia in Anhui] Liu X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):73–5, 126 (Eng. Abstr.) **(Chi)**

[Studies on Cnidium fruits by stereological method and computer image analysis] Qin L, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):9–11, 62 (Eng. Abstr.) **(Chi)**

[Textual study and resource investigation on traditional Chinese drugs duhuo, jiuyanduhuo and qianghuo] Wang Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):515–7, 574 (Eng. Abstr.) **(Chi)**

[Comparison of morphological and microscopical diagnostic characters of Hawthorn fruits (Crataegus species)] Gao GY, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):781–8 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Inhibition of influenza virus protein synthesis by a plant preparation from Geranium sanguineum L. Serkedjieva J. **Acta Virol** 1995 Feb;39(1):5–10

Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy. Gakunju DM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2606–9

Antifungal activity of new compounds from Nepeta leucophylla and Nepeta clarkei. Saxena J, et al. **Appl Environ Microbiol** 1996 Feb;62(2):702–4

Anti–elastase and anti–hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Facino RM, et al. **Arch Pharm (Weinheim)** 1995 Oct; 328(10):720–4

In vitro studies on the immunomodulating effects of polypodium leucotomos extract on human leukocyte fractions. Bernd A, et al. **Arzneimittelforschung** 1995 Aug; 45(8):901–4

Myocardial effects of flavonoids from Crataegus species. Schüssler M, et al. **Arzneimittelforschung** 1995 Aug; 45(8):842–5

Inhibition on platelet activation by shikonin derivatives isolated from Arnebia euchroma. Ko FN, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):329–34

Depolarizing neuromuscular blocking action of coryneine derived from aconite root in isolated mouse phrenic nerve–diaphragm muscles. Kimura M, et al. **Biol Pharm Bull** 1995 May;18(5):691–5

Cytotoxic activity of bryonolic acid isolated from transformed hairy roots of Trichosanthes kirilowii var. japonica. Kondo T, et al. **Biol Pharm Bull** 1995 May; 18(5):726–9

Inhibitory effects of methanolic extract from corydalis tuber against types I–IV allergic models. Matsuda H, et al. **Biol Pharm Bull** 1995 Jul;18(7):963–7

Studies of cuticle drugs from natural sources. III. Inhibitory effect of Myrica rubra on melanin biosynthesis. Matsuda H, et al. **Biol Pharm Bull** 1995 Aug;18(8):1148–50

The difference in hypoglycemic action between polygonati rhizoma and polygonati officinalis rhizoma. Miura T, et al. **Biol Pharm Bull** 1995 Nov;18(11):1605–6

Inhibitory effect of alkaloids extracted from the stem bark of Hunteria zeylanica on 5–lipoxygenase activity in vitro. Reanmongkol W, et al. **Biol Pharm Bull** 1995 Jun; 18(6):910–2

Studies on constituents with cytotoxic and cytostatic activity of two Turkish medicinal plants Phlomis armeniaca and Scutellaria salviifolia. Saracoglu I, et al. **Biol Pharm Bull** 1995 Oct;18(10):1396–400

Occurrence of nitrosatable amines in some Nigerian medicinal plants. Uhegbu FO, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):643–9

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257–64 (41 ref.)

Structural investigation of the polysaccharide fraction from the mucilage of Diceroaryum zanguebaricum Merr. Barone G, et al. **Carbohydr Res** 1996 Jan 4;280(1):111–9

Characterisation of the endo–polygalacturonase–resistant region of the pectin from Bupleurum falcatum L.—a polysaccharide with an active function in clearance of immune complexes. Matsumoto T, et al. **Carbohydr Res** 1995 Apr 30;270(2):221–9

Inhibition of the tumor promoting action of 12–O–tetradecanoylphorbol–13–acetate by tubeimoside III isolated from Bolbostemma paniculatum. Yu L, et al. **Carcinogenesis** 1995 Dec;16(12):3045–8

Oleanene–type triterpene glycosides from Puerariae Radix. II. Isolation of saponins and the application of tandem mass spectrometry to their structure determination. Arao T, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1176–9

Five new C–methyl flavonoids, the potent aldose reductase inhibitors from Matteuccia orientalis Trev. Basnet P, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1558–64

Naturally occurring 5–lipoxygenase inhibitors. VI. Structures of ardisiaquinones D, E, and F from Ardisia sieboldii. Fukuyama Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug; 43(8):1391–4

Tricycloillicinone, a novel prenylated c6–c3 compound increasing choline acetyltransferase (ChAT) activity, isolated from Illicium tashiroi. Fukuyama Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2270–2

Cytotoxic limonoids and tetranortriterpenoids from Melia azedarach. Itokawa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1171–5

Indonesian Medicinal Plants. XIV. Characterization of 3'–O–Caffeoylsweroside, a new secoiridoid glucoside, and kelampayosides A and B, two new phenolic apioglucosides, from the bark of Anthocephalus chinensis (Rubiaceae). Kitagawa I, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun; 44(6):1162–7

Studies on the constituents of Clematis species. VI. The constituents of Clematis stans Sieb. et Zucc. Kizu H, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2187–94

New bioactive monoterpene glycosides from Paeoniae Radix. Murakami N, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun; 44(6):1279–81

Isolation of inhibitors of TPA–induced mouse ear edema from Hoelen, Poria cocos. Nukaya H, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):847–9

Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Okada Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1385–7

Pharmacologically active components of Todopon Puok (Fagraea racemosa), a medicinal plant from Borneo. Okuyama E, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec; 43(12):2200–4

Studies on the constituents of Calliandra anomala (Kunth) Macbr. III. Structure elucidation of six acylated triterpenoidal saponins. Tani C, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):816–22

Studies on differentiation inducers. V. Steroid glycosides from periplocae radicis cortex. Umehara K, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1565–8

Medicinal foodstuff. III. Sugar beet. (1): Hypoglycemic oleanolic acid oligoglycosides, betavulgarosides I, II, III, and IV, from the root of Beta vulgaris L. (Chenopodiaceae). Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1212–7

Bioactive saponins and glycosides. I. Senegae radix. (1): E–senegasaponins a and b and Z–senegasaponins a and b, their inhibitory effect on alcohol absorption and hypoglycemic activity. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2115–22

Effects and mode of action of 1,4–naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites. Morello A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):119–28

Antiinflammatory effects of different extracts and harpagoside isolated from Scrophularia frutescens L. García D, et al. **Farmaco** 1996 Jun;51(6):443–6

Preventive and curative effects of Artemisia absinthium on acetaminophen and CCl4–induced hepatotoxicity. Gilani AH, et al. **Gen Pharmacol** 1995 Mar;26(2):309–15

Effect of Teucrium stocksianum on paracetamol–induced hepatotoxicity in mice. Rasheed RA, et al. **Gen Pharmacol** 1995 Mar;26(2):297–301

Dissociation between the mitogenic effect and antitumor activity of seed extract from Aeginetia indica L. Chai JG, et al. **Immunopharmacology** 1995 Sep;30(3):209–15

Biologically active principles isolated from Salacia oblonga wall. Augusti KT, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):415–7

Prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation of Myristica fragrans seed extract. Sharma A, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):407–10

Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera. Devi PU, et al. **Int J Radiat Biol** 1996 Feb;69(2):193–7

In vitro inhibition of Helicobacter pylori by extracts of thyme. Tabak M, et al. **J Appl Bacteriol** 1996 Jun; 80(6):667–72

Isolation of anti–HIV–1 lignans from Larrea tridentata by counter–current chromatography. Gnabre JN, et al. **J Chromatogr A** 1996 Jan 8;719(2):353–64

Analysis of the components of Lycopus europaeus L. in body fluids during metabolism studies. Comparison of capillary electrophoresis and high–performance liquid chromatography. Wojciechowski H, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):261–70

Selective extraction of quercetrin in vegetable drugs and urine by off–line coupling of boronic acid affinity chromatography and high–performance liquid chromatography. Bongartz D, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):223–30

Anti–inflammatory activity of Vitis elongata. Alam MS, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):59–60

The hepatoprotective cytochrome P–450 enzyme inhibitor isolated from the Nigerian medicinal plant Cochlospermum planchonii is a zinc salt. Aliyu R, et al. **J Ethnopharmacol** 1995 Oct;48(2):89–97

Cytotoxic and anti–tumour properties of certain taxa of Umbelliferae with special reference to Centella asiatica (L.) Urban. Babu TD, et al. **J Ethnopharmacol** 1995 Aug 11; 48(1):53–7

Analgesic activity of Psychotria colorata (Willd. ex R. & S.) Muell. Arg. alkaloids. Elisabetsky E, et al. **J Ethnopharmacol** 1995 Oct;48(2):77–83

In vitro screening of traditional medicines for anti–hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). Hansen K, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):43–51

Ervatamia coronaria: chemical constituents and some pharmacological activities. Henriques AT, et al. **J Ethnopharmacol** 1996 Jan;50(1):19–25

Biological activities of Annona glabra. Padmaja V, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):21–4

Evaluation of anti–inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF–induced exocytosis. Tunón H, et al. **J Ethnopharmacol** 1995 Oct;48(2):61–76

Antitumor germacranolides from Anvillea garcinii. Abdel Sattar E, et al. **J Nat Prod** 1996 Apr;59(4):403–5

Spiganthine, the cardioactive principle of Spigelia anthelmia. Achenbach H, et al. **J Nat Prod** 1995 Jul;58(7):1092–6

New antifungal bithienylacetylenes from Blumea obliqua. Ahmad VU, et al. **J Nat Prod** 1995 Sep;58(9):1426–9

An antimitotic and cytotoxic chalcone from Fissistigma lanuginosum. Alias Y, et al. **J Nat Prod** 1995 Aug; 58(8):1160–6

New polyoxypregnane ester derivatives from Leptadenia hastata. Aquino R, et al. **J Nat Prod** 1996 Jun;59(6):555–64

Addition of methyl thioglycolate and benzylamine to (Z)–ligustilide, a bioactive unsaturated lactone constituent of several herbal medicines. An improved synthesis of (Z)–ligustilide. Beck JJ, et al. **J Nat Prod** 1995 Jul; 58(7):1047–55

A reinvestigation of Maprounea triterpenes. Beutler JA, et al. **J Nat Prod** 1995 Jul;58(7):1039–46

Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark. Böhlke M, et al. **J Nat Prod** 1996 Jun;59(6):576–80

Isolation and structure identification of an active DNA strand–scission agent, (+)–3,4–di–hydroxy–8,9–methylenedioxypterocarpan. Chaudhuri SK, et al. **J Nat Prod** 1995 Dec;58(12):1966–9

New prenylflavones from the leaves of Epimedium saggitatum. Chen CC, et al. **J Nat Prod** 1996 Apr; 59(4):412–4

Tonkinecin, a novel bioactive annonaceous acetogenin from Uvaria tonkinesis. Chen Y, et al. **J Nat Prod** 1996 May; 59(5):507–9

Antifungal and molluscicidal saponins from Serjania salzmanniana. Ekabo OA, et al. **J Nat Prod** 1996 Apr; 59(4):431–5

Triterpenoid saponins from Mimosa pigra. Englert J, et al. **J Nat Prod** 1995 Aug;58(8):1265–9

Taxane–specific monoclonal antibodies: measurement of taxol, baccatin III, and "total taxanes" in Taxus brevifolia extracts by enzyme immunoassay. Grothaus PG, et al. **J Nat Prod** 1995 Jul;58(7):1003–14

Immunoenzymatic methods applied to the search for bioactive taxoids from Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Jul;58(7):1015–23

Two new taxoids from the stem bark of Taxus baccata. Guo Y, et al. **J Nat Prod** 1995 Dec;58(12):1906–12

Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. Haraguchi H, et al. **J Nat Prod** 1996 Apr;59(4):443–5

Bruceanols G and H cytotoxic quassinoids from Brucea antidysenterica. Imamura K, et al. **J Nat Prod** 1995 Dec; 58(12):1915–9

Triterpenoid saponins from Cephalaria transsylvanica. Kirmizigül S, et al. **J Nat Prod** 1996 Apr;59(4):415–8

Anti-AIDS agents, 21. Triterpenoid saponins as anti-HIV principles from fruits of Gleditsia japonica and Gymnocladus chinensis, and a structure-activity correlation. Konoshima T, et al. **J Nat Prod** 1995 Sep; 58(9):1372–7

Determination of oenothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum. Lesuisse D, et al. **J Nat Prod** 1996 May;59(5):490–2

Novel antiplatelet naphthalene from Rhamnus nakaharai. Lin CN, et al. **J Nat Prod** 1995 Dec;58(12):1934–40

Puqiedinone, a novel 5 alpha-cevanine alkaloid from the bulbs of Fritillaria puqiensis, an antitussive traditional Chinese medicine. Lin G, et al. **J Nat Prod** 1995 Nov; 58(11):1662–7

Oleanane triterpene saponins from the Chinese medicinal herb Clinopodium chinensis. Liu Z, et al. **J Nat Prod** 1995 Oct;58(10):1600–4

Triterpenoid saponins from Gypsophila oldhamiana. Liu Z, et al. **J Nat Prod** 1995 Oct;58(10):1632–5

HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. McCormick JL, et al. **J Nat Prod** 1996 May;59(5):469–71

Coriadienin, the first annonaceous acetogenin with two double bonds isolated from Annona coriaceae. Meneses da Silva EL, et al. **J Nat Prod** 1996 May;59(5):528–30

A new monodesmosidic triterpenoid saponin from the seeds of Vigna unguiculata subsp. unguiculata. Noorwala M, et al. **J Nat Prod** 1995 Jul;58(7):1070–4

Isolation of two new antiinflammatory biflavanoids from Sarcophyte piriei. Ogundaini A, et al. **J Nat Prod** 1996 Jun;59(6):587–90

Bruceosides D, E, and F, three new cytotoxic quassinoid glucosides from Brucea javanica. Ohnishi S, et al. **J Nat Prod** 1995 Jul;58(7):1032–8

Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase. Pengsuparp T, et al. **J Nat Prod** 1995 Jul;58(7):1024–31

Sesquiterpene/quinol from a New Zealand liverwort, Riccardia crassa. Perry NB, et al. **J Nat Prod** 1995 Jul; 58(7):1131–5

Constituents of Ardisia japonica and their in vitro anti-HIV activity. Piacente S, et al. **J Nat Prod** 1996 Jun;59(6):565–9

Pessoine and spinosine, two catecholic berbines from Annona spinescens. Queiroz EF, et al. **J Nat Prod** 1996 Apr; 59(4):438–40

Isolation and characterization of cytotoxic and antibacterial tetrasaccharide glycosides from Ipomoea stans. Reynolds WF, et al. **J Nat Prod** 1995 Nov;58(11):1730–4

Triterpenoid saponins from Bellis sylvestris. 2. Structures of partially deacylated saponins. Schöpke T, et al. **J Nat Prod** 1996 Apr;59(4):355–9

Rollinecins A and B: two new bioactive annonaceous acetogenins from Rollinia mucosa. Shi G, et al. **J Nat Prod** 1996 May;59(5):548–51

Nigranoic acid, a triterpenoid from Schisandra sphaerandra that inhibits HIV-1 reverse transcriptase. Sun HD, et al. **J Nat Prod** 1996 May;59(5):525–7

Diterpenoid alkaloids from Delphinium davisii. Ulubelen A, et al. **J Nat Prod** 1996 Apr;59(4):360–6

Santolindiacetylene, a polyacetylene derivative isolated from the essential oil of Santolina canescens. Utrilla MP, et al. **J Nat Prod** 1995 Nov;58(11):1749–52

Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides). Witherup KM, et al. **J Nat Prod** 1995 Aug; 58(8):1285–90

Additional bicactive acetogenins, annomutacin and (2,4-trans and cis)-10R-annonacin-A-ones, from the leaves of Annona muricata. Wu FE, et al. **J Nat Prod** 1995 Sep; 58(9):1430–7

Identification of ent-16 beta, 17-dihydroxykauran-19-oic acid as an anti-HIV principle and isolation of the new diterpenoids annosquamosins A and B from Annona squamosa. Wu YC, et al. **J Nat Prod** 1996 Jun;59(6):635–7

Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. Ye Q, et al. **J Nat Prod** 1995 Sep;58(9):1398–406

Effects of yew alkaloids and related compounds on guinea-pig isolated perfused heart and papillary muscle. Alloatti G, et al. **Life Sci** 1996;58(10):845–54

Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. White HL, et al. **Life Sci** 1996;58(16):1315–21

Preliminary studies of the antifungal activities of some medicinal plants against Basidiobolus and some other pathogenic fungi. Nwosu MO, et al. **Mycoses** 1995 May-Jun;38(5-6):191–5

Potential carcinogenicity of homoisoflavanoids and flavonoids from Resina sanguinis draconis (Dracaena cinnabari Balf.). Vachálková A, et al. **Neoplasma** 1995; 42(6):313–6

Amoebicidal compounds from medicinal plants. Di Stasi LC. **Parassitologia** 1995 Apr;37(1):29–39 (56 ref.)

A new large-scale process for taxol and related taxanes from Taxus brevifolia. Rao KV, et al. **Pharm Res** 1995 Jul; 12(7):1003–10

Solasodine glycosides of Solanum unguiculatum (A.) Rich. Sarg TM, et al. **Pharm World Sci** 1995 Nov 24;17(6):191–4

Blockade of lithium chloride-induced conditioned place aversion as a test for antiemetic agents: comparison of metoclopramide with combined extracts of Zingiber officinale and Ginkgo biloba. Frisch C, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):321–7

Evaluation of 137Cs activity in plant drugs and in some phytoderivatives from Chernobyl accident up to present (1986–1994). Curini M, et al. **Pharmacol Res** 1995 Jul-Aug; 32(1-2):69–74

Cytotoxicity of triterpenoid saponins. Part 1: Activities against tumor cells in vitro and hemolytical index. Bader G, et al. **Pharmazie** 1996 Jun;51(6):414–7

Inhibitory activity of isorhamnetin glycosides from Calendula officinalis L. on the activity of lipoxygenase. Bezákova L, et al. **Pharmazie** 1996 Feb;51(2):126–7

A new cholestane derivative of Abutilon bidentatum Hochst. and its bioactivity. Jain R, et al. **Pharmazie** 1996 Apr; 51(4):253

Luteolin 7-diglucuronide, the major flavonoid compound from Aloysia triphylla and Verbena officinalis. Carnat A, et al. **Planta Med** 1995 Oct;61(5):490

In vitro biological activities of alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **Planta Med** 1996 Feb; 62(1):22–7

Flavonoids of Artemisia austriaca. Cubukçu B, et al. **Planta Med** 1995 Oct;61(5):488

Sesquiterpenes with antibacterial activity from Epaltes mexicana. Kato T, et al. **Planta Med** 1996 Feb;62(1):66–7

Secoiridoid glucosides from Swertia mileensis. Kikuzaki H, et al. **Planta Med** 1996 Feb;62(1):35–8

Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Kobayashi Y, et al. **Planta Med** 1995 Oct; 61(5):414–8

Tannin constituents of Terminalia glaucescens. Koudou J, et al. **Planta Med** 1995 Oct;61(5):490–1

Inhibitory effects of protoberberine alkaloids from the roots of Coptis japonica on catecholamine biosynthesis in PC12 cells. Lee MK, et al. **Planta Med** 1996 Feb;62(1):31–4

An antibacterial thiophene from Balsamorhiza sagittata. Matsuura H, et al. **Planta Med** 1996 Feb;62(1):65–6

Lignans from barks of Hernandia nymphaefolia and H. peltata. Rahmani M, et al. **Planta Med** 1995 Oct;61(5):487–8

Immunomodulating activity of Echinacea gloriosa L., Echinacea angustifolia DC. and Rudbeckia speciosa Wenderoth ethanol-water extracts. Bukovský M, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):175–7

In vitro cytotoxicity of chaparrin from Castela texana. Calzado-Flores C, et al. **Proc West Pharmacol Soc** 1995; 38:49–50

Immobilization of frog sperm by exposure to Ruta chalepensis extract. Gijon E, et al. **Proc West Pharmacol Soc** 1995; 38:53–4

Cover illustration--regional sources of natural products: Taxomyces andreanae. Huxtable RJ. **Proc West Pharmacol Soc** 1995;38:1–4

Clinical testing of "amole" (Agave lecheguilla): phase 1-A. Segura JJ, et al. **Proc West Pharmacol Soc** 1995;38:71–2

Therapeutic utility, constituents and toxicity of some medicinal plants: a review. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Jun;37(3):255–8 (76 ref.)

Anti-inflammatory compounds isolated from Menyanthes trifoliata L. Huang C, et al. **Yao Hsueh Hsueh Pao** 1995; 30(8):621–6

[Quantitative changes of flavonoids in Epimedium koreanum Nakai in different collecting periods] Chen C, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):86–8, 127 (Eng. Abstr.) **(Chi)**

[Chemical constituents of stems and leaves of Fritillaria ussuriensis Maxim] Cui D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):298, 320 (Eng. Abstr.) **(Chi)**

[Restricting effects of geologic background system on genuine crude drugs in Sichuan] Fan J, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):12–4, 62 (Eng. Abstr.) **(Chi)**

[A comparative study on the chemical constituents of cultivated and wild fructus Gardeniae] Gao Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):654–6, 702 (Eng. Abstr.) **(Chi)**

[Effect of ultrasonic extraction on extraction rate of berberine] Guo X, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):673–5, 703 (Eng. Abstr.) **(Chi)**

[Quantitative determination of ursolic acid in folium Ilicis cornutae (gouguye) gathered in different and periods] Guo Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct; 20(10):591–2, 638 (Eng. Abstr.) **(Chi)**

[Determination of oleanolic acid in the root of Achyranthes bidentata Bl. from different places of production by TLC-scanning] Li X, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Aug;20(8):459–60, 511 (Eng. Abstr.) **(Chi)**

[Analysis of total saponins in traditional Chinese drug radix Astragali] Pan F, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):391–3, 446 (Eng. Abstr.) **(Chi)**

[Chemical constituents in the leaves of Mangifera persiciformis C.Y. Wu et Y.L. Ming] Si X, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):295–6, 320 (Eng. Abstr.) **(Chi)**

[Advances in the study of the chemical constituents of gardenia] Wang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):67–9, 72 (34 ref.) **(Chi)**

[Cytotoxicity of aspidospermane indole alkaloids with a modified tryptamine chain] Lewin G. **J Nat Prod** 1995 Jul; 58(7):1089–91 **(Fre)**

[Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart] Joseph G, et al. **Arzneimittelforschung** 1995 Dec;45(12):1261–5 (Eng. Abstr.) **(Ger)**

[Chemical studies on crude drug processing. X. On the constituents of rehmanniae radix (4): comparison of the constituents of various rehmanniae radixes originating in China, Korea, and Japan] Kitagawa I, et al. **Yakugaku Zasshi** 1995 Dec;115(12):992–1003 (Eng. Abstr.) **(Jpn)**

[Production of medicinal plants by soilless culture system. I. Studies of morphological characteristics and saikosaponins content in Bupleurum falcatum cultivated by Ebb & Flood system] Minami M, et al. **Yakugaku Zasshi** 1995 Oct;115(10):832–42 (Eng. Abstr.) **(Jpn)**

[Use of an activated chemiluminescence method for studying the pharmacologic properties of medicinal substances] Nanaeva MT, et al. **Vopr Med Khim** 1995 Sep-Oct; 41(5):48–50 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Medical ethnobotany of the Siddis of Uttara Kannada district, Karnataka, India. Bhandary MJ, et al. **J Ethnopharmacol** 1995 Jul 28;47(3):149–58 (15 ref.)

DRUG EFFECTS

Effects of copper sulfate on black bindweed (Polygonum convolvulus L.). Kjaer C, et al. **Ecotoxicol Environ Saf** 1996 Mar;33(2):110–7

ENZYMOLOGY

Purification and characterization of taxa-4(5),11(12)-diene synthase from Pacific yew (Taxus brevifolia) that catalyzes the first committed step of taxol biosynthesis. Hezari M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):437–44

Purification and properties of a plant beta-D-glucuronidase form Scutellaria root. Ikegami F, et al. **Biol Pharm Bull** 1995 Nov;18(11):1531–4

Cloning and analysis of a cDNA encoding farnesyl diphosphate synthase from Artemisia annua. Matsuhita Y, et al. **Gene** 1996 Jun 26;172(2):207–9

[Esterase isoenzyme of various types in rhizoma Gastrodiae] Pan R, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb; 21(2):84–6, 127 (Eng. Abstr.) **(Chi)**

[8 species of peroxidase isozymes and 2 varieties of Corydalis] Zhang Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan; 21(1):6–8, 62 (Eng. Abstr.) **(Chi)**

GENETICS

Amplification and sequence of a 5s-rRNA gene spacer region from the crude drug "angelica root". Mizukami H. **Biol Pharm Bull** 1995 Sep;18(9):1299–301

Molecular cloning and characterization of Rosa hybrida dihydroflavonol 4-reductase gene. Tanaka Y, et al. **Plant Cell Physiol** 1995 Sep;36(6):1023–31

[Karyological studies on the fruit of Gardenia jasminoides Ellis] Yang Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct;20(10):588–90, 638 (Eng. Abstr.) **(Chi)**

GROWTH & DEVELOPMENT

Protoplast culture and plant regeneration from the suspension cells of Gynostemma pentaphyllum (Thumb) Mak. Zhang H, et al. **Chin J Biotechnol** 1995;11(3):207–11

[Tissue culture of bulbus Fritillariae cirrhosae] Chen M, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Aug;20(8):461–2, 511 (Eng. Abstr.) **(Chi)**

[Experiment on the rapid reproduction of Fritillaria taipaiensis P.Y. Li] Liu Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):15–7, 63 (Eng. Abstr.) **(Chi)**

[Tissue culture and rapid propagation of Pinellia ternata (Thunb) Breit] Wan M, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep;20(9):526–9, 574 (Eng. Abstr.) **(Chi)**

[Ecological studies on the growth of Pinellia ternata (Thunb.) Breit.] Zhang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):395–7, 446 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Allergic contact dermatitis due to Centella asiatica: a new case. Gonzalo Garijo MA, et al. **Allergol Immunopathol (Madr)** 1996 May-Jun;24(3):132–4

Occupational asthma caused by sarsaparilla root dust. Vandenplas O, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1416–8

Immunogold probes for light and electron microscopic localization of Ole e I in several Oleaceae pollens. Fernandez MC, et al. **J Histochem Cytochem** 1996 Feb; 44(2):151–8

METABOLISM

Tissue cultures of Taxus baccata as a source of 10-deacetylbaccatin III, a precursor for the hemisynthesis of taxol. Zhiri A, et al. **Biol Chem Hoppe Seyler** 1995 Oct; 376(10):583–6

Effects of Hemerocallis flava on motor activity and the concentration of central monoamines and its metabolites in rats. Hsieh MT, et al. **J Ethnopharmacol** 1996 Jun; 52(2):71–6

The effect of herbicides on the qualitative properties of medicinal plants. Part 3: Content and composition of the essential oil from Melissa officinalis L. after application of Basagran. Vaverková S, et al. **Pharmazie** 1995 Dec; 50(12):835–6

[Preliminary study on physiology and biochemistry in Fritillaria thunbergii Miq. in the alternate process of new and old organs] Gao W, et al.
Chung Kuo Chung Yao Tsa Chih 1995 Dec;20(12):719–21, 762 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew, Taxus brevifolia. Stierle A, et al. **J Nat Prod** 1995 Sep;58(9):1315–24

Influence of physical parameters on the germ-reducing effect of microwave irradiation on medicinal plants. Brantner A, et al. **Pharmazie** 1995 Nov;50(11):762–6

PHYSIOLOGY

Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. McRae S. **Can Med Assoc J** 1996 Aug 1;155(3):293–5

PLANTS, TOXIC

see related

PLANT POISONING

Narthecium ossifragum associated photosensitization in sheep in the Faroe Islands. Flåøyen A, et al. **Acta Vet Scand** 1995; 36(2):277–8

The Queensland Poisonous Plants Committee: its history and functions. McKenzie RA. **Aust Vet J** 1995 Jan;72(1):10–7

Cicutoxin from Cicuta virosa—a new and potent potassium channel blocker in T lymphocytes. Strauss U, et al.
Biochem Biophys Res Commun 1996 Feb 15;219(2):332–6

Burns induced by plants. Lagey K, et al. **Burns** 1995 Nov; 21(7):542–3

Yew poisoning in sheep. Rae CA, et al. **Can Vet J** 1995 Jul; 36(7):446

Anaranthus retroflexus (redroot pigweed) poisoning in lambs. Rae CA, et al. **Can Vet J** 1995 Jul;36(7):446

Selectively cytotoxic diterpenes from Euphorbia poisonii. Fatope MO, et al. **J Med Chem** 1996 Feb 16;39(4):1005–8

Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Pena JM, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1359–60

Lectins as plant defense proteins. Peumans WJ, et al.
Plant Physiol 1995 Oct;109(2):347–52 (27 ref.)

Effect of peroxisomicine and related anthracenones on catalase activity. Moreno-Sepúlveda M, et al.
Planta Med 1995 Aug;61(4):337–40

Plant dermatitis. Possible culprits go far beyond poison ivy. Juckett G. **Postgrad Med** 1996 Sep;100(3):159–63, 167–71 (20 ref.)

Transitory complete atrioventricular block associated to ingestion of Nerium oleander. Nishioka S de A, et al.
Rev Assoc Med Bras 1995 Jan-Feb;41(1):60–2

Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

Poisonous plant identification: a comparison of databases designed for veterinary use. Cornell J, et al.
Vet Hum Toxicol 1995 Oct;37(5):482–5

The acute toxicity of Riedeliella graciflora in calves. Gorniak SL, et al. **Vet Hum Toxicol** 1995 Oct;37(5):447–8

Intoxication due to Achyrantes aspera L. Sanchez Perere LM, et al. **Vet Hum Toxicol** 1995 Dec;37(6):582

Toxicity of field bindweed (Convolvulus arvensis) to mice. Schultheiss PC, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):452–4

Effects on reproduction in female offspring from Sprague-Dawley rats fed 10% snakeweed (Gutierrezia microcephala) throughout pregnancy and concurrent treatment with safflower oil. Staley EC, et al.
Vet Hum Toxicol 1995 Oct;37(5):440–2

Tissue and serum swainsonine concentrations in sheep ingesting Astragalus lentiginosus (locoweed). Stegelmeier BL, et al. **Vet Hum Toxicol** 1995 Aug;37(4):336–9

Nephrotoxicity of Narthecium ossifragum in cattle in Norway. Flåøyen A, et al. **Vet Rec** 1995 Sep 9; 137(11):259–63

Field diagnosis of nitrite poisoning in cattle by testing aqueous humour samples with urine test strips. Montgomery JF, et al. **Vet Rec** 1995 Dec 2;137(23):593–4

Suspected annual mercury (Mercurialis annua) poisoning of lambs grazing fallow arable land. Welchman DB, et al.
Vet Rec 1995 Dec 2;137(23):592–3

CHEMISTRY

Anti-AIDS agents—XIX. Neotripterifordin, a novel anti-HIV principle from Tripterygium wilfordii: isolation and structural elucidation. Chen K, et al.
Bioorg Med Chem 1995 Oct;3(10):1345–8

Chemical and biological demonstration of the presence of monofluoroacetate in the leaves of Palicourea marcgravii St. Hil. de-Moraes-Moreau RL, et al.
Braz J Med Biol Res 1995 Jun;28(6):685–92

Transformation of grayanotoxin III to 10-epi-grayanotoxin III. Its X-ray crystallographic analysis and acute toxicity in mice. Terai T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1245–7

Causal connection between detoxification enzyme activity and consumption of a toxic plant compound. Snyder MJ, et al. **J Comp Physiol [A]** 1996 Aug;179(2):255–61

Bioactive isocoumarins and related metabolites from conifer endophytes. Findlay JA, et al. **J Nat Prod** 1995 Nov; 58(11):1759–66

Idiospermuline, a trimeric pyrrolidinoindoline alkaloid from the seed of Idiospermum australiense. Kuke RK, et al.
J Nat Prod 1995 Aug;58(8):1200–8

Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227–32; discussion 242 (54 ref.)

Toxicological data needed for safety evaluation and regulation on inherent plant toxins. Speijers GJ.
Nat Toxins 1995;3(4):222–6; discussion 242 (9 ref.)

Rhabdomyolysis and acute renal failure following blowpipe dart poisoning. Ho LM, et al. **Nephron** 1996;72(4):676–8

IMMUNOLOGY

V beta-specific deletion of mature thymocytes induced by the plant superantigen Urtica dioica agglutinin. Delcourt M, et al. **Cell Immunol** 1996 Mar 15;168(2):158–64

METABOLISM

Structures of toxic steroidal saponins from Narthecium asiaticum MAXIM. Inoue T, et al.
Chem Pharm Bull (Tokyo) 1995 Jul;43(7):1162–6

PLANTS, TRANSGENIC

Genetic modification of plants: significant issues and hurdles to success. Day PR. **Am J Clin Nutr** 1996 Apr; 63(4):651S–6S (34 ref.)

Transgenic plants on trial in the USA. Giddings LV.
Curr Opin Biotechnol 1996 Jun;7(3):275–80

High-frequency and efficient Agrobacterium-mediated transformation of Arabidopsis thaliana ecotypes "C24" and "Landsberg erecta" using Agrobacterium tumefaciens. Barghchi M. **Methods Mol Biol** 1995;44:135–47

Transformation of soybean (Glycine max) via Agrobacterium tumefaciens and analysis of transformed plants. Chee PP, et al. **Methods Mol Biol** 1995;44:101–19

Leaf disk transformation. Curtis IS, et al.
Methods Mol Biol 1995;44:59–70

NPTII assays for measuring gene expression and enzyme activity in transgenic plants. Curtis IS, et al.
Methods Mol Biol 1995;49:149–59 (20 ref.)

Agrobacterium-mediated antibiotic resistance for selection of somatic hybrids. The genus Lycopersicon as a model system. Davey MR, et al. **Methods Mol Biol** 1995;44:167–83

Transformation protocols for broadleaved trees. Fenning TM, et al. **Methods Mol Biol** 1995;44:149–65

Western blotting analysis. Fido RJ, et al.
Methods Mol Biol 1995;49:423–37 (24 ref.)

Leaf disk transformation using Agrobacterium tumefaciens-expression of heterologous genes in tobacco. Gallois P, et al. **Methods Mol Biol** 1995;49:39–48 (32 ref.)

Electroporation of tobacco leaf protoplasts using plasmid DNA or total genomic DNA. Gallois P, et al.
Methods Mol Biol 1995;55:89–107

Agrobacterium-mediated transformation of soft fruit Rubus, Ribes, and Fragaria. Graham J, et al.
Methods Mol Biol 1995;44:129–33

The beta-glucuronidase (gus) reporter gene system. Gene fusions; spectrophotometric, fluorometric, and histochemical detection. Hull GA, et al.
Methods Mol Biol 1995;49:125–41 (35 ref.)

Agrobacterium-mediated transformation of potato genotypes. Kumar A. **Methods Mol Biol** 1995;44:121–8

Peanut transformation. Mansur E, et al.
Methods Mol Biol 1995;44:87–100

Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)

Pollen electrotransformation in tobacco. Saunders JA, et al.
Methods Mol Biol 1995;55:81–8

Electroporation of Brassica. Siegemund F, et al.
Methods Mol Biol 1995;55:109–20

Applications of RT-PCR. Simpson CG, et al.
Methods Mol Biol 1995;49:257–69

Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49–61 (18 ref.)

Agrobacterium-mediated transformation of protoplasts from oilseed rape (Brassica napus L.). Thomzik JE.
Methods Mol Biol 1995;44:71–8

Agrobacterium-mediated transformation of stem disks from oilseed rape (Brassica napus L.). Thomzik JE.
Methods Mol Biol 1995;44:79–85

Risks from transgenic crops [letter] Timmons AM, et al.
Nature 1996 Apr 11;380(6574):487

Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Mitsuhara I, et al. **Plant Cell Physiol** 1996 Jan; 37(1):49–59

Derepression of the activity of genetically engineered heat shock factor causes constitutive synthesis of heat shock proteins and increased thermotolerance in transgenic Arabidopsis. Lee JH, et al. **Plant J** 1995 Oct;8(4):603–12

Comparison of different constitutive and inducible promoters for the overexpression of transgenes in Arabidopsis thaliana. Holtorf S, et al. **Plant Mol Biol** 1995 Nov; 29(4):637–46

Transgenic rice established to express corn cystatin exhibits strong inhibitory activity against insect gut proteinases. Irie K, et al. **Plant Mol Biol** 1996 Jan;30(1):149–57

Plant antibodies for immunotherapy. Ma JK, et al.
Plant Physiol 1995 Oct;109(2):341–6 (30 ref.)

[Detection of genetically engineered plants by polymerase chain reaction (PCR) using the FLAVR SAVR tomato as an example] Meyer R. **Z Lebensm Unters Forsch** 1995 Dec;201(6):583–6 (Eng. Abstr.) **(Ger)**

CHEMISTRY

A biotechnological approach to improving the nutritive value of alfalfa. Tabe LM, et al. **J Anim Sci** 1995 Sep;73(9):2752–9

IAA analysis in transgenic plants. Hall JF, et al.
Methods Mol Biol 1995;44:237–44

Quantifying phytohormones in transformed plants. Prinsen E, et al. **Methods Mol Biol** 1995;44:245–62

Identification of a Brazil-nut allergen in transgenic soybeans [see comments] Nordlee JA, et al. **N Engl J Med** 1996 Mar 14;334(11):688–92. Comment in: N Engl J Med 1996 Mar 14;334(11):726–8.

GENETICS

Prohevein is poorly processed but shows enhanced resistance to a chitin-binding fungus in transgenic tomato plants. Lee HI, et al. **Braz J Med Biol Res** 1995 Jul;28(7):743–50

Highly insect-resistant transgenic tobacco plants containing both B.t. and CpTI genes. Zhao R, et al.
Chin J Biotechnol 1995;11(1):1–7

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al.
Curr Top Microbiol Immunol 1995;197:91–103 (39 ref.)

Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al.
Curr Top Microbiol Immunol 1995;197:77–89 (70 ref.)

trans-inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al.
Curr Top Microbiol Immunol 1995;197:1–14 (30 ref.)

Gene silencing in transgenic plants: a heuristic autoregulation model. Meins F Jr, et al. **Curr Top Microbiol Immunol** 1995; 197:105–20 (55 ref.)

DNA methylation and transgene silencing in Petunia hybrida. Meyer P. **Curr Top Microbiol Immunol** 1995;197:15–28 (61 ref.)

Transgene inactivation in Arabidopsis thaliana. Scheid OM.
Curr Top Microbiol Immunol 1995;197:29–42 (57 ref.)

Modified 2S albumins with improved tryptophan content are correctly expressed in transgenic tobacco plants. Marcellino LH, et al. **FEBS Lett** 1996 May 6;385(3):154–8

Principles and applications of recombinant antibody phage display technology to plant biology. Crosby WL, et al.
Methods Cell Biol 1995;50:85–99

Flow cytometric analysis of transgene expression in higher plants: green-fluorescent protein. Galbraith DW, et al.
Methods Cell Biol 1995;50:3–14

Novel inducible/repressible gene expression systems. Gatz C. **Methods Cell Biol** 1995;50:411–24

Epitope tagging for the detection of fusion protein expression in transgenic plants. Guiltinan MJ, et al.
Methods Cell Biol 1995;49:143–51

Transgenic oilseed rape. How to assess the risk of outcrossing to wild relatives. Baranger A, et al. **Methods Mol Biol** 1995; 44:393–403

Transgene inactivation in Petunia hybrida is influenced by the properties of the foreign gene. Elomaa P, et al.
Mol Gen Genet 1995 Oct 25;248(6):649–56

The promoter from the rice nuclear gene encoding chloroplast aldolase confers mesophyll-specific and light-regulated expression in transgenic tobacco. Kagaya Y, et al. **Mol Gen Genet** 1995 Oct 25;248(6):668–74

Genetic analysis of the effects of re-transformation of transgenic lines of the moss Physcomitrella patens. Kammerer W, et al. **Mol Gen Genet** 1996 Feb 25; 250(3):380–2

Gene silencing in transgenic tobacco hybrids: frequency of the event and visualization of somatic inactivation pattern. Schmülling T, et al. **Mol Gen Genet** 1995 Dec 10; 249(4):375–90

PLANTS, TRANSGENIC

Transgenic Arabidopsis tester lines with dominant marker genes. Van Lijsebettens M, et al. **Mol Gen Genet** 1996 Jun 12;251(3):365–72

Vectors carrying two separate T-DNAs for co-transformation of higher plants mediated by Agrobacterium tumefaciens and segregation of transformants free from selection markers. Komari T, et al. **Plant J** 1996 Jul;10(1):165–74

Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

From plants to mammals [letter; comment] Matzke MA, et al. **Science** 1996 Mar 8;271(5254):1347–8. Comment on: Science 1995 Nov 17;270(5239):1120–1.

[Change in expression and inheritance of the marker gene nptII in progeny of Nicotiana tabacum L transgenic plants] Deineko EV, et al. **Dokl Akad Nauk** 1995 Sep; 344(3):407–11 **(Rus)**

GROWTH & DEVELOPMENT

Calmodulin binding to glutamate decarboxylase is required for regulation of glutamate and GABA metabolism and normal development in plants. Baum G, et al. **EMBO J** 1996 Jun 17;15(12):2988–96

IMMUNOLOGY

Allergies to transgenic foods—questions of policy [editorial; comment] Nestle M. **N Engl J Med** 1996 Mar 14; 334(11):726–8. Comment on: N Engl J Med 1996 Mar 14;334(11):688–92.

A mammalian 2–5A system functions as an antiviral pathway in transgenic plants. Mitra A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6780–5

METABOLISM

Calmodulin binding to glutamate decarboxylase is required for regulation of glutamate and GABA metabolism and normal development in plants. Baum G, et al. **EMBO J** 1996 Jun 17;15(12):2988–96

Assessing cadmium partitioning in transgenic plants. Wagner GJ. **Methods Mol Biol** 1995;44:295–308

Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

Accumulation of a sulphur-rich seed albumin from sunflower in the leaves of transgenic subterranean clover (Trifolium subterraneum L.). Khan MR, et al. **Transgenic Res** 1996 May;5(3):179–85

MICROBIOLOGY

Cold requirement for maximal activity of the bacterial ice nucleation protein INAZ in transgenic plants. van Zee K, et al. **Plant Mol Biol** 1996 Jan;30(1):207–11

PHYSIOLOGY

Manipulating photosynthesis in transgenic plants. Knight JS, et al. **Methods Mol Biol** 1995;44:263–80

VIROLOGY

Inhibition of brome mosaic virus (BMV) amplification in protoplasts from transgenic tobacco plants expressing replicable BMV RNAs. Kaido M, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2827–33

Genetic and biochemical dissection of transgenic RNA-mediated virus resistance. Goodwin J, et al. **Plant Cell** 1996 Jan;8(1):95–105

PLAQUE ASSAY

Plaque variations in clinical isolates of bovine coronavirus. Kapil S, et al. **J Vet Diagn Invest** 1995 Oct;7(4):538–9

Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

[Quantitative determination of the infective activity of the human immunodeficiency virus by plaque formation using monolayer cultures] Nosik MN, et al. **Vopr Virusol** 1995 Sep-Oct;40(5):202–5 (Eng. Abstr.) **(Rus)**

METHODS

Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus. Tebas P, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1287–91

Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. Ward RL, et al. **J Clin Microbiol** 1996 Apr;34(4):983–5

A blinded comparison of two methods of viral susceptibility testing: plaque reduction assay versus microplate in situ ELISA. Leahy BJ, et al. **J Virol Methods** 1996 Jan; 56(1):85–90

Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. Standring-Cox R, et al. **J Virol Methods** 1996 Jan; 56(1):3–11

PLAQUE THERAPY, RADIOISOTOPE see

BRACHYTHERAPY

PLASMA

Heparin contamination in coagulation testing and a protocol to avoid it and the risk of inappropriate FFP transfusion. Newman RS, et al. **Am J Clin Pathol** 1995 Oct;104(4):447–9

Endothelial cell proliferation is suppressed by plasma but not serum from women with preeclampsia. Smárason AK, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):787–93

Plasma supplementation is beneficial for coagulation during severe hemorrhagic shock. Lucas CE, et al. **Am J Surg** 1996 Apr;171(4):399–404

Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Poredoš P, et al. **Angiology** 1996 Mar;47(3):253–9

Correcting prolonged bleeding during renal transplantation with estrogen or plasma. Boyd GL, et al. **Arch Surg** 1996 Feb;131(2):160–5

Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Nibuya M, et al. **Biol Psychiatry** 1995 Jul 1;38(1):50–6

Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory. Favaloro EJ, et al. **Br J Biomed Sci** 1995 Dec;52(4):243–8

A comparative study of the effect of autologous platelet-rich plasma and fresh autologous whole blood on haemostasis after cardiac surgery. Yamamoto K, et al. **Cardiovasc Surg** 1996 Feb;4(1):9–14

An audit of fresh frozen plasma transfusion in intensive care patients. Gunawardana RH. **Ceylon Med J** 1996 Mar; 41(1):21

Plasma catecholamine levels during functional endoscopic sinus surgery. John G, et al. **Clin Otolaryngol** 1995 Jun; 20(3):213–5

Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy [see comments] Nowak-Göttl U, et al. **Haematologica** 1995 Sep-Oct; 80(5):451–3. Comment in: Haematologica 1996 Mar-Apr;81(2):191.

Plasma adsorption to charcoal and ion-exchange resin for treating postoperative hepatic failure. Iseki J, et al. **Hepatogastroenterology** 1995 Jul-Aug;42(4):394–8

Rapid measurement of plasma methadone in a clinical setting using florescence polarization immunoassay. Kell MJ, et al. **J Addict Dis** 1996;15(2):69–83

Raised plasma polyamine concentrations in patients with severe head injury [letter] Timothy J, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):209–10

The routine use of fresh frozen plasma in operations with cardiopulmonary bypass is not justified. Consten EC, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):162–7

Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Northern Neonatal Nursing Initiative Trial Group [see comments] **Lancet** 1996 Jul 27;348(9022):229–32. Comment in: Lancet 1996 Jul 27;348(9022):208–9.

HIV-2 infection among blood and plasma donors—United States, June 1992-June 1995. **Oncology (Huntingt)** 1995 Dec;9(12):1262–4

The use of EDTA plasma obviates the need for prewarmed tests [letter; comment] Pereira A, et al. **Transfusion** 1995 Oct;35(10):885–6. Comment on: Transfusion 1995 Mar;35(3):268–70. Comment on: Transfusion 1995 Mar;35(3):271–5.

Determinants of red cell, platelet, plasma, and cryoprecipitate transfusions during coronary artery bypass graft surgery: the Collaborative Hospital Transfusion Study. Surgenor DM, et al. **Transfusion** 1996 Jun;36(6):521–32

[Use of autologous blood, plasma and thrombocyte concentrates in heart surgery] Charvnát J, et al. **Cas Lek Cesk** 1995 Nov 1;134(21):686–8 (Eng. Abstr.) **(Cze)**

[Use of fresh frozen plasma in patient treatment. Indications illustrated by a literature review and a study of practice at a university hospital] Lahrmann C, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3467–70 (Eng. Abstr.) **(Dan)**

[Secured freeze-dried plasma. Its use in war conditions (letter)] Benefice S, et al. **Ann Fr Anesth Reanim** 1996; 15(1):101–5 **(Fre)**

[Effects of platelet-rich plasma on hemostasis and transfusion requirement in vascular surgery] Godet G, et al. **Ann Fr Anesth Reanim** 1995;14(3):265–70 (Eng. Abstr.) **(Fre)**

[Platelet-rich plasma (letter)] Waller C. **Ann Fr Anesth Reanim** 1995;14(6):536 **(Fre)**

[Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma] Mischke R, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jan;103(1):3–6 (Eng. Abstr.) **(Ger)**

[Platelet aggregation inhibition due to sodium hypochlorite. The effect of blood plasma components] Murina MA, et al. **Biull Eksp Biol Med** 1995 May;119(5):488–90 **(Rus)**

[The effect of plasmosorption on the healing dynamics of postoperative wounds in patients with suppurative-inflammatory processes of the maxillofacial area and diabetes mellitus] Zuev VP, et al. **Stomatologiia (Mosk)** 1995;74(3):36–7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Durham BH, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):422–3

Validity for epidemiological studies of long-term cryoconservation of steroid and protein hormones in serum and plasma. Bolelli G, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):509–13

Stability of ascorbic acid, carotenoids, retinol, and tocopherols in plasma stored at -70 degrees C for 4 years. Comstock GW, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):505–7

Estimation of cholesterol sulphate in blood plasma and in erythrocyte membranes from individuals with Down's syndrome or diabetes mellitus type I. Przybylska M, et al. **Clin Biochem** 1995 Dec;28(6):593–7

Comparison of von Willebrand factor and tissue plasminogen activator concentrations in plasma and serum. Nilsson TK, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):976–7

Quantitation of procholecystokinin and its products in plasma by processing-independent analysis. Paloheimo LI, et al. **Clin Chim Acta** 1995 Jun 30;238(1):21–33

Diphtheria antitoxin levels in US blood and plasma donors. Gupta RK, et al. **J Infect Dis** 1996 Jun;173(6):1493–7

Purification and analysis of plasmatic components of middle molecular weight in patients with uremic syndrome. Martín Mateo MC, et al. **Nephron** 1995;71(2):160–7

Plasma-ionized magnesium concentration in a child with magnesium-losing tubulopathy [letter] Truttmann AC, et al. **Nephron** 1995;71(2):238–9

Is heparinized plasma suitable for use in routine biochemistry? Donnelly JG, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug; 15(4):555–9

[Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of the consumption of food with an elevated content of this vitamin] Núñez Martín C, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):368–72 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Is heparinized plasma suitable for use in routine biochemistry? Donnelly JG, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug; 15(4):555–9

IMMUNOLOGY

Quantification of the endotoxin-neutralizing capacity of serum and plasma. Zhang GH, et al. **APMIS** 1995 Oct; 103(10):721–30

Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. Norrby-Teglund A, et al. **J Immunol** 1996 Apr 15;156(8):3057–64

Inhibition of hematopoiesis by a plasma factor in a case of aplastic anemia associated with systemic lupus erythematosus. Marqués JA, et al. **P R Health Sci J** 1995 Dec;14(4):293–6

Comparison of plasma and serum for antibody detection using DiaMed microtubes. Scott Y, et al. **Transfus Med** 1996 Mar; 6(1):65–7

METABOLISM

Topical nitroprusside may reduce histamine-induced plasma exudation in human nasal airways. Greiff L, et al. **Allergy** 1995 Jul;50(7):593–7

The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Benzie IFF, et al. **Anal Biochem** 1996 Jul 15;239(1):70–6

Activation of plasma components by leukocyte removal filters. Gu YJ, et al. **ASAIO J** 1994 Jul-Sep;40(3):M598–601

Plasma exudation in the skin measured by external detection of conversion electrons. Karambatsakidou A, et al. **Eur J Nucl Med** 1996 Mar;23(3):290–4

Jaundice in new born and erythrocyte and plasma antioxidant defence system. Majumder S, et al. **Indian J Exp Biol** 1995 Apr;33(4):303–5

An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. Aida Y, et al. **J Leukoc Biol** 1995 Dec;58(6):675–82

Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Jy W, et al. **Thromb Res** 1995 Dec 15;80(6):471–82

Erythrocyte-to-plasma distribution ratio of cyclosporine: a useful indicator to predict cyclosporine pharmacokinetics and physiological changes during cyclosporine monitoring. Shibata N, et al. **Transplant Proc** 1996 Jun;28(3):1313–5

[Lipid peroxidation and blood plasma chemiluminescence during artificial circulation] Mil'chakov VI, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):26–9 (Eng. Abstr.) **(Rus)**

[The estimation of free-radical lipid oxidation in the erythrocytes and blood plasma] Anoshina MIu, et al. **Fiziol Zh** 1994 Sep-Dec;40(5–6):51–6 (Eng. Abstr.) **(Rus)**

[The kinetics of radionuclide distribution between the plasma and formed elements of the blood in dogs] Kolosov IV,

et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):417-20 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Influence of plasma preparations and donor red blood cells on the antioxidant capacity of blood from newborn babies: an in vitro study. Moison RM, et al. **Acta Paediatr** 1996 Feb;85(2):220-4

Plasma potentiates the priming effects of endotoxin on platelet activating factor-induced pulmonary hypertension in the rabbit lung. Goldsmith JA, et al. **Anesth Analg** 1996 Aug;83(2):242-6

Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Cowley HC, et al. **Crit Care Med** 1996 Jul;24(7):1179-83

Cryoprecipitate-poor plasma fraction (cryosupernatant) in the treatment of thrombotic thrombocytopenic purpura at onset. A report of four cases. Perotti C, et al. **Haematologica** 1996 Mar-Apr;81(2):175-7

Bulk acoustic wave sensor for investigating hemorheological characteristics of plasma and its coagulation. Si SH, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3-4):135-43

Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. Chen CS, et al. **J Invest Dermatol** 1996 Feb;106(2):238-42

Relative viscosity of plasma--evaluation of a simple technique. Tauheed S, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):157-8

Method to create small photo-bleached volumes to monitor blood plasma flow in capillaries. Wieringa PA, et al. **Med Biol Eng Comput** 1995 Jul;33(4):563-70

Plasma skimming in vascular trees: numerical estimates of symmetry recovery lengths. Carr RT, et al. **Microcirculation** 1995 Dec;2(4):345-53 (25 ref.)

RADIATION EFFECTS

Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Chin S, et al. **Blood** 1995 Dec 1; 86(11):4331-6

[The behavior of the activation parameters of plasma coagulation under HDR-afterloading therapy in patients with endometrial carcinoma] Münstedt K, et al. **Strahlenther Onkol** 1996 Jan;172(1):39-42 (Eng. Abstr.) **(Ger)**

[The dynamic interactions of the level of blood plasma and erythrocyte membrane cholesterol under the influence of the laser irradiation of patients with ischemic heart disease] Vasil'ev AP, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan-Feb;(1):37-8 **(Rus)**

VIROLOGY

Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Chin S, et al. **Blood** 1995 Dec 1; 86(11):4331-6

Is safe always safe? Pooled plasma derivatives and viral hepatitis [editorial; comment] Mosley JW. **Gastroenterology** 1996 Apr;110(4):1307-10. Comment on: Gastroenterology 1996 Apr;110(4):1120-6.

Canada's Red Cross Society recalls plasma because of possible Creutzfeldt-Jakob disease contamination [letter] [published erratum appears in Med J Aust 1996 Jan 1;164(1):56] Davis RW. **Med J Aust** 1995 Nov 20; 163(10):560

Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay [see comments] Lee SR, et al. **Transfusion** 1995 Oct; 35(10):845-9. Comment in: Transfusion 1996 May;36(5):476-7.

Virally inactivated fresh frozen plasma. Williamson LM, et al. **Vox Sang** 1995;69(3):159-65 (45 ref.)

[The measurement of plasma viral loads in HIV-infected children. Their possible role in parenteral transmission] Apetrei C, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec;40(3-4):235-9 **(Rum)**

PLASMA CELL ANTIGENS PC-1 see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

PLASMA CELL DYSCRASIAS see **PARAPROTEINEMIAS**

PLASMA CELL GRANULOMA see **GRANULOMA, PLASMA CELL**

PLASMA CELL GRANULOMA, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PLASMA CELL GRANULOMA, PULMONARY see **GRANULOMA, PLASMA CELL, PULMONARY**

PLASMA-CELL LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMA CELLS

Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Witzig TE, et al. **Blood** 1996 Sep 1;88(5):1780-7

Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? Witzig TE, et al. **Leuk Lymphoma** 1995 Nov; 19(5-6):417-22

CYTOLOGY

A dual origin for IgA plasma cells in the murine small intestine. Kroese FG, et al. **Adv Exp Med Biol** 1995; 371A:435-40

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Lemoli RM, et al. **Blood** 1996 Feb 15;87(4):1625-34

Identification of early plasma cells in peripheral blood and their clinical significance. Harada Y, et al. **Br J Haematol** 1996 Jan;92(1):184-91

Methods for cell proliferation analysis by fluorescent image cytometry. Souchier C, et al. **Cytometry** 1995 Jul 1; 20(3):203-9

Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells. Teraoka H, et al. **Exp Cell Res** 1996 Jan 10;222(1):218-24

Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Rousset F, et al. **Int Immunol** 1995 Aug;7(8):1243-53

Isolation of bone marrow plasma cells by negative selection with immunomagnetic beads. Fillola G, et al. **J Immunol Methods** 1996 Mar 28;190(1):127-31

Increase in density of jejunal IgA2 cells during infancy without change in IgA1 cells. Hacsek G, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):307-11

DRUG EFFECTS

Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Masellis-Smith A, et al. **Blood** 1996 Mar 1;87(5):1891-9

IMMUNOLOGY

Characterization of cytokine producing T cells, TCR expression, and IgA plasma cells in salivary gland-associated tissues. Mega J, et al. **Adv Exp Med Biol** 1995;371B:1103-8

Immunophenotype and DNA cell content in multiple myeloma. San Miguel JF, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):735-59 (102 ref.)

High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma. Kawano MM, et al. **Br J Haematol** 1995 Dec; 91(4):860-4

A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometry [see comments] van Zaanen HC, et al. **Br J Haematol** 1995 Sep;91(1):55-9. Comment in: Br J Haematol 1996 Apr;93(1):251-2.

Immortalization of plasma cells by plasmid DNA and its hybridoma. Kanki T, et al. **Hum Antibodies Hybridomas** 1995;6(3):89-92

Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. Toellner KM, et al. **J Exp Med** 1996 May 1;183(5):2303-12

Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. Zack DJ, et al. **J Immunol** 1995 Nov 15;155(10):5057-63

Increase in density of jejunal IgA2 cells during infancy without change in IgA1 cells. Hacsek G, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):307-11

Very late antigen (VLA) expression by normal and neoplastic human plasma cells; including an assessment of antibodies submitted to the Vth International Workshop on Leucocyte Differentiation Antigens using human myeloma cell lines. Drew M, et al. **Leuk Res** 1996 Jul;20(7):619-24

Immunoglobulin-containing plasma cells recruited to cervical neoplasia. Edwards RP, et al. **Obstet Gynecol** 1996 Apr;87(4):520-6

METABOLISM

Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders [letter; comment] Smith SR, et al. **Br J Haematol** 1996 Mar; 92(3):767-8. Comment on: Br J Haematol 1995 Sep;91(1):116-20.

Plasma cell P170 expression and response to treatment in multiple myeloma. Patriarca F, et al. **Haematologica** 1996 May-Jun;81(3):232-7

Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation. Ito A, et al. **Pathol Int** 1995 Oct;45(10):715-20

Human intestinal B-cell blasts and plasma cells express the mucosal homing receptor integrin alpha 4 beta 7. Farstad IN, et al. **Scand J Immunol** 1995 Dec;42(6):662-72

PATHOLOGY

Primary cutaneous angioplasmocellular hyperplasia. González S, et al. **Am J Dermatopathol** 1995 Jun; 17(3):307-11

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan-Feb;16(1):545-7 (21 ref.)

Oral papillary plasmacytosis cleared by radiotherapy. Lee MS, et al. **Br J Dermatol** 1996 May;134(5):945-8

Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice. Dedera DA, et al. **Br J Haematol** 1996 Jul;94(1):53-61

The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Joshua D, et al. **Br J Haematol** 1996 Jul;94(1):76-81

Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection [letter; comment] Ocqueteau M, et al. **Br J Haematol** 1996 Apr;93(1):251-2. Comment on: Br J Haematol 1995 Sep;91(1):55-9.

Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53-5 (21 ref.)

Correlation between argyrophilic nucleolar organizer region counts and labelling index in multiple myeloma. Marmont F, et al. **Eur J Haematol** 1996 Jan-Feb;56(1-2):39-44

A new phenotypic classification of bone marrow plasmacytosis. Kawano MM, et al. **Int J Hematol** 1995 Jun; 61(4):179-88

Correlations between karyotype and cytologic findings in multiple myeloma. Weh HJ, et al. **Leukemia** 1995 Dec; 9(12):2119-22

Images in clinical medicine. Multiple myeloma. Andersen HS, et al. **N Engl J Med** 1996 Feb 22;334(8):513

Commonly used diagnostic criteria for pelvic inflammatory disease have poor sensitivity for plasma cell endometritis [see comments] Korn AP, et al. **Sex Transm Dis** 1995 Nov-Dec;22(6):335-41. Comment in: Sex Transm Dis 1995 Nov-Dec;22(6):342-3.

[Pseudo-myelomatous plasmacytosis of the bone marrow in a multicentric Castleman's disease] Molina T, et al. **Ann Pathol** 1996;16(2):133-6 (Eng. Abstr.) **(Fre)**

[Primary plasmacytoma of the lymph node (plasmocytic lymphoma). The differential diagnosis of nodal plasma-cell proliferates] Horny HP, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1734-8 (15 ref.) (Eng. Abstr.) **(Ger)**

[A case of multiple myeloma associated with abnormal plasma cells and M-protein in pleural effusion]. Araki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):196-9 (Eng. Abstr.) **(Jpn)**

[Stereometric characteristics of inflammatory gingival infiltrates] Bokor M, et al. **Med Pregl** 1994; 47(11-12):389-91 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Tsujimoto T, et al. **Blood** 1996 Apr 15;87(8):3375-83

T cell-induced B cell blasts differentiate into plasma cells when cultured on bone marrow stroma with IL-3 and IL-10. Merville P, et al. **Int Immunol** 1995 Apr;7(4):635-43

Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. Merville P, et al. **J Exp Med** 1996 Jan 1;183(1):227-36

[Multiple myeloma--the biology of malignant plasma cells] Paluszewska M. **Pol Arch Med Wewn** 1996 Jan;95(1):67-72 (33 ref.) **(Pol)**

SECRETION

Cholinergic modulation of immunoglobulin secretion from avian plasma cells: the role of cyclic mononucleotides. Cameron RH, et al. **J Neuroimmunol** 1995 Sep;61(2):223-30

ULTRASTRUCTURE

Iron granules in plasma cells: a particular morphologic aspect [letter] D'Angelo G, et al. **Am J Hematol** 1996 Jun; 52(2):124-5

Intracerebral infiltration by monoclonal plasmacytoid cells in Waldenstrom's macroglobulinemia--case report. Imai F, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):575-9

PLASMA EXCHANGE

Plasma exchange in childhood Guillain-Barré syndrome [letter] [corrected and republished letter originally printed in Acta Paediatr 1995 Mar;84(3):355] Hammersjö JA, et al. **Acta Paediatr** 1996 Apr;85(4):iv

Timing of plasma exchange therapy for thrombotic thrombocytopenia purpura: a brief clinical observation. Colflesh CR, et al. **Am J Med Sci** 1996 Apr;311(4):167-8

Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Guillevin L, et al. **Arthritis Rheum** 1995 Nov;38(11):1638-45

Plasmapheresis versus plasma perfusion in acute Guillain-Barré syndrome. Morosetti M, et al. **ASAIO J** 1994 Jul-Sep;40(3):M638-42

Thrombotic thrombocytopenic purpura in pregnancy:

successful treatment with plasma exchange. Case report and review of the literature. Mokrzycki MH, et al. **Blood Purif** 1995;13(5):271–82 (100 ref.)

Plasma exchange in patients with septic shock including acute renal failure. Stegmayr BG. **Blood Purif** 1996;14(1):102–8

Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment. Espigado I, et al. **Bone Marrow Transplant** 1995 Aug;16(2):313–6

Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Sarode R, et al. **Bone Marrow Transplant** 1995 Aug;16(2):271–5

Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3–4 bone marrow transplant-associated thrombotic microangiopathy. Zeigler ZR, et al. **Bone Marrow Transplant** 1996 Jan;17(1):81–6

A comparison between IVIg and plasma exchange in Guillain–Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB, et al. **Clin Neuropharmacol** 1995 Oct;18(5):377–90 (44 ref.)

High dose intravenous immune globulins and plasma exchange in Guillain–Barré Syndrome. Ravasio A, et al. **Ital J Neurol Sci** 1995 Oct;16(7):487–92

Successful surgical treatment of cardiac cirrhosis. Tricuspid surgery and plasma exchange. Toyoda Y, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):305–7

Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. Churchwell KB, et al. **J Clin Apheresis** 1995;10(4):171–7

Plasma separation for artificial liver support. LePage EB, et al. **J Clin Apheresis** 1995;10(2):70–5

Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. Owens MR, et al. **J Clin Apheresis** 1995;10(4):178–82

Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. Vamvakas EC, et al. **J Clin Apheresis** 1995; 10(4):163–70

Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain–Barré syndrome? Weinstein R. **J Clin Apheresis** 1995;10(3):150–7 (94 ref.)

Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. Dau PC. **J Neuroimmunol** 1995 Nov; 62(2):197–200

Plasma exchange in Kawasaki disease [letter] Takagi N, et al. **Lancet** 1995 Nov 11;346(8985):1307

Campylobactery jejuni Infection and treatment for Guillain–Barré Syndrome [comment] Jacobs BC, et al. **N Engl J Med** 1996 Jul 18;335(3):208–9. Comment on: N Engl J Med 1995 Nov 23;333(21):1374–9.

Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barré syndrome. Bril V, et al. **Neurology** 1996 Jan;46(1):100–3

Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Sørensen PS, et al. **Neurology** 1996 Jun; 46(6):1620–5

Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis. Goti P, et al. **Thorax** 1995 Oct;50(10):1080–6

[A prospective study of plasma exchange in the treatment of diffuse scleroderma] Ding C, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):616–9 (Eng. Abstr.) **(Chi)**

[Plasma exchange and severe Plasmodium falciparum malaria. Apropos of 2 cases] Bolandard F, et al. **Cah Anesthesiol** 1995;43(4):371–3 (Eng. Abstr.) **(Fre)**

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

[The effect of therapeutic plasma exchange on serum immunoglobulins and the clinical course of myasthenia gravis] Martić V, et al. **Vojnosanit Pregl** 1994 Mar–Apr; 51(2):122–5 (Eng. Abstr.) **(Scr)**

[Inefficacy of plasma perfusion in thrombotic thrombocytopenic purpura and early relapse after plasmapheresis (letter)] Bergua JM, et al. **Sangre (Barc)** 1995 Oct;40(5):439–40 **(Spa)**

ADVERSE EFFECTS

Cumulative reduction in serum cholinesterase following repeated therapeutic plasma exchange. Collard CD, et al. **J Clin Anesth** 1996 Feb;8(1):44–8

Pyrogen reactions to human serum albumin during plasma exchange. Pool M, et al. **J Clin Apheresis** 1995;10(2):81–4

METHODS

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)

Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Rock G, et al. **Br J Haematol** 1996 Aug;94(2):383–6

Blood filtration in children with severe sepsis: safe adjunctive therapy. Reeves JH, et al. **Intensive Care Med** 1995 Jun; 21(6):500–4

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy; different beneficial effects and their correlation to the clinical features. Kumazawa K, et al. **Intern Med** 1995 Jun;34(6):537–41

Therapeutic plasma exchange in renal diseases [editorial] Madore F, et al. **J Am Soc Nephrol** 1996 Mar;7(3):367–86 (133 ref.)

PLASMA FLOW, RENAL see **RENAL PLASMA FLOW**

PLASMA FLOW, RENAL, EFFECTIVE see **RENAL PLASMA FLOW, EFFECTIVE**

PLASMA MEMBRANE see **CELL MEMBRANE**

PLASMA PROKALLIKREIN see **PREKALLIKREIN**

PLASMA PROTEINS see **BLOOD PROTEINS**

PLASMA SUBSTITUTES

see related
BLOOD SUBSTITUTES

Hypotension during subarachnoid anaesthesia: haemodynamic effects of colloid and metaraminol. Critchley LA, et al. **Br J Anaesth** 1996 May;76(5):734–6

Hydroxyethylstarch compared with modified gelatin as volume preload before spinal anaesthesia for Caesarean section. Vercauteren MP, et al. **Br J Anaesth** 1996 May; 76(5):731–3

Decrease of fibronectin following repeated infusion of highly substituted hydroxyethyl starch. Treib J, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):71–5

Clot formation and gelatin-based plasma substitutes [letter; comment] Heath ML. **Lancet** 1996 May 11;347(9011):1336 . Comment on: Lancet 1996 Mar 23;347(9004):825.

Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. Miller JA, et al. **Stroke** 1995 Dec;26(12):2260–6

[Declaring infusion solutions with base excess and potential base excess] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S73–7 **(Ger)**

[Decrease of thrombocyte volume after several days infusion of highly substituted medium molecular weight hydroxyethyl starch (HAES 200/0.62)] Treib J, et al. **Wien Klin Wochenschr** 1996;108(1):20–3 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Prevention of hypotension after spinal anesthesia for cesarean section: six percent hetastarch versus lactated Ringer's solution [see comments] Riley ET, et al. **Anesth Analg** 1995 Oct;81(4):838–42. Comment in: Anesth Analg 1996 May;82(5):1108–9.

Crystalloid cardioplegia route of delivery and cardiac troponin I release. Chocron S, et al. **Ann Thorac Surg** 1996 Aug;62(2):481–5

The importance of colloid osmotic pressure measurements to prevent oncotic overdosage during cardiac surgery. Bartels C, et al. **J Cardiovasc Surg (Torino)** 1995 Oct; 36(5):417–22

Effects of small-volume infusion of 7.5% hypertonic saline/6% dextran-70 on the cardiovascular function of traumatic-hemorrhagic shock rats at high altitude. Mei JM, et al. **Shock** 1995 Dec;4(6):421–4

[Overuse of albumin] Svennevig JL. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):15 **(Nor)**

ADVERSE EFFECTS

Anaphylactoid reaction to Haemaccel [letter; comment] Fenwick DG, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):521–2. Comment on: Anaesth Intensive Care 1994 Feb;22(1):90–2. Comment on: Anaesth Intensive Care 1994 Jun;22(3):317–8.

The seven year itch [letter] Spittal MJ, et al. **Anaesthesia** 1995 Oct;50(10):913–4

Adverse effects of crystalloid cardioplegia and slow cooling for protection of immature rat hearts. Karck M, et al. **Ann Thorac Surg** 1996 Sep;62(3):702–9

Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethylstarch plasma expander. Cox NH, et al. **Br J Dermatol** 1996 Feb; 134(2):353–7

Multiple organ failure associated with dimethylsulfoxide and hydroxyethyl starch in autologous blood stem cell transplantation [letter] Nishihara G, et al. **Nephron** 1996; 72(2):356–7

Atrial fibrillation after blood and crystalloid cardioplegia in CABG patients. Pehkonen EJ, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):200–3

[Dextran-induced anaphylactoid reactions in two patients with gastrointestinal cancer] Miyamoto Y, et al. **Masui** 1996 Apr;45(4):500–3 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Boldt J, et al. **Anaesthesia** 1996 Jun;51(6):529–35

Hydroxyethyl starch solution attenuates blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Chi OZ, et al. **Anesth Analg** 1996 Aug; 83(2):336–41

Hypercoagulability induced by crystalloids [letter; comment] Farmery AD, et al. **Br J Anaesth** 1996 Jul;77(1):132. Comment on: Br J Anaesth 1996 Mar;76(3):412–4.

Rheological properties of commonly used plasma substitutes during preoperative normovolaemic acute haemodilution. Freyburger G, et al. **Br J Anaesth** 1996 Apr;76(4):519–25

Effect of steady shear stress on fluid filtration through the rabbit arterial wall in the presence of macromolecules. Karmakar N, et al. **Clin Exp Pharmacol Physiol** 1996 Apr; 23(4):299–304

Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Treib J, et al. **Eur J Haematol** 1996 Mar;56(3):168–72

Efficacy of pentastarch in granulocyte collection by centrifugal leukapheresis. Lee JH, et al. **J Clin Apheresis** 1995;10(4):198–202

A lipoprotein-cholesterol-albumin serum substitute stimulates Giardia lamblia encystation vesicle formation. Reiner DS, et al. **J Eukaryot Microbiol** 1995 Sep–Oct; 42(5):622–7

Evaluation of the effect of colloid (Haemaccel) on the bleeding time in the trauma patient. Evans PA, et al. **J R Soc Med** 1996 Feb;89(2):101P–4P

Clot formation and gelatin-based plasma substitutes [letter] Baddeley DT, et al. **Lancet** 1996 Jun 22;347(9017):1763

Reduced quality of in-vitro clot formation with gelatin-based plasma substitutes [letter] [see comments] Mardel SN, et al. **Lancet** 1996 Mar 23;347(9004):825. Comment in: Lancet 1996 May 11;347(9011):1336.

Effect of volume expansion on the natriuretic response to ouabain infusion. Yates NA, et al. **Ren Physiol Biochem** 1995 Nov–Dec;18(6):311–20

Estimating concentrations of total digoxin and digoxin-like immunoreactive substances in volume-expanded patients being treated with digoxin. Dasgupta A, et al. **Ther Drug Monit** 1996 Feb;18(1):34–9

[Induction of cytokines by colloidal plasma substitutes? (editorial; comment)] Krombach F. **Infusionsther Transfusionsmed** 1995 Dec;22(6):330–1. Comment on: Infusionsther Transfusionsmed 1995 Dec;22(6):332–8. **(Ger)**

[Effect of colloidal plasma substitutes on liberation of tumor necrosis factor-alpha (TNF-alpha) in human whole blood in vitro (see comments)] Sirtl C, et al. **Infusionsther Transfusionsmed** 1995 Dec;22(6):332–8 (Eng. Abstr.). Comment in: Infusionsther Transfusionsmed 1995 Dec;22(6):330–1. **(Ger)**

[The effect of intravenous administrations of a plasma substitute solution made from whey on gastric secretory function] Fedorov VI. **Fiziol Zh** 1995 Jan–Apr; 41(1–2):36–41 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Colloid vs crystalloid [letter; comment] Krochmal P. **Acad Emerg Med** 1995 Jul;2(7):665. Comment on: Acad Emerg Med 1994 Nov–Dec;1(6):507–8. Comment on: Acad Emerg Med 1994 Nov–Dec;1(6):572–9.

Diatrizoate and dextran treatment of sudden sensorineural hearing loss. Redleaf MI, et al. **Am J Otol** 1995 May; 16(3):295–303

Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Mortelmans YJ, et al. **Anesth Analg** 1995 Dec;81(6):1235–42

The effects of varying volumes of crystalloid administration before cesarean delivery on maternal hemodynamics and colloid osmotic pressure. Park GE, et al. **Anesth Analg** 1996 Aug;83(2):299–303

Crystalloids, colloids, and spinal anesthesia [letter; comment] Puri GD. **Anesth Analg** 1996 May;82(5):1108–9. Comment on: Anesth Analg 1995 Oct;81(4):838–42.

Crystalloid versus colloid versus colloid: all colloids are not created equal [editorial; comment] Traylor RJ, et al. **Anesth Analg** 1996 Aug;83(2):209–12. Comment on: Anesth Analg 1996 Aug;83(2):254–61. Comment on: Anesth Analg 1996 Aug;83(2):262–8.

Does the type of volume therapy influence endothelial-related coagulation in the critically ill? Boldt J, et al. **Br J Anaesth** 1995 Dec;75(6):740–6

Effect of crystalloid and colloid preloading on uteroplacental and maternal haemodynamic state during spinal anaesthesia for caesarean section. Karinen J, et al. **Br J Anaesth** 1995 Nov;75(5):531–5

Volume preloading, spinal anaesthesia and Caesarean section [letter] Lawes EG. **Br J Anaesth** 1996 Feb;76(2):334–5

Volume preloading, spinal anaesthesia and Caesarean section [letter] Mallick A, et al. **Br J Anaesth** 1996 Feb;76(2):335–6

The use of colloids in clinical practice. Cone A. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):155–9 (20 ref.)

Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%). Degrémont AC, et al. **Intensive Care Med** 1995 Jul;21(7):577–83

Evaluation of a hypertonic sodium chloride/dextran solution for treatment of traumatic shock in dogs. Schertel ER, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):366–70

Comparison of hetastarch with albumin for postoperative

volume expansion in children after cardiopulmonary bypass. Brutocao D, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):348–51

Effectiveness of different crystalloid i.v. solutions in establishing urine flow. Heller MB, et al. **J Emerg Med** 1996 Jan–Feb;14(1):1–3

Conservative management of ovarian hyperstimulation syndrome. Morris RS, et al. **J Reprod Med** 1995 Oct; 40(10):711–4

Hemodynamic, plasma volume, and prenodal skin lymph responses to varied resuscitation regimens. Saxe JM, et al. **J Trauma** 1996 Aug;41(2):283–9; discussion 289–90

A comparison of 4.5% human albumin solution and Haemaccel in neonates undergoing major surgery. Stoddart PA, et al. **Paediatr Anaesth** 1996;6(2):103–6

Hyperoncotic dextran and systemic aprotinin in necrotizing rodent pancreatitis. Huch K, et al. **Scand J Gastroenterol** 1995 Aug;30(8):812–6

Antegrade versus retrograde crystalloid cardioplegia: perioperative assessment of cardiac energy metabolism by means of myocardial lactate measurement. Noyez L, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):194–9

[Outcome of the use of albumin and colloid plasma substitutes from 1989 to 1993 in a French University Hospital Center] Audibert G, et al. **Ann Fr Anesth Reanim** 1995;14(6):517–22 (Eng. Abstr.) **(Fre)**

[Effect of polyethylene oxide on hemodynamic parameters in infusion therapy of irreversible hemorrhagic shock] Plotnikov MB, et al. **Gematol Transfuziol** 1996 Jan–Feb; 41(1):20–3 (Eng. Abstr.) **(Rus)**

PLASMA THROMBOPLASTIN ANTECEDENT see **FACTOR XI**

PLASMA THROMBOPLASTIN COMPONENT see **FACTOR IX**

PLASMA TRANSGLUTAMINASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

PLASMA VOLUME

see related
FLUID SHIFTS

Resistance exercise-induced fluid shifts: change in active muscle size and plasma volume. Ploutz-Snyder LL, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R536–43

Comparison of three different irrigation fluids used in transurethral prostatectomy based on plasma volume expansion and metabolic effects. Akan H, et al. **Br J Urol** 1996 Aug;78(2):224–7

Volume expansion increases right ventricular infarct size in dogs by reducing collateral perfusion. Johnston WE, et al. **Chest** 1996 Feb;109(2):494–503

Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study. Møller J, et al. **Clin Endocrinol (Oxf)** 1996 May; 44(5):533–9

Re-evaluation of Evans blue dye dilution method of plasma volume measurement. el-Sayed H, et al. **Clin Lab Haematol** 1995 Jun;17(2):189–94

Effects of long-term nitric oxide synthesis inhibition on plasma volume expansion and fetal growth in the pregnant rat. Salas SP, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1019–23

Dietary sodium intake and changes in plasma volume during short-term exercise training. Luetkemeier MJ. **Int J Sports Med** 1995 Oct;16(7):435–8

Hemodynamic, plasma volume, and prenodal skin lymph responses to varied resuscitation regimens. Saxe JM, et al. **J Trauma** 1996 Aug;41(2):283–9; discussion 289–90

Serial hematologic changes and pregnancy outcome. Whittaker PG, et al. **Obstet Gynecol** 1996 Jul;88(1):33–9

[Plasma volume in polycystic kidney disease] Merta M, et al. **Sb Lek** 1994;95(1):15–8 (Eng. Abstr.) **(Cze)**

[Inhibition of the neurohumoral axis after intravascular fluid depletion in congestive heart failure with water retention: mechanisms of the perpetuation of the syndrome] Marenzi G, et al. **Cardiologia** 1995 Jan;40(1):15–22 (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope [see comments] El-Sayed H, et al. **Heart** 1996 Feb;75(2):134–40 . Comment in: Heart 1996 Feb;75(2):114–5.

Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%). Degrémont AC, et al. **Intensive Care Med** 1995 Jul;21(7):577–83

All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Treib J, et al. **Transfusion** 1996 May; 36(5):450–5

PHYSIOLOGY

Pronounced plasma fluid loss into dependent regions on standing. Bjerkhoel P, et al. **Acta Physiol Scand** 1995 Jun; 154(2):275–6

Pronounced and rapid plasma volume reduction upon quiet standing as revealed by a novel approach to the determination of the intravascular volume change. Lundvall J, et al. **Acta Physiol Scand** 1995 Jun; 154(2):131–42

Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension. Jones MA, et al. **Clin Nephrol** 1995 Sep;44(3):193–200

An early effect of acute plasma volume expansion in humans on serum erythropoietin concentration. Szygula Z, et al. **Eur J Appl Physiol** 1995;72(1–2):106–10

Changes in plasma volume during prolonged restriction of motor activity: effect of chronic hyperhydration. Zorbas YG, et al. **Panminerva Med** 1995 Dec;37(4):220–7

Time course and mechanisms of decreased plasma volume during acute psychological stress and postural change in humans. Patterson SM, et al. **Psychophysiology** 1995 Nov; 32(6):538–45

PLASMA VOLUME EXPANDERS see **PLASMA SUBSTITUTES**

PLASMACYTES see **PLASMA CELLS**

PLASMACYTIC LEUKEMIA see **LEUKEMIA, PLASMACYTIC**

PLASMACYTOMA

Solitary phalanx plasmacytoma relapse with disseminated extramedullary plasmacytomas and myeloma after short duration of remission. Celik I, et al. **Anticancer Res** 1996 Mar–Apr;16(2):959–62

Primary plasmacytoma of the skin. Tüting T, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):386–90 (29 ref.)

Plasmacytoma of the testis. Iizumi T, et al. **Urol Int** 1995; 55(4):218–21

[Extramedullary plasmocytoma (EMP) of the head and neck: a series of 22 cases] Tesei F, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):437–42 (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice. Janz S, et al. **Cancer Biochem Biophys** 1995 Jun;15(1):25–34

COMPLICATIONS

Plasmacytoma as a cause of obstructive sleep apnea. Byrd RP Jr, et al. **Chest** 1996 Jun;109(6):1657–9

DIAGNOSIS

Primary pulmonary plasmacytoma diagnosed by transthoracic needle aspiration cytology and immunocytochemistry [letter] Husain M, et al. **Acta Cytol** 1996 May–Jun;40(3):622–4

Solitary plasmacytoma of the spine: relationship of IGM to tumour progression and recurrence. Cervoni L, et al. **Acta Neurochir (Wien)** 1995;135(3–4):122–5

Multiple myeloma presenting as plasmacytoma of the base of the skull [letter] Alegre A, et al. **Am J Hematol** 1996 May;52(1):60–1

Central nervous system involvement in multiple myeloma [letter] Demiroğlu H, et al. **Am J Hematol** 1996 Aug; 52(4):330

Non-paraganglioma jugular foramen lesions masquerading as glomus jugulare tumors. Megerian CA, et al. **Am J Otol** 1995 Jan;16(1):94–8

Extramedullary laryngeal plasmacytoma. Rodriguez-de-Velasquez A, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):483–6

Acute diplopia and a solitary lung mass: a unique presentation of light-chain myeloma. Foresman BH, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):371–2

[A rare tumor of the liver: solitary plasmacytoma (letter)] Loze S, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):960–1 **(Fre)**

[Pulmonary plasmacytoma. Apropos of a case. Review of the literature] Etienne G, et al. **Rev Pneumol Clin** 1995; 51(5):280–3 (22 ref.) (Eng. Abstr.) **(Fre)**

[Primary plasmacytoma of the lymph node (plasmocytic lymphoma). The differential diagnosis of nodal plasma-cell proliferates] Horny HP, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1734–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Plasmacytoma as a diagnostic problem--case report] Spaić R, et al. **Vojnosanit Pregl** 1994 Jul–Aug;51(4):333–6 (Eng. Abstr.) **(Scr)**

[Solitary plasmocytoma of the cecum (letter)] Bernal-Sprekelsen JC, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):163–4 **(Spa)**

DRUG THERAPY

Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Raynaud FI, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):1857–62

Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. Walton MI, et al. **Cancer Chemother Pharmacol** 1996;38(5):431–8

ETIOLOGY

A solitary plasmacytoma of donor origin arising 14 years after kidney allotransplantation. Shustik C, et al. **Br J Haematol** 1995 Sep;91(1):167–8

Plasmacytoma development in mice injected with silicone gels. Potter M, et al. **Curr Top Microbiol Immunol** 1996; 210:397–407

Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference. Weissinger EM, et al. **Int J Cancer** 1996 Jul 3;67(1):142–7

GENETICS

Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. Müller JR, et al. **Cancer Res** 1995 Nov 1; 55(21):5012–8

Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Müller JR, et al. **Cancer Res** 1996 Jan 15;56(2):419–23

The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas. Axelson H, et al. **Eur J Cancer** 1995 Nov;31A(12):2099–104

Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Hilbert DM, et al. **Immunity** 1996 Jul;5(1):81–9

An acute phase response factor/NF-kappa B site downstream of the junB gene that mediates responsiveness to interleukin-6 in a murine plasmacytoma. Brown RT, et al. **J Biol Chem** 1995 Dec 29;270(52):31129–35

Aberrant regulation of the IgH 3' enhancer by c-myc in plasmacytoma cells. Arulampalam V, et al. **Mol Immunol** 1995 Dec;32(17–18):1369–75

Early B-cell factor (EBF) down-regulates immunoglobulin heavy chain intron enhancer function in a plasmacytoma cell line. Akerblad P, et al. **Scand J Immunol** 1996 Jul; 44(1):89–92

IMMUNOLOGY

Sclerotic IgA myeloma and polyneuropathy: the POEMS syndrome. Case report [letter] Mertens I, et al. **Ann Oncol** 1995 Sep;6(7):731–2

Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation. Schwabe M, et al. **Cell Immunol** 1996 Feb 25;168(1):117–21

Specific decrease of Th1-like activity in mice with plasma cell tumors. Ruzek MC, et al. **Int Immunol** 1995 Jul; 7(7):1029–35

In vitro and in vivo recovery of IFN-gamma, but not IL-2, production by IL-12 in mice with plasma cell tumors. Ruzek MC, et al. **Int Immunol** 1996 Mar;8(3):413–22

Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. Gorelik L, et al. **J Immunol** 1996 Jun 1;156(11):4298–308

A combination of IL-10 and direct contact with plasma cell tumors decreases CD23 expression on splenic B cells. Ruzek MC, et al. **J Immunol** 1996 Mar 15;156(6):2124–32

Changes in abundance of IgG 2a mRNA in the nucleus and cytoplasm of a murine B-lymphoma before and after fusion to a myeloma cell. Milcarek C, et al. **Mol Immunol** 1996 May–Jun;33(7–8):691–701

Early B-cell factor (EBF) down-regulates immunoglobulin heavy chain intron enhancer function in a plasmacytoma cell line. Akerblad P, et al. **Scand J Immunol** 1996 Jul; 44(1):89–92

Suppression of tumour-specific cytotoxic T-cell responses against the syngeneic BALB/c plasmacytoma ADJ-PC-5 by tumour-induced CD8+ regulatory T cells via IFN-gamma. Pauels HG, et al. **Scand J Immunol** 1996 Apr; 43(4):421–30

Decreased expression and function of Vbeta6+ and Vbeta14+ T cells is associated with decreased Th1 cytokine production in mice with plasma cell tumors. Stefanski HE, et al. **Tumori** 1996 Jan–Feb;82(1):22–6

Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice. Li QX, et al. **Virology** 1995 Dec 20; 214(2):680–4

PATHOLOGY

Primary pulmonary plasmacytoma diagnosed by transthoracic needle aspiration cytology and immunocytochemistry [letter] Husain M, et al. **Acta Cytol** 1996 May–Jun;40(3):622–4

Non-paraganglioma jugular foramen lesions masquerading as glomus jugulare tumors. Megerian CA, et al. **Am J Otol** 1995 Jan;16(1):94–8

Primary extramedullary plasmacytoma of the liver. A case report. Weichhold W, et al. **Am J Surg Pathol** 1995 Oct; 19(10):1197–202

Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Galieni P, et al. **Ann Oncol** 1995 Sep;6(7):687–91

Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease. Case report and literature review. Ligato S, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):279–82 (32 ref.)

Interleukin–6 inhibits the chemotaxis of human malignant plasma cell lines. Shibayama H, et al. **Br J Haematol** 1996 Jun 1;93(3):534–41

Dietary phytohaemagglutinin slows down the proliferation of a mouse plasmacytoma (MPC–11) tumour in Balb/c mice. Pryme IF, et al. **Cancer Lett** 1996 Jun 5;103(2):151–5

Solitary intracranial plasmacytoma of the skull base. Prasad ML, et al. **Indian J Cancer** 1994 Sep;31(3):174–9

Multiple myeloma first presenting as cutaneous plasmacytoma. Hauschild A, et al. **J Am Acad Dermatol** 1996 Jan;34(1):146–8

VS38 immunostaining in melanocytic lesions. Shanks JH, et al. **J Clin Pathol** 1996 Mar;49(3):205–7

Painless mandibular gingival mass [clinical conference] Yoshida H, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1341–6

Primary extramedullary plasmacytoma in cyclosporine–induced gingival overgrowth. A case report. Pan WL, et al. **J Periodontol** 1995 Sep;66(9):804–7

Solitary plasmacytoma of the skull vault—case report. Matsuda M, et al. **Neurol Med Chir (Tokyo)** 1996 Jun; 36(6):388–92

Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature. Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130–8 (88 ref.)

Solitary extramedullary plasmocytoma of the breast with kappa monoclonal gammopathy. Alhan E, et al. **Pathologica** 1995 Feb;87(1):71–3

Osseous metaplasia associated with amyloid–producing plasmacytoma of bone: a report of two cases. Karasick D, et al. **Skeletal Radiol** 1996 Apr;25(3):263–7

The mechanisms of bone lesions in human plasmacytomas. Bataille R. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:40–7 (67 ref.)

[Plasmacytomas of the upper respiratory tract] Gegova A, et al. **Khirurgiia (Sofiia)** 1995;48(6):16–8 (Eng. Abstr.) **(Bul)**

[IgAk solitary bone plasmacytoma leading to the loss of heavy chain alpha (letter)] Costello R, et al. **Presse Med** 1995 Sep 16;24(26):1222 **(Fre)**

[Solitary plasmocytoma of the mandible. Report of one case and review of the literature] Ferrer Albiach C, et al. **An Otorrinolaringol Ibero Am** 1995;22(6):609–18 (16 ref.) (Eng. Abstr.) **(Spa)**

[Solitary nasal plasmocytoma] Giménez Vaíllo F, et al. **An Otorrinolaringol Ibero Am** 1995;22(4):419–26 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Extramedullary plasmacytoma of anorectum: case report. Mutiso VM. **East Afr Med J** 1996 Feb;73(2):149–50

[Diagnosis: plasmocytoma] Rodríguez Carbajal J. **Gac Med Mex** 1995 Jan–Feb;131(1):107–8 **(Spa)**

RADIOTHERAPY

Inadequately irradiated solitary extramedullary plasmacytoma of the orbit requiring exenteration. Ezra E, et al. **Am J Ophthalmol** 1995 Dec;120(6):803–5

Primary extramedullary plasmacytoma of the orbit. Aboud N, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):235–9

Long–term disease–free survival after plasmacytoma of the urethra: a case report and review of the literature. Mordkin RM, et al. **Urology** 1996 Jul;48(1):149–50 (7 ref.)

SECONDARY

Extramedullary plasmacytoma of maxillary sinus with later involvement of the gall bladder and subcutaneous tissues. Kondo H, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):330–1

SURGERY

Inadequately irradiated solitary extramedullary plasmacytoma of the orbit requiring exenteration. Ezra E, et al. **Am J Ophthalmol** 1995 Dec;120(6):803–5

Bone heterograft for chest wall reconstruction after sternal resection. Puma F, et al. **Ann Thorac Surg** 1996 Feb; 61(2):525–9

Spinal stabilisation in plasma cell disorders. Smith SR, et al. **Eur J Cancer** 1995;31A(9):1541–4

Solitary plasmacytoma of the skull. A case report. Kuzeyli K, et al. **Neurosurg Rev** 1995;18(2):139–42

[A solitary plasmacytoma of the lung] Bruns VA, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):295–6 **(Rus)**

THERAPY

Suicide gene therapy for plasma cell tumors. Dilber MS, et al. **Blood** 1996 Sep 15;88(6):2192–200

Leukemias and myeloma. Wiernik PH. **Cancer Chemother Biol Response Modif** 1996;16:347–75 (164 ref.)

Low–dose–melphalan–induced up–regulation of type–1 cytokine expression in the s.c. tumor nodule of MOPC–315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Gorelik L, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):363–74

Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Qin Z, et al. **Cancer Res** 1995 Nov 1;55(21):4747–51

Eradication of interleukin 5–transfected J558L plasmacytomas in mice by hydrogen peroxide–generating Stealth liposomes. Samoszuk MK, et al. **Cancer Res** 1996 Jan 1;56(1):87–90

Immunotherapy of a plasmacytoma with attenuated salmonella. Eisenstein TK, et al. **Med Oncol** 1995 Jun; 12(2):103–8

Diffuse plasmacytosis in a child with brainstem glioma following multiagent chemotherapy and intensive growth factor support. Csáki C, et al. **Med Pediatr Oncol** 1996 May;26(5):367–71

PLASMACYTOMA GROWTH FACTOR see **INTERLEUKIN–6**

PLASMALOGENS

BIOSYNTHESIS

Gastric mucosal peroxisomes and plasmalogen biosynthesis. Abugila MA, et al. **Biochem Soc Trans** 1995 Nov;23(4):578S

BLOOD

Simple analysis of plasmalogens in erythrocytes using gas chromatography/mass spectrometry with selected–ion monitoring acquisition. Caruso U. **Rapid Commun Mass Spectrom** 1996;10(10):1283–5

METABOLISM

Peroxisomes and plasmalogens along the intestine villus. Phipps AN, et al. **Biochem Soc Trans** 1995 Nov;23(4):577S

Rapid plasmenylethanolamine–selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde–3–phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. Glaser PE, et al. **Biochemistry** 1995 Sep 26;34(38):12193–203

Triggerable plasmalogen liposomes: improvement of system efficiency. Thompson DH, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):25–34

Plasmalogens and their oxidative degradation products in low and high density lipoprotein. Jira W, et al. **Chem Phys Lipids** 1996 Mar 29;79(2):95–100

PHARMACOLOGY

Delay of copper–catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Jürgens G, et al. **Chem Phys Lipids** 1995 Aug 1;77(1):25–31

PHYSIOLOGY

Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Ginsberg L, et al. **Brain Res** 1995 Nov 6;698(1–2):223–6

PLASMAPHERESIS

Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Muczynski KA. **Am J Nephrol** 1995;15(5):446–9

Treatment of recalcitrant leg ulcers in cryoglobulinemia types I and II with plasmapheresis. McGovern TW, et al. **Arch Dermatol** 1996 May;132(5):498–500

Plasmapheresis as preparatory method for thymectomy in myasthenia gravis. Seggia JC, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–A):411–5

The role of plasma exchange in the treatment of severe forms of hemolytic–uremic syndrome in childhood. Slaviček J, et al. **Artif Organs** 1995 Jun;19(6):506–10

Plasmapheresis versus plasma perfusion in acute Guillain–Barré syndrome. Morosetti M, et al. **ASAIO J** 1994 Jul–Sep;40(3):M638–42

Plasmapheresis in severe sepsis or septic shock. Stegmayr BG. **Blood Purif** 1996;14(1):94–101 (66 ref.)

Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis [letter] Izaki S, et al. **Br J Dermatol** 1996 May;134(5):987–9

Treatment of severe localized scleroderma by plasmapheresis—report of three cases. Wach F, et al. **Br J Dermatol** 1995 Oct;133(4):605–9

Systemic vascular resistance during high–volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption. Larsen FS, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):887–92

How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion. Würzner R, et al. **Immunology** 1996 Jul; 88(3):407–11

Plasmapheresis in the therapy of septic disease. Reinke P. **Int J Artif Organs** 1996 Feb;19(2):127–8 (11 ref.)

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia. Barbagallo CM, et al. **J Clin Apheresis** 1995;10(2):96–100

Immunologic rebound. Dau PC. **J Clin Apheresis** 1995; 10(4):210–7 (44 ref.)

Effect of therapeutic plasmapheresis on coagulation parameters [letter; comment] Prowse CV, et al. **J Clin Apheresis** 1995;10(2):103. Comment on: J Clin Apheresis 1994;9(3):202–3.

Plasmapheresis for a schizophrenic patient with drug–induced lupus anti–coagulant. Matsukawa Y, et al. **J Int Med Res** 1996 Jan–Feb;24(1):147–50

Amyloid associated muscle pseudohypertrophy: amelioration of motor dysfunction with plasmapheresis and dimethylsulphoxide [letter] Komiyama A, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):591–2

Successful plasmapheresis in Bickerstaff's brain stem encephalitis associated with anti–GQ1b antibody. Yuki N. **J Neurol Sci** 1995 Jul;131(1):108–10

A case of massive cisplatin overdose managed by plasmapheresis. Jung HK, et al. **Korean J Intern Med** 1995 Jul;10(2):150–4

Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia. Patel TC, et al. **Mayo Clin Proc** 1996 Jun;71(6):597–600 (14 ref.)

Plasmapheresis in Rasmussen's encephalitis [see comments] Andrews PI, et al. **Neurology** 1996 Jan;46(1):242–6. Comment in: Neurology 1996 Jan;46(1):9–11.

Evaluation of plasmapheresis on the removal of tobramycin. Kale–Pradhan PB, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):673–6

Churg–Strauss syndrome with peripheral polyneuropathy refractory to steroideal and immunosuppressive therapy successfully treated with plasma exchange. Fregoni V, et al. **Recenti Prog Med** 1995 Sep;86(9):353–4

Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Berglin E, et al. **Transpl Int** 1995;8(5):382–7

Pretransplantation plasmapheresis in HLA–sensitized patients: five years experience. Alarabi A, et al. **Transplant Proc** 1995 Dec;27(6):3448

The effect of plasmapheresis and deoxyspergualin or cyclophosphamide treatment on anti–porcine Gal–alpha (1,3)–Gal antibody titres in humans. Gannedahl G, et al. **Transplant Proc** 1996 Apr;28(2):551

Beneficial effect of plasmapheresis on the outcome of transplant patients. Haberal M, et al. **Transplant Proc** 1996 Aug;28(4):2336

Suppression of immunoglobulin resynthesis after plasmapheresis: efficacy of various immunosuppressive drugs—a study in rats. Kozlowski T, et al. **Transplant Proc** 1995 Dec;27(6):3545–6

The use of plasmapheresis and systemic heparinization in treating glomerular microthrombi in renal transplants. Merkel FK, et al. **Transplant Proc** 1995 Oct;27(5):2741–5

Endothelin–1 in patients with fulminant hepatic failure: influence of high–volume plasmapheresis. Therkelsen K, et al. **Transplant Proc** 1995 Dec;27(6):3508–9

[Epidemiological study of hepatitis C virus (HCV) infection in plasmapheresis and blood donors] Jin ZL, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug; 16(4):234–6 (Eng. Abstr.) **(Chi)**

[Use of plasmapheresis in a 62–year–old patient with severe infection] Koepp A, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):92–6 (Eng. Abstr.) **(Ger)**

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone] Feist E, et al. **Z Rheumatol** 1996 Mar–Apr; 55(2):127–32 (Eng. Abstr.) **(Ger)**

[Plasma– and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar–Apr;55(2):90–104 (165 ref.) (Eng. Abstr.) **(Ger)**

[Preoperative plasmapheresis for lung cancer with multiple myeloma] Tagawa T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1967–71 (Eng. Abstr.) **(Jpn)**

[Case of Fisher syndrome with pemphigus treated by immuno–adsorption plasmapheresis] Nishikage H, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):274–5 **(Jpn)**

[Marked clinical improvement by plasmapheresis in a patient with stiff–man syndrome: a case with a negative anti–GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897–900 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Use of plasmapheresis in the treatment of internal diseases] Usnarska–Zubkiewicz L. **Pol Arch Med Wewn** 1995 Sep; 94(3):250–8 (110 ref.) **(Pol)**

[Plasmapheresis as a method of intensive care in neurology] Piradov MA. **Anesteziol Reanimatol** 1996 Mar–Apr; (2):92–4 (3 ref.) **(Rus)**

[Experience in using plasmapheresis in comprehensive therapy of myelotoxic agranulocytosis in cancer patients] Legeza VI, et al. **Gematol Transfuziol** 1995 Jul–Aug; 40(4):21–3 (Eng. Abstr.) **(Rus)**

[Plasmapheresis in the treatment of diphtheritic polyneuropathy] Postnikov AA, et al. **Klin Med (Mosk)** 1995;73(6):54–5 **(Rus)**

[Plasmapheresis efficacy in the treatment of patients with chronic cholestatic hepatitis and primary biliary liver cirrhosis] Radchenko VG. **Lik Sprava** 1995 May–Jun; (5–6):160–3 (Eng. Abstr.) **(Rus)**

[The neurohumoral mechanisms of the efficacy of therapeutic plasmapheresis in patients with resistant forms of arterial hypertension] Volos BE, et al. **Lik Sprava** 1995 Jul–Aug; (7–8):11–4 **(Rus)**

[Preoperative plasma– and thrombocytapheresis in patients

with ischemic heart disease] Shilov VV, et al. **Vestn Khir Im I I Grek** 1995;154(2):77–81 **(Rus)**

[Plasmapheresis in clinical practice] Ljaljević M, et al. **Glas Srp Akad Nauka [Med]** 1994;(44):127–31 (Eng. Abstr.) **(Scc)**

[Successful treatment of acquired F:VIII C inhibitor after delivery using plasmapheresis and high doses of immunoglobulins] Belić A, et al. **Med Pregl** 1994; 47(9–10):359–61 (Eng. Abstr.) **(Scr)**

[Inefficacy of plasma perfusion in thrombotic thrombocytopenic purpura and early relapse after plasmapheresis (letter)] Bergua JM, et al. **Sangre (Barc)** 1995 Oct;40(5):439–40 **(Spa)**

[Hepatitis C virus in plasmapheresis donors] Padrón GJ, et al. **Sangre (Barc)** 1995 Jun;40(3):187–90 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY. **Clin Exp Immunol** 1996 May;104 Suppl 1:31–4 (25 ref.)

Risk factors of respiratory failure in children with Guillain–Barré syndrome. Rantala H, et al. **Pediatr Neurol** 1995 Nov;13(4):289–92

INSTRUMENTATION

A high selectivity cascade filtration technique for LDL-cholesterol and Lp(a) removal. Legallais C, et al. **Artif Organs** 1995 Sep;19(9):887–95

Clinical trials of a cryoglobulin filter. Siami GA, et al. **ASAIO J** 1994 Jul–Sep;40(3):M658–62

Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass. Vertress RA, et al. **ASAIO J** 1994 Jul–Sep;40(3):M560–4

[Current status of the plasmapheresis problem] Kalinin NN. **Gematol Transfuziol** 1995 Mar–Apr;40(2):46–8 (12 ref.) **(Rus)**

[Equipment for blood detoxication in critical care of patients] Pisarevskii AA, et al. **Med Tekh** 1995 Jul–Aug;(4):14–8 (Eng. Abstr.) **(Rus)**

METHODS

Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations [letter; comment] Galli AC, et al. **Anesth Analg** 1996 Apr;82(4):890. Comment on: Anesth Analg 1995 Aug;81(2):229–35.

Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Larsen FS, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):261–5

Tryptophan–immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment. Yuki N. **Neurology** 1996 Jun; 46(6):1644–51

Comparison of the effect of plasmapheresis using human albumin or dextran 40 on the survival of pig–to–dog renal xenografts. Abouna GM, et al. **Transplant Proc** 1996 Feb; 28(1):212–4

[A combination of exchange plasmapheresis with the extracorporeal laser irradiation of the erythrocyte mass as a new component in the treatment of suppurative diseases in pulmonology] Orlov SV, et al. **Vestn Khir Im I I Grek** 1995;154(2):82–3 **(Rus)**

[Experience with the use of pulsed plasmapheresis in therapeutic practice] Zavgorodniĭ GN, et al. **Voen Med Zh** 1995 Aug;(8):30–1 **(Rus)**

PLASMIDS

see related

EXTRACHROMOSOMAL INHERITANCE

Antibiotic resistance of Vibrio anguillarum, in relation to serovar and plasmid contents. Pedersen K, et al. **Acta Vet Scand** 1995;36(1):55–64

Epidemiological characterization of human and environmental Pseudomonas aeruginosa strains: use of plasmid pattern analysis in addition to other typing methods. Orsi N, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):653–64

Stability of plasmid pHV1431 in free and immobilized cell cultures. Effect of temperature. Craynest M, et al. **Ann N Y Acad Sci** 1996 May 15;782:311–22

Use of plasmid DNA for direct gene transfer and immunization. Davis HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:21–9 (29 ref.)

A URA3–promoter deletion in a pYES vector increases the expression level of a fungal lipase in Saccharomyces cerevisiae. Okkels JS. **Ann N Y Acad Sci** 1996 May 15; 782:202–7

Characterization of a conjugative staphylococcal mupirocin resistance plasmid. Morton TM, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1272–80

Restriction map of the 125-kilobase plasmid of Bacillus thuringiensis subsp. israelensis carrying the genes that encode delta–endotoxins active against mosquito larvae. Ben–Dov E, et al. **Appl Environ Microbiol** 1996 Sep; 62(9):3140–5

Increased mutagenesis mediated by cloned plasmid CAM–OCT genes: potential for expanding substrate ranges of Pseudomonas spp. McBeth DL, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3538–40

AbiG, a genotypically novel abortive infection mechanism encoded by plasmid pCI750 of Lactococcus lactis subsp. cremoris UC653. O'Connor L, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3075–82

A simple procedure for isolation of cloning vectors and endogenous plasmids from viridans group streptococci and Staphylococcus aureus. Vriesema AJ, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3527–9

Fast kinetic studies of plasmid DNA transfer in intact yeast cells mediated by electropulsation. Ganeva V, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):825–32

Characterization of bacterial cell membrane attachment sites of plasmid R6K. Jemilohun PF, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):186–92

The use of RT–PCR to distinguish between plasmid MnSOD transcripts and endogenous MnSOD mRNA. Li JJ, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):610–8

Structural analysis of invasion plasmid antigen D (IpaD) from Shigella flexneri. Marquart ME, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):963–70

Plasmid–encoded degradation of p–nitrophenol by Pseudomonas cepacia. Prakash D, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):375–81

Plasmid–mediated degradation of o–phthalate and salicylate by a Moraxella sp. Rani M, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):377–81

A new plasmid–encoded proteic killer gene system: cloning, sequencing, and analyzing hig locus of plasmid Rts1. Tian QB, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):280–4

Gene product identification and promoter analysis of hig locus of plasmid Rts1. Tian QB, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):679–84

E. coli growth inhibition by a high copy number derivative of plasmid pBR322. Valenzuela MS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):876–83

Transcriptional activation of ori lambda regulates lambda plasmid replication in amino acid–starved Escherichia coli cells. Węgrzyn A, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):978–84

Induction, not associated with host–cell re–activation of damaged plasmid DNA, of damaged–DNA–recognition proteins by retinoic acid and dibutyryl cyclic AMP in mammalian cells. Sun NK, et al. **Biochem J** 1996 Jan 15; 313 (Pt 2):441–5

The major, N2–Gua adduct of the (+)–anti–benzo[a]pyrene diol epoxide is capable of inducing G––>A and G––>C, in addition to G––>T, mutations. Jelinsky SA, et al. **Biochemistry** 1995 Oct 17;34(41):13545–53

Flow of structural information between four DNA conformational levels. Levin–Zaidman S, et al. **Biochemistry** 1996 Mar 5;35(9):2985–91

Characterization of two genes, p11 and p5, on the Borrelia burgdorferi 49–kilo base linear plasmid. Feng S, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):270–2

Open strands adjacent to iterons promote the binding of the replication initiator protein (Rep) of pSC101 to the unit sequence of the iterons in vitro. Fueki T, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):181–8

Converting an alcohol to an amine in a cationic lipid dramatically alters the co–lipid requirement, cellular transfection activity and the ultrastructure of DNA–cytofectin complexes. Wheeler CJ, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):1–11

A quantitative method for the determination of plasmid copy number in recombinant yeast. Fujimura H, et al. **Biologicals** 1996 Mar;24(1):67–70

Plasmid ligation using a sacrificial insert. Buntel CJ. **Biotechniques** 1995 Sep;19(3):351

Elimination of plasmid contamination from plant genomic DNA samples prior to PCR amplification of genes. Chen W, et al. **Biotechniques** 1995 Oct;19(4):536–8

Direct–rapid (DR) mutagenesis of large plasmids using PCR. Gatlin J, et al. **Biotechniques** 1995 Oct;19(4):559–64

Ligation– and PCR–based method for sequencing plasmid inserts. Goldsborough AS, et al. **Biotechniques** 1995 Dec; 19(6):910–2

Detergent–enhanced sequencing of heat–denatured plasmid DNA. Hutchison W, et al. **Biotechniques** 1995 Oct; 19(4):554–6

Isolation of plasmid DNA from mycobacteria using a resin–based alkaline lysis kit. King CH, et al. **Biotechniques** 1995 Sep;19(3):326–30

Fluorescence–based method for selection of recombinant plasmids. Roessner CA, et al. **Biotechniques** 1995 Nov; 19(5):760–4

Vector plasmid for insertional mutagenesis and directional cloning in Listeria spp. Schäferkordt S, et al. **Biotechniques** 1995 Nov;19(5):720–2, 724–5

PCR–based identification of AT–rich tri– and tetranucleotide repeat loci in an enriched plasmid library. Waldbieser GC. **Biotechniques** 1995 Nov;19(5):742–4

Short technical reports. Effects of lipopolysaccharide on transfection efficiency in eukaryotic cells. Weber M, et al. **Biotechniques** 1995 Dec;19(6):930–40

Detection of surface free radical activity of respirable industrial fibres using supercoiled phi X174 RF1 plasmid DNA. Gilmour PS, et al. **Carcinogenesis** 1995 Dec; 16(12):2973–9

Nucleotide–sequence analysis indicates that a DNA plasmid in a diseased isolate of Ophiostoma novo–ulmi is derived by recombination between two long repeat sequences in the mitochondrial large subunit ribosomal RNA gene. Abu–Amero SN, et al. **Curr Genet** 1995 Jun;28(1):54–9

Recombinational stability of replicating plasmids in Aspergillus nidulans during transformation, vegetative growth and sexual reproduction. Aleksenko AY, et al. **Curr Genet** 1995 Jun;28(1):87–93

Rearrangements of mitochondrial DNA and the mitochondrial fusion–promoting plasmid (mF) are associated with defective mitochondrial fusion in Physarum polycephalum. Takano H, et al. **Curr Genet** 1996 Feb; 29(3):257–64

Plasmid transfer for enhancing degradation capabilities. Rittmann BE, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:113–5

Trypanosoma cruzi: expression of interleukin–2 utilizing both supercoiled plasmids and linear DNAs. La Flamme AC, et al. **Exp Parasitol** 1996 Jun;83(1):159–63

The construction and characterization of an effective transpositional system based on IS30. Farkas T, et al. **FEBS Lett** 1996 Jul 15;390(1):53–8

Pathogenesis of Rhodococcus equi infection in mice: roles of virulence plasmids and granulomagenic activity of bacteria. Takai S, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):181–90

Construction of a modified mini–Tn5 lacZY non–antibiotic marker cassette: ecological evaluation of a lacZY marked Pseudomonas strain in the sugarbeet rhizosphere. Fedi S, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):251–7

General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid. Aagaard C, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):93–104 (38 ref.)

Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)

Factors affecting DNA damage caused by lipid hydroperoxides and aldehydes. Yang MH, et al. **Free Radic Biol Med** 1996;20(2):225–36

A pBRINT family of plasmids for integration of cloned DNA into the Escherichia coli chromosome. Balbás P, et al. **Gene** 1996 Jun 12;172(1):65–9

Identification of a native Dichelobacter nodosus plasmid and implications for the evolution of the vap regions. Billington SJ, et al. **Gene** 1996 Jun 12;172(1):111–6

Bacterial plasmid conjugation on semi–solid surfaces monitored with the green fluorescent protein (GFP) from Aequorea victoria as a marker. Christensen BB, et al. **Gene** 1996;173(1 Spec No):59–65

Two versatile eukaryotic vectors permitting epitope tagging, radiolabelling and nuclear localisation of expressed proteins. Georgiev O, et al. **Gene** 1996 Feb 12;168(2):165–7

Antibiotic–resistance cassettes for Bacillus subtilis. Guérout–Fleury AM, et al. **Gene** 1995 Dec 29; 167(1–2):335–6

Construction of lacIts and lacIqts expression plasmids and evaluation of the thermosensitive lac repressor. Hasan N, et al. **Gene** 1995 Sep 22;163(1):35–40

Plasmids with a kanamycin–resistance gene for site–directed mutagenesis using the oligodeoxyribonucleotide–directed dual amber method. Hashimoto–Gotoh T, et al. **Gene** 1995 Dec 29;167(1–2):333–4

Four new derivatives of the broad–host–range cloning vector pBBR1MCS, carrying different antibiotic–resistance cassettes. Kovach ME, et al. **Gene** 1995 Dec 1;166(1):175–6

A new set of useful cloning and expression vectors derived from pBlueScript. Mayer MP. **Gene** 1995 Sep 22; 163(1):41–6

VTR expression cassettes for engineering conditional phenotypes in Pseudomonas: activity of the Pu promoter of the TOL plasmid under limiting concentrations of the XylR activator protein. Pérez–Martín J, et al. **Gene** 1996 Jun 12;172(1):81–6

Cloning and comparison of mercury– and organomercurial–resistance determinants from a Pseudomonas stutzeri plasmid. Reniero D, et al. **Gene** 1995 Dec 1;166(1):77–82

Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Levy MY, et al. **Gene Ther** 1996 Mar;3(3):201–11

Investigation of neuropeptide gene transcription in sensory neurons transfected by microinjection of reporter plasmids. Mulderry PK, et al. **Gene Ther** 1994;1 Suppl 1:S22–3

Expression of human amyloid precursor proteins in cultured neuronal cells through the use of HSV–1 defective vectors. Wyborski RJ, et al. **Gene Ther** 1994;1 Suppl 1:S83

Role of Erf recombinase in P22–mediated plasmid transduction. Garzón A, et al. **Genetics** 1995 Jun; 140(2):427–34

Orientation dependence in homologous recombination. Yamamoto K, et al. **Genetics** 1996 May;143(1):27–36

The Salmonella dublin virulence plasmid does not modulate early T–cell responses in mice. Guilloteau LA, et al. **Infect Immun** 1996 Jan;64(1):222–9

The Salmonella virulence plasmid enhances Salmonella–induced lysis of macrophages and influences inflammatory responses. Guilloteau LA, et al. **Infect Immun** 1996 Aug;64(8):3385–93

Correlation of plasmids with infectivity of Borrelia burgdorferi sensu stricto type strain B31. Xu Y, et al. **Infect Immun** 1996 Sep;64(9):3870–6

A rapid mechanical lysing procedure for routine analysis of plasmids from lactobacilli, isolated from sourdoughs. Reinkemeier M, et al. **Int J Food Microbiol** 1996 Feb;

29(1):93–104
Sexuality of mitochondria: fusion, recombination, and plasmids. Kawano S, et al. **Int Rev Cytol** 1995;161:49–110 (179 ref.)
Characterization of a new plasmid-mediated extended-spectrum beta-lactamase from Serratia marcescens. Kunugita C, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1453–9
Extended-spectrum plasmid-mediated beta-lactamases. Sirot D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:19–34 (129 ref.)
Pediocin 5 production and plasmid stability during continuous free and immobilized cell cultures of Pediococcus acidilactici UL5. Huang J, et al. **J Appl Bacteriol** 1996 Jun;80(6):635–44
Sequence of plasmid pGT5 from the archaeon Pyrococcus abyssi: evidence for rolling-circle replication in a hyperthermophile. Erauso G, et al. **J Bacteriol** 1996 Jun; 178(11):3232–7
Conversion of a linear to a circular plasmid in the relapsing fever agent Borrelia hermsii. Ferdows MS, et al. **J Bacteriol** 1996 Feb;178(3):793–800
A Ti plasmid-encoded enzyme required for degradation of mannopine is functionally homologous to the T-region-encoded enzyme required for synthesis of this opine in crown gall tumors. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3285–92
Ti plasmid-encoded genes responsible for catabolism of the crown gall opine mannopine by Agrobacterium tumefaciens are homologs of the T-region genes responsible for synthesis of this opine by the plant tumor. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3275–84
Analysis of linear plasmid dimers in Borrelia burgdorferi sensu lato isolates: implications concerning the potential mechanism of linear plasmid replication. Marconi RT, et al. **J Bacteriol** 1996 Jun;178(11):3357–61
Redundant homosexual F transfer facilitates selection-induced reversion of plasmid mutations. Peters JE, et al. **J Bacteriol** 1996 Jun;178(11):3037–43
Borrelia burgdorferi supercoiled plasmids encode multicopy tandem open reading frames and a lipoprotein gene family. Porcella SF, et al. **J Bacteriol** 1996 Jun;178(11):3293–307
Single-stranded DNA-binding protein enhances the stability of CTG triplet repeats in Escherichia coli. Rosche WA, et al. **J Bacteriol** 1996 Aug;178(16):5042–4
Genetic analysis of plasmid determinants for microcin J25 production and immunity. Solbiati JO, et al. **J Bacteriol** 1996 Jun;178(12):3661–3
A family of genes located on four separate 32-kilobase circular plasmids in Borrelia burgdorferi B31. Stevenson B, et al. **J Bacteriol** 1996 Jun;178(12):3508–16
Cloning and genetic organization of the bacteriocin 31 determinant encoded on the Enterococcus faecalis pheromone-responsive conjugative plasmid pYI17. Tomita H, et al. **J Bacteriol** 1996 Jun;178(12):3585–93
TTA.TAA triplet repeats in plasmids form a non-H bonded structure. Ohshima K, et al. **J Biol Chem** 1996 Jul 12; 271(28):16784–91
Mechanisms of initiation and termination reactions in conjugative DNA processing. Independence of tight substrate binding and catalytic activity of relaxase (TraI) of IncPalpha plasmid RP4. Pansegrau W, et al. **J Biol Chem** 1996 May 31;271(22):13068–76
The plasmid RK2 initiation protein binds to the origin of replication as a monomer. Toukdarian AE, et al. **J Biol Chem** 1996 Mar 22;271(12):7072–8
Assignment of the crystal toxin genes of the mosquitocidal bacterium, Bacillus thuringiensis israelensis to a specific plasmid. Rady MH, et al. **J Egypt Soc Parasitol** 1996 Aug; 26(2):525–37
Isolation and curing of plasmid DNA from Bacillus thuringiensis israelensis strains showing variable insecticidal activities. Rady MH, et al. **J Egypt Soc Parasitol** 1996 Aug; 26(2):423–32
Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. Takai S, et al. **J Infect Dis** 1995 Nov;172(5):1306–11
Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. Mahato RI, et al. **J Pharm Sci** 1995 Nov;84(11):1267–71
Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. Caravokyri C, et al. **J Virol** 1995 Nov;69(11):6627–33
Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome. Giraud C, et al. **J Virol** 1995 Nov;69(11):6917–24
A plasmid-based reverse genetics system for influenza A virus. Pleschka S, et al. **J Virol** 1996 Jun;70(6):4188–92
Polymorphic distribution and molecular diversification of mitochondrial plasmid-like DNAs in the genus Oryza. Miyata S, et al. **Jpn J Genet** 1995 Oct;70(5):601–14
Analyzing protein-protein interactions using two-hybrid system. Bartel PL, et al. **Methods Enzymol** 1995;254:241–63
Identification of protein-protein interactions by lambda gt11 expression cloning. Blackwood EM, et al. **Methods Enzymol** 1995;254:229–40
Phi X174-type primosomal proteins: purification and assay. Marians KJ. **Methods Enzymol** 1995;262:507–21
Electroporation of Francisella tularensis. Baron GS, et al. **Methods Mol Biol** 1995;47:149–54
Isolation of YAC ends by plasmid rescue. Bates G. **Methods Mol Biol** 1996;54:139–44
Electroporation of Agrobacterium tumefaciens. den Dulk-Ras A, et al. **Methods Mol Biol** 1995;55:63–72
Electrotransformation of Pseudomonas. Dennis JJ, et al. **Methods Mol Biol** 1995;47:125–33
Gene transfer by electroporation in Tetrahymena. Gaertig J, et al. **Methods Mol Biol** 1995;47:331–48
Electroporation of tobacco leaf protoplasts using plasmid DNA or total genomic DNA. Gallois P, et al. **Methods Mol Biol** 1995;55:89–107
Ten-minute electrotransformation of Saccharomyces cerevisiae. Grey M, et al. **Methods Mol Biol** 1995;47:269–72
Transfer of episomal and integrated plasmids from Saccharomyces cerevisiae to Escherichia coli by electroporation. Gunn L, et al. **Methods Mol Biol** 1995; 47:55–66
A simple and rapid method for transformation of Vibrio species by electroporation. Hamashima H, et al. **Methods Mol Biol** 1995;47:155–60
Electroporation of Schizosaccharomyces pombe. Hood MT, et al. **Methods Mol Biol** 1995;47:273–8
Electroporation of DNA into the unicellular green alga Chlamydomonas reinhardtii. Keller LR. **Methods Mol Biol** 1995;55:73–9
Electroporation of Dictyostelium discoideum. Knecht D, et al. **Methods Mol Biol** 1995;47:321–30
Electrotransformation of Staphylococci. Lee JC. **Methods Mol Biol** 1995;47:209–16
Electrotransformation of Streptococci. McLaughlin RE, et al. **Methods Mol Biol** 1995;47:185–93
Transformation of Brucella species with suicide and broad host-range plasmids. McQuiston JR, et al. **Methods Mol Biol** 1995;47:143–8
Escherichia coli electrotransformation. Miller EM, et al. **Methods Mol Biol** 1995;47:105–13
Electroporation of mycobacteria. Parish T, et al. **Methods Mol Biol** 1995;47:237–52
Introduction of recombinant DNA into Clostridium spp. Phillips-Jones MK. **Methods Mol Biol** 1995;47:227–35
Transformation of maize by electroporation of embryos. Rhodes CA, et al. **Methods Mol Biol** 1995;55:121–31
Electrotransformation in Salmonella. Sanderson KE, et al. **Methods Mol Biol** 1995;47:115–23
Electroporation and efficient transformation of Enterococcus faecalis grown in high concentrations of glycine. Shepard BD, et al. **Methods Mol Biol** 1995;47:217–26
Genetic transformation of Bacteroides spp. using electroporation. Smith CJ. **Methods Mol Biol** 1995;47:161–9
Direct plasmid transfer between bacterial species and electrocuring. Withers HL. **Methods Mol Biol** 1995; 47:47–54
Plasmid coding for drug resistance and invasion of epithelial cells in enteropathogenic Escherichia coli 0111:H. Scaletsky IC, et al. **Microb Pathog** 1995 Jun;18(6):387–99
In vitro formation of a catabolic plasmid carrying Klebsiella pneumoniae DNA that allows growth of Escherichia coli K-12 on 3-hydroxybenzoate. Robson ND, et al. **Microbiology** 1996 Aug;142 (Pt 8):2115–20
Replication initiates at multiple dispersed sites in the ribosomal DNA plasmid of the protozoan parasite Entamoeba histolytica. Dhar SK, et al. **Mol Cell Biol** 1996 May;16(5):2314–24
Genetic diversity within mer genes directly amplified from communities of noncultivated soil and sediment bacteria. Bruce KD, et al. **Mol Ecol** 1995 Oct;4(5):605–12
Characterization of the replicon of plasmid pSW500 of Erwinia stewartii. Fu JF, et al. **Mol Gen Genet** 1996 Apr 10;250(6):699–704
recB recJ mutants of Salmonella typhimurium are deficient in transductional recombination, DNA repair and plasmid maintenance. Garzón A, et al. **Mol Gen Genet** 1996 Mar 20;250(5):570–80
Recombination between heterologous linear and circular mitochondrial plasmids in the fungus Neurospora. Griffiths AJ, et al. **Mol Gen Genet** 1995 Nov 1;249(1):25–36
Ti plasmid-encoded octopine and nopaline catabolism in Agrobacterium: specificities of the LysR-type regulators OccR and NocR, and protein-induced DNA bending. Kreusch D, et al. **Mol Gen Genet** 1995 Nov 1;249(1):102–10
Overproduction of the ATP-dependent nuclease AddAB improves the structural stability of a model plasmid system in Bacillus subtilis. Meima R, et al. **Mol Gen Genet** 1995 Aug 30;248(4):391–8
Multicopy plasmid suppression of stationary phase chaperone toxicity in Escherichia coli by phosphogluconate dehydratase and the N-terminus of DnaK. Rockabrand D, et al. **Mol Gen Genet** 1995 Dec 15;249(5):498–506
Structural and functional analysis of the single-strand origin of replication from the lactococcal plasmid pWV01. Seegers JF, et al. **Mol Gen Genet** 1995 Nov 1;249(1):43–50
Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Anderson ED, et al. **Mol Mar Biol Biotechnol** 1996 Jun;5(2):105–13
Three novel plasmid R6K proteins act in concert to distort DNA within the alpha and beta origins of DNA replication. Flashner Y, et al. **Mol Microbiol** 1996 Mar;19(5):985–96
Transcriptional organization and expression of nolXWBTUV, a locus that regulates cultivar-specific nodulation of soybean by Rhizobium fredii USDA257. Kovács LG, et al. **Mol Microbiol** 1995 Sep;17(5):923–33
pAM beta 1 resolvase has an atypical recombination site and requires a histone-like protein HU. Petit MA, et al. **Mol Microbiol** 1995 Oct;18(2):271–82
Plasmid transfer and expression of the transfer (tra) gene product of plasmid pIJ101 are temporally regulated during the Streptomyces lividans life cycle. Pettis GS, et al. **Mol Microbiol** 1996 Mar;19(5):1127–35
Molecular characterization of the Pseudomonas syringae pv. pisi plasmid-borne avirulence gene avrPpiB which matches the R3 resistance locus in pea. Cournoyer B, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):700–8
Post-UV survival of Escherichia coli strains carrying more than one UV-sensitising plasmid. Ambler JE, et al. **Mutat Res** 1996 Apr 13;351(2):181–6
Plasmid-based transgenic mouse model for studying in vivo mutations. Boerrigter ME, et al. **Nature** 1995 Oct 19; 377(6550):657–9 (16 ref.)
Hyper-negative template DNA supercoiling during transcription of the tetracycline-resistance gene in topA mutants is largely constrained in vivo. Albert AC, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):3093–9
Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Bielinska A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2176–82
Site-specific recombination by the beta protein from the streptococcal plasmid pSM19035: minimal recombination sequences and crossing over site. Canosa I, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2712–7
Molecular weight determination of plasmid DNA using electrospray ionization mass spectrometry. Cheng X, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2183–9
Initiator protein pi can bind independently to two domains of the gamma origin core of plasmid R6K: the direct repeats and the A+T-rich segment. Levchenko I, et al. **Nucleic Acids Res** 1996 May 15;24(10):1936–42
Asymmetric mutation around the recombination break point of immunoglobulin class switch sequences on extrachromosomal substrates. Li J, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2104–11
Interaction of the IciA protein with AT-rich regions in plasmid replication origins. Wei T, et al. **Nucleic Acids Res** 1996 May 15;24(10):1865–72
Transfer of non-T-DNA portions of the Agrobacterium tumefaciens Ti plasmid pTiA6 from the left terminus of TL-DNA. Ramanathan V, et al. **Plant Mol Biol** 1995 Sep; 28(6):1149–54
Mobilization of Bacillus thuringiensis plasmid pTX14-3. Andrup L, et al. **Plasmid** 1995 May;33(3):159–67
Replication enhancer requirement for recognition of heterologous replication origin by an initiator protein. Colombo D, et al. **Plasmid** 1995 May;33(3):232–4
Construction and properties of cloning vectors based on a 7.2-kb Rhizobium meliloti cryptic plasmid. Froissard D, et al. **Plasmid** 1995 May;33(3):226–31
Plasmid pRTL1 controlling 1-chloroalkane degradation by Rhodococcus rhodochrous NCIMB13064. Kulakova AN, et al. **Plasmid** 1995 May;33(3):208–17
A novel tetracycline-resistant determinant, tet(U), is encoded on the plasmid pKq10 in Enterococcus faecium. Ridenhour MB, et al. **Plasmid** 1996 Mar;35(2):71–80
Molecular analysis of closely related copper- and streptomycin-resistance plasmids in Pseudomonas syringae pv. syringae. Sundin GW, et al. **Plasmid** 1996 Mar; 35(2):98–107
Iron transport genes of the pJM1-mediated iron uptake system of Vibrio anguillarum are included in a transposonlike structure. Tolmasky ME, et al. **Plasmid** 1995 May;33(3):180–90
An episomal expression vector system for monitoring sequence-specific effects on mRNA stability in human cell lines. Wilson GM, et al. **Plasmid** 1995 May;33(3):198–207
A region of a Sym plasmid of Rhizobium leguminosarum biovar phaseoli has similarity to prokaryotic insertion sequences and to eukaryotic integrases. Yeoman KH, et al. **Plasmid** 1996 Mar;35(2):121–30
Novel insertion sequence-like element IS982 in lactococci. Yu W, et al. **Plasmid** 1995 May;33(3):218–25
Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Fang J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5753–8
Formation of stable cationic lipid/DNA complexes for gene transfer. Hofland HE, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7305–9
Complementation of the beige mutation in cultured cells by episomally replicating murine yeast artificial chromosomes. Perou CM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):5905–9
Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Wu Y, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1130–4
Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Pande H, et al. **Scand J Infect Dis Suppl** 1995;99:117–20
Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Sizemore DR, et al. **Science** 1995 Oct 13;270(5234):299–302
Growth-phase regulation of plasmid virulence genes in Salmonella. Guiney DG, et al. **Trends Microbiol** 1995 Jul; 3(7):275–9 (29 ref.)
Plasmids containing cos ends inhibit the replication of phage

phi CTX in Pseudomonas aeruginosa. Xiong G, et al. **Virus Res** 1996 Mar;41(1):77–87

[Analysis of carbapenem resistant plasmid isolated from Serratia marcescens] Yosue T. **Fukuoka Igaku Zasshi** 1996 May;87(5):116–26 (Eng. Abstr.) **(Jpn)**

[Design of a Yersinia pestis strain with increased protection] Anisimov AP, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):532–4 **(Rus)**

[Genetic study of plasmid pVM82 which contributes to the pathogenicity of the pseudotuberculosis pathogen] Il'ina TS, et al. **Genetika** 1995 Jul;31(7):877–82 (Eng. Abstr.) **(Rus)**

[Determination and comparative analysis of the nucleotide sequence for minireplicon fragments of the cryptic plasmid p1414 from the soil strain of Bacillus subtilis] Kanapina ASh, et al. **Genetika** 1995 Sep;31(9):1201–9 (Eng. Abstr.) **(Rus)**

[Effect of Yersinia pseudotuberculosis pVM82 on the activity of components of complement and phagocytosis by human blood neutrophils] Sever IS. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):23–6 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Gene transfer to the retina of rat by liposome eye drops. Matsuo T, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):947–50

Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. Meyer KB, et al. **Gene Ther** 1995 Sep; 2(7):450–60

Using electroporation and a slot cuvette to deliver plasmid DNA to insect embryos. Leopold RA, et al. **Genet Anal** 1996 Mar;12(5–6):197–200

Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non–human primates [see comments] Parker SE, et al. **Hum Gene Ther** 1995 May;6(5):575–90. Comment in: Hum Gene Ther 1995 May;6(5):549–50. Comment in: Hum Gene Ther 1995 May;6(5):551–2.

Gene transfer to synovial cells by intra–articular administration of plasmid DNA. Yovandich J, et al. **Hum Gene Ther** 1995 May;6(5):603–10

Gene transfer with liposomes to the intraocular tissues by different routes of administration. Masuda I, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1914–20

Electroporation of plasmid DNA into normal human fibroblasts. Ray FA. **Methods Mol Biol** 1995;48:133–40

A serum–resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Lewis JG, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3176–81

ANALYSIS

Quantitative polymerase chain reaction with enzyme–linked immunosorbent assay detection of selectively digested amplified sample and control DNA. Hahn M, et al. **Anal Biochem** 1995 Aug 10;229(2):236–48

Molecular characterization of the OXA–7 beta–lactamase gene. Scoulica E, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1379–82

Ribotyping and plasmid profiling of Vibrio anguillarum serovar O2 and Vibrio ordalii. Tiainen T, et al. **J Appl Bacteriol** 1995 Oct;79(4):384–92

Non–radioactive detection of oligonucleotide probes by photochemical amplification of dioxetanes. Schubert F, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4657–63

Molecular weight determination of megadalton DNA electrospray ions using charge detection time–of–flight mass spectrometry. Fuerstenau SD, et al. **Rapid Commun Mass Spectrom** 1995;9(15):1528–38

[The plasmid profile, a useful marker in studying a focus of Salmonella enteritidis food poisoning] Ionescu G, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):231–4 **(Rum)**

BIOSYNTHESIS

Hypothesis: hypersensitive plasmid copy number control for ColE1. Ehrenberg M. **Biophys J** 1996 Jan;70(1):135–45

Autonomously replicating plasmids carrying the AMA1 region in Penicillium chrysogenum. Fierro F, et al. **Curr Genet** 1996 Apr;29(5):482–9

Enterococcus faecalis plasmid pAD1 replication and maintenance. Weaver KE. **Dev Biol Stand** 1995;85:89–98

Single–step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Stemmer WP, et al. **Gene** 1995 Oct 16;164(1):49–53

Replication of a plasmid lacking the normal site for initiation of one strand. Becker EC, et al. **J Bacteriol** 1996 Aug; 178(16):4870–6

Efficient plasmid DNA replication in Xenopus egg extracts does not depend on prior chromatin assembly. Aquiles Sanchez J, et al. **J Biol Chem** 1995 Dec 15;270(50):29676–81

Complete replication of plasmid DNA containing a single UV–induced lesion in human cell extracts. Carty MP, et al. **J Biol Chem** 1996 Apr 19;271(16):9637–47

Analysis of left–handed Z–DNA formation in short d(CG)n sequences in Escherichia coli and Halobacterium halobium plasmids. Stabilization by increasing repeat length and DNA supercoiling but not salinity. Kim J, et al. **J Biol Chem** 1996 Apr 19;271(16):9340–6

Diversity of repC plasmid–replication sequences in Rhizobium leguminosarum. Turner SL, et al. **Microbiology** 1996 Jul;142 (Pt 7):1705–13

Sequences essential for replication of plasmid pIJ101 in Streptomyces lividans. Brasch MA, et al. **Plasmid** 1995 May;33(3):191–7

CHEMICAL SYNTHESIS

Total in vitro synthesis of plasmid DNA facilitates site–directed mutagenesis. Postina R, et al. **Anal Biochem** 1995 Dec 10;232(2):254–8

CHEMISTRY

A method for purification of DNA species by high–speed centrifugation of agarose gel slices. Wu W, et al. **Anal Biochem** 1995 Aug 10;229(2):350–2

Rigidity of a B–Z region incorporated into a plasmid as monitored by electron paramagnetic resonance. Strobel OK, et al. **Arch Biochem Biophys** 1995 Dec 20; 324(2):357–66

Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Reimer DL, et al. **Biochemistry** 1995 Oct 3;34(39):12877–83

Large–scale purification of plasmid DNA for biophysical and molecular biology studies. Baumann CG, et al. **Biotechniques** 1995 Dec;19(6):884–90

Preparation of pure plasmid or cosmid DNA using single–strand affinity matrix and gel–filtration spin columns. Pham TT, et al. **Biotechniques** 1996 Mar;20(3):492–7

Plasmid amplification–promoting sequences from the origin region of Chinese hamster dihydrofolate reductase gene do not promote position–independent chromosomal gene amplification. Brinton BT, et al. **Chromosoma** 1995 Nov; 104(2):143–51

Deamination of cytosine–containing pyrimidine photodimers in UV–irradiated DNA. Significance for UV light mutagenesis. Barak Y, et al. **J Biol Chem** 1995 Oct 13; 270(41):24174–9

Analysis of left–handed Z–DNA formation in short d(CG)n sequences in Escherichia coli and Halobacterium halobium plasmids. Stabilization by increasing repeat length and DNA supercoiling but not salinity. Kim J, et al. **J Biol Chem** 1996 Apr 19;271(16):9340–6

DNA knotting abolishes in vitro chromatin assembly. Rodríguez–Campos A. **J Biol Chem** 1996 Jun 14; 271(24):14150–5

Strand specificity of nicking of DNA at Chi sites by RecBCD enzyme. Modulation by ATP and magnesium levels. Taylor AF, et al. **J Biol Chem** 1995 Oct 13;270(41):24459–67

The size of the topological domain modulates the B–Z transition of a (TG)n containing repeat. Albert AC, et al. **J Biomol Struct Dyn** 1995 Aug;13(1):47–56

Single base–pair precision and structural rigidity in a small IHF–induced DNA loop. Nunes–Düby SE, et al. **J Mol Biol** 1995 Oct 20;253(2):228–42

Adjacent guanines as preferred sites for strand breaks in plasmid DNA irradiated with 193 nm and 248 nm UV laser light. Sies H, et al. **J Photochem Photobiol B** 1996 Jan; 32(1–2):97–102

Torsionally–strained DNA and intermolecular purine–purine–pyrimidine triple–helix formation. Musso M, et al. **Mol Cell Biochem** 1996 Jan 12;154(1):65–70

Genetic and molecular analysis of a regulatory region of the herbicide 2,4–dichlorophenoxyacetate catabolic plasmid pJP4. You IS, et al. **Mol Microbiol** 1995 Apr;16(2):321–31

Localized denaturation of oriT DNA within relaxosomes of the broad–host–range plasmid R1162. Zhang S, et al. **Mol Microbiol** 1995 Aug;17(4):727–35

RecA.oligonucleotide filaments bind in the minor groove of double–stranded DNA. Baliga R, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10393–7

Neutron and gamma–radiation sensitivity of plasmid DNA of varying superhelical density. Swenberg CE, et al. **Radiat Res** 1995 Dec;144(3):301–9

Plasmid profiles of Klebsiella pneumoniae isolated from bovine mastitis. Kikuchi N, et al. **Vet Microbiol** 1995 Nov; 47(1–2):9–15

Genes leave their characteristic marks on the melting profile of plasmid DNAs. Zubrzycki IZ, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):652–5

DRUG EFFECTS

Inhibition of episomal hepatitis B virus DNA in vitro by 2,4–diamino–7–(2–deoxy–2–fluoro–beta–D–arabinofuranosyl)–pyrrolo[2,3–d]pyrimidine. Ojwang JO, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2570–3

Selenium–containing compounds protect DNA from single–strand breaks caused by peroxynitrite. Roussyn I, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):216–8

One electron reduction of vanadate(V) to oxovanadium(IV) by low–molecular–weight biocomponents like saccharides and ascorbic acid: effect of oxovanadium(IV) complexes on pUC18 DNA and on lipid peroxidation in isolated rat hepatocytes. Sreedhara A, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):115–20

Modification of the recognition of restriction sites of plasmid DNA by the antitumor drug Pt–pentamidine. Pérez JM, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):851–6

The inhibitory effect of extracts from Fructus lycii and Rhizoma polygonati on in vitro DNA breakage by alternariol. Xu DS, et al. **Biomed Environ Sci** 1996 Mar; 9(1):67–70

Protection of plasmid pBR322 DNA by flavonoids against single–stranded breaks induced by singlet molecular oxygen. Devasagayam TP, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):97–103

GENETICS

Inhibition of transcription starting from bacteriophage lambda pR promoter during the stringent response in Escherichia coli: implications for lambda DNA replication. Szalewska–Palasz A, et al. **Acta Biochim Pol** 1995; 42(2):233–9

Single–step, ligase–free cloning of polymerase chain reaction products into any restriction site of any DNA plasmid. Garcés C, et al. **Anal Biochem** 1995 Sep 1;230(1):178–80

Large–scale production of palindrome DNA fragments. Palmer EL, et al. **Anal Biochem** 1995 Oct 10;231(1):109–14

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)

Cloning and characterization of a novel, plasmid–encoded trimethoprim–resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313. Dale GE, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1920–4

Transient expression assay for antisense RNAs using episomal replication of plasmids: effective reduction of retinoblastoma gene (Rb–1) product by its antisense RNA complementary to 3'–untranslated region. Kobayashi M, et al. **Antisense Res Dev** 1995 Summer;5(2):141–8

Structure and function of Tn5467, a Tn21–like transposon located on the Thiobacillus ferrooxidans broad–host–range plasmid pTF–FC2. Clennel AM, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4223–9

Gene transfer of Alcaligenes eutrophus JMP134 plasmid pJP4 to indigenous soil recipients. DiGiovanni GD, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2521–6

Nucleotide sequence and replication properties of the Bacillus borstelensis cryptic plasmid pHT926. Ebisu S, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3154–7

Cloning and DNA sequence analysis of two abortive infection phage resistance determinants from the lactococcal plasmid pNP40. Garvey P, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4321–8

Detection and characterization of broad–host–range plasmids in environmental bacteria by PCR. Götz A, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2621–8

The endosymbiont (Buchnera sp.) of the aphid Diuraphis noxia contains plasmids consisting of trpEG and tandem repeats of trpEG pseudogenes. Lai CY, et al. **Appl Environ Microbiol** 1996 Feb;62(2):332–9

Bacteriolytic activity caused by the presence of a novel lactococcal plasmid encoding lactococcins A, B, and M. Morgan S, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):2995–3001

Recombination of a 3–chlorobenzoate catabolic plasmid from Alcaligenes eutrophus NH9 mediated by direct repeat elements. Ogawa N, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3788–95

PCR detection of Ti and Ri plasmids from phytopathogenic Agrobacterium strains. Sawada H, et al. **Appl Environ Microbiol** 1995 Feb;61(2):828–31

Capture of a catabolic plasmid that encodes only 2,4–dichlorophenoxyacetic acid:alpha–ketoglutaric acid dioxygenase (TfdA) by genetic complementation. Top EM, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2470–6

Characterization of plasmid–encoded citrate permease (citP) genes from Leuconostoc species reveals high sequence conservation with the Lactococcus lactis citP gene. Vaughan EE, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):3172–6

A pAO1–encoded molybdopterin cofactor gene (moaA) of Arthrobacter nicotinovorans: characterization and site–directed mutagenesis of the encoded protein. Menéndez C, et al. **Arch Microbiol** 1995 Aug;164(2):142–51

Synthesis of a Cys949Tyr alpha 2–macroglobulin thiol ester mutant: co–transfection with wild–type alpha 2–macroglobulin in an episomal expression system. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):183–90

The counterion influence on cationic lipid–mediated transfection of plasmid DNA. Aberle AM, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):281–3

Identification of a gene for a chemoreceptor of the methyl–accepting type in the symbiotic plasmid of Rhizobium leguminosarum bv. viciae UPM791. Brito B, et al. **Biochim Biophys Acta** 1996 Jul 31;1308(1):7–11

DNaseI treatment is a prerequisite for the amplification of cDNA from episomal–based genes. Kienzle N, et al. **Biotechniques** 1996 Apr;20(4):612–6

Screening for recombinant plasmids in yeast colonies of the two–hybrid system using PCR. Schenk JA, et al. **Biotechniques** 1996 May;20(5):812–4, 816

Construction of a reporter plasmid that allows expression libraries to be exploited for the one–hybrid system. Wolf SS, et al. **Biotechniques** 1996 Apr;20(4):568–74

Gene transfer from bacteria to mammalian cells. Courvalin P, et al. **C R Acad Sci III** 1995 Dec;318(12):1207–12

Isolates of Neisseria gonorrhoeae in Ontario showing chromosomally–mediated resistance to penicillin combined with plasmid–mediated resistance to tetracycline. Harnett N, et al. **Can Commun Dis Rep** 1995 Aug 15;21(15):139–43 **(Eng, Fre)**

Characterization of the pTFI91–family replicon of Thiobacillus ferrooxidans plasmids. Chakravarty L, et al.

Can J Microbiol 1995 Apr-May;41(4-5):354-65

A physical map of the 85 kb virulence plasmid of Rhodococcus equi 103. de la Peña-Moctezuma A, et al. **Can J Vet Res** 1995 Jul;59(3):229-31

High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Nishi T, et al. **Cancer Res** 1996 Mar 1;56(5):1050-5

A secretion expression system using promoter and signal peptide of cholera toxin B subunit gene. Cao C, et al. **Chin J Biotechnol** 1995;11(2):79-86

High-level expression of human beta-interferon gene in the silkworm with new constructed BmNPV vector. Deng J, et al. **Chin J Biotechnol** 1995;11(2):109-17

High-level expression of the human tumor necrosis factor-alpha. Lü Z, et al. **Chin J Biotechnol** 1995; 11(1):37-44

Autonomous replication in Drosophila melanogaster tissue culture cells. Smith JG, et al. **Chromosoma** 1995 May; 103(9):597-605

Biology and clinical significance of virulence plasmids in Salmonella serovars. Guiney DG, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S146-51 (37 ref.)

Recombinant mitochondrial plasmids in Neurospora composed of Varkud and a new multimeric mitochondrial plasmid. Arganoza MT, et al. **Curr Genet** 1995 Dec; 29(1):34-43

The dynamics of mitochondrial plasmids in a Hawaiian population of Neurospora intermedia. Debets F, et al. **Curr Genet** 1995 Dec;29(1):44-9

Migration of the yeast linear DNA plasmid from the cytoplasm into the nucleus in Saccharomyces cerevisiae. Gunge N, et al. **Curr Genet** 1995 Aug;28(3):280-8

Induction of longevity by cytoplasmic transfer of a linear plasmid in Podospora anserina. Hermanns J, et al. **Curr Genet** 1996 Feb;29(3):250-6

Presence of a P1 bacteriophage sequence in transforming plasmids of Pleurotus ostreatus. Herzog RW, et al. **Curr Genet** 1995 Apr;27(5):460-5

The replication origin position and its relationship to a negative trans-acting transcription regulator encoded by Dictyostelium discoideum nuclear plasmid Ddp1. Kiyosawa H, et al. **Curr Genet** 1995 Apr;27(5):479-85

Nature of abortive transformation in Saccharomyces cerevisiae. Yap WY, et al. **Curr Genet** 1995 Nov; 28(6):517-20

Transformation of naturally competent Streptococcus mutans with replicative and non-replicative Tn916-containing plasmids: implications for a mechanism of transposition. Caufield PW, et al. **Dev Biol Stand** 1995;85:19-25

Pheromone-inducible gene regulation and signalling for the control of aggregation substance expression in the conjugative plasmid pCF10. Leonard BA, et al. **Dev Biol Stand** 1995;85:27-34

Characterization of the conjugation system associated with the Lactococcus lactis ssp. lactis plasmid pRS01. Mills DA, et al. **Dev Biol Stand** 1995;85:543-8

Cloning and characterization of the uvr (ultraviolet resistance) gene on conjugative plasmid pAD1 of Enterococcus faecalis. Tanimoto K, et al. **Dev Biol Stand** 1995;85:83-7

Enterococcus faecalis plasmid pAD1 replication and maintenance. Weaver KE. **Dev Biol Stand** 1995;85:89-98

Plasmid-mediated oligopeptide transport system in lactococci. Yu W, et al. **Dev Biol Stand** 1995;85:509-21

Plasmid insertional mutation may confer glucocorticoid responsiveness of cell growth. Chen GS, et al. **DNA Cell Biol** 1996 Feb;15(2):125-32

Evolution of the replication regions of IncI alpha and IncFII plasmids by exchanging their replication control systems. Kato A, et al. **DNA Res** 1994;1(5):201-12

IS1-mediated intramolecular rearrangements: formation of excised transposon circles and replicative deletions. Turlan C, et al. **EMBO J** 1995 Nov 1;14(21):5410-21

Enhancement of the polycation-mediated DNA uptake and cell transfection with Pluronic P85 block copolymer. Astafieva I, et al. **FEBS Lett** 1996 Jul 8;389(3):278-80

A dnaA box can functionally substitute for the priming signals in the oriV of the broad host-range plasmid RSF1010. Taguchi Y, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):169-72

Isolation and characterization of pLS1 plasmid mutants with increased copy numbers. Acebo P, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):85-91

Site-specific recombination in gram-positive theta-replicating plasmids. Alonso JC, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):1-10 (28 ref.)

Linear DNA plasmids of yeasts. Fukuhara H. **FEMS Microbiol Lett** 1995 Aug 15;131(1):1-9 (32 ref.)

Identification of the genes in multicopy plasmids affecting ompC and ompF expression in Escherichia coli. Jin T, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):225-31

Identification of the replication region of Lactobacillus acidophilus plasmid pLA103. Kanatani K, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1-2):127-30

Genomic heterogeneity in Chlorobium limicola: chromosomic and plasmidic differences among strains. Méndez-Alvarez S, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):279-85

Transfer of the IncJ plasmid R391 to recombination deficient Escherichia coli K12: evidence that R391 behaves as a conjugal transposon. Murphy DB, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):153-8

Giant linear plasmids of beta-lactam antibiotic producing Streptomyces. Netolitzky DJ, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):27-34

Dissection of the Yersinia enterocolitica virulence plasmid pYVO8 into an operating unit and virulence gene modules. Roggenkamp A, et al. **FEMS Microbiol Lett** 1995 Dec 1; 134(1):69-73

In vivo intermolecular recombination in Escherichia coli: application to plasmid constructions. Degryse E. **Gene** 1996 Apr 17;170(1):45-50

Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an Enterococcus faecium sex pheromone-response plasmid. Heaton MP, et al. **Gene** 1996 May 24;171(1):9-17

Genetic organization of a small cryptic plasmid of Helicobacter pylori. Heuermann D, et al. **Gene** 1995 Nov 7;165(1):17-24

A novel Escherichia coli lipoprotein expression vector. Jones TS, et al. **Gene** 1995 Nov 7;165(1):145-6

Construction of a series of pACYC-derived plasmid vectors. Nakano Y, et al. **Gene** 1995 Aug 30;162(1):157-8

Genetic organization of a DNA-processing region required for mobilization of a non-self-transmissible plasmid, pEC3, isolated from Erwinia carotovora subsp. carotovora. Nomura N, et al. **Gene** 1996 Apr 17;170(1):57-62

New plasmids carrying antibiotic-resistance cassettes. Reece KS, et al. **Gene** 1995 Nov 7;165(1):141-2

Sites for co-integration of large staphylococcal plasmids. Sohail M, et al. **Gene** 1995 Aug 30;162(1):63-8

New multifunctional Escherichia coli-Streptomyces shuttle vectors allowing blue-white screening on XGal plates. Wehmeier UF. **Gene** 1995 Nov 7;165(1):149-50

Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Liang X, et al. **Gene Ther** 1996 Apr;3(4):350-6

Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Scaria A, et al. **Gene Ther** 1995 Jun;2(4):295-8

Electroporation-mediated transfection of mammalian cells with crude plasmid DNA preparations. Tatsuka M, et al. **Genet Anal** 1995 Oct;12(2):113-7

Inheritance of mitochondrial DNA and plasmids in the ascomycetous fungus, Epichloë typhina. Chung KR, et al. **Genetics** 1996 Jan;142(1):259-65

Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Cao L, et al. **Hum Gene Ther** 1995 Nov;6(11):1497-501

A plasmid-based self-amplifying Sindbis virus vector. Herweijer H, et al. **Hum Gene Ther** 1995 Sep;6(9):1161-7

Chimeric plasmid transformation in Haemophilus influenzae. Khalap NV, et al. **Indian J Exp Biol** 1996 Apr;34(4):382-3

A rapid method for the preparation of plasmid DNA. Srivastava N. **Indian J Exp Biol** 1995 May;33(5):387-91

Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7. Bauer ME, et al. **Infect Immun** 1996 Jan;64(1):167-75

Characterization of the type strain of Campylobacter coli, CIP 70.80, by plasmid typing. Stonnet V, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):592-4

Characterization of atypical Aeromonas salmonicida isolates by ribotyping and plasmid profiling. Pedersen K, et al. **J Appl Bacteriol** 1996 Jan;80(1):37-44

The conjugal transfer system of Agrobacterium tumefaciens octopine-type Ti plasmids is closely related to the transfer system of an IncP plasmid and distantly related to Ti plasmid vir genes. Alt-Mörbe J, et al. **J Bacteriol** 1996 Jul;178(14):4248-57

The tra region of the nopaline-type Ti plasmid is a chimera with elements related to the transfer systems of RSF1010, RP4, and F. Farrand SK, et al. **J Bacteriol** 1996 Jul; 178(14):4233-47

Physical mapping of the conjugative bacteriocin plasmid pPD1 of Enterococcus faecalis and identification of the determinant related to the pheromone response. Fujimoto S, et al. **J Bacteriol** 1995 Oct;177(19):5574-81

Temperature affects the T-DNA transfer machinery of Agrobacterium tumefaciens. Fullner KJ, et al. **J Bacteriol** 1996 Mar;178(6):1498-504

Nucleotide sequence and characterization of the trbABC region of the IncI1 Plasmid R64: existence of the pnd gene for plasmid maintenance within the transfer region. Furuya N, et al. **J Bacteriol** 1996 Mar;178(6):1491-7

Expression of the TOL plasmid xylS gene in Pseudomonas putida occurs from a alpha 70-dependent promoter or from alpha 70- and alpha 54-dependent tandem promoters according to the compound used for growth. Gallegos MT, et al. **J Bacteriol** 1996 Apr;178(8):2356-61

Structure and organization of plasmid genes required to produce the translation inhibitor microcin C7. González-Pastor JE, et al. **J Bacteriol** 1995 Dec; 177(24):7131-40

In vitro binding of the Salmonella dublin virulence plasmid regulatory protein SpvR to the promoter regions of spvA and spvR. Grob P, et al. **J Bacteriol** 1996 Apr; 178(7):1813-20

Phase variation of Enterococcus faecalis pAD1 conjugation functions relates to changes in iteron sequence region. Heath DG, et al. **J Bacteriol** 1995 Oct;177(19):5453-9

Identification and analysis of the dissimilatory nitrous oxide reduction genes, nosRZDFY, of Rhizobium meliloti. Holloway P, et al. **J Bacteriol** 1996 Mar;178(6):1505-14

Purification and characterization of catabolic mannopine cyclase encoded by the Agrobacterium tumefaciens Ti plasmid pTi15955. Hong SB, et al. **J Bacteriol** 1996 Apr; 178(8):2427-30

Plasmid RK2 toxin protein ParE: purification and interaction with the ParD antitoxin protein. Johnson EP, et al. **J Bacteriol** 1996 Mar;178(5):1420-9

A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. Law J, et al. **J Bacteriol** 1995 Dec;177(24):7011-8

Characterization of the primary immunity region of the Escherichia coli linear plasmid prophage N15. Lobocka MB, et al. **J Bacteriol** 1996 May;178(10):2902-10

Genes encoding the pKM101 conjugal mating pore are negatively regulated by the plasmid-encoded KorA and KorB proteins. Moré MI, et al. **J Bacteriol** 1996 Aug; 178(15):4392-9

In vitro recognition of the replication origin of pLS1 and of plasmids of the pLS1 family by the RepB initiator protein. Moscoso M, et al. **J Bacteriol** 1995 Dec; 177(24):7041-9

Cloning and characterization of a region of Enterococcus faecalis plasmid pPD1 encoding pheromone inhibitor (ipd), pheromone sensitivity (traC), and pheromone shutdown (traB) genes. Nakayama J, et al. **J Bacteriol** 1995 Oct; 177(19):5567-73

Periplasmic location of the pesticin immunity protein suggests inactivation of pesticin in the periplasm. Pilsl H, et al. **J Bacteriol** 1996 Apr;178(8):2431-5

Lethality and survival of Klebsiella oxytoca evoked by conjugative IncN group plasmids. Rodriguez M, et al. **J Bacteriol** 1995 Nov;177(22):6352-61

Identification and properties of a novel clt locus in the Streptomyces phaechromogenes plasmid pJV1. Servín-González L. **J Bacteriol** 1996 Jul;178(14):4323-6

Mechanism of retrotransfer in conjugation: prior transfer of the conjugative plasmid is required. Sia EA, et al. **J Bacteriol** 1996 Mar;178(5):1457-64

Novel alleles of the Escherichia coli dnaA gene are defective in replication of pSC101 but not of oriC. Sutton MD, et al. **J Bacteriol** 1995 Nov;177(22):6657-65

Identification and functional analysis of the transfer region of plasmid pMEA300 of the methylotrophic actinomycete Amycolatopsis methanolica. Vrijbloed JW, et al. **J Bacteriol** 1995 Nov;177(22):6499-505

Molecular cloning with a pMEA300-derived shuttle vector and characterization of the Amycolatopsis methanolica prephenate dehydratase gene. Vrijbloed JW, et al. **J Bacteriol** 1995 Nov;177(22):6666-9

A ColE1-encoded gene directs entry exclusion of the plasmid. Yamada Y, et al. **J Bacteriol** 1995 Nov; 177(21):6064-8

Plasmid recombination by the RecBCD pathway of Escherichia coli. Zaman MM, et al. **J Bacteriol** 1996 Jul; 178(13):3840-5

Homology among nearly all plasmids infecting three Bacillus species. Zawadzki P, et al. **J Bacteriol** 1996 Jan; 178(1):191-8

Circular and linear plasmids of Lyme disease spirochetes have extensive homology: characterization of a repeated DNA element. Zückert WR, et al. **J Bacteriol** 1996 Apr; 178(8):2287-98

Construction of a plasmid used for the expression of a sevenfold-mutant barley beta-amylase with increased thermostability in Escherichia coli and properties of the sevenfold-mutant beta-amylase. Yoshigi N, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):562-7

Autoregulation of the plasmid addiction operon of bacteriophage P1. Magnuson R, et al. **J Biol Chem** 1996 Aug 2;271(31):18705-10

Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. Chaves F, et al. **J Clin Microbiol** 1996 May;34(5):1118-23

In vivo stability and discriminatory power of methicillin-resistant Staphylococcus aureus typing by restriction endonuclease analysis of plasmid DNA compared with those of other molecular methods. Hartstein AI, et al. **J Clin Microbiol** 1995 Aug;33(8):2022-6

Analysis and comparison of plasmid profiles of Borrelia burgdorferi sensu lato strains. Xu Y, et al. **J Clin Microbiol** 1995 Oct;33(10):2679-85

Klebsiella pneumoniae infections in Greek hospitals. Dissemination of plasmids encoding an SHV-5 type beta-lactamase. Legakis NJ, et al. **J Hosp Infect** 1995 Nov; 31(3):177-87

Plasmid R6K contains two functional oriTs which can assemble simultaneously in relaxosomes in vivo. Avila P, et al. **J Mol Biol** 1996 Aug 16;261(2):135-43

An unusually long-lived antisense RNA in plasmid copy number control: in vivo RNAs encoded by the streptococcal plasmid pIP501. Brantl S, et al. **J Mol Biol** 1996 Jan 19;255(2):275-88

Replication of plasmid R6K gamma origin in vivo and in vitro: dependence on IHF binding to the ihf1 site. Dellis S, et al. **J Mol Biol** 1996 Apr 5;257(3):550-60

Uneven distribution of GATC motifs in the Escherichia coli chromosome, its plasmids and its phages. Hénaut A, et al. **J Mol Biol** 1996 Apr 5;257(3):574-85

Cooperative and anticooperative effects in binding of the first and second plasmid Osym operators to a LacI tetramer: evidence for contributions of non-operator DNA binding by wrapping and looping. Levandoski MM, et al.

J Mol Biol 1996 Aug 2;260(5):697–717
P1 plasmid partition: a mutational analysis of ParB. Lobocka M, et al. **J Mol Biol** 1996 Jun 14;259(3):366–82
Physical and functional analysis of the prokaryotic enhancer of the sigma 54–promoters of the TOL plasmid of Pseudomonas putida. Pérez-Martín J, et al. **J Mol Biol** 1996 May 17;258(4):562–74
Dissection of the core and auxiliary sequences in the vegetative replication origin of promiscuous plasmid RK2. Shah DS, et al. **J Mol Biol** 1995 Dec 8;254(4):608–22
Nucleosomal arrangement of HIV–1 DNA: maps generated from an integrated genome and an EBV–based episomal model. Stanfield–Oakley SA, et al. **J Mol Biol** 1996 Mar 1;256(3):503–16
Distribution of restriction enzyme recognition sequences on broad host range plasmid RP4: molecular and evolutionary implications. Wilkins BM, et al. **J Mol Biol** 1996 May 10; 258(3):447–56
Construction of shuttle expression plasmid and stable expression of foreign gene in mycobacteria and E. coli. Huangfu YM, et al. **J Tongji Med Univ** 1995;15(3):138–42
One–step purification of recombinant proteins with the 6xHis tag and Ni–NTA resin. Crowe J, et al. **Methods Mol Biol** 1996;58:491–510
The rapid boiling method for small–scale preparation of plasmid DNA. Harwood AJ. **Methods Mol Biol** 1996; 58:265–7
Preparation of plasmid DNA using alkaline lysis. Joly E. **Methods Mol Biol** 1996;58:257–63
Plasmid preparations with diatomaceous earth. Machesky L. **Methods Mol Biol** 1996;58:269–72
Site–directed mutagenesis of double–stranded plasmids, domain substitution, and marker rescue by comutagenesis of restriction enzyme sites. Nickoloff JA, et al. **Methods Mol Biol** 1996;58:455–68
Introduction of cloning plasmids into Agrobacterium tumefaciens. Shaw CH. **Methods Mol Biol** 1995;49:33–7 (14 ref.)
Subcloning strategies and protocols. Taghian DG, et al. **Methods Mol Biol** 1996;58:221–35
Cloning PCR products using T–vectors. Trower MK, et al. **Methods Mol Biol** 1996;58:313–24
A protocol for site–directed mutagenesis employing a uracil–containing phagemid template. Trower MK. **Methods Mol Biol** 1996;58:469–76
Mutual adaptation of bacteriophage fd, pfd plasmids and their host strains. Geider K, et al. **Microbiol Res** 1995 Nov; 150(4):337–46
Natural plasmids of filamentous fungi. Griffiths AJ. **Microbiol Rev** 1995 Dec;59(4):673–85 (102 ref.)
Plasmid transfer during growth and survival of Escherichia coli. Muela A. **Microbiologia** 1995 Sep;11(3):369–72
High frequency of conjugation versus plasmid segregation of RP1 in epiphytic Pseudomonas syringae populations. Björklöf K, et al. **Microbiology** 1995 Oct;141 (Pt 10):2719–27
Distribution of the ardA family of antirestriction genes on conjugative plasmids. Chilley PM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2157–64
A plasmid encoding enzymes for nylon oligomer degradation: nucleotide sequence and analysis of pOAD2. Kato K, et al. **Microbiology** 1995 Oct;141 (Pt 10):2585–90
The 4–hydroxy–2–oxovalerate aldolase and acetaldehyde dehydrogenase (acylating) encoded by the nahM and nahO genes of the naphthalene catabolic plasmid pWW60–22 provide further evidence of conservation of meta–cleavage pathway gene sequences. Platt A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2223–33
The DNA and RNA polymerase genes of yeast plasmid pGKL2 are essential loci for plasmid integrity and maintenance. Schaffrath R, et al. **Microbiology** 1995 Oct; 141 (Pt 10):2591–9
Sequence and functional analysis of the Streptomyces phaeochromogenes plasmid pJV1 reveals a modular organization of Streptomyces plasmids that replicate by rolling circle. Servín–González L, et al. **Microbiology** 1995 Oct;141 (Pt 10):2499–510
The use of two–dimensional gradient plates to investigate the range of conditions under which conjugal plasmid transfer occurs. Venables WA, et al. **Microbiology** 1995 Oct;141 (Pt 10):2713–8
Stable episomal transfection of Entamoeba histolytica. Vines RR, et al. **Mol Biochem Parasitol** 1995 May;71(2):265–7
Genetic analysis of the effects of re–transformation of transgenic lines of the moss Physcomitrella patens. Kammerer W, et al. **Mol Gen Genet** 1996 Feb 25; 250(3):380–2
Genome mapping of Clostridium perfringens strains with I–CeuI shows many virulence genes to be plasmid–borne. Katayama S, et al. **Mol Gen Genet** 1996 Jul 26;251(6):720–6
Replication properties of ARS1 plasmids in Saccharomyces cerevisiae: dependence on the carbon source. Kirpekar F, et al. **Mol Gen Genet** 1996 Jul 26;251(6):716–9
Roa307, a protein encoded on Coxiella burnetii plasmid QpH1, shows homology to proteins encoded in the replication origin region of bacterial chromosomes. Lin Z, et al. **Mol Gen Genet** 1995 Aug 30;248(4):487–90
Two overlapping SOS–boxes in ColE operons are responsible for the viability of cells harboring the Col plasmid. Lu FM, et al. **Mol Gen Genet** 1996 Jun 24;251(4):407–11
Translational coupling and limited degradation of a polycistronic messenger modulate differential gene expression in the parD stability system of plasmid R1. Ruiz–Echevarría MJ, et al. **Mol Gen Genet** 1995 Sep 20; 248(5):599–609
Yeast killer plasmid pGKL2: molecular analysis of UCS5, a cytoplasmic promoter element essential for ORF5 gene function. Schaffrath R, et al. **Mol Gen Genet** 1996 Feb 25; 250(3):286–94
Identification of a partition and replication region in the Alcaligenes eutrophus megaplasmid pMOL28. Taghavi S, et al. **Mol Gen Genet** 1996 Feb 5;250(2):169–79
Analysis of Tn5 inversion events in Escherichia coli plasmids. Weber PC. **Mol Gen Genet** 1995 Aug 30;248(4):459–70
Characterization and regulation of the expression of FatB, an iron transport protein encoded by the pJM1 virulence plasmid. Actis LA, et al. **Mol Microbiol** 1995 Jul; 17(1):197–204
Rearrangements in the staphylococcal beta–lactamase–encoding plasmid, pIP1066, including a DNA inversion that generates two alternative transposons. Derbise A, et al. **Mol Microbiol** 1995 Aug;17(4):769–79
Organization of host–inducible transcripts on the symbiotic plasmid of Rhizobium sp. NGR234. Fellay R, et al. **Mol Microbiol** 1995 May;16(4):657–67
Plasmid pT181 replication is decreased at high levels of RepC per plasmid copy. Iordanescu S. **Mol Microbiol** 1995 May; 16(3):477–84
Programmed cell death in bacteria: proteic plasmid stabilization systems. Jensen RB, et al. **Mol Microbiol** 1995 Jul;17(2):205–10 (48 ref.)
Identification and characterization of a novel type of replication terminator with bidirectional activity on the Bacillus subtilis theta plasmid pLS20. Meijer WJ, et al. **Mol Microbiol** 1996 Mar;19(6):1295–306
The endogenous Bacillus subtilis (natto) plasmids pTA1015 and pTA1040 contain signal peptidase–encoding genes: identification of a new structural module on cryptic plasmids. Meijer WJ, et al. **Mol Microbiol** 1995 Aug; 17(4):621–31
An Agrobacterium virulence factor encoded by a Ti plasmid gene or a chromosomal gene is required for T–DNA transfer into plants. Pan SQ, et al. **Mol Microbiol** 1995 Jul; 17(2):259–69
A cytoplasmic gene–shuffle system in Kluyveromyces lactis: use of epitope tagging to detect a killer plasmid–encoded gene product. Schaffrath R, et al. **Mol Microbiol** 1996 Feb; 19(3):545–54
Identification of a novel virulence gene, virA, on the large plasmid of Shigella, involved in invasion and intercellular spreading. Uchiya K, et al. **Mol Microbiol** 1995 Jul; 17(2):241–50
Transcription–induced deletions in Escherichia coli plasmids. Vilette D, et al. **Mol Microbiol** 1995 Aug;17(3):493–504
Identification of the minimal replicon of plasmid pMEA300 of the methylotrophic actinomycete Amycolatopsis methanolica. Vrijbloed JW, et al. **Mol Microbiol** 1995 Oct; 18(1):21–31
Evaluation of a plasmid–based transgenic mouse model for detecting in vivo mutations. Dollé ME, et al. **Mutagenesis** 1996 Jan;11(1):111–8
Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Hoffman GR, et al. **Mutat Res** 1996 Mar 26; 351(1):33–43
A plasmid–encoded dihydrofolate reductase from trimethoprim–resistant bacteria has a novel D2–symmetric active site. Narayana N, et al. **Nat Struct Biol** 1995 Nov; 2(11):1018–25
Polymorphism of rRNA genes and plasmid analysis in the typing of Salmonella enterica serovar enteritidis from a Spanish health area. Gonzalez Hevia MA, et al. **New Microbiol** 1995 Oct;18(4):377–84
Specific binding of the replication protein of plasmid pPS10 to direct and inverted repeats is mediated by an HTH motif. García de Viedma D, et al. **Nucleic Acids Res** 1995 Dec 25;23(24):5048–54
A new horizon for pBR322: in vivo insertion of plasmid fragments into wide host range shuttle vectors. Kok M. **Nucleic Acids Res** 1995 Dec 25;23(24):5085–6
A strategy for quickly identifying all unique two–hybrid or library plasmids within a pool of yeast transformants. Patterson TE, et al. **Nucleic Acids Res** 1995 Oct 25; 23(20):4222–3
Disposition characteristics of plasmid DNA in the single–pass rat liver perfusion system. Yoshida M, et al. **Pharm Res** 1996 Apr;13(4):599–603
Electrotransformation of highly DNA–restrictive corynebacteria with synthetic DNA. Ankri S, et al. **Plasmid** 1996 Jan;35(1):62–6
Use of a DNA polymerase III bypass mutant of Escherichia coli, pcbA1, to isolate potentially useful mutations of a complex plasmid replicon. Banerjee S, et al. **Plasmid** 1996 Jan;35(1):58–61
Sequence analysis of an Erwinia stewartii plasmid, pSW100. Fu JF, et al. **Plasmid** 1995 Sep;34(2):75–84
Characterization of the replicon from the lactococcal theta–replicating plasmid pJW563. Gravesen A, et al. **Plasmid** 1995 Sep;34(2):105–18
Genetic analysis of the minimal replicon of plasmid pIP417 and comparison with the other encoding 5–nitroimidazole resistance plasmids from Bacteroides spp. Haggoud A, et al. **Plasmid** 1995 Sep;34(2):132–43
Identification and characterization of the genes of Enterococcus faecalis plasmid pCF10 involved in replication and in negative control of pheromone–inducible conjugation. Hedberg PJ, et al. **Plasmid** 1996 Jan; 35(1):46–57
Complete nucleotide sequence of the Sulfolobus islandicus multicopy plasmid pRN1. Keeling PJ, et al. **Plasmid** 1996 Mar;35(2):141–4
Multidrug resistance plasmid pSK108 from coagulase–negative staphylococci; relationships to Staphylococcus aureus qacC plasmids. Leelaporn A, et al. **Plasmid** 1995 Jul;34(1):62–7
Characterization of a 3.5–kbp plasmid from Helicobacter pylori. Minnis JA, et al. **Plasmid** 1995 Jul;34(1):22–36
Structural organization of pRAM4, a cryptic plasmid from Prevotella ruminicola. Ogata K, et al. **Plasmid** 1996 Mar; 35(2):91–7
Nucleotide sequence and analysis of pWC1, a pC194–type rolling circle replicon in Lactococcus lactis. Pillidge CJ, et al. **Plasmid** 1996 Mar;35(2):131–40
Construction of a cloning vector from a naturally occurring plasmid of Salmonella typhimurium. Roy RK, et al. **Plasmid** 1995 Sep;34(2):144–7
Development of a heterodimer plasmid system for the introduction of heterologous genes into streptococci. Shiroza T, et al. **Plasmid** 1995 Sep;34(2):85–95
Isolation and characterization of a novel insertion sequence element, IS1248, in Paracoccus denitrificans. Van Spanning RJ, et al. **Plasmid** 1995 Jul;34(1):11–21
Transformation of the methylotrophic actinomycete Amycolatopis methanolica with plasmid DNA: stimulatory effect of a pMEA300–encoded gene. Vrijbloed JW, et al. **Plasmid** 1995 Sep;34(2):96–104
Copy–up mutants of the plasmid RK2 replication initiation protein are defective in coupling RK2 replication origins. Blasina A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16; 93(8):3559–64
Characterization of non–virulence plasmids with homology to the virulence plasmid of Salmonella dublin. Aabo S, et al. **Res Microbiol** 1995 Nov–Dec;146(9):751–9
Mu transposase–stimulated illegitimate recombination of Tn3kan– and IS101–containing plasmids. Cameron RK, et al. **Res Microbiol** 1995 Oct;146(8):601–16
Molecular tools for the study of transcriptional regulation in Bacillus anthracis. Sirard JC, et al. **Res Microbiol** 1995 Nov–Dec;146(9):729–37
Pilus assembly by Agrobacterium T–DNA transfer genes. Fullner KJ, et al. **Science** 1996 Aug 23;273(5278):1107–9
Polynucleotide–mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)
In vivo cloning by homologous recombination in yeast using a two–plasmid–based system. Degryse E, et al. **Yeast** 1995 Jun 15;11(7):629–40
Kluyveromyces lactis killer plasmid pGKL2: molecular analysis of an essential gene, ORF5. Schaffrath R, et al. **Yeast** 1995 Jun 15;11(7):615–28
Analysis of copper–induced metallothionein expression using autonomously replicating plasmids in Candida glabrata. Thorvaldsen JL, et al. **Yeast** 1995 Dec;11(15):1501–11
The maintenance of self–replicating plasmids in Saccharomyces cerevisiae: mathematical modelling, computer simulations and experimental tests. Van der Sand ST, et al. **Yeast** 1995 Jun 15;11(7):641–58
Genes leave their characteristic marks on the melting profile of plasmid DNAs. Zubrzycki IZ, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):652–5
[Functional properties of a new line of immortalized human endothelial cells] Moldovan F, et al. **C R Acad Sci III** 1995 Sep;318(9):951–8 (Eng. Abstr.) **(Fre)**
[beta–Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov–Dec;146(9):761–71 (40 ref.) (Eng. Abstr.) **(Fre)**
[Genetic regulation of plasmid transfer] Pekhov AP, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):6–12 (37 ref.) **(Rus)**
[Killer genes from the leader region of conjugated plasmid R100 (incFII)] Zavil'gel'skiĭ GB, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):577–84 **(Rus)**
[Determinant of plasmid pBS221 resistance to potassium tellurite] Anisimova LA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):36–40 (Eng. Abstr.) **(Rus)**
[The characteristics of the interaction of Bacillus anthracis with host phagocytes in relation to the plasmid spectrum of the causative agent] Popov SF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):13–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Distribution, gene sequence and expression in vivo of the plasmid encoded fimbrial antigen of Salmonella serotype Enteritidis. Woodward MJ, et al. **Epidemiol Infect** 1996 Aug;117(1):17–28
DNA vaccines: what can we expect? Siegrist CA, et al. **Infect Agents Dis** 1996 Jan;5(1):55–9 (19 ref.)
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Raz E, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5141–5
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Sato Y, et al. **Science** 1996 Jul 19;273(5273):352–4

PLASMIDS

ISOLATION & PURIFICATION

A plasmid purification scheme for characterization of small fragments cloned into vectors. Benore-Parsons M, et al. **Anal Biochem** 1995 Oct 10;231(1):267-9

A filtration method for plasmid isolation using microtiter filter plates. Ruppert A, et al. **Anal Biochem** 1995 Sep 1; 230(1):130-4

Detection of "lost" plasmids from Escherichia coli using excess ampicillin. Wright AD, et al. **Anal Biochem** 1996 Apr 5;236(1):181-2

A method for purification of DNA species by high-speed centrifugation of agarose gel slices. Wu W, et al. **Anal Biochem** 1995 Aug 10;229(2):350-2

Detection and characterization of broad-host-range plasmids in environmental bacteria by PCR. Götz A, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2621-8

Construction of an integrative shuttle vector for Zymomonas mobilis. Delgado OD, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):23-6

Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Cotten M, et al. **Gene Ther** 1994 Jul;1(4):239-46

The virgin population of Neisseria gonorrhoeae in Stockholm has decreased and antimicrobial resistance is increasing. Bäckman M, et al. **Genitourin Med** 1995 Aug;71(4):234-8

Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials [see comments] Horn NA, et al. **Hum Gene Ther** 1995 May;6(5):565-73. Comment in: Hum Gene Ther 1995 May;6(5):549-50. Comment in: Hum Gene Ther 1995 May;6(5):551-2.

A rapid plasmid purification method for dideoxy sequencing. Griffin AM, et al. **Methods Mol Biol** 1996;58:367-71

Plasmid profile typing and plasmid fingerprinting. Threlfall EJ, et al. **Methods Mol Biol** 1995;46:225-36

Preparation of bacterial plasmid DNA. Tully M. **Methods Mol Biol** 1995;46:213-23

Formation of UV-photoadducts during DNA purification. Widlak P, et al. **Mutat Res** 1995 Aug;347(3-4):117-9

Ligation of nonmatching DNA molecule ends. Cimmino C, et al. **Plasmid** 1995 Jul;34(1):1-10

Characterization of the plasmid pMB1 from Bifidobacterium longum and its use for shuttle vector construction. Rossi M, et al. **Res Microbiol** 1996 Mar-Apr;147(3):133-43

Association with HeLa cells by Rhodococcus equi with and without the virulence plasmid. de la Peña-Moctezuma A, et al. **Vet Microbiol** 1995 Oct;46(4):383-92

METABOLISM

Mycobacterial DNA gyrase: enzyme purification and characterization of supercoiling activity. Wu LC, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):123-9

Decrease in the linking number of plasmid DNA in dnaA mutants of Escherichia coli. Mizushima T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):137-41

Human immunodeficiency virus type 1 integrase stabilizes a linearized HIV-1 LTR plasmid in vivo. Faust EA, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):745-58

RepD/D*: a protein-DNA adduct arising during plasmid replication. Thomas CD, et al. **Biochem Soc Trans** 1995 Aug;23(3):442S

Energy coupling in Escherichia coli DNA gyrase: the relationship between nucleotide binding, strand passage, and DNA supercoiling. Bates AD, et al. **Biochemistry** 1996 Feb 6;35(5):1408-16

P1 and P7 plasmid partition: ParB protein bound to its partition site makes a separate discriminator contact with the DNA that determines species specificity. Radnedge L, et al. **EMBO J** 1996 Mar 1;15(5):1155-62

Buffer composition mediates a switch between cooperative and independent binding of an initiator protein to DNA. Urh M, et al. **Gene** 1995 Oct 16;164(1):1-7

Interactions of the origin of replication (oriV) and initiation proteins (TrfA) of plasmid RK2 with submembrane domains of Escherichia coli. Mei J, et al. **J Bacteriol** 1995 Dec;177(23):6766-72

DNA binding by the coliphage 186 repressor protein CI. Dodd IB, et al. **J Biol Chem** 1996 May 10;271(19):11532-40

Ku80-deficient cells exhibit excess degradation of extrachromosomal DNA. Liang F, et al. **J Biol Chem** 1996 Jun 14;271(24):14405-11

Strand specificity of nicking of DNA at Chi sites by RecBCD enzyme. Modulation by ATP and magnesium levels. Taylor AF, et al. **J Biol Chem** 1995 Oct 13;270(41):24459-67

Sequential coupling between COPII and COPI vesicle coats in endoplasmic reticulum to Golgi transport. Aridor M, et al. **J Cell Biol** 1995 Nov;131(4):875-93

In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. Mahato RI, et al. **J Drug Target** 1995;3(2):149-57

Determination of sequence specificity between a plasmid replication initiator protein and the origin of replication. Thomas CD, et al. **J Mol Biol** 1995 Dec 1;254(3):381-91

The plasmid replicator AMA1 in Aspergillus nidulans in an inverted duplication of a low-copy-number dispersed genomic repeat. Aleksenko A, et al. **Mol Microbiol** 1996 Feb;19(3):565-74

Rec-A protein-mediated irreversible fixation of an oligodeoxyribonucleotide to specific site in DNA. Golub EI, et al. **Mutat Res** 1996 Apr 13;351(2):117-24

RecA.oligonucleotide filaments bind in the minor groove of double-stranded DNA. Baliga R, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10393-7

Linker histones affect patterns of digestion of supercoiled plasmids by single-strand-specific nucleases. Ivanchenko M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6970-4

[The binding of exogenous DNA pRK31acZ by rabbit spermatozoa, its transfer to oocytes and expression in preimplantation embryos] Kuznetsov AV, et al. **Ontogenez** 1995 Jul-Aug;26(4):300-9 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice [see comments] Lew D, et al. **Hum Gene Ther** 1995 May;6(5):553-64. Comment in: Hum Gene Ther 1995 May;6(5):549-50. Comment in: Hum Gene Ther 1995 May;6(5):551-2.

PHYSIOLOGY

Phenotypic and immunologic factors affecting plasmid-mediated in vivo gene transfer to rat diaphragm. Petrof BJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L1023-30

The effect of plasmid acquisition on potential virulence attributes of Pasteurella multocida. Lee MD, et al. **Avian Dis** 1995 Jul-Sep;39(3):451-7

Sigma s regulates pLS1 maintenance in stationary-phase Escherichia coli. Espinosa-Urgel M, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):45-50

Serum survival and plasmid possession by strains of Salmonella enteritidis, Salm. typhimurium and Salm. virchow. Chart H, et al. **J Appl Bacteriol** 1996 Jan; 80(1):31-6

Gene expression enhancement due to plasmid maintenance. Diaz-Ricci JC, et al. **J Bacteriol** 1995 Nov;177(22):6684-7

Cell-to-cell signaling in the symbiotic nitrogen-fixing bacterium Rhizobium leguminosarum: autoinduction of a stationary phase and rhizosphere-expressed genes. Gray KM, et al. **J Bacteriol** 1996 Jan;178(2):372-6

Stable episomal maintenance of yeast artificial chromosomes in human cells. Simpson K, et al. **Mol Cell Biol** 1996 Sep; 16(9):5117-26

RADIATION EFFECTS

A slot blot method for detection of ultraviolet photoproducts in DNA. Liu X, et al. **Anal Biochem** 1995 Aug 10; 229(2):323-8

Analysis of mutations induced by replication of UV-damaged plasmid DNA in HeLa cell extracts. Carty MP, et al. **Environ Mol Mutagen** 1995;26(2):139-46

Deamination of cytosine-containing pyrimidine photodimers in UV-irradiated DNA. Significance for UV light mutagenesis. Barak Y, et al. **J Biol Chem** 1995 Oct 13; 270(41):24174-9

Complete replication of plasmid DNA containing a single UV-induced lesion in human cell extracts. Carty MP, et al. **J Biol Chem** 1996 Apr 19;271(16):9637-47

Adjacent guanines as preferred sites for strand breaks in plasmid DNA irradiated with 193 nm and 248 nm UV laser light. Sies H, et al. **J Photochem Photobiol B** 1996 Jan; 32(1-2):97-102

Effects of vacuum UV and UVC radiation on dry Escherichia coli plasmid pUC19. II. Mutational specificity at the lacZ gene. Wehner J, et al. **J Photochem Photobiol B** 1995 Oct; 30(2-3):171-7

Formation of UV-photoadducts during DNA purification. Widlak P, et al. **Mutat Res** 1995 Aug;347(3-4):117-9

Rejoining of gamma-radiation-induced single-strand breaks in plasmid DNA by human cell extracts: dependence on the concentration of the hydroxyl radical scavenger, Tris. Hodgkins PS, et al. **Radiat Res** 1996 Jan;145(1):24-30

DNA breakage upon K-shell excitation of phosphorus as a model for direct effects in radiation biology. Le Sech C, et al. **Radiat Res** 1996 May;145(5):632-5

Neutron and gamma-radiation sensitivity of plasmid DNA of varying superhelical density. Swenberg CE, et al. **Radiat Res** 1995 Dec;144(3):301-9

THERAPEUTIC USE

Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Habib NA, et al. **Cancer Detect Prev** 1996;20(2):103-7

Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial [editorial; comment] Norman JA, et al. **Hum Gene Ther** 1995 May;6(5):549-50. Comment on: Hum Gene Ther 1995 May;6(5):553-64. Comment on: Hum Gene Ther 1995 May;6(5):565-73. Comment on: Hum Gene Ther 1995 May;6(5):575-90.

TOXICITY

Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates [see comments] Parker SE, et al. **Hum Gene Ther** 1995 May;6(5):575-90. Comment in: Hum Gene Ther 1995 May;6(5):549-50. Comment in: Hum Gene Ther 1995 May;6(5):551-2.

ULTRASTRUCTURE

Analysis of the structure of dimeric DNA catenanes by electron microscopy. Levene SD, et al. **Biophys J** 1995 Sep;69(3):1036-45

Atomic force microscopic study on topological structures of pBR322 DNA. Zhang P, et al. **Sci China C Life Sci** 1996 Feb;39(1):1-7

PLASMIN

ADVERSE EFFECTS

[Pneumonitis in a patient who inhaled a fibrinolysin-deoxyribonuclease mixture] Hasegawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1302-6 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Montes R, et al. **Br J Haematol** 1996 Mar; 92(4):979-85

Mediators of fibrinolysis in orthotopic liver transplantation. Cheema SP, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):24-7

[Plasminogen (PG), plasmin (PM)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:51-4 (20 ref.) **(Jpn)**

[alpha 2-Plasmin inhibitor-plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55-8 (13 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Tranexamic acid use during coronary artery bypass grafting [letter; comment] Rubens F, et al. **Ann Thorac Surg** 1996 Feb;61(2):774-5. Comment on: Ann Thorac Surg 1995 Mar;59(3):671-5.

Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Markland W, et al. **Biochemistry** 1996 Jun 18;35(24):8045-57

Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Meddahi A, et al. **Biochimie** 1995;77(9):703-6

Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. Kobayashi H, et al. **Br J Cancer** 1995 Nov;72(5):1131-7

Relationship between plasmin-trypsin-inhibitory and sialyltransferase activities. Nadkarni S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):465-71

Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid beta-protein precursor. Van Nostrand WE, et al. **J Biol Chem** 1995 Sep 29;270(39):22827-30

TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. Wisniewski HG, et al. **J Immunol** 1996 Feb 15;156(4):1609-15

Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions. Wanaka K, et al. **Thromb Res** 1996 Apr 1;82(1):79-86

Does tranexamic acid decrease bleeding in patients undergoing cardiopulmonary bypass? Connelly NR, et al. **Yale J Biol Med** 1994 Sep-Dec;67(5-6):265-8

BIOSYNTHESIS

The kidney is a major site of alpha(2)-antiplasmin production. Menoud PA, et al. **J Clin Invest** 1996 Jun 1;97(11):2478-84

Cellular receptors in the regulation of plasmin generation. Hajjar KA. **Thromb Haemost** 1995 Jul;74(1):294-301 (113 ref.)

DRUG EFFECTS

Purification and characterization of three alpha 2-antiplasmin and alpha 2-macroglobulin inactivating enzymes from the venom of the Mexican west coast rattlesnake (Crotalus basiliscus). Svoboda P, et al. **Toxicon** 1995 Oct; 33(10):1331-46

ISOLATION & PURIFICATION

Purification and characterization of piscivorase I and II, the fibrinolytic enzymes from eastern cottonmouth moccasin venom (Agkistrodon piscivorus piscivorus). Hahn BS, et al. **Toxicon** 1995 Jul;33(7):929-41

METABOLISM

Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195-207 (64 ref.)

ATP-regulated activity of the plasmin-streptokinase complex: a novel mechanism involving phosphorylation of streptokinase. Serrano RL, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):171-7

Mechanism of potentiation of tissue-type plasminogen activator. Lazos SA, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1071-77

Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Carr ME Jr, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):567-73

Plasmin-catalyzed proteolysis in colorectal neoplasia. Delbaldo C, et al. **Cancer Res** 1995 Oct 15;55(20):4688-95

Stabilization of plasmin by lysine derivatives. Ueshima S, et al. **Clin Chim Acta** 1996 Feb 9;245(1):7-18

Mutational analysis of a plasmin receptor protein expressed by group A streptococci. Winram SB, et al.

Dev Biol Stand 1995;85:199–202

Purification and characterisation of a plasmin-sensitive surface protein of Staphylococcus aureus. Hildén P, et al. **Eur J Biochem** 1996 Mar 15;236(3):904–10

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107–8

Reaction of human alpha2-antiplasmin and plasmin stopped-flow fluorescence kinetics. Christensen U, et al. **FEBS Lett** 1996 May 27;387(1):58–62

Autoproteolysis or plasmin-mediated cleavage of factor Xaalpha exposes a plasminogen binding site and inhibits coagulation. Pryzdial ELG, et al. **J Biol Chem** 1996 Jul 12;271(28):16614–20

The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. Whitelock JM, et al. **J Biol Chem** 1996 Apr 26; 271(17):10079–86

Factors affecting herd milk composition and milk plasmin at four levels of somatic cell counts. Ballou LU, et al. **J Dairy Sci** 1995 Oct;78(10):2186–95

Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci. Christner RB, et al. **J Infect Dis** 1996 Jan; 173(1):104–12

The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Winram SB, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2311–20

Plasmin, fibrin degradation and angiogenesis [letter; comment] [see comments] Thompson WD, et al. **Nat Med** 1996 May;2(5):493. Comment on: Nat Med 1996 Mar;2(3):287–92. Comment in: Nat Med 1996 Jul;2(7):725.

Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Pedersen OD, et al. **Thromb Haemost** 1995 May;73(5):835–40

TAT and PAP in hemodialysis patients: two cats in a bag? [letter] Haznedaroğlu IC, et al. **Thromb Res** 1995 Dec 1; 80(5):447–9

[The effect of calcium 2+ ions on the decomposition of canine and human fibrin(ogen) by (human) plasmin] Wolling H, et al. **Berl Munch Tierarztl Wochenschr** 1995 Oct;108(10):373–9 (Eng. Abstr.) **(Ger)**

[Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):75–6 (Eng. Abstr.) **(Pol)**

[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):86–8 (Eng. Abstr.) **(Pol)**

[The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells] Zhabin SG, et al. **Vopr Med Khim** 1995 May-Jun;41(3):34–7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2 Perides G, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):690–5

Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets. Liu L, et al. **Br J Haematol** 1996 Feb;92(2):458–65

Clearance of human factor XIa-inhibitor complexes in rats. Wuillemin WA, et al. **Br J Haematol** 1996 Jun 2;93(4):950–4

Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Reinartz J, et al. **Exp Cell Res** 1995 Oct;220(2):274–82

Plasmin stimulates expression of endothelin-1 mRNA and endothelin-1 release in vascular endothelial cells. Matsumura Y, et al. **Life Sci** 1996;58(13):1067–74

Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Grainger DJ, et al. **Nat Med** 1995 Sep;1(9):932–7

Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Rabhi-Sabile S, et al. **Thromb Haemost** 1995 Apr; 73(4):693–701

Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. Shi GY, et al. **Thromb Res** 1996 Jan 1;81(1):75–84

[The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells] Zhabin SG, et al. **Vopr Med Khim** 1995 May-Jun;41(3):34–7 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Khalil N, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):252–9

Cuts and scrapes? Plasmin heals! Vassalli JD, et al. **Nat Med** 1996 Mar;2(3):284–5 (13 ref.)

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)

TOXICITY

Endothelial cell injury induced by plasmin in vitro. Okajima K, et al. **J Lab Clin Med** 1995 Oct;126(4):377–84

PLASMINOGEN

ADMINISTRATION & DOSAGE

Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Freitag HJ, et al. **Neuroradiology** 1996 Feb;38(2):181–5

ANALYSIS

[Plasminogen (PG), plasmin (PM)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:51–4 (20 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Inhibition of plasminogen activation by triiodothyronine. al-Roof Higazi A, et al. **Thromb Res** 1995 Nov 15; 80(4):349–55

CEREBROSPINAL FLUID

Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Whitelaw A, et al. **Acta Paediatr** 1995 Aug; 84(8):933–6

CHEMISTRY

Streptokinase contains two independent plasminogen-binding sites. Nihalani D, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1245–54

Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid. Mathews II, et al. **Biochemistry** 1996 Feb 27;35(8):2567–76

Recombinant gene expression and 1H NMR characteristics of the kringle (2 + 3) supermodule: spectroscopic/functional individuality of plasminogen kringle domains. Söhndel S, et al. **Biochemistry** 1996 Feb 20;35(7):2357–64

Interaction of streptokinase and plasminogen. Studied with truncated streptokinase peptides. Young KC, et al. **J Biol Chem** 1995 Dec 8;270(49):29601–6

Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase. Wang J, et al. **Protein Sci** 1995 Sep;4(9):1768–79

Structure and function of microplasminogen: I. Methionine shuffling, chemical proteolysis, and proenzyme activation. Wang J, et al. **Protein Sci** 1995 Sep;4(9):1758–67

DEFICIENCY

Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Ploplis VA, et al. **Circulation** 1995 Nov 1;92(9):2585–93

Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report. Tavola A, et al. **Thromb Res** 1995 Nov 15;80(4):327–31

[Recurrent arterial thromboembolism in hereditary hypoplasminogenaemia] Hagendorff A, et al. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):263–8 (Eng. Abstr.) **(Ger)**

[Thrombotic complication in the course of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome; possible involvement of dysplasminogenemia (plasminogen Tochigi) in the pathogenesis of thrombosis] Takahashi H, et al. **Rinsho Ketsueki** 1996 Mar;37(3):249–54 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Comparison of immunological and functional assays for measurement of soluble fibrin. Dempfle CE, et al. **Thromb Haemost** 1995 Aug;74(2):673–9

Retinoic acid enhances plasminogen activation on the cell surface. Miwa K, et al. **Thromb Res** 1995 Oct 1;80(1):47–56

GENETICS

The distribution of plasminogen (PLG) polymorphism in the Namibian !Kung San and Kavango populations. Nabulsi AJ, et al. **Anthropol Anz** 1996 Jun;54(2):117–20

Recombinant gene expression and 1H NMR characteristics of the kringle (2 + 3) supermodule: spectroscopic/functional individuality of plasminogen kringle domains. Söhndel S, et al. **Biochemistry** 1996 Feb 20;35(7):2357–64

Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Ploplis VA, et al. **Circulation** 1995 Nov 1;92(9):2585–93

A TaqI polymorphism in a gene belonging to the human apoprotein(a)-plasminogen gene family on the telomeric region of chromosome 6 (6q26–27). Magnaghi P, et al. **Clin Genet** 1995 Jun;47(6):330

A recombination event in the closely linked plasminogen and apolipoprotein(a) gene loci. Magnaghi P, et al. **Clin Genet** 1995 Jun;47(6):285–9

Motifs resembling hepatocyte nuclear factor 1 and activator protein 3 mediate the tissue specificity of the human plasminogen gene. Meroni G, et al. **Eur J Biochem** 1996 Mar 1;236(2):373–82

The complete cDNA sequence encoding plasminogen from the European hedgehog (Erinaceus europaeus). Belczewski AR, et al. **Gene** 1996 Jun 1;171(2):271–4

Tissue plasminogen activator mRNA expression in granule neurons coincides with their migration in the developing cerebellum. Friedman GC, et al. **J Comp Neurol** 1995 Oct 2;360(4):658–70

Impaired wound healing in mice with a disrupted plasminogen gene [see comments] Romer J, et al. **Nat Med** 1996 Mar;2(3):287–92. Comment in: Nat Med 1996 May;2(5):493.

METABOLISM

Plasminogen activation on tumor cell surface and its involvement in human leukemia. Tapiovaara H, et al. **Adv Cancer Res** 1996;69:101–33 (317 ref.)

Comparative metabolism of plasminogen glycoforms I and II in the alloxan-diabetic rabbit. Hatton MW, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1017–23

Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2 Perides G, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):690–5

Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Hembrough TA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):763–9

Mechanism of potentiation of tissue-type plasminogen activator. Lazos SA, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1071–77

Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Hervio L, et al. **Biochemistry** 1995 Oct 17;34(41):13353–8

Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. Li XN, et al. **Biochemistry** 1996 May 14;35(19):6080–8

Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Carr ME Jr, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):567–73

RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets. Udvardy M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):481–5

Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Ronday HK, et al. **Br J Rheumatol** 1996 May; 35(5):416–23

Genetic modification of the streptokinase gene to study the interaction of streptokinase with plasminogen. Lizano S, et al. **Dev Biol Stand** 1995;85:195–8

Cloning, sequencing and functional overexpression of the Streptococcus equisimilis H46A gapC gene encoding a glyceraldehyde-3-phosphate dehydrogenase that also functions as a plasmin(ogen)-binding protein. Purification and biochemical characterization of the protein. Gase K, et al. **Eur J Biochem** 1996 Jul 1;239(1):42–51

Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Kost C, et al. **Eur J Biochem** 1996 Mar 1;236(2):682–8

Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. Lijnen HR, et al. **Eur J Biochem** 1995 Nov 15; 234(1):350–7

The importance of the hydrophobic components of the binding energies in the interaction of omega-amino acid ligands with isolated kringle polypeptide domains of human plasminogen. Menhart N, et al. **Int J Pept Protein Res** 1995 Dec;46(6):464–70

Analogs of human plasminogen that are labeled with fluorescence probes at the catalytic site of the zymogen. Preparation, characterization, and interaction with streptokinase. Bock PE, et al. **J Biol Chem** 1996 Jan 12; 271(2):1072–80

Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. Ellis V. **J Biol Chem** 1996 Jun 21;271(25):14779–84

Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. Higazi AAR, et al. **J Biol Chem** 1996 Jul 26;271(30):17650–5

Autoproteolysis or plasmin-mediated cleavage of factor Xaalpha exposes a plasminogen binding site and inhibits coagulation. Pryzdial ELG, et al. **J Biol Chem** 1996 Jul 12;271(28):16614–20

Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. Sakharov DV, et al. **J Biol Chem** 1996 Jan 26;271(4):2133–8

Composite poly(methyl methacrylate-methacrylic acid-2-hydroxyethyl methacrylate) latex for immunoassay. The case of plasminogen. Miksa B, et al. **J Biomater Sci Polym Ed** 1995;7(6):503–13

Carboxypeptidases: new regulators of plasminogen activation in vivo? [editorial; comment] Loskutoff DJ. **J Clin Invest** 1995 Nov;96(5):2104–5. Comment on: J Clin Invest 1995 Nov;96(5):2534–8.

Plasma carboxypeptidases as regulators of the plasminogen system [see comments] Redlitz A, et al. **J Clin Invest** 1995

Nov;96(5):2534–8. Comment in: J Clin Invest 1995 Nov;96(5):2104–5.

Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci. Christner RB, et al. **J Infect Dis** 1996 Jan; 173(1):104–12

Binding of human urokinase type plasminogen activator and plasminogen to Borrelia species. Klempner MS, et al. **J Infect Dis** 1996 Jul;174(1):97–104

Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. De Vries TJ, et al. **J Pathol** 1996 Jul;179(3):260–5

Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Brunner E, et al. **Lancet** 1996 Apr 13;347(9007):1008–13

Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Wang H, et al. **Microb Pathog** 1995 Mar;18(3):153–66

The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator. Bakker AH, et al. **Protein Eng** 1995 Mar;8(3):293–300

Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase. Wang J, et al. **Protein Sci** 1995 Sep;4(9):1768–79

Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t-PA-catalysed plasminogen activation. Haddeland U, et al. **Thromb Haemost** 1996 Feb; 75(2):326–31

Platelets and plasminogen activation. Loscalzo J, et al. **Thromb Haemost** 1995 Jul;74(1):291–3

Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Pekelharing HL, et al. **Thromb Haemost** 1996 Mar; 75(3):497–502

Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Wu JH, et al. **Thromb Haemost** 1995 Aug;74(2):711–7

Effect of fucoidan during activation of human plasminogen. Doctor VM, et al. **Thromb Res** 1995 Aug 1;79(3):237–47

Enhancing effect of platelets on staphylokinase-mediated clot lysis and plasminogen activation. Suehiro A, et al. **Thromb Res** 1995 Oct 15;80(2):135–42

Activating effect of the plasminogen activators on plasminogens of different mammalia species. Yakovlev SA, et al. **Thromb Res** 1995 Aug 15;79(4):423–8

Plasma plasminogen levels in early respiratory distress syndrome. Yurdakök M, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):195–7

[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):86–8 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen. Lijnen HR, et al. **Blood** 1996 Aug 1; 88(3):870–6

Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Lee E, et al. **Circ Res** 1996 Jan;78(1):44–9

Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Shatos MA, et al. **Circulation** 1996 Aug 15;94(4):636–42

Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. Li C, et al. **Exp Cell Res** 1996 Aug 1; 226(2):239–42

Angiostatin induces and sustains dormancy of human primary tumors in mice. O'Reilly MS, et al. **Nat Med** 1996 Jun; 2(6):689–92

PHYSIOLOGY

Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. O'Reilly MS, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:471–82

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

Plasminogen and wound healing [letter; comment] Rømer J, et al. **Nat Med** 1996 Jul;2(7):725. Comment on: Nat Med 1996 May;2(5):493.

Impaired wound healing in mice with a disrupted plasminogen gene [see comments] Romer J, et al. **Nat Med** 1996 Mar;2(3):287–92. Comment in: Nat Med 1996 May;2(5):493.

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)

SECRETION

[The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells] Zhabin SG, et al. **Vopr Med Khim** 1995 May–Jun;41(3):34–7 (Eng. Abstr.) **(Rus)**

PLASMINOGEN ACTIVATOR INHIBITOR 1

ANALYSIS

Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Zheng MH, et al. **Am J Pathol** 1995 Dec;147(6):1559–66

The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo–fetal bone formation in the human: an immunohistochemical study. Häckel C, et al. **Anat Embryol (Berl)** 1995 Oct;192(4):363–8

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2155–9 (37 ref.)

Cathepsin D and PAI-1 expression in human head and neck cancer. Zeillinger R, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):449–53

Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Robbie LA, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):539–45

Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V, et al. **Cancer** 1996 Mar 15;77(6):1079–88

Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Ganesh S, et al. **Cancer** 1996 Mar 15;77(6):1035–43

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Shahar E, et al. **Circulation** 1996 Jun 1;93(11):1970–5

Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. West MD, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):175–93

Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Rahr HB, et al. **Haemostasis** 1995 Sep–Oct; 25(5):248–56

Interleukin-1-mediated stimulation of prostaglandin E production is without effect on plasminogen activator activity in human granulosa lutein cell cultures. Hurwitz A, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3018–24

Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. Tuan TL, et al. **J Invest Dermatol** 1996 May;106(5):1007–11

Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma. Lim DJ, et al. **J Korean Med Sci** 1995 Oct;10(5):373–8

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. Foekens JA, et al. **J Natl Cancer Inst** 1995 May 17;87(10):751–6

Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. Hofmann R, et al. **J Urol** 1996 Mar;155(3):858–62

Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Wilson MJ, et al. **Prostate** 1996 Apr;28(4):239–50

von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Blann AD, et al. **Thromb Haemost** 1995 Aug;74(2):626–30

Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Brännström M, et al. **Thromb Haemost** 1995 Aug; 74(2):612–5

Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Declerck PJ, et al. **Thromb Haemost** 1995 Nov;74(5):1305–9

Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Gram J, et al. **Thromb Haemost** 1995 Aug; 74(2):718–21

Plasma plasminogen activator inhibitor activity in rats with nutritionally induced insulin resistance [letter] Scelles V, et al. **Thromb Haemost** 1995 Aug;74(2):806–7

Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Ito H, et al. **Virchows Arch** 1996 Feb;427(5):487–96

Plasminogen activator inhibitor type 1 in rat spermatozoa: localisation in the tail, in the acrosome and on the surface of the head. Manske M, et al. **Zygote** 1994 Aug;2(3):243–52

[Plasminogen activator inhibitor-1 (PAI-1)] Iwabuchi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:64–7 (22 ref.) **(Jpn)**

BIOSYNTHESIS

Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species. Cheng JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):100–5

Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. Ryan MP, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1041–6

Oversulfated fucoidan and heparin suppress endotoxin induction of plasminogen activator inhibitor-1 in cultured human endothelial cells: their possible mechanism of action. Soeda S, et al. **Biochim Biophys Acta** 1995 Oct 19; 1269(1):85–90

Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. Peiretti F, et al. **Blood** 1996 Jan 1;87(1):162–73

Plasminogen activator inhibitor 1 messenger RNA expression and molecular evidence for del(7)(q22) in uterine leiomyomas. Sourla A, et al. **Cancer Res** 1996 Jul 1; 56(13):3123–8

Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Lee E, et al. **Circ Res** 1996 Jan;78(1):44–9

Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Hamdan AD, et al. **Circulation** 1996 Mar 15;93(6):1073–8

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Lundgren CH, et al. **Circulation** 1996 Jan 1;93(1):106–10

Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Shatos MA, et al. **Circulation** 1996 Aug 15;94(4):636–42

Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Feener EP, et al. **Contrib Nephrol** 1996;118:180–7

Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha. Panagakos FS, et al. **Inflammation** 1995 Aug;19(4):423–43

Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Desruisseau S, et al. **Int J Cancer** 1996 Jun 11;66(6):796–801

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. Eitzman DT, et al. **J Clin Invest** 1996 Jan 1;97(1):232–7

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. Kerins DM, et al. **J Clin Invest** 1995 Nov;96(5):2515–20

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. Soff GA, et al. **J Clin Invest** 1995 Dec;96(6):2593–600

Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. Hong SI, et al. **J Korean Med Sci** 1996 Feb;11(1):33–7

Heparin-binding epidermal growth factor-like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Ushiro S, et al. **Jpn J Cancer Res** 1996 Jan;87(1):68–77

Complex intracellular signal transduction regulates tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) synthesis in cultured human umbilical vein endothelium. Rydholm H, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):323–30

Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors. Colucci M, et al. **Thromb Haemost** 1995 Dec;74(6):1516–20

The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1. Koike C, et al. **Thromb Haemost** 1996 Feb;75(2):298–302

Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. Shi GY, et al. **Thromb Res** 1996 Jan 1;81(1):75–84

BLOOD

Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Calles-Escandon J, et al. **Am J Clin Nutr** 1996 Jul; 64(1):7–11

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Meilahn EN, et al. **Am J Epidemiol** 1996 Jan 15; 143(2):159–66

Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S, et al. **Am J Kidney Dis** 1996 Jun;27(6):848–54

Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Beer NA, et al. **Am J Med Sci** 1996 May; 311(5):205–10

Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1. Lopez-Segura F, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):82–8

Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Räikkönen K, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):363–7

Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without

exercise in overweight postmenopausal women. Svendsen OL, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar; 16(3):381–5

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor–1 in dyslipidemias. Zitoun D, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):77–81

An enzyme immunoassay for the simultaneous determination of active type–1 plasminogen activator inhibitor (PAI–1), and t–PA/PAI–1 complexes. Nieuwenhuizen W, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):520–6

Leg ulcers and Klinefelter's syndrome: role of PAI–1 [letter] Pernod G, et al. **Br J Dermatol** 1996 Mar;134(3):605–6

Plasma plasminogen activator inhibitor–1, tissue plasminogen activator and serum lipoprotein(a) after reperfusion therapy in acute myocardial infarction: comparison between sequential and direct percutaneous transluminal coronary angioplasty. Hara M, et al. **Cardiology** 1995;86(5):407–10

Cytokines and plasminogen activator inhibitor–1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Gando S, et al. **Crit Care Med** 1995 Nov;23(11):1835–42

The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients. Lithner F, et al. **Diabet Med** 1995 Jul;12(7):590–4

Plasminogen activator inhibitor (PAI–1) activity is elevated in Asian and Caucasian subjects with non–insulin–dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non–diabetic Asians. Nagi DK, et al. **Diabet Med** 1996 Jan;13(1):59–64

Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Jokl R, et al. **Diabetes Care** 1995 Aug;18(8):1150–5

Fibrinolysis and diabetic retinopathy in NIDDM. Mansfield MW, et al. **Diabetes Care** 1995 Dec;18(12):1577–81

Enhanced levels of tissue–type plasminogen activator in borderline hypertension. Wall U, et al. **Hypertension** 1995 Nov;26(5):796–800

Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Bastard JP, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):836–8

Evaluation of tissue plasminogen activator and plasminogen activator inhibitor–1 levels in acute myocardial infarction. Yamada S, et al. **J Cardiol** 1996 Apr;27(4):171–8

The relationship between plasminogen activator inhibitor–1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. Kornelisse RF, et al. **J Infect Dis** 1996 May;173(5):1148–56

No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. Petersen KR, et al. **Metabolism** 1996 Jul;45(7):833–7

Plasminogen activator inhibitor–1 in nonobese subjects with non–insulin–dependent diabetes mellitus. Ito Y, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):287–91

Tissue plasminogen activator and plasminogen activator inhibitor–1 in stroke patients. Lindgren A, et al. **Stroke** 1996 Jun;27(6):1066–71

Relation between plasma PAI activity and adipsin levels [letter] Alessi MC, et al. **Thromb Haemost** 1995 Oct; 74(4):1200–2

Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Haj MA, et al. **Thromb Haemost** 1995 Dec;74(6):1528–32

Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor–1 in Caucasian patients with non–insulin–dependent diabetes mellitus. Mansfield MW, et al. **Thromb Haemost** 1995 Sep; 74(3):842–7

Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose–dependent effect on PAI–1 activity. Scarabin PY, et al. **Thromb Haemost** 1995 Sep; 74(3):928–32

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Dahl OE, et al. **Thromb Res** 1995 Nov 15;80(4):299–306

[Levels of tissue–type plasminogen activator (T–PA), its inhibitor (PAI–1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus] Kvasnička J, et al. **Cas Lek Cesk** 1996 Mar 20;135(6):174–7 (Eng. Abstr.) **(Cze)**

[Changes of the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor–1 in cerebral infarction induced by the venous occlusion] Wakamatsu S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep; 32(8–9):566–70 (Eng. Abstr.) **(Jpn)**

[Changes in plasma tissue plasminogen activator (t–PA) and plasminogen activator inhibitor 1 (PAI–1) by the interferon treatment for chronic hepatitis C] Hayashi T, et al. **Rinsho Byori** 1995 Sep;43(9):948–52 (Eng. Abstr.) **(Jpn)**

[Studies on the mechanism of hyperfibrinolysis in liver cirrhosis––changes of plasma t–PA, PAI–1 and active PAI–1 levels in liver cirrhosis] Matsuura R, et al. **Rinsho Byori** 1995 Dec;43(12):1256–60 (Eng. Abstr.) **(Jpn)**

[Activity of plasminogen activator inhibitor (PAI–1) in plasma of women treated after menopause with hormone replacement therapy] Ciepluch R, et al. **Pol Tyg Lek** 1995 Sep;50(36–39):13–5 (Eng. Abstr.) **(Pol)**

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma] Iwan–Ziętek I, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):91–3 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Time–resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Fa M, et al. **Biochemistry** 1995 Oct 24;34(42):13833–40

Substrate behavior of plasminogen activator inhibitor–1 is not associated with a lack of insertion of the reactive site loop. Gils A, et al. **Biochemistry** 1996 Jun 11;35(23):7474–81

Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue–type plasminogen activator by mass spectrometry and size–exclusion chromatography. Strömqvist M, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):103–9

The acid stabilization of plasminogen activator inhibitor–1 depends on protonation of a single group that affects loop insertion into beta–sheet A. Kvassman JO, et al. **J Biol Chem** 1995 Nov 17;270(46):27942–7

Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor–1. Aertgeerts K, et al. **Nat Struct Biol** 1995 Oct;2(10):891–7

Crystallization and X–ray diffraction data of the cleaved form of plasminogen activator inhibitor–1. Aertgeerts K, et al. **Proteins** 1995 Sep;23(1):118–21

Localization of a vitronectin binding region of plasminogen activator inhibitor–1. Padmanabhan J, et al. **Thromb Haemost** 1995 May;73(5):829–34

DEFICIENCY

Hereditary partial deficiency of plasminogen activator inhibitor–1 associated with a lifelong bleeding tendency. Takahashi Y, et al. **Int J Hematol** 1996 Jul;64(1):61–8

Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor–1 gene function in mice. Lijnen HR, et al. **Thromb Haemost** 1995 Oct;74(4):1126–31

GENETICS

Plasminogen activator inhibitor type–1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Sironi L, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):89–96

Characterization of a helicase–like transcription factor involved in the expression of the human plasminogen activator inhibitor–1 gene. Ding H, et al. **DNA Cell Biol** 1996 Jun;15(6):429–42

Coordinated expression of tissue–type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Liu K, et al. **Endocrinology** 1996 May; 137(5):2126–32

Angiotensin II regulation of plasminogen activator inhibitor–1 gene expression in neurons of normotensive and spontaneously hypertensive rat brains. Yu K, et al. **Endocrinology** 1996 Jun;137(6):2503–13

Sequence requirements in the reactive–center loop of plasminogen–activator inhibitor–1 for recognition of plasminogen activators. Tucker HM, et al. **Eur J Biochem** 1996 Apr 1;237(1):180–7

PAI–1 gene expression is growth state–regulated in cultured human epidermal keratinocytes during progression to confluence and postwounding. Staiano–Coico L, et al. **Exp Cell Res** 1996 Aug 25;227(1):123–34

Cloning of the mink plasminogen activator inhibitor type–1 messenger RNA: an mRNA with a short half life. Chuang TH, et al. **Gene** 1995 Sep 11;162(2):303–8

n–Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells. Smith TJ, et al. **Hepatology** 1996 Apr;23(4):866–71

Bleomycin–induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor–1 gene. Eitzman DT, et al. **J Clin Invest** 1996 Jan 1;97(1):232–7

Distribution and regulation of plasminogen activator inhibitor–1 in murine adipose tissue in vivo. Induction by tumor necrosis factor–alpha and lipopolysaccharide. Samad F, et al. **J Clin Invest** 1996 Jan 1;97(1):37–46

Differential expression of urokinase–type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor–promoting phorbol ester. Lund LR, et al. **J Invest Dermatol** 1996 Apr;106(4):622–30

Enhanced expression of PAI–1 in visceral fat: possible contributor to vascular disease in obesity. Shimomura I, et al. **Nat Med** 1996 Jul;2(7):800–3

Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Kunz C, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3710–7

Inhibition of NF–kappa B–Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase–type plasminogen activator (uPA) but not its inhibitor PAI–1. Reuning U, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3887–93

Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Leonardsson G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12446–50

Transcriptional regulation of tissue– and urokinase–type plasminogen activator genes by thrombin in human fetal lung fibroblasts. Hayakawa Y, et al. **Thromb Haemost** 1995 Aug;74(2):704–10

Plasminogen activator inhibitor–1 (PAI–1) promoter polymorphism and coronary artery disease in non–insulin–dependent diabetes. Mansfield MW, et al. **Thromb Haemost** 1995 Oct;74(4):1032–4

Plasminogen activator inhibitor–1 mRNA is induced by hemorrhage in endothelial and mesothelial cells of the rat liver. Yamashita M, et al. **Thromb Haemost** 1995 Sep; 74(3):933–7

The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor–1 (PAI–1) gene is associated with differences in plasma PAI–1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de l'Infarctus du Mycocarde. Ye S, et al. **Thromb Haemost** 1995 Sep;74(3):837–41

Up–regulation of type 1 plasminogen activator inhibitor messenger RNA with thrombotic changes in renal grafts. Wang Y, et al. **Transplantation** 1996 Mar 15;61(5):684–9

IMMUNOLOGY

Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor–1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. Debrock S, et al. **FEBS Lett** 1995 Dec 4;376(3):243–6

Recombinant rabbit Fab with binding activity to type–1 plasminogen activator inhibitor derived from a phage–display library against human alpha–granules. Lang IM, et al. **Gene** 1996 Jun 26;172(2):295–8

Identification of functional interaction sites on proteins using bacteriophage–displayed random epitope libraries. van Zonneveld AJ, et al. **Gene** 1995 Dec 29;167(1–2):49–52

Antigen levels of urokinase plasminogen activator and its receptor at the tumor–host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Buø L, et al. **Hum Pathol** 1995 Oct;26(10):1133–8

METABOLISM

Human endothelial cell damage by neutrophil–derived cathepsin G. Role of cytoskeleton rearrangement and matrix–bound plasminogen activator inhibitor–1. Iacoviello L, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):2037–46

Time–resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Fa M, et al. **Biochemistry** 1995 Oct 24;34(42):13833–40

Substrate behavior of plasminogen activator inhibitor–1 is not associated with a lack of insertion of the reactive site loop. Gils A, et al. **Biochemistry** 1996 Jun 11;35(23):7474–81

Regulation of type I plasminogen activator inhibitor by fibrin degradation products in rat lung fibroblasts. Hagood JS, et al. **Blood** 1996 May 1;87(9):3749–57

Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Hill SA, et al. **Blood** 1996 Jun 15;87(12):5061–73

Thrombospondin and transforming growth factor–beta 1 increase expression of urokinase–type plasminogen activator and plasminogen activator inhibitor–1 in human MDA–MB–231 breast cancer cells. Arnoletti JP, et al. **Cancer** 1995 Sep 15;76(6):998–1005

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Hofmann R, et al. **Cancer** 1996 Aug 1; 78(3):487–92

Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Addo–Boadu K, et al. **Cancer Lett** 1996 Jun 5;103(2):125–9

Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma–susceptible mice. de Vries TJ, et al. **Cancer Res** 1995 Oct 15;55(20):4681–7

Plasminogen activator inhibitor–1 and peritoneal transport in diabetic and non–diabetic peritoneal dialysis patients. Lin JJ, et al. **Clin Nephrol** 1995 Nov;44(5):310–5

Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor–1 in breast cancer tissues. Romain S, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):603–8

Immunohistochemical localization of urokinase–type plasminogen activator, type–1 plasminogen–activator inhibitor, urokinase receptor and alpha(2)–macroglobulin receptor in human breast carcinomas. Christensen L, et al. **Int J Cancer** 1996 May 16;66(4):441–52

Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor–donor fluorescence energy transfer. Aleshkov SB, et al. **J Biol Chem** 1996 Aug 30;271(35):21231–8

The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase–plasminogen activator inhibitor type I complexes. Argraves KM, et al. **J Biol Chem** 1995 Nov 3;270(44):26550–7

Structural and functional analysis of the plasminogen activator inhibitor–1 binding motif in the somatomedin B

domain of vitronectin. Deng G, et al. **J Biol Chem** 1996 May 31;271(22):12716–23

Calcium–dependent stabilization of type I plasminogen activator inhibitor within platelet alpha–granules. Lang IM, et al. **J Biol Chem** 1996 Feb 2;271(5):2754–61

Serpin–protease complexes are trapped as stable acyl–enzyme intermediates. Lawrence DA, et al. **J Biol Chem** 1995 Oct 27;270(43):25309–12

Plasminogen activator inhibitor–1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor–related proteins 1 and 2. Stefansson S, et al. **J Biol Chem** 1996 Apr 5;271(14):8215–20

Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue–type plasminogen activator. van Meijer M, et al. **J Biol Chem** 1996 Mar 29;271(13):7423–8

Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor–1 in primary cultures of rat calvarial osteoblasts. Allan EH, et al. **J Cell Physiol** 1995 Dec; 165(3):521–9

Differential growth state–dependent regulation of plasminogen activator inhibitor type–1 expression in senescent IMR–90 human diploid fibroblasts. Mu XC, et al. **J Cell Physiol** 1995 Dec;165(3):647–57

Expression of urokinase–type plasminogen activator and plasminogen activator inhibitor in colon disease. Miseljic S, et al. **J Clin Lab Anal** 1995;9(6):413–7

The imbalance of plasminogen activators and inhibitor in preeclampsia. Gao M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):9–16

Type–1 plasminogen activator inhibitor in human renal cell carcinoma. Wagner SN, et al. **J Pathol** 1996 May; 179(1):95–9

Elevated levels of plasminogen–activator inhibitor type 1 in atherosclerotic aorta. Shireman PK, et al. **J Vasc Surg** 1996 May;23(5):810–7; discussion 817–8

Induction of plasminogen activator inhibitor type 1 in murine lupus–like glomerulonephritis. Moll S, et al. **Kidney Int** 1995 Nov;48(5):1459–68

Correlations between plasminogen activator inhibitor–1 and peritoneal transport in pediatric CCPD patients. Lin JJ, et al. **Perit Dial Int** 1995 Jul–Sep;15(6):246–51

The PAI–1/vitronectin interaction: two cats in a bag? Deng G, et al. **Thromb Haemost** 1995 Jul;74(1):66–70 (47 ref.)

Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor–1 dependent, analogous to interactions of tissue–type plasminogen activator with these cells. Grimsley PG, et al. **Thromb Res** 1995 Aug 15; 79(4):353–61

Sphingomyelinase and cell–permeable ceramide analogs increase the release of plasminogen activator inhibitor–1 from cultured endothelial cells. Soeda S, et al. **Thromb Res** 1995 Dec 15;80(6):509–18

Effects of cadmium on the release of tissue plasminogen activator and plasminogen activator inhibitor type 1 from cultured human vascular smooth muscle cells and fibroblasts. Yamamoto C, et al. **Toxicology** 1996 Jan 8; 106(1–3):179–85

PHARMACOLOGY

Inhibition of Borrelia burgdorferi–bound fibrinolytic enzymes by alpha2–antiplasmin, PAI–1 and PAI–2 Perides G, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):690–5

Single–chain urokinase–type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Higazi AA, et al. **Blood** 1996 May 1; 87(9):3545–9

Construction, expression and the characterization of t–PA mutants with increased plasma half–life and resistance to inhibition by PAI–1. Liu S, et al. **Chin J Biotechnol** 1995; 11(1):17–25

The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease–inhibitor complex. Wilczynska M, et al. **J Biol Chem** 1995 Dec 15;270(50):29652–5

PHYSIOLOGY

Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF–beta 1. Petzelbauer E, et al. **Am J Pathol** 1996 Sep;149(3):923–31

Studies on the role of plasminogen activators and plasminogen activator inhibitor type–1 in rat corpus luteum of pregnancy. Liu YX, et al. **Biol Reprod** 1995 Nov; 53(5):1131–8

Lack of plasminogen activator inhibitor–1 effect in a transgenic mouse model of metastatic melanoma. Eitzman DT, et al. **Blood** 1996 Jun 1;87(11):4718–22

PAI–1–resistant t–PA: low doses prevent fibrin deposition in rabbits with increased PAI–1 activity. Krishnamurti C, et al. **Blood** 1996 Jan 1;87(1):14–9

The antibody to plasminogen activator inhibitor–1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Tsuchiya H, et al. **Gen Diagn Pathol** 1995 May; 141(1):41–8

Interleukin–1 induction of type–1 plasminogen activator inhibitor (PAI–1) gene expression in the mouse hepatocyte line, AML 12. Seki T, et al. **J Cell Physiol** 1996 Sep; 168(3):648–56

Characterization of the interaction of a complex of tissue–type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells. Kuiper J, et al. **Thromb Haemost** 1995 Nov;74(5):1298–304

Plasminogen activator inhibitor type–1 determines plasmin formation in patients with ischaemic heart disease. Pedersen OD, et al. **Thromb Haemost** 1995 May;73(5):835–40

Plasminogen activator inhibitor 1 (PAI–1) in plasma: its role in thrombotic disease. Wiman B. **Thromb Haemost** 1995 Jul;74(1):71–6 (65 ref.)

Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator [letter] Zenz W, et al. **Thromb Haemost** 1995 Aug;74(2):802–3

SECRETION

The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones. Sobel MI, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):801–8

Plasminogen activator inhibitor–1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Handt S, et al. **Blood** 1996 May 15;87(10):4204–13

Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Kawai Y, et al. **Blood** 1996 Mar 15;87(6):2314–21

Secretion of prostacyclin, tissue plasminogen activator and its inhibitor by cultured adult human endothelial cells grown on different matrices. Gillis C, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):127–33

Regulation of tissue–type plasminogen activator and plasminogen activator inhibitor type–1 in cultured rat Sertoli and Leydig cells. Liu Y, et al. **Sci China C Life Sci** 1996 Feb;39(1):37–44

PLASMINOGEN ACTIVATOR INHIBITOR 2

The enigma PAI–2. Gene expression, evolutionary and functional aspects. Bachmann F. **Thromb Haemost** 1995 Jul; 74(1):172–9 (55 ref.)

ANALYSIS

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2155–9 (37 ref.)

Plasminogen activator inhibitor type–2 in the lesional epidermis of lupus erythematosus. Bechtel MJ, et al. **Br J Dermatol** 1996 Mar;134(3):411–9

Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. West MD, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):175–93

Prognostic relevance of urokinase–type plasminogen activator (uPA) and plasminogen activator inhibitors PAI–1 and PAI–2 in gastric cancer. Ito H, et al. **Virchows Arch** 1996 Feb;427(5):487–96

BIOSYNTHESIS

Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. Ritchie H, et al. **Blood** 1995 Nov 1;86(9):3428–35

Differential expression of urokinase–type plasminogen activator (uPA), its receptor (uPA–R), and inhibitor type–2 (PAI–2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM, et al. **Exp Cell Res** 1995 Oct;220(2):415–23

Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors. Colucci M, et al. **Thromb Haemost** 1995 Dec;74(6):1516–20

Peripheral blood monocyte synthesis of plasminogen activator inhibitor 2 in response to native and modified LDL. Ritchie H, et al. **Thromb Haemost** 1995 Dec; 74(6):1521–7

BLOOD

Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Haj MA, et al. **Thromb Haemost** 1995 Dec;74(6):1528–32

CHEMISTRY

Intracellular polymerization of the serpin plasminogen activator inhibitor type 2. Mikus P, et al. **J Biol Chem** 1996 Apr 26;271(17):10048–53

GENETICS

A two–step recognition of signal sequences determines the translocation efficiency of proteins. Belin D, et al. **EMBO J** 1996 Feb 1;15(3):468–78

Differential expression of urokinase–type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor–promoting phorbol ester. Lund LR, et al. **J Invest Dermatol** 1996 Apr;106(4):622–30

Transcriptional regulation of tissue– and urokinase–type plasminogen activator genes by thrombin in human fetal lung fibroblasts. Hayakawa Y, et al. **Thromb Haemost** 1995 Aug;74(2):704–10

METABOLISM

Urokinase–type plasminogen–activator receptor associates to a cell surface molecule in monocytic cells. Ragno P, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):252–7

Expression of human plasminogen activator inhibitor–2 in the baculovirus expression system. Pei Y, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):923–8

Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma–susceptible mice. de Vries TJ, et al. **Cancer Res** 1995 Oct 15;55(20):4681–7

TCDD–inducible plasminogen activator inhibitor type 2 (PAI–2) in human hepatocytes, HepG2 and monocytic U937 cells. Gohl G, et al. **Carcinogenesis** 1996 Mar; 17(3):443–9

A two–step recognition of signal sequences determines the translocation efficiency of proteins. Belin D, et al. **EMBO J** 1996 Feb 1;15(3):468–78

Urokinase–type plasminogen activator/type–2 plasminogen–activator inhibitor complexes are not internalized upon binding to the urokinase–type–plasminogen–activator receptor in THP–1 cells. Interaction of urokinase–type plasminogen activator/type–2 plasminogen–activator inhibitor complexes with the cell surface. Ragno P, et al. **Eur J Biochem** 1995 Oct 15;233(2):514–9

Plasminogen activator inhibitor–2 expression in inflamed appendix. Whawell SA, et al. **Histopathology** 1995 Jul; 27(1):75–8

Inverse correlation between mRNA expression of plasminogen activator inhibitor–2 and lymph node metastasis in human breast cancer. Ishikawa N, et al. **Jpn J Cancer Res** 1996 May;87(5):480–7

PHARMACOLOGY

Inhibition of Borrelia burgdorferi–bound fibrinolytic enzymes by alpha2–antiplasmin, PAI–1 and PAI–2 Perides G, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):690–5

PHYSIOLOGY

Biological and clinical aspects of plasminogen activator inhibitor type 2. Kruithof EK, et al. **Blood** 1995 Dec 1; 86(11):4007–24 (282 ref.)

Plasminogen activator inhibitor type–2 (PAI–2) in human keratinocytes regulates pericellular urokinase–type plasminogen activator. Reinartz J, et al. **Exp Cell Res** 1996 Feb 25;223(1):91–101

Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha–induced apoptosis. Evidence for an alternate biological function. Dickinson JL, et al. **J Biol Chem** 1995 Nov 17;270(46):27894–904

PLASMINOGEN ACTIVATOR INHIBITOR 3 see **PROTEIN C INHIBITOR**

PLASMINOGEN ACTIVATOR INHIBITORS see **PLASMINOGEN INACTIVATORS**

PLASMINOGEN ACTIVATOR, TISSUE–TYPE see **ALTEPLASE**

PLASMINOGEN ACTIVATOR, UROKINASE–TYPE see **UROKINASE**

PLASMINOGEN ACTIVATORS

Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Rijken DC. **Baillieres Clin Haematol** 1995 Jun;8(2):291–312 (127 ref.)

Urokinase–type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)

ADMINISTRATION & DOSAGE

Factors predicting the outcome of intraarterial thrombolysis in peripheral arterial and graft occlusions. Sandbaek G, et al. **Acta Radiol** 1996 May;37(3 Pt 1):299–304

Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect. Park CS, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):649–52

Intracavitary urokinase therapy as an adjunct to percutaneous drainage in a patient with a multiloculated empyema [clinical conference] Ryan JM, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):643–7

Transcatheter therapy of thrombotic–occlusive lesions in saphenous vein grafts. Ceceña FA, et al. **Am J Cardiol** 1996 Jul 1;78(1):31–6

Intracoronary thrombolysis in the treatment of graft closure immediately after CABG. Dauerman HL, et al. **Ann Thorac Surg** 1996 Jul;62(1):280–3

Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery. Poplausky MR, et al. **Gastroenterology** 1996 May;110(5):1633–5

Recanalization of Chronically Occluded Aortocoronary Saphenous Vein Bypass Grafts With Long–Term, Low Dose Direct Infusion of Urokinase (ROBUST): a serial trial. Hartmann JR, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):60–6

Coronary angioplasty and intracoronary thrombolysis are of

limited efficacy in resolving early intracoronary stent thrombosis [see comments] Hasdai D, et al. **J Am Coll Cardiol** 1996 Aug;28(2):361–7. Comment in: J Am Coll Cardiol 1996 Aug;28(2):368–70.

Long–term intermittent urokinase therapy in patients with end–stage coronary artery disease and refractory angina pectoris: a randomized dose–response trial. Leschke M, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):575–84

[Local fibrinolysis in massive pulmonary thromboembolism (letter)] Garro P, et al. **Med Clin (Barc)** 1996 Mar 9; 106(9):354 **(Spa)**

ADVERSE EFFECTS

Choroidal hemorrhage associated with systemic tissue plasminogen activator. Khawly JA, et al. **Am J Ophthalmol** 1996 May;121(5):577–8

Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. McMechan SR, et al. **Br Heart J** 1995 Aug;74(2):205

Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction [letter] Kounis NG, et al. **Heart** 1996 Apr;75(4):427

ANALYSIS

The plasminogen activation system is upregulated in loosening of total hip prostheses. Nordsletten L, et al. **Acta Orthop Scand** 1996 Apr;67(2):143–8

Growth factors, tissue and urokinase–type plasminogen activators in venous ulcers. Lagattolla NR, et al. **Ann Cardiol Angeiol (Paris)** 1995 Jun–Aug;44(6):299–303

Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Belcher C, et al. **Ann Rheum Dis** 1996 Apr;55(4):230–6

Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. Göhring UJ, et al. **Anticancer Res** 1996 Mar–Apr;16(2):1011–8

Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. Ito Y, et al. **Anticancer Res** 1996 Jan–Feb;16(1):81–9

Molecular characterization of plasminogen activators in human gingival crevicular fluid. Brown JM, et al. **Arch Oral Biol** 1995 Sep;40(9):839–45

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Hofmann R, et al. **Cancer** 1996 Aug 1; 78(3):487–92

In vitro anti–proliferative and anti–invasive role of aminoterminal fragment of urokinase–type plasminogen activator on 8701–BC breast cancer cells. Luparello C, et al. **Eur J Cancer** 1996 Apr;32A(4):702–7

Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1105–9 (28 ref.)

Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Louwrens HD, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):289–93

Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. West MD, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):175–93

Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Rahr HB, et al. **Haemostasis** 1995 Sep–Oct; 25(5):248–56

Plasminogen activators, venous leg ulcers and reepithelialization. Lotti T, et al. **Int J Dermatol** 1995 Oct; 34(10):696–9

Expression of plasminogen activators in basal cell carcinoma. Spiers EM, et al. **J Pathol** 1996 Mar;178(3):290–6

Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Lyon PB, et al. **Prostate** 1995 Oct;27(4):179–86

Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Wilson MJ, et al. **Prostate** 1996 Apr;28(4):239–50

Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy. Rahr HB, et al. **Scand J Gastroenterol** 1996 Feb;31(2):170–4

Prognostic value of urokinase–type plasminogen activator in patients with superficial bladder cancer. Hasui Y, et al. **Urology** 1996 Jan;47(1):34–7

BIOSYNTHESIS

Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Reidy MA, et al. **Circ Res** 1996 Mar;78(3):405–14

Amplification and expression of recombinant genes in serum–independent Chinese hamster ovary cells. Gandor C, et al. **FEBS Lett** 1995 Dec 27;377(3):290–4

Thrombin increases expression of urokinase receptor by activation of the thrombin receptor. Yang Z, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2254–61

Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. Lim YT, et al. **J Cell Physiol** 1996 May;167(2):333–40

Expression of urokinase–type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. Hong SI, et al. **J Korean Med Sci** 1996 Feb;11(1):33–7

Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload. Carroll SM, et al. **J Mol Cell Cardiol** 1995 Jul;27(7):1427–41

BLOOD

Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Zwickl CM, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):243–54

Tissue plasminogen activator and plasminogen activator inhibitor–1 in stroke patients. Lindgren A, et al. **Stroke** 1996 Jun;27(6):1066–71

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma] Iwan–Ziętek I, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):91–3 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Lam XM, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1904–9

O–linked L–fucose is present in Desmodus rotundus salivary plasminogen activator. Gohlke M, et al. **J Biol Chem** 1996 Mar 29;271(13):7381–6

Application of capillary electrophoresis, high–performance liquid chromatography, on–line electrospray mass spectrometry and matrix–assisted laser desorption ionization—time of flight mass spectrometry to the characterization of single–chain plasminogen activator. Apffel A, et al. **J Chromatogr A** 1995 Nov 24; 717(1–2):41–60

Application of high–performance liquid chromatograph–electrospray ionization mass spectrometry and matrix–assisted laser–desorption ionization time–of–flight mass spectrometry in combination with selective enzymatic modifications in the characterization of glycosylation patterns in single–chain plasminogen activator. Apffel A, et al. **J Chromatogr A** 1996 Apr 26; 732(1):27–42

DEFICIENCY

Generation and characterization of urokinase receptor–deficient mice. Dewerchin M, et al. **J Clin Invest** 1996 Feb 1;97(3):870–8

Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor–1 gene function in mice. Lijnen HR, et al. **Thromb Haemost** 1995 Oct;74(4):1126–31

DRUG EFFECTS

Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells. Matsumoto H, et al. **Life Sci** 1996;59(2):85–96

ECONOMICS

Study assigns dollar value to alteplase–streptokinase debate [news] **Am J Health Syst Pharm** 1995 Aug 1;52(15):1600

GENETICS

Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Shetty S, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):78–87

Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Dichek DA, et al. **Circulation** 1996 Jan 15;93(2):301–9

Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia. Hayden SM, et al. **J Neurosci** 1996 Apr 1; 16(7):2307–17

Effects of retroviral–mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene. Huber TS, et al. **J Vasc Surg** 1995 Dec;22(6):795–803

Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Nielsen BS, et al. **Lab Invest** 1996 Jan;74(1):168–77

Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Kunz C, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3710–7

[Preventive effect of gene therapy with pro–uk gene on the formation of intimal hyperplasia of vascular anastomotic site] Chen L, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Mar;76(3):187–90 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Zwickl CM, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):243–54

Antigen levels of urokinase plasminogen activator and its receptor at the tumor–host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Bugø L, et al. **Hum Pathol** 1995 Oct;26(10):1133–8

ISOLATION & PURIFICATION

Extraction of plasminogen activator in the rat's submaxillary gland. Lucas ON, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(2):115–22

Characterization of a plasminogen activator produced by Acanthamoeba castellanii. Mitra MM, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):157–64

METABOLISM

Proteinase activity in invasive cancer of the breast. Correlation with tumor progression. Benítez–Bribiesca L, et al. **Arch Med Res** 1995;26 Spec No:S163–8

Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Kojima S, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):574–81

Advanced glycation end products stimulate plasminogen activator activity via GM–CSF in RAW 264.7 cells. Saishoji T, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):278–85

Regulation of rat granulosa cell plasminogen activator system: influence of interleukin–1 beta and ovarian follicular development. Karakji EG, et al. **Biol Reprod** 1995 Dec;53(6):1302–10

Presence of urokinase in serum–free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Mars WM, et al. **Cancer Res** 1996 Jun 15;56(12):2837–43

Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Wilson MJ, et al. **Cell Mol Biol Res** 1995;41(6):603–12

Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines. Brail LH, et al. **Clin Exp Metastasis** 1995 Nov;13(6):439–52

Attachment, invasion, chemotaxis, and proteinase expression of B16–BL6 melanoma cells exhibiting a low metastatic phenotype after exposure to dietary restriction of tyrosine and phenylalanine. Uhlenkott CE, et al. **Clin Exp Metastasis** 1996 Mar;14(2):125–37

Sequence requirements in the reactive–center loop of plasminogen–activator inhibitor–1 for recognition of plasminogen activators. Tucker HM, et al. **Eur J Biochem** 1996 Apr 1;237(1):180–7

Upregulation of cell–surface–associated plasminogen activation in cultured keratinocytes by interleukin–1 beta and tumor necrosis factor–alpha. Bechtel MJ, et al. **Exp Cell Res** 1996 Mar 15;223(2):395–404

The urokinase receptor is a major vitronectin–binding protein on endothelial cells. Kanse SM, et al. **Exp Cell Res** 1996 May 1;224(2):344–53

Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion. Huijzer JC, et al. **Int J Cancer** 1995 Sep 27; 63(1):92–9

Structural features mediating fibrin selectivity of vampire bat plasminogen activators. Bringmann P, et al. **J Biol Chem** 1995 Oct 27;270(43):25596–603

Interleukin–1–mediated stimulation of prostaglandin E production is without effect on plasminogen activator activity in human granulosa lutein cell cultures. Hurwitz A, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3018–24

Urokinase–type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2' CD11b/CD18) during neutrophil polarization. Kindzelskii AL, et al. **J Immunol** 1996 Jan 1;156(1):297–309

Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. Knoepfler PS, et al. **J Mol Cell Cardiol** 1995 Jun;27(6):1317–24

Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor–alpha and interleukin–1 beta through similar signal transduction pathways. Faber–Elman A, et al. **J Neurochem** 1995 Oct; 65(4):1524–35

Plasminogen activator activities in short–term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Festuccia C, et al. **Oncol Res** 1995;7(3–4):131–8

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D, et al. **Thromb Haemost** 1995 Jul; 74(1):167–71 (40 ref.)

PHARMACOKINETICS

Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Kuiper J, et al. **Thromb Haemost** 1995 Dec;74(6):1501–10

PHARMACOLOGY

T–cell lymphokines, interleukin–4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet–derived growth factor. Wang W, et al. **Circ Res** 1995 Dec;77(6):1095–106

Suppression of plasminogen activator inhibitor–1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Shatos MA, et al. **Circulation** 1996 Aug 15;94(4):636–42

Thrombolytic agents in development. Verstraete M, et al. **Drugs** 1995 Jul;50(1):29–42 (90 ref.)

The fibrinolytic activity of staphylokinase mutants in the fibrin plate assay. Hauptmann J, et al. **Haemostasis** 1995 Nov–Dec;25(6):272–6

Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. Modi NB, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):105–12

Thrombolysis with prourokinase versus urokinase: an in vitro comparison. Fox D, et al. **J Vasc Surg** 1996 Apr; 23(4):657–66

Activating effect of the plasminogen activators on plasminogens of different mammalia species. Yakovlev SA, et al. **Thromb Res** 1995 Aug 15;79(4):423–8

PHYSIOLOGY

Plasminogen activation on tumor cell surface and its involvement in human leukemia. Tapiovaara H, et al. **Adv Cancer Res** 1996;69:101–33 (317 ref.)

Interactions between endothelial secretogogues. Gryglewski RJ. **Ann Med** 1995 Jun;27(3):421–7 (80 ref.)

Studies on the role of plasminogen activators and plasminogen activator inhibitor type–1 in rat corpus luteum of pregnancy. Liu YX, et al. **Biol Reprod** 1995 Nov; 53(5):1131–8

Plasminogen activators and angiogenesis. Mignatti P, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):33–50 (137 ref.)

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Mueller BM. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):65–80 (80 ref.)

Mechanisms of pertussis toxin–induced myelomonocytic cell adhesion: role of Mac–1(CD11b/CD18) and urokinase receptor (CD87). Wong WS, et al. **Immunology** 1996 May; 88(1):90–7

Regulation of plasminogen activation, matrix metalloproteinases and urokinase–type plasminogen activator–mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin–1 alpha. de Bart AC, et al. **J Bone Miner Res** 1995 Sep;10(9):1374–84

Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Hildenbrand R, et al. **Pathol Res Pract** 1995 Jun;191(5):403–9

SECRETION

The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones. Sobel MI, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):801–8

THERAPEUTIC USE

Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial. Goldhaber SZ, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):314–8

Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Peuhkurinen K, et al. **Am Heart J** 1996 Jan;131(1):7–13

Effect of reperfusion modality on outcome in nonsmokers and smokers with acute myocardial infarction (a Primary Angioplasty in Myocardial Infarction [PAMI] substudy). PAMI Investigators. Bowers TR, et al. **Am J Cardiol** 1996 Sep 1;78(5):511–5

Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts. Denardo SJ, et al. **Am J Cardiol** 1995 Oct 15; 76(11):776–80

A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS–II Investigators. O'Connor CM, et al. **Am J Cardiol** 1996 Apr 15;77(10):791–7

Management of stroke complicating cardiac catheterization with recombinant tissue–type plasminogen activator. Oezbek C, et al. **Am J Cardiol** 1995 Oct 1;76(10):733–5

Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty. Schächinger V, et al. **Am J Cardiol** 1996 Jun 1; 77(14):1174–8

Influence of acute myocardial infarction location on in–hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Stone GW, et al. **Am J Cardiol** 1996 Jul 1;78(1):19–25

Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. Zahger D, et al. **Am J Cardiol** 1995 Oct 15;76(11):749–52

Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front–loaded recombinant tissue–type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group. Zeymer U, et al. **Am J Cardiol** 1995 Nov 15;76(14):997–1001

Minimally invasive management of acute superior mesenteric artery occlusion: combined urokinase and laparoscopic therapy. Regan F, et al. **Am J Gastroenterol** 1996 May; 91(5):1019–21

Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage [letter; comment] Hawkins WR. **Am J Ophthalmol** 1995 Oct; 120(4):550–2. Comment on: Am J Ophthalmol 1994 Nov 15;118(5):559–68.

Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Kamei M, et al. **Am J Ophthalmol** 1996 Mar;121(3):267–75

Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Comerota AJ, et al. **Am J Surg** 1996 Aug;172(2):105–12

Thrombolytic treatment of acute on chronic leg ischaemia. von Knorring S, et al. **Ann Chir Gynaecol** 1995;84(4):369–71

Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Whitelaw A, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul;75(1):F20–6

Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA) [letter] Johnson DW, et al. **Aust N Z J Med** 1995 Aug;25(4):370–1

Treatment of veno–occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Patton DF, et al. **Bone Marrow Transplant** 1996 Mar;17(3):443–7

Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator. Morse LS, et al. **Br J Ophthalmol** 1996 Jul;80(7):658–62

Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Martin U, et al. **Br J Pharmacol** 1996 May;118(2):271–6

Image–guided drainage of complicated pleural effusions and adjunctive use of intrapleural urokinase. What would Hippocrates think? [editorial; comment] Matsumoto AH. **Chest** 1995 Nov;108(5):1190–1. Comment on: Chest 1995 Nov;108(5):1252–9.

Treatment of complicated pleural fluid collections with image–guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252–9 (20 ref.). Comment in: Chest 1995 Nov;108(5):1190–1.

Thrombolytic therapy for acute cerebral vascular occlusion. Zhu T, et al. **Chin Med J (Engl)** 1995 Dec;108(12):930–1

Randomized comparison of coronary thrombolysis achieved with double–bolus reteplase (recombinant plasminogen activator) and front–loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Bode C, et al. **Circulation** 1996 Sep 1;94(5):891–8

Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Ragni M, et al. **Circulation** 1996 May 15;93(10):1913–8

Accelerated thrombolysis with high dose bolus t–PA extends the role of peripheral thrombolysis but may increase the risks. Braithwaite BD, et al. **Clin Radiol** 1995 Nov; 50(11):747–50

Topically applied recombinant tissue plasminogen activator for the treatment of venous ulcers. Preliminary report. Falanga V, et al. **Dermatol Surg** 1996 Jul;22(7):643–4

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102–36 (154 ref.)

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289–316 (185 ref.)

Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy [see comments] Baardman T, et al. **Eur Heart J** 1996 Feb;17(2):237–46. Comment in: Eur Heart J 1996 Feb;17(2):167–8.

Successful thrombolysis treatment of a spontaneous left main coronary artery dissection without subsequent surgery [letter] Leclercq F, et al. **Eur Heart J** 1996 Feb;17(2):320–1

Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size. Pizzetti G, et al. **Eur Heart J** 1996 Mar;17(3):421–8

Recombinant hirudin and front–loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT–I (hirudin for the improvement of thrombolysis). Zeymer U, et al. **Eur Heart J** 1995 Jul;16 Suppl D:22–7

Peripheral arterial occlusions: local low–dose thrombolytic therapy with recombinant tissue–type plasminogen activator (rt–PA). Hess H, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):97–104

Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Moriarty AP, et al. **Eye** 1995;9 (Pt 5):582–8

Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy. Hesse L, et al. **Ger J Ophthalmol** 1995 Nov;4(6):323–7

The use of tissue plasminogen activator in post–traumatic total hyphaema. Laatikainen L, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):67–8

Thrombolysis utilisation in acute myocardial infarction in Bahrain. Chawla AK, et al. **Indian Heart J** 1996 Mar–Apr; 48(2):155–8

Thrombotic occlusion of the left main coronary artery during stenting: successful management with intracoronary urokinase and autoperfusion balloon. Gambhir DS, et al. **Indian Heart J** 1996 May–Jun;48(3):273–5

Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator. Szymanski A, et al. **Int Ophthalmol** 1995;19(1):13–7

Use of fibrinolytic agents to coat wire implants to decrease infection. An animal model. Nakamoto DA, et al. **Invest Radiol** 1995 Jun;30(6):341–4

One–year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue–type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non–Q wave myocardial infarction. Anderson HV, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1643–50

Influence of cigarette smoking on rate of reopening of the infarct–related coronary artery after myocardial infarction: a multivariate analysis. de Chillou C, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1662–8

Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO–I) trial. Karnash SL, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1651–6

Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: a comparison with non–elderly patients. Gisselbrecht M, et al. **J Am Geriatr Soc** 1996 Feb;44(2):189–93

Third generation plasminogen activators in the treatment of acute myocardial infarction. Talley JD. **J Ark Med Soc** 1996 Apr;92(11):587–8 (6 ref.)

The impact of thrombolytic therapy on arterial and graft occlusions: a critical analysis. Bhatnagar PK, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):105–12

The safety and efficacy of low–dose tissue plasminogen activator in the treatment of systemic sclerosis. Wilson D, et al. **J Dermatol** 1995 Sep;22(9):637–42

Sigmoid sinus thrombosis associated with internal jugular venous occlusion: direct thrombolytic treatment. Gurley MB, et al. **J Endovasc Surg** 1996 Aug;3(3):306–14

t–PA for treating acute ischemic stroke. Shaughnessy AS, et al. **J Fam Pract** 1996 May;42(5):458–9

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t–PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)

Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). Lee PF, et al. **J Oculr Pharmacol Ther** 1995 Fall;11(3):227–32

Streptokinase versus alteplase in acute myocardial infarction. Friedman HS. **J R Soc Med** 1996 Aug;89(8):427–30

A new approach to the treatment of experimental septic shock. Hardaway RM, et al. **J Surg Res** 1996 Mar; 61(2):311–6

Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis. Whitley D, et al. **J Vasc Surg** 1996 May;23(5):851–8; discussion 858–9

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Aug 14;276(6):443

Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO–I investigators. Weaver WD, et al. **JAMA** 1996 Mar 13;275(10):777–82

A novel modified tissue–type plasminogen activator (t–PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis—comparison of native t–PA and urokinase. Saito M, et al. **Jpn Circ J** 1995 Aug;59(8):556–64

Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct–Dec;15(4):297–310 (145 ref.) . Comment in: Med Decis Making 1995 Oct–Dec;15(4):395–6.

Accelerated tPA versus streptokinase for suspected myocardial infarction: waiting for our Mountain Dew [editorial; comment] McNutt R, et al. **Med Decis Making** 1995 Oct–Dec;15(4):395–6. Comment on: Med Decis Making 1995 Oct–Dec;15(5):297–310.

Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction [see comments] Andreotti F, et al. **N Engl J Med** 1996 Jan 4;334(1):7–12. Comment in: N Engl J Med 1996 Jan 4;334(1):51–2. Comment in: N Engl J Med 1996 Jul 4;335(1):59; discussion 60–1. Comment in: N Engl J Med 1996 Jul 4;335(1):59–60; discussion 60–1.

Preinfarction angina [letter; comment] Kloner RA, et al. **N Engl J Med** 1996 Jul 4;335(1):59–60; discussion 60–1. Comment on: N Engl J Med 1996 Jan 4;334(1):7–12.

Preinfarction angina [letter; comment] Migrino RQ, et al. **N Engl J Med** 1996 Jul 4;335(1):59; discussion 60–1. Comment on: N Engl J Med 1996 Jan 4;334(1):7–12.

Tissue plasminogen activator in the surgical excision of subfoveal choroidal neovascular membranes. Thomas JW, et al. **Ophthalmic Surg** 1995 Jul–Aug;26(4):374–6

Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Lundy DC, et al. **Ophthalmology** 1996 Feb;103(2):274–82

Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. MacCumber MW, et al. **Ophthalmology** 1996 Feb; 103(2):269–73

Successful thrombolytic therapy using tissue–type plasminogen activator in Kawasaki disease. Tsubata S, et al. **Pediatr Cardiol** 1995 Jul–Aug;16(4):186–9

Use of urokinase in pregnancy. Two success stories. La Valleur J, et al. **Postgrad Med** 1996 May;99(5):269–70,

272–3
Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Coll GE, et al. **Retina** 1995;15(4):319–26
Therapeutic advantage of recombinant human plasminogen activator in endocarditis: evidence from experiments in rabbits. Meyer MW, et al. **Thromb Haemost** 1995 Apr; 73(4):680–2
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Paloma MJ, et al. **Thromb Haemost** 1995 Dec;74(6):1578–82
[Thrombolytic therapy in acute cerebral ischemia] Boysen G, et al. **Ugeskr Laeger** 1996 Feb 5;158(6):786–9 **(Dan)**
[Pharmacological therapeutic prospects of cerebral vasospasm] Hans P. **Ann Fr Anesth Reanim** 1996; 15(3):374–81 (Eng. Abstr.) **(Fre)**
[Thrombolytic therapy with rt-PA for thrombosis of tricuspid valve prosthesis during pregnancy] Azzano O, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):267–70 (Eng. Abstr.) **(Fre)**
[Renal venous thrombosis in the neonatal period: is there still a role for streptokinase? (letter)] Haddad J, et al. **Arch Pediatr** 1996 Apr;3(4):395–6 **(Fre)**
[GUSTO (Global Utilization of Streptokinase & t-PA for Occluded Coronary Arteries): comparison of four therapeutic strategies in acute myocardial infarction. Washington, 30 April 1993] **Internist (Berl)** 1993 Jul;34(7 Suppl):1–12 **(Ger)**
[Medical treatment for experimental retinal vein occlusion--thrombolytic effect of nasaruplase] Suzuki Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):27–33 (Eng. Abstr.) **(Jpn)**
[Thrombolysis (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**
[Brazilian study with alteplase in acute myocardial infarction--EBRALT] Batlouni M, et al. **Arq Bras Cardiol** 1995 Aug;65(2):175–9 (Eng. Abstr.) **(Por)**
[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen] Maksimenko AV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):48–51 **(Rus)**

PLASMINOGEN INACTIVATORS

Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Rijken DC. **Baillieres Clin Haematol** 1995 Jun;8(2):291–312 (127 ref.)

ANALYSIS

Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Belcher C, et al. **Ann Rheum Dis** 1996 Apr;55(4):230–6
Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. de Maat MP, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep; 16(9):1156–62
Evidence for an active fibrinolytic system in normal human bone marrow. McWilliam NA, et al. **Br J Haematol** 1996 Apr;93(1):170–6
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1105–9 (28 ref.)
Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Louwrens HD, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):289–93
Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Verpooten GA, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):347–51
Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy. Rahr HB, et al. **Scand J Gastroenterol** 1996 Feb;31(2):170–4

BIOSYNTHESIS

Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Reidy MA, et al. **Circ Res** 1996 Mar;78(3):405–14
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Paloma MJ, et al. **Thromb Haemost** 1995 Dec;74(6):1578–82

BLOOD

Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty. Hirashima O, et al. **Am Heart J** 1995 Nov;130(5):933–9
Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Ozoran K, et al. **Scand J Rheumatol** 1995;24(6):376–82
[Clinical significance of fibrinolytic system defectiveness in exercise induced myocardial ischemia and its mechanism] Deng H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):305–8 (Eng. Abstr.) **(Chi)**
[An analysis on the activity status of fibrinolytic system in Chinese patients with acute cerebral infarction] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):518–21 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

A molecular variant of plasminogen activator inhibitor of rat decidual tissue. Tarachand U, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1037–45

PLASMODIUM

see related

ANTIMALARIALS

Effects of Plasmodium vinckei hemozoin on the production of oxygen radicals and nitrogen oxides in murine macrophages. Prada J, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):620–4
Hemozoin differentially modulates the production of interleukin 6 and tumor necrosis factor in murine malaria. Prada J, et al. **Eur Cytokine Netw** 1995 Mar-Apr; 6(2):109–12

CHEMISTRY

Structural similarities among malaria toxins insulin second messengers, and bacterial endotoxin. Caro HN, et al. **Infect Immun** 1996 Aug;64(8):3438–41

CLASSIFICATION

Plasmodium: genus-conserved primers for species identification and quantitation. Li J, et al. **Exp Parasitol** 1995 Sep;81(2):182–90
The blood-stages of Plasmodium georgesi, P. gonderi and P. petersi: course of untreated infection in their natural hosts and additional morphological distinctive features. Poirriez J, et al. **Parasitology** 1995 Dec;111 (Pt 5):547–54
Bootstrap confidence levels for phylogenetic trees. Efron B, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7085–90

DRUG EFFECTS

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)
Antimalarial properties of soy-bean fat emulsions. Deharo E, et al. **Int J Parasitol** 1995 Dec;25(12):1457–62
Present development concerning antimalarial activity of phospholipid metabolism inhibitors with special reference to in vivo activity. Ancelin ML, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:85–90
Infected erythrocyte choline carrier inhibitors: exploring some potentialities inside Plasmodium phospholipid metabolism for eventual resistance acquisition. Vial HJ, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:91–7
Evaluation of resistant-reversal, CDRI compound 87/209 and its possible mode of action in rodent experimental malaria. Srivastava R, et al. **Trop Med Parasitol** 1995 Jun; 46(2):83–7
[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151–5 (20 ref.) (Eng. Abstr.) **(Dut)**

GENETICS

Plasmodium: genus-conserved primers for species identification and quantitation. Li J, et al. **Exp Parasitol** 1995 Sep;81(2):182–90
Molecular differentiation of two new world saurian Plasmodium species in different host species using the polymerase chain reaction. Wozniak EJ, et al. **J Parasitol** 1996 Apr;82(2):372–5
Attempted isolation of the gene encoding the 21 Kd Plasmodium berghei ookinete transmission blocking antigen from Plasmodium yoelli and Plasmodium vivax. Barker GC, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:37–41
Chromosomes and sexual development of rodent malaria parasites. Janse CJ, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:43–6
The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species. Longacre S. **Mol Biochem Parasitol** 1995 Oct;74(1):105–11
Comparison of introns in a cdc2-homologous gene within a number of Plasmodium species. Vinkenoog R, et al. **Mol Biochem Parasitol** 1995 May;71(2):233–41
A PCR test for avian malaria in Hawaiian birds. Feldman RA, et al. **Mol Ecol** 1995 Dec;4(6):663–73
Transfection and malaria. Wesson DM, et al. **Nat Med** 1995 Aug;1(8):745–7
Bootstrap confidence levels for phylogenetic trees. Efron B, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7085–90
[Cytoplasmic ribosomes of Plasmodium and prophylaxis of P. falciparum malaria by various antibiotics (editorial)] Charmot G. **Bull Soc Pathol Exot** 1995 Mar;88(4):147–8 **(Fre)**
[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Plasmodium vinckei vinckei and P. yoelii nigeriensis: pattern of gametocyte production and development. Gautret P, et al. **Parassitologia** 1995 Apr;37(1):17–24

IMMUNOLOGY

Rosette formation by Plasmodium coatneyi-infected erythrocytes of the Japanese macaque (Macaca fuscata). Kawai S, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):295–9
Parasitized erythrocyte membrane antigens of Plasmodium brasilianum: relationships with the ring-infected erythrocyte surface antigen of Plasmodium falciparum. Sulzer AJ, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):618–23
Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)
Cellular mechanisms in the immune response to malaria in Plasmodium vinckei-infected mice. Perlmann H, et al. **Infect Immun** 1995 Oct;63(10):3987–93
Patterns of acquired anti-malarial immunity in Sri Lanka. Gunewardena DM, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:63–5
Aspects of immunity for the AMA-1 family of molecules in humans and non-human primates malarias. Thomas AW, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:67–70
Naked DNA for malaria vaccines [news] Fricker J. **Mol Med Today** 1996 Mar;2(3):91
[Vaccines blocking transmission (letter)] Sauerwein R. **Med Trop (Mars)** 1995;55(4 Suppl):118 **(Fre)**
[Towards a vaccination against malaria] Ambroise-Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Distribution and abundance of two malarial parasites of the endemic Anolis lizard of Saba Island, Netherlands Antilles. Staats CM, et al. **J Parasitol** 1996 Jun;82(3):409–13
Epizootiology of the Japanese saurian malaria parasite, Plasmodium sasai. Telford SR Jr. **J Parasitol** 1996 Apr; 82(2):226–32
Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Snounou G. **Methods Mol Biol** 1996;50:263–91

PATHOGENICITY

Wildlife disease and conservation in Hawaii: pathogenicity of avian malaria (Plasmodium relictum) in experimentally infected iiwi (Vestiaria coccinea). Atkinson CT, et al. **Parasitology** 1995;111 Suppl:S59–69

PHYSIOLOGY

Regulation of infectivity of Plasmodium to the mosquito vector. Sinden RE, et al. **Adv Parasitol** 1996;38:53–117 (314 ref.)
Sulfated polyanions inhibit invasion of erythrocytes by plasmodial merozoites and cytoadherence of endothelial cells to parasitized erythrocytes. Xiao L, et al. **Infect Immun** 1996 Apr;64(4):1373–8
The Nigerian I/CDC strain of Plasmodium ovale in chimpanzees. Morris CL, et al. **J Parasitol** 1996 Jun; 82(3):444–8
Simian malaria at two sites in the Brazilian Amazon. I--The infection rates of Plasmodium brasilianum in non-human primates. Lourenço-de-Oliveira R, et al. **Mem Inst Oswaldo Cruz** 1995 May-Jun;90(3):331–9 (70 ref.)
The within-host cellular dynamics of bloodstage malaria: theoretical and experimental studies. Hetzel C, et al. **Parasitology** 1996 Jul;113 (Pt 1):25–38
Malaria hideout found in new mothers [news; comment] Williams N. **Science** 1996 Jun 7;272(5267):1416–7. Comment on: Science 1996 Jun 7;272(5267):1502–4.
[Malaria--biological aspects of an infectious disease of importance to humans] Hildebrandt JP. **Naturwissenschaften** 1996 Aug;83(8):359–69 (86 ref.) (Eng. Abstr.) **(Ger)**

PLASMODIUM BERGHEI

Decrease in platelet survival and total platelet sialic acid concentration in rats infected with Plasmodium bergei bergei. Inyang AL, et al. **Afr J Med Med Sci** 1995 Mar; 24(1):41–6
Studies on heme and heme oxygenase during Plasmodium berghei infection in golden hamsters. Sharma GD, et al. **Indian J Exp Biol** 1995 Nov;33(11):897–8
Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. Yañez DM, et al. **J Immunol** 1996 Aug 15;157(4):1620–4
Dietary iron supplementation does not aggravate experimental malaria in young rats. Cardoso MA, et al. **J Nutr** 1996 Feb;126(2):467–75
Wistar rat-Plasmodium berghei model does not approximate human congenital malaria. Fischer PR. **J Parasitol** 1996 Aug;82(4):635–7
Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Loiseau PM, et al. **Trop Med Int Health** 1996 Jun;1(3):379–84

DRUG EFFECTS

Heme oxygenase and related indices in chloroquine-resistant

and -sensitive strains of Plasmodium berghei. Srivastava P, et al. **Int J Parasitol** 1995 Sep;25(9):1061–4

Antimalarial activity of novel arylene bis(methylketone) compounds. Berger BJ, et al. **J Infect Dis** 1996 Sep; 174(3):659–62

Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. Sánchez-Delgado RA, et al. **J Med Chem** 1996 Mar 1;39(5):1095–99

Syntheses and antimalarial activities of N-substituted 11-azaartemisinins. Torok DS, et al. **J Med Chem** 1995 Dec 22;38(26):5045–50

Plasmodium berghei: sensitivity of chloroquine-resistant and chloroquine-sensitive strains to irradiation and the effect of irradiated malaria parasites on cytochrome P450-dependent monooxygenases. Song GH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):75–86

[Ca++ ion transport blockers as reversants of the drug resistance of malarial parasites. 1. The effect of verapamil on the resistance to chloroquine in vivo of Plasmodium berghei and in vitro of Plasmodium falciparum] Rabinovich SA, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar;(1):18–22 (Eng. Abstr.) **(Rus)**

[Malaria parasite DNA and RNA changes connected with acquired resistance to chloroquine] Pankova TG, et al. **Mol Biol (Mosk)** 1996 Jan-Feb;30(1):43–50 **(Rus)**

GENETICS

Isolation of a distally located gene possibly correlated with gametocyte production ability. Birago C, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:33–5

Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes. van Dijk MR, et al. **Science** 1996 Feb 2;271(5249):662–5

[Malaria parasite DNA and RNA changes connected with acquired resistance to chloroquine] Pankova TG, et al. **Mol Biol (Mosk)** 1996 Jan-Feb;30(1):43–50 **(Rus)**

IMMUNOLOGY

CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Renggli J, et al. **Immunol Lett** 1995 May;46(1–2):199–205

Attenuated immunogenic parasites are essential in the transfer of immunity to virulent Plasmodium berghei. Celluzzi CM, et al. **Immunology** 1995 Jul;85(3):509–15

A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Chatterjee S, et al. **Infect Immun** 1995 Nov; 63(11):4375–81

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Lanar DE, et al. **Infect Immun** 1996 May;64(5):1666–71

Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. Guichard G, et al. **J Biol Chem** 1995 Nov 3;270(44):26057–9

MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. White KL, et al. **J Immunol** 1996 May 1;156(9):3374–81

Susceptibility to Plasmodium berghei infection in rats is modulated by the acute phase response. Vreden SG, et al. **Parasite Immunol** 1995 Sep;17(9):445–50

Interferon-gamma and the induction of protective IgG2a antibodies in non-lethal Plasmodium berghei infections of mice. Waki S, et al. **Parasite Immunol** 1995 Oct; 17(10):503–8

Immunity to Plasmodium berghei exoerythrocytic forms derived from irradiated sporozoites. Chatterjee S, et al. **Parasitol Res** 1996;82(4):297–303

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Hioe CE, et al. **Vaccine** 1996 Apr;14(5):412–8

PATHOGENICITY

Effect of fatty acid treatment in cerebral malaria-susceptible and nonsusceptible strains of mice. Moumaris M, et al. **J Parasitol** 1995 Dec;81(6):997–9

PHYSIOLOGY

Proteolysis of a 34 kDa phosphoprotein coincident with a decrease in protein kinase activity during the erythrocytic schizont stage of the malaria parasite. Wiser MF. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):659–64

The within-host cellular dynamics of bloodstage malaria: theoretical and experimental studies. Hetzel C, et al. **Parasitology** 1996 Jul;113 (Pt 1):25–38

RADIATION EFFECTS

Plasmodium berghei: sensitivity of chloroquine-resistant and chloroquine-sensitive strains to irradiation and the effect of irradiated malaria parasites on cytochrome P450-dependent monooxygenases. Song GH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):75–86

PLASMODIUM CHABAUDI

Exacerbation of Plasmodium chabaudi malaria in mice by depletion of TCR alpha beta+ T cells, but not TCR gamma delta+ T cells. Sayles PC, et al. **Immunology** 1996 Jan; 87(1):29–33

In vivo regulation of nitric oxide production by tumor necrosis factor alpha and gamma interferon, but not by interleukin-4, during blood stage malaria in mice. Jacobs P, et al. **Infect Immun** 1996 Jan;64(1):44–9

A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Jacobs P, et al. **Infect Immun** 1996 Feb;64(2):535–41

Nitric oxide expression in the spleen, but not in the liver, correlates with resistance to blood-stage malaria in mice. Jacobs P, et al. **J Immunol** 1995 Dec 1;155(11):5306–13

Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. von der Weid T, et al. **J Immunol** 1996 Apr 1;156(7):2510–6

Expansion of the gammadelta T cell subset in vivo during bloodstage malaria in B cell-deficient mice. van der Heyde HC, et al. **J Leukoc Biol** 1996 Aug;60(2):221–9

Analysis of roles of natural killer cells in defense against Plasmodium chabaudi in mice. Kitaguchi T, et al. **Parasitol Res** 1996;82(4):352–7

Trafficking of Plasmodium chabaudi adami-infected erythrocytes within the mouse spleen. Yadava A, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4595–9

GROWTH & DEVELOPMENT

A megadalton protein (Pc2500) is present during the intraerythrocytic development of P. chabaudi. Garcia CR, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):983–9

IMMUNOLOGY

Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Crewther PE, et al. **Infect Immun** 1996 Aug;64(8):3310–7

Immunoglobulin E elevation in Plasmodium chabaudi malaria. Helmby H, et al. **Infect Immun** 1996 Apr; 64(4):1432–3

Reconstitution of B-cell-depleted mice with B cells restores Th2-type immune responses during Plasmodium chabaudi chabaudi infection. Taylor-Robinson AW, et al. **Infect Immun** 1996 Jan;64(1):366–70

alpha beta and gamma delta T cells in the immune response to the erythrocytic stages of malaria in mice. Langhorne J, et al. **Int Immunol** 1995 Jun;7(6):1005–11

Ig-isotype patterns of primary and secondary B cell responses to Plasmodium chabaudi chabaudi correlate with IFN-gamma and IL-4 cytokine production with CD45RB expression by CD4+ spleen cells. D'Império Lima MR, et al. **Scand J Immunol** 1996 Mar;43(3):263–70

METABOLISM

Processing of the Plasmodium chabaudi chabaudi AS merozoite surface protein 1 in vivo and in vitro. O'Dea KP, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):111–9

PHYSIOLOGY

Proteolysis of a 34 kDa phosphoprotein coincident with a decrease in protein kinase activity during the erythrocytic schizont stage of the malaria parasite. Wiser MF. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):659–64

PLASMODIUM CYNOMOLGI

Histochemical changes in host tissues from Plasmodium cynomolgi B infected rhesus monkey (Macaca mulatta). Mehrotra A, et al. **Indian J Exp Biol** 1996 Feb;34(2):155–8

Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. Puri SK, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):49–52

DRUG EFFECTS

Gametocytocidal activity of alpha/beta arteether by the oral route of administration. Tripathi R, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):652–4

Sodium beta-artelinate—a new potential gametocytocide. Tripathi R, et al. **Exp Parasitol** 1996 Apr;82(3):251–4

GENETICS

Sequence analysis of apical membrane antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):267–70

The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species. Longacre S. **Mol Biochem Parasitol** 1995 Oct;74(1):105–11

IMMUNOLOGY

Sequence analysis of apical membrane antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):267–70

PLASMODIUM FALCIPARUM

Cytoadherence characteristics of Plasmodium falciparum isolates from Thailand: evidence for chondroitin sulfate a as a cytoadherence receptor. Chaiyaroj SC, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):76–80

A novel pathway for Ca++ entry into Plasmodium falciparum-infected blood cells. Desai SA, et al. **Am J Trop Med Hyg** 1996 May;54(5):464–70

Anopheles minimus: its bionomics and role in the transmission of malaria in Assam, India. Dev V. **Bull World Health Organ** 1996;74(1):61–6

Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. Sherry BA, et al. **J Inflamm** 1995; 45(2):85–96

Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. François G, et al. **Planta Med** 1996 Apr;62(2):126–9

[Study of malaria vectors in the south-west of Madagascar] Rakotoson JD, et al. **Arch Inst Pasteur Madagascar** 1994; 61(2):70–2 (Eng. Abstr.) **(Fre)**

CHEMISTRY

High-performance liquid chromatographic analysis of biological and chemical heme polymerization. Berger BJ, et al. **Anal Biochem** 1995 Oct 10;231(1):151–6

Expression and secretion of malarial parasite beta-tubulin in Bacillus brevis. Bell A, et al. **Biochimie** 1995;77(4):256–61

Origins of the parasitophorous vacuole membrane of the malaria parasite: surface area of the parasitized red cell. Dluzewski AR, et al. **Eur J Cell Biol** 1995 Dec;68(4):446–9

Glycobiology of Plasmodium falciparum: an emerging area of research [letter] Hoessli DC, et al. **Glycoconj J** 1996 Feb;13(1):1–3 (33 ref.)

Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Carter R, et al. **Mol Biochem Parasitol** 1995 May;71(2):203–10

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17–18):1301–9

Contractile protein system in the asexual stages of the malaria parasite Plasmodium falciparum. Webb SE, et al. **Parasitology** 1996 May;112 (Pt 5):451–7

CYTOLOGY

Plasmodium falciparum: the adherence of erythrocytes infected with human malaria can be mimicked using pfalhesin-coated microspheres. Guthrie N, et al. **Cell Adhes Commun** 1995 Dec;3(5):407–17

DRUG EFFECTS

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)

Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Alin MH, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):639–45

In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum. Basco LK, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):388–91

In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea. Benito A, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):526–31

Effect of pH on in vitro potency of amantadine against Plasmodium falciparum. Evans SG, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):232–6

The effects of pyronaridine on the morphology of Plasmodium falciparum in Aotus trivirgatus. Kawai S, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):223–9

Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Murphy S, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):303–5

Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Reeder JC, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):209–13

Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Zindrou S, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):185–8

Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children. Sowunmi A, et al. **Ann Trop Paediatr** 1996 Mar;16(1):5–9

Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Chevion M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1902–5

Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Gassis S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):914–9

Simple, fast, and accurate fluorometric method to determine drug susceptibility of Plasmodium falciparum in 24-well suspension cultures. Smeijsters LJ, et al.

Antimicrob Agents Chemother 1996 Apr;40(4):835–8
Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Vennerstrom JL, et al.
Antimicrob Agents Chemother 1995 Dec;39(12):2671–7
Mechanisms of drug resistance in malaria. Cowman AF.
Aust N Z J Med 1995 Dec;25(6):837–44 (89 ref.)
Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Atamna H, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):693–700
Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Gamboa de Domínguez ND, et al. **Blood** 1996 May 15;87(10):4448–54
Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Glickstein H, et al. **Blood** 1996 Jun 1;87(11):4871–8
Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Liu DQ, et al.
Bull World Health Organ 1995;73(4):483–6
Response of Plasmodium falciparum to chloroquine and Fansidar in vivo and chloroquine and amodiaquine in vitro in Uganda. Nevill CG, et al. **East Afr Med J** 1995 Jun; 72(6):349–54
Plasmodium falciparum: recrudescence of parasites in culture. Nakazawa S, et al. **Exp Parasitol** 1995 Dec;81(4):556–63
Inhibition of invasion and intraerythrocytic development of Plasmodium falciparum by kinase inhibitors. Dluzewski AR, et al. **Experientia** 1996 Jun 15;52(6):621–3
Synthesis and activity of some quinolone derivatives against Plasmodium falciparum in vitro. Domínguez J, et al.
Farmaco 1996 Jun;51(6):407–12
In vitro antimalarial activity of monoterpenic fragment analogues of aplasmomycin. Biswas S, et al.
Indian J Exp Biol 1995 Jul;33(7):521–3
Antimalarial activity of novel arylene bis(methylketone) compounds. Berger BJ, et al. **J Infect Dis** 1996 Sep; 174(3):659–62
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. Udomsangpetch R, et al.
J Infect Dis 1996 Mar;173(3):691–8
Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. Tsafack A, et al.
J Lab Clin Med 1996 Jun;127(6):574–82
Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. Avery MA, et al. **J Med Chem** 1995 Dec 22;38(26):5038–44
In vitro antimalarial activity of chalcones and their derivatives. Li R, et al. **J Med Chem** 1995 Dec 22; 38(26):5031–7
Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. Sánchez-Delgado RA, et al. **J Med Chem** 1996 Mar 1;39(5):1095–99
Syntheses and antimalarial activities of N-substituted 11-azaartemisinins. Torok DS, et al. **J Med Chem** 1995 Dec 22;38(26):5045–50
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark. Böhlke M, et al. **J Nat Prod** 1996 Jun;59(6):576–80
Efficacy of a 3-day oral regimen of quinine in an area of northern Nigeria with low-grade resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine. Adagu SI, et al.
J Trop Med Hyg 1995 Oct;98(5):296–8
Chloroquine-resistant falciparum malaria in Mauritania [letter; comment] Gasquet M, et al. **Lancet** 1995 Dec 9; 346(8989):1556. Comment on: Lancet 1979 Dec 1;2(8153):1151–4.
Effects of artemisinin derivatives on malaria transmissibility. Price RN, et al. **Lancet** 1996 Jun 15;347(9016):1654–8
Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Basco LK, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):157–66
Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Eldin de Pecoulas P, et al. **Mol Cell Probes** 1995 Dec;9(6):391–7
Resistance of glucose-6-phosphate dehydrogenase deficiency to malaria: effects of fava bean hydroxypyrimidine glucosides on Plasmodium falciparum growth in culture and on the phagocytosis of infected cells. Ginsburg H, et al. **Parasitology** 1996 Jul;113 (Pt 1):7–18
Increasing chloroquine resistance — the Mpumalanga Lowveld story, 1990–1995 [letter] Kruger P, et al.
S Afr Med J 1996 Mar;86(3):280–1
Malaria research. Inbred parasites may spur resistance [news; comment] Schmidt KF. **Science** 1995 Sep 22;269(5231):1670 . Comment on: Science 1995 Sep 22;269(5231):1709–11.
Susceptibility of Plasmodium falciparum to chloroquine in tea garden tribes of Assam, India. Gogoi SC, et al.
Southeast Asian J Trop Med Public Health 1995 Jun; 26(2):228–30
Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J.
Southeast Asian J Trop Med Public Health 1995 Mar; 26(1):23–8 (18 ref.)
Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria. Adagu IS, et al.
Trans R Soc Trop Med Hyg 1995 Jul-Aug;89(4):422–5
Activity in vitro of chloroquine, cycloguanil, and mefloquine against African isolates of Plasmodium falciparum: presumptive evidence for chemoprophylactic efficacy in Central and West Africa. Basco LK, et al.
Trans R Soc Trop Med Hyg 1995 Nov-Dec;89(6):657–8
Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Cox-Singh J, et al.
Trans R Soc Trop Med Hyg 1995 Jul-Aug;89(4):436–7
Plasmodium falciparum: susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren. Landgraf B, et al.
Trans R Soc Trop Med Hyg 1994 Jul-Aug;88(4):440–2
The effect of cocaine on the growth of Plasmodium falciparum in vitro. Makler MT.
Trans R Soc Trop Med Hyg 1994 Jul-Aug;88(4):444
Stabilization of chloroquine resistance in vivo of Plasmodium falciparum in Edea, south Cameroon. Mulder B, et al.
Trans R Soc Trop Med Hyg 1994 Jul-Aug;88(4):445
High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Rønn AM, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr; 90(2):179–81
Artemether treatment of sulfadoxine/pyrimethamine-resistant Plasmodium falciparum malaria in children. Sowunmi A, et al.
Trans R Soc Trop Med Hyg 1995 Jul-Aug;89(4):435–6
Inverse correlation of sensitivity in vitro of Plasmodium falciparum to chloroquine and mefloquine in Ghana. Wernsdorfer WH, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):443–4
Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Wolday D, et al.
Trans R Soc Trop Med Hyg 1995 Nov-Dec;89(6):654–6
Photosensitized inactivation of Plasmodium falciparum in human red cells by phthalocyanines. Lustigman S, et al.
Transfusion 1996 Jun;36(6):543–6
[Sensitivity of Plasmodium falciparum to seven antimalarials in China-Laos border] Yang H, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(2):111–3 (Eng. Abstr.) **(Chi)**
[Sensitivity in vivo and in vitro of Plasmodium falciparum to chloroquine and amodiaquine in Bangangte (west Cameroon)] Agnamey PP, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):149–51 (Eng. Abstr.) **(Fre)**
[Plasmodium falciparum hematozoan morphological alterations in Gabon children treated with artemether] Kombila M, et al. **Med Trop (Mars)** 1995;55(4 Suppl):97–100 **(Fre)**
[Evaluation of Plasmodium falciparum resistance to antimalarial drugs] Parzy D, et al. **Med Trop (Mars)** 1995; 55(3):211–5 **(Fre)**
[How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region] Guiguemdé RT, et al.
Sante 1996 May-Jun;6(3):187–91 (Eng. Abstr.) **(Fre)**
[The evolution over time of the in-vitro resistance of Plasmodium falciparum to antimalarial drugs in 2 areas of the Brazilian Amazonia with distinct socioeconomic and geographic characteristics] Couto AA, et al.
Rev Soc Bras Med Trop 1995 Oct-Dec;28(4):357–65 (Eng. Abstr.) **(Por)**
[Ca++ ion transport blockers as reversants of the drug resistance of malarial parasites. 1. The effect of verapamil on the resistance to chloroquine in vivo of Plasmodium berghei and in vitro of Plasmodium falciparum] Rabinovich SA, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar;(1):18–22 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Aspartic proteinases from the human malaria parasite Plasmodium falciparum. Berry C, et al.
Adv Exp Med Biol 1995;362:511–8
A glutathione reductase-like flavoenzyme of the malaria parasite Plasmodium falciparum: structural considerations based on the DNA sequence. Becker K, et al.
Biochem Soc Trans 1996 Feb;24(1):67–72 (37 ref.)
Glucosamine 6-phosphate deaminase in Plasmodium falciparum. Weidanz JA, et al. **Br J Haematol** 1995 Nov; 91(3):578–86
Detection of plasmodium falciparum lactate dehydrogenase. A promising approach to quick diagnosis of malaria. Wang F, et al. **Chin Med J (Engl)** 1995 Nov;108(11):875–7
Molecular and biochemical characterization of a Plasmodium falciparum cyclophilin containing a cleavable signal sequence. Hirtzlin J, et al. **Eur J Biochem** 1995 Sep 15; 232(3):765–72
Glutathione reductase and glutamate dehydrogenase of Plasmodium falciparum, the causative agent of tropical malaria. Krauth-Siegel RL, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):345–50
Molecular cloning of CTP:phosphocholine cytidylyltransferase from Plasmodium falciparum. Yeo HJ, et al. **Eur J Biochem** 1995 Oct 1;233(1):62–72
The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum. Tosh K, et al. **Gene** 1995 Sep 22;163(1):151–4
Plasmodium falciparum proteinases: cloning of the putative gene coding for the merozoite proteinase for erythrocyte invasion (MPEI) and determination of hydrolysis sites of spectrin by Pf37 proteinase. Florent I, et al.
Mem Inst Oswaldo Cruz 1994;89 Suppl 2:47–9
A Plasmodium falciparum protein kinase with two unusually large kinase inserts. Kappes B, et al.
Mol Biochem Parasitol 1995 Jun;72(1-2):163–78
Plasmodium falciparum glutathione reductase exhibits sequence similarities with the human host enzyme in the core structure but differs at the ligand-binding sites. Müller S, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):11–8
Plasmodium falciparum lacks sialidase and trans-sialidase activity. Clough B, et al. **Parasitology** 1996 May;112 (Pt 5):443–9
Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Lauer SA, et al.
Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9181–5

GENETICS

Different genetic characteristics of Plasmodium falciparum isolates collected during successive clinical malaria episodes in Senegalese children. Contamin H, et al.
Am J Trop Med Hyg 1996 Jun;54(6):632–43
Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Reeder JC, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):209–13
Recombination associated with replication of malarial mitochondrial DNA. Preiser PR, et al. **EMBO J** 1996 Feb 1;15(3):684–93
The var genes of Plasmodium falciparum are located in the subtelomeric region of most chromosomes. Rubio JP, et al. **EMBO J** 1996 Aug 1;15(15):4069–77
Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from Plasmodium falciparum. Färber PM, et al.
Eur J Biochem 1996 Aug 1;239(3):655–61
Molecular cloning of CTP:phosphocholine cytidylyltransferase from Plasmodium falciparum. Yeo HJ, et al. **Eur J Biochem** 1995 Oct 1;233(1):62–72
Plasmodium falciparum: parasites defective in early stages of gametocytogenesis. Alano P, et al. **Exp Parasitol** 1995 Sep;81(2):227–35
Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Basco LK, et al.
Exp Parasitol 1996 Mar;82(2):97–103
Plasmodium falciparum: the small GTPase rab11. Langsley G, et al. **Exp Parasitol** 1996 Jul;83(2):250–1
Plasmodium falciparum: characterization of a 0.7-kbp, moderately repetitive sequence. Wasserman M, et al.
Exp Parasitol 1995 Sep;81(2):165–71
Allelic forms of the knob associated histidine-rich protein gene of Plasmodium falciparum. Kant R, et al.
FEBS Lett 1996 Feb 12;380(1-2):147–51
The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum. Tosh K, et al. **Gene** 1995 Sep 22;163(1):151–4
Toward a high-resolution Plasmodium falciparum linkage map: polymorphic markers from hundreds of simple sequence repeats. Su Xz, et al. **Genomics** 1996 May 1; 33(3):430–44
The ribosomal DNA loci in Plasmodium falciparum accumulate mutations independently. Rogers MJ, et al.
J Mol Biol 1995 Dec 15;254(5):881–91
Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. Wilson RJ, et al.
J Mol Biol 1996 Aug 16;261(2):155–72
PCR characterization of isolates from various endemic areas: diversity and turn over of Plasmodium falciparum populations are correlated with transmission. Daubersies P, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:9–12
Subtelomeric structure of Plasmodium falciparum chromosomes. Scotti R, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:31–2
COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Alano P, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):143–56
Sexual-stage-specific RNA expression of a new Plasmodium falciparum gene detected by in situ hybridisation. Baker DA, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):193–201
Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Basco LK, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):157–66
Merozoite surface antigen 2 (MSA-2) gene of Plasmodium falciparum strains from India. Bhattacharya P, et al.
Mol Biochem Parasitol 1995 Oct;74(1):125–7
Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Kang Y, et al.
Mol Biochem Parasitol 1995 Jul;73(1-2):103–10
A Plasmodium falciparum gene encoding a high mobility group protein box. Kun JF, et al.
Mol Biochem Parasitol 1995 May;71(2):249–53
Plasmodium falciparum glutathione reductase exhibits sequence similarities with the human host enzyme in the core structure but differs at the ligand-binding sites. Müller S, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):11–8
A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al.
Mol Biochem Parasitol 1995 Jul;73(1-2):241–4
Cloning and characterization of a Plasmodium falciparum cyclophilin gene that is stage-specifically expressed. Reddy

GR. **Mol Biochem Parasitol** 1995 Jul;73(1-2):111-21

Molecular cloning of a gene from Plasmodium falciparum that codes for a protein sharing motifs found in adhesive molecules from mammals and plasmodia. Trottein F, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):129-41

Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. Yang C, et al. **Mol Biochem Parasitol** 1995 May;71(2):291-4

tRNA genes transcribed from the plastid-like DNA of Plasmodium falciparum. Preiser P, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4329-36

Reduced extension temperatures required for PCR amplification of extremely A+T-rich DNA. Su XZ, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1574-5

Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum. Crabb BS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7289-94

The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Ruetz S, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9942-7

Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Volkman SK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8921-5

Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Wu Y, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1130-4

Estimation of numbers of malaria clones in blood samples. Hill WG, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22;262(1365):249-57

Structural features of the large subunit rRNA expressed in Plasmodium falciparum sporozoites that distinguish it from the asexually expressed subunit rRNA. Rogers MJ, et al. **RNA** 1996 Feb;2(2):134-45

Mating patterns in malaria parasite populations of Papua New Guinea [see comments] Paul RE, et al. **Science** 1995 Sep 22;269(5231):1709-11. Comment in: Science 1995 Sep 22;269(5231):1670. Comment in: Science 1996 Mar 1;271(5253):1300-1.

Self-fertilization, linkage disequilibrium, and strain in Plasmodium falciparum [letter; comment] Tibayrenc M, et al. **Science** 1996 Mar 1;271(5253):1300-1. Comment on: Science 1995 Sep 22;269(5231):1709-11.

Genome sequencing. Europeans move on from yeast to TB [news] Williams N. **Science** 1996 Apr 5;272(5258):27

Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Cox-Singh J, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):436-7

Association between antifol resistance in vitro and DHFR gene point mutation in Plasmodium falciparum isolates. de Pécoulas PE, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):181-2

[Expression of chemically synthesized hybrid genes of Plasmodium falciparum and preliminary characterization of expressed products] Li Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):94-8 (Eng. Abstr.) **(Chi)**

[Studies on diagnosis of falciparum malaria based on amplifying specific SSUrDNA fragment with nested PCR] Wan L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):174-7 (Eng. Abstr.) **(Chi)**

[Application of Plasmodium falciparum DNA extract from dried blood spot of falciparum malaria patient in polymerase chain reaction] Zhang L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):120-2 (Eng. Abstr.) **(Chi)**

GROWTH & DEVELOPMENT

Complete development of the liver stage of Plasmodium falciparum in a human hepatoma cell line. Karnasuta C, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):607-11

Bacterial population dynamics in three anopheline species: the impact on Plasmodium sporogonic development. Pumpuni CB, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):214-8

Quantification of Plasmodium falciparum sporozoites by ribosomal RNA detection. Vernick KD, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):430-8

Anti-sense oligodeoxynucleoside phosphorothioates nonspecifically inhibit invasion of red blood cells by malaria parasites. Ramasamy R, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):930-3

Plasmodium falciparum: parasites defective in early stages of gametocytogenesis. Alano P, et al. **Exp Parasitol** 1995 Sep;81(2):227-35

Plasmodium falciparum: recrudescence of parasites in culture. Nakazawa S, et al. **Exp Parasitol** 1995 Dec;81(4):556-63

Inhibition of invasion and intraerythrocytic development of Plasmodium falciparum by kinase inhibitors. Dluzewski AR, et al. **Experientia** 1996 Jun 15;52(6):621-3

Stage-specific expression of the calmodulin gene in Plasmodium falciparum. Orfa Rojas M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1118-23

A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. Bottius E, et al. **J Immunol** 1996 Apr 15; 156(8):2874-84

Proteolytic enzyme activity and Plasmodium falciparum sporogonic development in three species of Anopheles mosquitoes. Chege GM, et al. **J Parasitol** 1996 Feb; 82(1):11-6

Serum factors inhibitory for in vitro development of Plasmodium falciparum blood-stage parasites. Perlaza BL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:17-21

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23-6 (10 ref.)

Hypoxanthine: a low molecular weight factor essential for growth of erythrocytic Plasmodium falciparum in a serum-free medium. Asahi H, et al. **Parasitology** 1996 Jul; 113 (Pt 1):19-23

Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides. Barker RH Jr, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):514-8

Establishment of a SCID mouse model having circulating human red blood cells and a possible growth of Plasmodium falciparum in the mouse. Tsuji M, et al. **Vaccine** 1995;13(15):1389-92

[Experimental infections of Anopheles gambiae with Plasmodium falciparum gametocytes: epidemiology of malaria man-vector transmission in the urban milieu] Tchuinkam T, et al. **Med Trop (Mars)** 1995;55(4 Suppl):101-4 **(Fre)**

IMMUNOLOGY

Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Aribot G, et al. **Am J Trop Med Hyg** 1996 May;54(5):449-57

Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population. Beck HP, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):284-8

The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. II. Development of Aotus vociferans as a model for testing transmission-blocking vaccines. Collins WE, et al. **Am J Trop Med Hyg** 1996 Apr; 54(4):380-5

The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. I. Development in Aotus lemurinus griseimembra monkeys. Collins WE, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):372-9

Malaria and pregnancy in Cameroonian primigravidae: humoral and cellular immune responses to Plasmodium falciparum blood-stage antigens. Fievet N, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):612-7

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Gordon DM, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):63-8

Cross-reactive epitope among proteins in Plasmodium falciparum Maurer's clefts and primate leukocytes and platelets. Klotz FW, et al. **Am J Trop Med Hyg** 1996 Jun; 54(6):655-9

Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Rattanarithikul R, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):114-21

Infant parasite rates and immunoglobulin M seroprevalence as a measure of exposure to Plasmodium falciparum during a randomized controlled trial of insecticide-treated bed nets on the Kenyan coast. Snow RW, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):144-9

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Sturchler D, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):423-31

Parasitized erythrocyte membrane antigens of Plasmodium brasilianum: relationships with the ring-infected erythrocyte surface antigen of Plasmodium falciparum. Sulzer AJ, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):618-23

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. al-Yaman F, et al. **Am J Trop Med Hyg** 1996 May;54(5):443-8

Malaria cytoadherence: binding sites for an anti-adhesive antibody on Plasmodium falciparum-infected erythrocytes. Land KM, et al. **Ann Trop Med Parasitol** 1995 Dec; 89(6):685-6

A rapid dipstick antigen capture assay for the diagnosis of falciparum malaria. WHO Informal Consultation on Recent Advances in Diagnostic Techniques and Vaccines for Malaria. **Bull World Health Organ** 1996;74(1):47-54

Immunologic cross-reactivity between structural proteins of human T-cell lymphotropic virus type I and the blood stage of Plasmodium falciparum. Lal RB, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):5-10

Evidence for anti-Plasmodium falciparum antibodies that cross-react with human T-lymphotropic virus type I proteins in a population in Irian Jaya, Indonesia. Porter KR, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):11-5

Use of hydroethidine and flow cytometry to assess the effects of leukocytes on the malarial parasite Plasmodium falciparum. van der Heyde HC, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):417-25

Detection of anti-neutrophil cytoplasmic antibodies after acute Plasmodium falciparum malaria. Wenisch C, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):132-4

Anti-malaria antibody-producing B cell frequencies in adults after a Plasmodium falciparum outbreak in Madagascar. Migot F, et al. **Clin Exp Immunol** 1995 Dec;102(3):529-34

Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Lalvani A, et al. **Eur J Immunol** 1996 Apr;26(4):773-9

Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Ahlborg N, et al. **Exp Parasitol** 1996 Mar; 82(2):155-63

Plasmodium falciparum: characterization of toxin-associated proteins and identification of a hemoglobin containing parasite cytokine stimulator. Kristensen G, et al. **Exp Parasitol** 1996 Mar;82(2):147-54

Plasmodium falciparum: effects of membrane modulating agents on direct binding of rhoptry proteins to human erythrocytes. Ndengele MM, et al. **Exp Parasitol** 1995 Sep; 81(2):191-201

The effect of the length of a malarial epitope on its antigenicity and immunogenicity in an epitope presentation system using the Pseudomonas aeruginosa outer membrane protein OprF as the carrier. Wong RS, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2-3):209-14

Glycobiology of Plasmodium falciparum: an emerging area of research [letter] Hoessli DC, et al. **Glycoconj J** 1996 Feb;13(1):1-3 (33 ref.)

Randomized trial of SPf 66 P. falciparum vaccine in children. **Indian Pediatr** 1995 Feb;32(2):261-2

Plasmodium falciparum stimuli for human gammadelta T cells are related to phosphorylated antigens of mycobacteria. Behr C, et al. **Infect Immun** 1996 Aug; 64(8):2892-6

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Burghaus PA, et al. **Infect Immun** 1996 Sep;64(9):3614-9

A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Chatterjee S, et al. **Infect Immun** 1995 Nov; 63(11):4375-81

Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Høgh B, et al. **Infect Immun** 1995 Oct;63(10):4034-8

Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Hui GS, et al. **Infect Immun** 1996 May;64(5):1502-9

Tumor necrosis factor primes neutrophils to kill Staphylococcus aureus by an oxygen-dependent mechanism and Plasmodium falciparum by an oxygen-independent mechanism. Kowanko IC, et al. **Infect Immun** 1996 Aug;64(8):3435-7

Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Lal AA, et al. **Infect Immun** 1996 Mar;64(3):1054-9

Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro. Sharma P, et al. **Infect Immun** 1996 Jun;64(6):2172-9

Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Shi YP, et al. **Infect Immun** 1996 Jul; 64(7):2716-23

Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. Su S, et al. **Infect Immun** 1996 Jan;64(1):326-31

Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Taylor RR, et al. **Infect Immun** 1995 Nov;63(11):4382-8

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Tine JA, et al. **Infect Immun** 1996 Sep;64(9):3833-44

Plasmodium falciparum induces apoptosis in human mononuclear cells. Toure-Balde A, et al. **Infect Immun** 1996 Mar;64(3):744-50

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584-91

Antigens released at schizont burst stimulate Plasmodium falciparum-specific CD4+ T cells from non-exposed donors: potential for cross-reactive memory T cells to cause disease. Currier J, et al. **Int Immunol** 1995 May; 7(5):821-33

Coexistence of anti-salmonella agglutinins in falciparum malaria [letter] Khubnani H, et al. **J Assoc Physicians India** 1995 Aug;43(8):585-6

Upregulation of ICAM-1, IL-1 and reactive oxygen intermediates (ROI) by exogenous antigens from

Plasmodium falciparum parasites in vitro, and of sICAM-1 in the acute phase of malaria. Prada J, et al. **J Chemother** 1995 Oct;7(5):424–6

Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. Wizel B, et al. **J Exp Med** 1995 Nov 1; 182(5):1435–45

A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. Bottius E, et al. **J Immunol** 1996 Apr 15; 156(8):2874–84

T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. Krzych U, et al. **J Immunol** 1995 Oct 15;155(8):4072–7

Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. Schofield L, et al. **J Immunol** 1996 Mar 1;156(5):1886–96

Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. Tian JH, et al. **J Immunol** 1996 Aug 1; 157(3):1176–83

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765–9

Avian malaria seroprevalence in Jackass penguins (Spheniscus demersus) in South Africa. Graczyk TK, et al. **J Parasitol** 1995 Oct;81(5):703–7

Malaria vaccine in children under 12 months of age [letter; comment] Allen S, et al. **Lancet** 1995 Dec 9; 346(8989):1555–6. Comment on: Lancet 1995 Aug 19;346(8973):462–7.

Malaria vaccine in children under 12 months of age [letter; comment] Mulholland K. **Lancet** 1995 Dec 9; 346(8989):1554–5. Comment on: Lancet 1995 Aug 19;346(8973):462–7.

Prevalence of antibodies to potential malaria vaccine antigens in an endemic area of the State of Rondônia (Brazil). Balthazar-Guedes HC, et al. **Mem Inst Oswaldo Cruz** 1995 Jul-Aug;90(4):511–2

A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Oeuvray C, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:77–80

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:51–3 (13 ref.)

Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Terrientes ZI, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:55–61

COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Alano P, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):143–56

Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast. Moelans II, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):179–92

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):241–4

Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. Yang C, et al. **Mol Biochem Parasitol** 1995 May;71(2):291–4

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17-18):1301–9

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Kumar S, et al. **Mol Med** 1995 Mar; 1(3):325–32

Development of vaccines against falciparum malaria. Ramalingam S, et al. **Natl Med J India** 1996 May-Jun; 9(3):120–4 (71 ref.)

Antibodies to Pf155/RESA and circumsporozoite protein of Plasmodium falciparum in paired maternal-cord sera from Nigeria. Achidi EA, et al. **Parasite Immunol** 1995 Oct; 17(10):535–40

Immunogens containing sequences from antigen Pf332 induce Plasmodium falciparum-reactive antibodies which inhibit parasite growth but not cytoadherence. Ahlborg N, et al. **Parasite Immunol** 1995 Jul;17(7):341–52

Cytokine profiles for human V gamma 9+ T cells stimulated by Plasmodium falciparum. Goodier MR, et al. **Parasite Immunol** 1995 Aug;17(8):413–23

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Leach A, et al. **Parasite Immunol** 1995 Aug;17(8):441–4

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. al-Yaman F, et al. **Parasite Immunol** 1995 Sep;17(9):493–501

Variant antigens and endothelial receptor adhesion in Plasmodium falciparum. Gardner JP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3503–8

Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Dubois P, et al. **Res Immunol** 1995 May-Jun;146(4-5):263–75 (64 ref.)

SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach. Urdaneta M, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):259–69

Adhesion of Plasmodium falciparum-infected erythrocytes to human cells and secretion of cytokines (IL-1-beta, IL-1RA, IL-6, IL-8, IL-10, TGF beta, TNF alpha, G-CSF, GM-CSF. Wahlgren M, et al. **Scand J Immunol** 1995 Dec;42(6):626–36

Serious setback for Patarroyo vaccine [news] Marshall E. **Science** 1996 Sep 20;273(5282):1652

Humoral immune responses to the Plasmodium falciparum antigen Pf155 RESA in adults with differential clinical conditions from an Indian zone where malaria is endemic. Biswas S, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):219–27

Recognition of a 170 kD protein in mammalian Golgi complexes by an antibody against malarial intraerythrocytic lamellae. Li W, et al. **Tissue Cell** 1995 Aug;27(4):355–67

Malaria vaccines—now and the future. Targett GA. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):585–7 (26 ref.)

Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. al-Yaman F, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):555–9

[NANP]19-5.1. A malaria vaccine field trial in Nigerian children. Reber-Liske R, et al. **Trop Geogr Med** 1995; 47(2):61–3

Relationship of antibodies to soluble Plasmodium falciparum antigen (Pf70) and protection against malaria in a human population living under intense transmission in Kinshasa, Zaire. Tshefu K, et al. **Trop Med Parasitol** 1995 Jun; 46(2):72–6

Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens. Chatterjee S, et al. **Vaccine** 1995;13(15):1474–81

The effect of temperature on the stability of the synthetic SPf(66)n malaria vaccine. López MC, et al. **Vaccine** 1995 Sep;13(13):1180–2

[Preliminary study of a recombinant polyvalent vaccine of Plasmodium falciparum and its immunological activity] Li Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):325–8, 381 (Eng. Abstr.) **(Chi)**

[The inhibitory effects of immune sera against two recombinant hybrid antigens on the growth of Plasmodium falciparum in vitro] Li Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):209–13 (Eng. Abstr.) **(Chi)**

[Sequence analysis of apical membrane antigen I from a Plasmodium falciparum isolate collected from Mengpeng Township, Yunnan Province] Zhang L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):203–8 (Eng. Abstr.) **(Chi)**

[Immunology of human Plasmodium falciparum malaria] Vanham G, et al. **Ann Soc Belg Med Trop** 1995 Sep; 75(3):159–78 (53 ref.) (Eng. Abstr.) **(Fre)**

[Immune response against Plasmodium falciparum merozoite antigens and HLA restriction] Dieye A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):69–70 **(Fre)**

[Immunological factors blocking transmission (letter)] Mulder B. **Med Trop (Mars)** 1995;55(4 Suppl):116–8 **(Fre)**

[Antimalarial vaccination] Ambroise-Thomas P. **Sante** 1995 Nov-Dec;5(6):411–5 (19 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Short report: simultaneous detection by polymerase chain reaction of mosquito species and Plasmodium falciparum infection in Anopheles gambiae sensu lato. Bouare M, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):629–31

Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Daubersies P, et al. **Am J Trop Med Hyg** 1996 Jan; 54(1):18–26

Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Roper C, et al. **Am J Trop Med Hyg** 1996 Apr; 54(4):325–31

Prevalence of malaria parasitaemia in transfused donor blood in Benin City, Nigeria. Ibhanesebhor SE, et al. **Ann Trop Paediatr** 1996 Jun;16(2):93–5

A histological and immunohistological study of malarial placentas. Moshi EZ, et al. **APMIS** 1995 Oct; 103(10):737–43

Plasmodium falciparum: isolation of large numbers of parasite clones from infected blood samples. Kirkman LA, et al. **Exp Parasitol** 1996 Jun;83(1):147–9

Naturally acquired concomitant infections of bancroftian filariasis and human plasmodia in Orissa. Ghosh SK, et al. **Indian J Malariol** 1995 Mar;32(1):32–6

Identification of malaria-infected dried mosquitoes by biotinylated DNA probe. Liu KY, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):162–6

A rare presentation of falciparum malaria. Jain D, et al. **J Assoc Physicians India** 1995 Aug;43(8):582

Transplacental passage of Plasmodium falciparum and seroevaluation of newborns in northern Nigeria. Egwunyenga OA, et al. **J Commun Dis** 1995 Jun; 27(2):77–83

Frequent blood-feeding and restrictive sugar-feeding behavior enhance the malaria vector potential of Anopheles gambiae s.l. and An. funestus (Diptera:Culicidae) in western Kenya. Beier JC. **J Med Entomol** 1996 Jul;33(4):613–8

Detection of Plasmodium sporozoites in mosquitoes by polymerase chain reaction and oligonucleotide rDNA probe, without dissection of the salivary glands. Stoffels JA, et al. **Med Vet Entomol** 1995 Oct;9(4):433–7

The use of the polymerase chain reaction for more sensitive detection of Plasmodium falciparum. Felger I, et al. **P N G Med J** 1995 Mar;38(1):52–6

Plasmodium falciparum malaria in sympatric ethnic groups of Burkina Faso, west Africa. Modiano D, et al. **Parassitologia** 1995 Dec;37(2-3):255–9

Eleven-year-old girl with Plasmodium falciparum malaria and nephrotic syndrome. SangerTD. **Pediatr Infect Dis J** 1995 Dec;14(12):1107–8

Estimation of numbers of malaria clones in blood samples. Hill WG, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22;262(1365):249–57

Comparison between microscopic examination, ELISA and quantitative buffy coat analysis in the diagnosis of falciparum malaria in an endemic population. Tanpradist S, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar;26(1):38–45

Culturing Plasmodium falciparum from finger-prick samples of infected blood. Thaithong S, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):490

METABOLISM

Methionine recycling pathways and antimalarial drug design. Sufrin JR, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2511–5

Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Ansorge I, et al. **Biochem J** 1996 Apr 1; 315 (Pt 1):307–14

Recombination associated with replication of malarial mitochondrial DNA. Preiser PR, et al. **EMBO J** 1996 Feb 1;15(3):684–93

Increased levels of 4-hydroxynonenal in human monocytes fed with malarial pigment hemozoin. A possible clue for hemozoin toxicity. Schwarzer E, et al. **FEBS Lett** 1996 Jun 17;388(2-3):119–22

Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway. Tachado SD, et al. **J Immunol** 1996 Mar 1; 156(5):1897–1907

Chloroquine resistance is not associated with drug metabolism in Plasmodium falciparum. Berger BJ, et al. **J Parasitol** 1995 Dec;81(6):1004–8

The structure of the large subunit rRNA expressed in blood stages of Plasmodium falciparum. Waters AP, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):227–37

Haem polymerization in malaria [letter] Bendrat K, et al. **Nature** 1995 Nov 9;378(6553):138–9

Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Baruch DI, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3497–502

Plasmodium hemozoin formation mediated by histidine-rich proteins. Sullivan DJ Jr, et al. **Science** 1996 Jan 12; 271(5246):219–22

PARASITOLOGY

Novel anion dependence of induced cation transport in malaria-infected erythrocytes. Kirk K, et al. **J Biol Chem** 1995 Oct 13;270(41):24270–5

PATHOGENICITY

Plasmodium falciparum merozoite adhesion is mediated by sialic acid. DeLuca GM, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):726–32

An overview of pathophysiological theories in Plasmodium falciparum cerebral malaria with the special reference to the role of cytokines. Kotlowski A. **Bull Inst Marit Trop Med Gdynia** 1993-94;44-45(1-4):103–8 (37 ref.)

Transport pathways in the malaria-infected erythrocyte: characterization and their use as potential targets for chemotherapy. Ginsburg H. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:99–109 (82 ref.)

Plasmodium falciparum lacks sialidase and trans-sialidase activity. Clough B, et al. **Parasitology** 1996 May;112 (Pt 5):443–9

Variant antigens and endothelial receptor adhesion in Plasmodium falciparum. Gardner JP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3503–8

Chondroitin-4-sulphate (proteoglycan), a receptor for

PLASMODIUM FALCIPARUM

Plasmodium falciparum–infected erythrocyte adherence on brain microvascular endothelial cells. Robert C, et al. **Res Immunol** 1995 Jul–Aug;146(6):383–93

PHYSIOLOGY

Ultrastructural aspects of Plasmodium falciparum–infected erythrocyte adherence to endothelial cells of Saimiri brain microvasculature. Robert C, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):169–77

In search of a selective inhibitor of the induced transport of small solutes in Plasmodium falciparum–infected erythrocytes: effects of arylaminobenzoates. Kirk K, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):761–8

Reduced invasion and growth of Plasmodium falciparum into elliptocytic red blood cells with a combined deficiency of protein 4.1, glycophorin C, and p55. Chishti AH, et al. **Blood** 1996 Apr 15;87(8):3462–9

Role of the Plasmodium falciparum mature–parasite–infected erythrocyte surface antigen (MESA/PfEMP–2) in malarial infection of erythrocytes. Magowan C, et al. **Blood** 1995 Oct 15;86(8):3196–204

CD36 and intercellular adhesion molecule 1 mediate adhesion of developing Plasmodium falciparum gametocytes. Rogers NJ, et al. **Infect Immun** 1996 Apr;64(4):1480–3

N–linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum. Kimura EA, et al. **J Biol Chem** 1996 Jun 14;271(24):14452–61

Plasmodium falciparum rhoptry proteins of 140/130/110 kd (Rhop–H) are located in an electron lucent compartment in the neck of the rhoptries. Sam–Yellowe TY, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):224–31

The secretary pathway of plasmodium falciparum regulates transport of p82/RAP1 to the rhoptries. Howard RF, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):43–54

Malaria parasites enhance blood–feeding of their naturally infected vector Anopheles punctulatus. Koella JC, et al. **Parasitology** 1996 Aug;113 (Pt 2):105–9

The impact of variations in temperature on early Plasmodium falciparum development in Anopheles stephensi. Noden BH, et al. **Parasitology** 1995 Dec;111 (Pt 5):539–45

Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism. Gupta S, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):271–7 (39 ref.)

Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta [see comments] Fried M, et al. **Science** 1996 Jun 7;272(5267):1502–4. Comment in: Science 1996 Jun 7;272(5267):1416–7.

Self–fertilization, linkage disequilibrium, and strain in Plasmodium falciparum [letter; comment] Tibayrenc M, et al. **Science** 1996 Mar 1;271(5253):1300–1. Comment on: Science 1995 Sep 22;269(5231):1709–11.

The antimalarial drug, Ro 42–1611 (arteflene), does not affect cytoadherence and cytokine–inducing properties of Plasmodium falciparum malaria parasites. Jakobsen PH, et al. **Trop Med Parasitol** 1995 Jun;46(2):88–92

Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission–blocking monoclonal antibodies. Ploton IN, et al. **Vaccine** 1995 Sep;13(13):1161–9

ULTRASTRUCTURE

Plastid in human parasites [letter] McFadden GI, et al. **Nature** 1996 Jun 6;381(6582):482

Recent developments and rationale towards new strategies for malarial chemotherapy. Vial H. **Parasite** 1996 Mar; 3(1):3–23 (148 ref.)

[Plasmodium falciparum hematozoan morphological alterations in Gabon children treated with artemether] Kombila M, et al. **Med Trop (Mars)** 1995;55(4 Suppl):97–100 **(Fre)**

PLASMODIUM FALCIPARUM MALARIA see **MALARIA, FALCIPARUM**

PLASMODIUM GALLINACEUM

IMMUNOLOGY

Plasmodium gallinaceum: sporozoite invasion of Aedes aegypti salivary glands is inhibited by anti–gland antibodies and by lectins. Barreau C, et al. **Exp Parasitol** 1995 Nov; 81(3):332–43

Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. Ramirez AD, et al. **J Eukaryot Microbiol** 1995 Nov–Dec;42(6):705–8

ISOLATION & PURIFICATION

Plasmodium: a quantitative molecular assay for detection of sporogonic–stage malaria parasites. Vernick KD, et al. **Exp Parasitol** 1995 Dec;81(4):436–44

PHYSIOLOGY

Plasmodium gallinaceum: mosquito peritrophic matrix and the parasite–vector compatibility. Shahabuddin M, et al. **Exp Parasitol** 1995 Nov;81(3):386–93

Antibody–mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium gallinaceum. Shahabuddin M, et al. **Infect Immun** 1996 Mar; 64(3):739–43

PLASMODIUM INFECTIONS see **MALARIA**

PLASMODIUM KNOWLESI

Lipofuscin pigment in cerebellar Purkinje neurones and choroid plexus epithelial cells of macaque monkeys with Plasmodium knowlesi cerebral malaria: an electron microscopical observation. Ibiwoye MO, et al. **Zentralbl Veterinarmed [B]** 1995 May;42(3):140–6

METABOLISM

Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein–1. Blackman MJ, et al. **Exp Parasitol** 1996 Jul;83(2):229–39

PHYSIOLOGY

Sporozoite transmission of three strains of Plasmodium knowlesi to Aotus and Saimiri monkeys. Sullivan JS, et al. **J Parasitol** 1996 Apr;82(2):268–71

PLASMODIUM MALARIAE

ISOLATION & PURIFICATION

Naturally acquired concomitant infections of bancroftian filariasis and human plasmodia in Orissa. Ghosh SK, et al. **Indian J Malariol** 1995 Mar;32(1):32–6

Species–specific PCR detection of malaria parasites by microtiter plate hybridization: clinical study with malaria patients. Kimura M, et al. **J Clin Microbiol** 1995 Sep; 33(9):2342–6

The use of the polymerase chain reaction for more sensitive detection of Plasmodium falciparum. Felger I, et al. **P N G Med J** 1995 Mar;38(1):52–6

PLASMODIUM VIVAX

Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. Kano S, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1408–12

DRUG EFFECTS

Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand. Tan–ariya P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):426–9

GENETICS

Plasmodium vivax: favored gene frequencies of the merozoite surface protein–1 and the multiplicity of infection in a malaria endemic region. Kolakovich KA, et al. **Exp Parasitol** 1996 Jun;83(1):11–9

Phenotype and genotype diversity in the circumsporozoite proteins of Plasmodium vivax in Thailand. Rongnoparut P, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):201–10

GROWTH & DEVELOPMENT

Demonstration of in vitro cultured exoerythrocytic schizonts and hypnozoites of Plasmodium vivax (southern China isolate) by an immunoperoxidase antibody technique. Liu D, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):86–8

Antibodies to Anopheles midgut reduce vector competence for Plasmodium vivax malaria. Srikrishnaraj KA, et al. **Med Vet Entomol** 1995 Oct;9(4):353–7

Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes. Salas ML, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:115–9

[Effect of environmental temperature, cryopreservation and aging on Plasmodium vivax sporozoites developing into exoerythrocytic stages] Liu D, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):165–9 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Acquired transmission–blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Ramsey JM, et al. **Am J Trop Med Hyg** 1996 May;54(5):458–63

Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Rattanarithikul R, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):114–21

Prevalence of antibodies to the repeat epitope of the circumsporozoite protein of Plasmodium vivax in San Luis Potosi, Mexico. Mota J, et al. **Arch Med Res** 1996 Summer; 27(2):233–6

A malaria parasite toxin associated with Plasmodium vivax paroxysms. Wijesekera SK, et al. **Clin Exp Immunol** 1996 May;104(2):221–7

Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c mice. Herrera MA, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:71–6

Advances toward the development of an asexual blood stage MSP–1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

Plasmodium vivax: detection of blood parasites using fluorochrome labelled monoclonal antibodies. Perez HA, et al. **Parasite Immunol** 1995 Jun;17(6):305–12

ISOLATION & PURIFICATION

Naturally acquired concomitant infections of bancroftian filariasis and human plasmodia in Orissa. Ghosh SK, et al. **Indian J Malariol** 1995 Mar;32(1):32–6

Development of specific DNA probes and their usage in the detection of Plasmodium vivax infection in blood. Ayyanathan K, et al. **Mol Cell Probes** 1995 Aug;9(4):239–46

The use of the polymerase chain reaction for more sensitive detection of Plasmodium falciparum. Felger I, et al. **P N G Med J** 1995 Mar;38(1):52–6

Multiple invasion of red blood cells by Plasmodium vivax in vivo. Poirriez J, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):509–10

METABOLISM

Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)

PHYSIOLOGY

Experimental and field studies on some biological characteristics of Plasmodium vivax isolated from tropical and temperate zones of China. Yang B. **Chin Med J (Engl)** 1996 Apr;109(4):266–71

Observations on the biological nature of Plasmodium vivax sporozoites. Collins WE, et al. **J Parasitol** 1996 Apr; 82(2):216–9

Malaria parasites enhance blood–feeding of their naturally infected vector Anopheles punctulatus. Koella JC, et al. **Parasitology** 1996 Aug;113 (Pt 2):105–9

Rosette formation by Plasmodium vivax. Udomsanpetch R, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec; 89(6):635–7

[Observation on hypnozoite of different isolates of Plasmodium vivax in cultured materials] Shu H, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):185–8 (Eng. Abstr.) **(Chi)**

PLASMODIUM VIVAX MALARIA see **MALARIA, VIVAX**

PLASMODIUM YOELII

Studies on ammonia–metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. Agrawal A, et al. **Int J Parasitol** 1996 Apr; 26(4):451–5

Postprandial lymphatic flux and malaria. Deharo E, et al. **Parasite** 1995 Dec;2(4):417–8

[Relationship between tumour necrosis factor and anemia of malaria] Hou Y, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):134–7 (Eng. Abstr.) **(Chi)**

DRUG EFFECTS

The chemotherapy of rodent malaria. LII. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomers. Peters W, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):465–8

Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Atamna H, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):693–700

[A preliminary study on the inhibitory action of target–primaqine on the exoerythrocytic forms of Plasmodium yoelii yoelii] Song J, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):117–9 (Eng. Abstr.) **(Chi)**

GENETICS

Cloning and structural analysis of the gene for cAMP–dependent protein kinase catalytic subunit from Plasmodium yoelii. Saito–Ito A, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):1–5

Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. Doolan DL, et al. **J Biol Chem** 1996 Jul 26;271(30):17861–8

GROWTH & DEVELOPMENT

Effects of iron deficiency on the hepatic development of Plasmodium yoelii. Goma J, et al. **Parasite** 1995 Dec; 2(4):351–6

IMMUNOLOGY

Plasmodium yoelii: the role of the individual epidermal growth factor–like domains of the merozoite surface protein–1 in protection from malaria. Calvo PA, et al. **Exp Parasitol** 1996 Jan;82(1):54–64

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Daly TM, et al. **Infect Immun** 1996 Jul;64(7):2602–8

Cytokines and antibody subclass associated with protective immunity against blood–stage malaria in mice vaccinated

with the C terminus of merozoite surface protein 1 plus a novel adjuvant. De Souza JB, et al. **Infect Immun** 1996 Sep;64(9):3532–6

Protective immunity against malaria: cellular changes in the liver vary according to the method of immunization. Faure P, et al. **Parasite Immunol** 1995 Sep;17(9):469–77

The combined epidermal growth factor–like modules of Plasmodium yoelii Merozoite Surface Protein–1 are required for a protective immune response to the parasite. Ling IT, et al. **Parasite Immunol** 1995 Aug;17(8):425–33

A novel adjuvant for use with a blood–stage malaria vaccine. de Souza JB, et al. **Vaccine** 1995 Oct;13(14):1316–9

METABOLISM

Plasmodium yoelii: expression of circumsporozoite protein and sporozoite surface protein 2 by sporozoites in culture. Siu NF, et al. **Exp Parasitol** 1995 Dec;81(4):600–3

PATHOGENICITY

Noninfectious sporozoites in the salivary glands of a minimally susceptible anopheline mosquito. Noden BH, et al. **J Parasitol** 1995 Dec;81(6):912–5

Plasmodium yoelii nigeriensis: the effect of high and low intensity of infection upon the egg production and bloodmeal size of Anopheles stephensi during three gonotrophic cycles. Hogg JC, et al. **Parasitology** 1995 Dec; 111 (Pt 5):555–62

PHYSIOLOGY

Circulation in the lymphatic system and latency of Plasmodium merozoites. Preliminary note. Landau I, et al. **Parasite** 1995 Jun;2(2):185–6

PLASMOSOME see **CELL NUCLEOLUS**

PLASTER CASTS see **CASTS, SURGICAL**

PLASTER OF PARIS see **CALCIUM SULFATE**

PLASTIC CASTS see **CASTS, SURGICAL**

PLASTIC EMBEDDING

A simple and rapid staining technique for plastic embedded cartilage and bone. Grill V, et al. **Biotech Histochem** 1995 Mar;70(2):75–80

Immunohistochemical staining of plastic embedded bone marrow trephine biopsy specimens after microwave heating. McCluggage WG, et al. **J Clin Pathol** 1995 Sep; 48(9):840–4

A comparison between the effects of paraffin and plastic embedding of the normal and obstructed minipig detrusor muscle using the optical dissector. Nielsen KK, et al. **J Urol** 1995 Dec;154(6):2170–3

In situ enzyme histochemistry on plastic–embedded plant material. De Block M. **Methods Cell Biol** 1995;49:153–63

High–resolution light microscopy for interpretation of renal biopsies. Hoffmann EO. **Pediatr Nephrol** 1995 Dec; 9(6):763–9 (81 ref.)

METHODS

Method for embedding temporal bones of rats in methyl–methacrylate. Nageris B, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):783–5

Glycol methacrylate embedding of alginate–polylysine microencapsulated pancreatic islets. Fritschy WM, et al. **Biotech Histochem** 1995 Jul;70(4):188–93

Immunohistochemical detection of epidermal growth factor in glycol methacrylate embedded tissue. Ogborn MR, et al. **Biotech Histochem** 1995 Jul;70(4):202–4

Bromodeoxyuridine and iododeoxyuridine double immunostaining for epoxy resin sections. Sato Y, et al. **Biotech Histochem** 1995 Jul;70(4):169–74

Comparison of LR White and Unicryl as embedding media for light and electron immunomicroscopy of chromaffin cells. Goping G, et al. **J Histochem Cytochem** 1996 Mar; 44(3):289–95

A simple technique for flat osmicating and flat embedding of immunolabelled vibratome sections of the rat spinal cord for light and electron microscopy. Nguyen KB, et al. **J Neurosci Methods** 1996 Mar;65(1):51–4

Microwave oven heating enhances the ultrastructural detection of antigens in bioacryl–embedded tissue sections. Preda P, et al. **Microsc Res Tech** 1995 Sep 1;32(1):75–6

PLASTIC SURGERY see **SURGERY, PLASTIC**

PLASTICITY, NEURONAL see **NEURONAL PLASTICITY**

PLASTICIZERS

Plasticizer–level study of poly(vinyl chloride) ion–selective membranes. Simon MA, et al. **J Biomed Mater Res** 1996 Mar;30(3):313–20

Effect of microwave heating on the migration of dioctyladipate and acetyltributylcitrate plasticizers from food–grade PVC and PVDC/PVC films into olive oil and water. Badeka AB, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):313–7

ADVERSE EFFECTS

Anti–plasticizer specific IgE is present in the serum of transfused patients. Salkie ML, et al. **Clin Invest Med** 1995 Dec;18(6):419–23

ANALYSIS

Determination of plasticisers in food by gas chromatography–mass spectrometry with ion–trap mass detection. Lau OW, et al. **J Chromatogr A** 1996 Jun 21; 737(2):338–42

CHEMISTRY

A comparative study of platelets stored in polyvinyl chloride containers plasticised with butyryl trihexyl citrate or triethylhexyl trimellitate. Turner VS, et al. **Vox Sang** 1995; 69(3):195–200

METABOLISM

A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Jobling S, et al. **Environ Health Perspect** 1995 Jun;103(6):582–7

PHARMACOLOGY

Hypolipidemic agents alter hepatic mitochondrial respiration in vitro. Chance DS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):317–23

Biochemical, neuropathological and behavioral studies in hens induced by acute exposure of tri–ortho–cresyl phosphate. Nanda S, et al. **Int J Neurosci** 1995 Jun; 82(3–4):243–54

Effect of components of resilient denture–lining materials on the growth, acid production and colonization of Candida albicans. Nikawa H, et al. **J Oral Rehabil** 1995 Nov; 22(11):817–24

RADIATION EFFECTS

Effect of gamma–radiation on migration behaviour of dioctyladipate and acetyltributylcitrate plasticizers from food–grade PVC and PVDC/PVC films into olive oil. Goulas AE, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):74–8

TOXICITY

Acetyl tributyl citrate and dibutyl sebacate inhibit the growth of cultured mammalian cells. Mochida K, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):635–7

Administration of the plasticizer di (2–ethylhexyl) phthalate alters glycoconjugate profile. Selvam S, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):252–4

Biochemical, neuropathological and behavioral studies in hens induced by acute exposure of tri–ortho–cresyl phosphate. Nanda S, et al. **Int J Neurosci** 1995 Jun; 82(3–4):243–54

UK panics over phthalates in babymilk formulae [news] Bradbury J. **Lancet** 1996 Jun 1;347(9014):1541

Behavioral changes with alterations of choline acetyltransferase immunoreactivities induced by N–butyl benzenesulfonamide. Lee WY, et al. **Vet Hum Toxicol** 1995 Dec;37(6):537–42

PLASTICS

Mortality among workers at a plastics manufacturing and research and development facility: 1946–1988. Dell L, et al. **Am J Ind Med** 1995 Sep;28(3):373–84

A dangerous problem with plastic Yankauer suckers [letter] Woodey R, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):519–20

Plastic bags for stable storage of the water–soluble fraction of crude petroleum used in aquatic environment toxicity and tainting studies. Heras H, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):597–602

Plastic surgery's plastics. Ousterhout DK, et al. **Clin Plast Surg** 1996 Jan;23(1):183–90 (46 ref.)

Stimulation of arachidonic acid mobilization by adherence of resident peritoneal macrophages to plastic substrate. Lloret S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):403–8

Chlamydia trachomatis can be transmitted by a nonporous plastic surface in vitro. Novak KD, et al. **Cornea** 1995 Sep; 14(5):523–6

Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. De Palma GD, et al. **Gastrointest Endosc** 1996 May;43(5):478–82

Objective and subjective observations of low–temperature thermoplastic materials. Lee DB. **J Hand Ther** 1995 Apr–Jun;8(2):138–43 (7 ref.)

Methods for studying microbial colonization of plastics. Christensen GD, et al. **Methods Enzymol** 1995;253:477–500

[Plastic prostheses or self–expanding stents—is there an ideal drainage? Pro synthetics] Soehendra N, et al. **Bildgebung** 1995 Oct;62 Suppl 2:55–8 (23 ref.) **(Ger)**

[Life expectancy indicator for re–sterilizable plastic materials] Haindl H, et al. **Biomed Tech (Berl)** 1995 Jul–Aug; 40(7–8):210–3 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Contact urticaria from abietic acid. el Sayed F, et al. **Contact Dermatitis** 1995 Jun;32(6):361–2

Analysis of patients with allergic patch test reactions to a plastics and glues series. Tarvainen K. **Contact Dermatitis** 1995 Jun;32(6):346–51

ANALYSIS

Element residues in food contact plastics and their migration into food simulants, measured by inductively–coupled plasma–mass spectrometry. Fordham PJ, et al. **Food Addit Contam** 1995 Sep–Oct;12(5):651–69

[A method for determining global migration into model fluids from plastic packaging materials, in accordance with recommendations of the EWG commission] Lewandowska I, et al. **Rocz Panstw Zakl Hig** 1995;46(3):271–7 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Forces transmitted through EVA mouthguard materials of different types and thickness. Westerman B, et al. **Aust Dent J** 1995 Dec;40(6):389–91

Temperature dependence of toothbrush bristle morphology. An ultrastructural study. Franchi M, et al. **J Clin Periodontol** 1995 Aug;22(8):655–8

Modeling solute sorption into plastic tubing during organ perfusion and intravenous infusions. Roberts MS. **J Pharm Sci** 1996 Jun;85(6):655–65

[Characterization and simultaneous assay of polymers and additives composing multilayer plastic material for pharmaceutical use by FTIR] Yagoubi N, et al. **Ann Pharm Fr** 1996;54(3):126–30 (Eng. Abstr.) **(Fre)**

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

Bacteria associated with disintegrating plastic films under simulated aquatic environments. Leonas KK, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):948–55

PLASTIDS

Intron–encoded open reading frame of the GIY–YIG subclass in a plastid gene. Paquin B, et al. **Curr Genet** 1995 Jun;28(1):97–9

Marker rescue from the Nicotiana tabacum plastid genome using a plastid/Escherichia coli shuttle vector. Staub JM, et al. **Mol Gen Genet** 1995 Nov 1;249(1):37–42

Plastid in human parasites [letter] McFadden GI, et al. **Nature** 1996 Jun 6;381(6582):482

CHEMISTRY

Biochemistry and molecular biology of chromoplast development. Camara B, et al. **Int Rev Cytol** 1995; 163:175–247 (530 ref.)

Primary structure of cyanelle peptidoglycan of Cyanophora paradoxa: a prokaryotic cell wall as part of an organelle envelope. Pfanzagl B, et al. **J Bacteriol** 1996 Jan; 178(2):332–9

Far–red light blocks greening of Arabidopsis seedlings via a phytochrome A–mediated change in plastid development. Barnes SA, et al. **Plant Cell** 1996 Apr;8(4):601–15

ENZYMOLOGY

Deletion of rpoB reveals a second distinct transcription system in plastids of higher plants. Allison LA, et al. **EMBO J** 1996 Jun 3;15(11):2802–9

In vitro import of pre–ferredoxin–NADP+–oxidoreductase from Cyanophora paradoxa into cyanelles and into pea chloroplasts. Jakowitsch J, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):153–5

The plastid aldolase gene from Chlamydomonas reinhardtii: intron/exon organization, evolution, and promoter structure. Pelzer–Reith B, et al. **Mol Gen Genet** 1995 Aug 30;248(4):481–6

GENETICS

Structural and functional analysis of plastid genomes from parasitic plants: loss of an intron within the genus Cuscuta. Freyer R, et al. **Curr Genet** 1995 May;27(6):580–6

Phylogenetic position of the Chromista plastids based on small subunit rRNA coding regions. Medlin LK, et al. **Curr Genet** 1995 Nov;28(6):560–5

Localization and expression of the closely linked cyanelle genes for RNase P RNA and two transfer RNAs. Baum M, et al. **FEBS Lett** 1996 Mar 11;382(1–2):60–4

arc6, an extreme chloroplast division mutant of Arabidopsis also alters proplastid proliferation and morphology in shoot and root apices. Robertson EJ, et al. **J Cell Sci** 1995 Sep; 108 (Pt 9):2937–44

Complete gene map of the plastid–like DNA of the malaria parasite Plasmodium falciparum. Wilson RJ, et al. **J Mol Biol** 1996 Aug 16;261(2):155–72

An early origin of plastids within the cyanobacterial divergence is suggested by evolutionary trees based on complete 16S rRNA sequences. Nelissen B, et al. **Mol Biol Evol** 1995 Nov;12(6):1166–73

Sequence variation in the putative replication origins of the

PLASTIDS

five genetically distinct basic Euoenothera plastid chromosomes (plastomes). Hornung S, et al. **Mol Gen Genet** 1996 Jul 19;251(5):609–12

A ribosomal protein gene (rpl32) from tobacco chloroplast DNA is transcribed from alternative promoters: similarities in promoter region organization in plastid housekeeping genes. Vera A, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):518–25

tRNA genes transcribed from the plastid-like DNA of Plasmodium falciparum. Preiser P, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4329–36

The stroma of higher plant plastids contain ClpP and ClpC, functional homologs of Escherichia coli ClpP and ClpA: an archetypal two-component ATP-dependent protease. Shanklin J, et al. **Plant Cell** 1995 Oct;7(10):1713–22

Transcription, splicing and editing of plastid RNAs in the nonphotosynthetic plant Epifagus virginiana. Ems SC, et al. **Plant Mol Biol** 1995 Nov;29(4):721–33

Impaired splicing of the rps12 transcript in ribosome-deficient plastids. Hübschmann T, et al. **Plant Mol Biol** 1996 Jan;30(1):109–23

Characterization of a plastid-specific HSP90 homologue: identification of a cDNA sequence, phylogenetic descendence and analysis of its mRNA and protein expression. Schmitz G, et al. **Plant Mol Biol** 1996 Feb; 30(3):479–92

METABOLISM

The plastid-encoded ccsA gene is required for heme attachment to chloroplast c-type cytochromes. Xie Z, et al. **J Biol Chem** 1996 Mar 1;271(9):4632–9

Chromoplasts. Price CA, et al. **Methods Cell Biol** 1995; 50:189–207

The spinach AtpC and AtpD genes contain elements for light-regulated, plastid-dependent and organ-specific expression in the vicinity of the transcription start sites. Bolle C, et al. **Plant J** 1996 Jan;9(1):21–30

Divergent evolution of two plastid genes, rbcL and atpB, in a non-photosynthetic parasitic plant. Delavault P, et al. **Plant Mol Biol** 1995 Dec;29(5):1071–9

Formation of the ferritin iron mineral occurs in plastids. Waldo GS, et al. **Plant Physiol** 1995 Nov;109(3):797–802

PHYSIOLOGY

Biochemistry and molecular biology of chromoplast development. Camara B, et al. **Int Rev Cytol** 1995; 163:175–247 (530 ref.)

PLASTOCYANIN

BIOSYNTHESIS

The sequence surrounding the translation initiation codon of the pea plastocyanin gene increases translational efficiency of a reporter gene. Helliwell CA, et al. **Plant Mol Biol** 1995 Nov;29(3):621–6

CHEMISTRY

Light-induced charge separation between plastocyanin and the iron-sulfur clusters FA and FB in the complex of plastocyanin and photosystem I. Hippler M, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):414–8

Solution structure of reduced plastocyanin from the blue-green alga Anabaena variabilis. Badsberg U, et al. **Biochemistry** 1996 Jun 4;35(22):7021–31

Laser-flash kinetic analysis of the fast electron transfer from plastocyanin and cytochrome c6 to photosystem I. Experimental evidence on the evolution of the reaction mechanism. Hervás M, et al. **Biochemistry** 1995 Sep 12; 34(36):11321–6

Enforced interaction of one molecule of plastocyanin with two molecules of cytochrome c and an electron-transfer reaction involving the hydrophobic patch on the plastocyanin surface. Qin L, et al. **Biochemistry** 1996 Mar 19;35(11):3379–86

Site-directed mutagenetic study on the role of negative patches on silene plastocyanin in the interactions with cytochrome f and photosystem I. Lee BH, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1209–17

Ab initio determination of the crystal structure of cytochrome c6 and comparison with plastocyanin. Frazão C, et al. **Structure** 1995 Nov 15;3(11):1159–69

GENETICS

The sequence surrounding the translation initiation codon of the pea plastocyanin gene increases translational efficiency of a reporter gene. Helliwell CA, et al. **Plant Mol Biol** 1995 Nov;29(3):621–6

METABOLISM

Binding dynamics and electron transfer between plastocyanin and photosystem I. Drepper F, et al. **Biochemistry** 1996 Jan 30;35(4):1282–95

Structural dynamics in the plastocyanin-photosystem I electron-transfer complex as revealed by mutant studies. Sigfridsson K, et al. **Biochemistry** 1996 Jan 30;35(4):1249–57

Isolation of a psaF-deficient mutant of Chlamydomonas reinhardtii: efficient interaction of plastocyanin with the photosystem I reaction center is mediated by the PsaF subunit. Farah J, et al. **EMBO J** 1995 Oct 16;14(20):4976–84

Degradation of plastocyanin in copper-deficient Chlamydomonas reinhardtii. Evidence for a protease-susceptible conformation of the apoprotein and regulated proteolysis. Li HH, et al. **J Biol Chem** 1995 Oct 6;270(40):23504–10

RADIATION EFFECTS

Light-induced charge separation between plastocyanin and the iron-sulfur clusters FA and FB in the complex of plastocyanin and photosystem I. Hippler M, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):414–8

PLASTOQUINONE

ANALOGS & DERIVATIVES

The conformation of the isoprenyl chain relative to the semiquinone head in the primary electron acceptor (QA) of higher plant PSII (plastosemiquinone) differs from that in bacterial reaction centers (ubisemiquinone or menasemiquinone) by ca. 90 degrees. Zheng M, et al. **Biochemistry** 1996 Jul 9;35(27):8955–63

Activation/deactivation cycle of redox-controlled thylakoid protein phosphorylation. Role of plastoquinol bound to the reduced cytochrome bf complex. Vener AV, et al. **J Biol Chem** 1995 Oct 20;270(42):25225–32

CHEMISTRY

ESEEM study of the plastoquinone anion radical (QA.−) in 14N- and 15N-labeled photosystem II treated with CN. Deligiannakis Y, et al. **Biochemistry** 1995 Dec 12; 34(49):16030–8

Influence of the redox state of ubiquinones and plastoquinones on the order of lipid bilayers studied by fluorescence anisotropy of diphenylhexatriene and trimethylammonium diphenylhexatriene. Skowronek M, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):115–9

METABOLISM

Antioxidant activity of reduced plastoquinone in chloroplast thylakoid membranes. Hundal T, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):117–22

Biosynthesis of isoprenoids (carotenoids, sterols, prenyl side-chains of chlorophylls and plastoquinone) via a novel pyruvate/glyceraldehyde 3-phosphate non-mevalonate pathway in the green alga Scenedesmus obliquus. Schwender J, et al. **Biochem J** 1996 May 15;316 (Pt 1):73–80

Reconstitution of the endogenous plastoquinone pool in photosystem II (PS II) membrane fragments, inside-out-vesicles, and PS II core complexes from spinach. Kurreck J, et al. **Biochemistry** 1995 Dec 5; 34(48):15721–31

Light intensity regulation of cab gene transcription is signaled by the redox state of the plastoquinone pool. Escoubas JM, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10237–41

PLATANNA see **XENOPUS LAEVIS**

PLATELET ACTIVATING FACTOR

Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. Heery JM, et al. **J Clin Invest** 1995 Nov;96(5):2322–30

Platelet-activating factor: antagonists, terminators, molecular mimics, and microbial opportunism [editorial] Zimmerman GA, et al. **J Intern Med** 1996 Jun;239(6):463–6

Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Cundell DR, et al. **Nature** 1995 Oct 5;377(6548):435–8

[Inhalation of platelet-activating factor induced guinea pig airway hyperresponsiveness: role of eosinophils activation] Wang C, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):155–7, 190 (Eng. Abstr.) **(Chi)**

[Effect of KW-4679, a novel antiallergic drug, on platelet-activating factor (PAF)-induced bronchoconstriction, airway hyperresponsiveness and pulmonary cell accumulation in guinea pigs] Sasaki Y, et al. **Nippon Yakurigaku Zasshi** 1995 Nov;106(5):347–57 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Rapid tracheal infusion of surfactant versus bolus instillation in rabbits: effects on oxygenation, blood pressure and surfactant distribution. Segerer H, et al. **Biol Neonate** 1996; 69(2):119–27

Effects of liposome-entrapped platelet-activating factor in the isolated rat trachea. Costuleanu M, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):89–92

Platelet-activating factor augments lipopolysaccharide-induced nitric oxide formation by rat Kupffer cells. Mustafa SB, et al. **Hepatology** 1996 Jun; 23(6):1622–30

Nasal neutrophilia and release of myeloperoxidase induced by nasal challenge with platelet activating factor: different degrees of responsiveness in atopic and nonatopic subjects. Miadonna A, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):947–54

ADVERSE EFFECTS

Inhaled nitric oxide prevents experimental platelet activating factor-induced shock. Emil S, et al. **Arch Surg** 1996 Aug; 131(8):855–9; discussion 859–60

1 alpha,25-Dihydroxyvitamin D3 decreases scalding- and platelet-activating factor-induced high vascular permeability and tissue oedema. Chen SF, et al. **Pharmacol Toxicol** 1995 Jun;76(6):365–7

ANALOGS & DERIVATIVES

Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-Lyso-PAF and the antineoplastic (R)-ET-18-OMe. Xie X, et al. **Biochim Biophys Acta** 1996 Aug 14; 1283(1):111–8

Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties. Man RY, et al. **Br J Pharmacol** 1995 Nov;116(5):2359–64

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Guimbaud R, et al. **Dig Dis Sci** 1995 Dec;40(12):2635–40

Tissue levels of histamine, PAF-acether and lysopaf-acether in carrageenan-induced granuloma in rats. Aïssa J, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):182–6

The metabolism of platelet-activating factor in severe and cerebral malaria. Davis TM, et al. **J Infect** 1995 Nov; 31(3):181–8

Alkyl-PAF and acyl-PAF human neutrophil priming for enhanced fMLP- and rC5a-induced superoxide anion production. Pinckard RN, et al. **J Leukoc Biol** 1996 Feb; 59(2):219–28

Quantification of distinct molecular species of platelet activating factor in ulcerative colitis. Thyssen E, et al. **Lipids** 1996 Mar;31 Suppl:S255–9

ANALYSIS

Quantitation of platelet-activating factor in biological samples using liquid chromatography/mass spectrometry with column-switching technique. Oda Y, et al. **Anal Biochem** 1995 Oct 10;231(1):141–50

Molecular heterogeneity of PAF in normal human mixed saliva: quantitative mass spectral analysis after direct derivatization of PAF with pentafluorobenzoic anhydride. Woodard DS, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):137–47

Liver and plasma concentrations in paf-acether and its precursors after partial hepatectomy. Lombard MN, et al. **Cell Prolif** 1996 Jan;29(1):33–41

Enhanced levels of chemiluminescence and platelet activating factor in urease-positive gastric ulcers. Suzuki H, et al. **Free Radic Biol Med** 1996;20(3):449–54

A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. Aoki Y, et al. **J Immunol Methods** 1995 Oct 26;186(2):225–31

The effect of initial periodontal therapy on salivary platelet-activating factor levels in chronic adult periodontitis. Rasch MS, et al. **J Periodontol** 1995 Jul; 66(7):613–23

Biochemical evidence of platelet-activating factor (PAF) in human middle ear effusions. Furukawa M, et al. **Laryngoscope** 1995 Feb;105(2):188–91

Quantification of distinct molecular species of platelet activating factor in ulcerative colitis. Thyssen E, et al. **Lipids** 1996 Mar;31 Suppl:S255–9

Platelet-activating factor in brain regions after transient ischemia in gerbils. Nishida K, et al. **Stroke** 1996 Mar; 27(3):514–8; discussion 518–9

ANTAGONISTS & INHIBITORS

Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Hozawa S, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1198–202

A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Ono S, et al. **Am J Surg** 1996 Apr;171(4):409–15

Protective effect of a platelet-activating factor antagonist (WEB-2086) in postischemic renal failure. González-Fajardo JA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):16–21

Prevention of platelet-activating factor-induced gastrointestinal lesions in rats by the new specific antagonist N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl)[4-(2,4,6-triisopropylphe nyl) thiazol-2yl]amine. Giudice A, et al. **Arzneimittelforschung** 1996 Apr;46(4):407–12

Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn^{2+}). Evangelou A, et al. **Biol Trace Elem Res** 1995 Oct;50(1):43–55

Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock. De Kimpe SJ, et al. **Br J Pharmacol** 1995 Dec;116(8):3191–8

Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Kingsnorth AN, et al. **Br J Surg** 1995 Oct; 82(10):1414–20

The antagonistic effects of khellactones on platelet-activating factor, histamine, and leukotriene D4. Aida Y, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):859–67

Paf antagonists block induction of nitric oxide synthase in cultured macrophages and vascular smooth muscle cells. Arthur JF, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul; 22(6-7):452-4

Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist. Elder CA, et al. **Drug Metab Dispos** 1995 Jul;23(7):776-8

PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover. Catalán RE, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):183-8

Role of lipoxygenase metabolites in platelet-activating factor- and antigen-induced bronchial hyperresponsiveness and eosinophil infiltration. Seeds EA, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):369-76

Role of platelet-activating factor antagonism in haemorrhagic shock in pigs. Abu-Zidan FM, et al. **Eur Surg Res** 1995;27(6):379-88

Phomactin E, F, and G: new phomactin-group PAF antagonists from a marine fungus Phoma sp [letter] Sugano M, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1188-90

Effects of a paf-receptor antagonist on hemodynamics during and after cardiopulmonary bypass. Nathan N, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):647-52

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131-9 (62 ref.)

Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. Tunón H, et al. **J Ethnopharmacol** 1995 Oct;48(2):61-76

Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. Woodard DS, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):11-28

Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. Carceller E, et al. **J Med Chem** 1996 Jan 19;39(2):487-93

Superoxide dismutase attenuates effects of platelet-activating factor on gastric microcirculation. Schwappach JR, et al. **J Surg Res** 1995 Dec;59(6):733-8

Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock. Okano S, et al. **J Vet Med Sci** 1995 Aug;57(4):751-3

Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock. Okano S, et al. **J Vet Med Sci** 1995 Apr;57(2):385-7

Antiperoxidative effects of platelet activating factor antagonists against iron-dependent lipid peroxidation in murine ventricular membranes. Reddy DS, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):383-90

Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. Bagnis C, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):507-13

Inhibition of platelet-activating factor-induced retinal impairments by cholera and pertussis toxins. Cluzel J, et al. **Ophthalmic Res** 1995;27(3):153-7

Effect of a platelet-activating factor antagonist on pancreas perfusion after 24 h of ischemia. Leonhardt U, et al. **Pancreas** 1995 Aug;11(2):160-4

BB-882 is a potent antagonist of the haemodynamic changes induced by platelet-activating factor in pigs. Abu-Zidan FM, et al. **Pharmacol Toxicol** 1996 Jan;78(1):23-7

Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Cakici I, et al. **Pharmacol Toxicol** 1995 Jun;76(6):343-7

Luminol-chemiluminescence in free peritoneal cells in hemorrhagic shock in rats treated with PAF-receptor-antagonist BN 52021. Dębek W, et al. **Rocz Akad Med Bialymst** 1995;40(1):129-37

Ginkgolide BN 52021 protects against hemorrhagic shock-induced renal injury in rats. Kirejczyk JK, et al. **Rocz Akad Med Bialymst** 1995;40(1):65-76

Oxygen-derived free radicals in kidney in experimental hemorrhagic shock treated by PAF-receptor antagonist BN 52021. Kirejczyk JK, et al. **Rocz Akad Med Bialymst** 1995;40(1):77-87

Inhibitory effects of isoproterenol on PAF-induced endothelial cell permeability and morphological changes. Ding Z, et al. **Sci China C Life Sci** 1996 Feb;39(1):80-6

Inhibition of endotoxin-induced microvascular leakage by a platelet-activating factor antagonist and 5-lipoxygenase inhibitor. Klabunde RE, et al. **Shock** 1995 Nov;4(5):368-72

Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. Spiegel HU, et al. **Transplant Proc** 1995 Oct;27(5):2884-5

Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. Yin M, et al. **Transplant Proc** 1995 Oct;27(5):2844-6

The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Yin M, et al. **Transplantation** 1996 May 27;61(10):1443-6

[Effects of a platelet-activating factor antagonist ONO-6240 on antigen induced eosinophil infiltration into the airways] Shi H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov; 34(11):753-6 (Eng. Abstr.) **(Chi)**

[The effect of platelet-activating factor antagonists on early bacteria translocation of rat after burn injury] Qin X, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):217-8 (Eng. Abstr.) **(Chi)**

[Ginkgolides antagonizing some effects of platelet-activating factor in vitro] Dong JC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):606-8 (Eng. Abstr.) **(Chi)**

[Effects of ginkgolide B on isobaric hypoxic pulmonary hypertension in rats] Cheng D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):386-90 (Eng. Abstr.) **(Chi)**

[Inhibition of formation of superoxide radicals in leukocytes of hypercholesteremic patients under the effect of a lipid platelet activation factor antagonist] Muzia GI, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):45-8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

A higher production of platelet activating factor in ex vivo heterologously secondary dengue-2 virus infections. Yang KD, et al. **Acta Microbiol Immunol Hung** 1995;42(4):403-7

Inhibition of the production of platelet activating factor and of leukotriene B4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Tool AT, et al. **Arzneimittelforschung** 1995 Oct;45(10):1110-4

Alkylglycerophosphate acetyltransferase and lyso platelet activating factor acetyltransferase, two key enzymes in the synthesis of platelet activating factor, are found in neuronal nuclei isolated from cerebral cortex. Baker RR, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):257-63

PAF and haematopoiesis. X. Macrophage colony-stimulating factor and granulocyte macrophage colony-stimulating factor enhance platelet-activating factor acetylhydrolase production by human blood-derived macrophages. Dupuis F, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):27-32

Cyclosporin A (CsA) modulates the glomerular production of inflammatory mediators and proteoglycans in experimental nephrosis. Bustos C, et al. **Clin Exp Immunol** 1995 Dec;102(3):608-13

Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. Dentan C, et al. **Eur J Biochem** 1996 Feb 15;236(1):48-55

Regulation of platelet-activating factor production in gastric epithelial cells. Sobhani I, et al. **Eur J Clin Invest** 1996 Jan;26(1):53-8

Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Sibelius U, et al. **Infect Immun** 1996 Feb; 64(2):674-6

Production of PAF-acether by synovial fluid neutrophils in rheumatoid arthritis. Hilliquin P, et al. **Inflamm Res** 1995 Aug;44(8):313-6

The production of platelet-activating factor (PAF) during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it? Iatrou C, et al. **Int J Artif Organs** 1995 Jul;18(7):355-61

Activation of phospholipase A2 and acylation of lysophospholipids: the major regulators for platelet activating factor production in rat neutrophils. Naraba H, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):442-7

Ligation of the alpha 2-macroglobulin signaling receptor on macrophages induces synthesis of platelet activating factor. Misra UK, et al. **J Cell Biochem** 1996 Apr;61(1):39-47

Interleukin-6 stimulates neutrophil production of platelet-activating factor. Biffl WL, et al. **J Leukoc Biol** 1996 Apr;59(4):569-74

Increased brain levels of platelet-activating factor in a murine acquired immune deficiency syndrome are NMDA receptor-mediated. Nishida K, et al. **J Neurochem** 1996 Jan;66(1):433-5

Adherence of human monocytes to haemodialysis membranes: LFA 1 (CD11a/CD18) CR1 (CD35) and CR3 (CD11b/CD18) triggering promotes the biosynthesis of platelet-activating factor and adherence. Tetta C, et al. **Nephrol Dial Transplant** 1995;10(9):1679-88

Enzymes of platelet activating factor synthesis in brain. Baker RR. **Neurochem Res** 1995 Nov;20(11):1345-51 (70 ref.)

Production of platelet-activating factor by porcine brain microvascular endothelial cells in culture. Satoh K, et al. **Thromb Haemost** 1995 Nov;74(5):1335-9

CHEMICAL SYNTHESIS

A simple chemical synthesis of the ether analog of lysophosphatidylcholine and platelet-activating factor. Das AK, et al. **J Lipid Res** 1995 Nov;36(11):2459-68

CHEMISTRY

Molecular heterogeneity of PAF in normal human mixed saliva: quantitative mass spectral analysis after direct derivatization of PAF with pentafluorobenzoic anhydride. Woodard DS, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):137-47

Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-Lyso-PAF and the antineoplastic (R)-ET-18-OMe. Xie X, et al. **Biochim Biophys Acta** 1996 Aug 14; 1283(1):111-8

DRUG EFFECTS

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. Albert DH, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1595-606

Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. Ortiz JL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):200-6

IMMUNOLOGY

Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers. Hirashima Y, et al. **Acta Neurochir (Wien)** 1995;137(1-2):15-8

Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B cells. Patke CL, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):424-32

METABOLISM

Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. Svetlov SI, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):113-22

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Tselepis AD, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1764-73

Platelet microparticles: a carrier of platelet-activating factor? Iwamoto S, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):940-4

Characterization of a platelet-activating factor acetylhydrolase secreted by the nematode parasite Nippostrongylus brasiliensis. Grigg ME, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):541-7

Evidence for the production of platelet-activating factor by murine embryos and its putative role in the maternal physiology. Suzuki H, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):617-26

Platelet-activating factor receptor: gene expression and signal transduction. Izumi T, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):317-33 (231 ref.)

Plasma mediated neutrophil stimulation during coronary angioplasty: autocrine effect of platelet activating factor. Siminiak T, et al. **Br Heart J** 1995 Dec;74(6):625-30

Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Izaki S, et al. **Br J Dermatol** 1996 Jun;134(6):1060-4

Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages. Watanabe M, et al. **Br J Pharmacol** 1995 Oct;116(3):2141-7

Delayed elevation of platelet activating factor in ischemic hippocampus. Pettigrew LC, et al. **Brain Res** 1995 Sep 11; 691(1-2):243-7

Liver and plasma concentrations in paf-acether and its precursors after partial hepatectomy. Lombard MN, et al. **Cell Prolif** 1996 Jan;29(1):33-41

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Guimbaud R, et al. **Dig Dis Sci** 1995 Dec;40(12):2635-40

Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease [see comments] Goudevenos J, et al. **Eur Heart J** 1995 Aug; 16(8):1036-43. Comment in: Eur Heart J 1995 Aug;16(8):1017-9.

Improved metabolic control in patients with non-insulin-dependent diabetes mellitus is associated with a slower accumulation of glycation products in collagen. Salmela PI, et al. **Eur J Clin Invest** 1995 Jul;25(7):494-500

Specific high affinity binding of platelet activating factor to intact human blood neutrophils and eosinophils. Korth RM. **Int Arch Allergy Immunol** 1996 Jun;110(2):124-31

The role of N-glycosylation for functional expression of the human platelet-activating factor receptor. Glycosylation is required for efficient membrane trafficking. García Rodriguez C, et al. **J Biol Chem** 1995 Oct 20; 270(42):25178-84

Oxidative stress in gastric mucosal injury: role of platelet-activating factor-activated granulocytes. Fukumura D, et al. **J Gastroenterol** 1995 Oct;30(5):565-71

The metabolism of platelet-activating factor in severe and cerebral malaria. Davis TM, et al. **J Infect** 1995 Nov; 31(3):181-8

Identification of functional platelet-activating factor receptors on human keratinocytes. Travers JB, et al. **J Invest Dermatol** 1995 Dec;105(6):816-23

PAF and haematopoiesis: V. Platelet-activating factor and acetylhydrolase in human femoral bone marrow. Denizot Y, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):45-7

Platelet-activating factor receptor. Izumi T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):429-42 (77 ref.)

Platelet-activating factor production in stimulated macrophages is down-regulated by concurrently produced prostaglandin E2. Yamada M, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1607-14

Altered platelet activating factor metabolism in insulin

dependent diabetes mellitus. Memon RA, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):122–5

Platelet–activating factor concentrations in bone marrow of patients with lymphoid and nonlymphoid hematologic malignancies [letter] Denizot Y, et al. **Leukemia** 1995 Nov; 9(11):1982–3

PAF–acetylhydrolase activity and PAF levels in pancreas and plasma of well–fed, diabetic and fasted rat. Trapali M, et al. **Life Sci** 1996;59(10):849–57

Platelet–activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Iatrou C, et al. **Nephron** 1996;72(4):611–6

[Effect of platelet activating factor receptor at spinal cord neurocyte membrane on secondary damage after spinal cord injury] Xiao J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):120–3 (Eng. Abstr.) **(Chi)**

[The roles of platelet activating factor in intestinal mucosal barrier injury after burn] Yu P, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):393–5 (Eng. Abstr.) **(Chi)**

[Distribution of platelet activating factor in the pulmonary tissues of normal rats] Cheng D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):300–3 (Eng. Abstr.) **(Chi)**

[Biological role of cellular metabolites—structural analogs of platelet activating factor] Kulikov VI, et al. **Biokhimiia** 1996 Mar;61(3):387–403 (115 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Differential metabolism of exogenous platelet–activating factor by glandular epithelial and stromal cells of rabbit endometrium. Kudolo GB, et al. **J Reprod Fertil** 1995 Nov; 105(2):315–24

PHARMACOLOGY

PAF attenuates endothelium–dependent coronary arteriolar vasodilation. DeFily DV, et al. **Am J Physiol** 1996 Jun; 270(6 Pt 2):H2094–9

Susceptibility to platelet–activating factor–induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control. Longphre M, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):586–94

PAF–induced airways hyperreactivity is modulated by mast cells in mice. Longphre M, et al. **Am J Respir Cell Mol Biol** 1996 May;14(5):461–9

Salbutamol reduces pulmonary neutrophil sequestration of platelet–activating factor in humans. Masclans JR, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):529–32

Effect of pertussis toxin and B–oligomer on platelet–activating factor–induced generation of inositol phosphates in porcine alveolar macrophages. Dodam JR, et al. **Am J Vet Res** 1996 Apr;57(4):574–9

Ammonium ion minisensors form self–assembled bilayer lipid membranes using gramicidin as an ionophore. Modulation of ammonium selectivity by platelet–activating factor. Nikolelis DP, et al. **Anal Chem** 1996 May 15;68(10):1735–41

Plasma potentiates the priming effects of endotoxin on platelet activating factor–induced pulmonary hypertension in the rabbit lung. Goldsmith JA, et al. **Anesth Analg** 1996 Aug;83(2):242–6

Effects of platelet activating factor on mucociliary clearance of the eustachian tube. Ganbo T, et al. **Ann Otol Rhinol Laryngol** 1996 Feb;105(2):140–5

Effects of PAF on cardiac function and eicosanoid release in the isolated perfused rat heart: comparison between normotensive and spontaneously hypertensive rats. Giessler C, et al. **Basic Res Cardiol** 1995 Jul–Aug;90(4):337–47

Nitric oxide mediates the PAF–stimulated cyclic GMP production in hippocampal slices. Catalán RE, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):27–31

Mutation of an aspartate at position 63 in the human platelet–activating factor receptor augments binding affinity but abolishes G–protein–coupling and inositol phosphate production. Parent JL, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):968–75

Effect of platelet–activating factor on cell differentiation of Trypanosoma cruzi. Rodrigues CO, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):735–40

Ovine endometrium synthesizes and releases platelet–activating factor, which can cause the release of prostaglandin F2 alpha by the uterus in situ. Battye KM, et al. **Biol Reprod** 1996 Feb;54(2):355–63

Increased sensitivity of rat myometrium to the contractile effect of platelet activating factor before delivery. Kim BK, et al. **Br J Pharmacol** 1995 Aug;115(7):1211–4

Platelet–activating factor (PAF) does not affect diastolic function in isolated rat hearts. Muñoz HR, et al. **Cardiovasc Res** 1995 Dec;30(6):1028–32

Stimulation of platelet–activating factor (PAF) receptors increases inositol phosphate production and cytosolic free Ca2+ concentrations in N1E–115 neuroblastoma cells. Diserbo M, et al. **Cell Calcium** 1995 Jun;17(6):442–52

Oestradiol–17 beta modulates PAF–evoked phospholipase D activity but not inositide–lipid hydrolysis in human endometrial cell line, HEC–1B. Ahmed A, et al. **Cell Signal** 1995 May;7(4):403–9

Sea urchins—a new model for PAF research in embryology. Berdyshev EV, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):629–32

Platelet–activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Hurst JS, et al. **Curr Eye Res** 1995 Sep;14(9):769–75

Protein tyrosine phosphorylation in equine platelets: the effect of stimulation by thrombin and platelet–activating factor (PAF) [see comments] Dillon AM, et al. **Equine Vet J** 1995 Nov;27(6):448–58. Comment in: Equine Vet J 1995 Nov;27(6):407–10.

Platelet–activating factor and haematopoiesis. XI. Platelet–activating factor has no effect on the production of interleukin–6 and tumor necrosis factor–alpha by human bone marrow stromal cells. Denizot Y, et al. **Eur Cytokine Netw** 1996 Jan–Mar;7(1):75–7

Endogenous corticosteroids mediate the neutrophilia caused by platelet–activating factor in the mouse. Harris JG, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):9–18

Regional haemodynamic effects of platelet activating factor in the rat. King KA, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):187–93

Platelet–activating factor–induced loss of vascular responsiveness to noradrenaline in pithed rats: involvement of nitric oxide. Shiga T, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):151–6

Population of hepatic macrophages and response of perfused liver to platelet–activating factor during production of thioacetamide–induced cirrhosis in rats. Noda S, et al. **Hepatology** 1996 Aug;24(2):412–8

Recombinant tumour necrosis factor–alpha and platelet–activating factor synergistically increase intercellular adhesion molecule–1 and E–selectin–dependent neutrophil adherence to endothelium in vitro. Sterner–Kock A, et al. **Immunology** 1996 Mar; 87(3):454–60

Effects of physiologic soluble agonists on leukotriene C4 production and degranulation by human eosinophils. Takafuji S, et al. **Int Arch Allergy Immunol** 1995;108 Suppl 1:36–8

Platelet–activating factor enhances urokinase–type plasminogen activator gene expression in corneal epithelium. Tao Y, et al. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):2037–46

Platelet activating factor inhibits fluid transport by corneal endothelium. Zhu Z, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1899–906

Effects of platelet activating factor on mouse embryo implantation in vitro. Nishi O, et al. **J Assist Reprod Genet** 1995 May;12(5):330–4

Increased hypodense eosinophils after activation with PAF–acether and calcium ionophore in asthmatic subjects. Agrawal DK, et al. **J Asthma** 1996;33(4):213–9

Wortmannin inhibits mitogen–activated protein kinase activation by platelet–activating factor through a mechanism independent of p85/p110–type phosphatidylinositol 3–kinase. Ferby IM, et al. **J Biol Chem** 1996 May 17;271(20):11684–8

Biosynthesis of N–acetylsphingosine by platelet–activating factor: sphingosine CoA–independent transacetylase in HL–60 cels. Lee TC, et al. **J Biol Chem** 1996 Jan 5; 271(1):209–17

Mechanisms of platelet–activating factor–induced lipid body formation: requisite roles for 5–lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. Bozza PT, et al. **J Exp Med** 1996 Apr 1; 183(4):1515–25

Rapid oscillations of actin polymerization/depolymerization in polymorphonuclear leukocytes stimulated by leukotriene B4 and platelet–activating factor. Omann GM, et al. **J Immunol** 1995 Dec 1;155(11):5375–81

Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes. Tan XD, et al. **J Immunol** 1996 Apr 15;156(8):2985–90

Mechanisms involved in eosinophil migration. Platelet–activating factor–induced chemotaxis and interleukin–5–induced chemokinesis are mediated by different signals. Schweizer RC, et al. **J Leukoc Biol** 1996 Mar;59(3):347–56

Leukocyte–induced endothelial dysfunction in the rabbit basilar artery: modulation by platelet–activating factor. Akopov SE, et al. **J Lipid Mediat Cell Signal** 1995 May; 11(3):267–79

Platelet–activating factor mediated potentiation of stimulation–evoked catecholamine release and the rise in intracellular free Ca2+ concentration in adrenal chromaffin cells. Morita K, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):219–30

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet–activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

Nitric oxide mediates the inhibitory action of platelet–activating factor on angiotensin II–induced renal vasoconstriction, in vivo. Handa RK, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1486–91

Helicobacter pylori stimulates gastric acid secretion via platelet activating factor. Sobhani I, et al. **J Physiol Pharmacol** 1996 Mar;47(1):177–85

Superoxide dismutase attenuates effects of platelet–activating factor on gastric microcirculation. Schwappach JR, et al. **J Surg Res** 1995 Dec;59(6):733–8

L–type calcium channel blockers modulate the microvascular hyperpermeability induced by platelet–activating factor in vivo. Oshiro H, et al. **J Vasc Surg** 1995 Dec;22(6):732–9; discussion 739–41

Alpha 1 antitrypsin defective Lewis rats injected with heparin: comparison of the glomerular changes with those of Lewis rats produced anti BSA antibody. Nakatsuji T. **Keio J Med** 1996 Jun;45(2):109–13

Platelet activating factor modulates microvascular permeability through nitric oxide synthesis. Ramírez MM, et al. **Microvasc Res** 1995 Sep;50(2):223–34

Modulation of signal transduction in rat synaptoneurosomes by platelet activating factor. Domańska–Janik K, et al. **Mol Chem Neuropathol** 1995 May;25(1):51–67

Platelet–activating factor produces neuronal growth cone collapse. Clark GD, et al. **Neuroreport** 1995 Dec 15; 6(18):2569–75

Platelet–activating factor induces cell growth through tyrosine phosphorylation pathway in cultured rat mesangial cells. Komatsu H, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov; 37(11):622–31

Platelet–activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Soldi R, et al. **Oncogene** 1996 Aug 1;13(3):515–25

Comparative differences and combined effects of interleukin–8, leukotriene B4, and platelet–activating factor on neutrophil chemotaxis of the newborn. Tan ND, et al. **Pediatr Res** 1995 Jul;38(1):11–6

Platelet activating factor (PAF) stimulates release of PGI2 from inflamed rabbit gallbladder cell cultures. Myers SI, et al. **Prostaglandins** 1995 Jul;50(1):19–32

PAF effects on eicosanoid release in neonatal rat cardiomyocytes. Becker K, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):197–200

The influence of some cations on PAF–induced gastric mucosal damage in rats. Nechifor M, et al. **Rom J Physiol** 1993 Jul–Dec;30(3–4):151–4

Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients. Shindo K, et al. **Thorax** 1996 Feb;51(2):155–8

Cardiac electrophysiologic and ultrastructural effects of platelet–activating factor and its antagonist BN 52021. Kecskemeti V, et al. **Transplant Proc** 1995 Oct; 27(5):2819–20

[Suppression of platelet activating factor effects (PAF) on the retina by G–proteins inhibitors] Doly M, et al. **Ann Pharm Fr** 1996;54(2):64–7 (Eng. Abstr.) **(Fre)**

[Effect of BAY u3405–thromboxane A2 receptor antagonist, on biphasic airway responses induced by platelet–activating factor in actively sensitized guinea pigs] Arima M, et al. **Arerugi** 1995 Jul;44(7):701–7 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Platelet–activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti–PAF immunoglobulin titers. Hirashima Y, et al. **Acta Neurochir (Wien)** 1995;137(1–2):15–8

Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Gallego MJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):23–31

Effects of a PAF antagonist, Y–24180, on bronchial hyperresponsiveness in patients with asthma. Hozawa S, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1198–202

A clinical study on the significance of platelet–activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Ono S, et al. **Am J Surg** 1996 Apr;171(4):409–15

Activation of large conductance Ca(2+)–activated K+ channels in N1E–115 neuroblastoma cells by platelet–activating factor. Diserbo M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):745–8

Gut–derived mediators of multiple organ failure: platelet–activating factor and interleukin–6. Biffl WL, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):134–8 (21 ref.)

Augmentation of tumor metastasis by platelet–activating factor. Im SY, et al. **Cancer Res** 1996 Jun 1;56(11):2662–5

Plasma–mediated neutrophil activation during acute myocardial infarction: role of platelet–activating factor. Siminiak T, et al. **Clin Sci (Colch)** 1995 Aug;89(2):171–6

Role of platelet–activating factor in pathogenesis of galactosamine–lipopolysaccharide–induced liver injury. Komatsu Y, et al. **Dig Dis Sci** 1996 May;41(5):1030–7

Role of cytokines and platelet–activating factor in inflammatory bowel disease. Implications for therapy. Nassif A, et al. **Dis Colon Rectum** 1996 Feb;39(2):217–23 (66 ref.)

Role of tumor necrosis factor–alpha and platelet–activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Lupia E, et al. **Eur J Immunol** 1996 Aug;26(8):1690–4

RANTES and platelet–activating factor open Ca2+–activated K+ channels in eosinophils. Saito M, et al. **FASEB J** 1996 May;10(7):792–8

Platelet–activating factor enhances production of insulin–like growth factor binding proteins in a human adenocarcinoma cell line (HEC–1A) Giannini S, et al. **Gynecol Oncol** 1996 Jun;61(3):333–40

Involvement of platelet–activating factor in cytokine production and neutrophil activation after hepatic ischemia–reperfusion. Serizawa A, et al. **Hepatology** 1996

Jun;23(6):1656–63

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)

Platelet–activating–factor–mediated pathogenesis in Lyme disease. Isogai E, et al. **Infect Immun** 1996 Mar;64(3):1026–9

Pharmacological characterization of Sephadex–induced oedema in rat paws: predominant role of serotonin and platelet–activating factor. Francischi JN, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):398–406

Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet–activating factor. Antonopoulou S, et al. **Int J Biochem Cell Biol** 1996 Jan; 28(1):43–51

Factors associated with hyperdynamic or hypodynamic circulation and role of platelet–activating factor in hemodynamic alterations in bacterial peritonitis in conscious rats. Novo C, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):937–42

Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states [editorial; comment] Nadel JA. **J Clin Invest** 1996 Jun 15; 97(12):2689–90. Comment on: J Clin Invest 1996 Jun 15;97(12):2784–91.

Platelet–activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. Roth M, et al. **J Exp Med** 1996 Jul 1; 184(1):191–201

Role of endogenous platelet–activating factor in the regulation of pancreatic blood flow during caerulein stimulation. Ogura M, et al. **J Gastroenterol** 1996 Jun; 31(3):414–9

Autocrine/paracrine involvement of platelet–activating factor and transforming growth factor–beta in the induction of phosphatidylserine recognition by murine macrophages. Rose DM, et al. **J Immunol** 1995 Dec 15;155(12):5819–25

Platelet–activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury. Herbert JM, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):49–57

Platelet–activating factor mediates pulmonary macromolecular leak following intestinal ischemia–reperfusion. Carter MB, et al. **J Surg Res** 1996 Feb 1;60(2):403–8

Hypoxia/reoxygenation of human endothelium activates PMNs to detach endothelial cells via a PAF mechanism. Franciose RJ, et al. **J Surg Res** 1996 Mar;61(2):459–62

Interleukin–6 delays neutrophil apoptosis via a mechanism involving platelet–activating factor. Biffl WL, et al. **J Trauma** 1996 Apr;40(4):575–8; discussion 578–9

Platelet activating factor mediates cardiopulmonary dysfunction during graded bacteremic shock. Woolley DS, et al. **J Trauma** 1996 Aug;41(2):291–6; discussion 296–7

The mediators involved in endotoxin–induced vascular permeability increase in the rat skin and their interactions. Ueno A, et al. **Jpn J Pharmacol** 1996 Apr;70(4):285–90

Role of platelet activating factor in kidney transplant rejection in the rat. Butterly DW, et al. **Kidney Int** 1995 Aug;48(2):337–43

Platelet–activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

Multiple roles of platelet–activating factor in the nervous system. Bussolino F, et al. **Neurochem Int** 1995 May; 26(5):425–33 (75 ref.)

Lipids as axon guidance molecules? Clark GD, et al. **Neuroreport** 1995 Dec 15;6(18):2446

Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet–activating factor and interleukin 6. van der Poll T, et al. **Scand J Immunol** 1996 Jan;43(1):122–5

Platelet–activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Lorant DE, et al. **Semin Cell Biol** 1995 Oct; 6(5):295–303 (78 ref.)

Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha–naphthylisothiocyanate–induced hepatotoxicity. Bailie MB, et al. **Toxicol Lett** 1996 Feb; 84(2):89–95

[Lipid mediators and liver injury] Liu Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):363–6 (10 ref.) **(Chi)**

[Progression of renal insufficiency and platelet activating factor (PAF)] Camici M. **Minerva Med** 1996 Jun; 87(6):289–98 (100 ref.) (Eng. Abstr.) **(Ita)**

[Role of platelet activating factor on the formation of ischemic colitis] Idei H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1734–42 (Eng. Abstr.) **(Jpn)**

[The local activation of leukocytes and thrombocytes in periodontal diseases: the role of thrombocyte–activating factor] Leont'ev VK, et al. **Stomatologiia (Mosk)** 1996; 75(1):26–9 (Eng. Abstr.) **(Rus)**

SECRETION

Ovine endometrium synthesizes and releases platelet–activating factor, which can cause the release of prostaglandin F2 alpha by the uterus in situ. Battye KM, et al. **Biol Reprod** 1996 Feb;54(2):355–63

Platelet activating factor: release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion. Wardle TD, et al. **Gut** 1996 Mar;38(3):355–61

Signaling by E–selectin and ICAM–1 induces endothelial tissue factor production via autocrine secretion of platelet–activating factor and tumor necrosis factor alpha. Schmid E, et al. **J Interferon Cytokine Res** 1995 Sep; 15(9):819–25

URINE

Urinary excretion of platelet–activating factor in human and experimental nephrosis. Bustos C, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):282–6

PLATELET ACTIVATION

Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high–density lipoproteins in experimental diabetes. Ginon I, et al. **Acta Diabetol** 1995 Oct;32(3):170–5

Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Terres W, et al. **Am Heart J** 1995 Oct;130(4):711–6

Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Nurden P, et al. **Am J Hematol** 1996 Jan;51(1):79–84

The effects of hemodialysis on platelet activation with new and reprocessed regenerated cellulose dialyzers. Windus DW, et al. **Am J Kidney Dis** 1996 Mar;27(3):387–93

Dynamic redistribution of glycoprotein Ib/IX on surface–activated platelets. A second look. White JG, et al. **Am J Pathol** 1995 Oct;147(4):1057–67

Von Willebrand factor, thrombomodulin, thromboxane, beta–thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Herrick AL, et al. **Ann Rheum Dis** 1996 Feb;55(2):122–7

Moderate hypothermia reduces cardiopulmonary bypass–induced impairment of cerebrovascular responses to platelet products. Stamler A, et al. **Ann Thorac Surg** 1996 Jul;62(1):191–8

Association of localized Ca2+ gradients with redistribution of glycoprotein IIb–IIIa and F–actin in activated human blood platelets. Ariyoshi H, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):230–5

Platelet–derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Nomura S, et al. **Atherosclerosis** 1995 Aug;116(2):235–40

Inhibition of mitogen–activated protein kinase kinase does not impair primary activation of human platelets. Börsch–Haubold AG, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):207–12

Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+–ATPase inhibitors. Dachary–Prigent J, et al. **Biochemistry** 1995 Sep 12;34(36):11625–34

Variability of the thrombin– and ADP–induced Ca2+ response among human platelets measured using fluo–3 and fluorescent videomicroscopy. Tao J, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):164–74

Relative reactivity of platelets from thrombopoietin– and interleukin–6–treated dogs. Peng J, et al. **Blood** 1996 May 15;87(10):4158–63

Platelet activation. Blockmans D, et al. **Blood Rev** 1995 Sep; 9(3):143–56 (124 ref.)

Decreased platelet function in aortic valve stenosis: high shear platelet activation then inactivation. O'Brien JR, et al. **Br Heart J** 1995 Dec;74(6):641–4

Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Nierodzik ML, et al. **Br J Haematol** 1996 Feb;92(2):452–7

Optimally functional fluorescein isothiocyanate–labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Xia Z, et al. **Br J Haematol** 1996 Apr;93(1):204–14

Elevated platelet–derived microparticle levels during unstable angina. Singh N, et al. **Can J Cardiol** 1995 Dec; 11(11):1015–21

Spatial distribution and temporal change in cytosolic pH and [Ca2+] in resting and activated single human platelets. Ariyoshi H, et al. **Cell Calcium** 1995 May;17(5):317–26

Characterization of platelet activation and thrombin generation accompanying percutaneous transluminal coronary angioplasty. Vaitkus PT, et al. **Coron Artery Dis** 1995 Jul;6(7):587–92

Phosphatidylserine exposure on the platelet plasma membrane during A23187–induced activation is independent of cytoskeleton reorganization. Gaffet P, et al. **Eur J Cell Biol** 1995 Aug;67(4):336–45

Activated human platelets express beta2 integrin. Philippeaux MM, et al. **Eur J Haematol** 1996 Mar;56(3):130–7

Cap Z, a calcium insensitive capping protein in resting and activated platelets. Nachmias VT, et al. **FEBS Lett** 1996 Jan 15;378(3):258–62

Platelet activation in carotid sinuses triggers reflex sympathoinhibition and hypotension. Mao HZ, et al. **Hypertension** 1996 Mar;27(3 Pt 2):584–90

Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies. Mellgren K, et al. **Int J Artif Organs** 1995 Jun; 18(6):315–21

Neutrophil and platelet activation at balloon–injured coronary artery plaque in patients undergoing angioplasty. Neumann FJ, et al. **J Am Coll Cardiol** 1996 Mar 15; 27(4):819–24

Phospholipid degradation in rat calcium ionophore–activated platelets is catalyzed mainly by two discrete secretory phospholipase As. Yokoyama K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1280–7

Thrombin receptor activation and integrin engagement stimulate tyrosine phosphorylation of the proto–oncogene product, p95vav, in platelets. Cichowski K, et al. **J Biol Chem** 1996 Mar 29;271(13):7544–50

Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. Felding–Habermann B, et al. **J Biol Chem** 1996 Mar 8;271(10):5892–900

A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIb beta3. Kunicki TJ, et al. **J Biol Chem** 1996 Aug 23;271(34):20315–21

Phosphorylation of threonine 558 in the carboxyl–terminal actin–binding domain of moesin by thrombin activation of human platelets. Nakamura F, et al. **J Biol Chem** 1995 Dec 29;270(52):31377–85

Membrane phase transition of intact human platelets: correlation with cold–induced activation. Tablin F, et al. **J Cell Physiol** 1996 Aug;168(2):305–13

Activated platelets signal chemokine synthesis by human monocytes. Weyrich AS, et al. **J Clin Invest** 1996 Mar 15; 97(6):1525–34

Rapid secretion of intracellularly pre–stored interleukin–8 from rabbit platelets upon activation. Su SB, et al. **J Leukoc Biol** 1996 Mar;59(3):420–6

Platelet association with gingival tissue inflammation. Steinberg AD, et al. **J Periodontol** 1995 Oct;66(10):860–3

Thrombin–stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside. Azula FJ, et al. **Mol Pharmacol** 1996 Aug;50(2):367–79

Prothrombotic effects of environmental stress: changes in platelet function, hematocrit, and total plasma protein. Patterson SM, et al. **Psychosom Med** 1995 Nov–Dec; 57(6):592–9

Role of Fc gamma RIIA gene polymorphism in human platelet activation by monoclonal antibodies. Bachelot C, et al. **Thromb Haemost** 1995 Dec;74(6):1557–63

Demonstration of Rickettsia Conorii–induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. Davì G, et al. **Thromb Haemost** 1995 Aug;74(2):631–4

Platelet–derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Galli M, et al. **Thromb Haemost** 1996 Mar; 75(3):427–31

Flow cytometric detection of activated platelets in pregnant women prior to the development of pre–eclampsia. Janes SL, et al. **Thromb Haemost** 1995 Oct;74(4):1059–63

Platelet accumulation on fibrin–coated polyethylene: role of platelet activation and factor XIII. Rubens FD, et al. **Thromb Haemost** 1995 May;73(5):850–6

Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto–ATPases upon endothelial cell activation. Robson SC, et al. **Transplant Proc** 1996 Apr; 28(2):536

[Changes in platelet activity in invasive cardiologic procedures] Malý J, et al. **Vnitr Lek** 1996 May;42(5):314–9 (Eng. Abstr.) **(Cze)**

[Wallenberg's syndrome following minor neck trauma: a case associated with atlanto–axial subluxation, an anomaly of the axis, and platelet activation] Arai M. **Rinsho Shinkeigaku** 1995 Jun;35(6):670–2 (Eng. Abstr.) **(Jpn)**

[Diagnosis of intracardiac thrombi by various imaging techniques and activation of platelets and coagulation–fibrinolysis in patients with cardioembolic stroke] Uchiyama S, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):429–35 (Eng. Abstr.) **(Jpn)**

[The role of arachidonic acid cycle enzymes in platelet activation by low density lipoproteins] Vlasova II, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):376–9 **(Rus)**

DRUG EFFECTS

Effects of ionic and nonionic contrast media on in vitro and in vivo platelet activation. Albanese JR, et al. **Am J Cardiol** 1995 Nov 15;76(14):1059–63

High–density lipoprotein fails to inhibit serotonin–induced activation of blood platelets. Pfennig O, et al. **Am J Hematol** 1995 Dec;50(4):307–9

Influence of purified apoprotein E on platelet activation induced by serotonin. Pfennig O, et al. **Am J Hematol** 1996 Aug;52(4):319–21

Nitric oxide in the oxygenator sweep gas reduces platelet activation during experimental perfusion. Mellgren K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1194–8

Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Primack C, et al. **Ann Thorac Surg** 1996 Apr;61(4):1188–93

Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Langford EJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):51–5

Inhibition of surface–induced platelet activation by nitric oxide. Sly MK, et al. **ASAIO J** 1995 Jul–Sep;41(3):M394–8

Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Rodríguez–Liñares B, et al. **Biochem J** 1996 May 15;316 (Pt 1):93–8

Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor [published erratum appears in Biochem J 1996 Feb 1;313(Pt 3):1047] Yanaga F, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):471–8

Inhibition of collagen-induced platelet activation by arachidonyl trifluoromethyl ketone. McNicol A, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1795–802

Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Chen J, et al. **Blood** 1995 Dec 1; 86(11):4054–62

Recombinant scinderin, an F-actin severing protein, increases calcium-induced release of serotonin from permeabilized platelets, an effect blocked by two scinderin-derived actin-binding peptides and phosphatidylinositol 4,5-bisphosphate. Marcu MG, et al. **Blood** 1996 Jan 1; 87(1):20–4

Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Montrucchio G, et al. **Blood** 1996 Apr 1;87(7):2762–8

Retention of glycoprotein Ib/IX receptors on external surfaces of thrombin-activated platelets in suspension. White JG, et al. **Blood** 1995 Nov 1;86(9):3468–78

Inhibition of platelet function by A02131–1, a novel inhibitor of cGMP-specific phosphodiesterase, in vitro and in vivo. Yu SM, et al. **Blood** 1996 May 1;87(9):3758–67

Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Stewart MW, et al. **Br J Haematol** 1995 Sep;91(1):173–7

Reflex circulatory collapse following intrapulmonary entrapment of activated platelets: mediation via 5-HT3 receptor stimulation. Leaños OL, et al. **Br J Pharmacol** 1995 Oct;116(3):2048–52

Effects of methylglyoxal on platelet hydrogen peroxide accumulation, aggregation and release reaction. Leoncini G, et al. **Cell Biochem Funct** 1996 Jun;14(2):89–95

Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Leopold JA, et al. **Coron Artery Dis** 1995 Dec;6(12):923–9 (60 ref.)

Platelet and leukocyte activation after myocardial infarction. Influence of enalapril. Sylvén C, et al. **Eur Heart J** 1995 Dec;16(12):1800–6

Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor. Puri RN, et al. **J Cell Biochem** 1996 Apr;61(1):97–108

In vivo and in vitro studies of the role of HDL in platelet activation in normotensive and hypertensive subjects. Graham D, et al. **J Hum Hypertens** 1995 Sep;9(9):753–8

Fc gamma II receptor-mediated platelet activation induced by anti-CD9 monoclonal antibody opens Ca2+ channels which are distinct from those associated with Ca2+ store depletion. Kuroda K, et al. **J Immunol** 1995 Nov 1; 155(9):4427–36

The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Lees C, et al. **Obstet Gynecol** 1996 Jul; 88(1):14–9

Targeting of porcine pancreatic phospholipase A2 to human platelets: introduction of an RGD sequence by genetic engineering. Bekkers AC, et al. **Thromb Haemost** 1995 Oct; 74(4):1138–44

Modulation of platelet activation in vitro by thrombopoietin. Kojima H, et al. **Thromb Haemost** 1995 Dec;74(6):1541–5

Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction. Lasne D, et al. **Thromb Haemost** 1995 Nov; 74(5):1323–8

Platelet surface activation markers after DDAVP infusion in healthy subjects [letter] Tsakiris DA, et al. **Thromb Haemost** 1995 Sep;74(3):991–2

[Characterization of platelet activation induced by CD9 McAbs] Peng L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):365–70 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Brandt JT, et al. **Thromb Haemost** 1995 Dec;74(6):1564–72

Inhibition of platelet aggregation by an SLE-derived human hybridoma autoantibody against an activation-dependent antigen. Xu H, et al. **Thromb Haemost** 1995 Oct; 74(4):1152–62

PHYSIOLOGY

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Hyperoxia induces platelet activation and lung sequestration: an event dependent on tumor necrosis factor-alpha and CD11a. Barazzone C, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):107–14

Fibrinolysis profiles and platelet activation after endothelial cell seeding of prosthetic vascular grafts. Smyth JV, et al. **Ann Vasc Surg** 1995 Nov;9(6):542–6

Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Takahashi Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):453–9

The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Si-Tahar M, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):401–8

A binding site expressed on the surface of activated human platelets is shared by factor X and prothrombin. Scandura JM, et al. **Biochemistry** 1996 Jul 9;35(27):8890–902

Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa. Scandura JM, et al. **Biochemistry** 1996 Jul 9;35(27):8903–13

Tumor gangliosides enhance alpha2 beta1 integrin-dependent platelet activation. Valentino LA, et al. **Biochim Biophys Acta** 1996 May 24;1316(1):19–28

Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Ramaschi G, et al. **Blood** 1996 Mar 15;87(6):2308–13

Blood platelet heterogeneity: a functional hierarchy in the platelet population. Behnke O. **Br J Haematol** 1995 Dec; 91(4):991–9

Activated platelets in paroxysmal nocturnal haemoglobinuria. Gralnick HR, et al. **Br J Haematol** 1995 Nov;91(3):697–702

Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Wun T, et al. **Br J Haematol** 1996 Mar;92(4):968–72

Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin. Bozzo J, et al. **Cardiovasc Res** 1995 Nov;30(5):725–30

Transmembrane signalling: protein tyrosine phosphorylation and platelet activation [editorial; comment] Farndale RW, et al. **Equine Vet J** 1995 Nov;27(6):407–10. Comment on: Equine Vet J 1995 Nov;27(6):448–58.

Platelet reactivity, exercise, and stable coronary artery disease [editorial; comment] Hjemdahl P. **Eur Heart J** 1995 Aug;16(8):1017–9. Comment on: Eur Heart J 1995 Aug;16(8):1036–43.

Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Pasquet JM, et al. **Eur J Biochem** 1996 Aug 1;239(3):647–54

Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin. Puri RN, et al. **Eur J Biochem** 1996 Mar 15; 236(3):862–70

Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Gawaz M, et al. **Eur J Clin Invest** 1995 Nov;25(11):843–51

Smoking further increases platelet activity in patients with mild hypertension. Gleerup G, et al. **Eur J Clin Invest** 1996 Jan;26(1):49–52

Translocation of cortactin (p80/85) to the actin-based cytoskeleton during thrombin receptor-mediated platelet activation. Ozawa K, et al. **Exp Cell Res** 1995 Nov; 221(1):197–204

Phase specific association of heterotrimeric GTP-binding proteins with the actin-based cytoskeleton during thrombin receptor-mediated platelet activation. Ozawa K, et al. **FEBS Lett** 1996 Mar 11;382(1–2):159–63

Neutrophil-mediated platelet activation: a key role for serine proteinases. Renesto P, et al. **Gen Pharmacol** 1995 Sep; 26(5):905–10 (54 ref.)

Plateletpheresis-induced increase in platelet reactivity using different cell separators. Jung F, et al. **Infusionsther Transfusionsmed** 1995 Aug;22(4):237–43

Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. Börsch-Haubold AG, et al. **J Biol Chem** 1995 Oct 27; 270(43):25885–92

Particle volumetric residence time calculations in arterial geometries. Kunov MJ, et al. **J Biomech Eng** 1996 May; 118(2):158–64

Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)

Development of a whole platelet ELISA to detect circulating activated platelets. Amrani DL, et al. **J Lab Clin Med** 1995 Dec;126(6):603–11

Dominant contribution of 5-hydroxytryptamine over thromboxane A2 in contractile response of rabbit isolated aortic preparation to thrombin activated platelets. Nakanishi H, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov;90(2):255–67

Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218–23 (82 ref.)

Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)

Correlation of specific platelet activation markers with carotid arterial wall thickness. Ghaddar HB, et al. **Thromb Haemost** 1995 Sep;74(3):943–8

Ultrastructural detection of surface exposed phosphatidylserine on activated blood platelets. Stuart MC, et al. **Thromb Haemost** 1995 Oct;74(4):1145–51

Inhibitory effect of alcohol on cyclic GMP accumulation in human platelets. Dong QS, et al. **Thromb Res** 1995 Oct 15;80(2):143–51

[Do glycoproteins IIb/IIIa participate in activation of human platelet s by low density lipoproteins?] Bochkov VN, et al. **Biokhimiia** 1995 Aug;60(8):1187–94 (Eng. Abstr.) **(Rus)**

PLATELET ADHESIVENESS

see related

PLATELET MEMBRANE GLYCOPROTEINS

Platelet deposition and fibrinogen binding on surfaces coated with heparin or friction-reducing polymers. Anderson AB, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):859–63

The effects of hemodialysis on platelet deposition in prosthetic graft fistulas. Windus DW, et al. **Am J Kidney Dis** 1995 Oct;26(4):614–21

Inducible platelet adherence to human umbilical vein endothelium by anticardiolipin antibody-positive sera. Silver RK, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):702–7

Mechanisms-regulated platelet spreading after initial platelet contact with collagen. Wu CC, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):388–93

Biocompatibility of polysulfone II. Platelet adhesion and cho cell growth. Khang G, et al. **Biomed Mater Eng** 1995; 5(4):259–73

Prevention of platelet adhesion on the polysulfone porous catheter by saline solution perfusion, I. In vitro investigation. Khang G, et al. **Biomed Mater Eng** 1996; 6(1):47–66

Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Haimovich B, et al. **Blood** 1996 Jan 1;87(1):152–61

Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Kirchhofer D, et al. **Blood** 1995 Nov 15;86(10):3815–22

Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Kuijper PH, et al. **Blood** 1996 Apr 15;87(8):3271–81

Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Moroi M, et al. **Blood** 1996 Sep 15;88(6):2081–92

alphaIIb beta 3-integrin mediated adhesion of human platelets to a fibrinogen matrix triggers phospholipase C activation and phosphatidylinositol 3',4'-biphosphate accumulation. Gironcel D, et al. **FEBS Lett** 1996 Jul 8; 389(3):253–6

Binding of resting platelets to Candida albicans germ tubes. Robert R, et al. **Infect Immun** 1996 Sep;64(9):3752–7

Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? Mickelson JK, et al. **J Am Coll Cardiol** 1996 Aug;28(2):345–53

Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. Felding-Habermann B, et al. **J Biol Chem** 1996 Mar 8;271(10):5892–900

In vitro platelet adhesion to nonionic and ionic hydrogels with different water contents. Kulik E, et al. **J Biomed Mater Res** 1996 Mar;30(3):295–304

Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. Li JM, et al. **J Surg Res** 1996 Mar;61(2):543–8

Thrombogenicity of the human arterial wall after interventional thermal injury. Post MJ, et al. **J Vasc Res** 1996 Mar-Apr;33(2):156–63

Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Rosenblum WI, et al. **Stroke** 1996 Apr;27(4):709–11

Platelet accumulation on fibrin-coated polyethylene: role of platelet activation and factor XIII. Rubens FD, et al. **Thromb Haemost** 1995 May;73(5):850–6

The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Ruggeri ZM. **Thromb Haemost** 1995 Jul;74(1):460–3 (45 ref.)

Platelet adhesion to collagen. Sixma JJ, et al. **Thromb Haemost** 1995 Jul;74(1):454–9 (75 ref.)

Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1. Gralnick HR, et al. **Thromb Res** 1996 Jan 1; 81(1):113–9

[Thrombocyte adhesiveness and climate (letter)] Naess K. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2083–4 **(Nor)**

DRUG EFFECTS

Different adhesion types and active sensitivity of platelet subpopulations. Zhao B, et al. **Am J Hematol** 1996 Aug; 52(4):322–4

Thrombogenic properties of untreated and poly(ethylene oxide)-modified polymeric matrices useful for preparing intraarterial ion-selective electrodes. Espadas-Torre C, et al. **Anal Chem** 1995 Sep 15;67(18):3108–14

Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. André P, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):56–63

Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Sixma JJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):64–71

Prevention of platelet adhesion on polysulfone porous catheter by saline solution perfusion, II. Ex vivo and in vivo investigation. Khang G, et al. **Biomed Mater Eng** 1996; 6(2):123–34

The value of flow cytometric analysis of platelet glycoprotein

expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Dercksen MW, et al. **Blood** 1995 Nov 15;86(10):3771-82

Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. de Kossodo S, et al. **Br J Cancer** 1995 Nov;72(5):1165-72

Nitric oxide inhalation decreases pulmonary platelet and neutrophil sequestration during extracorporeal circulation in the pig. Malmros C, et al. **Crit Care Med** 1996 May; 24(5):845-9

Platelet and monoclonal antibody binding to fibrinogen adsorbed on glow-discharge-deposited polymers. Kiaei D, et al. **J Biomed Mater Res** 1995 Jun;29(6):729-39

Does the liquid method of electret forming influence the adhesion of blood platelets? Lowkis B, et al. **Polim Med** 1995;25(1-2):3-13

Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Reininger AJ, et al. **Thromb Haemost** 1995 Sep;74(3):853-8

Gelatin use impairs platelet adhesion during cardiac surgery. Tabuchi N, et al. **Thromb Haemost** 1995 Dec;74(6):1447-51

GENETICS

The molecular mechanism of platelet adhesion. Berndt MC, et al. **Aust N Z J Med** 1995 Dec;25(6):822-30 (57 ref.)

IMMUNOLOGY

Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies. Matsuno K, et al. **Br J Haematol** 1996 Mar;92(4):960-7

Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. Chiba M, et al. **J Immunol Methods** 1996 May 10;191(1):55-63

PHYSIOLOGY

Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions. Diaz-Ricart M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):883-8

Platelet adhesion to fibronectin in flow: the importance of von Willebrand factor and glycoprotein Ib. Beumer S, et al. **Blood** 1995 Nov 1;86(9):3452-60

On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Endenburg SC, et al. **Blood** 1995 Dec 1;86(11):4158-65

Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit--possible role of adenosine diphosphate. Weiss HJ, et al. **Blood** 1996 May 15;87(10):4214-22

Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Savage B, et al. **Cell** 1996 Jan 26;84(2):289-97

Endogenous endothelium-derived relaxing factor inhibits platelet adhesion under whole blood flow conditions ex vivo. Jen CJ, et al. **Chin J Physiol** 1995;38(3):147-51

Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Aigner S, et al. **Int Immunol** 1995 Oct;7(10):1557-65

Interventional thermal injury of the arterial wall: unfolding of von Willebrand factor and its increased binding to collagen after 55 degrees C heating. Post MJ, et al. **Thromb Haemost** 1996 Mar;75(3):515-9

The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Santoro SA, et al. **Thromb Haemost** 1995 Sep;74(3):813-21 (105 ref.)

Flow-related platelet deposition on subendothelium. Weiss HJ. **Thromb Haemost** 1995 Jul;74(1):117-22 (78 ref.)

PLATELET AGGREGATION

see related

PLATELET MEMBRANE GLYCOPROTEINS

Purine metabolite washout and platelet aggregation at reflow after tourniquet ischemia: effect of intravenous regional lidocaine. Naesh O, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1053-8

Plasma platelet aggregating factor and platelet aggregation studies in pre-eclampsia. Ahlawat S, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):428-31

Effect of heparin removal filter [letter]. White MM, et al. **Am J Clin Pathol** 1996 Mar;105(3):372

The influence of time of storage, temperature of storage, platelet number in platelet-rich plasma, packed cell, mean platelet volume, hemoglobin concentration, age, and sex on platelet aggregation test. Ho CH, et al. **Ann Hematol** 1995 Sep;71(3):129-33

Physical and chemical effects of red cells in the shear-induced aggregation of human platelets. Goldsmith HL, et al. **Biophys J** 1995 Oct;69(4):1584-95

Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Gabbeta J, et al. **Blood** 1996 Feb 15;87(4):1368-76

Platelet function, coagulation tests, and cardiopulmonary bypass: lack of correlation between pre-operative and intra-operative whole blood lumiaggregometry and peri-operative blood loss in patients receiving autologous platelet-rich plasma. Irani MS, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):428-32

Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Kawachi Y, et al. **Br J Haematol** 1996 Aug;94(2):413-6

Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency. Matijevic-Aleksic N, et al. **Br J Haematol** 1996 Jan;92(1):212-7

Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Xia Z, et al. **Br J Haematol** 1996 Apr;93(1):204-14

Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Hung J, et al. **Circulation** 1995 Nov 1;92(9):2432-6

Sensitivity to platelet aggregation appears related to the lipoprotein profile and atherosclerosis risk in humans and across species. Hayes KC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):349-53

Flow cytometer and imaging device used in combination. Kubota F, et al. **Cytometry** 1995 Oct 1;21(2):129-32

Bilateral ptosis with ophthalmoplegia in a 72-year-old woman with diabetes. Nakai A, et al. **Diabetes Res** 1994; 26(2):89-92

Glutathione, glutathione utilizing enzymes and thioltransferase in platelets of insulin-dependent diabetic patients: relation with platelet aggregation and with microangiopatic complications. Di Simplicio P, et al. **Eur J Clin Invest** 1995 Sep;25(9):665-9

Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. Rabhi-Sabile S, et al. **FEBS Lett** 1996 May 13;386(1):82-6

Hypoxia alters the energy metabolism and aggregation of washed human platelets. Akahori M, et al. **Haematologia (Budap)** 1995;26(4):191-8

Modifications of platelet shape change and ATP release during cardiopulmonary bypass. Jung G, et al. **Haemostasis** 1995 Jul-Aug;25(4):149-57

Shear stress-induced platelet aggregation in various types of von Willebrand disease. Nakagawa-Nishimura Y, et al. **Int J Hematol** 1995 Jun;61(4):189-96

Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. Law DA, et al. **J Biol Chem** 1996 May 3; 271(18):10811-5

Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen gamma chain C terminus. Rooney MM, et al. **J Biol Chem** 1996 Apr 12;271(15):8553-5

Effects of storage on in vitro platelet responses: comparison of ACD and Na citrate anticoagulated samples. Pignatelli P, et al. **J Clin Lab Anal** 1996;10(3):134-9

Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. Müller MR, et al. **J Pharmacol Toxicol Methods** 1995 Sep; 34(1):17-22

Effect of differential shear stress on platelet aggregation, surface thrombosis, and endothelialization of bilateral carotid-femoral grafts in the dog. Wu MH, et al. **J Vasc Surg** 1995 Oct;22(4):382-90; discussion 390-2

The evolution of platelet aggregability in patients undergoing catheter ablation for supraventricular tachycardia with radiofrequency energy: the role of antiplatelet therapy. Wang TL, et al. **Pacing Clin Electrophysiol** 1995 Nov; 18(11):1980-90

Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Heinmöller E, et al. **Scand J Gastroenterol** 1995 Oct;30(10):1008-16

Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Rosenblum WI, et al. **Stroke** 1996 Apr;27(4):709-11

Shear-induced platelet aggregation in normal subjects and stroke patients. Konstantopoulos K, et al. **Thromb Haemost** 1995 Nov;74(5):1329-34

Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia [letter; comment] Nguyên P, et al. **Thromb Haemost** 1995 Aug;74(2):804-5. Comment on: Thromb Haemost 1995 Jan;73(1):21-8.

Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736-42

Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Oleksowicz L, et al. **Thromb Res** 1995 Aug 1;79(3):261-74

Involvement of guanylate cyclase and phosphodiesterases in the functional heterogeneity of human blood platelet subpopulations. Opper C, et al. **Thromb Res** 1995 Dec 15; 80(6):461-70

Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine. Malyszko J, et al. **Transplant Proc** 1996 Jun;28(3):1954-7

Irradiation of fresh whole blood for prevention of transfusion-associated graft-versus-host disease does not impair platelet function and clinical hemostasis after open heart surgery. Lavee J, et al. **Vox Sang** 1995;69(2):104-9

[Platelet aggregation] Terada H. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:141-6 (11 ref.) **(Jpn)**

[Annexin V in human platelets and its physiological role] Shidara Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov;47(11):1269-70 **(Jpn)**

[Shear-induced platelet aggregation (SIPA) monitoring of hemostatic effect during platelet transfusion in a patient with Glanzmann's thrombasthenia: a comparison between SIPA and conventional platelet aggregation] Sugimoto M, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1332-5 (Eng. Abstr.) **(Jpn)**

[The comprehensive assessment of the aggregation status of the blood in patients operated on with the use of artificial circulation] Dement'eva II, et al. **Klin Lab Diagn** 1995 Nov-Dec;(6):93-5 **(Rus)**

[Platelet aggregation and the fibronectin level of the blood in children with chronic glomerulonephritis] Pinelis VG, et al. **Urol Nefrol (Mosk)** 1995 Jul-Aug;(4):17-9 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effect of intracellular free calcium mobilization on aggregation of umbilical cord blood platelets. Niida K, et al. **Acta Med Okayama** 1996 Feb;50(1):47-52

Influence of the beta-blocker therapy on neutrophil superoxide generation and platelet aggregation in experimental myocardial ischemia and reflow. Röth E, et al. **Acta Physiol Hung** 1995;83(2):163-70

Combined inhibitory effects of ethanol and adenosine on the responses of rabbit platelets to thrombin. Rand ML, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1279-85

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Harrington RA, et al. **Am J Cardiol** 1995 Dec 15;76(17):1222-7

Effects of in vivo cocaine administration on human platelet aggregation. Heesch CM, et al. **Am J Cardiol** 1996 Jul 15; 78(2):237-9

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437-44

Nitroprusside inhibition of platelet function is transient and reversible by catecholamine priming. Harris SN, et al. **Anesthesiology** 1995 Dec;83(6):1145-52

Direct inhibitory mechanisms of halothane on human platelet aggregation. Kohro S, et al. **Anesthesiology** 1996 Jul; 85(1):96-106; discussion 30A

Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Jesse RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:281-90

Effect of anticoagulation and inhibition of platelet aggregation on arterial versus venous microvascular thrombosis. Li X, et al. **Ann Plast Surg** 1995 Aug; 35(2):165-9; discussion 169-70

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Reilly TM, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2195-9

Two different inhibitory effects of pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid on adenosine diphosphate-induced human platelet aggregation. Windscheif U, et al. **Arzneimittelforschung** 1995 Sep;45(9):994-7

In vivo degradation of human fibrinogen A alpha: detection of cleavage sites and release of antithrombotic peptides. Ständker L, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):896-902

The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. Suidan HS, et al. **Biochem J** 1996 May 1;315 (Pt 3):939-45

Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: a comparison with Angeli's salt. Zamora R, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):333-9

Guanidine thiol--a new activator of soluble guanylate cyclase with antihypertensive and antiaggregatory properties. Severina IS, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):913-25

Protein kinase C inhibitor, chelerythrine, potentiates the adrenaline-mediated aggregation of human platelets through calcium influx. Shah BH, et al. **Biochem Mol Biol Int** 1996 May;38(6):1135-41

Effect of pyridoxal-5'-phosphate on aggregation of platelets from stored human concentrates induced by arachidonic acid. Nolan ML, et al. **Biochem Soc Trans** 1996 Feb; 24(1):95S

Occurrence and biological effects of cholesteryl sulfate on blood platelets. Blache D, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):291-6

Involvement of mercury in platelet aggregation--probable mechanism of action. Chaudhury S, et al. **Biomed Environ Sci** 1996 Mar;9(1):26-36

Effect of hematocrit on adenosine diphosphate-induced aggregation of human platelets in tube flow. Goldsmith HL, et al. **Biorheology** 1995 Sep-Oct;32(5):537-52

An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Hayward CP, et al. **Blood** 1996 Jun 15;87(12):4967-78

Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Oda A, et al. **Blood** 1996 Jun 1;87(11):4664-70

An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2.

Yuan Y, et al. **Blood** 1995 Dec 1;86(11):4166–74

RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets. Udvardy M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):481–5

A monoclonal antibody directed against a granule membrane glycoprotein (GMP–140/PADGEM, P–selectin, CD62P) inhibits ristocetin–induced platelet aggregation. Boukerche H, et al. **Br J Haematol** 1996 Feb;92(2):442–51

The thromboxane mimetic, U–46619, induces the aggregation of fish thrombocytes. Hill DJ, et al. **Br J Haematol** 1996 Jan;92(1):200–11

Dietary fibres reduce blood pressure, serum total cholesterol and platelet aggregation in rats. Bagger M, et al. **Br J Nutr** 1996 Mar;75(3):483–93

Verapamil influences the effect of nonionic contrast agent on platelet membrane structure and aggregation. Górski J, et al. **Bull Inst Marit Trop Med Gdynia** 1995; 46(1–4):59–65

Alterations in platelet function in patients receiving interleukin–6 as cytokine therapy. Oleksowicz L, et al. **Cancer Invest** 1996;14(4):307–16

Effects of methylglyoxal on platelet hydrogen peroxide accumulation, aggregation and release reaction. Leoncini G, et al. **Cell Biochem Funct** 1996 Jun;14(2):89–95

The effect of methylmercury (CH3HgCl) on the production of endothelium–derived relaxing factor (EDRF) by cultured human umbilical vascular endothelial cells based on its anti–aggregatory effect on human platelets. Ohno M, et al. **Cell Biol Toxicol** 1995 Dec;11(6):303–11

Influence of a selective 5HT1–receptor agonist GR43175 on platelet responsiveness. Tozzi–Ciancarelli MG, et al. **Cephalalgia** 1995 Dec;15(6):472–36

Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Okada Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1385–7

Effect of DC–015, a novel potent and selective alpha 1–adrenoceptor antagonist, comparison with prazosin on noradrenaline–induced platelet aggregation. Yen MH, et al. **Chin J Physiol** 1995;38(2):93–8

The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI). Jin L, et al. **Chin Med J (Engl)** 1995 Oct;108(10):783

Inhibitory effects of TA–993, a new 1,5–benzothiazepine derivative, on platelet aggregation. Odawara A, et al. **Circ Res** 1996 Apr;78(4):643–9

Stress–induced hemodynamic and hemostatic changes in patients with systemic hypertension: effect of verapamil. Gebara OC, et al. **Clin Cardiol** 1996 Mar;19(3):205–11

Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Pace–Asciak CR, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):163–82

Glyceryl trinitrate enhances the adenosine–induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti–aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

Effects of garlic extract on platelet aggregation: a randomized placebo–controlled double–blind study [see comments] Morris J, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):414–7. Comment in: Clin Exp Pharmacol Physiol 1995 Nov;22(11):888–9.

Effects of garlic extract on platelet aggregation [letter; comment] Myers SP, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):888–9. Comment on: Clin Exp Pharmacol Physiol 1995 Jun–Jul;22(6–7):414–7.

Nitric oxide inhalation decreases pulmonary platelet and neutrophil sequestration during extracorporeal circulation in the pig. Malmros C, et al. **Crit Care Med** 1996 May; 24(5):845–9

Potent activation of nitric oxide synthase by garlic: a basis for its therapeutic applications. Das I, et al. **Curr Med Res Opin** 1995;13(5):257–63

Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents. Rodier M, et al. **Diabetes Res Clin Pract** 1995 Apr;28(1):19–28

Chronic lead treatment accelerates photochemically induced platelet aggregation in cerebral microvessels of mice, in vivo. al Dhaheri AH, et al. **Environ Res** 1995 Apr; 69(1):51–8

An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP–induced hyperaggregability in streptozotocin–induced diabetic rats. Hotta N, et al. **Eur J Clin Invest** 1995 Dec;25(12):948–54

The effect of desmopressin on platelet aggregation defect in systemic amyloidosis: a preliminary report. Demiroğlu H, et al. **Eur J Haematol** 1996 May;56(5):283–6

Platelet aggregation is inhibited by phycolectins. Matsubara K, et al. **Experientia** 1996 Jun 15;52(6):540–3

Pyran derivatives XIX. (Dialkylamino) substituted 1–benzopyranones and naphthopyranones with platelet antiaggregating activity. Di Braccio M, et al. **Farmaco** 1995 Oct;50(10):703–11

Thrombopoietin, c–Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists–induced aggregation in platelets in vitro. Ezumi Y, et al. **FEBS Lett** 1995 Oct 23;374(1):48–52

A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg–Gly–Asp peptides. Kini RM, et al. **FEBS Lett** 1995 Nov 13;375(1–2):15–7

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar–Apr;10(2):91–8

Effects of diltiazem and verapamil on ADP–induced rabbit platelet shape change and aggregation. Dehpour AR, et al. **Gen Pharmacol** 1995 Oct;26(6):1295–9

Conditions that lithium inhibits or potentiates vasopressin V1–receptor–mediated platelet aggregation and [Ca++]i mobilization. Dehpour AR, et al. **Gen Pharmacol** 1995 Dec; 26(8):1659–67

Platelet aggregation and atrial natriuretic peptide. Ulker S, et al. **Gen Pharmacol** 1995 Oct;26(6):1409–12

Close relationships between serotonergic and fibrinolytic systems revealed by a monoamine oxidase inhibitor treatment in rats. Urano T, et al. **Haemostasis** 1995 Nov–Dec;25(6):277–82

New directions in anticoagulant and antiplatelet treatment [letter] O'Brien JR. **Heart** 1996 Apr;75(4):426

Bolesatine induces agglutination of rat platelets and human erythrocytes and platelets in vitro. Gachet C, et al. **Hum Exp Toxicol** 1996 Jan;15(1):26–9

Effects of insulin on calcium metabolism and platelet aggregation. Ishida M, et al. **Hypertension** 1996 Aug; 28(2):209–12

The biological activity of acetylated sphingosylphosphorylcholine derivatives. Zanglis A, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):63–74

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5–fluorouracil (CMF) causes a platelet aggregation defect. Kumar A, et al. **Int J Cancer** 1996 Apr 10;66(2):159–61

Oral L–arginine inhibits platelet aggregation but does not enhance endothelium–dependent dilation in healthy young men. Adams MR, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1054–61

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor–activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1665–71

Differential translocation of phospholipase C isozymes to integrin–mediated cytoskeletal complexes in thrombin–stimulated human platelets. Banno Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14989–94

Thrombin–induced platelet aggregation is inhibited by the heptapeptide Leu271–Ala277 of domain 3 in the heavy chain of high molecular weight kininogen. Kunapuli SP, et al. **J Biol Chem** 1996 May 10;271(19):11228–35

Role for p38 mitogen–activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. Saklatvala J, et al. **J Biol Chem** 1996 Mar 22;271(12):6586–9

Effects of lomefloxacin and sparfloxacin on human platelet aggregation. Losasso C, et al. **J Chemother** 1995 Oct; 7(5):420–3

Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. Freedman JE, et al. **J Clin Invest** 1996 Feb 15;97(4):979–87

Nitric oxide–mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. Salvemini D, et al. **J Clin Invest** 1996 Jun 1;97(11):2562–8

Pharmacokinetics of a new thromboxane A2 receptor antagonist, S–1452, and its effect on platelet aggregation in healthy volunteers. Fujimura A, et al. **J Clin Pharmacol** 1996 May;36(5):409–13

The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM. Nishimura M, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):330–3

An aldose reductase inhibitor, TAT, reduces ADP–induced platelet hyperaggregation in streptozotocin–induced diabetic rats with neuropathy. Hara T, et al. **J Lab Clin Med** 1995 Dec;126(6):541–7

A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men. Gooderham MH, et al. **J Nutr** 1996 Aug;126(8):2000–6

Synthesis and antiplatelet effects of omega–aminoalkoxylxanthones. Lin CN, et al. **J Pharm Pharmacol** 1995 Jul;47(7):588–94

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L–734,217. Cook JJ, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):62–73

Platelet lipoxygenase inhibitors attenuate thrombin– and thromboxane mimetic–induced intracellular calcium mobilization and platelet aggregation. Nyby MD, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):503–9

Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Bani D, et al. **Lab Invest** 1995 Nov;73(5):709–16

Neurotropin prevents neurophysiological abnormalities and ADP–induced hyperaggregability in rats with streptozotocin–induced diabetes. Hotta N, et al. **Life Sci** 1995;57(23):2101–11

Recombinant insulin–like growth factor–1 modulates aggregation in human platelets via extracellular calcium. Motani AS, et al. **Life Sci** 1996;58(15):PL269–74

Palmolein and groundnut oil have comparable effects on blood lipids and platelet aggregation in healthy Indian subjects. Ghafoorunissa, et al. **Lipids** 1995 Dec; 30(12):1163–9

Calcium–induced platelet aggregation in washed platelets from guinea pigs. Miyamae T, et al. **Pharmacology** 1995 Sep;51(3):180–5

Arylhydrazones and phenylsemicarbazones of 2–aminobenzophenones as antithrombotic agents. Andronati SA, et al. **Pharmazie** 1995 Sep;50(9):632–3

Potent antiplatelet, anti–inflammatory and antiallergic isoflavanquinones from the roots of Abrus precatorius. Kuo SC, et al. **Planta Med** 1995 Aug;61(4):307–12

Indolopyridoquinazoline alkaloids with antiplatelet aggregation activity from Zanthoxyium integrifoliolum. Sheen WS, et al. **Planta Med** 1996 Apr;62(2):175–6

Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Yin K, et al. **Prostaglandins** 1995 Sep;50(3):169–78

Low–dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin. Smith MJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):331–40

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan–Feb;37(1):12–6 (41 ref.)

Phosphatidylinositol 3–kinase inhibitor, wortmannin, inhibits 5–hydroxytryptamine–mediated potentiation of platelet aggregation induced by epinephrine. Shah BH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):157–64

Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries. Willerson JT, et al. **Tex Heart Inst J** 1996;23(1):1–8

Ristocetin–induced platelet agglutination stimulates GPIIb/IIIa–dependent calcium influx. Bertolino G, et al. **Thromb Haemost** 1995 Apr;73(4):689–92

On the role of platelet Fc gamma RIIa phenotype in heparin–induced thrombocytopenia. Brandt JT, et al. **Thromb Haemost** 1995 Dec;74(6):1564–72

Absence of in vitro cross–reaction of pentasaccharide with the plasma heparin–dependent factor of twenty–five patients with heparin–associated thrombocytopenia [letter] Elalamy I, et al. **Thromb Haemost** 1995 Nov;74(5):1384–5

Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Gallistl S, et al. **Thromb Haemost** 1995 Oct; 74(4):1163–8

Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Hardy E, et al. **Thromb Haemost** 1995 Oct;74(4):1132–7

Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Heptinstall S, et al. **Thromb Haemost** 1995 Nov;74(5):1310–5

Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy. Horn EH, et al. **Thromb Haemost** 1996 Feb;75(2):346–51

Human anti–streptokinase antibodies induce platelet aggregation in an Fc receptor (CD32) dependent manner. Lebrazi J, et al. **Thromb Haemost** 1995 Sep;74(3):938–42

A comparison of the effect of decorsin and two disintegrins, albolabrin and eristostatin, on platelet function. McLane MA, et al. **Thromb Haemost** 1995 Nov;74(5):1316–22

Oxidized LDL and reduction of the antiaggregating activity of nitric oxide derived from endothelial cells. Minuz P, et al. **Thromb Haemost** 1995 Oct;74(4):1175–9

Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Patrono C, et al. **Thromb Haemost** 1995 Jul;74(1):396–400 (45 ref.)

Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Reininger AJ, et al. **Thromb Haemost** 1995 Sep;74(3):853–8

Cigarette smoking sensitizes and desensitizes impedance–measured ADP–induced platelet aggregation in whole blood. Sharp DS, et al. **Thromb Haemost** 1995 Aug; 74(2):730–5

Inhibition of platelet aggregation by an SLE–derived human hybridoma autoantibody against an activation–dependent antigen. Xu H, et al. **Thromb Haemost** 1995 Oct; 74(4):1152–62

Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. Anfossi G, et al. **Thromb Res** 1996 Apr 1;82(1):57–68

Flurbinitroxybutylester: a novel anti–inflammatory drug has enhanced antithrombotic activity. Cirino G, et al. **Thromb Res** 1995 Jul 1;79(1):73–81

Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Kambayashi J, et al. **Thromb Res** 1996 Jan 1;81(1):85–90

Remnant–like lipoproteins stimulate whole blood platelet aggregation in vitro. Knöfler R, et al. **Thromb Res** 1995 Apr 15;78(2):161–71

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Minuz P, et al. **Thromb Res** 1995 Dec 1;80(5):367–76

Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. Mugiya S, et al. **Thromb Res** 1995 Aug 1;79(3):337–41

In vivo effect of bile salts on platelet aggregation in rats. Pereira J, et al. **Thromb Res** 1995 Nov 15;80(4):357–62

Inhibition of platelet aggregation and eicosanoid production

by phenolic components of olive oil. Petroni A, et al. **Thromb Res** 1995 Apr 15;78(2):151–60

A mimetic of the RGDF–peptide [arginine–glycine–aspartic acid–phenylalanine] blocks aggregation and flow–induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans. Pueyo C, et al. **Thromb Res** 1996 Jan 1;81(1):101–12

Quantitative measurement of various 5–HT receptor antagonists on platelet activation induced by serotonin. Qi R, et al. **Thromb Res** 1996 Jan 1;81(1):43–54

Inhibition of ADP–induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Riddell DR, et al. **Thromb Res** 1995 Dec 15;80(6):499–508

Inhibition of platelet aggregation in whole blood by alcohol. Torres Duarte AP, et al. **Thromb Res** 1995 Apr 15; 78(2):107–15

Anti–platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Umemura K, et al. **Thromb Res** 1995 Nov 1;80(3):209–16

Effects of stonustoxin (lethal factor from Synanceja horrida venom) on platelet aggregation. Khoo HE, et al. **Toxicon** 1995 Aug;33(8):1033–41

[Clinical and experimental study on inhibitory effect of sanhuang mixture on platelet aggregation] Huang WM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):465–7 (Eng. Abstr.) **(Chi)**

[Site–directed mutagenesis of the gene of Echistatin Leu14–Lys15–Glu16] Li H, et al. **I Chuan Hsueh Pao** 1996; 23(2):163–8 (Eng. Abstr.) **(Chi)**

[Effects of neferine and its combination with taurine on platelet aggregation and experimental thrombosis in rats] Huang HL, et al. **Yao Hsueh Hsueh Pao** 1995;30(7):486–90 (Eng. Abstr.) **(Chi)**

[Biochemical and pharmacologic properties of platelet aggregants and platelet antiaggregants of viper venoms in Tunisia] Marrakchi N, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):487–91 **(Fre)**

[Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats] Hart S, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):476–80 (Eng. Abstr.) **(Ger)**

[Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke] Oláh L, et al. **Orv Hetil** 1996 Mar 3;137(9):455–9 (Eng. Abstr.) **(Hun)**

[Effect of sn–2–acetylated analogs of phosphatidalic acid on release and aggregation of human platelets] Muzia GI, et al. **Biokhimiia** 1996 Mar;61(3):455–60 (Eng. Abstr.) **(Rus)**

[Platelet aggregation inhibition due to sodium hypochlorite. The effect of blood plasma components] Murina MA, et al. **Biull Eksp Biol Med** 1995 May;119(5):488–90 **(Rus)**

[Changes in the coagulating and aggregating activity of alpha–thrombin by a synthetic analog of the thymosin fragment alpha 1(24–28)] Strukova SM, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):26–9 **(Rus)**

[Protegrins––a new family of peptides of leukocytic origin, modulating the functional activity of platelets] Tkachenko SB, et al. **Dokl Akad Nauk** 1996 Mar;347(1):126–8 **(Rus)**

[Cerebral blood flow and thrombocyte aggregation at different times of hypokinesia and their regulation by antiaggregants] Akopian VP, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):16–8 (Eng. Abstr.) **(Rus)**

[The effect of new synthetic prostanoids on the aggregation activity of human thrombocytes] Petrukhina GN, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):45–8 (Eng. Abstr.) **(Rus)**

[The pro–platelet–aggregant effect of cocaine (letter)] Epelde Gonzalo F. **An Med Interna** 1996 May;13(5):253 **(Spa)**

[Effect of controlled hypotension using sodium nitroprusside on platelet aggregation] Heesen M, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):320–3 (Eng. Abstr.) **(Spa)**

GENETICS

The molecular mechanism of platelet adhesion. Berndt MC, et al. **Aust N Z J Med** 1995 Dec;25(6):822–30 (57 ref.)

Correlation analysis of blood pressure and platelet aggregation/vascular reactivity in SHRSP, WKY, F1 and backcross generations. Hamano M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S107–8

IMMUNOLOGY

EDTA–dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10–year follow–up. Bizzaro N. **Am J Hematol** 1995 Oct;50(2):103–9

Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Liu LX, et al. **Br J Haematol** 1995 Dec;91(4):976–82

Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation. Yano S, et al. **Eur J Immunol** 1995 Nov;25(11):3128–33

Platelet aggregation in IgE–mediated allergy with elevated soluble Fc epsilon RII/CD23 level. Rogala B, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):161–5

[Induction of human platelet aggregation by nerve tissue antigens and immune complexes] Matusevich LI, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):29–31 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Increased platelet aggregability in patients with vertigo, sudden deafness and facial palsy. Asakura M, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:399–400

Genetic polymorphism of the alpha 2–adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Freeman K, et al. **Am J Hypertens** 1995 Sep; 8(9):863–9

Uremic patients have decreased shear–induced platelet aggregation mediated by decreased availability of glycoprotein IIb–IIIa receptors. Sreedhara R, et al. **Am J Kidney Dis** 1996 Mar;27(3):355–64

Direct demonstration of radiolabeled von Willebrand factor binding to platelet glycoprotein Ib and IIb–IIIa in the presence of shear stress. McCrary JK, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):787–93

Involvement of calpain in integrin–mediated signal transduction. Inomata M, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):129–34

Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Takahashi Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):453–9

The hemorrhagin catrocollastatin inhibits collagen–induced platelet aggregation by binding to collagen via its disintegrin–like domain. Zhou Q, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):720–6

Internalization of bound fibrinogen modulates platelet aggregation. Wencel–Drake JD, et al. **Blood** 1996 Jan 15; 87(2):602–12

An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Yuan Y, et al. **Blood** 1995 Dec 1;86(11):4166–74

Daily variation of serum lipids in relation to the circadian rhythm of platelet aggregation in healthy male persons. Knöfler R, et al. **Clin Chim Acta** 1995 Aug 14;239(2):109–19

Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease [see comments] Goudevenos J, et al. **Eur Heart J** 1995 Aug; 16(8):1036–43. Comment in: Eur Heart J 1995 Aug;16(8):1017–9.

Characterisation of platelet aggregation induced by PC–3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. Swaim MW, et al. **Eur J Cancer** 1996 Apr;32A(4):715–21

Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers. Pellegrini N, et al. **Eur J Clin Nutr** 1996 Apr; 50(4):209–13

Plateletpheresis–induced increase in platelet reactivity using different cell separators. Jung F, et al. **Infusionsther Transfusionsmed** 1995 Aug;22(4):237–43

Inhibition of ADP–induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8–(4–bromo–2,3–dioxobutylthio)ADP. Puri RN, et al. **J Biol Chem** 1995 Oct 13;270(41):24482–8

Aggregatory characteristics and expression of the collagen adhesion receptor in fetal porcine platelets. Olutoye OO, et al. **J Pediatr Surg** 1995 Dec;30(12):1649–53

Anticoagulation for heparin–induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Koide M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2137–40

Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nakashima A, et al. **Nephron** 1996;73(1):34–40

Prostacyclin production at the human microvascular anastomosis: its effect on initial platelet deposition. Restifo RJ, et al. **Plast Reconstr Surg** 1996 Apr;97(4):784–91

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Moro MA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1480–5

Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb–IIIa functional activity. Jennings LK, et al. **Thromb Haemost** 1995 Dec;74(6):1551–6

Regulation of platelet aggregation by post–fibrinogen binding events. Insights provided by dithiothreitol–treated platelets. Peerschke EI. **Thromb Haemost** 1995 May;73(5):862–7

Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability. Orth M, et al. **Thromb Res** 1995 Aug 1;79(3):297–305

The normalization period of platelet aggregation in newborns. Tanindi S, et al. **Thromb Res** 1995 Oct 1; 80(1):57–62

Megakaryocyte growth and development factor (MGDF) moderately enhances in–vitro platelet aggregation. Toombs CF, et al. **Thromb Res** 1995 Oct 1;80(1):23–33

Reduced thrombogenicity of type VI collagen as compared to type I collagen. Zangari M, et al. **Thromb Res** 1995 Sep 15;79(5–6):429–36

Apyrase activity and adenosine diphosphate induced platelet aggregation inhibition by the salivary gland proteins of Culicoides variipennis, the North American vector of bluetongue viruses. Pérez de León AA, et al. **Vet Parasitol** 1996 Feb;61(3–4):327–38

[Evaluation of factors influencing platelet aggregation in patients with chronic glomerulonephritis (CGN)] Zdrojewski Z, et al. **Przegl Lek** 1996;53(5):434–8 (Eng. Abstr.) **(Pol)**

[The microcirculation in the mesentery of rats and thrombocyte aggregation during hypoglycemic coma] Shestakova SA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):99–104 (Eng. Abstr.) **(Rus)**

[Erythrocytes modulate the anti–aggregation effect of aspirin and dipyridamole. Study under static conditions and in a flow system] Bozzo J, et al. **Sangre (Barc)** 1996 Feb; 41(1):13–8 (Eng. Abstr.) **(Spa)**

PLATELET AGGREGATION INHIBITORS

Plasma P selectin (GMP–140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Halim A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):272–7

Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Noble S, et al. **Drugs Aging** 1996 Mar;8(3):214–32 (125 ref.)

Monamidocin, a novel fibrinogen receptor antagonist. I. Production isolation, characterization and structural elucidation. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1221–5

[Anagrelide. A selective inhibitor of thrombopoiesis] Hasselbalch HC, et al. **Ugeskr Laeger** 1996 Mar 18; 158(12):1693–5 **(Dan)**

ADMINISTRATION & DOSAGE

Patterns of aspirin use in middle–aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

Pharmacist–managed ticlopidine clinic [letter] Pecini M. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2030–1

Impact of polyunsaturated fatty acids on human colonic bacterial metabolism: an in vitro and in vivo study. Thompson L, et al. **Br J Nutr** 1995 Nov;74(5):733–41

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré–eclampsia com Aspirina) Collaborative Group [see comments] **Br J Obstet Gynaecol** 1996 Jan; 103(1):39–47. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):719–20.

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [letter; comment] Goffinet F, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):719–20. Comment on: Br J Obstet Gynaecol 1996 Jan;103(1):39–47.

Topical application of capsaicin and flap survival. Iinuma T, et al. **Br J Plast Surg** 1996 Jul;49(5):319–20

The heparin–induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors. Murphy KD, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):123–7

Aspirin and other platelet–active drugs. The relationship among dose, effectiveness, and side effects. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):247S–257S (148 ref.)

The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI). Jin L, et al. **Chin Med J (Engl)** 1995 Oct;108(10):783

The protective dose of the potent GPIIb/IIIa antagonist SC–54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Frederick LG, et al. **Circulation** 1996 Jan 1; 93(1):129–34

Differential dose–response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Kereiakes DJ, et al. **Circulation** 1996 Sep 1;94(5):906–10

How should clinicians choose treatment for preventing stroke when therapeutic trials are not available to guide the situation? **Eur Neurol** 1995;35(5):293–305; discussion 305–8

Dose of prophylactic aspirin in IHD and body weight [letter] Kumar H. **J Assoc Physicians India** 1995 Aug;43(8):586

Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. McAdam B, et al. **J Pharmacol Exp Ther** 1996 May;277(2):559–64

Adjusted–dose warfarin versus low–intensity, fixed–dose warfarin plus aspirin for high–risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. **Lancet** 1996 Sep 7; 348(9028):633–8

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments] Barst RJ, et al. **N Engl J Med** 1996 Feb 1;334(5):296–302. Comment in: N Engl J Med 1996 May 30;334(22):1477; discussion 1477–8.

Optimal oral anticoagulation for patients with mechanical heart valves [letter; comment] von Schacky C. **N Engl J Med** 1995 Nov 30;333(22):1504–5. Comment on: N Engl J Med 1995 Jul 6;333(1):11–7.

Effect of oral prostacyclin on microclots in tube lines of a hemodialysis system [letter] Ozasa H, et al. **Nephron** 1995; 71(1):106–7

Clinical effect of the anti–platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy––a multi–center study. Koide H,

et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):644–8

Platelet–activating factor–antagonists reduce implantation in mice at low doses only. O'Neill C. **Reprod Fertil Dev** 1995; 7(1):51–7

Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries. Willerson JT, et al. **Tex Heart Inst J** 1996;23(1):1–8

Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Heptinstall S, et al. **Thromb Haemost** 1995 Nov;74(5):1310–5

Increased plasma thrombin–antithrombin III complex levels in non–insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. Shimizu H, et al. **Thromb Haemost** 1995 Nov;74(5):1231–4

–Is prevention of pre–eclampsia with low dosage aspirin possible? Critical assessment of available studies– Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**

[Effect of calcium dobesilate on progression of diabetic retinopathy] Haas A, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):17–21 (Eng. Abstr.) **(Ger)**

[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886–9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890–4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**

[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily (letter; comment)] Förster W. **Z Kardiol** 1995 Dec;84(12):1043. Comment on: Z Kardiol 1995 Jun;84(6):496–8. **(Ger)**

[Response to the editorial by J. C. Frölich: Aspirin––yes, but 30 mg?? (letter; comment)] Förster W. **Z Kardiol** 1995 Dec;84(12):1044–5. Comment on: Z Kardiol 1995 May;84(5):344–7. **(Ger)**

[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily (letter)] Schrör K. **Z Kardiol** 1996 May;85(5):357 **(Ger)**

[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement] Toyohira H, et al. **Kyobu Geka** 1995 Aug; 48(9):749–55 (Eng. Abstr.) **(Jpn)**

[Treatment with ticlodipine after intracoronary stent implantation] Myreng Y, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1789–91 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Antiplatelet therapy, regional anesthesia, and spinal hematomas [letter; comment] Maclean A. **Anesth Analg** 1995 Nov;81(5):1116. Comment on: Anesth Analg 1995 Feb;80(2):303–9.

Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia. Thwaites BK, et al. **Anesth Analg** 1996 Jun;82(6):1176–81

Interference with anticoagulation monitoring by procainamide–induced lupus anticoagulant. Metzdorff MT, et al. **Ann Thorac Surg** 1996 Mar;61(3):994–5

Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low–dose warfarin vs conventional warfarin therapy. Blackshear JL, et al. **Arch Intern Med** 1996 Mar 25;156(6):658–60

Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215–9 (53 ref.)

Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Bar Dayan Y, et al. **Isr J Med Sci** 1996 May;32(5):288–91

Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. Cuiper LL, et al. **J Appl Physiol** 1996 Jan;80(1):191–7

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Dodenhoff RM. **J Bone Joint Surg Am** 1996 Jun;78(6):968. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Severe aplastic anemia induced by ticlopidine: report of a case. Su CC, et al. **J Formos Med Assoc** 1995 Nov; 94(11):689–91 (8 ref.)

Blood dycrasias and hematologic reactions in ticlopidine users [letter] Wysowksi DK, et al. **JAMA** 1996 Sep 25; 276(12):952

Ticlopidine and renal function [letter] Elsman P, et al. **Lancet** 1996 Jul 27;348(9022):273–4

Antiplatelet and anticoagulant therapy after coronary–artery stenting [letter] Schöneberger AA, et al. **N Engl J Med** 1996 Oct 10;335(15):1160; discussion 1161

Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Rowin J, et al. **Neurology** 1996 Jun;46(6):1775–6

Is there a link between acute spinal epidural hematoma and aspirin? Heye N. **Spine** 1995 Sep 1;20(17):1931–2

Cholestatic hepatitis: ticlopidine suspected [letter] Roy L, et al. **Therapie** 1995 Nov–Dec;50(6):593–4

Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. Tschugguel W, et al. **Thromb Res** 1995 Nov 1;80(3):225–33

[Adverse hematologic effects of ticlopidine (letter)] Lesesve JF, et al. **Therapie** 1995 Sep–Oct;50(5):468–70 (11 ref.) **(Fre)**

[Ticlopidine–induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor] Schneider AW, et al. **Med Klin** 1996 Jun 15; 91(6):417–9 **(Ger)**

[A lower–leg ulcer during hydroxyurea therapy for essential thrombocythemia] Iwama H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):937–9 (Eng. Abstr.) **(Jpn)**

[Thrombotic thrombocytopenic purpura associated with ticlopidine (letter)] Jimenez Moreno FJ, et al. **An Med Interna** 1996 Jan;13(1):46–7 **(Spa)**

[Cholestatic hepatitis and anemia induced by ticlopidine] Pascual S, et al. **Gastroenterol Hepatol** 1996 Apr; 19(4):208–9 (Eng. Abstr.) **(Spa)**

[Ticlopidine–induced lymphocytic colitis (letter)] Martinez Avilés P, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):317 **(Spa)**

BLOOD

Determination of the anti–platelet–activating factor BN–50727 and its metabolites in human plasma by high–performance liquid chromatography–solid–phase extraction. Pruñonosa J, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):281–90

CHEMICAL SYNTHESIS

Synthesis and antiplatelet activity of 1–tert–butylamino–3–(3–thienyloxy)–2–propanols. Abdallah S, et al. **Arch Pharm (Weinheim)** 1996 Apr; 329(4):216–22

New indole and pyridazinoindole analogs––synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation. Monge A, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):689–98

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, Part 33. From tetradecane– to octacosanediamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):191–6

Synthesis and antiplatelet, antiinflammatory and antiallergic activities of 2,3–disubstituted 1,4–naphthoquinones. Lien JC, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1181–7

Synthesis and thromboxane A2 antagonistic activity of [[1–aryl(or benzyl)–1–(benzenesulfonamido)methyl]phenyl]alkanoic acid derivatives. Sakurai S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):765–77

2–Arylmethyl–1,4–benzoquinones. I. Novel inhibitors of platelet aggregation: synthesis and pharmacological evaluation. Suzuki K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):139–44

Pyran derivatives XIX. (Dialkylamino) substituted 1–benzopyranones and naphthopyranones with platelet antiaggregating activity. Di Braccio M, et al. **Farmaco** 1995 Oct;50(10):703–11

A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg–Gly–Asp peptides. Kini RM, et al. **FEBS Lett** 1995 Nov 13;375(1–2):15–7

Design, synthesis, and structure–activity relationship studies of novel 1–[(1–acyl–4–piperidyl)methyl]–1H–2–methylimidazo[4,5–c]pyridine derivatives as potent, orally active platelet–activating factor antagonists. Carceller E, et al. **J Med Chem** 1996 Jan 19;39(2):487–93

Arylhydrazones and phenylsemicarbazones of 2–aminobenzophenones as antithrombotic agents. Andronati SA, et al. **Pharmazie** 1995 Sep;50(9):632–3

Pyrido[2,3–d]pyrimidin–4(3H)–one derivatives and 1,2,3,4–tetrahydro– pyrido[2,3–d]pyrimidine derivatives: synthesis and in vitro study of their activity against platelet aggregation. Hou G, et al. **Pharmazie** 1995 Nov; 50(11):719–22

[Synthesis and antiplatelet activity of 2–amino–4,5–diphenylthiazole derivatives] Inoue H, et al. **Yakugaku Zasshi** 1995 Aug;115(8):603–10 (Eng. Abstr.) **(Jpn)**

[Synthesis of new platelet aggregation inhibitors substituted with pyridylisoxazoles and their 4,5–dihydroanalogs] Demina OV, et al. **Bioorg Khim** 1995 Dec;21(12):933–40 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Structural analysis of a biologically active echistatin analogue des(46–49)–[Ala8,37]–echistatin gamma with three disulfide bonds by 2D–NMR and computer graphics. Chuang LC, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):246–54

In vivo degradation of human fibrinogen A alpha: detection of cleavage sites and release of antithrombotic peptides. Ständker L, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):896–902

Chemical mechanisms underlying the vasodilator and platelet anti–aggregating properties of S–nitroso–N–acetyl–DL–penicillamine and S–nitrosoglutathione. Askew SC, et al. **Bioorg Med Chem** 1995 Jan;3(1):1–9

A new nitric oxide (NO) releaser: spontaneous NO release from FK409. Fukuyama S, et al. **Free Radic Res** 1995 Nov; 23(5):443–52

Discovery of an orally active non–peptide fibrinogen receptor antagonist. Stilz HU, et al. **J Med Chem** 1996 May 24;39(11):2118–22

Do we know the complete sequence of metalloproteinase and nonenzymatic platelet aggregation inhibitor (disintegrin) precursor proteins? Kini RM. **Toxicon** 1995 Sep;33(9):1151–60

CONTRAINDICATIONS

[Contraindication of ATP related drugs for therapy of gout and uric acidemia (letter)] Domoto K. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1939–40 **(Jpn)**

DIAGNOSTIC USE

Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography. Rovai D, et al. **Eur Heart J** 1996 Feb;17(2):296–301

IMMUNOLOGY

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Reilly TM, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2195–9

Inhibition of platelet aggregation by an SLE–derived human hybridoma autoantibody against an activation–dependent antigen. Xu H, et al. **Thromb Haemost** 1995 Oct; 74(4):1152–62

ISOLATION & PURIFICATION

Inhibition on platelet activation by shikonin derivatives isolated from Arnebia euchroma. Ko FN, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):329–34

Isolation, characterization and pharmacological activity of Magydaris pastinacea (Lam) Paol. glucosides. Cerri R, et al. **Farmaco** 1995 Dec;50(12):841–8

Novel anti–platelet aggregation polypeptides from Vipera lebetina venom: isolation and characterization. Barbouche R, et al. **FEBS Lett** 1996 Aug 19;392(1):6–10

Herquline B, a new platelet aggregation inhibitor produced by Penicillium herquei Fg–372. Enomoto Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):50–3

Tachykinin antagonists screening from microbial origin. Hayashi K, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):110–2

New prenylflavones from the leaves of Epimedium saggitatum. Chen CC, et al. **J Nat Prod** 1996 Apr; 59(4):412–4

Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids. Chen KS, et al. **J Nat Prod** 1996 May;59(5):531–4

Novel antiplatelet naphthalene from Rhamnus nakaharai. Lin CN, et al. **J Nat Prod** 1995 Dec;58(12):1934–40

Potent antiplatelet, anti–inflammatory and antiallergic isoflavanquinones from the roots of Abrus precatorius. Kuo SC, et al. **Planta Med** 1995 Aug;61(4):307–12

Indolopyridoquinazoline alkaloids with antiplatelet aggregation activity from Zanthoxylum integrifoliolum. Sheen WS, et al. **Planta Med** 1996 Apr;62(2):175–6

Isolation and characterization of jararaca GPIb–BP, a snake venom antagonist specific to platelet glycoprotein Ib. Fujimura Y, et al. **Thromb Haemost** 1995 Aug;74(2):743–50

Crotavirin, a potent platelet aggregation inhibitor purified from the venom of the snake Crotalus viridis. Liu CZ, et al. **Toxicon** 1995 Oct;33(10):1289–98

5–hydroxy–3–vinyl–2(5H)–furanone––a new inhibitor of human synovial phospholipase A2 and platelet aggregation from fermentations of a Calyptella species (basidiomycetes). Lorenzen K, et al. **Z Naturforsch [C]** 1995 May–Jun; 50(5–6):403–9

METABOLISM

Binding affinities of isocarbacyclin methyl ester and its free acid to prostanoid receptors. Tanaka M, et al. **Arzneimittelforschung** 1995 Sep;45(9):967–70

Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins. Marcinkiewicz C, et al. **Biochem J** 1996 Aug 1; 317 (Pt 3):817–25

The formation of nitric oxide donors from peroxynitrite. Moro MA, et al. **Br J Pharmacol** 1995 Oct; 116(3):1999–2004

Recovery of endothelial cells and prostanoid production in endothelial cell–seeded grafts. Jensen N, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):54–9

The specific binding of the platelet–activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes. Svetlov SI, et al. **Life Sci** 1996;58(5):PL 81–6

PHARMACOKINETICS

Distribution behaviour of 131–iodine labelled trans–N,N'–bis–(ethoxy–carbonyl)–N–[4–(3–iodo–4–methoxyphenyl)butyl]–N' –5–phenylpentyl)–1,4–cyclohexanedimethanamine. Rehse K, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):731–6

Metabolic fate of the new antithrombotic agent aspalatone in rats. In vivo and in vitro study. Suh DY, et al. **Arzneimittelforschung** 1995 Oct;45(10):1071–4

Pharmacokinetics and pharmacodynamics of TP–9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue–type plasminogen activator, heparin, and aspirin in beagles. Modi NB, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):105–12

Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Aungst BJ, et al. **Pharm Res** 1996 Jan;13(1):114–9

The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs. Burcham DL, et al. **Pharm Res** 1995 Dec; 12(12):2065–70

PHARMACOLOGY

Relaxant effect of nitric oxide and prostacyclin on serotonin–induced vasocontraction of human umbilical artery. Okatani Y, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):108–12

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Harrington RA, et al. **Am J Cardiol** 1995 Dec 15;76(17):1222–7

Short–term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Saji T, et al. **Am J Cardiol** 1996 Jul 15; 78(2):244–7

Additional anticoagulant strategies for managing heparin–induced thrombocytopenia [letter] Nawarskas JJ, et al. **Am J Health Syst Pharm** 1996 Apr 15;53(8):945

Antiplatelet therapy. Schafer AI. **Am J Med** 1996 Aug; 101(2):199–209 (105 ref.)

Effects of a PAF antagonist, Y–24180, on bronchial hyperresponsiveness in patients with asthma. Hozawa S, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1198–202

Direct inhibitory mechanisms of halothane on human platelet aggregation. Kohro S, et al. **Anesthesiology** 1996 Jul; 85(1):96–106; discussion 30A

Platelet–activating factor (PAF) receptor antagonism by WEB 2170 improves the survival of ischaemic skeletal muscle. Lepore DA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):63–7

Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Jesse RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:281–90

Prostaglandin E1 or prostacyclin in Euro–Collins solution fails to improve lung preservation. Kukkonen S, et al. **Ann Thorac Surg** 1995 Dec;60(6):1617–22

Protective effect of a platelet–activating factor antagonist (WEB–2086) in postischemic renal failure. González–Fajardo JA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):16–21

Prostaglandin I1 analogues, SM–10902 and SM–10906, affect human keratinocytes and fibroblasts in vitro in a manner similar to PGE1: therapeutic potential for wound healing. Kaneko F, et al. **Arch Dermatol Res** 1995;287(6):539–45

Synthesis and antiplatelet activity of 1–tert–butylamino–3–(3–thienyloxy)–2–propanols. Abdallah S, et al. **Arch Pharm (Weinheim)** 1996 Apr; 329(4):216–22

New indole and pyridazinoindole analogs—synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation. Monge A, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):689–98

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, Part 33. From tetradecane– to octacosanediamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):191–6

Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Sixma JJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):64–71

Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Szczeklik A, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):948–54

Exhibition of anti–platelet effect of isocarbacyclin methyl ester and its free acid via an increase in cAMP in platelets. Aoki Y, et al. **Arzneimittelforschung** 1995 Sep;45(9):970–4

Anti–platelet effects of isocarbacyclin methyl ester on human and rabbit platelets in vitro. Inoue K, et al. **Arzneimittelforschung** 1995 Sep;45(9):975–9

Ex vivo anti–platelet effects of isocarbacyclin methyl ester incorporated in lipid microspheres in rabbits. Inoue K, et al. **Arzneimittelforschung** 1995 Sep;45(9):980–4

Two different inhibitory effects of pyridoxalphosphate–6–azophenyl–2',4'–disulfonic acid on adenosine diphosphate–induced human platelet aggregation. Windscheif U, et al. **Arzneimittelforschung** 1995 Sep;45(9):994–7

Nitric oxide regulates IL–8 expression in melanoma cells at the transcriptional level. Andrew PJ, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):949–56

Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Takahashi Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):453–9

The hemorrhagin catrocollastatin inhibits collagen–induced platelet aggregation by binding to collagen via its disintegrin–like domain. Zhou Q, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):720–6

The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. Suidan HS, et al. **Biochem J** 1996 May 1;315 (Pt 3):939–45

Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti–platelet activity of Piloty's acid: a comparison with Angeli's salt. Zamora R, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):333–9

Free radical induced biophysical modification of membrane lipids: a novel mechanism proposed for a haemorheological alteration induced by 4,5' 8–trimethyl psoralen. Nivsarkar M, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):625–33

Guanidine thiol—a new activator of soluble guanylate cyclase with antihypertensive and antiaggregatory properties. Severina IS, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):913–25

Protein kinase C inhibitor, chelerythrine, potentiates the adrenaline–mediated aggregation of human platelets through calcium influx. Shah BH, et al. **Biochem Mol Biol Int** 1996 May;38(6):1135–41

Inhibition of collagen–induced platelet activation by arachidonyl trifluoromethyl ketone. McNicol A, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1795–802

Formation of a highly stable complex between BN 50730 [tetrahydro–4,7,8,10 methyl–1(chloro–2 phenyl)–6 (methoxy–4 phenyl–carbamoyl)–9 pyrido [4',3'–4,5] thieno [3,2–f] triazolo–1,2,4 [4,3–a] diazepine–1,4] and the platelet–activating factor receptor in rabbit platelet membranes. Silva CL, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):193–6

A possible mechanism for the inhibition of blood platelet aggregation by pyridoxal–5'–phosphate. Harrington MG, et al. **Biochem Soc Trans** 1996 Feb;24(1):76S

Effect of pyridoxal–5'–phosphate on aggregation of platelets from stored human concentrates induced by arachidonic acid. Nolan ML, et al. **Biochem Soc Trans** 1996 Feb; 24(1):95S

Bothrojaracin: a potent two–site–directed thrombin inhibitor. Arocas V, et al. **Biochemistry** 1996 Jul 16;35(28):9083–9

Involvement of mercury in platelet aggregation—probable mechanism of action. Chaudhury S, et al. **Biomed Environ Sci** 1996 Mar;9(1):26–36

Synthesis of Hexahydrocyclopentimidazol–2–(1H)–one derivatives displaying selective DP–receptor agonist properties. Barraclough P, et al. **Bioorg Med Chem** 1996 Jan;4(1):81–90

An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Yuan Y, et al. **Blood** 1995 Dec 1;86(11):4166–74

RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2–antiplasmin) enhances plasminogen binding to platelets. Udvardy M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):481–5

Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3–integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Chiang HS, et al. **Br J Cancer** 1996 Apr;73(7):902–8

Systemic effects of S–nitroso–glutathione in the human following intravenous infusion. Ramsay B, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):101–2

Platelet sensitivity to prostaglandin E1 inhibition is reduced in pre–eclampsia but not in nonproteinuric gestational hypertension. Torres PJ, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):19–24

PPADS: an antagonist at endothelial P2Y–purinoceptors but not P2U–purinoceptors. Brown C, et al. **Br J Pharmacol** 1995 Nov;116(5):2413–6

Effect of trilinolein on cyclic nucleotide formation in human platelets: relationship with its antiplatelet effect and nitric oxide synthesis. Shen YC, et al. **Br J Pharmacol** 1995 Sep; 116(1):1644–8

YC–1 inhibited human platelet aggregation through NO–independent activation of soluble guanylate cyclase. Wu CC, et al. **Br J Pharmacol** 1995 Oct;116(3):1973–8

Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose–dependent inhibition of platelet function. Bhattacharya S, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):665–75

Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN–1 and sodium nitroprusside. Negrescu EV, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):619–29

Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin. Bozzo J, et al. **Cardiovasc Res** 1995 Nov;30(5):725–30

The effect of methylmercury (CH_3HgCl) on the production of endothelium–derived relaxing factor (EDRF) by cultured human umbilical vascular endothelial cells based on its anti–aggregatory effect on human platelets. Ohno M, et al. **Cell Biol Toxicol** 1995 Dec;11(6):303–11

The antagonistic effects of khellactones on platelet–activating factor, histamine, and leukotriene D4. Aida Y, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):859–67

Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Okada Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1385–7

2–Arylmethyl–1,4–benzoquinones. I. Novel inhibitors of platelet aggregation: synthesis and pharmacological evaluation. Suzuki K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):139–44

Inhibitory effects of TA–993, a new 1,5–benzothiazepine derivative, on platelet aggregation. Odawara A, et al. **Circ Res** 1996 Apr;78(4):643–9

The red wine phenolics trans–resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Pace–Asciak CR, et al. **Clin Chim Acta** 1995 Mar 31; 235(2):207–19

Glyceryl trinitrate enhances the adenosine–induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti–aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

Effects of garlic extract on platelet aggregation [letter; comment] Myers SP, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):888–9. Comment on: Clin Exp Pharmacol Physiol 1995 Jun–Jul;22(6–7):414–7.

Epoprostenol increases plasma level of atrial natriuretic peptide in humans. Nielsen CB, et al. **Clin Sci (Colch)** 1996 Feb;90(2):87–9

Effect of prostaglandin E1 on hepatic function after hepatectomy in patients with chronic liver disease. Une Y, et al. **Clin Ther** 1995 Nov–Dec;17(6):1118–25

Impaired insulin–induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Trovati M, et al. **Diabetes** 1995 Nov;44(11):1318–22

Antiplatelet drugs. A comparative review. Schrör K. **Drugs** 1995 Jul;50(1):7–28 (189 ref.)

Prostaglandin E1 increases binding of 123I–low–density lipoprotein to the human liver in vivo. Sinzinger H, et al. **Eur J Clin Pharmacol** 1996;49(6):515–20

Effects of alpha–trinositol administered extra– and intracellularly (using liposomes) on rat aorta rings. Brailoiu E, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):209–12

Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN–1 on platelet cyclic AMP. Fisch A, et al. **Eur J Pharmacol** 1995 May 26;289(3):455–61

Tranilast inhibits the effects of platelet–derived growth factor on cell proliferation and induction of nitric oxide. Hishikawa K, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):435–8

Regional haemodynamic effects of platelet activating factor in the rat. King KA, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):187–93

Platelet aggregation is inhibited by phycolectins. Matsubara K, et al. **Experientia** 1996 Jun 15;52(6):540–3

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar–Apr;10(2):91–8

Role of PAF in the late airway microvascular leakage induced by antigen in IgE–sensitized rat. Kyriacopoulos F, et al. **Fundam Clin Pharmacol** 1995;9(4):350–6

Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. Ueno Y, et al. **Gen Pharmacol** 1996 Jan; 27(1):101–3

Plasma serotonin and platelet aggregation during ischemia–reperfusion in dogs: effect of dipyridamole and coenzyme Q10. Choudhury NA, et al. **Haemostasis** 1996 Jan–Feb;26(1):38–44

Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats. Moreno A, et al. **Haemostasis** 1995 Jul–Aug;25(4):166–71

Effect of the H1–antagonist bromadryl on mast cells in pregnant rats ex vivo. Drábiková K, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S36–7

On the effect of the antihistaminic drug bromadryl on human platelets in vitro. Jančinová V, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S21–2

The H1–histamine antagonist Dithiaden inhibits human platelets in vitro. Nosál R, et al. **Inflamm Res** 1996 Mar; 45 Suppl 1:S29–30

The H1–histamine receptor antagonist dithiaden inhibits stimulated platelet aggregation, malondialdehyde formation and thromboxane production in vitro. Nosál R, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S14–5

Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Narita S, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):161–6

Vascular thromboxane formation in hemostasis mechanism: correlation between bleeding time and vascular TXB2 in a patient with congenital platelet cyclo–oxygenase deficiency. Fuse I, et al. **Int J Hematol** 1996 Jun; 63(4):317–24

Antiplatelet activity of synthetic and natural resveratrol in red wine. Bertelli AA, et al. **Int J Tissue React** 1995; 17(1):1–3

Oral L–arginine inhibits platelet aggregation but does not enhance endothelium–dependent dilation in healthy young men. Adams MR, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1054–61

Bassiatin, a new platelet aggregation inhibitor produced by Beauveria bassiana K–717. Kagamizono T, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1407–12

Monamidocin, a novel fibrinogen receptor antagonist. II. Biological activity and structure–activity relationships. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1226–33

Thrombin–induced platelet aggregation is inhibited by the heptapeptide Leu271–Ala277 of domain 3 in the heavy chain of high molecular weight kininogen. Kunapuli SP, et al. **J Biol Chem** 1996 May 10;271(19):11228–35

Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that

resembling the disintegrin elegantin. Lu X, et al. **J Biol Chem** 1996 Jan 5;271(1):289–94

Triabin, a highly potent exosite inhibitor of thrombin. Noeske-Jungblut C, et al. **J Biol Chem** 1995 Dec 1; 270(48):28629–34

Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP. Puri RN, et al. **J Biol Chem** 1995 Oct 13;270(41):24482–8

Variabilin, a novel RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Wang X, et al. **J Biol Chem** 1996 Jul 26;271(30):17785–90

Effect of beraprost, a stable prostacyclin analogue, on red blood cell deformability impairment in the presence of hypercholesterolemia in rabbits. Hayashi J, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):527–31

Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells. Leclerc NE, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S88–91

Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. Miyata M, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):20–6

Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. Modi NB, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):888–97

Effects of lomefloxacin and sparfloxacin on human platelet aggregation. Losasso C, et al. **J Chemother** 1995 Oct; 7(5):420–3

Thin-layer chromatography and high-performance liquid chromatography for the assay of fatty acid compositions of individual phospholipids in platelets from non-insulin-dependent diabetes mellitus patients: effect of eicosapentaenoic acid ethyl ester administration. Miwa H, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3; 677(2):217–23

Aspirin inhibits collagen-induced platelet serotonin release, as measured by microbore high-performance liquid chromatography with electrochemical detection. Tsai TH, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):404–7

Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. Salvemini D, et al. **J Clin Invest** 1996 Jun 1;97(11):2562–8

Effects of antiplatelet drug dilazep dihydrochloride on anionic sites and extracellular matrix (ECM) components in glomerular basement membrane of STZ-induced diabetic rats. Yamamoto M, et al. **J Clin Lab Anal** 1995; 9(6):380–6

The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure. Carlton LD, et al. **J Clin Pharmacol** 1996 Mar;36(3):247–56

The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure. Carlton LD, et al. **J Clin Pharmacol** 1996 Mar; 36(3):257–64

The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM. Nishimura M, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):330–3

Myocardial protection by N,N,N-trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin. Scalia R, et al. **J Leukoc Biol** 1996 Mar; 59(3):317–24

Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. Carceller E, et al. **J Med Chem** 1996 Jan 19;39(2):487–93

Discovery of an orally active non-peptide fibrinogen receptor antagonist. Stilz HU, et al. **J Med Chem** 1996 May 24;39(11):2118–22

Novel antiplatelet naphthalene from Rhamnus nakaharai. Lin CN, et al. **J Nat Prod** 1995 Dec;58(12):1934–40

2-Heteroaryl 2-substituted phenylketone derivatives and their inhibitory activity on platelet aggregation. Hsu LY, et al. **J Pharm Pharmacol** 1995 Sep;47(9):762–7

Synthesis and antiplatelet effects of omega-aminoalkoxylxanthones. Lin CN, et al. **J Pharm Pharmacol** 1995 Jul;47(7):588–94

Effect of KBT-3022, a new diphenylthiazole derivative, on platelet functions. Yokota K, et al. **J Pharm Pharmacol** 1995 Sep;47(9):768–74

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. Albert DH, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1595–606

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. Cook JJ, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):62–73

Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. Kawamura M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):502–10

Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1497–505

The effect of Beraprost sodium on the survival of subcutaneous transferred jejunum after vascular pedicle interruption in a rat model. Alexandrou K, et al. **J Reconstr Microsurg** 1996 Jan;12(1):39–46

Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock. Okano S, et al. **J Vet Med Sci** 1995 Aug;57(4):751–3

Inhibitory effect of KBT-3022, a new anti-platelet agent, on infiltration of polymorphonuclear leukocytes induced by leukotriene B4 or formyl-methionyl-leucyl-phenylalanine in mice. Yokota K, et al. **Jpn J Pharmacol** 1995 Jul;68(3):353–7

Inhibitory effects of the new anti-platelet agent KBT-3022 and its metabolite on rabbit neutrophil function in vitro. Yokota K, et al. **Jpn J Pharmacol** 1996 Apr;70(4):291–302

Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Bani D, et al. **Lab Invest** 1995 Nov;73(5):709–16

Inhibition of platelet aggregation by endocardial endothelial cells. Nosaka S, et al. **Life Sci** 1996;59(7):559–64

Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Wilson T, et al. **Life Sci** 1996; 59(1):PL15–21

The structure-activity relationship of lipoxygenase products of long-chain polyunsaturated fatty acids: effects on human platelet aggregation. Karanian JW, et al. **Lipids** 1996 Mar; 31 Suppl:S305–8

ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159–79 (206 ref.)

Effects of iloprost on salt-sensitive Dahl rats. Somova L. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):443–7

Effects of short-term treatment with the thromboxane synthesis blocker indobufen on pressor and depressor humoral factors in healthy humans. Zacharieva S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):615–9

Can hypertension during erythropoietin be prevented by antiplatelet therapy? [letter] Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 May;11(5):909–10

Effects of trapidil and suramin on growth factor-induced calcium response and tyrosine phosphorylation in human glioma cells. Bando K, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):631–8

Acceleration of nitric oxide (NO) release from FK409, a spontaneous NO releaser, in the presence of sulfhydryl-bearing compounds. Fukuyama S, et al. **Pharm Res** 1995 Dec;12(12):1948–52

Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Cakici I, et al. **Pharmacol Toxicol** 1995 Jun;76(6):343–7

Relation between cyclic GMP generation and cerebrovascular reactivity: modulation by NPY and alpha-trinositol. You J, et al. **Pharmacol Toxicol** 1995 Jul; 77(1):48–56

Pyrido[2,3-d]pyrimidin-4(3H)-one derivatives and 1,2,3,4-tetrahydro- pyrido[2,3-d]pyrimidine derivatives: synthesis and in vitro study of their activity against platelet aggregation. Hou G, et al. **Pharmazie** 1995 Nov; 50(11):719–22

Antiplatelet and vasorelaxing actions of some aporphinoids. Chen KS, et al. **Planta Med** 1996 Apr;62(2):133–6

The effect of a thromboxane A2 receptor antagonist BAY-u-3405 on experimental allergic reactions. Nagai H, et al. **Prostaglandins** 1995 Aug;50(2):75–87

Antithrombotic effect of topically applied 3-oxa-methano-prostaglandin I1 in the microcirculation and antiplatelet functions of its active form. Nishimura T, et al. **Prostaglandins** 1996 Feb;51(2):149–59

Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Yin K, et al. **Prostaglandins** 1995 Sep;50(3):169–78

Inhibition by beraprost sodium of thrombin-induced increase in endothelial macromolecular permeability. Imai-Sasaki R, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug;53(2):103–8

Effect of beraprost sodium (Procylin), a stable prostaglandin I2 analogue, on a dorsal skin flap model in rats. Alexandrou K, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar; 30(1):17–22

Effects of lipo-prostaglandin E1 on random pattern flaps in rabbits. Kuwahara H, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar; 30(1):23–8

Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia [letter] Kuhn W, et al. **Stroke** 1995 Oct;26(10):1959–60

A prostacyclin-sparing effect of indobufen vs. aspirin. De Caterina R, et al. **Thromb Haemost** 1996 Mar;75(3):510–4

Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Golino P, et al. **Thromb Haemost** 1995 Sep;74(3):974–9

Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Hardy E, et al. **Thromb Haemost** 1995 Oct;74(4):1132–7

Modulation of platelet activation in vitro by thrombopoietin. Kojima H, et al. **Thromb Haemost** 1995 Dec;74(6):1541–5

KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism. Lévy-Toledano S, et al. **Thromb Haemost** 1995 May;73(5):857–61

A comparison of the effect of decorsin and two disintegrins, albolabrin and eristostatin, on platelet function. McLane MA, et al. **Thromb Haemost** 1995 Nov;74(5):1316–22

Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Patrono C, et al. **Thromb Haemost** 1995 Jul;74(1):396–400 (45 ref.)

Interaction of echicetin with a high affinity thrombin binding site on platelet glycoprotein GPIb. Peng M, et al. **Thromb Haemost** 1995 Sep;74(3):954–7

Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection). Armstrong JK, et al. **Thromb Res** 1995 Sep 15;79(5-6):437–50

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Minuz P, et al. **Thromb Res** 1995 Dec 1;80(5):367–76

Antiplatelet functions of a stable prostacyclin analog, SM-10906 are exerted by its inhibitory effect on inositol 1,4,5-trisphosphate production and cytosolic Ca++ increase in rat platelets stimulated by thrombin. Nishimura T, et al. **Thromb Res** 1995 Aug 1;79(3):307–17

Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Petroni A, et al. **Thromb Res** 1995 Apr 15;78(2):151–60

Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Qi R, et al. **Thromb Res** 1996 Jan 1;81(1):43–54

Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Riddell DR, et al. **Thromb Res** 1995 Dec 15;80(6):499–508

Inhibition of platelet aggregation in whole blood by alcohol. Torres Duarte AP, et al. **Thromb Res** 1995 Apr 15; 78(2):107–15

Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Umemura K, et al. **Thromb Res** 1995 Nov 1;80(3):209–16

Inhibition of platelet GPIbIIIa prolongs survival of discordant cardiac xenografts. Lesnikoski BA, et al. **Transplant Proc** 1996 Apr;28(2):703

Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. Spiegel HU, et al. **Transplant Proc** 1995 Oct;27(5):2884–5

The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Yin M, et al. **Transplantation** 1996 May 27;61(10):1443–6

PGE0 inhibits collagen and glycosaminoglycan-synthesis in the rabbit arterial wall. Rodrigues M, et al. **Vasa** 1995; 24(4):333–6

Apyrase activity and adenosine diphosphate induced platelet aggregation inhibition by the salivary gland proteins of Culicoides variipennis, the North American vector of bluetongue viruses. Pérez de León AA, et al. **Vet Parasitol** 1996 Feb;61(3-4):327–38

[Effects of low dose aspirin on platelet function and prostaglandins metabolism in systemic and coronary circulation in patients with ischemia heart disease] Liu H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):595–8 (Eng. Abstr.) **(Chi)**

[Clinical and experimental study on inhibitory effect of sanhuang mixture on platelet aggregation] Huang WM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):465–7 (Eng. Abstr.) **(Chi)**

[Effect of Allitridi on deforming of peripheral leucocytes in patients with acute cerebral infarction] Mao JS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):395–7 (Eng. Abstr.) **(Chi)**

[Effects of neferine and its combination with taurine on platelet aggregation and experimental thrombosis in rats] Huang HL, et al. **Yao Hsueh Hsueh Pao** 1995;30(7):486–90 (Eng. Abstr.) **(Chi)**

[Comparison of the effects of ketorolac and aspirin on hemostasis in the rabbit] Samama CM, et al. **Ann Fr Anesth Reanim** 1995;14(5):393–8 (Eng. Abstr.) **(Fre)**

[Suppression of platelet activating factor effects (PAF) on the retina by G-proteins inhibitors] Doly M, et al. **Ann Pharm Fr** 1996;54(2):64–7 (Eng. Abstr.) **(Fre)**

[Biochemical and pharmacologic properties of platelet aggregants and platelet antiaggregants of viper venoms in Tunisia] Marrakchi N, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):487–91 **(Fre)**

[Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats] Hart S, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):476–80 (Eng. Abstr.) **(Ger)**

[Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155–9 (42 ref.) (Eng. Abstr.) **(Hun)**

[Effect of BAY u3405-thromboxane A2 receptor antagonist, on biphasic airway responses induced by platelet-activating factor in actively sensitized guinea pigs] Arima M, et al. **Arerugi** 1995 Jul;44(7):701–7 (Eng. Abstr.) **(Jpn)**

[Intravenous infusion of prostagrandin E1 during and after gastrectomy on postoperative hepato-renal functions in senile patients] Murakawa T, et al. **Masui** 1996 Mar; 45(3):356–61 (Eng. Abstr.) **(Jpn)**

[Studies on reversing effect of multidrug resistance by dipyridamole. I. modulation of epirubicin-induced effects on cell proliferation and cell cycle by dipyridamole]

Hayashi A, et al. **Yakugaku Zasshi** 1996 Mar;116(3):217–27 (Eng. Abstr.) **(Jpn)**

[Synthesis and antiplatelet activity of 2–amino–4,5–diphenylthiazole derivatives] Inoue H, et al. **Yakugaku Zasshi** 1995 Aug;115(8):603–10 (Eng. Abstr.) **(Jpn)**

[Effects of ethyl all–cis–5,8,11,14,17–icosapentaenoate on low density lipoprotein in rabbits] Yano T, et al. **Yakugaku Zasshi** 1995 Oct;115(10):843–51 (Eng. Abstr.) **(Jpn)**

[A new activator of soluble guanylate cyclase generated by nitric oxide and having antihypertensive and anti–aggregation properties] Busygina OG, et al. **Biokhimiia** 1995 Sep;60(9):1460–7 (Eng. Abstr.) **(Rus)**

[Platelet aggregation inhibition due to sodium hypochlorite. The effect of blood plasma components] Murina MA, et al. **Biull Eksp Biol Med** 1995 May;119(5):488–90 **(Rus)**

[Effect of nimodipine on the intracellular calcium level and platelet aggregation in ischemic stroke patients] Prianikova NA, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):317–20 **(Rus)**

[Cerebral blood flow and thrombocyte aggregation at different times of hypokinesia and their regulation by antiaggregants] Akopian VP, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):16–8 (Eng. Abstr.) **(Rus)**

[Preparations affecting arachidonic acid metabolism in the thrombocytes in the treatment of ischemic heart disease] Liusov VA, et al. **Eksp Klin Farmakol** 1995 Jul–Aug; 58(4):76–9 **(Rus)**

[Effect of controlled hypotension using sodium nitroprusside on platelet aggregation] Heesen M, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):320–3 (Eng. Abstr.) **(Spa)**

[Erythrocytes modulate the anti–aggregation effect of aspirin and dipyridamole. Study under static conditions and in a flow system] Bozzo J, et al. **Sangre (Barc)** 1996 Feb; 41(1):13–8 (Eng. Abstr.) **(Spa)**

SUPPLY & DISTRIBUTION

Home care company is single source for purchase of epoprostenol [news] **Am J Health Syst Pharm** 1996 May 1;53(9):976, 982

THERAPEUTIC USE

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six–month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Lefkovits J, et al. **Am J Cardiol** 1996 May 15;77(12):1045–51

A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS–II Investigators. O'Connor CM, et al. **Am J Cardiol** 1996 Apr 15;77(10):791–7

Intracoronary stenting without intravascular ultrasound guidance followed by antiplatelet therapy with aspirin alone in selected patients. Roy PR, et al. **Am J Cardiol** 1996 May 15;77(12):1105–7

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Beraprost sodium for refractory thrombotic thrombocytopenic purpura [letter] Kurosawa S, et al. **Am J Hematol** 1995 Nov;50(3):224

Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)

The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Botelho PJ, et al. **Am J Ophthalmol** 1996 Apr;121(4):450–1

A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study–1 (JETS–1) Group. Maruyama S, et al. **Angiology** 1995 Nov;46(11):999–1008

Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Nicolau DP, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1748–51

The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Gage BF, et al. **Arch Intern Med** 1996 Sep 9;156(16):1829–36

Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Langford EJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):51–5

Antiplatelet therapy and the prevention of thrombosis. Rodgers A, et al. **Aust N Z J Med** 1996 Apr;26(2):210–5 (19 ref.)

The pharmacological prevention of pre–eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)

Occlusive thrombosis in the femoral artery of the rabbit: a pharmacological model for evaluating antiplatelet and anticoagulant agents. Sugidachi A, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):57–64

Which diabetic patients should be taking aspirin? [editorial] Yudkin JS. **BMJ** 1995 Sep 9;311(7006):641–2

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Acute myocardial infarction [letter] Moher M. **Br J Gen Pract** 1995 Aug;45(397):444–5

Prediction of pre–eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin [see comments] Bower SJ, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):625–9 . Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Where next for prophylaxis against pre–eclampsia? [see comments] Pipkin FB, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):603–7. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Intravenous infusion of prostacyclin to prevent platelet thrombus during microvascular anastomoses. Gateley DR, et al. **Br J Plast Surg** 1996 Jun;49(4):249–50

Iloprost and salvage of a free flap. Renaud F, et al. **Br J Plast Surg** 1996 Jun;49(4):245–8

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)

Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina. Sakata K, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):601–7

The contribution of neutrophils to reperfusion arrhythmias and a possible role for antiadhesive pharmacological substances. Dhein S, et al. **Cardiovasc Res** 1995 Dec; 30(6):881–8

Beneficial effects of prostacyclin treatment on reperfusion of the myocardium. Katircioğlu SF, et al. **Cardiovasc Surg** 1995 Aug;3(4):405–8

Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno–occlusive disease. Davis LL, et al. **Chest** 1995 Dec;108(6):1754–6

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Coller BS. **Circulation** 1995 Nov 1;92(9):2373–80 (76 ref.)

A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound–guided stent implantation. Hall P, et al. **Circulation** 1996 Jan 15;93(2):215–22

Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Maalej N, et al. **Circulation** 1996 Mar 15; 93(6):1201–5

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high–risk coronary angioplasty. EPIC Investigators. Mark DB, et al. **Circulation** 1996 Aug 15;94(4):629–35

Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Mousa SA, et al. **Circulation** 1996 Feb 1;93(3):537–43

Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi–Hospital Eastern Atlantic Restenosis Trial (M–HEART II). Savage MP, et al. **Circulation** 1995 Dec 1;92(11):3194–200

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):181–9 (32 ref.)

Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May; 19(5):357–65 (109 ref.)

Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Lotke PA, et al. **Clin Orthop** 1996 Mar; (324):251–8

Use of prostacyclin in patients with continuous hemofiltration after open heart surgery. Klotz KF, et al. **Contrib Nephrol** 1995;116:136–9

Augmentation of thrombolysis with antiplatelet drugs. Coller BS. **Coron Artery Dis** 1995 Dec;6(12):911–4 (14 ref.)

Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947–55 (67 ref.)

Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)

Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo–controlled, randomized, double–blind, multicenter clinical trial [see comments] Abraham E, et al. **Crit Care Med** 1996 Jan;24(1):10–5. Comment in: Crit Care Med 1996 Jan;24(1):3.

Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389–98 (36 ref.)

Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Curr Opin Cardiol** 1995 Jul;10(4):420–6 (53 ref.)

Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Tsutsui K, et al. **Dermatology** 1996; 192(2):120–4

Long–term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme. Catella–Lawson F, et al. **Drug Saf** 1995 Aug;13(2):69–75 (53 ref.)

Aspirin for primary prevention of coronary disease. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:16–20 (23 ref.)

Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)

More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa–blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials [editorial] van de Werf F. **Eur Heart J** 1996 Mar;17(3):325–6

Aspirin and myocardial infarction: is one positive study enough? Verheugt FW. **Eur Heart J** 1995 Jul;16 Suppl E:13–5

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar–Apr;10(2):91–8

A meta–analysis of randomized, double–blind, placebo–controlled studies of the effect of buflomedil on intermittent claudication. Walker GA, et al. **Fundam Clin Pharmacol** 1995;9(4):387–94

Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi–system anticoagulation protocol. Glauber M, et al. **Int J Artif Organs** 1995 Oct;18(10):649–55

Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. van der Wieken LR, et al. **Int J Cardiol** 1995 Nov 24;52(2):125–34

Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double–blind clinical study vs placebo. Auteri A, et al. **Int J Clin Pharmacol Res** 1995; 15(2):57–63

Marked reduction in long–term cardiac deaths with aspirin after a coronary event. Multicenter Myocardial Ischemia Research Group. Goldstein RE, et al. **J Am Coll Cardiol** 1996 Aug;28(2):326–30

Randomized, double–blind, placebo–controlled dose–ranging study of tirofiban (MK–383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Kereiakes DJ, et al. **J Am Coll Cardiol** 1996 Mar 1; 27(3):536–42

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor–activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1665–71

A new therapeutic monoclonal antibody. Freeman PR. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):90–1

Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. Westrich GH, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):826–34

Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP–elevating effects of prostaglandin E1. Chirkov YY, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):961–6

Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. Isogaya M, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):947–52

Double–blind, placebo–controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. Kingma K, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):388–93

Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin. Merhi Y, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):1–5

Beneficial effects of beraprost sodium, a stable prostacyclin analogue, in diabetic cardiomyopathy. Ueno Y, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):603–7

Prostacyclin analog OP2507 prevents pulmonary arterial and airway constriction during lung preservation and reperfusion. Nawata S, et al. **J Heart Lung Transplant** 1996 May;15(5):470–4

A ferret model of electrical–induction of arterial thrombosis that is sensitive to aspirin. Schumacher WA, et al. **J Pharmacol Toxicol Methods** 1996 Feb;35(1):3–10

Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. Hilliquin P, et al. **J Rheumatol** 1995 Sep;22(9):1651–4

Aspirin for prevention of myocardial infarction. Mirvis DM. **J Tenn Med Assoc** 1995 Oct;88(10):392–4

Experimental studies on preventive effects of API0134 on vessel reocclusion after thrombolysis. Xiong YL, et al. **J Tongji Med Univ** 1995;15(2):77–81

Cost–effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation [letter; comment] Kan BD, et al. **JAMA** 1996 Mar 27;275(12):909; discussion 910. Comment on: JAMA 1995 Dec 20;274(23):1839–45.

Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Fukuyama J, et al. **Jpn J Pharmacol** 1996 Apr;70(4):321–7

Anti–thrombotic activity of KBT–3022 in experimental models of thrombosis. Yokota K, et al. **Jpn J Pharmacol** 1995 Jun;68(2):201–6

Low–molecular–weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group [see comments] **Lancet** 1996 Mar 2;347(9001):561–8. Comment in: Lancet 1996 Apr 27;347(9009):1191. Comment in: Lancet 1996 May 4;347(9010):1263.

Intra–arterial iloprost for limb ischaemia [letter] Motz E, et al. **Lancet** 1995 Nov 11;346(8985):1295

Failure of aspirin and diltiazem to prevent the formation of acute coronary thrombi in dogs. Morishima Y, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):273–7

Low-molecular-weight heparin for the treatment of acute ischemic stroke [letter; comment] Bloom JM. **N Engl J Med** 1996 May 23;334(21):1407. Comment on: N Engl J Med 1995 Dec 14;333(24):1588–93.

Platelets and coronary artery disease [editorial; comment] Handin RI. **N Engl J Med** 1996 Apr 25;334(17):1126–7. Comment on: N Engl J Med 1996 Apr 25;334(17):1084–9. Comment on: N Engl J Med 1996 Apr 25;334(17):1090–4.

Intravenous epoprostenol for primary pulmonary hypertension [letter; comment] Higenbottam T. **N Engl J Med** 1996 May 30;334(22):1477; discussion 1477–8 . Comment on: N Engl J Med 1996 Feb 1;334(5):296–302.

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [see comments] Schömig a, et al. **N Engl J Med** 1996 Apr 25; 334(17):1084–9. Comment in: N Engl J Med 1996 Apr 25;334(17):1126–8.

Intravenous epoprostenol for primary pulmonary hypertension [letter; comment] Schulze-Neick I, et al. **N Engl J Med** 1996 May 30;334(22):1477; discussion 1477–8 . Comment on: N Engl J Med 1996 Feb 1;334(5):296–302.

Aspirin and coronary disease [letter] Vogel RA. **N Engl J Med** 1996 Oct 10;335(15):1161–2

Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression. Norris RM, et al. **N Z Med J** 1996 Jul 26; 109(1026):278–80

Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Caravaca F, et al. **Nephrol Dial Transplant** 1995; 10(9):1720–4

Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function [letter] Frascà GM, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):392–3

Protection by Iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: an electron microscope study. Egemen N, et al. **Neurol Res** 1995 Aug;17(4):301–6

Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Toni D, et al. **Neurology** 1996 Feb; 46(2):341–5

The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Lees C, et al. **Obstet Gynecol** 1996 Jul; 88(1):14–9

The evolution of platelet aggregability in patients undergoing catheter ablation for supraventricular tachycardia with radiofrequency energy: the role of antiplatelet therapy. Wang TL, et al. **Pacing Clin Electrophysiol** 1995 Nov; 18(11):1980–90

Use of prostaglandin I2 in three small children at high risk of early renal graft thrombosis. Aufricht C, et al. **Pediatr Nephrol** 1996 Feb;10(1):86–7

Long-term aspirin therapy for hepatopulmonary syndrome. Song JY, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):917–20

The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction. Strachan DA, et al. **Scott Med J** 1995 Oct;40(5):151–2

Thromboxane-blocked swine as an experimental model of severe intravascular inflammation and septic shock. Jesmok G, et al. **Shock** 1995 Nov;4(5):379–83

Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.). Comment on: Stroke 1996 Apr;27(4):756–60.

Aspirin wars: the optimal dose of aspirin prevent stroke [editorial; comment] Hart RG, et al. **Stroke** 1996 Apr; 27(4):585–7 (45 ref.). Comment on: Stroke 1996 Apr;27(4):756–60.

In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Nishimura H, et al. **Stroke** 1996 Jun;27(6):1099–103; discussion 1104

Computed tomographic brain scans and antiplatelet therapy after stroke: a study of the quality of care in Dutch hospitals. van der Meulen JH, et al. **Stroke** 1996 Apr; 27(4):633–8

Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy [letter] Wildemann B, et al. **Stroke** 1996 Jan;27(1):149–51

Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)

New antiplatelet agents: platelet GPIIb/IIIa antagonists. Coller BS, et al. **Thromb Haemost** 1995 Jul;74(1):302–8 (38 ref.)

Antiplatelet therapy with aspirin: from clinical trials to practice. Goodnight SH. **Thromb Haemost** 1995 Jul; 74(1):401–5 (64 ref.)

Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464–72 (80 ref.)

Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Takiguchi Y, et al. **Thromb Haemost** 1995 Apr;73(4):683–8

Flurbinitroxybutylester: a novel anti-inflammatory drug has enhanced antithrombotic activity. Cirino G, et al. **Thromb Res** 1995 Jul 1;79(1):73–81

Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets. Dmoszyńska A, et al. **Thromb Res** 1995 Sep 15; 79(5–6):483–90

Another antithrombotic action of aspirin. O'Brien JR, et al. **Thromb Res** 1995 Oct 15;80(2):185–8

Inhibition of platelet GPIIbIIIa prolongs survival of discordant cardiac xenografts. Lesnikoski BA, et al. **Transplant Proc** 1996 Apr;28(2):703

Conditioning of liver grafts by donor bolus pretreatment with epoprostenol. Anthuber M, et al. **Transplantation** 1996 Jul 15;62(1):13–7

Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts. Candinas D, et al. **Transplantation** 1996 Jul 15;62(1):1–5

Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions [editorial; comment] Stratton JR. **West J Med** 1995 Aug;163(2):177–9. Comment on: West J Med 1995 Aug;163(2):145–57.

[Prevention and treatment effect of niacin on FES: experimental study] Zhang B, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):9–12 (Eng. Abstr.) **(Chi)**

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**

[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[Prostacyclin in the treatment of hemolytic-uremic syndrome: apropos of a case] Series C, et al. **Rev Med Interne** 1996;17(1):76–8 (Eng. Abstr.) **(Fre)**

[2nd European study on secondary prevention of stroke (ESPS 2). Respective roles of acetylsalicylic acid, dipyridamole and their combination] Franck G. **Rev Med Liege** 1995 Nov;50(11):491 **(Fre)**

[Antithrombotic agents and prevention of cerebrovascular accidents] Dewarrat A, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):629–34 (38 ref.) (Eng. Abstr.) **(Fre)**

[Preventive treatment of cerebrovascular accidents of arterial origin] Castillo V, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):159–63 (33 ref.) (Eng. Abstr.) **(Fre)**

-New perspectives in therapy of unstable angina- Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**

-New aspects in antithrombotic therapy--platelet inhibitors- Terres W, et al. **Herz** 1996 Feb;21(1):1–11 (89 ref.) (Eng. Abstr.) **(Ger)**

[Ticlopidine in coronary artery diseases] Porter T, et al. **Harefuah** 1995 Nov 15;129(10):427–30 (26 ref.) **(Heb)**

[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**

[Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500–15000 dalton)] Michelini S, et al. **Minerva Cardioangiol** 1996 Jan–Feb; 44(1–2):33–7 (Eng. Abstr.) **(Ita)**

[Usefulness of computerized dynamic capillaroscopy in the monitoring of treatment of progressive systemic sclerosis with synthetic prostacyclin] D'Emilia I, et al. **Recenti Prog Med** 1996 Mar;87(3):106–9 (Eng. Abstr.) **(Ita)**

[Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension] Saji T, et al. **J Cardiol** 1996 Apr; 27(4):197–205 (Eng. Abstr.) **(Jpn)**

[Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis] Kaburaki J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):29–35 (Eng. Abstr.) **(Jpn)**

[Systemic lupus erythematosus with pulmonary hypertension--normalization of pulmonary artery pressure by long-term administration of beraprost sodium] Ubukata M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1307–12 (Eng. Abstr.) **(Jpn)**

[The efficacy of "Ticlid" in treatment of diabetic retinopathy] Mirkiewicz-Sieradzka B, et al. **Klin Oczna** 1995 Jul–Sep; 97(7–8):244–7 (Eng. Abstr.) **(Pol)**

[The effect of indobufen on platelet function and dialyzer regeneration in patients on hemodialysis] Sokołowska B, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):475–82 (Eng. Abstr.) **(Pol)**

[A clinico-morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Ratner MIa, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):32–5 (Eng. Abstr.) **(Rus)**

[The effect of indobufen on patency in femoro-popliteal/crural bypass using artificial grafts] Cernak I, et al. **Vojnosanit Pregl** 1994 May–Jun;51(3):214–9 (Eng. Abstr.) **(Scr)**

[Prescription of platelet antiaggregants in secondary prevention of ischemic heart disease] Calpe Climent AV, et al. **Aten Primaria** 1996 Mar 15;17(4):268–72 (Eng. Abstr.) **(Spa)**

[Use of ticlopidine in primary care (letter)] Oliver AC, et al. **Aten Primaria** 1996 Mar 31;17(5):361–2 **(Spa)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**

[Platelet antiaggregants: a study of their use in Catalonia (letter)] Llop Margalef JC, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):557–8 **(Spa)**

[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar–Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) **(Spa)**

[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep–Oct;23(123):1091–5 (36 ref.) **(Spa)**

[Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin] Rey A, et al. **Rev Neurol** 1996 Feb; 24(126):214–8 (Eng. Abstr.) **(Spa)**

URINE

Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extraction. Pruñonosa J, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):388–92

Isolation and identification of seven metabolites of a water-soluble platelet aggregation inhibitor in rat urine. Tanaka M, et al. **Xenobiotica** 1995 Nov;25(11):1247–57

PLATELET ALLOANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET ALPHA-GRANULE MEMBRANE PROTEIN see **P-SELECTIN**

PLATELET ANTAGONISTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET ANTIAGGREGANTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET COUNT

Leucocyte count, platelet count and erythrocyte sedimentation rate in pulmonary tuberculosis. Akintunde EO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):131–4

EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up. Bizzaro N. **Am J Hematol** 1995 Oct;50(2):103–9

In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Klüter H, et al. **Ann Hematol** 1996 Aug;73(2):85–9

Murine thrombopoietin mRNA levels are modulated by platelet count. McCarty JM, et al. **Blood** 1995 Nov 15; 86(10):3668–75

Platelet count and platelet indices at various stages of normal pregnancy in smoking and non-smoking women. Mercelina-Roumans PE, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):267–9

Platelet count in EDTA-dependent pseudothrombocytopenia [letter] Lippi G, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):112–3

Platelet parameters detected by cell counter in an unusual case of extreme thrombocytosis. Roy S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S37–8

Synchronous fluctuation of interleukin-6 and platelet count in cyclic thrombocytopenia and thrombocytosis. Kuyama J, et al. **Intern Med** 1995 Jul;34(7):636–9

Mean platelet volume of normal pregnant women and severe preeclamptic women in Siriraj Hospital. Boriboonhirunsarn D, et al. **J Med Assoc Thai** 1995 Nov;78(11):586–9

Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. Müller MR, et al. **J Pharmacol Toxicol Methods** 1995 Sep; 34(1):17–22

The omnipotent platelet. Steinberg LA. **Med Hypotheses** 1996 Mar;46(3):188–90

The beginning of repeated hemodialysis treatment enhances some platelet functions in uremic patients [letter] Krawczyk W, et al. **Nephron** 1995;71(3):361–2

Effect of platelet count on serum and plasma potassium: evaluation using database information from two hospitals. Mäkelä K, et al. **Scand J Clin Lab Invest Suppl** 1995; 222:95–100

Leukocyte and platelet depletion protects the liver from damage induced by cholestasis and ischemia-reperfusion in the dog. Kuroda T, et al. **Scand J Gastroenterol** 1996 Feb;31(2):182–90

Mean platelet volume and acute ischemic stroke [letter; comment] Furiozzi F. **Stroke** 1996 May;27(5):1010–1. Comment on: Stroke 1995 Jun;26(6):995–9.

Influence of plasma platelets on activated protein C resistance assay [letter] Sidelmann J, et al. **Thromb Haemost** 1995 Sep; 74(3):993–4

Monitoring for undertransfusion. Mair B, et al. **Transfusion** 1996 Jun;36(6):533–5

Splenic function before and after pediatric liver transplantation. Kawarasaki H, et al. **Transplant Proc** 1996 Aug;28(4):2395–6

Comparative study of porcine and human blood coagulation systems: possible relevance in xenotransplantation. Reverdiau-Moalic P, et al. **Transplant Proc** 1996 Apr; 28(2):643–4

Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis. Eriksson L, et al. **Vox Sang** 1996;70(2):69–75

[Post-transfusion rise in thrombocytes: observations in a hematologic-oncologic patient sample] Böck M, et al. **Infusionsther Transfusionsmed** 1995 Dec;22(6):350–4 (Eng. Abstr.) **(Ger)**

[Thrombocyte collection with the A3p program using the blood cell separator Haemonetics MCS 3p (letter)] Moog R, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):60 **(Ger)**

[A relationship between the breakpoint of the bcr gene and some hematologic parameters in patients with chronic myelogenous leukemia] Seferyńska I, et al. **Acta Haematol Pol** 1995;26(4):385–91 (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part III: Biochemical hypothesis. The role of blood platelets] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):867–76 (26 ref.) (Eng. Abstr.) **(Pol)**

[The effect of blood from patients with idiopathic thrombocytopenia and thrombopoietin on the thrombocyte count in the blood of mice] Borota R, et al. **Med Pregl** 1995;48(3–4):87–9 (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Molineux G, et al. **Blood** 1996 Jul 1;88(1):366–76

Stimulation of thrombopoiesis in mice by fibroblast growth factor 9. Matsumoto-Yoshitomi S, et al. **Growth Factors** 1995;12(3):179–90

Effect of intravenous gammaglobulin (IVIG) on the platelet count in patients with Wiskott-Aldrich syndrome. Mathew P, et al. **Pediatr Allergy Immunol** 1995 May;6(2):91–4

[Decrease of thrombocyte volume after several days infusion of highly substituted medium molecular weight hydroxyethyl starch (HAES 200/0.62)] Treib J, et al. **Wien Klin Wochenschr** 1996;108(1):20–3 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Estimation of the lower limits of manual and automated platelet counting. Hänseler E, et al. **Am J Clin Pathol** 1996 Jun;105(6):782–7

Comparison of platelet counts in simultaneous venous and capillary blood samples using an automated platelet analyser. Tai DY, et al. **Singapore Med J** 1995 Jun; 36(3):263–6

METHODS

Estimation of the lower limits of manual and automated platelet counting. Hänseler E, et al. **Am J Clin Pathol** 1996 Jun;105(6):782–7

Enumeration of platelets by multiparameter flow cytometry using platelet-specific antibodies and fluorescent reference particles. Dickerhoff R, et al. **Clin Lab Haematol** 1995 Jun; 17(2):163–72

The effects of time from venepuncture and choice of anticoagulant on mean platelet volume estimations. Wynn RF, et al. **Clin Lab Haematol** 1995 Jun;17(2):173–6

Comparison of platelet counts in simultaneous venous and capillary blood samples using an automated platelet analyser. Tai DY, et al. **Singapore Med J** 1995 Jun; 36(3):263–6

Validating the platelet count. Tien SL. **Singapore Med J** 1995 Jun;36(3):255–6

RADIATION EFFECTS

Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. Yang FE, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):617–17

PLATELET-DERIVED GROWTH FACTOR

see related
RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

Reshaping the interstitium by platelet-derived growth factor. Implications for progressive renal disease. Nath KA. **Am J Pathol** 1996 Apr;148(4):1031–6 (63 ref.)

ADMINISTRATION & DOSAGE

Controlled release of platelet-derived growth factor using ethylene vinyl acetate copolymer (EVAc) coated on stainless-steel wires. Walsh WR, et al. **Biomaterials** 1995 Nov;16(17):1319–25

ADVERSE EFFECTS

Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Tang WW, et al. **Am J Pathol** 1996 Apr;148(4):1169–80

ANALYSIS

Plasma platelet-derived growth factor-B chain is elevated in patients with extensively large brain tumour. Kurimoto M, et al. **Acta Neurochir (Wien)** 1995;137(3–4):182–7

Immunohistochemical analysis of platelet-derived growth factor and basic fibroblast growth factor in cardiac biopsy and autopsy specimens of heart transplant patients. Shaddy RE, et al. **Am J Cardiol** 1996 Jun 1;77(14):1210–5

Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Alpers CE, et al. **Am J Pathol** 1996 Feb;148(2):439–51

Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Homma S, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2084–9

Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Gleich LL, et al. **Ann Otol Rhinol Laryngol** 1996 Sep;105(9):710–2

Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Maeda K, et al. **Br J Cancer** 1996 Apr;73(8):884–8

Expression of PDGF in relation to cell division in atherosclerotic intima of human carotid arteries. Ito M, et al. **Neurol Res** 1995 Oct;17(5):345–8

Immunocytochemical detection of growth factors (PDGF and TGF beta) in equine chronic pneumonia. Rodríguez A, et al. **Res Vet Sci** 1996 Jan;60(1):82–7

[The study of growth factors in human colostrum] Ye S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct; 30(10):591–3 (Eng. Abstr.) **(Chi)**

[Platelet-derived growth factor (PDGF)] Kaji K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:830–4 (12 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Pichler RH, et al. **Am J Pathol** 1996 Apr;148(4):1153–67

Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells. Zhang ZJ, et al. **Anticancer Res** 1996 Mar-Apr;16(2):717–23

Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Miyazawa K, et al. **Atherosclerosis** 1995 Dec;118(2):213–21

Anti-competence effects of synthetic phthalide derivatives on platelet-derived growth factor-induced DNA synthesis in primary cultures of rat aorta smooth muscle cells. Mimura Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1660–4

Competence effect of PDGF on Ki-67 antigen and DNA contents, and its inhibition by trichostatin-A and a butylydene phthalide BP-421 in primary smooth muscle cells of rat aorta by flow cytometry. Okabe M, et al. **Biol Pharm Bull** 1995 Dec;18(12):1665–70

Tranilast inhibits the effects of platelet-derived growth factor on cell proliferation and induction of nitric oxide. Hishikawa K, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):435–8

Viability of transgenic mice expressing a platelet derived growth factor (PDGF) antagonist in plasma. Liao X, et al. **J Investig Med** 1996 Apr;44(4):139–43

Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. Hynds DL, et al. **J Neurochem** 1995 Nov;65(5):2251–8

Fast and reproducible vascular neointima formation in the hamster carotid artery: effects of trapidil and captopril. Matsuno H, et al. **Thromb Haemost** 1995 Dec;74(6):1591–6

BIOSYNTHESIS

Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. Ohno I, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):639–47

Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Yamamoto Y, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):700–5

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)

PKC alpha regulates thrombin-induced PDGF-B chain gene expression in mesangial cells. Biswas P, et al. **FEBS Lett** 1995 Oct 9;373(2):146–50

Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. Khachigian LM, et al. **J Biol Chem** 1995 Nov 17;270(46):27679–86

c-sis/PDGF-B promoter transactivation by the Yax protein of human T-cell leukemia virus type 1. Trejo SR, et al. **J Biol Chem** 1996 Jun 14;271(24):14584–90

Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. Wilson E, et al. **J Clin Invest** 1995 Nov;96(5):2364–72

Regional differences in platelet-derived growth factor production by the canine aorta. Madura JA 2nd, et al. **J Vasc Res** 1996 Jan-Feb;33(1):53–61

Platelet-derived growth factor A-chain expression in developing and mature human kidneys and in Wilms' tumor. Alpers CE, et al. **Kidney Int** 1995 Jul;48(1):146–54

Epithelial cell proliferation in nasal polyps could be up-regulated by platelet-derived growth factor. Coste A, et al. **Laryngoscope** 1996 May;106(5 Pt 1):578–83

Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Kimura A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):237–42 (47 ref.)

Effects of cytomegalovirus infection on growth factor production in endothelial cells and fibroblasts. Garrett JS, et al. **Pediatr Res** 1995 Dec;38(6):1003–8

Pharmacological modulation of platelet-derived growth factor (B) mRNA expression in alveolar macrophages and adherent monocytes. Kotecha S, et al. **Pulm Pharmacol** 1994 Dec;7(6):383–91

Expression of platelet-derived growth factor beta receptor in chondrogenesis of perichondrial transplants. Ljung A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):289–95

Growth factor production by arterial and vein grafts: relevance to coronary artery bypass grafting. Sterpetti AV, et al. **Surgery** 1996 Sep;120(3):460–7

CHEMISTRY

Platelet-derived growth factor B-chain comprises the major part of enhanced released mitogen from aortic endothelial cells of stroke-prone spontaneously hypertensive rats. Sasahara M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22 Suppl 1:S123–5

Identification of three amino acid residues in the B-chain of platelet-derived growth factor with different importance for binding to PDGF alpha- and beta-receptors. Kreysing J, et al. **FEBS Lett** 1996 May 6;385(3):181–4

Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. Andersson M, et al. **Growth Factors** 1995;12(2):159–64

DRUG EFFECTS

Chrysotile asbestos induces PDGF-A chain-dependent proliferation in human and rat lung fibroblasts in vitro. Lasky JA, et al. **Chest** 1996 Mar;109(3 Suppl):26S–28S

GENETICS

In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Ueda M, et al. **Am J Pathol** 1996 Sep;149(3):831–43

Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients. Billett MA, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):399–406

Expression and function of a recombinant PDGF B gene in porcine arteries. Pompili VJ, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2254–64

Expression of platelet-derived growth factor B-chain in the mature rat brain and pituitary gland. Sasahara M, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):63–74

Multiple elements in the 5' untranslated region down-regulate c-sis messenger RNA translation. Horvath P, et al. **Cell Growth Differ** 1995 Sep;6(9):1103–10

Platelet-derived growth factor-A mRNA expression in fetal, normal adult, and atherosclerotic human aortas. Analysis by competitive polymerase chain reaction. Murry CE, et al. **Circulation** 1996 Mar 15;93(6):1095–106

Analysis of messenger ribonucleic acid and protein for the ligands and receptors of the platelet-derived growth factor signaling pathway in the placenta, extraembryonic membranes, and uterus during the latter half of murine gestation. Bidwell MC, et al. **Endocrinology** 1995 Nov; 136(11):5189–201

Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. Khachigian LM, et al. **J Biol Chem** 1995 Nov 17;270(46):27679–86

Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors. Liang Y, et al. **J Biol Chem** 1996 May 17; 271(20):11792–7

Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter. Scarpati EM, et al. **J Biol Chem** 1996 Feb 9;271(6):3025–32

Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action. Gnessi L, et al. **J Cell Biol** 1995 Nov;131(4):1105–21

Cytokine-regulated expression of platelet-derived growth factor gene and protein in cultured human astrocytes. Silberstein FC, et al. **J Neurochem** 1996 Apr;66(4):1409–17

The Rep68 protein of adeno-associated virus type 2 stimulates expression of the platelet-derived growth factor B c-sis proto-oncogene. Wonderling RS, et al. **J Virol** 1996 Jul;70(7):4783–6

Transcription and localization of growth factor mRNA in the bovine oviduct. Viuff D, et al. **Mol Reprod Dev** 1995 Sep;42(1):28–34

An Inr-containing sequence flanking the TATA box of the human c-sis (PDGF-B) proto-oncogene promoter

functions in cis as a co-activator for its intronic enhancer. Franklin GC, et al. **Oncogene** 1995 Nov 2;11(9):1873–84

Functional analysis of the SIS proximal element and its activating factors: regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells. Liang Y, et al. **Oncogene** 1996 Aug 15;13(4):863–71

S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227–44 (110 ref.)

Egr-1-induced endothelial gene expression: a common theme in vascular injury. Khachigian LM, et al. **Science** 1996 Mar 8;271(5254):1427–31

Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells. Kanthou C, et al. **Thromb Haemost** 1995 Nov;74(5):1340–7

Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. Lindner V. **Z Kardiol** 1995;84 Suppl 4:137–44

IMMUNOLOGY

Platelet-derived growth factor in asthma. Chanez P, et al. **Allergy** 1995 Nov;50(11):878–83

METABOLISM

Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Crowley ST, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1641–7

Differential effects of G-protein activators on 5-hydroxytryptamine and platelet-derived growth factor release from streptolysin-O-permeabilized human platelets. Padfield PJ, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):123–8

Dietary modulation of serum platelet-derived growth factor-AB levels. Ross JA, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):485–9

Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Maeda A, et al. **Chest** 1996 Mar;109(3):780–6

The degree of porosity influences the release of growth factors by healing polytetrafluoroethylene (PTFE) grafts. Lepidi S, et al. **Eur J Vasc Endovasc Surg** 1996 Jan; 11(1):36–41

Platelet-derived growth factor in human glioma. Westermark B, et al. **Glia** 1995 Nov;15(3):257–63 (60 ref.)

Time course of growth factor staining in a rabbit model of traumatic tractional retinal detachment. Westra I, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Sep;233(9):573–81

Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. Andersson M, et al. **Growth Factors** 1995;12(2):159–64

Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Tanizawa S, et al. **Heart** 1996 Jun;75(6):549–56

Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. Broome MA, et al. **J Biol Chem** 1996 Jul 12;271(28):16798–806

Structural role of extracellular domain 1 of alpha-platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding. Mahadevan D, et al. **J Biol Chem** 1995 Nov 17;270(46):27595–600

Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts. Patel BK, et al. **J Biol Chem** 1996 Sep 6;271(36):22175–82

Native and activated forms of alpha 2-macroglobulin increase expression of platelet-derived growth factor alpha-receptor in vascular smooth muscle cells. Evidence for autocrine transforming growth factor-beta activity. Weaver AM, et al. **J Biol Chem** 1995 Dec 22; 270(51):30741–8

Extracellular matrix is a source of mitogenically active platelet-derived growth factor. Field SL, et al. **J Cell Physiol** 1996 Aug;168(2):322–32

Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. Shimokawa H, et al. **J Clin Invest** 1996 Feb 1;97(3):769–76

Lipopolysaccharide up-regulates platelet-derived growth factor (PDGF) alpha-receptor expression in rat lung myofibroblasts and enhances response to all PDGF isoforms. Coin PG, et al. **J Immunol** 1996 Jun 15; 156(12):4797–806

Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. Langerak AW, et al. **J Pathol** 1996 Feb; 178(2):151–60

Lower cytokine release by fetal porcine platelets: a possible explanation for reduced inflammation after fetal wounding. Olutoye OO, et al. **J Pediatr Surg** 1996 Jan;31(1):91–5

Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. Nares S, et al. **J Periodontol** 1996 Mar;67(3):271–8

PDGF-B producing cells and PDGF-B gene expression in normal gingival and cyclosporine A-induced gingival overgrowth. Plemons JM, et al. **J Periodontol** 1996 Mar; 67(3):264–70

Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production. Sterpetti AV, et al. **J Vasc Surg** 1996 Apr; 23(4):568–75

Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src [see comments] Barone MV, et al. **Nature** 1995 Nov 30;378(6556):509–12. Comment in: Nature 1995 Nov 30;378(6556):438–9.

Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells. Li W, et al. **Oncogene** 1996 Aug 15;13(4):731–7

The fibroblast mitogenic activity released from human basophilic cell line KU812 is separate from tryptase and PDGF expression. Forsberg-Nilsson K, et al. **Scand J Immunol** 1996 Sep;44(3):267–72

PHARMACOLOGY

The stimulatory effects of PDGF and TGF-beta 1 on dermal fibroblast attachment. Ihn H, et al. **Acta Derm Venereol** 1995 Sep;75(5):367–71

Platelet-derived growth factor promotes endometrial epithelial cell proliferation. Munson L, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1820–5

The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. Failli P, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1133–9

PDGF and IL-1 induce and activate specific protein kinase C isoforms in mesangial cells. Ganz MB, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F108–13

PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Hirst SJ, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L415–28

Endothelin and PDGF enhance arachidonic acid release and DNA synthesis in vascular smooth muscle cells. Irons CE, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1642–6

Long-term chemotaxis studies on adherent cells: effect of platelet-derived growth factor-BB on human vascular smooth muscle cell migration. Benzakour O, et al. **Anal Biochem** 1995 Sep 20;230(2):215–23

Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)

Common and distinct elements in insulin and PDGF signaling. Myers MG Jr, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:369–87

Differential chemotactic responses mediated by platelet-derived growth factor alpha- and beta-receptors. Hayashi N, et al. **Arch Biochem Biophys** 1995 Oct 1; 322(2):423–8

Superoxide dismutase abolishes the platelet-derived growth factor-induced release of prostaglandin E2 by blocking induction of nitric oxide synthase: role of superoxide. Kelner MJ, et al. **Arch Biochem Biophys** 1995 Sep 10; 322(1):31–8

Sodium butyrate inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells. Ranganna K, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2273–83

Differential labelings suggest two specific phospholipid subclass hydrolysis promoted by PDGF-BB in vascular smooth muscle cells. Comminges C, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1008–13

Platelet-derived growth factor B-chain homodimer suppressing a convulsion of epilepsy model mouse El. Masuda Y, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):60–3

Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Saito Y, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):23–6

Type I A-kinase is activated by platelet-derived growth factor in mesangial cells. Throckmorton DC, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):692–6

Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. Navé BT, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):55–60

Modulatory role of platelet-derived growth factor on cytokine-induced nerve growth factor synthesis in rat glomerular mesangial cells. Plüss KM, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):707–11

Permissive effect of ceramide on growth factor-induced cell proliferation. Sasaki T, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):829–34

Inhibition of PDGF-induced phosphoinositide-turnover by glucopiericidin A. Ahn SC, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):125–32

CV-11974, the active metabolite of TCV-116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells. Sachinidis A, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):123–6

Different effects of platelet derived growth factor isoforms on DNA synthesis and migration in human vascular smooth muscle cells. Clunn GF, et al. **Biochem Soc Trans** 1995 Nov;23(4):608S

Inhibition of PDGF-induced phospholipase C activation by herbimycin A. Kim BY, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):33–6

Effect of controlled release of platelet-derived growth factor from a porous hydroxyapatite implant on bone ingrowth. Arm DM, et al. **Biomaterials** 1996 Apr;17(7):703–9

Recombinant PDGF enhances megakaryocytopoiesis in vitro. Yang M, et al. **Br J Haematol** 1995 Oct;91(2):285–9

Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells. Wijetunge S, et al. **Br J Pharmacol** 1995 Jun;115(3):534–8

Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)

Differential expression of alpha 1 type VIII collagen in injured platelet-derived growth factor-BB—stimulated rat carotid arteries. Bendeck MP, et al. **Circ Res** 1996 Sep; 79(3):524–31

EJ-Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet-derived growth factor-BB via phosphatidylinositol 3-kinase. Heldman AW, et al. **Circ Res** 1996 Feb;78(2):312–21

T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor. Wang W, et al. **Circ Res** 1995 Dec;77(6):1095–106

Effect of thrombin and PDGF on endothelin production in cultured mesangial cells derived from spontaneously hypertensive rats. Ikeda M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S197–8

Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF. Iwama A, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S318–20

Platelet-derived growth factor B-chain comprises the major part of enhanced released mitogen from aortic endothelial cells of stroke-prone spontaneously hypertensive rats. Sasahara M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22 Suppl 1:S123–5

Depletion of intracellular calcium stores facilitates the influx of extracellular calcium in platelet derived growth factor stimulated A172 glioblastoma cells. Vereb G Jr, et al. **Cytometry** 1996 May 1;24(1):64–73

Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage. Franchimont N, et al. **Endocrinology** 1995 Dec;136(12):5469–75

Transcriptional and posttranscriptional regulation of interstitial collagenase by platelet-derived growth factor BB in bone cell cultures. Varghese S, et al. **Endocrinology** 1996 Feb;137(2):431–7

The association of focal adhesion kinase with a 200-kDa protein that is tyrosine phosphorylated in response to platelet-derived growth factor. Chen HC, et al. **Eur J Biochem** 1996 Feb 1;235(3):495–500

Modulation of the platelet-derived-growth-factor-induced calcium signal by extracellular/intracellular pH in Syrian hamster embryo cells. Implications for the role of calcium in mitogenic signalling. Isfort RJ, et al. **Eur J Biochem** 1995 Dec 15;234(3):801–10

Different effects of insulin and platelet-derived growth factor on phosphatidylinositol 3-kinase at the subcellular level in 3T3-L1 adipocytes. A possible explanation for their specific effects on glucose transport. Ricort JM, et al. **Eur J Biochem** 1996 Jul 1;239(1):17–22

Influence of growth factors on growth and differentiation of 3T3-L1 preadipocytes in serum-free conditions. Bachmeier M, et al. **Eur J Cell Biol** 1995 Nov;68(3):323–9

Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro. Othberg A, et al. **Exp Brain Res** 1995;105(1):111–22

Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. Carlberg M, et al. **Exp Cell Res** 1996 Feb 25; 223(1):142–8

Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells. Cossette LJ, et al. **Exp Cell Res** 1996 Mar 15;223(2):459–66

Induction of fibroblast growth factor receptor-1 mRNA and protein by platelet-derived growth factor BB. Landgren E, et al. **Exp Cell Res** 1996 Mar 15;223(2):405–11

Treatment of human fibroblasts with vanadate and platelet-derived growth factor in the presence of serum inhibits collagen matrix contraction. Lin YC, et al. **Exp Cell Res** 1995 Nov;221(1):73–82

The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signaling pathways. Thömmes KB, et al. **Exp Cell Res** 1996 Jul 10;226(1):59–66

Are growth factors chemotactic agents? Zicha D, et al. **Exp Cell Res** 1995 Dec;221(2):526–9

Epidermal growth factor and platelet-derived growth factor regulate the activity of the insulin-like growth factor I gene promoter. Li S, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):195–206

Nitric oxide synthesis by rat pleural mesothelial cells: induction by growth factors and lipopolysaccharide. Owens MW, et al. **Exp Lung Res** 1995 Sep-Oct; 21(5):731–42

Activation of platelet-derived growth factor (PDGF) receptor dephosphorylation in intact Swiss 3T3 cells by elevators of intracellular Ca2+ and cAMP. Böhmer FD,

et al. **FEBS Lett** 1996 Aug 5;391(1-2):219-22

Synergistic induction of monocyte chemoattractant protein-1 (MCP-1) by platelet-derived growth factor and interleukin-1. Goppelt-Struebe M, et al. **FEBS Lett** 1995 Nov 6;374(3):375-8

Platelet-derived growth factor partly prevents chemically induced oligodendrocyte death and improves myelin-like membranes repair in vitro. Fressinaud C, et al. **Glia** 1996 Jan;16(1):40-50

PDGF-BB triggered cytoplasmic calcium responses in cells with endogenous or stably transfected PDGF beta-receptors. Ridefelt P, et al. **Growth Factors** 1995; 12(3):191-201

Interaction of adrenomedullin and platelet-derived growth factor on rat mesangial cell production of endothelin. Kohno M, et al. **Hypertension** 1996 Mar;27(3 Pt 2):663-7

The bradykinin B2 receptor is a delayed early response gene for platelet-derived growth factor in arterial smooth muscle cells. Dixon BS, et al. **J Biol Chem** 1996 Jun 7; 271(23):13324-32

Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression. Durante W, et al. **J Biol Chem** 1996 May 17;271(20):11838-43

The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor. Erpel T, et al. **J Biol Chem** 1996 Jul 12; 271(28):16807-12

Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappaB and a 90-kDa phosphoprotein coactivator. Freter RR, et al. **J Biol Chem** 1996 Jul 19;271(29):17417-24

Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells. Graves LM, et al. **J Biol Chem** 1996 Jan 5;271(1):505-11

Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene. Kirstein M, et al. **J Biol Chem** 1996 Jul 26;271(30):18231-6

Divergent mechanisms for homologous desensitization of p21ras by insulin and growth factors. Klarlund JK, et al. **J Biol Chem** 1995 Oct 6;270(40):23421-8

Cooperativity and segregation of function within the Ig-alpha/beta heterodimer of the B cell antigen receptor complex. Luisiri P, et al. **J Biol Chem** 1996 Mar 1; 271(9):5158-63

Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor. Novak U, et al. **J Biol Chem** 1996 Aug 2;271(31):18350-4

Requirement for phosphatidylinositol 3'-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin. Rankin S, et al. **J Biol Chem** 1996 Mar 29;271(13):7829-34

Identification of a domain within the carboxyl-terminal region of the beta platelet-derived growth factor (PDGF) receptor that mediates the high transforming activity of PDGF. Uren A, et al. **J Biol Chem** 1996 May 10; 271(19):11051-4

Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function. Valenzuela CF, et al. **J Biol Chem** 1996 Jul 5;271(27):16151-9

Differential modulation of G1 cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. Winston J, et al. **J Biol Chem** 1996 May 10;271(19):11253-60

Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis. Yokote K, et al. **J Biol Chem** 1996 Mar 1;271(9):5101-11

PDGF-BB, IGF-I and mechanical load stimulate DNA synthesis in avian tendon fibroblasts in vitro. Banes AJ, et al. **J Biomech** 1995 Dec;28(12):1505-13

ET-1 and PDGF BB induce MEK mRNA and protein expression in mesangial cells. Schramek H, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S95-9

Extracellular matrix alters PDGF regulation of fibroblast integrins. Xu J, et al. **J Cell Biol** 1996 Jan;132(1-2):239-49

Effect of retinoic acid in combination with platelet-derived growth factor-BB or transforming growth factor-beta on tissue inhibitor of metalloproteinases and collagenase secretion from human skin and synovial fibroblasts. Bigg HF, et al. **J Cell Physiol** 1996 Jan;166(1):84-93

Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. Hsu S, et al. **J Cell Physiol** 1995 Nov;165(2):239-45

Pregnancy-stimulated growth of vascular smooth muscle cells: importance of protein kinase C-dependent synergy between estrogen and platelet-derived growth factor. Keyes LE, et al. **J Cell Physiol** 1996 Jan;166(1):22-32

Smooth muscle cells isolated from the neointima after vascular injury exhibit altered responses to platelet-derived growth factor and other stimuli. Majack RA, et al. **J Cell Physiol** 1996 Apr;167(1):106-12

The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. Hugo C, et al. **J Clin Invest** 1996 Jun 1;97(11):2499-508

Ca2+ channel activation by platelet-derived growth factor-induced tyrosine phosphorylation and Ras guanine triphosphate-binding proteins in rat glomerular mesangial cells. Ma H, et al. **J Clin Invest** 1996 May 15;97(10):2332-41

The enhancement of cellular infiltration and vascularisation of a collagenous dermal implant in the rat by platelet-derived growth factor BB. Royce PM, et al. **J Dermatol Sci** 1995 Jul;10(1):42-52

Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. Hynds DL, et al. **J Neurochem** 1995 Nov;65(5):2251-8

Control of meningioma cell growth by platelet-derived growth factor (PDGF). Mauro A, et al. **J Neurol Sci** 1995 Aug;131(2):135-43

PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. Cheng B, et al. **J Neurosci** 1995 Nov;15(11):7095-104

Platelet-derived growth factor is a survival factor for PSA-NCAM+ oligodendrocyte pre-progenitor cells. Grinspan JB, et al. **J Neurosci Res** 1995 Jul 1;41(4):540-51

Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. Nishiyama A, et al. **J Neurosci Res** 1996 Feb 1;43(3):315-30

Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. Todo T, et al. **J Neurosurg** 1996 May;84(5):852-8; discussion 858-9

Effect of transforming growth factor-beta and platelet-derived growth factor-BB on articular cartilage in rats. Hulth A, et al. **J Orthop Res** 1996 Jul;14(4):547-53

Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet-derived growth factor and transforming growth factor beta. Spindler KP, et al. **J Orthop Res** 1996 Jul;14(4):542-6

Growth factor effects on the expression of collagenase and TIMP-1 in periodontal ligament cells. Alvares O, et al. **J Periodontol** 1995 Jul;66(7):552-8

The functional interaction of EGF and PDGF with bradykinin in the proliferation of human gingival fibroblasts. McAllister BS, et al. **J Periodontol** 1995 Jun; 66(6):429-37

Platelet-derived growth factor and wound contraction in the rat. Karr BP, et al. **J Surg Res** 1995 Dec;59(6):739-42

Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Hugo C, et al. **Kidney Int** 1995 Dec;48(6):1846-56

Identification of lysyl oxidase and other platelet-derived growth factor-inducible genes in vascular smooth muscle cells by differential screening. Green RS, et al. **Lab Invest** 1995 Oct;73(4):476-82

Wound healing: effects of closing tension, zyplast, and platelet-derived growth factor. Tzikas TL, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):322-7

Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Vignais ML, et al. **Mol Cell Biol** 1996 Apr;16(4):1759-69

Growth factor-induced Ca2+ responses are differentially modulated by nitric oxide via activation of a cyclic GMP-dependent pathway. Clementi E, et al. **Mol Pharmacol** 1995 Dec;48(6):1068-77

Mesangial cell DNA synthesis induced by hydrogen peroxide, interleukin-6, and platelet-derived growth factor: effects of indomethacin and dazmegrel. D'Souza RJ, et al. **Nephron** 1996;72(2):263-8

Gangliosides inhibit PDGF-induced signal transduction events in U-1242 MG human glioma cells. Saqr HE, et al. **Neurochem Res** 1995 Nov;20(11):1389-95

Effects of trapidil and suramin on growth factor-induced calcium response and tyrosine phosphorylation in human glioma cells. Bando K, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):631-8

Antiproliferative effect of multiple autocrine loop blockade in human malignant glioma cell lines. Kurimoto M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):723-7

The 3-phosphorylated phosphoinositide response of 3T3-L1 preadipose cells exposed to insulin, insulin-like growth factor-1, or platelet-derived growth factor. Sorisky A, et al. **Obes Res** 1996 Jan;4(1):9-19

The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells. Vaillancourt RR, et al. **Oncogene** 1996 Jul 4;13(1):151-9

Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts. Kim HR, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9500-4

Platelet-derived growth factor stimulates the secretion of hyaluronic acid by proliferating human vascular smooth muscle cells. Papakonstantinou E, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9881-5

Embryonic mesoderm cells spread in response to platelet-derived growth factor and signaling by phosphatidylinositol 3-kinase. Symes K, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9641-4

A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Yoshida M, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9570-4

Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Sundaresan M, et al. **Science** 1995 Oct 13;270(5234):296-9

Differential effects of platelet-derived growth factor isotypes on human smooth muscle cell proliferation and migration are mediated by distinct signaling pathways. Jiang B, et al. **Surgery** 1996 Aug;120(2):427-31; discussion 432

Sod and GSH inhibit the high glucose-induced oxidative damage and the PDGF increased secretion in cultured human endothelial cells. Curcio F, et al. **Thromb Haemost** 1995 Sep;74(3):969-73

[Effect of platelets and leukocytes on in vitro proliferation of muscle cells: role of platelet-derived chemical mediators] Cirillo P, et al. **Cardiologia** 1996 Feb;41(2):141-7 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33-52 (85 ref.)

Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Poon M, et al. **Am J Pathol** 1996 Jul;149(1):307-17

Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Yi ES, et al. **Am J Pathol** 1996 Aug;149(2):539-48

Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416-30 (67 ref.)

Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells. Potential role of FGF and PDGF. Calara F, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):187-93

An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. George SJ, et al. **Atherosclerosis** 1996 Feb;120(1-2):227-40

Basic fibroblast growth factor and PDGF in GI diseases. Szabo S, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):97-112 (68 ref.)

Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Potapova O, et al. **Cancer Res** 1996 Jan 15;56(2):280-6

PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Boström H, et al. **Cell** 1996 Jun 14;85(6):863-73

An ECM-bound, PDGF-like growth factor and a TGF-alpha-like growth factor are required for gastrulation and spiculogenesis in the Lytechinus embryo. Govindarajan V, et al. **Dev Biol** 1995 Dec;172(2):541-51

PDGF-A is required for normal murine cardiovascular development. Schattemann GC, et al. **Dev Biol** 1996 May 25;176(1):133-42

Role for platelet-derived growth factor-like and epidermal growth factor-like signaling pathways in gastrulation and spiculogenesis in the Lytechinus sea urchin embryo. Ramachandran RK, et al. **Dev Dyn** 1995 Sep;204(1):77-88

PDGF signalling is required for gastrulation of Xenopus laevis. Ataliotis P, et al. **Development** 1995 Sep; 121(9):3099-110

Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Inaba T, et al. **Diabetes** 1996 Apr;45(4):507-12

Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Grako KA, et al. **Exp Cell Res** 1995 Nov;221(1):231-40

Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. Marra F, et al. **FEBS Lett** 1995 Dec 4;376(3):141-5

Platelet-derived growth factor accelerates gastric epithelial restoration in a rabbit cultured cell model. Watanabe S, et al. **Gastroenterology** 1996 Mar;110(3):775-9

Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Potapova O, et al. **Int J Cancer** 1996 May 29;66(5):669-77

Role of platelet-derived growth factors in mouse development. Betsholtz C. **Int J Dev Biol** 1995 Oct; 39(5):817-25 (76 ref.)

Sphingosine and sphingosine 1-phosphate differentially modulate platelet-derived growth factor-BB-induced Ca2+ signaling in transformed oligodendrocytes. Fatatis A, et al. **J Biol Chem** 1996 Jan 5;271(1):295-301

Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. Liu P, et al. **J Biol Chem** 1996 Apr 26;271(17):10299-303

PDGF induction of alpha 2 integrin gene expression is mediated by protein kinase C-zeta. Xu J, et al. **J Cell Biol** 1996 Sep;134(5):1301-11

Intracellular signaling pathways required for rat vascular smooth muscle cell migration. Interactions between basic fibroblast growth factor and platelet-derived growth factor. Bilato C, et al. **J Clin Invest** 1995 Oct;96(4):1905-15

Growth factors and canine flexor tendon healing: initial studies in uninjured and repair models. Duffy FJ Jr, et al. **J Hand Surg [Am]** 1995 Jul;20(4):645-9

Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice--implications for the use of genetically modified keratinocytes to modulate dermal regeneration. Eming SA, et al. **J Invest Dermatol** 1995 Dec;105(6):756-63

Platelet-derived endothelial cell growth factor in human

colon cancer angiogenesis: role of infiltrating cells [see comments] Takahashi Y, et al. **J Natl Cancer Inst** 1996 Aug 21;88(16):1146–51. Comment in: J Natl Cancer Inst 1996 Aug 21;88(16):1091–2.

Phosphorylation of F1F0 ATPase delta–subunit is regulated by platelet-derived growth factor in mouse cortical neurons in vitro. Zhang FX, et al. **J Neurochem** 1995 Dec; 65(6):2812–5

Platelet–derived growth factor is a cofactor in the induction of 1 alpha(I) procollagen expression by transforming growth factor–beta 1 in smooth muscle cells. Halloran BG, et al. **J Vasc Surg** 1996 May;23(5):767–73; discussion 774

PDGF and TGF–beta contribute to the natural course of human IgA glomerulonephritis. Niemir ZI, et al. **Kidney Int** 1995 Nov;48(5):1530–41

PDGF and TGF–beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Throckmorton DC, et al. **Kidney Int** 1995 Jul; 48(1):111–7

Multiple roles for platelet–derived growth factor in renal disease. Floege J, et al. **Miner Electrolyte Metab** 1995; 21(4–5):271–82 (108 ref.)

Repression of p27kip1 synthesis by platelet–derived growth factor in BALB/c 3T3 cells. Agrawal D, et al. **Mol Cell Biol** 1996 Aug;16(8):4327–36

Interaction between undulated and Patch leads to an extreme form of spina bifida in double–mutant mice. Helwig U, et al. **Nat Genet** 1995 Sep;11(1):60–3

Platelet–derived growth factor in experimental glomerulonephritis. Zhang G, et al. **Nephrol Dial Transplant** 1995;10(6):787–95

PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Masliah E, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):549–56

Platelet–derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3–kinase. Moriya S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):151–5

Vascular endothelial growth factor and platelet–derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Anan K, et al. **Surgery** 1996 Mar;119(3):333–9

[PDGF–induced effect on cytosolic free calcium concentration of cultured retinal pericytes] Knorr M, et al. **Ophthalmologe** 1995 Oct;92(5):692–7 (Eng. Abstr.) **(Ger)**

SECRETION

Effect of endoluminal PTFE graft placement on cell proliferation, PDGF secretion, and intimal hyperplasia. Ombrellaro MP, et al. **J Surg Res** 1996 Jun;63(1):110–4

Effect of magnesium on secretion of platelet–derived growth factor by cultured human umbilical arterial endothelial cells. Kawano H, et al. **Magnes Res** 1995 Jun;8(2):137–44

THERAPEUTIC USE

Treatment of avascular ulcers with cytokine–induced tissue generation and skin grafting. Brown DM, et al. **Am J Surg** 1996 Feb;171(2):247–50

Platelet–derived growth factor–modulated guided tissue regenerative therapy. Cho MI, et al. **J Periodontol** 1995 Jun;66(6):522–30 (43 ref.)

Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet–derived growth factor. Park JB, et al. **J Periodontol** 1995 Jun;66(6):462–77

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

PLATELET–DERIVED GROWTH FACTOR RECEPTORS see **RECEPTORS, PLATELET–DERIVED GROWTH FACTOR**

PLATELET FACTOR 3

ANALYSIS

Platelet count and platelet factor 3 (PF–3) availability in sickle cell disease. Famodu AA, et al. **Br J Biomed Sci** 1995 Dec;52(4):323–4

METABOLISM

Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Jy W, et al. **Thromb Res** 1995 Dec 15;80(6):471–82

PLATELET FACTOR 4

Technetium–99m–white blood cell–specific imaging agent developed from platelet factor 4 to detect infection. Moyer BR, et al. **J Nucl Med** 1996 Apr;37(4):673–9

ADMINISTRATION & DOSAGE

A novel biological effect of platelet factor 4 (PF4): enhancement of LPS–induced tissue factor activity in monocytes. Engstad CS, et al. **J Leukoc Biol** 1995 Nov; 58(5):575–81

ANALYSIS

Plasma platelet–derived growth factor–B chain is elevated in patients with extensively large brain tumour. Kurimoto M, et al. **Acta Neurochir (Wien)** 1995;137(3–4):182–7

Platelet and coagulation factor variations induced in vitro by polyethylene terephthalate (Dacron) coated with pyrolytic carbon. Cenni E, et al. **Biomaterials** 1995 Sep; 16(13):973–6

Migraine—a haematological disorder? Malý J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(3):105–6

The platelet functions in stroke. Krajíčková D, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4–5):285–98

Correlation of specific platelet activation markers with carotid arterial wall thickness. Ghaddar HB, et al. **Thromb Haemost** 1995 Sep;74(3):943–8

[Platelet factor 4 (PF 4)] Kimura A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:109–11 (13 ref.) **(Jpn)**

CHEMISTRY

Heparin binding to platelet factor–4. An NMR and site–directed mutagenesis study: arginine residues are crucial for binding. Mayo KH, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):357–65

NMR solution structure of the 32–kDa platelet factor 4 ELR–motif N–terminal chimera: a symmetric tetramer. Mayo KH, et al. **Biochemistry** 1995 Sep 12; 34(36):11399–409

Carboxyterminal peptides with the dimeric form of PF4 retain the inhibitory effect on the growth of human megakaryoblastic cell lines [see comments] Lebeurier I, et al. **J Lab Clin Med** 1996 Feb;127(2):179–85. Comment in: J Lab Clin Med 1996 Feb;127(2):148–50.

IMMUNOLOGY

Generation of antibodies to heparin–PF4 complexes without thrombocytopenia in patients treated with unfractionated or low–molecular–weight heparin. Amiral J, et al. **Am J Hematol** 1996 Jun;52(2):90–5

Presence of autoantibodies to interleukin–8 or neutrophil–activating peptide–2 in patients with heparin–associated thrombocytopenia. Amiral J, et al. **Blood** 1996 Jul 15;88(2):410–6

Pathogenicity of IgA and/or IgM antibodies to heparin–PF4 complexes in patients with heparin–induced thrombocytopenia. Amiral J, et al. **Br J Haematol** 1996 Mar;92(4):954–9

METABOLISM

Differences in binding of platelet factor 4 to vascular endothelium in vivo and endothelial cells in vitro. Hansell P, et al. **Acta Physiol Scand** 1995 Aug;154(4):449–59

Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Hansell P, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H829–36

Heparin binding to platelet factor–4. An NMR and site–directed mutagenesis study: arginine residues are crucial for binding. Mayo KH, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):357–65

Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase. Frandsen NJ, et al. **Heart** 1996 Feb;75(2):141–4

Serglycin–binding proteins in activated macrophages and platelets. Kolset SO, et al. **J Leukoc Biol** 1996 Apr; 59(4):545–54

Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin–induced thrombocytopenia [letter; comment] Nguyên P, et al. **Thromb Haemost** 1995 Aug;74(2):804–5. Comment on: Thromb Haemost 1995 Jan;73(1):21–8.

PHARMACOLOGY

Carboxy–terminal peptides (C1–24 and C13–24 but not C1–13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. Lebeurier I, et al. **Br J Haematol** 1996 Jan; 92(1):29–34

Direct and reversible inhibition of platelet factor 4 on megakaryocyte development from CD34+ cord blood cells: comparative studies with transforming growth factor beta1. Xi X, et al. **Br J Haematol** 1996 May;93(2):265–72

High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. Daly TJ, et al. **J Biol Chem** 1995 Oct 6;270(40):23282–92

TNF–alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF–4 and IL–8 reveals different activity profiles of the two chemokines. Peterson F, et al. **J Immunol** 1996 Mar 1;156(5):1954–62

Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate. Maurer AM, et al. **J Lab Clin Med** 1996 Apr; 127(4):382–90

[Platelet factor 4 acts as both inhibitor and protector of hematopoietic precursor cells: possible mechanism of action] Han ZC, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Dec;28(4):415–26 (Eng. Abstr.) **(Chi)**

[Platelet factor 4, reversible inhibitor of megakaryocytogenesis, protector of megakaryocytes during chemotherapy] Caen JP, et al. **Bull Acad Natl Med** 1995 Nov;179(8):1657–70 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Platelets prime PMN via released PF4: mechanism of priming and synergy with GM–CSF. Aziz KA, et al. **Br J Haematol** 1995 Dec;91(4):846–53

PLATELET FUNCTION TESTS

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3–5 (26 ref.)

Flow cytometry: a clinical test of platelet function. Michelson AD. **Blood** 1996 Jun 15;87(12):4925–36 (145 ref.)

Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin–induced thrombocytopenia [letter; comment] Nguyên P, et al. **Thromb Haemost** 1995 Aug;74(2):804–5. Comment on: Thromb Haemost 1995 Jan;73(1):21–8.

INSTRUMENTATION

Quantitative measurement of various 5–HT receptor antagonists on platelet activation induced by serotonin. Qi R, et al. **Thromb Res** 1996 Jan 1;81(1):43–54

STANDARDS

Bleeding time: an unreliable predictor of clinical hemostasis. De Rossi SS, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1119–20 (21 ref.)

PLATELET GLYCOPROTEIN GPIB–IX COMPLEX

DEFICIENCY see **BERNARD–SOULIER SYNDROME**

METABOLISM

Ristocetin–induced platelet agglutination stimulates GPIIb/IIIa–dependent calcium influx. Bertolino G, et al. **Thromb Haemost** 1995 Apr;73(4):689–92

PLATELET GLYCOPROTEIN GPIB–IX COMPLEX

ANALYSIS

Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Kunishima S, et al. **Eur J Haematol** 1996 Jul;57(1):68–71

Increased but highly dispersed levels of plasma glycocalicin in patients with disseminated intravascular coagulation. Kunishima S, et al. **Eur J Haematol** 1996 Mar;56(3):173–7

Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis. Beer JH, et al. **Thromb Haemost** 1995 Apr;73(4):601–9

ANTAGONISTS & INHIBITORS

Isolation and characterization of jararaca GPIb–BP, a snake venom antagonist specific to platelet glycoprotein Ib. Fujimura Y, et al. **Thromb Haemost** 1995 Aug;74(2):743–50

BIOSYNTHESIS

Heterogeneous expression of glycoprotein Ib, IX and V in platelets from two patients with Bernard–Soulier syndrome caused by different genetic abnormalities. Noda M, et al. **Thromb Haemost** 1995 Dec;74(6):1411–5

Reduction of platelet surface GPIb expression induced by polymorphonuclear leukocytes. Schattner M, et al. **Thromb Res** 1995 Aug 1;79(3):319–24

CHEMISTRY

Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha. Miyata S, et al. **J Biol Chem** 1996 Apr 12; 271(15):9046–53

Mimotope/anti–mimotope probing of structural relationships in platelet glycoprotein Ib alpha. Miller JL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3565–9

GENETICS

Establishment and characterization of transgenic mice expressing human platelet glycoprotein Ib alpha. Kitaguchi T, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):418–24

Human platelet glycoproteins V and IX: mapping of two leucine–rich glycoprotein genes to chromosome 3 and analysis of structures. Yagi M, et al. **Biochemistry** 1995 Dec 12;34(49):16132–7

The genetic defect in two well–studied cases of Bernard–Soulier syndrome: a point mutation in the fifth leucine–rich repeat of platelet glycoprotein Ib alpha. Li C, et al. **Blood** 1995 Nov 15;86(10):3805–14

Systematic screening for genetic polymorphism in human platelet glycoprotein Ibalpha. Kaski S, et al. **Immunogenetics** 1996;44(3):170–6

Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and

functional GATA and Ets sites. Bastian LS, et al. **J Biol Chem** 1996 Aug 2;271(31):18554–60

Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. Hashimoto Y, et al. **J Biol Chem** 1995 Oct 13; 270(41):24532–9

Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard–Soulier syndrome. Ludlow LB, et al. **J Biol Chem** 1996 Sep 6;271(36):22076–80

Mimotope/anti–mimotope probing of structural relationships in platelet glycoprotein Ib alpha. Miller JL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3565–9

Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation–based typing. Legler TJ, et al. **Transfusion** 1996 May;36(5):426–31

IMMUNOLOGY

Antiplatelet antibodies during the course of HIV–preventive vaccine trial [letter] Kaplan C, et al. **AIDS** 1996 Apr; 10(4):447–9

Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Kiefel V, et al. **Ann Hematol** 1996 Apr;72(4):280–5

Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. He R, et al. **Blood** 1995 Nov 15;86(10):3789–96

Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet–reactive anti–HIV antibodies in thrombocytopenic narcotic addicts. Gonzalez–Conejero R, et al. **Br J Haematol** 1996 May; 93(2):464–71

Blood group A antigen expression in platelets is prominently associated with glycoprotein Ib and IIb. Evidence for an A1/A2 difference. Hou M, et al. **Transfus Med** 1996 Mar; 6(1):51–9

Alloimmunization against Iy, a low–frequency antigen on platelet glycoprotein Ib/IX as a cause of severe neonatal alloimmune thrombocytopenic purpura. Kiefel V, et al. **Vox Sang** 1995;69(3):250–4

METABOLISM

Effect of intracellular free calcium mobilization on aggregation of umbilical cord blood platelets. Niida K, et al. **Acta Med Okayama** 1996 Feb;50(1):47–52

Plasma P selectin (GMP–140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Halim A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):272–7

Prelabeled glycoprotein Ib/IX receptors are not cleared from exposed surfaces of thrombin–activated platelets. White JG, et al. **Am J Pathol** 1996 Aug;149(2):629–38

Dynamic redistribution of glycoprotein Ib/IX on surface–activated platelets. A second look. White JG, et al. **Am J Pathol** 1995 Oct;147(4):1057–67

Direct demonstration of radiolabeled von Willebrand factor binding to platelet glycoprotein Ib and IIb–IIIa in the presence of shear stress. McCrary JK, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):787–93

Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr–276–Glu–282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha–thrombin. Ward CM, et al. **Biochemistry** 1996 Apr 16;35(15):4929–38

Aggregation of mammalian cells expressing the platelet glycoprotein (GP) Ib–IX complex and the requirement for tyrosine sulfation of GP Ib alpha. Dong JF, et al. **Blood** 1995 Dec 1;86(11):4175–83

Thrombin–induced GPIb–IX centralization on the platelet surface requires actin assembly and myosin II activation. Kovacsovics TJ, et al. **Blood** 1996 Jan 15;87(2):618–29

The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal–mediated redistribution to the surface–connected canalicular system. Michelson AD, et al. **Blood** 1996 Feb 15;87(4):1396–408

The acylation of megakaryocyte proteins: glycoprotein IX is primarily myristoylated while glycoprotein Ib is palmitoylated. Schick PK, et al. **Blood** 1996 Feb 15; 87(4):1377–84

Retention of glycoprotein Ib/IX receptors on external surfaces of thrombin–activated platelets in suspension. White JG, et al. **Blood** 1995 Nov 1;86(9):3468–78

Degradation of platelet glycoprotein Ib by elastase released from primed neutrophils. Aziz KA, et al. **Br J Haematol** 1995 Sep;91(1):46–54

Fab–mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec; 91(4):944–50

The cytoplasmic domain of the alpha–subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib–IX complex to the cytoskeleton and regulates von Willebrand factor–induced changes in cell morphology. Cunningham JG, et al. **J Biol Chem** 1996 May 10;271(19):11581–7

Identification of a binding sequence for the 14–3–3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Ib alpha. Du X, et al. **J Biol Chem** 1996 Mar 29;271(13):7362–7

Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia [letter] Liani M, et al. **Nephron** 1996;72(4):716

Platelet adhesion receptors. Williams MJ, et al. **Semin Cell Biol** 1995 Oct;6(5):305–14 (75 ref.)

Interaction of echicetin with a high affinity thrombin binding site on platelet glycoprotein GPIb. Peng M, et al. **Thromb Haemost** 1995 Sep;74(3):954–7

Characterization of tumor–induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF–7 breast cancer cells. Oleksowicz L, et al. **Thromb Res** 1995 Aug 1;79(3):261–74

PHYSIOLOGY

Contributions of glycoprotein Ib and the seven transmembrane domain receptor to increases in platelet cytoplasmic [Ca2+] induced by alpha–thrombin. Greco NJ, et al. **Biochemistry** 1996 Jan 23;35(3):906–14

Differentiation of the two forms of GPIb functioning as receptors for alpha–thrombin and von Willebrand factor: Ca2+ responses of protease–treated human platelets activated with alpha–thrombin and the tethered ligand peptide. Greco NJ, et al. **Biochemistry** 1996 Jan 23; 35(3):915–21

Platelet adhesion to fibronectin in flow: the importance of von Willebrand factor and glycoprotein Ib. Beumer S, et al. **Blood** 1995 Nov 1;86(9):3452–60

Inhibition of cyclic flow variations by von Willebrand factor–glycoprotein Ib binding domain [letter; comment] Tousoulis D, et al. **Circulation** 1996 Mar 15;93(6):1255. Comment on: Circulation 1994 Dec;90(6):2976–81.

Protein tyrosine phosphorylation in human platelets during shear stress–induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736–42

PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX

Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. Murray LJ, et al. **Exp Hematol** 1996 Feb;24(2):236–45

ANALYSIS

Distribution of ligand–occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand–induced binding site recognized by monoclonal antibody AP6. Nurden P, et al. **Blood** 1996 Aug 1;88(3):887–99

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Wagner CL, et al. **Blood** 1996 Aug 1;88(3):907–14

GpIIb/IIIa+ subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to human thrombopoietin. Kato T, et al. **Exp Hematol** 1996 Aug;24(10):1209–14

Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz–Schatz stenting. Neumann FJ, et al. **J Am Coll Cardiol** 1996 Jan;27(1):15–21

ANTAGONISTS & INHIBITORS

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Platelet glycoprotein IIb/IIIa receptor inhibitors in coronary artery disease [editorial] Cohen M. **Ann Intern Med** 1996 May 1;124(9):843–4

Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. André P, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):56–63

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Reilly TM, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2195–9

Labeling a hydrazino nicotinamide–modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands. Liu S, et al. **Bioconjug Chem** 1996 Jan–Feb; 7(1):63–71

Role of collagen–adherent platelets in mediating fibrin formation in flowing whole blood. Kirchhofer D, et al. **Blood** 1995 Nov 15;86(10):3815–22

New directions in anticoagulant and antiplatelet treatment [editorial] Simoons ML, et al. **Br Heart J** 1995 Oct; 74(4):337–40 (33 ref.)

EPILOG and CAPTURE trials halted because of positive interim results [news] Ferguson JJ 3rd. **Circulation** 1996 Feb 15;93(4):637

The protective dose of the potent GPIIb/IIIa antagonist SC–54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Frederick LG, et al. **Circulation** 1996 Jan 1; 93(1):129–34

Differential dose–response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Kereiakes DJ, et al. **Circulation** 1996 Sep 1;94(5):906–10

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high–risk coronary angioplasty. EPIC Investigators. Mark DB, et al. **Circulation** 1996 Aug 15;94(4):629–35

Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Mousa SA, et al. **Circulation** 1996 Feb 1;93(3):537–43

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study [see comments] Théroux P, et al. **Circulation** 1996 Sep 1; 94(5):899–905. Comment in: Circulation 1996 Sep 1;94(5):866–8.

Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically? [editorial; comment] Willerson JT. **Circulation** 1996 Sep 1;94(5):866–8. Comment on: Circulation 1996 Sep 1;94(5):899–905.

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):181–9 (32 ref.)

Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947–55 (67 ref.)

Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Curr Opin Cardiol** 1995 Jul;10(4):420–6 (53 ref.)

Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)

More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa–blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials [editorial] van de Werf F. **Eur Heart J** 1996 Mar;17(3):325–6

Monamidocin, a novel fibrinogen receptor antagonist. II. Biological activity and structure–activity relationships. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1226–33

Monamidocin, a novel fibrinogen receptor antagonist. I. Production isolation, characterization and structural elucidation. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1221–5

Variabilin, a novel RGD–containing antagonist of glycoprotein IIb–IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Wang X, et al. **J Biol Chem** 1996 Jul 26;271(30):17785–90

Pharmacokinetics and pharmacodynamics of TP–9201, a GPIIbIIIa antagonist, in rats and dogs. Modi NB, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):888–97

Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis. Sudo Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):241–50

Thrombus imaging using technetium–99m–labeled high–potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. Pearson DA, et al. **J Med Chem** 1996 Mar 29;39(7):1372–82

Discovery of an orally active non–peptide fibrinogen receptor antagonist. Stilz HU, et al. **J Med Chem** 1996 May 24;39(11):2118–22

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Weller T, et al. **J Med Chem** 1996 Aug 2;39(16):3139–47

Antithrombotic effects of TAK–029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. Kawamura M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):502–10

A novel isolation method of a stable crystalline salt of a cyclic RGD peptide zwitterion. Maurin MB, et al. **Pharm Res** 1995 Nov;12(11):1810–2

New antiplatelet agents: platelet GPIIb/IIIa antagonists. Coller BS, et al. **Thromb Haemost** 1995 Jul;74(1):302–8 (38 ref.)

Pentamidine is a specific, non–peptide, GPIIb/IIIa antagonist. Cox D, et al. **Thromb Haemost** 1996 Mar; 75(3):503–9

Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti–platelet glycoprotein IIb/IIIa antibody in a baboon model. Kotzé HF, et al. **Thromb Haemost** 1995 Aug;74(2):751–7

Inhibition of platelet GPIIbIIIa prolongs survival of discordant cardiac xenografts. Lesnikoski BA, et al. **Transplant Proc** 1996 Apr;28(2):703

Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts. Candinas D, et al. **Transplantation** 1996 Jul 15;62(1):1–5

BIOSYNTHESIS

Glanzmann thrombasthenia in children from Argentina. Sassetti B, et al. **J Pediatr Hematol Oncol** 1996 Feb; 18(1):23–8

Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures. Pasha R, et al. **Lab Invest** 1995 Sep;73(3):403–8

Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Rabhi–Sabile S, et al. **Thromb Haemost** 1995 Apr; 73(4):693–701

PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX

CHEMISTRY

Integrin receptor GPIIb/IIIa bound state conformation of the fibrinogen gamma-chain C-terminal peptide 400-411: NMR and transfer NOE studies. Mayo KH, et al. **Biochemistry** 1996 Apr 9;35(14):4434-44

Sequence 274-368 in the beta 3-subunit of the integrin alpha IIb beta 3 provides a ligand recognition and binding domain for the gamma-chain of fibrinogen that is independent of platelet activation. Alemany M, et al. **Blood** 1996 Jan 15; 87(2):592-601

Thermal stability of individual domains in platelet glycoprotein IIbIIIa. Makogonenko EM, et al. **Eur J Biochem** 1996 Apr 1;237(1):205-11

RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen gamma-chain C-terminal peptide. Mayo KH, et al. **FEBS Lett** 1996 Jan 2;378(1):79-82

The cytoplasmic domain of alphaIIb beta3. A ternary complex of the integrin alpha and beta subunits and a divalent cation. Haas TA, et al. **J Biol Chem** 1996 Mar 15;271(11):6017-26

Critical residues of integrin alphaIIb subunit for binding of alphaIIbbeta3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3). Kamata T, et al. **J Biol Chem** 1996 Aug 2;271(31):18610-5

The amino-terminal one-third of alpha IIb defines the ligand recognition specificity of integrin alpha IIb beta 3. Loftus JC, et al. **J Biol Chem** 1996 Jan 26;271(4):2033-9

A common epitope on platelet integrin alpha IIb beta 3 (glycoprotein IIbIIIa; CD41b/CD61) and alpha M beta 2 (Mac-1; CDIIb/CD18) detected by a monoclonal antibody. De Nichilo MO, et al. **J Immunol** 1996 Jan 1;156(1):284-8

Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. McDevitt D, et al. **Mol Microbiol** 1995 Jun;16(5):895-907

Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies. Kosugi S, et al. **Thromb Haemost** 1996 Feb;75(2):339-45

The beta chain of the GPIIb molecule on ruminant leukocytes and platelets is not labelled by the sulfo-NHS-biotin method. Pintado CO, et al. **Vox Sang** 1995;69(3):248-9

[Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa] Khaspekova SG, et al. **Biokhimiia** 1996 Mar;61(3):412-28 (Eng. Abstr.) **(Rus)**

DEFICIENCY see THROMBASTHENIA

DRUG EFFECTS

Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function. Bhattacharya S, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):665-75

GENETICS

Glanzmann thrombasthenia due to a two amino acid deletion in the fourth calcium-binding domain of alpha IIb: demonstration of the importance of calcium-binding domains in the conformation of alpha IIb beta 3. Basani RB, et al. **Blood** 1996 Jul 1;88(1):167-73

An Ets/Sp1 interaction in the 5'-flanking region of the megakaryocyte-specific alpha IIb gene appears to stabilize Sp1 binding and is essential for expression of this TATA-less gene. Block KL, et al. **Blood** 1996 Sep 15; 88(6):2071-80

A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia. Grimaldi CM, et al. **Blood** 1996 Sep 1; 88(5):1666-75

The tissue-specific transcriptional regulation of the megakaryocytic glycoprotein IIb gene is controlled by interactions between a repressor and positive cis-acting elements. Prandini MH, et al. **Blood** 1996 Sep 15; 88(6):2062-70

Bilateral linkage between a new deletion polymorphism in intron 21 of the GP IIb gene and the HPA-3b (Bakb) determinant. Peyruchaud O, et al. **Br J Haematol** 1995 Nov; 91(3):747-51

Two regulation points for differentiation in the cell cycle of human megakaryocytes. Yoshino T, et al. **Br J Haematol** 1996 Mar;92(4):780-7

Influence of agr on fibrinogen binding in Staphylococcus aureus Newman. Wolz C, et al. **Infect Immun** 1996 Aug; 64(8):3142-7

Platelet glycoprotein IIIa PlA polymorphism in young men with myocardial infarction [letter; comment] Carter AM, et al. **Lancet** 1996 Aug 17;348(9025):485-6. Comment on: Lancet 1996 Jun 29;347(9018):1833.

Clues to the death of an Olympic champion [see comments] Goldschmidt-Clermont PJ, et al. **Lancet** 1996 Jun 29; 347(9018):1833. Comment in: Lancet 1996 Aug 17;348(9025):485-6.

Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction [letter] Carter AM, et al. **N Engl J Med** 1996 Oct 3;335(14):1072-3; discussion 1073-4

Platelets and coronary artery disease [editorial; comment] Handin RI. **N Engl J Med** 1996 Apr 25;334(17):1126-7. Comment on: N Engl J Med 1996 Apr 25;334(17):1084-9. Comment on: N Engl J Med 1996 Apr 25;334(17):1090-4.

Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction [letter] Marian AJ, et al. **N Engl J Med** 1996 Oct 3;335(14):1071-2; discussion 1073-4

A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis [see comments] Weiss EJ, et al. **N Engl J Med** 1996 Apr 25; 334(17):1090-4. Comment in: N Engl J Med 1996 Apr 25;334(17):1126-8.

Detection by PCR and HphI restriction analysis of a splice site mutation at the 5' end of intron 15 of the platelet GPIIb (alpha IIb integrin) gene responsible for Glanzmann's thrombasthenia type I in Gypsies originating from the Strasbourg area [letter] de la Salle C, et al. **Thromb Haemost** 1995 Sep;74(3):990-1

Abnormal processing of the glycoprotein IIb transcript due to a nonsense mutation in exon 17 associated with Glanzmann's thrombasthenia. Tomiyama Y, et al. **Thromb Haemost** 1995 Aug;74(2):811

Abnormal processing of the glycoprotein IIb transcript due to a nonsense mutation in exon 17 associated with Glanzmann's thrombasthenia. Tomiyama Y, et al. **Thromb Haemost** 1995 May;73(5):756-62

Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Legler TJ, et al. **Transfusion** 1996 May;36(5):426-31

IMMUNOLOGY

Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura [letter] Ozsoylu S. **Am J Hematol** 1996 Apr;51(4):328

Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Kiefel V, et al. **Ann Hematol** 1996 Apr;72(4):280-5

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051-7 (25 ref.)

Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Filion MC, et al. **Blood** 1996 Sep 15;88(6):2144-50

A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Griffin HM, et al. **Blood** 1995 Dec 15;86(12):4430-6

Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. Gonzalez-Conejero R, et al. **Br J Haematol** 1996 May; 93(2):464-71

Glycoprotein IIb/IIIa autoantigenic repertoire in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec;91(4):971-5

Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIa. Liu LX, et al. **Br J Haematol** 1995 Dec;91(4):976-82

Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Bettaieb A, et al. **Clin Exp Immunol** 1996 Jan; 103(1):19-23

Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Filion MC, et al. **Eur J Immunol** 1995 Nov; 25(11):3123-7

Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. Kaku S, et al. **Eur J Pharmacol** 1995 Jun 12;279(2-3):115-21

The monoclonal antibody, 7E3 and treatment of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Feb; 92(9):453-4

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Knight DM, et al. **Mol Immunol** 1995 Nov; 32(16):1271-81

Characterization of monoclonal antibodies to the alpha IIb beta 3 integrin on bovine platelets. Nthale JM, et al. **Scand J Immunol** 1995 Nov;42(5):524-8

Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies. Kosugi S, et al. **Thromb Haemost** 1996 Feb;75(2):339-45

Blood group A antigen expression in platelets is prominently associated with glycoprotein Ib and IIb. Evidence for an A1/A2 difference. Hou M, et al. **Transfus Med** 1996 Mar; 6(1):51-9

METABOLISM

Effect of intracellular free calcium mobilization on aggregation of umbilical cord blood platelets. Niida K, et al. **Acta Med Okayama** 1996 Feb;50(1):47-52

Involvement of calpain in integrin-mediated signal transduction. Inomata M, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):129-34

Association of localized Ca2+ gradients with redistribution of glycoprotein IIb-IIIa and F-actin in activated human blood platelets. Ariyoshi H, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):230-5

Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes. Leytin V, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):94-100

Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins. Marcinkiewicz C, et al. **Biochem J** 1996 Aug 1; 317 (Pt 3):817-25

The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD. Rahman S, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):223-32

Interactions of integrin GPIIb/IIIa-derived peptides with fibrinogen investigated by NMR spectroscopy. Yao LJ, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):161-70

NOE-derived conformation of GRGDSP cell adhesion recognition site in the presence of SDS micelles and integrin receptor GPIIB/IIIA. Mayo KH, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):95-102

Phorbol ester enhances integrin alpha IIb beta 3-dependent adhesion of human erythroleukemic cells to activation-dependent monoclonal antibodies. Boudignon-Proudhon C, et al. **Blood** 1996 Feb 1; 87(3):968-76

Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Gabbeta J, et al. **Blood** 1996 Feb 15;87(4):1368-76

Internalization of bound fibrinogen modulates platelet aggregation. Wencel-Drake JD, et al. **Blood** 1996 Jan 15; 87(2):602-12

Fab-mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec; 91(4):944-50

Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Zauli G, et al. **Br J Haematol** 1996 Mar;92(3):711-7

Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Wu C, et al. **Cell** 1995 Dec 1;83(5):715-24

Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. McLane MA, et al. **FEBS Lett** 1996 Aug 5;391(1-2):139-43

Tailoring echistatin to possess higher affinity for integrin alpha(IIb)beta(3). Yamada T, et al. **FEBS Lett** 1996 May 27;387(1):11-15

Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. Du X, et al. **J Biol Chem** 1995 Nov 3; 270(44):26146-51

The platelet cytoskeleton stabilizes the interaction between alphaIIbbeta3 and its ligand and induces selective movements of ligand-occupied integrin. Fox JE, et al. **J Biol Chem** 1996 Mar 22;271(12):7004-11

Critical residues of integrin alphaIIb subunit for binding of alphaIIbbeta3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3). Kamata T, et al. **J Biol Chem** 1996 Aug 2;271(31):18610-5

Direct binding of the platelet integrin alphaIIbbeta3 (GPIIb-IIIa) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alphaIIb and beta3. Knezevic I, et al. **J Biol Chem** 1996 Jul 5; 271(27):16416-21

A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIb beta3. Kunicki TJ, et al. **J Biol Chem** 1996 Aug 23;271(34):20315-21

Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. Law DA, et al. **J Biol Chem** 1996 May 3; 271(18):10811-5

Identification of a novel binding site to the integrin alphaIIbbeta3 located in the C-terminal heparin-binding domain of human plasma fibronectin. Mohri H, et al. **J Biol Chem** 1996 Jun 28;271(26):15724-8

Interaction of integrin alpha IIb beta 3 with multiple fibrinogen domains during platelet adhesion. Savage B, et al. **J Biol Chem** 1995 Dec 1;270(48):28812-7

Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha IIb beta 3. Smith JW, et al. **J Biol Chem** 1995 Dec 22; 270(51):30486-90

Ligand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit. Tozer EC, et al. **J Biol Chem** 1996 Sep 6;271(36):21978-84

Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets. Relative sctivation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alphaIIbbeta3 integrin. Zhang J, et al. **J Biol Chem** 1996 Mar 15; 271(11):6265-72

Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL-6, IL-6 receptor, mpl and

GATA genes. Okabe M, et al. **Leuk Res** 1995 Dec; 19(12):933–43

Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. McDevitt D, et al. **Mol Microbiol** 1995 Jun;16(5):895–907

Expression of fibrinogen receptors and GPIIb molecules on uraemic platelets: effect of recombinant human erythropoietin therapy. Krzesłowska J, et al. **Nephrol Dial Transplant** 1995;10(5):653–6

Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia [letter] Liani M, et al. **Nephron** 1996;72(4):716

Platelet adhesion receptors. Williams MJ, et al. **Semin Cell Biol** 1995 Oct;6(5):305–14 (75 ref.)

Ristocetin-induced platelet agglutination stimulates GPIIb/IIIa-dependent calcium influx. Bertolino G, et al. **Thromb Haemost** 1995 Apr;73(4):689–92

Mechanisms involved in platelet vessel wall interaction. Hawiger J. **Thromb Haemost** 1995 Jul;74(1):369–72 (37 ref.)

A new method for the assay of exposed platelet fibrinogen receptor using a chemiluminescent label. Katoh M, et al. **Thromb Haemost** 1995 Dec;74(6):1546–50

Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Oleksowicz L, et al. **Thromb Res** 1995 Aug 1;79(3):261–74

PHARMACOLOGY

alphaIIb beta 3-integrin mediated adhesion of human platelets to a fibrinogen matrix triggers phospholipase C activation and phosphatidylinositol 3',4'-biphosphate accumulation. Gironcel D, et al. **FEBS Lett** 1996 Jul 8; 389(3):253–6

PHYSIOLOGY

Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Sreedhara R, et al. **Am J Kidney Dis** 1996 Mar;27(3):355–64

Exposure of ligand-binding sites on platelet integrin alpha IIB/beta 3 by phosphorylation of the beta 3 subunit. van Willigen G, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):769–79

Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Haimovich B, et al. **Blood** 1996 Jan 1;87(1):152–61

Stimulation of platelet glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. Mazurov AV, et al. **FEBS Lett** 1996 Aug 5;391(1–2):84–8

Participation of alpha IIb beta 3 in platelet microparticle generation by collagen plus thrombin. Nomura S, et al. **Haemostasis** 1996 Jan–Feb;26(1):31–7

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". Reverter JC, et al. **J Clin Invest** 1996 Aug 1;98(3):863–74

Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. Li JM, et al. **J Surg Res** 1996 Mar;61(2):543–8

Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa. Holme PA, et al. **Thromb Haemost** 1995 Dec; 74(6):1533–40

Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Jennings LK, et al. **Thromb Haemost** 1995 Dec;74(6):1551–6

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282–90 (67 ref.)

Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736–42

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

[Do glycoproteins IIb/IIIa participate in activation of human platelet s by low density lipoproteins?] Bochkov VN, et al. **Biokhimiia** 1995 Aug;60(8):1187–94 (Eng. Abstr.) **(Rus)**

PLATELET GLYCOPROTEIN IV see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN IB see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIB see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIA see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIB see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN V see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IX see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEINS

Platelet-activating factor receptor. Izumi T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):429–42 (77 ref.)

AGONISTS

Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties. Man RY, et al. **Br J Pharmacol** 1995 Nov;116(5):2359–64

ANALYSIS

Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Semple JW, et al. **Blood** 1996 May 15;87(10):4245–54

Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies. Mellgren K, et al. **Int J Artif Organs** 1995 Jun; 18(6):315–21

Identification of functional platelet-activating factor receptors on human keratinocytes. Travers JB, et al. **J Invest Dermatol** 1995 Dec;105(6):816–23

Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Zipursky A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):341–7

Platelet membrane glycoproteins and microvesicles in blood from postoperative salvage: a study in cardiac bypass patients. Sloand E, et al. **Transfusion** 1995 Sep;35(9):738–44

[Dynamic observation of alpha-granule membrane protein 140 during the treatment of thrombolytic and anticoagulant therapy in patients with acute myocardial infarction] Ruan J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):253–5 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

Platelet-activating factor (PAF) receptor antagonism by WEB 2170 improves the survival of ischaemic skeletal muscle. Lepore DA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):63–7

Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes. Silva CL, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):193–6

Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties. Man RY, et al. **Br J Pharmacol** 1995 Nov;116(5):2359–64

PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover. Catalán RE, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):183–8

Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch. Foster AP, et al. **Inflamm Res** 1995 Oct;44(10):412–7

Sulfobacins A and B, novel von Willebrand factor receptor antagonists. I. Production, isolation, characterization and biological activities. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):924–8

Sulfobacins A and B, novel von Willebrand factor receptor antagonists. II. Structural elucidation. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):929–36

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

Influence of the platelet-activating factor receptor antagonist BN52021 on endotoxin-induced leukocyte adherence in rat mesenteric venules. Schmidt H, et al. **J Surg Res** 1996 Jan; 60(1):29–35

The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes. Svetlov SI, et al. **Life Sci** 1996;58(5):PL 81–6

Luminol-chemiluminescence in free peritoneal cells in hemorrhagic shock in rats treated with PAF-receptor-antagonist BN 52021. Dębek W, et al. **Rocz Akad Med Bialymst** 1995;40(1):129–37

Ginkgolide BN 52021 protects against hemorrhagic shock-induced renal injury in rats. Kirejczyk JK, et al. **Rocz Akad Med Bialymst** 1995;40(1):65–76

Oxygen-derived free radicals in kidney in experimental hemorrhagic shock treated by PAF-receptor antagonist BN 52021. Kirejczyk JK, et al. **Rocz Akad Med Bialymst** 1995;40(1):77–87

Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Takiguchi Y, et al. **Thromb Haemost** 1995 Apr;73(4):683–8

BIOSYNTHESIS

Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Furuno T, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):740–4

The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Dercksen MW, et al. **Blood** 1995 Nov 15;86(10):3771–82

Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Chiang HS, et al. **Br J Cancer** 1996 Apr;73(7):902–8

Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Carreiras F, et al. **Gynecol Oncol** 1996 Aug;62(2):260–7

Beta3 integrin expression in melanoma predicts subsequent metastasis. Hieken TJ, et al. **J Surg Res** 1996 Jun; 63(1):169–73

Tissue-specific response of the human platelet-activating factor receptor gene to retinoic acid and thyroid hormone by alternative promoter usage. Mutoh H, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):774–9

CHEMISTRY

CD36 is spatially associated with glycoprotein IIb-IIIa (alpha IIb beta 3) on the surface of resting platelets. Dorahy DJ, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):575–81

Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-Soulier syndrome. Sae-Tung G, et al. **Blood** 1996 Feb 15;87(4):1361–7

Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor. Parent JL, et al. **J Biol Chem** 1996 Apr 5;271(14):7949–55

The ligand recognition specificity of beta3 integrins. Suehiro K, et al. **J Biol Chem** 1996 Apr 26;271(17):10365–71

Divalent cations regulate the organization of integrins alpha v beta 3 and alpha v beta 5 on the cell surface. Stuiver I, et al. **J Cell Physiol** 1996 Sep;168(3):521–31

DEFICIENCY

Deficiency of P-selectin in a patient with grey platelet syndrome. Mazurov AV, et al. **Eur J Haematol** 1996 Jul; 57(1):38–41

DRUG EFFECTS

Verapamil influences the effect of nonionic contrast agent on platelet membrane structure and aggregation. Górski J, et al. **Bull Inst Marit Trop Med Gdynia** 1995; 46(1–4):59–65

Stimulation of platelet-activating factor (PAF) receptors increases inositol phosphate production and cytosolic free Ca2+ concentrations in N1E-115 neuroblastoma cells. Diserbo M, et al. **Cell Calcium** 1995 Jun;17(6):442–52

Effects of a paf-receptor antagonist on hemodynamics during and after cardiopulmonary bypass. Nathan N, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):647–52

Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor. Puri RN, et al. **J Cell Biochem** 1996 Apr;61(1):97–108

GENETICS

Distribution of platelet activating factor receptor mRNA along the rat nephron segments. Asano K, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):352–7

Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis. Danen EH, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):75–81

A murine platelet-activating factor receptor gene: cloning, chromosomal localization and up-regulation of expression by lipopolysaccharide in peritoneal resident macrophages. Ishii S, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):671–8

Platelet-activating factor receptor: gene expression and signal transduction. Izumi T, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):317–33 (231 ref.)

Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-Soulier syndrome. Sae-Tung G, et al. **Blood** 1996 Feb 15;87(4):1361–7

Genetic localization of Cd63, a member of the transmembrane 4 superfamily, reveals two distinct loci in the mouse genome. Gwynn B, et al. **Genomics** 1996 Jul 15; 35(2):389–91

Competition for a unique response element mediates retinoic acid inhibition of vitamin D3-stimulated transcription. Cao X, et al. **J Biol Chem** 1996 Aug 23;271(34):20650–4

Predominant expression of platelet-activating factor receptor in the rat brain microglia. Mori M, et al. **J Neurosci** 1996 Jun 1;16(11):3590–600

Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3. Ho PP, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):351–5

Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Nurden AT.

Thromb Haemost 1995 Jul;74(1):345–51 (53 ref.)
Molecular study of Glanzmann thrombasthenia in 3 patients issued from 2 different families. Vinciguerra C, et al. **Thromb Haemost** 1995 Sep;74(3):822–7
[Rapid detection of platelet glycoprotein IIb, IIIA gene variety by single strand conformation polymorphism analysis] Chen F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):341–3, 382 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Brighton TA, et al. **Blood** 1996 Jul 1; 88(1):194–201
Characterization of porcine platelet glycoproteins recognized by human natural "anti-gal" antibodies. Thibaudeau K, et al. **Blood** 1996 Jun 1;87(11):4636–42
Reactivity of autoantibodies from chronic ITP patients with recombinant glycoprotein IIIa peptides. Bowditch RD, et al. **Br J Haematol** 1995 Sep;91(1):178–84
Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Bettaieb A, et al. **Clin Exp Immunol** 1996 Jan; 103(1):19–23
Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Arfors L, et al. **Eur J Haematol** 1996 Apr;56(4):230–4
Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Eur J Haematol** 1995 Nov; 55(5):307–14
Platelet-specific antibodies in transfused patients. Uhrynowska M, et al. **Eur J Haematol** 1996 Apr; 56(4):248–51
Studies of platelet-bound and serum platelet-bindable immunoglobulins in dogs with idiopathic thrombocytopenic purpura. Lewis DC, et al. **Exp Hematol** 1996 May;24(6):696–701
Suppression of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta3 with low molecular weight antigen arrays. Watson DC, et al. **J Immunol** 1996 Apr 1;156(7):2443–50
Antibodies against human CD63 activate transfected rat basophilic leukemia (RBL-2H3) cells. Smith DA, et al. **Mol Immunol** 1995 Dec;32(17–18):1339–44
Characterization of monoclonal antibodies to the alpha IIb beta 3 integrin on bovine platelets. Nthale JM, et al. **Scand J Immunol** 1995 Nov;42(5):524–8
Human platelet alloantigens: recent findings, new perspectives. Newman PJ, et al. **Thromb Haemost** 1995 Jul; 74(1):234–9 (26 ref.)
[Characterization of platelet activation induced by CD9 McAbs] Peng L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):365–70 (Eng. Abstr.) **(Chi)**
[Platelet antigens: immunology and immuno-allergology] de Sousa JC, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):48–51 (22 ref.) (Eng. Abstr.) **(Fre)**
[Antiplatelet glycoprotein monoclonal antibodies: properties and practical value] Saffroy R, et al. **Ann Biol Clin (Paris)** 1995;53(3):97–105 (119 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Functional significance of platelet membrane glycoprotein p62 (GP VI), a putative collagen receptor. Ishibashi T, et al. **Int J Hematol** 1995 Aug;62(2):107–15

METABOLISM

Prelabeled glycoprotein Ib/IX receptors are not cleared from exposed surfaces of thrombin-activated platelets. White JG, et al. **Am J Pathol** 1996 Aug;149(2):629–38
Heparin effect on platelets and fibrinolysis [letter; comment] Wahba A, et al. **Ann Thorac Surg** 1996 May;61(5):1590–1 . Comment on: Ann Thorac Surg 1995 Oct;60(4):1008–14.
Mutation of an aspartate at position 63 in the human platelet-activating factor receptor augments binding affinity but abolishes G-protein-coupling and inositol phosphate production. Parent JL, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):968–75
CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Radford KJ, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):13–8
Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Ward CM, et al. **Biochemistry** 1996 Apr 16;35(15):4929–38
Liposomes bearing platelet proteins: a model for surface functions studies. Dalençon F, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):241–8
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Adida C, et al. **Blood** 1996 Aug 15; 88(4):1457–64
Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Berger G, et al. **Blood** 1996 Feb 15;87(4):1385–95
Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Cooney KA, et al. **Blood** 1996 Mar 15;87(6):2322–8
Platelet glycoprotein (Gp) IX associates with GpIb alpha in the platelet membrane GpIb complex. Wu G, et al. **Blood** 1996 Apr 1;87(7):2782–7
The P1A alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin beta 3 subunit. Kunicki TJ, et al. **Blood Cells Mol Dis** 1995;21(2):131–41
Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Bihour C, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):395–410
Degradation of platelet glycoprotein Ib by elastase released from primed neutrophils. Aziz KA, et al. **Br J Haematol** 1995 Sep;91(1):46–54
Differential role of protein tyrosine phosphorylation/dephosphorylation in affinity regulation of beta 1 and beta 3 integrin in human fibroblasts. Takagi J, et al. **Cell Struct Funct** 1995 Oct;20(5):403–13
Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Crippes BA, et al. **Endocrinology** 1996 Mar;137(3):918–24
Bone sialoprotein coated on glass and plastic surfaces is recognized by different beta 3 integrins. Flores ME, et al. **Exp Cell Res** 1996 Aug 25;227(1):40–6
Specific high affinity binding of platelet activating factor to intact human blood neutrophils and eosinophils. Korth RM. **Int Arch Allergy Immunol** 1996 Jun;110(2):124–31
The role of N-glycosylation for functional expression of the human platelet-activating factor receptor. Glycosylation is required for efficient membrane trafficking. García Rodriguez C, et al. **J Biol Chem** 1995 Oct 20; 270(42):25178–84
An allosteric Ca2+ binding site on the beta3-integrins that regulates the dissociation rate for RGD ligands. Hu DD, et al. **J Biol Chem** 1996 Sep 6;271(36):21745–51
A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIb beta3. Kunicki TJ, et al. **J Biol Chem** 1996 Aug 23;271(34):20315–21
A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. Aoki Y, et al. **J Immunol Methods** 1995 Oct 26;186(2):225–31
Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Berditchevski F, et al. **Mol Biol Cell** 1996 Feb;7(2):193–207
Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Cundell DR, et al. **Nature** 1995 Oct 5;377(6548):435–8
Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Jones JI, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2482–7
Platelet integrins. Ginsberg MH, et al. **Thromb Haemost** 1995 Jul;74(1):352–9 (176 ref.)
[Effect of platelet activating factor receptor at spinal cord neurocyte membrane on secondary damage after spinal cord injury] Xiao J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):120–3 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Differentiation of the two forms of GPIb functioning as receptors for alpha-thrombin and von Willebrand factor: Ca2+ responses of protease-treated human platelets activated with alpha-thrombin and the tethered ligand peptide. Greco NJ, et al. **Biochemistry** 1996 Jan 23; 35(3):915–21
Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Moroi M, et al. **Blood** 1996 Sep 15;88(6):2081–92
Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin. Puri RN, et al. **Eur J Biochem** 1996 Mar 15; 236(3):862–70
Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation. Ali H, et al. **J Biol Chem** 1996 Feb 9;271(6):3200–6
Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin-stimulated human platelets. Banno Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14989–94
Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. Felding-Habermann B, et al. **J Biol Chem** 1996 Mar 8;271(10):5892–900
Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. Ichinohe T, et al. **J Biol Chem** 1995 Nov 24;270(47):28029–36
Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP. Puri RN, et al. **J Biol Chem** 1995 Oct 13;270(41):24482–8
Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. Roth M, et al. **J Exp Med** 1996 Jul 1; 184(1):191–201
Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures. Pasha R, et al. **Lab Invest** 1995 Sep;73(3):403–8
Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)
Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)
Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1. Gralnick HR, et al. **Thromb Res** 1996 Jan 1; 81(1):113–9
[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

PLATELET NUMBER see **PLATELET COUNT**

PLATELET-SPECIFIC ANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET STORAGE POOL DEFICIENCY

BLOOD

Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit--possible role of adenosine diphosphate. Weiss HJ, et al. **Blood** 1996 May 15;87(10):4214–22

THERAPY

Platelet storage pool deficiency in pregnancy. Edozien LC, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):220

VETERINARY

Inherited prolonged bleeding time and platelet storage pool deficiency in the subtle gray (sut) mouse. Swank RT, et al. **Lab Anim Sci** 1996 Feb;46(1):56–60
Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADP deficiency. Callan MB, et al. **Thromb Haemost** 1995 Sep; 74(3):949–53

PLATELET TRANSFORMING GROWTH FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

PLATELET TRANSFUSION

Intractable acute autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia successfully treated with vincristine-loaded platelet infusion [letter] Sigler E, et al. **Am J Hematol** 1995 Dec;50(4):313–5
Autologous platelet transfusion in alloimmunized patients with acute leukemia. Funke I, et al. **Ann Hematol** 1995 Oct;71(4):169–73
In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Klüter H, et al. **Ann Hematol** 1996 Aug;73(2):85–9
Prestorage leukocyte depletion is not necessarily required for the prevention of refractoriness to platelet transfusion [letter; comment] de Wolf J, et al. **Blood** 1995 Oct 15; 86(8):3263–4. Comment on: Blood 1995 Apr 1;85(7):1736–41.
The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Hussein MA, et al. **Blood** 1996 May 1;87(9):3959–62
Platelet function, coagulation tests, and cardiopulmonary bypass: lack of correlation between pre-operative and intra-operative whole blood lumiaggregometry and peri-operative blood loss in patients receiving autologous platelet-rich plasma. Irani MS, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):428–32
Platelet storage pool deficiency in pregnancy. Edozien LC, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):220
Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Alcorta I, et al. **Br J Haematol** 1996 Apr;93(1):220–4
A comparative study of the effect of autologous platelet-rich plasma and fresh autologous whole blood on haemostasis after cardiac surgery. Yamamoto K, et al. **Cardiovasc Surg** 1996 Feb;4(1):9–14
Platelet transfusion therapy for medical and surgical patients. Hussein MA, et al. **Cleve Clin J Med** 1996 Jul-Aug; 63(4):245–50 (44 ref.)
Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers. Fanning J, et al. **Gynecol Oncol** 1995 Nov;59(2):191–3
Participation of platelets in protection against larval Taenia taeniaeformis infection in mice. Kakuda T, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):295–7
Clinical perspectives of platelet transfusions: defining the optimal dose. Strauss RG. **J Clin Apheresis** 1995; 10(3):124–7
Refractoriness to platelet transfusions in children with acute leukemia. DeCoteau J, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):306–10
A controlled trial of tranexamic acid therapy for the

reduction of bleeding during treatment of acute myeloid leukemia. Shpilberg O, et al. **Leuk Lymphoma** 1995 Sep; 19(1–2):141–4

Phase II study shows that significantly fewer rhIL-11 treated patients require platelet transfusions [news] **Oncology (Huntingt)** 1995 Aug;9(8):785

Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Korobelnik JF, et al. **Ophthalmology** 1996 Apr;103(4):590–4

Platelet transfusion and alternatives to transfusion in patients with malignancy. Vaickus L, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):588–96 (86 ref.)

Platelet transfusion. Machin SJ, et al. **Thromb Haemost** 1995 Jul;74(1):246–52 (46 ref.)

Platelet transfusion therapy in newborn infants. Blanchette VS, et al. **Transfus Med Rev** 1995 Jul;9(3):215–30 (82 ref.)

A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Blundell EL, et al. **Transfusion** 1996 Apr;36(4):296–302

A very simple method for counting white cells in platelet units collected by apheresis [letter] Borzini P, et al. **Transfusion** 1995 Oct;35(10):884–5

Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Chao FC, et al. **Transfusion** 1996 Jun;36(6):536–42

Elimination of potential mutagenicity in platelet concentrates that are virally inactivated with psoralens and ultraviolet A light. Margolis-Nunno H, et al. **Transfusion** 1995 Oct; 35(10):855–62

HLA class I-eluted platelets as an alternative to HLA-matched platelets [see comments] Novotny VM, et al. **Transfusion** 1996 May;36(5):438–44. Comment in: Transfusion 1996 May;36(5):388–91.

HLA-reduced platelets to overcome platelet refractoriness: can lemons help? [editorial; comment] Sirchia G. **Transfusion** 1996 May;36(5):388–91. Comment on: Transfusion 1996 May;36(5):438–44.

Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test. Skogen B, et al. **Transfusion** 1995 Oct;35(10):832–6

Determinants of red cell, platelet, plasma, and cryoprecipitate transfusions during coronary artery bypass graft surgery: the Collaborative Hospital Transfusion Study. Surgenor DM, et al. **Transfusion** 1996 Jun;36(6):521–32

Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis. Eriksson L, et al. **Vox Sang** 1996;70(2):69–75

The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Win N, et al. **Vox Sang** 1995; 69(2):138–9

[Use of autologous blood, plasma and thrombocyte concentrates in heart surgery] Charvaát J, et al. **Cas Lek Cesk** 1995 Nov 1;134(21):686–8 (Eng. Abstr.) **(Cze)**

[Thrombocyte concentrates prepared from the buffy coat. A modified method] Gašová Z, et al. **Cas Lek Cesk** 1996 Jan 31;135(3):89–91 (Eng. Abstr.) **(Cze)**

[Effects of platelet-rich plasma on hemostasis and transfusion requirement in vascular surgery] Godet G, et al. **Ann Fr Anesth Reanim** 1995;14(3):265–70 (Eng. Abstr.) **(Fre)**

[Platelet-rich plasma (letter)] Waller C. **Ann Fr Anesth Reanim** 1995;14(6):536 **(Fre)**

[Morphologic and functional changes in thrombocytes after deep freezing with DMSO] Böck M, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):76–9 (Eng. Abstr.) **(Ger)**

[Post-transfusion rise in thrombocytes: observations in a hematologic-oncologic patient sample] Böck M, et al. **Infusionsther Transfusionsmed** 1995 Dec;22(6):350–4 (Eng. Abstr.) **(Ger)**

[Shear-induced platelet aggregation (SIPA) monitoring of hemostatic effect during platelet transfusion in a patient with Glanzmann's thrombasthenia: a comparison between SIPA and conventional platelet aggregation] Sugimoto M, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1332–5 (Eng. Abstr.) **(Jpn)**

[The need of a registry of HLA-phenotyped platelet donors (editorial)] Castro Izaguirre E, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):696–9 **(Spa)**

ADVERSE EFFECTS

Prevention of transfusion-associated cytomegalovirus infection. Practice parameter. American Society of Clinical Pathologists. Przepiorka D, et al. **Am J Clin Pathol** 1996 Aug;106(2):163–9

Post-transfusion acquired malaria complicating orthotopic liver transplantation. Talabiska DG, et al. **Am J Gastroenterol** 1996 Feb;91(2):376–9

Hepatitis C virus infection in multi-transfused children with haematological malignancy. Myers B, et al. **Br J Haematol** 1995 Oct;91(2):480–2

Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Wadhwa M, et al. **Br J Haematol** 1996 Apr;93(1):225–34

Anti-plasticizer specific IgE is present in the serum of transfused patients. Salkie ML, et al. **Clin Invest Med** 1995 Dec;18(6):419–23

Sepsis associated with blood transfusion [letter] Dave J, et al. **Lancet** 1996 Jun 22;347(9017):1773

Anaphylaxis associated with white-cell reduction filter [letter] Sano H, et al. **Lancet** 1996 Apr 13;347(9007):1053

Retrograde transmission of Proteus mirabilis during platelet transfusion and the use of arbitrarily primed polymerase chain reaction for bacteria typing in suspected cases of transfusion transmission of infection. Engstrand M, et al. **Transfusion** 1995 Oct;35(10):871–3

Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Silliman CC, et al. **Transfusion** 1996 Feb;36(2):133–9

Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter [letter] Takahashi TA, et al. **Transfusion** 1995 Nov-Dec;35(11):967

Febrile neutropenia contributes to underreporting of potential septic platelet transfusion reactions [letter] Olsen KE, et al. **Vox Sang** 1996;70(2):118

Anaphylactic reactions associated with anti-Chido Antibody following platelet transfusions [letter] Wibaut B, et al. **Vox Sang** 1995;69(2):150–1

[Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment] Helleberg C, et al. **Ugeskr Laeger** 1995 Sep 11; 157(37):5082–6 (40 ref.) (Eng. Abstr.) **(Dan)**

INSTRUMENTATION

Development and evaluation of a shipping system for platelet components. George VM, et al. **Transfusion** 1996 Apr; 36(4):335–8

METHODS

Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations [letter; comment] Galli AC, et al. **Anesth Analg** 1996 Apr;82(4):890. Comment on: Anesth Analg 1995 Aug;81(2):229–35.

Autologous platelet-rich plasmapheresis in repeat cardiac surgery [letter; comment] Pivalizza EG, et al. **Anesth Analg** 1996 Apr;82(4):885–6. Comment on: Anesth Analg 1995 Aug;81(2):229–35.

Effects of storage time on quantitative and qualitative platelet function after transfusion. Rosenfeld BA, et al. **Anesthesiology** 1995 Dec;83(6):1167–72

A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions. Sintnicolaas K, et al. **Br J Haematol** 1996 Mar; 92(4):1005–10

Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: combined strategies for reducing platelet activation during storage. Mrowiec ZR, et al. **Transfusion** 1996 Jan;36(1):5–10

STANDARDS

Blood center perspective: defining the ideal platelet concentrate. Axelrod FB, et al. **J Clin Apheresis** 1995; 10(3):128–30

A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Bertolini F, et al. **Transfusion** 1996 Feb; 36(2):128–32

PLATELETPHERESIS

In-line filtration of platelet concentrates obtained with the Omnix blood cell separator. Moog R, et al. **Transfus Med** 1995 Dec;5(4):293–6

Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis. Eriksson L, et al. **Vox Sang** 1996;70(2):69–75

[Preoperative plasma- and thrombocytapheresis in patients with ischemic heart disease] Shilov VV, et al. **Vestn Khir Im I I Grek** 1995;154(2):77–81 **(Rus)**

ADVERSE EFFECTS

Efficacy and safety of plateletpheresis by donors with low-normal platelet counts. Rogers RL, et al. **J Clin Apheresis** 1995;10(4):194–7

INSTRUMENTATION

Plateletpheresis-induced increase in platelet reactivity using different cell separators. Jung F, et al. **Infusionsther Transfusionsmed** 1995 Aug;22(4):237–43

Comparison of different protocols in plateletpheresis with the haemonetics MCS 3p blood cell separator with respect to parameters of product quality. Moog R, et al. **Infusionsther Transfusionsmed** 1995 Aug;22(4):244–8

Evaluation of the single needle procedure in plateletpheresis with the fresenius AS 104 blood cell separator. Moog R, et al. **J Clin Apheresis** 1995;10(2):90–5

[Thrombocyte collection with the A3p program using the blood cell separator Haemonetics MCS 3p (letter)] Moog R, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):60 **(Ger)**

METHODS

Research and development in the blood bank: efforts of a hospital donor center to improve efficiency of in-line leukocyte reduction filters for automated plateletpheresis. Drew MJ, et al. **J Clin Apheresis** 1995;10(2):76–80

Leukoreduced platelet apheresis production with a modified COBE spectra collection protocol. Kuriyan M, et al. **J Clin Apheresis** 1995;10(2):85–6

PLATELETS see **BLOOD PLATELETS**

PLATICHTHYS see **FLOUNDER**

PLATINUM

see related
ORGANOPLATINUM COMPOUNDS

Endosaccular treatment of inoperable intracranial aneurysms with platinum coils. Byrne JV, et al. **Br J Neurosurg** 1995; 9(5):585–92

Interlocking detachable platinum coils, a controlled embolization device: early clinical experience. Reidy JF, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr; 19(2):85–90

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

Comparison of gold versus platinum electrodes on myocardial lesion size using radiofrequency energy. Simmons WN, et al. **Pacing Clin Electrophysiol** 1996 Apr; 19(4 Pt 1):398–402

ADVERSE EFFECTS

Contact stomatitis due to palladium and platinum in dental alloys. Koch P, et al. **Contact Dermatitis** 1996 Apr; 34(4):253–7

ANALYSIS

Detection of platinum species in plant material. Messerschmidt J, et al. **Electrophoresis** 1995 May; 16(5):800–3

Quantitative X-ray imaging of labelled molecules in tissues and cells. Kirk RG, et al. **J Microsc** 1996 Aug;183 (Pt 2):181–6

[Detection of platinum concentration in mice on administrated cisplatin--compared total reflection X-ray fluorescence spectrometry (TRXRF) with atomic absorption spectrometry (AAS)] Sasaki A, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):639–41 **(Jpn)**

BLOOD

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Ghazal-Aswad S, et al. **Cancer Chemother Pharmacol** 1996;37(5):429–34

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Ma J, et al. **Cancer Chemother Pharmacol** 1996;38(4):391–4

CHEMISTRY

Third generation antitumor platinum(II) complexes of the [1-(fluoro/difluorophenyl)-2-phenylethylenediamine]platinum(II) type. Gust R, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):595–603

Investigation of thiourea activated polyglutaraldehyde with bound Ag(I) or Pt(II) as an alternative to avidin for immobilizing biotin conjugates. Kim DH, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(5):555–63

Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(II), and intercalators. Boudvillain M, et al. **Met Ions Biol Syst** 1996; 33:87–104 (44 ref.)

PHARMACOKINETICS

Long-term pharmacokinetic behavior of platinum after cisplatin administration. Gamelin E, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):97–102

Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Johnsson A, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):23–31

Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Los G, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):150–4

THERAPEUTIC USE

Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Barakat RR, et al. **Gynecol Oncol** 1995 Dec;59(3):390–3

PLATINUM BLACK see **PLATINUM**

PLATINUM COMPOUNDS

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240-5 (26 ref.)

ADMINISTRATION & DOSAGE

[The use of polyplatilen in patients with malignant tumors of the skin and locomotor apparatus] Shalimov SA, et al. **Klin Khir** 1995;(6):4-6 **(Rus)**

[Effectiveness of free and liposomal forms of platinum and anthracycline antibiotics for hepatic metastasis of GA-1 and P-388 tumors in mice] Kaledin VI, et al. **Vopr Onkol** 1996;42(3):64-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Absence of relationship between degree of nonspecific and specific bronchial responsiveness in occupational asthma due to platinum salts. Merget R, et al. **Eur Respir J** 1996 Feb;9(2):211-6

Platinum salt sensitivity in refinery workers: incidence and effects of smoking and exposure. Calverley AE, et al. **Occup Environ Med** 1995 Oct;52(10):661-6

Allergy to complex platinum salts: A historical prospective cohort study. Niezborala M, et al. **Occup Environ Med** 1996 Apr;53(4):252-7

CHEMICAL SYNTHESIS

Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines. Anderson WK, et al. **J Med Chem** 1995 Sep 15;38(19):3789-97

CHEMISTRY

Third generation antitumor platinum(II) complexes of the [1-(fluoro/difluorophenyl)-2-phenylethylenediamine]platinum(II) type. Gust R, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):595-603

Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Farrell N, et al. **Biochemistry** 1995 Nov 28;34(47):145480-6

METABOLISM

Kinetic analysis of the reaction between d(TTGGCCAA) and [Pt(NH3)3(H2O)]2+ by enzymatic degradation of the products and ESI and MALDI mass spectrometries. Gonnet F, et al. **J Mass Spectrom** 1996 Jul;31(7):802-9

PHARMACOLOGY

Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Coluccia M, et al. **Chem Biol Interact** 1995 Dec 22;98(3):251-66

Synthesis, characterization, and DNA modification induced by a novel Pt-berenil compound with cytotoxic activity. González VM, et al. **J Inorg Biochem** 1996 Jul;63(1):57-68

A circular dichroism study of ethidium bromide binding to Z-DNA induced by dinuclear platinum complexes. Wu PK, et al. **J Inorg Biochem** 1996 Jul;63(1):9-18

Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines. Anderson WK, et al. **J Med Chem** 1995 Sep 15;38(19):3789-97

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242-52 (100 ref.)

THERAPEUTIC USE

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Lund B, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:61-2

Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Kusumoto T, et al. **Int J Hyperthermia** 1995 Jul-Aug;11(4):575-86

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242-52 (100 ref.)

PLATINUM COMPOUNDS, INORGANIC see **PLATINUM COMPOUNDS**

PLATINUM DIAMMINODICHLORIDE see **CISPLATIN**

PLATYBASIA

see related
ARNOLD-CHIARI DEFORMITY

ETIOLOGY

Traumatic basilar impression: case report. Kuroiwa T, et al. **Surg Neurol** 1995 Jul;44(1):31-2

GENETICS

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504-12 (48 ref.)

PLATYFISH see **CYPRINODONTIFORMES**

PLATYHELMINTHS

Vermiforms. Morowitz HJ. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):33-4

PHYSIOLOGY

Platyhelminth FMRFamide-related peptides. Shaw C, et al. **Int J Parasitol** 1996 Apr;26(4):335-45 (59 ref.)

ULTRASTRUCTURE

Ultrastructure of the gut caecal epithelium of Pricea multae (Monogenea: Polyopisthocotylea). Brennan GP, et al. **Parasitol Res** 1996;82(4):312-8

PLATYPUS

BLOOD

Hematological changes in the platypus (Ornithorhynchus anatinus) following capture. Whittington RJ, et al. **J Wildl Dis** 1995 Jul;31(3):386-90

PHYSIOLOGY

Morphology of the monotreme organ of Corti and macula lagena. Ladhams A, et al. **J Comp Neurol** 1996 Mar 4; 366(2):335-47

PLATYRRHINA see **CEBIDAE**

PLAY AND PLAYTHINGS

Motivating staff: the pain-free week. Harris P, et al. **Am J Nurs** 1996 Jul;96(7):23

Near-hanging caused by a toy necklace. Chin N, et al. **Ann Emerg Med** 1995 Oct;26(4):522-5

You can be in Jeopardy. Ford DA, et al. **AORN J** 1996 Mar;63(3):583-9

"Jumping beans" are almost identical with medicines [letter] Hewitt M. **BMJ** 1996 Mar 9;312(7031):638

Mental rotation at 7 years: relations with prenatal testosterone levels and spatial play experiences. Grimshaw GM, et al. **Brain Cogn** 1995 Oct;29(1):85-100

Migration of some toxic metals from crayons and water colors. Rastogi SC, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):527-33

Does play equipment conform to the Canadian standard? Lesage D, et al. **Can J Public Health** 1995 Jul-Aug; 86(4):279-83

Children's gender-based reasoning about toys. Martin CL, et al. **Child Dev** 1995 Oct;66(5):1453-71

The association between language and symbolic play at two years: evidence from deaf toddlers. Spencer PE. **Child Dev** 1996 Jun;67(3):867-76

Individual differences in young children's pretend play with mother and sibling: links to relationships and understanding of other people's feelings and beliefs. Youngblade LM, et al. **Child Dev** 1995 Oct;66(5):1472-92

A play-based methodology for assessing idiom comprehension in children with semantic-pragmatic difficulties. Kerbel D, et al. **Eur J Disord Commun** 1996; 31(1):65-75

Early modeling of drinking behavior by Native American elementary school children playing drunk. Mail PD. **Int J Addict** 1995 Jul;30(9):1187-97

Distorting reality for children: body size proportions of Barbie and Ken dolls. Brownell KD, et al. **Int J Eat Disord** 1995 Nov;18(3):295-8

Russian roulette: a case of questions not asked? Denny KM. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1682-3

The play approach to learning in the context of families and schools: an alternative paradigm for nutrition and fitness education in the 21st century. Rickard KA, et al. **J Am Diet Assoc** 1995 Oct;95(10):1121-6

Developing a research strategy for child accident prevention via a cross-cultural picture card game. Hugo J. **J Audiov Media Med** 1995 Mar;18(1):11-5

Generativity in the play of young people with autism. Lewis V, et al. **J Autism Dev Disord** 1995 Apr;25(2):105-21

Teaching symbolic play skills to children with autism using pivotal response training. Stahmer AC. **J Autism Dev Disord** 1995 Apr;25(2):123-41

What's real in children's fantasy play?: fantasy play across the transition to becoming a sibling. Kramer L. **J Child Psychol Psychiatry** 1996 Mar;37(3):329-37

Maternal education and maternal responsiveness as predictors of play competence in low birth weight, premature infants: a preliminary report. Fewell RR, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):100-4

Use of the Zaadi Doll to provide health education to children and families. O'Brien E. **J Pediatr Nurs** 1995 Aug; 10(4):266-7

Lego therapy. Altman A, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):48-9

Designing the death out of balloons [editorial; comment] Baker SP, et al. **JAMA** 1995 Dec 13;274(22):1805. Comment on: JAMA 1995 Dec 13;274(22):1763-6.

Reducing choking deaths in children [letter; comment] Flynn D. **JAMA** 1996 May 1;275(17):1313; discussion 1314. Comment on: JAMA 1995 Dec 13;274(22):1763-6.

Reducing choking deaths in children [letter; comment] Kerr HD. **JAMA** 1996 May 1;275(17):1313-4. Comment on: JAMA 1995 Dec 13;274(22):1763-6.

Lego asthma [letter] Tseng R, et al. **N Engl J Med** 1996 Feb 8;334(6):406-7

Pool cue chalk: a source of environmental lead. Miller MB, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):916-7

Enactment and play following medical trauma. An analytic case study. Goldberger M. **Psychoanal Study Child** 1995; 50:252-71

Psychological science and the use of anatomically detailed dolls in child sexual-abuse assessments. Koocher GP, et al. **Psychol Bull** 1995 Sep;118(2):199-222 (160 ref.)

Ring bubbles of dolphins. Marten K, et al. **Sci Am** 1996 Aug; 275(2):82-7

The air gun: toy or weapon? Friedman D, et al. **South Med J** 1996 May;89(5):475-8

[Accidents caused by inflatable bouncers in 0-19 year-olds in Denmark in 1993] Kirketerp-Møller K, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2251-3 (Eng. Abstr.) **(Dan)**

[Asphyxia caused by flippos (letter)] Bataille MR. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1704 **(Dut)**

[Choking due to 'flippos' (letter] Spierings P. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1133-4 **(Dut)**

[Guignol or the comedian's paradox] Marnier JP, et al. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):14-20 (Eng. Abstr.) **(Fre)**

[Reflex epilepsy with seizures induced by mental calculation, playing chess and scrabble] Rey M, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):116-20 (Eng. Abstr.) **(Fre)**

INJURIES

Small parts aspiration, ingestion, and choking in small children: findings of the small parts research project. Rider G, et al. **Risk Anal** 1996 Jun;16(3):321-30

PSYCHOLOGY

The answer is, "no! chess for fun". Hahn F. **Mo Med** 1995 Sep;92(9):564-5

PLAY THERAPY

The phallic child: its emergence and meaning in a clinical setting. Hunter J. **Am J Psychother** 1995 Summer; 49(3):428-45

Effects of sociodramatic play training on children with autism. Thorp DM, et al. **J Autism Dev Disord** 1995 Jun; 25(3):265-82

Lego therapy. Altman A, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):48-9

[Guignol or the comedian's paradox] Marnier JP, et al. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):14-20 (Eng. Abstr.) **(Fre)**

METHODS

Use of the Zaadi Doll to provide health education to children and families. O'Brien E. **J Pediatr Nurs** 1995 Aug; 10(4):266-7

The children of divorce, and techniques of play therapy. Alger I. **Psychiatr Serv** 1995 Oct;46(10):1003-4

PLEASURE-PAIN PRINCIPLE

[Anhedonia and sensation seeking] Loas G, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):524-7; discussion 527-8 (Eng. Abstr.) **(Fre)**

[Historical review of the concept of anhedonia] Olivares Diez JM. **Acta Psiquiatr Psicol Am Lat** 1995 May;41(2):148-61 (Eng. Abstr.) **(Spa)**

PLEROCERCOID LARVAE see **SPARGANUM**

PLESIOMONAS

Plesiomonas shigelloides: an unusual cause of diarrhea. Soweid AM, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2235-6

Aetiological role of Aeromonas and Plesiomonas species in human diarrhoeal illness in Nigeria [letter] Agbodaze D. **Cent Afr J Med** 1996 May;42(5):156-7

Plesiomonas shigelloides septicemia in a patient with primary hemochromatosis [letter] Delforge ML, et al. **Clin Infect Dis** 1995 Sep;21(3):692-3

Enteric Plesiomonas shigelloides infections in Finnish patients. Rautelin H, et al. **Scand J Infect Dis** 1995; 27(5):495-8

Migratory polyarthritis associated with Plesiomonas shigelloides infection. Gupta S. **Scand J Rheumatol** 1995; 24(5):323-5

CLASSIFICATION

[The importance of serotyping Plesiomonas shigelloides] Aldová E. **Epidemiol Mikrobiol Imunol** 1995 Dec; 44(4):147-54 (Eng. Abstr.) **(Cze)**

IMMUNOLOGY

Anti-Plesiomonas shigelloides agglutinating and complement-fixing antibody titres in normal individuals and diarrhoeal patients in Edo State, Nigeria. Ndip RN, et al. **J Diarrhoeal Dis Res** 1996 Mar;14(1):41-3

ISOLATION & PURIFICATION

Occurrence of Plesiomonas shigelloides in water environments of Rio de Janeiro city. de Mondino SS, et al. **Mem Inst Oswaldo Cruz** 1995 Jan-Feb;90(1):1-4

Antimicrobial therapy in Plesiomonas shigelloides-associated diarrhea in Thai children. Visitsunthorn N, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):86-90

PLESIOMONAS SHIGELLOIDES see **PLESIOMONAS**

PLETHYSMOGRAPHY

Evaluation of the peripheral circulatory status of the neonate during homeothermal adjustment by plethysmo-time-interval. Oishi M, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):147-50

Comparison of respiratory inductance plethysmography with thoracoabdominal compression in bronchial challenges in infants and young children. Springer C, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):665-9

Plethysmography: safety, effectiveness, and clinical utility in diagnosing vascular disease. Graham AA. **Health Technol Assess** 1996;(7):1-46 (182 ref.)

Cardiovascular effects of dobutamine stress testing in women with suspected coronary artery disease. Blomstrand P, et al. **Heart** 1996 May;75(5):463-8

INSTRUMENTATION

Plethysmography with optoelectronic sensors: comparison with mercury strain gauge plethysmography. Louisy F, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1191-7

Evaluation of a new air displacement plethysmograph for measuring human body composition. McCrory MA, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1686-91

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37-43 (77 ref.) **(Ger)**

[Microwave volumetry of the extremities: a technical measuring alternative to the noninvasive venous occlusion test] Blazek V, et al. **Biomed Tech (Berl)** 1995 Jul-Aug; 40(7-8):200-4 (Eng. Abstr.) **(Ger)**

METHODS

Non-invasive assessment of unstimulated forearm arterial compliance in human subjects. Impaired vasoreactivity in hypercholesterolaemia. Baldassarre D, et al. **Eur J Clin Invest** 1995 Nov;25(11):859-66

Investigating the origin of cyclic changes in limb volume using mercury-in-silastic strain gauge plethysmography in man. Christ F, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):259-72

A new air displacement method for the determination of human body composition. Dempster P, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1692-7

A critical assessment of uncalibrated respiratory inductance plethysmography (Respitrace) for the measurement of tidal breathing parameters in newborns and infants. Jackson E, et al. **Pediatr Pulmonol** 1995 Aug;20(2):119-24

Respiratory inductive plethysmography in the evaluation of lower airway obstruction during methacholine challenge in infants. Rusconi F, et al. **Pediatr Pulmonol** 1995 Dec; 20(6):396-402

PLETHYSMOGRAPHY, IMPEDANCE

Cost-effectiveness of pulmonary embolism diagnosis [letter; comment] Hampson NB. **Arch Intern Med** 1996 Jul 22; 156(14):1589. Comment on: Arch Intern Med 1996 Jan 8;156(1):68-72.

Comments on the interpretation of tissue impedance measurements during hemodialysis. Verheij R, et al. **Blood Purif** 1996;14(1):8-14

Insonation and impedance analysis in graft surveillance. Woodburn KR, et al. **Br J Surg** 1995 Sep;82(9):1222-5

Comparison of the accuracy of impedance plethysmography and compression ultrasonography in outpatients with clinically suspected deep vein thrombosis. A two centre paired-design prospective trial. Wells PS, et al. **Thromb Haemost** 1995 Dec;74(6):1423-7

ECONOMICS

Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Hull RD, et al. **Thromb Haemost** 1995 Jul;74(1):189-96

INSTRUMENTATION

Clinical application of ultrasonic blood rheography for vertigo. Fujita N, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:148-52

Pulse wave numerical analysis. Puls RJ, et al. **Med Hypotheses** 1996 Mar;46(3):276-80

[Device for rheographic studies] Losev IR, et al. **Med Tekh** 1996 Mar-Apr;(2):34 **(Rus)**

[The RA6-02 rheoanalyzer for studying systemic hemodynamics by the methods of tetrapolar and focusing rheography] Odinets GS. **Med Tekh** 1995 Nov-Dec; (6):21-4 (Eng. Abstr.) **(Rus)**

METHODS

Reduction of motion artifacts using a two-frequency impedance plethysmograph and adaptive filtering. Rosell J, et al. **IEEE Trans Biomed Eng** 1995 Oct;42(10):1044-8

Transbronchial regional electroplethysmography of the lungs. Mazhbich BI. **J Clin Monit** 1995 Jul;11(4):225-36

Voltage clamp method for the use of electrical admittance plethysmography in human body segments. Yamakoshi K, et al. **Med Biol Eng Comput** 1995 Sep;33(5):740-3

STANDARDS

IPG screening for asymptomatic DVT [letter; comment] Chong D. **Arch Phys Med Rehabil** 1996 Feb;77(2):211. Comment on: Arch Phys Med Rehabil 1995 Sep;76(9):833-9.

PLETHYSMOGRAPHY, IMPEDANCE, TRANSTHORACIC see **CARDIOGRAPHY, IMPEDANCE**

PLETHYSMOGRAPHY, WHOLE BODY

[Improved practical roentgenologic diagnosis of pulmonary emphysema using diagnostic lung function methods] Walther D, et al. **Rontgenpraxis** 1995 Dec;48(12):342-8 **(Ger)**

PLEURA

see related
PNEUMONOLYSIS

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488-93 (50 ref.)

Is flexible fiberoptic pleuroscopy more cost-effective compared with VATS? [letter; comment] Yim AP. **Chest** 1995 Oct;108(4):1179-80. Comment on: Chest 1995 Feb;107(2):424-9.

Improved technique for fiberoptic pleuroscopy [letter] Yim AP. **Chest** 1996 Jun;109(6):1667

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425-8 (41 ref.) . Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429-31.

Con: unreliable benefit after thoracotomy--epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429-31 (20 ref.) . Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425-8.

New regimen for interpleural block in children. Giaufré E, et al. **Paediatr Anaesth** 1995;5(2):125-8

[Pleural drainage vs video-assisted minimally invasive surgery in the treatment of spontaneous pneumothorax. A retrospective study] Sortini A, et al. **Minerva Chir** 1995 Nov;50(11):973-7 (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Ruptured bronchial artery aneurysm associated with pleural telangiectasis and tortuous portal obstruction: report of a case. Ishizaki N, et al. **Surg Today** 1995;25(9):852-4

CHEMISTRY

Lectin binding sites and immunocytochemical characterization of normal pleural mesothelium. Kortsik CS, et al. **Gen Diagn Pathol** 1995 Oct;141(2):141-6

CYTOLOGY

Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Fujino S, et al. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):508-15

DRUG EFFECTS

Effects of cigarette smoke and asbestos on airway, vascular and mesothelial cell proliferation. Sekhon H, et al. **Int J Exp Pathol** 1995 Dec;76(6):411-8

EMBRYOLOGY

Development of the human fetal visceral pleura. An ultrastructural study. Michailova KN. **Anat Anz** 1996 Jan; 178(1):91-9

IMMUNOLOGY

Alloxan diabetes reduces pleural mast cell numbers and the subsequent eosinophil influx induced by allergen in sensitized rats. Diaz BL, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):36-43

INJURIES

Pneumothorax during laparoscopic Nissen fundoplication. Yee R, et al. **Anaesth Intensive Care** 1996 Feb;24(1):93-6

Lung injury with pleuropericardial rupture successfully treated by video-assisted thoracoscopy: case report [see comments] Hermansson U, et al. **J Trauma** 1996 Jun; 40(6):1024-5. Comment in: J Trauma 1996 Jun;40(6):1047.

Is radiographic evaluation of the chest necessary following flank surgery? Poore RE, et al. **J Urol** 1996 Mar; 155(3):849-51

METABOLISM

Interpleural local anaesthesia: anatomical basis for mechanism of action. McKenzie AG, et al. **Br J Anaesth** 1996 Feb; 76(2):297-9

Characterization of proteoglycans produced by rat pleural mesothelial cells in vitro. Milligan SA, et al. **Exp Lung Res** 1995 Jul-Aug;21(4):559-75

Nitric oxide synthesis by rat pleural mesothelial cells: induction by growth factors and lipopolysaccharide. Owens MW, et al. **Exp Lung Res** 1995 Sep-Oct; 21(5):731-42

Nitric oxide-dependent N-nitrosating activity of rat pleural mesothelial cells. Owens MW, et al. **Free Radic Res** 1995 Oct;23(4):371-8

Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin alpha v beta 5. Boylan AM, et al. **J Clin Invest** 1995 Oct; 96(4):1987-2001

Synthesis of poly(ADP-ribose) in asbestos treated rat pleural mesothelial cells in culture. Dong HY, et al. **Mutat Res** 1995 Oct;331(2):197-204

PATHOLOGY

Calcifying fibrous pseudotumor of pleura. A report of three cases of a newly described entity involving the pleura. Pinkard NB, et al. **Am J Clin Pathol** 1996 Feb;105(2):189-94

Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Boutin C, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):444-9

Causes of pulmonary impairment in asbestos-exposed individuals with diffuse pleural thickening. Kee ST, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):789-93

A modified Abrams needle biopsy technique. Kirsch CM, et al. **Chest** 1995 Oct;108(4):982-6

Extensive idiopathic benign bilateral asynchronous pleural fibrosis. Lee-Chiong TL Jr, et al. **Chest** 1996 Feb; 109(2):564-5

False positive pleural biopsy and high CA125 levels in serum and pleural effusion in systemic lupus erythematosus. Yucel AE, et al. **Clin Rheumatol** 1996 Mar;15(2):197-9

The mesothelial cell and its role in asbestos-induced pleural injury. Kuwahara M, et al. **Int J Exp Pathol** 1995 Jun; 76(3):163-70 (58 ref.)

Diagnostic evaluation of pleural effusion and the role of needle pleural biopsy. Hussain SF, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):127-30

Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia. Bogers J, et al. **Pathol Res Pract** 1996 Jan;192(1):10-4

[Correlated multiple parameters in pleural effusion with pathology of pleurae for differential diagnosis of tuberculous and carcinomatous pleuritis] Yu S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):88-90, 128 (Eng. Abstr.) **(Chi)**

[Correlation between sensitivity of the cytogenetic and cytological analysis and thoracoscopic findings in the study of malignant pleural effusions] Vázquez Oliva R, et al. **Arch Bronconeumol** 1995 Nov;31(9):437-42 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Inhibition of factor Xa-mediated procoagulant activity of human lung fibroblasts and pleural mesothelial cells. Kumar A, et al. **Eur Respir J** 1995 Dec;8(12):2038-45

Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Bartlett RP, et al. **Mayo Clin Proc** 1995 Dec;70(12):1161-4

PHYSIOPATHOLOGY

Evaluation of life expectancy in selection of patients undergoing percutaneous cervical cordotomy or subarachnoid phenol block for pain control of costopleural syndrome [letter; comment] Orlandini G. **Pain** 1995 Jun; 61(3):492-3. Comment on: Pain 1994 Sep;58(3):325-30.

RADIOGRAPHY

Quantification of pneumothorax size on chest radiographs using interpleural distances: regression analysis based on volume measurements from helical CT. Collins CD, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1127-30

Relationship between retroperitoneal compartments and pleural sinus [letter; comment] Marsman JW. **AJR Am J Roentgenol** 1996 Mar;166(3):722-3. Comment on: AJR Am J Roentgenol 1995 May;164(5):1173-8.

Interventional radiology of the pleural space [letter; comment] Joseph AE, et al. **Clin Radiol** 1995 Nov; 50(11):810. Comment on: Clin Radiol 1995 Apr;50(4):205-14.

[The double band sign: pleural tuberculosis in x-ray computed tomography] Poey C, et al. **J Radiol** 1995 Aug;

76(8):511–2 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Cardiac and pleuropulmonary AL amyloid imaging with technetium–99m labelled aprotinin. Aprile C, et al. **Eur J Nucl Med** 1995 Dec;22(12):1393–401

SURGERY

Video–assisted thoracoscopic pleurectomy in the treatment of recurrent spontaneous pneumothorax. Rämö OJ, et al. **Ann Chir Gynaecol** 1995;84(3):272–5

Pleural slide technique for covering the left bronchial stump [letter; comment] Berrisford RG, et al. **Ann Thorac Surg** 1996 Jun;61(6):1876–7. Comment on: Ann Thorac Surg 1995 Sep;60(3):729–33.

Opening the pleura during internal mammary artery harvesting: advantages and disadvantages. Ali IM, et al. **Can J Surg** 1996 Feb;39(1):42–5

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long–term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. Sauter ER, et al. **J Surg Oncol** 1995 Oct;60(2):100–5

Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. Shimizu J, et al. **J Surg Oncol** 1996 Jan;61(1):1–6

[Prognosis of the surgical treatment for non–Hodgkin lymphoma originating from chronic tuberculous empyema—analysis of 11 cases with pleuropneumonectomy] Nakajima Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):484–92 (Eng. Abstr.) **(Jpn)**

[A syringe attachment for pleural puncture] Storozhuk VT, et al. **Vestn Khir Im I I Grek** 1995;154(3):79 **(Rus)**

[Pulmonary function after decortication of the lung] Ilić N, et al. **Lijec Vjesn** 1995 Nov–Dec;117(11–12):271–3 (Eng. Abstr.) **(Scr)**

ULTRASONOGRAPHY

Ultrasonography of the lungs, pleura, and mediastinum in healthy cows. Braun U, et al. **Am J Vet Res** 1996 Apr; 57(4):432–8

"Fluid color" sign: a useful indicator for discrimination between pleural thickening and pleural effusion. Wu RG, et al. **J Ultrasound Med** 1995 Oct;14(10):767–9

ULTRASTRUCTURE

Role of fibre characteristics on cytotoxicity and induction of anaphase/telophase aberrations in rat pleural mesothelial cells in vitro: correlations with in vivo animal findings. Yegles M, et al. **Carcinogenesis** 1995 Nov;16(11):2751–8

Differential expression of the microspike–associated protein moesin in human tissues. Schwartz–Albiez R, et al. **Eur J Cell Biol** 1995 Jul;67(3):189–98

PLEURAL DISEASES

Asbestos–related bilateral diffuse pleural thickening: natural history of radiographic and lung function abnormalities. Yates DH, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):301–6

Subarachnoid–pleural fistula as a complication of the lateral–extracavitary approach to thoracic intraspinal neurinoma. Díaz P, et al. **Spine** 1995 Jul 1;20(13):1515–8

New developments in asbestos–related pleural disease. Rudd RM. **Thorax** 1996 Feb;51(2):210–6 (59 ref.)

[Pleural amyloidosis. Apropos of a case and review of the literature] Quinquenel ML, et al. **Rev Pneumol Clin** 1996; 52(1):39–41 (12 ref.) (Eng. Abstr.) **(Fre)**

[Pleuro–pericardial cysts. Case reports and clinical–diagnostic as well as therapeutic considerations] Chisari A, et al. **Minerva Chir** 1995 Dec;50(12):1057–63 (Eng. Abstr.) **(Ita)**

[Catamenial pneumothorax (letter)] Abu–Shams K, et al. **An Med Interna** 1995 Jun;12(6):309–10 **(Spa)**

CHEMICALLY INDUCED

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

Occurrence of pleural plaques in workers with exposure to mineral wool. Järvholm B, et al. **Int Arch Occup Environ Health** 1995;67(5):343–6

COMPLICATIONS

Gastropleural fistula: an unusual cause of intractable postoperative nausea and vomiting. Biswas IH, et al. **Anesth Analg** 1996 Jul;83(1):186–8

Catamenial pneumothorax caused by thoracic endometriosis. Van Schil PE, et al. **Ann Thorac Surg** 1996 Aug;62(2):585–6

Recurrent left pleural effusion in a 44–year–old woman with a history of alcohol abuse. Iglesias JI, et al. **Chest** 1996 Aug;110(2):547–9

DIAGNOSIS

Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. Falaschi F, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):963–8

Medical thoracoscopy. Technical details. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):479–86 (27 ref.)

Medical thoracoscopy. Role in pleural and lung diseases. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):487–96 (85 ref.)

A case of bronchopleural fistula detected by monitoring plasma endothelin–1. Yamashita J, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):56–7

[Intrathoracic splenosis: a rare differential diagnosis of pleural space–occupying growth] Nücken HJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Dec;163(6):538–9 **(Ger)**

[Principles for assessment and diagnosis of work–related pulmonary and pleural diseases] Aasen TB, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):739–41 (23 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

Hemothorax after Lupron therapy of a patient with pleural endometriosis—a case report and literature review. Margolis MT, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):53–5

EPIDEMIOLOGY

[Epidemiologic survey of pleural plaques among inhabitants of Matsubase exposed to asbestos] Hiraoka T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):385–91 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

The pleural space and organ transplantation. Judson MA, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1153–65 (182 ref.)

Diagnosis of postpneumonectomy bronchopleural fistula using ventilation scintigraphy. Pigula FA, et al. **Ann Thorac Surg** 1995 Dec;60(6):1812–4

Descending necrotizing mediastinitis causing pleuroesophageal fistula. Successful treatment by combined transcervical and pleural drainage. Kruyt PM, et al. **Chest** 1996 May;109(5):1404–7

Extrapleural haematoma secondary to blunt chest trauma [letter] Murley RS, et al. **Eur J Cardiothorac Surg** 1996; 10(3):223

Right post pneumonectomy pleural empyema caused by an esophagopleural fistula due to an esophageal carcinoma. Oliaro A, et al. **J Cardiovasc Surg (Torino)** 1995 Dec; 36(6):607–9

Neonatal radiology casebook. Bronchopleural fistula and pneumothorax: complications of transpyloric feeding tube insertion. Karlowicz MG, et al. **J Perinatol** 1995 Sep–Oct; 15(5):432–3

[Pyoderma gangrenosum, subcorneal IgA pustulosis and recurrent neutrophilic pleural and pulmonary diseases in a patient with IgA gammopathy] Cartier H, et al. **Ann Dermatol Venereol** 1995;122(3):97–101 (Eng. Abstr.) **(Fre)**

[Pleuropulmonary manifestations of rheumatoid arthritis] Crestani B, et al. **Presse Med** 1996 May 18;25(17):807–12 (25 ref.) (Eng. Abstr.) **(Fre)**

[A case of solitary tuberculosis in lower lung field showing marked pleural indentation complicated with chronic renal failure with special reference to mechanism of of formation of pleural retraction] Hirata S, et al. **Kekkaku** 1995 Jul; 70(7):439–44 (Eng. Abstr.) **(Jpn)**

[Bronchopleural fistula following the use of automatic stapling devices for lung cancer] Motohiro A, et al. **Kyobu Geka** 1995 Nov;48(12):1016–8 (Eng. Abstr.) **(Jpn)**

[A case report of a bronchogenic cyst of the diaphragm causing rupturing into the left pleural cavity] Izumi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):208–11 (Eng. Abstr.) **(Jpn)**

[Pleural cryptococcosis in patients with human immunodeficiency virus infection] Mauri M, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):380–2 (Eng. Abstr.) **(Spa)**

METABOLISM

Immunoreactivity for c–fos and c–myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non–neoplastic mesothelium of the pleura. Ramael M, et al. **Histol Histopathol** 1995 Jul; 10(3):639–43

MICROBIOLOGY

Pleuropulmonary infection with chest wall infiltration by Eikenella corrodens. Killen JW, et al. **Thorax** 1996 Aug; 51(8):871–2

PATHOLOGY

Calcifying fibrous pseudotumor of pleura. A report of three cases of a newly described entity involving the pleura. Pinkard NB, et al. **Am J Clin Pathol** 1996 Feb;105(2):189–94

[Ultrastructural findings in pleural cysts in spontaneous pneumothorax] Becker HP, et al. **Chirurg** 1995 Aug; 66(8):787–93 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Use of a pericardial fat pad flap for preventing bronchopleural fistula: an experimental study focusing on the angiogenesis and cytokine production of the fat pad. Ichinose Y, et al. **Surg Today** 1995;25(9):811–5

RADIOGRAPHY

Re: Bronchopleural–subarachnoid fistula manifesting as intracranial gas on CT scans [letter; comment] Lerner EJ. **AJR Am J Roentgenol** 1996 Jun;166(6):1497. Comment on: AJR Am J Roentgenol 1995 Dec;165(6):1364–5.

Bronchopleural–subarachnoid fistula manifesting as intracranial gas on CT scans [see comments] Smith DN, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1364–5. Comment in: AJR Am J Roentgenol 1996 Jun;166(6):1497.

Peripheral bronchopleural fistulas: CT imaging features. Stern EJ, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):117–20

Pancreaticopleural fistula visualized by computed tomographic scan combined with endoscopic retrograde pancreatography. Kawashima A, et al. **Intern Med** 1996 Jan;35(1):30–2

Calcifying fibrous pseudotumor of pleura: radiologic features in three cases. Erasmus JJ, et al. **J Comput Assist Tomogr** 1996 Sep–Oct;20(5):763–5

Imaging of pleural diseases. Maffessanti M, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):138–44 (22 ref.)

Clinical problem–solving: diverted by the chief complaint [letter] Anderson K. **N Engl J Med** 1995 Nov 23; 333(21):1425

[Roentgen findings in pleural diseases] Uhrmeister P, et al. **Internist (Berl)** 1995 Sep;36(9):937–47; quiz 948 (0 ref.) **(Ger)**

RADIONUCLIDE IMAGING

Diagnosis of postpneumonectomy bronchopleural fistula using ventilation scintigraphy. Pigula FA, et al. **Ann Thorac Surg** 1995 Dec;60(6):1812–4

Localization of a bronchopleural fistula in a postpneumonectomy patient using ventilation scintigraphy. Ali SA, et al. **Clin Nucl Med** 1995 Oct;20(10):943

Pleural leak localization with Tc–99m pentetate aerosol in an AIDS patient with Pneumocystis carinii pneumonia. Cartland JP, et al. **Clin Nucl Med** 1996 May;21(5):408–9

SURGERY

Role of thoracoscopy (VATS) in pleural and pulmonary pathology. Van Schil P, et al. **Acta Chir Belg** 1996 Feb; 96(1):23–7 (28 ref.)

Closure of a postpneumonectomy main bronchus fistula using video–assisted mediastinal surgery. Azorin JF, et al. **Chest** 1996 Apr;109(4):1097–8

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

Bronchopleural fistula after pneumonectomy for lung cancer. al–Kattan K, et al. **Eur J Cardiothorac Surg** 1995; 9(9):479–82

Transsternal transpericardial operations in the treatment of bronchopleural fistulas after pneumonectomy. Stamatis G, et al. **Eur J Cardiothorac Surg** 1996;10(2):83–6

Previous intrapleural procedures do not adversely affect lung transplantation. Dusmet M, et al. **J Heart Lung Transplant** 1996 Mar;15(3):249–54

Bronchopleural fistula after pneumonectomy: repair and prevention with a deepithelialized latissimus dorsi myocutaneous island flap. Zoetmulder FA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1139–41

[Endoscopic treatment of a pancreatic–pleural fistula. Apropos of a case] Duchmann JC, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):837–40 (Eng. Abstr.) **(Fre)**

[Closure of bronchopleural fistula by video–assisted mediastinal surgery after pneumonectomy] Azorin JF, et al. **Presse Med** 1996 May 18;25(17):805–6 (Eng. Abstr.) **(Fre)**

[Omentoplasty in bronchopleural fistulas after pneumonectomy] Myrmel T, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3627–8 (Eng. Abstr.) **(Nor)**

THERAPY

Bronchopleural fistula: successful selective bronchial occlusion with a Fogarty's catheter in a preterm infant. Mosca F, et al. **Acta Paediatr** 1995 Sep;84(9):1079–82

Bronchopleural fistula and mechanical ventilation: a simple technique of management? Chaddouk EG. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1141–3

Respiratory alkalosis caused by assist control mechanical ventilation in a patient with a bronchopleural fistula. Pruitt RF, et al. **J Trauma** 1996 Mar;40(3):481–2

The needle–wire–dilator technique for the insertion of chest tubes in pediatric patients. Ahmed MY, et al. **Pediatr Emerg Care** 1995 Aug;11(4):252–4

[New potentials for assessing the efficacy of extracorporeal blood correction methods in treating patients with acute suppurative destructive diseases of the lungs and pleura] Bel'skikh AN, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):42–3 (Eng. Abstr.) **(Rus)**

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

ULTRASONOGRAPHY

Pancreaticopleural fistula diagnosed sonographically [letter] Duchmann JC, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1551

Occult post–thoracentesis hematoma presenting as a pleural mass. Wachsberg RH, et al. **J Clin Ultrasound** 1996 Jan; 24(1):43–4

VETERINARY

Pleuropulmonary abscessation in a horse caused by a gastric foreign body. Tremaine WH, et al. **Vet Rec** 1995 Jun 24; 136(25):637–8

PLEURAL EFFUSION

Pelvic endometriosis mimicking advanced ovarian cancer: presentation with pleural effusion, ascites, and elevated serum CA 125 level. Myers TJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):966–7

Evolution of idiopathic pleural effusion: a prospective, long–term follow–up study. Ferrer JS, et al. **Chest** 1996 Jun;109(6):1508–13

Bilateral tuberculous pleural effusions with markedly different characteristics. Murin S, et al. **Chest** 1996 Sep; 110(3):849–50

Tumour necrosis factor, interleukin–1 and adenosine deaminase in tuberculous pleural effusion. Orphanidou D, et al. **Respir Med** 1996 Feb;90(2):95–8

BLOOD

Determination of tissue polypeptide–specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul–Sep; 10(3):161–5

CHEMICALLY INDUCED

Lymphocytic pleural exudate in a patient receiving amiodarone. Carmichael LC, et al. **Br J Clin Pract** 1996 Jun;50(4):228–30

Pulmonary oedema and pleural effusion in two patients with primary pulmonary hypertension treated with calcium channel blockers. Chaouat A, et al. **Heart** 1996 Apr; 75(4):383

Interstitial lung disease with pleural effusion caused by simvastin. De Groot RE, et al. **J Intern Med** 1996 Apr; 239(4):361–3

Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy [letter; comment] Smith MD. **J Rheumatol** 1995 Jul;22(7):1439. Comment on: J Rheumatol 1994 May;21(5):934–7.

Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Al–Majed SA. **Respir Med** 1996 Apr;90(4):211–4

[Therapy–induced formation of ascites and pleural effusion during initial chemotherapy in a patient with non–Hodgkin's lymphoma. Ascites and pleural effusion during initial chemotherapy] Gruhn B, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):317–20 (Eng. Abstr.) **(Ger)**

CHEMISTRY

CA–15.3 assay in effusions: comparison with carcinoembryonic antigen and CA–125 assay and cytologic diagnosis. Pinto MM. **Acta Cytol** 1996 May–Jun; 40(3):437–42

Evaluation of CYFRA 21–1 in malignant and benign pleural effusions. Toumbis M, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2101–4

Folate receptor in malignant effusions of ovarian carcinoma. Holm J, et al. **APMIS** 1995 Sep;103(9):663–70

Validation of a commercial human fibronectin assay for use in dogs and cats. Hirschberger J, et al. **Aust Vet J** 1996 May;73(5):196–7

Testing the waters. Differentiating transudates from exudates [editorial; comment] [see comments] Antony VB, et al. **Chest** 1995 Nov;108(5):1191–2. Comment on: Chest 1995 Nov;108(5):1260–3. Comment in: Chest 1996 Jul;110(1):299–300.

Measurement of pleural fluid cholesterol and lactate dehydrogenase. A simple and accurate set of indicators for separating exudates from transudates [see comments] Costa M, et al. **Chest** 1995 Nov;108(5):1260–3. Comment in: Chest 1995 Nov;108(5):1191–2. Comment in: Chest 1996 Jul;110(1):299–300.

Detection of soluble adhesion molecules in pleural effusions. Hoffmann JC, et al. **Chest** 1996 Jul;110(1):107–13

Similar pleural fluid findings in pleuropulmonary tularemia and tuberculous pleurisy. Pettersson T, et al. **Chest** 1996 Feb;109(2):572–5

Evaluating pleural fluid [editorial; comment] Roth BJ. **Chest** 1996 Jul;110(1):7–8. Comment on: Chest 1996 Jul;110(1):97–101.

Serial pleural fluid analysis in a new experimental model of empyema. Sasse SA, et al. **Chest** 1996 Apr;109(4):1043–8

Interleukin–1 beta in pleural fluids of different etiologies. Its role as inflammatory mediator in empyema. Silva–Mejías C, et al. **Chest** 1995 Oct;108(4):942–5

Diagnostic value of cholesterol in pleural effusions. Ram KN, et al. **J Assoc Physicians India** 1995 Nov;43(11):748–50

Bioassay vs. immunoassay for quantification of interleukin–6 in biological fluids. Papadopoulos NG, et al. **J Clin Lab Anal** 1995;9(4):234–7

The diagnostic value of tuberculostearic acid in tuberculous pleural effusions. Yorgancioğlu A, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):108–11

Dot–enzyme–linked immunosorbent assay (Dot–ELISA) for detection of pneumococcal polysaccharide antigens in pleural fluid effusion samples. Comparison with bacterial culture, counterimmunoelectrophoresis and latex agglutination. Requejo HI, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):531–7

[A case of multiple myeloma associated with abnormal plasma cells and M–protein in pleural effusion]. Araki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):196–9 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Transudate vs exudate: genug! [editorial; comment] Bartter T, et al. **Chest** 1996 Jun;109(6):1419–21. Comment on: Chest 1996 Jun;109(6):1503–7.

Pleural fluid to serum cholinesterase ratio for the separation of transudates and exudates [see comments] Garcia–Pachon E, et al. **Chest** 1996 Jul;110(1):97–101. Comment in: Chest 1996 Jul;110(1):7–8.

Keep testing the waters [letter; comment] Romero S, et al. **Chest** 1996 Jul;110(1):299–300. Comment on: Chest 1995 Nov;108(5):1191–2. Comment on: Chest 1995 Nov;108(5):1260–3.

A study of Light's criteria and possible modifications for distinguishing exudative from transudative pleural effusions [see comments] Vives M, et al. **Chest** 1996 Jun; 109(6):1503–7. Comment in: Chest 1996 Jun;109(6):1419–21.

COMPLICATIONS

Pleural effusions: a new negative prognostic parameter for acute pancreatitis. Response to Dr. Lankisch et al [letter; comment] Ramesh H, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1898–9. Comment on: Am J Gastroenterol 1994 Oct;89(10):1849–51.

False positive pleural biopsy and high CA125 levels in serum and pleural effusion in systemic lupus erythematosus. Yucel AE, et al. **Clin Rheumatol** 1996 Mar;15(2):197–9

Familial pulmonary lymphatic hypoplasia associated with fetal pleural effusions. Thibeault DW, et al. **J Pediatr** 1995 Dec;127(6):979–83

[Management of HELLP syndrome before 32 weeks of amenorrhea. 22 cases] Audibert F, et al. **Presse Med** 1996 Feb 17;25(6):235–9 (Eng. Abstr.) **(Fre)**

[Chylothorax of unusual origin: post–radiation mediastino–pulmonary fibrosis (letter)] Perrin C, et al. **Presse Med** 1996 Feb 17;25(6):259 **(Fre)**

[Pancreatic pleural effusion. Diagnosis and therapy] Pleskovič L, et al. **Acta Chir Iugosl** 1990;37(2):229–37 (Eng. Abstr.) **(Slv)**

CONGENITAL

Extralobar pulmonary sequestration masquerading as a congenital pleural effusion. Boyer J, et al. **Pediatrics** 1996 Jan;97(1):115–7

CYTOLOGY

Similar pleural fluid findings in pleuropulmonary tularemia and tuberculous pleurisy. Pettersson T, et al. **Chest** 1996 Feb;109(2):572–5

Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Joseph MG, et al. **Mod Pathol** 1995 Aug;8(6):686–93

[Oncologic diagnosis of serous effusions in body cavities (cytologic study and evaluation of cholesterol and carcinoembryonic antigen levels)] Gulyás M, et al. **Orv Hetil** 1995 Nov 5;136(45):2453–8 (Eng. Abstr.) **(Hun)**

[Methodology of the study of pleural effusion cells] Zhestkov KG. **Klin Lab Diagn** 1996 Mar–Apr;(2):11–3 (Eng. Abstr.) **(Rus)**

[Bilateral pleural effusion and rheumatoid arthritis. Diagnostic value of pleural fluid cytology] Jareño Esteban J, et al. **Arch Bronconeumol** 1996 Mar;32(3):145–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnostic value of CA 72–4, carcinoembryonic antigen, CA 15–3, and CA 19–9 assay in pleural fluid. A study of 207 patients. Villena V, et al. **Cancer** 1996 Aug 15;78(4):736–40

Mucormycotic osteolytic rib lesion presenting as subacute pleural effusion. Wanishsawad C, et al. **Clin Infect Dis** 1996 Apr;22(4):715–16

Pleural amyloidosis: thoracoscopic aspects. Bontemps F, et al. **Eur Respir J** 1995 Jun;8(6):1025–7

Utility of a Mycobacterium tuberculosis GC–rich repetitive sequence in the diagnosis of tuberculous pleural effusion by PCR. Verma A, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):429–36

Pulmonary infiltrations. Sign of severe acute pancreatitis. Lankisch PG, et al. **Int J Pancreatol** 1996 Apr;19(2):113–5

T–cell lymphoma presenting with pericardial and pleural effusion as the initial and primary lesion: cytogenetic and molecular evidence. Yasuda H, et al. **Intern Med** 1996 Feb; 35(2):150–4

Gorham's syndrome with pleural effusion and colonic carcinoma. Ng SE, et al. **Singapore Med J** 1995 Feb; 36(1):102–4

[Presumed transudative pleural effusion?] Berger P, et al. **Rev Mal Respir** 1995;12(4):377–9 (Eng. Abstr.) **(Fre)**

[Differential diagnosis of exudative pleurisy] Shchennikov EL. **Klin Med (Mosk)** 1995;73(4):61–3 (Eng. Abstr.) **(Rus)**

[The diagnostic importance of determining tuberculosis antibodies by immunoenzyme analysis in exudative pleurisy] Uklistaia TA, et al. **Ter Arkh** 1996;68(3):71–3 (Eng. Abstr.) **(Rus)**

[Pseudochylothorax or cholesterol pleural effusions (letter; comment)] Rodríguez González–Moro JM, et al. **Arch Bronconeumol** 1995 Oct;31(8):431. Comment on: Arch Bronconeumol 1995 Feb;31(2):80–2. **(Spa)**

[Usefulness of biological markers in pleural effusion] Diez J de M, et al. **Rev Clin Esp** 1996 Feb;196(2):107–12 (73 ref.) **(Spa)**

DRUG THERAPY

Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect. Park CS, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):649–52

Lymphocytic pleural exudate in a patient receiving amiodarone. Carmichael LC, et al. **Br J Clin Pract** 1996 Jun;50(4):228–30

Pancreatic pleural effusion: an indication for emergency distal pancreatectomy and Roux–En–Y pancreatico–jejunostomy [letter; comment] Tsang TM, et al. **J Pediatr Surg** 1995 Nov;30(11):1632. Comment on: J Pediatr Surg 1994 Dec;29(12):1541–4.

Pleural effusion in ankylosing spondylitis; successful treatment with intra–pleural steroid administration. Tanaka H, et al. **Respir Med** 1995 Aug;89(7):509–11

[The effect of the ultraphonophoesis of deresinated naphthalan in patients with a history of exudative pleurisy] Insanov AB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):18–20 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Comparison of pancuronium and vecuronium for fetal neuromuscular blockade during invasive procedures. Watson WJ, et al. **J Matern Fetal Med** 1996 May–Jun; 5(3):151–4

ENZYMOLOGY

Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio. Increased specificity for the diagnosis of tuberculous pleuritis. Burgess LJ, et al. **Chest** 1996 Feb;109(2):414–9

Rapid automated determination of adenosine deaminase and lysozyme for differentiating tuberculous and nontuberculous pleural effusions. Villena V, et al. **Clin Chem** 1996 Feb;42(2):218–21

Adenosine deaminase isozymes in tuberculous pleural effusion [see comments] Shibagaki T, et al. **J Lab Clin Med** 1996 Apr;127(4):348–52. Comment in: J Lab Clin Med 1996 Apr;127(4):326–7.

Neurone–specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Nyberg P, et al. **Thorax** 1996 Jan;51(1):92–4

EPIDEMIOLOGY

Benign postpartum pleural effusion. Gourgoulianis KI, et al. **Eur Respir J** 1995 Oct;8(10):1748–50

Epidemiology of pleural effusions [letter] Burgess LJ, et al. **S Afr Med J** 1996 Feb;86(2):186

ETIOLOGY

Peritoneopleural communication associated with cirrhotic ascites: scintigraphic demonstration. Mittal BR, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):69–70

Tuberculous pleural effusion following coronary artery bypass graft. Meysman M, et al. **Acta Clin Belg** 1995; 50(5):305–9

Aortopulmonary collateral vessels and prolonged pleural effusions after modified Fontan procedures. Spicer RL, et al. **Am Heart J** 1996 Jun;131(6):1164–8

Pleural effusion in drowning. Morild I. **Am J Forensic Med Pathol** 1995 Sep;16(3):253–6

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft–versus–host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

Testing the waters. Differentiating transudates from exudates [editorial; comment] [see comments] Antony VB, et al. **Chest** 1995 Nov;108(5):1191–2. Comment on: Chest 1995 Nov;108(5):1260–3. Comment in: Chest 1996 Jul;110(1):299–300.

Recurrent left pleural effusion in a 44–year–old woman with a history of alcohol abuse. Iglesias JI, et al. **Chest** 1996 Aug;110(2):547–9

Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Judson MA, et

al. **Chest** 1996 May;109(5):1190–4

Complex pleural effusion associated with a subphrenic gallstone phlegmon following laparoscopic cholecystectomy. Neumeyer DA, et al. **Chest** 1996 Jan; 109(1):284–6

The etiology of pleural effusions in an area with high incidence of tuberculosis. Valdés L, et al. **Chest** 1996 Jan; 109(1):158–62

Late diagnosis of congenital diaphragmatic hernia with splenic infarction presenting as pleural effusion and respiratory distress. Jankowski RA, et al. **Clin Pediatr (Phila)** 1995 Oct;34(10):549–51

Pleural effusion as a presenting manifestation of giant cell arteritis. Gur H, et al. **Clin Rheumatol** 1996 Mar;15(2):200–3

Ascites, pleural, and pericardial effusions in acute pancreatitis. A prospective study of incidence, natural history, and prognostic role. Maringhini A, et al. **Dig Dis Sci** 1996 May;41(5):848–52

Bilateral pleural and pericardial effusions complicating insertion of a central venous catheter [letter] Mineo TC, et al. **Eur J Pediatr** 1996 Jan;155(1):68–9

Parapneumonic effusions secondary to community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Gil Suay V, et al. **Eur Respir J** 1995 Nov;8(11):1934–9

Adenosine deaminase in the diagnosis of tuberculosis pleural effusion [editorial] Sharma SK, et al. **Indian J Chest Dis Allied Sci** 1996 Apr–Jun;38(2):69–71

Sjögren's syndrome with pleural effusion. Ogihara T, et al. **Intern Med** 1995 Aug;34(8):811–4

Adult T cell leukemia clinically manifested with ascites and pleural effusion. Saburi Y, et al. **Intern Med** 1995 Aug; 34(8):815–8

Hepatic hydrothorax without diaphragmatic defect. An original surgical treatment. Montanari M, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):425–7

Pleural effusion associated with D-penicillamine therapy: a case report. Karkos C, et al. **J Clin Pharm Ther** 1996 Feb; 21(1):15–7

Systemic lupus erythematosus presenting as pleural effusion: report of a case. Wang DY, et al. **J Formos Med Assoc** 1995 Dec;94(12):746–9

Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma. Wilkinson RH Jr. **J Nucl Med** 1996 Apr;37(4):636–9

Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate. Shek Y, et al. **J Reprod Med** 1995 Jul;40(7):540–2

Erosion of inlet cannula of left ventricular assist device manifested as innocuous bleeding in stable patient: lessons learned in prevention of catastrophic consequences. Mehta SM, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):544–5

Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Bartlett RP, et al. **Mayo Clin Proc** 1995 Dec;70(12):1161–4

Cat-scratch disease associated with pleural effusions and encephalopathy in a child. Whitman BW, et al. **Respiration** 1995;62(3):171–3

Treatment of a pleural effusion due to Charcot's arthropathy. Linder SH. **South Med J** 1995 Nov;88(11):1179–80

Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion. Loncar R, et al. **Tumori** 1995 Nov–Dec;81(6):440–4

[Internal pancreatic fistula: surgical treatment] Pereira-Lima L, et al. **J Chir (Paris)** 1995 Nov;132(11):442–6 (Eng. Abstr.) **(Fre)**

[Complications in a patient with a jejuno-peritoneal shunt by the Le Veen technique] Fulgente R, et al. **Chir Ital** 1994;46(6):71–2 (Eng. Abstr.) **(Ita)**

[Primary Sjögren's syndrome accompanied by pleural effusion] Kashiwabara K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1325–9 (Eng. Abstr.) **(Jpn)**

[A case of systemic lupus erythematosus with pleural effusion, ascites and pericardial effusion] Koyama K, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):614–6 **(Jpn)**

[Pleural effusion of non-neoplastic etiology in a patient with a rare form of myeloma] Alvares E, et al. **Acta Med Port** 1995 Oct;8(10):579–84 (10 ref.) (Eng. Abstr.) **(Por)**

[Pleural effusion associated with lung cancer. Problems of classification according to TNM categories (editorial)] Cantó Armengod A. **Arch Bronconeumol** 1996 Mar; 32(3):115–7 **(Spa)**

[Bilateral pleural effusion and rheumatoid arthritis. Diagnostic value of pleural fluid cytology] Jareño Esteban J, et al. **Arch Bronconeumol** 1996 Mar;32(3):145–7 (Eng. Abstr.) **(Spa)**

[Pleural effusion associated with vertebral osteomyelitis (letter)] Mateos-Colino A, et al. **Arch Bronconeumol** 1995 Oct;31(8):430–1 **(Spa)**

[Myelomatous pleural effusion as presentation form of multiple myeloma (letter)] Acín P, et al. **Med Clin (Barc)** 1996 May 25;106(20):799 **(Spa)**

GENETICS

Familial fetal pleural effusions [letter] Fox GF, et al. **J Pediatr** 1996 Aug;129(2):316–7

[Pulmonary lymphangiectasis with spontaneous chylothorax in Noonan syndrome] Sailer M, et al. **Klin Padiatr** 1995 Sep-Oct;207(5):302–4 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

IL-8 in pleural effusion. Ceyhan BB, et al. **Respir Med** 1996 Apr;90(4):215–21

Soluble interleukin-6 receptor levels in pleural effusions. Yokoyama A, et al. **Respir Med** 1996 Jul;90(6):329–32

[The changes and clinical significance of interleukin 1 beta in pleural effusion] Yang T, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):85–7, 127–8 (Eng. Abstr.) **(Chi)**

[The significance of immune island appeared in pleural and peritoneal effusion] Zhou D, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):77–9, 127 (Eng. Abstr.) **(Chi)**

[Cellular immune response in tuberculosis: analysis of T-lymphocytes and their subsets, B-lymphocytes and natural cytotoxic cells in different tuberculosis states and body fluids] Montes Santiago J, et al. **Rev Clin Esp** 1996 Apr;196(4):223–7 (Eng. Abstr.) **(Spa)**

METABOLISM

Laser high performance liquid chromatography determination of prostaglandins in pleural effusions. Ikuta N, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):521–7

Clinical evaluation of copper and ceruloplasmin levels in effusions of malignant and benign origin. Yenisey C, et al. **Biochem Soc Trans** 1995 Nov;23(4):606S

Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Eagles G, et al. **Br J Cancer** 1996 Feb;73(3):377–81

Pleural fluid to serum cholinesterase ratio for the separation of transudates and exudates [see comments] Garcia-Pachon E, et al. **Chest** 1996 Jul;110(1):97–101. Comment in: Chest 1996 Jul;110(1):7–8.

Fibrinolytic and inflammatory processes in pleural effusions. Philip-Joët F, et al. **Eur Respir J** 1995 Aug;8(8):1352–6

Determination of tissue polypeptide-specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul–Sep; 10(3):161–5

Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer. Miya T, et al. **Jpn J Antibiot** 1995 Jul;48(7):960–4

Binding capacities of two immunomodulatory lectins, carrier-immobilized glycoligands and steroid hormones in lung cancer and the concentration of nitrite/nitrate in pleural effusions. Timoshenko AV, et al. **Lung Cancer** 1996 Feb;14(1):75–84

Tumor necrosis factor-alpha (TNF-alpha) in pleural fluids. Gürsel G, et al. **Tuber Lung Dis** 1995 Aug;76(4):370–1

[Measurement of gamma-interferon and its production capability in pleural effusion] Li W, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):94–6, 128 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

Mycobacterium avium-intracellulare pleuritis with massive pleural effusion. Okada Y, et al. **Eur Respir J** 1995 Aug; 8(8):1428–9

Clinical problem solving in geriatric medicine: an older man with a pleural effusion. Berg J, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1093–7 (41 ref.)

Diagnosis of tuberculous pericarditis with a fluorochrome stain. Nelson CT, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1004–7

[Toxic shock-like syndrome with Streptococcus pyogenes in a pleural effusion] Takamura K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):705–9 (Eng. Abstr.) **(Jpn)**

[Detection of Mycobacterium tuberculosis by amplification of mycobacterial DNA from pleural fluid and gastric juice: the comparison of IS6110 gene with Amplicor mycobacterium] Fusegawa H, et al. **Rinsho Byori** 1995 Sep; 43(9):941–7 (Eng. Abstr.) **(Jpn)**

[Young woman with cutaneous lupus and lung effusion] Porcel JM, et al. **Rev Clin Esp** 1995 Aug;195(8):583–4 **(Spa)**

NURSING

Clinical snapshot: pleural effusion. Collins PM, et al. **Am J Nurs** 1996 Jul;96(7):38–9

PARASITOLOGY

Pleural effusion and toxocariasis. Jeanfaivre T, et al. **Thorax** 1996 Jan;51(1):106–7

PATHOLOGY

Effusion cytology of hepatocellular carcinoma. Falconieri G, et al. **Acta Cytol** 1995 Sep-Oct;39(5):893–7

Quality control of immunocytochemical staining of effusions using a standardized method of cell processing. Kuenen-Boumeester V, et al. **Acta Cytol** 1996 May-Jun; 40(3):475–9

Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. Lee JS, et al. **Acta Cytol** 1996 Jul-Aug; 40(4):631–6

Cytology of Langerhans cell histiocytosis in effusions: a case report. Nagaoka S, et al. **Acta Cytol** 1996 May-Jun; 40(3):563–6

Significance of AgNOR count in differentiating malignant cells from reactive mesothelial cells in serous effusions. Sujathan K, et al. **Acta Cytol** 1996 Jul-Aug;40(4):724–8

Carbon-laden macrophages in pleural fluid of crack smokers. Singh B, et al. **Diagn Cytopathol** 1995 Nov;13(4):316–9

Idiopathic lobular panniculitis with specific pleural involvement. Kumagai-Kurata N, et al. **Eur Respir J** 1995 Sep;8(9):1613–5

Eosinophilic pleural effusion: is it always nondiagnostic? Fitzgerald DJ, et al. **J Fam Pract** 1996 Apr;42(4):405–7

Comparison of pleural fluid cytology and pleural biopsy in the evaluation of pleural effusion. Kumar ND, et al. **J Indian Med Assoc** 1995 Aug;93(8):307–9

Pleural fluid eosinophils suppress local IgE-mediated protein exudation in rats. Bandeira-Melo C, et al. **J Leukoc Biol** 1995 Oct;58(4):395–402

Diagnostic evaluation of pleural effusion and the role of needle pleural biopsy. Hussain SF, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):127–30

[A case of multiple myeloma associated with abnormal plasma cells and M-protein in pleural effusion]. Araki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):196–9 (Eng. Abstr.) **(Jpn)**

[Pleural needle biopsy in diagnosis of pleural effusion] Fijalkowski M, et al. **Pneumonol Alergol Pol** 1996; 64(1-2):64–7 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Anion gap in turpentine-induced pleural effusions. Correlation with pH and protein level. Paulson WD, et al. **Chest** 1996 Feb;109(2):504–9

Right ventricular diastolic collapse without hemodynamic compromise in a patient with large, bilateral pleural effusions. Venkatesh G, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):551–3

Effects of ventilation and pleural effusion on measurements of airway thermal volume and blood flow in dog lungs. Kano A, et al. **J Appl Physiol** 1995 Oct;79(4):1320–9

RADIOGRAPHY

Case of the month: that's torn it! Moss MS, et al. **Br J Radiol** 1996 May;69(821):479–80

Bronchogenic cyst presenting as mediastinal mass with pleural effusion. Khalil A, et al. **Eur Respir J** 1995 Dec; 8(12):2185–7

RADIONUCLIDE IMAGING

Peritoneopleural communication associated with cirrhotic ascites: scintigraphic demonstration. Mittal BR, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):69–70

Lung perfusion imaging in tricuspid atresia after Glenn and Fontan repair. Stevens MA, et al. **Clin Nucl Med** 1995 Oct; 20(10):941–2

Pleural effusion and ventilation/perfusion scan interpretation for acute pulmonary embolus. Goldberg SN, et al. **J Nucl Med** 1996 Aug;37(8):1310–3

SURGERY

Management of pleural effusion of cirrhotic origin. Mouroux J, et al. **Chest** 1996 Apr;109(4):1093–6

Hepatic hydrothorax without diaphragmatic defect. An original surgical treatment. Montanari M, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):425–7

[Another complication of thoracic drainage: perforation-intubation of the subclavian vein] Valette H, et al. **J Chir (Paris)** 1996 Apr;133(2):91–2 (Eng. Abstr.) **(Fre)**

THERAPY

Talc poudrage for treatment of pleural effusion in selected patients [see comments] Tampinco-Golos IC. **AORN J** 1995 Jul;62(1):83–6, 88–9, 91. Comment in: AORN J 1995 Sep;62(3):333–4.

Image-guided drainage of complicated pleural effusions and adjunctive use of intrapleural urokinase. What would Hippocrates think? [editorial; comment] Matsumoto AH. **Chest** 1995 Nov;108(5):1190–1. Comment on: Chest 1995 Nov;108(5):1252–9.

Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252–9 (20 ref.). Comment in: Chest 1995 Nov;108(5):1190–1.

Thoracoscopic management of pleural effusions [letter; comment] Yim AP. **Chest** 1995 Dec;108(6):1765–6. Comment on: Chest 1995 Mar;107(3):845–52.

Corynebacterium parvum versus tetracycline as pleural sclerosing agents in rabbits. Vargas FS, et al. **Eur Respir J** 1995 Dec;8(12):2174–7

Management of ascites and pleural effusions in ovarian hyperstimulation syndrome [letter; comment] Aboulghar M, et al. **Fertil Steril** 1995 Dec;64(6):1228–9. Comment on: Fertil Steril 1995 May;63(5):1114–7.

Chylous effusions in CLL [letter; comment] Sivakumaran M, et al. **Leuk Lymphoma** 1995 Jul;18(3-4):365–6. Comment on: Leuk Lymphoma 1993 Aug;10(6):507–10.

Chemical pleurodesis in the treatment of iterative neoplastic effusion. Batori M, et al. **Riv Eur Sci Med Farmacol** 1995

Jul-Aug;17(4):151-3

Aspiration of fetal pleural effusions or ascites may improve neonatal resuscitation. Cardwell MS. **South Med J** 1996 Feb;89(2):177-8

Treatment of a pleural effusion due to Charcot's arthropathy. Linder SH. **South Med J** 1995 Nov;88(11):1179-80

[Ultrasound-guided aspiration of pleural fluid] Atar E, et al. **Harefuah** 1996 Jan 1;130(1):16-7, 71 (Eng. Abstr.) **(Heb)**

[Pleuroscopy and talc pleurodesis in recurrent pleural effusions: experience with 51 cases] Panebianco V, et al. **G Chir** 1995 Oct;16(10):437-41 (Eng. Abstr.) **(Ita)**

[A method of cleansing the pleural cavity in patients with pleural empyema] Potapenkov MA, et al. **Klin Khir** 1995; (4):43-4 **(Rus)**

ULTRASONOGRAPHY

Right ventricular diastolic collapse without hemodynamic compromise in a patient with large, bilateral pleural effusions. Venkatesh G, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):551-3

"Fluid color" sign: a useful indicator for discrimination between pleural thickening and pleural effusion. Wu RG, et al. **J Ultrasound Med** 1995 Oct;14(10):767-9

VETERINARY

Progressive lymphangiectasis and recurrent chylothorax in a dog after thoracic duct ligation. Kerpsack SJ, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1059-62

Pleural effusion in cats: 82 cases (1987 to 1995). Davies C, et al. **J Small Anim Pract** 1996 May;37(5):217-24

Validation of the determination of the activity of adenosine deaminase in the body effusions of cats. Hirschberger J, et al. **Res Vet Sci** 1995 Nov;59(3):226-9

VIROLOGY

Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Said W, et al. **Blood** 1996 Jun 15;87(12):4937-43

PLEURAL EFFUSION, MALIGNANT

BLOOD

Determination of tissue polypeptide-specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul-Sep; 10(3):161-5

CHEMISTRY

Autoantibodies against p53 are not increased in human ascites and pleural effusions. Munker R, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):200-1

Interleukin-1 beta in pleural fluids of different etiologies. Its role as inflammatory mediator in empyema. Silva-Mejías C, et al. **Chest** 1995 Oct;108(4):942-5

[Coagulation and fibrinolysis parameters in neoplastic pleural exudates] Tałałaj J. **Pneumonol Alergol Pol** 1995; 63(5-6):339-43 (15 ref.) **(Pol)**

COMPLICATIONS

Pneumothorax after small-bore catheter placement for malignant pleural effusions. Chang YC, et al. **AJR Am J Roentgenol** 1996 May;166(5):1049-51

[Pleural effusion in plasmacytic leukemia] Matýšková M, et al. **Vnitr Lek** 1995 Jul;41(7):467-9 (Eng. Abstr.) **(Cze)**

CYTOLOGY

Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Joseph MG, et al. **Mod Pathol** 1995 Aug;8(6):686-93

[Oncologic diagnosis of serous effusions in body cavities (cytologic study and evaluation of cholesterol and carcinoembryonic antigen levels)] Gulyás M, et al. **Orv Hetil** 1995 Nov 5;136(45):2453-8 (Eng. Abstr.) **(Hun)**

[Relationship between intraoperative pleural lavage cytology and recurrence in pleural cavity after resection of lung metastasis from colorectal cancer] Kameyama M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1616-8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Differential diagnosis of malignant effusions [letter; comment] Ramael M, et al. **Am J Clin Pathol** 1996 Jan;105(1):132-3 . Comment on: Am J Clin Pathol 1995 Feb;103(2):206-14.

Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Villena V, et al. **Cancer** 1996 Aug 15;78(4):736-40

Thoracoscopic management of malignant pleural effusions. Yim AP, et al. **Chest** 1996 May;109(5):1234-8

Diagnostic utility of thoracentesis for neutropenic children with cancer. Desselle BC, et al. **Clin Infect Dis** 1995 Oct; 21(4):887-90

Diagnostic value of cholesterol in pleural effusions. Ram KN, et al. **J Assoc Physicians India** 1995 Nov;43(11):748-50

[Correlated multiple parameters in pleural effusion with pathology of pleurae for differential diagnosis of tuberculous and carcinomatous pleuritis] Yu S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):88-90, 128 (Eng. Abstr.) **(Chi)**

[Correlation between sensitivity of the cytogenetic and cytological analysis and thoracoscopic findings in the study of malignant pleural effusions] Vázquez Oliva R, et al. **Arch Bronconeumol** 1995 Nov;31(9):437-42 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Perrone F, et al. **Ann Oncol** 1995 Dec;6(10):1033-43 (93 ref.)

Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion--a randomised study. Bjermer L, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2203-8

ENZYMOLOGY

[Pharmacological and biochemical investigation of intracavital fluorinated pyrimidine chemotherapy] Shibata H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1613-5 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Lung cancer and ipsilateral pleural effusion. Rodriguez Panadero F. **Ann Oncol** 1995;6 Suppl 3:S25-7 (13 ref.)

Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Nador RG, et al. **Blood** 1996 Jul 15; 88(2):645-56

How should cancer presenting as a malignant pleural effusion be managed? Bonnefoi H, et al. **Br J Cancer** 1996 Sep; 74(5):832-5

Commentary: pleural empyema and malignancy--another dimension. Johnson PH, et al. **Thorax** 1996 Jan;51(1):107-8

Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion. Loncar R, et al. **Tumori** 1995 Nov-Dec;81(6):440-4

[Meigs syndrome presenting as diaphragmatic pleural nodules] Choh K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):80-4 (Eng. Abstr.) **(Jpn)**

GENETICS

Immunoglobulin gene rearrangement in T-cell-rich reactive pleural effusion of a patient with B-cell chronic lymphocytic leukemia. Miyahara M, et al. **Acta Haematol** 1996;96(1):41-4 (24 ref.)

FISH in the evaluation of pleural and ascitic fluids. Chen Z, et al. **Cancer Genet Cytogenet** 1995 Oct 15;84(2):116-9

IMMUNOLOGY

Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. Mantovani G, et al. **J Mol Med** 1995 Aug;73(8):409-16

[The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells] Guo Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):80-2, 127 (Eng. Abstr.) **(Chi)**

[Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma] Hazama S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1595-7 (Eng. Abstr.) **(Jpn)**

[T cell receptor V beta repertoire of locoregional lymphocytes in malignant effusions] Miyahara E, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1622-5 (Eng. Abstr.) **(Jpn)**

METABOLISM

Clinical evaluation of copper and ceruloplasmin levels in effusions of malignant and benign origin. Yenisey C, et al. **Biochem Soc Trans** 1995 Nov;23(4):606S

Elevation of interleukin-10 levels in malignant pleural effusion. Chen YM, et al. **Chest** 1996 Aug;110(2):433-6

Steroid receptors in pleural effusions of advanced breast cancer patients. Branković-Magić M, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):143-8

Determination of tissue polypeptide-specific antigen in pleural fluid and serum from patients with pleural effusion. Villena V, et al. **Int J Biol Markers** 1995 Jul-Sep; 10(3):161-5

Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. Teder P, et al. **Int J Cancer** 1996 Jul 29;67(3):393-8

MICROBIOLOGY

A malignant pleural effusion infected with Salmonella enteritidis. Gill GV, et al. **Thorax** 1996 Jan;51(1):104-5

PATHOLOGY

Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Antony VB, et al. **Chest** 1996 Mar;109(3 Suppl):21S-22S

A possible role of TGF-beta in the formation of malignant effusions. Ikubo A, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):27-32

Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54-60 (14 ref.)

Significance of epithelial membrane antigen in the work-up of problematic serous effusions. Singh HK, et al. **Diagn Cytopathol** 1995 Jul;13(1):3-7

Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells-a diagnostic aid in effusion cytology. Sujathan K, et al. **J Cancer Res Clin Oncol** 1996; 122(7):433-6

Comparison of pleural fluid cytology and pleural biopsy in the evaluation of pleural effusion. Kumar ND, et al. **J Indian Med Assoc** 1995 Aug;93(8):307-9

Detection of hyperdiploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization. Johnson TM, et al. **Mayo Clin Proc** 1996 Jul;71(7):643-8

[B-lymphocytes in the pleural effusion of chronic lymphocytic leukemia (letter)] Molina M, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):478 **(Spa)**

SURGERY

Port-site recurrence following video-assisted thoracoscopic surgery. Yim AP. **Surg Endosc** 1995 Oct;9(10):1133-5

THERAPY

Talc pleurodesis for treating malignant pleural effusions [letter; comment] Rodriguez-Panadero F. **Chest** 1995 Oct; 108(4):1178-9. Comment on: Chest 1994 Oct;106(4):1215-22.

Thoracoscopic management of malignant pleural effusions. Yim AP, et al. **Chest** 1996 May;109(5):1234-8

Thoracoscopic management of malignant pleural effusions. Colt HG. **Clin Chest Med** 1995 Sep;16(3):505-18 (108 ref.)

Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Kitsuki H, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):283-90

Ambulatory sclerotherapy for malignant pleural effusions. Patz EF Jr, et al. **Radiology** 1996 Apr;199(1):133-5

[Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)] Han B, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):91-3, 128 (Eng. Abstr.) **(Chi)**

[Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion] Mao G, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):83-4, 127 (Eng. Abstr.) **(Chi)**

[Results of phase III clinical trial of Pseudomonas jinanensis vaccine injection (PVI) in the treatment of malignant pleural effusion] Wang J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):458-60 (Eng. Abstr.) **(Chi)**

[Current treatment strategy in malignant pleural effusion] Türler A, et al. **Wien Klin Wochenschr** 1996;108(9):255-61 (56 ref.) (Eng. Abstr.) **(Ger)**

PLEURAL NEOPLASMS

Adenocarcinoma of the lung and mesothelioma [letter] Wolfe KQ, et al. **Histopathology** 1995 Oct;27(4):393-4

Pleuro-pulmonary blastoma: a case report and review of the literature. Schmaltz C, et al. **Med Pediatr Oncol** 1995 Dec; 25(6):479-84 (18 ref.)

Malignant mesothelioma of the pleura [letter] Oomman A, et al. **Natl Med J India** 1995 Sep-Oct;8(5):243-4

Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies. Donington JS, et al. **Surg Oncol** 1995 Aug; 4(4):175-85 (45 ref.)

Pleural mesothelioma with non-Hodgkin's lymphoma [letter] Hughes P, et al. **Thorax** 1995 Aug;50(8):915

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497-501 (15 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Antony VB, et al. **Chest** 1996 Mar;109(3 Suppl):21S-22S

CHEMICALLY INDUCED

Intrapleural administration of vitreous high duty ceramic fibres and heated devitrified ceramic fibres does not give rise to pleural mesothelioma in rats. Carthew P, et al. **Hum Exp Toxicol** 1995 Aug;14(8):657-61

[Potential role of environmental and domestic exposure to tremolite in pleural cancer in New Caledonia] Goldberg P, et al. **Rev Epidemiol Sante Publique** 1995;43(5):444-50 (Eng. Abstr.) **(Fre)**

PLEURAL NEOPLASMS

COMPLICATIONS

Hypoglycemia associated with localized fibrous mesothelioma of the pleura. Yokosaki Y, et al. **Sangyo Ika Daigaku Zasshi** 1995 Sep 1;17(3):191–7

Pleural non–Hodgkin's lymphoma arising in a patient with a chronic pyothorax. Hsu NY, et al. **Thorax** 1996 Jan; 51(1):103–4

[Spontaneous hydro–pneumothorax disclosing malignant mesothelioma. Apropos of 2 cases] Kolber C, et al. **Rev Pneumol Clin** 1996;52(1):42–4 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. Falaschi F, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):963–8

Benign fibrous mesothelioma of the pleura: MR imaging findings. Harris GN, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1143–4

Non–Hodgkin's lymphoma presenting as an encasing pleural mass [letter] Wittram C. **Br J Radiol** 1996 Jan;69(817):89

Malignant pleural mesothelioma. Sood S, et al. **Indian J Chest Dis Allied Sci** 1996 Apr–Jun;38(2):111–4

OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. Edwards C, et al. **J Clin Pathol** 1995 Jul;48(7):626–30

Multiple neoplasias: an oncologic reality [letter] Prados C, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):303

A 72–year–old man with shortness of breath [clinical conference] Bennett SK, et al. **Md Med J** 1996 Jul; 45(7):547–52

Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia. Bogers J, et al. **Pathol Res Pract** 1996 Jan;192(1):10–4

Methods to improve the diagnostic accuracy of malignant mesothelioma. Dejmek A. **Respir Med** 1996 Apr; 90(4):191–9 (129 ref.)

[Sarcomatous malignant mesothelioma diagnosed after death] Okuma S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):312–6 (Eng. Abstr.) **(Jpn)**

[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment] Mesía R, et al. **Arch Bronconeumol** 1995 Nov;31(9):455–9 (Eng. Abstr.) **(Spa)**

[Correlation between sensitivity of the cytogenetic and cytological analysis and thoracoscopic findings in the study of malignant pleural effusions] Vázquez Oliva R, et al. **Arch Bronconeumol** 1995 Nov;31(9):437–42 (Eng. Abstr.) **(Spa)**

[Dysphagia as an unusual form of presentation of malignant pleural mesothelioma] Mendoza H, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):217–20 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Phase II study of a short course of weekly high–dose cisplatin combined with long–term oral etoposide in pleural mesothelioma. Planting AS, et al. **Ann Oncol** 1995 Jul; 6(6):613–5

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter; comment] Anand A, et al. **Cancer** 1996 May 1; 77(9):1959–60. Comment on: Cancer 1995 Dec 1;76(11):2230–6.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments] Shin DM, et al. **Cancer** 1995 Dec 1; 76(11):2230–6. Comment in: Cancer 1996 May 1;77(9):1959–60.

Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Hunt KJ, et al. **Chest** 1996 May;109(5):1239–42

Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. Hastürk S, et al. **J Chemother** 1996 Apr;8(2):159–64

Chemotherapy in malignant pleural mesothelioma. A review. Ong ST, et al. **J Clin Oncol** 1996 Mar;14(3):1007–17 (79 ref.)

Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. Lee JD, et al. **J Surg Oncol** 1995 Dec;60(4):262–7

Use of photodynamic therapy for the management of pleural malignancies. Pass HI, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):360–7 (21 ref.)

Intracavitary photodynamic therapy for malignant pleural mesothelioma. Takita H, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):368–71

EPIDEMIOLOGY

Pleural mesothelioma in oil refinery workers [letter; comment] [see comments] Wong O. **Scand J Work Environ Health** 1995 Aug;21(4):301–9. Comment on: Scand J Work Environ Health 1994 Jun;20(3):213–5. Comment in: Scand J Work Environ Health 1996 Feb;22(1):67.

[Epidemiology of malignant pleural mesothelioma in the Nantes–Saint Nazaire region. Course in 1956–1992] Chailleux E, et al. **Rev Mal Respir** 1995;12(4):353–7 (Eng. Abstr.) **(Fre)**

[Epidemiology of malignant pleural mesothelioma in the region of Nantes–Saint–Nazaire (letter)] Coëtmeur D. **Rev Mal Respir** 1996 Jul;13(3):318 **(Fre)**

ETIOLOGY

Primary Epstein–Barr virus–related non–Hodgkin's lymphoma of the pleural cavity following long–standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288–91 (18 ref.)

Cancer of the lung, pleura, larynx and pharynx in an area with an asbestos–cement plant. Curin K, et al. **Arh Hig Rada Toksikol** 1995 Sep;46(3):289–300

Post–irradiation malignant mesothelioma. Cavazza A, et al. **Cancer** 1996 Apr 1;77(7):1379–85

Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients. Shannon VR, et al. **Cancer** 1995 Aug 1;76(3):437–41

Recent data on cancer due to asbestos in Sweden. Englund A. **Med Lav** 1995 Sep–Oct;86(5):435–9

The use of asbestos in Japan and China and malignancy related findings. Frank AL. **Med Lav** 1995 Sep–Oct; 86(5):457–60

Asbestos and cancer in Finland. Huuskonen MS, et al. **Med Lav** 1995 Sep–Oct;86(5):426–34

Mesotheliomas following exposure to asbestos used in railroads: 130 Italian cases. Maltoni C, et al. **Med Lav** 1995 Sep–Oct;86(5):461–77

Mesotheliomas following exposure to asbestos used in sugar refineries: report of 12 Italian cases. Maltoni C, et al. **Med Lav** 1995 Sep–Oct;86(5):478–83

European multicentric case control study on risk for mesothelioma after non–occupational (domestic and environmental) exposure to asbestos. Mollo F, et al. **Med Lav** 1995 Sep–Oct;86(5):496–500

Ignored occupational risks of asbestos mesotheliomas. Pinto C, et al. **Med Lav** 1995 Sep–Oct;86(5):484–9

Recent data on cancer due to asbestos in Germany. Rösler JA, et al. **Med Lav** 1995 Sep–Oct;86(5):440–8

GENETICS

Mesothelioma, asbestos, and reported history of cancer in first–degree relatives. Heineman EF, et al. **Cancer** 1996 Feb 1;77(3):549–54

Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case–control study. Huncharek M, et al. **Cancer Lett** 1996 Apr 19;102(1–2):205–8

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas [see comments] Bianchi AB, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10854–8. Comment in: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10819–20.

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.). Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

HISTORY

Mesotheliomas all: long before their time [editorial] Logan JS, et al. **Ulster Med J** 1996 May;65(1):1–2

METABOLISM

Immunoreactivity for c–fos and c–myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non–neoplastic mesothelium of the pleura. Ramael M, et al. **Histol Histopathol** 1995 Jul; 10(3):639–43

The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Gotzos V, et al. **Pathol Res Pract** 1996 Feb;192(2):137–47

MICROBIOLOGY

Absence of Kaposi's–sarcoma–associated herpesvirus–like DNA sequences (KSHV) in angiosarcomas developing in body–cavity and other sites [letter] Tomita Y, et al. **Int J Cancer** 1996 Mar 28;66(1):141–2

MORTALITY

Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Huncharek M, et al. **Anticancer Res** 1996 May–Jun;16(3A):1265–8

Occupational and environmental links to mesothelioma deaths occurring in Leeds during 1971–1987. Arblaster L, et al. **J Public Health Med** 1995 Sep;17(3):297–304

Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis. Coggon D, et al. **Occup Environ Med** 1995 Nov;52(11):775–7

PATHOLOGY

Pleuropulmonary blastoma with vascular invasion. Dobard GF, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):308

The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. Patz EF Jr, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):323–7

Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Boutin C, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):444–9

Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Québec. Dufresne A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):711–8

Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. Gaertner E, et al. **Am J Surg Pathol** 1996 Jan;20(1):36–45

Clinical course of human epithelial–type malignant pleural mesothelioma replicated in an orthotopic–transplant nude mouse model. Colt HG, et al. **Anticancer Res** 1996 Mar–Apr;16(2):633–9

Benign fibrous mesothelioma: report of a case. Morelli MM, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2877–82

Malignant pleural mesothelioma. a morphometric study. Serio G, et al. **Boll Soc Ital Biol Sper** 1995 Nov–Dec; 71(11–12):317–24

Malignant pleural mesothelioma. A proposed new staging system [editorial; comment] Jett JR. **Chest** 1995 Oct; 108(4):895–7 (18 ref.). Comment on: Chest 1995 Oct;108(4):1122–8.

Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Johansson L, et al. **Chest** 1996 Jan;109(1):109–14

Extensive pulmonary metastases in malignant pleural mesothelioma. A rare clinical and radiographic presentation. Ohishi N, et al. **Chest** 1996 Jul;110(1):296–8

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group [see comments] Rusch VW. **Chest** 1995 Oct;108(4):1122–8. Comment in: Chest 1995 Oct;108(4):895–7.

Benign fibrous mesothelioma of the pleura: MR study and pathologic correlation. Padovani B, et al. **Eur Radiol** 1996; 6(4):425–8

A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu–M1, Ber EP4, Tamm–Horsfall protein and thrombomodulin. Attanoos RL, et al. **Histopathology** 1995 Oct;27(4):361–6

Smooth muscle tumours of the pleura. Gibbs AR. **Histopathology** 1995 Sep;27(3):295–6 (17 ref.)

Smooth muscle tumours presenting as pleural neoplasms. Moran CA, et al. **Histopathology** 1995 Sep;27(3):227–34

The differential expression of N–cadherin and E–cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Peralta Soler A, et al. **Hum Pathol** 1995 Dec;26(12):1363–9

Solitary fibrous tumor [letter] Wetzel WJ. **Hum Pathol** 1996 May;27(5):513–4

Malignant mesothelioma of the pleura: interobserver variability. Andrion A, et al. **J Clin Pathol** 1995 Sep; 48(9):856–60

The importance of surgical staging in the treatment of malignant pleural mesothelioma. Rusch VW, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):815–25; discussion 825–6

Interleukin–6–mediated growth enhancement of cell lines derived from pyothorax–associated lymphoma. Kanno H, et al. **Lab Invest** 1996 Aug;75(2):167–73

A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Rusch VW. **Lung Cancer** 1996 Feb;14(1):1–12

Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist. Zampi G, et al. **Med Lav** 1995 Sep–Oct;86(5):389–92

Intracranial meningioma masquerading as a primary pleuropulmonary tumor. Hishima T, et al. **Pathol Int** 1995 Aug;45(8):617–21 (23 ref.)

Multiple skeletal muscle metastases from malignant pleural mesothelioma. Grellner W, et al. **Pathol Res Pract** 1995 Jun;191(5):456–60; discussion 461–2

Intracranial metastases from malignant pleural mesothelioma. Davies MJ, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(2):97–9

Malignant mesenchymoma of the pleura. Sheffield M, et al. **South Med J** 1996 May;89(5):526–8 (7 ref.)

Pleural mesothelioma with initial presentation as cervical lymphadenopathy. Wills EJ. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):389–94

[Pleural fibroma. Contribution of immunohistochemistry] Léna H, et al. **Rev Mal Respir** 1995;12(4):383–5 (Eng. Abstr.) **(Fre)**

[A case of localized fibrous mesothelioma arising from visceral pleura of the right lower lobe] Horiguchi T, et al. **Kyobu Geka** 1995 Sep;48(10):887–9 (Eng. Abstr.) **(Jpn)**

[A recurrence of benign fibrous mesothelioma of the pleura: a case report] Katakura H, et al. **Kyobu Geka** 1995 Aug; 48(9):800–4 (Eng. Abstr.) **(Jpn)**

[Pancoast syndrome in a patient with malignant lymphoma arising from the pleura] Kobara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):85–9 (Eng. Abstr.) **(Jpn)**

[Pleural fibroma with a cavity–like air space] Takeyama K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):700–4 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127–46 (81 ref.)

PREVENTION & CONTROL

[The modifying effect of long-term administration of ascorbic acid with drinking water on asbestos-induced pleural carcinogenesis in Wistar rats] Stadnikova NM, et al. **Vopr Onkol** 1996;42(1):85–8 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Chest case of the day. Malignant mesothelioma of the pleura presenting with spontaneous bilateral pneumothoraces. Dee PM. **AJR Am J Roentgenol** 1996 Jul;167(1):235, 239

Case report: non-Hodgkin's lymphoma presenting as an encasing pleural mass. Parnell AP, et al. **Br J Radiol** 1995 Aug;68(812):926–7

Calcification as a sign of sarcomatous degeneration of malignant pleural mesotheliomas: a new CT finding. Raizon A, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):42–4

[Roentgen findings in pleural diseases] Uhrmeister P, et al. **Internist (Berl)** 1995 Sep;36(9):937–47; quiz 948 (0 ref.) **(Ger)**

RADIONUCLIDE IMAGING

Metastatic pleural cancer in radionuclide angiocardiography. A pulmonary time–activity curve mimicking left–to–right cardiac shunt. Lee J, et al. **Clin Nucl Med** 1995 Nov; 20(11):1008–11

RADIOTHERAPY

Radiosensitivity of mesothelioma cell lines. Häkkinen AM, et al. **Acta Oncol** 1996;35(4):451–6

Preventive irradiation after invasive diagnostic and therapeutic procedures in malignant pleural mesothelioma [letter] Emri S, et al. **Chest** 1996 Jun;109(6):1665–6

Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Low EM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):317–8

SECONDARY

Metastatic pleural effusion as presenting sign of prostatic carcinoma. Druwé PM, et al. **Acta Clin Belg** 1995; 50(4):227–30

Hepatocellular carcinoma with pleural metastasis complicated by hemothorax. Takagi H, et al. **Am J Gastroenterol** 1996 Sep;91(9):1865–6

Case report: pleural encasement secondary to acinar adenocarcinoma of the submandibular gland. Hynes J, et al. **Br J Radiol** 1996 Mar;69(819):276–7 (12 ref.)

Metastatic pleural cancer in radionuclide angiocardiography. A pulmonary time–activity curve mimicking left–to–right cardiac shunt. Lee J, et al. **Clin Nucl Med** 1995 Nov; 20(11):1008–11

Intrathoracic hyperthermochemotherapeutic perfusion for the intrathoracic malignancies in gastric cancer. Fujimura T, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):878–84

[A case of recurrent breast carcinoma with metastatic foci in the lung and pleura treated successfully with biochemical modulation of 5-fluorouracil by low-dose cisplatin] Oura S, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1069–71 (Eng. Abstr.) **(Jpn)**

SURGERY

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long-term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. Shimizu J, et al. **J Surg Oncol** 1996 Jan;61(1):1–6

Intrapulmonary benign fibrous tumor of the pleura [letter; comment] Brunelli A, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1292–3. Comment on: J Thorac Cardiovasc Surg 1995 Aug;110(2):549–51.

The importance of surgical staging in the treatment of malignant pleural mesothelioma. Rusch VW, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):815–25; discussion 825–6

Thoracoscopic resection of a localized visceropleural mesothelioma. Matsuzoe D, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):324–6

[Benign pleural mesothelioma. Report of 2 cases] Ruff S, et al. **Langenbecks Arch Chir** 1995;380(6):345–9 (12 ref.) (Eng. Abstr.) **(Ger)**

[Prognosis of the surgical treatment for non-Hodgkin lymphoma originating from chronic tuberculous empyema--analysis of 11 cases with pleuropneumonectomy] Nakajima Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):484–92 (Eng. Abstr.) **(Jpn)**

THERAPY

Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Huncharek M, et al. **Anticancer Res** 1996 May–Jun;16(3A):1265–8

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I–II study. Goey SH, et al. **Br J Cancer** 1995 Nov;72(5):1283–8

Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Hoganson DK, et al. **Cancer Res** 1996 Mar 15;56(6):1315–23

Intrathoracic hyperthermochemotherapeutic perfusion for the intrathoracic malignancies in gastric cancer. Fujimura T, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):878–84

Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Elshami AA, et al. **Hum Gene Ther** 1996 Jan 20;7(2):141–8

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I–II study of weekly cisplatin/interferon alfa-2a. Soulié P, et al. **J Clin Oncol** 1996 Mar;14(3):878–85

Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. Sauter ER, et al. **J Surg Oncol** 1995 Oct;60(2):100–5

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127–46 (81 ref.)

Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Colleoni M, et al. **Tumori** 1996 Jan–Feb;82(1):53–6

[A case of recurrent breast carcinoma with metastatic foci in the lung and pleura treated successfully with biochemical modulation of 5-fluorouracil by low-dose cisplatin] Oura S, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1069–71 (Eng. Abstr.) **(Jpn)**

VIROLOGY

Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Said W, et al. **Blood** 1996 Jun 15;87(12):4937–43

Role of Epstein–Barr virus in pleural lymphomagenesis. Ohsawa M, et al. **Mod Pathol** 1995 Oct;8(8):848–53

PLEURAL RUB see **RESPIRATORY SOUNDS**

PLEURISY

[Purulent pleurisy in the child] Ndiaye O, et al. **Dakar Med** 1994;39(2):179–84 (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

Warfarin–induced eosinophilic pleurisy. Kuwahara T, et al. **Intern Med** 1995 Aug;34(8):794–6

Inhibitory action of indomethacin on neutrophil infiltration in monosodium urate-induced pleurisy in rats. Aihara S, et al. **Jpn J Pharmacol** 1995 Jul;68(3):271–7

Suggestive evidence for bromocriptine-induced pleurisy. Klaassen RJ, et al. **Neth J Med** 1996 Jun;48(6):232–6

[Drug-induced pleurisy] Benard A, et al. **Rev Mal Respir** 1996 Jul;13(3):227–34 (82 ref.) (Eng. Abstr.) **(Fre)**

[Adverse effects of ergot alkaloids. An important differential diagnosis from asbestos-induced pleuritis] Blomqvist A, et al. **Lakartidningen** 1996 May 29;93(22):2163–4 **(Swe)**

DIAGNOSIS

[Pleuro–mediastinitis in pulmonary actinomycosis as a rare differential bronchial carcinoma diagnosis] Orth M, et al. **Pneumologie** 1995 Sep;49(9):505–8 (Eng. Abstr.) **(Ger)**

[Differential diagnosis of exudative pleurisy] Shchennikov EL. **Klin Med (Mosk)** 1995;73(4):61–3 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Involvement of leukotrienes in allergic pleurisy in actively sensitized rats: inhibition by the lipoxygenase inhibitor T–0757 of the increase in vascular permeability and leukotriene E4 production. Kikuchi M, et al. **Inflamm Res** 1996 Apr;45(4):192–7

Anti–inflammatory effect of magnolol, isolated from Magnolia officinalis, on A23187-induced pleurisy in mice. Wang JP, et al. **J Pharm Pharmacol** 1995 Oct;47(10):857–60

[The effect of the ultraphonophoesis of deresinated naphthalan in patients with a history of exudative pleurisy] Insanov AB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):18–20 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Expression and modulatory effects of heme oxygenase in acute inflammation in the rat. Willis D. **Inflamm Res** 1995 Aug;44 Suppl 2:S218–20

ETIOLOGY

Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5–lipoxygenase inhibitor T–0757. Kikuchi M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1302–4

[Etiologic aspects and therapeutic problems of purulent pleurisy in Abidjan (Côte d'Ivoire)] Domoua K, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):199–202 (Eng. Abstr.) **(Fre)**

[Acute pleurisy secondary to ovarian hyperstimulation after in vitro fertilization] Caliandro R, et al. **Rev Mal Respir** 1996;13(1):68–70 (Eng. Abstr.) **(Fre)**

[Pleurisy disclosing Horton's disease (letter)] Colnot F. **Rev Med Interne** 1996;17(5):430–1 **(Fre)**

[A case of SLE with the onset of pleuritis showing eosinophilia and elevation of serum IgE] Kojima T, et al. **Fukuoka Igaku Zasshi** 1996 Apr;87(4):97–101 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Alloxan diabetes reduces pleural mast cell numbers and the subsequent eosinophil influx induced by allergen in sensitized rats. Diaz BL, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):36–43

[The changes and clinical significance of interleukin 1 beta in pleural effusion] Yang T, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):85–7, 127–8 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

Mycobacterium avium–intracellulare pleuritis with massive pleural effusion. Okada Y, et al. **Eur Respir J** 1995 Aug; 8(8):1428–9

[Saprophytic pleuritis with Candida parapsilosis] Nakagawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar; 34(3):341–4 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The role of ICAM–1 in the reverse passive Arthus reaction induced pleurisy in the rat. Fielding LE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S213–4

SURGERY

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long-term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

THERAPY

[Etiologic aspects and therapeutic problems of purulent pleurisy in Abidjan (Côte d'Ivoire)] Domoua K, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):199–202 (Eng. Abstr.) **(Fre)**

VIROLOGY

[Nephropathia epidemica with pleuritis] Männistö J, et al. **Duodecim** 1994;110(11):1087–9 **(Fin)**

PLEURISY, TUBERCULOUS see **TUBERCULOSIS, PLEURAL**

PLEURODELES

EMBRYOLOGY

The embryonic development of Pleurodeles waltl (Michah). Reappraisal of the Gallien–Durocher stage series. Beetschen JC. **Int J Dev Biol** 1995 Jun;39(3):425–6

The chronological development of the urodele amphibian Pleurodeles waltl (Michah). Shi DL, et al. **Int J Dev Biol** 1995 Jun;39(3):427–41

METABOLISM

In vivo metabolism of benzo(a)pyrene in a lower vertebrate, the newt Pleurodeles walt. Marty J, et al. **Ecotoxicol Environ Saf** 1995 Oct;32(1):51–7

Development of catecholamine systems in the central nervous system of the newt Pleurodeles waltlii as revealed by tyrosine hydroxylase immunohistochemistry. González A, et al. **J Comp Neurol** 1995 Sep 11;360(1):33–48

[An analysis of keratin expression in the cells of the retinal pigment epithelium during transdifferentiation in newts] Grigorian EN, et al. **Ontogenez** 1995 Jul–Aug;26(4):310–23 (Eng. Abstr.) **(Rus)**

PLEURODESIS

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

Medical thoracoscopy. Technical details. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):479–86 (27 ref.)

Thoracoscopic bullectomy and tetracycline pleurodesis for the treatment of spontaneous pneumothorax. Waterworth PD, et al. **Respir Med** 1995 Sep;89(8):563–6

Chemical pleurodesis in the treatment of iterative neoplastic effusion. Batori M, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug;17(4):151–3

Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Zanella A, et al. **Tumori** 1996 Jan–Feb;82(1):96–8

[Pleuroscopy and talc pleurodesis in recurrent pleural effusions: experience with 51 cases] Panebianco V, et al. **G Chir** 1995 Oct;16(10):437–41 (Eng. Abstr.) **(Ita)**

PLEURODESIS

METHODS

Talc pleurodesis for treating malignant pleural effusions [letter; comment] Rodriguez-Panadero F. **Chest** 1995 Oct; 108(4):1178-9. Comment on: Chest 1994 Oct;106(4):1215-22.

Comparison of silver nitrate and tetracycline as pleural sclerosing agents in rabbits. Vargas FS, et al. **Chest** 1995 Oct;108(4):1080-3

Corynebacterium parvum versus tetracycline as pleural sclerosing agents in rabbits. Vargas FS, et al. **Eur Respir J** 1995 Dec;8(12):2174-7

[Current treatment strategy in malignant pleural effusion] Türler A, et al. **Wien Klin Wochenschr** 1996;108(9):255-61 (56 ref.) (Eng. Abstr.) **(Ger)**

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596-8 (11 ref.) **(Spa)**

[Pleurodesis with the patient's own blood: the initial results in 14 cases] Blanco Blanco I, et al. **Arch Bronconeumol** 1996 May;32(5):230-6 (Eng. Abstr.) **(Spa)**

PLEURODYNIA, EPIDEMIC

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Myalgia epidemica in Switzerland 1940 (Bornholm disease in Gais and Teufen). 1941 (classical article)] Gaell O, et al. **Schweiz Med Wochenschr** 1995 Sep 23;125(38):1793-8 **(Ger)**

PLEURODYNIA VIRUS see **COXSACKIEVIRUSES B**

PLEURONECTES see **FLOUNDER**

PLEURONECTIFORMES see **FLATFISHES**

PLEUROPNEUMONIA

EPIDEMIOLOGY

[Clinico-epidemiological considerations of 30 cases of pulmonitis and pleuropulmonitis in childhood] De Luca L, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):237-41 (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

[A new case of meningococcal pleuro-pneumopathy] Parrot A, et al. **Rev Pneumol Clin** 1995;51(5):299 **(Fre)**

VETERINARY

Oral immunization with lung-pathogenic bacteria is protective against defined challenge in a pig aerosol infection model. Hensel A, et al. **Adv Exp Med Biol** 1995; 371B:803-6

Mucosal and serum IgA antibodies in pigs following infection with Actinobacillus pleuropneumoniae. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:935-8

Pleuropneumonia associated with pulmonary hydatidosis in a horse. McGorum BC, et al. **Equine Vet J** 1994 May; 26(3):249-50

Variations in urinary gamma glutamyl transferase/urinary creatinine ratio in horses with or without pleuropneumonia treated with gentamicin. Rossier Y, et al. **Equine Vet J** 1995 May;27(3):217-20

Evaluation of pig lungs following an experimental challenge with Actinobacillus pleuropneumoniae serotype 1 and 5 in pigs inoculated with either hemolysin protein and/or outer membrane proteins. Madsen ME, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):329-35

Prognosis for return to racing after recovery from infectious pleuropneumonia in thoroughbred racehorses: 70 cases (1984-1989). Seltzer KL, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1300-1

Diagnosis of contagious caprine pleuropneumonia by detection and identification of Mycoplasma capricolum subsp. capripneumoniae by PCR and restriction enzyme analysis. Bölske G, et al. **J Clin Microbiol** 1996 Apr; 34(4):785-91

Serotypes and antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from piglets with pleuropneumonia. Asawa T, et al. **J Vet Med Sci** 1995 Aug; 57(4):757-9

Suppurative pleuropneumonia and a pulmonary abscess in a ram: ultrasonographic and radiographic findings. Braun U, et al. **Schweiz Arch Tierheilkd** 1995;137(6):272-8

Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge. Hensel A, et al. **Vet Microbiol** 1995 Nov;47(1-2):27-41

Production and characterization of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1. Lairini K, et al. **Vet Microbiol** 1995 Oct;46(4):369-81

Acute pleuropneumonia in Barbary sheep (Amnotragus lervia) associated with Chromobacterium violaceum. Carrasco L, et al. **Vet Rec** 1996 May 18;138(20):499-500

Serological characterisation and antimicrobial susceptibility of Actinobacillus pleuropneumoniae strains isolated from pigs in Spain. Gutiérrez CB, et al. **Vet Rec** 1995 Jul 15; 137(3):62-4

[Induction of polyvalent immunity against Actinobacillus pleuropneumoniae in an experimental rat model] Herrera L, et al. **Rev Latinoam Microbiol** 1995 Apr-Jun; 37(2):147-52 (Eng. Abstr.) **(Spa)**

PLEUROPNEUMONIA, CONTAGIOUS

DIAGNOSIS

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603-9 (30 ref.)

[Complement fixation reaction for the serologic diagnosis of bovine contagious pleuropneumonia: application and interpretation of the results] Regalla J. **Rev Sci Tech** 1995 Sep;14(3):631-44 (11 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Overview and epidemiology of contagious bovine pleuropneumonia in Africa. Masiga WN, et al. **Rev Sci Tech** 1995 Sep;14(3):611-30 (26 ref.)

Surveillance of contagious bovine pleuropneumonia in Switzerland. Stärk KD, et al. **Rev Sci Tech** 1995 Sep; 14(3):621-9

Contagious caprine pleuropneumonia in Uganda and isolation of Mycoplasma capricolum subspecies capripneumoniae from goats and sheep. Bölske G, et al. **Vet Rec** 1995 Dec 2;137(23):594

MICROBIOLOGY

Mycoplasma mycoides subspecies mycoides (small colony variant): the agent of contagious bovine pleuropneumonia and member of the "Mycoplasma mycoides cluster". Nicholas RA, et al. **J Comp Pathol** 1995 Jul;113(1):1-27 (122 ref.)

Molecular epidemiology of Mycoplasma mycoides subsp. mycoides biotype Small Colony, the agent of contagious bovine pleuropneumonia. Poumarat F, et al. **Vet Microbiol** 1995 Dec;47(3-4):305-15

Use of PCR to detect Mycoplasma mycoides subspecies mycoides from nasal filter strips. Kaura HT, et al. **Vet Rec** 1996 May 4;138(18):444-5

MORTALITY

High mortality in goats associated with the isolation of a strain of Mycoplasma mycoides subsp. mycoides (Large Colony type). Rodríguez JL, et al. **Zentralbl Veterinarmed [B]** 1995 Dec;42(10):587-93

PREVENTION & CONTROL

Contagious bovine pleuropneumonia vaccines: the need for improvements. Rweyemamu MM, et al. **Rev Sci Tech** 1995 Sep;14(3):593-601 (14 ref.)

[Vaccination strategies for contagious bovine pleuropneumonia in Africa] Sylla D, et al. **Rev Sci Tech** 1995 Sep;14(3):577-92 (8 ref.) (Eng. Abstr.) **(Fre)**

PLEUROPNEUMONIA-LIKE ORGANISMS see **MYCOPLASMA**

PLEXUS COELIACUS see **CELIAC PLEXUS**

PLICAMYCIN

BIOSYNTHESIS

Characterization of Streptomyces argillaceus genes encoding a polyketide synthase involved in the biosynthesis of the antitumor mithramycin. Lombó F, et al. **Gene** 1996 Jun 12;172(1):87-91

METABOLISM

Biostructural chemistry of magnesium. regulation of mithramycin-DNA interactions by Mg2+ coordination. Huang HW, et al. **Biochimie** 1995;77(9):729-38

Visualising the dissociation of sequence selective ligands from individual binding sites on DNA. Fletcher MC, et al. **FEBS Lett** 1996 Feb 12;380(1-2):118-22

PHARMACOLOGY

Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter. Vigneswaran N, et al. **Biochemistry** 1996 Jan 30;35(4):1106-14

An ABC transporter is essential for resistance to the antitumor agent mithramycin in the producer Streptomyces argillaceus. Fernández E, et al. **Mol Gen Genet** 1996 Jul 26;251(6):692-8

PLOIDIES

The prognostic information of DNA ploidy and S-phase fraction may vary with histologic grade in endometrial carcinoma. Gudmundsson TE, et al. **Acta Oncol** 1995; 34(6):803-12

The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Nordal RR, et al. **Acta Oncol** 1995;34(6):797-802

Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis. Bardales RH, et al. **Am J Clin Pathol** 1996 Jul; 106(1):29-34

p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Lanza G Jr, et al. **Am J Clin Pathol** 1996 May;105(5):604-12

Lack of X inactivation associated with maternal X isodisomy: evidence for a counting mechanism prior to X inactivation during human embryogenesis. Migeon BR, et al. **Am J Hum Genet** 1996 Jan;58(1):161-70

Basaloid-squamous carcinoma of the esophagus. A clinicopathologic, DNA ploidy, and immunohistochemical study of seven cases. Abe K, et al. **Am J Surg Pathol** 1996 Apr;20(4):453-61

Heterogeneity of the chromatin fine structure in DNA-diploid breast cancer cells. Haroske G, et al. **Anal Cell Pathol** 1995 Apr;8(3):213-26

Cell proliferation and ploidy of human solid tumours: methodological experience with in vivo bromodeoxyuridine and DNA flow cytometry. Mazzini G, et al. **Anal Cell Pathol** 1996 Mar;10(2):101-13

Intratumoral regional heterogeneity of DNA ploidy patterns in colorectal carcinomas. Sasaki K, et al. **Anal Cell Pathol** 1995 Jun;8(4):323-30

Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma. Midulla C, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):157-62

DNA ploidy, cell kinetics, and epidermal growth factor receptor and HER2/neu oncoprotein expression in primary operable breast cancer. d'Agnano I, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:472-81

Ploidy as a prognostic feature in colonic adenocarcinoma. Takanishi DM Jr, et al. **Arch Surg** 1996 Jun;131(6):587-92

Variations of hepatic antioxidant systems and DNA ploidy in rats aged 2 to 8 months. Sanz N, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):123-30

P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Costa A, et al. **Br J Cancer** 1996 Apr;73(7):914-9

Flow cytometric DNA content analysis on squamous cell carcinomas according to the preceding lesions. Tamura A, et al. **Br J Dermatol** 1996 Jan;134(1):40-3

Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Angchaisuksiri P, et al. **Br J Haematol** 1996 Apr;93(1):13-7

Flow-cytometric DNA analysis of paraffin-embedded renal cell carcinoma tissue from patients treated by parenchymal-sparing surgery. Ciancio G, et al. **Br J Urol** 1995 Nov;76(5):570-4

P53 and ploidy assessed by flow cytometry in bladder washings. Griffiths TR, et al. **Br J Urol** 1995 Nov; 76(5):575-9

Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Iglehart JD, et al. **Breast Cancer Res Treat** 1995 Jun; 34(3):253-63

Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Chapman MA, et al. **Cancer** 1995 Aug 1;76(3):383-7

DNA index of glial tumors in children. Correlation with tumor grade and prognosis. Mathew P, et al. **Cancer** 1996 Aug 15;78(4):881-6

Near-tetraploidy in adult acute myelogenous leukemia. Clarke MR, et al. **Cancer Genet Cytogenet** 1996 Feb; 86(2):107-15

Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells. Geyp M, et al. **Cancer Genet Cytogenet** 1996 Apr;87(2):116-22

Genotypic characterization of a primary mucoepidermoid carcinoma of the parotid gland by cytogenetic, fluorescence in situ hybridization, and DNA ploidy analysis. el-Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):38-43

The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):137-45

Genome reorganization from polyteny to polyploidy in the nurse cells found in onion fly (Delia antiqua) and cabbage root fly (Delia radicum) ovaries (Diptera, Anthomyiidae). Hartman TP, et al. **Chromosome Res** 1995 Aug;3(5):271-80

Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates. Baldetorp B, et al. **Cytometry** 1995 Jun 15; 22(2):115-27

Contribution of ploidy and cell kinetics from fine-needle aspirates for the diagnosis of breast lesions: study of 606 consecutive cases. Daidone MG, et al. **Cytometry** 1995 Sep 15;22(3):177-80

Re: Impact of ploidy analysis on clinical care of patients [letter] Herman CJ. **Cytometry** 1995 Dec 15;22(4):330

Induction of tetraploid DNA content by mutant simian virus 40 T antigen that has reduced complex formation with p53. Lehman JM, et al. **Cytometry** 1996 Feb 1;23(2):126-30

DNA ploidy analysis by laser scanning cytometry (LSC) in colorectal cancers and comparison with flow cytometry. Sasaki K, et al. **Cytometry** 1996 Feb 1;23(2):106-9

Intratumoral heterogeneity of DNA ploidy in breast carcinomas: a flow cytometric assessment of sampling techniques. Schvimer M, et al. **Cytometry** 1995 Dec 15;

22(4):292–6
DNA ploidy and proliferation heterogeneity in human prostate cancers. Shankey TV, et al. **Cytometry** 1995 Sep 1;21(1):30–9
DNA ploidy and vimentin expression in primary breast cancer. Ioakim-Liossi A, et al. **Cytopathology** 1995 Oct; 6(5):325–30
Carcinoid tumor of the rectum. DNA ploidy is not a prognostic factor. Fitzgerald SD, et al. **Dis Colon Rectum** 1996 Jun;39(6):643–8
Prognostic value of ploidy, cell proliferation kinetics, and conventional clinicopathologic criteria in patients with colorectal carcinoma: a prospective study. Pietra N, et al. **Dis Colon Rectum** 1996 May;39(5):494–503
Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Karlsson M, et al. **Eur J Cancer** 1996 Feb;32A(2):357–62
Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Jacobsson S, et al. **Eur J Haematol** 1996 May;56(5):287–92
Full triploidy in a liveborn preterm infant [letter] Smets K, et al. **Eur J Pediatr** 1995 Aug;154(8):688
Study of tumour ploidy in early stages of buccal mucosa cancer. Mishra RC, et al. **Eur J Surg Oncol** 1996 Feb; 22(1):58–60
Dosage effects on gene expression in a maize ploidy series. Guo M, et al. **Genetics** 1996 Apr;142(4):1349–55
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Nordal RR, et al. **Gynecol Oncol** 1996 Aug;62(2):254–9
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment. Scheistrøen M, et al. **Gynecol Oncol** 1996 May;61(2):253–8
Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Zanetta GM, et al. **Gynecol Oncol** 1996 Feb; 60(2):213–6
Comparison of ploidy analysis by flow cytometry and image analysis in hydatidiform mole and non-molar abortion. Jeffers MD, et al. **Histopathology** 1995 Nov;27(5):415–21
DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Pich A, et al. **Hum Pathol** 1996 Jul;27(7):676–82
Prognostic significance of DNA index by flowcytometry in acute lymphoblastic leukaemia. Parikh PM, et al. **Indian J Med Res** 1995 Jul;102:24–7
A risk score for predicting outcome in patients with gastric cancer, based on stage, sialyl-Tn immunoreactivity and ploidy—a multivariate analysis. Victorzon M, et al. **Int J Cancer** 1996 Jul 17;67(2):190–3
Electron microscopy of the seminiferous epithelium in the triploid (ZZZ and ZZW) fowl, Gallus domesticus. Lin M, et al. **J Anat** 1995 Jun;186 (Pt 3):563–76
DNA ploidy level assessments in 83 human brain metastases. Relationship to the survival of 35 patients. Kiss R, et al. **J Cancer Res Clin Oncol** 1996;122(2):127–31
The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction. Sarbia M, et al. **J Cancer Res Clin Oncol** 1996;122(3):186–88
Interobserver variation in cell selection for DNA image cytometry. Carey FA, et al. **J Clin Pathol** 1995 Jul; 48(7):616–9
Image analysis evaluation of ploidy, S-phase fraction and nuclear area in canine mammary tumours. Destexhe E, et al. **J Comp Pathol** 1995 Oct;113(3):205–16
Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al. **J Hum Hypertens** 1995 Jun;9(6):497–500 (16 ref.)
DNA indices of primary and recurrent squamous cell carcinomas of the tongue and tonsil using image cytometry. Sarker SK, et al. **J Laryngol Otol** 1996 Mar;110(3):237–9
DNA ploidy of thyroid lesions. Cannon CR, et al. **J Miss State Med Assoc** 1995 Aug;36(8):237–40
The relation of radiosensitivity of hypopharyngeal squamous cell carcinoma to DNA ploidy. Monasebian DM, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):167–70
Genomic instability in colorectal carcinomas: comparison of different evaluation methods and their biological significance. Bocker T, et al. **J Pathol** 1996 May;179(1):15–9
Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy. Panizo-Santos A, et al. **J Pathol** 1995 Dec;177(4):431–7
The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):3–11 (38 ref.)
Re: Testicular seminoma: clinical significance of nuclear deoxyribonucleic acid ploidy pattern as studied by flow cytometry [letter; comment] Gross AJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):483. Comment on: J Urol 1995 Sep;154(3):1041–3; discussion 1044.
Value of deoxyribonucleic acid ploidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma. Ruiz-Cerdá JL, et al. **J Urol** 1996 Feb; 155(2):459–65
Clinical application of flow cytometry to urological malignancies. Tachibana M. **Keio J Med** 1996 Jun; 45(2):73–80 (54 ref.)
p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Weyrer K, et al. **Lab Invest** 1996 Jan; 74(1):279–89
Cell size heterogeneity in AML—DNA ploidy as another possible association [letter] Kwong YL. **Leuk Res** 1996 Jul; 20(7):625
DNA ploidy of hydatidiform moles and nonmolar conceptuses: a study using flow and tissue section image cytometry. Berezowsky J, et al. **Mod Pathol** 1995 Sep; 8(7):775–81
Induction of hypoploidy and cell cycle delay by acrylamide in somatic and germinal cells of male mice. Gassner P, et al. **Mutat Res** 1996 Apr 6;367(4):195–202
Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma [see comments] Ambros IM, et al. **N Engl J Med** 1996 Jun 6;334(23):1505–11. Comment in: N Engl J Med 1996 Jun 6;334(23):1537–9.
Rapidly growing histologically benign meningiomas: cell kinetic and deoxyribonucleic acid ploidy features: report of three cases. Kudoh C, et al. **Neurosurgery** 1995 Nov; 37(5):998–1000; discussion 1000–1
Multivariate analysis of DNA ploidy, steroid hormone receptors, and CA 125 as prognostic factors in ovarian carcinoma: a prospective study. Eissa S, et al. **Nutrition** 1995 Sep-Oct;11(5 Suppl):622–6
Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Victorzon M, et al. **Oncology** 1996 May-Jun;53(3):182–91
DNA measurements and ploidy determination of developmental stages in the life cycles of Theileria annulata and T. parva. Gauer M, et al. **Parasitol Res** 1995; 81(7):565–74
Functional haplodiploidy: a mechanism for the spread of insecticide resistance in an important international insect pest. Brun LO, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9861–5
A change of ploidy can modify epigenetic silencing. Mittelsten Scheid O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7114–9
Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DU145, and LNCaP prostatic cancer cell lines: relationship with DNA ploidy level. Janssen T, et al. **Prostate** 1995 Nov;27(5):277–86
Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF, et al. **Prostate** 1996 Jul;29(1):46–50
Development of the gonads in the triploid (ZZW and ZZZ) fowl, Gallus domesticus, and comparison with normal diploid males (ZZ) and females (ZW). Lin M, et al. **Reprod Fertil Dev** 1995;7(5):1185–97
DNA index and ploidy distinguish normal human parathyroids from parathyroid adenomas and primary hyperplastic parathyroids. Chryssochoos JT, et al. **Surgery** 1995 Dec;118(6):1041–9; discussion 1049–50
The peroxisome proliferations WY-14,643 and methylclofenapate induce hepatocyte ploidy alterations and ploidy-specific DNA synthesis in F344 rats. Miller RT, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):317–23
DNA content and cell kinetics in colorectal carcinoma: flow cytometric analysis of primary tumor and liver metastases. Danova M, et al. **Tumori** 1995 May-Jun;81(3 Suppl):12–5
Flow cytometric nuclear DNA content analysis of renal tumors in children: prognostic significance of nuclear DNA ploidy. Li P, et al. **Tumour Biol** 1995;16(6):385–93
Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer. Egawa S, et al. **Urology** 1996 Apr;47(4):548–52
Clinical significance of DNA ploidy pattern in stage III gastric cancer. Sakusabe M, et al. **World J Surg** 1996 Jan; 20(1):27–31
Scp160p, a new yeast protein associated with the nuclear membrane and the endoplasmic reticulum, is necessary for maintenance of exact ploidy. Wintersberger U, et al. **Yeast** 1995 Aug;11(10):929–44
The influence of ploidy on the distribution of cells in chimaeric mouse blastocysts. Everett CA, et al. **Zygote** 1996 Feb;4(1):59–66
[Flow cytometric DNA analysis of malignant potential in colorectal cancer] Ando Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:112–7 (Eng. Abstr.) **(Jpn)**
[DNA index as a significant prognostic indicator of colorectal cancer] Kimura O, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23 Suppl 2:118–24 (Eng. Abstr.) **(Jpn)**
[DNA ploidy pattern in resected human hepatocellular carcinomas from the view point of biological malignant potential] Saiki I, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23 Suppl 2:135–42 (Eng. Abstr.) **(Jpn)**
[Correlation between intratumor DNA ploidy distribution pattern and clinicopathologic variables in large-bowel carcinoma] Sasaki O, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:125–9 (Eng. Abstr.) **(Jpn)**
[Correlation between intratumor DNA ploidy distribution pattern and prognosis by tumor stage in colorectal carcinomas] Sasaki O, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:107–11 (Eng. Abstr.) **(Jpn)**
[Studies on nuclear DNA content in bladder cancers using flow cytometry] Toyota K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):45–53 (Eng. Abstr.) **(Jpn)**
[Tumor size and DNA ploidy changes in renal cell carcinomas—flow cytometric analysis of DNA content in renal cell carcinomas associated with von Hippel-Lindau disease] Nagamori S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):754–9 (Eng. Abstr.) **(Jpn)**
[Nuclear ploidy in atrial cardiomyocytes in patients with heart disease] Ibragimova IF, et al. **Arkh Patol** 1995 Nov-Dec;57(6):12–5 (Eng. Abstr.) **(Rus)**
[Possible use of parameters of tumor cell ploidies and carcinoembryonic antigen levels in the prognostication of epidermoid lung cancer] Khallenko VA, et al. **Vestn Ross Akad Med Nauk** 1996;(3):21–3 (Eng. Abstr.) **(Rus)**
[Significance of ploidy in prostatic cancer, quantified by a prospectively applicable procedure] Valle Gerhold J, et al. **Arch Esp Urol** 1996 Mar;49(2):139–45 (Eng. Abstr.) **(Spa)**

PLOTOSUS see CATFISH

PLUM POX VIRUS

ENZYMOLOGY

The RNA helicase CI from plum pox potyvirus has two regions involved in binding to RNA. Fernández A, et al. **FEBS Lett** 1996 Jun 17;388(2–3):206–10
Properties of the active plum pox potyvirus RNA polymerase complex in defined glycerol gradient fractions [published erratum appears in Virus Res 1995 Oct;38(2–3):317] Martin MT, et al. **Virus Res** 1995 Jul;37(2):127–37

ISOLATION & PURIFICATION

Localization of fruit tree viruses by immuno-tissue printing in infected shoots of Malus sp. and Prunus sp. Knapp E, et al. **J Virol Methods** 1995 Oct;55(2):157–73
Print-capture PCR: a simple and highly sensitive method for the detection of plum pox virus (PPV) in plant tissues. Olmos A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2192–3

PATHOGENICITY

Transmission by aphids of a naturally non-transmissible plum pox virus isolate with the aid of potato virus Y helper component. López-Moya JJ, et al. **J Gen Virol** 1995 Sep; 76 (Pt 9):2293–7

PLUMBING see SANITARY ENGINEERING

PLUMMER-VINSON SYNDROME

Plummer-Vinson syndrome. A case report and literature review. Hoffman RM, et al. **Arch Intern Med** 1995 Oct 9;155(18):2008–11 (25 ref.)

COMPLICATIONS

Dilation therapy of upper esophageal webs in two cases of Plummer-Vinson syndrome. Beyler AR, et al. **Endoscopy** 1996 Feb;28(2):266–7

PLURALISM see CULTURAL DIVERSITY

PLUTONIUM

Pulmonary carcinogenesis in the F344 and Wistar rat after inhalation of plutonium dioxide. Sanders CL, et al. **Radiat Res** 1995 Nov;144(2):206–14
[Method of determination of calcium in the hand by 238-Pu-Be source neutron activation] Zaĭchik VE, et al. **Kosm Biol Aviakosm Med** 1991 Sep-Oct;25(5):58–61 **(Rus)**
[State of cellular immunity effectors of the lung in inhalation exposure to low-transportable Pu-239] Sokol'nikov ME, et al. **Radiats Biol Radioecol** 1995 May-Jun;35(3):405–11 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

210Po and 210Pb intake by the Portuguese population: the contribution of seafood in the dietary intake of 210Po and 210Pb. Carvalho FP. **Health Phys** 1995 Oct;69(4):469–80
[Long-term consequences of the effects of single inhalation of Pu-239 in association with tributyl phosphate and hexachlorobutadiene in rats] Kalmykova ZI, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):88–93 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Long-term consequences of the effects of single inhalation of Pu-239 in association with tributyl phosphate and hexachlorobutadiene in rats] Kalmykova ZI, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):88–93 (Eng. Abstr.) **(Rus)**
[The "dose-response" mechanism of tumorigenesis in workers of radiochemical plants] Tokarskaia ZB, et al. **Vopr Onkol** 1996;42(1):48–52 (Eng. Abstr.) **(Rus)**

ANALYSIS

Distribution of 239,240Pu and 238Pu concentrations in sediments from the Ob and Yenisey Rivers and the Kara Sea. Baskaran M, et al. **Appl Radiat Isot** 1995 Nov; 46(11):1109–19

PLUTONIUM

Environmental plutonium in humans. Taylor DM. **Appl Radiat Isot** 1995 Nov;46(11):1245–52

Plutonium in the Savannah River Site environment. Carlton WH, et al. **Health Phys** 1996 Sep;71(3):290–9

Comparative distribution of 241 Am and 239,240 Pu in soils around the Rocky Flats Environmental Technology Site. Ibrahim SA, et al. **Health Phys** 1996 Apr;70(4):520–6

Comprehensive appraisal of 239 + 240Pu in soils around Rocky Flats, Colorado. Litaor MI, et al. **Health Phys** 1995 Dec;69(6):923–35

Natural radionuclide and plutonium content in Black Sea bottom sediments. Strezov A, et al. **Health Phys** 1996 Jan; 70(1):70–80

The gender-specific chest wall thickness prediction equations for routine measurements of 239Pu and 241Am within the lungs using HPGe detectors. Vickers LR. **Health Phys** 1996 Mar;70(3):346–57

METABOLISM

The distribution and effects of inhaled 239Pu(NO3)4 deposited in the liver of dogs. Dagle GE, et al. **Health Phys** 1996 Aug;71(2):198–205

Optimising the removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water. Gray SA, et al. **Hum Exp Toxicol** 1995 Nov; 14(11):902–8

[State of the lymphoid tissue of tracheobronchial lymph nodes in rats after incorporation in respiratory organs of low-transportable Pu-239] Sokol'nikov ME. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):133–8 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Changes in soft tissue concentrations of plutonium and americium with time after human occupational exposure. Filipy RE, et al. **Health Phys** 1996 Feb;70(2):153–9

Simplified organ retention functions for physiologically based recycling biokinetic models. Khursheed A, et al. **Health Phys** 1996 May;70(5):656–64

Octadentate catecholamide ligands for Pu(IV) based on linear or preorganized molecular backbones. Durbin PW, et al. **Hum Exp Toxicol** 1996 Apr;15(4):352–60

Efficacy of 3,4,3-LIHOPO for enhancing the excretion of plutonium from rat after simulated wound contamination as a tributyl-n-phosphate complex. Paquet F, et al. **Int J Radiat Biol** 1995 Dec;68(6):663–8

Treatment with 3,4,3-LIHOPO of simulated wounds contaminated with plutonium and americium in rat. Volf V, et al. **Int J Radiat Biol** 1996 Jul;70(1):109–14

PHARMACOLOGY

[Early ultrastructural lesions of kidney cells after intravenous administration of 239 plutonium citrate in rats] Thannoo DR, et al. **C R Acad Sci III** 1996 Feb;319(2):119–23 (Eng. Abstr.) **(Fre)**

TOXICITY

Soft tissue tumors induced by monomeric 239Pu. Lloyd RD, et al. **Health Phys** 1995 Oct;69(4):530–7

Hepatic effects of inhaled plutonium dioxide in beagles. Weller RE, et al. **Radiat Res** 1995 Oct;144(1):73–81

[Comparative study of hazards of energy plutonium and standard Pu-239 using non stochastic effects] Kalmykova ZI, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):94–103 (Eng. Abstr.) **(Rus)**

URINE

Assessment of plutonium exposures in Rongelap and Utirik populations by fission track analysis of urine. Sun LC, et al. **Appl Radiat Isot** 1995 Nov;46(11):1259–69

[Evaluation of the effects of biological and clinical factors on plutonium excretion in man] Men'shikh ZS, et al. **Radiats Biol Radioecol** 1996 Jan-Feb;36(1):104–8 (Eng. Abstr.) **(Rus)**

PMSG see **GONADOTROPINS, EQUINE**

PNEUMATIC SUITS see **G SUITS**

PNEUMATOSIS CYSTOIDES INTESTINALIS

Pneumatosis intestinalis: a review. Heng Y, et al. **Am J Gastroenterol** 1995 Oct;90(10):1747–58 (118 ref.)

Pneumatosis cystoides intestinalis—in Tanzania. Aziz MR, et al. **Cent Afr J Med** 1995 Jul;41(7):230–3

COMPLICATIONS

Pneumatosis cystoides intestinalis. Conservative approach in non surgical pneumoperitoneum: a case report and literature review. Brewaeys P, et al. **Acta Chir Belg** 1995; 95(4 Suppl):195–8 (25 ref.)

Bloody neonatal diaper. Guritzky RP, et al. **Ann Emerg Med** 1996 May;27(5):662–4

[Radiological case of the week (2). Intestinal wall gangrene in mesenterial infarction with intramural and intraportal gas] Krestin GP. **Schweiz Rundsch Med Prax** 1995 Oct 24; 84(43):1239–41 **(Ger)**

DIAGNOSIS

[Pneumatosis cystoides intestinalis] Christl SU, et al. **Dtsch Med Wochenschr** 1996 Feb 16;121(7):195–9 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Heliox treatment for pneumatosis cystoides coli [letter; comment] O'Toole PA, et al. **Lancet** 1995 Dec 2; 346(8988):1498–9. Comment on: Lancet 1995 May 13;345(8959):1220–2.

ETIOLOGY

Pneumatosis cystoides intestinalis in progressive systemic sclerosis: a case report and literature review. Quiroz ES, et al. **Am J Med Sci** 1995 Dec;310(6):252–5

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)

Residents' corner. Answer to case of the month #38. Pneumatosis intestinalis after bone marrow transplantation. Galland CC, et al. **Can Assoc Radiol J** 1996 Aug; 47(4):291–3

PATHOLOGY

Mixed connective tissue disease complicated by pneumatosis cystoides intestinalis and malabsorption syndrome: case report and literature review. Wakamatsu M, et al. **Pathol Int** 1995 Nov;45(11):875–8 (18 ref.)

RADIOGRAPHY

Small bowel Procardia XL tablet bezoar mimicking cystic pneumatosis intestinalis. Kwon HY, et al. **Abdom Imaging** 1996 Mar-Apr;21(2):142–4

Computed tomography in pneumatosis intestinalis: differential diagnosis and therapeutic consequences. Scheidler J, et al. **Abdom Imaging** 1995 Nov-Dec; 20(6):523–8

Pneumatosis intestinalis in adults with AIDS: clinical significance and imaging findings. Wood BJ, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1387–90

Intestinal obstruction in an elderly man. Azimuddin K, et al. **Postgrad Med J** 1995 Dec;71(842):759–61

[Pneumoperitoneum in asymptomatic pneumatosis intestinalis—much ado about nothing?] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):266–8 (10 ref.) **(Ger)**

[Interesting differential diagnosis: pneumatosis cystoides intestinalis] Kittner T, et al. **Rontgenpraxis** 1996 Mar; 49(3):58–60 **(Ger)**

SURGERY

A case of pneumatosis coli managed by restorative proctectomy and ileal pouch-anal anastomosis. Woodward A, et al. **Int J Colorectal Dis** 1995;10(3):181–2

ULTRASONOGRAPHY

Diagnosis of colonic pneumatosis cystoides intestinalis by endosonography. Bansal R, et al. **Gastrointest Endosc** 1995 Jul;42(1):90–3

Sonographic diagnosis of systemic venous gas in a patient with pneumatosis intestinalis. Soboleski D, et al. **Pediatr Radiol** 1995;25(6):480–1

PNEUMOCEPHALUS

An unusual cause of altered mental status. Counselman FL, et al. **J Emerg Med** 1995 Nov-Dec;13(6):757–63

Tension pneumocephalus following posterior cranial fossa surgery in sitting position. Tripathy P, et al. **J Indian Med Assoc** 1995 Mar;93(3):109–10

COMPLICATIONS

Chronic pneumocephalus presenting as frontal lobe syndrome. Garg RK, et al. **J Assoc Physicians India** 1995 Sep;43(9):645–6

Traumatic occlusion of the anterior cerebral artery—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):882–5 (7 ref.)

ETIOLOGY

Tension pneumocephalus after transsphenoidal surgery: two case reports. Yüceer N, et al. **Acta Neurochir (Wien)** 1995; 137(1-2):58–61

Re: Bronchopleural-subarachnoid fistula manifesting as intracranial gas on CT scans [letter; comment] Lerner EJ. **AJR Am J Roentgenol** 1996 Jun;166(6):1497. Comment on: AJR Am J Roentgenol 1995 Dec;165(6):1364–5.

Tension pneumocephalus: a complication of invasive ossifying fibroma of the paranasal sinuses. Tobey JD, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):711–3

Pneumocephalus: an unusual complication of resuscitation. Robbins PM, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):747–9

Pneumocephalus after spinal anesthesia. Avellanal M, et al. **Anesthesiology** 1996 Aug;85(2):423–5

Spontaneous otogenic pneumocephalus. Maier W, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):300–2

Midline approach to aneurysms: an unusual complication [letter; comment] Abduljabbar T. **Br J Neurosurg** 1995; 9(4):565. Comment on: Br J Neurosurg 1993;7(1):5–12.

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar-Apr; 17(2):152–6 (22 ref.)

Tension pneumocephalus—a rare complication of radiotherapy in nasopharyngeal carcinoma. Ng WF, et al. **Pathology** 1995 Apr;27(2):204–8

Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278–9 (5 ref.)

Iatrogenic pneumocephalus in a man with undifferentiated nasopharyngeal carcinoma. A case report. Guida M, et al. **Tumori** 1995 Jul-Aug;81(4):290–5

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Occipital air sinus causing intracerebral pneumocephalus. Case illustration. Roda JM, et al. **J Neurosurg** 1996 Jun; 84(6):1072

The "temporocele". Hashash M, et al. **J Otolaryngol** 1995 Dec;24(6):370–4

RADIOGRAPHY

Bronchopleural-subarachnoid fistula manifesting as intracranial gas on CT scans [see comments] Smith DN, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1364–5. Comment in: AJR Am J Roentgenol 1996 Jun;166(6):1497.

Tension pneumocephalus: a case following petrousectomy. Robin N, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6; 55(1-2):65–6

Pneumocephalus due to nasopharyngeal carcinoma: case report. Kiu MC, et al. **Neuroradiology** 1996 Jan;38(1):70–2 (24 ref.)

Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278–9 (5 ref.)

THERAPY

Theoretical assessment of normobaric oxygen therapy to treat pneumocephalus. Dexter F, et al. **Anesthesiology** 1996 Feb; 84(2):442–7

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar-Apr; 17(2):152–6 (22 ref.)

PNEUMOCOCCAL INFECTIONS

Pneumococcal pyomyositis. Case report, review of the literature, and comparison with classic pyomyositis caused by other bacteria. Collazos J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1470–4 (40 ref.)

The pneumococcal problem. Obaro SK, et al. **BMJ** 1996 Jun 15;312(7045):1521–5 (49 ref.)

Deep soft-tissue infections caused by Streptococcus pneumoniae. Kragsbjerg P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):1002–4

Pneumococcal virulence factors and host immune responses to them. Watson DA, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):479–90 (87 ref.)

Remediable recurrent meningitis. Rajeshwari K, et al. **Indian Pediatr** 1995 Apr;32(4):491–6 (28 ref.)

Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. Jernigan DB, et al. **JAMA** 1996 Jan 17;275(3):206–9

Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. Plouffe JF, et al. **JAMA** 1996 Jan 17;275(3):194–8

Pneumococci causing invasive disease in New Zealand, 1987-94: serogroup and serotype coverage and antibiotic resistances. Martin DR, et al. **N Z Med J** 1996 Aug 9; 109(1027):288–90

Septic arthritis and osteomyelitis caused by penicillin and cephalosporin-resistant Streptococcus pneumoniae in a children's hospital. Abbasi S, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):78–83

High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Duchin JS, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):745–50

Liver abscess: an unusual manifestation of pneumococcal infection. Lund-Tønnesen S. **Scand J Infect Dis** 1995; 27(4):397–8 (5 ref.)

[Pneumococcal tricuspid valve endocarditis] Rasmussen S, et al. **Ugeskr Laeger** 1995 Dec 11;157(50):7014–5 (Eng. Abstr.) **(Dan)**

[Eight cases of infection caused by the Streptococcus milleri group—significance of serum antibody titer and a comparative investigation of the backgrounds and factors of infections caused by Streptococcus milleri and Streptococcus pneumoniae] Kimura M, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):884–9 (Eng. Abstr.) **(Jpn)**

[Modern views on pneumococcal infections in infants and toddlers] Kotulová D, et al. **Bratisl Lek Listy** 1995 Jun; 96(6):317–21 (Eng. Abstr.) **(Slo)**

[Streptococcus pneumoniae spondylodiscitis (letter)] Escrivá B, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):198–9 **(Spa)**

COMPLICATIONS

Pneumococcal soft tissue infections in patients with systemic lupus erythematosus [letter; comment] Crowe HM, et al. **Clin Infect Dis** 1995 Jun;20(6):1571–2. Comment on: Clin Infect Dis 1994 Jul;19(1):149–51.

Recurrent Streptococcus pneumoniae endocarditis. Cunningham R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):526–8 (11 ref.)

Fatal pneumococcal septicemia in a patient with a connective tissue disease. Guertler AT, et al. **J Emerg Med** 1996 Jan–Feb;14(1):33–8

Aortic aneurysm complicating bacterial endocarditis in childhood. Davis EA, et al. **J Paediatr Child Health** 1996 Feb;32(1):68–70

Invasive pneumococcal disease in HIV-1 infected patients [letter; comment] Domingo P, et al. **Lancet** 1996 May 18; 347(9012):1414. Comment on: Lancet 1996 Mar 16;347(9003):718–23.

Hepatocellular injury in Streptococcus pneumoniae–associated hemolytic uremic syndrome in children. Pan CG, et al. **Pediatr Nephrol** 1995 Dec; 9(6):690–3

[Pneumococcal cellulitis, secondary septic arthritis (letter)] Lalin P, et al. **Presse Med** 1996 Jan 6–13;25(1):38 **(Fre)**

[Acute bilateral amaurosis in sphenoid empyema caused by Streptococcus pneumoniae] Mardin CY, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):381–3 (Eng. Abstr.) **(Ger)**

CONGENITAL

Congenital pneumococcal sepsis in one of a set of premature twins [letter] Hansen TW, et al. **Eur J Pediatr** 1995 Jul; 154(7):591

DIAGNOSIS

Acute onset of bilateral hemorrhagic leg lesions. Pneumococcal cellulitis. House NS, et al. **Arch Dermatol** 1996 Jan;132(1):81–2, 84–5

Rapid identification of Streptococcus pneumoniae by PCR amplification of ribosomal DNA spacer region. Saruta K, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):165–70

Evaluation of the invasive techniques for diagnosing bacterial respiratory infections. Pozzi E, et al. **J Chemother** 1995 Aug;7(4):286–91 (26 ref.)

Evaluation of sampling sites for detection of upper respiratory tract carriage of Streptococcus pneumoniae and Haemophilus influenzae among healthy Filipino infants. Capeding MR, et al. **J Clin Microbiol** 1995 Nov; 33(11):3077–9

Delay is deadly. Avery JK. **J Tenn Med Assoc** 1995 Nov; 88(11):437–8

Identification of a patient with Streptococcus pneumoniae bacteremia and meningitis by the polymerase chain reaction (PCR). Isaacman DJ, et al. **Mol Cell Probes** 1995 Jun; 9(3):157–60

[Purulent pericardial effusion with tamponade: a rare initial manifestation of o pneumococcal infection] Möller A, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):237–40 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pneumococcal infections in an era of multiple antibiotic resistance. Gray BM. **Adv Pediatr Infect Dis** 1996;11:55–99 (156 ref.)

Effect of oxymetazoline nose drops on acute sinusitis in the rabbit. Bende M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):222–5

In vivo efficacy of trovafloxacin (CP–99,219), a new quinolone with extended activities against gram–positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Girard AE, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2210–6

Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Knudsen JD, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1253–8

Timing of penicillin treatment influences the course of Streptococcus pneumoniae–induced middle ear inflammation. Sato K, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1896–8

Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits. Park SS, et al. **Arch Ophthalmol** 1995 Oct;113(10):1324–9

Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. Johnson AP, et al. **BMJ** 1996 Jun 8;312(7044):1454–6

Penicillin and multiply antibiotic–resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)

Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y, et al. **Drugs** 1995;49 Suppl 2:420–2

Problems in the management of penicillin–resistant pneumococci [letter] Boswell TC, et al. **J Hosp Infect** 1995 Jul;30(3):233–5

Mechanisms of the spread of penicillin resistance in Streptococcus pneumoniae strains causing meningitis in children in France. Doit C, et al. **J Infect Dis** 1996 Sep; 174(3):520–8

Association of penicillin–resistant pneumococci with residence in a pediatric chronic care facility. Mannheimer SB, et al. **J Infect Dis** 1996 Sep;174(3):513–9

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

Therapy for penicillin–resistant Streptococcus pneumoniae [editorial] Strachan SA, et al. **J Med Microbiol** 1995 Oct; 43(4):237–8

Risk factors for carriage of drug–resistant Streptococcus pneumoniae among children in Memphis, Tennessee [see comments] Arnold KE, et al. **J Pediatr** 1996 Jun; 128(6):757–64. Comment in: J Pediatr 1996 Jun;128(6):729–30.

Resisting the urge to prescribe [editorial; comment] Edwards KM. **J Pediatr** 1996 Jun;128(6):729–30. Comment on: J Pediatr 1996 Jun;128(6):757–64.

Antibiotic–resistant pneumococci [letter; comment] Friedland IR. **J Pediatr** 1996 Jun;128(6):862–3. Comment on: J Pediatr 1995 Oct;127(4):526–32.

Antibiotic–resistant pneumococcal infection in children with sickle cell disease in the United States. Wang WC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):140–4

A case of fatal sepsis in a child due to highly resistant Streptococcus pneumoniae. Vukelić D, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:90–1

Drug–resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? Australian Group on Antimicrobial Resistance (AGAR). Collignon PJ, et al. **Med J Aust** 1996 Jan 15;164(2):64–7

Drug–resist and Streptococcus pneumoniae [letter; comment] Clynes NE. **N Engl J Med** 1996 Jan 4;334(1):53–5. Comment on: N Engl J Med 1995 Aug 24;333(8):474–80. Comment on: N Engl J Med 1995 Aug 24;333(8):481–6.

Penicillin–resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Block SL, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):751–9

Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Bradley JS, et al. **Pediatr Infect Dis J** 1995 Dec; 14(12):1037–41

Occurrence of Streptococcus pneumoniae meningitis during vancomycin and cefotaxime therapy of septicemia in a patient with sickle cell disease. Chesney PJ, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1013–5

Comparison of the response to antimicrobial therapy of penicillin–resistant and penicillin–susceptible pneumococcal disease. Friedland IR. **Pediatr Infect Dis J** 1995 Oct;14(10):885–90

Effect of antibiotic therapy on the outcome of outpatients with unsuspected bacteremia. Harper MB, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):760–7

Penicillin–resistant pneumococci in the United States [letter] Mason EO Jr, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1017–8

[The therapeutic implications of pneumococcal penicillin resistance] Lior C, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):136–45 (82 ref.) **(Spa)**

[Pneumococcus resistance. Reconsiderations on its empirical treatment] Pallarés M. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):90–2 (13 ref.) **(Spa)**

[Penicillin resistant pneumococci. Do not close the day care centers for healthy children] Alestig K, et al. **Lakartidningen** 1996 Jun 12;93(24):2356–7; discussion 2357–8 **(Swe)**

EPIDEMIOLOGY

Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. Arason VA, et al. **BMJ** 1996 Aug 17; 313(7054):387–91

Pneumococcal bacteremia in two tertiary care hospitals in Winnipeg, Canada. Pneumococcal Bacteremia Study Group. Mirzanejad Y, et al. **Chest** 1996 Jan;109(1):173–8

Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Hedlund J, et al. **Clin Infect Dis** 1995 Oct;21(4):948–53

Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia. Gratten M, et al. **J Clin Microbiol** 1996 Feb;34(2):338–41

Association of penicillin–resistant pneumococci with residence in a pediatric chronic care facility. Mannheimer SB, et al. **J Infect Dis** 1996 Sep;174(3):513–9

Invasive pneumococcal infections in human immunodeficiency virus–infected children. Mao C, et al. **J Infect Dis** 1996 Apr;173(4):870–6

Invasive pneumococcal infection in children, 1981–92: a hospital–based study. Davis CW, et al. **J Paediatr Child Health** 1995 Aug;31(4):317–22

Antibiotic–resistant pneumococcal infection in children with sickle cell disease in the United States. Wang WC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):140–4

Invasive pneumococcal disease in a cohort of predominantly HIV–1 infected female sex–workers in Nairobi, Kenya [see comments] Gilks CF, et al. **Lancet** 1996 Mar 16; 347(9003):718–23. Comment in: Lancet 1996 May 18;347(9012):1414.

Pneumococcal seroepidemiologic study of Colombian and Minnesota children. Salazar JC, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1001–3

Penicillin–resistant Streptococcus pneumoniae and acute pulmonary infections: prevalence and severity. Korppi M. **Pediatr Pulmonol Suppl** 1995;11:10–1

ETHNOLOGY

Invasive pneumococcal disease in central Australia. Trotman J, et al. **Clin Infect Dis** 1995 Jun;20(6):1553–6

ETIOLOGY

Pneumococcal sepsis in a splenectomized patient [letter] Ong EL, et al. **Br J Gen Pract** 1995 Sep;45(398):502–3

Cellulitis and spondylitis due to Streptococcus pneumoniae [letter; comment] Cortés E, et al. **Clin Infect Dis** 1995 Sep; 21(3):696. Comment on: Clin Infect Dis 1994 Jul;19(1):149–51.

Pneumococcal soft–tissue infections [letter; comment] Cuenca–Estrella M, et al. **Clin Infect Dis** 1995 Sep; 21(3):697–8. Comment on: Clin Infect Dis 1994 Jul;19(1):149–51.

The molecular basis of pneumococcal infection: a hypothesis. Cundell D, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S204–11 (114 ref.)

Penicillin–resistant Streptococcus pneumoniae as a cause of postoperative endophthalmitis. Martin E, et al. **Clin Infect Dis** 1995 Nov;21(5):1340–1

Fatal pneumococcal septic shock in a patient with ulcerative colitis. van der Hoeven JG, et al. **Clin Infect Dis** 1996 May; 22(5):860–1

Early postsplenectomy arthritis caused by penicillin–resistant Streptococcus pneumoniae. Merle–Melet M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):159–60 (7 ref.)

Endophthalmitis after routine intra–ocular surgery in an asplenic patient. Fuller JR, et al. **J R Soc Med** 1995 Aug; 88(8):475P–476P

Pathogenesis of middle ear adhesions. Cayé–Thomasen P, et al. **Laryngoscope** 1996 Apr;106(4):463–9

Pneumococcal parotitis in a human immunodeficiency virus–infected child. Hanekom WA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1113–4

Overwhelming pneumococcal sepsis in two patients splenectomised more than ten years previously. Hassan IS, et al. **Scott Med J** 1996 Feb;41(1):17–9

[Pneumococcal septic arthritis in HIV infection] Trivalle C, et al. **Presse Med** 1995 Nov 4;24(33):1566–8 (13 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease. Norris CF, et al. **J Pediatr** 1996 Jun;128(6):813–9

IMMUNOLOGY

Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections. Hidalgo H, et al. **Ann Allergy Asthma Immunol** 1996 Apr; 76(4):341–6

Basophil–bound IgE and serum IgE directed against Haemophilus influenzae and Streptococcus pneumoniae in patients with chronic bronchitis during acute exacerbations. Kjaergard LL, et al. **APMIS** 1996 Jan;104(1):61–7

Recurrent pneumococcal bacteremia. A warning of immunodeficiency. Rodríguez–Créixems M, et al. **Arch Intern Med** 1996 Jul 8;156(13):1429–34

Managing patients with an absent or dysfunctional spleen. Uncertainty exists over frequency of blood tests to test antipneumococcal immunity [letter; comment] Kassianos GC. **BMJ** 1996 May 25;312(7042):1360; discussion 1361. Comment on: BMJ 1996 Feb 17;312(7028):430–4.

Nasopharyngeal antibodies to pneumococcal pneumolysin in children with acute otitis media. Virolainen A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):704–7

Antibody response to unconjugated Haemophilus influenzae b and pneumococcal polysaccharide vaccines in children with recurrent infections. Raby R, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):451–9

Detection of C–polysaccharide in serum of patients with Streptococcus pneumoniae bacteraemia. Gillespie SH, et al. **J Clin Pathol** 1995 Sep;48(9):803–6

Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E–selectin and P–selectin double mutant mice. Bullard DC, et al. **J Exp Med** 1996 May 1; 183(5):2329–36

Selectins and neutrophil traffic: margination and Streptococcus pneumoniae–induced emigration in murine lungs. Mizgerd JP, et al. **J Exp Med** 1996 Aug 1; 184(2):639–45

Antibody–secreting cells and their relation to humoral antibodies in serum and in nasopharyngeal aspirates in children with pneumococcal acute otitis media. Nieminen T, et al. **J Infect Dis** 1996 Jan;173(1):136–41

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. Anderson EL, et al. **J Pediatr** 1996 May; 128(5 Pt 1):649–53

METABOLISM

Pentoxifylline ameliorates pulmonary damage caused by Streptococcus pneumoniae infection in mouse. Cui X, et al. **Chin Med J (Engl)** 1995 Nov;108(11):864–9

PNEUMOCOCCAL INFECTIONS

MICROBIOLOGY

Study documents spread of drug-resistant pneumococci [news] **Am J Health Syst Pharm** 1995 Oct 15;52(20):2164

Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Kam KM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2667–70

Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Kauppinen MT, et al. **Arch Intern Med** 1996 Sep 9;156(16):1851–6

Invasive pneumococcal infection in a community hospital, 1993 to 1995. Characteristics of resistant strains. Orenstein JB. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):809–14

Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Hedlund J, et al. **Clin Infect Dis** 1995 Oct;21(4):948–53

Deep soft-tissue infections caused by Streptococcus pneumoniae. Kragsbjerg P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):1002–4

Distribution of serotypes of Streptococcus pneumoniae isolated from invasive infections over a 16-year period in the greater São Paulo area, Brazil. Brandileone MC, et al. **J Clin Microbiol** 1995 Oct;33(10):2789–91

Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia. Gratten M, et al. **J Clin Microbiol** 1996 Feb;34(2):338–41

Invasive Streptococcus pneumoniae infection associated with rapidly fatal outcome in Taiwan. Hsueh PR, et al. **J Formos Med Assoc** 1996 May;95(5):364–71

Penicillin-resistant pneumococci—an emerging threat to successful therapy. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:472–82

Subtyping of common pediatric pneumococcal serotypes from invasive disease and pharyngeal carriage in Finland. Takala AK, et al. **J Infect Dis** 1996 Jan;173(1):128–35

Streptococcus pneumoniae pelvic inflammatory disease. A case report. Chudacoff RM, et al. **J Reprod Med** 1995 Sep; 40(9):649–51

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. AlonsoDeVelasco E, et al. **Microbiol Rev** 1995 Dec;59(4):591–603 (163 ref.)

Capsular types of Streptococcus pneumoniae causing disease in children from Mexico City. Echániz-Aviles G, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):907–9

[Evolution of the susceptibility to penicillin G of Streptococcus pneumoniae at the Limoge University Hospital Center] Ploy MC, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):241–4 (Eng. Abstr.) **(Fre)**

[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Endocarditis caused by Streptococcus pneumoniae. Report of 3 new cases (letter)] Montejo M, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):573–5 **(Spa)**

MORTALITY

Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Afessa B, et al. **Clin Infect Dis** 1995 Aug;21(2):345–51

Invasive Streptococcus pneumoniae infection associated with rapidly fatal outcome in Taiwan. Hsueh PR, et al. **J Formos Med Assoc** 1996 May;95(5):364–71

PREVENTION & CONTROL

Humoral immune response to pneumococcal vaccination. Prevention of infections with Streptococcus pneumoniae by immunization. Konradsen HB. **APMIS Suppl** 1996; 60:1–28

Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Farr BM, et al. **Arch Intern Med** 1995 Nov 27;155(21):2336–40

Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Honkanen PO, et al. **Arch Intern Med** 1996 Jan 22;156(2):205–8

Managing patients with an absent or dysfunctional spleen. Guidelines do not discuss resistance to antibiotics among pneumococci [letter; comment] Lambert HP. **BMJ** 1996 May 25;312(7042):1361. Comment on: BMJ 1996 Feb 17;312(7028):430–4.

The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445–51 (35 ref.)

Use of pneumococcal vaccine [letter; comment] Fedson DS. **J Gen Intern Med** 1995 Jul;10(7):412. Comment on: J Gen Intern Med 1995 Jan;10(1):40–55.

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. Chan CY, et al. **J Infect Dis** 1996 Jan;173(1):256–8

Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. Giebink GS, et al. **J Infect Dis** 1996 Jan;173(1):119–27

Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. Sankilampi U, et al. **J Infect Dis** 1996 Feb;173(2):387–93

Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. Tart RC, et al. **J Infect Dis** 1996 Feb;173(2):380–6

Pneumococcal vaccine [editorial] Mayon-White RT. **J Med Microbiol** 1996 Jun;44(6):397–8

Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. Rutherford EJ, et al. **J Trauma** 1995 Sep;39(3):448–52

From the Centers for Disease Control and Prevention. Increasing pneumococcal vaccination rates among patients of a national health-care alliance—United States, 1993. **JAMA** 1995 Nov 1;274(17):1333–4

Conjugate vaccines hold hope for countering resistant pneumococcus [news] Stephenson J. **JAMA** 1995 Nov 1; 274(17):1327–8

Increasing pneumococcal vaccination rates among patients of a National Health-Care Alliance—United States, 1993. **MMWR Morb Mortal Wkly Rep** 1995 Oct 13;44(40):741–4

Pneumococcal vaccine in children and young adults with chronic renal disease. Fuchshuber A, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):468–73

Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Lee HJ, et al. **Vaccine** 1995 Nov;13(16):1533–8

[Pharma-clinics. Drug of the month. Polyvalent antipneumococcal vaccine (Pneumune)] Scheen AJ. **Rev Med Liege** 1996 Mar;51(3):257–8 **(Fre)**

[Misleading advertisment of pneumococcal vaccine! (letter)] Andersen BM. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2355 **(Nor)**

[Pneumococcal vaccine for children prior the year of 2000. Promising data on vaccine candidates] Wilhelmson B. **Lakartidningen** 1995 Oct 11;92(41):3781–2 **(Swe)**

RADIOGRAPHY

Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Kauppinen MT, et al. **Arch Intern Med** 1996 Sep 9;156(16):1851–6

THERAPY

Does ICU care determine the outcome of caring for patients with pneumococcal bacteremia? [letter; comment] Franklin CM. **Chest** 1995 Nov;108(5):1475. Comment on: Chest 1995 Feb;107(2):457–62.

TRANSMISSION

Mechanisms of the spread of penicillin resistance in Streptococcus pneumoniae strains causing meningitis in children in France. Doit C, et al. **J Infect Dis** 1996 Sep; 174(3):520–8

Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia. Reichler MR, et al. **J Infect Dis** 1996 Feb;173(2):374–9

PNEUMOCOCCUS see STREPTOCOCCUS PNEUMONIAE

PNEUMOCONIOSIS

BLOOD

Plasma levels of soluble tumour necrosis factor receptors are increased in coal miners with pneumoconiosis. Schins RP, et al. **Eur Respir J** 1995 Oct;8(10):1658–63

[Free radial activity in patients with pneumoconioses] Kohout J, et al. **Vnitr Lek** 1996 Jan;42(1):20–2 (Eng. Abstr.) **(Cze)**

COMPLICATIONS

Risk of gastric cancer in pneumoconiotic coal miners and the effect of respiratory impairment. Swaen GM, et al. **Occup Environ Med** 1995 Sep;52(9):606–10

[Paroxysmal melanoptysis secondary to the cavitation of pulmonary pneumoconiosis conglomerate] Haro M, et al. **Arch Bronconeumol** 1996 Apr;32(4):199–201 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Forced oscillation technique (FOT): a new tool for epidemiology of occupational lung diseases? Pham QT, et al. **Eur Respir J** 1995 Aug;8(8):1307–13

[Quantitative diagnosis of dust-macule type pneumoconiosis] Wang H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):290–3 (Eng. Abstr.) **(Chi)**

[Thyroid hormones in patients with acute exacerbations of pneumoconiosis] Kawakami M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):846–9 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Prevention and treatment of pneumoconiosis in China. Li YR. **Biomed Environ Sci** 1995 Sep;8(3):211–7

EPIDEMIOLOGY

Thermophilic actinomycetes in cane sugar mills: an aeromicrobiologic and seroepidemiologic study. Khan ZU, et al. **Antonie Van Leeuwenhoek** 1995;67(4):339–44

Results of pneumoconiosis examination—different trends among industries. Shinozaki T, et al. **Ind Health** 1995; 33(1):23–7

Dust and pneumoconiosis in the South African foundry industry. Rees D, et al. **S Afr Med J** 1994 Dec;84(12):851–5

[Retrospective study of pneumoconiosis in Champagne-Ardenne] Chuchla S, et al. **Rev Mal Respir** 1995;12(5):453–7 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Associations of blood group-related antigens to FEV1, wheezing, and asthma. Kauffmann F, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):76–82

Longitudinal and cross-sectional analyses of lung function in steelworkers. Wang ML, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1907–13

Pneumoconiosis and pulmonary function defects in silica-exposed fire brick workers. Liou SH, et al. **Arch Environ Health** 1996 May-Jun;51(3):227–33

Three cases of dental technician's pneumoconiosis related to cobalt-chromium-molybdenum dust exposure. Selden A, et al. **Chest** 1996 Mar;109(3):837–42

Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust [letter] Armbruster C, et al. **Lancet** 1996 Sep 7;348(9028):690

Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. McDonald JW, et al. **Mod Pathol** 1995 Oct;8(8):859–65 (24 ref.)

Exposure to cobalt chromium dust and lung disorders in dental technicians. Seldén AI, et al. **Thorax** 1995 Jul; 50(7):769–72

[Allergies in agriculture] Gassner M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):950–60 (37 ref.) (Eng. Abstr.) **(Ger)**

[Role of characteristics of the bronchopulmonary structure in the etiology of occupational diseases of the respiratory organs] Milishnikova VV, et al. **Med Tr Prom Ekol** 1995; (8):1–4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[Correlation between HLA antigens and immune status in dust-induced lung diseases in workers of machine-building industry] Tkach SI, et al. **Med Tr Prom Ekol** 1995;(8):22–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)

MORTALITY

Mortality pattern in men with pneumoconiosis in Poland. Starzyński Z, et al. **Int J Occup Med Environ Health** 1995; 8(3):223–9

The survival analyses of 2738 patients with simple pneumoconiosis. Yi Q, et al. **Occup Environ Med** 1996 Feb; 53(2):129–35

PATHOLOGY

Nonasbestos ferruginous bodies in sputum from a patient with graphite pneumoconiosis: a case report. Mazzucchelli L, et al. **Acta Cytol** 1996 May-Jun;40(3):552–4

Radiographic and pathologic correlation of coal workers' pneumoconiosis. Vallyathan V, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):741–8

Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. McDonald JW, et al. **Mod Pathol** 1995 Oct;8(8):859–65 (24 ref.)

Uncommon pneumoconioses: CT and pathologic findings. Akira M. **Radiology** 1995 Nov;197(2):403–9

PHYSIOPATHOLOGY

Longitudinal and cross-sectional analyses of lung function in steelworkers. Wang ML, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1907–13

Oxidative DNA damage in peripheral blood lymphocytes of coal workers. Schins RP, et al. **Int Arch Occup Environ Health** 1995;67(3):153–7

Pulmonary disability in former Appalachian coal miners. Young RC Jr, et al. **J Natl Med Assoc** 1996 Aug; 88(8):517–22

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

[Spirometric investigation and spiro-ergometric test in evaluation of exercise tolerance in patients suffering from aluminosis and silicosis] Serwatowski P, et al. **Pneumonol Alergol Pol** 1995;63(9–10):498–501 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Prevention and treatment of pneumoconiosis in China. Li YR. **Biomed Environ Sci** 1995 Sep;8(3):211–7

[Significance of the helmet respirator in the treatment of farmer's occupational asthma] Taivainen A, et al. **Duodecim** 1994;110(4):423–8 **(Fin)**

[Occupational lung diseases (editorial)] Karrer W. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):949 **(Ger)**

RADIOGRAPHY

Radiographic and pathologic correlation of coal workers' pneumoconiosis. Vallyathan V, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):741–8

The diagnostic value of conventional X-ray examination of the lungs in comparison with high-resolution computed tomography (HRCT), isotope perfusion scintigraphy and the diffusion capacity in patients with pneumoconiosis. Petrova E, et al. **Int J Occup Med Environ Health** 1995; 8(3):231–8

Uncommon pneumoconioses: CT and pathologic findings. Akira M. **Radiology** 1995 Nov;197(2):403–9

Diffuse infiltrative lung disease: clinical value of sliding-thin-slab maximum intensity projection CT scans in the detection of mild micronodular patterns [see comments] Remy-Jardin M, et al. **Radiology** 1996 Aug; 200(2):333–9. Comment in: Radiology 1996 Aug;200(2):312–7.

[Clinical study of pneumoconiosis featuring small nodules and without large opacities on high-resolution CT] Yamane K. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Apr; 56(5):288–93 (Eng. Abstr.) **(Jpn)**

[Hard metal lung with diffuse small nodular shadows] Yokota T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):465–70 (Eng. Abstr.) **(Jpn)**

[Computed tomography of pneumoconiosis] Zhang X, et al. **Sangyo Eiseigaku Zasshi** 1995 Sep;37(5):321–8 (77 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

The diagnostic value of conventional X-ray examination of the lungs in comparison with high-resolution computed tomography (HRCT), isotope perfusion scintigraphy and the diffusion capacity in patients with pneumoconiosis. Petrova E, et al. **Int J Occup Med Environ Health** 1995; 8(3):231–8

PNEUMOCYSTIS CARINII

CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. Wiley JA, et al. **J Immunol** 1995 Oct 1;155(7):3525–9

Madin Darby canine kidney: a new cell line for Pneumocystis carinii in vitro culture. Atzori C, et al. **Parasite** 1996 Jun; 3(2):183–5

CHEMISTRY

Fatty acid composition of the major phospholipids of Pneumocystic carinii: comparison with those in the lungs of normal and methylprednisolone-immunosuppressed rats. Guo Z, et al. **Infect Immun** 1996 Apr;64(4):1407–12

Composition of Pneumocystis carinii neutral lipids and identification of coenzyme Q10 as the major ubiquinone homolog. Ellis JE, et al. **J Eukaryot Microbiol** 1996 May-Jun;43(3):165–70

CLASSIFICATION

Typing of Pneumocystis carinii strains with type-specific oligonucleotide probes derived from nucleotide sequences of internal transcribed spacers of rRNA genes. Lu JJ, et al. **J Clin Microbiol** 1995 Nov;33(11):2973–7

CYTOLOGY

Attachment of Pneumocystis carinii to primary cultures of rat alveolar epithelial cells. Pottratz ST, et al. **Exp Cell Res** 1995 Dec;221(2):357–62

DRUG EFFECTS

Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Bartlett MS, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2436–41

Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine. Merali S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):973–8

Enhanced efficacy of a liposomal pentamidine preparation in Pneumocystis carinii in an ex vivo/in vitro culture model without feederlayer cells. Sahm M, et al. **Appl Parasitol** 1996 Jun;37(2):137–45

In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii [letter] Cirioni O, et al. **J Antimicrob Chemother** 1995 Oct;36(4):740–2

Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. Piper JR, et al. **J Med Chem** 1996 Mar 15;39(6):1271–80

ENZYMOLOGY

Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Hong YL, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1756–63

An H(+)-ATPase regulates cytoplasmic pH in Pneumocystis carinii trophozoites. Docampo R, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):681–4

Species-specific microhelix aminoacylation by a eukaryotic pathogen tRNA synthetase dependent on a single base pair. Quinn CL, et al. **Biochemistry** 1995 Oct 3;34(39):12489–95

Cloning and characterization of an ATPase gene from Pneumocystis carinii which closely resembles fungal H+ ATPases. Meade JC, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):298–307

Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii. Gangjee A, et al. **J Med Chem** 1996 Apr 26;39(9):1836–45

Non specific PCR products using rat-derived Pneumocystis carinii dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples. Ortona E, et al. **Mol Cell Probes** 1996 Jun;10(3):187–90

GENETICS

Diversity of host species and strains of Pneumocystis carinii is based on rRNA sequences. Shah JS, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):119–27

Multi-gene family of major surface glycoproteins of Pneumocystis carinii: full-size cDNA cloning and expression. Kitada K, et al. **DNA Res** 1994;1(2):57–66

MSG gene cluster encoding major cell surface glycoproteins of rat Pneumocystis carinii. Wada M, et al. **DNA Res** 1994; 1(4):163–8

Isoform diversity and tandem duplication of the glycoprotein A gene in ferret Pneumocystis carinii. Wright TW, et al. **DNA Res** 1995;2(2):77–88

Cloning and characterization of a conserved region of human and rhesus macaque Pneumocystis carinii gpA. Wright TW, et al. **Gene** 1995 Dec 29;167(1-2):185–9

Signal transduction in Pneumocystis carinii: characterization of the genes (pcg1) encoding the alpha subunit of the G protein (PCG1) of Pneumocystis carinii carinii and Pneumocystis carinii ratti. Smulian AG, et al. **Infect Immun** 1996 Mar;64(3):691–701

Antigenic differences associated with genetically distinct Pneumocystis carinii from rats. Vasquez J, et al. **Infect Immun** 1996 Jan;64(1):290–7

Analysis of genetic diversity at the arom locus in isolates of Pneumocystis carinii. Banerji S, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):675–9

Cloning and characterization of an ATPase gene from Pneumocystis carinii which closely resembles fungal H+ ATPases. Meade JC, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):298–307

An arrayed bacteriophage P1 genomic library of Pneumocystis carinii. Metcheva IS, et al. **J Eukaryot Microbiol** 1996 May-Jun;43(3):171–6

Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens. Atzori C, et al. **J Infect Dis** 1995 Dec; 172(6):1623–6

Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. Tsolaki AG, et al. **J Infect Dis** 1996 Jul;174(1):141–56

Genetic variability in different Pneumocystis isolates from man and rats. Ortona E, et al. **New Microbiol** 1995 Jul; 18(3):335–40

Detection of Pneumocystis carinii sequences in serum by polymerase chain reaction. Miyawaki H, et al. **Respir Med** 1996 Mar;90(3):153–7

GROWTH & DEVELOPMENT

The use of short-term cultures of Pneumocystis for drug testing. Sahm M, et al. **Appl Parasitol** 1996 Jan;37(1):45–53

Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. Shellito JE, et al. **J Infect Dis** 1996 Feb;173(2):432–9

Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Tamburrini E, et al. **J Med Microbiol** 1996 Aug;45(2):146–8

IMMUNOLOGY

Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes. Bartlett MS, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):511–6

Antigenic differences associated with genetically distinct Pneumocystis carinii from rats. Vasquez J, et al. **Infect Immun** 1996 Jan;64(1):290–7

Serum IgG antibody response to Pneumocystis carinii among immunosuppressed, malnourished and healthy rats. El Gebaly WM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):63–71

Pneumocystis carinii infection in transgenic B cell-deficient mice. Marcotte H, et al. **J Infect Dis** 1996 Apr; 173(4):1034–7

Immunoblot analysis for serum antibodies to Pneumocystis carinii by age and intensity of infection in rats. Hong ST, et al. **Korean J Parasitol** 1995 Sep;33(3):187–94

[Experimental and clinical study on pneumocystosis. IV. Use of a 4D7 monoclonal antibody to detect Pneumocystis carinii by immunoperoxidase staining] Mei Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):130–3 (Eng. Abstr.) **(Chi)**

[Serologic response of normal Korean children to Pneumocystis carinii as observed by immunoblot] Moon HN, et al. **Korean J Parasitol** 1995 Jun;33(2):101–6 (Eng. Abstr.) **(Kor)**

ISOLATION & PURIFICATION

Pneumocystis carinii thyroiditis diagnosis by fine needle aspiration cytology: a case report. Keyhani-Rofagha S, et al. **Acta Cytol** 1996 Mar-Apr;40(2):307–10

Comparison of histologic stains in the diagnosis of Pneumocystis carinii. Naimey GL, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1124–7

Role of Pneumocystis carinii DNA amplification by PCR on the diagnosis of Pneumocystis carinii pneumonia in patients with haematologic malignant diseases: report of four cases. Antinori A, et al. **Acta Haematol** 1995; 94(3):163–6

A rapid and inexpensive method for processing induced sputum for detection of Pneumocystis carinii. Rocha P, et al. **Am J Clin Pathol** 1996 Jan;105(1):52–7

Detection of Pneumocystis carinii, Mycobacterium tuberculosis, and cytomegalovirus in human immunodeficiency virus (HIV)-infected patients with hemophilia by polymerase chain reaction of induced sputum samples. Shimomoto H, et al. **Intern Med** 1995 Oct; 34(10):976–81

Detection of Pneumocystic carinii in immuno-suppressed rats by different histological stains and immunological assays. Hassan MM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):275–84

Analysis of genetic diversity at the arom locus in isolates of Pneumocystis carinii. Banerji S, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):675–9

Search for extrapulmonary Pneumocystis carinii in an animal model. Oz HS, et al. **J Parasitol** 1996 Apr;82(2):357–9

Pneumocystis carinii pneumonia in childhood systemic lupus erythematosus. Foster HE, et al. **J Rheumatol** 1996 Apr; 23(4):753–6

Pneumocystis carinii in Africa: an emerging pathogen? [comment] Russian DA, et al. **Lancet** 1995 Nov 11; 346(8985):1242–3. Comment on: Lancet 1995 Nov 11;346(8985):1258–61.

Correlation of Pneumocystis carinii PCR with clinical diagnosis in immunocompromised patients [letter] Weig M, et al. **Lancet** 1996 May 4;347(9010):1266

Variable efficiency of three primer pairs for the diagnosis of Pneumocystis carinii pneumonia by the polymerase chain reaction. De Luca A, et al. **Mol Cell Probes** 1995 Oct; 9(5):333–40

Simultaneous pulmonary infection by Nocardia asteroides and Pneumocystis carinii in a renal transplant patient. Ruiz LM, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):711–4

Polymerase chain reaction is more sensitive than standard cytologic stains in detecting Pneumocystis carinii in bronchoalveolar lavages from human immunodeficiency virus type 1-infected infants and children with pneumonia. Leibovitz E, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):714–6

Rapid simple and nested polymerase chain reaction for the diagnosis of Pneumocystis carinii pneumonia. Moonens F, et al. **Scand J Infect Dis** 1995;27(4):358–62

Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Skøt J, et al. **Scand J Infect Dis** 1995;27(4):363–7

Pneumonia in cats caused by Pneumocystis carinii purified from mouse lungs. Yuezhong Y, et al. **Vet Parasitol** 1996 Jan;61(1-2):171–5

METABOLISM

Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Williams MD, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):232–8

Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii. Hong YL, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):251–4

Uptake and metabolism of L-serine by Pneumocystis carinii carinii. Florin-Christensen M, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):669–75

Expression of variants of the major surface glycoprotein of Pneumocystis carinii. Angus CW, et al. **J Exp Med** 1996 Mar 1;183(3):1229–34

Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages [see comments] Limper AH, et al. **J Lab Clin Med** 1995 Nov;126(5):416–22 (37 ref.). Comment in: J Lab Clin Med 1995 Nov;126(5):414–5.

Surfactant protein binding to Pneumocystis carinii organisms [editorial; comment] Pottratz ST. **J Lab Clin Med** 1995 Nov;126(5):414–5 (18 ref.). Comment on: J Lab Clin Med 1995 Nov;126(5):416–22.

PATHOGENICITY

Pneumonia in cats caused by Pneumocystis carinii purified from mouse lungs. Yuezhong Y, et al. **Vet Parasitol** 1996 Jan;61(1-2):171–5

PHYSIOLOGY

Ultrastructural morphology of intermediate forms and forms suggestive of conjugation in the life cycle of Pneumocystis carinii. Itatani CA. **J Parasitol** 1996 Feb;82(1):163–71

Characterization of Pneumocystis carinii infection in Sorex araneus from southern Finland. Laakkonen J, et al. **J Wildl Dis** 1995 Apr;31(2):228–32

PNEUMOCYSTIS CARINII INFECTIONS

COMPLICATIONS

Cutaneous Pneumocystis carinii and Cryptococcus neoformans in AIDS. Sandler B, et al. **Br J Dermatol** 1996 Jan;134(1):159–63

Perforation of the small intestine in a patient with disseminated Pneumocystis carinii infection in AIDS. Bierhoff E, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):255–60

Acute hepatic and renal failure caused by Pneumocystis carinii in patients with AIDS. Boldorini R, et al. **J Clin Pathol** 1995 Oct;48(10):975–8

[Extra–pulmonary pneumocystosis in the course of AIDS. Report of a case] Terris B, et al. **Ann Pathol** 1996;16(1):41–4 (Eng. Abstr.) **(Fre)**

[Cytomegalovirus retinitis and Pneumocystis carinii choroidopathy in a patient with AIDS] Usui N, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):84–92 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Pneumocystis carinii thyroiditis diagnosis by fine needle aspiration cytology: a case report. Keyhani–Rofagha S, et al. **Acta Cytol** 1996 Mar–Apr;40(2):307–10

HIV–related Pneumocystis carinii thyroiditis: a unique case and literature review. Danahey DG, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):158–61 (15 ref.)

DRUG THERAPY

Management of adverse reactions to prophylactic trimethoprim–sulfamethoxazole in patients with human immunodeficiency virus infection. Belchi–Hernandez J, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):355–8

Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection. Jolley AE, et al. **J Clin Pharm Ther** 1995 Jun;20(3):121–30 (89 ref.)

Drugs for AIDS and associated infections. **Med Lett Drugs Ther** 1995 Oct 13;37(959):87–94

Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat. Brun–Pascaud M, et al. **Parasite** 1996 Jun;3(2):187–9

MICROBIOLOGY

Search for extrapulmonary Pneumocystis carinii in an animal model. Oz HS, et al. **J Parasitol** 1996 Apr;82(2):357–9

PREVENTION & CONTROL

Rhabdomyolysis and the acquired immunodeficiency syndrome [letter; comment] Beversdorf D, et al. **Neurology** 1996 May;46(5):1498. Comment on: Neurology 1994 Sep;44(9):1692–6.

PNEUMOCYSTIS CARINII PNEUMONIA see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMOENCEPHALOGRAPHY

METHODS

[Spontaneous cerebrospinal rhinorrhea: role of computerized opaque cisternography] Jouini S, et al. **Ann Radiol (Paris)** 1995;38(7–8):435–9 (Eng. Abstr.) **(Fre)**

PNEUMOGASTRIC NERVE see **VAGUS NERVE**

PNEUMOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMOMEDIASTINUM see **MEDIASTINAL EMPHYSEMA**

PNEUMONECTOMY

Functional effects of typical lung resections for primary bronchogenic carcinoma. Ilić N, et al. **Acta Med Croatica** 1996;50(2):87–91

Should pulmonary lesions be resected at the time of open heart surgery? Johnson JA, et al. **Am Surg** 1996 Apr; 62(4):300–3

Complication of the Univent tube [letter] Thielmeier KA, et al. **Anesthesiology** 1996 Feb;84(2):491

Resection of an unsuspected primary pulmonary choriocarcinoma. Canver CC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1249–51 (8 ref.)

Lung resection in patients with compromised pulmonary function. Cerfolio RJ, et al. **Ann Thorac Surg** 1996 Aug; 62(2):348–51

Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Harpole DH, et al. **Ann Thorac Surg** 1996 Mar;61(3):977–82

Postresection irradiation for T2 N0 M0 non–small cell carcinoma: a prospective, randomized study. Lafitte JJ, et al. **Ann Thorac Surg** 1996 Sep;62(3):830–4

Late contralateral lobectomy after single–lung transplantation for emphysema. Le Pimpec–Barthes F, et al. **Ann Thorac Surg** 1996 Jan;61(1):231–4

Use of the Heimlich valve to shorten hospital stay after lung reduction surgery for emphysema. McKenna RJ Jr, et al. **Ann Thorac Surg** 1996 Apr;61(4):1115–7

Video–assisted thoracoscopic resection of pulmonary sequestration in an infant. Mezzetti M, et al. **Ann Thorac Surg** 1996 Jun;61(6):1836–7; discussion 1837–8

Lung volume reduction surgery: lessons learned. Miller JI Jr, et al. **Ann Thorac Surg** 1996 May;61(5):1464–8; discussion 1468–9

Pneumonectomy for chronic infection: fraught with danger? [letter; comment] Munro DD, et al. **Ann Thorac Surg** 1996 Jan;61(1):280. Comment on: Ann Thorac Surg 1995 Feb;59(2):408–11.

1991. Contralateral pneumonectomy after single–lung transplantation for emphysema. Updated in 1996. Novick RJ, et al. **Ann Thorac Surg** 1996 Apr;61(4):1286–7

Unsuspected lung cancer found in work–up for lung reduction operation. Pigula FA, et al. **Ann Thorac Surg** 1996 Jan;61(1):174–6

Results of combined pulmonary resection and cardiac operation. Rao V, et al. **Ann Thorac Surg** 1996 Aug; 62(2):342–6; discussion 346–7

Mechanisms of right ventricular dysfunction after pulmonary resection. Reed CE, et al. **Ann Thorac Surg** 1996 Jul; 62(1):225–31; discussion 231–2

Pulmonary resection complicated by abrupt pericardial tamponade [letter] Tovar EA. **Ann Thorac Surg** 1995 Dec; 60(6):1864

Pulmonary endothelial permeability changes after major lung resection. Waller DA, et al. **Ann Thorac Surg** 1996 May; 61(5):1435–40

Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)

Lung resection in cystic fibrosis patients with localised pulmonary disease. Lucas J, et al. **Arch Dis Child** 1996 May; 74(5):449–51

Whole–lung vs lobe transplantation for adults [letter] Shapiro BJ, et al. **Arch Intern Med** 1996 Apr 22;156(8):908

Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA–N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Angeletti CA, et al. **Cancer** 1996 Aug 1; 78(3):409–15

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Kumar P, et al. **Cancer** 1996 Jun 1;77(11):2393–9

A randomized trial of adoptive immunotherapy with tumor–infiltrating lymphocytes and interleukin–2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma [see comments] Ratto GB, et al. **Cancer** 1996 Jul 15;78(2):244–51. Comment in: Cancer 1996 Jul 15;78(2):195–8.

Energy metabolism of thoracic surgical patients in the early postoperative period. Effect of posture. Brandi LS, et al. **Chest** 1996 Mar;109(3):630–7

Lung reduction surgery. Where are we heading? [editorial] Cutaia M. **Chest** 1996 Apr;109(4):866–9

VATS anatomic lung resections. The Hong Kong experience [editorial; comment] Landreneau RJ. **Chest** 1996 Jan; 109(1):1–2. Comment on: Diagn Imaging Clin Med 1996 Jan;109(1):13–7.

Volume reduction surgery. How selective should we be? [letter] Miller JD, et al. **Chest** 1996 Apr;109(4):1129–30

Lung volume reduction surgery: new expectations in the surgical treatment of lung cancer [letter] Munoz JI, et al. **Chest** 1996 Jun;109(6):1664

Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Snider GL. **Chest** 1996 Feb;109(2):540–8 (44 ref.)

Thoracoscopic lobectomy for benign diseases. Yim AP, et al. **Chest** 1996 Feb;109(2):554–6

Video–assisted thoracoscopic anatomic lung resections. The initial Hong Kong experience [see comments] Yim AP, et al. **Chest** 1996 Jan;109(1):13–7. Comment in: Clin Endocrinol (Oxf) 1996 Jan;109(1):1–2.

Study of endoscopic staple formation by specimen radiography on pulmonary wedges. Yim AP, et al. **Chest** 1995 Dec;108(6):1728–30

Evaluation of effect of lung resection on lobar ventilation and perfusion using intrabronchial capnography. Yoshimasu T, et al. **Chest** 1996 Jan;109(1):25–30

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long–term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

Pulmonary function and exercise capacity after lung resection. Bolliger CT, et al. **Eur Respir J** 1996 Mar; 9(3):415–21

Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy [letter; comment] Dieter RA. **Int Surg** 1995 Apr–Jun;80(2):195. Comment on: Int Surg 1994 Apr–Jun;79(2):124–9.

Modality of failure following resection of stage I and stage II non–small cell lung cancer. Ramacciato G, et al. **Int Surg** 1995 Apr–Jun;80(2):156–61

Singing the blues [letter] Peller A, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):618

Right post pneumonectomy pleural empyema caused by an esophagopleural fistula due to an esophageal carcinoma. Oliaro A, et al. **J Cardiovasc Surg (Torino)** 1995 Dec; 36(6):607–9

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Successful outcome of severe unilateral pulmonary interstitial emphysema after bi–lobectomy in a very low birthweight infant. Ahluwalia JS, et al. **J R Soc Med** 1996 Mar; 89(3):167P–8P

Long–term outcome after pneumonectomy for nonsmall cell lung cancer. Rocco PM, et al. **J Surg Oncol** 1996 Apr; 61(4):278–80

Comparison of early functional results after volume reduction or lung transplantation for chronic obstructive pulmonary disease [see comments] Gaissert HA, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):296–306; discussion 306–7. Comment in: J Thorac Cardiovasc Surg 1996 Feb;111(2):293–5.

Volume reduction of the native lung after single–lung transplantation for emphysema. Kapelanski DP, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):898–9

Completion pneumonectomy: indications and outcome. al–Kattan K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1125–9

Pulmonary function and postoperative complications after wedge and flap reconstructions of the main bronchus. Khargi K, et al. **J Thorac Cardiovasc Surg** 1996 Jul; 112(1):117–23

Right ventricular ejection fraction in the preoperative risk evaluation of candidates for pulmonary resection. Okada M, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):364–70

Lung reduction surgery: a true advance? [editorial; comment] Rusch VW. **J Thorac Cardiovasc Surg** 1996 Feb; 111(2):293–5. Comment on: J Thorac Cardiovasc Surg 1996 Feb;111(2):296–306; discussion 306–7. Comment on: J Thorac Cardiovasc Surg 1996 Feb;111(2):308–15; discussion 315–6. Comment on: J Thorac Cardiovasc Surg 1995 Feb;111(2):317–21; discussion 322.

Lung reduction surgery in chronic obstructive lung disease. Rogers RM, et al. **Med Clin North Am** 1996 May; 80(3):623–44 (42 ref.)

Associated movement as a sequel to thoracotomy: aberrant regeneration to the latissimus dorsi muscle. Kuwabara S, et al. **Mov Disord** 1995 Nov;10(6):788–90

Surgery to reduce lung volume [editorial; comment] Dantzker DR, et al. **N Engl J Med** 1996 Apr 25; 334(17):1128–9. Comment on: N Engl J Med 1996 Apr 25;334(17):1095–9.

"Keeling syndrome"—a late complication of pneumonectomy [letter] Robinson LA, et al. **N Engl J Med** 1996 Oct 3; 335(14):1074

Improvement in pulmonary function and elastic recoil after lung–reduction surgery for diffuse emphysema [see comments] Sciurba FC, et al. **N Engl J Med** 1996 Apr 25;334(17):1095–9. Comment in: N Engl J Med 1996 Apr 25;334(17):1128–7.

New regimen for interpleural block in children. Giaufré E, et al. **Paediatr Anaesth** 1995;5(2):125–8

The impact of 3–D radiotherapy planning after a pneumonectomy compared to a conventional treatment set–up. Schraube P, et al. **Radiother Oncol** 1995 Oct; 37(1):65–70

Pulmonary function 3–13 months after pneumonectomy, lobectomy or bilobectomy for lung cancer. Hjalmarsen A, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):71–4

Use of a pericardial fat pad flap for preventing bronchopleural fistula: an experimental study focusing on the angiogenesis and cytokine production of the fat pad. Ichinose Y, et al. **Surg Today** 1995;25(9):811–5

Left partial anomalous pulmonary venous connection found during a lobectomy for lung cancer: report of a case. Takamori S, et al. **Surg Today** 1995;25(11):982–3

Long–term graft function of right single–lung transplantation after contralateral pneumonectomy in the rat. Mizuta T, et al. **Transplant Proc** 1996 Apr;28(2):1081–3

[Lung scintigraphy and ergospirometry in prediction of postoperative course in lung resection candidates with increased risk of postoperative complications] Bolliger CT, et al. **Pneumologie** 1996 May;50(5):334–41 (Eng. Abstr.) **(Ger)**

[The role of surgery in the management of diffuse (N3) lung cancer] Politi L, et al. **Minerva Chir** 1995 Dec; 50(12):1039–42 (Eng. Abstr.) **(Ita)**

[Congenital cystic adenomatoid malformation of the lung: a case report in a newborn infant with severe respiratory failure and a review of the literature] Horio H, et al. **Kyobu Geka** 1995 Aug;48(9):805–7 (Eng. Abstr.) **(Jpn)**

[A case of right postpneumonectomy empyema treated by open window thoracostomy, thoracoplasty, pedicled omental flap and musculocutaneous flaps] Umemoto M, et al. **Kyobu Geka** 1996 Jun;49(6):441–4 (Eng. Abstr.) **(Jpn)**

[Effects of prostaglandin E1 on plasma cytokine levels during pneumonectomy] Matsumoto Y, et al. **Masui** 1996 Mar; 45(3):304–8 (Eng. Abstr.) **(Jpn)**

[Extracorporeal circulation for removal of carcinoma of the lung invading the left atrium] Wake M, et al. **Masui** 1995 Dec;44(12):1671–4 (Eng. Abstr.) **(Jpn)**

[Evaluation of the prognosis of patients with stage I non–small cell lung cancer with respect to predicted

postoperative lung function] Koizumi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):162–8 (Eng. Abstr.) **(Jpn)**

[Prognosis of the surgical treatment for non-Hodgkin lymphoma originating from chronic tuberculous empyema--analysis of 11 cases with pleuropneumonectomy] Nakajima Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):484–92 (Eng. Abstr.) **(Jpn)**

[A case report of pulmonary blastoma--well differentiated fetal adenocarcinoma] Okano T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):69–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Massive hemoptysis caused by disruption of a bronchial aneurysm diagnosed by microscopic examination of the resected lung] Nakamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):721–5 (Eng. Abstr.) **(Jpn)**

[The pathogenesis of hypoventilation in the operated lung] Vinnitskii LI, et al. **Anesteziol Reanimatol** 1996 Jan–Feb; (1):6–8 (Eng. Abstr.) **(Rus)**

[Long-term results of pneumonectomy in tuberculosis and chronic nonspecific lung diseases] Shalimov AA, et al. **Klin Khir** 1995;(11–12):3–5 **(Rus)**

[Effectiveness of different methods in the treatment of the main bronchus after pneumonectomy] Gillerg BM, et al. **Probl Tuberk** 1995;(4):31–4 (Eng. Abstr.) **(Rus)**

[Lung resection surgery in patients with functional limits] Izquierdo JM, et al. **Arch Bronconeumol** 1995 Aug–Sep; 31(7):328–32 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Alterations in spectral characteristics of heart rate variability as a correlate of cardiac autonomic dysfunction after esophagectomy or pulmonary resection. Kimura T, et al. **Anesthesiology** 1996 May;84(5):1068–76

Value of perioperative Doppler echocardiography in patients undergoing major lung resection. Amar D, et al. **Ann Thorac Surg** 1996 Feb;61(2):516–20

Diagnosis of postpneumonectomy bronchopleural fistula using ventilation scintigraphy. Pigula FA, et al. **Ann Thorac Surg** 1995 Dec;60(6):1812–4

Verapamil as prophylactic treatment for atrial fibrillation after lung operations. Van Mieghem W, et al. **Ann Thorac Surg** 1996 Apr;61(4):1083–5; discussion 1086

Closure of a postpneumonectomy main bronchus fistula using video-assisted mediastinal surgery. Azorin JF, et al. **Chest** 1996 Apr;109(4):1097–8

Treatment of left pneumonectomy syndrome with an expandable endobronchial prosthesis. Cordova FC, et al. **Chest** 1996 Feb;109(2):567–70

Percutaneous technique for management of persistent airspace with prolonged air leak using fibrin glue. Samuels LE, et al. **Chest** 1996 Jun;109(6):1653–5

Localization of a bronchopleural fistula in a postpneumonectomy patient using ventilation scintigraphy. Ali SA, et al. **Clin Nucl Med** 1995 Oct;20(10):943

Bronchopleural fistula after pneumonectomy for lung cancer. al-Kattan K, et al. **Eur J Cardiothorac Surg** 1995; 9(9):479–82

Late empyema after lobectomy for echinococcal disease of the lung. Rammos KS, et al. **Eur J Cardiothorac Surg** 1996; 10(2):144–5

Transsternal transpericardial operations in the treatment of bronchopleural fistulas after pneumonectomy. Stamatis G, et al. **Eur J Cardiothorac Surg** 1996;10(2):83–6

Reperfusion injury tourniquet syndrome caused by acute aortic occlusion due to embolism following pneumonectomy. Sonak RA, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):499–501

Inhaled nitric oxide for hemodynamic support after postpneumonectomy ARDS. Chiche JD, et al. **Intensive Care Med** 1995 Aug;21(8):675–8

Pneumoscrotum: an unusual complication of pulmonary resection. Raudat CW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):362–3 (16 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442–51 (52 ref.)

Delayed postpneumonectomy empyema. Schueckler OJ, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):515–7

Postoperative complications after pneumonectomy for treatment of lung cancer: multivariate analysis. Mitsudomi T, et al. **J Surg Oncol** 1996 Mar;61(3):218–22

Elective pneumonectomy for benign lung disease: modern-day mortality and morbidity. Conlan AA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1118–24

Bronchopleural fistula after pneumonectomy: repair and prevention with a deepithelialized latissimus dorsi myocutaneous island flap. Zoetmulder FA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1139–41

Postoperative infections in immunocompromised patients after oncological surgery. Ranchere JY, et al. **Support Care Cancer** 1995 Nov;3(6):409–13

A case of bronchopleural fistula detected by monitoring plasma endothelin-1. Yamashita J, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):56–7

[Early reoperation in chylothorax after thoracic surgery] Wakim R, et al. **Ann Chir** 1995;49(9):863–8 (Eng. Abstr.) **(Fre)**

[Unusual use of a tissue expander] Torossian JM, et al. **Ann Chir Plast Esthet** 1995 Aug;40(4):421–4 (Eng. Abstr.) **(Fre)**

[Right-to-left interatrial shunt with normal pulmonary pressures after pneumonectomy. Apropos of a case with severe cyanosis following left pneumonectomy] Arnaud-Crozat E, et al. **Arch Mal Coeur Vaiss** 1996 Jun; 89(6):761–4 (Eng. Abstr.) **(Fre)**

[A case of cardiac herniation following intrapericardial pneumonectomy after induction chemoradiotherapy] Nishiuchi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):63–8 (Eng. Abstr.) **(Jpn)**

[Exacerbation of idiopathic interstitial pneumonia after lobectomy for lung cancer] Horio H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):439–43 (Eng. Abstr.) **(Jpn)**

[Omentoplasty in bronchopleural fistulas after pneumonectomy] Myrmel T, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3627–8 (Eng. Abstr.) **(Nor)**

[Massive heart herniation after intrapericardial radical pneumonectomy (letter)] Rojas A, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):153 **(Spa)**

HISTORY

History of surgery for emphysema. Deslauriers J. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):43–51

INSTRUMENTATION

Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? [see comments] Asamura H, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1125–34. Comment in: J Thorac Cardiovasc Surg 1996 Jun;111(6):1123–4.

[Video thoracoscopic lobectomy. Surgical technique and results] Stamatis G, et al. **Chirurg** 1996 Apr;67(4):425–35 (Eng. Abstr.) **(Ger)**

METHODS

Pulmonary metastasectomy. Berry M, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):278–80

Lung volume reduction surgery. Case selection, operative technique, and clinical results. Daniel TM, et al. **Ann Surg** 1996 May;223(5):526–31; discussion 532–3

1986: Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases. Updated in 1995. Dartevelle PG, et al. **Ann Thorac Surg** 1995 Dec;60(6):1854–5

Evolution of pulmonary resection techniques and review of the bronchus-first method [see comments] Grismer JT, et al. **Ann Thorac Surg** 1995 Oct;60(4):1133–7. Comment in: Ann Thorac Surg 1996 May;61(5):1585.

Evolution of bronchus-first technique [letter; comment] Hurt R. **Ann Thorac Surg** 1996 May;61(5):1585. Comment on: Ann Thorac Surg 1995 Oct;60(4):1133–7.

Unilateral volume reduction after single-lung transplantation for emphysema. Kroshus TJ, et al. **Ann Thorac Surg** 1996 Aug;62(2):363–8

Thoracoscopic pulmonary resection [letter; comment] Lewis RJ, et al. **Ann Thorac Surg** 1995 Oct;60(4):1157–9. Comment on: Ann Thorac Surg 1995 Mar;59(3):736–7; discussion 737–8.

The current status of lung volume reduction operations for emphysema. Naunheim KS, et al. **Ann Thorac Surg** 1996 Aug;62(2):601–12 (97 ref.)

Unilateral video-assisted thoracic surgical lung reduction. Naunheim KS, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1092–8

Video-assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed? Yim AP, et al. **Aust N Z J Surg** 1995 Oct;65(10):737–9

Video assisted thoracoscopic staple resection of a giant bulla. Yim AP, et al. **Aust N Z J Surg** 1996 Jul;66(7):495–7

Early postoperative stress: video-assisted wedge resection/lobectomy vs conventional axillary thoracotomy. Tschernko EM, et al. **Chest** 1996 Jun;109(6):1636–42

Lung-volume reduction surgery for severe emphysema. Cooper JD, et al. **Chest Surg Clin N Am** 1995 Nov; 5(4):815–31

Thoracoscopic surgery for lung cancer using the two small skin incisional method. Two windows method. Iwasaki M, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):79–81

Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. Shimizu J, et al. **J Surg Oncol** 1996 Jan;61(1):1–6

Survival and function after sleeve lobectomy for lung cancer. Gaissert HA, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):948–53

Unilateral thoracoscopic surgical approach for diffuse emphysema. Keenan RJ, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):308–15; discussion 315–6

A randomized, prospective trial of stapled lung reduction versus laser bullectomy for diffuse emphysema [see comments] McKenna RJ Jr, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):317–21; discussion 322. Comment in: J Thorac Cardiovasc Surg 1996 Feb;111(2):293–5.

Trauma pneumonectomy revisited: the role of simultaneously stapled pneumonectomy. Wagner JW, et al. **J Trauma** 1996 Apr;40(4):590–4

Lung volume reduction surgery for severe emphysema. Cooper JD, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan; 8(1):52–60

Radiology of pulmonary emphysema and lung volume reduction surgery. Slone RM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):61–82 (61 ref.)

Anesthetic management for bilateral volume reduction surgery. Triantafillou AN. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):94–8

Evaluation of patients with emphysema for lung volume reduction surgery. Washington University Emphysema Surgery Group. Yusen RD, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):83–93

Results of lung volume reduction surgery in patients with emphysema. The Washington University Emphysema Surgery Group. Yusen RD, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):99–109

Carinal reconstruction under veno-venous bypass using a percutaneous cardiopulmonary bypass system. Horita K, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):46–9

Two-stage bronchoplasty for synchronous contralateral lung cancers. Saito H, et al. **Thorac Cardiovasc Surg** 1995 Jun; 43(3):176–7

[Results of repeated pulmonary resection in new homolateral neoplastic localization after conservative resection] Massard G, et al. **Ann Chir** 1995;49(9):835–40 (Eng. Abstr.) **(Fre)**

[The role of surgery in the management of diffuse (N3) lung cancer] Politi L, et al. **Minerva Chir** 1995 Dec; 50(12):1039–42 (Eng. Abstr.) **(Ita)**

[Tracheal sleeve lobectomy in the radical surgery for lung cancer] Politi L, et al. **Minerva Chir** 1995 Dec; 50(12):1043–7 (Eng. Abstr.) **(Ita)**

[A case of bilateral thoracoscopic partial resection for unilateral spontaneous pneumothorax] Kinugasa S, et al. **Kyobu Geka** 1995 Oct;48(11):978–81 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of resected small-sized (4 mm in diameter) lung cancer and its way of surgical treatment] Morita H. **Kyobu Geka** 1996 Mar;49(3):175–8; discussion 179–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic partial lung resection using staplers and polyglycolic acid (PGA) felts in an 85-year-old patient] Yoshiya K, et al. **Kyobu Geka** 1995 Sep;48(10):833–5 (Eng. Abstr.) **(Jpn)**

[Staged bilateral upper lobectomy of pathologically different synchronous double primary cancer] Taira O, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1858–64 (Eng. Abstr.) **(Jpn)**

[The choice of a treatment method in pulmonary hypoplasia in children] Rybal'chenko VF. **Klin Khir** 1995;(6):27–8 **(Rus)**

[A clinical trial of using ligation of the bronchus at its base in lung resections] Khasanov RM, et al. **Vestn Khir Im I I Grek** 1995;154(3):97–9 **(Rus)**

[Combined surgical treatment of malignant lung tumors] Giller DB, et al. **Vopr Onkol** 1996;42(1):89–92 (Eng. Abstr.) **(Rus)**

[Early peripheral cancer of the lung: long-term results of combined therapy using sparing resection techniques] Kharchenko VP, et al. **Vopr Onkol** 1996;42(2):77–81 (13 ref.) (Eng. Abstr.) **(Rus)**

MORTALITY

Preoperative assessment of the high-risk patient for lung resection. Pate P, et al. **Ann Thorac Surg** 1996 May; 61(5):1494–500

Long-term survival after bronchial sleeve resection: univariate and multivariate analyses. Van Schil PE, et al. **Ann Thorac Surg** 1996 Apr;61(4):1087–91

Results of pneumonectomy for cancer in patients with limited ventilatory function. Gebitekin C, et al. **Eur J Cardiothorac Surg** 1995;9(7):347–51

Elective pneumonectomy for benign lung disease: modern-day mortality and morbidity. Conlan AA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1118–24

REHABILITATION

Pleural slide technique for covering the left bronchial stump [letter; comment] Berrisford RG, et al. **Ann Thorac Surg** 1996 Jun;61(6):1876–7. Comment on: Ann Thorac Surg 1995 Sep;60(3):729–33.

PNEUMONIA

Community-acquired pneumonia: an update. Meeker DP, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):16–30 (97 ref.)

Etiopathogenesis and management of pneumonia. Mokshagundam SL, et al. **Compr Ther** 1995 Aug; 21(8):413–20 (23 ref.)

Pneumonitis in a lupus twin pregnancy: a case report. Comer M, et al. **Lupus** 1996 Apr;5(2):146–8

Community-acquired pneumonia [see comments] Bartlett JG, et al. **N Engl J Med** 1995 Dec 14;333(24):1618–24 (48 ref.) . Comment in: N Engl J Med 1996 Mar 28;334(13):861; discussion 862–3. Comment in: N Engl J Med 1996 Mar 28;334(13):862; discussion 862–3.

Community-acquired pneumonia [letter; comment] Halm EA, et al. **N Engl J Med** 1996 Mar 28;334(13):862; discussion 862–3. Comment on: N Engl J Med 1995 Dec 14;333(24):1618–24.

Delayed resolution of pneumonia. When is slow healing too slow? Cassiere H, et al. **Postgrad Med** 1996 Jan;99(1):151–4, 157–8 (9 ref.)

Community–acquired pneumonia requiring hospitalisation. Factors of importance for the short–and long term prognosis. Hedlund J. **Scand J Infect Dis Suppl** 1995; 97:1–60 (175 ref.)

Severe community–acquired pneumonia. Leeper KV Jr. **Semin Respir Infect** 1996 Jun;11(2):96–108 (82 ref.)

BLOOD

Pneumonitis–associated hyperprocalcitoninemia. Nylén ES, et al. **Am J Med Sci** 1996 Jul;312(1):12–8

Are routine blood cultures effective in the evaluation of patients clinically diagnosed to have nosocomial pneumonia? Chendrasekhar A. **Am Surg** 1996 May; 62(5):373–6

C–reactive protein. A clinical marker in community–acquired pneumonia. Smith RP, et al. **Chest** 1995 Nov; 108(5):1288–91

Variation in plasma lipid and lipoprotein concentrations in community–acquired pneumonia a six–month prospective study. Rodriguez Reguero JJ, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):245–9

Is there an unidentified defence mechanism against infection in human plasma? Aejmelaeus R, et al. **FEBS Lett** 1996 Apr 15;384(2):128–30

Serum vitamin A (retinol) concentrations and association with respiratory disease in premature infants. Coutsoudis A, et al. **J Trop Pediatr** 1995 Aug;41(4):230–3

Diagnostic and prognostic value of interleukin–6 and C–reactive protein in community–acquired pneumonia. Ortqvist A, et al. **Scand J Infect Dis** 1995;27(5):457–62

[Copper and ceruloplasmin concentrations in serum of infants with pneumonia] Sobol G, et al. **Pneumonol Alergol Pol** 1995;63(7–8):378–81 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. Robbins CG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L545–50

Taurine protects rat bronchioles from acute ozone–induced lung inflammation and hyperplasia. Schuller–Levis GB, et al. **Exp Lung Res** 1995 Nov–Dec;21(6):877–88

Nitrogen dioxide pneumonitis in ice hockey players. Karlson–Stiber C, et al. **J Intern Med** 1996 May; 239(5):451–6

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357–63 (34 ref.)

Pulmonary collapse and pneumonia due to inhalation of a waterproofing aerosol in female CD–1 mice. Yamashita M, et al. **J Toxicol Clin Toxicol** 1995;33(6):631–7

Effect of subchronic in vivo exposure to nitrogen dioxide on lung tissue inflammation, airway microvascular leakage, and in vitro bronchial muscle responsiveness in rats. Chitano P, et al. **Occup Environ Med** 1996 Jun;53(6):379–86

Elevated urinary cadmium concentrations in a patient with acute cadmium pneumonitis. Ando Y, et al. **Scand J Work Environ Health** 1996 Apr;22(2):150–3

[Opportunistic lung infections in patients with chronic obstructive lung disease; a side effect of inhalation steroids? (letter; comment)] Vooren PH. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):511–2. Comment on: Ned Tijdschr Geneeskd 1996 Jan 13;140(2):94–8. **(Dut)**

[Pneumonitis in a patient who inhaled a fibrinolysin–deoxyribonuclease mixture] Hasegawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1302–6 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

The use of misclassification costs to learn rule–based decision support models for cost–effective hospital admission strategies. Ambrosino R, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:304–8

COMPLICATIONS

Acute myeloblastic leukaemia presenting with herpes simplex type–1 viraemia and pneumonia. James E, et al. **Br J Haematol** 1996 May;93(2):401–2

Pneumonia in cancer patients. Whimbey E, et al. **Cancer Treat Res** 1995;79:185–210 (144 ref.)

Identifying early predictors of mortality in pediatric patients with acute leukemia and pneumonia. Randle CJ Jr, et al. **Chest** 1996 Feb;109(2):457–61

Catheter–related cutaneous aspergillosis complicated by fungemia and fatal pulmonary infection in an HIV–positive patient with acute lymphocytic leukemia. Girmenia C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):524–6

Chaetomium pneumonia in patient with acute myeloid leukaemia. Yeghen T, et al. **J Clin Pathol** 1996 Feb; 49(2):184–6

Toxoplasma pneumonia in a patient with AIDS [letter] Halme M, et al. **J Infect** 1995 Nov;31(3):252–3

Bronchiolitis obliterans organizing pneumonia: a community hospital experience. Clark JD, et al. **J Tenn Med Assoc** 1995 Nov;88(11):425–7

Predicting hypoxia in children with acute lower respiratory infection: a study in the highlands of Papua New Guinea. Dyke T, et al. **J Trop Pediatr** 1995 Aug;41(4):196–201

The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pierce MR, et al. **Pediatr Pulmonol** 1995 Jun;19(6):371–8 (89 ref.)

Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Watterberg KL, et al. **Pediatrics** 1996 Feb;97(2):210–5

Early decortication for postpneumonic empyema in children. Effect on pulmonary perfusion. Eren N, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):125–9

[The thrombophilic status of patients with inflammatory diseases] Lins M, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):855–9 (Eng. Abstr.) **(Ger)**

[Detection of Mycobacterium tuberculosis infection in children with bronchopulmonary diseases and evaluation of its role in the course of disease] Klochkova LV, et al. **Probl Tuberk** 1995;(5):37–9 (Eng. Abstr.) **(Rus)**

[Characteristics of the course and treatment of pulmonary tuberculosis associated with nonspecific respiratory diseases in children] Mitinskaia LA, et al. **Probl Tuberk** 1996; (2):13–6 (Eng. Abstr.) **(Rus)**

[An evaluation of the effect of magnetic–laser therapy on external respiratory function in complicated forms of acute pneumonia in children] Gaidashev EA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):12–4 (Eng. Abstr.) **(Rus)**

[Obliterating bronchiolitis with organized pneumonia. Experience in a general hospital] Barba Romero MA, et al. **Arch Bronconeumol** 1995 Nov;31(9):481–4 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Günther A, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):176–84

The value of clinical judgment in the diagnosis of nosocomial pneumonia. Helling TS, et al. **Am J Surg** 1996 Jun; 171(6):570–5

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)

The role of pulse oximetry. Its use as an indicator of severe respiratory disease in Peruvian children living at sea level. Respiratory Group in Peru. Madico G, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1259–63

HIV antibody test should be a routine investigation for undiagnosed pneumonia [letter] Scott GM. **BMJ** 1996 May 25;312(7042):1363

Invasive diagnostic methods for nosocomial pneumonia. Revisiting the folklore [editorial; comment] Buchalter SE, et al. **Chest** 1995 Dec;108(6):1492–4. Comment on: Chest 1995 Dec;108(6):1632–9.

Diagnostic testing of ICU–acquired pneumonia [letter; comment] Cykert S. **Chest** 1996 Jul;110(1):302. Comment on: Chest 1995 Dec;108(6):1632–9.

Serum KL–6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Kobayashi J, et al. **Chest** 1996 May; 109(5):1276–82

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

Hospital–acquired pneumonia. Wiblin RT, et al. **Curr Clin Top Infect Dis** 1996;16:194–214

Appropriateness of laboratory tests: requests for atypical pneumonia serology in a teaching hospital. Jackson LM, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):93–4

Evaluation of the invasive techniques for diagnosing bacterial respiratory infections. Pozzi E, et al. **J Chemother** 1995 Aug;7(4):286–91 (26 ref.)

Rejection criteria for endotracheal aspirates from pediatric patients. Zaidi AK, et al. **J Clin Microbiol** 1996 Feb; 34(2):352–4

Pneumonia in unexpected locations: an occult cause of pediatric abdominal pain. Kanegaye JT, et al. **J Emerg Med** 1995 Nov–Dec;13(6):773–9

Tachypnea as a predictor of pneumonia in febrile children. King EA, et al. **J Fam Pract** 1996 Jan;42(1):25

Community–acquired pneumonia. What's needed for accurate diagnosis. File TM Jr, et al. **Postgrad Med** 1996 Jan;99(1):95–102, 105–7 (13 ref.)

Neoplastic mimics of pneumonia. Casey KR. **Semin Respir Infect** 1995 Sep;10(3):131–42 (86 ref.)

Diagnosis of pulmonary infections in mechanically ventilated patients. Chastre J, et al. **Semin Respir Infect** 1996 Jun; 11(2):65–76 (58 ref.)

Radiation pneumonitis: a mimic of infectious pneumonitis. Salinas FV, et al. **Semin Respir Infect** 1995 Sep;10(3):143–53 (38 ref.)

Nosocomial pneumonia during mechanical ventilation: problems with diagnostic criteria [editorial] Brun–Buisson C. **Thorax** 1995 Nov;50(11):1128–30 (27 ref.)

Value of bronchoscopic pneumonia diagnosis: prospective study. Prokop A, et al. **World J Surg** 1996 Jan;20(1):22–6

[Diagnostic value of ultrasonically guided lung aspiration in pneumonia] Chen CH, et al. **J Formos Med Assoc** 1995 Dec;94 Suppl 2:S137–43 (Eng. Abstr.) **(Chi)**

[Disseminated Strongyloides stercoralis infection mimicking pneumonia] Yu JJ, et al. **J Formos Med Assoc** 1995 Dec; 94 Suppl 2:S162–5 (Eng. Abstr.) **(Chi)**

[Acute pulmonary infections at autopsy. A study of clinical and macroscopic diagnoses at autopsy compared with microscopic autopsy findings] Hjorth L, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6873–6 (Eng. Abstr.) **(Dan)**

[Nosocomial pneumonia] Jébrak G, et al. **Presse Med** 1996 Jun 8;25(20):944–50 (25 ref.) (Eng. Abstr.) **(Fre)**

[Acute community–acquired pneumonia of moderate and grave severity investigated by bronchoscopy. Analysis of 193 cases hospitalized in a general hospital] Vivès L, et al. **Rev Mal Respir** 1996;13(2):175–82 (Eng. Abstr.) **(Fre)**

[Sputum gram staining in pneumonia] Lode H. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):114–5 **(Ger)**

[Diagnostic value of protected bronchoalveolar lavage in HIV–associated pneumonia] Ewig S, et al. **Pneumologie** 1995 Oct;49(10):546–55 (Eng. Abstr.) **(Ger)**

[Therapeutic problems in pneumonia] Gonon M, et al. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1125–8 (Eng. Abstr.) **(Ger)**

[A case of undiagnosed pneumonia complicated by chronic pleural empyema] Leksowski K, et al. **Pneumonol Alergol Pol** 1995;63(7–8):434–5 **(Pol)**

[The usefulness of bronchofibroscopy in the diagnosis of lung neoplasms in patients with protracted pneumonia] Glória C, et al. **Acta Med Port** 1995 Sep;8(9):493–6 (Eng. Abstr.) **(Por)**

[Atypical pneumonias] Irigaray R, et al. **Arch Bronconeumol** 1996 Apr;32(4):187–95 (66 ref.) **(Spa)**

[Fever. Guess what is behind it (editorial)] Fernández Viladrich P. **Med Clin (Barc)** 1995 Oct 28;105(14):532–3 **(Spa)**

[Prediction of the presence of pneumonia in adults with fever] González Ortiz MA, et al. **Med Clin (Barc)** 1995 Oct 28; 105(14):521–4 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

New targets for surfactant replacement therapy: experimental and clinical aspects. Robertson B. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul;75(1):F1–3

Switch therapy in community–acquired pneumonia [letter; comment] Nathwani D, et al. **Arch Intern Med** 1996 Jun 10;156(11):1235. Comment on: Arch Intern Med 1995 Jun 26;155(12):1273–6.

Oral versus intravenous antibiotics. Exclusion of sickest patients invalidates study [letter; comment] Tsang P. **BMJ** 1995 Sep 9;311(7006):685. Comment on: BMJ 1995 May 27;310(6991):1360–2.

Potential interventions for the prevention of childhood pneumonia in developing countries: a meta–analysis of data from field trials to assess the impact of vitamin A supplementation on pneumonia morbidity and mortality. The Vitamin A and Pneumonia Working Group. **Bull World Health Organ** 1995;73(5):609–19

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

Lidocaine attenuates the hypotensive and inflammatory responses to endotoxemia in rabbits. Taniguchi T, et al. **Crit Care Med** 1996 Apr;24(4):642–6

Community–acquired pneumonia. Musher DM, et al. **Curr Clin Top Infect Dis** 1996;16:102–24 (36 ref.)

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Snydman D, et al. **Drugs** 1995; 49 Suppl 2:439–41

LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Buckley TL, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):103–9

Inhibition of some aspects of acute inflammation of guinea–pig lung by intraperitoneal dexamethasone and mifepristone: demonstration of agonist activity of mifepristone in the guinea–pig. Whelan CJ, et al. **Inflamm Res** 1995 Mar;44(3):131–8

A controlled trial of the effect of the 5–lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Kane GC, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):646–54

Effectiveness of oral antibiotic treatment in nursing–home acquired pneumonia [letter; comment] Buehrens PE. **J Am Geriatr Soc** 1995 Dec;43(12):1443; discussion 1443–4 . Comment on: J Am Geriatr Soc 1995 Mar;43(3):245–51.

Clinical investigation of traditional Chinese medicine and pharmacy in treating respiratory tract infections in AIDS. Li G, et al. **J Tradit Chin Med** 1996 Mar;16(1):3–6

A randomized trial of chloramphenicol vs. trimethoprim–sulfamethoxazole for the treatment of malnourished children with community–acquired pneumonia. Mulholland EK, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):959–65

Community–acquired pneumonia. Cost–effective antimicrobial therapy [see comments] Cunha BA. **Postgrad Med** 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.). Comment in: Postgrad Med 1996 Apr;99(4):62–4.

Choosing an antibiotic for pneumonia [letter; comment] Rashada SC. **Postgrad Med** 1996 Apr;99(4):62–4. Comment on: Postgrad Med 1996 Jan;99(1):109–10, 113–4, 117–9, passim.

Community–acquired pneumonia—is it time for the penicillin bullet to be replaced? Silva J Jr. **West J Med** 1996 Jan; 164(1):79–80

Initial management of community–acquired pneumonia. Gold JA. **Wis Med J** 1995;94(8):460–1

[Antibiotic therapy for pneumonias acquired outside the hospital] Achermann E, et al. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1057–9 (14 ref.) **(Ger)**

[Features of the course of the candida infection process during combined effect of medications] Khmel'nitskiĭ OK, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):506–10 **(Rus)**

[Antibiotics in pneumonia may be changed without clinical examination (letter)] Braconier JH, et al. **Lakartidningen** 1995 Nov 22;92(47):4411–2 **(Swe)**

ECONOMICS

The evaluation of screening methods to identify medically unnecessary hospital stay for patients with pneumonia. Hartz AJ, et al. **Int J Qual Health Care** 1996 Feb;8(1):3–11

ENZYMOLOGY

Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone-induced acute inflammation. Nadziejko C, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1592–8

EPIDEMIOLOGY

Potential interventions for the prevention of childhood pneumonia in developing countries: a meta-analysis of data from field trials to assess the impact of vitamin A supplementation on pneumonia morbidity and mortality. The Vitamin A and Pneumonia Working Group. **Bull World Health Organ** 1995;73(5):609–19

Hospital-acquired pneumonia. Wiblin RT, et al. **Curr Clin Top Infect Dis** 1996;16:194–214

Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Lange P, et al. **Eur Respir J** 1995 Oct;8(10):1694–8

On the epidemiology of some acute respiratory infections and the accompanying nonbacterial pneumonia in children. Stoilova J. **Folia Med (Plovdiv)** 1995;37(4A Suppl):97–8

Community-acquired lower respiratory tract infection in the elderly: a community-based study of incidence and outcome. Houston MS, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):347–56

Epidemiology of lower respiratory tract infections. Bariffi F, et al. **J Chemother** 1995 Aug;7(4):263–76 (79 ref.)

The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. Kauppinen MT, et al. **J Infect Dis** 1995 Nov;172(5):1330–5

Drug-resistant pneumococci increasingly common in elderly, study suggests [news] **Oncology (Huntingt)** 1996 Apr; 10(4):592–3

Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France). Sow O, et al. **Thorax** 1996 Apr;51(4):385–8

[Analysis of nosocomial infection in hospitalized critical and serious patients] Liu MD, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug; 16(4):231–3 (Eng. Abstr.) **(Chi)**

[Features of the course of acute pneumonia in the Amur region] Landyshev SIu, et al. **Probl Tuberk** 1995;(6):46–7 **(Rus)**

ETIOLOGY

Role of endotoxin in grain dust–induced lung inflammation in mice. Jagielo PJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L1052–9

Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. Robbins CG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L545–50

Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Cunnion KM, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):158–62

Complications of trauma care: risk analysis of pneumonia in 10,001 adult trauma patients. Bellemare JF, et al. **Am Surg** 1996 Mar;62(3):207–11

Grand Rounds—City Hospital, Nottingham. A complicated case of community acquired pneumonia [clinical conference] Johnson SR, et al. **BMJ** 1996 Apr 6; 312(7035):899–901

Predicting acute respiratory distress syndrome and intrapulmonary inflammation. Reid PT, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):499–502 (22 ref.)

Risk factors for childhood pneumonia among the urban poor in Fortaleza, Brazil: a case-–control study. Fonseca W, et al. **Bull World Health Organ** 1996;74(2):199–208

Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. Berkowitz N, et al. **Chest** 1995 Dec;108(6):1602–7

Pneumonia due to Fonsecaea pedrosoi and cerebral abscesses due to Emericella nidulans in a bone marrow transplant recipient. Morris A, et al. **Clin Infect Dis** 1995 Nov; 21(5):1346–8

Ventilator-associated pneumonia. Hauser CJ, et al. **Crit Care Med** 1996 May;24(5):900–1

Local anaesthetic sprays and pneumonia after gastroscopy [letter; comment] Scott BB. **Gut** 1995 Sep;37(3):445. Comment on: Gut 1995 Mar;36(3):462–7.

Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. McCoy RD, et al. **Hum Gene Ther** 1995 Dec;6(12):1553–60

Risk factors for pneumonia in nursing home residents [letter; comment] Volicer L, et al. **J Am Geriatr Soc** 1995 Dec; 43(12):1443–4. Comment on: J Am Geriatr Soc 1995 Mar;43(3):245–51.

Parenteral nutrition infused by epicutaneous catheter: pulmonary complication. Martinez-Tallo E, et al. **J Perinat Med** 1995;23(3):223–7

Pulmonary complications in inhalation injuries with associated cutaneous burn. Darling GE, et al. **J Trauma** 1996 Jan;40(1):83–9

Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. Thomason MH, et al. **J Trauma** 1996 Sep; 41(3):503–8

The relationship of alveolar permeability and pulmonary inflammation in patients with systemic lupus erythematosus. Tsai SC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):521–7

Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust [letter] Armbruster C, et al. **Lancet** 1996 Sep 7;348(9028):690

Pneumonia due to blastomyces dermatitidis in a European renal transplant recipient. Winkler S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1376–9 (13 ref.)

Anti-Jo-1 syndrome presenting as cryptogenic organizing pneumonia. Chan WM, et al. **Respir Med** 1995 Oct; 89(9):639–41

Recall lung pneumonitis due to carmustine after radiotherapy. Thomas PS, et al. **Thorax** 1995 Oct;50(10):1116–8

Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Singh N, et al. **Transplantation** 1996 Feb 15;61(3):396–401

[Pneumonia, biclonal gammopathy, paralysis of the fibular nerve and cerebrovascular insult (clinical conference)] Stahl H, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26; 84(39):1071–8 **(Ger)**

[Pneumonia in patients on the mechanical respirator] Ben-Abraham R, et al. **Harefuah** 1995 Jul;129(1–2):46–51 (35 ref.) **(Heb)**

[Diffuse tracheobronchial amyloidosis with airflow limitation and repeated pneumonias] Iwanaga T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):90–5 (Eng. Abstr.) **(Jpn)**

[Ultrasonographic examination of the heart as a basis for determining the cause of inflammatory infiltration changes in the lungs] Wiatr E, et al. **Pneumonol Alergol Pol** 1995; 63(7–8):440–5 (Eng. Abstr.) **(Pol)**

[Secondary pneumonias and their place in clinical cardiology] Asauliuk IK, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):87–90 (Eng. Abstr.) **(Rus)**

[The role of disorders in the pulmonary surfactant system in the pathogenesis of acute pneumonia] Zaltseva SI, et al. **Lik Sprava** 1995 May–Jun;(5–6):166–9 (Eng. Abstr.) **(Rus)**

[Characteristics of pneumonia in patients with pulmonary tuberculosis] Sadykov AS, et al. **Probl Tuberk** 1995;(5):34–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Role of inflammation in respiratory tract infections. Stockley RA. **Am J Med** 1995 Dec 29;99(6B):8S–13S (15 ref.)

Phenotypic analysis of airway eosinophils and lymphocytes in a Th-2–driven murine model of pulmonary inflammation. Watkins AD, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):20–34

Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Ahmed N, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1141–7

Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Chollet-Martin S, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):594–601

Community-acquired pneumonia: impact of immune status. Mundy LM, et al. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 1):1309–15

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Kane GC, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):646–54

Hantavirus serologies in patients hospitalized with community-acquired pneumonia. Auwaerter PG, et al. **J Infect Dis** 1996 Jan;173(1):237–9

Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Ortqvist A, et al. **Scand J Infect Dis** 1995;27(5):457–62

MICROBIOLOGY

Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Doré P, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1292–8

Blood culture in children with pneumonia [editorial] Baraff LJ. **Ann Emerg Med** 1996 Jun;27(6):774–6

Utility of blood cultures in pediatric patients found to have pneumonia in the emergency department. Hickey RW, et al. **Ann Emerg Med** 1996 Jun;27(6):721–5

Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Lieberman D, et al. **Chest** 1996 May;109(5):1243–9

Torulopsis pneumonia. A case report and review of the literature. Srivastava S, et al. **Chest** 1996 Sep;110(3):858–61

Coxiella burnetii (Q fever) pneumonia. Marrie TJ. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S253–64 (89 ref.)

Community-acquired pneumonia. Musher DM, et al. **Curr Clin Top Infect Dis** 1996;16:102–24 (36 ref.)

A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Leroy O, et al. **Intensive Care Med** 1995 Jan;21(1):24–31

Etiology and risk factors of adult pneumonia. Ginesu F, et al. **J Chemother** 1995 Aug;7(4):277–85 (32 ref.)

Bacterial pneumonia in adult patients with HIV infection. Moroni M, et al. **J Chemother** 1995 Aug;7(4):292–306

The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. Kauppinen MT, et al. **J Infect Dis** 1995 Nov;172(5):1330–5

Community-acquired pneumonia [letter; comment] Boersma WG, et al. **N Engl J Med** 1996 Mar 28;334(13):862; discussion 862–3. Comment on: N Engl J Med 1995 Dec 14;333(24):1618–24.

Community-acquired pneumonia [letter; comment] Mandell LA, et al. **N Engl J Med** 1996 Mar 28;334(13):861; discussion 862–3. Comment on: N Engl J Med 1995 Dec 14;333(24):1618–24.

Drug-resistant pneumococci increasingly common in elderly, study suggests [news] **Oncology (Huntingt)** 1996 Apr; 10(4):592–3

Determining etiology of pneumonia [letter; comment] Shann F. **Pediatr Infect Dis J** 1995 Oct;14(10):920–1. Comment on: Pediatr Infect Dis J 1994 Nov;13(11):975–82.

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Lieberman D, et al. **Thorax** 1996 Feb;51(2):179–84

[Chlamydia pneumoniae infection in patients with pneumonia, bronchitis and acute upper respiratory tract infection in Beijing] Ni A, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):388–91 (Eng. Abstr.) **(Chi)**

MORTALITY

Death rates among patients hospitalized with community-acquired pneumonia: a reexamination with data from three states. Markowitz JS, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1152–4

Identifying early predictors of mortality in pediatric patients with acute leukemia and pneumonia. Randle CJ Jr, et al. **Chest** 1996 Feb;109(2):457–61

A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Leroy O, et al. **Intensive Care Med** 1995 Jan;21(1):24–31

Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia [see comments] Fine MJ, et al. **J Gen Intern Med** 1995 Jul;10(7):359–68. Comment in: J Gen Intern Med 1995 Jul;10(7):406–8.

Using severity measures to predict the likelihood of death for pneumonia inpatients. Iezzoni LI, et al. **J Gen Intern Med** 1996 Jan;11(1):23–31

Host factors and pneumonia in hospitalised children. Agrawal PB, et al. **J Indian Med Assoc** 1995 Jul;93(7):271–2

Acute respiratory infections with special reference to pneumonia in underfives. Mishra S, et al. **J Indian Med Assoc** 1995 Sep;93(9):351–5

Prognostic factors in patients hospitalized with pneumonia. Limthongkul S, et al. **J Med Assoc Thai** 1995 Aug; 78(8):399–402

Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. Cook DJ, et al. **JAMA** 1996 Jan 24–31;275(4):308–14

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. Fine MJ, et al. **JAMA** 1996 Jan 10;275(2):134–41

Nosocomial pneumonia and mortality [letter] Nishioka SA. **JAMA** 1996 Jul 24–31;276(4):284

Severity measurement methods and judging hospital death rates for pneumonia. Iezzoni LI, et al. **Med Care** 1996 Jan; 34(1):11–28

[Pneumonia and mortality in patients requiring prolonged mechanical ventilation] Tanabe J, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):247–52 (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Disseminated Toxoplasma gondii infection presenting with a fulminant pneumonia [clinical conference] Miller RF, et al. **Genitourin Med** 1996 Apr;72(2):139–43

PATHOLOGY

Deformability and CD11/CD18 expression of sequestered neutrophils in normal and inflamed lungs. Brown DM, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):531–9

Differential cytology of bronchoalveolar lavage fluid in immunosuppressed children with pulmonary infiltrates. Ratjen F, et al. **Arch Dis Child** 1996 Jun;74(6):507–11

Alveolar macrophage kinetics and multinucleated giant cell formation after lung injury. Prieditis H, et al. **J Leukoc Biol** 1996 Apr;59(4):534–8

Neutrophil migration through preexisting holes in the basal laminae of alveolar capillaries and epithelium during streptococcal pneumonia. Walker DC, et al. **Microvasc Res** 1995 Nov;50(3):397–416

["Walking pneumonia" in primary sarcoma of the pulmonary artery] Theile A. **Pathologe** 1996 May;17(3):231–4 (Eng. Abstr.) **(Ger)**

[Pathomorphological study of cat lungs in a model of pneumonia] Kurambaev IaK, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):103–7 **(Rus)**

[Bronchiolitis obliterans and organized pneumonia: 2 clinico–histological entities of the pulmonary acinus (letter; comment)] Pacheco A, et al. **Arch Bronconeumol** 1995 Oct; 31(8):429–30. Comment on: Arch Bronconeumol 1995 Jan;31(1):1–2. **(Spa)**

PHYSIOPATHOLOGY

Pulmonary function tests in normal Indian children and changes in respiratory disorders. Srivastava A, et al. **Indian Pediatr** 1995 Jun;32(6):629–34

Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM–CSF in pulmonary inflammation. Xing Z, et al. **J Leukoc Biol** 1996 Apr; 59(4):481–8 (55 ref.)

Polymorphonuclear leucocyte traffic in lung inflammation [editorial] Hogg JC, et al. **Thorax** 1995 Aug;50(8):819–20 (24 ref.)

[Postoperative changes of maximum inspiratory and expiratory pressures in 3 pneumonia cases occurring after surgery for empyema] Nomori H, et al. **Kyobu Geka** 1996 Jun;49(6):445–8 (Eng. Abstr.) **(Jpn)**

[The role of the pulmonary parenchyma in regulating the functional properties of the thrombocytes in acute septic lung lesions] Shalaev SA, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):291–9 (Eng. Abstr.) **(Rus)**

[The reactions of the cardiovascular system in children suffering from inflammatory lung diseases to cold exposures] Iarosh AM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):28–30 **(Rus)**

PREVENTION & CONTROL

Postoperative atelectasis and pneumonia: risk factors. Brooks–Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

Utilizing quality assurance as a tool for reducing the risk of nosocomial ventilator–associated pneumonia. Joiner GA, et al. **Am J Med Qual** 1996 Summer;11(2):100–3

Ventilator circuit changes [letter; comment] Asbel LE, et al. **Ann Intern Med** 1996 May 15;124(10):929; discussion 929–30. Comment on: Ann Intern Med 1995 Aug 1;123(3):168–74.

Ventilator circuit changes [letter; comment] Dreyfuss D, et al. **Ann Intern Med** 1996 May 15;124(10):929; discussion 929–30. Comment on: Ann Intern Med 1995 Aug 1;123(3):168–74.

Effectiveness of control programs for pneumonia among children in China and Fiji. Shimouchi A, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S213–17

Prophylactic bronchial hygiene following cardiac surgery: what is necessary? [editorial; comment] Kacmarek RM. **Intensive Care Med** 1995 Jun;21(6):467–8. Comment on: Intensive Care Med 1995 Jun;21(6):469–74.

Process improvement plan for the reduction of nosocomial pneumonia in patients on ventilators. Nicotra D, et al. **J Nurs Care Qual** 1996 Jul;10(4):18–23

Role of corticosteroids in cystic fibrosis lung disease. Balfour–Lynn IM, et al. **J R Soc Med** 1996;89 Suppl 27:8–13 (37 ref.)

Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)

Potential interventions for preventing pneumonia among young children in developing countries: promoting maternal education. van Ginneken JK, et al. **Trop Med Int Health** 1996 Jun;1(3):283–94 (34 ref.)

Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Hughes EE, et al. **Vaccine** 1995 Dec; 13(18):1750–3

[Retrospective study of sputum culture after esophagectomy] Minamiya Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1138–44 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Interobserver reliability of the chest radiograph in community–acquired pneumonia. PORT Investigators. Albaum MN, et al. **Chest** 1996 Aug;110(2):343–50

Chronic pneumonia. Primary malignant non–Hodgkin's lymphoma of the lung arising in mucosa–associated lymphoid tissue. Chow WH, et al. **Chest** 1996 Sep; 110(3):838–40

Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Friedman EP, et al. **Clin Radiol** 1995 Nov;50(11):756–60

Images in clinical medicine. Inflammatory autobullectomy. Goodman RB, et al. **N Engl J Med** 1996 May 23; 334(21):1372–3

Chest radiographs in patients with community–acquired pneumonia. Granet KM, et al. **N J Med** 1996 Jun; 93(6):37–41

Radiographic mimics of pneumonia. Pulmonary disorders to consider in differential diagnosis. Cabreros LJ, et al. **Postgrad Med** 1996 Jan;99(1):139–42, 145–6 (0 ref.)

[High resolution computed tomography of the lung in neutropenic patients with fever] Heussel CP, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):368–75 (Eng. Abstr.) **(Ger)**

[Computed tomography and pulmonary pathology] Portnoi LM, et al. **Vestn Rentgenol Radiol** 1995 Sep–Oct;(5):5–12 (Eng. Abstr.) **(Rus)**

[Cavitary pneumonia in a neutropenic patient] Mesia R, et al. **Rev Clin Esp** 1995 Sep;195(9):659–60 **(Spa)**

[Three Swedish studies recommend radiographic check–ups after pneumonia] Holmberg H. **Lakartidningen** 1996 Aug 28;93(34):2862–3 **(Swe)**

[Lung X–ray as a control check–up after infection] Järhult B. **Lakartidningen** 1996 Jun 5;93(23):2262 **(Swe)**

[Radiographic check–up after pneumonia—generously but not routinely] Laarin S, et al. **Lakartidningen** 1996 Aug 28;93(34):2863 **(Swe)**

[Lung X–ray is an efficient, cheap, simple and harmless method] Szamosi A, et al. **Lakartidningen** 1996 Jun 5; 93(23):2262–3 **(Swe)**

RADIONUCLIDE IMAGING

Immunoscintigraphy with a 99Tcm–labelled anti–granulocyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS. Prvulovich EM, et al. **Nucl Med Commun** 1995 Oct; 16(10):838–45

REHABILITATION

[The use of magnetic fields in the combined rehabilitation of children with a history of acute pneumonia] Shovkun VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):40–1 **(Rus)**

SURGERY

Elective pneumonectomy for benign lung disease: modern–day mortality and morbidity. Conlan AA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1118–24

THERAPY

Guidelines for the initial management of community–acquired pneumonia: savory recipe or cookbook for disaster? Fein AM, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1149–53

Evaluation of a pneumonia practice guideline in an interventional trial. Weingarten SR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1110–5

Empiric outpatient management of HIV–related pneumonia: economical or unwise? [editorial] Masur H, et al. **Ann Intern Med** 1996 Feb 15;124(4):451–3

Preferences for home vs hospital care among low–risk patients with community–acquired pneumonia. Coley CM, et al. **Arch Intern Med** 1996 Jul 22;156(14):1565–71

Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul–Aug;49(4):205–10 (83 ref.)

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357–63 (34 ref.)

Management of ARI [editorial] Jalil F. **JPMA J Pak Med Assoc** 1996 Feb;46(2):28

[The use of protein preparations in the combined treatment of pneumonia patients] Novozhenov VG, et al. **Voen Med Zh** 1996 Mar;317(3):38–9 **(Rus)**

[An evaluation of the effect of magnetic–laser therapy on external respiratory function in complicated forms of acute pneumonia in children] Galdashev EA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):12–4 (Eng. Abstr.) **(Rus)**

VETERINARY

In vitro antibacterial activity of florfenicol against Actinobacillus pleuropneumoniae. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):363–4

An unusual coccidian parasite causing pneumonia in a northern cardinal (Cardinalis cardinalis). Baker DG, et al. **J Wildl Dis** 1996 Jan;32(1):130–2

Immunocytochemical detection of growth factors (PDGF and TGF beta) in equine chronic pneumonia. Rodríguez A, et al. **Res Vet Sci** 1996 Jan;60(1):82–7

Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Wilhelmsen CL, et al. **Vet Pathol** 1996 May; 33(3):296–302

Gross and light–microscopic features of ovine pulmonary hydatidosis and verminous pneumonias in Morocco. Bouljihad M, et al. **Zentralbl Veterinarmed [B]** 1995 Nov; 42(9):513–21

PNEUMONIA, ASPIRATION

Aspiration in patients in critical care units. Shifrin RY, et al. **Radiol Clin North Am** 1996 Jan;34(1):83–96 (33 ref.)

CHEMICALLY INDUCED

Accidental barium aspiration in a case of progressive bulbar palsy. Jha S, et al. **J Assoc Physicians India** 1995 Aug; 43(8):578

Fatal pulmonary aspiration of barium during oesophagography. Gombar KK, et al. **Trop Doct** 1995 Oct; 25(4):184–5

[Right–sided recurrent retention pneumonia of changing localization after aspiration of dental impression material with almost complete casting of a segmental bronchus in a previously healthy woman] Erren JP, et al. **Pneumologie** 1995 Nov;49(11):601–3 (Eng. Abstr.) **(Ger)**

[Acute lipoid pneumonia. Report of 2 cases] Lores L, et al. **Med Clin (Barc)** 1996 May 18;106(19):747–8 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Hypertonic saline treatment of acid aspiration–induced lung injury. Rabinovici R, et al. **J Surg Res** 1996 Jan; 60(1):176–80

DRUG THERAPY

Repeatedly successful closure of the larynx for the treatment of chronic aspiration with the use of botulinum toxin A. Pototschnig CA, et al. **Ann Otol Rhinol Laryngol** 1996 Jul; 105(7):521–4

Treatment of aspiration or tracheostomy–associated pneumonia in neurologically impaired children: effect of antimicrobials effective against anaerobic bacteria. Brook I. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):171–7

EPIDEMIOLOGY

Pulmonary aspiration in a long–term care setting: clinical and laboratory observations and an analysis of risk factors. Pick N, et al. **J Am Geriatr Soc** 1996 Jul;44(7):763–8

The incidence of aspiration associated with the laryngeal mask airway: a meta–analysis of published literature. Brimacombe JR, et al. **J Clin Anesth** 1995 Jun;7(4):297–305

ETIOLOGY

Acid aspiration induced lung injury. New insights and therapeutic options [editorial; comment] Matthay MA, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):277–8 . Comment on: Am J Respir Crit Care Med 1996 Aug;154(2 Pt 1):504–10.

Aspiration pneumonia following surgically placed feeding tubes. Fox KA, et al. **Am J Surg** 1995 Dec;170(6):564–6; discussion 566–7

The laryngeal mask airway in the intensive care unit [letter] Kinirons B. **Anaesthesia** 1996 Feb;51(2):202–3

Postoperative laryngeal competence. The laryngeal mask airway and tracheal tube compared. Stanley GD, et al. **Anaesthesia** 1995 Nov;50(11):985–6

Acute lung injury after instillation of human breast milk or infant formula into rabbits' lungs. O'Hare B, et al. **Anesthesiology** 1996 Jun;84(6):1386–91

Hot liquid aspiration and child abuse [letter] Su E, et al. **Ann Emerg Med** 1996 Aug;28(2):246–7

Pneumonia associated with aspiration following stroke. Teasell RW, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):707–9

Factors associated with early onset pneumonia in the severely brain–injured patient. Woratyla SP, et al. **Conn Med** 1995 Nov;59(11):643–7

Relation between Glasgow Coma Scale and aspiration pneumonia [letter] Adnet F, et al. **Lancet** 1996 Jul 13; 348(9020):123–4

[Aspiration bronchopneumonia as a complication of acute poisoning with psychotropic drugs] Todorović V, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):341–8 (Eng. Abstr.) **(Scr)**

[Pulmonary granulomatosis caused by lentil aspiration] Barrio Gómez de Agüero MI, et al. **Arch Bronconeumol** 1995 Nov; 31(9):485–7 (Eng. Abstr.) **(Spa)**

HISTORY

[Origins of preoperative fasting] Goerig M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):245–8 **(Ger)**

NURSING

Tube feeding aspiration. Pratt JC, et al. **Am J Nurs** 1996 May;96(5):37

PATHOLOGY

Lipid–laden alveolar macrophages as an indicator of aspiration pneumonia [letter; comment] Langston C, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):326–7. Comment on: Arch Pathol Lab Med 1995 Mar;119(3):229–31.

[Drowning by aspiration of oral saline administration] Kropp S, et al. **Arch Kriminol** 1996 Mar–Apr;197(3–4):76–80 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Oxygen desaturation on swallowing as a potential marker of aspiration in acute stroke. Zaidi NH, et al. **Age Ageing** 1995 Jul;24(4):267–70

Intercellular adhesion molecule–1 mediates acid aspiration–induced lung injury [see comments] Nagase T, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):504–10. Comment in: Am J Respir Crit Care Med 1996 Aug;154(2 Pt 1):277–8.

Subglottic air pressure: a key component of swallowing efficiency. Eibling DE, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):253–8 (19 ref.)

Effects of acid aspiration–induced lung injury on left

ventricular function. Schertel ER, et al. **Surgery** 1996 Jan; 119(1):81–8

PREVENTION & CONTROL

Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Orozco-Levi M, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1387–90

Airway protection with the new laryngeal mask prototype [letter] Brimacombe J. **Anaesthesia** 1996 Jun;51(6):602–3

Cricoid pressure: are two hands better than one? Cook TM. **Anaesthesia** 1996 Apr;51(4):365–8

The efficacy and optimum time of administration of ranitidine in the prevention of the acid aspiration syndrome. Escolano F, et al. **Anaesthesia** 1996 Feb;51(2):182–4

Acid aspiration prophylaxis for emergency Caesarean section. Stuart JC, et al. **Anaesthesia** 1996 May;51(5):415–21

On the new nasogastric tube with balloon for prevention of pulmonary aspiration of gastric contents [letter; comment] Kubota Y, et al. **Anesth Analg** 1995 Dec; 81(6):1316–7. Comment on: Anesth Analg 1995 Feb;80(2):378–83.

Prevention of aspiration during Combitube insertion [letter; comment] Southwick JP. **Anesth Analg** 1996 Jul; 83(1):197–8. Comment on: Anesth Analg 1995 Nov;81(5):1116–8.

Efficacy and safety of cricoid pressure needs scientific validation [letter] Jackson SH. **Anesthesiology** 1996 Mar; 84(3):751–2

Continuous oxygen insufflation using a speaking tracheostomy tube is effective in preventing aspiration during feeding. Naito Y, et al. **Anesthesiology** 1996 Feb; 84(2):448–50

Comparison of the effect of two dose schedules of oral omeprazole with oral ranitidine on gastric aspirate pH and volume in patients undergoing elective surgery. Levack ID, et al. **Br J Anaesth** 1996 Apr;76(4):567–9

Cricoid pressure decreases lower oesophageal sphincter tone in anaesthetized pigs. Chassard D, et al. **Can J Anaesth** 1996 Apr;43(4):414–7

[The child with minor trauma. Does observation of fasting times reduce the risk of aspiration?] Kraus GB, et al. **Anaesthesist** 1996 May;45(5):420–7 (71 ref.) (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Preoperative fasting and aspiration (editorial)] Martin E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(4):244–5 **(Ger)**

[Preoperative fasting and prevention of aspiration from the legal medicine viewpoint] Püschel K. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):248–50 **(Ger)**

[Conventional and new measures for prevention of aspiration] Roewer N. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):257–60 **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

[Reduction in frequency of pneumonia after stroke, following programmed swallowing evaluation] Gottlieb D, et al. **Harefuah** 1995 Jul;129(1–2):33–5, 78 (Eng. Abstr.) **(Heb)**

RADIOGRAPHY

[Analysis and radiologic staging of the type and severity of aspiration] Hannig C, et al. **Radiologe** 1995 Oct; 35(10):741–6 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

The radionuclide salivagram in children with pulmonary disease and a high risk of aspiration. Bar-Sever Z, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S130–3

SURGERY

Laryngotracheal separation under local anaesthesia for intractable salivary aspiration: cricoidectomy with fibrin glue support. Sone M, et al. **J Laryngol Otol** 1996 Jan; 110(1):72–4

THERAPY

Acid aspiration induced lung injury. New insights and therapeutic options [editorial; comment] Matthay MA, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):277–8 . Comment on: Am J Respir Crit Care Med 1996 Aug;154(2 Pt 1):504–10.

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

[Effects of transcutaneous silicon injection for aspiration caused by unilateral vocal cord paralysis] Ohmae Y, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Nov;98(11):1788–95 (Eng. Abstr.) **(Jpn)**

VETERINARY

What is your diagnosis? Severe cranioventral alveolar lung disease and generalized megaesophagus, with gastric dilatation and duodenal obstruction. Dennis LE, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1809–10

PNEUMONIA, BACTERIAL

Interleukin-8: a potent neutrophil chemotactic factor [letter] Papoff P, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F54

European Nosocomial Infection Survey: analysis of Irish data. Irish Intensive Care Nosocomial Pneumonia Survey Group. Marsh B, et al. **Ir Med J** 1996 May-Jun;89(3):96–8

Nosocomial pneumonia: trying to make sense of the literature. Broughton WA, et al. **Postgrad Med** 1996 Mar; 99(3):221–31, 235–6, 241–2 (31 ref.)

Nosocomial pneumonia. Lipchik RJ, et al. **Radiol Clin North Am** 1996 Jan;34(1):47–58 (69 ref.)

BLOOD

Elevated serum hepatocyte growth factor/scatter factor levels in inflammatory lung disease. Maeda J, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1587–91

Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Bohte R, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2801–2

Calprotectin as a marker of inflammation in cystic fibrosis. Golden BE, et al. **Arch Dis Child** 1996 Feb;74(2):136–9

Ureaplasma urealyticum as a cause of pneumonia in preterm infants: analysis of the white cell response. Panero A, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F37–40

Changes of serum concentration of lipid peroxidation products in patients with pneumonia. Nowak D, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):188–93

COMPLICATIONS

VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema. Angelillo Mackinlay TA, et al. **Ann Thorac Surg** 1996 Jun;61(6):1626–30

Legionella longbeachae pneumonia and Henoch-Schönlein purpura [letter] Gowardman JR, et al. **Aust N Z J Med** 1996 Apr;26(2):236–7

Rheumatic pneumonia: reappearance of a previously recognized complication of acute rheumatic fever. Burgert SJ, et al. **Clin Infect Dis** 1995 Oct;21(4):1020–2

Infections in patients with chronic adult T-cell leukemia/lymphoma: case report and review. Rhew DC, et al. **Clin Infect Dis** 1995 Oct;21(4):1014–6

Parapneumonic effusions secondary to community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Gil Suay V, et al. **Eur Respir J** 1995 Nov;8(11):1934–9

Bordetella bronchiseptica pneumonia in an AIDS patient: a new opportunistic infection [letter] Libanore M, et al. **Infection** 1995 Sep-Oct;23(5):312–3

Successful prevention of recurrent pneumonia caused by Pseudomonas aeruginosa in a patient with AIDS [letter] Ainsworth J. **Int J STD AIDS** 1995 Nov-Dec;6(6):454–5

A woman with two young children and left chest pain. Lamb FJ, et al. **Lancet** 1996 Mar 30;347(9005):870

The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Balough K, et al. **Pediatr Pulmonol** 1995 Aug;20(2):63–70

Analysis of restriction fragment length polymorphism and ribotyping of multiresistant Stenotrophomonas maltophilia isolated from persisting lung infection in a cystic fibrosis patient. Wüst J, et al. **Scand J Infect Dis** 1995;27(5):499–502

Bronchopulmonary infection with Mycobacterium malmoense presenting as a bronchoesophageal fistula. Schäfer H, et al. **Tuber Lung Dis** 1996 Jun;77(3):287–90

[Hypoxemic nosocomial pneumonia developing in excavation in a patient with Cushing disease] Mouas H, et al. **Rev Pneumol Clin** 1995;51(6):354–8 (Eng. Abstr.) **(Fre)**

[Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin-B after renal transplantation] Abe M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):737–40 (Eng. Abstr.) **(Jpn)**

[Urgent allogeneic bone marrow transplantation using a preparative regimen of cyclophosphamide anti-human thymocytes rabbit globulin in a patient with severe aplastic anemia with pneumonia] Okamoto T, et al. **Rinsho Ketsueki** 1996 Jan;37(1):72–6 (Eng. Abstr.) **(Jpn)**

[The effect of Aspergillus flavus metabolites on the development of experimental Klebsiella pneumonia] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):23–4 **(Rus)**

[Spontaneous bilateral pneumothorax (letter)] Alemany Francés ML, et al. **Arch Bronconeumol** 1996 Apr; 32(4):211–2 **(Spa)**

[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177–80 (57 ref.) (Eng. Abstr.) **(Spa)**

[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

[Young woman with cutaneous lupus and lung effusion] Porcel JM, et al. **Rev Clin Esp** 1995 Aug;195(8):583–4 **(Spa)**

[Pneumonia caused by Salmonella in a patient with myeloma (letter)] Fernández P, et al. **Sangre (Barc)** 1995 Jun; 40(3):234–5 **(Spa)**

DIAGNOSIS

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. **Am J Respir Crit Care Med** 1996 May;153(5):1711–25 (110 ref.)

Reliability of quantitative cultures of protected specimen brush after freezing. Georges H, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):855–7

Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Papazian L, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1982–91

Minibronchoalveolar lavage by respiratory therapists [letter; comment] Epstein MD. **Ann Intern Med** 1996 Jan 15; 124(2):274–5. Comment on: Ann Intern Med 1995 May 15;122(10):743–8.

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart-lung transplant recipients and a review of the literature. Bassiri AG, et al. **Chest** 1996 Apr;109(4):1109–11 (10 ref.)

Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. Dalhoff K, et al. **Chest** 1996 Aug;110(2):351–6

Prospective evaluation of a semiquantitative dip slide method compared with quantitative bacterial cultures of BAL fluid. Speich R, et al. **Chest** 1996 Jun;109(6):1423–9

Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Timsit JF, et al. **Chest** 1995 Oct;108(4):1036–40

Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia [see comments] Timsit JF, et al. **Chest** 1995 Dec;108(6):1632–9. Comment in: Chest 1995 Dec;108(6):1492–4. Comment in: Chest 1996 Jul;110(1):302.

Usefulness of airway visualization in the diagnosis of nosocomial pneumonia in ventilated patients. Timsit JF, et al. **Chest** 1996 Jul;110(1):172–9

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244–52 (120 ref.)

Elastin fibers and the diagnosis of bacterial pneumonia in the adult respiratory distress syndrome. Shepherd KE, et al. **Crit Care Med** 1995 Nov;23(11):1829–34

The role of bronchoalveolar lavage in the diagnosis of bacterial pneumonia. Sanchez Nieto JM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):839–50 (93 ref.)

Perioperative microbiologic monitoring of tracheal aspirates as a predictor of pulmonary complications after cardiac operations. Zickman B, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1213–8

Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: a prospective analysis. Croce MA, et al. **J Trauma** 1995 Dec;39(6):1134–9; discussion 1139–40

Pneumonia caused by nocardia caviae in a healthy neonate. Mufti P, et al. **JPMA J Pak Med Assoc** 1995 Oct; 45(10):272–3

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13–1996. A 51-year-old man with the adult respiratory distress syndrome [clinical conference] **N Engl J Med** 1996 Apr 25;334(17):1116–23

Atypical pneumonia. Extrapulmonary clues guide the way to diagnosis [published erratum appears in Postgrad Med 1996 Apr;99(4):64] Cunha BA, et al. **Postgrad Med** 1996 Jan;99(1):123–8, 131–2 (11 ref.)

Actinobacillus actinomycetemcomitans pneumonia with chest wall and subphrenic abscess. Chen AC, et al. **Scand J Infect Dis** 1995;27(3):289–90

Mycobacterium avium-intracellulare complex pneumonia in a non-HIV-infected individual: an increasingly recognized disease. Asnis DS, et al. **South Med J** 1996 May;89(5):522–5

Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Kauppinen MT, et al. **Thorax** 1996 Feb; 51(2):185–9

Diagnostic value of blood cytokine concentrations in acute pneumonia. Kragsbjerg P, et al. **Thorax** 1995 Dec; 50(12):1253–7

Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia. Torres A, et al. **Thorax** 1996 Apr;51(4):378–84

Pulmonary Nocardiosis in a patient with human immunodeficiency virus disease. Barrow KO, et al. **West Indian Med J** 1996 Jun;45(2):63–4

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al.

Dtsch Med Wochenschr 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Pleuro–mediastinitis in pulmonary actinomycosis as a rare differential bronchial carcinoma diagnosis] Orth M, et al. **Pneumologie** 1995 Sep;49(9):505–8 (Eng. Abstr.) **(Ger)**

[Cough, fever and exanthema (clinical conference)] Czerwenka W, et al. **Schweiz Rundsch Med Prax** 1996 Aug 20;85(34):1005–8 (Eng. Abstr.) **(Ger)**

[Spontaneous cure of pneumonia caused by Chlamydia pneumoniae] Miyashita N, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):934–9 (Eng. Abstr.) **(Jpn)**

[An atypical course of chlamydial infection] Ivashkin VT, et al. **Voen Med Zh** 1995 Sep;(9):35–9, 80 (Eng. Abstr.) **(Rus)**

[Optimization of the etiological diagnosis and adequate antibacterial therapy in acute disseminated pneumonias] Sinopal'nikov AI, et al. **Voen Med Zh** 1996 Feb;317(2):30–3, 79 (Eng. Abstr.) **(Rus)**

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

DRUG THERAPY

Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community–acquired and nosocomial pneumonias. Belliveau PP, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1024–7

A new therapeutic option for the treatment of pneumonia. McCabe R, et al. **Am J Med** 1996 Jun 24;100(6A):60S–67S

Effect of sodium nitroprusside and diethylcarbamazine on hypoxic pulmonary vasoconstriction and regional distribution of pulmonary blood flow in experimental pneumonia. Light RB. **Am J Respir Crit Care Med** 1996 Jan;153(1):325–30

Amoxicillin dose–effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Azoulay–Dupuis E, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):941–6

Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents. Masson ND, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1959–64

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

Use of vancomycin for the treatment of Corynebacterium xerosis pneumonia [letter; comment] Bayston R. **Clin Infect Dis** 1995 Jul;21(1):223. Comment on: Clin Infect Dis 1994 May;18(5):845–6.

Single daily dose of cefodizime in patients with community–acquired pneumonia: an open–label, controlled, randomized study. The Italian Multicentre Community–Acquired Pneumonia Group. De Palma M, et al. **Clin Ther** 1995 May–Jun;17(3):413–24

Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group. Bruch HP, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):203–7

Prospective evaluation of twice–daily cefotaxime in the treatment of hospitalized patients with severe infections. Keller C. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):159–61

Switch therapy in community–acquired pneumonia. Ramirez JA. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):219–23

Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study. Shah PM, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):171–2

Sparfloxacin empirical therapy in community–acquired pneumonia. Results of a meta–analysis of 2 comparative studies. Grassi GG, et al. **Drugs** 1995;49 Suppl 2:406–8

Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Siami GA, et al. **Drugs** 1995;49 Suppl 2:436–8

Treatment of community–acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin–clavulanic acid and erythromycin [see comments] Lode H, et al. **Eur Respir J** 1995 Dec;8(12):1999–2007. Comment in: Eur Respir J 1995 Dec;8(12):1996–8.

Empirical treatment of nonsevere community–acquired pneumonia: still a difficult issue [editorial; comment] Torres A, et al. **Eur Respir J** 1995 Dec;8(12):1996–8. Comment on: Eur Respir J 1996 Dec;8(12):1999–2007.

Treatment of aspiration or tracheostomy–associated pneumonia in neurologically impaired children: effect of antimicrobials effective against anaerobic bacteria. Brook I. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):171–7

Sparfloxacin for the treatment of community–acquired pneumonia: a pooled data analysis of two studies. Aubier M, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:73–82

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community–acquired pneumonia. French Study Group. Portier H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:83–91

Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. Beaucaire G. **J Chemother** 1995 Jun;7 Suppl 2:165–73

Interleukin–1 alpha (IL–1 alpha) production by alveolar macrophages in patients with acute lung diseases: the influence of zinc supplementation. Abu! HT, et al. **Mol Cell Biochem** 1995 May 24;146(2):139–45

Drug–resist and Streptococcus pneumoniae [letter; comment] Clynes NE. **N Engl J Med** 1996 Jan 4;334(1):53–5. Comment on: N Engl J Med 1995 Aug 24;333(8):474–80. Comment on: N Engl J Med 1995 Aug 24;333(8):481–6.

Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Bradley JS, et al. **Pediatr Infect Dis J** 1995 Dec; 14(12):1037–41

Ampicillin plus mecillinam vs. cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double–blind multicentre study evaluated by intention–to–treat analysis. Cronberg S, et al. **Scand J Infect Dis** 1995;27(5):463–8

[Fluoroquinolones in antimicrobial therapy and prophylaxis in surgery] Vyhnánek F, et al. **Rozhl Chir** 1995 Sep; 74(6):257–61 (Eng. Abstr.) **(Cze)**

[Treatment of bacterial pneumonias with cefuroxime–axetil. Predictive value of measurement of the in vitro susceptibility] Cluzel R, et al. **Pathol Biol (Paris)** 1996 Mar; 44(3):217–23 (Eng. Abstr.) **(Fre)**

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S–33S (30 ref.) (Eng. Abstr.) **(Fre)**

[A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double–blind method] Saito A, et al. **Jpn J Antibiot** 1996 Feb;49(2):144–74 (Eng. Abstr.) **(Jpn)**

[Combination therapy with arbekacin and fosfomycin against postoperative severe mixed–pneumonia of MRSA in primary lung cancer patients] Harada R, et al. **Kyobu Geka** 1995 Sep;48(10):836–40 (Eng. Abstr.) **(Jpn)**

[The use of cefuroxime (Zinacef) in bacterial pneumonias in children] Popa MI. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):220 **(Rum)**

[Optimization of the etiological diagnosis and adequate antibacterial therapy in acute disseminated pneumonias] Sinopal'nikov AI, et al. **Voen Med Zh** 1996 Feb;317(2):30–3, 79 (Eng. Abstr.) **(Rus)**

[Treatment of pneumonia under hospital conditions] Ponomarev D. **Vojnosanit Pregl** 1995 Mar–Apr; 52(2):135–41 (Eng. Abstr.) **(Scr)**

ECONOMICS

[Comparative study of the cost–/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study] Rodloff AC, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):172–80 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Distribution of human neutrophil elastase in diffuse alveolar damage and pneumonia in a case of neonatal sepsis. Fujita J, et al. **Respir Med** 1995 Aug;89(7):505–7

EPIDEMIOLOGY

Prevalence of Legionella pneumophila infection in children and its role in pediatric community–acquired atypical pneumonia. Hsu CM, et al. **Acta Paediatr Sin** 1996 May–Jun;37(3):188–92

Intermittent enteral feeding: the influence on respiratory and digestive tract colonization in mechanically ventilated intensive–care–unit patients. Bonten MJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):394–9

An outbreak of gentamicin–resistant Klebsiella pneumoniae in a neonatal ward. Shamseldin el Shafie S, et al. **Cent Eur J Public Health** 1995 Aug;3(3):129–31

Risk factors for the development of Haemophilus influenzae pneumonia in hospitalized adults. Barreiro B, et al. **Eur Respir J** 1995 Sep;8(9):1543–7

Nosocomial and community–acquired Legionella pneumonia: clinical comparative analysis. Pedro–Botet ML, et al. **Eur Respir J** 1995 Nov;8(11):1929–33

Chlamydia pneumoniae infection in children with lower respiratory tract infections. Yamada S. **Kurume Med J** 1995; 42(2):107–20

The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain [see comments] Sun L, et al. **Nat Med** 1995 Jul;1(7):661–6. Comment in: Nat Med 1995 Jul;1(7):626–7.

Penicillin–resistant Streptococcus pneumoniae and acute pulmonary infections: prevalence and severity. Korppi M. **Pediatr Pulmonol Suppl** 1995;11:10–1

Prevalence of pneumonia due to Legionella pneumophila and Mycoplasma pneumoniae in a population admitted to a department of internal medicine. Bozzoni M, et al. **Respiration** 1995;62(6):331–5

Bacterial pneumonia in recipients of bone marrow transplantation. A five–year prospective study. Lossos IS, et al. **Transplantation** 1995 Oct 15;60(7):672–8

[Clinico–epidemiological considerations of 30 cases of pulmonitis and pleuropulmonitis in childhood] De Luca L, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):237–41 (Eng. Abstr.) **(Ita)**

ETHNOLOGY

Ethnographic studies of ARI in Bolivia and their use by the national ARI programme. Hudelson P, et al. **Soc Sci Med** 1995 Dec;41(12):1677–83

ETIOLOGY

Pneumonia in intubated trauma patients. Microbiology and outcomes. Baker AM, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):343–9

The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double–blind study of sucralfate versus antacids. Bonten MJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1825–34

Effect of ventilator–associated pneumonia on mortality and morbidity. Papazian L, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):91–7

Ventilator circuit changes and nosocomial pneumonia [letter; comment] Dreyfuss D, et al. **Anesthesiology** 1995 Oct; 83(4):882–4. Comment on: Anesthesiology 1995 Apr;82(4):903–11.

Histopathologic and microbiologic aspects of ventilator–associated pneumonia [see comments] Fàbregas N, et al. **Anesthesiology** 1996 Apr;84(4):760–71. Comment in: Anesthesiology 1996 Apr;84(4):757–9.

The effect of late–onset ventilator–associated pneumonia in determining patient mortality. Kollef MH, et al. **Chest** 1995 Dec;108(6):1655–62

Pasteurella pneumotropica pneumonia in a patient with AIDS [letter] Cuadrado–Gómez LM, et al. **Clin Infect Dis** 1995 Aug;21(2):445–6

Lower respiratory tract infections following cardiac arrest and cardiopulmonary resuscitation. Rello J, et al. **Clin Infect Dis** 1995 Aug;21(2):310–4

Factors associated with early onset pneumonia in the severely brain–injured patient. Woratyla SP, et al. **Conn Med** 1995 Nov;59(11):643–7

Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Tang HB, et al. **Infect Immun** 1996 Jan;64(1):37–43

Role of the intercellular adhesion molecule–1(ICAM–1) in endotoxin–induced pneumonia evaluated using ICAM–1 antisense oligonucleotides, anti–ICAM–1 monoclonal antibodies, and ICAM–1 mutant mice. Kumasaka T, et al. **J Clin Invest** 1996 May 15;97(10):2362–9

Predisposition of specific pathogen–free lambs to Pasteurella haemolytica pneumonia by Bordetella parapertussis infection. Porter JF, et al. **J Comp Pathol** 1995 May; 112(4):381–9

New insights into the pathogenesis of ventilator–associated pneumonia. Inglis TJ. **J Hosp Infect** 1995 Jun;30 Suppl:409–13

Pneumonia in mechanically ventilated patients in Nan Hospital intensive care unit. Thanamee N, et al. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S102–4

Community–acquired pneumonia: is there difference in etiology between hospitalized and out–patients? Michetti G, et al. **Minerva Med** 1995 Sep;86(9):341–51

Fatal pneumonia complicating hypothermia for the treatment of postoperative junctional ectopic tachycardia. Matthys D, et al. **Pediatr Cardiol** 1995 Nov–Dec;16(6):294–6

Gastric alkalinization, pneumonia, and systemic infections: the controversy. Tryba M, et al. **Scand J Gastroenterol Suppl** 1995;210:53–9 (69 ref.)

Pneumonia in mechanically ventilated children. Brook I. **Scand J Infect Dis** 1995;27(6):619–22

[Disappearance of emphysematous bullae after infectious episodes] Guimard Y, et al. **Rev Pneumol Clin** 1995; 51(4):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Pneumonia in patients after extracorporeal circulation] Kłodkowska–Farner E, et al. **Pneumonol Alergol Pol** 1995; 63(7–8):371–7 (Eng. Abstr.) **(Pol)**

[Dog bite and Pasteurella multocida pneumonia (letter)] Pascal I, et al. **Med Clin (Barc)** 1996 May 18;106(19):757 **(Spa)**

IMMUNOLOGY

Role of CD 11/CD 18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa–induced pneumonia in rabbits. Kumasaka T, et al. **Am J Pathol** 1996 Apr;148(4):1297–305

Immunoglobulin A levels in bronchial samples during mechanical ventilation and onset of nosocomial pneumonia in critically ill patients. Annane D, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1585–90

Antibody response to Prevotella spp. in patients with ventilator–associated pneumonia. Grollier G, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):61–5

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

An adult diagnosed as hyper–IgM immunodeficiency syndrome. Hirasawa A, et al. **Intern Med** 1995 Jul; 34(7):640–2

Hospital acquired pulmonary nocardiosis complicating polymyositis. Gupta D, et al. **J Assoc Physicians India** 1995 Sep;43(9):641–2

Genetically determined differences in IL–10 and IFN–gamma

responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. Yang X, et al. **J Immunol** 1996 Jun 1;156(11):4338–44

Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. Greenberger MJ, et al. **J Infect Dis** 1996 Jan;173(1):159–65

Expression and regulation of chemokines in bacterial pneumonia. Standiford TJ, et al. **J Leukoc Biol** 1996 Jan; 59(1):24–8 (33 ref.)

Interleukin-1 alpha (IL-1 alpha) production by alveolar macrophages in patients with acute lung diseases: the influence of zinc supplementation. Abul HT, et al. **Mol Cell Biochem** 1995 May 24;146(2):139–45

The C5a chemoattractant receptor mediates mucosal defence to infection [see comments] Höpken UE, et al. **Nature** 1996 Sep 5;383(6595):86–9. Comment in: Nature 1996 Sep 5;383(6595):25–6.

[The correlation between psittacosis-ornithosis and the immune status in childhood: apropos 5 cases] De Luca L, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):243–4 (Eng. Abstr.) **(Ita)**

METABOLISM

Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Boutten A, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):336–42

Lung hyaluronan decreases during group B streptococcal pneumonia in neonatal piglets. Juul SE, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1567–70

GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Villard J, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1549–54

Activation of latent transforming growth factor beta during Chlamydia trachomatis-induced murine pneumonia. Williams DM, et al. **Res Microbiol** 1996 May;147(4):251–62

MICROBIOLOGY

Rhodococcus equi infection in 3 AIDS patients. Colebunders R, et al. **Acta Clin Belg** 1996;51(2):101–5

Nocardiosis: a rare cause of pleuropulmonary disease in the immunocompromised host. Toukap AN, et al. **Acta Clin Belg** 1996;51(3):161–5

Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation. Heurlin N, et al. **Acta Paediatr** 1996 Feb;85(2):168–72

Pneumonia associated with nosocomial sinusitis: a different risk according to the pathogen involved [letter; comment] Bert F, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1424–5. Comment on: Am J Respir Crit Care Med 1994 Sep;150(3):776–83.

Development of a peroxidase-antiperoxidase (PAP) technique for the identification of Haemophilus somnus in pneumonic calf lungs in Denmark. Tegtmeier C, et al. **APMIS** 1995 Jul-Aug;103(7-8):540–7

Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Kauppinen MT, et al. **Arch Intern Med** 1996 Sep 9;156(16):1851–6

Haemophilus pneumonia is a common cause of early pulmonary dysfunction following trauma. Spain DA, et al. **Arch Surg** 1995 Nov;130(11):1228–31; discussion 1231–2

Legionella longbeachae pneumonia and Henoch-Schönlein purpura [letter] Gowardman JR, et al. **Aust N Z J Med** 1996 Apr;26(2):236–7

Justifying the use of blood cultures when diagnosing community-acquired pneumonia [editorial; comment] Berk SL. **Chest** 1995 Oct;108(4):891–2. Comment on: Chest 1995 Oct;108(4):932–6.

Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks [see comments] Chalasani NP, et al. **Chest** 1995 Oct;108(4):932–6. Comment in: Chest 1995 Oct;108(4):891–2.

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244–52 (120 ref.)

Brain abscess due to Nocardia brasiliensis hematogenously spread from a pulmonary infection [letter] Naguib MT, et al. **Clin Infect Dis** 1995 Aug;21(2):459–60

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

Pseudomonas pickettii pneumonia in a diabetic patient. Ahkee S, et al. **J Ky Med Assoc** 1995 Nov;93(11):511–3

A novel simple method for quantifying bacteria from endotracheal aspirates. Flanagan PG, et al. **J Med Microbiol** 1996 Aug;45(2):153–4

Panic in the potting shed. The association between Legionella longbeachae serogroup 1 and potting soils in Australia. Ruehlemann SA, et al. **Med J Aust** 1996 Jan 1;164(1):36–8

Pseudomonas aeruginosa pneumonia/sepsis as an initial opportunistic infection in an HIV patient. Amundson DE, et al. **Mil Med** 1996 Mar;161(3):179

Tularemia fatality [letter; comment] Garrett CL. **N C Med J** 1995 Oct;56(10):476. Comment on: N C Med J 1995 Jul;56(7):314–7.

'Atypical' bacteria—a common cause of community-acquired pneumonia in hospitalised adults? [letter; comment] Potgieter P. S **Afr Med J** 1995 Oct;85(10):1031–2, 1034. Comment on: S Afr Med J 1994 Oct;84(10):678–82.

Analysis of restriction fragment length polymorphism and ribotyping of multiresistant Stenotrophomonas maltophilia isolated from persisting lung infection in a cystic fibrosis patient. Wüst J, et al. **Scand J Infect Dis** 1995;27(5):499–502

Acute community-acquired bacterial pneumonia in Human Immunodeficiency Virus (HIV) infected and non-HIV-infected adult patients in Cameroon: aetiology and outcome. Koulla-Shiro S, et al. **Tuber Lung Dis** 1996 Feb;77(1):47–51

[Pulmonary mycobacteriosis due to Mycobacterium xenopi" in-vitro sensitivity to classical antitubercular agents and clinical development] Baugnée PE, et al. **Acta Clin Belg** 1996;51(1):19–27 (Eng. Abstr.) **(Fre)**

[Clinical manifestations of actinomycosis: literature review apropos of a case] Liaudet L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):423–8 **(Fre)**

[Meningococcal pneumonia] Bourlaud I, et al. **Rev Pneumol Clin** 1995;51(2):90–2 (Eng. Abstr.) **(Fre)**

[Various new pathogens in pneumonia] Regamey C. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2171–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Cough, fever and exanthema (clinical conference)] Czerwenka W, et al. **Schweiz Rundsch Med Prax** 1996 Aug 20;85(34):1005–8 (Eng. Abstr.) **(Ger)**

[A case of Legionella micdadei pneumonia] Miyashita N, et al. **Kansenshogaku Zasshi** 1996 Mar;70(3):268–72 (Eng. Abstr.) **(Jpn)**

[Nocardia asteroides pneumonia in a patient undergoing a kidney transplant (letter)] Carpintero Y, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):65–6 **(Spa)**

MORTALITY

Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation. Heurlin N, et al. **Acta Paediatr** 1996 Feb;85(2):168–72

Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Timsit JF, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):116–23

Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crouch Brewer S, et al. **Chest** 1996 Apr; 109(4):1019–29

Nosocomial pneumonia and mortality among patients in intensive care units. Fagon JY, et al. **JAMA** 1996 Mar 20; 275(11):866–9

Identifying the killer in cystic fibrosis [comment] Hearst JE, et al. **Nat Med** 1995 Jul;1(7):626–7. Comment on: Nat Med 1995 Jul;1(7):661–6.

PATHOLOGY

Role of CD 11/CD 18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa-induced pneumonia in rabbits. Kumasaka T, et al. **Am J Pathol** 1996 Apr;148(4):1297–305

Streptococcus pyogenes infection in mice. Husmann LK, et al. **Microb Pathog** 1996 Apr;20(4):213–24

Neonatal Escherichia coli infection and segmental arterial necrosis: similarity to edema disease of weanling swine. de Chadarévian JP, et al. **Mod Pathol** 1995 May;8(4):446–9

PHYSIOPATHOLOGY

An animal model of pulmonary infection after single lung transplantation. Kim HK, et al. **Transplant Proc** 1996 Jun; 28(3):1816–7

[Mucociliary function in acute pneumonia] Gel'tser BI, et al. **Ter Arkh** 1996;68(3):77–80 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Changing heat and moisture exchangers every 48 hours rather than 24 hours does not affect their efficacy and the incidence of nosocomial pneumonia. Djedaini K, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1562–9

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Johansen HK, et al. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 1):1337–46

Pneumonia in intubated patients: role of respiratory airway care. Rello J, et al. **Am J Respir Crit Care Med** 1996 Jul; 154(1):111–5

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Prospective, randomized study of ventilator-associated pneumonia in patients with one versus three ventilator circuit changes per week. Long MN, et al. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):14–9

Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May-Jun;23(3):129–32 (31 ref.)

Bacterial pneumonia in HIV [letter; comment] Cohen JI. **N Engl J Med** 1996 Jan 18;334(3):195. Comment on: N Engl J Med 1995 Sep 28;333(13):845–51.

RADIOGRAPHY

Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Kauppinen MT, et al. **Arch Intern Med** 1996 Sep 9;156(16):1851–6

Pneumonia with an enlarged cardiac silhouette. Tirdel GB, et al. **Chest** 1996 May;109(5):1380–2

High resolution CT findings in community-acquired pneumonia. Tanaka N, et al. **J Comput Assist Tomogr** 1996 Jul-Aug;20(4):600–8

On round pneumonia in children [letter] Camargos PA, et al. **Pediatr Pulmonol** 1995 Sep;20(3):194–5

[Pulmonary complications in HIV-positive patients with minimal immune deficiency] Jacobi V, et al. **Rontgenpraxis** 1995 Sep;48(9):254–8 **(Ger)**

THERAPY

Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Johansen HK, et al. **Clin Exp Immunol** 1996 Feb;103(2):212–8

The management of pneumonia in children in developing countries. Shann F. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S218–25

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965–85 (113 ref.)

VETERINARY

Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):220–3

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Kenney DG, et al. **Equine Vet J** 1994 May;26(3):246–8

Molecular characterization of a ribonucleotide reductase (nrdF) gene fragment of Mycoplasma hyopneumoniae and assessment of the recombinant product as an experimental vaccine for enzootic pneumonia. Fagan PK, et al. **Infect Immun** 1996 Mar;64(3):1060–4

Immunohistochemical and pathological study of Mycoplasma bovis-associated lung abscesses in calves. Adegboye DS, et al. **J Vet Diagn Invest** 1995 Jul;7(3):333–7

Fibrinohemorrhagic pneumonia in pigs naturally infected with Streptococcus suis. Reams RY, et al. **J Vet Diagn Invest** 1995 Jul;7(3):406–8

Effect of physical defenses of the respiratory tract on the development of pneumonia in pigs inoculated endobronchially with Actinobacillus pleuropneumoniae. Narita M, et al. **J Vet Med Sci** 1995 Oct;57(5):839–44

Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. Mengelers MJ, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):243–53

Acute pneumonia in a Syrian hamster: isolation of a Corynebacterium species. Tansey G, et al. **Lab Anim Sci** 1995 Aug;45(4):366–7

Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol. Pabst R, et al. **Lung** 1995;173(4):233–41

Bacterial pneumonia associated with corticosteroid therapy in three horses. Mair TS. **Vet Rec** 1996 Mar 2;138(9):205–7

Mycoplasma canis in a British calf [letter] Nicholas RA, et al. **Vet Rec** 1995 Oct 21;137(17):443–4

[Demonstration of pneumonia in swine as a constant problem: culture and immunofluorescence microscopic studies of bronchioalveolar lavage (BAL) and serological findings] Runge M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar;109(3):101–7 (Eng. Abstr.) **(Ger)**

[Are nasal swabs for swine appropriate for the diagnosis of bacterial pneumonia agents?] Schöss P, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):427–30 (Eng. Abstr.) **(Ger)**

PNEUMONIA, EOSINOPHILIC see **PULMONARY EOSINOPHILIA**

PNEUMONIA, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONIA, INTERSTITIAL PLASMA CELL see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMONIA, LIPID

CHEMICALLY INDUCED

[Lipid pneumonia after aerosol therapy with gomenol in a 4-month-old child (letter)] Decocq G, et al. **Presse Med** 1996 Jun 15;25(21):994–5 **(Fre)**

[Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin-B after renal transplantation] Abe M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):737–40 (Eng. Abstr.) **(Jpn)**

PNEUMONIA, LIPID

COMPLICATIONS

Hypertrophic osteoarthropathy caused by lipoid pneumonia. Hugosson C, et al. **Pediatr Radiol** 1995;25(6):482–3

DIAGNOSIS

Case report. Chemical-shift MRI of exogenous lipoid pneumonia. Cox JE, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):465–7

A woman who took cod-liver oil and smoked. Dawson JK, et al. **Lancet** 1996 Jun 29;347(9018):1804

ETIOLOGY

Severe lipoid pneumonia following attempted suicide by mineral oil immersion. Hussain IR, et al. **Thorax** 1996 Jun; 51(6):652–3; discussion 656–7

PNEUMONIA, LOBAR

Severe community-acquired pneumonia in an elderly patient. Cassiere HA, et al. **Chest** 1996 Jun;109(6):1645–8

Bacteremic pneumococcal pneumonia. A community hospital experience. Lippmann ML, et al. **Chest** 1995 Dec; 108(6):1608–13

BLOOD

Changes of serum concentration of lipid peroxidation products in patients with pneumonia. Nowak D, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):188–93

COMPLICATIONS

Acute interstitial nephritis due to Chlamydia psittaci [letter] Branley P, et al. **Aust N Z J Med** 1995 Aug;25(4):365

Characterization of Streptococcus pneumoniae from human immunodeficiency virus--seropositive patients with acute and recurrent pneumonia. Jordens JZ, et al. **J Infect Dis** 1995 Oct;172(4):983–7

Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. Preheim LC, et al. **J Infect Dis** 1996 Jul;174(1):225–8

[An unusual complication of pneumococcal pneumonia: tamponade due to purulent pericarditis] Posthuma EF, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23;139(38):1913–5 **(Dut)**

[Pneumococcal pneumonia in a patient with HIV infection. Development to excavation. Apropos of a case] Venot P, et al. **Rev Pneumol Clin** 1996;52(1):29–32 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pneumococcal pericarditis: a rare complication of pneumonia. Hood RL, et al. **J Tenn Med Assoc** 1995 Dec; 88(12):465–6

Dot-enzyme-linked immunosorbent assay (Dot-ELISA) for detection of pneumococcal polysaccharide antigens in pleural fluid effusion samples. Comparison with bacterial culture, counterimmunoelectrophoresis and latex agglutination. Requejo HI, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):531–7

Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Kauppinen MT, et al. **Thorax** 1996 Feb; 51(2):185–9

[The diagnostic evaluation of rapid sputum technics for Pneumococcus in community-acquired pneumonia. The usefulness of Bayes theorem for clinical application] Menéndez Villanueva R. **Arch Bronconeumol** 1995 Aug–Sep;31(7):317–22 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

[Treatment of bacterial pneumonias with cefuroxime-axetil. Predictive value of measurement of the in vitro susceptibility] Cluzel R, et al. **Pathol Biol (Paris)** 1996 Mar; 44(3):217–23 (Eng. Abstr.) **(Fre)**

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[The particular case of azalides: antibiotic diapedesis. Experimental data from a murine model of pneumococcal pneumonia] Veber B, et al. **Pathol Biol (Paris)** 1995 Jun; 43(6):524–8 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The changing epidemiology of pneumococcal bacteremia in human immunodeficiency virus infection [letter] Earhart KC, et al. **J Infect Dis** 1996 Jul;174(1):242–4

Characterization of Streptococcus pneumoniae from human immunodeficiency virus--seropositive patients with acute and recurrent pneumonia. Jordens JZ, et al. **J Infect Dis** 1995 Oct;172(4):983–7

[Community acquired pneumonias in the region of Montpellier. Increase of pneumococci with reduced sensitivity to penicillins] Paganin F, et al. **Presse Med** 1995 Oct 7;24(29):1341–4 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU. Moine P, et al. **Scand J Infect Dis** 1995;27(3):201–6

[Pneumonia, recurrent respiratory infections and congenital tracheobronchomegaly (letter)] Montero Martinez MC, et al. **Arch Bronconeumol** 1996 Apr;32(4):209–10 **(Spa)**

IMMUNOLOGY

Polymorphonuclear leukocyte (PMN) migration in streptococcal pneumonia: comparison of older PMN with those recently released from the marrow. Lawrence E, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):217–24

Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Rubins JB, et al. **Am J Respir Crit Care Med** 1996 Apr; 153(4 Pt 1):1339–46

Selectins and neutrophil traffic: margination and Streptococcus pneumoniae-induced emigration in murine lungs. Mizgerd JP, et al. **J Exp Med** 1996 Aug 1; 184(2):639–45

METABOLISM

Pentoxifylline ameliorates pulmonary damage caused by Streptococcus pneumoniae infection in mouse. Cui X, et al. **Chin Med J (Engl)** 1995 Nov;108(11):864–9

MICROBIOLOGY

Streptococcus pneumoniae in the nasal cavity of mice causes lower respiratory tract infection after airway obstruction. Iizawa Y, et al. **J Med Microbiol** 1996 Jun;44(6):490–5

Escherichia coli lobar pneumonia: fatal infection in a patient with mental retardation. Jaffey PB, et al. **South Med J** 1996 Jun;89(6):628–30

[Evolution of the susceptibility to penicillin G of Streptococcus pneumoniae at the Limoge University Hospital Center] Ploy MC, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):241–4 (Eng. Abstr.) **(Fre)**

PATHOLOGY

[From general practice of an expert assessment service: heavy smoker died of acute heart failure in abscessed lobar pneumonia] Cyran W. **Z Arztl Fortbild (Jena)** 1995 Oct; 89(5):527–9 **(Ger)**

PHYSIOPATHOLOGY

Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury [see comments] Jolliet P, et al. **Intensive Care Med** 1996 Apr;22(4):277–85. Comment in: Intensive Care Med 1996 Apr;22(4):275–6.

PREVENTION & CONTROL

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Viral/bacterial vaccination rates in HIV-infected patients [letter] Bavry AA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):528–9

Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. Preheim LC, et al. **J Infect Dis** 1996 Jul;174(1):225–8

Pneumococcal conjugate vaccines. Eby R. **Pharm Biotechnol** 1995;6:695–718 (140 ref.)

Adult immunisation--too little, too late? [editorial] Slack R. **Public Health** 1995 Sep;109(5):309–10

Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Snow R, et al. **Public Health Rep** 1995 Nov–Dec;110(6):720–5

[Correct application of anti-pneumococci vaccination in France (editorial)] Aubier M, et al. **Rev Pneumol Clin** 1996; 52(1):7–8 **(Fre)**

[Serotypes of pneumococci isolated from children with pneumonia: implication of pneumococcal specific immunization] Hein N, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct; 50(5):280–3 (Eng. Abstr.) **(Por)**

[Combine the vaccination against influenza and pneumococcal infections. Great benefits for the elderly] Iwarson S. **Lakartidningen** 1995 Oct 11;92(41):3773–4 **(Swe)**

THERAPY

Appropriateness of hospitalization of patients with community-acquired pneumonia. Porath A, et al. **Ann Emerg Med** 1996 Feb;27(2):176–83

The management of pneumonia in children in developing countries. Shann F. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S218–25

Passive and active immunotherapy for experimental pneumococcal pneumonia by polyvalent human immunoglobulin or F(ab')2 fragments administered intranasally. Ramisse F, et al. **J Infect Dis** 1996 May; 173(5):1123–8

Successful extracorporeal membrane oxygenation (ECMO) support for fulminant community-acquired pneumococcal pneumonia. Codispoti M, et al. **Thorax** 1995 Dec; 50(12):1317–9; discussion 1323

TRANSMISSION

[Nosocomial transmission of pneumococcus] Dallügge-Tamm H, et al. **Immun Infekt** 1995 Oct; 23(5):185–6 (Eng. Abstr.) **(Ger)**

PNEUMONIA, MYCOPLASMA

More on Mycoplasma pneumoniae pneumonia [letter; comment] Cone LA, et al. **West J Med** 1995 Aug; 163(2):180; discussion 181–2. Comment on: West J Med 1995 Feb;162(2):133–42. Comment on: West J Med 1995 Feb;162(2):172–5.

More on Mycoplasma pneumoniae pneumonia [letter; comment] Dubins L. **West J Med** 1995 Aug;163(2):180–1; discussion 181–2. Comment on: West J Med 1995 Feb;162(2):133–42.

COMPLICATIONS

Advanced atrioventricular block associated with atrial tachycardia caused by Mycoplasma pneumoniae infection. Umemoto M, et al. **Acta Paediatr Jpn** 1995 Aug; 37(4):518–20

Methacholine inhalation challenge in patients with post-Mycoplasma pneumoniae pneumonia. Wongtim S, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):5–10

Mycoplasma pneumoniae as a cofactor in severe respiratory infections. Cimolai N, et al. **Clin Infect Dis** 1995 Nov; 21(5):1182–5

Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection [letter] Fournier S, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):558–9

A case of pneumonia with extrapulmonary manifestations. D'Agostino AM, et al. **Hosp Pract (Off Ed)** 1996 Feb 15; 31(2):34–5

Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Kim JS, et al. **Mov Disord** 1995 Jul;10(4):510–2

Adult respiratory distress syndrome due to mycoplasma pneumonia. Shah DC, et al. **Postgrad Med J** 1996 Apr; 72(846):241–2

Unusual manifestations of Mycoplasma pneumoniae infection in children. Hiew TM, et al. **Singapore Med J** 1995 Jun; 36(3):293–8

[Respiratory distress syndrome in an adult secondary to Mycoplasma pneumoniae infection (letter)] Turi L, et al. **Presse Med** 1996 Jan 27;25(3):127 **(Fre)**

[Transverse myelitis caused by Mycoplasma pneumoniae infection] Albucher JF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):350–3 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):203–6 (10 ref.)

An assessment of a new diagnostic indirect enzyme immunoassay for the detection of anti-Mycoplasma pneumoniae IgM. Cimolai N, et al. **Am J Clin Pathol** 1996 Feb;105(2):205–9

Microparticle agglutination versus antibody-capture enzyme immunoassay for diagnosis of community-acquired Mycoplasma pneumoniae pneumonia. Lieberman D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):577–84

A case of pneumonia with extrapulmonary manifestations. D'Agostino AM, et al. **Hosp Pract (Off Ed)** 1996 Feb 15; 31(2):34–5

Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. Ieven M, et al. **J Infect Dis** 1996 Jun;173(6):1445–52

Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection. Blackmore TK, et al. **Pathology** 1995 Apr;27(2):177–81

Enzyme-linked immunosorbent assay, complement fixation test and immunoelectroprecipitation test in the diagnosis of Mycoplasma pneumoniae infections--comparative analysis. Rastawicki W, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):477–84

[Detection of Mycoplasma pneumoniae by using polymerase chain reaction and nonradioactive DNA probes] Yamashita K, et al. **Rinsho Byori** 1995 Dec;43(12):1251–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection. Kaku M, et al. **Drugs** 1995;49 Suppl 2:412–3

Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issue [editorial; comment] Torres A, et al. **Eur Respir J** 1995 Dec;8(12):1996–8. Comment on: Eur Respir J 1996 Dec;8(12):1999–2007.

[Community-acquired pneumonia in children: importance of Mycoplasma pneumoniae infections and efficacy of antibiotics] Gendrel D, et al. **Presse Med** 1996 May 18; 25(17):793–7 (Eng. Abstr.) **(Fre)**

[Chemotherapeutic effectiveness of erythromycin, rifampicin and tetracyclines in chlamydiosis and mycoplasmosis in children] Vasilos LV, et al. **Antibiot Khimioter** 1995 Jun; 40(6):40–2 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Community-acquired pneumonia in older patients. Janssens JP, et al. **J Am Geriatr Soc** 1996 May;44(5):539–44

Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. Sasaki T, et al. **J Clin Microbiol** 1996 Feb;34(2):447–9

Prevalence of pneumonia due to Legionella pneumophila and Mycoplasma pneumoniae in a population admitted to a department of internal medicine. Bozzoni M, et al. **Respiration** 1995;62(6):331–5

[Clinico-epidemiological considerations of 30 cases of pulmonitis and pleuropulmonitis in childhood] De Luca L, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):237–41 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Mycoplasma pneumoniae pneumonia following assisted ventilation. Casalta JP, et al. **Am J Med** 1996 Aug; 101(2):165–9

IMMUNOLOGY

Isotype-specific antibody responses to acute Mycoplasma pneumoniae infection. Seggev JS, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):67–73

Number of specific antibody-secreting cells in the peripheral blood among children with mycoplasma pneumonia. Iseki M, et al. **Infect Immun** 1996 Jul;64(7):2799–803

Molecular mimicry by Mycoplasma pneumoniae to evade the induction of adherence inhibiting antibodies. Jacobs E, et al. **J Med Microbiol** 1995 Dec;43(6):422–9

Infection by Mycoplasma pneumoniae induces serum antibody against Gal-C [letter] Kusunoki S, et al. **Muscle Nerve** 1996 Feb;19(2):257–8

[Demonstration of the role of the idiotypic system in the physiopathology of autoimmune manifestations in Mycoplasma pneumoniae infections] Ben Aïssa-Fennira F, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):517–23 **(Fre)**

MICROBIOLOGY

Are outbreaks and sporadic respiratory infections by Mycoplasma pneumoniae due to two distinct subtypes? Jacobs E, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan; 15(1):38–44

Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. Sasaki T, et al. **J Clin Microbiol** 1996 Feb;34(2):447–9

PATHOLOGY

Chronic pulmonary infection caused by Mycoplasma pneumoniae leading to pulmonary arteriole remodeling and pulmonary hypertension in rats. Liu DX, et al. **J Tongji Med Univ** 1995;15(4):223–6

RADIOGRAPHY

Unusual manifestations of Mycoplasma pneumoniae infection in children. Hiew TM, et al. **Singapore Med J** 1995 Jun; 36(3):293–8

VETERINARY

Enzootic pneumonia: comparison of cough and lung lesions as predictors of weight gain in swine. Morris CR, et al. **Can J Vet Res** 1995 Jul;59(3):197–204

A field trial to evaluate a Mycoplasma hyopneumoniae vaccine: effects on lung lesions and growth rates in swine. Dohoo IR, et al. **Can Vet J** 1996 May;37(5):299–302

Immune responses to the capsular polysaccharide of Mycoplasma dispar in calves and mice. Bansal P, et al. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):259–68

Arbitrarily primed PCR analysis of Mycoplasma hyopneumoniae field isolates demonstrates genetic heterogeneity. Artiushin S, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):324–8

Mycoplasma bovis-associated pneumonia and arthritis complicated with pyogranulomatous tenosynovitis in calves. Adegboye DS, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):647–9

Polymerase chain reaction for Mycoplasma hyopneumoniae detection in tracheobronchiolar washings from pigs. Blanchard B, et al. **Mol Cell Probes** 1996 Feb;10(1):15–22

Porcine reproductive and respiratory syndrome virus does not exacerbate Mycoplasma hyopneumoniae infection in young pigs. Van Alstine WG, et al. **Vet Microbiol** 1996 Apr;49(3–4):297–303

PNEUMONIA, PNEUMOCOCCAL see **PNEUMONIA, LOBAR**

PNEUMONIA, PNEUMOCYSTIS CARINII

Case report: fulminating Pneumocystis carinii pneumonia [letter] Turner GD. **Cent Afr J Med** 1995 Sep;41(9):300–1

BLOOD

Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. Joos B, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2661–6

CHEMICALLY INDUCED

Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii. Oz HS, et al. **Lab Anim Sci** 1996 Feb;46(1):109–10

[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699–704 (18 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis [letter; comment] Vincent F, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1424. Comment on: Am J Respir Crit Care Med 1995 Mar;151(3 Pt 1):795–9.

Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis [letter; comment] Vincent F, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2202. Comment on: Am J Respir Crit Care Med 1995 Mar;151(3 Pt 1):795–9.

Spontaneous pneumothorax in the AIDS population. Spivak H, et al. **Am Surg** 1996 Sep;62(9):753–6

Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Godeau B, et al. **Ann Rheum Dis** 1995 Dec;54(12):991–4

Pleural leak localization with Tc-99m pentetate aerosol in an AIDS patient with Pneumocystis carinii pneumonia. Cartland JP, et al. **Clin Nucl Med** 1996 May;21(5):408–9

Community-based respiratory viral infections in HIV positive patients with lower respiratory tract disease: a prospective bronchoscopic study. Miller RF, et al. **Genitourin Med** 1996 Feb;72(1):9–11

Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. Principi N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):158–63

Pneumocystis carinii pneumonia in childhood systemic lupus erythematosus. Foster HE, et al. **J Rheumatol** 1996 Apr; 23(4):753–6

Pneumocystis carinii infection in patients with chronic bronchial disease [letter] Calderón EJ, et al. **Lancet** 1996 Apr 6;347(9006):977

Simultaneous pulmonary infection by Nocardia asteroides and Pneumocystis carinii in a renal transplant patient. Ruiz LM, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):711–4

Massive reversible pulmonary cysts in a patient with AIDS. Collazos J, et al. **Postgrad Med J** 1995 Dec;71(842):753–4

Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia. Sinicco A, et al. **Thorax** 1996 Apr;51(4):446–7: discussion 448–9

[Dysphagia, cavernous changes of the lungs and subarachnoid hemorrhage following kidney transplantation (clinical conference)] Fabbri J, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1874–82 (Eng. Abstr.) **(Ger)**

[Pneumocystis carinii pneumonia in a HTLV-I carrier with monoclonal proliferation of HTLV-I infected lymphocyte] Kawahigashi N, et al. **Rinsho Ketsueki** 1996 Apr; 37(4):317–22 (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii infection in AIDS patients. Current prognosis of the respiratory insufficiency (editorial)] Rello J, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):447–9 **(Spa)**

[Alveolitis and Pneumocystis carinii infection in a worker exposed to plaster (letter)] Sánchez Varilla JM, et al. **Rev Clin Esp** 1995 Aug;195(8):591 **(Spa)**

DIAGNOSIS

Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients. Comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase chain reaction. Armbruster C, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1089–93

Comparison of histologic stains in the diagnosis of Pneumocystis carinii. Naimey GL, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1124–7

Role of Pneumocystis carinii DNA amplification by PCR on the diagnosis of Pneumocystis carinii pneumonia in patients with haematologic malignant diseases: report of four cases. Antinori A, et al. **Acta Haematol** 1995; 94(3):163–6

Pneumocystis carinii pneumonia in preterm infants: report of two cases successfully diagnosed by non-bronchoscopic bronchoalveolar lavage. Panero A, et al. **Acta Paediatr** 1995 Nov;84(11):1309–11

A rapid and inexpensive method for processing induced sputum for detection of Pneumocystis carinii. Rocha P, et al. **Am J Clin Pathol** 1996 Jan;105(1):52–7

Empiric diagnosis of Pneumocystis carinii pneumonia. Questions of accuracy and equity [editorial; comment] Glassroth J. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1433–4. Comment on: Am J Respir Crit Care Med 1995 Nov;152(5 Pt 1):1435–42.

Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia [see comments] Horner RD, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1435–42 . Comment in: Am J Respir Crit Care Med 1995 Nov;152(t Pt 1):1433–4.

Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects. Chouaid C, et al. **Eur Respir J** 1995 Sep;8(9):1554–8

New diagnostic techniques for the detection of opportunistic pathogens involved in pneumonia in immunocompromised hosts [editorial] Oizumi K. **Intern Med** 1995 Oct; 34(10):933–4

Detection of Pneumocystis carinii, Mycobacterium tuberculosis, and cytomegalovirus in human immunodeficiency virus (HIV)-infected patients with hemophilia by polymerase chain reaction of induced sputum samples. Shimomoto H, et al. **Intern Med** 1995 Oct; 34(10):976–81

Comparison of PCR and standard cytological staining for detection of Pneumocystis carinii from respiratory specimens from patients with or at high risk for infection by human immunodeficiency virus. Leibovitz E, et al. **J Clin Microbiol** 1995 Nov;33(11):3004–7

Comparison of six different PCR methods for detection of Pneumocystis carinii. Lu JJ, et al. **J Clin Microbiol** 1995 Oct;33(10):2785–8

Ability of primary care physicians to diagnose and manage Pneumocystis carinii pneumonia. Curtis JR, et al. **J Gen Intern Med** 1995 Jul;10(7):395–9

Health insurance and utilization in Pneumocystis carinii pneumonia. Loue S, et al. **J Gen Intern Med** 1995 Aug; 10(8):461–3

Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens. Atzori C, et al. **J Infect Dis** 1995 Dec; 172(6):1623–6

Pneumocystis carinii pneumonia in Zimbabwe [see comments] Malin AS, et al. **Lancet** 1995 Nov 11; 346(8985):1258–61. Comment in: Lancet 1995 Nov 11;346(8985):1242–3. Comment in: Lancet 1996 Jan 13;347(8994):126; discussion 126–7.

Pneumocystis carinii in Africa: an emerging pathogen? [comment] Russian DA, et al. **Lancet** 1995 Nov 11; 346(8985):1242–3. Comment on: Lancet 1995 Nov 11;346(8985):1258–61.

Correlation of Pneumocystis carinii PCR with clinical diagnosis in immunocompromised patients [letter] Weig M, et al. **Lancet** 1996 May 4;347(9010):1266

Variable efficiency of three primer pairs for the diagnosis of Pneumocystis carinii pneumonia by the polymerase chain reaction. De Luca A, et al. **Mol Cell Probes** 1995 Oct; 9(5):333–40

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Polymerase chain reaction is more sensitive than standard cytologic stains in detecting Pneumocystis carinii in bronchoalveolar lavages from human immunodeficiency virus type 1-infected infants and children with pneumonia. Leibovitz E, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):714–6

Breathlessness in an Afro-Caribbean woman. Roberts HR, et al. **Postgrad Med J** 1996 Jun;72(848):377–9

Pneumocystic infections: the radiologist's perspective. Kuhlman JE. **Radiology** 1996 Mar;198(3):623–35 (96 ref.)

Detection of Pneumocystis carinii sequences in serum by polymerase chain reaction. Miyawaki H, et al. **Respir Med** 1996 Mar;90(3):153–7

Rapid simple and nested polymerase chain reaction for the diagnosis of Pneumocystis carinii pneumonia. Moonens F, et al. **Scand J Infect Dis** 1995;27(4):358–62

Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Skøt J, et al. **Scand J Infect Dis** 1995;27(4):363–7

[Experimental and clinical study on pneumocystosis. IV. Use of a 4D7 monoclonal antibody to detect Pneumocystis carinii by immunoperoxidase staining] Mei Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):130–3 (Eng. Abstr.) **(Chi)**

[Induced expectoration: its role in the diagnosis of pneumocystis carinii pneumonia] Cabié A, et al. **Presse Med** 1995 Jul 1–8;24(24):1119–20 (Eng. Abstr.) **(Fre)**

[Absence of regular medical follow-up: main cause of pneumocystosis diagnosed in patients with HIV infection in France in 1992 (letter)] Pradier C, et al. **Presse Med** 1995 Nov 11;24(34):1623 **(Fre)**

[Diagnostic strategies of pulmonary pneumocystis infection in patients with HIV infection. Decision analysis and medico-economic consequences] Chouaid C, et al. **Rev Mal Respir** 1996 Jul;13(3):265–72 (Eng. Abstr.) **(Fre)**

[Pneumocystis pneumonia in light of personal observations] Czerwionka-Szaflarska M, et al. **Pediatr Pol** 1995 Aug; 70(8):651–5 (Eng. Abstr.) **(Pol)**

[Pneumocystis carinii pneumonia. Diagnosis using immunofluorescence with monoclonal antibodies (letter)] Cruz Villuendas M, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):64–5 **(Spa)**

[Granulomatous pneumonitis: a clinical manifestation and atypical pathology of pneumocystosis in AIDS (letter)]

Macías J, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):797 **(Spa)**

DRUG THERAPY

Aerosolized pentamidine, cotrimoxazole and dapsone–pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antinori A, et al. **AIDS** 1995 Dec; 9(12):1343–50

Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. Martos A, et al. **AIDS** 1995 Sep;9(9):1037–41

Criteria for use of atovaquone oral suspension in adult inpatients and outpatients. Goodwin SD, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2460–2

Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim–sulfamethoxazole, dapsone–trimethoprim, and clindamycin–primaquine. ACTG 108 Study Group. Safrin S, et al. **Ann Intern Med** 1996 May 1;124(9):792–802

Monitoring of co–trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. Joos B, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2661–6

Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Merali S, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1442–4

Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Merali S, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2023–6

New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Schmatz DM, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1320–3

Employment of terbinafine against Pneumocystis carinii infection in rat models. Contini C, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:30–2; discussion 40

Consider anti-CMV therapy [letter; comment] Hawley PH, et al. **Chest** 1996 Apr;109(4):1130–1. Comment on: Chest 1995 Mar;107(3):595–7.

The safety of i.v. pentamidine administered in an ambulatory setting. Yeung KT, et al. **Chest** 1996 Jul;110(1):136–40

Pentamidine concentrations in a mother with AIDS and in her neonate [letter] Schwebke K, et al. **Clin Infect Dis** 1995 Jun;20(6):1569–70

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. Sin DD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):477–81

The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. Kunz S, et al. **J Antimicrob Chemother** 1995 Jul;36(1):137–55

Pneumatoceles in pneumocystic carinii pneumonia of AIDS and low dose trimethoprim–sulphamethoxazole therapy. Rosha D, et al. **J Assoc Physicians India** 1995 Sep; 43(9):635–7

Synthesis and DNA interactions of benzimidazole dications which have activity against opportunistic infections. Lombardy RL, et al. **J Med Chem** 1996 Mar 29; 39(7):1452–62

New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. Queener SF. **J Med Chem** 1995 Nov 24;38(24):4739–59 (158 ref.)

Corticosteroid therapy for Pneumocystis carinii pneumonia [letter; comment] Marriage SC, et al. **J Pediatr** 1995 Dec; 127(6):1007–8. Comment on: J Pediatr 1995 May;126(5 Pt 1):821–4.

Megaloblastic cytopenia in an AIDS patient treated with trimethoprim–sulfamethoxazole. Shami PJ, et al. **N C Med J** 1995 Dec;56(12):602–4

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

Acute severe autonomic insufficiency during pentamidine therapy [letter] Siddiqui MA, et al. **South Med J** 1995 Oct; 88(10):1087–8

[Intolerance to trimethoprim–sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al. **Ann Med Interne (Paris)** 1995;146(7):505–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150–5 (31 ref.) **(Ger)**

[Opportunistic protozoal infections] Levi G. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:39–43 **(Por)**

[Hypocalcemia and hypomagnesemia associated with the treatment with pentamidine in 2 patients with HIV infection (letter)] Cortés E, et al. **Med Clin (Barc)** 1996 May 11;106(18):717 **(Spa)**

ECONOMICS

Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia [see comments] Horner RD, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1435–42 . Comment in: Am J Respir Crit Care Med 1995 Nov;152(t Pt 1):1433–4.

EPIDEMIOLOGY

Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arend SM, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2436–41

Factors associated with the development of Pneumocystis carinii pneumonia [letter] Hoover DR. **Clin Infect Dis** 1996 Apr;22(4):738–9

Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Lundgren JD, et al. **Clin Infect Dis** 1995 Jul;21(1):106–13

Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries [letter] Hoover DR. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):485–6

From the Centers for Disease Control and Prevention. Pneumocystis pneumonia—Los Angeles, 1981 [classical article] **JAMA** 1996 Oct 2;276(13):1020–2

Pneumocystis carinii pneumonia in Africa [letter; comment] Gilks C, et al. **Lancet** 1996 Jan 13;347(8994):126; discussion 126–7. Comment on: Lancet 1995 Nov 11;346(8985):1258–61.

Pneumocystis carinii pneumonia in Africa [letter; comment] Hudson CP. **Lancet** 1996 Jan 13;347(8994):126; discussion 126–7. Comment on: Lancet 1995 Nov 11;346(8985):1258–61.

Pneumocystis carinii pneumonia in Africa [letter] Kamiya Y, et al. **Lancet** 1996 Apr 20;347(9008):1114–5

Pneumocystis pneumonia—Los Angeles. 1981 [classical article] **MMWR Morb Mortal Wkly Rep** 1996 Aug 30; 45(34):729–33

ETIOLOGY

Pneumocystis carinii pneumonia complicating methotrexate treatment of primary sclerosing cholangitis. Duerksen DR, et al. **Am J Gastroenterol** 1995 Oct;90(10):1886–7

Successful bone marrow transplantation in patients with recent Pneumocystis carinii pneumonia: report of two cases [letter] Martino R, et al. **Bone Marrow Transplant** 1995 Sep;16(3):491

Pneumocystis carinii and parasitic infections in transplantation. Fishman JA. **Infect Dis Clin North Am** 1995 Dec;9(4):1005–44 (128 ref.)

Patterns of opportunistic infections in patients with HIV infection. Finkelstein DM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):38–45

Pneumocystis carinii pneumonia associated with inhaled corticosteroids in an immunocompetent child with asthma. Sy ML, et al. **J Pediatr** 1995 Dec;127(6):1000–2

Pneumocystis carinii pneumonia during treatment for recurrent breast cancer: a case report. Koibuchi Y, et al. **Jpn J Clin Oncol** 1995 Oct;25(5):218–21

Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? [editorial; comment] Sepkowitz KA. **Mayo Clin Proc** 1996 Jan;71(1):102–3. Comment on: Mayo Clin Proc 1996 Jan;71(1):5–13.

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy [see comments] Yale SH, et al. **Mayo Clin Proc** 1996 Jan;71(1):5–13. Comment in: Mayo Clin Proc 1996 Jan;71(1):102–3.

Pneumocystis carinii pneumonia in renal transplant recipients. Branten AJ, et al. **Nephrol Dial Transplant** 1995; 10(7):1194–7

[Pneumocystis carinii pneumonia: an opportunistic infectious risk associated with systemic diseases and their treatment (editorial)] Jarrousse B. **Presse Med** 1996 Mar 2–9; 25(8):331–2 (Eng. Abstr.) **(Fre)**

[Nodular and cavitary pneumocystosis in a patient with hemophilia A and the acquired immunodeficiency syndrome] Yamakawa H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):117–20 (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. Tsolaki AG, et al. **J Infect Dis** 1996 Jul;174(1):141–56

IMMUNOLOGY

Alcohol ingestion impairs host defenses predisposing otherwise healthy mice to Pneumocystis carinii infection. D'Souza NB, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1219–25

Low CD4 lymphocyte count in a patient with P. carinii pneumonia after autologous bone marrow transplantation. Castagnola E, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):977–8

Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes. Bartlett MS, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):511–6

Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Gigliotti F, et al. **Infect Immun** 1996 Jun;64(6):1892–9

Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Hanano R, et al. **Infect Immun** 1996 Aug; 64(8):3201–9

T- and B-lymphocyte-independent formation of alveolar macrophage-derived multinucleated giant cells in murine Pneumocystis carinii pneumonia. Hanano R, et al. **Infect Immun** 1996 Jul;64(7):2821–3

Serum IgG antibody response to Pneumocystis carinii among immunosuppressed, malnourished and healthy rats. El Gebaly WM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):63–71

Detection of Pneumocystic carinii in immuno–suppressed rats by different histological stains and immunological assays. Hassan MM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):275–84

CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. Wiley JA, et al. **J Immunol** 1995 Oct 1;155(7):3525–9

Synthesis of tumor necrosis factor-alpha mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Rayment N, et al. **J Infect Dis** 1996 Sep;174(3):654–9

Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. Shellito JE, et al. **J Infect Dis** 1996 Feb;173(2):432–9

Immunoblot analysis for serum antibodies to Pneumocystis carinii by age and intensity of infection in rats. Hong ST, et al. **Korean J Parasitol** 1995 Sep;33(3):187–94

The role of T cells in infection-driven interstitial pneumonia after bone marrow transplantation in mice. Garvy BA, et al. **Transplantation** 1996 Aug 27;62(4):517–25

[Prognostic value of interleukin-8 in AIDS-related Pneumocystis carinii pneumonia] Benfield TL, et al. **Ugeskr Laeger** 1996 Mar 11;158(11):1513–7 (Eng. Abstr.) **(Dan)**

METABOLISM

GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Villard J, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1549–54

MICROBIOLOGY

Typing of Pneumocystis carinii strains with type-specific oligonucleotide probes derived from nucleotide sequences of internal transcribed spacers of rRNA genes. Lu JJ, et al. **J Clin Microbiol** 1995 Nov;33(11):2973–7

Analysis of genetic diversity at the arom locus in isolates of Pneumocystis carinii. Banerji S, et al. **J Eukaryot Microbiol** 1995 Nov–Dec;42(6):675–9

Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Tamburrini E, et al. **J Med Microbiol** 1996 Aug;45(2):146–8

Ultrastructural morphology of intermediate forms and forms suggestive of conjugation in the life cycle of Pneumocystis carinii. Itatani CA. **J Parasitol** 1996 Feb;82(1):163–71

MORTALITY

Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia. Bauer T, et al. **Infection** 1995 Sep–Oct;23(5):272–7

100% mortality of non-AIDS patients with Pneumocystis carinii pneumonia (PCP) requiring mechanical ventilation (MV) [letter] Schweigart U, et al. **Intensive Care Med** 1995 Sep;21(9):777–8

[Prognostic factors of Pneumocystis carinii pneumonia in AIDS] Hoen B, et al. **Presse Med** 1996 Mar 16;25(9):443–8 (Eng. Abstr.) **(Fre)**

PATHOLOGY

T- and B-lymphocyte-independent formation of alveolar macrophage-derived multinucleated giant cells in murine Pneumocystis carinii pneumonia. Hanano R, et al. **Infect Immun** 1996 Jul;64(7):2821–3

Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. Schiff D. **J Neurooncol** 1996 Mar; 27(3):235–40

Pneumocystis carinii pneumonia with an atypical granulomatous response. Flannery MT, et al. **South Med J** 1996 Apr;89(4):409–10

PHYSIOPATHOLOGY

Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Ewig S, et al. **Eur Respir J** 1995 Sep;8(9):1548–53

Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat. Phelps DS, et al.

Eur Respir J 1996 Mar;9(3):565–70

Persistent reduction in lung function after Pneumocystis carinii pneumonia in AIDS patients. Nelsing S, et al. **Scand J Infect Dis** 1995;27(4):351–5

Pneumonia in cats caused by Pneumocystis carinii purified from mouse lungs. Yuezhong Y, et al. **Vet Parasitol** 1996 Jan;61(1–2):171–5

PREVENTION & CONTROL

Recent advances in the prevention of pneumocystis carinii pneumonia. Hughes WT. **Adv Pediatr Infect Dis** 1996; 11:163–86 (74 ref.)

Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Beumont MG, et al. **Am J Med** 1996 Jun;100(6):611–6

Prophylaxis of pneumocystis pneumonia and toxoplasmosis [letter; comment] Zamora L, et al. **Ann Intern Med** 1996 Jun 15;124(12):1096. Comment on: Ann Intern Med 1995 May 15;122(10):755–61.

Antipneumocystis activity of 17C91, a prodrug of atovaquone. Comley JC, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2217–9

Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Hughes WT, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):962–5

A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ioannidis JP, et al. **Arch Intern Med** 1996 Jan 22;156(2):177–88

The effect of prophylaxis on the outcome of HIV-associated Pneumocystis carinii pneumonia [letter; comment] Ewig S. **Chest** 1996 Feb;109(2):586–7. Comment on: Chest 1995 Apr;107(4):1018–23.

An effectiveness community-based clinical trial of Respirgard II and Fisoneb nebulizers for Pneumocystis carinii prophylaxis with aerosol pentamidine in HIV-infected individuals. Toronto Aerosol Pentamidine Study (TAPS) Group. McIvor RA, et al. **Chest** 1996 Jul; 110(1):141–6

Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Saukkonen K, et al. **Chest** 1996 May;109(5):1250–5

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S128–9 (8 ref.)

Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Simonds RJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S44–8 (41 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)

Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis? [letter] Lyytikäinen O, et al. **Eur J Haematol** 1996 Mar; 56(3):188–9

Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. Principi N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):158–63

Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. Hennessy S, et al. **J Gen Intern Med** 1995 Jul;10(7):380–6

Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1995 Sep; 31(2):99–105

Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1996 Mar; 32(2):123–31

Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia [letter; comment] Weinberg GA. **J Infect Dis** 1996 Jul; 174(1):241–2. Comment on: J Infect Dis 1995 Sep;172(3):656–64.

Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan [letter] Monforte A, et al. **Lancet** 1995 Dec 2;346(8988):1488

Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? [editorial; comment] Sepkowitz KA. **Mayo Clin Proc** 1996 Jan;71(1):102–3. Comment on: Mayo Clin Proc 1996 Jan;71(1):5–13.

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy [see comments] Yale SH, et al. **Mayo Clin Proc** 1996 Jan;71(1):5–13. Comment in: Mayo Clin Proc 1996 Jan;71(1):102–3.

Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Freedberg KA, et al. **Med Decis Making** 1996 Jan–Mar;16(1):29–35

1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1995 Apr 28;44(RR-4):1–11

Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Thea DM, et al. **Pediatrics** 1996 Jan;97(1):59–64

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Nielsen TL, et al. **Scand J Infect Dis** 1995;27(3):217–20

[Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases] Lemež P, et al. **Vnitr Lek** 1995 Oct;41(10):688–91 (Eng. Abstr.) **(Cze)**

[Extra-pulmonary pneumocystosis in the course of AIDS. Report of a case] Terris B, et al. **Ann Pathol** 1996;16(1):41–4 (Eng. Abstr.) **(Fre)**

[Effect of primary prevention of Pneumocystis carinii pneumonia on the inaugural clinical and biological presentation of AIDS: 624 cases (Aquitaine Cohort, 1985–1994)] Morlat P, et al. **Rev Med Interne** 1995; 16(11):815–7 (Eng. Abstr.) **(Fre)**

[HIV-associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?] Ewig S, et al. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):83–9 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Case report: Pneumocystis carinii pneumonia presenting as a solitary cavitating lung lesion in non-HIV immunosuppressed patients. Uwyyed K, et al. **Br J Radiol** 1996 May;69(821):472–5

The radiological manifestations of the acquired immune deficiency syndrome--Part 1. Banerjee AK. **Int J STD AIDS** 1996 Jan–Feb;7(1):27–31

Spectrum of chest radiographic abnormalities in children with AIDS and Pneumocystis carinii pneumonia. Sivit CJ, et al. **Pediatr Radiol** 1995;25(5):389–92

Pneumothorax as the presenting sign of Pneumocystis carinii infection in an HIV-positive child with prior lymphocytic interstitial pneumonitis. Solomon KS, et al. **Pediatr Radiol** 1996;26(8):559–62

[Asymptomatic pulmonary pneumocytosis accidentally discovered in a patient with HIV infection (letter)] Schott R, et al. **Presse Med** 1996 Jan 20;25(2):81 **(Fre)**

[Pneumocystis carinii lung infections in AIDS patients: a study with high-resolution computed tomography (HRCT)] Bianco R, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):370–6 (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Serial indium-111-labelled IgG biodistribution in rat Pneumocystis carinii pneumonia: a tool to monitor the course and severity of the infection. Perenboom RM, et al. **Eur J Nucl Med** 1995 Oct;22(10):1129–32

Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. Oyen WJ, et al. **J Nucl Med** 1996 Aug;37(8):1392–7

THERAPY

100% mortality of non-AIDS patients with Pneumocystis carinii pneumonia (PCP) requiring mechanical ventilation (MV) [letter] Schweigart U, et al. **Intensive Care Med** 1995 Sep;21(9):777–8

Predictors of resource utilization for hospitalized patients with Pneumocystis carinii pneumonia (PCP): a summary of effects from the multi-city study of quality of PCP care. Horner RD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):379–85

[Pneumocystis carinii pneumonia in AIDS: retrospective analysis of 80 documented cases (1985–1993)] Morlat P, et al. **Rev Med Interne** 1996;17(1):25–33 (Eng. Abstr.) **(Fre)**

TRANSMISSION

[Pneumocystis pneumonia in a newborn] Czerwionka-Szaflarska M, et al. **Pediatr Pol** 1995 Aug; 70(8):687–9 (Eng. Abstr.) **(Pol)**

VETERINARY

Pneumocystis carinii infection in transgenic B cell-deficient mice. Marcotte H, et al. **J Infect Dis** 1996 Apr; 173(4):1034–7

Characterization of Pneumocystis carinii infection in Sorex araneus from southern Finland. Laakkonen J, et al. **J Wildl Dis** 1995 Apr;31(2):228–32

PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP

DIAGNOSIS

[Comparative studies of maedi-visna diagnosis: immunodiffusion test, enzyme immunoassay, immunoblot] Starick E, et al. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):138–42 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Multiple cases of maedi and visna in a flock in East Anglia [letter] Pritchard GC, et al. **Vet Rec** 1995 Oct 21; 137(17):443

IMMUNOLOGY

Immunohistological study of the depressed cutaneous DTH response in sheep naturally infected with an ovine lentivirus (Maedi-Visna virus). Pyrah IT, et al. **Clin Exp Immunol** 1996 Apr;104(1):32–6

In vitro response of lymphocytes from bronchoalveolar lavage fluid and peripheral blood to mitogen stimulation during natural maedi-visna virus infection. Begara I, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):75–88

Quantitation of transforming growth factor-beta in plasma and pulmonary epithelial lining fluid of sheep experimentally infected with maedi-visna virus. Begara I, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):261–73

CD8+ lymphocytes in bronchoalveolar lavage and blood: in vivo indicators of lung pathology caused by maedi-visna virus. Luján L, et al. **Vet Immunol Immunopathol** 1995 Nov; 49(1–2):89–100

PATHOLOGY

A perspective on Maedi-Visna in South Africa [letter] Vorster JH, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):2–3

CD8+ lymphocytes in bronchoalveolar lavage and blood: in vivo indicators of lung pathology caused by maedi-visna virus. Luján L, et al. **Vet Immunol Immunopathol** 1995 Nov; 49(1–2):89–100

PHYSIOPATHOLOGY

Distribution and quantitation of lung parenchymal contractile tissue in ovine lentivirus-induced lymphoid interstitial pneumonia. Do tissue forces limit lung distensibility? Collie DD, et al. **Lab Invest** 1995 Sep;73(3):441–7

PNEUMONIA, RADIATION see RADIATION PNEUMONITIS

PNEUMONIA, STAPHYLOCOCCAL

COMPLICATIONS

Hypercalcaemia in an immobilised patient with pneumonia. Mark S. **Br J Clin Pract** 1995 Nov–Dec;49(6):327–9

Fatal air embolism as a complication of staphylococcal pneumonia with pneumatoceles. Zuhdi MK, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):811–2

Pneumomediastinum and subcutaneous emphysema complicating staphylococcal pneumonia. Finnie IA, et al. **Ulster Med J** 1995 Apr;64(1):105–7

DRUG THERAPY

[Vancomycin-induced thrombocytopenia for MRSA pneumonia] Kishimoto T. **Rinsho Ketsueki** 1995 Aug; 36(8):768–73 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Community-acquired pneumonia due to Staphylococcus cohnii in an HIV-infected patient: case report and review. Mastroianni A, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):904–8

PREVENTION & CONTROL

[Vaccination against influenza superfluous in patients with (recurrent) staphylococcal infections] Sigurdsson V, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2316–7 **(Dut)**

RADIOGRAPHY

Radiographic features of staphylococcal pneumonia in adults and children. Macfarlane J, et al. **Thorax** 1996 May; 51(5):539–40

SURGERY

Staphylococcal pneumonia in childhood: will early surgical intervention lower mortality? Joosten KF, et al. **Pediatr Pulmonol** 1995 Aug;20(2):83–8

PNEUMONIA, VIRAL

A model of latent adenovirus 5 infection in the guinea pig (Cavia porcellus). Vitalis TZ, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):225–31

The spectrum of adult adenovirus pneumonia. Retalis P, et al. **Chest** 1996 Jun;109(6):1656–7

COMPLICATIONS

Influenza A pneumonitis following treatment of acute cardiac allograft rejection with murine monoclonal anti-CD3 antibody (OKT3). Embrey RP, et al. **Chest** 1995 Nov; 108(5):1456–9

Clinical course and treatment of adults with severe measles pneumonitis [letter; comment] Goetz MB, et al. **Clin Infect Dis** 1995 Aug;21(2):443. Comment on: Clin Infect Dis 1994 Sep;19(3):454–62.

Lobar emphysema associated with respiratory syncytial virus pneumonia. Newman B, et al. **Pediatr Radiol** 1995; 25(8):646–8

[Cytomegalovirus mononucleosis with cytomegalovirus pneumonia in an adult] Matsushita H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):726–30 (Eng. Abstr.) **(Jpn)**

[Varicella complicated by pericarditis and pneumonia] Rivera Civico F, et al. **An Med Interna** 1996 Mar;13(3):130–2 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosing cytomegalovirus pneumonia: comment on the concise communication by Aglas et al [letter; comment] Sneller MC, et al. **Arthritis Rheum** 1995 Oct;38(10):1528–9 . Comment on: Arthritis Rheum 1995 Feb;38(2):291–2.

Laboratory diagnosis of viral infections of the lung. Leland DS, et al. **Semin Respir Infect** 1995 Dec;10(4):189–98 (38 ref.)

Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)

[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?] Blot F, et al. **Rev Pneumol Clin** 1995; 51(6):309–20 (102 ref.) (Eng. Abstr.) **(Fre)**

[Detection and quantitation of cytomegalovirus DNA in plasma from patients with cytomegalovirus pneumonia] Tokimatsu I, et al. **Kansenshogaku Zasshi** 1995 Sep; 69(9):963–8 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Consider anti-CMV therapy [letter; comment] Hawley PH, et al. **Chest** 1996 Apr;109(4):1130–1. Comment on: Chest 1995 Mar;107(3):595–7.

Clinical course and treatment of adults with severe measles pneumonitis [letter; comment] Goetz MB, et al. **Clin Infect Dis** 1995 Aug;21(2):443. Comment on: Clin Infect Dis 1994 Sep;19(3):454–62.

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

Anti-infective therapy for viral pneumonia. Mahmood W, et al. **Semin Respir Infect** 1995 Dec;10(4):270–81 (39 ref.)

Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Sabroe I, et al. **Thorax** 1995 Nov;50(11):1219–20

[Varicella pneumonia with multiple nodular shadows after allogeneic bone marrow transplantation in chronic myeloid leukemia] Yano K, et al. **Rinsho Ketsueki** 1995 Nov; 36(11):1274–8 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Primary varicella in adults: pneumonia, pregnancy, and hospital admission. Baren JM, et al. **Ann Emerg Med** 1996 Aug;28(2):165–9

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352–7 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Papazian L, et al. **Anesthesiology** 1996 Feb;84(2):280–7

Severe respiratory insufficiency complicating Epstein-Barr virus infection: case report and review. Haller A, et al. **Clin Infect Dis** 1995 Jul;21(1):206–9 (24 ref.)

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Whimbey E, et al. **Clin Infect Dis** 1995 Aug;21(2):376–9

Adenovirus pneumonia in lung transplant recipients. Ohori NP, et al. **Hum Pathol** 1995 Oct;26(10):1073–9

Cytomegalovirus pneumonia after cardiovascular operations. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Aug; 112(2):547–8

Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. **MMWR Morb Mortal Wkly Rep** 1996 Jul 19;45(28):603–6

"Childhood" viruses as a cause of pneumonia in adults. Yang E, et al. **Semin Respir Infect** 1995 Dec;10(4):232–43 (40 ref.)

Fatal Cytomegalovirus pneumonia in a patient receiving corticosteroids and methotrexate for mixed connective tissue disease. Wallace JR, et al. **South Med J** 1996 Jul; 89(7):726–8

Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung. Molecular, immunocytochemical, and histopathologic investigations. Arbustini E, et al. **Transplantation** 1996 Feb 15;61(3):418–27

Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME, et al. **Transplantation** 1996 Jun 27;61(12):1716–20

[Clinical and x-ray features of lung lesions in influenza uncomplicated and complicated by pneumonia] Isakov VA, et al. **Vestn Ross Akad Med Nauk** 1995;(9):25–9 (Eng. Abstr.) **(Rus)**

[Varicella pneumonia in adults (letter)] Marti J, et al. **An Med Interna** 1995 Dec;12(12):618–9 **(Spa)**

IMMUNOLOGY

Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. Huffnagle GB, et al. **J Immunol** 1995 Oct 1;155(7):3507–16

Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Peper RL, et al. **Microb Pathog** 1995 Sep;19(3):175–83

Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Riddell SR. **Semin Respir Infect** 1995 Dec;10(4):199–208 (71 ref.)

PATHOLOGY

Cytologic manifestations of respiratory syncytial virus pneumonia in bronchoalveolar lavage fluid: a case report. Zaman SS, et al. **Acta Cytol** 1996 May-Jun;40(3):546–51

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31–1996. An 18-month old immunosuppressed boy with bilateral pulmonary infiltrates. **N Engl J Med** 1996 Oct 10;335(15):1133–40

PHYSIOPATHOLOGY

Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Akaike T, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2448–53

[Can outcome of varicella pneumonia be predicted in a non-immunosuppressed patient?] Jeanfaivre T, et al. **Rev Pneumol Clin** 1995;51(6):348–50 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Jiang J, et al. **Chin Med J (Engl)** 1995 Jun; 108(6):459–61

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. Boeckh M, et al. **J Infect Dis** 1995 Oct;172(4):939–43

Vaccines in the prevention of viral pneumonia. Betts RF. **Semin Respir Infect** 1995 Dec;10(4):282–7 (34 ref.)

RADIOGRAPHY

Cytomegalovirus pneumonia in transplant patients: CT findings. Kang EY, et al. **J Comput Assist Tomogr** 1996 Mar-Apr;20(2):295–9

Radiographic patterns and viral studies in childhood pneumonia at various ages. Wahlgren H, et al. **Pediatr Radiol** 1995;25(8):627–30

Role of the imaging specialist in the detection of opportunistic infection after lung transplantation: are we out of the loop? [editorial] Anderson DC. **Radiology** 1996 Aug;200(2):325–6

THERAPY

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965–85 (113 ref.)

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

VETERINARY

Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus [letter] Westbury HA, et al. **Aust Vet J** 1995 Jul;72(7):278–9

Fatal pneumonia in adult dairy cattle associated with active infection with bovine respiratory syncytial virus. Ellis JA, et al. **Can Vet J** 1996 Feb;37(2):103–5

VIROLOGY

Blood culture in children with pneumonia [editorial] Baraff LJ. **Ann Emerg Med** 1996 Jun;27(6):774–6

Respiratory syncytial virus, a rare cause of severe pneumonia following bone marrow transplantation. van Dissel JT, et al. **Ann Hematol** 1995 Nov;71(5):253–5

Clinico-pathological study of cytomegalovirus (CMV) in AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis. Dore GJ, et al. **Aust N Z J Med** 1995 Oct;25(5):503–6

Investigation of EB virus and cytomegalovirus in rapidly progressive interstitial pneumonitis in polymyositis/dermatomyositis by in situ hybridization and polymerase chain reaction. Hashimoto Y, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):298–306

Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Cobian L, et al. **Clin Infect Dis** 1995 Oct;21(4):1040–1

Severe measles pneumonitis in adults [letter; comment] Gubler J, et al. **Clin Infect Dis** 1995 Oct;21(4):1060–1. Comment on: Clin Infect Dis 1994 Sep;19(3):454–62.

Coinfection with human herpesvirus 6 variants A and B in lung tissue. Cone RW, et al. **J Clin Microbiol** 1996 Apr; 34(4):877–81

Quantitation of cytomegalovirus DNA and characterization of viral gene expression in bronchoalveolar cells of infected patients with and without pneumonitis. Boivin G, et al. **J Infect Dis** 1996 Jun;173(6):1304–12

Spontaneous, persistent infection of a B-cell lymphoma with adenovirus. Flomenberg P, et al. **J Med Virol** 1996 Mar; 48(3):267–72

Reovirus infection in rat lungs as a model to study the pathogenesis of viral pneumonia. Morin MJ, et al. **J Virol** 1996 Jan;70(1):541–8

The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Sparer TE, et al. **J Virol** 1996 Apr;70(4):2431–9

Human herpesvirus 6 as a possible cause of pneumonia. Cone RW. **Semin Respir Infect** 1995 Dec;10(4):254–8 (32 ref.)

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

[A 12-year-old girl with acute respiratory disease with pneumonia caused by adenovirus type 7] Wada Y, et al. **Kansenshogaku Zasshi** 1996 May;70(5):500–5 (Eng. Abstr.) **(Jpn)**

[Autopsy case of type-3 adenovirus pneumonia] Mizutani A, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1325–6 **(Jpn)**

PNEUMONIA VIRUS OF MICE see **PNEUMOVIRUS**

PNEUMONITIS, HYPERSENSITIVITY see **ALVEOLITIS, EXTRINSIC ALLERGIC**

PNEUMONITIS, HYPERSENSITIVITY, AVIAN see **BIRD FANCIER'S LUNG**

PNEUMONITIS, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONITIS, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONOLOGY see **PULMONARY DISEASE (SPECIALTY)**

PNEUMONOLYSIS

ADVERSE EFFECTS

Late extrusion of pulmonary plombage. Gunderman RB, et al. **Chest** 1996 Apr;109(4):1103–5

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

PNEUMOPERICARDIUM

DIAGNOSIS

[Pneumopericardium: a race against time! Case report and literature review] Alvarez L, et al. **Rev Med Brux** 1996 Jun;17(3):143–6 (15 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Gastropericardial fistula. Edwards JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):257–9

Spontaneous pneumopericardium related to active cytomegaloviral infection in a lung transplant recipient. The Groningen Lung Transplantation Group. Mannes GP, et al. **Eur Respir J** 1995 Oct;8(10):1803–5

Tension pneumopericardium following blunt injury. Capizzi PJ, et al. **J Trauma** 1995 Oct;39(4):775–80 (80 ref.)

[2 cases of tension pneumopericardium after unilateral lung transplantation] Fernández-Guisasola J, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):330–1 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

[Spontaneous pyopneumopericardium (letter)] Faraut C, et al. **Rev Med Interne** 1995;16(8):638 **(Fre)**

PNEUMOPERITONEUM

Effects of posture and pneumoperitoneum during anaesthesia on the indices of left ventricular filling. Gannedahl P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):160–6

DIAGNOSIS

[Surgical abdomen in a patient with human

immunodeficiency virus infection (clinical conference)] **Rev Clin Esp** 1996 Apr;196(4):264–9 **(Spa)**

ETIOLOGY

Pneumoperitoneum associated with manual ventilation using a bag–valve device [letter] López Rodríguez A, et al. **Acad Emerg Med** 1995 Oct;2(10):944

Pneumatosis cystoides intestinalis. Conservative approach in non surgical pneumoperitoneum: a case report and literature review. Brewaeys P, et al. **Acta Chir Belg** 1995; 95(4 Suppl):195–8 (25 ref.)

Colon perforation, bilateral pneumothoraces, pneumopericardium, pneumomediastinum, and subcutaneous emphysema complicating endoscopic polypectomy: anatomic and management considerations. Ho HC, et al. **Am Surg** 1996 Sep;62(9):770–4

Unexplained septicaemia and pneumoperitoneum in Vietnamese boat people: a self–inflicted condition? Chung CC, et al. **Aust N Z J Surg** 1996 Jan;66(1):26–8

Tension pneumoperitoneum: a potentially life–threatening complication of percutaneous endoscopic gastrojejunostomy. Kealey WD, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):334–5

Acute pneumoperitoneum in a patient on nocturnal intermittent peritoneal dialysis [letter] Albalate M, et al. **Nephron** 1996;72(2):358

[Effects of intraperitoneal insufflation on hematogenous seeding of abdominal infections. Preliminary results of an experimental study in rats] Dugue L, et al. **Ann Chir** 1995; 49(5):423–6 (Eng. Abstr.) **(Fre)**

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

[False pneumoperitoneum revealing Chilaiditi syndrome (letter)] Demarquay JF, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):733–4 **(Fre)**

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Spontaneous pneumoperitoneum associated with bronchial carcinoma (letter)] Hernández–Rodríguez J, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):81–2 **(Spa)**

[Asymptomatic pneumoperitoneum after fiber gastroscopy] López–Boado MA, et al. **Rev Esp Enferm Dig** 1996 May; 88(5):365–7 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Pathophysiologic features of a pneumoperitoneum at laparoscopy: a swine model. Volz J, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):132–40

Effects of CO2 pneumoperitoneum in pregnant ewes. Curet MJ, et al. **J Surg Res** 1996 Jun;63(1):339–44

Effect of a pneumoperitoneum on the extent and severity of peritonitis induced by gastric ulcer perforation in the rat. Bloechle C, et al. **Surg Endosc** 1995 Aug;9(8):898–901

[Influence of pneumoperitoneum on respiratory function during urological laparoscopic surgery] Ihara H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1307–12 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Diagnosis of minimal to moderate pneumoperitoneum. Baker SR. **Abdom Imaging** 1995 Sep–Oct;20(5):492–4

CT evaluation of infradiaphragmatic air in patients treated with mechanically assisted ventilation: a potential source of error. Balthazar EJ, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):731–4

Pneumomediastinum: old signs and new signs. Bejvan SM, et al. **AJR Am J Roentgenol** 1996 May;166(5):1041–8 (18 ref.)

The visible gallbladder: a plain film sign of pneumoperitoneum. Radin R, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):69–70

Significance of intraabdominal extraluminal air detected by CT scan in blunt abdominal trauma [letter; comment] Sherck J, et al. **J Trauma** 1996 Apr;40(4):674–5. Comment on: J Trauma 1995 Aug;39(2):331–3.

Atypical presentation in the elderly––case report of an acute abdomen. Yap KB, et al. **Singapore Med J** 1995 Feb; 36(1):96–8

Idiopathic spontaneous pneumoperitoneum––avoiding laparotomy––a case report. Clements WD, et al. **Ulster Med J** 1996 May;65(1):84–6

A case of free air in the peritoneum. Lee R, et al. **West J Med** 1995 Oct;163(4):387–8

[CT scanning in suspected ileus or pneumoperitoneum] Hansen HS, et al. **Ugeskr Laeger** 1996 Aug 19; 158(34):4759–62 (Eng. Abstr.) **(Dan)**

[Pneumoperitoneum in asymptomatic pneumatosis intestinalis––much ado about nothing?] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):266–8 (10 ref.) **(Ger)**

[Enhanced accuracy of the X–ray diagnosis of acute abdomen with patient in the supine (pregnancy standard) position] Szántó D, et al. **Orv Hetil** 1995 Oct 22;136(43):2329–32 (Eng. Abstr.) **(Hun)**

PNEUMOPERITONEUM, ARTIFICIAL

Hemodynamic changes due to Trendelenburg positioning and pneumoperitoneum during laparoscopic hysterectomy. Hirvonen EA, et al. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):949–55

The effects of neuromuscular block on peak airway pressure and abdominal elastance during pneumoperitoneum. Chassard D, et al. **Anesth Analg** 1996 Mar;82(3):525–7

Carbon dioxide output in laparoscopic cholecystectomy. Kazama T, et al. **Br J Anaesth** 1996 Apr;76(4):530–5

Effect of pneumoperitoneum and Trendelenburg position on gastro–oesophageal reflux and lower oesophageal sphincter pressure. Tournadre JP, et al. **Br J Anaesth** 1996 Jan; 76(1):130–2

Cardiopulmonary physiology and pathophysiology as a consequence of laparoscopic surgery. Sharma KC, et al. **Chest** 1996 Sep;110(3):810–5 (76 ref.)

Variance of cardiorespiratory parameters during gynaecological surgery with CO2–pneumoperitoneum [see comments] Schleifer W, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):167–70. Comment in: Endosc Surg Allied Technol 1995 Aug;3(4):154–5.

Pneumoperitoneum for laparoscopic surgery does not increase venous admixture. Odeberg S, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):541–8

The impact of pneumoperitoneum, pneumoretroperitoneum, and gasless laparoscopy on the systemic and renal hemodynamics. Chiu AW, et al. **J Am Coll Surg** 1995 Nov; 181(5):397–406

Laparoscopic pneumoperitoneum: the abdominal compartment syndrome revisited [editorial] Hunter JG. **J Am Coll Surg** 1995 Nov;181(5):469–70

Diagnostic pneumoperitoneum accurately predicts the presence of patent processus vaginalis. Downey EC, et al. **J Pediatr Surg** 1995 Sep;30(9):1271–2

Catecholamine release caused by carbon dioxide insufflation during laparoscopic surgery. Mikami O, et al. **J Urol** 1996 Apr;155(4):1368–71

Carbon dioxide and helium insufflation during laparoscopic radical nephrectomy in a patient with severe pulmonary disease. Wolf JS Jr, et al. **J Urol** 1996 Jun;155(6):2021

Determination of cardiorespiratory function and the optimum anesthetic regimen during laparoscopic surgery in the rat model. Dalton M, et al. **Surg Endosc** 1996 Mar; 10(3):297–300

Experimental carbon dioxide pulmonary embolization after vena cava laceration under pneumoperitoneum. Dion YM, et al. **Surg Endosc** 1995 Oct;9(10):1065–9

Converting from carbon dioxide to nitrous oxide pneumoperitoneum [letter] Gardner JG, et al. **Surg Endosc** 1995 Sep;9(9):1034–5

The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells. Hubens G, et al. **Surg Endosc** 1996 Aug;10(8):809–12

Laparoscopy without pneumoperitoneum. Effects of abdominal wall retraction versus carbon dioxide insufflation on hemodynamics and gas exchange in pigs. Rademaker BM, et al. **Surg Endosc** 1995 Jul;9(7):797–801

Effect of extraperitoneal carbon dioxide insufflation on intraoperative blood gas and hemodynamic changes. Wright DM, et al. **Surg Endosc** 1995 Nov;9(11):1169–72

Assessing the safety of pediatric laparoscopic surgery. Rayman R, et al. **Surg Laparosc Endosc** 1995 Dec; 5(6):437–43

Gut ischemia, oxidative stress, and bacterial translocation in elevated abdominal pressure in rats. Eleftheriadis E, et al. **World J Surg** 1996 Jan;20(1):11–6

ADVERSE EFFECTS

Bronchospasm during pneumoperitoneum. Kersten JR, et al. **Anesth Analg** 1995 Nov;81(5):1099–101

Intraabdominal fire during laparoscopic cholecystectomy [see comments] Greilich PE, et al. **Anesthesiology** 1995 Oct; 83(4):871–4. Comment in: Anesthesiology 1995 Oct;83(4):879.

Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position. O'Leary E, et al. **Br J Anaesth** 1996 May;76(5):640–4

Impact of pneumoperitoneum on trocar site implantation of colon cancer in hamster model. Jones DB, et al. **Dis Colon Rectum** 1995 Nov;38(11):1182–8

Air embolism and CO2 insufflators: the need for pre–use purging of tubing. **Health Devices** 1996 May–Jun; 25(5–6):214–5

Laparoscopic pneumoperitoneum: the abdominal compartment syndrome revisited [editorial] Hunter JG. **J Am Coll Surg** 1995 Nov;181(5):469–70

The effect of prolonged pneumoperitoneum on renal function in an animal model. McDougall EM, et al. **J Am Coll Surg** 1996 Apr;182(4):317–28

Alternative methods of exposure minimize cardiopulmonary risk in experimental animals during minimally invasive surgery. Davidson BS, et al. **Surg Endosc** 1996 Mar; 10(3):301–4

Hemodynamic and arterial blood gas changes during carbon dioxide and helium pneumoperitoneum in pigs. Shuto K, et al. **Surg Endosc** 1995 Nov;9(11):1173–8

[Diagnosis of heart arrest caused by CO2 embolism during laparoscopic surgery by monitoring of aortic blood flow and capnography] Gueugniaud PY, et al. **Ann Fr Anesth Reanim** 1995;14(5):417–20 (Eng. Abstr.) **(Fre)**

HISTORY

[From pneumoperitoneum to coelioscopy: Georg Kelling (1866–1945)––the pioneer of laparoscopy] Litynski G, et al. **Chirurg** 1996 Mar;67(3):283–7 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Extracorporeal pneumoperitoneum access bubble for endoscopic surgery. Cuschieri A, et al. **Am J Surg** 1995 Oct;170(4):391–4

High–flow laparoscopic insufflators. **Health Devices** 1995 Jul; 24(7):252–85

Isopneumic laparoscopy in general surgery and trauma: an update. Smith RS, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):387–92

[The aspiration pneumoperitoneum] Semm K. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):680–3 (Eng. Abstr.) **(Ger)**

METHODS

Conventional pneumoperitoneum compared with abdominal wall lift for laparoscopic cholecystectomy. Lindgren L, et al. **Br J Anaesth** 1995 Nov;75(5):567–72

A novel use for the Port–a–Cath: pneumoperitoneum in the repair of giant hernia. Näslund E, et al. **Eur J Surg** 1996 Apr;162(4):335–6

Alternative methods of exposure minimize cardiopulmonary risk in experimental animals during minimally invasive surgery. Davidson BS, et al. **Surg Endosc** 1996 Mar; 10(3):301–4

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

PNEUMORADIOGRAPHY

Plain X–ray films and air enema films reflect severe mucosal inflammation in acute ulcerative colitis. Almer S, et al. **Digestion** 1995;56(6):528–33

Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis [see comments] Almer S, et al. **Lancet** 1996 Jun 22;347(9017):1731–5. Comment in: Lancet 1996 Jun 22;347(9017):1708.

ADVERSE EFFECTS

The role of carbon dioxide and atmospheric air in double–contrast barium enema [see comments] Skovgaard N, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):436–9. Comment in: Abdom Imaging 1996 May–Jun;21(3):282–3.

HISTORY

[The history of angiocardiopneumography. Its beginnings] Quijano Pitman F. **Arch Inst Cardiol Mex** 1995 Sep–Oct; 65(5):468–71 **(Spa)**

METHODS

Small bowel enteroclysis: cons [comment] Bartram CI. **Abdom Imaging** 1996 May–Jun;21(3):245–6. Comment on: Abdom Imaging 1996 May–Jun;21(3):243–4.

Small bowel enteroclysis: pros [see comments] Nolan DJ. **Abdom Imaging** 1996 May–Jun;21(3):243–4. Comment in: Abdom Imaging 1996 May–Jun;21(3):245–6.

Re: the role of carbon dioxide and atmospheric air in double–contrast barium enema [letter; comment] Pochaczevsky R. **Abdom Imaging** 1996 May–Jun; 21(3):282–3. Comment on: Abdom Imaging 1995 Sep–Oct;20(5):436–9.

Air versus carbon dioxide insufflation in double contrast barium enemas: the role of active gaseous drainage. Jobling JC. **Br J Radiol** 1996 Jan;69(817):89–90

Technical note: an evaluation of the routine use of rectal air in computed tomography of the pelvis. Walkden SB, et al. **Br J Radiol** 1995 Dec;68(816):1364–6

Technical report: spiral CT pneumocolon for suspected colonic neoplasms. Amin Z, et al. **Clin Radiol** 1996 Jan; 51(1):56–61

Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Deignan R, et al. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.

Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Husien AM. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.

Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Rankine JJ. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.

STANDARDS

Childhood intussusception: management perspectives in 1995 [editorial; comment] Shiels WE 2nd. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):15–7. Comment on: J Pediatr Gastroenterol Nutr 1995 Jul;21(1):91–4.

PNEUMORETROPERITONEUM see **RETROPNEUMOPERITONEUM**

PNEUMOTHORAX

see related
HEMOPNEUMOTHORAX
HYDROPNEUMOTHORAX

Idiopathic, bilateral pneumothorax: case report in a young child. Dayan PS, et al. **J Emerg Med** 1995 Jul–Aug; 13(4):505–8

BLOOD

[The change of serum alpha 1-antitrypsin level in patients with spontaneous pneumothorax] Chen Y.
Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 1995 Aug; 18(4):228–9, 256 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

Case report: bilateral recurrent tension pneumothorax complicating combination chemotherapy for soft tissue sarcoma. Fenlon HM, et al. **Clin Radiol** 1996 Apr; 51(4):302–4

Local anesthesia infiltration as a cause of intraoperative tension pneumothorax in a young healthy woman undergoing breast augmentation with general anesthesia. Kaye AD, et al. **J Clin Anesth** 1995 Aug;7(5):422–4

[Spontaneous pneumothorax in response to chemotherapy of metastatic germinal tumor (letter)] Vicente P, et al.
An Med Interna 1995 Jun;12(6):307–8 **(Spa)**

COMPLICATIONS

Pneumothorax in patients with pulmonary tuberculosis [letter] Belmonte R, et al. **Clin Infect Dis** 1995 Jun; 20(6):1565

[Bilateral adrenal hemorrhage induced by stress. Radiological diagnosis. Apropos of a case] Armand JP, et al.
Ann Radiol (Paris) 1995;38(3):153–6 (Eng. Abstr.) **(Fre)**

[Pneumoscrotum after air leak from tension pneumothorax] Stavem K, et al. **Tidsskr Nor Laegeforen** 1996 Apr 20; 116(10):1214–5 (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

Acute chest pain in a tall, thin woman. Powell R, et al. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):33–4

[Guidelines for the diagnosis and treatment of pneumothorax. The Working Group of SEPAR. Sociedad Española de Neumología y Cirurgía Torácica] Sánchez-Lloret Tortosa J, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):339–45 **(Spa)**

[Fever and pulmonary cavitation in a 22-year-old woman with recurrent pneumothorax (clinical conference)] Rufi G, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):428–35 **(Spa)**

DRUG THERAPY

Successful conservative treatment of catamenial pneumothorax with GnRH agonist. Lolis D, et al.
Arch Gynecol Obstet 1995;256(3):163–6

Successful treatment of catamenial pneumothorax with danazol [letter] Morita Y, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):263–4

Acute mental status changes following intrapleural instillation of quinacrine for traumatic pneumothorax. Weingart SN, et al. **Psychosomatics** 1996 Jan–Feb; 37(1):74–8

EPIDEMIOLOGY

Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Kazerooni EA, et al.
Radiology 1996 Feb;198(2):371–5

ETIOLOGY

Pneumothorax: a complication of fine needle aspiration of breast tumors [letter; comment] Chen KT, et al.
Acta Cytol 1996 Jul–Aug;40(4):844–5. Comment on: Acta Cytol 1994 Sep–Oct;38(5):737–8.

Pneumothorax after small-bore catheter placement for malignant pleural effusions. Chang YC, et al.
AJR Am J Roentgenol 1996 May;166(5):1049–51

Thoracic endometriosis syndrome: new observations from an analysis of 110 cases. Joseph J, et al. **Am J Med** 1996 Feb;100(2):164–70

Clinical risk factors for pulmonary barotrauma: a multivariate analysis. Gammon RB, et al.
Am J Respir Crit Care Med 1995 Oct;152(4 Pt 1):1235–40

Carbon dioxide pneumothorax in laparoscopic surgery. Marcus DR, et al. **Am J Surg** 1996 May;171(5):464–6

Colon perforation, bilateral pneumothoraces, pneumopericardium, pneumomediastinum, and subcutaneous emphysema complicating endoscopic polypectomy: anatomic and management considerations. Ho HC, et al. **Am Surg** 1996 Sep;62(9):770–4

Pneumothoraces secondary to blunt abdominal trauma: aids to plain film radiographic diagnosis and relationship to solid organ injury. Miller JA, et al. **Am Surg** 1996 May; 62(5):416–20

Tension pneumothorax due to intrapulmonary placement of intercostal chest drain. McConaghy PM, et al.
Anaesth Intensive Care 1995 Aug;23(4):496–8

Pneumothorax during laparoscopic Nissen fundoplication. Yee R, et al. **Anaesth Intensive Care** 1996 Feb;24(1):93–6

Pneumothorax and laparoscopic fundoplication [letter; comment] Hanning CD, et al. **Anaesthesia** 1995 Dec; 50(12):1099–100. Comment on: Anaesthesia 1995 Jul;50(7):667–8.

Contralateral pneumothorax following thoracotomy for vertebrectomy. Spears FD, et al. **Anaesthesia** 1996 Jul; 51(7):685–6

Pneumothorax during laparoscopic fundoplication: diagnosis and treatment with positive end-expiratory pressure. Joris JL, et al. **Anesth Analg** 1995 Nov;81(5):993–1000

Pneumothorax and wound dehiscence related to collagenase deregulation: treatment with diphenylhydantoin. O'Toole MJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1646–50

Catamenial pneumothorax caused by thoracic endometriosis. Van Schil PE, et al. **Ann Thorac Surg** 1996 Aug;62(2):585–6

Pneumothorax complicating hypertrophic cardiomyopathy [letter] Singh H. **Can J Anaesth** 1996 Apr;43(4):419–20

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Pyopneumothorax associated with unsuspected endobronchial foreign body: a case report. Liu SF, et al.
Chang Keng I Hsueh 1995 Sep;18(3):292–6

Nonresolving spontaneous pneumothorax in a 38-year-old woman. Gill HS, et al. **Chest** 1996 Sep;110(3):835–7

Recurrent pneumothoraces in ventilated patients despite ipsilateral chest tubes. Heffner JE, et al. **Chest** 1995 Oct; 108(4):1053–8

AIDS-related spontaneous pneumothorax. Risk factors and treatment. Metersky ML, et al. **Chest** 1995 Oct; 108(4):946–51

Spontaneous pneumothorax in children with AIDS. Schroeder SA, et al. **Chest** 1995 Oct;108(4):1173–6 (25 ref.)

The role of functional respiratory tests in predicting pneumothorax during lung needle biopsy. Vitulo P, et al. **Chest** 1996 Mar;109(3):612–5

Risk factors for pneumothorax during percutaneous Hickman line insertion in patients with solid and haematological tumours. Harrington KJ, et al.
Clin Oncol (R Coll Radiol) 1995;7(6):373–6

Spontaneous pneumothorax in a patient with systemic sclerosis. Zeuner M, et al. **Clin Rheumatol** 1996 Mar; 15(2):211–3

Tension pneumothorax during ventilation via Ayre's T-piece. Sabar MA, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):143–6

Bilateral pneumothorax following percutaneous renal biopsy. Chaudhuri MK, et al. **Indian Pediatr** 1995 Nov; 32(11):1220–1

The influence of lung injury due to mechanical ventilation on the initiation of ECMO. Bartsch H, et al.
Int J Artif Organs 1995 Oct;18(10):565–8

Significant pneumothorax complicating a fractured clavicle. Williams RJ. **J Accid Emerg Med** 1995 Sep;12(3):218–9

Use of spirometry to predict risk of pneumothorax in CT-guided needle biopsy of the lung. García-Río F, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):20–3

Neonatal radiology casebook. Bronchopleural fistula and pneumothorax: complications of transpyloric feeding tube insertion. Karlowicz MG, et al. **J Perinatol** 1995 Sep–Oct; 15(5):432–3

Spontaneous pneumothorax in weightlifters. Marnejon T, et al. **J Sports Med Phys Fitness** 1995 Jun;35(2):124–6

Sudden severe barotrauma from self-inflating bag-valve devices. Silbergleit R, et al. **J Trauma** 1996 Feb;40(2):320–2

Primary spontaneous pneumothorax and smoking. Fox JT, et al. **Mil Med** 1996 Aug;161(8):489–90

Spontaneous pneumothorax in lymphomatoid granulomatosis. Slabbynck H, et al.
Monaldi Arch Chest Dis 1996 Jun;51(3):199–200

Postoperative airway problems in a child with Crouzon's syndrome. Payne JF, et al. **Paediatr Anaesth** 1995; 5(5):331–3

Localized pneumothorax with lobar collapse and diffuse obstructive airway disease. Nimkin K, et al.
Pediatr Radiol 1995;25(6):449–51

Localised pneumothorax with lobar collapse [letter] Petros A, et al. **Pediatr Radiol** 1996;26(3):238

Lung disease induced by drug addiction [letter; comment] Slade M, et al. **Thorax** 1996 May;51(5):556. Comment on: Thorax 1995 Nov;50(11):1125–7.

[Iatrogenic pneumothorax] Pelák Z, et al. **Rozhl Chir** 1995 Aug;74(5):242–4 (Eng. Abstr.) **(Cze)**

[Parietal problems in thoracic injuries by gunshot] Houdelette P. **J Chir (Paris)** 1996 Apr;133(2):82–90 (23 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous pneumothorax disclosing pulmonary sarcoidosis (letter)] Piaton E, et al. **Presse Med** 1995 Nov 11;24(34):1621 **(Fre)**

[Complications of an asthma crisis] Delafosse C, et al.
Rev Mal Respir 1996 Jul;13(3):313–5 **(Fre)**

[Spontaneous hydro-pneumothorax disclosing malignant mesothelioma. Apropos of 2 cases] Kolber C, et al.
Rev Pneumol Clin 1996;52(1):42–4 (Eng. Abstr.) **(Fre)**

[Retroperitoneal, mediastinal and subcutaneous emphysema with pneumothorax after colonoscopy] Goerg KJ, et al.
Dtsch Med Wochenschr 1996 May 24;121(21):693–6 (Eng. Abstr.) **(Ger)**

[Chronic necrotizing pulmonary aspergillosis complicated by pneumothorax] Kobashi Y, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Feb;34(2):210–5 (Eng. Abstr.) **(Jpn)**

[Swyer-James syndrome with bronchial asthma and recurrent spontaneous pneumothorax] Koura T, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Jun;34(6):731–6 (Eng. Abstr.) **(Jpn)**

[Bronchiolitis obliterans in a patient with chronic graft-versus-host disease after bone marrow transplantation] Matsumoto K, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Mar;34(3):345–9 (Eng. Abstr.) **(Jpn)**

[Pneumothorax from a nasogastric feeding tube] Nakano Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):63–6 (Eng. Abstr.) **(Jpn)**

[Primary lung cancer presenting as spontaneous pneumothorax] Tsukamoto T, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Sep;33(9):936–9 (Eng. Abstr.) **(Jpn)**

[Spontaneous pneumothorax and breast cancer] Pereira JR, et al. **Rev Assoc Med Bras** 1995 May–Jun;41(3):249–51 (Eng. Abstr.) **(Por)**

[Catamenial pneumothorax (letter)] Abu-Shams K, et al.
An Med Interna 1995 Jun;12(6):309–10 **(Spa)**

[2 cases of catamenial pneumothorax with a familial relationship (letter)] Marcos Sánchez F, et al.
An Med Interna 1996 May;13(5):254 **(Spa)**

[Spontaneous bilateral pneumothorax (letter)] Alemany Francés ML, et al. **Arch Bronconeumol** 1996 Apr; 32(4):211–2 **(Spa)**

[Spontaneous pneumothorax as initial manifestation of small-cell bronchogenic carcinoma (letter)] Calderón-Osuna E, et al. **Arch Bronconeumol** 1996 Mar; 32(3):156–7 **(Spa)**

[Iatrogenic pneumothorax following the placement of a nasogastric nutritional tube (letter)] Moreno Mata N, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):316–7 **(Spa)**

[Pneumothorax secondary to the placement of a nasogastric tube in a patient with a decreased level of consciousness (letter)] Velasco P, et al. **Gastroenterol Hepatol** 1996 May; 19(5):282–3 **(Spa)**

[Pneumothorax and pneumomediastinum after bronchoalveolar lavage: can be avoided? (letter; comment)] de Gracia J, et al. **Med Clin (Barc)** 1995 Nov 4;105(15):598 . Comment on: Med Clin (Barc) 1995 Mar 11;104(9):357–8. **(Spa)**

MORTALITY

[Mortality, mode of delivery, pneumothorax and intracranial hemorrhage in 859 extremely premature newborn infants between 1984–1992] Bösche C, et al.
Geburtshilfe Frauenheilkd 1996 Jun;56(6):322–7 (Eng. Abstr.) **(Ger)**

PATHOLOGY

[The morphological characteristics of the changes in spontaneous pneumothorax. Thoracoscopic observation] Radev R, et al. **Khirurgiia (Sofiia)** 1995;48(6):5–7 (Eng. Abstr.) **(Bul)**

[Ultrastructural findings in pleural cysts in spontaneous pneumothorax] Becker HP, et al. **Chirurg** 1995 Aug; 66(8):787–93 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Carbon dioxide pneumothorax in laparoscopic surgery. Marcus DR, et al. **Am J Surg** 1996 May;171(5):464–6

The role of functional respiratory tests in predicting pneumothorax during lung needle biopsy. Vitulo P, et al. **Chest** 1996 Mar;109(3):612–5

[ECG changes in left-sided pneumothorax] Stilling MV, et al. **Ugeskr Laeger** 1996 Aug 26;158(35):4924–6 (Eng. Abstr.) **(Dan)**

[Menstruation-associated (catamenial) pneumothorax and catamenial hemoptysis] Hamacher J, et al.
Schweiz Med Wochenschr 1996 May 25;126(21):924–32 (100 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of the effect of radical parietal pleurectomy on ventilatory function of the lungs in patients treated for recurrent spontaneous pneumothorax] Grodzki T.
Ann Acad Med Stetin 1994;40:237–46 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Fibrin glue for sealing the needle track after percutaneous lung biopsy: Part I—Experimental study. Petsas T, et al.
Cardiovasc Intervent Radiol 1995 Nov–Dec;18(6):373–7

Fibrin glue for sealing the needle track in fine-needle percutaneous lung biopsy using a coaxial system: Part II—Clinical study. Petsas T, et al.
Cardiovasc Intervent Radiol 1995 Nov–Dec;18(6):378–82

Prevention and management of related complication due to laparoscopic operation: pneumothorax, pneumomediastinum and subcutaneous emphysema. Zhou H, et al. **J Tongji Med Univ** 1996;16(1):45–7

[Clinical experience of the combined use of polyglycolide non-woven felt with fibrin glue to prevent postoperative pulmonary fistula] Mizuno H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1995 Sep;43(9):1559–64 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Quantification of pneumothorax size on chest radiographs using interpleural distances: regression analysis based on volume measurements from helical CT. Collins CD, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1127–30

Chest case of the day. Malignant mesothelioma of the pleura presenting with spontaneous bilateral pneumothoraces. Dee PM. **AJR Am J Roentgenol** 1996 Jul;167(1):235, 239

Comparison of upright inspiratory and expiratory chest radiographs for detecting pneumothoraces. Seow A, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):313–6

Pneumothoraces secondary to blunt abdominal trauma: aids to plain film radiographic diagnosis and relationship to solid organ injury. Miller JA, et al. **Am Surg** 1996 May; 62(5):416–20

Expiratory chest radiographs do not improve visibility of small apical pneumothoraces by enhanced contrast. Schramel FM, et al. **Eur Respir J** 1996 Mar;9(3):406–9

Is radiographic evaluation of the chest necessary following flank surgery? Poore RE, et al. **J Urol** 1996 Mar; 155(3):849–51

Pneumothorax as the presenting sign of Pneumocystis carinii infection in an HIV-positive child with prior lymphocytic interstitial pneumonitis. Solomon KS, et al. **Pediatr Radiol** 1996;26(8):559–62

[Manifestation of pneumothorax 7 days after port implantation. Report of a single case] Krupski G, et al. **Aktuelle Radiol** 1995 Nov;5(6):370–1 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Pleural leak localization with Tc-99m pentetate aerosol in an AIDS patient with Pneumocystis carinii pneumonia. Cartland JP, et al. **Clin Nucl Med** 1996 May;21(5):408–9

SURGERY

Video-assisted thoracoscopic pleurectomy in the treatment of recurrent spontaneous pneumothorax. Rämö OJ, et al. **Ann Chir Gynaecol** 1995;84(3):272–5

Immediate and long-term results after surgical treatment of primary spontaneous pneumothorax by VATS. Bertrand PC, et al. **Ann Thorac Surg** 1996 Jun;61(6):1641–5

Video-assisted thoracic surgery: primary therapy for spontaneous pneumothorax? Cole FH Jr, et al. **Ann Thorac Surg** 1995 Oct;60(4):931–3; discussion 934–5

Transaxillary minithoracotomy versus video-assisted thoracic surgery for spontaneous pneumothorax. Kim KH, et al. **Ann Thorac Surg** 1996 May;61(5):1510–2

Videothoracoscopic operations for bullous lung disease. Jacques LF. **Chest Surg Clin N Am** 1995 Nov;5(4):751–63 (29 ref.)

Surgery for complications of chronic obstructive lung disease. Tanaka F, et al. **Chest Surg Clin N Am** 1995 Nov; 5(4):797–813 (33 ref.)

Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. Tanaka H, et al. **Eur Respir J** 1995 Nov;8(11):1879–82

Needle thoracocentesis in tension pneumothorax: insufficient cannula length and potential failure. Britten S, et al. **Injury** 1996 Jun;27(5):321–2

Spontaneous pneumothorax: a single-institution, 12-year experience in patients under 16 years of age. Wilcox DT, et al. **J Pediatr Surg** 1995 Oct;30(10):1452–4

Video-assisted thoracoscopic treatment of spontaneous pneumothorax: technique and results of one hundred cases. Mouroux J, et al. **J Thorac Cardiovasc Surg** 1996 Aug; 112(2):385–91

Management of spontaneous pneumothorax during pregnancy: case report and review of the literature. VanWinter JT, et al. **Mayo Clin Proc** 1996 Mar; 71(3):249–52 (27 ref.)

Video-assisted thoracoscopic surgery for pneumothorax. Lee YM, et al. **Med J Malaysia** 1995 Dec;50(4):334–8

Thoracoscopic resection of parenchymal blebs in spontaneous pneumothorax. Indications, operative management and results. Elfeldt RJ, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):75–8

Herniation of the lung following video-assisted minithoracotomy. van den Brink WA, et al. **Surg Endosc** 1995 Jun;9(6):706–8 (10 ref.)

Video-assisted thoracoscopic suturing of apical bullae. An alternative to staple resection in the management of primary spontaneous pneumothorax. Yim AP. **Surg Endosc** 1995 Sep;9(9):1013–6

Video-assisted thoracoscopic surgery of bullous and bleb disorders of the lung using endoscopic stapling device. Ishida T, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):349–53

Pulmonary diseases and HIV infection [letter] Fisher M, et al. **Thorax** 1996 Feb;51(2):228

[Our procedure with patients with spontaneous pneumothorax] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):8–11 (Eng. Abstr.) **(Bul)**

[Thoracoscopy in persistent or recurrent spontaneous pneumothorax] Zhang D, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):456–8 (Eng. Abstr.) **(Chi)**

[Blood-patch treatment of headache occurring after post-dural puncture at the thoracic level] Marandon JY, et al. **Ann Fr Anesth Reanim** 1995;14(5):435–7 (Eng. Abstr.) **(Fre)**

[Thoracoscopic operation of secondary spontaneous pneumothorax] Hürtgen M, et al. **Chirurg** 1995 Oct; 66(10):994–6 (Eng. Abstr.) **(Ger)**

[Thoracoscopic operation of primary spontaneous pneumothorax] Hürtgen M, et al. **Chirurg** 1995 Sep; 66(9):890–4 (Eng. Abstr.) **(Ger)**

[Pleural drainage vs video-assisted minimally invasive surgery in the treatment of spontaneous pneumothorax. A retrospective study] Sortini A, et al. **Minerva Chir** 1995 Nov;50(11):973–7 (Eng. Abstr.) **(Ita)**

[A case of bilateral thoracoscopic partial resection for unilateral spontaneous pneumothorax] Kinugasa S, et al. **Kyobu Geka** 1995 Oct;48(11):978–81 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic partial lung resection using staplers and polyglycolic acid (PGA) felts in an 85-year-old patient] Yoshiya K, et al. **Kyobu Geka** 1995 Sep;48(10):833–5 (Eng. Abstr.) **(Jpn)**

[Thoracoscopic surgery versus axillary thoracotomy for spontaneous pneumothorax] Matsuzoe D, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):144–8 (Eng. Abstr.) **(Jpn)**

[Evaluation of the effect of radical parietal pleurectomy on ventilatory function of the lungs in patients treated for recurrent spontaneous pneumothorax] Grodzki T. **Ann Acad Med Stetin** 1994;40:237–46 (Eng. Abstr.) **(Pol)**

THERAPY

Demand valve ventilation in a swine pneumothorax model. Murray JM, et al. **Am J Emerg Med** 1996 Jan;14(1):13–5

Fibrin glue treatment for recurrent pneumothorax in a premature infant. Kuint J, et al. **Am J Perinatol** 1996 May; 13(4):245–7

Spontaneous pneumothorax in the AIDS population. Spivak H, et al. **Am Surg** 1996 Sep;62(9):753–6

Pneumothorax during laparoscopic fundoplication: diagnosis and treatment with positive end-expiratory pressure. Joris JL, et al. **Anesth Analg** 1995 Nov;81(5):993–1000

Managing in flight emergencies. Plane should not have left the ground [letter; comment] Buisseret PD. **BMJ** 1995 Dec 2;311(7018):1507–8. Comment on: BMJ 1995 Aug 5;311(7001):374–6.

Managing in flight emergencies. Glove and cannula approach is easier [letter; comment] Crawshaw CC. **BMJ** 1995 Dec 2;311(7018):1507. Comment on: BMJ 1995 Aug 5;311(7001):374–6.

Managing in flight emergencies. Emergency kit will now contain fatal dose of lignocaine [letter; comment] Gwinnutt CL, et al. **BMJ** 1995 Dec 2;311(7018):1507. Comment on: BMJ 1995 Aug 5;311(7001):374–6.

The cost of treatment of spontaneous pneumothorax with the thoracic vent compared with conventional thoracic drainage [letter; comment] Roeggla M, et al. **Chest** 1996 Jul;110(1):303. Comment on: Chest 1995 Aug;108(2):335–9.

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

Pre-hospital management of patients with severe thoracic injury. Coats TJ, et al. **Injury** 1995 Nov;26(9):581–5

A cure for pneumothorax during menstruation. Eckford SD, et al. **Lancet** 1996 Mar 16;347(9003):734

A new device for pleural drainage in newborn infants. Wood B, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):955–6

Aspiration of a large pneumothorax resulting from transthoracic needle biopsy. Yankelevitz DF, et al. **Radiology** 1996 Sep;200(3):695–7

Re-expansion pulmonary oedema following spontaneous pneumothorax. Rozenman J, et al. **Respir Med** 1996 Apr; 90(4):235–8

Thoracoscopic bullectomy and tetracycline pleurodesis for the treatment of spontaneous pneumothorax. Waterworth PD, et al. **Respir Med** 1995 Sep;89(8):563–6

Deficiencies of management of spontaneous pneumothoraces. Selby CD, et al. **Scott Med J** 1994 Jun;39(3):75–7

Treatment of pneumothorax during pregnancy. Levine AJ, et al. **Thorax** 1996 Mar;51(3):338–9;discussion 340–1

The management of pneumothorax with the thoracic vent versus conventional intercostal tube drainage. Röggla M, et al. **Wien Klin Wochenschr** 1996;108(11):330–3

[Perforation of the heart wall—a rare complication after thoracic drainage treatment] Domínguez Fernández E, et al. **Chirurg** 1995 Sep;66(9):920–2 (Eng. Abstr.) **(Ger)**

[Video-assisted thoracoscopy in the treatment of recurrent pneumothorax] De Giacomo T, et al. **Minerva Chir** 1995 Nov;50(11):967–71 (Eng. Abstr.) **(Ita)**

[Pleural drainage vs video-assisted minimally invasive surgery in the treatment of spontaneous pneumothorax. A retrospective study] Sortini A, et al. **Minerva Chir** 1995 Nov;50(11):973–7 (Eng. Abstr.) **(Ita)**

[Guidelines for the diagnosis and treatment of pneumothorax. The Working Group of SEPAR. Sociedad Española de Neumología y Cirurgia Torácica] Sánchez-Lloret Tortosa J, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):339–45 **(Spa)**

[High-frequency ventilation in a patient with bilateral tension pneumothorax caused by barotrauma and severe bronchospasm (letter)] Uña R, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):351 **(Spa)**

ULTRASONOGRAPHY

Detection and estimation of the volume of pneumothorax using real-time sonography: efficacy determined by receiver operating characteristic analysis. Sistrom CL, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):317–21

A bedside ultrasound sign ruling out pneumothorax in the critically ill. Lung sliding. Lichtenstein DA, et al. **Chest** 1995 Nov;108(5):1345–8

VETERINARY

Modification of a nonrebreathing circuit adapter to prevent barotrauma in anesthetized patients. McMurphy RM, et al. **Vet Surg** 1995 Jul-Aug;24(4):352–5

VIROLOGY

Spontaneous pneumothorax in the AIDS population. Spivak H, et al. **Am Surg** 1996 Sep;62(9):753–6

PNEUMOTHORAX, ARTIFICIAL

Decortication is a valuable option for late empyema after collapse therapy. Massard G, et al. **Ann Thorac Surg** 1995 Oct;60(4):888–95

Congenital partial absence of left pericardium: demonstration by computed tomography after artificial pneumothorax. Krishnan MN, et al. **Indian Heart J** 1996 Jan-Feb; 48(1):63–4

Treatment of tuberculous pleurisy with effusion by artificial pneumothorax. Li H, et al. **J Tongji Med Univ** 1996; 16(1):52–4, 64

ADVERSE EFFECTS

Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288–91 (18 ref.)

PNEUMOVIRUS

A sequential histopathologic and immunocytochemical study of chickens, turkey poults, and broiler breeders experimentally infected with turkey rhinotracheitis virus. Majó N, et al. **Avian Dis** 1995 Oct-Dec;39(4):887–96

ISOLATION & PURIFICATION

Turkey rhinotracheitis virus isolated from broiler chicken with swollen head syndrome in Japan. Tanaka M, et al. **J Vet Med Sci** 1995 Oct;57(5):939–41

Evaluation of different turkey rhinotracheitis viruses used as antigens for serological testing following live vaccination and challenge. Eterradossi N, et al. **Zentralbl Veterinarmed [B]** 1995 May;42(3):175–86

PNEUMOVIRUS INFECTIONS

PATHOLOGY

A sequential histopathologic and immunocytochemical study of chickens, turkey poults, and broiler breeders experimentally infected with turkey rhinotracheitis virus. Majó N, et al. **Avian Dis** 1995 Oct-Dec;39(4):887–96

VETERINARY

Turkey rhinotracheitis virus isolated from broiler chicken with swollen head syndrome in Japan. Tanaka M, et al. **J Vet Med Sci** 1995 Oct;57(5):939–41

Evaluation of different turkey rhinotracheitis viruses used as antigens for serological testing following live vaccination and challenge. Eterradossi N, et al. **Zentralbl Veterinarmed [B]** 1995 May;42(3):175–86

POCKET, PERIODONTAL see **PERIODONTAL POCKET**

PODIATRY

see related

FOOT DISEASES

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

The use of orthotic devices to correct plantar callus in people with diabetes. Colagiuri S, et al. **Diabetes Res Clin Pract** 1995 Apr;28(1):29–34

Surgical referrals as evidence of a de facto podiatric medical specialization. Grimm JW, et al. **J Am Podiatr Med Assoc** 1995 Sep;85(9):481–7

AIDS and the podiatric medical practice. Tinkle JD. **J Am Podiatr Med Assoc** 1995 Aug;85(8):420–7

Targeted screening for diabetes in community chiropody clinics. Gill GV, et al. **QJM** 1996 Mar;89(3):229–32

ECONOMICS

The orthopaedic/podiatric dilemma [see comments] Rudicel S. **Foot Ankle Int** 1995 Jun;16(6):378–80. Comment in: Foot Ankle Int 1995 Jun;16(6):381. Comment in: Foot Ankle Int 1995 Jun;16(6):382.

EDUCATION

Rewards of entering podiatric medicine and attitudes toward older adults. Chumbler NR, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):288–94

Podiatric educational enhancement project. A project

overview. Curry L. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):361–3

Partnership between a Veterans Affairs medical center and a podiatric medical college. Gorecki GA, et al. **J Am Podiatr Med Assoc** 1996 Aug;86(8):376–82

Podiatric medical education and practice. 1960s to the 21st century. Levy LA. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):370–5

Podiatric medical education. A view into the next century. McNevin AJ, et al. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):354–60

California Liaison Committee for Podiatric Medical Education and Training. Medio FJ, et al. **J Am Podiatr Med Assoc** 1996 Aug;86(8):364–9

HISTORY

History of residency selection issues in podiatric medicine. Dorcey EU, et al. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):390–5

INSTRUMENTATION

A comparison of the dynamic pedobarograph and EMED systems for measuring dynamic foot pressures. Quaney B, et al. **Foot Ankle Int** 1995 Sep;16(9):562–6

ORGANIZATION & ADMINISTRATION

Foot pathology in insulin dependent diabetes [letter; comment] Yale C, et al. **Arch Dis Child** 1996 Apr;74(4):368 . Comment on: Arch Dis Child 1995 Aug;73(2):151–3.

STANDARDS

Guidelines for the prevention of HIV transmission in the podiatric medical practice. Cope R. **J Am Podiatr Med Assoc** 1995 Aug;85(8):428–33

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334–46 (108 ref.)

Role of state licensing boards. Rathlesberger JH. **J Am Podiatr Med Assoc** 1996 Aug;86(8):383–9

Clinical audit of forefoot surgery performed by registered medical practitioners and podiatrists. Laxton C. **J Public Health Med** 1995 Sep;17(3):311–7

STATISTICS & NUMERICAL DATA

"Stand down for the homeless". Podiatric screening of a homeless population in Cleveland. Robbins JM, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):275–9

TRENDS

Elective foot surgery: relative roles of doctors of podiatric medicine and orthopaedic surgeons [letter; comment] Novicki DC. **Foot Ankle Int** 1995 Jun;16(6):382. Comment on: Foot Ankle Int 1995 Jun;16(6):378–80.

Elective foot surgery: relative roles of doctors of podiatric medicine and orthopedic surgeons [letter; comment] Weil LS. **Foot Ankle Int** 1995 Jun;16(6):381. Comment on: Foot Ankle Int 1995 Jun;16(6):378–80.

PODOPHYLLIN

ANALOGS & DERIVATIVES

Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. Ilyinskii PO, et al. **J Virol** 1996 May; 70(5):3118–26

THERAPEUTIC USE

Cryosurgery and podophyllum in combination for condylomata [letter; comment] McDow RA. **Am Fam Physician** 1996 May 1;53(6):1987–8, 1993. Comment on: Am Fam Physician 1995 Sep 15;52(4):1137–46, 1149–50.

Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Hellberg D, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):257–61

Autoimplantation technique in the treatment of anogenital warts: a clinico-immunological study. Usman N, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):55–7

PODOPHYLLOTOXIN

ADMINISTRATION & DOSAGE

A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts. Petersen CS, et al. **Genitourin Med** 1995 Dec; 71(6):391–2

Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Strand A, et al. **Genitourin Med** 1995 Dec;71(6):387–90

ADVERSE EFFECTS

Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Pui CH, et al. **Leukemia** 1995 Dec;9(12):1990–6

ANALOGS & DERIVATIVES

Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates. Gupta R, et al. **Anticancer Drug Des** 1996 Jun;11(4):325–38

Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors. Kamal A, et al. **Anticancer Drug Des** 1995 Oct;10(7):545–54

Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Mross K, et al. **Cancer Chemother Pharmacol** 1996;38(3):217–24

Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Hanauske AR, et al. **Eur J Cancer** 1995 Sep;31A(10):1677–81

Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach. Cho SJ, et al. **J Med Chem** 1996 Mar 29;39(7):1383–95

[HPLC determination of 4-[4"-(2",2",6",6"-tetramethyl-1"-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin in rat plasma and studies of its pharmacokinetics] Jia ZP, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):768–72 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Gieseler F, et al. **Leukemia** 1996 Jul; 10 Suppl 3:S46–S49

Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells. Anyanwutaku IO, et al. **Mol Pharmacol** 1996 Apr;49(4):721–6

THERAPEUTIC USE

Podophyllotoxin in the treatment of genital warts. Beutner KR. **Curr Probl Dermatol** 1996;24:227–32 (23 ref.)

Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Syed TA, et al. **Dermatology** 1995;191(2):129–32

Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Hellberg D, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):257–61

PODOVIRIDAE

GENETICS

E. coli SSB activates N4 virion RNA polymerase promoters by stabilizing a DNA hairpin required for promoter recognition. Glucksmann-Kuis MA, et al. **Cell** 1996 Jan 12;84(1):147–54

POECILIA

Biological control of mosquito larvae by Guppy fish. Elias M, et al. **Bangladesh Med Res Counc Bull** 1995 Aug; 21(2):81–6

GENETICS

Identification of major histocompatibility complex genes in the guppy, Poecilia reticulata. Sato A, et al. **Immunogenetics** 1996;43(1–2):38–49

METABOLISM

Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. Celander M, et al. **Arch Biochem Biophys** 1996 May 1;329(1):113–22

PARASITOLOGY

Host response to initial and challenge infections, following treatment, of Gyrodactylus bullatarudis and G. turnbulli (Monogenea) on the guppy (Poecilia reticulata). Richards GR, et al. **Parasitol Res** 1996;82(3):242–7

PHYSIOLOGY

Gill diffusion as a physiological mechanism for hydrogen peroxide elimination by fish. Wilhelm-Filho D, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2879–82

POEMS SYNDROME

POEMS syndrome in a female Italian patient. A case report. Bertola G, et al. **Recenti Prog Med** 1995 Nov;86(11):442–4

[Polyneuritis, endocrine disorders associated with plasma cell dyscrasia] Takatsuki K. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1117–21 (6 ref.) **(Jpn)**

BLOOD

Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome [letter] Watanabe O, et al. **Lancet** 1996 Mar 9;347(9002):702

CEREBROSPINAL FLUID

A case of Crow-Fukase syndrome with elevated soluble interleukin-6 receptor in cerebrospinal fluid. Response to double-filtration plasmapheresis and corticosteroids. Atsumi T, et al. **Acta Haematol** 1995;94(2):90–4

COMPLICATIONS

POEMS syndrome with central nervous system involvement: a case report. Tsunoda I, et al. **Fukushima J Med Sci** 1995 Jun;41(1):61–9

Thiamine deficiency and pulmonary hypertension in Crow-Fukase syndrome. Okura H, et al. **Intern Med** 1995 Jul;34(7):674–5

POEMS syndrome, arterial thrombosis and thrombocythaemia. Zenone T, et al. **J Intern Med** 1996 Aug;240(2):107–9

Hypoparathyroidism in POEMS syndrome [letter] Cabezas-Agricola JM, et al. **Lancet** 1996 Mar 9; 347(9002):701–2

Acute arterial obliteration: a new feature of the POEMS syndrome? Lesprit P, et al. **Medicine (Baltimore)** 1996 Jul; 75(4):226–32 (45 ref.)

[Nervous microangiopathy and POEMS syndrome] Maillot F, et al. **Rev Med Interne** 1995;16(12):934–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Fatal case of Crow-Fukase syndrome with kidney failure, acute consciousness disorder and thrombocytopenia] Yoshida H, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2078–9 **(Jpn)**

DIAGNOSIS

[Myocardiopathy in POEMS syndrome (letter)] Gacon PH, et al. **Ann Med Interne (Paris)** 1996;147(2):124–6 (16 ref.) **(Fre)**

DRUG THERAPY

All-trans-retinoic acid in POEMS syndrome. Therapeutic effect associated with decreased circulating levels of proinflammatory cytokines. Authier FJ, et al. **Arthritis Rheum** 1996 Aug;39(8):1423–6

ETHNOLOGY

POEMS syndrome in Chinese. Tang LM, et al. **Eur Neurol** 1995;35(6):349–53

ETIOLOGY

POEMS syndrome and Waldenström's macroglobulinaemia. Pavord SR, et al. **J Clin Pathol** 1996 Feb;49(2):181–2

IMMUNOLOGY

Sclerotic IgA myeloma and polyneuropathy: the POEMS syndrome. Case report [letter] Mertens I, et al. **Ann Oncol** 1995 Sep;6(7):731–2

PATHOLOGY

POEMS and Crow-Fukase syndrome: two cases giving rise to more questions about plasma cell dyscrasias. Bonanni F, et al. **In Vivo** 1995 May-Jun;9(3):193–4

Amyotrophic lateral sclerosis associated with multiple myeloma, endocrinopathy and skin changes suggestive of a POEMS syndrome variant. Gericke CA, et al. **J Neurol Sci** 1995 May;129 Suppl:58–60

PHYSIOPATHOLOGY

Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Gherardi RK, et al. **Blood** 1996 Feb 15;87(4):1458–65

[POEMS syndrome: role and value of interleukin-6] Andrès E, et al. **Rev Med Interne** 1996;17(2):145–9 (33 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[POEMS syndrome] Dieckmann C, et al. **Radiologe** 1995 Aug;35(8):528–30 (Eng. Abstr.) **(Ger)**

THERAPY

A case of Crow-Fukase syndrome with elevated soluble interleukin-6 receptor in cerebrospinal fluid. Response to double-filtration plasmapheresis and corticosteroids. Atsumi T, et al. **Acta Haematol** 1995;94(2):90–4

Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome [letter] Henze T, et al. **J Neurol** 1995 Jul;242(7):482–3

POETRY

Subject matter and poetic devices in psychotics' poetry. Rhodes N, et al. **Br J Med Psychol** 1995 Dec;68 (Pt 4):311–21

The expression of emotional distress in old English prose and verse. Nicholson S. **Cult Med Psychiatry** 1995 Sep; 19(3):327–38

The roots of Ariel: Sylvia Plath and her father's foot. Foster AV, et al. **Diabet Med** 1995 Jul;12(7):580–4

Schreber and Hölderlin: the concept of "a-father" or the

psychological origin of mental breakdown. Ver Eecke W. **J Am Acad Psychoanal** 1995 Fall;23(3):449–60

"I want to tell the whole world..." [editorial] Edelman M. **J Psychosoc Nurs Ment Health Serv** 1996 Apr;34(4):37–9

Poetry on rounds [letter; comment] Hobson J. **Lancet** 1996 Mar 30;347(9005):907. Comment on: Lancet 1996 Feb 17;347(8999):447–9.

Poetry on rounds: a model for the integration of humanities into residency training [see comments] Horowitz HW. **Lancet** 1996 Feb 17;347(8999):447–9. Comment in: Lancet 1996 Mar 30;347(9005):907. Comment in: Lancet 1996 Apr 13;347(9007):1046–7.

Poetry helps healing [letter] Philipp R, et al. **Lancet** 1996 Feb 3;347(8997):332–3

Poetry and the humanisation of medicine [letter; comment] Wever C, et al. **Lancet** 1996 Apr 13;347(9007):1046–7. Comment on: Lancet 1996 Feb 17;347(8999):447–9.

Language, poetry and attitude to sound. Ordinary meeting; Monday, 28th February, 1994. Douek E. **Trans Med Soc Lond** 1993–94;110:54–8

[Verlaine: long sobs on Normandy] Henry R. **Union Med Can** 1995 Mar;124(1):23–5 **(Fre)**

[Dyssocial identity disorder (double identity) in psychopathology and poetry] Tölle R. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):174–85 (Eng. Abstr.) **(Ger)**

[Henrik Wergeland's disease and death. 150th anniversary] Holck P. **Tidsskr Nor Laegeforen** 1995 Dec 10; 115(30):3734–7 (Eng. Abstr.) **(Nor)**

HISTORY

Samuel Johnson (1709–1784), British poet, critic, essayist, and lexicographer. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):52–5

Anatomical comparisons, metaphysical conceits: poets, physicians, and the motions of the heart. Rosen D. **Caduceus** 1995 Winter;11(3):184–206

Secrets of the couch and the grave: the Anne Sexton case. Pellegrino ED. **Camb Q Healthc Ethics** 1996 Spring; 5(2):189–203

The blindness of John Milton. Bartley GB. **Doc Ophthalmol** 1995;89(1–2):15–28

The child is father of the man. Wordsworth's Ode: Intimations of immortality and his secret sharers. Glenn J. **Psychoanal Study Child** 1995;50:383–97

[The physician–poet. The 200-year anniversary of the birth of John Keats] Hidvégi J, et al. **Orv Hetil** 1995 Dec 10; 136(50):2739–42 **(Hun)**

[Where intensive care and literature can meet. The conference in homage to Rui Carrington de Costa] Pinheiro A. **Acta Med Port** 1995 Sep;8(9):510–5 **(Por)**

["Being alive is to build bridges". German physician–writers during over four centuries] Böttiger LE. **Lakartidningen** 1996 Jan 3;93(1–2):59–62 **(Swe)**

POIKILODERMA CONGENITALE

COMPLICATIONS

Malignant eccrine poroma in a patient with Rothmund–Thomson syndrome [letter] Van Hees CL, et al. **Br J Dermatol** 1996 Apr;134(4):813–5

Myelodysplastic syndrome in a child with Rothmund–Thomson syndrome: a case report [letter] Rizzari C, et al. **J Pediatr Hematol Oncol** 1996 Feb; 18(1):96–7

Rothmund–Thomson syndrome and osteosarcoma. Cumin I, et al. **Med Pediatr Oncol** 1996 Jun;26(6):414–6

Osteogenic sarcoma in the Rothmund–Thomson syndrome. Leonard A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):249–53 (22 ref.)

[Rothmund–Thomson syndrome and osteosarcoma] Molina MI, et al. **Arch Pediatr** 1995 Sep;2(9):865–70 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Long-term follow-up of cutaneous changes in siblings with mandibuloacral dysplasia who were originally considered to have hereditary sclerosing poikiloderma. Fryburg JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):900–2

What syndrome is this? Rothmann–Thomson syndrome. Larralde M, et al. **Pediatr Dermatol** 1995 Sep;12(3):277–80

GENETICS

[Weary hereditary sclerosing poikiloderma] Fazio M, et al. **Ann Dermatol Venereol** 1995;122(9):618–20 (Eng. Abstr.) **(Fre)**

THERAPY

Myelodysplastic syndromes and RTS. Ilhan I, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):197

Rothmund–Thomson syndrome, malignant diseases, and treatment opportunities [letter] Rizzari C, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):195–6

POINT MUTATION

Clinical spectrum of the MELAS mutation in a large pedigree. Damian MS, et al. **Acta Neurol Scand** 1995 Nov; 92(5):409–15

Lack of point mutation of the APP gene in sporadic Alzheimer's disease in Japanese. Nonomura Y, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):138–41

Norrie–Warburg syndrome: two novel mutations in patients with classical clinical phenotype. Gal A, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):13–6

Spontaneous mutation of p53 gene in human papillomavirus type 16 E7-immortalized human laryngeal epithelial cells. Suzuki T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 522:94–8

The A985 to G mutation of the medium-chain acyl-CoA dehydrogenase gene and sudden infant death syndrome in Normandy. Lecoq I, et al. **Acta Paediatr** 1996 Feb; 85(2):145–7

Site-directed mutagenesis of a disulfide bridge in cathepsin D: expression, activation, purification, and characterization. Beyer BM, et al. **Adv Exp Med Biol** 1995;362:285–7

Evolution and persistence mechanisms of mouse hepatitis virus. Chen W, et al. **Adv Exp Med Biol** 1995;380:63–71

Mutants of HIV-1 protease with enhanced stability to autodegradation. Tomasselli AG, et al. **Adv Exp Med Biol** 1995;362:387–98

The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. Kaye S, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1221–5

Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears [see comments] Apple SK, et al. **Am J Clin Pathol** 1996 Mar;105(3):321–6. Comment in: Am J Clin Pathol 1996 Mar;105(3):257–9.

p53 protein expression and p53 mutation in thymic epithelial tumors [letter] Puglisi F. **Am J Clin Pathol** 1996 May; 105(5):657–8

Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Uehara H, et al. **Am J Gastroenterol** 1996 Aug;91(8):1616–21

Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Wakabayashi T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1848–51

Heteroduplex analysis in hemophilia B: detection of two novel factor IX gene mutations. Driscoll MC, et al. **Am J Hematol** 1996 Apr;51(4):324–7

Neonatal jaundice and molecular mutations in glucose-6-phosphate dehydrogenase deficient newborn infants. Huang CS, et al. **Am J Hematol** 1996 Jan; 51(1):19–25

Hemoglobin Debrousse (beta 96[FG3]Leu-->Pro): a new unstable hemoglobin with twofold increased oxygen affinity. Lacan P, et al. **Am J Hematol** 1996 Apr; 51(4):276–81

Two different mutations in codon 97 of the beta-globin gene cause Hb Malmö in Sweden. Landin B, et al. **Am J Hematol** 1996 Jan;51(1):32–6

Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII. Rick ME, et al. **Am J Hematol** 1996 Apr;51(4):302–6

Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families. Schneider A, et al. **Am J Hematol** 1995 Dec;50(4):263–8

Prenatal and molecular diagnosis of hemophilia B. Young JH, et al. **Am J Hematol** 1996 Aug;52(4):243–7

A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Barker DF, et al. **Am J Hum Genet** 1996 Jun;58(6):1157–65

Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Berman DB, et al. **Am J Hum Genet** 1996 Jun;58(6):1166–76

Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy. Feigenbaum V, et al. **Am J Hum Genet** 1996 Jun;58(6):1135–44

The Val192Leu mutation in the alpha-subunit of beta-hexosaminidase A is not associated with the B1-variant form of Tay-Sachs disease. Hou Y, et al. **Am J Hum Genet** 1996 Jul;59(1):52–8

Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease [see comments] Kluijtmans LA, et al. **Am J Hum Genet** 1996 Jan;58(1):35–41. Comment in: Am J Hum Genet 1996 Jan;58(1):17–20.

Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Litjens T, et al. **Am J Hum Genet** 1996 Jun;58(6):1127–34

Substitution of a conserved cysteine-996 in a cysteine-rich motif of the laminin alpha2-chain in congenital muscular dystrophy with partial deficiency of the protein. Nissinen M, et al. **Am J Hum Genet** 1996 Jun;58(6):1177–84

Analyses of loss-of-function mutations of the MITF gene suggest that haploinsufficiency is a cause of Waardenburg syndrome type 2A. Nobukuni Y, et al. **Am J Hum Genet** 1996 Jul;59(1):76–83

Simultaneous occurrence of the 11778 (ND4) and the 9438 (COX III) mtDNA mutations in Leber hereditary optic neuropathy: molecular, biochemical, and clinical findings [letter] Oostra RJ, et al. **Am J Hum Genet** 1995 Oct; 57(4):954–7

Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Rittig S, et al. **Am J Hum Genet** 1996 Jan; 58(1):107–17

Mutation analysis of very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: identification and characterization of mutant VLCAD cDNAs from four patients. Souri M, et al. **Am J Hum Genet** 1996 Jan; 58(1):97–106

Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without alpha-thalassemia. Villard L, et al. **Am J Hum Genet** 1996 Mar;58(3):499–505

VACTERL with the mitochondrial np 3243 point mutation. Damian MS, et al. **Am J Med Genet** 1996 Apr 24; 62(4):398–403

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161–6 (34 ref.)

The expanding clinical phenotype of the tRNA(Leu(UUR)) A-->G mutation at np 3243 of mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Feigenbaum A, et al. **Am J Med Genet** 1996 Apr 24;62(4):404–9

The clinical and molecular spectrum of androgen insensitivity syndromes. Hiort O, et al. **Am J Med Genet** 1996 May 3;63(1):218–22

Phenotypic expressions of a Gly 154Arg mutation in type II collagen in two unrelated patients with spondyloepimetaphyseal dysplasia (SEMD). Kaitila I, et al. **Am J Med Genet** 1996 May 3;63(1):111–22

An alpha 1(II) Gly913 to Cys substitution prevents the matrix incorporation of type II collagen which is replaced with type I and III collagens in cartilage from a patient with hypochondrogenesis. Mundlos S, et al. **Am J Med Genet** 1996 May 3;63(1):129–36

Radiological and histological variants of thanatophoric dysplasia are associated with common mutations in FGFR-3. Nerlich AG, et al. **Am J Med Genet** 1996 May 3;63(1):155–60

Pelizaeus-Merzbacher disease caused by a de novo mutation that originated in exon 2 of the maternal great-grandfather of the propositus. Pratt VM, et al. **Am J Med Genet** 1995 Jul 31;58(1):70–3

Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia. Schuster V, et al. **Am J Med Genet** 1996 May 3;63(1):318–22

Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Sinnecker GH, et al. **Am J Med Genet** 1996 May 3;63(1):223–30

Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia. Tanaka T, et al. **Am J Med Genet** 1996 Apr 9;67(2):208–11

Who is a carrier? Detection of unsuspected mutations in 21-hydroxylase deficiency. Witchel SS, et al. **Am J Med Genet** 1996 Jan 2;61(1):2–9

Substitution of arginine for glycine at position 154 of the alpha 1 chain of type I collagen in a variant of osteogenesis imperfecta: comparison to previous cases with the same mutation. Zhuang J, et al. **Am J Med Genet** 1996 Jan 11; 61(2):111–16

Autosomal dominant central areolar choroidal dystrophy caused by a mutation in codon 142 in the peripherin/RDS gene. Hoyng CB, et al. **Am J Ophthalmol** 1996 Jun; 121(6):623–9

Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. Giaretti W, et al. **Am J Pathol** 1996 Jul; 149(1):237–45

Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Hashimoto K, et al. **Am J Pathol** 1996 Jan;148(1):189–200

Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G) [see comments] Vidal R, et al. **Am J Pathol** 1996 Feb; 148(2):361–6. Comment in: Am J Pathol 1996 Feb;148(2):351–4.

Cystic fibrosis 3849+10kb C > T mutation associated with severe pulmonary disease and male fertility. Dreyfus DH, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):858–60

Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Reeder JC, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):209–13

Detection of single-base mutations by a competitive mobility shift assay. Chen M, et al. **Anal Biochem** 1996 Jul 15; 239(1):61–9

Polymerase chain reaction-based site-directed mutagenesis using magnetic beads. Fieschi J, et al. **Anal Biochem** 1996 Feb 15;234(2):210–4

Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors. Bouras M, et al. **Ann Biol Clin (Paris)** 1995; 53(10–11):549–55

A frame-shift mutation of the androgen receptor gene in a patient with receptor-negative complete testicular feminization: comparison with a single base substitution in a receptor-reduced incomplete form. Imai A, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):482–6

Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Keilson LM, et al. **Ann Intern Med** 1996 Feb 15; 124(4):425–8

Arg519–Cys mutation in COL2A1: evidence for multiple founders. Bleasel JF, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:215–8

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Characterization of recombinant human collagen II with Arg519–to–Cys substitution. Fertala A, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:251–3

K–ras2 mutation spectrum, DNA aneuploidy, and epithelial cell proliferation in colorectal adenomas. Giaretti W, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:261–3

Analysis of V kappa I and V lambda II light chain genes in the expressed B–cell repertoire. Manheimer–Lory A, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:301–11

Expression and regulation of clonally ignorant B cells. Thomas JW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:461–2

The G protein–coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

A beta–subunit mutation in the acetylcholine receptor channel gate causes severe slow–channel syndrome. Gomez CM, et al. **Ann Neurol** 1996 Jun;39(6):712–23

Multiple mutations in the GALC gene in a patient with adult–onset Krabbe disease. Luzi P, et al. **Ann Neurol** 1996 Jul;40(1):116–9

MELAS– and Kearns–Sayre–type commutation with myopathy and autoimmune polyendocrinopathy. Ohno K, et al. **Ann Neurol** 1996 Jun;39(6):761–6

SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Rouleau GA, et al. **Ann Neurol** 1996 Jan;39(1):128–31

Missense mutations of the PS–1/S182 gene in German early–onset Alzheimer's disease patients [letter] Sandbrink R, et al. **Ann Neurol** 1996 Aug;40(2):265–6

Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Weeks RA, et al. **Ann Neurol** 1996 Jul;40(1):49–54

Keratins and the skin. Fuchs E. **Ann Rev Cell Dev Biol** 1995; 11:123–53 (171 ref.)

Analysis of p53 abnormalities in endoscopic gastric biopsies. Imatani A, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2049–56

Molecular genetics of malignant insulinoma. Pavelic K, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1707–17

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Yamaguchi T, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2009–15

Point mutation in the pribnow box, the molecular basis of beta–lactamase overproduction in Klebsiella oxytoca. Fournier B, et al. **Antimicrob Agents Chemother** 1995 Jun; 39(6):1365–8

Mutations in katG gene sequences in isoniazid–resistant clinical isolates of Mycobacterium tuberculosis are rare. Pretorius GS, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2276–81

Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Takenouchi T, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1414–8

Reaction of wild–type C365S, and C458S saccharomyces cerevisiae phosphoenolpyruvate carboxykinases with fluorescent iodoacetamide derivatives. Krautwurst H, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):123–30

Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Ookawara T, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):35–40

White matter lesions and cognitive deterioration in presymptomatic carriers of the amyloid precursor protein gene codon 693 mutation. Bornebroek M, et al. **Arch Neurol** 1996 Jan;53(1):43–8

Sorsby fundus dystrophy. A family with the Ser181Cys mutation of the tissue inhibitor of metalloproteinases 3. Carrero–Valenzuela RD, et al. **Arch Ophthalmol** 1996 Jun; 114(6):737–8

Autosomal dominant cone–rod dystrophy associated with mutations in codon 244 (Asn244His) and codon 184 (Tyr184Ser) of the peripherin/RDS gene. Nakazawa M, et al. **Arch Ophthalmol** 1996 Jan;114(1):72–8

Audiovestibular findings in patients with deafness caused by a mitochondrial susceptibility mutation and precipitated by an inherited nuclear mutation or aminoglycosides. Braverman I, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):1001–4

The Trp23–Stop and Trp66–Gly mutations in the LDL receptor gene: common causes of familial hypercholesterolemia in Denmark. Jensen HK, et al. **Atherosclerosis** 1996 Feb;120(1–2):57–65

Does the presence of the 3500 mutant apolipoprotein B–100 in low density lipoprotein particles affect their atherogenicity? Maher VM, et al. **Atherosclerosis** 1995 Nov; 118(1):105–10

A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Ward AJ, et al. **Atherosclerosis** 1996 Feb; 120(1–2):83–91

A brave new world of cancer screening [letter; comment] Jass JR, et al. **Aust N Z J Med** 1995 Jun;25(3):255. Comment on: Aust N Z J Med 1994 Dec;24(6):677–8. Comment on: Aust N Z J Med 1994 Dec;24(6):682–6.

Antagonistic mutant proteins of interleukin–4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87–94 (27 ref.)

Use of protease sensitivity to probe the conformations of newly synthesised mutant forms of mitochondrial aspartate aminotransferase. Azzariti A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):800–7

Effect of microinjection of rap 2A point mutant proteins on maturation and mottling in Xenopus oocytes. Carnero A, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):748–54

Cysteine 99 of endothelial nitric oxide synthase (NOS–III) is critical for tetrahydrobiopterin–dependent NOS–III stability and activity. Chen PF, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1119–29

Mutation screening and identification of a sequence variation in the human ob gene coding region. Considine RV, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):735–9

A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus. Daimon M, et al. **Biochem Biophys Res Commun** 1995 Dec 5; 217(1):89–95

Study of the new stability properties induced by amino acid replacement of tyrosine 64 in cytochrome C553 from Desulfovibrio vulgaris Hildenborough using electrospray ionization mass spectrometry. Guy P, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):97–103

Point mutations in the first and third intracellular loops of the glucagon–like peptide–1 receptor alter intracellular signaling. Heller RS, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):624–32

Homozygous expression of a missense mutation at nucleotide 385 in the FUT2 gene associates with the Le(a+b+) partial–secretor phenotype in an Indonesian family. Henry S, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):675–8

Mitochondrial DNA 3394 mutation in the NADH dehydrogenase subunit 1 associated with non–insulin–dependent diabetes mellitus. Hirai M, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):951–5

Substitution at codon 269 (glutamine —> proline) of the leptin receptor (OB–R) cDNA is the only mutation found in the Zucker fatty (fa/fa) rat. Iida M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):597–604

Mutant mtDNA at 1555 A to G in 12S rRNA gene and hypersusceptibility of mitochondrial translation to streptomycin can be co–transferred to rho 0 HeLa cells. Inoue K, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):496–501

A mutation in the beta 3–adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Kadowaki H, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):555–60

Pancreatic islet cells express BST–1, a CD38–like surface molecule having ADP–ribosyl cyclase activity. Kajimoti Y, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):941–6

Instability at the H–ras minisatellite is associated with the spontaneous abortion of the embryo. Kiaris H, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):788–92

Accumulation of somatic nucleotide substitutions in mitochondrial DNA associated with the 3243 A–to–G tRNA(leu)(UUR) mutation in encephalomyopathy and cardiomyopathy. Kovalenko SA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):201–7

Proposed schizophrenia–related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Lundstrom K, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):1068–72

A second, elongated, alpha 2–globin mRNA is present in reticulocytes from normal persons and subjects with terminating codon or poly A mutations. Molchanova TP, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1184–90

Decreased affinity of apolipoprotein AII to high–density lipoprotein in patients with transthyretin–related amyloidosis (Met30, Gln89, Pro36, and Thr34). Nakamura M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):316–21

A novel mutation in the mitochondrial tRNA(Thr) gene associated with a mitochondrial encephalomyopathy. Nishino I, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):180–5

Galactose stabilizes various missense mutants of alpha–galactosidase in Fabry disease. Okumiya T, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1219–24

The mitochondrial DNA mutation ND6*14,484C associated with leber hereditary optic neuropathy, leads to deficiency of complex I of the respiratory chain. Oostra RJ, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1001–5

Novel nonsense proteolipid protein gene mutation as a cause of X–linked spastic paraplegia in twin males. Osaka H, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):835–41

Mutation of an aspartate at position 63 in the human platelet–activating factor receptor augments binding affinity but abolishes G–protein–coupling and inositol phosphate production. Parent JL, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):968–75

Replacement of the sole histidinyl residue in OmpF porin from E. coli by threonine (H21T) does not affect channel structure and function. Saint N, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):118–22

A novel mitochondrial DNA point mutation associated with mitochondrial encephalocardiomyopathy. Santorelli FM, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):835–40

A novel mitochondrial DNA point mutation in the tRNA(Ile) gene is associated with progressive external ophtalmoplegia. Silvestri G, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):623–7

Molecular cloning of rat leptin receptor isoform complementary DNAs–identification of a missense mutation in Zucker fatty (fa/fa) rats. Takaya K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):75–83

Polymorphisms and probable lack of mutation in a human mutT homolog, hMTH1, in hereditary nonpoliposis colorectal cancer. Wu C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1239–45

A single base–pair change (ATG—>ATC) nullifies the activity of cytosolic fumarase in Saccharomyces cerevisiae. Wu M, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):578–90

Classic steroid 11 beta–hydroxylase deficiency caused by a C—>G transversion in exon 7 of CYP11B1. Yang LX, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):723–8

A case of male–limited precocious puberty caused by a point mutation in the second transmembrane domain of the luteinizing hormone choriogonadotropin receptor gene. Yano K, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1036–42

Heterogeneity of the human Secretor alpha(1,2)fucosyltransferase gene among Lewis(a+b–) non–secretors. Yu LC, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):390–4

Phosphofructo–1–kinase: role of charge neutralization in the active site. Zheng RL, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):765–70

Altering kinetic mechanism and enzyme stability by mutagenesis of the dimer interface of glutathione reductase. Bashir A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):527–33

Mutation of an EF–hand Ca(2+)–binding motif in phospholipase C of Dictyostelium discoideum: inhibition of activity but no effect on Ca(2+)–dependence. Drayer AL, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):505–10

The role of palmitoylation of the guanine nucleotide binding protein G11 alpha in defining interaction with the plasma membrane. McCallum JF, et al. **Biochem J** 1995 Sep 15; 310 (Pt 3):1021–7

Covalent modification of engineered cysteines in the nicotinic acetylcholine receptor agonist–binding domain inhibits receptor activation. McLaughlin JT, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):765–9

Mutations of the basic amino acid transporter gene associated with cystinuria. Miyamoto K, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):951–5

Mutations of recombinant rat liver fatty acid–binding protein at residues 102 and 122 alter its structural integrity and affinity for physiological ligands. Thumser AE, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):943–9

Correlation of a missense mutation in the human Secretor alpha 1,2–fucosyltransferase gene with the Lewis(a+b+) phenotype: a potential molecular basis for the weak Secretor allele (Sew). Yu LC, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):329–32

Molecular genetic characterization and prenatal diagnosis in a family with Hunter disease. Grosso M, et al. **Biochem Mol Biol Int** 1995 May;35(6):1261–7

Novel use of limited primer extension in detecting mutations in human iduronate 2–sulfatase gene. Li P, et al. **Biochem Mol Biol Int** 1995 May;35(6):1299–305

Comparison between thymidylate synthase B of Bacillus subtilis ATCC6633 and 168. Montorsi M, et al. **Biochem Mol Biol Int** 1995 May;35(6):1245–51

Mitochondrial DNA mutations associated with the 11778 mutation in Leber's disease. Sawano T, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):693–700

D–glucose metabolism in lymphocytes of patients with mitochondrial point mutation of the tRNALeu(UUR) gene. Malaisse WJ, et al. **Biochem Mol Med** 1995 Apr;54(2):91–5

An A–to–G mutation at the +3 position of intron 8 of the HEXA gene is associated with exon 8 skipping and Tay–Sachs disease. Richard MM, et al. **Biochem Mol Med** 1995 Jun;55(1):74–6

Purification and partial characterisation of the E14K mutant of flavodoxin from Megasphaera elsdenii. Geoghegan SM, et al. **Biochem Soc Trans** 1996 Feb;24(1):27S

On the molecular basis of inhibition by excess substrate in wild–type and Y143F flavocytochrome b2. Mayer M, et al. **Biochem Soc Trans** 1996 Feb;24(1):15S

Cold–sensitive assembly of a mutant manganese–stabilizing protein caused by a Val to Ala replacement. Betts SD, et al. **Biochemistry** 1996 May 21;35(20):6302–7

Active site mutation of the C3–like ADP–ribosyltransferase from Clostridium limosum—analysis of glutamic acid 174. Böhmer J, et al. **Biochemistry** 1996 Jan 9;35(1):282–9

Alanine point-mutations in the reactive region of bovine pancreatic trypsin inhibitor: effects on the kinetics and thermodynamics of binding to beta-trypsin and alpha-chymotrypsin. Castro MJ, et al. **Biochemistry** 1996 Sep 3;35(35):11435–46

Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2'-deoxyuridine 5'-monophosphate. Costi PM, et al. **Biochemistry** 1996 Apr 2;35(13):3944–9

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Fan N, et al. **Biochemistry** 1996 Jul 30; 35(30):9737–45

Probing the conformation of the lactose permease of Escherichia coli by in situ site-directed sulfhydryl modification. Frillingos S, et al. **Biochemistry** 1996 Apr 2;35(13):3950–6

Active site mutations define the pathway for the cooperative activation of cAMP-dependent protein kinase. Herberg FW, et al. **Biochemistry** 1996 Mar 5;35(9):2934–42

Determinants of cofactor specificity in isocitrate dehydrogenase: structure of an engineered NADP+ --> NAD+ specificity-reversal mutant. Hurley JH, et al. **Biochemistry** 1996 May 7;35(18):5670–8

The major, N2-Gua adduct of the (+)-anti-benzo[a]pyrene diol epoxide is capable of inducing G-->A and G-->C, in addition to G-->T, mutations. Jelinsky SA, et al. **Biochemistry** 1995 Oct 17;34(41):13545–53

The structural basis for pseudoreversion of the E165D lesion by the secondary S96P mutation in triosephosphate isomerase depends on the positions of active site water molecules. Komives EA, et al. **Biochemistry** 1995 Oct 17; 34(41):13612–21

Conversion of serine-114 to cysteine-114 and the role of the active site nucleophile in acyl transfer by myristoyl-ACP thioesterase from Vibrio harveyi. Li J, et al. **Biochemistry** 1996 Aug 6;35(31):9967–73

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL, et al. **Biochemistry** 1995 Oct 17;34(41):13527–36

Structure of the R65Q mutant of yeast 3-phosphoglycerate kinase complexed with Mg-AMP-PNP and 3-phospho-D-glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

E461H-beta-galactosidase (Escherichia coli): altered divalent metal specificity and slow but reversible metal inactivation. Martinez-Bilbao M, et al. **Biochemistry** 1995 Oct 17; 34(41):13437–42

Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Millard CB, et al. **Biochemistry** 1995 Dec 12;34(49):15925–33

Targeted A --> T and G --> T mutations induced by site-specific deoxyadenosine and deoxyguanosine adducts, respectively, from the (+)-anti-diol epoxide of dibenz[a,j]anthracene in M13mp7L2. Min Z, et al. **Biochemistry** 1996 Apr 2;35(13):4128–38

Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5'-triphosphate. Robinson MJ, et al. **Biochemistry** 1996 May 7;35(18):5641–6

Interactions between mutant and wild-type band 3 subunits in hereditary Southeast Asian ovalocytic red blood cell membranes. Salhany JM, et al. **Biochemistry** 1996 Jan 9; 35(1):251–7

Mechanism of the reaction catalyzed by mandelate racemase: structure and mechanistic properties of the D270N mutant. Schafer SL, et al. **Biochemistry** 1996 May 7;35(18):5662–9

Site-directed mutagenesis of lysine382, the activator-binding site, of ADP-glucose pyrophosphorylase from Anabaena PCC 7120. Sheng J, et al. **Biochemistry** 1996 Mar 5; 35(9):3115–21

Effect of the His175-->Glu mutation on the heme pocket architecture of cytochrome c peroxidase. Smulevich G, et al. **Biochemistry** 1995 Oct 17;34(41):13485–90

Hydrogen bonds of water and C==O groups coordinate long-range structural changes in the L photointermediate of bacteriorhodopsin. Yamazaki Y, et al. **Biochemistry** 1996 Apr 2;35(13):4063–8

Mutational analysis of the catalytic subunit of muscle protein phosphatase-1. Zhang J, et al. **Biochemistry** 1996 May 21; 35(20):6276–82

Characterization of the mutant visual pigment responsible for congenital night blindness: a biochemical and Fourier-transform infrared spectroscopy study. Zvyaga TA, et al. **Biochemistry** 1996 Jun 11;35(23):7536–45

Characteristics of skeletal muscle chloride channel C1C-1 and point mutant R304E expressed in Sf-9 insect cells. Astill DS, et al. **Biochim Biophys Acta** 1996 Apr 26; 1280(2):178–86

Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis. Moriyama K, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):185–90

A point mutation within each of two ATP-binding motifs inactivates the functions of elongation factor 3. Yang H, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):303–8

Characterization of single site ricin toxin B chain mutants. Frankel A, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):30–7

Activation kinetics of recombinant mouse nicotinic acetylcholine receptors: mutations of alpha-subunit tyrosine 190 affect both binding and gating. Chen J, et al. **Biophys J** 1995 Sep;69(3):849–59

A mu-conotoxin-insensitive Na+ channel mutant: possible localization of a binding site at the outer vestibule. Dudley SC Jr, et al. **Biophys J** 1995 Nov;69(5):1657–65

Intramolecular charge transfer in the bacteriorhodopsin mutants Asp85-->Asn and Asp212-->Asn: effects of pH and anions. Moltke S, et al. **Biophys J** 1995 Nov; 69(5):2074–83

K-ras gene mutation related to histological atypias in human colorectal adenomas. Ajiki T, et al. **Biotech Histochem** 1995 Mar;70(2):90–4

A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome [letter] Aguilar-Martinez P, et al. **Blood** 1996 Sep 1;88(5):1895

Two-exon skipping due to a point mutation in p67-phox--deficient chronic granulomatous disease. Aoshima M, et al. **Blood** 1996 Sep 1;88(5):1841–5

A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. Arbini AA, et al. **Blood** 1996 Jun 15; 87(12):5085–94

Molecular analysis in three cases of X91- variant chronic granulomatous disease. Bu-Ghanim HN, et al. **Blood** 1995 Nov 1;86(9):3575–82

Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Cooney KA, et al. **Blood** 1996 Mar 15;87(6):2322–8

The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Duchemin J, et al. **Blood** 1995 Nov 1;86(9):3436–43

Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). Girelli D, et al. **Blood** 1995 Dec 1; 86(11):4050–3

Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Hassoun H, et al. **Blood** 1996 Mar 15;87(6):2538–45

Moderate reduction of beta-globin gene transcript by a novel mutation in the 5' untranslated region: a study of its interaction with other genotypes in two families. Ho PJ, et al. **Blood** 1996 Feb 1;87(3):1170–8

Primary structure of murine red blood cell-type pyruvate kinase (PK) and molecular characterization of PK deficiency identified in the CBA strain. Kanno H, et al. **Blood** 1995 Oct 15;86(8):3205–10

The genetic defect in two well-studied cases of Bernard-Soulier syndrome: a point mutation in the fifth leucine-rich repeat of platelet glycoprotein Ib alpha. Li C, et al. **Blood** 1995 Nov 15;86(10):3805–14

Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Mikkola H, et al. **Blood** 1996 Jan 1;87(1):141–51

Protein S deficiency type I: identification of point mutations in 9 of 10 families. Mustafa S, et al. **Blood** 1995 Nov 1; 86(9):3444–51

Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. Naylor CE, et al. **Blood** 1996 Apr 1; 87(7):2974–82

A gamma Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Niwa K, et al. **Blood** 1996 Jun 1;87(11):4686–94

A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Piao X, et al. **Blood** 1996 Apr 15;87(8):3117–23

Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene. Villa A, et al. **Blood** 1996 Aug 1;88(3):817–23

Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Yamazaki T, et al. **Blood** 1996 Jun 1;87(11):4643–50

Two common mutations causing factor XI deficiency in Ashkenazi Jews may point to a European origin [letter; comment] Zoossmann-Diskin A. **Blood** 1995 Oct 15; 86(8):3267–8. Comment on: Blood 1995 Jan 15;85(2):429–32.

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Smith DR, et al. **Br J Cancer** 1996 Jul;74(2):216–23

A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Speiser P, et al. **Br J Cancer** 1996 Jul;74(2):269–73

Hereditary angioedema caused by a point mutation of exon 7 in the C1 inhibitor gene. Ishii N, et al. **Br J Dermatol** 1996 Apr;134(4):731–3

Correlation of the clinical manifestations and gene mutations of Japanese xeroderma pigmentosum group A patients. Kondoh M, et al. **Br J Dermatol** 1995 Oct;133(4):579–85

Beta-thalassaemia in south-western Spain: high frequency of G-->A (IVS I-1) mutation. Benito A, et al. **Br J Haematol** 1996 Feb;92(2):336–8

A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non-lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia. Gattermann N, et al. **Br J Haematol** 1996 Jun 2;93(4):845–55

A case of refractory anaemia with p53 point mutation at codon 249 (AGG to ATG). Kikukawa M, et al. **Br J Haematol** 1996 Mar;92(4):831–3

Band 3 Chur: a variant associated with band 3-deficient hereditary spherocytosis and substitution in a highly conserved position of transmembrane segment 11. Maillet P, et al. **Br J Haematol** 1995 Dec;91(4):804–10

c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Nakata Y, et al. **Br J Haematol** 1995 Nov;91(3):661–3

Molecular genetics of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Spain: identification of two new point mutations in the G6PD gene. Rovira A, et al. **Br J Haematol** 1995 Sep;91(1):66–71

Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Rudzki Z, et al. **Br J Haematol** 1996 Aug;94(2):400–6

Three unrelated Gaucher's disease patients with three novel point mutations in the glucocerebrosidase gene (P266R, D315H and A318D). Walley AJ, et al. **Br J Haematol** 1995 Oct;91(2):330–2

Absence of N-RAS point mutations in peripheral blood cells of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinurea. White JR, et al. **Br J Haematol** 1995 Dec;91(4):921–3

Clinical and genetical manifestations in 34 families with Leber's hereditary optic neuropathy (LHON). Meire GM, et al. **Bull Soc Belge Ophtalmol** 1994;254:137–46

p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Ikenberg H, et al. **Cancer** 1995 Jul 1;76(1):57–66

Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P, et al. **Cancer** 1995 Aug 1; 76(3):479–89

K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Matsubara T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1752–7

High incidence of point mutation in K-ras codon 12 in carcinoma of the fallopian tube. Mizuuchi H, et al. **Cancer** 1995 Jul 1;76(1):86–90

Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Kunimi K, et al. **Cancer Detect Prev** 1996;20(3):218–22

p53 and K-ras in radon-associated lung adenocarcinoma. McDonald JW, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):791–3

Detection of K-ras mutation in a patient with multiple tumors [letter] Kadam P, et al. **Cancer Genet Cytogenet** 1996 Feb; 86(2):181–2

Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Taylor P, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):179–84

p53 gene mutation in thyroid carcinoma. Ho YS, et al. **Cancer Lett** 1996 May 15;103(1):57–63

p53 mutations in gastric cancers from Taiwan. Hsieh LL, et al. **Cancer Lett** 1996 Feb 27;100(1-2):107–13

G --> A mutation of ras genes and infrequent p53 gene mutation in rat transplantable thyroid carcinoma lines from tumors induced in vivo by N-bis(2-hydroxypropyl)nitrosamine. Kitahori Y, et al. **Cancer Lett** 1996 Feb 27;100(1-2):55–62

Frequent mutations of Ki-ras codon 12 in N-bis (2-hydroxypropyl)-nitrosamine-initiated thyroid, kidney and lung tumors in Wistar rats. Kitahori Y, et al. **Cancer Lett** 1995 Sep 25;96(2):155–61

p53 point mutation and survival in colorectal cancer patients. Goh HS, et al. **Cancer Res** 1995 Nov 15;55(22):5217–21

Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. Kubo A, et al. **Cancer Res** 1996 Mar 15;56(6):1232–6

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Marsh DJ, et al. **Cancer Res** 1996 Mar 15;56(6):1241–3

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Righetti SC, et al. **Cancer Res** 1996 Feb 15;56(4):689–93

p27/Kip1 mutation found in breast cancer. Spirin KS, et al. **Cancer Res** 1996 May 15;56(10):2400–4

p53 mutations in bladder tumors from arylamine-exposed workers. Taylor JA, et al. **Cancer Res** 1996 Jan 15; 56(2):294–8

ATM mutations in cancer families. Vořechovský I, et al. **Cancer Res** 1996 Sep 15;56(18):4130–3

A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Imai Y, et al. **Carcinogenesis** 1995 Oct;16(10):2441–5

Separation of transforming amino acid-substituting mutations in codons 12, 13 and 61 the N-ras gene by constant denaturant capillary electrophoresis (CDCE). Kumar R, et al. **Carcinogenesis** 1995 Nov;16(11):2667–73

Molecular analysis of mutations induced by 2-chloroacetaldehyde, the ultimate carcinogenic form of vinyl chloride, in human cells using shuttle vectors. Matsuda T, et al. **Carcinogenesis** 1995 Oct;16(10):2389–94

K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Matzinger SA, et al. **Carcinogenesis** 1995 Oct;16(10):2487-92

Mutagenic specificities and adduct distributions for 7-bromomethylbenz[a]anthracenes. Page JE, et al. **Carcinogenesis** 1996 Feb;17(2):283-8

p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Soini Y, et al. **Carcinogenesis** 1995 Nov;16(11):2879-81

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Chen H, et al. **Cell** 1996 Feb 9;84(3):491-5

Optimization of the PCR test for the mutation causing bovine leukocyte adhesion deficiency. Mirck MH, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):695-8

p53 mutations in non-small cell lung carcinomas in Hong Kong. Lung ML, et al. **Chest** 1996 Mar;109(3):718-26

Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood. Schiffer D, et al. **Childs Nerv Syst** 1995 Sep;11(9):517-22

Screening for mitochondrial DNA (mtDNA) point mutations using nonradioactive single strand conformation polymorphism (SSCP) analysis. Jaksch M, et al. **Clin Biochem** 1995 Oct;28(5):503-9

Three different point mutations in the butyrylcholinesterase gene of three Japanese subjects with a silent phenotype: possible Japanese type alleles. Sudo K, et al. **Clin Biochem** 1996 Apr;29(2):165-9

Nonisotopic detection of point mutations in CYP21B gene in steroid 21-hydroxylase deficiency. Ezquieta B, et al. **Clin Chem** 1996 Jul;42(7):1108-10

Identification of mutated p53 in cancer by non-gel-sieving capillary electrophoretic SSCP analysis [letter] Oto M, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1787-8

Amplification refractory mutation system to identify mutations in cystathionine beta-synthase deficiency. Tsai MY, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1775-7

Detection of point mutations in T lymphocytes. van Zeeland AA, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1841-3

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Marsh DJ, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):249-57

Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings. Ferlini A, et al. **Clin Genet** 1996 Jan;49(1):10-4

A novel insertional mutation of a single base on exon 12 of the dystrophin gene. Lasa A, et al. **Clin Genet** 1995 Sep; 48(3):128-30

Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Mrozikiewicz PM, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):376-82

Sequence repeat-induced disruption of the major heat-inducible HSP70 gene of Neurospora crassa. Chakraborty BN, et al. **Curr Genet** 1995 Dec;29(1):18-26

A point mutation in the 5'-untranslated leader that affects translational activation of the mitochondrial COX3 mRNA. Costanzo MC, et al. **Curr Genet** 1995 Jun;28(1):60-6

Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Singer MJ, et al. **Curr Top Microbiol Immunol** 1995; 197:165-77 (54 ref.)

'oint mutation analysis of archived cytogenetic slide DNA. Sago H, et al. **Cytogenet Cell Genet** 1996;73(4):343-6

Detection of a point mutation in poliovaccines with a water soluble carbodiimide reaction of DNA heteroduplexes. Amexis G, et al. **Dev Biol Stand** 1996;86:325

The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. Hansen LH, et al. **Diabetes** 1996 Jun;45(6):725-30

Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Inoue H, et al. **Diabetes** 1996 Jun;45(6):825-31

Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Sakagashira S, et al. **Diabetes** 1996 Sep; 45(9):1279-81

Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Velho G, et al. **Diabetes** 1996 Apr;45(4):478-87

Role of mitochondrial DNA tRNA leucine and glucagon receptor missense mutations in Utah white diabetic patients. Elbein SC, et al. **Diabetes Care** 1996 May;19(5):507-8

Absence of the Gly40-Ser mutation in the glucagon receptor among diabetic patients in the Netherlands [letter] Hart LM, et al. **Diabetes Care** 1995 Oct;18(10):1400-1

Insulin sensitivity in patients with NIDDM and the A-to-G mutation at nucleotide 3,243 of the mitochondrial tRNALeu(UUR) gene [letter] Iwasaki N, et al. **Diabetes Care** 1995 Jun;18(6):886-8

Glucokinase gene variants in subjects with late-onset NIDDM and impaired glucose tolerance. Laakso M, et al. **Diabetes Care** 1995 Mar;18(3):398-400

Unpleasant alcohol effect in diabetes associated with 3243 bp mitochondrial tRNALeu(UUR) mutation [letter] Suzuki Y, et al. **Diabetes Care** 1995 Jun;18(6):880-1

Extra-pancreatic manifestations in diabetes secondary to mitochondrial DNA point mutation within the tRNALeu(UUR) gene. Vialettes B, et al. **Diabetes Care** 1995 Jul;18(7):1023-8

Insulin and proinsulin secretion in subjects with abnormal glucose tolerance and a mitochondrial tRNA(Leu(UUR)) mutation [letter] Walker M, et al. **Diabetes Care** 1995 Nov; 18(11):1507-9

A patient with diabetes mellitus, cardiomyopathy, and a mitochondrial gene mutation: confirmation of a gene mutation in cardiac muscle. Kitaoka H, et al. **Diabetes Res Clin Pract** 1995 Jun;28(3):207-12

Macroangiopathy in a case of diabetes mellitus with mitochondrial tRNA(Leu)(UUR) mutation at position 3243 [letter] Suzuki Y, et al. **Diabetes Res Clin Pract** 1995 Jul; 29(1):69-71

A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the association with diabetes mellitus [see comments] Fujisawa T, et al. **Diabetologia** 1995 Aug; 38(8):983-5. Comment in: Diabetologia 1996 Feb;39(2):248.

Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Fujisawa T, et al. **Diabetologia** 1996 Mar;39(3):349-52

Lack of association between the Gly40Ser polymorphism in the glucagon receptor gene and NIDDM in Finland. Huang X, et al. **Diabetologia** 1995 Oct;38(10):1246-8

Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375-82 (53 ref.)

Are MELAS and diabetes mellitus caused solely by the same mutation at np 3243 of the mitochondrial gene? [letter] Odawara M, et al. **Diabetologia** 1995 Dec;38(12):1488-90

Decreased cerebral blood perfusion in an NIDDM patient with an A-to-G mutation in the mitochondrial gene; a possible contribution to cognition deficits in diabetes [comment] Odawara M, et al. **Diabetologia** 1995 Aug; 38(8):1004-5. Comment on: Diabetologia 1994 Jul;37(7):643-50.

Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA? [letter] Silvestre-Aillaud P, et al. **Diabetologia** 1995 Dec; 38(12):1485-6

HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. Tao T, et al. **Diabetologia** 1995 Aug;38(8):942-7

Variant sequences of the Hexokinase II gene in familial NIDDM. Taylor RW, et al. **Diabetologia** 1996 Mar; 39(3):322-8

Large-scale study of an A-to-G transition at position 3243 of the mitochondrial gene and IDDM in Japanese patients [letter] Uchigata Y, et al. **Diabetologia** 1996 Feb;39(2):245-6

Mutation in the mitochondrial tRNA(leu) at position 3243 and spontaneous abortions in Japanese women attending a clinic for diabetic pregnancies. Yanagisawa K, et al. **Diabetologia** 1995 Jul;38(7):809-15

Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Bosari S, et al. **Diagn Mol Pathol** 1995 Dec; 4(4):249-55

Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Liu XY, et al. **Diagn Mol Pathol** 1995 Sep;4(3):191-7

Frequent K-ras mutations in small bowel adenocarcinomas. Sutter T, et al. **Dig Dis Sci** 1996 Jan;41(1):115-8

Analysis of thyroid stimulating hormone-receptor mutations by temperature-gradient gel electrophoresis. Koch M, et al. **Electrophoresis** 1995 May;16(5):742-3

Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. Delaney SJ, et al. **EMBO J** 1996 Mar 1;15(5):955-63

Activating point mutations in the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors suggest the involvement of beta subunit dimerization and cell type-specific molecules in signalling. Jenkins BJ, et al. **EMBO J** 1995 Sep 1;14(17):4276-87

A point mutation in the microtubule binding region of the Ncd motor protein reduces motor velocity. Moore JD, et al. **EMBO J** 1996 Jul 1;15(13):3306-14

Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease. Okamoto T, et al. **EMBO J** 1996 Aug 1;15(15):3769-77

Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Webster MK, et al. **EMBO J** 1996 Feb 1;15(3):520-7

Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. Yamatsuji T, et al. **EMBO J** 1996 Feb 1;15(3):498-509

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S, et al. **Endocr J** 1995 Aug;42(4):527-36

Divergence between genotype and phenotype in relatives of patients with the intron 2 mutation of steroid-21-hydroxylase. Schulze E, et al. **Endocr Res** 1995 Feb-May;21(1-2):359-64

Structure-function studies on mutants of adrenal ferredoxin. Uhlmann H, et al. **Endocr Res** 1995 Feb-May; 21(1-2):307-12

Effects of Asn318 and Asp87Asn318 mutations on signal transduction by the gonadotropin-releasing hormone receptor and receptor regulation. Awara WM, et al. **Endocrinology** 1996 Feb;137(2):655-62

Analysis of in vivo mutation induced by N-ethyl-N-nitrosourea in the hprt gene of rat lymphocytes. Mittelstaedt RA, et al. **Environ Mol Mutagen** 1995;26(4):261-9

Reconsideration of the genetic risk assessment for ethylene oxide exposures. Preston RJ, et al. **Environ Mol Mutagen** 1995;26(3):189-202

Analysis of point mutations in the hprt gene of cancer patients treated with radioimmunoglobulin therapy. Skandalis A, et al. **Environ Mol Mutagen** 1995;26(3):213-7

Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125Cys or 127Ser. Xu D, et al. **Eur Cytokine Netw** 1995 Jul-Dec;6(4):237-44

Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille). Bezeaud A, et al. **Eur J Biochem** 1995 Nov 15;234(1):140-7

A single point mutation in the splice donor site of the low-density-lipoprotein-receptor gene produces intron read-through, exon-skipped and cryptic-site-utilized transcripts. Maruyama T, et al. **Eur J Biochem** 1995 Sep 15;232(3):700-5

Point mutations in the hydrophobic C-terminal region of ricin A chain indicate that Pro250 plays a key role in membrane translocation. Simpson JC, et al. **Eur J Biochem** 1995 Sep 1;232(2):458-63

Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. Shipman R, et al. **Eur J Cancer** 1996 Feb;32A(2):335-41

NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16). Panagopoulos I, et al. **Eur J Haematol** 1996 Jan-Feb;56(1-2):68-71

Identification of two new mutations in congenital erythropoietic porphyria. Bensidhoum M, et al. **Eur J Hum Genet** 1995;3(2):102-7

In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. Guldberg P, et al. **Eur J Pediatr** 1995 Jul;154(7):551-6

p53 mutations and overexpressions in Japanese breast cancer. Fukushima T, et al. **Eur J Surg Oncol** 1995 Dec; 21(6):595-600

Detection of point mutations in human tyrosinase gene by improved allele-specific amplification. Matsunaga J, et al. **Exp Dermatol** 1995 Dec;4(6):377-81

Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine platinum (cp) mutation. Beermann F, et al. **Exp Eye Res** 1995 Nov;61(5):599-607

A point mutation in the mitochondrial DNA of diabetes-prone BHE/cdb rats. Mathews CE, et al. **FASEB J** 1995 Dec;9(15):1638-42

Site-directed mutagenesis of Lys600 in phosphoenolpyruvate carboxylase of Flaveria trinervia: its roles in catalytic and regulatory functions. Gao Y, et al. **FEBS Lett** 1995 Nov 13;375(1-2):95-8

An actin point-mutation neighboring the 'hydrophobic plug' causes defects in the maintenance of cell polarity and septum organization in the fission yeast Schizosaccharomyces pombe. Ishiguro J, et al. **FEBS Lett** 1996 Sep 2;392(3):237-41

Keratin 9 point mutation in the pedigree of epidermolytic hereditary palmoplantar keratoderma perturbs keratin intermediate filament network formation. Kobayashi S, et al. **FEBS Lett** 1996 May 20;386(2-3):149-55

Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells. Lapie P, et al. **FEBS Lett** 1996 Mar 18;382(3):244-8

The weaver mutation changes the ion selectivity of the affected inwardly rectifying potassium channel GIRK2. Tong Y, et al. **FEBS Lett** 1996 Jul 15;390(1):63-8

The rate of thermal inactivation of Torpedo acetylcholinesterase is not reduced in the C231S mutant. Wilson EJ, et al. **FEBS Lett** 1996 Jan 29;379(2):161-4

Effect of single point mutations in citrate synthase on binding to GroEL. Zahn R, et al. **FEBS Lett** 1996 Feb 12; 380(1-2):152-6

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer [see comments] Iguchi H, et al. **Gastroenterology** 1996 Jan;110(1):221-6. Comment in: Gastroenterology 1996 Jan;110(1):306-10.

Construction of lacIts and lacIqts expression plasmids and evaluation of the thermosensitive lac repressor. Hasan N, et al. **Gene** 1995 Sep 22;163(1):35-40

Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human amyloid precursor protein gene. Duff K, et al. **Gene Ther** 1994 Jan;1(1):70-5

Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Ohnishi H, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):187-90

Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Telling GC, et al. **Genes Dev** 1996 Jul 15;10(14):1736-50

Rapid detection of common Chinese glucose-6-phosphate dehydrogenase (G6PD) mutations by denaturing gradient gel electrophoresis (DGGE). Lam VM, et al. **Genet Anal** 1996 Mar;12(5-6):201-6

Amino acid polymorphism and rare electrophoretic variants of G6PD from natural populations of Drosophila melanogaster. Eanes WF, et al. **Genetics** 1996 May; 143(1):401-6

The vacuolar ATPase of Neurospora crassa is indispensable: inactivation of the vma-1 gene by repeat-induced point mutation. Ferea TL, et al. **Genetics** 1996 May;143(1):147-54

Estimating substitution rates in ribosomal RNA genes.

Rzhetsky A. **Genetics** 1995 Oct;141(2):771–83

Two distinct temperature-sensitive alleles at the elav locus of Drosophila are suppressed nonsense mutations of the same tryptophan codon. Samson ML, et al. **Genetics** 1995 Nov;141(3):1101–11

A Crouzon syndrome synonymous mutation activates a 5' splice site within the IIIc exon of the FGFR2 gene. Del Gatto F, et al. **Genomics** 1995 Jun 10;27(3):558–9

Identification, expression, and pharmacology of a Cys23–Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Lappalainen J, et al. **Genomics** 1995 May 20;27(2):274–9

A homozygous nonsense mutation in the alpha 3 chain gene of laminin 5 (LAMA3) in Herlitz junctional epidermolysis bullosa: prenatal exclusion in a fetus at risk. McGrath JA, et al. **Genomics** 1995 Sep 1;29(1):282–4

Human fructose-1,6-bisphosphatase gene (FBP1): exon-intron organization, localization to chromosome bands 9q22.2–q22.3, and mutation screening in subjects with fructose-1,6-bisphosphatase deficiency. el-Maghrabi MR, et al. **Genomics** 1995 Jun 10;27(3):520–5

Cloning of the canine GALC cDNA and identification of the mutation causing globoid cell leukodystrophy in West Highland White and Cairn terriers. Victoria T, et al. **Genomics** 1996 May 1;33(3):457–62

Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Westberg J, et al. **Genomics** 1995 Sep 1;29(1):1–8

K-ras gene mutation in gall bladder carcinomas and dysplasia. Ajiki T, et al. **Gut** 1996 Mar;38(3):426–9

Clinical relevance of mutations in the precore genome of the hepatitis B virus. Tillmann H, et al. **Gut** 1995 Oct; 37(4):568–73

The PIG-A gene somatic mutation responsible for paroxysmal nocturnal hemoglobinuria. Rotoli B, et al. **Haematologica** 1995 Nov-Dec;80(6):539–45 (44 ref.)

Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. Yamauchi-Takihara K, et al. **Heart** 1996 Jul;76(1):63–5

Two fetal hemoglobin variants affecting the same residue: Hb F-Emirates [G gamma 59(E3)Lys-->Glu] and Hb F-Sacromonte [G gamma 59(E3)Lys-->Gln] Abbes S, et al. **Hemoglobin** 1995 May-Jul;19(3-4):173–82

A newly discovered beta O-thalassemia (IVS-II-850, G-->A) mutation in a north European family. Cürük MA, et al. **Hemoglobin** 1995 May-Jul;19(3-4):207–11

Hb Hakkari or alpha 2 beta 2 31(B13)Leu-->Arg, a severely unstable hemoglobin variant associated with numerous intra-erythroblastic inclusions and erythroid hyperplasia of the bone marrow. Gürgey A, et al. **Hemoglobin** 1995 May-Jul;19(3-4):165–72

Hb Kurosaki [alpha 7(A5)Lys-->Glu]: a new alpha chain variant found in a Japanese woman. Harano T, et al. **Hemoglobin** 1995 May-Jul;19(3-4):197–201

HB Mizuho or alpha 2 beta 2 68(E12)Leu-->Pro in a young Dutch boy. Harthoorn-Lasthuizen EJ, et al. **Hemoglobin** 1995 May-Jul;19(3-4):203–6

Hb Bibba or alpha 2 136(H19)Leu-->Pro beta 2 in a Caucasian family from Alabama. Prchal JT, et al. **Hemoglobin** 1995 May-Jul;19(3-4):151–64

High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Bozkaya H, et al. **Hepatology** 1996 Jul;24(1):32–7

Molecular analysis of the cystinuria disease gene: identification of four new mutations, one large deletion, and one polymorphism. Bisceglia L, et al. **Hum Genet** 1996 Oct;98(4):447–51

Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Braun A, et al. **Hum Genet** 1996 Feb;97(2):263–4

Detection of a de novo R1066H mutation in an Italian patient affected by cystic fibrosis. Cremonesi L, et al. **Hum Genet** 1996 Jul;98(1):119–21

Four adult patients with the missense mutation L206W and a mild cystic fibrosis phenotype. Desgeorges M, et al. **Hum Genet** 1995 Dec;96(6):717–20

Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. De Vitis LR, et al. **Hum Genet** 1996 May;97(5):638–41

Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Erdmann J, et al. **Hum Genet** 1996 May;97(5):614–9

Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Ferrando AA, et al. **Hum Genet** 1996 Jan;97(1):91–4

Characterization of two stop codon mutations in the galactose-1-phosphate uridyltransferase gene of three male galactosemic patients with severe clinical manifestation. Gathof BS, et al. **Hum Genet** 1995 Dec;96(6):721–5

Identification of the nucleotide substitution that generates the fourth polymorphic site in human deoxyribonuclease I (DNase I). Iida R, et al. **Hum Genet** 1996 Oct;98(4):415–8

Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure. Ko YL, et al. **Hum Genet** 1996 May; 97(5):585–90

The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: an analysis of 618 individuals. Ko YL, et al. **Hum Genet** 1996 Aug;98(2):176–7

A new mechanism in blue cone monochromatism. Ladekjaer-Mikkelsen AS, et al. **Hum Genet** 1996 Oct; 98(4):403–8

Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM, et al. **Hum Genet** 1996 Jan;97(1):11–4

The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism. Løvlie R, et al. **Hum Genet** 1996 Aug; 98(2):129–33

No evidence of genetic heterogeneity in Crouzon craniofacial dysostosis. Ma HW, et al. **Hum Genet** 1995 Dec;96(6):731–5

Three novel mutations in the interleukin-2 receptor gamma chain gene in four Japanese patients with X-linked severe combined immunodeficiency. Minegishi Y, et al. **Hum Genet** 1995 Dec;96(6):681–3

A new point mutation affecting the fourth transmembrane domain of PMP22 results in severe de novo Charcot-Marie-Tooth disease. Navon R, et al. **Hum Genet** 1996 May;97(5):685–7

Chinese achondroplasia is also defined by recurrent G380R mutations of the fibroblast growth factor receptor-3 gene. Niu DM, et al. **Hum Genet** 1996 Jul;98(1):65–7

A point mutation in exon 7 of the C1-inhibitor gene causing type I hereditary angioedema. Ono H, et al. **Hum Genet** 1996 Oct;98(4):452–3

A novel point mutation in congenital erythropoietic porphyria in two members of Japanese family. Tanigawa K, et al. **Hum Genet** 1996 May;97(5):557–60

A novel mutation in exon 17 of the beta-subunit of rod phosphodiesterase in two RP sisters of a consanguineous family. Valverde D, et al. **Hum Genet** 1996 Jan;97(1):35–8

Germline mosaicism for an alanine to valine substitution at residue beta 140 in hemoglobin Puttelange, a new variant with high oxygen affinity. Wajcman H, et al. **Hum Genet** 1995 Dec;96(6):711–6

Two novel gene mutations (Glu174-->Lys, Phe383-->Tyr) causing the "hepatic" form of carnitine palmitoyltransferase II deficiency. Yamamoto S, et al. **Hum Genet** 1996 Jul; 98(1):116–8

A method for rapid detection of arylsulfatase A pseudodeficiency mutations. Ricketts MH, et al. **Hum Hered** 1995 Jul-Aug;45(4):235–40

Biochemical characteristics of four common molecular variants in glucose-6-phosphate dehydrogenase-deficient Chinese in Singapore. Saha N, et al. **Hum Hered** 1995 Sep-Oct;45(5):253–7

Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Browne DL, et al. **Hum Mol Genet** 1995 Sep;4(9):1671–2

A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Bueno MR, et al. **Hum Mol Genet** 1995 Jul;4(7):1163–7

Pretibial epidermolysis bullosa: genetic linkage to COL7A1 and identification of a glycine-to-cysteine substitution in the triple-helical domain of type VII collagen. Christiano AM, et al. **Hum Mol Genet** 1995 Sep;4(9):1579–83

A G+1-->A transversion at the 5' splice site of intron 69 of the dystrophin gene causing the absence of peripheral nerve Dp116 and severe clinical involvement in a DMD patient. Comi GP, et al. **Hum Mol Genet** 1995 Nov; 4(11):2171–4

Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Kitamura Y, et al. **Hum Mol Genet** 1995 Oct;4(10):1987–8

Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Knappskog PM, et al. **Hum Mol Genet** 1995 Jul; 4(7):1209–12

Scanning of the Wiskott-Aldrich syndrome (WAS) gene: identification of 18 novel alterations including a possible mutation hotspot at Arg86 resulting in thrombocytopenia, a mild WAS phenotype. Kwan SP, et al. **Hum Mol Genet** 1995 Oct;4(10):1995–8

A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Laue L, et al. **Hum Mol Genet** 1995 Aug;4(8):1429–33

Do sequence variants in the major non-coding region of the mitochondrial genome influence mitochondrial mutations associated with disease? Marchington DR, et al. **Hum Mol Genet** 1996 Apr;5(4):473–9

A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame). Matsuda M, et al. **Hum Mol Genet** 1995 Jul; 4(7):1187–91

Epidermolysis bullosa simplex (Weber-Cockayne) associated with a novel missense mutation of Asp328 to Val in Linker 12 domain of keratin 5. Matsuki M, et al. **Hum Mol Genet** 1995 Oct;4(10):1999–2000

Multiple independent occurrence of the 3243 mutation in mitochondrial tRNA(leuUUR) in patients with the MELAS phenotype. Morten KJ, et al. **Hum Mol Genet** 1995 Sep;4(9):1689–91

Novel mutations and inactivation of both alleles of the APC gene in desmoid tumors. Palmirotta R, et al. **Hum Mol Genet** 1995 Oct;4(10):1979–81

A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). Peral B, et al. **Hum Mol Genet** 1996 Apr;5(4):539–42

Detection of BRCA1 mutations by the protein truncation test. Plummer SJ, et al. **Hum Mol Genet** 1995 Oct; 4(10):1989–91

A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. Rafi MA, et al. **Hum Mol Genet** 1995 Aug; 4(8):1285–9

A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Reymer PW, et al. **Hum Mol Genet** 1995 Sep;4(9):1543–9

Double mutant alleles: are they rare? Savov A, et al. **Hum Mol Genet** 1995 Jul;4(7):1169–71

Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. Shamsher MK, et al. **Hum Mol Genet** 1995 Oct;4(10):1875–81

A novel mutation in the Norrie disease gene predicted to disrupt the cystine knot growth factor motif. Strasberg P, et al. **Hum Mol Genet** 1995 Nov;4(11):2179–80

Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Suzuki H, et al. **Hum Mol Genet** 1995 Oct;4(10):1883–7

Intronic point mutation in the IL2RG gene causing X-linked severe combined immunodeficiency. Tassara C, et al. **Hum Mol Genet** 1995 Sep;4(9):1693–5

Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Tavormina PL, et al. **Hum Mol Genet** 1995 Nov;4(11):2175–7

T-->A transversion 11 bp from a splice acceptor site in the human gene for steroidogenic acute regulatory protein causes congenial lipoid adrenal hyperplasia. Tee MK, et al. **Hum Mol Genet** 1995 Dec;4(12):2299–305

Maternally inherited hearing loss, ataxia and myoclonus associated with a novel point mutation in mitochondrial tRNASer(UCN) gene. Tiranti V, et al. **Hum Mol Genet** 1995 Aug;4(8):1421–7

A novel nonsense mutation in the PKD1 gene (C3817T) is associated with autosomal dominant polycystic kidney disease (ADPKD) in a large three-generation Italian family. Turco AE, et al. **Hum Mol Genet** 1995 Aug; 4(8):1331–5

A newly identified aldolase B splicing mutation (G-->C, 5' intron 5) in hereditary fructose intolerance from New Zealand. Ali M, et al. **Hum Mutat** 1996;7(2):155–7

Novel nonsense mutation in the hypoxanthine guanine phosphoribosyltransferase gene and nonrandom X-inactivation causing Lesch-Nyhan syndrome in a female patient. Aral B, et al. **Hum Mutat** 1996;7(1):52–8

A novel missense mutation in exon 16 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene identified in CBAVD patients. Bienvenu T, et al. **Hum Mutat** 1996;7(2):182

Missense mutation A346P in the rhodopsin gene in one family with autosomal dominant retinitis pigmentosa. Borrego S, et al. **Hum Mutat** 1996;7(2):180–1

Two new nonsense mutations (Q80X; Q389X) in patients with severe Hunter syndrome (mucopolysaccharidosis type II.) Carrozzo R, et al. **Hum Mutat** 1996;7(2):184–5

A missense (T577I) mutation in the luteinizing hormone receptor gene associated with familial male-limited precocious puberty. Cocco S, et al. **Hum Mutat** 1996; 7(2):164–6

A novel splice-site mutation in the CD40L gene in a patient with X-linked hyper-IgM syndrome. Dezsö D, et al. **Hum Mutat** 1996;7(2):181–2

Mucopolysaccharidosis IVA: submicroscopic deletion of 16q24.3 and a novel R386C mutation of N-acetylgalactosamine-6-sulfate sulfatase gene in a classical Morquio disease. Fukuda S, et al. **Hum Mutat** 1996;7(2):123–34

Rapid detection of point mutations and polymorphisms of the alpha-globin genes by DGGE and SSCA. Harteveld KL, et al. **Hum Mutat** 1996;7(2):114–22

Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. Ireland HA, et al. **Hum Mutat** 1996;7(2):176–9

Two point mutations (313 + 1G --> A and 313 + 1G --> T) in the splice donor site of intron 3 of the low-density lipoprotein receptor gene are associated with familial hypercholesterolemia. Jensen HK, et al. **Hum Mutat** 1996;7(3):269–71

An LDL receptor promoter mutation in a heterozygous FH patient with dramatically skewed ratio between the two allelic mRNA variants. Jensen LG, et al. **Hum Mutat** 1996; 7(1):82–4

Efficient strategy for the detection of mutations in acrogeric Ehlers-Danlos syndrome type IV. Johnson PH, et al. **Hum Mutat** 1995;6(4):336–42

New point mutation (R301X) of the alpha-galactosidase A gene causing Fabry disease. Kawanishi C, et al. **Hum Mutat** 1995;6(2):186–7

Identification of a novel single base insertion in the adenomatous polyposis coli gene. Kotze MJ, et al. **Hum Mutat** 1996;7(1):68–9

A novel G499D substitution in the alpha 1(III) chain of type III collagen produces variable forms of Ehlers-Danlos syndrome type IV. McGrory J, et al. **Hum Mutat** 1996;

7(1):59–60
Identification of two sporadically derived mutations in the Von Hippel–Lindau gene. Martin RL, et al. **Hum Mutat** 1996;7(2):185
Human androgen insensitivity due to point mutations encoding amino acid substitutions in the androgen receptor steroid–binding domain. Murono K, et al. **Hum Mutat** 1995; 6(2):152–62
New point mutation (R243W) in the hormone binding domain of the c–erbA beta 1 gene in a family with generalized resistance to thyroid hormone. Pohlenz J, et al. **Hum Mutat** 1996;7(1):79–81
Nonsense mutations in a Becker muscular dystrophy and an intermediate patient. Prior TW, et al. **Hum Mutat** 1996; 7(1):72–5
A novel null mutation in the rhodopsin gene causing late onset autosomal dominant retinitis pigmentosa. Sánchez B, et al. **Hum Mutat** 1996;7(2):180
Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate–2–sulfatase gene in Japanese patients. Sukegawa K, et al. **Hum Mutat** 1995;6(2):136–43
Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging. ↓ Hart LM, et al. **Hum Mutat** 1996; 7(3):193–7
Novel mutations in the connexin 32 gene associated with X–linked Charcot–Marie tooth disease. Tan CC, et al. **Hum Mutat** 1996;7(2):167–71
Protein truncation test: analysis of two novel point mutations at the carboxy–terminus of the human dystrophin gene associated with mental retardation. Tuffery S, et al. **Hum Mutat** 1995;6(2):126–35
Substitution of A1498D in noncollagen domain of a5(IV) collagen chain associated with adult–onset X–linked Alport syndrome. Tverskaya S, et al. **Hum Mutat** 1996;7(2):149–50
Rapid restriction fragment analysis for screening four point mutations of the low–density lipoprotein receptor gene in French Canadians. Vohl MC, et al. **Hum Mutat** 1995; 6(3):243–6
HLA–A null allele with a stop codon, HLA–A*0215N, identified in a homozygous state in a healthy adult. Ishikawa Y, et al. **Immunogenetics** 1996;43(1–2):1–5
Identification of C to T mutation at position –236 bp in the human NRAMP1 gene promoter. Lewis LA, et al. **Immunogenetics** 1996;44(4):309–11
Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Lipscombe RJ, et al. **Immunology** 1995 Aug; 85(4):660–7
Maintenance of growth factor signaling through Ras in human colon carcinoma cells containing K–ras mutations. Buard A, et al. **Int J Cancer** 1996 Aug 7;67(4):539–46
Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well–differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR–SSCP. Gomyo Y, et al. **Int J Cancer** 1996 May 29;66(5):594–9
Detection of K–ras mutations in stools of patients with colorectal cancer by mutant–enriched PCR. Nollau P, et al. **Int J Cancer** 1996 May 3;66(3):332–6
A detailed analysis of K–ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Span M, et al. **Int J Cancer** 1996 Jun 21;69(3):241–5
Frequent occurrence of c–Ki–ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Tsuda H, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):255–9
Double mutations of the N–ras gene in a patient with acute myelomonocytic leukemia. Horiike S, et al. **Int J Hematol** 1995 Jun;61(4):205–13
Identification of the antithrombin III Kyoto mutation by restriction fragment length polymorphism analysis. Masuda H, et al. **Int J Hematol** 1995 Jun;61(4):197–204
The Bcl I polymorphism of the human uncoupling protein (ucp) gene is due to a point mutation in the 5'–flanking region. Cassard–Doulcier AM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):278–9
Detection of point mutations in K–ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. Ajiki T, et al. **Int J Pancreatol** 1995 Dec;18(3):215–20
Mutations in the p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Hillebrandt S, et al. **Int J Radiat Biol** 1996 Jan;69(1):39–45
Mitochondrial encephalomyopathy with A to G transition of mitochondrial transfer RNA(Leu(UUR)) 3,243 presenting hypertrophic cardiomyopathy. Hiruta Y, et al. **Intern Med** 1995 Jul;34(7):670–3
Hypertrophic cardiomyopathy in patients with diabetes mellitus associated with mitochondrial tRNA(Leu)(UUR) gene mutation [see comments] Yoshida R, et al. **Intern Med** 1995 Oct;34(10):953–8. Comment in: Intern Med 1995 Oct;34(10):931–2.
Clinicopathologic effects of the Q64ter rhodopsin mutation in retinitis pigmentosa. Milam AH, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):753–65
Light–induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Naash ML, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):775–82
Low incidence of retinitis pigmentosa among heterozygous carriers of a specific rhodopsin splice site mutation. Rosenfeld PJ, et al. **Invest Ophthalmol Vis Sci** 1995 Oct; 36(11):2186–92
Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4–quinolone drugs. Brown JC, et al. **J Antimicrob Chemother** 1996 Feb;37(2):351–6
Mutational analysis of a transmembrane segment in a bacterial chemoreceptor. Baumgartner JW, et al. **J Bacteriol** 1996 Aug;178(15):4651–60
Isolation of a pdxJ point mutation that bypasses the requirement for the PdxH oxidase in pyridoxal 5' –phosphate coenzyme biosynthesis in Escherichia coli K–12. Man TK, et al. **J Bacteriol** 1996 Apr;178(8):2445–9
Isolation and analysis of a fur mutant of Neisseria gonorrhoeae. Thomas CE, et al. **J Bacteriol** 1996 Jul; 178(14):4224–32
Cloning and sequence of the SCS2 gene, which can suppress the defect of INO1 expression in an inositol auxotrophic mutant of Saccharomyces cerevisiae. Nikawa J, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):39–45
Effects of point mutations at the flexible loop glycine–67 of Escherichia coli dihydrofolate reductase on its stability and function. Ohmae E, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):703–10
Decoupling of the bc1 complex in S. cerevisiae; point mutations affecting the cytochrome b gene bring new information about the structural aspect of the proton translocation. Bruel C, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):527–39
Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha–catenin. Aberle H, et al. **J Biol Chem** 1996 Jan 19;271(3):1520–6
Kinetic characterization of channel impaired mutants of tryptophan synthase. Anderson KS, et al. **J Biol Chem** 1995 Dec 15;270(50):29936–44
Substitutions of serine 775 in the alpha subunit of the Na,K–ATPase selectively disrupt K+ high affinity activation without affecting Na+ interaction. Argüello JM, et al. **J Biol Chem** 1995 Sep 29;270(39):22764–71
Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin–releasing hormone receptor. Arora KK, et al. **J Biol Chem** 1995 Sep 29;270(39):22820–6
An intramolecular triplex in the human gamma–globin 5'–flanking region is altered by point mutations associated with hereditary persistence of fetal hemoglobin. Bacolla A, et al. **J Biol Chem** 1995 Oct 13;270(41):24556–63
Overproduction of DNA cytosine methyltransferases causes methylation and C —> T mutations at non–canonical sites. Bandaru B, et al. **J Biol Chem** 1996 Mar 29;271(13):7851–9
Characterization of a dominant negative mutant of the cell cycle ubiquitin–conjugating enzyme Cdc34. Banerjee A, et al. **J Biol Chem** 1995 Nov 3;270(44):26209–15
Dissociation of hexameric Escherichia coli inorganic pyrophosphatase into trimers on His–136—>Gln or His–140—>Gln substitution and its effect on enzyme catalytic properties. Baykov AA, et al. **J Biol Chem** 1995 Dec 22;270(51):30804–12
Characterization of two activated mutants of human pp60c–src that escape c–Src kinase regulation by distinct mechanisms. Bjorge JD, et al. **J Biol Chem** 1995 Oct 13; 270(41):24222–8
Differential effects of Moloney murine leukemia virus reverse transcriptase mutations on RNase H activity in Mg2+ and Mn2+. Blain SW, et al. **J Biol Chem** 1996 Jan 19; 271(3):1448–54
A missense mutation in the FUT6 gene results in total absence of alpha3–fucosylation of human alpha1–acid glycoprotein. Brinkman–Van der Linden ECM, et al. **J Biol Chem** 1996 Jun 14;271(24):14492–5
Random mutagenesis of the sheep Na,K–ATPase alpha1 subunit generating the ouabain–resistant mutant L793P. Burns EL, et al. **J Biol Chem** 1996 Jul 5;271(27):15879–83
Structural studies on folding intermediates of serine hydroxymethyltransferase using single tryptophan mutants. Cai K, et al. **J Biol Chem** 1996 Feb 9;271(6):2987–94
Complementation of mutation in acyl–CoA:cholesterol acyltransferase (ACAT) fails to restore sterol regulation in ACAT–defective sterol–resistant hamster cells. Cao G, et al. **J Biol Chem** 1996 Jun 14;271(24):14642–8
A point mutation in interleukin–2 that alters ligand internalization. Chang DZ, et al. **J Biol Chem** 1996 Jun 7;271(23):13349–55
Mutations at two invariant nucleotides in the 3'–minor domain of Escherichia coli 16 S rRNA affecting translational initiation and initiation factor 3 function. Firpo MA, et al. **J Biol Chem** 1996 Mar 1;271(9):4693–8
Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. Foley BT, et al. **J Biol Chem** 1995 Sep 29;270(39):23218–25
The mitogen–activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. Gillespie–Brown J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28092–6
The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. Gimenez–Roqueplo AP, et al. **J Biol Chem** 1996 Apr 19;271(16):9838–44
Replacement of gly815 in helicase motif V alters the single–stranded DNA–dependent ATPase activity of the herpes simplex virus type 1 helicase–primase. Graves–Woodward KL, et al. **J Biol Chem** 1996 Jun 7; 271(23):13629–35
A single point mutation in epsilon–COP results in temperature–sensitive, lethal defects in membrane transport in a Chinese hamster ovary cell mutant. Guo Q, et al. **J Biol Chem** 1996 May 10;271(19):11191–6
An insulin receptor mutant (Asp707 —> Ala), involved in leprechaunism, is processed and transported to the cell surface but unable to bind insulin. Hart LM, et al. **J Biol Chem** 1996 Aug 2;271(31):18719–24
The common I172N mutation causes conformational change of cytochrome P450c21 revealed by systematic mutation, kinetic, and structural studies. Hsu LC, et al. **J Biol Chem** 1996 Feb 9;271(6):3306–10
Identification of two amino acid residues on the extracellular domain of the lutropin/choriogonadotropin receptor important in signaling. Huang J, et al. **J Biol Chem** 1995 Dec 15;270(50):30023–8
Reaction of the C30A mutant of trimethylamine dehydrogenase with diethylmethylamine. Huang L, et al. **J Biol Chem** 1996 Jun 7;271(23):13401–6
Beta–gamma subunit interaction is required for catalysis by H(+)–ATPase (ATP synthase). Beta subunit amino acid replacements suppress a gamma subunit mutation having a long unrelated carboxyl terminus. Jeanteur–De Beukelaer C, et al. **J Biol Chem** 1995 Sep 29;270(39):22850–4
Analysis of three DnaK mutant proteins suggests that progression through the ATPase cycle requires conformational changes. Kamath–Loeb AS, et al. **J Biol Chem** 1995 Dec 15;270(50):30051–9
Electrophoretic and spectral characterization of wild type and mutant adenovirus protease. Keyvani–Amineh H, et al. **J Biol Chem** 1995 Oct 6;270(40):23250–3
Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT–AC intron. Kohrman DC, et al. **J Biol Chem** 1996 Jul 19;271(29):17576–81
Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate–1 (IRS–1) but fail to mediate the biological effects of insulin. Evidence that IRS–1 phosphorylation is not sufficient for normal insulin action. Krook A, et al. **J Biol Chem** 1996 Mar 22; 271(12):7134–40
Molecular genetic analysis of the human Lewis histo–blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. Kudo T, et al. **J Biol Chem** 1996 Apr 19; 271(16):9830–7
Structural integrity of the gamma–carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa. Larson PJ, et al. **J Biol Chem** 1996 Feb 16;271(7):3869–76
Mutant and infectious prion proteins display common biochemical properties in cultured cells. Lehmann S, et al. **J Biol Chem** 1996 Jan 19;271(3):1633–7
Histidine patch thioredoxins. Mutant forms of thioredoxin with metal chelating affinity that provide for convenient purifications of thioredoxin fusion proteins. Lu Z, et al. **J Biol Chem** 1996 Mar 1;271(9):5059–65
The role of tryptophans 371 and 395 in the binding of antibiotics and the transport of sugars by the D–galactose–H+ symport protein (GalP) from Escherichia coli. McDonald TP, et al. **J Biol Chem** 1995 Dec 22; 270(51):30359–70
Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin. Maciejewski PM, et al. **J Biol Chem** 1995 Nov 17;270(46):27661–5
The role of Phe–92 in the Ca(2+)–induced conformational transition in the C–terminal domain of calmodulin. Meyer DF, et al. **J Biol Chem** 1996 May 10;271(19):11284–90
Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. Nauseef WM, et al. **J Biol Chem** 1996 Apr 19;271(16):9546–9
A single mutation of the neurokinin–2 (NK2) receptor prevents agonist–induced desensitization. Divergent conformational requirements for NK2 receptor signaling and agonist–induced desensitization in Xenopus oocytes. Nemeth K, et al. **J Biol Chem** 1995 Nov 17;270(46):27601–5
Rescue of the catalytic activity of an H42A mutant of horseradish peroxidase by exogenous imidazoles. Newmyer SL, et al. **J Biol Chem** 1996 Jun 21;271(25):14891–6
Mutation of amino acid residues in the putative transmembrane segments of the cardiac sarcolemmal Na+–Ca2+ exchanger. Nicoll DA, et al. **J Biol Chem** 1996 Jun 7;271(23):13385–91
Protein conformational changes during the bacteriorhodopsin photocycle. A Fourier transform infrared/resonance Raman study of the alkaline form of the mutant Asp–85—>Asn. Nilsson A, et al. **J Biol Chem** 1995 Dec 15;270(50):29746–51
The effect of amino acid substitutions in the conserved aromatic region of subunit II of cytochrome c oxidase in Saccharomyces cerevisiae. Overholtzer MH, et al. **J Biol Chem** 1996 Mar 29;271(13):7719–24
The multiple endocrine neoplasia type 2B point mutation alters long–term regulation and enhances the transforming capacity of the epidermal growth factor receptor. Pandit SD, et al. **J Biol Chem** 1996 Mar 8;271(10):5850–8
Mutations in the second largest subunit of RNA polymerase II cause 6–azauracil sensitivity in yeast and increased

transcriptional arrest in vitro. Powell W, et al. **J Biol Chem** 1996 Mar 22;271(12):6866–73

Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. Rosing J, et al. **J Biol Chem** 1995 Nov 17;270(46):27852–8

Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. Rossi A, et al. **J Biol Chem** 1996 Aug 2;271(31):18456–64

Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. Seibert FS, et al. **J Biol Chem** 1996 Jun 21; 271(25):15139–45

DNA strand exchange promoted by RecA K72R. Two reaction phases with different Mg2+ requirements. Shan Q, et al. **J Biol Chem** 1996 Mar 8;271(10):5712–24

Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. Smith-Sørensen B, et al. **J Biol Chem** 1996 Mar 8;271(10):5513–8

A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. Songyang Z, et al. **J Biol Chem** 1995 Nov 3; 270(44):26029–32

Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Spek CA, et al. **J Biol Chem** 1995 Oct 13;270(41):24216–21

Reengineering the nucleotide cofactor specificity of the RecA protein by mutation of aspartic acid 100. Stole E, et al. **J Biol Chem** 1996 Aug 2;271(31):18326–8

Point mutations in awdKpn which revert the prune/Killer of prune lethal interaction affect conserved residues that are involved in nucleoside diphosphate kinase substrate binding and catalysis. Timmons L, et al. **J Biol Chem** 1995 Sep 29;270(39):23021–30

Induced and spontaneous mutations at Ser202 of carboxypeptidase E. Effect on enzyme expression, activity, and intracellular routing. Varlamov O, et al. **J Biol Chem** 1996 Jun 14;271(24):13981–6

Selective modification of recombinant bovine placental lactogen by site-directed mutagenesis at its C terminus. Vashdi-Elberg D, et al. **J Biol Chem** 1996 Mar 8; 271(10):5558–64

Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189 —> Phe; Gly444 —> Arg) cause impaired C2 secretion. Wetsel RA, et al. **J Biol Chem** 1996 Mar 8;271(10):5824–31

A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. Wishart MJ, et al. **J Biol Chem** 1995 Nov 10;270(45):26782–5

Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. Wong MH, et al. **J Biol Chem** 1995 Nov 10; 270(45):27228–34

Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. Xie Y, et al. **J Biol Chem** 1995 Dec 22;270(51):30717–24

Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis. Yokote K, et al. **J Biol Chem** 1996 Mar 1;271(9):5101–11

Cleavage-dependent ligation by the FLP recombinase. Characterization of a mutant FLP protein with an alteration in a catalytic amino acid. Zhu XD, et al. **J Biol Chem** 1995 Sep 29;270(39):23044–54

Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. Papp T, et al. **J Cancer Res Clin Oncol** 1996;122(9):541–8

Proliferative heterogeneity of human renal cell carcinomas and prevalence of ras gene point mutations. Waldmann V, et al. **J Cancer Res Clin Oncol** 1996;122(4):207–13

Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. Elo JP, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3494–500

An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. Gromoll J, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1367–70

Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. Gross DJ, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):147–9

Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains [see comments] Health H 3rd, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1312–7. Comment in: J Clin Endocrinol Metab 1996 Apr;81(4):1309–11.

The role of androgen receptor gene mutations in male breast carcinoma. Hiort O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3404–7

Nonisotopic single strand conformation analysis of the 5 alpha-reductase type 2 gene for the diagnosis of 5 alpha-reductase deficiency. Hiort O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3415–8

A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. Lin NU, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2564–9

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Morishima A, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3689–98

Demonstration by transfection studies that mutations in the adrenocorticotropin receptor gene are one cause of the hereditary syndrome of glucocorticoid deficiency. Naville D, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1442–8

Functional analysis of a proline to serine mutation in codon 453 of the thyroid hormone receptor beta 1 gene. Ozata M, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3239–45

Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Romei C, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1619–22

A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females. Rösler A, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1827–31

Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. Russo D, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1548–51

A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. Rutishauser J, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):192–8

A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein [see comments] Woods KA, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1686–90. Comment in: J Clin Endocrinol Metab 1996 May;81(5):1683–5.

Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. Zedenius J, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3088–90

Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. Bao Y, et al. **J Clin Invest** 1996 Feb 15;97(4):941–8

Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val —> Asp). Brennan SO, et al. **J Clin Invest** 1995 Dec;96(6):2854–8

Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. Hirata T, et al. **J Clin Invest** 1996 Feb 15;97(4):949–56

Defective anion transport and marked spherocytosis with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle due to a nonsense mutation. Inaba M, et al. **J Clin Invest** 1996 Apr 15;97(8):1804–17

Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. Kluijtmans LA, et al. **J Clin Invest** 1996 Jul 15;98(2):285–9

An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). Kuivenhoven JA, et al. **J Clin Invest** 1996 Jul 15;98(2):358–64

A unique genetic and biochemical presentation of fish-eye disease. Kuivenhoven JA, et al. **J Clin Invest** 1995 Dec; 96(6):2783–91

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase [see comments] Stafforini DM, et al. **J Clin Invest** 1996 Jun 15;97(12):2784–91. Comment in: J Clin Invest 1996 Jun 15;97(12):2689–90.

Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene. Tamura H, et al. **J Clin Invest** 1996 Apr 1;97(7):1780–4

Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport [see comments] Tripodi G, et al. **J Clin Invest** 1996 Jun 15;97(12):2815–22. Comment in: J Clin Invest 1996 Jun 15;97(12):2691.

Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. Yamamoto T, et al. **J Clin Invest** 1996 Jul 1; 98(1):30–5

Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast. Howes GP, et al. **J Clin Pathol** 1996 Jul;49(7):570–3

A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. Brändle D, et al. **J Exp Med** 1996 Jun 1;183(6):2501–8

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. Robbins PF, et al. **J Exp Med** 1996 Mar 1;183(3):1185–92

Analysis of K-ras gene mutations in periampullary cancers, gallbladder cancers and cholangiocarcinomas from paraffin-embedded tissue sections. Lee JC, et al. **J Formos Med Assoc** 1995 Dec;94(12):719–23

Late onset hepatic failure due to hepatitis B virus with mutations in the pre-core region. Takase K, et al. **J Gastroenterol** 1995 Oct;30(5):672–6

Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis. Tsuda T, et al. **J Gastroenterol** 1995 Nov; 30 Suppl 8:30–2

Aflatoxin and p53 abnormality in duck hepatocellular carcinoma. Imazeki F, et al. **J Gastroenterol Hepatol** 1995 Nov-Dec;10(6):646–9

Detection of hepatitis B virus precore stop codon mutants by selective amplification method: frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. Nakahori S, et al. **J Gastroenterol Hepatol** 1995 Jul-Aug;10(4):419–25

Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: naturally occurring escape mutants. Lee YI, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1129–38

X gene and precore region mutations in the hepatitis B virus genome in persons positive for antibody to hepatitis B e antigen: comparison between asymptomatic "healthy" carriers and patients with severe chronic active hepatitis. Fukuda R, et al. **J Infect Dis** 1995 Nov;172(5):1191–7

Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896. Lindh M, et al. **J Infect Dis** 1995 Nov;172(5):1343–7

Clinical, biochemical, and molecular analysis of a maternally inherited case of Leigh syndrome (MILS) associated with the mtDNA T8993G point mutation. Degoul F, et al. **J Inherit Metab Dis** 1995;18(6):682–8

A novel point mutation at codon 269 of the ornithine transcarbamylase (OTC) gene causing neonatal onset of OTC deficiency. Zimmer KP, et al. **J Inherit Metab Dis** 1995;18(3):356–7

The RET proto-oncogene and cancer. Donis-Keller H. **J Intern Med** 1995 Oct;238(4):319–25

Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. Gagel RF, et al. **J Intern Med** 1995 Oct;238(4):333–41

From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. Lips CJ, et al. **J Intern Med** 1995 Oct;238(4):347–56

Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Mulligan LM, et al. **J Intern Med** 1995 Oct; 238(4):343–6

Keratin 14 gene mutations in patients with epidermolysis bullosa simplex [see comments] Chen H, et al. **J Invest Dermatol** 1995 Oct;105(4):629–32. Comment in: J Invest Dermatol 1995 Oct;105(4):529–31.

Cell survival and shuttle vector mutagenesis induced by ultraviolet A and ultraviolet B radiation in a human cell line. Robert C, et al. **J Invest Dermatol** 1996 Apr; 106(4):721–8

Two novel point mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly344—>Ser). Moriyama K, et al. **J Lipid Res** 1995 Nov; 36(11):2329–43

Severe cystic fibrosis phenotype in a delta F508/3272-26A-->G compound heterozygote [letter; comment] Bienvenu T, et al. **J Med Genet** 1995 Nov; 32(11):919. Comment on: J Med Genet 1995 May;32(5):406–7.

Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen. Cole WG, et al. **J Med Genet** 1996 Mar;33(3):193–6

A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy. Felbor U, et al. **J Med Genet** 1996 Mar; 33(3):233–6

Discordant segregation of Xq28 markers and a mutation in the L1 gene in a family with X linked hydrocephalus. Jouet M, et al. **J Med Genet** 1996 Mar;33(3):248–50

Identification of constitutively activating mutation of the luteinising hormone receptor in a family with male limited gonadotrophin independent precocious puberty (testotoxicosis). Kawate N, et al. **J Med Genet** 1995 Jul; 32(7):553–4

Point mutation of the mitochondrial tRNA(Leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness. Manouvrier S, et al. **J Med Genet** 1995 Aug;32(8):654–6

Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia. O'Brien RO, et al. **J Med Genet** 1995 Nov;32(11):913–4

Mutations in L1-CAM in two families with X linked complicated spastic paraplegia, MASA syndrome, and HSAS. Ruiz JC, et al. **J Med Genet** 1995 Jul;32(7):549–52

Molecular scanning of candidate mitochondrial tRNA genes in type 2 (non-insulin dependent) diabetes mellitus. Thomas AW, et al. **J Med Genet** 1996 Mar;33(3):253–6

Prevalence of precore-defective mutant of hepatitis B virus in HBV carriers. Niitsuma H, et al. **J Med Virol** 1995 Aug; 46(4):397–402

Base changes at positions 1014 and 578 of delta virus RNA in Greek isolates maintain base pair in rod conformation with efficient RNA editing. Yang A, et al.

J Med Virol 1995 Oct;47(2):113–9
6–Pyruvoyl tetrahydropterin synthase, an enzyme with a novel type of active site involving both zinc binding and an intersubunit catalytic triad motif; site–directed mutagenesis of the proposed active center, characterization of the metal binding site and modelling of substrate binding. Bürgisser DM, et al. J Mol Biol 1995 Oct 20;253(2):358–69
Isolation and characterization of IS10 transposase separation of function mutants: identification of amino acid residues in transposase that are important for active site function and the stability of transposition intermediates. Kennedy AK, et al. J Mol Biol 1996 Mar 1;256(3):533–47
Effect of folding on the export of ribose–binding protein studied with the genetically isolated suppressors for the signal sequence mutation. Song T, et al. J Mol Biol 1995 Oct 20;253(2):304–12
GABA receptor minigene rescues insecticide resistance phenotypes in Drosophila. Stilwell GE, et al. J Mol Biol 1995 Oct 20;253(2):223–7
Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X–ray structural analysis of the five isoleucine to valine mutants. Takano K, et al. J Mol Biol 1995 Nov 17;254(1):62–76
Characterization of normal and point–mutated human androgen receptors expressed in the baculovirus system. Beitel LK, et al. J Mol Endocrinol 1995 Oct;15(2):117–28
Evidence against heterozygous coagulation factor V 1691 G–>A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. Prohaska W, et al. J Mol Med 1995 Oct;73(10):521–4
Re: Detection of a point mutation in NQO1 (DT–diaphorase) in a patient with colon cancer [letter; comment] Rosvold EA, et al. J Natl Cancer Inst 1995 Dec 6;87(23):1802–3. Comment on: J Natl Cancer Inst 1995 Jul 5;87(13):1022–4.
Cerebral venous sinus thrombosis associated with factor V gene mutation [letter] Kimber TE, et al. J Neurol Neurosurg Psychiatry 1996 Aug;61(2):204–5
Codon 200 mutation in a new family of Chilean origin with Creutzfeldt–Jakob disease [letter] Salvatore M, et al. J Neurol Neurosurg Psychiatry 1996 Jul;61(1):111–2
Impaired mitochondrial translation in human myoblasts harbouring the mitochondrial DNA tRNA lysine 8344 A–>G (MERRF) mutation: relationship to proportion of mutant mitochondrial DNA. Hanna MG, et al. J Neurol Sci 1995 Jun;130(2):154–60
Infrequency of p53 gene mutations in ependymomas. Fink KL, et al. J Neurooncol 1996 Feb;27(2):111–5
Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy–body parkinsonism. Kösel S, et al. J Neurosci Res 1996 Apr 15;44(2):174–83
Bronchioloalveolar lung carcinomas: K–ras mutations are constant events in the mucinous subtype. Marchetti A, et al. J Pathol 1996 Jul;179(3):254–9
A prevalent mutation for galactosemia among black Americans. Lai K, et al. J Pediatr 1996 Jan;128(1):89–95
C–Ha–ras oncogene in oral leukoplakia tissues. Cheng P, et al. J Tongji Med Univ 1996;16(1):58–60
Priapism revealing ARG 506 to GLN factor V mutation. de Prost D, et al. J Urol 1996 Apr;155(4):1392
Transdominant mutants of I kappa B alpha block Tat–tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication. Beauparlant P, et al. J Virol 1996 Sep; 70(9):5777–85
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. Buckwold VE, et al. J Virol 1996 Sep; 70(9):5845–51
Sindbis virus RNA–negative mutants that fail to convert from minus–strand to plus–strand synthesis: role of the nsP2 protein. Dé I, et al. J Virol 1996 May;70(5):2706–19
Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML–containing nuclear structures. Everett R, et al. J Virol 1995 Nov; 69(11):7339–44
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Harrigan PR, et al. J Virol 1996 Sep;70(9):5930–4
Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. Kaplan AH, et al. J Virol 1996 Sep;70(9):5840–4
Role of mutations G–480 and C–6203 in the attenuation phenotype of Sabin type 1 poliovirus. McGoldrick A, et al. J Virol 1995 Dec;69(12):7601–5
Mutational analysis of the envelope protein of spleen necrosis virus. Martinez I, et al. J Virol 1996 Sep;70(9):6036–43
The phenotype in vitro and in infected cells of herpes simplex virus 1 alpha trans–inducing factor (VP16) carrying temperature–sensitive mutations introduced by substitution of cysteines. Poon AP, et al. J Virol 1995 Dec; 69(12):7658–67
A single hamster PrP amino acid blocks conversion to protease–resistant PrP in scrapie–infected mouse neuroblastoma cells. Priola SA, et al. J Virol 1995 Dec; 69(12):7754–8
A point mutation in the VP4 coding sequence of coxsackievirus B4 influences virulence. Ramsingh AI, et al. J Virol 1995 Nov;69(11):7278–81
Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses. Wei Y, et al. J Virol 1996 Sep;70(9):6455–8
Hepatitis delta virus mutant: effect on RNA editing. Wu TT, et al. J Virol 1995 Nov;69(11):7226–31
A novel somatic point mutation of the RET Proto–oncogene in tumor tissues of small cell lung cancer patients. Futami H, et al. Jpn J Cancer Res 1995 Dec;86(12):1127–30
Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Horie H, et al. Jpn J Cancer Res 1995 Aug; 86(8):737–42
Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two–stage polymerase chain reaction/restriction fragment length polymorphism analysis. Inoue S, et al. Jpn J Cancer Res 1995 Jul; 86(7):626–30
Molecular genetic diagnosis of von Hippel–Lindau disease: analysis of five Japanese families. Kanno H, et al. Jpn J Cancer Res 1996 May;87(5):423–8
Role of point mutation of the K–ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Kawano R, et al. Jpn J Cancer Res 1995 Sep;86(9):802–10
Effects of K–ras gene mutations in the development of lung lesions induced by 4–(N–methyl–n–nitrosamino)–1–(3–pyridyl)–1–butanone in A/J mice. Kawano R, et al. Jpn J Cancer Res 1996 Jan; 87(1):44–50
Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Komiya A, et al. Jpn J Cancer Res 1995 Jul;86(7):622–5
Low incidence of point mutations in H–, K– and N–ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Nishiyama Y, et al. Jpn J Cancer Res 1995 Dec;86(12):1150–8
Missense mutation of rhodopsin gene codon 15 found in Japanese autosomal dominant retinitis pigmentosa. Fujiki K, et al. Jpn J Hum Genet 1995 Sep;40(3):271–7
Three Japanese patients with Crigler–Najjar syndrome type I carry an identical nonsense mutation in the gene for UDP–glucuronosyltransferase. Koiwai O, et al. Jpn J Hum Genet 1995 Sep;40(3):253–7
The lethal hemolytic mutation in beta I sigma 2 spectrin Providence yields a null phenotype in neonatal skeletal muscle. Weed SA, et al. Lab Invest 1996 Jun;74(6):1117–29
Mutation analysis of presenillin 1 gene in Alzheimer's disease [letter] Boteva K, et al. Lancet 1996 Jan 13;347(8994):130–1
Activated protein C resistance in childhood stroke [letter] Ganesan V, et al. Lancet 1996 Jan 27;347(8996):260
Hot–spot mutations in hepatitis B virus X gene in hepatocellular carcinoma [letter] Hsia CC, et al. Lancet 1996 Aug 31;348(9027):625–6
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta–hydroxysteroid dehydrogenase type 2 gene. Stewart PM, et al. Lancet 1996 Jan 13;347(8994):88–91
Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida [see comments] van der Put NM, et al. Lancet 1995 Oct 21;346(8982):1070–1. Comment in: Lancet 1995 Dec 2;346(8988):1495–6. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1703. Comment in: Lancet 1996 Feb 3;347(8997):340.
New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families [letter] Wagner TM, et al. Lancet 1996 May 4;347(9010):1263
Bilateral sensorineural hearing loss associated with the point mutation in mitochondrial genome. Oshima T, et al. Laryngoscope 1996 Jan;106(1 Pt 1):43–8
Auditory findings in patients with maternally inherited diabetes and deafness harboring a point mutation in the mitochondrial transfer RNA(Leu) (UUR) gene. Yamasoba T, et al. Laryngoscope 1996 Jan;106(1 Pt 1):49–53
c–MYC gene abnormalities in high grade and centroblastic–centrocytic non–Hodgkins lymphoma. Levasseur M, et al. Leuk Lymphoma 1995 Jun; 18(1–2):131–6
P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Newcomb EW. Leuk Lymphoma 1995 Apr;17(3–4):211–21 (86 ref.)
Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma. Clark HM, et al. Leukemia 1996 May;10(5):844–7
The beta subunit common to the GM–CSF, IL–3 and IL–5 receptors is highly polymorphic but pathogenic point mutations in patients with acute myeloid leukaemia (AML) are rare. Freeburn RW, et al. Leukemia 1996 Jan; 10(1):123–9
p53 gene mutations in pediatric brain tumors. Felix CA, et al. Med Pediatr Oncol 1995 Dec;25(6):431–6
Oligodendrocyte development in PLP "pt" mutant rabbits: glycolipid antigens and PLP gene expression. Sypecka J, et al. Metab Brain Dis 1995 Dec;10(4):321–33
Inducible expression of Ras N17 dominant inhibitory protein. Cai H, et al. Methods Enzymol 1995;255:230–7
Vaccinia virus expression of p21 rasAsn–17. de Vries–Smits AM, et al. Methods Enzymol 1995;255:221–9
Detection of point mutations in Ras in tumor cell lines by denaturant gradient gel electrophoresis. Mikheev A, et al. Methods Enzymol 1995;255:442–51
Site–directed mutagenesis of antibody–variable regions. Gao QS, et al. Methods Mol Biol 1995;51:319–27
Structural requirements of parathyroid hormone/parathyroid hormone–related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida–Klein A, et al. Miner Electrolyte Metab 1995;21(1–3):177–9 (16 ref.)
Functional recovery of troponin I in a Drosophila heldup mutant after a second site mutation. Prado A, et al. Mol Biol Cell 1995 Nov;6(11):1433–41
Mutational spectra in the lacI gene in skin from 7,12–dimethylbenz[a]anthracene–treated and untreated transgenic mice. Gorelick NJ, et al. Mol Carcinog 1995 Sep;14(1):53–62
Mutations in ras oncogenes: rare events in ultraviolet B radiation–induced mouse skin tumorigenesis. Khan SG, et al. Mol Carcinog 1996 Feb;15(2):96–103
Hepatocarcinogenesis in BXH recombinant inbred strains of mice: analysis of diverse phenotypic effects of the hepatocarcinogen sensitivity loci. Lee GH, et al. Mol Carcinog 1995 Nov;14(3):190–7
Semidominant mutations in the yeast Rad51 protein and their relationships with the Srs2 helicase. Chanet R, et al. Mol Cell Biol 1996 Sep;16(9):4782–9
Effects of nonsense mutations on nuclear and cytoplasmic adenine phosphoribosyltransferase RNA. Kessler O, et al. Mol Cell Biol 1996 Aug;16(8):4426–35
A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T–cell lymphoma. Knaus PI, et al. Mol Cell Biol 1996 Jul;16(7):3480–9
Common core sequences are found in skeletal muscle slow– and fast–fiber–type–specific regulatory elements. Nakayama M, et al. Mol Cell Biol 1996 May;16(5):2408–17
Context effects on misreading and suppression at UAG codons in human cells. Phillips–Jones MK, et al. Mol Cell Biol 1995 Dec;15(12):6593–600
DNA methylation associated with repeat–induced point mutation in Neurospora crassa. Singer MJ, et al. Mol Cell Biol 1995 Oct;15(10):5586–97
Palmitoylation of either Cys–3 or Cys–5 is required for the biological activity of the Lck tyrosine protein kinase. Yurchak LK, et al. Mol Cell Biol 1995 Dec;15(12):6914–22
Molecular modeling and in vitro investigations of the human androgen receptor DNA–binding domain: application for the study of two mutations. Lobaccaro JM, et al. Mol Cell Endocrinol 1996 Feb 5;116(2):137–47
Functional properties of a mutant T3 receptor beta (R338W) identified in a subject with pituitary resistance to thyroid hormone. Sasaki S, et al. Mol Cell Endocrinol 1995 Aug 30;113(1):109–17
Fluorescence–based DNA minisequence analysis for detection of known single–base changes in genomic DNA. Kobayashi M, et al. Mol Cell Probes 1995 Jun;9(3):175–82
Simultaneous detection of fourteen Italian cystic fibrosis mutations in seven exons by reverse dot–blot analysis. Rady M, et al. Mol Cell Probes 1995 Oct;9(5):357–60
A fluorescent multiplex ARMS method for rapid mutation analysis. Zschocke J, et al. Mol Cell Probes 1995 Dec; 9(6):447–51
Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'–monophosphate and inositol phosphate–Ca2+ cascades. Parma J, et al. Mol Endocrinol 1995 Jun; 9(6):725–33
Partial inhibition of protein synthesis accelerates the synthesis of porphyrin in heme–deficient mutants of Escherichia coli. Nakayashiki T, et al. Mol Gen Genet 1995 Nov 15; 249(2):139–46
Detection of point mutations in chloroplast genes of Antirrhinum majus L. I. Identification of a point mutation in the psaB gene of a photosystem I plastome mutant. Schaffner C, et al. Mol Gen Genet 1995 Dec 15; 249(5):533–44
Construction of a novel bifunctional biogenic amine receptor by two point mutations of the H2–histamine receptor. DelValle J, et al. Mol Med 1995 Mar;1(3):280–6
A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema. Ocejo–Vinyals JG, et al. Mol Med 1995 Sep; 1(6):700–5
Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Spudich S, et al. Mol Med 1995 Sep;1(6):607–13
Point mutations of the alpha 1 beta 2 gamma 2 gamma–aminobutyric acid(A) receptor affecting modulation of the channel by ligands of the benzodiazepine binding site. Buhr A, et al. Mol Pharmacol 1996 Jun; 49(6):1080–4
A single nucleotide substitution in the alpha a gene confers oat pathogenicity to barley stripe mosaic virus strain ND18. Weiland JJ, et al. Mol Plant Microbe Interact 1996 Jan; 9(1):62–7
Aberrant splicing and truncated–protein expression due to a newly identified XPA gene mutation. Sato M, et al. Mutat Res 1996 Feb 15;362(2):199–208
Adult–onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha–tocopherol–transfer protein [see comments] Gotoda T, et al. N Engl J Med 1995 Nov 16;333(20):1313–8. Comment in: N Engl J Med 1995 Nov 16;333(20):1351–3.
Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. Kreuder J, et al. N Engl J Med 1996 Apr 25;334(17):1100–4

Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. Latronico AC, et al. **N Engl J Med** 1996 Feb 22;334(8):507-12

Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis [see comments] Mandel H, et al. **N Engl J Med** 1996 Mar 21;334(12):763-8. Comment in: N Engl J Med 1996 Jul 25;335(4):289; discussion 290.

A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor [see comments] Pearce SH, et al. **N Engl J Med** 1996 Oct 10; 335(15):1115-22. Comment in: N Engl J Med 1996 Oct 10;335(15):1144-5.

Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia [see comments] Schipani E, et al. **N Engl J Med** 1996 Sep 5;335(10):708-14. Comment in: N Engl J Med 1996 Sep 5;335(10):736-8.

Brief report: short stature caused by a mutant growth hormone [see comments] Takahashi Y, et al. **N Engl J Med** 1996 Feb 15;334(7):432-6. Comment in: N Engl J Med 1996 Feb 15;334(7):463-5.

The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. **Nat Genet** 1995 Oct;11(2):219-22

Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Beaumont C, et al. **Nat Genet** 1995 Dec; 11(4):444-6

Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Bourgeron T, et al. **Nat Genet** 1995 Oct;11(2):144-9

M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. De Souza AT, et al. **Nat Genet** 1995 Dec;11(4):447-9

Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Huang SH, et al. **Nat Genet** 1995 Dec;11(4):468-71

Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Imbeaud S, et al. **Nat Genet** 1995 Dec;11(4):382-8

The South African malady [news; comment] Jenkins T. **Nat Genet** 1996 May;13(1):7-9. Comment on: Nat Genet 1996 May;13(1):95-7.

A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria [see comments] Meissner PN, et al. **Nat Genet** 1996 May;13(1):95-7. Comment in: Nat Genet 1996 May;13(1):7-9.

Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Meyers GA, et al. **Nat Genet** 1995 Dec;11(4):462-4

A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation [see comments] Patil N, et al. **Nat Genet** 1995 Oct;11(2):126-9 . Comment in: Nat Genet 1995 Oct;11(2):107-9.

Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families [see comments] Phelan CM, et al. **Nat Genet** 1996 May;13(1):120-2. Comment in: Nat Genet 1996 May;13(1):16-7.

Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Poetter K, et al. **Nat Genet** 1996 May;13(1):63-9

Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Putnam EA, et al. **Nat Genet** 1995 Dec;11(4):456-8

Keratin 13 point mutation underlies the hereditary mucosal epithelial disorder white sponge nevus. Richard G, et al. **Nat Genet** 1995 Dec;11(4):453-5

Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Sood S, et al. **Nat Genet** 1996 Feb;12(2):209-11

A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Steinlein OK, et al. **Nat Genet** 1995 Oct;11(2):201-3

Settling the myelin protein zero question in CMT1B [letter; comment] Warner LE, et al. **Nat Genet** 1995 Oct; 11(2):119-20. Comment on: Nat Genet 1993 Sep;5(1):31-4.

Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Gabizon R, et al. **Nat Med** 1996 Jan;2(1):59-64

Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis [see comments] Schroeder SA, et al. **Nat Med** 1995 Jul; 1(7):703-5. Comment in: Nat Med 1995 Nov;1(11):1100-2.

Characterization of non-inducible Tet repressor mutants suggests conformational changes necessary for induction. Müller G, et al. **Nat Struct Biol** 1995 Aug;2(8):693-703

Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Födinger M, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):668-72

Polyneuropathy in the mtDNA base pair 3243 point mutation [letter; comment] Fang W. **Neurology** 1996 May; 46(5):1494-5; discussion 1495-6. Comment on: Neurology 1995 Jun;45(6):1188-92.

Polyneuropathy in the mtDNA base pain 3243 point mutation [letter; comment] King MD, et al. **Neurology** 1996 May; 46(5):1495-6. Comment on: Neurology 1995 Jun;45(6):1188-92.

Japanese siblings with missense mutation (717Val --> Ile) in amyloid precursor protein of early-onset Alzheimer's disease. Matsumura Y, et al. **Neurology** 1996 Jun; 46(6):1721-3

Japanese triplets with cerebrotendinous xanthomatosis are homozygous for a mutant gene coding for the sterol 27-hydroxylase (Arg441Trp). Nagai Y, et al. **Neurology** 1996 Feb;46(2):571-4

Late-onset muscle weakness in partial phosphofructokinase deficiency: a unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation. Sivakumar K, et al. **Neurology** 1996 May;46(5):1337-42

A MERRF/PEO overlap syndrome associated with the mitochondrial DNA 3243 mutation. Verma A, et al. **Neurology** 1996 May;46(5):1334-6

A single point mutation decreases picrotoxinin sensitivity of the human GABA receptor rho 1 subunit. Enz R, et al. **Neuroreport** 1995 Jul 31;6(11):1569-72

High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. Martins RN, et al. **Neuroreport** 1995 Dec 29;7(1):217-20

A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Perez-Tur J, et al. **Neuroreport** 1995 Dec 29;7(1):297-301

p53 gene mutation: software and database. Béroud C, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):147-50

Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Giannelli F, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):103-18

Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Hollstein M, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):141-6

Mutational analysis of a conserved motif of Agrobacterium tumefaciens VirD2. Vogel AM, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4087-91

Mutations at three sites in the Escherichia coli 23S ribosomal RNA binding region for protein L11 cause UGA-specific suppression and conditional lethality. Murgola EJ, et al. **Nucleic Acids Symp Ser** 1995;(33):70-2

A nucleoside diphosphate kinase A (nm23-H1) serine 120-->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction. Chang CL, et al. **Oncogene** 1996 Feb 1;12(3):659-67

Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T, et al. **Oncogene** 1996 Feb 1;12(3):481-7

Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Pocard M, et al. **Oncogene** 1996 Feb 15;12(4):875-82

Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Russo D, et al. **Oncogene** 1995 Nov 2;11(9):1907-11

A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas. Shridhar V, et al. **Oncogene** 1996 May 2;12(9):1931-9

A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents. Hashimoto S, et al. **Oncol Res** 1995;7(1):21-9

A point mutation in the RDS-peripherin gene in a Spanish family with central areolar choroidal dystrophy. Reig C, et al. **Ophthalmic Genet** 1995 Jun;16(2):39-44

Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Nikoskelainen EK, et al. **Ophthalmology** 1996 Mar; 103(3):504-14

K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362-8

Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutations. Kotze MJ, et al. **PCR Methods Appl** 1995 Jun;4(6):352-6

A common mutation site in the beta-galactosidase gene originates in Puerto Rico. Chiu NC, et al. **Pediatr Neurol** 1996 Jan;14(1):53-6

Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. De Meirleir L, et al. **Pediatr Neurol** 1995 Oct;13(3):242-6

Clinical heterogeneity associated with the mitochondrial DNA T8993C point mutation. Santorelli FM, et al. **Pediatr Res** 1996 May;39(5):914-7

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Brøsen K, et al. **Pharmacogenetics** 1995 Oct;5(5):312-7

A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Marez D, et al. **Pharmacogenetics** 1995 Oct;5(5):305-11

Lung cancer and mutations at the polymorphic NAT2 gene locus. Martínez C, et al. **Pharmacogenetics** 1995 Aug; 5(4):207-14

Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Rosvold EA, et al. **Pharmacogenetics** 1995 Aug; 5(4):199-206

R296C and other CYP2D6 mutations in Chinese. Wang SL, et al. **Pharmacogenetics** 1995 Dec;5(6):385-8

Missense mutations define a restricted segment in the C-terminal domain of phytochrome A critical to its regulatory activity. Xu Y, et al. **Plant Cell** 1995 Sep; 7(9):1433-43

First-trimester prenatal diagnosis of Crouzon syndrome. Schwartz M, et al. **Prenat Diagn** 1996 Feb;16(2):155-8

Adjacent pore-lining residues within sodium channels identified by paired cysteine mutagenesis. Bénitah JP, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7392-6

Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Brachmann RK, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4091-5

The rat extracellular superoxide dismutase dimer is converted to a tetramer by the exchange of a single amino acid. Carlsson LM, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5219-22

Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: the role of apurinic sites. Chakravarti D, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10422-6

Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Davis J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2996-3000

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. de Jong MD, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5501-6

Molecular basis for dysfunction of some mutant forms of methylmalonyl-CoA mutase: deductions from the structure of methionine synthase. Drennan CL, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5550-5

A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Emiliani S, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6377-81

Structure and function in rhodopsin: correct folding and misfolding in point mutants at and in proximity to the site of the retinitis pigmentosa mutation Leu-125-->Arg in the transmembrane helix C. Garriga P, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4560-4

Inhibition of immunoglobulin folding and secretion by dominant negative BiP ATPase mutants. Hendershot L, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5269-74

Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R. Iversen PO, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2785-9

Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. Johnen G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12384-8

Structure and function in rhodopsin: correct folding and misfolding in two point mutants in the intradiscal domain of rhodopsin identified in retinitis pigmentosa. Liu X, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4554-9

Transcribing of Escherichia coli genes with mutant T7 RNA polymerases: stability of lacZ mRNA inversely correlates with polymerase speed. Makarova OV, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12250-4

Mapping by multifragment cloning in vivo. Marykwas DL, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11701-5

Differential sensitivity of stilbenedisulfonates in their reaction with band 3 HT (Pro-868-->Leu). Salhany JM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11844-8

Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. Schneppenheim R, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3581-6

Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Tu PH, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3155-60

Point mutations in the Ki-ras2 gene of codon 12 in the Dunning R-3327 Prostatic Adenocarcinoma system. Blount LV, et al. **Prostate** 1996 Jan;28(1):44-50

Enzyme-catalyzed dehalogenation of pentachloroethane: why F87W-cytochrome P450cam is faster than wild type. Manchester JI, et al. **Protein Eng** 1995 Aug;8(8):801-7

Point mutations in the M2 region of the alpha, beta, or gamma subunit of the GABAA channel that abolish block by picrotoxin. Gurley D, et al. **Receptors Channels** 1995; 3(1):13-20

Macular dystrophy associated with monogenic Arg172Trp mutation of the peripherin/RDS gene in a Japanese family. Nakazawa M, et al. **Retina** 1995;15(6):518-23

Sorsby's fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases-3 gene on chromosome 22. Peters AL, et al. **Retina** 1995;15(6):480-5

Asymmetries generated by transcription-coupled repair in enterobacterial genes. Francino MP, et al. **Science** 1996 Apr 5;272(5258):107-9

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118-34 (79 ref.)

Use of PCR-PIRA for screening of a point mutation at codon 12 in K-ras oncogene obtained from paraffin embedded tissue sections. Chewawiwat N, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:329-32

The clinical severity of beta-thalassemia mutations in West Malaysia. George E.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:225–8

Duchenne muscular dystrophy. Matsuo M.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:166–71 (31 ref.)

Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:112–9 (39 ref.)

Expression of hemoglobin E in newborn. Sae-ung N, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:246–8

Molecular pathology of beta-thalassemia in Indonesia. Sofro AS. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:221–4

Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. Lee YY, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):556–63

Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke [letter] Albucher JF, et al. **Stroke** 1996 Apr;27(4):766–7

Three new crystal structures of point mutation variants of monoTIM: conformational flexibility of loop-1, loop-4 and loop-8. Borchert TV, et al. **Structure** 1995 Jul 15; 3(7):669–79

Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Pacini F, et al. **Surgery** 1995 Dec;118(6):1031–5

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov–Dec; 40(3):197–206 (123 ref.)

Purpura fulminans in a patient homozygous for a mutation in the protein C gene—prenatal diagnosis in a subsequent pregnancy [letter] Alessi MC, et al. **Thromb Haemost** 1996 Mar;75(3):525–6

Molecular analysis in factor XIIIA deficiency [letter] Aslam S, et al. **Thromb Haemost** 1995 May;73(5):895

Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors—correlation with absence of Arg506–Gln mutation of factor V gene [letter] Chan LC, et al. **Thromb Haemost** 1996 Mar;75(3):522–3

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.). Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

Phenotyping and genotyping of coagulation factor V Leiden. Engel H, et al. **Thromb Haemost** 1996 Feb;75(2):267–9

Identification of eight point mutations in protein S deficiency type I—analysis of 15 pedigrees. Gómez E, et al.
Thromb Haemost 1995 May;73(5):750–5

Characterization of a cDNA encoding murine coagulation factor VII. Idusogie E, et al. **Thromb Haemost** 1996 Mar; 75(3):481–7

Characterization of recombinant human coagulation factor XFriuli. Kim DJ, et al. **Thromb Haemost** 1996 Feb; 75(2):313–7

Detection of ten new mutations by screening the gene encoding factor IX of Danish hemophilia B patients. Nielsen LR, et al. **Thromb Haemost** 1995 May;73(5):774–8

Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Santagostino E, et al. **Thromb Haemost** 1995 Aug;74(2):619–21

Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. van de Locht LT, et al. **Thromb Haemost** 1995 Nov;74(5):1276–9

Inherited homozygous resistance to activated protein C [letter] Villa P, et al. **Thromb Haemost** 1995 Aug; 74(2):794–5

A point mutation in an invariant splice acceptor site results in a decreased mRNA level in a patient with severe coagulation factor XIII subunit A deficiency. Vreken P, et al. **Thromb Haemost** 1995 Aug;74(2):584–9

UHG-based mutation screening in type 2B von Willebrand's disease: detection of a candidate mutation Ser547Phe. Wood N, et al. **Thromb Haemost** 1996 Feb;75(2):363–7

Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Zöller B, et al.
Thromb Haemost 1996 Feb;75(2):270–4

Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. Greengard JS, et al. **Thromb Res** 1995 Dec 1;80(5):441–3

Prothrombin Molise I: documentation of a second incidence of replacement of a critical Arg near the active site. James HL, et al. **Thromb Res** 1995 Nov 15;80(4):363–6

Fibrinogen Claro—another dysfunctional fibrinogen variant with gamma 275 arginine—>histidine substitution. Steinmann C, et al. **Thromb Res** 1996 Jan 1;81(1):145–50

A novel point mutation (R243Q) in exon 7 of the c-erbA beta thyroid hormone receptor gene in a family with resistance to thyroid hormone. Onigata K, et al.
Thyroid 1995 Oct;5(5):355–8

Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Cox-Singh J, et al.
Trans R Soc Trop Med Hyg 1995 Jul–Aug;89(4):436–7

Association between antifol resistance in vitro and DHFR gene point mutation in Plasmodium falciparum isolates. de Pécoulas PE, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):181–2

Point mutations characterize KEL10, the KEL3, KEL4, and KEL21 alleles, and the KEL17 and KEL11 alleles. Lee S, et al. **Transfusion** 1996 Jun;36(6):490–4

Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Uchida T, et al. **Urol Int** 1995;55(2):63–7

Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. **Verh Dtsch Ges Pathol** 1995;79:L-LV

Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Aiken C, et al. **Virology** 1996 Mar 1; 217(1):293–300

Mutations affecting the UL21 gene contribute to avirulence of pseudorabies virus vaccine strain Bartha. Klupp BG, et al. **Virology** 1995 Oct 1;212(2):466–73

Defective point mutants of the encephalomyocarditis virus internal ribosome entry site can be complemented in trans. Van Der Velden A, et al. **Virology** 1995 Dec 1;214(1):82–90

The persistent variant of influenza C virus carries one characteristic point mutation in RNA segment 1. Lapatschek MS, et al. **Virus Res** 1995 Nov;39(1):47–54

A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Olsson ML, et al.
Vox Sang 1995;69(3):242–7

[A hot-spot mutation of p53 gene in nasopharyngeal carcinoma] Chen R, et al.
Chung Hua Chung Liu Tsa Chih 1995 Nov;17(6):401–4 (Eng. Abstr.) **(Chi)**

[Correlation between p53 nuclear protein accumulation and mutations of the p53 gene in human esophageal cancer from linxian] Liang Y, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):412–4 (Eng. Abstr.) **(Chi)**

[The relation between p53 mutations and tumor invasiveness of human hepatocellular carcinoma] Qin L, et al.
Chung Hua Chung Liu Tsa Chih 1995 Nov;17(6):405–8 (Eng. Abstr.) **(Chi)**

[p53 gene point mutation in human colorectal carcinoma] Xu W, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):328–31 (Eng. Abstr.) **(Chi)**

[Mutation of P53 gene in a highly metastatic human lung cancer cell line] Zhang B, et al.
Chung Hua Chung Liu Tsa Chih 1995 Jul;17(4):279–82 (Eng. Abstr.) **(Chi)**

[Rapid detection of platelet glycoprotein IIb, IIIA gene variety by single strand conformation polymorphism analysis] Chen F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):341–3, 382 (Eng. Abstr.) **(Chi)**

[Multiple gene alterations involved in the processor of human gastric carcinogenesis] Lu Y, et al.
Chung Hua I Hsueh Tsa Chih 1995 Nov;75(11):679–82, 710–1 (Eng. Abstr.) **(Chi)**

[Expression of 12 antibody escape mutants of hepatitis B virus surface antigen gene in mammalian cell by using an Epstein-Barr based vector] Ren H, et al.
Chung Hua I Hsueh Tsa Chih 1995 Jul;75(7):396–8, 444–5 (Eng. Abstr.) **(Chi)**

[Effects of interferon treatment on mutation of hepatitis B virus precore genome] Hu D, et al.
Chung Hua Nei Ko Tsa Chih 1995 Apr;34(4):229–31 (Eng. Abstr.) **(Chi)**

[A kinetic study of hepatitis B virus pre-C gene mutation] Tian Q, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr; 34(4):232–4 (Eng. Abstr.) **(Chi)**

[Proto-oncogene point mutation of c-Ha-ras in bronchogenic carcinoma] Wang L, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Aug; 17(4):281–5 (Eng. Abstr.) **(Chi)**

[Detection of p53 mutation using PCR-SSCP silver staining method] Zhao W, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Jun; 17(3):219–22 (Eng. Abstr.) **(Chi)**

[Analysis of beta-thalassemia mutations and prenated diagnosis in Chengdu population] Liu B, et al.
Hua Hsi I Ko Ta Hsueh Hsueh Pao 1995 Dec;26(4):361–6 (Eng. Abstr.) **(Chi)**

[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

[Glucokinase: the first hit in the hunt for a gene in late-onset diabetes (editorial)] Laakso M. **Duodecim** 1994;110(1):13–5 (18 ref.) **(Fin)**

[Activated protein C resistance and mutation of coagulation factor V (editorial)] Samama MM.
Arch Mal Coeur Vaiss 1996 Jun;89(6):669–70 **(Fre)**

[Huntington's chorea: clinical aspects, genetics and current diagnosis] Spiegel R. **Ther Umsch** 1995 Dec;52(12):814–20 (Eng. Abstr.) **(Ger)**

[Resistance to activated protein C—a novel cause of thrombophilia] Cycowitz Z, et al. **Harefuah** 1995 Jul; 129(1-2):1–5, 80 (Eng. Abstr.) **(Heb)**

[Ras gene analysis in mammary tumors of dogs by means of PCR-SSCP and direct genomic analysis] Castagnaro M. **Ann Ist Super Sanita** 1995;31(3):337–41 (Eng. Abstr.) **(Ita)**

[Audiologic evaluation in a family showing diabetes mellitus and deafness associated with a mutation in mitochondrial DNA] Tamagawa Y, et al.
Nippon Jibiinkoka Gakkai Kaiho 1995 Aug;98(8):1257–62 (Eng. Abstr.) **(Jpn)**

[Detection of a mutation in mitochondrial DNA in a family with sensorineural deafness and diabetes mellitus as the predominant clinical features] Tamagawa Y, et al.
Nippon Jibiinkoka Gakkai Kaiho 1995 Jul;98(7):1104–10 (Eng. Abstr.) **(Jpn)**

[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test] Arao S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1327–30 **(Jpn)**

[Detection of K-ras point mutations in the stool of patients with colorectal tumors] Kohata Y.
Nippon Shokakibyo Gakkai Zasshi 1996 Jun;93(6):391–7 (Eng. Abstr.) **(Jpn)**

[A Japanese family with paramyotonia congenita which has a mutation in the muscle sodium channel gene] Ochi H, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):893–6 (Eng. Abstr.) **(Jpn)**

[A family of X-linked motor and sensory neuropathy with a new type of connexin32 mutation] Ohnishi A, et al.
Rinsho Shinkeigaku 1995 Aug;35(8):843–9 (Eng. Abstr.) **(Jpn)**

[Familial amyotrophic lateral sclerosis showing variable clinical courses with (Leu84—>Val) mutation of Cu/Zn superoxide dismutase] Ohnishi A, et al.
Rinsho Shinkeigaku 1996 Mar;36(3):485–7 (Eng. Abstr.) **(Jpn)**

[A case of hereditary motor and sensory neuropathy type I with a new type of peripheral myelin protein (PMP)-22 mutation] Ohnishi A, et al. **Rinsho Shinkeigaku** 1995 Jul; 35(7):788–92 (Eng. Abstr.) **(Jpn)**

[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546–8 (11 ref.) **(Jpn)**

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**

[Detection of rare target gene with a point mutation by improved PCR] Tada M, et al.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):549–52 (7 ref.) **(Jpn)**

[Detection of dystrophin gene mutation carrier state] Bisko M, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):193–9; quiz 200 (Eng. Abstr.) **(Pol)**

[Point mutation G—>A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464–70 (11 ref.) (Eng. Abstr.) **(Pol)**

[Production and catalytic properties of point mutants Phe41—>His and Phe143—>Glu of horseradish peroxidase, expressed in Escherichia coli] Gazarian IG, et al. **Biokhimiia** 1995 Oct;60(10):1555–63 (Eng. Abstr.) **(Rus)**

[A new point mutation in the mitochondrial gene ND1, detected in a patient with type II diabetes] Kalinin VN, et al. **Genetika** 1995 Aug;31(8):1180–2 (Eng. Abstr.) **(Rus)**

GENETICS

Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Gabreëls-Festen AA, et al.
Acta Neuropathol (Berl) 1995;90(6):645–9

Aldolase B A149P mutation and hereditary fructose intolerance are not associated with sudden infant death syndrome. Aarskog NK, et al. **Acta Paediatr** 1995 Aug; 84(8):947–8

Analysis of CA repeats in first intron of class I ADH gene in Long-Evans Cinnamon rats developing fatal intoxication after ethanol intake. Katsuki S, et al.
Alcohol Clin Exp Res 1996 Feb;20(1 Suppl):33A–35A

Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilation. Tomono H, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1211–4

Glycine substitutions in the triple-helical region of type VII collagen result in a spectrum of dystrophic epidermolysis bullosa phenotypes and patterns of inheritance. Christiano AM, et al. **Am J Hum Genet** 1996 Apr;58(4):671–81

Compound heterozygosity for COL7A1 mutations in twins with dystrophic epidermolysis bullosa: a recessive paternal deletion/insertion mutation and a dominant negative maternal glycine substitution result in a severe phenotype. Christiano AM, et al. **Am J Hum Genet** 1996 Apr; 58(4):682–93

The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Filla A, et al. **Am J Hum Genet** 1996 Sep;59(3):554–60

Succinyl CoA: 3-oxoacid CoA transferase (SCOT): human cDNA cloning, human chromosomal mapping to 5p13, and mutation detection in a SCOT-deficient patient. Kassovska-Bratinova S, et al. **Am J Hum Genet** 1996 Sep;

59(3):519–28
Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Moran-Jimenez MJ, et al. **Am J Hum Genet** 1996 Apr;58(4):712–21
Evidence that specific mtDNA point mutations may not accumulate in skeletal muscle during normal human aging. Pallotti F, et al. **Am J Hum Genet** 1996 Sep;59(3):591–602
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Tai HL, et al. **Am J Hum Genet** 1996 Apr;58(4):694–702
Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. Thomas PM, et al. **Am J Hum Genet** 1996 Sep;59(3):510–8
RET proto-oncogene mutations and rearrangements in endocrine diseases [comment] Lloyd RV. **Am J Pathol** 1995 Dec;147(6):1539–44. Comment on: Am J Pathol 1995 Dec;147(6):1600–7.
Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland [see comments] Padberg BC, et al. **Am J Pathol** 1995 Dec; 147(6):1600–7. Comment in: Am J Pathol 1995 Dec;147(6):1539–44.
TP53 mutations in upper aerodigestive squamous cell carcinomas from a group of Brazilian patients. Nagai MA, et al. **Am J Surg** 1995 Nov;170(5):492–4
Mannose-binding protein in Chinese patients with systemic lupus erythematosus. Lau YL, et al. **Arthritis Rheum** 1996 Apr;39(4):706–8
Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Slingsby JH, et al. **Arthritis Rheum** 1996 Apr;39(4):663–70
Sporadic Leber hereditary optic neuropathy in Australia and New Zealand. Chan C, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):7–14
Arginine to tryptophan substitution in the active site of a human lactate dehydrogenase variant--LDHB GUA1: postulated effects on subunit structure and catalysis. Shonnard GC, et al. **Biochim Biophys Acta** 1996 Jan 17; 1315(1):9–14
Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)
Mutations in tumour suppressor gene p53 in two feline fibrosarcomas. Mayr B, et al. **Br Vet J** 1995 Nov-Dec; 151(6):707–13
Study on aneuploidy and p53 mutations in astrocytomas. Campomenosi P, et al. **Cancer Genet Cytogenet** 1996 Jun; 88(2):95–102
Association of minisatellite instability with c-myc amplification and K-ras mutation in methylcholanthrene-induced mouse sarcomas. Niwa O, et al. **Cancer Res** 1995 Dec 1;55(23):5670–6
Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Stegmaier K, et al. **Cancer Res** 1996 Mar 15;56(6):1413–7
Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D. Takayama K, et al. **Cancer Res** 1995 Dec 1; 55(23):5656–63
p53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas. Chang KW, et al. **Carcinogenesis** 1996 Mar;17(3):595–600
Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgene. Ogawa K, et al. **Carcinogenesis** 1996 Feb; 17(2):341–5
Determining the site and nature of DNA mutations with the cloned MutY mismatch repair enzyme. Xu JF, et al. **Carcinogenesis** 1996 Feb;17(2):321–6
Mutations in the first intron of the SHR renin gene disrupt putative regulatory elements. Yu H, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6-7):450–1
Clonal analysis of colorectal tumors using K-ras and p53 gene mutations as markers. Dix BR, et al. **Diagn Mol Pathol** 1995 Dec;4(4):261–5
Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617–27 (46 ref.)
Premature termination mutation (772Glu-->stop) in the hormone-binding domain of the androgen receptor in a patient with the receptor-negative form of complete androgen insensitivity syndrome. Imasaki K, et al. **Endocr J** 1995 Oct;42(5):643–8
TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587–606 (95 ref.)
Mitochondrial DNA mutations in myocardial diseases. Ozawa T. **Eur Heart J** 1995 Dec;16 Suppl O:10–4
The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas. Axelson H, et al. **Eur J Cancer** 1995 Nov;31A(12):2099–104
An amino acid change in novel protein D123 is responsible for temperature-sensitive G1-phase arrest in a mutant of rat fibroblast line 3Y1. Okuda A, et al. **Exp Cell Res** 1996 Mar 15;223(2):242–9
Identification of bldA mutants of Streptomyces griseus. Kwak J, et al. **Gene** 1996 May 24;171(1):75–8
A novel 5'-upstream mutation in the factor XII gene is associated with a TaqI restriction site in an Alu repeat in factor XII-deficient patients. Hofferbert S, et al. **Hum Genet** 1996 Jun;97(6):838–41
A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Kluwe L, et al. **Hum Genet** 1996 Feb;97(2):224–7
Superoxide dismutase 1: identification of a novel mutation in a case of familial amyotrophic lateral sclerosis. Kostrzewa M, et al. **Hum Genet** 1996 Jul;98(1):48–50
Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes. Nuytinck L, et al. **Hum Genet** 1996 Mar;97(3):324–9
Identification of four novel splice site mutations in the ornithine transcarbamylase gene. Oppliger Leibundgut E, et al. **Hum Genet** 1996 Feb;97(2):209–13
HbF-Lesvos: an HbF variant due to a novel G gamma mutation (:G gamma 75 ATA-->ACA) detected in a Greek family. Papadakis MN, et al. **Hum Genet** 1996 Feb; 97(2):260–2
Hb Costa Rica or alpha 2 beta 2 77(EF1)His --> Arg: the first example of a somatic cell mutation in a globin gene. Rodriguez Romero WE, et al. **Hum Genet** 1996 Jun; 97(6):829–33
A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Milasin J, et al. **Hum Mol Genet** 1996 Jan;5(1):73–9
Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Takahashi Y, et al. **Hum Mol Genet** 1996 Jan;5(1):81–84
Mutations in the myelin protein zero gene associated with Charcot-Marie-Tooth disease type 1B. Latour P, et al. **Hum Mutat** 1995;6(1):50–4
Detection of mutations conferring extended-spectrum activity on SHV beta-lactamases using polymerase chain reaction single strand conformational polymorphism (PCR-SSCP). M'Zali FH, et al. **J Antimicrob Chemother** 1996 Apr;37(4):797–802
The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. Takahashi K, et al. **J Gen Virol** 1995 Dec; 76 (Pt 12):3159–64
Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation. Watanabe H, et al. **Jpn J Cancer Res** 1996 May;87(5):466–74
Assessment of mitochondrial gene in proliferative vitreoretinal tissues from patients with familial diabetes mellitus. Isashiki Y, et al. **Jpn J Ophthalmol** 1996; 40(1):66–70
Detection of four mutations in six unrelated South African patients with acute intermittent porphyria. Ong PM, et al. **Mol Cell Probes** 1996 Feb;10(1):57–61
Quantitative and qualitative aspects of spontaneous specific-locus mutation in the ad-3 region of heterokaryon 12 of Neurospora crassa. de Serres FJ, et al. **Mutat Res** 1995 Nov;332(1-2):45–54
Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1-6):161–72 (112 ref.)
Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. Ikeda M, et al. **Neurology** 1995 Nov;45(11):2038–42
New point mutations and deletions of the connexin 32 gene in X-linked Charcot-Marie-Tooth neuropathy. Ionasescu V, et al. **Neuromuscul Disord** 1995 Jul;5(4):297–9
Serial MRI in early Creutzfeldt-Jacob disease with a point mutation of prion protein at codon 180. Ishida S, et al. **Neuroradiology** 1995 Oct;37(7):531–4
A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Varley JM, et al. **Oncogene** 1996 Jun 6;12(11):2437–42
A translational fidelity mutation in the universally conserved sarcin/ricin domain of 25S yeast ribosomal RNA. Liu R, et al. **RNA** 1996 Mar;2(3):254–63
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation. Fisher M, et al. **Stroke** 1996 Jul;27(7):1163–6
Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke [letter] [see comments] Lalouschek W, et al. **Stroke** 1995 Oct;26(10):1963–4. Comment in: Stroke 1996 Mar;27(3):573.
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Press RD, et al. **Stroke** 1996 Jan;27(1):44–8
Spontaneous mutation of cell oncogenes plays a minor role in neoplastic transformation of virus-induced murine T-cell lymphomas. Gasparotto D, et al. **Tumori** 1995 Jul-Aug; 81(4):268–72
Ras oncogene activation in benign and malignant colorectal tumours. Spandidos DA, et al. **Tumori** 1995 May-Jun;81(3 Suppl):7–11
Gastric adenoma-carcinoma sequence with special reference to p53 and Ki-ras gene alterations. Sakurai S, et al. **Virchows Arch** 1995;427(2):119–24
DNA sequencing and screening for point mutations in the human Lewis (FUT3) gene enables molecular genotyping of the human Lewis blood group system. Elmgren A, et al. **Vox Sang** 1996;70(2):97–103
Point mutations in lipoprotein lipase (LPL) gene: prevalence in normal and combined hyperlipidemic subjects. Gehrisch S, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:64–5
A flow cytometric competition technique for measuring interaction of LDL with cellular LDL-receptors applied to patients with mutant (Arg3500-->Gln) apolipoprotein B. Heath F, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:21–4
Detection of the apolipoprotein B-100 arg(3500) > gl mutation in familial defective apoB-100 by temperature-gradient gel electrophoresis. Koch M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:16–8
Detection of point mutations in lipoprotein lipase (LPL) gene by TGGE. Kostka H, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:62–3
[Decreased performance in the elderly. Etiology: stochastic mutations of mitochondrial DNA?] Kadenbach B. **Fortschr Med** 1995 Dec 20;113(35-36):510 **(Ger)**
[Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation] Gottschlich S, et al. **Laryngorhinootologie** 1996 May;75(5):301–5 (Eng. Abstr.) **(Ger)**
[The search for a mutation in the gene coding the beta-amyloid protein precursor gene in patients with Alzheimer-type dementias] Golimbet VE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):75–8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Abrams SI, et al. **Eur J Immunol** 1996 Feb;26(2):435–43
A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Armandola EA, et al. **Eur J Immunol** 1996 Aug; 26(8):1748–55
Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Ciernik IF, et al. **Hybridoma** 1995 Apr;14(2):139–42
A point mutation in IILA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Peace-Brewer AL, et al. **Immunity** 1996 May; 4(5):505–14
Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation? Brown M, et al. **J Immunol** 1996 May 1;156(9):3285–91

PHYSIOLOGY

pt point mutation in plp gene results in hyperexpression of MOG in hypomyelinated rabbit. Sypecka J. **Acta Neurobiol Exp (Warsz)** 1996;56(1):9–14
Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Gabreëls-Festen AA, et al. **Acta Neuropathol (Berl)** 1995;90(6):645–9
Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin. Damke H, et al. **J Cell Biol** 1995 Oct;131(1):69–80
Point mutation of adenosine triphosphate-binding motif generated rigor kinesin that selectively blocks anterograde lysosome membrane transport. Nakata T, et al. **J Cell Biol** 1995 Nov;131(4):1039–53
Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Malherbe P, et al. **Neurobiol Aging** 1996 Mar-Apr; 17(2):205–14
The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Kawamura M, et al. **Oncogene** 1996 Jun 6; 12(11):2361–7

RADIATION EFFECTS

Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma [see comments] van Elsas A, et al. **Am J Pathol** 1996 Sep;149(3):883–93. Comment in: Am J Pathol 1996 Sep;149(3):739–44.
Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles. Andersson M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):765–70

POINT-OF-CARE SYSTEMS

Bedside measurement of the third ventricle's diameter during episodes of arising intracranial pressure after head trauma. Using transcranial real-time sonography for a non-invasive examination of intracranial compensation mechanisms. Mursch K, et al. **Acta Neurochir (Wien)** 1995; 137(1-2):19–23; discussion 23–4
Laboratory and bedside evaluation of portable glucose meters [letter; comment] Arya SC. **Am J Clin Pathol** 1995 Oct; 104(4):483. Comment on: Am J Clin Pathol 1995 Feb;103(2):244–51.
Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)
Regulatory requirements (CLIA '88, JCAHO, CAP) for

decentralized testing. Ehrmeyer SS, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S40–9 (22 ref.)

Automated approaches to rapid-response testing. A comparative evaluation of point-of-care and centralized laboratory testing. Fleisher M, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S18–25

Airborne and rescue point-of-care testing. Herr DM, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S54–8

The satellite laboratory and point-of-care testing. Integration of information. Jacobs E, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S33–9 (17 ref.)

Guidelines for point-of-care testing. Improving patient outcomes. Kost GJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S111–27 (167 ref.)

Thrombosis and hemostasis testing at the point of care. Oberhardt BJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S72–8 (19 ref.)

Critical care profiling for informed treatment of severely ill patients. Shirey TL. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S79–87 (77 ref.)

Work activities before and after implementation of an automated dispensing system. Guerrero RM, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):548–54

Bedside measurement of factor VIII:C activity in individuals with hemophilia A. Kessler CM, et al. **Am J Hematol** 1996 Mar;51(3):181–5

Evaluation of an on-demand, ex vivo bedside blood gas monitor on pulmonary artery blood gas determinations. Franklin ML, et al. **Anesth Analg** 1996 Sep;83(3):500–4

College of American Pathologists Conference XXVIII: Alternate Site Testing. January 29–February 1, 1995. **Arch Pathol Lab Med** 1995 Oct;119(10):867–983

Alternate site testing. Information handling and reporting issues. Auerbach DM. **Arch Pathol Lab Med** 1995 Oct; 119(10):924–5

Alternate site testing. The old and new paradigm or the past is prologue. Bachner P. **Arch Pathol Lab Med** 1995 Oct; 119(10):881–5 (31 ref.)

Exploring the medical need for alternate site testing. A clinician's perspective. Becker RC. **Arch Pathol Lab Med** 1995 Oct;119(10):894–7 (47 ref.)

Alternate site testing. The regulatory perspective. Belanger AC. **Arch Pathol Lab Med** 1995 Oct;119(10):902–6

Development of a robotic near patient testing laboratory. Felder RA, et al. **Arch Pathol Lab Med** 1995 Oct; 119(10):948–51

The mobile laboratory in alternative site testing. Fuhrman SA, et al. **Arch Pathol Lab Med** 1995 Oct;119(10):939–42

Alternate site testing. The decision-making process. Geyer SJ. **Arch Pathol Lab Med** 1995 Oct;119(10):907–8

Successful alternatives to alternate site testing. Use of a pneumatic tube system to the central laboratory. Green M. **Arch Pathol Lab Med** 1995 Oct;119(10):943–7

College of American Pathologists Conference XXVIII on alternate site testing: introduction. Handorf CR. **Arch Pathol Lab Med** 1995 Oct;119(10):867–73 (9 ref.)

College of American Pathologists Conference XXVIII on alternate site testing. What must we now do? Howanitz PJ. **Arch Pathol Lab Med** 1995 Oct;119(10):979–83 (30 ref.)

Responsibilities in point-of-care testing. An institutional perspective. Lamb LS Jr. **Arch Pathol Lab Med** 1995 Oct; 119(10):886–9

Near patient blood glucose monitoring. Laposata M, et al. **Arch Pathol Lab Med** 1995 Oct;119(10):926–8

Designing a point-of-care program for coagulation testing. Macik BG. **Arch Pathol Lab Med** 1995 Oct;119(10):929–38 (34 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: keynote address. Global view of how alternate site testing fits in with medical care. O'Leary D. **Arch Pathol Lab Med** 1995 Oct;119(10):877–80

College of American Pathologists Conference XXVIII on alternate site testing: breakout sessions. Orians MA, et al. **Arch Pathol Lab Med** 1995 Oct;119(10):952–61

Reproducibility (precision) in alternate site testing. A clinician's perspective. Watts NB. **Arch Pathol Lab Med** 1995 Oct;119(10):914–7

College of American Pathologists Conference XXVIII on alternate site testing: keynote address. Reflections on a C major scale. Woodruff KH. **Arch Pathol Lab Med** 1995 Oct;119(10):876

Bedside tracheostomy in the intensive care unit. Wease GL, et al. **Arch Surg** 1996 May;131(5):552–4; discussion 554–5

A portable system for measuring bone mineral density in the pre-term neonatal forearm. Truscott JG, et al. **Br J Radiol** 1996 Jun;69(822):532–8

Bedside science reduces laboratory art [letter; comment] Waugh RA, et al. **Circulation** 1995 Nov 1;92(9):2762. Comment on: Circulation 1995 Apr 1;91(7):2089–92.

Evaluation of i-STAT portable clinical analyzer in a hemodialysis unit. Gault MH, et al. **Clin Biochem** 1996 Apr; 29(2):117–24

Bedside heparin monitoring by activated partial thromboplastin time measured with a dry reagent. Linder R, et al. **Clin Chem** 1996 Sep;42(9):1488–9

Impact of point-of-care testing on patients' length of stay in a large emergency department. Parvin CA, et al. **Clin Chem** 1996 May;42(5):711–7

Evaluation of the impact of a bedside terminal system in a rapidly changing community hospital. Brown SJ, et al. **Comput Nurs** 1995 Nov-Dec;13(6):280–4

Strategies for successful clinical information system selection. Staggers N, et al. **Comput Nurs** 1996 May-Jun;14(3):146–7, 155

Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable. Kranzler HR, et al. **Drug Alcohol Depend** 1995 Nov;40(1):55–62

A simplified procedure of direct calorimetry for bedside monitoring of the resting metabolic rate. Lange H, et al. **Eur J Appl Physiol** 1995;71(1):58–64

Point-of-care laboratory testing: is decentralized testing the best alternative for your hospital? **Health Devices** 1995 May-Jun;24(5–6):173–207

Near-patient stability studies. Barnes AR. **J Clin Pharm Ther** 1996 Feb;21(1):49–55

Computer-assisted trauma care prototype. Holzman TG, et al. **Medinfo** 1995;8 Pt 2:1685

Implementation of a clinical workstation for general practice. Lovell NH, et al. **Medinfo** 1995;8 Pt 1:777

Automation of the patient care documentation process in the home using hand-held computer technology. Russon GN. **Medinfo** 1995;8 Pt 1:778

Accessing oncology information at the point of care: experience using speech, pen, and 3-D interfaces with a knowledge server. Sherertz DD, et al. **Medinfo** 1995;8 Pt 1:792–5

An integrated approach for mobile information processing in hospitals. Werner R, et al. **Medinfo** 1995;8 Pt 1:395–9

Bedside diagnosis of wide QRS tachycardia [editorial; comment] Barold SS. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2109–15 (79 ref.). Comment on: Pacing Clin Electrophysiol 1995 Dec;18(12 Pt 1):2194–208.

Hand-held computing in the patient care setting: a pilot project. Karshmer JF, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:7–11

Diagnosing ischemia from the bedside monitor. Drew BJ, et al. **Prog Cardiovasc Nurs** 1996 Winter;11(1):45–6

Optimal conditions for white cell reduction in red cells by filtration at the patient's bedside. Sirchia G, et al. **Transfusion** 1996 Apr;36(4):322–7

[Use of multi-grid screens in intensive care units] Grunert JH, et al. **Aktuelle Radiol** 1995 Sep;5(5):293–6 (Eng. Abstr.) **(Ger)**

[Mobile blood gas and laboratory monitoring. A new technology in clinical routine] Martin J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):309–15 (Eng. Abstr.) **(Ger)**

ECONOMICS

Economic considerations of point-of-care testing. Keffer JH. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S107–10 (14 ref.)

Financial justification of alternate site testing. De Cresce RP, et al. **Arch Pathol Lab Med** 1995 Oct;119(10):898–901

The patient focused approach: a better way to run a hospital? Heymann TD, et al. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):142–4

Ward based X-ray facilities can improve services. Heymann TD, et al. **J R Coll Physicians Lond** 1996 Mar-Apr; 30(2):145–9

LEGISLATION & JURISPRUDENCE

Bedside computers and confidentiality. Gobis LJ. **Am J Nurs** 1995 Oct;95(10):75–6

ORGANIZATION & ADMINISTRATION

Current nursing practice of point-of-care laboratory diagnostic testing in critical care units. Lamb LS Jr, et al. **Am J Crit Care** 1995 Nov;4(6):429–34

Patient data management systems in intensive care—the situation in Europe. Metnitz PG, et al. **Intensive Care Med** 1995 Sep;21(9):703–15

Quality and efficiency at the point of care. Gage JS. **MD Comput** 1996 Jul-Aug;13(4):318–20

STANDARDS

Abdominal sonography for the diagnosis of bowel obstruction [editorial; comment] Bland KI. **Ann Surg** 1996 Mar;223(3):235–6. Comment on: Ann Surg 1996 Mar;223(3):237–41.

Desirable performance standards for imprecision and bias in alternate sites. The views of laboratory professionals. Fraser CG, et al. **Arch Pathol Lab Med** 1995 Oct; 119(10):909–13

Bedside glucose monitoring. Comparison of performance as studied by the College of American Pathologists Q-Probes program. Howanitz PJ, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):333–8

Bedside glucose monitoring quality control practices. A College of American Pathologists Q-Probes study of program quality control documentation, program characteristics, and accuracy performance in 544 institutions. Jones BA, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):339–45

Selecting a clinical information system that will grow with the institution. Badger K. **Comput Nurs** 1996 Jan-Feb; 14(1):23–4

The impact of computerized documentation on nurses' use of time. Pabst MK, et al. **Comput Nurs** 1996 Jan-Feb; 14(1):25–30

STATISTICS & NUMERICAL DATA

Point-of-care glucose testing: cost savings and ease of use with the Ames Glucometer Elite. Innanen VT, et al. **Clin Chem** 1995 Oct;41(10):1537–8

TRENDS

Near patient testing: is it here to stay? Hicks JM. **J Clin Pathol** 1996 Mar;49(3):191–3

Point of care computing and its relevance to the United States' health care reform movement. Albright JW, et al. **Medinfo** 1995;8 Pt 2:1643–7

POINT OF CARE TECHNOLOGY see **POINT-OF-CARE SYSTEMS**

POISON CONTROL CENTERS

1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Litovitz TL, et al. **Am J Emerg Med** 1996 Sep; 14(5):487–537

Closing poison control centers is fiscally foolish [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2079–80

Poison information and treatment systems. American College of Emergency Physicians. **Ann Emerg Med** 1996 Sep; 28(3):384

Treating CS gas injuries to the eye. Poisons centre will monitor cases [letter; comment] Wheeler H, et al. **BMJ** 1995 Sep 30;311(7009):871. Comment on: BMJ 1995 Jul 29;311(7000):276.

The use of poison prevention and education strategies to enhance the awareness of the poison information center and to prevent accidental pediatric poisonings. Krenzelok EP. **J Toxicol Clin Toxicol** 1995;33(6):663–7 (7 ref.)

Disaster planning—our finest hour? [editorial; comment] Woolf A. **J Toxicol Clin Toxicol** 1996;34(1):59–60. Comment on: J Toxicol Clin Toxicol 1996;34(1):53–8.

Utilization of expert consultants by poison centers in the United States. Chyka PA, et al. **Vet Hum Toxicol** 1995 Aug;37(4):369–70

Earth day, clean water and... [letter] Lucanie R. **Vet Hum Toxicol** 1995 Aug;37(4):378

Delay among the general public in telephoning a poison center. McKnight RH, et al. **Vet Hum Toxicol** 1996 Apr; 38(2):92–5

[Scorpion bites in southern France: experience at the poison-control centre of Marseilles (letter)] De Haro L, et al. **Presse Med** 1996 Apr 6;25(12):600 **(Fre)**

[Information and consultation toxicological center: results and prospects of activities] Litvinov NN, et al. **Med Tr Prom Ekol** 1996;(1):43–6 **(Rus)**

STANDARDS

Poison information and treatment systems. American College of Emergency Physicians. **Ann Emerg Med** 1996 May; 27(5):686

Disaster preparedness of poison control centers in the United States [see comments] Vilke GM, et al. **J Toxicol Clin Toxicol** 1996;34(1):53–8. Comment in: J Toxicol Clin Toxicol 1996;34(1):59–60.

Use of telephone recording devices by poison centers in the United States. Chyka PA, et al. **Vet Hum Toxicol** 1995 Oct;37(5):480–2

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

Re-engineering regional poison control center services. Wieland MJ. **Vet Hum Toxicol** 1996 Apr;38(2):137–9

STATISTICS & NUMERICAL DATA

Epidemiology of ingestions in a regional poison control center over twenty years. Wolfle J, et al. **Vet Hum Toxicol** 1995 Aug;37(4):367–8

POISON IVY see **TOXICODENDRON**

POISON IVY DERMATITIS see **DERMATITIS, TOXICODENDRON**

POISONING

see related

ANTIDOTES

Surgical treatment for caustic ingestion injury of the pharynx, larynx, and esophagus. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:116–9

Toxicology: why are we swinging the lead? [editorial] Dawson A. **Aust N Z J Med** 1995 Jun;25(3):187–8

Prevalence of alcohol histories in medical and nursing notes of patients admitted with self poisoning. Shepherd RM, et al. **BMJ** 1995 Sep 30;311(7009):847

Drug induced emergencies. Kapadia FN. **J Assoc Physicians India** 1995 Apr;43(4):269–72

Proceedings of the 5th World Congress for the World Federation of Associations of Clinical Toxicology Centers and Poison Control Centers. Taipei, Taiwan, November 8–11, 1994. **J Toxicol Clin Toxicol** 1995;33(6):573–739

Acute poisonings in Poland. Czerczak S, et al. **J Toxicol Clin Toxicol** 1995;33(6):669–75

Outcome following organ removal from poisoned donors in brain death status: a report of 12 cases and review of the literature. Hantson P, et al. **J Toxicol Clin Toxicol** 1995; 33(6):709–12 (8 ref.)

[Reality of drug poisoning and screening tests] Kudo K. **Fukuoka Igaku Zasshi** 1995 Nov;86(11):399–404 (3 ref.) **(Jpn)**

[Intoxications: current issues (editorial)] Muñoz González J, et al. **Rev Clin Esp** 1996 Mar;196(3):141–2 **(Spa)**

BLOOD

Determination of arsenic in blood and stomach contents by inductively coupled plasma/mass spectrometry (ICP/MS). Tanaka T, et al. **Forensic Sci Int** 1996 Jul 31;81(1):43–50

[Changes in the ratio of formed elements of the blood in acute exogenous poisoning in children] Neudakhin EV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):35–6 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Fulminant malignant arrythmia and multiorgan failure in acute arsenic poisoning [letter] Civantos DP, et al. **Chest** 1995 Dec;108(6):1774–5

Risks of extracorporeal membrane oxygenation: is there a role for use in the management of the acutely poisoned patient? Banner W Jr. **J Toxicol Clin Toxicol** 1996; 34(4):365–71 (18 ref.)

DIAGNOSIS

The poisoned patient: the role of the laboratory. Flanagan RJ. **Br J Biomed Sci** 1995 Sep;52(3):202–13 (30 ref.)

Application of biological monitoring to the diagnosis of poisoning. Ikeda M. **J Toxicol Clin Toxicol** 1995; 33(6):617–23 (32 ref.)

Toxicological and neuropsychological findings in patients presenting to an environmental toxicology service. Köppel C, et al. **J Toxicol Clin Toxicol** 1995;33(6):625–9

The use of REMEDI HS in toxicological diagnostics of patients poisoned with drugs at the Department of Toxicology Collegium Medicum of the Jagiellonian University in Kraków. Pach J, et al. **Przegl Lek** 1996; 53(4):377–9

[Recommendations for toxicologic studies in sudden, unexpected death] van Ingen G, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):179–81 **(Dut)**

[Detection of clozapine in hair after 1 years burial in soil grave] Ahrens B, et al. **Arch Kriminol** 1995 Nov–Dec; 196(5–6):138–42 (Eng. Abstr.) **(Ger)**

[The diagnosis of poisonings by technical fluids] Bonitenko Iulu. **Voen Med Zh** 1995 Aug;(8):18–23, 80 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Litovitz TL, et al. **Am J Emerg Med** 1996 Sep; 14(5):487–537

Epidemiology of Munchausen syndrome by proxy, non-accidental poisoning, and non-accidental suffocation. McClure RJ, et al. **Arch Dis Child** 1996 Jul;75(1):57–61

Pediatric poisonings. Goepp JG. **Clin Chem** 1996 Aug;42(8 Pt 2):1356–60 (11 ref.)

Clinical evaluation of the poisoned patient and toxic syndromes. Liang HK. **Clin Chem** 1996 Aug;42(8 Pt 2):1350–5 (20 ref.)

Changing pattern of childhood poisoning (1970–1989): experience of a large north Indian hospital. Singh S, et al. **Indian Pediatr** 1995 Mar;32(3):331–6

A survey of poisoning on older people in Tehran [letter] Ghazi-Khansari M, et al. **J Am Geriatr Soc** 1996 May; 44(5):615–6

The profile of acute poisonings in Harayana-Rohtak Study. Siwach SB, et al. **J Assoc Physicians India** 1995 Nov; 43(11):756–9

Evidence-based medicine in toxicology: where is the evidence? Buckley NA, et al. **Lancet** 1996 Apr 27; 347(9009):1167–9

Is Wednesday ½ child filled with woe? An evidence-based reassessment [letter] Buckley NA, et al. **Med J Aust** 1995 Dec 4–18;163(11–12):654

Causes of poisoning in children during the period 1990–1993. Kotwica M, et al. **Przegl Lek** 1996;53(4):329–33

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

Epidemiology of ingestions in a regional poison control center over twenty years. Wolfle J, et al. **Vet Hum Toxicol** 1995 Aug;37(4):367–8

[Human poisoning caused by chemicals for plant protection in 1994] Przybylska A. **Przegl Epidemiol** 1996;50(1–2):151–8 **(Pol)**

[Duties of an acute poisoning unit in a multiple profile provincial hospital] Lata S. **Przegl Lek** 1996;53(4):380–1 **(Pol)**

[Toxic contamination of the rural environment in the province of Krak'ow and incidence of acute poisoning in humans. Clinical problems] Wojdyła, et al. **Przegl Lek** 1996; 53(4):382–6 **(Pol)**

[Effect of electromagnetic fields of natural and anthropogenic origin on the frequency of pathology occurrence in St. Petersburg] Tiasto MI, et al. **Biofizika** 1995 Jul–Aug; 40(4):839–47 (Eng. Abstr.) **(Rus)**

[Epidemiology of acute poisoning: study of 613 cases in the Community of Madrid in 1994] Dorado Pombo S, et al. **Rev Clin Esp** 1996 Mar;196(3):150–6 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Evidence-based medicine in toxicology: where is the evidence? Buckley NA, et al. **Lancet** 1996 Apr 27; 347(9009):1167–9

[Human poisoning caused by chemicals for plant protection in 1994] Przybylska A. **Przegl Epidemiol** 1996;50(1–2):151–8 **(Pol)**

HISTORY

[Livia is not a poisoner (letter)] Koelbing HM. **Schweiz Rundsch Med Prax** 1996 Jun 11;85(24):806 **(Ger)**

MORTALITY

Lethal effects of the consumption of field levels of paraquat-contaminated plants on frog tadpoles. Bauer Dial CA, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):870–7

Mortality due to poisoning in a developing agricultural country: trends over 20 years. Senanayake N, et al. **Hum Exp Toxicol** 1995 Oct;14(10):808–11

A prospective study of fatal outcomes of poisoning in Tehran. Ghazi-Khansari M, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):449–52

PATHOLOGY

Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Fineschi V, et al. **Int J Legal Med** 1996;108(5):272–5

Pathology of experimentally induced chronic selenosis (alkali disease) in yearling cattle. O'Toole D, et al. **J Vet Diagn Invest** 1995 Jul;7(3):364–73

[Fatal sodium azide poisoning in a hospital: a preventable accident] Herbold M, et al. **Arch Kriminol** 1995 Nov–Dec; 196(5–6):143–8 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Cardiotoxic drugs. Derlet RW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):771–91 (93 ref.)

[Late effects of organophosphate poisoning on the heart] Lev E, et al. **Harefuah** 1995 Dec 1;129(11):507–11 (40 ref.) **(Heb)**

PREVENTION & CONTROL

Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al. **Drugs Aging** 1995 Oct;7(4):292–7 (32 ref.)

The use of poison prevention and education strategies to enhance the awareness of the poison information center and to prevent accidental pediatric poisonings. Krenzelok EP. **J Toxicol Clin Toxicol** 1995;33(6):663–7 (7 ref.)

Successful presentation techniques for poison prevention talks [letter] Dunn E. **Vet Hum Toxicol** 1995 Oct;37(5):479

REHABILITATION

[The theoretical bases of rehabilitation in exotoxicosis] Begliarov MI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):41–3 (42 ref.) **(Rus)**

THERAPY

Lithium poisoning treated by high-performance continuous arteriovenous and venovenous hemodiafiltration. Leblanc M, et al. **Am J Kidney Dis** 1996 Mar;27(3):365–72

Poison information and treatment systems. American College of Emergency Physicians. **Ann Emerg Med** 1996 May; 27(5):686

Differences between general practices in hospital admission rates for self-inflicted injury and self-poisoning: influence of socioeconomic factors. Smith T. **Br J Gen Pract** 1995 Sep;45(398):458–62

Advances in poison management. Bayer MJ, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1361–6 (32 ref.)

The poisoned patient. Toxicologic emergencies. Norris LH, et al. **Dent Clin North Am** 1995 Jul;39(3):595–619 (72 ref.)

Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al. **Drugs Aging** 1995 Oct;7(4):292–7 (32 ref.)

Bronchoscopy with persistent tracheobronchial lavage in acute intoxications with pulmonary affection. Krasteva S, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):56–7

An explanation on the limited efficacy of detoxication against VX toxicity by purified specific antibodies. Liao WG, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):90–4

Use of continuous renal replacement therapy for detoxification? Riegel W. **Int J Artif Organs** 1996 Feb; 19(2):111–2 (9 ref.)

Poison information services [letter; comment] Seth SD, et al. **Natl Med J India** 1995 Sep–Oct;8(5):246. Comment on: Natl Med J India 1995 Jan–Feb;8(1):47.

Intensified dialysis treatment of ethylene glycol intoxication. Sabeel AI, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):125–9

[Voluntary drug poisoning cases admitted to an emergency care unit] Staikowsky F, et al. **Presse Med** 1995 Sep 30; 24(28):1296–300 (Eng. Abstr.) **(Fre)**

[Theophylline poisoning--clinical course and treatment] Aksnes H, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10; 116(4):481–4 (Eng. Abstr.) **(Nor)**

[Removal of toxic substances from the body as a method for normalization of the functioning of the immune system] Lebedev KA, et al. **Fiziol Cheloveka** 1995 Sep–Oct; 21(5):131–43 (22 ref.) **(Rus)**

[The use of magnetic hemotherapy in combined detoxification in acute exogenous poisonings] Luzhnikov EA, et al. **Klin Med (Mosk)** 1995;73(3):37–40 (Eng. Abstr.) **(Rus)**

[Treatment of limb paralysis using low-frequency deep electric stimulation] Li Khao Lin'. **Med Tr Prom Ekol** 1995; (9):33–7 (Eng. Abstr.) **(Rus)**

URINE

[Green-blue urine, an important sign of possible intoxication with a suicidal intent (letter)] Rubio Barbón S, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):399 **(Spa)**

VETERINARY

Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats. Rumbeiha WK, et al. **Am J Vet Res** 1995 Nov; 56(11):1529–33

Salinomycin toxicosis in male breeder turkeys. Andreasen JR Jr, et al. **Avian Dis** 1995 Jul–Sep;39(3):638–42

Apparent selenium toxicity in emus (Dromaius novaehollandiae). Kinder LL, et al. **Avian Dis** 1995 Jul–Sep;39(3):652–7

Accumulation of gossypol enantiomers in ovine tissues. Kim HL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb;113(2):417–20

Sherlock Holmes and chemical poisons [editorial; comment] Frape DL. **Equine Vet J** 1996 Mar;28(2):89–91. Comment on: Equine Vet J 1996 Mar;28(2):161–2.

Water deprivation--sodium ion toxicosis in cattle. Osweiler GD, et al. **J Vet Diagn Invest** 1995 Oct;7(4):583–5

Dicoumarol (moldy sweet clover) toxicosis in a group of Holstein calves. Yamini B, et al. **J Vet Diagn Invest** 1995 Jul;7(3):420–2

Illegal poisoning [letter] Thompson D. **Vet Rec** 1996 Feb 24;138(8):192

[Heavy metal poisoning in relation to glucose-6-phosphate dehydrogenase activity in sheep erythrocytes] Košťová D, et al. **Vet Med (Praha)** 1995 Dec;40(12):371–5 (Eng. Abstr.) **(Slo)**

[The effect of supermethrin, an insecticide, on health status indicators in sheep during subchronic poisoning] Neuschl J, et al. **Vet Med (Praha)** 1995 Dec;40(12):377–82 (Eng. Abstr.) **(Slo)**

[Toxicologic evaluation of supermethrin, a pyrethroid insecticide, in rabbits and pheasants] Neuschl J, et al. **Vet Med (Praha)** 1995 Dec;40(12):383–6 (Eng. Abstr.) **(Slo)**

POISONS

Antagonism of cyanide toxicity by isosorbide dinitrate: possible role of nitric oxide. Sun P, et al. **Toxicology** 1995 Dec 15;104(1–3):105–11

ADVERSE EFFECTS

Contact hypersensitivity to arsenic in a crystal factory worker. Barbaud A, et al. **Contact Dermatitis** 1995 Oct; 33(4):272–3

Diabetes mellitus among Swedish art glass workers--an effect of arsenic exposure? Rahman M, et al. **Scand J Work Environ Health** 1996 Apr;22(2):146–9

ANALYSIS

Forensic science. Brettell TA, et al. **Anal Chem** 1995 Jun 15;67(12):273R–294R (843 ref.)

The poisoned patient: the role of the laboratory. Flanagan RJ. **Br J Biomed Sci** 1995 Sep;52(3):202–13 (30 ref.)

Evaluation of an HPTLC method for the determination of strychnine and crimidine in biological samples. De Saqui-Sannes P, et al. **J Anal Toxicol** 1996 May–Jun; 20(3):185–8

Simultaneous gas chromatographic determination of four toxic gases generally present in combustion atmospheres. Endecott BR, et al. **J Anal Toxicol** 1996 May–Jun; 20(3):189–94

The use of REMEDI HS in toxicological diagnostics of patients poisoned with drugs at the Department of Toxicology Collegium Medicum of the Jagiellonian University in Kraków. Pach J, et al. **Przegl Lek** 1996; 53(4):377–9

ANTAGONISTS & INHIBITORS see ANTIDOTES

BLOOD

Predictors of carbon monoxide and hydrogen cyanide exposure in smoke inhalation patients. Shusterman D, et al. **J Toxicol Clin Toxicol** 1996;34(1):61–71

METABOLISM

Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Huang RN, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):243–9

POISONS

PHARMACOLOGY

Cardiotoxic drugs. Derlet RW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):771–91 (93 ref.)

Competition between positive and negative allosteric effectors on muscarinic receptors. Proška J, et al. **Mol Pharmacol** 1995 Oct;48(4):696–702

POISONING

Incidental kill of dunlin and killdeer by strychnine. Warnock N, et al. **J Wildl Dis** 1995 Oct;31(4):566–9

Rhabdomyolysis and acute renal failure following blowpipe dart poisoning. Ho LM, et al. **Nephron** 1996;72(4):676–8

TOXICITY

The effects of injection of potassium cyanide into the sciatic nerve of the adult mouse: in vivo and electron microscopic studies. Hall SM. **J Neurocytol** 1972 Oct;1(3):233–54

ATP depletion by iodoacetate and cyanide in renal distal tubular cells. Lash LH, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):194–205

Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):253–72 (130 ref.)

URINE

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study. Buchet JP, et al. **Occup Environ Med** 1996 May;53(5):320–7

POISSON DISTRIBUTION

Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. Bonnefoix T, et al. **J Immunol Methods** 1996 Aug 14; 194(2):113–9

Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Gardner W, et al. **Psychol Bull** 1995 Nov;118(3):392–404

The design and analysis of randomized trials with recurrent events. Cook RJ. **Stat Med** 1995 Oct 15;14(19):2081–98

Distribution of genome shared IBD by half-sibs: approximation by the Poisson clumping heuristic. Bickeböller H, et al. **Theor Popul Biol** 1996 Aug;50(1):66–90

POKEWEED LECTINS see **POKEWEED MITOGENS**

POKEWEED MITOGENS

The proliferative responses of cow stripping milk and blood lymphocytes to pokeweed mitogen and ginseng in vitro. Concha C, et al. **Vet Res** 1996;27(2):107–15

GENETICS

A high degree of sequence homology in the putative carbohydrate recognition domains of pokeweed mitogen and wheat germ agglutinin: poly-N-acetyllactosamine-binding lectins from different species. Konami Y, et al. **Glycobiology** 1995 Oct;5(7):663–70

PHARMACOLOGY

The effect of medium derived from activated peripheral blood mononuclear cells on two intestinal cell lines. Kärnström U, et al. **Adv Exp Med Biol** 1995;371A:197–9

A simple and rapid flow cytometric method to measure lymphocyte activation in HIV+ subjects. Diminished response to pokeweed mitogen in early disease. Jagers E, et al. **Anal Cell Pathol** 1995 Jun;8(4):345–55

Transforming growth factor beta 1 inhibits interleukin-10 mRNA expression and production in pokeweed mitogen-stimulated peripheral blood mononuclear cells and T cells. Reinhold D, et al. **J Interferon Cytokine Res** 1995 Aug;15(8):685–90

Effects of concanavalin A and pokeweed lectins on microvillar membrane proteins during the organ culture of rabbit intestinal mucosa. Embaye H, et al. **Res Vet Sci** 1995 Jul;59(1):50–5

TOXICITY

Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. Lionetti P, et al. **Adv Exp Med Biol** 1995; 371A:493–6

POL GENE PRODUCTS see **GENE PRODUCTS, POL**

POL GENES see **GENES, POL**

POL POLYPROTEINS see **GENE PRODUCTS, POL**

POL PROTEIN see **GENE PRODUCTS, POL**

POL I see **DNA POLYMERASE I**

POL II see **DNA POLYMERASE II**

POL III see **DNA POLYMERASE III**

POLAND SYNDROME

[Radiological and clinical aspects of Poland syndrome] Terhaar O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):88–90 **(Ger)**

DIAGNOSIS

Intrafamilial phenotypic heterogeneity of the Poland complex: a case report. Parano E, et al. **Neuropediatrics** 1995 Aug;26(4):217–9

GENETICS

Intrafamilial phenotypic heterogeneity of the Poland complex: a case report. Parano E, et al. **Neuropediatrics** 1995 Aug;26(4):217–9

PATHOLOGY

True breast hypoplasia in Poland's syndrome [letter] Cooper RA. **AJR Am J Roentgenol** 1996 Jul;167(1):284

RADIOGRAPHY

Poland's syndrome: a mammographic presentation. Samuels TH, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):347–8

SURGERY

[Poland syndrome. Problems of reconstructive and aesthetic surgery—a clinical case] Martinazzoli A, et al. **G Chir** 1995 Nov-Dec;16(11-12):497–501 (Eng. Abstr.) **(Ita)**

POLAR RECOMBINATION see **GENE CONVERSION**

POLAR REGIONS see **COLD CLIMATE**

POLARITY OF TRANSCRIPTION see **POLARITY OF TRANSLATION**

POLARITY OF TRANSLATION

Resorption-cycle-dependent polarization of mRNAs for different subunits of V-ATPase in bone-resorbing osteoclasts. Laitala-Leinonen T, et al. **Mol Biol Cell** 1996 Jan;7(1):129–42

POLARIZATION, FLUORESCENCE see **FLUORESCENCE POLARIZATION**

POLARIZATION FLUOROIMMUNOASSAY see **FLUORESCENCE POLARIZATION IMMUNOASSAY**

POLARIZATION MICROSCOPY see **MICROSCOPY, POLARIZATION**

POLAROGRAPHY

METHODS

Polarographic determination of prenalterol hydrochloride through treatment with nitrous acid. Aly FA, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1127–31

POLARON see **GENE CONVERSION**

POLICE

Developing policies for automated speed enforcement: a survey of Michigan opinions. Streff FM, et al. **Accid Anal Prev** 1995 Aug;27(4):611–6

The role of work experience and individual beliefs in police officers' perceptions of date rape: an integration of quantitative and qualitative methods. Campbell R. **Am J Community Psychol** 1995 Apr;23(2):249–77

Safe storage of handguns. What do the police recommend? Denno DM, et al. **Arch Pediatr Adolesc Med** 1996 Sep; 150(9):927–31

Deaths in police custody are being analysed retrospectively [letter; comment] Norfolk G, et al. **BMJ** 1996 Apr 6; 312(7035):911. Comment on: BMJ 1996 Jan 6;312(7022):56.

Deaths in police custody [letter] [see comments] Patel V. **BMJ** 1996 Jan 6;312(7022):56. Comment in: BMJ 1996 Apr 6;312(7035):911.

Should doctors be more proactive as advocates for victims of violence? Shepherd J, et al. **BMJ** 1995 Dec 16; 311(7020):1617–21

California law enforcement agencies and the mentally ill offender. Husted JR, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):315–29

Increased sister chromatid exchange (SCE) frequencies in lymphocytes from traffic policemen exposed to automobile exhaust pollution. Chandrasekaran R, et al. **Hum Exp Toxicol** 1996 Apr;15(4):301–4

Development of a hearing performance standard for law enforcement officers. Punch JL, et al. **J Am Acad Audiol** 1996 Apr;7(2):113–9

Police officer candidate MMPI-2 performance: gender, ethnic, and normative factors. Kornfeld AD. **J Clin Psychol** 1995 Jul;51(4):536–40

Comparison of accident and emergency with police road injury data. Cercarelli LR, et al. **J Trauma** 1996 May; 40(5):805–9

The impact of cohesive groups in the trauma recovery context: police spouse survivors and duty-related death. Violanti JM. **J Trauma Stress** 1996 Apr;9(2):379–86

Outcome for psychiatric emergency patients seen by an outreach police-mental health team. Lamb HR, et al. **Psychiatr Serv** 1995 Dec;46(12):1267–71

A study of gunshot suicides in Northern Ireland from 1989 to 1993. Armour A. **Sci Justice** 1996 Jan-Mar;36(1):21–5

Police involvement in domestic violence: the interactive effects of victim injury, offender's history of violence, and race. Bachman R, et al. **Violence Vict** 1995 Summer; 10(2):91–106

[Evaluating vision after photorefractive keratectomy within the scope of legal police service requirement 300] Bodanowitz S, et al. **Klin Monatsbl Augenheilkd** 1995 Sep; 207(3):203–5 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Trends in police suicide. Violanti JM. **Psychol Rep** 1995 Oct; 77(2):688–90

UTILIZATION

Urban trauma transport of assaulted patients using nonmedical personnel [see comments] Branas CC, et al. **Acad Emerg Med** 1995 Jun;2(6):486–93. Comment in: Acad Emerg Med 1995 Jun;2(6):477–9.

POLICY MAKING

see related
HEALTH POLICY
PUBLIC POLICY

Making difficult health policy decisions: most choices are not simply life or death [comment] Evens RG. **AJR Am J Roentgenol** 1995 Dec;165(6):1329–30. Comment on: AJR Am J Roentgenol 1995 Dec;165(6):1323–8.

New measures can help to measure economic "externalities" [letter; comment] Mayo E. **BMJ** 1995 Sep 30;311(7009):878 . Comment on: BMJ 1995 Jul 1;311(6996):1–2.

Foundations' impact on policy making: results from a pilot study. Weissert CS, et al. **Health Aff (Millwood)** 1995 Winter;14(4):275–86 (31 ref.)

If it works for the military, why not Medicare? [news] MacPherson P. **Hosp Health Netw** 1996 Jul 20;70(14):40

Developing policies and guidelines. Brennan PJ, et al. **Infect Control Hosp Epidemiol** 1995 Sep;16(9):512–7

Joint nursing appointments: a vehicle for influencing health care change. Tamlyn D, et al. **J Adv Nurs** 1995 Sep; 22(3):490–3 (18 ref.)

Allocating health care: cost-utility analysis, informed democratic decision making, or the veil of ignorance? Goold SD. **J Health Polit Policy Law** 1996 Spring; 21(1):69–98 (41 ref.)

Lawmakers' views on the failure of health reform: a survey of members of Congress and staff. Hansen O, et al. **J Health Polit Policy Law** 1996 Spring;21(1):137–51

Talking heads and sleeping citizens: health policy making in a democracy. Jacobs LR. **J Health Polit Policy Law** 1996 Spring;21(1):129–35

Thinking, talking, acting [editorial] Peterson MA. **J Health Polit Policy Law** 1996 Spring;21(1):1–2

Public policy. A values orientation to health care policy. Kjervik DK. **J Prof Nurs** 1996 Mar-Apr;12(2):67

The shifting sands of graduate medical education. Dunn MR, et al. **JAMA** 1996 Sep 4;276(9):710–3

Bureaucratic intrusion impedes patient care [letter] Hunt RW. **Med J Aust** 1996 Sep 2;165(5):295

Developing a health informatics policy for South Africa. Power M. **Medinfo** 1995;8 Pt 2:1616–20

The ethical issues of futility from a community perspective. Churchill LR. **N C Med J** 1995 Sep;56(9):424–6

Lessons from communities in conversation. The Colorado experience. Murphy DJ. **N C Med J** 1995 Sep;56(9):428–30

A community policy on futility? A conversation of the North Carolina community [editorial] Sugarman J. **N C Med J** 1995 Sep;56(9):415–7

Policy-relevant research on infant mortality: rhetorical criticism of mass media. Rains JW. **Nurs Outlook** 1995 Jul-Aug;43(4):158–63

Using guidelines for education, policy making, and assessing quality of care. Hagan S. **Oncol Nurs Forum** 1995 Oct; 22(9):1435–6

An unpredictable mix ... [editorial] Nutbeam D. **Promot Educ** 1995 Jun-Sep;2(2-3):4–7 **(Eng, Fre)**

Cancer prevention policy. Authority and responsibility—who is in charge of carcinogenic hazards and their sequelae? Modan B. **Public Health Rev** 1995;23(2):119–26

Policy goals for health and safety. Lind NC. **Risk Anal** 1995 Dec;15(6):639–44

The use of geographical information systems in studies on environment and health. Briggs DJ, et al. **World Health Stat Q** 1995;48(2):85–94 (31 ref.)

Health and environment analysis for decision making. Corvalán C, et al. **World Health Stat Q** 1995;48(2):71–7 (16 ref.)

Linkage failures in ecological studies. Nurminen M. **World Health Stat Q** 1995;48(2):78–84 (20 ref.)

Decision-making in environmental health. Schwartz E, et al. **World Health Stat Q** 1995;48(2):164–70

Health and Environment Analysis for Decision-Making (HEADLAMP): field study in Accra, Ghana. Songsore

J, et al. **World Health Stat Q** 1995;48(2):108–17
Health and environment in São Paulo, Brazil: methods of data linkage and questions of policy. Stephens C, et al. **World Health Stat Q** 1995;48(2):95–107

POLIODYSTROPHIA CEREBRI see **CEREBRAL SCLEROSIS, DIFFUSE**

POLIOMYELITIS

see related
POSTPOLIOMYELITIS SYNDROME

Polio and small pox: diseases of historical interest because of vaccines. Will this also apply to Helicobacter pylori? Fennerty MB. **Am J Gastroenterol** 1996 Jan;91(1):170–1
The 45th annual John Stanley Coulter Lecture. Post-polio sequelae and the paradigms of the 50s: Newtie, Ozzie, and Harriet versus paradigms of caring and a future for rehabilitation in America. Bruno RL.
Arch Phys Med Rehabil 1995 Dec;76(12):1093–6
Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)
[The International Rotary Foundation is a great help in the eradication of poliomyelitis (letter)] Tillander H.
Lakartidningen 1996 Apr 3;93(14):1316 **(Swe)**

CHEMICALLY INDUCED

Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Weibel RE, et al.
Am J Public Health 1996 May;86(5):734–7

COMPLICATIONS

Chronic gastric volvulus—an unusual complication of poliomyelitis. Kumar A, et al. **Indian Pediatr** 1995 Apr; 32(4):502–4
A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease. Chen HH, et al. **Nat Med** 1995 Sep;1(9):927–31
[Late complications of poliomyelitis] Pal'chik AB, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(2):32–6 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

[Role of laboratory diagnosis in eradication project for poliomyelitis in countries of west Pacific-Ocean area] Hagiwara A. **Uirusu** 1995 Jun;45(1):67–8 **(Jpn)**

DRUG THERAPY

An open trial of pyridostigmine in post-poliomyelitis syndrome. Trojan DA, et al. **Can J Neurol Sci** 1995 Aug; 22(3):223–7

EPIDEMIOLOGY

Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Weibel RE, et al.
Am J Public Health 1996 May;86(5):734–7
Global eradication of polio by 2000 is not a realistic goal [letter] Howarth J. **BMJ** 1996 Sep 7;313(7057):627
Epidemiology and clinical characteristics of acute flaccid paralysis associated with non-polio enterovirus isolation: the experience in the Americas. Dietz V, et al.
Bull World Health Organ 1995;73(5):597–603
Polio eradication initiative [news] **Cent Afr J Med** 1995 Oct; 41(10):334
Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Rümke HC, et al. **Epidemiol Infect** 1995 Oct; 115(2):289–98 (31 ref.)
Immunization status of hospitalized children with acute paralytic poliomyelitis [letter] John TJ. **Indian Pediatr** 1996 Mar;33(3):246–7
Molecular characterization of a wild poliovirus type 3 epidemic in The Netherlands (1992 and 1993). Mulders MN, et al. **J Clin Microbiol** 1995 Dec;33(12):3252–6
From the Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication—South East Asia region, 1988–1994. **JAMA** 1995 Nov 15; 274(19):1498–9
Poliomyelitis outbreak in Zambia [letter] Mpabalwani EM, et al. **Lancet** 1996 Jun 8;347(9015):1633
Progress toward poliomyelitis eradication—Indonesia, 1995. **MMWR Morb Mortal Wkly Rep** 1996 Aug 16; 45(32):697–700
Progress toward poliomyelitis eradication—south east Asia region, 1988–1994. **MMWR Morb Mortal Wkly Rep** 1995 Oct 27;44(42):791, 797–801
Progress toward poliomyelitis eradication—eastern Mediterranean region, 1988–1994.
MMWR Morb Mortal Wkly Rep 1995 Nov 3;44(43):809–11, 817–8
Progress on polio in India [letter] Wyatt HV. **Nat Med** 1996 Jun;2(6):608
Reported annual incidence of poliomyelitis and acute flaccid paralysis (AFP), by WHO region. **Wkly Epidemiol Rec** 1996 Apr 26;71(17):128–9
[The Dutch poliomyelitis epidemic 1992/'93; invalidity and rehabilitation] van Asbeck FW. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1178–82 (Eng. Abstr.) **(Dut)**
[Polio vaccination today: critical remarks (letter; comment)] Allwinn R, et al. **Immun Infekt** 1995 Dec;23(6):III–IV, 234 . Comment on: Immun Infekt 1995 Aug;23(4):130–3. **(Ger)**
[Poliomyelitis surveillance: seroepidemiologic study on a Piedmont population sample] Maiello A, et al.
Ann Ist Super Sanita 1995;31(3):317–22 (Eng. Abstr.) **(Ita)**
[Poliomyelitis in Europe: 1950–1951] Oblapenko GP.
Tr Inst Im Pastera 1992;67:122–5 **(Rus)**
[Poliomyelitis and acute flaccid paralysis. Perspectives for its epidemiologic surveillance] Montesano-Castellanos R, et al. **Gac Med Mex** 1995 Jan-Feb;131(1):113–6 **(Spa)**
[Children with poliomyelitis in Sweden 1996] Borg K, et al. **Lakartidningen** 1996 Apr 24;93(17):1637–8 **(Swe)**

ETIOLOGY

Poliovirus biology and pathogenesis. Racaniello VR, et al. **Curr Top Microbiol Immunol** 1996;206:305–25 (103 ref.)
Vaccine-associated paralytic poliomyelitis [see comments] Sullivan AA, et al. **Med J Aust** 1995 Oct 16;163(8):423–4 . Comment in: Med J Aust 1996 Feb 19;164(4):255–6.
Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Izurieta HS, et al.
Pediatr Infect Dis J 1995 Oct;14(10):840–6
[Response to "Point de vue" in the Revue Médicale de la Suisse Romande of April 96 (RMSR, 116: 305–307, 1996)] Lorenz E. **Rev Med Suisse Romande** 1996 Jun;116(6):511 **(Fre)**

GENETICS

[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305–15; discussion 315–6 (27 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

History of poliomyelitis in the Czech Republic—Part III. Slonim D, et al. **Cent Eur J Public Health** 1995 Aug; 3(3):124–6
Before intensive therapy? Gilbertson AA. **J R Soc Med** 1995 Aug;88(8):459P–463P
Masaccio's cripple [letter; comment] Loschiavo F. **Lancet** 1996 Mar 2;347(9001):628. Comment on: Lancet 1995 Dec 23–30;346(8991–8892):1684–6.
Masaccio's cripple [letter; comment] Rose FC. **Lancet** 1996 Mar 2;347(9001):628. Comment on: Lancet 1995 Dec 23–30;346(8991–8892):1684–6.
[Poliomyelitis and artificial ventilation] Böhrer H, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun; 31(5):316–7 **(Ger)**

IMMUNOLOGY

Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Rümke HC, et al. **Epidemiol Infect** 1995 Oct; 115(2):289–98 (31 ref.)
Immunology of Theiler's murine encephalomyelitis virus infection. Oleszak EL, et al. **Immunol Res** 1995;14(1):13–33 (153 ref.)
Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)
Paralysis caused by acute myelitis in Theiler's murine encephalomyelitis virus strain GD VII infection is induced by CD4+ lymphocytes infiltrating the spinal cord. Kohanawa M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2251–6
Adoptively transferred CD8+ T lymphocytes provide protection against TMEV-induced demyelinating disease in BALB/c mice. Nicholson SM, et al. **J Immunol** 1996 Feb 1;156(3):1276–83
Flow cytometric and functional analyses of central nervous system-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease. Evidence for a CD4+ T cell-mediated pathology. Pope JG, et al.
J Immunol 1996 May 15;156(10):4050–8
Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. II. Persistent infection. Sapatino BV, et al. **J Neuroimmunol** 1995 Nov; 62(2):127–35
Lateralization of cutaneous inflammatory responses in patients with unilateral paresis after poliomyelitis. Tarkowski E, et al. **J Neuroimmunol** 1996 Jun;67(1):1–6
Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. I. Acute infection. Welsh CJ, et al. **J Neuroimmunol** 1995 Nov;62(2):119–25
Immunity to hepatitis B, poliomyelitis and measles in fully vaccinated aboriginal and Torres Strait Island children. Hanna JN, et al. **J Paediatr Child Health** 1995 Aug; 31(4):345–9
Enterovirus specific IgM responses in children with acute and chronic paralytic syndrome. Tuteja U, et al.
J Trop Med Hyg 1995 Dec;98(6):367–72
Infection of class II-deficient mice by the DA strain of Theiler's virus. Fiette L, et al. **J Virol** 1996 Jul;70(7):4811–5
Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. Njenga MK, et al. **J Virol** 1996 Mar;70(3):1729–37
VP1 and VP2 capsid proteins of Theiler's virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Lin X, et al. **Virology** 1995 Dec 1;214(1):91–9
[Antibody activity before polio vaccination] Müller HE.
Dtsch Med Wochenschr 1996 Apr 19;121(16):539 **(Ger)**
[Poliomyelitis surveillance: seroepidemiologic study on a Piedmont population sample] Maiello A, et al.
Ann Ist Super Sanita 1995;31(3):317–22 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al.
Microsc Res Tech 1995 Oct 15;32(3):215–29 (74 ref.)
Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

PHYSIOPATHOLOGY

Contractile properties in single muscle fibres from chronically overused motor units in relation to motoneuron firing properties in prior polio patients. Larsson L, et al.
J Neurol Sci 1995 Oct;132(2):182–92
Spontaneous CNS remyelination in beta 2 microglobulin-deficient mice following virus-induced demyelination. Miller DJ, et al. **J Neurosci** 1995 Dec; 15(12):8345–52
Mode of spread to and within the central nervous system after oral infection of neonatal mice with the DA strain of Theiler's murine encephalomyelitis virus. Ha-Lee YM, et al. **J Virol** 1995 Nov;69(11):7354–61
Fatigue of chronically overused motor units in prior polio patients. Grimby L, et al. **Muscle Nerve** 1996 Jun; 19(6):728–37
Muscle strength in postpolio patients: a prospective follow-up study. Ivanyi B, et al. **Muscle Nerve** 1996 Jun; 19(6):738–42
Lack of progression of neurologic deficit in survivors of paralytic polio: a 5-year prospective population-based study. Windebank AJ, et al. **Neurology** 1996 Jan;46(1):80–4

PREVENTION & CONTROL

Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Eichner M, et al. **Am J Epidemiol** 1996 Apr 15;143(8):816–22
Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. Parkkali T, et al. **APMIS** 1996 May;104(5):383–8
Mass polio vaccination [editorial] Chander J, et al. **BMJ** 1996 May 11;312(7040):1178–9
Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.
Bull World Health Organ 1996;74(3):253–68
Global eradication of poliomyelitis: benefit-cost analysis. Bart KJ, et al. **Bull World Health Organ** 1996;74(1):35–45
Statement on poliomyelitis vaccination for international travellers (evidence-based medicine recommendations). Committee to Advise on Tropical Medicine and Travel (CATMAT). **Can Commun Dis Rep** 1995 Aug 30; 21(16):145–8 **(Eng, Fre)**
Polio eradication initiative [news] **Cent Afr J Med** 1995 Oct; 41(10):334
Eradicating measles and poliomyelitis: 200 years after Jenner. **Commun Dis Rep CDR Wkly** 1996 May 24;6(21):181, 184
Winning the war against paralytic poliomyelitis. Wegmann A, et al. **Eur J Pediatr** 1995 Sep;154(9):691–3
Pulse immunization against poliomyelitis in India. Mittal SK. **Indian Pediatr** 1995 Aug;32(8):939–40; discussion 940–2
Pulse polio—should we be giving it? [see comments] Sanklecha MU. **Indian Pediatr** 1995 Apr;32(4):511–2. Comment in: Indian Pediatr 1995 Aug;32(8):938; discussion 939.
Pulse polio immunization [comment] Sanklecha MU. **Indian Pediatr** 1995 Aug;32(8):938; discussion 939. Comment on: Indian Pediatr 1995 Apr;32(4):511–2.
Polio eradication in India: pulse polio immunization. Sokhey J. **Indian Pediatr** 1996 Mar;33(3):254–6
A process evaluation of pulse polio immunization. Sokhey J, et al. **Indian Pediatr** 1996 Mar;33(3):257–61
Adoptively transferred CD8+ T lymphocytes provide protection against TMEV-induced demyelinating disease in BALB/c mice. Nicholson SM, et al. **J Immunol** 1996 Feb 1;156(3):1276–83
From the Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication—India. **JAMA** 1996 Jun 12;275(22):1718
Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States [see comments] Chen RT, et al.
JAMA 1996 Jun 5;275(21):1639–45. Comment in: JAMA

1996 Jun 5;275(21):1682–3.
Polio eradication—how near? [editorial; comment] Foege WH. **JAMA** 1996 Jun 5;275(21):1682–3. Comment on: JAMA 1996 Jun 5;275(21):1639–45.
Cost–effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. Miller MA, et al. **JAMA** 1996 Sep 25;276(12):967–71
Polio eradication initiative in Iraq [letter] Aylward B. **Lancet** 1996 Mar 9;347(9002):695
Oral poliomyelitis vaccines [letter; comment] Chen RT. **Lancet** 1996 May 25;347(9013):1496. Comment on: Lancet 1996 Mar 9;347(9002):630.
Oral poliomyelitis vaccines [letter; comment] Hanna J. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.
Sabin, Salk, or sequential? [see comments] Hull HF, et al. **Lancet** 1996 Mar 9;347(9002):630. Comment in: Lancet 1996 May 25;347(9013):1495. Comment in: Lancet 1996 May 25;347(9013):1495–6. Comment in: Lancet 1996 May 25;347(9013):1496.
Oral poliomyelitis vaccines [letter; comment] Katz SL. **Lancet** 1996 May 25;347(9013):1495–6. Comment on: Lancet 1996 Mar 9;347(9002):630.
Oral poliomyelitis vaccines [letter; comment] Patriarca PA. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.
Polyvalent vaccines and the National Immunisation Schedule [letter] Boughton CR. **Med J Aust** 1996 Jul 1;165(1):59–60
Polio vaccination and polio eradication [editorial] Herceg A, et al. **Med J Aust** 1995 Oct 16;163(8):399–400
Progress toward poliomyelitis eradication—Indonesia, 1995. **MMWR Morb Mortal Wkly Rep** 1996 Aug 16; 45(32):697–700
Progress toward poliomyelitis eradication—India, December 1995 and January 1996. **MMWR Morb Mortal Wkly Rep** 1996 May 10;45(18):370–3
Polio eradication programme in India [letter] Singh AJ. **Natl Med J India** 1996 May–Jun;9(3):144
Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA. **Pediatr Infect Dis J** 1995 Oct;14(10):835–9 (0 ref.)
Changing the US polio immunization schedule would be bad public health policy [comment] Judelsohn R. **Pediatrics** 1996 Jul;98(1):115–6. Comment on: Pediatrics 1996 Jul;98(1):116–7.
Poliovaccine policy—time for a change [comment] Katz SL. **Pediatrics** 1996 Jul;98(1):116–7. Comment on: Pediatrics 1996 Jul;98(1):115–6.
Polio immunisation: not there yet [news] van der Linde I. **S Afr Med J** 1995 Nov;85(11):1129
Expanded programme on immunization. Progress towards poliomyelitis eradication, WHO south–east Asia region, 1988–1994. **Wkly Epidemiol Rec** 1995 Nov 17;70(46):325–9 **(Eng, Fre)**
Expanded programme on immunization. Statement on poliomyelitis eradication. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):345–6 **(Eng, Fre)**
WHO policy statement on polio vaccines. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):346–7 **(Eng, Fre)**
Expanded programme on immunization. Progress towards poliomyelitis eradication, WHO Eastern Mediterranean Region, 1988–1994. **Wkly Epidemiol Rec** 1995 Dec 14; 70(48):341–3 **(Eng, Fre)**
Expanded programme on immunization. Progress towards the global eradication of poliomyelitis, 1995. **Wkly Epidemiol Rec** 1996 Jun 21;71(25):189–94 **(Eng, Fre)**
Expanded programme on immunization. National immunization days. India. **Wkly Epidemiol Rec** 1996 May 31;71(22):169–71 **(Eng, Fre)**
Expanded programme on immunization (EPI). Immunization in the English–speaking Caribbean. **Wkly Epidemiol Rec** 1996 Jul 19;71(29):217–23 **(Eng, Fre)**
Expanded programme on immunization. **Wkly Epidemiol Rec** 1996 Feb 16;71(7):53–4
[Efforts to eradicate poliomyelitis in the Czech Republic] Koza J. **Epidemiol Mikrobiol Imunol** 1996 Mar;45(1):11–4 (Eng. Abstr.) **(Cze)**
[Polio vaccination today: critical remarks (see comments)] Hof H, et al. **Immun Infekt** 1995 Aug;23(4):130–3 (6 ref.) (Eng. Abstr.). Comment in: Immun Infekt 1995 Dec;23(6):III–IV, 234. **(Ger)**
[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):675–84 (36 ref.) (Eng. Abstr.) **(Ita)**
[Poliomyelitis immunity status in the centro–meridional Italy] Ribera G, et al. **Ann Ig** 1995 Nov–Dec;7(6):421–9 (Eng. Abstr.) **(Ita)**
[Eradication project for poliomyelitis and surveillance of acute paralysis] Chiba Y, et al. **Uirusu** 1995 Jun;45(1):53–5 **(Jpn)**
[Eradication project for poliomyelitis in Laos] Chosa T. **Uirusu** 1995 Jun;45(1):61–4 **(Jpn)**
[Progress on eradication project for poliomyelitis in Mekong–delta area in Vietnam] Enda K, et al. **Uirusu** 1995 Jun;45(1):57–9 **(Jpn)**
[Role of laboratory diagnosis in eradication project for poliomyelitis in countries of west Pacific–Ocean area] Hagiwara A. **Uirusu** 1995 Jun;45(1):67–8 **(Jpn)**
[Role of clinical laboratories in eradication project for poliomyelitis in China] Hara M. **Uirusu** 1995 Jun;45(1):65–6 **(Jpn)**
[Global eradication project for poliomyelitis] Miyamura T. **Uirusu** 1995 Jun;45(1):51–2 (3 ref.) **(Jpn)**
[The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis] Bondarenko VI, et al. **Mikrobiol Z** 1995 Nov–Dec;57(6):41–5 (Eng. Abstr.) **(Rus)**
[Successes in global eradication of poliomyelitis: 1985–1994] **Vopr Virusol** 1995 Nov–Dec;40(6):284–6 **(Rus)**
[A world without polio by the year 2000 (editorial)] Vuković B. **Med Pregl** 1995;48(5–6):147–8 **(Scr)**
[Swedish polio–protection is satisfactory. But before the disease is eradicated, everybody should be vaccinated] Böttiger M, et al. **Lakartidningen** 1996 Jan 17;93(3):138–41 **(Swe)**
[Poliomyelitis may be eradicated. But WHO needs help with vaccine, monitoring and laboratory resources from developed countries] Böttiger M. **Lakartidningen** 1996 Jan 17;93(3):141–3 **(Swe)**

REHABILITATION

Endurance training effect on individuals with postpoliomyelitis. Ernstoff B, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):843–8
Progress on polio in India [letter] Wyatt HV. **Nat Med** 1996 Jun;2(6):608
[The Dutch poliomyelitis epidemic 1992/'93; invalidity and rehabilitation] van Asbeck FW. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1178–82 (Eng. Abstr.) **(Dut)**

THERAPY

Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Rodriguez M, et al. **Neurology** 1996 Feb;46(2):538–45

TRANSMISSION

Circulation of poliovirus during the poliomyelitis outbreak in The Netherlands in 1992–1993. Conyn–van Spaendonck MA, et al. **Am J Epidemiol** 1996 May 1;143(9):929–35

VIROLOGY

Genomic characterization of type 1 Sabin–related polioviruses isolated in Brazil. Friedrich F, et al. **Acta Virol** 1995 Feb;39(1):23–9
Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine–associated paralytic patients. Li J, et al. **Arch Virol** 1996;141(6):1047–54
Differential susceptibility of transgenic PVR Tg–mice to poliovirus strains with varying neurovirulence in relation with monkeys [letter; comment] Arya SC. **Biologicals** 1995 Jun;23(2):191. Comment on: Biologicals 1993 Sep;21(3):233–7.
Genomic characterization of type 2 polioviruses isolated from vaccine–associated cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Jul;28(7):733–42
Genomic characterization of type 3 polioviruses isolated from vaccine–associated poliomyelitis cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Feb;28(2):195–200
Epidemiology and clinical characteristics of acute flaccid paralysis associated with non–polio enterovirus isolation: the experience in the Americas. Dietz V, et al. **Bull World Health Organ** 1995;73(5):597–603
Molecular characterization of a wild poliovirus type 3 epidemic in The Netherlands (1992 and 1993). Mulders MN, et al. **J Clin Microbiol** 1995 Dec;33(12):3252–6
Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. Georgescu MM, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2343–8
Genetic divergence of poliovirus strains isolated in the Karachi region of Pakistan. Huovilainen A, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3079–88
Theiler's murine encephalomyelitis virus 3D RNA polymerase: its expression in the CNS and the specific immune response generated in persistently infected mice. Johnston IC, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2765–77
Vaccine–associated paralytic poliomyelitis [letter; comment] Catton M, et al. **Med J Aust** 1996 Feb 19;164(4):255–6. Comment on: Med J Aust 1995 Oct 16;163(8):423–4.
Intratypic differentiation of polioviruses isolated from suspected cases of poliomyelitis in Brazil during the period of 1990 to 1993. de Filippis AM, et al. **Mem Inst Oswaldo Cruz** 1994 Oct–Dec;89(4):513–8
Mouse neuropathogenic poliovirus strains cause damage in the central nervous system distinct from poliomyelitis. Gromeier M, et al. **Microb Pathog** 1995 Apr;18(4):253–67
Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis–motor neurone disease. Swanson NR, et al. **Neuromuscul Disord** 1995 Nov;5(6):457–65
Change in the type of wild poliovirus circulating in the Central African Republic between 1991 and 1994. Gouandjika I, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):576
Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Lu Z, et al. **Virology** 1996 Jun 15;220(2):285–9
Poliovirus neurovirulence correlates with the presence of a cryptic AUG upstream of the initiator codon. Slobodskaya OR, et al. **Virology** 1996 Jul 1;221(1):141–50

POLIOVIRUS VACCINE

Circulation of poliovirus during the poliomyelitis outbreak in The Netherlands in 1992–1993. Conyn–van Spaendonck MA, et al. **Am J Epidemiol** 1996 May 1;143(9):929–35
Polio and small pox: diseases of historical interest because of vaccines. Will this also apply to Helicobacter pylori? Fennerty MB. **Am J Gastroenterol** 1996 Jan;91(1):170–1
Mass polio vaccination [editorial] Chander J, et al. **BMJ** 1996 May 11;312(7040):1178–9
Sudden infant death syndrome and diphtheria–tetanus–pertussis–poliomyelitis vaccination status. Jonville–Bera AP, et al. **Fundam Clin Pharmacol** 1995;9(3):263–70
Polio vaccine schedule will change, but when? [news] Marwick C. **JAMA** 1996 Mar 20;275(11):827
Switch to inactivated polio vaccine recommended [news] Marwick C. **JAMA** 1996 Jul 10;276(2):89
ACIP moves ahead with plans for use of IPV [news] Marwick C. **JAMA** 1995 Nov 8;274(18):1417–8
Not everyone wants IPV; opposition gears up [news] Marwick C. **JAMA** 1995 Nov 22–29;274(20):1574–5
Cost–effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. Miller MA, et al. **JAMA** 1996 Sep 25;276(12):967–71
Oral poliomyelitis vaccines [letter; comment] Chen RT. **Lancet** 1996 May 25;347(9013):1496. Comment on: Lancet 1996 Mar 9;347(9002):630.
Oral poliomyelitis vaccines [letter; comment] Hanna J. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.
Sabin, Salk, or sequential? [see comments] Hull HF, et al. **Lancet** 1996 Mar 9;347(9002):630. Comment in: Lancet 1996 May 25;347(9013):1495. Comment in: Lancet 1996 May 25;347(9013):1495–6. Comment in: Lancet 1996 May 25;347(9013):1496.
Oral poliomyelitis vaccines [letter; comment] Katz SL. **Lancet** 1996 May 25;347(9013):1495–6. Comment on: Lancet 1996 Mar 9;347(9002):630.
Oral poliomyelitis vaccines [letter; comment] Patriarca PA. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.
[Polio vaccination today: critical remarks (letter; comment)] Allwinn R, et al. **Immun Infekt** 1995 Dec;23(6):III–IV, 234 . Comment on: Immun Infekt 1995 Aug;23(4):130–3. **(Ger)**

ADMINISTRATION & DOSAGE

The CDC's proposed revision of polio immunization policy: is it wise? [letter] Judelsohn R. **Am J Public Health** 1996 Jun;86(6):890
A process evaluation of pulse polio immunization. Sokhey J, et al. **Indian Pediatr** 1996 Mar;33(3):257–61
Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA. **Pediatr Infect Dis J** 1995 Oct;14(10):835–9 (0 ref.)
Parent comprehension of polio vaccine information pamphlets. Davis TC, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):804–10
Changing the US polio immunization schedule would be bad public health policy [comment] Judelsohn R. **Pediatrics** 1996 Jul;98(1):115–6. Comment on: Pediatrics 1996 Jul;98(1):116–7.
Poliovaccine policy—time for a change [comment] Katz SL. **Pediatrics** 1996 Jul;98(1):116–7. Comment on: Pediatrics 1996 Jul;98(1):115–6.
Expanded programme on immunization. Statement on poliomyelitis eradication. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):345–6 **(Eng, Fre)**
[Antibody activity before polio vaccination] Müller HE. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):539 **(Ger)**
[Swedish polio–protection is satisfactory. But before the disease is eradicated, everybody should be vaccinated] Böttiger M, et al. **Lakartidningen** 1996 Jan 17;93(3):138–41 **(Swe)**

ADVERSE EFFECTS

Differential susceptibility of transgenic PVR Tg–mice to poliovirus strains with varying neurovirulence in relation with monkeys [letter; comment] Arya SC. **Biologicals** 1995 Jun;23(2):191. Comment on: Biologicals 1993 Sep;21(3):233–7.
Genomic characterization of type 2 polioviruses isolated from vaccine–associated cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Jul;28(7):733–42
Genomic characterization of type 3 polioviruses isolated from vaccine–associated poliomyelitis cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Feb;28(2):195–200
Vitamin A and vaccines, the importance of side–effects [letter; comment] de Francisco A, et al. **Eur J Clin Nutr** 1996 Feb;50(2):122. Comment on: Eur J Clin Nutr 1995 Jan;49(1):73–4.
Surveillance of vaccine–related adverse events in the first year of life: a Manitoba cohort study. Roberts JD, et al. **J Clin Epidemiol** 1996 Jan;49(1):51–8
Vaccine–associated paralytic poliomyelitis [letter; comment] Catton M, et al. **Med J Aust** 1996 Feb 19;164(4):255–6. Comment on: Med J Aust 1995 Oct 16;163(8):423–4.
[Postvaccination myelitis. Aspect and course followed by MRI] Abdennebi A, et al. **J Radiol** 1996 May;77(5):363–6 (Eng. Abstr.) **(Fre)**

ANALYSIS

Quality control for screening-assays by means of control charts: polio vaccine testing as an example. Vogel I. **Dev Biol Stand** 1996;86:346

GENETICS

Detection of a point mutation in poliovaccines with a water soluble carbodiimide reaction of DNA heteroduplexes. Amexis G, et al. **Dev Biol Stand** 1996;86:325

Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. Georgescu MM, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2343-8

HISTORY

Poliovaccines: lessons learnt and forgotten. Wyatt HV. **Pubbl Stn Zool Napoli II** 1995;17(1):91-112

IMMUNOLOGY

Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats. Kersten GF, et al. **Biologicals** 1995 Jun; 23(2):179-83

Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Kroon FP, et al. **Clin Infect Dis** 1995 Nov;21(5):1197-203

Rat immunogenicity assay of inactivated poliovirus. Bevilacqua JM, et al. **Dev Biol Stand** 1996;86:121-7

Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents. Pregliasco F, et al. **Vaccine** 1996 Mar;14(4):267-9

Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Twomey T, et al. **Vaccine** 1995 Nov;13(16):1603-10

[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):675-84 (36 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man. Cayol M, et al. **Clin Sci (Colch)** 1995 Oct;89(4):389-96

Importance of experiments in poliovirus-susceptible transgenic mice for evaluating current potency tests of inactivated polio vaccine (IPV). Taffs R, et al. **Dev Biol Stand** 1996;86:345

Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents. Pregliasco F, et al. **Vaccine** 1996 Mar;14(4):267-9

STANDARDS

[Polio vaccination today: critical remarks (see comments)] Hof H, et al. **Immun Infekt** 1995 Aug;23(4):130-3 (6 ref.) (Eng. Abstr.). Comment in: Immun Infekt 1995 Dec;23(6):III-IV, 234. **(Ger)**

SUPPLY & DISTRIBUTION

[Poliomyelitis may be eradicated. But WHO needs help with vaccine, monitoring and laboratory resources from developed countries] Böttiger M. **Lakartidningen** 1996 Jan 17;93(3):141-3 **(Swe)**

TOXICITY

Evaluation of new approaches to poliovirus vaccine neurovirulence tests. Wood DJ. **Dev Biol Stand** 1996; 86:79-83 (16 ref.)

POLIOVIRUS VACCINE, ORAL

Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. **Bull World Health Organ** 1996;74(3):253-68

Global eradication of poliomyelitis: benefit-cost analysis. Bart KJ, et al. **Bull World Health Organ** 1996;74(1):35-45

Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt. Linkins RW, et al. **Bull World Health Organ** 1995;73(5):589-95

Absence of wild poliovirus circulation among healthy children in a rural area with high oral poliovirus vaccination coverage. Deshpande JM, et al. **Indian J Med Res** 1996 Jun;103:289-93

Storage and handling of vaccines by family doctors. Finnegan P, et al. **Ir Med J** 1996 Mar-Apr;89(2):64-6, 68

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107-11 (35 ref.)

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. McGoldrick A, et al. **J Virol** 1995 Dec;69(12):7601-5

Not everyone wants IPV; opposition gears up [news] Marwick C. **JAMA** 1995 Nov 22-29;274(20):1574-5

Oral poliomyelitis vaccines [letter; comment] Chen RT. **Lancet** 1996 May 25;347(9013):1496. Comment on: Lancet 1996 Mar 9;347(9002):630.

Oral poliomyelitis vaccines [letter; comment] Hanna J. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.

Sabin, Salk, or sequential? [see comments] Hull HF, et al. **Lancet** 1996 Mar 9;347(9002):630. Comment in: Lancet 1996 May 25;347(9013):1495. Comment in: Lancet 1996 May 25;347(9013):1495-6. Comment in: Lancet 1996 May 25;347(9013):1496.

Oral poliomyelitis vaccines [letter; comment] Katz SL. **Lancet** 1996 May 25;347(9013):1495-6. Comment on: Lancet 1996 Mar 9;347(9002):630.

Oral poliomyelitis vaccines [letter; comment] Patriarca PA. **Lancet** 1996 May 25;347(9013):1495. Comment on: Lancet 1996 Mar 9;347(9002):630.

Progress toward poliomyelitis eradication--eastern Mediterranean region, 1988-1994. **MMWR Morb Mortal Wkly Rep** 1995 Nov 3;44(43):809-11, 817-8

Albert Sabin's monkey experiments [letter; comment] Katz SL. **Pharos** 1996 Spring;59(2):43. Comment on: Pharos 1995 Fall;58(4):37.

Thermostabilization of live virus vaccines by heavy water (D2O). Wu R, et al. **Vaccine** 1995 Aug;13(12):1058-63

Expanded programme on immunization. Progress towards poliomyelitis eradication, WHO Eastern Mediterranean Region, 1988-1994. **Wkly Epidemiol Rec** 1995 Dec 14; 70(48):341-3 **(Eng, Fre)**

[Response to "Point de vue" in the Revue Médicale de la Suisse Romande of April 96 (RMSR, 116: 305-307, 1996)] Lorenz E. **Rev Med Suisse Romande** 1996 Jun;116(6):511 **(Fre)**

[Polio vaccination today: critical remarks (letter; comment)] Allwinn R, et al. **Immun Infekt** 1995 Dec;23(6):III-IV, 234 . Comment on: Immun Infekt 1995 Aug;23(4):130-3. **(Ger)**

ADMINISTRATION & DOSAGE

Immunization status of hospitalized children with acute paralytic poliomyelitis [letter] John TJ. **Indian Pediatr** 1996 Mar;33(3):246-7

Pulse immunization against poliomyelitis in India. Mittal SK. **Indian Pediatr** 1995 Aug;32(8):939-40; discussion 940-2

Can BCG be given along with DPT and polio? [letter] Paul Y. **Indian Pediatr** 1995 Jun;32(6):699-700

Pulse polio--should we be giving it? [see comments] Sanklecha MU. **Indian Pediatr** 1995 Apr;32(4):511-2. Comment in: Indian Pediatr 1995 Aug;32(8):938; discussion 939.

Pulse polio immunization [comment] Sanklecha MU. **Indian Pediatr** 1995 Aug;32(8):938; discussion 939. Comment on: Indian Pediatr 1995 Apr;32(4):511-2.

Polio eradication in India: pulse polio immunization. Sokhey J. **Indian Pediatr** 1996 Mar;33(3):254-6

Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. Rennels MB, et al. **J Infect Dis** 1996 Feb;173(2):306-13

From the Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication--India. **JAMA** 1996 Jun 12;275(22):1718

Progress toward poliomyelitis eradication--Indonesia, 1995. **MMWR Morb Mortal Wkly Rep** 1996 Aug 16; 45(32):697-700

Progress toward poliomyelitis eradication--India, December 1995 and January 1996. **MMWR Morb Mortal Wkly Rep** 1996 May 10;45(18):370-3

Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA. **Pediatr Infect Dis J** 1995 Oct;14(10):835-9 (0 ref.)

Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Lu Z, et al. **Virology** 1996 Jun 15;220(2):285-9

Expanded programme on immunization. National immunization days. India. **Wkly Epidemiol Rec** 1996 May 31;71(22):169-71 **(Eng, Fre)**

Expanded programme on immunization. Progress towards the global eradication of poliomyelitis, 1995. **Wkly Epidemiol Rec** 1996 Jun 21;71(25):189-94 **(Eng, Fre)**

Expanded programme on immunization. Statement on poliomyelitis eradication. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):345-6 **(Eng, Fre)**

Expanded programme on immunization. Progress towards poliomyelitis eradication, WHO south-east Asia region, 1988-1994. **Wkly Epidemiol Rec** 1995 Nov 17;70(46):325-9 **(Eng, Fre)**

WHO policy statement on polio vaccines. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):346-7 **(Eng, Fre)**

[Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan] Akoua-Koffi G, et al. **Bull Soc Pathol Exot** 1995;88(3):117-20 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Weibel RE, et al. **Am J Public Health** 1996 May;86(5):734-7

Vaccine-associated paralytic poliomyelitis [see comments] Sullivan AA, et al. **Med J Aust** 1995 Oct 16;163(8):423-4 . Comment in: Med J Aust 1996 Feb 19;164(4):255-6.

Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Izurieta HS, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):840-6

My response to "polio vaccines and the origin of AIDS" [letter; comment] Koprowski H. **Res Virol** 1995 May-Jun; 146(3):233-4. Comment on: Res Virol 1993 Mar-Apr;144(2):175-7.

GENETICS

Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil. Friedrich F, et al. **Acta Virol** 1995 Feb;39(1):23-9

Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Li J, et al. **Arch Virol** 1996;141(6):1047-54

HISTORY

Reminiscences of Albert Sabin and his successful strategy for the development of the live oral poliovirus vaccine. Chanock RM. **Proc Assoc Am Physicians** 1996 Mar; 108(2):117-26

IMMUNOLOGY

Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States [see comments] Chen RT, et al. **JAMA** 1996 Jun 5;275(21):1639-45. Comment in: JAMA 1996 Jun 5;275(21):1682-3.

Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Aristegui J, et al. **Vaccine** 1995 Aug; 13(11):973-7

Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. Da Villa G, et al. **Vaccine** 1995 Jun;13(9):795-8

[Application and development of immunity of childhood vaccines] Yang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Apr; 76(4):318-9 (21 ref.) **(Chi)**

[Surveillance of levels of neutralizing antibodies against poliovirus among children aged 0-3 in rural areas of Anhui Province] Shen Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):335-8 (Eng. Abstr.) **(Chi)**

[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):675-84 (36 ref.) (Eng. Abstr.) **(Ita)**

[The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis] Bondarenko VI, et al. **Mikrobiol Z** 1995 Nov-Dec;57(6):41-5 (Eng. Abstr.) **(Rus)**

[The immunogenicity of vaccines against diphtheria, tetanus, pertussis and polio administered orally on the vaccinal calendar at the age of 2, 4 and 6 months and their coadministration with a hepatitis B vaccine at 0, 2 and 6 months] Arístegui Fernández J, et al. **An Esp Pediatr** 1996 Jan;44(1):25-8 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Nasopharyngeal and systemic humoral responses induced by trivalent attenuated poliomyelitis vaccine in newborns. Padilla-Ramos JC, et al. **Adv Exp Med Biol** 1995; 371B:1601-4

STANDARDS

Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. Lu Z, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):273-80

Stabilising oral poliovaccine at high ambient temperatures. Newman JF, et al. **Vaccine** 1995;13(15):1431-5

POLIOVIRUSES

CLASSIFICATION

Comparative study of five methods for intratypic differentiation of polioviruses. van der Avoort HG, et al. **J Clin Microbiol** 1995 Oct;33(10):2562-6

Change in the type of wild poliovirus circulating in the Central African Republic between 1991 and 1994. Gouandjika I, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):576

DRUG EFFECTS

Thermostabilization of live virus vaccines by heavy water (D2O). Wu R, et al. **Vaccine** 1995 Aug;13(12):1058-63

ENZYMOLOGY

Inhibition of basal transcription by poliovirus: a virus-encoded protease (3Cpro) inhibits formation of TBP-TATA box complex in vitro. Yalamanchili P, et al. **J Virol** 1996 May;70(5):2922-9

DNA binding domain and subunit interactions of transcription factor IIIC revealed by dissection with poliovirus 3C protease. Shen Y, et al. **Mol Cell Biol** 1996

Aug;16(8):4163–71
Human protein Sam68 relocalization and interaction with poliovirus RNA polymerase in infected cells. McBride AE, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2296–301
Functional oligomerization of poliovirus RNA–dependent RNA polymerase. Pata JD, et al. **RNA** 1995 Jul;1(5):466–77
Poliovirus RNA polymerase mutation 3D–M394T results in a temperature–sensitive defect in RNA synthesis. Barton DJ, et al. **Virology** 1996 Mar 15;217(2):459–69
Mutations in the poliovirus 3CD proteinase S1–specificity pocket affect substrate recognition and RNA binding. Blair WS, et al. **Virology** 1996 Apr 1;218(1):1–13

GENETICS

A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X–linked CGD by selection for MDR1 expression. Sokolic RA, et al. **Blood** 1996 Jan 1;87(1):42–50
Anatomy of the poliovirus internal ribosome entry site. Ehrenfeld E, et al. **Curr Top Microbiol Immunol** 1995; 203:65–83 (86 ref.)
Genetic variation of the poliovirus genome with two VPg coding units. Cao X, et al. **EMBO J** 1996 Jan 2;15(1):23–33
Reverse transcription, amplification and sequencing of poliovirus RNA by Taq DNA polymerase. Grabko VI, et al. **FEBS Lett** 1996 Jun 3;387(2–3):189–92
Mutational analysis of the 3'–terminal extra–cistronic region of poliovirus RNA: secondary structure is not the only requirement for minus strand RNA replication. Pierangeli A, et al. **FEBS Lett** 1995 Nov 6;374(3):327–32
Molecular characterization of a wild poliovirus type 3 epidemic in The Netherlands (1992 and 1993). Mulders MN, et al. **J Clin Microbiol** 1995 Dec;33(12):3252–6
Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. Georgescu MM, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2343–8
Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. Lu Z, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):273–80
Reciprocal relationship between stem–loop potential and substitution density in retroviral quasispecies under positive Darwinian selection. Forsdyke DR. **J Mol Evol** 1995 Dec; 41(6):1022–37
Role of mutations G–480 and C–6203 in the attenuation phenotype of Sabin type 1 poliovirus. McGoldrick A, et al. **J Virol** 1995 Dec;69(12):7601–5
A new cis–acting element for RNA replication within the 5' noncoding region of poliovirus type 1 RNA. Shiroki K, et al. **J Virol** 1995 Nov;69(11):6825–32
Inhibition of basal transcription by poliovirus: a virus–encoded protease (3Cpro) inhibits formation of TBP–TATA box complex in vitro. Yalamanchili P, et al. **J Virol** 1996 May;70(5):2922–9
Mouse neuropathogenic poliovirus strains cause damage in the central nervous system distinct from poliomyelitis. Gromeier M, et al. **Microb Pathog** 1995 Apr;18(4):253–67
Role of the pyrimidine–rich tract on the translation of 'chimeric' polio–hepatitis A mRNAs with engineered 5'–terminal untranslated regions. Degener AM, et al. **Virus Res** 1995 Aug;37(3):291–303

GROWTH & DEVELOPMENT

Effect of glycerol on intracellular virus survival: implications for the clinical use of glycerol–preserved cadaver skin. Marshall L, et al. **Burns** 1995 Aug;21(5):356–61

IMMUNOLOGY

Sequence analysis of echoviruses in a major antigenic region eliciting enteroviral cross–reactive antibodies. Samuelson A, et al. **Arch Virol** 1995;140(11):2085–91
Enzyme–linked immunosorbent assay–based inhibition test for neutralizing antibodies to polioviruses as an alternative to the neutralization test in tissue culture. Edevåg G, et al. **J Clin Microbiol** 1995 Nov;33(11):2927–30
Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. Sedlik C, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2361–8
Seroprevalence of antibody against poliovirus in inner–city preschool children. Implications for vaccination policy in the United States [see comments] Chen RT, et al. **JAMA** 1996 Jun 5;275(21):1639–45. Comment, in: JAMA 1996 Jun 5;275(21):1682–3.
[Surveillance of levels of neutralizing antibodies against poliovirus among children aged 0–3 in rural areas of Anhui Province] Shen Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):335–8 (Eng. Abstr.) **(Chi)**
[Poliomyelitis surveillance: seroepidemiologic study on a Piedmont population sample] Maiello A, et al. **Ann Ist Super Sanita** 1995;31(3):317–22 (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

Poliovirus detection in environmental samples by cell cultures and hybridization test. Abdel Kader O, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):935–8
The removal of phages T1 and PP7, and poliovirus from fluids with hollow–fiber ultrafilters with molecular weight cut–offs of 50,000, 13,000, and 6000. Oshima KH, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):316–22
Absence of wild poliovirus circulation among healthy children in a rural area with high oral poliovirus vaccination coverage. Deshpande JM, et al. **Indian J Med Res** 1996 Jun;103:289–93
Intratypic differentiation of polioviruses isolated from suspected cases of poliomyelitis in Brazil during the period of 1990 to 1993. de Filippis AM, et al. **Mem Inst Oswaldo Cruz** 1994 Oct–Dec;89(4):513–8
Circulation of poliovirus among risk groups in Ibadan, Nigeria. Adu FD, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):126–7
[Role of laboratory diagnosis in eradication project for poliomyelitis in countries of west Pacific–Ocean area] Hagiwara A. **Uirusu** 1995 Jun;45(1):67–8 **(Jpn)**
[Role of clinical laboratories in eradication project for poliomyelitis in China] Hara M. **Uirusu** 1995 Jun;45(1):65–6 **(Jpn)**
[A method of concentrating viruses in environmental water sources] Kontorovich VB, et al. **Vopr Virusol** 1996 Jan–Feb;41(1):40–2 (Eng. Abstr.) **(Rus)**

METABOLISM

Poliovirus protein 3AB forms a complex with and stimulates the activity of the viral RNA polymerase, 3Dpol. Plotch SJ, et al. **J Virol** 1995 Nov;69(11):7169–79

PATHOGENICITY

Safety requirements for maintenance and distribution of transgenic mice susceptible to human viruses: the example of poliovirus–susceptible transgenic mice. Ghendon Y, et al. **Curr Top Microbiol Immunol** 1996;206:327–40 (31 ref.)
Poliovirus biology and pathogenesis. Racaniello VR, et al. **Curr Top Microbiol Immunol** 1996;206:305–25 (103 ref.)
The impact of interfacial interactions on poliovirus infectivity in detergent–treated cell monolayer cultures. Vanden Bossche G. **Microbiol Res** 1995 Sep;150(3):247–63
Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Gromeier M, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2370–5

PHYSIOLOGY

Low levels of poliovirus replication in primary human monocytes: possible interactions with lymphocytes. Eberle KE, et al. **Arch Virol** 1995;140(12):2135–50
Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage. Irurzun A, et al. **J Virol** 1995 Dec;69(12):7453–60
Persistent poliovirus infection of human fetal brain cells. Pavio N, et al. **J Virol** 1996 Sep;70(9):6395–401
A new cis–acting element for RNA replication within the 5' noncoding region of poliovirus type 1 RNA. Shiroki K, et al. **J Virol** 1995 Nov;69(11):6825–32
An aspartic acid at amino acid 108 is required to rescue infectious virus after transfection of a poliovirus cDNA containing a CGDD but not SGDD amino acid motif in 3Dpol. Walker DE, et al. **J Virol** 1995 Dec;69(12):8173–7
Activation of the translational suppressor 4E–BP1 following infection with encephalomyocarditis virus and poliovirus. Gingras AC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5578–83
Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Lu HH, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1412–7
K562 cell strains differ in their response to poliovirus infection. Benton PA, et al. **Virology** 1995 Oct 20; 213(1):7–18

POLIOVIRUSES, HUMAN 1–3

DRUG EFFECTS

Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Nikolaeva L, et al. **Acta Virol** 1995 Dec;39(5–6):235–41
Heat stabilized, infectious poliovirus. Ofori–Anyinam O, et al. **Vaccine** 1995 Aug;13(11):983–6

GENETICS

Genomic characterization of type 1 Sabin–related polioviruses isolated in Brazil. Friedrich F, et al. **Acta Virol** 1995 Feb;39(1):23–9
A virion concentration method for detection of human enteric viruses in oysters by PCR and oligoprobe hybridization. Jaykus LA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2074–80
Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine–associated paralytic patients. Li J, et al. **Arch Virol** 1996;141(6):1047–54
Genomic characterization of type 3 polioviruses isolated from vaccine–associated poliomyelitis cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Feb;28(2):195–200
Genomic characterization of type 2 polioviruses isolated from vaccine–associated cases in Brazil. Friedrich F, et al. **Braz J Med Biol Res** 1995 Jul;28(7):733–42
Genetic divergence of poliovirus strains isolated in the Karachi region of Pakistan. Huovilainen A, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3079–88
Sequences within a small yeast RNA required for inhibition of internal initiation of translation: interaction with La and other cellular proteins influences its inhibitory activity. Das S, et al. **J Virol** 1996 Mar;70(3):1624–32
Attenuation stem–loop lesions in the 5' noncoding region of poliovirus RNA: neuronal cell–specific translation defects. Haller AA, et al. **J Virol** 1996 Mar;70(3):1467–74
Release of virus–like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. Porter DC, et al. **J Virol** 1996 Apr;70(4):2643–9
Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Lu Z, et al. **Virology** 1996 Jun 15;220(2):285–9

IMMUNOLOGY

Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats. Kersten GF, et al. **Biologicals** 1995 Jun; 23(2):179–83
Immunity to hepatitis B, poliomyelitis and measles in fully vaccinated aboriginal and Torres Strait Island children. Hanna JN, et al. **J Paediatr Child Health** 1995 Aug; 31(4):345–9
Vaccine–associated paralytic poliomyelitis [letter; comment] Catton M, et al. **Med J Aust** 1996 Feb 19;164(4):255–6. Comment on: Med J Aust 1995 Oct 16;163(8):423–4.
Immune responses induced by administration of encapsidated poliovirus replicons which express HIV–1 gag and envelope proteins. Moldoveanu Z, et al. **Vaccine** 1995 Aug; 13(11):1013–22
Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Yim TJ, et al. **Virology** 1996 Apr 1;218(1):61–70
[Post–vaccination anti–poliomyelitis seroprevalence in an urban setting in Abidjan] Akoua–Koffi G, et al. **Bull Soc Pathol Exot** 1995;88(3):117–20 (Eng. Abstr.) **(Fre)**
[Poliomyelitis immunity status in the centro–meridional Italy] Ribera G, et al. **Ann Ig** 1995 Nov–Dec;7(6):421–9 (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

A virion concentration method for detection of human enteric viruses in oysters by PCR and oligoprobe hybridization. Jaykus LA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2074–80
Immunoaffinity concentration and purification of waterborne enteric viruses for detection by reverse transcriptase PCR. Schwab KJ, et al. **Appl Environ Microbiol** 1996 Jun; 62(6):2086–94
A simple device for the concentration and detection of enterovirus, hepatitis E virus and rotavirus from water samples by reverse transcription–polymerase chain reaction. Jothikumar N, et al. **J Virol Methods** 1995 Nov; 55(3):401–15
Increased sensitivity of poliovirus detection in tap water concentrates by reverse transcriptase–polymerase chain reaction. Ma JF, et al. **J Virol Methods** 1995 Nov; 55(3):295–302
"In vitro" and in animal model studies on a double virus–inactivated factor VIII concentrate. Arrighi S, et al. **Thromb Haemost** 1995 Sep;74(3):868–73

METABOLISM

Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating. Couderc T, et al. **J Virol** 1996 Jan; 70(1):305–12
Canyon rim residues, including antigenic determinants, modulate serotype–specific binding of polioviruses to mutants of the poliovirus receptor. Harber J, et al. **Virology** 1995 Dec 20;214(2):559–70

PATHOGENICITY

Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine–associated paralytic patients. Li J, et al. **Arch Virol** 1996;141(6):1047–54
Differential susceptibility of transgenic PVR Tg–mice to poliovirus strains with varying neurovirulence in relation with monkeys [letter; comment] Arya SC. **Biologicals** 1995 Jun;23(2):191. Comment on: Biologicals 1993 Sep;21(3):233–7.
Correlation between poliovirus type 1 Mahoney replication in blood cells and neurovirulence. Freistadt MS, et al. **J Virol** 1996 Sep;70(9):6486–92
Cell clones cured of persistent poliovirus infection display selective permissivity to the wild–type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants. Calvez V, et al. **Virology** 1995 Oct 1;212(2):309–22

PHYSIOLOGY

Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions. Piirainen L, et al. **Arch Virol** 1996;141(6):1011–20
Correlation between poliovirus type 1 Mahoney replication in blood cells and neurovirulence. Freistadt MS, et al. **J Virol** 1996 Sep;70(9):6486–92

POLIOVIRUSES, MURINE

The blood–brain barrier in virus–induced demyelination. Welsh CJ, et al. **Adv Exp Med Biol** 1995;383:105–16

Immunology of Theiler's murine encephalomyelitis virus infection. Oleszak EL, et al. **Immunol Res** 1995;14(1):13–33 (153 ref.)

Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. II. Persistent infection. Sapatino BV, et al. **J Neuroimmunol** 1995 Nov; 62(2):127–35

Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. I. Acute infection. Welsh CJ, et al. **J Neuroimmunol** 1995 Nov;62(2):119–25

Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)

Spontaneous CNS remyelination in beta 2 microglobulin–deficient mice following virus–induced demyelination. Miller DJ, et al. **J Neurosci** 1995 Dec; 15(12):8345–52

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Rodriguez M, et al. **Neurology** 1996 Feb;46(2):538–45

CHEMISTRY

The structure of a highly virulent Theiler's murine encephalomyelitis virus (GDVII) and implications for determinants of viral persistence. Luo M, et al. **Virology** 1996 Jun 1;220(1):246–50

ENZYMOLOGY

Theiler's murine encephalomyelitis virus 3D RNA polymerase: its expression in the CNS and the specific immune response generated in persistently infected mice. Johnston IC, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2765–77

GENETICS

Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBj14. Anderson MJ, et al. **Virology** 1996 May 1;219(1):140–9

Analysis of the leader and capsid coding regions of persistent and neurovirulent strains of Theiler's virus. Michiels T, et al. **Virology** 1995 Dec 20;214(2):550–8

[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305–15; discussion 315–6 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Influence of deletion of T cell receptor V beta genes on the Theiler's virus model of multiple sclerosis. Rodriguez M, et al. **Autoimmunity** 1994;19(4):221–30

Evolution of the T–cell repertoire during the course of experimental immune–mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)

Paralysis caused by acute myelitis in Theiler's murine encephalomyelitis virus strain GD VII infection is induced by CD4+ lymphocytes infiltrating the spinal cord. Kohanawa M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2251–6

Adoptively transferred CD8+ T lymphocytes provide protection against TMEV–induced demyelinating disease in BALB/c mice. Nicholson SM, et al. **J Immunol** 1996 Feb 1;156(3):1276–83

Flow cytometric and functional analyses of central nervous system–infiltrating cells in SJL/J mice with Theiler's virus–induced demyelinating disease. Evidence for a CD4+ T cell–mediated pathology. Pope JG, et al. **J Immunol** 1996 May 15;156(10):4050–8

Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus–induced demyelinating disease. Pullen LC, et al. **J Immunol** 1995 Nov 1;155(9):4497–503

Suppression of Theiler's murine encephalomyelitis virus induced demyelinating disease by administration of gangliosides. Inoue A, et al. **J Neuroimmunol** 1996 Jan; 64(1):45–53

Infection of class II–deficient mice by the DA strain of Theiler's virus. Fiette L, et al. **J Virol** 1996 Jul;70(7):4811–5

Theiler's virus persistence and demyelination in major histocompatibility complex class II–deficient mice. Njenga MK, et al. **J Virol** 1996 Mar;70(3):1729–37

VP1 and VP2 capsid proteins of Theiler's virus are targets of H–2D–restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Lin X, et al. **Virology** 1995 Dec 1;214(1):91–9

METABOLISM

Release of myelin basic protein–degrading proteolytic activity from microglia and macrophages after infection with Theiler's murine encephalomyelitis virus: comparison between susceptible and resistant mice. Liuzzi GM, et al. **J Neuroimmunol** 1995 Oct;62(1):91–102

The leader peptide of Theiler's murine encephalomyelitis virus is a zinc–binding protein. Chen HH, et al. **J Virol** 1995 Dec;69(12):8076–8

PATHOGENICITY

Mode of spread to and within the central nervous system after oral infection of neonatal mice with the DA strain of Theiler's murine encephalomyelitis virus. Ha–Lee YM, et al. **J Virol** 1995 Nov;69(11):7354–61

Gamma interferon is critical for resistance to Theiler's virus–induced demyelination. Rodriguez M, et al. **J Virol** 1995 Nov;69(11):7286–90

A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus–induced immune–mediated demyelinating disease. Chen HH, et al. **Nat Med** 1995 Sep;1(9):927–31

Poliovirus neurovirulence correlates with the presence of a cryptic AUG upstream of the initiator codon. Slobodskaya OR, et al. **Virology** 1996 Jul 1;221(1):141–50

PHYSIOLOGY

Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ, et al. **J Neurosci Res** 1995 Jun 15;41(3):291–6 (40 ref.)

Mode of spread to and within the central nervous system after oral infection of neonatal mice with the DA strain of Theiler's murine encephalomyelitis virus. Ha–Lee YM, et al. **J Virol** 1995 Nov;69(11):7354–61

Identification of a major T–cell epitope within VP3 amino acid residues 24 to 37 of Theiler's virus in demyelination–susceptible SJL/J mice. Yauch RL, et al. **J Virol** 1995 Nov;69(11):7315–8

POLISHES see **INDUSTRIAL OILS**

POLISHES, DENTAL see **DENTIFRICES**

POLITEF see **POLYTETRAFLUOROETHYLENE**

POLITICAL ACTIVITY see **POLITICS**

POLITICAL SYSTEMS

Prolegomena for an anti–dictatorship campaign. Kulenović M. **Acta Med Croatica** 1995;49(3):137–45

On the problems of expert opinion on Holocaust survivors submitted to the compensation authorities in Germany. Platz WE, et al. **Int J Law Psychiatry** 1995 Summer; 18(3):305–21

The holocaust and beyond. Tamez Morales A. **Int J Psychoanal** 1996 Feb;77 (Pt 1):147–8

Triangles and tribulations: the politics of Nazi symbols. Elman RA. **J Homosex** 1996;30(3):1–11

Four encounters between descendants of survivors and descendants of perpetrators of the Holocaust: building social bonds out of silence. Bar–On D. **Psychiatry** 1995 Aug;58(3):225–45

[Contemporary thoughts of a psychoanalyst. On some hidden consequences of "coping with the past" in relation to the national socialism era] Speidel H. **Z Psychosom Med Psychoanal** 1996;42(2):179–89 (Eng. Abstr.) **(Ger)**

[Child murders in Bagdad (letter)] Westberg G. **Lakartidningen** 1996 Jan 31;93(5):340–1 **(Swe)**

HISTORY

Killing in the name of healing: the active role of the German medical profession during the Third Reich. Ernst E. **Am J Med** 1996 May;100(5):579–81

Life events and visual symptoms of Adolf Hitler (with personal anecdotes). Cogan DG. **Doc Ophthalmol** 1995; 89(1–2):9–13

Male inverts and homosexuals: sex discourse in the anarchist Revista Blanca. Cleminson R. **J Homosex** 1995; 29(2–3):259–72

Communists, Social Democrats, and the homosexual movement in the Weimar Republic. Herzer M. **J Homosex** 1995;29(2–3):197–226

The "Jews" of the antifascist left: homosexuality and socialist resistance to Nazism. Oosterhuis H. **J Homosex** 1995; 29(2–3):227–57

[Gynecology in national socialism—or "the late apology"] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):753–71 **(Ger)**

[Emigration of German psychiatrists to England. 1: England as a refuge for psychiatrists] Peters UH. **Fortschr Neurol Psychiatr** 1996 May;64(5):161–7 (Eng. Abstr.) **(Ger)**

["Inhuman practices in gynecology in national socialization and its victims" (letter; comment)] Kindermann G, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):M83. Comment on: Geburtshilfe Frauenheilkd 1995 Jun;55(6):291–8. **(Ger)**

[Between individual therapy and political intervention: campaigns against "diseases of civilization" between 1920 and 1960] Roelcke V. **Gesundheitswesen** 1995 Aug–Sep; 57(8–9):443–51 (Eng. Abstr.) **(Ger)**

[A clinic in rapidly changing times. Recollections of the Cologne University Otorhinolaryngologic Clinic 1933–1953] Meyer zum Gottesberge A. **Laryngorhinootologie** 1995 Oct;74(10):645–9 **(Ger)**

[Is the psyche antiquated? A typology of psychotherapeutic critique of civilization in the works of Alexander Mitscherlich] Roelcke V. **Psychother Psychosom Med Psychol** 1995 Aug;45(8):277–84 (Eng. Abstr.) **(Ger)**

[The Wiener Klinische Wochenschrift from 1938 to 1945. On the 60th anniversary of its reappearance in 1946 (editorial)] Druml W. **Wien Klin Wochenschr** 1996; 108(13):381–4 **(Ger)**

[German medicine during the Nazi regime—cooperation and resistance] Lavik NJ. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3794–9 (Eng. Abstr.) **(Nor)**

POLITICS

Legislating away reality [editorial] Bassuk EL. **Am J Orthopsychiatry** 1995 Oct;65(4):460–1

Influence of current events on psychopathology [letter] Markowitz JC. **Am J Psychiatry** 1996 Feb;153(2):294–5

Cuban oncology surviving the 'periodo especial' [news] **Ann Oncol** 1995 Sep;6(7):626–8

Family planning: personal and political perspectives from Choiseul Province, Solomon Islands. Rowling D, et al. **Aust J Public Health** 1995 Dec;19(6):616–22

Doctors and medical politics [editorial] Carnall D. **BMJ** 1995 Dec 9;311(7019):1519–20

Labour's draft election manifesto [editorial] Klein R. **BMJ** 1996 Jul 13;313(7049):68

Torture continues in Algeria [letter; comment] Peel M. **BMJ** 1996 Jun 29;312(7047):1675. Comment on: BMJ 1996 Feb 3;312(7026):293–4.

Republicans subtly reform US medicine [news] Roberts J. **BMJ** 1995 Nov 4;311(7014):1188

Playing politics with the poor: the cities. Roberts J. **BMJ** 1995 Sep 30;311(7009):832

Ethical issues in healthcare prioritization: a political viewpoint. McColl. **Br J Urol** 1995 Nov;76 Suppl 2:55–7 (4 ref.)

Rationing health care: the political perspective. Hunter DJ. **Br Med Bull** 1995 Oct;51(4):876–84 (14 ref.)

The psychological, political, and economic realities of brain injury rehabilitation in the 1990s. Leri JE. **Brain Inj** 1995 Jul;9(5):533–42

Health and national security. Alleyne G. **Bull Pan Am Health Organ** 1996 Jun;30(2):158–63

Firearms public safety [editorial] Gabor T. **Can Fam Physician** 1996 Jun;42:1060–2, 1073–6 **(Eng, Fre)**

Psychiatric abuse in Cuba [letter; comment] Lago AM. **Can J Psychiatry** 1995 Aug;40(6):359–60. Comment on: Can J Psychiatry 1994 Mar;39(2):129.

The highs and lows of my political career. Draper L. **Can Med Assoc J** 1996 Mar 1;154(5):702–4

Is medicine moving to the right? Gray C. **Can Med Assoc J** 1995 Oct 15;153(8):1143–5

Treatment of psychiatric problems a growth industry in midst of Chile's booming economy. Sagaris L. **Can Med Assoc J** 1996 Jul 1;155(1):103–5

The effects of political violence on Palestinian children's behavior problems: a risk accumulation model. Garbarino J, et al. **Child Dev** 1996 Feb;67(1):33–45

Children: ethnic and political violence. Ladd GW, et al. **Child Dev** 1996 Feb;67(1):14–8

Can ideological commitment protect children's psychological well–being in situations of political violence? Punamäki RL. **Child Dev** 1996 Feb;67(1):55–69

Violent political contexts and the emotional concerns of township youth. Straker G, et al. **Child Dev** 1996 Feb; 67(1):46–54

Defensive development? Re–examining the role of the military in complex political emergencies. Stockton N. **Disasters** 1996 Jun;20(2):144–8

Family policies for an aging society: moving to the twenty–first century. Moen P, et al. **Gerontologist** 1995 Dec;35(6):825–30

Demagoguery and debate over Medicare reform. Reinhardt UE. **Health Aff (Millwood)** 1995 Winter;14(4):101–3

Health psychology and public policy: the political process. DeLeon PH, et al. **Health Psychol** 1995 Nov;14(6):493–9

Of technological targets and budgetary bombs: the dangers of depersonalized budgetary warfare. Keigher SM. **Health Soc Work** 1995 Nov;20(4):300–5

The governors' dangerous Medicaid endgame. Keigher SM. **Health Soc Work** 1996 May;21(2):151–7

Public health social work: pro bono publico [editorial] Poole DL. **Health Soc Work** 1995 Nov;20(4):243–5

Health care and the 1996 election. Blendon RJ, et al. **Inquiry** 1996 Spring;33(1):10–4

Concept abuse in the drug field. Agar M. **Int J Addict** 1995 Jul;30(9):1165–8

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

Caring for the wounded at Churchill's funeral. Ryan TJ.

Int J Dermatol 1995 Sep;34(9):665

As Congress stalls, HCFA rules. Doherty RB. **Internist (Berl)** 1996 Feb;37(2):21–3

Greg Ganske on Medicare reform. Ganske G. **Iowa Med** 1995 Nov;85(11):446–7

PACs are a reality [editorial] Hall J. **Iowa Med** 1995 Nov; 85(11):431

Knesset members' attitudes towards combat stress reaction casualties. Solomon Z, et al. **Isr J Psychiatry Relat Sci** 1996;33(2):110–20

Appraisal of self, social environment, and state authority as a possible mediator of posttraumatic stress disorder in tortured political activists. Başoğlu M, et al. **J Abnorm Psychol** 1996 May;105(2):232–6

The politics of nursing: a case study—clinical grading. Gavin JN. **J Adv Nurs** 1995 Aug;22(2):379–85

Washington 'train wreck' derails ADA issues. **J Am Diet Assoc** 1995 Oct;95(10):1092

Assessment of the AVMA Political Action Committee's recent past and future. Gearhart MS. **J Am Vet Med Assoc** 1996 Feb 15;208(4):476–7

Comparing the incommensurable: where science and politics collide [comment] Lee C. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):259–63. Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

Neuroreality. I. Dedicated demolition of the decade of the brain:the genuine threat to neurologic research from the animal radical right American Academy of Neurology Animal Studies Subcommitte. [editorial] Landau WM, et al. **J Child Neurol** 1995 Sep;10(5):343–5

Americans' political participation in the 1993–94 national health care reform debate. Brodie M. **J Health Polit Policy Law** 1996 Spring;21(1):99–128

Israel's health policy breakthrough: the politics of reform and the reform of politics. Chinitz D. **J Health Polit Policy Law** 1995 Winter;20(4):909–32

Publicity-stunt participation and sound bites polemics: the health care debate 1993–94. Disch L. **J Health Polit Policy Law** 1996 Spring;21(1):3–33 (78 ref.)

Health care reform: where do we go from here? Dukakis MS. **J Health Polit Policy Law** 1995 Fall;20(3):787–94

Prevention and government: health policy making in the United Kingdom and Germany. Freeman R. **J Health Polit Policy Law** 1995 Fall;20(3):745–65

Lawmakers' views on the failure of health reform: a survey of members of Congress and staff. Hansen O, et al. **J Health Polit Policy Law** 1996 Spring;21(1):137–51

Talking heads and sleeping citizens: health policy making in a democracy. Jacobs LR. **J Health Polit Policy Law** 1996 Spring;21(1):129–35

The Quinlan case revisited: a history of the cultural politics of medicine and the law. Stevens ML. **J Health Polit Policy Law** 1996 Summer;21(2):347–66; discussion 367–72

Congressional partisanship and the failure of moderate health care reform. Talbert J. **J Health Polit Policy Law** 1995 Winter;20(4):1033–50

From revolution to involution: the disappearance of the gay movement in France. Duyvendak JW. **J Homosex** 1995; 29(4):369–85

Triangles and tribulations: the politics of Nazi symbols. Elman RA. **J Homosex** 1996;30(3):1–11

Anarchism and homosexuality in Wilhelmine Germany: Senna Hoy, Erich Mühsam, John Henry Mackay. Fähnders W. **J Homosex** 1995;29(2–3):117–53

Between Marxism and psychoanalysis: antifascism and antihomosexuality in the Frankfurt School. Halle R. **J Homosex** 1995;29(4):295–317

Leftist sexual politics and homosexuality: a historical overview. Hekma G, et al. **J Homosex** 1995;29(2–3):1–40

Homosexuality and the Left in the Netherlands: 1890–1911. Hekma G. **J Homosex** 1995;29(2–3):97–115

Communists, Social Democrats, and the homosexual movement in the Weimar Republic. Herzer M. **J Homosex** 1995;29(2–3):197–226

Johann Baptist von Schweitzer: the queer Marx loved to hate. Kennedy H. **J Homosex** 1995;29(2–3):69–96

Anthony Blunt and Guy Burgess, gay spies. Sommer F. **J Homosex** 1995;29(4):273–93

The Church, the Stasi, and socialist integration: three stages of lesbian and gay emancipation in the former German Democratic Republic. Sweet DM. **J Homosex** 1995; 29(4):351–67

Homosexuality and the American left: the impact of Stonewall. Thorstad D. **J Homosex** 1995;29(4):319–49

Senator Mark Hatfield (R–OR). Chairman of the Senate Appropriations Committee [interview] Hatfield M. **J Investig Med** 1996 Jun;44(5):200–4

Indifference engenders shackles. Clark DM. **J Ky Med Assoc** 1996 Jun;94(6):217

Making a bad program worse: Clinton's attempt at Medicaid reform. Matthews M Jr. **J Med Assoc Ga** 1996 Apr; 85(2):81–3

A wolf in sheep's clothing: the Clinton health reform plan. Orient JM. **J Med Assoc Ga** 1996 Apr;85(2):93–6

The fourth epoch [editorial] England LE. **J Miss State Med Assoc** 1995 Dec;36(11):401

Transcript: remarks on Medicare reform from the AMA House of Delegates' annual meeting. Gingrich N. **J Miss State Med Assoc** 1995 Aug;36(8):243, 246–51

What do they really think about us? [editorial] Lockey M. **J Miss State Med Assoc** 1996 Jul;37(7):663

Health-care challenges: resource allocation, politics, and the impact on minorities [editorial] Walton TM Jr. **J Natl Med Assoc** 1996 Jul;88(7):415–6

Psychiatric episodes precipitated by elections. Bhugra D, et al. **J Nerv Ment Dis** 1996 Feb;184(2):129–30

Meanings of political participation among black and white women: political identity and social responsibility. Cole ER, et al. **J Pers Soc Psychol** 1996 Jul;71(1):130–40

Personal ideology polarity: its emotional foundation and its manifestation in individual value systems, religiosity, political orientation, and assumptions concerning human nature. de St. Aubin E. **J Pers Soc Psychol** 1996 Jul; 71(1):152–65

Identified and introjected forms of political internalization: extending self-determination theory. Koestner R, et al. **J Pers Soc Psychol** 1996 May;70(5):1025–36

Liberal or conservative? Gender, identity, and perception of historical religious positions. Bensko NL, et al. **J Psychol** 1995 Nov;129(6):629–41

Mental constructs and the cognitive reconstruction of the Berlin wall. Tijus CA, et al. **J Psychol** 1996 Jul; 130(4):401–11

Republican candidates beware—student nurses polled on politics [news] **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):11–2

Change and coping with change. Benatar SR. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):436–41

The great train crash approaches. Moore SR. **J R Soc Health** 1995 Oct;115(5):330

"A battle not man's but God's" [letter; comment] Rumbarger JJ. **J Stud Alcohol** 1996 Mar;57(2):220–1. Comment on: J Stud Alcohol 1995 Jan;56(1):110–21.

The personal is the political. Pepe JA. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):367–8

Relations between the United States and Cuba. A proposal for action [see comments] Chelala C. **JAMA** 1996 Feb 21; 275(7):559–60. Comment in: JAMA 1996 Jun 5;275(21):1633; discussion 1634. Comment in: JAMA 1996 Jun 5;275(21):1633–4.

What do Hillary Rodham Clinton and Newt Gingrich have in common? Drake DF. **JAMA** 1995 Oct 25;274(16):1316–8

Medicine and the US embargo against Cuba [letter; comment] Huertas E. **JAMA** 1996 Jun 5;275(21):1633; discussion 1634 . Comment on: JAMA 1996 Feb 21;275(7):559–60.

Medicine and the US embargo against Cuba [letter; comment] Kirkpatrick AF. **JAMA** 1996 Jun 5;275(21):1633–4. Comment on: JAMA 1996 Feb 21;275(7):559–60.

Medicine and the US embargo against Cuba [letter; comment] Martin GE. **JAMA** 1996 Jun 5;275(21):1633; discussion 1634. Comment on: JAMA 1996 Feb 21;275(7):559–60.

On affirmative action [see comments] Nickens HW, et al. **JAMA** 1996 Feb 21;275(7):572–4. Comment in: JAMA 1996 May 22–29;275(20):1547–8.

Democrats drop universal coverage [news] Skolnick AA. **JAMA** 1996 Sep 25;276(12):931

Who will vote for the uninsured in '96? [news] Voelker R. **JAMA** 1996 Sep 11;276(10):763

The politics of disclosure [editorial] **Lancet** 1996 Sep 7; 348(9028):627

Economics, politics, and the examination room: Pap testing in Italy [letter; comment] Attanasio AE. **Lancet** 1996 Mar 9;347(9002):694–5. Comment on: Lancet 1996 Jan 13;347(8994):124–5.

Hunger strike in Turkish prisons. Beynon J. **Lancet** 1996 Sep 14;348(9029):737

Labour faces health nightmares [news] Dean M. **Lancet** 1995 Oct 28;346(8983):1149

Work stress can cause political strain [news] Dean M. **Lancet** 1995 Oct 14;346(8981):1025

When the government shuts down [news] Greenberg DS. **Lancet** 1995 Dec 2;346(8988):1479

Republicans' swift health-legislation moves [news] Greenberg DS. **Lancet** 1995 Oct 21;346(8982):1089

Putting child abuse back on the political agenda. Males MA. **Lancet** 1996 Feb 24;347(9000):488

The politics of U.S. health care reform [comment] Bronstein JM. **Med Anthropol Q** 1996 Mar;10(1):20–4. Comment on: Med Anthropol Q 1996 Mar;10(1):3–19.

Market ideology in health care and the Catholic church [see comments] Harrington C. **Med Anthropol Q** 1996 Mar; 10(1):25–7; discussion 27–8. Comment in: Med Anthropol Q 1996 Mar;10(1):3–19.

The college student, the dentist, and the North Carolina senator: risk analysis and risk management of HIV transmission from health care worker to patient. Robinson EN Jr, et al. **Med Decis Making** 1996 Jan–Mar;16(1):86–91

"That puzleing problem": Isaac Newton and the political physiology of self. Iliffe R. **Med Hist** 1995 Oct;39(4):433–58

Politics and health care: beyond the federal-state wrangle. Sturgess GL. **Med J Aust** 1995 Oct 2;163(7):370–2

Politics and publishing: the Quality in Australian Health Care Study [editorial] Van Der Weyden MB. **Med J Aust** 1995 Nov 6;163(9):453–4

When medical research is beholden to politics [editorial; comment] Wodak AD. **Med J Aust** 1996 Jun 3; 164(11):649–50. Comment on: Med J Aust 1996 Jun 3;164(11):690–2. Comment on: Med J Aust 1996 Jun 3;164(11):692–3. Comment on: Med J Aust 1996 Jun 3;164(11):694–5.

MMA calls for geographic equity in Medicare bill. **Minn Med** 1995 Dec;78(12):33, 35

Governors propose controversial Medicaid changes –news–. **Minn Med** 1996 Apr;79(4):35, 37

Wellstone and Ramstad debate health care issues –news–. **Minn Med** 1996 Apr;79(4):35

Break the gridlock in Washington. Crimmins TJ. **Minn Med** 1996 Apr;79(4):34

AIDS. Public perceptions obscure medical discourse [editorial] Meyer CR. **Minn Med** 1995 Nov;78(11):5

Epidemic optic neuropathy in Cuba [letter] Garfield R. **N Engl J Med** 1996 Apr 18;334(16):1063; discussion 1063–4

Epidemic optic neuropathy in Cuba [letter] Kirkpatrick AF. **N Engl J Med** 1996 Apr 18;334(16):1063; discussion 1063–4

Dentistry at the millenium. Politics and public policy. Libin BM. **N Y State Dent J** 1996 May;62(5):42–5

Politics and genes [editorial] Culliton BJ. **Nat Med** 1995 Mar; 1(3):181

'Mad cow' politics tries to corral science [news] Butler D. **Nature** 1996 Sep 19;383(6597):209

Drug and cigarette company donations favour Republicans [news] Wadman M. **Nature** 1996 Sep 5;383(6595):5

Animal radical right [letter; comment] Martin PA. **Neurology** 1996 Mar;46(3):884. Comment on: Neurology 1995 Apr;45(4):609–10.

Animal radical right [letter; comment] Newmark J. **Neurology** 1996 Mar;46(3):883–4. Comment on: Neurology 1995 Apr;45(4):609–10.

Animal radical right [letter; comment] Nicely MC. **Neurology** 1996 Mar;46(3):883; discussion 884. Comment on: Neurology 1995 Apr;45(4):609–10.

Animal radical right [letter; comment] White HH. **Neurology** 1996 Mar;46(3):883–4; discussion 884. Comment on: Neurology 1995 Apr;45(4):609–10.

The politics of nutrition in North America. Levenstein HA. **Neurosci Biobehav Rev** 1996;20(1):75–8 (14 ref.)

Leaving the parental home: predictors for young adults raised in former East and West Germany. Silbereisen RK, et al. **New Dir Child Dev** 1996 Spring;(71):71–86

Physician–hospital ventures: is there added value? Lance MP. **Pa Med** 1996 Jun;99(6):22–3

Lincoln's words ring true in DC [editorial] Mills JW. **Pa Med** 1995 Oct;98(10):6

The time for political advocacy for children is now [editorial] Altemeier WA 3rd. **Pediatr Ann** 1995 Aug;24(8):396, 398

The practice of political medicine. Bergman AB. **Pediatr Ann** 1995 Aug;24(8):405–8

Political advocacy from a pediatrician's perspective. Berkelhamer JE. **Pediatr Ann** 1995 Aug;24(8):402–4

Influencing the political process through coalitions: the Michigan Council for Maternal and Child Health. Holm RS, et al. **Pediatr Ann** 1995 Aug;24(8):409–12

The review of parliamentary constituency boundaries—the reduction in the variation in electorates. Craig J. **Popul Trends** 1995 Autumn;(81):23–6

Pharmaceuticals and politics [editorial] Pelonero AL. **Psychiatr Serv** 1995 Sep;46(9):857

Lacan and the critique of legal ideology: reason and religion in law and politics. Caudill DS. **Psychoanal Rev** 1995 Oct; 82(5):683–702; discussion 703–7

Lacanian perspectives on political and social controversies: a symposium. Friedlander S. **Psychoanal Rev** 1995 Oct; 82(5):651–4

A psychoanalytic study of Alexander the Great. Thomas KR. **Psychoanal Rev** 1995 Dec;82(6):859–901

Environmental health and public health: are they compatible? Williamson JD. **Public Health** 1996 Jan;110(1):3–4

From a Bill to a Sir: Sir Raymond Hoffenberg [interview by Ina van der Linde] Hoffenberg R. **S Afr Med J** 1996 Mar;86(3):283–4

The herdboy who became head man [interview] Mkhize ZL. **S Afr Med J** 1994 Nov;84(11):775

Health care reform in the United States: on the road to nowhere (again)? [editorial] Barer ML, et al. **Soc Sci Med** 1995 Aug;41(4):453–60

Abortion in Turkey: a matter of state, family or individual decision. Gürsoy A. **Soc Sci Med** 1996 Feb;42(4):531–42

U.S. apartheid and the spread of AIDS to the suburbs: a multi-city analysis of the political economy of spatial epidemic threshold. Wallace R, et al. **Soc Sci Med** 1995 Aug;41(3):333–45

Change? What change? Entrenched constituencies, presidential politics scuttle balanced budget plan. Ortolon K. **Tex Med** 1996 Jul;92(7):34–6

Blood banking is not a "pharmaceutical industry" [letter] Kalmin ND. **Transfusion** 1996 Jun;36(6):582–3

Domestic violence and the politics of a statewide community. Hassler RS. **Womens Health Issues** 1995 Winter; 5(4):199–202

[Minister Borst supports geriatrics (editorial)] Ligthart GJ. **Tijdschr Gerontol Geriatr** 1995 Aug;26(4):150–1 **(Dut)**

[Vicissitudes of treating leprosy handicaps in Kapolowé, Zaïre] Vulliet F. **Acta Leprol** 1995;9(4):179–82 (Eng. Abstr.) **(Fre)**

[Changes in life expectancy and mortality in East Germany after reunification (1989–1992)] Häussler B, et al. **Gesundheitswesen** 1995 Jul;57(7):365–72 (Eng. Abstr.) **(Ger)**

[Health conferences—opportunities for cooperation between demands and reality] Meier B. **Gesundheitswesen** 1995 Oct; 57(10):645–51 (Eng. Abstr.) **(Ger)**

[Communications by the German Society of Dermatology. Comments and opinions on important problems in dermatology. Help yourself, then politics will help you (interview)] Burgdorf W. **Hautarzt** 1996 May;47(5):410–5

(Ger)

[First grade students in former East and West Berlin: socio-emotional adjustment and relation to attachment patterns of the children] Doerfel-Baasen D, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3-4):111-23 (Eng. Abstr.) **(Ger)**

["New" authoritarianism and right extremism. A time-related diagnostic conjecture] Brede K. **Psyche (Stuttg)** 1995 Nov; 49(11):1019-42 (Eng. Abstr.) **(Ger)**

[Darwinism, materialism and the revolution of 1848 in Germany. On the interaction of politics and science] Junker T. **Pubbl Stn Zool Napoli II** 1995;17(2):271-302 (Eng. Abstr.) **(Ger)**

[Report of the 9th World Conference on Tobacco and Health 10-14 October 1994 in Paris. Physicians and scientists promote political intervention: smoking is the greatest risk to health] Pötschke-Langer M. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):537-9 **(Ger)**

[Current status: nursing care insurance shortly before the introduction of the second stage--attempt at sociopolitical interim evaluation] Igl G. **Z Gerontol Geriatr** 1996 Mar-Apr;29(2):159-62 **(Ger)**

[Manual lymph drainage in new federal Germany] Klimaschewski H. **Z Lymphol** 1995 Dec;19(2):48-50 (Eng. Abstr.) **(Ger)**

[Rheumatologic patient management and research in Berlin at the intersection between East and West] Sieper J. **Z Rheumatol** 1995 Jul-Aug;54(4):213-4 (Eng. Abstr.) **(Ger)**

POLLEN

see related
ALLERGENS
HAY FEVER

Pollinosis etiologic relationship between excessive IL-4 production and down-regulation of the inflammation-suppressive system. Urushibata T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:68-73

Investigation of acid phosphatase as a possible IgE-binding marker for pollen allergens and their polymerized derivatives. Berrens L, et al. **Allergol Immunopathol (Madr)** 1995 Mar-Apr;23(2):79-84

Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Feliziani V, et al. **Allergol Immunopathol (Madr)** 1995 Sep-Oct; 23(5):224-30

Inhalant allergens: as a cause of respiratory allergy in east Mediterranean area, Turkey. Güneser S, et al. **Allergol Immunopathol (Madr)** 1996 May-Jun;24(3):116-9

Birch pollen related food hypersensitivity: as a para-occupational syndrome. Kalyoncu AF, et al. **Allergol Immunopathol (Madr)** 1995 Mar-Apr;23(2):94-5

Parietaria pollinosis: clinical and epidemiological aspects. Liccardi G, et al. **Allergy Asthma Proc** 1996 Jan-Feb; 17(1):23-9

Atopy and skin reactivity at school age in children followed up from birth, with special reference to atopy prevention in infancy and atopic findings at preschool age. Kuikka L, et al. **Allergy Proc** 1995 Nov-Dec;16(6):313-7

Seasonal characteristics of ragweed pollen dispersal in the United States. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):417-22

Allergic conjunctivitis caused by sugi (Cryptomeria japonica D. Don) pollen out of season. Fujishima H, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):113-7

Detection of specific IgE antibodies to Japanese cypress pollen in patients with nasal allergy: a comparative study with Japanese cedar. Ganbo T, et al. **Auris Nasus Larynx** 1995;22(3):158-64

Assessment of early- and late-phase nasal obstruction in atopic patients after nasal allergen challenge. Wang D, et al. **Clin Otolaryngol** 1995 Aug;20(4):368-73

Esoteric contact dermatitis. Part III: Ragweed dermatitis [news] Fisher AA. **Cutis** 1996 Apr;57(4):199-200

Tip-localized calcium entry fluctuates during pollen tube growth. Pierson ES, et al. **Dev Biol** 1996 Feb 25; 174(1):160-73

Expression of Zm13, a pollen specific maize protein, in Escherichia coli reveals IgE-binding capacity and allergenic potential. Heiss S, et al. **FEBS Lett** 1996 Mar 4;381(3):217-21

Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. Foresi A, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):274-82

Pollen-food allergy syndrome [letter] Lessof MH. **J Allergy Clin Immunol** 1996 Jul;98(1):239-40

Hypersensitivity to Japanese cedar (Cryptomeria japonica) pollen in dogs. Sasaki Y, et al. **J Vet Med Sci** 1995 Aug; 57(4):683-5

The pollen tube growth test. Kristen U, et al. **Methods Mol Biol** 1995;43:189-98

Pollen electrotransformation in tobacco. Saunders JA, et al. **Methods Mol Biol** 1995;55:81-8

Major basic protein and topical administration of ketotifen in pollinosis under natural allergen provocation. Kato M, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep-Oct; 57(5):269-72

The increase in hay fever: pollen, particulate matter and SO2 in ambient air. Seaton A, et al. **QJM** 1996 Apr;89(4):279-84

Study of nasal cytology in atopic patients after nasal allergen challenge. Wang D, et al. **Rhinology** 1995 Jun;33(2):78-81

[My use of the Association Française d'Etudes des Ambroisies pollen calendar for Lyon-Bron (P. Cour collector)] Bouteloup F. **Allerg Immunol (Paris)** 1995 Nov; 27(9):326-31 (Eng. Abstr.) **(Fre)**

[Prevalence of ragweed hayfever in the south and east of the greater Lyon region in 1993] Déchamp C, et al. **Allerg Immunol (Paris)** 1995 Nov;27(9):320, 323-5 (Eng. Abstr.) **(Fre)**

[Sugar beet pollen allergy as a rare occupational disease] Hohenleutner S, et al. **Hautarzt** 1996 Jun;47(6):462-4 (Eng. Abstr.) **(Ger)**

[Correlation between exposure to allergenic pollens and allergic manifestations] Rachmiel M, et al. **Harefuah** 1996 Apr 15;130(8):505-11, 584 (Eng. Abstr.) **(Heb)**

[An attempt of applying the image processing for the automatic estimation of sampled airborne pollen] Kawashima S, et al. **Arerugi** 1995 Sep;44(9):1150-8 (Eng. Abstr.) **(Jpn)**

[The pollen count of Cryptomeria japonica and nasal symptom of Cryptomeria japonica pollinosis patients in recent three years in Mie Prefecture] Masuda S, et al. **Arerugi** 1996 Jun;45(6):570-6 (Eng. Abstr.) **(Jpn)**

[Pollen dispersion of Cryptomeria japonica in autumn] Sugaya A, et al. **Arerugi** 1996 May;45(5):472-7 (Eng. Abstr.) **(Jpn)**

[Pollen information of airborne Japanese cedar pollen using a simulation method] Takahashi Y, et al. **Arerugi** 1996 Apr; 45(4):371-7 (Eng. Abstr.) **(Jpn)**

[Guidelines for standardization of allergens and cedar pollen allergen extract in Japan] Yasue H, et al. **Arerugi** 1996 Apr; 45(4):416-21 **(Jpn)**

[Relationships between atmospheric Sugi (Japanese cedar)-pollen counts and indices of climatic conditions] Kenda Y, et al. **Nippon Koshu Eisei Zasshi** 1995 Aug; 42(8):553-8 (Eng. Abstr.) **(Jpn)**

[The indices of the antioxidant system and the status of the cerebral blood supply in patients with an ischemic stroke on apitherapy] Samoliuk VA. **Vrach Delo** 1995 Jan-Feb; (1-2):68-70 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

Influence of the pH of the extraction medium on the composition of birch (Betula verrucosa) pollen extracts. Cadot P, et al. **Allergy** 1995 May;50(5):431-7

Basic isoforms of Par o 1, the major allergen of Parietaria officinalis pollen. Coscia MR, et al. **Allergy** 1995 Nov; 50(11):899-904

High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen. Susani M, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):250-63

Studies on the carbohydrate moieties of the timothy grass pollen allergen Phl p I. Petersen A, et al. **Electrophoresis** 1995 May;16(5):869-75

Molecular characterization of Api g 1, the major allergen of celery (Apium graveolens), and its immunological and structural relationships to a group of 17-kDa tree pollen allergens. Breiteneder H, et al. **Eur J Biochem** 1995 Oct 15;233(2):484-9

Calcium in pollen-pistil interaction in Petunia hybrida Hort. III. Localization of Ca2+ ions and Ca(2+)-ATPase in pollinated pistil. Bednarska E, et al. **Folia Histochem Cytobiol** 1995;33(2):125-32

Immunocytochemical localisation of actin and profilin in the generative cell of angiosperm pollen: TEM studies on high-pressure frozen and freeze-substituted Ledebouria socialis Roth (Hyacinthaceae). Hess MW, et al. **Histochem Cell Biol** 1995 Dec;104(6):443-51

Direct determination of allergens in ambient aerosols: methodological aspects. Schäppi GF, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):364-70

Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). Vrtala S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):781-7

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99-106

Comparative studies of allergenic extracts prepared from freshly collected, dried, or dried and defatted pollen. González Romano ML, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):142-7

CLASSIFICATION

Allergenic relationship between taxonomically diverse pollens. Pham NH, et al. **Clin Exp Allergy** 1995 Jul; 25(7):599-606

CYTOLOGY

Cryofixing single cells and multicellular specimens enhances structure and immunocytochemistry for light microscopy. Baskin TI, et al. **J Microsc** 1996 May;182 (Pt 2):149-61

Real-time two-photon confocal microscopy using a femtosecond, amplified Ti:sapphire system. Brakenhoff GJ, et al. **J Microsc** 1996 Mar;181 (Pt 3):253-9

Manipulation of pollen grains for gametophytic and sporophytic types of growth. Raghavan V. **Methods Cell Biol** 1995;49:367-75 (11 ref.)

EMBRYOLOGY

New in situ approaches to study the induction of pollen embryogenesis in Capsicum annuum L. González-Melendi P, et al. **Eur J Cell Biol** 1996 Apr;69(4):373-86

ENZYMOLOGY

IgE-binding trypsin inhibitors in plant pollen extracts. Berrens L, et al. **Experientia** 1995 Sep 29;51(9-10):953-5

GENETICS

A molecular perspective on pollination in flowering plants. Dodds PN, et al. **Cell** 1996 Apr 19;85(2):141-4 (20 ref.)

High-level expression of tree pollen isoallergens in Escherichia coli. Weiss C, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):282-7

Rapid optimization of electroporation conditions for plant cells, protoplasts, and pollen. Saunders JA, et al. **Mol Biotechnol** 1995 Jun;3(3):181-90

An anther-specific gene encoded by an S locus haplotype of Brassica produces complementary and differentially regulated transcripts. Boyes DC, et al. **Plant Cell** 1995 Aug; 7(8):1283-94

PCR and sequencing from a single pollen grain. Petersen G, et al. **Plant Mol Biol** 1996 Apr;31(1):189-91

GROWTH & DEVELOPMENT

Expression of heat shock factor and heat shock protein 70 genes during maize pollen development. Gagliardi D, et al. **Plant Mol Biol** 1995 Nov;29(4):841-56

IMMUNOLOGY

Angiolymphoid hyperplasia with eosinophilia associated with immunotherapy. Alonso L, et al. **Allergy** 1996 Mar; 51(3):199-200

Local reaction to ocular disodium cromoglycate. Barranco P, et al. **Allergy** 1996 Feb;51(2):133-4

Amount of pollen has an effect on the systemic and local levels of soluble ICAM-1 in patients with seasonal allergic rhinitis. Kato M, et al. **Allergy** 1996 Feb;51(2):128-32

Honey allergy is rare in patients sensitive to pollens. Kiistala R, et al. **Allergy** 1995 Oct;50(10):844-7

Cry j 2, a major allergen of Japanese cedar pollen, shows polymethylgalacturonase activity. Ohtsuki T, et al. **Allergy** 1995 Jun;50(6):483-8

Comparison of IgE and IgG antibody responses of atopic individuals with sensitization to tree and grass pollens. Olsen E, et al. **Allergy** 1995 Sep;50(9):734-40

Assessment of sensitization to holm oak (Quercus ilex) pollen in the Mérida area (Spain). Prados M, et al. **Allergy** 1995 May;50(5):456-9

Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Walker SM, et al. **Allergy** 1995 May;50(5):405-13

Characterization of Chenopodiales (Amaranthus retroflexus, Chenopodium album, Kochia scoparia, Salsola pestifer) pollen allergens. Würtzen PA, et al. **Allergy** 1995 Jun; 50(6):489-97

Birch-pollen antigenic activity of settled dust in rural and urban homes. Yli-Panula E, et al. **Allergy** 1995 Apr; 50(4):303-7

Comparison between outdoor and indoor airborne allergenic activity. D'Amato G, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):147-52

Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Dockhorn RJ, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):204-8

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):74-80

Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Litwin A, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):132-8

Specific pollen allergen activates eosinophils of the patient with chronic allergic contact urticaria. Panaszek B, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):253-8

Seasonal prevalence of air-borne pollen and spores in Kuala Lumpur, Malaysia. Ho TM, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):17-22

Induction of unresponsiveness of antigen-specific T lymphocytes by oral administration of cedar pollen extract in mice. Kohama Y, et al. **Biol Pharm Bull** 1995 Oct; 18(10):1315-9

Quantitation of the major allergen of several Parietaria pollens by an anti-Par 1 monoclonal antibody-based ELISA. Analysis of crossreactivity among purified Par j 1, Par o 1 and Par m 1 allergens. Ayuso R, et al. **Clin Exp Allergy** 1995 Oct;25(10):993-9

Podocarpus gracilior and Callitris verrucosa--newly identified allergens that crossreact with Cupressus sempervirens. Bar Dayan Y, et al. **Clin Exp Allergy** 1995 May;25(5):456-60

Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Ciprandi G, et al. **Clin Exp Allergy** 1995 Sep; 25(9):871-8

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Di Lorenzo G, et al. **Clin Exp Allergy** 1995 Oct;25(10):951-6

Effects of IL-4 and IL-13 on total and allergen specific IgE

production by cultured PBMC from allergic patients determined with recombinant pollen allergens. Dolecek C, et al. **Clin Exp Allergy** 1995 Sep;25(9):879–89

Food reactions in pollen and latex allergic patients [editorial] Frankland AW. **Clin Exp Allergy** 1995 Jul;25(7):580–1 (22 ref.)

Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosis. Hashimoto M, et al. **Clin Exp Allergy** 1995 Sep; 25(9):848–52

Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. Hoffmann-Sommergruber K, et al. **Clin Exp Allergy** 1996 Jan;26(1):79–87

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Menz G, et al. **Clin Exp Allergy** 1996 Jan;26(1):50–60

Spirometry and ventilation-perfusion inequality in patients with mild allergic asthma before and during the pollen season. Lagerstrand L, et al. **Clin Physiol** 1995 Jul; 15(4):355–64

The immunolocalization of nuclear antigens during the pollen developmental program and the induction of pollen embryogenesis. Testillano PS, et al. **Exp Cell Res** 1995 Nov; 221(1):41–54

Birch pollen allergens fail to evoke IgG1 responses in non-atopic individuals. Härfast B, et al. **Immunol Lett** 1995 Mar;45(3):223–4

Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Imada M, et al. **Immunology** 1995 Jul;85(3):373–80

Multiple B- and T-cell epitopes on a major allergen of Kentucky Bluegrass pollen. Zhang L, et al. **Immunology** 1996 Feb;87(2):283–90

The influence of betahistine on the dynamics of the cutaneous hypersensitivity reaction in patients with grass pollen allergy. Snyman JR, et al. **Immunopharmacology** 1995 Jun; 30(1):71–8

Allergy to natural honeys and camomile tea. Florido-Lopez JF, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):170–4

Allergic rhinitis to thuja pollen. Guerin B, et al. **Int Arch Allergy Immunol** 1996 May;110(1):91–4

Heterogeneity of pollen proteins within individual Betula pendula trees. Hjelmroos M, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):368–76

Identification and characterization of the major allergens of velvet grass (Holcus lanatus), Hol l 1 and Hol l 5. Schramm G, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):354–63

Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. Andri L, et al. **J Allergy Clin Immunol** 1996 Jan; 97(1 Pt 1):34–41

Detection of prognostic factors for oral allergy syndrome in patients with birch pollen hypersensitivity. Asero R, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):611–6

Cross-reactivity between the major allergen from olive pollen and unrelated glycoproteins: evidence of an epitope in the glycan moiety of the allergen. Batanero E, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1264–71

Food allergy to honey: pollen or bee products? Characterization of allergenic proteins in honey by means of immunoblotting. Bauer L, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):65–73

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. Bernstein DI, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):749–55

Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. Blaher B, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):124–32

A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. Day JH, et al. **J Allergy Clin Immunol** 1996 May;97(5):1050–7

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. Durham SR, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1356–65

Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. Ferreira FD, et al: **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):95–103

Characterization of Phl p 4, a major timothy grass (Phleum pratense) pollen allergen. Fischer S, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):189–98

Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. Ikagawa S, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):53–64

Assessment of skin prick test and serum specific IgE detection in the diagnosis of Cupressaceae pollinosis. Mari A, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):21–31

Parietaria judaica-specific T-cell clones from atopic patients: heterogeneity in restriction, V beta usage, and cytokine profile. Sallusto F, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):627–37

Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen. Smith PM, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):331–43

Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893–5 (29 ref.)

Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). Vrtala S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):781–7

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99–106

Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. Steinberger P, et al. **J Biol Chem** 1996 May 3; 271(18):10967–72

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. Ferreira F, et al. **J Exp Med** 1996 Feb 1;183(2):599–609

Immunogold probes for light and electron microscopic localization of Ole e I in several Oleaceae pollens. Fernandez MC, et al. **J Histochem Cytochem** 1996 Feb; 44(2):151–8

Application of reversed-phase high-performance liquid chromatography in the purification of major allergens from grass pollen. Fahlbusch B, et al. **J Immunol Methods** 1996 Jul 17;194(1):27–34

Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. Ariano R, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):126–32

Study of sensitivity to the pollen of Fraxinus spp. (Oleaceae) in Cordoba, Spain. Guerra F, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):166–70

Effect of hyposensitization for tree pollinosis on associated apple allergy. Herrmann D, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct;5(5):259–67

Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. Troise C, et al. **J Investig Allergol Clin Immunol** 1995 Jan–Feb;5(1):25–30

Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group I grass pollen isoallergens. Laffer S, et al. **Mol Immunol** 1996 Mar–Apr;33(4–5):417–26

Purification, characterization and molecular cloning of Cha o 1, a major allergen of Chamaecyparis obtusa (Japanese cypress) pollen. Suzuki M, et al. **Mol Immunol** 1996 Mar–Apr;33(4–5):451–60

Co-stimulation-induced release of pro-inflammatory cytokine interleukin-8 by allergen-specific T cells. Spinozzi F, et al. **Scand J Immunol** 1996 Jul;44(1):80–4

Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Djukanović R, et al. **Thorax** 1996 Jun; 51(6):575–81

Identification of a dog IgD-like molecule by a monoclonal antibody. Yang M, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):215–24

[Oral immunotherapy in oculorhinitis from Gramineae] Pacor ML, et al. **Recenti Prog Med** 1996 Jan;87(1):4–6 (Eng. Abstr.) **(Ita)**

[Airborne Japanese cedar allergens studied by immunoblotting technique using anti-Cry j I monoclonal antibody—comparison with actual pollen counts and effect of wind speed and directions] Iwaya M, et al. **Arerugi** 1995 Jul;44(7):670–7 (Eng. Abstr.) **(Jpn)**

[Seven years study on the incidence of Japanese cedar pollinosis among university students and its transition while in college] Nakamura S. **Arerugi** 1996 Apr;45(4):378–85 (Eng. Abstr.) **(Jpn)**

[Comparative study on the assay for IgE antibodies specific for Chamaecyparis obtusa pollen between AlaSTAT and CAP-RAST] Nohara O, et al. **Arerugi** 1996 Jun;45(6):562–9 (Eng. Abstr.) **(Jpn)**

[Relationship between birch pollen allergy and oral and pharyngeal hypersensitivity to fruit] Yamamoto T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1086–91 (Eng. Abstr.) **(Jpn)**

[Environmental factors influencing sensitization and onset of Japanese cedar pollinosis among junior high school students] Kato H, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):390–7 (Eng. Abstr.) **(Jpn)**

METABOLISM

Investigation of acid phosphatase as a possible IgE-binding marker for pollen allergens and their polymerized derivatives. Berrens L, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):79–84

PHYSIOLOGY

How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):447–57 (78 ref.)

Identification of genes required for pollen-stigma recognition in Arabidopsis thaliana. Hülskamp M, et al. **Plant J** 1995 Nov;8(5):703–14

ULTRASTRUCTURE

Confocal imaging and immunogold electron microscopy of changes in distribution of myosin during pollen hydration, germination and pollen tube growth in Nicotiana tabacum L. Tirlapur UK, et al. **Eur J Cell Biol** 1995 Jul;67(3):209–17

Identification and localization of three classes of myosins in pollen tubes of Lilium longiflorum and Nicotiana alata. Miller DD, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2549–63

POLONIUM

Induction of genomic instability in normal human bronchial epithelial cells by 238Pu alpha-particles. Kennedy CH, et al. **Carcinogenesis** 1996 Aug;17(8):1671–6

ANALYSIS

Investigations of the potential bioavailability of 210Po in some foodstuffs. Bulman RA, et al. **Sci Total Environ** 1995 Dec 1;173–174:151–8

PHARMACOKINETICS

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Desrues B, et al. **Br J Cancer** 1995 Nov; 72(5):1076–82

Combined chelation treatment for polonium after simulated wound contamination in rat. Volf V, et al. **Int J Radiat Biol** 1995 Oct;68(4):395–404

Investigations of the potential bioavailability of 210Po in some foodstuffs. Bulman RA, et al. **Sci Total Environ** 1995 Dec 1;173–174:151–8

POLOXALENE

Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Nash VJ, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):10–5

METABOLISM

Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model. West JL, et al. **Biomaterials** 1995 Oct;16(15):1153–6

PHARMACOKINETICS

Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. Li C, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):659–65

PHARMACOLOGY

Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Jagannath C, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1349–54

Enhanced protoplast growth at the interface between oxygenated fluorocarbon liquid and aqueous culture medium supplemented with pluronic F-68. Lowe KC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):417–22

Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Venne A, et al. **Cancer Res** 1996 Aug 15;56(16):3626–9

Studies of protective properties of pluronic and other agents on the hybridoma cell culture. Xu D, et al. **Chin J Biotechnol** 1995;11(2):101–7

Effect of pluronic L-81 on intestinal lipoprotein secretion in the rat. Pidlich J, et al. **Dig Dis Sci** 1996 Jul;41(7):1445–51

Relationship of phosphatidylcholine to hydrophobic surfactant on rat intestinal chylomicron secretion. Rodgers JB, et al. **Experientia** 1996 Jul 15;52(7):671–6

Enhancement of the polycation-mediated DNA uptake and cell transfection with Pluronic P85 block copolymer. Astafieva I, et al. **FEBS Lett** 1996 Jul 8;389(3):278–80

Poloxamer-188 revisited: a potentially valuable immune modulator [letter] Moghimi SM, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):766–8

Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection). Armstrong JK, et al. **Thromb Res** 1995 Sep 15;79(5–6):437–50

Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotypic antibodies against pseudorabies virus antigens. Zhou EM, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):113–22

THERAPEUTIC USE

Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii. Araujo FG, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2696–701

Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Jagannath C, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1349–54

Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. Follis F, et al. **J Invest Surg** 1996 Mar–Apr;9(2):149–56

POLOXALKOL see **POLOXALENE**

POLOXAMERS see **POLOXALENE**

POLVIDONE see **POVIDONE**

POLY A

Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Ashe MP, et al. **Genes Dev** 1995 Dec 1;9(23):3008-25

BIOSYNTHESIS

Isolation and characterization of two novel, cytoplasmically polyadenylated, oocyte-specific, mouse maternal RNAs. West MF, et al. **Dev Biol** 1996 Apr 10;175(1):132-41

Regulation of vasopressin (VP) gene expression in the bed nucleus of the stria terminalis: gonadal steroid-dependent changes in VP mRNA accumulation are associated with alterations in mRNA poly (A) tail length but are independent of the rate of VP gene transcription. Carter DA, et al. **J Neuroendocrinol** 1993 Oct;5(5):509-15

Repression of beta interferon gene expression in virus-infected cells is correlated with a poly(A) tail elongation. Dehlin E, et al. **Mol Cell Biol** 1996 Feb; 16(2):468-74

CHEMISTRY

Raman spectroscopy of the Ff gene V protein and complexes with poly(dA): nonspecific DNA recognition and binding. Benevides JM, et al. **Biochemistry** 1996 Jul 23;35(29):9603-9

FTIR study of a nonclassical dT10*dA10-dT10 intramolecular triple helix. Dagneaux C, et al. **Biochemistry** 1995 Nov 14;34(45):14815-8

Structure of the polyadenylation regulatory element of the human U1A pre-mRNA 3'-untranslated region and interaction with the U1A protein. Gubser CC, et al. **Biochemistry** 1996 Feb 20;35(7):2253-67

The organic crystallizing agent 2-methyl-2,4-pentanediol reduces DNA curvature by means of structural changes in A-tracts. Dlakic M, et al. **J Biol Chem** 1996 Jul 26; 271(30):17911-9

[Electrophoretic study of conformational transitions in poly(A) at acid pHs] Zarudnaia MI, et al. **Mol Biol (Mosk)** 1995 Sep-Oct;29(5):1040-7 **(Rus)**

GENETICS

Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Harker WG, et al. **Cancer Res** 1995 Nov 1;55(21):4962-71

The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation. Gallie DR, et al. **Gene** 1995 Nov 20;165(2):233-8

Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Myers SM, et al. **Oncogene** 1995 Nov 16;11(10):2039-45

METABOLISM

Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Bell DA, et al. **Cancer Res** 1995 Nov 15;55(22):5226-9

Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Harker WG, et al. **Cancer Res** 1995 Nov 1;55(21):4962-71

CPEB controls the cytoplasmic polyadenylation of cyclin, Cdk2 and c-mos mRNAs and is necessary for oocyte maturation in Xenopus. Stebbins-Boaz B, et al. **EMBO J** 1996 May 15;15(10):2582-92

Overexpression of poly(A) binding protein prevents maturation-specific deadenylation and translational inactivation in Xenopus oocytes. Wormington M, et al. **EMBO J** 1996 Feb 15;15(4):900-9

Increased epidermal growth factor expression produced by testosterone in the submaxillary gland of female mice is accompanied by changes in poly-A tail length and periodicity. Sheflin LG, et al. **Endocrinology** 1996 May; 137(5):2085-92

Assessment of transcript polyadenylation by 3' RACE: the response of epidermal growth factor messenger ribonucleic acid to thyroid hormone in the thyroid and submaxillary glands. Sheflin LG, et al. **Endocrinology** 1995 Dec; 136(12):5666-76

An intron enhancer recognized by splicing factors activates polyadenylation. Lou H, et al. **Genes Dev** 1996 Jan 15; 10(2):208-19

Ribosomal association of poly(A)-binding protein in poly(A)-deficient Saccharomyces cerevisiae. Proweller A, et al. **J Biol Chem** 1996 May 3;271(18):10859-65

Inhibition of poly(2'-fluoro-2'-deoxyadenylic acid)-directed-reverse transcriptase activity. Jucá MB, et al. **J Enzym Inhib** 1995;9(2):171-7

Sequences regulating poly(A) site selection within the adenovirus major late transcription unit influence the interaction of constitutive processing factors with the pre-mRNA. Gilmartin GM, et al. **J Virol** 1996 Mar; 70(3):1775-83

Regulation of herpes simplex virus poly (A) site usage and the action of immediate-early protein IE63 in the early-late switch. McGregor F, et al. **J Virol** 1996 Mar;70(3):1931-40

Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner. Edwalds-Gilbert G, et al. **Mol Cell Biol** 1995 Nov; 15(11):6420-9

3'-end-forming signals of yeast mRNA. Guo Z, et al. **Mol Cell Biol** 1995 Nov;15(11):5983-90

Role of polyadenylation in nucleocytoplasmic transport of mRNA. Huang Y, et al. **Mol Cell Biol** 1996 Apr; 16(4):1534-42

Temporal regulation of herpes simplex virus type 1 UL24 mRNA expression via differential polyadenylation. Cook WJ, et al. **Virology** 1996 Apr 1;218(1):204-13

PHARMACOLOGY

Histone-poly(A) hybrid molecules as tools to block nuclear pores. Cremer G, et al. **J Protein Chem** 1995 Apr; 14(3):151-9

RADIATION EFFECTS

Electron paramagnetic resonance investigation of X-irradiated poly(U), poly(A) and poly(A):poly(U): influence of hydration, packing and conformation on radical yield at 4 K. Mroczka NE, et al. **Radiat Res** 1995 Dec;144(3):251-7

POLY(A)+ MRNA see **RNA, MESSENGER**

POLY A POLYMERASE

BIOSYNTHESIS

Complex alternative RNA processing generates an unexpected diversity of poly(A) polymerase isoforms. Zhao W, et al. **Mol Cell Biol** 1996 May;16(5):2378-86

CHEMISTRY

Structure-function relationships in the Saccharomyces cerevisiae poly(A) polymerase. Identification of a novel RNA binding site and a domain that interacts with specificity factor(s). Zhelkovsky AM, et al. **J Biol Chem** 1995 Nov 3;270(44):26715-20

GENETICS

Mutational analysis of mammalian poly(A) polymerase identifies a region for primer binding and catalytic domain, homologous to the family X polymerases, and to other nucleotidyltransferases. Martin G, et al. **EMBO J** 1996 May 15;15(10):2593-603

The Schizosaccharomyces pombe pla1 gene encodes a poly(A) polymerase and can functionally replace its Saccharomyces cerevisiae homologue. Ohnacker M, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2585-91

METABOLISM

Use of vaccinia virus poly(A) polymerase for RNA 3'-end labeling with a chain-terminating nucleotide or a short 3' homopolymer tract. Thomson JG, et al. **Biotechniques** 1995 Sep;19(3):416-20, 422-5

CPEB controls the cytoplasmic polyadenylation of cyclin, Cdk2 and c-mos mRNAs and is necessary for oocyte maturation in Xenopus. Stebbins-Boaz B, et al. **EMBO J** 1996 May 15;15(10):2582-92

A plant poly(A) polymerase requires a novel RNA-binding protein for activity. Li QS, et al. **J Biol Chem** 1996 Aug 16;271(33):19831-5

Structure-function relationships in the Saccharomyces cerevisiae poly(A) polymerase. Identification of a novel RNA binding site and a domain that interacts with specificity factor(s). Zhelkovsky AM, et al. **J Biol Chem** 1995 Nov 3;270(44):26715-20

Biochemical and immunological identification and enrichment of poly(A) polymerase from human thymus. Kyriakopoulou C, et al. **Mol Cell Biochem** 1996 Jan 12; 154(1):9-16

Characterization of small nontranslated polyadenylylated RNAs in vaccinia virus-infected cells. Lu C, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2037-42

Poly (A) polymerases in the nucleus and cytoplasm of frog oocytes: dynamic changes during oocyte maturation and early development. Ballantyne S, et al. **RNA** 1995 Mar; 1(1):64-78

POLY(A)+ RNA see **RNA, MESSENGER**

POLY(A) TAIL see **RNA, MESSENGER**

POLY A-U

PHARMACOLOGY

Involvement of interleukin-6 and interferon-alpha in the poly(A).Poly(U)-induced 2',5'-oligoadenylate synthetase activity in the mouse monocyte-macrophage cell line, J774A1. Marin JG, et al. **J Interferon Cytokine Res** 1996 Mar;16(3):251-7

RADIATION EFFECTS

Electron paramagnetic resonance investigation of X-irradiated poly(U), poly(A) and poly(A):poly(U): influence of hydration, packing and conformation on radical yield at 4 K. Mroczka NE, et al. **Radiat Res** 1995 Dec;144(3):251-7

THERAPEUTIC USE

Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice. Park SJ, et al. **Int J Immunopharmacol** 1995 Jun;17(6):513-6

POLY ADENOSINE DIPHOSPHATE RIBOSE

BIOSYNTHESIS

Inhibition of poly(ADP-ribose) formation by 4-hydroxynonenal in primary cultures of rabbit synovial fibroblasts. Ullrich O, et al. **Biochem J** 1996 May 1;315 (Pt 3):705-8

Dissection of ADP-ribose polymer synthesis into individual steps of initiation, elongation, and branching. Alvarez-Gonzalez R, et al. **Biochimie** 1995;77(6):403-7

Lactate stimulation of macrophage-derived angiogenic activity is associated with inhibition of Poly(ADP-ribose) synthesis. Zabel DD, et al. **Lab Invest** 1996 Mar;74(3):644-9

Synthesis of poly(ADP-ribose) in asbestos treated rat pleural mesothelial cells in culture. Dong HY, et al. **Mutat Res** 1995 Oct;331(2):197-204

BLOOD

Biochemical characterization of ADP-ribose polymer metabolism in SLE. Chen HY, et al. **Lupus** 1996 Feb; 5(1):14-21

CHEMISTRY

Interactions of poly(ADP-ribose) with nuclear proteins. Althaus FR, et al. **Biochimie** 1995;77(6):423-32

GENETICS

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cao J, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):759-63

METABOLISM

Co-operative interactions of oligonucleosomal DNA with the H1e histone variant and its poly(ADP-ribosyl)ated isoform. D'erme M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):475-80

Equilibrium model in an in vitro poly(ADP-ribose) turnover system. Lagueux J, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):201-8

NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Berger NA, et al. **Biochimie** 1995;77(5):364-7 (16 ref.)

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394-8 (22 ref.)

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356-63 (41 ref.)

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385-93 (45 ref.)

Lupus and poly (ADP-ribose) [editorial] Shall S. **Lupus** 1996 Feb;5(1):1-3

The effect of niacin deficiency on diethylnitrosamine-induced hepatic poly(ADP-ribose) levels and altered hepatic foci in the Fischer-344 rat. Rawling JM, et al. **Nutr Cancer** 1995;24(2):111-9

POLY ADP RIBOSE see **POLY ADENOSINE DIPHOSPHATE RIBOSE**

POLY ADP RIBOSE POLYMERASE see **NAD+ ADP-RIBOSYLTRANSFERASE**

POLY(ADP-RIBOSE) SYNTHASE see **NAD+ ADP-RIBOSYLTRANSFERASE**

POLY C

Mutational analysis of the mengovirus poly(C) tract and surrounding heteropolymeric sequences. Martin LR, et al. **J Virol** 1996 Mar;70(3):2027-31

PHARMACOLOGY

Ribosome-associated ribonucleases from six-day larvae of the insect Ceratitis capitata. Kouyanou S, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1217-27

POLY DA-DT

CHEMISTRY

Modulation of cyclobutane pyrimidine dimer formation in a positioned nucleosome containing poly(dA.dT) tracts. Schieferstein U, et al. **Biochemistry** 1996 Jun 18; 35(24):7705–14

Mono–, di– and trimeric binding of a bis–netropsin to DNA. Zasedatelev AS, et al. **FEBS Lett** 1995 Nov 20;375(3):304–6

Structures of poly(dG–dC) and poly(dA–dT) stabilized by anions. Loprete DM, et al. **J Biomol Struct Dyn** 1995 Aug; 13(1):57–67

Intramolecular TAT triplex in (dA)58.(dT)58. influence of ions. Pečinka P, et al. **J Biomol Struct Dyn** 1995 Aug; 13(1):29–46

Examining the contribution of a dA+dT element to the conformation of Escherichia coli integration host factor–DNA complexes. Hales LM, et al. **Nucleic Acids Res** 1996 May 1;24(9):1780–6

IMMUNOLOGY

Antigenicity of poly(dA–dT) . poly(dA–dT) photocrosslinked with 8–methoxypsoralen. Arif Z, et al. **Arch Biochem Biophys** 1996 May 15;329(2):191–8

Binding of anti–double stranded (ds) DNA–positive sera to denatured (d) DNA and synthetic poly[dA–dT] x poly[dA–dT] double stranded copolymer in an ELISA format. Batinić D, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):343–7

METABOLISM

Binding of RecA to anti–parallel poly(dA).2poly(dT) triple helix DNA. Kim SK, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):129–33

PHARMACOLOGY

Activation of (ADP–ribose)polymerase by complexes of oligodeoxynucleotides. Karabashian LV, et al. **Biochem Soc Trans** 1996 Feb;24(1):41S

POLY(DEOXYADENYLATE–THYMIDYLATE) see **POLY DA–DT**

POLY DT see **POLY T**

POLY–HEMA see **POLYHYDROXYETHYL METHACRYLATE**

POLY I–C

ADMINISTRATION & DOSAGE

Long–term treatment of malignant gliomas with intramuscularly administered polyinosinic–polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Salazar AM, et al. **Neurosurgery** 1996 Jun;38(6):1096–103; discussion 1103–4

ANALYSIS

Quantitative fluorescence method for continuous measurement of DNA hybridization kinetics using a fluorescent intercalator. Yguerabide J, et al. **Anal Biochem** 1995 Jul 1;228(2):208–20

PHARMACOLOGY

The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid–polycytidylic acid. Anari MR, et al. **Drug Metab Dispos** 1995 May;23(5):536–41

Polyinosinic acid: polycytidylic acid promotes T helper type 1–specific immune responses by stimulating macrophage production of interferon–alpha and interleukin–12. Manetti R, et al. **Eur J Immunol** 1995 Sep;25(9):2656–60

THERAPEUTIC USE

Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Wong JP, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2574–6

Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. Puri SK, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):49–52

POLY(LACTIDE–CO–GLYCOSIDE) see **POLYGLACTIN 910**

POLY T

CHEMISTRY

FTIR study of a nonclassical dT10*dA10–dT10 intramolecular triple helix. Dagneaux C, et al. **Biochemistry** 1995 Nov 14;34(45):14815–8

Stability measurements of antisense oligonucleotides by capillary gel electrophoresis. Bruin GJ, et al. **J Chromatogr A** 1995 Aug 11;709(1):181–95

POLY U

CHEMISTRY

Application of a self–modeling curve resolution approach to the study of solvent effects on the acid–base and copper (II)–complexing behavior of polyuridylic acid. de Juan A, et al. **J Inorg Biochem** 1996 Aug 15;63(3):155–73

METABOLISM

A highly salt–dependent enthalpy change for Escherichia coli SSB protein–nucleic acid binding due to ion–protein interactions. Lohman TM, et al. **Biochemistry** 1996 Apr 23;35(16):5272–9

Poly(U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase. Kanai A, et al. **FEBS Lett** 1995 Dec 4;376(3):221–4

PHARMACOLOGY

Ribosome–associated ribonucleases from six–day larvae of the insect Ceratitis capitata. Kouyanou S, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1217–27

RADIATION EFFECTS

Formation of 5–hydroxy–5,6–dihydrouracil and release of undamaged uracil as a result of poly(U) irradiation in N2O–saturated aqueous solution. Grachev SA, et al. **Int J Radiat Biol** 1995 Nov;68(5):543–51

Inhibition of OH radical–induced strand break formation of poly(U) by Ru(bpy)32+ or Ru(phen)32+ attached to the polynucleotide. Tossi AB, et al. **Int J Radiat Biol** 1995 Nov;68(5):525–33

Electron paramagnetic resonance investigation of X–irradiated poly(U), poly(A) and poly(A):poly(U): influence of hydration, packing and conformation on radical yield at 4 K. Mroczka NE, et al. **Radiat Res** 1995 Dec;144(3):251–7

POLYACRYLAMIDE GEL ELECTROPHORESIS, TWO–DIMENSIONAL see **ELECTROPHORESIS, GEL, TWO–DIMENSIONAL**

POLYADENYLATE POLYMERASE see **POLY A POLYMERASE**

POLYADENYLATE SYNTHETASE see **POLY A POLYMERASE**

POLYADENYLIC ACIDS see **POLY A**

POLYAMIDES see **NYLONS**

POLYAMINES

Conjugates of glycosylated steroids and polyamines as novel nonviral gene delivery systems. Longley C, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:268–70

DNA triple helix stabilization by bisguanidinyl analogues of biogenic polyamines. Pallan PS, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):416–20

Sensitivity of polyamine–deficient Saccharomyces cerevisiae to elevated temperatures. Balasundaram D, et al. **J Bacteriol** 1996 May;178(9):2721–4

ADMINISTRATION & DOSAGE

Stable intracellular acidification upon polyamine depletion induced by alpha–difluoromethylornithine or N1,N12–bis(ethyl)spermine in L1210 leukaemia cells. Poulin R, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):749–56

ADVERSE EFFECTS

Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma. Fernandez C, et al. **Br J Cancer** 1995 Nov;72(5):1194–9

ANALYSIS

Maternal and zygotic expression of mRNA for S–adenosylmethionine decarboxylase and its relevance to the unique polyamine composition in Xenopus oocytes and embryos. Shinga J, et al. **Biochim Biophys Acta** 1996 Jul 31;1308(1):31–40

Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Gilad GM, et al. **Biol Psychiatry** 1995 Aug 15;38(4):227–34

Erythrocyte polyamine levels: an indication of successful engraftment of bone marrow in children. Bergeron C, et al. **Bone Marrow Transplant** 1995 Jul;16(1):27–30

Distribution of diaminopropane and acetylspermidine in Enterobacteriaceae. Hamana K. **Can J Microbiol** 1996 Feb; 42(2):107–14

Successful eradicating treatment of Helicobacter pylori in patients with chronic gastritis: gastric levels of cytokines, epidermal growth factor and polyamines before and after therapy. Messa C, et al. **Immunopharmacol Immunotoxicol** 1996 Feb;18(1):1–13

Automated determination of polyamines by high–performance liquid chromatography with simple sample preparation. van Eijk HM, et al. **J Chromatogr A** 1996 Apr 12;730(1–2):115–20

Improved high–performance liquid chromatographic method for the determination of polyamines as their benzoylated derivatives: application to P388 cancer cells. Schenkel E, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):189–97

Polyamine profiles in human milk, infant artificial formulas, and semi–elemental diets. Buts JP, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):44–9

High performance liquid chromatography separation and simultaneous fluorometric detection of trace amount of polyamines in cell culture media. Wang CB, et al. **J Tongji Med Univ** 1995;15(2):125–8

Quantifying polyamines in Agrobacterium rhizogenes strains and in Ri plasmid transformed cells. Bagni N, et al. **Methods Mol Biol** 1995;44:223–36

[Amines and pteridines] Shimpo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1515–20 (22 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Polyamine deprivation provokes an antalgic effect. Kergozien S, et al. **Life Sci** 1996;58(24):2209–15

BLOOD

Determination of erythrocyte polyamines as a predictive method in tumour diagnosis. An animal study with chemically induced tumours. Quemener V, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2517–22

How does the kidney deal with plasma polyamines? Brosnan ME, et al. **Biochem Soc Trans** 1995 Aug;23(3):469S

Red blood cell polyamines, anaemia and tumour growth in the rat. Quemener V, et al. **Eur J Cancer** 1996 Feb; 32A(2):316–21

Determination of polyamines in serum by high–performance capillary zone electrophoresis with indirect ultraviolet detection. Zhou G, et al. **J Chromatogr A** 1995 Nov 24; 717(1–2):345–9

Raised plasma polyamine concentrations in patients with severe head injury [letter] Timothy J, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):209–10

CHEMISTRY

Evaluation of the counterion condensation theory of polyelectrolytes. Stigter D. **Biophys J** 1995 Aug; 69(2):380–8

Interaction between the left–handed Z–DNA and polyamine–2. The crystal structure of the d(CG)3 and spermidine complex. Ohishi H, et al. **FEBS Lett** 1996 Aug 5;391(1–2):153–6

Neuroactive polyamine wasp toxins: nuclear magnetic resonance spectroscopic analysis of the protolytic properties of philanthotoxin–343. Jaroszewski JW, et al. **J Med Chem** 1996 Jan 19;39(2):515–21

Suppression of c–myc oncogene expression by a polyamine–complexed triplex forming oligonucleotide in MCF–7 breast cancer cells. Thomas TJ, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3594–9

[An affinity chromatography sorbent containing concanavalin A groups immobilized by complex formation with cobalt] Berezin VB, et al. **Prikl Biokhim Mikrobiol** 1995 Jul–Aug;31(4):400–4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Differential recognition of free and covalently bound polyamines by the monoclonal anti–spermine antibody SPM8–2. Delcros JG, et al. **J Immunol Methods** 1995 Sep 25;185(2):191–8

METABOLISM

Gastrin stimulates expression of protooncogene c–myc through a process involving polyamines in IEC–6 cells. Wang JY, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1474–81

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro. Johnson WC, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:136–47

Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL–alpha–difluoromethylornithine. Merali S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):973–8

Thermodynamic analysis of the oxidative deamination of polyamines by bovine serum amine oxidase. Stevanato R, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):374–8

Is polyamine decrease a common feature of apoptosis? Evidence from gamma rays– and heat shock–induced cell death. Grassilli E, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):708–14

A new model for disruption of the ornithine decarboxylase gene, SPE1, in Saccharomyces cerevisiae exhibits growth arrest and genetic instability at the MAT locus. Schwartz B, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):83–90

How does the kidney deal with plasma polyamines? Brosnan ME, et al. **Biochem Soc Trans** 1995 Aug;23(3):469S

Metabolism of L–arginine through polyamine and nitric oxide synthase pathways in proliferative or differentiated human colon carcinoma cells. Blachier F, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):255–62

Polyamine metabolism in the rat liver after orthotopic liver transplantation. Terakura M, et al.

Biochim Biophys Acta 1995 Oct 19;1245(2):207–14
Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Gilad GM, et al. **Biol Psychiatry** 1995 Aug 15;38(4):227–34
Increased polyamine levels and changes in the sensitivity to convulsions during chronic treatment with cocaine in mice. Shimosato K, et al. **Brain Res** 1995 Jul 3;684(2):243–7
Effect of kainate–induced seizure activity on the polyamine interconversion pathway in juvenile rat brain. Hayashi Y, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):96–9
Polyamine acetylation in rat brain during N–ethyl–N–nitrosourea–induced cerebral carcinogenesis. Sessa A, et al. **Cancer Lett** 1995 Oct 20;97(1):123–8
Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR–1065 and WR–33278. Mitchell JL, et al. **Carcinogenesis** 1995 Dec;16(12):3063–8
Polyamines and terminal deoxynucleotidyl transferase expression in KM 3 pre–B cell line during phorbol ester induced differentiation. Stabellini G, et al. **Cell Biol Int** 1995 Oct;19(10):821–5
Ion channels. A physiological function for polyamines? Forsythe ID. **Curr Biol** 1995 Nov 1;5(11):1248–51 (19 ref.)
Healing of chronic gastric ulcerations by L–arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Brzozowski T, et al. **Digestion** 1995;56(6):463–71
Influence of the size and source of the inoculum on biodegradation curves in closed–bottle tests. van Ginkel CG, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):218–23
Phosphorylation of Okazaki–like DNA fragments in mammalian cells and role of polyamines in the processing of this DNA. Pohjanpelto P, et al. **EMBO J** 1996 Mar 1;15(5):1193–200
Impairment of DNA replication within one cell cycle after seeding of cells in the presence of a polyamine–biosynthesis inhibitor. Fredlund JO, et al. **Eur J Biochem** 1996 May 1;237(3):539–44
Effects of gestational or neonatal treatment with alpha–difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry. Sparapani M, et al. **Exp Brain Res** 1996 Mar;108(3):433–40
Osmotic effects on the polyamine pathway of Neurospora crassa. Davis RH, et al. **Exp Mycol** 1995 Dec;19(4):314–9
Effects of female sex hormones on polyamine–oxidizing enzyme activities and polyamine concentrations in immature rat uterus and liver. Dimitrov O, et al. **Experientia** 1996 Aug 15;52(8):795–8
First report of the inhibition of arbuscular mycorrhizal infection of Pisum sativum by specific and irreversible inhibition of polyamine biosynthesis or by gibberellic acid treatment. El Ghachtouli N, et al. **FEBS Lett** 1996 May 6;385(3):189–92
Effects of polyamine imbalance on the induction of stress genes in hepatocarcinoma cells exposed to heat shock. Desiderio MA, et al. **Hepatology** 1996 Jul;24(1):150–6
DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)
Vitamin A status and metabolism of cutaneous polyamines in the hairless mouse after UV irradiation: action of beta–carotene and astaxanthin. Savouré N, et al. **Int J Vitam Nutr Res** 1995;65(2):79–86
Photoaffinity labeling of a cell surface polyamine binding protein. Felschow DM, et al. **J Biol Chem** 1995 Dec 1; 270(48):28705–11
Isolation of a polyamine transport deficient cell line from the human non–small cell lung carcinoma line NCI H157. Shao D, et al. **J Cell Physiol** 1996 Jan;166(1):43–8
Altered polyamine biosynthesis with aging after massive proximal small bowel resection in rat. Sakamoto K, et al. **J Gastroenterol** 1996 Jun;31(3):338–46
The mechanism of inward rectification of potassium channels: "long–pore plugging" by cytoplasmic polyamines. Lopatin AN, et al. **J Gen Physiol** 1995 Nov;106(5):923–55
Inhibition of polyamine synthesis alters hair follicle function and fiber composition. Hynd PI, et al. **J Invest Dermatol** 1996 Feb;106(2):249–53
Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. Bresink I, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):11–26
Polyamine modification increases the permeability of proteins at the blood–nerve and blood–brain barriers. Poduslo JF, et al. **J Neurochem** 1996 Apr;66(4):1599–609
Synthetic analogues of conantokin–G: NMDA antagonists acting through a novel polyamine–coupled site. Zhou LM, et al. **J Neurochem** 1996 Feb;66(2):620–8
Characterisation of a functional polyamine site on rat mast cells: association with a NMDA receptor macrocomplex. Purcell WM, et al. **J Neuroimmunol** 1996 Mar;65(1):49–53
Cysteine supplementation increases glutathione, but not polyamine, concentrations of the small intestine and colon of parenterally fed newborn rabbits. Pollack PF, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):364–72
Polyamines found in gingival fluid enhance the secretory and oxidative function of human polymorphonuclear leukocytes in vitro. Walters JD, et al. **J Periodontal Res** 1995 May;30(3):167–71
Block of native Ca(2+)–permeable AMPA receptors in rat brain by intracellular polyamines generates double rectification. Koh DS, et al. **J Physiol (Lond)** 1995 Jul 15; 486 (Pt 2):305–12
Effects of cationic diamidines on polyamine metabolism in the trypanosomatid Crithidia fasciculata. Calonge MM, et al. **Life Sci** 1996;59(12):PL191–7
Polyamine involvement in the cell cycle, apoptosis, and autoimmunity. Brooks WH. **Med Hypotheses** 1995 May; 44(5):331–8
Influence of sepsis and endotoxemia on polyamine metabolism in mucosa of small intestine in rats. Noguchi Y, et al. **Metabolism** 1996 Jan;45(1):28–33
Increased brain concentrations of polyamines in rats with encephalopathy due to a galactosamine–induced fulminant hepatic failure. Baraldi M, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):57–61
Intracellular polyamines mediate inward rectification of Ca(2+)–permeable alpha–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid receptors. Donevan SD, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9298–302
Sepsis stimulates polyamine biosynthesis in the liver and increases tissue levels of ornithine decarboxylase mRNA. Tiao G, et al. **Shock** 1995 Dec;4(6):403–10
In vivo, synergestic inhibition of MAT–LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low–dose cyclophosphamide. Cipolla B, et al. **Urol Res** 1996;24(2):93–8; discussion 99

PHARMACOLOGY

Specific modulation of cyclic ADP–ribose–induced Ca2+ release by polyamines. Chini EN, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1042–7
Polyamines inhibit myosin phosphatase and increase LC20 phosphorylation and force in smooth muscle. Swärd K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C563–71
The ability of polyamine analogues to induce Z–DNA structure in synthetic polynucleotid[illegible] vitro inversely correlates with their effects o[illegible] cytotoxicity of cis–diaminedichloroplatinum (II) (CDDP) in human brain tumor cell lines. Basu HS, et al. **Anticancer Res** 1996 Jan–Feb;16(1):39–47
Role of endogenous polyamines in the proliferation of normal hematopoietic progenitor cells: high–proliferative potential colony–forming cells (HPP–CFC), and low–proliferative potential colony–forming cells (LPP–CFC). Studies "in vitro". Zangheri EO, et al. **Biocell** 1996 Apr;20(1):97–103
Effect of polycation peptides on mitochondrial permeability transition. Rigobello MP, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):144–9
Stimulation in vitro of vitamin B12–dependent methionine synthase by polyamines. Kenyon SH, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):661–5
Kukoamine A and other hydrophobic acylpolyamines: potent and selective inhibitors of Crithidia fasciculata trypanothione reductase. Ponasik JA, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):371–5
Opposite effects of polyamines on glutamate deamination in isolated renal tubules and permeabilized kidney cortex mitochondria of rabbit. Jarzyna R, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):795–803
C–terminus determinants for Mg2+ and polyamine block of the inward rectifier K+ channel IRK1. Taglialatela M, et al. **EMBO J** 1995 Nov 15;14(22):5532–41
Regulation of apoptosis of interleukin 2–dependent mouse T–cell line by protein tyrosine phosphorylation and polyamines. Min A, et al. **J Cell Physiol** 1995 Dec; 165(3):615–23
Effect of polyamines on the separation of ovalbumin glycoforms by capillary electrophoresis. Legaz ME, et al. **J Chromatogr A** 1996 Jan 5;719(1):159–70
Synthesis of N,N'–substituted piperazine and homopiperazine derivatives with polyamine–like actions at N–methyl–D–aspartate receptors. Zhou LM, et al. **J Med Chem** 1995 Dec 8;38(25):4891–6
The potential of a novel polyamine transport inhibitor in cancer chemotherapy. Aziz SM, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):185–92
Block of alpha–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid (AMPA) receptors by polyamines and polyamine toxins. Washburn MS, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):669–78
Involvement of polyamines in the contragestational effect of hyperthermia. Cremades A, et al. **Life Sci** 1995; 57(14):1343–9
The in vitro action of polyamines on rat basilar and femoral artery contractile activity. Johnson TD, et al. **Life Sci** 1996; 59(7):529–36
Characterization of the effects of polyamines on the modulation of the N–methyl–D–aspartate receptor by glycine. Reynolds IJ, et al. **Neuropharmacology** 1995 Sep; 34(9):1147–57
Cationic facial amphiphiles: a promising class of transfection agents. Walker S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1585–90
Transgenic animals as models in the study of the neurobiological role of polyamines. Kauppinen RA, et al. **Prog Neurobiol** 1995 Dec;47(6):545–63 (140 ref.)
In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun; 88(3):271–92
Characterization of 2,4–dichlorophenoxyacetic acid transport and its relationship with polyamines in Azospirillum brasilense. Castro S, et al. **Toxicol Lett** 1996 Jan;84(1):33–6

POISONING

[Collagenosis–like syndromes as the possible manifestations of poisoning by the components of a compound] Sichko ZhV, et al. **Med Tr Prom Ekol** 1995;(11):44–6 **(Rus)**

TOXICITY

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro. Johnson WC, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:136–47
Multiple actions of arylalkylamine arthropod toxins on the N–methyl–D–aspartate receptor. Donevan SD, et al. **Neuroscience** 1996 Jan;70(2):361–75

URINE

[Polyamine and ornithine decarboxylase] Kubota S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:501–5 (20 ref.) **(Jpn)**

POLYAMINES, BIOGENIC see **BIOGENIC POLYAMINES**

POLYANGIACEAE see **MYXOCOCCALES**

POLYANGIUM see **MYXOCOCCALES**

POLYARTERITIS NODOSA

Polyarteritis nodosa with pulmonary vasculitis. Nick J, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):450–3
Microscopic polyangiitis: clinical aspects and treatment. Lhote F, et al. **Ann Med Interne (Paris)** 1996;147(3):165–77 (88 ref.)
Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome. Clinical aspects and treatment. Lhote F, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):911–47 (132 ref.)
Bilateral ureteral involvement in polyarteritis nodosa. Kaskarelis IS, et al. **Scand J Urol Nephrol** 1995 Sep; 29(3):323–6
[Isolated periarteritis nodosa of the gallbladder] Tsugu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):222–4 (21 ref.) **(Jpn)**

CHEMICALLY INDUCED

Characterization of the arteritis induced by infusion of rats with UK–61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate. Hanton G, et al. **Arch Toxicol** 1995;69(10):698–704
Microangiopathic hemolytic anemia secondary to cyclosporine therapy in a heart and liver transplant recipient [letter] Oteo JF, et al. **J Heart Lung Transplant** 1996 Mar;15(3):322–4

CLASSIFICATION

Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Watts RA, et al. **Arthritis Rheum** 1996 Jul;39(7):1208–12

COMPLICATIONS

Tongue necrosis due to vasculitis. Ekman–Joelsson BM, et al. **Acta Paediatr** 1995 Nov;84(11):1333–6
Multiple myeloma–associated systemic vasculopathy due to crystalglobulin or polyarteritis nodosa. Hasegawa H, et al. **Arthritis Rheum** 1996 Feb;39(2):330–4
Polyarteritis nodosa in human immunodeficiency virus infection: report of four cases and review of the literature. Font C, et al. **Br J Rheumatol** 1996 Aug;35(8):796–9 (31 ref.)
Splenic abscess [letter; comment] Carr ND, et al. **Br J Surg** 1996 Jan;83(1):134. Comment on: Br J Surg 1995 Mar;82(3):355.
HLA–B27 positive ankylosing spondylitis and polyarteritis nodosa: a case report. Galeazzi M, et al. **Clin Rheumatol** 1996 Mar;15(2):204–6
Kidney–limited recurrence in a patient with microscopic polyarteritis [see comments] Sato Y, et al. **Intern Med** 1995 Oct;34(10):1000–4 (18 ref.). Comment in: Intern Med 1995 Oct;34(10):936–7.
Recurrent haemobilia in a patient with polyarteritis nodosa. Bichile LS, et al. **J Assoc Physicians India** 1996 Jan; 44(1):49–50
Anaplastic colon carcinoma associated with necrotizing vasculitis. Paajanen H, et al. **J Clin Gastroenterol** 1995 Sep; 21(2):168–9
Acute sensorineural hearing loss following intravenous ketoralac administration. Schaab KC, et al. **J Emerg Med** 1995 Jul–Aug;13(4):509–13
Idiopathic CD4+ lymphocytopenia and systemic vasculitis. Bordin G, et al. **J Intern Med** 1996 Jul;240(1):37–41
Polyarteritis nodosa: ischaemic intestinal pain successfully treated with nitroglycerin. Dahlander B, et al. **J Intern Med** 1996 Jul;240(1):31–2
Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez–Taboada VM, et al. **Lupus** 1996 Feb;5(1):74–6

(21 ref.)
Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293–8 (17 ref.)
Polyarteritis nodosa presenting as perirenal hemorrhage. Singh S, et al. **Urol Int** 1995;55(2):105–7
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease] Fontaney F, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):940–3 (25 ref.) (Eng. Abstr.) **(Fre)**
[Otologic manifestations presenting and predominating in necrotizing angiitis] Depondt J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):249–52 (Eng. Abstr.) **(Fre)**
[Uterine localization of periarteritis nodosa disclosed by fever of long duration] Grasland A, et al. **Rev Med Interne** 1996; 17(1):58–60 (Eng. Abstr.) **(Fre)**
[Anicteric cholestasis in a 75-year-old man] Dubé F, et al. **Union Med Can** 1995 Mar;124(1):37–9 **(Fre)**
[Periarteritis nodosa cutanea. 20 years follow-up with leg pain, Raynaud syndrome and nail changes] Trüeb RM, et al. **Hautarzt** 1995 Aug;46(8):568–72 (Eng. Abstr.) **(Ger)**
[Polyangiitis overlap syndrome with multiple pulmonary aneurysms and renal vascular hypertension] Taguchi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):428–33 (Eng. Abstr.) **(Jpn)**
[A case of polyarteritis nodosa presenting acute cholecystitis] Tatsumi N, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1322–4 **(Jpn)**
[An autopsy case of segmental mediolytic arteritis (SMA) accompanied with microscopic polyarteritis nodosa] Ito MR, et al. **Ryumachi** 1995 Aug;35(4):693–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

15-year-old boy with abdominal pain and hypertension. Khanfar NM, et al. **Mayo Clin Proc** 1996 Jul;71(7):713–6
Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Guillevin L, et al. **Medicine (Baltimore)** 1996 Jan;75(1):17–28
Systemic fibromuscular dysplasia masquerading as polyarteritis nodosa. Siegert CE, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1356–8
[Periarteritis nodosa with initial ocular involvement] Pinto Ferreira F, et al. **J Fr Ophtalmol** 1995;18(12):788–93 (Eng. Abstr.) **(Fre)**
[Rupture of a renal artery aneurysm in polyarteritis nodosa: evaluation by DSA and comparison with MR angiography] Schmid MR, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):353–5 **(Ger)**
[Spontaneous kidney ruptures—a complication of panarteritis nodosa] Brkovic D, et al. **Urologe A** 1995 Nov;34(6):470–4 (Eng. Abstr.) **(Ger)**
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments] de Groot K, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):291–302 (59 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**
[Periarteritis nodosa with ruptures of the renal vessels and the persistence of the hepatitis B and C viruses in the blood] Semenkova EN, et al. **Klin Med (Mosk)** 1995;73(3):108–9 **(Rus)**
[Sensory polyneuropathy and neural conduction block as an initial manifestation of polyarteritis nodosa] Chico A, et al. **Rev Neurol** 1995 May–Jun;23(121):679–81 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Cutaneous polyarteritis nodosa [letter] Fitzgerald DA, et al. **Arch Dis Child** 1996 Apr;74(4):367

EPIDEMIOLOGY

Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Watts RA, et al. **Arthritis Rheum** 1996 Jul;39(7):1208–12
Occurrence rate of polyarteritis nodosa in chronic renal diseases [letter] Erk O, et al. **Nephron** 1996;72(2):365–6

ETHNOLOGY

Microscopic polyarteritis has a poor prognosis in Chinese. Li PK, et al. **J Rheumatol** 1995 Jul;22(7):1295–9

ETIOLOGY

IgA multiple myeloma presenting as Henoch–Schönlein purpura/polyarteritis nodosa overlap syndrome. Birchmore D, et al. **Arthritis Rheum** 1996 Apr;39(4):698–703
A patient with rheumatoid arthritis and microscopic polyarteritis [letter] Steuer A, et al. **Br J Rheumatol** 1995 Dec;34(12):1185–6
Severe necroziting vasculitis in a patient with hepatitis C virus infection treated by interferon. Pateron D, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):79–81
Development of polyarteritis nodosa in the course of inactive systemic lupus erythematosus. Vivancos J, et al. **Lupus** 1995 Dec;4(6):494–5
Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Guillevin L, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):238–53
Vasculitides in hairy cell leukemia. Hasler P, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):134–42 (48 ref.)

IMMUNOLOGY

Antineutrophil cytoplasmic antibodies (ANCA) and abnormal angiograms in polyarteritis nodosa and Churg–Strauss syndrome: indications for the diagnosis of microscopic polyangiitis. Guillevin L, et al. **Ann Med Interne (Paris)** 1995;146(8):548–50
Anti-neutrophil cytoplasm antibodies in patients with ACR criteria for polyarteritis nodosa: help for systemic vasculitis classification? Baranger TA, et al. **Autoimmunity** 1995; 20(1):33–7
Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P-ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386–8 (14 ref.)
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

MICROBIOLOGY

Picture of the month. Polyarteritis nodosa with angioedema. Cron RQ, et al. **Arch Pediatr Adolesc Med** 1996 Aug; 150(8):875–6

PATHOLOGY

Microscopic polyarteritis during polymyalgia rheumatica remission. Uematsu-Yanagita M, et al. **Am J Kidney Dis** 1996 Aug;28(2):289–91 (6 ref.)
Picture of the month. Polyarteritis nodosa with angioedema. Cron RQ, et al. **Arch Pediatr Adolesc Med** 1996 Aug; 150(8):875–6
Case records of the University of the Department of Medicine University of Mississippi Medical Center. Polyarteritis nodosa [clinical conference] Guynes RD, et al. **J Miss State Med Assoc** 1995 Dec;36(11):406–13
Six cases of microscopic polyarteritis exhibiting acute interstitial pneumonia [published erratum appears in Pathol Int 1995 Nov;45(11):901] Akikusa B, et al. **Pathol Int** 1995 Aug;45(8):580–8
[Pneumonia, biclonal gammopathy, paralysis of the fibular nerve and cerebrovascular insult (clinical conference)] Stahl H, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26; 84(39):1071–8 **(Ger)**

RADIOGRAPHY

Regressing microaneurysms in 5 cases of hepatitis B virus related polyarteritis nodosa. Darras-Joly C, et al. **J Rheumatol** 1995 May;22(5):876–80

THERAPY

Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Guillevin L, et al. **Arthritis Rheum** 1995 Nov;38(11):1638–45
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold-Keller E, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):303–9 (30 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

ULTRASONOGRAPHY

[Bilateral testicular ischemia in vasculitis. Differential diagnosis with torsion and the value of color Doppler ultrasonography] Suty JM, et al. **Prog Urol** 1995 Sep; 5(4):586–9 (Eng. Abstr.) **(Fre)**

VETERINARY

Pathologic features of naturally occurring juvenile polyarteritis in beagle dogs. Snyder PW, et al. **Vet Pathol** 1995 Jul;32(4):337–45

VIROLOGY

Extrahepatic manifestations of hepatitis C virus infection [letter; comment] Pollock JL. **Ann Intern Med** 1996 Aug 15;125(4):345; discussion 346. Comment on: Ann Intern Med 1995 Oct 15;123(8):615–20.
Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Guillevin L, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):238–53

POLYARTHRALGIA see **ARTHRALGIA**

POLYARTHRITIS see **ARTHRITIS**

POLYAZIRIDINE see **POLYETHYLENEIMINE**

POLYBROMINATED BIPHENYLS

ADVERSE EFFECTS

Breast cancer among women exposed to polybrominated biphenyls. Henderson AK, et al. **Epidemiology** 1995 Sep; 6(5):544–6

POLYBROMOBIPHENYL COMPOUNDS see **POLYBROMINATED BIPHENYLS**

POLYCARBOXYLATE CEMENT

CHEMISTRY

Rapid diffusion of the lipid phosphorus of phosphatidylglycerol liposomes through polycarbonate membranes is caused by the oxidation of the unsaturated fatty acids. Chow CY, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):168–76

POLYCHAETA

CHEMISTRY

Wheat germ agglutinin-reactive chains of giant hemoglobin from the polychaete Perinereis aibuhitensis. Matsubara K, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):215–23
Iron ligand recognition by monomeric hemoglobins. Stephanos JJ, et al. **Biochim Biophys Acta** 1996 Jul 18; 1295(2):209–21
Primary structure of a constituent polypeptide chain of the chlorocruorin from Sabellastarte indica. Suzuki T, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):189–93
The multi-hemoglobin system of the hydrothermal vent tube worm Riftia pachyptila. I. Reexamination of the number and masses of its constituents. Zal F, et al. **J Biol Chem** 1996 Apr 12;271(15):8869–74
The multi-hemoglobin system of the hydrothermal vent tube worm Riftia pachyptila. II. Complete polypeptide chain composition investigated by maximum entropy analysis of mass spectra. Zal F, et al. **J Biol Chem** 1996 Apr 12; 271(15):8875–81
Three-dimensional reconstruction of the chlorocruorin of the polychaete annelid Eudistylia vancouverii. de Haas F, et al. **J Mol Biol** 1996 Jan 12;255(1):140–53
Glycosylated threonine but not 4-hydroxyproline dominates the triple helix stabilizing positions in the sequence of a hydrothermal vent worm cuticle collagen. Mann K, et al. **J Mol Biol** 1996 Aug 16;261(2):255–66

DRUG EFFECTS

Chronic toxicity of phenanthrene to the marine polychaete worm, Nereis (Neanthes) arenaceodentata. Emery VL Jr, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):265–70
The polychaete Platynereis dumerilii (Audouin and Milne-Edwards): a new species for assessing the hazardous potential of chemicals in the marine environment. Hutchinson TH, et al. **Ecotoxicol Environ Saf** 1995 Aug; 31(3):271–81
Development of an in vivo genotoxicity assay using the marine worm Platynereis dumerilii (Polychaeta: Nereidae). Jha AN, et al. **Mutat Res** 1996 Feb 29;359(2):141–50

ENZYMOLOGY

An unusual dehalogenating peroxidase from the marine terebellid polychaete Amphitrite ornata. Chen YP, et al. **J Biol Chem** 1996 Mar 1;271(9):4609–12

GENETICS

Localization of a vertebrate telomeric sequence in the chromosomes of two marine worms (phylum Annelida: class polychaeta). Jha AN, et al. **Chromosome Res** 1995 Dec;3(8):507–8
Globin and globin gene structure of the nerve myoglobin of Aphrodite aculeata. Dewilde S, et al. **J Biol Chem** 1996 Aug 16;271(33):19865–70

METABOLISM

Oxygen binding properties of Eudistylia vancouverii chlorocruorin and its dodecamer subunit. Imai K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):613–8
Mitochondrial sulfide oxidation in Arenicola marina. Evidence for alternative electron pathways. Völkel S, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):231–7
Long-lasting exocytosis and massive structural reorganisation in the egg periphery during cortical reaction in Platynereis dumerilii (Annelida, Polychaeta). Kluge B, et al. **Zygote** 1995 May;3(2):141–56

POLYCHEMOTHERAPY see **DRUG THERAPY, COMBINATION**

POLYCHLORINATED BIPHENYLS

PCB and dioxin re-entry criteria for building surfaces and air. Michaud JM, et al. **J Expo Anal Environ Epidemiol** 1994 Apr–Jun;4(2):197–227

ADMINISTRATION & DOSAGE

Porphyrins as biomarkers of methylmercury and PCB exposure in experimental quail. Leonzio C, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):244–50

ADVERSE EFFECTS

Developmental neurotoxicology in the neonate—effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81–8 (26 ref.)

Halogenated organic compounds and the human immune system: preliminary report on a study in hobby fishermen. Løvik M, et al. **Arch Toxicol Suppl** 1996;18:15–20

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)

Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Rice DC. **Environ Health Perspect** 1995 Dec;103 Suppl 9:71–87 (221 ref.)

Intellectual impairment in children exposed to polychlorinated biphenyls in utero. Jacobsen JL, et al. **N Engl J Med** 1996 Sep 12;335(11):783–9

Maternal exposure to polychlorinated biphenyls inhibits long-term potentiation in the visual cortex of adult rats. Altmann L, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):53–6

Immunologic effects of background prenatal and postnatal exposure to dioxins and polychlorinated biphenyls in Dutch infants. Weisglas-Kuperus N, et al. **Pediatr Res** 1995 Sep; 38(3):404–10

Effects of polychlorinated biphenyl/dioxin exposure and feeding type on infants' mental and psychomotor development. Koopman-Esseboom C, et al. **Pediatrics** 1996 May;97(5):700–6

Decreased birthweight among infants born to women with a high dietary intake of fish contaminated with persistent organochlorine compounds. Rylander L, et al. **Scand J Work Environ Health** 1995 Oct;21(5):368–75

Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al. **Sci Total Environ** 1996 Jul 16;186(1–2):141–8 (37 ref.)

[In a 1970-built high school multiple increased PCB (polychlorinated biphenyl) readings in concentrations of around 3,800 micrograms /pro cubic meter were obtained] Rüdiger HW. **Internist (Berl)** 1995 Sep;36(9):931–2 **(Ger)**

[The mortality of female workers exposed to PCBs] Tironi A, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2–3):200–2 **(Ita)**

ANALYSIS

Polychlorinated biphenyl (PCB) and dichlorodiphenyl dichloroethylene (DDE) concentrations in the breast milk of women in Quebec. Dewailly E, et al. **Am J Public Health** 1996 Sep;86(9):1241–6

Semivolatile organic compounds in adipose tissue: estimated averages for the US population and selected subpopulations. Lordo RA, et al. **Am J Public Health** 1996 Sep;86(9):1253–9

A monoclonal immunoassay for the coplanar polychlorinated biphenyls. Chiu YW, et al. **Anal Chem** 1995 Nov 1; 67(21):3829–39

An integrated analytical method for determination of polychlorinated aryl methyl sulfone metabolites and polychlorinated hydrocarbon contaminants in biological matrices. Letcher RJ, et al. **Anal Chem** 1995 Nov 15; 67(22):4155–63

Gas phase infrared spectra of 209 polychlorinated biphenyl congeners using gas chromatography with Fourier transform infrared detection: internal standardization with a 13C-labelled congener. Bush B, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):322–6

Contaminants of fishes from Great Lakes-influenced sections and above dams of three Michigan rivers: III. Implications for health of bald eagles. Giesy JP, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):309–21

Organochlorine residues in tissues of striped dolphins affected by the 1990 Mediterranean epizootic: relationships with the fatty acid composition. Guitart R, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):79–83

Intranuclear distribution of 2,2',4,4',5,5'-hexachlorobiphenyl and 2,3,7,8,-tetrachlorodibenzo-p-dioxin. Glitz E, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):35–9

Polychlorinated biphenyl (PCB) congeners in mussel and other mollusc from Da Chen Island, East China Sea. Chu SG, et al. **Bull Environ Contam Toxicol** 1995 Nov; 55(5):682–8

Organochlorine residues in gyrfalcons (Falco rusticolus) in Iceland. Olafsdóttir K, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):382–9

Survey of consumption fish from Swedish waters for chlorinated pesticides and polychlorinated biphenyls. Atuma SS, et al. **Chemosphere** 1996 Sep;33(5):791–9

PCDD, PCDF, planar and other PCB levels in human milk in Japan. off Hashimoto S, et al. **Chemosphere** 1995 Nov; 31(9):4067–75

Perinatal exposure to polychlorinated biphenyls and dioxins through dietary intake. Huisman M, et al. **Chemosphere** 1995 Nov;31(10):4273–87

Polychlorinated diphenyl ethers, dibenzo-P-dioxins and dibenzofurans in Finnish human tissues compared to environmental samples. Koistinen J, et al. **Chemosphere** 1995 Nov;31(10):4259–71

Dioxins, furans and AHH-active PCB congeners in eggs of two gull species from the western Mediterranean. Pastor D, et al. **Chemosphere** 1995 Sep;31(6):3397–411

A survey of PCB congeners in U.K. cows' milk. Sewart A, et al. **Chemosphere** 1996 Jun;32(12):2481–92

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7–16 (106 ref.)

Analysis of polychlorinated biphenyls in fatty biological matrixes by on-line supercritical fluid extraction and supercritical fluid cleanup. Alley EG, et al. **J AOAC Int** 1995 Jul-Aug;78(4):1051–4

Determination of chlorobiphenyls in seal blubber, marine sediment, and fish: interlaboratory study. de Boer J, et al. **J AOAC Int** 1996 Jan-Feb;79(1):83–96

Reliability of the determinations of polychlorinated contaminants (biphenyls, dioxins, furans). Horwitz W, et al. **J AOAC Int** 1996 May-Jun;79(3):589–621 (55 ref.)

Current developments in the analysis of water pollution by polychlorinated biphenyls. Font G, et al. **J Chromatogr A** 1996 May 10;733(1–2):449–71 (154 ref.)

A comparison of the concentrations of certain chlorinated hydrocarbons and polychlorinated biphenyls in bone marrow and fat tissue of children and their concentrations in breast milk. Scheele J, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):11–4

PCDDs, PCDFs, and PCBs in human milk from different parts of Norway and Lithuania. Becher G, et al. **J Toxicol Environ Health** 1995 Oct;46(2):133–48

Response surface analysis of bioconcentration by chlorinated organics using molecular connectivity. Hall LH, et al. **SAR QSAR Environ Res** 1994;2(3):181–91

Vascular plants as sensitive indicators of lead and PCB transport from local sources in the Canadian Arctic. Dushenko WT, et al. **Sci Total Environ** 1996 Sep 20; 188(1):29–38

Comparison of Ah receptor-mediated luciferase and ethoxyresorufin-O-deethylase induction in H4IIE cells: implications for their use as bioanalytical tools for the detection of polyhalogenated aromatic hydrocarbons. Sanderson JT, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):316–25

[Occurrence of chlorinated pesticides and polychlorinated biphenyls in the stalls and outdoor environment in pig-fattening farms] Raszyk J, et al. **Vet Med (Praha)** 1996 Jun;41(6):165–71 (Eng. Abstr.) **(Cze)**

[Polychlorobiphenyl (PCB) levels in the adipose tissue of subjects living in the Province of Trento] Poli A, et al. **Ann Ig** 1995 Mar-Apr;7(2):83–90 **(Ita)**

ANTAGONISTS & INHIBITORS

Increased [3H]phorbol ester binding in rat cerebellar granule cells and inhibition of 45Ca2+ sequestration in rat cerebellum by polychlorinated diphenyl ether congeners and analogs: structure-activity relationships. Kodavanti PR, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):251–61

BLOOD

The role of DDE and polychlorinated biphenyl levels in preterm birth. Berkowitz GS, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):139–41

Synthesis and characterization of hydroxylated polychlorinated biphenyls (PCBs) identified in human serum. Safe S, et al. **Chemosphere** 1995 Aug;31(4):3017–23

Selective retention of hydroxylated PCB metabolites in blood. Bergman A, et al. **Environ Health Perspect** 1994 May;102(5):464–9

Decreased lymphocyte responses in free-ranging bottlenose dolphins (Tursiops truncatus) are associated with increased concentrations of PCBs and DDT in peripheral blood. Lahvis GP, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:67–72

Occupational and environmental lead and PCB exposure at a scrap metal dealer. Malkin R. **Environ Res** 1995 Jul; 70(1):20–3

Female rhesus monkeys dosed with Aroclor 1254: analysis of polychlorinated biphenyl congeners in dam's milk and in the blood of dams and their offspring before, during, and after gestation. Mes J, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):209–17

Liquid-gel partitioning using Lipidex in the determination of polychlorinated biphenyls, naphthalenes, dibenzo-p-dioxins and dibenzofurans in blood plasma. Weistrand C, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):207–17

CHEMICAL SYNTHESIS

Synthesis and characterization of hydroxylated polychlorinated biphenyls (PCBs) identified in human serum. Safe S, et al. **Chemosphere** 1995 Aug;31(4):3017–23

CHEMISTRY

Synthesis of a fluorescent analog of polychlorinated biphenyls for use in a continuous flow immunosensor assay. Charles PT, et al. **Bioconjug Chem** 1995 Nov-Dec; 6(6):691–4

Metabolic activation of PCBs to quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase. Amaro AR, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):623–9

Generator column determination of aqueous solubilities for non-ortho and mono-ortho substituted polychlorinated biphenyls. Hong CS, et al. **Chemosphere** 1995 Dec; 31(11–12):4549–57

Photocatalytic degradation of PCBs in TiO2 aqueous suspensions. Huang IW, et al. **Chemosphere** 1996 May; 32(9):1869–81

Using three-dimensional quantitative structure-activity relationships to examine estrogen receptor binding affinities of polychlorinated hydroxybiphenyls. Waller CL, et al. **Environ Health Perspect** 1995 Jul-Aug;103(7–8):702–7

Chemiluminescence emission during reactions between superoxide and selected aliphatic and aromatic halocarbons in aprotic media. Shoaf AR, et al. **J Biolumin Chemilumin** 1996 Jan-Feb;11(1):9–22

Solution structure of a mammalian PCB-binding protein in complex with a PCB [see comments] Härd T, et al. **Nat Struct Biol** 1995 Nov;2(11):983–9. Comment in: Nat Struct Biol 1995 Nov;2(11):919–22.

Twixt form and function [news; comment] Umland TC, et al. **Nat Struct Biol** 1995 Nov;2(11):919–22. Comment on: Nat Struct Biol 1995 Nov;2(11):983–9.

Increased [3H]phorbol ester binding in rat cerebellar granule cells and inhibition of 45Ca2+ sequestration in rat cerebellum by polychlorinated diphenyl ether congeners and analogs: structure-activity relationships. Kodavanti PR, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):251–61

METABOLISM

Sequential anaerobic-aerobic biodegradation of PCBs in soil slurry microcosms. Evans BS, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:885–94

Degradation of 4,4'-dichlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and 2,2',4,4',5,5'-hexachlorobiphenyl by the white rot fungus Phanerochaete chrysosporium. Dietrich D, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3904–9

Multiple genes encoding 2,3-dihydroxybiphenyl 1,2-dioxygenase in the gram-positive polychlorinated biphenyl-degrading bacterium Rhodococcus erythropolis TA421, isolated from a termite ecosystem. Maeda M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):549–55

Evaluation of strains isolated by growth on naphthalene and biphenyl for hybridization of genes to dioxygenase probes and polychlorinated biphenyl-degrading ability. Pellizari VH, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2053–8

Polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin equivalents in eggs of double-crested cormorants from a colony near Green Bay, Wisconsin, USA. Williams LL, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):327–33

Biodegradation of polychlorinated biphenyls by rhizobia: a novel finding. Damaj M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):908–15

Hamster liver cytochrome P450 (CYP2A8) as a 4-hydroxylase for 2,5,2',5'-tetrachlorobiphenyl. Koga N, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):685–8

Effect of cytochrome P450 inducers on liver microsomal metabolism of tetrachlorobiphenyls in rats, guinea pigs and hamsters. Koga N, et al. **Biol Pharm Bull** 1995 May; 18(5):705–10

Organochlorine compounds in three species of shellfish from Waikareao Estuary, Tauranga Harbour, New Zealand. Burggraaf S, et al. **Bull Environ Contam Toxicol** 1996 Jul; 57(1):111–7

Mercury and polychlorinated biphenyls in suspended particulate matter from the European Arctic seas. Joiris CR, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):893–900

Photodegradation of 2,2',5,5'-tetrachlorobiphenyl in hexane. Miao XS, et al. **Bull Environ Contam Toxicol** 1996 Apr; 56(4):571–4

Analysis of polychlorinated biphenyl-DNA adducts by 32P-postlabeling. Oakley GG, et al. **Carcinogenesis** 1996 Jan;17(1):109–14

CB pattern in the harbour porpoise: bioaccumulation, metabolism and evidence for cytochrome P450 IIB activity. Bruhn R, et al. **Chemosphere** 1995 Oct;31(7):3721–32

Organochlorine compounds in blubber, liver and brain in neonatal grey seal pups. Jenssen BM, et al. **Chemosphere** 1996 Jun;32(11):2115–25

Determination of PCB metabolites in Canadian human milk. Newsome WH, et al. **Chemosphere** 1996 Aug;33(3):559–65

Biochemistry and genetics of PCB metabolism. Furukawa K, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:21–3

Using three-dimensional quantitative structure-activity relationships to examine estrogen receptor binding affinities of polychlorinated hydroxybiphenyls. Waller CL, et al. **Environ Health Perspect** 1995 Jul-Aug;103(7–8):702–7

Sequence and expression of the bpdC1C2BADE genes involved in the initial steps of biphenyl/chlorobiphenyl degradation by Rhodococcus sp. M5. Wang Y, et al. **Gene** 1995 Oct 16;164(1):117–22

Crystallization and preliminary crystallographic analysis of a 2,3-dihydroxybiphenyl dioxygenase from Pseudomonas sp. strain KKS102 having polychlorinated biphenyl (PCB)-degrading activity. Sugiyama K, et al. **Proteins** 1995 Jul;22(3):284–6

Degradation of PCB in different soils by inoculated Alcaligenes xylosoxidans. Haluška L, et al. **Sci Total Environ** 1995 Dec 15;175(3):275–85

POLYCHLORINATED BIPHENYLS

Organochlorine residues in marine mammals from the northern hemisphere--a consideration of the composition of organochlorine residues in the blubber of marine mammals. Vetter W, et al. **Sci Total Environ** 1996 Jul 16; 186(1-2):29-39

Binding of a 3,3', 4,4'-tetrachlorobiphenyl (CB-77) metabolite to fetal transthyretin and effects on fetal thyroid hormone levels in mice. Darnerud PO, et al. **Toxicology** 1996 Jan 8;106(1-3):105-14

[Biodegradation of a commercial mixture of polychlorinated biphenyls] Casasco PV, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):39-44 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Congener-specific bioavailability of PCDD/Fs and coplanar PCBs in cows: laboratory and field measurements. Slob W, et al. **Chemosphere** 1995 Oct;31(8):3827-38

Dietary uptake of superlipophilic compounds by earthworms (Eisenia andrei). Belfroid A, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):185-91

Secular changes of PCB concentration accumulated in organs and tissues of Japanese from 1974 to 1989. Sugiyama S, et al. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):466-71

Uncertainty in estimated half-lives of PCBS in humans: impact on exposure assessment. Shirai JH, et al. **Sci Total Environ** 1996 Sep 9;187(3):199-210 (30 ref.)

Tissue distribution, metabolism, and excretion of 2,4,4'-trichlorobiphenyl (CB-28) in the rat. Moir D, et al. **Toxicol Ind Health** 1996 Jan-Feb;12(1):105-21

PHARMACOLOGY

Phosphorylation of c-Jun stimulated in primary cultured rat liver parenchymal cells by a coplanar polychlorinated biphenyl. Tanno K, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):863-6

Glutathione regulates 3,3',4,4'-tetrachlorobiphenyl induced cytochrome P450 metabolism: evidence for a cross-talk between the two major detoxication pathways. Otto DM, et al. **Biochem Mol Biol Int** 1996 May;38(6):1127-33

Effects of polychlorinated dibenzo-p-dioxin and dibenzofuran congeners in human lymphoblastoid cells on aryl hydrocarbon hydroxylase activity. Kiyohara C, et al. **Chemosphere** 1995 Oct;31(7):3673-80

Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3',4,4'-hexachlorobiphenyl. Aarts JM, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):463-74

Ortho-substituted polychlorinated biphenyls alter calcium regulation by a ryanodine receptor-mediated mechanism: structural specificity toward skeletal- and cardiac-type microsomal calcium release channels. Wong PW, et al. **Mol Pharmacol** 1996 Apr;49(4):740-51

Synergistic activation of estrogen receptor with combinations of environmental chemicals [see comments] Arnold SF, et al. **Science** 1996 Jun 7;272(5267):1489-92. Comment in: Science 1996 Jun 7;272(5267):1418. Comment in: Science 1996 Jun 7;272(5267):1451.

Environmental estrogens. New yeast study finds strength in numbers [news; comment] Kaiser J. **Science** 1996 Jun 7; 272(5267):1418. Comment on: Science 1996 Jun 7;272(5267):1489-92.

Environmental estrogens: can two "alrights" make a wrong? [comment] Simons SS Jr. **Science** 1996 Jun 7;272(5267):1451 . Comment on: Science 1996 Jun 7;272(5267):1489-92.

[The effect of methylcholanthrene and sovol induction on the functional activity of rat blood neutrophils in vivo] Novikov KN, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):485-8 **(Rus)**

POISONING

Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Guo YL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:117-22 (53 ref.)

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1-2):109-18 (54 ref.)

TOXICITY

Histopathology of postpartum placental sites in mink (Mustela vison) exposed to polychlorinated biphenyls or fractions thereof. Bäcklin BM, et al. **APMIS** 1995 Dec; 103(12):843-54

Environmental polychlorinated biphenyls: acute toxicity of landfill soil extract to female prepubertal rats. Hansen LG, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):334-43

The effects on mammals of pre- and postnatal environmental exposure to PCBS. The Dutch Collaborative PCB/Dioxin Study. Smits-van Prooije AE, et al. **Arch Toxicol Suppl** 1996;18:97-102 (22 ref.)

Mechanistical studies of the inhibition of intercellular communication by organochlorine compounds. Wärngård L, et al. **Arch Toxicol Suppl** 1996;18:149-59

Petroleum and chlorinated hydrocarbons in water from Lake Manzala and associated canals. Badawy MI, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):258-63

Induction of micronuclei in peripheral erythrocytes of Misgurnus anguillicaudatus by polychlorinated biphenyls. Chu S, et al. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):179-82

PCB burden and pattern in eggs of the curlew (Numenius arquata) and the black-tailed godwit (Limosa limosa) from northwest Germany. Denker E, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):886-92

Environmental contaminants and cholinesterase activity in the brain of fisher (Martes pennanti) harvested in northern Wisconsin. Gerstenberger SL, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):866-72

High levels of HCB and DDE associated with reproductive failure in prairie falcons (Falco mexicanus) from California. Jarman WM, et al. **Bull Environ Contam Toxicol** 1996 Jul; 57(1):8-15

Blood plasma levels of sex steroid hormones and vitellogenin in striped bass (Morone saxatilis) exposed to 3,3',4,4'-tetrachlorobiphenyl (TCB). Monosson E, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):782-7

Effects on PCBs on liver ultrastructure and monooxygenase activities in Japanese quail. Stouvenakers N, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):839-46

Evaluation of toxicity and sex-related variation of PCB levels in Mediterranean striped dolphins affected by an epizootic. Borrell A, et al. **Chemosphere** 1996 Jun;32(12):2359-69

Activities of cytochrome P450-dependent monooxygenases and antioxidant enzymes in different organs of Norway rats (Rattus norvegicus) inhabiting reference and contaminated sites. Fouchécourt MO, et al. **Chemosphere** 1995 Dec;31(11-12):4375-86

Temporal induction pattern of hepatic cytochrome P450 1A in thermally acclimated dab (Limanda limanda) treated with 3,3',4,4'-tetrachlorobiphenyl (CB77). Sleiderink HM, et al. **Chemosphere** 1996 Jun;32(12):2335-44

P450 induction by Aroclor 1254 and 3,3',4,4'-tetrachlorobiphenyl in cultured hepatocytes from rat, quail and man: interspecies comparison. Dubois M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):51-9

Effect of inducers and PCBs on the cytochrome P450 enzymes in cultured quail hepatocytes. Roelandt L, et al. **Ecotoxicol Environ Saf** 1995 Jul;31(2):158-63

The role of estrogen in turtle sex determination and the effect of PCBs. Crews D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:73-7 (19 ref.)

Immunotoxicity of PCBs (Aroclors) in relation to Great Lakes. Tryphonas H. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:35-46 (97 ref.)

Toxicity of PCB 77 (3,3',4,4'-tetrachlorobiphenyl) and PCB 118 (2,3',4,4'5-pentachlorobiphenyl) in the rat following subchronic dietary exposure. Chu I, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):282-92

Immunosuppressive activity of polychlorinated biphenyl mixtures and congeners: nonadditive (antagonistic) interactions. Harper N, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):131-9

Potency of a complex mixture of polychlorinated dibenzo-p-dioxin, dibenzofuran, and biphenyl congeners compared to 2,3,7,8-tetrachlorodibenzo-p-dioxin in causing fish early life stage mortality. Walker MK, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):178-86

Exposure to polychlorinated biphenyls causes endothelial cell dysfunction. Toborek M, et al. **J Biochem Toxicol** 1995 Aug;10(4):219-26

Effect of PCBs on spermatogenesis [letter; comment] Pflieger-Bruss S, et al. **Lancet** 1995 Oct 14; 346(8981):1040-1. Comment on: Lancet 1993 May 29;341(8857):1392-5.

PCBs do not induce DNA breakage in vitro in human lymphocytes. Belpaeme K, et al. **Mutagenesis** 1996 Jul; 11(4):383-9

DNA adducts and P450 induction in human, rat and avian liver cells after exposure to polychlorobiphenyls. Dubois M, et al. **Mutat Res** 1995 Dec;345(3-4):181-90

Interaction of 3,4,5,3',4'-pentachlorobiphenyl and 2,4,5,2',4',5'-hexachlorobiphenyl in promotion of altered hepatic foci in rats. Bager Y, et al. **Pharmacol Toxicol** 1995 Aug;77(2):149-54

3,3',4,4'-tetrachlorobiphenyl effects on antioxidant enzymes and glutathione status in different tissues of rainbow trout. Otto DM, et al. **Pharmacol Toxicol** 1995 Oct;77(4):281-7

A case study of cancer data set combinations for PCBs. Vater ST, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):2-10 (26 ref.)

Influence of PCBs and PCDDs on preimplantation mouse embryo development [letter; comment] Hanf V, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):495-6. Comment on: Reprod Toxicol 1994 Jan-Feb;8(1):69-73. Comment on: Reprod Toxicol 1994 Nov-Dec;8(6):487-93.

The regulation by gender, strain, dose, and feeding status of the induction of multiple forms of cytochrome P450 isozymes in rat hepatic microsomes by 2,4,5,2',4',5'-hexachlorobiphenyl. Ikegwuonu FI, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):33-41

Relative potencies of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls derived from hepatic porphyrin accumulation in mice. van Birgelen AP, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):98-109

Interactions of polychlorinated dibenzo-p-dioxin, dibenzofuran, and biphenyl congeners for producing rainbow trout early life stage mortality. Zabel EW, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):204-13

The effects of 2,2',4,4',5,5'-hexachlorobiphenyl cotreatment on the disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice. De Jongh J, et al. **Toxicol Lett** 1995 Oct; 80(1-3):131-7

Significant induction of a 54-kDa protein in rat liver with homologous alignment to mouse selenium binding protein by a coplanar polychlorinated biphenyl, 3,4,5,3',4'-pentachlorobiphenyl and 3-methylcholanthrene. Ishii Y, et al. **Toxicol Lett** 1996 Sep;87(1):1-9

Synergy of iron in the toxicity and carcinogenicity of polychlorinated biphenyls (PCBs) and related chemicals. Smith AG, et al. **Toxicol Lett** 1995 Dec;82-83:945-50

Use of toxic equivalency factors for risk assessment for dioxins and related compounds. Birnbaum LS, et al. **Toxicology** 1995 Dec 28;105(2-3):391-401

Binding of a 3,3', 4,4'-tetrachlorobiphenyl (CB-77) metabolite to fetal transthyretin and effects on fetal thyroid hormone levels in mice. Darnerud PO, et al. **Toxicology** 1996 Jan 8;106(1-3):105-14

[Comparative hazards of polychlorinated biphenyls and their substitutes by the indicators of material and functional accumulation] Zholdakova ZI, et al. **Gig Sanit** 1996 Mar-Apr;(2):31-4 **(Rus)**

POLYCHLOROBIPHENYL COMPOUNDS see **POLYCHLORINATED BIPHENYLS**

POLYCHLOROETHYLENE see **POLYVINYL CHLORIDE**

POLYCHLOROPRENE see **NEOPRENE**

POLYCHONDRITIS, CHRONIC ATROPHIC see **POLYCHONDRITIS, RELAPSING**

POLYCHONDRITIS, RELAPSING

COMPLICATIONS

Relapsing polychondritis and Behçet's syndrome in a patient with HIV infection [letter] Belzunegui J, et al. **Ann Rheum Dis** 1995 Sep;54(9):780

Joint symptoms in relapsing polychondritis. Balsa A, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):425-30

Graves' ophthalmopathy and relapsing polychondritis. Kung AW, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):501-3

Relapsing polychondritis associated with subclinical Sjögren's syndrome and phlegmon of the neck. Harada M, et al. **Intern Med** 1995 Aug;34(8):768-71

Relapsing polychondritis presented as inner ear involvement. Kimura Y, et al. **J Laryngol Otol** 1996 Feb;110(2):154-7

Optic neuropathy, headache, and diplopia with MRI suggestive of cerebral arteritis in relapsing polychondritis. Massry GG, et al. **J Neuroophthalmol** 1995 Sep;15(3):171-5

Lupus anticoagulant and thrombosis in relapsing polychondritis [letter] Quéré I, et al. **J Rheumatol** 1996 May;23(5):946-7

Relapsing polychondritis associated with rheumatoid arthritis. Hussain T, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):249-50

Chondrosarcoma in a patient with relapsing polychondritis. Fransen HR, et al. **Skeletal Radiol** 1995 Aug;24(6):477-80

[Isolated ocular recurrence of relapsing polychondritis. Apropos of a case] Gatinel D, et al. **J Fr Ophtalmol** 1996; 19(2):153-7 (7 ref.) (Eng. Abstr.) **(Fre)**

[Uncommon ophthalmological involvement in chronic atrophic polychondritis] Offret H, et al. **J Fr Ophtalmol** 1995;18(8-9):530-5 (Eng. Abstr.) **(Fre)**

[Severe polychondritis] Gillot JM, et al. **Rev Med Interne** 1995;16(12):971-2 **(Fre)**

[Relapsing polychondritis, thrombosis and antiphospholipid antibodies] Grasland A, et al. **Rev Med Interne** 1996; 17(3):231-3 (Eng. Abstr.) **(Fre)**

[Swelling of the ears, chest pain, cough (clinical conference)] Nickenig G, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):570-3 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[2 rare tracheal cartilage anomalies difficult to be differentiated] Ghedira H, et al. **Rev Pneumol Clin** 1995; 51(5):295-6 **(Fre)**

[Relapsing polychondritis with atypical presentation] Sánchez Muñoz LA, et al. **An Med Interna** 1996 Apr; 13(4):181-4 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Steroid sparing effect of methotrexate in relapsing polychondritis. Park J, et al. **J Rheumatol** 1996 May; 23(5):937-8

[Cyclosporin A therapy of chronic recurrent polychondritis] Diercks K, et al. **Hautarzt** 1996 May;47(5):376-7 (Eng. Abstr.) **(Ger)**

POLYCYCLIC COMPOUNDS see **POLYCYCLIC HYDROCARBONS**

POLYCYCLIC HYDROCARBONS

ADMINISTRATION & DOSAGE

Association of exposure to polycyclic aromatic hydrocarbons (estimated from job category) with concentration of 1-hydroxypyrene glucuronide in urine from workers at a

steel plant. Kang D, et al. **Occup Environ Med** 1995 Sep; 52(9):593–9

Exposure to polycyclic aromatic hydrocarbons in coal liquefaction workers: impact of a workwear policy on excretion of urinary 1–hydroxypyrene. Quinlan R, et al. **Occup Environ Med** 1995 Sep;52(9):600–5

ADVERSE EFFECTS

Cancer risk due to occupational exposure to polycyclic aromatic hydrocarbons. Nadon L, et al. **Am J Ind Med** 1995 Sep;28(3):303–24

[Morphological features of tissue reactions in combined treatment of experimental tuberculosis induced by xenobiotics] Pavlov VA, et al. **Probl Tuberk** 1995;(6):32–5 (Eng. Abstr.) **(Rus)**

ANALYSIS

Comparison of techniques for monitoring water–borne polycyclic mutagens: efficiency of blue rayon, Sep–Pak C18, and a biota, Corbicula, in concentrating benzo(a)pyrene in a model water system. Kira S, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):278–83

Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland. Ovrebø S, et al. **Environ Health Perspect** 1995 Sep;103(9):838–43

Urinary 1–naphthol and 1–pyrenol as indicators of exposure to coal tar products. Heikkilä P, et al. **Int Arch Occup Environ Health** 1995;67(3):211–7

Distribution of toxic and radiation components in air particulates. Rausch H, et al. **Sci Total Environ** 1995 Dec 1;173–174:283–91

Determination of polycyclic aromatic hydrocarbons in water and water–based alcoholic beverages. Moret S, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):322–6

[Quantitative analysis of gamma–schizandrin in manganbao granules, a complex prescription of Chinese medicine] He Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):541–3, 575 (Eng. Abstr.) **(Chi)**

[Risk for the Rostock water supply from the Warnov river by an old deposit at Schwann?] Randow FF, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):408–19 (Eng. Abstr.) **(Ger)**

[Atmospheric contamination by aromatic polycyclic hydrocarbons in an urban area] Poli A, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):783–92 (Eng. Abstr.) **(Ita)**

[Distribution of polycyclic aromatic hydrocarbons in the environment and personal exposure] Sišović A. **Arh Hig Rada Toksikol** 1995 Jun;46(2):243–58 (71 ref.) (Eng. Abstr.) **(Scr)**

CHEMICAL SYNTHESIS

Synthesis of 2–amido–2,3–dihydro–1H–phenalene derivatives as new conformationally restricted ligands for melatonin receptors. Mathé–Allainmat M, et al. **J Med Chem** 1996 Aug 2;39(16):3089–95

CHEMISTRY

Construction of the tetracyclic skeleton of leucothol A. 1,2,4a,5,6,7,8,9,10,10a,11,11a–dodecahydro–11–hydroxy–11–methyl–7–phenylthiomethyl–5aH–5a,8–methano–cyclohepta[b] naphthalen–10–one. Kraus GA, et al. **Acta Crystallogr C** 1995 Jul 15;51 (Pt 7):1366–8

Biocatalytic oxidation of polycyclic aromatic hydrocarbons by hemoglobin and hydrogen peroxide. Ortiz–Leon M, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):968–73

Destruction of some polycyclic heterocyclic compounds using oxidation by potassium permanganate. Barek J, et al. **IARC Sci Publ** 1991;(114):17–23

Destruction of some polycyclic heterocyclic compounds using oxidation by potassium permanganate in alkaline solution. Castegnaro M, et al. **IARC Sci Publ** 1991; (114):9–15

Degradation of some polycyclic heterocyclic compounds using hydrogen peroxide and iron(II) chloride. Kirso U, et al. **IARC Sci Publ** 1991;(114):25–30

Destruction of some polycyclic heterocyclic compounds using concentrated sulfuric acid. Lunn G, et al. **IARC Sci Publ** 1991;(114):31–6

Improving the affinity and selectivity of a nonpeptide series of cholecystokinin–B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton. Kalindjian SB, et al. **J Med Chem** 1995 Oct 13;38(21):4294–302

The form and bioavailability of non–ionic organic chemicals in sewage sludge–amended agricultural soils. Beck AJ, et al. **Sci Total Environ** 1996 Jun 21;185(1–3):125–49

IMMUNOLOGY

Metabolic requirements for induction of contact hypersensitivity to immunotoxic polyaromatic hydrocarbons. Anderson C, et al. **J Immunol** 1995 Oct 1; 155(7):3530–7

ISOLATION & PURIFICATION

Solid–phase extraction for the selective isolation of polycyclic aromatic hydrocarbons, azaarenes and heterocyclic aromatic amines in charcoal–grilled meat. Rivera L, et al. **J Chromatogr A** 1996 Apr 19;731(1–2):85–94

METABOLISM

Manganese peroxidase mRNA and enzyme activity levels during bioremediation of polycyclic aromatic hydrocarbon–contaminated soil with Phanerochaete chrysosporium. Bogan BW, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2381–6

Polycyclic aromatic hydrocarbon–degrading capabilities of Phanerochaete laevis HHB–1625 and its extracellular ligninolytic enzymes. Bogan BW, et al. **Appl Environ Microbiol** 1996 May;62(5):1597–603

Polycyclic aromatic hydrocarbon quinone–mediated oxidation reduction cycling catalysed by a human placental 17beta–hydroxysteroid dehydrogenase. Jarabak R, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):174–80

Biocatalytic oxidation of polycyclic aromatic hydrocarbons by hemoglobin and hydrogen peroxide. Ortiz–Leon M, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):968–73

Fossil fuel biodegradation: laboratory studies. Chapman PJ, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:79–83 (14 ref.)

Natural selection of PAH–degrading bacterial guilds at coal–tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107–11 (15 ref.)

Mechanisms for polycyclic aromatic hydrocarbon degradation by ligninolytic fungi. Hammel KE. **Environ Health Perspect** 1995 Jun;103 Suppl 5:41–3 (14 ref.)

Phylogenetic analysis of polycyclic aromatic hydrocarbon degrading mycobacteria by 16S rRNA sequencing. Wang RF, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):75–80

The impact of glutathione s–transferase M1 and cytochrome P450 1A1 genotypes on white–blood–cell polycyclic aromatic hydrocarbon–DNA adduct levels in humans. Rothman N, et al. **Mol Carcinog** 1995 Sep;14(1):63–8

A sensitive color ELISA for detecting polycyclic aromatic hydrocarbon–DNA adducts in human tissues. Mumford JL, et al. **Mutat Res** 1996 Apr 4;359(3):171–7

PHARMACOKINETICS

Dermal absorption of polycyclic aromatic hydrocarbons in the blood–perfused pig ear. VanRooij JG, et al. **J Appl Toxicol** 1995 May–Jun;15(3):193–200

The form and bioavailability of non–ionic organic chemicals in sewage sludge–amended agricultural soils. Beck AJ, et al. **Sci Total Environ** 1996 Jun 21;185(1–3):125–49

PHARMACOLOGY

Anti–human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase. Fujihashi T, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2000–7

Non–peptide cholecystokinin–B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. Kalindjian SB, et al. **J Med Chem** 1996 Apr 26;39(9):1806–15

Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Ip SP, et al. **Planta Med** 1995 Oct;61(5):398–401

TOXICITY

Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China with high lung cancer mortality associated with exposure to unvented coal smoke. Mumford JL, et al. **Carcinogenesis** 1995 Dec; 16(12):3031–6

A rapid and simple method for the analysis of 1–hydroxypyrene glucuronide: a potential biomarker for polycyclic aromatic hydrocarbon exposure. Singh R, et al. **Carcinogenesis** 1995 Dec;16(12):2909–15

Developmental toxicity study of clarified slurry oil (CSO) in the rat. Hoberman AM, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):34–40

Mutation spectra of chemical fractions of a complex mixture: role of nitroarenes in the mutagenic specificity of municipal waste incinerator emissions. DeMarini DM, et al. **Mutat Res** 1996 Jan 17;349(1):1–20

POLYCYCLIC HYDROCARBONS, AROMATIC

ADVERSE EFFECTS

Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)

[Symptoms of atopy in persons exposed to chronic immunosuppression of polycyclic aromatic hydrocarbons] Szczeklik J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):502–6 (Eng. Abstr.) **(Pol)**

ANALYSIS

Determination of polynuclear aromatic hydrocarbons present in asphaltenes from Mexican oil. A possible environmental risk. Dieck T, et al. **Arch Med Res** 1995 Winter;26(4):445–7

n–Alkanes and polynuclear aromatic hydrocarbons in fresh–frozen and precooked–frozen mussels. Hernández JE, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):461–8

Polycyclic aromatic hydrocarbon contamination in the Italian diet. Lodovici M, et al. **Food Addit Contam** 1995 Sep–Oct; 12(5):703–13

Estimating analytical variances in measurement of polycyclic aromatic hydrocarbons and application to monitoring contaminants in American lobster (Homarus americanus). Uthe JF, et al. **J AOAC Int** 1996 May–Jun;79(3):797–802

Evaluation of biomarkers in plasma, blood, and urine samples from coke oven workers: significance of exposure to polycyclic aromatic hydrocarbons. Ovrebø S, et al. **Occup Environ Med** 1995 Nov;52(11):750–6

Polycyclic aromatic hydrocarbons in central London air during 1991 and 1992. Brown JR, et al. **Sci Total Environ** 1996 Jan 5;177(1–3):73–84

Ancient life on Mars? [news; comment] Kerr RA. **Science** 1996 Aug 16;273(5277):864–6. Comment on: Science 1996 Aug 16;273(5277):924–30.

Search for past life on Mars: possible relic biogenic activity in martian meteorite ALH84001 [see comments] McKay DS, et al. **Science** 1996 Aug 16;273(5277):924–30. Comment in: Science 1996 Aug 16;273(5277):864–6.

Determination of polycyclic aromatic hydrocarbons in smoked fishery products from different smoking kilns. Karl H, et al. **Z Lebensm Unters Forsch** 1996 Jun;202(6):458–64

Monitoring of nitropolycyclic aromatic hydrocarbons in food using gas chromatography. Schlemitz S, et al. **Z Lebensm Unters Forsch** 1996 Jul;203(1):61–4

BLOOD

Quantification of polycyclic aromatic hydrocarbons and polychlorinated dibenzo–p–dioxins in human serum by combined micelle–mediated extraction (cloud–point extraction) and HPLC. Sirimanne SR, et al. **Anal Chem** 1996 May 1;68(9):1556–60

The impact of glutathione s–transferase M1 and cytochrome P450 1A1 genotypes on white–blood–cell polycyclic aromatic hydrocarbon–DNA adduct levels in humans. Rothman N, et al. **Mol Carcinog** 1995 Sep;14(1):63–8

CHEMICAL SYNTHESIS

An efficient route to N6 deoxyadenosine adducts of diol epoxides of carcinogenic polycyclic aromatic hydrocarbons. Kim SJ, et al. **Bioorg Med Chem** 1995 Jun; 3(6):811–22

CHEMISTRY

Relationship between resonance energy per pi–electron and carcinogenicity in arenes. Kurihara T, et al. **Anticancer Res** 1996 Mar–Apr;16(2):605–12

32P–postlabelling of bulky human DNA adducts enriched by different methods including immunoaffinity chromatography. Widlak P, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):99–107

Infrared emission spectra of candidate interstellar aromatic molecules. Cook DJ,, et al. **Nature** 1996 Mar 21; 380(6571):227–9

Application of neural networks in the QSAR analysis of percent effect biological data: comparison with adaptive least squares and nonlinear regression analysis. Wiese M, et al. **SAR QSAR Environ Res** 1993;1(2–3):137–52

METABOLISM

Environmental aspects of PAH biodegradation. Shuttleworth KL, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep; 54(1–3):291–302 (41 ref.)

Enumeration and phylogenetic analysis of polycyclic aromatic hydrocarbon–degrading marine bacteria from Puget sound sediments. Geiselbrecht AD, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3344–9

Phylogenetic comparison of two polycyclic aromatic hydrocarbon–degrading mycobacteria. Govindaswami M, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3221–6

Molecular cloning of novel genes for polycyclic aromatic hydrocarbon degradation from Comamonas testosteroni GZ39. Goyal AK, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):230–6

Actions of a versatile fluorene–degrading bacterial isolate on polycyclic aromatic compounds. Grifoll M, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3711–23

Plastic bags for stable storage of the water–soluble fraction of crude petroleum used in aquatic environment toxicity and tainting studies. Heras H, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):597–602

Glutathione S–transferase A1–1–catalysed conjugation of bay and fjord region diol epoxides or polycyclic aromatic hydrocarbons with glutathione. Jernstrom B, et al. **Carcinogenesis** 1996 Jul;17(7):1491–8

In vivo formation of mutagens by intraperitoneal administration of polycyclic aromatic hydrocarbons in animals during exposure to nitrogen dioxide. Miyanishi K, et al. **Carcinogenesis** 1996 Jul;17(7):1483–90

Environmental air pollution and DNA adducts in Copenhagen bus drivers—effect of GSTM1 and NAT2 genotypes on adduct levels. Nielsen PS, et al. **Carcinogenesis** 1996 May;17(5):1021–7

Studies of the binding of diolepoxide metabolites of polycyclic aromatic hydrocarbons to DNA using electrofluorescence polarization spectroscopy. Windsor SA, et al. **Carcinogenesis** 1996 Mar;17(3):605–8

Covalent binding of polycyclic aromatic hydrocarbon

components of manufactured gas plant residue to mouse lung and forestomach DNA. Weyand EH, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):955-62

Mass spectral identification of metabolites formed by microbial degradation of polycyclic aromatic hydrocarbons (PAH). Zink G, et al. **Chemosphere** 1995 Nov;31(9):4077-84

Macromolecular adducts caused by environmental chemicals. Neumann HG, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1835-40

Sequence and expression of an isocitrate dehydrogenase-encoding gene from a polycyclic aromatic hydrocarbon oxidizer, Sphingomonas yanoikuyae B1. Wang Y, et al. **Gene** 1996 Feb 2;168(1):15-21

Polycyclic aromatic hydrocarbons in placenta, maternal blood, umbilical cord blood and milk of Indian women. Madhavan ND, et al. **Hum Exp Toxicol** 1995 Jun; 14(6):503-6

Mycobacterium hodleri sp. nov., a new member of the fast-growing mycobacteria capable of degrading polycyclic aromatic hydrocarbons. Kleespies M, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):683-7

Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations. Andreassen A, et al. **Mutat Res** 1996 Jul 5;368(3-4):275-82

Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Cavalieri EL, et al. **Xenobiotica** 1995 Jul;25(7):677-88 (49 ref.)

[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):83-98 (71 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Bioaccumulation of polycyclic aromatic hydrocarbons by marine organisms. Meador JP, et al. **Rev Environ Contam Toxicol** 1995;143:79-165 (320 ref.)

PHARMACOLOGY

Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon ortho-quinones produced by dihydrodiol dehydrogenase. Flowers-Geary L, et al. **Chem Biol Interact** 1996 Jan 5;99(1-3):55-72

Cytochromes CYP1A1 and CYP1B1 in the rat mammary gland: cell-specific expression and regulation by polycyclic aromatic hydrocarbons and hormones. Christou M, et al. **Mol Cell Endocrinol** 1995 Nov 30;115(1):41-50

Modulatory effects of polycyclic aromatic hydrocarbons on the mutagenicity of 1-nitropyrene: a structure-activity relationship study. Cherng SH, et al. **Mutat Res** 1996 Apr 6;367(4):177-85

[Fjord-region polycyclic aromatic hydrocarbons: carcinogenic properties and mechanism of action] Likhachev AI, et al. **Vopr Onkol** 1996;42(1):23-33 (69 ref.) **(Rus)**

TOXICITY

Liver microsomal levels of cytochrome P4501A1 as biomarker for exposure and bioavailability of soil-bound polycyclic aromatic hydrocarbons. Roos PH, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):107-13

Evaluation of low-dosage environmental mutagens with a long-term, cultured epithelial cell line. Li CS, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):919-25

Differences in the tumorigenic activity of a pure hydrocarbon and a complex mixture following ingestion: benzo[alpha]pyrene vs manufactured gas plant residue. Weyand EH, et al. **Chem Res Toxicol** 1995 Oct-Nov; 8(7):949-54

Activities of cytochrome P450-dependent monooxygenases and antioxidant enzymes in different organs of Norway rats (Rattus norvegicus) inhabiting reference and contaminated sites. Fouchécourt MO, et al. **Chemosphere** 1995 Dec;31(11-12):4375-86

The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1-24 (109 ref.)

Increased polycyclic aromatic hydrocarbon toxicity following their photomodification in natural sunlight: impacts on the duckweed Lemna gibba L. G-3. Huang XD, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):194-200

A comparison of the Ames assay and Mutatox in assessing the mutagenic potential of contaminated dredged sediment. Jarvis AS, et al. **Ecotoxicol Environ Saf** 1996 Mar; 33(2):193-200

Photoinduced effects of polycyclic aromatic hydrocarbons on Brassica napus (Canola) during germination and early seedling development. Ren L, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):73-80

Induction of micronuclei and sister chromatid exchanges by polycyclic and N-heterocyclic aromatic hydrocarbons in cultured human lymphocytes. Warshawsky D, et al. **Environ Mol Mutagen** 1995;26(2):109-18

Mutagenicity and contents of polycyclic aromatic hydrocarbons in used and recycled motor oils. Clonfero E, et al. **Mutat Res** 1996 Jul 5;368(3-4):283-91

Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65-72 (85 ref.)

An efficient experimental design for detecting departure from additivity in mixtures of many chemicals. Gennings C. **Toxicology** 1995 Dec 28;105(2-3):189-97

Immunotoxicity of a reconstituted polynuclear aromatic hydrocarbon mixture in B6C3F1 mice. Harper N, et al. **Toxicology** 1996 May 3;109(1):31-8

Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Nesnow S, et al. **Toxicology** 1995 Dec 28; 105(2-3):403-13

Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157-69 (91 ref.)

Immunosuppressive potential of several polycyclic aromatic hydrocarbons (PAHs) found at a Superfund site: new model used to evaluate additive interactions between benzo[a]pyrene and TCDD. Silkworth JB, et al. **Toxicology** 1995 Dec 28;105(2-3):375-86

POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC**

POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

POLYCYSTIC OVARY SYNDROME

see related
HYPERANDROGENISM

Polycystic ovarian disease: a new look at an old subject. Udoff L, et al. **Curr Opin Obstet Gynecol** 1995 Oct; 7(5):340-3 (19 ref.)

Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Homburg R. **Hum Reprod** 1996 Jan;11(1):29-39 (123 ref.)

[The polycystic ovary syndrome] Zivný J. **Ceska Gynekol** 1995 Aug;60(4):206-16 **(Cze)**

BLOOD

Different responses of insulin, C-peptide, and testosterone to an oral glucose tolerance test in two groups of women with polycystic ovarian syndrome. Ke WX, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):166-9

Differences in serum luteinizing hormone measurements by immunoradiometric assay induced by kinetic manipulation of assay conditions are dependent on the endocrine milieu of serum. Olukoga AO, et al. **Ann Clin Biochem** 1996 Mar; 33 (Pt 2):107-11

Serum androgen changes during meal-induced hyperinsulinemia and after acute sequential blockade and hyperstimulation of insulin release in women with polycystic ovary syndrome. Parra A, et al. **Arch Med Res** 1995;26 Spec No:S209-17

Diurnal variation of sex hormone binding globulin and insulin-like growth factor binding protein-1 in women with polycystic ovary syndrome. Hamilton-Fairley D, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):159-65

Prevalence of an immunological LH beta-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Rajkhowa M, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):297-303

Serum immunoreactive inhibin levels in polycystic ovarian disease (PCOD) and hypogonadotropic amenorrhea. Mizunuma H, et al. **Endocr J** 1994 Aug;41(4):409-14

Serum from women with polycystic ovary syndrome inhibits fertilization and embryonic development in the murine in vitro fertilization model. Deaton JL, et al. **Fertil Steril** 1996 Jun;65(6):1224-8

Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. Morris RS, et al. **Fertil Steril** 1995 Dec;64(6):1099-103

Serum free testosterone in polycystic ovary syndrome measured with a new reference method. Penttilä TA, et al. **Fertil Steril** 1996 Jan;65(1):55-60

Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease. Taskin O, et al. **Fertil Steril** 1996 Jun;65(6):1115-8

The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. Lanzone A, et al. **Hum Reprod** 1995 Jul;10(7):1653-7

Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Norman RJ, et al. **Hum Reprod** 1995 Sep;10(9):2258-61

The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Tarlatzis BC, et al. **Hum Reprod** 1995 Oct;10(10):2545-9

Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels. Tropeano G, et al. **J Endocrinol Invest** 1996 Mar; 19(3):139-45

Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease. Espinosa de los Monteros A, et al. **Rev Invest Clin** 1995 Sep-Oct;47(5):347-53

CHEMICALLY INDUCED

Systemic treatment in the rat with epidermal growth factor causes polycystic growth of the ovaries. Christiansen JJ, et al. **APMIS** 1996 Feb;104(2):147-52

COMPLICATIONS

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Guzick DS, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1224-9; discussion 1229-32

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Robinson S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):277-84

Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response [see comments] Lazar L, et al. **Eur J Endocrinol** 1995 Oct; 133(4):403-6. Comment in: Eur J Endocrinol 1995 Oct;133(4):399-400.

Polycystic ovaries in association with müllerian anomalies. Ugur M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):57-9

Can metformin reduce insulin resistance in polycystic ovary syndrome? Açbay O, et al. **Fertil Steril** 1996 May; 65(5):946-9

A follicular scoring system for monitoring ovulation induction in polycystic ovary syndrome patients based solely on ultrasonographic estimation of follicular development. Ellenbogen A, et al. **Fertil Steril** 1996 Jun; 65(6):1175-7

Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F, et al. **Fertil Steril** 1996 Sep;66(3):354-61

Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Pucci E, et al. **Gynecol Endocrinol** 1995 Sep;9(3):221-8

Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Zalel Y, et al. **Gynecol Endocrinol** 1995 Dec;9(4):313-5

Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Ben-Chetrit A, et al. **Hum Reprod** 1995 Nov;10(11):3057-60 (34 ref.)

Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries. Hardy K, et al. **Hum Reprod** 1995 Aug; 10(8):2125-35

Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial. Homburg R, et al. **Hum Reprod** 1995 Oct;10(10):2550-3

Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. Lanzone A, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3501-6

Polycystic ovary syndrome [letter; comment] Zosmer A. **N Engl J Med** 1996 Mar 7;334(10):668. Comment on: N Engl J Med 1995 Sep 28;333(13):853-61.

Hirsutism in the United Arab Emirates: a hospital study. Gatee OB, et al. **Postgrad Med J** 1996 Mar;72(845):168-71

[Precocious puberty and polycystic ovarian syndrome: apropos of 13 cases] Pienkowski C, et al. **Arch Pediatr** 1995 Aug;2(8):729-34 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Balen AH, et al. **Hum Reprod** 1995 Aug; 10(8):2107-11

Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders. Herter LD, et al. **J Clin Ultrasound** 1996 Jun;24(5):243-8

[A rare case of concurrent endometrial carcinoma and PCO syndrome] Goluda M, et al. **Ginekol Pol** 1995 Aug; 66(8):484-5 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease. Wenzl R, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):298-9

Exploring the recovery phase after treatment with a gonadotrophin-releasing hormone-agonist for ovulation induction in polycystic ovary syndrome: three pilot trials. Scheele F, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):221-4

Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Ciotta L, et al. **Fertil Steril** 1996 Jan;65(1):61-7

Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome. Farhi J, et al. **Fertil Steril** 1995 Nov;64(5):930-5

The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Paoletti AM, et al. **Fertil Steril** 1996 Oct;66(4):527-32

The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with follicle-stimulating hormone in polycystic ovary syndrome:

a randomized study. van der Meer M, et al. **Fertil Steril** 1996 Oct;66(4):571–6

Polycystic ovarian syndrome: pregnancy outcome following in vitro fertilization–embryo transfer. Alcalay M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):119–23

Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. Fulghesu AM, et al. **Hum Reprod** 1995 Sep;10(9):2253–7

The growth hormone response to growth hormone–releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. Lanzone A, et al. **Hum Reprod** 1995 Jul;10(7):1653–7

The insulin–sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Dunaif A, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3299–306

Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. Korytkowski MT, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3327–34

Nitrendipine treatment in women with polycystic ovarian syndrome: evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone–binding globulin. Pasquali R, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3346–50

[Pharmacologic treatment for polycystic ovary syndrome] Maciejewska M. **Ginekol Pol** 1995 Oct;66(10):569–77 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome [see comments] Nestler JE, et al. **N Engl J Med** 1996 Aug 29;335(9):617–23. Comment in: N Engl J Med 1996 Aug 29;335(9):657–8.

ETIOLOGY

Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? [editorial; comment] Herzog AG. **Ann Neurol** 1996 May;39(5):559–60. Comment on: Ann Neurol 1996 May;39(5):579–84.

Temporolimbic epilepsy and polycystic ovary syndrome [letter; comment] Herzog AG. **Fertil Steril** 1996 Jan; 65(1):210–11. Comment on: Fertil Steril 1995 Jun;63(6):1195–9.

Polycystic ovary syndrome. Homburg R, et al. **Hum Reprod** 1996 Mar;11(3):465–6

[Gynecological diseases in obesity] Takahashi J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:388–91 (5 ref.) **(Jpn)**

[Molecular basis of polycystic ovarian syndrome] Katulski K, et al. **Ginekol Pol** 1995 Oct;66(10):561–8 (23 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Rajkhowa M, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):85–90

Bulimia nervosa and polycystic ovary syndrome. Jahanfar S, et al. **Gynecol Endocrinol** 1995 Jun;9(2):113–7

Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. Talbot JA, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1979–83

[The genetics of polycystic ovaries] Zergollern L. **Lijec Vjesn** 1996 Mar;118 Suppl 1:17–20 (Eng. Abstr.) **(Scr)**

IMMUNOLOGY

Circulating tumor necrosis factor (TNF)–alpha in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Naz RK, et al. **Am J Reprod Immunol** 1995 Sep;34(3):170–5

METABOLISM

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383–9 (35 ref.)

The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome. Carranza–Lira S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):161–4

Intrafollicular insulin–like growth factor–II levels in normally ovulating women and in patients with polycystic ovary syndrome. Barreca A, et al. **Fertil Steril** 1996 Apr; 65(4):739–45

Endometriosis and polycystic ovary syndrome: enhanced stimulatory effect of peritoneal fluid on progesterone release from human granulosa–lutein cells. Whitehead SA, et al. **Fertil Steril** 1996 Sep;66(3):487–9

Follistatin concentrations in follicular fluid of normal and polycystic ovaries. Erickson GF, et al. **Hum Reprod** 1995 Aug;10(8):2120–4

Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. Fulghesu AM, et al. **Hum Reprod** 1995 Sep;10(9):2253–7

Immunoactive interleukin–1 beta and tumour necrosis factor–alpha in thecal, stromal and granulosa cell cultures from normal and polycystic ovaries. Jasper M, et al. **Hum Reprod** 1995 Jun;10(6):1352–4

Insulin–like growth factor binding proteins in a natural pre–ovulatory follicle from a woman with polycystic ovary syndrome. Magoffin DA, et al. **Hum Reprod** 1995 Sep; 10(9):2248–52

Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. Apter D, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2966–73

Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. Korytkowski MT, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3327–34

Insulin–like growth factor (IGF) I and II, IGF–binding proteins, and IGF–binding protein proteases are produced by theca and stroma of normal and polycystic human ovaries. Mason HD, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):276–84

Modulation by insulin of follicle–stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. Willis D, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):302–9

Insulin and the polycystic ovary syndrome [editorial; comment] Utiger RD. **N Engl J Med** 1996 Aug 29; 335(9):657–8. Comment on: N Engl J Med 1996 Aug 29;335(9):617–23.

[Polycystic ovary syndrome: a disorder of insulin action and an increased risk for onset of non–insulin–dependent diabetes] Aganović I, et al. **Lijec Vjesn** 1996 Mar;118 Suppl 1:28–32 (Eng. Abstr.) **(Scr)**

PATHOLOGY

Functional integrity of granulosa cells from polycystic ovaries. Almahbobi G, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):571–80

Relationship between ultrasonography and histopathological changes in polycystic ovarian syndrome [letter; comment] Abdel Gadir A. **Hum Reprod** 1995 Jul;10(7):1879. Comment on: Hum Reprod 1994 Dec;9(12):2255–8.

Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type–I insulin–like growth factor receptor. Willis D, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3788–90

PHYSIOPATHOLOGY

Evidence of a disturbance of the hypothalamic–pituitary–adrenal axis in polycystic ovary syndrome: effect of naloxone. Lanzone A, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):73–7

Cardiac flow velocity in women with the polycystic ovary syndrome. Prelevic GM, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):677–81

No changes of peripheral insulin resistance in polycystic ovary syndrome after long–term reduction of endogenous androgens with leuprolide. Lasco A, et al. **Eur J Endocrinol** 1995 Dec;133(6):718–22

Early polycystic ovary–like syndrome in girls with central precocious puberty and exaggerated adrenal response [see comments] Lazar L, et al. **Eur J Endocrinol** 1995 Oct; 133(4):403–6. Comment in: Eur J Endocrinol 1995 Oct;133(4):399–400.

Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F, et al. **Fertil Steril** 1996 Sep;66(3):354–61

Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Paoletti AM, et al. **Fertil Steril** 1995 Dec;64(6):1094–8

Initial estradiol response predicts outcome of exogenous gonadotropins using a step–down dose regimen for induction of ovulation in polycystic ovary syndrome. Schoot DC, et al. **Fertil Steril** 1995 Dec;64(6):1081–7

Growth hormone and fertility—clinical studies. Homburg R. **Horm Res** 1996;45(1–2):81–5 (27 ref.)

Elevated ambulatory day–time blood pressure in women with polycystic ovary syndrome: a sign of a pre–hypertensive state? Holte J, et al. **Hum Reprod** 1996 Jan;11(1):23–8

Insulin resistant and non–resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):1951–6

GnRH analog administration in patients with polycystic ovarian disease. Meden–Vrtovec H. **Int J Gynaecol Obstet** 1995 Aug;50(2):179–83

Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. Lanzone A, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3501–6

[Physiopathology and therapy of polycystic ovary syndrome] Mihashi N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):814–23 (32 ref.) **(Jpn)**

SURGERY

Wedge resection to improve insulin resistance in polycystic ovary syndrome: a study among Chinese women. Wu XK, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):822–5

Laparoscopic management of polycystic ovarian disease. Rose BI. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):273–6 (30 ref.)

Further thoughts on surgical therapy for polycystic ovary syndrome [letter; comment] Balen A. **Fertil Steril** 1996 Jun; 65(6):1256–7; discussion 1257–8. Comment on: Fertil Steril 1995 Mar;63(3):439–63.

Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate–resistant patients with polycystic ovary syndrome. Farhi J, et al. **Fertil Steril** 1995 Nov;64(5):930–5

Further thoughts on surgical therapy for polycystic ovary syndrome [letter; comment] Kaaijk EM, et al. **Fertil Steril** 1996 Jun;65(6):1256; discussion 1257–8. Comment on: Fertil Steril 1995 Mar;63(3):439–63.

Further thoughts on surgical therapy for polycystic ovary syndrome [letter; comment] Van der Wat J. **Fertil Steril** 1996 Jun;65(6):1257; discussion 1257–8. Comment on: Fertil Steril 1995 Mar;63(3):439–63.

Post–operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study. Saravelos H, et al. **Hum Reprod** 1996 May;11(5):992–7

[Clinical and endocrine effects of laparoscopic ovarian surgery in patients with polycystic ovary syndrome] Rossmanith WG, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:103–7 (Eng. Abstr.) **(Ger)**

THERAPY

Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Buyalos RP, et al. **Fertil Steril** 1996 Jan;65(1):1–10 (63 ref.)

High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Kodama H, et al. **Hum Reprod** 1995 Aug;10(8):1962–7

Low–dose follicle–stimulating hormone treatment for polycystic ovarian disease. Grigoriou O, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):55–9

[Physiopathology and therapy of polycystic ovary syndrome] Mihashi N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):814–23 (32 ref.) **(Jpn)**

ULTRASONOGRAPHY

Polycystic ovaries in pre and post–menopausal women. Birdsall MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):269–76

Relationship between ultrasonography and histopathological changes in polycystic ovarian syndrome [letter; comment] Abdel Gadir A. **Hum Reprod** 1995 Jul;10(7):1879. Comment on: Hum Reprod 1994 Dec;9(12):2255–8.

Ovarian stromal blood flow in women with polycystic ovaries—a possible new marker for diagnosis? Zaidi J, et al. **Hum Reprod** 1995 Aug;10(8):1992–6

Sonographic incidence of polycystic ovaries in a gynecological population. Botsis D, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):182–5

[Polycystic ovary syndrome—Doppler parameters] Kupešić S, et al. **Lijec Vjesn** 1996 Mar;118 Suppl 1:42–4 (Eng. Abstr.) **(Scr)**

POLYCYTHEMIA

Deciphering polycythemia. Landaw SA. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):155–63,166

The myomatous erythrocytosis syndrome: a review. LevGur M, et al. **Obstet Gynecol** 1995 Dec;86(6):1026–30 (38 ref.)

BLOOD

Erythropoietin concentration in the serum from patients with primary thrombocythaemia [letter] Najean Y, et al. **Eur J Haematol** 1995 Oct;55(4):272–3

Increased erythropoietin response to venesection in erythrocytosic renal transplant patients. Oymak O, et al. **Int Urol Nephrol** 1995;27(2):223–7

Hormonal changes in normal and polycythemic high–altitude natives. Antezana AM, et al. **J Appl Physiol** 1995 Sep; 79(3):795–800

CLASSIFICATION

[Polycythemia (editorial)] Urasiński I. **Pol Arch Med Wewn** 1996 Mar;95(3):185–9 **(Pol)**

COMPLICATIONS

[Acute superior mesenteric artery thrombosis due to stress erythrocytosis] Honda K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):357–61 **(Jpn)**

CONGENITAL

Neonatal polycythemia and hyperviscosity. Werner EJ. **Clin Perinatol** 1995 Sep;22(3):693–710 (97 ref.)

DIAGNOSIS

Low serum erythropoietin—a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Messinezy M, et al. **Clin Lab Haematol** 1995 Sep; 17(3):217–20

DRUG THERAPY

Association of post–renal transplant erythrocytosis and microalbuminuria: response to angiotensin–converting enzyme inhibition. Mulhern JG, et al. **Am J Nephrol** 1995; 15(4):318–22

Effect of enalapril on erythrocytosis in hypertensive patients with renal disease. Shand BI, et al. **Blood Press** 1995 Jul; 4(4):238–40

Ketanserin: a new perspective in posttransplant erythrocytosis? Borawski J, et al. **Clin Transplant** 1996 Feb; 10(1 Pt 1):63–6

Correction of post-renal transplant erythrocytosis by enalapril. Rostaing L, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):399–406

Treatment of post-renal-transplant erythrosis: ACE inhibitors or theophylline? Ben Hmida M, et al. **Transplant Proc** 1995 Oct;27(5):2720–1

Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril. Hu RH, et al. **Transplant Proc** 1996 Jun;28(3):1545–7

Effect of captopril in the treatment of erythrocytosis after renal transplantation. Suh BY, et al. **Transplant Proc** 1996 Jun;28(3):1557–8

EPIDEMIOLOGY

Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Kessler M, et al. **Clin Nephrol** 1996 Feb;45(2):83–9

Erythrocytosis in renal transplant recipients. Hussain Z, et al. **Transplant Proc** 1995 Oct;27(5):2736

ETIOLOGY

Adult Wilms' tumour presenting as polycythaemia. Devine JC, et al. **Br J Urol** 1995 Nov;76(5):666–7

Unilateral hydronephrosis causing polycythemia and acute myocardial infarction. Dhavan PS, et al. **J Assoc Physicians India** 1996 Jan;44(1):51–2

Sarcoidosis presenting as polycythemia. A case report. Kashyap S, et al. **J Assoc Physicians India** 1995 Nov; 43(11):795–6

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)

Benign adenomatous kidney neoplasms in children with polycythemia: imaging findings. Comerci SC, et al. **Radiology** 1996 Jan;198(1):265–8

Pheochromocytoma associated with polycythemia: case report. Rezkalla MA, et al. **S D J Med** 1995 Oct; 48(10):349–51

Gouty arthritis in a patient with Ivemark syndrome [letter] Bhattacharjee M, et al. **South Med J** 1996 Aug;89(8):834–5

[The role of "hemochromatosis alleles" in the pathogenesis of polyglobulia after renal transplantation] Darocha Z, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):453–60 (Eng. Abstr.) **(Pol)**

[Pathogenesis of polyglobulia after kidney transplantation] Darocha Z, et al. **Postepy Hig Med Dosw** 1995;49(2):181–7 (46 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Familial polycythemia vera in father and daughter [letter] Inaba T, et al. **Am J Hematol** 1996 Feb;51(2):172

Two different mutations in codon 97 of the beta-globin gene cause Hb Malmö in Sweden. Landin B, et al. **Am J Hematol** 1996 Jan;51(1):32–6

PHYSIOPATHOLOGY

Erythrocytosis after renal transplantation: risk factors and relationship with GFR. Nankivell BJ, et al. **Clin Transplant** 1995 Oct;9(5):375–82

Thermal tolerance following artificially induced polycythaemia. Patterson MJ, et al. **Eur J Appl Physiol** 1995;71(5):416–23

Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. Petit RD, et al. **J Appl Physiol** 1995 Jul;79(1):229–35

PREVENTION & CONTROL

Preventive effect of enalapril on erythrocytosis after renal transplantation. Rhee SR, et al. **Transplant Proc** 1996 Jun; 28(3):1555–6

SURGERY

Allogeneic bone marrow transplantation for postpolycythemic myeloid metaplasia with myelofibrosis: a case report. de Revel T, et al. **Bone Marrow Transplant** 1995 Jul;16(1):187–9

THERAPY

Use of crystalloid or colloid for partial exchange transfusion in polycythemic newborns [letter] Wong W, et al. **Eur J Pediatr** 1996 Jan;155(1):68

Symptomatic neonatal polycythemia: comparison of partial exchange transfusion with saline versus plasma. Deorari AK, et al. **Indian Pediatr** 1995 Nov;32(11):1167–71

VETERINARY

Hypercalcaemia and erythrocytosis in a mare associated with a metastatic carcinoma. Cook G, et al. **Equine Vet J** 1995 Jul;27(4):316–8

[Case report: polycythemia in a horse] Steiger R, et al. **Schweiz Arch Tierheilkd** 1995;137(7):306–11 (Eng. Abstr.) **(Ger)**

POLYCYTHEMIA VERA

Natural history of polycythemia vera [letter] Shpilberg O, et al. **Ann Intern Med** 1996 Sep 15;125(6):514–5

Polycythemia vera. Knoop T. **Semin Oncol Nurs** 1996 Feb; 12(1):70–7 (31 ref.)

[Chronic myeloproliferative diseases. New knowledge about well known diseases] Aulitzky WE, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):600–4 (42 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Bucalossi A, et al. **Am J Hematol** 1996 May;52(1):14–20

Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea. Castello G, et al. **Ann Hematol** 1995 Sep;71(3):119–21

[Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera] Pósán E, et al. **Orv Hetil** 1996 Jan 14; 137(2):71–4 (Eng. Abstr.) **(Hun)**

CHEMICALLY INDUCED

Development of polycythaemia rubra vera following treatment for centroblastic lymphoma. Harrison P, et al. **Acta Haematol** 1996;96(2):113–4

COMPLICATIONS

Left ventricular and aortic valve thrombosis caused by polycythemia rubra vera successfully treated with streptokinase. al-Saif S, et al. **Am Heart J** 1996 Feb; 131(2):397–9

Occlusion of the superior mesenteric artery in a patient with polycythemia vera: resolution with percutaneous transluminal angioplasty. Bertrán X, et al. **Ann Hematol** 1996 Feb;72(2):89–91

Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Jeanmougin M, et al. **Ann Hematol** 1996 Aug;73(2):91–3

Polycythemia vera associated with metastatic carcinoid. Sham RL, et al. **Cancer Invest** 1996;14(2):120–3

Leukaemic risk in polycythaemia vera and essential thrombocytopenia [letter] Kwong YL. **Eur J Haematol** 1996 Jan–Feb;56(1–2):90–2

DIAGNOSIS

Beyond Bayes. Marchetti M, et al. **Haematologica** 1996 May–Jun;81(3):253–7

DRUG THERAPY

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S, et al. **Am J Hematol** 1996 May; 52(1):42–6

Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea. Castello G, et al. **Ann Hematol** 1995 Sep;71(3):119–21

Polycythaemia vera: response to treatment with angiotensin-converting enzyme inhibitor [letter] Nomura S, et al. **Eur J Haematol** 1996 Jul;57(1):117–9

[Polycytemia vera in an 11-year old girl] Nagy K, et al. **Orv Hetil** 1996 Jan 7;137(1):27–30 (Eng. Abstr.) **(Hun)**

[Alpha interferon in the therapy of polycythemia vera] Castello G, et al. **Recenti Prog Med** 1996 Jan;87(1):7–11 (Eng. Abstr.) **(Ita)**

[Evaluation of treatment results in patients with polycythemia rubra vera] Mital A, et al. **Pol Arch Med Wewn** 1996 May; 95(5):453–8 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Impaired activation of phospholipase D in polycythaemia vera–implications for the pathogenesis of the disease? Samuelsson J. **Leuk Lymphoma** 1995 Sep;19(1–2):21–6 (60 ref.)

The activity of glucose-6-phosphate dehydroxygenase and glutathione enzymes in red blood cells in patients with haemoblastoses. Kumerova A, et al. **Mater Med Pol** 1995 Jan–Mar;27(1):7–9

ETIOLOGY

Pathogenesis of polycythaemia vera. Green AR. **Lancet** 1996 Mar 30;347(9005):844–5

GENETICS

Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Le Couedic JP, et al. **Blood** 1996 Feb 15;87(4):1502–11

Derivative (y)t(Y;1)(q12;q12),+9 in a patient with polycythemia vera during transition into myelodysplasia. Raymakers R, et al. **Cancer Genet Cytogenet** 1996 May; 88(1):83–5

HISTORY

Polycythemia vera—a climatological disease. Berlin NI. **Trans Am Clin Climatol Assoc** 1994;106:25–36; discussion 36–7 (33 ref.)

PATHOLOGY

Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. Carneskog J, et al. **Eur J Haematol** 1996 Mar;56(3):158–62

Anaplastic B-cell (Ki-1) lymphoma developing in a patient with polycythemia vera. Steinberg E, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):507–9

[Abundant erythroblastic islands in bone marrow aspirate in a case of polycythemia vera. Various considerations on this anatomo-functional structure] Páez A, et al. **Sangre (Barc)** 1995 Aug;40(4):331–4 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. **Ann Intern Med** 1995 Nov 1;123(9):656–64

Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. Ramirez G, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):167–74

[Effects of erythrocytopheresis on the state of the left heart in patients with polycythemia vera: echocardiographic findings] Bessmel'tsev SS, et al. **Klin Med (Mosk)** 1995; 73(4):80–2 (Eng. Abstr.) **(Rus)**

THERAPY

Remission of polycythemia vera after surgical cure of acromegaly. Grellier P, et al. **Ann Intern Med** 1996 Mar 1;124(5):495–6

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Taylor PC, et al. **Br J Haematol** 1996 Jan;92(1):55–9 (36 ref.)

Long-term control of polycythemia rubra vera with recombinant alpha interferon. Clemons MJ, et al. **Hematol Oncol** 1996 Mar;14(1):37–40

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

Neocytoapheresis in the treatment of polycythemia vera. Centurioni R, et al. **Recenti Prog Med** 1996 Apr;87(4):161–3

[Long-term follow-up in polycythemia vera] Cohen-Goldenberg N, et al. **Harefuah** 1995 Jun 1; 128(11):673–6, 744 (Eng. Abstr.) **(Heb)**

[Effects of erythrocytopheresis on the state of the left heart in patients with polycythemia vera: echocardiographic findings] Bessmel'tsev SS, et al. **Klin Med (Mosk)** 1995; 73(4):80–2 (Eng. Abstr.) **(Rus)**

VETERINARY

Polycythemia vera in a cat and management with hydroxyurea. Evans LM, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):434–8

POLYCYTIDYLIC ACIDS see **POLY C**

POLYDACTYLY

Polysyndactyly and trigonocephaly with partial agenesis of corpus callosum [letter] Guzzetta V, et al. **Clin Dysmorphol** 1996 Apr;5(2):179–82

CLASSIFICATION

Subclassification of polydactyly [letter] Manske PR. **Br J Plast Surg** 1996 Mar;49(2):137

Subclassification terminology for polydactyly [letter] Manske PR. **J Hand Surg [Br]** 1995 Dec;20(6):857

Polydactyly [letter] Manske PR. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar;30(1):79

DIAGNOSIS

[The Townes-Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

EMBRYOLOGY

Effects of all-trans-retinoic acid on limb development in the genetic polydactyly mouse. Tamagawa M, et al. **J Toxicol Sci** 1995 Sep;20(4):383–93

GENETICS

Linkage of preaxial polydactyly type 2 to 7q36. Hing AV, et al. **Am J Med Genet** 1995 Aug 28;58(2):128–35

Jeune syndrome with tongue lobulation and preaxial polydactyly, and Jeune syndrome with situs inversus and asplenia: compound heterozygosity Jeune-Mohr and Jeune-Ivemark? Majewski E, et al. **Am J Med Genet** 1996 May 3;63(1):74–9

Achondrogenesis type II with polydactyly. Rittler M, et al. **Am J Med Genet** 1995 Nov 6;59(2):157–60

Severe congenital limb deficiencies, vertebral hypersegmentation, absent thymus and mirror polydactyly: a defect expression of a developmental control gene? Urioste M, et al. **Hum Genet** 1996 Feb;97(2):214–7

Human obesity does not segregate with the chromosomal regions of Prader-Willi, Bardet-Biedl, Cohen, Borjeson or Wilson-Turner syndromes. Reed DR, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):599–603

A hereditable combination of congenital anomalies. Agarwal RP, et al. **J Bone Joint Surg Br** 1996 May;78(3):492–4

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov;

32(11):896–900 (29 ref.)
Pallister–Hall and McKusick–Kaufmann syndromes [letter; comment] Lurie IW. **J Med Genet** 1995 Aug;32(8):668. Comment on: J Med Genet 1995 Feb;32(2):125–8.
HOX gene mutations—the wait is over. Sharpe P. **Nat Med** 1996 Jul;2(7):748–9
Atrioventricular septal defect and type A postaxial polydactyly without other major associated anomalies: a specific association. Levin SE, et al. **Pediatr Cardiol** 1995 Sep–Oct;16(5):242–6
Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Muragaki Y, et al. **Science** 1996 Apr 26;272(5261):548–51
[Meckel–Gruber syndrome] Flessa A, et al. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):66–8 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Ophthalmo acromelic syndrome [letter] Quarrell OW. **Clin Dysmorphol** 1995 Jul;4(3):272–3
Ultrastructural and morphometrical analyses of Leydig and Sertoli cells in the testes of rats with hereditary polydactylism. Hojo H, et al. **J Reprod Fertil** 1995 Jul; 104(2):331–5

RADIOGRAPHY

Tetrapolydactyly of postaxial type. Sener RN. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S234–5

SURGERY

Radial polydactyly: an outcome study. Ganley TJ, et al. **Ann Plast Surg** 1995 Jul;35(1):86–9
Suture ligation of supernumerary digits and 'tags': an outmoded practice? [letter] Frieden IJ, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1284
Thumb duplication at the metacarpophalangeal joint. Management and a new classification. Hung L, et al. **Clin Orthop** 1996 Feb;(323):31–41
Pedal polydactyly: an overview with case report. McCarthy GJ, et al. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):577–82
The zig–zag deformity in pre–axial polydactyly. A new cause and its treatment. Lourie GM, et al. **J Hand Surg [Br]** 1995 Aug;20(4):561–4
Unilateral duplication of the great toe with anterolateral tibial bowing. Weaver KM, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):73–7
Central–type eight–toed polydactyly associated with ipsilateral complex renogluteal agenesis: a case report with 8 years' follow–up. Wang HJ, et al. **J Pediatr Surg** 1996 Mar;31(3):444–6
A new surgical technique for postaxial polydactyly of the foot. Nakamura K, et al. **Plast Reconstr Surg** 1996 Jan; 97(1):133–8

ULTRASONOGRAPHY

First–trimester diagnosis of Meckel–Gruber syndrome by transabdominal sonography in a low–risk case. Braithwaite JM, et al. **Prenat Diagn** 1995 Dec;15(12):1168–70

VETERINARY

[Polydactyly in a foal—a case report] Weinhart G, et al. **Tierarztl Prax** 1996 Jun;24(3):275–7 (Eng. Abstr.) **(Ger)**

POLYDEOXYADENINE NUCLEOTIDES–POLYTHYMINE NUCLEOTIDES see **POLY DA–DT**

POLYDEOXYRIBONUCLEOTIDE LIGASES see **POLYDEOXYRIBONUCLEOTIDE SYNTHETASES**

POLYDEOXYRIBONUCLEOTIDE SYNTHETASES

Analysis of ligase chain reaction products via matrix–assisted laser desorption/ionization time–of–flight–mass spectrometry. Jurinke C, et al. **Anal Biochem** 1996 Jun 1; 237(2):174–81
Site–directed mutagenesis using thermostable enzymes. Wong F, et al. **Biotechniques** 1995 Jun;18(6):1034–8
The ligase chain reaction distinguishes hepatitis B virus S–gene variants. Karthigesu VD, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):127–32
Ligase chain reaction for detection of Neisseria gonorrhoeae in urogenital swabs. Ching S, et al. **J Clin Microbiol** 1995 Dec;33(12):3111–4
Combined PCR–oligonucleotide ligation assay for rapid detection of Salmonella serovars. Stone GG, et al. **J Clin Microbiol** 1995 Nov;33(11):2888–93
Evaluation of the sensitivity and specificity of a ligase chain reaction test kit for the detection of Chlamydia trachomatis. Miyashita N, et al. **J Clin Pathol** 1996 Jun;49(6):515–7
Ligase chain reaction. Shimer GH Jr, et al. **Methods Mol Biol** 1995;46:269–78
Ligation of nonmatching DNA molecule ends. Cimmino C, et al. **Plasmid** 1995 Jul;34(1):1–10

ANTAGONISTS & INHIBITORS

Linker histones inhibit T4 and Escherichia coli DNA ligases. Ray E, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):512–8
Natural–product inhibitors of human DNA ligase I. Tan GT, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):993–1000
Inhibition of human DNA ligase I activity by zinc and cadmium and the fidelity of ligation. Yang SW, et al. **Environ Mol Mutagen** 1996;28(1):19–25

CHEMISTRY

Crystal structure of an ATP–dependent DNA ligase from bacteriophage T7. Subramanya HS, et al. **Cell** 1996 May 17;85(4):607–15
SMC proteins constitute two subunits of the mammalian recombination complex RC–1. Jessberger R, et al. **EMBO J** 1996 Aug 1;15(15):4061–8
Characterization of DNA ligase from the fungus Coprinus cinereus. Matsuda S, et al. **Eur J Biochem** 1996 May 1; 237(3):691–7
Bacteriophage T7 DNA ligase. Overexpression, purification, crystallization, and characterization. Doherty AJ, et al. **J Biol Chem** 1996 May 10;271(19):11083–9
DNA ligase shows restraint. Riddihough G. **Nat Struct Biol** 1996 Jun;3(6):496

DEFICIENCY

Stimulation of repair replication by 3–aminobenzamide in human fibroblasts with ligase I deficiency. Cleaver JE. **Carcinogenesis** 1996 Jan;17(1):1–3

GENETICS

Xeroderma pigmentosum and molecular cloning of DNA repair genes. Boulikas T. **Anticancer Res** 1996 Mar–Apr; 16(2):693–708 (161 ref.)
Determining the site and nature of DNA mutations with the cloned MutY mismatch repair enzyme. Xu JF, et al. **Carcinogenesis** 1996 Feb;17(2):321–6
The cloning and characterization of a cDNA encoding Xenopus laevis DNA ligase I. Lepetit D, et al. **Gene** 1996 Jun 26;172(2):273–7
Genetic mapping and expression analysis of the murine DNA ligase I gene. Gariboldi M, et al. **Mol Carcinog** 1995 Oct; 14(2):71–4
Mammalian DNA ligase III: molecular cloning, chromosomal localization, and expression in spermatocytes undergoing meiotic recombination. Chen J, et al. **Mol Cell Biol** 1995 Oct;15(10):5412–22
RNA capping enzyme and DNA ligase: a superfamily of covalent nucleotidyl transferases. Shuman S, et al. **Mol Microbiol** 1995 Aug;17(3):405–10 (36 ref.)

METABOLISM

Prokaryotic DNA ligases unwind superhelical DNA. Ivanchenko M, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):498–505
Characterization of human DNA ligase I expressed in a baculovirus–insect cell system. Gallina A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):593–7
The accessibility of thiophosphorylated groups in DNA fragments to the enzymatic activity of ligases and restriction endonuclease Bbs I. Schenk JA, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):1037–43
Vaccinia virus DNA ligase: specificity, fidelity, and inhibition. Shuman S. **Biochemistry** 1995 Dec 12; 34(49):16138–47
Repair of base alkylation damage in targeted restriction endonuclease sequences of plasmid DNA. Musarrat J, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):201–11
Modulation of carcinogen–induced DNA damage and repair enzyme activity by dietary riboflavin. Webster RP, et al. **Cancer Lett** 1996 Jan 2;98(2):129–35
The N–terminal domain of human DNA ligase I contains the nuclear localization signal and directs the enzyme to sites of DNA replication. Montecucco A, et al. **EMBO J** 1995 Nov 1;14(21):5379–86
Bacteriophage T7 DNA ligase. Overexpression, purification, crystallization, and characterization. Doherty AJ, et al. **J Biol Chem** 1996 May 10;271(19):11083–9
Specific interaction of DNA polymerase beta and DNA ligase I in a multiprotein base excision repair complex from bovine testis. Prasad R, et al. **J Biol Chem** 1996 Jul 5; 271(27):16000–7
Analysis of the mammalian recombination protein complex RC–1. Jessberger R, et al. **Mutat Res** 1996 Feb 19; 350(1):217–27
Characterization of the XRCC1–DNA ligase III complex in vitro and its absence from mutant hamster cells. Caldecott KW, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4836–43
Improving the fidelity of Thermus thermophilus DNA ligase. Luo J, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):3071–8
Identification of essential residues in Thermus thermophilus DNA ligase. Luo J, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):3079–85
Detection of HCV RNA by the asymmetric gap ligase chain reaction. Marshall RL, et al. **PCR Methods Appl** 1994 Oct; 4(2):80–4
Comet assay analysis of repair of DNA strand breaks in normal and deficient human cells exposed to radiations and chemicals. Evidence for a repair pathway specificity of DNA ligation. Nocentini S. **Radiat Res** 1995 Nov; 144(2):170–80
Ligation of double–stranded and single–stranded [oligo(dT)] DNA by vaccinia virus DNA ligase. Odell M, et al. **Virology** 1996 Jul 1;221(1):120–9
[Polymerase chain reaction and ligase reactions. Principles, traditional methods, and innovations] Belokhvostov AS. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):21–6 (50 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

T4 DNA ligase modulates chromosome damage induced by restriction endonucleases through an error–free process. Ortiz T, et al. **Mutagenesis** 1995 Sep;10(5):399–402

PHYSIOLOGY

DNA lesion–recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)
Recognition and processing of damaged DNA. Lindahl T. **J Cell Sci Suppl** 1995;19:73–7 (33 ref.)
DNA ligase I is required for fetal liver erythropoiesis but is not essential for mammalian cell viability. Bentley D, et al. **Nat Genet** 1996 Aug;13(4):489–91

POLYDEOXYRIBONUCLEOTIDES

[Use of the pGB725 probe containing poly–TG–repeats for detecting polymorphic microsatellite loci in the genome of the chicken Gallus gallus domesticus] Churkina IV, et al. **Genetika** 1995 Sep;31(9):1189–93 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Factors affecting fidelity of DNA synthesis during PCR amplification of d(C–A)n.d(G–T)n microsatellite repeats. Hite JM, et al. **Nucleic Acids Res** 1996 Jun 15; 24(12):2429–34

CHEMISTRY

Equilibrium DNA binding of Sac7d protein from the hyperthermophile Sulfolobus acidocaldarius: fluorescence and circular dichroism studies. McAfee JG, et al. **Biochemistry** 1996 Apr 2;35(13):4034–45
Interactions of aristololactam beta–D–glucoside with right–handed and left–handed forms of synthetic deoxyribonucleic acid: spectroscopic and thermodynamic study. Ray A, et al. **Biochemistry** 1996 Jun 11; 35(23):7394–402
Characterization of the binding of YO to [poly(dA–dT)]2 and [poly(dG–dC)]2, and of the fluorescent properties of YO and YOYO complexed with the polynucleotides and double–stranded DNA. Larsson A, et al. **Biopolymers** 1995 Aug;36(2):153–67
Conformational transitions of poly(dI–dC) in aqueous solution as studied by classical Raman spectroscopy. Fabriciová G, et al. **Gen Physiol Biophys** 1995 Jun; 14(3):203–16
Determination of sugar conformations by NMR in larger DNA duplexes using both dipolar and scalar data: application to d(CATGTGACGTCACATG)2. Conte MR, et al. **J Biomol NMR** 1996 May;7(3):190–206
Use of electric linear dichroism and competition experiments with intercalating drugs to investigate the mode of binding of Hoechst 33258, berenil and DAPI to GC sequences. Colson P, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):351–66
Structures of poly(dG–dC) and poly(dA–dT) stabilized by anions. Loprete DM, et al. **J Biomol Struct Dyn** 1995 Aug; 13(1):57–67

GENETICS

Sequence of the polypyrimidine tract of the 3'–terminal 3' splicing signal can affect intron–dependent pre–mRNA processing in vivo. Liu X, et al. **Nucleic Acids Res** 1996 May 1;24(9):1765–73

IMMUNOLOGY

Specificity of monoclonal antibodies produced against phosphorothioate and ribo modified DNAs. Latimer LJ, et al. **Mol Immunol** 1995 Oct;32(14–15):1057–64

METABOLISM

Equilibrium DNA binding of Sac7d protein from the hyperthermophile Sulfolobus acidocaldarius: fluorescence and circular dichroism studies. McAfee JG, et al. **Biochemistry** 1996 Apr 2;35(13):4034–45
Optimization of competitor poly(dI–dC).poly(dI–dC) levels is advised in DNA–protein interaction studies involving enriched nuclear proteins. Larouche K, et al. **Biotechniques** 1996 Mar;20(3):439–44
Inhibition of poly(2'–fluoro–2'–deoxyadenylic acid)–directed–reverse transcriptase activity. Jucá MB, et al. **J Enzym Inhib** 1995;9(2):171–7

PHARMACOKINETICS

Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats. Fisher J, et al. **Thromb Res** 1996 Jan 1;81(1):55–63

PHARMACOLOGY

Polydeoxyribonucleotides and nitric oxide release from guinea–pig hearts during ischaemia and reperfusion. Masini

E, et al. **Br J Pharmacol** 1995 Jun;115(4):629–35
Is defibrotide's activity on leukocytes adenosine-receptor mediated? An "in vitro"—"ex vivo" appraisal. Alberico P, et al. **Thromb Res** 1995 Nov 15;80(4):281–9

THERAPEUTIC USE

Involvement of free radicals in the cardioprotective effect of defibrotide. Haklar G, et al. **Arzneimittelforschung** 1996 Apr;46(4):381–4
Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function [letter] Frascà GM, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):392–3
[Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500–15000 dalton)] Michelini S, et al. **Minerva Cardioangiol** 1996 Jan–Feb; 44(1–2):33–7 (Eng. Abstr.) **(Ita)**

POLYDIMETHYLSILOXANES see **DIMETHYLPOLYSILOXANES**

POLYDIOXANONE

Acromioclavicular reconstruction augmented with polydioxanonsulphate bands. Surgical technique and results. Hessmann M, et al. **Am J Sports Med** 1995 Sep–Oct; 23(5):552–6
Fixation of the Chevron osteotomy utilizing absorbable polydioxanon pins. Small HN, et al. **Foot Ankle Int** 1995 Jun;16(6):346–50
Absorbable sutures in tendon repair. A comparison of PDS with prolene in rabbit tendon repair. O'Broin ES, et al. **J Hand Surg [Br]** 1995 Aug;20(4):505–8
Skin closure using nylon and polydioxanone: a comparison of results. Edwards DJ, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):342–3
Absorbable clips for cystic duct ligation in laparoscopic cholecystectomy. Leung KL, et al. **Surg Endosc** 1996 Jan; 10(1):49–51
[Prevention of adhesions in the middle ear] von Scheel J. **Laryngorhinootologie** 1996 Apr;75(4):254 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Foreign-body reaction to absorbable fixation devices [letter] Frederick J, et al. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):396–8

PHARMACOLOGY

[Effects of polydioxanone and silk on normal cicatrisation of surgically injured myocardial tissue. An experimental model] Serrano-Gallardo G, et al. **Arch Inst Cardiol Mex** 1996 Jan–Feb;66(1):23–8 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Mechanical factors influencing the incidence of burst abdomen. Niggebrugge AH, et al. **Eur J Surg** 1995 Sep; 161(9):655–61
Absorbable sutures in tendon repair [letter] Amis AA. **J Hand Surg [Br]** 1996 Apr;21(2):286

POLYDNAVIRIDAE

GENETICS

Isolation and characterization of a member of the cysteine-rich gene family from Campoletis sonorensis polydnavirus. Cui L, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):797–809
Expression of polydnavirus genes under polydnavirus promoter regulation in insect larvae infected with baculovirus recombinants. Soldevila AI, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1379–88

PATHOGENICITY

Transformation of gypsy moth (Lymantria dispar) cell lines by infection with Glyptapanteles indiensis polydnavirus. McKelvey TA, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):764–70

POLYDYSTROPHIC DWARFISM see **MUCOPOLYSACCHARIDOSIS VI**

POLYDYSTROPHIC OLIGOPHRENIA see **MUCOPOLYSACCHARIDOSIS III**

POLYENDOCRINOPATHIES, AUTOIMMUNE

[Type III polyglandular autoimmune syndrome. Report of a case] Rodriguez Quiroz F, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):251–3 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. Böni R, et al. **Dermatology** 1995; 191(1):68–71
Silent myocardial rupture in a patient with diabetes and Addison's disease. Östermaier R, et al. **Int J Cardiol** 1995 Jun 2;50(1):75–8
The Vogt-Koyanagi-Harada syndrome: association with autoimmune polyglandular syndrome type 1. Jovic NS, et al. **Postgrad Med J** 1996 Aug;72(850):495–7
[Tolosa Hunt syndrome and autoimmune polyglandular syndrome. A rare case report] Cesareo R, et al. **Minerva Endocrinol** 1995 Jun;20(2):149–52 (13 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Case report: autoimmune polyglandular syndrome. Khalil S, et al. **N J Med** 1995 Oct;92(10):671–4 (22 ref.)
[Recurrent coma, computerized tomography findings in the brain and ECG changes] Kauppinen-Mäkelin R, et al. **Duodecim** 1994;110(11):1102–3, 1108 **(Fin)**

ETIOLOGY

Severe sensory-autonomic neuropathy and endocrinopathy in insulin-dependent diabetes. Watkins PJ, et al. **QJM** 1995 Nov;88(11):795–804

GENETICS

Isolation of cDNA for a novel human protein KNP-I that is homologous to the E. coli SCRP-27A protein from the autoimmune polyglandular disease type I (APECED) region of chromosome 21q22.3. Nagamine K, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):608–16

IMMUNOLOGY

Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II. Seissler J, et al. **Autoimmunity** 1994;19(4):231–8
Detection of candidal antigens in autoimmune polyglandular syndrome type I. Peterson P, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):290–4
Two cases of asymptomatic adrenocortical insufficiency with autoimmune thyroid disease. Koshiyama H, et al. **Endocr J** 1994 Aug;41(4):373–8
Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. Chen S, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1871–6
Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. Huang W, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2559–63
Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. Tuomi T, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1488–94
Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Rorsman F, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8626–9

METABOLISM

Comprehensive adrenocortical steroid measurements in two cases of Schmidt's syndrome. Tanaka T, et al. **Endocr J** 1994 Aug;41(4):379–86

POLYENES

Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):666–71 (32 ref.)
[Enigma of rapamycin] Terada N. **Seikagaku** 1995 Oct; 67(10):1241–5 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Is there a rationale to combine cyclosporin and sirolimus? [editorial] Kahan BD. **Nephrol Dial Transplant** 1996 Jan; 11(1):21–3
Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin. Dono K, et al. **Transplantation** 1995 Dec 15;60(11):1268–73
Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine. Hartner WC, et al. **Transplantation** 1995 Dec 15;60(11):1347–50
The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Kneteman NM, et al. **Transplantation** 1996 Apr 27;61(8):1206–10
Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus. Wang M, et al. **Transplantation** 1996 Feb 15;61(3):458–64

ADVERSE EFFECTS

In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blazar BR, et al. **Blood** 1996 May 1;87(9):4001–9
A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Johnson EM, et al. **Transplant Proc** 1996 Apr;28(2):987

BLOOD

Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Streit F, et al. **Clin Chem** 1996 Sep;42(9):1417–25

CHEMISTRY

Structure and biosynthesis of novel conjugated polyene fatty acids from the marine green alga Anadyomene stellata. Mikhailova MV, et al. **Lipids** 1995 Jul;30(7):583–9
Photostationary state compositions of retinal and related compounds included in beta-lactoglobulin. Effects of protein host on isomer distribution of polyene substrates. Li XY, et al. **Photochem Photobiol** 1995 Aug;62(2):361–6
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP [see comments] Choi J, et al. **Science** 1996 Jul 12;273(5272):239–42. Comment in: Science 1996 Jul 12;273(5272):183.

METABOLISM

FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. Cardenas ME, et al. **EMBO J** 1995 Dec 1;14(23):5892–907
Exogenous shikimic acid stimulates rapamycin biosynthesis in Streptomyces hygroscopicus. Fang A, et al. **Folia Microbiol (Praha)** 1995;40(6):607–10
Organization of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase. Aparicio JF, et al. **Gene** 1996 Feb 22;169(1):9–16
Missense mutations at the FKBP12-rapamycin-binding site of TOR1. Freeman K, et al. **Gene** 1996 Jun 12;172(1):143–7
Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase. Molnár I, et al. **Gene** 1996 Feb 22;169(1):1–7
TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. Lorenz MC, et al. **J Biol Chem** 1995 Nov 17;270(46):27531–7
Protein matchmaker may lead new gene therapy to the altar [news; comment] Balter M. **Science** 1996 Jul 12; 273(5272):183. Comment on: Science 1996 Jul 12;273(5272):239–42.
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP [see comments] Choi J, et al. **Science** 1996 Jul 12;273(5272):239–42. Comment in: Science 1996 Jul 12;273(5272):183.

PHARMACOKINETICS

A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Brattström C, et al. **Transplant Proc** 1996 Apr;28(2):985–6
A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Johnson EM, et al. **Transplant Proc** 1996 Apr;28(2):987
Pharmacokinetics of rapamycin. Yatscoff RW. **Transplant Proc** 1996 Apr;28(2):970–3 (28 ref.)

PHARMACOLOGY

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Joseph-Horne T, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1526–9
Both rapamycin-sensitive and -insensitive pathways are involved in the phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in response to insulin in rat epididymal fat-cells. Diggle TA, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):447–53
Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Jaster R, et al. **Biochem Pharmacol** 1996 May 3;51(9):1181–5
Role of p70 S6 kinase in lymphocyte activation. Frost V, et al. **Biochem Soc Trans** 1996 Feb;24(1):91S
Lack of inhibition of phosphoinositide 3-kinase enzyme activity by FKBP12/rapamycin. Hollis CM, et al. **Biochem Soc Trans** 1996 Feb;24(1):66S
Rapamycin-resistant human lymphoid cell lines. Kay JE, et al. **Biochem Soc Trans** 1996 Feb;24(1):89S
Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Seufferlein T, et al. **Cancer Res** 1996 Sep 1; 56(17):3895–7
Effects of rapamycin on ryanodine receptor/Ca(2+)-release channels from cardiac muscle. Kaftan E, et al. **Circ Res** 1996 Jun;78(6):990–7
Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro.

Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Sadoshima J, et al. **Circ Res** 1995 Dec;77(6):1040-52

The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Migita K, et al. **Clin Exp Immunol** 1996 Apr;104(1):86-91

Effect of rapamycin on the expression of the IL-2 receptor (CD25). Woerly G, et al. **Clin Exp Immunol** 1996 Feb; 103(2):322-7

Direct inhibition of human CD8+ lymphocyte activation by cyclosporine A and Rapamune-Sirolimus. Combates NJ, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):221-8

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Cardenas ME, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):472-7 (83 ref.)

Rapamycin (sirolimus, rapamune). Sehgal SN, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):482-7 (49 ref.)

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Beretta L, et al. **EMBO J** 1996 Feb 1;15(3):658-64

The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Pearson RB, et al. **EMBO J** 1995 Nov 1;14(21):5279-87

Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. Redpath NT, et al. **EMBO J** 1996 May 1;15(9):2291-7

Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Wera S, et al. **Endocr Res** 1995 Aug;21(3):623-33

Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast. Alarcon CM, et al. **Genes Dev** 1996 Feb 1;10(3):279-88

Hypersensitivity to rapamycin of BJAB B lymphoblastoid cells. Kay JE, et al. **Immunology** 1996 Mar;87(3):390-5

Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes. Bansbach CC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S179-80

Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation. Molnar-Kimber KL, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S189-90

Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Nagase T, et al. **Int J Cancer** 1996 Mar 1;65(5):620-6

Rapamycin inhibits the in vitro release of soluble interleukin-2 receptor by activated peripheral blood mononuclear cells (PBMC) independently of the mode of activation. Degiannis D, et al. **Int J Immunopharmacol** 1995 Jul;17(7):593-6

Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways. Azpiazu I, et al. **J Biol Chem** 1996 Mar 1;271(9):5033-9

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. Lorenz MC, et al. **J Biol Chem** 1995 Nov 17;270(46):27531-7

Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin. Wang DZ, et al. **J Biol Chem** 1995 Sep 29;270(39):22924-32

Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. Terada N, et al. **J Immunol** 1995 Oct 1;155(7):3418-26

Mechanism of action of the immunosuppressant rapamycin. Dumont FJ, et al. **Life Sci** 1996;58(5):373-95 (196 ref.)

A humanized system for pharmacologic control of gene expression [see comments] Rivera VM, et al. **Nat Med** 1996 Sep;2(9):1028-32. Comment in: Nat Med 1996 Sep;2(9):977-8.

A pharmacologic rheostat for gene therapy [comment] Wilson JM. **Nat Med** 1996 Sep;2(9):977-8. Comment on: Nat Med 1996 Sep;2(9):1028-32.

Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28-40 (135 ref.)

Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Yeh WC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11086-90

Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Yacyshyn BR, et al. **Scand J Immunol** 1996 Apr;43(4):449-55

Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Sehgal SN. **Ther Drug Monit** 1995 Dec;17(6):660-5 (43 ref.)

Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival. Hamashima T, et al. **Transpl Immunol** 1995 Dec;3(4):335-41

Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar-Kimber KL. **Transplant Proc** 1996 Apr;28(2):964-9 (127 ref.)

The immunosuppressive effect of rapamycin on mouse small bowel transplantation. Chen H, et al. **Transplantation** 1996 Feb 27;61(4):523-6

THERAPEUTIC USE

Pretreatment of donors and grafts with rapamycin: the effect on graft survival and the tissue drug retention. Chen H, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):321-3

Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse. Warner LM, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S205-6

Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. Wasowska B, et al. **J Immunol** 1996 Jan 1;156(1):395-404

Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Ito T, et al. **Jpn J Cancer Res** 1996 Feb; 87(2):113-6

Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):672-5 (17 ref.)

Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):676-80 (28 ref.)

A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Brattström C, et al. **Transplant Proc** 1996 Apr;28(2):985-6

Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model. Granger DK, et al. **Transplant Proc** 1996 Apr;28(2):984

Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients. Kneteman NM, et al. **Transplant Proc** 1995 Dec;27(6):3213

Rapamycin in experimental liver transplantation in the rat. Yoshimura N, et al. **Transplant Proc** 1996 Jun;28(3):1796-7

Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Schmid C, et al. **Transplantation** 1995 Oct 15;60(7):729-33

Case report--sirolimus rescue therapy for refractory renal allograft rejection. Slaton JW, et al. **Transplantation** 1996 Mar 27;61(6):977-9

TOXICITY

Activation of rabbit platelets by Ca2+ influx and thromboxane A2 release in an external Ca(2+)-dependent manner by zooxanthellatoxin-A, a novel polyol. Rho MC, et al. **Br J Pharmacol** 1995 Jun;115(3):433-40

Side effects of rapamycin in the rat. Chan CC, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):177-81

POLYERGIN see TRANSFORMING GROWTH FACTOR BETA

POLYESTERS

The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. Guidoin R, et al. **ASAIO J** 1994 Jul-Sep;40(3):M870-9

A Corethane/polyester composite vascular prosthesis for vascular access. Comparison with expanded polytetrafluoroethylene grafts in a canine model. Wilson GJ, et al. **ASAIO J** 1995 Jul-Sep;41(3):M728-34

Monocryl suture, a new ultra-pliable absorbable monofilament suture. Bezwada RS, et al. **Biomaterials** 1995 Oct;16(15):1141-8

Effectiveness of a bioabsorbable conduit in the repair of peripheral nerves. Nicoli Aldini N, et al. **Biomaterials** 1996 May;17(10):959-62

Electrophoresis of polyester-backed polyacrylamide gels. Bassam BJ, et al. **Biotechniques** 1995 Oct;19(4):568-70, 572-3

Section adherence to glass slides from polyester wax-embedded tissue for in situ hybridization. Shuttlesworth GA, et al. **Biotechniques** 1995 Jun; 18(6):948-50

Biodegradable pin fixation of osteochondral fragments of the knee. Matsusue Y, et al. **Clin Orthop** 1996 Jan;(322):166-73

Stability of polypeptide immunoreactants and polyvinyl alcohol as a blocking agent on polyester cloth during dry storage. Boyd S, et al. **Immunol Invest** 1995 Aug; 24(5):795-803

Biological and synthetic conduits in peripheral nerve repair: a comparative experimental study. Giardino R, et al. **Int J Artif Organs** 1995 Apr;18(4):225-30

Light-microscopic and electron-microscopic evaluation of short-term nerve regeneration using a biodegradable poly(DL-lactide-epsilon-caprolacton) nerve guide. den Dunnen WF, et al. **J Biomed Mater Res** 1996 May; 31(1):105-15

Biological performance of a degradable poly(lactic acid-epsilon-caprolactone) nerve guide: influence of tube dimensions. den Dunnen WF, et al. **J Biomed Mater Res** 1995 Jun;29(6):757-66

Enhancement of the mechanical properties of polylactides by solid-state extrusion. II. Poly(L-lactide), poly(L/D-lactide), and poly(L/DL-lactide. Ferguson S, et al. **J Biomed Mater Res** 1996 Apr;30(4):543-51

Enhancement of bone formation by drawn poly(L-lactide). Ikada Y, et al. **J Biomed Mater Res** 1996 Apr;30(4):553-8

Intraosseous plating with absorbable self-reinforced poly-L-lactide plates in the fixation of distal femoral osteotomies on rabbits. Koskikare K, et al. **J Biomed Mater Res** 1996 Apr;30(4):417-21

Polylactide macroporous biodegradable implants for cell transplantation. II. Preparation of polylactide foams by liquid-liquid phase separation. Schugens C, et al. **J Biomed Mater Res** 1996 Apr;30(4):449-61

Preparation of a macroporous biodegradable polylactide implant for neuronal transplantation. Schugens C, et al. **J Biomed Mater Res** 1995 Nov;29(11):1349-62

Local delivery of indomethacin by a polyorthoester inhibits reossification of experimental bone defects. Solheim E, et al. **J Biomed Mater Res** 1995 Sep;29(9):1141-6

Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Guterres SS, et al. **Pharm Res** 1995 Oct;12(10):1545-7

A biodegradable patch used as a pericardial substitute after cardiac surgery: 6- and 24-month evaluation with CT. Duvernoy O, et al. **Thorac Cardiovasc Surg** 1995 Oct; 43(5):271-4

[A 10-year follow-up study of bypass operations with double-velour dacron in the aortoiliofemoral position] Andreev A. **Khirurgiia (Sofiia)** 1995;48(5):17-22 (Eng. Abstr.) **(Bul)**

[Impregnated polyester prostheses: a theoretical advantage] Becquemin JP, et al. **J Mal Vasc** 1996;21 Suppl A:41-7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of ankle joint fractures with biodegradable screws and plates of poly-l-lactide] Eitenmüller J, et al. **Chirurg** 1996 Apr;67(4):413-8 (Eng. Abstr.) **(Ger)**

[Chest wall reconstruction using polyester mesh] Wazawa H, et al. **Kyobu Geka** 1996 Jan;49(1):13-6 (Eng. Abstr.) **(Jpn)**

[Evaluation of selected parameters of collagen metabolism in rats after implantation of copolymer d,l-lactide and E-caprolacton with cortisol and progesterone] Nowak M, et al. **Polim Med** 1995;25(3-4):25-35 (Eng. Abstr.) **(Pol)**

ADMINISTRATION & DOSAGE

Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. Calvo P, et al. **J Pharm Sci** 1996 May; 85(5):530-6

CHEMICAL SYNTHESIS

Production of poly(hydroxyalkanoic acid). Lee SY, et al. **Adv Biochem Eng Biotechnol** 1995;52:27-58 (131 ref.)

Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins. Huatan H, et al. **Biomaterials** 1995 Nov; 16(17):1297-303

Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Timofeevski SL, et al. **Pharm Res** 1996 Mar;13(3):476-80

CHEMISTRY

Histological evaluation of polyesterimide-insulated gold wires in brain. Yuen TG, et al. **Biomaterials** 1995 Aug; 16(12):951-6

Poly-3-hydroxybutyrate/polyphosphate complexes form voltage-activated Ca2+ channels in the plasma membranes of Escherichia coli. Reusch RN, et al. **Biophys J** 1995 Sep; 69(3):754-66

Effect of abrasion on protective properties of polyester and cotton/polyester blend fabrics. Shaw A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):935-41

Orientruded polylactide based body-absorbable osteosynthesis devices: a short review. Tunc DC. **J Biomater Sci Polym Ed** 1995;7(4):375-80 (9 ref.)

In vitro cell response to differences in poly-L-lactide crystallinity. Park A, et al. **J Biomed Mater Res** 1996 May; 31(1):117-30

The microencapsulation of protein using a novel ternary blend based on poly(epsilon-caprolactone). Huatan H, et al. **J Microencapsul** 1995 Sep-Oct;12(5):557-67

Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. Molpeceres J, et al. **J Pharm Sci** 1996 Feb;85(2):206-13

Effects of H+ liberated from hydrolytic cleavage of polyester microcapsules on their permeability and degradability. Sah H, et al. **J Pharm Sci** 1995 Nov; 84(11):1353-9

METABOLISM

Characteristics of poly(3-hydroxybutyric acid) synthesis by recombinant Escherichia coli. Lee SY, et al. **Ann N Y Acad Sci** 1996 May 15;782:133-42

Fusarium polycaprolactone depolymerase is cutinase. Murphy CA, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):456-60

Metabolic pathway for poly(3-hydroxybutyrate-co-3-hydroxyvalerate) formation in Nocardia corallina: inactivation of mutB by chromosomal integration of a kanamycin resistance gene. Valentin HF, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):372-9

A potential soft tissue filling material: chloramphenicol loaded poly(D,L-lactide) sponges. Kozluca A, et al. **Artif Organs** 1995 Sep;19(9):902-8

In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). Ignatius AA, et al. **Biomaterials** 1996 Apr;17(8):831-9

Bone-bonding behaviour of poly(ethylene oxide)-polybutylene terephthalate copolymer coatings and bulk implants: a comparative study. Radder AM, et al. **Biomaterials** 1995 May;16(7):507-13

POLYESTERS

Physico-mechanical properties of poly (epsilon-caprolactone) for the construction of rumino-reticulum devices for grazing animals. Vandamme TF, et al. **Biomaterials** 1995 Dec;16(18):1395-400

Poly-3-hydroxybutyrate/polyphosphate complexes form voltage-activated Ca2+ channels in the plasma membranes of Escherichia coli. Reusch RN, et al. **Biophys J** 1995 Sep; 69(3):754-66

Loss of pirimicarb residues from contaminated fabrics. Zhou K, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):29-33

Determination of the aerobic biodegradability of polymeric material in a laboratory controlled composting test. Pagga U, et al. **Chemosphere** 1995 Dec;31(11-12):4475-87

Clinical biocompatibility and degradation of polylevolactide screws in the ankle. Böstman OM, et al. **Clin Orthop** 1995 Nov;(320):101-9

Occurrence of polyhydroxyalkanoic acid granule-associated proteins related to the Alcaligenes eutrophus H16 GA24 protein in other bacteria. Wieczorek R, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):23-30

Isolation and identification of poly(3-hydroxyvalerate)-degrading strains of Pseudomonas lemoignei. Mergaert J, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):769-73

Genetic and physiological characterization of a Rhizobium etli mutant strain unable to synthesize poly-beta-hydroxybutyrate. Cevallos MA, et al. **J Bacteriol** 1996 Mar;178(6):1646-54

Poly(3-hydroxybutyrate) is associated with specific proteins in the cytoplasm and membranes of Escherichia coli. Huang R, et al. **J Biol Chem** 1996 Sep 6;271(36):22196-202

New hydrophilic polyesters and related polymers as bioerodible polymeric matrices. Chiellini E, et al. **J Biomater Sci Polym Ed** 1995;7(4):307-28 (34 ref.)

Immobilization of heparin on polylactide for application to degradable biomaterials in contact with blood. Seifert B, et al. **J Biomater Sci Polym Ed** 1995;7(3):277-87

Saccharomyces cerevisiae expressing bacterial polyhydroxybutyrate synthase produces poly-3-hydroxybutyrate. Leaf TA, et al. **Microbiology** 1996 May;142 (Pt 5):1169-80

Poly-beta-hydroxybutyrate (PHB) biosynthetic genes in Rhizobium meliloti 41. Tombolini R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2553-9

PHARMACOLOGY

In vitro cell response to differences in poly-L-lactide crystallinity. Park A, et al. **J Biomed Mater Res** 1996 May; 31(1):117-30

Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Timofeevski SL, et al. **Pharm Res** 1996 Mar;13(3):476-80

THERAPEUTIC USE

Case report: treatment of a carotid artery pseudoaneurism with a polyester covered nitinol stent. Nicholson A, et al. **Clin Radiol** 1995 Dec;50(12):872-3

Bone regeneration with resorbable polymeric membranes: treatment of diaphyseal bone defects in the rabbit radius with poly(L-lactide) membrane. A pilot study. Meinig RP, et al. **J Orthop Trauma** 1996;10(3):178-90

TOXICITY

Characterization of the cell response of cultured macrophages and fibroblasts to particles of short-chain poly[(R)-3-hydroxybutyric acid]. Saad B, et al. **J Biomed Mater Res** 1996 Apr;30(4):429-9

Assessment of DNA adducts and the frequency of 6-thioguanine resistant T-lymphocytes in F344 rats fed 2,4-toluenediamine or implanted with a toluenediisocyanate-containing polyester polyurethane foam. Delclos KB, et al. **Mutat Res** 1996 Apr 6;367(4):210-8

POLYETHYLENE GLYCOLS

Esophageal perforation after ingestion of colon lavage solution [letter] Eisen GM, et al. **Am J Gastroenterol** 1995 Nov;90(11):2074

Effect of adhered bacteria on the binding of Acanthamoeba to hydrogel lenses. Gorlin AI, et al. **Arch Ophthalmol** 1996 May;114(5):576-80

Hydrogel intracorneal lenses in aphakic eyes. Steinert RF, et al. **Arch Ophthalmol** 1996 Feb;114(2):135-41

Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Gaertner HF, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):38-44

Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers. Senter PD, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):389-94

Synthesis and physicochemical properties of protein conjugates with water-soluble poly(alkylene oxides). Topchieva IN, et al. **Bioconjug Chem** 1995 Jul-Aug; 6(4):380-8

Thermally gelling poloxamine Synperonic T908 solution as a vehicle for rectal drug delivery. Miyazaki S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1151-3

Permeability and biocompatibility of a new hydrogel used for encapsulation of hepatocytes. Honiger J, et al. **Biomaterials** 1995 Jul;16(10):753-9

In vitro biocompatibility testing of polymers for orthopaedic implants using cultured fibroblasts and osteoblasts. Morrison C, et al. **Biomaterials** 1995 Sep;16(13):987-92

Interaction of poly(ethylene-glycols) with air-water interfaces and lipid monolayers: investigations on surface pressure and surface potential. Winterhalter M, et al. **Biophys J** 1995 Oct;69(4):1372-81

A blinded clinical trial comparing conventional cleansing enema, Pico-salax and Golytely for barium enema bowel preparation. Lai AK, et al. **Clin Radiol** 1996 Aug; 51(8):566-9

Fused-silica capillaries with surface-bound dextran layer crosslinked with diepoxypolyethylene glycol for capillary electrophoresis of biological substances at reduced electroosmotic flow. Mechref Y, et al. **Electrophoresis** 1995 Apr;16(4):617-24

Evaluation of modified dichloran 18% glycerol (DG18) agar for enumerating fungi in wheat flour: a collaborative study. Beuchat LR, et al. **Int J Food Microbiol** 1996 Apr; 29(2-3):161-6

Preparation and characterization of alkylated poly(vinyl alcohol) hydrogels using alkyl halides. Duncan AC, et al. **J Biomater Sci Polym Ed** 1996;7(8):647-59

Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: histopathological evaluation in the animal eye. Vijayasekaran S, et al. **J Biomater Sci Polym Ed** 1996; 7(8):685-96

In vitro platelet adhesion to nonionic and ionic hydrogels with different water contents. Kulik E, et al. **J Biomed Mater Res** 1996 Mar;30(3):295-304

One-year results of the intrascleral glaucoma implant. Smith SG, et al. **J Cataract Refract Surg** 1995 Jul;21(4):453-6

Intracerebral implantation of hydrogel-coupled adhesion peptides: tissue reaction. Woerly S, et al. **J Neural Transplant Plast** 1995;5(4):245-55

Culture maintenance of isolated adult porcine pancreatic islets in three-dimensional gel matrices: morphologic and functional results. Falorni A, et al. **Pancreas** 1996 Apr; 12(3):221-9

Studies on dressings for mucosa of the oral cavity. Part 3: Effect of preparation technology on the physical and chemical properties of stomatological xerogel dressings. Malecka K, et al. **Pharmazie** 1996 Apr;51(4):240-1

An estimation of fatigue life for a carbon fibre/poly ether ether ketone hip joint prosthesis. Akay M, et al. **Proc Inst Mech Eng [H]** 1995;209(2):93-103

Preliminary results with a new hydrogel intraocular lens. Stanley JA. **Surv Ophthalmol** 1995 Jul-Aug;40(1):82-3

Autoadsorptions for the detection of alloantibodies--should polyethylene glycol be used? [letter] Champagne K, et al. **Transfusion** 1996 Apr;36(4):384

Comparison of the polyethylene glycol antiglobulin test and the use of enzymes in antibody detection and identification. Reisner R, et al. **Transfusion** 1996 Jun;36(6):487-9

[Orthograde intestinal irrigation or Fordtran solution for bowel preparation in elective colorectal surgery. Prospective outcome study] Seifert JK, et al. **Langenbecks Arch Chir** 1995;380(6):327-32 (Eng. Abstr.) **(Ger)**

[Polyethylene glycol versus sodium phosphate: comparison of 2 preparations for colonoscopy] Pontone P, et al. **G Chir** 1996 Mar;17(3):128-31 (Eng. Abstr.) **(Ita)**

[Experimental study on cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid] Tokuda K, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1641-3 (Eng. Abstr.) **(Jpn)**

[Change in argatroban concentration within the vessel wall after local administration using hydrogel-coated balloon catheter] Imanishi T, et al. **J Cardiol** 1996 May;27(5):267-71 (Eng. Abstr.) **(Jpn)**

[Prolonged antinociceptive effect after epidural injection of polyethylene glycol-morphine composites in rats] Okuda T, et al. **Masui** 1996 May;45(5):571-5 (Eng. Abstr.) **(Jpn)**

[Comparative study of the efficacy and tolerance of 2 types of colon cleansing] Fernández Seara J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):785-91 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Five days of whole-bowel irrigation in a case of pediatric iron ingestion. Kaczorowski JM, et al. **Ann Emerg Med** 1996 Feb;27(2):258-63

Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes. Hosoda J, et al. **Biol Pharm Bull** 1995 Sep;18(9):1234-7

Liver function and morphology after resuscitation from severe hemorrhagic shock with hemoglobin solutions or autologous blood. Eldridge J, et al. **Crit Care Med** 1996 Apr;24(4):663-71

Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Corazziari E, et al. **Dig Dis Sci** 1996 Aug;41(8):1636-42

Single-day, divided-dose oral sodium phosphate laxative versus intestinal lavage as preparation for colonoscopy: efficacy and patient tolerance. Henderson JM, et al. **Gastrointest Endosc** 1995 Sep;42(3):238-43

Bowel preparation for colonoscopy: a randomized prospective trail comparing sodium phosphate and polyethylene glycol in a predominantly elderly population. Thomson A, et al. **J Gastroenterol Hepatol** 1996 Feb; 11(2):103-7

Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. Greenwald RB, et al. **J Med Chem** 1996 May 10;39(10):1938-40

Bowel preparation before colonoscopy. Choosing the best lavage regimen. Tooson JD, et al. **Postgrad Med** 1996 Aug; 100(2):203-4, 207-12, 214 (30 ref.)

The quest for a more acceptable bowel preparation: comparison of a polyethylene glycol/electrolyte solution and a mannitol/Picolax mixture for colonoscopy. Saunders BP, et al. **Postgrad Med J** 1995 Aug;71(838):476-9

[Anaphylactoid reactions to an injectable solution of a cremophor-containing solution of multivitamins] Mounier P, et al. **Therapie** 1995 Nov-Dec;50(6):571-3 (Eng. Abstr.) **(Fre)**

[Effect of orthograde intestinal irrigation with Prepacol and polyethyleneglycol solution on duration of postoperative ileus after colorectal resections] Gründel K, et al. **Langenbecks Arch Chir** 1996;381(3):160-4 (Eng. Abstr.) **(Ger)**

[Sclerotherapy with 3% polidocanol for hydrocele testis] Mizoguchi H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1757-60 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution. Granberry MC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1232-35 (12 ref.)

Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Laine GA, et al. **Ann Pharmacother** 1995 Nov;29(11):1110-4

Acute blood pressure response to surfactant administration [letter; comment] Halley GC, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F197. Comment on: Arch Dis Child Fetal Neonatal Ed 1994 Nov;71(3):F174-8.

Changes in pulmonary artery pressure in infants with respiratory distress syndrome after treatment with Exosurf [letter] Rogers D. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F151

Esophageal rupture after routine bowel preparation for barium enema study [letter] Doris CI. **Can Assoc Radiol J** 1996 Apr;47(2):144

Contact sensitivity to Atlas G-1441. Pazzaglia M, et al. **Contact Dermatitis** 1995 Sep;33(3):208

Aphthoid lesions of the rectum [letter] Faigel DO, et al. **Gastrointest Endosc** 1996 May;43(5):528-9

[Acute respiratory distress syndrome with fatal outcome after inhalation of polyethylene glycol during preparation for colonoscopy (letter)] Hastier P, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):216-7 **(Fre)**

[Anaphylactoid reactions to an injectable solution of a cremophor-containing solution of multivitamins] Mounier P, et al. **Therapie** 1995 Nov-Dec;50(6):571-3 (Eng. Abstr.) **(Fre)**

[Complications of endoscopic sclerotherapy of esophageal varices] Jaspersen D, et al. **Leber Magen Darm** 1995 Jul; 25(4):171-4 (Eng. Abstr.) **(Ger)**

[Aethoxysterol] **Lakartidningen** 1995 Dec 20; 92(51-52):4914-6 **(Swe)**

ANALYSIS

Quantitative determination of polyethylene glycol based upon its salting out and partitioning of a dye into the resulting aqueous two-phase system. Guermant C, et al. **Anal Biochem** 1995 Sep 20;230(2):254-8

A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. Nag A, et al. **Anal Biochem** 1996 Jun 1; 237(2):224-31

CHEMICAL SYNTHESIS

Primary amino-terminal heterobifunctional poly(ethylene oxide). Facile synthesis of poly(ethylene oxide) with a primary amino group at one end and a hydroxyl group at the other end. Nagasaki Y, et al. **Bioconjug Chem** 1995 Nov-Dec;6(6):702-4

Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers. Senter PD, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):389-94

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). Kirpotin D, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):115-8

CHEMISTRY

Electrophoresis of polyethylene glycols and related materials as sodium dodecyl sulfate complexes. Zimmerman SB, et al. **Anal Biochem** 1996 Feb 15;234(2):190-3

Molecular sieving by polymer solutions: dependence on particle and polymer size, independence of polymer entanglement. Radko SP, et al. **Appl Theor Electrophor** 1995;5(2):79-87

Poly(ethylene glycol)-serum albumin hydrogel as matrix for enzyme immobilization: biomedical applications. D'Urso EM, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995;23(5):587-95

Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids. Holland JW, et al. **Biochemistry** 1996 Feb 27;35(8):2610-7

Poly(ethylene glycol)—lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Holland JW, et al. **Biochemistry** 1996 Feb 27;35(8):2618-24

Solution conformation of the extracellular domain of the human tumor necrosis factor receptor probed by Raman and UV-resonance Raman spectroscopy: structural effects of an engineered PEG linker. Tuma R, et al. **Biochemistry** 1995 Nov 21;34(46):15150-6

Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Vertut-Doï A, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):19-28

Synthesis of novel poly(ethylene glycol) derivatives having pendant amino groups and aggregating behavior of its mixture with fatty acid in water. Koyama Y, et al. **Bioconjug Chem** 1996 May-Jun;7(3):298-301

Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR. Zalipsky S, et al. **Bioconjug Chem** 1995 Nov-Dec;6(6):705-8

Permeability and blood compatibility properties of chitosan-poly(ethylene oxide) blend membranes for haemodialysis. Amiji MM. **Biomaterials** 1995 May; 16(8):593-9

Synthesis and properties of novel block copolymers containing poly(lactic-glycolic acid) and poly(ethyleneglycol) segments. Ferruti P, et al. **Biomaterials** 1995 Dec;16(18):1423-8

Surface modifications of alginate/poly(L-lysine) microcapsular membranes with poly(ethylene glycol) and poly(vinyl alcohol). Kung IM, et al. **Biomaterials** 1995 May; 16(8):649-55

Long-term compressive property durability of carbon fibre-reinforced polyetheretherketone composite in physiological saline. Zhang G, et al. **Biomaterials** 1996 Apr; 17(8):781-9

Interfacial thickness of liposomes containing poly(ethylene glycol)-cholesterol from electrophoresis. Janzen J, et al. **Biophys J** 1996 Jan;70(1):313-20

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Delgado C, et al. **Br J Cancer** 1996 Jan; 73(2):175-82

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). Kirpotin D, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):115-8

Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs. Felix AM, et al. **Int J Pept Protein Res** 1995 Sep-Oct;46(3-4):253-64

Synthetic cell-adhesive laminin peptide YIGSR conjugated with polyethylene glycol has improved antimetastatic activity due to a longer half-life in blood. Kaneda Y, et al. **Invasion Metastasis** 1995;15(3-4):156-62

Long-acting growth hormones produced by conjugation with polyethylene glycol. Clark R, et al. **J Biol Chem** 1996 Sep 6;271(36):21969-77

Swelling/syneresis phenomena in gel-forming interpolymer complexes. Bell CL, et al. **J Biomater Sci Polym Ed** 1996; 7(8):671-83

Polyethylene glycol-modified avidin: a novel agent for the selective extraction of biotinylated immune-complex in an aqueous two-phase system. Nishimura H, et al. **J Biomater Sci Polym Ed** 1995;7(3):289-96

Protein-rejecting ability of surface-bound dextran in end-on and side-on configurations: comparison to PEG. Osterberg E, et al. **J Biomed Mater Res** 1995 Jun;29(6):741-7

Poly(ethyleneoxide) for high-resolution and high-speed separation of DNA by capillary electrophoresis. Chang HT, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7; 669(1):113-23

Microparticles of BSA substituted with deoxycholic acid and triethylene glycol glutarate. Correlations between the physico-chemical properties of the matrix and the release kinetics. Orienti I, et al. **J Pharm Belg** 1996 May-Jun; 51(3):125-30

Water mobility in poly(ethylene glycol)-, poly(vinylpyrrolidone)-, and gelatin-water systems, as indicated by dielectric relaxation time, spin-lattice relaxation time, and water activity. Yoshioka S, et al. **J Pharm Sci** 1995 Sep;84(9):1072-7

The effect of polyethylene glycol on the charcoal adsorption of chlorpromazine studied by ion selective electrode potentiometry. Atta-Politou J, et al. **J Toxicol Clin Toxicol** 1996;34(3):307-16

Isolation of a novel association network in a polymer gel. Ilzhoefer JR, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):467-8

Absorption of ammonia by high water content hydrogel lenses: an inexpensive method of analysis. LaMotte J, et al. **Optom Vis Sci** 1995 Sep;72(9):605-7

Maltodextrins as lyoprotectants in the lyophilization of a model protein, LDH. Corveleyn S, et al. **Pharm Res** 1996 Jan;13(1):146-50

Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Jensen-Pippo KE, et al. **Pharm Res** 1996 Jan;13(1):102-7

Estimation of recombinant bovine somatotropin solubility by excluded-volume interaction with polyethylene glycols. Stevenson CL, et al. **Pharm Res** 1995 Nov;12(11):1671-6

Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Bouvier M, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4583-8

Lamellar biogels: fluid-membrane-based hydrogels containing polymer lipids. Warriner HE, et al. **Science** 1996 Feb 16;271(5251):969-73

[Polyoxyethylene tensides as vesicle components. 2.] Nürnberg E, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):331-8 (17 ref.) **(Ger)**

[Conjugates of alpha-chymotrypsin with polyalkylene oxides in hydrated reverse micelles] Efremova NV, et al. **Biokhimiia** 1996 Jan;61(1):160-9 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Inflammation: imaging with methoxy poly(ethylene glycol)-poly-L-lysine-DTPA, a long-circulating graft copolymer. Gupta H, et al. **Radiology** 1995 Dec; 197(3):665-9

[Single-contrast enema after colon lavage in the elderly patient] Battolla R, et al. **Radiol Med (Torino)** 1996 May; 91(5):610-5 (Eng. Abstr.) **(Ita)**

METABOLISM

Intraarterial perfusion of the hindlimb with pyridoxalated hemoglobin polyoxyethylene conjugate solution in anesthetized dogs. Kida Y, et al. **Artif Organs** 1995 Jun; 19(6):511-8

Kinetic and modelling studies of NAD+ and poly(ethylene glycol)-bound NAD+ in horse liver alcohol dehydrogenase. Vanhommerig SA, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):125-38

Hepatocyte culture on carbohydrate-modified star polyethylene oxide hydrogels. Lopina ST, et al. **Biomaterials** 1996 Mar;17(6):559-69

Bone-bonding behaviour of poly(ethylene oxide)-polybutylene terephthalate copolymer coatings and bulk implants: a comparative study. Radder AM, et al. **Biomaterials** 1995 May;16(7):507-13

Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model. West JL, et al. **Biomaterials** 1995 Oct;16(15):1153-6

Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: I: Preparation and in vitro characterization. Jean-François J, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):221-6

Effect of water-loading on the performance of polyethylene glycol as a marker of small intestinal permeability. Iqbal TH, et al. **Clin Sci (Colch)** 1995 Sep;89(3):299-303

Novel PDLLA/PEG copolymer micelles as drug carriers. Pişkin, et al. **J Biomater Sci Polym Ed** 1995;7(4):359-73

Ether-bond scission in the biodegradation of alcohol ethoxylate nonionic surfactants by Pseudomonas sp. strain SC25A. Tidswell EC, et al. **Microbiology** 1996 May;142 (Pt 5):1123-31

Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol. Paige AG, et al. **Pharm Res** 1995 Dec;12(12):1883-8

Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Patel VR, et al. **Pharm Res** 1996 Apr;13(4):588-93

Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Sako K, et al. **Pharm Res** 1996 Apr;13(4):594-8

PHARMACOKINETICS

Drug release from new bioartificial hydrogel. Gayet JC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(5):605-11

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):636-46

Medication with ursodeoxycholic acid enhances the biliary clearance of polyethylene glycol 900, but not mannitol. Friman S, et al. **Digestion** 1995;56(5):382-8

Increased gastric absorption of polyethylene glycols in atrophic gastritis. Söderholm JD, et al. **Digestion** 1996; 57(3):191-5

Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. Uster PS, et al. **FEBS Lett** 1996 May 20; 386(2-3):243-6

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. Rischin D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1297-301

The release of isoconazole nitrate from different suppository bases: in-vivo release of drug labelled with 99mTc in rabbits. Asikoglu M, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):717-20

Intestinal permeability to polyethylene glycols in monozygotic twins with Crohn's disease. Lindberg E, et al. **Scand J Gastroenterol** 1995 Aug;30(8):780-3

Balance/excretion of 3H- and 14C-tyloxapol in the male rabbit after intratracheal administration. DeAngelis RL, et al. **Xenobiotica** 1995 May;25(5):521-30

PHARMACOLOGY

Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Balaraman V, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1838-43

Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCl, and reduces viscosity of cystic fibrosis sputum. Ghio AJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):783-8

Use of a polyethylene glycol-peptide conjugate in a competition gel shift assay for screening potential antagonists of HIV-1 Tat protein binding to TAR RNA. Wang J, et al. **Anal Biochem** 1995 Dec 10;232(2):238-42

Influence of polyethylene glycol superoxide dismutase/catalase on altered opioid-induced pial artery dilation after brain injury. Thorogood MC, et al. **Anesthesiology** 1996 Mar;84(3):614-25

The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Borrel MN, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2069-76

Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Torchilin VP, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):75-83

Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol). Kawaguchi T, et al. **Biol Pharm Bull** 1995 Mar;18(3):474-6

Amino acids and peptides. XXVI. Laminin-related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. Kawasaki K, et al. **Biol Pharm Bull** 1995 Dec;18(12):1714-7

Effect of non-lytic concentrations of Brij series detergents on the metabolism-independent ion permeability properties of human erythrocytes. Miseta A, et al. **Biophys J** 1995 Dec;69(6):2563-8

Polyethylene glycol-mediated bacterial colony transformation. Kurien BT, et al. **Biotechniques** 1995 Jun; 18(6):1023-6

Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Harker LA, et al. **Blood** 1996 Jul 15;88(2):511-21

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Marshall D, et al. **Br J Cancer** 1996 Mar;73(5):565-72

Hypovolaemic and osmotic stimuli induce distinct patterns of c-Fos expression in the rat subformical organ. Smith DW, et al. **Brain Res** 1995 Nov 6;698(1-2):232-6

Amino acids and peptides. XXV. Preparation of fibronectin-related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. Kawasaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec; 43(12):2133-8

Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant Exosurf. Thomassen MJ, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):201-5

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):636-46

Intragastric polyethylene glycol-400 protects against ethanol-induced gastric mucosal lesions despite pretreatment with indomethacin or iodoacetamide. Gutiérrez-Cabano CA. **Dig Dis Sci** 1995 Sep;40(9):2029-36

Polyethylene glycol precipitates of serum contain a large proportion of uncomplexed immunoglobulins and C3. Crowley-Nowick PA, et al. **Immunol Invest** 1996 Jan-Mar; 25(1-2):91-101

Calixarenes with host-mediated potency in experimental tuberculosis: further evidence that macrophage lipids are involved in their mechanism of action. Hart PD, et al. **Infect Immun** 1996 Apr;64(4):1491-3

Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test. Miller MA, et al. **J Clin Microbiol** 1996 Jan;34(1):84-6

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. Greenwald RB, et al. **J Med Chem** 1996 Jan 19;39(2):424-31

Inhibition of the biologic activity of tumor necrosis factor maintains vascular endothelial cell function during hyperdynamic sepsis. Wang P, et al. **J Trauma** 1996 May; 40(5):694-700; discussion 701-1

Preparation and reactivation of demembranated, cytosol-free ram spermatozoa. San Agustin JT, et al. **Methods Cell Biol** 1995;47:251-5

Using macromolecular crowding agents to identify weak interactions within DNA replication complexes. Reddy MK, et al. **Methods Enzymol** 1995;262:466-76

Effect of nonionic surfactant on transport of model drugs in emulsions. Yoon KA, et al. **Pharm Res** 1996 Mar; 13(3):433-9

Effects of pelleting, lactose level, polyethylene glycol 4000, and guar gum compared to pectin on growth performances,

energy values, and losses of lactose, lactic acid, and water in chickens. Carré B, et al. **Poult Sci** 1995 Nov; 74(11):1810–9

Stretch–induced injury of cultured neuronal, glial, and endothelial cells. Effect of polyethylene glycol–conjugated superoxide dismutase. McKinney JS, et al. **Stroke** 1996 May;27(5):934–40

Effects of superoxide dismutase and U74389G on acute trimethyltin–induced cochlear dysfunction. Clerici WJ. **Toxicol Appl Pharmacol** 1996 Feb;136(2):236–42

Metabolic and functional effects of polyethylene glycol 20M and 2,3– butanedione monoxime during single flush or oxygenated microperfusion preservation: comparison with Plegisol. Bauza G, et al. **Transplant Proc** 1996 Feb; 28(1):284–5

How beneficial is the reduction of edema formation by polyethylene glycol during cardioplegic arrest? Kober IM, et al. **Transplant Proc** 1996 Feb;28(1):160–2

[Outcome of blood gas parameters during the first 24 years after Exosurf administration] Lenoir S, et al. **Arch Pediatr** 1996 Apr;3(4):324–8 (Eng. Abstr.) **(Fre)**

[Low–dose polyethylene glycol 4000: digestive effects. Randomized double–blind study in healthy subjects] Hudziak H, et al. **Gastroenterol Clin Biol** 1996;20(5):418–23 (Eng. Abstr.) **(Fre)**

[Effect of polyethylene oxide on hemodynamic parameters in infusion therapy of irreversible hemorrhagic shock] Plotnikov MB, et al. **Gematol Transfuziol** 1996 Jan–Feb; 41(1):20–3 (Eng. Abstr.) **(Rus)**

POISONING

Acute renal toxicity after ingestion of Lava light liquid. Erickson TB, et al. **Ann Emerg Med** 1996 Jun;27(6):781–4

STANDARDS

Determination of lubricating film thickness for permeable hydrogel and non–permeable polyurethane layers bonded to a rigid substrate with particular reference to cushion form hip joint replacements. McClure G, et al. **Proc Inst Mech Eng [H]** 1996;210(2):89–93

THERAPEUTIC USE

Therapy for lung failure using nitric oxide inhalation and surfactant replacement. Strüber M, et al. **Ann Thorac Surg** 1996 May;61(5):1543–5

Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment. Pennefather PM, et al. **Br J Ophthalmol** 1996 May;80(5):420–4

N–butyl–2–cyanoacrylate (Histoacryl) plus sclerotherapy versus sclerotherapy alone in the treatment of bleeding esophageal varices: a randomized prospective study [see comments] Feretis C, et al. **Endoscopy** 1995 Jun;27(5):355–7 . Comment in: Endoscopy 1995 Jun;27(5):392–6.

Screening for retinopathy of prematurity after surfactant treatment. Brunner–Di Pietro D, et al. **Eur J Pediatr** 1995; 154(9 Suppl 4):S90–4

Biopolymeric modification of superoxide dismutase (mPEG–SOD) to prevent muscular ischemia–reperfusion damage. Giardino R, et al. **Int J Artif Organs** 1995 Mar; 18(3):167–72

Multicystic recurrence of hydrocele testis after sclerosing with polidocanol followed by spontaneous cure. Fariña LA, et al. **Int Urol Nephrol** 1995;27(4):449–50

The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG–Hb) in a conscious porcine model. Conover CD, et al. **J Investig Med** 1996 Jun;44(5):238–46

PEG–SOD after head injury [letter; comment] Muizelaar JP, et al. **J Neurosurg** 1995 Nov;83(5):942. Comment on: J Neurosurg 1993 Mar;78(3):375–82.

Efficacy of adhesion barriers. Resorbable hydrogel, oxidized regenerated cellulose and hyaluronic acid. West JL, et al. **J Reprod Med** 1996 Mar;41(3):149–54

Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial [see comments] Young B, et al. **JAMA** 1996 Aug 21;276(7):538–43. Comment in: JAMA 1996 Aug 21;276(7):569–70.

Aerosolized surfactant in adults with sepsis–induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group [see comments] Anzueto A, et al. **N Engl J Med** 1996 May 30; 334(22):1417–21. Comment in: N Engl J Med 1996 May 30;334(22):1469–70.

The acute respiratory distress syndrome [editorial; comment] Matthay MA. **N Engl J Med** 1996 May 30;334(22):1469–70 . Comment on: N Engl J Med 1996 May 30;334(22):1417–21.

Efficacy of surfactant therapy in infants managed with CPAP. Alba J, et al. **Pediatr Pulmonol** 1995 Sep;20(3):172–6

A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont–Oxford Neonatal Network [see comments] **Pediatrics** 1996 Jan;97(1):1–6. Comment in: Pediatrics 1996 Jan;97(1):113–4.

Laser–induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Pomer S, et al. **Urol Int** 1995;55(4):197–201

[Prophylactic and correcting effect of polyethylene oxide Polyox WSR–301 in experimental lipoidosis in rats] Sokolova IA, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):587–9 **(Rus)**

[Use of polyethylene glycol in the treatment of puerperal constipation] Nardulli G, et al. **G E N** 1995 Jul–Sep; 49(3):224–6 (Eng. Abstr.) **(Spa)**

TOXICITY

Poly(ethylene glycol)–doxorubicin conjugates containing beta–lactamase–sensitive linkers. Senter PD, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):389–94

Preliminary studies of the toxic effects of non–ionic surfactants derived from lysine. Macián M, et al. **Toxicology** 1996 Jan 8;106(1–3):1–9

POLYETHYLENE TEREPHTHALATES

The Mersilene mesh suburethral sling: a clinical and urodynamic evaluation. Young SB, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1719–25; discussion 1725–6

Endothelial cell binding to Dacron modified with polyethylene oxide and peptide. Holt DB, et al. **ASAIO J** 1994 Jul–Sep;40(3):M858–63

The performance of commercially available sealed Dacron vascular grafts in intraarterial thrombolytic therapy. Trudell LA, et al. **ASAIO J** 1995 Jul–Sep;41(3):M633–5

New bioactivation mode for vascular prostheses made of Dacron polyester. Bonzon N, et al. **Biomaterials** 1995 Jul; 16(10):747–51

Carotid Dacron patch angioplasty: immediate and long–term results of a prospective series. Perler BA, et al. **Cardiovasc Surg** 1995 Dec;3(6):631–6 (43 ref.)

Carotid patches [letter; comment] Perkins JM, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):250–1. Comment on: Eur J Vasc Endovasc Surg 1995 Apr;9(3):351–2.

Degradation of Mersilene sutures [letter; comment] Liu C, et al. **Eye** 1995;9 (Pt 5):668–9. Comment on: Eye 1994;8 (Pt 6):676–9.

Management of recurrent and perivascular femoral hernias by giant prosthetic reinforcement of the visceral sac. Munshi IA, et al. **J Am Coll Surg** 1996 May;182(5):417–22

Apatite coated on organic polymers by biomimetic process: improvement in its adhesion to substrate by NaOH treatment. Tanahashi M, et al. **J Appl Biomater** 1994 Winter;5(4):339–47

Endothelial cells on Dacron vascular prostheses: adherence, growth, and susceptibility to neutrophils. Tunstall A, et al. **J Biomed Mater Res** 1995 Oct;29(10):1193–9

Clinical experience with a collagen impregnated woven Dacron graft. Tolan M, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):323–7

Accelerated healing of cardiovascular textiles promoted by an RGD peptide. Tweden KS, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S90–7

Unusual complication seven years after successful aortic recoarctation repair with a Dacron graft: acute thromboembolic leg ischemia caused by a mobile thrombus at the distal suture line. Berzins R, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):842–4

Endothelial coverage of endovascular Dacron grafts in dogs [letter; comment] Criado E, et al. **J Vasc Surg** 1996 Apr; 23(4):736–7. Comment on: J Vasc Surg 1995 Sep;22(3):306–14; discussion 314–5.

Acute platelet deposition after carotid endarterectomy in sheep: vein patch compared with gelatin–sealed Dacron and polytetrafluoroethylene patch closure. Margovsky AI, et al. **J Vasc Surg** 1996 Aug;24(2):200–6

Dacron–covered stent–grafts for the percutaneous treatment of carotid aneurysms: effectiveness and biocompatibility—experimental study in swine. Link J, et al. **Radiology** 1996 Aug;200(2):397–401

The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis. Akimoto F. **Surg Today** 1995;25(12):1027–33

Inflammatory reactions after vascular prosthesis implantation: a comparison of gelatin–sealed and unsealed Dacron prostheses. Utoh J, et al. **Surg Today** 1996;26(4):258–61

[A 10–year follow–up study of bypass operations with double–velour dacron in the aortoiliofemoral position] Andreev A. **Khirurgiia (Sofiia)** 1995;48(5):17–22 (Eng. Abstr.) **(Bul)**

[Biocompatibility of polyethylene terephthalate—PET—(Trevira strong)—an in vivo study of the sheep knee] Seitz H, et al. **Biomed Tech (Berl)** 1996 Jun;41(6):178–82 (Eng. Abstr.) **(Ger)**

[Management of an iliac artery aneurysm with percutaneous placement of a Dacron–nitinol vascular endoprosthesis] Sievert H, et al. **Z Kardiol** 1995 Oct;84(10):860–2 (Eng. Abstr.) **(Ger)**

[In vitro tissue factor production by human endothelial cells put in contact with polyethylene terephthalate with different texture] Cenni E, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):49–52 (Eng. Abstr.) **(Ita)**

[Experimental evaluation of a new gelatin–impregnated woven Dacron vascular prosthesis (CL301)] Sasajima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep; 43(9):1639–45 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Static headspace gas chromatography of acetaldehyde in aqueous foods and polythene terephthalate. Linssen J, et al. **Z Lebensm Unters Forsch** 1995 Sep;201(3):253–5

CHEMISTRY

Modification of polyethylene terephthalate (Dacron) via denier reduction: effects on material tensile strength, weight, and protein binding capabilities. Phaneuf MD, et al. **J Appl Biomater** 1995 Winter;6(4):289–99

Application of porous PEO/PBT copolymers for bone replacement. Radder AM, et al. **J Biomed Mater Res** 1996 Mar;30(3):341–51

METABOLISM

An immunohistochemical analysis of implanted woven Dacron and expanded polytetrafluoroethylene grafts in humans. Urayama H, et al. **Artif Organs** 1996 Jan;20(1):24–9

Histological evaluation of a biodegradable , Polyactive/hydroxyapatite membrane. Jansen JA, et al. **Biomaterials** 1995 Jul;16(11):819–27

PHARMACOLOGY

Adhesive protein expression on endothelial cells after contact in vitro with polyethylene terephthalate coated with pyrolytic carbon. Cenni E, et al. **Biomaterials** 1995 Nov; 16(16):1223–7

Platelet and coagulation factor variations induced in vitro by polyethylene terephthalate (Dacron) coated with pyrolytic carbon. Cenni E, et al. **Biomaterials** 1995 Sep; 16(13):973–6

Metabolic response of blood cells to synthetic graft–materials with special reference to a Fluoromer Passivated Dacron graft. An in vitro study using microcalorimetry. Swartbol P, et al. **Int J Artif Organs** 1995 Jul;18(7):372–9

THERAPEUTIC USE

Do collagen–impregnated knitted Dacron grafts reduce the need for transfusion in infrarenal aortic reconstruction? Barral X, et al. **Ann Vasc Surg** 1995 Jul;9(4):339–43

New Dacron tissue colonisable keratoprosthesis: clinical experience. Pintucci S, et al. **Br J Ophthalmol** 1995 Sep; 79(9):825–9

TOXICITY

Effects of organic and inorganic substances on the cell proliferation of L–929 fibroblasts and Tetrahymena pyriformis GL protozoa used for toxicological bioassays. Sauvant MP, et al. **Bull Environ Contam Toxicol** 1995 Aug; 55(2):171–8

Chemical and in vitro toxicological evaluations of water packaged in polyvinyl chloride and polyethylene terephthalate bottles. Sauvant MP, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):567–84

POLYETHYLENEIMINE

CHEMISTRY

Synthesis and use of quaternized polyethylenimine–coated zirconia for high–performance anion–exchange chromatography. McNeff C, et al. **Anal Chem** 1995 Nov 1;67(21):3886–92

PHARMACOLOGY

PEI6, a new basic secretagogue in rat peritoneal mast cells: characteristics of polyethylenimine PEI6 resemble those of compound 48/80. Suzuki–Nishimura T, et al. **Gen Pharmacol** 1995 Oct;26(6):1171–8 (41 ref.)

POLYETHYLENES

Hip–simulator ranking of polyethylene wear: comparisons between ceramic heads of different sizes. Clarke IC, et al. **Acta Orthop Scand** 1996 Apr;67(2):128–32

Polyethylene wear in Scanhip arthroplasty with a 22 or 32 mm head: 62 matched patients followed for 7–9 years. Kesteris U, et al. **Acta Orthop Scand** 1996 Apr;67(2):125–7

Bone wax template for the correction of enophthalmos with porous polyethylene implants. Harris GJ, et al. **Am J Ophthalmol** 1995 Oct;120(4):536–8

Herniography following indirect hernioplasty using the Marlex "mesh plug" technique. Kahn AM, et al. **Am Surg** 1995 Nov;61(11):947–8

Synthesis and physicochemical properties of protein conjugates with water–soluble poly(alkylene oxides). Topchieva IN, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):380–8

The natural history of ultra high molecular weight polyethylene [letter] Black J. **Clin Orthop** 1996 Feb; (323):341–2

Measurement of polyethylene wear in metal–backed acetabular cups. II. Clinical application. Devane PA, et al. **Clin Orthop** 1995 Oct;(319):317–26

Measurement of polyethylene wear in metal–backed acetabular cups. I. Three–dimensional technique. Devane PA, et al. **Clin Orthop** 1995 Oct;(319):303–16

Metal versus polyethylene wear particles in total hip replacements. A review. Doorn PF, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S206–16 (64 ref.)

Repair of neglected Achilles tendon ruptures with Marlex mesh. Choksey A, et al. **Injury** 1996 Apr;27(3):215–7

Factors influencing the longevity of UHMWPE tibial components. Heim CS, et al. **Instr Course Lect** 1996; 45:303–12 (110 ref.)

Treatment of psoriasis with polyethylene sheet bath PUVA. Streit V, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):208–10

Comparison of a new type of polytetrafluoroethylene patch (Mycro Mesh) and polypropylene prosthesis (Marlex) for repair of abdominal wall defects. Bellón JM, et al. **J Am Coll Surg** 1996 Jul;183(1):11–8

Intermittent micromotion and polyethylene particles inhibit bone ingrowth into titanium chambers in rabbits. Goodman S, et al. **J Appl Biomater** 1995 Fall;6(3):161–5

Migration of polyethylene wear debris in hip arthroplasties: a canine model. Kraemer WJ, et al. **J Appl Biomater** 1995 Winter;6(4):225–30

Compressive stress relaxation behavior of irradiated ultra-high molecular weight polyethylene at 37 degrees C. Waldman SD, et al. **J Appl Biomater** 1994 Winter; 5(4):333–8

Fracture of the femoral head after ceramic-on-polyethylene total hip arthroplasty. Callaway GH, et al. **J Arthroplasty** 1995 Dec;10(6):855–9

Tibial polyethylene failure after primary porous-coated anatomic total knee arthroplasty. Aids to diagnosis and revision. Knight JL, et al. **J Arthroplasty** 1995 Dec; 10(6):748–57

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

A sliding-distance-coupled finite element formulation for polyethylene wear in total hip arthroplasty. Maxian TA, et al. **J Biomech** 1996 May;29(5):687–92

Low-voltage scanning electron microscopic imaging of ultrahigh-molecular-weight polyethylene. Pienkowski D, et al. **J Biomed Mater Res** 1995 Oct;29(10):1167–74

Abrasive three-body wear of polyethylene caused by broken multifilament cables of a total hip prosthesis. A report of these cases. Bauer TW, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1244–7

Identification of orthopaedic wear debris [editorial; comment] Bauer TW. **J Bone Joint Surg Am** 1996 Apr; 78(4):479–83. Comment on: J Bone Joint Surg Am 1996 Apr;78(4):482–96. Comment on: J Bone Joint Surg Am 1996 Apr;78(4):497–504. Comment on: J Bone Joint Surg Am 1996 Apr;78(4):588–93.

The posterior stabilized total knee prothesis. Assessment of polyethylene damage and osteolysis after a ten-year-minimum follow-up [letter] Schmalzried TP. **J Bone Joint Surg Am** 1996 Sep;78(9):1446–7

Analysis of lymph nodes for polyethylene particles in patients who have had a primary joint replacement [see comments] Shea KG, et al. **J Bone Joint Surg Am** 1996 Apr; 78(4):497–504. Comment in: J Bone Joint Surg Am 1996 Apr;78(4):479–81.

Tissue ingrowth and differentiation in the bone-harvest chamber in the presence of cobalt-chromium-alloy and high-density-polyethylene particles [letter; comment] Surin V. **J Bone Joint Surg Am** 1996 May;78(5):793. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):1025–35.

Is polyethylene still the best prosthetic bearing surface? [editorial] Amis AA. **J Bone Joint Surg Br** 1996 May; 78(3):345–8 (39 ref.)

Immobilization of lipases on polyethylene and application to perilla oil hydrolysis for production of alpha-linolenic acid. Watanabe T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):307–12

The nonlinear partial volume effect and computed tomography densitometry of foam and lung. Kemerink GJ, et al. **Med Phys** 1995 Sep;22(9):1445–50

Biomaterial-associated infection with Candida albicans in mice. Różalska B, et al. **Microbiol Immunol** 1995; 39(7):443–50

SecureStrand cable system. Martin RJ. **Neurosurgery** 1996 Apr;38(4):842–3

Polyethylene: a bridge too far. Rorabeck CH, et al. **Orthopedics** 1995 Sep;18(9):881–3

The evaluation of nylon and polyethylene as build-up material in a neutron therapy beam. Hough JH, et al. **Phys Med Biol** 1995 Jul;40(7):1289–92

The histological appearance of the periprosthetic capsule in failed total hip arthroplasty differs depending on the presence of polyethylene acetabulum destruction, iliac bone damage and presence of infection. Rudzki Z, et al. **Pol J Pathol** 1996;47(1):19–25

Ultra-high molecular weight polyethylene wear debris generated in vivo and in laboratory tests; the influence of counterface roughness. Hailey JL, et al. **Proc Inst Mech Eng [H]** 1996;210(1):3–10

The wear of cross-linked polyethylene against itself. Joyce TJ, et al. **Proc Inst Mech Eng [H]** 1996;210(1):11–6

Reconstruction of chest wall after full-thickness resection. Two case reports. Suzuki T, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):145–7

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

Trial of polythene tobacco-wrap in prevention of hypothermia in neonates less than 1500 grams. van den Bosch CA, et al. **Trop Doct** 1996 Jan;26(1):26–8

[Effects of different sterilization procedures on degree of oxidation of ultra-high molecular weight polyethylene] Jerosch J, et al. **Biomed Tech (Berl)** 1995 Oct; 40(10):296–303 (Eng. Abstr.) **(Ger)**

[Scanning electron microscopy studies of morphologic changes in ultra-high molecular weight polyethylene materials after various processing steps] Jerosch J, et al. **Biomed Tech (Berl)** 1996 May;41(5):138–42 (Eng. Abstr.) **(Ger)**

[Ceramic acetabulum cup inserts for hip endoprostheses] Willmann G, et al. **Biomed Tech (Berl)** 1996 Apr; 41(4):98–105 (Eng. Abstr.) **(Ger)**

[Abrasion reducing polyethylene ceramic-metal compound hip prosthesis head] Hennig FF, et al. **Unfallchirurg** 1995 Oct;98(10):526–9 (Eng. Abstr.) **(Ger)**

[Nonelastic deformations of polyethylene inlays in hemiprostheses] Walther M, et al. **Zentralbl Chir** 1995; 120(9):734–8 (Eng. Abstr.) **(Ger)**

[Use of polypropylene (Marlex) prosthesis in the surgical treatment of inguinal and crural hernia] Campanelli GP, et al. **Minerva Chir** 1995 Jun;50(6):563–8 (Eng. Abstr.) **(Ita)**

[Use of porous plyethylene (Medpor) in maxillofacial surgery] Cenzi R, et al. **Minerva Stomatol** 1995 Dec; 44(12):559–82 (17 ref.) (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

Polyethylene particles or formaldehyde reaction [letter; comment] Anissian L. **Acta Orthop Scand** 1996 Apr; 67(2):205–6. Comment on: Acta Orthop Scand 1995 Aug;66(4):303–7.

ADVERSE EFFECTS

Pancreatic cancer among workers processing synthetic resins. Selenskas S, et al. **Am J Ind Med** 1995 Sep;28(3):385–98

The role of polyethylene properties in osteolysis after total hip replacement. Gómez-Barrena E, et al. **Instr Course Lect** 1996;45:187–97 (80 ref.)

Osteolysis of the acetabulum associated with a bipolar hemiarthroplasty. A late complication. Bose WJ, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1733–5

CHEMISTRY

Platelet deposition and fibrinogen binding on surfaces coated with heparin or friction-reducing polymers. Anderson AB, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):859–63

Effects of ions on partitioning of serum albumin and lysozyme in aqueous two-phase systems containing ethylene oxide/propylene oxide co-polymers. Johansson HO, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):289–98

Nonconsolidated polyethylene particles and oxidation in Charnley acetabular cups. Li S, et al. **Clin Orthop** 1995 Oct;(319):54–63

Effects of Tween 20 on the desorption of proteins from polymer surfaces. Feng M, et al. **J Biomater Sci Polym Ed** 1995;7(5):415–24

Changing crystallinity of polyethylene in the acetabular cups of Weller hip prostheses. Otfinowski J, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):802–5

METABOLISM

Immunochemical characterization of antibody-coated nanoparticles. Velge-Roussel F, et al. **Experientia** 1996 Aug 15;52(8):803–6

Stedim 6 and Clearflex, two new multilayer materials for infusion containers. Comparative study of their compatibility with five drugs versus glass flasks and polyvinyl chloride bags. Tchiakpé L, et al. **J Biomater Sci Polym Ed** 1995;7(3):199–206

Wear of polyethylene cups in total hip arthroplasty. A study of specimens retrieved post mortem. Sychterz CJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1193–200

PHARMACOLOGY

Does the liquid method of electret forming influence the adhesion of blood platelets? Lowkis B, et al. **Polim Med** 1995;25(1-2):3–13

POISONING

[Collagenosis-like syndromes as the possible manifestations of poisoning by the components of a compound] Sichko ZhV, et al. **Med Tr Prom Ekol** 1995;(11):44–6 **(Rus)**

RADIATION EFFECTS

Cell attachment to laser-induced AAm- and HEMA-grafted ethylene-propylene rubber as biomaterial: in vivo study. Mirzadeh H, et al. **Biomaterials** 1995 May;16(8):641–8

The Otto Aufranc Award. Impact of gamma sterilization on clinical performance of polyethylene in the hip. Sutula LC, et al. **Clin Orthop** 1995 Oct;(319):28–40

THERAPEUTIC USE

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Energy-shunting external hip protector attenuates the peak femoral impact force below the theoretical fracture threshold: an in vitro biomechanical study under falling conditions of the elderly. Parkkari J, et al. **J Bone Miner Res** 1995 Oct;10(10):1437–42

TOXICITY

Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Visuri T, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S280–9 (51 ref.)

POLYGALACTOSES see GALACTANS

POLYGALACTURONASE

BIOSYNTHESIS

The Erwinia chrysanthemi pecT gene regulates pectinase gene expression. Surgey N, et al. **J Bacteriol** 1996 Mar; 178(6):1593–9

Differential regulation of polygalacturonase and pectin methylesterase gene expression during and after heat stress in ripening tomato (Lycopersicon esculentum Mill.) fruits. Kagan-Zur V, et al. **Plant Mol Biol** 1995 Dec;29(6):1101–10

Detection method for polygalacturonase-producing strains of Saccharomyces cerevisiae. Gainvors A, et al. **Yeast** 1995 Dec;11(15):1493–9

CHEMISTRY

Implication of tryptophan and histidine in the active site of endo-polygalacturonase from Aspergillus ustus: elucidation of the reaction mechanism. Rao MN, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):167–73

GENETICS

Cloning and targeted disruption of enpg-1, encoding the major in vitro extracellular endopolygalacturonase of the chestnut blight fungus, Cryphonectria parasitica. Gao S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1984–90

Isolation and characterization of polygalacturonase genes (pecA and pecB) from Aspergillus flavus. Whitehead MP, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3316–22

Characterization of a multigene family encoding an endopolygalacturonase in Sclerotinia sclerotiorum. Fraissinet-Tachet L, et al. **Curr Genet** 1995 Dec;29(1):96–9

Isolation and sequence analysis of Clpg1, a gene coding for an endopolygalacturonase of the phytopathogenic fungus Colletotrichum lindemuthianum. Centis S, et al. **Gene** 1996 Apr 17;170(1):125–9

The extreme C-terminus is required for secretion of both the native polygalacturonase (PehA) and PehA-Bla hybrid proteins in Erwinia carotovora subsp. carotovora. Palomäki T, et al. **Mol Microbiol** 1995 Aug;17(3):449–59

[Detection of genetically engineered plants by polymerase chain reaction (PCR) using the FLAVR SAVR tomato as an example] Meyer R. **Z Lebensm Unters Forsch** 1995 Dec;201(6):583–6 (Eng. Abstr.) **(Ger)**

METABOLISM

Inversion of configuration during hydrolysis of alpha-1,4-galacturonidic linkage by three Aspergillus polygalacturonases. Biely P, et al. **FEBS Lett** 1996 Mar 18;382(3):249–55

An essential tyrosine residue of Aspergillus polygalacturonase. Stratilová E, et al. **FEBS Lett** 1996 Mar 11;382(1-2):164–6

Isolation and characterisation of a pod dehiscence zone-specific polygalacturonase from Brassica napus. Petersen M, et al. **Plant Mol Biol** 1996 Jun;31(3):517–27

Pectic polysaccharides from roots of Glycyrrhiza uralensis: possible contribution of neutral oligosaccharides in the galacturonase-resistant region to anti-complementary and mitogenic activities. Kiyohara H, et al. **Planta Med** 1996 Feb;62(1):14–9

PHARMACOLOGY

Elicitors and suppressors of hydroxyproline-rich glycoprotein accumulation are solubilized from plant cell walls by endopolygalacturonase. Boudart G, et al. **Eur J Biochem** 1995 Sep 1;232(2):449–57

SECRETION

The extreme C-terminus is required for secretion of both the native polygalacturonase (PehA) and PehA-Bla hybrid proteins in Erwinia carotovora subsp. carotovora. Palomäki T, et al. **Mol Microbiol** 1995 Aug;17(3):449–59

POLYGELINE

Hypotension during subarachnoid anaesthesia: haemodynamic effects of colloid and metaraminol. Critchley LA, et al. **Br J Anaesth** 1996 May;76(5):734–6

Clot formation and gelatin-based plasma substitutes [letter; comment] Heath ML. **Lancet** 1996 May 11;347(9011):1336 . Comment on: Lancet 1996 Mar 23;347(9004):825.

ADVERSE EFFECTS

Anaphylactoid reaction to Haemaccel [letter; comment] Fenwick DG, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):521–2. Comment on: Anaesth Intensive Care 1994 Feb;22(1):90–2. Comment on: Anaesth Intensive Care 1994 Jun;22(3):317–8.

PHARMACOLOGY

Evaluation of the effect of colloid (Haemaccel) on the

POLYGELINE

bleeding time in the trauma patient. Evans PA, et al. **J R Soc Med** 1996 Feb;89(2):101P–4P

Clot formation and gelatin-based plasma substitutes [letter] Baddeley DT, et al. **Lancet** 1996 Jun 22;347(9017):1763

THERAPEUTIC USE

A comparison of 4.5% human albumin solution and Haemaccel in neonates undergoing major surgery. Stoddart PA, et al. **Paediatr Anaesth** 1996;6(2):103–6

POLYGLACTIN 910

Vicryl-mesh wrap for the implantation of hydroxyapatite orbital implants: an animal model. Jordan DR, et al. **Can J Ophthalmol** 1995 Aug;30(5):241–6

The utility of polyglactin-910 mesh in the plastic reconstruction of the chest wall after en-bloc resection. Janni A, et al. **Eur J Surg Oncol** 1996 Aug;22(4):377–80

Periareolar mammaplasty: double skin technique with application of polyglactine or mixed mesh. Góes JC. **Plast Reconstr Surg** 1996 Apr;97(5):959–68

[Application of a peri-renal prosthesis (vicryl mesh) in the conservative treatment of multiple ruptured kidney fragments] Chaabouni MN, et al. **Ann Urol (Paris)** 1996; 30(2):61–3; discussion 64 (Eng. Abstr.) **(Fre)**

[Surgical abdominal access for prolapse using a Vicryl composite lattice. Preliminary study] Villet R, et al. **J Gynaecol Obstet Biol Reprod (Paris)** 1995;24(7):717–21 (Eng. Abstr.) **(Fre)**

[Resorbable intracutaneous suture as wound closure in cochlear implant] Laszig R, et al. **Laryngorhinootologie** 1995 Aug;74(8):518 (Eng. Abstr.) **(Ger)**

[Morphological evaluation of structural changes in the tracheal wall at the site of braided and monofilament sutures in experimental animals] Kharchenko VP, et al. **Probl Tuberk** 1995;(6):41–3 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Contaminated wounds: infection rates with subcutaneous sutures. Mehta PH, et al. **Ann Emerg Med** 1996 Jan; 27(1):43–8

THERAPEUTIC USE

Use of an absorbable polyglactin mesh for the prevention of incisional hernias. Pans A, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):265–8

Mechanical factors influencing the incidence of burst abdomen. Niggebrugge AH, et al. **Eur J Surg** 1995 Sep; 161(9):655–61

[Surgery for severe traumas of the kidney. Value of initial computed tomography, problem of surgical indication and use of a perirenal resorbable prosthesis of polyglactin 910] Bittard H, et al. **J Urol (Paris)** 1995;101(5–6):209–14 (Eng. Abstr.) **(Fre)**

POLYGLANDULAR TYPE I AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLANDULAR TYPE II AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLUCOSES see **GLUCANS**

POLYGLUTAMATE FOLATES see **PTEROYLPOLYGLUTAMIC ACIDS**

POLYGLUTAMIC ACID

ANALOGS & DERIVATIVES

Insulin-dependent suppression in glutamyl hydrolase activity and elevated cellular methotrexate polyglutamates. Galivan J, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1659–63

Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. Spinella MJ, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):703–12

Surface properties and biocompatibility of A-B-A type block copolymer membranes consisting of poly(gamma-benzyl-L-glutamate) as the A component and polyisoprene as the B component. Yoda R, et al. **Biomaterials** 1995 Nov;16(16):1203–9

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. Masson E, et al. **J Clin Invest** 1996 Jan 1;97(1):73–80

[Separation of methotrexate-polyglutamates by capillary electrophoresis and its application to the measurement of gamma-glutamyl hydrolase activity in human leukemia cells in culture] Takemura Y, et al. **Rinsho Byori** 1996 Jan; 44(1):51–6 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Molecular dynamics in sodium poly (L-glutamate) aqueous solutions analyzed by means of the stretched exponential decay of the Williams-Watts function. Bordi F, et al. **Biopolymers** 1995 Oct;36(4):539–45

METABOLISM

Effects of manganese (II) on Bacillus licheniformis ATCC 9945A physiology and gamma-poly(glutamic acid) formation. Cromwick AM, et al. **Int J Biol Macromol** 1995 Oct;17(5):259–67

Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site. Regulation by polyglutamylation. Larcher JC, et al. **J Biol Chem** 1996 Sep 6;271(36):22117–24

TOXICITY

Mechanism of the thesaurismosis and altered lysosomal dynamics induced by poly-D-glutamic acid in kidney proximal tubular cells. Kishore BK, et al. **Lab Invest** 1996 Jun;74(6):1025–37

Poly-D-glutamic acid induces an acute lysosomal thesaurismosis of proximal tubules and a marked proliferation of interstitium in rat kidney. Kishore BK, et al. **Lab Invest** 1996 Jun;74(6):1013–23

POLYGLYCOL METHACRYLATE see **POLYHYDROXYETHYL METHACRYLATE**

POLYGLYCOLIC ACID

Repair of bone defects with absorbable membranes. A study on rabbits. Ashammakhi N, et al. **Ann Chir Gynaecol** 1995; 84(3):309–15

Experimental study of nerve regeneration in a biodegradable tube made from collagen and polyglycolic acid. Kiyotani T, et al. **ASAIO J** 1995 Jul–Sep;41(3):M657–61

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

Selective splenic artery embolization or use of polyglycolic acid mesh in children with severe splenic trauma. Uroz Tristan J, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):310–2

Effect of self-reinforced polyglycolide membranes on cortical bone: an experimental study on rats. Ashammakhi N, et al. **J Biomed Mater Res** 1995 Jun;29(6):687–94

Biofix fixation techniques and results in foot surgery. Burns AE. **J Foot Ankle Surg** 1995 May–Jun;34(3):276–82

Infectious sequelae in the use of polyglycolic acid mesh for splenic salvage with intraperitoneal contamination. Wolf SE, et al. **J Surg Res** 1996 Mar;61(2):433–6

Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy [see comments] Talja M, et al. **J Urol** 1995 Dec;154(6):2089–92 . Comment in: J Urol 1995 Dec;154(6):2093–5.

Esophageal transection using a biofragmentable anastomosis ring in dogs. Han SL, et al. **Surg Today** 1995;25(9):802–5

Sutureless anastomosis using a biofragmentable anastomosis ring. Konishi F, et al. **Surg Today** 1995;25(9):783–9

Bedside placement of polyglycolic acid mesh: a novel treatment of uncomplicated abdominal wound dehiscence. Chendrasekhar A. **W V Med J** 1996 May–Jun;92(3):136–7

[Thoracoscopic partial lung resection using staplers and polyglycolic acid (PGA) felts in an 85-year-old patient] Yoshiya K, et al. **Kyobu Geka** 1995 Sep;48(10):833–5 (Eng. Abstr.) **(Jpn)**

[Clinical experience of the combined use of polyglycolide non-woven felt with fibrin glue to prevent postoperative pulmonary fistula] Mizuno H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1559–64 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Foreign-body reaction and the course of osteolysis after polyglycolide implants for fracture fixation: experimental study in sheep. Weiler A, et al. **J Bone Joint Surg Br** 1996 May;78(3):369–76

CHEMISTRY

Postoperative irradiation treatment and bioresorbable implants in orthopaedic surgery: an experimental in vitro study. Hofmann GO, et al. **Biomaterials** 1996 Jun; 17(11):1149–53

Stabilized polyglycolic acid fibre-based tubes for tissue engineering. Mooney DJ, et al. **Biomaterials** 1996 Jan; 17(2):115–24

METABOLISM

In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). Ignatius AA, et al. **Biomaterials** 1996 Apr;17(8):831–9

RADIATION EFFECTS

Postoperative irradiation treatment and bioresorbable implants in orthopaedic surgery: an experimental in vitro study. Hofmann GO, et al. **Biomaterials** 1996 Jun; 17(11):1149–53

THERAPEUTIC USE

Polylactic acid pins [letter; comment] Mainil-Varlet P. **Acta Orthop Scand** 1995 Dec;66(6):573–4. Comment on: Acta Orthop Scand 1994 Aug;65(4):472–5.

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Self-reinforced polyglycolic acid membrane: a bioresorbable material for orbital floor repair. Initial clinical report. McVicar I, et al. **Br J Oral Maxillofac Surg** 1995 Aug; 33(4):220–3

Randomized comparison of polyglycolic acid and polyglyconate sutures for abdominal fascial closure after laparotomy in patients with suspected impaired wound healing [letter; comment] Hewin DF. **Br J Surg** 1995 Dec; 82(12):1698–9. Comment on: Br J Surg 1995 Aug;82(8):1080–2.

POLYGLYCOLIDE see **POLYGLYCOLIC ACID**

POLYGONUM see **PLANTS, MEDICINAL**

POLYHYDRAMNIOS

Severity of polyhydramnios does not affect the prevalence of large-for-gestational-age newborn infants. Lazebnik N, et al. **J Ultrasound Med** 1996 May;15(5):385–8

COMPLICATIONS

Polyhydramnios-oligohydramnios in a twin pregnancy complicated by fetal glomerulocystic kidney disease. Watson WJ, et al. **Am J Perinatol** 1995 Nov;12(6):379–81

Successful outcome with serial amniocenteses for polyhydramnios complicating cystic adenomatoid malformation of the lung. Meagher SE, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):326–8

Does the amniotic fluid protein absorption contribute significantly to the fetal weight? Cheng W, et al. **J Paediatr Child Health** 1996 Feb;32(1):39–41

DIAGNOSIS

Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? Barnhard Y, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1523–7

ETIOLOGY

[The polyhydramnios symptom: analysis of 56 cases] Yaman C, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):287–90 (Eng. Abstr.) **(Ger)**

THERAPY

Successful outcome with serial amniocenteses for polyhydramnios complicating cystic adenomatoid malformation of the lung. Meagher SE, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):326–8

ULTRASONOGRAPHY

Prenatal diagnosis of epignathus causing acute polyhydramnios. Ekici E, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):498–501

Ultrasound diagnosis of the Pena Shokeir phenotype at 14 weeks of pregnancy. Ajayi RA, et al. **Prenat Diagn** 1995 Aug;15(8):762–4

Prenatal ultrasound findings in hydrolethalus: continuing difficulties in diagnosis. Norgard M, et al. **Prenat Diagn** 1996 Feb;16(2):173–9

[Polyhydramnios and its relationship with congenital malformations: ultrasonographic diagnosis] Gaxiola Castro R, et al. **Ginecol Obstet Mex** 1995 Dec;63:505–8 (12 ref.) (Eng. Abstr.) **(Spa)**

POLYHYDROXYETHYL METHACRYLATE

HTR polymer facial implants: a five-year clinical experience. Eppley BL, et al. **Aesthetic Plast Surg** 1995 Sep–Oct; 19(5):445–50

Dystrophic calcification of an implanted hydroxyethylmethacrylate intraocular lens. Bucher PJ, et al. **Arch Ophthalmol** 1995 Nov;113(11):1431–5

Covalent immobilization of alpha-amylase onto pHEMA microspheres: preparation and application to fixed bed reactor. Arica MY, et al. **Biomaterials** 1995 Jul;16(10):761–8

Ridge preservation: why not? Christensen GJ. **J Am Dent Assoc** 1996 May;127(5):669–70

Enhancement of mechanical strength of poly(2-hydroxyethyl methacrylate) sponges. Chirila TV, et al. **J Biomed Mater Res** 1995 Aug;29(8):1029–32

Protein A immobilized polyhydroxyethylmethacrylate beads for affinity sorption of human immunoglobulin G. Denizli A, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9; 668(1):13–9

A synthetic dural prosthesis constructed from hydroxyethylmethacrylate hydrogels. Bhatia S, et al. **J Neurosurg** 1995 Nov;83(5):897–902

ANALOGS & DERIVATIVES

Swelling/deswelling of anionic copolymer gels. Khare AR, et al. **Biomaterials** 1995 May;16(7):559–67

CHEMISTRY

Swelling/deswelling of anionic copolymer gels. Khare AR, et al. **Biomaterials** 1995 May;16(7):559–67

Artificial cornea: surface modification of silicone rubber membrane by graft polymerization of pHEMA via glow

discharge. Lee SD, et al. **Biomaterials** 1996 Mar; 17(6):587–95

Collagen and fibronectin immobilization on PHEMA microcarriers for hepatocyte attachment. Denizli A, et al. **Int J Artif Organs** 1995 Feb;18(2):90–5

Heparin–immobilized polyhydroxyethylmethacrylate microbeads for cholesterol removal: a preliminary report. Denizli A, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):157–61

POLYISOCYANATES see POLYURETHANES

POLYISOPRENYL PHOSPHATE OLIGOSACCHARIDES

IMMUNOLOGY

Oral immunoadjuvant activity of lipophilic derivatives of N–acetylglucosaminyl–beta(1—>4)–N–acetylmuramyl–L–alanyl–D–isoglutamin yl–(L)– 2,6–meso–diaminopimeric acid–(D)–amide. Ogawa T, et al. **Vaccine** 1995 Jul; 13(10):887–9

METABOLISM

Oligomannosides or oligosaccharide–lipids as potential substrates for rat liver cytosolic alpha–D–mannosidase. Grard T, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):787–92

Long–term effect of cyclic AMP on N–glycosylation is caused by an increase in the activity of the cis–prenyltransferase. Konrad M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):575–81

POLYISOPRENYL PHOSPHATE SUGARS

IMMUNOLOGY

Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)–dependent and only partially determined by the main LPS O antigen. Hormaeche CE, et al. **Vaccine** 1996 Mar;14(4):251–9

METABOLISM

Expression cloning of a novel suppressor of the Lec15 and Lec35 glycosylation mutations of Chinese hamster ovary cells. Ware FE, et al. **J Biol Chem** 1996 Jun 14; 271(24):13935–8

POLYISOPRENYL PHOSPHATES

BIOSYNTHESIS

Evidence for farnesol–mediated isoprenoid synthesis regulation in a halophilic archaeon, Haloferax volcanii. Tachibana A, et al. **FEBS Lett** 1996 Jan 22;379(1):43–6

Developmental and stress regulation of gene expression for plastid and cytosolic isoprenoid pathways in pepper fruits. Hugueney P, et al. **Plant Physiol** 1996 Jun;111(2):619–26

CHEMISTRY

Interaction of undecaprenyl phosphate with phospholipid bilayers. Janas T, et al. **Chem Phys Lipids** 1995 Aug 1; 77(1):89–97

METABOLISM

Cloning, expression, and characterization of (+)–delta–cadinene synthase: a catalyst for cotton phytoalexin biosynthesis. Chen XY, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):255–66

Compartmentalization of cholesterol biosynthesis. Conversion of mevalonate to farnesyl diphosphate occurs in the peroxisomes. Biardi L, et al. **J Biol Chem** 1996 Jan 19;271(3):1784–8

The farnesyl group of H–Ras facilitates the activation of a soluble upstream activator of mitogen–activated protein kinase. McGeady P, et al. **J Biol Chem** 1995 Nov 3; 270(44):26347–51

PHARMACOLOGY

Effects of N–3554S, a polyprenyl phosphate, on B16–F10 mouse melanoma cells. Shirane K, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):285–92

Geranylgeranyl diphosphate–based inhibitors of post–translational geranylgeranylation of cellular proteins. Macchia M, et al. **J Med Chem** 1996 Mar 29;39(7):1352–6

POLYKARYOCYTES see GIANT CELLS

POLYLYSINE

Glycosylated polylysine/DNA complexes: gene transfer efficiency in relation with the size and the sugar substitution level of glycosylated polylysines and with the plasmid size. Erbacher P, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):401–10

N epsilon–cyclosuccinyllysine: synthesis and formation from hemisuccinylated polylysine and its hapten conjugates with sulfamethoxazole during acid hydrolysis. Ressler C, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):82–7

Glycol methacrylate embedding of alginate–polylysine microencapsulated pancreatic islets. Fritschy WM, et al. **Biotech Histochem** 1995 Jul;70(4):188–93

Use of polylysine in solid–phase protein sequencing. Beg OU. **Biotechniques** 1995 Dec;19(6):876–80

Transgenesis in mice by cytoplasmic injection of polylysine/DNA mixtures. Page RL, et al. **Transgenic Res** 1995 Nov;4(6):353–60

ADMINISTRATION & DOSAGE

Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus–polylysine complexes. Ebbinghaus SW, et al. **Gene Ther** 1996 Apr;3(4):287–97

ANALOGS & DERIVATIVES

Gamma scintigraphy of 111In–labelled branched chain polypeptides (BCP) with a poly(L–lysine) backbone in mice with mammary carcinoma: effect of charge on biodistribution and tumour imaging potential. Pimm MV, et al. **Ann Nucl Med** 1995 Nov;9(4):247–51

Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Wong JP, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2574–6

Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly–L–lysine and administered by intramuscular route. Fiume L, et al. **Hepatology** 1995 Oct; 22(4 Pt 1):1072–7

Comparison of gadolinium–DTPA and polylysine–gadolinium–DTPA—enhanced magnetic resonance imaging of hepatocarcinoma in the rat. Grandin C, et al. **Invest Radiol** 1995 Oct;30(10):572–81

Liver targeting of adenine arabinoside monophosphate (ara–AMP) by coupling to lactosaminated human serum albumin. Fiume L, et al. **Ital J Gastroenterol** 1995 May; 27(4):189–92

Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. Puri SK, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):49–52

Acute occlusive ischemia of the rat intestine: early detection by MR imaging with polylysine–Gd–DTPA enhancement. Van Beers BE, et al. **J Magn Reson Imaging** 1995 Sep–Oct; 5(5):509–13

Myocardial perfusion and function in dogs with moderate coronary stenosis. Kraitchman DL, et al. **Magn Reson Med** 1996 May;35(5):771–80

Fate of DNA targeted to hepatocytes by asialoglycoprotein polylysine conjugates. Wu GW, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):211–7

Inflammation: imaging with methoxy poly(ethylene glycol)–poly–L–lysine–DTPA, a long–circulating graft copolymer. Gupta H, et al. **Radiology** 1995 Dec; 197(3):665–9

Membrane compactness affects the integrity and immunoprotection of alginate–poly–L–lysine–alginate microcapsules. Hsu BR, et al. **Transplant Proc** 1995 Dec; 27(6):3227–31

[Experimental evaluation of contrast medium enhanced high resolution MR angiography in the animal model. Gd–DTPA compared with Gd–DTPA–polylysine] Vogl TJ, et al. **Radiologe** 1996 Mar;36(3):254–62 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Surface modifications of alginate/poly(L–lysine) microcapsular membranes with poly(ethylene glycol) and poly(vinyl alcohol). Kung IM, et al. **Biomaterials** 1995 May; 16(8):649–55

Glycerol enhancement of ligand–polylysine/DNA transfection. Zauner W, et al. **Biotechniques** 1996 May; 20(5):905–13

Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA. Wolfert MA, et al. **Gene Ther** 1996 Mar;3(3):269–73

Inhibition of pulmonary surfactant biophysical activity by cationic polyamino acids. Bummer PM, et al. **Pharm Res** 1995 Nov;12(11):1658–63

Investigation of light–induced conformation changes in spiropyran–modified succinylated poly(L–lysine). Cooper TM, et al. **Photochem Photobiol** 1995 Aug;62(2):258–62

DIAGNOSTIC USE

Reperfused ischemia of the rat intestine: detection by MR imaging with polylysine–Gd–DTPA enhancement. Mottet I, et al. **Magn Reson Med** 1996 Jan;35(1):131–5

GENETICS

Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus–polylysine–DNA complexes. Scaria A, et al. **Gene Ther** 1995 Jun;2(4):295–8

METABOLISM

Oligonucleotide targeting to alveolar macrophages by mannose receptor–mediated endocytosis. Liang WW, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):227–34

PHARMACOKINETICS

Biodistribution in tumour–bearing mice of polycationic, amphoteric and polyanionic branched polypeptides with a poly(L–lysine) backbone labelled with 125I and 111In: tumour accumulation less than that of labelled serum proteins. Pimm MV, et al. **J Cancer Res Clin Oncol** 1996; 122(1):45–54

PHARMACOLOGY

Potentiation of cationic liposome–mediated gene delivery by polycations. Gao X, et al. **Biochemistry** 1996 Jan 23; 35(3):1027–36

Mechanism of liposome destabilization by polycationic amino acids. Epand RM, et al. **Biosci Rep** 1995 Jun;15(3):151–60

Polylysine enhances cationic liposome–mediated transfection of the hepatoblastoma cell line Hep G2. Mack KD, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):217–20

Polylysine cross–links axoplasmic neurofilaments into tight bundles. Brown A, et al. **Cell Motil Cytoskeleton** 1995; 31(1):9–21

High sensitivity of Mycobacterium species to the bactericidal activity by polylysine. Delihas N, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):233–7

Killing of Schistosoma mansoni sporocysts by Biomphalaria glabrata hemolymph in vitro: alteration of hemocyte behavior after poly–L–lysine treatment of plastic, and the kinetics of killing by different host strains. Boehmler AM, et al. **J Parasitol** 1996 Apr;82(2):332–5

RADIATION EFFECTS

Raman spectroscopic evidence for structural changes in poly–L–lysine induced by an approximately 50 mT static magnetic field. Verma SP, et al. **Bioelectromagnetics** 1996; 17(1):33–6

Investigation of light–induced conformation changes in spiropyran–modified succinylated poly(L–lysine). Cooper TM, et al. **Photochem Photobiol** 1995 Aug;62(2):258–62

POLYMENORRHEA see MENSTRUATION DISORDERS

POLYMERASE CHAIN REACTION

see related

SEQUENCE TAGGED SITES

A study of the steroid sulfatase gene in families with X–linked ichthyosis using polymerase chain reaction. Nomura K, et al. **Acta Derm Venereol** 1995 Sep;75(5):340–2

IgA2 genotyping by polymerase chain reaction (PCR) using allele–specific amplification primers. Takata S, et al. **Acta Med Okayama** 1996 Feb;50(1):1–9

In situ polymerase chain reaction detection of HTLV–I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T cell leukemia. Higuchi I, et al. **Acta Neuropathol (Berl)** 1995;90(3):323–7

Specific fingerprinting of nematodes by PCR with single primers to defined repetitive elements. Gasser RB, et al. **Acta Trop** 1995 Oct;60(2):127–31

A highly sensitive and rapid procedure for direct PCR detection of Leishmania infantum within human peripheral blood mononuclear cells. Ravel S, et al. **Acta Trop** 1995 Jun;59(3):187–96

Lymphokine mRNA expression in the human intestinal mucosa and PBL determined by quantitative RT/PCR. Braun–Elwert L, et al. **Adv Exp Med Biol** 1995;371A:27–30

Useful mutants of Zymomonas mobilis alcohol dehydrogenase–2 obtained by the use of polymerase chain reaction random mutagenesis. Rellos P, et al. **Adv Exp Med Biol** 1995;372:435–40

The sensitivity of HIV–1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra–uterine and intra–partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)

Detection of HIV–1 in surgical specimens from vitreous of AIDS patients [letter] Flynn TE, et al. **AIDS** 1995 Sep; 9(9):1103–4

Polymerase chain reaction–based K–ras mutation detection of pancreatic adenocarcinoma in routine cytology smears [see comments] Apple SK, et al. **Am J Clin Pathol** 1996 Mar;105(3):321–6. Comment in: Am J Clin Pathol 1996 Mar;105(3):257–9.

Clinical significance of a polymerase chain reaction assay for the detection of Mycobacterium tuberculosis. Choi YJ, et al. **Am J Clin Pathol** 1996 Feb;105(2):200–4

Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin's disease. Kamel OW, et al. **Am J Clin Pathol** 1995 Oct;104(4):419–23

Reverse transcriptase–polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia. Wells SJ, et al. **Am J Clin Pathol** 1996 Jun;105(6):756–60

Detection of human papillomavirus in extragenital Bowen's disease using in situ hybridization and polymerase chain reaction. Collina G, et al. **Am J Dermatopathol** 1995 Jun; 17(3):236–41

Erythema induratum of Bazin. A clinicopathological study of 20 cases and detection of Mycobacterium tuberculosis DNA in skin lesions by polymerase chain reaction. Schneider JW, et al. **Am J Dermatopathol** 1995 Aug; 17(4):350–6

Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using

competitive PCR. Hayashi J, et al. **Am J Gastroenterol** 1996 Feb;91(2):314–8

Choice of HCV RNA level determination [letter] Yarze JC, et al. **Am J Gastroenterol** 1996 Aug;91(8):1667

Quantitative analysis of MDR–1 gene expression in acute myeloid leukemia by reverse transcription polymerase chain reaction [letter] Cao QX, et al. **Am J Hematol** 1996 Aug;52(4):329

Clearance of PCR–detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath–1H [letter] DelleKarth G, et al. **Am J Hematol** 1995 Oct;50(2):146–7

Analysis of chimerism by PCR using mutant–specific primers and sequencing of B–gene region after allogenic bone marrow transplantation in sickle cell anemia [letter] Gürgey A, et al. **Am J Hematol** 1995 Dec;50(4):318–9

Bloodstream invasion in early Lyme disease: results from a prospective controlled blinded study using the polymerase chain reaction. **Am J Med** 1996 Aug;101(2):239

Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction: a study of 34 cases diagnosed in fetuses. Tanemura M, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):578–82

Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma. Shipley J, et al. **Am J Pathol** 1996 Feb;148(2):559–67

A rapid and safe method to detect fetal parvovirus B19 infection in amniotic fluid by polymerase chain reaction: report of a case. Nikkari S, et al. **Am J Perinatol** 1995 Nov;12(6):447–9

Rapid diagnosis of pleural tuberculosis by polymerase chain reaction. Querol JM, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1977–81

Polymerase chain reaction detection of Mycobacterium tuberculosis in formalin–fixed tissue. Rish JA, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1419–23

Short report: development of a new diagnostic method for Plasmodium falciparum infection using a reverse transcriptase–polymerase chain reaction. Abdullah NR, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):162–3

Comparison of the polymerase chain reaction and serology for the detection of canine visceral leishmaniasis. Ashford DA, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):251–5

A rapid, highly sensitive method for the detection of Francisella tularensis in clinical samples using the polymerase chain reaction. Fulop M, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):364–6

Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Roper C, et al. **Am J Trop Med Hyg** 1996 Apr; 54(4):325–31

Polymerase chain reaction for diagnosis and identification of distinct variants of Crimean–Congo hemorrhagic fever virus in the United Arab Emirates. Schwarz TF, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):190–6

Polymerase chain reaction–based technique for the detection of Wuchereria bancrofti in human blood samples, hydrocele fluid, and mosquito vectors. Siridewa K, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):72–6

Short report: polymerase chain reaction detection of hepatitis E virus in north African fecal samples. van Cuyck–Gandre H, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):134–5

A polymerase chain reaction assay for detection of the parasite Wuchereria bancrofti in human blood samples. Zhong M, et al. **Am J Trop Med Hyg** 1996 Apr; 54(4):357–63

A competitive single–step reverse transcriptase–polymerase chain reaction assay for quantification of heme oxygenase 1. Ahmed AH, et al. **Anal Biochem** 1996 May 15; 237(1):149–52

Analysis of polymerase chain reaction–amplified DNA products by mass spectrometry using matrix–assisted laser desorption and electrospray: current status. Doktycz MJ, et al. **Anal Biochem** 1995 Sep 20;230(2):205–14

Polymerase chain reaction–based site–directed mutagenesis using magnetic beads. Fieschi J, et al. **Anal Biochem** 1996 Feb 15;234(2):210–4

Processed pseudogenes interfere with reverse transcriptase–polymerase chain reaction controls. Garbay B, et al. **Anal Biochem** 1996 May 15;237(1):157–9

Single–step, ligase–free cloning of polymerase chain reaction products into any restriction site of any DNA plasmid. Garcés C, et al. **Anal Biochem** 1995 Sep 1;230(1):178–80

Inter–Alu polymerase chain reaction: advancements and applications. Kass DH, et al. **Anal Biochem** 1995 Jul 1; 228(2):185–93 (65 ref.)

A one–step polymerase chain reaction site–directed mutagenesis method for large gene–cassettes with high efficiency, yield, and fidelity. Ling M, et al. **Anal Biochem** 1995 Sep 1;230(1):167–72

PCR amplification of a polymorphic minisatellite VNTR locus in whiting (Merlangius merlangus L.). McGregor D, et al. **Anim Genet** 1996 Feb;27(1):49–51

PCR–SSCP in the ovine calpastatin gene. Roberts N, et al. **Anim Genet** 1996 Jun;27(3):211

Quantitation of hepatitis C viraemia by a competitive reverse transcription–polymerase chain reaction system. Lee AS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):98–102

Ocular Lyme borreliosis diagnosed by polymerase chain reaction on vitreous fluid [letter] Hilton E, et al. **Ann Intern Med** 1996 Sep 1;125(5):424–5

Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta–analysis with recommendations for clinical practice and study design. Owens DK, et al. **Ann Intern Med** 1996 May 1;124(9):803–15

Development of the antibody repertoire as revealed by single–cell PCR of FACS–sorted B–cell subsets. Kantor AB, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:224–7

Malignant catarrhal fever virus. Characterization of a United States isolate and development of diagnostic assays. Li H, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:198–210

Localization of HIV–1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Takahashi K, et al. **Ann Neurol** 1996 Jun;39(6):705–11

Polymerase chain reaction in situ hybridization—opening Pandora's box? [editorial] Wiley CA. **Ann Neurol** 1996 Jun; 39(6):691–2

Identification of some ectomycorrhizal basidiomycetes by PCR amplification of their gpd (glyceraldehyde–3–phosphate dehydrogenase) genes. Kreuzinger N, et al. **Appl Environ Microbiol** 1996 Sep; 62(9):3432–8

Single–strand conformation polymorphism analysis of PCR–amplified ribosomal DNA internal transcribed spacers to differentiate species of Aspergillus section Flavi. Kumeda Y, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2947–52

Detection of Cryptosporidium parvum in raw milk by PCR and oligonucleotide probe hybridization. Laberge I, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3259–64

PCR–restriction fragment length polymorphism identification and host range of single–spore isolates of the flexible Frankia sp. strain UFI 132715. Lumini E, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3026–9

IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows' milk in England and Wales. Millar D, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3446–52

Genetic relationships among strains of Xanthomonas fragariae based on random amplified polymorphic DNA PCR, repetitive extragenic palindromic PCR, and enterobacterial repetitive intergenic consensus PCR data and generation of multiplexed PCR primers useful for the identification of this phytopathogen. Pooler MR, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3121–7

Detection of aflatoxigenic molds in grains by PCR. Shapira R, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3270–3

Phytoplasma–specific PCR primers based on sequences of the 16S–23S rRNA spacer region. Smart CD, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2988–93

Detection of a single viable Cryptosporidium parvum oocyst in environmental water concentrates by reverse transcription–PCR. Stinear T, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3385–90

An improved strategy for HLA–DRB1 subtyping by digestion of PCR–amplified DNA with allele–specific restriction endonucleases. Danzé PM, et al. **Appl Theor Electrophor** 1995;5(1):7–13

Chronic lupoid leishmaniasis. Evaluation by polymerase chain reaction. Momeni AZ, et al. **Arch Dermatol** 1996 Feb;132(2):198–202

Spatial and temporal distribution of sonic hedgehog mRNA in the embryonic mouse mandible by reverse transcription/polymerase chain reaction and in situ hybridization analysis. Kronmiller JE, et al. **Arch Oral Biol** 1995 Sep;40(9):831–8

In search of the Holy Grail [editorial; comment] Oleske JM. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):39. Comment on: Arch Pediatr Adolesc Med 1996 Jan;150(1):40–5.

Polymerase chain reaction detection of the hemagglutinin gene from an attenuated measles vaccine strain in the peripheral mononuclear cells of children with autoimmune hepatitis. Kawashima H, et al. **Arch Virol** 1996; 141(5):877–84

Characterization of component–I gene of botulinum C2 toxin and PCR detection of its gene in clostridial species. Fujii N, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):353–9

The Na–K–Cl cotransporters in the rat cochlea: RT–PCR and partial sequence analysis. Hidaka H, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):425–30

Long–PCR of the ANP gene and PCR–SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172–8

Novel use of limited primer extension in detecting mutations in human iduronate 2–sulfatase gene. Li P, et al. **Biochem Mol Biol Int** 1995 May;35(6):1299–305

Amplification and sequence of a 5s–rRNA gene spacer region from the crude drug "angelica root". Mizukami H. **Biol Pharm Bull** 1995 Sep;18(9):1299–301

The genes encoding the 5HT1D alpha and 5HT1D beta receptors are unchanged in patients with panic disorder. Ohara K, et al. **Biol Psychiatry** 1996 Jan 1;39(1):5–10

Automated DNA purification and amplification from blood–stained cards using a robotic workstation. Belgrader P, et al. **Biotechniques** 1995 Sep;19(3):426–32

Elimination of plasmid contamination from plant genomic DNA samples prior to PCR amplification of genes. Chen W, et al. **Biotechniques** 1995 Oct;19(4):536–8

High–throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Day IN, et al. **Biotechniques** 1995 Nov;19(5):830–5

Ligation– and PCR–based method for sequencing plasmid inserts. Goldsborough AS, et al. **Biotechniques** 1995 Dec; 19(6):910–2

PCR screening of transgenic RAG–2 "knockout" immunodeficient mice. Horton RM, et al. **Biotechniques** 1995 Nov;19(5):690–1

Elimination of false–positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples. Jiang G, et al. **Biotechniques** 1995 Oct;19(4):566–8

Generation of diverse single–chain proteins using a universal (Gly4–Ser)3 encoding oligonucleotide. Lake DF, et al. **Biotechniques** 1995 Nov;19(5):700–2

PCR colony screening using the scintillation proximity assay to detect inserts in cloning vectors. Lerner CG, et al. **Biotechniques** 1995 Dec;19(6):914–7

Identification and cloning of integration site of DNA by PCR. Li SW, et al. **Biotechniques** 1996 Mar;20(3):356–8

Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Meyer T, et al. **Biotechniques** 1995 Oct;19(4):632–9

Mini–preparation of total RNA for RT–PCR from cultured human cells. Ogretmen B, et al. **Biotechniques** 1995 Sep; 19(3):374–6

Anomalies in direct pair–wise comparisons of RAPD fragments for genetic analysis. Pillay M, et al. **Biotechniques** 1995 Nov;19(5):694–6, 698

Chemiluminescent and colorimetric enzymatic assays for the detection of PCR–amplified Salmonella sp. products in microplates. Soumet C, et al. **Biotechniques** 1995 Nov; 19(5):792–6

Discriminating PCR artifacts using directed heteroduplex analysis (DHDA). Tang J, et al. **Biotechniques** 1995 Dec; 19(6):902–5

Single–step protocol for preparation of plant tissue for analysis by PCR. Thomson D, et al. **Biotechniques** 1995 Sep;19(3):394–7, 400

Efficient automated large–scale sequencing of unpurified PCR product. Tsui SK, et al. **Biotechniques** 1995 Oct; 19(4):577–8

PCR–based identification of AT–rich tri– and tetranucleotide repeat loci in an enriched plasmid library. Waldbieser GC. **Biotechniques** 1995 Nov;19(5):742–4

Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Frankenberger M, et al. **Blood** 1996 Jan 1;87(1):373–7

ABO glycosyltransferase genotyping by polymerase chain reaction using sequence–specific primers. Gassner C, et al. **Blood** 1996 Sep 1;88(5):1852–6

Analysis of rearranged T–cell receptor beta–chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Kneba M, et al. **Blood** 1995 Nov 15;86(10):3930–7

High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase–polymerase chain reaction, and P–80 immunostaining. Lamant L, et al. **Blood** 1996 Jan 1; 87(1):284–91

Dynamic changes in the locus control region of erythroid progenitor cells demonstrated by polymerase chain reaction. Yoo J, et al. **Blood** 1996 Mar 15;87(6):2558–67

Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Zhang JG, et al. **Blood** 1996 Mar 15;87(6):2588–93

Hepatitis A virus and polymerase chain reaction amplification: methodology and results. Robertson BH, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S27–31

Significance of CMV DNA PCR results in bone marrow transplant recipients [letter; comment] Koehler M, et al. **Bone Marrow Transplant** 1996 Mar;17(3):465–6. Comment on: Bone Marrow Transplant 1995 Apr;15(4):611–7.

PCR amplification of short tandem repeat sequences allows serial studies of chimaerism/engraftment following BMT in rodents. O'Neill PA, et al. **Bone Marrow Transplant** 1996 Feb;17(2):265–71

Molecular detection and serotypic analysis of enterovirus RNA in archival specimens from patients with acute myocarditis. Nicholson F, et al. **Br Heart J** 1995 Nov; 74(5):522–7

Analysis of cAMP RI alpha mRNA expression in breast cancer: evaluation of quantitative polymerase chain reaction for routine use. Bartlett JM, et al. **Br J Cancer** 1996 Jun;73(12):1538–44

Detection of circulating prostate–specific antigen–positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Fadlon EJ, et al. **Br J Cancer** 1996 Aug;74(3):400–5

Orificial tuberculosis: detection by polymerase chain reaction. Nachbar F, et al. **Br J Dermatol** 1996 Jul;135(1):106–9

t(8;21) detection by RT–PCR: an improved primer set convenient for the routine laboratory. Lynas C, et al. **Br J Haematol** 1995 Dec;91(4):924–6

Diagnostic assays in cytomegalovirus retinitis: detection of herpesvirus by simultaneous application of the polymerase chain reaction and local antibody analysis on ocular fluid [see comments] Doornenbal P, et al. **Br J Ophthalmol** 1996

Mar;80(3):235–40. Comment in: Br J Ophthalmol 1996 Mar;80(3):195–6.

The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase–polymerase chain reaction [letter] Hoon DS, et al. **Cancer** 1995 Aug 1;76(3):533–5

Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Iwasawa A, et al. **Cancer** 1996 Jun 1; 77(11):2275–9

Clonality analysis of B-lymphoid proliferations using the polymerase chain reaction [see comments] Lozano MD, et al. **Cancer** 1996 Apr 1;77(7):1349–55. Comment in: Cancer 1996 Apr 1;77(7):1223–5.

Utility of polymerase chain reaction in detecting B-cell clonality in lymphoid neoplasms [editorial; comment] Tbakhi A, et al. **Cancer** 1996 Apr 1;77(7):1223–5. Comment on: Cancer 1996 Apr 1;77(7):1349–55.

Detection of residual leukemic cells in acute lymphocytic leukemia of B-cells (B-ALL) by a nonradioactive PCR-based technique. Lendeckel U, et al. **Cancer Detect Prev** 1996;20(3):185–92

Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. Dalhoff K, et al. **Chest** 1996 Aug;110(2):351–6

Reliability of the polymerase chain reaction in the diagnosis of mycobacterial infection [letter; comment] García JE, et al. **Chest** 1996 Jul;110(1):300–1. Comment on: Chest 1995 Nov;108(5):1393–404.

Applications and limitations of polymerase chain reaction amplification [see comments] Ma TS. **Chest** 1995 Nov; 108(5):1393–404 (112 ref.). Comment in: Chest 1996 Jul;110(1):300–1.

Mapping of murine YACs containing the genes Cea2 and Cea4 after B1-PCR amplification and FISH-analysis. Rettenberger G, et al. **Chromosome Res** 1995 Dec; 3(8):473–8

A young adult with tuberculous meningitis diagnosed by polymerase chain reaction on serial CSF samples: a case report. Lin JJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Aug;56(2):134–8

Platelet-derived growth factor-A mRNA expression in fetal, normal adult, and atherosclerotic human aortas. Analysis by competitive polymerase chain reaction. Murry CE, et al. **Circulation** 1996 Mar 15;93(6):1095–106

Direct solid-phase sequence analysis of the human p53 gene by use of multiplex polymerase chain reaction and alpha-thiotriphosphate nucleotides [see comments] Berg C, et al. **Clin Chem** 1995 Oct;41(10):1461–6. Comment in: Clin Chem 1995 Oct;41(10):1407–9.

Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry. Galvan B, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1705–9

Rapid detection of the G1691A mutation of coagulation factor V by PCR-mediated site-directed mutagenesis. Guillerm C, et al. **Clin Chem** 1996 Feb;42(2):329

Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen [editorial; comment] Heston WD. **Clin Chem** 1995 Dec;41(12 Pt 1):1687–8. Comment on: Clin Chem 1995 Dec;41(12 Pt 1):1698–704.

Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen [see comments] Loric S, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1698–704. Comment in: Clin Chem 1995 Dec;41(12 Pt 1):1687–8.

Preimplantation diagnosis by whole-genome amplification, PCR amplification, and solid-phase minisequencing of blastomere DNA. Paunio T, et al. **Clin Chem** 1996 Sep; 42(9):1382–90

Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Pelkey TJ, et al. **Clin Chem** 1996 Sep;42(9):1369–81 (163 ref.)

HCV-RNA detection using different PCR methods in sera, cryoglobulins and peripheral blood mononuclear cells of patients with mixed cryoglobulinemia. de Maddalena C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S119–22

Use of the polymerase chain reaction and DNA sequencing for detection of Bartonella quintana in the aortic valve of a patient with culture-negative infective endocarditis. Jalava J, et al. **Clin Infect Dis** 1995 Oct;21(4):891–6

Involvement of synthesis and degradation pathways of collagen type IV in human glomerulosclerosis: molecular analysis by in situ reverse transcription and competitive polymerase chain reaction. Esposito C, et al. **Contrib Nephrol** 1996;118:12–6

The polymerase chain reaction: applications for the detection of foodborne pathogens. Hill WE. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):123–73 (294 ref.)

The challengers to PCR: a proliferation of chain reactions. Landegren U. **Curr Opin Biotechnol** 1996 Feb;7(1):95–7 (16 ref.)

Modern management of Rhesus disease. Yankowitz J, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):139–41

Application of DNA-based technologies in the diagnosis of sexually transmitted diseases. Mårdh PA, et al. **Curr Probl Dermatol** 1996;24:174–83 (43 ref.)

Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR). King A, et al. **Cytokine** 1995 May;7(4):364–71

Detection of common viruses using the polymerase chain reaction to assess levels of viral presence in type 1 (insulin-dependent) diabetic patients. Foy CA, et al. **Diabet Med** 1995 Nov;12(11):1002–8

Use of nondenaturing silver-stained polyacrylamide gel analysis of polymerase chain reaction amplification products for the differential diagnosis of Leptospira interrogans infection. Oliveira MA, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):343–8

Automation of polymerase chain reaction tests. Reduction of human errors leading to contamination. Wilke WW, et al. **Diagn Microbiol Infect Dis** 1995 Apr;21(4):181–5

Comparison of serologic analysis and in situ localization of PCR-amplified cDNA for the diagnosis of hepatitis C infection. Lidonnici K, et al. **Diagn Mol Pathol** 1995 Jun; 4(2):98–107

No Mycobacterium paratuberculosis found in Crohn's disease using polymerase chain reaction. Dumonceau JM, et al. **Dig Dis Sci** 1996 Feb;41(2):421–6

Rapid typing of variable number of tandem repeat locus in the human apolipoprotein B gene for DNA diagnosis of heart disease by polymerase chain reaction and capillary electrophoresis. Baba Y, et al. **Electrophoresis** 1995 Aug; 16(8):1437–40

Simple protocols for typing forensic biological evidence: chemiluminescent detection for human DNA quantitation and restriction fragment length polymorphism (RFLP) analyses and manual typing of polymerase chain reaction (PCR) amplified polymorphisms. Budowle B, et al. **Electrophoresis** 1995 Sep;16(9):1559–67

Flanking region sequences and internal repeat structure of the pYNH24 (D2S44) 2 kbp insert analyzed by polymerase chain reaction and partial digestion with RsaI. Holmlund G, et al. **Electrophoresis** 1995 Oct;16(10):1881–5

Polymerase chain reaction-based assays for the characterisation of plant genetic resources. Powell W, et al. **Electrophoresis** 1995 Sep;16(9):1726–30 (36 ref.)

Genotyping of human deoxyribonuclease I polymorphism by the polymerase chain reaction. Yasuda T, et al. **Electrophoresis** 1995 Oct;16(10):1889–93

The sequence of arrestins from rod and cone photoreceptors in the frogs Rana catesbeiana and Rana pipiens. Localization of gene transcripts by reverse-transcription polymerase chain reaction on isolated photoreceptors. Abdulaeva G, et al. **Eur J Biochem** 1995 Dec 1; 234(2):437–42

Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients. Schwürzer-Voit M, et al. **Eur J Cancer** 1996 Feb; 32A(2):264–8

Comparison of two PCR-based assays for detecting Mycoplasma genitalium in clinical specimens [letter] Deguchi T, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):629–31

An approach to the identification of the pathogens of bacterial meningitis by the polymerase chain reaction. Hall LM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec; 14(12):1090–4

Detection of HIV-1 proviral sequences in lymphocytes using a qualitative polymerase chain reaction assay. Marin MG, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):621–5

Detection of pathogenic fungi in human blood by the polymerase chain reaction. Polanco AM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):618–21

Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. Romano L, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov; 14(11):1011–14

Detection of Mycobacterium tuberculosis complex in clinical specimens by a commercial polymerase chain reaction kit. Stauffer F, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec; 14(12):1046–51

Evaluation of a commercial polymerase chain reaction assay for Chlamydia trachomatis and suggestions for improving sensitivity. Thomas BJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):719–23

Evaluation of pulsed-field gel electrophoresis and rep-PCR for the epidemiological analysis of Ochrobactrum anthropi strains. van Dijck P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1099–1102

Development of a rapid PCR method for identification of Helicobacter pylori in dental plaque and gastric biopsy specimens. Wahlfors J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):780–6

Quantification of Coxiella burnetii by polymerase chain reaction (PCR) and a colorimetric microtiter plate hybridization assay (CMHA). Fritz E, et al. **Eur J Epidemiol** 1995 Oct;11(5):549–57

Detection and identification of cagA of Helicobacter pylori by polymerase chain reaction. Awakawa T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S75–8

DNA forensic science 1995. Morton NE. **Eur J Hum Genet** 1995;3(2):139–44

Determination of DQB1 alleles using PCR amplification and allele-specific primers. Lepage V, et al. **Eur J Immunogenet** 1995 Oct;22(5):413–22

Multiplex ARMS-PCR-RFLP method for high-resolution typing of HLA-DRB1. Mitsunaga S, et al. **Eur J Immunogenet** 1995 Oct;22(5):371–92

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s–700s (95 ref.)

A highly sensitive polymerase chain reaction method reveals the ubiquitous presence of maternal cells in human umbilical cord blood. Petit T, et al. **Exp Hematol** 1995 Dec;23(14):1601–5

Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells. Schulze E, et al. **Exp Hematol** 1995 Dec; 23(14):1649–54

Onchocerca volvulus: development of a species specific polymerase chain reaction-based assay. Merriweather A, et al. **Exp Parasitol** 1996 Jun;83(1):164–6

Quantification of aminopeptidase N mRNA in T cells by competitive PCR. Wex T, et al. **FEBS Lett** 1995 Nov 6; 374(3):341–4

Rapid identification of Streptococcus pneumoniae by PCR amplification of ribosomal DNA spacer region. Saruta K, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):165–70

Birth of a healthy girl after preimplantation gender determination using a combination of polymerase chain reaction and fluorescent in situ hybridization analysis. Preimplantation Genetics Group. Verlinsky Y, et al. **Fertil Steril** 1996 Feb;65(2):358–60

Management of platelet and RhD maternal immunizations by PCR phenotypings after early amniocentesis. Sagot P, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):373–80

PCR DNA typing of stamps: evaluation of the DNA extraction. Fridez F, et al. **Forensic Sci Int** 1996 Apr 2; 78(2):103–10

Analysis of the D1S80 (pMCT118) VNTR locus polymorphism in a native Kuwaiti population by the polymerase chain reaction. al-Nassar KE, et al. **Forensic Sci Int** 1996 Apr 2;78(2):131–8

Distribution of the AMPFLPs YNZ22, 3'Apob and COL2A1 in the population of Galicia (NW Spain). Pestoni C, et al. **Forensic Sci Int** 1996 Jul 12;80(3):175–88

The iron-containing superoxide dismutase-encoding gene from Chlamydomonas reinhardtii obtained by direct and inverse PCR. Chen H, et al. **Gene** 1996 Feb 2;168(1):113–6

Template secondary structure can increase the error frequency of the DNA polymerase from Thermus aquaticus. Loewen PC, et al. **Gene** 1995 Oct 16;164(1):59–63

Creating seamless junctions independent of restriction sites in PCR cloning. Padgett KA, et al. **Gene** 1996 Feb 2; 168(1):31–5

Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Brothman AR, et al. **Genes Chromosomes Cancer** 1995 Aug; 13(4):278–84

Comparison of the Amplicor Chlamydia trachomatis test and cell culture for the detection of urogenital chlamydial infections. Catry MA, et al. **Genitourin Med** 1995 Aug; 71(4):247–50

Restriction fragment length polymorphisms in polymerase chain reaction amplified ribosomal DNAs of three Trichogramma (Hymenoptera: Trichogrammatidae) species. Sappal NP, et al. **Genome** 1995 Jun;38(3):419–25

A 37-marker PCR-based genetic linkage map of human chromosome 9: observations on mutations and positive interference. Zahn LM, et al. **Genomics** 1995 Jul 20; 28(2):140–6

Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction. Rowbotham DS, et al. **Gut** 1995 Nov;37(5):660–7

Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Wong YF, et al. **Gynecol Obstet Invest** 1995;40(3):209–12

Nonradioactive detection of monoclonal immunoglobulin heavy chain gene rearrangement with PCR-SSCP. Thunberg U, et al. **Hematol Pathol** 1995;9(3–4):141–53

A noninvasive 'swish and spit' method for collecting nucleated cells for HLA typing by PCR in population studies. Hayney MS, et al. **Hum Hered** 1996 Mar–Apr; 46(2):108–11

Polymerase chain reaction analysis of the Xba I polymorphism of the human complement C4 genes provides evidence for strong haplotype conservation. Witzel K, et al. **Hum Immunol** 1995 Jul;43(3):165–73

Diagnosis of congenital syphilis from placental examination: comparison of histopathology, Steiner stain, and polymerase chain reaction for Treponema pallidum DNA. Genest DR, et al. **Hum Pathol** 1996 Apr;27(4):366–72

Allelic drop-out and preferential amplification in single cells and human blastomeres: implications for preimplantation diagnosis of sex and cystic fibrosis. Findlay I, et al. **Hum Reprod** 1995 Jun;10(6):1609–18

Simultaneous amplification of the two most frequent mutations of infantile Tay-Sachs disease in single blastomeres. Sermon K, et al. **Hum Reprod** 1995 Aug; 10(8):2214–7

The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Soeth E, et al. **Int J Cancer** 1996 Aug 22;69(4):278–82

Significance of detection of enterovirus RNA in myocardial tissues by reverse transcription-polymerase chain reaction.

Ueno H, et al. **Int J Cardiol** 1995 Sep;51(2):157–64

The use of a PCR-generated invA probe for the detection of Salmonella spp. in artificially and naturally contaminated foods. Bülte M, et al. **Int J Food Microbiol** 1995 Aug; 26(3):335–44

Probes and polymerase chain reaction for detection of food-borne bacterial pathogens. Olsen JE, et al. **Int J Food Microbiol** 1995 Nov;28(1):1–78 (331 ref.)

Analysis of a short tandem repeat locus on chromosome 19 (D19S253). De Stefano F, et al. **Int J Legal Med** 1996; 108(5):256–8

Validation of mitochondrial DNA sequencing for forensic casework analysis. Wilson MR, et al. **Int J Legal Med** 1995; 108(2):68–74

Hungarian population data on the loci HLA-DQ alpha, LDLR, GYPA, HBGG, D7S8 and GC. Woller J, et al. **Int J Legal Med** 1996;108(5):280–2

Detection of Mycobacterium leprae in nerve lesions by the polymerase chain reaction. Chemouilli P, et al. **Int J Lepr Other Mycobact Dis** 1996 Mar;64(1):1–5

Comparison of Mycobacterium 23S rRNA sequences by high-temperature reverse transcription and PCR. Stone BB, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):811–9

A new approach to primer selection in polymerase chain reaction experiments. Pearson WR, et al. **Ismb** 1995; 3:285–91

False-positive polymerase chain reaction results for human papillomavirus in lichen planus. Potential laboratory pitfalls of this procedure. Boyd AS, et al. **J Am Acad Dermatol** 1996 Jul;35(1):42–6

PCR inhibition assay for DNA-targeted antibiotics. Hotta K, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1267–72

Polymerase chain reaction-restriction fragment length polymorphism analysis: a simple method for species identification in food. Meyer R, et al. **J AOAC Int** 1995 Nov–Dec;78(6):1542–51

Multiplex polymerase chain reaction to detect toxigenic Vibrio cholerae and to biotype Vibrio cholerae O1. Shangkuan YH, et al. **J Appl Bacteriol** 1995 Sep; 79(3):264–73

Membrane topology of the outer membrane protein OprH from Pseudomonas aeruginosa: PCR-mediated site-directed insertion and deletion mutagenesis. Rehm BH, et al. **J Bacteriol** 1996 Jun;178(11):3346–9

Multiple transcripts of human endothelin-A receptor gene detected by reverse transcription and the polymerase chain reaction. Miyamoto Y, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S29–31

Immunomagnetic PCR and DNA probe for detection and identification of Porphyromonas gingivalis. Benkirane RM, et al. **J Clin Microbiol** 1995 Nov;33(11):2908–12

PCR as a confirmatory test for human immunodeficiency virus type 1 infection in individuals with indeterminate western blot (immunoblot) profiles. Sethoe SY, et al. **J Clin Microbiol** 1995 Nov;33(11):3034–6

Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. Fields KK, et al. **J Clin Oncol** 1996 Jun;14(6):1868–76

Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. Mellado B, et al. **J Clin Oncol** 1996 Jul; 14(7):2091–7

Comparison of the HbH inclusion test and a PCR test in routine screening for alpha thalassaemia in Hong Kong. Chan AY, et al. **J Clin Pathol** 1996 May;49(5):411–3

Quantification of HIV DNA in the brain by PCR: differences between fresh frozen and formalin fixed tissue. Davison F, et al. **J Clin Pathol** 1996 May;49(5):425–7

Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast. Howes GP, et al. **J Clin Pathol** 1996 Jul;49(7):570–3

OCT embedded sections of pathological specimens as a source of high quality RNA for reverse transcriptase/polymerase chain reaction. Irving JA, et al. **J Clin Pathol** 1996 Mar;49(3):258–9

Detection by PCR of Toxoplasma gondii in blood in the diagnosis of cerebral toxoplasmosis in patients with AIDS. Lamoril J, et al. **J Clin Pathol** 1996 Jan;49(1):89–92

Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Treponema denticola detection in oral plaque samples using the polymerase chain reaction. Watanabe K, et al. **J Clin Periodontol** 1996 Mar; 23(3 Pt 1):212–9

The polymerase chain reaction and branching processes. Sun F. **J Comput Biol** 1995 Spring;2(1):63–86

Modeling the polymerase chain reaction. Weiss G, et al. **J Comput Biol** 1995 Spring;2(1):49–61

Quantitation of beta 1 triiodothyronine receptor mRNA in human tissues by competitive reverse transcription polymerase chain reaction. Meier-Heusler S, et al. **J Endocrinol Invest** 1995 Nov;18(10):767–73

Hungarian population data on seven PCR-based loci. Budowle B, et al. **J Forensic Sci** 1996 Jul;41(4):667–70

Korean population data on the PCR-based loci LDLR, GYPA, HBGG, D7S8, Gc, HLA-DQA1, and D1S80. Woo KM, et al. **J Forensic Sci** 1995 Jul;40(4):645–8

Rapid detection and biovar differentiation of Ureaplasma urealyticum in clinical specimens by PCR. Teng LJ, et al. **J Formos Med Assoc** 1995 Jul;94(7):396–400

Semiquantitative measurement of cytokine messenger RNA in endomyocardium and peripheral blood mononuclear cells from human heart transplant recipients. Lagoo AS, et al. **J Heart Lung Transplant** 1996 Feb;15(2):206–17

Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction. Schowengerdt KO, et al. **J Heart Lung Transplant** 1996 Feb;15(2):111–23

Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction. Grassi G, et al. **J Hepatol** 1995 Oct;23(4):403–11

Prevalence of hepatitis B or C virus infection in patients with fulminant viral hepatitis. An analysis using polymerase chain reaction. Inokuchi K, et al. **J Hepatol** 1996 Mar; 24(3):258–64

Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction. Vincent R, et al. **J Immunol** 1996 Jan 15; 156(2):603–10

Polymerase chain reaction for rapid diagnosis of respiratory adenovirus infection. Morris DJ, et al. **J Infect** 1996 Mar; 32(2):113–7

Comparison of the polymerase chain reaction and serology for the diagnosis of HTLV-I infection. van der Ryst E, et al. **J Infect** 1996 Mar;32(2):109–12

Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens. Atzori C, et al. **J Infect Dis** 1995 Dec; 172(6):1623–6

Polymerase chain reaction ribotyping: a "universal" approach? [letter; comment] Cartwright CP. **J Infect Dis** 1995 Dec;172(6):1638–9. Comment on: J Infect Dis 1995 Jan;171(1):204–8.

Cytomegalovirus DNA or RNA detection in blood: importance of the specimens chosen for amplification [letter; comment] Gozlan J. **J Infect Dis** 1995 Dec; 172(6):1641. Comment on: J Infect Dis 1995 Apr;171(4):1010–4.

False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus (HIV) type 1 in children infected with HIV strains of African origin [letter; comment] Haas J, et al. **J Infect Dis** 1996 Jul;174(1):244–5 . Comment on: J Infect Dis 1996 Jan;173(1):68–76.

False-positive polymerase chain reaction results in the diagnosis of herpes simplex encephalitis [letter; comment] Landry ML. **J Infect Dis** 1995 Dec;172(6):1641–3. Comment on: J Infect Dis 1995 Apr;171(4):857–63.

Virologic features of an astrovirus diarrhea outbreak in a day care center revealed by reverse transcriptase-polymerase chain reaction. Mitchell DK, et al. **J Infect Dis** 1995 Dec;172(6):1437–44

A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. van der Zee A, et al. **J Infect Dis** 1996 Jul; 174(1):89–96

Assignment of the human peroxisomal palmitoyl-CoA oxidase gene to chromosome 17q23-qter by PCR technique. Moghrabi NN, et al. **J Inherit Metab Dis** 1995; 18(6):705–9

The polymerase chain reaction: a revolutionary new procedure for the laboratory diagnosis of infectious disease. Buck GE. **J Ky Med Assoc** 1996 Apr;94(4):148–52 (23 ref.)

Polymerase chain reaction-based method for the detection of canine heartworm (Filarioidea: Onchocercidae) in mosquitoes (Diptera: Culicidae) and vertebrate hosts. Scoles GA, et al. **J Med Entomol** 1995 Nov;32(6):864–9

Rapid detection of rare variants and common polymorphisms in the APC gene by PCR-SSCP for presymptomatic diagnosis and showing allele loss. Gayther SA, et al. **J Med Genet** 1995 Jul;32(7):568–71

Polymerase chain reaction for the detection of Bordetella pertussis in clinical nasopharyngeal aspirates. Mastrantonio P, et al. **J Med Microbiol** 1996 Apr;44(4):261–6

A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. Vila J, et al. **J Med Microbiol** 1996 Jun;44(6):482–9

Comparison of coxsackie B neutralisation and enteroviral PCR in chronic fatigue patients. Nairn C, et al. **J Med Virol** 1995 Aug;46(4):310–3

Use of polymerase chain reaction and quantitative antibody tests in children born to human immunodeficiency virus-1-infected mothers. Newell ML, et al. **J Med Virol** 1995 Dec;47(4):330–5

Use of the polymerase chain reaction to detect genomes of human immunodeficiency virus and cytomegalovirus in post-mortem tissues. Webster A, et al. **J Med Virol** 1995 Sep;47(1):23–8

Human herpesvirus type 7 in blood donors: detection by the polymerase chain reaction. Wilborn F, et al. **J Med Virol** 1995 Sep;47(1):65–9

A mathematical analysis of in vitro molecular selection-amplification. Sun F, et al. **J Mol Biol** 1996 May 17;258(4):650–60

Polymerase chain reaction for detection of melanoma in peripheral blood: too early to assess clinical value [editorial; comment] Buzaid AC, et al. **J Natl Cancer Inst** 1996 May 1;88(9):569–70. Comment on: J Natl Cancer Inst 1996 May 1;88(9):590–4.

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma [see comments] Kunter U, et al. **J Natl Cancer Inst** 1996 May 1;88(9):590–4. Comment in: J Natl Cancer Inst 1996 May 1;88(9):569–70.

Limited value of cerebrospinal fluid for direct detection of Toxoplasma gondii in toxoplasmic encephalitis associated with AIDS. Eggers C, et al. **J Neurol** 1995 Oct; 242(10):644–9

Microsatellites and PCR genomic analysis. Koreth J, et al. **J Pathol** 1996 Mar;178(3):239–48 (152 ref.)

Monoclonality of B-cell lineage in primary pulmonary lymphoma demonstrated by immunoglobulin heavy chain gene sequence analysis of histologically non-definitive transbronchial biopsy specimens. Kurosu K, et al. **J Pathol** 1996 Mar;178(3):316–22

VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis. Theodorou I, et al. **J Pathol** 1996 Mar;178(3):303–10

Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study [see comments] Bremer JW, et al. **J Pediatr** 1996 Aug;129(2):198–207. Comment in: J Pediatr 1996 Aug;129(2):189–90.

PCR for identification and typing of Helicobacter pylori isolated from children. Dzierżanowska D, et al. **J Physiol Pharmacol** 1996 Mar;47(1):101–14

The limit of PCR amplification [letter] Dimitrov DS, et al. **J Theor Biol** 1996 Feb 21;178(4):425–6

Early identification of candiduria by polymerase chain reaction in high risk patients. Muncan P, et al. **J Urol** 1996 Jul;156(1):154–6

Rapid differentiation of closely related isolates of two plant viruses by polymerase chain reaction and restriction fragment length polymorphism analysis. Barbara DJ, et al. **J Virol Methods** 1995 Sep;55(1):121–31

Differential diagnosis of fish pathogenic rhabdoviruses by reverse transcriptase-dependent polymerase chain reaction. Bruchhof B, et al. **J Virol Methods** 1995 Sep;55(1):111–9

Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. Dion LD, et al. **J Virol Methods** 1996 Jan;56(1):99–107

Detection of potato leafroll virus in single aphids by the reverse transcription polymerase chain reaction and its potential epidemiological application. Singh RP, et al. **J Virol Methods** 1995 Sep;55(1):133–43

Identification of Zucchini yellow mosaic potyvirus by RT-PCR and analysis of sequence variability. Thomson KG, et al. **J Virol Methods** 1995 Sep;55(1):83–96

DNA probe hybridisation in microwells using a new bioluminescent system for the detection of PCR-amplified HIV-1 proviral DNA. Zammatteo N, et al. **J Virol Methods** 1995 Oct;55(2):185–97

DNA polymerase chain reaction for the diagnosis of vertical HIV infection [editorial; comment] Luzuriaga K, et al. **JAMA** 1996 May 1;275(17):1360–1. Comment on: JAMA 1996 May 1;275(17):1342–8.

A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants [see comments] Owens DK, et al. **JAMA** 1996 May 1;275(17):1342–8. Comment in: JAMA 1996 May 1;275(17):1360–1.

Identification of 29 rat genetic markers by arbitrarily primed polymerase chain reaction. Canzian F, et al. **Jpn J Cancer Res** 1996 Jul;87(7):669–75

Detection of gastric cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. Noguchi S, et al. **Jpn J Cancer Res** 1996 Jun;87(6):650–4

Semiquantitative analysis of periodontopathogens by gene amplification. Sumi Y, et al. **Jpn J Med Sci Biol** 1995 Aug; 48(4):177–91

Application of ABO genotyping using polymerase chain reaction method to assess engraftment in bone marrow transplantation--a case report. Chang CS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Oct; 11(10):574–7

Value of clinical symptoms, intrathecal specific antibody production and PCR in CSF in the diagnosis of childhood Lyme neuroborreliosis. Issakainen J, et al. **Klin Padiatr** 1996 May-Jun;208(3):106–9

Frequent reactivations of anti-HBe-positive chronic hepatitis B in patients with no demonstrable HBV DNA in serum by polymerase chain reaction. Lee HS, et al. **Korean J Intern Med** 1995 Jul;10(2):103–7

Loss of heterozygosity of multiple tumor suppressor genes in human gastric cancers by polymerase chain reaction. Cho JH, et al. **Lab Invest** 1996 Apr;74(4):835–41

Measurement by quantitative reverse transcription-polymerase chain reaction of the levels of tumor necrosis factor alpha mRNA in atherosclerotic arteries in Watanabe heritable hyperlipidemic rabbits. Lei X, et al. **Lab Invest** 1996 Jan;74(1):136–45

Blood-based PCR assay to detect pulmonary tuberculosis [letter] Aguado JM, et al. **Lancet** 1996 Jun 29; 347(9018):1836–7

HHV8 and skin cancers in immunosuppressed patients [letter] [published erratum appears in Lancet 1996 Jul 13;348(9020):138] Boshoff C, et al. **Lancet** 1996 Feb 3; 347(8997):338–9

Value of direct amplified test for diagnosis of tuberculosis.

Catanzaro A. **Lancet** 1996 Jun 1;347(9014):1500–1

Genetic diversity and HIV detection by PCR [letter; comment] Clewley JP. **Lancet** 1995 Dec 2;346(8988):1489 . Comment on: Lancet 1995 Sep 30;346(8979):912–3.

Polymerase chain reaction of cerebrospinal fluid to diagnose Whipple's disease [letter] Cohen L, et al. **Lancet** 1996 Feb 3;347(8997):329

Peripheral–blood–based PCR assay to identify patients with active pulmonary tuberculosis. Condos R, et al. **Lancet** 1996 Apr 20;347(9008):1082–5

Pitfalls of PCR: misdiagnosis of cerebral nocardia infection [letter; comment] Holliman RE, et al. **Lancet** 1996 Feb 3; 347(8997):335–6. Comment on: Lancet 1995 Nov 25;346(8987):1436.

Genetic diversity and HIV detection by polymerase chain reaction [letter] [see comments] Loussert–Ajaka I, et al. **Lancet** 1995 Sep 30;346(8979):912–3. Comment in: Lancet 1995 Dec 2;346(8988):1489.

Pitfalls of PCR: misdiagnosis of cerebral nocardia infection [letter] [see comments] McHugh TD, et al. **Lancet** 1995 Nov 25;346(8987):1436. Comment in: Lancet 1996 Feb 3;347(8997):335–6.

Limited role for PCR–based diagnosis of Whipple's disease from peripheral blood mononuclear cells [letter] Marth T, et al. **Lancet** 1996 Jul 6;348(9019):66–7

Correlation of Pneumocystis carinii PCR with clinical diagnosis in immunocompromised patients [letter] Weig M, et al. **Lancet** 1996 May 4;347(9010):1266

Detection of chromosomal translocations in leukemia–lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

Detection of c–myc oncogene amplification in a CML blastic phase patient with double minute chromosomes. Karasawa M, et al. **Leuk Res** 1996 Jan;20(1):85–91

Association of Epstein–Barr virus with human immunodeficiency virus–negative T cell lymphomas in Japan, in situ hybridization, polymerase chain reaction and immunohistochemical studies [letter] Hirose Y, et al. **Leukemia** 1996 Oct;10(10):1673–5

Measurement of minimal residual disease in acute leukemia [letter; comment] Morley A. **Leukemia** 1996 May; 10(5):920–2. Comment on: Leukemia 1995 Feb;9(2):321–8.

Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug–resistant tuberculosis. Cockerill FR 3rd, et al. **Mayo Clin Proc** 1996 Mar;71(3):221–9

Current and future applications of polymerase chain reaction for Mycobacterium tuberculosis [editorial] Haas DW. **Mayo Clin Proc** 1996 Mar;71(3):311–13

A polymerase chain reaction–based test for spinal and bulbar muscular atrophy. Wang Z, et al. **Mayo Clin Proc** 1996 Apr;71(4):397–8

PCR characterization of isolates from various endemic areas: diversity and turn over of Plasmodium falciparum populations are correlated with transmission. Daubersies P, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:9–12

Detection of Trypanosoma cruzi and Leishmania using the polymerase chain reaction. Degrave W, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):367–8

Use of molecular probes and PCR for detection and typing of Leishmania––a mini–review. Degrave W, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):463–9 (31 ref.)

YAC library screening. I. Preparation of hybridization filters and PCRpools. Cole CG, et al. **Methods Mol Biol** 1996; 54:23–31

YAC library screening. II. Hybridization and PCR–based screening protocols. Cole CG, et al. **Methods Mol Biol** 1996;54:33–47

YAC localization by fluorescence in situ hybridization. Senger G. **Methods Mol Biol** 1996;54:87–96

Detection of astroviruses from stool samples in Japan using reverse transcription and polymerase chain reaction amplification. Saito K, et al. **Microbiol Immunol** 1995; 39(10):825–8

Seminomas positive for Epstein–Barr virus by the polymerase chain reaction: viral RNA transcripts (Epstein–Barr–encoded small RNAs) are present in intratumoral lymphocytes but absent from the neoplastic cells. Fend F, et al. **Mod Pathol** 1995 Aug;8(6):622–5

Arbitrarily primed DNA fingerprinting for phylogenetic reconstruction in vertebrates: the Xiphophorus model. Borowsky RL, et al. **Mol Biol Evol** 1995 Nov;12(6):1022–32

Size homoplasy and mutational processes of interrupted microsatellites in two bee species, Apis mellifera and Bombus terrestris (Apidae). Estoup A, et al. **Mol Biol Evol** 1995 Nov;12(6):1074–84

Assessment of stress gene mRNAs (HSP–27, 60 and 70) in obstructed rabbit urinary bladder using a semi–quantitative RT–PCR method. Zhao Y, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):1–7

The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African black populations determined by the restriction profile of PCR–amplified DNA. Dandré F, et al. **Mol Cell Probes** 1995 Jun;9(3):189–93

Variable efficiency of three primer pairs for the diagnosis of Pneumocystis carinii pneumonia by the polymerase chain reaction. De Luca A, et al. **Mol Cell Probes** 1995 Oct; 9(5):333–40

Genetic markers for closely–related parasitic nematodes. Gasser RB, et al. **Mol Cell Probes** 1995 Oct;9(5):315–20

Molecular typing of Neisseria meningitidis serogroup A using the polymerase chain reaction and restriction endonuclease pattern analysis. Giorgini D, et al. **Mol Cell Probes** 1995 Oct;9(5):297–306

Identification of a patient with Streptococcus pneumoniae bacteremia and meningitis by the polymerase chain reaction (PCR). Isaacman DJ, et al. **Mol Cell Probes** 1995 Jun; 9(3):157–60

A simple, rapid and sensitive detection of salmonella in food by polymerase chain reaction. Jitrapakdee S, et al. **Mol Cell Probes** 1995 Dec;9(6):375–82

Molecular characterization of further dystrophin gene microsatellites. King SC, et al. **Mol Cell Probes** 1995 Oct; 9(5):361–70

Internal controls as performance monitors and quantitative standards in the detection by polymerase chain reaction of herpes simplex virus and cytomegalovirus in clinical specimens. Nash KA, et al. **Mol Cell Probes** 1995 Oct; 9(5):347–56

Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction. Oggioni MR, et al. **Mol Cell Probes** 1995 Oct;9(5):321–6

Evaluation of the effects of disinfectants on rotavirus RNA and infectivity by the polymerase chain reaction and cell–culture methods. Ojeh CK, et al. **Mol Cell Probes** 1995 Oct;9(5):341–6

Simultaneous detection of fourteen Italian cystic fibrosis mutations in seven exons by reverse dot–blot analysis. Rady M, et al. **Mol Cell Probes** 1995 Oct;9(5):357–60

Comparison of heteroduplex and single–strand conformation analyses, followed by ethidium fluorescence visualization, for the detection of mutations in four human genes. Rossetti S, et al. **Mol Cell Probes** 1995 Jun;9(3):195–200

A multiplex polymerase chain reaction for distinguishing Mycobacterium tuberculosis from Mycobacterium tuberculosis complex. Sinclair K, et al. **Mol Cell Probes** 1995 Oct;9(5):291–5

Evaluation of a PCR based assay for specific detection of Campylobacter jejuni in chicken washes. Winters DK, et al. **Mol Cell Probes** 1995 Oct;9(5):307–10

PCR amplification of intergenic spacers in the ribosomal DNA of Drosophila melanogaster reveals high levels of turnover in length and copy–number of spacers in geographically separated populations. Bowen T, et al. **Mol Ecol** 1995 Aug;4(4):419–27

Use of the PCR and fluorescent probes to recover SSU rRNA gene sequences from single cells of the ciliate protozoon Spathidium. Dyal PL, et al. **Mol Ecol** 1995 Aug; 4(4):499–503

PCR–based identification of wheat genomes. Sallares R, et al. **Mol Ecol** 1995 Aug;4(4):509–14

Chronic ethanol consumption differentially alters the expression of gamma–aminobutyric acidA receptor subunit mRNAs in rat cerebral cortex: competitive, quantitative reverse transcriptase–polymerase chain reaction analysis. Devaud LL, et al. **Mol Pharmacol** 1995 Nov;48(5):861–8

Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction. Fox SA, et al. **Muscle Nerve** 1996 Jan;19(1):23–8

Nucleic acid fingerprinting by PCR–based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: the role of semiquantitative polymerase chain reaction (PCR). Peiris JS, et al. **Nephrol Dial Transplant** 1995;10(7):1198–205

Quantitative RT–PCR for neuroendocrine studies. A minireview. Zamorano PL, et al. **Neuroendocrinology** 1996 May;63(5):397–407 (39 ref.)

Early diagnosis of tuberculous meningitis by polymerase chain reaction. Kox LF, et al. **Neurology** 1995 Dec; 45(12):2228–32

Hydroxyquinoline overcomes PCR inhibition by UV–damaged mineral oil. Gilgen M, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):4001–2

Rapid purification of recombinant Taq DNA polymerase by freezing and high temperature thawing of bacterial expression cultures. Grimm E, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4518–9

Vectorette PCR isolation of microsatellite repeat sequences using anchored dinucleotide repeat primers. Lench NJ, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2190–1

DNA rehybridization during PCR: the 'Cot effect' and its consequences. Mathieu–Daudé F, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2080–6

An efficient PCR mutagenesis strategy without gel purification [correction of purificiation] step that is amenable to automation. Séraphin B, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3276–7

Ready to use agarose encapsulated PCR reagents. Setterquist RA, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1580–1

Polymerase chain reaction targeting of single– and multiple–copy genes of mycobacteria in the diagnosis of tuberculosis. Mustafa AS, et al. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):665–9

The use of the polymerase chain reaction for more sensitive detection of Plasmodium falciparum. Felger I, et al. **P N G Med J** 1995 Mar;38(1):52–6

Detection of Toxoplasma gondii parasitemia by polymerase chain reaction in perorally infected mice. Paugam A, et al. **Parasite** 1995 Jun;2(2):181–4

Improved specificity of Trypanosoma cruzi identification by polymerase chain reaction using an oligonucleotide derived from the amino–terminal sequence of a Tc24 protein. Taibi A, et al. **Parasitology** 1995 Dec;111 (Pt 5):581–90

Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection. Blackmore TK, et al. **Pathology** 1995 Apr;27(2):177–81

Comparison of antigen detection, polymerase chain reaction and culture for detection of Chlamydia trachomatis in genital infection. Hallsworth PG, et al. **Pathology** 1995 Apr; 27(2):168–71

Effect of internal direct and inverted Alu repeat sequences on PCR. Ji W, et al. **PCR Methods Appl** 1994 Oct; 4(2):109–16

Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin–treated infants with pertussis. Edelman K, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):54–7

Molecular and cytogenetic analysis of a cerebellar primitive neuroectodermal tumor with prominent neuronal differentiation: detection of MYCN amplification by differential polymerase chain reaction and Southern blot analysis. Jay V, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):733–44

Molecular diagnosis of tuberculous peritonitis using DNA amplification in a patient with end–stage renal disease. Yap HK, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):86–9

HLA–Cw allele analysis by PCR–restriction fragment length polymorphism: study of known and additional alleles. Tatari Z, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8803–7

Amplification of the full–length hepatitis A virus genome by long reverse transcription–PCR and transcription of infectious RNA directly from the amplicon. Tellier R, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4370–3

A polymerase chain reaction–based method for the semiquantitative study of interleukin–8 mRNA in human basophil leukocytes. Markvardsen P, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):487–93

Genetic influence on the shaping of the human T–cell receptor repertoire: quantitative assessment by competitive polymerase chain reaction. Uhrberg M, et al. **Scand J Immunol** 1996 Aug;44(2):173–8

Human sex determination using multiplex polymerase chain reaction (PCR). Finch JL, et al. **Sci Justice** 1996 Apr–Jun; 36(2):93–5

Chancroid detected by polymerase chain reaction––Jackson, Mississippi, 1994–1995. **Sex Transm Dis** 1995 Nov–Dec; 22(6):385–6

PCR to detect Mycobacterium tuberculosis DNA in sputum samples from treated leprosy patients with putative tuberculosis. Rafi A, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):253–7

Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis. Dilworth JP, et al. **Thorax** 1996 Mar;51(3):320–2

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.). Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

Detection by PCR and HphI restriction analysis of a splice site mutation at the 5'end of intron 15 of the platelet GPIIb (alpha IIb integrin) gene responsible for Glanzmann's thrombasthenia type I in Gypsies originating from the Strasbourg area [letter] de la Salle C, et al. **Thromb Haemost** 1995 Sep;74(3):990–1

DNA length polymorphism present in the antithrombin III promoter region does not influence plasma antithrombin III activity levels [letter] Niessen RW, et al. **Thromb Haemost** 1996 Feb;75(2):376–7

Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506–factor V. Greengard JS, et al. **Thromb Res** 1995 Dec 1;80(5):441–3

Anchored PCR cloning of the novel HLA–Cw*0704 allele detected by PCR–SSP. Vilches C, et al. **Tissue Antigens** 1995 Jul;46(1):19–23

Clinical evaluation of polymerase chain reaction DNA amplification method for the diagnosis of pulmonary tuberculosis in patients with negative acid–fast bacilli smear. Mitarai S, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):13–23

Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Andresen K, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):133–5

Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north–eastern Brazil. Junqueira AC, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):129–32

A polymerase chain reaction assay to determine infection of Aedes polynesiensis by Wuchereria bancrofti. Nicolas L, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr; 90(2):136–9

Rh haemolytic disease of the newborn and Rh genotyping by RFLP––and allele–specific––PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317–24 (16 ref.)

Human platelet antigen–2 and –3 genotyping by PCR–SSP.

Metcalfe P, et al. **Transfus Med** 1995 Dec;5(4):285–8
Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al. **Transfus Med Rev** 1995 Oct;9(4):289–301 (58 ref.)
Retrograde transmission of Proteus mirabilis during platelet transfusion and the use of arbitrarily primed polymerase chain reaction for bacteria typing in suspected cases of transfusion transmission of infection. Engstrand M, et al. **Transfusion** 1995 Oct;35(10):871–3
Genotyping of KEL1 and KEL2 of the human Kell blood group system by the polymerase chain reaction with sequence–specific primers. Hessner MJ, et al. **Transfusion** 1996 Jun;36(6):495–9
Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation–based typing. Legler TJ, et al. **Transfusion** 1996 May;36(5):426–31
Detection of human cytomegalovirus myocardial involvement by polymerase chain reaction during systemic infection and correlation with pp65 antigenemia and DNAemia in infected heart recipients. Ghisetti V, et al. **Transplantation** 1996 Apr 15;61(7):1072–5
Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus. Yedidag EN, et al. **Transplantation** 1996 Jul 27;62(2):238–42
Polymerase chain reaction for detecting Onchocerca volvulus in pools of blackflies. Oskam L, et al. **Trop Med Int Health** 1996 Aug;1(4):522–7
Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. De Beenhouwer H, et al. **Tuber Lung Dis** 1995 Oct; 76(5):425–30
A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Doucet–Populaire F, et al. **Tuber Lung Dis** 1996 Aug;77(4):358–62
Is PCR a useful tool for the diagnosis of tuberculosis in 1995? [editorial] Grosset J, et al. **Tuber Lung Dis** 1995 Jun; 76(3):183–4
Diagnosis of tuberculous meningitis: a comparative analysis of 3 immunoassays, an immune complex assay and the polymerase chain reaction. Miörner H, et al. **Tuber Lung Dis** 1995 Oct;76(5):381–6
Evaluation of polymerase chain reaction for rapid diagnosis of clinically suspected tuberculous meningitis. Seth P, et al. **Tuber Lung Dis** 1996 Aug;77(4):353–7
The relevance of VDJ PCR protocols in detecting B–cell clonal expansion in lymphomas and other lymphoproliferative disorders. De Re V, et al. **Tumori** 1995 Nov–Dec;81(6):405–9
Rapid detection of thymidylate synthase gene expression levels by semi–quantitative competitive reverse transcriptase polymerase chain reaction followed by quantitative digital image analysis. Houze TA, et al. **Tumour Biol** 1996;17(5):306–19
Competitive polymerase chain reaction for the quantification of N–myc gene copy number in neuroblastoma. Inoue A, et al. **Tumour Biol** 1996;17(5):262–70
Use of polymerase chain reaction in the diagnosis of tuberculosis in cats and dogs. Aranaz A, et al. **Vet Rec** 1996 Mar 23;138(12):276–80
Detection of Salmonella enteritidis in eggs by the polymerase chain reaction. Woodward MJ, et al. **Vet Rec** 1996 Apr 27;138(17):411–3
Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus. Herchenröder O, et al. **Virology** 1995 Dec 20;214(2):685–9
Quantitative PCR as a method for monitoring retroviral infection on the gene level. Yolov AA, et al. **Virus Genes** 1995;10(1):45–51
PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus. Jantsch–Plunger V, et al. **Vox Sang** 1995;69(4):352–4
Prenatal fetal sex determination from maternal peripheral blood using polymerase chain reaction. Yang YH, et al. **Yonsei Med J** 1995 Sep;36(4):361–6
Discrimination of S. aureus strains by PCR for r–RNA gene spacer size polymorphism and comparison to SmaI macrorestriction patterns. Cuny C, et al. **Zentralbl Bakteriol** 1996 Apr;283(4):466–76
Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)
[Amplified fragment length polymorphism of the VNTR locus COL2A1 in Chinese population] Hou Y, et al. **I Chuan Hsueh Pao** 1995;22(4):245–51 (Eng. Abstr.) **(Chi)**
[A PCR marker–based selection for resistance to bacterial blight in rice] Lu C, et al. **I Chuan Hsueh Pao** 1996; 23(2):110–6 (Eng. Abstr.) **(Chi)**
[Molecular biology and prenatal diagnosis] Schwartz M. **Ugeskr Laeger** 1995 Oct 9;157(41):5703–6 **(Dan)**
[Children with acute lymphoblastic leukemia: prognostic significance of polymerase–chain–reaction analysis of minimal residual disease] Steenbergen EJ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):22–8 (Eng. Abstr.) **(Dut)**
[Cerebrospinal fluid diagnosis using polymerase chain reaction] van Manen SR, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1259–63 (38 ref.) **(Dut)**
[The polymerase chain reaction (PCR)] de Gee AL. **Tijdschr Diergeneeskd** 1995 Aug 15;120(16):470–1 **(Dut)**
[Polymerase chain reaction assay of HSV in the rapid diagnosis of encephalitis] Piiparinen H, et al. **Duodecim** 1995;111(2):129–33 **(Fin)**
[Is polymerase chain reaction practical in the diagnosis of microbes?] Ranki–Pesonen M. **Duodecim** 1994; 110(6):615–21 (15 ref.) **(Fin)**
[Genetic diagnosis of mycobacterium infections by polymerase chain reaction (PCR)] Perronne C, et al. **Ann Dermatol Venereol** 1995;122(4):213–5 (Eng. Abstr.) **(Fre)**
[Aseptic meningitis. Demonstration of bacterial DNA in cerebrospinal fluid by gene amplification] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(4):320–5 (28 ref.) (Eng. Abstr.) **(Fre)**
[Retrospective evaluation of the detection of Toxoplasma gondii by polymerase chain reaction in AIDS patients] Robert F, et al. **Presse Med** 1996 Mar 30;25(11):541–5 (Eng. Abstr.) **(Fre)**
[Clarification of a forced entry theft based on a beverage bottle left at the scene and PCR DNA typing of superficial saliva traces] Neuhuber F, et al. **Arch Kriminol** 1995 Nov–Dec;196(5–6):165–8 (Eng. Abstr.) **(Ger)**
[Corpse dismemberment with sequential identification and classification of body parts] Schmitt C, et al. **Arch Kriminol** 1995 Nov–Dec;196(5–6):129–37 (Eng. Abstr.) **(Ger)**
[HPV–5 typing with nested PCR and sequencing in epidermodysplasia verruciformis] Schaller J, et al. **Hautarzt** 1996 Jun;47(6):454–8 (Eng. Abstr.) **(Ger)**
[Importance of introduction of PCR in blood banks (editorial)] Gürtler L. **Infusionsther Transfusionsmed** 1996 Feb;23(1):4–6 **(Ger)**
[Infectious origin of Whipple disease (letter)] Schiller D. **Med Klin** 1996 May 15;91(5):323–4 **(Ger)**
[Detection of atypical mycobacterial endophthalmitis by PCR] Dockholm–Dworniczak B, et al. **Pathologe** 1996 Mar;17(2):115 **(Ger)**
[Detection of atypical mycobacterial endophthalmitis by PCR] Dockhorn–Dworniczak B, et al. **Pathologe** 1995 Sep; 16(5):364–7 (Eng. Abstr.) **(Ger)**
[Test for virus genotype (PCR) for greater safety in blood preparations] **Pharm Unserer Zeit** 1996 Apr;25(2):105 **(Ger)**
[Detection of Bartonella (Rochalimaea) henselae/B. quintana by polymerase chain reaction (PCR)] Goldenberger D, et al. **Schweiz Med Wochenschr** 1996 Feb 10;126(6):207–13 (Eng. Abstr.) **(Ger)**
[Pre–symptomatic diagnosis of Huntington disease by polymerase chain reaction] Tóth T, et al. **Orv Hetil** 1996 Mar 3;137(9):451–4 (25 ref.) (Eng. Abstr.) **(Hun)**
[New tests of virucidal activity of 2 disinfectants versus HBV DNA positive sera: slot–blot and polymerase chain reaction (PCR)] Vollaro L, et al. **Ann Ig** 1995 Jan–Feb;7(1):63–8 **(Ita)**
[Ras gene analysis in mammary tumors of dogs by means of PCR–SSCP and direct genomic analysis] Castagnaro M. **Ann Ist Super Sanita** 1995;31(3):337–41 (Eng. Abstr.) **(Ita)**
[In situ PCR: its applications and problems] Mukai M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):15–26 (42 ref.) **(Jpn)**
[Practical application of DNA–diagnosis in the Nippon Medical School Hospital] Kawanami O, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):401–5 (21 ref.) **(Jpn)**
[Direct sequencing for PCR products] Daikoku M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:305–9 (8 ref.) **(Jpn)**
[PCR–SSCP.direct sequencing] Kagimoto S. **Nippon Rinsho** 1995 Oct;53 Suppl:310–5 (5 ref.) **(Jpn)**
[Analyses of T–cell receptor repertoire in liver–infiltrating lymphocytes in chronic hepatitis B using PCR method] Kashii Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:155–60 **(Jpn)**
[Thermostable DNA Polymerases and PCR] Ishino Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):429–36 (42 ref.) **(Jpn)**
[PCR amplification on forensic science] Kasai K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):738–43 (20 ref.) **(Jpn)**
[Primer for PCR method, synthesis and purification] Kawase Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):446–52 (20 ref.) **(Jpn)**
[Application of PCR technique to mouse genetics] Kominami R, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):623–8 (21 ref.) **(Jpn)**
[Labelling of PCR products] Makino R. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):494–8 (6 ref.) **(Jpn)**
[Method of determining optimal PCR primers] Mitsuhashi M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):439–45 (8 ref.) **(Jpn)**
[PCR primer] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):437–9 **(Jpn)**
[Reaction conditions of PCR] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):425–8 (17 ref.) **(Jpn)**
[Treatment of clinical specimens for PCR] Nakata S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):456–60 **(Jpn)**
[PCR and DNA sequencing] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):522–30 (6 ref.) **(Jpn)**
[Isolation of DNA from cells and tissues for PCR] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):453–6 (4 ref.) **(Jpn)**
[Principles of PCR–based technologies] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):415–24 (17 ref.) **(Jpn)**
[Quantitative PCR: DNA quantification by PCR] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):499–502 (14 ref.) **(Jpn)**
[Diagnosis and follow–up in chronic myeloid leukemia. Detection and quantification of specific transcripts with the help of reverse transcriptase–polymerase chain reaction] Osland A, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):726–30 (Eng. Abstr.) **(Nor)**
[Oncogene neu in spontaneous and induced rat schwannomas: a study using polymerase chain reaction] Perantoni AO, et al. **Arkh Patol** 1995 Sep–Oct;57(5):38–42 (Eng. Abstr.) **(Rus)**
[Analysis of copies of the suffix–retroposon of Drosophila, produced using PCR on genomic DNA] Kolesnikov AV, et al. **Genetika** 1996 Jan;32(1):150–3 (Eng. Abstr.) **(Rus)**
[Physical mapping of Escherichia coli genome rearrangements using pulsed–field gel electrophoresis and the PCR method] Zaporozhets DA, et al. **Genetika** 1996 Jan;32(1):23–34 (Eng. Abstr.) **(Rus)**
[The polymerase chain reaction in the diagnosis of bacterial infections] Bezrukov VM, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):20–3 **(Rus)**
[Elaboration of the polymerase chain reaction system for subtype specific differentiation of influenza A virus strains] Tarasov KV, et al. **Vestn Ross Akad Med Nauk** 1995; (9):22–4 (Eng. Abstr.) **(Rus)**
[The diagnosis of chlamydiosis and urogenital mycoplasmosis by using the polymerase chain reaction] Skvortsov SV, et al. **Voen Med Zh** 1995 Jul;(7):49–50 **(Rus)**
[Detection of the presence of the hepatitis C viral genome in immunoglobulin preparations using RT–PCR] Glišić S, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):553–6 (Eng. Abstr.) **(Scr)**
[A comparative study of technics for the diagnosis of the human immunodeficiency virus in infants under 15 months by: viral cultivation, the polymerase chain reaction and antigen p24] Muñoz Fernández MA, et al. **An Esp Pediatr** 1996 Jun;44(6):540–4 (Eng. Abstr.) **(Spa)**
[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**
[Greater sensitivity of the PCR–SSCP technique compared with immunohistochemistry for the detection of exon 5 and 6 mutations of gene 53 in breast cancer] Dueñas González A, et al. **Med Clin (Barc)** 1996 May 18; 106(19):721–4 (Eng. Abstr.) **(Spa)**
[Herpetic encephalitis: diagnostic value of the polymerase chain reaction in cerebrospinal fluid (letter)] González R, et al. **Med Clin (Barc)** 1995 Sep 30;105(10):398–9 **(Spa)**
[Successful diagnosis of tuberculosis. PCR determination of tuberculosis on formalin–fixed preparations] Hagstam P, et al. **Lakartidningen** 1995 Oct 25;92(43):3992 **(Swe)**

INSTRUMENTATION

Quantitative polymerase chain reaction using a recombinant DNA internal standard and time–resolved fluorometry. Bortolin S, et al. **Anal Chem** 1996 Mar 1;68(5):834–40
Immunohistochemical staining of fixed tissue using antigen retrieval and a thermal cycler. Baker–Cairns B, et al. **Biotechniques** 1996 Apr;20(4):641–50
Comparison of SHARP signal system and Southern blot hybridization analysis for detection of cytomegalovirus in clinical specimens by PCR. Espy MJ, et al. **J Clin Microbiol** 1995 Nov;33(11):3028–30
Thermal cycler from recycled printer [letter] Frean J. **Lancet** 1996 Jul 13;348(9020):126
Chip PCR. I. Surface passivation of microfabricated silicon–glass chips for PCR. Shoffner MA, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):375–9
Microfabricated structures for integrated DNA analysis. Burns MA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5556–61
Analysis of double–stranded polymerase chain reaction products from the Bacillus cereus group by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Wunschel DS, et al. **Rapid Commun Mass Spectrom** 1996;10(1):29–35
[PCR machine] Kimura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):514–7 (7 ref.) **(Jpn)**

METHODS

Faster and cheaper PCR on a standard thermocycler. Sobczak K, et al. **Acta Biochim Pol** 1995;42(3):363–6
An efficient method of genomic DNA isolation from plant tissues. Stróżycki PM, et al. **Acta Biochim Pol** 1995; 42(3):329–31
Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolaou–stained cervical smears. Puranen M, et al. **Acta Cytol** 1996 May–Jun;40(3):391–5
Role of Pneumocystis carinii DNA amplification by PCR

on the diagnosis of Pneumocystis carinii pneumonia in patients with haematologic malignant diseases: report of four cases. Antinori A, et al. **Acta Haematol** 1995; 94(3):163–6

Human herpesvirus-6 genome in acute lymphoblastic leukemia: evidence against an etiologic relationship. Barozzi P, et al. **Acta Haematol** 1995;94(3):169–72

Detection of hepatitis C virus (HCV) by reverse transcription-polymerase chain reaction (RT-PCR) (a note). Falus A, et al. **Acta Microbiol Immunol Hung** 1995; 42(2):235–6

Detection of herpes simplex virus DNA by polymerase chain reaction in the cerebrospinal fluid of patients with viral meningoencephalitis using primers for the glycoprotein D gene. Kúdelová M, et al. **Acta Virol** 1995 Feb;39(1):11–7

Quantitative polymerase chain reaction for determination of different oxytocin receptor mRNA expression in non-pregnant and pregnant uterine tissue. Helmer H, et al. **Adv Exp Med Biol** 1995;395:487–8

The use of arms PCR and RFLP analysis in identifying genetic profiles of virulent, attenuated or vaccine strains of TGEV and PRCV. Lai CH, et al. **Adv Exp Med Biol** 1995;380:243–50

Identification of HIV-1 viral RNA in intestinal tissue from patients with early and late HIV infection [letter] McGowan I, et al. **AIDS** 1996 May;10(5):548–9

Interest and reliability of a polymerase chain reaction on bone-marrow samples in the diagnosis of visceral leishmaniasis in AIDS [letter] Piarroux R, et al. **AIDS** 1996 Apr;10(4):452–3

Nested polymerase chain reaction for diagnosis and monitoring treatment response in AIDS patients with tuberculous meningitis. Scarpellini P, et al. **AIDS** 1995 Aug; 9(8):895–900

A strategy for the identification of candidate genes for alcohol-related phenotypes and other human disorders using rapid polymerase chain reaction mapping of gene-based sequence-tagged sites. Berry R, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):821–3

A consensus polymerase chain reaction–oligonucleotide hybridization approach for the detection of chromosomal translocations in pediatric bone and soft tissue sarcomas. Barr FG, et al. **Am J Clin Pathol** 1995 Dec;104(6):627–33

Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues. Lim LC, et al. **Am J Clin Pathol** 1995 Dec;104(6):689–95

Polymerase chain reaction detection of Lyme disease: correlation with clinical manifestations and serologic responses. Mouritsen CL, et al. **Am J Clin Pathol** 1996 May;105(5):647–54

Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Pinyol M, et al. **Am J Clin Pathol** 1996 May; 105(5):532–7

Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Voelkerding KV, et al. **Am J Clin Pathol** 1996 Jul;106(1):100–6

Mitochondrial D-loop "signatures" produced by low-stringency single specific primer PCR constitute a simple comparative human identity test. Barreto G, et al. **Am J Hum Genet** 1996 Mar;58(3):609–16

Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay. Delahunty C, et al. **Am J Hum Genet** 1996 Jun; 58(6):1239–46

Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease [letter] Tayebi N, et al. **Am J Hum Genet** 1996 Sep;59(3):740–1

Differential display RT PCR of total RNA from human foreskin fibroblasts for investigation of androgen-dependent gene expression. Nitsche EM, et al. **Am J Med Genet** 1996 May 3;63(1):231–8

Direct detection of expanded trinucleotide repeats using PCR and DNA hybridization techniques. Petronis A, et al. **Am J Med Genet** 1996 Feb 16;67(1):85–91

Postmortem diagnosis of Fusarium panophthalmitis by the polymerase chain reaction. Alexandrakis G, et al. **Am J Ophthalmol** 1996 Feb;121(2):221–3

Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. de Boer JH, et al. **Am J Ophthalmol** 1996 Jun;121(6):650–8

Quantitative polymerase chain reaction in diagnosing ocular toxoplasmosis. Norose K, et al. **Am J Ophthalmol** 1996 Apr; 121(4):441–2

Detection of enterovirus 70 by polymerase chain reaction in acute hemorrhagic conjunctivitis. Uchio E, et al. **Am J Ophthalmol** 1996 Aug;122(2):273–5

Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression. Leygue E, et al. **Am J Pathol** 1996 Apr;148(4):1097–103

Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Noguchi S, et al. **Am J Pathol** 1996 Feb;148(2):649–56

Differential display RT-PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273–84 (72 ref.)

Site-specific mutagenesis by using an accurate recombinant polymerase chain reaction method. Ansaldi M, et al. **Anal Biochem** 1996 Feb 1;234(1):110–1

A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Arand M, et al. **Anal Biochem** 1996 Apr 5;236(1):184–6

A quantitative method of determining initial amounts of DNA by polymerase chain reaction cycle titration using digital imaging and a novel DNA stain. Becker A, et al. **Anal Biochem** 1996 Jun 1;237(2):204–7

Codon-based combinatorial alanine scanning site-directed mutagenesis: design, implementation, and polymerase chain reaction screening. Chatellier J, et al. **Anal Biochem** 1995 Aug 10;229(2):282–90

Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Doll MA, et al. **Anal Biochem** 1995 Nov 1;231(2):413–20

Ligation of hexamers on hexamer templates to produce primers for cycle sequencing or the polymerase chain reaction. Dunn JJ, et al. **Anal Biochem** 1995 Jun 10; 228(1):91–100

In situ polymerase chain reaction technique revealed by flow cytometry as a tool for gene detection. Gibellini D, et al. **Anal Biochem** 1995 Jul 1;228(2):252–8

Quantitative polymerase chain reaction with enzyme-linked immunosorbent assay detection of selectively digested amplified sample and control DNA. Hahn M, et al. **Anal Biochem** 1995 Aug 10;229(2):236–48

A technique for isolating single cells for analysis by reverse transcription polymerase chain reaction. Harbeck MC, et al. **Anal Biochem** 1995 Sep 1;230(1):193–6

Homogeneous quantitative assay of hepatitis C virus RNA by polymerase chain reaction in the presence of a fluorescent intercalater. Ishiguro T, et al. **Anal Biochem** 1995 Aug 10;229(2):207–13

Quantitative reverse transcriptase-polymerase chain reaction of eukaryotic mRNA with the prokaryotic chloramphenicol acetyltransferase RNA as a universal, internal standard. Jean L, et al. **Anal Biochem** 1996 Feb 15;234(2):224–6

Analysis of ligase chain reaction products via matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry. Jurinke C, et al. **Anal Biochem** 1996 Jun 1; 237(2):174–81

Analysis of promoter activity by polymerase chain reaction amplification of reporter gene mRNA. Kastenbauer S, et al. **Anal Biochem** 1996 Jan 1;233(1):137–9

A primer extension method for quantitation of in vitro synthesized mRNA transcripts directed by promoter elements containing multiple transcription initiation sites. Kosovsky MJ, et al. **Anal Biochem** 1995 Dec 10; 232(2):258–61

Single-site polymerase chain reaction through single oligonucleotide ligation. Lin Z, et al. **Anal Biochem** 1995 Nov 1;231(2):449–52

Inverted terminal repeats permit the average length of amplified DNA fragments to be regulated during preparation of cDNA libraries by polymerase chain reaction. Lukyanov KA, et al. **Anal Biochem** 1995 Aug 10;229(2):198–202

Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. Perfetti V, et al. **Anal Biochem** 1996 Jul 15;239(1):107–9

Generation of site-directed mutagenesis by extralong, high-fidelity polymerase chain reaction. Sang N, et al. **Anal Biochem** 1996 Jan 1;233(1):142–4

Revolutions in rapid amplification of cDNA ends: new strategies for polymerase chain reaction cloning of full-length cDNA ends. Schaefer BC. **Anal Biochem** 1995 May 20;227(2):255–73 (79 ref.)

Semiquantification of polymerase chain reaction product using a bead scintillation proximity assay and comparison with the Southern blot method. Schoenfeld A, et al. **Anal Biochem** 1995 Jun 10;228(1):164–7

An improved method for polymerase chain reaction using whole yeast cells. Wang H, et al. **Anal Biochem** 1996 May 15;237(1):145–6

Quantitative competitive polymerase chain reaction: analysis of amplified products of the HIV-1 gag gene by capillary electrophoresis with laser-induced fluorescence detection. Williams SJ, et al. **Anal Biochem** 1996 Apr 5;236(1):146–52

An RNA-competitive polymerase chain reaction method for human matrix gamma-carboxyglutamic acid protein mRNA measurement. Zhao J, et al. **Anal Biochem** 1995 Jun 10;228(1):162–4

Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears. Chua KL, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):221–9

A PCR-based diagnostic test for the endogenous retroviral element ev4 of chickens. Benkel BF. **Anim Genet** 1995 Oct; 26(5):369

Assignment of markers by using polymerase chain reaction on pools of swine flow-sorted chromosomes. Riquet J, et al. **Anim Genet** 1996 Jun;27(3):133–6

Simultaneous analysis of bovine kappa-casein and BLAD alleles by multiplex PCR followed by parallel digestion with two restriction enzymes. Zsolnai A, et al. **Anim Genet** 1996 Jun;27(3):207–9

Use of polymerase chain reaction in bovine babesiosis research. Buening GM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:466–8

Comparative sensitivity of two tests for the diagnosis of multiple hemoparasite infection of cattle. Figueroa JV, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:117–27

Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Rassenti LZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:463–73

The use of polymerase chain reaction to identify Pasteurella granulomatis from cattle. Veit HP, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:350–8

K-ras genotypes and prognosis in non-small-cell lung cancer. Rosell R, et al. **Ann Oncol** 1995;6 Suppl 3:S15–20

Competitive reverse transcriptase-PCR: an improved method for determination of c-erbB-2 gene expression. Schneeberger C, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):849–52

Estimating biodegradative gene numbers at a JP-5 contaminated site using PCR. Chandler DP, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:971–82

PCR for bioaerosol monitoring: sensitivity and environmental interference. Alvarez AJ, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3639–44

Nested PCR method for rapid and sensitive detection of Vibrio vulnificus in fish, sediments, and water. Arias CR, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3476–8

Collaborative evaluation of a method for the detection of Norwalk virus in shellfish tissues by PCR. Atmar RL, et al. **Appl Environ Microbiol** 1996 Jan;62(1):254–8

Detection of Norwalk virus and hepatitis A virus in shellfish tissues with the PCR. Atmar RL, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3014–8

Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes. Bassler HA, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3724–8

Specific PCR primers directed to identify cryI and cryIII genes within a Bacillus thuringiensis strain collection. Cerón J, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):3826–31

Isolation of a species-specific mitochondrial DNA sequence for identification of Tilletia indica, the Karnal bunt of wheat fungus. Ferreira MA, et al. **Appl Environ Microbiol** 1996 Jan;62(1):87–93

Detection and characterization of broad-host-range plasmids in environmental bacteria by PCR. Götz A, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2621–8

Direct detection of Listeria monocytogenes in 25 milliliters of raw milk by a two-step PCR with nested primers. Herman LM, et al. **Appl Environ Microbiol** 1995 Feb; 61(2):817–9

In situ PCR for visualization of microscale distribution of specific genes and gene products in prokaryotic communities. Hodson RE, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4074–82

Microscale detection of specific bacterial DNA in soil with a magnetic capture-hybridization and PCR amplification assay. Jacobsen CS. **Appl Environ Microbiol** 1995 Sep; 61(9):3347–52

Development of a PCR protocol for sensitive detection of Cryptosporidium oocysts in water samples. Johnson DW, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3849–55

Development of a PCR for identification of Naegleria fowleri from the environment. Kilvington S, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3764–7

Rapid and accurate identification of Escherichia coli K-12 strains. Kuhnert P, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):4135–9

Typing of rhizobia by PCR DNA fingerprinting and PCR-restriction fragment length polymorphism analysis of chromosomal and symbiotic gene regions: application to Rhizobium leguminosarum and its different biovars. Laguerre G, et al. **Appl Environ Microbiol** 1996 Jun; 62(6):2029–36

Simplified method for recovery and PCR detection of Cryptosporidium DNA from bovine feces. Leng X, et al. **Appl Environ Microbiol** 1996 Feb;62(2):643–7

A new method for direct detection of Listeria monocytogenes from foods by PCR. Makino S, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3745–7

Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chlamydia sp. strains. Ossewaarde JM, et al. **Appl Environ Microbiol** 1996 Feb;62(2):328–31

Detection of Legionella species in reclaimed water and air with the EnviroAmp Legionella PCR kit and direct fluorescent antibody staining. Palmer CJ, et al. **Appl Environ Microbiol** 1995 Feb;61(2):407–12

PCR detection of Ti and Ri plasmids from phytopathogenic Agrobacterium strains. Sawada H, et al. **Appl Environ Microbiol** 1995 Feb;61(2):828–31

Concentration and purification of beef extract mock eluates from water samples for the detection of enteroviruses, hepatitis A virus, and Norwalk virus by reverse transcription-PCR. Schwab KJ, et al. **Appl Environ Microbiol** 1995 Feb;61(2):531–7

Application of reverse transcriptase PCR for monitoring expression of the catabolic dmpN gene in a phenol-degrading sequencing batch reactor. Selvaratnam S, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3981–5

Bias caused by template annealing in the amplification of mixtures of 16S rRNA genes by PCR. Suzuki MT, et al.

Appl Environ Microbiol 1996 Feb;62(2):625–30
PCR for direct detection of indigenous uncultured magnetic cocci in sediment and phylogenetic analysis of amplified 16S ribosomal DNA. Thornhill RH, et al.
Appl Environ Microbiol 1995 Feb;61(2):495–500
Direct DNA extraction for PCR-mediated assays of soil organisms. Volossiouk T, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3972–6
DRB polymerase chain reaction fingerprinting, DQA oligotyping and mixed lymphocyte culture results in related bone marrow donors and recipients. Brojer E, et al.
Arch Immunol Ther Exp (Warsz) 1995;43(2):89–92
Use of spontaneously mutated human DNA as competitive internal standard for nucleic acid quantification by reverse transcription–polymerase chain reaction (RT–PCR). Rudnicka L, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(2):111–5
Acquired immunodeficiency syndrome—associated herpes simplex virus retinitis. Clinical description and use of a polymerase chain reaction—based assay as a diagnostic tool. Cunningham ET Jr, et al. **Arch Ophthalmol** 1996 Jul; 114(7):834–40
Detecting varicella–zoster virus DNA in iridocyclitis using polymerase chain reaction: a case of zoster sine herpete [letter] Yamamoto S, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1358–9
Utility of a rapid polymerase chain reaction panel for the detection of molecular changes in B-cell lymphoma. Abdel-Reheim FA, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):357–63
Prospective comparison of culture vs genome detection for diagnosis of enteroviral meningitis in childhood. Tanel RE, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):919–24
Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers. Achiron A, et al. **Arch Virol** 1996; 141(1):147–53
Development of polymerase chain reaction for specific identification of epizootic hemorrhagic disease virus serotype 1. Aradaib IE, et al. **Arch Virol** 1995; 140(12):2273–81
Detection of latent varicella zoster virus DNA and human gene sequences in human trigeminal ganglia by in situ amplification combined with in situ hybridization. Dueland AN, et al. **Arch Virol** 1995;140(11):2055–66
Polymerase chain reaction–based genotyping of the constant segment of immunoglobulin kappa shows weak or no association with rheumatoid arthritis. Singh R, et al.
Arthritis Rheum 1995 Oct;38(10):1526–7
Studies of intraspecies heterogeneity of mycoplasma synoviae, M. meleagridis, and M. iowae with arbitrarily primed polymerase chain reaction. Fan HH, et al.
Avian Dis 1995 Oct–Dec;39(4):766–77
Combining the technique of RNA fingerprinting and differential display to obtain differentially expressed mRNA. Diachenko LB, et al.
Biochem Biophys Res Commun 1996 Feb 27;219(3):824–8
Nested-polymerase chain reaction for the detection of Helicobacter pylori infection with novel primers designed by sequence analysis of urease A gene in clinically isolated bacterial strains. Kawamata O, et al.
Biochem Biophys Res Commun 1996 Feb 6;219(1):266–72
The use of RT–PCR to distinguish between plasmid MnSOD transcripts and endogenous MnSOD mRNA. Li JJ, et al.
Biochem Biophys Res Commun 1995 Nov 13;216(2):610–8
An AeI allele-specific nucleotide insertion at the blood group ABO locus and its detection using a sequence-specific polymerase chain reaction. Olsson ML, et al.
Biochem Biophys Res Commun 1995 Nov 13;216(2):642–7
Comparison of different quantitative PCR procedures in the analysis of the 4977-bp deletion in human mitochondrial DNA. Zhang C, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):450–5
Detection, simultaneous display and direct sequencing of multiple nuclear hormone receptor genes using bilaterally targeted RNA fingerprinting. Yoshikawa T, et al.
Biochim Biophys Acta 1995 Oct 17;1264(1):63–71
Identification of introns by reverse–transcription PCR. Alexander H, et al. **Biotechniques** 1996 May;20(5):778–80
Allele-specific HLA-DRB1 amplification of forensic evidence samples with mixed genotypes. Allen M, et al. **Biotechniques** 1995 Sep;19(3):454–63
Sensitive, nonradioactive differential display method using chemiluminescent detection. An G, et al. **Biotechniques** 1996 Mar;20(3):342–4, 346
Detection of DNA in single cells using an automated cell deposition unit and PCR. Bertram S, et al.
Biotechniques 1995 Oct;19(4):616–20
Construction of quantitative RT-PCR MIMICs. Borriello F, et al. **Biotechniques** 1995 Oct;19(4):580–2, 584
Secondary structure in the 3' UTR of EGF and the choice of reverse transcriptases affect the detection of message diversity by RT–PCR. Brooks EM, et al. **Biotechniques** 1995 Nov;19(5):806–12, 814–5
Screening of homozygous transgenic mice by comparative PCR. Chatelain G, et al. **Biotechniques** 1995 Jun; 18(6):958–60, 962
Spheroplast preparation facilitates PCR screening of yeast sequence. Chen HR, et al. **Biotechniques** 1995 Nov; 19(5):744–6, 748
Simultaneous extraction of DNA and RNA from nuclease-rich pathogenic protozoan Trichomonas vaginalis. Chou CF, et al. **Biotechniques** 1996 May; 20(5):790–1
Detection and capture of 35S-labeled gas released from reaction tubes during differential display PCR. Clinton M, et al. **Biotechniques** 1995 Nov;19(5):798–9
Method to identify biases in PCR amplification of T-cell receptor variable region genes. Daniel ES, et al.
Biotechniques 1996 Apr;20(4):600–2
Qualitative low-level internal control for nested RT-PCR. Denis MG, et al. **Biotechniques** 1995 Dec;19(6):906–8
Inhibition of PCR by mineral oil exposed to UV irradiation for prolonged periods. Dohner DE, et al. **Biotechniques** 1995 Jun;18(6):964–7
Quantitative RT–PCR on CYP1A1 heterogeneous nuclear RNA: a surrogate for the in vitro transcription run-on assay. Elferink CJ, et al. **Biotechniques** 1996 Mar; 20(3):470–7
Use of elevated reverse transcription reaction temperatures in RT–PCR. Freeman WM, et al. **Biotechniques** 1996 May; 20(5):782–3
Identification of DNA polymorphism by asymmetric–PCR SSCP. Fujita T, et al. **Biotechniques** 1995 Oct;19(4):532–4
Direct–rapid (DR) mutagenesis of large plasmids using PCR. Gatlin J, et al. **Biotechniques** 1995 Oct;19(4):559–64
Amplification of 18 dystrophin gene exons in DMD/BMD patients: simultaneous resolution by capillary electrophoresis in sieving liquid polymers. Gelfi C, et al. **Biotechniques** 1995 Aug;19(2):254–8, 260–3
PCR-based quantitation of transfected luciferase DNA: evaluation using an Entamoeba histolytica reporter construct. Gilchrist CA, et al. **Biotechniques** 1996 May; 20(5):764, 768, 770 passim
Long RT–PCR amplification of full-length enterovirus genome. Gow JW, et al. **Biotechniques** 1996 Apr; 20(4):582–4
High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. Hecker KH, et al. **Biotechniques** 1996 Mar;20(3):478–85
Comments on a recently published PCR method for site-directed mutagenesis. Heda GD. **Biotechniques** 1996 May;20(5):880
Rapid restriction mapping by use of long PCR. Her C, et al. **Biotechniques** 1995 Oct;19(4):530–2
Direct molecular analysis of archival tumor tissue for loss of heterozygosity. Johnson DR, et al. **Biotechniques** 1995 Aug;19(2):190–2
Sensitivity of tyrosinase mRNA detection by RT–PCR: rTth DNA polymerase vs. MMLV–RT and AmpliTaq polymerase. Juhasz A, et al. **Biotechniques** 1996 Apr; 20(4):592–600
Enzymatically produced composite primers: an application of T4 RNA ligase-coupled primers to PCR. Kaluz S, et al. **Biotechniques** 1995 Aug;19(2):182–4, 186
Identification of conserved sequences for PCR primer design by multiple alignments of dot matrix plots. Karikó K.
Biotechniques 1995 Jun;18(6):1048–9
DNaseI treatment is a prerequisite for the amplification of cDNA from episomal-based genes. Kienzle N, et al.
Biotechniques 1996 Apr;20(4):612–6
Single-step immunocapture RT–PCR in the detection of raspberry bushy dwarf virus. Kokko HI, et al.
Biotechniques 1996 May;20(5):842–6
Improvement of the gene splicing overlap (SOE) method. Lefebvre B, et al. **Biotechniques** 1995 Aug;19(2):186–8
Multiplex sets for the amplification of polymorphic short tandem repeat loci—silver stain and fluorescence detection. Lins AM, et al. **Biotechniques** 1996 May;20(5):882–9
Differential display from plant leaves using oligo(dT) magnetic bead mRNA isolation and hot air PCR. McKendree WL Jr, et al. **Biotechniques** 1995 Nov; 19(5):715–6, 719
Obtaining genetic markers by using double-stringency PCR with microsatellites and arbitrary primers. Matioli SR, et al. **Biotechniques** 1995 Nov;19(5):752–6, 758
Subtractive hybridization strategy using paramagnetic oligo(dT) beads and PCR. Mészáros M, et al.
Biotechniques 1996 Mar;20(3):413–9
Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Nijhuis M, et al. **Biotechniques** 1995 Aug; 19(2):178–80, 182
Isolation of DNA from stool and bodily fluids for PCR amplification. Nollau P, et al. **Biotechniques** 1996 May; 20(5):784–8
LA-PCR-based quick method for the identification of genes responsible for the complementation of Saccharomyces cerevisiae mutations. Ohya Y. **Biotechniques** 1996 May; 20(5):772–4, 778
Use of Multiscreen plates for the preparation of bacterial DNA suitable for PCR. Reek FH, et al. **Biotechniques** 1995 Aug;19(2):282–5
Screening for recombinant plasmids in yeast colonies of the two-hybrid system using PCR. Schenk JA, et al.
Biotechniques 1996 May;20(5):812–4, 816
PCR-mediated synthesis of exogenous competitors for quantitative RT–PCR. Schneeberger C, et al.
Biotechniques 1996 Mar;20(3):360–2
Nonradioactive characterization of low-level heteroplasmic mitochondrial DNA mutations by SSCP–PCR enrichment. Sherratt EJ, et al. **Biotechniques** 1996 Mar;20(3):430–2
PCR with random primers to obtain sequence from yeast artificial chromosome insert ends or plasmids. Swensen J. **Biotechniques** 1996 Mar;20(3):486–91
Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT–PCR. Tarnuzzer RW, et al. **Biotechniques** 1996 Apr;20(4):670–4
Amplification of divergent retroelements by PCR. Tristem M. **Biotechniques** 1996 Apr;20(4):608–12
Single-tube protocol for the extraction of DNA or RNA from paraffin-embedded tissues using a starch-based adhesive. Turbett GR, et al. **Biotechniques** 1996 May; 20(5):846–50, 852–3
Multiple mutant cDNAs from one reaction mixture using asymmetric primers in PCR. Wang F, et al.
Biotechniques 1995 Oct;19(4):556–9
Multiplex–PCR–based single–strand conformation polymorphism protocol for simultaneous analysis of up to five fragments of the low-density-lipoprotein receptor gene. Weiss N, et al. **Biotechniques** 1996 Mar;20(3):421–4, 426, 428–9
Method for constructing internal standards for use in competitive PCR. Zarlenga DS, et al. **Biotechniques** 1995 Sep;19(3):324–6
Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Akasaka T, et al. **Blood** 1996 Aug 1;88(3):985–94
Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Sarris AH, et al.
Blood 1996 Sep 1;88(5):1771–9
A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients. Testoni N, et al.
Blood 1996 May 1;87(9):3822–7
Novel CBFB–MYH11 fusion transcripts or reverse transcription–polymerase chain reaction artifacts? [letter; comment] van der Reijden BA, et al. **Blood** 1996 Mar 15; 87(6):2605. Comment on: Blood 1995 Sep 15;86(6):2449–50.
Development of a clonality assay for canine hematopoietic stem cells [letter] Wagner LA, et al. **Blood** 1995 Oct 15; 86(8):3265–7
Improved single–step PCR assay for sex identification post–allogeneic sex–mismatched BMT. Pugatsch T, et al.
Bone Marrow Transplant 1996 Feb;17(2):273–5
Detection of the heat-stable toxin coding gene (ST-gene) in enterotoxigenic Escherichia coli: development of a colour amplified PCR detection system. Fanning S, et al.
Br J Biomed Sci 1995 Dec;52(4):317–20
Direct sample polymerase chain reaction for the detection of Mycoplasma pneumoniae: a simple system for clinical application. Fink CG, et al. **Br J Biomed Sci** 1995 Mar; 52(1):9–13
Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription–polymerase chain reaction. Carr M, et al. **Br J Cancer** 1995 Dec;72(6):1427–34
RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase–n–polymerase chain reaction approach on archival–nested material. Williams GH, et al. **Br J Cancer** 1996 Aug;74(4):585–9
Rapid diagnosis of beta–thalassaemia by mutagenically separated polymerase chain reaction (MS–PCR) and its application to prenatal diagnosis. Chang JG, et al.
Br J Haematol 1995 Nov;91(3):602–7
The use of IgH fingerprinting and ASO–dependent PCR for the investigation of residual disease (MRD) in ALL. Chim JC, et al. **Br J Haematol** 1996 Jan;92(1):104–15
A simple method for synthesis of B-cell clonospecific probes. Saal RJ, et al. **Br J Haematol** 1995 Nov;91(3):575–7
Glass slide smears are a suitable source for RT–PCR–based analysis of chromosomal aberrations in leukaemias. Schoch R, et al. **Br J Haematol** 1996 Jan;92(1):140–2
Rapid and semiquantitative analysis of HSP72 and HSC73 heat shock mRNAs by mimic RT–PCR. Abe K, et al.
Brain Res 1995 Jun 19;683(2):251–3
Differential expression of somatostatin receptors by quantitative PCR in the rat brain. Viollet C, et al.
C R Acad Sci III 1995 Aug;318(8):851–7
Rapid detection of bovine herpesvirus 1 in the semen of infected bulls by a nested polymerase chain reaction assay. Masri SA, et al. **Can J Vet Res** 1996 Apr;60(2):100–7
Detection of Mycobacterium paratuberculosis in formalin–fixed paraffin–embedded tissues by the polymerase chain reaction. Plante Y, et al.
Can J Vet Res 1996 Apr;60(2):115–20
Looking forward in diagnostic pathology: the molecular superhighway [editorial; comment] Abati A, et al.
Cancer 1996 Jul 1;78(1):1–3. Comment on: Cancer 1996 Jul 1;78(1):10–6.
Polymerase chain reaction in the detection of micrometastases and circulating tumor cells [see comments] Ghossein RA, et al. **Cancer** 1996 Jul 1;78(1):10–6 (41 ref.) . Comment in: Cancer 1996 Jul 1;78(1):1–3.
Clonal analysis by polymerase chain reaction of B-cell lymphoma with late relapse: a report of five cases. Nishiuchi R, et al. **Cancer** 1996 Feb 15;77(4):757–62
Human metallothionein gene expression determined by quantitative reverse transcription–polymerase chain reaction as a biomarker of cadmium exposure. Ganguly S, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr; 5(4):297–301
The reliability of the differential polymerase chain reaction

compared to restriction fragment length polymorphism for the detection of gene loss in primary tumors. Sugawa N, et al. **Cancer Lett** 1996 Feb 6;99(2):139–46

Detection of a mutator phenotype in cancer cells by inter–Alu polymerase chain reaction. Krajinovic M, et al. **Cancer Res** 1996 Jun 15;56(12):2733–7

Simultaneous amplification of four DNA repair genes and beta–actin in human lymphocytes by multiplex reverse transcriptase–PCR. Wei Q, et al. **Cancer Res** 1995 Nov 1;55(21):5025–9

Detection of hepatitis C viral RNA: comparison of Amplicor single PCR and nested set PCR processes with HCV serology for hemodialyzed patients. Bogard M, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):725–30

Improvement of cervical Chlamydia detection in asymptomatic family planning attendees by using Amplicor Chlamydia trachomatis assay. Chout R, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):731–6

Automated determination of amplified PCR products: application to HCV viremia detection and quantification. Clossais Besnard N, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Nov;41(7):959–66

Determination of amplification level of the c–erbB–2 proto–oncogene in human breast carcinomas: a comparative study between non–radioactive and radioactive labelling. Edorh A, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Nov;41(7):967–73

PCR and non–isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):639–52 (94 ref.)

Detection and identification of Campylobacter spp. using the polymerase chain reaction. Giesendorf BA, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):625–38 (123 ref.)

The applications of the polymerase chain reaction in the life sciences. Lenstra JA. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):603–14 (89 ref.)

PCR–VNTRs (PCR–Variable Number of Tandem Repeats) in forensic science. Möller A, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):715–24

Cloning novel alfalfa cyclin sequences—a RACE–PCR approach. Russinova E, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):703–14

Basics of quantitative PCR 1: image analysis and quantitation of PCR products. Sundfors C, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):671–81

Quantitative analysis of lymphokine mRNA expression by an automated, non–radioactive method. Vandevyver C, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):683–94

Applications of random PCR. von Eggeling F, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):653–70 (70 ref.)

Diheteroduplex formation using gold labeled single–stranded PCR fragments and its application in electron microscopy. Bock CT, et al. **Chromosoma** 1995 May;103(9):653–7

Characterisation of repeated sequences from microdissected B chromosomes of Crepis capillaris. Jamilena M, et al. **Chromosoma** 1995 Nov;104(2):113–20

Determination of polymerase chain reaction products by time–resolved immunofluorometry. Bortolin S, et al. **Clin Biochem** 1996 Apr;29(2):179–82

Discrimination of Streptococcus pneumoniae from other upper respiratory tract streptococci by arbitrarily primed PCR. Messmer TO, et al. **Clin Biochem** 1995 Dec; 28(6):567–72

Rapid competitive PCR determination of relative gene expression in limiting tissue samples. Jiang YH, et al. **Clin Chem** 1996 Feb;42(2):227–31

Detection of immobilized amplicons by ELISA–like techniques. Oroskar AA, et al. **Clin Chem** 1996 Sep; 42(9):1547–55

A sensitive and specific PCR method to detect Helicobacter felis in a conventional mouse model. Kong L, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):73–8

PCR detection of colonization by Helicobacter pylori in conventional, euthymic mice based on the 16S ribosomal gene sequence. Smith JG, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):66–72

Cloning of porcine cytokine–specific cDNAs and detection of porcine tumor necrosis factor alpha, interleukin 6 (IL–6), and IL–1 beta gene expression by reverse transcription PCR and chemiluminescence hybridization. Vézina SA, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):665–71

Flow cytometric immunodetection of human immunodeficiency virus type 1 proviral DNA by heminested PCR and digoxigenin–labeled probes. Yang G, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):26–31

"Single step" PCR with a sensitivity similar to nested PCR for the detection of hepatitis C virus RNA. Farma E, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S59–61

Arbitrarily primed polymerase chain reaction analysis of periodontal pathogens: discriminative primers and genetic diversity. Chen C, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S301–3

Comprehensive typing of HLA–DPB1 alleles by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Sengar DP, et al. **Clin Invest Med** 1995 Dec; 18(6):465–72

Expression of collagens I, III, IV and V mRNA in excimer wounded rat cornea: analysis by semi–quantitative PCR. Power WJ, et al. **Curr Eye Res** 1995 Oct;14(10):879–86

A rapid and highly efficient method for PCR–based site–directed mutagenesis using only one new primer. Boles E, et al. **Curr Genet** 1995 Jul;28(2):197–8

Satellite DNA as a target for PCR–specific detection of the plant–parasitic nematode Meloidogyne hapla. Castagnone–Sereno P, et al. **Curr Genet** 1995 Nov; 28(6):566–70

Use of the polymerase chain reaction to identify coding sequences for chitin synthase isozymes in Phialophora verrucosa. Peng M, et al. **Curr Genet** 1995 May; 27(6):517–23

Recent advances in differential display. Liang P, et al. **Curr Opin Immunol** 1995 Apr;7(2):274–80 (41 ref.)

Amplification and detection of a Y–chromosome DNA sequence by fluorescence in situ polymerase chain reaction and flow cytometry using cells in suspension. Timm EA Jr, et al. **Cytometry** 1995 Sep 15;22(3):250–5

Flow cytometric detection of human immunodeficiency virus type 1 proviral DNA by the polymerase chain reaction incorporating digoxigenin– or fluorescein–labeled dUTP. Yang G, et al. **Cytometry** 1995 Oct 1;21(2):197–202

Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicals. Bruckner L, et al. **Dev Biol Stand** 1996; 86:175–82

Hepatitis B virus polymerase chain reaction—a possible alternative method to the in vivo assay using chimpanzees. Chudy M, et al. **Dev Biol Stand** 1996;86:328

A pitfall in the association study of ACE gene polymorphism [letter] Odawara M, et al. **Diabetes Care** 1996 May; 19(5):543–4

Improved polymerase chain reaction detection of clonal T–cell lymphoid neoplasms. Benhattar J, et al. **Diagn Mol Pathol** 1995 Jun;4(2):108–12

Introduction to quantitative reverse transcription polymerase chain reaction. Salomon RN. **Diagn Mol Pathol** 1995 Jun; 4(2):82–4 (8 ref.)

A rapid polymerase chain reaction–based technique for detecting clonal T–cell receptor gene rearrangements in cutaneous T–cell lymphomas of both the alpha beta and gamma delta varieties. Yu RC, et al. **Diagn Mol Pathol** 1996 Jun;5(2):121–6

HLA–B27 determination by polymerase chain reaction. Kilpatrick DC. **Dis Markers** 1996 Mar;12(4):247–51

Fidelity and predominant mutations produced by deep vent wild–type and exonuclease–deficient DNA polymerases during in vitro DNA amplification. Huang H, et al. **DNA Cell Biol** 1996 Jul;15(7):589–94

Chromosomal assignment of short cDNA sequences by PCR using overlapping and tailed short primers. Chae KS, et al. **DNA Res** 1994;1(3):149–55

A PCR–mediated method for cloning spot DNA on restriction landmark genomic scanning (RLGS) gel. Suzuki H, et al. **DNA Res** 1994;1(5):245–50

Application of dual internal standards for precise sizing of polymerase chain reaction products using capillary electrophoresis. Butler JM, et al. **Electrophoresis** 1995 Jun; 16(6):974–80

Immunoprinting reveals different genetic bases for (auto)immuno diseases. Epplen C, et al. **Electrophoresis** 1995 Sep;16(9):1693–7 (32 ref.)

Separation and quantitation of reverse transcriptase polymerase chain reaction fragments of basic fibroblast growth factor by capillary electrophoresis in polymer networks. Gelfi C, et al. **Electrophoresis** 1995 May; 16(5):780–3

The influence of proteins on silver staining of nucleic acids following polyacrylamide gel electrophoresis. Hilbert F, et al. **Electrophoresis** 1995 Jun;16(6):903–4

Temperature gradient gel electrophoresis for analysis of a polymerase chain reaction–based diagnostic clonality assay in the early stages of cutaneous T–cell lymphomas. Menke MA, et al. **Electrophoresis** 1995 May;16(5):733–8

Quantitation of polymerase chain reaction–amplified DNA fragments by capillary electrophoresis and laser–induced fluorescence detection. Vincent U, et al. **Electrophoresis** 1996 Mar;17(3):512–7

TCR beta PCR from crude preparations for restriction digest or sequencing. Clark LS, et al. **Environ Mol Mutagen** 1996; 27(1):34–8

Detection of pathogenic Yersinia enterocolitica using the multiplex polymerase chain reaction. Harnett N, et al. **Epidemiol Infect** 1996 Aug;117(1):59–67

Specific detection of Salmonella enterica serotype Enteritidis using the polymerase chain reaction. Lampel KA, et al. **Epidemiol Infect** 1996 Apr;116(2):137–45

Quantitative measurement of mouse cytokine mRNA by polymerase chain reaction. Jia GQ, et al. **Eur Cytokine Netw** 1995 Jul–Dec;6(4):253–5

Quantification of cytokine gene expression by competitive PCR using a colorimetric assay. Zou W, et al. **Eur Cytokine Netw** 1995 Jul–Dec;6(4):257–64

Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase–polymerase chain reaction (RT–PCR) for tyrosine hydroxylase mRNA. Burchill SA, et al. **Eur J Cancer** 1995;31A(4):553–6

A multiplex PCR assay for routine evaluation of deletion of the short arm of chromosome 1 in neuroblastoma. Schleiermacher G, et al. **Eur J Cancer** 1995;31A(4):535–8

Nested polymerase chain reaction for detection of hepatitis C virus RNA in blood derivatives. Gall–Trošelj K, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):733–6

Reverse transcription–polymerase chain reaction detection of collagen transcripts in healing human wounds. Hopkinson I, et al. **Eur J Clin Invest** 1995 Jul;25(7):539–42

Rapid polymerase chain reaction method for specific detection of toxigenic Clostridium difficile. Arzese A, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):716–9

HLA–DQB1 and DQA1 matching by ambient temperature PCR–SSCP. Clay TM, et al. **Eur J Immunogenet** 1995 Dec; 22(6):467–78

Rapid characterization of HLA class I alleles by gene mapping using ARMS PCR. Krausa P, et al. **Eur J Immunogenet** 1995 Jun;22(3):283–7

HLA–DQA1 and –DQB1 genotyping by PCR–RFLP, heteroduplex and homoduplex analysis. Teutsch SM, et al. **Eur J Immunogenet** 1996 Apr;23(2):107–20

Rapid detection of mitochondrial deletions by long–distance polymerase chain reaction [letter] Kreuder J, et al. **Eur J Pediatr** 1995 Dec;154(12):996

Diagnostic DNA amplification from individual tick eggs, larvae and nymphs. Zahler M, et al. **Exp Appl Acarol** 1995 Dec;19(12):731–6

RT–PCR and alternative methods to PCR for in vitro amplification of nucleic acids. Hagen–Mann K, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):150–5 (22 ref.)

Trypanosoma cruzi: parasite detection and strain discrimination in chronic chagasic patients from northeastern Brazil using PCR amplification of kinetoplast DNA and nonradioactive hybridization. Britto C, et al. **Exp Parasitol** 1995 Dec;81(4):462–71

Theileria sergenti and T. buffeli: polymerase chain reaction–based marker system for differentiating the parasite species from infected cattle blood and infected tick salivary gland. Kawazu S, et al. **Exp Parasitol** 1995 Dec; 81(4):430–5

Plasmodium: a quantitative molecular assay for detection of sporogonic–stage malaria parasites. Vernick KD, et al. **Exp Parasitol** 1995 Dec;81(4):436–44

Ultrarapid metabolizers of debrisoquine: characterization and PCR–based detection of alleles with duplication of the CYP2D6 gene. Løvlie R, et al. **FEBS Lett** 1996 Aug 19; 392(1):30–4

Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. Yamamoto S, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):85–90

Rapid, direct extraction of DNA from soils for PCR analysis using polyvinylpolypyrrolidone spin columns. Berthelet M, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):17–22

Development of a genus specific primer set for detection of Leishmania parasites by polymerase chain reaction. Bhattacharyya R, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):195–200

Rapid identification of Acremonium lolii and Acremonium coenophialum endophytes through arbitrarily primed PCR. Liu D, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1–2):95–8

The use of PCR to isolate a putative ABC transporter from Saccharopolyspora erythraea. O'Neill MP, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):189–95

A new set of primers for the detection of Toxoplasma gondii in amniotic fluid using polymerase chain reaction. Pelloux H, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):11–5

Flow cytometric detection of specific genes in genetically modified bacteria using in situ polymerase chain reaction. Porter J, et al. **FEMS Microbiol Lett** 1995 Dec 1; 134(1):51–6

Species–specific detection of Legionella using polymerase chain reaction and reverse dot–blotting. Robinson PN, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):111–9

Polymerase chain reaction–based detection of bacteria in semen. Jarvi K, et al. **Fertil Steril** 1996 Sep;66(3):463–7

Sex determination by simultaneous application of polymerase chain reaction and fluorescent in situ hybridization on the same blastomere of a pre–embryo. Sasabe Y, et al. **Fertil Steril** 1996 Sep;66(3):490–2

Evaluation and usefulness of reverse dot blot DNA–PolyMarker typing in forensic case work. Dimo–Simonin N, et al. **Forensic Sci Int** 1996 Jul 31; 81(1):61–72

Km genotyping by polymerase chain reaction (PCR) using allele–specific amplification primers. Yamamoto Y, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):85–93

Sex identification of archaeological human remains based on amplification of the X and Y amelogenin alleles. Faerman M, et al. **Gene** 1995 Dec 29;167(1–2):327–32

PCR haplotypes for the human Y chromosome based on alphoid satellite DNA variants and heteroduplex analysis. Santos FR, et al. **Gene** 1995 Nov 20;165(2):191–8

PCR strategies for isolation of the 5' end of an immunoglobulin–encoding bovine cDNA. Sinclair MC, et al. **Gene** 1995 Dec 29;167(1–2):285–9

Single–step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Stemmer WP, et al. **Gene** 1995 Oct 16;164(1):49–53

Identification of epidemiologic markers for Neisseria meningitidis using difference analysis. Strathdee CA, et al. **Gene** 1995 Dec 1;166(1):105–10

A recombinant PCR approach requiring only three non–chimeric primers to generate a minigene of interest. Chotani MA, et al. **Genet Anal** 1996 Jan;12(3–4):133–5

T–vector cloning and high performance PCR with SuperTth from Thermus thermophilus. Leal JF, et al. **Genet Anal** 1995 Oct;12(2):119–21

Use of 'long' polymerase chain reaction and magnetic beads for extraction of chromosome-specific cDNAs. Liang BC. **Genet Anal** 1995 Oct;12(2):105-8

A sensitive method of testing for transgenic mice using polymerase chain reaction-southern hybridization. Sato M, et al. **Genet Anal** 1995 Oct;12(2):109-11

A mass screening device of genome by polymerase chain reaction-restriction fragment-single strand conformation polymorphism analysis. Tawata M, et al. **Genet Anal** 1996 Jan;12(3-4):125-7

Sensitivity of a commercial polymerase chain reaction for different serovars of Chlamydia trachomatis present at low titre in clinical samples [letter] Frost EH, et al. **Genitourin Med** 1995 Oct;71(5):327-8

A PCR assay for detection of a 2RL.2BS wheat-rye chromosome translocation. Lee JH, et al. **Genome** 1996 Jun; 39(3):605-8

Long RT-PCR of the entire 8.5-kb NF1 open reading frame and mutation detection on agarose gels. Martinez JM, et al. **Genome Res** 1996 Jan;6(1):58-66

PCR-LIS-SSCP (Low ionic strength single-stranded conformation polymorphism)--a simple method for high-resolution allele typing of HLA-DRB1, -DQB1, and -DPB1. Maruya E, et al. **Genome Res** 1996 Jan;6(1):51-7

Reduction of mispriming in amplification reactions with restricted PCR. Puskás LG, et al. **Genome Res** 1995 Oct; 5(3):309-11

A commentary on the practical applications of competitive PCR. Raeymaekers L. **Genome Res** 1995 Aug;5(1):91-4

Approach to genotyping errors caused by nontemplated nucleotide addition by Taq DNA polymerase. Smith JR, et al. **Genome Res** 1995 Oct;5(3):312-7

Generation of entire human papillomavirus genomes by long PCR: frequency of errors produced during amplification. Stewart AC, et al. **Genome Res** 1995 Aug;5(1):79-88

A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Minami M, et al. **Genomics** 1995 Sep 20; 29(2):403-8

Detection of herpes simplex virus after penetrating keratoplasty by polymerase chain reaction: correlation of clinical and laboratory findings. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov;233(11):714-6

Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. Santini V, et al. **Haematologica** 1996 May-Jun;81(3):201-7

Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Moteki S, et al. **Hepatology** 1996 Jul;24(1):97-103

Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Yotsuyanagi H, et al. **Hepatology** 1996 Jul; 24(1):10-3

Polymerase chain reaction in situ: an appraisal of an emerging technique. Teo IA, et al. **Histochem J** 1995 Sep; 27(9):647-59 (67 ref.)

PCR in situ: aspects which reduce amplification and generate false-positive results. Teo IA, et al. **Histochem J** 1995 Sep; 27(9):660-9

Analysis of the BglI restriction fragment length polymorphism in the human factor VIII gene using "virtual PCR"--a novel approach employing the polymerase chain reaction in the absence of sequence information for the locus. Bowen DJ, et al. **Hum Genet** 1996 Aug;98(2):219-22

Generation of sequence-tagged sites from Xp22.3 by isolating common Alu-PCR products of radiation hybrids retaining overlapping human X chromosome fragments. Glass IA, et al. **Hum Genet** 1996 May;97(5):604-10

A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males. Haddad LA, et al. **Hum Genet** 1996 Jun;97(6):808-12

Reevaluation of the exact CAG repeat length in hereditary cerebellar ataxias using highly denaturing conditions and long PCR. Maruyama H, et al. **Hum Genet** 1996 May; 97(5):591-5

Non-invasive early prenatal molecular diagnosis using retrieved transcervical trophoblast cells. Massari A, et al. **Hum Genet** 1996 Feb;97(2):150-5

Rapid detection of trisomies 21 and 18 and sexing by quantitative fluorescent multiplex PCR. Pertl B, et al. **Hum Genet** 1996 Jul;98(1):55-9

Analysis of sex and delta F508 in single amniocytes using primer extension preamplification. Schaaff F, et al. **Hum Genet** 1996 Aug;98(2):158-61

Defining the allelic variants of HLA-A30 in the Sardinian population using amplification refractory mutation system--polymerase chain reaction. Krausa P, et al. **Hum Immunol** 1995 Sep;44(1):35-42

Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Maňlanka K, et al. **Hum Immunol** 1995 Sep;44(1):28-34

Improved oligonucleotide primer set for molecular diagnosis of X-linked agammaglobulinaemia: predominance of amino acid substitutions in the catalytic domain of Bruton's tyrosine kinase. Vořechovský I, et al. **Hum Mol Genet** 1995 Dec;4(12):2403-5

Simultaneous analysis of mutant and normal alleles for multiple cystic fibrosis mutations by the ligase chain reaction. Fang P, et al. **Hum Mutat** 1995;6(2):144-51

Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening. Orou A, et al. **Hum Mutat** 1995;6(2):163-9

Mutation detection by solid phase primer extension. Shumaker JM, et al. **Hum Mutat** 1996;7(4):346-54

Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Hsi ED, et al. **Hum Pathol** 1996 Mar;27(3):290-6

Optimal primer selection for clonality assessment by polymerase chain reaction analysis. III. Intermediate and high-grade B-cell neoplasms. Lombardo JF, et al. **Hum Pathol** 1996 Apr;27(4):373-80

Application of PCR for detection and identification of mycoplasma contamination in virus stocks. Hu M, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):710-5

Molecular nosocomial epidemiology: high speed typing of microbial pathogens by arbitrary primed polymerase chain reaction assays. van Belkum A, et al. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):658-66

Evaluation of the detection of Borrelia burgdorferi DNA in urine samples by polymerase chain reaction. Maiwald M, et al. **Infection** 1995 May-Jun;23(3):173-9

Detection of Epstein-Barr virus genome in squamous cell carcinomas of the larynx. Kiaris H, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):211-5

ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. An HX, et al. **Int J Cancer** 1995 Oct 20;64(5):291-7

Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Nollau P, et al. **Int J Cancer** 1996 May 3;66(3):332-6

Detection of human T-lymphotropic virus type-I DNA and mRNA in the lymph nodes; using polymerase chain reaction in situ hybridization (PCR/ISH) and reverse transcription (RT-PCR/ISH). Ohshima K, et al. **Int J Cancer** 1996 Mar 28;66(1):18-23

Diagnosis of cutaneous tuberculosis by polymerase chain reaction using a species-specific gene. Faizal M, et al. **Int J Dermatol** 1996 Mar;35(3):185-8

Misdiagnosis of tuberculosis in semen by the IS6110 PCR assay [letter] Tan WC, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):69-70

CMV-DNA detection in parenchymatous organs in cases of SIDS. Cecchi R, et al. **Int J Legal Med** 1995;107(6):291-5

Extraction of high quality DNA from bloodstains using diatoms. Günther S, et al. **Int J Legal Med** 1995; 108(3):154-6

DNA typing from human faeces. Hopwood AJ, et al. **Int J Legal Med** 1996;108(5):237-43

Detection of T to G mutation at position 59 in the Lewis gene by mismatch polymerase chain reaction. Koda Y, et al. **Int J Legal Med** 1995;107(6):280-2

High-resolution vertical PAGE: an alternative electrophoretic system with multiple forensic applications. Schneider HR, et al. **Int J Legal Med** 1996;108(5):276-9

GEDNAP IV and V. The 4th and 5th Stain Blind Trials using DNA technology. Wiegand P, et al. **Int J Legal Med** 1995;108(2):79-84

Detection of Neospora caninum DNA by the polymerase chain reaction. Payne S, et al. **Int J Parasitol** 1996 Apr; 26(4):347-51

Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. Conrad AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):425-35

A reverse transcriptase-PCR based assay for in-vitro antibiotic susceptibility testing of Chlamydia pneumoniae. Khan MA, et al. **J Antimicrob Chemother** 1996 Apr; 37(4):677-85

Detection of mutations conferring extended-spectrum activity on SHV beta-lactamases using polymerase chain reaction single strand conformational polymorphism (PCR-SSCP). M'Zali FH, et al. **J Antimicrob Chemother** 1996 Apr;37(4):797-802

Differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by a multiplex-polymerase chain reaction. Herrera EA, et al. **J Appl Bacteriol** 1996 Jun; 80(6):596-604

Use of two 16S DNA targeted oligonucleotides as PCR primers for the specific detection of Salmonella in foods. Lin CK, et al. **J Appl Bacteriol** 1996 Jun;80(6):659-66

Polymerase chain reaction for verification of fluorescent colonies of Erwinia chrysanthemi and Pseudomonas putida WCS358 in immunofluorescence colony staining. van der Wolf JM, et al. **J Appl Bacteriol** 1995 Nov;79(5):569-77

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163-9 (28 ref.)

Allelic dropout caused by allele-specific amplification failure in single-cell PCR of the cystic fibrosis delta F508 deletion. Dreesen JC, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):112-4

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96-103 (28 ref.)

Polymerase chain reaction amplification specificity: incidence of allele dropout using different DNA preparation methods for heterozygous single cells. Gitlin SA, et al. **J Assist Reprod Genet** 1996 Feb;13(2):107-11

Identifying the sex of human preimplantation embryos in X-linked disease: amplification efficiency of a Y-specific alphoid repeat from single blastomeres with two lysis protocols. Kontogianni EH, et al. **J Assist Reprod Genet** 1996 Feb;13(2):125-32

Reduced allele dropout in single-cell analysis for preimplantation genetic diagnosis of cystic fibrosis. Ray PF, et al. **J Assist Reprod Genet** 1996 Feb;13(2):104-6

Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). Rechitsky S, et al. **J Assist Reprod Genet** 1996 Feb;13(2):115-24

Use of PCR to isolate genes encoding sigma54-dependent activators from diverse bacteria. Kaufman RI, et al. **J Bacteriol** 1996 Jul;178(13):3967-70

A comparative study of PCR product detection and quantitation by electro-chemiluminescence and fluorescence. Yu H, et al. **J Biolumin Chemilumin** 1995 Jul-Aug;10(4):239-45

Intracellular localization of the mRNAs of argininosuccinate synthetase and argininosuccinate lyase around liver mitochondria, visualized by high-resolution in situ reverse transcription-polymerase chain reaction. Cohen NS. **J Cell Biochem** 1996 Apr;61(1):81-96

Analysis of ligase chain reaction products amplified in a silicon-glass chip using capillary electrophoresis. Cheng J, et al. **J Chromatogr A** 1996 Apr 26;732(1):151-8

Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. Lerat H, et al. **J Clin Invest** 1996 Feb 1;97(3):845-51

PCR in clinical diagnosis. Ronai Z, et al. **J Clin Lab Anal** 1995;9(4):269-83 (206 ref.)

PCR-based detection of Trypanosoma cruzi useful for specific diagnosis of human Chagas' disease [letter] **J Clin Microbiol** 1996 Feb;34(2):485-6

Identification of enteroviruses in clinical specimens by competitive PCR followed by genetic typing using sequence analysis. Arola A, et al. **J Clin Microbiol** 1996 Feb;34(2):313-8

PCR for diagnosis and follow-up of two cases of disseminated toxoplasmosis after kidney grafting [letter] Aubert D, et al. **J Clin Microbiol** 1996 May;34(5):1347

Molecular technique for rapid identification of mycobacteria. Avaniss-Aghajani E, et al. **J Clin Microbiol** 1996 Jan; 34(1):98-102

Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. Beall B, et al. **J Clin Microbiol** 1996 Apr;34(4):953-8

Evaluation of Amplicor PCR for direct detection of Mycobacterium tuberculosis from sputum specimens. Beavis KG, et al. **J Clin Microbiol** 1995 Oct;33(10):2582-6

Clinical evaluation of the Roche AMPLICOR PCR Mycobacterium tuberculosis test for detection of M. tuberculosis in respiratory specimens. Bergmann JS, et al. **J Clin Microbiol** 1996 May;34(5):1083-5

Detection of newly recognized rodent parvoviruses by PCR. Besselsen DG, et al. **J Clin Microbiol** 1995 Nov; 33(11):2859-63

Diagnosis of contagious caprine pleuropneumonia by detection and identification of Mycoplasma capricolum subsp. capripneumoniae by PCR and restriction enzyme analysis. Bölske G, et al. **J Clin Microbiol** 1996 Apr; 34(4):785-91

Use of PCR for prenatal and postnatal diagnosis of congenital rubella. Bosma TJ, et al. **J Clin Microbiol** 1995 Nov; 33(11):2881-7

Rapid identification of Campylobacter species by restriction fragment length polymorphism analysis of a PCR-amplified fragment of the gene coding for 16S rRNA. Cardarelli-Leite P, et al. **J Clin Microbiol** 1996 Jan; 34(1):62-7

Diagnosis of tuberculosis by Amplicor Mycobacterium tuberculosis test: a multicenter study. Carpentier E, et al. **J Clin Microbiol** 1995 Dec;33(12):3106-10

Identification and differentiation of Mycobacterium avium and M. intracellulare by PCR. Chen ZH, et al. **J Clin Microbiol** 1996 May;34(5):1267-9

Host DNA can interfere with detection of Borrelia burgdorferi in skin biopsy specimens by PCR. Cogswell FB, et al. **J Clin Microbiol** 1996 Apr;34(4):980-2

Comparison of PCR-based approaches to molecular epidemiologic analysis of Clostridium difficile. Collier MC, et al. **J Clin Microbiol** 1996 May;34(5):1153-7

Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellulare in blood culture fluids of AIDS patients [letter; comment] Cormican MG, et al. **J Clin Microbiol** 1995 Aug;33(8):2230. Comment on: J Clin Microbiol 1995 Mar;33(3):668-74.

Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. Coutlée F, et al. **J Clin Microbiol** 1995 Aug;33(8):1973-8

Sensitive PCR diagnosis of Infections by Enterocytozoon bieneusi (microsporidia) using primers based on the region coding for small-subunit rRNA. da Silva AJ, et al. **J Clin Microbiol** 1996 Apr;34(4):986-7

Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization. De Beenhouwer H, et al. **J Clin Microbiol** 1995 Nov;33(11):2994-8

Multiprimer PCR system for differential identification of mycobacteria in clinical samples. Del Portillo P, et al. **J Clin Microbiol** 1996 Feb;34(2):324-8

Molecular genotyping of methicillin-resistant

Staphylococcus aureus via fluorophore-enhanced repetitive-sequence PCR. Del Vecchio VG, et al. **J Clin Microbiol** 1995 Aug;33(8):2141-4

Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean. Devallois A, et al. **J Clin Microbiol** 1996 May;34(5):1065-8

Detection of Theileria annulata in blood samples of carrier cattle by PCR. d'Oliveira C, et al. **J Clin Microbiol** 1995 Oct;33(10):2665-9

Immunomagnetic separation and PCR for detection of Helicobacter pylori in water and stool specimens. Enroth H, et al. **J Clin Microbiol** 1995 Aug;33(8):2162-5

Identification of Actinobacillus actinomycetemcomitans in subgingival plaque by PCR. Flemmig TF, et al. **J Clin Microbiol** 1995 Dec;33(12):3102-5

PCR for detection of Clostridium botulinum type C in avian and environmental samples. Franciosa G, et al. **J Clin Microbiol** 1996 Apr;34(4):882-5

Detection of Escherichia coli O157:H7 by multiplex PCR. Fratamico PM, et al. **J Clin Microbiol** 1995 Aug; 33(8):2188-91

Detection of respiratory syncytial virus by reverse transcription-PCR and hybridization with a DNA enzyme immunoassay. Freymuth F, et al. **J Clin Microbiol** 1995 Dec;33(12):3352-5

Discrimination of Mycobacterium tuberculosis strains by PCR [letter; comment] Frothingham R. **J Clin Microbiol** 1995 Oct;33(10):2801-2. Comment on: J Clin Microbiol 1995 May;33(5):1418-20.

Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel. Gilbert LL, et al. **J Clin Microbiol** 1996 Jan;34(1):140-3

Discrimination of respiratory syncytial virus subgroups A and B by reverse transcription-PCR. Gottschalk J, et al. **J Clin Microbiol** 1996 Jan;34(1):41-3

Development of nested PCR based on the ViaB sequence to detect Salmonella typhi. Hashimoto Y, et al. **J Clin Microbiol** 1995 Nov;33(11):3082

Evaluation of mtp40 genomic fragment amplification for specific detection of Mycobacterium tuberculosis in clinical specimens. Herrera EA, et al. **J Clin Microbiol** 1996 May; 34(5):1108-13

Identification of bovine Neospora parasites by PCR amplification and specific small-subunit rRNA sequence probe hybridization. Ho MS, et al. **J Clin Microbiol** 1996 May;34(5):1203-8

Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche PCR-microwell plate hybridization method (AMPLICOR MYCOBACTERIUM) for direct detection of mycobacteria. Ichiyama S, et al. **J Clin Microbiol** 1996 Jan; 34(1):130-3

Improved PCR detection of Chlamydia trachomatis by using an altered method of specimen transport and high-quality endocervical specimens. Kellogg JA, et al. **J Clin Microbiol** 1995 Oct;33(10):2765-7

Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients. Kersulyte D, et al. **J Clin Microbiol** 1995 Aug;33(8):2216-9

Comparison of PCR and microscopic methods for detecting Trypanosoma cruzi. Kirchhoff LV, et al. **J Clin Microbiol** 1996 May;34(5):1171-5

Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study. Kirschner P, et al. **J Clin Microbiol** 1996 Feb;34(2):304-12

PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. Kox LF, et al. **J Clin Microbiol** 1995 Dec; 33(12):3225-33

Detection of cytomegalovirus in blood donors by PCR using the digene SHARP signal system assay: effects of sample preparation and detection methodology. Krajden M, et al. **J Clin Microbiol** 1996 Jan;34(1):29-33

PCR and direct fluorescent-antibody staining confirm Chlamydia trachomatis antigens in swabs and urine below the detection threshold of Chlamydiazyme enzyme immunoassay. Krepel J, et al. **J Clin Microbiol** 1995 Nov; 33(11):2847-9

Clinically practical seminested PCR for Burkholderia pseudomallei quantitated by enzyme immunoassay with and without solution hybridization. Kunakorn M, et al. **J Clin Microbiol** 1995 Aug;33(8):2131-5

Detecting bunyaviruses of the Bunyamwera and California serogroups by a PCR technique. Kuno G, et al. **J Clin Microbiol** 1996 May;34(5):1184-8

Diagnosis of Helicobacter pylori infection by PCR: comparison with other invasive techniques and detection of cagA gene in gastric biopsy specimens. Lage AP, et al. **J Clin Microbiol** 1995 Oct;33(10):2752-6

Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. Lan J, et al. **J Clin Microbiol** 1995 Dec; 33(12):3194-7

Single-step PCR for detection of Brucella spp. from blood and milk of infected animals. Leal-Klevezas DS, et al. **J Clin Microbiol** 1995 Dec;33(12):3087-90

Comparison of PCR and standard cytological staining for detection of Pneumocystis carinii from respiratory specimens from patients with or at high risk for infection by human immunodeficiency virus. Leibovitz E, et al. **J Clin Microbiol** 1995 Nov;33(11):3004-7

Investigation of sheep-associated malignant catarrhal fever virus infection in ruminants by PCR and competitive inhibition enzyme-linked immunosorbent assay. Li H, et al. **J Clin Microbiol** 1995 Aug;33(8):2048-53

Assessment of genetic markers for species differentiation within the Mycobacterium tuberculosis complex. Liébana E, et al. **J Clin Microbiol** 1996 Apr;34(4):933-8

Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. Lin HJ, et al. **J Clin Microbiol** 1996 Feb;34(2):329-33

Epidemiological typing of Flavimonas oryzihabitans by PCR and pulsed-field gel electrophoresis. Liu PY, et al. **J Clin Microbiol** 1996 Jan;34(1):68-70

Comparison of different PCR approaches for characterization of Burkholderia (Pseudomonas) cepacia isolates. Liu PY, et al. **J Clin Microbiol** 1995 Dec;33(12):3304-7

Molecular typing of Borrelia burgdorferi from Lyme disease patients by PCR-restriction fragment length polymorphism analysis. Liveris D, et al. **J Clin Microbiol** 1996 May; 34(5):1306-9

Comparison of ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for molecular typing of Listeria monocytogenes. Louie M, et al. **J Clin Microbiol** 1996 Jan;34(1):15-9

Comparison of six different PCR methods for detection of Pneumocystis carinii. Lu JJ, et al. **J Clin Microbiol** 1995 Oct;33(10):2785-8

Multiplex PCR for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Genitourinary specimens. Mahony JB, et al. **J Clin Microbiol** 1995 Nov; 33(11):3049-53

Quantitation of human immunodeficiency virus type 1 DNA by two PCR procedures coupled with enzyme-linked oligosorbent assay. Mallet F, et al. **J Clin Microbiol** 1995 Dec;33(12):3201-8

Sequence capture-PCR improves detection of mycobacterial DNA in clinical specimens. Mangiapan G, et al. **J Clin Microbiol** 1996 May;34(5):1209-15

PCR ribotyping and arbitrarily primed PCR for typing strains of Clostridium difficile from a Polish maternity hospital. Martirosian G, et al. **J Clin Microbiol** 1995 Aug; 33(8):2016-21

Rapid laboratory confirmation of human brucellosis by PCR analysis of a target sequence on the 31-kilodalton Brucella antigen DNA. Matar GM, et al. **J Clin Microbiol** 1996 Feb;34(2):477-8

Application of PCR for detection of toxigenic Corynebacterium diphtheriae strains isolated during the Russian diphtheria epidemic, 1990 through 1994. Mikhailovich VM, et al. **J Clin Microbiol** 1995 Nov; 33(11):3061-3

Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by Amplicor PCR. Moore DF, et al. **J Clin Microbiol** 1995 Oct;33(10):2686-91

IS6110-based PCR methods for detection of Mycobacterium tuberculosis [letter] Mulcahy GM, et al. **J Clin Microbiol** 1996 May;34(5):1348-9

Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR. Muñoz-Fernández MA, et al. **J Clin Microbiol** 1996 Feb; 34(2):404-8

PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. Nelson CT, et al. **J Clin Microbiol** 1995 Dec;33(12):3317-8

Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers. Orle KA, et al. **J Clin Microbiol** 1996 Jan;34(1):49-54

Use of PCR and direct immunofluorescence microscopy for confirmation of results obtained by Syva MicroTrak Chlamydia enzyme immunoassay. Ostergaard L, et al. **J Clin Microbiol** 1995 Oct;33(10):2620-3

Detection of Chlamydia trachomatis infections in women by Amplicor PCR: comparison of diagnostic performance with urine and cervical specimens. Pasternack R, et al. **J Clin Microbiol** 1996 Apr;34(4):995-8

Typing of Mycobacterium avium isolates by PCR. Picardeau M, et al. **J Clin Microbiol** 1996 Feb;34(2):389-92

Genetic diversity of Neisseria gonorrhoeae IB-2 and IB-6 isolates revealed by whole-cell repetitive element sequence-based PCR. Poh CL, et al. **J Clin Microbiol** 1996 Feb;34(2):292-5

Validation of nested Bordetella PCR in pertussis vaccine trial. Reizenstein E, et al. **J Clin Microbiol** 1996 Apr;34(4):810-5

Identification of murine helicobacters by PCR and restriction enzyme analyses. Riley LK, et al. **J Clin Microbiol** 1996 Apr;34(4):942-6

Amplification of Mycobacterium tuberculosis from peripheral blood. Rolfs A, et al. **J Clin Microbiol** 1995 Dec; 33(12):3312-4

Evaluation of PCR and indirect enzyme-linked immunosorbent assay on milk samples for diagnosis of brucellosis in dairy cattle. Romero C, et al. **J Clin Microbiol** 1995 Dec;33(12):3198-200

PCR strategy for identification and differentiation of small pox and other orthopoxviruses. Ropp SL, et al. **J Clin Microbiol** 1995 Aug;33(8):2069-76

Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. Roth WK, et al. **J Clin Microbiol** 1996 Feb;34(2):261-4

Comparison of Amplicor, in-house PCR, and conventional culture for detection of Mycobacterium tuberculosis in clinical samples. Schirm J, et al. **J Clin Microbiol** 1995 Dec;33(12):3221-4

Detection of human immunodeficiency virus type 1 proviral DNA by PCR using an electrochemiluminescence-tagged probe. Schutzbank TE, et al. **J Clin Microbiol** 1995 Aug; 33(8):2036-41

Characterization of Newcastle disease virus isolates by reverse transcription PCR coupled to direct nucleotide sequencing and development of sequence database for pathotype prediction and molecular epidemiological analysis. Seal BS, et al. **J Clin Microbiol** 1995 Oct; 33(10):2624-30

Quantitative PCR for human herpesviruses 6 and 7. Secchiero P, et al. **J Clin Microbiol** 1995 Aug;33(8):2124-30

Identification of widespread Helicobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay. Shames B, et al. **J Clin Microbiol** 1995 Nov; 33(11):2968-72

Detection of Salmonella typhi by nested PCR based on the ViaB sequence [letter; comment] Sharma KB, et al. **J Clin Microbiol** 1995 Dec;33(12):3361. Comment on: J Clin Microbiol 1995 Mar;33(3):775-7.

Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193-202

Immunomagnetic separation and solid-phase detection of Bordetella pertussis. Stark M, et al. **J Clin Microbiol** 1996 Apr;34(4):778-84

Combined PCR-oligonucleotide ligation assay for rapid detection of Salmonella serovars. Stone GG, et al. **J Clin Microbiol** 1995 Nov;33(11):2888-93

Comparison of arbitrarily primed PCR with restriction endonuclease and immunoblot analyses for typing Clostridium difficile isolates. Tang YJ, et al. **J Clin Microbiol** 1995 Dec;33(12):3169-73

Prior enrichment of human immunodeficiency virus DNA with probe DNA particles for efficient PCR diagnosis. Tano H, et al. **J Clin Microbiol** 1995 Sep;33(9):2489-91

Detection of Mycobacterium tuberculosis by PCR amplification with pan-Mycobacterium primers and hybridization to an M. tuberculosis-specific probe. Tevere VJ, et al. **J Clin Microbiol** 1996 Apr;34(4):918-23

Novel BOX repeat PCR assay for high-resolution typing of Streptococcus pneumoniae strains. van Belkum A, et al. **J Clin Microbiol** 1996 May;34(5):1176-9

PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. van Deventer AJ, et al. **J Clin Microbiol** 1996 Jan;34(1):25-8

Detection of Chlamydia trachomatis infection in urine samples from men and women by ligase chain reaction. van Doornum GJ, et al. **J Clin Microbiol** 1995 Aug; 33(8):2042-7

Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. Vannuffel P, et al. **J Clin Microbiol** 1995 Nov;33(11):2864-7

Case of recurrent Flavimonas oryzihabitans bacteremia associated with an implanted central venous catheter (Port-A-Cath): assessment of clonality by arbitrarily primed PCR. Verhasselt B, et al. **J Clin Microbiol** 1995 Nov;33(11):3047-8

Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Verweij PE, et al. **J Clin Microbiol** 1995 Dec;33(12):3150-3

New PCR assay for rapid and quantitative detection of human cytomegalovirus in cerebrospinal fluid. Vogel JU, et al. **J Clin Microbiol** 1996 Feb;34(2):482-3

PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. Walsh TJ, et al. **J Clin Microbiol** 1995 Dec;33(12):3216-20

Detection of Yersinia enterocolitica serogroup O:3 by a PCR method. Weynants V, et al. **J Clin Microbiol** 1996 May; 34(5):1224-7

Molecular identification of bacteria by fluorescence-based PCR-single-strand conformation polymorphism analysis of the 16S rRNA gene. Widjojoatmodjo MN, et al. **J Clin Microbiol** 1995 Oct;33(10):2601-6

Inhibition of PCR by aqueous and vitreous fluids. Wiedbrauk DL, et al. **J Clin Microbiol** 1995 Oct;33(10):2643-6

Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis. Wobeser WL, et al. **J Clin Microbiol** 1996 Jan;34(1):134-9

Genetic diversity in clinical isolates of the dimorphic fungus Blastomyces dermatitidis detected by a PCR-based random amplified polymorphic DNA assay. Yates-Siilata KE, et al. **J Clin Microbiol** 1995 Aug;33(8):2171-5

Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. Yerly S, et al. **J Clin Microbiol** 1996 Jan;34(1):199-201

Comparison of PCR detection of mecA with standard susceptibility testing methods to determine methicillin resistance in coagulase-negative staphylococci. York MK, et al. **J Clin Microbiol** 1996 Feb;34(2):249-53

Retrospective survey of chronic Q fever in Japan by using

PCR to detect Coxiella burnetii DNA in paraffin-embedded clinical samples. Yuasa Y, et al. **J Clin Microbiol** 1996 Apr;34(4):824-7

Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR. Yuen KY, et al. **J Clin Microbiol** 1995 Oct;33(10):2530-4

Strain-specific reverse transcriptase PCR assay: means to distinguish candidate vaccine from wild-type strains of respiratory syncytial virus. Zheng H, et al. **J Clin Microbiol** 1996 Feb;34(2):334-7

IS1533-based PCR assay for identification of Leptospira interrogans sensu lato serovars. Zuerner RL, et al. **J Clin Microbiol** 1995 Dec;33(12):3284-9

Single-tube nested PCR in the diagnosis of tuberculosis. Chan CM, et al. **J Clin Pathol** 1996 Apr;49(4):290-4

Diagnosis of lymphoma in paraffin wax sections by nested PCR and immunohistochemistry. Kitamura Y, et al. **J Clin Pathol** 1996 Apr;49(4):333-7

High prevalence of Helicobacter pylori in saliva demonstrated by a novel PCR assay. Li C, et al. **J Clin Pathol** 1995 Jul;48(7):662-6

Routine application of the polymerase chain reaction for detection of Mycobacterium tuberculosis in clinical samples. Noordhoek GT, et al. **J Clin Pathol** 1995 Sep; 48(9):810-4

A rapid and highly specific technique to detect hepatitis C RNA in frozen sections of liver. Sergi C, et al. **J Clin Pathol** 1996 May;49(5):369-72

Retrospective determination of HIV-1 status by a PCR method on paraffin wax embedded sections. Slavik T, et al. **J Clin Pathol** 1995 Aug;48(8):733-6

Primers designed for amplification of Echinococcus multilocularis DNA amplify the DNA of Encephalitozoon-like spores in the polymerase chain reaction. Furuya K, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):526-8

DNA polymorphism revealed by arbitrary primers polymerase chain reaction among Blastocystis strains isolated from humans, a chicken, and a reptile. Yoshikawa H, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):127-30

PCR amplification of animal DNA with human X-Y amelogenin primers used in gender determination. Buel E, et al. **J Forensic Sci** 1995 Jul;40(4):641-4

Confirmation of PM typing protocols for consistent and reliable results. Crouse CA, et al. **J Forensic Sci** 1996 May; 41(3):493-6

Post-amplification primer extension of heat-denatured AmpliType PCR products: effects on typing results. Grow M, et al. **J Forensic Sci** 1996 May;41(3):497-502

A method for the purification and recovery of genomic DNA from an HLA DQA1 amplification product and its subsequent amplification and typing with the AmpliType PM PCR Amplification and Typing Kit. Hochmeister MN, et al. **J Forensic Sci** 1995 Jul;40(4):649-33

Detection of D1S80 (pMCT118) locus polymorphism using semi-nested polymerase chain reaction in skeletal remains. Honda K, et al. **J Forensic Sci** 1995 Jul;40(4):637-40

Efficient and reliable PCR-based detection of the ABO blood group alleles: genotyping on stamps and other biological evidence samples. Liechti-Gallati S, et al. **J Forensic Sci** 1996 Jul;41(4):653-7

Analysis of the VNTR locus DXS52 by the Amp-FLP technique. Yun WM, et al. **J Forensic Sci** 1996 Sep; 41(5):859-61

Prevention of false results from preferential PCR amplification or VNTR alleles. Pai CY, et al. **J Formos Med Assoc** 1996 Jan;95(1):69-72

Persistent Epstein-Barr virus infection in the common marmoset (Callithrix jacchus). Cox C, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1173-80

Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. Daniel B, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2589-93

Cell-free cloning and biolistic inoculation of an infectious cDNA of potato virus Y. Fakhfakh H, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):519-23

Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. Haque T, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1169-72

Comparison of DNA fingerprinting by PFGE and PCR-RFLP of the coagulase gene to distinguish MRSA isolates. Nada T, et al. **J Hosp Infect** 1996 Apr;32(4):305-17

A one step PCR procedure for analysis of tumor specific T lymphocyte responses. Abu-hadid MM, et al. **J Immunol Methods** 1996 Mar 28;190(1):91-105

Simultaneous quantitation of multiple cytokine mRNAs by RT-PCR utilizing plate based EIA methodology. Hockett RD Jr, et al. **J Immunol Methods** 1995 Dec 1;187(2):273-85

Quantification of cytokine messenger RNA in transfected human T cells by RT-PCR and an automated electrochemiluminescence-based post-PCR detection system. Motmans K, et al. **J Immunol Methods** 1996 Mar 28;190(1):107-16

Soluble T cell receptors: detection and quantitative assay in fluid phase via ELISA or immuno-PCR. Sperl J, et al. **J Immunol Methods** 1995 Oct 26;186(2):181-94

The use of reverse transcription polymerase chain reaction to analyse large numbers of mRNA species from a single cell. Toellner KM, et al. **J Immunol Methods** 1996 May 10;191(1):71-5

Quantitative assessment of the human TCRBV repertoire by competitive PCR. Uhrberg M, et al. **J Immunol Methods** 1996 Aug 14;194(2):155-68

Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis. Hellyer TJ, et al. **J Infect Dis** 1996 Apr;173(4):934-41

Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. Ieven M, et al. **J Infect Dis** 1996 Jun;173(6):1445-52

The false-positive polymerase chain reaction and the ostrich [letter; comment] Jehuda-Cohen T. **J Infect Dis** 1995 Nov; 172(5):1420-1. Comment on: J Infect Dis 1994 Dec;170(6):1410-7.

A novel multiply primed polymerase chain reaction assay for identification of variant papG genes encoding the Gal(alpha 1-4)Gal-binding PapG adhesins of Escherichia coli. Johnson JR, et al. **J Infect Dis** 1996 Apr;173(4):920-6

Determining the prevalence of Onchocerca volvulus infection in vector populations by polymerase chain reaction screening of pools of black flies. Katholi CR, et al. **J Infect Dis** 1995 Nov;172(5):1414-7

Measurement of human herpesvirus 7 load in peripheral blood and saliva of healthy subjects by quantitative polymerase chain reaction. Kidd IM, et al. **J Infect Dis** 1996 Aug; 174(2):396-401

Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Klimov AI, et al. **J Infect Dis** 1995 Nov;172(5):1352-5

Evaluation of a polymerase chain reaction-based assay for diagnosis of Wuchereria bancrofti infection. McCarthy JS, et al. **J Infect Dis** 1996 Jun;173(6):1510-4

Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. Nocton JJ, et al. **J Infect Dis** 1996 Sep;174(3):623-7

Polymerase chain reaction-based assessment after macrofilaricidal therapy in Onchocerca volvulus infection. Nutman TB, et al. **J Infect Dis** 1996 Mar;173(3):773-6

Field evaluation of a polymerase chain reaction-based nonisotopic liquid hybridization assay for malaria diagnosis. Oliveira DA, et al. **J Infect Dis** 1996 May;173(5):1284-7

Localization of human T-cell lymphotropic virus-1 tax proviral sequences in skin biopsies of patients with mycosis fungoides by in situ polymerase chain reaction. Khan ZM, et al. **J Invest Dermatol** 1996 Apr;106(4):667-72

Nonradioactive arbitrarily primed polymerase chain reaction: a novel technique for detecting genetic defects in skin tumors. Vogt T, et al. **J Invest Dermatol** 1996 Jan; 106(1):194-7

Polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA in tissue and assessment of its utility in the diagnosis of hepatic granulomas. Diaz ML, et al. **J Lab Clin Med** 1996 Apr;127(4):359-63

Differential regulation of macrophage scavenger receptor isoforms: mRNA quantification using the polymerase chain reaction. Dufva M, et al. **J Lipid Res** 1995 Nov; 36(11):2282-90

Multiplex PCR to detect the dystrophin gene deletion in Thai patients. Mutirangura A, et al. **J Med Assoc Thai** 1995 Sep; 78(9):460-5

Evaluation of reverse transcriptase polymerase chain reaction for the detection of eastern equine encephalomyelitis virus during vector surveillance. Monroy AM, et al. **J Med Entomol** 1996 May;33(3):449-57

Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene. Whittall R, et al. **J Med Genet** 1995 Jul;32(7):509-15

Characterisation of Burkholderia cepacia from cystic fibrosis patients living in Wales by PCR ribotyping. Ryley HC, et al. **J Med Microbiol** 1995 Dec;43(6):436-41

Rapid detection and identification of pathogenic fungi by polymerase chain reaction amplification of large subunit ribosomal DNA. Haynes KA, et al. **J Med Vet Mycol** 1995 Sep-Oct;33(5):319-25

Two different PCR assays to detect enteroviral RNA in CSF samples from patients with acute aseptic meningitis. Casas I, et al. **J Med Virol** 1995 Dec;47(4):378-85

Human herpesvirus-6 DNA in the saliva of paediatric oncology patients and controls. Lyall EG, et al. **J Med Virol** 1995 Dec;47(4):317-22

Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. Revello MG, et al. **J Med Virol** 1995 Dec;47(4):462-6

Rapid HCV RNA detection by PCR followed by a new non-radioactive liquid hybridisation assay and comparison with RIBA. Schacker U, et al. **J Med Virol** 1995 Aug; 46(4):304-9

Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. Schmidt WN, et al. **J Med Virol** 1995 Oct;47(2):153-60

Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription-polymerase chain reaction. Maresh GA, et al. **J Neurochem** 1996 Sep; 67(3):1132-44

Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. Kiryu S, et al. **J Neurosci** 1995 Dec;15(12):7872-8

Simplified RT/PCR quantitation of gene transcripts in cultured neuroblastoma (SN49) and microglial (BV-2) cells using capillary electrophoresis and laser-induced fluorescence. Personett DA, et al. **J Neurosci Methods** 1996 Mar;65(1):77-91

Identification of opossums (Didelphis virginiana) as the putative definitive host of Sarcocystis neurona. Fenger CK, et al. **J Parasitol** 1995 Dec;81(6):916-9

Practical histological microdissection for PCR analysis. Going JJ, et al. **J Pathol** 1996 May;179(1):121-4

In situ PCR: pathologist's dream or nightmare? O'Leary JJ, et al. **J Pathol** 1996 Jan;178(1):11-20 (22 ref.)

The intracellular polymerase chain reaction for small CMV genomic sequences within heavily infected cellular sections. Ray RA, et al. **J Pathol** 1995 Oct;177(2):171-80

Diagnostic value of different PCR assays for the detection of mycobacterial DNA in granulomatous lymphadenopathy. Tötsch M, et al. **J Pathol** 1996 Feb; 178(2):221-6

Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. Scofield MA, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):1035-42

Detection of intestinal bacterial translocation using PCR. Kane TD, et al. **J Surg Res** 1996 Jun;63(1):59-63

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy [see comments] Olsson CA, et al. **J Urol** 1996 May;155(5):1557-62. Comment in: J Urol 1996 May;155(5):1661-2.

Differential-display polymerase chain reaction identifies nucleophosmin as an estrogen-regulated gene in human vascular smooth muscle cells. Koike H, et al. **J Vasc Surg** 1996 Mar;23(3):477-82

Detection of Anaplasma marginale DNA in bovine erythrocytes by slot-blot and in situ hybridization with a PCR-mediated digoxigenin-labeled DNA probe. Ge NL, et al. **J Vet Diagn Invest** 1995 Oct;7(4):465-72

Apparent outbreaks of Clostridium difficile-associated diarrhea in horses in a veterinary medical teaching hospital. Madewell BR, et al. **J Vet Diagn Invest** 1995 Jul;7(3):343-6

Detection of serotype G6 rotavirus in bovine field samples using a nonradioactive PCR-derived cDNA probe. Munoz M, et al. **J Vet Diagn Invest** 1995 Oct;7(4):546-8

Genome analysis of North American small ruminant lentiviruses by polymerase chain reaction and restriction enzyme analysis. Rosati S, et al. **J Vet Diagn Invest** 1995 Oct;7(4):437-43

Recognition of leukochimerism during genotyping for bovine leukocyte adhesion deficiency (BLAD) by polymerase-chain-reaction-amplified DNA extracted from blood. Ryncarz RE, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):569-72

Rapid detection of mycoplasma contamination in cell cultures by enzymatic detection of polymerase chain reaction (PCR) products. Kobayashi H, et al. **J Vet Med Sci** 1995 Aug; 57(4):769-71

A genetic analysis of mixed population in Theileria sergenti stocks and isolates using allele-specific polymerase chain reaction. Kubota S, et al. **J Vet Med Sci** 1995 Apr; 57(2):279-82

Detection of canine distemper virus nucleocapsid protein gene in canine peripheral blood mononuclear cells by RT-PCR. Shin Y, et al. **J Vet Med Sci** 1995 Jun; 57(3):439-45

Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. Lanford RE, et al. **J Virol** 1995 Dec;69(12):8079-83

PCR-in situ hybridization detection of human T-cell lymphotropic virus type 1 (HTLV-1) tax proviral DNA in peripheral blood lymphocytes of patients with HTLV-1-associated neurologic disease. Levin MC, et al. **J Virol** 1996 Feb;70(2):924-33

Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR. Ramakrishnan R, et al. **J Virol** 1996 Sep;70(9):6519-23

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. Zhu T, et al. **J Virol** 1996 May;70(5):3098-107

Detection of California serogroup Bunyaviruses in tissue culture and mosquito pools by PCR. Campbell WP, et al. **J Virol Methods** 1996 Apr 5;57(2):175-9

Rapid and sensitive detection of the bovine viral diarrhea virus genome in semen. Da Silva N, et al. **J Virol Methods** 1995 Oct;55(2):209-18

Detection of Tospovirus species by RT-PCR of the N-gene and restriction enzyme digestions of the products. Dewey RA, et al. **J Virol Methods** 1996 Jan;56(1):19-26

Detection of southern African human immunodeficiency virus type 1 subtypes by polymerase chain reaction: evaluation of different primer pairs and conditions. Engelbrecht S, et al. **J Virol Methods** 1995 Nov; 55(3):391-400

Colorimetric microtiter plate hybridization assay using monoclonal antibody for detection of an amplified human immunodeficiency virus target. Ferre-Aubineau V, et al.

J Virol Methods 1995 Sep;55(1):145–51
Comparison of conventional autoradiography with a new DNA enzyme immunoassay for the detection of hepatitis C virus–polymerase chain reaction amplification products. Feucht HH, et al. J Virol Methods 1995 Sep;55(1):105–10
Polymerase chain reaction method for determining ratios of human immunodeficiency virus proviral DNA to cellular genomic DNA in brain tissues of HIV-infected patients. Fujimura RK, et al. J Virol Methods 1995 Nov;55(3):309–25
Sensitive detection of group A rotaviruses by immunomagnetic separation and reverse transcription–polymerase chain reaction. Grinde B, et al. J Virol Methods 1995 Nov;55(3):327–38
Comparison of four RNA extraction methods for the detection of small round structured viruses in faecal specimens. Hale AD, et al. J Virol Methods 1996 Apr 5; 57(2):195–201
Typing of varicella zoster virus by amplification of DNA polymorphisms. Hawrami K, et al. J Virol Methods 1996 Apr 5;57(2):169–74
Detection of beet necrotic yellow vein virus using reverse transcription and polymerase chain reaction. Henry CM, et al. J Virol Methods 1995 Jul;54(1):15–28
Multiplex polymerase chain reaction for adenovirus and herpes simplex virus in eye swabs. Jackson R, et al. J Virol Methods 1996 Jan;56(1):41–8
A simple device for the concentration and detection of enterovirus, hepatitis E virus and rotavirus from water samples by reverse transcription–polymerase chain reaction. Jothikumar N, et al. J Virol Methods 1995 Nov; 55(3):401–15
SYBR green I DNA staining increases the detection sensitivity of viruses by polymerase chain reaction. Karlsen F, et al. J Virol Methods 1995 Sep;55(1):153–6
Consensus oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis. Leary TP, et al. J Virol Methods 1996 Jan;56(1):119–21
Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum: amplicor, branched-DNA, NASBA and in-house PCR. Lunel F, et al. J Virol Methods 1995 Aug;54(2–3):159–71
Increased sensitivity of poliovirus detection in tap water concentrates by reverse transcriptase–polymerase chain reaction. Ma JF, et al. J Virol Methods 1995 Nov; 55(3):295–302
Rapid cloning of uncharacterised tobacco rattle virus isolates using long template (LT) PCR. MacFarlane SA. J Virol Methods 1996 Jan;56(1):91–8
The design of strain-specific polymerase chain reactions for discrimination of the raccoon rabies virus strain from indigenous rabies viruses of Ontario. Nadin-Davis SA, et al. J Virol Methods 1996 Apr 5;57(2):141–56
Simultaneous polymerase chain reaction detection and restriction typing for the diagnosis of human genital papillomavirus infection. Pizzighella S, et al. J Virol Methods 1995 Oct;55(2):245–56
Localization of foot and mouth disease virus RNA in tissue culture infected cells via in situ polymerase chain reaction. Prato Murphy ML, et al. J Virol Methods 1995 Aug; 54(2–3):173–8
A simple touch-down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces. Schunck B, et al. J Virol Methods 1995 Nov; 55(3):427–33
Methods to remove inhibitors in sewage and other fecal wastes for enterovirus detection by the polymerase chain reaction. Shieh YS, et al. J Virol Methods 1995 Jul; 54(1):51–66
Detection of DNA and RNA plant viruses by PCR and RT-PCR using a rapid virus release protocol without tissue homogenization. Thomson D, et al. J Virol Methods 1995 Aug;54(2–3):85–95
Low-stringency single specific primer PCR, DNA sequencing and single-strand conformation polymorphism of PCR products for identification of genetic variants of human papillomavirus type 16. van Belkum A. J Virol Methods 1995 Nov;55(3):435–43
Quantification of HIV-1 proviral DNA and analysis of genomic diversity by polymerase chain reaction and temperature gradient gel electrophoresis. Wieland U, et al. J Virol Methods 1996 Apr 5;57(2):127–39
Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Inoue S, et al. Jpn J Cancer Res 1995 Jul; 86(7):626–30
Double determinant immuno-polymerase chain reaction: a sensitive method for detecting circulating antigens in human sera. Suzuki A, et al. Jpn J Cancer Res 1995 Sep; 86(9):885–9
Rapid genotyping of low density lipoprotein receptor knockout mice using a polymerase chain reaction technique. Gaw A, et al. Lab Anim 1995 Oct;29(4):447–9
Non-phenotypic detection of osteopetrotic (op/op) mutation by using PCR-SSCP analysis. Kaneko H, et al. Lab Anim 1995 Oct;29(4):442–6
Detection of Pasteurella pneumotropica in laboratory mice and rats by polymerase chain reaction. Wang RF, et al. Lab Anim Sci 1996 Feb;46(1):81–5
A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. Habano W, et al. Lab Invest 1996 May;74(5):933–40
HIV quantification: clinical applications [see comments] Volberding PA. Lancet 1996 Jan 13;347(8994):71–3. Comment in: Lancet 1996 Mar 30;347(9005):899.
Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Costello RT, et al. Leuk Lymphoma 1996 Jan;20(3–4):239–43
The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen–receptor gene sequences. Roberts WM, et al. Leuk Lymphoma 1996 Jan; 20(3–4):181–97 (50 ref.)
Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Diverio D, et al. Leukemia 1996 Jul;10(7):1214–6
Use of UITma DNA polymerase improves the PCR detection of rearranged immunoglobulin heavy chain CDR3 junctions. Linke B, et al. Leukemia 1995 Dec;9(12):2133–7
Control genes in reverse transcriptase–polymerase chain reaction assays. Lion T. Leukemia 1996 Sep;10(9):1527–8
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Melo JV, et al. Leukemia 1996 Jul;10(7):1217–21
Detection of evolving immunoglobulin heavy–chain gene rearrangements in acute lymphoblastic leukemia: a PCR–based assay employing overlapping DJH primers. Norris MD, et al. Leukemia 1995 Oct;9(10):1779–82
N–ras genes are not mutated in Hodgkin and Reed–Sternberg cells: results from single cell polymerase chain–reaction examinations. Trümper L, et al. Leukemia 1996 Apr; 10(4):727–30
Direct display of hematopoietic tyrosine kinase receptor expression profiles in KG1 cells by PCR using degenerate primers. Visser M, et al. Leukemia 1996 Aug;10(8):1395–9
Generation of chromosome fragment specific bovine DNA sequences by microdissection and DOP–PCR. Goldammer T, et al. Mamm Genome 1996 Apr;7(4):291–6
PCR–analyzed microsatellites for the inbred mouse strain 129/Sv, the strain most commonly used in gene knockout technology. Matouk C, et al. Mamm Genome 1996 Aug; 7(8):603–5
Use of interspersed repetitive sequences–PCR products for cDNA selection. Villard L, et al. Mamm Genome 1995 Sep; 6(9):617–22
Sequence–independent identification of infectious pathogens: an hypothesis. Sallie R. Med Hypotheses 1995 Aug; 45(2):131–4
Isolation of candidate genes by subtractive and sequential (Boolean) hybridization: an hypothesis. Sallie R. Med Hypotheses 1995 Aug;45(2):142–6
A strategy for the detection of de novo synthesis of nucleic acids: an hypothesis. Sallie R. Med Hypotheses 1995 Aug; 45(2):129–30
Detection of Plasmodium sporozoites in mosquitoes by polymerase chain reaction and oligonucleotide rDNA probe, without dissection of the salivary glands. Stoffels JA, et al. Med Vet Entomol 1995 Oct;9(4):433–7
Identification of new dynein heavy–chain genes by RNA–directed polymerase chain reaction. Asai DJ, et al. Methods Cell Biol 1995;47:579–85
Selection of protein binding sites from random nucleic acid sequences. Blackwell TK. Methods Enzymol 1995; 254:604–18
Analysis of altered gene expression by differential display. Liang P, et al. Methods Enzymol 1995;254:304–21
Representational difference analysis in detection of genetic lesions in cancer. Lisitsyn N, et al. Methods Enzymol 1995; 254:291–304
Polymerase chain reaction cloning of related genes. Sells MA, et al. Methods Enzymol 1995;254:184–95
Analysis of plant gene expression by reverse transcription–PCR. Bell M. Methods Mol Biol 1995; 49:291–9
Statistical analysis of arbitrarily primed PCR patterns in molecular taxonomic studies. Black WC 4th. Methods Mol Biol 1996;50:39–55
PCR detection of HIV. Böni J. Methods Mol Biol 1996; 50:93–107
Alu–PCR fingerprinting of YACs. Coffey A, et al. Methods Mol Biol 1996;54:97–114
PCR of the ribosomal DNA intergenic spacer regions as a method for identifying mosquitoes in the Anopheles gambiae complex. Cornel AJ, et al. Methods Mol Biol 1996; 50:321–32
Polymerase chain reaction. Delidow BC, et al. Methods Mol Biol 1996;58:275–92
Amplification with arbitrary primers. Di Rienzo A, et al. Methods Mol Biol 1996;54:123–9
Inverse polymerase chain reaction. Hartl DL, et al. Methods Mol Biol 1996;58:293–301
Direct sequencing of PCR products. Harwood JC, et al. Methods Mol Biol 1996;58:403–12
Direct radioactive labeling of polymerase chain reaction products. McDaniel T, et al. Methods Mol Biol 1996; 58:325–7
Identification of microorganisms using random primed PCR. Mileham AJ. Methods Mol Biol 1995;46:257–67
Improved PCR methods for identification of phytopathogenic viruses. Minafra A, et al. Methods Mol Biol 1996;50:81–91
The identification of dengue virus using PCR. Morita K. Methods Mol Biol 1996;50:127–32
End rescue from YACs using the vectorette. Ogilvie DJ, et al. Methods Mol Biol 1996;54:131–8
Polymerase chain reaction with degenerate oligonucleotide primers to clone gene family members. Preston GM. Methods Mol Biol 1996;58:303–12
RAPD–PCR with parasitic hymenoptera. Roehrdanz RL. Methods Mol Biol 1996;50:381–90
Ligase chain reaction. Shimer GH Jr, et al. Methods Mol Biol 1995;46:269–78
Polymerase chain reaction for the detection of Listeria species and Listeria monocytogenes. Siggens KW. Methods Mol Biol 1995;46:237–46
End–rescue of YAC clone inserts by inverse PCR. Silverman GA. Methods Mol Biol 1996;54:145–55
Applications of RT–PCR. Simpson CG, et al. Methods Mol Biol 1995;49:257–69
Thermal cycle dideoxy DNA sequencing. Slatko BE. Methods Mol Biol 1996;58:413–23
Development of bacterial species–specific DNA probes based on ribosomal RNA genes using PCR. Smith TJ, et al. Methods Mol Biol 1995;46:247–56
The use of consensus PCR and direct sequence analysis for the identification of HPV. Smits HL. Methods Mol Biol 1996;50:109–26
Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Snounou G. Methods Mol Biol 1996;50:263–91
A rapid PCR–based colony screening protocol for cloned inserts. Trower MK. Methods Mol Biol 1996;58:329–33
Cloning PCR products using T–vectors. Trower MK, et al. Methods Mol Biol 1996;58:313–24
The use of degenerate primers in conjunction with strain and species oligonucleotides to classify Onchocerca volvulus. Unnasch TR, et al. Methods Mol Biol 1996; 50:293–303
Detection and characterization of Leishmania parasites by DNA–based methods. Southern blotting and PCR. Van Eys GJ, et al. Methods Mol Biol 1996;50:227–42
Use of polymerase chain reaction to screen phage libraries. Yu L, et al. Methods Mol Biol 1996;58:335–9
Rapid and sensitive PCR detection of Vibrio trachuri pathogenic to Japanese horse mackerel (Trachurus japonicus). Iwamoto Y, et al. Microbiol Immunol 1995; 39(12):1003–6
Rapid identification by polymerase chain reaction of staphylococcal exfoliative toxin serotype A and B genes. Sakurai S, et al. Microbiol Immunol 1995;39(6):379–86
Genetic identification of Staphylococcus aureus by polymerase chain reaction using single–base–pair mismatch in 16S ribosomal RNA gene. Saruta K, et al. Microbiol Immunol 1995;39(11):839–44
PCR–fingerprinting used for comparison of ex type strains of Trichoderma species deposited in different culture collections. Kuhls K, et al. Microbiol Res 1995 Nov; 150(4):363–71
Application of the PCR technique to detect Phytophthora infestans in potato tubers and leaves. Niepold F, et al. Microbiol Res 1995 Nov;150(4):379–85
The combination of Gilbert/Maxam chemical sequencing and the dideoxynucleotide chain termination approach facilitates the construction of species specific PCR–primers based on diagnostic RAPD bands. Voigt K, et al. Microbiol Res 1995 Nov;150(4):373–7
The frequency of chimeric molecules as a consequence of PCR co–amplification of 16S rRNA genes from different bacterial species. Wang GC, et al. Microbiology 1996 May; 142 (Pt 5):1107–14
Analysis of the papillomavirus type 16 DNA amplification by PCR in SiHa and SLT cell lines. Ratiarson A. Microbios 1996;85(343):127–31
A new method for designing PCR primers specific for groups of sequences and its application to plant viruses. Antoniw J. Mol Biotechnol 1995 Oct;4(2):111–9
Detection and identification of Campylobacter coli and Campylobacter jejuni by two–step polymerase chain reaction. Comi G, et al. Mol Biotechnol 1995 Jun;3(3):266–8
Development of a novel, rapid processing protocol for polymerase chain reaction–based detection of bacterial infections in synovial fluids. Mariani BD, et al. Mol Biotechnol 1995 Dec;4(3):227–37
Precise large deletions by the PCR–based overlap extension method. Senanayake SD, et al. Mol Biotechnol 1995 Aug; 4(1):13–5
Quantitative detection of alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in aromatase–expressing human cells by competitive RT–PCR. Agarwal VR, et al. Mol Cell Probes 1995 Dec; 9(6):453–64
Evaluation of PCR and nested PCR for laboratory diagnosis of hepatitis C virus infection. Aslanzadeh J, et al. Mol Cell Probes 1996 Jun;10(3):173–8
Polymerase chain reaction of bacterial genomes with single universal primer: application to distinguishing mycobacteria species. Bahrmand AR, et al. Mol Cell Probes 1996 Apr;10(2):117–22
The use of mimics as internal standards to avoid false negatives in diagnostic PCR. Ballagi-Pordány A, et al. Mol Cell Probes 1996 Jun;10(3):159–64
Development of an amplification and hybridization assay for the specific and sensitive detection of Mycoplasma fermentans DNA. Berg S, et al. Mol Cell Probes 1996 Feb;

10(1):7-14
Polymerase chain reaction for Mycoplasma hyopneumoniae detection in tracheobronchiolar washings from pigs. Blanchard B, et al. **Mol Cell Probes** 1996 Feb;10(1):15-22
Detection of cytomegalovirus using 'boosted' nested PCR. Borg KL, et al. **Mol Cell Probes** 1995 Aug;9(4):251-7
Non isotopic automatable molecular procedures for the detection of enteroviruses. Bosch A, et al. **Mol Cell Probes** 1996 Apr;10(2):81-9
Use of the polymerase chain reaction to specifically amplify integrated HPV-16 DNA by virtue of its linkage to interspersed repetitive DNA. Carmody MW, et al. **Mol Cell Probes** 1996 Apr;10(2):107-16
Species-specific 18S rRNA gene amplification for the detection of P. falciparum and P. vivax malaria parasites. Das A, et al. **Mol Cell Probes** 1995 Jun;9(3):161-5
Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Eldin de Pecoulas P, et al. **Mol Cell Probes** 1995 Dec;9(6):391-7
Sequence-specific detection of PCR-amplified DNA by restriction enzyme release of hybrids. Estrada G, et al. **Mol Cell Probes** 1996 Jun;10(3):179-85
Development of an efficient PCR method for toxin typing of Actinobacillus pleuropneumoniae strains. Frey J, et al. **Mol Cell Probes** 1995 Aug;9(4):277-82
Development of a diagnostic polymerase chain reaction assay for detection of Mycoplasma hominis. Gallia GL, et al. **Mol Cell Probes** 1995 Dec;9(6):415-21
A rapid and convenient method to prepare DIG-labelled RNA probes for use in non-radioactive in situ hybridization. Gandrillon O, et al. **Mol Cell Probes** 1996 Feb;10(1):51-5
Arbitrarily-primed PCR confirms the differentiation of strains of Ureaplasma urealyticum into two biovars. Grattard F, et al. **Mol Cell Probes** 1995 Dec;9(6):383-9
PCR detection of the two 'Candidatus' Liberobacter species associated with greening disease of citrus. Jagoueix S, et al. **Mol Cell Probes** 1996 Feb;10(1):43-50
Development of a dual target-PCR for detection and characterization of measles virus in clinical specimens. Jin L, et al. **Mol Cell Probes** 1996 Jun;10(3):191-200
A RAPD-PCR derived marker can differentiate between pathogenic and non-pathogenic Sarcocystis species of sheep. Joachim A, et al. **Mol Cell Probes** 1996 Jun; 10(3):165-72
Quantitative multistandard RT-PCR assay using interspecies polymorphism. Khiri H, et al. **Mol Cell Probes** 1996 Jun; 10(3):201-11
Specific detection of Mycoplasma iowae using polymerase chain reaction. Laigret F, et al. **Mol Cell Probes** 1996 Feb; 10(1):23-9
Detection and genotyping of herpes simplex virus types 1 and 2 by polymerase chain reaction. Lucotte G, et al. **Mol Cell Probes** 1995 Oct;9(5):287-90
The sensitive detection of fluorescently labelled PCR products using an automated detection system. Maher M, et al. **Mol Cell Probes** 1995 Aug;9(4):265-76
'Fingerprinting' of HLA-DQA by polymerase chain reaction and heteroduplex analysis. Martinelli G, et al. **Mol Cell Probes** 1996 Apr;10(2):123-7
Non specific PCR products using rat-derived Pneumocystis carinii dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples. Ortona E, et al. **Mol Cell Probes** 1996 Jun;10(3):187-90
A quantitative polymerase chain reaction (PCR) assay completely discriminates between Duchenne and Becker muscular dystrophy deletion carriers and normal females. Pastore L, et al. **Mol Cell Probes** 1996 Apr;10(2):129-37
Quantification of polymerase chain reaction products: enzyme immunoassay based systems for digoxigenin- and biotin-labelled products that quantify either total or specific amplicons. Stevens J, et al. **Mol Cell Probes** 1996 Feb;10(1):31-41
Amplification of full-length HIV-2 envelope genes. Taveira NC, et al. **Mol Cell Probes** 1996 Apr;10(2):91-8
Development of a species-specific polymerase chain reaction assay for Gardnerella vaginalis. van Belkum A, et al. **Mol Cell Probes** 1995 Jun;9(3):167-74
An improved procedure for in situ RTPCR. Volpi L, et al. **Mol Cell Probes** 1996 Feb;10(1):63-6
Detection and molecular typing of Campylobacter jejuni in fecal samples by polymerase chain reaction. Waegel A, et al. **Mol Cell Probes** 1996 Apr;10(2):75-80
A fluorescent multiplex ARMS method for rapid mutation analysis. Zschocke J, et al. **Mol Cell Probes** 1995 Dec; 9(6):447-51
Ecological interaction between sympatric Mytilus species on the west coast of Canada investigated using PCR markers. Heath DD, et al. **Mol Ecol** 1996 Jun;5(3):443-7
A set of primers for the amplification of 20 chloroplast microsatellites in Pinaceae. Vendramin GG, et al. **Mol Ecol** 1996 Aug;5(4):595-8
Rapid detection of Vibrio cholerae contamination of seafood by polymerase chain reaction. Karunasagar I, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):365-8
Use of PCR-RFLP assays to detect genetic variation at single-copy nuclear loci in striped bass (Morone saxatilis). Leclerc GM, et al. **Mol Mar Biol Biotechnol** 1996 Jun; 5(2):138-44
Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Hardingham JE, et al. **Mol Med** 1995 Nov;1(7):789-94
Gene quantification now. Radich J. **Mol Med Today** 1996 Jun;2(6):228-9
A competitive polymerase chain reaction to quantify DNA of Leptosphaeria maculans during blackleg development in oilseed rape. Mahuku GS, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):761-7
Quantitation of heteroplasmy of mitochondrial tRNA(Leu(UUR)) gene using PCR-SSCP. Tanno Y, et al. **Muscle Nerve** 1995 Dec;18(12):1390-7
A method for the rapid generation of alpha- and classical satellite probes for human chromosome 9 by polymerase chain reaction using genomic DNA and their application to detect chromosomal alterations in interphase cells. Hasegawa LS, et al. **Mutagenesis** 1995 Nov;10(6):471-6
A modified quantitative polymerase chain reaction assay for measuring gene-specific repair of UV photoproducts in human cells. McCarthy MJ, et al. **Mutat Res** 1996 May 15;363(1):57-66
Universal fungus-specific primer systems and group-specific hybridization oligonucleotides for 18S rDNA. Kappe R, et al. **Mycoses** 1996 Jan-Feb;39(1-2):25-30
Marfan syndrome as a paradigm for transcript-targeted preimplantation diagnosis of heterozygous mutations. Eldadah ZA, et al. **Nat Med** 1995 Aug;1(8):798-803
How much weight should viral load carry? [news] [see comments] Steele FR. **Nat Med** 1996 May;2(5):502. Comment in: Nat Med 1996 Aug;2(8):832-3.
Simplified hot start PCR. Birch DE. **Nature** 1996 May 30; 381(6581):445-6
Reverse transcription polymerase chain reaction for cytokines in the mixed lymphocyte culture. Is there a role in renal transplantation? [editorial] Danzer SG, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1246-7 (10 ref.)
Nosocomial transmission of hepatitis C virus to hemodialysis patients: molecular epidemiology by polymerase chain reaction [letter] Sungur C, et al. **Nephron** 1995;71(3):363
Competitive reverse transcriptase-polymerase chain reaction using a synthetic internal RNA standard to quantitate transcripts for leukocyte-derived hormones. Liu Q, et al. **Neuroimmunomodulation** 1994 Jan;1(1):33-41
A reproducible assay of polymerase chain reaction to detect trinucleotide repeat expansion of Huntington's disease and senile chorea. Watanabe M, et al. **Neurol Res** 1996 Feb; 18(1):16-8
A simple and efficient method for apolipoprotein E genotype determination. Chapman J, et al. **Neurology** 1996 May; 46(5):1484-5
Use of a rapid and simple method to extract proviral DNA in the identification of HIV-1 by PCR. Tagliaferro L, et al. **New Microbiol** 1995 Jul;18(3):303-6
Identification of members of several homeobox genes in a planarian using a ligation-mediated polymerase chain reaction technique. Balavoine G. **Nucleic Acids Res** 1996 Apr 15;24(8):1547-53
Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Barrett MT, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3488-92
An analysis of differential display shows a strong bias towards high copy number mRNAs. Bertioli DJ, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4520-3
Non-radioisotopic differential display method to directly visualize and amplify differential bands on nylon membrane. Chen JJ, et al. **Nucleic Acids Res** 1996 Feb 15; 24(4):793-4
Chip PCR. II. Investigation of different PCR amplification systems in microbabricated silicon-glass chips. Cheng J, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):380-5
High primer concentration improves PCR amplification from random pools. Czerny T. **Nucleic Acids Res** 1996 Mar 1; 24(5):985-6
Efficient amplification using 'megaprimer' by asymmetric polymerase chain reaction. Datta AK. **Nucleic Acids Res** 1995 Nov 11;23(21):4530-1
Solid-phase reversible immobilization for the isolation of PCR products. DeAngelis MM, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4742-3
A method for preparation of fecal DNA suitable for PCR. Deuter R, et al. **Nucleic Acids Res** 1995 Sep 25; 23(18):3800-1
A novel ligation mediated-PCR based strategy for construction of subtraction libraries from limiting amounts of mRNA. Ghosh S. **Nucleic Acids Res** 1996 Feb 15; 24(4):795-6
Factors affecting fidelity of DNA synthesis during PCR amplification of d(C-A)n.d(G-T)n microsatellite repeats. Hite JM, et al. **Nucleic Acids Res** 1996 Jun 15; 24(12):2429-34
DNA damage and DNA sequence retrieval from ancient tissues. Höss M, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1304-7
Hetero-stagger cloning: efficient and rapid cloning of PCR products. Liu Z. **Nucleic Acids Res** 1996 Jun 15; 24(12):2458-9
Molecule by molecule PCR amplification of complex DNA mixtures for direct sequencing: an approach to in vitro cloning. Lukyanov KA, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2194-5
Enhanced direct amplification of Guthrie card DNA following selective elution of PCR inhibitors. Makowski GS, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3788-9
cRACE: a simple method for identification of the 5' end of mRNAs. Maruyama IN, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3796-7
Screening of differentially amplified cDNA products from RNA arbitrarily primed PCR fingerprints using single strand conformation polymorphism (SSCP) gels. Mathieu-Daudé F, et al. **Nucleic Acids Res** 1996 Apr 15; 24(8):1504-7
Print-capture PCR: a simple and highly sensitive method for the detection of plum pox virus (PPV) in plant tissues. Olmos A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2192-3
A rapid method for detecting specific amplified PCR fragments in microtiter plates. Ortiz A, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3280-1
Chip PCR. I. Surface passivation of microfabricated silicon-glass chips for PCR. Shoffner MA, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):375-9
Overcoming limitations of the mRNA differential display technique. Sompayrac L, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4738-9
Reduced extension temperatures required for PCR amplification of extremely A+T-rich DNA. Su XZ, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1574-5
Reliable genotyping of samples with very low DNA quantities using PCR. Taberlet P, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3189-94
Differentiation of the normal and mutant rat albumin genes on hepatic tissue sections by in situ PCR. Tokusashi Y, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3790-1
Prevention of product carry-over by single tube two-round (ST-2R) PCR: application to BCR-ABL analysis in chronic myelogenous leukemia. Trka J, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4736-7
Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. Vartanian JP, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2627-31
Rapid selection and classification of positive clones generated by mRNA differential display. Vögeli-Lange R, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1385-6
PCR product with strands of unequal length. Williams KP, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4220-1
Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Wright WE, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3794-5
DOP-vector PCR: a method for rapid isolation and sequencing of insert termini from PAC clones. Wu C, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2614-5
Single-stranded DNA ligation by T4 RNA ligase for PCR cloning of 5'-noncoding fragments and coding sequence of a specific gene. Zhang XH, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):990-1
Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Cavrois M, et al. **Oncogene** 1996 Jun 6;12(11):2419-23
Modulation of interleukin-1 receptor expression by transforming growth factor-beta in cultured rabbit articular chondrocytes: analysis by reverse transcription-polymerase chain reaction. Pronost S, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):147-55
Evidence of two genetic entities in Bothriocephalus funiculus (Cestoda) detected by arbitrary-primer polymerase chain reaction random amplified polymorphic DNA fingerprinting. Verneau O, et al. **Parasitol Res** 1995; 81(7):591-4
The usefulness of a rapid PCR methodology to detect rearranged Ig heavy chain genes in lymphoproliferative disease in a diagnostic setting. Angulo RI, et al. **Pathology** 1995 Oct;27(4):352-7
Comparison between three PCR methods for detection of human cytomegalovirus DNA. Carter IW, et al. **Pathology** 1995 Apr;27(2):161-4
Use of vectorette and subvectorette PCR to isolate transgene flanking DNA. Allen MJ, et al. **PCR Methods Appl** 1994 Oct;4(2):71-5
Minimal length requirement of the single-stranded tails for ligation-independent cloning (LIC) of PCR products. Aslanidis C, et al. **PCR Methods Appl** 1994 Dec;4(3):172-7
Direct gene quantitation by PCR reveals differential accumulation of ectopic enzyme in rat-1 cells, v-fos transformants, and revertants. Bahramian MB, et al. **PCR Methods Appl** 1994 Dec;4(3):145-53
Detection and differential display of expressed genes by DDRT-PCR. Bauer D, et al. **PCR Methods Appl** 1994 Oct; 4(2):S97-108
Specific amplification by PCR of rearranged genomic variable regions of immunoglobulin genes from mouse hybridoma cells. Berdoz J, et al. **PCR Methods Appl** 1995 Apr;4(5):256-64
Wax-embedded PCR reagents. Blair P, et al. **PCR Methods Appl** 1994 Dec;4(3):191-4
An efficient method for PCR analysis of mitochondrial DNA from paraffin-embedded archival heart tissue. Bobba A, et al. **PCR Methods Appl** 1995 Apr;4(5):309-10
Rapid method for separation of microsatellite alleles by the PhastSystem. Buzás Z, et al. **PCR Methods Appl** 1995 Jun; 4(6):380-1
Template integrity is essential for PCR amplification of 20- to 30-kb sequences from genomic DNA. Cheng S, et al. **PCR Methods Appl** 1995 Apr;4(5):294-8
Alteration of hairpin ribozyme specificity utilizing PCR. DeGrandis P, et al. **PCR Methods Appl** 1994 Dec; 4(3):139-44

Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. Delwart EL, et al. **PCR Methods Appl** 1995 Apr;4(5):S202–16

Rapid isolation of cDNA clones by aliquot testing via PCR amplification. Di Bacco A, et al. **PCR Methods Appl** 1994 Oct;4(2):126–8

A one–step coupled amplification and oligonucleotide ligation procedure for multiplex genetic typing. Eggerding FA. **PCR Methods Appl** 1995 Jun;4(6):337–45

Single–strand conformational polymorphism. Fujita K, et al. **PCR Methods Appl** 1994 Dec;4(3):S137–40

PCR with deoxyinosine–containing primers using DNA polymerases with proofreading activity. Fujiwara H, et al. **PCR Methods Appl** 1995 Feb;4(4):239–40

Vir typing: a long–PCR typing method for group A streptococci. Gardiner D, et al. **PCR Methods Appl** 1995 Apr;4(5):288–93

A simple "universal" DNA extraction procedure using SDS and proteinase K is compatible with direct PCR amplification. Goldenberger D, et al. **PCR Methods Appl** 1995 Jun;4(6):368–70

Quantitative analysis of specific mRNA transcripts using a competitive PCR assay with electrochemiluminescent detection. Heroux JA, et al. **PCR Methods Appl** 1995 Jun; 4(6):327–30

Construction of phagemid display libraries with PCR–amplified immunoglobulin sequences. Hogrefe HH, et al. **PCR Methods Appl** 1994 Oct;4(2):S109–22

Multiple fluorescence–based PCR–SSCP analysis with postlabeling. Iwahana H, et al. **PCR Methods Appl** 1995 Apr;4(5):275–82

Panhandle PCR. Jones DH. **PCR Methods Appl** 1995 Apr; 4(5):S195–201

Metastable single–strand DNA conformational polymorphism analysis results in enhanced polymorphism detection. Kasuga T, et al. **PCR Methods Appl** 1995 Feb; 4(4):227–33

Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low–density lipoprotein receptor gene mutations. Kotze MJ, et al. **PCR Methods Appl** 1995 Jun;4(6):352–6

Expression–PCR (E–PCR): overview and applications. Lanar DE, et al. **PCR Methods Appl** 1994 Oct;4(2):S92–6 (13 ref.)

Batched analysis of genotypes. LeDuc C, et al. **PCR Methods Appl** 1995 Jun;4(6):331–6

Rapid quantitative PCR for determination of relative gene expressions in tissue specimens. Lenz HJ, et al. **PCR Methods Appl** 1995 Apr;4(5):305–8

An efficient and optimized PCR method with high fidelity for site–directed mutagenesis. Liang Q, et al. **PCR Methods Appl** 1995 Apr;4(5):269–74

A comparison of methods for RNA extraction from lymphocytes for RT–PCR. Liedtke W, et al. **PCR Methods Appl** 1994 Dec;4(3):185–7

Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. Livak KJ, et al. **PCR Methods Appl** 1995 Jun;4(6):357–62

Construction of subtractive cDNA library using magnetic beads and PCR. Lönneborg A, et al. **PCR Methods Appl** 1995 Feb;4(4):S168–76

An evaluation of competitor type and size for use in the determination of mRNA by competitive PCR. McCulloch RK, et al. **PCR Methods Appl** 1995 Feb;4(4):219–26

Background–minimized cassette mutagenesis by PCR using cassette–specific selection markers: a useful general approach for studying structure–function relationships of multisubstrate enzymes. Majumder K, et al. **PCR Methods Appl** 1995 Feb;4(4):212–8

Detection of HCV RNA by the asymmetric gap ligase chain reaction. Marshall RL, et al. **PCR Methods Appl** 1994 Oct; 4(2):80–4

Reliability of PCR decontamination systems. Niederhauser C, et al. **PCR Methods Appl** 1994 Oct;4(2):117–23

Analysis of nonspecific DNA synthesis during in situ PCR and solution–phase PCR. Nuovo GJ, et al. **PCR Methods Appl** 1994 Oct;4(2):89–96

In situ PCR: protocols and applications. Nuovo GJ. **PCR Methods Appl** 1995 Feb;4(4):S151–67

DNA hybridization analysis of PCR products by non–gel sieving capillary electrophoresis. Oto M, et al. **PCR Methods Appl** 1995 Apr;4(5):303–4

Improved heteroduplex detection of single–base substitutions in PCR–amplified DNA. Peeters AV, et al. **PCR Methods Appl** 1994 Dec;4(3):188–90

PCR analysis of the H ferritin multigene family reveals the existence of two classes of processed pseudogenes. Quaresima B, et al. **PCR Methods Appl** 1994 Oct;4(2):85–8

Amplification of RNA. Rashtchian A. **PCR Methods Appl** 1994 Oct;4(2):S83–91

Advances in PCR–based detection of mycoplasmas contaminating cell cultures. Rawadi G, et al. **PCR Methods Appl** 1995 Feb;4(4):199–208 (70 ref.)

A method for rapid generation of competitive standard molecules for RT–PCR avoiding the problem of competitor/probe cross–reactions. Ross R, et al. **PCR Methods Appl** 1995 Jun;4(6):371–5

Optimization and troubleshooting in PCR. Roux KH. **PCR Methods Appl** 1995 Apr;4(5):S185–94

DNA fingerprinting of crude bacterial lysates using degenerate RAPD primers. Sakallah SA, et al. **PCR Methods Appl** 1995 Apr;4(5):265–8

Rapid and sensitive analysis of mRNA polyadenylation states by PCR. Sallés FJ, et al. **PCR Methods Appl** 1995 Jun; 4(6):317–21

Quantitative detection of reverse transcriptase–PCR products by means of a novel and sensitive DNA stain. Schneeberger C, et al. **PCR Methods Appl** 1995 Feb;4(4):234–8

Catch–linker + PCR labeling: a simple method to generate fluorescence in situ hybridization probes from yeast artificial chromosomes. Shibasaki Y, et al. **PCR Methods Appl** 1995 Feb;4(4):209–11

An improved method for semiquantification of gene amplification from archival material. Underwood MA, et al. **PCR Methods Appl** 1994 Dec;4(3):178–84

In vitro synthesis of novel genes: mutagenesis and recombination by PCR. Vallejo AN, et al. **PCR Methods Appl** 1994 Dec;4(3):S123–30

Rapid PCR site–directed mutagenesis. Weiner MP, et al. **PCR Methods Appl** 1994 Dec;4(3):S131–6

Genomic fingerprinting by microsatellite–primed PCR: a critical evaluation. Weising K, et al. **PCR Methods Appl** 1995 Apr;4(5):249–55

Amplification of gene fragments with very high G/C content: c7dGTP and the problem of visualizing the amplification products. Weiss J, et al. **PCR Methods Appl** 1994 Oct; 4(2):124–5

Development of competitive PCR and the QPCR system 5000 as a transcription–based screen. Wilkinson ET, et al. **PCR Methods Appl** 1995 Jun;4(6):363–7

Single–tube nested PCR with room–temperature–stable reagents. Wolff C, et al. **PCR Methods Appl** 1995 Jun; 4(6):376–9

Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. Wu NH, et al. **Pediatr Hematol Oncol** 1996 May–Jun; 13(3):257–63

Comparison of a rapid nonisotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. Kovacs A, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):948–54

Detection of Pseudomonas (Burkholderia) cepacia using PCR. Campbell PW 3rd, et al. **Pediatr Pulmonol** 1995 Jul; 20(1):44–9

Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction. Smith KC, et al. **Pediatrics** 1996 Feb;97(2):155–60

Detection of the poor metabolizer–associated CYP2D6(D) gene deletion allele by long–PCR technology. Steen VM, et al. **Pharmacogenetics** 1995 Aug;5(4):215–23

Efficient isolation and mapping of Arabidopsis thaliana T–DNA insert junctions by thermal asymmetric interlaced PCR. Liu YG, et al. **Plant J** 1995 Sep;8(3):457–63

Authentication of Panax species and their adulterants by random–primed polymerase chain reaction. Shaw PC, et al. **Planta Med** 1995 Oct;61(5):466–9

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother–to–child transmission. Fang G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12100–4

Overview of the most prevalent hypothalamus–specific mRNAs, as identified by directional tag PCR subtraction. Gautvik KM, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8733–8

Sequence specificity of triplex DNA formation: Analysis by a combinatorial approach, restriction endonuclease protection selection and amplification. Hardenbol P, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2811–6

Methylation–specific PCR: a novel PCR assay for methylation status of CpG islands. Herman JG, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9821–6

Multiplex genotype determination at a large number of gene loci. Lin Z, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2582–7

Analysis of differential gene expression by display of 3' end restriction fragments of cDNAs. Prashar Y, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):659–63

Heterogeneity of primer extension products in asymmetric PCR is due both to cleavage by a structure–specific exo/endonuclease activity of DNA polymerases and to premature stops. Tombline G, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2724–8

A RT–PCR study of gene expression in a mechanical injury model. Eng LF, et al. **Prog Brain Res** 1995;105:219–29 (29 ref.)

Molecular mass measurement of polymerase chain reaction products amplified from human blood DNA by electrospray ionization mass spectrometry. Naito Y, et al. **Rapid Commun Mass Spectrom** 1995;9(15):1484–6

A new quantitative RT–PCR assay for the vasoconstrictor endothelin. Lederer EB, et al. **Res Exp Med (Berl)** 1996; 196(2):77–86

Identification and strain differentiation of Mycobacterium species on the basis of DNA 16S–23S spacer region polymorphism. Abed Y, et al. **Res Microbiol** 1995 Jun; 146(5):405–13

Overproduction of the Brucella melitensis heat shock protein DnaK in Escherichia coli and its localization by use of specific monoclonal antibodies in B. melitensis cells and fractions. Cloeckaert A, et al. **Res Microbiol** 1996 Mar–Apr; 147(3):145–57

The distinction of pathogenic Vibrio cholerae groups using arbitrarily primed PCR fingerprints. Coelho A, et al. **Res Microbiol** 1995 Oct;146(8):671–83

Rapid identification of Mycobacterium xenopi from bacterial colonies or "Bactec" culture by the polymerase chain reaction and a luminescent sandwich hybridization assay. Fauville–Dufaux M, et al. **Res Microbiol** 1995 May; 146(4):349–56

Two geographically distinct isolates of Borrelia burgdorferi from the United States share a common unique ancestor. Kolbert CP, et al. **Res Microbiol** 1995 Jun;146(5):415–24

Development of a species–specific probe for Mycobacterium xenopi. Picardeau M, et al. **Res Microbiol** 1995 Mar–Apr; 146(3):237–43

Mycobacterium tuberculosis strains unidentified using the IS6110 probe can be detected by oligonucleotides derived from the Mt308 sequence. Thierry D, et al. **Res Microbiol** 1995 May;146(4):325–8

Comparison of arbitrarily primed polymerase chain reaction and cell envelope protein electrophoresis for analysis of Acinetobacter baumannii and A. junii outbreaks. Vaneechoutte M, et al. **Res Microbiol** 1995 Jul–Aug; 146(6):457–65

Evaluation of the applicability of amplified rDNA–restriction analysis (ARDRA) to identification of species of the genus Corynebacterium. Vaneechoutte M, et al. **Res Microbiol** 1995 Oct;146(8):633–41

Restriction fragment length polymorphism of polymerase chain reaction products applied to the differentiation of poultry campylobacters for epidemiological investigations. Ayling RD, et al. **Res Vet Sci** 1996 Mar;60(2):168–72

Stochastic events in the amplification of HTLV–I integration sites by linker–mediated PCR. Cavrois M, et al. **Res Virol** 1995 May–Jun;146(3):179–84

Detection of hepatitis C virus RNA by a reliable, optimized single–step reverse transcription polymerase chain reaction. Payan C, et al. **Res Virol** 1995 Sep–Oct;146(5):363–70

Nested RT–PCR for detection of sandfly fever virus, serotype Toscana, in clinical specimens, with confirmation by nucleotide sequence analysis. Schwarz TF, et al. **Res Virol** 1995 Sep–Oct;146(5):355–62

Rapid simple and nested polymerase chain reaction for the diagnosis of Pneumocystis carinii pneumonia. Moonens F, et al. **Scand J Infect Dis** 1995;27(4):358–62

Rapid diagnosis of bacterial meningitis by a seminested PCR strategy. Olcén P, et al. **Scand J Infect Dis** 1995;27(5):537–9

Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Skøt J, et al. **Scand J Infect Dis** 1995;27(4):363–7

Prenatal sex determination in Thai pregnant subjects by nested–PCR amplification of fetal Y chromosome–specific sequence. Attatippaholkun WH, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:315–21

Uses of dinucleotide/trinucleotide repeats in the diagnosis of genetic diseases. Chan V, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:179–81

Use of PCR–PIRA for screening of a point mutation at codon 12 in K–ras oncogene obtained from paraffin embedded tissue sections. Chewawiwat N, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:329–32

A simple non radioactive method for detecting beta–thalassemia/hbe disease: application to prenatal diagnosis. Fucharoen S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:278–81

Prenatal diagnosis of Hb Bart's hydrops fetalis by PCR technique: Pramongkutklao experience. Torcharus K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:287–90

Improved Method for factor V Leiden typing by PCR–SSP [letter; comment] Bellissimo DB, et al. **Thromb Haemost** 1996 Mar;75(3):520. Comment on: Thromb Haemost 1995 Sep;74(3):874–8.

Phenotyping and genotyping of coagulation factor V Leiden. Engel H, et al. **Thromb Haemost** 1996 Feb;75(2):267–9

The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance [see comments] Kirschbaum NE, et al. **Thromb Haemost** 1995 Sep;74(3):874–8. Comment in: Thromb Haemost 1996 Mar;75(3):520.

Detection of the factor V Leiden mutation using whole blood PCR [letter] Rees DC, et al. **Thromb Haemost** 1996 Mar; 75(3):520–1

A novel Italian haplotype predominates in HLA–B45–positive bone marrow donors: HLA–A2, CW*1601, B45, DRB1*1101, DRB3*0301, DQA1*0102, DQB1*0502. Daielli C, et al. **Tissue Antigens** 1996 Apr; 47(4):341–3

Complete generic and extensive fine–specificity typing of the HLA–B locus by the PCR–SSOP method. Fleischhauer K, et al. **Tissue Antigens** 1995 Oct;46(4):281–92

PCR–RFLP–based Mamu–DQB1 typing of rhesus monkeys: characterization of two novel alleles. Sauermann U, et al. **Tissue Antigens** 1996 Apr;47(4):319–28

A rapid HLA–DRB1*04 subtyping method using PCR and DNA heteroduplex generators. Savage DA, et al. **Tissue Antigens** 1996 Apr;47(4):284–92

Detection of Leishmania in the blood of early kala–azar patients with the aid of the polymerase chain reaction. Adhya S, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;

89(6):622–4
An improved method for polymerase chain reaction typing of granulocyte antigens NA1 and NA2 [letter; comment] Wolter LC. **Transfusion** 1995 Oct;35(10):885. Comment on: Transfusion 1995 Jan;35(1):54–7.
Usefulness of measurement of serum viral DNA using dot–blot hybridization and polymerase chain reaction in renal transplant patients with hepatitis B–positive viral infection. Cheng IK, et al. **Transplant Proc** 1996 Jun; 28(3):1493–4
Early diagnosis of CMV syndrome after kidney transplantation: comparison between CMV antigenemia and PCR assay. Tanabe K, et al. **Transplant Proc** 1996 Jun; 28(3):1508–10
Immunocytochemical assay for cytomegalovirus detection in peripheral blood for renal transplant patients in clinical practice. Wie SH, et al. **Transplant Proc** 1996 Jun; 28(3):1505–6
Serology versus polymerase chain reaction–sequence–specific primers in typing for HLA–DR in Pakistani populations. Zafar N, et al. **Transplant Proc** 1996 Jun;28(3):1270–1
Methods and reagents. Quantitative PCR: an accurate measure of mRNA? Hengen PN. **Trends Biochem Sci** 1995 Nov;20(11):476–7
Vectorette, splinkerette and boomerang DNA amplification. Hengen PN. **Trends Biochem Sci** 1995 Sep;20(9):372–3
Human beta–actin retropseudogenes interfere with RT–PCR. Dirnhofer S, et al. **Trends Genet** 1995 Oct;11(10):380–1
Inosine–containing primers for mRNA differential display. Rohrwild M, et al. **Trends Genet** 1995 Aug;11(8):300
Sleeping sickness in Zaire: a nested polymerase chain reaction improves the identification of Trypanosoma (Trypanozoon) brucei gambiense by specific kinetoplast DNA probes. Schares G, et al. **Trop Med Int Health** 1996 Feb;1(1):59–70
Differentiation of Mycobacterium species by restriction enzyme analysis of amplified 16S–23S ribosomal DNA spacer sequences. Lappayawichit P, et al. **Tuber Lung Dis** 1996 Jun;77(3):257–63
Polymerase chain reaction for non–invasive diagnosis of brain mass lesions caused by Mycobacterium tuberculosis: report of five cases in human immunodeficiency virus–positive subjects. Monno L, et al. **Tuber Lung Dis** 1996 Jun; 77(3):280–4
Establishment and evaluation of a multiplex polymerase chain reaction for detection of mycobacteria and specific identification of Mycobacterium tuberculosis complex. Mustafa AS, et al. **Tuber Lung Dis** 1995 Aug;76(4):336–43
Identification of Mycobacterium intracellulare by a polymerase chain reaction using species–specific primers. Yamazaki T, et al. **Tuber Lung Dis** 1995 Aug;76(4):330–5
Polymerase chain reaction in the diagnosis of urinary tract tuberculosis. van Vollenhoven P, et al. **Urol Res** 1996; 24(2):107–11
Differentiation of Cryptosporidium parvum, C. muris, and C. baileyi by PCR–RFLP analysis of the 18S rRNA gene. Leng X, et al. **Vet Parasitol** 1996 Mar;62(1–2):1–7
Detection of human papillomavirus in cervical intra–epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Zehbe I, et al. **Virchows Arch** 1996 Jun;428(3):151–7
Infectious transcripts of tick–borne encephalitis virus, generated in days by RT–PCR. Gritsun TS, et al. **Virology** 1995 Dec 20;214(2):611–8
Recovery of virtually full–length HIV–1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Salminen MO, et al. **Virology** 1995 Oct 20; 213(1):80–6
A nested polymerase chain reaction assay to differentiate pestiviruses. Sullivan DG, et al. **Virus Res** 1995 Oct; 38(2–3):231–9
A combination of two distinct in vitro amplification procedures for DNA typing of HLA–DRB and –DQB 1 alleles. Fischer GF, et al. **Vox Sang** 1995;69(4):328–35
DNA–based typing of human platelet antigen systems by polymerase chain reaction–single–strand conformation polymorphism method. Fujiwara K, et al. **Vox Sang** 1995; 69(4):347–51
Organ– and tissue–specific expression of the low density lipoprotein receptor. Rapid quantitation by competitive reverse transcriptasepolymerase chain reaction. Gebhardt A, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:127–8
Polymerase chain reaction assay for detection of Campylobacter coli and Campylobacter jejuni in poultry meat. Manzano M, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):370–86
[Direct analysis of the frequency of disomy in human sperm using the PRINS technique] Quenesson I, et al. **Ann Genet** 1995;38(2):85–9 (Eng. Abstr.) **(Fre)**
[In situ gene amplification on tissue sections (in situ PCR). A new technique for pathologists] Walker F, et al. **Ann Pathol** 1995;15(6):459–65 (Eng. Abstr.) **(Fre)**
[HLA–DQ genotyping using a modified technique of PCR–RFLP: application to HLA–DQA1 gene] Haras D, et al. **C R Acad Sci III** 1995 Sep;318(9):977–84 (Eng. Abstr.) **(Fre)**
[Study of mitochondrial DNA in Helix land snails by PCR–RFLP] Borgo R, et al. **C R Seances Soc Biol Fil** 1995;189(4):629–36 (Eng. Abstr.) **(Fre)**
[Detection of Chlamydia trachomatis infection by PCR in first voided urines in men] Bianchi A, et al. **Contracept Fertil Sex** 1995 Nov;23(11):686–7 (Eng. Abstr.) **(Fre)**
[Rh typing by PCR on amniotic cells] Mannessier L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):827–8 **(Fre)**
[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**
[Comparison of different phenotypic methods with polymerase chain reaction (PCR) for the detection of resistance to oxacillin in coagulase negative staphylococci] Zambardi G, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):310–4 (Eng. Abstr.) **(Fre)**
[Molecular biology in the diagnosis and phenotypic expression of familial hypercholesterolemia in French Canadians] Vohl MC, et al. **Union Med Can** 1995 Sep; 124(2):48–53 (23 ref.) **(Fre)**
[Prenatal determination of fetal rhesus factor in amnionic cells using polymerase chain reaction] Crombach G, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):577–9 (Eng. Abstr.) **(Ger)**
[Sequence analysis of PCR amplification products of old formalin fixed conisation tissue sections] Labeit D, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:148–51 (Eng. Abstr.) **(Ger)**
[Evaluating polymerase chain reaction for detection of C. trachomatis in urogenital smears] Näher H, et al. **Hautarzt** 1995 Oct;46(10):693–6 (Eng. Abstr.) **(Ger)**
[Detection of Mycobacterium tuberculosis complex with polymerase chain reaction (PCR)] Schröder U, et al. **Pneumologie** 1995 Sep;49(9):502–4 (Eng. Abstr.) **(Ger)**
[Use of polymerase chain reaction to reduce the use of animal studies: a project for the expression of the structural proteins of tick–borne meningoencephalitis virus] Adler H, et al. **Schweiz Arch Tierheilkd** 1996;138(2):59–62 (Eng. Abstr.) **(Ger)**
[PCR: basics and new developments] Berchtold MW, et al. **Schweiz Arch Tierheilkd** 1996;138(2):53–8 (0 ref.) (Eng. Abstr.) **(Ger)**
[Detection of feline coronavirus using RT–PCR: basis for the study of the pathogenesis of feline infectious peritonitis (FIP)] Fehr D, et al. **Schweiz Arch Tierheilkd** 1996; 138(2):74–9 (Eng. Abstr.) **(Ger)**
–Entrance of PCR for studying murine coronaviruses– Homberger FR, et al. **Schweiz Arch Tierheilkd** 1996; 138(2):67–73 (Eng. Abstr.) **(Ger)**
[Identification and characterization of new and unknown coronaviruses using RT–PCR and degenerate primers] Tobler K, et al. **Schweiz Arch Tierheilkd** 1996;138(2):80–6 (Eng. Abstr.) **(Ger)**
[Detection of genetically engineered plants by polymerase chain reaction (PCR) using the FLAVR SAVR tomato as an example] Meyer R. **Z Lebensm Unters Forsch** 1995 Dec;201(6):583–6 (Eng. Abstr.) **(Ger)**
[New technique: PCR method for diagnosis of patients with leprosy] Sugita Y. **Nippon Rai Gakkai Zasshi** 1995 Jul; 64(2):100–4 (17 ref.) **(Jpn)**
[Detection of hepatitis C virus RNA with reverse transcription–nested polymerase chain reaction] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:276–80 **(Jpn)**
[Quantitation of HCV–RNA by competitive–PCR] Kaneko S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:281–6 (5 ref.) **(Jpn)**
[Detection of hepatitis C virus (HCV) infected cell using in situ hybridization and PCR in situ hybridization] Kawai H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:307–11 (23 ref.) **(Jpn)**
[Method of detecting plus and minus strands of hepatitis C viral RNA by strand specific reverse transcription–polymerase chain reaction] Kawashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:294–9 (11 ref.) **(Jpn)**
[Detection of tumor markers by genetic diagnostic methods and its clinical application] Yamamoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1574–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Usefulness of PCR–SSCP using non–RI coloration method as a routine genetic analysis] Inano K, et al. **Rinsho Byori** 1996 Jan;44(1):90–2 (Eng. Abstr.) **(Jpn)**
[A PCR method for examining diarrhea––Escherichia coli] Itoh F, et al. **Rinsho Byori** 1995 Aug;43(8):772–5 (Eng. Abstr.) **(Jpn)**
[Detection of hepatitis B virus by using polymerase chain reaction and nonradioactive DNA probes. I. Identification of mutations in the precore region by PCR–direct sequencing and ASO probe method] Yamashita K, et al. **Rinsho Byori** 1995 Aug;43(8):836–42 (Eng. Abstr.) **(Jpn)**
[Representational difference analysis: identification of the differences between genomes] Aburatani H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):573–9 (11 ref.) **(Jpn)**
[Detection and analysis of human herpesvirus genomes by polymerase chain reaction] Aono T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):669–75 (24 ref.) **(Jpn)**
[In situ PCR: principles, problems and application to molecular biology] Aoyagi K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):608–13 (32 ref.) **(Jpn)**
[Problems in PCR] Hayashi K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):510–3 (7 ref.) **(Jpn)**
[RNase protection analysis] Horii A. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):561–3 (2 ref.) **(Jpn)**
[Immuno–PCR: a sensitive method for detecting antigen] Imai K, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):614–7 (13 ref.) **(Jpn)**
[In situ PCR detection of HTLV–1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656–9 (16 ref.) **(Jpn)**
[Hepatitis C virus] Kato N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):676–80 (19 ref.) **(Jpn)**
[Quantitative PCR] Kawakami B, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):503–9 (16 ref.) **(Jpn)**
[Molecular cloning of differentially expressed genes during plant somatic embryogenesis] Kayano T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):721–6 (32 ref.) **(Jpn)**
[AP–PCR genomic fingerprinting] Kohno T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):629–32 (3 ref.) **(Jpn)**
[Detection of gene expression using digoxigenin–labeled probes] Kubota S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):486–90 (14 ref.) **(Jpn)**
[Hemorrhagic fever renal syndrome–associated virus] Mizutani S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):696–9 **(Jpn)**
[LA PCR] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):585–94 (7 ref.) **(Jpn)**
[Hot start method] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):469–71 (3 ref.) **(Jpn)**
[Reverse transcriptase–polymerase chain reaction] Murakami Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):595–602 (12 ref.) **(Jpn)**
[PCR–RFLP analysis] Nagase S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):564–7 (6 ref.) **(Jpn)**
[Differential display analysis of mRNA] Nakagama H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):580–4 (4 ref.) **(Jpn)**
[Detection of Borna disease virus RNA by RT–PCR in PBMC] Nakaya T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):700–4 (20 ref.) **(Jpn)**
[Detection of DNA aberrations in human cancers by AP–PCR–SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633–7 (12 ref.) **(Jpn)**
[Denaturing gradient gel electrophoresis of DNA fragments attached with a GC–clamp] Satoh C, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):556–60 (15 ref.) **(Jpn)**
[Single–strand conformation polymorphism (SSCP) analysis: a convenient, rapid method for detection of single–base changes in DNA] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):539–45 (4 ref.) **(Jpn)**
[PCR application for paraffin–embedded tissues] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):463–6 (8 ref.) **(Jpn)**
[Histopathological application of in situ PCR (in situ hybridization after amplification by PCR)] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):660–3 (10 ref.) **(Jpn)**
[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546–8 (11 ref.) **(Jpn)**
[Molecular diagnosis of cancer by non–radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**
[Isolation of mRNA 5'–end using oigo–capping] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):603–7 (0 ref.) **(Jpn)**
[Detection of rare target gene with a point mutation by improved PCR] Tada M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):549–52 (7 ref.) **(Jpn)**
[Hot–start PCR by using antibody] Takahashi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):472–6 (12 ref.) **(Jpn)**
[Novel molecular technology for HIV detection and analysis] Tamatsukuri S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):686–95 (36 ref.) **(Jpn)**
[Application of PCR to hospital epidemiology] Tokue Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):705–7 (14 ref.) **(Jpn)**
[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664–8 (21 ref.) **(Jpn)**
[Site–directed mutagenesis by PCR] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):534–8 (13 ref.) **(Jpn)**
[Arbitrarily primed PCR: an unique technique for molecular genetical analysis] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):568–72 (12 ref.) **(Jpn)**
[PCR–SSOP (sequence specific oligonucleotide probe) method] Yasunaga S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):553–5 (3 ref.)

(Jpn)

[Slide PCR for gene mapping] Yoshida MC. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):652–5 (3 ref.) (Jpn)

[Use of polymerase chain reaction for detection of human cytomegalovirus in blood samples of children with suspected active infection with cytomegalovirus] Augustynowicz E, et al. **Pediatr Pol** 1995 Oct; 70(10):827–32 (Eng. Abstr.) (Pol)

[Identification analysis using PCR of fresh or fixed and paraffin wax embedded tissue] Pawłowski R. **Pol Tyg Lek** 1995 Sep;50(36–39):16–20 (Eng. Abstr.) (Pol)

[A method of selective PCR–amplification of genomic DNA fragments (SAGF method)] Zheleznaia LA, et al. **Biokhimiia** 1995 Sep;60(9):1363–70 (Eng. Abstr.) (Rus)

[The detection of infectious agents of viral and bacterial etiology by the polymerase chain reaction] Glukhov AI, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):32–5 (Rus)

[Polymerase chain reaction and ligase reactions. Principles, traditional methods, and innovations] Belokhvostov AS. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):21–6 (50 ref.) (Eng. Abstr.) (Rus)

[The analysis of DNA amplified fragment length polymorphism in forensic identification expertise: the possible sources of errors under nonoptimal conditions for the polymerase chain reaction] Gyské LI, et al. **Sud Med Ekspert** 1995 Oct–Dec;38(4):12–7 (Eng. Abstr.) (Rus)

[A method for differential cytolysis in the molecular genetic expert identification of material evidence: problems in optimizing the procedure] Gyské LI, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):16–21 (Eng. Abstr.) (Rus)

[The use of the polymerase chain reaction in the forensic medical study of hairs] Puchkov GF, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):21–3 (Eng. Abstr.) (Rus)

[The physical mapping of human chromosomes. The use of the polymerase chain reaction on unique DNA sequences with a known location on chromosome 3] Svetlova MP, et al. **Tsitologiia** 1995;37(8):813–9 (Eng. Abstr.) (Rus)

[A rapid method for determining the species attribution of bacteria in the genus Salmonella by using the polymerase chain reaction and restriction analysis] Chmeliauskaite VG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):78–9 (Rus)

[Primers for the genus-specific detection of Francisella tularensis in the polymerase chain reaction] Romanova LV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):77–80 (Eng. Abstr.) (Rus)

[The determination of monoclonality in B-cell lymphomas using the polymerase chain reaction technic on paraffin-embedded material] Alvarez García A, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):50–2 (Eng. Abstr.) (Spa)

[Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease] Kotliar N, et al. **Medicina (B Aires)** 1995;55(2):159–66 (Eng. Abstr.) (Spa)

STANDARDS

Forensic PCR. Primed, amplified, and ready for court. Noble D. **Anal Chem** 1995 Oct 1;67(19):613A–615A

Diagnosis of pediatric human immunodeficiency virus infection by means of a commercially available polymerase chain reaction gene amplification [see comments] Nelson RP Jr, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):40–5 . Comment in: Arch Pediatr Adolesc Med 1996 Jan;150(1):39.

Amplification of the conserved cytochrome b locus as a versatile internal control for PCR analysis in animals. Ron M, et al. **Biotechniques** 1996 Apr;20(4):604–8

Method for constructing internal standards for use in competitive PCR. Zarlenga DS, et al. **Biotechniques** 1995 Sep;19(3):324–6

A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood. Grundy JE, et al. **J Clin Microbiol** 1996 May;34(5):1166–70

Mathematical considerations of competitive polymerase chain reaction. Connolly AR, et al. **J Immunol Methods** 1995 Dec 1;187(2):201–11

Molecular analysis of the Huntington's disease gene in New Zealand. Whitefield JE, et al. **N Z Med J** 1996 Feb 9; 109(1015):27–30

Evidence of contamination in PCR laboratory disposables. Schmidt T, et al. **Naturwissenschaften** 1995 Sep; 82(9):423–31

Quality assurance and use of PCR in clinical trials. Reichelderfer PS, et al. **PCR Methods Appl** 1994 Dec; 4(3):S141–9

Towards standardizations of CMV DNA PCR assays. Ehrnst A, et al. **Scand J Infect Dis Suppl** 1995;99:16–8

[The PCR technique for screening of viruses should be improved (letter)] Eriksson B. **Lakartidningen** 1996 Feb 28; 93(9):763–4 (Swe)

TRENDS

[PCR: principles and prospects in clinical biology] Billiald P, et al. **Ann Pharm Fr** 1995;53(4):155–62 (79 ref.) (Eng. Abstr.) (Fre)

VETERINARY

Comparison of polymerase chain reaction and microbiological culture for detection of salmonellae in equine feces and environmental samples. Cohen ND, et al. **Am J Vet Res** 1996 Jun;57(6):780–6

Detection of Toxoplasma gondii in feline and canine biological samples by use of the polymerase chain reaction. Stiles J, et al. **Am J Vet Res** 1996 Mar;57(3):264–7

PCR amplification of crude blood on microscope slides in the diagnosis of Trypanosoma evansi infection in dairy cattle. Wuyts N, et al. **Ann Soc Belg Med Trop** 1995 Sep; 75(3):229–37

Rapid and sensitive polymerase chain reaction based detection and typing of foot-and-mouth disease virus in clinical samples and cell culture isolates, combined with a simultaneous differentiation with other genomically and/or symptomatically related viruses. Vangrysperre W, et al. **Arch Virol** 1996;141(2):331–44

Development of a polymerase chain reaction and a nonradioactive DNA probe for infectious laryngotracheitis virus. Abbas F, et al. **Avian Dis** 1996 Jan–Mar;40(1):56–62

Application of polymerase chain reaction with arbitrary primers to strain identification of Mycoplasma gallisepticum. Fan HH, et al. **Avian Dis** 1995 Oct–Dec; 39(4):729–35

Detection of Mycoplasma gallisepticum, M. synoviae, and M. iowae by multi-species polymerase chain reaction and restriction fragment length polymorphism. Garcia M, et al. **Avian Dis** 1995 Jul–Sep;39(3):606–16

Avian mycoplasma identification using polymerase chain reaction amplicon and restriction fragment length polymorphism analysis. Lauerman LH, et al. **Avian Dis** 1995 Oct–Dec;39(4):804–11

Polymerase chain reaction optimization for Mycoplasma gallisepticum and M. synoviae diagnosis. Silveira RM, et al. **Avian Dis** 1996 Jan–Mar;40(1):218–22

Optimization of the PCR test for the mutation causing bovine leukocyte adhesion deficiency. Mirck MH, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):695–8

Detection of bovine herpesvirus 1 in clinical samples by the polymerase chain reaction. Vilček S, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):249–50

Application of PCR for specific identification of epizootic hemorrhagic disease virus serotype 2. Aradaib IE, et al. **J Vet Diagn Invest** 1995 Jul;7(3):388–92

Nested polymerase chain reaction for detection of low levels of enterotoxigenic Clostridium perfringens in animal feces and meat. Miwa N, et al. **J Vet Med Sci** 1996 Mar; 58(3):197–203

A PCR test for avian malaria in Hawaiian birds. Feldman RA, et al. **Mol Ecol** 1995 Dec;4(6):663–73

Demonstration by reverse transcription–polymerase chain reaction of multiple cytokine mRNA expression in bovine alveolar macrophages and peripheral blood mononuclear cells. Ito T, et al. **Res Vet Sci** 1996 Jan;60(1):94–6

Relationship between clinical manifestations of footrot and specific DNA products of Dichelobacter nodosus amplified through PCR. Liu D, et al. **Res Vet Sci** 1995 Sep; 59(2):102–5

Detection of bovine herpesvirus 1 in the semen of experimentally infected bulls by dot-blot hybridisation, polymerase chain reaction and virus isolation. Xia JQ, et al. **Res Vet Sci** 1995 Sep;59(2):183–5

Reverse transcription combined with polymerase chain reaction as a detection method for pestiviral infections. Stadejek T, et al. **Rev Sci Tech** 1995 Sep;14(3):811–8

Nested PCR allows the characterization of TaqI and PstI RFLPs in the second exon of the caprine MHC class II DRB gene. Amills M, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):313–21

Detection of cytokine transcriptional profiles from bovine peripheral blood mononuclear cells and CD4+ lymphocytes by reverse transcriptase polymerase chain reaction. Covert J, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):39–50

In vitro amplification of the 16S rRNA genes from Mycoplasma bovis and Mycoplasma agalactiae by PCR. Chávez González YR, et al. **Vet Microbiol** 1995 Nov; 47(1–2):183–90

Detection of ileal symbiont intracellularis in porcine faecal samples by polymerase chain reaction. McCormick BM, et al. **Vet Microbiol** 1995 Dec;47(3–4):387–93

Retrospective diagnosis of bluetongue virus in stored frozen and fixed tissue samples using PCR. Parsonson IM, et al. **Vet Microbiol** 1995 Sep;46(1–3):143–9

Differentiation of African horse sickness viruses by polymerase chain reaction and segments 10 restriction patterns. Zientara S, et al. **Vet Microbiol** 1995 Dec; 47(3–4):365–75

Detection of Cryptosporidium parvum oocysts in faeces: comparison of conventional coproscopical methods and the polymerase chain reaction. Webster KA, et al. **Vet Parasitol** 1996 Jan;61(1–2):5–13

A reverse transcription–quantitative competitive polymerase chain reaction (RT–qcPCR) technique to measure cytokine gene expression in domestic mammals. Rottman JB, et al. **Vet Pathol** 1996 Mar;33(2):242–8

Polymerase chain reaction: a revolution in diagnosis of ocular leishmaniosis? Roze M. **Vet Q** 1995 Apr;17 Suppl 1:S47–8

Sample preparation for M paratuberculosis polymerase chain reaction in faeces and tissues [letter] Bleumink-Pluym NM, et al. **Vet Rec** 1994 Jul 30;135(5):120

Use of PCR to detect Mycoplasma mycoides subspecies mycoides from nasal filter strips. Kaura HT, et al. **Vet Rec** 1996 May 4;138(18):444–5

Use of the polymerase chain reaction (PCR) to differentiate serologically similar viral haemorrhagic septicaemia (VHS) virus isolates from Europe and America. Einer-Jensen K, et al. **Vet Res** 1995;26(5–6):464–9

Detection of trout haemorrhagic septicaemia rhabdovirus by capture with monoclonal antibodies and amplification with PCR. Estepa A, et al. **Vet Res** 1995;26(5–6):530–2

Applications of DNA amplification techniques in veterinary diagnostics. Pfeffer M, et al. **Vet Res Commun** 1995; 19(5):375–407 (284 ref.)

PCR screening for carriers of bovine leukocyte adhesion deficiency (BLAD) and uridine monophosphate synthase (DUMPS) in Argentine Holstein cattle. Poli MA, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):163–8

Early stages of rabbit haemorrhagic disease virus infection monitored by polymerase chain reaction. Guittré C, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):109–18

[The causative agent of PIA (porcine intestinal adenomatosis) can be demonstrated in swine manure via polymerase chain reaction (report of a demonstration] van der Stroom-Kruyswijk JH, et al. **Tijdschr Diergeneeskd** 1995 Dec 1;120(23):686–7 (Dut)

[Prospects of methods of bovine control of parentage] Margan U. **Berl Munch Tierarztl Wochenschr** 1996 Jan; 109(1):1–5 (Eng. Abstr.) (Ger)

[Comparison of different methods for the diagnosis of freemartinism—blood group serology, cytology and polymerase chain reaction] Justi A, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):471–4 (Eng. Abstr.) (Ger)

[Quantification of proviral FIV DNA using competitive PCR] Allenspach K, et al. **Schweiz Arch Tierheilkd** 1996; 138(2):87–92 (Eng. Abstr.) (Ger)

[RT-PCR: a tool for the generation of clones for research on canine distemper] Graber HU, et al. **Schweiz Arch Tierheilkd** 1996;138(2):99–103 (Eng. Abstr.) (Ger)

[Diagnosis of contagious diseases in animals using PCR] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1995; 137(12):531–6 (9 ref.) (Eng. Abstr.) (Ger)

[PCR: a look behind the scenes at bovine viral diarrhea virus] Stadler HP, et al. **Schweiz Arch Tierheilkd** 1996;138(2):63–6 (Eng. Abstr.) (Ger)

–PCR for the detection of lentiviruses from small ruminants– Zanoni RG, et al. **Schweiz Arch Tierheilkd** 1996;138(2):93–8 (Eng. Abstr.) (Ger)

POLYMERIC IMMUNOGLOBULIN RECEPTORS see **RECEPTORS, POLYMERIC IMMUNOGLOBULIN**

POLYMERS

see related
MACROMOLECULAR SYSTEMS

Diffusion of anaesthetic gases through different polymers. Marx T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):275–81

Bioadhesive polymers for oral drug delivery. Ríhová B, et al. **Adv Exp Med Biol** 1995;371B:1491–4

Polyglyconate (Maxon) versus nylon suture in midline abdominal incision closure: a prospective randomized trial. Carlson MA, et al. **Am Surg** 1995 Nov;61(11):980–3

Immobilized metal ion affinity capillary electrophoresis of proteins—a model for affinity capillary electrophoresis using soluble polymer-supported ligands. Haupt K, et al. **Anal Biochem** 1996 Feb 15;234(2):149–54

Feasibility of electrophoresis of a subcellular-sized particle in polymer solutions, using automated horizontal gel apparatus. Chang HT, et al. **Appl Theor Electrophor** 1995; 5(2):73–7

Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. Campbell EJ, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M853–7

Inhibition of bacterial adhesion and biofilm formation by a heparinized hydrophilic polymer. Nagaoka S, et al. **ASAIO J** 1995 Jul–Sep;41(3):M365–8

Design and properties of photocurable electroconductive polymers for use in biosensors. Nakayama Y, et al. **ASAIO J** 1995 Jul–Sep;41(3):M418–21

Microporous polymer surfaces prepared by an excimer laser ablation technique. Nakayama Y, et al. **ASAIO J** 1994 Jul–Sep;40(3):M590–3

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):332–51 (234 ref.)

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Athanasiou KA, et al. **Biomaterials** 1996 Jan; 17(2):93–102 (100 ref.)

Application of enzyme immunoassays for testing haemocompatibility of biomedical polymers. Groth T, et al. **Biomaterials** 1995 Sep;16(13):1009–15

High-impact poly(L/D-lactide) for fracture fixation: in vitro degradation and animal pilot study. Tams J, et al. **Biomaterials** 1995 Dec;16(18):1409–15

Prevention of platelet adhesion on polysulfone porous catheter by saline solution perfusion, II. Ex vivo and in vivo investigation. Khang G, et al. **Biomed Mater Eng** 1996;

6(2):123–34

Covalent enzyme immobilization on paramagnetic polyacrolein beads. Varlan AR, et al. **Biosens Bioelectron** 1996;11(4):443–8

Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries. De Scheerder IK, et al. **Cardiovasc Intervent Radiol** 1995 Jul–Aug;18(4):227–32

Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Uchida T, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1569–73

Poly-(L-lactic) acid membranes in palatal surgery in beagle dogs: clinical and histologic evaluation. In de Braekt MM, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):290–8

Role of bone substitutes. Hollinger JO, et al. **Clin Orthop** 1996 Mar;(324):55–65 (89 ref.)

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Apel A, et al. **Curr Eye Res** 1995 Aug;14(8):659–67

Further study on the use of uncharged beta-cyclodextrin polymer in capillary electrophoresis: enantiomeric separation of some alpha-hydroxy acids. Fanali S, et al. **Electrophoresis** 1995 Aug;16(8):1505–9

Separation and quantitation of reverse transcriptase polymerase chain reaction fragments of basic fibroblast growth factor by capillary electrophoresis in polymer networks. Gelfi C, et al. **Electrophoresis** 1995 May; 16(5):780–3

Capillary electrophoresis of rat liver microsomes in polymer solutions. Radko SP, et al. **Electrophoresis** 1995 Jun; 16(6):981–92

Theoretical treatment of pollutant transfer in a finite volume of food from a polymer packaging made of a recycled film and a functional barrier. Laoubi S, et al. **Food Addit Contam** 1996 Apr;13(3):293–306

Polymer-iodine inactivation of the human immunodeficiency virus. Shikani AH, et al. **J Am Coll Surg** 1996 Sep; 183(3):195–200

Reinforced poly(L-lactic acid) fibres as suture material. Lam KH, et al. **J Appl Biomater** 1995 Fall;6(3):191–7

Apatite coated on organic polymers by biomimetic process: improvement in its adhesion to substrate by NaOH treatment. Tanahashi M, et al. **J Appl Biomater** 1994 Winter;5(4):339–47

New biodegradable oligoesters for pharmaceutical application. Wada R, et al. **J Biomater Sci Polym Ed** 1996; 7(8):715–25

Studies on a new strategy for surface modification of polymeric biomaterials. Aldenhoff YB, et al. **J Biomed Mater Res** 1995 Aug;29(8):917–28

Canine bone response to tyrosine-derived polycarbonates and poly(L-lactic acid). Choueka J, et al. **J Biomed Mater Res** 1996 May;31(1):35–41

Articular cartilage repair using allogeneic perichondrocyte-seeded biodegradable porous polylactic acid (PLA): a tissue-engineering study. Chu CR, et al. **J Biomed Mater Res** 1995 Sep;29(9):1147–54

Poly(L-lactic acid) foams with cell seeding and controlled-release capacity. Lo H, et al. **J Biomed Mater Res** 1996 Apr;30(4):475–84

Delayed in vitro immune response to long-term intraperitoneal polymer implant in mice. Maurin N, et al. **J Biomed Mater Res** 1995 Dec;29(12):1493–8

Two year clinical study of a soft acrylic intraocular lens. Oshika T, et al. **J Cataract Refract Surg** 1996 Jan–Feb; 22(1):104–9

Polymeric surface modifications of tantalum stents. Fontaine AB, et al. **J Endovasc Surg** 1996 Aug;3(3):276–83

Orthosorb: a case of foreign-body reaction. Kalla TP, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):366–70

Bioabsorbable rods and pins for fixation of metacarpophalangeal arthrodesis of the thumb. Voche P, et al. **J Hand Surg [Am]** 1995 Nov;20(6):1032–6

Specific IgE determination using the CAP system: comparative evaluation with RAST. Alonso R, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):156–60

Polymers help guide cancer drugs to tumor targets—and keep them there [news] Reynolds T. **J Natl Cancer Inst** 1995 Nov 1;87(21):1582–4

Laser exposure of Parylene-C insulated microelectrodes. Schmidt EM, et al. **J Neurosci Methods** 1995 Nov; 62(1–2):89–92

Poly(L-lactide) implants for repair of human orbital floor defects: clinical and magnetic resonance imaging evaluation of long-term results. Cordewener FW, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):9–13; discussion 13–4

The influence of the design of two different bioresorbable barriers on the results of guided tissue regeneration therapy. An intra-individual comparative study in the monkey. Lundgren D, et al. **J Periodontol** 1995 Jul;66(7):605–12

New concept of microtubule dynamics and microtubule motor movement and new model of chromosome movement in mitosis. Semënov MV. **J Theor Biol** 1996 Mar 21;179(2):91–117

Aging of polymer networks as studied by material property NMR imaging. Hafner S, et al. **Magn Reson Imaging** 1995; 13(5):739–44

Adhesion of urogenital organisms to polymers and prosthetic devices. Reid G. **Methods Enzymol** 1995;253:514–9

Modern methods for rapid x-ray diffraction data collection from crystals of macromolecules. Garman EF. **Methods Mol Biol** 1996;56:87–126

Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Bielinska A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2176–82

Enzymatic synthesis of polymers containing nicotinamide mononucleotide. Liu R, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3742–9

The influence of buffer species and strength on diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Bodmeier R, et al. **Pharm Res** 1996 Jan;13(1):52–6

Polymeric microspheres prepared by spraying into compressed carbon dioxide. Bodmeier R, et al. **Pharm Res** 1995 Aug;12(8):1211–7

Determination of the surface tension of block copolymer micelles by phagocytosis. Rolland A, et al. **Pharm Res** 1995 Oct;12(10):1435–8

Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Kukowska-Latallo JF, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4897–902

Dressed polyions, counterion condensation, and adsorption excess in polyelectrolyte solutions. Mohanty U, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4342–4

Acoustic properties of some biocompatible polymers at body temperature. Guess JF, et al. **Ultrasound Med Biol** 1995; 21(2):273–7

[Adsorption of aclacinomycin A onto polyisobutylcyanoacrylate nanoparticles] Jiang X, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):163–6 (Eng. Abstr.) **(Chi)**

[Laparotomy closure with continuous polydioxanone sutures] Hoch J, et al. **Rozhl Chir** 1995 May;74(4):198–200 (Eng. Abstr.) **(Cze)**

[In vitro study of the properties of bioresorbable lactic acid polymer materials] Merloz P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(5):433–44 (Eng. Abstr.) **(Fre)**

[Mechanical duodenal stump suture. Report of experiences: metal staples versus resorbable staples] Tonus C, et al. **Chirurg** 1996 Mar;67(3):249–53 (Eng. Abstr.) **(Ger)**

[Induction of cervix ripening with hydrophilic Dilapan rods in pregnancy at term] Roztočil A, et al. **Zentralbl Gynakol** 1996;118(1):29–32 (Eng. Abstr.) **(Ger)**

[Experimental study on cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid] Tokuda K, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1641–3 (Eng. Abstr.) **(Jpn)**

[Aerosolization of lactide/glycolide copolymer (PLGA) nanospheres for pulmonary delivery of peptide-drugs] Niwa T, et al. **Yakugaku Zasshi** 1995 Sep;115(9):732–41 (Eng. Abstr.) **(Jpn)**

[Absorbable implants in traumatology of the musculoskeletal system] Siwiński D. **Chir Narzadow Ruchu Ortop Pol** 1995; 60(6):515–21 (Eng. Abstr.) **(Pol)**

[The antimutagenic activity of ternary diallyl copolymers] Aleksandrova VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):746–51 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Is misoprostol the drug of choice for induced cervical ripening in early pregnancy termination? Platz-Christensen JJ, et al. **Acta Obstet Gynecol Scand** 1995 Nov; 74(10):809–12

Application of polylactic acid polymer in the treatment of acute maxillary sinusitis in rabbits. Min YG, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):548–52

Xenobiotic polymers as vaccine vehicles. Payne LG, et al. **Adv Exp Med Biol** 1995;371B:1475–80

A prospective randomized evaluation of a hygroscopic cervical dilator, Dilapan, in the preinduction ripening of patients undergoing induction of labor. Gilson GJ, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):145–9

Polyols, breath hydrogen and fermentation revisited [letter] Livesey G. **Br J Nutr** 1995 Dec;74(6):867–8

Intraocular silicone oil for retinal detachment in AIDS: CT and MR appearances. Murray JG, et al. **Clin Radiol** 1996 Jun;51(6):415–7

Embryotoxicity and teratogenicity studies of poly (DL-lactide-co-glycolide) microspheres incorporated tetanus toxoid in Wistar rats. Chandrasekaran R, et al. **Hum Exp Toxicol** 1996 Apr;15(4):349–51

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Jones DH, et al. **Infect Immun** 1996 Feb; 64(2):489–94

Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Partidos CD, et al. **Mol Immunol** 1996 Apr;33(6):485–91

Polyphenols in our diet: do they matter? [editorial] Ferro-Luzzi A, et al. **Nutrition** 1995 Jul–Aug;11(4):399–400

Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Venier-Julienne MC, et al. **Pharm Acta Helv** 1996 Jul;71(2):121–8

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vordermeier HM, et al. **Vaccine** 1995 Nov;13(16):1576–82

ADVERSE EFFECTS

Thrombogenic properties of untreated and poly(ethylene oxide)-modified polymeric matrices useful for preparing intraarterial ion-selective electrodes. Espadas-Torre C, et al. **Anal Chem** 1995 Sep 15;67(18):3108–14

Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitor. Wakasa M, et al. **Clin Nephrol** 1995 Nov; 44 Suppl 1:S29–32

The effect of polylactic acid granules on the incidence of alveolar osteitis after mandibular third molar surgery. A prospective randomized study. Hooley JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):279–83

ANALYSIS

Polyion-sensitive membrane electrodes for biomedical analysis. Meyerhoff ME, et al. **Anal Chem** 1996 Mar 1; 68(5):168A–175A (20 ref.)

Biosensor based on an enzyme modified electrode for highly-sensitive measurement of polyphenols. Eremenko A, et al. **Biosens Bioelectron** 1995 Fall;10(8):717–22

Antibacterial polyphenols from olive oil mill waste waters. Capasso R, et al. **J Appl Bacteriol** 1995 Oct;79(4):393–8

A model for estimating the daily dietary intake of a substance from food-contact articles: styrene from polystyrene food-contact polymers. Lickly TD, et al. **Regul Toxicol Pharmacol** 1995 Jun;21(3):406–17

Thermospray-LC-MS analysis of various groups of polyphenols in tea. II: Chlorogenic acids, theaflavins and thearubigins. Kiehne A, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):299–302

[Characterization and simultaneous assay of polymers and additives composing multilayer plastic material for pharmaceutical use by FTIR] Yagoubi N, et al. **Ann Pharm Fr** 1996;54(3):126–30 (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

Synthesis of aromatic polyimides with sulfone diamine moieties for a novel membrane oxygenator. Kawakami H, et al. **ASAIO J** 1995 Jul–Sep;41(3):M379–83

Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties. Ishihara K, et al. **Biomaterials** 1995 Jul; 16(11):873–9

Azo polymeric hydrogels for colon targeted drug delivery. Shantha KL, et al. **Biomaterials** 1995 Nov;16(17):1313–8

Combined synthetic/CD strategy for the preparation and configurational assignments of model acyclic 1,3-polyols with a 1,2-diol terminal. Zhao N, et al. **Chirality** 1995; 7(8):636–51

Hydrolytic degradation of benzylated poly(beta-malic acid): influence of sample size, sample shape, and polymer composition. Mauduit J, et al. **J Biomater Sci Polym Ed** 1995;7(3):207–20

Studies on a new strategy for surface modification of polymeric biomaterials. Aldenhoff YB, et al. **J Biomed Mater Res** 1995 Aug;29(8):917–28

Development of vaccines based on formulations containing nonionic block copolymers. Brey RN. **Pharm Biotechnol** 1995;6:297–311 (52 ref.)

Reversible encapsulation of disc-shaped guests by a synthetic, self-assembled host. Grotzfeld RM, et al. **Science** 1996 Jan 26;271(5248):487–9

Self-assembling dendrimers [see comments] Zimmerman SC, et al. **Science** 1996 Feb 23;271(5252):1095–8. Comment in: Science 1996 Feb 23;271(5252):1077–8.

CHEMISTRY

Logarithmic growth in surface adsorption. Nygren H. **Adv Colloid Interface Sci** 1995 Dec 1;62(2–3):137–59 (71 ref.)

Platelet deposition and fibrinogen binding on surfaces coated with heparin or friction-reducing polymers. Anderson AB, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):859–63

Antibody-mimicking polymers as chiral stationary phases in HPLC. Kempe M. **Anal Chem** 1996 Jun 1;68(11):1948–53

Chromatography of proteins using polybutadiene-coated zirconia. Sun L, et al. **Anal Chem** 1995 Oct 15; 67(20):3717–21

Conducting polymers and the bioanalytical sciences: new tools for biomolecular communication. A review. Adeloju SB, et al. **Analyst** 1996 Jun;121(6):699–703 (46 ref.)

Covalent modification of mushroom tyrosinase with different amphiphic polymers for pharmaceutical and biocatalysis applications. Morpurgo M, et al. **Appl Biochem Biotechnol** 1996 Jan;56(1):59–72

Synthesis of polymer-bound 6-mercuric carboxylate DOPA precursors and solid phase labelling method of 6-radioiodinated L-DOPA. Kawai K, et al. **Appl Radiat Isot** 1996 Jan;47(1):37–44

Molecular sieving by polymer solutions: dependence on particle and polymer size, independence of polymer entanglement. Radko SP, et al. **Appl Theor Electrophor** 1995;5(2):79–87

Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Salah N, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):339–46

Dialyzer reuse: interaction between dialyzer membrane,

disinfectant (formalin), and blood during dialyzer reprocessing. Ng YY, et al. **Artif Organs** 1996 Jan; 20(1):53–5

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)

Large complexes of beta-poly(L-malate) with DNA polymerase alpha, histones, and other proteins in nuclei of growing plasmodia of Physarum polycephalum. Angerer B, et al. **Biochemistry** 1995 Nov 14;34(45):14741–51

Water-soluble block polycations as carriers for oligonucleotide delivery. Kabanov AV, et al. **Bioconjug Chem** 1995 Nov–Dec;6(6):639–43

Synthesis and properties of novel block copolymers containing poly(lactic-glycolic acid) and poly(ethyleneglycol) segments. Ferruti P, et al. **Biomaterials** 1995 Dec;16(18):1423–8

Characterization of hydrogels using nuclear magnetic resonance spectroscopy. Mathur AM, et al. **Biomaterials** 1996 Mar;17(6):547–57 (80 ref.)

Stabilized polyglycolic acid fibre-based tubes for tissue engineering. Mooney DJ, et al. **Biomaterials** 1996 Jan; 17(2):115–24

Surface properties and biocompatibility of A-B-A type block copolymer membranes consisting of poly(gamma-benzyl-L-glutamate) as the A component and polyisoprene as the B component. Yoda R, et al. **Biomaterials** 1995 Nov;16(16):1203–9

Prevention of platelet adhesion on the polysulfone porous catheter by saline solution perfusion, I. In vitro investigation. Khang G, et al. **Biomed Mater Eng** 1996; 6(1):47–66

Biocompatibility of polysulfone II. Platelet adhesion and cho cell growth. Khang G, et al. **Biomed Mater Eng** 1995; 5(4):259–73

Biocompatibility of polysulfone I. Surface modifications and characterizations. Khang G, et al. **Biomed Mater Eng** 1995; 5(4):245–58

Evaluation of the counterion condensation theory of polyelectrolytes. Stigter D. **Biophys J** 1995 Aug; 69(2):380–8

Surface modification of polymers: chemical, biological and surface analytical challenges. Ratner BD. **Biosens Bioelectron** 1995;10(9–10):797–804 (41 ref.)

Release of lidocaine from polymer film dosage forms. Danjo K, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1759–63

Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres. Uchida T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):235–6

Micropreparative one- and two-dimensional electrophoresis: improvement with new photopolymerization systems. Rabilloud T, et al. **Electrophoresis** 1995 Aug;16(8):1414–22

Prediction of potential protein-protein interaction sites from amino acid sequence. Identification of a fibrin polymerization site. Kini RM, et al. **FEBS Lett** 1996 Apr 29;385(1–2):81–6

Effects of temperature and mixing on polymer adjuvant migration to corn oil and water. Limm W, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):609–24

Marchantins and related polyphenols from liverwort: physico-chemical studies of their radical-scavenging properties. Schwartner C, et al. **Free Radic Biol Med** 1996; 20(2):237–44

Controlled release of newer quinolones from biodegradable systems based on poly(lactic acid). Andreopoulos AG. **J Biomater Appl** 1995 Oct;10(2):163–70

The creep behavior of acrylic denture base resins. Sadiku ER, et al. **J Biomater Appl** 1996 Jan;10(3):250–61

The effect of modification of acrylic resins on controlled release and bioadhesion. Vlachou M, et al. **J Biomater Appl** 1996 Jan;10(3):217–29

Three-dimensional degradable porous polymer-ceramic matrices for use in bone repair. Devin JE, et al. **J Biomater Sci Polym Ed** 1996;7(8):661–9

The influence of surface morphology and wettability on the inflammatory response against poly(L-lactic acid): a semi-quantitative study with monoclonal antibodies. Lam KH, et al. **J Biomed Mater Res** 1995 Aug;29(8):929–42

Biodegradable sponges for hepatocyte transplantation. Mooney DJ, et al. **J Biomed Mater Res** 1995 Aug; 29(8):959–65

Composite biomaterials based on ceramic polymers. I. Reinforced systems based on Al2O3/PMMA/PLLA. Rodríguez-Lorenzo LM, et al. **J Biomed Mater Res** 1996 Apr;30(4):515–22

Thermographic measurement of temperature change during resin composite polymerization in vivo. Hussey DL, et al. **J Dent** 1995 Oct;23(5):267–71

Water-soluble conductive polymer homogeneous immunoassay (SOPHIA). A novel immunoassay capable of automation. Englebienne P, et al. **J Immunol Methods** 1996 May 27;191(2):159–70

Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens. Kofler N, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):25–35

Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. Mammen M, et al. **J Med Chem** 1995 Oct 13;38(21):4179–90

Nitric oxide-releasing polymers containing the [N(O)NO]-group. Smith DJ, et al. **J Med Chem** 1996 Mar 1; 39(5):1148–56

Microencapsulation of lobster carotenoids within poly(vinyl alcohol) and poly(D,L-lactic acid) membranes. Sun ZM, et al. **J Microencapsul** 1995 Sep–Oct;12(5):495–504

The bond strength of polymers and metal surfaces using the 'silicoater' technique. Vojvodic D, et al. **J Oral Rehabil** 1995 Jul;22(7):493–9

Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation. Uchida T, et al. **J Pharm Pharmacol** 1995 Jul;47(7):556–60

New synthetic amphiphilic polymers for steric protection of liposomes in vivo. Torchilin VP, et al. **J Pharm Sci** 1995 Sep;84(9):1049–53

Isolation of a novel association network in a polymer gel. Ilzhoefer JR, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):467–8

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473–93 (15 ref.)

Adsorption of salmon calcitonin to PLGA microspheres. Calis S, et al. **Pharm Res** 1995 Jul;12(7):1072–6

Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Nakada Y, et al. **Pharm Res** 1996 Jan;13(1):38–43

Modelling mucoadhesion by use of surface energy terms obtained from the Lewis acid–Lewis base approach. II. Studies on anionic, cationic, and unionisable polymers. Rillosi M, et al. **Pharm Res** 1995 May;12(5):669–75

A novel method of preparing PLGA microcapsules utilizing methylethyl ketone. Sah H, et al. **Pharm Res** 1996 Mar; 13(3):360–7

A graphical method for the determination of the mode of hydrolysis of biodegradable polymers. Shih C. **Pharm Res** 1995 Dec;12(12):2036–60

Calculation of hydrolytic rate constants of poly(ortho ester)s from molecular weights determined by gel permeation chromatography. Shih C. **Pharm Res** 1995 Dec; 12(12):2041–8

On constructing folding heteropolymers. Ebeling M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8798–802

Comparing folding codes for proteins and polymers. Chan HS, et al. **Proteins** 1996 Mar;24(3):335–44

Molecular trees: a new branch of chemistry [comment] Bell TW. **Science** 1996 Feb 23;271(5252):1077–8 (19 ref.). Comment on: Science 1996 Feb 23;271(5252):1095–8.

New designs of macroporous polymers and supports: from separation to biocatalysis. Svec F, et al. **Science** 1996 Jul 12;273(5272):205–11 (48 ref.)

Molecular dynamics in stiff ionene below glass transition. Makrocka-Rydzyk M, et al. **Solid State Nucl Magn Reson** 1995 Aug;4(6):353–60

[Hygienic evaluation of work conditions in the production of liladox (starter of vinyl chloride polymerization)] Lemeshevskaia EP, et al. **Med Tr Prom Ekol** 1996;(1):37–9 **(Rus)**

ISOLATION & PURIFICATION

Partitioning and diffusion of proteins and linear polymers in polyacrylamide gels. Tong J, et al. **Biophys J** 1996 Mar; 70(3):1505–13

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

Polymer production by Klebsiella pneumoniae 4-hydroxyphenylacetic acid hydroxylase genes cloned in Escherichia coli. Gibello A, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4167–71

Description of a new polymer-secreting bacterium from a deep-sea hydrothermal vent, Alteromonas macleodii subsp. fijiensis, and preliminary characterization of the polymer. Raguenes G, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):67–73

Screening of microorganisms for biodegradation of poly(lactic-acid) and lactic acid-containing polymers. Torres A, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2393–7

Degradation of high molecular weight poly(L-lactide) in alkaline medium. Cam D, et al. **Biomaterials** 1995 Jul; 16(11):833–43

In situ assessment of cell viability within biodegradable polylactic acid polymer matrices. Chu CR, et al. **Biomaterials** 1995 Dec;16(18):1381–4

Mechanisms of polymer degradation and erosion. Göpferich A. **Biomaterials** 1996 Jan;17(2):103–14 (120 ref.)

Degradation of poly(D,L-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII). Landry FB, et al. **Biomaterials** 1996 Apr;17(7):715–23

Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Park TG. **Biomaterials** 1995 Oct;16(15):1123–30

Bone changes after experimental osteotomies fixed with absorbable self-reinforced poly-L-lactide screws or metallic screws studied by plain radiographs, quantitative computed tomography and magnetic resonance imaging. Viljanen J, et al. **Biomaterials** 1995 Nov;16(17):1353–8

Possible common properties of dietary fibre constituents and polyphenols. Bravo L, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S211–4

Biosynthesis and characterization of hydroxybutyrate-hydroxycaproate copolymers. Caballero KP, et al. **Int J Biol Macromol** 1995 Apr;17(2):86–92

Novel PDLLA/PEG copolymer micelles as drug carriers. Pişkin, et al. **J Biomater Sci Polym Ed** 1995;7(4):359–73

Liquid-gel partitioning using Lipidex in the determination of polychlorinated biphenyls, naphthalenes, dibenzo-p-dioxins and dibenzofurans in blood plasma. Weistrand C, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):207–17

Do Australian desert frogs co-accumulate counteracting solutes with urea during aestivation? Withers PC, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1809–16

Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen. Chang AC, et al. **J Pharm Sci** 1996 Feb;85(2):129–32

Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. Zalipsky S, et al. **J Pharm Sci** 1996 Feb;85(2):133–7

Control of protein-ligand recognition using a stimuli-responsive polymer. Stayton PS, et al. **Nature** 1995 Nov 30;378(6556):472–4

PHARMACOKINETICS

Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Hughes GS Jr, et al. **Crit Care Med** 1996 May;24(5):756–64

The use of polymers in the construction of controlled-release devices. Heller J. **NIDA Res Monogr** 1995;154:107–31 (33 ref.)

Adsorption of salmon calcitonin to PLGA microspheres. Calis S, et al. **Pharm Res** 1995 Jul;12(7):1072–6

Modelling mucoadhesion by use of surface energy terms obtained from the Lewis acid-Lewis base approach. II. Studies on anionic, cationic, and unionisable polymers. Rillosi M, et al. **Pharm Res** 1995 May;12(5):669–75

PHARMACOLOGY

Copolymer adjuvants. Brey RN. **Adv Exp Med Biol** 1995; 383:23–34 (47 ref.)

Random copolymers containing specific ratios of negatively charged and aromatic amino acids bind V3 disulfide loop and neutralize diverse HIV type 1 isolates. Javaherian K, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1163–8

White wine reduces the susceptibility of low-density lipoprotein to oxidation [letter; comment] Caldú P, et al. **Am J Clin Nutr** 1996 Mar;63(3):403–4. Comment on: Am J Clin Nutr 1995 Mar;61(3):549–54.

Potent inhibition of human immunodeficiency virus by MDL 101028, a novel sulphonic acid polymer. Taylor DL, et al. **Antiviral Res** 1995 Oct;28(2):159–73

The effects of endotoxin-contaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis. Arduino MJ, et al. **Artif Organs** 1995 Sep;19(9):880–6

Evaluation of the antithrombogenicity of a new microdomain structured copolymer. Kawahito K, et al. **Artif Organs** 1995 Aug;19(8):857–63

Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits. Wiseman SA, et al. **Atherosclerosis** 1996 Feb;120(1–2):15–23

Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Venne A, et al. **Cancer Res** 1996 Aug 15;56(16):3626–9

Inhibition of 1,2,4-benzenetriol-generated active oxygen species and induction of phase II enzymes by green tea polyphenols. Lee SF, et al. **Chem Biol Interact** 1995 Dec 22;98(3):283–301

Ultrapure polymerized bovine hemoglobin (UPPBHb) improves integrity of the isolated perfused rat kidney (IPRK): effects on function and structure. Willinger CC, et al. **Clin Nephrol** 1995 Jul;44(1):32–43

Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Giordano GG, et al. **Curr Eye Res** 1995 Sep; 14(9):761–8

Polytuftsin: its possible effects and mechanism during macrophage activation. Dhawan P, et al. **Immunol Lett** 1995 May;46(1–2):177–82

Antimutagenic effects of polyphenols isolated from Terminalia bellerica myroblan in Salmonella typhimurium. Padam SK, et al. **Indian J Exp Biol** 1996 Feb;34(2):98–102

Enhancement of neovascularization in regenerating skeletal muscle by the sustained release of erucamide from a polymer matrix. Mitchell CA, et al. **J Biomater Appl** 1996 Jan;10(3):230–49

Polysulphone inhibits final differentiation steps of osteogenesis in vitro. van Loon JJ, et al. **J Biomed Mater Res** 1995 Sep;29(9):1155–63

Nitric oxide-releasing polymers containing the [N(O)NO]-group. Smith DJ, et al. **J Med Chem** 1996 Mar 1; 39(5):1148–56

Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)

mutagenicity by black and green tea extracts and polyphenols. Apostolides Z, et al. **Mutat Res** 1996 Apr 4;359(3):159–63

Protection against ultraviolet-B radiation-induced local and systemic suppression of contact hypersensitivity and edema responses in C3H/HeN mice by green tea polyphenols. Katiyar SK, et al. **Photochem Photobiol** 1995 Nov; 62(5):855–61

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Schlegel PG, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5061–6

Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase. Itoh M, et al. **Virology** 1995 Oct 1;212(2):340–7

[Inhibition of colorectal carcinoma induced by 1, 2-dimethylhydrazine in mice with tea polyphenols] Pan H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):356–9 (Eng. Abstr.) **(Chi)**

[Analysis of the effects of selected polymers on morpho-dynamic features of rat hepatocytes] Spausta G. **Polim Med** 1995;25(1–2):33–55 (Eng. Abstr.) **(Pol)**

[A quaternary ammonium salt of oligomer 25 conidine accelerates skin wound healing in rats] Golenchenko VA, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):407–9 **(Rus)**

[Antiradical activity of a diallyl series ternary copolymer in realizing an antimutagenic effect] Odin AP, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):265–7 **(Rus)**

[The effect of the quaternary ammonium salt of conidine oligomer-25 (QAS CO-25) on the activity of prothrombin complex factors] Efimov VS, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):34–6 (Eng. Abstr.) **(Rus)**

[The antimutagenic activity of ternary diallyl copolymers] Aleksandrova VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):746–51 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Blood compatibility of tubular polymeric materials studied by biological surface interactions. Julio CA, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2565–8

THERAPEUTIC USE

Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685–94 (90 ref.)

Randomized comparison of polyglycolic acid and polyglyconate sutures for abdominal fascial closure after laparotomy in patients with suspected impaired wound healing [letter; comment] Hewin DF. **Br J Surg** 1995 Dec; 82(12):1698–9. Comment on: Br J Surg 1995 Aug;82(8):1080–2.

Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Hughes GS Jr, et al. **Crit Care Med** 1996 May;24(5):756–64

Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%). Degrémont AC, et al. **Intensive Care Med** 1995 Jul;21(7):577–83

Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169–80 (87 ref.)

Same-day Dilapan insertion before second-trimester dilatation and evacuation for a fetal anomaly or death. Patsner B. **J Reprod Med** 1996 Feb;41(2):71–2

Study on microvascular anastomosis of arteries with absorbable polyglyconate suture. Huang GK, et al. **Microsurgery** 1995;16(7):505–9

TOXICITY

A review of inhalation toxicology studies with para-aramid fibrils. Warheit DB. **Ann Occup Hyg** 1995 Oct;39(5):691–7 (14 ref.)

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993–94; 44–45(1–4):75–81 (21 ref.)

Histopathology of rabbit eyes with silicone-fluorosilicone copolymer oil as six months internal retinal tamponade. Doi M, et al. **Exp Eye Res** 1995 Oct;61(4):469–78

Safety evaluation of perfluoropolyethers, liquid polymers used in barrier creams and other skin-care products. Malinverno G, et al. **Food Chem Toxicol** 1996 Jul; 34(7):639–50

The influence of surface morphology and wettability on the inflammatory response against poly(L-lactic acid): a semi-quantitative study with monoclonal antibodies. Lam KH, et al. **J Biomed Mater Res** 1995 Aug;29(8):929–42

Incorporation of polylactide-polyglycolide in a cortical defect: neoangiogenesis and blood supply in a bone chamber. Winet H, et al. **J Orthop Res** 1995 Sep; 13(5):679–89

Influence of surface properties on the inflammatory response to polymeric nanoparticles. Fernández-Urrusuno R, et al. **Pharm Res** 1995 Sep;12(9):1385–7

POLYMETHACRYLIC ACIDS

Poly(methacrylic acid)-induced liposome aggregation for measuring drug entrapment. Oto EK, et al. **Anal Biochem** 1995 Jul 20;229(1):106–11

[Biocem—a new material for retrograde tooth root filling] Ilgenstein B, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:148–50 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

[A study on the effective way and dosage of intravas deferens injection of HFMC for male contraception] Yue L, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):408–10 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Murray RP, et al. **Chest** 1996 Feb;109(2):438–45

CHEMISTRY

A new drug delivery system using plasma-irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of water-soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192–5

Swelling/syneresis phenomena in gel-forming interpolymer complexes. Bell CL, et al. **J Biomater Sci Polym Ed** 1996; 7(8):671–83

Composite poly(methyl methacrylate-methacrylic acid-2-hydroxyethyl methacrylate) latex for immunoassay. The case of plasminogen. Miksa B, et al. **J Biomater Sci Polym Ed** 1995;7(6):503–13

METABOLISM

Cytoplasmic calcium level and membrane fluidity of platelets contacting poly(acrylamide-co-methacrylic acid) particles with different surface properties. Yui N, et al. **J Biomater Sci Polym Ed** 1995;7(3):253–64

Effects of membrane characteristics on cytokine production by mononuclear cells in regular haemodialysis patients. Kino K, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:29–33

Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Kamei S, et al. **Pharm Res** 1995 May;12(5):663–8

PHARMACOKINETICS

Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Ewe K, et al. **Z Gastroenterol** 1996 Apr;34(4):225–9

RADIATION EFFECTS

A new drug delivery system using plasma-irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of water-soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192–5

THERAPEUTIC USE

Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Sachs DP. **Arch Intern Med** 1995 Oct 9;155(18):1973–80

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Mar 27;275(12):902

Nicorette finds new place in smoking cessation [news] Voelker R. **JAMA** 1996 May 1;275(17):1301

The benefits and risks of over-the-counter availability of nicotine polacrilex ("nicotine gum"). Oster G, et al. **Med Care** 1996 May;34(5):389–402

[Biocem—a new material for retrograde root filling. The 5-year clinical results (see comments)] Ilgenstein B, et al. **Schweiz Monatsschr Zahnmed** 1995;105(8):1015–22 (Eng. Abstr.). Comment in: Schweiz Monatsschr Zahnmed 1995;105(8):1011, 1013. **(Ger)**

POLYMETHYLMETHACRYLATE see **METHYLMETHACRYLATES**

POLYMORPHISM (GENETICS)

Apolipoprotein polymorphism in Hungary. Császár A. **Acta Biomed Ateneo Parmense** 1995;66(3–4):169–74

Complement C4, factor B and C3 polymorphism in north India. Kramer J, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):315–9

Length polymorphism of heterochromatic segment of the Y chromosome in boys with acute leukemia. Erçal MD, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):614–6

Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Yoneya K, et al. **Am Heart J** 1995 Nov;130(5):1089–93

Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Kasi JC, et al. **Am J Cardiol** 1996 Apr 15;77(10):875–7

Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. Sanderson JE, et al. **Am J Cardiol** 1996 May 1;77(11):1008–10

Angiotensin-converting enzyme insertion/deletion polymorphism in angina pectoris with normal coronary arteriograms. Zhang Y, et al. **Am J Cardiol** 1996 Apr 15; 77(10):877–9

Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Schwartz BS, et al. **Am J Epidemiol** 1995 Oct 1; 142(7):738–45

Mutation rate in the hypervariable VNTR g3 (D7S22) is affected by allele length and a flanking DNA sequence polymorphism near the repeat array. Andreassen R, et al. **Am J Hum Genet** 1996 Aug;59(2):360–7

PRB1, PRB2, and PRB4 coded polymorphisms among human salivary concanavalin-A binding, II-1, and Po proline-rich proteins. Azen EA, et al. **Am J Hum Genet** 1996 Jan;58(1):143–53

Human beta-globin gene polymorphisms characterized in DNA extracted from ancient bones 12,000 years old. Béraud-Colomb E, et al. **Am J Hum Genet** 1995 Dec; 57(6):1267–74

Molecular basis and haplotyping of the alphaII domain polymorphisms of spectrin: application to the study of hereditary elliptocytosis and pyropoikilocytosis. Gallagher PG, et al. **Am J Hum Genet** 1996 Aug;59(2):351–9

Molecular genetics of cystinuria: identification of four new mutations and seven polymorphisms, and evidence for genetic heterogeneity. Gasparini P, et al. **Am J Hum Genet** 1995 Oct;57(4):781–8

Polymorphism in the interferon-alpha gene family. Golovleva I, et al. **Am J Hum Genet** 1996 Sep;59(3):570–8

mtDNA polymorphism in East Asian Populations, with special reference to the peopling of Japan. Horai S, et al. **Am J Hum Genet** 1996 Sep;59(3):579–90

A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44 Ala—>Gly), is the major polymorphic variant in tribal populations in India. Kaeda JS, et al. **Am J Hum Genet** 1995 Dec;57(6):1335–41

Codon 219 polymorphism of PRNP in healthy Caucasians and Creutzfeldt-Jakob disease patients [letter] Petraroli R, et al. **Am J Hum Genet** 1996 Apr;58(4):888–9

Genotyping of PCR-based polymorphisms and linkage-disequilibrium analysis at the NF1 locus. Purandare SM, et al. **Am J Hum Genet** 1996 Jul;59(1):159–66

Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Villard E, et al. **Am J Hum Genet** 1996 Jun;58(6):1268–78

Progressive myoclonus epilepsy EPM1 locus maps to a 175-kb interval in distal 21q. Virtaneva K, et al. **Am J Hum Genet** 1996 Jun;58(6):1247–53

Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Freeman K, et al. **Am J Hypertens** 1995 Sep; 8(9):863–9

No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Schmidt S, et al. **Am J Kidney Dis** 1995 Nov;26(5):727–31

No evidence for allelic association between bipolar disorder and monoamine oxidase A gene polymorphisms. Craddock N, et al. **Am J Med Genet** 1995 Aug 14;60(4):322–4

Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder. Crawford F, et al. **Am J Med Genet** 1995 Aug 14;60(4):332–4

No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Daniels J, et al. **Am J Med Genet** 1995 Feb 27;60(1):85–7

Short tandem repeat polymorphism linkage studies in a new family with X-linked mental retardation (MRX20). Lazzarini A, et al. **Am J Med Genet** 1995 Jul 17;57(4):552–7

Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Liu Q, et al. **Am J Med Genet** 1995 Apr 24; 60(2):165–71

Mapping of the serotonin 5-HT1D alpha autoreceptor gene (HTR1D) on chromosome 1 using a silent polymorphism in the coding region. Ozaki N, et al. **Am J Med Genet** 1995 Apr 24;60(2):162–4

Lack association between schizophrenia and the CYP2D6 gene polymorphisms [letter] Pirmohamed M, et al. **Am J Med Genet** 1996 Apr 9;67(2):236–7

No association detected between a D3 receptor gene-expressed variant and schizophrenia. Rothschild LG, et al. **Am J Med Genet** 1996 Apr 9;67(2):232–4

Two single base polymorphisms in introns 41 and 16 of the NF1 gene. Shen MH, et al. **Am J Med Genet** 1995 Apr 24;60(2):147–9

Preliminary evidence for an association of a dinucleotide repeat polymorphism at the MAOA gene with early onset alcoholism/substance abuse. Vanyukov MM, et al. **Am J Med Genet** 1995 Apr 24;60(2):122–6

When is ancient polymorphism a potential problem for molecular phylogenetics? Rogers J, et al. **Am J Phys Anthropol** 1995 Oct;98(2):216–8; discussion 224–8

Lack of association between polymorphisms in the 5-HT2A

receptor gene and the antipsychotic response to clozapine. Malhotra AK, et al. **Am J Psychiatry** 1996 Aug; 153(8):1092–4

Polymorphism of angiotensin–converting enzyme gene in sarcoidosis. Arbustini E, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):851–4

Genetic similarity among Central and South American populations of Leishmania (Viannia) braziliensis. Kreutzer RD. **Am J Trop Med Hyg** 1996 Jul;55(1):106–10

Evaluation of common electrophoretic methods in determining the molecular weight of apolipoprotein(a) polymorphs. Furbee JW Jr, et al. **Anal Biochem** 1996 Feb 1;234(1):66–73

Angiotensin–converting enzyme gene polymorphism in essential hypertensive patients in Japanese population. Maguchi M, et al. **Angiology** 1996 Jul;47(7):643–8

Cloning and characterization of 414 polymorphic porcine microsatellites. Alexander LJ, et al. **Anim Genet** 1996 Jun; 27(3):137–48

Genetic control of PI and GC variants in the American mink. Borodin GP, et al. **Anim Genet** 1995 Dec;26(6):435–7

Genotyping of Bison bonasus kappa–casein gene following DNA sequence amplification. Burzynska B, et al. **Anim Genet** 1995 Oct;26(5):335–6

Polymorphic CAC/T repetitive sequences in the pig genome 1. Coppieters W, et al. **Anim Genet** 1995 Oct;26(5):327–30

Ovine dinucleotide repeat polymorphism at the McM15, McM152, McM159, McM164 and McM210 loci. Davies KP, et al. **Anim Genet** 1995 Oct;26(5):371

Ovine dinucleotide repeat polymorphism at the CSRD226 and CSRD232 loci. Davies KP, et al. **Anim Genet** 1995 Oct;26(5):372

UCD001: a bovine cosmid containing a polymorphic dinucleotide repeat maps to chromosome 4. Flavin N, et al. **Anim Genet** 1995 Oct;26(5):372–3

Ten novel chicken dinucleotide repeat polymorphisms. Gibbs M, et al. **Anim Genet** 1995 Dec;26(6):443–4

Polymorphic sheep microsatellites at the McM2, McM131, McM135, McM136, McM140, McM200, McM214, McM373, McM505, McM507 and McM512 loci. Hulme DJ, et al. **Anim Genet** 1995 Oct;26(5):369–70

Ovine dinucleotide repeat polymorphism at the McM218, McM150 and McM138 loci. Hulme DJ, et al. **Anim Genet** 1996 Feb;27(1):57

Five bovine polymorphic dinucleotide microsatellite loci (DIK008, DIK010, DIK015, DIK016 and DIK020). Inoue M, et al. **Anim Genet** 1995 Dec;26(6):447–8

A polymorphic bovine dinucleotide repeat D12S25 (IOBT323) at chromosome 12q24. Jørgensen CB, et al. **Anim Genet** 1995 Dec;26(6):447

Random amplified polymorphic DNA in cattle and sheep: application for detecting genetic variation. Kantanen J, et al. **Anim Genet** 1995 Oct;26(5):315–20

A panel of polymorphic bovine, ovine and caprine microsatellite markers. Kemp SJ, et al. **Anim Genet** 1995 Oct;26(5):299–306

Caprine microsatellite dinucleotide repeat polymorphisms at the SR–CRSP–11, SR–CRSP–12, SR–CRSP–13, SR–CRSP–14 and SR–CRSP–15 loci. Kogi J, et al. **Anim Genet** 1995 Dec;26(6):449

Seven bovine dinucleotide repeat polymorphisms: RM042, RM128, RM134, RM154, RM162, RM181, RM509. Kossarek LM, et al. **Anim Genet** 1996 Feb;27(1):61–3

Transfer of bovine microsatellites to the cervine (Cervus elaphus). Kühn R, et al. **Anim Genet** 1996 Jun;27(3):199–201

Dinucleotide repeat polymorphism at the porcine TNFA locus. Looft C, et al. **Anim Genet** 1995 Oct;26(5):366–7

Characterization and linkage mapping of ten sheep microsatellite markers derived from a sheep x hamster cell hybrid. Lumsden JM, et al. **Anim Genet** 1996 Jun; 27(3):203–6

Isolation and characterization of 45 polymorphic microsatellites from the bovine genome. Ma RZ, et al. **Anim Genet** 1996 Feb;27(1):43–7

Expression of multiple DQB genes in Bos indicus cattle. Marello KL, et al. **Anim Genet** 1995 Oct;26(5):345–9

A set of polymorphic DNA microsatellites useful in swamp and river buffalo (Bubalus bubalis). Moore SS, et al. **Anim Genet** 1995 Oct;26(5):355–9

A highly polymorphic bovine dinucleotide repeat D19S4 (IOBT 34) at chromosome 19q21. Olsaker I, et al. **Anim Genet** 1996 Feb;27(1):58–9

A highly polymorphic bovine dinucleotide repeat D3S40 (IOBT 250) derived from a chimeric cosmid clone. Olsaker I, et al. **Anim Genet** 1996 Feb;27(1):59

Two polymorphic microsatellite markers close to the ovine NRAMP gene. Pitel F, et al. **Anim Genet** 1996 Feb; 27(1):60–1

A polymorphic (GAAA)n microsatellite in a canine Wilms tumor 1 (WT1) gene intron. Shibuya H, et al. **Anim Genet** 1996 Feb;27(1):59–60

A second polymorphism in exon 2 of the BoLA–DYA gene. Skow LC, et al. **Anim Genet** 1996 Jun;27(3):216–7

Polymorphic Atlantic salmon, Salmo salar L., microsatellites at the SSOSL438, SSOSL439 and SSOSL444 loci. Slettan A, et al. **Anim Genet** 1996 Feb;27(1):57–8

A polymorphic dinucleotide repeat microsatellite in Atlantic salmon, Salmo salar (SSOSL436). Slettan A, et al. **Anim Genet** 1995 Oct;26(5):368

Five bovine polymorphic dinucleotide microsatellite loci (DIK021, DIK023, DIK024, DIK026 and DIK028). Watanabe T, et al. **Anim Genet** 1995 Dec;26(6):448–9

Five polymorphic bovine microsatellite loci: IDVGA–62A, IDVGA–71, IDVGA–82, IDVGA–88, IDVGA–90. Zhang Y, et al. **Anim Genet** 1995 Oct;26(5):365–6

Identification of a polymorphism in the coding region of the p27Kip1 gene. Cavé H, et al. **Ann Genet** 1995;38(2):108

Deletion polymorphism of the angiotensin I–converting enzyme gene is associated with increased plasma angiotensin–converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Winkelmann BR, et al. **Ann Intern Med** 1996 Jul 1;125(1):19–25

Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease. Ladero JM, et al. **Ann Med** 1995 Oct;27(5):555–8

The association of polymorphic N–acetyltransferase (NAT2) with breast cancer risk. Ambrosone CB, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:250–2

Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer–type neurofibrillary tangle formation. März W, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:276–80

Lack of association of trinucleotide repeat polymorphisms in very–low–density lipoprotein receptor gene with Alzheimer's disease. Chung H, et al. **Ann Neurol** 1996 Jun; 39(6):800–3

Review of studies of polymorphic blood systems in the Aymara indigenous population from Bolivia, Peru, and Chile. Dittmar M. **Anthropol Anz** 1995 Dec;53(4):289–315 (55 ref.)

Plasma protein polymorphisms (HP; TF and GC subtypes) in Friuli Venezia Giulia (northeast Italy). Fuciarelli M, et al. **Anthropol Anz** 1995 Dec;53(4):317–25

Charge polymorphism in human lung cell pro–cathepsin B. Werle B, et al. **Anticancer Res** 1996 Jan–Feb;16(1):49–53

Identification of genetic heterogeneity in the Cryptosporidium parvum ribosomal repeat. Carraway M, et al. **Appl Environ Microbiol** 1996 Feb;62(2):712–6

Molecular polymorphism distribution in phenotypically distinct populations of wine yeast strains. Nadal D, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1944–50

Genetic diversity and phylogeny of toxic cyanobacteria determined by DNA polymorphisms within the phycocyanin locus. Neilan BA, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3875–83

An improved strategy for HLA–DRB1 subtyping by digestion of PCR–amplified DNA with allele–specific restriction endonucleases. Danzé PM, et al. **Appl Theor Electrophor** 1995;5(1):7–13

Characterization and prevalence of a polymorphism in the 3' untranslated region of cytochrome P4501A1 in cancer–prone Atlantic tomcod. Roy NK, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):204–13

Carrier detection in Duchenne and Becker muscular dystrophy using dinucleotide repeat polymorphisms. A study in Mexican families. Arenas D, et al. **Arch Med Res** 1996 Summer;27(2):151–6

The dopamine D2 receptor gene TaqI A1 polymorphism and alcoholism in a Mexican population. Cruz C, et al. **Arch Med Res** 1995 Winter;26(4):421–6

Molecular studies of Mendelian disorders, embryonic neoplasias, and polymorphisms in selected samples of the general population. A contribution to the genetic characterization of the Mexican population. Salamanca F, et al. **Arch Med Res** 1995;26 Spec No:S69–75

Glutathione–S–transferase (GST) theta polymorphism influences background SCE rate. Schröder KR, et al. **Arch Toxicol** 1995;69(7):505–7

Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357–61 (28 ref.)

Genome polymorphism of human adenoviruses of subgenus C. Adrian T. **Arch Virol** 1996;141(6):1021–31

Genetic variation in populations of kennedya yellow mosaic tymovirus. Skotnicki ML, et al. **Arch Virol** 1996; 141(1):99–110

Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Bernardi F, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):72–6

Deletion polymorphism in the angiotensin–converting enzyme gene in patients with a history of ischemic stroke. Margaglione M, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):304–9

The acute rise in plasma fibrinogen concentration with exercise is influenced by the G–453–A polymorphism of the beta–fibrinogen gene. Montgomery HE, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):386–91

Polymorphic markers in apolipoprotein C–III gene flanking regions and hypertriglyceridemia. Surguchov AP, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):941–7

Genotype distribution of angiotensin–converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Wang XL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):115–9

Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Duits AJ, et al. **Arthritis Rheum** 1995 Dec;38(12):1832–6

Polyglot and polymorphism. An HLA update. Nepom BS, et al. **Arthritis Rheum** 1995 Dec;38(12):1715–21 (4 ref.)

Apolipoprotein E polymorphism in middle–aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Braeckman L, et al. **Atherosclerosis** 1996 Feb;120(1–2):67–73

Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Kamboh MI, et al. **Atherosclerosis** 1995 Sep;117(1):73–81

Apolipoprotein B (apo B) signal peptide length polymorphisms are associated with apo B, low density lipoprotein cholesterol, and glucose levels in Mexican Americans. Kammerer CM, et al. **Atherosclerosis** 1996 Feb; 120(1–2):37–45

Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Régis–Bailly A, et al. **Atherosclerosis** 1995 Nov; 118(1):23–34

DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Turner PR, et al. **Atherosclerosis** 1995 Aug;116(2):221–34

A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Ward AJ, et al. **Atherosclerosis** 1996 Feb; 120(1–2):83–91

Association of polymorphisms of the apolipoprotein B gene with coronary heart disease in Han Chinese. Ye P, et al. **Atherosclerosis** 1995 Sep;117(1):43–50

Linkage and association studies in insulin–dependent diabetes with a new dinucleotide repeat polymorphism at the GAD65 locus. Wapelhorst B, et al. **Autoimmunity** 1995; 21(2):127–30

Polymorphic functional imprinting of the human IGF2 gene among individuals, in blood cells, is associated with H19 expression. Giannoukakis N, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1014–9

Thrombin receptor polymorphism in Chinese hamster. Hartmann T, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):974–80

Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Jounaïdi Y, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):466–70

Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. Le F, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):461–7

Proposed schizophrenia–related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Lundstrom K, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):1068–72

Clonal analysis of isolated single fundic and pyloric gland of stomach using X–linked polymorphism. Nomura S, et al. **Biochem Biophys Res Commun** 1996 Sep 13; 226(2):385–90

Monoclonal antibody against the polymorphic site distinguishes apolipoprotein E4 from other isoforms. Nukina N, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):467–72

Protoporphyrinogen oxidase: complete genomic sequence and polymorphisms in the human gene. Puy H, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):226–30

Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Sano M, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):378–83

Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Shimoda–Matsubayashi S, et al. **Biochem Biophys Res Commun** 1996 Sep 13; 226(2):561–5

Polymorphisms and probable lack of mutation in a human mutT homolog, hMTH1, in hereditary nonpoliposis colorectal cancer. Wu C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1239–45

Human CFTR gene sequences in regions flanking exon 10: a simple repeat sequence polymorphism in intron 9. Xu Z, et al. **Biochem Biophys Res Commun** 1996 Feb 6; 219(1):140–5

Identification of a 130–kDa albumin in tuatara (Sphenodon) and detection of a novel albumin polymorphism. Brown MA, et al. **Biochem Genet** 1995 Jun;33(5–6):189–204

Polymorphism of blood plasma esterases in geese of the Anser genus (Aves: Anseriformes). Kuznetsov SB. **Biochem Genet** 1995 Jun;33(5–6):183–7

Identification of polymorphism at the glutathione S–transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Inskip A, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):713–6

Structure of Leishmania lipophosphoglycan: inter– and intra–specific polymorphism in Old World species. McConville MJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):807–18

Polymorphism of the yeast pyruvate carboxylase 2 gene and protein: effects on protein biotinylation. Val DL, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):817–25

Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population. Harn HJ, et al. **Biochem Mol Biol Int** 1995 May;35(6):1175–81

Tests of random mating for a highly polymorphic locus: application to HLA data. Jin K, et al. **Biometrics** 1995 Sep;

51(3):1064–76

Anomalies in direct pair-wise comparisons of RAPD fragments for genetic analysis. Pillay M, et al. **Biotechniques** 1995 Nov;19(5):694–6, 698

Variation of fetal hemoglobin and F-cell number with the LCR–HS2 polymorphism in nonanemic individuals [letter] Merghoub T, et al. **Blood** 1996 Mar 15;87(6):2607

Polymorphic variation in the human protein C (PROC) gene promoter can influence transcriptional efficiency in vitro. Scopes D, et al. **Blood Coagul Fibrinolysis** 1995 Jun; 6(4):317–21

Functional analysis of an unusual length polymorphism in the human antithrombin III (AT3) gene promoter. Winter PC, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):659–64

Fc epsilon RI–beta polymorphisms unlikely to contribute substantially to genetic risk of allergic disease [letter; comment] Hall IP, et al. **BMJ** 1996 Feb 3;312(7026):311 . Comment on: BMJ 1995 Sep 23;311(7008):776–9.

Fc epsilon RI–beta polymorphism and risk of atopy in a general population sample [see comments] Hill MR, et al. **BMJ** 1995 Sep 23;311(7008):776–9. Comment in: BMJ 1996 Feb 3;312(7026):311.

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Parving HH, et al. **BMJ** 1996 Sep 7;313(7057):591–4

Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Arbustini E, et al. **Br Heart J** 1995 Dec;74(6):584–91

Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Koopmann J, et al. **Br J Cancer** 1995 Nov;72(5):1230–3

A–793 G to A transition in the factor IX gene promoter is polymorphic in the Caucasian population. Rai HK, et al. **Br J Haematol** 1996 Feb;92(2):501–3

Absence of correlation between IL–1 alpha intron 6 polymorphism and rheumatoid arthritis. Bailly S, et al. **Br J Rheumatol** 1995 Dec;34(12):1123–6

Polymorphism of the heat–shock protein gene HSP70–2 in systemic lupus erythematosus. Pablos JL, et al. **Br J Rheumatol** 1995 Aug;34(8):721–3

Polymorphism and smoking in bladder carcinogenesis. Chinegwundoh FI, et al. **Br J Urol** 1996 May;77(5):672–5

Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. Barger–Lux MJ, et al. **Calcif Tissue Int** 1995 Aug;57(2):161–2

Genetic variation of apolipoprotein B can produce both low and high levels of apoB–containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G–92G (79 ref.)

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:93G–96G (25 ref.)

Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case–control study. Kato S, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1654–61

Polymorphism in the N–acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N–acetylation activity in bladder and colon tissue. Bell DA, et al. **Cancer Res** 1995 Nov 15;55(22):5226–9

Combined analysis of inherited polymorphisms in arylamine N–acetyltransferase 2, glutathione S–transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Brockmöller J, et al. **Cancer Res** 1996 Sep 1;56(17):3915–25

Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S–transferase genes in patients with non–small cell lung cancer. Goto I, et al. **Cancer Res** 1996 Aug 15;56(16):3725–30

Re: S. J. London et al., Lung cancer risk in African–Americans in relation to a race–specific CYP1A1 polymorphism. Cancer Res., 55: 6035–6037, 1995 [letter] Taioli E, et al. **Cancer Res** 1996 Sep 15;56(18):4275–7

Association of prostate cancer with vitamin D receptor gene polymorphism. Taylor JA, et al. **Cancer Res** 1996 Sep 15; 56(18):4108–10

ATM mutations in cancer families. Vořechovský I, et al. **Cancer Res** 1996 Sep 15;56(18):4130–3

Polymorphism at the glutathione S–transferase locus GSTM3: interactions with cytochrome P450 and glutathione S–transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Yengi L, et al. **Cancer Res** 1996 May 1;56(9):1974–7

Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27–65 (249 ref.)

P53 polymorphisms and haplotypes in lung cancer. Birgander R, et al. **Carcinogenesis** 1995 Sep;16(9):2233–6

Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Dolžan V, et al. **Carcinogenesis** 1995 Nov;16(11):2675–8

A polymorphism at codon 160 of human O6–methylguanine–DNA methyltransferase gene in young patients with adult type cancers and functional assay. Imai Y, et al. **Carcinogenesis** 1995 Oct;16(10):2441–5

Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Kihara M, et al. **Carcinogenesis** 1995 Oct;16(10):2331–6

Human connexin 37 is polymorphic but not mutated in tumours. Krutovskikh V, et al. **Carcinogenesis** 1996 Aug; 17(8):1761–3

Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Murata M, et al. **Carcinogenesis** 1996 Feb;17(2):261–4

p53 polymorphisms and haplotypes in breast cancer. Själander A, et al. **Carcinogenesis** 1996 Jun;17(6):1313–6

Polymorphism in the beta chain of IAq versus IAp influences presentation of protein but not peptide antigens. Lambert LE, et al. **Cell Immunol** 1995 Oct 15;165(2):202–10

Robertsonian polymorphism in the marine gastropod, Nucella lapillus: advances in karyology using rDNA loci and NORs. Pascoe PL, et al. **Chromosoma** 1996 Mar; 104(6):455–60

DNA organization and polymorphism of a wild–type Drosophila telomere region. Walter MF, et al. **Chromosoma** 1995 Dec;104(4):229–41

Molecular analysis of chromosomal polymorphism in the South American cricetid, Graomys griseoflavus. Zambelli A, et al. **Chromosome Res** 1995 Sep;3(6):361–7

Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas–Temoins sur l'Infarctus du Myocarde. Behague I, et al. **Circulation** 1996 Feb 1;93(3):440–9

Influence of angiotensin–converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Benetos A, et al. **Circulation** 1996 Aug 15;94(4):698–703

Gene polymorphism but not catalytic activity of angiotensin I–converting enzyme is associated with coronary artery disease and myocardial infarction in low–risk patients. Gardemann A, et al. **Circulation** 1995 Nov 15;92(10):2796–9

Angiotensin–converting enzyme gene polymorphism in ischemic heart disease [letter; comment] Hellstrom HR. **Circulation** 1996 Mar 15;93(6):1256–7. Comment on: Circulation 1995 Apr 15;91(8):2120–4.

Angiotensin–converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non–insulin–dependent diabetic patients. Hosoi M, et al. **Circulation** 1996 Aug 15;94(4):704–7

Ischemic stroke and the gene for angiotensin–converting enzyme in Japanese hypertensives. Kario K, et al. **Circulation** 1996 May 1;93(9):1630–3

Multiplex, fluorescent, solid–phase minisequencing for efficient screening of DNA sequence variation. Pastinen T, et al. **Clin Chem** 1996 Sep;42(9):1391–7

Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Rajkhowa M, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):85–90

Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Botto M, et al. **Clin Exp Immunol** 1996 May;104(2):264–8

Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Bouma G, et al. **Clin Exp Immunol** 1996 Mar;103(3):391–6

Lack of association of apolipoprotein E polymorphism with plasma Lp(a) levels in the Chinese. Heng CK, et al. **Clin Genet** 1995 Sep;48(3):113–9

A TaqI and a BamHI polymorphism in the COL4A4 gene on chromosome 2q35–37. Hertz JM, et al. **Clin Genet** 1995 Sep;48(3):162–3

The PvuII restriction site in the second intron of the human steroid 21–hydroxylase gene CYP21 is polymorphic. Koppens PF, et al. **Clin Genet** 1995 Aug;48(2):109–10

Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Yorioka T, et al. **Clin Nephrol** 1995 Aug;44(2):80–5

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192–209 (103 ref.)

Genetic analysis of the S–mephenytoin polymorphism in a Chinese population. de Morais SM, et al. **Clin Pharmacol Ther** 1995 Oct;58(4):404–11

Electrophoretic polymorphism in rabbit tear lysozyme. Saleh AM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep;112(1):21–30

Role of angiotensin–converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249–53 (21 ref.)

Hypervariable microsatellites provide a general source of polymorphic DNA markers for the chloroplast genome. Powell W, et al. **Curr Biol** 1995 Sep 1;5(9):1023–9

Inheritance of chromosome–length polymorphisms in Ophiostoma ulmi (sensu lato). Dewar K, et al. **Curr Genet** 1995 May;27(6):541–9

Electrophoretic karyotype of Dipodascus (Endomyces) magnusii: two main intraspecific chromosomal polymorphisms associated with the difference in total genome size. Filipp D, et al. **Curr Genet** 1995 Dec; 29(1):81–7

Structural polymorphism and function of HLA–B27. López de Castro JA. **Curr Opin Rheumatol** 1995 Jul;7(4):270–8

Molecular analysis of a novel subtelomeric repeat with polymorphic chromosomal distribution. Martin–Gallardo A, et al. **Cytogenet Cell Genet** 1995;71(3):289–95

Eight new polymorphic microsatellites in mouse gene loci. Santos J, et al. **Cytogenet Cell Genet** 1995;71(3):223–4

Locus on chromosome 18 cosegregates with diabetes in the BB/OK rat subline. Klöting I, et al. **Diabete Metab** 1995 Dec;21(5):338–44

The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Considine RV, et al. **Diabetes** 1996 Jul;45(7):992–4

A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Fogarty DG, et al. **Diabetes** 1996 Sep;45(9):1204–8

An approach for identifying simple sequence repeat DNA polymorphisms near cloned cDNAs and genes. Linkage studies of the islet amyloid polypeptide/amylin and liver glycogen synthase genes and NIDDM. Gambino V, et al. **Diabetes** 1996 Mar;45(3):291–4

Isolation, characterization, and chromosomal mapping of the human insulin promoter factor 1 (IPF–1) gene. Inoue H, et al. **Diabetes** 1996 Jun;45(6):789–94

Insulin gene 5' flanking polymorphism. Length of class 1 alleles in number of repeat units. McGinnis RE, et al. **Diabetes** 1995 Nov;44(11):1296–302

Polymorphism at the rad gene is not associated with NIDDM in Finns. Orho M, et al. **Diabetes** 1996 Apr;45(4):429–33

Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Tarnow L, et al. **Diabetes** 1996 Mar;45(3):367–369

Mitochondrial FAD–glycerophosphate dehydrogenase and G–protein–coupled inwardly rectifying K+ channel: No evidence for linkage in maturity–onset diabetes of the young or NIDDM. Warren–Perry MG, et al. **Diabetes** 1996 May;45(5):639–41

Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Boemi M, et al. **Diabetes Care** 1995 Apr;18(4):504–8

Lipoprotein(a), apolipoprotein(a) polymorphism, and insulin treatment in type II diabetic patients [letter] Buscaglia P, et al. **Diabetes Care** 1995 Aug;18(8):1202–3

Angiotensin I–converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Fujisawa T, et al. **Diabetes Care** 1995 Jul;18(7):983–5

Polymorphism of complement C4 and susceptibility to IDDM and microvascular complications. Lhotta K, et al. **Diabetes Care** 1996 Jan;19(1):53–5

A pitfall in the association study of ACE gene polymorphism [letter] Odawara M, et al. **Diabetes Care** 1996 May; 19(5):543–4

Gly40Ser substitution in the glucagon receptor is rarely involved in the pathogenesis of NIDDM in Japanese patients [letter] Odawara M, et al. **Diabetes Care** 1996 May; 19(5):547

CA–repeated microsatellite polymorphism of the glucokinase gene and its association with non–insulin–dependent diabetes mellitus in Taiwanese. Wu HP, et al. **Diabetes Res Clin Pract** 1995 Oct;30(1):21–6

Insertion/deletion polymorphism in the angiotensin–I–converting enzyme gene [letter] Demaine A, et al. **Diabetologia** 1995 Dec;38(12):1495–6

Association between a polymorphism in the angiotensin–converting enzyme gene and microvascular complications in Japanese patients with NIDDM. Doi Y, et al. **Diabetologia** 1996 Jan;39(1):97–102

The glycogen synthase gene in NIDDM and hypertension [letter] Hamada Y, et al. **Diabetologia** 1995 Oct; 38(10):1249–50

Lack of association between the Gly40Ser polymorphism in the glucagon receptor gene and NIDDM in Finland. Huang X, et al. **Diabetologia** 1995 Oct;38(10):1246–8

Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance. Laakso M, et al. **Diabetologia** 1995 May;38(5):617–22

In Finland insulin gene region encoded susceptibility to IDDM exerts maximum effect when there is low HLA–DR associated risk. DiMe (Childhood Diabetes in Finland) Study Group. Metcalfe KA, et al. **Diabetologia** 1995 Oct; 38(10):1223–9

Identification of the aminoacid polymorphisms in hexokinase II in Japanese subjects [letter] Shimada F, et al. **Diabetologia** 1996 Jan;39(1):123–4

Insertion/deletion polymorphism in the angiotensin–I–converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Tarnow L, et al. **Diabetologia** 1995 Jul; 38(7):798–803

Variant sequences of the Hexokinase II gene in familial NIDDM. Taylor RW, et al. **Diabetologia** 1996 Mar; 39(3):322–8

Molecular scanning of the insulin receptor substrate–1 (IRS–1) gene in Japanese patients with NIDDM: identification of five novel polymorphisms. Ura S, et al. **Diabetologia** 1996 May;39(5):600–8

Simple non–radioactive methods of analysis of polymorphic markers flanking human apolipoprotein C–III gene. Surguchov AP, et al. **Dis Markers** 1995 Aug;12(3):167–73

Human drug–metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)

A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. Peller S, et al. **DNA Cell Biol** 1995 Dec; 14(12):983–90

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism.

Szumlanski C, et al. **DNA Cell Biol** 1996 Jan;15(1):17–30

Arylamine N–acetyltransferases. Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes. Wagner CR, et al. **Drug Metab Dispos** 1996 Feb;24(2):245–53

Association of protein polymorphism among pepper (Capsicum annuum L.) inbred lines with agronomic performance of their crosses. Posch A, et al. **Electrophoresis** 1995 May;16(5):860–4

Temperature–gradient gel electrophoresis as a screening tool for polymorphisms in multigene families. Schlötterer C. **Electrophoresis** 1995 May;16(5):722–8

Variation in the expression of human 3 beta–hydroxysteroid dehydrogenase. Russell AJ, et al. **Endocr Res** 1995 Feb–May;21(1–2):485–94

Haplotype analysis of CYP11B2. White PC, et al. **Endocr Res** 1995 Feb–May;21(1–2):437–42

Functional characteristics of a variant thyrotropin receptor. Tonacchera M, et al. **Eur J Biochem** 1996 Jun 1; 238(2):490–4

Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Nemeth A, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):799–804

Association between deletion polymorphism of the angiotensin–converting enzyme gene and cerebral atherosclerosis. Sertic J, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):301–4

HLA–G polymorphism and allelic association with HLA–A in a Finnish population. Karhukorpi J, et al. **Eur J Immunogenet** 1996 Apr;23(2):153–5

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161–77 (129 ref.)

Strong association between the responder status of the FC gamma II receptor and recurrent spontaneous abortion. Lorenz A, et al. **Eur J Immunogenet** 1995 Oct;22(5):397–401

TNF2, a polymorphism of the tumour necrosis–alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Manus RM, et al. **Eur J Immunol** 1996 Sep;26(9):2113–8

HLA, Gm, and Km polymorphisms and immunity to infectious diseases in South Amerinds. Black FL, et al. **Exp Clin Immunogenet** 1995;12(3):206–16

Length polymorphism of the human complement component C4 gene is due to an ancient retroviral integration. Chu X, et al. **Exp Clin Immunogenet** 1995;12(2):74–81

Echinococcus multilocularis: microsatellite polymorphism in U1 snRNA genes. Bretagne S, et al. **Exp Parasitol** 1996 Apr;82(3):324–8

Third genetic polymorphism of tear proteins Rtp–3 in the rat. Woszczyński M. **Folia Biol (Krakow)** 1995; 43(1–2):69–73

Karyotype polymorphism in the slender loris (Loris tardigradus). Goonan PM, et al. **Folia Primatol (Basel)** 1995; 65(2):100–9

Sequence determination of an allele ladder for the STR polymorphism at the CD4 locus and application of the ladder in testing an Austrian Caucasian population sample. Glock B, et al. **Forensic Sci Int** 1996 Apr 2;78(2):125–30

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)

Analysis of the D1S80 (pMCT118) VNTR locus polymorphism in a native Kuwaiti population by the polymerase chain reaction. al–Nassar KE, et al. **Forensic Sci Int** 1996 Apr 2;78(2):131–8

Distribution of the AMPFLPs YNZ22, 3'Apob and COL2A1 in the population of Galicia (NW Spain). Pestoni C, et al. **Forensic Sci Int** 1996 Jul 12;80(3):175–88

Km genotyping by polymerase chain reaction (PCR) using allele–specific amplification primers. Yamamoto Y, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):85–93

Distribution of ACP1, AK1 and ALAD polymorphisms in northern Portugal. Amorim A, et al. **Gene Geogr** 1994 Aug; 8(2):147–50

Distribution of the HLA–DQA1 polymorphism in the population of the Basque Country (Spain). Esparza B, et al. **Gene Geogr** 1995 Apr;9(1):53–8

Polymorphism of phosphoglucomutase 1 (PGM1) in five Han subpopulations in China. Hu J, et al. **Gene Geogr** 1995 Apr; 9(1):1–4

Distribution of group specific component (GC) and transferrin (TF) subtypes in populations of Sri Lanka. Jayasekara R, et al. **Gene Geogr** 1994 Aug;8(2):151–6

alpha–1–Antitrypsin (Pi) polymorphism in Serbia: deviation of Pi M subtype distribution from the Hardy–Weinberg equilibrium. Jelić–Ivanović Z, et al. **Gene Geogr** 1994 Aug; 8(2):129–35

Red cell isoenzyme polymorphism in the East Slovakian population. Juríčková J, et al. **Gene Geogr** 1994 Aug; 8(2):117–20

Distribution of ApoBII, MCT118 (D1S80), YNZ22 (D17S30), and COL2A1 Amp–FLPs (amplified fragment length polymorphisms) in Caucasoid population of Slovakia. Kádasi L, et al. **Gene Geogr** 1994 Aug;8(2):121–7

Rhesus polymorphism in New Caledonia. I. Genetic structures of three local populations [see comments] Louis FJ, et al. **Gene Geogr** 1994 Aug;8(2):81–90. Comment in: Gene Geogr 1994 Aug;8(2):91.

Genetic polymorphisms of red cell enzymes in tribes of Andhra Pradesh, India. Naidu JM, et al. **Gene Geogr** 1995 Apr;9(1):7–14

Genetic polymorphisms of the Caucasus ethnic groups: distribution of some blood group genetic markers (Part II). Nasidze IS. **Gene Geogr** 1995 Aug;9(2):117–67

Genetic polymorphisms of the Caucasus ethnic groups: distribution of some serum protein and red cell enzyme genetic markers (Part I). Nasidze IS. **Gene Geogr** 1995 Aug; 9(2):91–116

DNA profiling of the VNTR locus D2S44 in the population of Madras City and in the tribal Kotas of the Nilgiri Hills, south India. Pandian SK, et al. **Gene Geogr** 1995 Aug; 9(2):65–90

Serum protein polymorphism in Chuetas (Majorcan Jews)—GC, A2HS, ORM, ITI and HP. Picornell A, et al. **Gene Geogr** 1994 Aug;8(2):137–45

Rhesus polymorphism in New Caledonia. II. Genetic comparison with other Oceanians [comment] Sanchez–Mazas A, et al. **Gene Geogr** 1994 Aug;8(2):91–8 . Comment on: Gene Geogr 1994 Aug;8(2):81–90.

Polymorphism at VNTR locus 3 to the apolipoprotein B gene in a Tunisian population: difference from other ethnic groups. Buresi C, et al. **Genet Epidemiol** 1995;12(4):381–9

No association of apolipoprotein A–IV codon 347 and 360 variation with atherosclerosis and lipid transport in a sample of mixed hyperlipidemics. Carrejo MH, et al. **Genet Epidemiol** 1995;12(4):371–80

Population genetic study of the human dopamine transporter gene (DAT1). Doucette–Stamm LA, et al. **Genet Epidemiol** 1995;12(3):303–8

Angiotensin–converting enzyme genotypes in the high– and low–risk area for coronary heart disease in Finland. Perola M, et al. **Genet Epidemiol** 1995;12(4):391–9

Data simulation for GAW9 problems 1 and 2. Speer MC, et al. **Genet Epidemiol** 1995;12(6):561–4

New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Wang XL, et al. **Genet Epidemiol** 1996;13(1):1–10

An adaptive chromosomal polymorphism affecting size–related traits, and longevity selection in a natural population of Drosophila buzzatii. Norry FM, et al. **Genetica** 1995;96(3):285–91

Enzyme polymorphism in Drosophila melanogaster populations collected in two different habitats in Hungary. Pecsenye K, et al. **Genetica** 1995;96(3):257–68

The hitchhiking effect on the site frequency spectrum of DNA polymorphisms. Braverman JM, et al. **Genetics** 1995 Jun;140(2):783–96

The genetical and environmental determination of phally polymorphism in the freshwater snail Bulinus truncatus. Doums C, et al. **Genetics** 1996 Jan;142(1):217–25

Amino acid polymorphism and rare electrophoretic variants of G6PD from natural populations of Drosophila melanogaster. Eanes WF, et al. **Genetics** 1996 May; 143(1):401–6

New statistical tests of neutrality for DNA samples from a population. Fu YX. **Genetics** 1996 May;143(1):557–70

Detecting heterogeneity of substitution along DNA and protein sequences. Gross PJ, et al. **Genetics** 1996 May; 143(1):589–602

Dynamics of repeat polymorphisms under a forward–backward mutation model: within– and between–population variability at microsatellite loci. Kimmel M, et al. **Genetics** 1996 May;143(1):549–55

Genetic map of randomly amplified DNA polymorphisms closely linked to the mating type locus of Tetrahymena thermophila. Lynch TJ, et al. **Genetics** 1995 Dec; 141(4):1315–25

H–2 polymorphisms are more uniformly distributed than allozyme polymorphisms in natural populations of house mice. Nadeau JH, et al. **Genetics** 1988 Jan;118(1):131–40

Nucleotide polymorphism in the 5' promoter region of esterase 6 in Drosophila melanogaster and its relationship to enzyme activity variation. Odgers WA, et al. **Genetics** 1995 Sep;141(1):215–22

Time–series analysis of seasonal changes of the O inversion polymorphism of Drosophila subobscura. Rodríguez–Trelles F, et al. **Genetics** 1996 Jan;142(1):179–87

Properties of statistical tests of neutrality for DNA polymorphism data. Simonsen KL, et al. **Genetics** 1995 Sep; 141(1):413–29

Molecular basis of polymorphism at the esterase–5B locus in Drosophila pseudoobscura. Veuille M, et al. **Genetics** 1995 Sep;141(1):255–62

Mapping of digested and undigested random amplified microsatellite polymorphisms in barley. Becker J, et al. **Genome** 1995 Oct;38(5):991–8

Analysis of genetic diversity in a sweetpotato (Ipomoea batatas) germplasm collection using DNA amplification fingerprinting. He G, et al. **Genome** 1995 Oct;38(5):938–45

Useful DNA polymorphisms are identified by snapback, a midrepetitive element in Tribolium castaneum. Stuart JJ, et al. **Genome** 1996 Jun;39(3):568–78

Analysis of the genetic composition of anther–derived potato by randomly amplified polymorphic DNA and simple sequence repeats. Veilleux RE, et al. **Genome** 1995 Dec; 38(6):1153–62

Isolation of tetranucleotide repeat polymorphisms flanking the BRCA1 gene. Bennett–Baker PE, et al. **Genomics** 1996 Feb 15;32(1):163–7

Frequency and polymorphism of simple sequence repeats in a contiguous 685–kb DNA sequence containing the human T–cell receptor beta–chain gene complex. Charmley P, et al. **Genomics** 1995 Oct 10;29(3):760–5

Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. Durocher F, et al. **Genomics** 1995 Oct 10; 29(3):781–3

Increasing the information content of STS–based genome maps: identifying polymorphisms in mapped STSs. Kwok PY, et al. **Genomics** 1996 Jan 1;31(1):123–6

Human gamma–aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization, and tissue expression. Lin SW, et al. **Genomics** 1996 Jun 15; 34(3):376–80

Toward a high–resolution Plasmodium falciparum linkage map: polymorphic markers from hundreds of simple sequence repeats. Su Xz, et al. **Genomics** 1996 May 1; 33(3):430–44

Molecular cloning and structural characterization of the human histidase gene (HAL). Suchi M, et al. **Genomics** 1995 Sep 1;29(1):98–104

Cloning and mapping of the U2af1–rs2 gene with a high transmission distortion in interspecific backcross progeny. Yamaoka T, et al. **Genomics** 1995 May 20;27(2):337–40

Practical application of three polymorphic microsatellites in intron 40 of the human von Willebrand factor gene. Casaña P, et al. **Haemostasis** 1995 Nov–Dec;25(6):264–71

A novel DNA polymorphism of the human A gamma–globin gene (A gamma–588, A––>G) is linked with the XMN / polymorphism (G gamma–158, C––>T). Patrinos GP, et al. **Hemoglobin** 1995;19(6):419–23

High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Tanaka F, et al. **Hepatology** 1996 Feb; 23(2):234–9

Polymorphism and genetic relatedness among wild and cultivated rice species determined by AP–PCR analysis. Yi QM, et al. **Hereditas** 1995;122(2):135–41

Measuring selective effects of modifier gene polymorphisms on the Bare locus of Drosophila subobscura. Alvarez G, et al. **Heredity** 1996 Apr;76 (Pt 4):404–11

A population genetic analysis of chloroplast DNA in Phacelia. Levy F, et al. **Heredity** 1996 Feb;76 (Pt 2):143–55

HLA affinities of Iyers, a Brahmin population of Tamil Nadu, South India. Balakrishnan K, et al. **Hum Biol** 1996 Aug; 68(4):523–37

Is there increased fertility in adult males with the sickle cell trait? Ezeh UO, et al. **Hum Biol** 1996 Aug;68(4):555–62

DYS19, D12S67, and D1S80 polymorphisms in population samples from southern Italy and Greece. Falcone E, et al. **Hum Biol** 1995 Oct;67(5):689–701

Genetic polymorphism of the 3'VNTR region of the human dopaminergic function gene DAT1 (human dopamine transporter gene) in the Mongolian population. Nakatome M, et al. **Hum Biol** 1996 Aug;68(4):509–15

Sub–Saharan influence on the Canary Islands population deduced from G6PD gene sequence analysis. Pinto FM, et al. **Hum Biol** 1996 Aug;68(4):517–22

Genetic diversity among selected ethnic subpopulations of Australia: evidence from three highly polymorphic DNA loci. Robinson SL, et al. **Hum Biol** 1996 Aug;68(4):489–508

Single nucleotide polymorphisms in the human E–cadherin gene. Becker KF, et al. **Hum Genet** 1995 Dec;96(6):739–40

A new polymorphism of arylsulfatase A within the coding region. Berger J, et al. **Hum Genet** 1996 Sep;98(3):348–50

Molecular analysis of the cystinuria disease gene: identification of four new mutations, one large deletion, and one polymorphism. Bisceglia L, et al. **Hum Genet** 1996 Oct;98(4):447–51

ACP1 and human adaptability. 1. Association with common diseases: a case–control study. Bottini E, et al. **Hum Genet** 1995 Dec;96(6):629–37

A novel sequence polymorphism in the promoter region of the human B2–bradykinin receptor gene. Braun A, et al. **Hum Genet** 1996 May;97(5):688–9

Detection of a C–insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Brinkman BM, et al. **Hum Genet** 1995 Oct;96(4):493

Complex mutational events at the HumD21S11 locus. Brinkmann B, et al. **Hum Genet** 1996 Jul;98(1):60–4

The world–wide distribution of allele frequencies at the human dopamine D4 receptor locus. Chang FM, et al. **Hum Genet** 1996 Jul;98(1):91–101

Novel interleukin–1 receptor antagonist exon polymorphisms and their use in allele–specific mRNA assessment. Clay FE, et al. **Hum Genet** 1996 Jun;97(6):723–6

Dinucleotide repeat polymorphism in the human ceruloplasmin gene. Daimon M, et al. **Hum Genet** 1995 Dec;96(6):736

Characterization of two stop codon mutations in the galactose–1–phosphate uridyltransferase gene of three male galactosemic patients with severe clinical manifestation. Gathof BS, et al. **Hum Genet** 1995 Dec;96(6):721–5

Dinucleotide repeat polymorphism at the D5S99 locus on chromosome 5q33–34. Groenewald IM, et al. **Hum Genet** 1995 Oct;96(4):497–9

Screening for human mitochondrial DNA polymorphisms with denaturing gradient gel electrophoresis. Hanekamp JS, et al. **Hum Genet** 1996 Aug;98(2):243–5

A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR). Kohonen–Corish MR, et al. **Hum Genet** 1996 Jan; 97(1):124–5

A novel polymorphism in the coding region of CYBB, the human gp91-phox gene. Kuribayashi F, et al. **Hum Genet** 1996 May;97(5):611-3

Interaction between ABO blood groups and ADA genetic polymorphism during intrauterine life. A comparative analysis of couples with habitual abortion and normal puerperae delivering a live-born infant. Lucarini N, et al. **Hum Genet** 1995 Nov;96(5):527-31

Polymorphic tri- and tetranucleotide repeats in exons 1 and 8 of the myelin oligodendrocyte glycoprotein (MOG) gene. Malfroy L, et al. **Hum Genet** 1995 Dec;96(6):737-8

Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany. Malle E, et al. **Hum Genet** 1996 Sep;98(3):285-90

Polymorphic (AAT) in trinucleotide repeats derived from a human brain cDNA library. Margolis RL, et al. **Hum Genet** 1995 Oct;96(4):495-6

DNA polymorphisms and linkage disequilibrium in the angiotensinogen gene. Morgan L, et al. **Hum Genet** 1996 Aug;98(2):194-8

Detection of a novel nonsense mutation and an intragenic polymorphism in the PKD1 gene of a Cypriot family with autosomal dominant polycystic kidney disease. Neophytou P, et al. **Hum Genet** 1996 Oct;98(4):437-42

Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes. Ogasawara K, et al. **Hum Genet** 1996 Jun; 97(6):777-83

Polymorphism in the 3' untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. Ramus SJ, et al. **Hum Genet** 1995 Dec;96(6):741-3

Geographic differences in the allele frequencies of the human Y-linked tetranucleotide polymorphism DYS19. Santos FR, et al. **Hum Genet** 1996 Mar;97(3):309-13

Psychosis and genes with trinucleotide repeat polymorphism. Sasaki T, et al. **Hum Genet** 1996 Feb;97(2):244-6

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Shaikh S, et al. **Hum Genet** 1996 Jun;97(6):714-9

Mapping eight new polymorphisms in 11q13 in the vicinity of multiple endocrine neoplasia type 1: identification of a new distal recombinant. Smith CM, et al. **Hum Genet** 1995 Oct;96(4):377-87

Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Suzuki K, et al. **Hum Genet** 1996 Oct;98(4):393-5

Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Tokino T, et al. **Hum Genet** 1996 May;97(5):625-31

Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Tycko B, et al. **Hum Genet** 1996 Oct;98(4):430-6

Association of CTG repeats and the 1-kb Alu insertion/deletion polymorphism at the myotonin protein kinase gene in the Japanese population suggests a common Eurasian origin of the myotonic dystrophy mutation. Yamagata H, et al. **Hum Genet** 1996 Feb;97(2):145-7

Linkage disequilibrium between two loci (5' untranslated exon 1 and intron 5-DdeI) of the antithrombin III gene in three ethnic groups in Singapore. Liu Y, et al. **Hum Hered** 1995 Jul-Aug;45(4):192-8

CA repeat polymorphism of the endothelial nitric oxide synthase gene in the Japanese. Nakayama T, et al. **Hum Hered** 1995 Sep-Oct;45(5):301-2

Analysis of locus heterogeneity in Waardenburg syndrome types 1 and 2 using highly informative microsatellite markers. Reynolds JE, et al. **Hum Hered** 1995 Sep-Oct; 45(5):243-52

A previously unknown polymorphism located within the RB1 locus only present in Asian individuals. Schubert EL, et al. **Hum Hered** 1996 Mar-Apr;46(2):118-20

Orosomucoid phenotyping with monoclonal antibodies:polymorphic occurrence of ORM1*Q0 in aboriginal Taiwanese populations. Umetsu K, et al. **Hum Hered** 1995 Jul-Aug;45(4):181-5

DNA polymorphism at the ABO locus in the Chinese population of Hong Kong. Yip SP, et al. **Hum Hered** 1995 Sep-Oct;45(5):266-71

TCRBV12 genes are polymorphic but the protein products encoded by each gene are conserved. Deulofeut H, et al. **Hum Immunol** 1995 Jul;43(3):227-30

HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Hagihara M, et al. **Hum Immunol** 1995 Jun;43(2):95-100

HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Howell WM, et al. **Hum Immunol** 1995 May; 43(1):29-37

A rare neutral polymorphism in 21-hydroxylase genes as HLA haplotype marker. Evidence for strong founder effect in the Finnish population. Narko K, et al. **Hum Immunol** 1995 May;43(1):66-71

Three highly polymorphic microsatellites at the human myelin oligodendrocyte glycoprotein locus, 100 kb telomeric to HLA-F. Characterization and relation to HLA haplotypes. Roth MP, et al. **Hum Immunol** 1995 Aug; 43(4):276-82

TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Westman P, et al. **Hum Immunol** 1995 Dec;44(4):236-42

Polymerase chain reaction analysis of the Xba I polymorphism of the human complement C4 genes provides evidence for strong haplotype conservation. Witzel K, et al. **Hum Immunol** 1995 Jul;43(3):165-73

An integrated physical and genetic map of a 35 Mb region on chromosome Xp22.3-Xp21.3. Ferrero GB, et al. **Hum Mol Genet** 1995 Oct;4(10):1821-7

Survey of trinucleotide repeats in the human genome: assessment of their utility as genetic markers. Gastier JM, et al. **Hum Mol Genet** 1995 Oct;4(10):1829-36

A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hansen L, et al. **Hum Mol Genet** 1995 Aug;4(8):1313-20

Microsatellite instability at a single locus (D11S988) on chromosome 11p15.5 as a late event in mammary tumorigenesis. Karnik P, et al. **Hum Mol Genet** 1995 Oct; 4(10):1889-94

New polymorphic microsatellite markers place the haemochromatosis gene telomeric to D6S105. Raha-Chowdhury R, et al. **Hum Mol Genet** 1995 Oct; 4(10):1869-74

A collection of tri- and tetranucleotide repeat markers used to generate high quality, high resolution human genome-wide linkage maps. Sheffield VC, et al. **Hum Mol Genet** 1995 Oct;4(10):1837-44

Population genetics of trinucleotide repeat polymorphisms. Watkins WS, et al. **Hum Mol Genet** 1995 Sep;4(9):1485-91

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1-6 (40 ref.)

French CF family genotype analysis shows that the R297Q mutation is a rare polymorphism. Dorval I, et al. **Hum Mutat** 1995;6(4):334-5

An Alu1- polymorphism in the HEXA gene is common in Ashkenazi and Sephardic Jews, Israeli Arabs, and French Canadians of Quebec and northern New England. Grinshpun J, et al. **Hum Mutat** 1995;6(1):89-90

Myelin protein zero (MPZ) gene mutations in nonduplication type 1 Charcot-Marie-Tooth disease. Roa BB, et al. **Hum Mutat** 1996;7(1):36-45

Using information content and base frequencies to distinguish mutations from genetic polymorphisms in splice junction recognition sites. Rogan PK, et al. **Hum Mutat** 1995; 6(1):74-6

Insulin receptor gene polymorphism and hyperinsulinemia in hypertensive patients. Fujioka Y, et al. **Hypertens Res** 1995 Sep;18(3):215-8

Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Bloem LJ, et al. **Hypertension** 1996 Jan;27(1):62-6

Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Doria A, et al. **Hypertension** 1996 May;27(5):1134-9

Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects. Schalin-Jäntti C, et al. **Hypertension** 1996 Jan;27(1):67-71

Polymorphism of DRA among equids. Albright-Fraser DG, et al. **Immunogenetics** 1996;43(5):315-7

Identifying DNA polymorphisms in human TCRA/D variable genes by direct sequencing of PCR products. Boysen C, et al. **Immunogenetics** 1996;44(2):121-7

An intragenic polymorphism in the human tumor necrosis factor alpha (TNFA) chain-encoding gene. D'Alfonso S, et al. **Immunogenetics** 1996;44(4):321-2

A polymorphic dinucleotide repeat in the human IL-10 promoter. Eskdale J, et al. **Immunogenetics** 1995; 42(5):444-5

Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB1 genes. Singal DP, et al. **Immunogenetics** 1996;43(1-2):50-6

HLA-G gene polymorphism in a Japanese population. Yamashita T, et al. **Immunogenetics** 1996;44(3):186-91

Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13-31 (45 ref.)

A "minimal essential Mhc" and an "unrecognized Mhc": two extremes in selection for polymorphism. Kaufman J, et al. **Immunol Rev** 1995 Feb;143:63-88 (84 ref.)

Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113-22 (25 ref.)

Pathogen-based models favoring MHC genetic diversity. Potts WK, et al. **Immunol Rev** 1995 Feb;143:181-97 (37 ref.)

Exonic MHC-DRB polymorphisms and intronic simple repeat sequences: Janus' faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199-224 (55 ref.)

A genetic herd-immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263-92 (70 ref.)

Inversion polymorphism in Drosophila ananassae: persistence of inversions, heterosis and intra- and inter-chromosomal associations in experimental populations of mixed geographic origin. Singh BN, et al. **Indian J Exp Biol** 1995 Sep;33(9):641-5

Highly polymorphic repetitive sequences in Rhynchosciara americana genome. Yussa M, et al. **Insect Biochem Mol Biol** 1995 Sep;25(8):909-14

Genetic polymorphism of the H1 subunit of inter-alpha-trypsin inhibitor. Harada A, et al. **Int J Legal Med** 1995;108(2):113-5

Evaluation of an ACTBP2 ladder composed of 26 sequenced alleles. Möller A, et al. **Int J Legal Med** 1995;108(2):75-8

Analysis of the genetic polymorphism of Borrelia burgdorferi sensu lato by multilocus enzyme electrophoresis. Balmelli T, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):167-72

Intraspecific variation in small-subunit rRNA sequences in GenBank: why single sequences may not adequately represent prokaryotic taxa. Clayton RA, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):595-9

The differentiation of Bordetella parapertussis and Bordetella bronchiseptica from humans and animals as determined by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. van der Zee A, et al. **Int J Syst Bacteriol** 1996 Jul; 46(3):640-7

Test for association of DDT resistance with inversion polymorphism in Anopheles arabiensis from Ethiopia. Nigatu W, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):238-40

Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. Schmidt A, et al. **J Am Soc Nephrol** 1996 Feb;7(2):314-7

Individual multilocus genotypes using microsatellite polymorphisms to permit the analysis of the genetic variability within and between Italian beef cattle breeds. Ciampolini R, et al. **J Anim Sci** 1995 Nov;73(11):3259-68

Spiralin polymorphism in strains of Spiroplasma citri is not due to differences in posttranslational palmitoylation. Foissac X, et al. **J Bacteriol** 1996 May;178(10):2934-40

A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. Baier LJ, et al. **J Biol Chem** 1996 May 3;271(18):10892-6

Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. Petersen RB, et al. **J Biol Chem** 1996 May 24; 271(21):12661-8

A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding. Telen MJ, et al. **J Biol Chem** 1996 Mar 22;271(12):7147-53

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289-93 (43 ref.)

Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. Garnero P, et al. **J Bone Miner Res** 1995 Sep;10(9):1283-8

Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. Stevens PA, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S9-12

Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains [see comments] Health H 3rd, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1312-7. Comment in: J Clin Endocrinol Metab 1996 Apr;81(4):1309-11.

The role of luteinizing hormone-beta gene polymorphism in the onset and progression of puberty in healthy boys. Raivio T, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3278-82

Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. Sigal RJ, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1657-9

Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. Yballe CM, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1607-12

A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. Almind K, et al. **J Clin Invest** 1996 Jun 1;97(11):2569-75

Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. Huang Y, et al. **J Clin Invest** 1995 Dec;96(6):2693-701

Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. Oike Y, et al. **J Clin Invest** 1995 Dec;96(6):2975-9

Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease. Wang XL, et al. **J Clin Invest** 1996 Jul 15;98(2):372-7

Molecular polymorphism of the lyme disease agent Borrelia garinii in northern Europe is influenced by a novel enzootic Borrelia focus in the North Atlantic. Bunikis J, et al. **J Clin Microbiol** 1996 Feb;34(2):364-8

Polymorphisms in the bovine beta-casein 5' flanking region. Bleck GT, et al. **J Dairy Sci** 1996 Mar;79(3):347-9

Relationships between polymorphism for mitochondrial deoxyribonucleic acid and yield traits of Holstein cows. Boettcher PJ, et al. **J Dairy Sci** 1996 Apr;79(4):647-54

Angiotensin-converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. Panagiotopoulos S, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):272-6

DNA polymorphism revealed by arbitrary primers polymerase chain reaction among Blastocystis strains isolated from humans, a chicken, and a reptile. Yoshikawa H, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):127-30

Polymorphism in tumor necrosis factor genes associated with

mucocutaneous leishmaniasis. Cabrera M, et al. **J Exp Med** 1995 Nov 1;182(5):1259–64

HLA–DQB1 codon 57 is critical for peptide binding and recognition. Kwok WW, et al. **J Exp Med** 1996 Mar 1; 183(3):1253–8

Clonal stability of blood cell lineages indicated by X–chromosomal transcriptional polymorphism. Prchal JT, et al. **J Exp Med** 1996 Feb 1;183(2):561–7

Allelic ladder characterization of the short tandem repeat polymorphism in intron 6 of the lipoprotein lipase gene and its application in an Austrian Caucasian population study. Glock B, et al. **J Forensic Sci** 1996 Jul;41(4):579–81

Genetic polymorphism of alpha–2–HS–glycoprotein in northern Bavaria (Germany). Simplified AHSG–phenotyping by isoelectric focusing using dry gels. Hausmann R, et al. **J Forensic Sci** 1995 Nov;40(6):1068–71

Genetic polymorphism of the inter–alpha–trypsin inhibitor (ITI) in Cádiz Province, southern Spain. Romero Palanco JL, et al. **J Forensic Sci** 1996 Jul;41(4):664–6

Epidermal cells on stubs used for detection of GSR with SEM–EDX: analysis of DNA polymorphisms. Torre C, et al. **J Forensic Sci** 1996 Jul;41(4):658–9

Amino acid polymorphisms of PrP with reference to onset of scrapie in Suffolk and Corriedale sheep in Japan. Ikeda T, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2577–81

RAPD variation within and among natural populations of trembling aspen (Populus tremuloides Michx.) from Alberta. Yeh FC, et al. **J Hered** 1995 Nov–Dec; 86(6):454–60

Lack of association between HLA class II polymorphisms and essential hypertension in a Belgian population. Gu XX, et al. **J Hum Hypertens** 1995 Jul;9(7):553–5

Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin–angiotensin system in Caucasian and Afro–Caribbean peoples. Barley J, et al. **J Hypertens** 1996 Jan;10(1):31–5

Ethnic differences in angiotensin converting enzyme gene polymorphism [letter] Johanning GL, et al. **J Hypertens** 1995 Jun;13(6):710–1

Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. Rutledge DR, et al. **J Hypertens** 1995 Sep;13(9):953–5

Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. neoformans in patients with AIDS or other immunosuppressive conditions. Chen SC, et al. **J Infect Dis** 1996 Mar;173(3):754–8

The region coding for the helix termination motif and the adjacent intron 6 of the human type I hair keratin gene hHa2 contains three natural, closely spaced polymorphic sites. Winter H, et al. **J Invest Dermatol** 1996 Mar; 106(3):544–8

Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. Jemaa R, et al. **J Lipid Res** 1995 Oct;36(10):2141–6

The angiotensin–I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. Foy CA, et al. **J Med Genet** 1996 Apr;33(4):336–7

The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non–smokers. Thomas AE, et al. **J Med Genet** 1995 Aug; 32(8):585–9

Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282–305 (115 ref.)

Random amplified polymorphic DNA for strain delineation within Candida tropicalis. Lin D, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):241–6

Polymorphism, monomorphism, and sequences in conserved microsatellites in primate species. Blanquer–Maumont A, et al. **J Mol Evol** 1995 Oct;41(4):492–7

Polymorphism and concerted evolution in a tandemly repeated gene family: 5S ribosomal DNA in diploid and allopolyploid cottons. Cronn RC, et al. **J Mol Evol** 1996 Jun;42(6):685–705

Y–chromosome DNA haplotypes in Basques [letter] Lucotte G, et al. **J Mol Evol** 1996 Apr;42(4):472–5

Insertion/deletion polymorphism in the angiotensin–converting enzyme gene associated with macroangiopathy and blood pressure in patients with non–insulin–dependent diabetes mellitus. Ukkola O, et al. **J Mol Med** 1995 Jun;73(6):307–11

Polymorphism of glutathione S–transferase M1 and lung cancer risk among African–Americans and Caucasians in Los Angeles County, California. London SJ, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1246–53

Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. Mitra AB, et al. **J Natl Cancer Inst** 1995 May 17;87(10):742–5

An interleukin 1–receptor–antagonist gene polymorphism is not associated with multiple sclerosis. Huang WX, et al. **J Neuroimmunol** 1996 Jul;67(2):143–4

Arg296 to Cys296 polymorphism in exon 6 of cytochrome P–450–2D6 (CYP2D6) is not associated with multiple system atrophy [letter] Bandmann O, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):557

Neuropathological diagnosis and CAG repeat expansion in Huntington's disease. Xuereb JH, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):78–81

CAG repeat expansion of Machado–Joseph disease in the Japanese: analysis of the repeat instability for parental transmission, and correlation with disease phenotype. Sasaki H, et al. **J Neurol Sci** 1995 Nov;133(1–2):128–33

HLA–DPB1 polymorphism in patients with rheumatoid arthritis in Taiwan. Yen JH, et al. **J Rheumatol** 1995 Nov; 22(11):2034–7

Unusually high frequency of Epstein–Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T–cell recognition: implications for virus evolution. Burrows JM, et al. **J Virol** 1996 Apr;70(4):2490–6

Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity. Estable MC, et al. **J Virol** 1996 Jun; 70(6):4053–62

Typing of varicella zoster virus by amplification of DNA polymorphisms. Hawrami K, et al. **J Virol Methods** 1996 Apr 5;57(2):169–74

Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan. Takahashi K, et al. **Jpn Heart J** 1995 Sep;36(5):557–64

The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Kiyohara C, et al. **Jpn J Cancer Res** 1996 Jan;87(1):18–24

Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Komiya A, et al. **Jpn J Cancer Res** 1995 Jul;86(7):622–5

Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Wu WJ, et al. **Jpn J Cancer Res** 1995 Aug;86(8):730–6

Adaptive significance of amylase polymorphism in Drosophila. X. Analysis of alpha–amylase activity of two amylase variants in individual Drosophila subobscura flies. Stojiljković V, et al. **Jpn J Genet** 1995 Aug;70(4):487–95

U.K. Prospective Diabetes Study. XV: Relationship of renin–angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Dudley CR, et al. **Kidney Int** 1995 Dec;48(6):1907–11

TNFB gene polymorphism in patients with systemic lupus erythematosus in Korean. Kim HY, et al. **Korean J Intern Med** 1995 Jul;10(2):130–6

Interstrain polymorphisms of isoenzyme profiles and mitochondrial DNA fingerprints among seven strains assigned to Acanthamoeba polyphaga. Kong HH, et al. **Korean J Parasitol** 1995 Dec;33(4):331–40

5HT 2a receptor T102C polymorphism and schizophrenia [letter]. Arranz MJ, et al. **Lancet** 1996 Jun 29; 347(9018):1831–2

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Bouras C, et al. **Lancet** 1996 Apr 27; 347(9009):1185–6. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

p53 polymorphism in ovarian and breast cancer [letter; comment] Campbell IG, et al. **Lancet** 1996 Feb 10; 347(8998):393–4. Comment on: Lancet 1995 Apr 15;345(8955):994.

5HT 2a receptor T102C polymorphism and schizophrenia [letter]. Clifford CP, et al. **Lancet** 1996 Jun 29; 347(9018):1830

Interleukin–1 receptor antagonist gene polymorphism and multiple sclerosis [letter] Crusius JB, et al. **Lancet** 1995 Oct 7;346(8980):979

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] [see comments] Higuchi S, et al. **Lancet** 1996 Apr 27;347(9009):1186. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment in: Lancet 1996 Jun 1;347(9014):1560.

5HT 2a receptor T102C polymorphism and schizophrenia [letter]. Jönsson E, et al. **Lancet** 1996 Jun 29;347(9018):1831

Presenilin–1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group [letter; comment] [see comments] Kehoe P, et al. **Lancet** 1996 Apr 27; 347(9009):1185. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment in: Lancet 1996 Jun 1;347(9014):1560.

Serotonin transporter gene polymorphism and affective disorder [letter; comment] Kunugi H, et al. **Lancet** 1996 May 11;347(9011):1340. Comment on: Lancet 1996 Mar 16;347(9003):731–3.

Effect of angiotensinogen gene T235 variant on the development of diabetic complications in type II diabetes mellitus [letter; comment] McLaughlin KJ, et al. **Lancet** 1995 Oct 28;346(8983):1160. Comment on: Lancet 1995 Jun 24;345(8965):1600–3.

Polymorphism in serotonin transporter gene associated with susceptibility to major depression [see comments] Ogilvie AD, et al. **Lancet** 1996 Mar 16;347(9003):731–3. Comment in: Lancet 1996 May 11;347(9011):1340. Comment in: Lancet 1996 May 11;347(9011):1340–1.

Presenilin–1 polymorphism and Alzheimer's disease. The Alzheimer's Study Group [letter; comment] Pérez–Tur J, et al. **Lancet** 1996 Jun 1;347(9014):1560–1. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

5HT 2a receptor T102C polymorphism and schizophrenia [letter]. Sasaki T, et al. **Lancet** 1996 Jun 29;347(9018):1832

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Scott WK, et al. **Lancet** 1996 Jun 1; 347(9014):1560. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment on: Lancet 1996 Apr 27;347(9009):1185. Comment on: Lancet 1996 Apr 27;347(9009):1186.

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Scott WK, et al. **Lancet** 1996 Apr 27; 347(9009):1186–7. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

Serotonin transporter gene polymorphism and affective disorder [letter; comment] Stöber G, et al. **Lancet** 1996 May 11;347(9011):1340–1. Comment on: Lancet 1996 Mar 16;347(9003):731–3.

Association between angiotensin–converting–enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG, et al. **Lancet** 1996 Jan 13;347(8994):94–5

Association between schizophrenia and T102C polymorphism of the 5–hydroxytryptamine type 2a–receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group [see comments] Williams J, et al. **Lancet** 1996 May 11;347(9011):1294–6. Comment in: Lancet 1996 May 11;347(9011):1274.

Interethnic differences in hip fracture rate and the vitamin D receptor polymorphism [letter] Young RP, et al. **Lancet** 1996 Sep 7;348(9028):688–9

The beta subunit common to the GM–CSF, IL–3 and IL–5 receptors is highly polymorphic but pathogenic point mutations in patients with acute myeloid leukaemia (AML) are rare. Freeburn RW, et al. **Leukemia** 1996 Jan; 10(1):123–9

Angiotensin converting enzyme gene polymorphism and renal artery resistance in patients with insulin dependent diabetes mellitus. Fukumoto S, et al. **Life Sci** 1996; 59(8):629–37

Cloning of a polymorphic sequence from the nontranscribed spacer of horse rDNA. Anglana M, et al. **Mamm Genome** 1996 Jul;7(7):539–41

Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region. Burnett RC, et al. **Mamm Genome** 1995 Sep;6(9):684–5

Mapping new murine polymorphisms detected by random amplified polymorphic DNA (RAPD) PCR. Cheah Y, et al. **Mamm Genome** 1996 Jul;7(7):549–50

Mapping new murine polymorphisms detected by random amplified polymorphic DNA (RAPD) PCR. Cheah YC, et al. **Mamm Genome** 1996 Sep;7(9):714

Identification and genetic mapping of random amplified polymorphic DNA (RAPD) markers to the sheep genome. Cushwa WT, et al. **Mamm Genome** 1996 Aug;7(8):580–5

Genetic map of 16 polymorphic markers forming three linkage groups assigned to rat chromosome 4. Goldmuntz EA, et al. **Mamm Genome** 1995 Jul;6(7):459–63

Close linkage of three neuronal genes on distal mouse chromosome 15. Jones JM, et al. **Mamm Genome** 1996 Sep; 7(9):696–7

Two polymorphic dinucleotide repeats in the rat dystrophin gene, including the conserved 3' UTR repeat. Millwood IY, et al. **Mamm Genome** 1995 Sep;6(9):668–9

A polymorphic trinucleotide repeat sequence mapping to distal mouse chromosome 4. Morgan LJ, et al. **Mamm Genome** 1996 Jul;7(7):553–4

Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains. Otsen M, et al. **Mamm Genome** 1995 Sep;6(9):595–601

Predictability of heterozygosity scores and polymorphism information content values for rat genetic markers. Pettersson A, et al. **Mamm Genome** 1995 Aug;6(8):512–20

Strain distribution pattern for SSLP markers in the SWXJ recombinant inbred strain set: chromosomes 7 to X. Shultz KL, et al. **Mamm Genome** 1996 Jul;7(7):526–32

A linkage map of porcine chromosome 7 composed of 19 short tandem repeat polymorphisms. Wilkie PJ, et al. **Mamm Genome** 1996 Aug;7(8):631–3

Sensitivity to dietary obesity linked to a locus on chromosome 15 in a CAST/Ei x C57BL/6J F2 intercross. York B, et al. **Mamm Genome** 1996 Sep;7(9):677–81

Anopheles arabiensis and An. gambiae chromosomal inversion polymorphism, feeding and resting behaviour in relation to insecticide house–spraying in Tanzania. Mnzava AE, et al. **Med Vet Entomol** 1995 Jul;9(3):316–24

DNA polymorphism of schistosomes and their snail hosts. Simpson AJ, et al. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr; 90(2):211–3

Postprandial lipoprotein metabolism in normotriglyceridemic non–insulin–dependent diabetic patients: influence of apolipoprotein E polymorphism. Reznik Y, et al. **Metabolism** 1996 Jan;45(1):63–71

Detection of an amino acid polymorphism in hormone–sensitive lipase in Japanese subjects. Shimada F, et al. **Metabolism** 1996 Jul;45(7):862–4

The inlA gene required for cell invasion is conserved and specific to Listeria monocytogenes. Poyart C, et al. **Microbiology** 1996 Jan;142 (Pt 1):173–80

A polymorphic minisatellite sequence in the subtelomeric regions of chromosomes I and V in Leishmania infantum. Ravel C, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):31–41

Structure and sequence variation of the genes encoding the polymorphic, immunodominant molecule (PIM), an antigen of Theileria parva recognized by inhibitory monoclonal antibodies. Toye P, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):165–77

The impact of population expansion and mutation rate heterogeneity on DNA sequence polymorphism. Aris–Brosou S, et al. **Mol Biol Evol** 1996 Mar;13(3):494–504

Positive selection and sequence rearrangements generate extensive polymorphism in the gamete recognition protein bindin. Metz EC, et al. **Mol Biol Evol** 1996 Feb; 13(2):397–406

Excess amino acid polymorphism in mitochondrial DNA:

contrasts among genes from Drosophila, mice, and humans. Rand DM, et al. **Mol Biol Evol** 1996 Jul;13(6):735–48

A nonlinear method for estimating nucleotide polymorphism from restriction maps. Rice KA. **Mol Biol Evol** 1996 Mar; 13(3):505–9

A novel measure of genetic distance for highly polymorphic tandem repeat loci. Shriver MD, et al. **Mol Biol Evol** 1995 Sep;12(5):914–20

'Fingerprinting' of HLA–DQA by polymerase chain reaction and heteroduplex analysis. Martinelli G, et al. **Mol Cell Probes** 1996 Apr;10(2):123–7

Allele and genotype frequencies of eight DNA polymorphisms in the Italian population. Trabetti E, et al. **Mol Cell Probes** 1995 Jun;9(3):183–8

RAPD identification of microsatellites in Daphnia. Ender A, et al. **Mol Ecol** 1996 Jun;5(3):437–41

Widespread geographical distribution of mitochondrial haplotypes in rock–dwelling cichlid fishes from Lake Tanganyika. Meyer A, et al. **Mol Ecol** 1996 Jun;5(3):341–50

A wide–range survey of cross–species microsatellite amplification in birds. Primmer CR, et al. **Mol Ecol** 1996 Jun;5(3):365–78

Marker enrichment and high–resolution map of the segment of potato chromosome VII harbouring the nematode resistance gene Gro1. Ballvora A, et al. **Mol Gen Genet** 1995 Nov 1;249(1):82–90

Combined mapping of AFLP and RFLP markers in barley. Becker J, et al. **Mol Gen Genet** 1995 Nov 1;249(1):65–73

Direct isolation of cDNA sequences from specific chromosomal regions of the tomato genome by the differential display technique. Hannappel U, et al. **Mol Gen Genet** 1995 Nov 1;249(1):19–24

A high–resolution map of the vicinity of the R1 locus on chromosome V of potato based on RFLP and AFLP markers. Meksem K, et al. **Mol Gen Genet** 1995 Nov 1; 249(1):74–81

Genomic organization and sequence of the human NRAMP gene: identification and mapping of a promoter region polymorphism. Blackwell JM, et al. **Mol Med** 1995 Jan; 1(2):194–205

Private polymorphisms: how many? How old? How useful for genetic taxonomies? Thompson EA, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):220–31

Gene pool similarities of potato cyst nematode populations assessed by AFLP analysis. Folkertsma RT, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):47–54

Molecular polymorphisms associated with host range in the highly conserved genomes of burrowing nematodes, Radopholus spp. Kaplan DT, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):32–8

Polymorphism of adhesion molecule CD31 and its role in acute graft–versus–host disease [see comments] Behar E, et al. **N Engl J Med** 1996 Feb 1;334(5):286–91. Comment in: N Engl J Med 1996 Feb 1;334(5):323–4.

Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction [letter] Carter AM, et al. **N Engl J Med** 1996 Oct 3;335(14):1072–3; discussion 1073–4

Platelets and coronary artery disease [editorial; comment] Handin RI. **N Engl J Med** 1996 Apr 25;334(17):1126–7. Comment on: N Engl J Med 1996 Apr 25;334(17):1084–9. Comment on: N Engl J Med 1996 Apr 25;334(17):1090–4.

Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction [letter] Marian AJ, et al. **N Engl J Med** 1996 Oct 3;335(14):1071–2; discussion 1073–4

A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis [see comments] Weiss EJ, et al. **N Engl J Med** 1996 Apr 25; 334(17):1090–4. Comment in: N Engl J Med 1996 Apr 25;334(17):1126–8.

BRCA2 germline mutations in male breast cancer cases and breast cancer families. Couch FJ, et al. **Nat Genet** 1996 May;13(1):123–5

Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays. Kozal MJ, et al. **Nat Med** 1996 Jul;2(7):753–9

A smoking–dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Wang XL, et al. **Nat Med** 1996 Jan; 2(1):41–5

Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757–9 (31 ref.)

Polymorphisms in the alanine:glyoxylate aminotransferase gene and their application to the prenatal diagnosis of primary hyperoxaluria type 1. Rumsby G, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:30–2

Angiotensin–converting enzyme polymorphism and development of diabetic nephropathy in non–insulin–dependent diabetes mellitus. Mizuiri S, et al. **Nephron** 1995;70(4):455–9

Angiotensin–converting enzyme (ACE) polymorphisms, angiotensin II, ACE inhibitors and glomerulosclerosis—a hypothesis [letter] Roy–Chaudhury P, et al. **Nephron** 1995; 71(3):359

Acetylcholinesterase in tentacles of Octopus vulgaris (Cephalopoda). Histochemical localization and characterization of a specific high salt–soluble and heparin–soluble fraction of globular forms. Talesa V, et al. **Neurochem Int** 1995 Aug;27(2):201–11

Origins and evolution of Huntington disease chromosomes. Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. **Neurology** 1996 Feb; 46(2):413–9

A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Mui S, et al. **Neurology** 1996 Jul;47(1):196–201

Linkage and mutation analysis of Charcot–Marie–Tooth neuropathy type 2 families with chromosomes 1p35–p36 and Xq13. Timmerman V, et al. **Neurology** 1996 May; 46(5):1311–8

Apolipoprotein E polymorphism and susceptibility to early– and late–onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. Nunomura A, et al. **Neurosci Lett** 1996 Mar 8;206(1):17–20

Polymorphism of rRNA genes and plasmid analysis in the typing of Salmonella enterica serovar enteritidis from a Spanish health area. Gonzalez Hevia MA, et al. **New Microbiol** 1995 Oct;18(4):377–84

Hybridization of microsatellites to RAPD: a new source of polymorphic markers. Richardson T, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3798–9

A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Tangir J, et al. **Oncogene** 1996 Feb 15;12(4):735–40

Evidence of two genetic entities in Bothriocephalus funiculus (Cestoda) detected by arbitrary–primer polymerase chain reaction random amplified polymorphic DNA fingerprinting. Verneau O, et al. **Parasitol Res** 1995; 81(7):591–4

Enzyme polymorphism in Endotrypanum and numerical analysis of isoenzyme data. Franco AM, et al. **Parasitology** 1996 Jul;113 (Pt 1):39–48

Single–strand conformational polymorphism. Fujita K, et al. **PCR Methods Appl** 1994 Dec;4(3):S137–40

Generation of DNA–based markers in specific genome regions by two–primer RAPD reactions. Hu J, et al. **PCR Methods Appl** 1995 Jun;4(6):346–51

Batched analysis of genotypes. LeDuc C, et al. **PCR Methods Appl** 1995 Jun;4(6):331–6

p53 codon 213 (A–G) polymorphism in a Turkish population. Ilhan I, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct; 12(5):499–501

Proceedings of the 14th Sapporo Cancer Seminar on genetic polymorphism and cancer susceptibility. 6–9 July 1994. **Pharmacogenetics** 1995;5 Spec No:i, S59–176

Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Bartsch H, et al. **Pharmacogenetics** 1995;5 Spec No:S84–90

Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129–34 (44 ref.)

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii–Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149–53 (30 ref.)

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Furuya H, et al. **Pharmacogenetics** 1995 Dec;5(6):389–92

Conjugation of carcinogens by theta class glutathione s–transferases: mechanisms and relevance to variations in human risk. Guengerich FP, et al. **Pharmacogenetics** 1995; 5 Spec No:S103–7

Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154–60 (42 ref.)

Metabolic polymorphisms and carcinogen–DNA adduct formation in human populations. Kaderlik KR, et al. **Pharmacogenetics** 1995;5 Spec No:S108–17 (112 ref.)

Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case–control study of gastric cancer and liver disease. Kato S, et al. **Pharmacogenetics** 1995;5 Spec No:S141–4

Genetic polymorphisms of drug–metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)

Glutathione S transferase–theta (GSTT1) genetic polymorphism among Chinese, Malays and Indians in Singapore. Lee EJ, et al. **Pharmacogenetics** 1995 Oct; 5(5):332–4

Higher activity of polymorphic thiopurine S–methyltransferase in erythrocytes from neonates compared to adults. McLeod HL, et al. **Pharmacogenetics** 1995 Oct;5(5):281–6

Lung cancer and mutations at the polymorphic NAT2 gene locus. Martínez C, et al. **Pharmacogenetics** 1995 Aug; 5(4):207–14

Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Rosvold EA, et al. **Pharmacogenetics** 1995 Aug; 5(4):199–206

Genetic polymorphisms and susceptibility to cancer development. Sugimura T, et al. **Pharmacogenetics** 1995;5 Spec No:S161–5

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Wanwimolruk S, et al. **Pharmacogenetics** 1995 Aug; 5(4):193–8

Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. Warholm M, et al. **Pharmacogenetics** 1995 Aug;5(4):252–4

Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Yokoi T, et al. **Pharmacogenetics** 1995;5 Spec No:S65–9

Incomplete editing of rps12 transcripts results in the synthesis of polymorphic polypeptides in plant mitochondria. Phreaner CG, et al. **Plant Cell** 1996 Jan;8(1):107–17

Random amplified polymorphic DNA comparisons among broiler lines selected for incidence of tibial dyschondroplasia. Zhang X, et al. **Poult Sci** 1995 Aug; 74(8):1253–8

Restricted and conserved T–cell repertoires involved in allorecognition of class II major histocompatibility complex. De Palma R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8836–40

Ancestral major histocompatibility complex DRB genes beget conserved patterns of localized polymorphisms. Gaur LK, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5380–3

Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)

Maintenance of pre–mRNA secondary structure by epistatic selection. Kirby DA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9047–51

DNA sequences of Alu elements indicate a recent replacement of the human autosomal genetic complement. Knight A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4360–4

Multiplex genotype determination at a large number of gene loci. Lin Z, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2582–7

Imprinting of the gene encoding a human cyclin–dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Matsuoka S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3026–30

Alignment of a 1.2–Mb chromosomal region from three strains of Rhodobacter capsulatus reveals a significantly mosaic structure. Nikolskaya T, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10609–13

On signal sequence polymorphisms and diseases of distribution. Rosenblum JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4471–3

Long, polymorphic microsatellites in simple organisms. Field D, et al. **Proc R Soc Lond B Biol Sci** 1996 Feb 22; 263(1367):209–15

Association study of bipolar disorder using a functional polymorphism (Ser311—>Cys) in the dopamine D2 receptor gene. Craddock N, et al. **Psychiatr Genet** 1995 Summer;5(2):63–5

Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1–q32. Lin MW, et al. **Psychiatr Genet** 1995 Fall;5(3):117–26

Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Pociot F, et al. **Scand J Immunol** 1995 Oct;42(4):501–4

Effect of polymorphism in the Drosophila regulatory gene Ultrabithorax on homeotic stability [see comments] Gibson G, et al. **Science** 1996 Jan 12;271(5246):200–3. Comment in: Science 1996 Jan 12;271(5246):160–1.

Selector genes, polymorphisms, and evolution [comment] Tautz D. **Science** 1996 Jan 12;271(5246):160–1. Comment on: Science 1996 Jan 12;271(5246):200–3.

Global patterns of linkage disequilibrium at the CD4 locus and modern human origins [see comments] Tishkoff SA, et al. **Science** 1996 Mar 8;271(5254):1380–7. Comment in: Science 1996 Mar 8;271(5254):1364.

Characterization of cDNA clones containing CCA trinucleotide repeats derived from human brain. Margolis RL, et al. **Somat Cell Mol Genet** 1995 Jul;21(4):279–84

Usefulness of dinucleotide polymorphism markers in genetic analysis of Duchenne's muscular dystrophy cases in Singapore. Lai PS, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:175–8

Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Basun H, et al. **Stroke** 1996 Aug;27(8):1310–5

Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Furuya K, et al. **Thorax** 1996 Aug;51(8):777–80

Beta 2 adrenoceptor polymorphisms: are they clinically important? [editorial] Hall IP. **Thorax** 1996 Apr;51(4):351–3

Role of Fc gamma RIIA gene polymorphism in human platelet activation by monoclonal antibodies. Bachelot C, et al. **Thromb Haemost** 1995 Dec;74(6):1557–63

An amino acid polymorphism in histidine–rich glycoprotein (HRG) explains 59% of the variance in plasma HRG levels. Hennis BC, et al. **Thromb Haemost** 1995 Dec;74(6):1497–50

Identification and genetic analysis of a common molecular variant of histidine–rich glycoprotein with a difference of 2kD in apparent molecular weight. Hennis BC, et al. **Thromb Haemost** 1995 Dec;74(6):1491–6

Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Nurden AT. **Thromb Haemost** 1995 Jul;74(1):345–51 (53 ref.)

The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor–1 (PAI–1) gene is associated with differences in plasma PAI–1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de l'nfarctus du Mycocarde. Ye S, et al. **Thromb Haemost** 1995 Sep;74(3):837–41

Normal function in vivo of a homozygotic polymorphism

in the human thyrotropin receptor. Cuddihy RM, et al. **Thyroid** 1995 Aug;5(4):255–7

Molecular analysis of HLA class II polymorphism in Croatians. Grubić Z, et al. **Tissue Antigens** 1995 Oct; 46(4):293–8

DQCAR microsatellite polymorphisms in three selected HLA class II–associated diseases. Mignot E, et al. **Tissue Antigens** 1995 Oct;46(4):299–304

Steroid 21–hydroxylase gene polymorphism in Addison's disease patients. Peterson P, et al. **Tissue Antigens** 1995 Jul;46(1):63–7

Heat shock protein 70 gene polymorphisms and multiple sclerosis. Ramachandran S, et al. **Tissue Antigens** 1995 Aug; 46(2):140–1 (18 ref.)

DNA markers in forensic medicine. Mayr WR. **Transfus Clin Biol** 1995;2(4):325–8 (4 ref.)

Polymorphism within the human anti–pig repertoire. Goldberg LC, et al. **Transplant Proc** 1996 Apr;28(2):549–50

HLA compatibility can be predicted by matching only three residues with outward oriented sidechains. Takemoto S, et al. **Transplant Proc** 1996 Jun;28(3):1264–6

Polymorphism in the number of genes encoding long–wavelength–sensitive cone pigments among males with normal color vision. Neitz M, et al. **Vision Res** 1995 Sep;35(17):2395–407

DNA recommendations––1994 report concerning further recommendations of the DNA Commission of the ISFH regarding PCR–based polymorphisms in STR (short tandem repeat) systems. **Vox Sang** 1995;69(1):70–1

Physiological and molecular characterization of flor yeasts: polymorphism of flor yeast populations. Martínez P, et al. **Yeast** 1995 Nov;11(14):1399–411

Use of the single strand conformation polymorphism method for rapid screening for mutations in the low density lipoprotein receptor gene in patients with familial hypercholesterolemia: effect on plasma lipid levels of different classes of mutations. Gudnason V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:6–8

Prochymosin polymorphism in calves of black–and–white cattle and their crosses with Simental bulls. Wiśliński M, et al. **Zentralbl Veterinarmed A** 1995 Aug;42(6):389–96

[Genetic polymorphism of properdin factor B in the Han population in Chengdu, China] Chen G, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):424–6 (Eng. Abstr.) **(Chi)**

[Mitochondrial DNA polymorphism in the Han, Miao, Buyi, and Shui ethnic groups from Guizhou province] Jin H, et al. **I Chuan Hsueh Pao** 1995;22(1):1–11 (Eng. Abstr.) **(Chi)**

[Apolipoprotein E polymorphism and Alzheimer disease] van der Weide J, et al. **Tijdschr Gerontol Geriatr** 1996 Apr; 27(2):73–7 (Eng. Abstr.) **(Dut)**

[Apolipoprotein E polymorphism and serum cholesterol levels in Finnish children and adolescents] Lehtimäki T, et al. **Duodecim** 1994;110(14):1313–9 **(Fin)**

[Alzheimer's disease and the association of genetic polymorphism of apolipoprotein E and liquor beta protein in Finns] Lehtimäki T, et al. **Duodecim** 1995;111(5):401–7 **(Fin)**

[Hypertrophic cardiomyopathy: practical application of genetic research] Guicheney P, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):569–71 (Eng. Abstr.) **(Fre)**

[Genetics of dilated cardiomyopathies] Sacrez A. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):591–3 (Eng. Abstr.) **(Fre)**

[Genes and obesity: the ob gene product and the beta3–adrenergic receptor] Ferre P. **Diabetes Metab** 1996 Feb;22(1):77–9 **(Fre)**

[Study of class I HLA polymorphism in the Tunisian population] Hmida S, et al. **Transfus Clin Biol** 1995; 2(5):381–6 (Eng. Abstr.) **(Fre)**

[A polymorphism study of the DNA extracted from dental tissues] Dell'Osso G, et al. **Minerva Stomatol** 1995 May; 44(5):205–9 (Eng. Abstr.) **(Ita)**

[Analysis of a genetic factor of metal allergy––polymorphism of HLA–DR, –DQ gene] Saito K. **Kokubyo Gakkai Zasshi** 1996 Mar;63(1):53–69 (Eng. Abstr.) **(Jpn)**

[Effect of vitamin D receptor gene polymorphism and lifestyle on bone mineral density and bone mineral density decrement rate] Yamagata Z, et al. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):968–75 (Eng. Abstr.) **(Jpn)**

[A study on the rhodopsin gene in Japanese retinitis pigmentosa––screening of mutation by restriction endonucreases and frequencies of DNA polymorphisms] Kawano H, et al. **Nippon Ganka Gakkai Zasshi** 1995 Oct; 99(10):1151–7 (Eng. Abstr.) **(Jpn)**

[Sequence polymorphism of mitochondrial DNA and its forensic application] Yoshii T, et al. **Nippon Hoigaku Zasshi** 1995 Aug;49(4):242–50 (Eng. Abstr.) **(Jpn)**

[Association of cytochrome P–450 1A1 (CYP1A1) gene polymorphism to smoking status and hematologic findings] Shinozaki S, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr; 43(4):308–14 (Eng. Abstr.) **(Jpn)**

[Apolipoprotein E polymorphism in Alzheimer's disease] Shimohama S. **Nippon Ronen Igakkai Zasshi** 1996 Mar; 33(3):173–7 **(Jpn)**

[Application of molecular biology to occupational health field––the frequency of gene polymorphism of cytochrome P450 1A1 and glutathione S–transferase M1 in patients with lung, oral and urothelial cancer] Katoh T. **Sangyo Ika Daigaku Zasshi** 1995 Dec 1;17(4):271–8 (Eng. Abstr.) **(Jpn)**

[Genetic polymorphism of a human gene locus containing the tumor necrosis factor gene: new markers of susceptibility to multiple sclerosis] Sudomoina MA, et al. **Dokl Akad Nauk** 1995 Jul;343(1):119–22 **(Rus)**

[Genetic divergence of certain indigenous and commercial breeds of Eurasian cattle (Bos taurus)] Bannikova LV, et al. **Genetika** 1995 Jul;31(7):971–82 (Eng. Abstr.) **(Rus)**

[Use of the pGB725 probe containing poly–TG–repeats for detecting polymorphic microsatellite loci in the genome of the chicken Gallus gallus domesticus] Churkina IV, et al. **Genetika** 1995 Sep;31(9):1189–93 (Eng. Abstr.) **(Rus)**

[Polymorphism of mitochondrial DNA region V in native and migrant inhabitants of Northeast Asia] Maliarchuk BA, et al. **Genetika** 1995 Sep;31(9):1308–13 (Eng. Abstr.) **(Rus)**

[Inter–tissue differences in the C–polymorphic regions of human embryo chromosomes: possible role of DNA methylation] Nazarenko SA, et al. **Genetika** 1995 Nov; 31(11):1578–81 (Eng. Abstr.) **(Rus)**

[Fingerprinting of potato species and cultivar using RAPD–PCR] Oranisian AS, et al. **Genetika** 1996 Mar; 32(3):448–51 (Eng. Abstr.) **(Rus)**

[Polymorphism of biochemical markers in European bison (bison bonasus)] Sipko TP, et al. **Genetika** 1996 Mar; 32(3):400–5 (Eng. Abstr.) **(Rus)**

[Genetic polymorphism in barley detected by arbitrary primers] Sivolap IuM, et al. **Genetika** 1995 Oct; 31(10):1358–64 (Eng. Abstr.) **(Rus)**

[DNA polymorphism of the BoLA–DRB3 gene in cattle in connection with resistance and susceptibility to leukemia] Sulimova GE, et al. **Genetika** 1995 Sep;31(9):1294–9 (Eng. Abstr.) **(Rus)**

[Polymorphism at codon 117 of the granulocyte–macrophage colony–stimulating factor (GM–CSF) gene] Tagiev AF, et al. **Genetika** 1995 Oct;31(10):1370–4 (Eng. Abstr.) **(Rus)**

[Polymorphism of enzymes involved in drug metabolism: gene structure and enzymatic activity] Krynetskii EI. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):33–42 (58 ref.) **(Rus)**

[Intragenomic polymorphism of ribosomal RNA genes from human chromosome 13] Kuprianova NS, et al. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):51–60 **(Rus)**

[Genetic polymorphism and immune diseases] Gómez de la Concha E. **An R Acad Nac Med (Madr)** 1995;112(3):521–31 **(Spa)**

GENETICS

Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Stengård JH, et al. **Acta Neurol Scand** 1995 Oct;92(4):297–8

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Alcohol–metabolizing enzyme polymorphisms and alcoholism in Japan. Maezawa Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):951–4

Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Novoradovsky A, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1105–10

Association of alcoholism with the N–glycosylation polymorphism of pseudodeficient human arylsulfatase A. Park DS, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):228–33

ADH2 gene polymorphisms are determinants of alcohol pharmacokinetics. Thomasson HR, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1494–9

mtDNA provides the first known marker distinguishing proto–Indians from the other Caucasoids; it probably predates the diversification between Indians and Orientals. Passarino G, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):121–6

Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Okuizumi K, et al. **Ann Neurol** 1996 Aug;40(2):251–4

Genetic studies in Alzheimer's disease with an NACP/alpha–synuclein polymorphism. Xia Y, et al. **Ann Neurol** 1996 Aug;40(2):207–15

The distribution of plasminogen (PLG) polymorphism in the Namibian !Kung San and Kavango populations. Nabulsi AJ, et al. **Anthropol Anz** 1996 Jun;54(2):117–20

Immune–genetic study of the new populations of Sierra Morena (Spain) through HLA polymorphisms of class I. Sánchez García F, et al. **Anthropol Anz** 1995 Sep; 53(3):209–19

Glyoxalase 1 (GLO1) polymorphism in eight geographical regions of Turkey. Togan I, et al. **Anthropol Anz** 1996 Jun; 54(2):121–4

Synergy between T cell receptor beta gene polymorphism and HLA–DR4 in susceptibility to rheumatoid arthritis. Mu H, et al. **Arthritis Rheum** 1996 Jun;39(6):931–7

An improved method of data collection for transferrin polymorphism in coho salmon (Oncorhynchus kisutch). Van Doornik DM, et al. **Biochem Genet** 1995 Aug; 33(7–8):257–60

No association between alcoholism and multiple polymorphisms at the dopamine D2 receptor gene (DRD2) in three distinct Taiwanese populations. Lu RB, et al. **Biol Psychiatry** 1996 Mar 15;39(6):419–29

Vitamin D receptor polymorphism, bone mineral density, and osteoporotic vertebral fracture: studies in a UK population. Houston LA, et al. **Bone** 1996 Mar;18(3):249–52

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Wanwimolruk S, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):166–9

Random amplified polymorphic DNA markers of the Brassica alboglabra chromosome of a B. campestris–alboglabra addition line. Jørgensen RB, et al. **Chromosome Res** 1996 Feb;4(2):111–4

Polymorphisms in drug–metabolizing enzymes as modifiers of cancer risk. Spurr NK, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1864–9

Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Nagi DK, et al. **Diabet Med** 1995 Nov;12(11):997–1001

A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population. Klausen IC, et al. **Eur J Epidemiol** 1995 Oct;11(5):563–8

Non–syndromic deafness associated with a mutation and a polymorphism in the mitochondrial 12S ribosomal RNA gene in a large Zairean pedigree. Matthijs G, et al. **Eur J Hum Genet** 1996;4(1):46–51

Efficient immune responses in mice lacking N–region diversity. Gilfillan S, et al. **Eur J Immunol** 1995 Nov; 25(11):3115–22

Strain typing of Lentinula edodes by random amplified polymorphic DNA assay. Zhang Y, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):17–20

Presymptomatic diagnosis of familial adenomatous polyposis using intragenic polymorphisms and CA repeats flanking the APC gene. Hayes VM, et al. **Genet Couns** 1996;7(1):1–7

Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489–97 (29 ref.)

Butyrylcholinesterase polymorphisms (BCHE and CHE2 loci) in Brazilian Indian and admixed populations. Alcântara VM, et al. **Hum Biol** 1995 Oct;67(5):717–26

The tetranucleotide repeat polymorphism D21S1245 demonstrates hypermutability in germline and somatic cells. Talbot CC Jr, et al. **Hum Mol Genet** 1995 Jul;4(7):1193–9

Rapid detection of point mutations and polymorphisms of the alpha–globin genes by DGGE and SSCA. Harteveld KL, et al. **Hum Mutat** 1996;7(2):114–22

Advantages of RT–PCR and denaturing gradient gel electrophoresis for analysis of genomic imprinting: detection of new mouse and human expressed polymorphisms. Nakao M, et al. **Hum Mutat** 1996; 7(2):144–8

Evolution of major histocompatibility complex polymorphisms and T–cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33–62 (96 ref.)

Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Oyama T, et al. **Int Arch Occup Environ Health** 1995; 67(4):253–6

Structural variation of novel alleles at the Hum vWA and Hum FES/FPS short tandem repeat loci. Barber MD, et al. **Int J Legal Med** 1995;108(1):31–5

Rapid communication: bovine dinucleotide repeat polymorphisms ABS010, ABS011, ABS012, ABS013, and ABS014. Pfister–Genskow MA, et al. **J Anim Sci** 1995 Oct; 73(10):3189

Microsatellite DNA polymorphism analysis in a case of an illegal cattle purchase. Beamonte D, et al. **J Forensic Sci** 1995 Jul;40(4):692–4

Detection of D1S80 (pMCT118) locus polymorphism using semi–nested polymerase chain reaction in skeletal remains. Honda K, et al. **J Forensic Sci** 1995 Jul;40(4):637–40

Validation of multiplex polymorphic STR amplification sets developed for personal identification applications. Micka KA, et al. **J Forensic Sci** 1996 Jul;41(4):582–90

Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin–angiotensin system genes. Dudley C, et al. **J Hypertens** 1996 Feb;14(2):259–62

Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine. Broyer M, et al. **J Inherit Metab Dis** 1996;19(1):65–75

Debrisoquine hydroxylase polymorphism in Leber's hereditary optic neuropathy [letter] Chalmers RM, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):588

Genetic susceptibility to multiple sclerosis may be linked to polymorphism of the myelin basic protein gene. Ibsen SN, et al. **J Neurol Sci** 1995 Jul;131(1):96–8

Neuropathological evaluation and apolipoprotein E gene polymorphism analysis in diffuse Lewy body disease. Kawanishi C, et al. **J Neurol Sci** 1996 Mar;136(1–2):140–2

Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease. Norris CF, et al. **J Pediatr** 1996 Jun;128(6):813–9

Three dinucleotide repeat polymorphisms at the D8S1217, D8S1220, and D8S1221 loci. Mitsuda N, et al. **Jpn J Hum Genet** 1995 Sep;40(3):283–5

Two dinucleotide repeat polymorphisms at the D8S1442 and D8S1443 loci. Nakura J, et al. **Jpn J Hum Genet** 1995 Sep; 40(3):281–2

A highly polymorphic dinucleotide repeat at the D8S1222

locus. Ye L, et al. **Jpn J Hum Genet** 1995 Sep;40(3):287–8
Chromosome–length polymorphism in fungi. Zolan ME. **Microbiol Rev** 1995 Dec;59(4):686–98 (145 ref.)
Genetic bases of the chromosomal polymorphism of industrial yeasts. Benítez T, et al. **Microbiologia** 1995 Sep; 11(3):383–5
Molecular characterization of Fanconi anaemia group C (FAC) gene polymorphisms. Savoia A, et al. **Mol Cell Probes** 1996 Jun;10(3):213–8
The alpha–adducin polymorphism: a paradigm to analyse the genetics of primary hypertension [editorial] Bianchi G, et al. **Nephrol Dial Transplant** 1995;10(6):763–6
Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Siddons MA, et al. **Neurosci Lett** 1996 Apr 12;208(1):65–8
The maintenance of genetic polymorphism in small island populations: large mammals in the Hebrides. Pemberton JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Jun 29;351(1341):745–52
A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. Vanyukov MM, et al. **Psychiatry Res** 1995 Nov 29; 59(1–2):35–41
Angiotensin–converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Catto A, et al. **Stroke** 1996 Mar;27(3):435–40
Patterns of genetic polymorphism maintained by fluctuating selection with overlapping generations. Ellner S, et al. **Theor Popul Biol** 1996 Aug;50(1):31–65
Thyroperoxidase microsatellite polymorphism in thyroid diseases. Pirro MT, et al. **Thyroid** 1995 Dec;5(6):461–4
Use of the single strand conformation polymorphism method for rapid screening for mutations in the low density lipoprotein receptor gene in patients with familial hypercholesterolemia: effect on plasma lipid levels of different classes of mutations. Gudnason V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:6–8
[Genetic polymorphism in Gilbert–Meulengracht syndrome (GMS)] Fengler JD, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:81–2 (Eng. Abstr.) **(Ger)**
[Does an association between angiotensin I converting enzyme gene polymorphism and the prevalence of diabetic nephropathy in patients with diabetes type II exist?] Strojek K, et al. **Pol Arch Med Wewn** 1995 Sep;94(3):214–8 (Eng. Abstr.) **(Pol)**
[Analysis of angiotensin converting enzyme (ACE) polymorphism in patients with myocardial infarction in the Polish population] Trzeciak T, et al. **Pol Arch Med Wewn** 1996 Jan;95(1):35–40 (Eng. Abstr.) **(Pol)**
[The DNA polymorphism in the inhabitants of Ukraine detected with an M13 phage–based probe] Maliuta SS, et al. **Tsitol Genet** 1996 Jan–Feb;30(1):31–5 (Eng. Abstr.) **(Rus)**
[Alcohol dehydrogenase polymorphism and the genotypic adaptation of D. melanogaster to the action of selective factors] Totskii VN, et al. **Tsitol Genet** 1995 Nov–Dec; 29(6):54–9 (Eng. Abstr.) **(Rus)**
[Paternity study applying DNA polymorphism: evaluation of methods traditionally used in Chile] Armanet L, et al. **Rev Med Chil** 1995 May;123(5):560–6 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

A functionally significant allelic polymorphism in a T cell receptor V beta gene segment. Vessey SJ, et al. **Eur J Immunol** 1996 Jul;26(7):1660–3
Fluorescent detection of microsatellite polymorphisms: properdin deficiency linked to PFC microsatellite. Agardi D, et al. **Exp Clin Immunogenet** 1995;12(2):111–4
DRB1*1316: evolutionary and functional implications of a novel polymorphism at codon 86. Dinauer DM, et al. **Hum Immunol** 1996 Jan;45(1):37–41
Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis factor genes. McManus R, et al. **Hum Immunol** 1996 Jan;45(1):24–31
Microsatellite polymorphism between the tumor necrosis factor and HLA–B genes in Behçet's disease. Mizuki N, et al. **Hum Immunol** 1995 Jun;43(2):129–35
Genetic polymorphism of the human tumor necrosis factor region in insulin–dependent diabetes mellitus. Linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Monos DS, et al. **Hum Immunol** 1995 Oct; 44(2):70–9
Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA–B53. Smith KJ, et al. **Immunity** 1996 Mar; 4(3):215–28
The origins of HLA–A,B,C polymorphism. Parham P, et al. **Immunol Rev** 1995 Feb;143:141–80 (57 ref.)
MHC diversity and selection. Takahata N. **Immunol Rev** 1995 Feb;143:225–47 (43 ref.)
Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249–62 (54 ref.)
Structure and expression of a divergent canine class I gene. Burnett RC, et al. **J Immunol** 1995 Nov 1;155(9):4278–85
A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. de Haas M, et al. **J Immunol** 1996 Apr 15; 156(8):3948–55
Biotinylation of cell surface MHC molecules: a complementary tool for the study of MHC class II polymorphism in cattle. Schuberth HJ, et al. **J Immunol Methods** 1996 Jan 16;189(1):89–98
Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Ishihara M, et al. **Tissue Antigens** 1995 Jul; 46(1):59–62
Polymorphism in the LMP2 and LMP7 genes and adult rheumatoid arthritis: no relationship with disease susceptibility or outcome. Maksymowych WP, et al. **Tissue Antigens** 1995 Aug;46(2):136–9
Comparative analysis of HLA polymorphism at the serologic and molecular level in Moroccan and Ashkenazi Jews. Roitberg–Tambur A, et al. **Tissue Antigens** 1995 Aug; 46(2):104–10

PHYSIOLOGY

Debrisoquine/sparteine–type polymorphic drug metabolism in wild Clethrionomys rufocanus. Hoshi H, et al. **Drug Metab Dispos** 1995 Nov;23(11):1301–3

POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

Detection of allele loss on chromosome 16q in DNA isolated from fine needle aspiration specimens of breast tumors. A simulation study using surgically resected specimens. Tsuda H, et al. **Acta Cytol** 1996 Jul–Aug;40(4):625–30
Apolipoprotein AI–CIII–AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Rigoli L, et al. **Acta Diabetol** 1995 Dec;32(4):251–6
The use of arms PCR and RFLP analysis in identifying genetic profiles of virulent, attenuated or vaccine strains of TGEV and PRCV. Lai CH, et al. **Adv Exp Med Biol** 1995;380:243–50
Nucleotide sequence and restriction fragment length polymorphism analysis of the long terminal repeat of human T cell leukemia virus type II. Eiraku N, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):625–36
Analysis of CA repeats in first intron of class I ADH gene in Long–Evans Cinnamon rats developing fatal intoxication after ethanol intake. Katsuki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):33A–35A
Effects of cimetidine on blood ethanol levels after alcohol ingestion and genetic polymorphisms of sigma–alcohol dehydrogenase in Japanese. Kawashima O, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):36A–39A
Association of restriction fragment–length polymorphisms in the alcohol dehydrogenase 2 gene with alcoholic brain atrophy. Maezawa Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):29A–32A
Angiotensin–converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Pfeufer A, et al. **Am J Cardiol** 1996 Aug 1;78(3):362–4
Factor V R506Q gene mutation analysis by PCR–RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Voelkerding KV, et al. **Am J Clin Pathol** 1996 Jul;106(1):100–6
Molecular definition of red cell Rh haplotypes by tightly linked SphI RFLPs. Huang CH, et al. **Am J Hum Genet** 1996 Jan;58(1):133–42
Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Inayama Y, et al. **Am J Med Genet** 1996 Feb 16;67(1):103–5
No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O–methyltransferase activity. Daniels JK, et al. **Am J Psychiatry** 1996 Feb;153(2):268–70
Discrimination of all members of the Anopheles punctulatus complex by polymerase chain reaction—restriction fragment length polymorphism analysis. Beebe NW, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):478–81
Determination of human NAT2 acetylator genotype by restriction fragment–length polymorphism and allele–specific amplification. Doll MA, et al. **Anal Biochem** 1995 Nov 1;231(2):413–20
Interlaboratory comparison of autoradiographic DNA profiling measurements. 3. Repeatability and reproducibility of restriction fragment length polymorphism band sizing, particularly bands of molecular size > 10K base pairs. Stolorow AM, et al. **Anal Chem** 1996 Jun 1;68(11):1941–7
TaqI RFLP at the LIPC locus in baboons. Cole SA, et al. **Anim Genet** 1996 Feb;27(1):63
MspI RFLP at the CETP locus in baboons. Cole SA, et al. **Anim Genet** 1996 Feb;27(1):63
A TaqI polymorphism at the porcine arachidonate 12–lipoxygenase (ALOX12) locus. Coscelli MB, et al. **Anim Genet** 1995 Dec;26(6):446–7
A PstI RFLP at the porcine beta–myosin heavy chain (MYHCB) locus. Davoli R, et al. **Anim Genet** 1995 Oct; 26(5):374
An EcoRI polymorphism at the amylase 1 (AMY1) locus in cattle. Elduque C, et al. **Anim Genet** 1995 Oct;26(5):367
RFLPs at the amylase 1 locus in cattle. Elduque C, et al. **Anim Genet** 1996 Jun;27(3):213
The equine MSH–R TaqI RFLP is not informative for hair colour in Arabian horses. Kriegesmann B, et al. **Anim Genet** 1996 Feb;27(1):64
PCR/RFLP markers in the canine gamma–D–crystallin gene. Shibuya H, et al. **Anim Genet** 1995 Dec;26(6):445–6
Restriction fragment length polymorphism in amplification products of the bovine butyrophilin gene: assignment of bovine butyrophilin to bovine chromosome 23. Taylor C, et al. **Anim Genet** 1996 Jun;27(3):183–5
A Bgl/II RFLP at the porcine calpastatin (CAST) locus. Zambonelli P, et al. **Anim Genet** 1995 Oct;26(5):373
Mapping the soluble angiotensin binding protein (ABP1) locus to porcine chromosome 16. Zhang W, et al. **Anim Genet** 1995 Oct;26(5):337–9
Arg519–Cys mutation in COL2A1: evidence for multiple founders. Bleasel JF, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:215–8
Polymorphism and utilization of human VH Genes. Milner EC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:50–61 (23 ref.)
Ethnic differences in VH gene polymorphism. Sasso EH, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:72–3
Molecular differentiation of Keratinomyces (Trichophyton) species. Guillamón JM, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):223–7
Molecular characterization and identification of Saprolegnia by restriction analysis of genes coding for ribosomal RNA. Molina FI, et al. **Antonie Van Leeuwenhoek** 1995 Jul; 68(1):65–74
A computer–simulated restriction fragment length polymorphism analysis of bacterial small–subunit rRNA genes: efficacy of selected tetrameric restriction enzymes for studies of microbial diversity in nature. Moyer CL, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2501–7
Molecular analysis of environmental and human isolates of Salmonella typhi. Thong KL, et al. **Appl Environ Microbiol** 1996 Jan;62(1):271–4
A chemiluminescence–based detection system for human DNA quantitation and restriction fragment length polymorphism (RFLP) analysis. Giusti AM, et al. **Appl Theor Electrophor** 1995;5(2):89–98
SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208–21
Detection of carriers of haemophilia A: use of bioassays and restriction fragment length polymorphisms (RFLP). Rudzki Z, et al. **Aust N Z J Med** 1996 Apr;26(2):195–205
T–cell receptor polymorphisms in Tlingit Indians with rheumatoid arthritis. Charmley P, et al. **Autoimmunity** 1994; 19(4):247–51
Detection of Mycoplasma gallisepticum, M. synoviae, and M. iowae by multi–species polymerase chain reaction and restriction fragment length polymorphism. Garcia M, et al. **Avian Dis** 1995 Jul–Sep;39(3):606–16
Avian mycoplasma identification using polymerase chain reaction amplicon and restriction fragment length polymorphism analysis. Lauerman LH, et al. **Avian Dis** 1995 Oct–Dec;39(4):804–11
An Mse I RFLP in the human CTLA4 promotor. Deichmann K, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):817–8
Instability at the H–ras minisatellite is associated with the spontaneous abortion of the embryo. Kiaris H, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):788–92
Detection and analysis of the human D4 dopamine receptor gene (DRD4) sequence variant in the Japanese and Mongolian population. Nakatome M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):773–6
A novel donor splice site mutation in the glycogen debranching enzyme gene is associated with glycogen storage disease type III. Okubo M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):493–9
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II. Shieh JJ, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):322–6
The atrial natriuretic peptide gene in patients with familial primary open–angle glaucoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):221–5
Polymorphisms and probable lack of mutation in a human mutT homolog, hMTH1, in hereditary nonpoliposis colorectal cancer. Wu C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1239–45
Classic steroid 11 beta–hydroxylase deficiency caused by a C—>G transversion in exon 7 of CYP11B1. Yang LX, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):723–8
Heterogeneity of the human Secretor alpha(1,2)fucosyltransferase gene among Lewis(a+b–) non–secretors. Yu LC, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):390–4
Identification of polymorphism at the glutathione S–transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Inskip A, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):713–6
Analysis of mutations at the adenine phosphoribosyltransferase gene locus in wild–type and thymidine kinase–deficient Friend cells. Hyland PL, et al. **Biochem Soc Trans** 1996 Feb;24(1):105S
Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Meyer T, et al. **Biotechniques** 1995 Oct;19(4):632–9
The major histocompatibility complex region marked by HSP70–1 and HSP70–2 variants is associated with clozapine–induced agranulocytosis in two different ethnic

groups. Corzo D, et al. **Blood** 1995 Nov 15;86(10):3835–40

Restriction fragment length polymorphism (RFLP) analysis and tuberculosis epidemiology. Gómez Marín JE, et al. **Bull Pan Am Health Organ** 1995 Sep;29(3):226–36

Restriction fragment length polymorphism of the apolipoprotein B gene and response to dietary fat and cholesterol. Abbey M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:79G–85G

Detection of additional restriction fragment length polymorphisms among the weakly virulent (nonaggressive) and highly virulent (aggressive) isolates of Leptosphaeria maculans. Patterson NA, et al. **Can J Microbiol** 1995 Dec; 41(12):1135–41

L-MYC allelotype in renal cell carcinoma. Presti JC Jr, et al. **Cancer Genet Cytogenet** 1996 May;88(1):66–8

Frequent mutations of Ki-ras codon 12 in N-bis (2-hydroxypropyl)-nitrosamine-initiated thyroid, kidney and lung tumors in Wistar rats. Kitahori Y, et al. **Cancer Lett** 1995 Sep 25;96(2):155–61

The reliability of the differential polymerase chain reaction compared to restriction fragment length polymorphism for the detection of gene loss in primary tumors. Sugawa N, et al. **Cancer Lett** 1996 Feb 6;99(2):139–46

Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Martinsson T, et al. **Cancer Res** 1995 Dec 1;55(23):5681–6

Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Kihara M, et al. **Carcinogenesis** 1995 Oct;16(10):2331–6

Distribution of an NcoI polymorphism in the lymphotoxin alpha gene in Dutch patients with inflamatory bowel diseases. Xia B, et al. **Chin Med J (Engl)** 1995 Oct; 108(10):739–42

Restriction fragment length polymorphism (RFLP) analysis of genomic DNA of 5 strains of Trichinella spiralis in China. Wang H, et al. **Chin Med Sci J** 1995 Sep;10(3):131–5

Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of coronary artery disease and diabetes. Wang XL, et al. **Circulation** 1996 Apr 1; 93(7):1339–45

Apolipoprotein B 3' hypervariable repeat genotype: association with plasma lipid concentration, coronary artery disease, and other restriction fragment polymorphisms. Wu JH, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):927–32

A highly informative BamHI RFLP in the type IV collagen alpha 5 chain gene (COL4A5). Chan SY, et al. **Clin Genet** 1995 May;47(5):276–7

A TaqI RFLP in the type IV collagen alpha 5 chain gene (COL4A5) with the rare allele more frequently found in seven Chinese Alport syndrome patients. Chan SY, et al. **Clin Genet** 1995 May;47(5):278–9

A TaqI polymorphism in a gene belonging to the human apoprotein(a)–plasminogen gene family on the telomeric region of chromosome 6 (6q26–27). Magnaghi P, et al. **Clin Genet** 1995 Jun;47(6):330

A frequent HhaI polymorphism in intron 9 of the low density lipoprotein receptor gene detected by the denaturing gradient gel electrophoresis technique. Nissen H, et al. **Clin Genet** 1995 Oct;48(4):221–2

Association analyses of NsiI RFLP of human insulin receptor gene in hypertensives. Schrader AP, et al. **Clin Genet** 1996 Feb;49(2):74–8

Comprehensive typing of HLA-DPB1 alleles by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). Sengar DP, et al. **Clin Invest Med** 1995 Dec; 18(6):465–72

The chromosomal region which includes the recombinator cog in Neurospora crassa is highly polymorphic. Yeadon PJ, et al. **Curr Genet** 1995 Jul;28(2):155–63

Characterization of polymorphisms of an interleukin 1 receptor type 1 gene (IL1RI) promotor region (P2) and their relation to insulin-dependent diabetes mellitus (IDDM). The Danish Study Group of Diabetes in Childhood. Bergholdt R, et al. **Cytokine** 1995 Oct; 7(7):727–33

Lyme disease in Japan. Analysis of Borrelia species using rRNA gene restriction fragment length polymorphism. Hashimoto Y, et al. **Dermatology** 1995;191(3):193–8

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Gremlich S, et al. **Diabetes** 1995 Oct;44(10):1202–8

Insulin gene 5' flanking polymorphism. Length of class 1 alleles in number of repeat units. McGinnis RE, et al. **Diabetes** 1995 Nov;44(11):1296–302

A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the association with diabetes mellitus [see comments] Fujisawa T, et al. **Diabetologia** 1995 Aug; 38(8):983–5. Comment in: Diabetologia 1996 Feb;39(2):248.

HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. Tao T, et al. **Diabetologia** 1995 Aug;38(8):942–7

DNA profiling of banana and plantain cultivars using random amplified polymorphic DNA (RAPD) and restriction fragment length polymorphism (RFLP) markers. Bhat KV, et al. **Electrophoresis** 1995 Sep;16(9):1736–45

Simple protocols for typing forensic biological evidence: chemiluminescent detection for human DNA quantitation and restriction fragment length polymorphism (RFLP) analyses and manual typing of polymerase chain reaction (PCR) amplified polymorphisms. Budowle B, et al. **Electrophoresis** 1995 Sep;16(9):1559–67

Highly repetitive DNA sequence elements from Orseolia oryzae (Wood-Mason) discriminate between the Indian isolates and the Asian rice gall midge and the paspalum midge. Ehtesham NZ, et al. **Electrophoresis** 1995 Sep; 16(9):1762–5

Polymorphic human specific Alu insertions as markers for human identification. Novick GE, et al. **Electrophoresis** 1995 Sep;16(9):1596–601

DNA polymorphism analysis in five endangered species of Meconopsis (Himalayan poppy) using multi-copy sequence-based probes. Sulaiman IM, et al. **Electrophoresis** 1995 Sep;16(9):1746–9

Genotyping of human deoxyribonuclease I polymorphism by the polymerase chain reaction. Yasuda T, et al. **Electrophoresis** 1995 Oct;16(10):1889–93

An epidemiological study of Vibrio cholerae O1 in the Australian environment based on rRNA gene polymorphisms. Desmarchelier PM, et al. **Epidemiol Infect** 1995 Dec;115(3):435–46

Analysis of methicillin-resistant and methicillin-susceptible Staphylococcus aureus by a molecular typing method based on coagulase gene polymorphisms. Kobayashi N, et al. **Epidemiol Infect** 1995 Dec;115(3):419–26

Major histocompatibility complex class II and complement polymorphisms in postpartum thyroiditis. Parkes AB, et al. **Eur J Endocrinol** 1996 Apr;134(4):449–53

Multiplex ARMS-PCR-RFLP method for high-resolution typing of HLA-DRB1. Mitsunaga S, et al. **Eur J Immunogenet** 1995 Oct;22(5):371–92

PVU II polymorphism of LST-1 (leucocyte specific transcript-1) in type I diabetes mellitus, Graves' disease and healthy controls. Rau H, et al. **Eur J Immunogenet** 1995 Jun;22(3):277–82

HLA-DQA1 and -DQB1 genotyping by PCR-RFLP, heteroduplex and homoduplex analysis. Teutsch SM, et al. **Eur J Immunogenet** 1996 Apr;23(2):107–20

A novel TaqI/DQA RFLP associated with HLA-DR9, DQ9 (DQA1*0302). Vilches C, et al. **Eur J Immunogenet** 1995 Jun;22(3):261–4

Immunoglobulin allotypes and RFLPs in disease association. Propert D. **Exp Clin Immunogenet** 1995;12(3):198–205 (42 ref.)

Phylogenetic resolution of Morchella, Verpa, and Disciotis [Pezizales: Morchellaceae] based on restriction enzyme analysis of the 28S ribosomal RNA gene. Bunyard BA, et al. **Exp Mycol** 1995 Sep;19(3):223–33

Diversity of Trypanosoma cruzi stocks and clones derived from Chagas disease patients. II. Isozyme and RFLP characterizations. Lauria-Pires L, et al. **Exp Parasitol** 1996 Mar;82(2):182–90

Minisatellites corresponding to the human polycore probes 33.6 and 33.15 in the genome of the most 'primitive' known eukaryote Giardia lamblia. Carnaby S, et al. **Gene** 1995 Dec 1;166(1):167–72

Polymorphism of the mouse E2A gene due to an intronic deletion of 536 bp. Marlow SA, et al. **Gene** 1996 Feb 12; 168(2):143–9

Apolipoprotein B gene DNA polymorphisms (EcoRI and MspI) and serum lipid levels in the Serbian healthy population: interaction of rare alleles and smoking and cholesterol levels. Glišić S, et al. **Genet Epidemiol** 1995; 12(5):499–508

Restriction fragment length polymorphisms in polymerase chain reaction amplified ribosomal DNAs of three Trichogramma (Hymenoptera: Trichogrammatidae) species. Sappal NP, et al. **Genome** 1995 Jun;38(3):419–25

Genomic organization of 57 ribosomal protein genes in rice (Oryza sativa L.) through RFLP mapping. Wu J, et al. **Genome** 1995 Dec;38(6):1189–200

Chromosomal assignment of four testis-expressed mouse genes from a new family of transmembrane proteins (ADAMs) involved in cell-cell adhesion and fusion. Cho C, et al. **Genomics** 1996 Jun 15;34(3):413–7

Characterization of human lymphoid cell lines GM9947 and GM9948 as intra- and interlaboratory reference standards for DNA typing. Frégeau CJ, et al. **Genomics** 1995 Jul 20;28(2):184–97

Index, comprehensive microsatellite, and unified linkage maps of human chromosome 14 with cytogenetic tie points and a telomere microsatellite marker. Pandit SD, et al. **Genomics** 1995 Oct 10;29(3):653–64

Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. Yamauchi M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1136–42

Allele and haplotype frequency distribution of the EcoRI, RsaI, and MspI COL1A2 RFLPs among various human populations. Pepe G, et al. **Hum Biol** 1995 Dec;67(6):905–20

A new XmnI polymorphism in the regulatory region of the corticotropin releasing hormone gene. Baerwald CG, et al. **Hum Genet** 1996 May;97(5):697–8

Analysis of the BglI restriction fragment length polymorphism in the human factor VIII gene using "virtual PCR"—a novel approach employing the polymerase chain reaction in the absence of sequence information for the locus. Bowen DJ, et al. **Hum Genet** 1996 Aug;98(2):219–22

Genotype-phenotype correlation in a series of 167 deletion and non-deletion patients with Prader-Willi syndrome. Gillessen-Kaesbach G, et al. **Hum Genet** 1995 Dec; 96(6):638–43

A novel 5'-upstream mutation in the factor XII gene is associated with a TaqI restriction site in an Alu repeat in factor XII-deficient patients. Hofferbert S, et al. **Hum Genet** 1996 Jun;97(6):838–41

Identification of the nucleotide substitution that generates the fourth polymorphic site in human deoxyribonuclease I (DNase I). Iida R, et al. **Hum Genet** 1996 Oct;98(4):415–8

Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Kauma H, et al. **Hum Genet** 1996 Feb;97(2):156–62

Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure. Ko YL, et al. **Hum Genet** 1996 May; 97(5):585–90

Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. Kozák L, et al. **Hum Genet** 1995 Oct;96(4):472–6

Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Tishkoff SA, et al. **Hum Genet** 1996 Jun;97(6):759–64

Human desmin gene: cDNA sequence, regional localization and exclusion of the locus in a familial desmin-related myopathy. Vicart P, et al. **Hum Genet** 1996 Oct;98(4):422–9

Linkage disequilibrium between two loci (5' untranslated exon 1 and intron 5-DdeI) of the antithrombin III gene in three ethnic groups in Singapore. Liu Y, et al. **Hum Hered** 1995 Jul-Aug;45(4):192–8

Five restriction fragment length polymorphisms of the APOA1-C3 gene and their influence on lipids and apolipoproteins in healthy Chinese. Saha N, et al. **Hum Hered** 1995 Nov-Dec;45(6):303–10

Placental and germ cell alkaline phosphatase RFLPs and haplotypes associated with spontaneous abortion. Wennberg C, et al. **Hum Hered** 1995 Sep-Oct;45(5):272–7

The 8.5-kb PstI allele of the stress protein gene, Hsp70-2: an independent risk factor for systemic lupus erythematosus in African Americans? Jarjour W, et al. **Hum Immunol** 1996 Jan;45(1):59–63

Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. Shamsher MK, et al. **Hum Mol Genet** 1995 Oct;4(10):1875–81

Hind III genomic polymorphism of the C3b receptor (CR1) in patients with SLE: low erythrocyte CR1 expression is an acquired phenomenon. Kumar A, et al. **Immunol Cell Biol** 1995 Oct;73(5):457–62

Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Oyama T, et al. **Int Arch Occup Environ Health** 1995; 67(4):253–6

Detection of Epstein-Barr virus genome in squamous cell carcinomas of the larynx. Kiaris H, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):211–5

Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Nollau P, et al. **Int J Cancer** 1996 May 3;66(3):332–6

Identification of the antithrombin III Kyoto mutation by restriction fragment length polymorphism analysis. Masuda H, et al. **Int J Hematol** 1995 Jun;61(4):197–204

Spanish population data on 7 tetrameric short tandem repeat loci. Martin P, et al. **Int J Legal Med** 1995;108(3):145–9

Short tandem repeat (STR) system HumD21S11: population genetic study on an Italian population. Piccinini A, et al. **Int J Legal Med** 1995;108(3):165–6

A Dutch population study of the STR Loci HUMTHO1, HUMFES/FPS, HUMVWA31/1 and HUMF13A1, conducted for forensic purposes. Sjerps M, et al. **Int J Legal Med** 1995;108(3):127–34

GEDNAP IV and V. The 4th and 5th Stain Blind Trials using DNA technology. Wiegand P, et al. **Int J Legal Med** 1995;108(2):79–84

The Bcl I polymorphism of the human uncoupling protein (ucp) gene is due to a point mutation in the 5'-flanking region. Cassard-Doulcier AM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):278–9

Use of pulsed-field gel electrophoresis as an epidemiologic tool during an outbreak of Pseudomonas aeruginosa lung infections in an intensive care unit. Talon D, et al. **Intensive Care Med** 1995 Dec;21(12):996–1002

Rapid communication: a TaqI restriction fragment length polymorphism in the bovine calpastatin gene. Cockett NE, et al. **J Anim Sci** 1995 Dec;73(12):3790

Relationship of restriction fragment length polymorphisms (RFLP) at the bovine calpastatin locus to calpastatin activity and meat tenderness. Lonergan SM, et al. **J Anim Sci** 1995 Dec;73(12):3608–12

Rapid communication: restriction fragment length polymorphism in amplification products of the bovine growth hormone-releasing hormone gene. Moody DE, et al. **J Anim Sci** 1995 Dec;73(12):3789

Use of the coagulase gene typing method for detection of carriers of methicillin-resistant Staphylococcus aureus. Lawrence C, et al. **J Antimicrob Chemother** 1996 Apr; 37(4):687–96

Polymerase chain reaction-restriction fragment length polymorphism analysis: a simple method for species identification in food. Meyer R, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1542–51

Host-mediated modification of PvuII restriction in

Mycobacterium tuberculosis. van Soolingen D, et al. **J Bacteriol** 1996 Jan;178(1):78–84

Bacterial diversity at surface water in three locations within the Baltic sea as revealed by culture-dependent molecular techniques. Hantula J, et al. **J Basic Microbiol** 1996; 36(3):163–76

Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. Foley BT, et al. **J Biol Chem** 1995 Sep 29;270(39):23218–25

Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189 —> Phe; Gly444 —> Arg) cause impaired C2 secretion. Wetsel RA, et al. **J Biol Chem** 1996 Mar 8;271(10):5824–31

The BumI vitamin D receptor restriction fragment length polymorphism (BB) predicts low bone density in premenopausal black and white women. Fleet JC, et al. **J Bone Miner Res** 1995 Jun;10(6):985–90

Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. Zerwekh JE, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2960–5

Correlation between DNA restriction fragment length polymorphisms in Leptospira interrogans serovar pomona type kennewicki and host animal source. Bolin CA, et al. **J Clin Microbiol** 1996 Feb;34(2):424–5

Rapid identification of Campylobacter species by restriction fragment length polymorphism analysis of a PCR-amplified fragment of the gene coding for 16S rRNA. Cardarelli-Leite P, et al. **J Clin Microbiol** 1996 Jan; 34(1):62–7

Genomic study of Rickettsia akari by pulsed-field gel electrophoresis. Eremeeva M, et al. **J Clin Microbiol** 1995 Nov;33(11):3022–4

Molecular epidemiology of toxigenic Vibrio cholerae in Bangladesh studied by numerical analysis of rRNA gene restriction patterns. Faruque SM, et al. **J Clin Microbiol** 1995 Nov;33(11):2833–8

Comprehensive ribotyping scheme for heat-stable serotypes of Campylobacter jejuni. Fitzgerald C, et al. **J Clin Microbiol** 1996 Feb;34(2):265–9

Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxidans by DNA restriction fragment length polymorphism [letter; comment] Frederiksen W. **J Clin Microbiol** 1995 Nov;33(11):3081. Comment on: J Clin Microbiol 1994 Oct;32(10):2631.

Molecular typing of Borrelia burgdorferi from Lyme disease patients by PCR-restriction fragment length polymorphism analysis. Liveris D, et al. **J Clin Microbiol** 1996 May; 34(5):1306–9

Restriction fragment length polymorphism of flagellin genes of Campylobacter jejuni and/or C. coli isolates from Egypt. Mohran ZS, et al. **J Clin Microbiol** 1996 May;34(5):1216–9

Restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, India, by use of direct-repeat probe. Sahadevan R, et al. **J Clin Microbiol** 1995 Nov;33(11):3037–9

Molecular epidemiology of Escherichia coli O157:H7 by restriction fragment length polymorphism using Shiga-like toxin genes. Samadpour M. **J Clin Microbiol** 1995 Aug; 33(8):2150–4

Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. Sasaki T, et al. **J Clin Microbiol** 1996 Feb;34(2):447–9

Restriction fragment length polymorphism of the tdh and trh genes in clinical Vibrio parahaemolyticus strains. Suthienkul O, et al. **J Clin Microbiol** 1996 May;34(5):1293–5

Chemiluminescent detection of RFLP patterns in forensic DNA analysis. Johnson ED, et al. **J Forensic Sci** 1996 Jul; 41(4):569–78

A new extremely large allele at the D1S80 (MCT118) locus. Kádasi L, et al. **J Forensic Sci** 1995 Sep;40(5):906–7

Validation of probe EFD52 (D17S26) for forensic DNA analysis. Nelson MS, et al. **J Forensic Sci** 1996 Jul; 41(4):557–68

Association of a restriction fragment length polymorphism in the alcohol dehydrogenase 2 gene with Japanese alcoholic liver cirrhosis. Yamauchi M, et al. **J Hepatol** 1995 Nov;23(5):519–23

Comparison of DNA fingerprinting by PFGE and PCR-RFLP of the coagulase gene to distinguish MRSA isolates. Nada T, et al. **J Hosp Infect** 1996 Apr;32(4):305–17

Discriminatory power and usefulness of pulsed-field gel electrophoresis in epidemiological studies of Pseudomonas aeruginosa. Talon D, et al. **J Hosp Infect** 1996 Feb; 32(2):135–45

RFLPs for linkage analysis in families with glycogen storage disease type III. Mishori-Dery A, et al. **J Inherit Metab Dis** 1995;18(2):207–10

Presymptomatic diagnosis in Portuguese FAP families using intragenic RFLPs and (CA)n flanking markers by fluorescence based semiautomated DNA analysis. Almeida R, et al. **J Med Genet** 1996 Mar;33(3):244–7

Rapid differentiation of Prevotella intermedia and P. nigrescens by 16S rDNA PCR-RFLP. Milsom SE, et al. **J Med Microbiol** 1996 Jan;44(1):41–3

A thyroid hormone receptor beta gene polymorphism associated with Graves' disease. Tassi V, et al. **J Mol Endocrinol** 1995 Dec;15(3):267–72

Sex in Escherichia coli does not disrupt the clonal structure of the population: evidence from random amplified polymorphic DNA and restriction-fragment-length polymorphism. Desjardins P, et al. **J Mol Evol** 1995 Oct; 41(4):440–8

Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. Pryhuber KG, et al. **J Rheumatol** 1996 Apr;23(4):747–52

Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. Presti JC Jr, et al. **J Urol** 1996 Jul;156(1):281–5

Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. Picard FJ, et al. **J Virol** 1995 Nov;69(11):7248–56

Rapid differentiation of closely related isolates of two plant viruses by polymerase chain reaction and restriction fragment length polymorphism analysis. Barbara DJ, et al. **J Virol Methods** 1995 Sep;55(1):121–31

Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Inoue S, et al. **Jpn J Cancer Res** 1995 Jul; 86(7):626–30

Polymorphic distribution and molecular diversification of mitochondrial plasmid-like DNAs in the genus Oryza. Miyata S, et al. **Jpn J Genet** 1995 Oct;70(5):601–14

Detection of MspI RFLP in human THY1 gene by the polymerase chain reaction. Fu J, et al. **Jpn J Hum Genet** 1995 Sep;40(3):279–80

Lack of association between the MHC linked OTF3 gene and systemic lupus erythematosus. Pablos JL, et al. **Lupus** 1995 Oct;4(5):390–2

Genetic mapping of the human and mouse phospholipase C genes. Lyu MS, et al. **Mamm Genome** 1996 Jul;7(7):501–4

Molecular mapping of genes for flagellar proteins in Chlamydomonas. Silflow CD, et al. **Methods Cell Biol** 1995;47:525–30

ITS-RFLP matching for identification of fungi. Gardes M, et al. **Methods Mol Biol** 1996;50:177–86

Restriction fragment length polymorphism (RFLP) analyses. Distinguishing African and European honey bees. Hall HG. **Methods Mol Biol** 1996;50:333–66

Restriction site polymorphism of the genes encoding the major 25 kDa and 36 kDa outer-membrane proteins of Brucella. Cloeckaert A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2111–21

Attenuated typhoid vaccine Salmonella typhi Ty21a: fingerprinting and quality control. McKenna AJ. et al. **Microbiology** 1995 Aug;141 (Pt 8):1993–2002

Extensive polymorphism at the Gp63 locus in field isolates of Leishmania peruviana. Espinoza JR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):203–13

Phylogenetic history of LINE-1 among arvicolid rodents. Modi WS. **Mol Biol Evol** 1996 May;13(5):633–41

Interchromosomal exchange of genetic information between gene arrangements on the third chromosome of Drosophila pseudoobscura. Popadić A, et al. **Mol Biol Evol** 1995 Sep; 12(5):938–43

The evolutionary history of Drosophila buzzatii. XXX. Mitochondrial DNA polymorphism in original and colonizing populations. Rossi MS, et al. **Mol Biol Evol** 1996 Feb;13(2):314–23

Male and female mitochondrial DNA lineages in the blue mussel (Mytilus edulis) species group. Stewart DT, et al. **Mol Biol Evol** 1995 Sep;12(5):735–47

A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Fueyo J, et al. **Mol Cell Probes** 1995 Dec;9(6):465–6

Genetic markers for closely-related parasitic nematodes. Gasser RB, et al. **Mol Cell Probes** 1995 Oct;9(5):315–20

Two restriction fragment length polymorphisms at the apolipoprotein AIV (apoAIV) locus. Martin I, et al. **Mol Cell Probes** 1995 Oct;9(5):371–2

Spatial analysis of nuclear and mitochondrial RFLP genotypes in populations of the chestnut blight fungus, Cryphonectria parasitica. Milgroom MG, et al. **Mol Ecol** 1995 Oct;4(5):633–42

Marker enrichment and high-resolution map of the segment of potato chromosome VII harbouring the nematode resistance gene Gro1. Ballvora A, et al. **Mol Gen Genet** 1995 Nov 1;249(1):82–90

Combined mapping of AFLP and RFLP markers in barley. Becker J, et al. **Mol Gen Genet** 1995 Nov 1;249(1):65–73

QTL analysis of flowering time in Arabidopsis thaliana. Clarke JH, et al. **Mol Gen Genet** 1995 Aug 21;248(3):278–86

A high-resolution map of the vicinity of the R1 locus on chromosome V of potato based on RFLP and AFLP markers. Meksem K, et al. **Mol Gen Genet** 1995 Nov 1; 249(1):74–81

The established Yersinia pestis biovars are characterized by typical patterns of I-CeuI restriction fragment length polymorphism. Rakin A, et al. **Mol Gen Mikrobiol Virusol** 1995 Jul–Sep;(3):26–9

Genetics of scnDNA polymorphisms in juvenile oysters (Crassostrea virginica). Part I: Characterizing the inheritance of polymorphisms in controlled crosses. Hu YP, et al. **Mol Mar Biol Biotechnol** 1996 Jun;5(2):123–9

Use of PCR-RFLP assays to detect genetic variation at single-copy nuclear loci in striped bass (Morone saxatilis). Leclerc GM, et al. **Mol Mar Biol Biotechnol** 1996 Jun; 5(2):138–44

Gradient of genomic diversity in the Pseudomonas aeruginosa chromosome. Römling U, et al. **Mol Microbiol** 1995 Jul;17(2):323–32

Mitochondrial DNA analysis of Exophiala spinifera. Ishizaki H, et al. **Mycopathologia** 1995 Aug;131(2):67–70

T-cell receptor beta-chain gene polymorphism and the prognosis of IgA nephropathy in Japanese patients [letter] Nagasawa R, et al. **Nephron** 1995;70(4):502–3

Japanese triplets with cerebrotendinous xanthomatosis are homozygous for a mutant gene coding for the sterol 27-hydroxylase (Arg441Trp). Nagai Y, et al. **Neurology** 1996 Feb;46(2):571–4

p53 allelic imbalance in astrocytoma detected using fluorescent PCR of microsatellite repeat polymorphisms. al-Sarraj S, et al. **Neuropathol Appl Neurobiol** 1995 Aug; 21(4):344–51

AFLP-based mRNA fingerprinting. Money T, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2616–7

Allelotype of neuroblastoma. Takita J, et al. **Oncogene** 1995 Nov 2;11(9):1829–34

Pseudomonas (Burkholderia) cepacia in children with cystic fibrosis: epidemiological investigation by analysis or restriction fragment length polymorphism. Valcin M, et al. **Pathol Biol (Paris)** 1996 May;44(5):442–6

Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Kato S, et al. **Pharmacogenetics** 1995;5 Spec No:S141–4

Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)

Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Lucas D, et al. **Pharmacogenetics** 1995 Oct;5(5):298–304

Distribution of neuronal nicotinic acetylcholine receptor gene restriction fragment length polymorphisms in inbred and partially inbred mice. Nagavarapu U, et al. **Pharmacogenetics** 1995 Oct;5(5):326–31

Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pirmohamed M, et al. **Pharmacogenetics** 1995 Dec;5(6):351–7

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Steen VM, et al. **Pharmacogenetics** 1995 Aug;5(4):215–23

CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Sugimura H, et al. **Pharmacogenetics** 1995;5 Spec No:S145–8

Visualization of differential gene expression using a novel method of RNA fingerprinting based on AFLP: analysis of gene expression during potato tuber development. Bachem CW, et al. **Plant J** 1996 May;9(5):745–53

Survey of major histocompatibility complex class II haplotypes in four turkey lines using restriction fragment length polymorphism analysis with nonradioactive DNA detection. Zhu J, et al. **Poult Sci** 1995 Jul;74(7):1067–73

Geographical structuring in the mtDNA of Italians. Barbujani G, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9171–5

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Galipeau PC, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7081–4

The chicken beta 2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: a small, G+C-rich gene with X and Y boxes in the promoter. Riegert P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1243–8

Unexpected beta2-microglobulin sequence diversity in individual rainbow trout. Shum BP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2779–84

HLA-Cw allele analysis by PCR-restriction fragment length polymorphism: study of known and additional alleles. Tatari Z, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8803–7

Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene. Cichon S, et al. **Psychiatr Genet** 1995 Fall;5(3):97–103

Dopamine D3 receptor gene polymorphism and the psychiatric symptoms seen in first-break schizophrenic patients. Inada T, et al. **Psychiatr Genet** 1995 Fall; 5(3):113–6

Dopamine D1, D2 and D3 receptor genes in alcohol dependence. Sander T, et al. **Psychiatr Genet** 1995 Winter; 5(4):171–6

Characterization of multilocus lesions in human cells exposed to X radiation and radon. Chaudhry MA, et al. **Radiat Res** 1996 Jan;145(1):31–8

Ribosomal DNA polymorphism in the genus Bifidobacterium. Mangin I, et al. **Res Microbiol** 1996 Mar-Apr;147(3):183–92

DNA fingerprinting by random amplified polymorphic DNA and restriction fragment length polymorphism is useful for yeast typing. Paffetti D, et al. **Res Microbiol** 1995 Sep; 146(7):587–94

Restriction fragment length polymorphism of polymerase chain reaction products applied to the differentiation of poultry campylobacters for epidemiological investigations. Ayling RD, et al. **Res Vet Sci** 1996 Mar;60(2):168–72

The relation between the PST1 restriction fragment length polymorphism at the APO-AI locus and plasma APO-AI concentrations in marathon runners. Ziman MR, et al. **S Afr Med J** 1995 Oct;85(10):1013–6

Deoxyribonucleic acid profiling by restriction fragment length polymorphism analysis--a compilation of validation

studies. Tahir MA, et al. **Sci Justice** 1996 Jul-Sep; 36(3):173-82

DNA polymorphisms for carrier detection of hemophilia in Thailand. Chuansumrit A, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:201-6

Restriction fragment length polymorphism of genes of the alpha 2(XI) collagen, bone morphogenetic protein-2, alkaline phosphatase, and tumor necrosis factor-alpha among patients with ossification of posterior longitudinal ligament and controls from the Japanese population. Koga H, et al. **Spine** 1996 Feb 15;21(4):469-73

Restriction fragment length polymorphism typing of Mycobacterium tuberculosis. Hayward AC. **Thorax** 1995 Nov;50(11):1211-8 (66 ref.)

Protein S mRNA in patients with protein S deficiency. Sacchi E, et al. **Thromb Haemost** 1995 May;73(5):746-9

Rh haemolytic disease of the newborn and Rh genotyping by RFLP--and allele-specific--PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317-24 (16 ref.)

Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al.
Transfus Med Rev 1995 Oct;9(4):289-301 (58 ref.)

Tracking H-2 alleles in transgenic mice by RFLP and heteroduplex analysis. Shanmugam V, et al.
Transgenic Res 1996 May;5(3):203-8

Babesia canis: evidence for genetic diversity among isolates revealed by restriction fragment length polymorphism analysis. Citard T, et al. **Trop Med Parasitol** 1995 Sep; 46(3):172-9

IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Das S, et al. **Tuber Lung Dis** 1995 Dec;76(6):550-4

Nested PCR allows the characterization of TaqI and PstI RFLPs in the second exon of the caprine MHC class II DRB gene. Amills M, et al.
Vet Immunol Immunopathol 1995 Oct;48(3-4):313-21

Analyses of restriction fragment patterns (RFPs) and pathogenicity in baby mice of equine herpesvirus 1 and 4 (EHV-1 and EHV-4) strains circulating in Danish horses. Palfi V, et al. **Vet Microbiol** 1995 Nov;47(1-2):199-204

Characterization by restriction endonuclease analysis and DNA hybridization using IS900 of bovine, ovine, caprine and human dependent strains of Mycobacterium paratuberculosis isolated in various localities. Pavlík I, et al. **Vet Microbiol** 1995 Aug;45(4):311-8

Differentiation of Cryptosporidium parvum, C. muris, and C. baileyi by PCR-RFLP analysis of the 18S rRNA gene. Leng X, et al. **Vet Parasitol** 1996 Mar;62(1-2):1-7

[DNA-fingerprinting and tuberculosis] Bauer JO, et al.
Ugeskr Laeger 1996 Feb 19;158(8):1084-5 (Eng. Abstr.) **(Dan)**

[Genetic polymorphism of M. tuberculosis strains in Antananaviro] Rasolofo-Razanamparany V, et al.
Arch Inst Pasteur Madagascar 1995;62(1):59-64 (Eng. Abstr.) **(Fre)**

[Study of mitochondrial DNA in Helix land snails by PCR-RFLP] Borgo R, et al. **C R Seances Soc Biol Fil** 1995;189(4):629-36 (Eng. Abstr.) **(Fre)**

[Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis] Lemaitre N, et al. **Pathol Biol (Paris)** 1996 May;44(5):452-5 (Eng. Abstr.) **(Fre)**

[Population study in West Austria using DNA single locus probes] Zehethofer K, et al. **Wien Klin Wochenschr** 1995; 107(19):574-7 (Eng. Abstr.) **(Ger)**

[Paternity determination using the RFLP method in DNA probes] Lászik A, et al. **Orv Hetil** 1995 Sep 24; 136(39):2117-9 (Eng. Abstr.) **(Hun)**

[Epidemiology of Mycobacterium tuberculosis infection based on RFLP analysis] Takahashi M, et al. **Kekkaku** 1995 Sep;70(9):553-9 (Eng. Abstr.) **(Jpn)**

[Identification of Capnocytophaga species by microplate hybridization method, and its restriction endonuclease digestion patterns] Fujita S, et al. **Rinsho Byori** 1995 Oct; 43(10):1066-70 (Eng. Abstr.) **(Jpn)**

[PCR-RFLP analysis] Nagase S, et al.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):564-7 (6 ref.) **(Jpn)**

[Polymorphic variability of apolipoprotein B genes and insulin receptor in essential hypertension] Pisarska M.
Pol Arch Med Wewn 1996 Mar;95(3):205-11 (Eng. Abstr.) **(Pol)**

[A simple method for detecting the order of relation location of fragments in constructing a paired restriction map] Balakirev ES. **Genetika** 1995 Oct;31(10):1445-8 (Eng. Abstr.) **(Rus)**

[Polymorphism of placental alkaline phosphatase on the level of DNA and protein in the Mordovian population] Bekman G, et al. **Genetika** 1996 Mar;32(3):420-4 (Eng. Abstr.) **(Rus)**

[Mitochondrial DNA variation in native inhabitants of Siberia with reconstructions of the evolutional history of the American Indians. Restriction polymorphism] Sukernik RI, et al. **Genetika** 1996 Mar;32(3):432-9 (Eng. Abstr.) **(Rus)**

[The analysis of DNA amplified fragment length polymorphism in forensic identification expertise: the possible sources of errors under nonoptimal conditions for the polymerase chain reaction] Gyské LI, et al.
Sud Med Ekspert 1995 Oct-Dec;38(4):12-7 (Eng. Abstr.) **(Rus)**

[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul-Aug;29(4):84-7 (33 ref.) (Eng. Abstr.) **(Rus)**

[IS6110 for typing strains of Mycobacterium tuberculosis: application of a standardized protocol with computerized image analysis] Coll P, et al.
Enferm Infecc Microbiol Clin 1995 Aug-Sep;13(7):391-7 (Eng. Abstr.) **(Spa)**

POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. Perry RT, et al.
Am J Med Genet 1995 Feb 27;60(1):12-8

Who is a carrier? Detection of unsuspected mutations in 21-hydroxylase deficiency. Witchel SS, et al.
Am J Med Genet 1996 Jan 2;61(1):2-9

Detection and identification of Ki-ras exon 1 mutations by minigel single-strand conformation polymorphism. Ulvik A, et al. **Anal Biochem** 1995 Nov 20;232(1):137-8

Survey on swine SINEs (PRE-1) as candidates for SSCP markers in genetic linkage analysis. Harumi T, et al.
Anim Genet 1995 Dec;26(6):403-6

PCR-SSCP in the ovine calpastatin gene. Roberts N, et al.
Anim Genet 1996 Jun;27(3):211

SSCP analysis of pig mitochondrial DNA D-loop region polymorphism. Takeda K, et al. **Anim Genet** 1995 Oct; 26(5):321-6

Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Ouabdesselam S, et al.
Antimicrob Agents Chemother 1995 Aug;39(8):1667-70

A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient. Lam S, et al.
Biochem Biophys Res Commun 1996 Feb 27;219(3):853-8

Relative ratios of mRNA molecules encoded by genes with homologous sequences using fluorescence-based single-strand conformation polymorphism analysis. Maekawa M, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):520-5

Long-PCR of the ANP gene and PCR-SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al.
Biochem Biophys Res Commun 1995 Oct 4;215(1):172-8

Identification of DNA polymorphism by asymmetric-PCR SSCP. Fujita T, et al. **Biotechniques** 1995 Oct;19(4):532-4

High-resolution SSCP analysis using polyacrylamide agarose composite gel and a background-free silver staining method. Peng H, et al. **Biotechniques** 1995 Sep;19(3):410-4

Nonradioactive characterization of low-level heteroplasmic mitochondrial DNA mutations by SSCP-PCR enrichment. Sherratt EJ, et al. **Biotechniques** 1996 Mar;20(3):430-2

Multiplex-PCR-based single-strand conformation polymorphism protocol for simultaneous analysis of up to five fragments of the low-density-lipoprotein receptor gene. Weiss N, et al. **Biotechniques** 1996 Mar;20(3):421-4, 426, 428-9

p53 gene mutation in thyroid carcinoma. Ho YS, et al.
Cancer Lett 1996 May 15;103(1):57-63

Screening for mitochondrial DNA (mtDNA) point mutations using nonradioactive single strand conformation polymorphism (SSCP) analysis. Jaksch M, et al.
Clin Biochem 1995 Oct;28(5):503-9

High sensitivity of the single-strand conformation polymorphism method for detecting sequence variations in the low-density lipoprotein receptor gene validated by DNA sequencing. Jensen HK, et al. **Clin Chem** 1996 Aug; 42(8 Pt 1):1140-6

Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas. Faccenda E, et al.
Clin Endocrinol (Oxf) 1996 Mar;44(3):341-7

Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Rosenwasser LJ, et al.
Clin Exp Allergy 1995 Nov;25 Suppl 2:74-8; discussion 95-6

Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Inoue H, et al. **Diabetes** 1996 Jun;45(6):825-31

Identification of the aminoacid polymorphisms in hexokinase II in Japanese subjects [letter] Shimada F, et al.
Diabetologia 1996 Jan;39(1):123-4

HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. Tao T, et al.
Diabetologia 1995 Aug;38(8):942-7

Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Bosari S, et al. **Diagn Mol Pathol** 1995 Dec; 4(4):249-55

Single strand conformational polymorphism using capillary electrophoresis with two-dye laser-induced fluorescence detection. Hebenbrock K, et al. **Electrophoresis** 1995 Aug; 16(8):1429-36

Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. Baird DM, et al. **EMBO J** 1995 Nov 1;14(21):5433-43

Evaluation of non-radioactive temperature gradient SSCP analysis and of temperature gradient gel electrophoresis for the detection of HPV 6-variants in condylomata acuminata and Buschke-Loewenstein tumours. Rübben A, et al. **Eur J Epidemiol** 1995 Oct;11(5):501-6

HLA-DQB1 and DQA1 matching by ambient temperature PCR-SSCP. Clay TM, et al. **Eur J Immunogenet** 1995 Dec; 22(6):467-78

Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Ohnishi H, et al.
Genes Chromosomes Cancer 1996 Mar;15(3):187-90

Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence-based single-strand conformation polymorphism analysis using blunt-end DNA fragments. Sugano K, et al.
Genes Chromosomes Cancer 1996 Mar;15(3):157-64

A mass screening device of genome by polymerase chain reaction-restriction fragment-single strand conformation polymorphism analysis. Tawata M, et al. **Genet Anal** 1996 Jan;12(3-4):125-7

PCR-LIS-SSCP (Low ionic strength single-stranded conformation polymorphism)--a simple method for high-resolution allele typing of HLA-DRB1, -DQB1, and -DPB1. Maruya E, et al. **Genome Res** 1996 Jan;6(1):51-7

Identification of mutations by RNA conformational polymorphism "bar code" analysis. Lenz HJ, et al.
Genomics 1995 Nov 1;30(1):120-2

Polymorphism in and localization of the gene LCP2 (SLP-76) to chromosome 5q33.1-qter. Sunden SLF, et al.
Genomics 1996 Jul 1;35(1):269-70

Nonradioactive detection of monoclonal immunoglobulin heavy chain gene rearrangement with PCR-SSCP. Thunberg U, et al. **Hematol Pathol** 1995;9(3-4):141-53

Single-stranded DNA conformation polymorphism at the Rdl locus in Hypothenemus hampei (Coleoptera: Scolytidae). Borsa P, et al. **Heredity** 1996 Feb;76 (Pt 2):124-9

Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. De Vitis LR, et al.
Hum Genet 1996 May;97(5):632-7

Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. De Vitis LR, et al. **Hum Genet** 1996 May;97(5):638-41

Frequent DNA variant in exon 2a of the survival motor neuron gene (SMN): a further possibility for distinguishing the two copies of the gene. Hahnen ET, et al.
Hum Genet 1996 Jul;98(1):122-3

Identification of the nucleotide substitution that generates the fourth polymorphic site in human deoxyribonuclease I (DNase I). Iida R, et al. **Hum Genet** 1996 Oct;98(4):415-8

An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Marez D, et al.
Hum Genet 1996 May;97(5):668-70

Genomic structure and PCR-SSCP analysis of the human CD40 ligand gene: its application to prenatal screening for X-linked hyper-IgM syndrome. Seyama K, et al.
Hum Genet 1996 Feb;97(2):180-5

DNA polymorphisms in adhesion molecule genes--a new risk factor for early atherosclerosis. Wenzel K, et al.
Hum Genet 1996 Jan;97(1):15-20

A novel HLA-DR13 allele (DRB1*1314) identified by single-strand conformation polymorphism analysis and confirmed by direct sequencing. Blaszcyk R, et al.
Hum Immunol 1995 Aug;43(4):309-12

Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Matsushima M, et al.
Hum Mol Genet 1995 Oct;4(10):1953-6

SSCP detection of novel mutations in patients with Emery-Dreifuss muscular dystrophy: definition of a small C-terminal region required for emerin function. Nigro V, et al. **Hum Mol Genet** 1995 Oct;4(10):2003-4

Nonisotopic single strand conformation analysis of the 5 alpha-reductase type 2 gene for the diagnosis of 5 alpha-reductase deficiency. Hiort O, et al.
J Clin Endocrinol Metab 1996 Sep;81(9):3415-8

A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome. Lin Q, et al.
J Clin Invest 1996 Jan 1;97(1):196-201

Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. Pearce SH, et al. **J Clin Invest** 1995 Dec;96(6):2683-92

Typing of LaCrosse, snowshoe hare, and Tahyna viruses by analyses of single-strand conformation polymorphisms of the small RNA segments. Black WC, et al.
J Clin Microbiol 1995 Dec;33(12):3179-82

Molecular subtyping of human T-cell lymphotropic virus type 2 by single-strand conformation polymorphism analysis. Retrovirus Epidemiology Donor Study Group. Heneine W, et al. **J Clin Microbiol** 1995 Dec;33(12):3260-3

PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. Walsh TJ, et al. **J Clin Microbiol** 1995 Dec;33(12):3216-20

Molecular identification of bacteria by fluorescence-based PCR-single-strand conformation polymorphism analysis of the 16S rRNA gene. Widjojoatmodjo MN, et al.
J Clin Microbiol 1995 Oct;33(10):2601-6

Direct assessment of junctional diversity in rearranged T cell receptor beta chain encoding genes by combined heteroduplex and single strand conformation polymorphism (SSCP) analysis. Offermans MT, et al. **J Immunol Methods** 1996 May 10;191(1):21-31

Detection of four novel mutations in the iduronate-2-sulphatase gene by single-strand conformation polymorphism analysis of genomic amplicons. Li P, et al. **J Inherit Metab Dis** 1996;19(1):93-4

Rapid detection of rare variants and common polymorphisms in the APC gene by PCR-SSCP for presymptomatic diagnosis and showing allele loss. Gaythер SA, et al. **J Med Genet** 1995 Jul;32(7):568-71

Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene. Whittall R, et al. **J Med Genet** 1995 Jul;32(7):509-15

DNA single strand conformation polymorphism identifies five defined strains of hepatitis B virus (HBV) during an outbreak of HBV infection in an oncology unit. Hardie DR, et al. **J Med Virol** 1996 May;49(1):49-54

Low-stringency single specific primer PCR, DNA sequencing and single-strand conformation polymorphism of PCR products for identification of genetic variants of human papillomavirus type 16. van Belkum A. **J Virol Methods** 1995 Nov;55(3):435-43

Molecular genetic diagnosis of von Hippel-Lindau disease: analysis of five Japanese families. Kanno H, et al. **Jpn J Cancer Res** 1996 May;87(5):423-8

Non-phenotypic detection of osteopetrotic (op/op) mutation by using PCR-SSCP analysis. Kaneko H, et al. **Lab Anim** 1995 Oct;29(4):442-6

Single-strand conformational polymorphism (SSCP) for the identification of endomycorrhizal fungi. Simon L. **Methods Mol Biol** 1996;50:193-7

Molecular screening of genetic defects with RNA-SSCP analysis: the PKU and cystinuria model. Giannattasio S, et al. **Mol Cell Probes** 1995 Jun;9(3):201-5

Comparison of heteroduplex and single-strand conformation analyses, followed by ethidium fluorescence visualization, for the detection of mutations in four human genes. Rossetti S, et al. **Mol Cell Probes** 1995 Jun;9(3):195-200

Quantitation of heteroplasmy of mitochondrial tRNA(Leu(UUR)) gene using PCR-SSCP. Tanno Y, et al. **Muscle Nerve** 1995 Dec;18(12):1390-7

Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Poetter K, et al. **Nat Genet** 1996 May;13(1):63-9

High resolution SSCP by optimization of the temperature by transverse TGGE. Chen X, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4524-5

Transverse temperature-gradient single-strand conformation polymorphism analysis for temperature optimization of 'Cold'-SSCP mutation detection. Grace MB, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4224-6

Screening of differentially amplified cDNA products from RNA arbitrarily primed PCR fingerprints using single strand conformation polymorphism (SSCP) gels. Mathieu-Daudé F, et al. **Nucleic Acids Res** 1996 Apr 15; 24(8):1504-7

Single-strand conformation polymorphism analysis of the epidermal growth factor receptor at codon 497. Lopez ME, et al. **Pancreas** 1996 Apr;12(3):216-20

Multiple fluorescence-based PCR-SSCP analysis with postlabeling. Iwahana H, et al. **PCR Methods Appl** 1995 Apr;4(5):275-82

Metastable single-strand DNA conformational polymorphism analysis results in enhanced polymorphism detection. Kasuga T, et al. **PCR Methods Appl** 1995 Feb; 4(4):227-33

Parameters affecting the sensitivities of dideoxy fingerprinting and SSCP. Liu Q, et al. **PCR Methods Appl** 1994 Oct;4(2):97-108

An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Broly F, et al. **Pharmacogenetics** 1995 Dec;5(6):373-84

A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Marez D, et al. **Pharmacogenetics** 1995 Oct;5(5):305-11

Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Rosvold EA, et al. **Pharmacogenetics** 1995 Aug; 5(4):199-206

Molecular prenatal diagnosis of 3-hydroxy-3-methylglutaryl CoA lyase deficiency. Mitchell GA, et al. **Prenat Diagn** 1995 Aug;15(8):725-9

Molecular markers reveal cryptic sex in the human pathogen Coccidioides immitis. Burt A, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):770-3

A novel HLA-A24 allele (A*2405) identified by single-strand conformation polymorphism analysis and confirmed by solid-phase sequencing and isoelectric focusing. Blasczyk R, et al. **Tissue Antigens** 1995 Jul; 46(1):54-8

A novel HLA-A30 allele (A*3004) identified by single-strand conformation polymorphism analysis and confirmed by solid-phase sequencing. Blasczyk R, et al. **Tissue Antigens** 1995 Oct;46(4):322-6

Human platelet antigen-2 and -3 genotyping by PCR-SSP. Metcalfe P, et al. **Transfus Med** 1995 Dec;5(4):285-8

Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis. Wilton S, et al. **Trends Genet** 1995 Sep; 11(9):341

Detection of aberrations in androgen receptor gene by analysis of single-stranded conformation polymorphisms in polymerase chain reaction products. Kondoh N, et al. **Urol Res** 1995;23(4):227-30

DNA-based typing of human platelet antigen systems by polymerase chain reaction-single-strand conformation polymorphism method. Fujiwara K, et al. **Vox Sang** 1995; 69(4):347-51

[PCR-SSCP.direct sequencing] Kagimoto S. **Nippon Rinsho** 1995 Oct;53 Suppl:310-5 (5 ref.) **(Jpn)**

[Analysis of hepatitis C virus quasispecies populations using PCR-SSCP method] Kurosaki M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:339-45 (16 ref.) **(Jpn)**

[Evaluation of the number of clones and the degree of nucleotide diversity of the HCV genome by FSSA (fluorescence single strand conformation polymorphism and sequence analysis) in patients with chronic active hepatitis C receiving interferon therapy] Kajimura K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr; 93(4):249-54 (Eng. Abstr.) **(Jpn)**

[Detection of DNA aberrations in human cancers by AP-PCR-SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633-7 (12 ref.) **(Jpn)**

[Single-strand conformation polymorphism (SSCP) analysis: a convenient, rapid method for detection of single-base changes in DNA] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):539-45 (4 ref.) **(Jpn)**

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638-42 (8 ref.) **(Jpn)**

[Absence of DNA polymorphisms on the region of the APOV gene coding the proposed low density lipoprotein-binding domain of the ApoB-100 protein] Shevtsov SP. **Genetika** 1996 Feb;32(2):295-7 (Eng. Abstr.) **(Rus)**

[Greater sensitivity of the PCR-SSCP technique compared with immunohistochemistry for the detection of exon 5 and 6 mutations of gene 53 in breast cancer] Dueñas González A, et al. **Med Clin (Barc)** 1996 May 18; 106(19):721-4 (Eng. Abstr.) **(Spa)**

POLYMORPHONUCLEAR LEUKOCYTES see **NEUTROPHILS**

POLYMYALGIA RHEUMATICA

see related

TEMPORAL ARTERITIS

Polymyalgia rheumatica and giant cell arteritis. Cimmino MA, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):515-27 (60 ref.)

BLOOD

Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis [letter] Caplanne D, et al. **Ann Rheum Dis** 1996 Jun;55(6):403-4

Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Helfgott SM, et al. **Arthritis Rheum** 1996 Feb;39(2):304-7

Cytokines in polymyalgia rheumatica [letter; comment] Tellus M, et al. **Arthritis Rheum** 1996 Jul;39(7):1264-5. Comment on: Arthritis Rheum 1993 Sep;36(9):1286-94.

Polymyalgia rheumatica [letter] Murphy PT, et al. **Lancet** 1996 Aug 24;348(9026):550

Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Wällberg-Jonsson S, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):309-15

COMPLICATIONS

Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases. Salvarani C, et al. **Arthritis Rheum** 1996 Jan;39(1):73-80

Polymyalgia rheumatica in patients with myelodysplastic syndromes [letter] Hubscher O, et al. **J Rheumatol** 1996 Apr;23(4):792-3

Polymyalgia rheumatica, temporal arteritis and malignancy. Speed CA, et al. **Postgrad Med J** 1995 Aug;71(838):500-2

[Giant cell arteritis of the lower limbs in rhizomelic pseudopolyarthritis (letter)] Viallard JF, et al. **Ann Med Interne (Paris)** 1996;147(3):225-7 **(Fre)**

[Polymyalgia rheumatica associated with myelodysplasia] Gurgo A, et al. **Clin Ter** 1996 Mar;147(3):107-11 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Polymyalgic presentation of enterovirus infection: a cause of diagnostic confusion [letter] Stevens RJ, et al. **Ann Rheum Dis** 1996 Feb;55(2):147-8

A case of Zieve's syndrome presenting with myalgia: not to be confused with polymyalgia rheumatica [letter] Martin JC, et al. **Br J Rheumatol** 1996 May;35(5):495-6

Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis [see comments] Kassimos D, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):641-4. Comment in: Clin Exp Rheumatol 1995 Sep-Oct;13(5):571-2.

Cytidine deaminase--a new differential tool distinguishing elderly onset rheumatoid arthritis from polymyalgia rheumatica? [editorial; comment] Williams RC Jr. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):571-2. Comment on: Clin Exp Rheumatol 1995 Sep-Oct;13(5):641-4.

Non-giant cell arteritis of the temporal artery presenting as the polymyalgia rheumatica-temporal arteritis syndrome. Lesser RS, et al. **J Rheumatol** 1995 Nov;22(11):2177-82

Raised ESR in polymyalgia rheumatica no longer a sine qua non? Ortiz Z, et al. **Lancet** 1996 Jul 6;348(9019):4-5

Polymyalgia rheumatica [letter] Salvarani C, et al. **Lancet** 1996 Aug 24;348(9026):550-1

Polymyalgia rheumatica [letter] Sweetman BJ. **Lancet** 1996 Aug 24;348(9026):550

[Polymyalgia rheumatica] Efimenko IS, et al. **Ter Arkh** 1995; 67(11):71-3 (17 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Krogsgaard MR, et al. **Ann Rheum Dis** 1996 Feb;55(2):143-6

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? van der Veen MJ, et al. **Ann Rheum Dis** 1996 Apr;55(4):218-23

Polymyalgia rheumatica and giant cell arteritis [letter; comment] Myles AB. **BMJ** 1995 Nov 4;311(7014):1232. Comment on: BMJ 1995 Aug 12;311(7002):455.

Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. Di Munno O, et al. **J Rheumatol** 1995 Aug;22(8):1492-8

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. Ferraccioli G, et al. **J Rheumatol** 1996 Apr;23(4):624-8

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. Krogsgaard MR, et al. **J Rheumatol** 1995 Sep;22(9):1660-2

[Methotrexate therapy of polymyalgia rheumatica] Wagener P. **Z Rheumatol** 1995 Nov-Dec;54(6):413-6 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The prevalence of soft tissue rheumatism. A who-ilar copcord study. Darmawan J, et al. **Rheumatol Int** 1995; 15(3):121-4

ETIOLOGY

Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient [letter] Mok CC, et al. **Br J Rheumatol** 1996 May;35(5):496-7

Polymyalgia rheumatica with temporal arteritis following intravesical Calmette-Guérin bacillus immunotherapy for bladder cancer [letter] Genereau T, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):110

[Apropos of rheumatic manifestations of celiac disease: a case of Horton disease? (letter)] Garat H, et al. **Presse Med** 1996 Jan 6-13;25(1):39 **(Fre)**

[Polymyalgia rheumatica presenting pulmonary epidermoid carcinoma (letter)] Fernández Guerra J, et al. **Arch Bronconeumol** 1996 Mar;32(3):155 **(Spa)**

GENETICS

[HLA DRB1 polymorphism in rhizomelic pseudo-polyarthritis and Horton disease] Labbe P, et al. **Rev Med Interne** 1995;16(10):778-81 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Meliconi R, et al. **Arthritis Rheum** 1996 Jul;39(7):1199-207

The relationship of anti-endothelial cell antibodies to anti-phospholipid antibodies in patients with giant cell arteritis and/or polymyalgia rheumatica. Le Tonquèze M, et al. **Autoimmunity** 1995;20(1):59-66

Clonally expanded CD8 T cells in patients with polymyalgia rheumatica and giant cell arteritis. Martinez-Taboada VM, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):263-70

A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis. Chakravarty K, et al. **J Rheumatol** 1995 Sep;22(9):1694-7

PATHOLOGY

Microscopic polyarteritis during polymyalgia rheumatica remission. Uematsu-Yanagita M, et al. **Am J Kidney Dis** 1996 Aug;28(2):289-91 (6 ref.)

Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Mertens JC, et al. **Clin Rheumatol** 1995 Nov;14(6):650-5

SURGERY

[Treatment of rhizomelic arthrosis of the thumb by partial resection of the trapezium and rib cartilage autograft. Preliminary results] Tropet Y, et al. **Chirurgie** 1994–95; 120(10):563–7 (Eng. Abstr.) **(Fre)**

POLYMYOSITIS

Inflammatory myopathies. Oddis CV, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):497–514 (57 ref.)

Polymyositis–associated overlap syndromes [editorial] Venables PJ. **Br J Rheumatol** 1996 Apr;35(4):305–6

[Polymyositis and dermatomyositis. Current status] Cherin P, et al. **Ann Dermatol Venereol** 1995;122(6–7):447–54 (71 ref.) **(Fre)**

BLOOD

Elevated serum levels of manganese superoxide dismutase in polymyositis and dermatomyositis. Mokuno K, et al. **Neurology** 1996 May;46(5):1445–7

[Serum levels of soluble adhesion molecules in patients with inflammatory myopathies] Murata K, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):12–6 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Case report: polymyositis–induced myoglobinuric acute renal failure. Thakur V, et al. **Am J Med Sci** 1996 Aug; 312(2):85–7 (11 ref.)

Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Shapiro J, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):331–5

Adult respiratory distress syndrome in polymyositis patients with the anti–Jo–1 antibody. Clawson K, et al. **Arthritis Rheum** 1995 Oct;38(10):1519–23

Polymyositis, dermatomyositis and malignant melanoma [letter; comment] Sais G. **Br J Dermatol** 1995 Dec; 133(6):1012. Comment on: Br J Dermatol 1995 Feb;132(2):312–3.

Digital clubbing associated with polymyositis and interstitial lung disease. Grathwohl KW, et al. **Chest** 1995 Dec; 108(6):1751–2

Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Imasaki T, et al. **Intern Med** 1996 Mar;35(3):231–5 (22 ref.)

Polymyositis associated with thymoma and the subsequent development of pure red cell aplasia. Katabami S, et al. **Intern Med** 1995 Jun;34(6):569–73

Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma [letter] Ko KF, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):558–9

Scleroderma, polymyositis, and hairy cell leukemia. Blanche P, et al. **J Rheumatol** 1995 Jul;22(7):1384–5

Polymyositis, arthritis, and proteinuria in a patient with adult celiac disease. Evron E, et al. **J Rheumatol** 1996 Apr; 23(4):782–3

Cardiac manifestations in polymyositis/dermatomyositis: how to get to heart of the matter [editorial] Lie JT. **J Rheumatol** 1995 May;22(5):809–11

Polymyositis: a cause of acute renal failure. Lewington AJ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):699–701

Anti–Jo–1 syndrome presenting as cryptogenic organizing pneumonia. Chan WM, et al. **Respir Med** 1995 Oct; 89(9):639–41

[Association of polymyositis and rheumatoid arthritis. Apropos of a new case not related to drug ingestion] Jardin H, et al. **Rev Med Interne** 1996;17(4):321–4 (27 ref.) (Eng. Abstr.) **(Fre)**

[Anesthetic management for colon resection in a patient with polymyositis] Fujita A, et al. **Masui** 1996 Mar;45(3):334–6 (Eng. Abstr.) **(Jpn)**

[Successful therapy with cyclosporine in a case with interstitial pneumonitis associated with polymyositis] Soga T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr; 19(2):157–62 (Eng. Abstr.) **(Jpn)**

[A case of interstitial pneumonia in polymyositis difficult to distinguish from gold pneumonitis] Maeda K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):745–9 (Eng. Abstr.) **(Jpn)**

[A case of polymyositis associated with extensive disturbance of cardiac conduction] Takeda S, et al. **Ryumachi** 1995 Jun; 35(3):575–9 (Eng. Abstr.) **(Jpn)**

[Recurrent bronchiolitis obliterans organizing pneumonia as first manifestation of polymyositis] Falga Tirado C, et al. **An Med Interna** 1995 Oct;12(10):498–500 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Clinical characteristics of HTLV–1 associated dermato–polymyositis. Seven cases from Martinique. Smadja D, et al. **Acta Neurol Scand** 1995 Sep;92(3):206–12

Re: Cost–effectiveness of MR imaging in evaluating polymyositis [letter; comment] Fleckenstein JL. **AJR Am J Roentgenol** 1996 Aug;167(2):531–2. Comment on: AJR Am J Roentgenol 1995 Dec;165(6):1469–71.

Cost–effectiveness of MR imaging in evaluating polymyositis [see comments] Schweitzer ME, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1469–71. Comment in: AJR Am J Roentgenol 1996 Aug;167(2):531–2.

Churg–Strauss syndrome presenting as polymyositis. De Vlam K, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):505–7

Racial variation in serum creatine kinase levels. Johnston JD, et al. **J R Soc Med** 1996 Aug;89(8):462–4

Amiodarone–induced neuromyopathy mimicking polymyositis [letter] Bonnet C, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):468

[Myositis, polysynovitis and pulmonary fibrosis: anti–Jo–1 syndrome] Perrenoud FG, et al. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):120–3 (Eng. Abstr.) **(Fre)**

[Case report and discussion of a patient with polymyositis, fibrosing alveolitis and scleroderma–like involvement of the right hand] Wunderlin B, et al. **Z Rheumatol** 1996 May–Jun;55(3):188–97 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Effective treatment of anti Jo–1 antibody–positive polymyositis with cyclosporine [letter] Tellus MM, et al. **Br J Rheumatol** 1995 Dec;34(12):1187–8

Polymyositis and chronic graft–versus–host disease: efficacy of intravenous gammaglobulin and methotrexate. Blanche P, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):377–9

Hospital acquired pulmonary nocardiosis complicating polymyositis. Gupta D, et al. **J Assoc Physicians India** 1995 Sep;43(9):641–2

[Anti–Jo–1–positive polymyositis with interstitial alveolitis and pericardial effusion. Overview of 3 years treatment] Krajnc I. **Wien Klin Wochenschr** 1995;107(19):590–2 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Risk assessment of polymyositis/dermatomyositis after treatment with injectable bovine collagen implants. Hanke CW, et al. **J Am Acad Dermatol** 1996 Mar;34(3):450–4

Elevated cancer incidence in patients with dermatomyositis: a population based study. Airio A, et al. **J Rheumatol** 1995 Jul;22(7):1300–3

ETIOLOGY

Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection [letter; comment] Ferri C, et al. **Arthritis Rheum** 1996 Jun;39(6):1074–5. Comment on: Arthritis Rheum 1995 Mar;38(3):437–9.

Myositis associated with interleukin–2 therapy in a patient with metastatic renal cell carcinoma. Esteva–Lorenzo FJ, et al. **Cancer** 1995 Oct 1;76(7):1219–23

Pyomyositis and septic arthritis due to Bacteroides fragilis in an immunocompetent patient. Calvo–Alén J, et al. **Clin Infect Dis** 1995 Nov;21(5):1344

Tropical pyomyositis. Ansaloni L. **World J Surg** 1996 Jun; 20(5):613–7

[Association of polymyositis, myasthenia gravis and thymoma (letter)] de Lacroix–Szmania I, et al. **Rev Med Interne** 1996; 17(4):344–5 **(Fre)**

[Anti–synthetase syndrome: a special subgroup of idiopathic inflammatory myopathies. Apropos of 3 case reports] Perret L, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16; 85(16):508–12 (Eng. Abstr.) **(Fre)**

[Polymyositis after interferon beta treatment of chronic hepatitis type C] Iguchi H, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):22–4 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome [letter] Sharma A, et al. **Ann Rheum Dis** 1995 Sep;54(9):780–1

Adult respiratory distress syndrome in polymyositis patients with the anti–Jo–1 antibody. Clawson K, et al. **Arthritis Rheum** 1995 Oct;38(10):1519–23

Sensitivity and specificity of anti–Jo–1 antibodies in autoimmune diseases with myositis. Vázquez–Abad D, et al. **Arthritis Rheum** 1996 Feb;39(2):292–6

Changing autoantibody profiles with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis. Satoh M, et al. **Br J Rheumatol** 1995 Oct;34(10):915–9

METABOLISM

Differential expression of perforin in muscle–infiltrating T cells in polymyositis and dermatomyositis. Goebels N, et al. **J Clin Invest** 1996 Jun 15;97(12):2905–10

MICROBIOLOGY

Bacterial pyomyositis due to Streptococcus pneumoniae in a previously healthy man [letter] Gamboa F, et al. **Scand J Rheumatol** 1995;24(6):396

PATHOLOGY

Anterior horn cell degeneration in polymyositis associated with human T lymphotropic virus Type–1 in patients from Barbados. Corbin DO, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):625–8

[Bifocal lesion of striated muscle (hamartoma or focal myositis) in the course of Proteus syndrome] Nodari F, et al. **Ann Pathol** 1996;16(1):53–5 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Shapiro J, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):331–5

A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Clarke AE, et al. **Arthritis Rheum** 1995 Sep;38(9):1218–24

[Skeletal muscle weakness in a young woman] Meretoja P, et al. **Duodecim** 1994;110(23–24):2219–22 **(Fin)**

RADIOGRAPHY

Tuberculous myositis: CT and sonographic findings in two cases. Wilbur AC, et al. **J Clin Ultrasound** 1995 Oct; 23(8):495–9

RADIONUCLIDE IMAGING

Bone scintigraphy in a patient with polymyositis. Cuartero–Plaza A, et al. **Clin Nucl Med** 1995 Oct;20(10):930

ULTRASONOGRAPHY

Tuberculous myositis: CT and sonographic findings in two cases. Wilbur AC, et al. **J Clin Ultrasound** 1995 Oct; 23(8):495–9

VIROLOGY

Polymyositis, arthritis, and uveitis in a macaque experimentally infected with human T lymphotropic virus type I. Beilke MA, et al. **Arthritis Rheum** 1996 Apr; 39(4):610–5

Human T cell leukemia/lymphoma virus type I DNA and polymyositis/dermatomyositis: comment on the article by Sherman et al [letter; comment] Couderc LJ, et al. **Arthritis Rheum** 1996 Mar;39(3):535. Comment on: Arthritis Rheum 1995 May;38(5):690–8.

Polymyositis in HTLV–I infected patient [letter] Khanlou H, et al. **J Intern Med** 1996 Apr;239(4):371

Acute polymyositis and myoglobinuric renal failure associated with influenza A infection. Holt P, et al. **N Z Med J** 1995 Nov 10;108(1011):463

POLYMYXIN

PHARMACOLOGY

Characterization of lipopolysaccharides of polymyxin–resistant and polymyxin–sensitive Klebsiella pneumoniae O3. Helander IM, et al. **Eur J Biochem** 1996 Apr 1;237(1):272–8

Increased substitution of phosphate groups in lipopolysaccharides and lipid A of polymyxin–resistant mutants of Salmonella typhimurium and Escherichia coli. Helander IM, et al. **Prog Clin Biol Res** 1995;392:15–23

Molecular genetics of polymyxin resistance in Salmonella typhimurium. Roland KL, et al. **Prog Clin Biol Res** 1995; 392:3–14

[Intensification of the ionophoric effect of polymyxin M by free fatty acids. Dependence of the length of the fatty acid chain] Podgaets ER, et al. **Biofizika** 1995 Mar–Apr; 40(2):317–22 (Eng. Abstr.) **(Rus)**

POLYMYXIN B

ADMINISTRATION & DOSAGE

Failure of topical polymyxin B to improve mild plaque psoriasis [letter] Stutz JA, et al. **Arch Dermatol** 1996 Feb; 132(2):231

A double–blind comparative study of ofloxacin otic drops versus neomycin–polymyxin B–hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. Tong MC, et al. **J Laryngol Otol** 1996 Apr; 110(4):309–14

ADVERSE EFFECTS

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

Anaphylaxis from bacitracin and polymyxin B (Polysporin) ointment. Knowles SR, et al. **Int J Dermatol** 1995 Aug; 34(8):572–3

Safety of ototopical antibiotics [letter; comment] Masaki M. **Laryngoscope** 1996 Mar;106(3 Pt 1):370. Comment on: Laryngoscope 1995 May;105(5 Pt 1):472–4.

ANALOGS & DERIVATIVES

Conformation of polymyxin B analogs in DMSO from NMR spectra and molecular modeling. Liao SY, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):312–20

CHEMISTRY

Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Srimal S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):679–86

Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts. Cajal Y, et al. **Biochemistry** 1996 May 7;35(18):5684–95

Intermembrane molecular contacts by polymyxin B mediate exchange of phospholipids. Cajal Y, et al. **Biochemistry** 1996 Jan 9;35(1):299–308

POLYMYXIN B

PHARMACOLOGY

Polymyxin B prevents increased sympathetic activity and alveolar macrophage tumor necrosis factor release in parenterally fed rats. Johnson KM, et al. **Arch Surg** 1995 Dec;130(12):1294–9; discussion 1299–300

Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Srimal S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):679–86

Inhibition of lipopolysaccharide-induced TNF-alpha production by semisynthetic polymyxin-B conjugated dextran. Coyne CP, et al. **Biotechnol Ther** 1994–95; 5(3–4):137–62 (108 ref.)

Semi-synthesis of polymyxin-B conjugated ovalbumin: evaluation of lipopolysaccharide binding avidity and neutralization of induced tnf-alpha synthesis. Coyne CP, et al. **Biotherapy** 1994;8(1):69–83

Inhibition of vascular contractions to alpha-adrenoceptor agonists by polymyxin B: impact of heart failure state. Forster C. **Eur J Pharmacol** 1995 Sep 5;283(1–3):241–50

Starvation- and Stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in Salmonella typhimurium is RpoS (sigma(S)) independent and occurs through both phoP-dependent and -independent pathways. McLeod GI, et al. **J Bacteriol** 1996 Jul;178(13):3683–8

In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525–9

Effects of a subtherapeutic dose of polymyxin B on gut origin endotoxin/bacterial translocation [letter; comment] Freund HR, et al. **J Trauma** 1996 Jan;40(1):171. Comment on: J Trauma 1995 Jun;38(6):924–30.

Lipopolysaccharides of polymyxin B–resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Nummila K, et al. **Mol Microbiol** 1995 Apr; 16(2):271–8

Bacterial responses to host–defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

THERAPEUTIC USE

Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Bucklin SE, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1462–6

Results of a survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution. Wagner RS. **Clin Ther** 1995 Sep–Oct; 17(5):875–81

Reduction of endotoxin-induced inflammation of the middle ear by polymyxin B. Darrow DH, et al. **Laryngoscope** 1996 Aug;106(8):1028–33

POLYMYXIN E see **COLISTIN**

POLYNEURITIS

BLOOD

[Effect of diabetic control on the progression of neuropathy] Hasegawa O, et al. **No To Shinkei** 1995 Dec;47(12):1179–82 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Respiratory insufficiency in adults with diphtheric polyneuropathy] Popova LM, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):9–13 (Eng. Abstr.) **(Rus)**

[Neuromuscular gait disorders in pediatric age] Martínez Menéndez B, et al. **Rev Neurol** 1995 Mar–Apr; 23(120):307–10 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Recurrent Miller Fisher syndrome. Significance of anti-GQ1B antibodies] Dewarrat A, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):180–4 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation. in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). **Neurology** 1995 Oct;45(10):1832–6

ETIOLOGY

Multiple symmetric lipomatosis presenting with polyneuropathy. Teplitsky V, et al. **Isr J Med Sci** 1995 Nov;31(11):693–5

[Electroneuromyography in patients with severe diphtheric polyneuropathy under conditions of artificial ventilation of the lungs] Airapetian KV, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):21–3 **(Rus)**

[Respiratory insufficiency in adults with diphtheric polyneuropathy] Popova LM, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):9–13 (Eng. Abstr.) **(Rus)**

[Cranial polyneuritis as initial manifestation of Lyme disease (letter)] Garcia Roman JM, et al. **An Med Interna** 1995 Dec;12(12):621–2 **(Spa)**

IMMUNOLOGY

Are autoimmune mechanisms involved in critical illness polyneuropathy? [letter] Terasako K, et al. **Intensive Care Med** 1995 Jan;21(1):96–7

PHYSIOPATHOLOGY

Vestibular dysfunction in chronic inflammatory demyelinating polyneuropathy. Frohman EM, et al. **Ann Neurol** 1996 Apr;39(4):529–35

THERAPY

Churg–Strauss syndrome with peripheral polyneuropathy refractory to steroideal and immunosuppressive therapy successfully treated with plasma exchange. Fregoni V, et al. **Recenti Prog Med** 1995 Sep;86(9):353–4

[The treatment of distal neuropathy—an important means for preventing the development of diabetic gangrene] Datsun IH, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):25–9 (29 ref.) **(Ukr)**

VETERINARY

[Communication: fast – faster.....too late? (letter)] Beijer HA. **Tijdschr Diergeneeskd** 1996 Jun 15;121(12):361, 364 **(Dut)**

VIROLOGY

Polyneuritis cranialis due to varicella–zoster virus in the absence of rash. Osaki Y, et al. **Neurology** 1995 Dec; 45(12):2293

POLYNUCLEAR AROMATIC HYDROCARBONS see **POLYCYCLIC HYDROCARBONS, AROMATIC**

POLYNUCLEOTIDE ADENYLYLTRANSFERASE see **POLY A POLYMERASE**

POLYNUCLEOTIDE HYDROXYLKINASE

CHEMISTRY

Solid–phase synthesis of oligoribonucleotides using T4 RNA ligase and T4 polynucleotide kinase. Vratskikh LV, et al. **Biochimie** 1995;77(4):227–32

METABOLISM

Kinetic and thermodynamic characterization of the reaction catalyzed by a polynucleotide kinase ribozyme. Lorsch JR, et al. **Biochemistry** 1995 Nov 21;34(46):15315–27

POLYNUCLEOTIDE KINASE see **POLYNUCLEOTIDE HYDROXYLKINASE**

POLYNUCLEOTIDE PHOSPHORYLASE

GENETICS

Properties of a Bacillus subtilis polynucleotide phosphorylase deletion strain. Wang W, et al. **J Bacteriol** 1996 Apr; 178(8):2375–82

ISOLATION & PURIFICATION

Proteins associated with RNase E in a multicomponent ribonucleolytic complex Miczak A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3865–9

METABOLISM

Guanosine pentaphosphate synthetase from Streptomyces antibioticus is also a polynucleotide phosphorylase. Jones GH, et al. **J Bacteriol** 1996 Jul;178(14):4281–8

Polynucleotide phosphorylase is required for the rapid degradation of the RNase E-processed rpsO mRNA of Escherichia coli devoid of its 3' hairpin. Braun F, et al. **Mol Microbiol** 1996 Mar;19(5):997–1005

Enzymatic synthesis of polymers containing nicotinamide mononucleotide. Liu R, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3742–9

POLYNUCLEOTIDES

ADMINISTRATION & DOSAGE

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Polynucleotide-mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)

BIOSYNTHESIS

Enzymatic synthesis of polymers containing nicotinamide mononucleotide. Liu R, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3742–9

CHEMISTRY

The B form to Z form transition of poly(dG-m5dC) is sensitive to neutral solutes through an osmotic stress. Preisler RS, et al. **Biochemistry** 1995 Nov 7;34(44):14400–7

The interaction of copper tetrakis(4–N–methylpyridyl) porphine with polynucleotides studied by ultraviolet resonance Raman spectroscopy. Wheeler GV, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):399–412

Application of combinatorial libraries and protein engineering to the discovery of novel anti–thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)

GENETICS

[The passive transfer by Drosophila spermatozoa of exogenous DNA molecules or synthetic polynucleotides into fertilizable eggs] Gershenzon SM. **Tsitol Genet** 1996 Jan–Feb;30(1):5–8 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

14th International Symposium on the Separation and Analysis of Proteins, Peptides and Polynucleotides. Heidelberg, Germany, 2–4 November 1994. **J Chromatogr A** 1995 Sep 8;711(1):1–233

METABOLISM

A general method of analysis of ligand binding to competing macromolecules using the spectroscopic signal originating from a reference macromolecule. Application to Escherichia coli replicative helicase DnaB protein nucleic acid interactions. Jezewska MJ, et al. **Biochemistry** 1996 Feb 20;35(7):2117–28

Binding studies of a triple–helical peptide model of macrophage scavenger receptor to tetraplex nucleic acids. Mielewczyk SS, et al. **Biochemistry** 1996 Sep 3; 35(35):11396–402

Interaction of yeast elongation factor 3 with polynucleotides, ribosomal RNA and ribosomal subunits. Kovalchuke O, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):336–42

PHARMACOKINETICS

Delivery of oligonucleotides and polynucleotides [editorial] Crooke ST. **J Drug Target** 1995;3(3):185–90

POLYOMAVIRUS

Production of avian polyomavirus seronegative budgerigars (Melopsittacus undulatus) from seropositive adults. Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):897–9

Characterization of the avian polyomavirus–associated glomerulopathy of nestling parrots. Phalen DN, et al. **Avian Dis** 1996 Jan–Mar;40(1):140–9

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

The murine Fc–gamma (Fc gamma) receptor type II B1 is a tumorigenicity–enhancing factor in polyoma–virus–transformed 3T3 cells. Zusman T, et al. **Int J Cancer** 1996 Jan 17;65(2):221–9

Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105–9 (23 ref.)

The role of ovarian hormones, age and mammary gland development in polyomavirus mammary tumorigenesis. Rondinelli RH, et al. **Oncogene** 1995 Nov 2;11(9):1817–27

[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja–Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Polyoma tumor development in neonatally polyoma–virus–infected CD4–/– and CD8–/– single knockout and CD4–/–8–/– double knockout mice. Berke Z, et al. **Int J Cancer** 1996 Jul 29;67(3):405–8

Efficient replication of polyomavirus DNA in a cell–free system supplemented with Escherichia coli single–stranded DNA binding protein, which exhibits species–specificity in the requirement for DNA polymerase alpha–primase. Eki T, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):435–41

Genetic and structural analysis of a virulence determinant in polyomavirus VP1. Bauer PH, et al. **J Virol** 1995 Dec; 69(12):7925–31

An enhancer of recombination in polyomavirus DNA. Gendron D, et al. **J Virol** 1996 Jul;70(7):4748–60

Elements of the polyomavirus replication origin required for homologous recombination mediated by large T antigen. Laurent S, et al. **J Virol** 1995 Nov;69(11):7304–8

Sequences flanking the pentanucleotide T–antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication. Li L, et al. **J Virol** 1995 Dec;69(12):7570–8

Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3–kinase in activation of pp70 S6 kinase. Dahl J, et al. **Mol Cell Biol** 1996 Jun;16(6):2728–35

Analysis of mutagenesis in UV–sensitive mouse lymphoma L5178Y–R cells with a polyomavirus–based shuttle vector. Zernik–Kobak M, et al. **Mutat Res** 1995 Aug;344(1–2):31–9

The sequence and context of the 5' splice site govern the

nuclear stability of polyoma virus late RNAs. Barrett NL, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4812–7

IMMUNOLOGY

Activation and nuclear translocation of mitogen–activated protein kinases by polyomavirus middle–T or serum depend on phosphatidylinositol 3–kinase. Urich M, et al. **J Biol Chem** 1995 Dec 8;270(49):29286–92

Suppression of platelet–derived growth factor alpha– and beta–receptor mRNA levels in human fibroblasts by SV40 T/t antigen. Wang JL, et al. **J Cell Physiol** 1996 Jan; 166(1):12–21

T cell–independent antibody–mediated clearance of polyoma virus in T cell–deficient mice. Szomolanyi–Tsuda E, et al. **J Exp Med** 1996 Feb 1;183(2):403–11

A short peptide eluted from the H–2Kb molecule of a polyomavirus–positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus–specific immunity. Berke Z, et al. **J Virol** 1996 May;70(5):3093–7

Genetic analysis of polyomavirus large T nuclear localization: nuclear localization is required for productive association with pRb family members. Howes SH, et al. **J Virol** 1996 Jun;70(6):3581–8

ISOLATION & PURIFICATION

Polyomavirus–infected oligodendrocytes and macrophages within astrocytes in progressive multifocal leukoencephalopathy (PML). Mesquita R, et al. **APMIS** 1996 Feb;104(2):153–60

Detection of polyomaviral DNA sequences in normal and adenomatous human pituitary tissues using the polymerase chain reaction. Woloschak M, et al. **Cancer** 1995 Aug 1; 76(3):490–6

Development and application of an immunohistochemical staining technique to detect avian polyomaviral antigen in tissue sections. Fitzgerald SD, et al. **J Vet Diagn Invest** 1995 Oct;7(4):444–50

METABOLISM

In vitro phosphorylation of the polyomavirus major capsid protein VP1 on serine 66 by casein kinase II. Li M, et al. **J Biol Chem** 1995 Oct 27;270(43):26006–11

Murine polyomavirus and simian virus 40 large T antigens produce different structural alterations in viral origin DNA. Bhattacharyya S, et al. **J Virol** 1995 Dec;69(12):7579–85

Expression of the polyomavirus minor capsid proteins VP2 and VP3 in Escherichia coli: in vitro interactions with recombinant VP1 capsomeres. Delos SE, et al. **J Virol** 1995 Dec;69(12):7734–42

Sequences flanking the pentanucleotide T–antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication. Li L, et al. **J Virol** 1995 Dec;69(12):7570–8

Characterization of two novel YY1 binding sites in the polyomavirus late promoter. Martelli F, et al. **J Virol** 1996 Mar;70(3):1433–8

Methylation of the polyomavirus major capsid protein VP1. Burton KS, et al. **Virus Res** 1996 Feb;40(2):141–7

PATHOGENICITY

Genetic and structural analysis of a virulence determinant in polyomavirus VP1. Bauer PH, et al. **J Virol** 1995 Dec; 69(12):7925–31

PHYSIOLOGY

In vivo and in vitro association of hsc70 with polyomavirus capsid proteins. Cripe TP, et al. **J Virol** 1995 Dec; 69(12):7807–13

ULTRASTRUCTURE

Conserved features in papillomavirus and polyomavirus capsids. Belnap DM, et al. **J Mol Biol** 1996 Jun 7; 259(2):249–63

A model–based approach for determining orientations of biological macromolecules imaged by cryoelectron microscopy. Baker TS, et al. **J Struct Biol** 1996 Jan–Feb; 116(1):120–30

POLYOMAVIRUS HOMINIS 1

BK virus infection in a kidney allograft diagnosed by needle biopsy. Purighalla R, et al. **Am J Kidney Dis** 1995 Oct; 26(4):671–3

BK virus–induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1835–42 (40 ref.)

BK virus encephalitis in an immunocompetent patient. Voltz R, et al. **Arch Neurol** 1996 Jan;53(1):101–3

Hypothesis: "Rogue cell"–type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Neel JV, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2690–5

DRUG EFFECTS

The in vitro effect of monensin on BK polyomavirus replication. Pietropaolo V, et al. **New Microbiol** 1995 Oct; 18(4):341–9

[Use of cell culture for the research of cytotoxic and antiviral effects of a natural extract of Amaryllidaceae] Husson GP, et al. **C R Seances Soc Biol Fil** 1995;189(4):679–92 (Eng. Abstr.) **(Fre)**

GENETICS

Interaction of human polyomavirus BK with the tumor–suppressor protein p53. Shivakumar CV, et al. **Oncogene** 1996 Jul 18;13(2):323–32

DNA rearrangements impairing BK virus productive infection in urinary tract tumors. Monini P, et al. **Virology** 1995 Dec 1;214(1):273–9

Noncoding control region of naturally occurring BK virus variants: sequence comparison and functional analysis. Moens U, et al. **Virus Genes** 1995;10(3):261–75 (112 ref.)

GROWTH & DEVELOPMENT

BK virus and a new type of JC virus excreted by HIV–1 positive patients in rural Tanzania. Agostini HT, et al. **Arch Virol** 1995;140(11):1919–34

ISOLATION & PURIFICATION

Large T antigen coding sequences of two DNA tumor viruses, BK and SV40, and nonrandom chromosome changes in two glioblastoma cell lines. Tognon M, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):17–23

Latent BK virus infection and Kaposi's sarcoma pathogenesis. Monini P, et al. **Int J Cancer** 1996 Jun 11;66(6):717–22

Chimeric BK virus DNA episomes in a papillary urothelial bladder carcinoma. Monini P, et al. **Intervirology** 1995; 38(5):304–8

JCV–DNA and BKV–DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)

PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. Ferrante P, et al. **J Med Virol** 1995 Nov;47(3):219–25

METABOLISM

Interaction of human polyomavirus BK with the tumor–suppressor protein p53. Shivakumar CV, et al. **Oncogene** 1996 Jul 18;13(2):323–32

PATHOGENICITY

Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Laszlo D, et al. **Haematologica** 1995 Sep–Oct;80(5):421–5

PHYSIOLOGY

BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. Harris KF, et al. **J Virol** 1996 Apr;70(4):2378–86

POLYOMAVIRUS HOMINIS 2

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)

Evidence for GEAPS, novel Glial E2F1–Associated Proteins in hamster glioma cells induced by the human neurotropic polyomavirus, JCV. Raj GV, et al. **Oncogene** 1996 Mar 21;12(6):1279–88

Hypothesis: "Rogue cell"–type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Neel JV, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2690–5

CLASSIFICATION

Geographical distribution of the human polyomavirus JC virus type A and B and isolation of a new type from Ghana. Guo J, et al. **J Gen Virol** 1996 May;77 (Pt 5):919–27

Functional comparison of PML–type and archetype strains of JC virus. Sock E, et al. **J Virol** 1996 Mar;70(3):1512–20

GENETICS

Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. Agostini HT, et al. **J Clin Microbiol** 1996 Jan;34(1):159–64

Human JC virus nuclear factor 1 binding motifs and large tumor antigen region rquired for transactivation of late promoter. Kumar KU, et al. **J Neurochem** 1996 Aug; 67(2):473–81

Transcription of the JC virus archetype late genome: importance of the kappa B and the 23–base–pair motifs in late promoter activity in glial cells. Mayreddy RP, et al. **J Virol** 1996 Apr;70(4):2387–93

Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polymavirus early protein. Franks RR, et al. **Oncogene** 1996 Jun 20; 12(12):2573–8

Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Daniel AM, et al. **Virology** 1996 Feb 1;216(1):90–101

Human JC virus cAMP response elements functional for enhanced glial cell expression in differentiating embryonal carcinoma cells. Kumar KU, et al. **Virology** 1996 Jan 15; 215(2):178–85

Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)

p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T–antigen. Staib C, et al. **Virology** 1996 May 1;219(1):237–46

GROWTH & DEVELOPMENT

BK virus and a new type of JC virus excreted by HIV–1 positive patients in rural Tanzania. Agostini HT, et al. **Arch Virol** 1995;140(11):1919–34

Establishment and characterization of a carrier cell culture producing high titres of polyoma JC virus. Nukuzuma S, et al. **J Med Virol** 1995 Dec;47(4):370–7

[Analysis of the cellular tropism of human polyoma JC virus (JCV)] Itoh S. **Hokkaido Igaku Zasshi** 1995 Sep; 70(5):765–74 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Evidence that the soluble factors secreted by activated immune cells suppress replication of human neurotropic JC virus DNA in glial cells. Chang CF, et al. **Virology** 1996 Jul 1;221(1):226–31

Biochemical characterization and localization of JC virus large T antigen phosphorylation domains. Swenson JJ, et al. **Virology** 1995 Oct 1;212(2):295–308

ISOLATION & PURIFICATION

Detection of JC virus DNA in the peripheral blood leukocytes of HIV–infected patients. Dubois V, et al. **AIDS** 1996 Apr;10(4):353–8

JCV–DNA and BKV–DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)

Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. Agostini HT, et al. **J Clin Microbiol** 1996 Jan;34(1):159–64

Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS–related progressive multifocal leukoencephalopathy. de Luca A, et al. **J Clin Microbiol** 1996 May;34(5):1343–6

PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. Ferrante P, et al. **J Med Virol** 1995 Nov;47(3):219–25

Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Rencic A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7352–7

METABOLISM

Transcriptional regulation of human polyomavirus JC: evidence for a functional interaction between RelA (p65) and the Y–box–binding protein, YB–1. Raj GV, et al. **J Virol** 1996 Sep;70(9):5944–53

Purified JC virus T antigen derived from insect cells preferentially interacts with binding site II of the viral core origin under replication conditions. Bollag B, et al. **Virology** 1996 Apr 1;218(1):81–93

PHYSIOLOGY

Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence–specific single–stranded DNA–binding protein Pur alpha. Chang CF, et al. **J Virol** 1996 Jun;70(6):4150–6

A model for mixed virus disease: co–infection with Moloney murine leukemia virus potentiates runting induced by polyomavirus (A2 strain) in Balb/c and NIH Swiss mice. Atencio IA, et al. **Virology** 1995 Oct 1;212(2):356–66

POLYOMAVIRUS LARGE T ANTIGENS see ANTIGENS, POLYOMAVIRUS TRANSFORMING

POLYOMAVIRUS MACACAE

Growth–suppressive activities of serine protease inhibitors, ONO–3403 and ONO–5046, toward normal and transformed murine fibroblasts. Hiwasa T, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1823–6

The Fanconi anemia complementation group C gene (FAC) suppresses transformation of mutant fibroblasts by the SV40 virus. Liu JM, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):685–90

Cytokine production by SV40–transformed adherent synovial cells from rheumatoid arthritis patients. Shimozato O, et al. **Cytokine** 1996 Jan;8(1):99–105

Immortalization of cat iris sphincter smooth muscle cells by SV40 virus: growth, morphological, biochemical and pharmacological characteristics. Ocklind A, et al. **Exp Eye Res** 1995 Nov;61(5):535–45

Studies of specific gene induction during apoptosis of cell lines conditionally immortalized by SV40. Guénal I, et al. **FEBS Lett** 1995 Nov 6;374(3):384–6

ENZYMOLOGY

Unwinding of the third strand of a DNA triple helix, a novel

activity of the SV40 large T-antigen helicase. Kopel V, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):330–5

GENETICS

Nucleic acid vaccination against virally induced tumors. Bright RK, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:241–51

Establishment and characterization of immortalized human coronary endothelial cells. Nakano R, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):715–22

A model for the T-antigen-induced structural alteration of the SV40 replication origin based upon experiments with specific probes for bent, straight, and unwound DNA. Han FX, et al. **Biochemistry** 1996 Jun 18;35(24):7993–8001

Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Kosukegawa A, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):37–45

Triple helix directed psoralen adducts induce a low frequency of recombination in an SV40 shuttle vector. Sandor Z, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):235–40

Normal human endometrial cells in culture: characterization and immortalization of epithelial and stromal cells by SV 40 large T antigen. Merviel P, et al. **Biol Cell** 1995; 84(3):187–93

Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. Basolo F, et al. **Br J Cancer** 1996 Jun; 73(11):1356–61

Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene. Kulkarni PS, et al. **Carcinogenesis** 1995 Oct;16(10):2515–21

Inhibition of cleavage by restriction endonucleases due to modifications induced in SV40 DNA by methyl methanesulfonate. Ghaskadbi S, et al. **Cell Mol Biol Res** 1995;41(1):59–66

Temperature sensitive simian virus 40 large T antigen immortalization of murine odontoblast cell cultures: establishment of clonal odontoblast cell line. MacDougall M, et al. **Connect Tissue Res** 1995;33(1–3):97–103

DNA polymerase epsilon may be dispensable for SV40- but not cellular-DNA replication. Zlotkin T, et al. **EMBO J** 1996 May 1;15(9):2298–305

Scleroderma-derived human fibroblasts retain abnormal phenotypic and functional characteristics following retroviral transduction with the SV40 tsT antigen. Xu S, et al. **Exp Cell Res** 1995 Oct;220(2):407–14

SV40-mediated immortalization of human fibroblasts. Ozer HL, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):303–10 (30 ref.)

Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture. Albright CD, et al. **FASEB J** 1996 Mar;10(4):510–6

Expression of the human cGMP-dependent protein kinase II gene is lost upon introduction of SV40 T antigen or immortalization in human cells. Fujii M, et al. **FEBS Lett** 1995 Nov 20;375(3):263–7

AP-4- and AP-5-like proteins from mouse L cells are trans-activators and bind to the GT-II region of SV40 early TRE in a mutually exclusive manner. Hou YT, et al. **Gene** 1995 Sep 11;162(2):197–203

Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Harms JS, et al. **Hum Gene Ther** 1995 Oct;6(10):1291–7

Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression? Bond JA, et al. **Int J Cancer** 1996 Aug 7;67(4):563–72

Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin. Cobuzzi RJ Jr, et al. **J Biol Chem** 1996 Aug 16;271(33):19852–9

Suppression of gene expression on the simian virus 40 major late promoter by human TR4 orphan receptor. A member of the steroid receptor superfamily. Lee HJ, et al. **J Biol Chem** 1995 Dec 15;270(50):30129–33

Transcription-positive cofactor 4 forms complexes with HSSB (RPA) on single-stranded DNA and influences HSSB-dependent enzymatic synthesis of simian virus 40 DNA. Pan ZQ, et al. **J Biol Chem** 1996 Sep 6; 271(36):22111–6

The simian virus 40 packaging signal ses is composed of redundant DNA elements which are partly interchangeable. Dalyot-Herman N, et al. **J Mol Biol** 1996 May 31;259(1):69–80

The stability of nucleosomes at the replication fork. Gasser R, et al. **J Mol Biol** 1996 May 3;258(2):224–39

Topological complexity of SV40 minichromosomes. Givens RM, et al. **J Mol Biol** 1996 Mar 22;257(1):53–65

Identification of Simian virus 40 promoter DNA sequences capable of conferring restriction endonuclease hypersensitivity. Hermansen R, et al. **J Virol** 1996 Jun; 70(6):3416–22

Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. Stubdal H, et al. **J Virol** 1996 May;70(5):2781–8

In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes. Wiesmüller L, et al. **J Virol** 1996 Feb;70(2):737–44

Identification of eukaryotic DNA replication proteins using simian virus 40 in vitro replication system. Brush GS, et al. **Methods Enzymol** 1995;262:522–48

Induction of circles of heterogeneous sizes in carcinogen-treated cells: two-dimensional gel analysis of circular DNA molecules. Cohen S, et al. **Mol Cell Biol** 1996 May;16(5):2002–14

Stimulation of nuclear import by simian virus 40-transformed cell extracts is dependent on protein kinase activity. Feldherr C, et al. **Mol Cell Biol** 1995 Dec;15(12):7043–9

Rat embryo fibroblasts immortalized with simian virus 40 large T antigen undergo senescence upon its inactivation. Gonos ES, et al. **Mol Cell Biol** 1996 Sep;16(9):5127–38

Keratin expression and steroidogenesis in rat granulosa cells, transformed with the Kirsten-ras and SV40 oncogenes singly and in combination. Pan J, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):231–9

Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Kananen K, et al. **Mol Endocrinol** 1995 May; 9(5):616–27

Effects of cell cycle dependent histone H1 phosphorylation on chromatin structure and chromatin replication. Halmer L, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1420–7

Database of mutations that alter the large tumor antigen in simian virus 40. Kierstead TD, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):125–6

Experimentally determined weight matrix definitions of the initiator and TBP binding site elements of promoters. Kraus RJ, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1531–9

SV40-like sequences in human bone tumors. Carbone M, et al. **Oncogene** 1996 Aug 1;13(3):527–35

p53 represses SV40 transcription by preventing formation of transcription complexes. Perrem K, et al. **Oncogene** 1995 Oct 5;11(7):1299–307

Simian virus 40 late gene expression is regulated by members of the steroid/thyroid hormone receptor superfamily. Zuo F, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8586–90

Modification of radiation-induced strand breaks by glutathione: comparison of single- and double-strand breaks in SV40 DNA. Ayene IS, et al. **Radiat Res** 1995 Oct;144(1):1–8

Study on simian virus 40 DNA synthesis in herpes simplex virus-infected cells. Blümel J, et al. **Virology** 1996 Mar 1;217(1):407–12

Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Lednicky JA, et al. **Virology** 1995 Oct 1;212(2):710–7

Identification of a variable region at the carboxy terminus of SV40 large T-antigen. Stewart AR, et al. **Virology** 1996 Jul 15;221(2):355–61

[Functional properties of a new line of immortalized human endothelial cells] Moldovan F, et al. **C R Acad Sci III** 1995 Sep;318(9):951–8 (Eng. Abstr.) **(Fre)**

[Eukaryotic DNA replication: analysis of reconstitution of SV40 DNA replication] Waga S. **Seikagaku** 1995 Sep; 67(9):1142–8 (19 ref.) **(Jpn)**

IMMUNOLOGY

Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Bright RK, et al. **Cancer Res** 1996 Mar 1; 56(5):1126–30

Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Boyce BF, et al. **Endocrinology** 1995 Dec;136(12):5751–9

A melanoma cell line sensitive to expression of a fusion protein binding the retinoblastoma protein family pocket domain. Khan S, et al. **Exp Cell Res** 1996 Feb 25; 223(1):171–82

Mutation of p53 is not a prerequisite for immortalization of human fibroblasts by SV40 T antigen. Moorwood K, et al. **Exp Cell Res** 1996 Mar 15;223(2):308–13

SV40-adenovirus immortalized cell lines derived from mouse lymphoid dendritic cell preparations. Ohnishi K, et al. **Immunol Cell Biol** 1995 Jun;73(3):205–11

Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Antonia SJ, et al. **Int Immunol** 1995 May;7(5):715–25

SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. Chen H, et al. **J Biol Chem** 1996 Jun 14;271(24):13959–67

Estradiol-dependent uterine leiomyomas in transgenic mice. Romagnolo B, et al. **J Clin Invest** 1996 Aug 1;98(3):777–84

Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen. Requirement of CD8+ T lymphocytes. Zerrahn J, et al. **J Immunol** 1996 May 15; 156(10):3919–24

Mechanisms of simian virus 40 T-antigen activation by phosphorylation of threonine 124. McVey D, et al. **J Virol** 1996 Jun;70(6):3887–93

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. Mylin LM, et al. **J Virol** 1995 Nov;69(11):6665–77

An N-terminal deletion mutant of simian virus 40 (SV40) large T antigen oligomerizes incorrectly on SV40 DNA but retains the ability to bind to DNA polymerase alpha and replicate SV40 DNA in vitro. Weisshart K, et al. **J Virol** 1996 Jun;70(6):3509–16

Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation. Zalvide J, et al. **Mol Cell Biol** 1995 Oct;15(10):5800–10

Trans-splicing and alternative-tandem-cis-splicing: two ways by which mammalian cells generate a truncated SV40 T-antigen. Eul J, et al. **Nucleic Acids Res** 1996 May 1; 24(9):1653–61

Compensatory apoptosis in response to SV40 large T antigen expression in the liver. Allemand I, et al. **Oncogene** 1995 Dec 21;11(12):2583–90

Fas-dependent apoptosis is impaired by SV40 T-antigen in transgenic liver. Rouquet N, et al. **Oncogene** 1995 Sep 21; 11(6):1061–7

Relationship between expression of epidermal growth factor and simian virus 40 T antigen in a line of transgenic mice. Lafond RE, et al. **Transgenic Res** 1995 Sep;4(5):306–14

[The characteristics of the transport into the nucleus of conjugates with normal and mutant nucleophilic sequences] Barbul AI, et al. **Tsitologiia** 1995;37(12):1223–9 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Large T antigen coding sequences of two DNA tumor viruses, BK and SV40, and nonrandom chromosome changes in two glioblastoma cell lines. Tognon M, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):17–23

Failure to confirm presence of SV40 sequences in human tumours [letter] Krainer M, et al. **Eur J Cancer** 1995 Oct; 31A(11):1893

Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. Cristaudo A, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):29–34

Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Lednicky JA, et al. **Virology** 1995 Oct 1;212(2):710–7

METABOLISM

Fast inducible repair of microinjected UV-irradiated SV40 DNA in monkey kidney cells. Ghaskadbi S, et al. **Cell Mol Biol Res** 1995;41(1):67–72

TAF-like function of SV40 large T antigen. Damania B, et al. **Genes Dev** 1996 Jun 1;10(11):1369–81

Murine polyomavirus and simian virus 40 large T antigens produce different structural alterations in viral origin DNA. Bhattacharyya S, et al. **J Virol** 1995 Dec;69(12):7579–85

Analysis of a nuclear localization signal of simian virus 40 major capsid protein Vp1. Ishii N, et al. **J Virol** 1996 Feb; 70(2):1317–22

The major transcriptional transactivation domain of simian virus 40 large T antigen associates nonconcurrently with multiple components of the transcriptional preinitiation complex. Johnston SD, et al. **J Virol** 1996 Feb; 70(2):1191–202

Identification of eukaryotic DNA replication proteins using simian virus 40 in vitro replication system. Brush GS, et al. **Methods Enzymol** 1995;262:522–48

Association with capsid proteins promotes nuclear targeting of simian virus 40 DNA. Nakanishi A, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):96–100

PHYSIOLOGY

Increase in total protein following infection of CV-1 cells with SV40 virus as assayed by flow cytometry. Lehman JM, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):806–10

Activation of the human thymidine kinase (TK) promoter by simian virus 40 large T antigen requires both the T antigen pRb family-binding domain and TK promoter sequences resembling E2F-binding sites. Anderson MM, et al. **J Virol** 1996 Sep;70(9):6304–13

The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain. Higgins C, et al. **J Virol** 1996 Feb;70(2):745–52

The inhibition of cultured myoblast differentiation by the simian virus 40 large T antigen occurs after myogenin expression and Rb up-regulation and is not exerted by transformation-competent cytoplasmic mutants. Tedesco D, et al. **J Virol** 1995 Nov;69(11):6947–57

Species-specific replication of simian virus 40 DNA in vitro requires the p180 subunit of human DNA polymerase alpha-primase. Stadlbauer F, et al. **Mol Cell Biol** 1996 Jan; 16(1):94–104

Reduced levels of alpha1(XI) procollagen mRNA in SV40-transformed cells. Sompayrac L, et al. **Virology** 1996 Apr 15;218(2):412–6

RADIATION EFFECTS

Inhibition of initiation of simian virus 40 DNA replication during acute response of cells irradiated by ultraviolet light. Wang YC, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3149–57

POLYOMAVIRUS MIDDLE T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS SMALL T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS T PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TRANSFORMING ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TUMOR ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOXYETHYLENE POLYOXYPROPYLENE POLYOXYETHYLENE POLYMER see **POLOXALENE**

POLYOXYETHYLENES see **POLYETHYLENE GLYCOLS**

POLYPENTOSE SULFATE see **PENTOSAN SULFURIC POLYESTER**

POLYPEPTIDES see **PEPTIDES**

POLYPHLORETIN PHOSPHATE

THERAPEUTIC USE

Effects of prostaglandin antagonist phloretin derivatives on mouse ear edema induced with different skin irritants. Blazsó G, et al. **Prostaglandins** 1995 Sep;50(3):161–8

POLYPHOSPHATES

ANALYSIS

In situ 31P nuclear magnetic resonance for observation of polyphosphate and catabolite responses of chemostat–cultivated Saccharomyces cerevisiae after alkalinization. Castro CD, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4448–53

CHEMICAL SYNTHESIS

[New and large scale syntheses of nucleoside polyphosphates] Ishikawa M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1333–41 (22 ref.) **(Jpn)**

CHEMISTRY

Poly–3–hydroxybutyrate/polyphosphate complexes form voltage–activated Ca2+ channels in the plasma membranes of Escherichia coli. Reusch RN, et al. **Biophys J** 1995 Sep; 69(3):754–66

METABOLISM

Genetic manipulation of polyphosphate metabolism affects cadmium tolerance in Escherichia coli. Keasling JD, et al. **Appl Environ Microbiol** 1996 Feb;62(2):743–6

Initial rate and equilibrium isotope exchange studies on the ATP–dependent activity of polyphosphate Glucokinase from Propionibacterium shermanii. Kowalczyk TH, et al. **Biochemistry** 1996 May 28;35(21):6777–85

Poly–3–hydroxybutyrate/polyphosphate complexes form voltage–activated Ca2+ channels in the plasma membranes of Escherichia coli. Reusch RN, et al. **Biophys J** 1995 Sep; 69(3):754–66

Inorganic polyphosphate supports resistance and survival of stationary–phase Escherichia coli. Rao NN, et al. **J Bacteriol** 1996 Mar;178(5):1394–400

PHARMACOLOGY

Effect of stunning time and polyphosphates on quality of cooked chicken breast meat. Young LL, et al. **Poult Sci** 1996 May;75(5):677–81

POLYPHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOL PHOSPHATES**

POLYPLOIDY

Maternal origin of extra haploid set of chromosomes in third trimester triploid fetuses. Dietzsch E, et al. **Am J Med Genet** 1995 Sep 25;58(4):360–4

Clinicopathologic study of tetraploid hydropic villous tissues. Fukunaga M, et al. **Arch Pathol Lab Med** 1996 Jun; 120(6):569–72

The important role of PKC in controlling polyploidy formation in cultured fibrosarcoma cell line. Zong ZP, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1009–15

Factors regulating megakaryocyte progenitor commitment to polyploidization. Paulus JM, et al. **C R Acad Sci III** 1995 Jul;318(7):779–84

Heterogeneity, polyploidy, aneusomy, and 9p deletion in human glioblastoma multiforme. Park SH, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):127–35

A brief staurosporine treatment of mitotic cells triggers premature exit from mitosis and polyploid cell formation. Hall LL, et al. **Cancer Res** 1996 Aug 1;56(15):3551–9

A comparison of the propensity for gene amplification between near–tetraploid and near–diploid V79 clones resistant to 150 nM methotrexate. Hashimoto MW, et al. **Carcinogenesis** 1996 Mar;17(3):389–94

Further insights on chromosomal pairing of autopolyploids: a triploid and tetraploids of rye. Santos JL, et al. **Chromosoma** 1995 Dec;104(4):298–307

Detection of triploidy in fish using the cytokinesis–blocked method for erythrocyte and hepatic cells. al–Sabti K. **Cytobios** 1995;82(330):181–7

Effect of insulin on in vitro development of tetraploid mouse embryos. Koizumi N, et al. **Exp Anim** 1996 Apr; 45(2):179–81

The involvement of the rho gene product, a small molecular weight GTP–binding protein, in polyploidization of a human megakaryocytic cell line, CMK. Takada M, et al. **Exp Hematol** 1996 Mar;24(4):524–30

Atypical polypoid adenomyomas of the uterus. Fukunaga M, et al. **Histopathology** 1995 Jul;27(1):35–42 (18 ref.)

Polyploidy and failed fertilization in in–vitro fertilization are related to patient's age and gamete quality. Yie SM, et al. **Hum Reprod** 1996 Mar;11(3):614–7

Effect of long–term treatment with propionyl–L–carnitine on smooth muscle cell polyploidy in spontaneously hypertensive rats. Mauriello A, et al. **Hypertension** 1996 Aug;28(2):177–82

Variation in radiosensitivity due to cell age and split–dose recovery in polykaryons induced by cytochalasin. Court JB, et al. **Int J Radiat Biol** 1995 Dec;68(6):647–54

Prediction of the initial slope of the acute clonogenic survival curve by the post–irradiation behaviour of cytochalasin–induced polykaryons. Davies HE, et al. **Int J Radiat Biol** 1995 Dec;68(6):631–45

Increased stringency of the 1,25–dihydroxyvitamin D3–induced G1 to S phase block in polyploid HL60 cells. Zhang F, et al. **J Cell Physiol** 1996 Jul;168(1):18–25

Hybridization between tetraploid and diploid species of treefrogs (Genus hyla). Mable BK, et al. **J Hered** 1995 Nov–Dec;86(6):432–40

Alterations in beta–adrenoceptors and polyploidy in cultured aortic smooth muscle cells from different age groups of spontaneously hypertensive rats and Wistar–Kyoto rats. Conyers RB, et al. **J Hypertens** 1995 May;13(5):507–15

Cytogenetic and clinical characteristics of a case involving complete duplication of Xpter–>Xq13. Jalal SM, et al. **J Med Genet** 1996 Mar;33(3):237–9

On the theory of partially inbreeding finite populations. IV. The effective population size for polyploids reproducing by partial selfing. Pollak E, et al. **Math Biosci** 1996 Jul 1;135(1):69–84

Electrofusion of mouse embryos to produce tetraploids. Petzoldt U. **Methods Mol Biol** 1995;48:331–40

Novel alterations in CDK1/cyclin B1 kinase complex formation occur during the acquisition of a polyploid DNA content. Datta NS, et al. **Mol Biol Cell** 1996 Feb; 7(2):209–23

Characterisation of the double genome structure of modern sugarcane cultivars (Saccharum spp.) by molecular cytogenetics. D'Hont A, et al. **Mol Gen Genet** 1996 Mar 7;250(4):405–13

Tetraploids of the lung fluke Paragonimus westermani found in China. Terasaki K, et al. **Parasitol Res** 1995;81(7):627–30

DNA flow cytometric analysis of abortions. A simple method for detection of triploidy and tetraploidy in the trophoblastic cells. Ruá S, et al. **Pathologica** 1995 Apr; 87(2):107–11

Triploidy, imprinting, and hCG levels in maternal serum screening [letter] Eiben B, et al. **Prenat Diagn** 1996 Apr; 16(4):377–8

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Galipeau PC, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7081–4

Hypothesis: "Rogue cell"–type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Neel JV, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2690–5

Heterogeneity and progression of renal cell carcinomas as revealed by DNA cytofluorometry and the significance of the presence of polyploid cells. Kushima M, et al. **Urol Res** 1995;23(6):381–6

Induction of polyploidy in adenovirus E1–transformed cells by the mitotic inhibitor colcemid. Kranenburg O, et al. **Virus Res** 1996 Feb;40(2):185–90

[Triploidy—a cause of fetal growth retardation and less than normal amniotic fluid] Karjalainen E, et al. **Duodecim** 1995; 111(7):627–9 **(Fin)**

[Polyploidy in the myocardium. Compensatory reserve of the heart] Brodskiĭ VIa. **Biull Eksp Biol Med** 1995 May; 119(5):454–9 (49 ref.) **(Rus)**

[The polyploidization characteristics of the hepatocytes of the mouse–like hamster Calomyscus mystax] Anatskaia OV, et al. **Tsitologiia** 1995;37(8):791–7 (Eng. Abstr.) **(Rus)**

[The rate of polyploid fertilization of ovocytes in in vitro fertilization in patients with an increased ovarian response] Tabš N, et al. **Med Pregl** 1994;47(11–12):381–3 (Eng. Abstr.) **(Scr)**

POLYPORACEAE

Effects of semi–purified dietary fibers isolated from Lagenaria siceraria, Raphanus sativus and Lentinus edodes on fecal steroid excretions in rats. Sannoumaru Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr;42(2):97–110

In vitro antifungal activity of Polyporaceae against yeasts and dermatophytes. Steinmetz MD, et al. **Mycoses** 1995 Jul–Aug;38(7–8):305–9

CHEMISTRY

Radical scavenger and antihepatotoxic activity of Ganoderma formosanum, Ganoderma lucidum and Ganoderma neo–japonicum. Lin JM, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):33–41

New steroid acids from Antrodia cinnamomea, a fungal parasite of Cinnamomum micranthum. Chen CH, et al. **J Nat Prod** 1995 Nov;58(11):1655–61

ENZYMOLOGY

Lip–like genes in Phanerochaete sordida and Ceriporiopsis subvermispora, white rot fungi with no detectable lignin peroxidase activity. Rajakumar S, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2660–3

The gene, protein and glycan structures of laccase from Pleurotus ostreatus. Giardina P, et al. **Eur J Biochem** 1996 Feb 1;235(3):508–15

Purification and catalytic properties of two manganese peroxidase isoenzymes from Pleurotus eryngii. Martínez MJ, et al. **Eur J Biochem** 1996 Apr 15;237(2):424–32

[Effect of carbon and nitrogen sources on the cellulolytic activity of Trametes trogii] Levin L, et al. **Rev Argent Microbiol** 1995 Jan–Mar;27(1):11–20 (Eng. Abstr.) **(Spa)**

GENETICS

Lip–like genes in Phanerochaete sordida and Ceriporiopsis subvermispora, white rot fungi with no detectable lignin peroxidase activity. Rajakumar S, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2660–3

Strain typing of Lentinula edodes by random amplified polymorphic DNA assay. Zhang Y, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):17–20

Genetic differentiation in Fomitopsis pinicola (Schwarts: Fr.) Karst studied by means of arbitrary primed–PCR. Högberg N, et al. **Mol Ecol** 1995 Dec;4(6):675–80

Metastable single–strand DNA conformational polymorphism analysis results in enhanced polymorphism detection. Kasuga T, et al. **PCR Methods Appl** 1995 Feb; 4(4):227–33

METABOLISM

Metabolism of phenanthrene by the white rot fungus Pleurotus ostreatus. Bezalel L, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2547–53

Correlation of brightening with cumulative enzyme activity related to lignin biodegradation during biobleaching of kraft pulp by white rot fungi in the solid–state fermentation system. Katagiri N, et al. **Appl Environ Microbiol** 1995 Feb; 61(2):617–22

Effect of manganese on preferential degradation of lignin by Pleurotus ostreatus during solid–state fermentation. Kerem Z, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):3057–62

A fungal metabolite mediates degradation of non–phenolic lignin structures and synthetic lignin by laccase. Eggert C, et al. **FEBS Lett** 1996 Aug 5;391(1–2):144–8

POLYPOSIS COLI, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPOSIS SYNDROME, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPROPYLENES

Greater risk of incisional hernia with morbidly obese than steroid–dependent patients and low recurrence with prefascial polypropylene mesh. Sugerman HJ, et al. **Am J Surg** 1996 Jan;171(1):80–4

Do topical antibiotics provide improved prophylaxis against bacterial growth in the presence of polypropylene mesh? Troy MG, et al. **Am J Surg** 1996 Apr;171(4):391–3

Herniography following indirect hernioplasty using the Marlex "mesh plug" technique. Kahn AM, et al. **Am Surg** 1995 Nov;61(11):947–8

Synthesis and physicochemical properties of protein conjugates with water–soluble poly(alkylene oxides). Topchieva IN, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):380–8

Colocutaneous fistula formation following polypropylene mesh placement for repair of a ventral hernia: diagnosis by colonoscopy. DeGuzman LJ, et al. **Endoscopy** 1995 Aug;27(6):459–61

Repair of neglected Achilles tendon ruptures with Marlex mesh. Choksey A, et al. **Injury** 1996 Apr;27(3):215–7

Comparison of a new type of polytetrafluoroethylene patch (Mycro Mesh) and polypropylene prosthesis (Marlex) for repair of abdominal wall defects. Bellón JM, et al. **J Am Coll Surg** 1996 Jul;183(1):11–8

Absorbable sutures in tendon repair. A comparison of PDS with prolene in rabbit tendon repair. O'Broin ES, et al. **J Hand Surg [Br]** 1995 Aug;20(4):505–8

Intestine submucosa and polypropylene mesh for abdominal wall repair in dogs. Clarke KM, et al. **J Surg Res** 1996 Jan;60(1):107–14

Monofilament polypropylene sutures in aortic valve replacement [letter; comment] Kärkölä P, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):286–7. Comment on: J Thorac Cardiovasc Surg 1995 Mar;109(3):536–44; discussion 544–5.

Comparison of nylon and polypropylene sutures in a microvenous thrombosis model. Ustüner TE, et al.

Microsurgery 1995;16(8):533–5

Ultra-high molecular weight polyethylene wear debris generated in vivo and in laboratory tests; the influence of counterface roughness. Hailey JL, et al. **Proc Inst Mech Eng [H]** 1996;210(1):3–10

Reconstruction of chest wall after full-thickness resection. Two case reports. Suzuki T, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):145–7

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

Meshlaparostomy—a comparison between polypropylene mesh and indigenous nylon net. Shah SR, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):49–54

[Morphologic aspects of alloplastic augmentation in replacement of the posterior cruciate ligament. An experimental study on the sheep] Bosch U, et al. **Unfallchirurg** 1996 Mar;99(3):183–90 (Eng. Abstr.) **(Ger)**

[Use of polypropylene (Marlex) prosthesis in the surgical treatment of inguinal and crural hernia] Campanelli GP, et al. **Minerva Chir** 1995 Jun;50(6):563–8 (Eng. Abstr.) **(Ita)**

[Evaluation of blood absorption, hemostatic ability and purity of a polyepoxy compound cross-linked cotton type collagen hemostat] Tomizawa Y, et al. **Kyobu Geka** 1996 Feb;49(2):126–9 (Eng. Abstr.) **(Jpn)**

[Morphological evaluation of structural changes in the tracheal wall at the site of braided and monofilament sutures in experimental animals] Kharchenko VP, et al. **Probl Tuberk** 1995;(6):41–3 (Eng. Abstr.) **(Rus)**

[Tracheal suture with a monofilament thread in animal experiments] Mil'kov SB. **Probl Tuberk** 1996;(2):46–7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Comparison of the degree of abdominal adhesion formation associated with chromic catgut and polypropylene suture materials. Rochat MC, et al. **Am J Vet Res** 1996 Jun; 57(6):943–7

CHEMISTRY

Stability of octreotide acetate in polypropylene syringes at 5 and –20 degrees C. Ripley RG, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1910–1

Effects of ions on partitioning of serum albumin and lysozyme in aqueous two-phase systems containing ethylene oxide/propylene oxide co-polymers. Johansson HO, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):289–98

Analysis of a vinyl pyrrolidone/poly(propylene fumarate) resorbable bone cement. Gresser JD, et al. **J Biomed Mater Res** 1995 Oct;29(10):1241–7

Polypropylene tube surfaces may induce denaturation and multimerization of DNA [letter; comment] Belotserkovskii BP, et al. **Science** 1996 Jan 12;271(5246):222–3. Comment on: Science 1994 Apr 15;264(5157):433–6.

RADIATION EFFECTS

Cell attachment to laser-induced AAm- and HEMA-grafted ethylene-propylene rubber as biomaterial: in vivo study. Mirzadeh H, et al. **Biomaterials** 1995 May;16(8):641–8

THERAPEUTIC USE

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Energy-shunting external hip protector attenuates the peak femoral impact force below the theoretical fracture threshold: an in vitro biomechanical study under falling conditions of the elderly. Parkkari J, et al. **J Bone Miner Res** 1995 Oct;10(10):1437–42

Absorbable sutures in tendon repair [letter] Amis AA. **J Hand Surg [Br]** 1996 Apr;21(2):286

TOXICITY

Histologic evaluation of tissue reactivity and absorption in response to a new synthetic fluorescent pigmented polypropylene suture material in rats. Beardsley SL, et al. **Am J Vet Res** 1995 Sep;56(9):1248–52

POLYPROTEINS see PROTEINS

POLYPS

[Fibroepithelial polyps of the ureter and the kidney pelvis. Report of 3 cases] Robert M, et al. **Prog Urol** 1996 Apr; 6(2):282–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Large cystic polyps of the stomach] Covotta A, et al. **G Chir** 1995 Mar;16(3):107–8 (Eng. Abstr.) **(Ita)**

[Inflammatory polyp of the extra-hepatic bile duct] Adachi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):149–51 (7 ref.) **(Jpn)**

[Polyp and polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):348–51 (12 ref.) **(Jpn)**

[Pseudotumors of the gallbladder] Iwase H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):329–32 (20 ref.) **(Jpn)**

[Granulation polyp of the gallbladder, inflammation of the Rokitansky-Aschoff sinus] Liao CM, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):321–3 (6 ref.) **(Jpn)**

[Inflammatory polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):248–50 (22 ref.) **(Jpn)**

[Hyperplastic polyp, metaplastic polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):256–8 (22 ref.) **(Jpn)**

[Fibrous polyp of the gallbladder] Takashimizu I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):295–8 (16 ref.) **(Jpn)**

[Fibroepithelial polyp of the gallbladder] Tokoi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):292–4 (8 ref.) **(Jpn)**

BLOOD

[Extreme increase in the blood erythroblast count in a patient with iron-deficiency anemia and asplenia] Ramos Fernández de Soria R, et al. **Sangre (Barc)** 1996 Feb; 41(1):65–7 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Massive endometrial polyp after tamoxifen therapy. Divers MJ. **Br J Clin Pract** 1995 Sep–Oct;49(5):275–6

Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. McGonigle KF, et al. **Cancer Lett** 1996 Mar 19; 101(1):59–66

CLASSIFICATION

Functional trauma of the vocal folds: classification and management strategies. Milutinović Z, et al. **Folia Phoniatr Logop** 1996;48(2):78–85

Histologic classification of endoscopically removed flat colorectal polyps: a multicentric study. Rubio CA, et al. **Jpn J Cancer Res** 1996 Aug;87(8):849–55

COMPLICATIONS

Necrotizing sialometaplasia coincident with ipsilateral infarcted antral polyps [letter] Bell GW, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):129–31

A multicenter, multiyear, case–controlled study of the risk of colonic polyps in patients with gastric polyps. Are gastric adenomas a new indication for surveillance colonoscopy? Cappell MS, et al. **J Clin Gastroenterol** 1995 Oct;21(3):198–202

[Respiratory insufficiency caused by a vocal cord polyp. An accidental finding during respiratory function tests] Larsen KM, et al. **Ugeskr Laeger** 1995 Nov 6;157(45):6272–3 (Eng. Abstr.) **(Dan)**

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Acute cholecystitis caused by cystic polyp] Roig Vila JV, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):752–3 (Eng. Abstr.) **(Spa)**

CONGENITAL

Congenital midline cervical cleft. Case report and review. Maschka DA, et al. **Ann Otol Rhinol Laryngol** 1995 Oct; 104(10 Pt 1):808–11

Hairy polyp of the oropharynx: an unusual cause of intermittent neonatal airway obstruction. Walsh RM, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):129–34

DIAGNOSIS

Heterotopic gastric mucosa presenting as gallbladder polyps. Leyman P, et al. **Acta Chir Belg** 1996 Jun;96(3):128–9

Regurgitated giant fibrovascular polyp of the esophagus [letter] Lee KN, et al. **AJR Am J Roentgenol** 1996 Mar; 166(3):730

Placental polyp: MR imaging findings [letter; comment] Suzuki N, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1554. Comment on: AJR Am J Roentgenol 1993 Aug;161(2):345–6.

Endoscopic features of gastric inflammatory fibroid polyps. Matsushita M, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1595–8

MR imaging of atypical polypoid adenomyoma. Yamashita Y, et al. **Comput Med Imaging Graph** 1995 Jul–Aug; 19(4):351–5

Malignant fibrous histiocytoma presenting as an endobronchial polyp of the carina. Shijubo N, et al. **Eur Respir J** 1995 Aug;8(8):1430–1

Eosinophilic granuloma presenting as chronic otitis media: pitfalls in the diagnosis of aural polyps in children. DeRowe A, et al. **J Otolaryngol** 1995 Aug;24(4):258–60

Value of videostroboscopic parameters in differentiating true vocal fold cysts from polyps. Shohet JA, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):19–26

Gastroduodenal polyps in familial adenomatous polyposis. Marcello PW, et al. **Surg Endosc** 1996 Apr;10(4):418–21

[Polyps of the posterior urethra in children. A case report and a proposal of a new diagnostic algorithm] Castriota-Scanderbeg A, et al. **Radiol Med (Torino)** 1995 Oct;90(4):508–10 **(Ita)**

[Polyps of the urethra and bladder in children] Rumiantseva GN, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):45–6 **(Rus)**

DRUG THERAPY

Vocal fold submucosal infusion technique in phonomicrosurgery. Kass ES, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):341–7

Inflammatory bronchial polyps associated with asthma: resolution with inhaled corticosteroid. Niimi A, et al. **Eur Respir J** 1995 Jul;8(7):1237–9

ETIOLOGY

Endobronchial inflammatory polyp after thoracoabdominal aneurysm surgery: a late complication of use of a double-lumen endobronchial tube. Ikeda M, et al. **Anesthesiology** 1996 May;84(5):1234–6

Granulomatous polyp: a complication of the Mitroffanoff appendico-vesicostomy. Drake M, et al. **Br J Urol** 1996 Jul;78(1):142–3

Crohn's esophagitis: a unique cause of esophageal polyposis. Walker RS, et al. **Gastrointest Endosc** 1996 May;43(5):511–5

[A case of inflammatory bronchial polyp under treatment of tuberculosis] Ichiki H, et al. **Kekkaku** 1995 Sep; 70(9):517–20 (Eng. Abstr.) **(Jpn)**

GENETICS

An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Bol S, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):88–90

Molecular evidence links lymphomatous polyposis of the gastrointestinal tract with mantle cell lymphoma. Smir BN, et al. **Hum Pathol** 1995 Nov;26(11):1282–5

HISTORY

Postal diagnosis: breaking the bad news in the 17th century. Forrester J. **BMJ** 1995 Dec 23–30;311(7021):1694–6

METABOLISM

Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value. Klapan I, et al. **Am J Otolaryngol** 1995 Nov–Dec;16(6):396–402

PATHOLOGY

Serous surface papillary carcinoma of the ovary metastatic to a cervical polyp. A case report. Jiménez-Ayala M, et al. **Acta Cytol** 1996 Jul–Aug;40(4):765–9

Malignant transformation of benign epithelial gastric polyps. Orlowska J, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2152–9

Ultrasound-guided percutaneous transhepatic fine needle aspiration cytology study of gallbladder polypoid lesions. Wu SS, et al. **Am J Gastroenterol** 1996 Aug;91(8):1591–4

Carcinoma in gastric hyperplastic polyps. A phenotypic study. Zea-Iriarte WL, et al. **Dig Dis Sci** 1996 Feb; 41(2):377–86

Bilateral vocal fold polyps. Sataloff RT, et al. **Ear Nose Throat J** 1995 Nov;74(11):742

Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Defago MR, et al. **Endoscopy** 1996 Feb;28(2):267

Atypical stromal cells in a hyperplastic endometrial polyp. Creagh TM, et al. **Histopathology** 1995 Oct;27(4):386–7

Patterns of immunoreactivity to an anti-fibronectin polyclonal antibody in formalin-fixed, paraffin-embedded oral tissues are dependent on methods of antigen retrieval. Mighell AJ, et al. **J Histochem Cytochem** 1995 Nov; 43(11):1107–14

Bilateral hairy polyp of the oropharynx. Franco V, et al. **J Laryngol Otol** 1996 Mar;110(3):288–90

Polypoid carcinoma of the tongue. Ide F, et al. **J Oral Pathol Med** 1996 Feb;25(2):90–2

Histologic classification of endoscopically removed flat colorectal polyps: a multicentric study. Rubio CA, et al. **Jpn J Cancer Res** 1996 Aug;87(8):849–55

Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Norlander T, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):196–203

Fibroepithelial polyps of the renal pelvis: report of two cases and review of the literature. Fernández Aceñero MJ, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):133–6 (10 ref.)

Leiomyosarcoma of the maxillary gingiva: a case report. Mizutani H, et al. **Nagoya J Med Sci** 1995 Dec; 58(3–4):165–70

Lymphangiomatous polyp of the palatine tonsil. Roth M. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):172–3

Signet ring cell carcinoma in hyperplastic polyp. Zea-Iriarte WL, et al. **Scand J Gastroenterol** 1995 Jun;30(6):604–8 (26 ref.)

Poorly differentiated adenocarcinoma in a gastric hyperplastic polyp [letter] Gotoh Y, et al. **South Med J** 1996 Apr;89(4):453–4

Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. Hizawa K, et al. **Surg Endosc** 1995 Jun;9(6):714–8

Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. Toda K, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):267–71

Fundic gland polyps [letter; comment] Declich P, et al. **Virchows Arch** 1995;427(2):227. Comment on: Virchows Arch A Pathol Anat Histopathol 1993;422(4):337–40.

[Study on relationship between nail-fold microcirculation and histopathology of patients with vocal cord polyp and blood stasis syndrome] Wang DF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep; 15(9):522–4 (Eng. Abstr.) **(Chi)**

[A bizarre excrescence of the umbilicus in a 1-month-old child] Delplace J, et al. **Rev Med Brux** 1996 Jun;17(3):140–2 (Eng. Abstr.) **(Fre)**

[Pedicled polypoid carcinosarcoma: a very rare esophageal tumor] de Mas CR, et al. **Leber Magen Darm** 1995 Jul; 25(4):180–2 (Eng. Abstr.) **(Ger)**

[Polipoid melanoma] Török L, et al. **Orv Hetil** 1996 Feb 25;137(8):401–3 (Eng. Abstr.) **(Hun)**

[Small polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):287–9 (5 ref.) **(Jpn)**

[Cholesterol polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):280–2 (8 ref.) **(Jpn)**

[Pseudopolyp of the gallbladder] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):273–4 (5 ref.) **(Jpn)**

RADIOGRAPHY

Fibrovascular polyps of the esophagus: clinical, radiographic, and pathologic findings in 16 patients. Levine MS, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):781–7

Radiological case of the month. Eosinophilic gastroenteropathy. Mezoff AG, et al. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1169–70

Quiz case of the month. Giant fibrovascular polyp. Rodriguez Delgado LE, et al. **Eur Radiol** 1996;6(2):239–40

The association of intrauterine filling defects on hysterosalpingogram with endometriosis. McBean JH, et al. **Fertil Steril** 1996 Oct;66(4):522–6

Detection of colorectal polyps by computed tomographic colography: feasibility of a novel technique. Hara AK, et al. **Gastroenterology** 1996 Jan;110(1):284–90

CT evaluation of small polypoid lesions of the gallbladder. Furukawa H, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):800–10

[Hyperplastic gastric polyposis and familial colonic adenomas. Apropos of a case] Davion T, et al. **Gastroenterol Clin Biol** 1996;20(3):298–302 (Eng. Abstr.) **(Fre)**

[Obstructive inflammatory fibroid polyp of the cardia (letter)] Dewailly A, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):646–7 **(Fre)**

[CT findings of the small polypoid lesions of the gallbladder (2cm or less PLG): differentiation between benign and malignant disease on unenhanced CT] Shindoh N. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):102–8 (Eng. Abstr.) **(Jpn)**

SURGERY

Vocal fold submucosal infusion technique in phonomicrosurgery. Kass ES, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):341–7

Congenital midline cervical cleft. Case report and review. Maschka DA, et al. **Ann Otol Rhinol Laryngol** 1995 Oct; 104(10 Pt 1):808–11

An ureteric polyp resected by ureteroscopy. Kawachi Y, et al. **Br J Urol** 1996 Aug;78(2):312–4

Endoscopic management of fibroepithelial polyps in the ureter. Sharma NK, et al. **Br J Urol** 1996 Jul;78(1):131–2

Further refinements of the polyp snare for interuterine surgery—a new modality for treatment of myomas and polyps. McLucas B. **Endosc Surg Allied Technol** 1995 Apr–Jun;3(2–3):101–4

Cervical polyp in the menopause and the need for fractional dilatation and curettage. Neri A, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):53–5

Fibroepithelial ureteral polyp—a case report; endoscopic removal of large ureteral polyp. Kim H, et al. **J Korean Med Sci** 1996 Feb;11(1):80–3

Use of neodymium: yttrium-aluminum-garnet laser for removal of a congenital posterior urethral polyp in a 3-year-old child: a case report and review of the literature. Gentle DL, et al. **Urology** 1996 Mar;47(3):445–7

[Benign neoplasms of the urethra in women] Uzunova I. **Khirurgiia (Sofiia)** 1994;47(5):29–30 (Eng. Abstr.) **(Bul)**

[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611–4 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Dilatation and curettage in patients with cervical polyps: a retrospective analysis [letter; comment] Griffiths M. **Br J Obstet Gynaecol** 1995 Dec;102(12):1018. Comment on: Br J Obstet Gynaecol 1995 May;102(5):415–7.

Dilatation and currettage in patients with cervical polyps: a retrospective analysis [letter; comment] Habiba M, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1018. Comment on: Br J Obstet Gynaecol 1995 May;102(5):415–7.

ULTRASONOGRAPHY

Evaluation of the endometrial cavity during menopause. Maia H Jr, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):61–6

Giant hyperplastic polyp of the gallbladder: a case report. Kubota K, et al. **J Clin Ultrasound** 1996 May;24(4):203–6

Sonohysterography in the detection of endometrial pathology [letter] Vandendael A, et al. **S Afr Med J** 1995 Nov; 85(11):1197

[Management of polypoid lesions of the gallbladder by endoscopic ultrasonography (EUS)—a retrospective study to establish the diagnostic criteria and a prospective study to evaluate its reliability] Sugahara E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1846–57 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Histologic structure of antrochoanal polyps. Min YG, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):543–7

Immunohistochemical characterization of benign laryngeal lesions. Courey MS, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):525–31

POLYRADICULITIS

ETIOLOGY

[Neurologic complications of surgery of the spine in adults] Benazet JP, et al. **Chirurgie** 1994–95;120(11):39–42 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

A predominantly motor polyradiculopathy of Lyme disease. Scelsa SN, et al. **Muscle Nerve** 1996 Jun;19(6):780–3

THERAPY

Inflammatory neuropathies—pathogenesis and the role of intravenous immune globulin. van der Meché FG, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):63S–69S (64 ref.)

VIROLOGY

Cytomegalovirus polyradiculopathy in HIV-infected patients. Meier PA, et al. **J Gen Intern Med** 1996 Jan; 11(1):47–9

POLYRADICULONEURITIS

Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Léger JM. **Curr Opin Neurol** 1995 Oct;8(5):359–63 (23 ref.)

Recurrent Guillain-Barré syndrome in Japan. Baba M, et al. **Intern Med** 1995 Oct;34(10):1015–8

Landry-Guillain-Barre-Strohl syndrome in pregnancy. Yaginuma Y, et al. **J Obstet Gynaecol Res** 1996 Feb; 22(1):47–9

Methodologic issues in clinical research: the example of Guillain-Barré syndrome [editorial] Lasky T. **Neuroepidemiology** 1996;15(2):57–61

The concept and classification of Guillain-Barré syndrome and related disorders [editorial] Hughes RA. **Rev Neurol (Paris)** 1995 May;151(5):291–4

[Guillain-Barré syndrome. Variation on the theme] Karlsen B, et al. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):242–5 (Eng. Abstr.) **(Nor)**

BLOOD

Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. Créange A, et al. **J Neuroimmunol** 1996 Aug; 68(1–2):95–9

Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. Vedeler CA, et al. **J Neuroimmunol** 1996 Jun;67(1):17–20

GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Kusunoki S, et al. **Neurology** 1996 Jul;47(1):237–42

CEREBROSPINAL FLUID

Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barré syndrome. Ikeda M, et al. **Intern Med** 1995 Aug;34(8):734–7

Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. Vedeler CA, et al. **J Neuroimmunol** 1996 Jun;67(1):17–20

On the nature of endogenous antiexcitatory factors in the cerebrospinal fluid of patients with demyelinating neurological disease. Brinkmeier H, et al. **Muscle Nerve** 1996 Jan;19(1):54–62

CHEMICALLY INDUCED

Gangliosides and Guillain-Barré syndrome. Raschetti R, et al. **J Clin Epidemiol** 1995 Nov;48(11):1399–405

Polyradiculoneuropathy induced by gold therapy [letter] Navaux F, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):467

COMPLICATIONS

Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Panjwani M, et al. **Am J Kidney Dis** 1996 Feb;27(2):279–83 (20 ref.)

Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Rees JH, et al. **Ann Neurol** 1995 Nov; 38(5):809–16

Neuropathies in HIV infection. Dalakas MC, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):199–218 (65 ref.)

Acute eosinophilic pneumonia accompanied by Guillain-Barré syndrome. Ishiura Y, et al. **Br J Clin Pract** 1996 Jul–Aug;50(5):283–5

Microangiopathic haemolytic anaemia and systemic vasculitis. Ross CN, et al. **Br J Rheumatol** 1996 Apr; 35(4):377–9

Severe hypertension: an unusual presentation of Guillain-Barré syndrome in a child with brucellosis. Al-Eissa YA, et al. **Eur J Pediatr** 1996 Jan;155(1):53–5

Longitudinal study of serum and cerebrospinal fluid (CSF) class-specific antibodies against Campylobacter jejuni and GM1 ganglioside in Guillain-Barré syndrome. Kimura F, et al. **Intern Med** 1995 Oct;34(10):1009–14

Inflammatory demyelinating polyradiculitis in a patient with acute disseminated encephalomyelitis (ADEM). Kinoshita A, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):87–90

Comments on Pentland and Donald [letter] Genis D, et al. **Pain** 1996 Feb;64(2):402–3

[A case of Guillain-Barré syndrome associated with SIADH, treated by intravenous gammaglobulins] De Decker V, et al. **Acta Clin Belg** 1996;51(3):170–4 (13 ref.) (Eng. Abstr.) **(Fre)**

[Taste disturbance as an initial manifestation of Guillain-Barré syndrome in a 14-year-old girl] Dejima S, et al. **No To Hattatsu** 1995 Nov;27(6):492–5 (Eng. Abstr.) **(Jpn)**

[Guillain-Barré syndrome associated with external ophthalmoplegia, consciousness disturbance, and extensor plantar responses: an overlap between Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis] Kitazawa K, et al. **Rinsho Shinkeigaku** 1995 Jun; 35(6):626–32 (30 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)

Traveler's diarrhea, Campylobacter jejuni, and acute motor axonal neuropathy [letter] Yuki N, et al. **Ann Neurol** 1996 Mar;39(3):416–7

Guillain-Barre syndrome in six cities and provinces of northern China: is it a new entity? Zhang X, et al. **Chin Med J (Engl)** 1995 Oct;108(10):734–8 (27 ref.)

Hydrocephalus in Guillain-Barré syndrome. Erşahin Y, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):253–5

Guillain-Barré syndrome or "new" Chinese paralytic syndrome in northern China? Tang XF, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 101(2):105–9

Acute inflammatory demyelinating neuropathy: a critical evaluation of diagnostic criteria for demyelination. Das KB, et al. **Electromyogr Clin Neurophysiol** 1995 Dec;35(8):451–5

Acute multifocal motor neuropathy with early spontaneous recovery: a distinct syndrome from Guillain-Barré syndrome? Wöhrle JC, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb;36(1):37–41

Guillain Barre syndrome-electrodiagnostic features and therapeutic observations. Shankar V, et al. **J Assoc Physicians India** 1995 Oct;43(10):670–2

Recurrent Guillain Barre' Syndrome: a clinical, electrophysiological and morphological study. Taly AB, et al. **J Assoc Physicians India** 1995 Apr;43(4):249–52

Guillain-Barré syndrome: a pediatric challenge [editorial] Delgado MR. **J Child Neurol** 1996 Jan;11(1):1–3

Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. Jones HR. **J Child Neurol** 1996 Jan; 11(1):4–12 (76 ref.)

Anti-beta-tubulin antibodies have no diagnostic value in patients with chronic inflammatory demyelinating polyneuropathy. van Schaik IN, et al. **J Neurol** 1995 Sep; 242(9):599–603

Axonal CIDP: a premature concept? Feasby TE. **Muscle Nerve** 1996 Mar;19(3):372–4 (16 ref.)

[Biermer disease simulating acute polyradiculoneuritis. Apropos of a case disclosing the disease (letter)] Leone J, et al. **Ann Med Interne (Paris)** 1995;146(6):447–8 **(Fre)**

[Early diagnosis of Guillain-Barré syndrome by electric stimulations of the nerve roots] Boulesteix JM, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):569–75 (Eng. Abstr.) **(Fre)**

[The Guillain-Barré syndrome in childhood] Tarallo MR, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):283–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Anterior nerve roots enhancement on MRI in a case of Guillain-Barré syndrome] Yanagihara K, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1037–9 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Immunoglobulin therapy in Guillain-Barré syndrome in children [see comments] Nicolaides P, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1110–4. Comment

in: Dev Med Child Neurol 1996 Apr;38(4):371–2.
Do corticosteroids influence the disease course or mortality in Guillain–Barre' syndrome? Singh NK, et al. **J Assoc Physicians India** 1996 Jan;44(1):22–4
Encephalopathy associated with intravenous immunoglobulin treatment for Guillain–Barré syndrome [letter] Harkness K, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):586
[A case of Guillain–Barré syndrome associated with anti–GM2 antibody due to cytomegalovirus infection—special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652–6 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun–Jul;11(6):220–8 (56 ref.) **(Spa)**
[Guillain–Barré syndrome and gangliosides] Diez–Tejedor E, et al. **Rev Neurol** 1995 Jul–Aug;23(122):896–919 **(Spa)**

EPIDEMIOLOGY

Guillain–Barré syndrome in South–West Stockholm, 1973–1991, 3. Clinicoepidemiological subgroups. de Pedro–Cuesta J, et al. **Acta Neurol Scand** 1996 Feb–Mar; 93(2–3):175–83
Age and Guillain–Barré syndrome severity. Sheth RD, et al. **Muscle Nerve** 1996 Mar;19(3):375–7

ETIOLOGY

Acute encephalopathy and polyneuropathy after disulfiram intoxication. Zorzon M, et al. **Alcohol Alcohol** 1995 Sep; 30(5):629–31
Traveler's diarrhea, Campylobacter jejuni, and acute motor axonal neuropathy [letter] Yuki N, et al. **Ann Neurol** 1996 Mar;39(3):416–7
Guillain Barré syndrome, a possible side effect of buffy coat transfusion and IFN alpha therapy in relapsed CML after bone marrow transplantation [letter] Schwarzer A, et al. **Ann Oncol** 1995 Jul;6(6):617
Guillain–Barré syndrome: an unusual complication after snake bite. Chuang TY, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):729–31
Vaccines and Guillain–Barré syndrome [letter] Hughes R, et al. **BMJ** 1996 Jun 8;312(7044):1475–6
Miller–Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Salloway S, et al. **Infect Immun** 1996 Aug;64(8):2945–9
Guillain–Barré as an autoimmune disease. Shoenfeld Y, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):318–26
Guillain–Barré syndrome after an operation on the spine. A case report. Riebel GD, et al. **J Bone Joint Surg Am** 1995 Oct;77(10):1565–7
Fulminant Guillain–Barré syndrome with quadriplegia and total paresis of motor cranial nerves as a result of segmental demyelination. Tan AK, et al. **J Neurol Sci** 1995 Dec; 134(1–2):203–6
Campylobacter jejuni infection and Guillain–Barre syndrome [letter; comment] Aguago JM, et al. **N Engl J Med** 1996 Mar 21;334(12):802. Comment on: N Engl J Med 1995 Nov 23;333(21):1374–9.
Guillain–Barré syndrome as an extraintestinal manifestation of Crohn's disease. de la Fuente–Fernández R, et al. **Postgrad Med J** 1995 Jul;71(837):437–8
[Risk factors for Guillain–Barre syndrome in northern China: a case–control study] Zhang Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug; 17(4):291–5 (Eng. Abstr.) **(Chi)**
[Guillain–Barré syndrome in a patient with chronic active hepatitis C (letter)] Zylberberg H, et al. **Gastroenterol Clin Biol** 1995 May;19(5):551 **(Fre)**
[Guillain–Barré syndrome complicating cytomegalovirus infection in an immunocompetent adult] Lecocq P, et al. **Rev Med Interne** 1995;16(11):847–9 (Eng. Abstr.) **(Fre)**
[Respiratory insufficiency caused by early summer meningoencephalitis with polyradiculitis. 2 case reports] Wiebel M, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:64–6 **(Ger)**
[Neuropathy and anti–ganglioside antibodies] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):629–34 (13 ref.) **(Jpn)**
[Campylobacter jejuni and autoimmune–mediated neurologic diseases: pathogenesis of Guillain–Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991–1003 (41 ref.) **(Jpn)**
[The pathogenetic mechanisms of the development of experimental allergic polyradiculoneuritis] Komandenko NI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):41–5 (Eng. Abstr.) **(Rus)**

GENETICS

HLA–class II alleles in Guillain–Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. Rees JH, et al. **J Neuroimmunol** 1995 Oct;62(1):53–7

IMMUNOLOGY

Anti–GD1a ganglioside antibodies in peripheral motor syndromes. Carpo M, et al. **Ann Neurol** 1996 Apr; 39(4):539–43
Pathology of the motor–sensory axonal Guillain–Barré syndrome [see comments] Griffin JW, et al. **Ann Neurol** 1996 Jan;39(1):17–28. Comment in: Ann Neurol 1996 Jan;39(1):4–5.
Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Hafer–Macko CE, et al. **Ann Neurol** 1996 May;39(5):625–35
Campylobacter jejuni infections and anti–GM1 antibodies in Guillain–Barré syndrome. Jacobs BC, et al. **Ann Neurol** 1996 Aug;40(2):181–7
The axon in Guillain–Barré syndrome: immune target or innocent bystander? [editorial; comment] Powell HC, et al. **Ann Neurol** 1996 Jan;39(1):4–5. Comment on: Ann Neurol 1996 Jan;39(1):17–28.
Anti–ganglioside GM1 antibodies in Guillain–Barré syndrome and their relationship to Campylobacter jejuni infection. Rees JH, et al. **Ann Neurol** 1995 Nov; 38(5):809–16
Pathogenesis of inflammatory demyelination: implications for therapy [editorial] Hartung HP. **Curr Opin Neurol** 1995 Jun;8(3):191–9 (49 ref.)
Guillain–Barré as an autoimmune disease. Shoenfeld Y, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):318–26
Myelin– and microbe–specific antibodies in Guillain–Barré syndrome. Terryberry J, et al. **J Clin Lab Anal** 1995; 9(5):308–19
HLA and anti–GQ1b IgG antibody in Miller Fisher syndrome and Guillain–Barré syndrome. Chiba A, et al. **J Neuroimmunol** 1995 Aug;61(1):85–8
Association of anti–GM2 antibodies in Guillain–Barré syndrome with acute cytomegalovirus infection. Irie S, et al. **J Neuroimmunol** 1996 Aug;68(1–2):19–26
HLA–class II alleles in Guillain–Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. Rees JH, et al. **J Neuroimmunol** 1995 Oct;62(1):53–7
The clinical correlates of IgG antiganglioside antibodies [letter; comment] Iñiguez C, et al. **Muscle Nerve** 1995 Dec; 18(12):1490–2. Comment on: Muscle Nerve 1994 Jan;17(1):100–4.
Guillain–Barré syndrome: clinical and immunological aspects. Rostami AM. **Springer Semin Immunopathol** 1995; 17(1):29–42 (94 ref.)

MICROBIOLOGY

The axon in Guillain–Barré syndrome: immune target or innocent bystander? [editorial; comment] Powell HC, et al. **Ann Neurol** 1996 Jan;39(1):4–5. Comment on: Ann Neurol 1996 Jan;39(1):17–28.
The changing concepts of Guillain–Barré syndrome [editorial; comment] Bolton CF. **N Engl J Med** 1995 Nov 23;333(21):1415–7. Comment on: N Engl J Med 1995 Nov 23;333(21):1374–9.
Campylobacter jejuni infection and Guillain–Barré syndrome [see comments] Rees JH, et al. **N Engl J Med** 1995 Nov 23;333(21):1374–9. Comment in: N Engl J Med 1995 Nov 23;333(21):1415–7. Comment in: N Engl J Med 1996 Mar 21;334(12):802. Comment in: N Engl J Med 1996 Jul 18;335(3):208–9.
[Axonal Guillain–Barré syndrome associated with anti–GalNAc–GD1a antibody subsequent to Campylobacter jejuni (PEN 43) enteritis] Ihara Y, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):901–3 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pathology of the motor–sensory axonal Guillain–Barré syndrome [see comments] Griffin JW, et al. **Ann Neurol** 1996 Jan;39(1):17–28. Comment in: Ann Neurol 1996 Jan;39(1):4–5.
Guillain–Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases [letter] Menkes DL, et al. **Brain** 1996 Apr;119 (Pt 2):676–80
Inflammatory demyelinating polyradiculitis in a patient with acute disseminated encephalomyelitis (ADEM). Kinoshita A, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):87–90
Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain–Barré syndrome. Li CY, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep; 61(3):279–84
Hypertrophic neuritis due to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a postmortem pathological study. Matsuda M, et al. **Muscle Nerve** 1996 Feb;19(2):163–9
Inflammatory infiltrates in sural nerve biopsies in Guillain–Barre syndrome and chronic inflammatory demyelinating neuropathy. Schmidt B, et al. **Muscle Nerve** 1996 Apr;19(4):474–87
Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Midroni G, et al. **Neurology** 1996 May;46(5):1206–12
Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Oh SJ, et al. **Neurology** 1995 Oct; 45(10):1828–32
[Value of gadolinium magnetic resonance imaging of the lumbosacral roots in acute polyradiculoneuritis] Fayolle H, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):267–70 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Sympathetic skin response in Guillain–Barré syndrome. Taly AB, et al. **Clin Auton Res** 1995 Sep;5(4):215–9
Critical illness polyneuropathy in adolescence. Dimachkie MM, et al. **J Child Neurol** 1995 Sep;10(5):409–11
Electrophysiological studies in Guillain–Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni. Vriesendorp FJ, et al. **J Neurol** 1995 Jul;242(7):460–5
Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain–Barré syndrome. Dutch Guillain–Barré Study Group. Meulstee J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):482–6
Respiratory electrophysiological studies in Guillain–Barré syndrome. Zifko U, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):191–4
Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guillain–Barré syndrome. Flachenecker P, et al. **Neurology** 1996 Jul;47(1):102–8
Liver function disturbances in Guillain–Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain–Barré Study Group. Oomes PG, et al. **Neurology** 1996 Jan;46(1):96–100
Neurologic complications of lumbar epidural anesthesia and analgesia. Yuen EC, et al. **Neurology** 1995 Oct; 45(10):1795–801

RADIOGRAPHY

Videofluoroscopic evaluation of patients with Guillain–Barré syndrome. Chen MY, et al. **Dysphagia** 1996 Winter; 11(1):11–3

REHABILITATION

[The use of pulsed and continuous UHF electrical fields in the rehabilitation of patients with the Guillain–Barré syndrome and other peripheral myelinopathies] Gorbunov FE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(5):22–6 (Eng. Abstr.) **(Rus)**

THERAPY

Plasma exchange in childhood Guillain–Barré syndrome [letter] [corrected and republished letter originally printed in Acta Paediatr 1995 Mar;84(3):355] Hammersjö JA, et al. **Acta Paediatr** 1996 Apr;85(4):iv
Guillain–Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)
Natural history and treatment effects in Guillain–Barré syndrome: a multicentre study. Korinthenberg R, et al. **Arch Dis Child** 1996 Apr;74(4):281–7
Guillain–Barré syndrome in pregnancy—two case reports and a discussion on management. Bolik A, et al. **Arch Gynecol Obstet** 1995;256(4):199–203
Plasmapheresis versus plasma perfusion in acute Guillain–Barré syndrome. Morosetti M, et al. **ASAIO J** 1994 Jul–Sep;40(3):M638–42
Intravenous IgG in Guillain–Barré syndrome [editorial] Hughes RA. **BMJ** 1996 Aug 17;313(7054):376–7
A comparison between IVIg and plasma exchange in Guillain–Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB, et al. **Clin Neuropharmacol** 1995 Oct;18(5):377–90 (44 ref.)
'Immunoglobulin therapy in Guillain–Barré syndrome in children' [letter; comment] Ganesan V, et al. **Dev Med Child Neurol** 1996 Apr;38(4):371–2. Comment on: Dev Med Child Neurol 1995 Dec;37(12):1110–4.
Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy; different beneficial effects and their correlation to the clinical features. Kumazawa K, et al. **Intern Med** 1995 Jun;34(6):537–41
High dose intravenous immune globulins and plasma exchange in Guillain–Barré Syndrome. Ravasio A, et al. **Ital J Neurol Sci** 1995 Oct;16(7):487–92
Guillain Barre syndrome–electrodiagnostic features and therapeutic observations. Shankar V, et al. **J Assoc Physicians India** 1995 Oct;43(10):670–2
Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain–Barré syndrome? Weinstein R. **J Clin Apheresis** 1995;10(3):150–7 (94 ref.)
Immunoglobulins i.v.: a new approach to the treatment of Guillain–Barré syndrome. Fasanaro AM, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):17–20
Campylobactery jejuni Infection and treatment for Guillain–Barré Syndrome [comment] Jacobs BC, et al. **N Engl J Med** 1996 Jul 18;335(3):208–9. Comment on: N Engl J Med 1995 Nov 23;333(21):1374–9.
Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barré syndrome. Bril V, et al. **Neurology** 1996 Jan;46(1):100–3
Reversible encephalopathy with cerebral vasospasm in a Guillain–Barré syndrome patient treated with intravenous immunoglobulin. Voltz R, et al. **Neurology** 1996 Jan; 46(1):250–1
Tryptophan–immobilized column adsorbs immunoglobulin G anti–GQ1b antibody from Fisher's syndrome: A new approach to treatment. Yuki N. **Neurology** 1996 Jun; 46(6):1644–51
Risk factors of respiratory failure in children with

Guillain-Barré syndrome. Rantala H, et al. **Pediatr Neurol** 1995 Nov;13(4):289–92

Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Gürses N, et al. **Scand J Infect Dis** 1995;27(3):241–3

Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Lesprit P, et al. **Scand J Rheumatol** 1996; 25(3):177–9

[Case of Fisher syndrome with pemphigus treated by immuno-adsorption plasmapheresis] Nishikage H, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):274–5 **(Jpn)**

[Treatment of Guillain-Barré syndrome] Zagar M. **Lijec Vjesn** 1995 Sep-Oct;117(9–10):246–9 (31 ref.) (Eng. Abstr.) **(Scr)**

[Combined treatment using electrostimulation of the radicular-vascular syndromes in lumbar osteochondrosis] Zachatko TM. **Lik Sprava** 1995 Jul-Aug;(7–8):106–9 (Eng. Abstr.) **(Ukr)**

VETERINARY

Acute canine polyradiculoneuritis. High ME. **Can Vet J** 1996 May;37(5):305

VIROLOGY

Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. Irie S, et al. **J Neuroimmunol** 1996 Aug;68(1–2):19–26

POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE see **POLYNUCLEOTIDE PHOSPHORYLASE**

POLYRIBONUCLEOTIDE SYNTHETASE

Single-site polymerase chain reaction through single oligonucleotide ligation. Lin Z, et al. **Anal Biochem** 1995 Nov 1;231(2):449–52

CHEMISTRY

Solid-phase synthesis of oligoribonucleotides using T4 RNA ligase and T4 polynucleotide kinase. Vratskikh LV, et al. **Biochimie** 1995;77(4):227–32

DRUG EFFECTS

Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. Zingarelli B, et al. **J Immunol** 1996 Jan 1;156(1):350–8

METABOLISM

Trypanosoma brucei RNA editing. A full round of uridylate insertional editing in vitro mediated by endonuclease and RNA ligase. Piller KJ, et al. **J Biol Chem** 1996 Mar 1; 271(9):4613–9

Uridine insertion into preedited mRNA by a mitochondrial extract from Leishmania tarentolae: stereochemical evidence for the enzyme cascade model. Frech GC, et al. **Mol Cell Biol** 1996 Aug;16(8):4584–9

POLYRIBONUCLEOTIDE SYNTHETASES see **POLYRIBONUCLEOTIDE SYNTHETASE**

POLYRIBONUCLEOTIDES

ADMINISTRATION & DOSAGE

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608–19 (135 ref.)

METABOLISM

A residue to residue hydrogen bond mediates the nucleotide specificity of ribonuclease A. delCardayré SB, et al. **J Mol Biol** 1995 Sep 22;252(3):328–36

POLYRIBOSOMES

CHEMISTRY

Methods for isolation and analysis of polyribosomes. Davies E, et al. **Methods Cell Biol** 1995;50:209–22

DRUG EFFECTS

Hydrogen peroxide induces the expression of adapt15, a novel RNA associated with polysomes in hamster HA-1 cells. Crawford DR, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):256–64

ENZYMOLOGY

Ribosome-associated ribonucleases from six-day larvae of the insect Ceratitis capitata. Kouyanou S, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1217–27

GENETICS

Assessment of translational regulation by run-off translation of polysomes in vitro. Vayda ME. **Methods Cell Biol** 1995; 50:349–59

The polyribosomal protein bound to the 3' end of histone mRNA can function in histone pre-mRNA processing. Dominski Z, et al. **RNA** 1995 Nov;1(9):915–23

METABOLISM

Hydrogen peroxide induces the expression of adapt15, a novel RNA associated with polysomes in hamster HA-1 cells. Crawford DR, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):256–64

Efficient extraction and partial purification of the polyribosome-associated stem-loop binding protein bound to the 3' end of histone mRNA. Hanson RJ, et al. **Biochemistry** 1996 Feb 20;35(7):2146–56

A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes. Visa N, et al. **Cell** 1996 Jan 26;84(2):253–64

The polyribosomal protein bound to the 3' end of histone mRNA can function in histone pre-mRNA processing. Dominski Z, et al. **Nucleic Acids Symp Ser** 1995;(33):234–6

Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Rousseau D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1065–70

Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: relationship to translational control. Peffley DM, et al. **Somat Cell Mol Genet** 1995 May;21(3):189–204

PHYSIOLOGY

Polyribosome dynamics: size-distribution as a function of attachment, translocation and release of ribosomes. Singh UN. **J Theor Biol** 1996 Mar 21;179(2):147–59

ULTRASTRUCTURE

Methods for isolation and analysis of polyribosomes. Davies E, et al. **Methods Cell Biol** 1995;50:209–22

POLYSACCHARIDE-LYASES

ANTAGONISTS & INHIBITORS

Inhibition of platelet heparitinase by phosphorothioate DNA oligonucleotides. Graham LD, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):239–46

BIOSYNTHESIS

The Erwinia chrysanthemi pecT gene regulates pectinase gene expression. Surgey N, et al. **J Bacteriol** 1996 Mar; 178(6):1593–9

Human protein disulfide isomerase functionally complements a dsbA mutation and enhances the yield of pectate lyase C in Escherichia coli. Humphreys DP, et al. **J Biol Chem** 1995 Nov 24;270(47):28210–5

CHEMISTRY

Heparinase I from Flavobacterium heparinum. Identification of a critical histidine residue essential for catalysis as probed by chemical modification and site-directed mutagenesis. Godavarti R, et al. **Biochemistry** 1996 May 28; 35(21):6846–52

Heparinase I from Flavobacterium heparinum: the role of the cysteine residue in catalysis as probed by chemical modification and site-directed mutagenesis. Sasisekharan R, et al. **Biochemistry** 1995 Nov 7;34(44):14441–8

Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain. Sasisekharan R, et al. **J Biol Chem** 1996 Feb 9; 271(6):3124–31

Structures of five sulfated hexasaccharides prepared from porcine intestinal heparin using bacterial heparinase. Structural variants with apparent biosynthetic precursor-product relationships for the antithrombin III-binding site. Tsuda H, et al. **J Biol Chem** 1996 May 3;271(18):10495–502

Characterization of the pelL gene encoding a novel pectate lyase of Erwinia chrysanthemi 3937. Lojkowska E, et al. **Mol Microbiol** 1995 Jun;16(6):1183–95

Circular dichroism of the parallel beta helical proteins pectate lyase C and E. Sieber V, et al. **Proteins** 1995 Sep;23(1):32–7

DIAGNOSTIC USE

Heparinase and thromboelastography in liver transplantation for a patient with von Willebrand's disease. Pivalizza EG. **Anesthesiology** 1996 May;84(5):1236–9

GENETICS

Purification and characterization of an extracellular pectate lyase from an Amycolata sp. Brühlmann F. **Appl Environ Microbiol** 1995 Oct;61(10):3580–5

Characterization of Erwinia chrysanthemi by pectinolytic isozyme polymorphism and restriction fragment length polymorphism analysis of PCR-amplified fragments of pel genes. Nassar A, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2228–35

Isolation and expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum. Su H, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2723–34

Cloning of a new pectate lyase gene pelC from Fusarium solani f. sp. pisi (Nectria haematococca, mating type VI) and characterization of the gene product expressed in Pichia pastoris. Guo W, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):352–60

Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Godavarti R, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):751–8

Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. Ernst S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):589–97

Cloning, nucleotide sequence determination and expression of the Staphylococcus aureus hyaluronate lyase gene. Farrell AM, et al. **FEMS Microbiol Lett** 1995 Jul 15; 130(1):81–5

Increased efficiency of alkaline phosphatase production levels in Escherichia coli using a degenerate PelB signal sequence. Le Calvez H, et al. **Gene** 1996 Apr 17;170(1):51–5

Cloning of a novel constitutively expressed pectate lyase gene pelB from Fusarium solani f. sp. pisi (Nectria haematococca, mating type VI) and characterization of the gene product expressed in Pichia pastoris. Guo W, et al. **J Bacteriol** 1995 Dec;177(24):7070–7

Characterization of the pelL gene encoding a novel pectate lyase of Erwinia chrysanthemi 3937. Lojkowska E, et al. **Mol Microbiol** 1995 Jun;16(6):1183–95

Cloning of a pectate lyase gene from Xanthomonas campestris pv. malvacearum and comparison of its sequence relationship with pel genes of soft-rot Erwinia and Pseudomonas. Liao CH, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):14–21

ISOLATION & PURIFICATION

Purification and characterization of an extracellular pectate lyase from an Amycolata sp. Brühlmann F. **Appl Environ Microbiol** 1995 Oct;61(10):3580–5

Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. Ernst S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):589–97

METABOLISM

Activation of platelet heparitinase by vascular cell lysates. Graham LD, et al. **Biochem Mol Biol Int** 1995 Oct; 37(2):231–7

Heparinase I from Flavobacterium heparinum. Identification of a critical histidine residue essential for catalysis as probed by chemical modification and site-directed mutagenesis. Godavarti R, et al. **Biochemistry** 1996 May 28; 35(21):6846–52

Enzymatic degradation of cell walls of apples and characterization of solubilized products. Capek P, et al. **Int J Biol Macromol** 1995 Dec;17(6):337–40

Some preliminary results on the action of rhamnogalacturonase on rhamnogalacturonan oligosaccharides from beet pulp. Renard CM, et al. **Int J Biol Macromol** 1995 Dec;17(6):333–6

Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain. Sasisekharan R, et al. **J Biol Chem** 1996 Feb 9; 271(6):3124–31

High-performance liquid chromatographic identification of eight constitutional disaccharides from heparan sulfate isomers digested with heparitinases. Murata K, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):3–10

Rhamnogalacturonase B from Aspergillus aculeatus is a rhamnogalacturonan alpha-L-rhamnopyranosyl-(1-->4)-alpha-D-galactopyranosyluronide lyase. Mutter M, et al. **Plant Physiol** 1996 Jan;110(1):73–7

PHARMACOLOGY

Heparinase I (neutralase) reversal of systemic anticoagulation. Michelsen LG, et al. **Anesthesiology** 1996 Aug;85(2):339–46

Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity. Mrsny RJ, et al. **Pulm Pharmacol** 1994 Dec;7(6):357–66

PHYSIOLOGY

Alginate synthesis in Pseudomonas aeruginosa: the role of AlgL (alginate lyase) and AlgX. Monday SR, et al. **J Bacteriol** 1996 Feb;178(3):625–32

SECRETION

Expression of an Erwinia pectate lyase in three species of Aspergillus. Bartling S, et al. **Curr Genet** 1996 Apr; 29(5):474–81

POLYSACCHARIDES

Biotinylated L-selectin ligand analogs as cytochemical probes in cytospin preparations. Vass JA, et al. **Folia Histochem Cytobiol** 1995;33(1):39–41

A high degree of sequence homology in the putative carbohydrate recognition domains of pokeweed mitogen and wheat germ agglutinin: poly-N-acetyllactosamine-binding lectins from different species. Konami Y, et al. **Glycobiology** 1995 Oct;5(7):663–70

Enantiomer separation of basic drugs by capillary electrophoresis using ionic and neutral polysaccharides as chiral selectors. Nishi H. **J Chromatogr A** 1996 May 31; 735(1–2):345–51

Enantiomeric separation of diltiazem, clentiazem, and its related compounds by capillary electrophoresis using polysaccharides. Nishi H, et al. **J Chromatogr Sci** 1995 Dec; 33(12):698–703

Dementia of frontal lobe type due to adult polyglucosan body disease. Boulan-Predseil P, et al. **J Neurol** 1995 Aug; 242(8):512–6

ADMINISTRATION & DOSAGE

Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist. Ernst H, et al. **J Clin Ultrasound** 1996 Jan; 24(1):31–5

ADVERSE EFFECTS

Asthma to carob bean flour [letter] Scoditti A, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):81

ANALYSIS

Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Bigge JC, et al. **Anal Biochem** 1995 Sep 20;230(2):229–38

The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans. Jaques AJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):427–37

An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine). Wang R, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):867–72

Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Chomczynski P, et al. **Biotechniques** 1995 Dec;19(6):942–5

Histochemical demonstration of different types of poly-N-acetyllactosamine structures in human thyroid neoplasms using lectins and endo-beta-galactosidase digestion. Ito N, et al. **Histochem J** 1995 Aug;27(8):620–9

Occurrence of poly(alpha2,8-deaminoneuraminic acid) in mammalian tissues: widespread and developmentally regulated but highly selective expression on glycoproteins. Ziak M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2759–63

[A semi-quantitative measurement of glycocalyx and an ATP bioluminescent assay for the analysis of Pseudomonas aeruginosa biofilm] Ono N. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1440–9 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Mechanisms in the glucansucrase synthesis of polysaccharides and oligosaccharides from sucrose. Robyt JF. **Adv Carbohydr Chem Biochem** 1995;51:133–68 (146 ref.)

Murine beta 1,4-galactosyltransferase. Analysis of a gene that serves both a housekeeping and a cell specific function. Shaper JH, et al. **Adv Exp Med Biol** 1995;376:95–104 (33 ref.)

Intraspecific variability and exopolysaccharide production in Aureobasidium pullulans. Yurlova NA, et al. **Antonie Van Leeuwenhoek** 1995 Jul;68(1):57–63

N-acetyl-D-neuraminic acid lyase generates the sialic acid for colominic acid biosynthesis in Escherichia coli K1. Ferrero MA, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):157–65

In the biosynthesis of N-glycans in connective tissue of the snail Lymnaea stagnalis of incorporation GlcNAc by beta 2GlcNAc-transferase I is an essential prerequisite for the action of beta 2GlcNAc-transferase II and beta 2Xyl-transferase. Mulder H, et al. **Eur J Biochem** 1995 Aug 15;232(1):272–83

Characterization of a novel mucin sulphotransferase activity synthesizing sulphated O-glycan core 1,3-sulphate-Gal beta 1-3GalNAc alpha-R. Kuhns W, et al. **Glycobiology** 1995 Oct;5(7):689–97

Elongation of the N-glycans of fowl plague virus hemagglutinin expressed in Spodoptera frugiperda (Sf9) cells by coexpression of human beta 1,2-N-acetylglucosaminyltransferase I. Wagner R, et al. **Glycobiology** 1996 Mar;6(2):165–75

Cyclic (1-->2)-beta-D-glucans excreted by the glucuronan-producing strain Rhizobium meliloti M5N1CS (NCIMB 40472) and by the succinoglycan-producing strain Rhizobium meliloti M5N1. Michaud P, et al. **Int J Biol Macromol** 1995 Dec;17(6):369–72

Polysaccharide production by Pediococcus pentosaceus from wine. Manca de Nadra MC, et al. **Int J Food Microbiol** 1995 Oct;27(2-3):101–6

Identification of a second RcsA protein, a positive regulator of colanic acid capsular polysaccharide genes, in Escherichia coli. Dierksen KP, et al. **J Bacteriol** 1996 Aug; 178(16):5053–6

Osmotic shock induction of capsule synthesis in Escherichia coli K-12. Sledjeski DD, et al. **J Bacteriol** 1996 Feb; 178(4):1204–6

Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid. Stevenson G, et al. **J Bacteriol** 1996 Aug;178(16):4885–93

LEC14, a dominant Chinese hamster ovary glycosylation mutant expresses complex N-glycans with a new N-acetylglucosamine residue in the core region. Raju TS, et al. **J Biol Chem** 1996 Mar 29;271(13):7484–93

Expression and glycosylation of the filamentous brush border glycocalyx (FBBG) during rabbit enterocyte differentiation along the crypt-villus axis. Maury J, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2705–13

[Effect of desertomycin on the synthesis of cell wall polymers in Saccharomyces uvarum] Benallaoua S, et al. **Can J Microbiol** 1995 Aug;41(8):722–9 (Eng. Abstr.) **(Fre)**

BLOOD

Enzymatic analysis of cell surface lactosaminyl glycans by flow cytometry. Bollheimer LC, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):30–40

CHEMISTRY

Inflammatory cytokines controlling branching of N-heteroglycans of acute phase protein. Gryska K, et al. **Adv Exp Med Biol** 1995;376:239–45

Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Lee SC, et al. **Am J Pathol** 1996 Apr; 148(4):1267–74

The sugar composition and partial structure of the self-induced endogenous elicitor from potato. Monden T, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):768–73

Influence of the extent of branching on solution conformations of complex oligosaccharides: a molecular dynamics and NMR study of a penta-antennary "bisected" N-glycan. Rutherford TJ, et al. **Biochemistry** 1995 Oct 31; 34(43):14131–7

Structural and conformational analysis of glycan moieties in situ on isotopically 13C, 15N-enriched recombinant human chorionic gonadotropin. Weller CT, et al. **Biochemistry** 1996 Jul 9;35(27):8815–23

Synthesis, characterization and properties of sialylated catalase. Fernandes AI, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):90–6

Structural analysis of alkaline-soluble polysaccharide, P-1, from the kernels of Prunus mume Sieb. et Zucc. Dogasaki C, et al. **Biol Pharm Bull** 1995 Mar;18(3):377–81

An estrogen-dependent sheep oviductal glycoprotein has glycan linkages typical of sialomucins and does not contain chitinase activity. DeSouza MM, et al. **Biol Reprod** 1995 Dec;53(6):1517–26

Activation of the complement system by polysaccharidic surfaces bearing carboxymethyl, carboxymethylbenzylamide and carboxymethylbenzylamide sulphonate groups. Toufik J, et al. **Biomaterials** 1995 Sep;16(13):993–1002

A molecular builder for carbohydrates: application to polysaccharides and complex carbohydrates. Engelsen SB, et al. **Biopolymers** 1996 Sep;39(3):417–33

Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy. Bacon BE, et al. **Carbohydr Res** 1995 Oct 23;276(2):365–86

Structural investigation of the polysaccharide fraction from the mucilage of Diceroaryum zanguebaricum Merr. Barone G, et al. **Carbohydr Res** 1996 Jan 4;280(1):111–9

Structural analysis of cyclamen seed xyloglucan oligosaccharides using cellulase digestion and spectroscopic methods. Braccini I, et al. **Carbohydr Res** 1995 Oct 16; 276(1):167–81

Structural investigation of cell-wall polysaccharides from Neosartorya: relationships with their putative anamorphs of Aspergillus. Leal JA, et al. **Carbohydr Res** 1995 Aug 25;273(2):255–62

Sequencing of xyloglucan oligosaccharides by partial Driselase digestion: the preparation and quantitative and qualitative analysis of two new tetrasaccharides. Lorences EP, et al. **Carbohydr Res** 1995 Aug 11;272(2):C15

Structure of a galactan from cell walls of Bifidobacterium catenulatum YIT4016. Nagaoka M, et al. **Carbohydr Res** 1996 Feb 23;281(2):285–91

Reductive cleavage of glycosides with borane complexes in the presence of boron trifluoride etherate. Oh IH, et al. **Carbohydr Res** 1995 Dec 20;278(2):329–38

Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry. Read SM, et al. **Carbohydr Res** 1996 Feb 23;281(2):187–201

The glycans of horseradish peroxidase. Yang BY, et al. **Carbohydr Res** 1996 Jun 21;287(2):203–12

Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189–219 (166 ref.)

The gene, protein and glycan structures of laccase from Pleurotus ostreatus. Giardina P, et al. **Eur J Biochem** 1996 Feb 1;235(3):508–15

Occurrence and structural analysis of highly sulfated multiantennary N-linked glycan chains derived from a fertilization-associated carbohydrate-rich glycoprotein in unfertilized eggs of Tribolodon hakonensis. Taguchi T, et al. **Eur J Biochem** 1996 Jun 1;238(2):357–67

Physical properties of polysaccharides in food. Brosio E. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S63–7 (7 ref.)

Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms. Albasini M, et al. **Farmaco** 1995 Sep;50(9):633–42

The hypothetical N-glycan charge: a number that characterizes protein glycosylation. Hermentin P, et al. **Glycobiology** 1996 Mar;6(2):217–30

Specific beta glucanases as tools for polysaccharide structure determination. Mishra C, et al. **Glycobiology** 1995 Oct; 5(7):645–54 (84 ref.)

Isolation and structural characterization of fucosylated gangliosides with linear poly-N-acetyllactosaminyl chains from human granulocytes. Müthing J, et al. **Glycobiology** 1996 Mar;6(2):147–56

A precise structural analysis of a fertilization-associated carbohydrate-rich glycopeptide isolated from the fertilized eggs of euryhaline killi fish (Fundulus heteroclitus). Novel penta-antennary N-glycan chains with a bisecting N-acetylglucosaminyl residue. Taguchi T, et al. **Glycobiology** 1995 Sep;5(6):611–24

Glycan modification of a thermostable recombinant (1-3, 1-4)-beta-glucanase secreted from Saccharomyces cerevisiae is determined by strain and culture conditions. Meldgaard M, et al. **Glycoconj J** 1995 Jun;12(3):380–90

Structural similarities among malaria toxins insulin second messengers, and bacterial endotoxin. Caro HN, et al. **Infect Immun** 1996 Aug;64(8):3438–41

Polysaccharide-peptide complexes from the cultured mycelia of the mushroom Coriolus versicolor and their culture medium activate mouse lymphocytes and macrophages. Wang HX, et al. **Int J Biochem Cell Biol** 1996 May; 28(5):601–7

Structure-activity relationship of antithrombotic polysaccharide derivatives. Franz G, et al. **Int J Biol Macromol** 1995 Dec;17(6):311–4 (16 ref.)

Characterisation of sorbed water molecules on neutral and ionic polysaccharides. Fringant C, et al. **Int J Biol Macromol** 1996 Jun;18(4):281–6

Computer modelling of sulfated carbohydrates: applications to carrageenans. Le Questel JY, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):161–75

Oligosaccharides derived from the xyloglucan isolated from the seeds of Hymenaea courbaril var. stilbocarpa. Lima NN, et al. **Int J Biol Macromol** 1995 Dec;17(6):413–5

Some novel N-fatty acyl derivatives of a microbial galactosaminan. Zhang M, et al. **Int J Biol Macromol** 1996 Jun;18(4):307–9

Use of a biosensor based on surface plasmon resonance and biotinyl glycans for analysis of sugar binding specificities of lectins. Shinohara Y, et al. **J Biochem (Tokyo)** 1995 May; 117(5):1076–82

Structures of the glycosyl-phosphatidylinositol anchors of porcine and human renal membrane dipeptidase. Comprehensive structural studies on the porcine anchor and interspecies comparison of the glycan core structures. Brewis IA, et al. **J Biol Chem** 1995 Sep 29;270(39):22946–56

Charge distribution of flanking amino acids influences O-glycan acquisition in vivo. Nehrke K, et al. **J Biol Chem** 1996 Mar 22;271(12):7061–5

Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells. Wilkins PP, et al. **J Biol Chem** 1996 Aug 2;271(31):18732–42

Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). Thornton BP, et al. **J Immunol** 1996 Feb 1;156(3):1235–46

The recharacterization of a polysaccharide iron complex (Niferex). Coe EM, et al. **J Inorg Biochem** 1995 Jun; 58(4):269–78

Sedimentation equilibrium as thermodynamic tool. Laue TM. **Methods Enzymol** 1995;259:427–52

Maltodextrins as lyoprotectants in the lyophilization of a model protein, LDH. Corveleyn S, et al. **Pharm Res** 1996 Jan;13(1):146–50

Certain functional properties of gums derived from some lesser known tropical legumes (Afzelia africana, Detarium microcarpum and Mucuna flagellipes). Onweluzo JC, et al. **Plant Foods Hum Nutr** 1995 Jul;48(1):55–63

Substitution of L-fucose by L-galactose in cell walls of Arabidopsis mur1. Zablackis E, et al. **Science** 1996 Jun 21; 272(5269):1808–10

[Composition, physico-chemical properties and molecular superstructure of dietary fiber preparations of the cellan type] Dongowski G, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):46–54 (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

Re: Color Doppler sonography of hepatic tumors with a galactose-based contrast agent [letter; comment] Tanaka S, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):217. Comment on: AJR Am J Roentgenol 1994 Nov;163(5):1099–104.

Hysterosalpingo-contrast sonography (HyCoSy) for determining tubal patency. Degenhardt F, et al.

Clin Radiol 1996 Feb;51 Suppl 1:15–8

Improved Doppler detection of proximal left anterior descending coronary artery stenosis after intravenous injection of a lung-crossing contrast agent: a transesophageal Doppler echocardiographic study. Caiati C, et al. **J Am Coll Cardiol** 1996 May;27(6):1413–21

Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist. Ernst H, et al. **J Clin Ultrasound** 1996 Jan; 24(1):31–5

Improvement of perineal sonographic bladder neck imaging with ultrasound contrast medium. Schaer GN, et al. **Obstet Gynecol** 1995 Dec;86(6):950–4

Microbubble contrast agent for color Doppler US: effect on breast masses. Work in progress. Kedar RP, et al. **Radiology** 1996 Mar;198(3):679–86

Usefulness of ultrasound contrast medium in perineal sonography for visualization of bladder neck funneling--first observations. Schaer GN, et al. **Urology** 1996 Mar;47(3):452–3

[Transesophageal contrast echocardiography, open foramen ovale and aneurysm of the atrial septum. Experiences with D-galactose suspension] Andresen H. **Ultraschall Med** 1995 Dec;16(6):275–8 (Eng. Abstr.) **(Ger)**

GENETICS

The regulation of cell- and tissue-specific expression of glycans by glycosyltransferases. Dinter A, et al. **Adv Exp Med Biol** 1995;376:53–82 (187 ref.)

RcsC-mediated induction of colanic acid by secretion of streptokinase in Escherichia coli K-12. Lee SH, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):189–93

The induction of neurotrophin and TRK receptor mRNA expression during early avian embryogenesis. Baig MA, et al. **Int J Dev Neurosci** 1996 Feb;14(1):55–60

The construction and characterization of colanic acid deficient mutants in an extraintestinal isolate of Escherichia coli (O4/K54/H5). Russo TA, et al. **Microb Pathog** 1995 Apr;18(4):269–78

IMMUNOLOGY

Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Mukherjee J, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1398–405

Expression of alpha-3/4-monofucosylated polylactosaminoglycan epitope, as defined by monoclonal antibody FW6, is a marker of the colorectal adenoma–carcinoma sequence. Baldus SE, et al. **Cancer** 1995 Sep 15;76(6):954–60

Antibody response to polyribosyl-ribitol phosphate antigen of Haemophilus influenzae in Ecuadorian and German children. Brüssow H, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):21–5

Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Retini C, et al. **Infect Immun** 1996 Aug; 64(8):2897–903

Binding of anti-band 3 autoantibody to sialylated poly-N-acetyllactosaminyl sugar chains of band 3 glycoprotein on polyvinylidene difluoride membrane and sepharose gel: further evidence for anti-band 3 autoantibody binding to the sugar chains of oxidized and senescent erythrocytes. Ando K, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):639–47

The continuing saga of complement receptor type 3 (CR3) [editorial; comment] Todd RF 3rd. **J Clin Invest** 1996 Jul 1;98(1):1–2. Comment on: J Clin Invest 1996 Jul 1;98(1):50–61.

Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. Valadon P, et al. **J Mol Biol** 1996 Aug 9; 261(1):11–22

Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Schønning K, et al. **Virology** 1996 Apr 1;218(1):134–40

N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Sjölander S, et al. **Virology** 1996 Jan 15;215(2):124–33

ISOLATION & PURIFICATION

Effect of cations on the elution of pectic polysaccharides from anion-exchange resins. Cheng L, et al. **Anal Biochem** 1995 Jun 10;228(1):109–14

Separation and characterization of O-deacylated lipooligosaccharides and glycans derived from Moraxella catarrhalis using capillary electrophoresis-electrospray mass spectrometry and tandem mass spectrometry. Kelly J, et al. **Anal Biochem** 1996 Jan 1;233(1):15–30

Polysaccharides in fungi. XXXV. Anti diabetic activity of an acidic polysaccharide from the fruiting bodies of Tremella aurantia. Kiho T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1627–9

A new polysaccharide from a traditional Nigerian plant food: Detarium senegalense Gmelin. Wang Q, et al. **Carbohydr Res** 1996 Apr 30;284(2):229–39

In vitro antiviral activities of sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides) against human immunodeficiency virus and other enveloped viruses. Hasui M, et al. **Int J Biol Macromol** 1995 Oct; 17(5):293–7

Polysaccharides from the seeds of Senna multijuga. Rechia CG, et al. **Int J Biol Macromol** 1995 Dec;17(6):409–12

Isolation of phosphooligosaccharide/phosphoinositol glycan from caveolae and cytosol of insulin-stimulated cells. Parpal S, et al. **J Cell Biol** 1995 Oct;131(1):125–35

Certain functional properties of gums derived from some lesser known tropical legumes (Afzelia africana, Detarium microcarpum and Mucuna flagellipes). Onweluzo JC, et al. **Plant Foods Hum Nutr** 1995 Jul;48(1):55–63

[Purification and properties of polysaccharide PPIII from Sterculia lychnophora Hance] Chen J, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):39–41, 64 (Eng. Abstr.) **(Chi)**

METABOLISM

Pretreatment of sugar cane bagasse hemicellulose hydrolysate for xylitol production by yeast. Dominguez JM, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:49–56

Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Czarnowska E, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):357–64

Stereochemical course of glucan hydrolysis by barley (1-->3)- and (1-->3, 1-->4)-beta-glucanases. Chen L, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):112–6

The influence of the period of adaptation on the digestibility of diets containing different types of indigestible polysaccharides in rats. Brunsgaard G, et al. **Br J Nutr** 1995 Dec;74(6):833–48

Taurocholic acid adsorption during non-starch polysaccharide fermentation: an in vitro study. Gelissen IC, et al. **Br J Nutr** 1995 Aug;74(2):221–8

Glycans of the trabecular meshwork in primary open angle glaucoma. Chapman SA, et al. **Br J Ophthalmol** 1996 May; 80(5):435–44

Contribution of oligosaccharide and polysaccharide digestion, and excreta losses of lactic acid and short chain fatty acids, to dietary metabolisable energy values in broiler chickens and adult cockerels. Carré B, et al. **Br Poult Sci** 1995 Sep;36(4):611–29

Metabolism of xyloglucan generates xylose-deficient oligosaccharide subunits of this polysaccharide in etiolated peas. Guillén R, et al. **Carbohydr Res** 1995 Nov 22; 277(2):291–311

Synthesis of pentasaccharide analogues of the N-glycan substrates of N-acetylglucosaminyltransferases III, IV and V using tetrasaccharide precursors and recombinant beta-(1-->2)-N-acetylglucosaminyltransferase II. Reck F, et al. **Carbohydr Res** 1995 Oct 2;275(2):221–9

Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion. Evidence that multivalency enhances the saccharide binding to L-selectin. Maaheimo H, et al. **Eur J Biochem** 1995 Dec 1;234(2):616–25

NMR studies of the action of hypochlorous acid on native pig articular cartilage. Schiller J, et al. **Eur J Biochem** 1995 Oct 15;233(2):672–6

The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)

Catabolism of glycan moieties of lipid intermediates leads to a single Man5GlcNAc oligosaccharide isomer: a study with permeabilized CHO cells. Kmiécik D, et al. **Glycobiology** 1995 Jul;5(5):483–94

Insertion into Aspergillus nidulans of functional UDP-GlcNAc: alpha 3-D- mannoside beta-1,2-N-acetylglucosaminyl-transferase I, the enzyme catalysing the first committed step from oligomannose to hybrid and complex N-glycans. Kalsner I, et al. **Glycoconj J** 1995 Jun;12(3):360–70

Histochemical demonstration and analysis of poly-N-acetyllactosamine structures in normal and malignant human tissues. Ito N, et al. **Histol Histopathol** 1996 Jan;11(1):203–14 (110 ref.)

Glycans of bovine lactoferrin function as receptors for the type 1 fimbrial lectin of Escherichia coli. Teraguchi S, et al. **Infect Immun** 1996 Mar;64(3):1075–7

Changes in wall-bound polysaccharidase activities during the culture cycle of a Rubus fruticosus cell suspension. Faïk A, et al. **Int J Biol Macromol** 1995 Dec;17(6):381–6

Effects of salts on production and on O-acetylation of glucuronan excreted by the Rhizobium meliloti M5N1 CS strain. Roblot C, et al. **Int J Biol Macromol** 1995 Dec; 17(6):365–8

Cell-wall polysaccharides in growing poplar bark tissue. Viëtor RJ, et al. **Int J Biol Macromol** 1995 Dec;17(6):341–4

Identification of the promoter region for the colanic acid polysaccharide biosynthetic genes in Escherichia coli K-12. Stout V. **J Bacteriol** 1996 Jul;178(14):4273–80

Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation. Hoffman R, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3591–8

Evolution of digestion of carbohydrates in the separate parts of the digestive tract of the edible snail Helix lucorum (Gastropoda: Pulmonata: Stylommatophora) during a complete 24-hour cycle and the first days of starvation. Flari V, et al. **J Comp Physiol [B]** 1996;165(7):580–91

Intake of rye bread ileostomists increases ileal excretion of fiber polysaccharide components and organic acids but does not increase plasma or urine lignans and isoflavonoids. Pettersson D, et al. **J Nutr** 1996 Jun;126(6):1594–600

Transient, lectin-like association of calreticulin with folding intermediates of cellular and viral glycoproteins. Peterson JR, et al. **Mol Biol Cell** 1995 Sep;6(9):1173–84

Turning lysozyme upside down [news; comment] Kirby AJ. **Nat Struct Biol** 1995 Nov;2(11):923–5. Comment on: Nat Struct Biol 1995 Nov;2(11):1007–11.

N-glycans as apical sorting signals in epithelial cells. Scheiffele P, et al. **Nature** 1995 Nov 2;378(6552):96–8

Glycans with N-acetyllactosamine type 2-like residues covering adult Schistosoma mansoni, and glycomimesis as a putative mechanism of immune evasion. Schmidt J. **Parasitology** 1995 Sep;111 (Pt 3):325–36

PHARMACOLOGY

Fucoidin, a potent inhibitor of leukocyte rolling, prevents neutrophil influx into phorbol-ester-induced inflammatory sites in rabbit lungs. Shimaoka M, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):307–11

Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Itoh H, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1937–47

Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Riou D, et al. **Anticancer Res** 1996 May-Jun;16(3A):1213–8

An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine). Wang R, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):867–72

Oversulfated fucoidan and heparin suppress endotoxin induction of plasminogen activator inhibitor-1 in cultured human endothelial cells: their possible mechanism of action. Soeda S, et al. **Biochim Biophys Acta** 1995 Oct 19; 1269(1):85–90

A polysaccharide fraction of shosaiko-to active in augmentation of natural killer activity by oral administration. Yamaoka Y, et al. **Biol Pharm Bull** 1995 Jun;18(6):846–9

Relationships between chemical characteristics and anticomplementary activity of fucans. Blondin C, et al. **Biomaterials** 1996 Mar;17(6):597–603

Activation of the complement system by polysaccharidic surfaces bearing carboxymethyl, carboxymethylbenzylamide and carboxymethylbenzylamide sulphonate groups. Toufik J, et al. **Biomaterials** 1995 Sep;16(13):993–1002

Relationship between reduction of complement activation by polysaccharide surfaces bearing diethylaminoethyl groups and their degree of substitution. Toufik J, et al. **Biomaterials** 1995 Sep;16(14):1081–8

Selective activation of heparin cofactor II by a sulfated polysaccharide isolated from the leaves of Artemisia princeps. Hayakawa Y, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):643–9

Inhibition of angiogenesis and murine tumour growth by laminarin sulphate. Hoffman R, et al. **Br J Cancer** 1996 May;73(10):1183–6

Inhibition of human leukocyte elastase by chemically and naturally oversulfated galactosaminoglycans. Bartolucci C, et al. **Carbohydr Res** 1995 Oct 23;276(2):401–8

An inositol phosphoglycan from Trypanosoma cruzi inhibits ACTH action in calf adrenocortical cells. Vila MC, et al. **Cell Signal** 1995 May;7(4):331–9

B-lymphocyte-stimulating polysaccharide from mushroom Phellinus linteus. Song KS, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2105–8

Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Zhang PL, et al. **Circ Res** 1995 Dec;77(6):1240–5

Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested. MacLaren DP, et al. **Clin Sci (Colch)** 1995 Aug;89(2):137–43

Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist. Sakamoto K, et al. **Diabetologia** 1995 May;38(5):536–42

Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Vecchiarelli A, et al. **Infect Immun** 1996 Jul; 64(7):2846–9

In vitro antiviral activities of sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides) against human immunodeficiency virus and other enveloped viruses. Hasui M, et al. **Int J Biol Macromol** 1995 Oct; 17(5):293–7

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. Shyng SL, et al. **J Biol Chem** 1995 Dec 15;270(50):30221–9

Collagen synthesis by vascular smooth muscle cells in the presence of antiproliferative polysaccharides. Logeart D, et al. **J Biomed Mater Res** 1996 Apr;30(4):501–8

Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. Dong ZM, et al. **J Clin Invest** 1996 Feb 1;97(3):689–98

Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. Blackstock R. **J Med Vet Mycol** 1996 Jan-Feb;

34(1):19–30

Alteration of Ca2+ fluxes in brain microsomes by K+ and Na+: modulation by sulfated polysaccharides and trifluoperazine. Rocha JB, et al. **J Neurochem** 1996 Feb; 66(2):772–8

Hemicellulose does not affect iron bioavailability in chicks. Fly AD, et al. **J Nutr** 1996 Jan;126(1):308–16

Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals. Boevé ER, et al. **J Urol** 1996 Jan;155(1):368–73

Crystal–cell interaction inhibition by polysaccharides. Verkoelen CF, et al. **J Urol** 1996 Feb;155(2):749–52

Neurotropin prevents neurophysiological abnormalities and ADP–induced hyperaggregability in rats with streptozotocin–induced diabetes. Hotta N, et al. **Life Sci** 1995;57(23):2101–11

Induction in the mouse of gene expression of immunomodulating cytokines by mushroom polysaccharide–protein complexes. Liu F, et al. **Life Sci** 1996;58(21):1795–803

Stimulatory effect of hormonal signaling factors on (Ca(2+)–Mg2+)–ATPase activity in rat liver plasma membranes: cross talk with regucalcin. Takahashi H, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):1–7

Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non–peptide antagonist for atrial natriuretic peptide receptor. Silberbach M, et al. **Pediatr Res** 1995 Nov;38(5):722–8

Analysis of polysaccharide taste in hamsters: behavioral and neural studies. Rehnberg BG, et al. **Physiol Behav** 1996 Mar;59(3):505–16

Pectic polysaccharides from roots of Glycyrrhiza uralensis: possible contribution of neutral oligosaccharides in the galacturonase–resistant region to anti–complementary and mitogenic activities. Kiyohara H, et al. **Planta Med** 1996 Feb;62(1):14–9

Effect of oral administration of a pectic polysaccharide fraction from a kampo (Japanese herbal) medicine "juzen–taiho–to" on antibody response of mice. Kiyohara H, et al. **Planta Med** 1995 Oct;61(5):429–34

Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Dong Y, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):140–8

Absence of in vitro cross–reaction of pentasaccharide with the plasma heparin–dependent factor of twenty–five patients with heparin–associated thrombocytopenia [letter] Elalamy I, et al. **Thromb Haemost** 1995 Nov;74(5):1384–5

Effect of fucoidan during activation of human plasminogen. Doctor VM, et al. **Thromb Res** 1995 Aug 1;79(3):237–47

Comparison of saccharides as osmotic impermeants during hypothermic lung graft preservation. Hopkinson DN, et al. **Transplantation** 1996 Jun 27;61(12):1667–71

Effects of Phytolacca acinosa polysaccharides I combined with interleukin–2 on the cytotoxicity of murine splenocytes against tumor cells. Wang HB, et al. **Yao Hsueh Hsueh Pao** 1995;30(6):401–7

[Effect of Achyranthes bidentata polysaccharides (ABP) on antitumor activity and immune function of S180–bearing mice] Yu S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):275–8 (Eng. Abstr.) **(Chi)**

[The effects of zhuling–duotang, hepatitis B vaccine and bacillus Calmette–Guerin on immunoactivities of peripheral blood mononuclear cells: an in vitro research] Li L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):392–5 (Eng. Abstr.) **(Chi)**

[Effects of emodin, sennosides and rheum polysaccharides on free calcium in isolated rat liver cells] Lin XZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):419–21 (Eng. Abstr.) **(Chi)**

[Study on effect of polysaccharides of ginseng on peripheral blood mononuclear cell induced interleukin–2 production and activity of its receptors in vitro] Ma L, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):411–3 (Eng. Abstr.) **(Chi)**

[Effects of Astragalus polysaccharides and ginsenosides of Ginseng stems and leaves on lymphocytes membrane fluidity and lipid peroxidation in traumatized mice] Liang H, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):558–60, inside backcover (Eng. Abstr.) **(Chi)**

[Protective effects of Tribulus terrestris L. polysaccharide on genetic damage] Liu Q, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):427–9, 449 (Eng. Abstr.) **(Chi)**

[Protective action of Lycium barbarum L. (LbL) and betaine on lipid peroxidation of erythrocyte membrane induced by H2O2] Ren B, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):303–4, inside cover (Eng. Abstr.) **(Chi)**

[Progress in the research of plant polysaccharides] Tian G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):441–4 (31 ref.) **(Chi)**

[Active antisenile constituents in Cistanche deserticola Y. C. Ma] Xue D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):687–9, 704 (Eng. Abstr.) **(Chi)**

[The effects of Salvia miltiorrhiza and polysaccharide sulphate on the adhesion of erythrocytes of the patients with cerebral thrombosis to cultured endothelial cells] Wang L, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):381–5 (Eng. Abstr.) **(Chi)**

[The effect of the polysaccharide fraction of Korean ginseng on learning and memory in rats (exemplified by active avoidance reactions)] Liubimov II, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):169–73 **(Rus)**

[The characteristics of the neurophysiological mechanisms of the acquisition and extinction of defensive behavior in rabbits under the action of the immunomodulator neurotropin] Murtazina EP. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):748–56 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Carbohydrate–mediated sorting in aggregating embryonal carcinoma cells. Boubelík M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):283–8

Effect of polysialic acid on the behavior of retinal ganglion cell axons during growth into the optic tract and tectum. Yin X, et al. **Development** 1995 Oct;121(10):3439–46

Glycosyltransferase mutants: key to new insights in glycobiology. Stanley P, et al. **FASEB J** 1995 Nov; 9(14):1436–44 (48 ref.)

[Binding of IgA1 to monocyte/macrophage cell lines (THP–1, U937) in IgA nephropathy—a possible role of O–glycan in the IgA1 molecule] Horii A, et al. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):558–63 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Photoperiod affects the expression of neural cell adhesion molecule and polysialic acid in the hypothalamus of the Siberian hamster. Lee W, et al. **Brain Res** 1995 Aug 28; 690(1):64–72

SECRETION

Characterisation of the morphogenetic course and secretion of two different types of mucoid material by granulated metrial gland/lymphokine–activated killer cells. Dyugovskaya L, et al. **J Anat** 1995 Dec;187 (Pt 3):693–708

THERAPEUTIC USE

Polysaccharides in fungi. XXXV. Anti diabetic activity of an acidic polysaccharide from the fruiting bodies of Tremella aurantia. Kiho T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1627–9

Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity. Hershkoviz R, et al. **J Autoimmun** 1995 Oct;8(5):741–50

Efficacy and tolerance of insoluble carob fraction in the treatment of travellers' diarrhoea. Hostettler M, et al. **J Diarrhoeal Dis Res** 1995 Sep;13(3):155–8

[Effectiveness of non–starch polysaccharide crylan in experimental hyperlipidemia] Remezova OV, et al. **Vopr Pitan** 1995;(2):14–6 (Eng. Abstr.) **(Rus)**

TOXICITY

Lack of carcinogenicity of tamarind seed polysaccharide in B6C3F1 mice. Sano M, et al. **Food Chem Toxicol** 1996 May; 34(5):463–7

ULTRASTRUCTURE

Short report: Electron microscopic demonstration of extracellular structure of Burkholderia pseudomallei. Puthucheary SD, et al. **Am J Trop Med Hyg** 1996 Mar; 54(3):313–4

POLYSACCHARIDES, BACTERIAL

Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle–aged men. Dickstein K, et al. **Am J Ophthalmol** 1996 Apr; 121(4):367–71

Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. Hargreaves RM, et al. **BMJ** 1996 Jan 20;312(7024):160–1

Haemophilus influenzae vaccine: maximizing uptake [letter] Booy R, et al. **Br J Gen Pract** 1995 Oct;45(399):563

Bacterial polysaccharides in sickness and in health. The 1995 Fleming Lecture. Roberts IS. **Microbiology** 1995 Sep;141 (Pt 9):2023–31 (95 ref.)

Haemophilus influenzae: capsule vaccine and capsulation genetics. Kroll JS, et al. **Mol Med Today** 1996 Apr; 2(4):160–5 (37 ref.)

[Radiation–protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Administration of two vaccines, DTP and Hib, in one single injection [letter] De Bont B. **Acta Clin Belg** 1995; 50(4):246–7

National Advisory Committee on Immunization (NACI). Supplementary statement on Typhim VI polysaccharide capsular vaccine. **Can Commun Dis Rep** 1995 Nov 30; 21(22):197–200 **(Eng, Fre)**

The contribution of the case–control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. Mills OF, et al. **J Clin Epidemiol** 1996 Jun;49(6):631–6 (34 ref.)

Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Begg NT, et al. **Vaccine** 1995 Nov;13(16):1547–50

ADVERSE EFFECTS

Gianotti–Crosti syndrome as a result of vaccination and Epstein–Barr virus infection [letter] Lacour M, et al. **Eur J Pediatr** 1995 Aug;154(8):688–9

ANALYSIS

Effect of the surface composition of motile Escherichia coli and motile Salmonella species on the direction of galvanotaxis. Shi W, et al. **J Bacteriol** 1996 Feb; 178(4):1113–9

Characterization of Streptococcus sanguis isolated from patients with Behçet's disease. Yokota K, et al. **Microbiol Immunol** 1995;39(9):729–32

Dot–enzyme–linked immunosorbent assay (Dot–ELISA) for detection of pneumococcal polysaccharide antigens in pleural fluid effusion samples. Comparison with bacterial culture, counterimmunoelectrophoresis and latex agglutination. Requejo HI, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):531–7

BIOSYNTHESIS

Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Mikušová K, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2484–9

Comamonas testosteroni colony phenotype influences exopolysaccharide production and coaggregation with yeast cells. Bossier P, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2687–91

Identification of exopolysaccharides produced by fluorescent pseudomonads associated with commercial mushroom (Agaricus bisporus) production. Fett WF, et al. **Appl Environ Microbiol** 1995 Feb;61(2):513–7

Production and rheological properties of a succinoglycan from Pseudomonas sp. 31260 grown on wood hydrolysates. Meade MJ, et al. **Can J Microbiol** 1995 Dec;41(12):1147–52

Determination of the structure of the exopolysaccharide produced by Lactobacillus sake 0–1. Robijn GW, et al. **Carbohydr Res** 1995 Oct 16;276(1):117–36

Effect of iron limitation on the amount of slime produced by strains of Staphylococcus epidermidis. Elçi S, et al. **Cytobios** 1995;84(338–339):141–6

Homologous integration and transposition to identify genes involved in the production of exopolysaccharides in Streptococcus thermophilus. Stingele F, et al. **Dev Biol Stand** 1995;85:487–93

Respiratory activity is essential for post–exponential–phase production of type 5 capsular polysaccharide by Staphylococcus aureus. Dassy B, et al. **Infect Immun** 1996 Jul;64(7):2408–14

Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Paoletti LC, et al. **Infect Immun** 1996 Apr;64(4):1220–6

Cyclic (1—>2)–beta–D–glucans excreted by the glucuronan–producing strain Rhizobium meliloti M5N1CS (NCIMB 40472) and by the succinoglycan–producing strain Rhizobium meliloti M5N1. Michaud P, et al. **Int J Biol Macromol** 1995 Dec;17(6):369–72

Positive autoregulation of vipR expression in ViaB region–encoded Vi antigen of Salmonella typhi. Hashimoto Y, et al. **J Bacteriol** 1996 Mar;178(5):1430–6

Promoter analysis of the Xanthomonas campestris pv. campestris gum operon directing biosynthesis of the xanthan polysaccharide. Katzen F, et al. **J Bacteriol** 1996 Jul;178(14):4313–8

Identification and characterization of the eps (Exopolysaccharide) gene cluster from Streptococcus thermophilus Sfi6. Stingele F, et al. **J Bacteriol** 1996 Mar; 178(6):1680–90

Characterization of the rcsA and rcsB genes from Salmonella typhi: rcsB through tviA is involved in regulation of Vi antigen synthesis. Virlogeux I, et al. **J Bacteriol** 1996 Mar; 178(6):1691–8

Phase–shift of polysaccharide capsule expression in group B streptococci, type III. Sellin M, et al. **Microb Pathog** 1995 Jun;18(6):401–15

Genetic transfer of amylovoran and stewartan synthesis between Erwinia amylovora and Erwinia stewartii. Bernhard F, et al. **Microbiology** 1996 May;142 (Pt 5):1087–96

Low–molecular–weight succinoglycan is predominantly produced by Rhizobium meliloti strains carrying a mutated ExoP protein characterized by a periplasmic N–terminal domain and a missing C–terminal domain. Becker A, et al. **Mol Microbiol** 1995 Apr;16(2):191–203

Characterization of cpsF and its product CMP–N–acetylneuraminic acid synthetase, a group B streptococcal enzyme that can function in K1 capsular polysaccharide biosynthesis in Escherichia coli. Haft RF, et al. **Mol Microbiol** 1996 Feb;19(3):555–63

Molecular characterization of the eps gene cluster of Pseudomonas solanacearum and its transcriptional

regulation at a single promoter. Huang J, et al. **Mol Microbiol** 1995 Jun;16(5):977–89

Region 2 of the Escherichia coli K5 capsule gene cluster encoding proteins for the biosynthesis of the K5 polysaccharide. Petit C, et al. **Mol Microbiol** 1995 Aug; 17(4):611–20

mucS, a gene involved in activation of galactoglucan (EPS II) synthesis gene expression in Rhizobium meliloti. Astete SG, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):395–400

Complementation analyses of Pseudomonas solanacearum extracellular polysaccharide mutants and identification of genes responsive to EpsR. McWilliams R, et al. **Mol Plant Microbe Interact** 1995 Nov–Dec;8(6):837–44

[The effect of the conditions for Neisseria meningitidis cultivation on the protein composition in the protein–polysaccharide complex—the base of meningococcal serogroup B vaccine] Kuvakina VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):60–3 (Eng. Abstr.) **(Rus)**

[The growth dynamics and biosynthetic properties of Haemophilus influenza under different cultivation conditions] Strel'nikova LM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):12–3 **(Rus)**

BLOOD

Detection of C-polysaccharide in serum of patients with Streptococcus pneumoniae bacteraemia. Gillespie SH, et al. **J Clin Pathol** 1995 Sep;48(9):803–6

CHEMISTRY

Determination of the size and degree of acetyl substitution of oligosaccharides from Neisseria meningitidis group A by ionspray mass spectrometry. Cescutti P, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):444–50

Transferred nuclear Overhauser enhancement experiments show that the monoclonal antibody strep 9 selects a local minimum conformation of a Streptococcus group A trisaccharide–hapten. Weimar T, et al. **Biochemistry** 1995 Oct 17;34(41):13672–81

Encapsulation of urease enzyme in xanthan–alginate spheres. Elçin YM. **Biomaterials** 1995 Oct;16(15):1157–61

Dynamic simulations of the molecular conformations of wild type and mutant xanthan polymers suggest that conformational differences may contribute to observed differences in viscosity. Levy S, et al. **Biopolymers** 1996 Feb;38(2):251–72

Vacuum ultraviolet circular dichroism of gellan–family polymer films from water and dimethyl sulfoxide. Arndt ER, et al. **Carbohydr Res** 1996 Jan 4;280(1):15–26

Lipo–oligosaccharide of Campylobacter lari strain PC 637. Structure of the liberated oligosaccharide and an associated extracellular polysaccharide. Aspinall GO, et al. **Carbohydr Res** 1995 Dec 27;279:227–44

Lipo–oligosaccharide of the Campylobacter lari type strain ATCC 35221. Structure of the liberated oligosaccharide and an associated extracellular polysaccharide. Aspinall GO, et al. **Carbohydr Res** 1995 Dec 27;279:245–64

The structure of the acidic exopolysaccharide produced by Pseudomonas "gingeri" strain Pf9. Cescutti P, et al. **Carbohydr Res** 1995 Oct 2;275(2):371–9

Degradation of double–stranded xanthan by hydrogen peroxide in the presence of ferrous ions: comparison to acid hydrolysis. Christensen BE, et al. **Carbohydr Res** 1996 Jan 4;280(1):85–99

NMR reinvestigation of the capsular K27 polysaccharide (K27 antigen) from Escherichia coli O8:K27:H–. Jann B, et al. **Carbohydr Res** 1995 Nov 22;277(2):353–8

Structure of an acidic microcapsular glycan from the reference strain (C.D.C. 866–57) for Serratia marcescens serogroup O1. Johansson A, et al. **Carbohydr Res** 1995 Apr 30;270(2):191–9

Structural studies on a cell wall polysaccharide from Bifidobacterium longum YIT4028. Nagaoka M, et al. **Carbohydr Res** 1995 Sep 8;274:245–9

Synthesis of a pentasaccharide fragment of Polysaccharide II of Mycobacterium tuberculosis. Pozsgay V, et al. **Carbohydr Res** 1995 Nov 7;277(1):51–66

Larch arabinogalactan for hepatic drug delivery: isolation and characterization of a 9 kDa arabinogalactan fragment. Prescott JH, et al. **Carbohydr Res** 1995 Nov 30; 278(1):113–28

Determination of the structure of the exopolysaccharide produced by Lactobacillus sake 0–1. Robijn GW, et al. **Carbohydr Res** 1995 Oct 16;276(1):117–36

The structure of the exopolysaccharide produced by Lactobacillus helveticus 766. Robijn GW, et al. **Carbohydr Res** 1995 Oct 16;276(1):137–54

Conformational analysis of oligosaccharides corresponding to the cell–wall polysaccharide of the Streptococcus group A by Metropolis Monte Carlo simulations. Stuike–Prill R, et al. **Carbohydr Res** 1995 Dec 27;279:59–73

Structure of an exocellular polysaccharide of Lactobacillus helveticus TN–4, a spontaneous mutant strain of Lactobacillus helveticus TY1–2. Yamamoto Y, et al. **Carbohydr Res** 1995 Oct 2;275(2):319–32

A conformational model for cyclic beta–(1—>2)–linked glucans based on NMR analysis of the beta–glucans produced by Xanthomonas campestris. York WS. **Carbohydr Res** 1995 Dec 20;278(2):205–25

Phase–shift of capsule expression in group B streptococci type III. Sellin M, et al. **Dev Biol Stand** 1995;85:245–9

Structure of the capsular polysaccharide of Vibrio cholerae O139 synonym Bengal containing D–galactose 4,6–cyclophosphate. Knirel YA, et al. **Eur J Biochem** 1995 Sep 1;232(2):391–6

Structural elucidation of novel methylglucose–containing polysaccharides from Mycobacterium xenopi. Tuffal G, et al. **Eur J Biochem** 1995 Oct 1;233(1):377–83

Lectin recognition of host–like saccharide motifs in streptococcal cell wall polysaccharides. Cisar JO, et al. **Glycobiology** 1995 Oct;5(7):655–62

Purification and characterization of the staphylococcal slime–associated antigen and its occurrence among Staphylococcus epidermis clinical isolates. Baldassarri L, et al. **Infect Immun** 1996 Aug;64(8):3410–5

NMR studies of succinoglycan repeating–unit octasaccharides from Rhizobium meliloti and Agrobacterium radiobacter. Chouly C, et al. **Int J Biol Macromol** 1995 Dec;17(6):357–63

Identification by NMR spectroscopy of oligosaccharides obtained by acidolysis of the capsular polysaccharides of a thermal biomass. Gloaguen V, et al. **Int J Biol Macromol** 1995 Dec;17(6):387–93

Application of two–dimensional NMR spectroscopy and molecular dynamics simulations to the conformational analysis of oligosaccharides corresponding to the cell–wall polysaccharide of Streptococcus group A. Kreis UC, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):117–30

Conformations and flexibility of native and re–natured xanthan in aqueous solutions. Milas M, et al. **Int J Biol Macromol** 1996 Apr;18(3):211–21

Cell–associated glucans of Burkholderia solanacearum and Xanthomonas campestris pv. citri: a new family of periplasmic glucans. Talaga P, et al. **J Bacteriol** 1996 Apr; 178(8):2263–71

Rheological characterization of xanthan gum and hydroxypropylmethyl cellulose with respect to controlled–release drug delivery. Talukdar MM, et al. **J Pharm Sci** 1996 May;85(5):537–40

Molecular size characterization of Haemophilus influenzae type b polysaccharide–protein conjugate vaccines. Plumb JE, et al. **Vaccine** 1996 Apr;14(5):399–404

ECONOMICS

Economic aspects of a general vaccination against invasive disease caused by Haemophilus influenzae type b (Hib) via the experience of the Children's Hospital La Fe, Valencia, Spain. Asensi F, et al. **Vaccine** 1995 Nov;13(16):1563–6

GENETICS

Polysaccharide expression in Lactococci. Dierksen KP, et al. **Dev Biol Stand** 1995;85:469–80

Capsules and cassettes: genetic organization of the capsule locus of Streptococcus pneumoniae. Dillard JP, et al. **Dev Biol Stand** 1995;85:261–5

Nucleotide sequence analysis of genes essential for production of Streptococcus pneumoniae type 19F capsular polysaccharide. Guildolin A, et al. **Dev Biol Stand** 1995; 85:267–71

Characterization of the capsular polysaccharide genes of group B streptococci. Rubens CE, et al. **Dev Biol Stand** 1995;85:237–44 (31 ref.)

Homologous integration and transposition to identify genes involved in the production of exopolysaccharides in Streptococcus thermophilus. Stingele F, et al. **Dev Biol Stand** 1995;85:487–93

Pathogenicity island evaluation in Escherichia coli K1 by crossing with laboratory strain K–12. Bloch CA, et al. **Infect Immun** 1996 Aug;64(8):3218–23

Distribution of the rol gene encoding the regulator of lipopolysaccharide O–chain length in Escherichia coli and its influence on the expression of group I capsular K antigens. Dodgson C, et al. **J Bacteriol** 1996 Apr; 178(7):1895–902

Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus. Sau S, et al. **J Bacteriol** 1996 Apr;178(7):2118–26

Extension of the Rhizobium meliloti succinoglycan biosynthesis gene cluster: identification of the exsA gene encoding an ABC transporter protein, and the exsB gene which probably codes for a regulator of succinoglycan biosynthesis. Becker A, et al. **Mol Gen Genet** 1995 Dec 15;249(5):487–97

IMMUNOLOGY

A comparative study of the immune response to poly–[alpha(2—>8)–N–acetyl neuraminic acid] Diaz Romero J, et al. **Adv Exp Med Biol** 1995;371A:543–8

Ontogeny of the mucosal immune response against different types of pneumococcal polysaccharide in rat. van den Dobbelsteen GP, et al. **Adv Exp Med Biol** 1995;371A:415–9

Mucosal and systemic immunization with pneumococcal polysaccharide type 3, 4 and 14 in the rat. van den Dobbelsteen GP, et al. **Adv Exp Med Biol** 1995; 371B:1605–10

Antibody responses to polysaccharide and polysaccharide–conjugate vaccines after treatment of Hodgkin disease. Molrine DC, et al. **Ann Intern Med** 1995 Dec 1;123(11):828–34

The immunoglobulin gene repertoire to Haemophilus influenzae type b. Carroll WL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:374–7

Patterns of V–region gene segment association in the human antibody response to Haemophilus influenzae type B capsular polysaccharide. Pinchuk GV, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:378–80

Structure–function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Shaw DR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:370–3

The antibody response after immunization with pneumococcal polysaccharide vaccine in splenectomized mice: the effect of re–immunization with pneumococcal antigens. Aaberge IS, et al. **APMIS** 1996 Apr;104(4):307–17

Response of human immunodeficiency virus–exposed and –infected infants to Haemophilus influenzae type b conjugate vaccine. Rutstein RM, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):838–41

Transferred nuclear Overhauser enhancement experiments show that the monoclonal antibody strep 9 selects a local minimum conformation of a Streptococcus group A trisaccharide–hapten. Weimar T, et al. **Biochemistry** 1995 Oct 17;34(41):13672–81

Antibody response after immunization of Brazilian children with serogroup C meningococcal polysaccharide noncovalently complexed with outer membrane proteins. Milagres LG, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):981–9

National Advisory Committee on Immunization (NACI). Supplementary statement on Typhim VI polysaccharide capsular vaccine. **Can Commun Dis Rep** 1995 Nov 30; 21(22):197–200 **(Eng, Fre)**

The pathogenic role of Staphylococcus epidermidis capsular polysaccharide/adhesin in a low–inoculum rabbit model of prosthetic valve endocarditis. Shiro H, et al. **Circulation** 1995 Nov 1;92(9):2715–22

Antibody response to polyribosyl–ribitol phosphate antigen of Haemophilus influenzae in Ecuadorian and German children. Brüssow H, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):21–5

Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Granoff DM, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):574–82

Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme–linked immunosorbent assay. Madore DV, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):84–8

Measurement of pneumococcal capsular polysaccharide serotype–specific immunoglobulin G in human serum, a method for assigning weight–based units to proposed reference sera. Rudolph KM, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):526–30

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10–1 (16 ref.)

Evaluation of the response of human humoral antibodies to Salmonella typhi lipopolysaccharide in an area of endemic typhoid fever. Shaheen HI, et al. **Clin Infect Dis** 1995 Oct; 21(4):1012–3

Immune responses to the capsular polysaccharide of Mycoplasma dispar in calves and mice. Bansal P, et al. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):259–68

Antibodies that react with the capsular polysaccharide of Vibrio vulnificus are detectable in infected patients, and in persons without known exposure to the organism. Fiore A, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):165–7

Deficient antipneumococcal polysaccharide responses in HIV–seropositive patients. Loeliger AE, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):33–41

Cell surface determinants on typhoid–specific B cells isolated from peripheral blood after oral Ty21a typhoid vaccination in humans. Penttila IA, et al. **Immunol Cell Biol** 1995 Jun; 73(3):198–204

T–cell dependent response to immune complexes abrogates B–cell unresponsiveness to pneumococcal cell wall polysaccharide. Caulfield MJ, et al. **Immunology** 1995 Nov; 86(3):331–5

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide–tetanus toxoid conjugate vaccines of Vibrio vulnificus. Devi SJ, et al. **Infect Immun** 1996 Jun;64(6):2220–4

A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP–specific antibodies protect mice against bacterial challenge. Fattom AI, et al. **Infect Immun** 1996 May;64(5):1659–65

Immunogenicity of group B Streptococcus type III polysaccharide–tetanus toxoid vaccine in baboons. Paoletti LC, et al. **Infect Immun** 1996 Feb;64(2):677–9

Antibodies to Haemophilus influenzae type b polysaccharide affect bacterial adherence and multiplication. van Alphen L, et al. **Infect Immun** 1996 Mar;64(3):995–1001

Actinobacillus actinomycetemcomitans serotype b–specific polysaccharide antigen stimulates production of chemotactic factors and inflammatory cytokines by human monocytes. Yamaguchi N, et al. **Infect Immun** 1996 Jul; 64(7):2563–70

Role of the capsular polysaccharide–like serotype–specific antigen in resistance of Actinobacillus actinomycetemcomitans to phagocytosis by human polymorphonuclear leukocytes. Yamaguchi N, et al. **Infect Immun** 1995 Dec;63(12):4589–94

Assessment of the direct effectiveness of BC meningococcal

vaccine in Rio de Janeiro, Brazil: a case-control study. Noronha CP, et al. **Int J Epidemiol** 1995 Oct;24(5):1050-7

Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. Peset Llopis MJ, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):1015-24

Antibody response to unconjugated Haemophilus influenzae b and pneumococcal polysaccharide vaccines in children with recurrent infections. Raby R, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):451-9

Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. Welch PG, et al. **J Am Soc Nephrol** 1996 Feb;7(2):247-53

Good and laudable pus [editorial; comment] Gorbach SL. **J Clin Invest** 1995 Dec;96(6):2545. Comment on: J Clin Invest 1995 Dec;96(6):2727-31.

Simplified procedure for preparation of sensitized latex particles to detect capsular polysaccharides: application to typing and diagnosis of Actinobacillus pleuropneumoniae. Inzana TJ. **J Clin Microbiol** 1995 Sep;33(9):2297-303

A quantitative ELISA for antigen-specific IgG subclasses using equivalence dilutions of anti-kappa and anti-subclass specific secondary reagents. Application to the study of the murine immune response against the capsular polysaccharide of Neisseria meningitidis serogroup B. Colino J, et al. **J Immunol Methods** 1996 Apr 19; 190(2):221-34

Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates. Zielen S, et al. **J Immunol Methods** 1996 Jun 14;193(1):1-7

Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. Giebink GS, et al. **J Infect Dis** 1996 Jan;173(1):119-27

Quantitative determination of antibodies to type III group B streptococcal polysaccharide. Guttormsen HK, et al. **J Infect Dis** 1996 Jan;173(1):142-50

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. Käyhty H, et al. **J Infect Dis** 1995 Nov;172(5):1273-8

Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. Kurikka S, et al. **J Infect Dis** 1995 Nov;172(5):1268-72

Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. Mandrell RE, et al. **J Infect Dis** 1995 Nov; 172(5):1279-89

Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. Mascart-Lemone F, et al. **J Infect Dis** 1995 Nov;172(5):1253-60

A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. Nahm MH, et al. **J Infect Dis** 1996 Jan;173(1):113-8

Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea. Kim YR, et al. **J Korean Med Sci** 1995 Oct;10(5):314-7

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. Anderson EL, et al. **J Pediatr** 1996 May; 128(5 Pt 1):649-53

Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. King WJ, et al. **J Pediatr** 1996 Feb;128(2):196-202

Immediate burn wound excision restores antibody synthesis to bacterial antigen. Yamamoto H, et al. **J Surg Res** 1996 Jun;63(1):157-62

Correlation of the polysaccharide antigens of Francisella tularensis with virulence in experimental mice. Fujita H, et al. **Microbiol Immunol** 1995;39(12):1007-9

Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Hutchins WA, et al. **Mol Immunol** 1996 Apr;33(6):503-10

Shigella lipopolysaccharide antibodies in pediatric populations. Passwell JH, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):859-65

A simple, quantitative, reproducible avidin-biotin ELISA for the evaluation of group B streptococcus type-specific antibodies in humans. Basham LE, et al. **Vaccine** 1996 Apr; 14(5):439-45

Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Fattom A, et al. **Vaccine** 1995 Oct;13(14):1288-93

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Klugman KP, et al. **Vaccine** 1996 Apr;14(5):435-8

Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Kotloff KL, et al. **Vaccine** 1996 Apr;14(5):446-50

Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Siber GR, et al. **Vaccine** 1995 Apr; 13(6):525-31

Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Srinand S, et al. **Vet Microbiol** 1996 Apr; 49(3-4):181-95

ISOLATION & PURIFICATION

Purification of commercial gellan to monovalent cation salts results in acute modification of solution and gel-forming properties. Doner LW, et al. **Carbohydr Res** 1995 Aug 25; 273(2):225-33

Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Steinmetz I, et al. **Infect Immun** 1995 Oct;63(10):3959-65

A novel cell surface polysaccharide in Pseudomonas putida WCS358, which shares characteristics with Escherichia coli K antigens, is not involved in root colonization. de Weger LA, et al. **J Bacteriol** 1996 Apr;178(7):1955-61

Isolation and structural analysis of polysaccharide containing galactofuranose from the cell walls of Bifidobacterium infantis. Tone-Shimokawa Y, et al. **J Bacteriol** 1996 Jan; 178(1):317-20

Isolation and structural characterization of adhesin polysaccharide receptors. Cassels FJ, et al. **Methods Enzymol** 1995;253:69-91 (44 ref.)

Extracellular and surface-exposed polysaccharides of non-tuberculous mycobacteria. Lemassu A, et al. **Microbiology** 1996 Jun;142 (Pt 6):1513-20

[Purification of serotype d-- and e--specific antigens from Actinobacillus actinomycetemcomitans and seroclassification of clinical isolates from periodontal patients] Yamamoto M. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):174-87 (Eng. Abstr.) **(Jpn)**

[The acid exopolysaccharide of the causative agent of melioidosis] Denisov II, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):16-7 **(Rus)**

[Isolation of xanthan from Xanthomonas campesteris B-1459 in mechanically agitated fermentors] Lorda GS, et al. **Rev Argent Microbiol** 1995 Jul-Sep;27(3):146-55 (Eng. Abstr.) **(Spa)**

METABOLISM

Description of a new polymer-secreting bacterium from a deep-sea hydrothermal vent, Alteromonas macleodii subsp. fijiensis, and preliminary characterization of the polymer. Raguenes G, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):67-73

Biosynthesis of dermatan sulphate. Defructosylated Escherichia coli K4 capsular polysaccharide as a substrate for the D-glucuronyl C-5 epimerase, and an indication of a two-base reaction mechanism. Hannesson HH, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):589-96

Lysozyme substrates. Höltje JV. **EXS** 1996;75:105-10 (34 ref.)

Cyclic (1-->2)-beta-D-glucans excreted by the glucuronan-producing strain Rhizobium meliloti M5N1CS (NCIMB 40472) and by the succinoglycan-producing strain Rhizobium meliloti M5N1. Michaud P, et al. **Int J Biol Macromol** 1995 Dec;17(6):369-72

Effects of salts on production and on O-acetylation of glucuronan excreted by the Rhizobium meliloti M5N1 CS strain. Roblot C, et al. **Int J Biol Macromol** 1995 Dec; 17(6):365-8

Bacillus curdlanolyticus sp. nov. and Bacillus kobensis sp. nov., which hydrolyze resistant curdlan. Kanzawa Y, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):515-21

The role of extracellular polysaccharide substance produced by Staphylococcus epidermidis in miliaria. Mowad CM, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):729-33

Analysis of the enzymatic cleavage (beta elimination) of the capsular K5 polysaccharide of Escherichia coli by the K5-specific coliphage: reexamination. Hänfling P, et al. **J Bacteriol** 1996 Aug;178(15):4747-50

Observation of encapsulated lactic acid bacteria using confocal scanning laser microscopy. Hassan AN, et al. **J Dairy Sci** 1995 Dec;78(12):2624-8

[Carbohydrate receptors for Mycoplasma fermentans adhesion on human epithelial tissues] Skrypal' IH, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):17-22 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Lipoteichoic acid-induced neutrophil adhesion via E-selectin to human umbilical vein endothelial cells (HUVECs). Kawamura N, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1208-15

Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Gupta RK, et al. **Dev Biol Stand** 1996;86:283-96

Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin). Thurman GB, et al. **J Cancer Res Clin Oncol** 1996; 122(9):549-53

Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis [see comments] Tzianabos AO, et al. **J Clin Invest** 1995 Dec; 96(6):2727-31. Comment in: J Clin Invest 1996 Dec;96(6):2545.

K1 and K3 capsular antigens of Klebsiella induce tumor necrosis factor activities. Choy YM, et al. **Life Sci** 1996; 58(9):PL153-8

[The effect of streptococcal group A polysaccharide on PHA-induced T-cell proliferation] Bazanova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):71-3 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Opsono-phagocytosis of non-encapsulated Haemophilus influenzae. Vogel L, et al. **Adv Exp Med Biol** 1995; 371A:695-8

Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316-41 (260 ref.)

A cell-surface polysaccharide that facilitates rapid population migration by differentiated swarm cells of Proteus mirabilis. Gygi D, et al. **Mol Microbiol** 1995 Sep;17(6):1167-75

THERAPEUTIC USE

Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. van der Reijden WA, et al. **Arthritis Rheum** 1996 Jan;39(1):57-63

TOXICITY

The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells. Gibson FC 3rd, et al. **Infect Immun** 1996 Mar;64(3):1065-9

POLYSOMES see **POLYRIBOSOMES**

POLYSOMNOGRAPHY

Spectral analysis in cyclic changes of human sleep evaluation. Pracka D, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):255-8

The relation of intracranial pressure B-waves to different sleep stages in patients with suspected normal pressure hydrocephalus. Krauss JK, et al. **Acta Neurochir (Wien)** 1995;136(3-4):195-203

Validation of the Newcastle Scale through sleep polysomnographic studies in major depression: comparison with age matched controls. Souery D, et al. **Acta Psychiatr Belg** 1994 Mar-Apr;94(2):110

Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society. **Am J Respir Crit Care Med** 1996 Feb;153(2):866-78

Analysis of EEG transients by means of matching pursuit. Durka PJ, et al. **Ann Biomed Eng** 1995 Sep-Oct; 23(5):608-11

Polysomnography in the evaluation of readiness for decannulation in children. Tunkel DE, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):721-4

Sleep onset abnormalities in depressed adolescents. Dahl RE, et al. **Biol Psychiatry** 1996 Mar 15;39(6):400-10

Relationship between delta activity during all-night sleep and negative symptoms in schizophrenia: a preliminary study. Kajimura N, et al. **Biol Psychiatry** 1996 Mar 15; 39(6):451-4

Electroencephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: I. Comparison during acute depressive states. Thase ME, et al. **Biol Psychiatry** 1995 Oct 15;38(8):506-15

Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea. Helfaer MA, et al. **Crit Care Med** 1996 Aug;24(8):1323-7

Relationship between the Newcastle scale and sleep polysomnographic variables in major depression: a controlled study. Hubain PP, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):129-34

Sleep in healthy elderly subjects: a 24-hour ambulatory polysomnographic study. Gigli GL, et al. **Int J Neurosci** 1996 Apr;85(3-4):263-71

Usefulness of polysomnographic studies in the differential diagnosis of insomnia. Vgontzas AN, et al. **Int J Neurosci** 1995 May;82(1-2):47-60

Sustained facial muscle activity during REM sleep and its correlation with depression. Perlis ML, et al. **J Affect Disord** 1995 Dec 18;35(4):163-71

Normal sleep architecture in infants and children. Kahn A, et al. **J Clin Neurophysiol** 1996 May;13(3):184-97 (100 ref.)

The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208-18 (50 ref.)

Obstructive sleep apnea in infants and young children. Ward SL, et al. **J Clin Neurophysiol** 1996 May;13(3):198-207 (40 ref.)

Structured psychiatric interview and ambulatory sleep monitoring in young psychophysiological insomniacs. Zucconi M, et al. **J Clin Psychiatry** 1996 Aug;57(8):364-70

Sleep bruxism: validity of clinical research diagnostic criteria in a controlled polysomnographic study. Lavigne GJ, et al. **J Dent Res** 1996 Jan;75(1):546-52

Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. Keshavan MS, et al. **J Psychiatr Res** 1995 Jul-Aug;29(4):303-14

Diagnostic testing. Sleep disorders. Mahowald MW. **Neurol Clin** 1996 Feb;14(1):183-200 (86 ref.)

Progressive cortical synchronization of ponto-geniculo-occipital potentials during rapid eye movement sleep. Amzica F, et al. **Neuroscience** 1996 May;

72(2):309–14
Slow wave sleep and computed tomographic measures of brain morphology in schizophrenia. Benson KL, et al. **Psychiatry Res** 1996 Mar 29;60(2–3):125–34
MESAM4 evaluated nocturnal respiration disturbances in myasthenia gravis. Sonka K, et al. **Sb Lek** 1996;97(1):97–102
Subjective estimates of sleep differ from polysomnographic measurements in obstructive sleep apnea patients. McCall WV, et al. **Sleep** 1995 Oct;18(8):646–50
Comparison of polysomnography with ResCare Autoset in the diagnosis of the sleep apnoea/hypopnoea syndrome. Bradley PA, et al. **Thorax** 1995 Nov;50(11):1201–3
Accuracy of an intelligent CPAP machine with in-built diagnostic abilities in detecting apnoeas: a comparison with polysomnography. Gugger M, et al. **Thorax** 1995 Nov; 50(11):1199–201
Adequacy of prescribing nasal continuous positive airway pressure therapy for the sleep apnoea/hypopnoea syndrome on the basis of night time respiratory recording variables. Montserrat JM, et al. **Thorax** 1995 Sep;50(9):969–71
Validation of British Thoracic Society guidelines for the diagnosis of the sleep apnoea/hypopnoea syndrome: can polysomnography be avoided? Ryan PJ, et al. **Thorax** 1995 Sep;50(9):972–5
Gastroesophageal reflux in patients with sleep apnea syndrome. Graf KI, et al. **Z Gastroenterol** 1995 Dec; 33(12):689–93
[Cartographic analysis of sleep spindles in thalamic lesions] Dive D, et al. **Acta Psychiatr Belg** 1994 Mar–Apr; 94(2):106–7 **(Fre)**
[Hypersomnia in multiple sclerosis] Schlüter B, et al. **Klin Padiatr** 1996 May–Jun;208(3):103–5 (Eng. Abstr.) **(Ger)**
[Patients of an ambulatory sleep center—critical variables of insomniacs] Hoffmann RM, et al. **Wien Med Wochenschr** 1995;145(17–18):478–80 (Eng. Abstr.) **(Ger)**
[Polysomnographic structure of subjective "awake" and "asleep" nocturnal segments] Kraemer S, et al. **Wien Med Wochenschr** 1995;145(17–18):481–2 (Eng. Abstr.) **(Ger)**
[Temporal correlations between nocturnal spontaneous erections and sleep stages] Vesely B, et al. **Wien Med Wochenschr** 1995;145(17–18):495–6 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Luthringer R, et al. **Biol Psychiatry** 1995 Jul 15;38(2):98–104
Polygraphic sleep measures differentiate alcoholics and stimulant abusers during short-term abstinence. Thompson PM, et al. **Biol Psychiatry** 1995 Dec 15;38(12):831–6
Repeated penicillin-induced amygdala epileptic focus in freely moving cats. EEG, polysomnographic (23-h recording), and brain mapping study. Fernández-Guardiola A, et al. **Epilepsy Res** 1995 Oct;22(2):127–36
Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. Van Bemmel AL, et al. **J Affect Disord** 1995 Oct 9;35(1–2):11–9

INSTRUMENTATION

Quantitative topographic electroencephalographic mapping during drowsiness and sleep onset. Broughton R, et al. **J Clin Neurophysiol** 1995 Jul;12(4):372–86
Automatic Oxford-Medilog 9200 sleep staging scoring: comparison with visual analysis. Sforza E, et al. **J Clin Neurophysiol** 1996 May;13(3):227–33
Automated scoring of sleep in the neonatal lamb. Grant DA, et al. **Sleep** 1995 Jul;18(6):439–45
[Rest-activity cycle in man] Wallner F. **Biomed Tech (Berl)** 1996 May;41(5):132–7 (Eng. Abstr.) **(Ger)**
[Detection of rapid eye movement with rapidly adapting neuronal fuzzy systems in imprecise REM syntax] Wallner F. **Biomed Tech (Berl)** 1996 Apr;41(4):84–90 (Eng. Abstr.) **(Ger)**
[Validation of the Sleep-Doc-Porti system for ambulatory sleep apnea diagnosis] Teschler H, et al. **Pneumologie** 1995 Sep;49(9):496–501 (Eng. Abstr.) **(Ger)**
[Spectral analysis of arterial oxygen saturation and RR intervals in patients with obstructive sleep apnea] Keyl C, et al. **Wien Med Wochenschr** 1995;145(17–18):515–6 (Eng. Abstr.) **(Ger)**
[Approximation of sleep duration and sleep efficiency using actography] Wallner F, et al. **Wien Med Wochenschr** 1995; 145(17–18):497–8 (Eng. Abstr.) **(Ger)**

METHODS

Can sleep and wakefulness be distinguished in children by cardiorespiratory and videotape recordings? Morielli A, et al. **Chest** 1996 Mar;109(3):680–7
Sleep deprivation worsens obstructive sleep apnea. Comparison between diurnal and nocturnal polysomnography. Persson HE, et al. **Chest** 1996 Mar; 109(3):645–50
Methodological issues in coding sleep states in immature infants. Sahni R, et al. **Dev Psychobiol** 1995 Mar; 28(2):85–101

POLYSORBATE 20 see **POLYSORBATES**

POLYSORBATE 80 see **POLYSORBATES**

POLYSORBATES

Tween 80-solubilized Newcastle disease virus prepared as a water-in-oil-in-water vaccine. Cajavec S, et al. **Avian Dis** 1996 Jan–Mar;40(1):193–201

ADMINISTRATION & DOSAGE

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):683–93

CHEMICAL SYNTHESIS

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Ott G, et al. **Pharm Biotechnol** 1995; 6:277–96 (36 ref.)

PHARMACOLOGY

In vivo modulators of antibody kinetics. Jekunen A, et al. **Acta Oncol** 1996;35(3):267–71
Cardiovascular effects of the microsphere suspending agent, Tween 80, in pigs. Grund F, et al. **Acta Physiol Scand** 1995 Nov;155(3):331–2
Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Ellis AG, et al. **Cancer Chemother Pharmacol** 1996;38(1):81–7
Effects of polysorbates and Cremophor EL on vascular responses in rat aorta. Zengil H, et al. **Experientia** 1995 Nov 15;51(11):1055–9
Effects of Tween 20 on the desorption of proteins from polymer surfaces. Feng M, et al. **J Biomater Sci Polym Ed** 1995;7(5):415–24
Tween 20 selectively enhances naturally occurring anticardiolipin antibody binding in ELISA procedures [letter; comment] Cheng HM. **J Immunol Methods** 1996 May 10;191(1):87–91. Comment on: J Immunol Methods 1994 Sep 30;175(1):107–14.

POLYSTYRENES

Preparation and characterization of high-surface-area polymer substrates for microcalorimetry. Lee VA, et al. **J Biomed Mater Res** 1996 May;31(1):51–62
Polystyrene as an affinity chromatography matrix for the purification of antibodies. Staak C, et al. **J Immunol Methods** 1996 Aug 14;194(2):141–6
Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene. San Millan R, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2271–7

ADMINISTRATION & DOSAGE

Rectally administered sodium polystyrene sulfonate. Gales MA, et al. **Am J Health Syst Pharm** 1995 Dec 15; 52(24):2813–5
[A successful treatment using SMANCS-TAE for hepatocellular carcinoma with tumor thrombus in the portal trunk] Fukushima M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1073–6 (Eng. Abstr.) **(Jpn)**
[Two cases of long-term survival with hepatocellular carcinoma following targeting therapy with SMANCS/lipiodol] Inoue Y, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):99–101 (Eng. Abstr.) **(Jpn)**
[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer] Takiya S, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1205–8 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr; 13(3):167–70 (12 ref.)
Polystyrene microspheres decrease bronchial artery resistance in anesthetized sheep. Pearse DB, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1037–43
Intestinal obstruction complicating calcium polystyrene sulphonate therapy [letter] García-Pardo G, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):751

ANALYSIS

A model for estimating the daily dietary intake of a substance from food-contact articles: styrene from polystyrene food-contact polymers. Lickly TD, et al. **Regul Toxicol Pharmacol** 1995 Jun;21(3):406–17

CHEMISTRY

Amination of polystyrene microwells: application to the covalent grafting of DNA probes for hybridization assays. Zammatteo N, et al. **Anal Biochem** 1996 Apr 5;236(1):85–94
Feasibility of electrophoresis of a subcellular-sized particle in polymer solutions, using automated horizontal gel apparatus. Chang HT, et al. **Appl Theor Electrophor** 1995; 5(2):73–7
Effect of pretreatment of wells in polystyrene plates on adsorption of some human serum proteins. Kochanowska IE, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):135–9
Adhesion and proliferation of cultured human aortic smooth muscle cells on polystyrene implanted with N+, F+ and Ar+ ions: correlation with polymer surface polarity and carbonization. Bačáková L, et al. **Biomaterials** 1996 Jun; 17(11):1121–6
Biospecific interactions of Vitamin K-dependent factors with phospholipid-like polystyrene derivatives. Part I: Factor II. Migonney V, et al. **Biomaterials** 1996 Apr;17(8):823–9
Mapping of endogenous lectins in macrophages colonizing an implanted polymer surface—effect of polymer structure. Smetana K Jr, et al. **Biomaterials** 1995 Oct;16(15):1149–52
Molecular diversity of peptidomimetics: approaches to the solid-phase synthesis of peptidosulfonamides. de Bont DB, et al. **Bioorg Med Chem** 1996 May;4(5):667–72
Passive adsorption of immunologically active and inactive synthetic peptides to polystyrene is influenced by the proportion of non-polar residues in the peptide. Sällberg M, et al. **Immunol Lett** 1995 May;46(1–2):25–30
Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties. Ayhan H, et al. **J Biomater Sci Polym Ed** 1995;7(4):329–42
Structural effect of galactose residue in synthetic glycoconjugates on interaction with rat hepatocytes. Yura H, et al. **J Biomed Mater Res** 1995 Dec;29(12):1557–65
[Sorption properties of Polish sorbents of the 2nd generation in relation to phenobarbital] Jurkowski P, et al. **Polim Med** 1995;25(3–4):47–50 (Eng. Abstr.) **(Pol)**

METABOLISM

Adsorption of fibronectin and vitronectin onto Primaria and tissue culture polystyrene and relationship to the mechanism of initial attachment of human vein endothelial cells and BHK-21 fibroblasts. Steele JG, et al. **Biomaterials** 1995 Sep;16(14):1057–67
Binding of beta 2 glycoprotein I to activated polystyrene and its recognition by human IgG autoantibodies. Keil LB, et al. **Biotechnol Appl Biochem** 1995 Dec;22 (Pt 3):305–13
Coadsorption of IgG and BSA onto sulfonated polystyrene latex: I. Sequential and competitive coadsorption isotherms. Peula JM, et al. **J Biomater Sci Polym Ed** 1995;7(3):231–40
Coadsorption of IgG and BSA onto sulfonated polystyrene latex: II. Colloidal stability and immunoreactivity. Peula JM, et al. **J Biomater Sci Polym Ed** 1995;7(3):241–51

PHARMACOKINETICS

Translocation of particulates across the gut wall—a quantitative approach. Simon L, et al. **J Drug Target** 1995; 3(3):217–9
The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat. Eyles J, et al. **J Pharm Pharmacol** 1995 Jul;47(7):561–5
Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. Simon BH, et al. **J Pharm Sci** 1995 Oct;84(10):1249–53

PHARMACOLOGY

In vitro binding of lithium using the cation exchange resin sodium polystyrene sulfonate [letter; comment] Linakis JG, et al. **Am J Emerg Med** 1995 Nov;13(6):669–70. Comment on: Am J Emerg Med 1995 May;13(3):294–6.
Superoxide dismutase derivative reduces oxidative damage in skeletal muscle of rats during exhaustive exercise. Radák Z, et al. **J Appl Physiol** 1995 Jul;79(1):129–35
Pathophysiological effect of hepatic ischemia and reperfusion after hepatectomy in dogs with obstructive jaundice, focusing on the effect of coenzyme Q10 and styrene-co-maleic acid superoxide dismutase. Ogura Y, et al. **J Gastroenterol** 1996 Jun;31(3):379–86
Inhibition of puromycin-induced renal injury by a superoxide dismutase derivative with prolonged in vivo half-life. Nishimura Y, et al. **Nephron** 1995;70(4):460–5
Antitumor activity of zinostatin stimalamer (YM881) in human hepatoma cell lines and VX2 liver tumor-bearing rabbits. Tanaka S, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):155–63
Antitumor mechanisms of zinostatin stimalamer (YM881). Tanaka S, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):165–76

THERAPEUTIC USE

Effect of delayed treatment with sodium polystyrene sulfonate on serum lithium concentrations in mice. Linakis JG, et al. **Acad Emerg Med** 1995 Aug;2(8):681–5
In-vivo binding of lithium using the cation exchange resin sodium polystyrene sulfonate. Gehrke JC, et al. **Am J Emerg Med** 1996 Jan;14(1):37–8
Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer. Masuda E, et al. **Cancer Res** 1996 Apr 15;56(8):1868–73

POLYTEF see **POLYTETRAFLUOROETHYLENE**

POLYTETRAFLUOROETHYLENE

Gore-Tex for nasal augmentation: a recent series and a review of the literature. Queen TA, et al. **Ann Otol Rhinol Laryngol** 1995 Nov;104(11):850–2

Limb salvage with microvascular free flap reconstruction using simultaneous polytetrafluoroethylene graft for inflow. Kasabian AK, et al. **Ann Plast Surg** 1995 Sep;35(3):310–5

A simple method of achieving rapid haemostasis in PTFE grafts after on-table angiography. Whyman MR, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):388–9

Pathologic aspects of polytetrafluoroethylene sutures in human heart. Minatoya K, et al. **Ann Thorac Surg** 1996 Mar;61(3):883–7

Femoropopliteal bypass for claudication: vein vs. PTFE. Allen BT, et al. **Ann Vasc Surg** 1996 Mar;10(2):178–85

Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins. Chen C, et al. **Ann Vasc Surg** 1996 Mar;10(2):147–55

Clinical and CT evaluation of a new stretch polytetrafluoroethylene aortic graft. Erdoes LS, et al. **Ann Vasc Surg** 1995 Sep;9(5):441–7

Wide polytef (Gore-Tex) implants in lip augmentation and nasolabial groove correction. Conrad K, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):664–70

The use of expanded polytetrafluoroethylene (Gore-Tex) in rhinoplasty. A 6-year experience. Godin MS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1131–6 (20 ref.)

Expanded polytef for reconstructing postparotidectomy defects and preventing Frey's syndrome. Shemen LJ. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1307–9

Healing characteristics of hybrid and conventional polytetrafluoroethylene vascular grafts. Martakos P, et al. **ASAIO J** 1995 Jul-Sep;41(3):M735–41

A Corethane/polyester composite vascular prosthesis for vascular access. Comparison with expanded polytetrafluoroethylene grafts in a canine model. Wilson GJ, et al. **ASAIO J** 1995 Jul-Sep;41(3):M728–34

Effects of different osteopromotive membrane porosities on experimental bone neogenesis in rats. Zellin G, et al. **Biomaterials** 1996 Apr;17(7):695–702

Procel burn cover used as a total body dressing in burns. Trop M, et al. **Burns** 1995 Nov;21(7):544–5

Suitability of incorporated vascular stents for surgical patch-plasty: an experimental study. Schürmann K, et al. **Cardiovasc Intervent Radiol** 1995 Jul-Aug;18(4):233–8

Percutaneous endoluminal stent-graft repair of an old traumatic femoral arteriovenous fistula. Uflacker R, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr;19(2):120–2

Thrombus formation on polytetrafluoroethylene surfaces: the importance of von Willebrand factor. Cho JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):645–51

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132–6 (37 ref.)

Guided bone regeneration in calvarial bone defects using polytetrafluoroethylene membranes. Bosch C, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):311–7

An analysis of vocal cord paralysis before and after Teflon injection using combined glottography. Livesey JR, et al. **Clin Otolaryngol** 1995 Oct;20(5):423–7

The current status of expanded polytetrafluoroethylene (Gore-Tex) in facial plastic surgery. Levine B, et al. **Ear Nose Throat J** 1995 Oct;74(10):681–2, 684 (17 ref.)

Factors affecting the lifespan of autologous and synthetic arteriovenous access routes for haemodialysis. Lazarides MK, et al. **Eur J Surg** 1996 Apr;162(4):297–301

The degree of porosity influences the release of growth factors by healing polytetrafluoroethylene (PTFE) grafts. Lepidi S, et al. **Eur J Vasc Endovasc Surg** 1996 Jan; 11(1):36–41

The aortic polytetrafluoroethylene graft: further experience. Mohan CR, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):158–63

Collagen synthesized in fluorocarbon polymer implant in the rabbit cornea. Drubaix I, et al. **Exp Eye Res** 1996 Apr; 62(4):367–76

Use of a fibroblastic matrix improves the results of mesothelial-cell seeding on vascular prostheses of polytetrafluoroethylene. Buján J, et al. **Histol Histopathol** 1995 Oct;10(4):803–10

Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study. Simoni G, et al. **Int Angiol** 1996 Mar;15(1):50–6

Experience with e-PTFE membrane application to bone grafting of cleft maxilla. Piette E, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):327–32

Comparison of a new type of polytetrafluoroethylene patch (Mycro Mesh) and polypropylene prosthesis (Marlex) for repair of abdominal wall defects. Bellón JM, et al. **J Am Coll Surg** 1996 Jul;183(1):11–8

A method to trim multilayered polytetrafluoroethylene grafts. Gelbfish GA, et al. **J Am Coll Surg** 1996 Jun; 182(6):552–4

Effect of external reinforcement on the patency of infrainguinal polytetrafluoroethylene arterial grafts. Sullivan TM, et al. **J Am Coll Surg** 1996 Mar;182(3):211–4

Similarity in behavior of polytetrafluoroethylene (ePTFE) prostheses implanted into different interfaces. Bellón JM, et al. **J Biomed Mater Res** 1996 May;31(1):1–9

Assessments of thrombogenicity by three in vitro techniques. Student Research Award in the Undergraduate, Master Candidate, or Health Science Degree Candidate Category, 21st annual meeting of the Society for Biomaterials, San Francisco, CA, March 18–22, 1995. Skarada DJ, et al. **J Biomed Mater Res** 1995 Sep;29(9):1039–45

Peroneal arteriovenous fistula as a complication of above-knee femoropopliteal polytetrafluoroethylene graft thrombectomy with the Fogarty catheter. Aćin F, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):113–5

Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. Tsai KT, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):149–52

Periodontal pathogens on polytetrafluoroethylene membrane for guided tissue regeneration inhibit healing. Nowzari H, et al. **J Clin Periodontol** 1995 Jun;22(6):469–74

Cine MRI in the evaluation of the Proplast-Teflon TMJ interpositional implant. Dorsay TA, et al. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):800–3

Use of synthetic material in sling surgery: a minimally invasive approach. Norris JP, et al. **J Endourol** 1996 Jun; 10(3):227–30

Cellular activity in e-PTFE reconstructed pulleys and adjacent regions of deep flexor tendons. An experimental biochemical study in rabbits. Hanff G, et al. **J Hand Surg [Br]** 1996 Jun;21(3):419–23

Accelerated healing of cardiovascular textiles promoted by an RGD peptide. Tweden KS, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S90–7

Enhanced neointima formation and attachment on the high-porosity inner surface of modified PTFE vascular grafts. Nagae T, et al. **J Invest Surg** 1995 Jul-Aug; 8(4):235–42

Clinical and microbiological observations of early polytetrafluoroethylene membrane exposure in guided bone regeneration. Case reports in primates. Fritz ME, et al. **J Periodontol** 1996 Mar;67(3):245–9

A Comparative study of ePTFE periodontal membranes with and without decalcified freeze-dried bone allografts for the regeneration of interproximal intraosseous defects. Mellado JR, et al. **J Periodontol** 1995 Sep;66(9):751–5

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511–21 (37 ref.)

Scanning electron microscopy evaluation of endothelial regeneration in 1-mm PTFE prostheses. Lanzetta M, et al. **J Reconstr Microsurg** 1996 Jan;12(1):47–53

Effect of endoluminal PTFE graft placement on cell proliferation, PDGF secretion, and intimal hyperplasia. Ombrellaro MP, et al. **J Surg Res** 1996 Jun;63(1):110–4

Long-term followup of patients with tumor thrombi from renal cell carcinoma and total replacement of the inferior vena cava using an expanded polytetrafluoroethylene tubular graft. Okada Y, et al. **J Urol** 1996 Feb;155(2):444–6; discussion 447

Complementary distal arteriovenous fistula and deep vein interposition: a five-year experience with a new technique to improve infrapopliteal prosthetic bypass patency. Ascer E, et al. **J Vasc Surg** 1996 Jul;24(1):134–43

Cultured human endothelial cells seeded on expanded polytetrafluoroethylene support thrombin-mediated activation of protein C. Gillis-Haegerstrand C, et al. **J Vasc Surg** 1996 Aug;24(2):226–34

Effects of retroviral-mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene. Huber TS, et al. **J Vasc Surg** 1995 Dec;22(6):795–803

Arteries from human beings are less infectible by Staphylococcus aureus than polytetrafluoroethylene in an aortic dog model. Koskas F, et al. **J Vasc Surg** 1996 Mar; 23(3):472–6

Acute platelet deposition after carotid endarterectomy in sheep: vein patch compared with gelatin-sealed Dacron and polytetrafluoroethylene patch closure. Margovsky AI, et al. **J Vasc Surg** 1996 Aug;24(2):200–6

Polytetrafluoroethylene bypasses to infrapopliteal arteries without cuffs or patches: a better option than amputation in patients without autologous vein. Parsons RE, et al. **J Vasc Surg** 1996 Feb;23(2):347–54; discussion 355–6

Expanded polytetrafluoroethylene patch angioplasty in carotid endarterectomy. Rhodes VJ. **J Vasc Surg** 1995 Dec; 22(6):724–30; discussion 730–1

The merit of polytetrafluoroethylene extensions and interposition grafts to salvage failing infrainguinal vein bypasses. Sanchez LA, et al. **J Vasc Surg** 1996 Feb; 23(2):329–35

Growth factor production after polytetrafluoroethylene and vein arterial grafting: an experimental study. Sterpetti AV, et al. **J Vasc Surg** 1996 Mar;23(3):452–60

A randomized prospective clinical trial of the Taylor patch [letter] Wright JG. **J Vasc Surg** 1996 Feb;23(2):376–7

Gore-Tex implants for the correction of thin lips. Ellis DA, et al. **Laryngoscope** 1995 Feb;105(2):207–9

Magnetic resonance angiography of dialysis access shunts: initial results. Waldman GJ, et al. **Magn Reson Imaging** 1996;14(2):197–200

Neo-endothelialisation of PTFE microvascular grafts: a five-year experience. Lanzetta M, et al. **Microsurgery** 1995; 16(6):404–11 (35 ref.)

Clinical use of microvascular PTFE grafts. Lanzetta M. **Microsurgery** 1995;16(6):412–5

Postoperative catheterization, urinary retention, and permanent voiding dysfunction after polytetrafluoroethylene suburethral sling placement. Weinberger MW, et al. **Obstet Gynecol** 1996 Jan;87(1):50–4

Blowout fractures of the orbit [letter; comment] Hardin JC Jr. **Plast Reconstr Surg** 1996 May;97(6):1302. Comment on: Plast Reconstr Surg 1994 Apr;93(4):856–9.

Use of Gore-Tex [letter; comment] Lassus C. **Plast Reconstr Surg** 1996 Feb;97(2):491–2. Comment on: Plast Reconstr Surg 1995 Jun;95(7):1334.

ePTFE (Gore-Tex) facial augmentation [letter] Maas CS. **Plast Reconstr Surg** 1996 Apr;97(5):1076–7

The 3M precise microvascular anastomotic system for implanting PTFE microvenous prostheses into the rat femoral vein. Oguchi H, et al. **Plast Reconstr Surg** 1996 Mar;97(3):662–5

Gore-Tex patch repair of the anterior rectus sheath in free rectus abdominis muscle and myocutaneous flaps. Pennington DG, et al. **Plast Reconstr Surg** 1996 Jun; 97(7):1436–40; discussion 1441–2

The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis. Akimoto F. **Surg Today** 1995;25(12):1027–33

Laparoscopic repair of an abdominal hernia using an expanded polytetrafluoroethylene patch secured by a four-corner tacking technique. Tagaya N, et al. **Surg Today** 1995;25(10):930–1

Microwave digestion using dual PTFE containers for analysis of trace elements in small amounts of biological samples. Mizushima R, et al. **Tohoku J Exp Med** 1996 Jan; 178(1):75–9

Follow-up results of synthetic vascular grafts in children undergoing hemodialysis. Nayir A, et al. **Turk J Pediatr** 1995 Jul-Sep;37(3):223–8

Gore-Tex in bolstering closure of renal parenchyma defects [letter] Melekos MD. **Urology** 1995 Dec;46(6):901

Neointimized Gore-Tex graft for ureteral prosthesis in the dog. Peters JJ, et al. **Urology** 1996 Sep;48(3):379–82

Long-segment ureteral replacement with expanded polytetrafluoroethylene grafts. Sabanegh ES Jr, et al. **Urology** 1996 Aug;48(2):312–6

[Establishment of arteriovenous anastomoses with interposition of ePTFE (Goretex) prostheses] Bachleda P, et al. **Rozhl Chir** 1996 Jan;75(1):26–30 (Eng. Abstr.) **(Cze)**

[Surgical therapy of malignant thoracic wall tumors] Gellert K, et al. **Chirurg** 1995 Dec;66(12):1220–3; discussion 1224 (Eng. Abstr.) **(Ger)**

[Palliative treatment of tetralogy of Fallot using a PTFE (polytetrafluoroethylene) vascular graft] Weber UT, et al. **Schweiz Arch Tierheilkd** 1995;137(10):480–4 (Eng. Abstr.) **(Ger)**

[Acute rupture of an aneurysm of the popliteal artery: case report] Manouguian S. **Zentralbl Chir** 1996;121(5):405–7 (Eng. Abstr.) **(Ger)**

[Healing process of high porous EPTFE graft wrapped in the omental pedicle flap—experimental study of portal vein replacement] Tanaka E. **Hokkaido Igaku Zasshi** 1995 Sep; 70(5):697–715 (Eng. Abstr.) **(Jpn)**

[Pulmonary artery banding using expanded polytetrafluoroethylene suture] Yamamoto S, et al. **Kyobu Geka** 1996 Apr;49(4):285–7 (Eng. Abstr.) **(Jpn)**

[Use of tarflen ventilation tubes in treatment of secretory otitis media in children] Namysłowski G, et al. **Pediatr Pol** 1995 Aug;70(8):657–60 (Eng. Abstr.) **(Pol)**

[Arterial revascularization of liver graft with PTFE vascular prosthesis] Calleja Kempin J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):828–9 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Correlation of the endoscopic appearance with clinical outcome for submucous Polytef paste injection in vesico-ureteric reflux. Dewan PA, et al. **Aust N Z J Surg** 1995 Sep;65(9):642–4

Correlation of the endoscopic appearance with clinical outcome for submucous Polytef paste injection in vesico-ureteric reflux [letter] Hughes PD. **Aust N Z J Surg** 1996 Feb;66(2):120

How we do it: use of a venous cannulation needle for endoscopic Teflon injection to the vocal folds. Strachan D, et al. **J Laryngol Otol** 1995 Dec;109(12):1184–5

Endoscopic correction of vesicoureteral reflux secondary to posterior urethral valves. Puri P, et al. **J Urol** 1996 Aug; 156(2 Pt 2):680–2

Intraesophageal Polytef injection for the treatment of reflux esophagitis. Shafik A. **Surg Endosc** 1996 Mar;10(3):329–31

Does technique or material used affect bladder tissue reactions when injecting teflon or silicone paste? Smith DP, et al. **Urology** 1996 Jul;48(1):119–23

[Implantation microsurgery in the phoniatric practice] Vasilenko IuS, et al. **Vestn Otorinolaringol** 1995 Sep-Oct; (5):13–6 (Eng. Abstr.) **(Rus)**

[Our experience in endoscopic teflon treatment in vesicoureteral reflux in children] Angulo JM, et al. **Cir Pediatr** 1995 Oct;8(4):161–3 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Teflon granuloma presenting as an enlarging, gadolinium

enhancing, posterior fossa mass with progressive hearing loss following microvascular decompression. Megerian CA, et al. **Am J Otol** 1995 Nov;16(6):783–6

Skin migration following periurethral polytetrafluorethylene injection for urinary incontinence. Dewan PA, et al. **Aust N Z J Surg** 1996 Jan;66(1):57–9

Ultrafine particles as a potential environmental health hazard. Studies with model particles. Oberdörster G, et al. **Chest** 1996 Mar;109(3 Suppl):68S–69S

Brain injury in a healthy child one year after periureteral injection of Teflon. Borgatti R, et al. **Pediatrics** 1996 Aug; 98(2 Pt 1):290–1

Gore-Tex nasal augmentation [letter; comment] Taylor CO, et al. **Plast Reconstr Surg** 1996 Jan;97(1):252. Comment on: Plast Reconstr Surg 1994 Aug;94(2):241–8; discussion 249–50. Comment on: Plast Reconstr Surg 1995 Apr;95(5):932–3.

[Spontaneous and recent thrombosis of tetrafluoroethylene vascular prostheses secondary to progression of atherosclerosis of the lower limbs. 2 cases (letter)] Desoutter P, et al. **Presse Med** 1996 Apr 6;25(12):600–1 **(Fre)**

ANALOGS & DERIVATIVES

Neuronal cell attachment to fluorinated ethylene propylene films with covalently immobilized laminin oligopeptides YIGSR and IKVAV. II. Ranieri JP, et al. **J Biomed Mater Res** 1995 Jun;29(6):779–85

Synthesis and characterization of fluoropolymeric substrata with immobilized minimal peptide sequences for cell adhesion studies. I. Vargo TG, et al. **J Biomed Mater Res** 1995 Jun;29(6):767–78

CHEMISTRY

Negative Poisson ratios and strain-dependent mechanical properties in arterial prostheses. Caddock BD, et al. **Biomaterials** 1995 Sep;16(14):1109–15

Healing of mandibular defects with different biodegradable and non-biodegradable membranes: an experimental study in rats. Zellin G, et al. **Biomaterials** 1995 May;16(8):601–9

METABOLISM

Long-term follow-up of 6–8 mm brachioaxillary polytetrafluorethylene grafts for hemodialysis. Polo JR, et al. **Artif Organs** 1995 Nov;19(11):1181–4

An immunohistochemical analysis of implanted woven Dacron and expanded polytetrafluoroethylene grafts in humans. Urayama H, et al. **Artif Organs** 1996 Jan;20(1):24–9

Evaluation of guided bone regeneration in rabbit tibia using bioresorbable and non-resorbable membranes. Piattelli A, et al. **Biomaterials** 1996 Apr;17(8):791–6

PHARMACOKINETICS

Retention of particles inhaled in boli with and without induced bronchoconstriction. Scheuch G, et al. **Exp Lung Res** 1995 Nov-Dec;21(6):901–16

PHARMACOLOGY

Metabolic response of blood cells to synthetic graft-materials with special reference to a Fluoromer Passivated Dacron graft. An in vitro study using microcalorimetry. Swartbol P, et al. **Int J Artif Organs** 1995 Jul;18(7):372–9

Protein interactions with particulate Teflon: implications for the foreign body response. Zardeneta G, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):873–8

The biologic role of B2 integrins in the host response to expanded polytetrafluoroethylene. Benton LD, et al. **J Surg Res** 1996 Aug;64(2):116–9

ePTFE coating with fibrin glue, FGF-1, and heparin: effect on retention of seeded endothelial cells. Gosselin C, et al. **J Surg Res** 1996 Feb 1;60(2):327–32

POISONING

[Generalized osteopathy with pathological fractures in a patient with long-term exposure to fluorine-containing plastics] Rhomberg W, et al. **Schweiz Med Wochenschr** 1995 Dec 2;125(48):2330–7 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Efficacy of STING in the treatment of vesico-ureteric reflux in neuropathic bladder. Misra D. **Br J Urol** 1996 Feb; 77(2):328–9

Expanded polytetrafluoroethylene surgical membrane in ovarian surgery on the rabbit. Biocompatibility, adhesion prevention properties and ability to preserve reproductive capacity. Magro B, et al. **J Reprod Med** 1996 Feb;41(2):73–8

Massive bleeding at resternotomy despite a polytetrafluoroethylene surgical membrane [letter; comment] Stark J. **J Thorac Cardiovasc Surg** 1996 Apr; 111(4):903–4. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):274–5.

Expanded polytetrafluoroethylene augmentation of the lower face. Sherris DA, et al. **Laryngoscope** 1996 May;106(5 Pt 1):658–63

Pericardial substitute and emergency resternotomy: life-saving combination. Bacaner TJ, et al. **Pediatr Cardiol** 1996 Nov-Dec;17(6):396–8

Pseudointimal hyperplasia of ridged outer wall polytetrafluoroethylene vascular prostheses. Shibuya T, et al. **Surg Today** 1996;26(5):333–9

POLYTHYMIDYLIC ACIDS see POLY T

POLYURETHANES

Treatment of esophageal fistulas with a new polyurethane-covered, self-expanding mesh stent: a prospective study. Bethge N, et al. **Am J Gastroenterol** 1995 Dec;90(12):2143–6

Split-thickness skin graft donor site management. A randomized prospective trial comparing a hydrophilic polyurethane absorbent foam dressing with a petrolatum gauze dressing. Weber RS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1145–9

In vitro studies of immobilized heparin and sulfonated polyurethane using epifluorescent video microscopy. Nojiri C, et al. **ASAIO J** 1995 Jul-Sep;41(3):M389–94

A Corethane/polyester composite vascular prosthesis for vascular access. Comparison with expanded polytetrafluoroethylene grafts in a canine model. Wilson GJ, et al. **ASAIO J** 1995 Jul-Sep;41(3):M728–34

Experimental study of bioactive polyurethane sponge as an artificial trachea. Yanagi M, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M412–8

Role of leucocytes in coagulation induced by artificial surfaces: investigation of expression of Mac-1, granulocyte elastase release and leucocyte adhesion on modified polyurethanes. Sundaram S, et al. **Biomaterials** 1996 May; 17(10):1041–7

Development of a model for assessment of biomaterial encrustation in the upper urinary tract. Tunney MM, et al. **Biomaterials** 1996 May;17(10):1025–9

The male polyurethane condom: a review of current knowledge. Rosenberg MJ, et al. **Contraception** 1996 Mar; 53(3):141–6 (18 ref.)

The new female and male polyurethane condoms [news] Fisher AA. **Cutis** 1995 Aug;56(2):82

Resistance to bacterial aggression involving exposed nonresorbable membranes in the oral cavity. Leghissa GC, et al. **Int J Oral Maxillofac Implants** 1996 Mar-Apr; 11(2):210–5

Development of silastic polyurethane (Angioflex) materials with antibacterial agent. Rathinam K, et al. **J Biomater Appl** 1996 Jan;10(3):210–6

Novel compliant and tissue-permeable microporous polyurethane vascular prosthesis fabricated using an excimer laser ablation technique. Doi K, et al. **J Biomed Mater Res** 1996 May;31(1):27–33

Role for interleukin-4 in foreign-body giant cell formation on a poly(etherurethane urea) in vivo. Kao WJ, et al. **J Biomed Mater Res** 1995 Oct;29(10):1267–75

Contact activation during incubation of five different polyurethanes or glass in plasma. van der Kamp KW, et al. **J Biomed Mater Res** 1995 Oct;29(10):1303–6

Polymeric surface modifications of tantalum stents. Fontaine AB, et al. **J Endovasc Surg** 1996 Aug;3(3):276–83

First clinical application of the Medos-HIA ventricular support system: monitoring of the thrombotic risk by means of the biomarker prothrombin fragment F1 + 2 and scanning electron microscopy evaluation. Guldner NW, et al. **J Heart Lung Transplant** 1996 Mar;15(3):291–6

Evaluation of an aliphatic polyurethane as a microsphere matrix for sustained theophylline delivery. Subhaga CS, et al. **J Microencapsul** 1995 Nov-Dec;12(6):617–25

Biodegradation of polyurethane foam, revisited, in the rat model. Sinclair TM, et al. **Plast Reconstr Surg** 1995 Nov; 96(6):1326–35

Determination of the curvatures and bending strains in open trileaflet heart valves. Corden J, et al. **Proc Inst Mech Eng [H]** 1995;209(2):121–8

[Small-caliber polyurethane arterial prosthesis: clinical and angiomorphological follow-up of 20 patients in a prospective study] Gloor B, et al. **Swiss Surg Suppl** 1996; Suppl 1:13–8 (Eng. Abstr.) **(Fre)**

[Tissue reaction to implanted polyurethane designed for parts of the artificial heart] Staniszewska-Kuś J, et al. **Polim Med** 1995;25(3–4):3–18 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Biomarkers of exposure, antibodies, and respiratory symptoms in workers heating polyurethane glue. Skarping G, et al. **Occup Environ Med** 1996 Mar;53(3):180–7

[Extrinsic allergic alveolitis caused by isocyanates (letter)] Pedrouzo Bardelas J, et al. **Med Clin (Barc)** 1996 May 18; 106(19):756–7 **(Spa)**

CHEMICAL SYNTHESIS

Preparation and surface characterization of functional group-grafted and heparin-immobilized polyurethanes by plasma glow discharge. Kang IK, et al. **Biomaterials** 1996 Apr;17(8):841–7

CHEMISTRY

Negative Poisson ratios and strain-dependent mechanical properties in arterial prostheses. Caddock BD, et al. **Biomaterials** 1995 Sep;16(14):1109–15

Physical and biological effects of a surface coating procedure on polyurethane catheters. Francois P, et al. **Biomaterials** 1996 Apr;17(7):667–78

Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties. Ishihara K, et al. **Biomaterials** 1995 Jul; 16(11):873–9

The relative safety of gamma-ray, autoclave, and ethylene oxide gas sterilization of thermosetting polyurethane. Shintani H. **Biomed Instrum Technol** 1995 Nov-Dec; 29(6):513–9

Contact allergy to allyl glycidyl ether present as an impurity in 3-glycidyloxypropyltrimethoxysilane, a fixing additive in silicone and polyurethane resins. Dooms-Goossens A, et al. **Contact Dermatitis** 1995 Jul;33(1):17–9

Formation and elution of toxic compounds from sterilized medical products: methylenedianiline formation in polyurethane. Shintani H. **J Biomater Appl** 1995 Jul; 10(1):23–58

FT-IR spectroscopic studies of polyurethanes: IV. Studies of the effect of the presence of processing aids on the hemocompatibility of polyurethanes. Bandekar J, et al. **J Biomater Sci Polym Ed** 1995;7(6):485–501

Effects of Tween 20 on the desorption of proteins from polymer surfaces. Feng M, et al. **J Biomater Sci Polym Ed** 1995;7(5):415–24

Comparison of transverse strength and dimensional variations between die stone, die epoxy resin, and die polyurethane resin. Derrien G, et al. **J Prosthet Dent** 1995 Dec; 74(6):569–74

ISOLATION & PURIFICATION

Effect of toluene extraction on Biomer surface: II. An atomic force microscopy study. Nurdin N, et al. **J Biomater Sci Polym Ed** 1995;7(5):425–38

METABOLISM

Fabrication and characterization of dipalmitoylphosphatidylcholine-attracting elastomeric material for joint replacements. Williams PF 3rd, et al. **Biomaterials** 1995 Oct;16(15):1169–74

Degradation of polyetherurethane by subcutaneous implantation into rats. II. Changes of contact angles, infrared spectra, and nuclear magnetic resonance spectra. Sato M, et al. **J Biomed Mater Res** 1995 Oct;29(10):1201–13

STANDARDS

Use of porous polyurethanes for meniscal reconstruction and meniscal prostheses. de Groot JH, et al. **Biomaterials** 1996 Jan;17(2):163–73

Determination of lubricating film thickness for permeable hydrogel and non-permeable polyurethane layers bonded to a rigid substrate with particular reference to cushion form hip joint replacements. McClure G, et al. **Proc Inst Mech Eng [H]** 1996;210(2):89–93

TOXICITY

Effect of biomaterial surface charge on the inflammatory response: evaluation of cellular infiltration and TNF alpha production. Hunt JA, et al. **J Biomed Mater Res** 1996 May; 31(1):139–44

Studies on the tumor-promoting activity of polyurethanes: depletion of inhibitory action of metabolic cooperation on the surface of a polyalkyleneurethane but not a polyetherurethane. Tsuchiya T, et al. **J Biomed Mater Res** 1995 Jul;29(7):835–41

Assessment of DNA adducts and the frequency of 6-thioguanine resistant T-lymphocytes in F344 rats fed 2,4-toluenediamine or implanted with a toluenediisocyanate-containing polyester polyurethane foam. Delclos KB, et al. **Mutat Res** 1996 Apr 6;367(4):210–8

POLYURIA

CHEMICALLY INDUCED

Lithium induced polyuria and renal vasopressin receptor density. Hensen J, et al. **Nephrol Dial Transplant** 1996 Apr; 11(4):622–7

DRUG THERAPY

Ketorolac appears to decrease polyuria during intracranial surgery. Williams EL. **J Neurosurg Anesthesiol** 1996 Jan; 8(1):35–9

ETIOLOGY

Extreme polyuria: decompensated diabetes mellitus and/or diabetes insipidus? Delhaye F, et al. **Intensive Care Med** 1995 Jun;21(6):515–21

Severe hypercalcemia and polyuria in a near-drowning victim. Machi T, et al. **Intern Med** 1995 Sep;34(9):868–71

A case of renovascular hypertension with marked polyuria after percutaneous transluminal renal angioplasty. Tamatani M, et al. **Nephron** 1996;73(1):79–85

Night-time polyuria and nocturia. Matthiesen TB, et al. **Scand J Urol Nephrol Suppl** 1995;173:81–2

URINE

Challenging consults: application of principles of physiology

and biochemistry to the bedside. Osmotic diuresis: the importance of counting the number of osmoles excreted. Levin A, et al. **Clin Invest Med** 1995 Oct;18(5):401-5

VETERINARY

The differential diagnosis of polyuria/polydipsia in dogs. Belshaw BE. **Vet Q** 1995 Apr;17 Suppl 1:S19-21 (0 ref.)

POLYURIDYLIC ACIDS see **POLY U**

POLYVIDON see **POVIDONE**

POLYVINYL ALCOHOL

Viscoelastic and thermal properties of collagen/poly(vinyl alcohol) blends. Sarti B, et al. **Biomaterials** 1995 Jul; 16(10):785-92

In vitro removal of human IgG by pseudobiospecific affinity membrane filtration on a large scale. A preliminary report. Bueno SM, et al. **Int J Artif Organs** 1995 Jul;18(7):392-8

Preparation and characterization of alkylated poly(vinyl alcohol) hydrogels using alkyl halides. Duncan AC, et al. **J Biomater Sci Polym Ed** 1996;7(8):647-59

Improved localization of fluorescent tyramides for fluorescence in situ hybridization using dextran sulfate and polyvinyl alcohol. van Gijlswijk RP, et al. **J Histochem Cytochem** 1996 Apr;44(4):389-92

The use of Merocel nasal packs in the treatment of epistaxis. Pringle MB, et al. **J Laryngol Otol** 1996 Jun;110(6):543-6

Application of polyvinyl alcohol hydrogel membrane as anti-adhesive interposition after spinal surgery. Hiraizumi Y, et al. **Spine** 1995 Nov 1;20(21):2272-7

Long survival of xenografted bioartificial pancreas with a mesh-reinforced polyvinyl alcohol hydrogel bag employing a B-cell line (MIN6). Hayashi H, et al. **Transplant Proc** 1996 Jun;28(3):1428-9

CHEMISTRY

Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Cascone MG, et al. **Biomaterials** 1995 May;16(7):569-74

Surface modifications of alginate/poly(L-lysine) microcapsular membranes with poly(ethylene glycol) and poly(vinyl alcohol). Kung IM, et al. **Biomaterials** 1995 May; 16(8):649-55

Bioartificial materials based on collagen: 2. Mixtures of soluble collagen and poly(vinylalcohol) cross-linked with gaseous glutaraldehyde. Barbani N, et al. **J Biomater Sci Polym Ed** 1995;7(6):471-84

Novel magnetic microspheres on the basis of poly(vinyl alcohol) as affinity medium for quantitative detection of glycated haemoglobin. Müller-Schulte D, et al. **J Chromatogr A** 1995 Sep 8;711(1):53-60

Microencapsulation of lobster carotenoids within poly(vinyl alcohol) and poly(D,L-lactic acid) membranes. Sun ZM, et al. **J Microencapsul** 1995 Sep-Oct;12(5):495-504

PHARMACOLOGY

Stability of polypeptide immunoreactants and polyvinyl alcohol as a blocking agent on polyester cloth during dry storage. Boyd S, et al. **Immunol Invest** 1995 Aug; 24(5):795-803

Effect of Merocel vaginal sponge on growth of Staphylococcus aureus and production of toxic shock syndrome-associated toxins. Schlievert PM. **J Am Coll Surg** 1996 Jul;183(1):19-24

THERAPEUTIC USE

Periadventitial delivery of heparin in the prevention of microvenous thrombosis. Hirigoyen MB, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1097-102

POLYVINYL CHLORIDE

Friction loss in straight pipes of unplasticized polyvinyl chloride. Iwasaki T, et al. **Ind Health** 1996;34(3):245-56

Comparison of chemical dehydration and critical point drying for the stabilization and visualization of aging biofilm present on interior surfaces of PVC distribution pipe. Carr JH, et al. **J Appl Bacteriol** 1996 Feb;80(2):225-32

Plasticizer-level study of poly(vinyl chloride) ion-selective membranes. Simon MA, et al. **J Biomed Mater Res** 1996 Mar;30(3):313-20

Saline soaked pledgets prevent carbon dioxide laser-induced endotracheal tube cuff ignition. Sosis MB. **J Clin Anesth** 1995 Aug;7(5):395-7

Thetford plastics fire, October 1991: the role of a preventive medical team in chemical incidents. Baxter PJ, et al. **Occup Environ Med** 1995 Oct;52(10):694-8

[Igniting the endotracheal tube in tracheotomy with electrocautery. How it should not be done] Albegger KW. **HNO** 1996 May;44(5):271 **(Ger)**

[Occupational hygiene in major production of polyvinyl chloride] Lemeshevskaia EP, et al. **Med Tr Prom Ekol** 1995; (6):17-20 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul-Aug;111(4):299-313 (121 ref.)

[Medical prophylaxis of occupational intoxication in polyvinyl chloride industry] Maniashin IuA, et al. **Med Tr Prom Ekol** 1995;(8):25-8 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Effect of gamma-radiation on migration behaviour of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil. Goulas AE, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):74-8

CHEMISTRY

Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light. McMullin ST, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2018-20

Availability of lorazepam after simulated administration from glass and polyvinyl chloride containers. Mancano MA, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2213-6

Leaching and corrosion of polyvinyl chloride (PVC) tubes in a dialysis water distribution system. Cappelli G, et al. **Int J Artif Organs** 1995 May;18(5):261-3

A comparative study of platelets stored in polyvinyl chloride containers plasticised with butyryl trihexyl citrate or triethylhexyl trimellitate. Turner VS, et al. **Vox Sang** 1995; 69(3):195-200

METABOLISM

In vitro and in vivo studies of the effect of the concentration of plasticizer di(2-ethylhexyl) phthalate on the blood compatibility of plasticized poly(vinyl chloride) drain tubes. Kicheva YI, et al. **Biomaterials** 1995 May;16(7):575-9

Release of foreign bodies (particles) by clinical use of intravenous infusion sets. Madsen H, et al. **Biomaterials** 1996 Apr;17(7):663-6

Pilot study on the contamination of drinking water by organotin compounds from PVC materials. Sadiki AI, et al. **Chemosphere** 1996 Jun;32(12):2389-98

Stedim 6 and Clearflex, two new multilayer materials for infusion containers. Comparative study of their compatibility with five drugs versus glass flasks and polyvinyl chloride bags. Tchiakpé L, et al. **J Biomater Sci Polym Ed** 1995;7(3):199-206

RADIATION EFFECTS

Effect of microwave heating on the migration of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil and water. Badeka AB, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):313-7

TOXICITY

Effects of organic and inorganic substances on the cell proliferation of L-929 fibroblasts and Tetrahymena pyriformis GL protozoa used for toxicological bioassays. Sauvant MP, et al. **Bull Environ Contam Toxicol** 1995 Aug; 55(2):171-8

Chemical and in vitro toxicological evaluations of water packaged in polyvinyl chloride and polyethylene terephthalate bottles. Sauvant MP, et al. **Food Addit Contam** 1995 Jul-Aug;12(4):567-84

Poly(vinyl chloride) formulations: acute toxicity to cultured human cell lines. Smith MD, et al. **J Biomater Sci Polym Ed** 1995;7(5):453-9

[Toxicity of chemicals produced by thermal destruction of synthetic materials based on polyvinyl chloride and used in coal mines] Bolonova LN, et al. **Med Tr Prom Ekol** 1996;(2):24-7 (Eng. Abstr.) **(Rus)**

POLYVINYLPYRIDINE N-OXIDE

THERAPEUTIC USE

A biochemical study on combined treatment of experimental silicosis with tetradrine-PVNO and tetradrine-QOHP in rats. Yu L, et al. **Biomed Environ Sci** 1995 Sep;8(3):265-8

POLYVINYLPYRROLIDONE see **POVIDONE**

POLYVINYLPYRROLIDONE IODINE see **POVIDONE-IODINE**

POLYVINYLS

Peptide-mass profiles of polyvinylidene difluoride-bound proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the presence of nonionic detergents. Gharahdaghi F, et al. **Anal Biochem** 1996 Jan 1;233(1):94-9

New methods using polyvinylidene difluoride membranes to detect enzymes involved in glycosphingolipid metabolism. Ishikawa D, et al. **Anal Biochem** 1995 Oct 10;231(1):13-9

Rapid immunodetection on polyvinylidene fluoride membrane blots without blocking. Mansfield MA. **Anal Biochem** 1995 Jul 20;229(1):140-3

Western blot analysis of epidermal growth factor using gelatin-coated polyvinylidene difluoride membranes. Nishi N, et al. **Anal Biochem** 1995 May 20;227(2):401-2

Polyvinylidene fluoride (PVDF) as a biomaterial: from polymeric raw material to monofilament vascular suture. Laroche G, et al. **J Biomed Mater Res** 1995 Dec; 29(12):1525-36

Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support. Schielen P, et al. **J Immunol Methods** 1995 Dec 15; 188(1):33-41

Manufacture and release characteristics of Elvax polymers containing glutamate receptor antagonists. Smith AL, et al. **J Neurosci Methods** 1995 Aug;60(1-2):211-7

A new material for splinting neonatal limb deformities. Bell E, et al. **J Pediatr Orthop** 1995 Sep-Oct;15(5):613-6

Tissue management with a new gingival retraction material: a preliminary clinical report. Ferrari M, et al. **J Prosthet Dent** 1996 Mar;75(3):242-7

Cervical dilation from laminaria tents and synthetic osmotic dilators used for 6 hours before abortion. Kline SB, et al. **Obstet Gynecol** 1995 Dec;86(6):931-5

Controlled release of substituted benzoic and naphthoic acids using Carbopol gels: measurement of drug concentration profiles and correlation to release rate kinetics. French DL, et al. **Pharm Res** 1995 Oct;12(10):1513-20

ADVERSE EFFECTS

Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Murray RP, et al. **Chest** 1996 Feb;109(2):438-45

Contact dermatitis from carboxyvinyl polymer. Hisa T, et al. **Contact Dermatitis** 1995 Oct;33(4):271

CHEMISTRY

Forces transmitted through EVA mouthguard materials of different types and thickness. Westerman B, et al. **Aust Dent J** 1995 Dec;40(6):389-91

Controlled release of platelet-derived growth factor using ethylene vinyl acetate copolymer (EVAc) coated on stainless-steel wires. Walsh WR, et al. **Biomaterials** 1995 Nov;16(17):1319-25

The use of Fourier transform infrared spectrometry for monitoring the retention of polymers in the vitreous humour. Dalton PD, et al. **Biomed Mater Eng** 1995; 5(3):185-93

Preparation of void-free casts from vinyl polysiloxane impressions. Sherfudhin H, et al. **J Dent** 1996 Jan-Mar; 24(1-2):95-8

Clarification of immunoblots on polyvinylidene difluoride (PVDF) membranes for transmission densitometry. Tarlton JF, et al. **J Immunol Methods** 1996 May 10;191(1):65-9

Precorneal clearance of mucoadhesive microspheres from the rabbit eye. Durrani AM, et al. **J Pharm Pharmacol** 1995 Jul;47(7):581-4

Influence of pH on the release of propranolol hydrochloride from matrices containing hydroxypropylmethylcellulose K4M and carbopol 974. Perez-Marcos B, et al. **J Pharm Sci** 1996 Mar;85(3):330-4

Effect of provisional luting agents on polyvinyl siloxane impression material. Jones RH, et al. **J Prosthet Dent** 1996 Apr;75(4):360-3

[Sorption properties of Polish sorbents of the 2nd generation in relation to phenobarbital] Jurkowski P, et al. **Polim Med** 1995;25(3-4):47-50 (Eng. Abstr.) **(Pol)**

METABOLISM

Polyvinylidene fluoride monofilament sutures: can they be used safely for long-term anastomoses in the thoracic aorta? Laroche G, et al. **Artif Organs** 1995 Nov;19(11):1190-9

Enhancement of the polycation-mediated DNA uptake and cell transfection with Pluronic P85 block copolymer. Astafieva I, et al. **FEBS Lett** 1996 Jul 8;389(3):278-80

DNA affinity to biological membranes is enhanced due to complexation with hydrophobized polycation. Yaroslavov AA, et al. **FEBS Lett** 1996 Apr 15;384(2):177-80

PHARMACOLOGY

Polyethylene sulfonate: a tight-binding inhibitor of 6-phosphogluconate dehydrogenase of Cryptococcus neoformans. Niehaus WG, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):325-30

Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. Bai JP, et al. **J Pharm Sci** 1995 Nov;84(11):1291-4

Effect of poly(vinylsulfonate) on murine AA amyloid: a high-resolution ultrastructural study. Inoue S, et al. **Lab Invest** 1996 Jun;74(6):1081-90

RADIATION EFFECTS

Effect of microwave heating on the migration of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil and water. Badeka AB, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):313-7

THERAPEUTIC USE

Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Sachs DP. **Arch Intern Med** 1995 Oct 9;155(18):1973-80

A prospective randomized controlled trial comparing the use of merocel nasal tampons and BIPP in the control of acute epistaxis. Corbridge RJ, et al. **Clin Otolaryngol** 1995 Aug; 20(4):305-7

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Mar 27;275(12):902

Nicorette finds new place in smoking cessation [news] Voelker R. **JAMA** 1996 May 1;275(17):1301

The benefits and risks of over-the-counter availability of nicotine polacrilex ("nicotine gum"). Oster G, et al. **Med Care** 1996 May;34(5):389–402

[Transvenous closure of persistent ductus arteriosus with an Ivalon plug] Fassbender D, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):653–7 (36 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: histopathological evaluation in the animal eye. Vijayasekaran S, et al. **J Biomater Sci Polym Ed** 1996; 7(8):685–96

POMC see **PRO-OPIOMELANOCORTIN**

POMPE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE II**

POMPHOLYX see **ECZEMA, DYSHIDROTIC**

PONGIDAE

Sir Alister Hardy's paradigm (AAT) [letter] Young GB. **Nutr Health** 1995;10(3):281–282

ANATOMY & HISTOLOGY

Emissary canals in the hominoidea and their phylogenetic significance. Braga J. **Folia Primatol (Basel)** 1995; 65(3):144–53

Aquatic ape theory, speech origins, and brain differences with apes and monkeys. Verhaegen M. **Med Hypotheses** 1995 May;44(5):409–13

CLASSIFICATION

Emissary canals in the hominoidea and their phylogenetic significance. Braga J. **Folia Primatol (Basel)** 1995; 65(3):144–53

Palaeoanthropology. The nature of the evidence [news; comment] Andrews P, et al. **Nature** 1996 Jan 11; 379(6561):123–4. Comment on: Nature 1996 Jan 11;379(6561):156–9.

A Dryopithecus skeleton and the origins of great-ape locomotion [see comments] Moyà-Solà S, et al. **Nature** 1996 Jan 11;379(6561):156–9. Comment in: Nature 1996 Jan 11;379(6561):123.

GENETICS

Comparative fluorescence in situ hybridization mapping of primate chromosomes with Alu polymerase chain reaction generated probes from human/rodent somatic cell hybrids. Müller S, et al. **Chromosome Res** 1996 Jan;4(1):38–42

Regional localization of human M-BCR gene to chromosome 23 band q11 in the great apes. Samonte RV, et al. **Genetica** 1996 Jul;98(1):111–3

Presence and abundance of CENP-B box sequences in great ape subsets of primate-specific alpha-satellite DNA. Haaf T, et al. **J Mol Evol** 1995 Oct;41(4):487–91

ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. Martins RN, et al. **Neuroreport** 1995 Jul 31;6(11):1513–6

GROWTH & DEVELOPMENT

Socioecology and the ontogeny of sexual size dimorphism in anthropoid primates. Leigh SR. **Am J Phys Anthropol** 1995 Aug;97(4):339–56

PHYSIOLOGY

Aquatic ape theory, speech origins, and brain differences with apes and monkeys. Verhaegen M. **Med Hypotheses** 1995 May;44(5):409–13

PONGIDAE DISEASES see **APE DISEASES**

PONGO PYGMAEUS

Dental pathology in Pongo satyrus borneensis. Stoner KE. **Am J Phys Anthropol** 1995 Nov;98(3):307–21

CLASSIFICATION

Tricky relatives: consecutive dichotomous speciation of gorilla, chimpanzee and hominids testified by immunological determinants. Bauer K, et al. **Naturwissenschaften** 1995 Nov;82(11):517–20

GENETICS

The ZNF75 zinc finger gene subfamily: isolation and mapping of the four members in humans and great apes. Villa A, et al. **Genomics** 1996 Jul 15;35(2):312–20

Gorilla and orangutan c-myc nucleotide sequences: inference on hominoid phylogeny. Mohammad-Ali K, et al. **J Mol Evol** 1995 Sep;41(3):262–76

MICROBIOLOGY

Mycobacterium tuberculosis infection in an orangutan (Pongo pygmaeus). Shin NS, et al. **J Vet Med Sci** 1995 Oct;57(5):951–3

PHYSIOLOGY

Segment inertial properties of primates: new techniques for laboratory and field studies of locomotion. Crompton RH, et al. **Am J Phys Anthropol** 1996 Apr;99(4):547–70

Growth pattern of the maxillary sinus in orang-utan based on measurements of CT scans. Koppe T, et al. **Okajimas Folia Anat Jpn** 1995 May;72(1):37–43

PSYCHOLOGY

Use of social information in the problem solving of orangutans (Pongo pygmaeus) and human children (Homo sapiens). Call J, et al. **J Comp Psychol** 1995 Sep; 109(3):308–20

Manufacture and use of tools in wild Sumatran orangutans. Implications for human evolution. van Schaik CP, et al. **Naturwissenschaften** 1996 Apr;83(4):186–8

PONS

Aspergillus flavus meningitis and pontine hemorrhage in an older patient [letter] Adunsky A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):739–40

Ataxic hemiparesis with bilateral leg ataxia from pontine infarct [letter] Withiam-Leitch S, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):557–8

Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. Molloy PT, et al. **J Neurosurg** 1996 Mar;84(3):430–6 (45 ref.)

Pontine haemorrhage causing disturbance of taste. Sunada I, et al. **Neuroradiology** 1995 Nov;37(8):659

Pilocytic astrocytoma presenting as an extra-axial tumor in the cerebellopontine angle: case report. Beutler AS, et al. **Neurosurgery** 1995 Jul;37(1):125–8

[A surgically treated case of ventrally exophytic pontine glioma] Suga T, et al. **No Shinkei Geka** 1995 Nov; 23(11):1037–42 (Eng. Abstr.) **(Jpn)**

[A case of dissecting aneurysm of the basilar artery presented as superior pons type of Foville's syndrome] Nakaso K, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1040–3 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Pathways from cell groups of the paramedian tracts to the floccular region. Büttner-Ennever JA, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:532–40

The parabrachio-subfornical organ projection in the rat. Gu GB, et al. **Brain Res Bull** 1995;38(1):41–7

Topographical organization in the early postnatal corticopontine projection: a carbocyanine dye and 3-D computer reconstruction study in the rat. Leergaard TB, et al. **J Comp Neurol** 1995 Oct 9;361(1):77–94

Chemical topography of efferent projections from the median preoptic nucleus to pontine monoaminergic cell groups in the rat. Zardetto-Smith AM, et al. **Neurosci Lett** 1995 Oct 27;199(3):215–9

BLOOD SUPPLY

Slow-flow vascular malformations of the pons: capillary telangiectasias? Barr RM, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):71–8

Pontine tegmentum hematoma: a case report with the "one-and-a-half" syndrome without pyramidal tract deficit. Azevedo Júnior D. **Arq Neuropsiquiatr** 1995 Sep; 53(3-A):475–80

Bilateral thalamic infarctions can sometimes accompany midbrain infarction and rarely accompany pontine infarction [letter] Oishi M, et al. **J Neuroimaging** 1996 Jul; 6(3):202

Transient ipsilateral blood flow reduction in the thalamus and cerebral cortex after pontine infarction. Kuroda S, et al. **Neuroradiology** 1996 Apr;38(3):239–42

Audiologic findings in unilateral deafness resulting from contralateral pontine infarct. Doyle KJ, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):482–6

Pontine lesions may produce paralysis of upward gaze [letter; comment] Alpert JN. **Stroke** 1996 Mar;27(3):568–9. Comment on: Stroke 1995 Aug;26(8):1467–70.

[Visual illusion with 90-degree forward rotation on the sagittal plane due to acute paramedian pontine infarction] Tanaka H, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):34–7 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Distribution of alpha 2-adrenergic binding sites in the parabrachial complex of the rat. Herbert H, et al. **Anat Embryol (Berl)** 1995 Dec;192(6):507–16

CYTOLOGY

Morphology of neurons in the superficial layers of the rabbit's superior colliculus projecting ipsilaterally to the pons. Pérez-Samartín AL, et al. **Arch Ital Biol** 1995 Oct; 133(4):217–35

Glutamatergic inputs from the pedunculopontine nucleus to midbrain dopaminergic neurons in primates: Phaseolus vulgaris-leucoagglutinin anterograde labeling combined with postembedding glutamate and GABA immunohistochemistry. Charara A, et al. **J Comp Neurol** 1996 Jan 8;364(2):254–66

GABAergic neurons in the rat pontomesencephalic tegmentum: codistribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. Ford B, et al. **J Comp Neurol** 1995 Dec 11;363(2):177–96

Colocalization of ionotropic glutamate receptor subunits with NADPH-diaphorase-containing neurons in the rat mesopontine tegmentum. Inglis WL, et al. **J Comp Neurol** 1996 Apr 22;368(1):17–32

Prefrontal cortex projections to the basilar pons in rhesus monkey: implications for the cerebellar contribution to higher function. Schmahmann JD, et al. **Neurosci Lett** 1995 Oct 27;199(3):175–8

Mesopontine neurons in schizophrenia. Garcia-Rill E, et al. **Neuroscience** 1995 May;66(2):321–35

DRUG EFFECTS

Infusion of NMDA antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response. Peterson SL. **Brain Res** 1995 Dec 8; 702(1-2):101–9

Modulation of dopamine efflux in the nucleus accumbens after cholinergic stimulation of the ventral tegmental area in intact, pedunculopontine tegmental nucleus-lesioned, and laterodorsal tegmental nucleus-lesioned rats. Blaha CD, et al. **J Neurosci** 1996 Jan 15;16(2):714–22

Nitric oxide synthase inhibition decreases pontine acetylcholine release. Leonard TO, et al. **Neuroreport** 1995 Jul 31;6(11):1525–9

EMBRYOLOGY

Involvement of Wnt-1 in the formation of the mes/metencephalic boundary. Bally-Cuif L, et al. **Mech Dev** 1995 Sep;53(1):23–34

ENZYMOLOGY

Topographical organization of NADPH-diaphorase positive neurons and fibres in dorsal ponto-mesencephalic tegmentum in the rat brain. Petrovický P, et al. **J Hirnforsch** 1995;36(4):539–45

IMMUNOLOGY

Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease. van Zwieten EJ, et al. **Brain Res** 1996 Mar 4; 711(1-2):146–52

INJURIES

Traumatic ponto-medullary tear: a case report. Stan AC, et al. **Forensic Sci Int** 1996 Jan 12;77(1-2):37–43

METABOLISM

Relationship between muscarinic receptor subtypes and cyclic nucleotides in pons-medulla oblongata. Ge XQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):408–11

Immunocytochemical evaluation of the blood-brain barrier to endogenous albumin in the olfactory bulb and pons of senescence-accelerated mice (SAM). Ueno M, et al. **Histochem Cell Biol** 1996 Mar;105(3):203–12

Glutamate-like immunoreactivity in synaptic terminals of the posterior cingulopontine pathway: a light and electron microscopic study in the rabbit. Azkue J, et al. **J Chem Neuroanat** 1995 Dec;9(4):261–9

Evidence for corticotropin-releasing hormone projections from Barrington's nucleus to the periaqueductal gray and dorsal motor nucleus of the vagus in the rat. Valentino RJ, et al. **J Comp Neurol** 1995 Dec 18;363(3):402–22

Differential distribution of AMPA-selective glutamate receptor subunits in the parabrachial nucleus of the rat. Chamberlin NL, et al. **Neuroscience** 1995 Sep;68(2):435–43

PATHOLOGY

Nonhemorrhagic pontine infarct in a child following mild head trauma. Tannebaum RD, et al. **Acad Emerg Med** 1995 Jun;2(6):523–6

The prenatal age critical for the development of the pontosubicular necrosis. Sohma O, et al. **Acta Neuropathol (Berl)** 1995;90(1):7–10

Intra-axial endophytic primitive neuroectodermal tumors in the pons: clinical, radiological, and immunohistochemical aspects in four children. Behnke J, et al. **Childs Nerv Syst** 1996 Mar;12(3):125–9

Musical hallucinations: interplay of degenerative brain disease, psychosis, and culture in a Chinese woman. Stephane M, et al. **J Nerv Ment Dis** 1996 Jan;184(1):59–61

Bilateral infarction of the rostral pontine tegmentum as a cause of isolated bilateral supranuclear sixth nerve palsy related to hypertension [letter] Lopez JM, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):238–9

Blepharospasm in association with a lower pontine lesion. Aramideh M, et al. **Neurology** 1996 Feb;46(2):476–8

Isolated infarcts of the pons. Bassetti C, et al. **Neurology** 1996 Jan;46(1):165–75

Pontine lesions in idiopathic narcolepsy. Plazzi G, et al. **Neurology** 1996 May;46(5):1250–4

Oculopalatal myoclonus after the one-and-a-half syndrome with facial nerve palsy. Wolin MJ, et al. **Ophthalmology** 1996 Jan;103(1):177-80

[Pontine hematoma: a form of presentation in familial cavernous angiomatosis] Deyá E, et al. **Neurologia** 1995 Oct;10(8):350-1 **(Spa)**

[Image of the month: pontine cavernoma] Santamarta D, et al. **Neurologia** 1996 Jun-Jul;11(6):229 **(Spa)**

PHYSIOLOGY

Bilateral lesions of the pedunculopontine tegmental nucleus affect feeding induced by electrical stimulation of the ventral tegmental area. Trojniar W, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(3):201-6

Trigeminal motor nucleus and pontile respiratory regulation. Pokorski M, et al. **Adv Exp Med Biol** 1995;393:59-62

Nucleus basalis magnocellularis and pedunculopontine tegmental nucleus: control of the slow EEG waves in rats. Kleiner S, et al. **Arch Ital Biol** 1996 Mar;134(2):153-67

Non-NMDA glutamatergic excitatory transmission in the descending limb of the spinobulbospinal micturition reflex pathway of the rat. Matsumoto G, et al. **Brain Res** 1995 Sep 25;693(1-2):246-50

Effects of lidocaine injections into the lateral parabrachial nucleus on dipsogenic and pressor responses to central angiotensin II in rats. Menani JV, et al. **Brain Res** 1995 Oct 16;695(2):250-2

Role of lateral parabrachial nucleus in the inhibition of water intake produced by right atrial stretch. Ohman LE, et al. **Brain Res** 1995 Oct 16;695(2):275-8

Parabrachial nucleus projection to the amygdala in the rat: electrophysiological and anatomical observations. Jhamandas JH, et al. **Brain Res Bull** 1996;39(2):115-26

Responses of pontine neurons of the big brown bat, Eptesicus fuscus, to temporally patterned sound pulses. Wu MI, et al. **Hear Res** 1995 May;85(1-2):155-68

Electrical stimulation of the pontine omnipause area inhibits eye blink. Mays LE, et al. **J Am Optom Assoc** 1995 Jul; 66(7):419-22

Activity of neurons in the medial pontomedullary reticular formation during orienting movements in alert head-free cats. Isa T, et al. **J Neurophysiol** 1995 Jul;74(1):73-95

Taste responses in neurons in the nucleus of the solitary tract that do and do not project to the parabrachial pons. Monroe S, et al. **J Neurophysiol** 1995 Jul;74(1):249-57

Cholinergic, GABAergic, and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. Bevan MD, et al. **J Neurosci** 1995 Nov; 15(11):7105-20

Somatostatin in the pontine reticular formation modulates fear potentiation of the acoustic startle response: an anatomical, electrophysiological, and behavioral study. Fendt M, et al. **J Neurosci** 1996 May 1;16(9):3097-103

Pre- and postsynaptic glutamate receptors at a giant excitatory synapse in rat auditory brainstem slices. Barnes-Davies M, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):387-406

Pre- and postsynaptic whole-cell recordings in the medial nucleus of the trapezoid body of the rat. Borst JG, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):825-40

The functional expression of a pontine pneumotaxic centre in neonatal rats. Fung ML, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):579-91

Role of the parabrachial nucleus in ventilatory responses of awake rats. Mizusawa A, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):877-84

Different functions of rat's pedunculopontine tegmental nucleus are reflected in cortical EEG. Bringmann A. **Neuroreport** 1995 Oct 23;6(15):2065-8

The pontomesencephalic tegmentum delays the peak latency of the visual evoked potential in rats. Bringmann A. **Neurosci Lett** 1995 Dec 29;202(1-2):13-6

Inhibitory influence from the nucleus reticularis pontis oralis on the micturition reflex induced by electrical stimulation of the pontine micturition center in cats. Kimura Y, et al. **Neurosci Lett** 1995 Aug 11;195(3):214-6

Central regulation of micturition in the rat the corticotropin-releasing hormone from Barrington's nucleus. Pavcovich LA, et al. **Neurosci Lett** 1995 Aug 25; 196(3):185-8

Stimulus effects of the medial pontine reticular formation and the mesencephalic locomotor region upon medullary reticulospinal neurons in acute decerebrate cats. Iwakiri H, et al. **Neurosci Res** 1995 Aug;23(1):47-53

Mild electrical stimulation of pontine tegmentum around locus coeruleus reduces rapid eye movement sleep in rats. Singh S, et al. **Neurosci Res** 1996 Feb;24(3):227-35

Progressive cortical synchronization of ponto-geniculo-occipital potentials during rapid eye movement sleep. Amzica F, et al. **Neuroscience** 1996 May; 72(2):309-14

Putative cholinergic neurons of the pedunculopontine tegmental nucleus projecting to the superior colliculus consist of sensory responsive and unresponsive populations which are functionally distinct from other mesopontine neurons. Krauthamer GM, et al. **Neuroscience** 1995 Nov; 69(2):507-17

Tegmental pedunculopontine nucleus lesions do not block cocaine reward. Parker JL, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):77-83

Self-stimulation of the MFB following parabrachial lesions. Waraczynski M, et al. **Physiol Behav** 1995 Sep;58(3):559-66

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. **Prog Neurobiol** 1995 Sep;47(1):1-29 (205 ref.)

Gustatory function in the parabrachial nuclei: implications from lesion studies in rats. Spector AC. **Rev Neurosci** 1995 Apr-Jun;6(2):143-75 (163 ref.)

[Projections from pontine pneumotaxic center to medullary Bötzinger complex in cats] Song G, et al. **Sheng Li Hsueh Pao** 1996 Feb;48(1):59-64 (Eng. Abstr.) **(Chi)**

[Antidromal and synaptic activation of the neurons of the associative parietal cortex in cats evoked by impulses from the pontine nuclei proper] Papoian EV. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):10-7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

An unusual case of central pontine myelinolysis. Joseph AP, et al. **Alcohol Alcohol** 1995 Jul;30(4):423-5

Central pontine myelinolysis following 'slow' correction of hyponatremia. Pradhan S, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):340-3

Pontine myelinolysis following correction of hyponatraemia. Loo CS, et al. **Med J Malaysia** 1995 Jun;50(2):180-2

The striatal dopaminergic catalepsy mechanism is not necessary for the expression of pontine catalepsy produced by carbachol injections into the pontine reticular formation. Elazar Z, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug;352(2):187-93

Blepharospasm in association with a lower pontine lesion. Aramideh M, et al. **Neurology** 1996 Feb;46(2):476-8

Successful removal of cryptic arteriovenous malformation located at the upper ventral pons via subtemporal transtentorial approach. Nagata K, et al. **Surg Neurol** 1996 Aug;46(2):116-21

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32-6

[Pontine hemorrhage as a cause of peripheral facial paralysis] Martínez-García FA, et al. **Rev Neurol** 1996 Aug; 24(132):984-6 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368-70 (28 ref.)

Intra-axial endophytic primitive neuroectodermal tumors in the pons: clinical, radiological, and immunohistochemical aspects in four children. Behnke J, et al. **Childs Nerv Syst** 1996 Mar;12(3):125-9

SURGERY

Hypersomnia associated with a focal pontine lesion. Ganji SS, et al. **Clin Electroencephalogr** 1996 Jan;27(1):52-6

Successful removal of cryptic arteriovenous malformation located at the upper ventral pons via subtemporal transtentorial approach. Nagata K, et al. **Surg Neurol** 1996 Aug;46(2):116-21

ULTRASTRUCTURE

Ultrastructural evidence for a paucity of projections from the lumbosacral cord to the pontine micturition center or M-region in the cat: a new concept for the organization of the micturition reflex with the periaqueductal gray as central relay. Blok BF, et al. **J Comp Neurol** 1995 Aug 21;359(2):300-9

An ultrastructural study of cholinergic and non-cholinergic neurons in the laterodorsal and pedunculopontine tegmental nuclei in the rat. Honda T, et al. **Neuroscience** 1995 Oct;68(3):837-53

PONSINOMYCIN see **MIOCAMYCIN**

PONTINE MYELINOLYSIS, CENTRAL see **MYELINOLYSIS, CENTRAL PONTINE**

POPLITEAL ARTERY

Chronic consumption coagulopathy and popliteal aneurysm [letter] Kaplanski G, et al. **Am J Hematol** 1996 Mar; 51(3):245-6

Neurofibromatosis and arterial aneurysms. Huppman JL, et al. **Am Surg** 1996 Apr;62(4):311-4

Multiple nonanastomotic aneurysms in an external velour ringed Dacron femoropopliteal vascular prosthesis. AbuRahma AF, et al. **Ann Vasc Surg** 1995 Sep;9(5):493-6

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al. **Ann Vasc Surg** 1995 Jul;9(4):397-400 (8 ref.)

An unusual variant of popliteal artery entrapment. Gamagami RA, et al. **Ann Vasc Surg** 1995 Sep;9(5):467-70

Posterior exposure of the popliteal artery in reoperative vascular surgery. Gelabert HA, et al. **Ann Vasc Surg** 1996 Jan;10(1):53-8

Ruptured infected popliteal artery aneurysm. Wilson P, et al. **Ann Vasc Surg** 1995 Sep;9(5):497-9

Successful exclusion of a large femoropopliteal aneurysm with a covered nitinol stent. Dorffner R, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr;19(2):117-9

Ankle-arm index, angiography, and duplex ultrasonography after recanalization of occlusions in femoropopliteal arteries: comparison of long-term results. Winter-Warnars HAO, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug; 19(4):234-8

Technical report: Recanalisation of all three infrapopliteal arteries by subintimal angioplasty. Nydahl S, et al. **Clin Radiol** 1996 May;51(5):366-7

Popliteal artery entrapment caused by bony exostosis. Cook TA, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):238-9

Unravelling the familial tendency to aneurysmal disease: popliteal aneurysm, hypertension and fibrillin genotype. MacSweeney ST, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):162-6

The value of duplex surveillance after endovascular intervention for femoropopliteal obstructive disease. Tielbeek AV, et al. **Eur J Vasc Endovasc Surg** 1996 Aug; 12(2):145-50

Long-term results with a Palmaz stent in the femoropopliteal arteries. Chatelard P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):67-72

Long-term results with a Palmaz stent in the femoropopliteal arteries. Chatelard P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:67-72

Results of transluminal angioplasty of infra-popliteal arteries. Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:33-7

Stent graft for popliteal aneurysms. Six cases with Cragg Endo-Pro System 1 Mintec. Marcadé JP. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:41-4

Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324-6 (4 ref.)

A serious vascular complication of internal fixation of a tibial plateau fracture: a cautionary tale from which several lessons can be learned. Rawes ML, et al. **J Trauma** 1996 Feb;40(2):323-5

Regarding "should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis?" [letter] Bell PR, et al. **J Vasc Surg** 1996 Aug;24(2):298-9

The incidence of iliac, femoral, and popliteal artery aneurysms in hospitalized patients. Lawrence PF, et al. **J Vasc Surg** 1995 Oct;22(4):409-15; discussion 415-6

True infrapopliteal artery aneurysms: report of two cases and literature review. Mönig SP, et al. **J Vasc Surg** 1996 Aug; 24(2):276-8 (20 ref.)

Popliteal vein thrombosis associated with femoral osteochondroma and popliteal artery pseudoaneurysm. Scott EM, et al. **Postgrad Med J** 1995 Jul;71(837):441-2

Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. Henry M, et al. **Radiology** 1995 Oct; 197(1):167-74

Femoropopliteal artery: initial and 6-month results of color duplex US-guided percutaneous transluminal angioplasty [see comments] Katzenschlager R, et al. **Radiology** 1996 May;199(2):331-4. Comment in: Radiology 1996 May;199(2):317-8.

Femoropopliteal angioplasty with US guidance: an example of a niche market [editorial; comment] Polak JF. **Radiology** 1996 May;199(2):317-8. Comment on: Radiology 1996 May;199(2):331-4.

Popliteal artery entrapment syndrome. Anatomic and embryologic bases, diagnostic and therapeutic considerations following a series of 15 cases with a review of the literature. Rosset E, et al. **Surg Radiol Anat** 1995; 17(2):161-9, 23-7 (89 ref.) **(Eng, Fre)**

Haemorrhage due to laceration of an aberrant inferior epigastric artery during femoropopliteal PTA in an obese patient; a rare complication of a high antegrade femoral puncture. Lampmann LE, et al. **Vasa** 1995;24(4):382-4

[Percutaneous intentional extraluminal recanalization of the femoropopliteal artery. Initial experiences and results] Vandenbosch G, et al. **J Belge Radiol** 1996 Jun;79(3):129-32 (Eng. Abstr.) **(Dut)**

[Acute femoro-popliteal ischemia. New therapeutic approach. Respective role of thrombo-aspiration and in situ thrombolysis] Beyssen B, et al. **Chirurgie** 1996; 121(2):127-32 (Eng. Abstr.) **(Fre)**

[Percutaneous treatment of popliteal aneurysms using a covered stent: preliminary clinical experience] Gieskes L, et al. **J Mal Vasc** 1995;20(4):264-7 (Eng. Abstr.) **(Fre)**

[The popliteal artery entrapment syndrome in an older patient. Its diagnosis after unsuccessful laser-assisted percutaneous transluminal angioplasty] Bail DH, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):336-40 (18 ref.) (Eng. Abstr.) **(Ger)**

[The initial results of percutaneous therapy of popliteal aneurysms with stents] Link J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):244-8 (Eng. Abstr.) **(Ger)**

[Femoro-popliteal bypass with reversed saphenous vein. Experience in a General Surgery Department] Falco E, et al. **Minerva Chir** 1995 Oct;50(10):883-8 (Eng. Abstr.) **(Ita)**

[Aneurysms of the popliteal artery. A clinical case and revision of the literature] Giani L, et al. **Minerva Chir** 1995 Nov;50(11):1019-23 (21 ref.) (Eng. Abstr.) **(Ita)**

[Popliteal aneurysm] Giavazzi T, et al. **Minerva Chir** 1995 Sep;50(9):763-5 (Eng. Abstr.) **(Ita)**

[Method of cascade shunting in the treatment of femoral-popliteal segment occlusion] Sergeev OA. **Klin Khir** 1995;(11-12):42-3 **(Rus)**

ABNORMALITIES

Pulseless foot after stab wound to the calf: clue to a therapeutically important arterial variant. Bejvan SM, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):666

ANATOMY & HISTOLOGY

Anatomo-radiological study of the popliteal artery during knee flexion. Avisse C, et al. **Surg Radiol Anat** 1995; 17(3):255–62

INJURIES

Predictors of amputation for popliteal artery injuries. Fainzilber G, et al. **Am J Surg** 1995 Dec;170(6):568–70; discussion 570–1

Popliteal artery injury after total knee arthroplasty. Mureebe L, et al. **Am Surg** 1996 May;62(5):366–8

Acute popliteal arterial injury: the role of angioscopy. Alimi Y, et al. **Ann Vasc Surg** 1995 Jul;9(4):361–8

Popliteal artery injury complicating arthroscopic meniscectomy. Potter D, et al. **Arthroscopy** 1995 Dec; 11(6):723–6

Intentional extraluminal recanalisation of the femoropopliteal segment following perforation during percutaneous transluminal angioplasty. Nasim A, et al.
Eur J Vasc Endovasc Surg 1996 Aug;12(2):246–9

Vascular injury following closed proximal tibial fracture: beware the extension injury. Housden PL, et al. **Injury** 1995 Dec;26(10):698–701

Pure hyperextension of the knee causing popliteal artery injury. Jones S, et al. **Injury** 1996 Jun;27(5):355–6

Arteriovenous fistula after fibular osteotomy leading to recurrent haemarthroses in a total knee replacement. Haddad FS, et al. **J Bone Joint Surg Br** 1996 May; 78(3):458–60

Lower limb trauma with injury to the popliteal vessels [see comments] Prêtre R, et al. **J Trauma** 1996 Apr; 40(4):595–601. Comment in: J Trauma 1996 Apr;40(4):669–70.

Bilateral popliteal artery injury from bumper crush injury. Tominaga GT, et al. **J Trauma** 1996 Feb;40(2):311–3 (19 ref.)

Blunt popliteal vascular injuries: combined trauma to integument, skeleton, muscle, nerve, and vessels [editorial; comment] Trafton PG. **J Trauma** 1996 Apr;40(4):669–70. Comment on: J Trauma 1996 Apr;40(4):595–601.

[Management of blunt injury of the popliteal artery] Prêtre R, et al. **Swiss Surg** 1995;(2):110–3 (Eng. Abstr.) **(Fre)**

[Injury of the popliteal artery & the popliteal branches: analysis of 31 consecutive cases] Filippini A, et al.
Ann Ital Chir 1995 Nov–Dec;66(6):871–6; discussion 876–7 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Re: Comparison of efficacy in crossing femoropopliteal artery occlusions with movable core and hydrophilic guidewires [letter; comment] Hartnell GG.
Cardiovasc Intervent Radiol 1995 Jul–Aug;18(4):274–5. Comment on: Cardiovasc Intervent Radiol 1994 Nov–Dec;17(6):319–22.

Popliteal artery pseudoaneurysm revealed by deep vein thrombosis after arthroscopic meniscectomy. Guermazi A, et al. **Eur Radiol** 1996;6(2):217–9

Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. Stanley B, et al. **J Vasc Surg** 1996 Apr;23(4):679–85

Cystic adventitial disease of the popliteal artery--a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173–80 (20 ref.)

PHYSIOPATHOLOGY

Intermittent calf and foot compression increases lower extremity blood flow. Eze AR, et al. **Am J Surg** 1996 Aug; 172(2):130–4; discussion 135

RADIOGRAPHY

Preoperative vascular imaging for the fibular osteocutaneous flap. Carroll WR, et al.
Arch Otolaryngol Head Neck Surg 1996 Jul;122(7):708–12

Arterial tortuosity in the femoropopliteal region during knee flexion: a magnetic resonance angiographic study. Wensing PJ, et al. **J Anat** 1995 Aug;187 (Pt 1):133–9

Comparison of intravascular ultrasonography and intraarterial digital subtraction angiography after directional atherectomy of short lesions in femoropopliteal arteries. Tielbeek AV, et al. **J Vasc Surg** 1996 Mar; 23(3):436–45

Anatomo-radiological study of the popliteal artery during knee flexion. Avisse C, et al. **Surg Radiol Anat** 1995; 17(3):255–62

SURGERY

Management and outcome of infrapopliteal arterial graft infections with distal graft involvement. Calligaro KD, et al. **Am J Surg** 1996 Aug;172(2):178–80

A comparison of postoperative thrombotic potential following abdominal aortic surgery, carotid endarterectomy, and femoro-popliteal bypass. Gibbs NM, et al. **Anaesth Intensive Care** 1996 Feb;24(1):11–4

Acute popliteal arterial injury: the role of angioscopy. Alimi Y, et al. **Ann Vasc Surg** 1995 Jul;9(4):361–8

Femoropopliteal bypass for claudication: vein vs. PTFE. Allen BT, et al. **Ann Vasc Surg** 1996 Mar;10(2):178–85

Anastomosis over a stent for heavily calcified arteries. Coggia M, et al. **Ann Vasc Surg** 1995;9 Suppl:S39–44

Role of vascular endoscopy in aortoiliac and femoropopliteal thromboendarterectomy. Kogel H, et al.
Cardiovasc Surg 1996 Feb;4(1):93–6

Sequential aortofemoropopliteal/distal bypass for treatment of critical lower-limb ischaemia. Zukauskas G, et al.
Cardiovasc Surg 1995 Dec;3(6):671–8

Femoropopliteal bypass [letter] Breek JC, et al.
Eur J Vasc Endovasc Surg 1995 Oct;10(3):384

The crossover femoropopliteal bypass: a useful option for unilaterial iliofemoral occlusive disease. Chalmers RT, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):330–4

Lymph drainage and the development of post-reconstructive leg oedema is not influenced by the type of inguinal incision. A prospective randomised study in patients undergoing femoropopliteal bypass surgery. Haaverstad R, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):316–22

Endovascular remote endarterectomy in femoropopliteal occlusive disease: one-year clinical experience with the ring strip cutter device. Ho GH, et al.
Eur J Vasc Endovasc Surg 1996 Jul;12(1):105–12

A safe combined surgical/radiological approach to endoluminal graft stenting of a popliteal aneurysm. Joyce WP, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):489–91

Durability of short bypasses to infragenicular arteries. Shah DM, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):440–4

Refinements of the in situ vein bypass: towards a more "closed" technique. van Dijk LC, et al.
Eur J Vasc Endovasc Surg 1996 Aug;12(2):136–8

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al.
Eur J Vasc Endovasc Surg 1996 Feb;11(2):243–6 (5 ref.)

Popliteal-to-tibial bypass for acute leg ischemia complicating aortic reconstruction. Porcellini M, et al. **G Chir** 1996 Apr; 17(4):166–70

Stent graft for popliteal aneurysms. Six cases with Cragg Endo-Pro System 1 Mintec. Marcadé JP.
J Cardiovasc Surg (Torino) 1996 Jun;37(3 Suppl 1):41–4

Endovascular remote endarterectomy in femoropopliteal long segmental occlusive disease. A new surgical technique illustrated and preliminary results using a ring strip cutter device. Moll FL, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):39–40

Endovascular remote endarterectomy in femoropopliteal long segmental occlusive disease. A new surgical technique illustrated and preliminary results using a ring strip cutter device. Moll FL, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:39–40

Femoropopliteal venous bypass studied with intravascular ultrasound: a case report. van der Lugt A, et al.
J Endovasc Surg 1996 Aug;3(3):315–20

Results of bypass to the popliteal and tibial arteries with alternative sources of autogenous vein. Gentile AT, et al.
J Vasc Surg 1996 Feb;23(2):272–9; discussion 279–80

Polytetrafluoroethylene bypasses to infrapopliteal arteries without cuffs or patches: a better option than amputation in patients without autologous vein. Parsons RE, et al.
J Vasc Surg 1996 Feb;23(2):347–54; discussion 355–6

The merit of polytetrafluoroethylene extensions and interposition grafts to salvage failing infrainguinal vein bypasses. Sanchez LA, et al. **J Vasc Surg** 1996 Feb; 23(2):329–35

Infrapopliteal bypass for critical limb ischaemia. Early experience in the French West Indies. Deneuville M, et al. **West Indian Med J** 1996 Jun;45(2):55–9

[Treatment of an exposed femoral-popliteal bypass: ex-situ replacement] Gouny P, et al. **J Mal Vasc** 1996;21 Suppl A:152–7 (Eng. Abstr.) **(Fre)**

[Aneurysms of the popliteal artery. Intravascular bypass using the internal saphenous vein] Roux D, et al.
Presse Med 1995 Dec 16–23;24(39):1899–1900 (Eng. Abstr.) **(Fre)**

[Small-caliber polyurethane arterial prosthesis: clinical and angiomorphological follow-up of 20 patients in a prospective study] Gloor B, et al. **Swiss Surg Suppl** 1996; Suppl 1:13–8 (Eng. Abstr.) **(Fre)**

[Acute rupture of an aneurysm of the popliteal artery: case report] Manouguian S. **Zentralbl Chir** 1996;121(5):405–7 (Eng. Abstr.) **(Ger)**

[Efficacy of the popliteal to distal bypass in salvage of the ischemic diabetic foot] Cavallini M, et al. **Ann Ital Chir** 1995 Jul–Aug;66(4):473–8 (Eng. Abstr.) **(Ita)**

[Injury of the popliteal artery & the popliteal branches: analysis of 31 consecutive cases] Filippini A, et al.
Ann Ital Chir 1995 Nov–Dec;66(6):871–6; discussion 876–7 (Eng. Abstr.) **(Ita)**

[Aneurysm of the popliteal artery in a patient over 80 years of age] Bellitti R, et al. **Minerva Cardioangiol** 1995 Jun; 43(6):287–8 (Eng. Abstr.) **(Ita)**

[The multistage surgical treatment of multiple spontaneous arterial aneurysms] Ermolaev VL, et al.
Vestn Khir Im I I Grek 1992 Nov–Dec;149(11–12):340–2 **(Rus)**

[The outcomes of reconstructive-reparative operations in atherosclerotic lesions of the femoral-popliteal segment] Veretenin VA, et al. **Voen Med Zh** 1995 Aug;(8):37–41 **(Rus)**

[The effect of indobufen on patency in femoro-popliteal/crural bypass using artificial grafts] Cernak I, et al. **Vojnosanit Pregl** 1994 May–Jun;51(3):214–9 (Eng. Abstr.) **(Scr)**

[The short bypass in the treatment of popliteal artery occlusion] Prochotský A, et al. **Bratisl Lek Listy** 1995 Sep; 96(9):499–502 (Eng. Abstr.) **(Slo)**

ULTRASONOGRAPHY

The original calibre of the lower limbs arteries as a possible risk factor for complications of atherosclerosis: a statistical investigation in 90 subjects by echocolor-doppler. Macchi C, et al. **Arch Ital Anat Embriol** 1994 Oct–Dec;99(4):219–28

Colour duplex ultrasonographic imaging and provocation of popliteal artery compression. Akkersdijk WL, et al.
Eur J Vasc Endovasc Surg 1995 Oct;10(3):342–5

Popliteal vein compression due to popliteal artery aneurysm: effects of aneurysm size. Kotval PS, et al.
J Ultrasound Med 1995 Nov;14(11):805–11

Interobserver variation in duplex sonographic scanning in the femoropopliteal tract. Winter-Warnars HA, et al.
J Ultrasound Med 1996 Jun;15(6):421–8; discussion 329–30

Demonstration of cystic adventitial disease by intravascular ultrasound imaging. Koppensteiner R, et al.
J Vasc Surg 1996 Mar;23(3):534–6 (9 ref.)

Comparison of intravascular ultrasonography and intraarterial digital subtraction angiography after directional atherectomy of short lesions in femoropopliteal arteries. Tielbeek AV, et al. **J Vasc Surg** 1996 Mar; 23(3):436–45

Blood flow in free muscle flaps measured by color Doppler ultrasonography. Salmi AM, et al. **Microsurgery** 1995; 16(10):666–72

[Ultrasonic angiography in diagnosis of peripheral vascular disease] Zhang Q, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):422–4 (Eng. Abstr.) **(Chi)**

[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131–7 (39 ref.) (Eng. Abstr.) **(Ger)**

POPLITEAL CYST

A 47-year-old woman with a swollen leg. Rosian R, et al.
Cleve Clin J Med 1995 Sep–Oct;62(5):281–4

COMPLICATIONS

Bilateral Baker's cyst in a patient with psoriatic arthritis of pediatric onset [letter] Lepore L, et al.
Clin Exp Rheumatol 1996 Jan–Feb;14(1):109–10

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)

Anterior dissection of popliteal cyst causing anterior compartment syndrome. Hammoudeh M, et al.
J Rheumatol 1995 Jul;22(7):1377–9

DIAGNOSIS

Popliteal cysts on MR imaging: value as an ancillary sign of meniscal tears [letter; comment] Lenchik L, et al.
AJR Am J Roentgenol 1996 May;166(5):1232. Comment on: AJR Am J Roentgenol 1994 Dec;163(6):1419–23.

Baker's cyst as a clinical presentation of brucellosis. Blanco R, et al. **Clin Infect Dis** 1996 May;22(5):872–3

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)

[Adventitial cyst of the popliteal artery. Imaging and percutaneous treatment] Cholot M, et al. **J Radiol** 1996 Mar;77(3):201–4 (Eng. Abstr.) **(Fre)**

[Pseudothrombophlebitis due to an expansive popliteal cyst associated with Reiter's syndrome] Mangiafico RA, et al.
Minerva Med 1995 Sep;86(9):391–4 (14 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Baker's cyst as a clinical presentation of brucellosis. Blanco R, et al. **Clin Infect Dis** 1996 May;22(5):872–3

An avoidable complication of septic arthritis. Atkinson K.
J Tenn Med Assoc 1996 Jan;89(1):16–7

[Pseudothrombophlebitis syndrome in Reiter's syndrome] Marques Filho J. **Rev Assoc Med Bras** 1995 May–Jun; 41(3):252–4 (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

[Spontaneous regression of a sub-adventitial cyst of the popliteal artery] Soury P, et al. **J Mal Vasc** 1995; 20(4):323–5 (Eng. Abstr.) **(Fre)**

SURGERY

Computed tomography--guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732–3 (22 ref.)

ULTRASONOGRAPHY

Baker's cyst in rheumatoid arthritis: an ultrasonographic study with a high resolution technique. Andonopoulos AP, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):633–6

POPLITEAL VEIN

Popliteal vein aneurysm. al Zahrani HA. **Cardiovasc Surg** 1995 Oct;3(5):505–7 (11 ref.)

The femoropopliteal vein. Ultrasound anatomy, diagnosis, and office surgery. Georgiev M. **Dermatol Surg** 1996 Jan; 22(1):57–62

Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis [letter] Villa P, et al. **Lancet** 1996 Feb 10;347(8998):397

Association of membranous nephropathy with familial resistance to activated protein C. Montinaro V, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2133–6

Popliteal vein thrombosis associated with femoral osteochondroma and popliteal artery pseudoaneurysm. Scott EM, et al. **Postgrad Med J** 1995 Jul;71(837):441–2

[True popliteal venous aneurysm. 2 cases (letter)] Vuong PN, et al. **Presse Med** 1996 Apr 27;25(15):733 **(Fre)**

[Diagnostic approach to popliteal venous aneurysm] Ravelli C, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):9–14 (Eng. Abstr.) **(Ita)**

INJURIES

Lower limb trauma with injury to the popliteal vessels [see comments] Prêtre R, et al. **J Trauma** 1996 Apr; 40(4):595–601. Comment in: J Trauma 1996 Apr;40(4):669–70.

Blunt popliteal vascular injuries: combined trauma to integument, skeleton, muscle, nerve, and vessels [editorial; comment] Trafton PG. **J Trauma** 1996 Apr;40(4):669–70. Comment on: J Trauma 1996 Apr;40(4):595–601.

PHYSIOLOGY

Venous hemodynamics during impulse foot pumping. Killewich LA, et al. **J Vasc Surg** 1995 Nov;22(5):598–605

PHYSIOPATHOLOGY

Valvular function of peripheral veins after hyperemic dilation. Andersson J, et al. **J Vasc Surg** 1996 Apr; 23(4):611–5

SURGERY

Analysis of autogenous vein femoral-infrapopliteal bypass for limb salvage in the elderly. Hearn AT, et al. **Cardiovasc Surg** 1996 Feb;4(1):105–9

ULTRASONOGRAPHY

Popliteal vein compression due to popliteal artery aneurysm: effects of aneurysm size. Kotval PS, et al. **J Ultrasound Med** 1995 Nov;14(11):805–11

Can the US examination for lower extremity deep venous thrombosis be abbreviated? A prospective study of 755 examinations. Frederick MG, et al. **Radiology** 1996 Apr; 199(1):45–7

POPPY see **PAPAVER**

POPULATION

Measuring the use of the population perspective on internal medicine attending rounds. Raik B, et al. **Acad Med** 1995 Nov;70(11):1047–9

Use of a multiparametric panel to target subpopulations in a heterogeneous solid tumor model for improved analytical accuracy. O'Brien MC, et al. **Cytometry** 1995 Sep 1; 21(1):76–83

Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Sauter G, et al. **Cytometry** 1995 Sep 1;21(1):40–6

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.). Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.

The impact of estimation method and population adjustment on Canadian life table estimates. Ng E, et al. **Health Rep** 1995;7(3):15–22 **(Eng, Fre)**

Heterogeneity of astrocytes in human optic nerve head. Ye H, et al. **J Comp Neurol** 1995 Nov 27;362(4):441–52

POPULATION-BASED PLANNING see **COMMUNITY HEALTH PLANNING**

POPULATION CONTROL

see related
ABORTION, LEGAL
CONTRACEPTION
FAMILY PLANNING
FAMILY PLANNING POLICY
STERILIZATION, SEXUAL

The population "wolf" and demographic entrapment in Rwanda [letter] King M. **Am J Public Health** 1996 Jul; 86(7):1030–1

Population and women's reproductive health: an international perspective. Miller K, et al. **Annu Rev Public Health** 1996; 17:359–82 (79 ref.)

Contemplating a one child world. Fundamental rethinking is needed [letter; comment] Butler C. **BMJ** 1996 Apr 6; 312(7035):907. Comment on: BMJ 1995 Dec 23–30;311(7021):1651–2.

Contemplating a one child world. Medical profession should give more decisive leadership [letter; comment] Last J. **BMJ** 1996 Apr 6;312(7035):907. Comment on: BMJ 1995 Dec 23–30;311(7021):1651–2.

Contemplating a one child world [editorial] [see comments] McMichael AJ. **BMJ** 1995 Dec 23–30;311(7021):1651–2. Comment in: BMJ 1996 Apr 6;312(7035):907. Comment in: BMJ 1996 Apr 6;312(7035):907–8.

Contemplating a one child world. Medical students should be taught to appraise evidence on global health issues [letter; comment] Peel M, et al. **BMJ** 1996 Apr 6; 312(7035):907–8. Comment on: BMJ 1995 Dec 23–30;311(7021):1651–2. Comment on: BMJ 1995 Dec 23–30;311(7021):1677–80. Comment on: BMJ 1995 Dec 23–30;311(7021):1681–4.

After Cairo [letter; comment] Bonnici JL. **Br J Obstet Gynaecol** 1996 Jan;103(1):91; discussion 92–3 . Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):436–8.

After Cairo [letter; comment] Kelly J. **Br J Obstet Gynaecol** 1996 Jan;103(1):91–3. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):436–8.

World population day [editorial] Caldwell JC. **Med J Aust** 1996 Jul 15;165(2):72–3

Health education campaign on population control: lessons from Iran. Montazeri A. **Public Health** 1995 Nov; 109(6):425–30

[Voluntary, controlled limited reproduction in humans--a conflict to modern evolutionary biology?] Schröder I. **Anthropol Anz** 1995 Sep;53(3):277–84 (Eng. Abstr.) **(Ger)**

[From Cairo to Pekin: reflections about a problem involving the whole planet] Poveda J. **Med Clin (Barc)** 1996 Jun 1; 107(1):26–8 **(Spa)**

ECONOMICS

An economic analysis of Chinese fertility behavior. Liu GG, et al. **Soc Sci Med** 1996 Apr;42(7):1027–37

LEGISLATION & JURISPRUDENCE

Population policy and eugenics in China [editorial] [see comments] Pearson V. **Br J Psychiatry** 1995 Jul;167(1):1–4 . Comment in: Br J Psychiatry 1995 Nov;167(5):697–8.

TRENDS

Cairo: repackaging population control. Simons H. **Int J Health Serv** 1995;25(3):559–66

Immunization to regulate fertility: biological and cultural frameworks. Schrater AF. **Soc Sci Med** 1995 Sep; 41(5):657–71 (85 ref.)

Implementing the ICPD's message. Jain A. **Stud Fam Plann** 1995 Sep–Oct;26(5):296–8

[Future prospects in contraception] Rabe T, et al. **Arch Gynecol Obstet** 1995;257(1–4):541–7 **(Ger)**

POPULATION DENSITY

see related
CROWDING
SOCIAL ISOLATION

The population "wolf" and demographic entrapment in Rwanda [letter] King M. **Am J Public Health** 1996 Jul; 86(7):1030–1

Detecting domestic vectors of Chagas disease: a comparative trial of six methods in north-west Argentina. Gürtler RE, et al. **Bull World Health Organ** 1995;73(4):487–94

Childhood leukemia in metropolitan regions in the United States: a possible relation to population density? Muirhead CR. **Cancer Causes Control** 1995 Sep;6(5):383–8

Density and age-specific mortality [comment] Curtsinger JW. **Genetica** 1995;96(3):179–82; discussion 183–6, 187–9. Comment on: Genetica 1993;91(1–3):99–109.

Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Kuhner MK, et al. **Genetics** 1995 Aug;140(4):1421–30

Changes in the number of veterinarians and number of people in the United States, 1990 to 1994. Gehrke BC. **J Am Vet Med Assoc** 1996 Feb 15;208(4):486–7

Intercommunity differences in acid aerosol (H+)/sulfate (SO_4^{2-}) ratios. Ozkaynak H, et al. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):35–55

Reproductive performance on the Maltese Islands during the First World War. Savona-Ventura C. **J R Army Med Corps** 1995 Jun;141(2):107–11

Fatal motor vehicle crashes: variations of crash characteristics within rural regions of different population densities. Muelleman RL, et al. **J Trauma** 1996 Aug; 41(2):315–20

Health in Nepal [letter] King M. **Lancet** 1996 Jun 22; 347(9017):1768

Lumped-density population models of pioneer-climax type and stability analysis of Hopf bifurcations. Selgrade JF, et al. **Math Biosci** 1996 Jul 1;135(1):1–21

The impact of population expansion and mutation rate heterogeneity on DNA sequence polymorphism. Aris-Brosou S, et al. **Mol Biol Evol** 1996 Mar;13(3):494–504

Local government reorganisation in Scotland and Wales. Jackson G, et al. **Popul Trends** 1996 Spring;(83):43–52

Delayed density-dependence in a small-rodent population. Agrell J, et al. **Proc R Soc Lond B Biol Sci** 1995 Oct 23; 262(1363):65–70

Divergence time and population size in the lineage leading to modern humans. Takahata N, et al. **Theor Popul Biol** 1995 Oct;48(2):198–221

Susceptibility to rubella infection in females at high risk. Immune protection associated to population density. Yamamoto L, et al. **Trop Geogr Med** 1995;47(6):235–8

Double think--a reply [comment] King M, et al. **World Health Forum** 1995;16(3):293–8. Comment on: World Health Forum 1994;15(4):382–6.

[Regional variations in health services: various methodological problems] Koehn V, et al. **Soz Praventivmed** 1996;41(2):63–9 (Eng. Abstr.) **(Fre)**

POPULATION DISTRIBUTION see **DEMOGRAPHY**

POPULATION DYNAMICS

Population dynamics of a meiotic/mitotic expansion model for the fragile X syndrome. Ashley AE, et al. **Am J Hum Genet** 1995 Dec;57(6):1414–25

Beyond population statistics [editorial; comment] Silver G. **Am J Public Health** 1995 Oct;85(10):1345–6. Comment on: Am J Public Health 1995 Oct;85(10):1356–60.

Secular change in height in Austria: an effect of population stratification? Weber G, et al. **Ann Hum Biol** 1995 Jul–Aug; 22(4):277–88

Population mixing and the incidence of childhood leukaemias: retrospective comparison in rural areas of New Zealand. Dockerty JD, et al. **BMJ** 1996 May 11; 312(7040):1203–4

Europe's aging population [news] Watson R. **BMJ** 1996 Jun 8;312(7044):1442

Childhood leukemia and rural population movements: Greece, Italy, and other countries. Kinlen LJ, et al. **Cancer Causes Control** 1995 Sep;6(5):445–50

Interpolating demography with families and households. Goldscheider FK. **Demography** 1995 Aug;32(3):471–80

Immigration cohorts and residential overcrowding in southern California. Myers D, et al. **Demography** 1996 Feb; 33(1):51–65

Demographic effects of natural disasters: a case study of Hurricane Andrew. Smith SK, et al. **Demography** 1996 May;33(2):265–75

The role of secondary sex ratios in the declining sex ratio of India. Sachar RK, et al. **Indian J Public Health** 1995 Jan–Mar;39(1):12–5

Malthusian parameter on the Finnish population in the 20th century. Juhola K, et al. **Int J Biomed Comput** 1996 Mar; 41(1):5–11

The impact of ageing upon the need for medical beds: a Monte-Carlo simulation. Weinberg J. **J Public Health Med** 1995 Sep;17(3):290–6

A note on population dynamics. Suematsu K, et al. **J Theor Biol** 1995 Aug 7;175(3):317–24

Spatially explicit models for the population dynamics of a species colonizing an island. Cantrell RS, et al. **Math Biosci** 1996 Aug;136(1):65–107

Sinks, sources, and spotted owls: a territorial population model with continuous mortality and discrete birth. Carroll JE, et al. **Math Biosci** 1995 Oct;129(2):169–88

Carrier-borne epidemic models incorporating population mobility. Clancy D. **Math Biosci** 1996 Mar;132(2):185–204

A predator-prey model with optimal suppression of reproduction in the prey. Gyllenberg M, et al. **Math Biosci** 1996 Jun;134(2):119–52

An augmented Clark model for stability of populations. Mertz G, et al. **Math Biosci** 1996 Jan 15;131(2):157–71

Adaptive optimization and the harvest of biological populations. Williams BK. **Math Biosci** 1996 Aug; 136(1):1–20

Yellow fever: ecology, epidemiology, and role in the collapse of the Classic lowland Maya civilization. Wilkinson RL. **Med Anthropol** 1995 Jul;16(3):269–94

In the red zone [letter] Blarer A, et al. **Nature** 1996 Apr 18;380(6575):589–90

Unexpected dominance of high frequencies in chaotic nonlinear population models. Cohen JE. **Nature** 1995 Dec 7;378(6557):610–2

Red/blue chaotic power spectra [letter] Kaitala V, et al. **Nature** 1996 May 16;381(6579):198–9

Red/blue chaotic power spectra [letter] Sugihara G. **Nature** 1996 May 16;381(6579):198–9

Red/blue chaotic power spectra [letter] White A, et al. **Nature** 1996 May 16;381(6579):198

Low birthweight in Germany 1990–92. Dammann O, et al. **Paediatr Perinat Epidemiol** 1996 Apr;10(2):130–5

Population review: (3). Migration to from and within the United Kingdom. Champion T. **Popul Trends** 1996 Spring; (83):5–16

1993-based subnational population projections for England. Hornsey D. **Popul Trends** 1995 Autumn;(81):31–6

Unusual dynamics of extinction in a simple ecological model. Sinha S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1504–8

Earth's carrying capacity [letter; comment] Gawne T. **Science** 1995 Nov 10;270(5238):898. Comment on: Science 1995 Jul 21;269(5222):341–6.

Discrete clutch sizes, local mate competition, and the evolution of precise sex allocation. Nagelkerke CJ. **Theor Popul Biol** 1996 Jun;49(3):314–43

[Gerontology and an aging population. Reduction in fundamental research] [editorial] Goedhard WJ. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):195–6 **(Dut)**

[Value of population approach in the study of pharmacokinetic variability in pediatrics] Burtin P, et al. **Arch Pediatr** 1996;3 Suppl 1:239s–241s **(Fre)**

[Effect of solar and geomagnetic activity on population dynamics among residents of Russia] Zaitseva SA, et al. **Biofizika** 1995 Jul–Aug;40(4):861–4 (Eng. Abstr.) **(Rus)**

[Immunoreactivity of Clethrionomys species voles at various phases of the population cycle] Moshkin MP, et al. **Dokl Akad Nauk** 1995 Nov;345(2):280–2 **(Rus)**

POPULATION EXPLOSION see POPULATION GROWTH

POPULATION GROWTH

Human population growth: local dynamics—global effects. Dochy F. **Acta Biotheor** 1995 Sep;43(3):241–7

The growth in the US uninsured population: trends in Hispanic subgroups, 1977 to 1992. Berk ML, et al. **Am J Public Health** 1996 Apr;86(4):572–6

Contemplating a one child world [editorial] [see comments] McMichael AJ. **BMJ** 1995 Dec 23–30;311(7021):1651–2. Comment in: BMJ 1996 Apr 6;312(7035):907. Comment in: BMJ 1996 Apr 6;312(7035):907–8.

After Cairo [letter; comment] Bonnici JL. **Br J Obstet Gynaecol** 1996 Jan;103(1):91; discussion 92–3 . Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):436–8.

After Cairo [letter; comment] Kelly J. **Br J Obstet Gynaecol** 1996 Jan;103(1):91–3. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):436–8.

The cost of living [news] **Environ Health Perspect** 1995 Sep; 103(9):787–8

What more of us means. Clay R. **Environ Health Perspect** 1995 Dec;103(12):1092–5

Elderly demographic profiles of U.S. states: impacts of "new elderly births," migration, and immigration. Frey WH. **Gerontologist** 1995 Dec;35(6):761–70

Family policies for an aging society: moving to the twenty-first century. Moen P, et al. **Gerontologist** 1995 Dec;35(6):825–30

Big cities, small targets [editorial] **Lancet** 1996 Jun 15; 347(9016):1637

Redefining the unacceptable [see comments] Last J. **Lancet** 1995 Dec 23–30;346(8991–8992):1642–3. Comment in: Lancet 1996 Mar 2;347(9001):621.

Lumped-density population models of pioneer–climax type and stability analysis of Hopf bifurcations. Selgrade JF, et al. **Math Biosci** 1996 Jul 1;135(1):1–21

The need for medical ecology [editorial] Collee J. **Med Confl Surviv** 1996 Jan–Mar;12(1):1–3

Medicine, population and war. Parsons J. **Med Confl Surviv** 1996 Jan–Mar;12(1):23–34

World population day [editorial] Caldwell JC. **Med J Aust** 1996 Jul 15;165(2):72–3

The number of segregating sites in expanding human populations, with implications for estimates of demographic parameters. Bertorelle G, et al. **Mol Biol Evol** 1995 Sep; 12(5):887–92

Earth's carrying capacity [letter; comment] Gawne T. **Science** 1995 Nov 10;270(5238):898. Comment on: Science 1995 Jul 21;269(5222):341–6.

Effects of multi-family housing on marital fertility in Iran: population policy implications. Paydarfar AA. **Soc Biol** 1995 Fall–Winter;42(3–4):214–25

Population growth, resources and health: challenges for public health professionals. Martin J. **Soz Praventivmed** 1995;40(5):270–4

Geographic changes in state population growth. Kranczer S. **Stat Bull Metrop Insur Co** 1996 Apr–Jun;77(2):31–5

Bangladesh 1993–94: results from the Demographic and Health Survey. **Stud Fam Plann** 1995 Sep–Oct; 26(5):299–303

Population growth in the 21st century: cause for crisis or celebration? Cleland J. **Trop Med Int Health** 1996 Feb; 1(1):15–26 (22 ref.)

[Fertility] Tica V. **Contracept Fertil Sex** 1996 Mar; 24(3):173–83 (110 ref.) **(Fre)**

[The current and future age structure of women in our society] Heinrich R. **Arch Gynecol Obstet** 1995; 257(1–4):76–82 **(Ger)**

[Geriatrics, a social medicine challenge] Schettler G. **Versicherungsmedizin** 1996 Jun 1;48(3):90–2 (Eng. Abstr.) **(Ger)**

[Population growth, health and development] Costa e Silva JA. **An R Acad Nac Med (Madr)** 1996;Spec No:97–112 **(Por)**

[A model of the population growth of the Earth] Kapitsa SP. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):111–28 (Eng. Abstr.) **(Rus)**

[From Cairo to Pekin: reflections about a problem involving the whole planet] Poveda J. **Med Clin (Barc)** 1996 Jun 1; 107(1):26–8 **(Spa)**

POPULATION SIZE see POPULATION DENSITY

POPULATION SURVEILLANCE

The Australian Capital Territory Injury Surveillance and Prevention Project. McClure RJ, et al. **Acad Emerg Med** 1995 Jun;2(6):529–34

The role of communication in surgical wound infection surveillance [editorial] Mertens R, et al. **Acta Chir Belg** 1996 Feb;96(1):1–2

Surgical wound infection surveillance: results from the Belgian hospital network. Ronveaux O, et al. **Acta Chir Belg** 1996 Feb;96(1):3–10

To what extent is female alcohol dependence and abuse known in the health care system? The use of multi-source information in a Swedish population survey. Spak F. **Acta Psychiatr Scand** 1996 Feb;93(2):87–91

The Health of the Nation target on syringe sharing: a role for routine surveillance in assessing progress and targeting interventions. Durante AJ, et al. **Addiction** 1995 Oct; 90(10):1389–96

HIV saliva test for surveillance and surveys [letter] Wongba C, et al. **AIDS** 1995 Sep;9(9):1104–5

Trends in the AIDS epidemic among men who reported sex with men in New York City: 1981–1993. Fordyce EJ, et al. **AIDS Educ Prev** 1995;7(5 Suppl):3–12

Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. Morris M, et al. **AIDS Educ Prev** 1995;7(5 Suppl):24–35

Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis [see comments] Bernstein CN, et al. **Am J Gastroenterol** 1995 Dec;90(12):2106–14. Comment in: Am J Gastroenterol 1995 Dec;90(12):2090–2. Comment in: Am J Gastroenterol 1996 Jul;91(7):1472–3.

Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? [editorial; comment] Cohen RD, et al. **Am J Gastroenterol** 1995 Dec;90(12):2090–2. Comment on: Am J Gastroenterol 1995 Dec;90(12):2106–14.

Re: Bernstein et al: surveillance colonoscopy in ulcerative colitis [letter; comment] Lashner BA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1472–3. Comment on: Am J Gastroenterol 1995 Dec;90(12):2106–14.

Principles of screening and surveillance. Parsonnet J, et al. **Am J Gastroenterol** 1996 May;91(5):847–9

The role of surveillance in the hierarchy of prevention. Halperin WE. **Am J Ind Med** 1996 Apr;29(4):321–3

Breast cancer surveillance: ambulatory care focus in residency may influence practice patterns. Borum ML. **Am J Med Sci** 1996 Sep;312(3):123–5

Lifetime and five-year prevalence of homelessness in the United States: new evidence on an old debate. Link B, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):347–54

Extent of undiagnosed HIV infection in hospitalized patients: assessment by linkage of seroprevalence and surveillance methods. Trepka MJ, et al. **Am J Prev Med** 1996 May–Jun; 12(3):195–202

Semiautomated method for the quantitation of plasma or sera androstenedione, testosterone, and dihydrotestosterone in population studies. Walker VR, et al. **Anal Biochem** 1996 Feb 15;234(2):194–203

Diabetes mellitus, race, and socioeconomic status. A population-based study. Brancati FL, et al. **Ann Epidemiol** 1996 Jan;6(1):67–73

Using administratively collected hospital discharge data for AIDS surveillance. Payne SM, et al. **Ann Epidemiol** 1995 Sep;5(5):337–46

Federal scene. Introducing Annals of Epidemiology Federal scene section. Snider DE, et al. **Ann Epidemiol** 1996 Jan; 6(1):1–3

Reproducibility of the women's module of the Behavioral Risk Factor Surveillance System questionnaire. Stein AD, et al. **Ann Epidemiol** 1996 Jan;6(1):47–52

Lyme disease surveillance in Maryland, 1992. Steinberg SH, et al. **Ann Epidemiol** 1996 Jan;6(1):24–9

Inhalation accidents reported to the SWORD surveillance project 1990–1993. Sallie B, et al. **Ann Occup Hyg** 1996 Apr;40(2):211–21

Surveillance after curative colon cancer resection: practice patterns of surgical subspecialists [see comments] Virgo KS, et al. **Ann Surg Oncol** 1995 Nov;2(6):472–82. Comment in: Ann Surg Oncol 1995 Nov;2(6):467–8.

Haemophilus influenzae type b disease in the western region of The Gambia: background surveillance for a vaccine efficacy trial. Adegbola RA, et al. **Ann Trop Paediatr** 1996 Jun;16(2):103–11

Half of physicians are unaware of surveillance system for Creutzfeldt-Jakob disease [letter] Franks A, et al. **BMJ** 1996 May 25;312(7042):1358

Data on birth weight in developing countries: can surveys help? Boerma JT, et al. **Bull World Health Organ** 1996; 74(2):209–16

Evaluation of immunization coverage by lot quality assurance sampling compared with 30-cluster sampling in a primary health centre in India. Singh J, et al. **Bull World Health Organ** 1996;74(3):269–74

Surveillance of congenital rubella syndrome and other rubella-associated adverse pregnancy outcomes. **Can Commun Dis Rep** 1996 Mar 1;22(5):35–7

How tumor stage affects surgeons' surveillance strategies after colon cancer surgery. Johnson FE, et al. **Cancer** 1995 Oct 15;76(8):1325–9

Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Cannan CR, et al. **Circulation** 1995 Nov 1;92(9):2488–95

Legionnaires' disease surveillance: England and Wales 1994. Joseph CA, et al. **Commun Dis Rep CDR Rev** 1995 Nov 10;5(12):R180–3

British Paediatric Association Surveillance Unit: ninth annual report. **Commun Dis Rep CDR Wkly** 1996 Feb 2;6(5):37

Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Bassères N, et al. **Dermatology** 1995;191(3):199–203

Surveillance of mortality and cancer incidence among Swedish graphite electrode workers. Gustavsson P, et al. **Environ Res** 1995 Jul;70(1):7–10

The role of heightened surveillance in an outbreak of Escherichia coli O157.H7. Roberts CL, et al. **Epidemiol Infect** 1995 Dec;115(3):447–54

Counting isn't easy [editorial] Feinleib M. **Epidemiology** 1995 Jul;6(4):343–5

Life expectancy in four U.S. racial/ethnic populations: 1990. Hahn RA, et al. **Epidemiology** 1995 Jul;6(4):350–5

Completeness of AIDS reporting and quality of AIDS death certification in Tuscany (Italy): a linkage study between surveillance system of cases and death certificates. Barchielli A, et al. **Eur J Epidemiol** 1995 Oct;11(5):513–7

Validation of the surveillance system for new cases of tuberculosis in a province of northern Italy. Varese Tuberculosis Study Group. Migliori GB, et al. **Eur Respir J** 1995 Aug;8(8):1252–8

Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Berchuck A, et al. **Gynecol Oncol** 1995 Oct;59(1):20–4

Estimation of adult HIV prevalence as of the end of 1994 in India. Anthony B, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):79–85

Sexually transmitted disease services in Madras: could their role in AIDS prevention be strengthened? Kantharaj K, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):93–9

Process of implementation of National Iodine Deficiency Disorders Control Programme activities in Himachal Pradesh, India. Kapil U, et al. **Indian J Public Health** 1995 Oct–Dec;39(4):172–5

Indicators to monitor progress of National Iodine Deficiency Disorders Control Programme (NIDDCP) and some observations on iodised salt in west Bengal. Kumar S. **Indian J Public Health** 1995 Oct–Dec;39(4):141–7

Rijiv Gandhi mission for the elimination of IDD in Madhya Pradesh. Shukla A. **Indian J Public Health** 1995 Oct–Dec; 39(4):152–9

National Iodine Deficiency Disorders Control Programme in India. Tiwari BK, et al. **Indian J Public Health** 1995 Oct–Dec;39(4):148–51

Recorded criteria as a "gold standard" for sensitivity and specificity estimates of surveillance of nosocomial infection: a novel method to measure job performance. Ehrenkranz NJ, et al. **Infect Control Hosp Epidemiol** 1995 Dec; 16(12):697–702

Population laboratories and health needs assessment. Clarke M. **Int J Epidemiol** 1995;24 Suppl 1:S65–8 (26 ref.)

Global self-ratings of health and mortality: hazard in the North Carolina Piedmont. Hays JC, et al. **J Clin Epidemiol** 1996 Sep;49(9):969–79

Coronary events in Khartoum, Sudan. Khalil SI, et al. **J Clin Epidemiol** 1996 Sep;49(9):1013–6

Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. Roberts JD, et al. **J Clin Epidemiol** 1996 Jan;49(1):51–8

Early childhood surveillance of developmental disorders by a birth defects surveillance system: methods, prevalence comparisons, and mortality patterns. Kirby RS, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):318–26

Surveillance system of infectious diseases in Japan. Ohshiro H, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S81–5

Importance of participation rate in sampling of data in population based studies, with special reference to bone mass in Sweden. Düppe H, et al. **J Epidemiol Community Health** 1996 Apr;50(2):170–3

Colorectal cancer: the role of screening and surveillance. Westergaard H. **J Investig Med** 1996 Jun;44(5):216–27 (104 ref.)

Quarterly Communicable Disease Review April to June 1995. From the PHLS Communicable Disease Surveillance Centre. Adak B, et al. **J Public Health Med** 1995 Dec; 17(4):484–9

Survey of knowledge of and awareness about melanoma—United States, 1995. From the Center for Disease Control and Prevention. **JAMA** 1996 May 22–29; 275(20):1537–8

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Mar 27;275(12):902

Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. Pirkle JL, et al. **JAMA** 1996 Apr 24;275(16):1233–40

Utility of emergency, telephone-based national surveillance for Hantavirus pulmonary syndrome. Hantavirus Task Force. Tappero JW, et al. **JAMA** 1996 Feb 7; 275(5):398–400

Surveillance for neonatal tetanus in high-risk areas [letter] Aylward RB, et al. **Lancet** 1996 Mar 9;347(9002):690–1

Increasing multiple myeloma mortality rates in the elderly: demonstration of increasing dependency with increasing age upon age group population size. Riggs JE. **Mech Ageing Dev** 1995 Jul 14;81(2–3):131–8

Measuring the health of the population. Cohen MM, et al. **Med Care** 1995 Dec;33(12 Suppl):DS21–42

Data and information requirements for determining veterans' access to health care. Smith ME, et al. **Med Care** 1996 Mar;34(3 Suppl):MS45–54

Managing HIV. Part 8: Controlling an epidemic. 8.6 Epidemiological surveillance for HIV and AIDS. Kaldor JM, et al. **Med J Aust** 1996 Sep 2;165(5):268–71

A computer system for epidemiological surveillance. Comas T, et al. **Medinfo** 1995;8 Pt 1:482

Comments on POPULIS. 1. Without universal coverage, health care use data do not provide population health [comment] Greenfield L. **Milbank Q** 1996;74(1):33–6. Comment on: Milbank Q 1996;74(1):3–31.

Prevalence of spina bifida at birth—United States, 1983–1990: a comparison of two surveillance systems. Lary JM, et al. **MMWR CDC Surveill Summ** 1996 Apr 19;45(2):15–26

National surveillance for infectious diseases, 1995. **MMWR Morb Mortal Wkly Rep** 1995 Oct 6;44(39):737–9

Establishment of a national surveillance program for antimicrobial resistance in Salmonella. **MMWR Morb Mortal Wkly Rep** 1996 Feb 9;45(5):110–1

Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. **MMWR Morb Mortal Wkly Rep** 1996 Feb 16;45(RR-1 Suppl):1–20

Survey of knowledge of and awareness about melanoma—United States, 1995. **MMWR Morb Mortal Wkly Rep** 1996 May 3;45(17):346–9

...but new plans for surveillance are still being proposed [news] Fox JL. **Nat Med** 1996 Jul;2(7):733

Plague in India. Ramalingaswami V. **Nat Med** 1995 Dec; 1(12):1237–9

Target populations and interventions in prevention research: what is high risk? Pentz MA. **NIDA Res Monogr** 1994; 139:75–93 (32 ref.)

Enzyme immunoassays for total and allergen specific IgE in population studies. Doekes G, et al. **Occup Environ Med** 1996 Jan;53(1):63–70

Medical monitoring: can we do better? Ellis J. **Occup Health Saf** 1996 May;65(5):19, 25

A systematic approach to health surveillance in the workplace [see comments] Bell JG, et al. **Occup Med (Oxf)** 1995 Dec;45(6):305–10. Comment in: Occup Med (Oxf) 1996 Jun;46(3):245–6.

Autism in Angelman syndrome: a population-based study. Steffenburg S, et al. **Pediatr Neurol** 1996 Feb;14(2):131–6

Comparison of cancer deaths in England and Wales and the developed world by age and gender 1973–92, and, new malignancies in England and Wales 1971–88. Pritchard C, et al. **Public Health** 1996 Jan;110(1):49–59

The need for epidemic intelligence. Bloch AB, et al. **Public Health Rep** 1996 Jan–Feb;111(1):26–31; discussion 32–3 (57 ref.)

Birth defects surveillance and the future of public health. Hanson JW. **Public Health Rep** 1995 Nov–Dec; 110(6):698–9

Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis. Safa AA, et al. **Radiology** 1996 Jun;199(3):653–7

A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas. The Funen Adenoma Follow-up Study. Jørgensen OD, et al. **Scand J Gastroenterol** 1995 Jul; 30(7):686–92

Acute severe low back pain. A population-based study of prevalence and care-seeking. Carey TS, et al. **Spine** 1996 Feb 1;21(3):339–44

Analysing geographically-related disease data [editorial] Cliff AD. **Stat Methods Med Res** 1995 Jun;4(2):93–101

Review of the Wisconsin DHSS report on health concerns attributed to reformulated gasoline use in southeastern Wisconsin [editorial] Rudo K. **Toxicol Ind Health** 1995 Sep–Oct;11(5):463–6 (3 ref.)

Influenza. **Wkly Epidemiol Rec** 1995 Dec 8;70(49):348–350 **(Eng, Fre)**

Arbovirus surveillance. **Wkly Epidemiol Rec** 1995 Nov 17; 70(46):329–31 **(Eng, Fre)**

Ebola haemorrhagic fever. **Wkly Epidemiol Rec** 1995 Aug 25;70(34):241–2 **(Eng, Fre)**

[Role of regional health observation posts: structure, operation, actions] Garros B. **Bull Acad Natl Med** 1995 May;179(5):941–8; discussion 949–50 (Eng. Abstr.) **(Fre)**

[The role of general practitioners in post-occupational health care in an industrial area] Chau N, et al. **Cah Sociol Demogr Med** 1995 Jan–Mar;35(1):33–51 **(Fre)**

["Health in France": the merits of one report (editorial)] Ducimetière P. **Rev Epidemiol Sante Publique** 1995 Dec; 43(6):517 **(Fre)**

[Nosocomial infections in Germany—assessment and prevention. NIDEP Study, I: On prevalence in surgery] Kampf G, et al. **Chirurg** 1996 Jun;67(6):637–42 (Eng. Abstr.) **(Ger)**

[Trends in alcohol consumption in Switzerland from 1975–1992] Schmid H, et al. **Schweiz Med Wochenschr** 1996 Jun 22;126(25):1099–106 (Eng. Abstr.) **(Ger)**

[The surveillance of voluntary interruptions of pregnancy in Umbria] Bellini P, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):112–4 **(Ita)**

[The surveillance of reproductive health in the work environment] Ciani Passeri A, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):186–90 **(Ita)**

[Infections due to central catheterizations in a cardiac intensive care unit: an evaluation of 6 months of continuous surveillance. The nursing personnel of a cardiac intensive care unit] Mazzoli S, et al. **G Ital Cardiol** 1995 Aug; 25(8):991–8 (Eng. Abstr.) **(Ita)**

[A nation-wide surveillance of pathogen in elderly patients with urinary tract infections. 1st Report: Distribution of pathogen] Kumazawa J, et al. **Kansenshogaku Zasshi** 1995 Jul;69(7):790–6 (Eng. Abstr.) **(Jpn)**

[A nation-wide surveillance of pathogen in elderly patients with urinary tract infections. 2nd Report: Sensitivities of pathogen for oral antibacterial agents] Kumazawa J, et al. **Kansenshogaku Zasshi** 1995 Jul;69(7):797–810 (Eng. Abstr.) **(Jpn)**

[Trend of tuberculosis among young people observed from data of nationwide surveillance system] Tokudome O. **Kekkaku** 1995 Sep;70(9):525–36 (Eng. Abstr.) **(Jpn)**

[Analysis of cause of recent rise in number of foreigners reported to HIV/AIDS surveillance in Japan] Kihara M, et al. **Nippon Koshu Eisei Zasshi** 1995 Aug;42(8):569–78 (Eng. Abstr.) **(Jpn)**

[Use of unified methods in microbiologic monitoring of penicillin resistance in Pneumococcus] Shevchuk MS, et al. **Antibiot Khimioter** 1995 Aug;40(8):46–9 (Eng. Abstr.) **(Rus)**

[Population monitoring of the physical development of the pediatric population] Iampol'skaia IuA. **Gig Sanit** 1996 Jan–Feb;(1):24–6 **(Rus)**

[The Epidemiological Health Surveillance Center of the Ministry of Defense of the Russian Federation under the reform of the military medical service] Masalin IuM. **Voen Med Zh** 1996 Jan;317(1):45–7 **(Rus)**

[The epidemiological surveillance of natural-focus infections in medical service practice] Repetilo BA, et al. **Voen Med Zh** 1995 Jul;(7):28–31 **(Rus)**

[The epidemiological health surveillance of the working conditions for servicemen in weapons and military equipment parks] Sergeev SM. **Voen Med Zh** 1995 Oct; (10):59–62 **(Rus)**

[The missions of the medical service of the Army and Navy in accomplishing epidemiological health surveillance in support of radiation safety] Shishkanov AP, et al. **Voen Med Zh** 1995 Jul;(7):22–4 **(Rus)**

[The epidemiological surveillance of hospital infections linked to methicillin-resistant Staphylococcus aureus] Musina LT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):64–7 (Eng. Abstr.) **(Rus)**

[Epidemiological surveillance of homicides and suicides. A report on the Cali workshop] **Bol Oficina Sanit Panam** 1996 Apr;120(4):316–24 (Eng. Abstr.) **(Spa)**

[Poliomyelitis and acute flaccid paralysis. Perspectives for its epidemiologic surveillance] Montesano-Castellanos R, et al. **Gac Med Mex** 1995 Jan–Feb;131(1):113–6 **(Spa)**

[Surveillance without surnames: dream or reality (letter)] de Mateo S, et al. **Gac Sanit** 1995 Jul–Aug;9(49):276–8 **(Spa)**

[Epidemiologic surveillance system for reportable diseases at the hospital] Martínez JL, et al. **Gac Sanit** 1995 Sep–Oct; 9(50):295–301 (Eng. Abstr.) **(Spa)**

[An evaluation of the epidemiological surveillance system for infectious diseases in the Barcelona Olympic Games of 1992] Pañella H, et al. **Gac Sanit** 1995 Mar–Apr; 9(47):84–90 (Eng. Abstr.) **(Spa)**

[The epidemiological situation of dengue in America. The challenges for its surveillance and control] Clark GG. **Salud Publica Mex** 1995;37 Suppl:S5–11 (Eng. Abstr.) **(Spa)**

[The epidemiological surveillance of dengue in Mexico] Montesano-Castellanos R, et al. **Salud Publica Mex** 1995; 37 Suppl:S64–76 (Eng. Abstr.) **(Spa)**

METHODS

Hospital-based surveillance and emerging patterns of HIV transmission. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA) [letter] De Chabalier F, et al. **AIDS** 1996 May;10(5):551–2

Where's the virus? Monitoring current HIV transmission patterns [letter] Sorvillo F, et al. **AIDS** 1996 May; 10(5):552–3

Assessment of surveillance for meningococcal disease in New York State, 1991. Ackman DM, et al. **Am J Epidemiol** 1996 Jul 1;144(1):78–82

Relations of changes in coronary disease rates and changes in risk factor levels: methodological issues and a practical example. Dobson A, et al. **Am J Epidemiol** 1996 May 15; 143(10):1025–34

Tracking strategies involving fourteen sources for locating a transient study sample: parents of sudden infant death syndrome infants and control infants. Klonoff-Cohen H. **Am J Epidemiol** 1996 Jul 1;144(1):98–101

Comment: Toward a coordinated system for the surveillance of environmental health hazards [see comments] Hertz-Picciotto I. **Am J Public Health** 1996 May; 86(5):638–41. Comment in: Am J Public Health 1996 May;86(5):624–5. Comment in: Am J Public Health 1996 May;86(5):633–8.

Toward a holistic approach to public health surveillance [editorial; comment] Levy BS. **Am J Public Health** 1996 May;86(5):624–5. Comment on: Am J Public Health 1996 May;86(5):625–7. Comment on: Am J Public Health 1996 May;86(5):633–8. Comment on: Am J Public Health 1996 May;86(5):638–41.

Tuberculosis surveillance in the United States: case definitions used by state health departments. McCombs SB, et al. **Am J Public Health** 1996 May;86(5):728–31

From disease surveillance to the surveillance of risk factors [see comments] Morabia A. **Am J Public Health** 1996 May; 86(5):625–7. Comment in: Am J Public Health 1996 May;86(5):624–5.

Surveillance in environmental public health: issues, systems, and sources [see comments] Thacker SB, et al. **Am J Public Health** 1996 May;86(5):633–8 (51 ref.). Comment in: Am J Public Health 1996 May;86(5):624–5. Comment in: Am J Public Health 1996 May;86(5):638–41.

The surveillance of birth defects: the usefulness of the revised US standard birth certificate. Watkins ML, et al. **Am J Public Health** 1996 May;86(5):731–4

Evaluation of the emergency department logbook for population-based surveillance of firearm-related injury. Coben JH, et al. **Ann Emerg Med** 1996 Aug;28(2):188–93

Method to electronically collect emergency department data. Schootman M, et al. **Ann Emerg Med** 1996 Aug;28(2):213–9

Development of an emergency department-based injury surveillance system. Williams JM, et al. **Ann Emerg Med** 1996 Jan;27(1):59–65

Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ives DG, et al. **Ann Epidemiol** 1995 Jul;5(4):278–85

A connective tissue disease screening questionnaire for population studies. Karlson EW, et al. **Ann Epidemiol** 1995 Jul;5(4):297–302

The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)

Monitoring cardiovascular disease in Zimbabwe: a review of needs and options. Razum O. **Cent Afr J Med** 1996 Apr; 42(4):120–4 (23 ref.)

The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994. **Commun Dis Rep CDR Rev** 1996 Jan 5;6(1):R1–21

Influenza surveillance in England and Wales: October 1994 to June 1995. Hutchinson EJ, et al. **Commun Dis Rep CDR Rev** 1995 Dec 8;5(13):R200–4

What does morbidity have to do with disability? Chamie M. **Disabil Rehabil** 1995 Oct;17(7):323–37

The Canadian database on disability issues: a national application of the ICIDH. Furrie AD. **Disabil Rehabil** 1995 Oct;17(7):344–9

Croatian initial experience with the suitability of the ICIDH for classifying health status. Strnad M, et al. **Disabil Rehabil** 1995 Oct;17(7):364–8

Use of geographic information systems in epidemiology (GIS-Epi). **Epidemiol Bull** 1996 Mar;17(1):1–6

The role of surveillance after infrainguinal bypass grafting. Giannoukas AD, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):279–89 (107 ref.)

Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Reddoch JM, et al. **Gynecol Oncol** 1995 Nov;59(2):221–5

The evolution of targeted populations in a school-based tuberculin testing program. Denison AV, et al. **Image J Nurs Sch** 1995 Winter;27(4):263–6

A comparison of a 30-cluster survey method used in India and a purposive method in the estimation of immunization coverages in Tamil Nadu. Murthy BN, et al. **Indian Pediatr** 1995 Jan;32(1):129–35

The computer-based patient record: the role of the hospital epidemiologist. Classen DC, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):729–36 (32 ref.)

Surveillance of antibiotic resistance: learning to live with bias [editorial; comment] Gaynes R. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):623–6. Comment on: Infect Control Hosp Epidemiol 1995 Nov;16(11):638–41.

Surgical site infections: simplifying the definitions. Gurevich I. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):667–8

The need for surveillance for antimicrobial resistance [see comments] Lorian V. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):638–41. Comment in: Infect Control Hosp Epidemiol 1995 Nov;16(11):623–6.

A not quite as quick but much cleaner alternative to the Expanded Programme on Immunization (EPI) Cluster Survey design. Turner AG, et al. **Int J Epidemiol** 1996 Feb;25(1):198–203

A qualitative evaluation of the post accident notification system to health visitors. Reynolds L. **J Adv Nurs** 1996 Jan;23(1):97–105

Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. White AD, et al. **J Clin Epidemiol** 1996 Feb;49(2):223–33

Major chemical incidents—a response, the role of the Consultant in Communicable Disease Control and the case of need for a national surveillance-resource centre. Ayres PJ. **J Public Health Med** 1995 Jun;17(2):164–70

Pilot study of the introduction of the J95 health data collection system. Jefferson TO, et al. **J R Army Med Corps** 1996 Feb;142(1):25–9

Comparison of accident and emergency with police road injury data. Cercarelli LR, et al. **J Trauma** 1996 May; 40(5):805–9

An experimental network of general practitioners for purposes of epidemiological surveillance in Italy. Mariotti

S, et al. **Medinfo** 1995;8 Pt 2:1533–4
Population health and health care use: an information system for policy makers [see comments] Roos NP, et al. **Milbank Q** 1996;74(1):3–31. Comment in: Milbank Q 1996;74(1):3–31. Comment in: Milbank Q 1996;74(1):37–41.
Enzyme immunoassays for total and allergen specific IgE in population studies. Doekes G, et al. **Occup Environ Med** 1996 Jan;53(1):63–70
Using census information to estimate GP practice morbidity. Buckingham K. **Public Health** 1996 May;110(3):191–5
Surveillance for fetal alcohol syndrome in Colorado. Miller LA, et al. **Public Health Rep** 1995 Nov–Dec;110(6):690–7
Tuberculosis surveillance using death certificate data, New York City, 1992. Washko RM, et al. **Public Health Rep** 1996 May–Jun;111(3):251–5
Detecting induced abortions from reports of pregnancy terminations in DHS calendar data. Magnani RJ, et al. **Stud Fam Plann** 1996 Jan–Feb;27(1):36–43
Maternal mortality in Kwazulu/Natal: need for an information database system and confidential enquiry into maternal deaths in developing countries. Moodley D, et al. **Trop Doct** 1996 Apr;26(2):50–4
Evaluation and monitoring of action on alcohol. Targets, indicators and monitoring and reporting systems for action on alcohol. Anderson P, et al. **WHO Reg Publ Eur Ser** 1995;59:1–89
Linkage of health workers' records: example of estimating perinatal mortality rates [letter] Singh A, et al. **World Health Forum** 1996;17(3):295–6
[Difficulties in the realization and implementation of a national survey on the Annual Risk of Tuberculosis Infection in Madagascar] Ranaivoson G, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):65–7 (Eng. Abstr.) **(Fre)**
[Public health surveillance and the environment] Quénel P. **Rev Epidemiol Sante Publique** 1995;43(5):412–22 (38 ref.) (Eng. Abstr.) **(Fre)**
[Entomological surveillance in Mauritius] Gopaul R. **Sante** 1995 Nov–Dec;5(6):401–5 (Eng. Abstr.) **(Fre)**
[Intra-urban mortality by vascular diseases: a small scale ecological approach] Veillette S, et al. **Union Med Can** 1995 Sep;124(2):27–36 **(Fre)**
[Improvement in microbiological studies to objectivize epidemiological health surveillance] Maksimov AN, et al. **Voen Med Zh** 1995 Jul;(7):51–4 **(Rus)**

PORCELAIN see **DENTAL PORCELAIN**

PORCELAIN-METAL ALLOYS see **METAL CERAMIC ALLOYS**

PORCINE CIRCOVIRUS see **CIRCOVIRUS**

PORCINE ENTEROVIRUSES see **ENTEROVIRUSES, PORCINE**

PORCINE GASTROENTERITIS, TRANSMISSIBLE see **GASTROENTERITIS, TRANSMISSIBLE, OF SWINE**

PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS see **CORONAVIRUS**

PORCINE INFLUENZA VIRUS TYPE A see **ORTHOMYXOVIRUS TYPE A, PORCINE**

PORCINE TRANSMISSIBLE GASTROENTERITIS VIRUS see **GASTROENTERITIS VIRUS, PORCINE TRANSMISSIBLE**

PORCINE XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

PORCINE XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

PORCUPINES see **RODENTIA**

PORE PROTEINS see **PORINS**

PORFIROMYCIN

PHARMACOLOGY

Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin. Sartorelli AC, et al. **Adv Enzyme Regul** 1995;35:117–30

TOXICITY

Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Belcourt MF, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):456–60

PORGIES see **PERCIFORMES**

PORIFERA

Three more cyclotheonamides, C, D, and E, potent thrombin inhibitors from the marine sponge Theonella swinhoei. Nakao Y, et al. **Bioorg Med Chem** 1995 Aug;3(8):1115–22
Bioactive alkaloids from the tropical marine sponge Axinella carteri. Supriyono A, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):669–74

CHEMISTRY

Exact mass determination for elemental analysis of ions produced by matrix-assisted laser desorption. Wu J, et al. **Anal Chem** 1995 Oct 15;67(20):3788–92
Marine natural products. XXXVI. Biologically active polyacetylenes, adociacetylenes A, B, C, and D, from an Okinawan Marine sponge of Adocia sp. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):720–4
Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1598–600
Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp. Peppard JV, et al. **J Biol Chem** 1996 Mar 29;271(13):7281–4
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp. Concepción GP, et al. **J Med Chem** 1995 Oct 27; 38(22):4503–7
Further brominated bis- and tris-indole alkaloids from the deep-water New Caledonian marine sponge Orina Sp. Bifulco G, et al. **J Nat Prod** 1995 Aug;58(8):1254–60
Cacospongionolide B, a new sesterterpene from the sponge Fasciospongia cavernosa. De Rosa S, et al. **J Nat Prod** 1995 Nov;58(11):1776–80
Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. Fu X, et al. **J Nat Prod** 1995 Sep;58(9):1384–91
Mechanism-based antitumor screening of Caribbean marine organisms: isolation and structure determination of novel diterpenoids from the gorgonian Eunicea tourneforti. Govindan M, et al. **J Nat Prod** 1995 Aug;58(8):1174–84
Antitumor activity and stereochemistry of acetylenic alcohols from the sponge Cribrochalina vasculum. Hallock YF, et al. **J Nat Prod** 1995 Dec;58(12):1801–7
Cytotoxic compounds from a two-sponge association. Jung JH, et al. **J Nat Prod** 1995 Nov;58(11):1722–6
Cytotoxicity and mode of action of aeroplysinin-1 and a related dienonefrom the sponge Aplysina aerophoba. Koulman A, et al. **J Nat Prod** 1996 Jun;59(6):591–4
Halistanol disulfate B, a novel sulfated sterol from the sponge Pachastrella sp.: inhibitor of endothelin converting enzyme. Patil AD, et al. **J Nat Prod** 1996 Jun;59(6):606–8
Sodwanones G, H, and I, new cytotoxic triterpenes from a marine sponge. Rudi A, et al. **J Nat Prod** 1995 Nov; 58(11):1702–12
Globostellatic acids A–D, new cytotoxic isomalabaricane triterpenes from the marine sponge Stelletta globostellata. Ryu G, et al. **J Nat Prod** 1996 May;59(5):512–4
Three new cytotoxic sesterterpenes from the marine sponge Hyrtios cf. erectus. Ryu G, et al. **J Nat Prod** 1996 May; 59(5):515–7
New azacyclopropene derivatives from Dysidea fragilis collected in Pohnpei. Salomon CE, et al. **J Nat Prod** 1995 Sep;58(9):1463–6
Makaluvamines H–M and damirone C from the pohnpeian sponge Zyzzya fuliginosa. Schmidt EW, et al. **J Nat Prod** 1995 Dec;58(12):1861–7
Naturally occurring somatostatin and vasoactive intestinal peptide inhibitors. Isolation of alkaloids from two marine sponges. Vassas A, et al. **Planta Med** 1996 Feb;62(1):28–30
New cytotoxic steroids from the marine sponge Dysidea fragilis coming from the lagoon of Venice. Aiello A, et al. **Steroids** 1995 Oct;60(10):666–73
Sterols from the Caribbean sponge Neofibularia nolitangere. Isolation of two novel polyhydroxysteroids. Costantino V, et al. **Steroids** 1995 Nov;60(11):768–72
New polar steroids from the sponges Trachyopsis halichondroides and Cymbastela coralliophila. Makarieva TN, et al. **Steroids** 1995 Apr;60(4):316–20
Structures of nine oxygenated 4-methylene sterols from Hachijo marine sponge Theonella swinhoei. Sugo Y, et al. **Steroids** 1995 Nov;60(11):738–42
Effect of alkaloid toxins from tropical marine sponges on membrane sodium currents. Rentas AL, et al. **Toxicon** 1995 Apr;33(4):491–7

CYTOLOGY

Unusual presence and intranuclear storage of silica crystals in the freshwater sponges Ephydatia muelleri and Spongilla lacustris (Porifera: Spongillidae). Imsiecke G, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Sep;41(6):827–32
Effects of exogenous cAMP on the morphology and behavior of dissociated cells of the sponge Clathrina cerebrum (Porifera, Calcarea). Gaino E, et al. **Eur J Cell Biol** 1996 May;70(1):92–6
Formation of spicules by sclerocytes from the freshwater sponge Ephydatia muelleri in short-term cultures in vitro. Imsiecke G, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul–Aug;31(7):528–35
Cell adhesion in sponges: potentiation by a cell surface 68 kDa proteoglycan-binding protein. Varner JA. **J Cell Sci** 1995 Sep;108 (Pt 9):3119–26

ENZYMOLOGY

Metal content and conformation of the metalloprotease from the marine sponge Spheciospongia vesparia. Arreguín R, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):827–33
The (2'-5')oligoadenylate synthetase is present in the lowest multicellular organisms, the marine sponges. Demonstration of the existence and identification of its reaction products. Kuusksalu A, et al. **Eur J Biochem** 1995 Sep 1;232(2):351–7

METABOLISM

Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A2 activity and some inflammatory responses. Gil B, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):281–8
Two classes of metabolites from Theonella swinhoei are localized in distinct populations of bacterial symbionts. Bewley CA, et al. **Experientia** 1996 Jul 15;52(7):716–22
Isolation of a sponge-derived extracellular matrix adhesion protein. Varner JA. **J Biol Chem** 1996 Jul 5; 271(27):16119–25
Biosynthesis of brominated tyrosine metabolites by Aplysina fistularis. Carney JR, et al. **J Nat Prod** 1995 Jul; 58(7):971–85
Biotransformation of genotoxic agents in marine sponges. Mechanisms and modulation. De Flora S, et al. **Mutagenesis** 1995 Jul;10(4):357–64
Molecular evolution of the Ca(2+)-binding photoproteins of the Hydrozoa. Tsuji FI, et al. **Photochem Photobiol** 1995 Oct;62(4):657–61

MICROBIOLOGY

Two classes of metabolites from Theonella swinhoei are localized in distinct populations of bacterial symbionts. Bewley CA, et al. **Experientia** 1996 Jul 15;52(7):716–22
A psychrophilic crenarchaeon inhabits a marine sponge: Cenarchaeum symbiosum gen. nov., sp. nov. Preston CM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6241–6

PORINS

Porins of Escherichia coli: unidirectional gating by pressure. Le Dain AC, et al. **EMBO J** 1996 Jul 15;15(14):3524–8

ANALYSIS

Porin-type 1 proteins in sarcoplasmic reticulum and plasmalemma of striated muscle fibres. Junankar PR, et al. **J Muscle Res Cell Motil** 1995 Dec;16(6):595–610

BIOSYNTHESIS

Pore-forming activity of Coxiella burnetii outer membrane protein oligomer comprised of 29.5- and 31-kDa polypeptides. Inhibition of porin activity by monoclonal antibodies 4E8 and 4D6. Banerjee-Bhatnagar N, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:378–401
Expression of porin from Rhodopseudomonas blastica in Escherichia coli inclusion bodies and folding into exact native structure. Schmid B, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):111–4
Loss of porins following carbapenem-resistance selection and adherence modification in enterobacteria. Raimondi A, et al. **J Chemother** 1995 Jun;7(3):171–4

CHEMISTRY

Replacement of the sole histidinyl residue in OmpF porin from E. coli by threonine (H21T) does not affect channel structure and function. Saint N, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):118–22
Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75–87 (74 ref.)
PhoE signal peptide inserts into micelles as a dynamic helix-break-helix structure, which is modulated by the environment. A two-dimensional 1H NMR study. Chupin V, et al. **Biochemistry** 1995 Sep 12;34(36):11617–24
Porins: general to specific, native to engineered passive pores. Schulz GE. **Curr Opin Struct Biol** 1996 Aug;6(4):485–90 (61 ref.)
Role of the N- and C-termini of porin in import into the outer membrane of Neurospora mitochondria. Court DA, et al. **FEBS Lett** 1996 Jul 15;390(1):73–7
Purification and refolding of recombinant Haemophilus influenzae type b porin produced in Bacillus subtilis. Dahan D, et al. **FEBS Lett** 1996 Sep 2;392(3):304–8
Expression of porin from Rhodopseudomonas blastica in Escherichia coli inclusion bodies and folding into exact native structure. Schmid B, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):111–4
Isolation and characterization of a conserved porin protein from Helicobacter pylori. Doig P, et al. **J Bacteriol** 1995 Oct;177(19):5447–52
Characterization of a porin from the outer membrane of Vibrio anguillarum. Simón M, et al. **J Bacteriol** 1996 Jul; 178(14):4182–8
Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930–40 (121 ref.)
Heterologous production of the P1 porin of Neisseria meningitidis in bacillus subtilis: the effect of an N-terminal extension on the presentation of native-like epitopes. Muttilainen S, et al. **Microb Pathog** 1995 May;18(5):365–71
Purification, characterization, crystallization, and preliminary X-ray results from Paracoccus denitrificans porin. Hirsch

A, et al. **Proteins** 1995 Oct;23(2):282–4

DIAGNOSTIC USE

[Use of porin from the outer membrane of Yersinia pseudotuberculosis for serodiagnosis of pseudotuberculosis] Novikova OD, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):199–202 **(Rus)**

GENETICS

Altered voltage sensitivity of mutant OmpC porin channels. Bishop ND, et al. **FEBS Lett** 1996 Feb 5;379(3):295–8

Heterologous expression of Escherichia coli porin genes in Salmonella typhi Ty2: regulation by medium osmolarity, temperature and oxygen availability. Contreras I, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1–2):105–11

Identification of the genes in multicopy plasmids affecting ompC and ompF expression in Escherichia coli. Jin T, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):225–31

Aeromonas salmonicida possesses two genes encoding homologs of the major outer membrane protein, OmpA. Costello GM, et al. **J Bacteriol** 1996 Mar;178(6):1623–30

Sequence analysis, expression, and binding activity of recombinant major outer sheath protein (Msp) of Treponema denticola. Fenno JC, et al. **J Bacteriol** 1996 May;178(9):2489–97

Strong function-related homology between the pore-forming colicins K and 5. Pilsl H, et al. **J Bacteriol** 1995 Dec; 177(23):6973–7

Isolation and characterization of the structural gene for OmpL, a pressure-regulated porin-like protein from the deep-sea bacterium Photobacterium species strain SS9. Welch TJ, et al. **J Bacteriol** 1996 Aug;178(16):5027–31

Restriction site polymorphism of the genes encoding the major 25 kDa and 36 kDa outer-membrane proteins of Brucella. Cloeckaert A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2111–21

Lipopolysaccharide and porin of Roseobacter denitrificans, confirming its phylogenetic relationship to the alpha-3 subgroup of Proteobacteria. Neumann U, et al. **Microbiology** 1995 Aug;141 (Pt 8):2013–7

The maintenance of strain structure in populations of recombining infectious agents [see comments] Gupta S, et al. **Nat Med** 1996 Apr;2(4):437–42. Comment in: Nat Med 1996 Apr;2(4):401–3.

IMMUNOLOGY

Immunity to Pseudomonas aeruginosa induced by OprF following intestinal immunization. Cripps AW, et al. **Adv Exp Med Biol** 1995;371B:761–3

Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization. López-Macías C, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:285–8

Immune response to porins isolated from Salmonella typhi in different mouse strains. González CR, et al. **Arch Med Res** 1995;26 Spec No:S99–103

Salmonella-specific monoclonal antibodies against recombinant Salmonella typhi 36-kilodalton porin. Kissel V, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):250–2

The effect of the length of a malarial epitope on its antigenicity and immunogenicity in an epitope presentation system using the Pseudomonas aeruginosa outer membrane protein OprF as the carrier. Wong RS, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):209–14

Production of ScFv antibody fragments following immunization with a phage-displayed fusion protein and analysis of reactivity to surface-exposed epitopes of the protein F of Pseudomonas aeruginosa by cytofluorometry. Kermani P, et al. **Hybridoma** 1995 Aug;14(4):323–8

Interleukin-1 and interleukin-6 gene expression in human monocytes stimulated with Salmonella typhimurium porins. Galdiero M, et al. **Immunology** 1995 Dec;86(4):612–9

Antigenic determinants of the OmpC porin from Salmonella typhimurium. Singh SP, et al. **Infect Immun** 1995 Dec; 63(12):4600–5

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. van der Voort ER, et al. **Infect Immun** 1996 Jul;64(7):2745–51

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. Idänpään-Heikkilä I, et al. **J Med Microbiol** 1995 Nov;43(5):335–43

Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Suker J, et al. **Microbiology** 1996 Jan;142 (Pt 1):63–9

Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Hughes EE, et al. **Vaccine** 1995 Dec; 13(18):1750–3

ISOLATION & PURIFICATION

The porins from the halophilic species Ectothiorhodospira shaposhnikovii and Ectothiorhodospira vacuolata. Wolf E, et al. **Arch Microbiol** 1996 Sep;166(3):169–75

Porins of Vibrio cholerae: purification and characterization of OmpU. Chakrabarti SR, et al. **J Bacteriol** 1996 Jan; 178(2):524–30

Virulent strain associated outer membrane proteins of Borrelia burgdorferi. Skare JT, et al. **J Clin Invest** 1995 Nov;96(5):2380–92

METABOLISM

Replacement of the sole histidinyl residue in OmpF porin from E. coli by threonine (H21T) does not affect channel structure and function. Saint N, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):118–22

Mode of insertion of the signal sequence of a bacterial precursor protein into phospholipid bilayers as revealed by cysteine-based site-directed spectroscopy. Keller RC, et al. **Biochemistry** 1996 Mar 5;35(9):3063–71

Cadaverine induces closing of E. coli porins. delaVega AL, et al. **EMBO J** 1995 Dec 1;14(23):6058–65

Non-bilayer lipids are required for efficient protein transport across the plasma membrane of Escherichia coli. Rietveld AG, et al. **EMBO J** 1995 Nov 15;14(22):5506–13

Influence of the signal sequence and chaperone SecB on the interaction between precursor protein prePhoE and phospholipids. Van Raalte AL, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):207–14

Role of the N- and C-termini of porin in import into the outer membrane of Neurospora mitochondria. Court DA, et al. **FEBS Lett** 1996 Jul 15;390(1):73–7

A peptidoglycan binding domain in the porin-associated protein (PAP) of Rhodospirillum rubrum FR1. Neumann U, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):55–8

The major surface protein complex of Treponema denticola depolarizes and induces ion channels in HeLa cell membranes. Mathers DA, et al. **Infect Immun** 1996 Aug; 64(8):2904–10

Sequence analysis, expression, and binding activity of recombinant major outer sheath protein (Msp) of Treponema denticola. Fenno JC, et al. **J Bacteriol** 1996 May;178(9):2489–97

Porin activity of the native and recombinant outer membrane protein Oms28 of Borrelia burgdorferi. Skare JT, et al. **J Bacteriol** 1996 Aug;178(16):4909–18

The role of specific lysine residues in the passage of anions through the Pseudomonas aeruginosa porin OprP. Sukhan A, et al. **J Biol Chem** 1996 Aug 30;271(35):21239–42

Bacterial resistance to cephalosporins as a function of outer membrane permeability and access to their target. James PA, et al. **J Chemother** 1996 Feb;8 Suppl 2:37–47

Comparison of transient and successful fusion pores connecting influenza hemagglutinin expressing cells to planar membranes. Melikyan GB, et al. **J Gen Physiol** 1995 Nov;106(5):803–19

Direct measurement of the association of a protein with a family of membrane receptors. Evans LJ, et al. **J Mol Biol** 1996 Feb 2;255(4):559–63

Rate constants of sugar transport through two LamB mutants of Escherichia coli: comparison with wild-type maltoporin and LamB of Salmonella typhimurium. Jordy M, et al. **J Mol Biol** 1996 Jun 21;259(4):666–78

Structure of the mosquitocidal delta-endotoxin CytB from Bacillus thuringiensis sp. kyushuensis and implications for membrane pore formation. Li J, et al. **J Mol Biol** 1996 Mar 22;257(1):129–52

Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930–40 (121 ref.)

Protein C (OprC) of the outer membrane of Pseudomonas aeruginosa is a copper-regulated channel protein. Yoneyama H, et al. **Microbiology** 1996 Aug;142 (Pt 8):2137–44

SlyA, a regulatory protein from Salmonella typhimurium, induces a haemolytic and pore-forming protein in Escherichia coli. Ludwig A, et al. **Mol Gen Genet** 1995 Dec 15;249(5):474–86

Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059–66 (84 ref.)

Delta mu H+ dependency of in vitro protein translocation into Escherichia coli inner-membrane vesicles varies with the signal-sequence core-region composition. Nouwen N, et al. **Mol Microbiol** 1996 Mar;19(6):1205–14

The deletion of 70 amino acids near the N-terminal end of the sucrose-specific porin ScrY causes its functional similarity to LamB in vivo and in vitro. Schülein K, et al. **Mol Microbiol** 1995 Aug;17(4):757–67

Probabilistic secretion of quanta at somatic motor-nerve terminals: the fusion-pore model, quantal detection and autoinhibition. Thomson PC, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Aug 29; 349(1328):197–214

Characterization of a new vacuolar membrane aquaporin sensitive to mercury at a unique site. Daniels MJ, et al. **Plant Cell** 1996 Apr;8(4):587–99

Restoration of pore-forming activity in staphylococcal alpha-hemolysin by targeted covalent modification. Walker B, et al. **Protein Eng** 1995 May;8(5):491–5

PHARMACOLOGY

Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. Wetzler LW, et al. **J Exp Med** 1996 Mar 1;183(3):1151–9

Growth hormone modulates IL-alpha and IFN-gamma release by murine splenocytes activated by LPS or porins of Salmonella typhimurium. Sommese L, et al. **J Med Microbiol** 1996 Jul;45(1):40–7

Morphological changes induced in HEp-2 cells by Salmonella typhimurium porins. De Martino L, et al. **J Submicrosc Cytol Pathol** 1995 Oct;27(4):445–9

Effect of LPS and porins on lymphocytes evaluated by calorimetry. Gorga F, et al. **New Microbiol** 1995 Jul; 18(3):331–4

ULTRASTRUCTURE

Direct phasing in protein electron crystallography--phase extension and the prospects for ab initio determinations. Dorset DL. **Acta Crystallogr A** 1996 May 1;52 (Pt 3):480–9

Topology of the membrane protein LamB by epitope tagging and a comparison with the X-ray model. Newton SM, et al. **J Bacteriol** 1996 Jun;178(12):3447–56

PORNOGRAPHY see **EROTICA**

POROKERATOSIS

COMPLICATIONS

Porokeratosis and cutaneous malignancy. A review. Sasson M, et al. **Dermatol Surg** 1996 Apr;22(4):339–42 (30 ref.)

Mutilating lesion in porokeratosis of Mibelli [letter] Kanwar AJ. **Dermatology** 1996;192(2):192

Porokeratosis of Mibelli and HIV-infection. Rodríguez EA, et al. **Int J Dermatol** 1996 Jun;35(6):402–4

CONGENITAL

Linear porokeratosis presenting as erosions in the newborn period. Fisher CA, et al. **Pediatr Dermatol** 1995 Dec; 12(4):318–22

DIAGNOSIS

Giant porokeratosis [letter] Thappa DM, et al. **J Dermatol** 1995 Dec;22(12):964–5

ETIOLOGY

Rapid development of disseminated superficial porokeratosis after transplant induction therapy. Fields LL, et al. **Bone Marrow Transplant** 1995 Jun;15(6):993–5

Disseminated superficial porokeratosis: what is the association with ultraviolet radiation? Ibbotson SH. **Clin Exp Dermatol** 1996 Jan;21(1):48–50

GENETICS

[Mibelli porokeratosis in 2 brothers] Yedomon HG, et al. **Ann Dermatol Venereol** 1996;123(3):171–3 (Eng. Abstr.) **(Fre)**

[Porokeratosis plantaris, palmaris et disseminataa with multiple filiform hyperkeratoses and nail dystrophy] Itin PH. **Hautarzt** 1995 Dec;46(12):869–72 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Disseminated epidermolytic acanthoma with disseminated superficial porokeratosis and verruca vulgaris in an immunosuppressed patient. Chun SI, et al. **J Dermatol** 1995 Sep;22(9):690–2

METABOLISM

Linear porokeratosis with multiple squamous cell carcinomas: study of p53 expression in porokeratosis and squamous cell carcinoma [letter] Sasaki S, et al. **Br J Dermatol** 1996 Jun; 134(6):1151–3

Immunohistochemical detection of p53 tumor suppressor protein in porokeratosis. Urano Y, et al. **J Dermatol** 1996 May;23(5):365–8

PATHOLOGY

Mutilating lesions in porokeratosis of Mibelli. Handa S, et al. **Dermatology** 1995;191(1):62–4

Genital porokeratosis of Mibelli. Neri I, et al. **Genitourin Med** 1995 Dec;71(6):410–1

Destructive facial porokeratosis. Rahbari H, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1049–50 (7 ref.)

Squamous cell carcinoma arising from giant porokeratosis: a case with extensive metastasis and hypercalcemia. Sawai T, et al. **J Am Acad Dermatol** 1996 Mar;34(3):507–9

Linear porokeratosis presenting as erosions in the newborn period. Fisher CA, et al. **Pediatr Dermatol** 1995 Dec; 12(4):318–22

[Linear porokeratosis] Fabrizi G, et al. **Ann Dermatol Venereol** 1995;122(6–7):460 **(Fre)**

POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA see **POROKERATOSIS**

PORP see **OSSICULAR REPLACEMENT PROSTHESIS**

PORPHOBILINOGEN

METABOLISM

Discovery that the assembly of the dipyrromethane cofactor of porphobilinogen deaminase holoenzyme proceeds initially by the reaction of preuroporphyrinogen with the apoenzyme. Shoolingin-Jordan PM, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):373–6

Evidence of an essential lysine in pig liver 5-aminolevulinic

acid dehydratase. Sopena de Kracoff YE, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1331–9

URINE

Is the Watson–Schwartz screening method for porphobilinogen reliable? [letter; comment] Buttery JE. **Clin Chem** 1995 Nov;41(11):1670–1. Comment on: Clin Chem 1995 Feb;41(2):323–4.

PORPHOBILINOGEN AMMONIA-LYASE see **PORPHOBILINOGEN DEAMINASE**

PORPHOBILINOGEN DEAMINASE

ANALYSIS

Yeast porphobilinogen deaminase also forms enzyme–pyrrole intermediates. Correa Garcia S, et al. **Enzyme Protein** 1994–95;48(5–6):275–81

[Porphobilinogen deaminase (PBGD)] Kondo M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:891–4 (21 ref.) **(Jpn)**

BLOOD

Asymptomatic erythrocyte disorder presenting as increased porphobilinogen deaminase and uroporphyrinogen decarboxylase [letter] Anderson KE, et al. **Clin Chem** 1995 Nov;41(11):1670

Heme synthesis in chronic renal failure: the effects of hemodialysis, peritoneal dialysis and erythropoietin treatment. Siersema PD, et al. **Nephron** 1995;71(3):297–302

CHEMISTRY

Porphobilinogen deaminase and uroporphyrinogen III synthase: structure, molecular biology, and mechanism. Shoolingin–Jordan PM. **J Bioenerg Biomembr** 1995 Apr; 27(2):181–95 (111 ref.)

DEFICIENCY

Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Lindberg RL, et al. **Nat Genet** 1996 Feb;12(2):195–9

GENETICS

Acute intermittent porphyria: a single–base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide. Lee GY, et al. **Am J Med Genet** 1995 Aug 28;58(2):155–8

R325X mutation in exon 15 of the hydroxymethylbilane synthase gene identified in two Danish families with acute intermittent porphyria. Petersen NE, et al. **Clin Chem** 1996 Jan;42(1):106–7

Porphobilinogen deaminase gene structure and molecular defects. Deybach JC, et al. **J Bioenerg Biomembr** 1995 Apr; 27(2):197–205 (73 ref.)

Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at –22 bp from the 5' splice site causes skipping of exon 3. Llewellyn DH, et al. **J Med Genet** 1996 May; 33(5):437–8

Detection of four mutations in six unrelated South African patients with acute intermittent porphyria. Ong PM, et al. **Mol Cell Probes** 1996 Feb;10(1):57–61

METABOLISM

Erythrocyte uroporphyrinogen I synthase in rats treated with the hepatic carcinogen diethylnitrosamine. de Calmanovici RW, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(1):49–52

Discovery that the assembly of the dipyrromethane cofactor of porphobilinogen deaminase holoenzyme proceeds initially by the reaction of preuroporphyrinogen with the apoenzyme. Shoolingin–Jordan PM, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):373–6

Yeast porphobilinogen deaminase also forms enzyme–pyrrole intermediates. Correa Garcia S, et al. **Enzyme Protein** 1994–95;48(5–6):275–81

PORPHOBILINOGEN SYNTHASE see **AMINOLEVULINIC ACID DEHYDRATASE**

PORPHYRIA

Proceedings of the Laboratory Medicine '95 11th IFCC European Congress of Clinical Chemistry, Tampere, Finland, 2–7 July 1995 and International Symposium on Porphyrias and Heme–related Disorders: Molecular Basis, Diagnostic, and Clinical Aspects, Helsinki, Finland, 28 June–2 July 1995. Abstracts. **Scand J Clin Lab Invest Suppl** 1995;223:1–165

CHEMICALLY INDUCED

Porphyria, propofol and rats [letter; comment] Gorchein A. **Br J Anaesth** 1996 Jan;76(1):172. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Porphyria, propofol and rats [letter; comment] Tidmarsh MD. **Br J Anaesth** 1996 Jan;76(1):171–2. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Comparative biotransformation of hexachlorobenzene and hexafluorobenzene in relation to the induction of porphyria. Rietjens IM, et al. **Eur J Pharmacol** 1995 Dec 7; 293(4):293–9

CLASSIFICATION

[Porphyrias] Komatsu M. **Ryoikibetsu Shokogun Shirizu** 1995; (8):410–3 (7 ref.) **(Jpn)**

COMPLICATIONS

Epilepsy in porphyria [letter; comment] Reynolds NC Jr. **Neurology** 1996 May;46(5):1497–8. Comment on: Neurology 1995 Mar;45(3 Pt 1):594–5. Comment on: Neurology 1995 Jun;45(6):1216–7.

[Hepato–erythropoietic porphyria] Boudghène–Stambouli O, et al. **Ann Dermatol Venereol** 1995;122(9):615–7 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Angiographic demonstration of reversible cerebral vasospasm in porphyric encephalopathy. Black KS, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1650–2

Diagnosis and serendipity [letter] Miller PR. **Am J Psychiatry** 1995 Oct;152(10):1530

The porphyrias: a brief overview based on 25 years of experience (1969–1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain. Mascaro JM. **J Dermatol** 1995 Nov; 22(11):823–8 (28 ref.)

The diagnosis and follow–up of porphyria. Ratnaike S, et al. **Pathology** 1995 Apr;27(2):142–53 (59 ref.)

Porphyria: reexamination of psychiatric implications. Burgovne K, et al. **Psychother Psychosom** 1995; 64(3–4):121–30 (75 ref.)

DRUG THERAPY

Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Gross U, et al. **Horm Metab Res** 1995 Aug; 27(8):379–83

ENZYMOLOGY

Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at –22 bp from the 5' splice site causes skipping of exon 3. Llewellyn DH, et al. **J Med Genet** 1996 May; 33(5):437–8

ETIOLOGY

delta–Aminolevulinic acid dehydratase deficiency porphyria (ADP) with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a 69–year–old woman. Muraoka A, et al. **Kobe J Med Sci** 1995 Apr;41(1–2):23–31

GENETICS

Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):239–48 (55 ref.)

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

[Diagnostic porphyrinopathies in hereditary hyperbilirubinemia] Frank M, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:111–3 (Eng. Abstr.) **(Ger)**

HISTORY

King George III's urine and indigo blue. Arnold WN. **Lancet** 1996 Jun 29;347(9018):1811–3

Did George III have porphyria? [letter] Aldrich CK. **Pharos** 1995 Fall;58(4):37

METABOLISM

Diseases of metabolism (porphyrias). McCarroll NA. **Anal Chem** 1995 Jun 15;67(12):425R–4284 (60 ref.)

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

PATHOLOGY

Cortical brain lesions in acute intermittent porphyria [letter; comment] Sze G. **Ann Intern Med** 1996 Sep 1;125(5):422–3 . Comment on: Ann Intern Med 1995 Oct 15;123(8):598–600.

PHYSIOPATHOLOGY

The prooxidant effect of 5–aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Demasi M, et al. **Free Radic Biol Med** 1996;20(3):291–9

PSYCHOLOGY

The prooxidant effect of 5–aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Demasi M, et al. **Free Radic Biol Med** 1996;20(3):291–9

Porphyria: reexamination of psychiatric implications. Burgovne K, et al. **Psychother Psychosom** 1995; 64(3–4):121–30 (75 ref.)

THERAPY

Three cases of acute porphyria–experience with heme therapy in one case [letter] Bhootra K, et al. **J Assoc Physicians India** 1995 Apr;43(4):303–4

Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):239–48 (55 ref.)

URINE

Is the Watson–Schwartz screening method for porphobilinogen reliable? [letter; comment] Buttery JE. **Clin Chem** 1995 Nov;41(11):1670–1. Comment on: Clin Chem 1995 Feb;41(2):323–4.

VETERINARY

Accumulation of protoporphyrin isomers I and III, and multiple decarboxylation products of uroporphyrin in a case of porphyria in a slaughtered pig. Roels S, et al. **Zentralbl Veterinarmed A** 1995 Apr;42(2):145–51

PORPHYRIA, ACUTE INTERMITTENT

Porphyria, cardiopulmonary bypass, and volatile anesthetics [letter] Pivalizza EG, et al. **Anesth Analg** 1996 Sep;83(3):658

CHEMICALLY INDUCED

Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Yandel ML, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):261–3

Precipitation of acute intermittent porphyria by chloroquin. Puri AS, et al. **Indian Pediatr** 1996 Mar;33(3):241–3

[Acute porphyria and multiple organ failure during treatment with lamotrigine] Gregersen H, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4091–2 (Eng. Abstr.) **(Dan)**

[Epileptic insults, cerebral infarct and rhabdomyolysis as complication of amphetamine use (letter)] Roebroek RM, et al. **Ned Tijdschr Geneeskd** 1996 Jul 20;140(29):1519 **(Dut)**

COMPLICATIONS

Mitral valve replacement in a patient with acute intermittent porphyria. Stevens JJ, et al. **Anesth Analg** 1996 Feb; 82(2):416–8

Treatment of Parkinson's disease in a patient with acute intermittent porphyria [letter] Gorchein A. **Br J Clin Pharmacol** 1995 Jul;40(1):105–6

[Epilepsy is difficult to treat during an attack of porphyria] Bylesjö EI, et al. **Lakartidningen** 1996 Jun 26; 93(26–27):2506–8 (15 ref.) **(Swe)**

DIAGNOSIS

[Abdominal pain (clinical conference)] Hartmeier SH, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):126–30 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Patient–controlled analgesia with pethidine in acute intermittent porphyria (letter)] Muehlenberg K, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1454 **(Ger)**

EPIDEMIOLOGY

Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Bylesjö I, et al. **Epilepsia** 1996 Mar;37(3):230–5

GENETICS

Acute intermittent porphyria: a single–base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide. Lee GY, et al. **Am J Med Genet** 1995 Aug 28;58(2):155–8

R325X mutation in exon 15 of the hydroxymethylbilane synthase gene identified in two Danish families with acute intermittent porphyria. Petersen NE, et al. **Clin Chem** 1996 Jan;42(1):106–7

De–novo mutation and sporadic presentation of acute intermittent porphyria. Whatley SD, et al. **Lancet** 1995 Oct 14;346(8981):1007–8

Detection of four mutations in six unrelated South African patients with acute intermittent porphyria. Ong PM, et al. **Mol Cell Probes** 1996 Feb;10(1):57–61

[Acute intermittent porphyria in 2 Moroccan families. Clinical and biological study] Aquaron R, et al. **Rev Med Interne** 1996;17(6):477–81 (21 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat. Puy H, et al. **J Clin Invest** 1996 Jan 1;97(1):104–10

Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Lindberg RL, et al. **Nat Genet** 1996 Feb;12(2):195–9

PORPHYRIA, ACUTE INTERMITTENT

PHYSIOPATHOLOGY

Assessment of autonomic nerve function in acute intermittent porphyria; a study based on spectral analysis of heart rate variability. Blom H, et al. **J Intern Med** 1996 Aug; 240(2):73–9

PORPHYRIA CUTANEA TARDA

[Porphyria cutanea tarda (chronic hepatic porphyria)] Köstler E, et al. **Dtsch Med Wochenschr** 1995 Oct 13; 120(41):1405–10 (50 ref.) **(Ger)**

BLOOD

Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda. Rocchi E, et al. **Eur J Clin Invest** 1995 Jul;25(7):510–4

CHEMICALLY INDUCED

Porphyria cutanea tarda associated with carbamazepine treatment [letter] Leo RJ, et al. **Am J Psychiatry** 1996 Mar; 153(3):443–4

Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. Ruggian JC, et al. **J Am Soc Nephrol** 1996 Mar;7(3):397–402

COMPLICATIONS

Symptomatic porphyria cutanea tarda and B-immunoblastic lymphoma: is there an association? [letter] Younossi ZM, et al. **Am J Hematol** 1996 Mar;51(3):252–3

Hepatitis C virus infection and porphyria cutanea tarda in Australasia [letter] Salmon P, et al. **Arch Dermatol** 1996 Jan;132(1):91

Coexistence of subacute cutaneous lupus erythematosus and porphyria cutanea tarda: a case report. Camisa C, et al. **Cutis** 1995 Aug;56(2):101–3

Dual porphyria of coexisting variegata and cutanea tarda. Sieg I, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul; 33(7):405–10

Porphyria cutanea tarda preceding AIDS [letter] Ash S, et al. **Lancet** 1996 Jan 20;347(8995):190

[Porphyria cutanea tarda and hepatitis C virus infection. Clinical and virological study] Cribier B, et al. **Ann Dermatol Venereol** 1996;123(3):200–2 (Eng. Abstr.) **(Fre)**

[Pseudoporphyria in patients with kidney disease on hemodialysis] Mijailović B, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):591–3 **(Scr)**

[Porphyria cutanea tarda, hepatocarcinoma and hepatitis C virus infection (letter)] Rodríguez Cuartero A, et al. **An Med Interna** 1995 Oct;12(10):517–8 **(Spa)**

[Association of porphyria cutanea tarda and hepatitis C virus] Martín-Vivaldi Martínez R, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):213–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Porphyria cutanea tarda: a clinical review. Cohen DJ, et al. **Compr Ther** 1996 Mar;22(3):175–8 (11 ref.)

Transcutaneous oxygen tension in patients with and without pericapillary fibrin cuffs in chronic venous insufficiency, porphyria cutanea tarda and non-venous leg ulcers. Neumann HA, et al. **Vasa** 1996;25(2):127–33

[Liver cirrhosis and chronic hepatic porphyria] Pätzold K, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:114–5 (Eng. Abstr.) **(Ger)**

[A case of porphyria cutanea tarda in an 11-year-old boy] Pindycka-Piaszczyńska M, et al. **Pediatr Pol** 1995 Jun; 70(6):515–8 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Very low-dose chloroquine treatment for porphyria cutanea tarda [letter] Drago F, et al. **Acta Derm Venereol** 1995 Jul; 75(4):329–30

EPIDEMIOLOGY

[Porphyria cutanea tarda in Languedoc-Roussillon. Epidemiological study in 24 years (letter)] Vallat C, et al. **Presse Med** 1996 May 4–11;25(16):775 **(Fre)**

ETIOLOGY

Hepatitis C as another possible cause of porphyria cutanea tarda and systemic lupus erythematosus: comment on the article by Kutz and Bridges [letter] Nepveu K, et al. **Arthritis Rheum** 1996 Feb;39(2):352–4

[Cutaneous pigmentation, only manifestation of porphyria cutanea tarda in a HIV-1 positive patient] Pascual C, et al. **Ann Dermatol Venereol** 1996;123(4):262–4 (Eng. Abstr.) **(Fre)**

[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**

[Skin manifestations related to hepatitis C viruses] Doutre MS, et al. **Rev Med Interne** 1995;16(9):666–72 (71 ref.) (Eng. Abstr.) **(Fre)**

[Role of hepatitis C virus in porphyria cutanea tarda hepatopathy] Quecedo L, et al. **Med Clin (Barc)** 1996 Mar 9;106(9):321–4 (Eng. Abstr.) **(Spa)**

GENETICS

Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Moran-Jimenez MJ, et al. **Am J Hum Genet** 1996 Apr;58(4):712–21

PATHOLOGY

The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron. Siersema PD, et al. **J Hepatol** 1995 Sep;23(3):259–67

THERAPY

[Monthly question: how should porphyria cutanea tarda be treated?] Lacour JP. **Ann Dermatol Venereol** 1996; 123(4):292–4 **(Fre)**

PORPHYRIA, ERYTHROHEPATIC

BLOOD

Burst-forming units-erythroid from erythropoietic protoporphyria patients fluoresce under 405 nm light [letter] Mathews-Roth MM, et al. **Blood** 1996 May 15; 87(10):4480–1

COMPLICATIONS

Liver failure in erythropoietic protoporphyria [letter; comment] Sarkany RP, et al. **J Am Acad Dermatol** 1996 Mar;34(3):540–1. Comment on: J Am Acad Dermatol 1995 Feb;32(2 Pt 1):297–8.

Erythropoietic protoporphyria presenting in an adult. Henderson CA, et al. **J R Soc Med** 1995 Aug; 88(8):476P–477P (8 ref.)

DIAGNOSIS

Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Da Silva V, et al. **Clin Chim Acta** 1995 Jul 14;238(2):163–8

DRUG THERAPY

Erythropoietic protoporphyria [letter] Mathews-Roth MM. **Br J Dermatol** 1996 May;134(5):977

Treatment of erythropoietic protoporphyria with hydroxyethylrutosides. Schoemaker JH, et al. **Dermatology** 1995;191(1):36–8

Beta-carotene serum levels in patients with erythropoietic protoporphyria on treatment with the synthetic all-trans isomer or a natural isomeric mixture of beta-carotene. von Laar J, et al. **J Photochem Photobiol B** 1996 Apr; 33(2):157–62

ENZYMOLOGY

Molecular characterization of a novel defect occurring de novo associated with erythropoietic protoporphyria. Wang X. **Biochim Biophys Acta** 1996 Aug 23;1316(3):149–52

Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. Goerz G, et al. **Br J Dermatol** 1996 May;134(5):880–5

The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. Taketani S, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):231–8 (57 ref.)

ETIOLOGY

Erythropoietic protoporphyria without cutaneous photosensitivity and with ringed sideroblasts in an atomic bomb survivor [letter] Takeda Y, et al. **Lancet** 1996 Feb 10;347(8998):395–6

GENETICS

Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Gouya L, et al. **Am J Hum Genet** 1996 Feb;58(2):292–9

A novel mutation in the ferrochelatase gene associated with erythropoietic protoporphyria. Imoto S, et al. **Br J Haematol** 1996 Jul;94(1):191–7

The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. Taketani S, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):231–8 (57 ref.)

Four novel mutations in the ferrochelatase gene among erythropoietic protoporphyria patients. Henriksson M, et al. **J Invest Dermatol** 1996 Feb;106(2):346–50

PHYSIOPATHOLOGY

[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Porphyrin-induced biliary cirrhosis in protoporphyria: indications for liver transplantation] Steinmüller T, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:116–9 (Eng. Abstr.) **(Ger)**

THERAPY

Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells. Magness ST, et al. **Hum Gene Ther** 1995 Oct;6(10):1285–90

Recurrent hepatic allograft injury in erythropoietic protoporphyria. de Torres I, et al. **Transplantation** 1996 May 15;61(9):1412–3

[Liver cirrhosis in protoporphyria: bile acid therapy and liver transplantation] Frank M, et al. **Z Gastroenterol** 1995 Jul; 33(7):399–403 (Eng. Abstr.) **(Ger)**

VETERINARY

Bovine congenital erythropoietic protoporphyria in a pedigree Limousin heifer. Buchanan M, et al. **Vet Rec** 1995 Jun 24;136(25):640

PORPHYRIA, ERYTHROPOIETIC

Congenital erythropoietic porphyria. Abraham L, et al. **Indian Pediatr** 1995 Jan;32(1):99–100

Porphyria and vampirism: another myth in the making [editorial] Cox AM. **Postgrad Med J** 1995 Nov; 71(841):643–4

BLOOD

Erythropoietic protoporphyria: two populations of reticulocytes, with and without protoporphyrin. Brun A, et al. **Eur J Clin Invest** 1996 Apr;26(4):270–8

COMPLICATIONS

Congenital erythropoietic porphyria associated with nephrotic syndrome and renal siderosis. Lange B, et al. **Acta Paediatr** 1995 Nov;84(11):1325–8

Glibenclamide-induced photosensitivity in a diabetic patient with erythropoietic protoporphyria [letter] Fujii S, et al. **Am J Hematol** 1995 Nov;50(3):223

Ocular complication in congenital erythropoietic porphyria. Tanigawa K, et al. **Ophthalmologica** 1996;210(3):183–5

DIAGNOSIS

[Xeroderma pigmentosum and Günther disease] Gueganton C, et al. **Ann Chir Plast Esthet** 1995 Aug;40(4):425–7 **(Fre)**

ETIOLOGY

Solar urticaria in a 6-year-old child [clinical conference] Williams-Arya P, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):141–3

GENETICS

Identification of two new mutations in congenital erythropoietic porphyria. Bensidhoum M, et al. **Eur J Hum Genet** 1995;3(2):102–7

A novel point mutation in congenital erythropoietic porphyria in two members of Japanese family. Tanigawa K, et al. **Hum Genet** 1996 May;97(5):557–60

Molecular basis of congenital erythropoietic porphyria: mutations in the human uroporphyrinogen III synthase gene. Xu W, et al. **Hum Mutat** 1996;7(3):187–92

METABOLISM

Excretion pattern of faecal coproporphyrin isomers I–IV in human porphyrias. Jacob K, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):893–901

Congenital erythropoietic porphyria: clinical, biochemical, and enzymatic profile of a severely affected infant. Huang JL, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):924–7

[Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure] de Verneuil H, et al. **Arch Pediatr** 1995 Aug; 2(8):755–61 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Evaluation and clinical application of the Enterotest for the determination of human biliary porphyrin composition. Beukeveld GJ, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):453–62

THERAPY

Correction of congenital erythropoietic porphyria by bone marrow transplantation. Thomas C, et al. **J Pediatr** 1996 Sep;129(3):453–6

PORPHYRIA, ERYTHROPOIETIC, CONGENITAL see **PORPHYRIA, ERYTHROPOIETIC**

PORPHYRIA, HEPATIC

Hereditary coproporphyria. Paterson A, et al. **Ulster Med J** 1994 Oct;63(2):248–50

CHEMICALLY INDUCED

Testing the porphyrinogenicity of propofol in a primed rat model [see comments] Böhrer H, et al. **Br J Anaesth** 1995 Sep;75(3):334–8. Comment in: Br J Anaesth 1996 Jan;76(1):171–2. Comment in: Br J Anaesth 1996 Jan;76(1):172.

Synergy of iron in the toxicity and carcinogenicity of polychlorinated biphenyls (PCBs) and related chemicals. Smith AG, et al. **Toxicol Lett** 1995 Dec;82–83:945–50

COMPLICATIONS

Dual porphyria of coexisting variegata and cutanea tarda. Sieg I, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul; 33(7):405–10

Epilepsy in porphyria [letter; comment] Reynolds NC Jr. **Neurology** 1996 May;46(5):1497–8. Comment on: Neurology 1995 Mar;45(3 Pt 1):594–5. Comment on: Neurology 1995 Jun;45(6):1216–7.

[Acute hepatic porphyria and its neurological syndrome] Bont A, et al. **Schweiz Med Wochenschr** 1996 Jan 9; 126(1–2):6–14 (45 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Porphyria variegata. Apropos of a case] Virgili P, et al. **Encephale** 1995 Nov–Dec;21(6):467–71 (Eng. Abstr.) **(Fre)**

[Liver cirrhosis and chronic hepatic porphyria] Pätzold K, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:114–5 (Eng. Abstr.) **(Ger)**

[A case report of variegate porphyria] Shimizu H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1221–4 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Grandchamp B, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):215–9 (22 ref.)

A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria [see comments] Meissner PN, et al. **Nat Genet** 1996 May;13(1):95–7. Comment in: Nat Genet 1996 May;13(1):7–9.

GENETICS

Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP) [letter] Scarlett JD, et al. **Aust N Z J Med** 1995 Dec;25(6):742–3

Mapping of the variegate porphyria (VP) gene: contradictory evidence for linkage between VP and microsatellite markers at chromosome 14q32. Warnich L, et al. **Hum Genet** 1996 May;97(5):690–2

Partial characterization and assignment of the gene for protoporphyrinogen oxidase and variegate porphyria to human chromosome 1q23. Roberts AG, et al. **Hum Mol Genet** 1995 Dec;4(12):2387–90

Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Grandchamp B, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):215–9 (22 ref.)

The South African malady [news; comment] Jenkins T. **Nat Genet** 1996 May;13(1):7–9. Comment on: Nat Genet 1996 May;13(1):95–7.

A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria [see comments] Meissner PN, et al. **Nat Genet** 1996 May;13(1):95–7. Comment in: Nat Genet 1996 May;13(1):7–9.

Variegate porphyria breakthrough [news] Spencer Jones JH. **S Afr Med J** 1996 Jun;86(6):626

METABOLISM

Excretion pattern of faecal coproporphyrin isomers I–IV in human porphyrias. Jacob K, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):893–901

PHYSIOPATHOLOGY

Evaluation and clinical application of the Enterotest for the determination of human biliary porphyrin composition. Beukeveld GJ, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):453–62

PSYCHOLOGY

[Porphyria and psychiatric manifestations] Pérez Bravo A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):319–21 (Eng. Abstr.) **(Spa)**

PORPHYRIA, VARIEGATE see **PORPHYRIA, HEPATIC**

PORPHYRIN-METAL CHELATASE see **FERROCHELATASE**

PORPHYRINS

see related

PORPHOBILINOGEN

Coenzyme M methylase activity of the 480-kilodalton corrinoid protein from Methanosarcina barkeri. Tallant TC, et al. **J Bacteriol** 1996 Mar;178(5):1295–301

Fluorescent porphyrin counterstaining of chromatin DNA in conjunction with immunofluorescence methods using FITC-labelled antibodies. Juarranz A, et al. **J Microsc** 1996 Apr;182 (Pt 1):46–9

[Molecular design of oligonucleotide porphyrin derivatives] Shimidzu T. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1357–63 (18 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Comparison of local intravascular drug-delivery catheter systems. Gonschior P, et al. **Am Heart J** 1995 Dec; 130(6):1174–81

Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Husain D, et al. **Arch Ophthalmol** 1996 Aug;114(8):978–85

Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Molpus KL, et al. **Cancer Res** 1996 Mar 1;56(5):1075–82

Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Peterson CM, et al. **Cancer Res** 1996 Sep 1;56(17):3980–5

Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Kramer M, et al. **Ophthalmology** 1996 Mar;103(3):427–38

ANALYSIS

Porphyrins as biomarkers of methylmercury and PCB exposure in experimental quail. Leonzio C, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):244–50

Evaluation and clinical application of the Enterotest for the determination of human biliary porphyrin composition. Beukeveld GJ, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):453–62

Evaluation of a first-line spectrophotometric screening test for increased faecal porphyrin concentration. Zuijderhoudt FM, et al. **Eur J Clin Chem Clin Biochem** 1995 May; 33(5):285–8

Porphyrin concentrations in various human tissues. Goerz G, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):218–20

The diagnosis and follow-up of porphyria. Ratnaike S, et al. **Pathology** 1995 Apr;27(2):142–53 (59 ref.)

[Porphyrin] Kakishita E. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:871–6 (9 ref.) **(Jpn)**

[Spectroscopic diagnosis of stomach diseases based on laser-induced fluorescence of endogenous porphyrins] Kuzin MI, et al. **Khirurgiia (Mosk)** 1995;(5):35–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

The effects of bromocriptine and prolactin on porphyrin biosynthesis and morphology in the female hamster harderian gland. Shah SW, et al. **J Comp Physiol [B]** 1996; 166(2):144–9

Partial inhibition of protein synthesis accelerates the synthesis of porphyrin in heme-deficient mutants of Escherichia coli. Nakayashiki T, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):139–46

The effect of ALA and radiation on porphyrin/heme biosynthesis in endothelial cells. He D, et al. **Photochem Photobiol** 1995 Jun;61(6):656–61

Porphyrin production and excretion by long-term cultures of adult rat hepatocytes and effect of lead exposure. Quintanilla-Vega B, et al. **Toxicology** 1995 Sep 18; 102(3):275–83

BLOOD

Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection. Nomura N, et al. **Arch Dermatol** 1996 Aug;132(8):906–10

Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Da Silva V, et al. **Clin Chim Acta** 1995 Jul 14;238(2):163–8

Heme synthesis in chronic renal failure: the effects of hemodialysis, peritoneal dialysis and erythropoietin treatment. Siersema PD, et al. **Nephron** 1995;71(3):297–302

CHEMISTRY

Chloro(5,10,15,20-tetraphenylporphyrinato)manganese(III) with 4/m symmetry. Cheng B, et al. **Acta Crystallogr C** 1996 Feb 15;52 (Pt 2):361–3

Surface active peptide-mediated porphyrin aggregation. Venkatesh B, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):390–6

Recognition of anionic porphyrins by DNA aptamers. Li Y, et al. **Biochemistry** 1996 May 28;35(21):6911–22

Resonance Raman spectroscopic identification of a histidine ligand of b595 and the nature of the ligation of chlorin d in the fully reduced Escherichia coli cytochrome bd oxidase. Sun J, et al. **Biochemistry** 1996 Feb 20; 35(7):2403–12

A conformational change in the methyltransferase from Clostridium thermoaceticum facilitates the methyl transfer from (6S)-methyltetrahydrofolate to the corrinoid/iron-sulfur protein in the Acetyl-CoA pathway. Zhao S, et al. **Biochemistry** 1996 Feb 20;35(7):2476–81

Perturbations in DNA structure upon interaction with porphyrins revealed by chemical probes, DNA footprinting and molecular modelling. Ford KG, et al. **Bioorg Med Chem** 1995 Jun;3(6):671–7

Redox behaviour of phenolic porphyrins in basic solutions: a reappraisal. Milgrom LR, et al. **Free Radic Res** 1996 Jan; 24(1):19–29

Confirmation of the Mukerjee term in an extended Corrin-Harkins relation using an anionic amphiphilic drug. Franchini MK, et al. **J Pharm Sci** 1996 Feb;85(2):220–7

The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). Aveline BM, et al. **J Photochem Photobiol B** 1995 Oct; 30(2–3):161–9

Spectral characterization of the benzoporphyrin derivative monoacid ring-A photoproduct formed in fetal calf solutions during irradiation offh 694 nm continuous-wave radiation. Gillies R, et al. **J Photochem Photobiol B** 1996 Mar;33(1):87–90

Photophysical properties of porphyrins in biological membranes. Ricchelli F. **J Photochem Photobiol B** 1995 Aug;29(2–3):109–18 (94 ref.)

Spectroscopic studies of photobleaching and photoproduct formation of porphyrins used in tumour therapy. Rotomskis R, et al. **J Photochem Photobiol B** 1996 Mar;33(1):61–7

On the molecular spin density and the electrostatic potential as determinants of the relaxivity of metalloporphyrins. Mercier GA Jr. **Magn Reson Imaging** 1995;13(6):807–17

Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367–97 (114 ref.)

Interactions between N-aspartyl chlorin e6, detergent micelles and plasma lipoproteins. Kessel D. **Photochem Photobiol** 1995 Jun;61(6):646–9

Age-related changes in the human lens as monitored by detection of porphyrin excited states. Roberts JE, et al. **Photochem Photobiol** 1995 Aug;62(2):339–41

Porphyrin pi-cation and protein radicals in peroxidase catalysis and inhibition by anti-thyroid chemicals. Doerge DR, et al. **Xenobiotica** 1995 Jul;25(7):761–7

METABOLISM

The bronze baby syndrome: evidence of increased tissue concentration of copper porphyrins. Rubaltelli FF, et al. **Acta Paediatr** 1996 Mar;85(3):381–4

Oxidation of 9-alkylanthracenes by cytochrome P450 2B1, horseradish peroxidase, and iron tetraphenylporphine/iodosylbenzene systems: anaerobic and aerobic mechanisms. Anzenbacher P, et al. **Biochemistry** 1996 Feb 27;35(8):2512–20

Formation of a porphyrin pi-cation radical in the fluoride complex of horseradish peroxidase. Farhangrazi ZS, et al. **Biochemistry** 1995 Nov 21;34(46):14970–4

Mechanistic studies of the methyltransferase from Clostridium thermoaceticum: origin of the pH dependence of the methyl group transfer from methyltetrahydrofolate to the corrinoid/iron-sulfur protein. Zhao S, et al. **Biochemistry** 1995 Nov 21;34(46):15075–83

Involvement of peripheral-type benzodiazepine receptors in the intracellular transport of heme and porphyrins. Taketani S, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):875–80

Formation of water-soluble porphyrins and protoporphyrin IX in 5-aminolevulinic-acid-incubated carcinoma cells. Dietel W, et al. **J Photochem Photobiol B** 1996 May; 33(3):225–31

A catalytic DNA for porphyrin metallation [letter] Li Y, et al. **Nat Struct Biol** 1996 Sep;3(9):743–7

Distribution of 5-aminolevulinic acid-induced porphyrins in nodulouleerative basal cell carcinoma. Peng Q, et al. **Photochem Photobiol** 1995 Nov;62(5):906–13

Age-related changes in the human lens as monitored by detection of porphyrin excited states. Roberts JE, et al. **Photochem Photobiol** 1995 Aug;62(2):339–41

Relative potencies of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls derived from hepatic porphyrin accumulation in mice. van Birgelen AP, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):98–109

PHARMACOKINETICS

Accumulation of benzoporphyrin derivative in malignant and host cell populations of the murine RIF tumor [published erratum appears in Cancer Lett 1996 Jan 19;99(1):133] Korbelik M, et al. **Cancer Lett** 1995 Nov 6;97(2):249–54

In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Schmidt-Erfurth U, et al. **Lasers Surg Med** 1995;17(2):178–88

Binding of manganese and iron tetraphenylporphine sulfonates to albumin is relevant to their contrast properties. Yushmanov VE, et al. **Magn Reson Imaging** 1996; 14(3):255–61

Evaluation of new benzoporphyrin derivatives with enhanced PDT efficacy. Pandey RK, et al. **Photochem Photobiol** 1995 Oct;62(4):764–8

[Dynamics of photosensitizer in the cell] Aizawa K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):22–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The porphyrins in cancer and virus research. Pethö G. **Acta Physiol Hung** 1995;83(2):113–9

Photodamaging effects of tetraphenylporphycene in a human carcinoma cell line. Villanueva A, et al. **Anticancer Drug Des** 1996 Mar;11(2):89–99

Cationic porphyrin derivatives as inhibitors of polyamine catabolism. Libby PR, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1527–30

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Orenstein A, et al. **Br J Cancer** 1996 Apr;

PORPHYRINS

73(8):937–44
Cytotoxic, nuclear, and growth inhibitory effects of photodynamic drugs on pancreatic carcinoma cells. Ward AJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):39–47
Photodynamic therapy–mediated oxidative stress can induce expression of heat shock proteins. Gomer CJ, et al. **Cancer Res** 1996 May 15;56(10):2355–60
Vascular pattern in the chorioallantoic membrane (CAM) after laser/photosensitive compound treatment. II. Microscopic findings. Klepáček I, et al. **Folia Biol (Praha)** 1995;41(3–4):190–6
Assessment of the cytotoxicity of the photosensitizing drug BPD verteporfin using human vascular smooth muscle cells in culture. Labow RS, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):728–36
In vivo damage to chorioallantoic membrane blood vessels by porphycene–induced photodynamic therapy. Gottfried V, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):115–21
Photodynamic inactivation of cell–free HIV strains by a red–absorbing chlorin–type photosensitizer. Grandadam M, et al. **J Photochem Photobiol B** 1995 Dec;31(3):171–7
Meso–substituted cationic porphyrins as efficient photosensitizers of gram–positive and gram–negative bacteria. Merchat M, et al. **J Photochem Photobiol B** 1996 Feb;32(3):153–7
Enhancement of the antitumor effect by combined use of high–energy shock waves and ATX–70. Maruyama M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):800–1
Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Cincotta L, et al. **Photochem Photobiol** 1996 Feb;63(2):229–37
Apoptosis or necrosis following Photofrin photosensitization: influence of the incubation protocol. Dellinger M. **Photochem Photobiol** 1996 Jul;64(1):182–7
Sites of photodamage in vivo and in vitro by a cationic porphyrin. Kessel D, et al. **Photochem Photobiol** 1995 Nov; 62(5):875–81
Structure–activity relationship of porphines for photoinactivation of bacteria. Nitzan Y, et al. **Photochem Photobiol** 1995 Aug;62(2):342–7
5,20–bis(4–sulphophenyl)–10,15–bis (2–methoxy–4–sulphophenyl)–21–thiaporphyrin as a new potent sensitizer in photodynamic therapy. Ziółkowski P, et al. **Tumori** 1995 Sep–Oct;81(5):364–9
[Tissue autofluorescence damping mechanisms, sensitized by tumorotrophic dyes] Oganesian VA, et al. **Biofizika** 1995 Nov–Dec;40(6):1308–12 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Photosensitization of murine tumor, vasculature and skin by 5–aminolevulinic acid–induced porphyrin. Henderson BW, et al. **Photochem Photobiol** 1995 Oct;62(4):780–9
Non–iron porphyrins cause tumbling to blue light by an Escherichia coli mutant defective in hemG. Yang H, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2459–63

RADIATION EFFECTS

The effect of ALA and radiation on porphyrin/heme biosynthesis in endothelial cells. He D, et al. **Photochem Photobiol** 1995 Jun;61(6):656–61

THERAPEUTIC USE

Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Young LH, et al. **Arch Ophthalmol** 1996 Feb;114(2):186–92
Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. Karagianis G, et al. **Br J Cancer** 1996 Feb;73(4):514–21
Benzoporphyrin–lipoprotein–mediated photodestruction of intraocular tumors. Schmidt–Erfurth U, et al. **Exp Eye Res** 1996 Jan;62(1):1–10
Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser. van Gool CA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):435–40
Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers. Dellian M, et al. **Int J Cancer** 1996 Jan 17;65(2):246–8
Control of hypertrophic scar growth using antibody–targeted photolysis. Wolfort SF, et al. **J Surg Res** 1996 Apr; 62(1):17–22
Sonodynamically induced antitumor effect of a gallium–porphyrin complex, ATX–70. Yumita N, et al. **Jpn J Cancer Res** 1996 Mar;87(3):310–6
Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)
Laser–induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Pomer S, et al. **Urol Int** 1995;55(4):197–201
[Assessment of the possibility of using the photodynamic effect in rheumatology] Tauraitis VA, et al. **Biofizika** 1992 Mar–Apr;37(2):345–51 (Eng. Abstr.) **(Rus)**

TOXICITY

Evaluation of new benzoporphyrin derivatives with enhanced PDT efficacy. Pandey RK, et al. **Photochem Photobiol** 1995 Oct;62(4):764–8
Meso–tetra–(4–sulfonatophenyl)–porphine of low neurotoxicity. Střelečková E, et al. **Sb Lek** 1995;96(1):7–13

URINE

Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Gross U, et al. **Horm Metab Res** 1995 Aug; 27(8):379–83
Time–dependent porphyric response in mice subchronically exposed to arsenic. García–Vargas G, et al. **Hum Exp Toxicol** 1995 Jun;14(6):475–83
Absence of circadian variations in urinary porphyrin excretion in normal subjects. Enriquez de Salamanca R, et al. **Int J Biochem Cell Biol** 1995 Sep;27(9):933–5
The validity of spot urine samples for low–level occupational mercury exposure assessment and relationship to porphyrin and creatinine excretion rates. Martin MD, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):239–44

PORPHYROMONAS

CLASSIFICATION

Reclassification of Oribaculum catoniae (Moore and Moore 1994) as Porphyromonas catoniae comb. nov. and emendation of the genus Porphyromonas. Willems A, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):578–81

DRUG EFFECTS

Resistance to beta–lactam antibiotics and beta–lactamase production of Bacteroides, Porphyromonas and Prevotella strains. Nagy E, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):287–99

ENZYMOLOGY

Enzymatic profiles of Prevotella, Porphyromonas, and Bacteroides species obtained with the API ZYM system and Rosco diagnostic tablets. Durmaz B, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S192–4

IMMUNOLOGY

Serum responses of cats with periodontal/gingival disease to members of the genus Porphyromonas. Norris JM, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S314–6

PORPHYROMONAS GINGIVALIS

CHEMISTRY

Identification of Porphyromonas gingivalis prefimbrilin possessing a long leader peptide: possible involvement of trypsin–like protease in fimbrilin maturation. Onoe T, et al. **Microb Pathog** 1995 Nov;19(5):351–64
Purification of major fimbrial proteins of Porphyromonas gingivalis. Lee JY, et al. **Protein Expr Purif** 1995 Aug; 6(4):496–500

CLASSIFICATION

Arbitrarily primed polymerase chain reaction analysis of periodontal pathogens: discriminative primers and genetic diversity. Chen C, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S301–3
Immunomagnetic PCR and DNA probe for detection and identification of Porphyromonas gingivalis. Benkirane RM, et al. **J Clin Microbiol** 1995 Nov;33(11):2908–12

DRUG EFFECTS

In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Miyake Y, et al. **J Periodontal Res** 1995 Jul; 30(4):290–3

ENZYMOLOGY

Active site structure of a hemagglutinating protease from Porphyromonas gingivalis: similarity to clostripain. Nishikata M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):547–53
Molecular analysis of surface–associated enzymes of Porphyromonas gingivalis. Gharbia SE, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S160–6
Polymerase chain reaction analysis of the Porphyromonas gingivalis collagenase gene. Slots J, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S167–8
Immunological characterization and localization of a Porphyromonas gingivalis BApNA–hydrolyzing protease possessing hemagglutinating activity. Hinode D, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):211–7
Identification of a chromosomally encoded kanamycin acetylase in Porphyromonas gingivalis. Kato T, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):301–6
Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation of C5 augments proteinase digestion of C5. Discipio RG, et al. **Immunology** 1996 Apr;87(4):660–7
Effect of free and vesicle–bound cysteine proteinases of Porphyromonas gingivalis on plasma clot formation: implications for bleeding tendency at periodontitis sites. Imamura T, et al. **Infect Immun** 1995 Dec;63(12):4877–82
Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Jagels MA, et al. **Infect Immun** 1996 Jun;64(6):1984–91
Cysteine protease of Porphyromonas gingivalis 381 enhances binding of fimbriae to cultured human fibroblasts and matrix proteins. Kontani M, et al. **Infect Immun** 1996 Mar; 64(3):756–62
Involvement of arginine–specific cysteine proteinase (Arg–gingipain) in fimbriation of Porphyromonas gingivalis. Nakayama K, et al. **J Bacteriol** 1996 May; 178(10):2818–24
Construction and characterization of arginine–specific cysteine proteinase (Arg–gingipain)–deficient mutants of Porphyromonas gingivalis. Evidence for significant contribution of Arg–gingipain to virulence. Nakayama K, et al. **J Biol Chem** 1995 Oct 6;270(40):23619–26
Comparative study of four proteases from spent culture media of Porphyromonas gingivalis (FAY–19M–1). Bedi GS. **Prep Biochem** 1995 Aug;25(3):133–54
Porphyromonas gingivalis: a proteinase/gene accounting audit. Potempa J, et al. **Trends Microbiol** 1995 Nov; 3(11):430–4 (30 ref.)

GENETICS

Expression and immunogenicity of a cloned Porphyromonas gingivalis hemagglutinin in Salmonella typhimurium. Dusek DM, et al. **Adv Exp Med Biol** 1995;371B:1119–21
Characterization of a Porphyromonas gingivalis gene prtR that encodes an arginine–specific thiol proteinase and multiple adhesins. Slakeski N, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):605–10
Cloning, expression and sequence analysis of the genes encoding the heterodimeric methylmalonyl–CoA mutase of Porphyromonas gingivalis W50. Jackson CA, et al. **Gene** 1995 Dec 29;167(1–2):127–32
Characterization of an adherence and antigenic determinant of the ArgI protease of Porphyromonas gingivalis which is present on multiple gene products. Curtis MA, et al. **Infect Immun** 1996 Jul;64(7):2532–9
Porphyromonas gingivalis genes isolated by screening for epithelial cell attachment. Duncan MJ, et al. **Infect Immun** 1996 Sep;64(9):3624–31
Construction and preliminary characterization of three hemagglutinin mutants of Porphyromonas gingivalis. Lépine G, et al. **Infect Immun** 1996 Apr;64(4):1467–72
Analysis of the prtP gene encoding porphypain, a cysteine proteinase of Porphyromonas gingivalis. Barkocy–Gallagher GA, et al. **J Bacteriol** 1996 May; 178(10):2734–41
Construction and characterization of arginine–specific cysteine proteinase (Arg–gingipain)–deficient mutants of Porphyromonas gingivalis. Evidence for significant contribution of Arg–gingipain to virulence. Nakayama K, et al. **J Biol Chem** 1995 Oct 6;270(40):23619–26
A murC gene in Porphyromonas gingivalis 381. Ansai T, et al. **Microbiology** 1995 Sep;141 (Pt 9):2047–52

GROWTH & DEVELOPMENT

Development of a simple chemically defined medium for Porphyromonas gingivalis: requirement for alpha–ketoglutarate. Milner P, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):125–30
Effect of concentration of compounds containing iron on the growth of Porphyromonas gingivalis. Shizukuishi S, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):313–7

IMMUNOLOGY

Expression and immunogenicity of a cloned Porphyromonas gingivalis hemagglutinin in Salmonella typhimurium. Dusek DM, et al. **Adv Exp Med Biol** 1995;371B:1119–21
Generation and distribution of antibody secreting cells in salivary glands of mice immunized with Porphyromonas gingivalis fimbriae. Hamada S, et al. **Adv Exp Med Biol** 1995;371B:1113–7
Purification and characterization of Porphyromonas gingivalis outer membrane antigens. Polak B, et al. **Arch Oral Biol** 1995 Oct;40(10):905–12
Establishment of peripheral blood and gingival T lymphocyte clones responsive to Porphyromonas gingivalis. Gemmell E, et al. **Aust Dent J** 1996 Apr;41(2):113–7
Immunochemical characterisation and epitope mapping of a novel fimbrial protein (Pg–II fimbria) of Porphyromonas gingivalis. Ogawa T, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):247–55
Tyrosine protein phosphorylation in murine B lymphocytes by stimulation with lipopolysaccharide from Porphyromonas gingivalis. Kimura S, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):1–6
Characterization, genetic analysis, and expression of a protease antigen (PrpRI) of Porphyromonas gingivalis W50. Aduse–Opoku J, et al. **Infect Immun** 1995 Dec; 63(12):4744–54
Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Booth V, et al. **Infect Immun** 1996 Feb;64(2):422–7
Antigenic, structural, and functional relationships between fimbriae and the hemagglutinating adhesin HA–Ag2 of Porphyromonas gingivalis. Chandad F, et al. **Infect Immun** 1995 Dec;63(12):4755–63
Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Cunningham MD, et al. **Infect Immun** 1996 Sep;64(9):3601–8

Characterization of an adherence and antigenic determinant of the ArgI protease of Porphyromonas gingivalis which is present on multiple gene products. Curtis MA, et al. **Infect Immun** 1996 Jul;64(7):2532–9

Hemin–induced modifications of the antigenicity and hemin–binding capacity of Porphyromonas gingivalis lipopolysaccharide. Cutler CW, et al. **Infect Immun** 1996 Jun;64(6):2282–7

Identification of murine protective epitopes on the Porphyromonas gingivalis fimbrillin molecule. Deslauriers M, et al. **Infect Immun** 1996 Feb;64(2):434–40

In vivo induction of apoptosis and immune responses in mice by administration of lipopolysaccharide from Porphyromonas gingivalis. Isogai E, et al. **Infect Immun** 1996 Apr;64(4):1461–6

Porphyromonas gingivalis lipopolysaccharide is poorly recognized by molecular components of innate host defense in a mouse model of early inflammation. Reife RA, et al. **Infect Immun** 1995 Dec;63(12):4686–94

Specific serum IgA titres as realistic indicators of treatment prognoses. Landry RG. **Int Dent J** 1995 Aug;45(4):267–74

Characterization of T lymphocyte clones derived from Porphyromonas gingivalis infected subjects. Gemmell E, et al. **J Periodontal Res** 1996 Jan;31(1):47–56

Influence of periodontal bacteria and disease status on V beta expression in T cells. Mathur A, et al. **J Periodontal Res** 1995 Sep;30(5):369–73

Reactive antibodies in sera from pubertal and adult gingivitis patients against various Porphyromonas gingivalis antigens. Nakagawa T, et al. **J Periodontal Res** 1995 Nov; 30(6):396–403

Detection of antigenic proteins in Porphyromonas gingivalis using two–dimensional electrophoresis and western blots. Tani M, et al. **J Periodontal Res** 1995 May;30(3):172–80

ISOLATION & PURIFICATION

Putative periodontal pathogens colonizing oral mucous membranes in denture–wearing subjects with a past history of periodontitis. Danser MM, et al. **J Clin Periodontol** 1995 Nov;22(11):854–9

The effect of a single mechanical treatment on the subgingival microflora in patients with HIV–associated gingivitis. Hofer D, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):180–7

The natural history of periodontal disease. The correlation of selected microbiological parameters with disease severity in Sri Lankan tea workers. Preus HR, et al. **J Clin Periodontol** 1995 Sep;22(9):674–8

Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Treponema denticola detection in oral plaque samples using the polymerase chain reaction. Watanabe K, et al. **J Clin Periodontol** 1996 Mar; 23(3 Pt 1):212–9

Simultaneous detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis by a rapid PCR method. Wahlfors J, et al. **J Dent Res** 1995 Nov;74(11):1796–801

Distribution of Porphyromonas gingivalis and Treponema denticola in human subgingival plaque at different periodontal pocket depths examined by immunohistochemical methods. Kigure T, et al. **J Periodontal Res** 1995 Sep;30(5):332–41

Comparison of randomly cloned and whole genomic DNA probes for the detection of Porphyromonas gingivalis and Bacteroides forsythus. Wong M, et al. **J Periodontal Res** 1996 Jan;31(1):27–35

Bacterial colonization of the external and internal sulci and of cellulose membranes at time of retrieval. Novaes AB Jr, et al. **J Periodontol** 1995 Oct;66(10):864–9

Analytical performance of an immunologic–based periodontal bacterial test for simultaneous detection and differentiation of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia. Snyder B, et al. **J Periodontol** 1996 May;67(5):497–505

Semiquantitative analysis of periodontopathogens by gene amplification. Sumi Y, et al. **Jpn J Med Sci Biol** 1995 Aug; 48(4):177–91

METABOLISM

Fibronectin binding domain of P. gingivalis fimbriae. Sojar HT, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):785–92

Binding of hemoglobin by Porphyromonas gingivalis. Amano A, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):63–7

Development of a simple chemically defined medium for Porphyromonas gingivalis: requirement for alpha–ketoglutarate. Milner P, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):125–30

Interaction of Porphyromonas gingivalis with transferrin. Tazaki K, et al. **FEMS Microbiol Lett** 1995 Sep 1; 131(2):161–6

Binding of hemoglobin to the envelope of Porphyromonas gingivalis and isolation of the hemoglobin–binding protein. Fujimura S, et al. **Infect Immun** 1996 Jun;64(6):2339–42

Porphyromonas gingivalis fimbrillin is one of the fibronectin–binding proteins. Murakami Y, et al. **Infect Immun** 1996 Jul;64(7):2571–6

Characterization of the binding activities of proteinase–adhesin complexes from Porphyromonas gingivalis. Pike RN, et al. **J Bacteriol** 1996 May; 178(10):2876–82

Effects of Porphyromonas gingivalis culture products on the morphology of peripheral blood polymorphonuclear leucocytes from periodontitis patients and healthy subjects. Scragg MA, et al. **J Clin Periodontol** 1995 Aug; 22(8):585–90

Effect of Porphyromonas gingivalis ATCC 33277 vesicle on adherence of Streptococcus mutans OMZ 70 to the experimental pellicle. Kamaguchi A, et al. **Microbiol Immunol** 1995;39(7):521–4

PATHOGENICITY

Mixed infection with Porphyromonas gingivalis and Fusobacterium nucleatum in a murine lesion model: potential synergistic effects on virulence. Feuille F, et al. **Infect Immun** 1996 Jun;64(6):2094–100

Porphyromonas gingivalis invasion of gingival epithelial cells. Lamont RJ, et al. **Infect Immun** 1995 Oct; 63(10):3878–85

Porphyromonas gingivalis fimbrillin is one of the fibronectin–binding proteins. Murakami Y, et al. **Infect Immun** 1996 Jul;64(7):2571–6

Trypsin–like protease activity of Porphyromonas gingivalis as a potential virulence factor in a murine lesion model. Kesavalu L, et al. **Microb Pathog** 1996 Jan;20(1):1–10

PHYSIOLOGY

Structural domains of Porphyromonas gingivalis recombinant fimbrillin that mediate binding to salivary proline–rich protein and statherin. Amano A, et al. **Infect Immun** 1996 May;64(5):1631–7

Selection and phenotypic characterization of nonhemagglutinating mutants of Porphyromonas gingivalis. Chandad F, et al. **Infect Immun** 1996 Mar; 64(3):952–8

Porphyromonas gingivalis FDC381 multiplies and persists within human oral epithelial cells in vitro. Madianos PN, et al. **Infect Immun** 1996 Feb;64(2):660–4

In vitro permeability evaluation and colonization of membranes for periodontal regeneration by Porphyromonas gingivalis. Ricci G, et al. **J Periodontol** 1996 May;67(5):490–6

Repopulation of periodontal pockets by microbial pathogens in the absence of supportive therapy. Shiloah J, et al. **J Periodontol** 1996 Feb;67(2):130–9

Porphyromonas gingivalis endotoxin affinity for dental ceramics. Robinson FG, et al. **J Prosthet Dent** 1996 Feb; 75(2):217–27

PORPOISES see **DOLPHINS**

PORTACAVAL SHUNT, SURGICAL

Focal nodular hyperplasia in an adolescent with glycogen storage disease type I with mesocaval shunt operation in childhood: a case report and review of the literature. Sakatoku H, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):172–5

Cardiac function during orthotopic liver transplantation with venovenous bypass. Cheema SP, et al. **Anaesthesia** 1995 Sep;50(9):776–8

Selective use of veno–venous bypass in orthotopic liver transplantation. Johnson MW, et al. **Clin Transplant** 1996 Apr;10(2):181–5

Disruption of circadian locomotor activity in rats after portacaval anastomosis is not gender dependent. Steindl PE, et al. **Hepatology** 1995 Dec;22(6):1763–8

Portocaval shunt, an H3–antagonist and plasma hormone levels. Fogel WA, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S52–3

Long–term effects of portocaval anastomosis in rats on brain levels of histamine and methylhistamine. Lozeva V, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S54–5

Emergency shunt for variceal bleeding [letter; comment] Orloff MJ. **J Am Coll Surg** 1995 Oct;181(4):386–8. Comment on: J Am Coll Surg 1995 Mar;180(3):337–9.

A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent–shunt. Jalan R, et al. **J Hepatol** 1995 Dec;23(6):697–705

The effect of partial portal decompression on portal blood flow and effective hepatic blood flow in man: a prospective study. Rosemurgy AS, et al. **J Surg Res** 1995 Dec; 59(6):627–30

Haemostatic and immunological sequelae of portacaval shunt in rats. Robson SC, et al. **Liver** 1995 Dec;15(6):293–9

Effect of probenecid on 5–hydroxyindoleacetic acid in cisternal cerebrospinal fluid of rats with portacaval anastomosis. Bergeron M, et al. **Neurochem Res** 1995 Aug; 20(8):963–7

Postreperfusion syndrome in swine liver transplantation: comparison between orthotopic liver transplantation and total hepatectomy with portacaval shunt using aortic graft. Ishine N, et al. **Transplant Proc** 1996 Jun;28(3):1756–8

[Latero–lateral portocaval anastomosis in the surgical treatment of portal hypertension: evaluation of a mean follow up of 14 years] Leggeri A, et al. **Ann Ital Chir** 1996 Jan–Feb;67(1):49–58; discussion 58–9 (Eng. Abstr.) **(Ita)**

[Brain and liver amino acids in rats with portacaval anastomosis in acute alcoholic intoxication] Ostrovskiĭ Slu, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):93–9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Eliminating metabolic abnormalities of portacaval shunting by restoring normal liver blood flow. Hawkins PA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1037–42

Hepatic morphonuclear alterations following portacaval shunt in the rat. Ravelingien N, et al. **J Surg Res** 1996 Mar;61(2):491–5

[Hemocholecystitis after intrahepatic portacaval anastomosis by transjugular approach: treatment by cholecystostomy and endoscopic sphincterotomy (letter)] Estermann F, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):120–1 **(Fre)**

[Eck fistula syndrome] Fukasawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):220–5 (22 ref.) **(Jpn)**

METHODS

Surgical salvage after failed transjugular intrahepatic portosystemic shunting. Landen S, et al. **Acta Chir Belg** 1995;95(4 Suppl):176–8

The effect of small–diameter H–graft portacaval shunts on portal blood flow. Rosemurgy AS 2nd, et al. **Am J Surg** 1996 Jan;171(1):154–6; discussion 156–7

Narrow versus wide diameter portacaval H–graft shunts. Henderson JM. **HPB Surg** 1995 Jun;8(3):208–9

VETERINARY

Surgical creation of portacaval shunts during temporary intestinal arterial and venous occlusion in dogs. Allen SW, et al. **Am J Vet Res** 1996 Apr;57(4):588–91

PORTAL PRESSURE

Portal–systemic shunting in a patient with normal portal vain pressures and histological evidence of idiopathic portal hypertension. Sugimura T, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):301–4

DRUG EFFECTS

The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. Forrest EH, et al. **J Hepatol** 1995 Sep;23(3):254–8

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis [see comments] Feu F, et al. **Lancet** 1995 Oct 21;346(8982):1056–9. Comment in: Lancet 1995 Oct 21;346(8982):1046–7.

PHYSIOLOGY

Relationship between directly measured portal pressure gradient and variceal hemorrhage. Jalan R, et al. **Am J Gastroenterol** 1995 Nov;90(11):1994–6

Distinct behavior of portal venous and arterial vascular waterfalls in porcine liver. Belloucif S, et al. **J Crit Care** 1995 Sep;10(3):104–14

PORTAL SYSTEM

see related
LIVER CIRCULATION
PORTOGRAPHY

Portal pyelophlebitis identified by CT scan in a patient with ischemic bowel. Ghani A, et al. **Am Surg** 1995 Dec; 61(12):1039–40

Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Rockey DC, et al. **Hepatology** 1996 Jul;24(1):233–40

Development of circulatory and metabolic shock following transient portal triad occlusion. Gonce ME, et al. **J Surg Res** 1995 Nov;59(5):534–43

Effects of hypovolemic shock and reperfusion on liver blood flow in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Aug;57(4):703–8

Serum analysis using high performance liquid chromatography in porcine liver transplantation. Ito K, et al. **Transplant Proc** 1996 Jun;28(3):1771–2

Detrimental effect of immediate portal hypertension in canine quarter orthotopic liver transplantation. Maeda I, et al. **Transplant Proc** 1996 Jun;28(3):1759–60

Influence of portoarterial reflux on the development of hepatic arterial thrombosis in auxiliary partial liver transplantation in the rat. Yoo CH, et al. **Transplant Proc** 1996 Jun;28(3):1775–7

ABNORMALITIES

Glomerulopathy in dogs with congenital portosystemic shunts. Tisdall PL, et al. **Aust Vet J** 1996 Feb;73(2):52–4

Congenital anomalies of the portal venous system and azygos system [letter; comment] Hawkins SP, et al. **Clin Radiol** 1996 Feb;51(2):150. Comment on: Clin Radiol 1993 Sep;48(3):207–9. Comment on: Clin Radiol 1995 Mar;50(3):174–6.

Congenital extra–hepatic portocaval shunt. Concerning a case of antenatal diagnosis. Mboyo A, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):243–5

Multiple extrahepatic portosystemic shunts in dogs: 30 cases (1981–1993). Boothe HW, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1849–54

Correlation of ultrasonographic findings with surgical, portographic, and necropsy findings in dogs and cats with

portosystemic shunts: 63 cases (1987–1993). Holt DE, et al. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1190–3

Intraoperative use of subtraction angiography and an ultrasonic aspirator to improve identification and isolation of an intrahepatic portosystemic shunt in a dog. Tobias KS, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):888–90

Per rectal portal scintigraphy in the diagnosis and management of feline congenital portosystemic shunts. Forster-van Hijfte MA, et al. **J Small Anim Pract** 1996 Jan;37(1):7–11

Ultrasonographic diagnosis of congenital portosystemic shunt in 14 cats. Lamb CR, et al. **J Small Anim Pract** 1996 May; 37(5):205–9

Portosystemic communications: follow-up of 32 cases. Smith KR, et al. **J Small Anim Pract** 1995 Oct;36(10):435–40

Validity of serum bile acids for portocaval shunt screening [letter; comment] Belford C. **Vet Rec** 1996 Mar 23; 138(12):288. Comment on: Vet Rec 1996 Feb 3;138(5):105–7. Comment on: Vet Rec 1996 Feb 17;138(7):167–8.

Transient metabolic hyperammonaemia in young Irish wolfhounds [see comments] Meyer HP, et al. **Vet Rec** 1996 Feb 3;138(5):105–7. Comment in: Vet Rec 1996 Feb 17;138(7):167–8. Comment in: Vet Rec 1996 Mar 23;138(12):288.

Long-term results of complete and partial ligation of congenital portosystemic shunts in dogs. Hottinger HA, et al. **Vet Surg** 1995 Jul-Aug;24(4):331–6

[Late manifestation of congenital intrahepatic portacaval shunt in a healthy liver] Kerleau JM, et al. **Rev Med Interne** 1995;16(8):616–8 (7 ref.) (Eng. Abstr.) **(Fre)**

[Clinical case. Long-haired dachshund, male, 3 1/2 years] Meyer-Lindenberg A, et al. **Tierarztl Prax** 1996 Apr; 24(2):102, 174–6 **(Ger)**

ANATOMY & HISTOLOGY

[Anatomico-functional correlations between the pulmonary and portal circulations: the prerequisites for a modern functional imaging diagnosis] Sallustio G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):394–404 (27 ref.) (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Tincani E, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):893–7

Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Albillos A, et al. **Gastroenterology** 1995 Oct; 109(4):1257–65

Ameliorative effect of gabexate mesilate on the disturbed microcirculation following prolonged cold ischemia of the liver. Hossain MA, et al. **Transplant Proc** 1996 Feb; 28(1):331–2

EMBRYOLOGY

[Proliferation of capillary endothelium in the primary plexus of the hypothalamo-hypophyseal portal circulatory system during rat ontogenesis] Ivanova IP, et al. **Biull Eksp Biol Med** 1995 May;119(5):462–4 **(Rus)**

INNERVATION

An electrophysiological study on amino acid sensors in the hepato-portal system in the rat. Niijima A, et al. **Obes Res** 1995 Dec;3 Suppl 5:741S–745S

METABOLISM

Depressed sensitivity of the hepatoportal NaCl receptors in rats with carbon tetrachloride-induced liver cirrhosis. Tanaka K, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1390–5

Hypothalamic-pituitary corticotroph function after shunting of magnocellular vasopressin and oxytocin to the hypophyseal portal circulation. Makara GB, et al. **Endocrinology** 1996 Feb;137(2):580–6

Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. Pagliassotti MJ, et al. **J Clin Invest** 1996 Jan 1;97(1):81–91

Portal insulin delivery is superior to peripheral delivery in handling of portally delivered glucose. Kubota M, et al. **Metabolism** 1996 Feb;45(2):150–4

Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs. Kwon Y, et al. **Pharm Res** 1996 Apr;13(4):566–9

Quantitative analysis of glycogen content in hepatocytes of portal and central lobule zones of normal human liver and in patients with chronic hepatitis of different etiology. Kudryavtseva MV, et al. **Tissue Cell** 1996 Jun;28(3):279–85

PATHOLOGY

Time-of-flight MR angiography of the portal venous system: value compared with other imaging procedures. Hughes LA, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):375–8

Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Tuchweber B, et al. **Lab Invest** 1996 Jan;74(1):265–78

[An immunohistochemical analysis in portal lymphocytic aggregation of chronic hepatitis C] Tsuno S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:635–41 (24 ref.) **(Jpn)**

PHYSIOLOGY

The effect of small-diameter H-graft portacaval shunts on portal blood flow. Rosemurgy AS 2nd, et al. **Am J Surg** 1996 Jan;171(1):154–6; discussion 156–7

Echo-Doppler evaluation of reverse flow sign in the intrahepatic portal branches after surgery. Nishihara K, et al. **Ann Surg** 1996 Apr;223(4):370–6

Effects of bathing in hot water on portal hemodynamics in healthy subjects and in patients with compensated liver cirrhosis. Koda M, et al. **Intern Med** 1995 Jul;34(7):628–31

Circadian changes in net nutrient fluxes across the portal-drained viscera, the liver, and the hindquarters in preruminant calves. Ortigues I, et al. **J Anim Sci** 1996 Apr; 74(4):895–907

An anatomic and physiological model of hepatic vascular system. Fine DR, et al. **J Appl Physiol** 1995 Sep; 79(3):1008–26

Effect of changes in vascular tone on the haemodynamic characteristics of the portal vascular bed of the isolated perfused rat liver. Grossman HJ, et al. **J Gastroenterol Hepatol** 1995 Jul-Aug;10(4):459–64

Focal sparing of liver parenchyma in steatosis: role of the gallbladder and its vessels [see comments] Aubin B, et al. **J Ultrasound Med** 1995 Feb;14(2):77–80. Comment in: J Ultrasound Med 1996 Jan;15(1):89–90.

The effect of indomethacin on liver blood flow and oxygen supply-uptake relationship in the dog. Kinoshita G, et al. **J Vet Med Sci** 1995 Apr;57(2):193–7

Control of motor and secretory functions of the stomach by a portal glucose signal. Sakaguchi T. **Neurosci Biobehav Rev** 1995 Fall;19(3):469–78 (134 ref.)

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA. **Semin Gastrointest Dis** 1995 Jul;6(3):165–77 (58 ref.)

Portal insulin delivery prevents hyperinsulinemia in rats with renal-mesenteric vein anastomosis after renal islet transplants. Guan J, et al. **Transplant Proc** 1995 Dec; 27(6):3237

PHYSIOPATHOLOGY

Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. Goseki N, et al. **Cancer** 1995 Sep 1; 76(5):736–42

Hemodynamic effects of hypothyroidism induced by methimazole in normal and portal hypertensive rats. Oren R, et al. **Dig Dis Sci** 1995 Sep;40(9):1941–5

Hemodynamic analysis of findings in patients with portal hypertension: multicenter analysis in Japan. Japan Portal Hypertension Study Group. Aoki H, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1030–8

Portal blood velocity and portal blood flow in patients with chronic viral hepatitis: relation to histological liver fibrosis. Koda M, et al. **Hepatogastroenterology** 1996 Jan-Feb; 43(7):199–202

The effect of partial portal decompression on portal blood flow and effective hepatic blood flow in man: a prospective study. Rosemurgy AS, et al. **J Surg Res** 1995 Dec; 59(6):627–30

Consequences of acute closure of a decompressed portal system [letter; comment] Bookstein JJ. **J Vasc Interv Radiol** 1995 Jul-Aug;6(4):659. Comment on: J Vasc Interv Radiol 1994 Nov-Dec;5(6):831–4.

Effect of spontaneous splenorenal shunts on portal hemodynamics: limited regression of varices after transjugular intrahepatic portosystemic shunt creation. Murphy TP, et al. **J Vasc Interv Radiol** 1995 Sep-Oct; 6(5):700–2

Prognostic value of portal haemodynamics. Westaby D. **Lancet** 1995 Oct 21;346(8982):1046–7

Magnetic resonance imaging-derived parameter of portal flow predicts volume-mediated pulmonary hypertension in liver transplantation candidates. Kuo PC, et al. **Surgery** 1995 Oct;118(4):685–91; discussion 691–2

[Hemodynamic changes in portal system after transjugular intrahepatic portosystemic shunts (TIPS)] Li W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):476–8 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Angiographic evaluation after portal blood flow preserving operations. Mercado MA, et al. **J Clin Gastroenterol** 1995 Sep;21(2):149–53

Images in clinical medicine. Gas in the portal venous system. Kundrotas LW, et al. **N Engl J Med** 1996 Sep 19; 335(12):864

RADIONUCLIDE IMAGING

Hepatic distribution of blood flow from the superior or inferior mesenteric vein mapped by portal scintigraphy with iodine-123-iodoamphetamine. Shiomi S, et al. **J Nucl Med** 1996 Jan;37(1):51–4

Per rectal portal scintigraphy in the diagnosis and management of feline congenital portosystemic shunts. Forster-van Hijfte MA, et al. **J Small Anim Pract** 1996 Jan;37(1):7–11

SURGERY

Portosystemic communications: follow-up of 32 cases. Smith KR, et al. **J Small Anim Pract** 1995 Oct;36(10):435–40

Clinical experience with the intrahepatic posterior approach to the portal triad for right hepatectomy and right segmental resection. Maddern GJ, et al. **World J Surg** 1995 Sep-Oct;19(5):764–7

ULTRASONOGRAPHY

Sonography useful after TIPS. Ott DJ. **Am J Gastroenterol** 1996 Apr;91(4):814–5

Portal hypertension: review of data and influence on management. Caletti GC, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):655–65 (29 ref.)

Asymptomatic extrahepatic portal obstruction without portal hypertensive findings detected in ultrasonic mass screening. Koda M, et al. **Hepatogastroenterology** 1995 Jul-Aug; 42(4):406–10

PORTAL VEIN

see related

PORTOGRAPHY

Short-segment jejunal stenosis complicating subacute portomesenteric venous thrombosis in a patient with protein S deficiency type II. Arentsen JC, et al. **Am J Gastroenterol** 1996 Aug;91(8):1653–4

The "pseudo-cholangiocarcinoma sign" in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels. Bayraktar Y, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2015–9

The incidence of protein C deficiency in thrombosis-related portal hypertension. Majluf-Cruz A, et al. **Am J Gastroenterol** 1996 May;91(5):976–80

Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)

Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel. Toyosaka A, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1610–5

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163–5 (11 ref.)

Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Nurden P, et al. **Am J Hematol** 1996 Jan;51(1):79–84

Surgical creation of portacaval shunts during temporary intestinal arterial and venous occlusion in dogs. Allen SW, et al. **Am J Vet Res** 1996 Apr;57(4):588–91

Suppurative pylephlebitis and pylethrombosis: the role of anticoagulation. Duffy FJ Jr, et al. **Am Surg** 1995 Dec; 61(12):1041–4

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)

Hepatic-portal venous gas associated with ileus. Quirke TE. **Am Surg** 1995 Dec;61(12):1084–6 (12 ref.)

Portal vein thrombosis due to antithrombin III deficiency. A case report. Yonemitsu Y, et al. **Angiology** 1995 Nov; 46(11):1043–7

Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Belghiti J, et al. **Ann Surg** 1996 Aug;224(2):155–61

Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Uesaka K, et al. **Ann Surg** 1996 Jan;223(1):77–83

Improved results of liver transplantation in patients with portal vein thrombosis. Seu P, et al. **Arch Surg** 1996 Aug; 131(8):840–4; discussion 844–5

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Skarsgard ED, et al. **Can J Surg** 1995 Oct; 38(5):459–63

Transjugular insertion of biliary stents (TIBS) in two patients with malignant obstruction, ascites, and coagulopathy. Amygdalos MA, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr;19(2):107–9

Percutaneous transhepatic treatment of a posttransplant portal vein thrombosis and a preexisting spontaneous splenorenal shunt. Bilbao JI, et al. **Cardiovasc Intervent Radiol** 1995 Sep-Oct;18(5):323–6

Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein. Katsumori T, et al. **Cardiovasc Intervent Radiol** 1995 Jul-Aug;18(4):217–21

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Procacci C, et al. **Cardiovasc Intervent Radiol** 1995 Nov-Dec;18(6):399–402 (15 ref.)

Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)

Portal vein thrombosis following endoscopic variceal

sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Politoske D, et al. **Dig Dis Sci** 1996 Jan;41(1):185–90

Effectiveness of combined anticoagulant therapy for extending portal vein thrombosis in Crohn's disease. Report of a case. Tsujikawa T, et al. **Dis Colon Rectum** 1996 Jul; 39(7):823–5

Endoscopic management of obstructive jaundice due to portal cavernoma [letter; comment] Yatto GN, et al. **Endoscopy** 1995 Aug;27(6):462–3. Comment on: Endoscopy 1993 Aug;25(6):423–5.

Angiographic embolization of intrahepatic arterioportal fistula. Taourel P, et al. **Eur Radiol** 1996;6(4):510–3

Hepatic adenine nucleotides and DNA synthesis during the regenerative and atrophic process of the liver lobes after selective portal vein ligation. Kameoka N, et al. **Eur Surg Res** 1996;28(3):212–21

Association of coeliac disease and portal venous thrombosis [letter] Zenjari T, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):953–4

Choledocholithiasis associated with portal biliopathy in patients with extrahepatic portal vein obstruction: management with endoscopic sphincterotomy. Bhatia V, et al. **Gastrointest Endosc** 1995 Aug;42(2):178–81

Hepatic portal venous gas after transgastric EUS-guided fine-needle aspiration of an accessory spleen. Pfaffenbach B, et al. **Gastrointest Endosc** 1996 May;43(5):515–8

Extracorporeal circulation and hypothermic perfusion for caval tumor thrombus complicating hepatocellular carcinoma: a case report. Hamazaki K, et al. **Hepatogastroenterology** 1995 Jul;42(3):282–5

Effects of long-term administration of octreotide in portal vein–stenosed rats. Lin HC, et al. **Hepatology** 1996 Mar; 23(3):537–43

Selective portal vein embolization with absolute ethanol induces hepatic hypertrophy and makes more extensive hepatectomy possible. Ogasawara K, et al. **Hepatology** 1996 Feb;23(2):338–45

Portal vein embolization with steel coils and absolute ethanol: a comparative experimental study with canine liver. Yamakado K, et al. **Hepatology** 1995 Dec;22(6):1812–8

Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. Yki-Järvinen H, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3227–32

Portal hypertension due to incomplete membranous obstruction of the portal vein. Bayraktar Y, et al. **J Clin Gastroenterol** 1995 Oct;21(3):260–2

Hepatic portal vein gas following blunt colon injury: report of a case. Ho MC, et al. **J Formos Med Assoc** 1995 Sep; 94(9):578–80

Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. Yen FS, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):237–40

Triangular cord': a sonographic finding applicable in the diagnosis of biliary atresia. Choi SO, et al. **J Pediatr Surg** 1996 Mar;31(3):363–6

Vascular complications after pediatric liver transplantation. Lallier M, et al. **J Pediatr Surg** 1995 Aug;30(8):1122–6

A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. Gayowski TJ, et al. **J Surg Res** 1996 Feb 1;60(2):333–8

Portal vein branch occlusion induces cell proliferation of cholestatic rat liver. Mizuno S, et al. **J Surg Res** 1996 Jan; 60(1):249–57

Reversible portal venous gas in hypertrophic pyloric stenosis: detection by ultrasound. Sorantin E, et al. **J Ultrasound Med** 1995 Sep;14(9):699–701

Percutaneous management of suppurative pylephlebitis. Dean JW, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):585–8

31-year-old woman with an enlarged tender liver [see comments] de Celis G, et al. **Lancet** 1995 Nov 11; 346(8985):1270. Comment in: Lancet 1996 Jan 27;347(8996):266.

Acute portal vein thrombosis at the onset of a nephrotic syndrome. Plaisier EM, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):696–8

Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Nagino M, et al. **Radiology** 1996 Aug; 200(2):559–63

Hepatic artery resistance in portal vein thrombosis [letter; comment] Piscaglia F, et al. **Radiology** 1996 Jul; 200(1):285–6. Comment on: Radiology 1995 Jul;196(1):95–8. Comment on: Radiology 1995 Aug;196(2):489–92.

Resected acinar cell carcinoma of the pancreas with tumor thrombus extending into the main portal vein: report of a case. Ueda T, et al. **Surg Today** 1996;26(5):357–60

Islet cell implantation into the pouched amniotic membrane on the side of the portal vein in dogs. Ghanavi J, et al. **Transplant Proc** 1995 Oct;27(5):2644

Thermodiffusion as a novel method for continuous monitoring of the hepatic microcirculation after liver transplantation. Klar E, et al. **Transplant Proc** 1995 Oct; 27(5):2610–2

[Morphologic verification of neoplastic portal vein obstruction] Hořejšová M, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):655–7 (Eng. Abstr.) **(Cze)**

[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506–>Gln mutation of the gene of factor V] Levoir D, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):729–31 (Eng. Abstr.) **(Fre)**

[Postpartum mesenteric–portal thrombosis of pseudotumor presentation] Gbazi C, et al. **J Radiol** 1996 Jun;77(6):437–9 (Eng. Abstr.) **(Fre)**

[Post-traumatic thrombosis of the portal vein] Beaufort P, et al. **Presse Med** 1996 Feb 17;25(6):247–8 (Eng. Abstr.) **(Fre)**

[Hemostatic embolization of hepatocellular carcinoma with portal vein thrombosis complicated by hemoperitoneum] Masbou J, et al. **Presse Med** 1996 Feb 24;25(7):281–3 (Eng. Abstr.) **(Fre)**

[Portal vein and hepatic vein thrombosis in occult myeloproliferative syndrome. Progression of thrombosis under heparin therapy] Frey HR, et al. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1437–41 (Eng. Abstr.) **(Ger)**

[Hemobilia due to a portobiliary fistula as a complication of a fine-needle liver biopsy] De Santis M, et al. **Radiol Med (Torino)** 1996 Apr;91(4):482–5 (18 ref.) **(Ita)**

[A successful treatment using SMANCS–TAE for hepatocellular carcinoma with tumor thrombus in the portal trunk] Fukushima M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1073–6 (Eng. Abstr.) **(Jpn)**

[Two hepatocellular carcinoma patients with biloma after transarterial embolization with lipiodol (Lip–TAE) leading to occlusion of portal vein] Haneda T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1665–8 (Eng. Abstr.) **(Jpn)**

[Portal embolization using lipiodol–gelatin sponge] Ohkawa M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Apr; 56(5):323–4 (Eng. Abstr.) **(Jpn)**

[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**

[Contrast enhanced color Doppler sonography in a hepatocellular carcinoma case with portal tumor thrombus] Tanaka S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):54–6 **(Jpn)**

[Porto-systemic shunt] Hamazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):243–7 (21 ref.) **(Jpn)**

[Intrahepatic portal–hepatic venous fistula] Iwahashi K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):214–7 (19 ref.) **(Jpn)**

[Extrahepatic portal vein aneurysm] Iwasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):180–3 (24 ref.) **(Jpn)**

[Portal vein thrombosis] Kajikawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):239–42 (24 ref.) **(Jpn)**

[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210–3 (21 ref.) **(Jpn)**

[Intrahepatic arteriovenous fistula] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):207–9 (23 ref.) **(Jpn)**

[Intrahepatic portal vein aneurysm] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):218–20 (19 ref.) **(Jpn)**

[Ultrasonic diagnosis of cavernous transformation of the portal vein in newborn infants] Pykov MI, et al. **Vestn Rentgenol Radiol** 1995 Jul–Aug;(4):36–8 **(Rus)**

[Regression of portal vein thrombus after intravascular treatment of a patient with hepatic metastasis of carcinoid] Tarazov PG, et al. **Vestn Rentgenol Radiol** 1995 May–Jun; (3):51–2 **(Rus)**

[Fatal outcome after hepatic artery embolization in spontaneous arterioportal fistula in a patient with liver cirrhosis] Tarazov PG. **Vestn Rentgenol Radiol** 1996 Jan–Feb;(1):47–8 **(Rus)**

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

ABNORMALITIES

An unusual cause of congenital ascites. Puvabanditsin S, et al. **Acta Paediatr** 1995 Jul;84(7):829–30

Ultrasound diagnosis of portocaval anastomosis in infants—a report of eight cases. Farrant P, et al. **Br J Radiol** 1996 May;69(821):389–93

Total anomalous pulmonary venous connection to the portal vein. Wyttenbach M, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):113–6

Diagnosis of an accessory portal vein and its clinical implications for portosystemic shunts. Zhang JS, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):239–41

Case report: percutaneous transhepatic portographic embolization (PTPE) for recurrent hepatic encephalopathy derived from intrahepatic portal-systemic shunts. Sezai S, et al. **Clin Radiol** 1995 Nov;50(11):807–9

Patent ductus venosus associated with a hyperintense globus pallidum on T1-weighted magnetic resonance imaging and pulmonary hypertension. Yanai S, et al. **Eur J Pediatr** 1995 Jul;154(7):526–9

Congenital extra-hepatic portocaval shunt. Concerning a case of antenatal diagnosis. Mboyo A, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):243–5

Congenital intrahepatic portosystemic venous shunt: sonographic and magnetic resonance imaging. Santamaría G, et al. **Eur Radiol** 1996;6(1):76–8

Resection of metastatic liver cancer in a patient with an anomalous intrahepatic portal system: a case report. Hiei K, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):1002–7

Congenital absence of portal venous system associated with a large inferior mesenteric–caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286–90 (17 ref.)

What is your diagnosis? Portoazygos shunt and urinary calculi in a dog. Tillson DM, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):561–2

Familial occurrence of cavernous transformation of the portal vein. Ramirez RO, et al. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):313–8

Preduodenal portal vein: a cause of prenatally diagnosed duodenal obstruction. Choi SO, et al. **J Pediatr Surg** 1995 Oct;30(10):1521–2

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127–30 (15 ref.)

Prenatal sonographic findings of agenesis of the right and left portal veins and associated intrahepatic portosystemic shunts. Gonçalves LF, et al. **J Ultrasound Med** 1995 Nov; 14(11):849–52

Congenital hepatoportal arteriovenous fistula [letter; comment] Stringer MD, et al. **Surgery** 1996 Feb; 119(2):235–6. Comment on: Surgery 1995 Feb;117(2):170–4.

Hepatic arterioportal fistulas: surgical ligation of embolization? [letter; comment] Tarazov PG. **Surgery** 1996 Feb;119(2):237. Comment on: Surgery 1995 Feb;117(2):170–4.

Portal hypertension associated with primary hypoplasia of the hepatic portal vein in dogs. Van den Ingh TS, et al. **Vet Rec** 1995 Oct 21;137(17):424–7

Long-term clinical outcome after partial ligation of single extrahepatic vascular anomalies in 20 dogs. Komtebedde J, et al. **Vet Surg** 1995 Sep–Oct;24(5):379–83

[Biliary reoperation with the correction of portal hypertension in a female patient with a congenital anomaly] Damianov D, et al. **Khirurgiia (Sofiia)** 1995;48(4):52–4 **(Bul)**

[Congenital anomaly of the portal venous system] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):231–4 (22 ref.) **(Jpn)**

[Congenital intrahepatic venous shunt as a cause of hepatic encephalopathy] Cosme Jiménez A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):460–3 (25 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Comparison of portal vein anatomy and bony anatomic landmarks. Darcy MD, et al. **Radiology** 1996 Sep; 200(3):707–10

Variation of the intrahepatic portal vein; angiographic demonstration and application in living-related hepatic transplantation. Cheng YF, et al. **Transplant Proc** 1996 Jun; 28(3):1667–8

Anatomic basis and technique of procurement of subsegment III from living donors for liver transplantation. Văn Minh T. **Transplant Proc** 1996 Feb;28(1):59–60

CHEMISTRY

Distribution of endothelin-1-receptor subtypes in rat portal vein. Filippelli A, et al. **J Cardiovasc Pharmacol** 1996 Jan; 27(1):113–18

CYTOLOGY

Manipulation of xenogeneic skin and/or renal graft survival in the rat-mouse concordant combination by portal vein pretransplant transfusion. Gorczynski RM, et al. **Transpl Immunol** 1995 Dec;3(4):321–9

DRUG EFFECTS

Differential actions of exogenous and intracellular spermine on contractile activity in smooth muscle of rat portal vein. Nilsson BO, et al. **Acta Physiol Scand** 1995 Jul; 154(3):355–65

Effects of BRL55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide-resistant, ATP-sensitive potassium current. Edwards G, et al. **Br J Pharmacol** 1995 Jul;115(6):1027–37

Distribution of endothelin-1-receptor subtypes in rat portal vein. Filippelli A, et al. **J Cardiovasc Pharmacol** 1996 Jan; 27(1):113–18

Loss of maximum attenuation and receptor reserve for isoprenaline at the beta 2-adrenoceptors of the portal veins of hypertensive rats. Doggrell SA, et al. **J Hypertens** 1995 Sep;13(9):1023–9

Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes. Macrez-Leprêtre N, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):468–75

INJURIES

Rapidly progressive portal hypertension 23 years after

post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442-6 (30 ref.)
The continuing need to formalize pre-hospital triage, highlighted by a case of unusual injury. Lavis M, et al. **J Accid Emerg Med** 1995 Sep;12(3):206-7
Intrahepatic arterioportal fistula stemming from percutaneous biliary drainage: unusual cause of postoperative massive hemobilia. Chang HT, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):76-8
Portal triad injuries. Jurkovich GJ, et al. **J Trauma** 1995 Sep; 39(3):426-34
Liver infarction produced by dual vessels occlusion due to trauma and TAE: long follow up using CT, US, and MRI. Takakuwa T, et al. **Med J Osaka Univ** 1993 Sep; 41-42(1-4):23-7
Formation of a fatal arterioportal fistula following needle liver biopsy in a child with a living-related liver transplant: report of a case. Otobe Y, et al. **Surg Today** 1995; 25(10):916-9
[Portal vein thrombosis and rupture of the esophagus secondary to a barotrauma] Prignet JM, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):103-5 (Eng. Abstr.) **(Fre)**

METABOLISM

CGRP innervation and receptors during aging of male and female hepatic rat portal veins. Carrier N, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):53-60
Effect of temperature on spontaneous Ca2+-activated Cl- currents in rabbit portal vein cells. Helliwell RM, et al. **Pflugers Arch** 1995 Nov;431(1):28-31
Effects of calciseptine on unitary barium channel currents in guinea-pig portal vein. Teramoto N, et al. **Pflugers Arch** 1996 Jul;432(3):462-70

PATHOLOGY

Time-of-flight MR angiography of the portal venous system: value compared with other imaging procedures. Hughes LA, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):375-8
Preoperative staging of cancer of the pancreas: value of MR angiography versus conventional angiography in detecting portal venous invasion. McFarland EG, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):37-43
Clinical aspects and imaging patterns with ultrasonography and endoscopy in hepatosplenic schistosomiasis in Uganda. Ravera M, et al. **East Afr Med J** 1996 Apr;73(4):228-32
Hepatic inflow vessels caliber as an index for liver function. Ezaki T, et al. **Hepatogastroenterology** 1996 Mar-Apr; 43(8):427-31
Unusual tumors causing extrahepatic portal venous obstruction. Sharma BC, et al. **HPB Surg** 1996;9(3):165-7
Venous tumor thrombosis and cavernous transformation of the portal vein in a patient with gastric carcinoma. Ishikawa M, et al. **J Gastroenterol** 1995 Aug;30(4):529-33
Transient increased segmental hepatic enhancement distal to portal vein obstruction on dynamic gadolinium-enhanced gradient echo MR images. Schlund JF, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):375-7
Portal vein thrombosis complicating hepatocellular carcinoma. Value of ultrasound-guided fine-needle biopsy of the thrombus in the therapeutic management. Cedrone A, et al. **Liver** 1996 Apr;16(2):94-8
Portal magnetic resonance angiography. Finn JP, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):271-80 (31 ref.)
Hepatoportal sclerosis. Bioulac-Sage P, et al. **Semin Liver Dis** 1995 Nov;15(4):329-39 (32 ref.)
[Hepatoportal sclerosis, nodular regenerative hyperplasia, incomplete septal cirrhosis: lesions of hepatic microcirculation?] Bernard PH, et al. **Gastroenterol Clin Biol** 1996;20(4):335-8 (30 ref.) **(Fre)**
[Magnetic resonance angiography of the portal vein in liver transplant recipients] Pavone P, et al. **Radiol Med (Torino)** 1996 Jun;91(6):760-3 (Eng. Abstr.) **(Ita)**
[Cavernous transformation of the portal vein] Ukita M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):228-30 (18 ref.) **(Jpn)**
[Our experience in the management of portal cavernoma in children] Broto J, et al. **Cir Pediatr** 1995 Jul;8(3):99-101 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Variability of consecutive in vivo MR flow measurements in the main portal vein. Hara AK, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1311-5
Redistribution of portal venous but not hepatic arterial flow is induced by hepatic nerve stimulation in the perfused rat liver. Stuart ET, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):99-108
Effects of phospholipase C inhibitors on Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by alpha 1A- and alpha 2A-adrenoceptors in rat portal vein myocytes. Macrez-Leprêtre N, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):30-4
Augmented endogenous nitric oxide production in partial portal vein-ligated rats. Hori N, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):506-11
Transjugular intrahepatic portosystemic shunt: correlation of portal vein velocity measurements and portosystemic pressure gradients. Shapiro RS, et al. **Comput Med Imaging Graph** 1995 Jul-Aug;19(4):343-50
Adenosine does not mediate renal sodium retention and peripheral vasodilation elicited by partial portal vein ligation in rats. Murakami S, et al. **Hepatology** 1996 Feb; 23(2):346-52
Analysis of models for quantification of arterial and portal blood flow in the human liver using PET. Taniguchi H, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):135-44
Unpurified islet cell transplantation in diabetic rats. Nomura Y, et al. **Transplant Proc** 1996 Jun;28(3):1849-50

PHYSIOPATHOLOGY

Vagal and sympathetic components of the heart rate reflex in chronic portal vein stenosis. Battarbee HD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G892-901
Portal vein velocity by duplex Doppler ultrasound as an indication of the clinical severity of portal hypertension. Kuo CH, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):217-23
Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Bolognesi M, et al. **Hepatology** 1996 May;23(5):1035-40
Portal venous blood flow unaltered in cirrhotic patients given metoclopramide injections. Ohta M, et al. **Ital J Gastroenterol** 1995 Jun;27(5):239-43
Portal-systemic shunting in a patient with normal portal vain pressures and histological evidence of idiopathic portal hypertension. Sugimura T, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):301-4
Experimental atrophy/hypertrophy complex (AHC) of the liver: portal vein, but not bile duct obstruction, is the main driving force for the development of AHC in the rat. Schweizer W, et al. **J Hepatol** 1995 Jul;23(1):71-8
Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. Kauffman WM, et al. **J Ultrasound Med** 1995 Nov;14(11):877-9
Spontaneous portal-right renal vein shunt in portal hypertension. McLoughlin RF, et al. **J Ultrasound Med** 1995 Dec;14(12):959-61
Postprandial reversal of the portal venous flow in a patient with liver cirrhosis. de Vries PJ, et al. **Neth J Med** 1995 Nov;47(5):235-40
Nitric oxide does not contribute to sodium retention and peripheral vasodilation induced by partial portal vein ligation in rats. Murakami S, et al. **Ren Physiol Biochem** 1995 Jul-Aug;18(4):198-208
Hepatic hypoperfusion after intestinal reperfusion. Turnage RH, et al. **Surgery** 1996 Feb;119(2):151-60
[Measurement of portal and splenic venous flow volume (PV and SV), congestion index (CI) and SV/PV% in various liver diseases using by Doppler echo-sonography] Sato S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):331-7 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Calcifications of portal venous system wall: CT findings in three patients. Egiebor O, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):477-9 (7 ref.)
Gastrointestinal case of the day. Portal and mesenteric vein thrombosis. Gay SB, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):241, 243
Hepatic lymphography: another trick for portal vein location during transjugular intrahepatic portosystemic shunts [letter] Ghysels MP, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):467-8
Portal venous gas in a cardiac transplant patient [letter; comment] Ozgur HT, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):992-3. Comment on: AJR Am J Roentgenol 1995 Aug;165(2):338-9.
Applicability of prostaglandin E1 indirect portal vein angiography in patients with portal hypertension. Peng Z, et al. **Chin Med J (Engl)** 1995 May;108(5):323-7
Linear hepatic gas shadows in a woman with acute abdominal pain. Hariharan R, et al. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):37-8
Early enhancement of tumor thrombus in the portal vein on two-phase helical CT. Lin JP, et al. **J Comput Assist Tomogr** 1996 Jul-Aug;20(4):653-5
The application of prostaglandin E1 indirect portal vein angiography and color Doppler ultrasound in patients with post-devascularization portal hypertension. Peng ZH, et al. **J Tongji Med Univ** 1995;15(3):154-7
Portal vein patency in candidates for liver transplantation: MR angiographic analysis. Silverman JM, et al. **Radiology** 1995 Oct;197(1):147-52
Relationship between intrahepatic vessels and computer-generated hepatic scissurae: an in vitro assay. Fasel JH, et al. **Surg Radiol Anat** 1996;18(1):43-6
[Portal hypertension with hepatic-portal fistula on a cirrhotic liver] Gailleton R, et al. **Ann Chir** 1996;50(3):276-8 (Eng. Abstr.) **(Fre)**
[Association of extrahepatic aneurysm of the hepatic artery and aneurysm of the portal trunk in a patient with liver cirrhosis (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):958-60 **(Fre)**
[Septic portal vein thrombosis as a rare complication of Crohn disease with retroperitoneal abscess] Diehl SJ, et al. **Aktuelle Radiol** 1996 Mar;6(2):99-101 (Eng. Abstr.) **(Ger)**
[Histopathological analysis of A-P shunt in peripheral intrahepatic cholangiocarcinoma] Akiyama M. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):739-44 (Eng. Abstr.) **(Jpn)**
[Hepatic portal venous gas] Kudo M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):595-7 (18 ref.) **(Jpn)**

SURGERY

Carcinoma of the periampullary region: who benefits from portal vein resection? Roder JD, et al. **Am J Surg** 1996 Jan;171(1):170-4; discussion 174-5
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Fuhrman GM, et al. **Ann Surg** 1996 Feb; 223(2):154-62
Functional contribution of preoperative portal vein occlusion to hepatectomy. With special reference to hepatic energy charge and DNA synthesis after hepatectomy in rats. Chijiiwa K, et al. **Arch Surg** 1996 Jul;131(7):779-84
Operative injury to the hepatic artery [letter; comment] Lowell JA, et al. **Arch Surg** 1996 Jul;131(7):788. Comment on: Arch Surg 1996 Feb;131(2):211-5.
Elevated mitochondrial gene expression during rat liver regeneration after portal vein ligation. Shimizu Y, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1222-9
Temporary shunt between right portal vein and vena cava in living related liver transplantation. Kawasaki S, et al. **J Am Coll Surg** 1996 Jul;183(1):74-6
Mesoportal bypass: a unique operation for mesenteric hypertension. Silvestri F, et al. **J Vasc Surg** 1995 Dec; 22(6):764-8
Rats with portal-caval vein transposition show hyperinsulinemia and insulin resistance. Williamson MP, et al. **Metabolism** 1996 Jan;45(1):120-5
A novel paper cuff for vascular reconstruction in canine liver transplantation. Fukumoto T, et al. **Surg Today** 1996; 26(4):295-7
Successful management of portal hypertension following artificial arterioportal shunting: report of a case. Ko S, et al. **Surg Today** 1995;25(6):557-9
Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855-8 (11 ref.)
New technique of orthotopic segmental pancreas transplantation with portal venous drainage established by interposing the splenic vessels. Suzuki Y, et al. **Transplant Proc** 1996 Jun;28(3):1804-6
Original extrahilar approach for hepatic portal revascularization and relief of extrahepatic portal hypertension related to later portal vein thrombosis after pediatric liver transplantation. Long term results. de Ville de Goyet J, et al. **Transplantation** 1996 Jul 15;62(1):71-5
Arterialization of the portal vein in orthotopic and auxiliary liver transplantation. A report of three cases. Erhard J, et al. **Transplantation** 1995 Oct 27;60(8):877-9
Long-term clinical outcome after partial ligation of single extrahepatic vascular anomalies in 20 dogs. Komtebedde J, et al. **Vet Surg** 1995 Sep-Oct;24(5):379-83
[Percutaneous puncture technique for portofemorosubclavicular venovenous bypass in orthotopic liver transplantation] Giebler R, et al. **Anaesthesist** 1996 Jan;45(1):59-65 (Eng. Abstr.) **(Ger)**
[Extended partial Kausch-Whipple duodenopancreatectomy by resection of tumor infiltrated vascular segments] Keck H, et al. **Zentralbl Chir** 1995;120(10):809-14 (Eng. Abstr.) **(Ger)**
[An experimental study of blood supply to the bile duct under arterio-portal shunting] Munemura T. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):591-608 (Eng. Abstr.) **(Jpn)**
[Healing process of high porous EPTFE graft wrapped in the omental pedicle flap—experimental study of portal vein replacement] Tanaka E. **Hokkaido Igaku Zasshi** 1995 Sep; 70(5):697-715 (Eng. Abstr.) **(Jpn)**
[Deportalization of the pancreatic venous outflow in the combined treatment of diabetics] Ol'shanetskiĭ AA, et al. **Klin Khir** 1995;(9-10):3-5 **(Rus)**

ULTRASONOGRAPHY

Hypoechoic periportal encasement in Chédiak-Higashi syndrome [letter] Barzilai M, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):726-7
Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. De Gaetano AM, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1151-5
Extrahepatic portal vein stenosis in recipients of living-donor allografts: Doppler sonography. Lee J, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):85-90
Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268-9 (8 ref.)
Sequential evaluation of portal venous hemodynamics by Doppler ultrasound in patients with severe acute hepatitis. Tai D, et al. **Am J Gastroenterol** 1996 Mar;91(3):545-50
Ultrasonography in a Senegalese community recently exposed to Schistosoma mansoni infection. Kardorff R, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):586-90
Intraportal endovascular ultrasonography in the diagnosis of portal vein invasion by pancreatobiliary carcinoma. Kaneko T, et al. **Ann Surg** 1995 Dec;222(6):711-8
Pancreatic allograft thrombosis: diagnostic and therapeutic

importance of splenic venous flow velocity. Nghiem DD. **Clin Transplant** 1995 Oct;9(5):390–5

Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Tamada K, et al. **Endoscopy** 1995 Oct;27(8):573–8

Duplex Doppler endosonography in the diagnosis of splenic vein, portal vein, and portosystemic shunt thrombosis. Wiersema MJ, et al. **Gastrointest Endosc** 1995 Jul; 42(1):19–26

Paraumbilical vein patency in cirrhosis: effects on hepatic hemodynamics evaluated by Doppler sonography. Sacerdoti D, et al. **Hepatology** 1995 Dec;22(6):1689–94

Flow reversal in the right anterior branch of the portal vein: "bicolor portal vein" color Doppler analysis. Donoso L, et al. **J Clin Ultrasound** 1995 Sep;23(7):429–34

Inter–observer variability of portal hemodynamics measured by Doppler ultrasound on three different locations of portal vein. Tai DI, et al. **J Clin Ultrasound** 1996 Feb;24(2):61–6

Ultrasound–guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. De Sio I, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec; 10(6):662–5

Echo–Doppler measurements of portal vein and superior mesenteric artery blood flow in humans: inter– and intra–observer short–term reproducibility. Iwao T, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):40–6

Hepatic portal venous gas with hyperbaric decompression: ultrasonographic identification. Butler BD, et al. **J Ultrasound Med** 1995 Dec;14(12):967–70

Prenatal sonographic findings of agenesis of the right and left portal veins and associated intrahepatic portosystemic shunts. Gonçalves LF, et al. **J Ultrasound Med** 1995 Nov; 14(11):849–52

Duplex Doppler sonography of changes in portal vein flow in healthy term newborn infants after feeding. Kao SC, et al. **J Ultrasound Med** 1996 Feb;15(2):121–5

Impact of colour Doppler sonography on detection of thrombosis of the hepatic artery and the portal vein after liver transplantation. Hellinger A, et al. **Langenbecks Arch Chir** 1996;381(3):182–5

Portal vein thrombosis complicating hepatocellular carcinoma. Value of ultrasound–guided fine–needle biopsy of the thrombus in the therapeutic management. Cedrone A, et al. **Liver** 1996 Apr;16(2):94–8

Sonographic diagnosis of systemic venous gas in a patient with pneumatosis intestinalis. Soboleski D, et al. **Pediatr Radiol** 1995;25(6):480–1

Doppler US of helical flow in the portal vein. Rosenthal SJ, et al. **Radiographics** 1995 Sep;15(5):1103–11

[Portal thrombosis and liver cirrhosis. Value of ultrasound–guided puncture–biopsy of the thrombus] Duchmann JC, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):581–6 (Eng. Abstr.) **(Fre)**

[Doppler examination of portal venous flow in liver neoplasms] Wanat–Wiśniewska M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):222–7 (Eng. Abstr.) **(Pol)**

[Portal blood flow studied in children with portal hypertension using Doppler duplex echocardiography] López Barrio AM, et al. **An Esp Pediatr** 1996 Feb; 44(2):92–6 (Eng. Abstr.) **(Spa)**

[Evaluation of the portal blood flow in healthy children by Doppler duplex echography] López Barrio AM, et al. **An Esp Pediatr** 1996 Jan;44(1):45–9 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Intrahepatic portal–venous changes in dogs with dirofilariasis: scanning electron microscopy of resin casts of vasculature. Ninomiya H, et al. **J Vet Med Sci** 1995 Apr;57(2):367–71

PORTASYSTEMIC SHUNT, SURGICAL

Doppler velocity criteria for transjugular intrahepatic portosystemic shunt (TIPS) stenosis [letter; comment] Chong WK, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):215–6. Comment on: AJR Am J Roentgenol 1995 May;164(5):1119–24.

Hepatic lymphography: another trick for portal vein location during transjugular intrahepatic portosystemic shunts [letter] Ghysels MP, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):467–8

Improvement of thrombocytopenia due to hypertension after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Alvarez OA, et al. **Am J Gastroenterol** 1996 Jan;91(1):134–7

Disappearance of the pseudo–cholangiocarcinoma sign after TIPSS. Görgül A, et al. **Am J Gastroenterol** 1996 Jan; 91(1):150–4

Sonography useful after TIPS. Ott DJ. **Am J Gastroenterol** 1996 Apr;91(4):814–5

Treatment of Budd–Chiari syndrome with portosystemic shunt or liver transplantation. Hemming AW, et al. **Am J Surg** 1996 Jan;171(1):176–80; discussion 180–1

Distal splenorenal shunt versus 10–mm low–diameter mesocaval shunt for variceal hemorrhage. Mercado MA, et al. **Am J Surg** 1996 Jun;171(6):591–5

A retrospective study of the efficacy of transjugular intrahepatic portosystemic shunts. Meyer KM, et al. **Am Surg** 1996 Jan;62(1):76–80

Rheolytic thrombectomy of an acutely thrombosed transjugular intrahepatic portosystemic stent shunt. Müller–Hülsbeck S, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):294–7

Diagnosis of an accessory portal vein and its clinical implications for portosystemic shunts. Zhang JS, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):239–41

Transjugular intrahepatic portosystemic shunt (TIPS) for Budd–Chiari syndrome. Uhl MD, et al. **Dig Dis Sci** 1996 Jul;41(7):1494–9

Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt. Sort P, et al. **Endoscopy** 1995 Oct;27(8):626–7

TIPS: a new therapy for esophageal variceal bleeding caused by EHBA. Schweizer P, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):211–5

Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Cabrera J, et al. **Gastroenterology** 1996 Mar; 110(3):832–9

Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Sanyal AJ, et al. **Gastroenterology** 1996 Jul; 111(1):138–46

Tips for the treatment of refractory ascites. Siuta M, et al. **Gastroenterology** 1996 Mar;110(3):956–8

Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Shen–Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282–6 (25 ref.)

Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation. Lerut J, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):985–7

The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Shiffman ML, et al. **Hepatology** 1995 Nov; 22(5):1591–7 (78 ref.)

Transjugular intrahepatic portosystemic shunt: is it the ultimate solution for refractory ascites? Wong F, et al. **Hepatology** 1995 Nov;22(5):1613–5

Emergency transjugular intrahepatic portosystemic shunt in patients with active variceal bleeding and hepatocarcinoma. Mingoli A, et al. **Ital J Gastroenterol** 1995 Jul–Aug; 27(6):309–12

Angiographic evaluation after portal blood flow preserving operations. Mercado MA, et al. **J Clin Gastroenterol** 1995 Sep;21(2):149–53

The transjugular intrahepatic portosystemic stent–shunt: a review of the literature and own experiences. Rössle M, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):293–8 (48 ref.)

Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent–shunt for variceal haemorrhage. Jalan R, et al. **J Hepatol** 1995 Aug;23(2):123–8

Comparison of ultrasound, CT, and MR imaging in the evaluation of candidates for TIPS. Kraus BB, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):571–8

Recurrent bleeding from ileal varices treated by transjugular intrahepatic portosystemic shunt: value of Doppler ultrasonography in diagnosis and follow–up. Guth E, et al. **J Ultrasound Med** 1996 Jan;15(1):67–9

Transjugular intrahepatic portosystemic shunt placement for variceal bleeding: predictors of mortality. Encarnacion CE, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):687–94

Effect of spontaneous splenorenal shunts on portal hemodynamics: limited regression of varices after transjugular intrahepatic portosystemic shunt creation. Murphy TP, et al. **J Vasc Interv Radiol** 1995 Sep–Oct; 6(5):700–2

Thoracic duct–cutaneous fistula in a patient with cirrhosis of the liver: successful treatment with a transjugular intrahepatic portosystemic shunt. Rosser BG, et al. **Mayo Clin Proc** 1996 Aug;71(8):793–6

Haemodynamic changes in children with portal hypertension during the postoperative period. Ismail–Zade IA, et al. **Paediatr Anaesth** 1995;5(5):311–7

Budd–Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Blum U, et al. **Radiology** 1995 Dec; 197(3):805–11

Judicious use of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt and renal blood flow [comment] Cope C, et al. **Radiology** 1995 Dec; 197(3):588. Comment on: Radiology 1995 Dec;197(3):587.

Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. Crenshaw WB, et al. **Radiology** 1996 Jul;200(1):185–92

Risk of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt [see comments] Jalan R, et al. **Radiology** 1995 Dec;197(3):587. Comment in: Radiology 1995 Dec;197(3):588.

Fulminant hepatic failure from the Budd–Chiari syndrome. A bridge to transplantation with transjugular intrahepatic portosystemic shunt. Kuo PC, et al. **Transplantation** 1996 Jul 27;62(2):294–6

[Intrahepatic portasystemic shunt as a salvage treatment of uncontrolled hemorrhage caused by rupture of esophageal varices in patients with liver cirrhosis] Azoulay D, et al. **Presse Med** 1996 May 25;25(18):842–6 (Eng. Abstr.) **(Fre)**

[Color Doppler sonographic assessment of intrahepatic hemodynamics and shunt patency after transjugular intrahepatic portosystemic shunt (TIPS)] Hirai T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun;56(7):470–6 (Eng. Abstr.) **(Jpn)**

[Shunt patency after creation of a transjugular intrahepatic portosystemic shunt: evaluation with Doppler ultrasound] Kimura M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 May; 56(6):364–7 (Eng. Abstr.) **(Jpn)**

[Transjugular intrahepatic portosystemic shunt for upper gastrointestinal bleeding due to portal hypertension: 2–year results] Saito H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1266–74 (Eng. Abstr.) **(Jpn)**

[Portal hypertension and splenic circulation] Romero Torres R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S110–7 (31 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Pulmonary edema after transjugular intrahepatic portosystemic shunt [letter] Willoughby PH, et al. **Anesth Analg** 1996 Apr;82(4):895–6

Mortality during transjugular intrahepatic portosystemic shunt placement. Yonker–Sell AE, et al. **Anesthesiology** 1996 Jan;84(1):231–3 (17 ref.)

Percutaneous retrieval of a Strecker stent misplaced during TIPS. Moulin G, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):337–9

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Riggio O, et al. **Dig Dis Sci** 1996 Mar;41(3):578–84

Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome [editorial; comment] Conn HO. **Hepatology** 1996 Jan;23(1):177–81. Comment on: Hepatology 1996 Jan;23(1):32–9.

The hematologic consequences of transjugular intrahepatic portosystemic shunts [see comments] Sanyal AJ, et al. **Hepatology** 1996 Jan;23(1):32–9. Comment in: Hepatology 1996 Jan;23(1):177–81.

Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Van der Linden P, et al. **Hepatology** 1996 May;23(5):982–7

Consequences of acute closure of a decompressed portal system [letter; comment] Bookstein JJ. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):659. Comment on: J Vasc Interv Radiol 1994 Nov–Dec;5(6):831–4.

Liver transplantation complicated by malpositioned transjugular intrahepatic portosystemic shunts. Wilson MW, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):695–9

Rats with portal–caval vein transposition show hyperinsulinemia and insulin resistance. Williamson MP, et al. **Metabolism** 1996 Jan;45(1):120–5

[Physiopathology and surgical treatment of hepatic encephalopathy after porto–caval anastomosis] Porcheron J, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct; 31(5):287–94 (60 ref.) (Eng. Abstr.) **(Fre)**

[Prevalence of hepatocellular carcinoma in cirrhotic patients with with portosystemic shunt. Cohort analysis] Elizalde JI, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):189–93 (Eng. Abstr.) **(Spa)**

[Transjugular intrahepatic portosystemic shunt and intravascular hemolysis (letter)] Montes J, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):439 **(Spa)**

INSTRUMENTATION

Post–TIPS hepatic encephalopathy treated by occlusion balloon–assisted retrograde embolization of a coexisting spontaneous splenorenal shunt. Shioyama Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):53–5

Transjugular intrahepatic portosystemic shunt procedure: efficacy of 10–mm versus 12–mm Wallstents. Kuhn–Fulton J, et al. **Radiology** 1996 Jun;199(3):658–64

[Initial clinical experiences with TIPS (transjugular intrahepatic portasystemic stent–shunt) (see comments)] Nolte W, et al. **Leber Magen Darm** 1995 Dec;25(6):264–6, 269–70 (Eng. Abstr.). Comment in: Leber Magen Darm 1995 Dec;25(6):248. **(Ger)**

[Transjugular intrahepatic portosystemic shunt (TIPS): survived the trial by fire? (editorial; comment)] Rössle M. **Leber Magen Darm** 1995 Dec;25(6):248. Comment on: Leber Magen Darm 1995 Dec;25(6):264–70. **(Ger)**

METHODS

Surgical salvage after failed transjugular intrahepatic portosystemic shunting. Landen S, et al. **Acta Chir Belg** 1995;95(4 Suppl):176–8

Transjugular intrahepatic portosystemic shunts: is TIPSS definitive therapy? [editorial; comment] Collins JC. **Am J Gastroenterol** 1995 Nov;90(11):1913–4. Comment on: Am J Gastroenterol 1995 Nov;90(11):1932–7.

A comparative study of emergency transjugular intrahepatic portosystemic stent–shunt and esophageal transection in the management of uncontrolled variceal hemorrhage [see comments] Jalan R, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1932–7. Comment in: Am J Gastroenterol 1995 Nov;90(11):1913–4.

Medium aperture meso–caval shunts reliably prevent recurrent variceal hemorrhages. Scudamore CH, et al. **Am J Surg** 1996 May;171(5):490–4

Transjugular intrahepatic portasystemic stent–shunt in the

treatment of variceal haemorrhage. Jalan R, et al. **Br J Surg** 1995 Sep;82(9):1158–64 (46 ref.)

Who's for tips? [editorial] [see comments] Dick R, et al. **Clin Radiol** 1995 Sep;50(9):590–2. Comment in: Clin Radiol 1996 Mar;51(3):231–2.

Transjugular intrahepatic portosystemic shunt: correlation of portal vein velocity measurements and portosystemic pressure gradients. Shapiro RS, et al. **Comput Med Imaging Graph** 1995 Jul–Aug;19(4):343–50

Transjugular intrahepatic portosystemic shunt: a medical perspective. Sanyal AJ, et al. **Dig Dis** 1995 May–Jun; 13(3):153–62 (47 ref.)

Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Rodríguez–Laiz JM, et al. **Dig Dis Sci** 1995 Oct;40(10):2121–7

Temporary shunt between right portal vein and vena cava in living related liver transplantation. Kawasaki S, et al. **J Am Coll Surg** 1996 Jul;183(1):74–6

Hepato–pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent–shunt (TIPS) [letter] Allgaier HP, et al. **J Hepatol** 1995 Jul;23(1):102

Transjugular intrahepatic portal–systemic shunt [editorial] Sherlock S. **J Intern Med** 1996 Feb;239(2):95–8 (25 ref.)

Venovenous bypass for major hepatic and caval trauma. Baumgartner F, et al. **J Trauma** 1995 Oct;39(4):671–3

Portal hypertension revisited [editorial] Hayes PC. **QJM** 1995 Nov;88(11):751–4

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA. **Semin Gastrointest Dis** 1995 Jul;6(3):165–77 (58 ref.)

Comparison of a modified Sugiura procedure with portal systemic shunt for prevention of recurrent variceal bleeding in cirrhosis. Borgonovo G, et al. **Surgery** 1996 Feb; 119(2):214–21

[Hemodynamic changes in portal system after transjugular intrahepatic portosystemic shunts (TIPS)] Li W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):476–8 (Eng. Abstr.) **(Chi)**

[Transjugular intrahepatic portosystemic stent shunt performed under ultrasonic guidance] Xu G, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):336–8 (Eng. Abstr.) **(Chi)**

[Transjugular placement of an intrahepatic portosystemic shunt as current treatment for complications of portal hypertension] Buiskool RA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):659–64 (Eng. Abstr.) **(Dut)**

[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580–6; discussion 587–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Portasystemic anastomosis by transjugular approach: treatment of active and refractory hemorrhage caused by rupture of esophageal varices. Results in 11 patients] Bizollon T, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):903–8 (Eng. Abstr.) **(Fre)**

[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent–shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1773–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Esophageal varices. Shunt therapy and embolization] Jost R, et al. **Schweiz Rundsch Med Prax** 1995 Dec 19; 84(51–52):1540–2 **(Ger)**

[Esophageal varices. Surgical shunts] Largiadèr F. **Schweiz Rundsch Med Prax** 1995 Dec 19;84(51–52):1543 **(Ger)**

[A case of refractory ascites successfully treated with transjugular intrahepatic portosystemic shunt] Kanazawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):373–6 **(Jpn)**

[Transjugular intrahepatic portasystemic shunt. A new therapeutic method in portal hypertension] Tesdal IK, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):968–72 (Eng. Abstr.) **(Nor)**

[The clinical efficacy and complications of the transjugular intrahepatic portosystemic shunt–stent] Santolaria Piedrafita S, et al. **Rev Clin Esp** 1995 Sep;195(9):609–13 (Eng. Abstr.) **(Spa)**

PORTOENTEROSTOMY, HEPATIC

Long–term results with the Kasai operation for biliary atresia. Karrer FM, et al. **Arch Surg** 1996 May;131(5):493–6

ADVERSE EFFECTS

The intussusception antireflux valve is ineffective in preventing cholangitis in biliary atresia. Sartorelli KH, et al. **J Pediatr Surg** 1996 Mar;31(3):403–6

METHODS

Is there a place for the Kasai procedure in biliary atresia? Grosfeld J. **Curr Opin Gen Surg** 1994;:168–72 (22 ref.)

The Kasai procedure in the treatment of biliary atresia. Oh M, et al. **J Pediatr Surg** 1995 Jul;30(7):1077–80; discussion 1080–1

The intussusception antireflux valve is ineffective in preventing cholangitis in biliary atresia. Sartorelli KH, et al. **J Pediatr Surg** 1996 Mar;31(3):403–6

[A clinical analysis of internal or external diversion in biliary atresia] Soto Beauregard C, et al. **An Esp Pediatr** 1996 Feb; 44(2):126–8 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Current status of 21 patients who have survived more than 20 years since undergoing surgery for biliary atresia. Nio M, et al. **J Pediatr Surg** 1996 Mar;31(3):381–4

PORTOGRAPHY

Hepatocellular carcinoma: findings on spiral CT during arterial portography. Soyer P, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):541–6

Portographic evaluation for recurrent esophagogastric varices following devascularization surgery. Hsieh JS, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):21–6

CT during arterial portography. Soyer P. **Eur Radiol** 1996; 6(3):349–57 (69 ref.)

Malignant hepatic hilar tumors: can ultrasonography be used as an alternative to angiography with CT arterial portography for determination of resectability? Hann LE, et al. **J Ultrasound Med** 1996 Jan;15(1):37–45

Hepatocellular carcinoma: detection with double–phase helical CT during arterial portography. Ichikawa T, et al. **Radiology** 1996 Jan;198(1):284–7

[Triphasic spiral CT in the diagnosis of liver diseases: comparison with CT arteriography and CT arterio–portography] Oberstein A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jun;164(6):449–56 (Eng. Abstr.) **(Ger)**

[The role of portography with computed tomography in the diagnosis of liver metastases from colorectal neoplasms] Leone A, et al. **Radiol Med (Torino)** 1996 Jan–Feb; 91(1–2):86–90 (Eng. Abstr.) **(Ita)**

METHODS

CT during arterial portography: comparison of injection into the splenic versus superior mesenteric artery. McDermott VG, et al. **Radiology** 1996 Jun;199(3):627–31

Detection of hepatic metastases: ferumoxides–enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography [see comments] Senéterre E, et al. **Radiology** 1996 Sep;200(3):785–92. Comment in: Radiology 1996 Sep;200(3):610–1.

Will ferumoxides–enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future [editorial; comment] Soyer P. **Radiology** 1996 Sep;200(3):610–1. Comment on: Radiology 1996 Sep;200(3):785–92.

[Spiral CT portography in preoperative diagnosis of liver metastases] Richter GM, et al. **Chirurg** 1996 Jun;67(6):630–6 (Eng. Abstr.) **(Ger)**

PORTOSYSTEMIC ENCEPHALOPATHY see **HEPATIC ENCEPHALOPATHY**

PORTOSYSTEMIC SHUNT, SURGICAL see **PORTASYSTEMIC SHUNT, SURGICAL**

PORTRAITS

HISTORY

Dr. Gachet. Seufert WD. **Can Med Assoc J** 1996 May 15; 154(10):1523 **(Eng, Fre)**

POSITION DESCRIPTION see **JOB DESCRIPTION**

POSITIVE END–EXPIRATORY PRESSURE see **POSITIVE–PRESSURE RESPIRATION**

POSITIVE–PRESSURE RESPIRATION

Effect of continuous positive airway pressure (CPAP) in patients with chronic obstructive pulmonary disease (COPD) depending on intrinsic PEEP levels. van den Berg B, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1097–102

Mechanical ventilation increases substance P concentration in the vagus, sympathetic, and phrenic nerves. Balzamo E, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):153–7

Effects of PEEP on acinar gas transfer in healthy and lung–injured dogs. Barnas GM, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1241–7

Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Chin K, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1972–6

Efficacy of dead–space washout in mechanically ventilated premature newborns. Danan C, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1571–6

Effects of CPAP on cardiac output in pigs with pacing–induced congestive heart failure. Genovese J, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1847–53

CPAP improves inspiratory muscle strength in patients with heart failure and central sleep apnea. Granton JT, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):277–82

Randomized prospective trial of noninvasive positive pressure ventilation in acute respiratory failure [letter; comment] Hawker F, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1188–9. Comment on: Am J Respir Crit Care Med 1995 Jun;151(6):1799–806.

CPAP with hypervolemia [letter; comment] Permutt S, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1187–8. Comment on: Am J Respir Crit Care Med 1995 Jul;152(1):142–7.

Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance. Richards GN, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):182–6

Mean airway pressure as an index of mean alveolar pressure. Valta P, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1825–30

Influence of treatment on muscle sympathetic nerve activity in sleep apnea. Waradekar NV, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1333–8

A comparative evaluation of pressure–triggering and flow–triggering in pressure support ventilation (PSV) for neonates using an animal model. Uchiyama A, et al. **Anaesth Intensive Care** 1995 Jun;23(3):302–6

Comparison of end–tidal PCO2 and average alveolar expired PCO2 during positive end–expiratory pressure. Breen PH, et al. **Anesth Analg** 1996 Feb;82(2):368–73

Auto–positive end–expiratory pressure during one–lung ventilation using a double–lumen endobronchial tube. Yokota K, et al. **Anesth Analg** 1996 May;82(5):1007–10

Problems in assessing the effect of nebulized prostacyclin in patients whose lungs are ventilated [letter; comment] Fletcher G, et al. **Anesthesiology** 1996 Jan;84(1):242–3. Comment on: Anesthesiology 1995 Jun;82(6):1507–11.

Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans [see comments] Mathru M, et al. **Anesthesiology** 1996 Feb;84(2):273–9. Comment in: Anesthesiology 1996 Feb;84(2):253–5.

Cardiorespiratory effects of positive end–expiratory pressure during progressive tidal volume reduction (permissive hypercapnia) in patients with acute respiratory distress syndrome. Ranieri VM, et al. **Anesthesiology** 1995 Oct; 83(4):710–20

Questioning conventional wisdom. New technology applied to investigating an old problem [editorial; comment] Robotham JL. **Anesthesiology** 1996 Feb;84(2):253–5. Comment on: Anesthesiology 1996 Feb;84(2):273–9.

Treatment of acute bronchospasm with beta–adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Pollack CV Jr, et al. **Ann Emerg Med** 1995 Nov;26(5):552–7

Pressure support ventilation. Dekel B, et al. **Arch Intern Med** 1996 Feb 26;156(4):369–73 (44 ref.)

Positive pressure ventilation and the laryngeal mask airway in ophthalmic anaesthesia [letter; comment] Wainwright AC. **Br J Anaesth** 1995 Aug;75(2):249–50. Comment on: Br J Anaesth 1994 Oct;73(4):543–4. Comment on: Br J Anaesth 1995 Apr;74(4):489–90.

Positive end–expiratory pressure and lung compliance: effect on delivered tidal volume. Pan PH, et al. **Can J Anaesth** 1995 Sep;42(9):831–5

Noninvasive positive–pressure ventilation via face mask during bronchoscopy with BAL in high–risk hypoxemic patients. Antonelli M, et al. **Chest** 1996 Sep;110(3):724–8

Breathing frequency and pattern are poor predictors of work of breathing in patients receiving pressure support ventilation. Banner MJ, et al. **Chest** 1995 Nov; 108(5):1338–44

Mechanism of relief of tachypnea during pressure support ventilation. Berger KI, et al. **Chest** 1996 May;109(5):1320–7

Volemic status influences the response of plasma atrial natriuretic factor to positive airway pressure. Beuret P, et al. **Chest** 1996 May;109(5):1313–9

Respiratory effort during sleep apneas after interruption of long–term CPAP treatment in patients with obstructive sleep apnea. Boudewyns A, et al. **Chest** 1996 Jul; 110(1):120–7

Positive end–expiratory pressure prevents the loss of respiratory compliance during low tidal volume ventilation in acute lung injury patients. Cereda M, et al. **Chest** 1996 Feb;109(2):480–5

A crossover study comparing the efficacy of continuous positive airway pressure with anterior mandibular positioning devices on patients with obstructive sleep apnea. Clark GT, et al. **Chest** 1996 Jun;109(6):1477–83

Self–reported use of CPAP and benefits of CPAP therapy: a patient survey [see comments] Engleman HM, et al. **Chest** 1996 Jun;109(6):1470–6. Comment in: Chest 1996 Jun;109(6):1416–7.

A randomized crossover study of an oral appliance vs nasal–continuous positive airway pressure in the treatment of mild–moderate obstructive sleep apnea [see comments] Ferguson KA, et al. **Chest** 1996 May;109(5):1269–75. Comment in: Chest 1996 May;109(5):1140–1.

Technology assessment [editorial; comment] Goodenberger DM. **Chest** 1995 Dec;108(6):1487–8. Comment on: Chest 1995 Dec;108(6):1572–6.

Effect of tracheal gas insufflation on demand valve triggering and total work during continuous positive airway pressure ventilation. Hoyt JD, et al. **Chest** 1996 Sep;110(3):775–83

Tidal volume, PEEP, and barotrauma. An open and shut case? [editorial] Marini JJ. **Chest** 1996 Feb;109(2):302–4

Noninvasive positive pressure ventilation in status asthmaticus. Meduri GU, et al. **Chest** 1996 Sep; 110(3):767–74

Sleep apnea after 1 year domiciliary nasal–continuous

positive airway pressure and attempted weight reduction. Potential for weaning from continuous positive airway pressure. Noseda A, et al. **Chest** 1996 Jan;109(1):138–43

Cardiopulmonary effects of positive pressure ventilation during acute lung injury. Romand JA, et al. **Chest** 1995 Oct;108(4):1041–8

Noninvasive nasal mask ventilation beyond the ICU for an exacerbation of chronic respiratory insufficiency [see comments] Servera E, et al. **Chest** 1995 Dec;108(6):1572–6 . Comment in: Chest 1995 Dec;108(6):1487–8.

OSA and cardiovascular morbidity: Will CPAP prove to be effective? [editorial] Zwillich CW. **Chest** 1996 Jun; 109(6):1416–7

Use of noninvasive positive pressure ventilation via nasal mask in patients with respiratory distress after extubation. Chiang AA, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1995 Aug; 56(2):94–101

Short-term effects of nasal pressure support ventilation in acute exacerbation of hypercapnic COPD. Lien TC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May; 57(5):335–42

Treatment of obstructive sleep apnea: the role of nasal continuous positive airway pressure. Patel SR, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):12–5 (29 ref.)

Treatment of obstructive sleep apnea in pediatric patients. Behavioral intervention for compliance with nasal continuous positive airway pressure. Rains JC.
Clin Pediatr (Phila) 1995 Oct;34(10):535–41

Hepatic venous catheterization in patients undergoing positive end-expiratory pressure ventilation after OLT: technique and clinical impact. Kaisers U, et al.
Clin Transplant 1995 Aug;9(4):301–6

Ventilation with positive end-expiratory pressure reduces extravascular lung water and increases lymphatic flow in hydrostatic pulmonary edema. Fernández Mondéjar E, et al. **Crit Care Med** 1996 Sep;24(9):1562–7

Positive end-expiratory pressure-induced hemodynamic changes are reflected in the arterial pressure waveform. Pizov R, et al. **Crit Care Med** 1996 Aug;24(8):1381–7

Inverse ratio ventilation: simply an alternative, or something more? [letter; comment] Rimensberger P, et al.
Crit Care Med 1995 Oct;23(10):1786–9 (14 ref.). Comment on: Crit Care Med 1995 Feb;23(2):224–8.

An intrinsic positive end-expiratory pressure lung model, with and without flow limitation. Yang KL, et al.
Crit Care Med 1996 Jul;24(7):1261–5

Servocontrolled generator to measure respiratory impedance from 0.25 to 26 Hz in ventilated patients at different PEEP levels. Farré R, et al. **Eur Respir J** 1995 Jul;8(7):1222–7

Efficacy of noninvasive CPAP in COPD with acute respiratory failure. Goldberg P, et al. **Eur Respir J** 1995 Nov;8(11):1894–900

Comparative effects of pressure support ventilation and intermittent positive pressure breathing (IPPB) in non-intubated healthy subjects. Mancebo J, et al.
Eur Respir J 1995 Nov;8(11):1901–9

Chest tube insertion in the ventilated patient. Peek GJ, et al. **Injury** 1995 Jul;26(6):425–6

Superimposed inspiratory work of the Siemens Servo 300 ventilator during continuous positive airway pressure. Tan IK, et al. **Intensive Care Med** 1995 Dec;21(12):1023–6

Comparative evaluation of the haemodynamic effects of continuous negative external pressure (CNEP) and positive end-expiratory pressure (PEEP) in mechanically ventilated trauma patients. Torelli L, et al. **Intensive Care Med** 1995 Jan;21(1):67–70

Daytime hypertension and the effects of short-term nasal continuous positive airway pressure treatment in obstructive sleep apnea syndrome. Akashiba T, et al.
Intern Med 1995 Jun;34(6):528–32

Continuous positive airway pressure increases blood pressure variability [letter; comment] Kardos A, et al.
J Am Coll Cardiol 1995 Dec;26(7):1756–7. Comment on: J Am Coll Cardiol 1995 Mar 1;25(3):672–9.

Erythropoietin levels with treatment of obstructive sleep apnea. Cahan C, et al. **J Appl Physiol** 1995 Oct; 79(4):1278–85

Effects of nasal positive-pressure hyperventilation on the glottis in normal awake subjects. Jounieaux V, et al.
J Appl Physiol 1995 Jul;79(1):176–85

Effects of nasal positive-pressure hyperventilation on the glottis in normal sleeping subjects. Jounieaux V, et al.
J Appl Physiol 1995 Jul;79(1):186–93

Respiratory response to positive inspiratory pressure in the cat: effects of CO2 and vagal integrity. Shams H, et al.
J Appl Physiol 1995 Nov;79(5):1704–10

Determinants of systolic pressure variation in patients ventilated after vascular surgery. Baeaussier M, et al.
J Cardiothorac Vasc Anesth 1995 Oct;9(5):547–51

Pressure support improves efficiency of spontaneous breathing during inhalation anesthesia. Bosek V, et al.
J Clin Anesth 1996 Feb;8(1):9–12

Positive end-expiratory pressure: effect on delivered tidal volume [letter] Pan PH, et al. **J Clin Anesth** 1995 Aug; 7(5):443–4

Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. Guilleminault C, et al.
J Pediatr 1995 Dec;127(6):905–12

Erectile dysfunction in sleep apnea and response to CPAP. Karacan I, et al. **J Sex Marital Ther** 1995 Winter; 21(4):239–47

Effects of CPAP treatment on psychological status in patients with severe obstructive sleep apnoea. Borak J, et al.
J Sleep Res 1996 Jun;5(2):123–7

Effects of oxygen, positive end-expiratory pressure, and carbon dioxide on oxygen delivery in an animal model of the univentricular heart [see comments] Riordan CJ, et al.
J Thorac Cardiovasc Surg 1996 Sep;112(3):644–54. Comment in: J Thorac Cardiovasc Surg 1996 Sep;112(3):655–7.

The effects of positive end-expiratory pressure of intrapulmonary shunt and ventilatory deadspace in nonhypoxic trauma patients. Vigil AR, et al. **J Trauma** 1996 Apr;40(4):618–22; discussion 622–3

Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a 3-month controlled trial. Gay PC, et al. **Mayo Clin Proc** 1996 Jun; 71(6):533–42

Noninvasive ventilation in the management of decompensated COPD. Polkey MI, et al.
Monaldi Arch Chest Dis 1995 Oct;50(5):378–82 (31 ref.)

Nasal mask positive pressure ventilation in paediatric patients with type II respiratory failure. Hertzog JH, et al.
Paediatr Anaesth 1996;6(3):219–24

Independent right lung high frequency and left lung conventional ventilation in the management of severe air leak during ARDS. Wippermann CF, et al.
Paediatr Anaesth 1995;5(3):189–92

Efficacy of surfactant therapy in infants managed with CPAP. Alba J, et al. **Pediatr Pulmonol** 1995 Sep;20(3):172–6

The use of nasal CPAP in children. Waters KA, et al.
Pediatr Pulmonol Suppl 1995;11:91–3

Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Merritt TA, et al.
Pediatr Res 1995 Aug;38(2):211–7

Pre- versus post-ventilatory surfactant treatment in surfactant-deficient preterm lambs. Cummings JJ, et al.
Reprod Fertil Dev 1995;7(5):1333–8

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

Use of the Epworth Sleepiness Scale to demonstrate response to treatment with nasal continuous positive airways pressure in patients with obstructive sleep apnoea. Hardinge FM, et al. **Respir Med** 1995 Oct;89(9):617–20

Effects of inspiratory pressure support on oxygenation and central haemodynamics in the normal heart during the postoperative period. Nørregaard O, et al. **Respir Med** 1996 Aug;90(7):415–7

How does positive end-expiratory pressure decrease CO2 elimination from the lung? Breen PH, et al.
Respir Physiol 1996 Mar;103(3):233–42

Chronic CO2 drive in patients with obstructive sleep apnea and effect of CPAP. Verbraecken J, et al.
Respir Physiol 1995 Sep;101(3):279–87

Comparison of polysomnography with ResCare Autoset in the diagnosis of the sleep apnoea/hypopnoea syndrome. Bradley PA, et al. **Thorax** 1995 Nov;50(11):1201–3

Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Grunstein RR. **Thorax** 1995 Oct;50(10):1106–13 (56 ref.)

Accuracy of an intelligent CPAP machine with in-built diagnostic abilities in detecting apnoeas: a comparison with polysomnography. Gugger M, et al. **Thorax** 1995 Nov; 50(11):1199–201

Continuous nasal positive airway pressure with a mouth leak: effect on nasal mucosal blood flux and nasal geometry. Hayes MJ, et al. **Thorax** 1995 Nov;50(11):1179–82

Adequacy of prescribing nasal continuous positive airway pressure therapy for the sleep apnoea/hypopnoea syndrome on the basis of night time respiratory recording variables. Montserrat JM, et al. **Thorax** 1995 Sep;50(9):969–71

Effect of chronic continuous positive airway pressure (CPAP) therapy on upper airway size in patients with sleep apnoea/hypopnoea syndrome. Mortimore IL, et al.
Thorax 1996 Feb;51(2):190–2

Non-invasive mechanical ventilation: the benefits of the BiPAP system. Teba L, et al. **W V Med J** 1996 Jan–Feb; 92(1):18–21

[Weaning from respirators via biphasic positive airway pressure] Porsborg PA, et al. **Ugeskr Laeger** 1996 Jan 22; 158(4):430–1 (Eng. Abstr.) **(Dan)**

[Effects of mechanical ventilation with PEEP on right to left intra-cardiac shunt caused by patent foramen ovale] Védrinne JM, et al. **Ann Fr Anesth Reanim** 1995; 14(5):387–92 (Eng. Abstr.) **(Fre)**

["Treatment of total atelectasis of the left lung in severe ARDS with side-separated ventilation and surfactant administration" (see comments] Knoch M, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 May; 31(4):270–3 (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 May;31(4):197–9. **(Ger)**

[Perioperative use of noninvasive ventilation] Karg O, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:38–40 (Eng. Abstr.) **(Ger)**

[Nasal positive pressure ventilation--renewal of ventilation technique] Shpirer I, et al. **Harefuah** 1995 Dec 15; 129(12):586–90 (43 ref.) **(Heb)**

[Acute effect of use of the Flutter on expectoration of sputum in patients with chronic respiratory diseases] Nakamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):180–5 (Eng. Abstr.) **(Jpn)**

[Effect continuous positive airway pressure (CPAP) on left ventricular diastolic function in patients with obstructive sleep apnea syndrome--OSAS] Chazan R, et al.
Pol Arch Med Wewn 1995 Jul;94(1):8–13 (Eng. Abstr.) **(Pol)**

[Effect of positive pressure respiration on diurnal catecholamine excretion by patients with obstructive sleep apnea] Cieślicki J, et al. **Pol Arch Med Wewn** 1996 Feb; 95(2):106–10 (Eng. Abstr.) **(Pol)**

[Clinical picture and outcome of conservative treatment for obstructive sleep apnea] Mańkowski M, et al.
Pol Arch Med Wewn 1995 Mar;93(3):234–41 (Eng. Abstr.) **(Pol)**

[Pulmonary ventilation with assisted pressure. Technical aspects and features of use] Koniukov IuA, et al.
Anesteziol Reanimatol 1995 Jul–Aug;(4):49–57 (83 ref.) **(Rus)**

[The inverse inspiration-expiration relationship. Alternative ventilation in severe acute pulmonary failure] Rydenhag A, et al. **Lakartidningen** 1996 Feb 14;93(7):561, 565 **(Swe)**

ADVERSE EFFECTS

CT evaluation of infradiaphragmatic air in patients treated with mechanically assisted ventilation: a potential source of error. Balthazar EJ, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):731–4

Unattended continuous positive airway pressure titration. Clinical relevance and cardiorespiratory hazards of the method. Juhász J, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):359–65

Severe hyperventilation and respiratory alkalosis during pressure-support ventilation: report of a hazard. Chui PT, et al. **Anaesthesia** 1995 Nov;50(11):978–80

Other local effects of nasal-continuous positive airway pressure [letter; comment] Prados C, et al. **Chest** 1995 Nov; 108(5):1478. Comment on: Chest 1995 Feb;107(2):375–81.

Correction of blood pH attenuates changes in hemodynamics and organ blood flow during permissive hypercapnia. Cardenas VJ Jr, et al. **Crit Care Med** 1996 May; 24(5):827–34

Transesophageal echocardiographic study of venous air embolism following pneumomediastinum in dogs. Morris WP, et al. **Intensive Care Med** 1995 Oct;21(10):790–6

Ventilatory management casebook. Systemic air embolism: a potentially fatal complication of ventilator therapy. Kumar P, et al. **J Perinatol** 1995 Jul–Aug;15(4):341–3

Neither dopamine nor dobutamine reverses the depression in mesenteric blood flow caused by positive end-expiratory pressure. Azar G, et al. **J Trauma** 1996 May;40(5):679–85; discussion 685–7

Auto-PEEP and electromechanical dissociation [letter] Lapinsky SE, et al. **N Engl J Med** 1996 Aug 29;335(9):674

The effect of continuous positive airway pressures on lung volumes in tetraplegic patients. Harvey LA, et al.
Paraplegia 1996 Jan;34(1):54–8

Lymphatic air embolism: a new hypothesis regarding the pathogenesis of neonatal systemic air embolism [see comments] Booth TN, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S220–7. Comment in: Pediatr Radiol 1995 Nov;25 Suppl 1:S228–9.

Commentary: lymphatic air embolism: a proposed hypothesis [comment] Effmann E, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S228–9. Comment on: Pediatr Radiol 1995 Nov;25 Suppl 1:S220–7.

INSTRUMENTATION

Automated continuous positive airway pressure titration for obstructive sleep apnea syndrome. Teschler H, et al.
Am J Respir Crit Care Med 1996 Sep;154(3 Pt 1):734–40

Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure nasal mask ventilation [editorial; comment] deLemos RA. **Chest** 1995 Oct;108(4):894–5. Comment on: Chest 1995 Oct;108(4):1059–64.

CPAP machine performance and altitude. Fromm RE Jr, et al. **Chest** 1995 Dec;108(6):1577–80

Automatic control of airway pressure for treatment of obstructive sleep apnea. Behbehani K, et al.
IEEE Trans Biomed Eng 1995 Oct;42(10):1007–16

Flow-triggering reduces inspiratory effort during weaning from mechanical ventilation. Polese G, et al.
Intensive Care Med 1995 Aug;21(8):682–6

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

Does continuous positive airway pressure (CPAP) during weaning from intermittent mandatory ventilation in very low birth weight infants have risks or benefits? A controlled trial. Tapia JL, et al. **Pediatr Pulmonol** 1995 May; 19(5):269–74

[BiPAP (Biphasic Positive Airway Pressure)--an apparatus for non-invasive respiratory support] Nørregaard FO, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):409–12 (Eng. Abstr.) **(Dan)**

[Biphasic positive "airway pressure" (BIPAP). Principles and clinical applications of a new ventilatory method in acute

respiratory insufficiency] Sydow M, et al. **Internist (Berl)** 1995 Aug;36(8):802–11 (38 ref.) **(Ger)**

[Change in nCPAP pressure in repeated follow-up of patients with obstructive sleep apnea] Geisler P. **Wien Med Wochenschr** 1995;145(17–18):506–7 (Eng. Abstr.) **(Ger)**

[Assisted ventilation via nasal mask in patients hospitalized in a pneumology ward for decompensation of their chronic air-flow obstruction] Servera E, et al. **Arch Bronconeumol** 1995 Oct;31(8):399–402 (Eng. Abstr.) **(Spa)**

METHODS

Bi-level positive airway pressure support system use in acute congestive heart failure: preliminary case series. Sacchetti AD, et al. **Acad Emerg Med** 1995 Aug;2(8):714–8 (21 ref.)

CPAP treatment of obstructive sleep apnoea and neurodevelopmental deficits. Tirosh E, et al. **Acta Paediatr** 1995 Jul;84(7):791–4

CPAP: possible ED applications [letter] Grant J. **Am J Emerg Med** 1995 Nov;13(6):684–5

Unattended continuous positive airway pressure titration. Clinical relevance and cardiorespiratory hazards of the method. Juhász J, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):359–65

Comparison between nocturnal nasal positive pressure ventilation combined with oxygen therapy and oxygen monotherapy in patients with severe COPD. Lin CC. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):353–8

Efficacy of auto-CPAP in the treatment of obstructive sleep apnea/hypopnea syndrome. Meurice JC, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):794–8

Time-course of stepwise CPAP titration. Behavior of respiratory and neurological variables. Montserrat JM, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1854–9

Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Patrick W, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1005–11

Positive pressure ventilation with the laryngeal mask airway in children. Gursoy F, et al. **Anesth Analg** 1996 Jan; 82(1):33–8

Pneumothorax during laparoscopic fundoplication: diagnosis and treatment with positive end-expiratory pressure. Joris JL, et al. **Anesth Analg** 1995 Nov;81(5):993–1000

Feasibility study of the use of bilevel positive airway pressure for respiratory support in the emergency department. Pollack C Jr, et al. **Ann Emerg Med** 1996 Feb;27(2):189–92

Another positive-pressure tip [letter; comment] Pollack CV Jr. **Ann Emerg Med** 1995 Nov;26(5):658. Comment on: Ann Emerg Med 1995 Apr;25(4):554–5.

A technique of positive-pressure single-lung ventilation via a silicone T-Y stent. Quigley RL, et al. **Ann Thorac Surg** 1996 Aug;62(2):570–1

Upper airway obstruction during midazolam sedation: modification by nasal CPAP. Nozaki-Taguchi N, et al. **Can J Anaesth** 1995 Aug;42(8):685–90

Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure (BiPAP) nasal mask ventilation [see comments] Fortenberry JD, et al. **Chest** 1995 Oct;108(4):1059–64. Comment in: Chest 1995 Oct;108(4):894–5.

The effects of applied vs auto-PEEP on local lung unit pressure and volume in a four-unit lung model. Kacmarek RM, et al. **Chest** 1995 Oct;108(4):1073–9

Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with acute hypercapnic and hypoxemic respiratory failure. Meduri GU, et al. **Chest** 1996 Jan;109(1):179–93

Closed-loop control of airway occlusion pressure at 0.1 second (P0.1) applied to pressure-support ventilation: algorithm and application in intubated patients. Iotti GA, et al. **Crit Care Med** 1996 May;24(5):771–9

Volume-controlled versus biphasic positive airway pressure ventilation in leukopenic patients with severe respiratory failure. Kiehl M, et al. **Crit Care Med** 1996 May;24(5):780–4

P0.1 is a useful parameter in setting the level of pressure support ventilation [see comments] Alberti A, et al. **Intensive Care Med** 1995 Jul;21(7):547–53. Comment in: Intensive Care Med 1995 Jul;21(7):545–6.

Primary laryngospasm in a patient with Parkinson's disease: treatment with CPAP via minitracheostomy following intubation [letter] Fikkers BF, et al. **Intensive Care Med** 1995 Oct;21(10):863–4

Pressure control ventilation and minitracheotomy in treating severe flail chest trauma. Gregoretti C, et al. **Intensive Care Med** 1995 Dec;21(12):1054–6

Physiological effects of reduced tidal volume at constant minute ventilation and inspiratory flow rate in acute respiratory distress syndrome. Kiiski R, et al. **Intensive Care Med** 1996 Mar;22(3):192–8

Effects of different triggering systems and external PEEP on trigger capability of the ventilator. Konyukov YA, et al. **Intensive Care Med** 1996 Apr;22(4):363–8

The automatic selection of ventilation parameters during the initial phase of mechanical ventilation. Laubscher TP, et al. **Intensive Care Med** 1996 Mar;22(3):199–207

Permissive hypercapnia in ARDS: just do it? [editorial; comment] Lewandowski K. **Intensive Care Med** 1996 Mar; 22(3):179–81 (13 ref.). Comment on: Intensive Care Med 1996 Mar;22(3):182–91.

Comparison of the effects of pressure support ventilation delivered by three different ventilators during weaning from mechanical ventilation. Mancebo J, et al. **Intensive Care Med** 1995 Nov;21(11):913–9

Respiratory response and inspiratory effort during pressure support ventilation in COPD patients [see comments] Nava S, et al. **Intensive Care Med** 1995 Nov;21(11):871–9. Comment in: Intensive Care Med 1995 Nov;21(11):867–70.

Inspiratory effort and measurement of dynamic intrinsic PEEP in COPD patients: effects of ventilator triggering systems. Ranieri VM, et al. **Intensive Care Med** 1995 Nov; 21(11):896–903

Mask physiotherapy in patients after heart surgery: a controlled study [see comments] Richter Larsen K, et al. **Intensive Care Med** 1995 Jun;21(6):469–74. Comment in: Intensive Care Med 1995 Jun;21(6):467–8.

Wasted efforts and dyssynchrony: is the patient-ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.). Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

Effect of low-level PEEP on inspiratory work of breathing in intubated patients, both with healthy lungs and with COPD. Sydow M, et al. **Intensive Care Med** 1995 Nov; 21(11):887–95

A potential clinical method for calculating transmural left ventricular filling pressure during positive end-expiratory pressure ventilation: an intraoperative study in humans. Smiseth OA, et al. **J Am Coll Cardiol** 1996 Jan;27(1):155–60

Clinical evaluation of oscillating positive expiratory pressure for enhancing expectoration in diseases other than cystic fibrosis. Ambrosino N, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):269–75

Noninvasive ventilation for exacerbations of chronic obstructive pulmonary disease [letter; comment] Baumel MJ, et al. **N Engl J Med** 1996 Mar 14;334(11):735–6. Comment on: N Engl J Med 1995 Sep 28;333(13):817–22.

Noninvasive positive pressure ventilation: what is its role in treating acute respiratory failure? Curreri JP, et al. **Postgrad Med** 1996 Jun;99(6):221–4, 227–30 (12 ref.)

[Invasive ventilation. Classification, technique and clinical experiences with BiPAP/APRV (Biphasic Positive Airway Pressure/Airway Pressure Release Ventilation)] Antonsen K, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):413–9 (23 ref.) (Eng. Abstr.) **(Dan)**

[New technique of nasal continuous positive pressure in neonatology] Claris O, et al. **Arch Pediatr** 1996 May; 3(5):452–6 (Eng. Abstr.) **(Fre)**

[Medical treatment of snoring and obstructive sleep apnea syndrome] Krieger J. **Schweiz Rundsch Med Prax** 1996 May 21;85(21):692–5 (Eng. Abstr.) **(Fre)**

[The limitation of synchronization of pressure support ventilation (PSV) in ARDS] Orii R, et al. **Masui** 1995 Sep; 44(9):1254–7 (Eng. Abstr.) **(Jpn)**

[Pressure-regulated pulmonary ventilation with an inverse ratio of the duration of the inhalation and exhalation phases] Nikolaenko EM, et al. **Anesteziol Reanimatol** 1996 Jan–Feb; (1):43–8 (Eng. Abstr.) **(Rus)**

[Successful treatment with nCPAP. Regain of memory after cured sleep apnea] Appelberg J, et al. **Lakartidningen** 1996 Sep 4;93(36):3045–7 **(Swe)**

PSYCHOLOGY

Successful treatment of comorbid panic disorder and sleep apnea with continuous positive airway pressure [letter] Enns MW, et al. **Psychosomatics** 1995 Nov–Dec; 36(6):585–6

[Compliance with nasal positive pressure (CPAP) in obstructive sleep apnea syndrome] Kaplan V, et al. **Schweiz Med Wochenschr** 1996 Jan 9;126(1–2):15–21 (Eng. Abstr.) **(Ger)**

[Compliance with nCPAP therapy: is prediction possible?] Broderick A, et al. **Wien Med Wochenschr** 1995; 145(17–18):504–5 (Eng. Abstr.) **(Ger)**

[Subjective well-being in obstructive sleep apnea syndrome before and after nCPAP therapy] Hetzel C, et al. **Wien Med Wochenschr** 1995;145(17–18):510–1 (Eng. Abstr.) **(Ger)**

[Long-term follow-up of CPAP therapy in patients with obstructive sleep apnea] Hohenhaus-Beer A, et al. **Wien Med Wochenschr** 1995;145(17–18):512–4 (Eng. Abstr.) **(Ger)**

[Effect of treatment of patients with sleep apnea with a nCPAP device on stress coping and well-being] Weissenberg A, et al. **Wien Med Wochenschr** 1995; 145(17–18):523–4 (Eng. Abstr.) **(Ger)**

STANDARDS

Increase in cardiac output and PEEP as mechanism of pulmonary optimization. Curiel C, et al. **Rev Esp Fisiol** 1995 Mar;51(1):7–15

POSITIVE-PRESSURE RESPIRATION, INTRINSIC

Life-threatening inadvertent positive end-expiratory pressure. Stenson BJ, et al. **Am J Perinatol** 1995 Sep; 12(5):336–8

Intrinsic positive end-expiratory pressure (PEEPi). Rossi A, et al. **Intensive Care Med** 1995 Jun;21(6):522–36 (107 ref.)

DIAGNOSIS

Intrinsic positive end-expiratory pressure during one-lung ventilation for thoracic surgery. The influence of preoperative pulmonary function. Bardoczky GI, et al. **Chest** 1996 Jul;110(1):180–4

Inspiratory effort and measurement of dynamic intrinsic PEEP in COPD patients: effects of ventilator triggering systems. Ranieri VM, et al. **Intensive Care Med** 1995 Nov; 21(11):896–903

ETIOLOGY

Inadvertent PEEP in a paediatric breathing system [letter] Jones RM. **Anaesthesia** 1996 Feb;51(2):203–4

Low measured auto-positive end-expiratory pressure during mechanical ventilation of patients with' severe asthma: hidden auto-positive end-expiratory pressure [see comments] Leatherman JW, et al. **Crit Care Med** 1996 Mar; 24(3):541–6. Comment in: Crit Care Med 1996 Mar;24(3):379–80.

Occult, occult auto-PEEP in status asthmaticus [editorial; comment] Stewart TE, et al. **Crit Care Med** 1996 Mar; 24(3):379–80 (13 ref.). Comment on: Crit Care Med 1996 Mar;24(3):541–6.

Effects of breathing patterns on mechanically ventilated patients with chronic obstructive pulmonary disease and dynamic hyperinflation. Georgopoulos D, et al. **Intensive Care Med** 1995 Nov;21(11):880–6

Wasted efforts and dyssynchrony: is the patient-ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.). Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

PHYSIOPATHOLOGY

The load of inspiratory muscles in patients needing mechanical ventilation. Zakynthinos SG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1248–55

The effects of applied vs auto-PEEP on local lung unit pressure and volume in a four-unit lung model. Kacmarek RM, et al. **Chest** 1995 Oct;108(4):1073–9

Oxygenation remains unaffected by increased inspiration-to-expiration ratio but impairs hemodynamics in surfactant-depleted piglets. Lichtwarck-Aschoff M, et al. **Intensive Care Med** 1996 Apr;22(4):329–35

POSITIVE-PRESSURE RESPIRATION, OCCULT see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

POSITIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

POSITRON-EMISSION TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED**

POSITRONS see **ELECTRONS**

POST AND CORE TECHNIQUE

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part II: Clinical application of basic concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug;61(8):696–701, 703, 705–7 (46 ref.)

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part I: Basic theoretical concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug; 61(8):685–8, 690, 693–5 (40 ref.)

Periodontal bone loss of teeth with metal posts. A radiographic study. Eliasson S, et al. **J Clin Periodontol** 1995 Nov;22(11):850–3

An in vitro investigation of cast post and partial core design. Patel A, et al. **J Dent** 1996 Jul;24(4):281–7

The evaluation of post-retained crowns using a custom-designed fatigue machine. Orr JF, et al. **J Oral Rehabil** 1996 Mar;23(3):179–85

Comparison of the torsional forces at failure for seven endodontic post systems. Cohen BI, et al. **J Prosthet Dent** 1995 Oct;74(4):350–7

A fast and efficient method for cast core provisional restoration of anterior teeth. Dylina TJ, et al. **J Prosthet Dent** 1995 Sep;74(3):319–20

Influence of post dimension on stress distribution in dentin. Holmes DC, et al. **J Prosthet Dent** 1996 Feb;75(2):140–7

Shear bond strength of several new core materials. Levartovsky S, et al. **J Prosthet Dent** 1996 Feb;75(2):154–8

Measurement of hydrostatic pressures during simulated post cementation. Morando G, et al. **J Prosthet Dent** 1995 Dec; 74(6):586–90

Restoration of pulpless teeth: application of traditional principles in present and future contexts. Morgano SM. **J Prosthet Dent** 1996 Apr;75(4):375–80 (66 ref.)

Retention and failure mode after cyclic loading in two post and core systems. Stegaroiu R, et al. **J Prosthet Dent** 1996 May;75(5):506–11

A time-saving method for indirect fabrication of cast posts and cores. von Krammer R. **J Prosthet Dent** 1996 Aug; 76(2):209–11

Biaxial flexural strength and indentation fracture toughness of three new dental core ceramics. Wagner WC, et al. **J Prosthet Dent** 1996 Aug;76(2):140–4

Apical root strain as a function of post extension into a composite resin core. Walton JN, et al. **J Prosthet Dent**

1996 May;75(5):499–505
Practical considerations and technical procedures for post-retained restorations. Zuckerman GR. **J Prosthet Dent** 1996 Feb;75(2):135–9

INSTRUMENTATION

Comparison of fatigue for three prefabricated threaded post systems. Kahn FH, et al. **J Prosthet Dent** 1996 Feb; 75(2):148–53
[Indications and results of transdental fixation with the Wirz Syntacoben screw in frontal tooth reconstruction] Dammer R, et al. **Fortschr Kiefer Gesichtschir** 1995;40:139–41 (Eng. Abstr.) **(Ger)**
[The stress transmission of prefabricated root canal posts] Städtler P, et al. **Schweiz Monatsschr Zahnmed** 1995; 105(11):1418–24 (Eng. Abstr.) **(Ger)**

POSTAGE STAMPS see **PHILATELY**

POSTAL SERVICE

The challenge of postal medicine [letter] Rothschild BM. **Ann Intern Med** 1996 Feb 15;124(4):454–5
Unsolicited mailings to dermatologists [letter; comment] Precopio MJ. **Arch Dermatol** 1995 Dec;131(12):1464–5. Comment on: Arch Dermatol 1995 May;131(5):530–2.
Mass mailing campaigns to promote screening for cervical cancer: do they work, and do they continue to work? Byles JE, et al. **Aust N Z J Public Health** 1996 Jun;20(3):254–60
Survival of anaerobes in original specimens transported by overnight mail services. Baron EJ, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S174–7
Timing payments to subjects of mail surveys: cost-effectiveness and bias. Schweitzer M, et al. **J Clin Epidemiol** 1995 Nov;48(11):1325–9
Follow up of patients after valvular surgery: mail vs. telephone. Armstrong CS, et al. **J Heart Valve Dis** 1995 Jul;4(4):346–9

STATISTICS & NUMERICAL DATA

The impact of mailing fecal occult blood test kits on return rate in a community cancer screening center. Mahon SM. **Oncol Nurs Forum** 1995 Sep;22(8):1259–63

POSTANESTHESIA NURSING

[Postoperative treatment and follow-up] Kvalsvik O. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):849–53 (Eng. Abstr.) **(Nor)**

INSTRUMENTATION

Airway monitoring in the post anaesthetic recovery room [letter] Jones D, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):115–6

POST-ANESTHESIA NURSING see **POSTANESTHESIA NURSING**

POSTCHOLECYSTECTOMY SYNDROME

[Cystic duct and gallbladder remnant] Ishihara F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):425–7 (14 ref.) **(Jpn)**
[Postcholecystectomy syndrome] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):459–61 (19 ref.) **(Jpn)**

ETIOLOGY

[Follow-up results of laparoscopic cholecystectomy] Buess GF, et al. **Chirurg** 1995 Oct;66(10):982–9 (Eng. Abstr.) **(Ger)**

THERAPY

–Bile duct stenoses and leakage after cholecystectomy: endoscopic diagnosis, therapy and treatment outcome– Krömer MU, et al. **Z Gastroenterol** 1996 Mar;34(3):167–72 (Eng. Abstr.) **(Ger)**

POSTCOITAL CONTRACEPTIVES see **CONTRACEPTIVES, POSTCOITAL**

POSTCOMMISSUROTOMY SYNDROME see **POSTPERICARDIOTOMY SYNDROME**

POSTENCEPHALITIC PARKINSONISM see **PARKINSON DISEASE, POSTENCEPHALITIC**

POSTERIOR CRUCIATE LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
MEDIAL COLLATERAL LIGAMENT, KNEE

Total knee arthroplasty. Li E, et al. **J Arthroplasty** 1995 Aug; 10(4):560–8; discussion 568–70
[Symposium: posterior cruciate ligament] **Rev Chir Orthop Reparatrice Appar Mot** 1995;81 Suppl 2:21–72 **(Fre)**

ANATOMY & HISTOLOGY

Extrasynovial spaces of the cruciate ligaments: anatomy, MR imaging, and diagnostic implications. Lee SH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1433–7
The human posterior cruciate ligament complex: an interdisciplinary study. Ligament morphology and biomechanical evaluation. Harner CD, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):736–45
Fiber orientation of posterior cruciate ligament: an experimental morphological and functional study, Part 2. Inderster A, et al. **Clin Anat** 1995;8(5):315–22
The menisco-femoral ligaments. Wan AC, et al. **Clin Anat** 1995;8(5):323–6
The fibre bundle anatomy of human cruciate ligaments. Mommersteeg TJ, et al. **J Anat** 1995 Oct;187 (Pt 2):461–71
Posterior cruciate ligament (PCL) reconstruction—an in vitro study of isometry. Part II. Tests using an experimental PCL graft model. Petermann J, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):104–6
Posterior cruciate ligament (PCL) reconstruction—an in vitro study of isometry. Part I. Tests using a string linkage model. Trus P, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):100–3

INJURIES

Posterior cruciate ligament injuries. New treatment options. Miller MD, et al. **Am J Knee Surg** 1995 Fall;8(4):145–54 (53 ref.)
Long-term followup of the untreated isolated posterior cruciate ligament-deficient knee. Boynton MD, et al. **Am J Sports Med** 1996 May–Jun;24(3):306–10
Primary repair for posterior cruciate ligament injuries. An eight-year followup of fifty-three patients. Richter M, et al. **Am J Sports Med** 1996 May–Jun;24(3):298–305
Posterior cruciate ligament injuries in trauma patients: Part II. Fanelli GC, et al. **Arthroscopy** 1995 Oct;11(5):526–9
Histopathological evaluation of canine stifle joint synovial membrane collected at the time of repair of cranial cruciate ligament rupture. Galloway RH, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):289–94
Conservative treatment of isolated injuries to the posterior cruciate ligament in athletes. Shino K, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):895–900
MRI of meniscus and cruciate ligament tears correlated with arthroscopy. Chen MC, et al. **J Formos Med Assoc** 1995 Oct;94(10):605–11
Ligamentous instability of the knee in children sustaining fractures of the femur: a prospective study with knee examination under anesthesia. Buckley SL, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):206–9
Proceedings of the ESSKA Scientific Workshop on Reconstruction of the Anterior and Posterior Cruciate Ligaments. Amis AA, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):124–32
Retropatellar forces after rupture of the PCL and patello-tibial transfixation: an in vitro study. Hagena FW, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):31–7
Positioning of the posterior cruciate ligament. Juergensen K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):133–7 (21 ref.)
[Treatment of posterior cruciate ligament rupture and recent knee dislocations by olecranisation of the patella without surgical repair] Rouvillain JL, et al. **Int Orthop** 1995; 19(5):269–74 (Eng. Abstr.) **(Fre)**
[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**
[Morphologic aspects of alloplastic augmentation in replacement of the posterior cruciate ligament. An experimental study on the sheep] Bosch U, et al. **Unfallchirurg** 1996 Mar;99(3):183–90 (Eng. Abstr.) **(Ger)**
[Rupture of the posterior cruciate ligament: status of current treatment] Lobenhoffer P, et al. **Unfallchirurg** 1996 Jun; 99(6):382–99 (118 ref.) (Eng. Abstr.) **(Ger)**
[The posterior cruciate ligament: step child in research and the clinic (editorial)] Tscherne H, et al. **Unfallchirurg** 1996 Jun;99(6):381 **(Ger)**
[Diagnosis and therapy of cruciate ligament injuries in childhood. Clinical results] Wening JV, et al. **Unfallchirurgie** 1995 Dec;21(6):285–91 (Eng. Abstr.) **(Ger)**
[Biomechanics and semeiotics of traumatic lesions of the posterior cruciate ligament using magnetic resonance] Iovane A, et al. **Radiol Med (Torino)** 1995 Dec;90(6):707–13 (Eng. Abstr.) **(Ita)**

PATHOLOGY

[Functional anatomy of the posterior cruciate ligament] Krudwig WK. **Unfallchirurgie** 1996 Apr;22(2):49–56 (Eng. Abstr.) **(Ger)**
[Biomechanics and semeiotics of traumatic lesions of the posterior cruciate ligament using magnetic resonance] Iovane A, et al. **Radiol Med (Torino)** 1995 Dec;90(6):707–13 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

The human posterior cruciate ligament complex: an interdisciplinary study. Ligament morphology and biomechanical evaluation. Harner CD, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):736–45
In-situ forces in the human posterior cruciate ligament in response to posterior tibial loading. Carlin GJ, et al. **Ann Biomed Eng** 1996 Mar–Apr;24(2):193–7
A sagittal plane model of the knee and cruciate ligaments with application of a sensitivity analysis. Beynnon B, et al. **J Biomech Eng** 1996 May;118(2):227–39
Effects of combined knee loadings on posterior cruciate ligament force generation. Markolf KL, et al. **J Orthop Res** 1996 Jul;14(4):633–8
A biomechanical analysis of joint contact forces in the posterior cruciate deficient knee. MacDonald P, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):252–5

PHYSIOPATHOLOGY

Decreased posterior tibial slope increases strain in the posterior cruciate ligament following total knee arthroplasty. Singerman R, et al. **J Arthroplasty** 1996 Jan; 11(1):99–103

SURGERY

Relationship between retention of the posterior cruciate ligament and postoperative flexion in total knee arthroplasty. Yokoyama Y, et al. **Acta Med Okayama** 1995 Dec;49(6):295–300
Posterior cruciate ligament injuries. New treatment options. Miller MD, et al. **Am J Knee Surg** 1995 Fall;8(4):145–54 (53 ref.)
The effect of femoral tunnel position and graft tensioning technique on posterior laxity of the posterior cruciate ligament-reconstructed knee. Burns WC 2nd, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):424–30
Primary repair for posterior cruciate ligament injuries. An eight-year followup of fifty-three patients. Richter M, et al. **Am J Sports Med** 1996 May–Jun;24(3):298–305
Allograft reconstruction of the anterior and posterior cruciate ligaments after traumatic knee dislocation. Shapiro MS, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):580–7
In vitro study of knee stability after posterior cruciate ligament reconstruction. Pearsall AW 4TH, et al. **Clin Orthop** 1996 Jun;(327):264–71
Collagen fibril diameter distribution in patellar tendon autografts after posterior cruciate ligament reconstruction in sheep: changes over time. Moeller HD, et al. **J Anat** 1995 Aug;187 (Pt 1):161–7
Proceedings of the ESSKA Scientific Workshop on Reconstruction of the Anterior and Posterior Cruciate Ligaments. Amis AA, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):124–32
Reconstruction of the posterior cruciate ligament with LAD-augmented semitendinosus and gracilis tendons: a preliminary report. Fujii K, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):148–51
Positioning of the posterior cruciate ligament. Juergensen K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):133–7 (21 ref.)
Reconstruction of the posterior cruciate ligament using a new drill-guide. Odensten M, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(1):39–43
Posterior cruciate ligament (PCL) reconstruction—an in vitro study of isometry. Part II. Tests using an experimental PCL graft model. Petermann J, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):104–6
Posterior cruciate ligament (PCL) reconstruction—an in vitro study of isometry. Part I. Tests using a string linkage model. Trus P, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):100–3
Controversial issues in knee arthroplasty. Rorabeck CH, et al. **Orthopedics** 1995 Sep;18(9):905–14
[Uncemented knee prosthesis. Results apropos of 58 cases with a minimum of 5-year follow-up] Gacon G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):505–13 (Eng. Abstr.) **(Fre)**
[Influence of the tibial slope on tibial translation and mobility of non-constrained total knee prosthesis] Migaud H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):7–13 (Eng. Abstr.) **(Fre)**
[Long-term results in complex knee injuries using sutures and reconstruction of the posterior cruciate ligament] Birkner W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec; 133(6):530–4 (Eng. Abstr.) **(Ger)**

POSTERIOR INFERIOR CEREBELLAR ARTERY SYNDROME see **WALLENBERG'S SYNDROME**

POSTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

POSTGASTRECTOMY SYNDROMES

Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Friess H, et al. **Am J Gastroenterol** 1996 Feb;91(2):341–7
[Cholelithiasis following gastrectomy] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):388–90 (26 ref.) **(Jpn)**

DIAGNOSIS

Neuromyotonia in alcoholic patients with gastrectomy. Voiculescu V, et al. **Rom J Neurol Psychiatry** 1995 Jan–Mar;33(1):3–6

POSTGASTRECTOMY SYNDROMES

[A new method of studying gastric emptying in gastrectomized patients] Martínez Castro R, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):769–73 (Eng. Abstr.) **(Spa)**

DIET THERAPY

Post-gastrectomy gastronomy [letter] Willson M. **Eur J Surg Oncol** 1995 Dec;21(6):693

DRUG THERAPY

Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Vaezi MF, et al. **Dig Dis Sci** 1996 Apr;41(4):754–63

EPIDEMIOLOGY

Complications after elective gastric resection for duodenal ulcer. Multivariate analysis of risk factors. Lorusso D, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):247–50

Cholelithiasis and cholecystitis after gastrectomy for gastric carcinoma: a comparison of lymphadenectomy of varying extent. Wu CC, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):867–72

[Anastomositis after a Billroth–II gastric resection with a transverse gastroenteroanastomosis] Gervaziev VB, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):221–5 **(Rus)**

ETIOLOGY

Risk of gallstones following gastrectomy in Japanese men. Ikeda Y, et al. **Surg Today** 1995;25(6):515–8

[The patient after total gastrectomy] Armbrecht U. **Z Gastroenterol** 1996 Jun;34 Suppl 2:24–5 **(Ger)**

[Sequelae of stomach resection and gastrectomy and its consequences] Kirchner R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:20–3 (18 ref.) **(Ger)**

[Effects of total gastrectomy on the nutritional status] Hidalgo Pascual M, et al. **Rev Esp Enferm Dig** 1995 Oct; 87(10):697–701 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Preservation of the lower esophageal sphincter during total gastrectomy for gastric cancer to prevent postoperative reflux esophagitis. Hirai T, et al. **Surg Today** 1995; 25(6):507–14

[Vagus-saving D2 procedure for early gastric carcinoma] Miwa K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):286–90 (11 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

[Coping with illness in the postoperative phase following gastrectomy] Theissen HH. **Z Gastroenterol** 1996 Jun;34 Suppl 2:29–31 **(Ger)**

RADIONUCLIDE IMAGING

A composite score of enterogastric reflux quantitation on 99mTc-HIDA scintigraphy. Zoras O, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):847–50

REHABILITATION

[Expectations of the family physician from inpatient rehabilitation exemplified by patients recovering from gastrectomy] Jork K. **Z Gastroenterol** 1996 Jun;34 Suppl 2:26–8 **(Ger)**

SURGERY

Successful surgical treatment of secondary Kwashiorkor after total gastrectomy: report of a case. Kadowaki A, et al. **Surg Today** 1995;25(6):548–51

[Surgical treatment of diseases of operated stomach] Bondarev VI, et al. **Khirurgiia (Mosk)** 1995;(6):17–20 (Eng. Abstr.) **(Rus)**

POSTIMPLANTATION PHASE

Efficient isolation of novel mouse genes differentially expressed in early postimplantation embryos. Bettenhausen B, et al. **Genomics** 1995 Aug 10;28(3):436–41

Post-implantation mouse embryos have the capability to generate and release reactive oxygen species. Gagioti S, et al. **Reprod Fertil Dev** 1995;7(5):1111–6

DRUG EFFECTS

Interlaboratory evaluation of embryotoxicity in the postimplantation rat embryo culture. Piersma AH, et al. **Reprod Toxicol** 1995 May–Jun;9(3):275–80

GENETICS

Identification of genes showing altered expression in preimplantation and early postimplantation parthenogenetic embryos. Mann M, et al. **Dev Genet** 1995; 17(3):223–32

Developmentally regulated gene expression of thrombomodulin in postimplantation mouse embryos. Weiler-Guettler H, et al. **Development** 1996 Jul; 122(7):2271–81

PHYSIOLOGY

Expression of M-twist during postimplantation development of the mouse. Füchtbauer EM. **Dev Dyn** 1995 Nov; 204(3):316–22

POST-INFARCTION HEART RUPTURE see **HEART RUPTURE, POST-INFARCTION**

POSTMARKETING PRODUCT SURVEILLANCE see **PRODUCT SURVEILLANCE, POSTMARKETING**

POSTMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY see **ESTROGEN REPLACEMENT THERAPY**

POSTMENOPAUSAL OSTEOPOROSIS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSE

Hysteroscopic surgery in postmenopausal women. Cravello L, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):563–6

How should we investigate women with postmenopausal bleeding? Gupta JK, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):475–9

Ocular hypertensive effect of menopause with and without systemic hypertension. Qureshi IA. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):266–9

Transvaginal ultrasonograph and endometrial thickness [letter] Smith CB. **Am Fam Physician** 1996 May 15; 53(7):2282–3

Transvaginal ultrasonography in nonpregnant and postmenopausal women. Weissman AM, et al. **Am Fam Physician** 1996 May 1;53(6):2065–72 (23 ref.)

Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-SO4) to cardiovascular risk factors in postmenopausal women. Haffner SM, et al. **Am J Epidemiol** 1995 Nov 1;142(9):925–34

Intake of vitamins A, C, and E and postmenopausal breast cancer. The Iowa Women's Health Study. Kushi LH, et al. **Am J Epidemiol** 1996 Jul 15;144(2):165–74

Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Zheng W, et al. **Am J Epidemiol** 1996 Jul 15;144(2):175–82

Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women. Zheng W, et al. **Am J Epidemiol** 1995 Nov 1;142(9):955–60

Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Cline JM, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):93–100

Value of transvaginal ultrasonography and hysteroscopy in the evaluation of postmenopausal women with metrorrhagia [letter; comment] de Mend Onça R, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1352–3. Comment on: Am J Obstet Gynecol 1995 Feb;172(2 Pt 1):547–52.

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Gilabert J, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1849–54

Hysteroscopy as gold standard for evaluation of abnormal uterine bleeding [letter; comment] Gimpelson RJ, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1637–8. Comment on: Am J Obstet Gynecol 1995 May;172(5):1488–94.

Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Giraud GD, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1708–17; discussion 1717–8

Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Shushan A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):141–4

Postmenopausal hormone therapy and systemic lupus erythematosus [letter; comment] Buyon JP, et al. **Ann Intern Med** 1995 Dec 15;123(12):961; discussion 962 . Comment on: Ann Intern Med 1995 Mar 15;122(6):430–3.

Postmenopausal hormone therapy and systemic lupus erythematosus [letter; comment] Piette JC, et al. **Ann Intern Med** 1995 Dec 15;123(12):961–2. Comment on: Ann Intern Med 1995 Mar 15;122(6):430–3.

Leisure, home, and occupational physical activity and cardiovascular risk factors in postmenopausal women. The Postmenopausal Estrogens/Progestins Intervention (PEPI) Study. Greendale GA, et al. **Arch Intern Med** 1996 Feb 26;156(4):418–24

Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Lemaitre RN, et al. **Arch Intern Med** 1995 Nov 27;155(21):2302–8

Postmenopausal cystitis [editorial] Cardozo L. **BMJ** 1996 Jul 20;313(7050):129

The effect of topical oestradiol on skin collagen of postmenopausal women. Varila E, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):985–9

Postmenopausal oestrogens and arteries. Vyas S, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):942–6 (30 ref.)

Walking program reduces elevated cholesterol in women postmenopause. Ready AE, et al. **Can J Cardiol** 1995 Nov; 11(10):905–12

A closer look at reproductive technology and postmenopausal motherhood [comment] Parks JA. **Can Med Assoc J** 1996 Apr 15;154(8):1189–91 (10 ref.). Comment on: Can Med Assoc J 1994 Aug 1;151(3):353, 355.

The expression of insulin-like growth factor and its binding protein mRNA in the endometrium of postmenopausal patients with breast cancer receiving tamoxifen. Laatikainen TJ, et al. **Cancer** 1995 Oct 15;76(8):1406–10

Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Vuento MH, et al. **Cancer** 1995 Oct 1;76(7):1214–8

Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Zeleniuch-Jacquotte A, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):857–60

Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Guetta V, et al. **Circulation** 1996 May 15;93(10):1928–37 (153 ref.)

Health consequences of short- and long-term postmenopausal hormone therapy. Weiss NS. **Clin Chem** 1996 Aug;42(8 Pt 2):1342–4 (17 ref.)

Polycystic ovaries in pre and post-menopausal women. Birdsall MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):269–76

Novel low-dosage hormonal replacement therapy complements dietary treatment of moderately hypercholesterolemic postmenopausal women. Wolfe BM, et al. **Clin Invest Med** 1995 Oct;18(5):362–9

Fertility after menopause: a case report. Ziegler WF, et al. **Del Med J** 1996 Apr;68(4):217–20

Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? The Atherosclerosis Risk in Communities Study Investigators. Robinson JC, et al. **Diabetes Care** 1996 May;19(5):480–5

Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Lipworth L, et al. **Epidemiology** 1996 Jan; 7(1):96–100

Post menopausal vaginal bleeding due to vaginal wall leech infestation [see comments] Hailemariam B. **Ethiop Med J** 1995 Jul;33(3):183–5. Comment in: Ethiop Med J 1995 Oct;33(4):271.

Post menopausal vaginal bleeding due to vaginal wall leech infestation [letter; comment] Mekasha A. **Ethiop Med J** 1995 Oct;33(4):271. Comment on: Ethiop Med J 1995 Jul;33(3):183–5.

Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? Sancho-Garnier H, et al. **Eur J Cancer** 1995 Oct;31A(11):1851–5

Effect of a new cyclical sequential postmenopausal HRT on lipoprotein, apoprotein and thrombophilia profile. Habiba M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):89–94

Vaginal foreign bodies in women in postmenopause and in senium. Jaluvka V, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):167–9

Mechanisms whereby oestrogens influence arterial health. Stevenson JC. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):39–42 (30 ref.)

Endopap-versus Pipelle-sampling in the diagnosis of postmenopausal endometrial disease. Van den Bosch T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):91–4

Review of the endometrial safety during intravaginal treatment with estriol. Vooijs GP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):101–6 (50 ref.)

Depressive symptomatology of post-menopausal breast cancer patients: a comparison of women recently treated by mastectomy or by breast-conserving therapy. Rijken M, et al. **Eur J Surg Oncol** 1995 Oct;21(5):498–503

Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Cline JM, et al. **Fertil Steril** 1996 May; 65(5):1031–5

Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Nagele F, et al. **Fertil Steril** 1996 Jun;65(6):1145–50

The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Sener AB, et al. **Fertil Steril** 1996 Feb;65(2):354–7

Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Bolaji II, et al. **Gynecol Endocrinol** 1996 Feb; 10(1):41–7

Hysterectomy increases the symptomatology of postmenopausal syndrome. Hartmann BW, et al. **Gynecol Endocrinol** 1995 Sep;9(3):247–52

Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen [see comments] Cohen I, et al. **Gynecol Oncol** 1996 Jan;60(1):54–8. Comment in: Gynecol Oncol 1996 Apr;61(1):158–60.

Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Strigini FA, et al. **Gynecol Oncol** 1996 Apr;61(1):68–72

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Tomás E, et al. **Gynecol Oncol** 1995 Nov;59(2):261–6

Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Kimura D. **Horm Behav** 1995 Sep;29(3):312–21

Body size indices and breast cancer risk before and after

menopause. Franceschi S, et al. **Int J Cancer** 1996 Jul 17; 67(2):181–6

The risks and benefits of estrogen replacement therapy: Leisure World. Paganini-Hill A. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:54–62 (37 ref.)

Compliance to hormone replacement therapy. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:23–32 (51 ref.)

Is HRT indicated for the prevention of cardiovascular disease? Samsioe G. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:33–9 (17 ref.)

The importance of life style after menopause. Zichella L. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:9–15 (19 ref.)

Transvaginal sonography and progesterone challenge for identifying endometrial pathology in postmenopausal women. Malinova M, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):49–53

The Women's Health Initiative: be part of the answer! [interview] Tinker L. **J Am Diet Assoc** 1995 Dec; 95(12):1375

Counseling postmenopausal women about preventive hormone therapy. AGS Clinical Practice Committee. **J Am Geriatr Soc** 1996 Sep;44(9):1120–2

Should older women use estrogen replacement? [editorial; comment] Johnson SR. **J Am Geriatr Soc** 1996 Jan; 44(1):89–90. Comment on: J Am Geriatr Soc 1996 Jan;44(1):1–6.

The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. Grey AB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3191–5

Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause--a clinical research center study. McKane WR, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3458–64

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Buzdar A, et al. **J Clin Oncol** 1996 Jul;14(7):2000–11

Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. Couzi RJ, et al. **J Clin Oncol** 1995 Nov;13(11):2737–44

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

The sensitivity and specificity of vaginal sonography in detecting endometrial abnormalities in women with postmenopausal bleeding. Wolman I, et al. **J Clin Ultrasound** 1996 Feb;24(2):79–82

Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy. Marabini R, et al. **J Endocrinol Invest** 1996 Mar; 19(3):154–8

More about: a prospective study of endogenous estrogens and breast cancer in postmenopausal women [letter; comment] Pasternack BS. **J Natl Cancer Inst** 1995 Nov 1;87(21):1642–3. Comment on: J Natl Cancer Inst 1995 Aug 16;87(16):1207–9. Comment on: J Natl Cancer Inst 1995 Sep 20;87(18):1414–5.

Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Lichtman R. **J Nurse Midwifery** 1996 May-Jun;41(3):195–210 (109 ref.)

Use of a gonadotropin-releasing hormone agonist in the evaluation of postmenopausal virilization due to ovarian hyperthecosis. A case report. Koroscil TM, et al. **J Reprod Med** 1996 Apr;41(4):259–62

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. Lien EA, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):229–31

Transvaginal color Doppler assessment of endometrial status in normal postmenopausal women: the effect of hormone replacement therapy. Bonilla-Musoles F, et al. **J Ultrasound Med** 1995 Jul;14(7):503–7

Transvaginal hysterosonography: comparison with biopsy in the evaluation of postmenopausal bleeding. Dubinsky TJ, et al. **J Ultrasound Med** 1995 Dec;14(12):887–93

Comparison of the clinicopathological characteristics of premenopausal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. Yasumizu T, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):152–6

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease [see comments] Tang MX, et al. **Lancet** 1996 Aug 17;348(9025):429–32. Comment in: Lancet 1996 Aug 17;348(9025):420–1.

The demography of menopause. Hill K. **Maturitas** 1996 Mar; 23(2):113–27 (18 ref.)

Clinical trial of the estradiol vaginal ring in the U.S. Nachtigall LE. **Maturitas** 1995 Dec;22 Suppl:S43–7

The prevalence of urogenital symptoms in postmenopausal women. Stenberg A, et al. **Maturitas** 1995 Dec;22 Suppl:S17–S20 (22 ref.)

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7-8):531–41 (20 ref.)

Postmenopausal squamous atypia: a spectrum including "pseudo-koilocytosis" [see comments] Jovanovic AS, et al. **Mod Pathol** 1995 May;8(4):408–12. Comment in: Mod Pathol 1996 Feb;9(2):158.

Correspondence re: AS Jovanovic, CM McLachlin, WR Welch, CP Crum. Postmenopausal squamous atypia: a spectrum including "pseudo-koilocytosis." Mod Pathol 8:408, 1995 [letter; comment] Mittal K. **Mod Pathol** 1996 Feb;9(2):158. Comment on: Mod Pathol 1995 May;8(4):408–12.

Adenomyosis--an ignored uterine disease [letter; comment] Thylan S. **Nurse Pract** 1995 Sep;20(9):8–9. Comment on: Nurse Pract 1995 Apr;20(4):32–4, 39–40, 43.

Reduced mortality associated with long-term postmenopausal estrogen therapy. Ettinger B, et al. **Obstet Gynecol** 1996 Jan;87(1):6–12

Postmenopausal hormone therapy and breast cancer. Speroff L. **Obstet Gynecol** 1996 Feb;87(2 Suppl):44S–54S (81 ref.)

Postmenopausal bartholin gland enlargement: a hospital-based cancer risk assessment. Visco AG, et al. **Obstet Gynecol** 1996 Feb;87(2):286–90

Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Gambacciani M, et al. **Osteoporos Int** 1995; 5(6):467–71

Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. Gonnelli S, et al. **Osteoporos Int** 1995;5(6):413–8 (40 ref.)

The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Grodstein F, et al. **Prog Cardiovasc Dis** 1995 Nov-Dec;38(3):199–210 (86 ref.)

Coronary arteriography in estrogen-treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov-Dec; 38(3):211–22 (34 ref.)

Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Levine D, et al. **Radiology** 1995 Dec;197(3):603–8

Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis. Franklyn JA, et al. **Thyroid** 1995 Oct;5(5):359–63

Clinical implication of hormone treatment in postmenopausal kidney transplants. Hung CJ, et al. **Transplant Proc** 1996 Jun;28(3):1548–50

Endometrial ultrasonography – An alternative to invasive assessment in women with postmenopausal vaginal bleeding. Cecchini S, et al. **Tumori** 1996 Jan-Feb;82(1):38–9

A feasibility study of screening for endometrial carcinoma in postmenopausal women by ultrasonography. Ciatto S, et al. **Tumori** 1995 Sep-Oct;81(5):334–7

[A comparative study of the potentials of a cytological method, the progesterone test and echography in the early detection of endometrial carcinoma in women in the postmenopause] Ivanov S, et al. **Akush Ginekol (Sofiia)** 1994;33(2):31–2 (Eng. Abstr.) **(Bul)**

[Physical activity and bone mineral content in postmenopausal women] Eiken PA. **Ugeskr Laeger** 1995 Sep 11;157(37):5086–91 (47 ref.) (Eng. Abstr.) **(Dan)**

[Nature turned away from us. Viewpoint of the Commission Medical Ethics of the KNMG (Royal Dutch Medical Society) concerning postmenopausal IVF (in-vitro fertilization) (editorial)] Zwart H. **Tijdschr Gerontol Geriatr** 1996 Jun;27(3):94–6 **(Dut)**

[Pregnancy after diagnosis of menopause] Jamin C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):677–81 (55 ref.) (Eng. Abstr.) **(Fre)**

[Reflections on compliance in menopause hormone replacement therapy] Berthet J, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):548–51 (0 ref.) (Eng. Abstr.) **(Fre)**

[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435–41 (18 ref.) (Eng. Abstr.) **(Fre)**

[The role of outpatient service for postmenopausal women and its use in the screening for hypertension and its risk factors] Szántó F, et al. **Orv Hetil** 1995 Oct 15; 136(42):2283–6 (Eng. Abstr.) **(Hun)**

[Malignant gynecologic neoplasms during menopause. Authors' experience] Patacchiola F, et al. **Minerva Ginecol** 1995 Jun;47(6):239–44 (Eng. Abstr.) **(Ita)**

[Ovarian tumors in menopausal patients] Struzziero E, et al. **Minerva Ginecol** 1996 Jan-Feb;48(1-2):17–8 (Eng. Abstr.) **(Ita)**

[Transvaginal echography in patients with postmenopausal metrorrhagia] Taviani A, et al. **Minerva Ginecol** 1995 Sep; 47(9):369–72 (Eng. Abstr.) **(Ita)**

[Nutritional status in women and estrogen production in surgical menopause] Curčić A, et al. **Med Pregl** 1996; 49(1-2):54–6 (Eng. Abstr.) **(Scr)**

[Factors possibly associated with the age at the onset of menopause. Multicenter study] Alvarado Zaldívar G, et al. **Ginecol Obstet Mex** 1995 Oct;63:432–8 (Eng. Abstr.) **(Spa)**

[Decrease of labor absenteeism associated with hormone replacement therapy in postmenopausal women] Blümel JE, et al. **Rev Med Chil** 1995 Aug;123(8):948–53 (Eng. Abstr.) **(Spa)**

BLOOD

Effects of a diet low in copper on copper-status indicators in postmenopausal women. Milne DB, et al. **Am J Clin Nutr** 1996 Mar;63(3):358–64

Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy. Wander RC, et al. **Am J Clin Nutr** 1996 Feb;63(2):184–93

Patterns of luteinizing and follicle-stimulating hormone pulsatility in menopausal women: correlation with plasma testosterone level and vasomotor instability episodes. Fossum GT, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):795–800

Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. Haines C, et al. **Arch Intern Med** 1996 Apr 22;156(8):866–72

Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Kim CJ, et al. **Arch Intern Med** 1996 Aug 12-26;156(15):1693–700

Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. Svendsen OL, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar; 16(3):381–5

Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women [see comments] Barrett-Connor E, et al. **BMJ** 1995 Nov 4; 311(7014):1193–6. Comment in: BMJ 1996 Mar 23;312(7033):777.

Endogenous sex hormones and cardiovascular disease in postmenopausal women. Other sources of variability should have been taken into account [letter; comment] Muti P, et al. **BMJ** 1996 Mar 23;312(7033):777. Comment on: BMJ 1995 Nov 4;311(7014):1193–6.

Changes in vitamin-D metabolites and parathyroid hormone in plasma following cholecalciferol administration to pre- and postmenopausal women in the Netherlands in early spring and to postmenopausal women in Curaçao. Van Der Klis FR, et al. **Br J Nutr** 1996 Apr;75(4):637–46

Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Hankinson SE, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):649–54

Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Burger HG, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):413–8

A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization. Chico A, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):645–9

Oestrogen effects on calcitriol levels in post-menopausal women: a comparison of oral versus transdermal administration. Dick IM, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):219–24

Marked hyperinsulinaemia in postmenopausal, healthy Indian (Asian) women. Berger GM, et al. **Diabet Med** 1995 Sep; 12(9):788–95

Plasma homocysteine and menopausal status. Wouters MG, et al. **Eur J Clin Invest** 1995 Nov;25(11):801–5

The effect of surgical castration on lipid metabolism in premenopausal and postmenopausal women. Goldman GA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun; 66(2):133–6

Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch. Habiba M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):165–8

The effects of hormone replacement therapy on plasma vitamin E levels in post-menopausal women. Wu J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):151–4

The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman. Verhelst J, et al. **Fertil Steril** 1995 Nov;64(5):969–71

Insulin-like growth factor (IGF)-I levels in postmenopausal women receiving tibolone. Hopkins KD, et al. **Horm Metab Res** 1995 Aug;27(8):387–8

Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women. Weinstein RE, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):1–8

Effects of endurance exercise and hormone replacement therapy on serum lipids in older women [see comments] Binder EF, et al. **J Am Geriatr Soc** 1996 Mar;44(3):231–6 . Comment in: J Am Geriatr Soc 1996 Mar;44(3):331–2.

Exercise, hormone therapy, and lipoproteins in women [editorial; comment] Grady D. **J Am Geriatr Soc** 1996 Mar; 44(3):331–2. Comment on: J Am Geriatr Soc 1996 Mar;44(3):231–6.

Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. Barrett-Connor E, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):59–64

Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. Ylikorkala O, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3384–7

Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. Geisler J, et al. **J Endocrinol** 1995 Aug;146(2):359–63

Serum sex hormone levels after menopause and subsequent breast cancer. Berrino F, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):291–6

Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Pedersen BJ, et al. **Osteoporos Int** 1995;5(6):472–7

[Contemporary views on estrogen replacement therapy. II. Hormonal therapy in women with imminent ischemic heart

disease] Krasomski G. **Ginekol Pol** 1995 Feb;66(2):93–6 (27 ref.) (Eng. Abstr.) **(Pol)**

[Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy] Ciepluch R, et al. **Pol Tyg Lek** 1995 Sep;50(36–39):13–5 (Eng. Abstr.) **(Pol)**

[Serum lipids in surgical and natural postmenopause] Curčić A, et al. **Med Pregl** 1995;48(7–8):226–9 (Eng. Abstr.) **(Scr)**

[Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma] Pavić S, et al. **Med Pregl** 1995;48(5–6):159–61 (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman. Ciepluch R, et al. **Acta Haematol Pol** 1996; 27(1):21–5

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Guetta V, et al. **Am J Cardiol** 1995 Nov 15; 76(14):1072–3

In normal postmenopausal women physiologic estrogen replacement therapy fails to improve exercise tolerance: a randomized, double-blind, placebo-controlled, crossover trial. Snabes MC, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):110–4

Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. Haines C, et al. **Arch Intern Med** 1996 Apr 22;156(8):866–72

Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions. Vassilopoulou-Sellin R, et al. **Cancer** 1996 Sep 1; 78(5):1043–8

Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE) [see comments] Handa VL, et al. **J Am Geriatr Soc** 1996 Jan;44(1):1–6. Comment in: J Am Geriatr Soc 1996 Jan;44(1):89–90.

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. Powles TJ, et al. **J Clin Oncol** 1996 Jan;14(1):78–84

Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. Sagraves R. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):2S–10S (46 ref.)

Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. Grodstein F, et al. **N Engl J Med** 1996 Aug 15;335(7):453–61

Hormone replacement therapy: estrogen after menopause. Gibaldi M. **Pharmacotherapy** 1996 May-Jun;16(3):366–75

Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Saletu B, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):321–9

[Postmenopausal atrophic colpitis—its local treatment with low-dose estradiol] Rachev E. **Akush Ginekol (Sofiia)** 1995; 34(1):41–2 **(Bul)**

[Variability of bone response to hormone replacement therapy] Ruiz JC, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun;90(5–6):263–4, 267–74 (Eng. Abstr.) **(Fre)**

[Estrogens in menopause—therapy and prevention. I. Hormone substitution in climacteric and postmenopause] Wuttke W. **Internist (Berl)** 1996 Apr;37(4):402–5 (50 ref.) **(Ger)**

[Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women] Nishibe A, et al. **Nippon Ronen Igakkai Zasshi** 1996 May; 33(5):353–9 (Eng. Abstr.) **(Jpn)**

[The influence of modified sequential therapy on lipid metabolism in postmenopausal women] b1anosz S, et al. **Ginekol Pol** 1995 May;66(5):284–8 (Eng. Abstr.) **(Pol)**

[Effect of Kliogest therapy on serum blood lipids in postmenopausal women] Warenik-Szymankiewicz A, et al. **Ginekol Pol** 1995 Sep;66(9):541–6 (Eng. Abstr.) **(Pol)**

GENETICS

Segregation analysis of breast cancer in a population-based sample of postmenopausal probands: The Iowa Women's Health Study. Chen PL, et al. **Genet Epidemiol** 1995; 12(4):401–15

METABOLISM

A longitudinal study of the effect of sodium and calcium intakes on regional bone density in postmenopausal women [see comments] Devine A, et al. **Am J Clin Nutr** 1995 Oct; 62(4):740–5. Comment in: Am J Clin Nutr 1996 May;63(5):787–8.

Visceral adiposity is associated with increased lipid oxidation in obese, postmenopausal women [see comments] Nicklas BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5):918–22. Comment in: Am J Clin Nutr 1996 Jun;63(6):977–8.

Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Brinton EA. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):431–40

The myometrium of postmenopausal women produces prolactin in response to human chorionic gonadotropin and alpha-subunit in vitro. Stewart EA, et al. **Fertil Steril** 1995 Nov;64(5):972–6

Genetic influence on bone turnover in postmenopausal twins. Garnero P, et al. **J Clin Endocrinol Metab** 1996 Jan; 81(1):140–6

Resistive training increases insulin action in postmenopausal women. Ryan AS, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M199–205

alpha-Tocopherol influences in vivo indices of lipid peroxidation in postmenopausal women given fish oil. Wander RC, et al. **J Nutr** 1996 Mar;126(3):643–52

Estradiol and testosterone in specific regions of the human female brain in different endocrine states. Bixo M, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):297–303

Oral administration of micronized progesterone: a review and more experience. McAuley JW, et al. **Pharmacotherapy** 1996 May-Jun;16(3):453–7

The 5-year reproducibility of calcium-related biochemical variables in postmenopausal women. Morris HA, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):383–9

No effect of beta-carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, postmenopausal women. Nenseter MS, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):477–85

PHYSIOLOGY

Age, weight, body mass index and endometrial thickness in postmenopausal women. Van den Bosch T, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):181–2

Evaluation of bone density with peripheral quantitative computed tomography in healthy premenopausal, perimenopausal, and postmenopausal women. Hernández ER, et al. **Age Ageing** 1995 Sep;24(5):447–50

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Meilahn EN, et al. **Am J Epidemiol** 1996 Jan 15; 143(2):159–66

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Grey AB, et al. **Am J Med** 1995 Dec;99(6):636–41

Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Troisi RJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1183–8

Body weight and bone mineral density in hyperparathyroidism [letter] Grey A, et al. **Ann Intern Med** 1995 Nov 1;123(9):732

Recent postmenopause, but not ER status, identifies a subset of primary breast cancer patients with a higher risk of relapse. Traina A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:491–5

The natural history of kyphosis in postmenopausal women. Puche RC, et al. **Bone** 1995 Sep;17(3):239–46

Vertebral deformity in the thoracic spine in post-menopausal women: value of lumbar spine bone density. Grey C, et al. **Br J Radiol** 1996 Feb;69(818):137–42

Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Reeve J, et al. **Calcif Tissue Int** 1995 Aug;57(2):105–10

Hypertension in postmenopausal women: pathophysiology and management. Oparil S. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):438–42 (26 ref.)

Factors associated with glucose and insulin levels in healthy postmenopausal women. Barrett-Connor E, et al. **Diabetes Care** 1996 Apr;19(4):333–40

Assessment of dietary phylloquinone intake and vitamin K status in postmenopausal women. Booth SL, et al. **Eur J Clin Nutr** 1995 Nov;49(11):832–41

Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. Reubinoff BE, et al. **Fertil Steril** 1995 Nov;64(5):963–8

Effects of chronic estrogen replacement therapy on beat-to-beat blood pressure dynamics in healthy postmenopausal women. Lipsitz LA, et al. **Hypertension** 1995 Oct;26(4):711–5

The response to treatment of overweight in postmenopausal women is not related to fat distribution. Svendsen OL, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):496–502

Resistive training increases fat-free mass and maintains RMR despite weight loss in postmenopausal women. Ryan AS, et al. **J Appl Physiol** 1995 Sep;79(3):818–23

Mode of pulsatile follicle-stimulating hormone secretion in gonadal hormone-sufficient and -deficient women—a clinical research center study. Booth RA Jr, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3208–14

Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. Kassem M, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):513–8

Effect of sodium valproate on luteinizing hormone secretion in pre- and postmenopausal women and its modulation by naloxone infusion. Popovic V, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2520–4

Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. Raisz LG, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):37–43

North Central Cancer Treatment Group (NCCTG). Loprinzi CL. **J Natl Cancer Inst Monogr** 1996;(20):79–80

Practical management of postmenopausal women with low bone mineral density. Taga M. **J Obstet Gynaecol** 1995 Feb;21(1):99–105

Possible acceleration of age effects on cognition following menopause. Halbreich U, et al. **J Psychiatr Res** 1995 May-Jun;29(3):153–63

Normal uterine arterial blood flow in postmenopausal women assessed by transvaginal color Doppler ultrasonography. Bonilla-Musoles F, et al. **J Ultrasound Med** 1995 Jul; 14(7):491–4; quiz 495–6

Hormones, mood, and cognitive functioning in postmenopausal women. Sherwin BB. **Obstet Gynecol** 1996 Feb;87(2 Suppl):20S–26S

Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Adami S, et al. **Osteoporos Int** 1996;6(1):8–13

Age-related changes in Os calcis ultrasonic indices: a 2-year prospective study. Schott AM, et al. **Osteoporos Int** 1995; 5(6):478–83

The effect of menopause and hormone replacement therapy on bone alkaline phosphatase. Alexandersen P, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):571–6

[Role of the family doctor in the complex treatment of early and late consequences of postmenopause. Effect of estrogen-progestogen on osteoporosis] Farkas M. **Acta Pharm Hung** 1995 May;65(3):77–89 (Eng. Abstr.) **(Hun)**

[Bone mineral density of the lumbar spine and its relation to biological and lifestyle factors in middle-aged and aged Japanese women (Part 3). Relationships of physical fitness and lifestyle factors to bone mineral density in premenopausal and postmenopausal women] Kajita E, et al. **Nippon Eiseigaku Zasshi** 1995 Oct;50(4):893–900 (Eng. Abstr.) **(Jpn)**

[Bone mineral density in postmenopausal elderly women with type 2 diabetes] Horiuchi T, et al. **Nippon Ronen Igakkai Zasshi** 1995 Nov;32(11):756–60 (Eng. Abstr.) **(Jpn)**

[Evaluation of bone loss in postmenopausal women during the first 5 years after menopause] Pluskiewicz W, et al. **Ginekol Pol** 1995 Nov;66(11):640–5 (Eng. Abstr.) **(Pol)**

[Most common neoplasms of female genital organs and hypo-thalamic-hypophysial-ovarian regulation in the postmenopausal period] Rzepka-Górska I, et al. **Ginekol Pol** 1995 Jan;66(1):36–40 (Eng. Abstr.) **(Pol)**

[Evaluation of bone density using the DEXA method and ultrasonography in women after menopause during treatment with vitamin D] Korczyk P, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):30–1, 42 (Eng. Abstr.) **(Pol)**

[Thyroid function and menopausal status in benign and malignant breast diseases] Pavić Z, et al. **Med Pregl** 1995; 48(7–8):231–3 (Eng. Abstr.) **(Scr)**

PSYCHOLOGY

Hormones, mood, and cognitive functioning in postmenopausal women. Sherwin BB. **Obstet Gynecol** 1996 Feb;87(2 Suppl):20S–26S

POSTMORTEM CHANGES

MR appearance of cerebral Drancunculus borealis infection. Chicaneria A, et al. **AJNR Am J Neuroradiol** 1996 Apr; 17(4):798–9

Postmortem diffusion of alcohol from the stomach. Pounder DJ, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):89–96

Delay of adenosine triphosphate depletion and hypoxanthine formation in rabbit lung after death. Van Raemdonck DE, et al. **Ann Thorac Surg** 1996 Jul;62(1):233–40; discussion 240–1

Culture and drug biotransformation capacity of adult human keratinocytes from post-mortem skin. Hirel B, et al. **Br J Dermatol** 1996 May;134(5):831–6

Histopathological alterations of turkey skeletal muscle observed at the slaughterhouse. Cherel Y, et al. **Br Poult Sci** 1995 Jul;36(3):443–53

Detection of false lithium readings in whole-blood specimens from cadavers by flame photometry [letter] Green TR, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1302

Comparative histomorphology between isoproterenol-induced early lesions and postmortem artifacts in the rat heart. Kemi M, et al. **Exp Anim** 1995 Jul;44(3):245–9

Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. Schmid PC, et al. **FEBS Lett** 1995 Nov 13; 375(1–2):117–20

Diagnostic value of ions as markers for differentiating antemortem from postmortem wounds. Chen YC, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):157–61

Distinguishing antemortem from postmortem injuries by LTB4 quantification. He L, et al. **Forensic Sci Int** 1996 Jul 31;81(1):11–6

Diagnostic ability of D-dimer in the establishment of the vitality of wounds. Hernández-Cueto C, et al. **Forensic Sci Int** 1995 Dec 18;76(2):141–9

Detection of toluene in an adipoceratous body. Inoue H, et

al. **Forensic Sci Int** 1996 Apr 2;78(2):119–24

Postmortem electrical excitability of skeletal muscle: preliminary investigation of an animal model. Jones MD, et al. **Forensic Sci Int** 1995 Dec 18;76(2):91–6

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1–2):49–61 (25 ref.)

Postmortem degradation of administered ethanol-d6 and production of endogenous ethanol: experimental studies using rats and rabbits. Takayasu T, et al. **Forensic Sci Int** 1995 Dec 18;76(2):129–40

Experimental studies on postmortem diffusion of ethanol-d6 using rats. Takayasu T, et al. **Forensic Sci Int** 1995 Dec 29;76(3):179–88

Study on electrocution death by low-voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)

Postmortem metabolic and morphologic alterations of the dog brain thalamus with use of in vivo 1H magnetic resonance spectroscopy and electron microscopy. Choe BY, et al. **Invest Radiol** 1995 May;30(5):269–74

Modification of early-postmortem muscle pH and use of postmortem aging to improve beef tenderness. Eilers JD, et al. **J Anim Sci** 1996 Apr;74(4):790–8

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting comparisons of purified myofibrils and whole muscle preparations for evaluating titin and nebulin in postmortem bovine muscle. Huff-Lonergan E, et al. **J Anim Sci** 1996 Apr;74(4):779–85

Proteolysis of specific muscle structural proteins by mu-calpain at low pH and temperature is similar to degradation in postmortem bovine muscle. Huff-Lonergan E, et al. **J Anim Sci** 1996 May;74(5):993–1008

Electrical measurement for detecting early postmortem changes in porcine muscle. Whitman TA, et al. **J Anim Sci** 1996 Jan;74(1):80–90

Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. Kempe K, et al. **J Biol Chem** 1996 Jul 19;271(29):17287–95

Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. Gomez HF, et al. **J Forensic Sci** 1995 Nov;40(6):980–2

A preliminary investigation of postmortem tooth loss. McKeown AH, et al. **J Forensic Sci** 1995 Sep;40(5):755–7

Postmortem stability of cocaine and cocaethylene in blood and tissues of humans and rabbits. Moriya F, et al. **J Forensic Sci** 1996 Jul;41(4):612–6

Microwave-enhanced in situ end-labeling of fragmented DNA: parametric studies in relation to postmortem delay and fixation of rat and human brain. Lucassen PJ, et al. **J Histochem Cytochem** 1995 Nov;43(11):1163–71

Diagnosis of fatal infantile defects of the mitochondrial respiratory chain: age dependence and postmortem analysis of enzyme activities. Majander A, et al. **J Neurol Sci** 1995 Dec;134(1–2):95–102

Magnetic resonance axonography of the rat spinal cord: postmortem effects. Matsuzawa H, et al. **J Neurosurg** 1995 Dec;83(6):1023–8

When does the lung die? Time course of high energy phosphate depletion and relationship to lung viability after "death". D'Armini AM, et al. **J Surg Res** 1995 Oct; 59(4):468–74

Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Li X, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):115–22

Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Greenwood AF, et al. **Neuroscience** 1995 Nov;69(1):125–38

An autopsy case of abandoned infant body with severe destruction. Funayama M, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):92–7

Identification of human skeletal remains with a mandibular static bone cavity by comparison between ante- and post-mortem dental orthopantomograms: a case report. Nagai K, et al. **Nippon Hoigaku Zasshi** 1995 Oct; 49(5):309–13

Influence of antemortem medication on the determination of brain death. Saito T, et al. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):484–7

Hepatocyte vacuolation and autolytic changes in the liver of pilot whales, Globicephala melas, stranded on Cape Cod, MA, USA. Moore MJ, et al. **Sci Total Environ** 1996 Jul 16;186(1–2):105–8

[Detection of clozapine in hair after 1 years burial in soil grave] Ahrens B, et al. **Arch Kriminol** 1995 Nov–Dec; 196(5–6):138–42 (Eng. Abstr.) **(Ger)**

[Person identification with video super-projection] Bajnóczky I. **Arch Kriminol** 1995 Jul–Aug;196(1–2):18–23 (Eng. Abstr.) **(Ger)**

[Dactyloscopy of mummified cadavers] Ineichen M, et al. **Arch Kriminol** 1995 Sep–Oct;196(3–4):87–92 (Eng. Abstr.) **(Ger)**

[Corpse dismemberment with sequential identification and classification of body parts] Schmitt C, et al. **Arch Kriminol** 1995 Nov–Dec;196(5–6):129–37 (Eng. Abstr.) **(Ger)**

[Postmortem changes in ear canal resonance and tympanic membrane impedance in the human ear] Vitzthum HG, et al. **Laryngorhinootologie** 1996 May;75(5):270–4 (Eng. Abstr.) **(Ger)**

[HLA typing of donor corneas with extended post mortem time] Ventura AC, et al. **Ophthalmologe** 1996 Jun; 93(3):262–7 (Eng. Abstr.) **(Ger)**

[Relationship among "kenshi" (inquest), "kenshi" (postmortem examination) and "ken-an" (postmortem inspection) in Japan] Mikami H, et al. **Nippon Hoigaku Zasshi** 1995 Dec; 49(6):488–97 (74 ref.) (Eng. Abstr.) **(Jpn)**

[The dynamics of the amino acid concentration in cadaveric organs in the late postmortem period] Alybaeva KN. **Sud Med Ekspert** 1995 Jul–Sep;38(3):13–5 **(Rus)**

[Biochemical study of the tissue lipids in a human corpse in a state of adipocere] Manulik AF, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):14–5 (Eng. Abstr.) **(Rus)**

[Establishing the time of death by the putrefactive transformation of the corpse] Zharov VV. **Sud Med Ekspert** 1996 Apr–Jun;39(2):5–7 (Eng. Abstr.) **(Rus)**

POSTNATAL CARE

Postpartum care. Stover AM, et al. **Am Fam Physician** 1995 Oct;52(5):1465–72 (32 ref.)

Disclosure of Duchenne muscular dystrophy after newborn screening. Parsons E, et al. **Arch Dis Child** 1996 Jun; 74(6):550–3

US warns against early discharge of babies [news] Roberts J. **BMJ** 1995 Oct 21;311(7012):1041–2

The 6-week postnatal visit [letter] Oates S. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):222

Maternal care receptivity and its relation to perinatal and neonatal mortality. A rural study. Bhardwaj N, et al. **Indian Pediatr** 1995 Apr;32(4):416–23

Drive-through deliveries [editorial] Haller KB. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):9

Follow-up home care [letter; comment] Lawrence DM. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):119. Comment on: J Obstet Gynecol Neonatal Nurs 1995 Oct;24(8):701.

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec; 20(6):346 (9 ref.)

Helping postpartum rural adolescents visualize future goals. Walsh SM, et al. **MCN Am J Matern Child Nurs** 1995 Sep–Oct;20(5):276–9

Traditional Chinese medicine (TCM) expert system in postpartum nursing. Shi PY. **Medinfo** 1995;8 Pt 2:1032

To stay or not to stay? That is the question [comment] [see comments] Parisi VM, et al. **N Engl J Med** 1995 Dec 14; 333(24):1635–7. Comment on: N Engl J Med 1995 Dec 14;333(24):1647–51. Comment in: N Engl J Med 1996 Apr 25;334(17):1134; discussion 1135.

Length of the hospital stay for mothers and newborns [letter; comment] Solomon GL. **N Engl J Med** 1996 Apr 25; 334(17):1134; discussion 1135. Comment on: N Engl J Med 1995 Dec 14;333(24):1635–7.

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Policy. Mass. squelches drive-through deliveries [news] **Hosp Health Netw** 1996 Feb 5;70(3):14

LEGISLATION & JURISPRUDENCE

Average postpartum length of stay for uncomplicated deliveries—New Jersey, 1995. **MMWR Morb Mortal Wkly Rep** 1996 Aug 16;45(32):700–4

Women and children first [see comments] Annas GJ. **N Engl J Med** 1995 Dec 14;333(24):1647–51. Comment in: N Engl J Med 1995 Dec 14;333(24):1635–7.

METHODS

Eliminating language barriers for non-English-speaking patients. Hornberger JC, et al. **Med Care** 1996 Aug; 34(8):845–56

[The therapeutic and prophylactic use of physical factors in the postpartum period: methods and technological features] Zheleznova EB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):41–3 **(Rus)**

ORGANIZATION & ADMINISTRATION

Reduced schedule of antenatal visits. Postnatal care also requires evaluation [letter; comment] Bell R. **BMJ** 1996 Jul 20;313(7050):168; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.

The 6-week postnatal visit: are we doing it right? Sharif K, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):7–10 (18 ref.)

Postpartum safety and satisfaction following early discharge. Dalby DM, et al. **Can J Public Health** 1996 Mar–Apr; 87(2):90–4

Employers. Workers' health is retailer's business. Montague J. **Hosp Health Netw** 1996 May 20;70(10):41–2

Follow-up home care [letter; comment] [see comments] Liberto TL. **J Obstet Gynecol Neonatal Nurs** 1995 Oct; 24(8):701. Comment on: J Obstet Gynecol Neonatal Nurs 1995 Jan;24(1):17–21. Comment in: J Obstet Gynecol Neonatal Nurs 1996 Feb;25(2):119.

Managing very-low-birth-weight babies at home in a rural area [letter] Daga SR, et al. **World Health Forum** 1996; 17(3):289–90

STANDARDS

The effects of newborn early discharge on hospital readmissions. Fox MH, et al. **Am J Med Qual** 1995 Winter; 10(4):206–12

Managing a snappy birthday [editorial] Meier CF. **Obstet Gynecol Surv** 1995 Dec;50(12):837–8

TRENDS

Association between duration of neonatal hospital stay and readmission rate [see comments] Lee KS, et al. **J Pediatr** 1995 Nov;127(5):758–66. Comment in: J Pediatr 1995 Nov;127(5):736–7.

POSTNATAL DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTNIDATION PHASE see **POSTIMPLANTATION PHASE**

POSTOPERATIVE CARE

Continuous passive motion compared to active physical therapy after knee arthroplasty: similar hospitalization times in a randomized study of 68 patients. Montgomery F, et al. **Acta Orthop Scand** 1996 Feb;67(1):7–9

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Perioperative management of the alcohol-dependent patient. Chiang PP. **Am Fam Physician** 1995 Dec;52(8):2267–73

Effect of lateral position on arterial and venous blood gases in postoperative cardiac surgery patients. Banasik JL, et al. **Am J Crit Care** 1996 Mar;5(2):121–6

Physician survey on the care of children with tracheotomies. Woolley AL, et al. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):50–3

Decreasing unplanned extubations in the surgical intensive care unit. Tominaga GT, et al. **Am J Surg** 1995 Dec; 170(6):586–9; discussion 589–90

The clear liquid diet is no longer a necessity in the routine postoperative management of surgical patients. Jeffery KM, et al. **Am Surg** 1996 Mar;62(3):167–70

Postoperative management strategies may obviate the need for most preoperative cardiac testing [letter] Rosenfeld BA, et al. **Anesthesiology** 1996 May;84(5):1266–8

Benign breast surgery: is there a need for outpatient follow-up? Wakefield SE, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):457–9

Protein-sparing therapy after major abdominal surgery: lack of clinical effects. Protein-Sparing Therapy Study Group. Doglietto GB, et al. **Ann Surg** 1996 Apr;223(4):357–62

Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula. Kenler AS, et al. **Ann Surg** 1996 Mar;223(3):316–33

A model for predicting transfusion after coronary artery bypass grafting. Magovern JA, et al. **Ann Thorac Surg** 1996 Jan;61(1):27–32

Drainage after thyroid and parathyroid surgery [letter] Davis O. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):898

Effect of cold therapy following anterior cruciate ligament reconstructive surgery [letter; comment] Lindenbaum BL. **Arthroscopy** 1995 Aug;11(4):515–6. Comment on: Arthroscopy 1994 Oct;10(5):530–3.

A simple and safe technique for drainage tube insertion after laparoscopic cholecystectomy. Evans PM, et al. **Aust N Z J Surg** 1996 May;66(5):312

Enteral nutrition after surgery [editorial; comment] Souba WW. **BMJ** 1996 Apr 6;312(7035):864. Comment on: BMJ 1996 Apr 6;312(7035):869–71.

Surveillance imaging of the operated artery does not alter clinical outcome following carotid endarterectomy. Naylor AR, et al. **Br J Surg** 1996 Apr;83(4):522–6

Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590–7 (88 ref.)

Shared care for open heart surgery: 21 years' experience. FitzGibbon GM, et al. **Can J Cardiol** 1996 Jan;12(1):59–64

Energy metabolism of thoracic surgical patients in the early postoperative period. Effect of posture. Brandi LS, et al. **Chest** 1996 Mar;109(3):630–7

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):424S–430S (30 ref.)

Clinical study of the effects of latissimus dorsi muscle flap stimulation after cardiomyoplasty. Hagège AA, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II210–5

Perioperative care of the elderly patient: special considerations. Miller DL. **Cleve Clin J Med** 1995 Nov–Dec;62(6):383–90

The perioperative use of ceftriaxone as infection prophylaxis in neurosurgery. Zhao JZ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):285–9

Age-related postoperative morphine requirements in children following major surgery—an assessment using

patient-controlled analgesia (PCA). Hansen TG, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):29-31

Immune and nutritional effects of early enteral nutrition after major abdominal operations. Braga M, et al. **Eur J Surg** 1996 Feb;162(2):105-12

Postoperative radiotherapy of patients with supratentorial astroglial tumours. Ianeva M. **Folia Med (Plovdiv)** 1995; 37(4A Suppl):48

Nasogastric decompression following laparotomy. Soybel DI. **Gastroenterology** 1996 Feb;110(2):645-6

Incidence of adenomyosis [letter; comment] Thylan S. **Gynecol Oncol** 1996 Apr;61(1):158-60. Comment on: Gynecol Oncol 1996 Jan;60(1):54-8.

Suprapubic drainage following operative pelviscopy [letter] Csiszár P. **Int J Gynaecol Obstet** 1995 Sep;50(3):301-2

Perioperative use of total parenteral nutrition. Variations in guidelines and practice in three Norwegian hospitals. Mjaaland M, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):741-9

Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Eagle KA, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):910-48

Effects of continuous passive motion following Austin bunionectomy. A prospective review. Connor JC, et al. **J Am Podiatr Med Assoc** 1995 Dec;85(12):744-8

Respiratory monitoring during postoperative analgesia. Gordh T, et al. **J Clin Monit** 1995 Nov;11(6):365-72

Early versus late range of motion following cubital tunnel surgery. Warwick L, et al. **J Hand Ther** 1995 Oct-Dec; 8(4):245-8

Is a community-based mastoid microsuction service feasible: the audit of a pilot project. Lewis C, et al. **J Laryngol Otol** 1995 Oct;109(10):971-4

Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. Beath SV, et al. **J Pediatr Surg** 1996 Apr;31(4):604-6

Transanastomotic feeding tubes in repair of esophageal atresia. Moriarty KP, et al. **J Pediatr Surg** 1996 Jan; 31(1):53-4; discussion 54-5

Randomized comparison of oral and intravenous fluid regimens after gallbladder surgery. Cassell OC, et al. **J R Soc Med** 1996 May;89(5):249-52

Validity of ultrasonography for postoperative monitoring in pediatric urology. Paduano L, et al. **J Urol** 1996 Mar; 155(3):1053-6

The effect on energy and nitrogen metabolism by continuous, bolus, or sequential infusion of a defined total parenteral nutrition formulation in patients after major surgical procedures. Sandström R, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):333-40

Structured triglycerides were well tolerated and induced increased whole body fat oxidation compared with long-chain triglycerides in postoperative patients. Sandström R, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):381-6

Preoperative assessment and postoperative management of the elderly surgical patient [see comments] Finucane P, et al. **Med J Aust** 1995 Sep 18;163(6):328-30. Comment in: Med J Aust 1996 Mar 18;164(6):383-4.

Preoperative assessment and postoperative management of the elderly surgical patient [letter; comment] Gelb JJ. **Med J Aust** 1996 Mar 18;164(6):383-4. Comment on: Med J Aust 1995 Sep 18;163(6):328-30.

Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group [see comments] Kurz A, et al. **N Engl J Med** 1996 May 9; 334(19):1209-15. Comment in: N Engl J Med 1996 May 9;334(19):1263-4.

Perioperative antimicrobial prophylaxis in neurosurgery: clinical trial of systemic flomoxef administration and saline containing gentamicin for irrigation. Yamamoto M, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):370-6

Postoperative management of cesarean patients: the effect of immediate feeding on the incidence of ileus. Kramer RL, et al. **Obstet Gynecol** 1996 Jul;88(1):29-32

Early oral feeding after cesarean delivery. Soriano D, et al. **Obstet Gynecol** 1996 Jun;87(6):1006-8

Effect of motion on digital nerve repair in a fresh cadaver model. Malczewski MC, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1672-5

A simple self-retaining splint for conjunctival fornix reconstruction [letter] Mokal NJ, et al. **Plast Reconstr Surg** 1996 Jul;98(1):181-2

Techniques to minimize blood loss and simplify postoperative care of buttock skin-graft donor sites [letter] Tenenhaus M, et al. **Plast Reconstr Surg** 1996 May;97(6):1312-3

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195-8, 201, 205 (15 ref.)

A comparison of patient teaching outcomes among postoperative coronary artery bypass graft (CABG) patients. Barnason S, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):11-20

Comparison of arterial and capillary blood glucose with the use of the Accu-Chek III. Chaisson KM. **Prog Cardiovasc Nurs** 1995 Fall;10(4):27-30

Removal of epicardial pacing wires: an expanded role for nurses. Wollan DL. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):21-6

Minimal follow-up after functional endoscopic sinus surgery. Does it affect outcome? Ryan RM, et al. **Rhinology** 1996 Mar;34(1):44-5

Preventive effect of simultaneously infused lipid emulsion against thrombophlebitis during postoperative peripheral parenteral nutrition. Matsusue S, et al. **Surg Today** 1995; 25(8):667-71

Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Heiss MM, et al. **Surgery** 1996 May;119(5):523-7

Dressing for surgical wounds of the penis. Bishoff JT, et al. **Urology** 1996 Feb;47(2):250-1

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Coetzee LJ, et al. **Urology** 1996 Feb; 47(2):232-5

[Perioperative artificial nutrition programmed for the adult surgical patient. Saint-Mandé, December 16, 1994: The Francophone Society of Enteral and Parenteral Nutrition and the French Society of Anesthesia and Resuscitation] **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):310-9 (0 ref.) **(Fre)**

[Therapeutic hydrophilic bandage lenses after perforating keratoplasty in severe eye chemical burns] Kuckelkorn R, et al. **Klin Monatsbl Augenheilkd** 1995 Aug;207(2):95-101 (Eng. Abstr.) **(Ger)**

[Perioperative use of noninvasive ventilation] Karg O, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:38-40 (Eng. Abstr.) **(Ger)**

[Irradiation in cervical carcinoma after radical surgery: what is the target volume? Is prophylactic irradiation of the para-aortal area effective?] Atzinger A. **Strahlenther Onkol** 1996 Apr;172(4):229-30 **(Ger)**

[A randomized comparison of adjuvant radiation therapy alone with sequential chemo-/radiotherapy in the treatment of resected non-small-cell bronchial carcinoma (NSCLC)] Rübe C. **Strahlenther Onkol** 1996 Jun; 172(6):345-6 **(Ger)**

[Follow-up care of living kidney donors] Bock HA, et al. **Ther Umsch** 1995 Sep;52(9):590-3 (Eng. Abstr.) **(Ger)**

[Management of patients with transplants in clinical practice (editorial)] Frey FJ. **Ther Umsch** 1995 Sep;52(9):561-2 **(Ger)**

[Immediate post-operative enteral nutrition] Dominioni L, et al. **Chir Ital** 1994;46(6):36-41 (Eng. Abstr.) **(Ita)**

[The importance of using computed tomographic scanning in breast irradiation after conservative treatment] Sciacero P, et al. **Radiol Med (Torino)** 1996 Apr;91(4):448-51 (Eng. Abstr.) **(Ita)**

[Problems of postoperative care in urinary diversion: ureterocutaneostomy] Hirano A. **Hinyokika Kiyo** 1995 Nov;41(11):921-6 (Eng. Abstr.) **(Jpn)**

[Complications and quality of life in patients with ileal conduit diversion] Momose H, et al. **Hinyokika Kiyo** 1995 Nov;41(11):927-35 (Eng. Abstr.) **(Jpn)**

[Postoperative care of continent urinary reservoirs] Mori Y. **Hinyokika Kiyo** 1995 Nov;41(11):937-40 (Eng. Abstr.) **(Jpn)**

[Postoperative care of neobladder using a detubularized intestinal segment] Nakamura I, et al. **Hinyokika Kiyo** 1995 Nov;41(11):941-5 (Eng. Abstr.) **(Jpn)**

[Postoperative complications of self-catheterizable continent urinary diversions (Kock, Indiana, and appendiceal Mainz pouch) and patient care] Okada Y, et al. **Hinyokika Kiyo** 1995 Nov;41(11):947-52 (Eng. Abstr.) **(Jpn)**

[Anesthetic and postoperative care of a patient with Crigler-Najjar syndrome type II] Hamada T, et al. **Masui** 1996 Mar;45(3):345-7 (Eng. Abstr.) **(Jpn)**

[Postoperative management following open heart surgery by thoracic epidural anesthesia] Konishi A, et al. **Masui** 1995 Aug;44(8):1113-7 (Eng. Abstr.) **(Jpn)**

[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162-6; discussion S173-6 (1 ref.) **(Jpn)**

[Perioperative management of esophageal cancer--correlation between postoperative complication and oxygen consumption] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):654-5 **(Jpn)**

[Perioperative metabolism and its management in esophageal cancer] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May; 43(5):656-7 **(Jpn)**

[Perioperative management in esophageal cancer. Timing for starting postoperative enteral nutrition] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):658-60 **(Jpn)**

[Total intravenous anesthesia and postoperative continuous epidural infusion in thoracic esophageal cancer surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):661-2 **(Jpn)**

[Peri- and postoperative courses in patients undergoing concomitant cardiac and pulmonary operations] Irie T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun; 44(6):747-54 (Eng. Abstr.) **(Jpn)**

[Postoperative treatment and follow-up] Kvalsvik O. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):849-53 (Eng. Abstr.) **(Nor)**

[Patient-controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):66-71 (145 ref.) **(Rus)**

[The effect of plasmosorption on the healing dynamics of postoperative wounds in patients with suppurative-inflammatory processes of the maxillofacial area and diabetes mellitus] Zuev VP, et al. **Stomatologiia (Mosk)** 1995;74(3):36-7 (Eng. Abstr.) **(Rus)**

[The effect of HBO therapy in the early postoperative period on the late outcomes of "compelled" suturing in perforated gastroduodenal ulcers] Belokurov IuN, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):124-7 (Eng. Abstr.) **(Rus)**

[The correction of the fatty acid composition of the erythrocyte membranes by infusions of fat emulsions following operations on the stomach] Dzis' RP. **Vestn Khir Im I I Grek** 1992 Nov-Dec;149(11-12):377-80 (Eng. Abstr.) **(Rus)**

[Isoflurane versus propofol for sedation after heart surgery] Gómez JI, et al. **Rev Esp Anestesiol Reanim** 1995 Aug-Sep; 42(7):261-8 (Eng. Abstr.) **(Spa)**

[Influence of hematopoietic growth factors on transfusion support following autologous bone marrow transplantation] Galende J, et al. **Sangre (Barc)** 1995 Aug;40(4):281-7 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Fluticasone propionate is associated with severe infection after endoscopic polypectomy. Mostafa BE. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):729-31

ECONOMICS

An economic evaluation of propofol/fentanyl compared with midazolam/fentanyl on recovery in the ICU following cardiac surgery. Sherry KM, et al. **Anaesthesia** 1996 Apr; 51(4):312-7

Oxygen is cost effective [letter; comment] Groudine SB, et al. **Anesth Analg** 1995 Oct;81(4):891. Comment on: Anesth Analg 1995 Feb;80(2):368-72.

The satisfaction and savings of early discharge with drain in situ following axillary lymphadenectomy in the treatment of breast cancer. Holcombe C, et al. **Eur J Surg Oncol** 1995 Dec;21(6):604-6

Radiographic cost reduction strategy in total joint arthroplasty. A prospective analysis. Ververeli PA, et al. **J Arthroplasty** 1996 Apr;11(3):277-280

Cost-effective preoperative evaluation, operative treatment, and postoperative follow-up in the breast cancer patient. Cady B. **Surg Clin North Am** 1996 Feb;76(1):25-34

HISTORY

Dark rooms and bandages discarded in the after-treatment of cataract operations, iridectomies, etc. 1886 [classical article] Michel CE. **Arch Ophthalmol** 1996 Sep; 114(9):1134-5; discussion 1135

INSTRUMENTATION

Use of the Heimlich valve to shorten hospital stay after lung reduction surgery for emphysema. McKenna RJ Jr, et al. **Ann Thorac Surg** 1996 Apr;61(4):1115-7

A dual hinge external pin appliance for stability and function following partial mandibulectomy. Zide MF, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):236-7

Arterial pressure-gradient estimation postcardiopulmonary bypass using a Tycos gauge [letter] Coleman ET, et al. **Perfusion** 1995 Sep;10(5):347-9

Postoperative "bridge fixing method" in cleft lip surgery [letter] Tezel E, et al. **Plast Reconstr Surg** 1995 Oct; 96(5):1235-6

METHODS

A rapid recovery program for cardiac surgery patients. Riddle MM, et al. **Am J Crit Care** 1996 Mar;5(2):152-9

The delivery of oxygen by a venturi T piece. Campbell DJ, et al. **Anaesthesia** 1996 Jun;51(6):558-60

Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients [see comments] Schröter J, et al. **Anaesthesia** 1995 Oct;50(10):850-4. Comment in: Anaesthesia 1996 Jun;51(6):611.

Epinephrine decreases postoperative requirements for continuous thoracic epidural fentanyl infusions. Baron CM, et al. **Anesth Analg** 1996 Apr;82(4):760-5

Postoperative analgesia with continuous epidural sufentanil and bupivacaine: a prospective study in 614 patients. Broekema AA, et al. **Anesth Analg** 1996 Apr;82(4):754-9

Postoperative care following single-stage laryngotracheoplasty. Bauman NM, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):317-22

Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):163-7 (29 ref.)

Audit of pain after nasal surgery. Thomas DM, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):380-2

Early removal of drains and discharge of breast cancer surgery patients: a controlled prospective clinical trial. Yii M, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):377-9

Mechanisms to reduce hospital stays. Engelman RM. **Ann Thorac Surg** 1996 Feb;61(2 Suppl):S26-9; discussion S33-4

Randomised trial of safety and efficacy of immediate

postoperative enteral feeding in patients undergoing gastrointestinal resection [see comments] Carr CS, et al. **BMJ** 1996 Apr 6;312(7035):869–71. Comment in: **BMJ** 1996 Apr 6;312(7035):864. Comment in: BMJ 1996 Jul 27;313(7051):229–30. Comment in: BMJ 1996 Jul 27;313(7051):230.

Comparison between oxygen consumption calculated by Fick's principle using a continuous thermodilution technique and measured by indirect calorimetry. Bizouarn P, et al. **Br J Anaesth** 1995 Dec;75(6):719–23

Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection. Spies CD, et al. **Br J Anaesth** 1995 Dec;75(6):734–9

Fast-tracking in cardiac surgery. Aps C. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):139–42 (5 ref.)

First day follow up for routine phacoemulsification? Whitefield L, et al. **Br J Ophthalmol** 1996 Feb;80(2):148–50

Breast feeding or spoon feeding after cleft lip repair: a prospective, randomised study. Darzi MA, et al. **Br J Plast Surg** 1996 Jan;49(1):24–6

Early division of pedicled flaps using a simple device: a new technique. George A, et al. **Br J Plast Surg** 1996 Mar; 49(2):119–22

Nephrostomy track brachytherapy following percutaneous resection of transitional cell carcinoma of the renal pelvis. Shepherd SF, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(6):385–7

Postoperative removal of pressure by eyeglasses [letter; comment] Kaplan R. **Dermatol Surg** 1995 Nov;21(11):995 . Comment on: J Dermatol Surg Oncol 1991 Nov;17(11):906–8.

Laser skin resurfacing. Pre- and posttreatment guidelines. Lowe NJ, et al. **Dermatol Surg** 1995 Dec;21(12):1017–9

Minimizing postoperative care and adhesions following endoscopic sinus surgery. Brennan LG. **Ear Nose Throat J** 1996 Jan;75(1):45–8

Semi-continuous versus injectate cardiac output measurement in intensive care patients after cardiac surgery. Böttiger BW, et al. **Intensive Care Med** 1996 Apr; 22(4):312–8

Prophylactic bronchial hygiene following cardiac surgery: what is necessary? [editorial; comment] Kacmarek RM. **Intensive Care Med** 1995 Jun;21(6):467–8. Comment on: Intensive Care Med 1995 Jun;21(6):469–74.

Post-operative delivery of liquid diets [editorial; comment] Deitel M. **J Am Coll Nutr** 1996 Apr;15(2):111–2. Comment on: J Am Coll Nutr 1996 Apr;15(2):144–6.

Postoperative treatment of internally fixed ankle fractures: a prospective randomised study. van Laarhoven CJ, et al. **J Bone Joint Surg Br** 1996 May;78(3):395–9

Target-controlled infusion delivery systems: application outside the operating room. Bovill JG, et al. **J Clin Anesth** 1996 May;8(3 Suppl):21S–25S (33 ref.)

Tumor bed implant brachytherapy for residual carcinoma after palliative esophagectomy. Kato H, et al. **J Surg Oncol** 1996 Jul;62(3):214–7

Is radiographic evaluation of the chest necessary following flank surgery? Poore RE, et al. **J Urol** 1996 Mar; 155(3):849–51

Is intensive care necessary following carotid endarterectomy? Ammar AD. **Kans Med** 1995 Fall;96(3):125–6

Drainage following radical hysterectomy and pelvic lymphadenectomy: dogma or need? Lopes AD, et al. **Obstet Gynecol** 1995 Dec;86(6):960–3

Exit-site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336–9 (28 ref.)

Management of post-ethmoidectomy crust formation: randomized single-blind clinical trial comparing pressurized seawater versus antiseptic/mucolytic saline. Pigret D, et al. **Rhinology** 1996 Mar;34(1):38–40

Ambulatory paediatric surgery. The development of a day-care surgical centre. Rode H, et al. **S Afr Med J** 1994 Dec;84(12):829–33

Perioperative care in the elderly urologic patient. Smith R, et al. **Urol Clin North Am** 1996 Feb;23(1):27–41 (51 ref.)

[Experience in treating episiotomies after labor with ice] Despodova TS, et al. **Akush Ginekol (Sofiia)** 1995; 34(3):26–7 (Eng. Abstr.) **(Bul)**

[Systen—transdermal estradiol for substitution following surgical menopause] Rachev E, et al. **Akush Ginekol (Sofiia)** 1995;34(3):74–6 (Eng. Abstr.) **(Bul)**

[Postoperative analgesia] Radev R, et al. **Khirurgiia (Sofiia)** 1995;48(5):29–32 (Eng. Abstr.) **(Bul)**

[Recommendations of the jury. Peri-operative artificial nutrition]. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:5–16 **(Fre)**

[Pre- and post-operative enteral nutrition in elective surgery in adults. Techniques, advantages and adverse effects] Beau P. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:121–6 (Eng. Abstr.) **(Fre)**

[Role of trace elements and vitamins in peri-operative nutrition] Berger MM. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:82–94 (Eng. Abstr.) **(Fre)**

[In which patients and for which procedures has the efficacy of postoperative artificial nutrition be proven?] Blanloeil Y. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:54–65 (Eng. Abstr.) **(Fre)**

[Caloric and nitrogen intake during pre- and post-operative periods. method and duration] Cohen S, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:75–81 (Eng. Abstr.) **(Fre)**

[Role of new nitrogen substrates during peri-operative artificial nutrition in adults] Cynober L. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:102–6 (Eng. Abstr.) **(Fre)**

[How to assess and monitor postoperative artificial nutrition?] Delafosse B. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:27–32 (Eng. Abstr.) **(Fre)**

[Respective indications of enteral or parenteral nutrition during pre- and post-operative periods] Petit J, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:127–36 (Eng. Abstr.) **(Fre)**

[Techniques of salvage of blood lost during the postoperative period] Vignon D. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:63–80 **(Fre)**

[Value of early oral feeding after a cesarean section] Benzineb N, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun; 90(5–6):281–2, 285 (Eng. Abstr.) **(Fre)**

[Patient management following cardiac transplantation] Seydoux C, et al. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1913–22 (103 ref.) (Eng. Abstr.) **(Fre)**

[Orthodontic pre- and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11–20 (19 ref.) **(Ger)**

[Effects of postoperative care on wound healing after endonasal paranasal sinus surgery] Weber R, et al. **Laryngorhinootologie** 1996 Apr;75(4):208–14 (Eng. Abstr.) **(Ger)**

[The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?] Souchon R, et al. **Strahlenther Onkol** 1995 Nov; 171(11):630–40 (83 ref.) (Eng. Abstr.) **(Ger)**

[The use of an early postoperative interstitial-hyperthermia combination therapy in malignant gliomas] Stahl H, et al. **Strahlenther Onkol** 1995 Sep;171(9):510–24 (Eng. Abstr.) **(Ger)**

[Management of children and adolescents with kidney transplantation] Bianchetti MG, et al. **Ther Umsch** 1995 Sep;52(9):602–7 (Eng. Abstr.) **(Ger)**

[Timing postoperative irrigation treatment after colostomy] Neuhäuser K. **Z Gastroenterol** 1996 Jun;34 Suppl 2:59–61 **(Ger)**

[Postoperative infusion therapy: electrolyte solution in comparison with hypocaloric glucose and carbohydrate exchange-amino acid solutions] Jauch KW, et al. **Zentralbl Chir** 1995;120(9):682–8 (Eng. Abstr.) **(Ger)**

[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

[The epidural administration of pentamine as a method for stimulating the functions of the small intestine in the early postoperative period] Dol'nikov NA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):24–6 (Eng. Abstr.) **(Rus)**

[Our experience with the pre- and postoperative management of middle-aged and elderly patients undergoing a urological surgical intervention] Gorilovskiĭ LM. **Ter Arkh** 1995;67(10):51–3 **(Rus)**

[Phytoperfusion of the bladder after adenomectomy] Davidov MI, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct; (5):19–20 (Eng. Abstr.) **(Rus)**

[Laser radiation in the infrared range in the treatment of aseptic postoperative wounds] Efendiev AI, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):291–3 (Eng. Abstr.) **(Rus)**

[The individual immunotherapy of the intracranial complications after neurosurgical operations] Khil'ko VA, et al. **Vestn Khir Im I I Grek** 1995;154(2):29–30 (Eng. Abstr.) **(Rus)**

[The treatment and prosthesis after an interilioabdominal amputation for sarcomas of the bones and soft tissues] Trishkin VA, et al. **Vestn Khir Im I I Grek** 1995;154(2):53–6 (Eng. Abstr.) **(Rus)**

[The characteristics of drainage after operations on the brain] Gizatullin ShKh. **Voen Med Zh** 1996 Mar;317(3):31–4, 80 (Eng. Abstr.) **(Rus)**

[Physiotherapeutic methods in the postoperative period in acute pancreatitis patients] Larionov KS, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May-Jun; (3):16–8 (Eng. Abstr.) **(Rus)**

[The maintenance treatment of patients with stomach cancer who have undergone a radical surgical intervention] Lazarev AF. **Vopr Onkol** 1995;41(2):127–8 **(Rus)**

[Check-ups via telephone after day surgery. An effective part of quality assurance work] Persson BM, et al. **Lakartidningen** 1996 Jun 12;93(24):2331–2 **(Swe)**

NURSING

The pre- and postsurgical nursing of women with stress incontinence. Berglund AL, et al. **J Adv Nurs** 1996 Mar; 23(3):502–11

STANDARDS

Postoperative management of cataract surgery patients by ophthalmologists and optometrists. Bass EB, et al. **Arch Ophthalmol** 1996 Sep;114(9):1121–7

Feasibility and safety of 1-day postoperative hospitalization for carotid endarterectomy. Kaufman JL, et al. **Arch Surg** 1996 Jul;131(7):751–5

Early discharge after open appendicectomy. Lord RV, et al. **Aust N Z J Surg** 1996 Jun;66(6):361–5

Cost and prevention of pressure ulcers in an acute teaching hospital. Lapsley HM, et al. **Int J Qual Health Care** 1996 Feb;8(1):61–6

STATISTICS & NUMERICAL DATA

A survey of post-operative care after day case surgery. Wedderburn AW, et al. **Ann R Coll Surg Engl** 1996 Mar; 78(2 Suppl):70–1

TRENDS

The high dependency unit: where to now? Edbrooke DL. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):161–2

[Physiotherapy in the rehabilitative treatment following gynecological operations in children and adolescents: the current trends] Strugatskiĭ VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):41–3 **(Rus)**

VETERINARY

[Caruncle removal in cattle—subsequent treatment and use of a new cervix dilator] Glock H. **Tierarztl Prax** 1996 Apr; 24(2):103–7 (Eng. Abstr.) **(Ger)**

POSTOPERATIVE COMPLICATIONS

Postoperative complaints after spinal and thiopentone-isoflurane anaesthesia in patients undergoing orthopaedic surgery. Spinal versus general anaesthesia. Standl T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):222–6

Are neurologic events occurring during carotid artery surgery predictive of postoperative neurologic complications? Walleck P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):167–70

Possible complications of sagittal osteotomy of the mandibular ramus. Neméth T. **Acta Chir Plast** 1995; 37(2):45–6

Complications requiring hospitalization after third-molar surgery. Berge TI. **Acta Odontol Scand** 1996 Feb;54(1):24–8

Intraocular pressure elevation caused by massive and prolonged hemorrhage after trabeculotomy ab externo. Tanihara H, et al. **Acta Ophthalmol Scand** 1995 Jun; 73(3):281–2

Osteoarthritis of the elbow following an extensive Darrach procedure. Stuer P, et al. **Acta Orthop Belg** 1996 Mar; 62(1):62–5

Unpredictable progression of osteolysis following cementless hip arthroplasty. 24 femoral components followed for 6–10 years. Learmonth ID, et al. **Acta Orthop Scand** 1996 Jun; 67(3):245–8

Metallic or absorbable implants for ankle fractures: a comparative study of infections in 3,111 cases. Sinisaari I, et al. **Acta Orthop Scand** 1996 Feb;67(1):16–8

Mediastinitis due to perforation. Gryga A, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:73–4

Subperiosteal facelifting: complications and the dissatisfied patient. Scheflan M, et al. **Aesthetic Plast Surg** 1996 Winter; 20(1):33–6

Periportal low attenuation due to hepatic necrosis in a patient after liver transplant. Meyer JI, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):98–9

Comparison of early and late complications in patients undergoing coronary artery bypass graft surgery with and without concomitant placement of an implantable cardioverter defibrillator. Daoud EG, et al. **Am Heart J** 1995 Oct;130(4):780–5

Acquired coronary artery fistula in children after ventricular septal myectomy of the right or left ventricular outflow tract. Gildein HP, et al. **Am Heart J** 1995 Nov; 130(5):1124–6

Stand-alone stenting of the left main coronary artery and 16-month patency despite sepsis and complicated hospital course. Lee S, et al. **Am Heart J** 1995 Dec;130(6):1289–92

Use of positron emission tomography for prediction of perioperative and late cardiac events before vascular surgery. Marwick TH, et al. **Am Heart J** 1995 Dec; 130(6):1196–202

Percutaneous use of stents to correct pulmonary artery stenosis in young children after cavopulmonary anastomosis. Moore JW, et al. **Am Heart J** 1995 Dec; 130(6):1245–9

Right atrial thrombus mimicking myxoma in a heart transplant recipient. Rankin JM, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):452–4

Spasm of the gastroepiploic artery used for coronary artery bypass grafting. Cate CM, et al. **Am J Cardiol** 1996 May 1;77(11):1022–3

Obstruction of the proximal pulmonary artery branches after banding of the pulmonary trunk. Hiraishi S, et al. **Am J Cardiol** 1995 Oct 15;76(11):842–6

Clinical markers, management, and long-term follow-up of early ischemia after coronary artery bypass grafting. Pimentel CX, et al. **Am J Cardiol** 1995 Nov 1;76(12):967–70

Complications from cesarean section [letter; comment] Zellers RA, et al. **Am J Clin Pathol** 1996 Feb;105(2):251 . Comment on: Am J Clin Pathol 1995 Jun;103(6):681–4.

The effect of thoracic surgery on pulmonary function. Hallfeldt KK, et al. **Am J Crit Care** 1995 Sep;4(5):352–4

Acute gastrointestinal complications after cardiac surgery. Halm MA. **Am J Crit Care** 1996 Mar;5(2):109–18; quiz

119–20 (34 ref.)
Demystifying the postoperative GI problems after esophagectomy. Law S. **Am J Gastroenterol** 1996 Feb; 91(2):400–1
Nausea after endometrial resection [letter; comment] Hahn RG. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):294. Comment on: Am J Obstet Gynecol 1995 Mar;172(3):939–45.
Fluid absorption during operative hysteroscopy: incidence, prevention, monitoring? [letter; comment] Hulka JF. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):294–6. Comment on: Am J Obstet Gynecol 1995 Mar;172(3):939–45.
Gastrointestinal hemorrhage during pregnancy in a patient with a history of vertical-banded gastroplasty. Ramirez MM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1630–1
Visual field defects after macular hole surgery. Boldt HC, et al. **Am J Ophthalmol** 1996 Sep;122(3):371–81
Reversible loss of light perception after vitreoretinal surgery. Kangas TA, et al. **Am J Ophthalmol** 1995 Dec;120(6):751–6
Late onset of corneal scar after excimer laser photorefractive keratectomy. Meyer JC, et al. **Am J Ophthalmol** 1996 May; 121(5):529–39
Acquired lower eyelid epiblepharon. Park RI, et al. **Am J Ophthalmol** 1996 Sep;122(3):449–51
Venous infarction following translabyrinthine access to the cerebellopontine angle. Leonetti JP, et al. **Am J Otol** 1994 Nov;15(6):723–7
Determinants and impact of headache after acoustic neuroma surgery. Pedrosa CA, et al. **Am J Otol** 1994 Nov; 15(6):793–7
Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Oudejans JJ, et al. **Am J Pathol** 1995 Oct;147(4):923–33
Long-term followup of Bankart reconstruction. Incidence of late degenerative glenohumeral arthrosis. Rosenberg BN, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):538–44
Arthroscopic findings associated with roof impingement of an anterior cruciate ligament graft. Watanabe BM, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):616–25
Delayed gastric emptying after gastric surgery. Bar-Natan M, et al. **Am J Surg** 1996 Jul;172(1):24–8
Incidence and prophylaxis of deep vein thrombosis in a high risk trauma population. Britt LD, et al. **Am J Surg** 1996 Jul;172(1):13–4
Hospital admission following ambulatory surgery. Greenburg AG, et al. **Am J Surg** 1996 Jul;172(1):21–3
Abdominal wall hernias in patients with abdominal aortic aneurysmal versus aortoiliac occlusive disease. Hall KA, et al. **Am J Surg** 1995 Dec;170(6):572–5; discussion 575–6
Thrombolysis theraphy in patients with femoropopliteal synthetic graft occulsions. Ikeda Y, et al. **Am J Surg** 1996 Feb;171(2):251–4
Operative complications and quality improvement [editorial] Lee JT. **Am J Surg** 1996 Jun;171(6):545–7
Patient-controlled analgesia and prolonged ileus after uncomplicated colectomy. Petros JG, et al. **Am J Surg** 1995 Oct;170(4):371–4
Neuralgia after inguinal hernia repair. Bower S, et al. **Am Surg** 1996 Aug;62(8):664–7
Effect of epidural analgesia on postoperative ileus after ileal pouch-anal anastomosis. Kanazi GE, et al. **Am Surg** 1996 Jun;62(6):499–502
Colonic ischemia: the Achilles heel of ruptured aortic aneurysm repair. Piotrowski JJ, et al. **Am Surg** 1996 Jul; 62(7):557–60; discussion 560–1
Postoperative atrial fibrillation due to full bladder [letter] Griffin M, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):752–3
Postoperative morbidity following cataract surgery. A comparison of local and general anaesthesia. Barker JP, et al. **Anaesthesia** 1996 May;51(5):435–7
Anterior spinal artery syndrome [letter; comment] Djurberg H. **Anaesthesia** 1996 Apr;51(4):407. Comment on: Anaesthesia 1995 Aug;50(8):745–6.
Compartment syndrome with severe rhabdomyolysis in the postoperative period following major vascular surgery. Ferreira TA, et al. **Anaesthesia** 1996 Jul;51(7):692–4
The effect of different end-tidal volatile agent and carbon dioxide concentrations upon the incidence of postoperative shivering. Harwood RJ, et al. **Anaesthesia** 1995 Sep; 50(9):786–8
Peri-operative hypoxaemia in children undergoing application of a plaster jacket for scoliosis. Lovell AT, et al. **Anaesthesia** 1996 Feb;51(2):119–22
Postanaesthetic shivering in children. Lyons B, et al. **Anaesthesia** 1996 May;51(5):442–5
Compartment syndrome following prolonged positioning in the lithotomy position [letter] MacIntyre PA. **Anaesthesia** 1996 May;51(5):511
Delayed amniotic fluid embolism following caesarean section under spinal anaesthesia. Margarson MP. **Anaesthesia** 1995 Sep;50(9):804–6
The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)
Diclofenac and post-tonsillectomy haemorrhage [letter] Purday J, et al. **Anaesthesia** 1995 Sep;50(9):827–8
Intra-operative tracheal obstruction by tumour fragments [letter; comment] Satur CM, et al. **Anaesthesia** 1995 Dec; 50(12):1102–3. Comment on: Anaesthesia 1995 Mar;50(3):249–50.
Contralateral pneumothorax following thoracotomy for vertebrectomy. Spears FD, et al. **Anaesthesia** 1996 Jul; 51(7):685–6
Silent myocardial ischaemia in patients undergoing transurethral prostatectomy. A study to evaluate risk scoring and anaesthetic technique with outcome. Windsor A, et al. **Anaesthesia** 1996 Aug;51(8):728–32
Laryngospasm following extubation in children [letter; comment] [see comments] Young A, et al. **Anaesthesia** 1995 Sep;50(9):827. Comment on: Anaesthesia 1995 Apr;50(4):375. Comment in: Anaesthesia 1996 Jan;51(1):94.
Paraplegia in a patient who by chance missed the insertion of an epidural catheter [letter] Konstantinidou AS, et al. **Anesth Analg** 1996 May;82(5):1110
Transient blindness during hysteroscopy: a rare complication [see comments] Levin H, et al. **Anesth Analg** 1995 Oct; 81(4):880–1. Comment in: Anesth Analg 1996 Jul;83(1):196.
Optic nerve injury: role of the anesthesiologist? [letter; comment] Roth S, et al. **Anesth Analg** 1996 Feb;82(2):435–6 . Comment on: Anesth Analg 1995 May;80(5):1018–29.
The role of the phrenic nerves in stress response in upper abdominal surgery. Segawa H, et al. **Anesth Analg** 1996 Jun;82(6):1215–24
Postoperative anisocoria: neurogenic or phenylephrine induced? A rapid diagnostic test. Sitzman BT, et al. **Anesth Analg** 1996 Sep;83(3):633–5
Unexplained transient postoperative myocardial dysfunction in a previously healthy child. Spiekermann BF, et al. **Anesth Analg** 1996 Feb;82(2):419–20
Jugular venous desaturation due to epidural hematoma after craniotomy. Walder B, et al. **Anesth Analg** 1996 Feb; 82(2):421–2
Spinal cord infarction after surgery in a patient in the hyperlordotic position. Amoiridis G, et al. **Anesthesiology** 1996 Jan;84(1):228–30
Spinal cord infarction after surgery in a patient in the hyperlordotic position [letter] Bromage PR. **Anesthesiology** 1996 Aug;85(2):429–30
Prolonged luminal narrowing of internal mammary artery graft after percutaneous transluminal angioplasty. Ishizaka N, et al. **Angiology** 1996 Jul;47(7):735–8
Echocardiography for assessing cardiac risk in patients having noncardiac surgery. Study of Perioperative Ischemia Research Group. Halm EA, et al. **Ann Intern Med** 1996 Sep 15;125(6):433–41
Re: Absence of postoperative hyponatremia in young women [letter; comment] Ayus JC, et al. **Ann Neurol** 1995 Oct; 38(4):696–7. Comment on: Ann Neurol 1994 May;35(5):626–8.
Thrombocytosis after major lower extremity trauma: mechanism and possible role in free flap failure. Choe EI, et al. **Ann Plast Surg** 1996 May;36(5):489–94
Does ganglionectomy destabilize the wrist over the long-term? Kivett WF, et al. **Ann Plast Surg** 1996 May; 36(5):466–8
Osteomyelitis of the symphysis pubis after inguinal hernia repair. Baxandall RC, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):65–6
Significant risk factors in elective colorectal surgery. Kingston RD, et al. **Ann R Coll Surg Engl** 1995 Sep; 77(5):369–71
Severe hyponatraemia in elderly patients: cause for concern [see comments] Tolias CM. **Ann R Coll Surg Engl** 1995 Sep;77(5):346–8. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):73.
Acute appendicitis: does removal of a normal appendix matter, what is the value of diagnostic accuracy and is surgical delay important? [see comments] Walker SJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):358–63. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):73.
Visceral ischemia and organ dysfunction after thoracoabdominal aortic aneurysm repair. A clinical and cost analysis. Harward TR, et al. **Ann Surg** 1996 Jun; 223(6):729–34; discussion 734–6
Success and complications of pancreatic transplantation at one institution. Jones JW, et al. **Ann Surg** 1996 Jun; 223(6):757–62; discussion 762–4
Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Su CH, et al. **Ann Surg** 1996 Apr;223(4):384–94
Development of subneopulmonary obstruction early after arterial switch operation in an adult. Alexi-Meskishvili V, et al. **Ann Thorac Surg** 1996 May;61(5):1518–20
CABG in octogenarians: early and late events and actuarial survival in comparison with a matched population [see comments] Cane ME, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1033–7. Comment in: Ann Thorac Surg 1995 Oct;60(4):875–6.
Embolization of biologic glue during repair of aortic dissection. Carrel T, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1118–20
Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liason Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Edmunds LH Jr, et al. **Ann Thorac Surg** 1996 Sep;62(3):932–5
Severe chest wall construction from growth retardation after too extensive and too early (< 4 years) pectus excavatum repair: an alert [letter] Haller JA Jr. **Ann Thorac Surg** 1995 Dec;60(6):1857–8
Chest wall constriction after too extensive and too early operations for pectus excavatum. Haller JA Jr, et al. **Ann Thorac Surg** 1996 Jun;61(6):1618–24; discussion 1625
Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Harpole DH, et al. **Ann Thorac Surg** 1996 Mar;61(3):977–82
Aortic aneurysms at the site of the repair of coarctation of the aorta: a review of 48 patients. Knyshov GV, et al. **Ann Thorac Surg** 1996 Mar;61(3):935–9
Left atrioventricular valve incompetence after repair of common atrioventricular canal defects. Michielon G, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S604–9
Mesenteric ischemia after a cardiac operation: conservative treatment with local vasodilation. Niederhäuser U, et al. **Ann Thorac Surg** 1996 Jun;61(6):1817–9
Mortality and neurologic morbidity after repair of traumatic aortic disruption. Nocolosi AC, et al. **Ann Thorac Surg** 1996 Mar;61(3):875–8
Retained sponge after thoracotomy that mimicked aspergilloma. Nomori H, et al. **Ann Thorac Surg** 1996 May; 61(5):1535–6
Right ventricular failure [letter; comment] Pessik CS, et al. **Ann Thorac Surg** 1996 Aug;62(2):630. Comment on: Ann Thorac Surg 1996 Feb;61(2):706–7.
Nitric oxide treatment for pulmonary hypertension after neonatal cardiac operation. Shah AS, et al. **Ann Thorac Surg** 1995 Dec;60(6):1791–3
Mycoplasma hominis infections occurring in cardiovascular surgical patients. Sielaff TD, et al. **Ann Thorac Surg** 1996 Jan;61(1):99–103 (21 ref.)
Dissection of an allograft ascending aorta after aortic root replacement. Smith JA, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1011–2
Postoperative management of cerebral air embolism: gas physiology for surgeons. Tovar EA, et al. **Ann Thorac Surg** 1995 Oct;60(4):1138–42
Heart transplantation complicated by a patent foramen ovale of the recipient atrial septum. Yun KL, et al. **Ann Thorac Surg** 1996 Sep;62(3):897–9
Incidence of vocal fold paralysis in infants undergoing ligation of patent ductus arteriosus. Zbar RI, et al. **Ann Thorac Surg** 1996 Mar;61(3):814–6
Silent brain infarct after carotid artery surgery: incidence and prevention. Alimi Y, et al. **Ann Vasc Surg** 1995;9 Suppl:S76–80
Internal iliac artery aneurysm following aortic reconstruction. Brings HA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):59–62
Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. Giangola G, et al. **Ann Vasc Surg** 1996 Mar;10(2):138–42
Recovery from laparoscopic cholecystectomy procedures. Cason CL, et al. **AORN J** 1996 Jun;63(6):1099–103, 1106–8, 1111–2 passim
Infections after renal transplantation. Recipient factors affecting their incidence. Minardi D, et al. **Arch Ital Urol Androl** 1995 Sep;67(4):243–7
Vascular consequences of retinectomy. Bourke RD, et al. **Arch Ophthalmol** 1996 Feb;114(2):155–60
Clinical analysis of steep central islands after excimer laser photorefractive keratectomy. Krueger RR, et al. **Arch Ophthalmol** 1996 Apr;114(4):377–81
Sight-threatening complications after radial keratotomy [editorial; comment] McDonnell PJ. **Arch Ophthalmol** 1996 Feb;114(2):211–2 (5 ref.). Comment on: Arch Ophthalmol 1996 Feb;114(2):129–34.
Fascia lata plasty in recurrent posterior dislocation after total hip arthroplasty. Strømsøe K, et al. **Arch Orthop Trauma Surg** 1995;114(5):292–4
Short-stay outpatient tonsillectomy [letter] Berry YJ. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):897; discussion 897–8
Outcome and complications of extended cranial-base resection requiring microvascular free-tissue transfer. Clayman GL, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov;121(11):1253–7
Conductive hearing loss following retrolabyrinthine surgery. Parikh AA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):841–3
Critical analysis of the operative treatment of Hirschsprung's disease. Fortuna RS, et al. **Arch Surg** 1996 May; 131(5):520–4; discussion 524–5
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Hurst RD, et al. **Arch Surg** 1996 May; 131(5):497–500; discussion 501–2
Risks of synchronous gastrointestinal or biliary surgery with splenectomy for hematologic disease. McAneny, D, et al. **Arch Surg** 1996 Apr;131(4):372–6
Autograft bone-patella tendon-bone plug comminution with loss of ligament fixation and stability. Berg EE. **Arthroscopy** 1996 Apr;12(2):232–5
Tibial bone plug resorption with extra-articular cyst: a rare complication of anterior cruciate ligament reconstruction. Brettler D, et al. **Arthroscopy** 1995 Aug;11(4):478–81
Complications in hip arthroscopy. Funke EL, et al. **Arthroscopy** 1996 Apr;12(2):156–9
Tourniquet-induced tibial nerve palsy complicating anterior cruciate ligament reconstruction. Guanche CA. **Arthroscopy** 1995 Oct;11(5):620–2
Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995

Aug;11(4):486–94 (25 ref.)
Early uterine prolapse following colponeedle suspension. Neuman M, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):339–40
Complications of the Caldwell–Luc operation and how to avoid them [letter] Bartley J, et al. **Aust N Z J Surg** 1996 Feb;66(2):119
Complications of an abdominal stoma: an analysis of 322 stomas. Cheung MT. **Aust N Z J Surg** 1995 Nov; 65(11):808–11
Hyperparathyroidism presenting as pancreatitis or complicated by postoperative pancreatitis. Shepherd JJ. **Aust N Z J Surg** 1996 Feb;66(2):85–7
Acute aortic dissection as a complication of coronary artery surgery. Subramaniam P, et al. **Aust N Z J Surg** 1996 Jul; 66(7):498–500
Colorectal resection in Victoria:a comparison of hospital based and individual audit. Thompson GA, et al. **Aust N Z J Surg** 1996 Aug;66(8):520–4
Factors affecting morbidity and mortality following surgical intervention in patients with intracranial meningioma. Turgut M, et al. **Aust N Z J Surg** 1996 Mar;66(3):144–50
Posttransplantation lymphoproliferative gingival disease. Broudy VC, et al. **Blood** 1995 Oct 15;86(8):2891
Atrial arrhythmias and pacing after orthotopic heart transplantation: bicaval versus standard atrial anastomosis. Grant SC, et al. **Br Heart J** 1995 Aug;74(2):149–53
Right to left interatrial communications after the modified Fontan procedure: identification and management with transcatheter occlusion. Hsu HS, et al. **Br Heart J** 1995 Nov;74(5):548–52
Long–term complications of cardiac transplantation [editorial] Parameshwar J, et al. **Br Heart J** 1995 Oct; 74(4):341–2
Postoperative brachial plexus neuropathy after total knee replacement under spinal anaesthesia. Eggers KA, et al. **Br J Anaesth** 1995 Nov;75(5):642–4
Influence of inspired nitrogen concentration during anaesthesia for coronary artery bypass grafting on postoperative atelectasis. Joyce CJ, et al. **Br J Anaesth** 1995 Oct;75(4):422–7
Postoperative sleep disturbances: mechanisms and clinical implications. Rosenberg–Adamsen S, et al. **Br J Anaesth** 1996 Apr;76(4):552–9 (71 ref.)
Breast cancer incidence subsequent to surgical reduction of the female breast. Baasch M, et al. **Br J Cancer** 1996 Apr; 73(7):961–3
Ligation of the superior mesenteric vein: a cautionary tale. Nydahl S. **Br J Clin Pract** 1996 Jul–Aug;50(5):281–2
Scrotal suppuration after appendicitis [letter] Pal KM. **Br J Clin Pract** 1995 Sep–Oct;49(5):279–80
The occurrence of bacteraemia with skin surgery. Carmichael AJ, et al. **Br J Dermatol** 1996 Jan;134(1):120–2
Alopecia universalis in liver transplant patients treated with cyclosporin [letter] Monti M, et al. **Br J Dermatol** 1995 Oct;133(4):663–4
Contact lens fitting after photorefractive keratectomy. Astin CL, et al. **Br J Ophthalmol** 1996 Jul;80(7):597–603
Primary vitrectomy for pseudophakic retinal detachment. Bartz–Schmidt KU, et al. **Br J Ophthalmol** 1996 Apr; 80(4):346–9
Results of surgery for epiretinal membranes and their recurrences. Grewing R, et al. **Br J Ophthalmol** 1996 Apr; 80(4):323–6
The emerging roles of topical non–steroidal anti–inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)
Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease [see comments] Mietz H, et al. **Br J Ophthalmol** 1995 Oct;79(10):874–7. Comment in: Br J Ophthalmol 1995 Oct;79(10):871–2.
In vivo human lens epithelial cell proliferation on the anterior surface of PMMA intraocular lenses. Pande MV, et al. **Br J Ophthalmol** 1996 May;80(5):469–74
Management of a patient with pseudophakic malignant glaucoma; role of ultrasound biomicroscopy [letter] Park M, et al. **Br J Ophthalmol** 1996 Jul;80(7):676–7
Postoperative abnormalities of the choriocapillaris in exudative age–related macular degeneration. Pollack JS, et al. **Br J Ophthalmol** 1996 Apr;80(4):314–8
Aqueous contamination during small incision cataract surgery: a lesson in study design [editorial; comment] Towler H. **Br J Ophthalmol** 1995 Oct;79(10):873 (12 ref.) . Comment on: Br J Ophthalmol 1995 Oct;79(10):878–80.
Retina to retina adhesions following suprachoroidal haemorrhage [letter] Weinberg DV, et al. **Br J Ophthalmol** 1996 Jul;80(7):674
Non–union of mandibulotomy sites following irradiation for squamous cell carcinoma of the oral cavity. Altman K, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):62–5
Irreversible muscle contracture after functioning free muscle transplantation using ipsilateral facial nerve for reinnervation [letter; comment] Fisher J, et al. **Br J Plast Surg** 1995 Oct;48(7):518. Comment on: Br J Plast Surg 1995 Jan;48(1):1–7.
Irreversible muscle contracture after functioning free muscle transfer for facial palsy [letter; comment] Harrison DH. **Br J Plast Surg** 1995 Oct;48(7):518–9. Comment on: Br J Plast Surg 1995 Jan;48(1):1–7.
Restricted mandibular opening complicating intraoral galeal flap reconstruction and radiotherapy: case report. Tighe JV. **Br J Plast Surg** 1996 Apr;49(3):187–9
Case report: pulmonary calcification after liver transplantation in children. Winter EM, et al. **Br J Radiol** 1995 Aug;68(812):923–5
Diaphragmatic herniation after penetrating trauma. Degiannis E, et al. **Br J Surg** 1996 Jan;83(1):88–91
Tethered spinal cord: the effect of neurosurgery on the lower urinary tract and male sexual function. Boemers TM, et al. **Br J Urol** 1995 Dec;76(6):747–51
Fournier's gangrene following delayed rupture of an ileal neobladder (Hautmann). Kyriakidis A. **Br J Urol** 1995 Nov; 76(5):668
Bladder and erectile dysfunction before and after rectal surgery for cancer. Leveckis J, et al. **Br J Urol** 1995 Dec; 76(6):752–6
Vascular complications in reconstructive and replantation surgery. Frankovičová M, et al. **Bratisl Lek Listy** 1996 Apr; 97(4):204–7
Results of congenital dislocation of the hip joint with open reduction followed up to an age of fifteen years or more. Sugimoto N, et al. **Bull Hosp Jt Dis** 1993–95;53(4):30–6
Anaesthetic care and audit: 150 years on [editorial; comment] Davies JM. **Can J Anaesth** 1996 Apr;43(4):323–6. Comment on: Can J Anaesth 1996 Apr;43(4):333–40. **(Eng, Fre)**
Planned and unplanned postoperative admissions to critical care for mechanical ventilation [see comments] Rose DK, et al. **Can J Anaesth** 1996 Apr;43(4):333–40. Comment in: Can J Anaesth 1996 Apr;43(4):323–6.
Perioperative train–of–four monitoring and residual curarization. Shorten GD, et al. **Can J Anaesth** 1995 Aug; 42(8):711–5
"Unexplained" delayed death from fungal meningitis after meningioma resection. Hurlbert RJ, et al. **Can J Neurol Sci** 1995 Aug;22(3):239–43
Opening the pleura during internal mammary artery harvesting: advantages and disadvantages. Ali IM, et al. **Can J Surg** 1996 Feb;39(1):42–5
Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule 1 interaction in surgical–stress–enhanced experimental metastasis. Higashiyama A, et al. **Cancer Immunol Immunother** 1996 May;42(4):231–6
Stenting for pulmonary artery stenosis following the Ross procedure. Lima VC, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):259–61
Relationship of early postoperative dysrhythmias and long–term outcome after resection of non–small cell lung cancer. Amar D, et al. **Chest** 1996 Aug;110(2):437–9
Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. Berkowitz N, et al. **Chest** 1995 Dec;108(6):1602–7
Pulmonary edema in a woman following fetal surgery. DiFederico EM, et al. **Chest** 1996 Apr;109(4):1114–7
Delayed right heart failure following lung transplantation. Kirshbom PM, et al. **Chest** 1996 Feb;109(2):575–7 (9 ref.)
Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Kshettry VR, et al. **Chest** 1996 Sep;110(3):704–9
Risk of pulmonary complications after elective abdominal surgery [see comments] Lawrence VA, et al. **Chest** 1996 Sep;110(3):744–50. Comment in: Chest 1996 Sep;110(3):587–9.
Preoperative prediction of postoperative respiratory outcome. Coronary artery bypass grafting. Spivack SD, et al. **Chest** 1996 May;109(5):1222–30
Cardiopulmonary bypass temperature does not affect postoperative euthyroid sick syndrome? Thrush DN, et al. **Chest** 1995 Dec;108(6):1541–5
Hyponatremia in central partial diabetes insipidus due to postoperative hypothalamic tumor. Arisaka O, et al. **Childs Nerv Syst** 1995 Dec;11(12):712–4
Congestive heart failure after surgical correction of mitral regurgitation. A long–term study. Enriquez–Sarano M, et al. **Circulation** 1995 Nov 1;92(9):2496–503
Left ventricular dysfunction on exercise long–term after total repair of tetralogy of Fallot. Kondo C, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II250–5
Thromboembolic complications after Fontan operations. Rosenthal DN, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II287–93
Postoperative confusion in a 42–year–old man. Isaacson JH. **Cleve Clin J Med** 1995 Nov–Dec;62(6):370–1
Assessment of cardiac risk in noncardiac surgery. Forgosh LB, et al. **Clin Cardiol** 1995 Oct;18(10):556–62 (45 ref.)
Prognosis of patients with frequent premature ventricular complexes and nonsustained ventricular tachycardia after coronary artery bypass graft surgery. Pinto RP, et al. **Clin Cardiol** 1996 Apr;19(4):321–4
Pulmonary complications of liver transplantation. O'Brien JD, et al. **Clin Chest Med** 1996 Mar;17(1):99–114 (95 ref.)
Evaluation of endotoxiuria for diagnosis of urinary tract infection after major surgical procedures. Berger D, et al. **Clin Chim Acta** 1996 Jan 31;244(2):155–61
Nocturnal breathing abnormalities in acromegaly after adenomectomy. Pelttari L, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):175–82
Pelvic pathology after hysterectomy. A pictorial essay. Kasales CJ, et al. **Clin Imaging** 1995 Jul–Sep;19(3):210–7 (5 ref.)
Urinoma in a renal transplant patient. Goerres G, et al. **Clin Nucl Med** 1996 Jun;21(6):503–5
Successful treatment of chylothorax by bleomycin for Gorham's disease. Aoki M, et al. **Clin Orthop** 1996 Sep; (330):193–7
Complications of iliac crest bone graft harvesting. Arrington ED, et al. **Clin Orthop** 1996 Aug;(329):300–9
Ceramic femoral head fractures in total hip arthroplasty. Fritsch EW, et al. **Clin Orthop** 1996 Jul;(328):129–36
Suprascapular neuropathy after distal clavicle excision. Mallon WJ, et al. **Clin Orthop** 1996 Aug;(329):207–11
Supracondylar femoral fracture following total knee arthroplasty. Moran MC, et al. **Clin Orthop** 1996 Mar; (324):196–209
Component design affecting patellofemoral complications after total knee arthroplasty. Theiss SM, et al. **Clin Orthop** 1996 May;(326):183–7
Haemorrhage as a complication of inferior turbinectomy: a comparison of anterior and radical trimming. Garth RJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):236–8
The use of topical 5% lignocaine ointment for the relief of pain associated with post–operative nasal packing. Kuo MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):357–9
Audiovestibular complications of non–otological surgery. Mahoney CF, et al. **Clin Otolaryngol** 1995 Dec;20(6):510–6 (53 ref.)
Diclofenac and post–tonsillectomy haemorrhage [letter; comment] Robb PJ, et al. **Clin Otolaryngol** 1995 Oct; 20(5):483–4. Comment on: Clin Otolaryngol 1994 Aug;19(4):344–5.
Complications of skull base surgery. Nguyen TT, et al. **Clin Plast Surg** 1995 Jul;22(3):573–80 (18 ref.)
Complications of shoulder instability surgery. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):973–1000 (153 ref.)
Long–term complication following subtotal pancreatectomy for nesidioblastosis: a case report. Chevalier SG. **Conn Med** 1996 Jun;60(6):335–8
Budd–Chiari syndrome following pretransplantation nephrectomy in an ADPKD patient with liver cysts. Dionisio P, et al. **Contrib Nephrol** 1995;115:163–6
Complications of urogynaecological surgery. Neale R. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):400–3 (21 ref.)
Postoperative fatigue. Christensen T. **Dan Med Bull** 1995 Sep; 42(4):314–22 (132 ref.)
Posttransplant epidermoid cysts secondary to small graft hair transplantation. Whiting DA, et al. **Dermatol Surg** 1995 Oct;21(10):863–6
Cytology of suture granulomas in post–hysterectomy vaginal smears. Bardales RH, et al. **Diagn Cytopathol** 1995 Nov; 13(4):336–8
Cholestasis induced hyperthyroidism after liver transplantation. Lersch C, et al. **Digestion** 1995;56(5):429–32
Anastomotic leak after double–stapled low colorectal resection. Averbach AM, et al. **Dis Colon Rectum** 1996 Jul;39(7):780–7
Retractor–induced femoral neuropathy [letter] Balz JB. **Dis Colon Rectum** 1996 May;39(5):591
Femoral neuropathy secondary to the use of a self–retaining retractor. Report of three cases and review of the literature. Brasch RC, et al. **Dis Colon Rectum** 1995 Oct;38(10):1115–8
Treatment of perianal infection following bone marrow transplantation. Cohen JS, et al. **Dis Colon Rectum** 1996 Sep;39(9):981–5
Anal fistula surgery. Factors associated with recurrence and incontinence. Garcia–Aguilar J, et al. **Dis Colon Rectum** 1996 Jul;39(7):723–9
A pilot study of factors influencing bowel function after colorectal anastomosis. Graf W, et al. **Dis Colon Rectum** 1996 Jul;39(7):744–9
Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Ståhlberg D, et al. **Dis Colon Rectum** 1996 Sep;39(9):1012–8
Colorectal complications following cardiac surgery. Six–year experience. Visser T, et al. **Dis Colon Rectum** 1995 Nov; 38(11):1210–3
Late dysphagia after presternal colon interposition. Urschel JD. **Dysphagia** 1996 Winter;11(1):75–7
Postoperative bleeding in tonsillectomy patients. Szeremeta W, et al. **Ear Nose Throat J** 1996 Jun;75(6):373–6
Necrotising fasciitis—a rare complication of percutaneous endoscopic gastrostomy. Evans DA, et al. **Endoscopy** 1995 Oct;27(8):627
The value of histological analysis of occluded biliary endoprostheses. Pescatore P, et al. **Endoscopy** 1995 Oct; 27(8):597–600
Dormia baskets impacted in the bile duct: release by extracorporeal shock–wave lithotripsy. Sauter G, et al. **Endoscopy** 1995 Jun;27(5):384–7
Afferent loop syndrome due to scarring of a stomal ulcer following a Billroth II gastrectomy. Tsutsui S, et al. **Endoscopy** 1995 Jun;27(5):410
Low vagal tone and supraventricular ectopic activity predict atrial fibrillation and flutter after coronary artery bypass grafting. Frost L, et al. **Eur Heart J** 1995 Jun;16(6):825–31
Percutaneous transluminal coronary angioplasty of aorta ostial, non–aorta ostial, and branch ostial stenoses: acute and long–term outcome. Tan KH, et al. **Eur Heart J** 1995 May;16(5):631–9
Acute ischaemic cerebrovascular accident after autologous bone marrow transplantation [letter] van der Lelie J, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):95–7
Late complication of ureteric damage following hysterectomy. Currie I, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):139–40
Extrapyramidal disorder secondary to cytomegalovirus infection and toxoplasmosis after liver transplantation.

Coelho JC, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):110–1
Vein patch rupture: early complication of carotid endarterectomy. Blok JG, et al. **Eur J Surg** 1995 Jul; 161(7):519–21 (17 ref.)
Incisional hernia after midline laparotomy: a prospective study. Israelsson LA, et al. **Eur J Surg** 1996 Feb; 162(2):125–9
Chylothorax complicating Ivor Lewis oesophagectomy. Zografos GN, et al. **Eur J Surg** 1996 Feb;162(2):147–8
Pelvic and periaortic pertioneal closure or non-closure at lymphadenectomy in ovarian cancer: effects on morbidity and adhesion formation. Kadanali S, et al. **Eur J Surg Oncol** 1996 Jun;22(3):282–5
Stent flexibility: an essential feature in the treatment of dynamic airway collapse. Hautmann H, et al. **Eur Respir J** 1996 Mar;9(3):609–11
Aortobronchial fistula after correction of congenital cardiovascular abnormalities. Hiep-van Casteren SC, et al. **Eur Respir J** 1995 Oct;8(10):1796–8
Vitreous loss during cataract surgery [letter; comment] Chignell AH. **Eye** 1995;9 (Pt 4):539–40. Comment on: Eye 1993;7 (Pt 6):735–9.
Ectopic retinal tacks [letter] Lehmann OJ, et al. **Eye** 1995; 9 (Pt 3):378–9
Encysted Tenon's bleb over superiorly placed single-plate Molteno implant causing proptosis and strabismus [letter] Pandit J, et al. **Eye** 1995;9 (Pt 3):379–81
The incidence of fallopian tube patency after transcervical resection of the endometrium including rollerball diathermy to the tubal ostia. Istre O, et al. **Fertil Steril** 1996 Jan;65(1):198–200
Neuropathologic findings after organ transplantation. An autopsy study. Schwechheimer K, et al. **Gen Diagn Pathol** 1995 May;141(1):35–9
Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Bonnet M, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Dec; 233(12):789–91
Cubital tunnel surgery. Complications and treatment of failures. Jackson LC, et al. **Hand Clin** 1996 May; 12(2):449–56
Complications of nonoperative and operative treatment of carpal tunnel syndrome. Urbaniak JR, et al. **Hand Clin** 1996 May;12(2):325–35
Surgical access to tumors of the cervicothoracic junction. Kraus DH, et al. **Head Neck** 1995 Mar-Apr;17(2):131–6
Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar-Apr; 17(2):152–6 (22 ref.)
Outcome analysis of Zenker's diverticulectomy and cricopharyngeal myotomy. Witterick IJ, et al. **Head Neck** 1995 Sep-Oct;17(5):382–8
Divalproex sodium and other medications for headache following craniotomy for acoustic neuroma. Hendler N, et al. **Headache** 1995 Sep;35(8):490–3
Fatal giant cell myocarditis after resection of thymoma. Glennon PE, et al. **Heart** 1996 May;75(5):531–2
Clinicopathological features of gastric cancer in the remnant stomach. Fujiwara T, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):416–9
Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Farges O, et al. **Hepatology** 1996 Feb;23(2):240–8
Percutaneous transluminal rotational atherectomy for treatment of in-stent restenosis. Khanolkar UB. **Indian Heart J** 1996 May-Jun;48(3):281–2
Klebsiella oxytoca meningitis: frequent association with neurosurgical procedures. Tang LM, et al. **Infection** 1995 May-Jun;23(3):163–7
Complications of tympanostomy tubes in an inner city clinic population. Goldstein NA, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):87–99
Lingual pressures induced by mouthgags. Senders CW, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug;33(1):53–60
The role of relaparoscopy in the management of bile leaks after laparoscopic cholecystectomy. Sefr R, et al. **Int Surg** 1995 Oct-Dec;80(4):356–7
Transurethral incision of the bladder neck: an objective and subjective evaluation of its efficacy. el-Baz MA, et al. **Int Urol Nephrol** 1995;27(6):717–21
Early and late complications of uretero-enteric anastomosis. Böszörményi-Nagy G, et al. **Int Urol Nephrol** 1995; 27(3):261–5
Enzymatic evaluation of renal damage caused by different therapeutic procedures for kidney stone disease. Sakkas G, et al. **Int Urol Nephrol** 1995;27(6):669–77
Prophylactic bronchial hygiene following cardiac surgery: what is necessary? [editorial; comment] Kacmarek RM. **Intensive Care Med** 1995 Jun;21(6):467–8. Comment on: Intensive Care Med 1995 Jun;21(6):469–74.
Changing trends in acute peptic ulcer surgery in a district surgical unit. Barry MC, et al. **Ir J Med Sci** 1996 Apr-Jun; 165(2):109–12
Remarks on the complications following ACL reconstruction using synthetic ligaments. Savarese A, et al. **Ital J Orthop Traumatol** 1993;19(1):79–86
Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. Kimmings AN, et al. **J Am Coll Surg** 1995 Dec;181(6):567–81 (186 ref.)
Treating the oral sequelae of an acoustic neuroma. Whitaker EJ, et al. **J Am Dent Assoc** 1996 Feb;127(2):231–3
Foreign-body reaction to absorbable fixation devices [letter] Frederick J, et al. **J Am Podiatr Med Assoc** 1996 Aug; 86(8):396–8
Review of the effect of fixation on complication rate in the base wedge osteotomy. Higgins KR, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):327–30
Valvulitis involving a bioprosthetic valve in a patient with systemic lupus erythematosus. Gordon RJ, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):104–7
Popliteus tendon dysfunction following total knee arthroplasty. Barnes CL, et al. **J Arthroplasty** 1995 Aug; 10(4):543–5
Heterotopic ossification following primary total knee arthroplasty [see comments] Furia JP, et al. **J Arthroplasty** 1995 Aug;10(4):413–9. Comment in: J Arthroplasty 1996 Feb;11(2):223–4.
Postoperative fracture of the host femur in allograft-prosthetic reconstruction of the hip. Moran MC. **J Arthroplasty** 1995 Aug;10(4):550–3
Increasing prevalence of femoral lysis in cementless total hip arthroplasty. Smith E, et al. **J Arthroplasty** 1995 Aug; 10(4):407–12
Reversible osteolysis. Steinberg GG. **J Arthroplasty** 1995 Aug;10(4):556–9
Anterior iliopsoas impingement after total hip arthroplasty. Trousdale RT, et al. **J Arthroplasty** 1995 Aug;10(4):546–9
Donor-site morbidity with use of vascularized autogenous fibular grafts. Vail TP, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):204–11
Postoperative complications and mortality associated with operative delay in older patients who have a fracture of the hip. Zuckerman JD, et al. **J Bone Joint Surg Am** 1995 Oct;77(10):1551–6
Uncommon postoperative temporomandibular joint complications [letter; comment] Mulrooney R. **J Can Dent Assoc** 1995 Sep;61(9):745–6, 809. Comment on: J Can Dent Assoc 1995 May;61(5):403–9.
The effect of the single aortic cross-clamp technique on cardiac and cerebral complications during coronary bypass surgery. Aranki SF, et al. **J Card Surg** 1995 Jul;10(4 Suppl):498–502
Predictors of stroke after cardiac surgery. Cernaianu AC, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):334–9
Does cardiopulmonary bypass temperature correlate with postoperative central nervous system dysfunction? Engelman RM, et al. **J Card Surg** 1995 Jul;10(4 Suppl):493–7
A critical assessment of neurological risk during warm heart surgery. Guyton RA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):488–92
Myocardial ischemia after cardiopulmonary bypass. Jain U. **J Card Surg** 1995 Jul;10(4 Suppl):520–6 (97 ref.)
Poststernotomy mediastinitis treated by transposition of the greater omentum. Krabatsch T, et al. **J Card Surg** 1995 Nov;10(6):637–43
The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481–7 (50 ref.)
The management of chylothorax/chylopericardium following pediatric cardiac surgery: a 10-year experience. Nguyen DM, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):302–8
Risk factors for stroke following coronary bypass surgery. Rao V, et al. **J Card Surg** 1995 Jul;10(4 Suppl):468–74
Case 4—1995. Perioperative myocardial infarction in a patient undergoing abdominal aortic aneurysm resection: perioperative risk assessment [clinical conference] Fehr DM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):452–9
The incidence of significant pericardial effusion and tamponade following major aortic root surgery. Alkhulaifi AM, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):385–9
Open cardiac massage and periresuscitative cardiopulmonary bypass for cardiac arrest following cardiac surgery. Feng WC, et al. **J Cardiovasc Surg (Torino)** 1995 Aug; 36(4):319–21
Incisional hernias: incidence following abdominal aortic aneurysm repair. Johnson B, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):487–90
Longterm efficiency of high dose inotropic support in an infant after repair of Fallot's tetralogy. Korbmacher B, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):409–11
Right post pneumonectomy pleural empyema caused by an esophagopleural fistula due to an esophageal carcinoma. Oliaro A, et al. **J Cardiovasc Surg (Torino)** 1995 Dec; 36(6):607–9
Consultation Section. How would you manage an eye that developed inflammatory response after uncomplicated phacoemulsification with intraocular lens implantation? **J Cataract Refract Surg** 1995 Jul;21(4):366–70
Endothelial changes following refractive surgery. Frueh BE, et al. **J Cataract Refract Surg** 1996 May;22(4):490–6 (47 ref.)
Corneal optical irregularity after excimer laser photorefractive keratectomy. The Summit Photorefractive Keratectomy Topography Study Group. Hersh PS, et al. **J Cataract Refract Surg** 1996 Mar;22(2):197–204
Comparison of the induced astigmatism after temporal clear corneal tunnel incisions of different sizes. Kohnen T, et al. **J Cataract Refract Surg** 1995 Jul;21(4):417–24
Decentration of plate-haptic lenses [letter] Mackool RJ. **J Cataract Refract Surg** 1996 May;22(4):396
Total anterior capsule closure after silicone intraocular lens implantation. Martínez Toldos JJ, et al. **J Cataract Refract Surg** 1996 Mar;22(2):269–71
Corneal subepithelial infiltrates following photorefractive keratectomy [letter] Probst LE 5th, et al. **J Cataract Refract Surg** 1996 Apr;22(3):281
Complications and results of phacoemulsification performed by residents. Tarbet KJ, et al. **J Cataract Refract Surg** 1995 Nov;21(6):661–5
Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. de Vile CJ, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2734–7
The postcholecystectomy syndrome. A role for duodenogastric reflux. Abu Farsakh NA, et al. **J Clin Gastroenterol** 1996 Apr;22(3):197–201
Colonic carcinoma after duodenocolic anastomosis. Ephgrave KS, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):244–5
Endoscopic findings and overtube-related complications associated with esophageal variceal ligation. Holderman WH, et al. **J Clin Gastroenterol** 1995 Sep;21(2):91–4
Diagnosis of right ventricular overload by body surface QRST isointegral maps in children with postoperative right bundle branch block. Asano Y, et al. **J Electrocardiol** 1995 Jul;28(3):209–21
QRST isointegral map reflects the sudden reduction of right ventricular pressure after balloon pulmonary valvuloplasty. Izumida N, et al. **J Electrocardiol** 1995 Jul;28(3):223–9
An unusual cause of altered mental status. Counselman FL, et al. **J Emerg Med** 1995 Nov-Dec;13(6):757–63
Postoperative transient bradycardia and asystole after bilateral bunionectomies performed using spinal anesthesia. Agostinelli JR, et al. **J Foot Ankle Surg** 1995 Sep-Oct; 34(5):498–500; discussion 511–2
Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. Haque T, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1169–72
Over-distraction of the radiocarpal and midcarpal joints with external fixation of comminuted distal radial fractures [letter] Combalía A. **J Hand Surg [Br]** 1996 Apr;21(2):289
Late complications after open carpal tunnel decompression. Kluge W, et al. **J Hand Surg [Br]** 1996 Apr;21(2):205–7
Mortality and morbidity after mitral valve repair: the importance of left ventricular dysfunction. Lee EM, et al. **J Heart Valve Dis** 1995 Sep;4(5):460–8; discussion 469–70
Late-onset hepatic failure: clinical features, serology and outcome following transplantation. Ellis AJ, et al. **J Hepatol** 1995 Oct;23(4):363–72
Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. Jalan R, et al. **J Hepatol** 1995 Aug;23(2):123–8
Postoperative lumbar pseudomeningocele. Bhatoe HS. **J Indian Med Assoc** 1995 Jul;93(7):280, 282
Tension pneumocephalus following posterior cranial fossa surgery in sitting position. Tripathy P, et al. **J Indian Med Assoc** 1995 Mar;93(3):109–10
Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. Follis F, et al. **J Invest Surg** 1996 Mar-Apr;9(2):149–56
A case-control study of postoperative pulmonary complications after laparoscopic and open cholecystectomy. Hall JC, et al. **J Laparoendosc Surg** 1996 Apr;6(2):87–92
Pre-operative information in mastoidectomy: what about the facial nerve and hearing loss [letter] Dawes PJ. **J Laryngol Otol** 1996 Jul;110(7):710–1
Recurrent frontal sinusitis complicating orbital decompression in Graves' disease. Lee WC. **J Laryngol Otol** 1996 Jul;110(7):670–2
Complications of paediatric tonsillectomy post-discharge. Lee WC, et al. **J Laryngol Otol** 1996 Feb;110(2):136–40
Atlanto-axial subluxation (Grisel's syndrome) following otolaryngological diseases and procedures. Samuel D, et al. **J Laryngol Otol** 1995 Oct;109(10):1005–9
Pre-operative information in mastoidectomy: what about the facial nerve and hearing loss? Wormald PJ. **J Laryngol Otol** 1996 Jan;110(1):10–2 (8 ref.)
An outbreak of post-operative endophthalmitis in Lampang Hospital. Pitaksiripan S, et al. **J Med Assoc Thai** 1995 Jul; 78 Suppl 2:S95–8
Postoperative nausea vomiting (PONV): influence of bowel manipulation during intraabdominal surgery. Sirivanasandha P. **J Med Assoc Thai** 1995 Oct; 78(10):547–53
Neuropathological sequelae of long-term allogeneic and syngeneic neural transplantation into the hippocampus. Patel SN, et al. **J Neural Transplant Plast** 1995;5(4):211–22
Recurrent cerebral arteriovenous malformations after negative postoperative angiograms. Kader A, et al. **J Neurosurg** 1996 Jul;85(1):14–8
Delayed hyponatremia [letter; comment] Landolt AM. **J Neurosurg** 1996 Jan;84(1):150–1. Comment on: J Neurosurg 1995 Aug;83(2):363–7.
Brainstem tethering in Dandy-Walker syndrome: a complication of cystoperitoneal shunting. Case report. Liu JC, et al. **J Neurosurg** 1995 Dec;83(6):1072–4
Dural arteriovenous fistula of the posterior fossa developing after surgical occlusion of the sigmoid sinus. Report of five cases. Sakaki T, et al. **J Neurosurg** 1996 Jan;84(1):113–8

Ischemic optic neuropathy [letter; comment] Smith FP. **J Neurosurg** 1996 Jan;84(1):149–50. Comment on: J Neurosurg 1995 Aug;83(2):348–9.

Incidence of deep–vein thrombosis in patients with fractures of the lower extremity distal to the hip. Abelseth G, et al. **J Orthop Trauma** 1996;10(4):230–5

Early complications with external fixation of pediatric femoral shaft fractures. Gregory P, et al. **J Orthop Trauma** 1996;10(3):191–8

The complications and difficulties of management of nonunion in the severely obese. Jupiter JB, et al. **J Orthop Trauma** 1995;9(5):363–70

Fecal incontinence after the surgical treatment of Hirschsprung disease. Catto–Smith AG, et al. **J Pediatr** 1995 Dec;127(6):954–7

Description of posterior fossa syndrome in children after posterior fossa brain tumor surgery. Kirk EA, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):181–7

Malacoplakia involving the surgical wound in a 4 year old. Ciftci AO, et al. **J Pediatr Surg** 1995 Nov;30(11):1596–7

Complications after surgical intervention for necrotizing enterocolitis: a multicenter review. Horwitz JR, et al. **J Pediatr Surg** 1995 Jul;30(7):994–8; discussion 998–9

Long–term complications in cases of isolated esophageal atresia treated with esophageal anastomosis. Lindahl H, et al. **J Pediatr Surg** 1995 Aug;30(8):1222–3

Distal penile lymphoedema following hypospadias repair: a case report. Gaston P, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):97–8

Post–mastectomy seroma: a new look into the aetiology of an old problem. Kumar S, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):292–4

A crowded ureter. McCahy PJ, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):326–8

Infection after splenectomy [letter] Dignan AP. **J R Soc Med** 1996 Jul;89(7):419

Endophthalmitis after routine intra–ocular surgery in an asplenic patient. Fuller JR, et al. **J R Soc Med** 1995 Aug; 88(8):475P–476P

Combined wedge resection and relaxing incisions for astigmatism after penetrating keratoplasty. Belmont SC, et al. **J Refract Surg** 1995 Nov–Dec;11(6):472–6

Long–term stability of refraction after intrastromal suture correction of hyperopia following radial keratotomy. Lyle WA, et al. **J Refract Surg** 1995 Nov–Dec;11(6):485–9

Severe maternal and fetal electrolyte imbalance in pregnancy after gastric surgery for morbid obesity. A case report. Weissman A, et al. **J Reprod Med** 1995 Nov;40(11):813–6

Salvage of failed total elbow arthroplasty. Ferlic DC, et al. **J Shoulder Elbow Surg** 1995 Jul–Aug;4(4):290–7

Late complications in elbow arthroplasty. Gschwend N, et al. **J Shoulder Elbow Surg** 1996 Mar–Apr;5(2 Pt 1):86–96

Cutaneous nerve lesions of the shoulder and arm after arthroscopic shoulder surgery. Segmüller HE, et al. **J Shoulder Elbow Surg** 1995 Jul–Aug;4(4):254–8

Postoperative complications after pneumonectomy for treatment of lung cancer: multivariate analysis. Mitsudomi T, et al. **J Surg Oncol** 1996 Mar;61(3):218–22

Rectovaginal fistula following low circular stapled anastomosis in women with rectal cancer. Sugarbaker PH. **J Surg Oncol** 1996 Feb;61(2):155–8

Ten–year experience with surgical treatment of partial atrioventricular septal defect: risk factors in the early postoperative period. Baufreton C, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):14–20

Unusual complication seven years after successful aortic recoarctation repair with a Dacron graft: acute thromboembolic leg ischemia caused by a mobile thrombus at the distal suture line. Berzins R, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):842–4

Morbidity outcome in early versus conventional tracheal extubation after coronary artery bypass grafting: a prospective randomized controlled trial. Cheng DC, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):755–64

Acquired aortopulmonary fistula in pseudoaneurysm of the aorta six years after a Bentall operation. Chevalier P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1143–4

Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. Edmunds LH Jr, et al. **J Thorac Cardiovasc Surg** 1996 Sep; 112(3):708–11

Pulmonary function and postoperative complications after wedge and flap reconstructions of the main bronchus. Khargi K, et al. **J Thorac Cardiovasc Surg** 1996 Jul; 112(1):117–23

Late failure of internal thoracic artery grafts caused by sequelae of mediastinitis or its treatment. Noyez L, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):896–7

Predictors of low cardiac output syndrome after coronary artery bypass. Rao V, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):38–51

Complications after negative laparotomy for trauma: long–term follow–up in a health maintenance organization. Morrison JE, et al. **J Trauma** 1996 Sep;41(3):509–13

Ventriculoperitoneal shunt infection after augmentation cystoplasty. Matthews GJ, et al. **J Urol** 1996 Feb; 155(2):686–8

Pregnancy in a patient with an ileal substitute bladder followed by severe destabilization of the pelvic support. Schilling A, et al. **J Urol** 1996 Apr;155(4):1389–90

Delayed graft function in renal transplantation: etiology, management and long–term significance. Shoskes DA, et al. **J Urol** 1996 Jun;155(6):1831–40 (141 ref.)

Complications of penile lengthening and augmentation seen at 1 referral center. Wessells H, et al. **J Urol** 1996 May; 155(5):1617–20

Carotid endarterectomy saphenous vein patch rupture revisited: selective use on the basis of vein diameter. Archie JP. **J Vasc Surg** 1996 Sep;24(3):346–51; discussion 351–2

Differences in early versus late extracavitary arterial graft infections. Calligaro KD, et al. **J Vasc Surg** 1995 Dec; 22(6):680–5; discussion 685–8

Pelvic radiation therapy as a risk factor for ischemic colitis complicating abdominal aortic reconstruction. Israeli D, et al. **J Vasc Surg** 1996 Apr;23(4):706–9

Progressive enlargement of a Miller vein cuff [letter] Mackenzie RK, et al. **J Vasc Surg** 1996 Aug;24(2):302–3

Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. Safi HJ, et al. **J Vasc Surg** 1996 Sep;24(3):338–44; discussion 344–5

Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. Mathew JP, et al. **JAMA** 1996 Jul 24–31; 276(4):300–6

Post–operative problems following anterior cruciate ligament reconstruction. Almekinders LC, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):78–82

Problems in regaining full extension of the knee after anterior cruciate ligament reconstruction: does arthrofibrosis exist? [see comments] Dandy DJ, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):76–9. Comment in: Knee Surg Sports Traumatol Arthrosc 1994;2(4):259–60.

Patellectomy and osteoarthritis: arthroscopic findings following previous patellectomy. Feller JA, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):159–61

Haemolytic anaemia after mitral valve repair [letter; comment] Dol YL, et al. **Lancet** 1996 May 11; 347(9011):1330–1. Comment on: Lancet 1996 Mar 16;347(9003):765.

Are varicella zoster and herpes simplex sentinel lesions for cytomegalovirus in renal transplant recipients? [letter] Lippmann BJ, et al. **Lancet** 1995 Sep 30;346(8979):914–5

Cyclical myometrial haemorrhage after endometrial resection [letter] Nagele F, et al. **Lancet** 1996 Apr 27; 347(9009):1192–3

Cerebrospinal fluid drainage in the management of CSF leak following acoustic neuroma surgery. Fishman AJ, et al. **Laryngoscope** 1996 Aug;106(8):1002–4

Pulmonary atelectasis after reconstruction with a latissimus dorsi myocutaneous flap. Wax MK, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):268–72

Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Loprinzi CL, et al. **Mayo Clin Proc** 1996 Jun;71(6):552–5

Neurosurgery and iatrogenic transmission of Creutzfeldt–Jakob disease. Newcombe RL. **Med J Aust** 1996 May 20;164(10):603–4

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477–9 (28 ref.)

Severe hypercalcemia following neonatal liver transplantation. Bartosh SM, et al. **Miner Electrolyte Metab** 1995;21(6):428–30

Outbreaks of postoperative bacterial endophthalmitis caused by intrinsically contaminated ophthalmic solutions—Thailand, 1992, and Canada, 1993. **MMWR Morb Mortal Wkly Rep** 1996 Jun 14;45(23):491–4

Abolition of sympathetic skin responses following endoscopic thoracic sympathectomy. Lefaucheur JP, et al. **Muscle Nerve** 1996 May;19(5):581–6

"Keeling syndrome"—a late complication of pneumonectomy [letter] Robinson LA, et al. **N Engl J Med** 1996 Oct 3; 335(14):1074

Sudeck's atrophy of the left tibiotarsal joint in a renal transplant patient: effects of medical and physical therapy [letter] Campieri C, et al. **Nephron** 1995;71(1):122–3

Herniation of the third ventricle into empty sella caused by surgery for pituitary apoplexy—case report. Kobayashi S, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):451–4

Long–term results and complications using augmentation cystoplasty in reconstructive urology. Flood HD, et al. **Neurourol Urodyn** 1995;14(4):297–309

Uterine size and risk of complications among women undergoing abdominal hysterectomy for leiomyomas. Hillis SD, et al. **Obstet Gynecol** 1996 Apr;87(4):539–43

Long–term effects of vaginal dissection on the innervation of the striated urethral sphincter. Zivkovic F, et al. **Obstet Gynecol** 1996 Feb;87(2):257–60

Post–splenectomy sepsis—the role of occupational health. Brew I, et al. **Occup Med (Oxf)** 1996 Jun;46(3):231–2

Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Lerner SE, et al. **Oncology (Huntingt)** 1995 May;9(5):379–82; discussion 382, 385–6, 389

Chemosis following blepharoplasty [letter; comment] Sutcliffe RT. **Ophthalmic Surg** 1995 Jul–Aug;26(4):290–1. Comment on: Ophthalmic Surg 1994 Sep–Oct;25(9):593–6.

Retinal hemorrhages associated with ocular decompression after glaucoma surgery. Dudley DF, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):147–50

Encapsulated filtering blebs [letter; comment] Cox TA. **Ophthalmology** 1996 Jan;103(1):1–2. Comment on: Ophthalmology 1994 Apr;101(4):629–34.

Refractive changes during 72–hour exposure to high altitude after refractive surgery. Mader TH, et al. **Ophthalmology** 1996 Aug;103(8):1188–95

Effects of simulated high altitude on patients who have had radial keratotomy. Ng JD, et al. **Ophthalmology** 1996 Mar; 103(3):452–7

"Late endophthalmitis"—filtering surgery time bomb? [editorial] Parrish R, et al. **Ophthalmology** 1996 Aug; 103(8):1167–8

Comparison of the morbidity associated with maxillary fractures treated by maxillomandibular and rigid internal fixation. Haug RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):629–37

Cyclops lesion. Olson PN, et al. **Orthopedics** 1995 Oct; 18(10):1041, 1044–5

Thromboembolic complications following trauma surgery: incidence and outcomes. Paiement GD. **Orthopedics** 1995 Jul;18 Suppl:12–4

Postoperative carotid artery rupture caused by actinomyces infection. Friedman HD, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):145–7

Day case survey of postoperative nausea and vomiting [letter] Mawer RJ, et al. **Paediatr Anaesth** 1995;5(3):203–5

Postoperative airway problems in a child with Crouzon's syndrome. Payne JF, et al. **Paediatr Anaesth** 1995; 5(5):331–3

Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)

Factors associated with stroke following the Fontan procedure. Day RW, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):270–5

Late development of functional subvalvar stenosis after repair of truncus arteriosus. Delius RE, et al. **Pediatr Cardiol** 1996 Nov–Dec;17(6):393–5

Fatal Salmonella typhimurium infection of a vascular graft in an infant. Juneja R, et al. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):330–1

Fatal pneumonia complicating hypothermia for the treatment of postoperative junctional ectopic tachycardia. Matthys D, et al. **Pediatr Cardiol** 1995 Nov–Dec;16(6):294–6

Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella. Vogel M, et al. **Pediatr Cardiol** 1996 Nov–Dec; 17(6):416–8

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

Sequestered fluid and breast implant malposition. Brink RR. **Plast Reconstr Surg** 1996 Sep;98(4):679–84

Abdominal hernia after fasciotomy of the external oblique muscle for abdominal wall closure in TRAM surgery [letter; comment] de Elejabeitia González J, et al. **Plast Reconstr Surg** 1996 Jul;98(1):182–3. Comment on: Plast Reconstr Surg 1992 Oct;90(4):608–13.

Complications, untoward events, and reality [editorial] Hallock GG. **Plast Reconstr Surg** 1996 May;97(6):1238–40

Acute puerperal mastitis in the augmented breast. Johnson PE, et al. **Plast Reconstr Surg** 1996 Sep;98(4):723–5

Complications of harvesting cranial bone grafts [letter; comment] [see comments] Keen M. **Plast Reconstr Surg** 1995 Dec;96(7):1753. Comment on: Plast Reconstr Surg 1995 Jan;95(1):5–13; discussion 14–20. Comment in: Plast Reconstr Surg 1996 Sep;98(3):567.

Curettage: an alternative to capsulectomy after breast implant removal [letter] Siegel RJ. **Plast Reconstr Surg** 1996 Apr; 97(4):870–1

Vitiligo at incision lines [letter] Velidedeoğlu H, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1482–3

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

Myocardial infarction following sternal surgery. Aggarwal RK, et al. **Postgrad Med J** 1996 Aug;72(850):498–9

Coronary subclavian steal syndrome following coronary by–pass surgery. Kneale BJ, et al. **Postgrad Med J** 1996 Jun;72(848):358–60

Sleep disturbances post coronary artery bypass surgery. Schaefer KM, et al. **Prog Cardiovasc Nurs** 1996 Winter; 11(1):5–14

Radial artery occlusion in primary antiphospholipid syndrome after aortic valve replacement [letter] Asherson RA, et al. **S Afr Med J** 1995 Oct;85(10):1042

Clinical and physiological aspects of ileal pouch–anal anastomosis. Salemans JM, et al. **Scand J Gastroenterol Suppl** 1995;212:3–12 (98 ref.)

Carcinogenesis after remote peptic ulcer surgery: the long–term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)

Morbidity of donor and recipient sites after free flap surgery. A prospective study. Salmi A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):337–41

Donor site morbidity of radial forearm flaps. A clinical and ultrasonographic evaluation. Suominen S, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar; 30(1):57–61

Postoperative urinary retention--why the patient cannot void. Tammela T. **Scand J Urol Nephrol Suppl** 1995; 175:75–7

Clinical characteristics of recurrent sciatica after lumbar discectomy. Jönsson B, et al. **Spine** 1996 Feb 15;21(4):500–5

Complications after transpedicular stabilization of the spine [letter; comment] Winter RB. **Spine** 1995 Aug 15; 20(16):1847–8. Comment on: Spine 1994 Dec 15;19(24):2774–9.

Complications of laparoscopic cholecystectomy in HIV and AIDS patients. Carroll BJ, et al. **Surg Endosc** 1995 Aug; 9(8):874–8

Postoperative complications of anti-reflux surgery. Outcomes and costs. Kozarek RA. **Surg Endosc** 1995 Dec; 9(12):1332–4

Spermatic granuloma. An uncommon complication of the tension-free hernia repair. Silich RC, et al. **Surg Endosc** 1996 May;10(5):537–9

Intraabdominal abscesses following laparoscopic and open appendectomies. Tang E, et al. **Surg Endosc** 1996 Mar; 10(3):327–8

Acute left atrial thrombus causing cardiogenic shock following mitral valve replacement: report of a case. Okada K, et al. **Surg Today** 1995;25(7):643–5

Aneurysm following ligation of patent ductus arteriosus [see comments] De DH, et al. **Tex Heart Inst J** 1995;22(4):324–6 . Comment in: Tex Heart Inst J 1996;23(1):71–2.

Retained intraaortic balloon. Case report and review of the literature. Grande AM, et al. **Tex Heart Inst J** 1995; 22(4):332–4 (19 ref.)

Massive haemoptysis complicating prosthetic patch pulmonary embolism after atrial septal defect repair. Haro M, et al. **Thorax** 1995 Aug;50(8):911–2

Duct-to-duct biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Distante V, et al. **Transpl Int** 1996;9(2):126–30

Extracorporeal membrane oxygenation for lung transplant recipients with primary severe donor lung dysfunction. Zenati M, et al. **Transpl Int** 1996;9(3):227–30

Ophthalmological problems in renal transplant patients. Aydin P, et al. **Transplant Proc** 1996 Aug;28(4):2312–3

Incidence of cytomegalovirus infection in kidney recipients. Bilgin N, et al. **Transplant Proc** 1996 Aug;28(4):2314–5

Tumors after renal transplantation. Büyükpamukçu N, et al. **Transplant Proc** 1996 Aug;28(4):2317–8

Octreotide effects on pancreatic graft pancreatitis in inbred pigs. Chao SH, et al. **Transplant Proc** 1996 Jun; 28(3):1799–801

Unique triple malignancies following renal transplantation. Chen CS, et al. **Transplant Proc** 1996 Jun;28(3):1607–8

Successful treatment of invasive mucormycosis following liver transplantation. Chen YS, et al. **Transplant Proc** 1996 Jun;28(3):1708–9

Effects of cytomegalovirus infection on renal function in kidney transplant recipients. Choi SJ, et al. **Transplant Proc** 1996 Jun;28(3):1523–4

Perforated gastrointestinal lymphomas in kidney transplant recipients. Chu SH, et al. **Transplant Proc** 1996 Jun; 28(3):1478–9

Anastomotic artery stenosis in living related kidney transplantation: the impact of anastomotic technique. Ersöz S, et al. **Transplant Proc** 1996 Aug;28(4):2331–2

Tertiary hyperparathyroidism after renal transplantation. Fang JT, et al. **Transplant Proc** 1996 Jun;28(3):1484–5

The influence of donor factors on development of hypertension following cadaveric renal transplantation in nonhypertensive recipients. Fleishhacker JF, et al. **Transplant Proc** 1996 Feb;28(1):418–9

Reconstruction of the gastroduodenal artery in pancreatic transplantation. Han DJ. **Transplant Proc** 1996 Jun; 28(3):1727–8

Enteric conversion of bladder-drained pancreas allograft. Han DJ. **Transplant Proc** 1996 Jun;28(3):1729

Does atherosclerosis of the hypogastric artery in the recipient influence renal allograft function and blood pressure? Harada H, et al. **Transplant Proc** 1996 Jun;28(3):1621–2

Analysis of perioperative respiratory complications in 100 consecutive cases of pediatric living-related donor liver transplantation. Hasegawa S, et al. **Transplant Proc** 1996 Jun;28(3):1673

Six cases of tracheobronchomalacia in perioperative pediatric living-related donor liver transplant recipients. Hasegawa S, et al. **Transplant Proc** 1996 Jun;28(3):1679

Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril. Hu RH, et al. **Transplant Proc** 1996 Jun;28(3):1545–7

Tuberculosis in renal allograft recipients. Hussain Z, et al. **Transplant Proc** 1996 Jun;28(3):1516–7

Commercial living-nonrelated renal transplantation: observations on early complications. Hussein MM, et al. **Transplant Proc** 1996 Jun;28(3):1941–4

Successful retransplantation for recurrent posttransplant hepatitis B virus infection in the primary allograft. Ishitani M, et al. **Transplant Proc** 1996 Jun;28(3):1714–6

Bacterial and fungal infections after living related donor liver transplantation. Itoh K, et al. **Transplant Proc** 1996 Aug; 28(4):2404–5

Effect of recipient T cell subset depletion on graft coronary arteriosclerosis induction in the rat retransplant model. Izutani H, et al. **Transplant Proc** 1996 Jun;28(3):1828–9

Incidence of post kidney transplantation neoplasm in Thailand. Jirasiritham S, et al. **Transplant Proc** 1996 Jun; 28(3):1586–7

Detection of cytomegalovirus infection in renal transplant recipients in Korea. Kahng KW, et al. **Transplant Proc** 1996 Jun;28(3):1507

Major urological complications in 1051 consecutive renal transplants. Karakayali H, et al. **Transplant Proc** 1996 Aug; 28(4):2339–40

Hypertension following renal transplantation. Kim HC, et al. **Transplant Proc** 1996 Jun;28(3):1486–7

Causes of hospital admission following successful renal transplantation. Kim HC, et al. **Transplant Proc** 1996 Jun; 28(3):1603

An animal model of pulmonary infection after single lung transplantation. Kim HK, et al. **Transplant Proc** 1996 Jun; 28(3):1816–7

De novo cancer in transplant recipients. Kim MS, et al. **Transplant Proc** 1996 Jun;28(3):1651–2

Correlation between proteinuria and prognosis of transplant IgA nephropathy. Kimata N, et al. **Transplant Proc** 1996 Jun;28(3):1537–9

Urological complications in renal transplantation. Koga S, et al. **Transplant Proc** 1996 Jun;28(3):1472–3

Transplant nephrectomy in 927 kidney transplantations. Koh YB, et al. **Transplant Proc** 1996 Jun;28(3):1470–1

Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. Kokado Y, et al. **Transplant Proc** 1996 Jun;28(3):1600–2

Kidney transplantation from hepatitis B surface antigen (HBsAg)-positive donors: changes of relative HBV genomic copy number after transplantation. Lai MK, et al. **Transplant Proc** 1996 Jun;28(3):1518–9

Post-renal transplant diabetes in Sri Lanka. Lanerolle RD, et al. **Transplant Proc** 1996 Jun;28(3):1945–7

Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Lee KH, et al. **Transplant Proc** 1996 Jun;28(3):1488–9

Asymptomatic cytomegalovirus infection in renal transplants: treatment or no treatment. Lee PC, et al. **Transplant Proc** 1996 Jun;28(3):1513–5

The mismatch of donor/recipient size influences development of proteinuria in allograft kidney transplants. Lee SW, et al. **Transplant Proc** 1996 Jun;28(3):1480–1

Donor characteristics for liver transplantation and risk factors for early poor graft function and survival. Lee YJ, et al. **Transplant Proc** 1996 Jun;28(3):1663–4

Neurologic complications after orthotopic liver transplantation including central pontine myelinolysis. Lee YJ, et al. **Transplant Proc** 1996 Jun;28(3):1674–5

De novo hepatitis B virus infection after orthotopic liver transplantation. Liu PP, et al. **Transplant Proc** 1996 Jun; 28(3):1684–6

Clinical study and experience in cadaveric kidney transplantation for 15 years. Lixin Y, et al. **Transplant Proc** 1996 Jun;28(3):1568–70

Varicella-zoster infection in cyclosporine A-treated renal transplant patients. Lo CY, et al. **Transplant Proc** 1996 Jun; 28(3):1511–2

Percutaneous transluminal angioplasty for transplant renal artery stenosis. Lo CY, et al. **Transplant Proc** 1996 Jun; 28(3):1468–9

Detrimental effect of immediate portal hypertension in canine quarter orthotopic liver transplantation. Maeda I, et al. **Transplant Proc** 1996 Jun;28(3):1759–60

Hepatitis C in kidney transplant patients. Oka T, et al. **Transplant Proc** 1996 Jun;28(3):1163–7

Clinical and psychosocial consequences of renal transplantation in children. Park CH, et al. **Transplant Proc** 1996 Jun;28(3):1604–6

Clinical manifestations of tuberculosis in renal transplant patients. Park SB, et al. **Transplant Proc** 1996 Jun; 28(3):1520–2

Neoplasia: an example of plasticity of the immune response. Penn I. **Transplant Proc** 1996 Aug;28(4):2089–93 (29 ref.)

Preventive effect of enalapril on erythrocytosis after renal transplantation. Rhee SR, et al. **Transplant Proc** 1996 Jun; 28(3):1555–6

Ocular complications in renal allograft recipients with special reference to steroid cataractogenic factor. Saito S, et al. **Transplant Proc** 1996 Jun;28(3):1474–5

Transplant glomerulopathy--a clinicopathological study. Shu KH, et al. **Transplant Proc** 1996 Jun;28(3):1527–8

Effect of captopril in the treatment of erythrocytosis after renal transplantation. Suh BY, et al. **Transplant Proc** 1996 Jun;28(3):1557–8

Reoperative procedures after orthotopic liver transplantation. Sun CK, et al. **Transplant Proc** 1996 Jun;28(3):1676–8

Clinical evaluation of factor analysis by dynamic-SPECT for transplanted kidneys. Takahashi N, et al. **Transplant Proc** 1996 Jun;28(3):1636–43

Early diagnosis of CMV syndrome after kidney transplantation: comparison between CMV antigenemia and PCR assay. Tanabe K, et al. **Transplant Proc** 1996 Jun; 28(3):1508–10

Tuberculosis after renal transplantation. Tokat Y, et al. **Transplant Proc** 1996 Aug;28(4):2353–4

Clinical implication of the presence of hepatitis C virus antibodies after kidney transplantation in Japan. Tomikawa S, et al. **Transplant Proc** 1996 Jun;28(3):1498–500

Immunocytochemical assay for cytomegalovirus detection in peripheral blood for renal transplant patients in clinical practice. Wie SH, et al. **Transplant Proc** 1996 Jun; 28(3):1505–6

Treatment of peripheral leukopenia after cadaveric kidney transplantation. Xiwen B, et al. **Transplant Proc** 1996 Jun; 28(3):1631–2

Massive proteinuria after renal transplantation treated with LDL-apheresis. Yanagisawa T, et al. **Transplant Proc** 1996 Jun;28(3):1482–3

Biliary complications in long-term recipients of reduced-size liver transplants. Yang MD, et al. **Transplant Proc** 1996 Jun;28(3):1680–1

Hyperamylasemia in kidney transplant recipients. Yokoyama I, et al. **Transplant Proc** 1996 Jun;28(3):1476–7

Influence of portoarterial reflux on the development of hepatic arterial thrombosis in auxiliary partial liver transplantation in the rat. Yoo CH, et al. **Transplant Proc** 1996 Jun;28(3):1775–7

Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME, et al. **Transplantation** 1996 Jun 27;61(12):1716–20

"Acquired" subvalvular aortic stenosis after repair of several congenital cardiac defects. Tokel K, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):177–82

Successful pregnancy after bilateral internal iliac artery ligation monitored by color Doppler imaging. Papp Z, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):211–2

A unique perineal herniation of large bladder diverticulum: successful surgical repair through posterior sagittal approach. Gong M, et al. **Urology** 1996 Apr;47(4):569–72

Femoral nerve neuropathy after the psoas hitch procedure. Kowalczyk JJ, et al. **Urology** 1996 Apr;47(4):563–5

[Mesenteric vein thrombosis after devasculation for portal hypertension] Chen Q, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):295–7 (Eng. Abstr.) **(Chi)**

[Postoperative residual intracranial aneurysms] Wang S, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):428–9 (Eng. Abstr.) **(Chi)**

[Lack of ossification of the skull after surgery for craniosynostosis. A study of risk factors apropos of 592 cases] Prévot M, et al. **Ann Chir Plast Esthet** 1996 Feb; 41(1):45–57 (Eng. Abstr.) **(Fre)**

[Hypophyseal surgery: experience in Paris] Derome P. **Ann Endocrinol (Paris)** 1995;56(6):627–9 **(Fre)**

[Hypophyseal surgery: experience in Montreal] Hardy J. **Ann Endocrinol (Paris)** 1995;56(6):625–6 **(Fre)**

[Role of preoperative nutritional status on postoperative morbidity] Di Costanzo J. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:33–8 (Eng. Abstr.) **(Fre)**

[Postoperative disorders of hemostasis caused by antifactor V circulating anticoagulant] Leclerc J, et al. **Ann Fr Anesth Reanim** 1995;14(3):303–5 (Eng. Abstr.) **(Fre)**

[Effect of postoperative complications on nutritional status: therapeutic consequences] Levraut J, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:66–74 (Eng. Abstr.) **(Fre)**

[Treatment of velopharyngeal stenosis after pharyngotomy for chronic snoring. Apropos of 13 cases] Chabolle F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):324–9 (Eng. Abstr.) **(Fre)**

[Arrhythmia after surgery for congenital cardiopathies. What studies? What treatment?] Friedli B. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):351–7 (Eng. Abstr.) **(Fre)**

[Pulmonary vein stenosis. Description of a sutureless surgical procedure using the pericardium in situ] Lacour-Gayet F, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):633–6 (Eng. Abstr.) **(Fre)**

[Post-heart surgery auricular fibrillation] Pagé PL, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:38A–43A (45 ref.) **(Fre)**

[Macular fibrosis after surgery of retinal detachment] Girard P, et al. **J Fr Ophtalmol** 1996;19(5):335–40 (Eng. Abstr.) **(Fre)**

[Risk factors of postoperative proliferative vitreoretinopathy in giant tears] Yanyali A, et al. **J Fr Ophtalmol** 1996; 19(3):175–80 (Eng. Abstr.) **(Fre)**

[Vascular complications of lumbar disk surgery. Report of two cases and review of the literature on 122 cases] Pillet JC, et al. **J Mal Vasc** 1995;20(3):219–23 (85 ref.) (Eng. Abstr.) **(Fre)**

[Insidious growth of peritoneal cysts several years after pelvic surgery. Ultrasonographic and x-ray computed tomographic aspects] De Blay V, et al. **J Radiol** 1996 May; 77(5):339–42 (Eng. Abstr.) **(Fre)**

[Postoperative low patella. Treatment by lengthening of the patellar tendon] Dejour D, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(4):286–95 (Eng. Abstr.) **(Fre)**

[Contralateral preventive screwing in proximal femoral epiphysiolysis] Ghanem I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):130–6 (Eng. Abstr.) **(Fre)**

[Thyroid surgery: risks and complications. Apropos of 134 cases] Duclos JY, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):199–207 (25 ref.) (Eng. Abstr.) **(Fre)**

[Fecal incontinence after rectal resection] Merkle P. **Dtsch Med Wochenschr** 1996 May 17;121(20):675–6 **(Ger)**

[Transplant vasculopathy following heart transplantation] Weis M, et al. **Dtsch Med Wochenschr** 1995 Sep 29;

120(39):1327–33 (50 ref.) **(Ger)**

[Rheumatic manifestations of transplant recipients] Levy G, et al. **Harefuah** 1996 Apr 15;130(8):546–8 (23 ref.) **(Heb)**

[Complications of the surgical treatment of hemorrhoids and its therapy] Corno F, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):813–6 (15 ref.) (Eng. Abstr.) **(Ita)**

[Cholecystectomy with laparoscopy and laparotomy. Analysis of the complications] Beltramo M, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):627–31 (Eng. Abstr.) **(Ita)**

[Clinical study on cerebrovascular diseases after renal transplantation] Nagano T, et al. **Hinyokika Kiyo** 1995 Aug; 41(8):585–8 (Eng. Abstr.) **(Jpn)**

[A case of Acanthamoeba keratitis after operation for cataract] Takatsu M, et al. **Kansenshogaku Zasshi** 1995 Oct; 69(10):1159–61 (Eng. Abstr.) **(Jpn)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Anticoagulant related hemorrhage and thromboembolism after valvular surgery] Okada K, et al. **Kyobu Geka** 1996 Mar;49(3):190–3 (Eng. Abstr.) **(Jpn)**

[The clinical scoring system for predicting the risk of intraoperative and postoperative bronchospasm] Harada J, et al. **Masui** 1995 Oct;44(10):1415–20 (Eng. Abstr.) **(Jpn)**

[Risk factors for pulmonary hypertensive crisis (PHC) following VSD repair in infants] Matsumoto M, et al. **Masui** 1995 Sep;44(9):1208–12 (Eng. Abstr.) **(Jpn)**

[A case of encapsulated filtering bleb after trabeculectomy] Watanabe H, et al. **Nippon Ganka Gakkai Zasshi** 1995 Oct; 99(10):1190–5 (Eng. Abstr.) **(Jpn)**

[A case report of a left atrial ball thrombus at 16 years after mitral valve replacement] Iida M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):539–44 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical characteristics of pancreatitis after cardiovascular surgery] Ikegami H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1720–9 (Eng. Abstr.) **(Jpn)**

[Cerebral infarction after the cardiovascular operation] Mizuhara A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1907–12 (Eng. Abstr.) **(Jpn)**

[Factors affecting the occurrence of anastomotic leakage after graft replacement of type A aortic dissection] Sako H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1736–40 (Eng. Abstr.) **(Jpn)**

[A case of dural AVM detected after STA–MCA anastomosis] Igase K, et al. **No Shinkei Geka** 1996 Jan; 24(1):81–5 (Eng. Abstr.) **(Jpn)**

[Anterior choroidal artery territory infarction with transcortical sensory aphasia after a neck clipping of left internal carotid artery aneurysms: a case report] Takei A, et al. **No Shinkei Geka** 1996 Jan;24(1):63–7 (Eng. Abstr.) **(Jpn)**

[Cerebrospinal fluid leak after cranial base surgery] Yamakami I, et al. **No Shinkei Geka** 1996 Jan;24(1):29–33 (Eng. Abstr.) **(Jpn)**

[Eck fistula syndrome] Fukasawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):220–5 (22 ref.) **(Jpn)**

[Post operative bile duct stricture] Hoshino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):155–8 (8 ref.) **(Jpn)**

[Postoperative acute cholecystitis] Nakajima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):213–5 (7 ref.) **(Jpn)**

[Post-operative liver failure] Omori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):256–8 (18 ref.) **(Jpn)**

[Postoperative liver damage, postoperative jaundice, and benign postoperative cholestasis] Ouchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):538–40 (6 ref.) **(Jpn)**

[A case of postoperative hyponatremia caused by Sheehan syndrome associated with lung carcinoma] Ozaki S, et al. **Sangyo Ika Daigaku Zasshi** 1995 Sep 1;17(3):199–205 (Eng. Abstr.) **(Jpn)**

[Infections in intensive care units. A challenge for the specialist of infectious diseases?] von der Lippe E, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3508–10 (12 ref.) (Eng. Abstr.) **(Nor)**

[Errors and complications in treatment of lateral humeral condyle fractures in children] Lejman T, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(2):123–8 (Eng. Abstr.) **(Pol)**

[Orthopedic problems in children after surgical treatment for lipoma of the conus medullaris] Lejman T, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):39–45 (Eng. Abstr.) **(Pol)**

[Extensive, bleeding skin cancer on the back in a postoperative scar] Kococik Z, et al. **Wiad Lek** 1994 Oct; 47(19–20):788–90 (Eng. Abstr.) **(Pol)**

[Mutism after posterior fossa tumor surgery. Report of 2 cases (see comments)] Wagner R, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):94–7 (Eng. Abstr.). Comment in: Arq Neuropsiquiatr 1995 Sep;53(3–A):533–4. **(Por)**

[Significance of the energetic value of respiration in the assessment of the degree of strain of compensatory mechanisms in respiratory insufficiency] Bondarenko AV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):3–5 (Eng. Abstr.) **(Rus)**

[Complications after resection of the liver] Al'perovich BI, et al. **Khirurgiia (Mosk)** 1995;(6):41–3 (Eng. Abstr.) **(Rus)**

[Dermal autograft in surgery of postoperative abdominal hernia] Galimov OV, et al. **Klin Khir** 1995;(7–8):51–2 **(Rus)**

[Prevention of complications in laparoscopic cholecystectomy] Vecherko VN, et al. **Klin Khir** 1995; (4):10–2 **(Rus)**

[Computer screening in the determination of groups at risk for postvagotomy syndromes] Lirman AV, et al. **Klin Med (Mosk)** 1995;73(6):62 **(Rus)**

[Principal factors affecting postoperative astigmatism after cataract extraction] Naim Dzheries Dzhadalla Kaĭkikh. **Vestn Oftalmol** 1995 Jul–Sep;111(3):34–6 (49 ref.) **(Rus)**

[Anastomosis suture technic and complications of esophagocoloplasty in corrosive lesions] Knežević J, et al. **Acta Chir Iugosl** 1994;41(2 Suppl 2):235–7 (Eng. Abstr.) **(Scr)**

[Complications in reconstructive procedures on arteries in the lower extremities] Radak D, et al. **Acta Chir Iugosl** 1990;37(2):181–8 (Eng. Abstr.) **(Scr)**

[Complications in esophagojejunal anastomosis] Randelović T, et al. **Acta Chir Iugosl** 1994;41(2 Suppl 2):225–8 (Eng. Abstr.) **(Scr)**

[Causes of complications in the early postoperative period after heart surgery Dadić D, et al. **Lijec Vjesn** 1995 Jun; 117 Suppl 2:78–80 (Eng. Abstr.) **(Scr)**

[Consciousness disorders in patients after carotid artery surgery] Grabić D, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:67–8 (Eng. Abstr.) **(Scr)**

[Multiorgan dysfunction syndrome (MODS) caused by long bone fractures in young persons] Rakarić–Poznanović M, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:85–7 (Eng. Abstr.) **(Scr)**

[Incidence and localization of deep venous thrombosis and disorders of pulmonary perfusion in patients after surgery in colorectal carcinoma] Marković S, et al. **Vojnosanit Pregl** 1994 May–Jun;51(3):208–13 (Eng. Abstr.) **(Scr)**

[The effect of age and risk factors on postoperative complications and mortality in patients with surgery for colorectal carcinoma] Příbelský M, et al. **Bratisl Lek Listy** 1996 Jan;97(1):50–3 (Eng. Abstr.) **(Slo)**

[Meningitis and cerebrospinal liquid fistula as a complication from the surgery of endolymphatic sac] Muñoz Colado M, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug; 46(4):317–9 (Eng. Abstr.) **(Spa)**

[Problems associated with nephrectomy of transplanted kidneys] Martínez Urrutia MJ, et al. **Cir Pediatr** 1995 Oct; 8(4):151–4 (Eng. Abstr.) **(Spa)**

[Rhabdomyolysis as an infrequent complication of scoliosis surgery (letter)] Colomina MJ, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):400–1 **(Spa)**

[Estimation of cost associated with incorrect surgical prophylaxis in a third level hospital center] Díaz Molina C, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):349–55 (Eng. Abstr.) **(Spa)**

[Nerve injuries in rectal surgery] Räf L. **Lakartidningen** 1996 Apr 24;93(17):1649–50 **(Swe)**

BLOOD

Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Lee TH, et al. **Am J Cardiol** 1996 May 15;77(12):1031–6

Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery [see comments] Sumner AE, et al. **Ann Intern Med** 1996 Mar 1;124(5):469–76. Comment in: Ann Intern Med 1996 Mar 1;124(5):509–11.

Thrombophilia and the surgeon. Rhodes EG. **Ann R Coll Surg Engl** 1996 Jul;78(4):331–5 (33 ref.)

Fibrinolysis profiles and platelet activation after endothelial cell seeding of prosthetic vascular grafts. Smyth JV, et al. **Ann Vasc Surg** 1995 Nov;9(6):542–6

Inter–relationships between glutamine and other biochemical and immunological changes after major vascular surgery. Greig JE, et al. **Br J Biomed Sci** 1996 Jun;53(2):116–21

Thrombomodulin in intensive care patients. Boldt J, et al. **Intensive Care Med** 1995 Aug;21(8):645–50

Serum C–reactive protein levels after total hip and knee arthroplasty. Niskanen RO, et al. **J Bone Joint Surg Br** 1996 May;78(3):431–3

Changes in coagulatory profile after orthopedic surgery. Wei KL, et al. **J Formos Med Assoc** 1995 Sep;94(9):541–7

Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. Faulk WP, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S158–64

Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. Valantine HA. **J Heart Lung Transplant** 1995 Nov–Dec; 14(6 Pt 2):S234–7

Thyroid function and serum thyroid binding proteins in prepubertal and pubertal children with chronic renal insufficiency receiving conservative treatment, undergoing hemodialysis, or receiving care after renal transplantation. Castellano M, et al. **J Pediatr** 1996 Jun;128(6):784–90

Re: Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass [letter; comment] Semjonow A, et al. **J Urol** 1996 Jan;155(1):295–6. Comment on: J Urol 1994 Dec;152(6 Pt 1):2043–5.

The omnipotent platelet. Steinberg LA. **Med Hypotheses** 1996 Mar;46(3):188–90

Does it exist also a "late" post–surgical hypoparathyroidism? Potestà P, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec; 16(5–6):99–101

Alterations in coagulation and fibrinolysis after surgery for aortic aneurysm. Oba J, et al. **Surg Today** 1995;25(6):532–5

Plasma hepatocyte growth factor levels are increased in systemic inflammatory response syndrome. Sakon M, et al. **Surg Today** 1996;26(4):236–41

Inflammatory reactions after vascular prosthesis implantation: a comparison of gelatin–sealed and unsealed Dacron prostheses. Utoh J, et al. **Surg Today** 1996;26(4):258–61

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Dahl OE, et al. **Thromb Res** 1995 Nov 15;80(4):299–306

Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery––relation to major thromboembolism and mortality. Fragmin Multicentre Study Group. Flordal PA, et al. **Thromb Res** 1995 Dec 15;80(6):491–7

Soluble fibrin in plasma before and after surgery for benign and malignant colorectal disease. Iversen LH, et al. **Thromb Res** 1995 Sep 15;79(5–6):471–81

Platelet membrane glycoproteins and microvesicles in blood from postoperative salvage: a study in cardiac bypass patients. Sloand E, et al. **Transfusion** 1995 Sep;35(9):738–44

Release of glucagon–like peptide 1 (GLP–1 [7–36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Nauck MA, et al. **Z Gastroenterol** 1996 Mar;34(3):159–66

[Clinical observation and study of blood phosphate concentration changes in postoperative patients] Chen L, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):276–8 (Eng. Abstr.) **(Chi)**

[Thrombomodulin as endothelial cell marker in heart surgery patients] Böhrer H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):417–9 (Eng. Abstr.) **(Ger)**

[Clinical and endocrine effects of laparoscopic ovarian surgery in patients with polycystic ovary syndrome] Rossmanith WG, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:103–7 (Eng. Abstr.) **(Ger)**

[Is radical prostatectomy a suitable model for determination of PSA half–life?] Brändle E, et al. **Urologe A** 1995 Sep; 34(5):419–23 (Eng. Abstr.) **(Ger)**

[The intravascular formation of kinins in the brain studied as a new approach to the problem of the re–circulatory complications in the surgical treatment of cerebral ischemia] Makevnina LG, et al. **Vestn Ross Akad Med Nauk** 1995;(12):13–7 (Eng. Abstr.) **(Rus)**

[Extreme increase in the blood erythroblast count in a patient with iron–deficiency anemia and asplenia] Ramos Fernández de Soria R, et al. **Sangre (Barc)** 1996 Feb; 41(1):65–7 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

[The immunological reactions and enzymatic activity of the cerebrospinal fluid in intracranial complications following neurosurgical operations] Khil'ko VA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul–Sep;(3):25–7 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. Kitamura A, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):368–71

Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. Olsen TW, et al. **Am J Ophthalmol** 1996 May;121(5):575–7

Antibiotic patterns associated with fungal colonization in critically ill surgical patients. D'Amelio LF, et al. **Am Surg** 1995 Dec;61(12):1049–53

Nonopioid analgesics shorten the duration of postoperative ileus. Ferraz AA, et al. **Am Surg** 1995 Dec;61(12):1079–83

Respiratory arrest in two children following postoperative flushing of suxamethonium from the deadspace of intravenous cannulae. Davidson A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):97–8

Transient femoral nerve palsy after ilioinguinal block [letter] Derrick JL, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):115

Post suxamethonium myalgia––will we never learn? [letter; comment] van den Berg AA, et al. **Anaesth Intensive Care** 1996 Feb;24(1):116–7. Comment on: Anaesth Intensive Care 1994 Oct;22(5):576–9.

Erythromycin as a prokinetic agent in children [letter] Hall JE, et al. **Anaesthesia** 1996 May;51(5):503–4

Spinal haematoma and central neural blockade [letter] Knowles P, et al. **Anaesthesia** 1996 Aug;51(8):803

Epidural hematoma associated with enoxaparin. Hynson JM, et al. **Anesth Analg** 1996 May;82(5):1072–5

Hepatotoxicity after desflurane anesthesia. Martin JL, et al. **Anesthesiology** 1995 Nov;83(5):1125–9

Severe hyponatraemia in elderly patients: cause for concern [letter] Hornick P. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):230

Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? [letter; comment] Price AJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):395. Comment on: Ann R Coll Surg Engl 1995 Jan;77(1):35-7.

Aprotinin in staged heart transplantation: anaphylactic potential of repeated exposure [letter; comment] Martinelli L, et al. **Ann Thorac Surg** 1996 Apr;61(4):1288-9. Comment on: Ann Thorac Surg 1995 May;59(5):1063-7; discussion 1068.

Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Otley CC, et al. **Arch Dermatol** 1996 Feb; 132(2):161-6

Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Tramèr M, et al. **Br J Anaesth** 1996 Feb;76(2):186-93

Cognitive failures after general anaesthesia for day-case surgery. Tzabar Y, et al. **Br J Anaesth** 1996 Feb;76(2):194-7

Effect of ketorolac on bleeding time and postoperative pain in children: a double-blind, placebo-controlled comparison with meperidine. Bean-Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25-30

Pulmonary edema following naloxone administration in a healthy orthopedic patient [letter] Johnson C, et al. **J Clin Anesth** 1995 Jun;7(4):356-7

Microangiopathic hemolytic anemia secondary to cyclosporine therapy in a heart and liver transplant recipient [letter] Oteo JF, et al. **J Heart Lung Transplant** 1996 Mar;15(3):322-4

Iatrogenic acute angle closure glaucoma masked by general anaesthesia and intensive care. Lotery AJ, et al. **Ulster Med J** 1995 Oct;64(2):178-80

Ketorolac-induced postoperative acute renal failure: a case report. Patel NY, et al. **Wis Med J** 1995;94(8):445-7

[The effect of propofol on vomiting after strabismus surgery in children] Klockgether-Radke A, et al. **Anaesthesist** 1995 Nov;44(11):755-60 (Eng. Abstr.) **(Ger)**

[Magnesium deficiency after kidney transplantation and cyclosporine therapy] Rob PM. **Fortschr Med** 1996 Apr 10;114(10):125-6 **(Ger)**

[Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841-6 (45 ref.) (Eng. Abstr.) **(Ger)**

[Intraocular silicone oil tamponade. A clinico-pathologic study of 36 enucleated eyes] Knorr HL, et al. **Ophthalmologe** 1996 Apr;93(2):130-8 (Eng. Abstr.) **(Ger)**

[Relevance of heparin-induced type II thrombocytopenia in surgery: report of 3 cases] Manouguian S. **Vasa** 1996; 25(2):188-93 (Eng. Abstr.) **(Ger)**

[Heparin-associated type II thrombocytopenia as a cause of multiple thromboembolism complications] Scheffold N, et al. **Vasa** 1996;25(2):168-73 (Eng. Abstr.) **(Ger)**

[Effects of cyclosporin A on various indices of cholestasis in kidney transplant recipients] Soresi M, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):65-9 (Eng. Abstr.) **(Ita)**

[Convulsive seizure after craniotomy--comparison of isoflurane anesthesia and sevoflurane anesthesia] Hashimoto K, et al. **Masui** 1995 Aug;44(8):1139-42 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

[Registration of postoperative complications to improve results of surgery (letter)] Heineman MJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1621 **(Dut)**

[Complications specific to the types of pseudophakia] Vasinca DI. **Oftalmologia** 1996 Apr-Jun;40(2):176-9 (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Surgical relations of Crohn's disease and the frequency of recurrence. Ihász M, et al. **Acta Chir Hung** 1995-96; 35(1-2):63-75

Increase of interleukin-6 plasma levels after elective craniotomy: influence of interleukin-10 and catecholamines. Heesen M, et al. **Acta Neurochir (Wien)** 1996;138(1):77-80

Effect of ultra-early referral on management outcome in subarachnoid haemorrhage. Inagawa T. **Acta Neurochir (Wien)** 1995;136(1-2):51-61

Long-term follow-up of the residual intracanalicular tumours after subtotal removal of acoustic neurinomas. Kameyama S, et al. **Acta Neurochir (Wien)** 1996; 138(2):206-9

Cross-sectional areas of lumbar muscles after surgical treatment of lumbar disc herniation. A study with magnetic resonance imaging after microdiscectomy or percutaneous nucleotomy. Kotilainen E, et al. **Acta Neurochir (Wien)** 1995;133(1-2):7-12

Does a routine operation for intracranial aneurysm incur brain damage? Rabow L, et al. **Acta Neurochir (Wien)** 1995; 133(1-2):13-6

PMN granulocyte elastase--an early indicator of postoperative spondylodiscitis? Schneider T, et al. **Acta Neurochir (Wien)** 1995;136(1-2):16-20

Bovine dowels for anterior cervical fusion: experience in 66 patients with a note on postoperative CT and MRI appearance. Sutter B, et al. **Acta Neurochir (Wien)** 1995; 137(3-4):192-8

Neurological outcome in coronary artery surgery with and without cardiopulmonary bypass. Malheiros SM, et al. **Acta Neurol Scand** 1995 Sep;92(3):256-60

High frequency deficit of the vestibular system after acoustic neurinoma surgery. Hirvonen T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:16-8

A further critical assessment of the efficacy of endolymphatic sac surgery. Huang TS, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:263-9

Nystagmus measured by ENG after stapes surgery. Koizuka I, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:258-9

Retained sponge in the neck: MR appearance [letter] Boyvat F, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1564-5

Cardiac sarcoma metastatic to the brain. Colon G, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1739-41

CT and MR appearance of otolaryngologic packing materials. Hartley C, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1697-702

MR evaluation of frontal sinus osteoplastic flaps with autogenous fat grafts. Loevner LA, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1721-6

Complications of laparoscopic cholecystectomy: imaging and intervention. McGahan JP, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1089-97

Complications after anterior cruciate ligament reconstruction: radiographic and MR findings. Recht MP, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):705-10

Exercise echocardiography, angiography, and intracoronary ultrasound after cardiac transplantation. Cohn JM, et al. **Am J Cardiol** 1996 Jun 1;77(14):1216-9

Detection of hepatitis C after liver transplantation. Four serologic tests compared. Donegan E, et al. **Am J Clin Pathol** 1995 Dec;104(6):673-9

Post-renal transplantation hyponatremia. Zaltzman JS. **Am J Kidney Dis** 1996 Apr;27(4):599-602

Comparison of techniques for detecting digital neuropathy. Chiou-Tan FY, et al. **Am J Phys Med Rehabil** 1996 Jul-Aug;75(4):278-82

The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Guilinger RA, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2037-43

Supraventricular tachyarrhythmias in the surgical intensive care unit: an under-recognized event. Bender JS. **Am Surg** 1996 Jan;62(1):73-5

Late Clostridium perfringens breast implant infection after dental treatment. Hunter JG, et al. **Ann Plast Surg** 1996 Mar;36(3):309-12

Onset timing of delayed complications and criteria of follow-up after operation for esophageal achalasia. Di Simone MP, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1106-10; discussion 1110-1

Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder. Cumming S, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):293-8

Early detection and treatment of myocardial ischaemia after operation using continual ambulatory arterial pressure monitoring and ECG ST segment analysis. Edwards ND, et al. **Br J Anaesth** 1995 Oct;75(4):491-4

Use of the abbreviated mental test to detect postoperative delirium in elderly people. Ní Chonchubhair A, et al. **Br J Anaesth** 1995 Oct;75(4):481-2

Quality of life and cognitive deficits after subarachnoid haemorrhage. Hütter BO, et al. **Br J Neurosurg** 1995; 9(4):465-75

Donated organs as a source of cytomegalovirus (CMV) in renal transplant patients. Costa SC, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2573-8

Diagnostic yield of bronchoscopies after isolated lung transplantation [see comments] Baz MA, et al. **Chest** 1996 Jul;110(1):84-8. Comment in: Chest 1996 Jul;101(1):6-7.

Comparison of some criteria for diagnosing a myocardial infarction after aorto-coronary bypass grafting (CABG). Backman C, et al. **Clin Physiol** 1995 Jul;15(4):307-17

Humoral tea leaves: what's at the bottom of the cup? [editorial] Woolf P. **Crit Care Med** 1995 Dec;23(12):1943-4

Seromas in the breast: imaging findings. Soo MS, et al. **Crit Rev Diagn Imaging** 1995;36(5):385-440 (34 ref.)

Colocutaneous fistula formation following polypropylene mesh placement for repair of a ventral hernia: diagnosis by colonoscopy. DeGuzman LJ, et al. **Endoscopy** 1995 Aug;27(6):459-61

Influence of coronary artery bypass grafting on ventricular late potentials as a predictive factor for ventricular arrhythmias during short- and long-term follow-up. Frielingsdorf J, et al. **Eur Heart J** 1995 May;16(5):660-6

The relationship between sigmoidal intramucosal pH and intestinal arterial occlusion during aortic reconstructive surgery. Klok T, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):304-7

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243-6 (5 ref.)

Results of systematic speech sound monitoring in children with cleft palate. Ainoda N, et al. **Folia Phoniatr Logop** 1996;48(2):86-91

Venous thromboembolism in coronary artery surgery. Briffa N, et al. **Heart** 1996 May;75(5):433

Diagnosing infection of extracardiac conduit in children. Kawamura S, et al. **Heart Vessels** 1995;10(4):214-7

Early detection of graft dysfunction after orthotopic liver transplantation in man by serum and biliary bile acid analysis. Baumgartner U, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):950-60

The Mini Mental State Exam as a predictor of neuropsychological functioning after cardiac surgery. Burker EJ, et al. **Int J Psychiatry Med** 1995;25(3):263-76

The risk of postoperative deconditioning in older adults [letter; comment] Shahar A, et al. **J Am Geriatr Soc** 1996 Apr;44(4):471. Comment on: J Am Geriatr Soc 1995 Jul;43(7):811-21.

Spirometric changes after open mitral surgery. Vaidya R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):295-300

Usefulness of QRST isointegral maps for the diagnosis of right ventricular pressure overload in patients with surgically repaired tetralogy of Fallot complicated by right bundle block. Hayabuchi Y, et al. **J Electrocardiol** 1996 Apr;29(2):111-7

Magnetic resonance imaging for diagnosis of digital flexor tendon rupture after primary repair. Calandruccio JH, et al. **J Hand Surg [Br]** 1995 Jun;20(3):289-90

Flow-volume loop contours after single lung transplantation [letter; comment] Dicicco BS, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):799. Comment on: J Heart Lung Transplant 1994 May-Jun;13(3):508-13.

Magnetic resonance imaging after frontal sinus surgery with fat obliteration. Keerl R, et al. **J Laryngol Otol** 1995 Nov; 109(11):1115-9

MR imaging in graft-dependent recurrent hyperparathyroidism after parathyroidectomy and autotransplantation. Hergan K, et al. **J Magn Reson Imaging** 1995 Sep-Oct;5(5):541-4

Stereophotogrammetric and clinical evaluation of morbidity after removal of lower third molars by two different surgical techniques. Mocan A, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):171-5

Risk factor control five years after coronary bypass grafting. Skinner JS, et al. **J R Coll Physicians Lond** 1996 Mar-Apr; 30(2):136-41

Imaging of the total hip arthroplasty. Allen AM, et al. **J South Orthop Assoc** 1995 Summer;4(2):96-123 (71 ref.)

Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? McDonald ML, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1135-8; discussion 1139-40

Long-term follow-up (10 to 17 years) after Mustard repair for transposition of the great arteries. Meijboom F, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1158-68

Objective assessment of gastroesophageal reflux after short esophagomyotomy for achalasia with the use of manometry and pH monitoring. Streitz JM Jr, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):107-12; discussion 112-3

Perioperative microbiologic monitoring of tracheal aspirates as a predictor of pulmonary complications after cardiac operations. Zickman B, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1213-8

Donor-site morbidity after harvest of a bone-tendon-bone patellar tendon autograft. Kohn D, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):219-23

Preoperative identification of patients at risk for delirium after major head and neck cancer surgery. Weed HG, et al. **Laryngoscope** 1995 Oct;105(10):1066-8

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125-32 (47 ref.)

MRI of spinal cord and vertebral body infarction in the anterior spinal artery syndrome. Haddad MC, et al. **Neuroradiology** 1996 Feb;38(2):161-2

Acute disseminated encephalomyelitis (ADEM) or ADEM-like inflammatory changes in a heart-lung transplant recipient: a case report. Horowitz MB, et al. **Neuroradiology** 1995 Aug;37(6):434-7

Laminectomy-induced arachnoradiculitis: a postoperative serial MRI study. Matsui H, et al. **Neuroradiology** 1995 Nov;37(8):660-6

Midcervical flexion myelopathy after posterior fossa surgery in the sitting position: case report. Haisa T, et al. **Neurosurgery** 1996 Apr;38(4):819-21; discussion 821-2

Titanium aneurysm clips: Part III--Clinical application in 16 patients with subarachnoid hemorrhage. Lawton MT, et al. **Neurosurgery** 1996 Jun;38(6):1170-5

Surveillance imaging in children with primitive neuroectodermal tumors. Mendel E, et al. **Neurosurgery** 1996 Apr;38(4):692-4; discussion 694-5

Postoperative magnetic resonance imaging with titanium implants of the thoracic and lumbar spine. Ortiz O, et al. **Neurosurgery** 1996 Apr;38(4):741-5

Association between peridural scar and recurrent radicular pain after lumbar discectomy: magnetic resonance evaluation. ADCON-L European Study Group. Ross JS, et al. **Neurosurgery** 1996 Apr;38(4):855-61; discussion 861-3

Ambulatory blood pressure in patients with occult recurrent coarctation of the aorta. Parrish MD, et al. **Pediatr Cardiol** 1995 Jul-Aug;16(4):166-71

Evidence for a patent fibrous tract in fractured, outgrown, or disconnected ventriculoperitoneal shunts. Clyde BL, et al. **Pediatr Neurosurg** 1995;23(1):20-5

Imaging of post-transplant spindle cell tumors. Pollock AN, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S118-21

Color monitoring after replantation. Kiyoshige Y, et al. **Plast Reconstr Surg** 1996 Feb;97(2):463-8

Complications of flexor tendon repair in the hand: MR

imaging assessment. Drapé JL, et al. **Radiology** 1996 Jan; 198(1):219–24

Renal tubular dysfunction after urinary diversion. Kristjansson A, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):407–12

Postoperative cervical pseudomeningocele with herniation of the spinal cord. Hosono N, et al. **Spine** 1995 Oct 1; 20(19):2147–50

Postsurgical ossified extradural cyst of the lumbar spine: a case report. Saito H, et al. **Spine** 1996 Feb 1;21(3):386–8

Upper gastrointestinal endoscopic and histologic findings before and after vertical banded gastroplasty. Papavramidis ST, et al. **Surg Endosc** 1996 Aug;10(8):825–30

Clinical and experimental studies of the limulus test after digestive surgery. Kimura Y, et al. **Surg Today** 1995; 25(9):790–4

Severity and predicted outcome of postoperative Pseudomonas aeruginosa infections. Kodama T, et al. **Surg Today** 1995;25(8):672–8

A case of bronchopleural fistula detected by monitoring plasma endothelin-1. Yamashita J, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):56–7

Varicose vein stripping—a prospective study of the thrombotic risk and the diagnostic significance of preoperative color coded duplex sonography. Böhler K, et al. **Thromb Haemost** 1995 Apr;73(4):597–600

A comparison of direct, indirect, and fiberoptic laryngoscopy to evaluate vocal cord paralysis after thyroid surgery. Lacoste L, et al. **Thyroid** 1996 Feb;6(1):17–21

Detection of lipid peroxidation products by malondialdehyde (MDA–TBA reaction) in organ transplantation. Auer T, et al. **Transplant Proc** 1995 Oct;27(5):2749–51

Quantitative determination of urine proteins: a rapid, noninvasive, sensitive, and inexpensive method to monitor renal grafts. Hoyer J, et al. **Transplant Proc** 1995 Oct; 27(5):2571–2

Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser. McCoy EP, et al. **Ulster Med J** 1994 Apr;63(1):103–7

The ileal neobladder—updated experience with 306 patients. Flohr P, et al. **World J Urol** 1996;14(1):22–6

Crohn's disease presented by episiotomy dehiscence and perineal fistula. Matorras R, et al. **Zentralbl Gynakol** 1995; 117(9):491–3

Coecal volvulus following caesarean section. Rasmussen KL, et al. **Zentralbl Gynakol** 1995;117(9):498–9

[Endometriosis in the cicatrix after a cesarean section] Dzhodzheva D, et al. **Khirurgiia (Sofiia)** 1995;48(5):71–2 **(Bul)**

[The TUR syndrome] Glogov S. **Khirurgiia (Sofiia)** 1995; 48(5):66–70 (32 ref.) (Eng. Abstr.) **(Bul)**

[False signs of hypoxemia when using the dye Patent Blue V] Freudendal-Pedersen A, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):284–5 (Eng. Abstr.) **(Dan)**

[Diagnosis of secondary aortointestinal fistulae] Schantz V. **Ugeskr Laeger** 1996 Aug 19;158(34):4771–2 (Eng. Abstr.) **(Dan)**

[Complications after surgical treatment of malign thyroid diseases] Sørensen EW, et al. **Ugeskr Laeger** 1995 Oct 23; 157(43):5975–9 (Eng. Abstr.) **(Dan)**

[Surgical treatment of goiter at a central hospital. A consecutive study with special emphasis on surgical complications] Vestergaard EM, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5979–82 (Eng. Abstr.) **(Dan)**

–Possibilities and limits of imaging for evaluating breast implants– Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135–47 (31 ref.) **(Fre)**

[Prediction of respiratory complications after surgery of the abdominal aorta] Durand M, et al. **Can J Anaesth** 1995 Dec;42(12):1101–7 (Eng. Abstr.) **(Fre)**

[Thyrotoxic crisis—a difficult diagnosis in a polytrauma patient—a case report] Anwar N, et al. **Anaesthesiol Reanim** 1996;21(2):51–2 (Eng. Abstr.) **(Ger)**

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76–80 (24 ref.) (Eng. Abstr.) **(Ger)**

[Nuclear magnetic resonance tomography study of the position of the discus articularis after dislocation fractures] Eckelt U, et al. **Fortschr Kiefer Gesichtschir** 1996;41:115–7 (Eng. Abstr.) **(Ger)**

[Neurologic examinations for facial nerve damage in surgically treated mandibular collum fractures] Sader R, et al. **Fortschr Kiefer Gesichtschir** 1996;41:143–5 (Eng. Abstr.) **(Ger)**

[Differential diagnosis of rejection after kidney transplantation. Noninvasive rapid diagnosis by determining special urinary proteins] Steinhoff J. **Fortschr Med** 1995 Dec 20;113(35–36):507–9 (Eng. Abstr.) **(Ger)**

[Nail changes within the scope of reflex dystrophy] Studer EM, et al. **Hautarzt** 1996 Mar;47(3):206–8 (Eng. Abstr.) **(Ger)**

[Confocal in vivo microscopy after 15 mm sclerocorneoplasty à chaud in necrotizing keratitis] Slowik C, et al. **Klin Monatsbl Augenheilkd** 1996 Apr;208(4):246–50 (Eng. Abstr.) **(Ger)**

[Subjective and objective evaluation of the outcome of rhinoplasty. A retrospective study] Gräber I, et al. **Laryngorhinootologie** 1995 Aug;74(8):495–9 (Eng. Abstr.) **(Ger)**

[Lung scintigraphy and ergospirometry in prediction of postoperative course in lung resection candidates with increased risk of postoperative complications] Bolliger CT, et al. **Pneumologie** 1996 May;50(5):334–41 (Eng. Abstr.) **(Ger)**

[CT and MRI of small intestine interposition after oropharyngeal tumor resection] Našel C, et al. **Radiologe** 1996 Mar;36(3):217–20 (Eng. Abstr.) **(Ger)**

[Titanium aneurysm clips and their advantages in diagnostic imaging] Piepgras A, et al. **Radiologe** 1995 Nov; 35(11):830–3 (Eng. Abstr.) **(Ger)**

[Initial experiences with MR-mammography in after-care following surgical flap treatment of breast carcinoma] Kurtz B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):295–300 (Eng. Abstr.) **(Ger)**

[MR imaging of a patient positioning-induced compartment syndrome of both lower legs after surgery in dorsal surgical position] Rominger MB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):338–40 **(Ger)**

[Ultrasound and mammography follow-up of findings after breast saving operation and adjuvant irradiation] Mundinger A, et al. **Ultraschall Med** 1996 Feb;17(1):7–13 (Eng. Abstr.) **(Ger)**

[Nephrogenic adenoma after kidney transplantation] Colombo T, et al. **Urologe A** 1995 Nov;34(6):489–93 (Eng. Abstr.) **(Ger)**

[Differential diagnostic evaluation of a dysfunctional kidney transplant by magnetic resonance tomography] Sievers KW, et al. **Urologe A** 1995 Nov;34(6):475–9 (Eng. Abstr.) **(Ger)**

[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma–polyarthritis or bypass arthritis] Kanzler S, et al. **Z Gastroenterol** 1995 Aug;33(8):449–53 (Eng. Abstr.) **(Ger)**

[Single left coronary artery after orthotopic heart transplantation: angiography and intravascular ultrasound findings] Kerber S, et al. **Z Kardiol** 1995 Aug;84(8):616–20 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of "malnutrition" risk factors (editorial)] Müller JM. **Zentralbl Chir** 1995;120(9):667–9 **(Ger)**

[Symptoms of ovarian failure after hysterectomy in premenopausal women. A retrospective study based on postoperative perception of 245 women] Habelt K, et al. **Zentralbl Gynakol** 1996;118(4):206–12 (Eng. Abstr.) **(Ger)**

[Abdominal wall endometriosis imitating incisional hernia] Kaplan O, et al. **Harefuah** 1995 Sep;129(5–6):182–3, 223 (Eng. Abstr.) **(Heb)**

[Magnetic resonance imaging in assessing the complications of cardiac surgery involving the ascending aorta] Fedriga E, et al. **Radiol Med (Torino)** 1995 Sep;90(3):238–43 (Eng. Abstr.) **(Ita)**

[The role of magnetic resonance angiography in the assessment of arterial stenosis in the transplanted kidney] Grazioli L, et al. **Radiol Med (Torino)** 1996 Jan–Feb; 91(1–2):101–6 (Eng. Abstr.) **(Ita)**

[Serum cardiac troponin-T in coronary artery bypass graft and mitral valve replacement] Hara K, et al. **Masui** 1995 Oct;44(10):1334–8 (Eng. Abstr.) **(Jpn)**

[Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation] Ostgaard G. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):57–60 (43 ref.) (Eng. Abstr.) **(Nor)**

[The loss of a right muscle in the orbit intra- or postoperatively] Voinea L, et al. **Oftalmologia** 1996 Apr–Jun;40(2):120–4 (Eng. Abstr.) **(Rum)**

[The diagnosis and prevention of hemostatic system disorders in the surgical treatment of patients with cancer of the large intestine] Elizarova AL, et al. **Klin Lab Diagn** 1995 Nov–Dec;(6):91–3 (Eng. Abstr.) **(Rus)**

[The cytology of the urinary sediment in the differential diagnosis of the complications in patients with kidney allografts] Bogdanova NB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):13–7 (Eng. Abstr.) **(Rus)**

[The diagnosis and surgical treatment of suppurative-inflammatory lesions of the rib cage] Bagirov MM, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):344–7 **(Rus)**

[THe diagnostic and treatment characteristics of strangulated postoperative hernias] Barkov AA, et al. **Vestn Khir Im I I Grek** 1995;154(2):37–9 (Eng. Abstr.) **(Rus)**

[Anastomositis after gastric resection and its treatment] Godlevskiĭ AI, et al. **Vestn Khir Im I I Grek** 1995; 154(2):110–1 **(Rus)**

[Imaging of the transplanted liver] Weili FS, et al. **Bratisl Lek Listy** 1996 Apr;97(4):208–15 (Eng. Abstr.) **(Slo)**

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

[Pulmonary infiltrates and respiratory failure in a heart transplant patient with a primary cytomegalovirus infection (clinical conference)] Fortún J, et al. **Rev Clin Esp** 1995 Sep;195(9):649–56 **(Spa)**

[Routine cystoscopy after Burch cystoplasty in incontinence? (letter)] Virtanen HS. **Lakartidningen** 1995 Oct 18; 92(42):3868–9 **(Swe)**

DIET THERAPY

Effect of mild dietary protein restriction on urinary protein excretion in patients with renal transplant fibrosis. Biesenbach G, et al. **Wien Med Wochenschr** 1996; 146(4):75–8

DRUG THERAPY

Inotropic agents in the treatment of postoperative low cardiac output syndrome. Husedžinović I, et al. **Acta Med Croatica** 1995;49(4–5):201–5 (55 ref.)

Effects of intravenous nitroglycerin combined with dopamine on intracranial pressure and cerebral arteriovenous oxygen difference in patients with acute subarachnoid haemorrhage. Iwanaga H, et al. **Acta Neurochir (Wien)** 1995;136(3–4):175–80

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)

Fungal infection in surgical patients. Dean DA, et al. **Am J Surg** 1996 Mar;171(3):374–82 (100 ref.)

Use of growth hormone for postoperative respiratory failure. Knox JB, et al. **Am J Surg** 1996 Jun;171(6):576–80

The treatment of postoperative shivering [letter; comment] Crossley AW, et al. **Anaesthesia** 1995 Nov;50(11):1010–1. Comment on: Anaesthesia 1995 Mar;50(3):214–7.

Postoperative nausea and vomiting—the importance of power [letter; comment] Yentis SM. **Anaesthesia** 1995 Nov; 50(11):1007–8. Comment on: Anaesthesia 1995 Jul;50(7):654–6.

Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients. Bosek V, et al. **Ann Surg Oncol** 1996 Jan;3(1):62–6

Nitric oxide might reduce the need for extracorporeal support in children with critical postoperative pulmonary hypertension. Goldman AP, et al. **Ann Thorac Surg** 1996 Sep;62(3):750–5

Amiodarone for ventricular tachycardia after coronary artery bypass grafting [letter] [see comments] Terada Y, et al. **Ann Thorac Surg** 1995 Oct;60(4):1155. Comment in: Ann Thorac Surg 1996 Jun;61(6):1874.

Human chorionic gonadotropin adjuvant therapy for patients with Leydig cell dysfunction after varicocelectomy. Yamamoto M, et al. **Arch Androl** 1995 Jul–Aug;35(1):49–55

Using botulinum toxin A to improve speech and swallowing function following total laryngectomy. Crary MA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):760–3

Methylene blue fails to improve hypoxaemia post orthotopic liver transplantation (OLT) [letter] Thomson A, et al. **Aust N Z J Med** 1995 Jun;25(3):262

Aggressive treatment for postcardiac transplant lymphoproliferation. Swinnen LJ, et al. **Blood** 1995 Nov 1;86(9):3333–40

Cardiorespiratory effects of continuous i.v. administration of the ACE inhibitor enalaprilat in the critically ill. Boldt J, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):415–22

Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Yandel ML, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):261–3

Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344–64 (79 ref.)

Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Sclafani AP, et al. **Dermatol Surg** 1996 Jun;22(6):569–74

Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group. Bruch HP, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):203–7

Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131–56 (186 ref.)

Possibilities of scar treatment after thoracic surgery. Maragakis M, et al. **Drugs Exp Clin Res** 1995;21(5):199–206

Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. **Eur Heart J** 1995 Dec; 16(12):1825–32

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587–91

Phenylephrine and pilocarpine in the treatment of post-operative irido-corneal adhesion. Tabandeh H, et al. **Eye** 1995;9 (Pt 4):452–5

Enalaprilat controls postoperative hypertension while maintaining cardiac function and systemic oxygenation after neurosurgery. Tohmo H, et al. **Intensive Care Med** 1995 Aug;21(8):651–6

Transient effects of inhaled nitric oxide for prolonged postoperative treatment of hypoxemia after surgical correction of total anomalous pulmonary venous return. Morris GN, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):713–6

Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient. Anand BS, et al. **J Clin Gastroenterol** 1996 Mar;22(2):144–6

Cytomegalovirus antigenemia as a marker for antiviral therapy after heart transplantation [letter] Iberer F, et al.

J Heart Lung Transplant 1996 Mar;15(3):314–5

Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group. Mannes GP, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):781–4

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S246–9 (16 ref.)

The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. Sandoz/CVIS Investigators. Miller L, et al.
J Heart Lung Transplant 1995 Nov–Dec;14(6 Pt 2):S227–34

Cholesterol–lowering therapy after heart transplantation: a 12–month randomized trial. Pflugfelder PW, et al.
J Heart Lung Transplant 1995 Jul–Aug;14(4):613–22

A prospective randomized study to assess the efficacy of post–operative nasal medication after endonasal surgery. Spraggs PD, et al. **J Laryngol Otol** 1995 Jul;109(7):618–21

Neurosurgery in a patient with Creutzfeldt–Jakob disease after pituitary derived growth hormone therapy in childhood. Holmes SJ, et al.
J Neurol Neurosurg Psychiatry 1996 Mar;60(3):333–5

The treatment of endophthalmitis after cataract surgery: review of 26 cases. Parkkari M, et al.
J Ocul Pharmacol Ther 1995 Fall;11(3):349–59

Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. Cirisano FD, et al. **J Reprod Med** 1996 Mar; 41(3):191–4

Reproducibility of postoperative courses after surgical removal of symmetrically impacted wisdom teeth. Björnsson GA, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):345–56

Recovery of gastrointestinal motility from post–operative ileus in dogs: effects of Leu13–motilin (KW–5139) and prostaglandin F2 alpha. Yokoyama T, et al.
Neurogastroenterol Motil 1995 Dec;7(4):199–210

Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. MacCumber MW, et al. **Ophthalmology** 1996 Feb; 103(2):269–73

Management of postoperative Acremonium endophthalmitis. Weissgold DJ, et al. **Ophthalmology** 1996 May; 103(5):749–56

Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement. Colwell CW Jr. **Orthopedics** 1995 Jul;18 Suppl:21–3

Nicardipine: perioperative applications in children. Tobias JD, et al. **Paediatr Anaesth** 1995;5(3):171–6

Catheter–directed thrombolysis with recombinant tissue plasminogen activator for acute pulmonary embolism after fontan operation. Beitzke A, et al. **Pediatr Cardiol** 1996 Nov–Dec;17(6):410–2

Correction of post–renal transplant erythrocytosis by enalapril. Rostaing L, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):399–406

The morbidity of heparin therapy after development of pulmonary embolus in patients undergoing thoracolumbar or lumbar spinal fusion. Cain JE Jr, et al. **Spine** 1995 Jul 15;20(14):1600–3

Treatment of post–renal–transplant erythrosis: ACE inhibitors or theophylline? Ben Hmida M, et al.
Transplant Proc 1995 Oct;27(5):2720–1

Immunological controls of postoperative infections in colorectal tumours. Farina EC, et al. **Tumori** 1995 May–Jun;81(3 Suppl):84–8

[Fluoroquinolones in antimicrobial therapy and prophylaxis in surgery] Vyhnánek F, et al. **Rozhl Chir** 1995 Sep; 74(6):257–61 (Eng. Abstr.) **(Cze)**

[Enoximone—clinical experiences in heart surgery] Krüger AD, et al. **Anaesthesiol Reanim** 1996;21(3):60–8 (Eng. Abstr.) **(Ger)**

[Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation] Kuse ER, et al. **Anaesthesist** 1996 Apr;45(4):351–8 (Eng. Abstr.) **(Ger)**

[Prevention and treatment of postoperative nausea and vomiting with 5–HT3–receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200–4 (47 ref.) (Eng. Abstr.) **(Ger)**

[Does chronic oral treatment with beta–receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?] Günnicker M, et al. **Herz** 1995 Dec;20(6):399–411 (Eng. Abstr.) **(Ger)**

[Postoperative thrombolytic therapy] Kolben M, et al.
Internist (Berl) 1996 Jun;37(6):619–22 (27 ref.) **(Ger)**

[Postoperative intraocular pressure in the first days after intraocular administration of hyaluronic acid solution with different viscosities] Kohnen T, et al.
Klin Monatsbl Augenheilkd 1995 Jul;207(1):29–36 (Eng. Abstr.) **(Ger)**

[Wobenzyme and diuretic therapy in lymphedema after breast operation] Korpan MI, et al. **Wien Med Wochenschr** 1996; 146(4):67–72; discussion 74 (Eng. Abstr.) **(Ger)**

[Improvement of perioperative hemodynamics and gas exchange by inhalation of nitric oxide in children with congenital cardiopulmonary defects] Breuer J, et al.
Z Kardiol 1995 Dec;84(12):1009–17 (Eng. Abstr.) **(Ger)**

[Combination therapy with arbekacin and fosfomycin against postoperative severe mixed–pneumonia of MRSA in primary lung cancer patients] Harada R, et al.
Kyobu Geka 1995 Sep;48(10):836–40 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of congenital atypical coarctation of the aorta and postoperative management for hypertension] Ohno H, et al. **Kyobu Geka** 1995 Dec;48(13):1131–4 (Eng. Abstr.) **(Jpn)**

[Use of growth hormone during catabolic state in a patient in postoperative intensive care] Gjerde S, et al.
Tidsskr Nor Laegeforen 1995 Oct 10;115(24):3028–30 (Eng. Abstr.) **(Nor)**

[An assessment of the efficacy of Lomir in treating hypertension in patients in the early period after aortocoronary bypass operations] Tskhovrebov SV, et al.
Anesteziol Reanimatol 1996 Jan–Feb;(1):58–60 (Eng. Abstr.) **(Rus)**

[The mechanisms of the cytoprotective action of prostacyclin in acute postoperative parotitis] Dolgov SN, et al.
Stomatologiia (Mosk) 1995;74(2):46–7 (Eng. Abstr.) **(Rus)**

[Therapy of the fibrin reaction after intraocular surgery using fibrinolytic agents] Sisková E, et al. **Cesk Oftalmol** 1995 Sep;51(4):222–6 (Eng. Abstr.) **(Slo)**

[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al.
An Esp Pediatr 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995)] Gerardo Pérez D, et al.
G E N 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost containment: at what expense? [editorial; comment] Kapur PA. **Anesth Analg** 1995 Nov;81(5):897–9. Comment on: Anesth Analg 1995 Nov;81(5):939–44.

The retained surgical sponge. Kaiser CW, et al.
Ann Surg 1996 Jul;224(1):79–84

The additional hospital costs generated in the management of complications of pacemaker and defibrillator implantations. Ferguson TB Jr, et al.
J Thorac Cardiovasc Surg 1996 Apr; 111(4):742–51;discussion 751–2

The economics of revision arthroplasty. Barrack RL.
Orthopedics 1995 Sep;18(9):874–5

Potential for reduction in morbidity and cost with total leucocyte control for cardiac surgery. Ortolano GA.
Perfusion 1995 Sep;10(5):283–90

[Nosocomial infection in BPH: economic costs and increase in hospital stay] Fernández Arjona M, et al.
Actas Urol Esp 1996 Mar;20(3):269–73 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Peroperative and immediate postoperative adverse events in patients undergoing elective general and orthopaedic surgery. The Gothenburg study of perioperative risk (PROPER). Part II. Ouchterlony J, et al.
Acta Anaesthesiol Scand 1995 Jul;39(5):643–52

Complications after elective gastric resection for duodenal ulcer. Multivariate analysis of risk factors. Lorusso D, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):247–50

Decreased incidence of postoperative pericardial effusions after cardiac surgery for congenital heart disease. Prabhu AS, et al. **Am J Cardiol** 1996 Apr 1;77(9):774–6

Effects of sacrocolposuspension on the lower urinary tract. Varner RE, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1684–8; discussion 1688–9

The Mersilene mesh suburethral sling: a clinical and urodynamic evaluation. Young SB, et al.
Am J Obstet Gynecol 1995 Dec;173(6):1719–25; discussion 1725–6

Total hip arthroplasty: use and select complications in the US Medicare population. Baron JA, et al.
Am J Public Health 1996 Jan;86(1):70–2

Increased incidence of nosocomial infections in obese surgical patients. Choban PS, et al. **Am Surg** 1995 Nov; 61(11):1001–5

Early complications and long–term survival in severely obese coronary bypass patients. Rohs T Jr, et al. **Am Surg** 1995 Nov;61(11):949–53

Acute cholecystitis in diabetic patients. Shpitz B, et al.
Am Surg 1995 Nov;61(11):964–7

Incidence and risk factors for early small bowel obstruction after celiotomy for penetrating abdominal trauma. Tortella BJ, et al. **Am Surg** 1995 Nov;61(11):956–8

Vocal fold paralysis following the anterior approach to the cervical spine. Netterville JL, et al.
Ann Otol Rhinol Laryngol 1996 Feb;105(2):85–91

Dysphagia after laparoscopic antireflux surgery. The impact of operative technique. Hunter JG, et al. **Ann Surg** 1996 Jul;224(1):51–7

A prospective study of laparoscopic spinal fusion. Technique and operative complications. Mahvi DM, et al.
Ann Surg 1996 Jul;224(1):85–90

The Spanish Monostrut Study Group: a ten–year experience with 8,599 implants. Aris A, et al. **Ann Thorac Surg** 1996 Jul;62(1):40–7

Complications of thoracoscopy. Krasna MJ, et al.
Ann Thorac Surg 1996 Apr;61(4):1066–9

Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Koshy M, et al. **Blood** 1995 Nov 15;86(10):3676–84

Standard orthotopic heart transplantation versus total orthotopic heart transplantation. A transesophageal echocardiography study of the incidence of left atrial thrombosis. Derumeaux G, et al. **Circulation** 1995 Nov 1; 92(9 Suppl):II196–201

Mediastinitis after coronary artery bypass graft surgery. Risk factors and long–term survival. Milano CA, et al.
Circulation 1995 Oct 15;92(8):2245–51 (18 ref.)

Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low–flow cardiopulmonary bypass and circulatory arrest. Wernovsky G, et al. **Circulation** 1995 Oct 15;92(8):2226–35

Factors predisposing to post–renal transplant erythrocytosis. A prospective matched–pair control study. Kessler M, et al. **Clin Nephrol** 1996 Feb;45(2):83–9

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Riggio O, et al. **Dig Dis Sci** 1996 Mar;41(3):578–84

Dynamic graciloplasty. Complications and management. Geerdes BP, et al. **Dis Colon Rectum** 1996 Aug;39(8):912–7

Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working Group on Arrhythmias of the European Society of Cardiology. Hindricks G. **Eur Heart J** 1996 Jan; 17(1):82–8

Management of the isolated congenital tracheo–oesophageal fistula. Crabbe DC, et al. **Eur J Pediatr Surg** 1996 Apr; 6(2):67–9

Long–term functional results and quality of life after colon interposition for long–gap oesophageal atresia. Ure BM, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):206–10

Surgical mortality and morbidity in malignant obstructive jaundice: a prospective multivariate analysis. Lacaine F, et al. **Eur J Surg** 1995 Oct;161(10):729–34

Secondary aortoenteric fistulae—changes from 1973 to 1993. Bergqvist D, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):425–8

Incidence and clinical presentation of bowel ischaemia after aortoiliac surgery—2930 operations from a population–based registry in Sweden. Björck M, et al.
Eur J Vasc Endovasc Surg 1996 Aug;12(2):139–44

Outcome of selective patching following carotid endarterectomy. Golledge J, et al.
Eur J Vasc Endovasc Surg 1996 May;11(4):458–63

Incisional hernias are more common in aneurysmal arterial disease. Holland AJ, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):196–200

Anastomotic femoral aneurysms: increase in interval between primary operation and aneurysm formation. Levi N, et al.
Eur J Vasc Endovasc Surg 1996 Feb;11(2):207–9

Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Rahr HB, et al. **Haemostasis** 1995 Sep–Oct; 25(5):248–56

Using physician claims to identify postoperative complications of carotid endarterectomy. Mitchell JB, et al. **Health Serv Res** 1996 Jun;31(2):141–52

Recurrence and soiling after surgery for anal fistulae [letter; comment] Pescatori M. **Int J Colorectal Dis** 1995;10(4):235 . Comment on: Int J Colorectal Dis 1995;10(2):94–6.

Improved early morbidity and mortality after Fontan operation: the Mayo Clinic experience, 1987 to 1992. Cetta F, et al. **J Am Coll Cardiol** 1996 Aug;28(2):480–6

Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates [see comments] L'Italien GJ, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):779–86. Comment in: J Am Coll Cardiol 1996 Mar 15;27(4):799–802.

Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. Lawrence VA, et al. **J Gen Intern Med** 1995 Dec;10(12):671–8

Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study. Smart FW, et al. **J Heart Lung Transplant** 1996 Apr;15(4):329–41

Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. Chozick BS, et al.
J Neurosurg 1996 Mar;84(3):382–6

Femoral lengthening using the callotasis method: study of the complications in a series of 70 cases in children and adolescents. Glorion C, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):161–7

Results of tibial lengthening with the Ilizarov technique. Stanitski DF, et al. **J Pediatr Orthop** 1996 Mar–Apr; 16(2):168–72

Stapler design and strictures at the esophagogastric anastomosis. Berrisford RG, et al.
J Thorac Cardiovasc Surg 1996 Jan;111(1):142–6

Risk factors for postoperative morbidity. Ferraris VA, et al.
J Thorac Cardiovasc Surg 1996 Apr; 111(4):731–38;discussion 738–41

Urological problems after surgical treatment of scoliosis in children with myelomeningocele. Boemers TM, et al.
J Urol 1996 Mar;155(3):1066–9

The ileal neobladder in women: 9 years of experience with 18 patients. Hautmann RE, et al. **J Urol** 1996 Jan; 155(1):76–81

Contralateral reflux after unilateral ureteral reimplantation. Hoenig DM, et al. **J Urol** 1996 Jul;156(1):196–7

Influence of patient-related variables on the outcome of carotid endarterectomy. Golledge J, et al. **J Vasc Surg** 1996 Jul;24(1):120–6

Compression of the descending duodenum after reconstruction of infrarenal aortic aneurysm [letter] Rijken AM, et al. **J Vasc Surg** 1996 Jul;24(1):178–9

The relationship between coronary angioplasty procedure volume and major complications [see comments] Kimmel SE, et al. **JAMA** 1995 Oct 11;274(14):1137–42. Comment in: JAMA 1995 Oct 11;274(14):1169–70. Comment in: JAMA 1996 Feb 28;275(8):595; discussion 596. Comment in: JAMA 1996 Feb 28;275(8):595–6.

Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. Wen SW, et al. **JAMA** 1995 Dec 6;274(21):1687–91

Complications of endoscopic sinus surgery in a residency training program. Kinsella JB, et al. **Laryngoscope** 1995 Oct;105(10):1029–32

Comorbidity-adjusted complication risk: a new outcome quality measure. Brailer DJ, et al. **Med Care** 1996 May; 34(5):490–505

The incidence of deep venous thrombosis after laparoscopic cholecystectomy [see comments] Patel MI, et al. **Med J Aust** 1996 Jun 3;164(11):652–4, 656. Comment in: Med J Aust 1996 Jun 3;164(11):646–7.

Fungaemia in hospitalized patients. Perduca M, et al. **Mycoses** 1995 Sep–Oct;38(9–10):385–7

Conservative versus aggressive transfusion regimens in sickle cell disease [letter] Apfelroth S. **N Engl J Med** 1995 Dec 14;333(24):1641–2

Postoperative catheterization, urinary retention, and permanent voiding dysfunction after polytetrafluroethylene suburethral sling placement. Weinberger MW, et al. **Obstet Gynecol** 1996 Jan;87(1):50–4

Early complications of abdominal and vaginal hysterectomy. Harris WJ. **Obstet Gynecol Surv** 1995 Nov;50(11):795–805 (65 ref.)

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

Increased rate of hysterectomy in women undergoing surgery for osteoarthritis of the knee. Inoue K, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):205–9

Stoma recurrence after laryngectomy: an analysis of risk factors. Zbären P, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):569–75

Postoperative nausea and vomiting in paediatric surgical inpatients. Byers GF, et al. **Paediatr Anaesth** 1995; 5(4):253–6

Comparison of 25 G and 29 G Quincke spinal needles in paediatric day case surgery. A prospective randomized study of the puncture characteristics, success rate and postoperative complaints. Kokki H, et al. **Paediatr Anaesth** 1996;6(2):115–9

Bone fractures in children undergoing orthotopic liver transplantation. Hill SA, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S112–7

Biliary complications in one hundred adult liver transplantations. Koivusalo A, et al. **Scand J Gastroenterol** 1996 May;31(5):506–11

The morbidity of heparin therapy after development of pulmonary embolus in patients undergoing thoracolumbar or lumbar spinal fusion. Cain JE Jr, et al. **Spine** 1995 Jul 15;20(14):1600–3

Laparoscopic cholecystectomy. Intraoperative findings and postoperative complications. Bonatsos G, et al. **Surg Endosc** 1995 Aug;9(8):889–93

Laparoscopic choleocystostomy with delayed cholecystectomy as an alternative to conversion to open procedure. Kuster GG, et al. **Surg Endosc** 1996 Apr; 10(4):426–8

Laparoscopic cholecystectomy in cirrhotic patients. D'Albuquerque LA, et al. **Surg Laparosc Endosc** 1995 Aug; 5(4):272–6

Prospective analysis of perioperative morbidity in one hundred consecutive colectomies for ulcerative colitis. Hurst RD, et al. **Surgery** 1995 Oct;118(4):748–54; discussion 754–5

Relevance of bacterial cultures of abdominal aortic aneurysm contents. van der Vliet JA, et al. **Surgery** 1996 Feb; 119(2):129–32

Distribution and occlusiveness of thrombi in patients with surveillance detected deep vein thrombosis after hip surgery. Ascani A, et al. **Thromb Haemost** 1996 Feb; 75(2):239–41

Cutaneous manifestations in renal transplant patients. Amiransari B, et al. **Transplant Proc** 1995 Oct;27(5):2734

Early operative morbidity and mortality in 1051 consecutive kidney transplants over 20 years at our centers. Arslan G, et al. **Transplant Proc** 1996 Aug;28(4):2311

Increased late rejection in cytomegalovirus-immunoglobulin-M-positive heart transplantation patients. Bunke M, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):44–5

Vascular complications following 200 liver transplants. Datsis K, et al. **Transplant Proc** 1995 Oct;27(5):2607

Recurrent cytomegalovirus disease in solid-organ transplant recipients. Falagas ME, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):34–7 (23 ref.)

The impact of hepatic function on infection following liver transplantation. Golling M, et al. **Transplant Proc** 1995 Oct; 27(5):2608–9

Influence of HLA mismatching on the incidence of cytomegalovirus infection in living-related renal transplantations. Haberal M, et al. **Transplant Proc** 1995 Oct;27(5):2687–90

Surgical complications in kidney transplantation: experience from 1200 transplants performed over 20 years at six hospitals in central Japan. Hashimoto Y, et al. **Transplant Proc** 1996 Jun;28(3):1465–7

CNS infections in renal transplant recipients. Hashmi A, et al. **Transplant Proc** 1995 Oct;27(5):2735

Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Ho M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):38–40 (36 ref.)

Erythrocytosis in renal transplant recipients. Hussain Z, et al. **Transplant Proc** 1995 Oct;27(5):2736

Infectious complications in the first 100 days after renal transplantation. Kumar MS, et al. **Transplant Proc** 1995 Oct;27(5):2705–6

Quality of life after renal transplantation. Lee HM. **Transplant Proc** 1996 Jun;28(3):1171

Urinary tract infection vs renal allograft rejection. Mehraban D, et al. **Transplant Proc** 1995 Oct;27(5):2712–4

High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression. Sakhuja V, et al. **Transplant Proc** 1995 Oct;27(5):2728–30

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

Gastrointestinal complications in renal transplantation. Tokat Y, et al. **Transplant Proc** 1996 Aug;28(4):2351–2

Musculoskeletal problems after kidney transplantation. Tuncay IC, et al. **Transplant Proc** 1995 Oct;27(5):2581–2

Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder. Walker RC. **Transplant Proc** 1995 Oct;27(5 Suppl 1):41

Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Stegall MD, et al. **Transplantation** 1995 Nov 15;60(9):1057–60

Urethral obstruction after anti-incontinence surgery in women: evaluation, methodology, and surgical results. Austin P, et al. **Urology** 1996 Jun;47(6):890–4

[The postoperative complications and risk factors in heart operations with extracorporeal circulation] Kozhukharov B, et al. **Khirurgiia (Soflia)** 1995;48(1):23–9 (Eng. Abstr.) **(Bul)**

[Urethral strictures following transurethral resection of the prostate] Neĭkov K, et al. **Khirurgiia (Sofiia)** 1994; 47(3):19–21 (Eng. Abstr.) **(Bul)**

[Late symptoms among patients surgically treated for breast cancer. A questionnaire in the county of Southern Jutland] Husted H, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6868–72 (Eng. Abstr.) **(Dan)**

[Registration of postoperative complications to improve the results of surgery] Roukema JA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):781–4 (Eng. Abstr.) **(Dut)**

[Morbidity and mortality after elective surgery of complicated aneurysms] Lacroix H, et al. **J Mal Vasc** 1996; 21 Suppl A:63–7 (Eng. Abstr.) **(Fre)**

[The risks of percutaneous endoscopic gastrostomy] Gossner L, et al. **Dtsch Med Wochenschr** 1995 Dec 22; 120(51–52):1768–72 (Eng. Abstr.) **(Ger)**

[Transplant reaction after keratoplasty for keratoconus. Frequency and risk factors] Schönherr U, et al. **Ophthalmologe** 1996 Jun;93(3):227–31 (Eng. Abstr.) **(Ger)**

[Retrospective study of postoperative infectious morbidity following cesarean section] Di Lieto A, et al. **Minerva Ginecol** 1996 Mar;48(3):85–92 (45 ref.) (Eng. Abstr.) **(Ita)**

[Postoperative nausea, vomiting and pain in laparoscopic cholecystectomy: a comparison with minilaparotomy-cholecystectomy] Kobayashi N, et al. **Masui** 1996 Apr;45(4):474–8 (Eng. Abstr.) **(Jpn)**

[Incidence and prevention of cerebrovascular complications in thoracic aortic aneurysm surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):744–6 **(Jpn)**

[Neurological complications in coronary surgery in patients who have previously undergone carotid endarterectomy] Cardoso P, et al. **Rev Port Cardiol** 1995 Nov;14(11):869–72 **(Por)**

[Isolated disease of the descending anterior artery: the relationship between the angiographic characteristics and the occurrence of angina after myocardial revascularization] Patrício L, et al. **Rev Port Cardiol** 1995 Nov;14(11):881–4 **(Por)**

[Postoperative complications and mortality in abdominal aortic aneurysm surgery] Figueira A, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):412–6 (Eng. Abstr.) **(Spa)**

[Identification of patients with a high risk of needing prolonged mechanical ventilation after coronary surgery] León-Vallés M, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):82–8 (Eng. Abstr.) **(Spa)**

[Peptic ulcer: late complications of the surgical treatment] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):273–81 (109 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Small bowel obstruction after laparoscopic inguinal hernia repair: a case report. Vanclooster P, et al. **Acta Chir Belg** 1995;95(4 Suppl):199–200

The results and failures of creating a pelvic reservoir in oncology (surgery, urology). Baradnay G, et al. **Acta Chir Hung** 1995–96;35(1–2):119–27

Current thoughts on penile prosthetic surgery. Pryor JP. **Acta Chir Hung** 1995–96;35(1–2):129–35 (4 ref.)

Tuberculous pleural effusion following coronary artery bypass graft. Meysman M, et al. **Acta Clin Belg** 1995; 50(5):305–9

Laparoscopic cholecystectomy: a multicenter study of 17 hospitals. Tsuge H, et al. **Acta Med Okayama** 1995 Dec; 49(6):301–8

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119–31 (46 ref.)

The transzygomatic approach: a long-term clinical review. Honeybul S, et al. **Acta Neurochir (Wien)** 1995; 136(3–4):111–6

Factors influencing the outcome of operative treatment for lumbar spinal stenosis. Lehto MU, et al. **Acta Neurochir (Wien)** 1995;137(1–2):25–8

Tension pneumocephalus after transsphenoidal surgery: two case reports. Yüceer N, et al. **Acta Neurochir (Wien)** 1995; 137(1–2):58–61

Occipito-cervical fixation in rheumatoid arthritis--an analysis of surgical risk factors in 163 patients. Zygmunt SC, et al. **Acta Neurochir (Wien)** 1995;135(1–2):25–31

Latest advances in epilepsy surgery. Silfvenius H. **Acta Neurol Scand Suppl** 1995;162:11–6 (32 ref.)

Sonographic assessment of the vaginal vault following hysterectomy [letter; comment] Neri A, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):192–3. Comment on: Acta Obstet Gynecol Scand 1995 Mar;74(3):220–3.

High complication rates with pelvic allografts. Experience of 22 sarcoma resections. Ozaki T, et al. **Acta Orthop Scand** 1996 Aug;67(4):333–8

The risk of vestibular function loss after intracochlear implantation. Huygen PL, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:270–2

Mucous cyst: postrhinoplasty complication. Flaherty G, et al. **Aesthetic Plast Surg** 1996 Winter;20(1):29–31

The incidence of complications after caesarean section in 156 HIV-positive women. Semprini AE, et al. **AIDS** 1995 Aug; 9(8):913–7

Accessory hepatic vein to pulmonary venous atrium as a cause of cyanosis after the Fontan operation. Fernandez-Martorell P, et al. **Am J Cardiol** 1996 Jun 15; 77(15):1386–7

Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Gelb AB, et al. **Am J Clin Pathol** 1996 Jul; 106(1):87–99

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254–8 (23 ref.)

Infections linked to lax handling of propofol [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2061, 2066

Teflon granuloma presenting as an enlarging, gadolinium enhancing, posterior fossa mass with progressive hearing loss following microvascular decompression. Megerian CA, et al. **Am J Otol** 1995 Nov;16(6):783–6

Herniation of the temporomandibular joint into the external auditory canal: a complication of otologic surgery. Selesnick SH, et al. **Am J Otol** 1995 Nov;16(6):751–7

New-onset auditory hallucinations after right temporal lobectomy [letter] Bremer J. **Am J Psychiatry** 1996 Mar; 153(3):442–3

Effect of anesthetic technique on cardiac morbidity following carotid artery surgery. Ombrellaro MP, et al. **Am J Surg** 1996 Apr;171(4):387–90

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Testicular atrophy and neuropathy in herniorrhaphy. Skandalakis JE, et al. **Am Surg** 1996 Sep;62(9):775–82

Hyponatraemia in the transurethral resection of prostate syndrome. Dixon B, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):102–3

Postoperative laryngeal competence. The laryngeal mask airway and tracheal tube compared. Stanley GD, et al. **Anaesthesia** 1995 Nov;50(11):985–6

Gastropleural fistula: an unusual cause of intractable postoperative nausea and vomiting. Biswas IH, et al. **Anesth Analg** 1996 Jul;83(1):186–8

Postoperative onset of idiopathic brachial neuritis. Fibuch EE, et al. **Anesthesiology** 1996 Feb;84(2):455–8

Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. Haering JM, et al. **Anesthesiology** 1996 Aug;85(2):254–9

Pediatric caudal epidural catheter sequestration: an unusual complication. Lenox WC, et al. **Anesthesiology** 1995 Nov; 83(5):1112–4

Role of epidural anesthesia and analgesia on postoperative patient outcome [letter; comment] Leung JM. **Anesthesiology** 1995 Nov;83(5):1132. Comment on: Anesthesiology 1995 Jun;82(6):1474–506.

Lumbar stenosis complicating retained epidural catheter tip. Staats PS, et al. **Anesthesiology** 1995 Nov;83(5):1115–8

Tourniquet paralysis in microsurgery. Landi A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):89–93

Oesophageal atresia--need for life-long follow-up? Lindahl H. **Ann Chir Gynaecol** 1995;84(2):235–9 (27 ref.)

Delayed and progressive hearing loss after microvascular decompression of cranial nerves. Fuse T, et al. **Ann Otol Rhinol Laryngol** 1996 Feb;105(2):158–61

Pneumolabyrinth as a computed tomographic finding in poststapedectomy vertigo. Isaacson JE, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):974–6

Complications of 50 consecutive limited wrist fusions by a single surgeon. Brown RE, et al. **Ann Plast Surg** 1995 Jul; 35(1):46–53

Tissue expanders and magnetic resonance imaging: the "hot" breast implant. Duffy FJ Jr, et al. **Ann Plast Surg** 1995 Dec;35(6):647–9

Foreign material in postoperative adhesions. Luijendijk RW, et al. **Ann Surg** 1996 Mar;223(3):242–8

Complications and outcome of external hemipelvectomy in the management of pelvic tumors. Apffelstaedt JP, et al. **Ann Surg Oncol** 1996 May;3(3):304–9

Vascular complications of lung transplantation. Clark SC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1079–82 (7 ref.)

Irreversible tetraplegia after tracheal resection. Dominguez J, et al. **Ann Thorac Surg** 1996 Jul;62(1):278–80

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Coronary–pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264–5 (7 ref.)

Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241–2 (11 ref.)

Complications and failures of video–assisted thoracic surgery: experience from two centers in Asia. Yim AP, et al. **Ann Thorac Surg** 1996 Feb;61(2):538–41

Complications of laparoscopic cholecystectomy. Jones DB, et al. **Annu Rev Med** 1996;47:31–44 (45 ref.)

Self–induced bacteremia. Case report. Kristensen B, et al. **APMIS** 1995 Jun;103(6):475–6

Laser 'miniconisation' and the outcome of subsequent pregnancy. Békássy Z, et al. **Arch Gynecol Obstet** 1996; 258(2):75–9

Pregnancy and corneal allograft rejection [letter] Fulton JC, et al. **Arch Ophthalmol** 1996 Jun;114(6):765

Overcorrection after excimer laser treatment of myopia and myopic astigmatism. Melbourne Excimer Laser Group [see comments] Vajpayee RB, et al. **Arch Ophthalmol** 1996 Mar; 114(3):252–6. Comment in: Arch Ophthalmol 1996 Mar;114(3):338–9.

Fluticasone propionate is associated with severe infection after endoscopic polypectomy. Mostafa BE. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):729–31

Long–term peritoneal dialysis before transplantation and intra–abdominal infection after simultaneous pancreas–kidney transplantations. Papalois BE, et al. **Arch Surg** 1996 Jul;131(7):761–6

Neurological complications of ankle arthroscopy. Ferkel RD, et al. **Arthroscopy** 1996 Apr;12(2):200–8

Dermatitis complicating saphenous nerve injury after arthroscopic debridement of a medial meniscal cyst. Logue EJ 3rd, et al. **Arthroscopy** 1996 Apr;12(2):228–31

Kinking of the liver segment displaced after right hepatic lobectomy: an unusual cause of icterus. Nakashima K, et al. **Aust N Z J Surg** 1996 Feb;66(2):126–7

Postoperative pulmonary complications. Obesity, pain, and sedation are important [letter; comment] Higgs A. **BMJ** 1996 May 4;312(7039):1159; discussion 1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

Perioperative myocardial infarction in peripheral vascular surgery. Mamode N, et al. **BMJ** 1996 Jun 1; 312(7043):1396–7

Post traumatic stress disorders [letter] Cundy JM. **Br J Anaesth** 1995 Oct;75(4):501–2

Prediction of postoperative nausea and vomiting using a logistic regression model. Toner CC, et al. **Br J Anaesth** 1996 Mar;76(3):347–51

Midline approach to aneurysms: an unusual complication [letter; comment] Abduljabbar T. **Br J Neurosurg** 1995; 9(4):565. Comment on: Br J Neurosurg 1993;7(1):5–12.

Medulloblastoma: factors influencing the educational potential of surviving children. Kimmings E, et al. **Br J Neurosurg** 1995;9(5):611–7

Bacterial endophthalmitis after anterior chamber paracentesis [letter] Helbig H, et al. **Br J Ophthalmol** 1995 Sep;79(9):866

Effect of squint surgery on pupillary diameter. James CB, et al. **Br J Ophthalmol** 1995 Nov;79(11):991–2

Compartment haematoma complicating closed fasciotomy. Hirshberg A, et al. **Br J Surg** 1996 Jul;83(7):950

Audit of outcome of major surgery in the elderly. Walsh TH. **Br J Surg** 1996 Jan;83(1):92–7

Osteomyelitis complicating Burch colposuspension. Hall J, et al. **Br J Urol** 1996 Mar;77(3):470–1

Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction [see comments] Hasan ST, et al. **Br J Urol** 1995 Nov;76(5):551–7. Comment in: Br J Urol 1996 May;77(5):764–5.

Interstitial ureteritis following cystectomy for interstitial cystitis. Smith GL, et al. **Br J Urol** 1996 Apr;77(4):607–8

Dismembered pyeloplasty in infants under the age of 12 months. Woo HH, et al. **Br J Urol** 1996 Mar;77(3):449–51

Paraplegia following surgical correction of scoliosis with Cotrel–Dubousset instrumentation. Bar–On Z, et al. **Bull Hosp Jt Dis** 1995;54(1):32–4

Diplopia as an uncommon complication of cataract surgery. D'Haens M, et al. **Bull Soc Belge Ophtalmol** 1995;257:43–8

Central retinal artery occlusion after back surgery: a case report. Mertens E, et al. **Bull Soc Belge Ophtalmol** 1995; 255:127–31

A comparison of percutaneous and operative tracheostomies in intensive care patients. Crofts SL, et al. **Can J Anaesth** 1995 Sep;42(9):775–9

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Medial rectus muscle weakness imitating a slipped muscle following medial optic nerve sheath decompression. Ing EB, et al. **Can J Ophthalmol** 1995 Aug;30(5):259–62

Cerebrospinal fluid shunt infections in infants. Dallacasa P, et al. **Childs Nerv Syst** 1995 Nov;11(11):643–8; discussion 649

Intermittent warm blood cardioplegia. Warm Heart Investigators. Lichtenstein SV, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II341–6

Bacteroides fragilis arthritis following cesarean section. Failla DM, et al. **Clin Infect Dis** 1995 Nov;21(5):1341–2

Penicillin–resistant Streptococcus pneumoniae as a cause of postoperative endophthalmitis. Martin E, et al. **Clin Infect Dis** 1995 Nov;21(5):1340–1

Severe hypertriglyceridemia post–renal graft: is there a relationship with infection by cytomegalovirus? [letter] Adeva M, et al. **Clin Nephrol** 1996 Feb;45(2):137–8

Occurrence of cancers in immunosuppressed organ transplant recipients. Penn I. **Clin Transpl** 1994;:99–109

Urologic complications after simultaneous pancreas–kidney transplantation: hand–sewn versus stapled duodenocystostomy. Douzdjian V, et al. **Clin Transplant** 1995 Oct;9(5):396–400

Origin of atypical reflux symptoms. A case study showing the importance of reflux composition and posture. Shay SS, et al. **Dig Dis Sci** 1996 Mar;41(3):505–11

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301–4 (14 ref.)

Constipation after dynamic graciloplasty [letter] Geerdes BP, et al. **Dis Colon Rectum** 1996 Aug;39(8):943

Surgical therapy for obesity can induce a vitamin A deficiency syndrome. Anastasi M, et al. **Doc Ophthalmol** 1995;90(2):143–55

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Choking spells following septorhinoplasty secondary to displaced nasal packing. Yanagisawa E, et al. **Ear Nose Throat J** 1995 Nov;74(11):744–6

Pattern of postoperative pyrexia in Khartoum. Fadl Alla AI, et al. **East Afr Med J** 1996 Jan;73(1):78–80

Cystic duct remnant duodenal fistulization as a cause of misconceived endoscopic sphincterotomy and the consequent massive bleeding. Flis V, et al. **Endoscopy** 1995 Aug;27(6):465

Delayed complications thirty–six years after hemispherectomy: a case report. Kalkanis SN, et al. **Epilepsia** 1996 Aug;37(8):758–62

Arrhythmia catheter ablation: new prospects [editorial; comment] Mary–Rabine L. **Eur Heart J** 1995 Jul; 16(7):875–6. Comment on: Eur Heart J 1995 Jul;16(7):961–6.

Nausea and vomiting after laparoscopic surgery: a comparison of propofol and thiopentone/halothane anaesthesia. Klockgether–Radke A, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):3–9

Respiratory complications after surgical treatment of esophageal cancer. A study of 309 patients according to the type of resection. Dumont P, et al. **Eur J Cardiothorac Surg** 1995;9(10):539–43

Sternotomy infection due to Mycoplasma hominis and Ureaplasma urealyticum. Pigrau C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):597–8

Adult patients with a short bowel due to Crohn's disease often start with a short normal bowel. Nightingale JM, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):989–91

Dumping syndrome in a young child. de Vries TW, et al. **Eur J Pediatr** 1995 Aug;154(8):624–6

Influence of abdominal incision on the formation of postoperative peritoneal adhesions: an experimental study in rats. Moreno A, et al. **Eur J Surg** 1996 Mar;162(3):181–5

Aortofemoral surgery and sexual function. Cormio L, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):453–7

Lymph drainage and the development of post–reconstructive leg oedema is not influenced by the type of inguinal incision. A prospective randomised study in patients undergoing femoropopliteal bypass surgery. Haaverstad R, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):316–22

Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)

Central retinal artery occlusion after spinal surgery. Sys J, et al. **Eur Spine J** 1996;5(1):74–5

Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852–9

Malignant tumor developed in colon–esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):797–9 (19 ref.)

Interruption of hepatic arterial blood flow after resection of pancreaticobiliary carcinoma. Tsuge H, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):966–74

Severe intravascular haemolysis following coil occlusion of patent ductus arteriosus. Kapoor A, et al. **Indian Heart J** 1996 Mar–Apr;48(2):173–4

Complications of cataract surgery. Reddy MK. **Indian J Ophthalmol** 1995 Dec;43(4):201–9

Factors related to the occurrence of postoperative complications following penetrating gastric injuries. Coimbra R, et al. **Injury** 1995 Sep;26(7):463–6

Iatrogenic pectus carinatum. A case report. Haje SA. **Int Orthop** 1995;19(6):370–3

Primary hyperaldosteronism. Analysis of risk factors associated with persistent postoperative hypertension. Fronticelli CM, et al. **Int Surg** 1995 Apr–Jun;80(2):175–7

Cholecystectomy: comparison of minilaparotomy and laparoscopy. Mäkinen AM, et al. **Int Surg** 1995 Apr–Jun; 80(2):99–101

Laparoscopic cholecystectomy: the Dammam Central Hospital experience. Meshikhes AW, et al. **Int Surg** 1995 Apr–Jun;80(2):102–4

Predicting infection in critically ill surgical patients: usefulness of bacteriuria [letter; comment] Bensousan TA, et al. **Intensive Care Med** 1995 Jul;21(7):621–2. Comment on: Intensive Care Med 1994 Jul;20(6):425–30.

Increased oxygen consumption after cardiac surgery is associated with the inflammatory response to endotoxemia. Oudemans–van Straaten HM, et al. **Intensive Care Med** 1996 Apr;22(4):294–300

The effect of ward design on the well–being of post–operative patients. Pattison HM, et al. **J Adv Nurs** 1996 Apr;23(4):820–6

Early changes in ventricular septal defect size and ventricular geometry in the single left ventricle after volume–unloading surgery. Donofrio MT, et al. **J Am Coll Cardiol** 1995 Oct;26(4):1008–15

Intrahepatic bile duct stenosis causing intrahepatic calculi formation following excision of a choledochal cyst. Ando H, et al. **J Am Coll Surg** 1996 Jul;183(1):56–60

Epidemiology of anemia in older patients with hip fracture [letter] Lombardi G, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):740–1

Total hip arthroplasty in patients who have chronic lymphocytic leukemia. McGrory BJ, et al. **J Arthroplasty** 1995 Dec;10(6):758–63

Predicting quality–of–life outcomes following total joint arthroplasty. Limitations of the SF–36 Health Status Questionnaire. McGuigan FX, et al. **J Arthroplasty** 1995 Dec;10(6):742–7

Perioperative bladder management after primary total hip arthroplasty. Oishi CS, et al. **J Arthroplasty** 1995 Dec; 10(6):732–6

Comparative outcomes of total joint arthroplasty. Ritter MA, et al. **J Arthroplasty** 1995 Dec;10(6):737–41

Condylar failure of the Lacey Rotating–Hinge total knee. Scott CE, et al. **J Arthroplasty** 1996 Feb;11(2):214–6

Patellar clunk syndrome in total knee arthroplasty without patellar resurfacing. Shoji H, et al. **J Arthroplasty** 1996 Feb;11(2):198–201

Miller–Galante unicompartmental knee arthroplasty at 2– to 5–year follow–up evaluations. Voss F, et al. **J Arthroplasty** 1995 Dec;10(6):764–71

The elevated–rim acetabular liner in total hip arthroplasty: relationship to postoperative dislocation. Cobb TK, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):80–6

Toxic shock syndrome complicating orthopaedic manipulation of bone. A report of two cases. Herold BC, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):903–6

Perioperative complications of anterior procedures on the spine. McDonnell MF, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):839–47

Surgical experience related to dislocations after total hip arthroplasty. Hedlundh U, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):206–9

Thermal necrosis after tibial reaming for intramedullary nail fixation. A report of three cases. Leunig M, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):584–7 (26 ref.)

Ischemia of spinal cord following elective operative procedures of the infrarenal abdominal aorta. Dimakakos P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):243–7

Laceration of the phrenic artery. A life–threatening complication after repair of pectus excavatum. Paret G, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):193–4

Time limitation of postural retrograde cerebral perfusion during cerebral hypothermic circulatory arrest. A report of an unsuccessful case. Sasaguri S, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):125–7

A role for nitric oxide in the vasoplegic syndrome. Speziale G, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):301–3

Compartment–syndrome of the lower extremity after CABG. van den Wildenberg FA, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):237–41

Consultation section. What would you advise for a patient who has had episodic pupillary capture? **J Cataract Refract Surg** 1996 Jan–Feb;22(1):8–13

Regression after photorefractive keratectomy for myopia. Goggin M, et al. **J Cataract Refract Surg** 1996 Mar;

22(2):194–6
Efficacy and safety of excimer laser photorefractive keratectomy and radial keratotomy for bilateral myopia. el-Maghraby A, et al. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):51–8
Two year clinical study of a soft acrylic intraocular lens. Oshika T, et al. **J Cataract Refract Surg** 1996 Jan–Feb; 22(1):104–9
Long-term course of induced astigmatism after clear corneal incision cataract surgery. Pfleger T, et al. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):72–7
Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal. Young CC, et al. **J Clin Anesth** 1995 Dec;7(8):652–6
Surgical hemostasis by pneumatic ankle tourniquet during 3027 podiatric operations. Derner R, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):236–46 (87 ref.)
Biliary strictures after liver transplantation: clinical picture, correlates and outcomes. Feller RB, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):21–5
Charcot arthropathy following digital replantation. Vanderhooft E, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):683–6
The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: preliminary insights from a multicenter intravascular ultrasound study. Multicenter Intravascular Ultrasound Transplant Study Group. Hauptman PJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S238–42
The effect of left ventricular systolic function on long term survival in mitral and aortic regurgitation. Michel PL, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S160–8; discussion S168–9
Can cavitation bubbles generated by mechanical heart valves be detected by transcranial Doppler? Shu MC, et al. **J Heart Valve Dis** 1995 Sep;4(5):542–52; discussion 552
Regurgitation through the morphologically pulmonary valve after additional aortopulmonary anastomosis. Uemura H, et al. **J Heart Valve Dis** 1995 Mar;4(2):176–81
Diaphragmatic paralysis following scalenotomy for thoracic outlet syndrome. Heine M, et al. **J Ky Med Assoc** 1996 Jan;94(1):13–5
Bile leak following laparoscopic cholecystectomy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):233–6
Small bowel obstruction following endoscopic extraperitoneal–preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263–6 (10 ref.)
Laparoscopically assisted vaginal hysterectomy: a review of 106 cases. Martel MJ, et al. **J Laparoendosc Surg** 1995 Dec; 5(6):371–5
Causes of failure of combined approach tympanoplasty in the treatment of acquired cholesteatomas of the middle ear and the mastoid. Kapur TR. **J Laryngol Otol** 1995 Aug; 109(8):710–2
Impaired procedural learning after damage to the left supplementary motor area (SMA). Ackermann H, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):94–7
Hypomania after temporal lobectomy: a sequela to the increased excitability of the residual temporal lobe? [letter] Kanemoto K. **J Neurol Neurosurg Psychiatry** 1995 Oct; 59(4):448–9
The potential risks, complications, and prevention of deep vein thrombosis in oral and maxillofacial surgery patients. Solomon JM, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1441–7 (28 ref.)
Horner's syndrome after vertical ramus osteotomy: report of a case. Weissgold DJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):913–4
Toxic shock syndrome as a complication of orthopaedic surgery. Grimes J, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):666–71 (28 ref.)
Central compartment pressure monitoring following clubfoot release. Hanlon M, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):63–6
Parenteral nutrition–related cholestasis in postsurgical neonates: multivariate analysis of risk factors. Beath SV, et al. **J Pediatr Surg** 1996 Apr;31(4):604–6
Male infertility after surgery for imperforate anus. Holt B, et al. **J Pediatr Surg** 1995 Dec;30(12):1677–9
Bilateral ureteral obstruction after appendectomy in children. Hugen CA, et al. **J Pediatr Surg** 1995 Dec;30(12):1666–7
Restorative proctocolectomy for ulcerative colitis in children—is the J-pouch better than straight pull-through? Rintala RJ, et al. **J Pediatr Surg** 1996 Apr;31(4):530–3
Long-term gastrointestinal morbidity in patients with congenital diaphragmatic defects. Vanamo K, et al. **J Pediatr Surg** 1996 Apr;31(4):551–4
Dyslipoproteinemia in renal transplantation. Gunjotikar RV, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):10–2
Centration of excimer laser photorefractive keratectomy and changes in astigmatism. Aktunç R, et al. **J Refract Surg** 1996 Feb;12(2):S268–71
Stability and complications of photorefractive keratectomy over 2.5 years. Koufala CJ, et al. **J Refract Surg** 1996 Feb; 12(2):S264–6
Disability glare after excimer laser photorefractive keratectomy for myopia. Niesen UM, et al. **J Refract Surg** 1996 Feb;12(2):S267–8
Heterotopic ossification after acromioplasty and distal clavicle resection. Berg EE, et al. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):188–93
Benign anastomotic strictures after transhiatal esophagectomy and cervical esophagogastrostomy: risk factors and management. Honkoop P, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1141–6; discussion 1147–8
Conversion of modified Fontan procedure to lateral atrial tunnel cavopulmonary anastomosis. Kreutzer J, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1169–76
Severe left ventricular outflow tract obstruction despite sliding leaflet technique for repair of the mitral valve. Meyns B, et al. **J Thorac Cardiovasc Surg** 1996 Jul; 112(1):187–8
Thoracoscopic release of tracheopexy stitch causing phrenic nerve paralysis in an infant. Oyarzun R, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):188–90
Thoracic compartment syndrome. Kaplan LJ, et al. **J Trauma** 1996 Feb;40(2):291–3
Posttraumatic inflammatory response, secondary operations, and late multiple organ failure. Waydhas C, et al. **J Trauma** 1996 Apr;40(4):624–30; discussion 630–1
Impotence and incontinence after immediate realignment of posterior urethral trauma: result of injury or management? Kotkin L, et al. **J Urol** 1996 May;155(5):1600–3
Necrotizing venulitis and in situ saphenous vein bypass [letter] Cartier R, et al. **J Vasc Surg** 1996 Jul;24(1):179–81
Intracerebral hemorrhage after carotid endarterectomy associated with ipsilateral fibrinoid necrosis: a consequence of the hyperperfusion syndrome? Mansoor GA, et al. **J Vasc Surg** 1996 Jan;23(1):147–51 (20 ref.)
Transfusion vs anesthesia–related hepatitis [letter; comment] Abouleish AE, et al. **JAMA** 1996 Feb 7;275(5):361–2. Comment on: JAMA 1995 Nov 1;274(17):1368–73.
Complication rates as a measure of quality of care [letter; comment] Daley J, et al. **JAMA** 1995 Dec 6;274(21):1674–5 . Comment on: JAMA 1995 Jul 26;274(4):317–23.
Postoperative diaphragmatic dysfunction in patients undergoing open–heart surgery. Chang CZ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Nov; 11(11):626–32
Pooled plasma derivatives and Creutzfeldt–Jakob disease [letter] de Silva R. **Lancet** 1996 Apr 6;347(9006):967
Psychogenic coma after use of general anesthesia for ethmoidectomy. Weber JG, et al. **Mayo Clin Proc** 1996 Aug;71(8):797–800
Liver infarction produced by dual vessels occlusion due to trauma and TAE: long follow up using CT, US, and MRI. Takakuwa T, et al. **Med J Osaka Univ** 1993 Sep; 41–42(1–4):23–7
Gracilis donor site morbidity. Carr MM, et al. **Microsurgery** 1995;16(9):598–600
Vascular complications after free tissue transfer. Rieck B, et al. **Microsurgery** 1995;16(6):400–3
Laparoscopic–assisted hysterectomy in a rural Minnesota hospital. Tietz CA. **Minn Med** 1995 Dec;78(12):31–2, 52–3
Propofol and postoperative infections [letter; comment] Bach A, et al. **N Engl J Med** 1995 Nov 30;333(22):1505–6; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.
Hypertension and the kidney: new insights from results of renal transplantation studies. Rettig R, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:9–16 (45 ref.)
Headaches after inadvertent lumbar puncture during bone marrow harvest. Lieberman F, et al. **Neurology** 1996 Jan; 46(1):268–9
Cerebellar mutism: report of seven cases and review of the literature. Erşahin Y, et al. **Neurosurgery** 1996 Jan; 38(1):60–5;discussion 66 (30 ref.)
Early discharge after carotid endarterectomy. Harbaugh KS, et al. **Neurosurgery** 1995 Aug;37(2):219–24; discussion 224–5
The relevance of hemodynamic factors to perioperative ischemic complications in childhood moyamoya disease. Iwama T, et al. **Neurosurgery** 1996 Jun;38(6):1120–5; discussion 1125–6
Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)
Revascularization and aneurysm surgery: current techniques, indications, and outcome. Lawton MT, et al. **Neurosurgery** 1996 Jan;38(1):83–92; discussion 92–4
The significance of artificial cerebrospinal fluid as perfusate and endoneurosurgery. Oka K, et al. **Neurosurgery** 1996 Apr;38(4):733–6
Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686–90; discussion 690–1 (28 ref.)
Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)
Bypass coaptation procedures for cervical nerve root avulsion. Yamada S, et al. **Neurosurgery** 1996 Jun; 38(6):1145–51; discussion 1151–2
Diplopia after surgical repair of orbital floor fractures. Biesman BS, et al. **Ophthal Plast Reconstr Surg** 1996 Mar; 12(1):9–16; discussion 17
Complications of tarsoconjunctival grafts. Hawes MJ, et al. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):45–50
Morning-to-evening change in refraction, corneal curvature, and visual acuity 11 years after radial keratotomy in the prospective evaluation of radial keratotomy study. The PERK Study Group. McDonnell PJ, et al. **Ophthalmology** 1996 Feb;103(2):233–9
Metal/metal articulating interfaces. Böhler N. **Orthopedics** 1995 Sep;18(9):879–80
Joint arthroplasty: one step forward, two steps back [editorial] Booth RE Jr. **Orthopedics** 1995 Sep;18(9):783–6
Cemented arthroplasty: a long look back. Callaghan JJ. **Orthopedics** 1995 Sep;18(9):803
Precoat components: another look. Callaghan JJ. **Orthopedics** 1995 Sep;18(9):884
Failure mechanisms of hip arthroplasty. Callaghan JJ. **Orthopedics** 1995 Sep;18(9):849–50
Mechanisms of knee implant failure. Rorabeck CH. **Orthopedics** 1995 Sep;18(9):915–8
Polyethylene: a bridge too far. Rorabeck CH, et al. **Orthopedics** 1995 Sep;18(9):881–3
Solution options: unitized stem design. Vaughn BK. **Orthopedics** 1995 Sep;18(9):827–8
Ointment granuloma complications after cosmetic and otologic surgery. Corcoran ME, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):634–8
Can persistent cerebral damage be caused by hyperglycaemia? Bush GH, et al. **Paediatr Anaesth** 1995; 5(6):385–7
Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)
Intraventricular hemorrhage complicating ventricular catheter revision: incidence and effect on shunt survival. Brownlee RD, et al. **Pediatr Neurosurg** 1995;22(6):315–20
Complications of fourth-ventricular shunts. Lee M, et al. **Pediatr Neurosurg** 1995;22(6):309–13; discussion 314
Multifocal osteolysis following limb-sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)
Posterior urethral diverticula: a complication of surgery for high anorectal malformations. Vinnicombe SJ, et al. **Pediatr Radiol** 1996;26(2):120–6
CAPD—a risk factor in renal transplantation? ARF after transplantation. Lambert MC, et al. **Perit Dial Int** 1996;16 Suppl 1:S495–8
Unusual complication in a gracilis myocutaneous free flap [letter] Cavadas PC, et al. **Plast Reconstr Surg** 1996 Mar; 97(3):683
Partial deflation of a saline breast implant [letter] Cederna JP. **Plast Reconstr Surg** 1996 Mar;97(3):684
Alteration in facial sensibility in adolescents following sagittal split and chin osteotomies of the mandible. Posnick JC, et al. **Plast Reconstr Surg** 1996 Apr;97(5):920–7
The triple-phase response—problems of water balance after pituitary surgery. Lindsay RS, et al. **Postgrad Med J** 1995 Jul;71(837):439–41
External abdominal hernia of mucocele of the appendix in drain–tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)
Capsular contracture after lumpectomy and radiation therapy in patients who have undergone uncomplicated bilateral augmentation mammoplasty. Mark RJ, et al. **Radiology** 1996 Sep;200(3):621–5
Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)
Cholecystectomy as a risk factor for colorectal cancer: a meta–analysis. Reid FD, et al. **Scand J Gastroenterol** 1996 Feb;31(2):160–9
Long term results of skin expansion. Aubert JP, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):233–8
Effect of method of cleft palate repair on the quality of speech at the age of 6 years. Haapanen ML. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):245–50
Casting the implant for reconstruction of pectus excavatum. Hougaard G, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):227–31
Fluid absorption during transurethral bladder surgery. Ekengren J, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):319–20
Microsurgical correction of posttesticular obstruction. Peroperative findings and postoperative semen quality. Gunnarsson M, et al. **Scand J Urol Nephrol** 1995 Jun; 29(2):197–205
Burch colposuspension for stress urinary incontinence. 5–year results in 153 women. Kinn AC. **Scand J Urol Nephrol** 1995 Dec;29(4):449–55
Defining the role of the radial artery. Barner HB. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):3–9
Evaluation of patients with emphysema for lung volume reduction surgery. Washington University Emphysema Surgery Group. Yusen RD, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):83–93
Results of lung volume reduction surgery in patients with emphysema. The Washington University Emphysema Surgery Group. Yusen RD, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):99–109
A complication of spinal decompression. A case report. Woods DA, et al. **Spine** 1995 Nov 15;20(22):2467–9
Clinical and manometric results of laparoscopic partial (Toupet) and complete (Rosetti–Nissen) fundoplication. Bell RCW, et al. **Surg Endosc** 1996 Jul;10(7):724–8
Colectomy: the role of laparoscopy. Scott HJ, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):382–6
Richter hernia: a rare complication of laparoscopy. Williams MD, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):419–21
Complication of epidural fat graft in lumbar spine disc surgery: case report. Cobanoğlu S, et al. **Surg Neurol** 1995

Nov;44(5):479–81; discussion 481–2
Cerebrospinal fluid leak after acoustic neuroma surgery. Nutik SL, et al. **Surg Neurol** 1995 Jun;43(6):553–6; discussion 556–7
Rapid enlargement of a syringomyelia cavity following syringo–subarachnoid shunt: case report. Takayasu M, et al. **Surg Neurol** 1996 Apr;45(4):366–9
Repair of a ruptured aortic arch aneurysm complicated by postoperative paraplegia: report of a case. Hadama T, et al. **Surg Today** 1996;26(1):60–3
Postoperative chylothorax following partial resection of mediastinal lymphangioma: report of a case. Matsuzoe D, et al. **Surg Today** 1995;25(9):827–9
Development of postoperative delirium in relation to a room change in the general surgical unit. Tsutsui S, et al. **Surg Today** 1996;26(4):292–4
Early postoperative small bowel obstruction caused by spilled gallstones during laparoscopic cholecystectomy. Huynh T, et al. **Surgery** 1996 Mar;119(3):352–3
Prospective study of wound complications in continuous infrainguinal incisions after lower limb arterial reconstruction: incidence, risk factors, and cost. Kent KC, et al. **Surgery** 1996 Apr;119(4):378–83
Nerve injury associated with laparoscopic inguinal herniorrhaphy. Sampath P, et al. **Surgery** 1995 Nov; 118(5):829–33
Successful myocardial revascularization and neurologic recovery in a patient with prolonged refractory cardiac arrest and a chronically occluded left internal carotid artery. Tovar EA, et al. **Tex Heart Inst J** 1995;22(3):271–3
Transfusion–associated cancer recurrence and postoperative infection: meta–analysis of randomized, controlled clinical trials. Vamvakas EC. **Transfusion** 1996 Feb;36(2):175–86
Wound complications after simultaneous pancreas–kidney transplants: midline versus transverse incision. Douzdjian V, et al. **Transplant Proc** 1995 Dec;27(6):3130–2
Laparoscopic management of posttransplant pelvic lymphoceles. Oyen O, et al. **Transplant Proc** 1995 Dec; 27(6):3449–50
Ileal–ileal intussusception: an unusual complication following enterocystoplasty. Mordkin R, et al. **Urology** 1996 Jan; 47(1):138–9
Comparison of bladder rupture pressure after intestinal bladder augmentation (ileocystoplasty) and myomyotomy (autoaugmentation). Rivas DA, et al. **Urology** 1996 Jul; 48(1):40–6
Intestinal ischemia following surgery for aorto–iliac disease. A review of 502 consecutive aortic reconstructions. Järvinen O, et al. **Vasa** 1996;25(2):148–55
Coelioscopic cholecystectomy: experience with 2006 cases. Dubois F, et al. **World J Surg** 1995 Sep–Oct;19(5):748–52
Reconstruction of the food passage after total gastrectomy: randomized trial. Fuchs KH, et al. **World J Surg** 1995 Sep–Oct;19(5):698–705; discussion 705–6
A comparison of survival and side effects in two periods with a different approach to radical hysterectomy as treatment of cervical cancer stages Ib and IIa. Knudsen HJ, et al. **Zentralbl Gynakol** 1995;117(9):476–80
[Deviatio ileopancreatica a modo Scopinaro and intrauterine fetal hypotrophy] Tsenov A, et al. **Akush Ginekol (Sofiia)** 1994;33(2):45–7 **(Bul)**
[A case of gangrenous appendicitis complicated by an anaerobic gas infection in the retroperitoneal space and right thigh] Iarŭmov N, et al. **Khirurgiia (Sofiia)** 1995; 48(5):72–3 **(Bul)**
[Acute abdominal complications after thoracic–pulmonary operations] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):44–6 (Eng. Abstr.) **(Bul)**
[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):47–9 (0 ref.) **(Bul)**
[Vascular complications in kidney transplantation (a review of the literature and the authors' own experience)] Nikolovski M, et al. **Khirurgiia (Sofiia)** 1994;47(5):30–3 (60 ref.) (Eng. Abstr.) **(Bul)**
[Phacoemulsification and clear cornea incision: review of 100 initial cases] Lendi B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):273–4 (Eng. Abstr.) **(Fre)**
[Severe pulmonary complications following venous air embolism in neurosurgical operations in sitting position—2 case reports] Schaffranietz L, et al. **Anaesthesiol Reanim** 1995;20(1):12–5 (Eng. Abstr.) **(Ger)**
[Acute spinal subdural hematoma after attempted spinal anesthesia] Likar R, et al. **Anaesthesist** 1996 Jan;45(1):66–9 (Eng. Abstr.) **(Ger)**
[Postoperative mediastinal and subcutaneous emphysema after intubation narcosis] Obenhaus T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):318–20 (Eng. Abstr.) **(Ger)**
[Status of laparoscopic cholecystectomy] Pistorius GA, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov;30(7):438–41 **(Ger)**
–Indications and complications of ambulatory surgery in a general practice operating room– Baertschi U. **Arch Gynecol Obstet** 1995;256 Suppl:S1–5 **(Ger)**
–Breast neoplasms: axillary lymph node excision—at what price– Rageth JC. **Arch Gynecol Obstet** 1995;256 Suppl:S85–92 (45 ref.) **(Ger)**
–Complications. Surgical endoscopy versus gynecologic minimal invasive surgery– Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21–31 (18 ref.) **(Ger)**
–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A. **Arch Gynecol Obstet** 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**
[Laparoscopic versus conventional appendectomy: a prospective randomized study] Henle KP, et al. **Chirurg** 1996 May;67(5):526–30; discussion 522 (Eng. Abstr.) **(Ger)**
[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**
[Long–term outcome of surgical therapy of acute necrotizing pancreatitis] Kriwanek S, et al. **Chirurg** 1996 Mar; 67(3):244–8 (Eng. Abstr.) **(Ger)**
[Quality assurance in goiter surgery by rate of recurrent nerve paralysis] Miller W, et al. **Chirurg** 1995 Dec;66(12):1210–4 (Eng. Abstr.) **(Ger)**
[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**
[Subjective assessment of quality of life, pain and surgical success after laparotomy for Crohn disease] Post S, et al. **Chirurg** 1995 Aug;66(8):800–6 (Eng. Abstr.) **(Ger)**
[Abdominal trauma and pelvic injury in the growth period] Rieger H, et al. **Chirurg** 1996 Mar;67(3):261–7 (Eng. Abstr.) **(Ger)**
[Risk factors for recurrence of Crohn disease after intestinal resection] Speranza V. **Chirurg** 1995 Aug;66(8):751–6 (Eng. Abstr.) **(Ger)**
[Quality of life after cancer–caused rectal resection (letter)] Carl P. **Dtsch Med Wochenschr** 1996 May 3;121(18):609 **(Ger)**
[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):953–7 (45 ref.) **(Ger)**
[Osteoporosis following heart transplantation. Pathogenesis and therapy] Stempfle HU. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1103–7 (44 ref.) **(Ger)**
[Experiences and results in management of mandibular fractures with the modified Krenkel lag screw—a retrospective study] Enislidis G, et al. **Fortschr Kiefer Gesichtschir** 1996;41:96–9 (Eng. Abstr.) **(Ger)**
[Wound management after wisdom tooth osteotomy] Hellner D, et al. **Fortschr Kiefer Gesichtschir** 1995;40:136–9 (Eng. Abstr.) **(Ger)**
[Severe complications after surgical removal of wisdom teeth] Locher MC, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:123–8 (55 ref.) (Eng. Abstr.) **(Ger)**
[Results of compression osteosynthesis with intraoral approach in 922 mandibular fractures] Luhr HG, et al. **Fortschr Kiefer Gesichtschir** 1996;41:77–80 (Eng. Abstr.) **(Ger)**
[Late outcome and complications of mandibular compression osteosynthesis with intraoral approach—a 10–year study] Reinert S, et al. **Fortschr Kiefer Gesichtschir** 1996;41:74–7 (Eng. Abstr.) **(Ger)**
[Complications in bimaxillary surgical interventions] Sailer HF, et al. **Fortschr Kiefer Gesichtschir** 1995;40:41–9 (65 ref.) **(Ger)**
[Long–term follow–up of tooth transplantation from the functional and periodontal viewpoint] Terheyden H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:84–7 (Eng. Abstr.) **(Ger)**
[Complications of surgical wisdom tooth removal of the maxilla. A clinical and roentgenologic study of 1,013 patients with statistical evaluation] Wächter R, et al. **Fortschr Kiefer Gesichtschir** 1995;40:128–33 (Eng. Abstr.) **(Ger)**
[Synovectomy of the knee joint in rheumatoid arthritis. Follow–up studies] Fritsch E, et al. **Fortschr Med** 1995 Dec 10;113(34):487–9 (Eng. Abstr.) **(Ger)**
[Introduction of laparoscopic surgery in extrauterine pregnancy] Rempen A. **Geburtshilfe Frauenheilkd** 1995 Jul; 55(7):357–64 (28 ref.) (Eng. Abstr.) **(Ger)**
[Peripartal hysterectomy—definition, follow–up and risk] Remy N, et al. **Geburtshilfe Frauenheilkd** 1994 Nov; 54(11):593–7 (Eng. Abstr.) **(Ger)**
[Continent urinary diversion and pregnancy] Voges GE, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):711–5 (Eng. Abstr.) **(Ger)**
[The clinical picture of endoscopically treated extrauterine pregnancy. Postoperative follow–up of 677 endoscopically operated extrauterine pregnancies 1983–1993] Zöckler R, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):365–8 (Eng. Abstr.) **(Ger)**
[Pre–vesicle ureteral obstruction as a sequela of Bruch colposuspension for urinary stress incontinence and partial prolapse. A case from the expert assessment files] Schwenzer T, et al. **Gynakologe** 1995 Aug;28(4):276–7 **(Ger)**
[Donor site defect after removal of free and pedicled forearm flaps: functional and cosmetic results] Hülsbergen–Krüger S, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):70–5 (Eng. Abstr.) **(Ger)**
[2 1/2 years experience with endoscopic carpal tunnel release] Mascharka Z. **Handchir Mikrochir Plast Chir** 1996 May;28(3):138–42 (Eng. Abstr.) **(Ger)**
[Carpal tunnel syndrome. A comparison of endoscopic and open surgical treatment] Skorpik G, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):133–7 (Eng. Abstr.) **(Ger)**
[Long–term outcome of the donor site after free, microvascular pedicled iliac crest transplantation: experiences with 95 cases] Stock W, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):233–41 (Eng. Abstr.) **(Ger)**
[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**
[Long–term outcome of tympanoplasty in chronic suppurative middle ear infection in childhood] Feilen SE, et al. **HNO** 1996 Mar;44(3):143–7 (Eng. Abstr.) **(Ger)**
[Diagnosis and therapy of dysphagia after partial horizontal laryngectomy] Hartmann S, et al. **HNO** 1996 May; 44(5):258–63 (Eng. Abstr.) **(Ger)**
[Complications with cochlear implants in childhood] Laszig R. **HNO** 1996 Mar;44(3):119–20 **(Ger)**
[Glare sensitivity of phakic and pseudophakic eyes] Eisenmann D, et al. **Klin Monatsbl Augenheilkd** 1996 Feb; 208(2):87–92 (Eng. Abstr.) **(Ger)**
[Induced astigmatism in extracapsular cataract extraction with tunnel incision and various wound closures] Häberle H, et al. **Klin Monatsbl Augenheilkd** 1995 Sep;207(3):176–9 (Eng. Abstr.) **(Ger)**
[Thermal photodisruptive laser iridotomy. A retrospective long–term study] Motschmann M, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):22–8 (Eng. Abstr.) **(Ger)**
[Lens astigmatism in connection with implantation of a foldable one–piece silicone lens in a patient] Spiegel D, et al. **Klin Monatsbl Augenheilkd** 1995 Sep;207(3):197–9 (Eng. Abstr.) **(Ger)**
[Effect of orthograde intestinal irrigation with Prepacol and polyethyleneglycol solution on duration of postoperative ileus after colorectal resections] Gründel K, et al. **Langenbecks Arch Chir** 1996;381(3):160–4 (Eng. Abstr.) **(Ger)**
[Effects of surgical therapy of obstructive snoring on swallowing and voice quality] Keilmann A, et al. **Laryngorhinootologie** 1995 Sep;74(9):555–8 (Eng. Abstr.) **(Ger)**
[Experiences with transverse resections and vertical incisions in treatment of tracheal stenoses and tracheal injuries] Stoll W, et al. **Laryngorhinootologie** 1996 Mar;75(3):160–5 (Eng. Abstr.) **(Ger)**
[Gastroesophageal reflux—surgical indications, laparoscopic surgical technique, results] Dreuw B, et al. **Leber Magen Darm** 1996 Mar;26(2):88–94, 97 (Eng. Abstr.) **(Ger)**
[Analysis of postoperative seizure recurrence after 65 temporal lobe partial resections] Schulz R, et al. **Nervenarzt** 1995 Dec;66(12):901–6 (Eng. Abstr.) **(Ger)**
[Binocular vision in idiopathic macular foramen. Pre– and postoperative findings] Eckardt U, et al. **Ophthalmologe** 1995 Oct;92(5):626–30 (Eng. Abstr.) **(Ger)**
[Late vision loss after focal hemorrhagic chorioretinopathy] Pauleikhoff D, et al. **Ophthalmologe** 1996 Apr;93(2):163–7 (Eng. Abstr.) **(Ger)**
[Long–term outcome after silicone oil removal] Pavlovic S, et al. **Ophthalmologe** 1995 Oct;92(5):672–6 (Eng. Abstr.) **(Ger)**
[Complications of preventive cryoretinopexy in retinal foramina and degeneration in 1,000 eyes] Reuter U, et al. **Ophthalmologe** 1996 Apr;93(2):139–43 (Eng. Abstr.) **(Ger)**
[Retinal detachment despite preventive coagulation] Schroeder W, et al. **Ophthalmologe** 1996 Apr;93(2):144–8 (Eng. Abstr.) **(Ger)**
[Current evaluation of myopia correction with the excimer laser] Seiler T. **Ophthalmologe** 1995 Aug;92(4):379–84 (18 ref.) (Eng. Abstr.) **(Ger)**
[Keratomileusis in situ in high grade myopia. Initial results] Wiegand W, et al. **Ophthalmologe** 1995 Aug;92(4):402–9 (Eng. Abstr.) **(Ger)**
[Intrastromal keratectomy in high myopia. 1 year results] Wiegand W, et al. **Ophthalmologe** 1996 Jun;93(3):237–41 (Eng. Abstr.) **(Ger)**
[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274–91 (59 ref.) (Eng. Abstr.) **(Ger)**
[How safe is laparoscopic colon surgery?] Christen D, et al. **Schweiz Med Wochenschr** 1995 Aug 26;125(34):1597–601 (Eng. Abstr.) **(Ger)**
[Coronary endothelial dysfunction and graft atheromatosis following heart transplantation] Vassalli G. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1923–30 (51 ref.) (Eng. Abstr.) **(Ger)**
[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**
[Dislocated intra–articular calcaneus fractures. Long–term follow–up after open reposition and osteosynthesis] Funk EM, et al. **Unfallchirurg** 1995 Oct;98(10):501–6 (Eng. Abstr.) **(Ger)**
[Late results of surgical treatment of Tossy III acromioclavicular joint separation with the Balser plate] Graupe F, et al. **Unfallchirurg** 1995 Aug;98(8):422–6 (Eng. Abstr.) **(Ger)**
[Pelvic fractures: epidemiology, therapy and long–term outcome. Overview of the multicenter study of the Pelvis Study Group] Pohlemann T, et al. **Unfallchirurg** 1996 Mar; 99(3):160–7 (Eng. Abstr.) **(Ger)**

[Outcome evaluation after unstable injuries of the pelvic ring] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):249–59 (Eng. Abstr.) **(Ger)**

[Pelvic injuries: low incidence but unsatisfactory outcome (editorial)] Tscherne H, et al. **Unfallchirurg** 1996 Mar; 99(3):159 **(Ger)**

[Leg length inequality after childhood femoral fractures—permanent or temporary phenomenon?] Wessel L, et al. **Unfallchirurg** 1996 Apr;99(4):275–82 (Eng. Abstr.) **(Ger)**

[Recurrent hemarthrosis after cruciate ligament refixation by wire suture. A case report] Berwarth H, et al. **Unfallchirurgie** 1996 Apr;22(2):88–90 (Eng. Abstr.) **(Ger)**

[Proximal humerus shaft fracture as a complication after keyhole-plasty. A case report] Friedel R, et al. **Unfallchirurgie** 1995 Aug;21(4):198–201 (Eng. Abstr.) **(Ger)**

[Clinical relevance of fat embolism. Review of the literature] Hirschnitz C, et al. **Unfallchirurgie** 1996 Apr;22(2):57–73 (Eng. Abstr.) **(Ger)**

[Inlay dislocations after primary, cement-free hip joint replacement] Kleihues H, et al. **Unfallchirurgie** 1995 Aug; 21(4):202–3 (Eng. Abstr.) **(Ger)**

[Complications in 283 cruciate ligament replacement operations with free patellar tendon transplantation. Modification by surgical technique and surgery timing] Passler JM, et al. **Unfallchirurgie** 1995 Oct;21(5):240–6 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of cruciate ligament injuries in childhood. Clinical results] Wening JV, et al. **Unfallchirurgie** 1995 Dec;21(6):285–91 (Eng. Abstr.) **(Ger)**

[Risk and prognosis of hip para-articular fractures. A comparison of treatment results of femoral neck and pertrochanteric femoral fractures] Wissing H, et al. **Unfallchirurgie** 1996 Apr;22(2):74–84 (Eng. Abstr.) **(Ger)**

[Continuous in situ cold perfusion with HTK solution in conservative surgery of kidney tumor] de Petriconi R, et al. **Urologe A** 1995 Nov;34(6):449–56 (Eng. Abstr.) **(Ger)**

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238–45 (20 ref.) (Eng. Abstr.) **(Ger)**

[Follow-up of kidney function in children with former posterior urethral valves] Rösch W, et al. **Urologe A** 1995 Nov;34(6):457–60 (Eng. Abstr.) **(Ger)**

[Chylous ascites, a rare complication of aortic surgery] Halloul Z, et al. **Vasa** 1995;24(4):377–81 (Eng. Abstr.) **(Ger)**

[Sexual function after transurethral prostate resection] Lunglmayr G. **Wien Med Wochenschr** 1996;146(8):175–7 (Eng. Abstr.) **(Ger)**

[Delayed stenosis after endoscopic sphincterotomy (EST)?] Adler A, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:143–6 (Eng. Abstr.) **(Ger)**

[Incidence of intervention-related heart valve lesions after high-frequency catheter ablation of the left-side accessory atrioventricular conduction pathways] Neuzner J, et al. **Z Kardiol** 1995 Dec;84(12):1002–8 (Eng. Abstr.) **(Ger)**

–Aneurysm of the pulmonary artery and pulmonary artery hypertension 22 years after Mustard reversal operation in transposition of great vessels– Wagdi P, et al. **Z Kardiol** 1996 Feb;85(2):104–7 (Eng. Abstr.) **(Ger)**

[Gigantic arm lymphedema] Rüger K. **Z Lymphol** 1995 Aug; 19(1):12–5 (Eng. Abstr.) **(Ger)**

[Significance of the radial compression syndrome for the diagnosis and surgical therapy of so-called epicondylitis humeri radialis (Epic. hum. rad.)] Totkas D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):317–22 (73 ref.) (Eng. Abstr.) **(Ger)**

[Various possibilities for managing subtrochanteric fractures] Bülhoff H, et al. **Zentralbl Chir** 1995;120(11):881–6 (Eng. Abstr.) **(Ger)**

[Long-term outcome after conservative treatment of pelvic ring injuries and conclusions for current management] Fell M, et al. **Zentralbl Chir** 1995;120(11):899–904; discussion 904 (Eng. Abstr.) **(Ger)**

[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Classification, therapy and complications of pediatric femoral neck fractures] Hahn MP, et al. **Zentralbl Chir** 1995;120(11):832–40 (56 ref.) (Eng. Abstr.) **(Ger)**

[10 years experience with vertical banded gastroplasty for operative therapy of morbid obesity] Hell E, et al. **Zentralbl Chir** 1996;121(5):363–9 (Eng. Abstr.) **(Ger)**

[Long-term results of surgical and conservative treatment of ruptures of the long biceps tendon] Zimmer-Amrhein S, et al. **Zentralbl Chir** 1996;121(5):394–400 (Eng. Abstr.) **(Ger)**

[Laparoscopy-assisted vaginal hysterectomy (LAVH)—a comparison between vaginal and abdominal hysterectomy with reference to intra- and postoperative quality parameters] Bojahr B, et al. **Zentralbl Gynakol** 1995; 117(11):585–91 (Eng. Abstr.) **(Ger)**

[Dura-plasty in intracranial operations] Ernestus RI, et al. **Zentralbl Neurochir** 1995;56(3):106–10 (20 ref.) (Eng. Abstr.) **(Ger)**

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al. **G Chir** 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) **(Ita)**

[Choledochal calculosis due to a suture thread] Lo Casto RM, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):63–5 (11 ref.) (Eng. Abstr.) **(Ita)**

[Incidence of nausea and vomiting after cholecystectomy performed via laparotomy or laparoscopy] Iitomi T, et al. **Masui** 1995 Dec;44(12):1627–31 (Eng. Abstr.) **(Jpn)**

[Cerebral oxygen saturation (rSo2) during open heart surgery and postoperative brain dysfunction] Konishi A, et al. **Masui** 1995 Oct;44(10):1322–6 (Eng. Abstr.) **(Jpn)**

[Change of the cognitive function after open heart surgery] Konishi A, et al. **Masui** 1995 Aug;44(8):1107–12 (Eng. Abstr.) **(Jpn)**

[Relationship between retained microbubbles and neuropsychologic alterations after cardiac operation] Ohnishi Y, et al. **Masui** 1995 Oct;44(10):1327–33 (Eng. Abstr.) **(Jpn)**

[Long-term study of patients with pulmonary tuberculosis sequelae after bilateral thoracoplasty-airway obstruction and its causes] Zhou C, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1180–5 (Eng. Abstr.) **(Jpn)**

[Small hepatocellular carcinoma. New concepts on intrahepatic recurrence after hepatectomy in orthotopic liver transplantation] Oliveira e Silva A, et al. **Arq Gastroenterol** 1995 Jan–Mar;32(1):15–8 (Eng. Abstr.) **(Por)**

[Mutism after posterior fossa tumor surgery: report of 2 cases (letter; comment)] Plese JP, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–A):533–4. Comment on: Arq Neuropsiquiatr 1995 Mar;53(1):94–7. **(Por)**

[Complications of allogeneic microsurgical transplantation of a limb (composite tissue), in rats] Ferreira LM, et al. **Rev Assoc Med Bras** 1995 May–Jun;41(3):213–8 (Eng. Abstr.) **(Por)**

[Corneal edema, a complication of cataract surgery] Chercota V. **Oftalmologia** 1995 Oct–Dec;39(4):343–8 (9 ref.) (Eng. Abstr.) **(Rum)**

[Complications of retinal detachment surgery] Iliuță C. **Oftalmologia** 1996 Apr–Jun;40(2):169–75 (Eng. Abstr.) **(Rum)**

[Uveal inflammation secondary to lens implantation] Medelet E. **Oftalmologia** 1996 Apr–Jun;40(2):145–9 (Eng. Abstr.) **(Rum)**

[The pathogenesis of hypoventilation in the operated lung] Vinnitskiĭ LI, et al. **Anesteziol Reanimatol** 1996 Jan–Feb; (1):6–8 (Eng. Abstr.) **(Rus)**

[Role of acid-base balance of the blood in the pathogenesis of acute gastroduodenal ulcers in surgery patients] Skriabin ON, et al. **Klin Med (Mosk)** 1995;73(4):100 **(Rus)**

[The complications of transurethral resection of the bladder for tumor] Chepurov AK, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):21–3 (Eng. Abstr.) **(Rus)**

[The complications of endo-corpora cavernosa prosthesis] Shcheplev PA, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct; (5):49–52 **(Rus)**

[A familial form of nephrolithiasis in patients following kidney transplantation?] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):14–6 (Eng. Abstr.) **(Rus)**

[The pathogenesis, diagnosis and treatment of postvagotomy diarrhea] Gorbashko AI. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):254–62 (Eng. Abstr.) **(Rus)**

[Acute postoperative gastroduodenal erosions and ulcers] Priĭma OB. **Vestn Khir Im I I Grek** 1992 Feb;148(2):247–51 (44 ref.) **(Rus)**

[Massive lymphorrhea as a severe complication of pancreatoduodenal resection] Radnaev VU, et al. **Vestn Khir Im I I Grek** 1995;154(3):77–8 **(Rus)**

[The invagination of an excluded loop of small intestine after a jejunoileal bypass operation in patients with pathological obesity] Sedletskiĭ IuI, et al. **Vestn Khir Im I I Grek** 1995; 154(2):92–4 **(Rus)**

[Postvagotomy diarrhea] Trofimov VM, et al. **Vestn Khir Im I I Grek** 1995;154(2):49–52 (Eng. Abstr.) **(Rus)**

[The complications of a Nissen fundoplication in diaphragmatic hiatal hernias] Vasil'ev VN, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):225–30 **(Rus)**

[The radiculoischemia syndrome after prosthesis of the aorta] Zamiatin VV, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):335–7 **(Rus)**

[Postoperative progressive peritonitis in patients wounded in the abdomen] Mamuchishvili NK, et al. **Voen Med Zh** 1995 Nov;(11):31–3 **(Rus)**

[Prognosis of ischemic complications following early surgical treatment of cerebral aneurysms] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct–Dec; (4):11–3 (Eng. Abstr.) **(Rus)**

[Rhabdomyolysis and acute kidney failure after an orthopedic intervention] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):385–6 (20 ref.) **(Spa)**

[Effects of urethropexy on urination. A price to pay?] Salinas Casado J, et al. **Arch Esp Urol** 1995 Sep;48(7):709–16 (Eng. Abstr.) **(Spa)**

[Transjugular intrahepatic portosystemic shunt and intravascular hemolysis (letter)] Montes J, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):439 **(Spa)**

[The clinical efficacy and complications of the transjugular intrahepatic portosystemic shunt-stent] Santolaria Piedrafita S, et al. **Rev Clin Esp** 1995 Sep;195(9):609–13 (Eng. Abstr.) **(Spa)**

[Subcutaneous emphysema and pneumomediastinum as late complications of a difficult intubation (letter)] Benito MC, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):436–7 **(Spa)**

[2 cases of tension pneumopericardium after unilateral lung transplantation] Fernández-Guisasola J, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):330–1 (Eng. Abstr.) **(Spa)**

[Infectious complications in patients undergoing a heart transplant] Bouza E, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:96–107 (Eng. Abstr.) **(Spa)**

[Lymphoproliferative disease and cancer in the transplant patient] Herreros J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:129–34 (44 ref.) (Eng. Abstr.) **(Spa)**

[The significance of cytomegalovirus infection in the period after a heart transplant] Manito N, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:108–14 (36 ref.) (Eng. Abstr.) **(Spa)**

[Graft vascular disease. Its pathogenesis and diagnosis] Muñoz Aguilera R, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:115–28 (164 ref.) (Eng. Abstr.) **(Spa)**

[Do diagnostic laparoscopy and the use of drains favor the appearance of cutaneous metastases after oncological surgery? (letter)] Rosado R, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):231–2 **(Spa)**

[Diabetes insipidus. A possibly life-threatening condition during anesthesia] Brink M, et al. **Lakartidningen** 1995 Nov 1;92(44):4098–9 **(Swe)**

IMMUNOLOGY

Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Faro A, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1442–7

Postcardiac injury syndrome. An immunologic pleural fluid analysis. Kim S, et al. **Chest** 1996 Feb;109(2):570–2

Predictive value of IgG subclass levels for infectious complications in renal transplant recipients. Wieneke H, et al. **Clin Nephrol** 1996 Jan;45(1):22–8

Possible role of T-cell surface molecule gene expression in the mixed lymphocyte culture for predicting transplantation-related complications after allogeneic bone marrow transplantation [letter] Tanaka J, et al. **Eur J Haematol** 1995 Oct;55(4):282–4

Alterations in lymphocyte subsets as prognosticators of postoperative infections. Gennari R, et al. **Eur J Surg** 1995 Jul;161(7):493–9

EBNA expression in Reed-Sternberg like cells in post-transplant lymphoproliferative disorders [letter; comment] Chetty R, et al. **J Clin Pathol** 1996 Mar;49(3):270 . Comment on: J Clin Pathol 1995 Sep;48(9):845–8.

Refractory immune thrombocytopenia after heart transplantation: a case report. Dhar SC, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):785–7

Epstein-Barr virus infection in heart and heart-lung transplant recipients: incidence and clinical impact. Gray J, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):640–6

Cellular and humoral immunity to vascular endothelium and the development of cardiac allograft vasculopathy. Hosenpud JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S185–7

Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S111–5 (31 ref.)

Characterization of endothelial antigens associated with transplant-associated coronary artery disease. Wheeler CH, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S188–97

Paracoccidioidomycosis in a renal transplant recipient. Shikanai-Yasuda MA, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):411–4

Human immunodeficiency virus and the trauma patient: factors influencing postoperative infectious complications. Guth AA, et al. **J Trauma** 1996 Aug;41(2):251–5; discussion 255–6

The influence of trauma on changes in neutrophil granulocyte function assessed by an analysis of granulocyte migration. Hofer HP, et al. **Langenbecks Arch Chir** 1996;381(3):148–54

Haemostatic and immunological sequelae of portacaval shunt in rats. Robson SC, et al. **Liver** 1995 Dec;15(6):293–9

Complications linked to chronic peritoneal dialysis in children after kidney transplantation: experience of the Italian Registry of Pediatric Chronic Peritoneal Dialysis. Andreetta B, et al. **Perit Dial Int** 1996;16 Suppl 1:S570–3

Can laparoscopic surgery improve the immune response to surgery in an HIV-positive patient? [letter] Oliveira L, et al. **Surg Endosc** 1996 Jul;10(7):779

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

[Level of immunoglobulins A, G and M in the postoperative period] Dressler C, et al. **Anaesthesiol Reanim** 1995; 20(4):101–8 (Eng. Abstr.) **(Ger)**

[Effect of surgical trauma on NK cell activity in esophageal carcinoma after transmediastinal dissection vs. transthoracic en bloc resection] Bruns C, et al. **Langenbecks Arch Chir** 1996;381(3):175–81 (Eng. Abstr.) **(Ger)**

METABOLISM

Substance P—an underlying factor for pouchitis? Prospective

study of substance P- and vasoactive intestinal polypeptide-immunoreactive innervation and mast cells. Keränen U, et al. **Dig Dis Sci** 1996 Aug;41(8):1665-71

Substance P- and vasoactive intestinal polypeptide-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Keränen U, et al. **Dig Dis Sci** 1996 Aug; 41(8):1658-64

Prospective evaluation of faecal fatty acid excretion in short bowel syndrome in newborns. Heineman E, et al. **J Pediatr Surg** 1996 Apr;31(4):520-5

[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620-4 (15 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Ochrobactrum anthropi endophthalmitis after uncomplicated cataract surgery. Braun M, et al. **Am J Ophthalmol** 1996 Aug;122(2):272-3

Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Han DP, et al. **Am J Ophthalmol** 1996 Jul;122(1):1-17

Unilateral Malassezia furfur blepharitis after perforating keratoplasty [letter] Tóth J, et al. **Br J Ophthalmol** 1996 May;80(5):488

Bartonella henselae: etiology of pulmonary nodules in a patient with depressed cell-mediated immunity. Caniza MA, et al. **Clin Infect Dis** 1995 Jun;20(6):1505-11

Incidence of anaerobic bacterial infection following transurethral instrumentation. Mohanty NK, et al. **Indian J Pathol Microbiol** 1996 Jan;39(1):33-6

Mycobacterium haemophilum infections in bone marrow transplant recipients. White MH, et al. **Transplantation** 1995 Nov 15;60(9):957-60

[Septic ascites: a rare post-operative complication] La Torre F, et al. **G Chir** 1995 Nov-Dec;16(11-12):507-9 (Eng. Abstr.) **(Ita)**

[Isolation rate of E. coli from surgical infections and their susceptibilities] Shinagawa N, et al. **Jpn J Antibiot** 1996 May;49(5):456-64 (Eng. Abstr.) **(Jpn)**

[A case of a patient with post-operative empyema due to Mycobacterium chelonae] Takemoto N, et al. **Kyobu Geka** 1996 Apr;49(4):301-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Postoperative bacteriuria and urinary tract infections in gynecological patients] Schiøtz HA. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):246-8 (Eng. Abstr.) **(Nor)**

[Neurosurgical infections] Martínez E, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):34-43 (161 ref.) **(Spa)**

MORTALITY

A prospective study of urinary retention and risk of death after proximal femoral fracture. Smith NK, et al. **Age Ageing** 1996 Mar;25(2):150-4

Surgery in the very old patient: evaluation of factors linked to postoperative morbidity and mortality. Di Palo S, et al. **Aging (Milano)** 1995 Apr;7(2):110-6

Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Nieto-Rodriguez JA, et al. **Ann Surg** 1996 Jan;223(1):70-6

Morbidity and mortality after thoracoscopic pneumonoplasty. Fujita RA, et al. **Ann Thorac Surg** 1996 Jul;62(1):251-7

Ruptured abdominal aortic aneurysm: impact of comorbidity and postoperative complications on outcome. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):535-41

Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Holm T, et al. **Br J Surg** 1996 Jul;83(7):964-8

Does concomitant aortic bypass and renal artery revascularization using the retroperitoneal approach increase perioperative risk? Darling RC 3rd, et al. **Cardiovasc Surg** 1995 Aug;3(4):421-3

Comparison of APACHE II scoring in liver and kidney transplant recipients versus trauma and general surgical patients in a single intensive-care unit. Sawyer RG, et al. **Clin Transplant** 1995 Oct;9(5):401-5

Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Pilz G, et al. **Crit Care Med** 1996 Apr;24(4):596-600

Quality of care in adult heart surgery: proposal for a self-assessment approach based on a French multicenter study. Roques F, et al. **Eur J Cardiothorac Surg** 1995; 9(8):433-9; discussion 439-40

The Edinburgh Cardiac Surgery Score survival prediction in the long-stay ICU cardiac surgical patient. Thompson MJ, et al. **Eur J Cardiothorac Surg** 1995;9(8):419-25

Survival and quality of life in patients with protracted recovery from cardiac surgery. Can we predict poor outcome? Treasure T, et al. **Eur J Cardiothorac Surg** 1995; 9(8):426-31; discussion 431-2

Pancreaticoduodenectomy under epidural anesthesia without endotracheal intubation for the elderly. Nakashima H, et al. **Int Surg** 1995 Apr-Jun;80(2):125-7

Hospital volume, calendar age, and short term outcomes in patients undergoing repair of abdominal aortic aneurysms: the Ontario experience, 1988-92. Wen SW, et al. **J Epidemiol Community Health** 1996 Apr;50(2):207-13

Prognostic determinants of six-month morbidity and mortality in heart transplant recipients. The Italian Study Group on Infection in Heart Transplantation. De Maria R, et al. **J Heart Lung Transplant** 1996 Feb;15(2):124-35

Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. Freimark D, et al. **J Heart Lung Transplant** 1996 Feb;15(2):150-9

Donor-recipient size matching in pediatric heart transplantation: a word of caution about small grafts. Tamisier D, et al. **J Heart Lung Transplant** 1996 Feb; 15(2):190-5

Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. Valentine VG, et al. **J Heart Lung Transplant** 1996 Apr; 15(4):371-83

Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. Yeatman M, et al. **J Heart Lung Transplant** 1996 Feb;15(2):144-9

Prognostic indicators in congenital diaphragmatic hernia. Dimitriou G, et al. **J Pediatr Surg** 1995 Dec;30(12):1694-7

Severity of disease score as a predictor of mortality after caval filter insertion. McLoughlin RF, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):715-9

Audit of surgical delay in relationship to outcome after proximal femoral fracture. Beringer TR, et al. **Ulster Med J** 1996 May;65(1):32-8

Prediction of early cardiac morbidity and mortality following aorto-iliac reconstruction: comparison between clinical scoring systems, echocardiography and dipyridamole-thallium scanning. Carrel T, et al. **Vasa** 1995; 24(4):362-7

Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan [see comments] Lee WJ, et al. **World J Surg** 1995 Sep-Oct;19(5):707-13. Comment in: World J Surg 1996 Jul-Aug;20(6):725.

Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Kiwit JC, et al. **Zentralbl Neurochir** 1996;57(2):76-88

[Perioperative risk in heart surgery. An original material and review of difficulties in correct comparisons with other materials] Sanchez Garcia R, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6720-5 (Eng. Abstr.) **(Dan)**

[Severity scores underestimate the seriousness of acute renal failure after emergency surgery] Frikha M, et al. **Ann Fr Anesth Reanim** 1995;14(6):478-83 (Eng. Abstr.) **(Fre)**

[Risk factors in elderly surgical patients. A prospective study] Tschantz P, et al. **Swiss Surg** 1995;(3):140-7 (Eng. Abstr.) **(Fre)**

[Risk assessment before elective visceral surgery interventions] Klotz HP, et al. **Swiss Surg** 1995;(3):136-9 (Eng. Abstr.) **(Ger)**

[Heart surgery in the elderly] Klima U, et al. **Wien Klin Wochenschr** 1995;107(21):645-50 (Eng. Abstr.) **(Ger)**

[Early and late outcome of gastrectomy de principe] Dietl F, et al. **Zentralbl Chir** 1995;120(10):800-3 (Eng. Abstr.) **(Ger)**

[Lymph node excision in stomach cancer--a statistical analysis of survival and surgical mortality] Hassdenteufel A, et al. **Zentralbl Chir** 1995;120(10):791-4 (Eng. Abstr.) **(Ger)**

[Effect of lymph node dissection on prognosis of colon carcinoma] Klupp J, et al. **Zentralbl Chir** 1995; 120(10):821-5 (Eng. Abstr.) **(Ger)**

[Postoperative morbidity/mortality in gastric cancer according to the rules of the Japanese Society: preliminary report] Onorato A, et al. **G E N** 1995 Jul-Sep;49(3):202-7 (Eng. Abstr.) **(Spa)**

NURSING

Assessment of postdischarge concerns of coronary artery bypass graft patients. Wu CY. **J Cardiovasc Nurs** 1995 Oct; 10(1):1-7

Deep vein thrombosis and pulmonary emboli in neuroscience patients. Fowler SB. **J Neurosci Nurs** 1995 Aug;27(4):224-8

PATHOLOGY

Histopathologic and immunohistochemical analysis of the filtration bleb after unsuccessful glaucoma seton implantation. Classen L, et al. **Am J Ophthalmol** 1996 Aug; 122(2):205-12

Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Schindler MB, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1347-52

Pouch-anal cancer after restorative proctocolectomy for familial adenomatous polyposis. von Herbay A, et al. **Am J Surg Pathol** 1996 Aug;20(8):995-9

Validation of the Banff criteria for acute rejection in renal transplant biopsies [see comments] Dittmer ID, et al. **Aust N Z J Med** 1995 Dec;25(6):681-7. Comment in: Aust N Z J Med 1995 Dec;25(6):663-5.

Gallstone ileus following endoscopic sphincterotomy. Gandhi A, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):229-30

Histopathology of episcleral fibrosis after trabeculectomy with and without mitomycin C. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jun;234(6):364-8

A clinopathologic review of 8 liver graft primary nonfunctions. Colina F, et al. **Hepatogastroenterology** 1995 Jul;42(3):212-21

Long-term endothelial cell loss following phacoemulsification through a temporal clear corneal incision. Dick HB, et al. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):63-71

Effect of peripheral subepithelial fibrosis on corneal transplant topography. Geggel HS. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):135-8

Continuous curvilinear capsulorhexis and intraocular lens biocompatibility. Pande M, et al. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):89-97

Localized bullous separation of Descemet's membrane after previous cataract surgery. Singh D. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):147-9

After-cataract formation in newborn rabbits implanted with intraocular lenses. Zetterström C, et al. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):85-8

Proliferative activity in metastatic malignant melanoma: comparison of pre-treatment and post-treatment metastases. Barksdale SK, et al. **J Cutan Pathol** 1995 Aug; 22(4):354-8

Transplant arterial vasculopathy: evidence for a dual pattern of endothelial injury and the source of smooth muscle cells in lesions of intimal hyperplasia. Aziz S, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S123-36

Utility of surveillance biopsies in infant heart transplant recipients. Balzer DT, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1095-101

Does intracoronary ultrasound conflict with pathology? Comments from a panel discussion. Billingham ME. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S211-4

Short-term survivors of pediatric heart transplantation: an autopsy study of their pulmonary vascular disease. Collins MH, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1116-25

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S142-9 (84 ref.)

Persistence of interstitial inflammation after episodes of cardiac rejection associated with systemic infection. Durham JR, et al. **J Heart Lung Transplant** 1995 Jul-Aug; 14(4):774-80

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S149-58 (59 ref.)

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S207-11 (20 ref.)

Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. Pomerance A, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):761-73

Cytokine-mediated fibronectin production and transendothelial migration of lymphocytes in the mechanism of cardiac allograft vascular disease: efficacy of novel therapeutic approaches. Rabinovitch M, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S116-23

Direct retroperitoneoscopic adrenalectomy in the porcine model. Hoenig DM, et al. **J Laparoendosc Surg** 1995 Dec; 5(6):385-8

Post-stapedectomy reparative granuloma: a misnomer. Fenton JE, et al. **J Laryngol Otol** 1996 Feb;110(2):185-8

Incision depth vs. incision number in the rupture strength of pig eyes following radial keratotomy. Kung JS, et al. **J Refract Surg** 1996 Feb;12(2):S294-6

Effect of rat mesenchymal stem cells on development of abdominal adhesions after surgery. Lucas PA, et al. **J Surg Res** 1996 May;62(2):229-32

Post-transplantation lymphoproliferative disorder in the renal transplant ureter. Senel MF, et al. **J Urol** 1996 Jun; 155(6):2025

Natural course of postsurgical adhesions. Bakkum EA, et al. **Microsurgery** 1995;16(9):650-4

Endophthalmitis in patients with retained lens fragments after phacoemulsification. Kim JE, et al. **Ophthalmology** 1996 Apr;103(4):575-8

Osteolysis: a generic problem. Bauer TW, et al. **Orthopedics** 1995 Sep;18(9):791-4

The lessons of acetabular component fixation. Harris WH. **Orthopedics** 1995 Sep;18(9):811-2

Orthotopic bladder substitutes: histopathologic risk factors. Nabeeh A, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):463-7

Recurrent hemolytic uremic syndrome in a renal transplant patient during pregnancy. Søilling J, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):507-10

MR imaging of cerebrospinal fluid rhinorrhea following the suboccipital approach to the cerebellopontine angle and the internal auditory canal: report of the two cases. Kabuto M, et al. **Surg Neurol** 1996 Apr;45(4):336-40

[A clinico-morphological study of cancer of the gastric stump following an operation for benign disease] Khubaveshka B, et al. **Khirurgiia (Sofiia)** 1995;48(4):23-5 (Eng. Abstr.) **(Bul)**

[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230-8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Spherulocytosis (myospherulosis) of the paranasal sinuses] Godbersen GS, et al. **HNO** 1995 Sep;43(9):552–5 (Eng. Abstr.) **(Ger)**

[Descemetocele after Excimer laser phototherapeutic keratectomy in herpes simplex virus-induced keratitis: a clinico-pathologic correlation] Bialasiewicz AA, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):120–3 (Eng. Abstr.) **(Ger)**

[Endothelial cell loss after phacoemulsification and 3.5 vs. 5 mm corneal tunnel incision] Dick B, et al. **Ophthalmologe** 1995 Aug;92(4):476–83 (Eng. Abstr.) **(Ger)**

[Recurrent vitreoretinal membranes in intravitreal silicon oil tamponade. Morphologic and immunohistochemical studies] Heidenkummer HP, et al. **Ophthalmologe** 1996 Apr; 93(2):121–5 (Eng. Abstr.) **(Ger)**

[Changes in bulbus geometry after conventional detachment surgery. Study using video keratoscopy] Müller-Albach KA, et al. **Ophthalmologe** 1995 Oct;92(5):677–80 (Eng. Abstr.) **(Ger)**

[Corneal changes and corneal healing after keratomileusis in situ. In vivo studies using confocal slit-scanning microscopy] Nagel S, et al. **Ophthalmologe** 1995 Aug; 92(4):397–401 (Eng. Abstr.) **(Ger)**

[Predicting recurrent pterygium based on morphologic and immunohistologic parameters] Rohrbach IM, et al. **Ophthalmologe** 1995 Aug;92(4):463–8 (Eng. Abstr.) **(Ger)**

[Scar formation in the cornea after photorefractive keratectomy] Seiler T, et al. **Ophthalmologe** 1995 Aug; 92(4):492–5 (Eng. Abstr.) **(Ger)**

[Neurocysticercosis] Roos G, et al. **Pathologe** 1995 Sep; 16(5):348–53 (Eng. Abstr.) **(Ger)**

[Minor abdominal trauma by laparoscopic surgery? Comparison of adhesion formation and intestinal motility after laparoscopic and conventional operations in the dog] Tittel A, et al. **Zentralbl Chir** 1996;121(4):329–34 (Eng. Abstr.) **(Ger)**

[Intrafascial hysterectomy ("CISH" method; cervical intrafascial Semm hysterectomy)—can the risk of cervix stump carcinoma be calculated?] Kruczynski D, et al. **Zentralbl Gynakol** 1996;118(1):1–5 (Eng. Abstr.) **(Ger)**

[Surgical treatment of benign prostatic hypertrophy and Kelami syndrome] Bodo G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):81–3 (Eng. Abstr.) **(Ita)**

[Epididymal malacoplakia in a heart transplant recipient: clinico-pathologic study of a case] Soria Corón MR, et al. **Arch Esp Urol** 1996 Mar;49(2):172–6 (15 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The blink reflex before and after percutaneous glycerol rhizotomy in patients with trigeminal neuralgia—a prospective study of 28 patients. Kumar R, et al. **Acta Neurochir (Wien)** 1995;137(1-2):85–8

Correlation of fornix damage with memory impairment in six cases of colloid cyst removal. McMackin D, et al. **Acta Neurochir (Wien)** 1995;135(1-2):12–8

Life satisfaction and sexuality in patients operated for epilepsy. Christianson SA, et al. **Acta Neurol Scand** 1995 Jul;92(1):1–6

Regression of moyamoya vessels and hemodynamic changes after successful revascularization in childhood moyamoya disease. Kashiwagi S, et al. **Acta Neurol Scand Suppl** 1996; 166:85–8

Presence and removal of arteriovenous malformation: Impact of regional cerebral blood flow, as assessed with xenon/CT. Van Roost D, et al. **Acta Neurol Scand Suppl** 1996; 166:136–8

Surgical modulation of the natural course of collateral circulation in chronic ischemic patients. Yamashita T, et al. **Acta Neurol Scand Suppl** 1996;166:74–8

Modulation of cerebral hemodynamics by surgical revascularization in patients with moyamoya disease. Yamashita T, et al. **Acta Neurol Scand Suppl** 1996;166:82–4

The effect of unilateral posterior semicircular canal inactivation on the human vestibulo-ocular reflex. Aw ST, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:260–2

"Dumping" of activity within the VOR is possible after unilateral vestibular neurectomy. Brantberg K, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:57–8

Torsional eye velocity components during yaw angular acceleration identify the side of unilateral vestibular deafferentation. Haslwanter T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:62–4

Vertical and torsional VOR in posterior canal occlusion. Kanayama R, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:362–5

Perceptual studies in patients with vestibular neurectomy. Kanayama R, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:408–11

Postural control and vestibular function in patients selected for cochlear implantation. Magnusson M, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:277–8

Quantitative evaluation of the motor deficit after supplementary sensorimotor area resection. Morrell F, et al. **Adv Neurol** 1996;70:451–9

Mobility after proximal femoral fracture: the relevance of leg extensor power, postural sway and other factors. Lamb SE, et al. **Age Ageing** 1995 Jul;24(4):308–14

Relationship between gastroesophageal reflux and gastric emptying after distal gastrectomy. Fujiwara Y, et al. **Am J Gastroenterol** 1996 Jan;91(1):75–9

Delayed onset facial nerve dysfunction following acoustic neuroma surgery. Lalwani AK, et al. **Am J Otol** 1995 Nov; 16(6):758–64

Facial nerve stimulation after successful multichannel cochlear implantation. Shea JJ 3rd, et al. **Am J Otol** 1994 Nov;15(6):752–6

Importance of crossover innervation in digital nerve repair demonstrated by nerve isolation technique. Tadjalli HE, et al. **Ann Plast Surg** 1995 Jul;35(1):32–5

Digital nerve repair: relationship between severity of injury and sensibility recovery. Tadjalli HE, et al. **Ann Plast Surg** 1995 Jul;35(1):36–40

Route of nutritional supply influences local, systemic, and remote organ responses to intraperitoneal bacterial challenge. Lin MT, et al. **Ann Surg** 1996 Jan;223(1):84–93

Mechanisms of right ventricular dysfunction after pulmonary resection. Reed CE, et al. **Ann Thorac Surg** 1996 Jul; 62(1):225–31; discussion 231–2

Loss of vertical palpebral fissure height on downgaze in acquired blepharoptosis [see comments] Olson JJ, et al. **Arch Ophthalmol** 1995 Oct;113(10):1293–7. Comment in: Arch Ophthalmol 1996 Jun;114(6):774.

Postoperative shivering: the influence of body temperature [editorial] Crossley AW. **BMJ** 1995 Sep 23;311(7008):764–5

Recognition memory for words and faces following unilateral temporal lobectomy. Morris RG, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):571–6

Swallowing performance following anterior cervical spine surgery. Stewart M, et al. **Br J Neurosurg** 1995;9(5):605–9

Does an aortopulmonary shunt before repair of tetralogy of Fallot limit exercise tolerance in long-term survivors? Leyh R, et al. **Cardiovasc Surg** 1995 Aug;3(4):369–74

Interventional physiology. Part XIII: Role of large pectoralis branch artery in flow through a patent left internal mammary artery conduit. Kern MJ, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):240–4

Bronchodilator response at low lung volumes predicts bronchiolitis obliterans in lung transplant recipients. Rajagopalan N, et al. **Chest** 1996 Feb;109(2):405–7

The light-flash-evoked response as a possible indicator of increased intracranial pressure in hydrocephalus. Sjöström A, et al. **Childs Nerv Syst** 1995 Jul;11(7):381–7; discussion 387

New aspects concerning the regulation of the post-operative acute phase reaction during cardiac surgery. Berger D, et al. **Clin Chim Acta** 1995 Aug 14;239(2):121–30

Erythrocytosis after renal transplantation: risk factors and relationship with GFR. Nankivell BJ, et al. **Clin Transplant** 1995 Oct;9(5):375–82

Influence of patient sex and clinical history on working capacity and myocardial ischemia after coronary artery bypass surgery. Sjöland H, et al. **Coron Artery Dis** 1995 Jul;6(7):561–71

Impaired naming and preserved reading: a complete dissociation. Breen K, et al. **Cortex** 1995 Sep;31(3):583–8

Fornix damage and memory. A case report. Calabrese P, et al. **Cortex** 1995 Sep;31(3):555–64

Cognitive effects of resecting basal temporal language areas. Krauss GL, et al. **Epilepsia** 1996 May;37(5):476–83

Lung function in relation to haemodynamic status after atrial redirection for transposition of the great arteries. Gilljam T, et al. **Eur Heart J** 1995 Dec;16(12):1952–9

Haemodynamic and metabolic effects of surface rewarming after coronary revascularization. Cavaliere F, et al. **Eur J Cardiothorac Surg** 1995;9(10):582–6

Posterior sagittal anorectoplasty: functional results of primary and secondary operations in comparison to the pull-through method in anorectal malformations. Mulder W, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):170–3

Sensation in the anal region and rectum after surgery for anorectal malformations. Nagashima M, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):167–9

Is haemodynamical compromise a specific cause of border zone brain infarcts following cardiac surgery? Hupperts R, et al. **Eur Neurol** 1995;35(5):276–80

Incidence and pathophysiological relevance of postoperative endotoxemia. Berger D, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):285–90

Frequency, manifestations, and correlates of impaired healing of saphenous vein harvest incisions. Wipke-Tevis DD, et al. **Heart Lung** 1996 Mar-Apr;25(2):108–16

A clinopathologic review of 8 liver graft primary nonfunctions. Colina F, et al. **Hepatogastroenterology** 1995 Jul;42(3):212–21

A proposal mechanism of early delayed gastric emptying after pylorus preserving pancreatoduodenectomy. Ueno T, et al. **Hepatogastroenterology** 1995 Jul;42(3):269–74

Endotoxemia is associated with renal dysfunction in liver transplantation recipients during the first postoperative week. Yokoyama I, et al. **Hepatogastroenterology** 1995 Jul; 42(3):205–8

Transaxillary first rib resection for thoracic outlet syndrome: follow-up of 9 cases. Hussein EA, et al. **Int Angiol** 1995 Dec;14(4):404–9

Atrial ectopic activity and atrial fibrillation/flutter after coronary artery bypass surgery. A case-base study controlling for confounding from age, beta-blocker treatment, and time distance from operation. Frost L, et al. **Int J Cardiol** 1995 Jun 30;50(2):153–62

Time course of endothelial function in epicardial conduit coronary arteries and in the microcirculation in the long-term follow-up after cardiac transplantation. Hartmann A, et al. **Int J Cardiol** 1996 Feb;53(2):127–36

The comparison of vascular reactivities of arterial and venous grafts to vasodilators: management of graft spasm. Uydeş-Doğan BS, et al. **Int J Cardiol** 1996 Feb; 53(2):137–45

Tolerance of chronically-diseased liver to prolonged hemihepatic ischemia during hepatectomy. Kim YI, et al. **Int Surg** 1995 Apr-Jun;80(2):108–10

Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. Havenga K, et al. **J Am Coll Surg** 1996 Jun;182(6):495–502

Measurement of bone mineral density by dual-energy x-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem. Kiratli BJ, et al. **J Arthroplasty** 1996 Feb;11(2):184–93

Significance of the Trendelenburg test in total hip arthroplasty. Influence of lateral approaches. Pai VS. **J Arthroplasty** 1996 Feb;11(2):174–9

Role of inflammatory mediators and adhesion molecules in the pathogenesis of aseptic loosening in total hip arthroplasties. Sabokbar A, et al. **J Arthroplasty** 1995 Dec; 10(6):810–6

Modified trabeculectomy/trabeculotomy with no-stitch cataract surgery. Bloomberg LB. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):14–22

Corneal epithelial permeability after excimer laser photorefractive keratectomy. Kim KS, et al. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):44–50

Sudden postoperative death of a "recreational" drug user [letter] Colclough GW, et al. **J Clin Anesth** 1996 Mar; 8(2):168–9

Midcarpal arthrodesis. Siegel JM, et al. **J Hand Surg [Am]** 1996 Mar;21(2):179–82

Dynamic scapholunate instability: results of operative treatment with dorsal capsulodesis. Wintman BI, et al. **J Hand Surg [Am]** 1995 Nov;20(6):971–9

Allograft Coronary Disease: A Basic Science and Clinical Review. Proceedings of the 2nd International Symposium. St. Louis, Missouri, January 31-February 1, 1996. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S109–254

Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. Bando K, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):692–8

Basis for aerobic impairment in patients after heart transplantation. Bussières LM, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1073–80

Increased incidence of chronotropic incompetence in older donor hearts. Chau EM, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):743–8

Successful transplantation of a donor heart with prior non-Q-wave myocardial infarction [letter] Frigerio M, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):797–8

Influence of the exercise protocol on hemodynamic, gas exchange, and neurohumoral responses to exercise in heart transplant recipients. Gullestad L, et al. **J Heart Lung Transplant** 1996 Mar;15(3):304–13

Occult restrictive hemodynamics after pediatric heart transplantation. Pahl E, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1109–15

Optimal size matching in single lung transplantation. Park SJ, et al. **J Heart Lung Transplant** 1995 Jul-Aug; 14(4):671–5

Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second. Patterson GM, et al. **J Heart Lung Transplant** 1996 Feb;15(2):175–81

Incidence of phrenic neuropathy after isolated lung transplantation. The Loyola University Lung Transplant Group. Sheridan PH Jr, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):684–91

Left atrial dysfunction after orthotopic heart transplantation [letter] Starling RC, et al. **J Heart Lung Transplant** 1996 Apr;15(4):431–2

Temporary loss of intraoperative motor-evoked potential and permanent loss of somatosensory-evoked potentials associated with a postoperative sensory deficit. Lorenzini NA, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):142–7

Long-term effects of gastric transposition in children: a physiological study. Davenport M, et al. **J Pediatr Surg** 1996 Apr;31(4):588–93

Mathematical simulation of retinal image contrast after photorefractive keratectomy with a diaphragm mask. Ludwig K, et al. **J Refract Surg** 1996 Feb;12(2):248–53

Outcomes in surgical treatment of femoral neck fracture: analysis of failures secondary to osteonecrosis. Vail TP, et al. **J South Orthop Assoc** 1995 Summer;4(2):83–90

Surgical technique and atrial arrhythmias after total cavopulmonary connection [letter; comment] Gandhi SK, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1291–2. Comment on: J Thorac Cardiovasc Surg 1995 Sep;110(3):625–32.

Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting. Patel RL, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1267–79

Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. te Velthuis H, et al. **J Thorac Cardiovasc Surg** 1995

Dec;110(6):1663–9

Post–prostatectomy incontinence: urodynamic findings and treatment outcomes. Leach GE, et al. **J Urol** 1996 Apr; 155(4):1256–9

Bone mineral loss and recovery after cardiac transplantation [letter] Henderson NK, et al. **Lancet** 1995 Sep 30; 346(8979):905

Quantitative criteria for predicting thyroplasty type I outcome. Omori K, et al. **Laryngoscope** 1996 Jun; 106(6):689–93

Associated movement as a sequel to thoracotomy: aberrant regeneration to the latissimus dorsi muscle. Kuwabara S, et al. **Mov Disord** 1995 Nov;10(6):788–90

Neuromuscular complications associated with liver transplantation. Wijdicks EF, et al. **Muscle Nerve** 1996 Jun; 19(6):696–700

A case of renovascular hypertension with marked polyuria after percutaneous transluminal renal angioplasty. Tamatani M, et al. **Nephron** 1996;73(1):79–85

Recovery of gastrointestinal motility from post–operative ileus in dogs: effects of Leu13–motilin (KW–5139) and prostaglandin F2 alpha. Yokoyama T, et al. **Neurogastroenterol Motil** 1995 Dec;7(4):199–210

Brain damage and postoperative hyponatremia: the role of gender. Ayus JC, et al. **Neurology** 1996 Feb;46(2):323–8 (72 ref.)

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

Predictors of ability to walk after selective dorsal rhizotomy in children with cerebral palsy. Chicoine MR, et al. **Neurosurgery** 1996 Apr;38(4):711–4; discussion 714

The mapping and continuous monitoring of the intrinsic motor nuclei during brain stem surgery. Eisner W, et al. **Neurosurgery** 1995 Aug;37(2):255–65

Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885–93 (39 ref.)

On the pathogenesis of the radiculopathy complicating multilevel corpectomy. Saunders RL. **Neurosurgery** 1995 Sep;37(3):408–12; discussion 412–3

Intracerebral microdialysis of glutamate and aspartate in two vascular territories after aneurysmal subarachnoid hemorrhage. Säveland H, et al. **Neurosurgery** 1996 Jan; 38(1):12–9; discussion 19–20

Transient cerebellar mutism after posterior fossa surgery in children. Van Calenbergh F, et al. **Neurosurgery** 1995 Nov; 37(5):894–8 (32 ref.)

Extent of medial temporal resection on outcome from anterior temporal lobectomy: a randomized prospective study. Wyler AR, et al. **Neurosurgery** 1995 Nov; 37(5):982–90; discussion 990–1

Cerebral hyperemia after arteriovenous malformation resection is related to "breakthrough" complications but not to feeding artery pressure. The Columbia University Arteriovenous Malformation Study Project. Young WL, et al. **Neurosurgery** 1996 Jun;38(6):1085–93; discussion 1093–5

Extensor mechanism complications after total knee arthroplasty. Stulberg SD. **Orthopedics** 1995 Sep; 18(9):919–20

The JT interval as a depolarization independent measurement of repolarization: lessons from catheter ablation of the Wolff–Parkinson–White syndrome. Salim MA, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2158–62

Persistent hemolysis after transcatheter occlusion of a patent ductus arteriosus: surgical ligation of the duct over the occlusion device. Chisholm JC, et al. **Pediatr Cardiol** 1995 Jul–Aug;16(4):194–6

Late pulmonary function following repair of tracheoesophageal fistula or esophageal atresia. Robertson DF, et al. **Pediatr Pulmonol** 1995 Jul;20(1):21–6

Cold–induced vasospasm after finger replantation; abnormal sensory regeneration and sensitisation of cold nociceptors. Povlsen B. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar;30(1):63–6

Voiding dysfunction and urodynamic findings in patients with lumbar spinal stenosis and the effect of decompressive laminectomy. Hellström PA, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):167–71

Manual performance in leukotomized and unleukotomized individuals with schizophrenia. Carnahan H, et al. **Schizophr Res** 1995 Nov;17(3):267–78

Evaluation of pain perception after anterior capsulotomy: a case report. Talbot JD, et al. **Somatosens Mot Res** 1995; 12(2):115–26

Laparoscopic reoperations after failed and complicated antireflux operations. DePaula AL, et al. **Surg Endosc** 1995 Jun;9(6):681–6

Nitric oxide and active oxygen species in severe sepsis and surgically stressed patients. Tanjoh K, et al. **Surg Today** 1995;25(9):774–7

Clinical outcome of orthopaedic patients with negative lower limb venography at discharge. Agnelli G, et al. **Thromb Haemost** 1995 Oct;74(4):1042–4

Structural and functional aspects of the thoracic stomach. Chattopadhyay TK, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):55–8

Remission of severe alcoholic polyneuropathy after liver transplantation. Spahn TW, et al. **Z Gastroenterol** 1995 Dec; 33(12):711–4

Effect of endoscopic sphincterotomy on sphincter of Oddi manometry results in patients with or without papillary stenosis. Wehrmann T, et al. **Z Gastroenterol** 1995 Nov; 33(11):662–8

[Spontaneous resolution of urodynamically proven sphincter lesion following surgery for prostatic hyperplasia] Fuglsig S, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2126–8 (Eng. Abstr.) **(Dan)**

[Urodynamic study of obstruction induced by vesicoureteral reflux surgery with submucosal advance in beagle female dogs] Guillonneau B, et al. **Prog Urol** 1995 Dec;5(6):933–40; discussion 940–1 (Eng. Abstr.) **(Fre)**

[Complications caused by patient positioning in unidentified "thoracic outlet syndrome"] Peterson T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):516–8 (Eng. Abstr.) **(Ger)**

[Metabolic alkalosis after heart surgery interventions in childhood] Schranz D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S65–8 **(Ger)**

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

[Contra cervix extirpation] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):362–71 (25 ref.) **(Ger)**

[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

[Follow–up of tooth vitality with laser Doppler flowmetry in transplanted teeth] Mensdorff–Pouilly N, et al. **Fortschr Kiefer Gesichtschir** 1995;40:80–3 (Eng. Abstr.) **(Ger)**

[Incidence and regeneration time of disorders of the inferior alveolar nerve in osteosynthesis of mandibular fractures—a prospective clinical study] Schultze–Mosgau S, et al. **Fortschr Kiefer Gesichtschir** 1996;41:108–11 (Eng. Abstr.) **(Ger)**

[Manometric and clinical long–term outcome after grade III perineal rupture] Anthuber C, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:137–41 (Eng. Abstr.) **(Ger)**

[Effect of needle suspension on continence mechanisms] Pieber D, et al. **Gynakol Geburtshilfliche Rundsch** 1995; 35(3):170–2 (Eng. Abstr.) **(Ger)**

[5 years results of incontinence operations] Tamussino K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):175–6 (Eng. Abstr.) **(Ger)**

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**

[Experimental principles for preserving annulo–ventricular integrity of the mitral valve] Gams E, et al. **Herz** 1996 Jun;21(3):144–58 (Eng. Abstr.) **(Ger)**

[Stapes–plasty and diving sports. Is diving after stapes–plasty really indicated? (letter)] Strutz J. **HNO** 1995 Aug; 43(8):465, discussion 466 **(Ger)**

[Stapes–plasty and diving sports. Condition of the ear and diving capacity (letter)] Zeller T. **HNO** 1995 Aug; 43(8):465–6 **(Ger)**

[How reproducible and stable is intraocular pressure reduction after extracapsular cataract extraction?] Jahn CE, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):348–52 (Eng. Abstr.) **(Ger)**

[Biomechanical study of corneal stability after radial keratotomy] Kohlhaas M, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):285–7 (Eng. Abstr.) **(Ger)**

[Motility and binocular function after radial episcleral buckle] Schrader WF, et al. **Klin Monatsbl Augenheilkd** 1995 Oct; 207(4):224–31 (Eng. Abstr.) **(Ger)**

[Evaluation of deprivation manifestations of the auditory system in patients with unilateral middle ear deafness before and after surgical therapy] Vorwerk U, et al. **Laryngorhinootologie** 1996 Apr;75(4):195–8 (Eng. Abstr.) **(Ger)**

[Photorefractive keratectomy (PRK). The limits of our knowledge] Epstein D. **Ophthalmologe** 1995 Aug; 92(4):385–8 (Eng. Abstr.) **(Ger)**

[Results of cyclodialysis combined goniotomy in treatment of dysgenetic glaucoma] Klemm M, et al. **Ophthalmologe** 1995 Aug;92(4):531–5 (Eng. Abstr.) **(Ger)**

[Decrease of retinal image contrast after photorefractive keratectomy, improvement within the scope of surface restitution] Ludwig K, et al. **Ophthalmologe** 1996 Jun; 93(3):232–6 (Eng. Abstr.) **(Ger)**

[Postoperative stress on by dynamic hip screw or endoprostheses treated femoral neck and pertrochanteric femoral fractures in elderly patients] Tucci M, et al. **Swiss Surg** 1996;(2):67–71 (Eng. Abstr.) **(Ger)**

[Biomechanical study of the initial stability of various arthrodesis methods for the upper ankle joint] Pommer A, et al. **Unfallchirurg** 1995 Oct;98(10):535–9 (Eng. Abstr.) **(Ger)**

[Functional treatment of acute rupture of the Achilles tendon. An experimental biomechanical study] Thermann H, et al. **Unfallchirurg** 1995 Oct;98(10):507–13 (Eng. Abstr.) **(Ger)**

[Postoperative homeostatic imbalance after trauma surgical interventions of various degrees in polytrauma] Waydhas C, et al. **Unfallchirurg** 1995 Sep;98(9):455–63 (Eng. Abstr.) **(Ger)**

[Muscle incoordination phenomena after surgical management of proximal rupture of the biceps tendon] Schmidt I, et al. **Unfallchirurgie** 1995 Oct;21(5):227–32 (Eng. Abstr.) **(Ger)**

[Electromyography studies of surgically managed knee ligament ruptures. A retrospective analysis of defined injury patterns] Wening JV, et al. **Unfallchirurgie** 1996 Feb; 22(1):20–9 (Eng. Abstr.) **(Ger)**

[Electrocardiographic examinations after orthotopic heart transplantation] Kriehuber E. **Wien Med Wochenschr** 1995; 145(21):587–94 (Eng. Abstr.) **(Ger)**

[Changes in fecal bile acid excretion after proctocolectomy] Brüwer M, et al. **Z Gastroenterol** 1996 Feb;34(2):105–10 (Eng. Abstr.) **(Ger)**

[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Methodology of microtransducer manometry in the anal canal] Schaube J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:100–1 **(Ger)**

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Stress reaction of pulmonary artery pressure in the early and chronic phase after heart transplantation: comparison with healthy control probands] Schnaack S, et al. **Z Kardiol** 1995 Nov;84(11):930–8 (Eng. Abstr.) **(Ger)**

[Measuring spatial micro–movement of the femur shaft of endoprostheses in relation to the spatial force system] Nägerl H, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr; 134(2):99–110 (Eng. Abstr.) **(Ger)**

[Postoperative changes of maximum inspiratory and expiratory pressures in 3 pneumonia cases occurring after surgery for empyema] Nomori H, et al. **Kyobu Geka** 1996 Jun;49(6):445–8 (Eng. Abstr.) **(Jpn)**

[Strength of leg and foot muscles after surgical treatment for clubfoot] Napiontek M, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(5):393–401 (Eng. Abstr.) **(Pol)**

[Physiology and physiopathology of postoperative disease. Therapeutic implications] Vara–Thorbeck R. **Nutr Hosp** 1995 Sep–Oct;10(5):286–96 (68 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Monitoring and treatment of cerebral hyperperfusion in the immediate postoperative period following craniotomy for supratentorial tumors [letter; comment] Chieregato A, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1138–9. Comment on: Acta Anaesthesiol Scand 1994 Apr;38(3):271–5.

Effect of P–6 acupressure on prevention of nausea and vomiting after epidural morphine for post–cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):372–5

Heterotopic ossification after hip arthroplasty: a randomized double–blind multicenter study tenoxicam in 147 hips. Gebuhr P, et al. **Acta Orthop Scand** 1996 Feb;67(1):29–32

Hearing preservation in acoustic tumour surgery. Samii M, et al. **Adv Tech Stand Neurosurg** 1995;22:343–73

Wetting solutions in aspirative lipoplasty: a plea for safety in liposuction [editorial] Fodor PB. **Aesthetic Plast Surg** 1995 Jul–Aug;19(4):379–80

Prevention and treatment of linear scar formation in the scalp: basic principles of the mechanism of scar formation. Inaba Y, et al. **Aesthetic Plast Surg** 1995 Jul–Aug;19(4):369–78

Beta–carbolines in chronic alcoholics undergoing elective tumor resection. Spies CD, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):969–76

"Bailout" coronary stenting in patients with a recent myocardial infarction. Thomas CN, et al. **Am J Cardiol** 1996 Mar 15;77(8):653–5

Postoperative atelectasis and pneumonia: risk factors. Brooks–Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

Transvaginal sacrospinous colpopexy: anatomic landmarks to be aware of to minimize complications [see comments] Verdeja AM, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1468–9. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):235–6.

Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. Nasir MA, et al. **Am J Ophthalmol** 1996 May;121(5):554–60

Beware of absent femoral pulse (or how to prevent major complications after minor procedures) [letter; comment] Ezzet KA, et al. **Am J Orthop** 1995 Sep;24(9):713, 716. Comment on: Am J Orthop 1995 May;24(3):265–8.

Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus. Stannard JP, et al. **Am J Orthop** 1996 Feb;25(2):127–34

Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2. Black FO, et al. **Am J Otol** 1995 Jul;16(4):431–43 (51 ref.)

Autologous fibrin glue in the prevention of cerebrospinal fluid leak following acoustic neuroma surgery. Lebowitz RA, et al. **Am J Otol** 1995 Mar;16(2):172–4

Meatal facial nerve decompression in acoustic neuroma resection. Sargent EW, et al. **Am J Otol** 1995 Jul; 16(4):457–64

The transconjunctival approach in the trauma setting: avoidance of complications. Fedok FG. **Am J Otolaryngol** 1996 Jan-Feb;17(1):16–21

The effect of femoral tunnel position and graft tensioning technique on posterior laxity of the posterior cruciate ligament–reconstructed knee. Burns WC 2nd, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):424–30

The effect of drilling and soft tissue grafting across open growth plates. A histologic study. Stadelmaier DM, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):431–5

Morbidity risk assessment in the surgically anemic patient. Carson JL. **Am J Surg** 1995 Dec;170(6A Suppl):32S–36S (53 ref.)

Blood-flow augmentation of intermittent pneumatic compression systems used for prevention of deep vein thrombosis prior to surgery. Flam E, et al. **Am J Surg** 1996 Mar;171(3):312–5

Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Goldberg MA. **Am J Surg** 1995 Dec;170(6A Suppl):37S–43S

Surgical infections: prevention and treatment—1965 to 1995. Nichols RL. **Am J Surg** 1996 Jul;172(1):68–74 (54 ref.)

Elimination of the Roux stasis syndrome using a new type of "uncut Roux" limb. Tu BN, et al. **Am J Surg** 1995 Oct; 170(4):381–6

Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. Major CP Jr, et al. **Am Surg** 1996 Jan;62(1):45–51

A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Arfeen Z, et al. **Anaesth Intensive Care** 1995 Aug;23(4):449–52

A double-blind randomized prospective study comparing ondansetron with droperidol in the prevention of emesis following strabismus surgery. Davis A, et al. **Anaesth Intensive Care** 1995 Aug;23(4):438–43

Intraoperative ventilation with air and oxygen during laparoscopic cholecystectomy decreases the degree of postoperative hypoxaemia. Fujii Y, et al. **Anaesth Intensive Care** 1996 Feb;24(1):42–4

Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. Paech MJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):548–54

Pain and vomiting after vitreoretinal surgery: a potential role for local anaesthesia. Williams N, et al. **Anaesth Intensive Care** 1995 Aug;23(4):444–8

Tropisetron and metoclopramide in the prevention of postoperative nausea and vomiting. A comparative, placebo controlled study in patients undergoing ophthalmic surgery. Ali-Melkkilä T, et al. **Anaesthesia** 1996 Mar; 51(3):232–5

The efficacy and optimum time of administration of ranitidine in the prevention of the acid aspiration syndrome. Escolano F, et al. **Anaesthesia** 1996 Feb;51(2):182–4

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255–62 (63 ref.)

Infusions of subhypnotic doses of propofol for the prevention of postoperative nausea and vomiting. Montgomery JE, et al. **Anaesthesia** 1996 Jun;51(6):554–7

Prophylactic nitroglycerine and incidence of myocardial ischemia in high risk patients following major surgery [letter] Pancoast P, et al. **Anaesthesia** 1996 Apr;51(4):405

Postoperative emesis following otoplasty in children. Paxton D, et al. **Anaesthesia** 1995 Dec;50(12):1083–5

Acid aspiration prophylaxis for emergency Caesarean section. Stuart JC, et al. **Anaesthesia** 1996 May;51(5):415–21

The effect of prophylactic clonidine on postoperative shivering. A large prospective double-blind study. Vanderstappen I, et al. **Anaesthesia** 1996 Apr;51(4):351–5

Tropisetron for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery. Alon E, et al. **Anesth Analg** 1996 Feb;82(2):338–41

Effects of ondansetron on emesis in the first 24 hours after craniotomy in children. Furst SR, et al. **Anesth Analg** 1996 Aug;83(2):325–8

The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. Gratz I, et al. **Anesth Analg** 1996 Sep;83(3):565–9

Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. Pueyo FJ, et al. **Anesth Analg** 1996 Jul;83(1):117–22

A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Tang J, et al. **Anesth Analg** 1996 Aug;83(2):304–13

Changing anesthesiologists' practice patterns. Can it be done? Cohen MM, et al. **Anesthesiology** 1996 Aug;85(2):260–9

Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery. Davis PJ, et al. **Anesthesiology** 1995 Nov;83(5):956–60

Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group. Khalil S, et al. **Anesthesiology** 1996 Aug;85(2):270–6

Vomiting and recovery after outpatient tonsillectomy and adenoidectomy in children. Comparison of four anesthetic techniques using nitrous oxide with halothane or propofol. Ved SA, et al. **Anesthesiology** 1996 Jul;85(1):4–10

Prevention of neuroma in elective digital amputations by utilization of neurovascular island flap. St-Laurent JY, et al. **Ann Chir Main Memb Super** 1996;15(1):50–4

Preemptive ganciclovir therapy in renal transplantation [letter] Brennan DC, et al. **Ann Intern Med** 1996 Apr 1; 124(7):693

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Leclerc JR, et al. **Ann Intern Med** 1996 Apr 1;124(7):619–26

Preemptive ganciclovir therapy in renal transplantation [letter] Tamm M, et al. **Ann Intern Med** 1996 Apr 1; 124(7):693–4

Refinements of pre-, intra-, and postoperative care to prevent complications of vaginoplasty in male transsexuals. Karim RB, et al. **Ann Plast Surg** 1995 Sep;35(3):279–84

Morbidity of varicose vein surgery: auditing the benefit of changing clinical practice. Miller GV, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):345–9

Written discharge advice sheets reduce visits to the general practitioner. Raine C, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1 Suppl):19–20

Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty. Unwin AJ, et al. **Ann R Coll Surg Engl** 1995 Sep; 77(5):351–4

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) . Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

Lateral tunnel suture line variation reduces atrial flutter after the modified Fontan operation. Gandhi SK, et al. **Ann Thorac Surg** 1996 May;61(5):1299–309

Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Katsaros D, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1131–5

Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Klemperer JD, et al. **Ann Thorac Surg** 1996 May;61(5):1323–7; discussion 1328–9

Obliteration of the left atrial appendage: a concept worth testing [editorial; comment] Lindsay BD. **Ann Thorac Surg** 1996 Feb;61(2):515. Comment on: Ann Thorac Surg 1996 Feb;61(2):565–9. Comment on: Ann Thorac Surg 1996 Feb;61(2):755–9.

Early clinical results of retrograde cerebral perfusion for aortic arch operations in Japan. Usui A, et al. **Ann Thorac Surg** 1996 Jul;62(1):94–103; discussion 103–4

Verapamil as prophylactic treatment for atrial fibrillation after lung operations. Van Mieghem W, et al. **Ann Thorac Surg** 1996 Apr;61(4):1083–5; discussion 1086

Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group. Samama CM, et al. **Ann Vasc Surg** 1995;9 Suppl:S45–53

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059–63, 1066–79; quiz 1080–6 (38 ref.)

Antiseptic catheter gel and urinary tract infection after short-term postoperative catheterization in women. Schiøtz HA. **Arch Gynecol Obstet** 1996;258(2):97–100

Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Sarasin FP, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1661–8

Expanded polytef for reconstructing postparotidectomy defects and preventing Frey's syndrome. Shemen LJ. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1307–9

Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. DiGiuseppe JA, et al. **Arch Pathol Lab Med** 1996 Mar; 120(3):282–5

Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Sarasin FP, et al. **Arch Surg** 1996 Jul;131(7):694–7; discussion 698

Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. Palevsky PM, et al. **ASAIO J** 1995 Oct-Dec;41(4):847–9

Heparin thromboprophylaxis via indwelling subcutaneous teflon cannula. Pouw L, et al. **Aust N Z J Surg** 1995 Nov; 65(11):793–5

Heterotopic bone formation affecting the hip joint is preventable in high risk patients by post-operative radiation. Spry NA, et al. **Australas Radiol** 1995 Nov; 39(4):379–83

Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model. West JL, et al. **Biomaterials** 1995 Oct;16(15):1153–6

Use of placebo in studies of postoperative vomiting is unethical [letter] Adams AK. **BMJ** 1996 Jul 27; 313(7051):233

Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials [see comments] Aspinall RL, et al. **BMJ** 1995 Sep 30;311(7009):844–6. Comment in: BMJ 1995 Sep 30;311(7009):821–2. Comment in: BMJ 1996 Jan 20;312(7024):183.

Postoperative deep vein thrombosis and surgery for varicose veins [letter; comment] Bounameaux H, et al. **BMJ** 1996 May 4;312(7039):1158. Comment on: BMJ 1996 Jan 27;312(7025):198–9.

Postoperative pulmonary complications. Laparoscopic surgery leads to better postoperative pulmonary function [letter; comment] Haigh A, et al. **BMJ** 1996 May 4; 312(7039):1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

Prevention of respiratory complications after abdominal surgery: a randomised clinical trial [see comments] Hall JC, et al. **BMJ** 1996 Jan 20;312(7024):148–52; discussion 152–3. Comment in: BMJ 1996 May 4;312(7039):1158–9; discussion 1159–60. Comment in: BMJ 1996 May 4;312(7039):1159; discussion 1159–60. Comment in: BMJ 1996 May 4;312(7039):1159–60.

Placebo controlled trials of ondansetron for postoperative nausea and vomiting [letter; comment] Palmer JB, et al. **BMJ** 1996 Jan 20;312(7024):183. Comment on: BMJ 1995 Sep 30;311(7009):844–6.

Postoperative pulmonary complications. Adequate pain relief is also necessary [letter; comment] Quinn AC, et al. **BMJ** 1996 May 4;312(7039):1159; discussion 1159–60. Comment on: BMJ 1996 Jan 20;312(7024):148–52; discussion 152–3.

Prevention of postoperative venous thromboembolism. Bullingham A, et al. **Br J Anaesth** 1995 Nov;75(5):622–30 (85 ref.)

Single dose i.v. tropisetron in the prevention of postoperative nausea and vomiting after gynaecological surgery. Capouet V, et al. **Br J Anaesth** 1996 Jan;76(1):54–60

Effect of transdermal hyoscine on nausea and vomiting [letter; comment] Foster RN. **Br J Anaesth** 1996 May; 76(5):749–50. Comment on: Br J Anaesth 1996 Jan;76(1):49–53.

Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia [see comments] Honkavaara P. **Br J Anaesth** 1996 Jan; 76(1):49–53. Comment in: Br J Anaesth 1996 May;76(5):749–50.

Comparison of the effect of two dose schedules of oral omeprazole with oral ranitidine on gastric aspirate pH and volume in patients undergoing elective surgery. Levack ID, et al. **Br J Anaesth** 1996 Apr;76(4):567–9

Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. López-Olaondo L, et al. **Br J Anaesth** 1996 Jun; 76(6):835–40

Venous thromboembolism and cardiovascular surgery [letter] McDonald DS. **Br J Anaesth** 1996 Mar;76(3):473

Prevention of vomiting after paediatric strabismus surgery [letter] Morton NS. **Br J Anaesth** 1996 Mar;76(3):473–4

Preoperative infusion of amino acids prevents postoperative hypothermia. Selldén E, et al. **Br J Anaesth** 1996 Feb; 76(2):227–34

Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556–61 (48 ref.)

Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. van den Berg AA. **Br J Anaesth** 1996 Mar;76(3):449–51

Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting. Wilson AJ, et al. **Br J Anaesth** 1996 Apr;76(4):515–8

Changing incidence of atrial fibrillation following coronary artery bypass grafting: a retrospective analysis. Gaylard E. **Br J Clin Pract** 1996 Apr–May;50(3):164–5

The preoperative assessment of stroke risk in lesions involving the internal carotid artery. Ungersböck K, et al. **Br J Neurosurg** 1995;9(4):477–86

Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. Bömer TG, et al. **Br J Ophthalmol** 1995 Sep;79(9):809–13

Intravenous infusion of prostacyclin to prevent platelet thrombus during microvascular anastomoses. Gateley DR, et al. **Br J Plast Surg** 1996 Jun;49(4):249–50

Iloprost and salvage of a free flap. Renaud F, et al. **Br J Plast Surg** 1996 Jun;49(4):245–8

Case report: radiation prevention of heterotopic ossification after bone and joint surgery in sites other than hips. Lo TC, et al. **Br J Radiol** 1996 Jul;69(823):673–7

Varicose vein surgery and deep vein thrombosis. Campbell WB, et al. **Br J Surg** 1995 Nov;82(11):1494–7

Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis [see comments] Friess H, et al. **Br J Surg** 1995 Sep;82(9):1270–3. Comment in: Br J Surg 1996 Mar;83(3):422–3.

Prevention of postoperative nausea and vomiting with granisetron: a randomized, double-blind comparison with droperidol. Fujii Y, et al. **Can J Anaesth** 1995 Oct; 42(10):852–6

Perioperative administration of caffeine tablets for prevention of postoperative headaches. Hampl KF, et al. **Can J Anaesth** 1995 Sep;42(9):789–92

Oral clonidine premedication reduces vomiting in children after strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1995 Nov;42(11):977–81

Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized,

double-blind comparison with placebo. Naguib M, et al. **Can J Anaesth** 1996 Mar;43(3):226–31

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5

Recovery room problems or problems in the PACU. Rose DK. **Can J Anaesth** 1996 May;43(5 Pt 2):R116–28 (50 ref.) **(Eng, Fre)**

Ondansetron is a better prophylactic antiemetic than droperidol for tonsillectomy in children. Splinter WM, et al. **Can J Anaesth** 1995 Oct;42(10):848–51

Management of postoperative pain and emesis. White PF. **Can J Anaesth** 1995 Nov;42(11):1053–5

Modified Blalock-Taussig shunts: to heparinize or not to heparinize? Mullen JC, et al. **Can J Cardiol** 1996 Jul; 12(7):645–7

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

Intermittent pneumatic compression for the prevention of venous thromboembolism [editorial; comment] Hull RD, et al. **Chest** 1996 Jan;109(1):6–9. Comment on: Chest 1996 Jan;109(1):82–5.

The effect of physical therapy on respiratory complications following cardiac valve surgery. Johnson D, et al. **Chest** 1996 Mar;109(3):638–44

Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Jiang J, et al. **Chin Med J (Engl)** 1995 Jun; 108(6):459–61

The practical research on the rectangular valve anastomosis to prevent regurgitation in effecting a radical cure of antral gastric carcinoma. Baoping Z, et al. **Chirurgia (Bucur)** 1995; 44(3):25–8

Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo [see comments] Dunn PF, et al. **Circulation** 1996 Apr 1; 93(7):1439–46. Comment in: Circulation 1996 Apr 1;93(7):1319–20.

Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Gent M, et al. **Circulation** 1996 Jan 1;93(1):80–4

Wound healing in beagle dogs after palatal repair without denudation of bone. Leenstra TS, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):363–9; discussion 369–70

Postoperative pulmonary complications: risk assessment, prevention, and treatment. Hayden SP, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):401–7 (27 ref.)

Deep venous thrombosis: low-molecular-weight heparins in perioperative prophylaxis. Merli G. **Cleve Clin J Med** 1995 Nov–Dec;62(6):368–9

Role of calcium channel blockers in diabetic renal transplant patients: preliminary observations on protection from sepsis. Weinrauch LA, et al. **Clin Nephrol** 1995 Sep; 44(3):185–92

Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Lotke PA, et al. **Clin Orthop** 1996 Mar; (324):251–8

Do ventilated packs reduce post-operative eustachian tube dysfunction? Morgan NJ, et al. **Clin Otolaryngol** 1995 Oct; 20(5):411–2

Antibiotic prophylaxis and head and neck surgery--what about pulmonary complications? [editorial] Morton RP. **Clin Otolaryngol** 1996 Apr;21(2):97–8

Management of asplenic patients in South Buckinghamshire: an audit of local practice. MacInnes J, et al. **Commun Dis Rep CDR Rev** 1995 Nov 10;5(12):R173–7

Preoperative cardiac risk assessment and management. Abrams J. **Curr Opin Gen Surg** 1993;:13–8 (30 ref.)

Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19–25 (45 ref.)

Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)

Consecutive wide and long single hair-bearing transposition flaps in combination with hair transplantation for the management of slot formation after alopecia reducing surgery. Brandy DA. **Dermatol Surg** 1996 Apr; 22(4):355–62; discussion 363

Recovery of gastrointestinal motility following open versus laparoscopic colon resection in dogs. Hotokezaka M, et al. **Dig Dis Sci** 1996 Apr;41(4):705–10

Island flap anoplasty for treatment of transsphincteric fistula-in-ano. Del Pino A, et al. **Dis Colon Rectum** 1996 Feb;39(2):224–6

Adults born with high anorectal atresia--how do they manage? Hassink EA, et al. **Dis Colon Rectum** 1996 Jun; 39(6):695–9

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke-Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)

Antimicrobial prophylaxis in surgery in Belgian hospitals: room for improvement. Kurz X, et al. **Eur J Surg** 1996 Jan;162(1):15–21

Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran. Wiig JN, et al. **Eur J Surg** 1995 Sep;161(9):663–8

Epidural scar tissue formation after spinal surgery: an experimental study. Pospiech J, et al. **Eur Spine J** 1995; 4(4):213–9

Does fibrin glue improve drainage after axillary lymph node dissection? Prospective and randomized study in humans. Vaxman F, et al. **Eur Surg Res** 1995;27(5):346–52

The effect of prophylactic acetazolamide in patients undergoing extensive retinal detachment repair. Edmunds B, et al. **Eye** 1996;10 (Pt 3):328–30

Dissolution of pseudophakic fibrinous exudate with intraocular streptokinase. Mullaney PB, et al. **Eye** 1996;10 (Pt 3):362–6

Drug choice in preventing postoperative Crohn's disease [letter; comment] Korelitz BI. **Gastroenterology** 1996 Feb; 110(2):652–3. Comment on: Gastroenterology 1995 Aug;109(2):404–13.

Femoral vein stasis during laparoscopic cholecystectomy: effects of graded elastic compression leg bandages in preventing thrombus formation. Ido K, et al. **Gastrointest Endosc** 1995 Aug;42(2):151–5

The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haas S. **Haemostasis** 1996;26 Suppl 2:39–48 (21 ref.)

Headache following removal of acoustic neuroma [letter; comment] Vijayan N. **Headache** 1995 Nov–Dec;35(10):639 . Comment on: Headache 1995 Feb;35(2):98–100.

Effects of human growth hormone on the catabolic state after surgical trauma. Vara-Thorbeck R, et al. **Horm Res** 1996; 45(1–2):55–60

Prevention of post-surgical adhesion formation using aspirin in a rodent model: a preliminary report. Golan A, et al. **Hum Reprod** 1995 Jul;10(7):1797–800

Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. Keckstein J, et al. **Hum Reprod** 1996 Mar;11(3):579–82

Prevention of complications after autogenous bone-patellar tendon-bone ACL reconstruction. Shelbourne KD, et al. **Instr Course Lect** 1996;45:253–62 (30 ref.)

Laparoscopy for adhesion prevention following myomectomy. Uğur M, et al. **Int J Gynaecol Obstet** 1996 May;53(2):145–9

Fractioned drilling--a technique for wedge osteotomy of the knee. Sabo D, et al. **Int Orthop** 1995;19(6):352–4

Mask physiotherapy in patients after heart surgery: a controlled study [see comments] Richter Larsen K, et al. **Intensive Care Med** 1995 Jun;21(6):469–74. Comment in: Intensive Care Med 1995 Jun;21(6):467–8.

Computerized vectorcardiography for improved perioperative cardiac monitoring in vascular surgery. Gannedahl PE, et al. **J Am Coll Surg** 1996 Jun;182(6):530–6

The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Hilbrands LB, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2073–81

Corrosion at the interface. A possible solution to cobalt-chrome heads on titanium alloy stems. Yerby SA, et al. **J Arthroplasty** 1996 Feb;11(2):157–62

Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. Pellegrini VD Jr, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):870–81

Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. Westrich GH, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):826–34

Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. Hui AC, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):550–4

Preventing iris capture [letter] Fechner PU. **J Cataract Refract Surg** 1996 May;22(4):395

Avoiding complications associated with iris retractor use in small pupil cataract extraction. Masket S. **J Cataract Refract Surg** 1996 Mar;22(2):168–71

Early interferon therapy and abortion of posttransfusion hepatitis C viral infection. Yang SS, et al. **J Clin Gastroenterol** 1995 Jul;21(1):38–41

Changing physicians' practice patterns [news] **J Clin Monit** 1995 Nov;11(6):412–3

Intra-operative scalp expansion for wound closure without tension in craniosynostosis operation--technical innovation. Onishi K, et al. **J Craniomaxillofac Surg** 1995 Oct;23(5):317–20

Does peri-operative guanethidine prevent reflex sympathetic dystrophy? Gschwind C, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):773–5

Estrogen and prevention of transplant atherosclerosis. Foegh ML, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S170–2

Reverse telescope anastomotic technique reduces the incidence of bronchial stricture. Rabinov M, et al. **J Heart Lung Transplant** 1996 Mar;15(3):243–8

Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):659–65

Minimizing trochar site herniation in laparoscopic cholecystectomy. Schwartzman A, et al. **J Laparoendosc Surg** 1995 Jun;5(3):157–61

Modifications of the Caldwell-Luc procedure for the prevention of post-operative sensitivity disorders. Ferekidis E, et al. **J Laryngol Otol** 1996 Mar;110(3):228–31

An audit of prophylactic antibiotic treatment following tonsillectomy in children. Lee WC, et al. **J Laryngol Otol** 1996 Apr;110(4):357–9

Does furosemide prevent hypertension during perioperative splenectomy in thalassemic children? Suwanchinda V, et al. **J Med Assoc Thai** 1995 Oct;78(10):542–6

Retrograde dissection of the temporalis muscle preventing muscle atrophy for pterional craniotomy. Technical note. Oikawa S, et al. **J Neurosurg** 1996 Feb;84(2):297–9

Early oral hydration: a novel regimen for management after elective cesarean section. Abd Rabbo S. **J Obstet Gynaecol** 1995 Dec;21(6):563–7

Technique for fixation of the Frost suture. Murphy MT, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1360–1

Submandibular duct repositioning after excision of floor of mouth cancer. Ord RA, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1075–8; discussion 1078–9

Prevention of heterotopic bone formation after acetabular fracture fixation by single-dose radiation therapy: a preliminary report. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):258–63

Prevention of tissue injury and postsurgical adhesions by precoating tissues with hyaluronic acid solutions. Burns JW, et al. **J Surg Res** 1995 Dec;59(6):644–52

Using dipyridamole-thallium imaging to reduce cardiac risk in aortic reconstruction. Erickson CA, et al. **J Surg Res** 1996 Feb 1;60(2):422–8

Local release of fibrinolytic agents for adhesion prevention. Hill-West JL, et al. **J Surg Res** 1995 Dec;59(6):759–63

Is DVT prophylaxis overemphasized? A randomized prospective study. Kosir MA, et al. **J Surg Res** 1996 Feb 1;60(2):289–92

Short-term effect of monocuspid valves on pulmonary insufficiency and clinical outcome after surgical repair of tetralogy of Fallot. Bigras JL, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):33–7

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. Jansen PG, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):829–34

Monofilament polypropylene sutures in aortic valve replacement [letter; comment] Kärkölä P, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):286–7. Comment on: J Thorac Cardiovasc Surg 1995 Mar;109(3):536–44; discussion 544–5.

Leukocyte and platelet depletion with a blood cell separator: effects on lung injury after cardiac surgery with cardiopulmonary bypass. Morioka K, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):45–54

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)

RE: The chance for fertility in adolescent boys after corrective surgery for varicocele [letter] Harrison RH 3rd. **J Urol** 1996 May;155(5):1704

Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. Safi HJ, et al. **J Vasc Surg** 1996 Feb;23(2):223–8; discussion 229

Value of the staged segmental crossclamp to the aorta technique and reimplantation of intercostal arteries for the prevention of spinal complications associated with surgery for descending and thoraco-abdominal aortic aneurysms. Nakajima N, et al. **Jpn Heart J** 1996 May;37(3):275–84

Aminoacid infusions to prevent postoperative hypothermia. Duthie DJ. **Lancet** 1996 May 4;347(9010):1199

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 [see comments] Eriksson BI, et al. **Lancet** 1996 Mar 9;347(9002):635–9. Comment in: Lancet 1996 Mar 9;347(9002):632–3. Comment in: Lancet 1996 Jun 1;347(9014):1561–2.

Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo [see comments] Planes A, et al. **Lancet** 1996 Jul 27;348(9022):224–8. Comment in: Lancet 1996 Jul 27;348(9022):209–10.

Upper limb disease in women treated for breast cancer [see comments] Sainsbury R. **Lancet** 1995 Dec 2;346(8988):1444 . Comment in: Lancet 1996 Feb 17;347(8999):473.

Major orthopaedic surgery and post-discharge DVT [comment] ten Cate JW, et al. **Lancet** 1996 Jul 27; 348(9022):209–10. Comment on: Lancet 1996 Jul 27;348(9022):224–8.

Hirudin CGP 39393 as thromboprophylaxis [letter; comment] Williams DJ, et al. **Lancet** 1996 Jun 1;347(9014):1561–2. Comment on: Lancet 1996 Mar 9;347(9002):635–9.

Preventive management of cerebrospinal fluid leakage in translabyrinthine surgery. Meyerson LR, et al. **Laryngoscope** 1996 May;106(5 Pt 1):610–3

Prevention of postoperative venous thromboembolism [editorial; comment] Chong BH. **Med J Aust** 1996 Jun 3; 164(11):646–7 (13 ref.). Comment on: Med J Aust 1996 Jun 3;164(11):652–4, 656.

Postsplenectomy overwhelming sepsis: reducing the risks [editorial] Spelman DW. **Med J Aust** 1996 Jun 3;164(11):648

Can varying flow velocity across an arterial anastomosis prevent thromboembolic injury? Barker JH, et al. **Microsurgery** 1995;16(5):349–56

Propofol and postoperative infections [letter; comment] Grounds RM. **N Engl J Med** 1995 Nov 30;333(22):1506; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Kolbitsch C, et al. **N Engl J Med** 1995 Nov 30; 333(22):1506–7. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [see comments] Schömig a, et al. **N Engl J Med** 1996 Apr 25; 334(17):1084–9. Comment in: N Engl J Med 1996 Apr 25;334(17):1126–8.

Sequelae of carpal tunnel surgery: rationale for the design of a surgical approach. Abdullah AF, et al. **Neurosurgery** 1995 Nov;37(5):931–5; discussion 935–6

Short-term perioperative anticonvulsant prophylaxis for the surgical treatment of low-risk patients with intracranial aneurysms. Baker CJ, et al. **Neurosurgery** 1995 Nov; 37(5):863–70; discussion 870–1

Prevention of postoperative urinary stress incontinence after surgery for genitourinary prolapse. Colombo M, et al. **Obstet Gynecol** 1996 Feb;87(2):266–71

Postoperative management of cesarean patients: the effect of immediate feeding on the incidence of ileus. Kramer RL, et al. **Obstet Gynecol** 1996 Jul;88(1):29–32

A randomized controlled trial of postoperative nasogastric tube decompression in gynecologic oncology patients undergoing intra-abdominal surgery. Pearl ML, et al. **Obstet Gynecol** 1996 Sep;88(3):399–402

Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Sawaya GF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):884–90

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part I. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):806–20 (189 ref.)

Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Roberts CW. **Ophthalmology** 1996 Apr;103(4):636–9

Preventing DVT following total knee replacement: a review of recent clinical trials. Fitzgerald RH Jr. **Orthopedics** 1995 Jul;18 Suppl:10–1

Thromboembolism after THR: prophylaxis and treatment. Salvati EA. **Orthopedics** 1995 Sep;18(9):838–41

Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge. Turpie AG. **Orthopedics** 1995 Jul;18 Suppl:15–7

Propofol reduces the incidence of vomiting after tonsillectomy in children. Barst SM, et al. **Paediatr Anaesth** 1995;5(4):249–52

Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Chisakuta AM, et al. **Paediatr Anaesth** 1995;5(2):97–100

Pericardial substitute and emergency resternotomy: life-saving combination. Bacaner TJ, et al. **Pediatr Cardiol** 1996 Nov-Dec;17(6):396–8

Randomized trial of the efficacy of trimethoprim-sulfamethoxazole and prednisone in preventing post-tympanostomy tube morbidity. Daly KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1068–74

The effect of Biocell texturing and povidone-iodine irrigation on capsular contracture around saline-inflatable breast implants. Burkhardt BR, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1317–25

Abdominal closure after TRAM flaps [letter; comment] Drever JM. **Plast Reconstr Surg** 1996 Apr;97(5):1080. Comment on: Plast Reconstr Surg 1995 Jun;95(7):1185–94.

Three helpful hints for face lift surgery [letter] Kaye BL. **Plast Reconstr Surg** 1995 Nov;96(6):1485–6

Gore-Tex patch repair of the anterior rectus sheath in free rectus abdominis muscle and myocutaneous flaps. Pennington DG, et al. **Plast Reconstr Surg** 1996 Jun; 97(7):1436–40; discussion 1441–2

Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Perkins SW, et al. **Plast Reconstr Surg** 1996 Sep;98(3):427–33; discussion 434–5

Influence of steroids on postoperative swelling after facialplasty: a prospective, randomized study. Rapaport DP, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1547–52

Hernia prevention and aesthetic contouring of the abdomen following TRAM flap breast reconstruction by the use of polypropylene mesh. Zienowicz RJ, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1346–50

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

Nutritional assessment and surgical risk markers in children submitted to cardiac surgery. Leite HP, et al. **Rev Paul Med** 1995 Jan-Feb;113(1):706–14

Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy. Iberer F, et al. **Scand J Infect Dis Suppl** 1995;99:100–3

Headache prevention in retrosigmoid vestibular nerve section. Baldwin RL. **South Med J** 1996 Apr;89(4):375–9

Vaginal scrub prophylaxis in abdominal hysterectomy. Vinkomin V. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):188–92

Application of polyvinyl alcohol hydrogel membrane as anti-adhesive interposition after spinal surgery. Hiraizumi Y, et al. **Spine** 1995 Nov 1;20(21):2272–7

The effect of interposition membrane on the outcome of lumbar laminectomy and discectomy. MacKay MA, et al. **Spine** 1995 Aug 15;20(16):1793–6

Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Legault C, et al. **Stroke** 1996 Apr;27(4):593–8

A double-blinded evaluation of intraperitoneal bupivacaine vs saline for the reduction of postoperative pain and nausea after laparoscopic cholecystectomy. Szem JW, et al. **Surg Endosc** 1996 Jan;10(1):44–8

Adhesion formation after laparoscopic anterior resection in a porcine model: a pilot study. Reissman P, et al. **Surg Laparosc Endosc** 1996 Apr;6(2):136–9

Chronic subdural hematomas and seizures: the role of prophylactic anticonvulsive medication. Sabo RA, et al. **Surg Neurol** 1995 Jun;43(6):579–82

Prevention of local recurrence by extended lymphadenectomy for rectal cancer. Suzuki K, et al. **Surg Today** 1995;25(9):795–801

Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia? [letter] Cummins D, et al. **Thromb Haemost** 1995 May;73(5):890

Pre-operative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Ginsberg JS, et al. **Thromb Haemost** 1995 Aug;74(2):602–5

A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Horbach T, et al. **Thromb Haemost** 1996 Feb;75(2):246–50

Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Nurmohamed MT, et al. **Thromb Haemost** 1996 Feb;75(2):233–8

Prophylaxis of deep vein thrombosis in orthopaedic surgery [letter; comment] Pechlaner C, et al. **Thromb Haemost** 1995 Apr;73(4):727–8. Comment on: Thromb Haemost 1994 Nov;72(5):663–5.

Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Ham JM, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):31–3

Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)

Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Uber L, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):42–3

Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. Bergqvist D, et al. **Vasa** 1996;25(2):156–60

Antioxidative vitamin treatment: effect on lipid peroxidation and limb swelling after revascularization operations. Rabl H, et al. **World J Surg** 1995 Sep-Oct;19(5):738–44

Can the use of growth hormone reduce the postoperative fatigue syndrome? Vara-Thorbeck R, et al. **World J Surg** 1996 Jan;20(1):81–6; discussion 86–7

[A single-stage 2-layer suture in cesarean section--the effect of the surgical technic on postoperative febrile conditions] Popov I, et al. **Akush Ginekol (Sofiia)** 1994;33(2):13–5 (Eng. Abstr.) **(Bul)**

[Prevention and treatment of surgical complications of tracheobronchoplastic procedures. An analysis of 22 cases] Jiang G, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):358–61 (Eng. Abstr.) **(Chi)**

[Indications of tracheotomy before uvulopalatopharyngoplasty in patients with severe obstructive sleep apnea syndrome] Zhang L, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):138–9 (Eng. Abstr.) **(Chi)**

[Experimental research on using macromolecule sodium hyaluronate to prevent flexior tendon adhesion] Chen Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):526–8 (Eng. Abstr.) **(Chi)**

[Experimental study of sodium hyaluronate products on prevention of tendon adhesion] Xu J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):529–31 (Eng. Abstr.) **(Chi)**

[Prospective randomized comparison of the effects of pefloxacin and clindamycin with cefoxitin after hepatobiliary and pancreatic operations] Fried M, et al. **Rozhl Chir** 1995 Sep;74(6):290–2 (Eng. Abstr.) **(Cze)**

[Eight days of naproxen therapy can prevent heterotopic ossification after total hip alloplasty] Gebuhr PH, et al. **Ugeskr Laeger** 1996 Feb 19;158(8):1076–8 (Eng. Abstr.) **(Dan)**

[Prevention of postoperative nausea and vomiting by lorazepam] Laraki M, et al. **Cah Anesthesiol** 1996; 44(2):159–62 (Eng. Abstr.) **(Fre)**

[Can the incidence of infectious complications in digestive surgery be reduced? Role of antibiotic prophylaxis (1100) cases (editorial)] Champault G. **G Chir** 1995 Oct; 16(10):401–6 **(Fre)**

[Coronary assessment and surgery for aortic aneurysm: systematic coronarography] Fabiani JN. **J Mal Vasc** 1996; 21 Suppl A:10–2 (Eng. Abstr.) **(Fre)**

[Selective indications of cardiac studies before aortic surgery] Alimi YS, et al. **Presse Med** 1995 Nov 11;24(34):1598–602 (Eng. Abstr.) **(Fre)**

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative vomiting after pars plana vitrectomy] Heinke W, et al. **Anaesthesiol Reanim** 1996;21(2):47–50 (Eng. Abstr.) **(Ger)**

[Remarks on the work of A. Klockgether-Radke et al. The effect of propofol on vomiting in children following strabismus surgery (letter)] Holas A, et al. **Anaesthesist** 1996 May;45(5):464–7 **(Ger)**

[Alcohol administration for prevention of withdrawal delirium in alcohol dependent surgical intensive care patients: pro] Engelhardt W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):183–4 **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Preoperative fasting and aspiration (editorial)] Martin E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(4):244–5 **(Ger)**

[Conventional and new measures for prevention of aspiration] Roewer N. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):257–60 **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

[Prevention of thrombosis with fraxiparin 0.3 after arthroscopic interventions] Holland K, et al. **Fortschr Med** 1995 Aug 20;113(22–23):335–6 (Eng. Abstr.) **(Ger)**

[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery] Schain FH. **Fortschr Med** 1996 Apr 30;114(12):149–52 (Eng. Abstr.) **(Ger)**

[Risk and prevention of thromboembolism complications in gynecologic malignancies] Graf AH, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):37–9 (Eng. Abstr.) **(Ger)**

[Valve reconstruction for mitral valve insufficiency. Aspects of surgical technique] Birnbaum DE. **Herz** 1996 Jun; 21(3):159–65 (Eng. Abstr.) **(Ger)**

[Significance of Staphylococcus aureus in nose operations. Risk of toxic shock syndrome?] Pennekamp A, et al. **HNO** 1995 Nov;43(11):664–8 (Eng. Abstr.) **(Ger)**

[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) **(Ger)**

[Anti-inflammatory effects and aqueous humor concentration of various nonsteroidal anti-inflammatory drugs in extracapsular cataract surgery] Hessemer V, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):161–6 (Eng. Abstr.) **(Ger)**

[Prevention of adhesions in the middle ear] von Scheel J. **Laryngorhinootologie** 1996 Apr;75(4):254 (Eng. Abstr.) **(Ger)**

[Preoperative risk assessment of children with Duchenne muscular dystrophy and relevance for anesthesia and intra- and postoperative course] Wollinsky KH, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:34–7 (Eng. Abstr.) **(Ger)**

[Should postoperative thromboembolism prevention be extended to the post-hospitalization phase?] Irani S, et al. **Schweiz Med Wochenschr** 1996 Mar 9;126(10):386–91 (Eng. Abstr.) **(Ger)**

[Pharmacotherapy aspects during Harrington's method of spinal surgery] Koch HJ. **Soz Praventivmed** 1995; 40(4):230–3 (Eng. Abstr.) **(Ger)**

[Preoperative measures in emergencies] Leutenegger A. **Swiss Surg** 1995;(3):148–51 (Eng. Abstr.) **(Ger)**

[Preoperative assessment in an area without continuous medical anesthesia service] Scharplatz D. **Swiss Surg** 1995; (3):162–4 (Eng. Abstr.) **(Ger)**

[Preoperative assessment from the viewpoint of the anesthetist (editorial)] Scheidegger D. **Swiss Surg** 1995; (3):128–9 **(Ger)**

[Dentogenic sources of infection in patients with awaiting heart valve replacement] Krennmair G, et al. **Wien Klin Wochenschr** 1996;108(10):289–92 (Eng. Abstr.) **(Ger)**

[Open thrombendarterectomy of the carotid arteries with routine intraluminal shunt implantation, a reliable method for decreasing the risk of apoplexy--results of 11 years experience with 546 consecutive elective interventions] Schneider J, et al. **Zentralbl Chir** 1995;120(8):624–9 (Eng. Abstr.) **(Ger)**

[Characteristics of rare ovarian tumors--possibilities of organ preservation] Grischke EM, et al. **Zentralbl Gynakol** 1996; 118(6):322–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

[Preserving fertility in early cervix carcinoma: trachelectomy with laparoscopic lymphadenectomy] Schneider A, et al. **Zentralbl Gynakol** 1996;118(1):6–8 (Eng. Abstr.) **(Ger)**

[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years] Slunsky R. **Zentralbl Gynakol** 1995;117(11):598–601 (Eng. Abstr.) **(Ger)**

[Effect of prostaglandin E1 on arterial ketone body ratio during and after hepatectomy] Nakayama M, et al. **Masui** 1995 Sep;44(9):1224–7 (Eng. Abstr.) **(Jpn)**

[Perioperative management of a patient with severe bronchial asthma attack] Ochiai N, et al. **Masui** 1995 Aug; 44(8):1124–7 (Eng. Abstr.) **(Jpn)**

[Strategies for treating cerebrovascular complications in CABG patients] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):735–6 **(Jpn)**

[The effectiveness of cerebrovascular complication prevention in single clamp coronary artery bypass surgery and non-clamping selective cerebral perfusion thoracic aorta aneurysm surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):737–40 **(Jpn)**

[Basic and clinical studies on the prevention of postoperative MRSA infections in esophageal cancer] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):663–5 **(Jpn)**

[The effectiveness of preoperative steroid therapy in preventing postoperative circulatory system complications in surgery of esophageal cancer] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):652–5 **(Jpn)**

[Carotid screening with duplex scanning before coronary artery bypass] Fukuda I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):478–83 (Eng. Abstr.) **(Jpn)**

[Retrospective study of sputum culture after esophagectomy] Minamiya Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1138–44 (Eng. Abstr.) **(Jpn)**

[Clinical experience of the combined use of polyglycolide non-woven felt with fibrin glue to prevent postoperative pulmonary fistula] Mizuno H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1559–64 (Eng. Abstr.) **(Jpn)**

[Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation] Sakai R, et al. **Rinsho Ketsueki** 1996 Jan;37(1):14–21 (Eng. Abstr.) **(Jpn)**

[Treatment with ticlodipine after intracoronary stent implantation] Myreng Y, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1789–91 (Eng. Abstr.) **(Nor)**

[The prevention of adhesion formation in surgical gynecology (the role of suture materials and barriers)] Mynbaev OA, et al. **Akush Ginekol (Mosk)** 1995;(5):37–40 (38 ref.) **(Rus)**

[The preventive role of large doses of aprotinin in decreasing the degree of metabolic disorders during aortocoronary bypass operations] Dement'eva II, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):55–8 (Eng. Abstr.) **(Rus)**

[Method of prevention of pancreatic necrosis and failure of sutures of the duodenal stump in stomach resection] Lavrov AS, et al. **Klin Khir** 1996;(1):49–50 **(Rus)**

[Prevention of the development of venous thromboembolism in surgical patients] Shevchenko SI, et al. **Klin Khir** 1995; (11–12):40–2 **(Rus)**

[Methods of prevention of complications and improving results of relaparotomy in the experience of aviation medicine] Zaitsev VT, et al. **Klin Khir** 1995;(5):49–51 **(Rus)**

[Low doses of heparin in the prevention of postoperative thrombosis of deep veins of the lower limbs] Baeshko AA, et al. **Klin Med (Mosk)** 1995;73(5):60–2 (Eng. Abstr.) **(Rus)**

[A method of tubular resection of the stomach with the application of a lateral antireflux esophagofundic anastomosis in cardial ulcers] Kleshchevnikova VP, et al. **Vestn Khir Im I I Grek** 1995;154(2):84–5 **(Rus)**

[The prevention of early postoperative complications in perforated pyloroduodenal ulcer] Kul'chiev AA, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):331–5 (Eng. Abstr.) **(Rus)**

[The optimization of the heparin prophylaxis of postoperative thromboembolic complications] Nozdrachev IuI. **Vestn Khir Im I I Grek** 1995;154(2):61–5 (Eng. Abstr.) **(Rus)**

[The results of a 15-year observation of patients with an autotransplant of thyroid gland fragments performed to prevent postoperative hypothyroidism] Sheverdin IuP. **Vestn Khir Im I I Grek** 1992 Feb;148(2):152–6 (Eng. Abstr.) **(Rus)**

[The prevention and treatment of pulmonary complications following emergency operations on the abdominal cavity organs in patients over 60] Zaitsev VT, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):216–20 **(Rus)**

[An experimental validation of hyaluronidase electrophoresis for the prevention of postoperative adhesions] Adamian LV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun;(3):18–20 (Eng. Abstr.) **(Rus)**

[Use of taurolin in the prevention of septic complications in emergency abdominal surgery] Popović M, et al. **Acta Chir Iugosl** 1991;38(1):23–33 (Eng. Abstr.) **(Sce)**

[Prevention of thromboembolic disease in gynecologic surgery] Lugonja V, et al. **Med Pregl** 1995;48(1–2):30–1 (Eng. Abstr.) **(Scr)**

[Comprehensive prevention of postoperative thrombosis] Labaš P, et al. **Bratisl Lek Listy** 1996 Feb;97(2):90–4 (Eng. Abstr.) **(Slo)**

[Prediction of continence in patients with neurogenic bladder who will be treated with bladder augmentation] Romero Maroto J, et al. **Actas Urol Esp** 1995 Nov–Dec; 19(10):777–82 (Eng. Abstr.) **(Spa)**

[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery] Bustos-Molina F, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):138–41 (Eng. Abstr.) **(Spa)**

[Infusion of propofol as anesthetic and antiemetic drug] Castaño I, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep; 42(7):257–60 (Eng. Abstr.) **(Spa)**

[Peroperative cholangiography is a good weapon against injuries. Surgery of gallstones is still done without access to radiography] Larsson M, et al. **Lakartidningen** 1996 May 29;93(22):2165–6 **(Swe)**

[How to avoid nerve damage in rectal surgery (letter)] Ojerskog B. **Lakartidningen** 1996 Jul 24;93(30–31):2649 **(Swe)**

PSYCHOLOGY

Binge eating following biliopancreatic diversion for obesity. Adami GF, et al. **Appetite** 1995 Oct;25(2):177–88

Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Price LH, et al. **Biol Psychiatry** 1995 Oct 15;38(8):498–505

Psychological and cardiovascular predictors of anaesthesia induction, operative and post-operative complications in minor gynaecological surgery. Abbott J, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):613–25

Psychosocial outcome of liver transplant [letter; comment] Howard LM, et al. **Br J Psychiatry** 1995 Aug;167(2):267–8 . Comment on: Br J Psychiatry 1995 Apr;166(4):521–4.

Anorexia nervosa following gastroplasty in the male: two cases. Bonne OB, et al. **Int J Eat Disord** 1996 Jan; 19(1):105–8

Eating disturbances before and after vertical banded gastroplasty: a pilot study. Hsu LK, et al. **Int J Eat Disord** 1996 Jan;19(1):23–34

Impact of psychologic functioning, medical severity, and family functioning in pediatric heart transplantation. DeMaso DR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1102–8

Prolonged dysphagia after orthognathic surgery: report of a case and review of the literature. Nagler RM, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):523–5 (21 ref.)

Psychiatric consequences of radical curative surgery for gastric cancer. Everitt NJ, et al. **J R Soc Med** 1995 Sep; 88(9):516–7

Children's preoperative coping and its effects on postoperative anxiety and return to normal activity. LaMontagne LL, et al. **Nurs Res** 1996 May–Jun;45(3):141–7

Pseudoseizures after epilepsy surgery. Krahn LE, et al. **Psychosomatics** 1995 Sep–Oct;36(5):487–93

Determinants of health-related quality of life after temporal lobe epilepsy surgery. Rose KJ, et al. **Qual Life Res** 1996 Jun;5(3):395–402

A long-term follow-up of 108 vasectomized men. Good counselling routines are important. Ehn BE, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):477–81

[Psychiatric morbidity in connection with surgical treatment of epilepsy. A short-term follow-up of patients with amygdalohippocampectomy] Naylor AS, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5245–50 (Eng. Abstr.) **(Dan)**

[Hysterectomy. Indications, abuse, psychological impact] Barrat J, et al. **Bull Acad Natl Med** 1995 Dec; 179(9):1855–69; discussion 1869–70 (Eng. Abstr.) **(Fre)**

[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas] Graupe F, et al. **Chirurg** 1996 Jun;67(6):604–9; discussion 609–10 (Eng. Abstr.) **(Ger)**

[Breast and genital cancer patients—psychosocial examination in the pre- and postoperative phase] Stauber M. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M66–8 **(Ger)**

[Quality assurance in tumor surgery—the effect of tumor surgery interventions on the quality of life of patients with urologic tumors] Biermann CW, et al. **Swiss Surg** 1995; (6):283–9; discussion 289–90 (Eng. Abstr.) **(Ger)**

[Pediatric femoral shaft fracture: effect of treatment procedure on results with reference to somatic and psychological aspects] Braun W, et al. **Unfallchirurg** 1995 Aug;98(8):449–53 (Eng. Abstr.) **(Ger)**

[Quality of life of over 60-year-old patients with breast and uterine carcinoma, 5 years after primary operation] Neises M, et al. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):136–42 (Eng. Abstr.) **(Ger)**

[Effect of treated genital cancer on sexual functions of the woman] Urbánek V, et al. **Zentralbl Gynakol** 1996; 118(1):9–17 (Eng. Abstr.) **(Ger)**

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Significance of the computed tomography finding of subcapsular hepatic necrosis in liver transplantation. Feld R, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):161–5

Appendiceal stump abscess. Filippi de la Palavesa MM, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):65–6

Enzymatic digestion of the urethra after pancreatic transplantation: a case report. Mullaney JM, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):563–5

A long-term follow-up study in direct cerebral aneurysm surgery. Kamitani H, et al. **Acta Neurochir (Wien)** 1995; 133(3–4):134–40

Iatrogenic dissecting aneurysm of the internal carotid artery. Kinugasa K, et al. **Acta Neurochir (Wien)** 1995; 137(3–4):226–31

One hundred and twenty-seven cases of acute subdural haematoma operated on. Correlation between CT scan findings and outcome. Massaro F, et al. **Acta Neurochir (Wien)** 1996;138(2):185–91

Lesions of the corpus callosum in hydrocephalic patients with ventricular drainage—a CT-study. Spreer J, et al. **Acta Neurochir (Wien)** 1996;138(2):174–8 '

Postoperative imaging of the multichannel cochlear implant. Shpizner BA, et al. **AJNR Am J Neuroradiol** 1995 Aug; 16(7):1517–24

Nonbiliary laparoscopic gastrointestinal surgery: role of CT in diagnosis and management of complication. Daly B, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):455–9

Hepatic tumors treated by cryosurgery: normal CT appearance. Kuszyk BS, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):363–8

Complications of lung transplantation: radiologic findings. Murray JG, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1405–11

Endovascular repair of abdominal aortic aneurysm: value of postoperative follow-up with helical CT. Rozenblit A, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1473–9

Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. Sheng R, et al. **AJR Am J Roentgenol** 1996 May;166(5):1109–13

Bronchopleural-subarachnoid fistula manifesting as intracranial gas on CT scans [see comments] Smith DN, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1364–5. Comment in: AJR Am J Roentgenol 1996 Jun;166(6):1497.

Osteocutaneous lateral arm flap in hand reconstruction. Teoh LC, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):15–20

Tension pneumocephalus: a case following petrousectomy. Robin N, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6; 55(1–2):65–6

Stereotactic multiple arc radiotherapy. I. Vascular malformations of the brain: an analysis of the first 108 patients. Sebag-Montefiore DJ, et al. **Br J Neurosurg** 1995; 9(4):441–52

Case report: paravesical suture granuloma resembling bladder carcinoma on CT scanning. Carroll KM, et al. **Br J Radiol** 1996 May;69(821):476–8

Portographic evaluation for recurrent esophagogastric varices following devascularization surgery. Hsieh JS, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):21–6

Coronary artery fistula after heart transplantation: a disappearing entity? Lazar JM, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):10–3

Critical role of pulmonary angiography in the diagnosis of pulmonary emboli following cardiac surgery. Ramos RS, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):112–7; discussion 118

Proximal migration and subcutaneous coiling of a peritoneal catheter: report of two cases. Kim KJ, et al. **Childs Nerv Syst** 1995 Jul;11(7):428–31

'De novo' aneurysm formation: report of two cases. Maiuri F, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):233–8

Magnetic resonance imaging of the pelvis. New orthopaedic applications. Potter HG, et al. **Clin Orthop** 1995 Oct; (319):223–31

Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis. Lausen I, et al. **Eur J Radiol** 1995 Sep;20(3):200–4

Abdominal pain after breast cancer surgery. Yale SH, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):18, 21–2

Value of computed tomography in patients with persistent vertigo after stapes surgery. Kösling S, et al. **Invest Radiol** 1995 Dec;30(12):712–5

Heterotopic ossification following primary total knee arthroplasty [letter; comment] Harwin SF. **J Arthroplasty** 1996 Feb;11(2):223–4. Comment on: J Arthroplasty 1995 Aug;10(4):413–9.

Total hip arthroplasty using the Zweymuller stem implanted without cement. A prospective study of consecutive patients with minimum 3-year follow-up period. Huo MH, et al. **J Arthroplasty** 1995 Dec;10(6):793–9

Increasing incidence of femoral osteolysis in association with uncemented Harris-Galante total hip arthroplasty. A follow-up report. Maloney WJ, et al. **J Arthroplasty** 1996 Feb;11(2):130–4

Cementless total knee arthroplasty in obese patients. A comparison with a matched control group. Mont MA, et al. **J Arthroplasty** 1996 Feb;11(2):153–6

Osteolysis in cemented versus cementless acetabular components. Nayak NK, et al. **J Arthroplasty** 1996 Feb; 11(2):135–40

Can simple radiographs be predictive of total hip dislocation? Pollard JA, et al. **J Arthroplasty** 1995 Dec;10(6):800–4

Long-term results of total knee arthroplasty in class 3 and 4 rheumatoid arthritis. Rodriguez JA, et al.

J Arthroplasty 1996 Feb;11(2):141-5
Radiographic appearance and structural properties of proximal femoral bone in total hip arthroplasty patients. Rosson JW, et al. **J Arthroplasty** 1996 Feb;11(2):180-3
Biofix fixation techniques and results in foot surgery. Burns AE. **J Foot Ankle Surg** 1995 May-Jun;34(3):276-82
Orthosorb: a case of foreign-body reaction. Kalla TP, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):366-70
Brain edema after carotid surgery. Breen JC, et al. **Neurology** 1996 Jan;46(1):175-81
C1-C2 posterior cervical fusion: long-term evaluation of results and efficacy. Coyne TJ, et al. **Neurosurgery** 1995 Oct;37(4):688-92; discussion 692-3
Prospective analysis by computed tomography and long-term outcome of 23 adult patients with chronic idiopathic hydrocephalus. Raftopoulos C, et al. **Neurosurgery** 1996 Jan;38(1):51-9
Cementless acetabular components: optimums and outcomes. Engh CA Sr, et al. **Orthopedics** 1995 Sep;18(9):813-5
Radiographic findings after pectus excavatum repair. Lancaster L, et al. **Pediatr Radiol** 1995;25(6):452-4
Noncardiac thoracic surgical procedures. Definitions, indications, and postoperative radiology. Bhalla M. **Radiol Clin North Am** 1996 Jan;34(1):137-55 (28 ref.)
Radiologic evaluation of the patient after cardiac surgery. Henry DA. **Radiol Clin North Am** 1996 Jan;34(1):119-35 (43 ref.)
Role of the imaging specialist in the detection of opportunistic infection after lung transplantation: are we out of the loop? [editorial] Anderson DC. **Radiology** 1996 Aug;200(2):325-6
Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Shreeniwas R, et al. **Radiology** 1996 Aug;200(2):349-56
Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367-8 (12 ref.)
Radiology of pulmonary emphysema and lung volume reduction surgery. Slone RM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):61-82 (61 ref.)
Evaluation of lumbar spine fusion. Plain radiographs versus direct surgical exploration and observation. Kant AP, et al. **Spine** 1995 Nov 1;20(21):2313-7
The role of ERCP in laparoscopic cholecystectomy-related cystic duct stump leaks. Himal HS. **Surg Endosc** 1996 Jun; 10(6):653-5
Analysis of symptomatic patients after cholecystectomy: is the term post-cholecystectomy syndrome an anachronism? Anand AC, et al. **Trop Gastroenterol** 1995 Apr-Jun; 16(2):126-31
[Richter hernia in trocar site after laparoscopic herniotomy] Bendsen AK, et al. **Ugeskr Laeger** 1995 Nov 13; 157(46):6438-9 (Eng. Abstr.) **(Dan)**
[Thrombosis of the upper thoracic inflow vessel. Spiral CT and 3-D reconstruction] Lenglinger FX, et al. **Aktuelle Radiol** 1996 Mar;6(2):108-9 (Eng. Abstr.) **(Ger)**
[Conservative versus surgical therapy of unilateral fractures of the collum mandibulae--anatomic and functional results with special reference to computer-assisted 3-dimensional axiographic registration of condylar paths] Feifel H, et al. **Fortschr Kiefer Gesichtschir** 1996;41:124-7 (Eng. Abstr.) **(Ger)**
[Bone stability after bimaxillary surgery] Hoffmeister B, et al. **Fortschr Kiefer Gesichtschir** 1995;40:57-65 **(Ger)**
[Results of follow-up of temporomandibular joint fractures in 30 children] Kellenberger M, et al. **Fortschr Kiefer Gesichtschir** 1996;41:138-42 (Eng. Abstr.) **(Ger)**
[Late results of 15 years and longer after mandibular condyle fractures] Stoll P, et al. **Fortschr Kiefer Gesichtschir** 1996; 41:127-30 (Eng. Abstr.) **(Ger)**
[Intermediate-term treatment outcome after fractures of the proximal radius] Krüger-Franke M, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):258-63 (Eng. Abstr.) **(Ger)**
[Quiz on an unusual orbital masquerade syndrome] Gloor B, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):377-80 (Eng. Abstr.) **(Ger)**
[Delayed stenosis after esophageal reconstruction with colon interposition 35 years ago] Bohndorf M. **Laryngorhinootologie** 1995 Dec;74(12):768-71 (Eng. Abstr.) **(Ger)**
[Spiral CT for detection of heart valve disease with complex postoperative changes] Becker C, et al. **Radiologe** 1996 Apr; 36(4):365-7 **(Ger)**
[Videocinematography and pre- and postoperative diagnosis of lip-maxillary-palatal clefts] Hess U, et al. **Radiologe** 1995 Oct;35(10):712-5 (Eng. Abstr.) **(Ger)**
[Computerized tomography assisted follow-up of arthroscopic implantation of hydroxylapatite implants in fractures of the head of the tibial. Preliminary results of CT-controlled quantitative evaluation of healing and foreign body reaction to calcium hydroxyapatite implants] Liebig T, et al. **Rontgenpraxis** 1996 Jun;49(6):141-4 **(Ger)**
[Modified double contrast examination of the stomach in obese patients after vertical gastroplasty] Raissaki MT, et al. **Rontgenpraxis** 1995 Nov;48(11):319-23 **(Ger)**
[Intraoperative and postoperative insertion control of anterior cruciate ligament-plasty. A radiologic measuring method (quadrant method)] Bernard M, et al. **Unfallchirurg** 1996 May;99(5):332-40 (Eng. Abstr.) **(Ger)**
[Surgical treatment of acute, complete acromioclavicular joint dislocation. Indications, technique and results] Fremerey RW, et al. **Unfallchirurg** 1996 May;99(5):341-5 (Eng. Abstr.) **(Ger)**
[Rotational instability of trochanteric femoral fractures secured with the dynamic hip screw. A radiologic analysis] Lustenberger A, et al. **Unfallchirurg** 1995 Oct;98(10):514-7 (Eng. Abstr.) **(Ger)**
[Quantitative follow-up of callus distraction with dual-energy roentgen absorptiometry (DEXA)] Sabo D, et al. **Unfallchirurg** 1995 Nov;98(11):559-65 (Eng. Abstr.) **(Ger)**
[Injuries of the medial collateral ligament and anterior cruciate ligament of the knee joint and Lemaire surgical functional treatment. Long-term outcome] Schmid F. **Unfallchirurgie** 1996 Jun;22(3):124-9 (Eng. Abstr.) **(Ger)**
[Dislocation fracture of the head of the tibia. I. Results of surgical treatment] Wiedemann M, et al. **Unfallchirurgie** 1995 Aug;21(4):175-87 (Eng. Abstr.) **(Ger)**
[Recurrent thromboses in a 32-year-old pregnant patient with permanent vena cava filter] Kröger K, et al. **Vasa** 1995;24(4):385-8 (Eng. Abstr.) **(Ger)**
[Long-term outcome of Dega acetabulum-plasty] Reichel H, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar-Apr; 134(2):131-6 (Eng. Abstr.) **(Ger)**
[The mobile segment above fusion] Schulitz KP, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar-Apr;134(2):171-6 (Eng. Abstr.) **(Ger)**
[Nonvascular interventional radiology in the treatment of post-liver transplant complications. The clinico-radiological correlations and technical considerations] Rossi M, et al. **Radiol Med (Torino)** 1995 Sep;90(3):291-7 (Eng. Abstr.) **(Ita)**
[A false incisional hernia during coumarin anticoagulation] Gabriel HM, et al. **Acta Med Port** 1995 Oct;8(10):589-90 (Eng. Abstr.) **(Por)**

RADIONUCLIDE IMAGING

Additive value of thallium single-photon emission computed tomography myocardial imaging for prediction of perioperative events in clinically selected high cardiac risk patients having abdominal aortic surgery. Vanzetto G, et al. **Am J Cardiol** 1996 Jan 15;77(2):143-8
Visualization of a postoperative bile leak during cholescintigraphy. Morphine augmentation prevents a false-negative study. Andrews RT, et al. **Clin Nucl Med** 1995 Jul;20(7):642-3
The diagnosis of anastomotic leak after gastroesophagostomy with biliary scintigraphy. Herrlin K. **Clin Nucl Med** 1995 Aug;20(8):709-11
Anastomotic leak of pancreatic transplant demonstrated by radionuclide cystography. Mouratidis B, et al. **Clin Nucl Med** 1995 Aug;20(8):742-3
Bile leak after T-tube removal--a scintigraphic study. Kacker LK, et al. **Hepatogastroenterology** 1995 Nov-Dec; 42(6):975-8
Detection of perioperative coronary vasospasm on iodine-123-MIBG, thallium-201 and iodine-123-BMIPP myocardial SPECT images. Kodama K, et al. **J Nucl Med** 1995 Nov;36(11):2050-2
Pulmonary perfusion after endovascular stenting of pulmonary artery stenosis. Oyen WJ, et al. **J Nucl Med** 1995 Nov;36(11):2006-8
Technetium-99m-albumin colloid lymphoscintigraphy in postoperative lymphocele. Perrymore WD, et al. **J Nucl Med** 1996 Sep;37(9):1517-8
[Conventional nuclear medical diagnosis in the after care of heart transplantation] Puskás C, et al. **Nuklearmedizin** 1996 Feb;35(1):31-7 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Sclafani AP, et al. **Dermatol Surg** 1996 Jun;22(6):569-74
[Postoperative, conventional fractionated radiotherapy for prevention of heterotopic ossification after total endoprosthesis of the hip joint] Heyd R, et al. **Rontgenpraxis** 1995 Aug;48(8):233-7 (Eng. Abstr.) **(Ger)**
[Laser radiation in the infrared range in the treatment of aseptic postoperative wounds] Efendiev AI, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):291-3 (Eng. Abstr.) **(Rus)**

REHABILITATION

Prospective, randomized trial of splinting after carpal tunnel release. Bury TF, et al. **Ann Plast Surg** 1995 Jul;35(1):19-22
Behavioural training during acute brain trauma rehabilitation: an empirical case study. Slifer KJ, et al. **Brain Inj** 1995 Aug-Sep;9(6):585-93
Posttraumatic stiffness in the hand. Putnam MD. **Clin Orthop** 1996 Jun;(327):182-90 (47 ref.)
Early active mobilization of tendon grafts using mesh reinforced suture techniques. Silfverskiöld KL, et al. **J Hand Surg [Br]** 1995 Jun;20(3):301-7
The management of dysphagia in jugular foramen surgery. Fenton JE, et al. **J Laryngol Otol** 1996 Feb;110(2):144-7
Psychosocial adjustment in Norwegian adults who had undergone standardised treatment of complete cleft lip and palate. I. Education, employment and marriage. Ramstad T, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):251-7
[Concept for a functional status and handicap-adjustment treatment and rehabilitation service chain in neurologic and neurosurgical management in Germany ("phase model")] Schupp W. **Nervenarzt** 1995 Dec;66(12):907-14 (Eng. Abstr.) **(Ger)**
[Rehabilitation of children and adolescents after organ transplantation] Pichlmayr R, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):80-5 (Eng. Abstr.) **(Ger)**
[Managing stoma complications] Lutz A. **Z Gastroenterol** 1996 Jun;34 Suppl 2:57-8 **(Ger)**
[After-care rehabilitation after pancreas operations] Rosemeyer D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:37-40 **(Ger)**
[Quality of life of tumor patients with colostomy] Schaube J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:55-6 **(Ger)**
[Diagnosis of performance and function in after-care rehabilitation: principles for medical expert assessment] Tittor W. **Z Gastroenterol** 1996 Jun;34 Suppl 2:32-3 **(Ger)**
[After-care rehabilitation after liver transplantation] Zilly W. **Z Gastroenterol** 1996 Jun;34 Suppl 2:34-6 **(Ger)**
[Sequelae of manipulation of the postmastectomy arm] Klimaschewski H. **Z Lymphol** 1996 Jun;20(1):43-5 **(Ger)**

SURGERY

Complicated marginal ulcers after surgery for duodenal ulcer. Alhan E, et al. **Acta Chir Hung** 1995-96;35(1-2):77-85
Revision arthroplasty of the hip with extensive bone loss. Preliminary study. Lakatos J, et al. **Acta Chir Hung** 1995-96;35(1-2):103-11
The outcome of pancreatic fistulas developed after surgery for pancreatic pseudocysts. Magyar A, et al. **Acta Chir Hung** 1995-96;35(1-2):169-76
The role of excimer laser photorefractive keratectomy in treatment of residual myopia followed by radial keratotomy. Nagy ZZ, et al. **Acta Chir Hung** 1995-96; 35(1-2):13-9
Study on early re-rupture of intracranial aneurysms. Aoyagi N, et al. **Acta Neurochir (Wien)** 1996;138(1):12-8
Frequency and causes of shunt revisions in different cerebrospinal fluid shunt types. Borgbjerg BM, et al. **Acta Neurochir (Wien)** 1995;136(3-4):189-94
Surgical treatment of late neurological deterioration in children with myelodysplasia. Caldarelli M, et al. **Acta Neurochir (Wien)** 1995;137(3-4):199-206
Effect of CO2 laser on spinal epidural fibrosis. Colak A, et al. **Acta Neurochir (Wien)** 1996;138(2):162-6
Total intraventricular migration of unisystem ventriculo-peritoneal shunt. Eljamel MS, et al. **Acta Neurochir (Wien)** 1995;136(3-4):217-8
Transpedicular reduction and stabilization for postlaminectomy lumbar instability. Lee TC. **Acta Neurochir (Wien)** 1996;138(2):139-44; discussion 144-5
Hypoglosso-facial nerve anastomosis. Linnet J, et al. **Acta Neurochir (Wien)** 1995;133(3-4):112-5
Pathogenetic factors in chronic subdural haematoma and causes of recurrence after drainage. Stroobandt G, et al. **Acta Neurochir (Wien)** 1995;137(1-2):6-14
Frequent TIA in the territory fed by the anastomosed STA after combined therapeutic ICA occlusion and extracranial-intracranial bypass: case report. Takeuchi S, et al. **Acta Neurochir (Wien)** 1995;133(3-4):206-10
A severely overcorrected high tibial osteotomy: revision by osteotomy and a long stem component. Uchinou S, et al. **Acta Orthop Scand** 1996 Apr;67(2):193-4
Radiofrequency ablation of the His bundle for malignant atrial flutter after Mustard procedure for transposition of the great arteries. Vaksmann G, et al. **Am J Cardiol** 1996 Mar 15;77(8):669-70
Internal stents and postsurgical bile leaks [letter; comment] Barthel JS. **Am J Gastroenterol** 1996 Jul;91(7):1469-70. Comment on: Am J Gastroenterol 1995 Dec;90(12):2128-33.
Postoperative complications requiring relaparotomies after 700 gastretomies performed for gastric cancer. Shchepotin IB, et al. **Am J Surg** 1996 Feb;171(2):270-3
Reoperations after failed antireflux procedures. Siewert JR, et al. **Ann Chir Gynaecol** 1995;84(2):122-8 (29 ref.)
Limb salvage with microvascular free flap reconstruction using simultaneous polytetrafluoroethylene graft for inflow. Kasabian AK, et al. **Ann Plast Surg** 1995 Sep;35(3):310-5
First web space release with the dorsal hand rotation flap: closing the donor site. Marble K, et al. **Ann Plast Surg** 1995 Jul;35(1):83-5
Survival after resection and duodenocolostomy for massive mesenteric infarction after aortic surgery. Williams IM, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):69-70
Characterization and surgical ablation of atrial flutter after the classic Fontan repair. Gandhi SK, et al. **Ann Thorac Surg** 1996 Jun;61(6):1666-78; discussion 1678-9
Decortication is a valuable option for late empyema after collapse therapy. Massard G, et al. **Ann Thorac Surg** 1995 Oct;60(4):888-95
1991. Contralateral pneumonectomy after single-lung transplantation for emphysema. Updated in 1996. Novick RJ, et al. **Ann Thorac Surg** 1996 Apr;61(4):1286-7
Dacron coronary graft obstruction after composite graft replacement of aortic root. Sekine S, et al. **Ann Thorac Surg** 1995 Oct;60(4):1123-5; discussion 1125-6

Arthroscopic arthrolysis for flexion contracture following intraarticular reconstruction of the anterior cruciate ligament. Reider B, et al. **Arthroscopy** 1996 Apr; 12(2):165–73

A method for the treatment of ureteric complications following renal transplantation. Insall RL, et al. **Aust N Z J Surg** 1995 Sep;65(9):654–7

Vaginal evisceration. Balasubramanian R, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):218

Adult postrepair myelomeningocoele and tethered cord syndrome: good surgical outcome after abrupt neurological decline. Fuller AG, et al. **Br J Neurosurg** 1995;9(5):659–66

Outcome after repeat lumbar microdiscectomy. Haglund MM, et al. **Br J Neurosurg** 1995;9(4):487–95

De novo development of saccular aneurysms: report of two cases. Parekh HC, et al. **Br J Neurosurg** 1995;9(5):695–8

Glaucoma laser suture lysis. Macken P, et al. **Br J Ophthalmol** 1996 May;80(5):398–401

Excimer retreatment for scarring and regression after photorefractive keratectomy for myopia. Sutton G, et al. **Br J Ophthalmol** 1995 Aug;79(8):756–9

Free combined parascapular flap and latissimus dorsi muscle flap for facial palsy and neck reconstruction. Kimata Y, et al. **Br J Plast Surg** 1995 Oct;48(7):515–7

Long-term results of mitral valve repair for non-rheumatic mitral regurgitation. Aoyagi S, et al. **Cardiovasc Surg** 1995 Aug;3(4):387–92

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441–4

Rotational atherectomy in restenotic lesions at the distal saphenous vein graft anastomosis. Cardenas JR, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):53–7; discussion 58

Shunt-valve noise as an unusual reason for shunt revision. Kolenda H, et al. **Childs Nerv Syst** 1995 Aug;11(8):489–91

Free tissue coverage of wound complications following Achilles tendon rupture surgery. Leppilahti J, et al. **Clin Orthop** 1996 Jul;(328):171–6

Muscle flaps in total knee arthroplasty. Markovich GD, et al. **Clin Orthop** 1995 Dec;(321):122–30

The role of the Davis graft technique in the treatment of chronic post-mastoidectomy otorrhoea. Walsh RM, et al. **Clin Otolaryngol** 1996 Apr;21(2):162–7

Sensitivity versus cost effectiveness in postoperative follow-up for colorectal cancer. Biggs CG, et al. **Curr Opin Gen Surg** 1994;:94–102

Conversion of the failing ileoanal pouch to reservoir-ileostomy rather than to ileostomy alone. Ecker KW, et al. **Dis Colon Rectum** 1996 Sep;39(9):977–80

Internal pudendal flap anoplasty for severe anal stenosis. Report of a case. Saldana E, et al. **Dis Colon Rectum** 1996 Mar;39(3):350–2

Endoscopic capsulotomy by means of laser--a new therapeutic method in cases of capsular contracture. Herrmann U. **Endosc Surg Allied Technol** 1995 Apr–Jun; 3(2–3):112–4

Thoracoscopic creation of a pericardial window for recurrent pericardial effusion after heart transplantation. Brandt M, et al. **Eur J Cardiothorac Surg** 1996;10(3):220–2

Medical treatment of postappendectomy intraperitoneal abscesses in children. Héloury Y, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):149–51

Partial or near-total pancreatectomy for nesidioblastosis? Parashar K, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):146–8

Mitrofanoff stoma--an iceberg of problems? Searles JM, et al. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:19–20

Iatrogenic AV-fistula treated by a graft-covered self-expandable stent. Brunkwall J, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):243–5

Cataract extraction following vitrectomy and silicone oil tamponade. Baer RM, et al. **Eye** 1995;9 (Pt 3):309–12

Surgical revision after failed lateral ankle reconstruction. Sammarco GJ, et al. **Foot Ankle Int** 1995 Dec;16(12):748–53

Endovascular stent placement for pulmonary venous obstruction after Mustard operation for transposition of the great arteries. Abdulhamed JM, et al. **Heart** 1996 Feb; 75(2):210–2

Recurrent common bile duct stones associated with periampullary duodenal diverticula and calcium bilirubinate stones. Miyazawa Y, et al. **Int Surg** 1995 Apr–Jun;80(2):120–4

Catheter ablation of clinical intraatrial reentrant tachycardias resulting from previous atrial surgery: localizing and transecting the critical isthmus. Baker BM, et al. **J Am Coll Cardiol** 1996 Aug;28(2):411–7

Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study. de Jong E, et al. **J Am Coll Surg** 1996 Jun; 182(6):503–8

Resection arthroplasty of the hip. Ballard WT, et al. **J Arthroplasty** 1995 Dec;10(6):772–9

Fracture of the femoral head after ceramic-on-polyethylene total hip arthroplasty. Callaway GH, et al. **J Arthroplasty** 1995 Dec;10(6):855–9

Fracture of an alumina ceramic head in total hip arthroplasty. Higuchi F, et al. **J Arthroplasty** 1995 Dec;10(6):851–4

Catastrophic failure of modular zirconia-ceramic femoral head components after total hip arthroplasty. Hummer CD 3rd, et al. **J Arthroplasty** 1995 Dec;10(6):848–50

Tibial polyethylene failure after primary porous-coated anatomic total knee arthroplasty. Aids to diagnosis and revision. Knight JL, et al. **J Arthroplasty** 1995 Dec; 10(6):748–57

Ceramic head failure. Krikler S, et al. **J Arthroplasty** 1995 Dec;10(6):860–2

Arthroscopic treatment of peripatellar fibrosis after total knee arthroplasty. Markel DC, et al. **J Arthroplasty** 1996 Apr; 11(3):293–7

Management of patellar clunk under local anesthesia. Messieh M. **J Arthroplasty** 1996 Feb;11(2):202–3

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

Removal and reinsertion of cemented femoral components during acetabular revision. Nabors ED, et al. **J Arthroplasty** 1996 Feb;11(2):146–52

Intraoperative modular stem lengthening to treat periprosthetic femur fracture. Ries MD. **J Arthroplasty** 1996 Feb;11(2):204–5

Use of a supracondylar nail for treatment of a supracondylar fracture of the femur following total knee arthroplasty. Smith WJ, et al. **J Arthroplasty** 1996 Feb;11(2):210–3

Treatment of a stiff shoulder after posterior capsulorrhaphy. A report of three cases. Warner JJ, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1419–21

Hypermetabolism during bilateral single-lung transplantation requiring cardiopulmonary bypass. Chaney MA. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):565–70

Transverse keratotomy to correct high corneal astigmatism after cataract surgery. Güell JL, et al. **J Cataract Refract Surg** 1996 Apr;22(3):331–6

Neodymium:YAG laser optical opening for retained Descemet's membrane after penetrating keratoplasty. Masket S, et al. **J Cataract Refract Surg** 1996 Jan–Feb; 22(1):139–41

Cementless reimplantation of hydroxyapatite-coated total hips after periprosthetic infections. Lai KA, et al. **J Formos Med Assoc** 1996 Jun;95(6):452–7

Salvage of the failed Darrach procedure. Kleinman WB, et al. **J Hand Surg [Am]** 1995 Nov;20(6):951–8

Repeat Russe bone grafting after failed bone graft surgery for scaphoid non-union. Bynum EB, et al. **J Hand Surg [Br]** 1995 Jun;20(3):373–8

Scapho-trapezoid arthritis. A cause of residual pain after arthroplasty of the trapezio-metacarpal joint. Irwin AS, et al. **J Hand Surg [Br]** 1995 Jun;20(3):346–52

The zig-zag deformity in pre-axial polydactyly. A new cause and its treatment. Lourie GM, et al. **J Hand Surg [Br]** 1995 Aug;20(4):561–4

Previous intrapleural procedures do not adversely affect lung transplantation. Dusmet M, et al. **J Heart Lung Transplant** 1996 Mar;15(3):249–54

Successful dynamic cardiomyoplasty after heart transplantation [letter] Herreros JM, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1218–20

Single lung transplantation followed by contralateral bullectomy for bullous emphysema. Kuno R, et al. **J Heart Lung Transplant** 1996 Apr;15(4):389–94

Cardiac allograft vasculopathy: the potential role for transmyocardial laser revascularization. March RJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S242–6

Management of biliary complications after heart transplantation. Peterseim DS, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):623–31

Lung retransplantation: institutional report on a series of twenty patients. Wekerle T, et al. **J Heart Lung Transplant** 1996 Feb;15(2):182–9

Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. Miller DL, et al. **J Heart Valve Dis** 1995 Mar;4(2):160–5

Lost gallstones found in a hernial sac. Rosin D, et al. **J Laparoendosc Surg** 1995 Dec;5(6):409–11

Management of carotid artery exposure with pectoralis major myofascial flap transfer and split-thickness skin coverage. Leemans CR, et al. **J Laryngol Otol** 1995 Dec; 109(12):1176–80

The management of limb-length discrepancies in children after treatment of osteosarcoma and Ewing's sarcoma. González-Herranz P, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):561–5

Management of leg-length disparities after tumor surgery [editorial] Moseley CF. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):559–60

Intestinal neuronal dysplasia as a cause of surgical failure in Hirschsprung's disease: a new modality for surgical management. Banani SA, et al. **J Pediatr Surg** 1996 Apr; 31(4):572–4

Laparoscopic and thoracoscopic assistance with CSF shunts in children. Holcomb GW 3rd, et al. **J Pediatr Surg** 1995 Dec;30(12):1642–3

Use of the donor iliac vein to replace the retrohepatic vena cava in pediatric reduced-size liver retransplantation. Pillay SP, et al. **J Pediatr Surg** 1995 Dec;30(12):1698–9

Unilateral inguinal hernia in girls: is routine contralateral exploration justified? Ulman I, et al. **J Pediatr Surg** 1995 Dec;30(12):1684–6

Avoidance of stomas and delayed anastomosis for bowel necrosis: the 'clip and drop-back' technique. Vaughan WG, et al. **J Pediatr Surg** 1996 Apr;31(4):542–5

Ilizarov bone transport for the treatment of chronic osteomyelitis: a rare complication. Gateley DR, et al. **J R Soc Med** 1996 Jun;89(6):348P–50P

Functioning free muscle transplantation to the lower leg. Kobayashi S, et al. **J Reconstr Microsurg** 1995 Sep; 11(5):319–25

Corneal topography, arcuate keratotomy, and compression sutures for astigmatism after penetrating keratoplasty. Koffler BH, et al. **J Refract Surg** 1996 Feb;12(2):S306–9

Successful phototherapeutic keratectomy for recurrent erosions in bullous keratopathy. Thomann U, et al. **J Refract Surg** 1996 Feb;12(2):S290–2

Postoperative rupture of a hepatic artery aneurysm. A case report. McNamara MF. **J Reprod Med** 1995 Oct; 40(10):736–8

Early thoracic duct ligation for postoperative chylothorax. Sieczka EM, et al. **J Surg Oncol** 1996 Jan;61(1):56–60 (27 ref.)

Reoperation after valve repair for mitral regurgitation: early and intermediate results. Cerfolio RJ, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1177–83; discussion 1183–4

Valved atrial septal patch [letter; comment] Leyro-Diaz RM. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):285–6. Comment on: J Thorac Cardiovasc Surg 1994 Jul;108(1):134–9.

Fascial sling correction of kinked efferent limb in patients with continent diversion and catheterization difficulty. Chancellor MB, et al. **J Urol** 1996 Jul;156(1):162–3

Percutaneous transrenal electro-incision of ureterointestinal anastomotic strictures: long-term results and comparison of fluoroscopic and endoscopic guidance. Cornud F, et al. **J Urol** 1996 May;155(5):1575–8

A new technique for reconstruction of the common bile duct after severe injury by laparoscopic cholecystectomy. Erhard J, et al. **Langenbecks Arch Chir** 1995;380(6):304–7

Protein-losing enteropathy after the Fontan operation: successful treatment by percutaneous fenestration of the atrial septum. Warnes CA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):378–9

The free vascularised fibular transfer as a definitive treatment in femoral septic non-unions. Nonnenmacher J, et al. **Microsurgery** 1995;16(6):383–7

Treatment of primary graft dysfunction after kidney transplantation by renal artery stent. Krumme B, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):208–10

A long-term complication of burying a shunt valve in the skull. Ammar A, et al. **Neurosurg Rev** 1995;18(1):65–7

Spontaneous regeneration of the foramen magnum after decompressive suboccipital craniectomy in Chiari malformation: case report. Aoki N, et al. **Neurosurgery** 1995 Aug;37(2):340–2

Reconstruction of the spinal accessory nerve with an anastomosis to the dorsal C3 branch: technical note. Braun V, et al. **Neurosurgery** 1996 Jan;38(1):208–10

Use of intracranial pressure monitoring in the management of childhood hydrocephalus and shunt-related problems. Fouyas IP, et al. **Neurosurgery** 1996 Apr;38(4):726–31; discussion 731–2

Resolution of traumatic hypertrophic periodontoid cicatrix after posterior cervical fusion: case report. Pare MC, et al. **Neurosurgery** 1995 Sep;37(3):531–3; discussion 533–4

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

Posterior interosseous nerve palsy after brachiocephalic arteriovenous fistula construction: report of two cases. Sawin PD, et al. **Neurosurgery** 1995 Sep;37(3):537–9; discussion 539–40

Technical issues in carotid artery surgery 1995 [letter; comment] Yablon JS. **Neurosurgery** 1995 Dec;37(6):1232. Comment on: Neurosurgery 1995 Apr;36(4):629–47.

Prevention and management of complications associated with the hydroxyapatite implant. Kaltreider SA, et al. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):18–31

Postoperative manipulation of the Krupin valve. Weiss HS. **Ophthalmic Surg Lasers** 1996 Feb;27(2):151–3

Managing recurrent neovascularization after subfoveal surgery in presumed ocular histoplasmosis syndrome. Melberg NS, et al. **Ophthalmology** 1996 Jul; 103(7):1064–7;discussion 1067–8

Supracondylar fractures: all or nothing. Booth RE Jr. **Orthopedics** 1995 Sep;18(9):921–2

Solution options: modular hip stem design. Cameron HU. **Orthopedics** 1995 Sep;18(9):824–6

Revision total knee arthroplasty: how much constraint is necessary? Cuckler JM. **Orthopedics** 1995 Sep;18(9):932–3, 936 (11 ref.)

Hip challenges: what would you do? Dorr LD, et al. **Orthopedics** 1995 Sep;18(9):937–40

Cementless revision for femoral failure. Glassman AH, et al. **Orthopedics** 1995 Sep;18(9):851–3

Cemented revision for femoral failure. Harris WH. **Orthopedics** 1995 Sep;18(9):854–5

Management of the structurally deficient femur in revision total hip replacement. Head WC, et al. **Orthopedics** 1995 Sep;18(9):865–8

Operative management of the infected knee. Petty W. **Orthopedics** 1995 Sep;18(9):927–9

Bone loss: prosthetic and augmentation method. Scott RD. **Orthopedics** 1995 Sep;18(9):923–6

Revision TKA: is cement really necessary? Whiteside LA. **Orthopedics** 1995 Sep;18(9):930–1

Prosthetic management of velopharyngeal insufficiency induced by uvulopalatopharyngoplasty. Finkelstein Y, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):611–6

Successful radiofrequency catheter ablation for macroreentrant ventricular tachycardias in a patient with tetralogy of Fallot after corrective surgery. Chinushi M, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1713–6

Restoration of sensitivity after removal of the sural nerve. A new application of latero-terminal neurorraphy. Viterbo F, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):658–60

Patch-grafting for regional femoral bone loss in cementless revision hip arthroplasty. Hussell JG, et al. **S Afr J Surg** 1995 Dec;33(4):179–83

The surgical management of allograft coronary disease: a paradigm shift. Miller LW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):133–8 (54 ref.)

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

The laparoscopic second look for ischemic bowel disease. Slutzki S, et al. **Surg Endosc** 1996 Jul;10(7):729–31

Laparoscopic cholecystectomy following autogenous breast reconstruction with a TRAM flap. Williams JK, et al. **Surg Endosc** 1995 Jun;9(6):719–23

Laparoscopic removal of a gallbladder remnant. Gurel M, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):410–1

Laparoscopic repair of large incisional hernias. Park A, et al. **Surg Laparosc Endosc** 1996 Apr;6(2):123–8

Synchronous double cancers of the remnant stomach and pancreas: report of a case. Miyaguni T, et al. **Surg Today** 1995;25(12):1038–42

Periosteal chondroma developing in a rib at the side of a chest wall wound from a previous thoracotomy: report of a case. Morisaki Y, et al. **Surg Today** 1996;26(1):57–9

Laparoscopic management of posttransplant pelvic lymphoceles. Oyen O, et al. **Transplant Proc** 1995 Dec; 27(6):3449–50

Haemorrhage due to laceration of an aberrant inferior epigastric artery during femoropopliteal PTA in an obese patient; a rare complication of a high antegrade femoral puncture. Lampmann LE, et al. **Vasa** 1995;24(4):382–4

Nd: YAG laser lysis of the fibrinous membrane and remnant substance on the anterior surface of intraocular lens. Lin Z, et al. **Yen Ko Hsueh Pao** 1995 Sep;11(3):128–30

[The surgical reconstruction of the chest wall using muscle flaps in patients with mediastinitis following heart operations] Davidkov L, et al. **Khirurgiia (Sofiia)** 1995; 48(1):73–5 (Eng. Abstr.) **(Bul)**

[Benign and iatrogenic damages to the bile ducts] Dimitrova V. **Khirurgiia (Sofiia)** 1994;47(6):36–9 **(Bul)**

[The repair of extensive evisceration using an absorbable prosthesis] Levasseur JC, et al. **Khirurgiia (Sofiia)** 1995; 48(4):34–7 (Eng. Abstr.) **(Bul)**

[The surgical correction of postoperative urinary incontinence] Panchev P, et al. **Khirurgiia (Sofiia)** 1994; 47(3):40–1 **(Bul)**

[Celioscopic treatment of acute obstructions caused by adhesions of the small intestine. Experience of 35 cases] Parent S, et al. **J Chir (Paris)** 1995 Oct;132(10):382–5 (Eng. Abstr.) **(Fre)**

[Muscle relaxation with atracurium in myasthenia gravis] Walz R, et al. **Anaesthesiol Reanim** 1996;21(2):43–6 (Eng. Abstr.) **(Ger)**

[Retromuscular alloplasty of large scar hernias: a simple staple attachment technique] Amid PK, et al. **Chirurg** 1996 Jun;67(6):648–52 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of postoperative chyloperitoneum] Bauwens K, et al. **Chirurg** 1996 Jun;67(6):658–60 (Eng. Abstr.) **(Ger)**

[Hip para-articular femoral fracture in total endoprosthesis] Buchholz J, et al. **Chirurg** 1995 Nov;66(11):1120–5 (Eng. Abstr.) **(Ger)**

[Surgical therapy of recurrent Crohn disease] Buhr HJ, et al. **Chirurg** 1995 Aug;66(8):764–73 (35 ref.) (Eng. Abstr.) **(Ger)**

[Spontaneous rupture of aberrant bile ducts in choledocholithiasis] Büttner D, et al. **Chirurg** 1995 Dec; 66(12):1268–71 (Eng. Abstr.) **(Ger)**

[Results of treatment of scar and fistula carcinomas] Faschingbauer M, et al. **Chirurg** 1995 Nov;66(11):1141–5 (Eng. Abstr.) **(Ger)**

[Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?] Graupe F, et al. **Chirurg** 1995 Dec;66(12):1239–44; discussion 1245–6 (Eng. Abstr.) **(Ger)**

[Preperitoneal prosthesis implantation in surgical management of recurrent inguinal hernia. Retrospective evaluation of our results 1989–1994] Langer I, et al. **Chirurg** 1996 Apr;67(4):394–402 (Eng. Abstr.) **(Ger)**

[Mandibular fractures due to implant management--incidence, mechanism of injury and therapeutic characteristics] Carls FR, et al. **Fortschr Kiefer Gesichtschir** 1996;41:106–8 (Eng. Abstr.) **(Ger)**

[The "incompletely operated" surgical patient as an emergency in the oral surgery clinic] Eufinger H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:104–6 (Eng. Abstr.) **(Ger)**

[Mandibular micrognathism as a sequela of early childhood capitulum fractures and their treatment using distraction osteogenesis] Klein C, et al. **Fortschr Kiefer Gesichtschir** 1996;41:147–51 (Eng. Abstr.) **(Ger)**

[Dento-alveolar surgery of the irradiated jaw: is infected osteoradionecrosis a preventable complication?] Konter U, et al. **Fortschr Kiefer Gesichtschir** 1995;40:160–2 (Eng. Abstr.) **(Ger)**

–Chronic tubo-ovarian abscess with vaginal fistula after vaginal hysterectomy: combined laparoscopic-vaginal therapy- Rempen A. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):226–8 (Eng. Abstr.) **(Ger)**

[External fixation for support in soft tissue reconstruction in hand surgery] Pennig D, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):264–8 (Eng. Abstr.) **(Ger)**

[Branchiogenic anomalies (with special reference to severe and complicated outcome)] Piza-Katzer H, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):227–32 (Eng. Abstr.) **(Ger)**

[Complications of endoscopic carpal tunnel operations] Piza-Katzer H, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):156–9 (Eng. Abstr.) **(Ger)**

[Mucociliary clearance of radically operated maxillary sinuses and effect of endoscopic ethmoid bone revision on the mucociliary system] Behrbohm H, et al. **HNO** 1996 Apr;44(4):186–91 (Eng. Abstr.) **(Ger)**

[Risk factors for retinal redetachment by proliferative vitreoretinopathy after episcleral surgery for pseudophakic retinal detachment] Bartz-Schmidt KU, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):82–6 (Eng. Abstr.) **(Ger)**

[Comments on the letter to the editor regarding "Phototherapeutic keratectomy in recurrences of granular corneal dystrophy after keratoplasty" (letter)] Kroll P. **Klin Monatsbl Augenheilkd** 1995 Nov;207(5):343 **(Ger)**

[Revision operations after tenotomy of the medial rectus muscle] Krzizok T, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):361–7 (Eng. Abstr.) **(Ger)**

[Comment on: "Phototherapeutic keratectomy in recurrence of granular corneal dystrophy after keratoplasty" (letter; comment)] Vogel M. **Klin Monatsbl Augenheilkd** 1995 Aug; 207(2):143. Comment on: Klin Monatsbl Augenheilkd 1995 Mar;206(3):184–7. **(Ger)**

[Reconstruction of bile duct injuries (editorial)] Bodner E. **Langenbecks Arch Chir** 1995;380(6):303 **(Ger)**

[Tradition and progress in correction of large hernias (editorial; comment)] Feifel G. **Langenbecks Arch Chir** 1995;380(5):247–8. Comment on: Langenbecks Arch Chir 1995;380(5):249–52. **(Ger)**

[Segmental displacement by callus distraction in extended tibial defects] Prokop A, et al. **Langenbecks Arch Chir** 1996; 381(2):82–7 (Eng. Abstr.) **(Ger)**

[Mesh reinforced cutis-plasty (see comments)] Schütter FW, et al. **Langenbecks Arch Chir** 1995;380(5):249–52 (Eng. Abstr.). Comment in: Langenbecks Arch Chir 1995;380(5):247–8. **(Ger)**

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

[Early indications for surgical vocal cord medial relocation in unilateral recurrent nerve paralysis in advanced age] Rosanowski F, et al. **Laryngorhinootologie** 1996 May; 75(5):290–2 (Eng. Abstr.) **(Ger)**

[Reconstruction of speech and chewing function after extensive tumor resection in the area of the jaw and face] Schmelzeisen R, et al. **Laryngorhinootologie** 1996 Apr; 75(4):231–8 (Eng. Abstr.) **(Ger)**

[Treatment error in rhinoseptoplasty and foreshortening of the soft tissues of the palate with considerable nasal obstruction due to osseochondrous nose abnormality and deviated septum] Wienke A. **Laryngorhinootologie** 1996 Apr;75(4):257–8 **(Ger)**

[Surgical treatment of intra-abdominal abscesses (see comments)] Seelig MH, et al. **Leber Magen Darm** 1996 May;26(3):151–4 (Eng. Abstr.). Comment in: Leber Magen Darm 1996 May;26(3):130–1. **(Ger)**

[Excimer laser phototherapeutic keratectomy (PTK) and modified bare sclera technique for treatment of pterygium] Förster W, et al. **Ophthalmologe** 1995 Aug;92(4):424–6 (Eng. Abstr.) **(Ger)**

[Long-term stability of astigmatism after suture correction in penetrating keratoplasty] Heider W, et al. **Ophthalmologe** 1995 Aug;92(4):433–8 (Eng. Abstr.) **(Ger)**

[Prospective study of surgical therapy of pterygium: bare sclera technique vs. free conjunctiva-limbus transplant] Hille K, et al. **Ophthalmologe** 1996 Jun;93(3):224–6 (Eng. Abstr.) **(Ger)**

[Autologous conjunctiva-limbus transplantation in treatment of primary and recurrent pterygium] Starc S, et al. **Ophthalmologe** 1996 Jun;93(3):219–23 (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of bile leakage following laparoscopic cholecystectomy] Kupferschmidt H, et al. **Schweiz Med Wochenschr Suppl** 1996;79:89S–93S (Eng. Abstr.) **(Ger)**

[Abdominal cicatricial hernia--results of various surgical techniques] Küng C, et al. **Swiss Surg** 1995;(6):274–8 (Eng. Abstr.) **(Ger)**

[Proximal humeral multiple fragment fractures--failures after T-plate osteosynthesis] Speck M, et al. **Swiss Surg** 1996; (2):51–6 (Eng. Abstr.) **(Ger)**

[Osteosynthesis of the hand--indications, technique, results] Thomann YR, et al. **Swiss Surg** 1996;(2):57–61 (Eng. Abstr.) **(Ger)**

[Post-traumatic shoulder arthrodeses--indications, technique, results] Dávid A, et al. **Unfallchirurg** 1995 Nov; 98(11):566–9 (Eng. Abstr.) **(Ger)**

[Experiences with plate osteosynthesis in treatment of peri- and sub-prosthetic femoral fractures] Berkhoff M, et al. **Unfallchirurgie** 1995 Oct;21(5):233–9 (Eng. Abstr.) **(Ger)**

[Progression of arthrosis after alloplasty--what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Surgical outcome in chronic subdural hematoma] Piotrowski WP, et al. **Unfallchirurgie** 1996 Jun;22(3):110–6 (Eng. Abstr.) **(Ger)**

[Indications for transplant nephrectomy with reference to possible complications] Höppner W, et al. **Urologe A** 1995 Nov;34(6):485–8 (Eng. Abstr.) **(Ger)**

[3-dimensional reconstruction for planning surgical reconstruction of tumors in the single kidney] Leissner J, et al. **Urologe A** 1995 Nov;34(6):466–9 (Eng. Abstr.) **(Ger)**

[Indications and results of ex-vivo surgery of the kidney] Petritsch PH, et al. **Wien Klin Wochenschr** 1995; 107(23):731–5 (Eng. Abstr.) **(Ger)**

[Prognosis of hip endoprostheses after disorders of wound healing] Böhler M, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar-Apr;134(2):125–30 (Eng. Abstr.) **(Ger)**

[Laparoscopic repair of ventral abdominal wall hernias] Bärlehner E, et al. **Zentralbl Chir** 1996;121(4):307–11; discussion 311–2 (Eng. Abstr.) **(Ger)**

[Surgical correction of bile duct injuries after laparoscopic cholecystectomy] Hosch SB, et al. **Zentralbl Chir** 1996; 121(4):290–3 (Eng. Abstr.) **(Ger)**

[Long-term results of cemented total endoprostheses of the hip joint] Möllenhoff G, et al. **Zentralbl Chir** 1995; 120(9):716–20 (Eng. Abstr.) **(Ger)**

[Treatment of supracondylar femoral fracture proximal to a knee joint endoprosthesis by retrograde interlocking nailing] Ostermann PA, et al. **Zentralbl Chir** 1995; 120(9):731–3 (Eng. Abstr.) **(Ger)**

[Results of revision and new operation in arteriovenous shunt complications] Schumann M, et al. **Zentralbl Chir** 1996; 121(5):376–9 (Eng. Abstr.) **(Ger)**

[Enema-induced hyperphosphatemia in ileus of the small and large intestine] Wilmanns C, et al. **Zentralbl Chir** 1995; 120(12):981–3 (Eng. Abstr.) **(Ger)**

[Hemiprosthesis in femoral neck fracture] Wölfel R, et al. **Zentralbl Chir** 1995;120(9):721–4 (Eng. Abstr.) **(Ger)**

[Unilateral pulmonary embolectomy without extracorporeal circulation. A report of a clinical case] Barboso G, et al. **Acta Biomed Ateneo Parmense** 1995;66(1-2):53–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Our experience in the emergency treatment of secondary aortoenteric fistulae. The preliminary results of the use of aortic homografts] Novali C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):87–94 (Eng. Abstr.) **(Ita)**

[A modified Damus-Kaye-Stansel anastomosis for restrictive bulvoventricular foramen developed 5 years after Fontan procedure] Morishita A, et al. **Kyobu Geka** 1995 Dec; 48(13):1105–9 (Eng. Abstr.) **(Jpn)**

[A case report of an operation for graft stenosis with complete obstruction of the coronary artery] Oda K, et al. **Kyobu Geka** 1995 Aug;48(9):785–7 (Eng. Abstr.) **(Jpn)**

[Late pericardial effusion after open-heart surgery: usefulness of pericardiocentesis under echocardiographic guidance] Suehiro S, et al. **Kyobu Geka** 1996 Feb;49(2):105–10 (Eng. Abstr.) **(Jpn)**

[A successful repair of aortic regurgitation and right ventricular aneurysm long after correction of tetralogy of Fallot] Tambara K, et al. **Kyobu Geka** 1996 Feb;49(2):131–4 (Eng. Abstr.) **(Jpn)**

[A case of right postpneumonectomy empyema treated by open window thoracostomy, thoracoplasty, pedicled omental flap and musculocutaneous flaps] Umemoto M, et al. **Kyobu Geka** 1996 Jun;49(6):441–4 (Eng. Abstr.) **(Jpn)**

[Successful treatment of an infected pseudoaneurysm of the ascending aorta with omental transfer--a case report] Inoue T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1166–70 (Eng. Abstr.) **(Jpn)**

[A case of a univentricular heart developed subaortic stenosis after fontan operation] Kasahara S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):83–8 (Eng. Abstr.) **(Jpn)**

[Reoperation of a pseudoaneurysm eroding the sternum under hypothermic arrest of the brain through left thoracotomy] Kubo K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):188–91 (Eng. Abstr.) **(Jpn)**

[A case of visceral ischemia associated with acute type IIIb aortic dissection] Moizumi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1023–7 (Eng. Abstr.) **(Jpn)**

[Omentoplasty in bronchopleural fistulas after pneumonectomy] Myrmel T, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3627–8 (Eng. Abstr.) **(Nor)**

[Rare foreign body in the lumen of the small intestine] Piecuch J, et al. **Ginekol Pol** 1995 Dec;66(12):697–9 (Eng. Abstr.) **(Pol)**

[Surgical treatment of diseases of operated stomach] Bondarev VI, et al. **Khirurgiia (Mosk)** 1995;(6):17–20 (Eng. Abstr.) **(Rus)**

[Late seqelae of surgical treatment for ozena] Aksenov VM, et al. **Vestn Otorinolaringol** 1996 Jan-Feb;(1):50–1 **(Rus)**

[Postoperative infection as an indication for hysterectomy after cesarean section] Milašinović L, et al. **Med Pregl** 1996; 49(5–6):221–4 (Eng. Abstr.) **(Scr)**

THERAPY

Dilation of strictures after esophageal resection and reconstruction. Tóta J, et al. **Acta Chir Hung** 1995–96; 35(1–2):137–47

Treatment of the failed back surgery syndrome due to lumbo–sacral epidural fibrosis. Fiume D, et al. **Acta Neurochir Suppl (Wien)** 1995;64:116–8

Spinal cord stimulation versus reoperation for failed back surgery syndrome: a prospective, randomized study design. North RB, et al. **Acta Neurochir Suppl (Wien)** 1995;64:106–8

Endoscopic management of pancreatic duct leak complicated by retrogastric abscess. Sarzen CD. **Am J Gastroenterol** 1995 Nov;90(11):2039–41

Water–soluble contrast material has no therapeutic effect on postoperative small–bowel obstruction: results of a prospective, randomized clinical trial. Feigin E, et al. **Am J Surg** 1996 Feb;171(2):227–9

Successful application of hypothermia combined with intra–aortic balloon pump support to low–cardiac–output state after open heart surgery. Moriyama Y, et al. **Angiology** 1996 Jun;47(6):595–9

A novel method for the treatment of localised intrathoracic anastomotic leakage. Jameson JS, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):225–7

Therapeutic implications for heparin–induced thrombocytopenia and thrombosis [letter; comment] Kalangos A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1159–60 . Comment on: Ann Thorac Surg 1995 Feb;59(2):508–9.

Hemopump treatment in patients with postcardiotomy heart failure. Lönn U, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1067–71

Use of the Heimlich valve to shorten hospital stay after lung reduction surgery for emphysema. McKenna RJ Jr, et al. **Ann Thorac Surg** 1996 Apr;61(4):1115–7

Echocardiography–guided pericardiocentesis with a needle attached to a probe. Suehiro S, et al. **Ann Thorac Surg** 1996 Feb;61(2):741–2

BioMedicus ventricular assistance for postcardiotomy heart failure: evaluation of univentricular assistance. Perko MJ, et al. **Artif Organs** 1995 Jul;19(7):777–81

Cervical haematoma and airway obstruction [letter; comment] Calder I, et al. **Br J Anaesth** 1996 Jun;76(6):888–9 . Comment on: Br J Anaesth 1996 Jan;76(1):156–9.

Bacterial pericarditis after heart transplantation: successful management of two cases with catheter drainage and antibiotics. Davies RA, et al. **Can J Cardiol** 1996 Jul; 12(7):641–4

Restoration of mechanical atrial function after electrical cardioversion of chronic atrial fibrillation in patients after surgical treatment of mitral valve disease—hemodynamic effects and prognostic value of maintenance of sinus rhythm. Szyszka A, et al. **Cardiology** 1996 Mar–Apr; 87(2):98–103

Embolization of a high–output postnephrectomy aortocaval fistula with Gianturco coils and cyanoacrylate. Cekirge S, et al. **Cardiovasc Interveat Radiol** 1996 Jan–Feb;19(1):56–8

Effort thrombosis: effective treatment with vascular stent after unrelieved venous stenosis following a surgical release procedure. Cohen GS, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):37–9

Evaluation and complications of direct graft puncture in thrombolysis and other interventional techniques. Cowling MG, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr; 19(2):82–4

Rheolytic thrombectomy of an acutely thrombosed transjugular intrahepatic portosystemic stent shunt. Müller–Hülsbeck S, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):294–7

Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient. Propst A, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):181–3

The radiological management of biliary complications following liver transplantation. Rieber A, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):242–7

Embolization of an hepatic artery pseudoaneurysm following laparoscopic cholecystectomy. Rivitz SM, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):43–6

Dual guiding catheters for saphenous venous graft protection during native coronary angioplasty. Freund N, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):255–8

Repeat embolization of the side branch of the internal mammary artery graft by gelatin sponge particles and micro coils. Ishizaka N, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):245–9; discussion 250

Balloon angioplasty of the internal mammary artery trunk for early postoperative ischemia: a case report. Kollar A, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):49–51

Gradual angioplasty and stent implantation to treat complete superior vena cava occlusion after Mustard procedure. Schranz D, et al. **Cathet Cardiovasc Diagn** 1996 May; 38(1):87–90; discussion 91

Influenza A pneumonitis following treatment of acute cardiac allograft rejection with murine monoclonal anti–CD3 antibody (OKT3). Embrey RP, et al. **Chest** 1995 Nov; 108(5):1456–9

Transarterial embolization of vein of Galen aneurysmal malformation after unsuccessful stereotactic radiosurgery. Report of three cases. Watban JA, et al. **Childs Nerv Syst** 1995 Jul;11(7):406–8

Abdominal scar endometriosis: report of 28 cases. Xiang Y, et al. **Chin Med Sci J** 1995 Sep;10(3):188–90

Generation of tumor–specific T lymphocytes for the treatment of posttransplant lymphoma. DiMaio JM, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II202–5

Acute obstructive sleep apnea as a complication of sphincter pharyngoplasty. Witt PD, et al. **Cleft Palate Craniofac J** 1996 May;33(3):183–9

Nutrition support following liver transplantation: comparison of jejunal versus parenteral routes. Mehta PL, et al. **Clin Transplant** 1995 Oct;9(5):364–9

Multiple organ failure. Buchman TG. **Curr Opin Gen Surg** 1993;:26–31 (30 ref.)

Critical care and trauma [editorial] Gann DS, et al. **Curr Opin Gen Surg** 1994;:3–5

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

Biofeedback therapy in rectal prolapse patients. Hämäläinen KJ, et al. **Dis Colon Rectum** 1996 Mar;39(3):262–5

Combined hydrostatic and pneumatic balloon dilatation of the post–gastrectomy "hourglass" stomach. Dickey W, et al. **Endoscopy** 1995 May;27(4):344

Effect of a radiant heater on post–operative hypothermia: comparison with a reflective blanket. Bredahl C, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):565–9

Complication of intra–aortic balloon pumping in a pediatric patient. Van de Wal HJ, et al. **Eur J Cardiothorac Surg** 1995;9(10):602–3

Endoscopic treatment of biliary leakage after laparoscopic cholecystectomy. May GR. **Gastrointest Endosc** 1996 Feb; 43(2 Pt 1):180–1

Plasma adsorption to charcoal and ion–exchange resin for treating postoperative hepatic failure. Iseki J, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):394–8

Inhaled nitric oxide for hemodynamic support after postpneumonectomy ARDS. Chiche JD, et al. **Intensive Care Med** 1995 Aug;21(8):675–8

Drainage of tense ascites in children after cardiac surgery. Baden HP, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):720–1

Angioplasty of distal venous bypasses: is it worth the cost? Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:59–65

Successful surgical treatment of cardiac cirrhosis. Tricuspid surgery and plasma exchange. Toyoda Y, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):305–7

Transscleral fixation of posterior chamber intraocular lenses in the absence of capsular support. Helal M, et al. **J Cataract Refract Surg** 1996 Apr;22(3):347–51

Re–forming the flat anterior chamber with Healon. Osher RH, et al. **J Cataract Refract Surg** 1996 May;22(4):411–5

Transrectal ultrasound of the prostate bed after collagen injection. Salomon CG, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):279–82

Endoscopic management of postoperative bile leak. Saraswat VA, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):148–51

Transesophageal echocardiographic identification of a malpositioned extracorporeal membrane oxygenation cannula. Katz WE, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):790–2

Long–term follow–up of heart transplant recipients requiring permanent pacemakers. Raghavan C, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1081–9

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)

Pulmonary perfusion after endovascular stenting of pulmonary artery stenosis. Oyen WJ, et al. **J Nucl Med** 1995 Nov;36(11):2006–8

Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303–11 (49 ref.)

Ischemic colitis complicating abdominal aortic aneurysm surgery in the U.S. veteran. Longo WE, et al. **J Surg Res** 1996 Feb 1;60(2):351–4

Controlled limb reperfusion in patients having cardiac operations. Beyersdorf F, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):873–81

Atherosclerotic lesions of the gastroepiploic artery: one case requiring postoperative dilation and some interesting postmortem observations. Carrel T, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1768–70

Ventilatory support with a cuirass respirator after resection of bullous emphysema: report of a case. Chihara K, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1281–3

Measurement of lung oxygen consumption in a patient after double–lung transplant. Lee KH, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1764–5

Post–transplant renal artery stenosis: impact of therapy on long–term kidney function and blood pressure control. Sankari BR, et al. **J Urol** 1996 Jun;155(6):1860–4

Simple percutaneous arteriovenous graft ligation [letter] Sottiurai VS, et al. **J Vasc Surg** 1996 Jul;24(1):175–6

Pancreatojejunal sutural insufficiency occurring after pancreatoduodenectomy and countermeasures. Kinoshita H, et al. **Kurume Med J** 1995;42(4):221–9

Management of carotid artery rupture by monitored endovascular therapeutic occlusion (1988–1994). Citardi MJ, et al. **Laryngoscope** 1995 Oct;105(10):1086–92

Worsening of renal function in a renal transplant patient treated with granulocyte colony–stimulating factor [letter] Minguez C, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2166–7

Effect of balloon angioplasty on high grade symptomatic vasospasm after subarachnoid hemorrhage. Fujii Y, et al. **Neurosurg Rev** 1995;18(1):7–13

Balloon angioplasty immediately after surgical clipping for symptomatic vasospasm on admission. Report of four cases. Fujii Y, et al. **Neurosurg Rev** 1995;18(2):79–84

Iatrogenic canalicular foreign body. Kramár P, et al. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):65–7

Management of bleb leaks after glaucoma filtering surgery. Use of autologous fibrin tissue glue as an alternative. Asrani SG, et al. **Ophthalmology** 1996 Feb;103(2):294–8

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

Recurrent angina pectoris in patients with internal mammary artery to coronary artery bypass: treatment with coil embolization of unligated side branches. Chavan A, et al. **Radiology** 1996 Aug;200(2):433–6

Biliary strictures in liver transplant recipients: treatment with metal stents. Culp WC, et al. **Radiology** 1996 May; 199(2):339–46

Successful management of portal hypertension following artificial arterioportal shunting: report of a case. Ko S, et al. **Surg Today** 1995;25(6):557–9

Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Gallon AM. **Thorax** 1996 Apr;51(4):429–32

Cryofiltration apheresis for treatment of cryoglobulin–induced glomerulonephritis in renal transplant. Siami GA, et al. **Transplant Proc** 1995 Oct; 27(5):2583–4

Treatment of leukopenia with granulocyte–macrophage colony–stimulating factor after heart transplantation. Wasler A, et al. **Transplant Proc** 1995 Oct;27(5):2633–4

Effects of growth factors and L–arginine on ischemic skin flaps in rats. Walls CM, et al. **Vet Surg** 1995 Nov–Dec; 24(6):484–91

The therapeutic value of HPA–1a–negative platelet transfusion in post–transfusion purpura complicated by life–threatening haemorrhage. Win N, et al. **Vox Sang** 1995; 69(2):138–9

Trial of Badoe's maintenance solution. Ofori–Kuma F, et al. **West Afr J Med** 1995 Apr–Jun;14(2):72–7

Update on the Carney II procedure. Barre PH, et al. **World J Urol** 1996;14(1):27–8

[A case of a successfully conservatively treated ureterovaginal fistula of gynecological origin] Petrov P, et al. **Khirurgiia (Sofiia)** 1995;48(5):76–7 **(Bul)**

[Postoperative management of crisis of myasthenia gravis: analysis of 20 patients] Wang L, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):234–5 (Eng. Abstr.) **(Chi)**

–Breast implants: prevention and therapy of early and late complications. New products and alternatives (interview)– Maillard GF, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S155–62 **(Fre, Ger)**

[Patient management following cardiac transplantation] Seydoux C, et al. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1913–22 (103 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide in therapy of pulmonary hypertension after correction of congenital single atrium] Strauss JM, et al. **Anaesthesiol Reanim** 1995;20(6):162–5 (Eng. Abstr.) **(Ger)**

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

[Perforation of the heart wall—a rare complication after thoracic drainage treatment] Domínguez Fernández E, et al. **Chirurg** 1995 Sep;66(9):920–2 (Eng. Abstr.) **(Ger)**

[Intermittent impulse compression. An alternative in therapy of post–traumatic and postoperative edema] Stöckle U, et al. **Chirurg** 1996 May;67(5):539–45 (Eng. Abstr.) **(Ger)**

–Intravesical electrostimulation for treatment of bladder dysfunction. Initial experiences after gynecological operations– Kölle D, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):221–5 (Eng. Abstr.) **(Ger)**

[Use of plasmapheresis in a 62–year–old patient with severe infection] Koepp A, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):92–6 (Eng. Abstr.) **(Ger)**

[Anastomotic recurrence with tumor stenosis after Billroth II gastrectomy for adenocarcinoma: implantation of 2 metal stents as palliative therapy] Krömer MU, et al. **Leber Magen Darm** 1995 Jul;25(4):176–9 (Eng. Abstr.) **(Ger)**

[Perioperative use of noninvasive ventilation] Karg O, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:38–40 (Eng. Abstr.) **(Ger)**

[Incidence, clinical aspects and therapy of late pericardial tamponade following heart surgery] Wilhelm M, et al. **Swiss Surg** 1996;(3):92–6 (Eng. Abstr.) **(Ger)**

[Wound drainage with a continuous high vacuum drainage system and a drainage system with variable vacuum] Heissing R, et al. **Unfallchirurg** 1995 Oct;98(10):522–5 (Eng. Abstr.) **(Ger)**

[Postoperative ischemic ileocolitis in the elderly. Suggested therapy with intraluminal administration of oxygen and glutamine] Mangiante G, et al. **Chir Ital** 1994;46(6):80–5 (Eng. Abstr.) **(Ita)**

[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) **(Ita)**

[Nonvascular interventional radiology in the treatment of post–liver transplant complications. The clinico–radiological correlations and technical considerations] Rossi M, et al. **Radiol Med (Torino)** 1995 Sep;90(3):291–7 (Eng. Abstr.) **(Ita)**

[Analysis of tracheostomy for patients after thoracic esophageal cancer resection] Izumi K, et al. **Kyobu Geka** 1995 Sep;48(10):811–5; discussion 815–9 (Eng. Abstr.) **(Jpn)**

[A successful circulatory assist in acute left heart failure after a rapid two–stage arterial switch operation] Jung E, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1160–5 (Eng. Abstr.) **(Jpn)**

[Operative complications of obese patients and its countermeasure] Kawamura I. **Nippon Rinsho** 1995 Jun;53 Suppl:545–9 (16 ref.) **(Jpn)**

[Criteria for the choice of the extracorporeal detoxication method in patients with postoperative renal failure] Nikiforov IuV, et al. **Anesteziol Reanimatol** 1995 Jul–Aug; (4):38–41 (Eng. Abstr.) **(Rus)**

[Somatosensory evoked potentials in the evaluation of the effectiveness of intensive therapy of ischemic complications in neurosurgical patients] Shchekut'ev GA, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):23–6 (Eng. Abstr.) **(Rus)**

[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):45–9 (122 ref.) **(Rus)**

[The individual immunotherapy of the intracranial complications after neurosurgical operations] Khil'ko VA, et al. **Vestn Khir Im I I Grek** 1995;154(2):29–30 (Eng. Abstr.) **(Rus)**

[The treatment and prevention of postoperative pancreatitis] Veronskiĭ GI, et al. **Vestn Khir Im I I Grek** 1995;154(2):20–3 **(Rus)**

[Urological management of renal transplant patients] Acosta Otero A. **Bol Asoc Med P R** 1995 May–Jun;87(5–6):100–2 **(Spa)**

[High–frequency ventilation in a patient with bilateral tension pneumothorax caused by barotrauma and severe bronchospasm (letter)] Uña R, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):351 **(Spa)**

[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez–Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60–4 (22 ref.) (Eng. Abstr.) **(Spa)**

[The use of autologous blood in treating urinary incontinence after performing a transurethral operation] Ukhal' MI, et al. **Klin Khir** 1995;(6):52 **(Ukr)**

ULTRASONOGRAPHY

Postoperative chylous ascites. Mladinić–Vulić D, et al. **Acta Paediatr** 1995 Aug;84(8):949–51

Accuracy of sonography in the evaluation of calf deep vein thrombosis in both postoperative surveillance and symptomatic patients [see comments] Atri M, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1361–7. Comment in: AJR Am J Roentgenol 1996 Jun;166(6):1368–9.

Screening for deep venous thrombosis in asymptomatic postoperative orthopedic patients using color Doppler sonography: analysis of prevalence and risk factors. Davidson HC, et al. **AJR Am J Roentgenol** 1996 Mar; 166(3):659–62

Pseudoaneurysm of the breast. Wilkes AN, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):625–6

Pericardial hematoma causing saphenous vein graft compression. Shehata AR, et al. **Am Heart J** 1996 Mar; 131(3):598–9

Diagnosis of intermittent obstruction of mechanical mitral valve prostheses by Doppler echocardiography. Shahid M, et al. **Am J Cardiol** 1995 Dec 15;76(17):1305–9

Timing to perform echocardiography for the detection of pericardial effusion after surgical repair of congenital heart disease [letter] Yip AS, et al. **Am J Cardiol** 1996 Sep 1; 78(5):609–10

Sonography useful after TIPS. Ott DJ. **Am J Gastroenterol** 1996 Apr;91(4):814–5

Right ventricular dysfunction in low output syndrome after cardiac operations: assessment by transesophageal echocardiography [see comments] Dávila–Román VG, et al. **Ann Thorac Surg** 1995 Oct;60(4):1081–6. Comment in: Ann Thorac Surg 1996 Jul;62(1):319.

Long–term surveillance by duplex scanning of nonrevised infragenicular graft stenosis. Ho GH, et al. **Ann Vasc Surg** 1995 Nov;9(6):547–53

Prospective surveillance for perioperative venous thrombosis. Experience in 2643 patients. Flinn WR, et al. **Arch Surg** 1996 May;131(5):472–80

Experience with color–coded duplex sonography after combined kidney/pancreas transplantation—preliminary results. Lang H, et al. **Bildgebung** 1996 Jun;63(2):90–3

Pseudoaneurysm following aortic homograft: clinical implications? Oechslin E, et al. **Br Heart J** 1995 Dec; 74(6):645–9

The detection of breast implant rupture using ultrasound. Park AJ, et al. **Br J Plast Surg** 1996 Jul;49(5):299–301

Doppler echocardiographic determination of geometric orifice areas in mechanical aortic valve prostheses. Henneke KH, et al. **Cardiology** 1995;86(6):508–13

Isolated right atrial tamponade after open heart surgery: role of echocardiography in diagnosis and management. Saner HE, et al. **Cardiology** 1995;86(6):464–72

Echo–Doppler diagnosis of renal allograft artery stenosis. Merkus JW, et al. **Clin Transplant** 1995 Oct;9(5):383–9

Pancreatic allograft thrombosis: diagnostic and therapeutic importance of splenic venous flow velocity. Nghiem DD. **Clin Transplant** 1995 Oct;9(5):390–5

Left atrial paralysis after mitral valve replacement [letter] Tomcsányi J, et al. **Eur Heart J** 1995 Dec;16(12):2008–9

Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis. Lausen I, et al. **Eur J Radiol** 1995 Sep;20(3):200–4

Diagnostic value of transesophageal compared with transthoracic echocardiography in suspected prosthetic valve endocarditis. Morguet AJ, et al. **Herz** 1995 Dec; 20(6):390–8

Impaired left atrial function after heart transplantation: disparate contribution of donor and recipient atrial components studied on–line with quantitative echocardiography. Cresci S, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):647–53

Quantitative analysis of transplant coronary artery disease with use of intracoronary ultrasound. Johnson JA, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S198–202

Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. Kobashigawa JA, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S221–6

Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. Mehra MR, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):632–9

Prevalence and distribution of transplant coronary artery disease: insights from intravascular ultrasound imaging. Tuzcu EM, et al. **J Heart Lung Transplant** 1995 Nov–Dec; 14(6 Pt 2):S202–7

Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. Yeung AC, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S215–20

Sonography in the postoperative evaluation of laparoscopic inguinal hernia repair. Furtschegger A, et al. **J Ultrasound Med** 1995 Sep;14(9):679–84

Use of laparoscopic ultrasonography to detect ovarian remnants. Nezhat F, et al. **J Ultrasound Med** 1996 Jun; 15(6):487–8

Validity of ultrasonography for postoperative monitoring in pediatric urology. Paduano L, et al. **J Urol** 1996 Mar; 155(3):1053–6

Impact of colour Doppler sonography on detection of thrombosis of the hepatic artery and the portal vein after liver transplantation. Hellinger A, et al. **Langenbecks Arch Chir** 1996;381(3):182–5

Use of ultrasonography to evaluate muscle thickness and blood flow in free flaps. Salmi A, et al. **Microsurgery** 1995; 16(9):601–5

Hepatic artery thrombosis after liver transplantation: temporal accuracy of diagnosis with duplex US and the syndrome of impending thrombosis [see comments] Nolten A, et al. **Radiology** 1996 Feb;198(2):553–9. Comment in: Radiology 1996 Aug;200(2):586–7.

Hepatic artery thrombosis [letter; comment] Wachsberg RH. **Radiology** 1996 Aug;200(2):586–7. Comment on: Radiology 1996 Feb;198(2):553–9.

Doppler ultrasonographic evaluation of hepatic circulation in patients following Kasai's operation for biliary atresia. Nakada M, et al. **Surg Today** 1995;25(12):1023–6

Diagnostic value of compression ultrasonography and fibrinogen–related parameters for the detection of postoperative deep vein thrombosis following elective hip replacement: a pilot study. Crippa L, et al. **Thromb Haemost** 1995 Nov;74(5):1235–9

Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery? Magnusson M, et al. **Thromb Haemost** 1996 Feb;75(2):242–5

Do routinely registered preoperative data provide prognostic information on the short–term outcome of distal bypass surgery? Rosén L, et al. **Vasa** 1996;25(2):114–20

[Malignant ciliary block glaucoma after deep sclerotomy—ultrasound biomicroscopy imaging] Chiou AG, et al. **Klin Monatsbl Augenheilkd** 1996 May; 208(5):279–81 (Eng. Abstr.) **(Fre)**

[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism] Bruch C, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25–26):829–33 (23 ref.) (Eng. Abstr.) **(Ger)**

[Vaginal ultrasound of surgical gynecologic complications] Klug PW. **Gynakologe** 1995 Aug;28(4):262–9 (25 ref.) **(Ger)**

[Free fatty tissue transplantation in the area of the face] Drommer RB, et al. **Hautarzt** 1995 Sep;46(9):628–31 (Eng. Abstr.) **(Ger)**

[Examination technique of ultrasound follow–up of pharyngeal closure after laryngectomy] Eistert B, et al. **Laryngorhinootologie** 1995 Dec;74(12):756–60 (Eng. Abstr.) **(Ger)**

[Ultrasound diagnosis of acute appendicitis—possibilities and limits of the method—results of prospective and retrospective clinical studies] Uebel P, et al. **Ultraschall Med** 1996 Jun;17(3):100–5 (Eng. Abstr.) **(Ger)**

[Ultrasound imaging and localization of metal implants. A clinical study] Grechenig W, et al. **Unfallchirurgie** 1996 Jun;22(3):117–23 (Eng. Abstr.) **(Ger)**

[Elective lymph node dissection in malignant melanoma—status of color Doppler findings] Omlor G, et al. **Zentralbl Chir** 1996;121(6):469–73 (Eng. Abstr.) **(Ger)**

[An algorithm for the ultrasonic monitoring of patients who have undergone cystectomy] Sitdykov EN, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):41–4 **(Rus)**

URINE

Transient 'milky urine' after cardiac catheterization: another unreported cause of non–parasitic chyluria [letter] Chen HS, et al. **Nephron** 1996;72(2):367–8

VETERINARY

Acute post–treatment enterocolitis in 13 horses treated in a Norwegian surgical ward. Larsen J, et al. **Acta Vet Scand** 1996;37(2):203–11

Hydrocele formation after castration in 3 geldings. Colbourne CM, et al. **Aust Vet J** 1996 Apr;73(4):156–7

The risks of the game: the confidential enquiry into perioperative equine fatalities [editorial] Johnston GM. **Br Vet J** 1995 Jul–Aug;151(4):347–50 (8 ref.)

Haemobartonella canis infection following splenectomy and transfusion. Lester SJ, et al. **Can Vet J** 1995 Jul;36(7):444–5

Comparison of herniorrhaphy versus clamping of umbilical hernias in horses: a retrospective study of 93 cases (1982–1994). Riley CB, et al. **Can Vet J** 1996 May; 37(5):295–8

Presumptive, iatrogenic gastric outflow obstruction associated with prior gastric surgery. Fossum TW, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):391–5

Hematological and biochemical changes and results of aerobic bacteriological culturing in dogs undergoing splenectomy. Richardson EF, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):199–210

Case–control study of the association between intraoperative administration of nafcillin and acute postoperative development of azotemia. Pascoe PJ, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1043–7

Postoperative complications of elective surgeries in dogs and cats determined by examining electronic and paper medical records. Pollari FL, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1882–6

Fracture of the humerus after cancellous bone graft harvesting in a dog. Ferguson JF. **J Small Anim Pract** 1996 May;37(5):232–4

Ovarian remnant syndrome in dogs and cats: 46 cases (1988–1992). Miller DM. **J Vet Diagn Invest** 1995 Oct; 7(4):572–4

Ileal cannulation and associated complications in dogs. Hill RC, et al. **Lab Anim Sci** 1996 Feb;46(1):77–80

Jejunal intussusception: a complication of functional end–to–end stapled anastomoses in two ponies. Frankeny RL, et al. **Vet Surg** 1995 Nov–Dec;24(6):515–7

Confidential enquiry into perioperative equine fatalities (CEPEF) [letter] Johnston GM, et al. **Vet Surg** 1995 Nov–Dec;24(6):518–9

Complications of celiotomy incisions in horses. Wilson DA, et al. **Vet Surg** 1995 Nov–Dec;24(6):506–14

[Practical experiences in the therapy of postoperative uremic crises] Bilkei G, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jun;108(6):230–2 (Eng. Abstr.) **(Ger)**

VIROLOGY

Epstein–Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Alfieri C, et al. **Blood** 1996 Jan 15;87(2):812–7

BCL–2 but not its Epstein–Barr virus–encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders [see comments] Murray PG, et al. **Blood** 1996 Jan 15;87(2):706–11. Comment in: Blood 1996 Jun 15;87(12):5395.

Cytomegalovirus infection in marrow transplantation. Boeckh M, et al. **Cancer Treat Res** 1995;76:97–136 (203 ref.)

Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Cobian L, et al. **Clin Infect Dis** 1995 Oct;21(4):1040–1

Infection of human endothelial cells with Epstein–Barr virus. Jones K, et al. **J Exp Med** 1995 Nov 1;182(5):1213–21

IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients. Kraat YJ, et al. **J Med Virol** 1996 Mar;48(3):289–94

Extrahepatic biliary stricture associated with cytomegalovirus in a liver transplant recipient. Kowdley KV, et al. **Transpl Int** 1996;9(2):161–3

Acute hemorrhagic cystitis by adenovirus type 11 with and without type 37 after kidney transplantation. Umekawa T, et al. **Urol Int** 1996;56(2):114–6

POSTOPERATIVE HEMORRHAGE

Deceptive prothrombin and activated partial thromboplastin times in alcoholic cirrhosis. Sirikonda PR, et al. **J Natl Med Assoc** 1996 May;88(5):306–9

Laser-assisted uvulopalatoplasty: postoperative complications. Walker RP, et al. **Laryngoscope** 1996 Jul; 106(7):834–8

[Is it useful to collect blood drained during the 6 postoperative hours in orthopedic surgery? (letter)] Grouille D. **Ann Fr Anesth Reanim** 1995;14(4):377 **(Fre)**

BLOOD

The relationship between hematocrit, blood lost, and blood transfused in total knee replacement. Implications for postoperative blood salvage and reinfusion. Goodnough LT, et al. **Am J Knee Surg** 1995 Summer;8(3):83–7

Analysis of changes in coagulation factors after postoperative blood loss in burn and non-burn patients. Chang P, et al. **Burns** 1995 Sep;21(6):432–6

CHEMICALLY INDUCED

Intraoperative ketorolac and posttonsillectomy bleeding. Judkins JH, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):937–40

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Dodenhoff RM. **J Bone Joint Surg Am** 1996 Jun;78(6):968. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Linville D. **J Bone Joint Surg Am** 1996 Jun;78(6):967–8. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Risk of operative site bleeding with parenteral ketorolac [letter; comment] Gumprecht T. **JAMA** 1996 Aug 7; 276(5):372. Comment on: JAMA 1996 Feb 7;275(5):376–82.

Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study [see comments] Strom BL, et al. **JAMA** 1996 Feb 7; 275(5):376–82. Comment in: JAMA 1996 Aug 7;276(5):372.

Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369–74 (64 ref.)

[Bleeding after endoscopic biopsy and polypectomy—do nonsteroidal anti-rheumatic drugs increase the risk?] von Ritter C, et al. **Z Gastroenterol** 1995 Nov;33(11):683–4 **(Ger)**

DIAGNOSIS

Sonoclot analysis. Hett DA, et al. **Br J Anaesth** 1995 Dec; 75(6):771–6 (41 ref.)

Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. Moulton MJ, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):1037–46

DRUG THERAPY

Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. Benoni G, et al. **J Bone Joint Surg Br** 1996 May; 78(3):434–40

[Hemostatic mechanism associated with aprotinin during and after the extracorporeal circulation for cardiac and great vessel surgery] Takaori M, et al. **Masui** 1995 Dec; 44(12):1661–6 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Would day-case adult tonsillectomy be safe? Moralee SJ, et al. **J Laryngol Otol** 1995 Dec;109(12):1166–7

ETIOLOGY

Anesthesia, blood loss, and coagulopathy during transurethral resection of the prostate [letter; comment] Hahn RG. **Anesth Analg** 1996 Jul;83(1):195. Comment on: Anesth Analg 1995 Oct;81(4):680–5.

The clinical usefulness of the preoperative bleeding time. Gewirtz AS, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):353–6

Delayed massive haemorrhage after pancreatic and biliary surgery. van Berge Henegouwen MI, et al. **Br J Surg** 1995 Nov;82(11):1527–31

Life threatening secondary haemorrhage following endoscopic laser ablation of the prostate in an anti-coagulated patient. Bellringer JF, et al. **Br J Urol** 1996 Mar;77(3):463–4

Delayed hemorrhage following endoscopic retrograde sphincterotomy for choledocholithiasis. Gholson CF, et al. **Dig Dis Sci** 1996 May;41(5):831–4

Intraoperative clotting factor dilution and activated hemostasis in children with Ewing's sarcoma or osteosarcoma: a prospective longitudinal study. Nowak-Göttl U, et al. **Haematologica** 1995 Jul-Aug; 80(4):311–7

Intraabdominal bleeding following laparoscopic adnexal surgery. A report of three cases. Wong SM, et al. **J Reprod Med** 1996 Apr;41(4):294–6

Post tonsillectomy hemorrhage: a ten-year retrospective study. Schroeder WA Jr. **Mo Med** 1995 Sep;92(9):592–5

Hemorrhage risk after stereotactic radiosurgery of cerebral arteriovenous malformations. Pollock BE, et al. **Neurosurgery** 1996 Apr;38(4):652–9; discussion 659–61

Intraabdominal hemorrhage complicating surgical management of necrotizing pancreatitis. Tsiotos GG, et al. **Pancreas** 1996 Mar;12(2):126–30

[Hemorrhagic complications of ORL surgery] Boisson-Bertrand D, et al. **Cah Anesthesiol** 1995; 43(5):489–95 (48 ref.) **(Fre)**

[Intra-abdominal bleeding after myocardial infarction with cardiopulmonary resuscitation and thrombolytic therapy] Adams HA, et al. **Anaesthesist** 1995 Aug;44(8):585–9 (Eng. Abstr.) **(Ger)**

[Critical comments from the ENT physician viewpoint on Ciaglia percutaneous dilatative tracheostomy] Deitmer T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec;30(8):501–3 **(Ger)**

[Treatment after and patient education before tonsillectomy] Wienke A. **Laryngorhinootologie** 1996 Mar;75(3):184–5 **(Ger)**

[Massive epistaxis as a rare complication in the immediate postoperative period following heart surgery (letter)] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):117–8 **(Spa)**

GENETICS

Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage. Weinstock DJ, et al. **J Pediatr Surg** 1995 Dec;30(12):1746–7

PREVENTION & CONTROL

A randomized trial of open versus closed vaginal vault in the prevention of postoperative morbidity after abdominal hysterectomy. Colombo M, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1807–11

Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Shore-Lesserson L, et al. **Anesth Analg** 1996 Jul;83(1):18–26

Surgical bleeding and calcium antagonists [letter; comment] Hynynen M, et al. **BMJ** 1996 Feb 3;312(7026):313. Comment on: BMJ 1995 Mar 25;310(6982):776–7.

Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass. John LC, et al. **Br J Clin Pract** 1996 Jun;50(4):203–6 (66 ref.)

The mechanism of postoperative blood loss reduction by ultrafiltration in cardiac surgery is unlikely to be only mediated by hemoconcentration of coagulation factors. Journois D, et al. **Contrib Nephrol** 1995;116:150–3

Hemostasis for dental surgery. Rogerson KC. **Dent Clin North Am** 1995 Jul;39(3):649–62

Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. von Hoch F, et al. **Eur Heart J** 1995 May;16(5):640–6

Effects of modified positioning and mobilization of back pain and delayed bleeding in patients who had received heparin and undergone angiography: a pilot study. Pooler-Lunse C, et al. **Heart Lung** 1996 Mar-Apr;25(2):117–23

Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Ylikorkala O, et al. **Hum Reprod** 1995 Jun;10(6):1470–4

Altering anticoagulation therapy: a survey of physicians. Wahl MJ, et al. **J Am Dent Assoc** 1996 May;127(5):625–6, 629–30, 633–4 passim

Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. Menichetti A, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):401–7

Antifibrinolytic therapy: treat whom and with what? [letter] Horrow JC. **J Clin Anesth** 1995 Dec;7(8):690

A technique to prevent bleeding after Ross procedure. Kumar AS, et al. **J Heart Valve Dis** 1995 Jul;4(4):405–6

A simple technique for anticipating and managing secondary puncture site hemorrhage during laparoscopic surgery. A report of two cases. Lewis JE. **J Reprod Med** 1995 Oct; 40(10):729–30

Massive bleeding at resternotomy despite a polytetrafluoroethylene surgical membrane [letter; comment] Stark J. **J Thorac Cardiovasc Surg** 1996 Apr; 111(4):903–4. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):274–5.

Evaluation of Surgicel Nu-knit, Merocel and Vasolene gauze nasal packs: a randomized trial. Shinkwin CA, et al. **Rhinology** 1996 Mar;34(1):41–3

Antifibrinolytic therapy in cardiac surgery. Chen RH, et al. **Tex Heart Inst J** 1995;22(3):211–5 (73 ref.)

Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216–30 (167 ref.)

Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Penta de Peppo A, et al. **Tex Heart Inst J** 1995; 22(3):231–6

The effect of desmopressin on reducing blood loss in cardiac surgery—a meta-analysis of double-blind, placebo-controlled trials. Cattaneo M, et al. **Thromb Haemost** 1995 Oct;74(4):1064–70

Irradiation of fresh whole blood for prevention of transfusion-associated graft-versus-host disease does not impair platelet function and clinical hemostasis after open heart surgery. Lavee J, et al. **Vox Sang** 1995;69(2):104–9

[Hemorrhages during dental surgery: their prevention and treatment. General Session of the National Academy of Pharmacy and Dental Surgery, Wednesday, 28 June 1995] Dreano J. **Ann Pharm Fr** 1996;54(1):1–2 **(Fre)**

RADIONUCLIDE IMAGING

Bleeding from postoperative (hepato-jejunostomy—Roux en Y) anastomosis demonstrated by labeled RBCs. Hardoff R, et al. **Clin Nucl Med** 1995 Dec;20(12):1104–5

SURGERY

Unplanned reoperation for bleeding. Scher KS. **Am Surg** 1996 Jan;62(1):52–5

Laparoscopic cholecystectomy: a case of postoperative hemorrhage successfully treated by laparoscopic reintervention. Ido K, et al. **Endoscopy** 1996 Feb;28(2):265

Surgical pearl: using the liposuction cannula/syringe apparatus for conservative evacuation of postoperative hematomas. Goldberg LH, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1061–2

Endoscopic band ligation for treatment of post-polypectomy bleeding. Pfaffenbach B, et al. **Z Gastroenterol** 1996 Apr; 34(4):241–2

THERAPY

Arterial embolization to control renal hemorrhage in patients with percutaneous nephrostomy. Ueda J, et al. **Abdom Imaging** 1996 Jul-Aug;21(4):361–3

High-frequency oscillatory ventilation in the management of infants with pulmonary hemorrhage after cardiac surgery. Baden HP, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):578–80

Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261–4 (26 ref.)

Surgicel in the control of post-tonsillectomy bleeding. Goodman RS. **Laryngoscope** 1996 Aug;106(8):1044–6

POSTOPERATIVE PERIOD

Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Pruitt JH, et al. **Blood** 1996 Apr 15; 87(8):3282–8

Relationship between health status and postoperative return to work. Lawrence K, et al. **J Public Health Med** 1996 Mar;18(1):49–53

POSTOPERATIVE WOUND INFECTION see **SURGICAL WOUND INFECTION**

POSTOVULATORY PHASE see **LUTEAL PHASE**

POSTPARTUM DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTPARTUM HEMORRHAGE

DRUG THERAPY

A placebo-controlled trial of oral ergometrine to reduce postpartum hemorrhage. de Groot AN, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):464–8

[Treatment of post-partum atonic hemorrhage with prostaglandin F2 alpha analogs] Jelinek J, et al. **Ceska Gynekol** 1995 Dec;60(6):290–2 (Eng. Abstr.) **(Cze)**

EPIDEMIOLOGY

Postpartum haemorrhage. Jouppila P. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):446–50 (20 ref.)

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Secondary post partum haemorrhage due to uterine wound dehiscence. Larsen JV, et al. **Cent Afr J Med** 1995 Sep; 41(9):294–6

Post partum intra-abdominal hemorrhage due to placenta percreta. Veenstra MJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):253–6

Primary thrombocythaemia presenting as postpartum haemorrhage: a case report. Rashid Z, et al. **J Obstet Gynaecol** 1995 Jun;21(3):221–5

Negligent delay or judgement call gone bad. Avery JK. **J Tenn Med Assoc** 1995 Dec;88(12):467, 469

[Uterine inversion: a cause of obstetric hemorrhage not to be missed. Discussion] Pessonnier A, et al. **Rev Fr Gynecol Obstet** 1995 Jul-Sep;90(7-9):362–6 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of postpartum haemorrhage. de Groot AN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):619–31 (41 ref.)

[Summary of National Symposium on Improving Quality of Obstetric Care for Safe Motherhood] Xing S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):134–71 **(Chi)**

[Prevention and treatment of hemorrhage in obstetrical

hospitals] Zarubina EN, et al. **Akush Ginekol (Mosk)** 1995; (4):19–22 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Arterial embolization of post-partum hemorrhage. Devroede F, et al. **J Belge Radiol** 1995 Dec;78(6):337–8

SURGERY

[Successful treatment of drug refractory uterine atony by fundus compression sutures] Schnarwyler B, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):151–3 (Eng. Abstr.) **(Ger)**

THERAPY

Pelvic arterial embolization following hysterectomy and bilateral internal iliac artery ligation for intractable primary post partum haemorrhage. Collins CD, et al. **Clin Radiol** 1995 Oct;50(10):710–3; discussion 713–4

Postpartum haemorrhage. Jouppila P. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):446–50 (20 ref.)

Management of difficult intra operative bleeding by abdominal packing: report of four cases. Lassey AT, et al. **East Afr Med J** 1995 Aug;72(8):542–3

Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Merland JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):141–3 (20 ref.)

Arterial embolization of post-partum hemorrhage. Devroede F, et al. **J Belge Radiol** 1995 Dec;78(6):337–8

[Hemorrhage during the third stage of labor and the postpartum period] Hohlfeld P. **Rev Med Suisse Romande** 1996 Apr;116(4):261–5 (33 ref.) **(Fre)**

[Autologous blood donation in obstetrics] wa Djamba D, et al. **Anaesthesist** 1995 Sep;44(9):631–3 (Eng. Abstr.) **(Ger)**

[Autologous blood collection in pregnancy. Prospective study] Rech F, et al. **Minerva Ginecol** 1995 Sep; 47(9):355–63 (Eng. Abstr.) **(Ita)**

[Analysis of therapeutic methods used in puerperium complicated by hemorrhagic shock] Skorupa A, et al. **Ginekol Pol** 1996 Jan;67(1):7–11 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Transvaginal sonohysterography: a new aid in the diagnosis of residual trophoblastic tissue. Wolman I, et al. **J Clin Ultrasound** 1996 Jun;24(5):257–61

POSTPARTUM PERIOD see **PUERPERIUM**

POSTPERICARDIOTOMY SYNDROME

ETIOLOGY

Postpericardiotomy syndrome and cardiac tamponade following transvenous pacemaker placement. Miller GL, et al. **Clin Cardiol** 1996 Mar;19(3):255–6

[Postpericardiotomy syndrome; a rare complication of transcavitary cardiac pacing: apropos of a case] Goutal H, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1901–3 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Postcardiac injury syndrome. An immunologic pleural fluid analysis. Kim S, et al. **Chest** 1996 Feb;109(2):570–2

RADIONUCLIDE IMAGING

Use of SPECT to evaluate postcardiotomy delirium [letter] Doyle M, et al. **Am J Psychiatry** 1996 Jun;153(6):838–9

POSTPHLEBITIC DISEASE see **POSTPHLEBITIC SYNDROME**

POSTPHLEBITIC SYNDROME

Pathogenesis and pathophysiology of the post-thrombotic syndrome: clinical implications. Rutherford RB. **Semin Vasc Surg** 1996 Mar;9(1):21–5 (22 ref.)

DIAGNOSIS

Increasing the sensitivity of the diagnosis of chronic venous obstruction [letter] Illig KA, et al. **J Vasc Surg** 1996 Jul; 24(1):176–8

[The diagnosis and treatment of postthrombotic disease] Kokhan EP, et al. **Voen Med Zh** 1992 Feb;(2):45–7, 79 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The site of residual abnormalities in the leg veins in long-term follow-up after deep vein thrombosis and their relationship to the development of the post-thrombotic syndrome. Johnson BF, et al. **Int Angiol** 1996 Mar;15(1):14–9

ULTRASONOGRAPHY

[Ultrasound diagnosis in post-thrombotic syndrome. Comparative study with color duplex, cw-Doppler and B-image ultrasound] Evers EJ, et al. **Ultraschall Med** 1995 Dec;16(6):259–63 (Eng. Abstr.) **(Ger)**

POSTPHLEBITIC ULCER see **POSTPHLEBITIC SYNDROME**

POSTPOLIOMYELITIS MUSCULAR ATROPHY see **POSTPOLIOMYELITIS SYNDROME**

POSTPOLIOMYELITIS SYNDROME

The challenge of the continuing effects of poliomyelitis in New Zealand. Botting CH, et al. **N Z Med J** 1995 Sep 22;108(1008):386–8 (26 ref.)

[Postpoliomyelitis syndrome and progressive postpoliomyelitis muscular atrophy] Bednařík J, et al. **Cas Lek Cesk** 1995 Dec 6;134(23):746–8 (25 ref.) (Eng. Abstr.) **(Cze)**

COMPLICATIONS

Postpoliomyelitis pain treated with gabapentin [letter] Zapp JJ. **Am Fam Physician** 1996 Jun;53(8):2442, 2445

Achalasia. A possible late cause of postpolio dysphagia. Benini L, et al. **Dig Dis Sci** 1996 Mar;41(3):516–8 (20 ref.)

Talonavicular joint arthrodesis for paralytic post poliomyelitis forefoot instability. Faraj AA. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):166–8

DIAGNOSIS

To test or refer: what are the benefits? [letter; comment] Standley JM. **Can Fam Physician** 1995 Aug;41:1289, 1291, 1293. Comment on: Can Fam Physician 1995 Apr;41:669–72.

Recognizing post-polio syndrome. Bartfeld H, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):95–7, 101–3, 107 passim (6 ref.)

[Late complications of poliomyelitis] Pal'chik AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(2):32–6 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Screening on lameness caused by poliomyelitis in Anhui Province] Dai ZW, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr; 17(2):80–2 (Eng. Abstr.) **(Chi)**

[Postpolio syndrome: retrospective study in a former polio clinic] Grehl O, et al. **Schweiz Rundsch Med Prax** 1996 Jan 3;85(1–2):14–20 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Electromyographic and neuromuscular variables in post-polio subjects. Rodriquez AA, et al. **Arch Phys Med Rehabil** 1995 Nov;76(11):989–93

Postpoliomyelitis syndrome problems of knee function: a review. Grant AD, et al. **Bull Hosp Jt Dis** 1993–95; 53(4):27–9 (16 ref.)

Muscle strength in postpolio patients: a prospective follow-up study. Ivanyi B, et al. **Muscle Nerve** 1996 Jun; 19(6):738–42

Acoustic myography during isometric fatigue in postpolio and control subjects. Rodriguez AA, et al. **Muscle Nerve** 1996 Mar;19(3):384–7

Post-polio muscle dysfunction 29th ENMC workshop 14–16 October 1994, Naarden, the Netherlands. Borg K. **Neuromuscul Disord** 1996 Jan;6(1):75–80

A comparison of symptoms between Swedish and American post-polio individuals and assessment of lower limb strength--a four-year cohort study. Agre JC, et al. **Scand J Rehabil Med** 1995 Sep;27(3):183–92

[Post-polio syndrome; the limit of neuromuscular adaptation?] Nollet F, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1169–73 (39 ref.) **(Dut)**

REHABILITATION

Low-intensity, alternate-day exercise improves muscle performance without apparent adverse effect in postpolio patients. Agre JC, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):50–8

[Advantages and disadvantages of invasive and noninvasive artificial respiration exemplified by a patient with postpolio syndrome] Pahnke J, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:68–9 **(Ger)**

SURGERY

Review of Elmslie's triple arthrodesis for post-polio pes calcaneovalgus deformity. Faraj AA. **J Foot Ankle Surg** 1995 May–Jun;34(3):319–21

VIROLOGY

Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. Muir P, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1469–76

POST-SURGICAL NURSING see **POSTANESTHESIA NURSING**

POST-TRANSCRIPTIONAL RNA MODIFICATION see **RNA PROCESSING, POST-TRANSCRIPTIONAL**

POST-TRANSLATIONAL ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

POST-TRANSLATIONAL PROTEIN MODIFICATION see **PROTEIN PROCESSING, POST-TRANSLATIONAL**

POST-TRAUMATIC NEOPLASMS see **NEOPLASMS, POST-TRAUMATIC**

POST-TRAUMATIC STRESS DISORDERS see **STRESS DISORDERS, POST-TRAUMATIC**

POSTURAL DRAINAGE see **DRAINAGE, POSTURAL**

POSTURE

see related
HYPOTENSION, ORTHOSTATIC
KINESICS

How drivers sit in cars. Parkin S, et al. **Accid Anal Prev** 1995 Dec;27(6):777–83

Effects of posture and pneumoperitoneum during anaesthesia on the indices of left ventricular filling. Gannedahl P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):160–6

Thermoregulatory response in female patients during lower abdominal surgery in the head-down tilt position. Hirose M, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):475–9

Hemodynamic changes due to Trendelenburg positioning and pneumoperitoneum during laparoscopic hysterectomy. Hirvonen EA, et al. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):949–55

The effect of continuous epidural infusion of ropivacaine (0.1%, 0.2% and 0.3%) on nerve conduction velocity and postural control in volunteers. Zaric D, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):342–9

Postural stability differentiates "lower body" from idiopathic parkinsonism. Trenkwalder C, et al. **Acta Neurol Scand** 1995 Jun;91(6):444–52

Scoliosis elasticity assessed by manual traction: 49 juvenile and adolescent idiopathic cases. Soucacos PK, et al. **Acta Orthop Scand** 1996 Apr;67(2):169–72

Effects of loratadine on postural control. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:310–2

Postural control after propofol anaesthesia in minor surgery. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:313–6

Effects of body position on upper airway size and shape in patients with obstructive sleep apnea. Pevernagie DA, et al. **Acta Psychiatr Belg** 1994 Mar–Apr;94(2):101–3

Clinical aspects of negative myoclonus. Obeso JA, et al. **Adv Neurol** 1995;67:1–7

Blood pressure readings in the elderly: seated or standing? [letter; comment] Wilson RS. **Am Fam Physician** 1996 May 15;53(7):2282. Comment on: Am Fam Physician 1995 Sep 15;52(4):1161–5.

Upright postures and isoproterenol infusion for provocation of neurocardiogenic syncope: a comparison of standing and head-up tilting. Hou ZY, et al. **Am Heart J** 1995 Dec; 130(6):1210–5

Treatment of orthostatic tachycardia with erythropoietin. Hoeldtke RD, et al. **Am J Med** 1995 Nov;99(5):525–9

Positioning your patient properly. Metzler DJ, et al. **Am J Nurs** 1996 Mar;96(3):33–7 (21 ref.)

The effect of thigh-length support stockings on the hemodynamic response to ambulation in pregnancy. Hobel CJ, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1734–40; discussion 1740–1

Effects of a program on symmetrical posture in patients with hemiplegia: A single-subject design. Wu SH, et al. **Am J Occup Ther** 1996 Jan;50(1):17–23

Associations among upper airway structure, body position, and obesity in skeletal Class I male patients with obstructive sleep apnea. Ono T, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):625–34

Clinical utility of lateral head tilt posturography. Chandra NS, et al. **Am J Otol** 1996 Mar;17(2):271–7

Estrogen replacement therapy and postural stability in the elderly. Goebel JA, et al. **Am J Otol** 1995 Jul;16(4):470–4

Postural stability following mild head or whiplash injuries [letter; comment] Katsarkas A. **Am J Otol** 1996 Jan; 17(1):172–4. Comment on: Am J Otol 1995 Mar;16(2):216–21.

Benign paroxysmal positional vertigo: analysis of 44 cases treated by the canalith repositioning procedure of Epley. Weider DJ, et al. **Am J Otol** 1994 May;15(3):321–6 (44 ref.)

Effect of body position on the blood gases and ventilation volume of infants with chronic lung disease before and after feeding. Mizuno K, et al. **Am J Perinatol** 1995 Jul; 12(4):275–7

Camptocormia: a biomechanical analysis. A case report. Abdulhadi HM, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):310–3

Role of weight-bearing function on expression of myosin isoforms during regeneration of rat soleus muscles. Bigard XA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C763–71

Influence of gravity and body position on normal oropharyngeal swallowing. Johnsson F, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G653–8

Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Orozco-Levi M, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1387-90

Compartment syndrome following prolonged positioning in the lithotomy position [letter] MacIntyre PA. **Anaesthesia** 1996 May;51(5):511

Gastric regurgitation during general anaesthesia in different positions with the laryngeal mask airway. el Mikatti N, et al. **Anaesthesia** 1995 Dec;50(12):1053-5

Maternal position during induction of spinal anaesthesia for caesarean section [letter; comment] Serpell MG, et al. **Anaesthesia** 1995 Oct;50(10):921-2. Comment on: Anaesthesia 1995 Apr;50(4):363-5.

Prone position and oxygenation [letter; comment] Nishikawa T. **Anesth Analg** 1996 Apr;82(4):885. Comment on: Anesth Analg 1995 May;80(5):955-60.

The influence of carbon dioxide and body position on near-infrared spectroscopic assessment of cerebral hemoglobin oxygen saturation. Pollard V, et al. **Anesth Analg** 1996 Feb;82(2):278-87

Rhabdomyolysis and myonecrosis in a patient in the lateral decubitus position. Mathes DD, et al. **Anesthesiology** 1996 Mar;84(3):727-9

Orthostatic vasoconstrictor response in patients with occlusive arterial disease assessed by laser Doppler flux and transcutaneous oximetry. Caspary LA, et al. **Angiology** 1996 Feb;47(2):165-73

A flexible solution for emergency intubation difficulties. Nocera A. **Ann Emerg Med** 1996 May;27(5):665-7

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059-63, 1066-79; quiz 1080-6 (38 ref.)

Postural effect on respiratory sinus arrhythmia with various respiratory frequencies. Kobayashi H. **Appl Human Sci** 1996 Mar;15(2):87-91

Postural vertigo. Quick relief from the postural vertigo component of vestibular diseases. Kohut RI. **Arch Fam Med** 1996 Mar;5(3):172-3

Meta-analysis of the sensitivity and specificity of platform posturography. Di Fabio RP. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):150-6

Complications of the canalith repositioning procedure. Herdman SJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):281-6

Identification of static and dynamic postural instability following traumatic brain injury. Geurts AC, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):639-44

Age and gender effects on postural control measures. Hageman PA, et al. **Arch Phys Med Rehabil** 1995 Oct; 76(10):961-5

Adding loads to occupied wheelchairs: effect on static rear and forward stability. Kirby RL, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):183-6

The stretch reflex response in the normal and spastic ankle: effect of ankle position. Meinders M, et al. **Arch Phys Med Rehabil** 1996 May;77(5):487-92

Power spectrum of the fast Fourier transform for measurement of standing balance. Liu SH, et al. **Aust J Sci Med Sport** 1995 Sep;27(3):62-7

Effects of posture and accumulated airway secretions on tracheal mucociliary transport in the horse. Raidal SL, et al. **Aust Vet J** 1996 Feb;73(2):45-9

The effects of motion direction, body axis, and posture on motion sickness induced by low frequency linear oscillation. Golding JF, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1046-51

Sudden infant death syndrome: after the "back to sleep" campaign [editorial; comment] Dwyer T, et al. **BMJ** 1996 Jul 27;313(7051):180-1. Comment on: BMJ 1996 Jul 27;313(7051):191-5. Comment on: BMJ 1996 Jul 27;313(7051):195-8.

Environment of infants during sleep and risk of the sudden infant death syndrome: results of 1993-5 case-control study for confidential inquiry into stillbirths and deaths in infancy. Confidential Enquiry into Stillbirths and Deaths Regional Coordinators and Researchers [see comments] Fleming PJ, et al. **BMJ** 1996 Jul 27;313(7051):191-5. Comment in: BMJ 1996 Jul 27;313(7051):180-1.

Treatment for benign positional vertigo [letter; comment] [see comments] Weiner GM. **BMJ** 1996 Jan 6;312(7022):54. Comment on: BMJ 1995 Aug 19;311(7003):489-91. Comment in: BMJ 1996 May 18;312(7041):1300.

Removal of lumbar extradural catheters [letter; comment] Christie IW. **Br J Anaesth** 1995 Nov;75(5):666. Comment on: Br J Anaesth 1995 Jun;74(6):722.

Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position. O'Leary E, et al. **Br J Anaesth** 1996 May;76(5):640-4

Effect of pneumoperitoneum and Trendelenburg position on gastro-oesophageal reflux and lower oesophageal sphincter pressure. Tournadre JP, et al. **Br J Anaesth** 1996 Jan; 76(1):130-2

Postural control and vestibulospinal function in patients selected for cochlear implantation. Magnusson M, et al. **Br J Audiol** 1995 Aug;29(4):231-6

Benign paroxysmal positional vertigo. Gordon N. **Br J Clin Pract** 1996 Jun;50(4):208-10 (17 ref.)

Standing at work and preterm delivery [letter; comment] Morrison JJ, et al. **Br J Obstet Gynaecol** 1995 Nov; 102(11):936-7. Comment on: Br J Obstet Gynaecol 1995 Mar;102(3):198-206.

Risk of compartment syndrome and aortic thrombosis following prolonged surgery in the Lloyd-Davies position. Harris SA, et al. **Br J Urol** 1996 May;77(5):752-3

Push-ups: a new technique in intravenous urography. Murphy JM, et al. **Br J Urol** 1996 Jun;77(6):916-7

Central retinal artery occlusion after back surgery: a case report. Mertens E, et al. **Bull Soc Belge Ophtalmol** 1995; 255:127-31

Seated versus standing cycling in competitive road cyclists: uphill climbing and maximal oxygen uptake. Tanaka H, et al. **Can J Appl Physiol** 1996 Apr;21(2):149-54

A controlled study of the autonomic changes produced by habitual cigarette smoking in healthy subjects. Lucini D, et al. **Cardiovasc Res** 1996 Apr;31(4):633-9

Energy metabolism of thoracic surgical patients in the early postoperative period. Effect of posture. Brandi LS, et al. **Chest** 1996 Mar;109(3):630-7

Effect of jaw position and posture on forced inspiratory airflow in normal subjects and patients with obstructive sleep apnea. Masumi S, et al. **Chest** 1996 Jun;109(6):1484-9

The effects of clonidine on cardiovascular responses to standing in healthy volunteers. Coupland NJ, et al. **Clin Auton Res** 1995 Jun;5(3):171-7

Comparison of autonomic function using Valsalva ratio and 30:15 postural ratio prior to and after haemodialysis treatment. Rosansky SJ, et al. **Clin Auton Res** 1995 Jun; 5(3):151-4

Composition of interstitial fluid. Fogh-Andersen N, et al. **Clin Chem** 1995 Oct;41(10):1522-5

Peroneal nerve palsy and compartment syndrome in bilateral femoral fractures. Carlson DA, et al. **Clin Orthop** 1995 Nov; (320):115-8

Posturography--applications and limitations in the management of the dizzy patient. Harcourt JP. **Clin Otolaryngol** 1995 Aug;20(4):299-302 (24 ref.)

Infant sleep position and the sudden infant death syndrome. A survey of pediatric recommendations. Carolan PL, et al. **Clin Pediatr (Phila)** 1995 Aug;34(8):402-9

Heart rate and blood pressure variability in orthostatic syncope. Lagi A, et al. **Clin Sci (Colch)** 1996;91 Suppl:62-4

Considering imperfections using 3D imaging system in angle obtaining, angle signal distance computing and multivariate distance graphing. Loslever P. **Comput Methods Programs Biomed** 1995 Aug;47(3):197-204

Effect of early lead exposure on children's postural balance. Bhattacharya A, et al. **Dev Med Child Neurol** 1995 Oct; 37(10):861-78

The effects of the saddle seat on seated postural control and upper-extremity movement in children with cerebral palsy. Reid DT. **Dev Med Child Neurol** 1996 Sep;38(9):805-15

Postural stability in diabetic polyneuropathy. Boucher P, et al. **Diabetes Care** 1995 May;18(5):638-45

Postural rearrangement in IDDM patients with peripheral neuropathy. Giacomini PG, et al. **Diabetes Care** 1996 Apr; 19(4):372-4

Body sway in diabetic neuropathy. Uccioli L, et al. **Diabetes Care** 1995 Mar;18(3):339-44

The effect of body position on bioelectrical resistance in individuals with spinal cord injury. Allison GT, et al. **Disabil Rehabil** 1995 Nov-Dec;17(8):424-9

Blood pressure and heart rate response to head-up position in full-term newborns. Andrásyová D, et al. **Early Hum Dev** 1996 Mar 22;44(3):169-78

Characteristics of aldosterone-producing adenoma responsive to upright posture. Toraya S, et al. **Endocr J** 1995 Aug;42(4):481-7

Adjustments of posture and viewing parameters of the eye to changes in the screen height of the visual display terminal. Villanueva MB, et al. **Ergonomics** 1996 Jul; 39(7):933-45

The venous pump does not affect the indifference point for electrical impedance in humans. Perko G, et al. **Eur J Appl Physiol** 1995;72(1-2):179-82

Oesophageal acid clearance in patients with systemic sclerosis: effect of body position. Basilisco G, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):205-9

The relationship between surface and radiological deformity in adolescent idiopathic scoliosis: effect of change in body position. Scutt ND, et al. **Eur Spine J** 1996;5(2):85-90

Patient positioning devices: innovations for set-up precision, speed, and patient comfort. Graham MV, et al. **Front Radiat Ther Oncol** 1996;29:115-22

Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Kaiser HJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug;233(8):484-8

Cluster headache: cardiovascular responses to head-up tilt. Kruszewski P, et al. **Headache** 1995 Sep;35(8):465-9

Syncope and salt [editorial; comment] Lord S, et al. **Heart** 1996 Feb;75(2):114-5. Comment on: Heart 1996 Feb;75(2):134-40.

Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope [see comments] El-Sayed H, et al. **Heart** 1996 Feb;75(2):134-40. Comment in: Heart 1996 Feb;75(2):114-5.

Effects of modified positioning and mobilization of back pain and delayed bleeding in patients who had received heparin and undergone angiography: a pilot study. Pooler-Lunse C, et al. **Heart Lung** 1996 Mar-Apr;25(2):117-23

The effect of posture on central blood volume in patients with preascitic cirrhosis on a sodium-restricted diet. Wong F, et al. **Hepatology** 1996 May;23(5):1141-7

Orthostatic hypertension due to vascular adrenergic hypersensitivity. Benowitz NL, et al. **Hypertension** 1996 Jul;28(1):42-6

Tilting enhances visualization of lower extremity veins with duplex colour flow imaging. Goushegir G, et al. **Int Angiol** 1995 Dec;14(4):395-6

An interview technique for recording work postures in epidemiological studies. Music-Norrtälje Study Group. Wiktorin C, et al. **Int J Epidemiol** 1996 Feb;25(1):171-80

Effects of pinna position on head-related transfer functions in the cat. Young ED, et al. **J Acoust Soc Am** 1996 May; 99(5):3064-76

The effect of body positioning upon maximal oxygenation of patients with unilateral lung pathology. Yeaw EM. **J Adv Nurs** 1996 Jan;23(1):55-61

Postural adjustments produced by moving visual (horizontal optokinetic) patterns. Blanks RH, et al. **J Am Acad Audiol** 1996 Jan;7(1):39-48

How the two sides of the heart adapt to graded impedance to venous return with head-up tilting. Guazzi M, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1732-40

Intraindividual reproducibility of postprandial and orthostatic blood pressure changes in older nursing-home patients: relationship with chronic use of cardiovascular medications. Jansen RW, et al. **J Am Geriatr Soc** 1996 Apr; 44(4):383-9

Effect of left and right lateral decubitus positions on Doppler mitral flow patterns in patients with severe congestive heart failure. Berensztein CS, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):86-90

A comparison of spinal ligaments--differences between bipeds and quadrupeds. Jiang H, et al. **J Anat** 1995 Aug; 187 (Pt 1):85-91

The role of the vertebral laminae in the stability of the cervical spine. Pal GP, et al. **J Anat** 1996 Apr;188 (Pt 2):485-9

Correcting trunk muscle geometry obtained from MRI and CT scans of supine postures for use in standing postures. McGill SM, et al. **J Biomech** 1996 May;29(5):643-6

Temporal approach with patients unable to lie flat [letter; comment] Cassen JH. **J Cataract Refract Surg** 1995 Sep; 21(5):486. Comment on: J Cataract Refract Surg 1995 Mar;21(2):111.

Sleeping position and upper airways bacterial flora: relevance to cot death. Bell S, et al. **J Clin Pathol** 1996 Feb; 49(2):170-2

Hepatodiaphragmatic interposition of the colon in the upright and supine position. Prassopoulos PK, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):151-3

Visual control of posture during walking: functional specificity. Warren WH, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):818-38

Postural balance and its sensory-motor correlates in 75-year-old men and women: a cross-national comparative study. Era P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M53-63

Postural sensitivity to visual flow in aging adults with and without balance problems. Sundermier L, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M45-52

Development of mat weaving frame for better posture using ergonomic principles. Paileeklee S, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):59-61

Benign paroxysmal positional vertigo of the horizontal canal. De la Meilleure G, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):68-71

Bent spine syndrome. Serratrice G, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):51-4

Pediatric gastric emptying: value of right lateral and upright positioning. Villanueva-Meyer J, et al. **J Nucl Med** 1996 Aug;37(8):1356-8

Interinnominate motion and symmetry: comparison between gymnasts and nongymnasts. Barakatt E, et al. **J Orthop Sports Phys Ther** 1996 May;23(5):309-19

Clinical measurement of head and shoulder posture variables. Harrison AL, et al. **J Orthop Sports Phys Ther** 1996 Jun; 23(6):353-61

The effect of knee and foot position on the electromyographical activity of the superficial quadriceps. Signorile JF, et al. **J Orthop Sports Phys Ther** 1995 Jul; 22(1):2-9

Post-treatment instructions in the nonsurgical management of benign paroxysmal positional vertigo. Massoud EA, et al. **J Otolaryngol** 1996 Apr;25(2):121-5

Effect of a postural support nappy on 'flattened posture' of the lower extremeties in very preterm infants. Monterosso L, et al. **J Paediatr Child Health** 1995 Aug;31(4):350-4

The effect of posture change on the position of the skin marks for the transverse horizontal axis. O'Boyle KH, et al. **J Prosthet Dent** 1996 May;75(5):545-51

Effects of donor position on harvested lung quality. Sekela ME, et al. **J Surg Res** 1996 Mar;61(2):509-13

Pediatric cervical-spine immobilization: achieving neutral position? Curran C, et al. **J Trauma** 1995 Oct;39(4):729-32

Head slippage during broad-frequency rotational chair testing. Hanson JM, et al. **J Vestib Res** 1995 Sep-Oct; 5(5):371-6

Dizziness of suspected cervical origin distinguished by posturographic assessment of human postural dynamics. Karlberg M, et al. **J Vestib Res** 1996 Jan-Feb;6(1):37-47

Influence of body position on breathing and its implications for the evaluation and treatment of speech and voice

disorders. Hoit JD. **J Voice** 1995 Dec;9(4):341–7 (37 ref.)
Defecation induced deep venous thrombosis. A case report. Chew G, et al. **Jpn Heart J** 1996 May;37(3):409–15
A study of different postures on isometric lifting strength in normal college students. Lin JH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):678–85
Effect of body position on isometric arm lifting strength. Lin JH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Feb;12(2):93–103
Curing benign positional vertigo in a 3D flight simulator [letter] Lempert T, et al. **Lancet** 1996 Apr 27; 347(9009):1192
An unusual mechanism of recumbent syncope [letter] Wiebe S. **Lancet** 1996 Jun 22;347(9017):1769–70
Neck flexion and extension in children with Down syndrome: a somatosensory study. Abramson PJ, et al. **Laryngoscope** 1995 Nov;105(11):1209–12
The evolution of bipedalism and assisted birth. Trevathan WR. **Med Anthropol Q** 1996 Jun;10(2):287–90
Supraventricular tachycardia: response to cardioinversion. Heaton PA. **Med J Aust** 1995 Dec 4–18;163(11–12):595–6
Long latency postural reflexes are under supraspinal dopaminergic control. Bloem BR, et al. **Mov Disord** 1995 Sep;10(5):580–8
Postural finger tremor exhibited by Parkinson patients and age-matched subjects. Palmer SS, et al. **Mov Disord** 1995 Sep;10(5):658–63
The effect of wrist position on the conduction velocity of the ulnar nerve. Rutkove SB, et al. **Muscle Nerve** 1996 May;19(5):657–8
Active counter-positioning treatment of deformational occipital plagiocephaly. Hellbusch JL, et al. **Nebr Med J** 1995 Dec;80(12):344–9
Inhibitory effect of baclofen on lordosis in female and male rats with dorsal raphe nucleus lesion or septal cut. Kakeyama M, et al. **Neuroendocrinology** 1996 Mar; 63(3):290–6
Postural changes in proximal gastric volume and pressure measured using a gastric barostat. Hebbard GS, et al. **Neurogastroenterol Motil** 1995 Sep;7(3):169–74
Phobic postural vertigo. Brandt T. **Neurology** 1996 Jun; 46(6):1515–9 (31 ref.)
Associated postural adjustments are impaired by a lesion of the cortex. Palmer E, et al. **Neurology** 1996 Feb;46(2):471–5
Another kind of knapsack palsy. Pringle CE, et al. **Neurology** 1996 Feb;46(2):585–6
Postural stability among manganese exposed workers. Chia SE, et al. **Neurotoxicology** 1995 Fall;16(3):519–26
Body position, age and mass effect of adiposity on adipose tissue red cell flux in morbid obesity. Klassen GA, et al. **Obes Res** 1996 Mar;4(2):145–51
Dynamic posturography [letter; comment] Hamid MA. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):842–3. Comment on: Otolaryngol Head Neck Surg 1995 Jun;112(6):676–88.
Plasma catecholamines and cyclic AMP response during head-up tilt test in patients with neurocardiogenic (vasodepressor) syncope. Abe H, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1419–26
Assessment of the effect of head and neck position on upper airway anatomy in sedated paediatric patients using magnetic resonance imaging. Shorten GD, et al. **Paediatr Anaesth** 1995;5(4):243–8
Effect of neck rotation on the timing and pattern of infant tidal breathing. Downs JA, et al. **Pediatr Pulmonol** 1995 Dec;20(6):380–6
A community-based survey of infant sleep position. Pediatric Research in Office Practices Network. Chessare JB, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):893–6
An initial evaluation of work fatigue and circadian changes as assessed by multiplate posturography. Kohen-Raz R, et al. **Percept Mot Skills** 1996 Apr;82(2):547–57
Age-related changes in postural control and locomotion. Okuzumi H, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):991–4
An analysis of a performance by the violinist D. Oistrakh: the hypothetical role of postural tonic-static and entourage movements. Ruggieri V, et al. **Percept Mot Skills** 1996 Feb; 82(1):291–300
Head position and spinal position as determinants of perceived emotional state. Schouwstra SJ, et al. **Percept Mot Skills** 1995 Oct;81(2):673–4
Intertester reliability of a modified version of McKenzie's lateral shift assessments obtained on patients with low back pain. Donahue MS, et al. **Phys Ther** 1996 Jul;76(7):706–16; discussion 717–26
Determining consistency of elbow joint threshold angle in elbow flexor muscles with spastic hypertonia. Wolf SL, et al. **Phys Ther** 1996 Jun;76(6):586–600
Effects of ascites and body position on gas exchange in patients with cirrhosis. Chang SC, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):143–50
Positioning post-outpatient cardiac catheterization. Rein A, et al. **Prog Cardiovasc Nurs** 1995 Fall;10(4):4–10
The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs. Molewijk HE, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):81–90
A new patient positioning system using magnetic implants and magnetic field sensors [letter] Lennernäs B, et al. **Radiother Oncol** 1995 Dec;37(3):249–50
The effect of posture on the induction of epidural anesthesia for peripheral vascular surgery. Whalley DG, et al. **Reg Anesth** 1995 Sep–Oct;20(5):407–11
Dependency of upper airway patency on head position: the effect of muscle contraction. Odeh M, et al. **Respir Physiol** 1995 Jun;100(3):239–44
A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):203–14
Sources of variance in exposure to nonneutral trunk postures in varying work situations. van der Beek AJ, et al. **Scand J Work Environ Health** 1995 Jun;21(3):215–22
Functional outcome in rats transferred to an enriched environment 15 days after focal brain ischemia. Johansson BB. **Stroke** 1996 Feb;27(2):324–6
Postprandial and orthostatic cardiovascular changes after acute stroke. Robinson TG, et al. **Stroke** 1995 Oct; 26(10):1811–6
"Stand-up" urologic endoscopy. McRoberts JW, et al. **Urology** 1996 Feb;47(2):201–3
[Sleeping position and covering of infants in the fall of 1994] Burgmeijer RJ, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9; 139(49):2568–71 (Eng. Abstr.) **(Dut)**
[Gastroesophageal reflux in infants; recommendations for diagnosis and treatment (letter; comment)] de Jonge GA. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1759. Comment on: Ned Tijdschr Geneeskd 1995 Feb 25;139(8):366–70. Comment on: Ned Tijdschr Geneeskd 1995 May 27;139(21):1103–4. **(Dut)**
[Deglutition disorders: choice of diet and compensatory posture] Amberger P, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):811–6 (Eng. Abstr.) **(Fre)**
[Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis] Bellon AK, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1077–83 (Eng. Abstr.) **(Ger)**
[Benign paroxysmal positional vertigo] Holtmann S. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):113–4 **(Ger)**
[Benign paroxysmal postural vertigo: basis and its therapy in clinical practice] Waespe W. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):434–9 (Eng. Abstr.) **(Ger)**
[Effect of elevated head position in bed in therapy of gastroesophageal reflux] Pollmann H, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:93–9 (Eng. Abstr.) **(Ger)**
[Effect of tilting on cyclodeviation in nine diagnostic positions of gaze in normal subjects with Awaya's New Cyclo Tests] Nomura H, et al. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):1030–5 (Eng. Abstr.) **(Jpn)**
[Chronic recurrent pulmonary thromboembolism associated with sedentary work] Ogura T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb;34(2):194–9 (Eng. Abstr.) **(Jpn)**
[Abnormal head drooping in facioscapulohumeral muscular dystrophy] Ichikawa Y, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):503–6 (Eng. Abstr.) **(Jpn)**
[Antigravity suit used for neurosurgical operations in sitting position] Szpiro-Zurkowska A, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):241–9 (Eng. Abstr.) **(Pol)**
[Sloping posture on the unwell side for treatment of pulmonary tuberculosis combined with use of modern intensive antitubercular chemotherapy] Dobrzyński Z. **Pneumonol Alergol Pol** 1995;63(11–12):639–44 (Eng. Abstr.) **(Pol)**
[Postural changes during echocardiography. Is this manoeuver necessary in the differential diagnosis of fixed and free floating thrombus?] Tatani SB, et al. **Arq Bras Cardiol** 1995 Aug;65(2):163–5 (Eng. Abstr.) **(Por)**
[Use of dispersion analysis in the evaluation of the effects of immersion and individual differences on the variability of orthostatic reactions] Mikhaĭlov VM, et al. **Aviakosm Ekolog Med** 1995;29(6):26–32 (Eng. Abstr.) **(Rus)**
[Response of regional vascular tone to orthostatic and gravitational effects] Vartbaronov RA, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):6–8 (Eng. Abstr.) **(Rus)**
[Positioning nystagmus] Grigor'ev GM. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):20–3 (Eng. Abstr.) **(Rus)**
[Changes in the indices of standing and walking in patients with infantile cerebral palsy under the influence of low doses of Nakom] Brin IL, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):39–43 (Eng. Abstr.) **(Rus)**
[Improper body posture of bus drivers] Jelčić I. **Arh Hig Rada Toksikol** 1995 Mar;46(1):89–93 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Subjective postural vertical in peripheral and central vestibular disorders. Bisdorff AR, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:68–71
Vestibular plasticity following orbital spaceflight: recovery from postflight postural instability. Black FO, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:450–4
The visual vertigo syndrome. Bronstein AM. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:45–8
Three-dimensional (3-D) eye movement analysis in patients with positioning nystagmus. Fetter M, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:369–71
Dose-related effects of alcohol on dynamic posturography and oculomotor measures. Goebel JA, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:212–5
Discrimination of patients with acoustic neuroma and peripheral vestibular lesions with human posture dynamics. Johansson R, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 1:27–8
Impaired postural control in patients with cervico-brachial pain. Karlberg M, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:440–2
Randomized perturbed posturography in abstinent chronic alcoholics. Ledin T. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:447–9
Influence of cerebrospinal fluid tapping on dynamic equilibrium in suspected hydrocephalus. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:317–9
Postural control and vestibular function in patients selected for cochlear implantation. Magnusson M, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:277–8
New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)
Posturography: head stabilisation compared with platform recording. Application in vestibular disorders. Norré ME. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:434–6
Vestibular stimulation perturbs human stance also at higher frequencies. Petersen H, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:443–6
Postural control in Menière's disease and acoustic neurinoma when studied on a linearly oscillating platform. Pyykkö I, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:19–21
Nystagmus in benign paroxysmal positional vertigo: a three-component analysis. Yagi T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:238–40
Pronounced plasma fluid loss into dependent regions on standing. Bjerkhoel P, et al. **Acta Physiol Scand** 1995 Jun; 154(2):275–6
Protein loss and capillary protein permeability in dependent regions upon quiet standing. Bjerkhoel P, et al. **Acta Physiol Scand** 1995 Jul;154(3):311–20
Pronounced and rapid plasma volume reduction upon quiet standing as revealed by a novel approach to the determination of the intravascular volume change. Lundvall J, et al. **Acta Physiol Scand** 1995 Jun; 154(2):131–42
Redistribution of body fluids during postural manipulations. Maw GJ, et al. **Acta Physiol Scand** 1995 Oct;155(2):157–63
Sympathetic influence on cardiovascular responses to sustained head-up tilt in humans. Pedersen M, et al. **Acta Physiol Scand** 1995 Dec;155(4):435–44
Neuroanatomical and neurophysiological bases of postural control. Mori S, et al. **Adv Neurol** 1995;67:289–303 (59 ref.)
Mobility after proximal femoral fracture: the relevance of leg extensor power, postural sway and other factors. Lamb SE, et al. **Age Ageing** 1995 Jul;24(4):308–14
Orthostasis in Alzheimer disease: a retrospective analysis. Jhee SS, et al. **Alzheimer Dis Assoc Disord** 1995 Winter; 9(4):243–6
Effect of lateral position on arterial and venous blood gases in postoperative cardiac surgery patients. Banasik JL, et al. **Am J Crit Care** 1996 Mar;5(2):121–6
The effect of posture on gastroesophageal reflux event frequency and composition during fasting. Shay SS, et al. **Am J Gastroenterol** 1996 Jan;91(1):54–60
Renin-angiotensin-aldosterone system, RR interval, and blood pressure variability during postural changes in borderline arterial hypertension. Duprez DA, et al. **Am J Hypertens** 1995 Jul;8(7):683–8
Decreases in postural change in finger blood flow in ceramic painters chronically exposed to low level lead. Ishida M, et al. **Am J Ind Med** 1996 May;29(5):547–53
Abnormalities in posturography and estimations of visual vertical and horizontal in multiple sclerosis. Jackson RT, et al. **Am J Otol** 1995 Jan;16(1):88–93
Role of the renin-angiotensin system in mediating the effects of posture on renal function. Reinhart GA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R282–8
Laparoscopic anatomy of the abdomen in dorsally recumbent horses. Galuppo LD, et al. **Am J Vet Res** 1996 Jun; 57(6):923–31
The effect of posture on late postoperative oxygenation. Mynster T, et al. **Anaesthesia** 1996 Mar;51(3):225–7
Evaluation of nonlinear dynamics in postural steadiness time series. Myklebust JB, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):711–9
An improved muscle-reflex actuator for use in large-scale neuro-musculoskeletal models. Winters JM. **Ann Biomed Eng** 1995 Jul–Aug;23(4):359–74
Postural changes in respiratory airflow pressure and resistance in nasal, hypopharyngeal, and pharyngeal airway in normal subjects. Tvinnereim M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):218–21
Physical fitness and cardiopulmonary baroreflex to passive head-up tilt. Hayashi H, et al. **Appl Human Sci** 1995 Jul; 14(4):167–76
Circulatory regulation during supine and sitting intermittent

isometric handgrip in a hot environment. Lee CF, et al. **Appl Human Sci** 1995 Sep;14(5):211–8

A study on the difference of human sensation evaluation to whole-body vibration in sitting and lying postures. Liu JZ, et al. **Appl Human Sci** 1995 Sep;14(5):219–26

Physiological and subjective responses to standing showers, sitting showers, and sink baths. Ohnaka T, et al. **Appl Human Sci** 1995 Sep;14(5):235–9

Assessment of pulmonary mechanics and breathing patterns during posturally induced glossoptosis in infants. Cozzi F, et al. **Arch Dis Child** 1996 Jun;74(6):512–6

Postural and symptomatic improvement after physiotherapy in patients with dizziness of suspected cervical origin. Karlberg M, et al. **Arch Phys Med Rehabil** 1996 Sep; 77(9):874–82

Visual influence on contact pressure of hemiplegic patients through photoelastic sole image. Kitamura J, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):14–8

Posture effect on seating interface biomechanics: comparison between two seating cushions. Koo TK, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):40–7

Sitting balance: its relation to function in individuals with hemiparesis. Nichols DS, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):865–9

Factors affecting differences in supine, sitting, and standing heart rate: the Israeli CORDIS Study. Kristal-Boneh E, et al. **Aviat Space Environ Med** 1995 Aug;66(8):775–9

Comparison of heart rate and arterial pressure spectra during head up tilt and a matched level of LBNP. Patwardhan AR, et al. **Aviat Space Environ Med** 1995 Sep;66(9):865–71

Blood volume change and redistribution after change in posture. Theodoridis GC, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1097–102

Organization of motor and posture patterns in paradise fish (Macropodus opercularis): environmental and genetic components of phenotypical correlation structures. Gerlai R, et al. **Behav Genet** 1995 Jul;25(4):385–96

HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height. Miklyaeva EI, et al. **Behav Neurosci** 1996 Feb;110(1):117–25

Plasma neurotransmitters, blood pressure, and heart rate during supine-resting, orthostasis, and moderate exercise conditions in major depressed patients. Lechin F, et al. **Biol Psychiatry** 1995 Aug 1;38(3):166–73

Somatic graviception. Mittelstaedt H. **Biol Psychol** 1996 Jan 5;42(1–2):53–74

PRES- and orthostatic-induced heart-rate changes as markers of labile hypertension: magnitude and reliability measures. Rau H, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):105–15

Squatting revisited: comparison of haemodynamic responses in normal individuals and heart transplantation recipients. Hanson P, et al. **Br Heart J** 1995 Aug;74(2):154–8

Posture in low-risk pre-term infants of 30 weeks postmenstrual age. van Oostenbrugge RJ, et al. **Brain Dev** 1995 Jul–Aug;17(4):253–5

Comparison of aero-bars versus traditional cycling postures on physiological parameters during submaximal cycling. Sheel AW, et al. **Can J Appl Physiol** 1996 Feb;21(1):16–22

Response to orthostatic stress predicts office-daytime blood pressure difference, but not nocturnal blood pressure fall in mild essential hypertensives: results of the harvest trial. Narkiewicz K, et al. **Clin Exp Pharmacol Physiol** 1995 Oct; 22(10):743–7

Power spectral analysis of heart rate variability during graded head-up tilting in patients with vasodepressor syncope. Prinz-Zaiss M, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):472–4

Posture in systemic lupus erythematosus. Giacomini P, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):357–60

Effect of posture on baroreflex sensitivity in healthy subjects. Hartikainen J, et al. **Clin Physiol** 1995 Nov;15(6):571–9

Brain and muscle oxygen saturation during head-up-tilt-induced central hypovolaemia in humans. Madsen P, et al. **Clin Physiol** 1995 Sep;15(5):523–33

Clinical approach to cardiovascular reflex testing. Ajsmit A, et al. **Clin Sci (Colch)** 1996;91 Suppl:108–12

Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects. Jellema WT, et al. **Clin Sci (Colch)** 1996 Aug; 91(2):193–200

Poincaré plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Kamen PW, et al. **Clin Sci (Colch)** 1996 Aug;91(2):201–8

Regulation of immediate blood pressure response to orthostasis in patients with fixed ventricular pacemaker rhythm. Rudas L, et al. **Clin Sci (Colch)** 1996;91 Suppl:97–100

Impact of changes in respiratory frequency and posture on power spectral analysis of heart rate and systolic blood pressure variability in normal subjects and patients with heart failure. Sanderson JE, et al. **Clin Sci (Colch)** 1996 Jul;91(1):35–43

Postural control in children with spastic diplegia: muscle activity during perturbations in sitting. Brogren E, et al. **Dev Med Child Neurol** 1996 May;38(5):379–88

Development of the upright postural sway of children. Usui N, et al. **Dev Med Child Neurol** 1995 Nov;37(11):985–96

Origin of atypical reflux symptoms. A case study showing the importance of reflux composition and posture. Shay SS, et al. **Dig Dis Sci** 1996 Mar;41(3):505–11

Postural modulation of the soleus H reflex in young and old subjects. Koceja DM, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):387–93

Effect of postural and load variation on the coordination of the leg muscles in concentric jumping movement. Eloranta V. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb; 36(1):59–64

An analysis of scanning postures among grocery cashiers and its relationship to checkstand design. Grant KA, et al. **Ergonomics** 1995 Oct;38(10):2078–90

Postural adaptations to workbench modifications in standing workers. Whistance RS, et al. **Ergonomics** 1995 Dec; 38(12):2485–503

Renin-angiotensin-aldosterone system, RR-interval and blood pressure variability during postural changes after myocardial infarction. Duprez D, et al. **Eur Heart J** 1995 Aug;16(8):1050–6

Sympathetic predominance followed by functional denervation in the progression of chronic heart failure. Guzzetti S, et al. **Eur Heart J** 1995 Aug;16(8):1100–7

Influence of posture on middle cerebral artery mean flow velocity in humans. Savin E, et al. **Eur J Appl Physiol** 1995;71(2–3):161–5

European Spine Society--the AcroMed Prize for Spinal Research 1995. Unexpected load and asymmetric posture as etiologic factors in low back pain. Magnusson ML, et al. **Eur Spine J** 1996;5(1):23–35

The role of motor action in anticipatory postural adjustments studied with self-induced and externally triggered perturbations. Aruin AS, et al. **Exp Brain Res** 1995; 106(2):291–300

Age-related changes in open-loop and closed-loop postural control mechanisms. Collins JJ, et al. **Exp Brain Res** 1995; 104(3):480–92

The effects of spaceflight on open-loop and closed-loop postural control mechanisms: human neurovestibular studies on SLS-2. Collins JJ, et al. **Exp Brain Res** 1995; 107(1):145–50

The role of anticipatory postural adjustments and gravity in gait initiation. Lepers R, et al. **Exp Brain Res** 1995; 107(1):118–24

Influence of auditory precuing on automatic postural responses. McChesney JW, et al. **Exp Brain Res** 1996 Mar; 108(2):315–20

Role of somatosensory and vestibular cues in attenuating visually induced human postural sway. Peterka RJ, et al. **Exp Brain Res** 1995;105(1):101–10

Head and trunk movements in the frontal plane during complex dynamic equilibrium tasks in humans. Pozzo T, et al. **Exp Brain Res** 1995;106(2):327–38

Early and late stretch responses of human foot muscles induced by perturbation of stance. Schieppati M, et al. **Exp Brain Res** 1995;105(3):411–22

Measurement of visco-elastic properties of muscles around the ankle during standing. Ishida A, et al. **Front Med Biol Eng** 1996;7(1):35–43

Assessment of autonomic function using complex demodulation and posture entrainment techniques: an application to normal subjects and diabetic patients. Kamal A. **Front Med Biol Eng** 1996;7(1):1–10

Does the supine position worsen respiratory function in elderly subjects? Vitacca M, et al. **Gerontology** 1996; 42(1):46–53

Dangling: a review of relevant physiology, research, and practice. Winslow EH, et al. **Heart Lung** 1995 Jul–Aug; 24(4):263–72 (35 ref.)

Free and total dopamine in human plasma: effects of posture, age and some pathophysiological conditions. Hashizume K, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S205–7

Postural vasoconstrictor response in human heart failure. Mahy IR, et al. **Int J Microcirc Clin Exp** 1995 May–Jun; 15(3):137–42

Visual stabilization of posture in persons with central visual field loss. Turano KA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1483–91

Alteration of heat production in young calves in relation to posture. Schrama JW, et al. **J Anim Sci** 1995 Aug; 73(8):2254–62

Effect of posture, route of respiration, and negative pressure on palatal muscle activity in humans. Mortimore IL, et al. **J Appl Physiol** 1995 Aug;79(2):448–54

Interaction between postural and respiratory control of human intercostal muscles. Rimmer KP, et al. **J Appl Physiol** 1995 Nov;79(5):1556–61

Changes in sympathoadrenal response to standing in humans after spaceflight. Whitson PA, et al. **J Appl Physiol** 1995 Aug;79(2):428–33

Effects of posture on respiratory mechanics in obesity. Yap JC, et al. **J Appl Physiol** 1995 Oct;79(4):1199–205

Optimizing the determination of the body center of mass. Kingma I, et al. **J Biomech** 1995 Sep;28(9):1137–42

Cyclotorsion in the seated and supine patient. Smith EM Jr, et al. **J Cataract Refract Surg** 1995 Jul;21(4):402–3

Effects of Trendelenburg and reverse Trendelenburg postures on lung and chest wall mechanics. Fahy BG, et al. **J Clin Anesth** 1996 May;8(3):236–44

The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Gupta SK, et al. **J Clin Pharmacol** 1995 Nov;35(11):1083–93

Caudal medullary pathways to lumbosacral motoneuronal cell groups in the cat: evidence for direct projections possibly representing the final common pathway for lordosis. Vanderhorst VG, et al. **J Comp Neurol** 1995 Aug 28;359(3):457–75

Age differences in postural stability are increased by additional cognitive demands. Maylor EA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):P143–54

Visual vertigo syndrome: clinical and posturography findings. Bronstein AM. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):472–6

Differences in cardiovascular responses to supine exercise and to standing after exercise in two clinical subgroups of Shy-Drager syndrome (multiple system atrophy). Smith GD, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep; 61(3):297–303

Clinical correlates of motor performance during paced postural tasks in Parkinson's disease. Beckley DJ, et al. **J Neurol Sci** 1995 Oct;132(2):133–8

Perception of passive whole-body rotations in the absence of neck and body proprioception. Blouin J, et al. **J Neurophysiol** 1995 Nov;74(5):2216–9

Influence of instruction, prediction, and afferent sensory information on the postural organization of step initiation. Burleigh A, et al. **J Neurophysiol** 1996 Apr;75(4):1619–28

Postural and synergic control for three-dimensional movements of reaching and grasping. Desmurget M, et al. **J Neurophysiol** 1995 Aug;74(2):905–10

Adaptive control for backward quadrupedal walking V. Mutable activation of bifunctional thigh muscles. Pratt CA, et al. **J Neurophysiol** 1996 Feb;75(2):832–42

Plasticity of the extensor group I pathway controlling the stance to swing transition in the cat. Whelan PJ, et al. **J Neurophysiol** 1995 Dec;74(6):2782–7

Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36–47 (45 ref.)

Effect of orthotics on postural sway following inversion ankle sprain. Guskiewicz KM, et al. **J Orthop Sports Phys Ther** 1996 May;23(5):326–31

Time course of 'set'-related changes in muscle responses to stance perturbation in humans. Schieppati M, et al. **J Physiol (Lond)** 1995 Sep 15;487 (Pt 3):787–96

Asymmetry in walking performance and postural sway in patients with chronic unilateral cerebral infarction. Titianova EB, et al. **J Rehabil Res Dev** 1995 Oct; 32(3):236–44

Modifications of plasma levels of tissue factor pathway inhibitor and endothelin-1 induced by a reverse Trendelenburg position: influence of elastic compression--preliminary results. Arcelus JI, et al. **J Vasc Surg** 1995 Nov;22(5):568–72

Geometric adjustments to account for eye eccentricity in processing horizontal and vertical eye and head movement data. Huebner WP, et al. **J Vestib Res** 1995 Jul–Aug; 5(4):299–322

Influence of arousal and attention on the control of postural sway. Maki BE, et al. **J Vestib Res** 1996 Jan–Feb;6(1):53–9

Vestibularly evoked potentials (VESTEPs) of the horizontal semicircular canals under different body positions in space. Probst T, et al. **J Vestib Res** 1995 Jul–Aug;5(4):253–63

Visual vertigo. Sawle G. **Lancet** 1996 Apr 13;347(9007):986–7

Galvanic-induced postural movements as a test of vestibular function in humans. Cass SP, et al. **Laryngoscope** 1996 Apr; 106(4):423–30

A positional maneuver for treatment of horizontal-canal benign positional vertigo. Lempert T, et al. **Laryngoscope** 1996 Apr;106(4):476–8

Measurement of lung mechanics at different lung volumes and esophageal levels in normal subjects: effect of posture change. Baydur A, et al. **Lung** 1996;174(3):139–51

Dystonic postures generated from complex repetitive discharges. Preston DC, et al. **Neurology** 1996 Jan; 46(1):257–8

Horizontal canal benign paroxysmal positioning vertigo: reversible ipsilateral caloric hypoexcitability caused by canalolithiasis? Strupp M, et al. **Neurology** 1995 Nov; 45(11):2072–6

A positron emission tomography study of primary orthostatic tremor. Wills AJ, et al. **Neurology** 1996 Mar;46(3):747–52

The influence of head rotation on human upright posture during balanced bilateral vibration. Gurfinkel VS, et al. **Neuroreport** 1995 Dec 29;7(1):137–40

Trunk and head stabilization during the first months of independent walking. Ledebt A, et al. **Neuroreport** 1995 Sep 11;6(13):1737–40

Relationships between the force of voluntary leg movements and the associated postural adjustments. Béraud P, et al. **Neurosci Lett** 1995 Jul 21;194(3):177–80

Effect of posture on the onset of fictive locomotion in the decerebrate rabbit preparation. Bonnot A, et al. **Neurosci Lett** 1996 Apr 12;208(1):9–12

Open-loop and closed-loop postural control mechanisms in Parkinson's disease: increased mediolateral activity during quiet standing. Mitchell SL, et al. **Neurosci Lett** 1995 Sep 8;197(2):133–6

Different effect of height on latency of leg and foot short- and medium- latency EMG responses to perturbation of stance in humans. Nardone A, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):89–92

Naloxone and initial estrogen action to induce lordosis in ovariectomized rats: the effect of a cut between the septum and preoptic area. Torii M, et al. **Neurosci Lett** 1995 Aug

11;195(3):167–70
Kinesthetic reference for human orthograde posture. Gurfinkel VS, et al. **Neuroscience** 1995 Sep;68(1):229–43
Midcervical flexion myelopathy after posterior fossa surgery in the sitting position: case report. Haisa T, et al. **Neurosurgery** 1996 Apr;38(4):819–21; discussion 821–2
A comparison of standing steadiness measurements from two devices: covariates and normal values. Letz R, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):83–8
The effects of maternal position and cardiac output on intrapulmonary shunt in normal third–trimester pregnancy. Hankins GD, et al. **Obstet Gynecol** 1996 Sep;88(3):327–30
Cumulative concentrations of blood lead and postural stability. Chia SE, et al. **Occup Environ Med** 1996 Apr; 53(4):264–8
The Waterloo Vision and Mobility Study: postural control strategies in subjects with ARM. Elliott DB, et al. **Ophthalmic Physiol Opt** 1995 Nov;15(6):553–9
Positional nystagmus in asymptomatic human subjects. McAuley JR, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):545–53
Changes of QT intervals associated with postural change in patients with chronic atrial fibrillation. Malik M, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):490–5
Dependence of atrial sensing function on posture in a single–lead atrial triggered ventricular (VDD) pacemaker. Toivonen L, et al. **Pacing Clin Electrophysiol** 1996 Mar; 19(3):309–13
Sonographic measurement of renal length in children: does the position of the patient matter? Carrico CWT, et al. **Pediatr Radiol** 1996;26(8):553–5
Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long–chain polyunsaturated fatty acids. Agostoni C, et al. **Pediatr Res** 1995 Aug;38(2):262–6
Bodily perception in the organization of postural attitude and movement. Ruggieri V, et al. **Percept Mot Skills** 1996 Feb; 82(1):307–12
The effect of solid ankle–foot orthoses on movement patterns used in a supine–to–stand rising task. King LA, et al. **Phys Ther** 1995 Nov;75(11):952–64
The effect of hamstring muscle stretching on standing posture and on lumbar and hip motions during forward bending. Li Y, et al. **Phys Ther** 1996 Aug;76(8):836–45; discussion 845–9
Time course and mechanisms of decreased plasma volume during acute psychological stress and postural change in humans. Patterson SM, et al. **Psychophysiology** 1995 Nov; 32(6):538–45
The ambulatory measurement of posture, thigh acceleration, and muscle tension and their relationship to heart rate. Tuomisto MT, et al. **Psychophysiology** 1996 Jul; 33(4):409–15
Nasal resistance in recumbency and sleep. Miljeteig H, et al. **Rhinology** 1995 Jun;33(2):82–3
Acoustic cues and postural control. Petersen H, et al. **Scand J Rehabil Med** 1995 Jun;27(2):99–104
Why leg crossing? The influence of common postures on abdominal muscle activity. Snijders CJ, et al. **Spine** 1995 Sep 15;20(18):1989–93
Analysis of static and kinetic abnormalities typical of torticollis, and postoperative changes. Caputi F, et al. **Stereotact Funct Neurosurg** 1995;64(1):16–31
Electromyographic (EMG) study of the elbow flexors during supination and pronation of the forearm. Naito A, et al. **Tohoku J Exp Med** 1995 Apr;175(4):285–8
Changes in plasma vasopressin levels and cardiovascular function due to postural changes in diabetic neuropathy. Sato K, et al. **Tohoku J Exp Med** 1995 Sep;177(1):49–60
Neural networks that co–ordinate locomotion and body orientation in lamprey. Grillner S, et al. **Trends Neurosci** 1995 Jun;18(6):270–9 (64 ref.)
Gastro–oesophageal reflux during anaesthesia in the dog: the effect of age, positioning and type of surgical procedure. Galatos AD, et al. **Vet Rec** 1995 Nov 11;137(20):513–6
Hemodynamic regulation during postural tilt assessed by heart rate– and blood–pressure variability combined with impedance cardiography. Tank J, et al. **Wien Med Wochenschr** 1995;145(22):616–25
[Body positions which increase orthostatic tolerance] Wieling W, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1394–7 (22 ref.) **(Dut)**
[Complications caused by patient positioning in unidentified "thoracic outlet syndrome"] Peterson T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):516–8 (Eng. Abstr.) **(Ger)**
[Relationship between sleeping position and sudden infant death syndrome] Eidelman A, et al. **Harefuah** 1995 Sep; 129(5–6):197–200 (38 ref.) **(Heb)**
[Nicardipine attenuates the sympathetic reflex of orthostatism: do dihydropyridine–sensitive calcium channels regulate noradrenaline release?] Mercuro G, et al. **Cardiologia** 1992 Jul;37(7):465–7 (Eng. Abstr.) **(Ita)**
[Mandibular movements and the position of the head] Chersoni S. **Minerva Stomatol** 1995 Jun;44(6):285–9 (Eng. Abstr.) **(Ita)**
[Quantitative changes in cerebral blood flow of Shy–Drager syndrome induced by upright position: assessment by 99mTc–HMPAO] Gomi T, et al. **Kaku Igaku** 1995 Nov; 32(11):1255–8 (Eng. Abstr.) **(Jpn)**
[Jaw position, head position, body posture: development of an integrated system of examination, Part I] Takigawa T, et al. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):441–50 (23 ref.) (Eng. Abstr.) **(Jpn)**
[The role of gravitational tidal changes in regulating the systemic response of circulation and respiration to orthostasis] Raibshtein VA, et al. **Biofizika** 1995 Jul–Aug; 40(4):805–12 (Eng. Abstr.) **(Rus)**
[Maintenance of vertical posture during simultaneous vibration of the calf and anterior tibial muscles] Gurfinkel' VS, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):106–20 **(Rus)**
[Effect of postural muscle vibration on equilibrium maintenance in the frontal plane at various levels of stability] Gurfinkel' VS, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):83–92 **(Rus)**
[Detection of latent arterial hypertension using a complex of hemodynamic parameters in exercise tests] Vilkov VG. **Fiziol Cheloveka** 1996 May–Jun;22(3):76–80 **(Rus)**
[The dependence of ortho– and antiorthostatic hemodynamic reactions on the initial (controllable) tonus of the arterial vessels in rats] Osadchiĭ TI, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):111–26 (Eng. Abstr.) **(Rus)**
[The interrelation of mechanisms regulating postural stability and voluntary precise movement in athletes] Pryĭmakov OO. **Fiziol Zh** 1995 May–Aug;41(3–4):49–54 (Eng. Abstr.) **(Ukr)**

POSTVIRAL FATIGUE SYNDROME see **FATIGUE SYNDROME, CHRONIC**

POTASSIUM

see related
HYPERKALEMIA
HYPOKALEMIA

Low–potassium solution for lung preservation in the setting of high–flow reperfusion. DeLima NF, et al. **Ann Thorac Surg** 1996 Mar;61(3):973–6
Aggregation of acidic lipid vesicles by myelin basic protein: dependence on potassium concentration. Jo E, et al. **Biochemistry** 1995 Oct 17;34(41):13705–16
Na–dependent glutamate transport in high K and high glutathione (HK/HG) and high K and low glutathione (HK/LG) dog red blood cells. Fujise H, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):22–6
Hyperkalaemic cardiac arrest. May occur secondary to misuse of diuretics and potassium supplements [letter] Strivens E, et al. **BMJ** 1996 Sep 14;313(7058):693

ADMINISTRATION & DOSAGE

The importance of glucose–insulin–potassium with cardiopulmonary bypass prior to cardioplegic arrest in open–heart surgery. Rudež I, et al. **Lijec Vjesn** 1995 Jun; 117 Suppl 2:105–6
Effect of sodium concentration in a carbohydrate–electrolyte solution on intestinal absorption. Gisolfi CV, et al. **Med Sci Sports Exerc** 1995 Oct;27(10):1414–20

ADVERSE EFFECTS

Fibroproliferative disorder of the antrum after an alkali ingestion. Naon H, et al. **Am J Gastroenterol** 1996 Feb; 91(2):383–4
Oesophageal ulceration secondary to potassium tablets. Stanley AJ, et al. **Scott Med J** 1994 Aug;39(4):118–9

ANALYSIS

Potassium is not a good solute to estimate residual volume in CAPD. Abensur H, et al. **Adv Perit Dial** 1995;11:45–7
Comparison of five body–composition methods in peritoneal dialysis patients. Stall SH, et al. **Am J Clin Nutr** 1996 Aug; 64(2):125–30
Comparison of UW solution and St. Thomas' solution in the rat: importance of potassium concentration. Rosenfeldt FL, et al. **Ann Thorac Surg** 1996 Feb;61(2):576–84
The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Hunter KD, et al. **Arch Oral Biol** 1995 Nov; 40(11):983–9
Tissue potassium, selenium, and iron levels associated with gastric cancer progression. Wu CW, et al. **Dig Dis Sci** 1996 Jan;41(1):119–25
Body composition derived from whole body counting of potassium in growth hormone–deficient adults: a possible low intracellular potassium concentration. Davies JS, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1720–3
Effects of voltage clamping on epithelial cell composition in toad urinary bladder studied with x–ray microanalysis. Bowler JM, et al. **J Membr Biol** 1995 May;145(2):175–85
Sensitivity of valinomycin–based K(+)–selective micro–electrodes to inhibitors of K+ transport. Fitzgerald EM, et al. **J Neurosci Methods** 1995 Jul;59(2):273–7

ANTAGONISTS & INHIBITORS

Inhibition by halothane of potassium–stimulated acetylcholine release from rat cortical slices. Griffiths R, et al. **Br J Pharmacol** 1995 Oct;116(4):2310–4
Beta–amyloid–related peptides inhibit potassium–evoked acetylcholine release from rat hippocampal slices. Kar S, et al. **J Neurosci** 1996 Feb 1;16(3):1034–40
Down–regulation of protein kinase C activity preferentially attenuates high K(+)–stimulated tyrosine hydroxylase activity in adrenal chromaffin cells cultured with insulin–like growth factor–I. Dahmer MK. **Neurosci Lett** 1995 Dec 8;201(2):99–102

BLOOD

Computerized form of Siggaard–Andersen's double chart. Jabor A, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:113–7
Measurements of sodium and potassium in newborns and prematures by ion–selective electrodes and flame photometry: influence of lipid and protein content of blood. Kau N, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:107–11
Exercise ventilation and K+ in patients with COPD. Positive and negative work. Rooyackers JM, et al. **Adv Exp Med Biol** 1995;393:213–7
Epinephrine–induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Darbar D, et al. **Am J Cardiol** 1996 Jun 15;77(15):1351–5
Effect of albuterol treatment on subsequent dialytic potassium removal. Allon M, et al. **Am J Kidney Dis** 1995 Oct; 26(4):607–13
Resistance to osmotic lysis in BXD–31 mouse erythrocytes: association with upregulated K–Cl cotransport. Armsby CC, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C866–77
K+ balance during exercise and role of beta–adrenergic stimulation. Hallén J, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1347–54
Effect of surface–attached heparin on the response of potassium–selective electrodes. Brooks KA, et al. **Anal Chem** 1996 Apr 15;68(8):1439–43
Potassium ion–selective optodes based on the calix[6]arene hexaester and application in human serum assay. Chan WH, et al. **Analyst** 1996 Apr;121(4):531–4
A reply to: "Evaluation of methods for sodium, potassium, and chloride determination in relation to the analytical quality goals" [letter] Chalas J, et al. **Ann Biol Clin (Paris)** 1995;53(4):239–40
Effect of standard–dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men. Witt JM, et al. **Ann Pharmacother** 1996 Apr;30(4):347–50
Increased cation permeability in mutant mouse red blood cells with defective membrane skeletons. Joiner CH, et al. **Blood** 1995 Dec 1;86(11):4307–14
Commentary: replication of results [comment] Buckley–Sharp MD, et al. **BMJ** 1996 Jun 29;312(7047):1653 . Comment on: BMJ 1996 Jun 29;312(7047):1652–3.
Variation in plasma potassium when using collection tubes containing gel separators [letter] Jowitt S, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1300
Changes of erythrocyte ouabain maximum binding after birth in neonates—in relation to erythrocyte sodium and potassium concentrations. Matsuo Y, et al. **Early Hum Dev** 1995 Aug 30;43(1):59–69
Adrenaline, cyclic AMP and potassium during general anaesthesia with and without epidural analgesia. Löfgren A, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):487–94
Kinetics of plasma potassium concentrations during exhausting exercise in trained and untrained men. Marcos E, et al. **Eur J Appl Physiol** 1995;71(2–3):207–14
Further comments on the importance of serum potassium concentrations on early hepatic encephalopathy [letter; comment] Conn HO. **Hepatology** 1996 Jan;23(1):190. Comment on: Hepatology 1994 Dec;20(6):1637–40.
Total body potassium and serum potassium among eating disorder patients. Powers PS, et al. **Int J Eat Disord** 1995 Nov;18(3):269–76
Aldosterone responses to hyperkalemia in healthy elderly humans. Mulkerrin E, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1459–62
Plasma digoxin immunoreactivity and arterial potassium relaxation after quinapril therapy in hypertensive rats. Kähönen M, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):832–7
Do iodinated contrast media increase serum potassium levels? Hayakawa K, et al. **Radiology** 1996 Aug;200(2):407–11
Multicomponent analysis of biological fluids with the arrays of sparingly selective ion–selective electrodes. Hodinář. **Sb Lek** 1995;96(4):323–8
Effect of platelet count on serum and plasma potassium: evaluation using database information from two hospitals. Mäkelä K, et al. **Scand J Clin Lab Invest Suppl** 1995; 222:95–100
Citrinin produces acute adverse changes in renal function and ultrastructure in pentobarbital–anesthetized dogs without concomitant reductions in [potassium]plasma. Krejci ME, et al. **Toxicology** 1996 Jan 8;106(1–3):167–77
Potassium loss from leucodepleted red cells following gamma–irradiation [letter] Swann ID, et al. **Vox Sang** 1996; 70(2):117–8
[Conn's adenoma. Diagnostic and prognostic value of the measurement of potassium, renin, aldosterone levels and the aldosterone/renin ratio] Massien–Simon C, et al. **Presse Med** 1995 Sep 23;24(27):1238–42 (Eng. Abstr.) **(Fre)**
[Potassium] Kinouchi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:753–7 (26 ref.) **(Jpn)**
[The thrombocyte count and potassium concentration of the blood in acute nonlymphoblastic leukemia (towards an understanding of the regulatory mechanisms of

hemopoiesis)] Genkin AA, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):14-8 (Eng. Abstr.) **(Rus)**
[Potassium ion transport in the erythrocytes of the frog Rana ridibunda] Agalakova NI, et al. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):161-9 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Src-transformation of mouse fibroblasts induces a Ca(2+)-activated K+, current without changing the T-type Ca2+ current. Draheim HJ, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):57-63
Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness. Paula S, et al. **Biophys J** 1996 Jan; 70(1):339-48
Evaluation of a high sodium-low potassium cold-storage solution by the isolated perfused rat kidney technique. Ramella SG, et al. **Nephrol Dial Transplant** 1995; 10(6):842-6
Crystallographic evidence for the action of potassium, thallium, and lithium ions on fructose-1,6-bisphosphatase. Villeret V, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8916-20

DEFICIENCY see POTASSIUM DEFICIENCY

METABOLISM

Effect of K+ accumulation removal and high extracellular osmolarity on K+ current in insect axonal membrane. Stankiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):95-102
In vitro electrogenic K secretion in the frog semicircular canal: absence of effect of streptomycin. Ferrary E, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:181-3
K+ balance in humans during exercise. Hallén J. **Acta Physiol Scand** 1996 Mar;156(3):279-86 (38 ref.)
Measurement of the total concentration of functional Na+, K(+)-pumps in rumen epithelium. Kristensen NB, et al. **Acta Physiol Scand** 1995 Sep;155(1):67-76
Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335-46 (68 ref.)
Extrarenal potassium adaptation: review of a concept [editorial] Spital A, et al. **Am J Nephrol** 1995;15(5):367-73 (29 ref.)
Potassium-wasting nephropathy in an outbreak of chronic organic mercurial intoxication. Szylman P, et al. **Am J Nephrol** 1995;15(6):514-20
Anoxic brain failure in an ectothermic vertebrate: release of amino acids and K+ in rainbow trout thalamus. Hylland P, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1077-84
Effect of aldosterone on renal potassium conservation in the rat. Ornt DB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1003-8
Regulation of colonic ion transport by GRP. I. GRP stimulates transepithelial K and Na secretion. Traynor TR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C848-58
Coupling of entry to exit by peritubular K+ permeability in a mathematical model of rat proximal tubule. Weinstein AM. **Am J Physiol** 1996 Jul;271(1 Pt 2):F158-68
Propofol reduces neuronal transmission damage and attenuates the changes in calcium, potassium, and sodium during hyperthermic anoxia in the rat hippocampal slice. Amorim P, et al. **Anesthesiology** 1995 Dec;83(6):1254-65
A novel approach for imaging the influx of Ca2+, Na+, and K+ in the same cell at subcellular resolution. Ion microscopy imaging of stable tracer isotopes. Chandra S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:295-8
Furosemide-sensitive K+ transport in transformed and nontransformed rat liver epithelial cells: regulation by protein kinase C and involvement in cell growth. Anger JP, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr; 329(2):307-18
Effects of inhibitors and activators of ATP-regulated K+ channel on mitochondrial potassium uniport. Szewczyk A, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):477-84
Electrogenic K+ transport by the Kdp-ATPase of Escherichia coli. Fendler K, et al. **Biochemistry** 1996 Jun 18;35(24):8009-17
Estimation of the distance change between cysteine-457 and the nucleotide binding site when sodium pump changes conformation from E1 to E2 by fluorescence energy transfer measurements. Lin SH, et al. **Biochemistry** 1996 Jun 25;35(25):8419-28
Endogenous K+/H+ exchange activity in the Sf9 insect cell line. Vachon V, et al. **Biochemistry** 1995 Nov 21; 34(46):15157-64
The role of plasma membrane K+ and Ca2+ permeabilities for glucose induction of slow Ca2+ oscillations in pancreatic beta-cells. Eberhardson M, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):67-72
Cation transport in mitochondria—the potassium cycle. Garlid KD. **Biochim Biophys Acta** 1996 Jul 18; 1275(1-2):123-6
Transport of competing Na and K ions by (222) C10-cryptand, an ionizable mobile carrier: effects of pH and temperature. Loiseau A, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):107-17
Stimulation of oxidative phosphorylation by electrophoretic K+ entry associated to electroneutral K+/H+ exchange in yeast mitochondria. Manon S, et al. **Biochim Biophys Acta** 1995 Oct 10;1231(3):282-8
H+, K+, and Na+ transport across phospholipid vesicular membrane by the combined action of proton uncoupler 2,4-dinitrophenol and valinomycin. Prabhananda BS, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):193-9
Pattern of potassium ion and proton currents in the ovariole of the cockroach, Periplaneta americana, indicates future embryonic polarity. Kunkel JG, et al. **Biol Bull** 1995 Oct-Nov;189(2):197-8
N-terminal quarter part of tetracycline transporter from pACYC184 complements K+ uptake activity in K+ uptake-deficient mutants of Escherichia coli and Vibrio alginolyticus. Nakamura T, et al. **Biol Pharm Bull** 1995 Sep;18(9):1189-93
Concentrations of sodium, potassium and cortisol in saliva, and self-reported chronic work stress factors. Burton RF, et al. **Biol Psychol** 1996 Feb 5;42(3):425-38
Cation-dependent uptake of zinc in human fibroblasts. Ackland ML, et al. **Biometals** 1996 Jan;9(1):29-37
A quantitative description of the E-4031-sensitive repolarization current in rabbit ventricular myocytes. Clay JR, et al. **Biophys J** 1995 Nov;69(5):1830-7
Recovery from C-type inactivation is modulated by extracellular potassium. Levy DI, et al. **Biophys J** 1996 Feb;70(2):798-805
Effects of intracellular K+ and Rb+ on gating of embryonic rat telencephalon Ca(2+)-activated K+ channels. Mienville JM, et al. **Biophys J** 1996 Feb;70(2):778-85
Contributions of a negatively charged residue in the hydrophobic domain of the IRK1 inwardly rectifying K+ channel to K(+)-selective permeation. Reuveny E, et al. **Biophys J** 1996 Feb;70(2):754-61
Potassium current inhibition by nonselective cation channel-mediated sodium entry in rat pheochromocytoma (PC-12) cells. Strübing C, et al. **Biophys J** 1996 Apr; 70(4):1662-8
Thrombin receptors activate potassium and chloride channels. Sullivan R, et al. **Blood** 1996 Jan 15;87(2):648-56
The effect of neuropeptide Y on sodium, chloride and potassium transport across the rat distal colon. Strabel D, et al. **Br J Pharmacol** 1995 Jul;115(6):1071-9
Influence of age on the clearance of K+ from the extracellular space of rat hippocampal slices. Roberts EL Jr, et al. **Brain Res** 1996 Feb 5;708(1-2):16-20
Beta-amyloid1-40 inhibits electrically stimulated release of [3H]norepinephrine and enhances the internal calcium response to low potassium in rat cortex: prevention with a free radical scavenger. Li M, et al. **Brain Res Bull** 1996; 39(5):299-303
Depressed transient outward current in single hypertrophied cardiomyocytes isolated from the right ventricle of ferret heart. Potreau D, et al. **Cardiovasc Res** 1995 Sep; 30(3):440-8
Mechanism of high K+ and Tl+ uptake in cultured human glioma cells. Brismar T, et al. **Cell Mol Neurobiol** 1995 Jun;15(3):351-60
Ca2+ entry through the store-mediated pathway directly activates only the K+ current but the subsequent Ca2+ release from the store activates both K+ and Cl- currents in submandibular gland acinar cells of the rat. Wakui M, et al. **Cell Signal** 1995 Nov;7(8):783-91
Proton and potassium transport by H+/K(+)-ATPases. van Driel IR, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):952-60 (91 ref.)
Electrical responses and K+ activity changes to light in the ocellus of the planarian Dugesia japonica. Azuma K, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):593-9
Magnesium repletion and its effect on potassium homeostasis in critically ill adults: results of a double-blind, randomized, controlled trial. Hamill-Ruth RJ, et al. **Crit Care Med** 1996 Jan;24(1):38-45
Calcium-activated potassium current in cultured rabbit retinal pigment epithelial cells. Tao Q, et al. **Curr Eye Res** 1996 Mar;15(3):237-46
Molecular characterization of the epithelial Na-K-Cl cotransporter isoforms. Payne JA, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):493-503 (73 ref.)
The electroneutral sodium-(potassium)-chloride co-transporter family: a journey from fish to the renal co-transporters [editorial] Hebert SC, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):389-91
Potassium homeostasis and hyperkalemic syndromes. Clark BA, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):573-91 (84 ref.)
Changes in Na+, K(+)-adenosinetriphosphatase, citrate synthase and K+ in sheep skeletal muscle during immobilization and remobilization. Jebens E, et al. **Eur J Appl Physiol** 1995;71(5):386-95
Potassium ions and the molecular-chaperone activity of DnaK. Feifel B, et al. **Eur J Biochem** 1996 Apr 1; 237(1):318-21
Red blood cell cation transports in uraemic anaemia: evidence for an increased K/Cl co-transport activity. Effects of dialysis and erythropoietin treatment. De Franceschi L, et al. **Eur J Clin Invest** 1995 Oct;25(10):762-8
Chronotropic action of Na+, K+, Cl- cotransport inhibition in the isolated rat heart. Harper AA, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):299-305
Cromakalim- and RP 49356-induced 42K+ and 86Rb+ efflux in rat myometrium. Piper IT, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):1-8
Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Gustafson T, et al. **Eur Respir J** 1996 Feb;9(2):237-40
The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920-6 (49 ref.)
Ionic transport in the plasma membrane of carrot protoplasts from embryogenic cell-suspension cultures. Bregante M, et al. **FEBS Lett** 1996 Feb 12;380(1-2):97-102
Evidence for direct involvement of the sarcoplasmic reticulum Ca(2+)-ATPase in a passive monovalent cation (K+/Na+) exchange. de Jesus F, et al. **FEBS Lett** 1995 Dec 4;376(3):167-71
Streptozotocin, an inducer of NAD+ decrease, attenuates M-potassium current inhibition by ATP,' bradykinin, angiotensin II, endothelin 1 and acetylcholine in NG108-15 cells. Higashida H, et al. **FEBS Lett** 1996 Feb 5; 379(3):236-8
Depletion of intracellular calcium stores activates an outward potassium current in mast and RBL-1 cells that is correlated with CRAC channel activation. Hoth M. **FEBS Lett** 1996 Jul 29;390(3):285-8
The capacity to transport potassium influences sodium tolerance in Saccharomyces cerevisiae. Gómez MJ, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):157-60
Inward and outward rectifying potassium currents in Saccharomyces cerevisiae mediated by endogenous and heterelogously expressed ion channels. Bertl A, et al. **Folia Microbiol (Praha)** 1994;39(6):507-9
Sodium tolerance depends on the capacity to transport potassium in Saccharomyces cerevisiae. Gómez MJ, et al. **Folia Microbiol (Praha)** 1994;39(6):519-20
Effects of insulin on potassium currents of rat ventricular myocytes in streptozotocin diabetes. Magyar J, et al. **Gen Physiol Biophys** 1995 Jun;14(3):191-201
Synaptic feed-backs mediated by potassium ions. Matyushkin DP, et al. **Gen Physiol Biophys** 1995 Oct;14(5):369-81 (45 ref.)
Combined effects of adrenalectomy and noise exposure on compound action potentials, endocochlear potentials and endolymphatic potassium concentrations. Ma YL, et al. **Hear Res** 1995 Nov;91(1-2):79-86
Frequency and luminance-dependent blood flow and K+ ion changes during flicker stimuli in cat optic nerve head. Buerk DG, et al. **Invest Ophthalmol Vis Sci** 1995 Oct; 36(11):2216-27
Beta-adrenergic stimulation of Na+, K+, Cl- cotransport in fetal nonpigmented ciliary epithelial cells. Crook RB, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1047-57
The Activity of the high-affinity K+ uptake system Kdp sensitizes cells of Escherichia coli to methylglyoxal. Ferguson GP, et al. **J Bacteriol** 1996 Jul;178(13):3957-61
Low-affinity potassium uptake system in the archaeon Methanobacterium thermoautotrophicum: overproduction of a 31-kilodalton membrane protein during growth on low-potassium medium. Glasemacher J, et al. **J Bacteriol** 1996 Feb;178(3):728-34
Lactococcin G is a potassium ion-conducting, two-component bacteriocin. Moll G, et al. **J Bacteriol** 1996 Feb;178(3):600-5
Substitutions of serine 775 in the alpha subunit of the Na,K-ATPase selectively disrupt K+ high affinity activation without affecting Na+ interaction. Argüello JM, et al. **J Biol Chem** 1995 Sep 29;270(39):22764-71
Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. Doi T, et al. **J Biol Chem** 1996 Jul 19;271(29):17261-6
Substitutions of glutamate 781 in the Na,K-ATPase alpha subunit demonstrate reduced cation selectivity and an increased affinity for ATP. Koster JC, et al. **J Biol Chem** 1996 Feb 2;271(5):2413-21
The ntpJ gene in the Enterococcus hirae ntp operon encodes a component of KtrII potassium transport system functionally independent of vacuolar Na+-ATPase. Murata T, et al. **J Biol Chem** 1996 Apr 26;271(17):10042-7
Involvement of direct phosphorylation in the regulation of the rat parotid Na(+)-K(+)-2Cl- cotransporter. Tanimura A, et al. **J Biol Chem** 1995 Oct 20;270(42):25252-8
Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80-kDa mdr1a gene product. Thévenod F, et al. **J Biol Chem** 1996 Feb 9;271(6):3300-5
Metabolic stress opens K+ channels in hepatoma cells through a Ca2+- and protein kinase calpha-dependent mechanism. Wang Y, et al. **J Biol Chem** 1996 Jul 26; 271(30):18107-13
Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia. Miyazaki T, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):949-56
Modulation of caffeine contractures in mammalian skeletal muscles by variation of extracellular potassium. Gallant EM, et al. **J Cell Physiol** 1995 Nov;165(2):254-60
Nitric oxide modulates the CBF response to increased extracellular potassium. Dreier JP, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):914-9
Expression of the mouse Na-K-2Cl cotransporter, mBSC2, in the terminal inner medullary collecting duct, the glomerular and extraglomerular mesangium, and the glomerular afferent arteriole. Kaplan MR, et al. **J Clin Invest** 1996 Aug 1;98(3):723-30

Expression of the Na–K–2Cl cotransporter by macula densa and thick ascending limb cells of rat and rabbit nephron. Obermüller N, et al. **J Clin Invest** 1996 Aug 1;98(3):635–40

K(+)- and HCO3(-)-dependent acid–base transport in squid giant axons II. Base influx. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):845–62

K(+)- and HCO3(-)-dependent acid–base transport in squid giant axons. I. Base efflux. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):821–44

Na+, K+, and Cl- transport in resting pancreatic acinar cells. Zhao H, et al. **J Gen Physiol** 1995 Dec;106(6):1225–42

Ionophore properties of monensin derivatives studied on human erythrocytes by 23Na NMR and K+ and H+ potentiometry· relationship with antimicrobial and antimalarial activities. Rochdi M, et al. **J Med Chem** 1996 Jan 19;39(2):588–95

Two types of A–channels in Lymnaea neurons. Alekseev SI, et al. **J Membr Biol** 1995 Aug;146(3):327–41

Sequential potassium binding at the extracellular side of the Na,K–pump. Bühler R, et al. **J Membr Biol** 1995 May; 145(2):165–73

Evidence for Na–K–Cl cotransport in alveolar epithelial cells: effect of phorbol ester and osmotic stress. Clerici C, et al. **J Membr Biol** 1995 Oct;147(3):295–304

Hydrochlorothiazide action on the apical Cl–, Ca2+ and K+ conductances in rabbit gallbladder epithelium. Presence of an apamin–sensitive, Ca(2+)–activated K+ conductance. Cremaschi D, et al. **J Membr Biol** 1995 Sep; 147(2):159–71

Effect of mutation of potassium–efflux system, KefA, on mechanosensitive channels in the cytoplasmic membrane of Escherichia coli. Cui C, et al. **J Membr Biol** 1996 Mar; 150(2):143–52

Properties of voltage–gated potassium currents of microglia differentiated with granulocyte/macrophage colony–stimulating factor. Eder C, et al. **J Membr Biol** 1995 Sep;147(2):137–46

Single K+ channels in embryonic leech ganglion cells. Frey G, et al. **J Membr Biol** 1996 May;151(2):113–22

Cultured giant fiber lobe of squid expresses three distinct potassium channel activities in selective combinations. Griggs WD, et al. **J Membr Biol** 1996 Jul;152(1):25–37

K+ channels and the intracellular calcium signal in human melanoma cell proliferation. Lepple–Wienhues A, et al. **J Membr Biol** 1996 May;151(2):149–57

DIDS increases K+ secretion through an IsK channel in apical membrane of vestibular dark cell epithelium of gerbil. Shen Z, et al. **J Membr Biol** 1995 Aug;146(3):283–91

Ionic permeabilities induced by Bacillus thuringiensis in Sf9 cells. Vachon V, et al. **J Membr Biol** 1995 Nov; 148(1):57–63

Hypo–osmotic challenge stimulates transepithelial K+ secretion and activates apical IsK channel in vestibular dark cells. Wangemann P, et al. **J Membr Biol** 1995 Oct; 147(3):263–73

The relation between extracellular potassium concentration and pH in the border zone during regional ischemia in isolated porcine hearts. Coronel R, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):2069–73

Potassium regulation during exercise and recovery in humans: implications for skeletal and cardiac muscle. Lindinger MI. **J Mol Cell Cardiol** 1995 Apr;27(4):1011–22 (83 ref.)

Effects of training on potassium homeostasis during exercise. McKenna MJ. **J Mol Cell Cardiol** 1995 Apr;27(4):941–9 (52 ref.)

Alteration of Ca2+ fluxes in brain microsomes by K+ and Na+: modulation by sulfated polysaccharides and trifluoperazine. Rocha JB, et al. **J Neurochem** 1996 Feb; 66(2):772–8

Extracellular potassium, volume fraction, and tortuosity in rat hippocampal CA1, CA3, and cortical slices during ischemia. Pérez–Pinzón MA, et al. **J Neurophysiol** 1995 Aug;74(2):565–73

Relationship between synaptic activity and prolonged field bursts in the dentate gyrus of the rat hippocampal slice. Schweitzer JS, et al. **J Neurophysiol** 1995 Nov; 74(5):1947–52

Distribution of high–conductance Ca(2+)–activated K+ channels in rat brain: targeting to axons and nerve terminals. Knaus HG, et al. **J Neurosci** 1996 Feb 1; 16(3):955–63

A G–protein–activated inwardly rectifying K+ channel (GIRK4) from human hippocampus associates with other GIRK channels. Spauschus A, et al. **J Neurosci** 1996 Feb 1;16(3):930–8

Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. Villarroel A, et al. **J Neurosci** 1996 Feb 1;16(3):1016–25

Sensitivity of valinomycin–based K(+)–selective micro–electrodes to inhibitors of K+ transport. Fitzgerald EM, et al. **J Neurosci Methods** 1995 Jul;59(2):273–7

Different spatial patterns of [Ca2+] increase caused by N– and L–type Ca2+ channel activation in frog olfactory bulb neurones. Bischofberger J, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):305–17

Regulation of renal Na+,K(+)–ATPase in rat thick ascending limb during K+ depletion: evidence for modulation of Na+ affinity. Buffin–Meyer B, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):623–32

Membrane properties of the granule cells of the islands of Calleja of the rat studied in vitro. Halliwell JV, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):421–40

Developmental changes in blood–brain barrier potassium permeability in the rat: relation to brain growth. Keep RF, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):439–48

Non–selective cation current of guinea–pig endocardial endothelial cells. Manabe K, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):407–19

Thyroid status and diabetes modulate regional differences in potassium currents in rat ventricle. Shimoni Y, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):673–88

Estimated potassium reflection coefficient in perfused proximal convoluted tubules of the anaesthetized rat in vivo. Wareing M, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):153–61

Contribution of shrinkage of extracellular space to extracellular K+ accumulation in myocardial ischaemia of the rabbit. Yan GX, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):215–28

The effects of cellular hypoxia on contraction and extracellular ion accumulation in isolated human detrusor smooth muscle. Thomas PJ, et al. **J Urol** 1996 Feb; 155(2):726–31

View of K+ secretion through the apical K channel of cortical collecting duct. Wang WH. **Kidney Int** 1995 Oct; 48(4):1024–30 (87 ref.)

Progressive cellular dehydration and proteolysis in critically ill patients. Finn PJ, et al. **Lancet** 1996 Mar 9; 347(9002):654–6

Chronic fatigue syndrome: is total body potassium important? [letter; comment] Burnet RB, et al. **Med J Aust** 1996 Mar 18;164(6):384. Comment on: Med J Aust 1995 Sep 18;163(6):314–8.

Functional expression of a vertebrate inwardly rectifying K+ channel in yeast. Tang W, et al. **Mol Biol Cell** 1995 Sep; 6(9):1231–40

Potassium channel activation by glutathione–S–conjugates in Escherichia coli: protection against methylglyoxal is mediated by cytoplasmic acidification. Ferguson GP, et al. **Mol Microbiol** 1995 Sep;17(6):1025–33

Acid–base and potassium homeostasis. Krapf R. **Nephrol Dial Transplant** 1995;10(9):1537–9

Intracellular calcium directly inhibits potassium M channels in excised membrane patches from rat sympathetic neurons. Selyanko AA, et al. **Neuron** 1996 Jan;16(1):151–62

Extracellular potassium elevations in the hippocampus of rats with long–term pilocarpine seizures. Köhling R, et al. **Neurosci Lett** 1995 Dec 1;201(1):87–91

Histamine–induced prolonged depolarization in rat supraoptic neurons: G–protein–mediated, Ca(2+)–independent suppression of K+ leakage conductance. Li Z, et al. **Neuroscience** 1996 Jan; 70(1):145–58

Histamine–evoked potassium release in the mouse and guinea pig pancreas. Rosado JA, et al. **Pancreas** 1996 May; 12(4):396–400

An endogenous inactivating inward–rectifying potassium current in oocytes of Xenopus laevis. Bauer CK, et al. **Pflugers Arch** 1996 Sep;432(5):812–20

Relation between extracellular [K+], membrane potential and contraction in rat soleus muscle: modulation by the Na+–K+ pump. Cairns SP, et al. **Pflugers Arch** 1995 Oct; 430(6):909–15

3–Isobutyl–1–methylxanthine (IBMX) affects potassium permeability in rat sensory neurones via pathways that are sensitive and insensitive to [Ca2+]in. Usachev Y, et al. **Pflugers Arch** 1995 Jul;430(3):420–8

Cytochrome P450 inhibitors attenuate the hypotonic shock–induced increases in K+ efflux in LLC–PK1 cells. DelliPizzi AM, et al. **Pharmacology** 1995 Jun;50(6):348–56

Regulation of Arabidopsis thaliana (L.) Heynh Arginine decarboxylase by potassium deficiency stress. Watson MB, et al. **Plant Physiol** 1996 Aug;111(4):1077–83

Guanidine derivative U–37883A, inhibits mitochondrial K+ uniport. Szewczyk A, et al. **Pol J Pharmacol** 1995 Jul–Aug; 47(4):339–44

Glutamate is required to maintain the steady–state potassium pool in Salmonella typhimurium. Yan D, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6527–31

Primary structure and functional expression of a cGMP–gated potassium channel. Yao X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11711–5

Effects of glyburide on renal tubule transport and potassium–channel activity. Wang T, et al. **Ren Physiol Biochem** 1995 Jul–Aug;18(4):169–82

Early elemental and ionic changes in cultured cells after stimulation with epidermal growth factor. Beesley JE, et al. **Scanning Microsc** 1995 Mar;9(1):231–7; discussion 237–8

Use–dependent blockers and exit rate of the last ion from the multi–ion pore of a K+ channel. Baukrowitz T, et al. **Science** 1996 Feb 2;271(5249):653–6

Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor [see comments] Inagaki N, et al. **Science** 1995 Nov 17;270(5239):1166–70. Comment in: Science 1995 Nov 17;270(5239):1159.

Sodium–driven potassium uptake by the plant potassium transporter HKT1 and mutations conferring salt tolerance [see comments] Rubio F, et al. **Science** 1995 Dec 8; 270(5242):1660–3. Comment in: Science 1996 Aug 16;273(5277):977–9.

High–affinity potassium uptake in plants [letter; comment] Walker NA, et al. **Science** 1996 Aug 16;273(5277):977–9. Comment on: Science 1995 Dec 8;270(5242):1660–3.

The effects of extracellular ions on beta–blocker cardiotoxicity. Kerns W 2nd, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):1–7

[Transport of ions across alveolar epithelial cells in resected human lungs] Sakuma T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):966–72 (Eng. Abstr.) **(Jpn)**

[Role of hypoxia factor in changes of ionic composition of blood and muscle tissue in experimental botulinum poisoning] Morrison VV. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):27–9 (Eng. Abstr.) **(Rus)**

[Role of components of formate–hydrogen–lyase in forming molecular hydrogen and their connection with proton–potassium exchange in anaerobically grown Escherichia coli] Bagramian KA, et al. **Biofizika** 1996 Mar–Apr;41(2):369–76 (Eng. Abstr.) **(Rus)**

[Character of K+ absorption and its interaction with membrane protein pumps in Escherichia coli, grown under anaerobic conditions in the presence of nitrate] Bagramian KA, et al. **Biofizika** 1996 Mar–Apr;41(2):377–83 (Eng. Abstr.) **(Rus)**

[Effect of verapamil and anesthetics on the level of sodium and potassium ions in frog muscles. Role of hydrophobic interactions] Nesterov VP, et al. **Biofizika** 1996 Jan–Feb; 41(1):110–5 (Eng. Abstr.) **(Rus)**

[Changes in the concentration of sodium and potassium ions in the blood and gastrocnemius muscle in hyperoxia] Sokolianskii IF. **Fiziol Zh** 1995 May–Aug;41(3–4):81–5 (Eng. Abstr.) **(Rus)**

[Distribution of polyamines in Escherichia coli and their role in potassium exchange between the cell and the environment during aerobiosis–anaerobiosis transitions] Tkachenko AG, et al. **Mikrobiologiia** 1996 Jan–Feb; 65(1):10–4 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Increased inward passive permeability in vitro to sodium in uraemic erythrocytes. Corry DB, et al. **Clin Sci (Colch)** 1996 Jan;90(1):3–8

The osmotic response of the isolated, unfixed mouse tectorial membrane to isosmotic solutions: effect of Na+, K+, and Ca2+ concentration. Shah DM, et al. **Hear Res** 1995 Jul; 87(1–2):187–207

Histamine–sensitive 86Rb transport in cultured type–2 astrocytes of rat brain. Huszti Z, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S46–7

PHARMACOLOGY

Effect of verapamil on restoration of cardiac performance in raised [K+]o by adrenergic stimulation in the rabbit. O'Neill M, et al. **Acta Physiol Scand** 1995 Jul;154(3):367–76

The excitation of carotid body chemoreceptors of the cat by potassium and noradrenaline. Heinert G, et al. **Adv Exp Med Biol** 1995;393:323–30

Agonists increase the sensitivity of contractile elements for Ca++ in pregnant rat myometrium. Izumi H, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):199–206

Effect of potassium supplementation on blood pressure in African Americans on a low–potassium diet. A randomized, double–blind, placebo–controlled trial. Brancati FL, et al. **Arch Intern Med** 1996 Jan 8;156(1):61–7

Pre–steady–state kinetic study of the effects of K+ on the partial reactions of the catalytic cycle of the plasma membrane Ca(2+)–ATPase. Herscher CJ, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):673–7

Ketamine inhibits K+ evoked [3H] noradrenaline release from SH–SY5Y cells by reducing calcium influx. Sikand KS, et al. **Biochem Soc Trans** 1995 Aug;23(3):417S

Exchange of K+ or Cs+ for Na+ induces local and long–range changes in the three–dimensional structure of the tryptophan synthase alpha2beta2 complex. Rhee S, et al. **Biochemistry** 1996 Apr 2;35(13):4211–21

Structural influence of cation binding to recombinant human brain S100b: evidence for calcium–induced exposure of a hydrophobic surface. Smith SP, et al. **Biochemistry** 1996 Jul 9;35(27):8805–14

Kinetics and mechanisms of activation and inhibition of porcine liver fructose–1,6–bisphosphatase by monovalent cations. Zhang R, et al. **Biochemistry** 1996 Mar 5; 35(9):3038–43

The A1 agonist CCPA reduced bisoxonol–monitored membrane potential depolarization elicited by high K+ in cerebrocortical nerve endings. Amoroso S, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):67–73

Effect of current direction and K+ on polarization of the frog gastric mucosa proton pump. Carrasquer G, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):41–7

KN–62, a calcium/calmodulin–dependent protein kinase II inhibitor, inhibits high potassium–stimulated prolactin secretion and intracellular calcium increases in anterior pituitary cells. Cui ZJ, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):343–7

Monovalent cations differentially affect membrane surface properties and membrane curvature, as revealed by fluorescent probes and dynamic light scattering. Kraayenhof R, et al. **Biochim Biophys Acta** 1996 Jul 25; 1282(2):293–302

Arginine uptake through a novel cationic amino acid:K+ symporter, System R+, in brush border membrane vesicles from larval Manduca sexta midgut. Liu Z, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):25–31

Cationic lysine uptake by System R+ and zwitterionic lysine

uptake by System B in brush border membrane vesicles from larval Manduca sexta midgut. Liu Z, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):32–8

Recovery from C-type inactivation is modulated by extracellular potassium. Levy DI, et al. **Biophys J** 1996 Feb;70(2):798–805

Endogenous nitric oxide modulation of potassium–induced changes in guinea–pig airway tone. Folkerts G, et al. **Br J Pharmacol** 1995 Aug;115(7):1194–8

Endothelium–dependent relaxation to acetylcholine in bovine oviductal arteries: mediation by nitric oxide and changes in apamin–sensitive K+ conductance. García–Pascual A, et al. **Br J Pharmacol** 1995 Aug;115(7):1221–30

Activation of phospholipase C in SH–SY5Y neuroblastoma cells by potassium–induced calcium entry. Smart D, et al. **Br J Pharmacol** 1995 Sep;116(2):1797–800

Modulation of the isoprenaline–induced membrane hyperpolarization of mouse skeletal muscle cells. van Mil HG, et al. **Br J Pharmacol** 1995 Dec;116(7):2881–8

Moderate elevation of extracellular potassium transiently inhibits regeneration of sensory axons in cultured adult sciatic nerves. Edström A, et al. **Brain Res** 1995 Sep 25; 693(1–2):148–54

Effect of extracellular K+ on the intracellular free Ca2+ concentration in leech glial cells and Retzius neurones. Hochstrate P, et al. **Brain Res** 1995 Oct 23;696(1–2):231–41

Neuropeptide Y potentiation of potassium–induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo. Pavia JM, et al. **Brain Res** 1995 Aug 28;690(1):108–11

Halothane, but not alpha–chloralose, blocks potassium–evoked cortical spreading depression in cats. Saito R, et al. **Brain Res** 1995 Nov 13;699(1):109–15

High potassium promotes differentiation of retinal neurons but does not favor rod differentiation. Araki M, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):103–14

Role of voltage oscillations in the automaticity of sheep cardiac Purkinje fibers. Spiegler PA, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1165–80

Interrelationship between magnesium and potassium in preventing myocardial ischemia–reperfusion arrhythmia. Xiang S, et al. **Chin Med J (Engl)** 1996 Apr;109(4):282–5

Potassium induces multiple steroidogenic enzymes in cultured rat zona glomerulosa cells. Yagci A, et al. **Endocrinology** 1996 Jun;137(6):2406–14

Selective up–regulation of alpha 1–chimaerin mRNA in SK–N–SH neuroblastoma cells by K+/–induced depolarisation. Dong JM, et al. **Eur J Biochem** 1996 Mar 15;236(3):820–6

Elevated potassium enhances glutamate vulnerability of dopaminergic neurons developing in mesencephalic cell cultures. Andreeva N, et al. **Exp Neurol** 1996 Feb; 137(2):255–62

Regional differences in the contractile and intracellular Ca2+ responses of the guinea–pig vas deferens to neurotransmitters and excess K+. Kato K, et al. **Exp Physiol** 1995 Sep;80(5):721–33

Effects of potassium on the expression and stability of the general amino acid permease of Saccharomyces. Rosas G, et al. **Folia Microbiol (Praha)** 1994;39(6):543

Effects of nifedipine ryanodine and cyclopiazonic acid on tension development of ileal longitudinal muscle by manganese ions in Ca(2+)–free high–K+ medium. Nasu T, et al. **Gen Pharmacol** 1995 Oct;26(6):1255–60

High potassium–evoked release of ATP from rabbit pulmonary artery via endogenous noradrenaline. Takeuchi K, et al. **Gen Pharmacol** 1995 Oct;26(6):1385–90

Effects of calcium antagonist drugs on acetylcholine and high K responses of a molluscan muscle Neptunea antiqua. Alohan FI. **Gen Physiol Biophys** 1995 Oct;14(5):419–26

The Na(+)–Ca2+ exchange system in rat glial cells in culture: activation by external monovalent cations. Holgado A, et al. **Glia** 1995 Jun;14(2):77–86

The influence of water potassium concentration on 137Cs excretion from fish. Nasvit OI. **Health Phys** 1996 Jul; 71(1):34–6

Evidence that glutathione is the unidentified amine (Unk 2.5) released by high potassium into cochlear fluids. Bobbin RP, et al. **Hear Res** 1995 Jul;87(1–2):49–54

Histamine H3 receptor inhibition of K(+)–evoked release of acetylcholine from rat cortex in vivo. Blandina P, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S54–5

Renal vascular morphology in male Dahl rats on high–salt diet: effect of potassium. Wu X, et al. **J Am Soc Nephrol** 1996 Feb;7(2):338–44

Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. Doi T, et al. **J Biol Chem** 1996 Jul 19;271(29):17261–6

Endothelial cell oxidant generation during K(+)–induced membrane depolarization. al–Mehdi AB, et al. **J Cell Physiol** 1996 Feb;166(2):274–80

Evidence against high extracellular glutamate promoting the elicitation of spreading depression by potassium. Obrenovitch TP, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):923–31

The pacemaker current in cardiac Purkinje myocytes. Vassalle M, et al. **J Gen Physiol** 1995 Sep;106(3):559–78

Low magnesium enhances the pro–arrhythmic effect of low potassium in the hypertrophied rat heart but not in the normal rat heart. Evans SJ, et al. **J Hypertens** 1996 May; 14(5):635–44

Protective effect of amiloride during hypothermic hyperkalemic preservation: a 31P NMR study in isolated pig hearts. Kupriyanov VV, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2237–48

Modulation by ionotropic excitatory amino acids and potassium of (+/–)–1–aminocyclopentane–trans–1,3–dicarboxylic acid–stimulated phosphoinositide hydrolysis in mouse cerebellar granule cells. Gorman AM, et al. **J Neurochem** 1995 Dec;65(6):2473–83

Potassium–induced stimulation of glutamate uptake in mouse cerebral astrocytes: the role of intracellular pH. Judd MG, et al. **J Neurochem** 1996 Jan;66(1):169–76

Cd(2+)–and K(+)–evoked ACh release induce different synaptophysin and synaptobrevin immunolabelling at the frog neuromuscular junction. Colasante C, et al. **J Neurocytol** 1995 Aug;24(8):547–58

Accumulation of inactivation in a cloned transient K+ channel (AKv1.1a) of Aplysia. Furukawa Y. **J Neurophysiol** 1995 Sep;74(3):1248–57

Potassium deprivation–induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE–like protease activity, and reactive oxygen species. Schulz JB, et al. **J Neurosci** 1996 Aug 1;16(15):4696–706

Participation of endogenous noradrenaline in the release of ATP by high potassium in the rat caudal artery. Shinozuka K, et al. **Jpn J Pharmacol** 1995 May;68(1):125–7

Effects of morphine–3–glucuronide and morphine on the K+–evoked release of [3H]–glutamic acid and [14C]–gamma–aminobutyric acid from rat brain synaptosomes. Bartlett SE, et al. **Life Sci** 1996;58(5):447–54

Responses of cremasteric arterioles of spontaneously hypertensive rats to changes in extracellular K+ concentration. Lombard JH, et al. **Microcirculation** 1995 Dec;2(4):355–62

Age–related changes in potassium–evoked overflow of dopamine in the striatum of the rhesus monkey. Gerhardt GA, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):939–46

Chloride ions, potassium stimulation and release of endogenous taurine from cerebral cortical slices from 3 day old and 3 month old mice. Oja SS, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):313–8

Methylfolate modulates potassium evoked neuro–secretion: evidence for a role at the pteridine cofactor level of tyrosine 3–hydroxylase. Lucock MD, et al. **Neurochem Res** 1995 Jun;20(6):727–36

omega–Aga IVA selectively inhibits the calcium–dependent fraction of the evoked release of [3H]GABA from synaptosomes. Sitges M, et al. **Neurochem Res** 1995 Sep; 20(9):1065–71

Functional role and histological demonstration of nitric–oxide–mediated inhibitory nerves in dog sphincter of Oddi. Tanobe Y, et al. **Neurogastroenterol Motil** 1995 Dec;7(4):219–27

Modulation of K+ current by frequency and external [K+]: a tale of two inactivation mechanisms. Baukrowitz T, et al. **Neuron** 1995 Oct;15(4):951–60

Potentiation by K+ of anoxic release of newly synthesized neuronal glutamate. Huang R, et al. **Neuroreport** 1995 Nov 27;6(17):2404–8

The effect of PhTx3 on the release of 3H–acetylcholine induced by tityustoxin and potassium in brain cortical slices and myenteric plexus. Gomez RS, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):131–3

Pharmacological characteristics of potassium–induced, glycogenolysis in astrocytes. Subbarao KV, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):45–8

Nerve growth factor withdrawal induces the apoptotic death of developing septal cholinergic neurons in vitro: protection by cyclic AMP analogue and high potassium. Kew JN, et al. **Neuroscience** 1996 Jan;70(2):329–39

Positively charged oligonucleotides overcome potassium–mediated inhibition of triplex DNA formation. Dagle JM, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2143–9

Modulation of delayed rectifier K+ channel activity by external K+ ions in Xenopus axon. Safronov BV, et al. **Pflugers Arch** 1995 Oct;430(6):879–86

Effect of glutamic acid on broilers given submarginal crude protein with adequate essential amino acids using feeds high and low in potassium. Moran ET Jr, et al. **Poult Sci** 1996 Jan;75(1):120–9

Effects of magnesium, sodium, calcium or potassium intakes on magnesium content in rat skeletal muscle. Gros P, et al. **Rev Esp Fisiol** 1995 Mar;51(1):1–5

Effects of hypothermia and hyperpotassium on alveolar fluid clearance in the resected human lung. Sakuma T, et al. **Surg Today** 1995;25(8):694–700

Isotonic versus hypertonic initial hyperkalemic reperfusion after cardioplegic arrest in isolated hearts. Habazettl H, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):123–8

[Effect of some cations on activity of macrotetralide synthase during development of Streptomyces chrysomallus subsp. Macrotetalidi] Sverdlova AN, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):16–23 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Role of potassium in the regulation of systemic physiological function during exercise. Paterson DJ. **Acta Physiol Scand** 1996 Mar;156(3):287–94 (77 ref.)

Potassium and fatigue: the pros and cons. Sjøgaard G. **Acta Physiol Scand** 1996 Mar;156(3):257–64 (58 ref.)

Role of interstitial potassium. Sjøgaard G, et al. **Adv Exp Med Biol** 1995;384:69–80 (81 ref.)

Protein kinase C inhibits delayed rectifier K+ current in rabbit vascular smooth muscle cells. Aiello EA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H109–19

Effect of pH on potassium and proton conductance in renal proximal tubule. Gu X, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F289–308

Ca(2+)–dependent K+ current in arterial smooth muscle cells from aldosterone–salt hypertensive rats. Liu Y, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1246–57

Nitric oxide modulates a calcium–activated potassium current in muscle cells from opossum esophagus. Murray JA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G606–12

Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes. Wang DW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1288–96

Identification and characteristics of delayed rectifier K+ current in fetal mouse ventricular myocytes. Wang L, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2088–93

Dual effects of arachidonic acid on ATP–sensitive K+ current of coronary smooth muscle cells. Xu X, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1957–62

Routes of calcium entry and extrusion in turtle hair cells. Tucker T, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:123–37 (44 ref.)

Regulation of the potassium current and cytosolic Ca2+ release induced by 2–methylthio ATP in hippocampal neurons. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):428–33

The effect of juglone on the membrane potential and whole–cell K+ currents of human lymphocytes. Varga Z, et al. **Biochem Biophys Res Commun** 1996 Jan 26; 218(3):828–32

Characterization of inhibition by haloperidol and chlorpromazine of a voltage–activated K+ current in rat phaeochromocytoma cells. Nakazawa K, et al. **Br J Pharmacol** 1995 Nov;116(6):2603–10

Hydrogen peroxide hyperpolarizes rat CA1 pyramidal neurons by inducing an increase in potassium conductance. Seutin V, et al. **Brain Res** 1995 Jun 19;683(2):275–8

Dual role of K+ and Na+ on the transport of [3H]–gamma–aminobutyric acid by synaptic plasma membrane vesicles. Gonçalves PP, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):161–5

Interaction of cytotoxic T lymphocytes and guinea pig ventricular myocytes. Pharmacological modulation by blocking K+ currents in cytotoxic T lymphocytes. Felzen B, et al. **Circ Res** 1996 Feb;78(2):253–61

Two components of delayed rectifier current in canine atrium and ventricle. Does IKs play a role in the reverse rate dependence of class III agents? Gintant GA. **Circ Res** 1996 Jan;78(1):26–37

K+ currents in human coronary artery vascular smooth muscle cells. Gollasch M, et al. **Circ Res** 1996 Apr; 78(4):676–88

Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Li GR, et al. **Circ Res** 1996 Apr;78(4):689–96

Angiotensin II decreases a resting K+ conductance in rat bulbospinal neurons of the C1 area. Li YW, et al. **Circ Res** 1996 Feb;78(2):274–82

Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use–dependence. Yang T, et al. **Circulation** 1996 Feb 1; 93(3):407–11

Properties of a delayed rectifier potassium current in dentate granule cells isolated from the hippocampus of patients with chronic temporal lobe epilepsy. Beck H, et al. **Epilepsia** 1996 Sep;37(9):892–901

Ultracytochemical localization of ouabain–sensitive K(+)–dependent paranitrophenylphosphatase in rat sciatic nerve fibers. Dolapchieva S. **Eur J Morphol** 1995 Jul; 33(3):247–55

The rate of Wallerian degeneration in cultured neurons from wild type and C57BL/WldS mice depends on time in culture and may be extended in the presence of elevated K+ levels. Buckmaster EA, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1596–602

Properties of K+ conductances in cat retinal ganglion cells during the period of activity–mediated refinements in retinofugal pathways. Skaliora I, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1558–68

Compensating effects of opposing changes in putrescine (2+) and K+ concentrations on lac repressor–lac operator binding: in vitro thermodynamic analysis and in vivo relevance. Capp MW, et al. **J Mol Biol** 1996 Apr 26; 258(1):25–36

Differential influence of extracellular and intracellular pH on K+ accumulation in ischaemic mammalian cardiac tissue. Vanheel B, et al. **J Mol Cell Cardiol** 1995 Jul; 27(7):1443–55

Endothelin–1 increases arachidonic acid release in C6 glioma cells through a potassium–modulated influx of calcium. Dunican DJ, et al. **J Neurochem** 1996 Aug;67(2):830–7

Two voltage–dependent K+ conductances with complementary functions in postsynaptic integration at a central auditory synapse. Brew HM, et al. **J Neurosci** 1995 Dec;15(12):8011–22

Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q–type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor.

Mackie K, et al. **J Neurosci** 1995 Oct;15(10):6552–61

Neurokinin A depolarizes neurons of bullfrog dorsal root ganglia by suppressing K+ conductances. Akasu T, et al. **Kurume Med J** 1995;42(3):167–76

Depolarization accelerates the decay of K+ contractures in rat skeletal muscle fibers. Patterson MF, et al. **Muscle Nerve** 1996 Aug;19(8):1025–36

Melatonin biosynthesis in photoreceptor–enriched chick retinal cell cultures: role of cyclic AMP in the K(+)–evoked, Ca(2+)–dependent induction of serotonin N–acetyltransferase activity. Gan J, et al. **Neurochem Int** 1995 Aug;27(2):147–55

Developmental changes of K(+)–dependent para–nitrophenylphosphatase (Na(+)–K(+)–ATPase) distribution in the synaptic regions in the cerebral cortex of rats. Dolapchieva S. **Neurosci Res** 1996 Feb;24(3):309–12

Ionic currents in cultured rat suprachiasmatic neurons. Walsh IB, et al. **Neuroscience** 1995 Dec;69(3):915–29

Regulatory volume decrease in a renal distal tubular cell line (A6). I. Role of K+ and Cl–. De Smet P, et al. **Pflugers Arch** 1995 Oct;430(6):936–44

Quantitative RT–PCR analysis of mRNAs encoding a colonic putative H, K–ATPase alpha subunit along the rat nephron: effect of K+ depletion. Marsy S, et al. **Pflugers Arch** 1996 Jul;432(3):494–500

[The antidromic action of K+ in the synapses intensifying their orthodromic action] Matiushkin DP, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):152–4 **(Rus)**

[The effect of calcium antagonists and the potassium depolarization of plasma membranes on pepsinogen extrusion by dispersed gastric glands] Dubyts'kyi LO, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):108–12 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Potassium conversion of ventricular fibrillation [letter; comment] Robicsek F. **Ann Thorac Surg** 1996 Aug; 62(2):624. Comment on: Ann Thorac Surg 1996 Jan;61(1):275.

Genetically defined therapy of inherited long–QT syndrome. Correction of abnormal repolarization by potassium. Compton SJ, et al. **Circulation** 1996 Sep 1;94(5):1018–22

Combinations of potassium, calcium, and magnesium supplements in hypertension. Sacks FM, et al. **Hypertension** 1995 Dec;26(6 Pt 1):950–6

Effect of high potassium diets on the vascular and renal prostaglandin system in stroke–prone spontaneously hypertensive rats. Ishimitsu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):255–60

URINE

The effects of high urinary potassium concentration on pelvic nerve mechanoreceptors and 'silent' afferents from the rat bladder. Wen J, et al. **Adv Exp Med Biol** 1995;385:237–9

The role of angiotensin AT1 receptors in the diuretic, natriuretic, kaliuretic and blood pressure responses induced by angiotensin II activation of the median preoptic nucleus in conscious rats. Ferreira–do–Vale C, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1097–101

Losartan (DUP–753) blocks the natriuretic, kaliuretic and antidiuretic effect of intracerebroventricular injection of carbachol in water–loaded rats. Saad WA, et al. **Braz J Med Biol Res** 1996 Apr;29(4):511–3

Urinary sodium, potassium, calcium, urea, and creatinine determination by Ektachem 250. Granouillet R, et al. **Clin Chem** 1996 Jan;42(1):105–6

Effects of K–ATP blocking guanidine diuretics during experimental kaliuresis in rats and dogs. Humphrey SJ. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):519–28

Urea recycling: an aid to the excretion of potassium during antidiuresis. Halperin ML, et al. **Nephron** 1996;72(4):507–11 (32 ref.)

Renal tubular handling of potassium in children with insulin–dependent diabetes mellitus. Rodríguez–Soriano J, et al. **Pediatr Nephrol** 1996 Feb;10(1):1–6

[Effects of potassium chloride and triamterene on kaliuresis, natriuresis and diuresis in congestive heart failure] Kabakov AI, et al. **Klin Med (Mosk)** 1995;73(5):33–5 (Eng. Abstr.) **(Rus)**

POTASSIUM ANTIMONYLTARTRATE see **ANTIMONY POTASSIUM TARTRATE**

POTASSIUM BICHROMATE see **POTASSIUM DICHROMATE**

POTASSIUM CHANNELS

see related
NA(+)–K(+)–EXCHANGING ATPASE

A prokaryotic potassium ion channel with two predicted transmembrane segments from Streptomyces lividans. Schrempf H, et al. **EMBO J** 1995 Nov 1;14(21):5170–8

Dynamic changes of mechanically activated channels and K+ channels at injury site of peripheral nerve in rat. Ling Y, et al. **Sci China C Life Sci** 1996 Feb;39(1):71–9

[Whole cell recording of sodium, potassium and calcium currents of cultured neonatal rat sympathetic neurons] He XP, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):441–7 (Eng. Abstr.) **(Chi)**

[About K+ channels] Higashida H, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2275–9 (29 ref.) **(Jpn)**

[A pH–sensitive K+ channel] Suzuki M. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2307–10 (8 ref.) **(Jpn)**

[3,4–diaminopyridine in the treatment of myasthenic syndromes. Practical aspects (letter)] Vilchez JJ, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):37–8 **(Spa)**

AGONISTS

K+ channel openers produce epithelium–dependent relaxation of the guinea–pig trachea. Shikada K, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):193–7

KATP–channel openers protect against increased cytosolic calcium during ischaemia and reperfusion. Behling RW, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1809–17

Activation of ATP–dependent K+ channels enhances myocardial protection due to cold high potassium cardioplegia: a force–frequency relationship study. Sugimoto S, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1867–81

L–735,334, a novel sesquiterpenoid potassium channel–agonist from Trichoderma virens. Lee SH, et al. **J Nat Prod** 1995 Dec;58(12):1822–8

MCI–154 activates the Ca(2+)–activated K+ channel of vascular smooth muscle cells. Miyoshi H, et al. **Life Sci** 1995 Mar 3;56(15):PL291–8

Characterization and regulation of apamin–binding K+ channels in skeletal muscle. Vigdor–Alboim S, et al. **Muscle Nerve** 1996 Mar;19(3):331–7

Relaxation of subarachnoid hemorrhage–induced spasm of rabbit basilar artery by the K+ channel activator cromakalim. Zuccarello M, et al. **Stroke** 1996 Feb; 27(2):311–6

[Potassium channel activators: comparative structural study of pinacidil, diazoxide and cromakalim] Dupont L, et al. **Ann Pharm Fr** 1995;53(5):201–8 (Eng. Abstr.) **(Fre)**

ANALYSIS

The cation distribution set by surface charges explains a paradoxical membrane excitability behavior. Genet S, et al. **C R Acad Sci III** 1996 Apr;319(4):263–8

Immunolocalization of an inwardly rectifying K+ channel, K(AB)–2 (Kir4.1), in the basolateral membrane of renal distal tubular epithelia. Ito M, et al. **FEBS Lett** 1996 Jun 10;388(1):11–5

Characterization of potassium and chloride channels in the basolateral membrane of bovine nonpigmented ciliary epithelial cells. Edelman JL, et al. **Invest Ophthalmol Vis Sci** 1995 Dec;36(13):2706–16

Distribution of high–conductance Ca(2+)–activated K+ channels in rat brain: targeting to axons and nerve terminals. Knaus HG, et al. **J Neurosci** 1996 Feb 1; 16(3):955–63

G–protein–gated inward rectifier K+ channel proteins (GIRK1) are present in the soma and dendrites as well as in nerve terminals of specific neurons in the brain. Ponce A, et al. **J Neurosci** 1996 Mar 15;16(6):1990–2001

Whole–cell analysis of NGK2 (mKv3.1a) K+ channels stably expressed in mouse fibroblast cells. Kawamura T, et al. **Neurosci Lett** 1995 Sep 8;197(2):164–6

ANTAGONISTS & INHIBITORS

Molecular mechanisms of K+ channel blockade: 4–aminopyridine interaction with a cloned cardiac transient K+ (Kv1.4) channel. Rasmusson RL, et al. **Adv Exp Med Biol** 1995;382:11–22

Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium. Kersten JR, et al. **Anesth Analg** 1996 Jul; 83(1):27–33

Inhibitory effects of ketamine and halothane on recombinant potassium channels from mammalian brain. Kulkarni RS, et al. **Anesthesiology** 1996 Apr;84(4):900–9

Modulation of action potential duration by inhibition of the transient outward current in sheep cardiac Purkinje fibers. Berger F, et al. **Basic Res Cardiol** 1995 May–Jun; 90(3):185–91

Effects of anesthesia and K+ ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Cohen MV, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):410–7

Immunosuppressors inhibit voltage–gated potassium channels in human peripheral blood lymphocytes. Panyi G, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):254–8

Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage–dependent potassium channels in human T–lymphocytes and rat brain. Pennington MW, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):696–701

Cicutoxin from Cicuta virosa—a new and potent potassium channel blocker in T lymphocytes. Strauss U, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):332–6

The effect of juglone on the membrane potential and whole–cell K+ currents of human lymphocytes. Varga Z, et al. **Biochem Biophys Res Commun** 1996 Jan 26; 218(3):828–32

A novel structural class of K+–channel blocking toxin from the scorpion Pandinus imperator. Olamendi–Portugal T, et al. **Biochem J** 1996 May 1;315 (Pt 3):977–81

Structural and functional features of noxiustoxin: a K+ channel blocker. Gurrola GB, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):527–35

Synthesis and structural characterisation of analogues of the potassium channel blocker charybdotoxin. Dyke TR, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):31–8

Multiple residues specify external tetraethylammonium blockade in voltage–gated potassium channels. Pascual JM, et al. **Biophys J** 1995 Aug;69(2):428–34

Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Valenzuela C, et al. **Biophys J** 1995 Aug;69(2):418–27

Differential effects of potassium channel blockers on extracellular concentrations of dopamine and 5–HT in the striatum of conscious rats. Dawson LA, et al. **Br J Pharmacol** 1995 Dec;116(8):3260–4

The pharmacological properties of K+ currents from rabbit isolated aortic smooth muscle cells. Halliday FC, et al. **Br J Pharmacol** 1995 Dec;116(8):3139–48

Increase in action potential duration and inhibition of the delayed rectifier outward current IK by berberine in cat ventricular myocytes. Sánchez–Chapula J. **Br J Pharmacol** 1996 Apr;117(7):1427–34

Metabotropic glutamate receptor inhibition of visceral afferent potassium currents. Hay M, et al. **Brain Res** 1995 Nov 6;698(1–2):169–74

Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5–hydroxydecanoate. Hide EJ, et al. **Cardiovasc Res** 1996 Jun;31(6):941–6

Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open–channel block by methanesulfonanilides. Spector PS, et al. **Circ Res** 1996 Mar;78(3):499–503

ATP–dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Olschewski A, et al. **Circulation** 1996 Feb 15;93(4):656–9

Kv8.1, a new neuronal potassium channel subunit with specific inhibitory properties towards Shab and Shaw channels. Hugnot JP, et al. **EMBO J** 1996 Jul 1; 15(13):3322–31

Diadenosine–hexaphosphate is an inhibitory ligand of myocardial ATP–sensitive K+ channels. Jovanović A, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):R1–2

Salicylaldoxime blocks K+ and Ca2+ currents in rat cardiac myocytes. Karhu S, et al. **Eur J Pharmacol** 1995 Jun 6; 279(1):7–13

Novel effects of dendrotoxin homologues on subtypes of mammalian Kv1 potassium channels expressed in Xenopus oocytes. Robertson B, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):26–30

Dihydropyridines and verapamil inhibit voltage–dependent K+ current in isolated outer hair cells of the guinea pig. Lin X, et al. **Hear Res** 1995 Aug;88(1–2):36–46

Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Pennington MW, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):354–8

Effect of K+ channel blockade on fatigue in rat diaphragm muscle. Van Lunteren E, et al. **J Appl Physiol** 1995 Sep; 79(3):738–47

Kalicludines and kaliseptine. Two different classes of sea anemone toxins for voltage sensitive K+ channels. Schweitz H, et al. **J Biol Chem** 1995 Oct 20;270(42):25121–6

Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff–Parkinson–White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):198–206

Selective Ik blocker almokalant exhibits class III—specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings [see comments] Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):530–40. Comment in: J Cardiovasc Pharmacol 1995 Oct;26(4):524–7.

Use–dependent effects of the class III antiarrhythmic agent NE–10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L–type calcium currents. Fermini B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):259–71

Terfenadine blocks time–dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes. Ming Z, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):761–9

K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. Vanoli E, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):847–54

Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease [see comments] Brugnara C, et al. **J Clin Invest** 1996 Mar 1;97(5):1227–34. Comment in: J Clin Invest 1996 Mar 1;97(5):1135.

Sickle cell disease: a step closer to the dream [editorial; comment] Mohandas N, et al. **J Clin Invest** 1996 Mar 1; 97(5):1135. Comment on: J Clin Invest 1996 Mar 1;97(5):1227–34.

Mechanism of K+ channel block by verapamil and related

compounds in rat alveolar epithelial cells. DeCoursey TE. **J Gen Physiol** 1995 Oct;106(4):745–79

Synthesis and pharmacological testing of dequalinium analogues as blockers of the apamin-sensitive Ca(2+)-activated K+ channel: variation of the length of the alkylene chain. Galanakis D, et al. **J Med Chem** 1996 Aug 30;39(18):3592–5

Synthesis and quantitative structure-activity relationship of a novel series of small conductance Ca(2+)-activated K+ channel blockers related to dequalinium. Galanakis D, et al. **J Med Chem** 1996 Jan 19;39(2):359–70

Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. Brugnara C, et al. **J Membr Biol** 1995 Sep;147(1):71–82

Quaternary ammonium ion blockade of IK in nerve axons revisited. Open channel block vs. state independent block. Clay JR. **J Membr Biol** 1995 Sep;147(1):23–34

Modulation of the inwardly rectifying K+ channel in isolated human atrial myocytes by alpha 1-adrenergic stimulation. Sato R, et al. **J Membr Biol** 1995 Nov; 148(2):185–91

Ryanodine induced block of a cloned human cardiac potassium channel. Bhattacharyya ML, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1931–5

Evidence for the induction of repetitive action potentials in synaptosomes by K+-channel inhibitors: an analysis of plasma membrane ion fluxes. Tibbs GR, et al. **J Neurochem** 1996 Jul;67(1):389–97

Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. Villarroel A, et al. **J Neurosci** 1996 Feb 1;16(3):1016–25

Selective block of Ca(2+)-dependent K+ current in crayfish neuromuscular system and chromaffin cells by sea anemone Bunodosoma cangicum venom. Araque A, et al. **J Neurosci Res** 1995 Nov 1;42(4):539–46

Blockade of K+ channels induced by AMPA/kainate receptor activation in mouse oligodendrocyte precursor cells is mediated by Na+ entry. Borges K, et al. **J Neurosci Res** 1995 Nov 1;42(4):579–93

Effect of selective inhibition of potassium channels on vasorelaxing response to cromakalim, nitroglycerin and nitric oxide of canine coronary arteries. Pataricza J, et al. **J Pharm Pharmacol** 1995 Nov;47(11):921–5

Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. Bril A, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):637–46

Effect of tolbutamide on the rate of fatigue and recovery in frog sartorius muscle. Comtois A, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1061–6

Effects of Ca2+ and K+ channel blockers on nerve impulses recorded from guinea-pig postganglionic sympathetic nerve terminals. Brock JA, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):389–402

Influence of permeating ions on potassium channel block by external tetraethylammonium. Ikeda SR, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):267–72

The effects of K+ channel blockers on the spontaneous electrical and contractile activity in the proximal renal pelvis of the guinea pig. Lang RJ, et al. **J Urol** 1996 Jan; 155(1):332–6

Inhibitory effect of ethanol on voltage-dependent potassium currents in single aortic smooth muscle cells. Wu SN, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):514–20

Inhibition of cAMP mediated relaxation in rat coronary vessels by block of Ca++ activated K+ channels. Price JM, et al. **Life Sci** 1996;58(24):2225–32

Mapping the block of a cloned human inward rectifier potassium channel by dofetilide. Kiehn J, et al. **Mol Pharmacol** 1996 Aug;50(2):380–7

Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells. Lee K, et al. **Mol Pharmacol** 1996 Apr;49(4):715–20

High affinity open channel block by dofetilide of HERG expressed in a human cell line. Snyders DJ, et al. **Mol Pharmacol** 1996 Jun;49(6):949–55

Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone [letter] Tudor JE, et al. **Nat Struct Biol** 1996 Apr;3(4):317–20

Inhibition of an inwardly rectifying K+ channel by G-protein alpha-subunits. Schreibmayer W, et al. **Nature** 1996 Apr 18;380(6575):624–7

An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Swartz KJ, et al. **Neuron** 1995 Oct;15(4):941–9

Molecular single-cell analysis identifies somatostatin type 1 (sst1) receptors to block inwardly rectifying K+ channels in rat brain oligodendrocytes. Karschin A. **Neuroreport** 1995 Dec 29;7(1):121–4

Diadenosine polyphosphate-induced inhibition of cardiac KATP channels: operative state-dependent regulation by a nucleoside diphosphate. Jovanovic A, et al. **Pflugers Arch** 1996 Mar;431(5):800–2

The Ba2+ block of the ATP-sensitive K+ current of mouse pancreatic beta-cells. Takano M, et al. **Pflugers Arch** 1996 Feb;431(4):625–31

Receptor stimulation causes slow inhibition of IRK1 inwardly rectifying K+ channels by direct protein kinase A-mediated phosphorylation. Wischmeyer E, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5819–23

Solution structure of the potassium channel inhibitor agitoxin 2: caliper for probing channel geometry. Krezel AM, et al. **Protein Sci** 1995 Aug;4(8):1478–89

Putative M-type potassium channels in neuroblastoma-glioma hybrid cells: inhibition by muscarine and bradykinin. Selyanko AA, et al. **Receptors Channels** 1995;3(2):147–59

Effects of glyburide on renal tubule transport and potassium-channel activity. Wang T, et al. **Ren Physiol Biochem** 1995 Jul-Aug;18(4):169–82

Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel. Baukrowitz T, et al. **Science** 1996 Feb 2;271(5249):653–6

Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Webster WS, et al. **Teratology** 1996 Mar;53(3):168–75

Mercury (Hg 2+) enhances the depressant effect of kainate on Ca-inactivated potassium current in telencephalic cells derived from chick embryos. Dyatlov VA, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):285–97

Compared toxicity of the potassium channel blockers, apamin and dendrotoxin. Lallement G, et al. **Toxicology** 1995 Dec 15;104(1-3):47–52

Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Adler M, et al. **Toxicon** 1996 Feb;34(2):237–49

BIOSYNTHESIS

Functional expression and cellular mRNA localization of a G protein-activated K+ inward rectifier isolated from rat brain. Dissmann E, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):474–9

A novel ubiquitously distributed isoform of GIRK2 (GIRK2B) enhances GIRK1 expression of the G-protein-gated K+ current in Xenopus oocytes. Isomoto S, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):286–91

Neural control of the expression of a Ca(2+)-activated K+ channel involved in the induction of myotonic-like characteristics. Ramírez BU, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):39–49

A human pancreatic islet inwardly rectifying potassium channel: cDNA cloning, determination of the genomic structure and genetic variations in Japanese NIDDM patients. Tanizawa Y, et al. **Diabetologia** 1996 Apr; 39(4):447–52

Time, voltage and ionic concentration dependence of rectification of h-erg expressed in Xenopus oocytes. Wang S, et al. **FEBS Lett** 1996 Jul 1;389(2):167–73

Pancreatic islet cells express a family of inwardly rectifying K+ channel subunits which interact to form G-protein-activated channels. Ferrer J, et al. **J Biol Chem** 1995 Nov 3;270(44):26086–91

Cloning and characterization of the promoter for a potassium channel expressed in high frequency firing neurons. Gan L, et al. **J Biol Chem** 1996 Mar 8;271(10):5859–65

GH3 cell-specific expression of Kv1.5 gene. Regulation by a silencer containing a dinucleotide repetitive element. Mori Y, et al. **J Biol Chem** 1995 Nov 17;270(46):27788–96

Transcriptional activation of RACTK1 K+ channel gene by apical alkalization in renal cortical collecting duct cells. Ikeda M, et al. **J Clin Invest** 1996 Jul 15;98(2):474–81

Serotonin and protein kinase C modulation of a rat brain inwardly rectifying K+ channel expressed in xenopus oocytes. DiMagno L, et al. **Pflugers Arch** 1996 Jan; 431(3):335–40

Expression of an Arabidopsis potassium channel gene in guard cells. Nakamura RL, et al. **Plant Physiol** 1995 Oct; 109(2):371–4

CHEMISTRY

Immunological and physical characterization of the brain G protein-gated muscarinic potassium channel. Inanobe A, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1238–44

Structure analysis of a recombinant voltage-gated potassium channel (Kv1.1) N-terminus using FTIR spectroscopy and thermal denaturation. Abbott GW, et al. **Biochem Soc Trans** 1995 Aug;23(3):479S

Sequence analysis and molecular dynamics studies of potassium channel transmembrane helices. Kerr ID, et al. **Biochem Soc Trans** 1995 Aug;23(3):415S

Structural characterisation of a slowly activating potassium channel (IsK). Mercer EA, et al. **Biochem Soc Trans** 1995 Aug;23(3):478S

Probing a potassium channel pore with an engineered protonatable site. Lu Z, et al. **Biochemistry** 1995 Oct 10; 34(40):13133–8

A symmetry-driven search for electrostatic interaction partners in charybdotoxin and a voltage-gated K+ channel. Naini AA, et al. **Biochemistry** 1996 May 21; 35(20):6181–7

Coassembly of synthetic segments of shaker K+ channel within phospholipid membranes. Peled-Zehavi H, et al. **Biochemistry** 1996 May 28;35(21):6828–38

Cooperative subunit interactions in C-type inactivation of K channels. Ogielska EM, et al. **Biophys J** 1995 Dec; 69(6):2449–57

Contributions of a negatively charged residue in the hydrophobic domain of the IRK1 inwardly rectifying K+ channel to K(+)-selective permeation. Reuveny E, et al. **Biophys J** 1996 Feb;70(2):754–61

A random flight chain model for the tether of the Shaker K+ channel inactivation domain. Timpe LC, et al. **Biophys J** 1995 Dec;69(6):2415–8

The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57–66 (37 ref.)

TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure. Lesage F, et al. **EMBO J** 1996 Mar 1;15(5):1004–11

Dominant negative chimeras provide evidence for homo and heteromultimeric assembly of inward rectifier K+ channel proteins via their N-terminal end. Fink M, et al. **FEBS Lett** 1996 Jan 2;378(1):64–8

Molecular determinants of external barium block in Shaker potassium channels. Hurst RS, et al. **FEBS Lett** 1996 Jun 10;388(1):59–65

A calcium switch for the functional coupling between alpha (hslo) and beta subunits (Kv,cabeta) of maxi K channels. Meera P, et al. **FEBS Lett** 1996 Apr 29;385(1-2):127–8

The voltage-dependent K+ channel (Kv1.5) cloned from rabbit heart and facilitation of inactivation of the delayed rectifier current by the rat beta subunit. Sasaki Y, et al. **FEBS Lett** 1995 Sep 18;372(1):20–4

The K+ channel inward rectifier subunits form a channel similar to neuronal G protein-gated K+ channel. Velimirovic BM, et al. **FEBS Lett** 1996 Jan 22;379(1):31–7

Time, voltage and ionic concentration dependence of rectification of h-erg expressed in Xenopus oocytes. Wang S, et al. **FEBS Lett** 1996 Jul 1;389(2):167–73

A weakly inward rectifying potassium channel of the salmon brain. Glutamate 179 in the second transmembrane domain is insufficient for strong rectification. Kubo Y, et al. **J Biol Chem** 1996 Jun 28;271(26):15729–35

A pH-sensitive yeast outward rectifier K+ channel with two pore domains and novel gating properties. Lesage F, et al. **J Biol Chem** 1996 Feb 23;271(8):4183–7

Shaker K+ channel T1 domain self-tetramerizes to a stable structure. Pfaffinger PJ, et al. **J Biol Chem** 1995 Dec 1; 270(48):28595–600

Voltage-gated K+ channels contain multiple intersubunit association sites. Tu L, et al. **J Biol Chem** 1996 Aug 2; 271(31):18904–11

Assembly of voltage-gated potassium channels. Conserved hydrophilic motifs determine subfamily-specific interactions between the alpha-subunits. Xu J, et al. **J Biol Chem** 1995 Oct 20;270(42):24761–8

Structural motifs underlying voltage-dependent K+ channel function. Taglialatela M, et al. **Kidney Int** 1995 Oct; 48(4):918–22 (80 ref.)

Picture story. Probing the pore. Riddihough G. **Nat Struct Biol** 1996 Feb;3(2):121

Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Aiyar J, et al. **Neuron** 1995 Nov;15(5):1169–81

Dynamic rearrangement of the outer mouth of a K+ channel during gating. Liu Y, et al. **Neuron** 1996 Apr;16(4):859–67

Conversion of a delayed rectifier K+ channel to a voltage-gated inward rectifier K+ channel by three amino acid substitutions. Miller AG, et al. **Neuron** 1996 Apr; 16(4):853–8

A strongly interacting pair of residues on the contact surface of charybdotoxin and a Shaker K+ channel. Naranjo D, et al. **Neuron** 1996 Jan;16(1):123–30

Spatial localization of the K+ channel selectivity filter by mutant cycle-based structure analysis. Ranganathan R, et al. **Neuron** 1996 Jan;16(1):131–9

Identification of structural elements involved in G protein gating of the GIRK1 potassium channel. Slesinger PA, et al. **Neuron** 1995 Nov;15(5):1145–56

Determination of the subunit stoichiometry of an inwardly rectifying potassium channel. Yang J, et al. **Neuron** 1995 Dec;15(6):1441–7

Evidence that plant K+ channel proteins have two different types of subunits. Tang H, et al. **Plant Physiol** 1995 Sep; 109(1):327–30

Three distinct structural environments of a transmembrane domain in the inwardly rectifying potassium channel ROMK1 defined by perturbation. Choe S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12046–9

A structural motif for the voltage-gated potassium channel pore. Lipkind GM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9215–9

Mutation of conserved negatively charged residues in the S2 and S3 transmembrane segments of a mammalian K+ channel selectively modulates channel gating. Planells-Cases R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9422–6

Subunit-dependent assembly of inward-rectifier K+ channels. Glowatzki E, et al. **Proc R Soc Lond B Biol Sci** 1995 Aug 22;261(1361):251–61

Secondary structure prediction of the H5 pore of potassium channels. Soman KV, et al. **Protein Eng** 1995 Apr; 8(4):397–401

Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor [see comments] Inagaki N, et al. **Science** 1995 Nov 17;270(5239):1166–70. Comment in: Science 1995 Nov 17;270(5239):1159.

Direct physical measure of conformational rearrangement underlying potassium channel gating. Mannuzzu LM, et al. **Science** 1996 Jan 12;271(5246):213–6

[Primary structure and biophysical properties of inward

rectifier K+ channels] Kubo Y.
Tanpakushitsu Kakusan Koso 1995 Nov;40(15):2288–96 (37 ref.) **(Jpn)**

CLASSIFICATION

Two types of A-channels in Lymnaea neurons. Alekseev SI, et al. **J Membr Biol** 1995 Aug;146(3):327–41
Cultured giant fiber lobe of squid expresses three distinct potassium channel activities in selective combinations. Griggs WD, et al. **J Membr Biol** 1996 Jul;152(1):25–37

DRUG EFFECTS

Effects of thiol-modifying agents on KATP channels in guinea pig ventricular cells. Coetzee WA, et al.
Am J Physiol 1995 Nov;269(5 Pt 2):H1625–33
ATP-sensitive K+ channel opener pinacidil augments beta 1-adrenoceptor-induced coronary vasodilation in dogs. Katsuda Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2210–5
Regulation of ATP-sensitive K+ channel by membrane-bound protein phosphatases in rat principal tubule cell. Kubokawa M, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):F355–62
Inhibition of a fast inwardly rectifying potassium conductance by barbiturates. Gibbons SJ, et al.
Anesth Analg 1996 Jun;82(6):1242–6
Myocardial protection with potassium-channel openers is as effective as St. Thomas' solution in the rabbit heart. Lawton JS, et al. **Ann Thorac Surg** 1996 Jul;62(1):31–8; discussion 38–9
Calcitonin gene-related peptide activates the K+ channels of vascular smooth muscle cells via adenylate cyclase. Miyoshi H, et al. **Basic Res Cardiol** 1995 Jul–Aug; 90(4):332–6
Modulation of K+ channel currents by serum amineoxidase in neurons. Wu L, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):47–52
Effects of inhibitors and activators of ATP-regulated K+ channel on mitochondrial potassium uniport. Szewczyk A, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):477–84
Propofol blocks voltage-gated potassium channels in human T lymphocytes. Mozrzymas JW, et al.
Biochem Pharmacol 1996 Sep 27;52(6):843–9
Exogenous heat shock protein hsp70 activates potassium channels in U937 cells. Negulyaev YA, et al.
Biochim Biophys Acta 1996 Jun 13;1282(1):156–62
Recovery from C-type inactivation is modulated by extracellular potassium. Levy DI, et al. **Biophys J** 1996 Feb;70(2):798–805
Halothane and potassium channels in airway smooth muscle. Fukushima T, et al. **Br J Anaesth** 1996 Jun;76(6):847–53
Effects of BRL55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide-resistant, ATP-sensitive potassium current. Edwards G, et al.
Br J Pharmacol 1995 Jul;115(6):1027–37
Comparison of the effects of fenamates on Ca-activated chloride and potassium currents in rabbit portal vein smooth muscle cells. Greenwood IA, et al.
Br J Pharmacol 1995 Dec;116(7):2939–48
SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells. Hara Y, et al. **Br J Pharmacol** 1995 Nov;116(6):2750–6
Endothelin-1-induced reduction of myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. Hide EJ, et al. **Br J Pharmacol** 1995 Nov;116(6):2597–602
The lack of a role for potassium channel opening in the action of relaxin in the rat isolated uterus; a comparison with levcromakalim and salbutamol. Hughes SJ, et al.
Br J Pharmacol 1996 Apr;117(7):1435–42
Effect of KC399, a newly synthesized K+ channel opener, on acetylcholine-induced electrical and mechanical activities in rabbit tracheal smooth muscle. Kamei K, et al. **Br J Pharmacol** 1995 Aug;115(8):1493–501
Direct demonstration of sulphonylurea-sensitive KATP channels on nerve terminals of the rat motor cortex. Lee K, et al. **Br J Pharmacol** 1995 Jun;115(3):385–7
Potentiation of P1075-induced K+ channel opening by stimulation of adenylate cyclase in rat isolated aorta. Linde C, et al. **Br J Pharmacol** 1995 Jun;115(3):515–21
A comparison of the effects of SCA40, NS 004 and NS 1619 on large conductance Ca(2+)-activated K+ channels in bovine tracheal smooth muscle cells in culture. Macmillan S, et al. **Br J Pharmacol** 1995 Sep;116(1):1656–60
Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells. Nakazawa K, et al.
Br J Pharmacol 1995 Nov;116(6):2603–10
Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels. Sato T, et al.
Br J Pharmacol 1995 Jun;115(3):381–2
Activation or block of adenosine triphosphate-sensitive potassium channel have opposite effects on postcardioplegic myocardial dysfunction, "stunning". A multivariate prediction based on relative operating characteristic curve. Puddu PE, et al. **Cardiologia** 1995 Sep; 40(9):667–77
Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs. Liu Q, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):23–30
KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Ferdinandy P, et al. **Cardiovasc Res** 1995 Nov;30(5):781–7
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Grover GJ, et al. **Cardiovasc Res** 1995 Nov;30(5):731–8
Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1–17 (94 ref.)
Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Kondo T, et al. **Cardiovasc Res** 1996 May;31(5):683–7
ATP-sensitive potassium channels, transmural ischemia and the ECG implications for the non-insulin dependent diabetic patient? [editorial] Wilde AA. **Cardiovasc Res** 1996 May;31(5):688–90
Novel potassium channel activators: synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives. Matsumoto Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):103–14
Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers. Yamamoto S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):734–45
Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Archer SL, et al. **Circ Res** 1996 Mar;78(3):431–42
Cloned human inward rectifier K+ channel as a target for class III methanesulfonanilides. Kiehn J, et al. **Circ Res** 1995 Dec;77(6):1151–5
Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Liu Y, et al. **Circ Res** 1996 Mar; 78(3):443–54
Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. White RE, et al. **Circ Res** 1995 Nov;77(5):936–42
The effects of nitric oxide on the membrane potential and ionic currents of mouse pancreatic B cells. Krippeit-Drews P, et al. **Endocrinology** 1995 Dec;136(12):5363–9
Noradrenaline increases K-conductance and reduces glutamatergic transmission in the mouse entorhinal cortex by activation of alpha 2-adrenoreceptors. Pralong E, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2370–8
Differential vasorelaxant effects of levcromakalim and P1060 in the isolated KCl- and RbCl-precontracted human saphenous vein: possible involvement of intracellular Ca2+ stores. Criddle DN, et al. **Eur J Pharmacol** 1995 Nov 14; 286(2):123–30
Comparative effects of K+ channel modulating agents on contractions of rat intestinal smooth muscle. Davies MP, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):249–56
The effect of K+ channel openers on submucosal gland function and epithelial transport of the ferret trachea, in vitro. Griffin A. **Eur J Pharmacol** 1995 Jul 14;280(3):317–25
The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts. Grover GJ, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):271–4
Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). Herzer T, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):205–8
K+ channel blockers do not modify relaxation of guinea-pig uterine artery evoked by acetylcholine. Jovanović A, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):95–100
NS 1619 activates BKCa channel activity in rat cortical neurones. Lee K, et al. **Eur J Pharmacol** 1995 Jul 4; 280(2):215–9
Cromakalim- and RP 49356-induced 42K+ and 86Rb+ efflux in rat myometrium. Piper IT, et al.
Eur J Pharmacol 1995 Sep 5;283(1-3):1–8
K+ channel openers delay intestinal transit and have antidiarrheal activity. Poggioli R, et al.
Eur J Pharmacol 1995 Dec 12;287(2):207–9
Effects of K+ channel blockers and openers on antinociception induced by agonists of 5-HT1A receptors. Robles LI, et al. **Eur J Pharmacol** 1996 Jan 11; 295(2-3):181–8
Possible mechanism of oxygen radical production by human eosinophils mediated by K+ channel activation. Saito M, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):217–9
Ca(2+)-activated outward-rectifier K+ channels and histamine release by rat gastric enterochromaffin-like cells. Sakai H, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):153–8
Modulation of Ca(2+)-activated K+ channel activity by tyrosine kinase inhibitors in vascular smooth muscle cell. Xiong Z, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):117–23
Antiarrhythmic and bradycardic drugs inhibit currents of cloned K+ channels, KV1.2 and KV1.4. Yamagishi T, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):151–9
M-type K+ current inhibition by a toxin fron the scorpion Buthus eupeus. Filippov AK, et al. **FEBS Lett** 1996 Apr 22;384(3):277–80
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. Suessbrich H, et al. **FEBS Lett** 1996 Apr 29; 385(1-2):77–80
Effect of exercise and 2-deoxyglucose on the K+ channel opener action of CGRP in the guinea pig ureter. Maggi CA, et al. **Gen Pharmacol** 1996 Jan;27(1):95–100
The effect of AL0671, a novel potassium channel opener, on potassium current in rat aortic smooth muscle cells. Matzno S, et al. **Gen Pharmacol** 1995 Oct;26(6):1327–34
Diazepam decreases the response to the electrical stimulation of the nerve-skin preparation of the toad Caudiverbera caudiverbera. Norris B, et al. **Gen Pharmacol** 1995 Nov; 26(7):1607–11
Endothelin-1 inhibition of the ATP-sensitive K+ channel in guinea-pig ventricular cardiomyocytes. Satoh H.
Gen Pharmacol 1995 Nov;26(7):1549–52
Tetraethylammonium effects on cochlear potentials in the guinea pig. van Emst MG, et al. **Hear Res** 1995 Aug; 88(1-2):27–35
Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats. Ohya Y, et al. **Hypertension** 1996 Jun; 27(6):1234–9
Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance. Ujhelyi MR, et al.
J Am Coll Cardiol 1996 May;27(6):1534–42
ATP-sensitive K+ channel blockade impairs O2 extraction during progressive ischemia in pig hindlimb. Vallet B, et al. **J Appl Physiol** 1995 Dec;79(6):2035–42
Prostaglandin E2 stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability. Li Q, et al. **J Biol Chem** 1996 Aug 2; 271(31):18651–6
Cesium and the pacemaker current [letter] DiFrancesco D. **J Cardiovasc Electrophysiol** 1995 Dec;6(12):1152–5
Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. Akai K, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):541–7
Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. Grover GJ, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):145–52
Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution. Grover GJ, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):698–706
Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine. Izumi H, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):189–97
Endothelin-1 partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells. Kobayashi S, et al.
J Cardiovasc Pharmacol 1996 Jan;27(1):12–9
K+ channel-opening properties of a novel compound, NIP-121, in guinea pig myocardium as compared with those of cromakalim. Matsuda T, et al.
J Cardiovasc Pharmacol 1995 Oct;26(4):608–13
Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia. Miyazaki T, et al.
J Cardiovasc Pharmacol 1995 Dec;26(6):949–56
Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia. Rees SA, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):280–8
Cardiovascular effects of the novel potassium channel opener UR-8225. Tamargo J, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):295–305
Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. Uematsu T, et al. **J Clin Pharmacol** 1996 May;36(5):439–51
Effect of arachidonic acid on activity of the apical K+ channel in the thick ascending limb of the rat kidney. Wang W, et al. **J Gen Physiol** 1995 Oct;106(4):727–43
No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension. Ligtenberg JJ, et al. **J Hum Hypertens** 1996 Apr;10(4):269–76
Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al.
J Hum Hypertens 1995 Aug;9(8):691–3 (22 ref.)
Regulation of calcium-activated potassium channels by S-nitrosothiol compounds and cyclic guanosine monophosphate in rabbit coronary artery myocytes. George MJ, et al. **J Investig Med** 1995 Oct;43(5):451–8
cGMP modulates transport across the ciliary epithelium. Carré DA, et al. **J Membr Biol** 1995 Aug;146(3):293–305
NaF potentiates a K(+)-selective ion channel in G292 osteoblastic cells. Gofa A, et al. **J Membr Biol** 1996 Feb; 149(3):211–9
DIDS increases K+ secretion through an IsK channel in apical membrane of vestibular dark cell epithelium of gerbil. Shen Z, et al. **J Membr Biol** 1995 Aug;146(3):283–91
The high-affinity sulphonylurea receptor regulates KATP channels in nerve terminals of the rat motor cortex. Lee K, et al. **J Neurochem** 1996 Jun;66(6):2562–71
Relationship between changes of glomus cell current and neural response of rat carotid body. Cheng PM, et al.
J Neurophysiol 1995 Nov;74(5):2077–86
Cholecystokinin depolarizes rat thalamic reticular neurons by suppressing a K+ conductance. Cox CL, et al.
J Neurophysiol 1995 Sep;74(3):990–1000
Diverse current and voltage responses to baclofen in an identified molluscan photoreceptor. Matzel LD, et al.
J Neurophysiol 1995 Aug;74(2):506–18
Effects of glucose deprivation on NMDA-induced current

and intracellular Ca2+ in rat substantia nigra neurons. Nakashima Y, et al. **J Neurophysiol** 1996 Feb;75(2):740–9

Acetylcholine–induced potassium current of guinea pig outer hair cells: its dependence on a calcium influx through nicotinic–like receptors. Blanchet C, et al. **J Neurosci** 1996 Apr 15;16(8):2574–84

Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor–mediated K+ channel block. Gallo V, et al. **J Neurosci** 1996 Apr 15;16(8):2659–70

[Ca2+]i elevations detected by BK channels during Ca2+ influx and muscarine–mediated release of Ca2+ from intracellular stores in rat chromaffin cells. Prakriya M, et al. **J Neurosci** 1996 Jul 15;16(14):4344–59

Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. Villarroel A, et al. **J Neurosci** 1996 Apr 15;16(8):2522–32

Inhibition of the ATP–sensitive potassium channel in the guinea pig substantia nigra by BMS 181100 is not mediated by a sigma–binding site. O'Callaghan JF, et al. **J Neurosci Res** 1995 Sep 1;42(1):85–96

5–HT3 receptor–independent inhibition of the depolarization–induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron. Toral J, et al. **J Pharm Pharmacol** 1995 Jul;47(7):618–22

Dual actions of the novel class III antiarrhythmic drug NE–10064 on delayed potassium channel currents in guinea pig ventricular and sinoatrial node cells. Davies MP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1149–54

Pinacidil relaxes porcine and human coronary arteries by activating ATP–dependent potassium channels in smooth muscle cells. Gollasch M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):681–92

BMS–180448, a novel glyburide–reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs. Grover GJ, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):380–7

KR–30450, a newly synthesized benzopyran derivative, activates the cardiac ATP–sensitive K+ channel. Kwak YG, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):807–12

Activation of ATP–dependent K+ channels and inhibition of insulin release: effect of BPDZ 62. Lebrun P, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):156–62

Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes. McLarnon JG, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):389–96

A G protein, not cyclic AMP, mediates effects of VIP on the inwardly rectifying K+ channels in endothelial cells. Pasyk EA, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):690–6

The actions of prostaglandin E2 on potassium currents in rat tail artery vascular smooth muscle cells: regulation by protein kinase A and protein kinase C. Ren J, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):394–402

Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. Ren J, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):710–9

Intracellular [Mg++] determines specificity of K+ channel block by a class III antiarrhythmic drug. Sudo GZ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):951–7

Diabetes and ATP–sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. Tosaki A, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1115–23

Depolarization–induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)

Effect of isosorbiddinitrate on exogenously expressed slowly activating K+ channels and endogenous K+ channels in Xenopus oocytes. Busch AE, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):735–41

A rate theory model for Mg2+ block of ATP–dependent potassium channels of rat skeletal muscle. Davies NW, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):817–26

Distinct effects of Ca2+ and voltage on the activation and deactivation of cloned Ca(2+)–activated K+ channels. DiChiara TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):403–18

Inhibition of ACh release at an Aplysia synapse by neurotoxic phospholipases A2: specific receptors and mechanisms of action. Fossier P, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):29–40

Enhancement of delayed rectifier K+ current by P2–purinoceptor stimulation in guinea–pig atrial cells. Matsuura H, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):647–58

Activation of the muscarinic K+ channel by P2–purinoceptors via pertussis toxin–sensitive G proteins in guinea–pig atrial cells. Matsuura H, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):659–71

Activation by intracellular ATP of a potassium channel in neurones from rat basomedial hypothalamus. Rowe IC, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):97–113

Osmo– and mechanosensitivity of the transient outward K+ current in a mammalian neuronal cell line. Schoenmakers TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):419–30

Potassium channel openers prevent potassium–induced calcium loading of cardiac cells: possible implications in cardioplegia. López JR, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):820–31

Hyperpolarized cardiac arrest with a potassium–channel opener, aprikalim. Maskal SL, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1083–95

Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection? Menasché P, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1606–13; discussion 1613–4

Effects of potassium channel modulators cromakalim, tetraethylammonium and glibenclamide on the contractility of the isolated human ureter. de Moura RS, et al. **J Urol** 1996 Jul;156(1):276–80

Effects of Y–26763, a novel K–channel opener, on electrical responses of smooth muscles in the guinea pig bladder. Hashitani H, et al. **J Urol** 1996 Apr;155(4):1454–8

Comparative study of vasodilator effects of the potassium channel openers NIP–121 and levcromakalim in dogs and rats. Yamashita T, et al. **Jpn J Pharmacol** 1995 Jun; 68(2):145–52

Effect of d–sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d–Sotalol. Waldo AL, et al. **Lancet** 1996 Jul 6; 348(9019):7–12

Reciprocal modulation of ATP–sensitive K+ channel activity in rat ventricular myocytes by phosphorylation of tyrosine and serine/threonine residues. Kwak YG, et al. **Life Sci** 1996;58(11):897–904

Potassium channel activation by glutathione–S–conjugates in Escherichia coli: protection against methylglyoxal is mediated by cytoplasmic acidification. Ferguson GP, et al. **Mol Microbiol** 1995 Sep;17(6):1025–33

Ethanol increases the activity of large conductance, Ca(2+)–activated K+ channels in isolated neurohypophysial terminals. Dopico AM, et al. **Mol Pharmacol** 1996 Jan;49(1):40–8

Novel pharmacological properties of transient potassium currents in central neurons revealed by N–bromoacetamide and other chemical modifiers. Huang RC. **Mol Pharmacol** 1995 Sep;48(3):451–8

Suppression of two cloned smooth muscle–derived delayed rectifier potassium channels by cholinergic agonists and phorbol esters. Vogalis F, et al. **Mol Pharmacol** 1995 Dec; 48(6):1015–23

Characterization of the sensitivity of cardiac outwardly–rectifying K+ channels to class III antiarrhythmics: the influence of inhibitory sulfonamide derivatives. Benz I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):313–21

Patch clamp study of histamine activated potassium currents on rabbit olfactory bulb neurons. Jahn K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):386–93

Cardiac ATP–sensitive K+ channel: a target for diadenosine 5',5''–P1,P5–pentaphosphate. Jovanovic A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):241–4

Differential effects of organotin compounds on voltage–gated potassium currents in lymphocytes and neuroblastoma cells. Oortgiesen M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):136–43

Modulation of K+ current by frequency and external [K+]: a tale of two inactivation mechanisms. Baukrowitz T, et al. **Neuron** 1995 Oct;15(4):951–60

Intracellular calcium directly inhibits potassium M channels in excised membrane patches from rat sympathetic neurons. Selyanko AA, et al. **Neuron** 1996 Jan;16(1):151–62

MinK residues line a potassium channel pore. Wang KW, et al. **Neuron** 1996 Mar;16(3):571–7

Adenosine activates the potassium channel via a P2 purinoceptor but not via an adenosine receptor in cultured rat superior colliculus neurons. Ikeuchi Y, et al. **Neurosci Lett** 1995 Oct 6;198(3):205–8

Involvement of potassium and calcium channels at the locus coeruleus in fentanyl–induced muscular rigidity in the rat. Lee TY, et al. **Neurosci Lett** 1995 Oct 27;199(3):195–8

Effects of potassium channel openers in isolated human cerebral arteries. Hempelmann RG, et al. **Neurosurgery** 1995 Dec;37(6):1146–53

Caffeine enhancement of electrical activity through direct blockade of inward rectifying K+ currents in GH3 rat anterior pituitary cells. Barros F, et al. **Pflugers Arch** 1996 Jan;431(3):443–51

Functional linkage of the cardiac ATP–sensitive K+ channel to the actin cytoskeleton. Furukawa T, et al. **Pflugers Arch** 1996 Feb;431(4):504–12

Activation of ATP–sensitive potassium channels in follicle–enclosed xenopus oocytes by the epileptogenic agent pentylenetetrazol. Klöcker N, et al. **Pflugers Arch** 1996 Mar;431(5):736–40

Modulation of Ca2+–activated K+ channels by Mg2+ and ATP in frog oxyntic cells. Komatsu H, et al. **Pflugers Arch** 1996 Feb;431(4):494–503

Immature properties of large–conductance calcium–activated potassium channels in rat neuroepithelium. Mienville JM, et al. **Pflugers Arch** 1996 Mar;431(5):763–70

Modulation of delayed rectifier K+ channel activity by external K+ ions in Xenopus axon. Safronov BV, et al. **Pflugers Arch** 1995 Oct;430(6):879–86

The role of ATP–sensitive potassium channels in striatal dopamine release: an in vivo microdialysis study. Tanaka T, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):831–5

Activators of sodium, calcium and potassium channels modulate the cardiac effects of quinidine in vitro. Brasch H. **Pharmacol Toxicol** 1995 Nov;77(5):346–51

Inhibition of ATP–sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS–551. Martin DK, et al. **Pharmacol Toxicol** 1995 Jul; 77(1):65–70

Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor. Li JH, et al. **Pharmacology** 1995 Jun; 51(1):33–42

K–channel opening activity of ZD6169 and its analogs: effect on 86Rb efflux and 3H–P1075 binding in bladder smooth muscle. Trivedi S, et al. **Pharmacology** 1995 Jun; 50(6):388–97

Guanidine derivative U–37883A, inhibits mitochondrial K+ uniport. Szewczyk A, et al. **Pol J Pharmacol** 1995 Jul–Aug; 47(4):339–44

Sensitivity to abscisic acid of guard–cell K+ channels is suppressed by abi1–1, a mutant Arabidopsis gene encoding a putative protein phosphatase. Armstrong F, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9520–4

Solution structure of P01, a natural scorpion peptide structurally analogous to scorpion toxins specific for apamin–sensitive potassium channel. Blanc E, et al. **Proteins** 1996 Mar;24(3):359–69

Scorpion venoms: taking the sting out of lung disease. Rogers DF. **Thorax** 1996 May;51(5):546–8 (12 ref.)

Mercury (Hg 2+) enhances the depressant effect of kainate on Ca–inactivated potassium current in telencephalic cells derived from chick embryos. Dyatlov VA, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):285–97

Structure–activity studies on scorpion toxins that block potassium channels. Harvey AL, et al. **Toxicon** 1995 Apr; 33(4):425–36

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

The effects of glibenclamide, a blocker of K+ ATP–sensitive potassium channels, on diaphragmatic fatigue during endotoxaemia in pigs. Aguggini G, et al. **Vet Res Commun** 1996;20(2):183–90

[Inhibitory effect of tocainide on calcium current and potassium current in guinea pig ventricular myocytes] Wu BW, et al. **Yao Hsueh Hsueh Pao** 1995;30(6):412–6 (Eng. Abstr.) **(Chi)**

[Anomalous transport of cations upon stimulation of a Ca–dependent K–channel in rehydrated erythrocytes] Rudenko SV, et al. **Biokhimiia** 1995 Jul;60(7):1146–54 (Eng. Abstr.) **(Rus)**

[Effect of chlorofos on high–threshold potassium and calcium channels in the neuronal membrane] Bukanova IuV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):59–62 **(Rus)**

[The effect of docosatrienoic acid on the potassium channels of outward rectification in the membrane of rat peritoneal macrophages] Krutetskaia ZI, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):111–9 (Eng. Abstr.) **(Rus)**

[The effect of adriamycin and ethidium bromide on the Ca2(+)–dependent K channel of human erythrocytes] Davtian TK, et al. **Tsitologiia** 1996;38(2):135–44 (Eng. Abstr.) **(Rus)**

GENETICS

Inactivation of the first nucleotide–binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. Thomas PM, et al. **Am J Hum Genet** 1996 Sep;59(3):510–8

A human calcium–activated potassium channel gene expressed in vascular smooth muscle. McCobb DP, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H767–77

Genomic structure and regulation of Kcn1, a cGMP–gated potassium channel. Yao X, et al. **Am J Physiol** 1996 Jul; 271(1 Pt 2):F37–41

In situ hybridization reveals extensive diversity of K+ channel mRNA in isolated ferret cardiac myocytes. Brahmajothi MV, et al. **Circ Res** 1996 Jun;78(6):1083–9

Differential response to Na+ channel blockade, beta–adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long–QT syndrome. Priori SG, et al. **Circ Res** 1996 Jun;78(6):1009–15

Anti–minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Yang T, et al. **Circ Res** 1995 Dec;77(6):1246–53

Missense mutation in the pore region of HERG causes familial long QT syndrome. Benson DW, et al. **Circulation** 1996 May 15;93(10):1791–5

Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene–specific therapy [see comments] Schwartz PJ, et al. **Circulation** 1995 Dec 15;92(12):3381–6 . Comment in: Circulation 1995 Dec 15;92(12):3373–5.

The inward rectifier potassium channel family. Doupnik CA, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):268–77 (86 ref.)

Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Inoue H, et al. **Diabetes** 1996 Jun;45(6):825–31

Identification of microsatellite markers near the human genes encoding the beta–cell ATP–sensitive K+ channel and linkage studies with NIDDM in Japanese. Iwasaki N, et al. **Diabetes** 1996 Feb;45(2):267–9

Mitochondrial FAD-glycerophosphate dehydrogenase and G-protein-coupled inwardly rectifying K+ channel: No evidence for linkage in maturity-onset diabetes of the young or NIDDM. Warren-Perry MG, et al. **Diabetes** 1996 May;45(5):639-41

Linkage studies in NIDDM with markers near the sulphonylurea receptor gene. Stirling B, et al. **Diabetologia** 1995 Dec;38(12):1479-81

A human pancreatic islet inwardly rectifying potassium channel: cDNA cloning, determination of the genomic structure and genetic variations in Japanese NIDDM patients. Tanizawa Y, et al. **Diabetologia** 1996 Apr; 39(4):447-52

Distribution of mRNA encoding the inwardly rectifying K+ channel, BIR1 in rat tissues. Dixon AK, et al. **FEBS Lett** 1995 Oct 23;374(1):135-40

Isolation of an ion channel gene from Arabidopsis thaliana using the H5 signature sequence from voltage-dependent K+ channels. Ketchum KA, et al. **FEBS Lett** 1996 Jan 2;378(1):19-26

Functional expression of the plant K+ channel KAT1 in insect cells. Marten I, et al. **FEBS Lett** 1996 Feb 19; 380(3):229-32

Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. Sakura H, et al. **FEBS Lett** 1995 Dec 27;377(3):338-44

The use of the rat LAP LCR and promoter for the high-level constitutive expression of K+ channel cDNAs in a rat liver cell line. Shelton PA, et al. **FEBS Lett** 1996 Aug 12;391(3):282-6

The weaver mutation changes the ion selectivity of the affected inwardly rectifying potassium channel GIRK2. Tong Y, et al. **FEBS Lett** 1996 Jul 15;390(1):63-8

Heteromeric channel formation and Ca(2+)-free media reduce the toxic effect of the weaver Kir 3.2 allele. Tucker SJ, et al. **FEBS Lett** 1996 Jul 29;390(3):253-7

YKC1 encodes the depolarization-activated K+ channel in the plasma membrane of yeast. Zhou XL, et al. **FEBS Lett** 1995 Oct 9;373(2):170-6

The lobster shaw gene: cloning, sequence analysis and comparison to fly shaw. Baro DJ, et al. **Gene** 1996 May 8;170(2):267-70

Cloning and functional expression of a human gene, hIRK1, encoding the heart inward rectifier K+-channel. Wood LS, et al. **Gene** 1995 Oct 3;163(2):313-7

A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Auburger G, et al. **Genomics** 1996 Jan 1;31(1):90-4

cDNA sequence, gene structure, and chromosomal localization of the human ATP-sensitive potassium channel, uKATP-1, gene (KCNJ8). Inagaki N, et al. **Genomics** 1995 Nov 1;30(1):102-4

Assignment of human G-protein-coupled inward rectifier K+ channel homolog GIRK3 gene to chromosome 1q21-q23. Lesage F, et al. **Genomics** 1995 Oct 10; 29(3):808-9

Molecular genetic analysis of distal mouse chromosome 6 defines gene order and positions of the deafwaddler and opisthotonos mutations. Street VA, et al. **Genomics** 1995 Sep 1;29(1):123-30

Assignment of KATP-1, the cardiac ATP-sensitive potassium channel gene (KCNJ5), to human chromosome 11q24. Tucker SJ, et al. **Genomics** 1995 Jul 1;28(1):127-8

Identification of a Ser857-Asn857 substitution in DRK1 (KCNB1), population frequencies and lack of association to the low voltage alpha EEG trait. Mazzanti CM, et al. **Hum Genet** 1996 Aug;98(2):134-7

Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Browne DL, et al. **Hum Mol Genet** 1995 Sep;4(9):1671-2

Expression and function of voltage-dependent potassium channel genes in human airway smooth muscle. Adda S, et al. **J Biol Chem** 1996 May 31;271(22):13239-43

A novel K+ channel beta-subunit (hKv beta 1.3) is produced via alternative mRNA splicing. England SK, et al. **J Biol Chem** 1995 Dec 1;270(48):28531-4

Cloning and characterization of the promoter for a potassium channel expressed in high frequency firing neurons. Gan L, et al. **J Biol Chem** 1996 Mar 8;271(10):5859-65

Molecular properties of neuronal G-protein-activated inwardly rectifying K+ channels. Lesage F, et al. **J Biol Chem** 1995 Dec 1;270(48):28660-7

GH3 cell-specific expression of Kv1.5 gene. Regulation by a silencer containing a dinucleotide repetitive element. Mori Y, et al. **J Biol Chem** 1995 Nov 17;270(46):27788-96

Immunochemical characterization and developmental expression of Shaker potassium channels from the nervous system of Drosophila. Rogero O, et al. **J Biol Chem** 1995 Oct 27;270(43):25746-51

Characterization of the transcription unit of mouse Kv1.4, a voltage-gated potassium channel gene. Wymore RS, et al. **J Biol Chem** 1996 Jun 28;271(26):15629-34

Increased resistance to extracellular cation block by mutation of the pore domain of the Arabidopsis inward-rectifying K+ channel KAT1. Ichida AM, et al. **J Membr Biol** 1996 May;151(1):53-62

N-type inactivation in the mammalian Shaker K+ channel Kv1.4. Lee TE, et al. **J Membr Biol** 1996 Jun;151(3):225-35

A strongly inwardly rectifying K+ channel that is sensitive to ATP. Collins A, et al. **J Neurosci** 1996 Jan;16(1):1-9

Temporal regulation of Shaker- and Shab-like potassium channel gene expression in single embryonic spinal neurons during K+ current development. Gurantz D, et al. **J Neurosci** 1996 May 15;16(10):3287-95

IRK(1-3) and GIRK(1-4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. Karschin C, et al. **J Neurosci** 1996 Jun 1;16(11):3559-70

A unique P-region residue is required for slow voltage-dependent gating of a G protein-activated inward rectifier K+ channel expressed in Xenopus oocytes. Kofuji P, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):633-45

High-resolution mapping of the genes Kcnb3 and Ly63 on distal mouse chromosome 4. Coleman MP, et al. **Mamm Genome** 1996 Jul;7(7):552-3

Coexpression with potassium channel subunits used to clone the Y2 receptor for neuropeptide Y. Rimland JM, et al. **Mol Pharmacol** 1996 Mar;49(3):387-90

Third and long (QT) [editorial] **Nat Genet** 1996 Jan;12(1):1-2

Tune into the weaver channel [news; comment] Goldowitz D, et al. **Nat Genet** 1995 Oct;11(2):107-9. Comment on: Nat Genet 1995 Oct;11(2):126-9.

A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation [see comments] Patil N, et al. **Nat Genet** 1995 Oct;11(2):126-9 . Comment in: Nat Genet 1995 Oct;11(2):107-9.

Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Wang Q, et al. **Nat Genet** 1996 Jan;12(1):17-23

Functional analysis of the weaver mutant GIRK2 K+ channel and rescue of weaver granule cells. Kofuji P, et al. **Neuron** 1996 May;16(5):941-52

Surfing the DNA databases for K+ channels nets yet more diversity. Salkoff L, et al. **Neuron** 1995 Sep;15(3):489-92 (35 ref.)

Beta subunits promote K+ channel surface expression through effects early in biosynthesis. Shi G, et al. **Neuron** 1996 Apr;16(4):843-52

Molecular physiology of cardiac potassium channels. Deal KK, et al. **Physiol Rev** 1996 Jan;76(1):49-67 (186 ref.)

Organization and expression of the gene coding for the potassium transport system AKT1 of Arabidopsis thaliana. Basset M, et al. **Plant Mol Biol** 1995 Dec;29(5):947-58

Multiple genes, tissue specificity, and expression-dependent modulationcontribute to the functional diversity of potassium channels in Arabidopsis thaliana. Cao Y, et al. **Plant Physiol** 1995 Nov;109(3):1093-106

Evidence that plant K+ channel proteins have two different types of subunits. Tang H, et al. **Plant Physiol** 1995 Sep; 109(1):327-30

Primary structure and functional expression of a cGMP-gated potassium channel. Yao X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11711-5

The molecular organization of voltage-dependent K+ channels in vivo. Sheng M, et al. **Prog Brain Res** 1995; 105:87-93 (30 ref.)

A multigene family of novel K+ channels from Paramecium tetraurelia. Jegla T, et al. **Receptors Channels** 1995; 3(1):51-60

HERG sequence correction [letter] Trudeau MC, et al. **Science** 1996 May 24;272(5265):1087

IMMUNOLOGY

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves [see comments] Shillito P, et al. **Ann Neurol** 1995 Nov; 38(5):714-22. Comment in: Ann Neurol 1995 Nov;38(5):701-2.

ISOLATION & PURIFICATION

Immunohistochemical localization of a Shaker-related voltage-gated potassium channel protein in Schistosoma mansoni (Trematoda: Digenea). Kim E, et al. **Exp Parasitol** 1995 Dec;81(4):421-9

Molecular and functional characterization of a rat brain Kv beta 3 potassium channel subunit. Heinemann SH, et al. **FEBS Lett** 1995 Dec 27;377(3):383-9

Purification and characterization of epithelial Ca(2+)-activated K+ channels. Klaerke DA. **Kidney Int** 1995 Oct;48(4):1047-56 (63 ref.)

METABOLISM

Effect of K+ accumulation removal and high extracellular osmolarity on K+ current in insect axonal membrane. Stankiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):95-102

Different properties of the atrial G protein-gated K+ channels activated by extracellular ATP and adenosine. Fu C, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1349-58

Regulation of ATP-sensitive K+ channel by membrane-bound protein phosphatases in rat principal tubule cell. Kubokawa M, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):F355-62

Flow-mediated NO release from endothelial cells is independent of K+ channel activation or intracellular Ca2+. O'Neill WC. **Am J Physiol** 1995 Oct;269(4 Pt 1):C863-9

KATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Qian YZ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H23-8

Muscarine-gated K+ channel: subunit stoichiometry and structural domains essential for G protein stimulation. Tucker SJ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H379-85

Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Gross GJ, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):31-4 (12 ref.)

G protein-gated K+ channel (GIRK1) protein is expressed presynaptically in the paraventricular nucleus of the hypothalamus. Morishige KI, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):300-5

Modulation of K+ channel currents by serum amineoxidase in neurons. Wu L, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):47-52

Evidence for a K+ channel requirement in spreading of rat basophilic leukemia cells on fibronectin-coated surfaces. Zigrino P, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):51-8

Functional reconstitution of the large-conductance, calcium-activated potassium channel purified from bovine aortic smooth muscle. Giangiacomo KM, et al. **Biochemistry** 1995 Dec 5;34(48):15849-62

[125I]margatoxin, an extraordinarily high affinity ligand for voltage-gated potassium channels in mammalian brain. Knaus HG, et al. **Biochemistry** 1995 Oct 17;34(41):13627-34

A symmetry-driven search for electrostatic interaction partners in charybdotoxin and a voltage-gated K+ channel. Naini AA, et al. **Biochemistry** 1996 May 21; 35(20):6181-7

Coassembly of synthetic segments of shaker K+ channel within phospholipid membranes. Peled-Zehavi H, et al. **Biochemistry** 1996 May 28;35(21):6828-38

Photolabile derivatives of 125I-apamin: defining the structural criteria required for labeling high and low molecular mass polypeptides associated with small conductance Ca(2+)-activated K+ channels. Wadsworth JD, et al. **Biochemistry** 1996 Jun 18;35(24):7917-27

Regulation of ATP-sensitive potassium channels by phosphorylation. Light P. **Biochim Biophys Acta** 1996 May 6;1286(1):65-73 (139 ref.)

Conduction properties of the M-channel in rat sympathetic neurons. Cloues R, et al. **Biophys J** 1996 Feb;70(2):806-12

Beta-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons. Good TA, et al. **Biophys J** 1996 Jan;70(1):296-304

Recovery from C-type inactivation is modulated by extracellular potassium. Levy DI, et al. **Biophys J** 1996 Feb;70(2):798-805

Effects of intracellular K+ and Rb+ on gating of embryonic rat telencephalon Ca(2+)-activated K+ channels. Mienville JM, et al. **Biophys J** 1996 Feb;70(2):778-85

Contributions of a negatively charged residue in the hydrophobic domain of the IRK1 inwardly rectifying K+ channel to K(+)-selective permeation. Reuveny E, et al. **Biophys J** 1996 Feb;70(2):754-61

Two barium binding sites on a maxi K+ channel from human vas deferens epithelial cells. Sohma Y, et al. **Biophys J** 1996 Mar;70(3):1316-25

Thrombin receptors activate potassium and chloride channels. Sullivan R, et al. **Blood** 1996 Jan 15;87(2):648-56

Involvement of G-protein alpha il subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors. Brown NA, et al. **Br J Pharmacol** 1995 Nov;116(5):2346-8

Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Hide EJ, et al. **Br J Pharmacol** 1995 Nov;116(5):2435-40

Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Wooltorton JR, et al. **Br J Pharmacol** 1995 Oct;116(4):2191-200

Apamin, a selective SK potassium channel blocker, suppresses REM sleep without a compensatory rebound. Benington JH, et al. **Brain Res** 1995 Sep 18;692(1-2):86-92

Dual regulation by mu, delta and kappa opioid receptor agonists of K+ conductance of DRG neurons and neuroblastoma X DRG neuron hybrid F11 cells. Fan SF, et al. **Brain Res** 1995 Oct 23;696(1-2):97-105

Sodium and potassium current in neonatal rat carotid body cells following chronic in vivo hypoxia. Hempleman SC. **Brain Res** 1995 Nov 13;699(1):42-50

Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes. Clapp LH. **Cardiovasc Res** 1995 Sep;30(3):460-8

Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts. Grover GJ, et al. **Cardiovasc Res** 1996 Apr; 31(4):511-7

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318-25 (73 ref.)

Evidence for the involvement of the ATP-sensitive potassium channel in a novel model of hypoxic preconditioning in dogs. Mei DA, et al. **Cardiovasc Res** 1995 Aug;30(2):222-30

Pharmacology of the high-affinity apamin receptor in rabbit heart. Schetz JA, et al. **Cardiovasc Res** 1995 Nov; 30(5):755-62

Immunological stimulation of single rat basophilic leukemia RBL-2H3 cells co-activates Ca(2+)-entry and K(+)-channels. Gericke M, et al. **Cell Calcium** 1995 Jan; 17(1):71-83

Antiarrhythmic drug binding sites in cardiac K+ channels [editorial; comment] Colatsky TJ. **Circ Res** 1996 Jun; 78(6):1115–6. Comment on: Circ Res 1996 Jun;78(6):1105–14.

Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Hu K, et al. **Circ Res** 1996 Mar;78(3):492–8

Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels. A possible mechanistic link to ischemic preconditioning. Light PE, et al. **Circ Res** 1996 Sep;79(3):399–406

Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Speechly-Dick ME, et al. **Circ Res** 1995 Nov;77(5):1030–5

Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. White RE, et al. **Circ Res** 1995 Nov;77(5):936–42

Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding [see comments] Yeola SW, et al. **Circ Res** 1996 Jun;78(6):1105–14. Comment in: Circ Res 1996 Jun;78(6):1115–6.

ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Olschewski A, et al. **Circulation** 1996 Feb 15;93(4):656–9

Increased Ca2+ influx in the resting state maintains the myogenic tone and activates charybdotoxin-sensitive K+ channels in femoral arteries from young SHR. Asano M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S225–7

Calcium-activated potassium current in cultured rabbit retinal pigment epithelial cells. Tao Q, et al. **Curr Eye Res** 1996 Mar;15(3):237–46

The structure, regulation and pathophysiology of potassium channels. Desir GV. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):402–5 (22 ref.)

A cAMP regulated K+-selective channel from the sea urchin sperm plasma membrane. Labarca P, et al. **Dev Biol** 1996 Mar 15;174(2):271–80

Involvement of K(Ca) channels and stretch-activated channels in calcium influx, triggering membrane fusion of chick embryonic myoblasts. Shin KS, et al. **Dev Biol** 1996 Apr 10;175(1):14–23

Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism. Pulido N, et al. **Diabetologia** 1996 Jan;39(1):22–7

Kv8.1, a new neuronal potassium channel subunit with specific inhibitory properties towards Shab and Shaw channels. Hugnot JP, et al. **EMBO J** 1996 Jul 1; 15(13):3322–31

Subunit positional effects revealed by novel heteromeric inwardly rectifying K+ channels. Pessia M, et al. **EMBO J** 1996 Jun 17;15(12):2980–7

C-terminus determinants for Mg2+ and polyamine block of the inward rectifier K+ channel IRK1. Taglialatela M, et al. **EMBO J** 1995 Nov 15;14(22):5532–41

Calcitonin gene-related peptide rapidly inhibits calcium uptake in osteoblastic cell lines via activation of adenosine triphosphate-sensitive potassium channels. Kawase T, et al. **Endocrinology** 1996 Mar;137(3):984–90

Evidence for decreased calcium dependent potassium conductance in hippocampal CA3 neurons of genetically epilepsy-prone rats. Verma-Ahuja S, et al. **Epilepsy Res** 1995 Oct;22(2):137–44

Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific co-localizations in rat brain. Veh RW, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2189–205

Characterization of the binding sites for [3H]glibenclamide in rat liver membranes. Inoue Y, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):77–82

Imidazoline compounds inhibit KATP channels in guinea pig ventricular myocytes. Lee K, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):309–12

Inhibition of ATP-sensitive K+ channels of mouse skeletal muscle by disopyramide. Moser C, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):35–41

Calcium-dependent, slowly inactivating potassium currents in cultured neurons of rat neocortex. Hamon B, et al. **Exp Brain Res** 1995;107(2):197–204

Regulation of airway cholinergic neurotransmission by Ca(2+)-activated K+ channel and Na(+)-K+ adenosinetriphosphatase. Tagaya E, et al. **Exp Lung Res** 1995 Sep–Oct;21(5):683–94

Opposing effects of oxidants and antioxidants on K+ channel activity and tone in rat vascular tissue. Reeve HL, et al. **Exp Physiol** 1995 Sep;80(5):825–34

Ca(2+)-activated Cl- and K+ channels and their modulation by endothelin-1 in rat pulmonary arterial smooth muscle cells. Salter KJ, et al. **Exp Physiol** 1995 Sep;80(5):815–24

Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)

Ionic transport in the plasma membrane of carrot protoplasts from embryogenic cell-suspension cultures. Bregante M, et al. **FEBS Lett** 1996 Feb 12;380(1–2):97–102

Differential distribution of classical inwardly rectifying potassium channel mRNAs in the brain: comparison of IRK2 with IRK1 and IRK3. Horio Y, et al. **FEBS Lett** 1996 Feb 5;379(3):239–43

Characterization of a new peptide from Tityus serrulatus scorpion venom which is a ligand of the apamin-binding site. Legros C, et al. **FEBS Lett** 1996 Jul 15;390(1):81–4

Activation of G protein-coupled inward rectifier K+ channels in brain neurons requires association of G protein beta gamma subunits with cell membrane. Nakajima Y, et al. **FEBS Lett** 1996 Jul 22;390(2):217–20

Kir2.2v: a possible negative regulator of the inwardly rectifying K+ channel Kir2.2. Namba N, et al. **FEBS Lett** 1996 May 20;386(2–3):211–4

Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. Sakura H, et al. **FEBS Lett** 1995 Dec 27;377(3):338–44

Slow inactivation conserved in heteromultimeric voltage-dependent K+ channels between Shaker (Kv1) and Shaw (Kv3) subfamilies. Shahidullah M, et al. **FEBS Lett** 1995 Sep 11;371(3):307–10

Heteromeric channel formation and Ca(2+)-free media reduce the toxic effect of the weaver Kir 3.2 allele. Tucker SJ, et al. **FEBS Lett** 1996 Jul 29;390(3):253–7

Do voltage-gated Kv1.1 and inward rectifier Kir2.1 potassium channels form heteromultimers? Tytgat J, et al. **FEBS Lett** 1996 Jul 29;390(3):280–4

The ethosuximide-induced hyperpolarization of smooth muscle tissues--a cause of functional changes in the gastrointestinal tract of rats--is provoked by CA(2+)-dependent K(+)-efflux. Kristev A, et al. **Folia Med (Plovdiv)** 1994;36(4):13–22

Characterization of a voltage-dependent potassium channel in squid Schwann cells reconstituted in planar lipid bilayers. Noceti F, et al. **Glia** 1995 Sep;15(1):33–42

Potassium currents in endfeet of isolated Müller cells from the frog retina. Skatchkov SN, et al. **Glia** 1995 Sep; 15(1):54–64

Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel. Yabe K, et al. **Heart Vessels** 1995;10(6):294–303

Structure-activity relationship study of a scorpion toxin with high affinity for apamin-sensitive potassium channels by means of the solution structure of analogues. Inisan AG, et al. **Int J Pept Protein Res** 1995 May;45(5):441–50

ATP-sensitive K+ channels are not involved in ischemia-reperfusion lung endothelial injury. Khimenko PL, et al. **J Appl Physiol** 1995 Aug;79(2):554–9

Regulation by spermine of native inward rectifier K+ channels in RBL-1 cells. Bianchi L, et al. **J Biol Chem** 1996 Mar 15;271(11):6114–21

Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets. Detimary P, et al. **J Biol Chem** 1996 Aug 23;271(34):20559–65

Specificity of coupling of muscarinic receptor isoforms to a novel chick inward-rectifying acetylcholine- senstive K+ channel. Gadbut AP, et al. **J Biol Chem** 1996 Mar 15;271(11):6398–402

The cardiac inward rectifier K+ channel subunit, CIR, does not comprise the ATP-sensitive K+ channel, IKATP. Krapivinsky G, et al. **J Biol Chem** 1995 Dec 1; 270(48):28777–9

G beta gamma binds directly to the G protein-gated K+ channel, IKACh. Krapivinsky G, et al. **J Biol Chem** 1995 Dec 8;270(49):29059–62

Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. Larsson O, et al. **J Biol Chem** 1996 May 3;271(18):10623–6

Prostaglandin E2 stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability. Li Q, et al. **J Biol Chem** 1996 Aug 2; 271(31):18651–6

Selective interaction of voltage-gated K+ channel beta-subunits with alpha-subunits. Nakahira K, et al. **J Biol Chem** 1996 Mar 22;271(12):7084–9

Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. Szabò I, et al. **J Biol Chem** 1996 Aug 23; 271(34):20465–9

Expression of Kv1.1 delayed rectifier potassium channels in Lec mutant Chinese hamster ovary cell lines reveals a role for sialidation in channel function. Thornhill WB, et al. **J Biol Chem** 1996 Aug 9;271(32):19093–8

Voltage-gated K+ channels contain multiple intersubunit association sites. Tu L, et al. **J Biol Chem** 1996 Aug 2; 271(31):18904–11

The alpha-dendrotoxin footprint on a mammalian potassium channel. Tytgat J, et al. **J Biol Chem** 1995 Oct 20; 270(42):24776–81

Metabolic stress opens K+ channels in hepatoma cells through a Ca2+- and protein kinase calpha-dependent mechanism. Wang Y, et al. **J Biol Chem** 1996 Jul 26; 271(30):18107–13

Participation of nucleoside-diphosphate kinase in muscarinic K+ channel activation does not involve GTP formation. Xu L, et al. **J Biol Chem** 1996 Aug 30;271(35):21120–5

A domain on the G protein beta subunit interacts with both adenylyl cyclase 2 and the muscarinic atrial potassium channel. Yan K, et al. **J Biol Chem** 1996 Jul 26; 271(30):17597–600

Properties of Ca(2+)-dependent K+ channels of human gingival fibroblasts. Takahashi A, et al. **J Dent Res** 1995 Aug;74(8):1507–12

Cd2+ regulation of the hyperpolarization-activated current IAB in crayfish muscle. Araque A, et al. **J Gen Physiol** 1995 Jun;105(6):725–44

Voltage-gated and Ca(2+)-activated K+ channels in intact human T lymphocytes. Noninvasive measurements of membrane currents, membrane potential, and intracellular calcium. Verheugen JA, et al. **J Gen Physiol** 1995 Jun; 105(6):765–94

Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats. Numaguchi K, et al. **J Hypertens** 1996 Feb;14(2):183–9

Cyclic adenosine 3',5'-monophosphate increases the open probability of potassium channels in activated human T cells. Oleson DR, et al. **J Immunol** 1996 Aug 1; 157(3):1080–6

Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion. Atwal KS, et al. **J Med Chem** 1996 Jan 5;39(1):304–13

Two types of A-channels in Lymnaea neurons. Alekseev SI, et al. **J Membr Biol** 1995 Aug;146(3):327–41

Direct control of a large conductance K(+)-selective channel by G-proteins in adrenal chromaffin granule membranes. Arispe N, et al. **J Membr Biol** 1995 Sep; 147(2):109–19

Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. Brugnara C, et al. **J Membr Biol** 1995 Sep;147(1):71–82

An inactivating inward-rectifying K current present in prolactin cells from the pituitary of lactating rats. Corrette BJ, et al. **J Membr Biol** 1996 Mar;150(2):185–95

Single K+ channels in embryonic leech ganglion cells. Frey G, et al. **J Membr Biol** 1996 May;151(2):113–22

Two novel toxins from the venom of the scorpion Pandinus imperator show that the N-terminal amino acid sequence is important for their affinities towards Shaker B K+ channels. Gómez-Lagunas F, et al. **J Membr Biol** 1996 Jul;152(1):49–56

Regulation of Ca2+-activated K+ channel from rabbit distal colon epithelium by phosphorylation and dephosphorylation. Klaerke DA, et al. **J Membr Biol** 1996 May;151(1):11–8

K+ channels and the intracellular calcium signal in human melanoma cell proliferation. Lepple-Wienhues A, et al. **J Membr Biol** 1996 May;151(2):149–57

Activation of maxi-K channels by parathyroid hormone and prostaglandin E2 in human osteoblast bone cells. Moreau R, et al. **J Membr Biol** 1996 Mar;150(2):175–84

Modulation of the serotonin-activated K+ channel by G protein subunits and nucleotides in rat hippocampal neurons. Oh U, et al. **J Membr Biol** 1995 Oct;147(3):241–53

Characterization of the G protein coupling of SRIF and beta-adrenergic receptors to the maxi KCa channel in insulin-secreting cells. Ribalet B, et al. **J Membr Biol** 1995 Nov;148(2):111–25

The pH-sensitivity of transepithelial K+ transport in vestibular dark cells. Wangemann P, et al. **J Membr Biol** 1995 Oct;147(3):255–62

Hypo-osmotic challenge stimulates transepithelial K+ secretion and activates apical IsK channel in vestibular dark cells. Wangemann P, et al. **J Membr Biol** 1995 Oct; 147(3):263–73

The permeation of ammonium through a voltage-independent K+ channel in the plasma membrane of rye roots. White PJ. **J Membr Biol** 1996 Jul;152(1):89–99

Progression of cardiac potassium current modification after brief exposure to reactive oxygen. Tarr M, et al. **J Mol Cell Cardiol** 1995 May;27(5):1099–109

The high-affinity sulphonylurea receptor regulates KATP channels in nerve terminals of the rat motor cortex. Lee K, et al. **J Neurochem** 1996 Jun;66(6):2562–71

Selective inhibition of the slow K+ current at motor nerve ending by plasma from a myasthenia gravis patient. Shi Y, et al. **J Neurol Sci** 1995 Jun;130(2):165–70

Electrophysiological and pharmacological characterization of a mammalian Shaw channel expressed in NIH 3T3 fibroblasts. Kanemasa T, et al. **J Neurophysiol** 1995 Jul; 74(1):207–17

Potentiation of a slow Ca(2+)-dependent K+ current by intracellular Ca2+ chelators in hippocampal CA1 neurons of rat brain slices. Zhang L, et al. **J Neurophysiol** 1995 Dec;74(6):2225–41

Xenopus spinal neurons express Kv2 potassium channel transcripts during embryonic development. Burger C, et al. **J Neurosci** 1996 Feb 15;16(4):1412–21

Multiple Shaker potassium channels in a primitive metazoan. Jegla T, et al. **J Neurosci** 1995 Dec;15(12):7989–99

Inwardly rectifying K+ channels that may participate in K+ buffering are localized in microvilli of Schwann cells. Mi H, et al. **J Neurosci** 1996 Apr 15;16(8):2421–9

A G-protein-activated inwardly rectifying K+ channel (GIRK4) from human hippocampus associates with other GIRK channels. Spauschus A, et al. **J Neurosci** 1996 Feb 1;16(3):930–8

Chronic opioid treatment of neuroblastoma x dorsal root ganglion neuron hybrid F11 cells results in elevated GM1

ganglioside and cyclic adenosine monophosphate levels and onset of naloxone-evoked decreases in membrane K+ currents. Wu G, et al. **J Neurosci Res** 1995 Nov 1; 42(4):493–503

Closed- and open-state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5. Bouchard R, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):864–76

Hypoxic relaxation in functionally intact cattle coronary artery segments involves K+ ATP channels. Kalsner S. **J Pharmacol Exp Ther** 1995 Dec;275(3):1219–26

Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)

A rapidly activating type of outward rectifier K+ current and A-current in rat suprachiasmatic nucleus neurones. Bouskila Y, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):339–50

Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate. Bünemann M, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):701–77

An ATP-sensitive potassium conductance in rabbit arterial endothelial cells. Katnik C, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):595–606

Nitric oxide activates multiple potassium channels in canine colonic smooth muscle. Koh SD, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):735–43

beta-adrenergic and cholinergic modulation of the inwardly rectifying K+ current in guinea-pig ventricular myocytes. Koumi S, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):647–59

Beta-adrenergic and cholinergic modulation of inward rectifier K+ channel function and phosphorylation in guinea-pig ventricle. Koumi S, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):661–78

Characterization of an ATP-modulated large conductance Ca(2+)-activated K+ channel present in rat cortical neurones. Lee K, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):319–37

Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. Murphy ME, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):47–58

Volume regulation in a toad epithelial cell line: role of coactivation of K+ and Cl- channels. Nilius B, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):367–78

C-type inactivation controls recovery in a fast inactivating cardiac K+ channel (Kv1.4) expressed in Xenopus oocytes. Rasmusson RL, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):709–21

Target-derived factors regulate the expression of Ca(2+)-activated K+ currents in developing chick sympathetic neurones. Raucher S, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):605–14

Receptor kinase-dependent desensitization of the muscarinic K+ current in rat atrial cells. Shui Z, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):359–66

Modification by protons of frog skeletal muscle KATP channels: effects on ion conduction and nucleotide inhibition. Vivaudou M, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):629–45

A slowly activating Ca(2+)-dependent K+ current that plays a role in termination of swimming in Xenopus embryos. Wall MJ, et al. **J Physiol (Lond)** 1995 Sep 15;487 (Pt 3):557–72

Potassium currents in adult rat intracardiac neurones. Xi-Moy SX, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):15–31

Molecular characterization of voltage and cyclic nucleotide-gated potassium channels in kidney. Desir GV. **Kidney Int** 1995 Oct;48(4):1031–5 (57 ref.)

Renal potassium channels: an overview. Giebisch G. **Kidney Int** 1995 Oct;48(4):1004–9 (46 ref.)

Cross-talk between sodium and potassium channels in tight epithelia. Harvey BJ. **Kidney Int** 1995 Oct;48(4):1191–9 (100 ref.)

An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Hebert SC. **Kidney Int** 1995 Oct; 48(4):1010–6 (66 ref.)

K+ channels in the basolateral membrane of rat cortical collecting duct. Hirsch J, et al. **Kidney Int** 1995 Oct; 48(4):1036–46 (89 ref.)

Purification and characterization of epithelial Ca(2+)-activated K+ channels. Klaerke DA. **Kidney Int** 1995 Oct;48(4):1047–56 (63 ref.)

View of K+ secretion through the apical K channel of cortical collecting duct. Wang WH. **Kidney Int** 1995 Oct; 48(4):1024–30 (87 ref.)

Cross-talk and the role of KATP channels in the proximal tubule. Welling PA. **Kidney Int** 1995 Oct;48(4):1017–23 (79 ref.)

Structure-activity relationship of quaternary ammonium ions at the external tetraethylammonium binding site of cloned potassium channels. Jarolimek W, et al. **Mol Pharmacol** 1996 Jan;49(1):165–71

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. Ammälä C, et al. **Nature** 1996 Feb 8;379(6565):545–8

Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Furukawa K, et al. **Nature** 1996 Jan 4;379(6560):74–8

Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases. Kim E, et al. **Nature** 1995 Nov 2;378(6552):85–8

The inward rectification mechanism of the HERG cardiac potassium channel [see comments] Smith PL, et al. **Nature** 1996 Feb 29;379(6568):833–6. Comment in: Nature 1996 Feb 29;379(6568):767–8.

Evidence that BKCa channel activation contributes to K+ channel opener induced relaxation of the porcine coronary artery. Balwierczak JL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):213–21

Patch-clamp study on T-lymphocyte potassium conductance in patients with chronic renal failure. Teisseyre A, et al. **Nephron** 1996;72(4):587–94

Evidence that direct binding of G beta gamma to the GIRK1 G protein-gated inwardly rectifying K+ channel is important for channel activation. Huang CL, et al. **Neuron** 1995 Nov;15(5):1133–43

Hypomyelination alters K+ channel expression in mouse mutants shiverer and Trembler. Wang H, et al. **Neuron** 1995 Dec;15(6):1337–47

K+ currents of human T-lymphocytes are unaffected by Alzheimer's disease and amyloid beta protein. Cohen CD, et al. **Neurosci Lett** 1996 Jan 5;202(3):177–80

Effects of myosin light chain kinase inhibitors on delayed rectifier potassium current in bullfrog sympathetic neurons. Tokimasa T. **Neurosci Lett** 1995 Sep 1;197(1):75–7

Evidence for a sodium-dependent potassium conductance in frog myelinated axon. Poulter MO, et al. **Neuroscience** 1995 Sep;68(2):487–95

Cloning of a pH sensitive K+ channel in the kidney. Suzuki M. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):422–7 (15 ref.)

Maxi K+ channels in the basolateral membrane of the exocrine frog skin gland regulated by intracellular calcium and pH. Andersen HK, et al. **Pflugers Arch** 1995 Nov; 431(1):52–65

An endogenous inactivating inward-rectifying potassium current in oocytes of Xenopus laevis. Bauer CK, et al. **Pflugers Arch** 1996 Sep;432(5):812–20

A transient, RCK4-like K+ current in cultured Xenopus olfactory bulb neurons. Engel J, et al. **Pflugers Arch** 1996 Sep;432(5):845–52

Coexistence of two classes of glibenclamide-inhibitable ATP-regulated K+ channels in avian skeletal muscle. Fosset M, et al. **Pflugers Arch** 1995 Nov;431(1):117–24

The selectivity of different external binding sites for quaternary ammonium ions in cloned potassium channels. Jarolimek W, et al. **Pflugers Arch** 1995 Sep;430(5):672–81

Caffeine- and histamine-induced oscillations of K(Ca) current in single smooth muscle cells of rabbit cerebral artery. Kang TM, et al. **Pflugers Arch** 1995 Nov; 431(1):91–100

Neuropeptide Y2-type receptor-mediated activation of large-conductance Ca(2+)-sensitive K+ channels in a human neuroblastoma cell line. Lemos VS, et al. **Pflugers Arch** 1995 Aug;430(4):534–40

cAMP stimulation of CFTR-expressing Xenopus oocytes activates a chromanol-inhibitable K+ conductance. Mall M, et al. **Pflugers Arch** 1996 Jul;432(3):516–22

Different modulation of Ca-activated K channels by the intracellular redox potential in pulmonary and ear arterial smooth muscle cells of the rabbit. Park MK, et al. **Pflugers Arch** 1995 Jul;430(3):308–14

Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. Schwab A, et al. **Pflugers Arch** 1995 Sep;430(5):802–7

Changes of pH affect calcium currents but not outward potassium currents in rat myometrial cells. Shmigol AV, et al. **Pflugers Arch** 1995 Nov;431(1):135–7

Modulation of Ca2+ oscillation and apamin-sensitive, Ca2+-activated K+ current in rat gonadotropes. Tse A, et al. **Pflugers Arch** 1995 Sep;430(5):645–52

ATP-Dependent inhibition of Ca2+-activated K+ channels in vascular smooth muscle cells by neuropeptide Y. Xiong Z, et al. **Pflugers Arch** 1995 Nov;431(1):110–6

Potassium currents in rat colonic smooth muscle cells and changes during development and aging. Xiong Z, et al. **Pflugers Arch** 1995 Aug;430(4):563–72

Barium block of the muscarinic potassium current in guinea-pig atrial cells. Zang WJ, et al. **Pflugers Arch** 1995 Jul;430(3):348–57

Inhibition of food intake in rats by the K+ channel opener cromakalim. Del Prete E, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):839–42

Susceptibility of cloned K+ channels to reactive oxygen species. Duprat F, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11796–800

Oscillations in KATP channel activity promote oscillations in cytoplasmic free Ca2+ concentration in the pancreatic beta cell. Larsson O, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5161–5

min K channels form by assembly of at least 14 subunits. Tzounopoulos T, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9593–7

Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Hilgemann DW, et al. **Science** 1996 Aug 16;273(5277):956–9

Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor [see comments] Inagaki N, et al. **Science** 1995 Nov 17;270(5239):1166–70. Comment in: Science 1995 Nov 17;270(5239):1159.

Nonselective and G betagamma-insensitive weaver K+ channels. Navarro B, et al. **Science** 1996 Jun 28; 272(5270):1950–3

Relaxation of arterial smooth muscle by calcium sparks [see comments] Nelson MT, et al. **Science** 1995 Oct 27; 270(5236):633–7. Comment in: Science 1995 Oct 27;270(5236):588–9.

Adenosine diphosphate as an intracellular regulator of insulin secretion. Nichols CG, et al. **Science** 1996 Jun 21; 272(5269):1785–7

ATP-sensitive K+ channels: paradigm lost, paradigm regained [comment] Philipson LH. **Science** 1995 Nov 17; 270(5239):1159. Comment on: Science 1995 Nov 17;270(5239):1166–70.

Structure of beta 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. Kwong PD, et al. **Structure** 1995 Oct 15;3(10):1109–19

[Ischemic preconditioning to pharmacologic activation of the ATP-dependent potassium channels] Rossi G. **Recenti Prog Med** 1996 Apr;87(4):172–4 **(Ita)**

[Molecular mechanism of the G protein regulation of inwardly rectifying potassium channels] Yamada M, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2297–306 (36 ref.) **(Jpn)**

PHARMACOLOGY

Effect of the potassium channel opener YM934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. Masuda N, et al. **J Urol** 1995 Nov; 154(5):1914–20

Pharmacological characterization of the isolated canine prostate. Normandin DE, et al. **J Urol** 1996 May; 155(5):1758–61

PHYSIOLOGY

Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203–12 (50 ref.)

Effect of purinergic blockers on outward current in isolated smooth muscle cells of the sheep bladder. Cotton KD, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C969–73

Nitric oxide mediates outward potassium currents in opossum esophageal circular smooth muscle. Jury J, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G932–8

ATP-sensitive K+ currents in cerebral arterial smooth muscle: pharmacological and hormonal modulation. Kleppisch T, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1634–40

G protein regulation of cardiac muscarinic potassium channel. Kurachi Y. **Am J Physiol** 1995 Oct;269(4 Pt 1):C821–30 (80 ref.)

Role of K+ATP channels and EDRF in reactive hyperemia in the hindquarters vascular bed of cats. Minkes RK, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1704–12

Different responses of epicardium and endocardium to KATP channel modulators during regional ischemia. Miyoshi S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H140–7

Enhanced role of K+ channels in relaxations of hypercholesterolemic rabbit carotid artery to NO. Najibi S, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H805–11

Pharmacology of ATP-sensitive K+ currents in smooth muscle cells from rabbit mesenteric artery. Quayle JM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1112–8

Opioids contribute to hypoxia-induced pial artery dilation through activation of ATP-sensitive K+ channels. Shankar V, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H997–1002

Role of large Ca(2+)-activated K+ channels in regulation of mesangial contraction by nitroprusside and ANP. Stockand JD, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1773–9

Electrophysiological characterization of RACTK1 K+ channel in stable cell line. Suzuki M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C964–8

Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)

Modulation of cell membrane potential in cultured vascular endothelium. Vaca L, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C819–24

Sodium nitroprusside stimulates Ca2+ -activated K+ channels in porcine tracheal smooth muscle cells. Yamakage M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L338–45

Ionic conductances and hair cell tuning in the turtle cochlea. Art JJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:103–22 (27 ref.)

Is potassium channel opening an effective form of preconditioning before cardioplegia? Menasché P, et al. **Ann Thorac Surg** 1996 Jun;61(6):1764–8

Myocardial potassium channels: electrophysiological and molecular diversity. Barry DM, et al. **Annu Rev Physiol** 1996;58:363–94 (211 ref.)

Do ATP-sensitive potassium channels play a role in myocardial stunning? Gross GJ. **Basic Res Cardiol** 1995 Jul-Aug;90(4):266–8 (10 ref.)

Activation of large conductance Ca(2+)-activated K+ channels in N1E-115 neuroblastoma cells by platelet-activating factor. Diserbo M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):745–8

Activation of calcium-sensitive potassium channels in L6 skeletal myocytes by arginine vasopressin requires extracellular calcium. Gosling M, et al.

Biochem Biophys Res Commun 1995 Dec 26;217(3):1163–8
Abnormal activation of K+ channels underlies relaxation to bacterial lipopolysaccharide in rat aorta. Hall S, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):184–90
Sulfhydryl redox modulates ATP-sensitive K+ channels in rabbit ventricular myocytes. Han J, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):900–3
ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1022–8
Dual effects of ATP on the potassium channel and intracellular Ca2+ release in smooth muscle cells of the bovine brain arteries. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1071–7
P2 purinoceptor-operated potassium channel in rat cerebellar neurons. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):67–71
Regulation of the potassium current and cytosolic Ca2+ release induced by 2-methylthio ATP in hippocampal neurons. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):428–33
A novel ubiquitously distributed isoform of GIRK2 (GIRK2B) enhances GIRK1 expression of the G-protein-gated K+ current in Xenopus oocytes. Isomoto S, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):286–91
Effects of the nitric oxide synthase inhibitor N omega nitro-L-arginine methyl ester on electrical activity and ion channels of mouse pancreatic B cells. Krippeit-Drews P, et al. **Biochem Biophys Res Commun** 1996 Jul 5; 224(1):199–205
Properties of the Kv1.1 rat brain potassium channels expressed in mammalian cells: temperature effects. Moran O, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):915–20
Voltage-dependent potassium channels in white adipocytes. Ramirez-Ponce MP, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):250–6
Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium-conductive pathway. Seftel AD, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):382–7
Rat inwardly rectifying potassium channel Kir6.2: cloning electrophysiological characterization, and decreased expression in pancreatic islets of male Zucker diabetic fatty rats. Tokuyama Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):532–8
Cuprous ions activate glibenclamide-sensitive potassium channel in liver mitochondria. Wojtczak L, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):468–73
Ion channels in the chloroplast envelope membrane. Heiber T, et al. **Biochemistry** 1995 Dec 12;34(49):15906–17
A possible role of the ATP-sensitive potassium ion channel in determining the duration of spike-bursts in mouse pancreatic beta-cells. Ding WG, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):219–26
ATP increases Ca(2+)-activated K+ channel activity in isolated rat arterial smooth muscle cells. Hartley SA, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):192–8
Exogenous heat shock protein hsp70 activates potassium channels in U937 cells. Negulyaev YA, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):156–62
Conducting and voltage-dependent behaviors of potassium ion channels reconstituted from diaphragm sarcoplasmic reticulum: comparison with the cardiac isoform. Picher M, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):93–103
Bistability in cerebellar Purkinje cell dendrites modelled with high-threshold calcium and delayed-rectifier potassium channels. Yuen GL, et al. **Biol Cybern** 1995 Sep; 73(4):375–88
Spontaneous electrical and calcium oscillations in unstimulated pituitary gonadotrophs. Li YX, et al. **Biophys J** 1995 Sep;69(3):785–95
Cooperative subunit interactions in C-type inactivation of K channels. Ogielska EM, et al. **Biophys J** 1995 Dec; 69(6):2449–57
C-type inactivation of a voltage-gated K+ channel occurs by a cooperative mechanism. Panyi G, et al. **Biophys J** 1995 Sep;69(3):896–903
Unilateral exposure of Shaker B potassium channels to hyperosmolar solutions. Starkus JG, et al. **Biophys J** 1995 Sep;69(3):860–72
A random flight chain model for the tether of the Shaker K+ channel inactivation domain. Timpe LC, et al. **Biophys J** 1995 Dec;69(6):2415–8
Induction of endogenous channels by high levels of heterologous membrane proteins in Xenopus oocytes. Tzounopoulos T, et al. **Biophys J** 1995 Sep;69(3):904–8
GnRH-induced cytosolic calcium oscillations in pituitary gonadotrophs: phase resetting by membrane depolarization. Vergara LA, et al. **Biophys J** 1995 Oct;69(4):1606–14
Effects of calcium on mitochondrial NAD(P)H in paced rat ventricular myocytes. White RL, et al. **Biophys J** 1995 Dec; 69(6):2790–9
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy. de Franceschi L, et al. **Blood** 1996 Feb 1;87(3):1188–95
Effects of BRL55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide-resistant, ATP-sensitive potassium current. Edwards G, et al **Br J Pharmacol** 1995 Jul;115(6):1027–37
Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells. Nakazawa K, et al. **Br J Pharmacol** 1995 Nov;116(6):2603–10
The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart. Randall MD. **Br J Pharmacol** 1995 Dec; 116(7):3068–74
The involvement of ATP-sensitive potassium channels in beta-adrenoceptor-mediated vasorelaxation in the rat isolated mesenteric arterial bed. Randall MD, et al. **Br J Pharmacol** 1995 Jun;115(4):607–12
Involvement of nitric oxide in the non-adrenergic non-cholinergic neurotransmission of horse deep penile arteries: role of charybdotoxin-sensitive K(+)-channels. Simonsen U, et al. **Br J Pharmacol** 1995 Nov; 116(6):2582–90
Desensitization of the mu-opioid activation of phospholipase C in SH-SY5Y cells: the role of protein kinases C and A and Ca(2+)-activated K+ currents. Smart D, et al. **Br J Pharmacol** 1995 Nov;116(6):2655–60
Potassium currents in human freshly isolated bronchial smooth muscle cells. Snetkov VA, et al. **Br J Pharmacol** 1995 Jul;115(6):1117–25
Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Zhang HL, et al. **Br J Pharmacol** 1996 May;118(1):105–14
Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Zygmunt PM, et al. **Br J Pharmacol** 1996 Apr; 117(7):1600–6
The excitability of CA1 pyramidal cell dendrites is modulated by a local Ca(2+)-dependent K(+)-conductance. Andreasen M, et al. **Brain Res** 1995 Nov 6;698(1–2):193–203
Developmental and activity-dependent changes in K+ currents in satellite glial cells in mouse superior cervical ganglion. Konishi T. **Brain Res** 1996 Feb 5;708(1–2):7–15
Calcium-activated potassium channels are involved in the response of mouse Leydig cells to human chorionic gonadotropin. Carnio EC, et al. **Braz J Med Biol Res** 1995 Jul;28(7):813–24
The potassium A-current, low firing rates and rebound excitation in Hodgkin-Huxley models. Rush ME, et al. **Bull Math Biol** 1995 Nov;57(6):899–929
Outward currents underlying repolarization in human atrial myocytes. Firek L, et al. **Cardiovasc Res** 1995 Jul;30(1):31–8
Identification of domains conferring G protein regulation on inward rectifier potassium channels. Kunkel MT, et al. **Cell** 1995 Nov 3;83(3):443–9
Co-assembly of potassium channel subunits in Drosophila: the combinatorial hypothesis revisited. Wu CF, et al. **Chin J Physiol** 1995;38(3):131–8 (50 ref.)
Description of a nonselective cation current in human atrium. Crumb WJ Jr, et al. **Circ Res** 1995 Nov;77(5):950–6
K+ currents in human coronary artery vascular smooth muscle cells. Gollasch M, et al. **Circ Res** 1996 Apr; 78(4):676–88
Acidosis-induced coronary arteriolar dilation is mediated by ATP-sensitive potassium channels in vascular smooth muscle. Ishizaka H, et al. **Circ Res** 1996 Jan;78(1):50–7
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Li GR, et al. **Circ Res** 1996 Apr;78(4):689–96
Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Li GR, et al. **Circ Res** 1996 May;78(5):903–15
Distribution and physiological roles of ATP-sensitive K+ channels in the vertebrobasilar system of the rabbit. Nagao T, et al. **Circ Res** 1996 Feb;78(2):238–43
Divergent mechanisms of ATP-sensitive K+ channel-induced vasodilation in renal afferent and efferent arterioles. Evidence of L-type Ca2+ channel-dependent and -independent actions of pinacidil. Reslerova M, et al. **Circ Res** 1995 Dec;77(6):1114–20
Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Schultz JE, et al. **Circ Res** 1996 Jun; 78(6):1100–4
Cell distension-induced increase of the delayed rectifier K+ current in guinea pig ventricular myocytes. Wang Z, et al. **Circ Res** 1996 Mar;78(3):466–74
Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels. Koning MM, et al. **Circulation** 1996 Jan 1;93(1):178–86
Of oocytes and runny noses [editorial; comment] Rosen MR. **Circulation** 1996 Aug 15;94(4):607–9 (20 ref.). Comment on: Circulation 1996 Aug 15;94(4):817–23.
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine [see comments] Roy M, et al. **Circulation** 1996 Aug 15;94(4):817–23. Comment in: Circulation 1996 Aug 15;94(4):607–9.
Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning. Shigematsu S, et al. **Circulation** 1995 Oct 15;92(8):2266–75
Delayed rectifier channels in human ventricular myocytes. Veldkamp MW, et al. **Circulation** 1995 Dec 15; 92(12):3497–504
Molecular and functional diversity of K+ channels. Christie MJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):944–51 (68 ref.)
Role of cerebral ATP-sensitive K+ channels in arterial pressure regulation during acute cerebral ischaemia in SHR and WKY rats. Nishimura M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S70–2
Prolactin induced analgesia is dependent on ATP sensitive potassium channels. Shewade DG, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):635–6
Effects of intermittent pressure-induced strain on the electrophysiology of cultured human chondrocytes: evidence for the presence of stretch-activated membrane ion channels. Wright M, et al. **Clin Sci (Colch)** 1996 Jan; 90(1):61–71
K+ channels: generating excitement in pancreatic beta-cells. Dukes ID, et al. **Diabetes** 1996 Jul;45(7):845–53 (143 ref.)
The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81–9 (72 ref.)
The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57–66 (37 ref.)
The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)
Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)
Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Gromada J, et al. **Diabetologia** 1995 Sep; 38(9):1025–32
Inward rectifier potassium channels in plants differ from their animal counterparts in response to voltage and channel modulators. Hedrich R, et al. **Eur Biophys J** 1995; 24(2):107–15
Cryptolepine-induced vasodilation in the isolated perfused kidney of the rat: role of G-proteins, K+ and Ca2+ channels. Oyekan AO. **Eur J Pharmacol** 1995 Oct 4; 285(1):1–9
Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1–9 (100 ref.)
Cytoskeletal control of rectification and expression of four substates in cardiac inward rectifier K+ channels. Mazzanti M, et al. **FASEB J** 1996 Feb;10(2):357–61
RANTES and platelet-activating factor open Ca2+-activated K+ channels in eosinophils. Saito M, et al. **FASEB J** 1996 May;10(7):792–8
Dose-dependent activation and block by bisG10, a K+ channel blocker, of mouse and frog skeletal muscle KATP channels. Allard B, et al. **FEBS Lett** 1995 Nov 20; 375(3):215–9
Subunit-specific inhibition of inward-rectifier K+ channels by quinidine. Doi T, et al. **FEBS Lett** 1995 Nov 20; 375(3):193–6
Voltage-gated K+ currents of mouse dendritic cells. Fischer HG, et al. **FEBS Lett** 1995 Oct 9;373(2):127–30
Characterization of a new peptide from Tityus serrulatus scorpion venom which is a ligand of the apamin-binding site. Legros C, et al. **FEBS Lett** 1996 Jul 15;390(1):81–4
A calcium switch for the functional coupling between alpha (hslo) and beta subunits (KV,Ca beta) of maxi K channels. Meera P, et al. **FEBS Lett** 1996 Mar 11;382(1–2):84–8
Adenosine evokes potassium currents by protein kinase C activated via a novel signaling pathway in superior colliculus neurons. Nishizaki T, et al. **FEBS Lett** 1996 Jan 2;378(1):1–6
Modulation by protein kinase C activation of rat brain delayed-rectifier K+ channel expressed in Xenopus oocytes. Peretz T, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):71–6
The voltage-dependent K+ channel (Kv1.5) cloned from rabbit heart and facilitation of inactivation of the delayed rectifier current by the rat beta subunit. Sasaki Y, et al. **FEBS Lett** 1995 Sep 18;372(1):20–4
The modulation of the rate of inactivation of the mKv1.1 K+ channel by the beta subunit, Kv beta 1 and lack of effect of a Kv beta 1 N-terminal peptide. Stephens GJ, et al. **FEBS Lett** 1996 Jan 15;378(3):250–2
The weaver mutation changes the ion selectivity of the affected inwardly rectifying potassium channel GIRK2. Tong Y, et al. **FEBS Lett** 1996 Jul 15;390(1):63–8
YKC1 encodes the depolarization-activated K+ channel in the plasma membrane of yeast. Zhou XL, et al. **FEBS Lett** 1995 Oct 9;373(2):170–6
Inward and outward rectifying potassium currents in Saccharomyces cerevisiae mediated by endogenous and heterelogously expressed ion channels. Bertl A, et al. **Folia Microbiol (Praha)** 1994;39(6):507–9
Protective effects of the K+ ATP channel opener, aprikalim, against free radicals in isolated rabbit hearts. Pignac J, et al. **Free Radic Biol Med** 1996;20(3):383–9
Age-dependent changes in voltage-gated calcium channels and ATP-dependent potassium channels in Fischer 344 rats. Bangalore R, et al. **Gen Pharmacol** 1995 Oct; 26(6):1237–42
Properties of slow early potassium current in neurons of snail Helix pomatia. Solntseva EI. **Gen Pharmacol** 1995 Dec; 26(8):1719–26
Three components of potassium outward current in cells isolated from the circular layer of guinea-pig ileum. Duridanova DB, et al. **Gen Physiol Biophys** 1995 Apr; 14(2):125–37

Cyclic GMP-induced activation of potassium currents by sarcoplasmic reticulum Ca2+ pump-dependent mechanism. Duridanova DB, et al. **Gen Physiol Biophys** 1995 Apr;14(2):139–51

Developmental regulation of Na+ and K+ conductances in glial cells of mouse hippocampal brain slices. Kressin K, et al. **Glia** 1995 Oct;15(2):173–87

Characteristics of two basolateral potassium channel populations in human colonic crypts. Lomax RB, et al. **Gut** 1996 Feb;38(2):243–7

Inwardly rectifying K+ currents in isolated human retinal pigment epithelial cells. Hughes BA, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1125–39

Pulmonary vasoreactivity to endothelin-1 at elevated vascular tone is modulated by potassium channels. Barman SA. **J Appl Physiol** 1996 Jan;80(1):91–8

Excitable properties and underlying Na+ and K+ currents in neurons from the guinea-pig jugular ganglion. Christian EP, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):75–86

Role of cyclic AMP and protein kinase A in K+ channel activation by calcitonin gene-related peptide (CGRP) in the guinea-pig ureter. Maggi CA, et al. **J Auton Pharmacol** 1995 Oct;15(5):403–19

Cytoplasmic and extracellular IsK peptides activate endogenous K+ and Cl- channels in Xenopus oocytes. Evidence for regulatory function. Ben-Efraim I, et al. **J Biol Chem** 1996 Apr 12;271(15):8768–71

Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. Doi T, et al. **J Biol Chem** 1996 Jul 19;271(29):17261–6

The mitochondrial KATP channel as a receptor for potassium channel openers. Garlid KD, et al. **J Biol Chem** 1996 Apr 12;271(15):8796–9

A pH-sensitive yeast outward rectifier K+ channel with two pore domains and novel gating properties. Lesage F, et al. **J Biol Chem** 1996 Feb 23;271(8):4183–7

Role of tyrosine phosphorylation in potassium channel activation. Functional association with prolactin receptor and JAK2 tyrosine kinase. Prevarskaya NB, et al. **J Biol Chem** 1995 Oct 13;270(41):24292–9

Spermidine release from xenopus oocytes. Electrodiffusion through a membrane channel. Sha Q, et al. **J Biol Chem** 1996 Feb 16;271(7):3392–7

Glucocorticoids block protein kinase A inhibition of calcium-activated potassium channels. Shipston MJ, et al. **J Biol Chem** 1996 Apr 19;271(16):9197–200

Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80-kDa mdr1a gene product. Thévenod F, et al. **J Biol Chem** 1996 Feb 9;271(6):3300–5

Inhibitory interactions between two inward rectifier K+ channel subunits mediated by the transmembrane domains. Tucker SJ, et al. **J Biol Chem** 1996 Mar 8;271(10):5866–70

Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv beta 2.1 subunits. Uebele VN, et al. **J Biol Chem** 1996 Feb 2;271(5):2406–12

Identification of strong modifications in cation selectivity in an Arabidopsis inward rectifying potassium channel by mutant selection in yeast. Uozumi N, et al. **J Biol Chem** 1995 Oct 13;270(41):24276–81

Phosphorylation of the ATP-sensitive, inwardly rectifying K+ channel, ROMK, by cyclic AMP-dependent protein kinase. Xu ZC, et al. **J Biol Chem** 1996 Apr 19; 271(16):9313–9

Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. Zhang L, et al. **J Biol Chem** 1996 May 10;271(19):11449–54

Protein phosphatase 2A is essential for the activation of Ca2+-activated K+ currents by cGMP-dependent protein kinase in tracheal smooth muscle and Chinese hamster ovary cells. Zhou XB, et al. **J Biol Chem** 1996 Aug 16;271(33):19760–7

The role of ATP sensitive potassium channels in myocardial protection. Cason BA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):441–4 (32 ref.)

Transmembrane potential responses during HL-60 promyelocyte differentiation. Brent LH, et al. **J Cell Physiol** 1996 Jul;168(1):155–65

Inhibitory effect of ATP-sensitive K+ channel regulators on forskolin-stimulated short-circuit current across the isolated mucosa of the rat colon. Huang Y, et al. **J Cell Physiol** 1996 Sep;168(3):678–83

Effects of intracellular Mg2+ on the properties of large-conductance, Ca(2+)-dependent K+ channels in rat cerebrovascular smooth muscle cells. Zhang X, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1066–74

Role of K+ ATP channels and adenosine in the regulation of coronary blood flow during exercise with normal and restricted coronary blood flow. Duncker DJ, et al. **J Clin Invest** 1996 Feb 15;97(4):996–1009

beta-Adrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myocytes. Alteration in channel response to beta-adrenergic stimulation in failing human hearts. Koumi S, et al. **J Clin Invest** 1995 Dec;96(6):2870–81

Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. Yao X, et al. **J Clin Invest** 1996 Jun 1; 97(11):2525–33

Dynamic modification of dendritic cable properties and synaptic transmission by voltage-gated potassium channels. Wilson CJ. **J Comput Neurosci** 1995 Jun;2(2):91–115

Intrinsic gating properties of a cloned G protein-activated inward rectifier K+ channel. Doupnik CA, et al. **J Gen Physiol** 1995 Jul;106(1):1–23

External barium block of Shaker potassium channels: evidence for two binding sites. Hurst RS, et al. **J Gen Physiol** 1995 Dec;106(6):1069–87

The mechanism of inward rectification of potassium channels: "long-pore plugging" by cytoplasmic polyamines. Lopatin AN, et al. **J Gen Physiol** 1995 Nov;106(5):923–55

Rectifying conductance substates in a large conductance Ca(2+)-activated K+ channel: evidence for a fluctuating barrier mechanism. Moss GW, et al. **J Gen Physiol** 1996 Jan;107(1):47–68

Cell swelling has differential effects on the rapid and slow components of delayed rectifier potassium current in guinea pig cardiac myocytes. Rees SA, et al. **J Gen Physiol** 1995 Dec;106(6):1151–70

Fast inactivation causes rectification of the IKr channel. Spector PS, et al. **J Gen Physiol** 1996 May;107(5):611–9

Regulation of the hyperpolarization-activated K+ channel in the lateral membrane of the cortical collecting duct. Wang WH. **J Gen Physiol** 1995 Jul;106(1):25–43

T cell activation is regulated by voltage-dependent and calcium-activated potassium channels. Rader RK, et al. **J Immunol** 1996 Feb 15;156(4):1425–30

Endotoxin-induced L-arginine pathway produces nitric oxide and modulates the Ca2+-activated K+ channel in cultured human dermal papilla cells. Nameda Y, et al. **J Invest Dermatol** 1996 Feb;106(2):342–5

3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships. de Tullio P, et al. **J Med Chem** 1996 Feb 16;39(4):937–48

Mechanisms of K+ channel regulation. Breitwieser GE. **J Membr Biol** 1996 Jul;152(1):1–11 (197 ref.)

The ACh-evoked, Ca2+-activated whole-cell K+ current in mouse mandibular secretory cells. Whole-cell and fluorescence studies. Hayashi T, et al. **J Membr Biol** 1996 Aug;152(3):253–9

The Ach-evoked Ca2+-activated K+ current in mouse mandibular secretory cells. Single channel studies. Hayashi T, et al. **J Membr Biol** 1996 May;151(1):19–27

Single-channel analysis of a delayed rectifier K+ channel in Xenopus myelinated nerve. Koh DS, et al. **J Membr Biol** 1996 Feb;149(3):221–32

Characterization of the acetylcholine-sensitive muscarinic K+ channel in isolated feline atrial and ventricular myocytes. Koumi S, et al. **J Membr Biol** 1995 May; 145(2):143–50

Human macrophages contain a stretch-sensitive potassium channel that is activated by adherence and cytokines. Martin DK, et al. **J Membr Biol** 1995 Oct;147(3):305–15

Calcium-sensitivity of the plasmalemmal delayed rectifier potassium current suggests that calcium influx in pulvinar protoplasts from Mimosa pudica L. can be revealed by hyperpolarization. Stoeckel H, et al. **J Membr Biol** 1995 Jul;146(2):201–9

Kinetic analysis of two simultaneously activated K+ currents in root cell protoplasts of Plantago media L. Vogelzang SA, et al. **J Membr Biol** 1995 Jul;146(1):59–71

Potassium channels and preconditioning of isolated rabbit cardiomyocytes: effects of glyburide and pinacidil. Armstrong SC, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1765–74

Calcium and potassium currents in the fast coxal depressor motor neuron of the cockroach Periplaneta americana. David JA, et al. **J Neurophysiol** 1995 Nov;74(5):2043–50

Inwardly rectifying potassium conductance can accelerate the hyperpolarizing response in retinal horizontal cells. Dong CJ, et al. **J Neurophysiol** 1995 Dec;74(6):2258–65

Accumulation of inactivation in a cloned transient K+ channel (AKv1.1a) of Aplysia. Furukawa Y. **J Neurophysiol** 1995 Sep;74(3):1248–57

Development of voltage-activated potassium currents in cultured cerebellar granule neurons under different growth conditions. Gorter JA, et al. **J Neurophysiol** 1995 Jul; 74(1):298–306

Comparison of voltage-dependent potassium currents in rat pyramidal neurons acutely isolated from hippocampal regions CA1 and CA3. Klee R, et al. **J Neurophysiol** 1995 Nov;74(5):1982–95

G alpha o1 decapeptide modulates the hippocampal 5-HT1A potassium current. Oleskevich S. **J Neurophysiol** 1995 Nov; 74(5):2189–93

Dopamine modulates the slow Ca(2+)-activated K+ current IAHP via cyclic AMP-dependent protein kinase in hippocampal neurons. Pedarzani P, et al. **J Neurophysiol** 1995 Dec;74(6):2749–53

Cellular short-term memory from a slow potassium conductance. Turrigiano GG, et al. **J Neurophysiol** 1996 Feb;75(2):963–6

Evidence for a contribution of ICa to serotonergic modulation of IK,Ca in Hermissenda photoreceptors. Yamoah EN, et al. **J Neurophysiol** 1995 Sep;74(3):1349–54

Layer-specific properties of the transient K current (IA) in piriform cortex. Banks MI, et al. **J Neurosci** 1996 Jun 15; 16(12):3862–76

Phenotypic alteration of a human BK (hSlo) channel by hSlobeta subunit coexpression: changes in blocker sensitivity, activation/relaxation and inactivation kinetics, and protein kinase A modulation. Dworetzky SI, et al. **J Neurosci** 1996 Aug 1;16(15):4543–50

A slowly inactivating potassium current in CA3 pyramidal cells of rat hippocampus in vitro. Lüthi A, et al. **J Neurosci** 1996 Jan 15;16(2):586–94

Homogeneous development of electrical excitability via heterogeneous ion channel expression. Ribera AB. **J Neurosci** 1996 Feb 1;16(3):1123–30

Repetitive depletion and recovery of intracellular K+ in retinal Müller glial cells during whole-cell voltage-clamp. Francke M, et al. **J Neurosci Methods** 1995 Sep-Oct; 61(1–2):169–84

L-type voltage-dependent Ca2+ and ATP-sensitive K+ channels are not involved in the regulation of bovine ciliary muscle contractility. Kageyama M, et al. **J Ocul Pharmacol Ther** 1995 Winter;11(4):553–63

Increased function of voltage-dependent Ca++ channels and Ca(++)-activated K+ channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. Asano M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):775–83

A novel P1 purinoceptor activates an outward K+ current in follicular oocytes of Xenopus laevis. King BF, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):93–100

Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes. McLarnon JG, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):389–96

A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. Arcangeli A, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):455–71

Characteristics of type I and type II K+ channels in rabbit cultured Schwann cells. Baker MD, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):79–95

Kinetic characterization of the voltage-gated currents possessed by Xenopus embryo spinal neurons. Dale N. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):473–88

A-type potassium current modulated by A1 adenosine receptor in frog melanotrophs. Mei YA, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):431–42

Apamin-sensitive K+ channels mediate an endothelium-dependent hyperpolarization in rabbit mesenteric arteries. Murphy ME, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):723–34

Single voltage-activated Na+ and K+ channels in the somata of rat motoneurones. Safronov BV, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):91–106

Osmo- and mechanosensitivity of the transient outward K+ current in a mammalian neuronal cell line. Schoenmakers TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):419–30

Potassium currents underlying the oscillatory response in hair cells of the goldfish sacculus. Sugihara I, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):443–53

KATP channel mediation of anoxia-induced outward current in rat dorsal vagal neurons in vitro. Trapp S, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):37–50

Whole-cell K+ currents in identified olfactory bulb output neurones of rats. Wang XY, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):63–77

Roles of arachidonic acid, lipoxygenases and phosphatases in calcium-dependent modulation of M-current in bullfrog sympathetic neurons. Yu SP. **J Physiol (Lond)** 1995 Sep 15;487 (Pt 3):797–811

Voltage-gated potassium currents in stratum oriens-alveus inhibitory neurones of the rat CA1 hippocampus. Zhang L, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):647–60

Potassium conductances underlying repolarization and after-hyperpolarization in rat CA1 hippocampal interneurones. Zhang L, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):661–72

A simple model of K+ channel activation in nerve membrane. Clay JR. **J Theor Biol** 1995 Jul 12;175(2):257–62

Adenosine triphosphate-sensitive K+ channels mediate postcardioplegia coronary hyperemia. Wang SY, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1073–82

Role of nitric oxide and potassium channels in the cholinergic relaxation of rabbit ear and femoral arteries: effects of cooling. García-Villalón AL, et al. **J Vasc Res** 1995 Nov-Dec;32(6):387–97

Structural motifs underlying voltage-dependent K+ channel function. Taglialatela M, et al. **Kidney Int** 1995 Oct; 48(4):918–22 (80 ref.)

Effects of alpha adrenergic stimulation on time independent potassium current of isolated ventricular myocytes. Gorostiza P, et al. **Life Sci** 1995 Mar 17;56(17):1407–14

Allergic airway response and potassium channels: histamine release and airway inflammation. Ichinose M, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:36–9

Modulation of a Ca(2+)-activated K+ channel by angiotensin II in rat adrenal glomerulosa cells: involvement of a G protein. Payet MD, et al. **Mol Endocrinol** 1995 Aug; 9(8):935–47

Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Gribkoff VK, et al. **Mol Pharmacol** 1996 Jul;50(1):206–17

Novel pharmacological properties of transient potassium currents in central neurons revealed by N-bromoacetamide and other chemical modifiers. Huang RC. **Mol Pharmacol** 1995 Sep;48(3):451–8

Modulation of the inwardly rectifying potassium channel

IRK1 by the m1 muscarinic receptor. Jones SV. **Mol Pharmacol** 1996 Apr;49(4):662–7

Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Lakhlani PP, et al. **Mol Pharmacol** 1996 Jul;50(1):96–103

k-Opioid receptor activation of a dendrotoxin-sensitive potassium channel mediates presynaptic inhibition of mossy fiber neurotransmitter release. Simmons ML, et al. **Mol Pharmacol** 1996 Jul;50(1):80–5

Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells. Walsh KB, et al. **Mol Pharmacol** 1996 Feb;49(2):379–86

D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Werner P, et al. **Mol Pharmacol** 1996 Apr;49(4):656–61

A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation [see comments] Patil N, et al. **Nat Genet** 1995 Oct;11(2):126–9 . Comment in: Nat Genet 1995 Oct;11(2):107–9.

The inconstancy of the human heart [news; comment] Miller C. **Nature** 1996 Feb 29;379(6568):767–8. Comment on: Nature 1996 Feb 29;379(6568):833–75.

Large- and small-conductance Ca(2+)-activated K+ channels: their role in the nicotinic receptor-mediated catecholamine secretion in bovine adrenal medulla. Wada A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):545–9

Clinical relevance of ATP-dependent potassium channels. Ligtenberg JJ, et al. **Neth J Med** 1995 Nov;47(5):241–51 (82 ref.)

The role of various calcium and potassium channels in the regulation of somatodendritic serotonin release. Bagdy E, et al. **Neurochem Res** 1995 Dec;20(12):1409–15

Axonal channelopathies: an evolving concept in the pathogenesis of peripheral nerve disorders. Gutmann L, et al. **Neurology** 1996 Jul;47(1):18–21

Episodic ataxia results from voltage-dependent potassium channels with altered functions. Adelman JP, et al. **Neuron** 1995 Dec;15(6):1449–54

Contribution of the S4 segment to gating charge in the Shaker K+ channel. Aggarwal SK, et al. **Neuron** 1996 Jun; 16(6):1169–77

Modulation of K+ current by frequency and external [K+]: a tale of two inactivation mechanisms. Baukrowitz T, et al. **Neuron** 1995 Oct;15(4):951–60

Identification and molecular localization of a pH-sensing domain for the inward rectifier potassium channel HIR. Coulter KL, et al. **Neuron** 1995 Nov;15(5):1157–68

Activation of light-dependent K+ channels in ciliary invertebrate photoreceptors involves cGMP but not the IP3/Ca2+ cascade. del Pilar Gomez M, et al. **Neuron** 1995 Sep;15(3):607–18

A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Inagaki N, et al. **Neuron** 1996 May;16(5):1011–7

Functional analysis of the weaver mutant GIRK2 K+ channel and rescue of weaver granule cells. Kofuji P, et al. **Neuron** 1996 May;16(5):941–52

Dynamic rearrangement of the outer mouth of a K+ channel during gating. Liu Y, et al. **Neuron** 1996 Apr;16(4):859–67

Calcineurin regulates M channel modal gating in sympathetic neurons. Marrion NV. **Neuron** 1996 Jan;16(1):163–73

Conversion of a delayed rectifier K+ channel to a voltage-gated inward rectifier K+ channel by three amino acid substitutions. Miller AG, et al. **Neuron** 1996 Apr; 16(4):853–8

Voltage-sensing residues in the S2 and S4 segments of the Shaker K+ channel. Seoh SA, et al. **Neuron** 1996 Jun; 16(6):1159–67

Identification of structural elements involved in G protein gating of the GIRK1 potassium channel. Slesinger PA, et al. **Neuron** 1995 Nov;15(5):1145–56

MinK residues line a potassium channel pore. Wang KW, et al. **Neuron** 1996 Mar;16(3):571–7

Determination of the subunit stoichiometry of an inwardly rectifying potassium channel. Yang J, et al. **Neuron** 1995 Dec;15(6):1441–7

Kinetics of A-currents in sympathetic preganglionic neurones and glial cells. Bordey A, et al. **Neuroreport** 1995 Dec 29;7(1):37–40

In situ recordings of presumed folliculo-stellate cells in the intermediate lobe of the pituitary gland of Xenopus laevis. Borst JG, et al. **Neurosci Lett** 1996 May 3;209(1):61–4

Hippocampal slices from prion protein null mice: disrupted Ca(2+)-activated K+ currents. Colling SB, et al. **Neurosci Lett** 1996 May 3;209(1):49–52

Proton modulation of outward K+ currents in interferon-gamma-activated microglia. Eder C, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):101–4

Inactivation of a high conductance calcium dependent potassium current in rat hippocampal neurons. McLarnon JG. **Neurosci Lett** 1995 Jun 23;193(1):5–8

An adenosine triphosphate (ATP)-sensitive K+ channel of rat neocortical neurons is bi-gated by intracellular ATP and voltage: a novel channel gating mechanism? Tang XD, et al. **Neurosci Lett** 1995 Jun 30;193(2):93–6

Different voltage-dependent potassium conductances regulate action potential repolarization and excitability in frog myelinated axon. Poulter MO, et al. **Neuroscience** 1995 Sep;68(2):497–504

Fast, persistent, Ca(2+)-dependent K+ current controls graded electrical activity in crayfish muscle. Araque A, et al. **Pflugers Arch** 1995 Aug;430(4):541–51

Caffeine enhancement of electrical activity through direct blockade of inward rectifying K+ currents in GH3 rat anterior pituitary cells. Barros F, et al. **Pflugers Arch** 1996 Jan;431(3):443–51

Natriuretic peptides increase a K+ conductance in rat mesangial cells. Cermak R, et al. **Pflugers Arch** 1996 Feb; 431(4):571–7

Serotonin and protein kinase C modulation of a rat brain inwardly rectifying K+ channel expressed in xenopus oocytes. DiMagno L, et al. **Pflugers Arch** 1996 Jan; 431(3):335–40

Direct measurements of Ca(2+)-activated K+ currents in inner hair cells of the guinea-pig cochlea using photolabile Ca2+ chelators. Dulon D, et al. **Pflugers Arch** 1995 Jul; 430(3):365–73

Characteristics of the delayed rectifier K current compared in myocytes isolated from the atrioventricular node and ventricle of the rabbit heart. Howarth FC, et al. **Pflugers Arch** 1996 Mar;431(5):713–22

Changes to erythrocyte membrane cation permeability induced by a bacterial toxin. Huntley JS, et al. **Pflugers Arch** 1996 Feb;431(4):668–70

Shear activated channels in cell-attached patches of cultured bovine aortic endothelial cells. Jacobs ER, et al. **Pflugers Arch** 1995 Nov;431(1):129–31

Activation of ATP-sensitive potassium channels in follicle-enclosed xenopus oocytes by the epileptogenic agent pentylenetetrazol. Klöcker N, et al. **Pflugers Arch** 1996 Mar;431(5):736–40

Regulation of smooth muscle delayed rectifier K+ channels by protein kinase A. Koh SD, et al. **Pflugers Arch** 1996 Jul;432(3):401–12

Modulation of Ca2+-activated K+ channels by Mg2+ and ATP in frog oxyntic cells. Komatsu H, et al. **Pflugers Arch** 1996 Feb;431(4):494–503

Immature properties of large-conductance calcium-activated potassium channels in rat neuroepithelium. Mienville JM, et al. **Pflugers Arch** 1996 Mar;431(5):763–70

Evidence that Ca/calmodulin-dependent protein kinase mediates the modulation of the Ca2+-dependent K+ current, IAHP, by acetylcholine, but not by glutamate, in hippocampal neurons. Pedarzani P, et al. **Pflugers Arch** 1996 Mar;431(5):723–8

Modification of C-type inactivating Shaker potassium channels by chloramine-T. Schlief T, et al. **Pflugers Arch** 1996 Feb;431(4):483–93

K+ channel antisense oligodeoxynucleotides inhibit cytokine-induced expansion of human hemopoietic progenitors. Shirihai O, et al. **Pflugers Arch** 1996 Feb; 431(4):632–8

beta-Adrenoceptor stimulation activates large-conductance Ca2+-activated K+ channels in smooth muscle cells from basilar artery of guinea pig. Song Y, et al. **Pflugers Arch** 1995 Oct;430(6):984–93

Cysteine-modifying reagents alter the gating of the rat cloned potassium channel Kv1.4. Stephens GJ, et al. **Pflugers Arch** 1996 Jan;431(3):435–42

The Ba2+ block of the ATP-sensitive K+ current of mouse pancreatic beta-cells. Takano M, et al. **Pflugers Arch** 1996 Feb;431(4):625–31

Molecular physiology of cardiac potassium channels. Deal KK, et al. **Physiol Rev** 1996 Jan;76(1):49–67 (186 ref.)

Three distinct structural environments of a transmembrane domain in the inwardly rectifying potassium channel ROMK1 defined by perturbation. Choe S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12046–9

Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Kleppisch T, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12441–5

A structural motif for the voltage-gated potassium channel pore. Lipkind GM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9215–9

Mutation of conserved negatively charged residues in the S2 and S3 transmembrane segments of a mammalian K+ channel selectively modulates channel gating. Planells-Cases R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9422–6

Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Sanguinetti MC, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2208–12

Microheterogeneity in heteromultimeric assemblies formed by Shaker (Kv1) and Shaw (Kv3) subfamilies of voltage-gated K+ channels. Shahidullah M, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):309–17

Potassium currents in motoneurones. McLarnon JG. **Prog Neurobiol** 1995 Dec;47(6):513–31 (82 ref.)

Characteristics of the inward-rectifying potassium current in mouse ventricular myocytes and its relation to early after-depolarization. Zhou Y, et al. **Sci China C Life Sci** 1996 Apr;39(2):133–43

A K+ channel worthy of attention [comment] Hille B. **Science** 1996 Sep 20;273(5282):1677. Comment on: Science 1996 Sep 20;273(5282):1709–14.

Ion channels: opening the gate. Kelner KL. **Science** 1996 Feb 2;271(5249):615

Small-conductance, calcium-activated potassium channels from mammalian brain [see comments] Köhler M, et al. **Science** 1996 Sep 20;273(5282):1709–14. Comment in: Science 1996 Sep 20;273(5282):1677.

Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Alkayed NJ, et al. **Stroke** 1996 May;27(5):971–9

Role of cyclic AMP in dopamine modulation of potassium channels on rat striatal neurons: regulation of a subconductance state. Greif GJ, et al. **Synapse** 1995 Nov; 21(3):275–7

Outward potassium currents activated by depolarization in rat globus pallidus. Stefani A, et al. **Synapse** 1995 Jun; 20(2):131–6

Ca(2+)-activated K+ currents in neurones: types, physiological roles and modulation. Sah P. **Trends Neurosci** 1996 Apr;19(4):150–4 (66 ref.)

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

[Inward rectifier potassium current in cultured embryonic chick ventricular myocytes and effect of culture time] Cai Z, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep; 26(3):291–5 (Eng. Abstr.) **(Chi)**

[Hyperpolarization-relaxation coupling in vascular smooth muscle] Yanagisawa T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):157–69 (57 ref.) (Eng. Abstr.) **(Jpn)**

[Primary structure and biophysical properties of inward rectifier K+ channels] Kubo Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2288–96 (37 ref.) **(Jpn)**

[Molecular structure and function of voltage-dependent K channels] Yamane T, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2280–7 (36 ref.) **(Jpn)**

[The dynamics of the ion currents in the membrane of an isolated mollusk neuron under the action of high pressure] Shushakov VV, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):114–8 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Light removes inactivation of the A-type potassium channels in scallop hyperpolarizing photoreceptors. Shimatani Y, et al. **J Neurosci** 1995 Oct;15(10):6489–97

ULTRASTRUCTURE

Imaging ROMK1 inwardly rectifying ATP-sensitive K+ channel protein using atomic force microscopy. Henderson RM, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8756–60

POTASSIUM CHLORIDE

NMR studies on water and polymer diffusion in dextran gels. Influence of potassium ions on microstructure formation and gelation mechanism. Watanabe T, et al. **Magn Reson Med** 1996 May;35(5):697–705

ADMINISTRATION & DOSAGE

Epidural injection of potassium hydrochloride [letter] Vercauteren M, et al. **Acta Anaesthesiol Scand** 1996 Apr; 40(4):505

Conversion of postischemic ventricular fibrillation with intraaortic infusion of potassium chloride [letter] [see comments] Ovrum E, et al. **Ann Thorac Surg** 1996 Jan; 61(1):275. Comment in: Ann Thorac Surg 1996 Aug;62(2):624.

Potassium conversion of ventricular fibrillation [letter; comment] Robicsek F. **Ann Thorac Surg** 1996 Jan;61(1):275 . Comment on: Ann Thorac Surg 1995 Jul;60(1):156–9.

[Preparation of suppurative wounds for autodermatoplasty with electrochemially activated solutions] Legchilo AN, et al. **Khirurgiia (Mosk)** 1996;(1):57–8 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Inadvertent epidural injection of potassium chloride. Report of two cases. Liu K, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1134–7

ANALYSIS

[Ion-selective microelectrodes: principle and application of in vivo measurements of ionic concentrations in cochlear endolymph] Li W, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):135–7 (Eng. Abstr.) **(Chi)**

METABOLISM

Ion selectivity of volume regulatory mechanisms present during a hypoosmotic challenge in vestibular dark cells. Shiga N, et al. **Biochim Biophys Acta** 1995 Nov 22; 1240(1):48–54

PHARMACOLOGY

Continuous exposure of cultured rat cerebellar macroneurons to ethanol-depressed NMDA and KCl-stimulated elevations of intracellular calcium. Zou JY, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):840–5

Differential tachykinin receptor subtype activation in capsaicin and KCl contractions of guinea pig trachealis. Mitchell RW, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L837–42

A revisitation on the mechanism of action of KCl-induced vascular smooth muscle contraction: a key role of cation binding to the plasma membrane. Kravtsov GM, et al.

Biol Signals 1995 May-Jun;4(3):160-7
Cation effects on the conformations of muscle and non-muscle alpha-actinins. Wenegieme EF, et al. **Biometals** 1996 Jul;9(3):259-65
Effect of swimming on vascular reactivity to phenylephrine and KCl in male rats. Jansakul C. **Br J Pharmacol** 1995 Jun;115(4):587-94
Involvement of class A calcium channels in the KCl induced Ca2+ influx in hippocampal synaptosomes. Malva JO, et al. **Brain Res** 1995 Oct 23;696(1-2):242-5
A morphometric analysis of exocytosis in KCl-stimulated bovine chromaffin cells. Fox GQ. **Cell Tissue Res** 1996 May;284(2):303-16
Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli. Study in perfused rat pancreas. Salas M, et al. **Diabete Metab** 1995 Oct; 21(4):269-73
Altered [Ca2+]i mobilization in diabetic cardiomyocytes: responses to caffeine, KCl, ouabain, and ATP. Yu JZ, et al. **Diabetes Res Clin Pract** 1995 Oct;30(1):9-20
Effects of pH and KCl on the conformations of creatine kinase from rabbit muscle. Infrared, circular dichroic and fluorescence studies. Raimbault C, et al. **Eur J Biochem** 1995 Dec 1;234(2):570-8
The role of potassium ion and extracellular alkalization in reinitiation of human spermatozoa preserved in electrolyte-free solution at 4 degrees C. Saito K, et al. **Fertil Steril** 1996 Jun;65(6):1214-8
Disruption of reconstituted nucleosomes. The effect of particle concentration, MgCl2 and KCl concentration, the histone tails, and temperature. Godde JS, et al. **J Biol Chem** 1995 Nov 17;270(46):27399-402
Potassium chloride effects on the hormonal signal transduction mechanisms underlying phasic myometrial contractions. Phillippe M, et al. **J Endocrinol** 1995 Sep; 146(3):485-93
Contractile dysfunction caused by normothermic ischaemia and KCL arrest in the isolated pig heart: a 31P NMR study. Kupriyanov VV, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1715-30
Functional reconstitution of KCl-evoked, Ca(2+)-dependent acetylcholine release system in Xenopus oocytes microinjected with presynaptic plasma membranes and synaptic vesicles. Canals JM, et al. **J Neurosci Res** 1996 Apr 15;44(2):106-14
Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. Huang YT, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):535-41
Improvement in functional recovery of the isolated guinea pig heart after hyperkalemic reperfusion with adenosine. Habazettl H, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):74-84
Role of inward and delayed rectifier currents in generation of early afterdepolarization in guinea pig ventricular myocytes under K(+)-free or low K+ superfusion. Fan JS, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan-Feb; 18(1):25-32
GABA concentrations in the striatum following repetitive cerebral ischemia. Mainprize T, et al. **Neurochem Res** 1995 Aug;20(8):957-61
Release of immunoreactive interleukin-1-alpha from rat hypothalamic explants is increased by bacterial lipopolysaccharide and high KCL concentrations. Mirtella A, et al. **Neuroimmunomodulation** 1994 Jan;1(1):23-7
Depolarizing stimuli induce high levels of dopamine synthesis in fetal rat sensory neurons. Hertzberg T, et al. **Neuroreport** 1995 Dec 29;7(1):233-7
[The effect of certain ions on the realization of the phase-dependent action of the vagus nerve on the heart rhythm in cats] Cherednik IL, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):65-70 (Eng. Abstr.) **(Rus)**
[Effects of potassium chloride and triamterene on kaliuresis, natriuresis and diuresis in congestive heart failure] Kabakov AI, et al. **Klin Med (Mosk)** 1995;73(5):33-5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The role of the vascular endothelium in the contractile responses of human chorionic plate artery in pre-eclampsia to prostaglandin F2 alpha, 5-hydroxytryptamine, and potassium chloride. Ezimokhai M, et al. **Res Exp Med (Berl)** 1995;195(3):171-82

TOXICITY

Dose-dependent promotion effects of potassium chloride on glandular stomach carcinogenesis in rats after initiation with N-methyl-N'-nitro-N-nitrosoguanidine and the synergistic influence with sodium chloride. Nishikawa A, et al. **Cancer Res** 1995 Nov 15;55(22):5238-41

POTASSIUM COMPOUNDS

In-vivo evaluation of a feldspathic ceramic system: 2-year results. Friedl KH, et al. **J Dent** 1996 Jan-Mar; 24(1-2):25-31
[Substitution of ascorbic acid for potassium bromide in the making of French bread] Corrales X, et al. **Arch Latinoam Nutr** 1993 Sep;43(3):234-40 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Administration of potassium perchlorate to improve the quality of gated blood pool imaging [letter] Ercan MT, et al. **Eur J Nucl Med** 1995 Nov;22(11):1356
[Comparison between intermittent retrograde cold blood cardioplegia and retrograde crystalloid cardioplegia] Yamazaki I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):467-71 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Early reaction type allergies and diseases of the respiratory passages in employees from persulphate production. Wrbitzky R, et al. **Int Arch Occup Environ Health** 1995; 67(6):413-7

CHEMISTRY

Factors affecting production of compound A from the interaction of sevoflurane with Baralyme and soda lime. Fang ZX, et al. **Anesth Analg** 1996 Apr;82(4):775-81
Reaction of ferrate (VI)/ferrate (V) with hydrogen peroxide and superoxide anion--a stopped-flow and premix pulse radiolysis study. Rush JD, et al. **Free Radic Res** 1996 Mar; 24(3):187-98
27Al magic-angle spinning nuclear magnetic resonance satellite transition spectroscopy of glasses in the system K2O-Al2O3-SiO2. Mundus C, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):79-88

PHARMACOLOGY

Effects of K+, pH and glutamate on 45Ca kinetics in hippocampal brain slices. Newman GC, et al. **J Neurosci Methods** 1995 Jun;59(1):111-20

POISONING

A case of blindness caused by acute iodine poisoning. Tong Y. **Chin Med J (Engl)** 1995 Jul;108(7):555-6
Bromide toxicosis secondary to renal insufficiency in an epileptic dog. Nichols ES, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):231-3

THERAPEUTIC USE

Metabolic recovery after global myocardial ischemia: effects of blood cardioplegic solutions. Carrier M, et al. **Can J Cardiol** 1996 Jun;12(6):607-11
High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. Shaw N, et al. **J Am Vet Med Assoc** 1996 Jan 15; 208(2):234-6

TOXICITY

Arsenic and chromium enhance transformation of bovine papillomavirus DNA-transfected C3H/10T1/2 cells. Kowalski LA, et al. **Cancer Lett** 1996 May 15;103(1):65-9

POTASSIUM CYANIDE

Cyanylation of the thiol of the cysteine of flavodoxin from Anabaena PCC 7119. Gallagher ME, et al. **Biochem Soc Trans** 1996 Feb;24(1):40S

ANTAGONISTS & INHIBITORS

Antagonistic effect of melatonin against cyanide-induced seizures and acute lethality in mice. Yamamoto H, et al. **Toxicol Lett** 1996 Sep;87(1):19-24
Effect of atropine on cyanide-induced acute lethality in mice. Yamamoto H. **Toxicol Lett** 1995 Oct;80(1-3):29-33
Antagonism of cyanide toxicity by isosorbide dinitrate: possible role of nitric oxide. Sun P, et al. **Toxicology** 1995 Dec 15;104(1-3):105-11

PHARMACOLOGY

Hydrogen oxidation by membranes from autotrophically grown Alcaligenes eutrophus H16: role of the cyanide-resistant pathway in energy transduction. Komen R, et al. **Arch Microbiol** 1996 Jun;165(6):418-20
Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration. Albury MS, et al. **J Biol Chem** 1996 Jul 19;271(29):17062-6
Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. Myers KM, et al. **J Neurochem** 1995 Dec;65(6):2432-40

POISONING

Neurological sequelae of cyanide intoxication--the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. Rosenow F, et al. **Ann Neurol** 1995 Nov;38(5):825-8
Relation between plasma lactate and blood cyanide concentrations in acute cyanide poisoning [see comments] Baud FJ, et al. **BMJ** 1996 Jan 6;312(7022):26-7. Comment in: BMJ 1996 Apr 20;312(7037):1039.
Delayed onset generalised dystonia after cyanide poisoning. Borgohain R, et al. **Clin Neurol Neurosurg** 1995 Aug; 97(3):213-5
Antidotal effect of dihydroxyacetone against cyanide toxicity in vivo. Niknahad H, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):186-91
Victims of cyanide poisoning make suitable organ donors [letter] Puig JM, et al. **Transpl Int** 1996;9(1):87-8

TOXICITY

Oxygen dependence of hepatocyte susceptibility to mitochondrial respiratory inhibitors. Niknahad H, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1859-65
Cyanide-induced apoptosis and oxidative stress in differentiated PC12 cells. Mills EM, et al. **J Neurochem** 1996 Sep;67(3):1039-46
The effects of injection of potassium cyanide into the sciatic nerve of the adult mouse: in vivo and electron microscopic studies. Hall SM. **J Neurocytol** 1972 Oct;1(3):233-54
Cyanide-induced neurotoxicity involves nitric oxide and reactive oxygen species generation after N-methyl-D-aspartate receptor activation. Gunasekar PG, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):150-5
ATP depletion by iodoacetate and cyanide in renal distal tubular cells. Lash LH, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):194-205
Paradoxical increase in peroxisomal cyanide-insensitive respiration following dietary exposure to WY-14,643 in the perfused liver. Bojes HK, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):202-9
Effect of atropine on cyanide-induced acute lethality in mice. Yamamoto H. **Toxicol Lett** 1995 Oct;80(1-3):29-33

POTASSIUM DEFICIENCY

see related
HYPOKALEMIA

COMPLICATIONS

Potassium depletion and salt-sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions. Wu X, et al. **Clin Exp Hypertens** 1995 Aug; 17(6):989-1008
Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. Jovanovic-Peterson L, et al. **J Am Coll Nutr** 1996 Feb;15(1):14-20 (64 ref.)
Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Bernardo JF, et al. **Nephron** 1995; 70(2):235-41

METABOLISM

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305-11 (51 ref.)
Alpha 2B-adrenergic receptors: immunolocalization and regulation by potassium depletion in rat kidney. Huang L, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F1015-26
Growth hormone (GH) receptor and GH-binding protein deficiency in the growth failure of potassium-depleted rats. Hochberg Z, et al. **J Endocrinol** 1995 Nov;147(2):253-8

PHYSIOPATHOLOGY

Role of skeletal muscle sodium pumps in the adaptation to potassium deprivation. McDonough AA, et al. **Acta Physiol Scand** 1996 Mar;156(3):295-304 (77 ref.)

POTASSIUM DICHROMATE

ADVERSE EFFECTS

Chromate allergy from 'antifreeze-antiboil'. Freeman S. **Australas J Dermatol** 1995 Aug;36(3):168
Allergic contact dermatitis to tefillin [letter; comment] Ross B, et al. **J Am Acad Dermatol** 1996 Jan;34(1):152-3. Comment on: J Am Acad Dermatol 1995 May;32(5 Pt 1):812-3.

CHEMISTRY

Effect of change in shape factor of a single crystal on its dissolution behavior. Dali MV, et al. **Pharm Res** 1996 Jan; 13(1):155-62

PHARMACOLOGY

Chromium(VI)-induced nuclear factor-kappa B activation in intact cells via free radical reactions. Ye J, et al. **Carcinogenesis** 1995 Oct;16(10):2401-5

TOXICITY

Assessment of the toxicity to algae of colored substances. Comber MH, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):922-8
Effects of Cr (VI) on ATPases in the brain and muscle of mudskipper, Boleophthalmus dentatus. Kundu R, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):723-9
Formation of paramagnetic chromium in liver of mice treated with dichromate (VI). Ueno S, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):165-71
An international evaluation of the murine local lymph node assay and comparison of modified procedures. Kimber I, et al. **Toxicology** 1995 Nov 20;103(1):63-73
Chromium fetotoxicity in mice during late pregnancy. Junaid M, et al. **Vet Hum Toxicol** 1995 Aug;37(4):320-3

POTASSIUM, DIETARY

ADMINISTRATION & DOSAGE

High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. Ishimitsu T, et al. **J Vasc Res** 1995 Nov-Dec; 32(6):406-12

The effect of increased salt intake on blood pressure of chimpanzees [see comments] Denton D, et al. **Nat Med** 1995 Oct;1(10):1009-16. Comment in: Nat Med 1995 Oct;1(10):994-6. Comment in: Nat Med 1996 Jan;2(1):2-4. Comment in: Nat Med 1996 Jan;2(1):3-4.

ADVERSE EFFECTS

Dietary salt and blood pressure [comment] Dyer AR, et al. **Nat Med** 1995 Oct;1(10):994-6 (18 ref.). Comment on: Nat Med 1995 Oct;1(10):1009-16.

CHEMISTRY see POTASSIUM/chemistry

PHARMACOLOGY

A compartmental model predicts that dietary potassium affects lithium dynamics in rats. Everts HB, et al. **J Nutr** 1996 May;126(5):1445-54

POTASSIUM GLUTAMATE see **GLUTAMATES**

POTASSIUM IODIDE

Utilization of glass HPLC autosampler vials as cuvettes in an iodometric assay of hydroperoxides. Caldwell CR. **Anal Biochem** 1996 Feb 15;234(2):234-6

ADMINISTRATION & DOSAGE

Earliest prevention of endemic goiter by iodine supplementation during pregnancy. Liesenkötter KP, et al. **Eur J Endocrinol** 1996 Apr;134(4):443-8

Correlation of plasma calcium with experimentally elevated cholesterol and triglycerides in laying hens. Harms RH, et al. **Poult Sci** 1995 Oct;74(10):1708-11

Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Yeung SC, et al. **Thyroid** 1995 Oct;5(5):403-5

[Incidence of endemic goiter--environmental factors and iodine prophylaxis in Southern Poland] Lutyński R. **Przegl Epidemiol** 1995;49(3):341-4 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Osmotic regulation of cytokine synthesis in vitro. Shapiro L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12230-4

THERAPEUTIC USE

[Clinical and metabolic response in goats with iodopenia after administration of potassium iodide] Bíreš J, et al. **Vet Med (Praha)** 1996 Jun;41(6):177-82 (Eng. Abstr.) **(Slo)**

POTASSIUM MAGNESIUM ASPARAGINATE see **POTASSIUM MAGNESIUM ASPARTATE**

POTASSIUM MAGNESIUM ASPARTATE

PHARMACOLOGY

[Effect of panangin on regenerative processes in tissues during lengthening of the extremities] Bazarnyĭ VV, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):308-9 **(Rus)**

POTASSIUM PERMANGANATE

CHEMISTRY

Structural distortions induced by integration host factor (IHF) at the H' site of phage lambda probed by (+)-CC-1065, pluramycin, and KMnO4 and by DNA cyclization studies. Sun D, et al. **Biochemistry** 1996 Aug 20;35(33):10815-27

Destruction of patulin and some other mycotoxins using potassium permanganate under alkaline conditions. Castegnaro M, et al. **IARC Sci Publ** 1991;(113):35-40

Understanding C-H bond oxidations: H. and H- transfer in the oxidation of toluene by permanganate [see comments] Gardner KA, et al. **Science** 1995 Sep 29;269(5232):1849-51 . Comment in: Science 1995 Sep 29;269(5232):1833.

PHARMACOLOGY

Effect of potassium permanganate, cobalt chloride and vitamin B complex on the haematological parameters of cadmium treated common carp, Cyprinus carpio. Kaviraj A, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(2):73-7

Immunohistochemical techniques: the effect of melanin bleaching [see comments] Foss AJ, et al. **Br J Biomed Sci** 1995 Mar;52(1):22-5. Comment in: Br J Biomed Sci 1995 Dec;52(4):325-6.

POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

POTASSIUM RADIOISOTOPES

ANALYSIS

An evaluation of ratio systems in radioecological studies. McGee EJ, et al. **Health Phys** 1996 Feb;70(2):215-21

Analysis of body-burden measurements of 137Cs and 40K in a Japanese group over a period of 5 years following the Chernobyl accident. Uchiyama M, et al. **Health Phys** 1996 Sep;71(3):320-5

Comparison of body composition measured by total body potassium and infrared interactance. Flynn MA, et al. **J Am Coll Nutr** 1995 Dec;14(6):652-5

POTATO VIRUS X see **POTEXVIRUS**

POTATO VIRUS Y see **POTYVIRUS**

POTATOES

Wheat bran suppresses potato starch--potentiated colorectal tumorigenesis at the aberrant crypt stage in a rat model. Young GP, et al. **Gastroenterology** 1996 Feb;110(2):508-14

Studies on glucoamylase produced from Aspergillus awamori (NRRL-3112) and their effect on saccharification of potato starch. Kumar Soni S, et al. **Indian J Exp Biol** 1995 Dec; 33(12):957-61

Mexican papita viroid: putative ancestor of crop viroids. Martínez-Soriano JP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9397-401

Digestion of wheat gluten and potato protein by the preruminant calf: digestibility, amino acid composition and immunoreactive proteins in ileal digesta. Branco-Pardal P, et al. **Reprod Nutr Dev** 1995;35(6):639-54

CHEMISTRY

Determination of thiabendazole residues in white and sweet potatoes by liquid chromatography with fluorescence detection. Arenas RV, et al. **J AOAC Int** 1995 Nov-Dec; 78(6):1455-8

The status of trace elements in staple foods. II. Some effects of cereal and potato processing. Brüggemann J, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):7-11

ENZYMOLOGY

Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Handa M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):916-23

The multiplicity of enzymatic DNA reduction: a new purification procedure for a DHA reducing protein from potato tubers. De Tullio MC, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun;71(5-6):163-70

Evidence for an association of ndh B, ndh J gene products and ferredoxin-NADP-reductase as components of a chloroplastic NAD(P)H dehydrogenase complex. Guedeney G, et al. **FEBS Lett** 1996 Jan 15;378(3):277-80

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423-36 (110 ref.)

Characterization of three potato lipoxygenases with distinct enzymatic activities and different organ-specific and wound-regulated expression patterns. Royo J, et al. **J Biol Chem** 1996 Aug 30;271(35):21012-9

Potato D-enzyme catalyzes the cyclization of amylose to produce cycloamylose, a novel cyclic glucan. Takaha T, et al. **J Biol Chem** 1996 Feb 9;271(6):2902-8

Cytochrome-c reductase/processing peptidase complex from potato mitochondria. Braun HP, et al. **Methods Enzymol** 1995;260:70-82

Cis-elements important for the expression of the ADP-glucose pyrophosphorylase small-subunit are located both upstream and downstream form its structural gene. Nakata PA, et al. **Mol Gen Genet** 1996 Mar 20; 250(5):581-92

Identification of the major starch synthase in the soluble fraction of potato tubers. Marshall J, et al. **Plant Cell** 1996 Jul;8(7):1121-35

A cytosolic phospholipase A2 from potato tissues appears to be patatin. Senda K, et al. **Plant Cell Physiol** 1996 Apr; 37(3):347-53

Accumulation of cytosolic glyceraldehyde-3-phosphate dehydrogenase RNA under biological stress conditions and elicitor treatments in potato. Laxalt AM, et al. **Plant Mol Biol** 1996 Mar;30(5):961-72

A reverse transcriptase activity in potato mitochondria. Moenne A, et al. **Plant Mol Biol** 1996 May;31(2):365-72

Adenosine 5'-diphosphate-glucose pyrophosphorylase from potato tuber. Significance of the N terminus of the small subunit for catalytic properties and heat stability. Ballicora MA, et al. **Plant Physiol** 1995 Sep;109(1):245-51

Polyphenol oxidase in potato. A multigene family that exhibits differential expression patterns. Thygesen PW, et al. **Plant Physiol** 1995 Oct;109(2):525-31

Molecular characterization of the plastidic glucose-6-phosphate dehydrogenase from potato in comparison to its cytosolic counterpart. von Schaewen A, et al. **Plant Physiol** 1995 Dec;109(4):1327-35

Mutagenesis of the potato ADPglucose pyrophosphorylase and characterization of an allosteric mutant defective in 3-phosphoglycerate activation. Greene TW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1509-13

GENETICS

Splicing and editing of rps10 transcripts in potato mitochondria. Zanlungo S, et al. **Curr Genet** 1995 May; 27(6):565-71

Molecular characterization of the spliceosomal proteins U1A and U2B" from higher plants. Simpson GG, et al. **EMBO J** 1995 Sep 15;14(18):4540-50

Chloroplast pentose-5-phosphate 3-epimerase from potato: cloning, cDNA sequence, and tissue-specific enzyme accumulation. Teige M, et al. **FEBS Lett** 1995 Dec 27; 377(3):349-52

Nucleotide sequences of novel potato (Solanum tuberosum L.) MADS-box cDNAs and their expression in vegetative organs. Kang SG, et al. **Gene** 1995 Dec 12;166(2):329-30

Segregation and recombination of Solanum brevidens synteny groups in progeny of somatic hybrids with S. tuberosum: intragenomic equals or exceeds intergenomic recombination. McGrath JM, et al. **Genetics** 1996 Apr; 142(4):1335-48

Analysis of the genetic composition of anther-derived potato by randomly amplified polymorphic DNA and simple sequence repeats. Veilleux RE, et al. **Genome** 1995 Dec; 38(6):1153-62

Agrobacterium-mediated transformation of potato genotypes. Kumar A. **Methods Mol Biol** 1995;44:121-8

Marker enrichment and high-resolution map of the segment of potato chromosome VII harbouring the nematode resistance gene Gro1. Ballvora A, et al. **Mol Gen Genet** 1995 Nov 1;249(1):82-90

A high-resolution map of the vicinity of the R1 locus on chromosome V of potato based on RFLP and AFLP markers. Meksem K, et al. **Mol Gen Genet** 1995 Nov 1; 249(1):74-81

Infections with various types of organisms stimulate transcription from a short promoter fragment of the potato gst1 gene. Strittmatter G, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):68-73

Exon skipping induced by cold stress in a potato invertase gene transcript. Bournay AS, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2347-51

A potato Sus3 sucrose synthase gene contains a context-dependent 3' element and a leader intron with both positive and negative tissue-specific effects. Fu H, et al. **Plant Cell** 1995 Sep;7(9):1395-403

Sink- and vascular-associated sucrose synthase functions are encoded by different gene classes in potato. Fu H, et al. **Plant Cell** 1995 Sep;7(9):1369-85

High-level tuber expression and sucrose inducibility of a potato Sus4 sucrose synthase gene require 5' and 3' flanking sequences and the leader intron. Fu H, et al. **Plant Cell** 1995 Sep;7(9):1387-94

The coat protein of potato virus X is a strain-specific elicitor of Rx1-mediated virus resistance in potato. Bendahmane A, et al. **Plant J** 1995 Dec;8(6):933-41

Expression of Escherichia coli branching enzyme in tubers of amylose-free transgenic potato leads to an increased branching degree of the amylopectin. Kortstee AJ, et al. **Plant J** 1996 Jul;10(1):83-90

A novel MADS-box gene of potato (Solanum tuberosum L.) expressed during the early stages of tuberization. Kang SG, et al. **Plant Mol Biol** 1996 May;31(2):379-86

Characterization of the potato mitochondrial transcription unit containing 'native' trnS (GCU), trnF (GAA) and trnP (UGG). Remacle C, et al. **Plant Mol Biol** 1996 Feb; 30(3):553-63

The starch phosphorylase gene is subjected to different modes of regulation in starch-containing tissues of potato. St-Pierre B, et al. **Plant Mol Biol** 1996 Mar;30(6):1087-98

Evidence for the expression of the triosephosphate translocator gene in green and non-green tissue of tomato and potato. Schünemann D, et al. **Plant Mol Biol** 1996 Apr;31(1):101-11

Molecular analysis of a pistil-specific gene expressed in the stigma and cortex of Solanum tuberosum. Van Eldik GJ, et al. **Plant Mol Biol** 1996 Jan;30(1):171-6

A potato cDNA encoding a homologue of mammalian multidrug resistant P-glycoprotein. Wang W, et al. **Plant Mol Biol** 1996 Jun;31(3):683-7

Adenosine 5'-diphosphate-glucose pyrophosphorylase from potato tuber. Significance of the N terminus of the small subunit for catalytic properties and heat stability. Ballicora MA, et al. **Plant Physiol** 1995 Sep;109(1):245-51

Molecular cloning and characterization of a soluble inorganic pyrophosphatase in potato. du Jardin P, et al. **Plant Physiol** 1995 Nov;109(3):853-60

Function of phytochrome A in potato plants as revealed through the study of transgenic plants. Heyer AG, et al. **Plant Physiol** 1995 Sep;109(1):53-61

Genetic modification of respiratory capacity in potato. Hiser C, et al. **Plant Physiol** 1996 Jan;110(1):277-86

[Mechanism of action of the plant hormone jasmonate. 1. Jasomonate-interacting proteins that regulate transcription of the p. pinII potato gene] Gurevich AI, et al. **Bioorg Khim** 1996 Feb;22(2):101-7 (Eng. Abstr.) **(Rus)**

[Fingerprinting of potato species and cultivar using RAPD-PCR] Oranisian AS, et al. **Genetika** 1996 Mar; 32(3):448-51 (Eng. Abstr.) **(Rus)**

METABOLISM

Molecular cloning and immunocytochemical localization of jasmonic acid inducible cathepsin D inhibitors from potato. Strukelj B, et al. **Adv Exp Med Biol** 1995;362:293–8

Electroporation of small RNAs into plant protoplasts: mitochondrial uptake of transfer RNAs. Wintz H, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):204–10

Splicing and editing of rps10 transcripts in potato mitochondria. Zanlungo S, et al. **Curr Genet** 1995 May; 27(6):565–71

Fate and impact of pesticides applied to potato cultures: the Nicolet River basin. Caux PY, et al. **Ecotoxicol Environ Saf** 1996 Mar;33(2):175–85

Mitochondria are a major site for folate and thymidylate synthesis in plants. Neuburger M, et al. **J Biol Chem** 1996 Apr 19;271(16):9466–72

Transfer RNA import into plant mitochondria. Marechal-Drouard L, et al. **Methods Enzymol** 1995; 260:310–27

A single editing event is a prerequisite for efficient processing of potato mitochondrial phenylalanine tRNA. Marechal-Drouard L, et al. **Mol Cell Biol** 1996 Jul; 16(7):3504–10

A receptor for protein import into potato mitochondria. Heins L, et al. **Plant J** 1996 Jun;9(6):829–39

Expression of Escherichia coli branching enzyme in tubers of amylose-free transgenic potato leads to an increased branching degree of the amylopectin. Kortstee AJ, et al. **Plant J** 1996 Jul;10(1):83–90

Isolation of a polyubiquitin promoter and its expression in transgenic potato plants. Garbarino JE, et al. **Plant Physiol** 1995 Dec;109(4):1371–8

Function of phytochrome A in potato plants as revealed through the study of transgenic plants. Heyer AG, et al. **Plant Physiol** 1995 Sep;109(1):53–61

MICROBIOLOGY

Application of the PCR technique to detect Phytophthora infestans in potato tubers and leaves. Niepold F, et al. **Microbiol Res** 1995 Nov;150(4):379–85

Presence of Ty1-copia group retrotransposon sequences in the potato late blight pathogen Phytophthora infestans. Tooley PW, et al. **Mol Plant Microbe Interact** 1996 May; 9(4):305–9

PHYSIOLOGY

Suppression of the hypersensitive response in potato by acetyl salicylic acid. Lee M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):309–11

The sugar composition and partial structure of the self-induced endogenous elicitor from potato. Monden T, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):768–73

Protoplast electrofusion and regeneration in potato. Cheng J, et al. **Methods Mol Biol** 1995;55:181–8

Visualization of differential gene expression using a novel method of RNA fingerprinting based on AFLP: analysis of gene expression during potato tuber development. Bachem CW, et al. **Plant J** 1996 May;9(5):745–53

Reduction of the cytosolic fructose-1,6-bisphosphatase in transgenic potato plants limits photosynthetic sucrose biosynthesis with no impact on plant growth and tuber yield. Zrenner R, et al. **Plant J** 1996 May;9(5):671–81

TOXICITY

A study of the toxic hazard that might be associated with the consumption of green potato tops. Phillips BJ, et al. **Food Chem Toxicol** 1996 May;34(5):439–48

VIROLOGY

Optimum conditions for the storage of potato virus S. Cefovská N, et al. **Acta Virol** 1995 Feb;39(1):51–2

Comparison of the nucleotide sequences of the 3'-terminal regions of one aphid and two non-aphid transmissible isolates of potato A potyvirus. Andrejeva J, et al. **Arch Virol** 1996;141(7):1207–19

Ultrastructural study of acquisition and retention of potato leafroll luteovirus in the alimentary canal of its aphid vector, Myzus persicae Sulz. Garret A, et al. **Arch Virol** 1996;141(7):1279–92

Pseudorecombination and complementation between potato yellow mosaic geminivirus and tomato golden mosaic geminivirus. Sung YK, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2809–15

Only one of four possible secondary structures of the central conserved region of potato spindle tuber viroid is a substrate for processing in a potato nuclear extract. Baumstark T, et al. **Nucleic Acids Res** 1995 Nov 11; 23(21):4246–54

The coat protein of potato virus X is a strain-specific elicitor of Rx1-mediated virus resistance in potato. Bendahmane A, et al. **Plant J** 1995 Dec;8(6):933–41

POTENTIOMETRY

Potentiometric and spectroscopic studies on the copper(II) complexes of peptide hormones containing disulfide bridges. Danyi P, et al. **J Inorg Biochem** 1995 Oct; 60(1):69–78

Intramolecular domain-domain interactions and intermolecular self-association in bovine prothrombin. A potentiometric and laser light-scattering study. Koehler KA, et al. **J Protein Chem** 1995 Oct;14(7):537–48

Potentiometric, enantioselective sensors for alkyl and aryl ammonium ions of pharmaceutical significance, based on lipophilic cyclodextrins. Kataky R, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):409–19

INSTRUMENTATION

A plug-in minielectrode for measurements in stirred photometric cuvettes. Rustenbeck I, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3–4):105–12

METHODS

Potentiometric anion selectivity of polymer membranes doped with palladium organophosphine complex. Badr IH, et al. **Anal Chem** 1995 Aug 1;67(15):2613–8

Influence of nonionic surfactants on the potentiometric response of hydrogen ion-selective polymeric membrane electrodes. Espadas-Torre C, et al. **Anal Chem** 1996 May 1;68(9):1623–31

The effect of polyethylene glycol on the charcoal adsorption of chlorpromazine studied by ion selective electrode potentiometry. Atta-Politou J, et al. **J Toxicol Clin Toxicol** 1996;34(3):307–16

STATISTICS & NUMERICAL DATA

Analyzer-dependent differences in results for ionized calcium, ionized magnesium, sodium, and pH. Hristova EN, et al. **Clin Chem** 1995 Nov;41(11):1649–53

POTEXVIRUS

GENETICS

Characterization of cassava common mosaic virus and a defective RNA species. Calvert LA, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):525–30

Synthesis of potato virus X RNAs by membrane-containing extracts. Doronin SV, et al. **J Virol** 1996 Jul;70(7):4795–9

Coat protein sequence of a resistance-breaking strain of potato virus X isolated in Argentina. Feigelstock DA, et al. **Virus Genes** 1995;10(3):289–92

METABOLISM

Subcellular immunolocalization of the coat protein of two potexviruses in infected Chenopodium quinoa. Rouleau M, et al. **Virology** 1995 Dec 1;214(1):314–8

PATHOGENICITY

The coat protein of potato virus X is a strain-specific elicitor of Rx1-mediated virus resistance in potato. Bendahmane A, et al. **Plant J** 1995 Dec;8(6):933–41

PHYSIOLOGY

The coat protein of potato virus X is a strain-specific elicitor of Rx1-mediated virus resistance in potato. Bendahmane A, et al. **Plant J** 1995 Dec;8(6):933–41

Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. Cruz SS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6286–90

The open reading frame of bamboo mosaic potexvirus satellite RNA is not essential for its replication and can be replaced with a bacterial gene. Lin NS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3138–42

Cell-to-cell movement of potato virus X is associated with a change in the size-exclusion limit of plasmodesmata in trichome cells of Nicotiana clevelandii. Angell SM, et al. **Virology** 1996 Feb 1;216(1):197–201

ULTRASTRUCTURE

An appraisal of the banded and paracrystalline cytoplasmic inclusions induced in cymbidium mosaic potexvirus- and odontoglossum ringspot tobamovirus infected orchid cells using confocal laser scanning microscropy. Wong SM, et al. **Arch Virol** 1996;141(2):231–42

POTTOS see **LORISIDAE**

POTT'S DISEASE see **TUBERCULOSIS, SPINAL**

POTYVIRUS

CHEMISTRY

Nucleic acid-binding properties of a bacterially expressed potato virus Y helper component-proteinase. Maia IG, et al. **J Gen Virol** 1996 May;77 (Pt 5):869–77

CLASSIFICATION

Molecular evidence that the whitefly-transmitted sweetpotato mild mottle virus belongs to a distinct genus of the Potyviridae. Colinet D, et al. **Arch Virol** 1996; 141(1):125–35

Determination of the taxonomic position and characterization of yam mosaic virus isolates based on sequence data of the 5'-terminal part of the coat protein cistron. Duterme O, et al. **Arch Virol** 1996;141(6):1067–75

Improved diagnosis of cowpea aphid-borne mosaic virus in Africa: significance for cowpea seed-indexing, breeding programs and potyvirus taxonomy. Huguenot C, et al. **Arch Virol** 1996;141(1):137–45

ENZYMOLOGY

Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):191–5

Expression, purification, and identification of a novel self-cleavage site of the Nla C-terminal 27-kDa protease of turnip mosaic potyvirus C5. Kim DH, et al. **Virology** 1995 Nov 10;213(2):517–25

Characterization of Nla protease from turnip mosaic potyvirus exhibiting a low-temperature optimum catalytic activity. Kim DH, et al. **Virology** 1996 Jul 1;221(1):245–9

GENETICS

Comparison of the nucleotide sequences of the 3'-terminal regions of one aphid and two non-aphid transmissible isolates of potato A potyvirus. Andrejeva J, et al. **Arch Virol** 1996;141(7):1207–19

Determination of the taxonomic position and characterization of yam mosaic virus isolates based on sequence data of the 5'-terminal part of the coat protein cistron. Duterme O, et al. **Arch Virol** 1996;141(6):1067–75

The complete nucleotide sequence of bean yellow mosaic potyvirus RNA. Guyatt KJ, et al. **Arch Virol** 1996; 141(7):1231–46

Nucleotide sequence of the capsid protein gene of papaya leaf-distortion mosaic potyvirus. Maoka T, et al. **Arch Virol** 1996;141(1):197–204

Nucleotide and deduced amino acid sequence of the 3' end of the BYMV-MI genome. Mathews A, et al. **Arch Virol** 1995;140(12):2269–72

Sequence of the 3'-terminal region of a Zimbabwe isolate of cowpea aphid-borne mosaic virus (CABMV). Sithole-Niang I, et al. **Arch Virol** 1996;141(5):935–43

The cDNA sequence and infectious transcripts of peanut stripe virus. Flasinski S, et al. **Gene** 1996 Jun 1; 171(2):299–300

The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation. Gallie DR, et al. **Gene** 1995 Nov 20;165(2):233–8

Cell-free cloning and biolistic inoculation of an infectious cDNA of potato virus Y. Fakhfakh H, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):519–23

Particle bombardment drastically increases the infectivity of cloned DNA of zucchini yellow mosaic potyvirus. Gal-On A, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3223–7

Biological and molecular properties of a pathotype P-1 and a pathotype P-4 isolate of pea seed-borne mosaic virus. Johansen IE, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1329–33

Genomic reassortment of barley mild mosaic virus: evidence for the involvement of RNA1 in pathogenicity. Kashiwazaki S, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):581–5

Frequent occurrence of recombinant potyvirus isolates. Revers F, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1953–65

Roles of the sequence encoding tobacco etch virus capsid protein in genome amplification: requirements for the translation process and a cis-active element. Mahajan S, et al. **J Virol** 1996 Jul;70(7):4370–9

RNA-mediated resistance with nonstructural genes from the tobacco etch virus genome. Swaney S, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec;8(6):1004–11

Characterization of fungally and mechanically transmitted isolates of barley mild mosaic virus: two strains in competition. Dessens JT, et al. **Virology** 1995 Oct 1; 212(2):383–91

The complete nucleotide sequence of barley mild mosaic virus RNA1 and its relationship with other members of the Potyviridae. Meyer M, et al. **Virology** 1996 May 1; 219(1):268–73

Nucleotide sequence of a strain of tobacco etch virus that does not cause Tabasco pepper wilt. Chu M, et al. **Virus Genes** 1995;10(3):283–8

Reason for non-aphid transmissibility in a strain of Kalanchoë mosaic potyvirus. Husted K. **Virus Genes** 1995;11(1):59–61

The complete nucleotide sequence and genome organization of bean common mosaic virus (NL3 strain). Fang GW, et al. **Virus Res** 1995 Nov;39(1):13–23

The complete nucleotide sequence of RNA-2 of a fungally-transmitted UK isolate of barley mild mosaic bymovirus and identification of amino acid combinations possibly involved in fungus transmission. Peerenboom E, et al. **Virus Res** 1996 Feb;40(2):149–59

Infectious in vitro transcripts from cloned cDNA of the potato A potyvirus. Puurand U, et al. **Virus Res** 1996 Feb; 40(2):135–40

Molecular characterisation of UK isolates of barley yellow mosaic bymovirus. Shi NN, et al. **Virus Res** 1995 Oct; 38(2–3):193–204

[Transgenic Brassica napus resistant to turnip mosaic virus] Lu A, et al. **I Chuan Hsueh Pao** 1996;23(1):77–83 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Expression, purification, and use as an antigen of recombinant sugarcane mosaic virus coat protein. Smith GR, et al. **Arch Virol** 1995;140(10):1817–31

POTYVIRUS

ISOLATION & PURIFICATION

Identification of Zucchini yellow mosaic potyvirus by RT-PCR and analysis of sequence variability. Thomson KG, et al. **J Virol Methods** 1995 Sep;55(1):83-96

METABOLISM

Cooperative binding to nucleic acids by barley yellow mosaic bymovirus coat protein and characterization of a nucleic acid-binding domain. Reichel C, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):587-92

A potyvirus polymerase interacts with the viral coat protein and VPg in yeast cells. Hong Y, et al. **Virology** 1995 Dec 1;214(1):159-66

Inhibition of viral aphid transmission by the N-terminus of the maize dwarf mosaic virus coat protein. Salomon R, et al. **Virology** 1995 Nov 10;213(2):676-9

PATHOGENICITY

Particle bombardment drastically increases the infectivity of cloned DNA of zucchini yellow mosaic potyvirus. Gal-On A, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3223-7

Biological and molecular properties of a pathotype P-1 and a pathotype P-4 isolate of pea seed-borne mosaic virus. Johansen IE, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1329-33

Switches in the mode of transmission select for or against a poorly aphid-transmissible strain of potato virus Y with reduced helper component and virus accumulation. Legavre T, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1343-7

Effective resistance to potyvirus infection conferred by expression of antisense RNA in transgenic plants. Hammond J, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):674-82

Genetic and biochemical dissection of transgenic RNA-mediated virus resistance. Goodwin J, et al. **Plant Cell** 1996 Jan;8(1):95-105

PHYSIOLOGY

Replication slippage in the evolution of potyviruses. Hancock JM, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3229-32

Potyviral HC-Pro: a multifunctional protein. Maia IG, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1335-41 (51 ref.)

In vitro transcripts of a full-length cDNA of a naturally deleted RNA2 of barley mild mosaic virus (BaMMV) replicate in BaMMV-infected plants. Timpe U, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2619-23

Loss of potyvirus transmissibility and helper-component activity correlate with non-retention of virions in aphid stylets. Wang RY, et al. **J Gen Virol** 1996 May;77 (Pt 5):861-7

Suppression of long-distance movement of tobacco etch virus in a nonsusceptible host. Schaad MC, et al. **J Virol** 1996 Apr;70(4):2556-61

Replacement of the tyrosine residue that links a potyviral VPg to the viral RNA is lethal. Murphy JF, et al. **Virology** 1996 Jun 15;220(2):535-8

POULTRY

Cryopreservation of poultry semen. Tselutin K, et al. **Br Poult Sci** 1995 Dec;36(5):805-11

Respiratory function in poultry workers and pharmacologic characterization of poultry dust extract. Zuskin E, et al. **Environ Res** 1995 Jul;70(1):11-9

Estimating the economic benefits of avoiding food-borne risk: is 'willingness to pay' feasible? Donaldson C, et al. **Epidemiol Infect** 1996 Jun;116(3):285-94

The speciation and subtyping of campylobacter isolates from sewage plants and waste water from a connected poultry abattoir using molecular techniques. Koenraad PM, et al. **Epidemiol Infect** 1995 Dec;115(3):485-94

Antibiotic susceptibility of campylobacter isolates from sewage and poultry abattoir drain water. Koenraad PM, et al. **Epidemiol Infect** 1995 Dec;115(3):475-83

Playing chicken with people: the occupational safety and health consequences of throughput über alles. Linder M. **Int J Health Serv** 1995;25(4):633-66 (184 ref.)

Occupational exposure to poultry and prevalence of antibodies against Marek's disease virus and avian leukosis retroviruses. Choudat D, et al. **Occup Environ Med** 1996 Jun;53(6):403-10

Biodegradability and microbial activities during composting of poultry litter. Atkinson CF, et al. **Poult Sci** 1996 May; 75(5):608-17

Analysis of the causes of high rates of carcase rejection at a poultry processing plant. Yogaratnam V. **Vet Rec** 1995 Aug 26;137(9):215-7

Polymerase chain reaction assay for detection of Campylobacter coli and Campylobacter jejuni in poultry meat. Manzano M, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):370-86

[50-year anniversary Group Poultry Sciences. Poultry practice at the turn of the century] Ubbink S. **Tijdschr Diergeneeskd** 1996 May 15;121(10):292-5 **(Dut)**

[Structural changes in the poultry production industry and in the tasks of veterinarians] Hafez HM. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):265-8 (Eng. Abstr.) **(Ger)**

[Aspects of animal welfare relevant to poultry exhibitions] Mantel T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):129-30 (Eng. Abstr.) **(Ger)**

[Lipid peroxidation and antioxidant system in neurovascular disorders among poultry farm workers] Dobzhanskiĭ IS, et al. **Med Tr Prom Ekol** 1995;(10):37-9 (Eng. Abstr.) **(Rus)**

[The characteristics of the protein and lipid metabolic indices of poultry farmers with extrinsic allergic alveolitis] Reheda MS. **Fiziol Zh** 1994 Sep-Dec;40(5-6):118-20 (Eng. Abstr.) **(Ukr)**

ANATOMY & HISTOLOGY

Liquid chromatographic determination of furazolidone in swine serum and avian egg. Yoshida K, et al. **J AOAC Int** 1995 Jul-Aug;78(4):1126-9

GENETICS

Maximizing selection efficiency for categorical traits. Meuwissen TH, et al. **J Anim Sci** 1995 Jul;73(7):1933-9

Monophyletic origin and unique dispersal patterns of domestic fowls. Fumihito A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6792-5

GROWTH & DEVELOPMENT

Incremental changes in and distribution of chick weight with hen age in four poultry species. Shalev BA, et al. **Br Poult Sci** 1995 Jul;36(3):415-24

IMMUNOLOGY

Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicals. Bruckner L, et al. **Dev Biol Stand** 1996; 86:175-82

MICROBIOLOGY

Detection of Mycoplasma gallisepticum, M. synoviae, and M. iowae by multi-species polymerase chain reaction and restriction fragment length polymorphism. Garcia M, et al. **Avian Dis** 1995 Jul-Sep;39(3):606-16

Polymerase chain reaction-restriction fragment length polymorphism analysis: a simple method for species identification in food. Meyer R, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1542-51

Penner serotyping of Campylobacter isolates from poultry, with absorbed pooled antisera. Jacobs-Reitsma WF, et al. **J Appl Bacteriol** 1995 Sep;79(3):286-91

Prevalence of Salmonella enteritidis in poultry shell eggs in Arkansas. Schutze GE, et al. **South Med J** 1996 Sep; 89(9):889-91

Molecular studies on avian strains of Pasteurella multocida in Australia. Diallo IS, et al. **Vet Microbiol** 1995 Sep; 46(1-3):335-42

Phenotypic characterisation of Pasteurella multocida isolates from Australian poultry. Fegan N, et al. **Vet Microbiol** 1995 Dec;47(3-4):281-6

Susceptibility of poultry lactobacilli to ionophore antibiotics. Marounek M, et al. **Zentralbl Veterinarmed [B]** 1995 Jun; 42(4):193-6

PHYSIOLOGY

["Breeding for distress" in fowl] Bartels T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):117-9 (34 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicals. Bruckner L, et al. **Dev Biol Stand** 1996; 86:175-82

POULTRY DISEASES

Salmonella enteritidis in eggs, cloacal swab specimens, and internal organs of experimentally infected White Leghorn chickens. Bichler LA, et al. **Am J Vet Res** 1996 Apr; 57(4):489-95

Eimeria tenella and E. acervulina: differences in ability to elicit cross-species protection as compared with the turkey coccidium, E. adenoeides. Augustine PC, et al. **Avian Dis** 1995 Oct-Dec;39(4):709-17

Efficacy of miconazole nitrate against favus in oriental breed chickens. Bradley FA, et al. **Avian Dis** 1995 Oct-Dec; 39(4):900-1

Quantification of experimental Salmonella enteritidis carrier state in B13 leghorn chicks. Duchet-Suchaux M, et al. **Avian Dis** 1995 Oct-Dec;39(4):796-803

Studies of intraspecies heterogeneity of mycoplasma synoviae, M. meleagridis, and M. iowae with arbitrarily primed polymerase chain reaction. Fan HH, et al. **Avian Dis** 1995 Oct-Dec;39(4):766-77

Application of polymerase chain reaction with arbitrary primers to strain identification of Mycoplasma gallisepticum. Fan HH, et al. **Avian Dis** 1995 Oct-Dec; 39(4):729-35

Dual infection of chickens with pox and infectious laryngotracheitis (ILT) confirmed with specific pox and ILT DNA dot-blot hybridization assays. Fatunmbi OO, et al. **Avian Dis** 1995 Oct-Dec;39(4):925-30

Natural infection with attaching and effacing Escherichia coli (O 103:H-) in chicks. Fukui H, et al. **Avian Dis** 1995 Oct-Dec;39(4):912-8

A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Khoury CA, et al. **Avian Dis** 1995 Oct-Dec;39(4):812-20

Invasion of Caco-2 cells by Salmonella typhimurium (Copenhagen) isolates from healthy and sick chickens. Kottom TJ, et al. **Avian Dis** 1995 Oct-Dec;39(4):867-72

Avian mycoplasma identification using polymerase chain reaction amplicon and restriction fragment length polymorphism analysis. Lauerman LH, et al. **Avian Dis** 1995 Oct-Dec;39(4):804-11

Immunohistochemical study of a chondroitin-6-sulfate in growth plates of broiler chickens with high and low genetic predispositions to tibial dyschondroplasia. Ling J, et al. **Avian Dis** 1996 Jan-Mar;40(1):88-98

The identification of an 18,000-molecular-weight antigen specific to big liver and spleen disease. McAlinden VA, et al. **Avian Dis** 1995 Oct-Dec;39(4):788-95

A sequential histopathologic and immunocytochemical study of chickens, turkey poults, and broiler breeders experimentally infected with turkey rhinotracheitis virus. Majó N, et al. **Avian Dis** 1995 Oct-Dec;39(4):887-96

Immunosuppressive potential and pathogenicity of an avian adenovirus isolate involved in hydropericardium syndrome in broilers. Naeem K, et al. **Avian Dis** 1995 Oct-Dec; 39(4):723-8

Intratracheal infection of chickens with Salmonella enteritidis and the effect of feed and water deprivation. Nakamura M, et al. **Avian Dis** 1995 Oct-Dec;39(4):853-8

Experimental reduction of eggshell conductance during incubation. I. effect on the susceptibility to ascites syndrome. Odom TW, et al. **Avian Dis** 1995 Oct-Dec; 39(4):821-9

Evaluation of enrofloxacin against egg transmission of Mycoplasma gallisepticum. Ortiz A, et al. **Avian Dis** 1995 Oct-Dec;39(4):830-6

Pathogenicity and persistence of Salmonella enteritidis and egg contamination in normal and infectious bursal disease virus-infected leghorn chicks. Phillips RA, et al. **Avian Dis** 1995 Oct-Dec;39(4):778-87

Receptivity and susceptibility of the domestic duck (Anas platyrhynchos), the Muscovy duck (Cairina moschata), and their hybrid, the mule duck, to an experimental infection by Eimeria mulardi. Sercy O, et al. **Avian Dis** 1996 Jan-Mar;40(1):23-7

Histopathology and epidemiology of condemnations due to squamous cell carcinoma in broiler chickens in North Carolina. Weinstock D, et al. **Avian Dis** 1995 Oct-Dec; 39(4):676-86

Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV. Whitfill CE, et al. **Avian Dis** 1995 Oct-Dec;39(4):687-99

Ascaridia dissimilis larval migration associated with enteritis and low market weights in meat turkeys. Willoughby DH, et al. **Avian Dis** 1995 Oct-Dec;39(4):837-43

Esophageal trichomoniasis in chickens. Willoughby DH, et al. **Avian Dis** 1995 Oct-Dec;39(4):919-24

In vivo role of tumor necrosis-like factor in Eimeria tenella infection. Zhang S, et al. **Avian Dis** 1995 Oct-Dec; 39(4):859-66

Studies on the efficacy of combined immunostimulant-antibiotic therapy against experimental Mycoplasma gallisepticum infection in chickens. Hanafy MS, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):408-9

Expression of aberrantly spliced growth hormone receptor mRNA in the sex-linked dwarf chicken, Gifu 20. Tanaka M, et al. **Growth Regul** 1995 Dec;5(4):218-23

Intratesticular retention of sperm and premature decline in fertility in the domestic rooster, Gallus domesticus. Muncher Y, et al. **J Exp Zool** 1995 Sep 1;273(1):76-81

Gross and histologic lesions of adenovirus group I in guinea fowl. Charlton BR, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):552-4

Experimental hepatitis induced by Campylobacter jejuni infection in Japanese quail (Coturnix coturnix japonica). Misawa N, et al. **J Vet Med Sci** 1996 Mar;58(3):205-10

Protoporphyric disorder in livers of broiler chickens. Shiozawa M, et al. **J Vet Med Sci** 1995 Jun;57(3):549-51

Recent characterization of Salmonella strains isolated from chickens in Zambia. Tuchili L, et al. **J Vet Med Sci** 1996 Jan;58(1):77-8

Pulmonary arteriole hypertrophy in broilers with pulmonary hypertension syndrome (ascites). Enkvetchakul B, et al. **Poult Sci** 1995 Oct;74(10):1677-82

Immunolocalization of basic fibroblastic growth factor in avian tibial dyschondroplastic cartilage. Twal WO, et al. **Poult Sci** 1996 Jan;75(1):130-4

Restriction fragment length polymorphism of polymerase chain reaction products applied to the differentiation of poultry campylobacters for epidemiological investigations. Ayling RD, et al. **Res Vet Sci** 1996 Mar;60(2):168-72

Density and breaking strength of bones of mortalities among caged layers. McCoy MA, et al. **Res Vet Sci** 1996 Mar; 60(2):185-6

Sequential studies of endochondral ossification and serum 1,25-dihydroxycholecalciferol in broiler chickens between one and 21 days of age. Parkinson G, et al. **Res Vet Sci** 1996 Mar;60(2):173-8

Molecular studies on avian strains of Pasteurella multocida in Australia. Diallo IS, et al. **Vet Microbiol** 1995 Sep;

46(1-3):335-42

Chlamydia psittaci in turkeys: pathogenesis of infections in avian serovars A, B and D. Vanrompay D, et al. **Vet Microbiol** 1995 Dec;47(3-4):245-56

Serum sensitivity and apathogenicity for chickens and chick embryos of Escherichia coli J5 strain. Abdul-Aziz TA, et al. **Vet Res** 1996;27(3):267-71

[Resistance to tetracycline of E. coli of chicken intestines after prophylactic treatment of animal feed with bioptivet GB] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov;108(11):412-7 (Eng. Abstr.) **(Ger)**

[Structural changes in the poultry production industry and in the tasks of veterinarians] Hafez HM. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):265-8 (Eng. Abstr.) **(Ger)**

[Endomycoses--a problem in the diagnosis of Chlamydia psittaci infections in chickens] Reetz J, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Sep;102(9):360-5 (Eng. Abstr.) **(Ger)**

[Animal housing climatic quality in various harmful conditions in broiler production to avoid heat stress in summer] Tegethoff V, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar;103(3):87-91 (Eng. Abstr.) **(Ger)**

[Skin diseases as a reason for condemnation of broiler carcasses] Bergmann V, et al. **Tierarztl Prax** 1995 Aug; 23(4):374-80 (Eng. Abstr.) **(Ger)**

BLOOD

Pulsatile secretion of prolactin in laying and incubating turkey hens. Proudman JA, et al. **Domest Anim Endocrinol** 1996 May;13(3):277-82

Alterations in blood leukocyte populations in Smyth line chickens with autoimmune vitiligo. Erf GF, et al. **Poult Sci** 1996 Mar;75(3):351-6

Hematocrit values and mortality from ascites in cold-stressed broilers from parents selected by hematocrit. Shlosberg A, et al. **Poult Sci** 1996 Jan;75(1):1-5

CHEMICALLY INDUCED

Experimental furazolidone toxicosis in broiler chicks: effect of dosage, duration and age upon clinical signs and some blood parameters. Zaman Q, et al. **Acta Vet Hung** 1995; 43(2-3):359-67

Salinomycin toxicosis in male breeder turkeys. Andreasen JR Jr, et al. **Avian Dis** 1995 Jul-Sep;39(3):638-42

Fatty liver-hemorrhagic syndrome observed in commercial layers fed diets containing chelated minerals. Branton SL, et al. **Avian Dis** 1995 Jul-Sep;39(3):631-5

Cyclophosphamide (Cytoxan)-induced hematologic alterations in specific-pathogen-free chickens. Fulton RM, et al. **Avian Dis** 1996 Jan-Mar;40(1):1-12

Copper sulfate toxicosis in commercial laying hens. Gilbert RW, et al. **Avian Dis** 1996 Jan-Mar;40(1):236-9

Acute cardiotoxicity of moniliformin in broiler chickens as measured by electrocardiography. Nagaraj RY, et al. **Avian Dis** 1996 Jan-Mar;40(1):223-7

Effect of concurrent feeding of furazolidone and sodium chloride upon some clinical, pathological and cardiac morphometric parameters in broiler chicks. Islam N, et al. **Zentralbl Veterinarmed A** 1995 Apr;42(2):91-8

DIAGNOSIS

Polymerase chain reaction optimization for Mycoplasma gallisepticum and M. synoviae diagnosis. Silveira RM, et al. **Avian Dis** 1996 Jan-Mar;40(1):218-22

Development and application of enzyme-linked immunosorbent assay for specific detection of Salmonella enteritidis infections in chickens based on antibodies to SEF14 fimbrial antigen. Thorns CJ, et al. **J Clin Microbiol** 1996 Apr;34(4):792-7

Evaluation of SEF14 fimbrial dot blot and flagellar western blot tests as indicators of Salmonella enteritidis infection in chickens. Cooper GL, et al. **Vet Rec** 1996 Feb 17; 138(7):149-53

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul-Sep;27(3):156-74 (62 ref.) **(Spa)**

DIET THERAPY

Interaction between nutrition and Eimeria acervulina infection in broiler chickens: diet compositions that improve fat digestion during Eimeria acervulina infection. Adams C, et al. **Br J Nutr** 1996 Jun;75(6):875-80

DRUG THERAPY

Potentiation of ionophorous anticoccidials with dihydroquinolines: compatibility of lasalocid and semduramicin with duokvin. Varga I, et al. **Int J Parasitol** 1995 Oct;25(10):1243-5

Potentiation of ionophorous anticoccidials with duokvin: battery trials against Cryptosporidium baileyi in chickens. Varga I, et al. **J Parasitol** 1995 Oct;81(5):777-80

Characteristics of the anticoccidial activity of 6-azauracil. Kobayashi N, et al. **J Vet Med Sci** 1996 Feb;58(2):115-20

Antagonistic effect of nucleic acid precursors on the anticoccidial activity of 6-azauracil. Kobayashi N, et al. **J Vet Med Sci** 1996 Feb;58(2):121-7

Investigation for the characteristic anticoccidial activity of diclazuril in battery trials. Matsuno T, et al. **J Vet Med Sci** 1996 Feb;58(2):129-33

Efficacy of maduramicin against turkey coccidiosis in battery: a clinical and pathological study. Cerruti Sola S, et al. **Schweiz Arch Tierheilkd** 1996;138(4):201-6

Preliminary observations on the efficacy of an iodophor in reducing the mortality in chickens experimentally affected by the 'hydropericardium syndrome'. Abdul-Aziz TA, et al. **Vet Res Commun** 1996;20(2):191-4

ENZYMOLOGY

[Activity of alpha-amylase, trypsin and lipase in pancreas and duodenal contents of Ascaridia galli infected chickens fed with various proteins] Zółtowska K, et al. **Wiad Parazytol** 1995;41(2):217-20 (Eng. Abstr.) **(Pol)**

[The influence of various levels of carotene and protein in the diet on the index of invasion and digestive enzyme activity in chickens infected with Ascaridia galli] Zółtowska K, et al. **Wiad Parazytol** 1996;42(1):65-9 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Salmonella enteritidis: the egg and I [letter; comment] Swarbrick O. **Aust Vet J** 1995 Oct;72(10):398-9. Comment on: Aust Vet J 1995 Mar;72(3):108-15.

Reopening Russia's doors to US poultry: the team approach pays off [news] Canonico G. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1773-5

Outbreaks of fowl cholera in Muscovy ducks (Cairina moschata) on a farm in Aomori Prefecture. Takahashi S, et al. **J Vet Med Sci** 1996 Mar;58(3):269-72

An outbreak of goose parvovirus infection in Japan. Takehara K, et al. **J Vet Med Sci** 1995 Aug;57(4):777-9

Does pulmonary hypertension syndrome (ascites) occur more frequently in broilers medicated with monensin? Chapman ME, et al. **Poult Sci** 1995 Oct;74(10):1591-6

The effects of continuously or diurnally fed melatonin on broiler performance and health. Clark WD, et al. **Poult Sci** 1995 Nov;74(11):1900-4

The effects of alternative electrical and mechanical stunning methods on hemorrhaging and meat quality of broiler breast and thigh muscles. Hillebrand SJ, et al. **Poult Sci** 1996 May;75(5):664-71

Prevalence of the poultry red mite, Dermanyssus gallinae, in different types of production systems for egg layers in Sweden. Höglund J, et al. **Poult Sci** 1995 Nov; 74(11):1793-8

Bronchodilator, oxygen level, and temperature effects on ascites incidence in broiler chickens. Vanhooser SL, et al. **Poult Sci** 1995 Oct;74(10):1586-90

Characterisation of Campylobacters from Malaysia. Tay ST, et al. **Singapore Med J** 1995 Jun;36(3):282-4

Field outbreak of infectious stunting syndrome in broiler chickens in Jordan. Abdul-Aziz TA. **Trop Anim Health Prod** 1995 Aug;27(3):173-4

Australian studies on Newcastle disease virus. The French heritage. Spradbrow PB, et al. **Vet Microbiol** 1995 Sep; 46(1-3):15-9, 1-2 (14 ref.)

Mice as carriers of Salmonella enteritidis on persistently infected poultry units. Davies RH, et al. **Vet Rec** 1995 Sep 30;137(14):337-41

Effects of current and waveform on the incidence of breast meat haemorrhages in electrically stunned broiler chicken carcases. Gregory NG, et al. **Vet Rec** 1995 Sep 9; 137(11):263-5

A possible association between Salmonella livingstone strains from man and poultry in Scotland. Old DC, et al. **Vet Rec** 1995 Nov 18;137(21):544

ETIOLOGY

A comparative study of avian reovirus pathogenicity: virus spread and replication and induction of lesions. Ni Y, et al. **Avian Dis** 1995 Jul-Sep;39(3):554-66

Skeletal muscle sarcoplasmic calcium regulation and sudden death syndrome in chickens. Reiner G, et al. **Br Poult Sci** 1995 Sep;36(4):667-75

Is hypothalamic prostaglandin E2 involved in avian fever? Fraifeld V, et al. **Life Sci** 1995 Mar 10;56(16):1343-6

Development of an L6 myoblast in vitro model of moniliformin toxicosis. Reams R, et al. **Mycopathologia** 1996;133(2):105-14

Ascites syndrome in a turkey reared above 2000 metres [letter] Duff JP, et al. **Vet Rec** 1995 Sep 16;137(12):300

[The mystery of the staggering turkeys: a differential diagnostic puzzle] Braunius WW. **Tijdschr Diergeneeskd** 1996 Aug 15;121(16):444-5 (Eng. Abstr.) **(Dut)**

GENETICS

Ovarian morphology and follicular development in sex-linked imperfect albino (s(al)-s) and nonalbino hens before or after a forced moult. Su H, et al. **Br Poult Sci** 1995 Sep;36(4):645-53

Response of three class-IV major histocompatibility complex haplotypes to Eimeria acervulina in meat-type chickens. Uni Z, et al. **Br Poult Sci** 1995 Sep;36(4):555-61

Structural organization, sequence, and expression of the chicken NRAMP1 gene encoding the natural resistance-associated macrophage protein 1. Hu J, et al. **DNA Cell Biol** 1996 Feb;15(2):113-23

Skin allograft survival in chicken strains with spontaneous autoimmune diseases. Dietrich HM, et al. **Poult Sci** 1996 Mar;75(3):285-93

Heritability of ascites and the ratio of right to total ventricle weight in broiler breeder male lines. Lubritz DL, et al. **Poult Sci** 1995 Jul;74(7):1237-41

A method for separating sex-linked imperfect albino (S*ALS) and nonalbino embryos before hatch. Santos GA, et al. **Poult Sci** 1996 May;75(5):585-8

Effects of sex-linked imperfect albinism (sal-s) in the chicken on the relationships of plasma concentrations of progesterone and 17 beta-estradiol with egg production. Su H, et al. **Poult Sci** 1996 Jan;75(1):13-9

Effect of selection for high or low incidence of tibial dyschondroplasia for seven generations on live performance. Yalcin S, et al. **Poult Sci** 1995 Sep; 74(9):1411-7

Random amplified polymorphic DNA comparisons among broiler lines selected for incidence of tibial dyschondroplasia. Zhang X, et al. **Poult Sci** 1995 Aug; 74(8):1253-8

IMMUNOLOGY

Characterization of monoclonal antibodies against infections laryngotracheitis virus. Abbas F, et al. **Avian Dis** 1996 Jan-Mar;40(1):49-55

Immunity to eimeria tenella in chickens: phenotypical and functional changes in peripheral blood T-cell subsets. Breed DG, et al. **Avian Dis** 1996 Jan-Mar;40(1):37-48

Comparison of enzyme-linked immunosorbent assay and hemagglutination-inhibition for detection of antibody to Mycoplasma gallisepticum in commercial broiler, fair and exhibition, and experimentally infected birds. Ewing ML, et al. **Avian Dis** 1996 Jan-Mar;40(1):13-22

In ovo oral vaccination with Campylobacter jejuni establishes early development of intestinal immunity in chickens. Noor SM, et al. **Br Poult Sci** 1995 Sep;36(4):563-73

Avian coccidiosis: changes in intestinal lymphocyte populations associated with the development of immunity to Eimeria maxima. Rothwell L, et al. **Parasite Immunol** 1995 Oct;17(10):525-33

Cytotoxicity in chicken alimentary secretions as measured by a derivative of the tumor necrosis factor assay. Arnold JW, et al. **Poult Sci** 1996 Mar;75(3):329-34

The influence of major histocompatibility complex genotypes on resistance to Pasteurella multocida and Newcastle disease virus in turkeys. Nestor KE, et al. **Poult Sci** 1996 Jan;75(1):29-33

Growth, immunoresponsiveness, and disease resistance of diverse stocks of chickens reared under two nutritional regimens. Praharaj NK, et al. **Poult Sci** 1995 Nov; 74(11):1721-9

Occurrence of haemagglutination-inhibition antibodies against egg drop syndrome 1976 virus in broilers. Singh JK, et al. **Trop Anim Health Prod** 1995 Aug;27(3):167-70

Effect of passively administered immunoglobulin G on the colonization and clearance of Bordetella avium in turkeys. Suresh P, et al. **Vet Immunol Immunopathol** 1995 Dec; 49(3):229-39

Detection of antibodies to Salmonella enteritidis in sera and yolks from experimentally and naturally infected chickens. Desmidt M, et al. **Vet Rec** 1996 Mar 9;138(10):223-6

[Freund's complete adjuvant in the chicken: efficient immunostimulation with severe local inflammatory reaction] Wanke R, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):243-53 (Eng. Abstr.) **(Ger)**

[Development of humoral precipitating antibodies to Campylobacter spp. in chickens] Glünder G. **Zentralbl Veterinarmed [B]** 1995 Apr;42(2):89-99 (Eng. Abstr.) **(Ger)**

METABOLISM

Interaction between nutrition and Eimeria acervulina infection in broiler chickens: development of an experimental infection model. Adams C, et al. **Br J Nutr** 1996 Jun;75(6):867-73

The influence of dietary fatty acids and vitamin E on plasma prostanoids and liver microsomal alkane production in broiler chickens with regard to nutritional encephalomalacia. Fuhrmann H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):553-61

[Tissue lipid peroxidation in nutritional encephalomalacia of broiler chickens] Fuhrmann H, et al. **Zentralbl Veterinarmed A** 1996 Mar;43(1):9-21 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Relationship of sex, age, and concurrent intestinal disease to necrotic enteritis in turkeys. Droual R, et al. **Avian Dis** 1995 Jul-Sep;39(3):599-605

The comparative virulence for chicks of Salmonella enteritidis phage type 4 isolates and isolates of phage types commonly found in poultry in the United States. Gast RK, et al. **Avian Dis** 1995 Jul-Sep;39(3):567-74

Relationship between body-weight gain after movement of chickens to an unfamiliar cage and response to Escherichia coli challenge infection. Gross WB. **Avian Dis** 1995 Jul-Sep;39(3):636-7

The effect of bacterial surface structures on the pathogenesis of Salmonella typhimurium infection in chickens. Lee MD, et al. **Avian Dis** 1996 Jan-Mar;40(1):28-36

Experimental reproduction of endocarditis with Pasteurella gallinarum in mature leghorn chickens. Tjahjowati G, et

al. **Avian Dis** 1995 Jul-Sep;39(3):489-98

World Health Organisation--supervised interlaboratory comparison of ELISAs for the serological detection of Salmonella enterica serotype Enteritidis in chickens. Barrow PA, et al. **Epidemiol Infect** 1996 Aug;117(1):69-77

Increased colonization potential of Campylobacter jejuni strain 81116 after passage through chickens and its implication on the rate of transmission within flocks. Cawthraw SA, et al. **Epidemiol Infect** 1996 Aug; 117(1):213-5

Escherichia coli cellulitis in broiler chickens: clonal relationships among strains and analysis of virulence-associated factors of isolates from diseased birds. Ngeleka M, et al. **Infect Immun** 1996 Aug;64(8):3118-26

An application of the augmented randomized complete block design to poultry research. Boyle CR, et al. **Poult Sci** 1996 May;75(5):601-7

Eimeria tenella infection induces recrudescence of previous Salmonella enteritidis infection in chickens. Qin ZR, et al. **Poult Sci** 1995 Nov;74(11):1786-92

Characterisation of Campylobacters from Malaysia. Tay ST, et al. **Singapore Med J** 1995 Jun;36(3):282-4

Expression of P and type 1 (F1) fimbriae in pathogenic Escherichia coli from poultry. Dozois CM, et al. **Vet Microbiol** 1995 Aug;45(4):297-309

Endocarditis in broiler breeder rearers due to Enterococcus hirae [letter] McNamee PT, et al. **Vet Rec** 1996 Mar 9; 138(10):240

[Evaluation of selective culture media for the isolation of Salmonella from poultry] Yuño MM, et al. **Rev Argent Microbiol** 1995 Apr-Jun;27(2):57-69 (Eng. Abstr.) **(Spa)**

MORTALITY

Food safety requires vision and vigilance. Emerging disease in young turkeys causes heavy mortality [news] Reed CA, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):323

Hematocrit values and mortality from ascites in cold-stressed broilers from parents selected by hematocrit. Shlosberg A, et al. **Poult Sci** 1996 Jan;75(1):1-5

PARASITOLOGY

Epidemiological studies of coccidiosis in the domesticated fowl (Gallus gallus): I. The fate of ingested oocysts of Eimeria tenella during the prepatent period in susceptible chicks. Williams RB. **Appl Parasitol** 1995 May;36(2):83-9

Epidemiological studies of coccidiosis in the domesticated fowl (Gallus gallus): II. Physical condition and survival of Eimeria acervulina oocysts in poultry-house litter. Williams RB. **Appl Parasitol** 1995 May;36(2):90-6

Runting of ducklings associated with Cochlosoma anatis infection. Bollinger TK, et al. **Avian Dis** 1996 Jan-Mar; 40(1):181-5

Esophageal and proventricular cryptosporidiosis in a chicken. Goodwin MA. **Avian Dis** 1995 Jul-Sep;39(3):643-5

Increasing the yield of Eimeria tenella oocysts in primary chicken kidney cells. Zhang J, et al. **Avian Dis** 1996 Jan-Mar;40(1):63-7

Age-dependent resistance to Cryptosporidium baileyi infection in chickens. Sréter T, et al. **J Parasitol** 1995 Oct; 81(5):827-9

Eimeria acervulina infection: evidence for the involvement of CD8+ T lymphocytes in sporozoite transport and host protection. Trout JM, et al. **Poult Sci** 1995 Jul; 74(7):1117-25

The gastro-intestinal helminth infections of domestic fowl in Dschang, western Cameroon. Mpoame M, et al. **Rev Elev Med Vet Pays Trop** 1995;48(2):147-51

PATHOLOGY

Complex study of the physiological role of cadmium. III. Cadmium loading trials on broiler chickens. Bokori J, et al. **Acta Vet Hung** 1995;43(2-3):195-228

Experimental reproduction of severe hypoglycemia and spiking mortality syndrome using field-derived and embryo-passaged preparations. Davis JF, et al. **Avian Dis** 1996 Jan-Mar;40(1):158-72

Multicentric histiocytosis in young chickens. Gross and light microscopic pathology. Hafner S, et al. **Avian Dis** 1996 Jan-Mar;40(1):202-9

Avian infectious bronchitis: viral persistence in the harderian gland and histological changes after eyedrop vaccination. Toro H, et al. **Avian Dis** 1996 Jan-Mar;40(1):114-20

Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. Li CY, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep; 61(3):279-84

Experimental reproduction of proventriculitis using homogenates of proventricular tissue. Bayyari GR, et al. **Poult Sci** 1995 Nov;74(11):1799-809

Malignant melanocytic neural crest tumor in a young chicken (Gallus domesticus). Hafner S, et al. **Vet Pathol** 1995 Sep; 32(5):535-7

Immunohistochemical detection of lymphocyte subpopulations in the tarsal joints of chickens with experimental viral arthritis. Pertile TL, et al. **Vet Pathol** 1996 May;33(3):303-10

Poorly differentiated pancreatic adenocarcinoma in a chicken. Abdul-Aziz TA. **Vet Rec** 1995 Oct 14;137(16):408

PHYSIOPATHOLOGY

Relationship of sex, age, and concurrent intestinal disease to necrotic enteritis in turkeys. Droual R, et al. **Avian Dis** 1995 Jul-Sep;39(3):599-605

Relationship between body-weight gain after movement of chickens to an unfamiliar cage and response to Escherichia coli challenge infection. Gross WB. **Avian Dis** 1995 Jul-Sep;39(3):636-7

Hemorrhages in muscles of broiler chickens: the relationships among blood variables at various rearing temperature regimens. Kranen RW, et al. **Poult Sci** 1996 Apr; 75(4):570-6

Effects of supplemental ascorbic acid on the performance of broiler chickens exposed to multiple concurrent stressors. McKee JS, et al. **Poult Sci** 1995 Nov; 74(11):1772-85

Electrocardiographic evaluation of broilers during the onset of pulmonary hypertension initiated by unilateral pulmonary artery occlusion. Wideman RF Jr, et al. **Poult Sci** 1996 Mar;75(3):407-16

Effect of selection for high or low incidence of tibial dyschondroplasia for seven generations on live performance. Yalcin S, et al. **Poult Sci** 1995 Sep; 74(9):1411-7

PREVENTION & CONTROL

Effect of semduramicin, salinomycin, and monensin on performance, shank pigmentation, and coccidial lesions in broiler chickens in floor pens. McDougald LR, et al. **Avian Dis** 1996 Jan-Mar;40(1):68-71

Efficacy of Salmonella enteritidis (SE)-immune lymphokines from chickens and turkeys on SE liver invasion in one-day-old chicks and turkey poults. Ziprin RL, et al. **Avian Dis** 1996 Jan-Mar;40(1):186-92

Interaction between dietary 1,25-dihydroxycholecalciferol and calcium and effects of management on the occurrence of tibial dyschondroplasia, leg abnormalities and performance in broiler chickens. Rennie JS, et al. **Br Poult Sci** 1995 Jul;36(3):465-77

Replacement of challenge procedures in the evaluation of poultry vaccines. Jungbäck C, et al. **Dev Biol Stand** 1996; 86:157-63

Attempts to immunize chickens with Cryptosporidium baileyi oocyst extract. Hornok S, et al. **J Parasitol** 1996 Aug; 82(4):650-2

Effectiveness of an inactivated goose parvovirus vaccine in Muscovy ducks. Takehara K, et al. **J Vet Med Sci** 1995 Dec;57(6):1093-5

Salmonella exclusion in broiler chicks by the competitive action of adult gut microflora. Abu-Ruwaida AS, et al. **Microbios** 1995;83(334):59-69

Reduction in incidence of experimental fowl typhoid by incorporation of a commercial formic acid preparation (Bio-Add) into poultry feed. Berchieri A Jr, et al. **Poult Sci** 1996 Mar;75(3):339-41

Treatment of commercial broiler chickens with a characterized culture of cecal bacteria to reduce salmonellae colonization. Corrier DE, et al. **Poult Sci** 1995 Jul;74(7):1093-101

Effects of dietary calcium and 1,25-dihydroxycholecalciferol on the development of tibial dyschondroplasia in broilers during the starter and grower periods. Elliot MA, et al. **Poult Sci** 1995 Sep;74(9):1495-505

Effect of dietary 1,25-dihydroxycholecalciferol level on broiler performance. Roberson KD, et al. **Poult Sci** 1996 Jan;75(1):90-4

The effect of in ovo oocyst or sporocyst inoculation on response to subsequent coccidial challenge. Watkins KL, et al. **Poult Sci** 1995 Oct;74(10):1597-602

Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273-91 (27 ref.)

Application of disinfectants in poultry hatcheries. Samberg Y, et al. **Rev Sci Tech** 1995 Jun;14(2):365-80 (31 ref.)

Asymmetric deletion of the junction between the short unique region and the inverted repeat does not affect viral growth in culture and vaccine-induced immunity against Marek's disease. Sonoda K, et al. **Vaccine** 1996 Mar; 14(4):277-84

Stimulation of avian respiratory phagocytes by Pasteurella multocida: effects of the route of exposure, bacterial dosage and strain, and the age of chickens. Hassanin HH, et al. **Vet Microbiol** 1995 Oct;46(4):401-13

Effect of antibiotic treatment on competitive exclusion against Salmonella enteritidis PT4 in broilers. Bolder NM, et al. **Vet Rec** 1995 Sep 30;137(14):350-1

Availability of medicines for poultry produced for meat [letter] Laing P. **Vet Rec** 1995 Dec 9;137(24):623

A live attenuated vaccine for the control of avian coccidiosis: trials in broiler breeders and replacement layer flocks in the United Kingdom. Shirley MW, et al. **Vet Rec** 1995 Oct 28;137(18):453-7

Prevention of spontaneous autoimmune thyroiditis in the obese strain (OS) chickens by treatment with a monoclonal anti-CD4 antibody. Cihak J, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):211-6

[Model for experimental efficacy testing of control measures against Salmonella infections in poultry] Methner U, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):225-8 (Eng. Abstr.) **(Ger)**

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul-Sep;27(3):156-74 (62 ref.) **(Spa)**

TRANSMISSION

Hydropericardium syndrome in broiler chickens: its contagious nature and pathology. Abdul-Aziz TA, et al. **Res Vet Sci** 1995 Nov;59(3):219-21

Contribution of the lesser mealworm beetle (Alphitobius diaperinus) to carriage of Salmonella enteritidis in poultry. Davies RH, et al. **Vet Rec** 1995 Oct 14;137(16):407-8

Infection model for hatching chicks infected with Salmonella enteritidis. Methner U, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):471-80

Experimental oral infection of specific pathogen-free laying hens and cocks with Salmonella enteritidis strains. Methner U, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):459-69

VIROLOGY

Development of a polymerase chain reaction and a nonradioactive DNA probe for infectious laryngotracheitis virus. Abbas F, et al. **Avian Dis** 1996 Jan-Mar;40(1):56-62

The comparative virulence for chicks of Salmonella enteritidis phage type 4 isolates and isolates of phage types commonly found in poultry in the United States. Gast RK, et al. **Avian Dis** 1995 Jul-Sep;39(3):567-74

Synergism between chicken anemia virus (CAV) and avian reovirus following dual infection of 1-day-old chicks by a natural route. McNeilly F, et al. **Avian Dis** 1995 Jul-Sep; 39(3):532-7

Comparison of the genomic short regions of a vaccine strain (SA-2) and a virulent strain (CSW-1) of infectious laryngotracheitis virus (Gallid herpesvirus 1). Trist HM, et al. **Avian Dis** 1996 Jan-Mar;40(1):130-9

Influence of subclinical virus infections and other factors on broiler flock performance. Jørgensen PH, et al. **Br Poult Sci** 1995 Jul;36(3):455-63

Turkey rhinotracheitis virus isolated from broiler chicken with swollen head syndrome in Japan. Tanaka M, et al. **J Vet Med Sci** 1995 Oct;57(5):939-41

Kinetic analysis of T cells and antibody production in chickens infected with Marek's disease virus. Yamamoto H, et al. **J Vet Med Sci** 1995 Oct;57(5):945-6

The noncoding and surface envelope coding sequences of myeloblastosis-associated virus are respectively responsible for nephroblastoma development and renal hyperplasia. Joliot V, et al. **J Virol** 1996 Apr;70(4):2576-80

Pathogenesis of type II avian adenovirus infection in turkeys: in vivo immune cell tropism and tissue distribution of the virus. Suresh M, et al. **J Virol** 1996 Jan;70(1):30-6

The immunodominant proteins of reticuloendotheliosis virus. Davidson I, et al. **Vet Microbiol** 1996 Apr;49(3-4):273-84

An antigen detection immunoassay for big liver and spleen disease agent. Ellis TM, et al. **Vet Microbiol** 1995 Sep; 46(1-3):315-26

A survey of the presence of a new infectious bronchitis virus designated 4/91 (793B). Cook JK, et al. **Vet Rec** 1996 Feb 24;138(8):178-80

Isolation of Yucaipa virus [letter] Shihmanter E, et al. **Vet Rec** 1995 Sep 9;137(11):276

Pathogenicity of quail's inclusion body hepatitis virus (avian adenovirus-1) for Japanese quails and broiler chicks. Singh A, et al. **Vet Res Commun** 1995;19(6):545-51

Evaluation of different turkey rhinotracheitis viruses used as antigens for serological testing following live vaccination and challenge. Eterradossi N, et al. **Zentralbl Veterinarmed [B]** 1995 May;42(3):175-86

POULTRY PRODUCTS

see related
EGGS

The effect of enzyme predigestion on the quality of poultry by-product meal from whole turkey mortality. Barbour GW, et al. **Poult Sci** 1995 Jul;74(7):1180-90

POUR PLATE COUNT see **COLONY COUNT, MICROBIAL**

POVERTY

see related
CULTURAL DEPRIVATION

Alma: coping with culture, poverty, and disability. Blanche EI. **Am J Occup Ther** 1996 Apr;50(4):265-76

Families who live in chronic poverty: meeting the challenge of family-centered services. Humphry R. **Am J Occup Ther** 1995 Jul-Aug;49(7):687-93

The impact of extended maternity services on prenatal care use among Medicaid women. Farrow DC, et al. **Am J Prev Med** 1996 Mar-Apr;12(2):103-7

Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Geller AC, et al. **Am J Public Health** 1996 Apr;86(4):538-44

Daily movement, adiposity, and blood glucose among older adults of middle to lower socioeconomic status [letter] Pescatello LS, et al. **Am J Public Health** 1996 Apr; 86(4):592-3

Decreasing premature Norplant removals among low-income recipients. Radecki S, et al. **Am J Public Health** 1996 Jun;86(6):881-2

HIV risk behaviors among women living in low-income, inner-city housing developments. Sikkema KJ, et al.

Am J Public Health 1996 Aug;86(8 Pt 1):1123–8
Coming to voice: the power of emancipatory community interventions. Drevdahl D. **ANS Adv Nurs Sci** 1995 Dec; 18(2):13–24 (50 ref.)
Implementing the COACH relationship model: health promotion for mothers and children. Hanks C, et al. **ANS Adv Nurs Sci** 1995 Dec;18(2):57–66
In perspective: voices of the disadvantaged on health care system reform. Underwood SM, et al. **Appl Nurs Res** 1996 Aug;9(3):144–7
Caring for Simona. Hammer SG. **Arch Fam Med** 1996 Jun; 5(6):327
Myocardial infarction in a low income area of Mexico City. Prevalence and clinical characteristics. González C, et al. **Arch Med Res** 1995 Autumn;26(3):233–8
Immunization status of poor children [letter] Bradford BJ, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):883
Policy and poverty. Child and community health in Philadelphia, 1900 to 1930. Brosco JP. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1381–7
What mothers say about why poor children fall behind on immunizations. A summary of focus groups in North Carolina. Lannon C, et al. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1070–5
Housing subsidies and pediatric undernutrition. Meyers A, et al. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1079–84
A randomized, controlled effectiveness trial of an AIDS prevention program for low-income African-American youths. Stanton BF, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):363–72
Multimodal-therapy breast salvage in the urban poor with locally advanced cancer. Boddie AW, et al. **Arch Surg** 1996 Apr;131(4):424–9
Food consumption of parents on low incomes. Buchhorn D. **Aust J Public Health** 1995 Aug;19(4):427–9
Socioeconomic indices and suicide rate in Queensland. Cantor CH, et al. **Aust J Public Health** 1995 Aug; 19(4):417–20
Collecting food-related data from low socioeconomic groups: how adequate are our current research designs? Turrell G, et al. **Aust J Public Health** 1995 Aug;19(4):410–6
George Adlington Syme Oration. The International Year of Tolerance: its challenge to Australia. Wilson R. **Aust N Z J Surg** 1995 Dec;65(12):833–7
Dietary energy intake, energy expenditure and activity pattern among selected rural and urban poor in Bangladesh. Abdullah M, et al. **Bangladesh Med Res Counc Bull** 1995 Apr;21(1):1–10
Health for all by the year 2000? [editorial] Bergström S, et al. **BMJ** 1996 Aug 10;313(7053):316
Pregnant women receiving benefit in Britain eat badly [news] Claxton R. **BMJ** 1995 Nov 25;311(7017):1390
Poverty spreads among children in Britain [news] Dillner L. **BMJ** 1996 Apr 20;312(7037):996–7
Deprivation and cause specific morbidity: evidence from the Somerset and Avon survey of health. Eachus J, et al. **BMJ** 1996 Feb 3;312(7026):287–92
Health network will work to reduce poverty [news] Kalbfuss E. **BMJ** 1995 Nov 11;311(7015):1249–50
Extreme poverty: an obligation ignored [editorial] Kevany J. **BMJ** 1996 Jul 13;313(7049):65–6
Suicide and deprivation in Scotland [see comments] McLoone P. **BMJ** 1996 Mar 2;312(7030):543–4. Comment in: BMJ 1996 Jun 15;312(7045):1538.
Retrospective study of influence of deprivation on uptake of cardiac rehabilitation. Pell J, et al. **BMJ** 1996 Aug 3; 313(7052):267–8
Playing politics with the poor: the cities. Roberts J. **BMJ** 1995 Sep 30;311(7009):832
All together now: why social deprivation matters to everyone. Watt GC. **BMJ** 1996 Apr 20;312(7037):1026–9
Perceived risks and benefits of alcohol, cigarette, and drug use among urban low-income African-American early adolescents. Feigelman S, et al. **Bull N Y Acad Med** 1995 Summer;72(1):57–75
Burns incidence in low-income suburbs of Maputo City, Mozambique [letter] Barradas R, et al. **Burns** 1996 Mar; 22(2):167
Canadians pay for harsh economic policies with their health, physicians warn. OReilly M. **Can Med Assoc J** 1995 Dec 1;153(11):1647–9
The relationship between caries, fluoridation and material deprivation in five-year-old children in Country Durham. Provart SJ, et al. **Community Dent Health** 1995 Dec; 12(4):200–3
Malnutrition and poverty in the early stages of famine: North Darfur, 1988–90. Jaspars S, et al. **Disasters** 1995 Sep; 19(3):198–215
Strategic elements for environmental justice. **Environ Health Perspect** 1995 Sep;103(9):796–800
Cancer among special populations: women, ethnic minorities, and the poor. Haynes A. **Environ Health Perspect** 1995 Nov;103 Suppl 8:319–20 (10 ref.)
Child malnutrition in poor smallholder households in rural Kenya: an in-depth situation analysis. Kigutha HN, et al. **Eur J Clin Nutr** 1995 Sep;49(9):691–702
Multiple partners, risky partners and HIV risk among low-income urban women. Wagstaff DA, et al. **Fam Plann Perspect** 1995 Nov-Dec;27(6):241–5
The effects of Medicaid expansions on insurance coverage of children. Dubay LC, et al. **Future Child** 1996 Spring; 6(1):152–61
The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)
Complex marital histories and economic well-being: the continuing legacy of divorce and widowhood as the HRS cohort approaches retirement. Holden KC, et al. **Gerontologist** 1996 Jun;36(3):383–90
Reverse mortgages and the economic status of elderly women. Morgan BA, et al. **Gerontologist** 1996 Jun; 36(3):400–5
Mobilizing a low-income African-American community around tobacco control: a force field analysis. Ellis GA, et al. **Health Educ Q** 1995 Nov;22(4):443–57
Determinants of dental user groups among an elderly, low-income population. Kuthy RA, et al. **Health Serv Res** 1996 Feb;30(6):809–25
Policy. Health and lack of wealth [news] **Hosp Health Netw** 1996 May 20;70(10):12
Feeding practices and growth among low-income Peruvian infants: a comparison of internationally-recommended definitions. Piwoz EG, et al. **Int J Epidemiol** 1996 Feb; 25(1):103–14
Relationship between birth weight and biochemical measures of maternal nutritional status at delivery in Bangladeshi urban poors. Hasin A, et al. **Int J Food Sci Nutr** 1996 May; 47(3):273–9
A geographical distribution of mortality and deprivation. Howell F, et al. **Ir Med J** 1993 May;86(3):96–9
Heterosexual experiences and partnerships of urban, low-income African-American and Hispanic youth. Norris AE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):288–300
Grandmother co-residence, parenting, and child development among low income, urban teen mothers. Black MM, et al. **J Adolesc Health** 1996 Mar;18(3):218–26
Is the clinical spectrum of gonorrhea changing? Mandegar M, et al. **J Adolesc Health** 1995 Aug;17(2):123–7
Dietary intake and anthropometric status of 7 to 9 year old children in economically disadvantaged communities in Ontario [see comments] Evers SE, et al. **J Am Coll Nutr** 1995 Dec;14(6):595–603. Comment in: J Am Coll Nutr 1995 Dec;14(6):561–2.
High-risk nutrient intakes among low-income Mexican women in Chicago, Illinois. Ballew C, et al. **J Am Diet Assoc** 1995 Dec;95(12):1409–13
Focus groups identify desirable features of nutrition programs for low-income mothers of preschool children. Reed DB. **J Am Diet Assoc** 1996 May;96(5):501–3
Nutritional risk in inner-city-dwelling older black Americans. Miller DK, et al. **J Am Geriatr Soc** 1996 Aug; 44(8):959–62
The prevalence of grandmothers as primary caregivers in a poor pediatric population. Joslin D, et al. **J Community Health** 1995 Oct;20(5):383–401
The prevalence of dental anxiety in children from low-income families and its relationship to personality traits. Raadal M, et al. **J Dent Res** 1995 Aug;74(8):1439–43
Is enumeration district level an improvement on ward level analysis in studies of deprivation and health? Carr-Hill R, et al. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S28–9
Ambulatory health services provided to low-income and homeless adult patients in a major community health center. Gelberg L, et al. **J Gen Intern Med** 1996 Mar;11(3):156–62
Aggregating poor and near-poor elderly under different resource definitions. Rendall MS. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):S209–16
Coping with the cost of prescription drugs. Strickland WJ, et al. **J Health Care Poor Underserved** 1996;7(1):50–62
Voluntary public health insurance for low-income families: the decision to enroll. Madden CW, et al. **J Health Polit Policy Law** 1995 Winter;20(4):955–72
Patterns of use of oral rehydration therapy in an urban slum community. Bhandari N, et al. **J Indian Med Assoc** 1995 Jun;93(6):239–42
Better access for the poor may improve lung cancer survival [news] Holzman D. **J Natl Cancer Inst** 1995 Aug 16; 87(16):1212
Breast and cervical cancer screening among low-income women: impact of a simple centralized HMO intervention. Hardy RE, et al. **J Natl Med Assoc** 1996 Jun;88(6):381–4
Zinc supplementation reduces the incidence of persistent diarrhea and dysentery among low socioeconomic children in India. Sazawal S, et al. **J Nutr** 1996 Feb;126(2):443–50
Occupational injuries in a poor inner-city population. Frumkin H, et al. **J Occup Environ Med** 1995 Dec; 37(12):1374–82
Higher rates of SIDS persist in low income groups. Ford RP, et al. **J Paediatr Child Health** 1995 Oct;31(5):408–11
Dental care satisfaction: the reliability and validity of the DSQ in a low-income population. Golletz D, et al. **J Public Health Dent** 1995 Fall;55(4):210–7
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3–8 (47 ref.)
The world's poor children [editorial] Costello A. **J R Soc Med** 1996 Aug;89(8):421–2
The pain of Christmas [editorial] Thomison JB. **J Tenn Med Assoc** 1995 Dec;88(12):472–3
The characteristics and needs of sheltered homeless and low-income housed mothers. Bassuk EL, et al. **JAMA** 1996 Aug 28;276(8):640–6
Helping postpartum rural adolescents visualize future goals. Walsh SM, et al. **MCN Am J Matern Child Nurs** 1995 Sep-Oct;20(5):276–9
Local responses to expanded Medicaid coverage for pregnant women. Dubay LC, et al. **Milbank Q** 1995;73(4):535–63
Poverty and infant mortality—United States, 1988. **MMWR Morb Mortal Wkly Rep** 1995 Dec 15;44(49):922–7
Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1–20 (37 ref.)
Social support among impoverished women. Nyamathi A, et al. **Nurs Res** 1995 Nov-Dec;44(6):376–8
Old, poor & malnourished. Stitt S, et al. **Nutr Health** 1995; 10(2):135–54
Rural deprivation. Bonnar BC. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):26–9 (21 ref.)
Determining crucial correlates of breast self-examination in older women with low incomes. Morrison C. **Oncol Nurs Forum** 1996 Jan-Feb;23(1):83–93
Poverty and health. Racine AD. **Pediatr Rev** 1995 Oct; 16(10):396–7
The association between parental smoking and the diet quality of low-income children. Johnson RK, et al. **Pediatrics** 1996 Mar;97(3):312–7
Mortality in regions and local authority districts in the 1990s: exploring the relationship with deprivation. Drever F, et al. **Popul Trends** 1995 Winter;(82):19–26
Breast cancer screening and associated factors for low-income African-American women. Mickey RM, et al. **Prev Med** 1995 Sep;24(5):467–76
Inequalities in health: the interaction between socio-economic and personal circumstances. Blank N, et al. **Public Health** 1996 May;110(3):157–62
Peer education: a strategy for improving health education in disadvantaged areas in Belfast. McAleavy G, et al. **Public Health** 1996 Jan;110(1):31–6
Evaluation of an interagency home visiting program to reduce postneonatal mortality in disadvantaged communities. Barnes-Boyd C, et al. **Public Health Nurs** 1996 Jun;13(3):201–8
Using critical feminist principles to analyze programs for low-income urban women. Reutter L, et al. **Public Health Nurs** 1995 Dec;12(6):424–31
Diversity in the rural poor: differences between households with and without telephones. Selby-Harrington ML, et al. **Public Health Nurs** 1995 Dec;12(6):386–92
Physical comorbidity and medical care use in children with emotional problems [see comments] Angel RJ, et al. **Public Health Rep** 1996 Mar-Apr;111(2):140–5. Comment in: Public Health Rep 1996 Mar-Apr;111(2):138–9.
Multidimensional causal model of dental caries development in low-income preschool children. Litt MD, et al. **Public Health Rep** 1995 Sep-Oct;110(5):607–17
Health care access of poverty-level older adults in subsidized public housing. Malmgren JA, et al. **Public Health Rep** 1996 May-Jun;111(3):260–3
Predictors of maintained high-risk behaviors among impoverished women. Nyamathi AM, et al. **Public Health Rep** 1995 Sep-Oct;110(5):600–6
Levels and predictors of HIV risk behavior among women in low-income public housing developments. Sikkema KJ, et al. **Public Health Rep** 1995 Nov-Dec;110(6):707–13
Indicators of poverty in SA [news] Spencer Jones JH. **S Afr Med J** 1996 Jun;86(6):630
Malnutrition, poverty and intellectual development. Brown JL, et al. **Sci Am** 1996 Feb;274(2):38–43
AIDS and ethnicity [letter; comment] Males M. **Science** 1996 Mar 15;271(5255):1479–80; discussion 1480–1. Comment on: Science 1995 Nov 24;270(5240):1372–5.
How sick is the West of Scotland? Age specific comparisons with national datasets on a range of health measures. West P, et al. **Scott Med J** 1994 Aug;39(4):101–9
Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)
Social roles and physical health: the case of female disadvantage in poor countries [letter; comment] Gürsoy A. **Soc Sci Med** 1996 Feb;42(4):625–7. Comment on: Soc Sci Med 1995 Jan;40(2):147–61.
Social insurance provisions for children with disabilities in selected industrialized countries. Zeitzer IR. **Soc Secur Bull** 1995 Fall;58(3):32–48
Problems with public health outreach. Azzarto J. **Soc Work Health Care** 1995;22(1):57–67 (20 ref.)
Perceived social support and adjustment to mastectomy in socioeconomically disadvantaged black women. Beder J. **Soc Work Health Care** 1995;22(2):55–71
Computer integrated drug prevention: a new approach to teach lower socioeconomic 5th and 6th grade Israeli children to say no to drugs. Gropper M, et al. **Soc Work Health Care** 1995;22(2):87–103
The challenge of an inner city practice. Rea GR. **Ulster Med J** 1995 Apr;64(1):17–30
Reproductive health practices of HMOs serving urban low-income women. Houston-Hamilton A. **West J Med** 1995 Sep;163(3 Suppl):57–63
Does universal health care coverage mean universal accessibility? Examining the Canadian experience of poor,

prenatal women. Morton AM, et al.
Womens Health Issues 1995 Fall;5(3):139–42

Double think--a reply [comment] King M, et al.
World Health Forum 1995;16(3):293–8. Comment on: World Health Forum 1994;15(4):382–6.

[Rate of precocious sexual intercourse in adolescents in disadvantaged socioeconomic environments. (University of Quebec in Montreal)] Thériault J, et al.
Contracept Fertil Sex 1995 Sep;23(9):545–51 (Eng. Abstr.) **(Fre)**

[Social inequalities and prevention: vaccination status of adolescents] De Spiegelaere M, et al.
Rev Epidemiol Sante Publique 1996 Jun;44(3):228–36 (Eng. Abstr.) **(Fre)**

[Evaluation of "Wallstrasse 16", day facility for the homeless and needy in Basel] Coda P, et al. **Soz Praventivmed** 1996; 41 Suppl 1:S69–75 (Eng. Abstr.) **(Ger)**

[Diseases of the poor. Anniversary of the WHO tropical disease research project] Austveg B, et al.
Tidsskr Nor Laegeforen 1995 Sep 10;115(21):2633–4 **(Nor)**

[Poverty in Mexico. I. Methodology and evolution] Boltvinik J. **Salud Publica Mex** 1995 Jul–Aug;37(4):288–97 (Eng. Abstr.) **(Spa)**

[Poverty in Mexico. II. Magnitude] Boltvinik J.
Salud Publica Mex 1995 Jul–Aug;37(4):298–309 (Eng. Abstr.) **(Spa)**

[WHO's World Health Report 1995: Z59.5 is the most frequent cause of death] Bergström S. **Lakartidningen** 1996 Mar 6;93(10):917–20 **(Swe)**

CLASSIFICATION

Identifying deprived areas using indices from the 1991 census and information about the recipients of community charge and council tax benefit. Jones S.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S65–71

ECONOMICS

The influence of OASDI and SSI payments on the poverty status of families with children. Kearney JR, et al.
Soc Secur Bull 1995 Fall;58(3):3–14

ETHNOLOGY

Effects of sustained nurse/mother contact on infant outcomes among low–income African–American families. Barnes–Boyd C. **Public Health Nurs** 1995 Dec;12(6):378–85

HISTORY

To pauperize or empower: public health nursing at the turn of the 20th and 21st centuries. Erickson GP.
Public Health Nurs 1996 Jun;13(3):163–9

LEGISLATION & JURISPRUDENCE

Legislating away reality [editorial] Bassuk EL.
Am J Orthopsychiatry 1995 Oct;65(4):460–1

Housing reform: getting tough on poor people [editorial] Connelly J. **BMJ** 1996 Feb 3;312(7026):262–3

The war on the war on poverty [news] Greenberg DS.
Lancet 1995 Oct 7;346(8980):955–6

PSYCHOLOGY

Immigrant families coping with schizophrenia. Behavioral family intervention v. case management with a low–income Spanish–speaking population. Telles C, et al.
Br J Psychiatry 1995 Oct;167(4):473–9

Self–perceptions, motivation, and school functioning of low–income maltreated and comparison children. Barnett D, et al. **Child Abuse Negl** 1996 May;20(5):397–410

The Pictorial Scale of Perceived Competence and Social Acceptance: does it work with low–income urban children? Fantuzzo JW, et al. **Child Dev** 1996 Jun;67(3):1071–84

Kinship support and maternal and adolescent well–being in economically disadvantaged African–American families. Taylor RD, et al. **Child Dev** 1995 Dec;66(6):1585–97

Financial stress linked to periodontal disease [news]
J Am Dent Assoc 1995 Oct;126(10):1346

Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)

Partnerships for people with serious mental illness who live below the poverty line. Lafave HG, et al.
Psychiatr Serv 1995 Oct;46(10):1071–3

STATISTICS & NUMERICAL DATA

Income distribution and mortality: cross sectional ecological study of the Robin Hood index in the United States [see comments] Kennedy BP, et al. **BMJ** 1996 Apr 20; 312(7037):1004–7. Comment in: BMJ 1996 Apr 20;312(7037):987–8.

Risk of child abuse or neglect in a cohort of low–income children. Kotch JB, et al. **Child Abuse Negl** 1995 Sep; 19(9):1115–30

Poverty and death in the United States--1973 and 1991. Hahn RA, et al. **Epidemiology** 1995 Sep;6(5):490–7

Nutrient intake amongst adolescent girls belonging to poor socioeconomic group of rural area of Rajasthan. Chaturvedi S, et al. **Indian Pediatr** 1996 Mar;33(3):197–201

Poverty and malnutrition in two countries [editorial; comment] Karp R. **J Am Coll Nutr** 1995 Dec;14(6):561–2 . Comment on: J Am Coll Nutr 1995 Dec;14(6):595–603.

The association of near poverty status with cancer incidence among black and white adults. Gorey KM, et al.
J Community Health 1995 Aug;20(4):359–66

Limiting long–term illness and its associations with mortality and indicators of social deprivation. Bentham G, et al.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S57–64

Deprivation indices: their interpretation and use in relation to health. Carstairs V. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S3–8 (27 ref.)

Single measures of deprivation. Folwell K.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S51–6

The importance of normalisation in the construction of deprivation indices. Gilthorpe MS.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S45–50

Census based deprivation indices: their weighting and validation. Gordon D. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S39–44

Outpatients care of HIV–1–infected destitute people: a study in Paris, France [letter] Chauvin P, et al. **Lancet** 1996 Aug 17;348(9025):480

A measurement model of the Medical Outcomes Study 36–Item Short–Form Health Survey in a clinical sample of disadvantaged, older, black, and white men and women. Wolinsky FD, et al. **Med Care** 1996 Jun;34(6):537–48

Ingredients of urban pediatric health care: fourth world pediatrics [comment] Rosen JF. **Pediatrics** 1996 Jun;97(6 Pt 1):898–9. Comment on: Pediatrics 1996 Jun;97(6 Pt 1):785–90.

Drugs, poverty, pregnancy, and foster care in Los Angeles, California, 1989 to 1991. Lewis MA, et al. **West J Med** 1995 Nov;163(5):435–40

[6 weeks as a physician in a poverty shelter. Report of experiences in Cali, Columbia] Stollhoff K.
Fortschr Med 1995 Dec 10;113(34):50–2 **(Ger)**

POVERTY AREAS

Hepatotoxicity from isoniazid and rifampin in inner–city AIDS patients [see comments] Ozick LA, et al.
Am J Gastroenterol 1995 Nov;90(11):1978–80. Comment in: Am J Gastroenterol 1996 Jul;91(7):1471–2.

Factors associated with unrecognized HIV–1 infection in an inner–city emergency department. Alpert PL, et al.
Ann Emerg Med 1996 Aug;28(2):159–64

Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. Denning DW, et al.
Ann Trop Paediatr 1995 Sep;15(3):209–16

Deprivation and bronchiolitis. Spencer N, et al.
Arch Dis Child 1996 Jan;74(1):50–2

Analysis from inner London of deprivation payments based on enumeration districts rather than wards [see comments] Crayford T, et al. **BMJ** 1995 Sep 23;311(7008):787–8. Comment in: BMJ 1996 Jan 20;312(7024):183–4.

Deprivation payments should be based on enumeration districts [letter; comment] Hastings A. **BMJ** 1996 Jan 20; 312(7024):183–4. Comment on: BMJ 1995 Sep 23;311(7008):787–8.

Deprivation payments revisited (again) [editorial; comment] Hobbs R, et al. **BMJ** 1996 Sep 14;313(7058):641–2. Comment on: BMJ 1996 Sep 14;313(7058):669–70.

Deprivation payments to general practitioners: limitations of census data [see comments] Majeed FA, et al. **BMJ** 1996 Sep 14;313(7058):669–70. Comment in: BMJ 1996 Sep 14;313(7058):641–2.

There is hope yet for the development of primary health care in deprived areas. Thomas P. **Br J Gen Pract** 1995 Nov;45(400):572–4

Conjunctival impression cytology with transfer (CICT) to detect pre–clinical vitamin A deficiency among slum children in India. Chowdhury S, et al. **Br J Nutr** 1996 May;75(5):785–90

Prevalence of VDRL sero–positivity in women in reproductive age group in an urban slum community in Bombay. Pandit DD, et al. **Indian J Public Health** 1995 Jan–Mar;39(1):4–7

Measuring disadvantage: changes in the underprivileged area, Townsend, and Carstairs scores 1981–91. Dolan SA, et al.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S30–3

Smoking behaviour can be predicted by neighbourhood deprivation measures. Kleinschmidt I, et al.
J Epidemiol Community Health 1995 Dec;49 Suppl 2:S72–7

Inner–city hospitals: a call for research. Gautam K, et al.
J Health Care Poor Underserved 1995;6(4):387–402 (49 ref.)

Community level cancer control in a Texas barrio: Part II--Base–line and preliminary outcome findings. McAlister AL, et al. **J Natl Cancer Inst Monogr** 1995;(18):123–6

Community level cancer control in a Texas barrio: Part I--Theoretical basis, implementation, and process evaluation. Ramirez AG, et al.
J Natl Cancer Inst Monogr 1995;(18):117–22

Tobacco and alcohol billboards in 50 Chicago neighborhoods: market segmentation to sell dangerous products to the poor. Hackbarth DP, et al.
J Public Health Policy 1995;16(2):213–30

Hematologic effect of vitamin A supplementation in anemic Pakistani children. Khan I, et al.
JPMA J Pak Med Assoc 1996 Feb;46(2):34–8

Treating sick young infants in urban slum setting [letter] Bhandari N, et al. **Lancet** 1996 Jun 22;347(9017):1774–5

Effect of indoor air pollution on the respiratory system of women using different fuels for cooking in an urban slum of Pondicherry. Dutt D, et al. **Natl Med J India** 1996 May–Jun;9(3):113–7

[Nutritional status of school children in poverty conditions from urban and rural areas. Metropolitan region. Chile. 1986–1987] Ivanovic D, et al. **Rev Med Chil** 1995 Apr; 123(4):509–25 (Eng. Abstr.) **(Spa)**

POVIDONE

Comparison between a two–layer discontinuous Percoll gradient and swim–up for sperm preparation on normal and abnormal semen samples. Chen SU, et al.
J Assist Reprod Genet 1995 Nov;12(10):698–703

Sperm quality improvement in cryopreserved human semen [see comments] Sharma RK, et al. **J Urol** 1996 Sep; 156(3):1008–12. Comment in: J Urol 1996 Sep;156(3):1013.

ADVERSE EFFECTS

Anaphylactic shock following povidone. Gonzalo Garijo MA, et al. **Ann Pharmacother** 1996 Jan;30(1):37–40

ANALOGS & DERIVATIVES

[A study on the establishment of the specification of polyvinylpolypyrroridone as a food additive] Kawasaki Y, et al. **Eisei Shikenjo Hokoku** 1995;(113):77–80 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Physical and biological effects of a surface coating procedure on polyurethane catheters. Francois P, et al.
Biomaterials 1996 Apr;17(7):667–78

Dielectric analysis in the characterization of amorphous pharmaceutical solids. 1. Molecular mobility in poly(vinylpyrrolidone)–water systems in the glassy state. Duddu SP, et al. **J Pharm Sci** 1995 Jun;84(6):773–6

Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. Yoshioka M, et al.
J Pharm Sci 1995 Aug;84(8):983–6

Water mobility in poly(ethylene glycol)–, poly(vinylpyrrolidone)–, and gelatin–water systems, as indicated by dielectric relaxation time, spin–lattice relaxation time, and water activity. Yoshioka S, et al.
J Pharm Sci 1995 Sep;84(9):1072–7

PHARMACOLOGY

The influence of polyvinylpyrrolidone on freezing of bovine IVF blastocysts following biopsy. Suzuki T, et al.
Cryobiology 1995 Dec;32(6):505–10

Effect of Percoll wash on sperm motion parameters and subsequent fertility in intrauterine insemination cycles. Swanson ML, et al. **J Assist Reprod Genet** 1995 Jan; 12(1):48–54

THERAPEUTIC USE

The effect of povidone–iodine solution applied at the conclusion of ophthalmic surgery [letter; comment] Sanchez–Thorin JC. **Am J Ophthalmol** 1995 Dec; 120(6):806–8. Comment on: Am J Ophthalmol 1995 Jun;119(6):701–5.

POVIDONE–IODINE

ADMINISTRATION & DOSAGE

[The use of the preparation Betadiner in some forms of colpitis] Marinov B, et al. **Akush Ginekol (Sofiia)** 1995; 34(1):39–40 **(Bul)**

[Efficacy of various methods for preoperative vaginal antisepsis] Enzelsberger H, et al.
Geburtshilfe Frauenheilkd 1995 Dec;55(12):707–10 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Topical iodine and neonatal hypothyroidism. Gordon CM, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1336–9

Skin ulceration due to povidone–iodine. Mochida K, et al.
Contact Dermatitis 1995 Jul;33(1):61–2

PHARMACOKINETICS

Effect on neonatal thyroid function of povidone–iodine used on mothers during perinatal period. Koga Y, et al.
J Obstet Gynaecol 1995 Dec;21(6):581–5

PHARMACOLOGY

[Betadine for antisepsis of the conjunctival sac] Philips RH, et al. **Klin Oczna** 1995 Jul–Sep;97(7–8):255–6 (Eng. Abstr.) **(Pol)**

POISONING

Iatrogenic iodine toxicity [letter] Borron SW.
J Toxicol Clin Toxicol 1996;34(5):531–3

Fatal iatrogenic iodine toxicity in a nine–week old infant. Kurt TL, et al. **J Toxicol Clin Toxicol** 1996;34(2):231–4

THERAPEUTIC USE

Immune response inhibition by irrigating subchondral bone with cytotoxic agents. Rodrigo JJ, et al. **Clin Orthop** 1996 May;(326):96–106

Preventing post–treatment bacteremia: comparing topical povidone–iodine and chlorhexidine [see comments] Rahn R, et al. **J Am Dent Assoc** 1995 Aug;126(8):1145–9. Comment in: J Am Dent Assoc 1995 Nov;126(11):1474, 1476.

The effect of Biocell texturing and povidone–iodine irrigation on capsular contracture around saline–inflatable breast implants. Burkhardt BR, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1317–25

Field trial evaluation of two teat dips containing nisin or polyvinylpyrrolidone iodophor designed for use before and after milking. Sérieys F, et al. **Vet Res** 1996;27(3):295–303

[Sclerotherapy with Betadine for simple cysts of the kidney. Apropos of 7 cases] Ibnatya A, et al. **J Urol (Paris)** 1995; 101(5–6):237–9 (Eng. Abstr.) **(Fre)**

[Effectiveness of local treatment using a PVP–iodine compound for retained placenta in cows] Geiser S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):264–8 (Eng. Abstr.) **(Ger)**

[Povidone–iodine eyedrops for the prevention of newborn conjunctivitis] Buchmann P. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1645 **(Ger)**

[The use of Betadine in surgery] Osipov IS, et al. **Voen Med Zh** 1996 Feb;317(2):35–7 **(Rus)**

TOXICITY

Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts. Kaysinger KK, et al. **J Orthop Trauma** 1995;9(4):303–11

POWASSAN VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

POWDERS

Automated system for the on–line monitoring of powder blending processes using near–infrared spectroscopy. Part I. System development and control. Hailey PA, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):551–9

Structure of disintegrating pellets with regard to fractal geometry. Schröder M, et al. **Pharm Res** 1995 Nov; 12(11):1694–700

[Effectiveness and acceptance of powder inhalants] Köhler D. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1401–4 **(Ger)**

ADVERSE EFFECTS

Latex allergens in glove–powdering slurries. Lundberg M, et al. **Allergy** 1995 Apr;50(4):378–80

CHEMISTRY

The effect of particle fragmentation and deformation on the interparticulate bond formation process during powder compaction. Eriksson M, et al. **Pharm Res** 1995 Jul; 12(7):1031–9

Development of a flow microcalorimetry method for the assessment of surface properties of powders. Sheridan PL, et al. **Pharm Res** 1995 Jul;12(7):1025–30

POWER (PSYCHOLOGY)

see related

SOCIAL CONTROL, INFORMAL

Risky heterosexual practices amongst women over 30: gender, power and long term relationships. Maxwell C, et al. **AIDS Care** 1995;7(3):277–93

The power of physicians: autonomy and balance in a changing system. Friedman E. **Am J Med** 1995 Dec; 99(6):579–86

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)

Seven ways to empower dying patients. Ray MC. **Am J Nurs** 1996 May;96(5):56–7

Building an empowerment policy paradigm: self–reported strengths of homeless mothers. Banyard VL, et al. **Am J Orthopsychiatry** 1995 Oct;65(4):479–91

Power, professionalism, and patient advocacy. Flynn MB. **Am J Surg** 1995 Nov;170(5):407–9

Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)

Power, boundaries, intersubjectivity. Owen IR. **Br J Med Psychol** 1995 Jun;68 (Pt 2):97–107

The paradoxical power of the depressed patient: a problem for the ranking theory of depression. Price J, et al. **Br J Med Psychol** 1995 Sep;68 (Pt 3):193–206; discussion 207–22 (37 ref.)

Power, gender stereotypes and perceptions of heterosexual couples. Smoreda Z. **Br J Soc Psychol** 1995 Dec;34 (Pt 4):421–35

The disempowerment of psychiatrists [letter] Mai FM. **Can J Psychiatry** 1995 Nov;40(9):568–9

Patient empowerment and the traditional medical model. A case of irreconcilable differences? Anderson RM. **Diabetes Care** 1995 Mar;18(3):412–5

Patient empowerment. Results of a randomized controlled trial. Anderson RM, et al. **Diabetes Care** 1995 Jul; 18(7):943–9

Power and the female condom [letter] Stockbridge EL. **Fam Plann Perspect** 1996 Mar–Apr;28(2):78–9

Decision–making influence: an empirical study of social workers in nursing homes. Kruzich JM, et al. **Health Soc Work** 1995 Aug;20(3):215–22

Power and structure in primary care [editorial; comment] Weingarten MA. **Isr J Med Sci** 1996 Jul;32(7):570–2. Comment on: Isr J Med Sci 1996 Jul;32(7):545–50. Comment on: Isr J Med Sci 1996 Jul;32(7):551–4. Comment on: Isr J Med Sci 1996 Jul;32(7):555–60.

Terms of address: implications for nursing. Bowie I. **J Adv Nurs** 1996 Jan;23(1):113–9 (17 ref.)

Deputed power of medical control: the hidden message in the ritual of oral shift reports. Ekman I, et al. **J Adv Nurs** 1995 Nov;22(5):1006–11

Conflict, enactment, empowerment: conditions of independent therapeutic nursing intervention. Kubsch SM. **J Adv Nurs** 1996 Jan;23(1):192–200

Employed Mexican women as mothers and partners: valued, empowered and overloaded. Meleis AI, et al. **J Adv Nurs** 1996 Jan;23(1):82–90

An analysis of the concept of empowerment. Rodwell CM. **J Adv Nurs** 1996 Feb;23(2):305–13 (74 ref.)

Gender–power relations and safer sex negotiation. Taylor BM. **J Adv Nurs** 1995 Oct;22(4):687–93 (46 ref.)

Dyslexia: empowering parents to become their child's educational advocate. Linday LA. **J Dev Behav Pediatr** 1995 Oct;16(5):359–61

Registered nurse empowerment. Model testing and implications for nurse administrators. Klakovich MD. **J Nurs Adm** 1996 May;26(5):29–35

The (over) zealous executives. O'Leary LT. **J Nurs Adm** 1996 Apr;26(4):18–20

The RN–BSN student: developing a model of empowerment. Worrell JD, et al. **J Nurs Educ** 1996 Mar;35(3):127–30

Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):233–9 (25 ref.)

A model for practice guideline adaptation and implementation: empowerment of the physician [see comments] Wise CG, et al. **Jt Comm J Qual Improv** 1995 Sep;21(9):465–76. Comment in: Jt Comm J Qual Improv 1996 Feb;22(2):83–4.

Knowledge, power and experience: variation in physicians' perceptions of breast cancer risk factors. McMullin JM, et al. **Med Anthropol** 1996 Mar;16(4):295–317

Mandinka mothers and nurslings: power and reproduction. Whittemore RD, et al. **Med Anthropol Q** 1996 Mar; 10(1):45–62

Suicide, homicide, and a history of oppression in the Caribbean nations. Lester D. **Psychol Rep** 1995 Dec;77(3 Pt 1):942

Systemic perspective on obesity in childhood: a preliminary study on power interactions between mother and child. Valtolina G, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1219–28

Development and psychometric testing of the Leddy Healthiness Scale. Leddy SK. **Res Nurs Health** 1996 Oct; 19(5):431–40

Powerlessness, health and mortality: a longitudinal study of older men and mature women. Seeman M, et al. **Soc Sci Med** 1995 Aug;41(4):517–25

[Patients' right and physicians' power] Lindqvist M. **Duodecim** 1995;111(1):96–9 **(Fin)**

POWER, PERSONAL see **POWER (PSYCHOLOGY)**

POWER PLANTS

Effects of radiation on the production of immunoglobulins in children subsequent to the Chernobyl disaster. Titov LP, et al. **Allergy Proc** 1995 Jul–Aug;16(4):185–93

Power–line magnetic fields are likely related to leukemia in children (despite the opinion of the American Physical Society). Liboff AR. **Altern Ther Health Med** 1996 Mar; 2(2):46–50

The great power–line scare. Park RL. **Altern Ther Health Med** 1996 Mar;2(2):46–51

Seeks caution in light of power–line research [letter] Satti JA. **Altern Ther Health Med** 1996 Jul;2(4):20, 22

Occupational respiratory cancer and exposure to asbestos: a case–control study in a cohort of workers in the electricity and gas industry. Imbernon E, et al. **Am J Ind Med** 1995 Sep;28(3):339–52

Adult leukemia and proximity–based surrogates for exposure to Pilgrim plant's nuclear emissions. Morris MS, et al. **Arch Environ Health** 1996 Jul–Aug;51(4):266–74

Characteristics of thyroid ultrasound pictures in children with nodular thyroid changes effected by radionuclides. Drozd VM, et al. **Bildgebung** 1995 Dec;62(4):236–41

Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries [see comments] Bigbee WL, et al. **BMJ** 1996 Apr 27;312(7038):1078–9. Comment in: BMJ 1996 Apr 27;312(7038):1052–3.

Chernobyl 10 years on [editorial; comment] Henshaw DL. **BMJ** 1996 Apr 27;312(7038):1052–3. Comment on: BMJ 1996 Apr 27;312(7038):1078–9.

Childhood leukaemia in Europe after Chernobyl: 5 year follow–up. Parkin DM, et al. **Br J Cancer** 1996 Apr; 73(8):1006–12

Children of Chernobyl [news] **Environ Health Perspect** 1995 Nov;103(11):990

Use of outpatient clinics as a health indicator for communities around a coal–fired power plant. Goren AI, et al. **Environ Health Perspect** 1995 Dec;103(12):1110–5

Health effects in a casual sample of immigrants to Israel from areas contaminated by the Chernobyl explosion. Kordysh EA, et al. **Environ Health Perspect** 1995 Oct;103(10):936–41

Biokinetics of nuclear fuel compounds and biological effects of nonuniform radiation. Lang S, et al. **Environ Health Perspect** 1995 Oct;103(10):920–34 (191 ref.)

A post–Chernobyl rise in thyroid cancer in Connecticut, USA. Mangano JJ. **Eur J Cancer Prev** 1996 Feb;5(1):75–81

Countermeasures for radiocesium in animal products in Norway after the Chernobyl accident—techniques, effectiveness, and costs. Brynildsen LI, et al. **Health Phys** 1996 May;70(5):665–72

Environmental radiation real–time monitoring system permanently installed near Qinshan Nuclear Power Plant. Ding M, et al. **Health Phys** 1996 Mar;70(3):415–7

Model testing using Chernobyl data: III. Atmospheric resuspension of radionuclides in Ukrainian regions impacted by Chernobyl fallout. Garger EK, et al. **Health Phys** 1996 Jan;70(1):18–24

An approach to evaluating bias and uncertainty in estimates of external dose obtained from personal dosimeters. Gilbert ES, et al. **Health Phys** 1996 Mar;70(3):336–45

Opportunities for the testing of environmental transport models using data obtained following the Chernobyl accident. Hoffman FO, et al. **Health Phys** 1996 Jan; 70(1):5–7

Model testing using Chernobyl data: I. Wash–off of 90Sr and 137Cs from two experimental plots established in the vicinity of the Chernobyl reactor. Konoplev AV, et al. **Health Phys** 1996 Jan;70(1):8–12

Model testing using Chernobyl data: II. Assessment of the consequences of the radioactive contamination of the Chernobyl Nuclear Power Plant cooling pond. Kryshev II, et al. **Health Phys** 1996 Jan;70(1):13–7

Effective doses due to external irradiation from the Chernobyl accident for different population groups of Ukraine. Likhtariov I, et al. **Health Phys** 1996 Jan; 70(1):87–98

Comparison of dose histories for U.S. nuclear power plant workers, based on records held by a major dosimetry service company and on the NRC REIRS database. Muirhead CR, et al. **Health Phys** 1996 May;70(5):645–50

Neutron fields inside containment of a CANDU600–PHWR power plant. Nunes JC, et al. **Health Phys** 1996 Aug; 71(2):235–47

Radiation impact from lignite burning due to 226Ra in Greek coal–fired power plants. Papastefanou C. **Health Phys** 1996 Feb;70(2):187–91

Outdoor field evaluation of passive tritiated water vapor samplers at Canadian power reactor sites. Wood MJ. **Health Phys** 1996 Feb;70(2):258–67

CaSO4:Dy and LiF:Mg, Cu, P thermoluminescent dosimeters for environmental monitoring in ambient areas of a nuclear power plant. Zeng XS, et al. **Health Phys** 1996 Mar; 70(3):367–71

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. **Int J Cancer** 1996 Jul 29;67(3):343–52 (33 ref.)

Mutations in the p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Hillebrandt S, et al. **Int J Radiat Biol** 1996 Jan;69(1):39–45

Hanford Health Information Archives offers unique history of exposure to radiation in US Northwest [news] Gaie M. **JAMA** 1996 Aug 7;276(5):354

Health effects in survivors of the Chernobyl disaster [letter] Quastel MR, et al. **JAMA** 1996 Jun 26;275(24):1881–2

Chernobyl and hypothyroidism [letter] Mangano JJ. **Lancet** 1996 May 25;347(9013):1482–3

Chernobyl and hypothyroidism [letter] Williams D. **Lancet** 1996 Aug 17;348(9025):476–7

Chromosome aberrations in workers of nuclear–power plants. Chung HW, et al. **Mutat Res** 1996 Mar 9;350(2):307–14

Retrospective dose estimates in Estonian Chernobyl clean–up workers by means of FISH. Granath F, et al. **Mutat Res** 1996 Jul 10;369(1–2):7–12

Chromosome aberrations and rogue cells in lymphocytes of Chernobyl clean–up workers. Lazutka JR. **Mutat Res** 1996 Mar 9;350(2):315–29

Chernobyl's legacy to science [editorial] [see comments] **Nature** 1996 Apr 25;380(6576):653. Comment in: Nature 1996 Jun 20;381(6584):642.

Chernobyl damage 'underestimated' [news] Abbott A, et al. **Nature** 1996 Apr 25;380(6576):658

High levels of genetic change in rodents of Chernobyl [see comments] Baker RJ, et al. **Nature** 1996 Apr 25; 380(6576):707–8. Comment in: Nature 1996 Apr 25;380(6576):665–6.

Links in childhood leukaemia [news; comment] Darby SC, et al. **Nature** 1996 Jul 25;382(6589):303–4. Comment on: Nature 1996 Jul 25;382(6589):352–3.

Human minisatellite mutation rate after the Chernobyl accident [see comments] Dubrova YE, et al. **Nature** 1996 Apr 25;380(6576):683–6. Comment in: Nature 1996 Apr 25;380(6576):665–6.

Life in the hot zone around Chernobyl [news; comment] Hillis DM. **Nature** 1996 Apr 25;380(6576):665–6. Comment on: Nature 1996 Apr 25;380(6576):683–6. Comment on:

Nature 1996 Apr 25;380(6576):707–8.

Call for more research into health effects of Chernobyl accident [news] Masood E. **Nature** 1995 Nov 30; 378(6556):429

Infant leukaemia after in utero exposure to radiation from Chernobyl [see comments] Petridou E, et al. **Nature** 1996 Jul 25;382(6589):352–3. Comment in: Nature 1996 Jul 25;382(6589):303–4.

Effects of radiation on children [letter] Satoh C, et al. **Nature** 1996 Sep 19;383(6597):226

Chernobyl legacy [letter; comment] Voice E. **Nature** 1996 Jun 20;381(6584):642. Comment on: Nature 1996 Apr 25;380(6576):653.

Exposure to magnetic fields estimated from last job held in an electrical utility in Québec, Canada: a validation study. Baris D, et al. **Occup Environ Med** 1996 May;53(5):334–8

Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Nikiforov YE, et al. **Oncogene** 1996 Aug 15;13(4):687–93

Evaluation of 137Cs activity in plant drugs and in some phytoderivatives from Chernobyl accident up to present (1986–1994). Curini M, et al. **Pharmacol Res** 1995 Jul–Aug; 32(1–2):69–74

Physical fitness and CHD risk factors in operators and managers of nuclear and thermal power plants situated in environmentally different regions of the Czech Republic. Brandejský P, et al. **Sb Lek** 1994;95(2):127–38

Residual Chernobyl fallout and Sellafield pollutants found on the Isle of Man. McKenna P, et al. **Sci Total Environ** 1995 Dec 1;173–174:7–14

Atmospheric deposition of cosmogenic 7Be and 137Cs from fallout of the Chernobyl accident. Papastefanou C, et al. **Sci Total Environ** 1995 Aug 18;170(1–2):151–6

Distribution of toxic and radiation components in air particulates. Rausch H, et al. **Sci Total Environ** 1995 Dec 1;173–174:283–91

Children become the first victims of fallout [news] Balter M. **Science** 1996 Apr 19;272(5260):357–60

Chernobyl's thyroid cancer toll [news] Balter M. **Science** 1995 Dec 15;270(5243):1758–9

Radioactive waste at Ward Valley [letter] Budin E. **Science** 1995 Sep 22;269(5231):1655–7

Chernobyl research becomes international growth industry [news] Williams N, et al. **Science** 1996 Apr 19; 272(5260):355–6

Leukemia studies continue to draw a blank [news] Williams N. **Science** 1996 Apr 19;272(5260):358

Chernobyl and thyroid [editorial] Yamashita S, et al. **Thyroid** 1995 Jun;5(3):153–4

[A case of non-Hodgkin T-cell lymphoma with predominantly cutaneous manifestations] di Tondo U, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):537–42 (Eng. Abstr.) **(Ita)**

[Consequences of the reactor breakdown at Chernobyl 10 years after the catastrophe] Jankowski J. **Med Pr** 1996; 47(4):319–29 (Eng. Abstr.) **(Pol)**

[Cytogenetic study of residents three years and more after the accident at the Chernobyl Atomic Power Plant] Bochkov NP, et al. **Dokl Akad Nauk** 1995 Dec;345(6):843–4 **(Rus)**

[Detection and nature of melanin-containing centers in bronchoalveolar smears and blood of persons responsible for cleaning up after the accident at the Chernobyl Atomic Energy Station] Pulatova MK, et al. **Dokl Akad Nauk** 1995 Nov;345(1):130–4 **(Rus)**

[Adaptive changes in autonomic functions in liquidators of the accident at the Chernobyl nuclear power plant in the process of conducting rehabilitation measures] Fudin NA, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):137–45 **(Rus)**

[Dynamics of objective audiometry parameters in liquidators of the accident at the Chernobyl nuclear power plant] Zabolotnyĭ DI, et al. **Fiziol Cheloveka** 1995 Jul–Aug; 21(4):119–22 **(Rus)**

[Quantitative and cytologic changes in various types of blood leukocytes in liquidators 5–6 years after the accident at the Chernobyl power plant] Zak KP, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):39–42 (Eng. Abstr.) **(Rus)**

[Genetic sequelae of the accident at the Chernobyl nuclear power plant in house mice (Mus musculus)] Pomerantseva MD, et al. **Genetika** 1996 Feb;32(2):298–303 (Eng. Abstr.) **(Rus)**

[Dna repair activity in children exposed to small doses of ionizing radiation as a result of the accident at the Chernobyl nuclear power station] Unizhakov SV, et al. **Genetika** 1995 Oct;31(10):1433–7 (Eng. Abstr.) **(Rus)**

[State of the visual function in locomotive team personnel working in zones of radioactive pollution] Sosnova TL, et al. **Gig Sanit** 1995 Sep–Oct;(5):43–5 (Eng. Abstr.) **(Rus)**

[Immune and microcirculatory disorders and their correction in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station who have neuroasomatic pathology] Frolov VM, et al. **Lik Sprava** 1995 May–Jun;(5–6):22–5 (Eng. Abstr.) **(Rus)**

[Tolerance for physical loading and its determinative factors in persons who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Khomaziuk IN. **Lik Sprava** 1995 May–Jun; (5–6):31–5 **(Rus)**

[The clinical and biochemical characteristics of the status of stomach cancer patients who were exposed to ionizing radiation as a result of the accident at the Chernobyl Atomic Electric Power Station] Korobko VB, et al. **Lik Sprava** 1995 May–Jun;(5–6):19–22 (Eng. Abstr.) **(Rus)**

[The functional status of the hypophyseal–thyroid and hypophyseal–adrenal systems in breast cancer patients taking into account their exposure to the factors of the accident at the Chernobyl Atomic Electric Power Station] Maevskaia LP. **Lik Sprava** 1995 May–Jun;(5–6):29–31 (Eng. Abstr.) **(Rus)**

[The systematics of mental disorders related to the sequelae of the accident at the Chernobyl Atomic Electric Power Station] Napreenko AK, et al. **Lik Sprava** 1995 May–Jun; (5–6):25–9 (Eng. Abstr.) **(Rus)**

[The correction of free-radical oxidation processes in patients with chronic cholecystitis subjected to ionizing radiation exposure] Pasieshvili LM. **Lik Sprava** 1995 Jul–Aug; (7–8):54–6 (Eng. Abstr.) **(Rus)**

[The health status of children up to 14 years old living in an area of long-term post-accident exposure to low doses of ionizing radiation] Ponomarenko VM. **Lik Sprava** 1995 May–Jun;(5–6):12–5 (Eng. Abstr.) **(Rus)**

[Lipid indices in the expirate of persons subjected to ionizing radiation exposure] Protsiuk RG, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):56–9 (Eng. Abstr.) **(Rus)**

[Low doses of ionizing radiation and short- and long-term hematologic changes (review of the literature)] Soldatov SK, et al. **Med Tr Prom Ekol** 1995;(9):20–3 **(Rus)**

[The genetic consequences of the radioactive contamination of populations of Arabidopsis thaliana growing in a 30-kilometer area of the accident at the Chernobyl Atomic Electric Power Station] Abramov VI, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):676–89 (Eng. Abstr.) **(Rus)**

[Regularities of changes in Cs-137 contents in animal products in the territory of the Russian Federation polluted as a consequence of the Chernobyl AES accident] Fesenko SV, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):316–27 (Eng. Abstr.) **(Rus)**

[Study of reproductive behavior in Russian and Byelarus populations exposed to ionizing radiation as a consequence of the Chernobyl AES accident] Golovko OV, et al. **Radiats Biol Radioecol** 1996 Jan–Feb;36(1):3–8 (Eng. Abstr.) **(Rus)**

[Radiosensitivity and postradiation kinetics of megakaryocyte release of the bone marrow (analysis based on data of the Chernobyl AES accident sequelae)] Gruzdev GP, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):250–63 (Eng. Abstr.) **(Rus)**

[The genetic consequences of the Chernobyl accident. The monitoring of congenital developmental defects in newborn infants in Kaluga Province] Guzeev GG, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):640–6 (Eng. Abstr.) **(Rus)**

[An assessment of the absorbed doses in cattle over the course of the first year after the accident at the Chernobyl Atomic Electric Power Station] Iastrebkov IuA, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):845–50 (Eng. Abstr.) **(Rus)**

[The genetic effect in Pinus sylvestris L. populations of the eastern Urals radioactive trace from the control area of the accident at the Chernobyl Atomic Electric Power Station and from the region of the nuclear device tests at the Semipalatinsk proving grounds] Kal'chenko VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):702–7 (Eng. Abstr.) **(Rus)**

[The cytogenetic examination of different groups of children living in regions of Bryansk Province contaminated as a result of the Chernobyl accident] Khandogina EK, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):618–25 (Eng. Abstr.) **(Rus)**

[The dynamics of the radiation damage and recovery processes in coniferous stands in a 10-kilometer control zone of the accident at the Chernobyl Atomic Electric Power Station] Kozubov GM, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):836–44 (Eng. Abstr.) **(Rus)**

[Soil-plant linkage and expected doses in humans from incorporated long-lived radionuclides] Kravets AP, et al. **Radiats Biol Radioecol** 1996 Jan–Feb;36(1):9–16 (Eng. Abstr.) **(Rus)**

[Modification of the genetic effect of radiation in mice exposed in the region of the Chernobyl Atomic Electric Power Station] Pomerantseva MD, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):765–73 (Eng. Abstr.) **(Rus)**

[Assessment of factors determining the dynamics of pollution by Cs-137 of agricultural production after the Chernobyl AES accident] Sanzharova NI, et al. **Radiats Biol Radioecol** 1995 May–Jun;35(3):307–15 (Eng. Abstr.) **(Rus)**

[UV-induced unscheduled DNA synthesis in the peripheral blood lymphocytes of participants in the clean-up of the aftereffects of Chernobyl accident] Semov AB. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):740–5 (Eng. Abstr.) **(Rus)**

[The relationship between respiratory system reactivity and neutrophil metabolism in hypoxia in persons subjected to ionizing radiation exposure] Serebrovskaia TV, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):400–4 (Eng. Abstr.) **(Rus)**

[Chemiluminescence, blood lipid peroxidation and neutrophil activity during the hypoxic training of persons subjected to ionizing radiation exposure] Serebrovskaia ZA, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):394–9 (Eng. Abstr.) **(Rus)**

[The monitoring of natural populations of Dactylis glomerata L. in the area of the accident at the Chernobyl Atomic Electric Power Station] Shershunova VI, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):690–5 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in persons who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station] Shevchenko VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):646–54 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in natural populations of Crepis tectorum exposed to chronic irradiation in the region of the Chernobyl Atomic Electric Power Station. An analysis of the frequency of chromosome aberrations and karyotype changes in the 3rd and 4th years after the accident] Shevchenko VV, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):695–701 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in Crepis tectorum populations growing in Bryansk Province observed in the 7th year after the accident at the Chernobyl Atomic Electric Power Station] Shevchenko VV, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):720–5 (Eng. Abstr.) **(Rus)**

[The role of immunological changes in diseases in regions contaminated by radionuclides after the accident at the Chernobyl Atomic Electric Power Station] Shubik VM, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):332–7 (Eng. Abstr.) **(Rus)**

[The use of the FISH method for reconstructing the absorbed doses received by participants in the clean-up of the accident at the Chernobyl Atomic Electric Power Station] Snigireva GP, et al. **Radiats Biol Radioecol** 1995 Sep–Oct; 35(5):654–61 (Eng. Abstr.) **(Rus)**

[Radiation sensitivity of the seeds of winter wheat from chronically exposed agrocenosis] Ul'ianenko LN, et al. **Radiats Biol Radioecol** 1995 May–Jun;35(3):428–34 (Eng. Abstr.) **(Rus)**

[Stable chromosome aberrations in the lymphocytes of the peripheral blood in persons who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station] Vorobtsova IE, et al. **Radiats Biol Radioecol** 1995 Sep–Oct; 35(5):636–40 (Eng. Abstr.) **(Rus)**

[The cytogenetic examination of children in the Saint Petersburg region who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station. The frequency of unstable chromosome aberrations in the peripheral blood lymphocytes] Vorobtsova IE, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):630–5 (Eng. Abstr.) **(Rus)**

[Respiratory tract damage in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Antonov NS, et al. **Ter Arkh** 1996; 68(3):12–4 (Eng. Abstr.) **(Rus)**

[The prevalence of respiratory organ diseases among those who cleaned up the accident at the Chernobyl Atomic Electric Power Station] Antonov NS, et al. **Ter Arkh** 1996; 68(3):17–9 (Eng. Abstr.) **(Rus)**

[The rehabilitation under alpine conditions of the participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station who are ill with chronic bronchitis] Brimkulov NN, et al. **Ter Arkh** 1996;68(3):34–7 (Eng. Abstr.) **(Rus)**

[The morphological characteristics of the alveolar macrophages in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station at a late period (1)] Cherniaev AL, et al. **Ter Arkh** 1996;68(3):19–23 (Eng. Abstr.) **(Rus)**

[Respiratory organ pathology in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station (editorial)] Chuchalin AG. **Ter Arkh** 1996; 68(3):5–7 **(Rus)**

[The presence of cesium-137 in the tissue of a lung tumor in someone who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Grobova OM, et al. **Ter Arkh** 1996;68(3):26–30 (Eng. Abstr.) **(Rus)**

[Respiratory organ pathology in the participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station] Maracheva AV, et al. **Ter Arkh** 1996; 68(3):8–12 (Eng. Abstr.) **(Rus)**

[Respiratory and hemodynamic disorders in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Pashkova TL, et al. **Ter Arkh** 1996;68(3):14–6 (Eng. Abstr.) **(Rus)**

[The results of the combined programmed treatment of those who cleaned up the accident at the Chernobyl Atomic Electric Power Station who suffer from respiratory organ diseases] Tatarskiĭ AR, et al. **Ter Arkh** 1996;68(3):30–3 (Eng. Abstr.) **(Rus)**

[An evaluation of the role of radiation and nonradiation factors in the development of lung cancer in workers at a radiochemical enterprise (1)] Tokarskaia ZB, et al. **Ter Arkh** 1996;68(3):37–40 (Eng. Abstr.) **(Rus)**

[The pathomorphology of the pulmonary infectious complications in acute radiation sickness (based on the autopsy data from persons who died as a result of the accident at the Chernobyl Atomic Electric Power Station] Vlasov PA, et al. **Ter Arkh** 1996;68(3):23–6 (Eng. Abstr.)

(Rus)
[Radiation-induced cytogenetic markers detected 8 years after the accident at the Chernobyl Atomic Electric Power Station by different methods of analyzing metaphase chromosome preparations in persons who have had acute radiation sickness] Pilinskaia MA, et al. **Tsitol Genet** 1995 Sep-Oct;29(5):3-11 (Eng. Abstr.) (Rus)
[The effect of chronic ionizing radiation at low doses on a number of reproductive indices in CC57W/Mv mice from an experimental Chernobyl population] Stolina MR, et al. **Tsitol Genet** 1996 Jan-Feb;30(1):53-8 (Eng. Abstr.) (Rus)
[The radiation factors impacting on people in accidents at atomic power installations] Cherniak SI, et al. **Voen Med Zh** 1992 Feb;(2):52-6 (Rus)
[The organization of health and hygiene measures among the troops working in the cleanup of the aftermath of the Chernobyl catastrophe in 1986] Chvyrev VG, et al. **Voen Med Zh** 1996 Apr;317(4):4-7, 79 (Eng. Abstr.) (Rus)
[131I as a factor in radiation exposure] Korolev VI. **Voen Med Zh** 1992 Feb;(2):56-8 (Rus)
[A hygienic analysis of the irradiation doses of those cleaning up the aftermath of the accident at the Chernobyl Atomic Electric Power Station (based on data from the All-Army Registry)] Shantyr' II, et al. **Voen Med Zh** 1995 Mar;(3):58-63, 80 (Eng. Abstr.) (Rus)
[The dynamic cytochemical indices of the blood in helicopter pilots who participated in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Smirnov NA, et al. **Voen Med Zh** 1995 Aug;(8):42-3 (Rus)
[The assessment at a sanatorium of the mental status of children who were victims of the Chernobyl catastrophe] Lysenko VI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov-Dec;(6):31-3 (Eng. Abstr.) (Rus)
[Malignant thyroid neoplasms in the territories of the Russian Federation exposed as a consequence of the accident at the Chernobyl Atomic Electric Power Station] Remennik LV, et al. **Vopr Onkol** 1995;41(2):29-34 (Rus)
[A case of prolonged hematopoietic depression after acute radiation sickness in a man who worked in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station] Klimenko VI, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):41-3 (Rus)
[The autonomic regulation of the cardiovascular system in subjects with the autonomic dystonia syndrome subjected to ionizing radiation exposure as a result of the accident at the Chernobyl Atomic Electric Power Station] Niagu AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):32-5 (Eng. Abstr.) (Rus)
[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz-Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100-2, 4105 (18 ref.) (Swe)
[The microwave therapy of patients with duodenal peptic ulcer who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Babak Ola, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):51-3 (Eng. Abstr.) (Ukr)
[The characteristics of disorders of general adaptation reactions in people who suffered as a consequence of the accident at the Chernobyl Atomic Electric Power Station and their correction by means of balneo- and phytotherapy] Sarancha SM, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):47-51 (Eng. Abstr.) (Ukr)
[The metabolic aspects of the sequelae of the accident at the Chernobyl Atomic Electric Power Station in the course of kidney diseases] Vozianov OF, et al. **Lik Sprava** 1995 May-Jun;(5-6):15-9 (Eng. Abstr.) (Ukr)

STATISTICS & NUMERICAL DATA

[The irradiation levels of the participants in the cleanup of the aftermath of the Chernobyl accident in 1986-1987 and the verification of the dosimetric data] Il'in LA, et al. **Radiats Biol Radioecol** 1995 Nov-Dec;35(6):803-28 (Eng. Abstr.) (Rus)
[The results of a study of disability among those who participated in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station (based on data from the Ukrainian National Registry)] Nagornaia AM, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):36-7 (Rus)

POWER, PROFESSIONAL see **POWER (PSYCHOLOGY)**

POWER, SOCIAL see **POWER (PSYCHOLOGY)**

POWER SOURCES

see related
BIOELECTRIC ENERGY SOURCES

The battery enigma: are third-party rechargeable batteries as good as OEMs? Shenoy DG, et al. **Biomed Instrum Technol** 1995 Jul-Aug;29(4):299-306
Power sources in endoscopic surgery. Sutton C. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):248-56 (43 ref.)
Mn concentration in organs of rats after implantation of battery cathode material. Janssens S, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):224-7
Transmission-line electric field induction in humans using charge simulation method. Abdel-Salam M, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1105-9
Assessing historical exposures of children to power-frequency magnetic fields. Kaune WT, et al. **J Expo Anal Environ Epidemiol** 1994 Apr-Jun;4(2):149-70
Power sources. Luciano AA. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):423-43 (36 ref.)
Upper aerodigestive cancer in battery manufacturers and steel workers exposed to mineral acid mists. Coggon D, et al. **Occup Environ Med** 1996 Jul;53(7):445-9
Determinants of dual chamber pulse generators longevity. Markewitz A, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2116-20
[The voltage-dependence of battery-operated light-curing units] Ernst CP, et al. **Schweiz Monatsschr Zahnmed** 1995;105(10):1317-21 (Ger, Fre)

ADVERSE EFFECTS

Audible alarm battery failure on Bear 3 ventilators. **Health Devices** 1995 Jul;24(7):287-8
Electromagnetic fields, radon, and cancer. Toburen LH. **Lancet** 1996 Apr 20;347(9008):1059-60
Health risks of electric and magnetic fields caused by high-voltage systems in Finland. Valjus J. **Scand J Work Environ Health** 1996 Apr;22(2):85-93 (31 ref.)

STANDARDS

Third-party and OEM battery performances [letter] Kaplan M. **Biomed Instrum Technol** 1995 Nov-Dec;29(6):470
Use of an uninterruptible power supply in a molecular biology laboratory. Rubin SA. **Biotechniques** 1995 Dec;19(6):900-01

SUPPLY & DISTRIBUTION

Providing fluoroscopy in the CCL during electrical power interruptions. Coiro DJ, et al. **Biomed Instrum Technol** 1995 Nov-Dec;29(6):489-94

POWER SOURCES, BIOELECTRIC see **BIOELECTRIC ENERGY SOURCES**

POWER SUPPLIES see **POWER SOURCES**

POXVIRIDAE

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241-56 (87 ref.)

CLASSIFICATION

Characterization of camelpoxvirus isolates from Africa and Asia. Renner-Müller IC, et al. **Vet Microbiol** 1995 Aug;45(4):371-81

ENZYMOLOGY

Nucleotide sequence of the thymidine kinase gene of raccoon poxvirus. Lutze-Wallace C, et al. **Virus Genes** 1995;10(1):81-4

GENETICS

Poxvirus-based vectors as vaccine candidates. Pincus S, et al. **Biologicals** 1995 Jun;23(2):159-64 (31 ref.)
The establishment of a genetic map of orf virus reveals a pattern of genomic organization that is highly conserved among divergent poxviruses. Mercer AA, et al. **Virology** 1995 Oct 1;212(2):698-704

IMMUNOLOGY

Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus. Wasmoen TL, et al. **Adv Exp Med Biol** 1995;380:221-8
[Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature] Mayr B, et al. **Tierarztl Prax** 1995 Dec;23(6):542-52 (39 ref.) (Eng. Abstr.) (Ger)

ISOLATION & PURIFICATION

Characterization of camelpoxvirus isolates from Africa and Asia. Renner-Müller IC, et al. **Vet Microbiol** 1995 Aug;45(4):371-81

PHYSIOLOGY

Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Alcamí A, et al. **Immunol Today** 1995 Oct;16(10):474-8 (39 ref.)
Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Büttner M, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):237-50

POXVIRIDAE INFECTIONS

ENZYMOLOGY

Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia. Müllbacher A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5783-7

EPIDEMIOLOGY

[Clinical findings and diagnosis of a severs parapoxvirus epidemic in Finnish reindeer] Büttner M, et al. **Tierarztl Prax** 1995 Dec;23(6):614-8 (Eng. Abstr.) (Ger)

VETERINARY

Pox in ostrich chicks. Raidal SR, et al. **Aust Vet J** 1996 Jan;73(1):32-3
Serology of Orthopoxvirus cameli infection in dromedary camels: analysis by ELISA and western blotting. Azwai SM, et al. **Comp Immunol Microbiol Infect Dis** 1996 Jan;19(1):65-78
Serological survey for orthopoxvirus infection of wild mammals in areas where a recombinant rabies virus is used to vaccinate foxes. Boulanger D, et al. **Vet Rec** 1996 Mar 16;138(11):247-9
Isolation of a parapoxvirus from a grey seal (Halichoerus grypus). Nettleton PF, et al. **Vet Rec** 1995 Nov 25;137(22):562-4
An investigation into the health and welfare of red squirrels, Sciurus vulgaris, involved in reintroduction studies. Sainsbury AW, et al. **Vet Rec** 1995 Oct 7;137(15):367-70
Parapoxvirus infection in red squirrels [letter] Sainsbury T, et al. **Vet Rec** 1996 Apr 20;138(16):400
[Clinical findings and diagnosis of a severs parapoxvirus epidemic in Finnish reindeer] Büttner M, et al. **Tierarztl Prax** 1995 Dec;23(6):614-8 (Eng. Abstr.) (Ger)
[Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature] Mayr B, et al. **Tierarztl Prax** 1995 Dec;23(6):542-52 (39 ref.) (Eng. Abstr.) (Ger)

POXVIRUS AVIUM see **AVIPOXVIRUS**

POXVIRUS INFECTIONS see **POXVIRIDAE INFECTIONS**

POXVIRUS MURIS see **ECTROMELIA VIRUS**

POXVIRUS MYXOMATIS see **MYXOMA VIRUS**

POXVIRUS OFFICINALE see **VACCINIA VIRUS**

POXVIRUS VARIOLAE see **VARIOLA VIRUS**

PP39(C-MOS) see **PROTO-ONCOGENE PROTEINS C-MOS**

PP60(C-SRC) see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

PP60(V-SRC) see **ONCOGENE PROTEIN PP60(V-SRC)**

PPLO see **MYCOPLASMA**

PRACTICE (PSYCHOLOGY)

Homework compliance, perceptions of control, and outcome of cognitive-behavioral treatment of social phobia. Leung AW, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):423-32
Mental rotation at 7 years: relations with prenatal testosterone levels and spatial play experiences. Grimshaw GM, et al. **Brain Cogn** 1995 Oct;29(1):85-100
Effect of type of practice in a computer-aided design environment in visualizing three-dimensional objects from two-dimensional orthographic projections] Duesbury RT, et al. **J Appl Psychol** 1996 Jun;81(3):249-60
Range of planning in music performance. Palmer C, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct;21(5):947-62
The experiential facilitation of memory development in the home environment. Pierce SH, et al. **J Genet Psychol** 1996 Sep;157(3):331-47
Self-handicapping and intrinsic motivation: buffering intrinsic motivation from the threat of failure. Deppe RK, et al. **J Pers Soc Psychol** 1996 Apr;70(4):868-76
Effects of practice with and without knowledge of results on jitter and shimmer levels in normally speaking women. Ferrand CT. **J Voice** 1995 Dec;9(4):419-23
Single and multiple test repetition priming in implicit memory. Brown AS, et al. **Memory** 1996 Mar;4(2):159-73
Effects of practice on tip-of-the-tongue states. Smith SM, et al. **Memory** 1994 Mar;2(1):31-49
Role of preoperative and postoperative sensorimotor training on restoration of the equilibrium behavior in adult mice following cerebellectomy. Caston J, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):195-202
Effects of age and level of work experience on occurrence of accidents. Cellier JM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):931-40
Characteristics of motor performance, learning, warm-up decrement, and reminiscence during a balancing task. Etnyre BR, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):1027-30
Development of content: influences on girls' junior high school volleyball success in practice and achievement. Pellett TL, et al. **Percept Mot Skills** 1996 Feb;82(1):219-24
Imagery and physical practice in the acquisition of gross motor timing of coincidence by adolescents with mild

mental retardation. Porretta DL, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1171–83

The effects of neurodevelopmental treatment versus practice on the reaching of children with spastic cerebral palsy. Fetters L, et al. **Phys Ther** 1996 Apr;76(4):346–58

On the mechanisms of plasticity in young and older adults after instruction in the method of loci: evidence for an amplification model. Verhaeghen P, et al. **Psychol Aging** 1996 Mar;11(1):164–78

The effect of enactment on memory for order. Olofsson U. **Psychol Res** 1996;59(1):75–9

Consequences of a motor programming deficit for rehearsal and written sentence comprehension. Martin RC, et al. **Q J Exp Psychol A** 1995 Aug;48(3):536–72

Practice schedule effects on the performance and learning of low- and high-skilled students: an applied study. Hebert EP, et al. **Res Q Exerc Sport** 1996 Mar;67(1):52–8

The contextual interference effect in parameter modifications of the same generalized motor program. Sekiya H, et al. **Res Q Exerc Sport** 1996 Mar;67(1):59–68

PRACTICE GUIDELINES

Implications of practice parameters (guidelines). Spector SL. **Allergy Proc** 1995 Nov–Dec;16(6):303–4

AAP tuberculin testing recommendations [news] **Am Fam Physician** 1996 May 15;53(7):2378

American Psychiatric Association releases guideline on the psychiatric evaluation of adults. **Am Fam Physician** 1996 May 1;53(6):2195–6

ACC/AHA collaborate on guidelines for the evaluation and management of heart failure. **Am Fam Physician** 1996 May 1;53(6):2196–8

The family physician's role in adolescent idiopathic scoliosis [editorial; comment] DiGuiseppi CG, et al. **Am Fam Physician** 1996 May 15;53(7):2268–72. Comment on: Am Fam Physician 1996 May 15;53(7):2327–34.

Cost of vaginal delivery vs. repeated cesarean section [letter] Gillette RD. **Am Fam Physician** 1996 May 15;53(7):2284, 2287

Preterm labor: ACOG guidelines for care [editorial; comment] Lefevre ML. **Am Fam Physician** 1995 Nov 15; 52(7):2000–2, 2006. Comment on: Am Fam Physician 1995 Nov 15;52(7):2105–6.

New guidelines on treating hypertension in diabetics [editorial] Siwek J. **Am Fam Physician** 1996 May 1; 53(6):1982, 1984

Questions remain about shocking asystole [letter] Stewart JA. **Am J Emerg Med** 1996 May;14(3):337–8

Standards set for COPD management [news] **Am J Health Syst Pharm** 1996 Feb 15;53(4):361

Effect of prescribing guidelines on the use of neuromuscular blocking agents. Gora-Harper ML, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1900–4

Disease management program for asthma: baseline assessment of resource use. MacKinnon NJ, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):535–41

Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Garner JS. **Am J Infect Control** 1996 Feb;24(1):24–31

A study of patient satisfaction and adherence to preventive care practice guidelines [see comments] Weingarten SR, et al. **Am J Med** 1995 Dec;99(6):590–6. Comment in: Am J Med 1995 Dec;99(6):588–9.

Dissemination of genetic risk information to relatives in the fragile X syndrome: guidelines for genetic counselors. McConkie-Rosell A, et al. **Am J Med Genet** 1995 Dec 4;59(4):426–30

Uniform billing data in hospital planning, marketing and clinical guidelines. Gideon DM, et al. **Am J Med Qual** 1996 Spring;11(1):S63–5

Clinical practice guidelines for post-stroke rehabilitation and occupational therapy practice. Trombly C. **Am J Occup Ther** 1995 Jul–Aug;49(7):711–4

Prenatal hospitalization and compliance with guidelines for prenatal care. Haas JS, et al. **Am J Public Health** 1996 Jun;86(6):815–9

Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster? Fein AM, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1149–53

Evaluation of a pneumonia practice guideline in an interventional trial. Weingarten SR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1110–5

Establishing practice guidelines for surgical blood management. Goodnough LT, et al. **Am J Surg** 1995 Dec; 170(6A Suppl):16S–20S

Tracheal extubation of children in the operating room after atrial septal defect repair as part of a clinical practice guideline. Laussen PC, et al. **Anesth Analg** 1996 May; 82(5):988–93

Practice guidelines and treatment of patients with von Willebrand's disease [letter] Slaughter TF, et al. **Anesthesiology** 1996 Aug;85(2):441–2

A strategy to promote the rational use of laboratory tests. Guideline. Pannall P, et al. **Ann Biol Clin (Paris)** 1995; 53(9):515–7

Proceedings of the Second Chicago Symposium on Advances in CPR Research and guidelines for laboratory research: foreword. Becker BL, et al. **Ann Emerg Med** 1996 May; 27(5):539–41

Proceedings from the first international symposium on pain research in emergency medicine: Foreword. Ducharme J. **Ann Emerg Med** 1996 Apr;27(4):399–403

Emergency medicine clinical guidelines: we can make them, but will we use them? [editorial; comment] Schriger DL. **Ann Emerg Med** 1996 May;27(5):655–7. Comment on: Ann Emerg Med 1996 May;27(5):606–9.

Delayed in-hospital defibrillation [letter] Stewart JA. **Ann Emerg Med** 1996 Jan;27(1):104–5

Establishing pain policies in emergency medicine. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):408–11 (31 ref.)

ACEP chest pain policy: emergency physician awareness [see comments] Wigder HN, et al. **Ann Emerg Med** 1996 May; 27(5):606–9. Comment in: Ann Emerg Med 1996 May;27(5):655–7.

Physician compliance with guidelines [letter; comment] Jung BC. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):77–8. Comment on: Ann Intern Med 1995 Feb 15;122(4):277–82.

Treatment of infective endocarditis [editorial] Kaye D. **Ann Intern Med** 1996 Mar 15;124(6):606–8

Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Pestotnik SL, et al. **Ann Intern Med** 1996 May 15;124(10):884–90

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Hassan W. **Ann Rheum Dis** 1996 May; 55(5):273–5

Practice guidelines for the early referral of patients to cancer specialists [editorial] Gardner B. **Ann Surg Oncol** 1996 Mar; 3(2):109

Developing evidence-based clinical practice guidelines: lessons learned by the US Preventive Services Task Force. Woolf SH, et al. **Annu Rev Public Health** 1996;17:511–38 (104 ref.)

Practice guidelines for the prediction and prevention of pressure ulcers: evaluating the evidence. Harrison MB, et al. **Appl Nurs Res** 1996 Feb;9(1):9–17

Paediatricians' knowledge of cardiac arrest guidelines. Buss PW, et al. **Arch Dis Child** 1996 Jan;74(1):47–9

Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. McLaughlin TJ, et al. **Arch Intern Med** 1996 Apr 8;156(7):799–805

Computer reminders to implement preventive care guidelines for hospitalized patients. Overhage JM, et al. **Arch Intern Med** 1996 Jul 22;156(14):1551–6

The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Raschke RA, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1645–9

Trends in diagnostic testing following a national guideline for evaluation of dyspepsia. Schwartz LM, et al. **Arch Intern Med** 1996 Apr 22;156(8):873–5

Evidence-based medicine, critical pathways, practice guidelines, and managed care. Reflections on the prevention and care of stroke [see comments] Ringel SP, et al. **Arch Neurol** 1996 Sep;53(9):867–71. Comment in: Arch Neurol 1996 Sep;53(9):848.

Some guidelines about practice guidelines [editorial; comment] Ruddy S. **Arthritis Rheum** 1995 Nov; 38(11):1533–4. Comment on: Arthritis Rheum 1995 Nov;38(11):1535–40. Comment on: Arthritis Rheum 1995 Nov;38(11):1541–6.

Health outcomes, health promotion and improved public health in Australia [editorial] Nutbeam D. **Aust J Public Health** 1995 Aug;19(4):326–8

Review of new guidelines for management of dyslipidaemia. Betteridge DJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):867–90 (64 ref.)

The ITP practice guideline: what, why, and for whom? [editorial; comment] Lichtin A. **Blood** 1996 Jul 1;88(1):1–2 . Comment on: Blood 1996 Jul 1;88(1):3–40—.

GMSC's advice on intrapartum care is unhelpful [letter] Bradbrook J, et al. **BMJ** 1996 Apr 6;312(7035):910–1

Confusion over use of placebos in clinical trials [editorial; comment] Collier J. **BMJ** 1995 Sep 30;311(7009):821–2. Comment on: BMJ 1995 Sep 30;311(7009):844–6.

North of England evidence based guidelines development project: methods of guideline development. Eccles M, et al. **BMJ** 1996 Mar 23;312(7033):760–2

What constitutes controlled hypertension? Patient based comparison of hypertension guidelines [see comments] Fahey TP, et al. **BMJ** 1996 Jul 13;313(7049):93–6. Comment in: BMJ 1996 Jul 13;313(7049):64–5.

Clinical guidelines in the independent health care sector [editorial] Fairfield G, et al. **BMJ** 1996 Jun 22; 312(7046):1554–5

Do clinical guidelines introduced with practice based education improve care of asthmatic and diabetic patients? A randomised controlled trial in general practices in east London. Feder G, et al. **BMJ** 1995 Dec 2;311(7018):1473–8

Clinical guidelines may obviate need for thought [letter; comment] Heaney D. **BMJ** 1996 Mar 16;312(7032):706. Comment on: BMJ 1995 Dec 9;311(7019):1517–8.

Clinical guidelines and the law [editorial] [see comments] Hurwitz B. **BMJ** 1995 Dec 9;311(7019):1517–8. Comment in: BMJ 1996 Mar 16;312(7032):706.

Guidelines for managing raised blood pressure [editorial; comment] Jackson RT, et al. **BMJ** 1996 Jul 13; 313(7049):64–5. Comment on: BMJ 1996 Jul 13;313(7049):93–6.

General practitioners' management of acute back pain: a survey of reported practice compared with clinical guidelines [see comments] Little P, et al. **BMJ** 1996 Feb 24;312(7029):485–8. Comment in: BMJ 1996 Jun 8;312(7044):1480. Comment in: BMJ 1996 Jun 8;312(7044):1481.

Ensuring that guidelines are effective. Pilot of patient held guidelines is under way [letter; comment] Rao JN, et al. **BMJ** 1995 Oct 14;311(7011):1023. Comment on: BMJ 1995 Jul 22;311(6999):237–42.

Dutch doctors tighten euthanasia guidelines [news] Sheldon T. **BMJ** 1995 Sep 16;311(7007):708

Israel issues guidelines on prolonging life [news] Siegel-Itzkovich J. **BMJ** 1996 Mar 23;312(7033):727

Review of prescribed treatment for children with asthma in 1990 [see comments] Warner JO. **BMJ** 1995 Sep 9; 311(7006):663–6. Comment in: BMJ 1995 Dec 16;311(7020):1644–5; discussion 1645. Comment in: BMJ 1995 Dec 16;311(7020):1645.

Ensuring that guidelines are effective. Give them to the patient [letter; comment] Williamson C. **BMJ** 1995 Oct 14; 311(7011):1023. Comment on: BMJ 1995 Jul 22;311(6999):237–42.

Clinical guidelines in primary care: a survey of general practitioners' attitudes and behaviour. Siriwardena AN. **Br J Gen Pract** 1995 Dec;45(401):643–7

Clinical practice guidelines—do they enhance value for money in health care? Grimshaw JM, et al. **Br Med Bull** 1995 Oct;51(4):927–40 (33 ref.)

Clinical practice guidelines. New-to-practice family physicians' attitudes. Ferrier BM, et al. **Can Fam Physician** 1996 Mar;42:463–8

Whose guidelines are they, anyway? Mammography utilization in Ontario. Goel V. **Can J Public Health** 1996 May–Jun;87(3):181–2

DNR orders in stroke [letter] Alexandrov AV, et al. **Can Med Assoc J** 1996 Aug 1;155(3):276–7

Setting priorities and selecting topics for clinical practice guidelines. Battista RN, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1233–7

Selling guidelines door to door [letter; comment] Brock GI, et al. **Can Med Assoc J** 1996 Mar 15;154(6):755–6. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1073–7.

Proceedings of the 1994 Canadian Clinical Practice Guidelines Network Workshop. Carter AO, et al. **Can Med Assoc J** 1995 Dec 15;153(12):1715–9

Report on activities and attitudes of organizations active in the clinical practice guidelines field. Carter AO, et al. **Can Med Assoc J** 1995 Oct 1;153(7):901–7

Regulated analgesics and pain control [letter; comment] Clark AJ, et al. **Can Med Assoc J** 1996 May 15;154(10):1472, 1474; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Regulated analgesics and pain control [letter; comment] Jovey RD. **Can Med Assoc J** 1996 May 15;154(10):1476; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Clinical practice guidelines and the law. Kluge EH. **Can Med Assoc J** 1996 Sep 1;155(5):574–6

Qualitative evaluation of the Canadian Medical Association's counselling guidelines for HIV serologic testing. Rowan MS, et al. **Can Med Assoc J** 1996 Mar 1;154(5):665–71

After 4 years' work, revised Code of Ethics goes to General Council for decision. Sawyer DM, et al. **Can Med Assoc J** 1996 Aug 1;155(3):314–5

Consensus finally achieved on resuscitative interventions. Williams JR. **Can Med Assoc J** 1995 Dec 1;153(11):1641–2

Commentary on the new Guide to Clinical Preventive Services [see comments] Henry CA, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):141–6. Comment in: Cleve Clin J Med 1996 May–Jun;63(3):136.

Impact of guidelines for antihypertensive treatment on clinical practice. Chalmers J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):415–23 (15 ref.)

Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S138–41 (0 ref.)

Implementation of guidelines for radiographic projections [letter] Butt WP. **Clin Radiol** 1995 Sep;50(9):662

Guidance on control of tuberculosis. **Commun Dis Rep CDR Wkly** 1996 Jul 12;6(28):239, 242

Economic issues in the development and use of practice guidelines: an application to resource allocation in dentistry. Birch S, et al. **Community Dent Health** 1996 Jun; 13(2):70–5

Deep medical knowledge to design clinical guidelines. Barahona P, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct;48(1–2):27–34

A call for specific codes for diabetes foot and eye care. Mayfield JA, et al. **Diabetes Care** 1995 Mar;18(3):418–21

Clinical management of the NIDDM patient. Impact of the American Diabetes Association practice guidelines, 1985–1993. Endocrine Fellows Foundation Study Group. Stolar MW. **Diabetes Care** 1995 May;18(5):701–7

Good laboratory practice. Ojwang PJ. **East Afr Med J** 1996 May;73(5 Suppl):S2–4

Variations in the screening history and appropriateness of management of cervical cancer in South East England. Wolfe CD, et al. **Eur J Cancer** 1996 Jun;32A(7):1198–204

Guidelines for surgeons in the management of symptomatic breast disease in the United Kingdom [letter; comment]

Catterall A. **Eur J Surg Oncol** 1996 Apr;22(2):202. Comment on: Eur J Surg Oncol 1995 Oct;21 Suppl A:1–13.

Growing consensus in COPD? [editorial; comment] Vermeire P. **Eur Respir J** 1995 Aug;8(8):1250–1. Comment on: Eur Respir J 1995 Aug;8(8):1398–420.

Local clinical guidelines: description and evaluation of a participative method for their development and implementation. Onion CW, et al. **Fam Pract** 1996 Feb; 13(1):28–34

Implementation of guidelines on stroke prevention. Steffensen FH, et al. **Fam Pract** 1995 Sep;12(3):269–73

The ASGE guidelines for the appropriate use of upper gastrointestinal endoscopy in an open access system [see comments] Minoli G, et al. **Gastrointest Endosc** 1995 Nov; 42(5):387–9. Comment in: Gastrointest Endosc 1995 Nov;42(5):490–1.

Outcomes research and practice guidelines. Upstream issues for downstream users. Gifford F. **Hastings Cent Rep** 1996 Mar–Apr;26(2):38–44

Developing a local protocol for the management of lipid disorders in general practice. Foster KN, et al. **Health Bull (Edinb)** 1996 May;54(3):270–5

The Scottish Intercollegiate Guidelines Network Initiative: getting validated guidelines into local practice. Petrie JC, et al. **Health Bull (Edinb)** 1995 Nov;53(6):345–8

Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Coulter I, et al. **Health Serv Res** 1995 Oct;30(4):577–91 (34 ref.)

Richard Doyle [interview by Mark Hagland] Doyle R. **Hosp Health Netw** 1995 Dec 5;69(23):46–7

Fetoscopy, fetal–tissue sampling and the ESHRE guidelines on prenatal diagnosis [letter] Simpson JL, et al. **Hum Reprod** 1996 Mar;11(3):682

Perioperative use of total parenteral nutrition. Variations in guidelines and practice in three Norwegian hospitals. Mjaaland M, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):741–9

A survey of teaching and the use of clinical guidelines in accident and emergency departments. Hormbrey P, et al. **J Accid Emerg Med** 1996 Mar;13(2):129–33

President's page: quantity and quality--Is 75 the answer? [news] Kennedy JW. **J Am Coll Cardiol** 1996 Jan; 27(1):236–7

Application of American College of Surgeons' field triage guidelines by pre-hospital personnel. Norcross ED, et al. **J Am Coll Surg** 1995 Dec;181(6):539–44

Assessing the FDA guidelines for ordering dental radiographs [see comments] Atchison KA, et al. **J Am Dent Assoc** 1995 Oct;126(10):1372–83. Comment in: J Am Dent Assoc 1996 Jan;127(1):16.

The legal implications of clinical practice guidelines. Keyes GG. **J Am Dent Assoc** 1996 Jun;127(6):795–800

Practice parameters in dentistry: where do we stand? Shugars DA, et al. **J Am Dent Assoc** 1995 Aug;126(8):1134–43 (36 ref.)

Radiographic guidelines [letter; comment] Weisman MI. **J Am Dent Assoc** 1996 Apr;127(4):426, 428. Comment on: J Am Dent Assoc 1996 Jan;127(1):16.

Clinical practice guidelines and position statements: the American Geriatrics Society Approach [editorial; comment] Katz PR, et al. **J Am Geriatr Soc** 1996 Sep; 44(9):1123–4. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1108–11. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1112–3. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1114–7. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1118–9.

When the bill comes due for the autonomy of demented older adults, who pays? [editorial; comment] Rhymes JA, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1437–8. Comment on: J Am Geriatr Soc 1995 Dec;43(12):1423–9.

Clinical practice guidelines: their purposes and uses [see comments] Taler G. **J Am Geriatr Soc** 1996 Sep; 44(9):1108–11 (25 ref.). Comment in: J Am Geriatr Soc 1996 Sep;44(9):1123–4.

Trade-offs in producing patient-specific recommendations from a computer-based clinical guideline: a case study. Miller PL, et al. **J Am Med Inform Assoc** 1995 Jul–Aug; 2(4):238–42

Computerizing guidelines to improve care and patient outcomes: the example of heart failure. Tierney WM, et al. **J Am Med Inform Assoc** 1995 Sep–Oct;2(5):316–22

Hospital guidelines for diagnosis-related groups/osteopathic manipulative treatment [see comments] Feely RA. **J Am Osteopath Assoc** 1995 Sep;95(9):528–32. Comment in: J Am Osteopath Assoc 1995 Sep;95(9):522, 524.

Agency for health care policy and research: Clinical practice guidelines for heart failure. Dunbar SB, et al. **J Cardiovasc Nurs** 1996 Jan;10(2):85–8

Hope or experience? Clinical practice guidelines in family practice [editorial] Worrall G, et al. **J Fam Pract** 1996 Apr; 42(4):353–6 (33 ref.)

Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system [see comments] Aucott JN, et al. **J Gen Intern Med** 1996 Mar;11(3):139–46. Comment in: J Gen Intern Med 1996 Mar;11(3):185–6.

Guidelines: the next generation [letter] Casanova JE. **J Gen Intern Med** 1996 Mar;11(3):190

Reconnoitering critical pathways and guidelines [editorial; comment] Mulrow CD. **J Gen Intern Med** 1996 Mar; 11(3):185–6. Comment on: J Gen Intern Med 1996 Mar;11(3):139–46. Comment on: J Gen Intern Med 1996 Mar;11(3):174–5. Comment on: J Gen Intern Med 1996 Mar;11(3):176–8.

Teaching an old dog new tricks [editorial; comment] Schwartz JS, et al. **J Gen Intern Med** 1995 Jun;10(6):353–4 . Comment on: J Gen Intern Med 1995 Jun;10(6):342–5.

Medical practice guidelines in malpractice litigation: an early retrospective. Hyams AL, et al. **J Health Polit Policy Law** 1996 Summer;21(2):289–313

Guidelines for the establishment and operation of human milk banks in the UK [letter] Balmer SE, et al. **J Hosp Infect** 1995 Oct;31(2):155–6

Clinical guidelines: implementing them won't be easy [news] McNeil C. **J Natl Cancer Inst** 1996 Apr 17;88(8):488–90

Development of guidelines for the management of severe head injury. Narayan RK. **J Neurotrauma** 1995 Oct; 12(5):907–12

Reducing variation in patient care. Nursing responds to capitation. Lowe A. **J Nurs Adm** 1996 Jan;26(1):14–20

Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Alderslade R. **J Public Health Med** 1995 Sep; 17(3):335–42 (7 ref.)

RANZCP guidelines for psychotropic drugs: application to hospital inpatients. Royal Australian and New Zealand College of Psychiatrists. Parke J. **J Qual Clin Pract** 1996 Mar;16(1):19–30

Clinical practice guidelines [editorial] Wright M. **J Qual Clin Pract** 1996 Mar;16(1):3–4

Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee [see comments] **JAMA** 1995 Dec 20; 274(23):1874–80 (67 ref.). Comment in: JAMA 1995 Dec 20;274(23):1881–2.

Evidence-based medicine meets cost–effectiveness analysis [editorial; comment] Clancy CM, et al. **JAMA** 1996 Jul 24–31;276(4):329–30. Comment on: JAMA 1996 Jul 24–31;276(4):285–92.

When will adequate pain treatment be the norm? [editorial; comment] [see comments] Hill CS Jr. **JAMA** 1995 Dec 20;274(23):1881–2. Comment on: JAMA 1995 Dec 20;274(23):1870–3. Comment on: JAMA 1995 Dec 20;274(23):1874–80. Comment in: JAMA 1996 May 1;275(17):1310; discussion 1311. Comment in: JAMA 1996 May 1;275(17):1310–1. Comment in: JAMA 1996 May 1;275(17):1311.

The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870–3 (40 ref.). Comment in: JAMA 1995 Dec 20;274(23):1881–2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835–6.

Clinical practice guidelines for smoking cessation [letter; comment] Perry RF. **JAMA** 1996 Aug 14;276(6):448. Comment on: JAMA 1996 Apr 24;275(16):1270–80.

New prevention guidelines called 'state of the art' [news] Voelker R. **JAMA** 1996 Feb 21;275(7):505

The shape of resistance ... the shapers of change. Greer AL. **Jt Comm J Qual Improv** 1995 Jul;21(7):328–32

Phase II of the AHCPR-sponsored heart failure guideline: translating practice recommendations into review criteria. Hadorn DC, et al. **Jt Comm J Qual Improv** 1996 Apr; 22(4):265–76

Organizational strategies for implementing clinical guidelines [see comments] Kaluzny AD, et al. **Jt Comm J Qual Improv** 1995 Jul;21(7):347–51. Comment in: Jt Comm J Qual Improv 1995 Jul;21(7):336–9.

Developing and implementing health care guidelines for group medical practices: an interview with Gordon Mosser [interview by Stephen L. Davidow] Mosser G. **Jt Comm J Qual Improv** 1996 Apr;22(4):293–9

The focused review process: a utilization management firm's experience with length of stay guidelines. Nelson MF, et al. **Jt Comm J Qual Improv** 1995 Sep;21(9):477–87

Collaborating outside the box: when employers and providers take on environmental barriers to guideline implementation. Reinertsen JL. **Jt Comm J Qual Improv** 1995 Nov; 21(11):612–8

Lessons for guidelines from the diffusion of innovations. Rogers EM. **Jt Comm J Qual Improv** 1995 Jul;21(7):324–8

The New York State Task Force on Clinical Guidelines and Medical Technology Assessment. Servis KW, et al. **Jt Comm J Qual Improv** 1996 Feb;22(2):134–40

Practice guidelines: at the interface of medicine and law [letter; comment] Uzych L. **Jt Comm J Qual Improv** 1996 Feb;22(2):83–4. Comment on: Jt Comm J Qual Improv 1995 Sep;21(9):465–76.

New breast-screening guidelines for Sweden [news] Awuonda M. **Lancet** 1996 Apr 6;347(9006):963

Formulation of guidelines for treatment [letter] Bishop MC. **Lancet** 1996 Feb 3;347(8997):331

European guidelines on resuscitation [letter] Dick W, et al. **Lancet** 1996 Jun 1;347(9014):1558

Impact of clinical practice guidelines [letter] Froehlich P, et al. **Lancet** 1995 Oct 14;346(8981):1039–40

Have expert panel guidelines kept pace with new concepts in hypertension? [see comments] Levy D. **Lancet** 1995 Oct 28;346(8983):1112–3. Comment in: Lancet 1995 Dec 16;346(8990):1631.

Dangers of European resuscitation guidelines [letter] O'Kane D, et al. **Lancet** 1996 Feb 10;347(8998):400–1

Legal implications of clinical practice guidelines in emergency medicine. Rosoff AJ. **Leg Med** 1995;:1–15

AHCPR releases new clinical practice guidelines [news] **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):50–2

Are differences in practitioners' acceptance of a quality assurance intervention related to their performance? Hargraves JL, et al. **Med Care** 1996 Sep;34(9 Suppl):SS77–86

Consistency in performance among primary care practitioners. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS52–66

What makes quality assurance effective? Results from a randomized, controlled trial in 16 primary care group practices. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS29–39

The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Pathman DE, et al. **Med Care** 1996 Sep; 34(9):873–89

The move towards evidence-based medicine [letter; comment] Compton J, et al. **Med J Aust** 1995 Sep 18; 163(6):333. Comment on: Med J Aust 1995 Jul 17;163(2):60–1.

Thyroid function testing and clinical practice guidelines [editorial; comment] Lazarus L. **Med J Aust** 1996 Mar 18; 164(6):324–5. Comment on: Med J Aust 1996 Mar 18;164(6):329–32.

Clinical practice guidelines [letter; comment] O'Brien PE. **Med J Aust** 1996 Jan 1;164(1):54. Comment on: Med J Aust 1995 Aug 7;163(3):144–5.

General practice reforms: in search of the lowest common denominator [editorial] Saltman DC. **Med J Aust** 1996 Feb 19;164(4):196–7

Multipurpose practice guideline modules for clinical decision analysis and quality improvement. Balas EA, et al. **Medinfo** 1995;8 Pt 2:1001–4

Necessity of extensive comprehensive databases for the improvement and test of diagnostic guidelines. Densow D, et al. **Medinfo** 1995;8 Pt 2:1055–8

Presentation of clinical guidelines via a rule-based expert charting system. Schriger DL, et al. **Medinfo** 1995;8 Pt 2:1018–21

Failure of implementation of the National Heart Foundation of New Zealand guidelines for the management of dyslipidaemia. Patel H, et al. **N Z Med J** 1996 Feb 9; 109(1015):24–6

Implementing tuberculosis control guidelines in a hospital environment. Walls C. **N Z Med J** 1996 Jan 26; 109(1014):12–3

Cancer genetics group drafts guidelines [news] Wadman M. **Nature** 1996 Jun 13;381(6583):543

Clinical practice guidelines as a new source of middle-range theory: focus on acute pain. Good M, et al. **Nurs Outlook** 1996 Mar–Apr;44(2):74–9

Developing pain management education using guidelines. Carter LW, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1435

Standard of care for pain management interventions. Coyne PJ. **Oncol Nurs Forum** 1995 Oct;22(9):1437–8

Guidelines supplement comprehensive staff education program. Derby S, et al. **Oncol Nurs Forum** 1995 Oct; 22(9):1438

Putting guidelines to work in an ambulatory care setting. Dolan CS. **Oncol Nurs Forum** 1995 Oct;22(9):1436

Using guidelines for education, policy making, and assessing quality of care. Hagan S. **Oncol Nurs Forum** 1995 Oct; 22(9):1435–6

Implementing guidelines on acute pain management. Person L. **Oncol Nurs Forum** 1995 Oct;22(9):1436–7

Why oncologists should get involved in practice guideline development. ASCO Health Services Committee Program. **Oncology (Huntingt)** 1995 May;9(5):412, 415 (0 ref.)

The role of oncology clinical practice guidelines in the managed care era. Winn RJ. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):177–83 (28 ref.)

White paper on cataract surgery. American Academy of Ophthalmology and American Society of Cataract and Refractive Surgery. **Ophthalmology** 1996 Jul;103(7):1152–6

Management guidelines for improvement of otolaryngology referrals from primary care physicians. Benninger MS, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):446–52

Structured guidelines for the use of influenza vaccine among children with chronic pulmonary disorders. Hayden GF, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):895–9

The man who has two watches: dealing with discrepancies in clinical guidelines. Nazarian LF. **Pediatr Rev** 1995 Sep; 16(9):323–4

Quality improvement: an ACQIP exercise on the management of otitis media. Sebring RH. **Pediatr Rev** 1996 Jul;17(7):251–6

Practice and guidelines [letter; comment] Benjamin JT. **Pediatrics** 1996 Apr;97(4):604–5. Comment on: Pediatrics 1995 May;95(5):623–7.

The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic--a comment. Holt RJ, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):480–1; discussion 482–3

The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic. Matsuyama JR, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):608–13

Narrowing the gray zone. How clinical practice guidelines can improve the decision-making process [editorial] Larsen RR. **Postgrad Med** 1996 Aug;100(2):17–8, 23–4

PRACTICE GUIDELINES

Healthcare guidelines as engines for improvement [editorial] Mosser G, et al. **Postgrad Med** 1996 Sep;100(3):15–8

Clinical guidelines and their implementation. Forrest D, et al. **Postgrad Med J** 1996 Jan;72(843):19–22 (13 ref.)

Are blood tests of value in the primary assessment and resuscitation of patients in the A&E department? [letter] Tormey WP. **Postgrad Med J** 1995 Sep;71(839):575

Do accident and emergency senior house officers know the British guidelines on the management of acute asthma? Ulahannan T, et al. **Postgrad Med J** 1996 Mar;72(845):162–3

An architecture for a distributed guideline server. Barnes M, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :233–7

The impact of a guideline-driven computer charting system on the emergency care of patients with acute low back pain. Day F, et al.
Proc Annu Symp Comput Appl Med Care 1995;:576–80

Representation of clinical practice guidelines through an interactive World-Wide-Web interface. Liem EB, et al.
Proc Annu Symp Comput Appl Med Care 1995;:223–7

A model for adapting clinical guidelines for electronic implementation in primary care. Lobach DF.
Proc Annu Symp Comput Appl Med Care 1995;:581–5

Computerized practice guidelines for heart failure management: the HeartMan system. Margolis A, et al.
Proc Annu Symp Comput Appl Med Care 1995;:228–32

A computer-generated reminder system improves physician compliance with diabetes preventive care guidelines. Nilasena DS, et al.
Proc Annu Symp Comput Appl Med Care 1995;:640–5

Clinical guidelines. Now or never [editorial] Gruman J, et al. **Psychosomatics** 1995 Nov–Dec;36(6):519–21

C–L psychiatry residency training guidelines. Another milestone [editorial] Hayes JR. **Psychosomatics** 1996 Jan–Feb;37(1):1–2

Clinical practice guidelines now on CD–ROM for libraries [new] **Public Health Rep** 1995 Nov–Dec;110(6):655–6

Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Barnes PJ. **Respir Med** 1996 Aug;90(7):379–84 (44 ref.)

Guidelines in asthma [editorial] Harrison BD. **Respir Med** 1996 Aug;90(7):375–8

Inhaled sodium cromoglycate. Holgate ST. **Respir Med** 1996 Aug;90(7):387–90 (45 ref.)

The efficacy and therapeutic position of nedocromil sodium. Holgate ST. **Respir Med** 1996 Aug;90(7):391–4 (32 ref.)

Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385–6 (15 ref.)

Hypertension management guidelines [letter] Borok G. **S Afr Med J** 1996 Apr;86(4):375–6; discussion 376, 378

Hypertension management guidelines [letter] Couper ID. **S Afr Med J** 1996 Apr;86(4):374; discussion 376, 378

Hypertension 1996—simplified guidelines for primary care nurses and medical students. Opie LH. **S Afr Med J** 1996 Apr;86(4):357–8

Hypertension management guidelines [letter] van Bogaert LJ. **S Afr Med J** 1996 Apr;86(4):374–5; discussion 376, 378

Do general practitioners need guidelines? [editorial] Mäkelä M. **Scand J Prim Health Care** 1996 Mar;14(1):2–3

Any need for guidelines in the management of chronic obstructive pulmonary disease (COPD)? Leuenberger P. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2163

Do-not-resuscitate orders: towards a policy in Singapore [see comments] Sahadevan S, et al. **Singapore Med J** 1995 Jun; 36(3):267–70 (28 ref.). Comment in: Singapore Med J 1995 Jun;36(3):258–9.

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281–301 (49 ref.)

Practice guidelines in surgery. Wright JG, et al. **Surgery** 1996 Jun;119(6):706–9 (29 ref.)

The use of medical audit for producing guidelines of medical practice. McGeorge A. **Swiss Surg** 1995;(1):29–34

[The standard 'Allergic and Hyperreactive rhinitis' of the Dutch Society of Family Physicians; reaction from the viewpoint of family practice] Knottnerus JA.
Ned Tijdschr Geneeskd 1995 Sep 2;139(35):1774–6 **(Dut)**

[The standard 'Allergic and hyperreactive rhinitis' of the Dutch Society of Family Physicians; reaction from the allergological viewpoint] Pelikan Z.
Ned Tijdschr Geneeskd 1995 Sep 2;139(35):1776–7 **(Dut)**

[Recommendations for clinical practice. Methodological bases and use] Durieux P, et al.
Ann Med Interne (Paris) 1995;146(6):438–46 (50 ref.) **(Fre)**

[Example of common pathology: antibiotic prescription in current pediatric practice] Beley G. **Arch Pediatr** 1996;3 Suppl 1:272s–274s **(Fre)**

[Indications for explorations in gastroesophageal reflux] Dupont C, et al. **Arch Pediatr** 1996;3 Suppl 1:268s–271s **(Fre)**

[Comments of the National union of private hospitalization in oncology on the project "Standards, options and recommendations"] **Bull Cancer (Paris)** 1995 Oct; 82(10):885–8 **(Fre)**

[Impact of recommendations for "good practice" on the quality of care] Anhoury P. **Bull Cancer (Paris)** 1995 Oct; 82(10):879–84 **(Fre)**

[Standards, options and recommendations for the practice of external radiotherapy and brachytherapy in oncology. National Federation of Centers for the fight against Cancer] Bey P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):811–22 (81 ref.) **(Fre)**

[Standards, options and recommendations for the multidisciplinary organization of oncology] Chardot C, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):780–94 **(Fre)**

[Good practice and what then?] Demard F, et al.
Bull Cancer (Paris) 1995 Oct;82(10):889–90 **(Fre)**

[How to develop clinical practice guidelines?] Dosquet P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):754–60 **(Fre)**

[Considerations on the organization of oncologic-genetic consultations (a first step towards the publication of clinical practice guidelines)] Eisinger F, et al.
Bull Cancer (Paris) 1995 Oct;82(10):865–78 **(Fre)**

[Methodology of the development of diagnostic and therapeutic standards, options and recommendations in oncology] Fervers B, et al. **Bull Cancer (Paris)** 1995 Oct; 82(10):761–7 **(Fre)**

[Hypertension. A new way to approach an old problem] Aubin M. **Can Fam Physician** 1996 Apr;42:702–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Advantages and disadvantages of consensus conferences (letter)] Monsonego J. **Contracept Fertil Sex** 1996 Apr; 24(4):261 **(Fre)**

[Recommendations for clinical practice or consensus conferences?] Matillon Y, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24 Suppl 1:1–3 **(Fre)**

[Methods for formulating recommendations for clinical practice] Dosquet P, et al. **J Radiol** 1995 Nov;76(11):1004–6 **(Fre)**

[A brief plea against the use of guidelines in medicine] Savoy J. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2168–70 (Eng. Abstr.) **(Fre)**

[Development of guidelines in medicine—art or knowledge?] Selbmann HK. **Chirurg** 1996 Mar;67(3):suppl 61–5 **(Ger)**

[Guidelines for the diagnosis and treatment of chronic obstructive lung disease—effective and necessary] Brändli O. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2164–7 (Eng. Abstr.) **(Ger)**

[Standards, guidelines and principles for clinical trials: medical products] Ziegler WJ, et al. **Swiss Surg** 1995; (1):81–3 (Eng. Abstr.) **(Ger)**

[Guidelines for clinical practice: instructions for use (editorial)] Grilli R. **Recenti Prog Med** 1995 Nov; 86(11):453–5 **(Ita)**

[Guidelines for the treatment of asthma] Akiyama K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):199–204 (3 ref.) **(Jpn)**

[Guide line for gene therapy] Takaku F.
Tanpakushitsu Kakusan Koso 1995 Dec;40(17):2498–502 (4 ref.) **(Jpn)**

[Clinical practice guidelines: is their development worthwhile? (editorial)] Guerra Romero L, et al.
Med Clin (Barc) 1995 Sep 9;105(7):257–60 **(Spa)**

[Clinical practice guidelines (letter)] Jovell AJ, et al.
Med Clin (Barc) 1996 Feb 24;106(7):278–9 **(Spa)**

STANDARDS

Practice guidelines and professional challenges: what psychotherapists need to do [comment] Kocsis JH.
Arch Gen Psychiatry 1996 Apr;53(4):303–4. Comment on: Arch Gen Psychiatry 1996 Apr;53(4):283–90.

The role of psychotherapy in the treatment of depression: review of two practice guidelines [comment] McIntyre JS, et al. **Arch Gen Psychiatry** 1996 Apr;53(4):291–3. Comment on: Arch Gen Psychiatry 1996 Apr;53(4):283–90.

The role of psychotherapy in the treatment of depression: review of two practice guidelines [comment] Merriam AE, et al. **Arch Gen Psychiatry** 1996 Apr;53(4):301–2. Comment on: Arch Gen Psychiatry 1996 Apr;53(4):283–90.

The role of psychotherapy in the treatment of depression: review of two practice guidelines [see comments] Persons JB, et al. **Arch Gen Psychiatry** 1996 Apr;53(4):283–90. Comment in: Arch Gen Psychiatry 1996 Apr;53(4):291–3. Comment in: Arch Gen Psychiatry 1996 Apr;53(4):298–300. Comment in: Arch Gen Psychiatry 1996 Apr;53(4):301–2. Comment in: Arch Gen Psychiatry 1996 Apr;53(4):303–4.

The role of psychotherapy in the treatment of depression: review of two practice guidelines [comment] Rush AJ. **Arch Gen Psychiatry** 1996 Apr;53(4):298–300. Comment on: Arch Gen Psychiatry 1996 Apr;53(4):283–90.

The dilemma of practice guideline development [editorial] Obstbaum SA. **Arch Ophthalmol** 1996 Sep;114(9):1128

Evaluation of clinical practice guidelines. Basinski AS.
Can Med Assoc J 1995 Dec 1;153(11):1575–81 (40 ref.)

Paradox, process and perception: the role of organizations in clinical practice guidelines development [see comments] Lewis S. **Can Med Assoc J** 1995 Oct 15;153(8):1073–7. Comment in: Can Med Assoc J 1996 Mar 15;154(6):755–6.

Outcomes that matter [editorial] Butler C.
Dev Med Child Neurol 1995 Sep;37(9):753–4

An audit of the 1995 Royal College of Ophthalmologists guidelines for screening for retinopathy of prematurity applied retrospectively in one regional neonatal intensive care unit. Fleck BW, et al. **Eye** 1995;9 (Pt 6 Su):31–5

Developing policies and guidelines. Brennan PJ, et al.
Infect Control Hosp Epidemiol 1995 Sep;16(9):512–7

Clinical guidelines: an introduction to their development and implementation. Duff LA, et al. **J Adv Nurs** 1996 May; 23(5):887–95 (35 ref.)

The development and significance of optometric clinical practice guidelines [editorial] Amos JF, et al.
J Am Optom Assoc 1995 Aug;66(8):464–5

Clinicolegal aspects of practice guidelines for pediatric eye and vision examination. Hatch SW. **J Am Optom Assoc** 1995 Aug;66(8):501–9

Clinical practice guidelines in oncology: pros and cons [editorial] Markman M. **J Cancer Res Clin Oncol** 1996; 122(7):381–2 (5 ref.)

Rating the quality of evidence for clinical practice guidelines. Hadorn DC, et al. **J Clin Epidemiol** 1996 Jul;49(7):749–54

Practice guidelines. What are internists looking for? [see comments] Hayward RS, et al. **J Gen Intern Med** 1996 Mar;11(3):176–8. Comment in: J Gen Intern Med 1996 Mar;11(3):185–6.

Clinical indicators in colorectal surgery. Thompson GA, et al. **J Qual Clin Pract** 1996 Mar;16(1):31–5; discussion 37

Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. Guyatt GH, et al. **JAMA** 1995 Dec 13;274(22):1800–4

User's guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. Wilson MC, et al. **JAMA** 1995 Nov 22–29;274(20):1630–2

A model for practice guideline adaptation and implementation: empowerment of the physician [see comments] Wise CG, et al. **Jt Comm J Qual Improv** 1995 Sep;21(9):465–76. Comment in: Jt Comm J Qual Improv 1996 Feb;22(2):83–4.

Glaucoma care and conformance with preferred practice patterns. Examination of the private, community-based ophthalmologist. Hertzog LH, et al. **Ophthalmology** 1996 Jul;103(7):1009–13

Clinical guidelines [letter; comment] Hardern RD.
Postgrad Med J 1995 Sep;71(839):574–5. Comment on: Postgrad Med J 1995 Jan;71(831):3–9.

The development and meaning of appropriateness guidelines. Mendelson EB. **Radiol Clin North Am** 1995 Nov; 33(6):1081–4

Evaluation of a lead screening program in Houston, Tex. Mazur LJ, et al. **Tex Med** 1996 Jan;92(1):54–7

[Family physicians mind your affairs! (letter)] Wiersma TJ.
Ned Tijdschr Geneeskd 1995 Oct 7;139(40):2052–3 **(Dut)**

PRACTICE MANAGEMENT, DENTAL

Report from Denver 1996.
Am J Orthod Dentofacial Orthop 1996 Sep;110(3):332–4

Database or spreadsheet—what's the difference. Abelson MN. **Am J Orthod Dentofacial Orthop** 1996 Mar; 109(3):329–31

Computerized archiving of records. Abelson MN.
Am J Orthod Dentofacial Orthop 1995 Nov;108(5):562–4

A special kind of computerized reporting system. Bellavia DC, et al. **Am J Orthod Dentofacial Orthop** 1995 Dec; 108(6):663–7

Practical marketing for dentistry. 1. What is marketing? Ball R. **Br Dent J** 1996 May 25;180(10):385–8

Practical marketing for dentistry. 3. Relationship marketing and patient/customer satisfaction. Ball R. **Br Dent J** 1996 Jun 22;180(12):467–72

Practical marketing for dentistry. 2. The core concepts of marketing. Ball R. **Br Dent J** 1996 Jun 8;180(11):427–32

Practical marketing for dentistry 6. Market segmentation and targeting. Ball R. **Br Dent J** 1996 Aug 10;181(3):105–10

Mike Grace speaks to Beverley Dewey [interview] Grace M. **Br Dent J** 1996 Jan 20;180(2):48–9

Private practice [letter] Knott N. **Br Dent J** 1996 May 25; 180(10):368

Private practice: salvation or nemesis for the dental profession? [editorial] Landes DP. **Br Dent J** 1996 Feb 10; 180(3):82–3

Interview with Fiona Stuart-Wilson [interview by Teresa Jane Waddington] Stuart-Wilson F. **Br Dent J** 1995 Nov 25;179(10):367–9

MRI update: the effect of dentist attire on patient perceptions of skill, caring and professionalism. Waddington TJ.
Br Dent J 1996 Feb 10;180(3):86–7

"Starting from scratch". Ferguson KR, et al. **Br J Orthod** 1996 Feb;23(1):85–7

Dental practice considerations. Griffin AP, et al.
Dent Clin North Am 1995 Oct;39(4):861–75 (14 ref.)

The service model. Chambers DW. **J Am Coll Dent** 1995 Fall;62(3):49–51

The verticalization of dentistry [editorial] Chambers DW.
J Am Coll Dent 1995 Fall;62(3):2–5

Strategic planning. Chambers DW. **J Am Coll Dent** 1996 Summer;63(2):37–9

Ethical checklist for dental practice. Rinchuse DJ, et al.
J Am Coll Dent 1995 Fall;62(3):45–8

Increasing patient service by effective use of dental hygienists. Christiensen GJ. **J Am Dent Assoc** 1995 Sep; 126(9):1291–4

Telephone planning: the key to improved patient service and reduced stress. de St. Georges JM. **J Am Dent Assoc** 1995 Oct;126(10):1434–7

EDI: novocaine for managing your dental claims [see comments] Morgese AL. **J Am Dent Assoc** 1995 Dec; 126(12):1670–3. Comment in: J Am Dent Assoc 1996 Apr;127(4):424.

Creating value for your staff. Manji I. **J Can Dent Assoc** 1995 Oct;61(10):837–9

Beyond the bells and whistles: hi-tech/high care dentistry. Manji I. **J Can Dent Assoc** 1996 Aug;62(8):658–61
Going up or down? Manji I. **J Can Dent Assoc** 1996 Jan; 62(1):33–5
Thriving in the Information Age: Information Organization and Management Tools in Dental Practice. Seattle, Washington, June 15–16, 1995. **J Dent Educ** 1996 Jan; 60(1):12–80
Resource management in dental practice. Ringenberg T. **J Dent Educ** 1996 Jan;60(1):24–7
Beginning to understand contract analysis. Wils W. **J Dent Educ** 1996 Apr;60(4):390–3
The electronic window to the world. Zimmerman JL. **J Dent Educ** 1996 Jan;60(1):33–40
Computers are here. Now what do we do with them? [editorial] Albert SB. **N Y State Dent J** 1995 Oct;61(8):4–6
The dental information superhighway. Opportunity and challenge. Antenucci EL. **N Y State Dent J** 1995 Oct; 61(8):54–7
Choosing practice management software. How sophisticated should you get? Miller MC. **N Y State Dent J** 1995 Oct; 61(8):42–6
Sexual harassment in the dental office. A model policy. Plunkett L. **N Y State Dent J** 1995 Oct;61(8):48–52
Selling/buying a dental practice. Winter L. **N Y State Dent J** 1995 Aug–Sep;61(7):52–5

ECONOMICS

Comment on cost, risk, regulation, fees [letter; comment] Helmholdt RD. **Am J Orthod Dentofacial Orthop** 1996 Jan; 109(1):22A. Comment on: Am J Orthod Dentofacial Orthop 1995 Jun;107(6):16A–17A.
The ABC's of computer embezzlement. Schulhof B. **Am J Orthod Dentofacial Orthop** 1996 Jul;110(1):112–3
Is your pediatric practice keeping pace with the improving picture of dental economics? Waldman HB. **ASDC J Dent Child** 1995 May–Jun;62(3):210–4
Promotional flyers [letter] Walford WF. **J Can Dent Assoc** 1996 May;62(5):384
Office overhead expense insurance: understanding the sometimes "misunderstood" plan. Wright J. **J Can Dent Assoc** 1995 Sep;61(9):756–8, 760
Valuation of a dental practice. Mastracchio NJ Jr. **N Y State Dent J** 1996 Jan;62(1):46–50

LEGISLATION & JURISPRUDENCE

The interview and hiring process according to the Americans with Disabilities Act and the Equal Employment Opportunities Commission. Part I. Eash C. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):570–1
When a patient is bankrupt. Jerrold L. **Am J Orthod Dentofacial Orthop** 1996 Mar;109(3):332–3
Ethics and competition law [editorial] Harcourt JK. **Aust Dent J** 1995 Aug;40(4):271
The Dental Practice Board. Orthodontics—the current status. Hinman C. **Br J Orthod** 1995 Aug;22(3):287–90
What is a conspiracy? A review of the nation's antitrust laws [see comments] Sfikas PM. **J Am Dent Assoc** 1995 Oct; 126(10):1438–9. Comment in: J Am Dent Assoc 1995 Dec;126(12):1598.
What dentists need to know about employment law. Sfikas PM. **J Am Dent Assoc** 1996 Jan;127(1):124–6
Hold-harmless agreements. What every dentist needs to know. Sfikas PM. **J Am Dent Assoc** 1996 Jun;127(6):804–5
What is restraint of trade? A review of the nation's antitrust laws. Sfikas PM. **J Am Dent Assoc** 1995 Nov; 126(11):1547–9
What dentists need to know about employment law. Sfikas PM. **J Am Dent Assoc** 1996 Feb;127(2):268–9
Infection control [letter] Hill CR. **J Can Dent Assoc** 1995 Oct;61(10):824
Independent contractors beware. IRS declares war on New York dentists. Plunkett LR. **N Y State Dent J** 1995 Oct; 61(8):12–5
When an employee becomes pregnant. Employer's rights and responsibilities. Plunkett LR. **N Y State Dent J** 1996 Jan; 62(1):9–11
[Competitor clause in practice takeover contracts. Opinion of the Higher Regional Court Koblenz, 5-25-1994] Rieger HJ. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):285–6 **(Ger)**

ORGANIZATION & ADMINISTRATION

Office policies and benefits update. Part II. Eash C. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):667–8
Practical marketing for dentistry. 4. Marketing strategy and planning for dental organisations. Ball R. **Br Dent J** 1996 Jul 6;181(1):29–35
MRI update. Waddington TJ. **Br Dent J** 1995 Oct 7; 179(7):242
MRI—the story so far. Waddington TJ. **Br Dent J** 1995 Nov 11;179(9):322–3
Building a better practice. **J Am Dent Assoc** 1996 Jul; 127(7):871–80
Managed care 'what ifs?' [letter] Stark JL. **J Am Dent Assoc** 1996 May;127(5):550, 552, 554
Oralife managed care plan is a no GO. Brookfield JR. **J Can Dent Assoc** 1996 May;62(5):389
The marketing mind. Manji I. **J Can Dent Assoc** 1996 Jun; 62(6):483–4
Establishing a competitive advantage through quality management. George RJ. **N Z Dent J** 1996 Jun; 92(408):49–51

STANDARDS

Dentistry as a business [letter] Enright CM. **J Am Dent Assoc** 1996 Feb;127(2):160
Continuous quality improvement and dental practice: a marriage of necessity. Weintraub AM. **J Am Dent Assoc** 1996 Jul;127(7):1099–106
The American Dental Association's commitment to electronic data interchange. Narcisi JP. **J Dent Educ** 1996 Jan;60(1):28–32

STATISTICS & NUMERICAL DATA

The growth of new dental practices established in the North West of England and North Wales between 1985 and 1990 [see comments] Lennon MA, et al. **Br Dent J** 1995 Sep 9;179(5):180–2. Comment in: Br Dent J 1995 Nov 25;179(10):372.
Growth of new dental practices [letter; comment] Rich MH. **Br Dent J** 1995 Nov 25;179(10):372. Comment on: Br Dent J 1995 Sep 9;179(5):180–2.
Dentist service rates and distribution of practice styles over time. Brennan DS, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):145–51
A survey of ethical dilemmas and practical problems encountered by practicing dentists. Kress GC, et al. **J Am Dent Assoc** 1995 Nov;126(11):1554–62

TRENDS

The practice of dentistry, year 2005: a vision. Preston JD. **J Dent Educ** 1996 Jan;60(1):68–75

PRACTICE MANAGEMENT, MEDICAL

Diagnostic radiologists' nonhospital practices: high-technology and other characteristics of radiology offices. Deitch CH, et al. **AJR Am J Roentgenol** 1996 Sep; 167(3):591–5
Physician patterns in the provision of health care to their own employees [letter; comment] Gebhart RM, et al. **Arch Fam Med** 1996 Feb;5(2):68–9. Comment on: Arch Fam Med 1995 Aug;4(8):686–9; discussion 690.
The effect of managed care on nuclear cardiology. Michnich ME, et al. **J Nucl Cardiol** 1996 Jan–Feb;3(1):65–71
Prescribing costs in general practice fundholding [letter; comment] Wilson R, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1710–1. Comment on: Lancet 1995 Oct 28;346(8983):1139–42.
General practice reform: the shared management model [letter; comment] Butler CD. **Med J Aust** 1996 Jun 17; 164(12):754–5. Comment on: Med J Aust 1996 Feb 19;164(4):221–3.
Issues for fundholding in Australian general practice. Pritchard DA, et al. **Med J Aust** 1996 Feb 19;164(4):215–9
Advice for preventing sexual misconduct charges. **Mich Med** 1996 Jun;95(6):12–3
Thriving in a managed care environment. Madigan WE. **Mich Med** 1995 Nov;94(11):27–9
To be or not to be an employed physician. Physicians have more choices than they may think. Ward R. **Mich Med** 1995 Aug;94(8):17–9
Delegation of authority. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep; 115(3):191–4
Patient impatience can cost your practice business. Bernet PM. **Pa Med** 1995 Nov;98(11):40
Office managers: nobody knows the trouble they see. Marrone S. **Pa Med** 1995 Sep;98(9):34–6
Bringing your office into the computer age. Do you really need all the bells and whistles? Potts JF. **Postgrad Med** 1996 May;99(5):29–30, 32
Overcoming the limitations of proprietary computerized billing systems to enhance patient care. Arbogast JG, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:722–6
How to be a good hospital locum in the UK [editorial] Thenabadu A. S **Afr Med J** 1995 Oct;85(10):991–2
Getting organized. Pros and cons of business structures for medical practice. Stern MZ. **Tex Med** 1995 Sep;91(9):24–6
Advice for organized medicine [letter] Shinn WT, et al. **Va Med Q** 1996 Summer;123(3):152
Veterinary Practice Management Association [letter] Sheridan J. **Vet Rec** 1996 Mar 2;138(9):216
[Physician and Internet] van Straalen WR, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):39–43 **(Dut)**
[The chief clinician of universities—resident of hospitals: his pedagogic impact] Pidhorz LE. **J Chir (Paris)** 1995 Oct; 132(10):406–13 (Eng. Abstr.) **(Fre)**
[Methods for formulating recommendations for clinical practice] Dosquet P, et al. **J Radiol** 1995 Nov;76(11):1004–6 **(Fre)**

ECONOMICS

Practice revenue and cost distribution for ophthalmology, 1988 to 1993. Khadem J, et al. **Arch Ophthalmol** 1996 May; 114(5):600–3
Effects of global competition on health care administration in Finland and the United States. What you can do to save your practice. Thompson JW, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):241–50
Income generation in the NHS: opportunity or myth? Roddis MJ. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):67–8
Capitated practices. Do they work [editorial] Gibson GA. **Can Fam Physician** 1996 Apr;42:589–92, 600–4 **(Eng, Fre)**
Caveats for physicians in the financing of practice networks. Frenkel M. **J Health Care Finance** 1996 Spring;22(3):49–51
Michigan tax changes: the impact on you and your practice. Copping BD. **Mich Med** 1995 Aug;94(8):22–4
Oncology carve-outs another managed care option [news] **Oncology (Huntingt)** 1996 Apr;10(4):588
Telemedicine and the payment system. Fisher GR 3rd. **Pa Med** 1995 Nov;98(11):32–4
10 good reasons to stay independent. For private-practice physicians thinking about selling their practices. Orlowski SR. **Pa Med** 1995 Oct;98(10):11a–13a
Management perspective: survival of the practice of pediatric infectious diseases—yes ... but .... Grizzard MB. **Pediatr Infect Dis J** 1995 Nov;14(11):1026–9
Making the cap fit. What you need to know about capitation. BeSaw L. **Tex Med** 1996 Jan;92(1):24–9
Telephone use and costs in a group subspecialty practice [letter] Gogel HK, et al. **West J Med** 1995 Aug; 163(2):183–4

LEGISLATION & JURISPRUDENCE

Tax-exempt integrated delivery systems: Part 2, Stark I and Stark II. Vogel PL, et al. **Mo Med** 1995 Sep;92(9):572–3
Who's the boss? Ortolon K. **Tex Med** 1996 Jun;92(6):30–2
ADA is changing the way physicians practice medicine. Barratt K, et al. **Wis Med J** 1996 Jan;95(1):54–6
[Selection of candidates by the qualification committee in the sale of a practice. Opinion of the Social Court Münster, 10-5-1995] Rieger HJ. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):318–20 **(Ger)**

ORGANIZATION & ADMINISTRATION

Solo or partnership. Urschel HC Jr. **Ann Thorac Surg** 1995 Nov;60(5):1473–5; discussion 1490–3
An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Leininger LS, et al. **Arch Fam Med** 1996 Feb;5(2):108–15
A 10-year experience in pediatric after-hours telecommunications. Pert JC, et al. **Curr Opin Pediatr** 1996 Apr;8(2):181–7
Explaining variations in the frequency of night visits in general practice. Whynes DK, et al. **Fam Pract** 1996 Apr; 13(2):174–8
Nursing homes: what you need to know for quality patient care. Cefalu CA. **Geriatrics** 1995 Dec;50(12):37–40, 49–50 (22 ref.)
Answers to your questions on Medicaid managed care. **Indiana Med** 1996 May–Jun;89(3):260–3
How solo physicians view their practices. Carlson B. **Indiana Med** 1996 May–Jun;89(3):250–4
Managed care needs proactive physicians [interview by Bob Carlson] Hochstetler M. **Indiana Med** 1996 May–Jun; 89(3):242–8
The information driveway: data management for the rest of us. Cushing M Jr. **MD Comput** 1996 Jul–Aug;13(4):347–50
Practice management, health maintenance, and the use of computers in today's medical office. Brooks RJ, et al. **Med Clin North Am** 1996 Mar;80(2):279–97
Visits to three POs provide valuable information. Wolff TM. **Mich Med** 1995 Aug;94(8):12–5
Qualitative differences between urban and rural practice. Mungall IJ. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):10–2
Practice policies must do more today. The Health Care Group. McGraw SE. **Pa Med** 1995 Oct;98(10):24–5
[Regulated working time and guaranteed leisure time for Finnish physicians? (interview by Eva Oldinger)] Eklund B. **Nord Med** 1996 May;111(5):152–3, 155 **(Swe)**

STANDARDS

Patients' perceptions of office medical practice: judging quality through the patients' eyes. Epstein KR, et al. **Am J Med Qual** 1996 Summer;11(2):73–80
Facts about the fax: MDs advised to be cautious. Capen K. **Can Med Assoc J** 1995 Oct 15;153(8):1152–3
Caveat emptor. Scoping out the primary care practice game. Kaufman N. **Hosp Health Netw** 1995 Nov 5;69(21):38–9
The provision of specialist rheumatology care: implications from a survey of rheumatologists in Ontario, Canada [see comments] Hawker GA, et al. **J Rheumatol** 1995 May; 22(5):959–66. Comment in: J Rheumatol 1995 May;22(5):805–6.

TRENDS

Preparing your practice for change: thoracic surgery into the next decade. Symposium held September 24–25, 1994, Atlanta, Georgia. **Ann Thorac Surg** 1995 Nov; 60(5):1463–556
Successful practice in a managed care environment: managing costs while managing care. Freston JW. **Gastroenterology** 1996 Aug;111(2):516–8
Boom (and bust) in the physician management market. **Hosp Health Netw** 1995 Dec 20;69(24):47–8
Medical express ... physician practice management. Tokarski

C. **Hosp Health Netw** 1995 Dec 5;69(23):38–40
Current trends in physicians' practice arrangements. From owners to employees. Kletke PR, et al. **JAMA** 1996 Aug 21;276(7):555–60
Workload: changes and trends. Walker R.
Occas Pap R Coll Gen Pract 1995 Sep;(71):13–4

PRACTICE PATTERNS, PROFESSIONAL see **PHYSICIAN'S PRACTICE PATTERNS**

PRADER-WILLI SYNDROME

COMPLICATIONS

Type I diabetes mellitus, ketoacidosis and thromboembolism in an adolescent with Prader–Willi syndrome [letter] Anhalt H, et al. **Acta Paediatr** 1996 Apr;85(4):516
Rectal bleeding in Prader–Willi syndrome. Bhargava SA, et al. **Pediatrics** 1996 Feb;97(2):265–7
Kleine–Levin syndrome in a boy with Prader–Willi syndrome. Gau SF, et al. **Sleep** 1996 Jan;19(1):13–7
[Effects of hypocaloric diet on respiratory manifestations in Willi–Prader syndrome] Deschildre A, et al.
Arch Pediatr 1995 Nov;2(11):1075–9 (Eng. Abstr.) **(Fre)**
[Genetic syndrome with obesity] Tsuda K, et al.
Nippon Rinsho 1995 Jun;53 Suppl:436–40 (19 ref.) **(Jpn)**

DIAGNOSIS

Diagnosis of the Prader–Willi syndrome by proving the absence of the unmethylated PW71 DNA fragment. Lindgren AC, et al. **Acta Paediatr** 1996 Feb;85(2):195–8
Diagnostic testing for Prader–Willi and Angleman syndromes: Report of the ASHG/ACMG Test and Technology Transfer Committee. **Am J Hum Genet** 1996 May;58(5):1085–8
Allele-specific replication of 15q11–q13 loci: a diagnostic test for detection of uniparental disomy. White LM, et al.
Am J Hum Genet 1996 Aug;59(2):423–30
Molecular diagnosis of Prader–Willi syndrome: comparison of cytogenetic and molecular genetic data including parent of origin dependent methylation DNA patterns [letter] Butler MG. **Am J Med Genet** 1996 Jan 11;61(2):188–90
PW71 methylation test for Prader–Willi and Angelman syndromes [letter] Dittrich B, et al. **Am J Med Genet** 1996 Jan 11;61(2):196–7
Fluorescent in situ hybridization for evaluation of Prader–Willi and Angelman syndromes [letter; comment] Wenger SL, et al. **Am J Med Genet** 1995 Jul 17;57(4):639 . Comment on: Am J Med Genet 1994 Aug 1;52(1):85–91.
Confirmation of a clinical diagnosis of Prader–Willi syndrome by fluorescence in situ hybridization (FISH). Joseph A, et al. **Del Med J** 1995 Dec;67(12):620–2
Maladaptive behaviour in Prader–Willi syndrome in adult life. Clarke DJ, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):159–65
Ocular findings in a patient with Prader–Willi syndrome. Wang XC, et al. **Jpn J Ophthalmol** 1995;39(3):284–9
Genetic testing for Prader–Willi and Angelman syndromes. Schad CR, et al. **Mayo Clin Proc** 1995 Dec;70(12):1195–6
MR of the pituitary in patients with Prader–Willi syndrome: size determination and imaging findings. Miller L, et al.
Pediatr Radiol 1996;26(1):43–7
Prenatal diagnosis of uniparental disomy 15 following trisomy 15 mosaicism. Christian SL, et al. **Prenat Diagn** 1996 Apr; 16(4):323–32
Onset of menses in two adult patients with Prader–Willi syndrome treated with fluoxetine. Warnock JK, et al.
Psychopharmacol Bull 1995;31(2):239–42

DRUG THERAPY

Effects of mazindol in two patients with Prader–Willi syndrome. Itoh M, et al. **Pediatr Neurol** 1995 Nov; 13(4):349–51
Onset of menses in two adult patients with Prader–Willi syndrome treated with fluoxetine. Warnock JK, et al.
Psychopharmacol Bull 1995;31(2):239–42

EPIDEMIOLOGY

Frequency of the Prader–Willi syndrome in the San-in district, Japan. Ehara H, et al. **Brain Dev** 1995 Sep–Oct; 17(5):324–6

GENETICS

Diagnosis of the Prader–Willi syndrome by proving the absence of the unmethylated PW71 DNA fragment. Lindgren AC, et al. **Acta Paediatr** 1996 Feb;85(2):195–8
Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. Glenn CC, et al.
Am J Hum Genet 1996 Feb;58(2):335–46
The impact of imprinting: Prader–Willi syndrome resulting from chromosome translocation, recombination, and nondisjunction. Toth-Fejel S, et al. **Am J Hum Genet** 1996 May;58(5):1008–16
Deletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader–Willi syndrome detected by fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q. Ishikawa T, et al. **Am J Med Genet** 1996 Apr 24; 62(4):350–2
DNA methylation patterns in human tissues of uniparental origin using a zinc-finger gene (ZNF127) from the Angelman/Prader–Willi region. Mowery-Rushton PA, et al. **Am J Med Genet** 1996 Jan 11;61(2):140–6
Sister chromatid exchange in Prader–Willi syndrome families [letter] Wenger SL. **Clin Genet** 1995 Sep;48(3):167–8
Parental exposure to hydrocarbons in Prader–Willi syndrome. Akefeldt A, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1101–9
Routine screening for microdeletions by FISH in 77 patients suspected of having Prader–Willi or Angelman syndromes using YAC clone 273A2 (D15S10). Erdel M, et al.
Hum Genet 1996 Jun;97(6):784–93
Genotype–phenotype correlation in a series of 167 deletion and non–deletion patients with Prader–Willi syndrome. Gillessen–Kaesbach G, et al. **Hum Genet** 1995 Dec; 96(6):638–43
Chromosomal localization of the human and mouse histidine decarboxylase genes by in situ hybridization. Exclusion of the HDC gene from the Prader–Willi syndrome region. Malzac P, et al. **Hum Genet** 1996 Mar;97(3):359–61
Breakage in the SNRPN locus in a balanced 46,XY,t(15;19) Prader–Willi syndrome patient. Sun Y, et al.
Hum Mol Genet 1996 Apr;5(4):517–24
Human obesity does not segregate with the chromosomal regions of Prader–Willi, Bardet–Biedl, Cohen, Borjeson or Wilson–Turner syndromes. Reed DR, et al.
Int J Obes Relat Metab Disord 1995 Sep;19(9):599–603
Prader–Willi syndrome: clinical and molecular cytogenetic investigations. Hou JW, et al. **J Formos Med Assoc** 1996 Jun;95(6):474–9
Exclusion of SNRPN as a major determinant of Prader–Willi syndrome by a translocation breakpoint. Schulze A, et al.
Nat Genet 1996 Apr;12(4):452–4
Sporadic occurrence of nondeletion Prader–Willi syndrome in two cases: a female with maternal uniparental disomy and a male with complex chromosomal rearrangement. Murthy SK, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):650–2
Homologous association of oppositely imprinted chromosomal domains. LaSalle JM, et al. **Science** 1996 May 3;272(5262):725–8
[Prader–Willi syndrome in association with self-injury behavior and premature craniosynostosis] Fehlow P, et al.
Klin Padiatr 1996 May–Jun;208(3):135–6 (Eng. Abstr.) **(Ger)**

METABOLISM

Growth hormone (GH) treatment up–regulates GH receptor mRNA levels in adipocytes from patients with GH deficiency and Prader–Willi syndrome. Kamel A, et al.
Pediatr Res 1995 Sep;38(3):418–21

PHYSIOPATHOLOGY

Photoanthropometric study of craniofacial traits of individuals with Prader–Willi syndrome. Butler MG, et al.
Am J Med Genet 1995 Jul 31;58(1):38–45
Arousal and cardiorespiratory responses to hypoxia in Prader–Willi syndrome. Arens R, et al.
Am J Respir Crit Care Med 1996 Jan;153(1):283–7
Hypercapnic arousal responses in Prader–Willi syndrome. Livingston FR, et al. **Chest** 1995 Dec;108(6):1627–31

PSYCHOLOGY

[Psychological aspects of Prader–Willi syndrome. Results of a parent survey] Sarimski K. **Z Kinder Jugenpsychiatr** 1995 Dec;23(4):267–74 (Eng. Abstr.) **(Ger)**

SURGERY

[Bronchospasm during anesthesia in a patient with Prader–Willi syndrome] Kawahito S, et al. **Masui** 1995 Dec;44(12):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Prader–Willi syndrome: effects of weight loss on sleep–disordered breathing, daytime sleepiness and REM sleep disturbance. Vgontzas AN, et al. **Acta Paediatr** 1995 Jul;84(7):813–4
Characteristics of the eating disorder in Prader–Willi syndrome: implications for treatment. Holland AJ, et al.
J Intellect Disabil Res 1995 Oct;39 (Pt 5):373–81

PRAIRIE DOGS see **SCIURIDAE**

PRAJMALINE

POISONING

[Cardiogenic shock and ventricular fibrillation induced by prajmalium and metoprolol poisoning] Almási R, et al.
Orv Hetil 1996 Mar 31;137(13):695–700 (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

[Magnesium or proajmaline (neogilurytmal) in treatment of recurrences of paroxysmal supraventricular tachyarrhythmias?] Dłużniewski M, et al. **Wiad Lek** 1994 Oct;47(19–20):721–4 (Eng. Abstr.) **(Pol)**

PRAJMALIUM see **PRAJMALINE**

PRALIDOXIME COMPOUNDS

Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Schwarz M, et al.
Brain Res Mol Brain Res 1995 Jul;31(1–2):101–10

PHARMACOKINETICS

Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. Medicis JJ, et al.
J Toxicol Clin Toxicol 1996;34(3):289–95

THERAPEUTIC USE

[Emergency treatment of respiratory failure induced by acute organophosphorus (editorial)] Wang H, et al.
Chung Hua Nei Ko Tsa Chih 1995 Jun;34(6):365–6 **(Chi)**

PRAOMYS see **MURIDAE**

PRASTERONE

ADMINISTRATION & DOSAGE

Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. Casson PR, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):649–53
Effects of dehydroepiandrosterone on MNU–induced breast cancer in Sprague–Dawley rats. Lubet RA, et al.
Ann N Y Acad Sci 1995 Dec 29;774:340–1
Pleotropic effects of dietary DHEA. Milewich L, et al.
Ann N Y Acad Sci 1995 Dec 29;774:149–70
Replacement of DHEA in aging men and women. Potential remedial effects. Yen SS, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:128–42

ANALOGS & DERIVATIVES

Dehydroepiandrosterone sulphate in the diagnosis of osteoporosis. Miklós S. **Acta Biomed Ateneo Parmense** 1995; 66(3–4):139–46
Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA–SO4) to cardiovascular risk factors in postmenopausal women. Haffner SM, et al.
Am J Epidemiol 1995 Nov 1;142(9):925–34
Lack of effect of exercise training on dehydroepiandrosterone–sulfate. Milani RV, et al.
Am J Med Sci 1995 Dec;310(6):242–6
Dynamics of the fetal adrenal, cholesterol, and apolipoprotein B responses to antenatal betamethasone therapy. Parker CR Jr, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):562–5
Effect of dehydroepiandrosterone sulfate on maternal cardiac function in term pregnancy. Hata T, et al.
Am J Perinatol 1996 Jan;13(1):11–3
DHEAS as an effective vaccine adjuvant in elderly humans. Proof–of–principle studies. Araneo B, et al.
Ann N Y Acad Sci 1995 Dec 29;774:232–48
The epidemiology of DHEAS and cardiovascular disease. Barrett–Connor E, et al. **Ann N Y Acad Sci** 1995 Dec 29; 774:259–70
Effects of dehydroepiandrosterone sulfate and stress on hippocampal electrophysiological plasticity. Diamond DM, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:304–7
Dehydroepiandrosterone and coronary atherosclerosis. Herrington DM. **Ann N Y Acad Sci** 1995 Dec 29;774:271–80
Biosynthesis of DHEAS by the human adrenal cortex and its age–related decline. Hornsby PJ. **Ann N Y Acad Sci** 1995 Dec 29;774:29–46 (64 ref.)
DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:16–28 (70 ref.)
Effects of aging and long–term calorie restriction on DHEA and DHEA sulfate in rhesus monkeys. Lane MA, et al.
Ann N Y Acad Sci 1995 Dec 29;774:319–22
Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111–20 (86 ref.)
Adrenal androgen biosynthesis with special attention to P450c17. Mason JI, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:47–58
Regulation of human dehydroepiandrosterone metabolism by insulin. Nestler JE. **Ann N Y Acad Sci** 1995 Dec 29; 774:73–81
Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al.
Ann N Y Acad Sci 1995 Dec 29;774:200–16 (129 ref.)
Relationship between humoral immunoaugmenting properties of DHEAS and IgD–receptor expression in young and aged mice. Swenson CD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:249–58
Dehydroepiandrosterone sulfate and aging. Vermeulen A.
Ann N Y Acad Sci 1995 Dec 29;774:121–7 (54 ref.)
Metabolism of dehydroepiandrosterone sulphate by breast cysts: possible role in the development of breast cancer. Lai LC. **Cancer Detect Prev** 1995;19(5):441–5
Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Lu LJ, et al.
Cancer Epidemiol Biomarkers Prev 1996 Jan;5(1):63–70
Dehydroepiandrosterone sulphate in critical illness: effect of

dopamine. Van den Berghe G, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):457–63

Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. de la Torre B, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):345–8

Relationship between serum dehydroepiandrosterone sulfate, androstenedione, and sex hormones in men and women. Phillips GB. **Eur J Endocrinol** 1996 Feb;134(2):201–6

Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Casson PR, et al. **Fertil Steril** 1996 May;65(5):950–3

Ovulation induction in clomiphene–resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Trott EA, et al. **Fertil Steril** 1996 Sep; 66(3):484–6

Dehydroepiandrosterone sulfate in a long–term care aged population. Legrain S, et al. **Gerontology** 1995;41(6):343–51

Biochemical changes in the cervical tissue of rabbit induced by interleukin–8, interleukin–1beta, dehydroepiandrosterone sulphate and prostaglandin E2: a comparative study. El Maradny E, et al. **Hum Reprod** 1996 May;11(5):1099–104

Effects of dehydroepiandrosterone sulfate on cellular calcium responsiveness and vascular contractility. Barbagallo M, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1065–9

Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women. Weinstein RE, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):1–8

Plasma androgens in autism. Tordjman S, et al. **J Autism Dev Disord** 1995 Jun;25(3):295–304

Suppression of maternal adrenal dehydroepiandrosterone and dehydroepiandrosterone sulfate production by estrogen during baboon pregnancy. Albrecht ED, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3201–8

Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist–hip ratio, and noninsulin–dependent diabetes in postmenopausal women: the Rancho Bernardo Study. Barrett–Connor E, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):59–64

Low dehydroepiandrosterone sulfate (DHEA–S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. Bencsik Z, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1726–9

Disparate effects of weight reduction by diet on serum dehydroepiandrosterone–sulfate levels in obese men and women. Jakubowicz DJ, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3373–6

Disparate effects of weight reduction by diet on serum dehydroepiandrosterone–sulfate levels in obese men and women [letter] Remer T. **J Clin Endocrinol Metab** 1996 Jul;81(7):2751–2

Longitudinal study of adrenal steroids in a cohort of HIV–infected patients with hemophilia [see comments] Chatterton RT Jr, et al. **J Lab Clin Med** 1996 Jun; 127(6):545–52. Comment in: J Lab Clin Med 1996 Jun;127(6):522–3.

Sex hormone status and bone mineral density in men with rheumatoid arthritis. Mateo L, et al. **J Rheumatol** 1995 Aug; 22(8):1455–60

Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus. Straub RH, et al. **J Rheumatol** 1996 May;23(5):856–61

Transport of dehydroepiandrosterone and dehydroepiandrosterone sulphate into rat hepatocytes. Reuter S, et al. **J Steroid Biochem Mol Biol** 1995 Sep; 54(5–6):227–35

Peroxisome proliferator–activated receptor alpha required for gene induction by dehydroepiandrosterone–3 beta–sulfate. Peters JM, et al. **Mol Pharmacol** 1996 Jul; 50(1):67–74

Maternal serum dehydroepiandrosterone sulfate levels and the efficiency of labor in young nulliparas. Goolsby L, et al. **Obstet Gynecol** 1996 Jul;88(1):56–9

Competing pathway involved in allylic acetoxylation of androst–5–en–17–one, and oxidation of allylic alcohols with chromium oxides. Numazawa M, et al. **Steroids** 1995 Aug; 60(8):499–505

The syntheses of 3 beta–steroidal diacylglyceryl sulfides, sulfoxides, and sulfones. Williams JR, et al. **Steroids** 1995 Apr;60(4):321–3

Studies on the synthesis of dehydroepiandrosterone (DHEA) phosphatide. Williams JR, et al. **Steroids** 1995 Apr; 60(4):333–6

Steroid hormone levels in patients with advanced breast cancer during therapy with droloxifene: a pilot study. Dalski J, et al. **Tumori** 1996 Jan–Feb;82(1):45–7

The short–term effect of dietary pectin on plasma levels and renal excretion of dehydroepiandrosterone sulfate. Remer T, et al. **Z Ernahrungswiss** 1996 Mar;35(1):32–8

[The effect of dehydroepiandrosterone sulfate on cervical maturation during pregnancy] Koyuncu F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):630–3 (Eng. Abstr.) **(Fre)**

[Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA–S)] Okabe T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:460–3 (10 ref.) **(Jpn)**

[Prolonged remission of female hyperandrogenism after discontinuing glucocorticoid therapy] Devoto E, et al. **Rev Med Chil** 1995 Feb;123(2):207–14 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Suppression of maternal adrenal dehydroepiandrosterone and dehydroepiandrosterone sulfate production by estrogen during baboon pregnancy. Albrecht ED, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3201–8

BIOSYNTHESIS

Adrenal androgen biosynthesis with special attention to P450c17. Mason JI, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:47–58

Selective increases in adrenal steroidogenic capacity during acute respiratory disease in infants. Hanukoglu A, et al. **Eur J Endocrinol** 1995 Nov;133(5):552–6

BLOOD

Dehydroepiandrosterone and coronary atherosclerosis. Herrington DM. **Ann N Y Acad Sci** 1995 Dec 29;774:271–80

Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin–releasing hormone in Alzheimer's disease. Näsman B, et al. **Biol Psychiatry** 1996 Mar 1;39(5):311–8

Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women. Weinstein RE, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):1–8

Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist–hip ratio, and noninsulin–dependent diabetes in postmenopausal women: the Rancho Bernardo Study. Barrett–Connor E, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):59–64

Spotlight on DHEA: a marker for progression of HIV infection? [editorial; comment] Brind J. **J Lab Clin Med** 1996 Jun;127(6):522–3. Comment on: J Lab Clin Med 1996 Jun;127(6):545–52.

Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. Leblhuber F, et al. **J Neurol Sci** 1995 Sep;132(1):76–9

Dehydroepiandrosterone sulphate (DHEAS) concentrations and amyotrophic lateral sclerosis. Eisen A, et al. **Muscle Nerve** 1995 Dec;18(12):1481–3

[Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA–S)] Okabe T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:460–3 (10 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Studies on the synthesis of dehydroepiandrosterone (DHEA) phosphatide. Williams JR, et al. **Steroids** 1995 Apr; 60(4):333–6

CHEMISTRY

Solid state characterization of dehydroepiandrosterone. Chang LC, et al. **J Pharm Sci** 1995 Oct;84(10):1169–79

DEFICIENCY

Dehydroepiandrosterone and insulinaemia. Svačina S, et al. **Sb Lek** 1995;96(4):303–6

HISTORY

An abbreviated account of some aspects of the biochemistry of DHEA, 1934–1995. Lieberman S. **Ann N Y Acad Sci** 1995 Dec 29;774:1–15 (34 ref.)

IMMUNOLOGY

Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Danenberg HD, et al. **Vaccine** 1995;13(15):1445–8

METABOLISM

Sex differences in dehydroepiandrosterone metabolism in rodents. Hobe G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 774:308–11

7 alpha–Hydroxylation of the adrenal androgens dehydroepiandrosterone and androst–5–ene–3 beta, 17 beta–diol predominates in differentiating human adipose stromal cells. Khalil MW, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:316–8

DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:16–28 (70 ref.)

Effects of aging and long–term calorie restriction on DHEA and DHEA sulfate in rhesus monkeys. Lane MA, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:319–22

Metabolism of dehydroepiandrosterone. Longcope C. **Ann N Y Acad Sci** 1995 Dec 29;774:143–8

Regulation of human dehydroepiandrosterone metabolism by insulin. Nestler JE. **Ann N Y Acad Sci** 1995 Dec 29; 774:73–81

Formation of pregnenolone– and dehydroepiandrosterone–fatty acid esters by lecithin–cholesterol acyltransferase in human plasma high density lipoproteins. Lavallée B, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):306–12

The synthesis of 19–norandrostenedione from dehydroepiandrosterone in equine placenta is inhibited by aromatase inhibitors 4–hydroxyandrostenedione and fadrozole. Moslemi S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):613–8

3 beta–hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. Vanson A, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):342–50

Transport of dehydroepiandrosterone and dehydroepiandrosterone sulphate into rat hepatocytes. Reuter S, et al. **J Steroid Biochem Mol Biol** 1995 Sep; 54(5–6):227–35

PHARMACOLOGY

Dehydroepiandrosterone modulates the spontaneous and IL–6 stimulated fibrinogen production of human hepatoma cells. Fehér KG, et al. **Acta Microbiol Immunol Hung** 1995; 42(2):229–33

Effect of dehydroepiandrosterone sulfate on fetal middle cerebral artery flow velocity waveforms in term pregnancy. Hata T, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):343–6

Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Beer NA, et al. **Am J Med Sci** 1996 May; 311(5):205–10

Dehydroepiandrosterone attenuates study–induced declines in insulin sensitivity in postmenopausal women. Bates GW Jr, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:291–3

Dehydroepiandrosterone enhances influenza immunization in aged mice. Danenberg HD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:297–9

Dehydroepiandrosterone augments M1–muscarinic receptor–stimulated amyloid precursor protein secretion in desensitized PC12M1 cells. Danenberg HD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:300–3

Effect of dehydroepiandrosterone on cyclic–guanosine monophosphate in men of advancing age. Jakubowicz D, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:312–5

Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Jesse RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:281–90

Induction of thermogenic enzymes by DHEA and its metabolites. Lardy H, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:171–9

DHEA diminishes fat food intake in lean and obese Zucker rats. Porter JR, et al. **Ann N Y Acad Sci** 1995 Dec 29; 774:329–31

Regulation of cytochromes P450 by DHEA and its anticarcinogenic action. Prough RA, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:187–99

Effect of dehydroepiandrosterone on rat thyroxine binding globulin, a protein upregulated during aging. Vranckx R, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:335–6

Dehydroepiandrosterone and macronutrient selection by obese Zucker rats (fa/fa). Svec F, et al. **Appetite** 1995 Oct; 25(2):143–54

Increase of lipid peroxidation in rat liver microsomes by dehydroepiandrosterone feeding. Swierczynski J, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):193–8

Dose–response study of dehydroepiandrosterone sulfate on dentate gyrus long–term potentiation. Yoo A, et al. **Exp Neurol** 1996 Jan;137(1):151–6

Dehydroepiandrosterone sulfate suppresses hippocampal recurrent inhibition and synchronizes neuronal activity to theta rhythm. Steffensen SC. **Hippocampus** 1995;5(4):320–8

Effect of dehydroepiandrosterone on mitogen–induced lymphocyte proliferation and cytokine production in young and old F344 rats. Pahlavani MA, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):9–14

Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Daynes RA, et al. **Infect Immun** 1996 Apr;64(4):1100–9

The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food intake and hypothalamic neurotransmitters. Porter JR, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):480–8

Up–regulation of high–affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. Okabe T, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2993–6

Dehydroepiandrosterone modulation of lipopolysaccharide–stimulated monocyte cytotoxicity. McLachlan JA, et al. **J Immunol** 1996 Jan 1;156(1):328–35

Effects of dehydroepiandrosterone (DHEA) on pituitary prolactin and arcuate nucleus neuron tyrosine hydroxylase mRNA levels in the rat. Garcia de Yebenes E, et al. **J Neuroendocrinol** 1995 Aug;7(8):589–95

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. Bergeron R, et al. **J Neurosci** 1996 Feb 1;16(3):1193–202

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167–72 (61 ref.)

Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Araghiniknam M, et al. **Life Sci** 1996;59(11):PL147–57

Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone. Webb SJ, et al. **Mol Pharmacol** 1996 Feb;49(2):276–87

Influence of small doses of dehydroepiandrosterone on the inception of the hormonal function of testes of sexually immature monkeys. Goncharov NP, et al.

PRASTERONE

Neurosci Behav Physiol 1995 Jul–Aug;25(4):340–3
The neurosteroid dehydroepiandrosterone sulfate (DHEAS) enhances hippocampal primed burst, but not long–term, potentiation. Diamond DM, et al. **Neurosci Lett** 1996 Jan 5;202(3):204–8
Effect of DHEA on macronutrient selection by Zucker rats. Svec F, et al. **Physiol Behav** 1996 Apr–May;59(4–5):721–7
[Effect of sex steroids on serum amyloid P–component (female protein) in rats] Hashimoto S, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Oct; 47(10):1041–7 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Dehydroepiandrosterone (DHEA) and Aging. Proceedings of a conference. Washington, D.C., June 17–19, 1995. **Ann N Y Acad Sci** 1995 Dec 29;774:ix–xiv, 1–350
Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111–20 (86 ref.)
Dehydroepiandrosterone (DHEA) is a neuroactive neurosteroid. Robel P, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:82–110 (75 ref.)
Dehydroepiandrosterone sulfate and aging. Vermeulen A. **Ann N Y Acad Sci** 1995 Dec 29;774:121–7 (54 ref.)
A review of dehydroepiandrosterone (DHEA). Shealy CN. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):308–13 (52 ref.)
Dehydroepiandrosterone (DHEA): a fountain of youth? [editorial] Baulieu EE. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3147–51 (14 ref.)
Dehydroepiandrosterone and body fat. Clore JN. **Obes Res** 1995 Nov;3 Suppl 4:613S–616S (46 ref.)
[Obesity and associated metabolic disorders] Sonka J. **Sb Lek** 1995;96(4):349–52 **(Cze)**
[Physiologic importance of dehydroepiandrosterone] Danenberg HD, et al. **Harefuah** 1996 Mar 1;130(5):353–6 (44 ref.) **(Heb)**

SECRETION

Stimulation of the secretion of dehydroepiandrosterone by melatonin in mouse adrenals in vitro. Haus E, et al. **Life Sci** 1996;58(14):PL263–7
Adrenal secretion during major depression in 8– to 16–year–olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Goodyer IM, et al. **Psychol Med** 1996 Mar;26(2):245–56
Adrenal secretion and major depression in 8– to 16–year–olds, II. Influence of co–morbidity at presentation. Herbert J, et al. **Psychol Med** 1996 Mar;26(2):257–63

THERAPEUTIC USE

Mechanism of cancer preventive action of DHEA. Role of glucose–6–phosphate dehydrogenase. Schwartz AG, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:180–6 (57 ref.)
Antidepressant and cognition–enhancing effects of DHEA in major depression. Wolkowitz OM, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:337–9
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double–blind, placebo–controlled, randomized clinical trial. van Vollenhoven RF, et al. **Arthritis Rheum** 1995 Dec;38(12):1826–31
Hormone replacement for men [editorial] Weksler ME. **BMJ** 1996 Apr 6;312(7035):859–60
Exceptional chemopreventive activity of low–dose dehydroepiandrosterone in the rat mammary gland. McCormick DL, et al. **Cancer Res** 1996 Apr 15; 56(8):1724–6
Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Shibata M, et al. **Cancer Res** 1995 Nov 1;55(21):4870–4
Cancer prevention with dehydroepiandrosterone and non–androgenic structural analogs. Schwartz AG, et al. **J Cell Biochem Suppl** 1995;22:210–7 (58 ref.)
The antiobesity effect of dehydroepiandrosterone in castrated or noncastrated obese Zucker male rats. Taniguchi S, et al. **Obes Res** 1995 Dec;3 Suppl 5:639S–643S
Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Danenberg HD, et al. **Vaccine** 1995;13(15):1445–8

TOXICITY

Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. Orner GA, et al. **Carcinogenesis** 1995 Dec;16(12):2893–8
Sequential appearance and ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and female rats treated with dehydroepiandrosterone. Metzger C, et al. **Toxicol Pathol** 1995 Sep–Oct;23(5):591–605

PRAUSNITZ–KUSTNER TEST see **INTRADERMAL TESTS**

PRAVASTATIN

ADMINISTRATION & DOSAGE

Evidence for a synergistic effect of calcium channel blockers with lipid–lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Jukema JW, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):425–30
Statins and coronary heart disease [letter; comment] Thompson GR. **Lancet** 1996 Jul 6;348(9019):57. Comment on: Lancet 1996 May 18;347(9012):1389–90.
Tissue–selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Koga T, et al. **Lipids** 1995 Aug;30(8):775–9

ADVERSE EFFECTS

Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3–hydroxy–3–methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Rosenberg AD, et al. **Anesth Analg** 1995 Nov;81(5):1089–91
Pravastatin–induced rhabdomyolysis in a patient with mixed connective tissue disease. Hino I, et al. **Arthritis Rheum** 1996 Jul;39(7):1259–60
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors—simvastatin and pravastatin [letter] England JD, et al. **Aust N Z J Med** 1995 Aug;25(4):374–5
Pravastatin: interaction with oral anticoagulant? Trenque T, et al. **BMJ** 1996 Apr 6;312(7035):886
Effectiveness and safety of low–dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. Chan P, et al. **J Clin Pharmacol** 1996 May;36(5):422–7

ANALOGS & DERIVATIVES

3–Hydroxy–3–methylglutaryl–coenzyme A reductase inhibitors: oxime ether analogs of pravastatin. Turabi N, et al. **Bioorg Med Chem** 1995 Nov;3(11):1479–84

ECONOMICS

Pharmaco–economic assessment of the HMG–CoA reductase inhibitors [see comments] Smart AJ, et al. **S Afr Med J** 1994 Dec;84(12):834–7. Comment in: S Afr Med J 1995 May;85(5):388–91.

METABOLISM

Cloning, characterization and expression of the gene encoding cytochrome P–450sca–2 from Streptomyces carbophilus involved in production of pravastatin, a specific HMG–CoA reductase inhibitor. Watanabe I, et al. **Gene** 1995 Sep 22;163(1):81–5

PHARMACOKINETICS

Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Ishigami M, et al. **Pharm Res** 1995 Nov;12(11):1741–5
Proton–cotransport of pravastatin across intestinal brush–border membrane. Tamai I, et al. **Pharm Res** 1995 Nov;12(11):1727–32

PHARMACOLOGY

Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia. Feillet C, et al. **Atherosclerosis** 1995 Dec;118(2):251–8
Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro. van Vliet AK, et al. **Biochim Biophys Acta** 1996 Jun 11; 1301(3):237–41
Effects of HMG–CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Veerkamp JH, et al. **Biochim Biophys Acta** 1996 Apr 12; 1315(3):217–22
HMG–CoA reductase inhibitor affects blood pressure and vascular reactivity. Li N, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S316–7
Effects of pravastatin on lipid levels, in vitro oxidizability of non–HDL lipoproteins and microalbuminuria in IDDM patients. Zhang A, et al. **Diabetes Res Clin Pract** 1995 Sep; 29(3):189–94
Does the HMG–CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile? Smit JW, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):197–200
Potential risk of myopathy by HMG–CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. Pierno S, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1490–6
The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3–hydroxy–3–methylglutaryl coenzyme A inhibitor, between once– and twice–daily treatment regimens in beagle dogs and rabbits. Fujioka T, et al. **Jpn J Pharmacol** 1996 Apr;70(4):329–35
Inhibition of cholesterol synthesis and hepatic 3–hydroxy–3–methylglutaryl—CoA reductase in rats by simvastatin and pravastatin. Del Puppo M, et al. **Lipids** 1995 Nov;30(11):1057–61
Tissue–selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Koga T, et al. **Lipids** 1995 Aug;30(8):775–9
Effects of long–term treatment with low–dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Tazuma S, et al. **Metabolism** 1995 Nov;44(11):1410–2
Influence of cholesterol–lowering on plasma membrane lipids and function. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):123–36
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—a combined analysis of three large–scale randomized trials: Long–term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). **Am J Cardiol** 1995 Nov 1;76(12):899–905
Cost–effectiveness of pravastatin in secondary prevention of coronary artery disease. Ashraf T, et al. **Am J Cardiol** 1996 Aug 15;78(4):409–14
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC–II). Byington RP, et al. **Am J Cardiol** 1995 Sep 28;76(9):54C–59C
Fluvastatin versus pravastatin [letter] Chilton R. **Am J Cardiol** 1996 Jul 1;78(1):127
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. de Groot E, et al. **Am J Cardiol** 1995 Sep 28;76(9):40C–46C
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Furberg CD, et al. **Am J Cardiol** 1995 Sep 28; 76(9):60C–63C
The efficacy and safety of pravastatin in patients aged 60 to 85 years with low–density lipoprotein cholesterol > 160 mg/dl. Glasser SP, et al. **Am J Cardiol** 1996 Jan 1; 77(1):83–5
The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Salonen R, et al. **Am J Cardiol** 1995 Sep 28;76(9):34C–39C
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Shepherd J. **Am J Cardiol** 1995 Sep 28;76(9):113C–117C
Prospective meta–analysis of cholesterol–lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. Simes RJ. **Am J Cardiol** 1995 Sep 28;76(9):122C–126C
Management of the Long–Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Tonkin AM. **Am J Cardiol** 1995 Sep 28;76(9):107C–112C
Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. Weir MR, et al. **Am J Cardiol** 1996 Mar 1;77(7):475–9
The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Chan P, et al. **Am J Hypertens** 1995 Nov;8(11):1099–104
Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Raskin P, et al. **Am J Med** 1995 Oct; 99(4):362–9
The influence of angiographic endpoints on the outcome of lipid intervention studies. A proposal for standardization. REGRESS study group. Jukema JW, et al. **Angiology** 1996 Jul;47(7):633–42
Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Shiomi M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1938–44
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol–lowering therapies in familial hypercholesterolemia. Tomochika Y, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):955–62
Therapy with HMG CoA reductase inhibitors: characteristics of the long–term permanence of hypocholesterolemic activity. Pazzucconi F, et al. **Atherosclerosis** 1995 Oct; 117(2):189–98
Clinical significance of pravastatin study results [letter] Diosy A. **Can Med Assoc J** 1996 Aug 15;155(4):369–70
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Byington RP, et al. **Circulation** 1995 Nov 1;92(9):2419–25
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Lacoste L, et al. **Circulation** 1995 Dec 1; 92(11):3172–7
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. Pitt B, et al.

J Am Coll Cardiol 1995 Nov 1;26(5):1133–9

Effectiveness and safety of low–dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. Chan P, et al. **J Clin Pharmacol** 1996 May;36(5):422–7

Cholesterol–lowering agent in men without CHD. Millard P, et al. **J Fam Pract** 1996 Mar;42(3):223–4

Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. Lijnen P, et al. **J Hum Hypertens** 1995 Jul;9(7):557–64

Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study. Lindholm LH, et al. **J Intern Med** 1996 Jul;240(1):13–22

Chemoprevention by pravastatin, a 3–hydroxy–3–methylglutaryl–coenzyme A reductase inhibitor, of N–methyl–N–nitrosourea–induced colon carcinogenesis in F344 rats. Narisawa T, et al. **Jpn J Cancer Res** 1996 Aug;87(8):798–804

Statins and coronary heart disease [see comments] Fey R, et al. **Lancet** 1996 May 18;347(9012):1389–90. Comment in: Lancet 1996 Jul 6;348(9019):57.

Statins and coronary heart disease [letter; comment] Grimes DS. **Lancet** 1996 Jul 6;348(9019):57. Comment on: Lancet 1995 Nov 25;346(8987):1378–9. Comment on: Lancet 1996 May 18;347(9012):1389–90.

Statins prevent coronary heart disease [see comments] Oliver MF. **Lancet** 1995 Nov 25;346(8987):1378–9. Comment in: Lancet 1996 Jul 6;348(9019):57.

Drugs in cardiac transplantation [letter; comment] Ballantyne CM. **N Engl J Med** 1996 Feb 8;334(6):400–1; discussion 401–2. Comment on: N Engl J Med 1995 Sep 7;333(10):621–7. Comment on: N Engl J Med 1995 Sep 7;333(10):628–33.

Prevention of coronary heart disease with pravastatin [letter; comment] Davis DR. **N Engl J Med** 1996 May 16; 334(20):1334; discussion 1335. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7. Comment on: N Engl J Med 1995 Nov 16;333(20):1350–1.

Lowering cholesterol with drugs and diet [editorial; comment] [see comments] Pedersen TR. **N Engl J Med** 1995 Nov 16;333(20):1350–1. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7. Comment on: N Engl J Med 1995 Nov 16;333(20):1308–12. Comment in: N Engl J Med 1996 May 16;334(20):1334; discussion 1335.

Prevention of coronary heart disease with pravastatin [letter; comment] Rogers S. **N Engl J Med** 1996 May 16; 334(20):1333; discussion 1334–5. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7.

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. Sacks FM, et al. N **Engl J Med** 1996 Oct 3;335(14):1001–9

Prevention of coronary heart disease with pravastatin [letter; comment] Samani NJ, et al. **N Engl J Med** 1996 May 16; 334(20):1333–4; discussion 1334–5. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments] Shepherd J, et al. **N Engl J Med** 1995 Nov 16;333(20):1301–7. Comment in: N Engl J Med 1995 Nov 16;333(20):1350–1. Comment in: N Engl J Med 1996 May 16;334(20):1333; discussion 1334–5. Comment in: N Engl J Med 1996 May 16;334(20):1333–4; discussion 1334–5. Comment in: N Engl J Med 1996 May 16;334(20):1334; discussion 1334–5.

Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia. Morris R, et al. **N Z Med J** 1996 Aug 23;109(1028):319–22

Short–term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Knipscheer HC, et al. **Pediatr Res** 1996 May;39(5):867–71

Pravastatin improves outcome for heart transplant recipients [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C113–4

Islet protective effect of pravastatin from nonspecific inflammation in mouse pancreatic islet isografts. Arita S, et al. **Transplant Proc** 1996 Apr;28(2):924

The effect of pravastatin on acute rejection after kidney transplantation—a pilot study. Katznelson S, et al. **Transplantation** 1996 May 27;61(10):1469–74

[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program] Byington RP, et al. **Fortschr Med** 1996 Mar 20;114(8):91–8 (Eng. Abstr.) **(Ger)**

[Victory in primary prevention—or? Can we afford to translate results from the West–of–Scotland Study into general practice?] Klose G. **Fortschr Med** 1996 Jun 20; 114(17):231–2 **(Ger)**

[Prevention of coronary disease using pravastatin in men with hyperlipidemia (editorial)] Evéquoz D. **Schweiz Rundsch Med Prax** 1996 Aug 20;85(34):989–90 **(Ger)**

[Comparison of pravastatin and diet in the treatment of hypercholesterolemia] Palazzuoli V, et al. **Clin Ter** 1995 Oct;146(10):587–93 (Eng. Abstr.) **(Ita)**

[Statin therapy of individuals with high risk for coronary disease] Holme I. **Tidsskr Nor Laegeforen** 1996 May 10; 116(12):1479–81 (Eng. Abstr.) **(Nor)**

[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels] Santos RD, et al. **Arq Bras Cardiol** 1995 Aug;65(2):181–3 (Eng. Abstr.) **(Por)**

[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post–transplantation hyperlipemia (letter; comment)] Martínez–Castelao A. **Med Clin (Barc)** 1995 Nov 25;105(18):719. Comment on: Med Clin (Barc) 1994 Feb 5;102(4):139–41. **(Spa)**

[Limitation of atherosclerosis in coronary arteries with pravastatin (PLAC I)] Mancini GB. **Rev Esp Cardiol** 1995; 48 Suppl 2:11–3 (Eng. Abstr.) **(Spa)**

[A new study on hypercholesterolemia. Statin is effective against heart disease] Olsson AG. **Lakartidningen** 1996 May 29;93(22):2131–3 **(Swe)**

TOXICITY

Differential sensitivity of C2–C12 striated muscle cells to lovastatin and pravastatin. Gadbut AP, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2397–402

PRAWNS see **SHRIMP**

PRAYER HEALING see **MENTAL HEALING**

PRAYING MANTIS see **ORTHOPTERA**

PRAZIQUANTEL

ADMINISTRATION & DOSAGE

Effects of free and liposomized praziquantel on worm burden and antibody response in mice infected with Mesocestoides corti tetrathyridia. Hrčkova G, et al. **J Helminthol** 1995 Sep;69(3):213–21

Single–day praziquantel therapy for neurocysticercosis [letter] Corona T, et al. **N Engl J Med** 1996 Jan 11; 334(2):125

ANALOGS & DERIVATIVES

[The procedure for the wide use of praziquantel in a complex of measures to control opisthorchiasis. 2. The tolerance and efficacy of Russian–made azinox in mass treatment in foci] Zavoĭkin VD, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):32–4 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Risk identification using structural concepts: the potential carcinogenicity of praziquantel. Rosenkranz HS, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):152–61

HISTORY

[Original Mexican contributions to medicine. Praziquantel and neurocysticercosis. An honorable and transcendent Mexican priority] Quijano–Pitman F. **Gac Med Mex** 1995 Mar–Apr;131(2):241–2 **(Spa)**

PHARMACOKINETICS

Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone. Na–Bangchang K, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):120–3

PHARMACOLOGY

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Ismail M, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):214–8

Effect of praziquantel on serum glucose and insulin levels in normal and hyperglycemic rats. el–Kashef HA, et al. **Arzneimittelforschung** 1996 Apr;46(4):433–5

Immunopharmacological aspects of praziquantel. Nyazema NZ, et al. **Cent Afr J Med** 1995 Sep;41(9):284–8

Praziquantel treatment normalizes intestinal myoelectric alterations associated with Hymenolepis diminuta–infected rats. Dwinell MB, et al. **J Parasitol** 1995 Dec;81(6):979–84

Time course of the effect of praziquantel on Schistosoma mansoni attachment in vitro: comparison with its effects on worm length and motility. da Silva SP, et al. **Parasitol Res** 1995;81(7):543–8

Temporal differences in praziquantel– and oxamniquine–induced tegumental damage to adult Schistosoma mansoni: implications for drug–antibody synergy. Fallon PG, et al. **Parasitology** 1996 Jan;112 (Pt 1):47–58

THERAPEUTIC USE

Effective, single–dose treatment or porcine cysticercosis with oxfendazole. Gonzales AE, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):391–4

Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Philippines: a randomized trial of praziquantel versus placebo. McGarvey ST, et al. **Am J Trop Med Hyg** 1996 May;54(5):498–502

Immune response of mice infected with Schistosoma mansoni is modulated by antifibrotic treatment. Giboda M, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):415–24

A community–based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Sukwa TY. **Ann Trop Med Parasitol** 1993 Apr; 87(2):185–94

Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Carpio A, et al. **Arch Intern Med** 1995 Oct 9;155(18):1982–8

Effect of some parasitic infection on neurotransmitters in the brain of experimentally infected mice before and after treatment. Abdel Ghafar AE, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):497–508

Variations of direct fluorescent antibody test and serum bile acids levels following praziquantel treatment in Schistosoma mansoni experimentally infected mice. Khalil HM, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):583–97

Effect of anti–schistosomal treatment on schistosomal hepatic pathology: an experimental study in Syrian golden hamsters. Moustafa FE, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):517–24

Observations on possible immunity to reinfection among school children after schistosomiasis treatment. Nagaty IM, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):443–52

Schistosomiasis japonica in the Philippines: the long–term impact of population–based chemotherapy on infection, transmission, and morbidity. Olveda RM, et al. **J Infect Dis** 1996 Jul;174(1):163–72

Efficacy of praziquantel in natural populations of mallards infected with avian schistosomes. Reimink RL, et al. **J Parasitol** 1995 Dec;81(6):1027–9

Treatment of schistosomiasis: gathering stones together. Lambertucci JR. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr; 90(2):161–4

Case 4–1996: paralysis due to schistosomiasis [letter; comment] Cook J, et al. N **Engl J Med** 1996 Jun 6; 334(23):1548; discussion 1548–9. Comment on: N Engl J Med 1996 Feb 8;334(6):382–9.

Targeted chemotherapy for parasite infestations in rural black preschool children. Taylor M, et al. **S Afr Med J** 1995 Sep;85(9):870–4

Acute clonorchiasis. Ip M, et al. **Scand J Infect Dis** 1995; 27(6):645–6

Antibodies in serum of patients with clonorchiasis before and after treatment. Lin YL, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):114–9

Impact of population–based selective chemotherapy on prevalence and intensity of Schistosoma mansoni infections in the Nile Delta: Kafr El Sheikh. Barakat R, et al. **Trop Geogr Med** 1995;47(6):266–70

Changes in prevalence, intensity of infection and morbidity due to Schistosoma japonicum infection in a community following a single treatment with praziquantel. Zhao G, et al. **Trop Geogr Med** 1995;47(6):289–92

Effects of praziquantel on experimental Schistosoma bovis infection in goats. Johansen MV, et al. **Vet Parasitol** 1996 Mar;62(1–2):83–91

Efficacy of pyrantel embonate and praziquantel against the equine tapeworm Anoplocephaloides mamillana. Proudman CJ, et al. **Vet Rec** 1995 Jul 8;137(2):45–6

[Effect of praziquantel treatment on serum circulating soluble egg antigen–antibody complex (SEAIC) level in mice infected with Schistosoma japonicum] Shi G, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):189–92 (Eng. Abstr.) **(Chi)**

[Schistosomiasis at Marselisborg hospital 1981–1990] Tarp BD, et al. **Ugeskr Laeger** 1996 Feb 12;158(7):911–4 (Eng. Abstr.) **(Dan)**

[Efficacy and tolerance of praziquantel (Biltricide) in the treatment of distomatosis caused by Fasciola hepatica] Moreau JA, et al. **Gastroenterol Clin Biol** 1995 May; 19(5):514–9 (Eng. Abstr.) **(Fre)**

[The myeloperoxidase of the polymorphonuclear leukocytes as a marker of the stage of Opisthorchis invasion and as an indicator of the efficacy of chemotherapy] Iakovleva VV, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):34–7 (Eng. Abstr.) **(Rus)**

[Praziquantel in the treatment of human echinococcosis] Redžić B, et al. **Vojnosanit Pregl** 1995 Mar–Apr;52(2):155–9 (Eng. Abstr.) **(Scr)**

TOXICITY

Risk identification using structural concepts: the potential carcinogenicity of praziquantel. Rosenkranz HS, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):152–61

Lethal effect of oxamniquine and praziquantel on mice experimentally infected with Schistosoma mansoni. Tonelli SM, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul–Aug; 37(4):361–3

PRAZOSIN

ADMINISTRATION & DOSAGE

Influence of repeated prazosin administration on cardiovascular responses in rats and rabbits. Hui SC, et al. **Experientia** 1996 Jan 16;52(1):66–9

Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Albillos A, et al. **Gastroenterology** 1995 Oct; 109(4):1257–65

ADVERSE EFFECTS

Polyarthralgia associated with prazosin use [letter] Bell A, et al. **Ann Pharmacother** 1995 Sep;29(9):937

omega–Conotoxin GVIA and prazosin, but not felodipine,

cause postural hypotension in rabbits. Hawkes AL, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):711–6

ANALOGS & DERIVATIVES

Administration of terazosin capsules through feeding tubes [letter] Cheng L. **Am J Health Syst Pharm** 1995 Sep 15; 52(18):2031

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437–44

Blood pressure–lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul–Aug;5(7):413–6 (17 ref.)

A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats. Ramage AG, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):645–50

Alpha–1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Cavallini G. **Eur Urol** 1995;28(2):126–30

Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Kaplan SA, et al. **Eur Urol** 1995;28(3):223–8

Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood. McCarty R, et al. **Hypertension** 1996 May;27(5):1115–20

Actions of terazosin and its enantiomers at subtypes of alpha 1– and alpha 2–adrenoceptors in vitro. Hancock AA, et al. **J Recept Signal Transduct Res** 1995 Sep–Dec; 15(7–8):863–85

Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. Perkash I. **J Spinal Cord Med** 1995 Oct;18(4):236–9

Re: Randomized double–blind study comparing the efficacy of terazosin versus placebo in women with prostatism–like symptoms [letter; comment] Frankel G. **J Urol** 1996 Mar; 155(3):1039. Comment on: J Urol 1995 Jul;154(1):116–8.

Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. Witjes WP, et al. **J Urol** 1996 Apr;155(4):1117–23

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments] Lepor H, et al. **N Engl J Med** 1996 Aug 22;335(8):533–9 . Comment in: N Engl J Med 1996 Aug 22;335(8):586–7.

Treatment of benign prostatic hyperplasia [editorial; comment] Walsh PC. **N Engl J Med** 1996 Aug 22; 335(8):586–7. Comment on: N Engl J Med 1996 Aug 22;335(8):533–9.

A multicenter, randomized, double–blind, placebo–controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Elhilali MM, et al. **Urology** 1996 Mar;47(3):335–42

The cost–effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Hillman AL, et al. **Urology** 1996 Feb; 47(2):169–78

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia [see comments] Lowe FC, et al. **Urology** 1995 Oct;46(4):477–83. Comment in: Urology 1996 Jan;47(1):152.

The Hytrin Community Assessment Trial study: a one–year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Roehrborn CG, et al. **Urology** 1996 Feb;47(2):159–68

[Pharma–clinics. Drug of the month. Terazosine (Hytrin)] Scheen AJ. **Rev Med Liege** 1995 Dec;50(12):540–1 **(Fre)**

[A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia] Pushkar' Dlu, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):32–5 (Eng. Abstr.) **(Rus)**

BLOOD

High–performance liquid chromatography using electrochemical detection for the determination of prazosin in biological samples. Rathinavelu A, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):177–82

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

METABOLISM

Subtype selectivity of a new alpha 1–adrenoceptor antagonist, JTH–601: comparison with prazosin. Muramatsu I, et al. **Eur J Pharmacol** 1996 Apr 4; 300(1–2):155–7

Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1–adrenoceptor subtypes and in human prostate. Michel MC, et al. **J Auton Pharmacol** 1996 Feb;16(1):21–8

PHARMACOKINETICS

The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Andros E, et al. **Eur J Clin Pharmacol** 1996;50(1–2):41–6

Disposition of a new rate–controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Bourget P, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):233–41

PHARMACOLOGY

Urethral pressure response to smooth and skeletal muscle relaxants in anesthetized, adult male cats with naturally acquired urethral obstruction. Straeter–Knowlen IM, et al. **Am J Vet Res** 1995 Jul;56(7):919–23

Vascular alpha–adrenoceptors: from the gene to the human. Bylund DB, et al. **Can J Physiol Pharmacol** 1995 May; 73(5):533–43 (87 ref.)

Low concentrations of angiotensin II unmask vasoconstrictory alpha 2–adrenoceptors in isolated perfused kidneys of spontaneously hypertensive rats. Bohmann C, et al. **Cardiovasc Res** 1995 Dec;30(6):857–65

Effects of prazosin on rat, guinea pig and human cardiac tissues. Su MJ, et al. **Chin J Physiol** 1995;38(3):159–69

Effect of DC–015, a novel potent and selective alpha 1–adrenoceptor antagonist, comparison with prazosin on noradrenaline–induced platelet aggregation. Yen MH, et al. **Chin J Physiol** 1995;38(2):93–8

alpha 1–Adrenoceptors on rabbit aortic smooth muscle cells in culture and in experimental intimal thickening. Manderson JA, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):912–8

Alpha 1–adrenergic receptor antagonist blocks acute cocaine action on the compound action potential of the auditory nerve in the chinchilla. Shivapuja BG, et al. **Drug Alcohol Depend** 1995 Nov;40(1):43–8

The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Andros E, et al. **Eur J Clin Pharmacol** 1996;50(1–2):41–6

Effects of combined block of alpha 1–adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats. Riekkinen M, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):9–16

Prazosin–induced blockade of extraneuronal uptake facilitates dopaminergic modulation of muscle twitches in rat vas deferens. Elmallah AI, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):932–6

Alpha 1– and alpha 2–adrenoreceptor actions of phentolamine and prazosin on breathing movements in fetal sheep in utero. Giussani DA, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):249–55

Effects of alpha–adrenergic activation on the shift of electrolytes and fluid after hemorrhage in rats. Nagashima K. **Jpn J Physiol** 1995;45(3):381–95

Microwave–induced lethal heat stress: effects of phentolamine, prazosin and metoprolol. Jauchem JR, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):241–8

Studies on the role of 5–HT1A autoreceptors and alpha 1–adrenoceptors in the inhibition of 5–HT release—I. BMY7378 and prazosin. Hjorth S, et al. **Neuropharmacology** 1995 Jun;34(6):615–20

Inhibition by intrathecal prazosin but not yohimbine of fentanyl–induced muscular rigidity in the rat. Lui PW, et al. **Neurosci Lett** 1995 Dec 8;201(2):167–70

Role of alpha 1 and alpha 2–adrenoceptors of the lateral hypothalamic area on urinary excretion caused by centrally administered angiotensin II. Saad WA, et al. **Neurosci Lett** 1995 Jul 21;194(3):169–72

Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat. Constantinou CE, et al. **Neurourol Urodyn** 1996;15(1):85–101

Effect of phenylephrine and prazosin on the somatostatinergic system in the rat frontoparietal cortex. López–Sañudo S, et al. **Peptides** 1995;16(8):1453–9

Prevention of cyclosporine–induced nephrotoxicity by prazosin hydrochloride, an alpha–1–adrenoreceptor blocker. Ishikawa A, et al. **Transplant Proc** 1996 Jun; 28(3):1360–1

THERAPEUTIC USE

Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. Dutkiewicz S. **Mater Med Pol** 1995 Jan–Mar; 27(1):15–7

[The effect of cilazapril and prazosin on insulin sensitivity in patients with essential hypertension] Cirić J, et al. **Med Pregl** 1995;48(9–10):326–8 (Eng. Abstr.) **(Scr)**

TOXICITY

Effects of endophyte–infected tall fescue, environmental temperature and prazosin injection on the rat. Larson BT, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 May;114(1):39–44

PRE–B–CELL LEUKEMIA see LEUKEMIA, PRE–B–CELL

PREALBUMIN

ANALYSIS

Maternal and neonatal plasma transthyretin (prealbumin) concentrations and birth weight of newborn infants. Jain SK, et al. **Biol Neonate** 1995;68(1):10–4

C reactive protein and prealbumin as markers of disease activity in shigellosis. Khan WA, et al. **Gut** 1995 Sep; 37(3):402–5

Amniotic fluid prealbumin as a potential marker of fetal abnormalities. Lolis D, et al. **Gynecol Obstet Invest** 1995; 40(4):231–5

Study of serum prealbumin and serum alpha fetoprotein in cases of fulminant hepatic failure. Jain SK, et al. **J Assoc Physicians India** 1995 Jul;43(7):462–3

[Orosomucoid prealbumin ratio in bronchopulmonary cancers] Charet JC, et al. **Ann Biol Clin (Paris)** 1995; 53(3):131–4 (Eng. Abstr.) **(Fre)**

[Prealbumin] Nakano E. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:186–8 (10 ref.) **(Jpn)**

BIOSYNTHESIS

Impaired synthesis of retinol–binding protein and transthyretin in rat liver with bile duct obstruction. Imamine T, et al. **Dig Dis Sci** 1996 May;41(5):1038–42

The human lacrimal gland synthesizes apolipoprotein D mRNA in addition to tear prealbumin mRNA, both species encoding members of the lipocalin superfamily. Holzfeind P, et al. **Exp Eye Res** 1995 Oct;61(4):495–500

Transthyretin expression in medulloblastomas and medulloblastoma cell lines. Albrecht S, et al. **Neuropathol Appl Neurobiol** 1995 Oct;21(5):399–409

CEREBROSPINAL FLUID

[Transthyretin and albumin in cerebrospinal fluid in patients with acute leukemias or lymphomas of high grade malignancy] Millo B, et al. **Acta Haematol Pol** 1996; 27(1):73–7 (Eng. Abstr.) **(Pol)**

CHEMISTRY

1H NMR studies of peptide fragments from the N–terminus of chicken and human transthyretin. Wilce JA, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1153–9

The acid–mediated denaturation pathway of transthyretin yields a conformational intermediate that can self–assemble into amyloid. Lai Z, et al. **Biochemistry** 1996 May 21; 35(20):6470–82

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL, et al. **Biochemistry** 1995 Oct 17;34(41):13527–36

The crystal structure of transthyretin from chicken. Sunde M, et al. **Eur J Biochem** 1996 Mar 1;236(2):491–9

Crystal structure of the transthyretin–retinoic–acid complex. Zanotti G, et al. **Eur J Biochem** 1995 Dec 1;234(2):563–9

Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Gustavsson A, et al. **Lab Invest** 1995 Nov;73(5):703–8

GENETICS

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1–2):31–40 (140 ref.)

Familial amyloid polyneuropathy associated with transthyretin Gly42 mutation: a quantitative light and electron microscopic study of the peripheral nervous system. Toyooka K, et al. **Acta Neuropathol (Berl)** 1995; 90(5):516–25

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351–4 (19 ref.). Comment on: Am J Pathol 1996 Feb;148(2):361–6.

Meningocerebrovascular amyloidosis associated with a novel transthyretin mis–sense mutation at codon 18 (TTRD 18G) [see comments] Vidal R, et al. **Am J Pathol** 1996 Feb; 148(2):361–6. Comment in: Am J Pathol 1996 Feb;148(2):351–4.

Decreased affinity of apolipoprotein AII to high–density lipoprotein in patients with transthyretin–related amyloidosis (Met30, Gln89, Pro36, and Thr34). Nakamura M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):316–21

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL, et al. **Biochemistry** 1995 Oct 17;34(41):13527–36

Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings. Ferlini A, et al. **Clin Genet** 1996 Jan;49(1):10–4

Wallaby transthyretin. Brack CM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):523–9

Revised transthyretin Ile 122 allele frequency in African–Americans. Jacobson DR, et al. **Hum Genet** 1996 Aug;98(2):236–8

A new family with hyperthyroxinemia caused by transthyretin Val109 misdiagnosed as thyrotoxicosis and resistance to thyroid hormone—a clinical research center study. Refetoff S, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3335–40

Amyloid fibril composition and transthyretin gene structure

in senile systemic amyloidosis. Gustavsson A, et al. **Lab Invest** 1995 Nov;73(5):703–8

What is genetic anticipation? [letter] Ando Y, et al. **Lancet** 1996 Aug 3;348(9023):331–2

A new isoleucine substitution of Val–20 in transthyretin tetramers selectively impairs dimer–dimer contacts and causes systemic amyloidosis. Jenne DE, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6302–7

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov–Dec; 40(3):197–206 (123 ref.)

IMMUNOLOGY

[Autoimmune asthenospermia induced by an epididymal protein, ovine prealbumin (oPES)] Fournier–Delpech S, et al. **Reprod Nutr Dev** 1995;35(4):427–36 (Eng. Abstr.) **(Fre)**

METABOLISM

Decreased affinity of apolipoprotein AII to high–density lipoprotein in patients with transthyretin–related amyloidosis (Met30, Gln89, Pro36, and Thr34). Nakamura M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):316–21

Retinoid binding to retinol–binding protein and the interference with the interaction with transthyretin. Malpeli G, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):48–54

Prealbumin, retinol–binding protein, and total salivary IgA in children with AIDS. Slobodianik NH, et al. **Clin Chem** 1996 Mar;42(3):471–2

Retinol binding protein and transthyretin are secreted as a complex formed in the endoplasmic reticulum in HepG2 human hepatocarcinoma cells. Bellovino D, et al. **Exp Cell Res** 1996 Jan 10;222(1):77–83

Thyroid homeostasis and retinol circulating complex relationships in a severe iodine–deficient area of Senegal. Centanni M, et al. **J Endocrinol Invest** 1995 Sep; 18(8):608–12

Oral supplementation with branched–chain amino acids improves transthyretin turnover in rats with carbon tetrachloride–induced liver cirrhosis. Usui T, et al. **J Nutr** 1996 May;126(5):1412–20

Influence of nonesterified fatty acids and lysolecithins on thyroxine binding to thyroxine–binding globulin and transthyretin. Lim CF, et al. **Thyroid** 1995 Aug;5(4):319–24

Binding of a 3,3', 4,4'–tetrachlorobiphenyl (CB–77) metabolite to fetal transthyretin and effects on fetal thyroid hormone levels in mice. Darnerud PO, et al. **Toxicology** 1996 Jan 8;106(1–3):105–14

PHARMACOLOGY

Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta–amyloid peptide in cultured vascular smooth muscle cells. Mazur–Kolecka B, et al. **Brain Res** 1995 Nov 6; 698(1–2):217–22

PHYSIOLOGY

'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Bonifácio MJ, et al. **Biochim Biophys Acta** 1996 May 24; 1316(1):35–42

Hormone delivery systems to the brain–transthyretin. Schreiber G, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(2):75–80 (51 ref.)

ULTRASTRUCTURE

Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. Serpell LC, et al. **J Mol Biol** 1995 Nov 24;254(2):113–8

PREANESTHETIC MEDICATION

Patient–controlled premedication by i.v. midazolam for ambulatory surgery. Bernard JM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):331–7

Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Tarkkila P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):983–6

Naproxen premedication for laparoscopic sterilization [letter] Limb RI, et al. **Anaesth Intensive Care** 1995 Jun;23(3):405

The efficacy and optimum time of administration of ranitidine in the prevention of the acid aspiration syndrome. Escolano F, et al. **Anaesthesia** 1996 Feb;51(2):182–4

Erythromycin as a prokinetic agent in children [letter] Hall JE, et al. **Anaesthesia** 1996 May;51(5):503–4

The effect of pre–incisional infiltration with lignocaine on postoperative pain after molar teeth extraction under general anaesthesia. Tordoff SG, et al. **Anaesthesia** 1996 Jun;51(6):585–7

Oral clonidine premedication reduces postoperative pain in children. Mikawa K, et al. **Anesth Analg** 1996 Feb; 82(2):225–30

Preincisional infiltration with bupivacaine in tonsillectomy. Johansen M, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):261–3

Rocuronium pretreatment reduces suxamethonium–induced myalgia: comparison with vecuronium. Findlay GP, et al. **Br J Anaesth** 1996 Apr;76(4):526–9

Sublingual triazolam versus peroral diazepam as a premedication for general anaesthesia. Penttilä HJ, et al. **Can J Anaesth** 1995 Oct;42(10):862–8

Safety and effectiveness of an oral premedication regimen before cardiac surgery. Böttiger BW, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):341–4

A placebo–controlled trial using intravenous atropine as an adjunct to conscious sedation in pediatric esophagogastroduodenoscopy. Hofley MA, et al. **Gastrointest Endosc** 1995 Nov;42(5):457–60

Effect of oral clonidine premedication on anesthetic requirement, hormonal response, hemodynamics, and recovery in coronary artery bypass graft surgery patients. Howie MB, et al. **J Clin Anesth** 1996 Jun;8(4):263–72

Use of analgesics during propofol sedation: a comparison of ketorolac, dezocine, and fentanyl. Ramirez–Ruiz M, et al. **J Clin Anesth** 1995 Sep;7(6):481–5

Evaluation of oral midazolam as pre–medication in day care surgery in adult Pakistani patients. Ahmed N, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):239–41

Use of oral premedicants in pediatric dental population. Krost BG, et al. **N Y State Dent J** 1996 Jan;62(1):40–3 (8 ref.)

Oral transmucosal fentanyl citrate for preanaesthetic medication of paediatric cardiac surgery patients. Friesen RH, et al. **Paediatr Anaesth** 1995;5(1):29–33

Ketamine plus midazolam, a most effective paediatric oral premedicant. Warner DL, et al. **Paediatr Anaesth** 1995; 5(5):293–5

Can pre–emptive interpleural block reduce perioperative anesthetic and analgesic requirements? Abdulatif M, et al. **Reg Anesth** 1995 Jul–Aug;20(4):296–302

Preoperative spinal bupivacaine does not reduce postoperative morphine requirement in women undergoing total abdominal hysterectomy. Dakin MJ, et al. **Reg Anesth** 1996 Mar–Apr;21(2):99–102

Hydroxyzine premedication—does it provide better anxiolysis than a placebo? Boon JH, et al. **S Afr Med J** 1996 Jun;86(6):661–4

Transfusion medicine issues in the practice of anesthesiology [letter; comment] Alparin JB. **Transfus Med Rev** 1995 Oct; 9(4):339. Comment on: Transfus Med Rev 1995 Jan;9(1):60–78.

[Postoperative vomiting after pars plana vitrectomy] Heinke W, et al. **Anaesthesiol Reanim** 1996;21(2):47–50 (Eng. Abstr.) **(Ger)**

[Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety] Mielke L, et al. **Anaesthesiol Reanim** 1995; 20(6):144–8 (Eng. Abstr.) **(Ger)**

[Anxiolysis, sedation, and stress reduction following oral premedication with midazolam in adults. A comparison with dipotassium clorazepate and placebo] Berendes E, et al. **Anaesthesist** 1996 Jun;45(6):506–11 (Eng. Abstr.) **(Ger)**

[Premedication of coronary risk patients—results of a survey] Böttiger BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):148–54 (Eng. Abstr.) **(Ger)**

[Profile of the effect of succinylcholine after pre–curarization with atracurium, vecuronium or pancuronium] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):304–8 (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz–Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Effect of premedication and barbiturate hypnotics on motor evoked potentials induced by magnetic cortex stimulation] Nadstawek J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):361–5 (Eng. Abstr.) **(Ger)**

[Conventional and new measures for prevention of aspiration] Roewer N. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):257–60 **(Ger)**

[Differential administration of non–opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient–controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr;31(3):143–7 (Eng. Abstr.) **(Ger)**

[0.15 mg clonidine as oral premedication in retrobulbar anesthesia] Weindler J, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):410–3 (Eng. Abstr.) **(Ger)**

[Premedication in children: a comparison of oral midazolam and rectal bromazepam] Kambara N, et al. **Masui** 1995 Dec; 44(12):1707–11 (Eng. Abstr.) **(Jpn)**

[The use of low dose midazolam for the management of spinal anesthesia] Nagahama H, et al. **Masui** 1996 May;45(5):593–8 (Eng. Abstr.) **(Jpn)**

[The effects of preoperative drinking and H2 blocker on gastric acid secretion] Suzuki A, et al. **Masui** 1996 Apr; 45(4):445–8 (Eng. Abstr.) **(Jpn)**

[A trial of the use of the nondepolarizing muscle relaxant isocyuronium bromide in anesthesiology] Rudenko MI, et al. **Voen Med Zh** 1995 Nov;(11):33–5 **(Rus)**

[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery] Bustos–Molina F, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):138–41 (Eng. Abstr.) **(Spa)**

[Comparative study of clonidine and lidocaine on the attenuation of the intraocular pressure increase associated with laryngoscopy and endotracheal intubation] Núñez M, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):312–5 (Eng. Abstr.) **(Spa)**

[Reduction of the need for isoflurane and of postoperative pain with preanesthetic intrathecal morphine (letter; comment)] Sabaté A. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):349–51. Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):41–6. **(Spa)**

METHODS

Comparison of nicardipine, diltiazem and verapamil for controlling the cardiovascular responses to tracheal intubation. Mikawa K, et al. **Br J Anaesth** 1996 Feb; 76(2):221–6

Comparison of rectal to intranasal administration of midazolam for premedication of children. Khazin V, et al. **Mil Med** 1995 Nov;160(11):579–81

[Plasma catecholamine level and clinical parameters—quality criteria for premedication in childhood] Burkhardt U, et al. **Anaesthesiol Reanim** 1995;20(4):88–96 (Eng. Abstr.) **(Ger)**

[Jet injection, a new method for the induction of anesthesia in children] Zsigmond KE, et al. **Orv Hetil** 1995 Nov 5; 136(45):2459–62 (Eng. Abstr.) **(Hun)**

VETERINARY

Premedication of fragile dogs and cats. Brock N. **Can Vet J** 1995 Aug;36(8):474–5

Evaluation of five common induction protocols by comparison of hemodynamic responses to surgical manipulation in halothane–anesthetized horses. Wagner AE, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):252–7

Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1996 Feb;37(2):79–83

[Premedication in dogs with increased anesthesia risk] Hellebrekers LJ. **Tijdschr Diergeneeskd** 1996 Mar 15; 121(6):176–7 **(Dut)**

PREBETA–LIPOPROTEINS see LIPOPROTEINS, VLDL

PRECANCEROUS CONDITIONS

Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Riddell RH. **Am J Gastroenterol** 1996 May; 91(5):864–72 (69 ref.)

Prospectives for cutaneous malignant melanoma. Considerations of the precursor state and heritability. Clark WH, et al. **Br Med Bull** 1995 Jul;51(3):717–46 (104 ref.)

Barrett's oesophagus and colorectal carcinoma [letter; comment] Morgan G. **Lancet** 1996 Jan 6;347(8993):66–7. Comment on: Lancet 1995 Nov 25;346(8987):1391–4.

Oral lichen planus and its association with squamous cell carcinoma: an update on pathogenesis and treatment implications. Duffey DC, et al. **Laryngoscope** 1996 Mar; 106(3 Pt 1):357–62

Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Lynch HT, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):406–10 (24 ref.)

Premalignant changes in ulcerative colitis. Nixon JB, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):386–93 (52 ref.)

The woman at high risk for breast cancer. Importance of hyperplasia. Page DL. **Surg Clin North Am** 1996 Apr; 76(2):221–30 (43 ref.)

[Precancerous and cancerous involvement of the uterine cervix. Results of a survey conducted by the "Genital Cancers" group of Ile–de–France, May 1990–May 1992, based on 8,805 biopsies] Sastre–Garau X, et al. **Bull Cancer (Paris)** 1996 May;83(5):400–6 (Eng. Abstr.) **(Fre)**

[The study of the evolution of laryngeal premalignant lesions] Rodríguez García L, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):129–33 (Eng. Abstr.) **(Spa)**

BLOOD

[Relationship between serum micronutrients and precancerous gastric lesions] Zhang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul; 29(4):198–201 (Eng. Abstr.) **(Chi)**

BLOOD SUPPLY

A quantitative investigation of immunocytochemically stained blood vessels in normal, benign, premalignant and malignant human oral cheek epithelium. Jin Y, et al. **Virchows Arch** 1995;427(2):145–51

CHEMICALLY INDUCED

Changes in tRNA pattern in ethionine–induced rat putative preneoplastic hepatocyte nodules. Kanduc D, et al. **Biochem Mol Biol Int** 1996 May;38(6):1191–7

Distribution of lymphoid nodules, aberrant crypt foci and tumours in the colon of carcinogen–treated rats. Cameron IL, et al. **Br J Cancer** 1996 Apr;73(7):893–8

Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserine. Visser CJ, et al. **Br J Cancer** 1996 Jul;74(1):92–8

Refined carbohydrate enhancement of aberrant crypt foci (ACF) in rat colon induced by the food–borne carcinogen 2–amino–3–methyl–imidazo[4,5–f]quinoline (IQ).

Kristiansen E, et al. **Cancer Lett** 1996 Aug 2;105(2):147–51

Acetylator genotype (NAT2)–dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2'–dimethyl–4–aminobiphenyl. Feng Y, et al. **Cancer Res** 1996 Feb 1;56(3):527–31

Effect of amount and types of dietary fat on intestinal bacterial 7 alpha–dehydroxylase and phosphatidylinositol–specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Reddy BS, et al. **Cancer Res** 1996 May 15;56(10):2314–20

Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Kolaja KL, et al. **Carcinogenesis** 1996 May;17(5):947–54

DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. Ochiai M, et al. **Carcinogenesis** 1996 Jan;17(1):95–8

Effect of acetylator genotype on 3,2'–dimethyl–4–aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Paulsen JE, et al. **Carcinogenesis** 1996 Mar;17(3):459–65

Unexpected antagonistic action of 3,2'–dimethyl–4–aminobiphenyl on aberrant crypt induction by 1,2–dimethylhydrazine or azoxymethane in rat colon. Steffensen IL, et al. **Carcinogenesis** 1995 Dec; 16(12):2981–8

Enhancement of esophageal carcinogenesis in male F344 rats by dietary phenylhexyl isothiocyanate. Stoner GD, et al. **Carcinogenesis** 1995 Oct;16(10):2473–6

Preliminary observations on possible premalignant changes in bone marrow adjacent to worn total hip arthroplasty implants. Case CP, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S269–79

Promotion of hepatic preneoplastic lesions in male B6C3F1 mice by unleaded gasoline. Standeven AM, et al. **Environ Health Perspect** 1995 Jul–Aug;103(7–8):696–700

Suppressing effects of 6–(2,5–dichlorophenyl)–2,4–diamino–1,3,5–triazine and related synthetic compounds on azoxymethane–induced aberrant crypt foci in rat colon. Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):549–54

Dose–dependent induction of 8–hydroxyguanine and preneoplastic foci in rat liver by a food–derived carcinogen, 2–amino–3,8–dimethylimidazo[4,5–f]quinoxaline, at low dose levels. Kato T, et al. **Jpn J Cancer Res** 1996 Feb; 87(2):127–33

Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N–ethyl–N–hydroxyethylnitrosamine. Yaono M, et al. **Jpn J Cancer Res** 1995 Aug;86(8):718–23

Expression of c–myc in altered hepatic foci induced in rats by various single doses of diethylnitrosamine and promotion by 0.05% phenobarbital. Deguchi T, et al. **Mol Carcinog** 1995 Nov;14(3):152–9

Lack of carcinogenicity of daminozide, alone or in combination with its contaminant 1,1–dimethylhydrazine, in a medium–term bioassay. Cabral R, et al. **Teratog Carcinog Mutagen** 1995–96;15(6):307–12

Chronic feeding study of deoxynivalenol in B6C3F1 male and female mice. Iverson F, et al. **Teratog Carcinog Mutagen** 1995–96;15(6):283–306

Clofibrate–induced neoplastic development in the rat liver is associated with decreased connexin 32 expression but not with a co–ordinated shift in expression of marker enzymes. Tsuda H, et al. **Toxicol Lett** 1995 Dec; 82–83:693–9

Rapid induction of preneoplastic liver foci in embryonal turkey liver by diethylnitrosamine. Enzmann H, et al. **Toxicol Pathol** 1995 Sep–Oct;23(5):560–9

Progressive effects of malachite green at varying concentrations on the development of N–nitrosodiethylamine induced hepatic preneoplastic lesions in rats. Rao KV, et al. **Tumori** 1996 May–Jun; 82(3):280–6

Renal cysts and associated renal tumours in male ddY mice injected with ferric nitrilotriacetate. Kondo A, et al. **Virchows Arch** 1995;427(1):91–9

CHEMISTRY

Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Steeg PS, et al. **Am J Pathol** 1996 Sep;149(3):733–8 (49 ref.)

Prognostic significance of high expression of proliferating cell nuclear antigen in patients with intestinal metaplasia. Blasco–Olaetxea E, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):963–7

Topographical immunohistochemical expression of bcl–2 protein in human liver lesions. Skopelitou A, et al. **Anticancer Res** 1996 Mar–Apr;16(2):975–8

Non–homogeneous marking of distal colonic mucosa using Dolichos biflorus lectin. Rosenberg DW. **Cancer Lett** 1995 Nov 27;98(1):33–7

Dual phenotypic expression of hepatocytes and bile ductular markers in developing and preneoplastic rat liver. Tee LB, et al. **Carcinogenesis** 1996 Feb;17(2):251–9

p53 in malignant and benign liver lesions. Schaff Z, et al. **Eur J Cancer** 1995 Oct;31A(11):1847–50

Multistep progression from an oestrogen–dependent growth towards an autonomous growth in breast carcinogenesis. Schmitt FC. **Eur J Cancer** 1995 Nov;31A(12):2049–52

p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Hutson R, et al. **Histopathology** 1995 Oct;27(4):367–71

Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. Seregard S. **J Clin Pathol** 1996 Apr;49(4):338–42

Expression of EGF, EGFR and PCNA in laryngeal lesions. Wen QH, et al. **J Laryngol Otol** 1995 Jul;109(7):630–6

Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. De Vita S, et al. **J Rheumatol** 1995 Sep;22(9):1674–80

Changes in the expression of matrix proteases and of the transcription factor c–Ets–1 during progression of precancerous bronchial lesions. Bolon I, et al. **Lab Invest** 1996 Jul;75(1):1–13

[Biological markers of precancer of the large intestine] Zagrebin VM. **Arkh Patol** 1995 Jul–Aug;57(4):89–92 (50 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Functional trauma of the vocal folds: classification and management strategies. Milutinović Z, et al. **Folia Phoniatr Logop** 1996;48(2):78–85

[Modern approach to classification of precancerous conditions and vulvar dystrophy] Djurdjević S, et al. **Med Pregl** 1995;48(11–12):399–404 (Eng. Abstr.) **(Scr)**

COMPLICATIONS

Mixed cryoglobulinemia as a possible preneoplastic disorder. La Civita L, et al. **Arthritis Rheum** 1995 Dec; 38(12):1859–60

Natural history of low–grade squamous intraepithelial lesions in women infected with human immunodeficiency virus [letter] Belafsky P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):511–2

CONGENITAL

Point mutations of the c–Ki–ras gene in carcinoma and atypical epithelium associated with congenital biliary dilation. Tomono H, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1211–4

DIAGNOSIS

False positive cervical smears: a cytometric and histological study. Nenning H, et al. **Anal Cell Pathol** 1995 Jul;9(1):61–8

The use of artificial intelligence to identify people at risk of oral cancer and precancer [see comments] Speight PM, et al. **Br Dent J** 1995 Nov 25;179(10):382–7. Comment in: Br Dent J 1996 Apr 20;180(8):284.

Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Deligdisch L, et al. **Cancer** 1995 Sep 15;76(6):1027–34

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179–82 (17 ref.)

A non–invasive test for the pre–cancerous breast. Simpson HW, et al. **Eur J Cancer** 1995 Oct;31A(11):1768–72

Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Filella X, et al. **Int J Cancer** 1995 Dec 11;63(6):780–4

Detection of premalignant oral lesions: a 10 year retrospective study in Alberta. Peters E, et al. **J Can Dent Assoc** 1995 Sep;61(9):775–8

Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions. Steinbeck ZRG, et al. **Melanoma Res** 1996 Feb;6(1):37–43

Cancer surveillance colonoscopy in ulcerative colitis: sense or nonsense? Schapiro M. **Schweiz Med Wochenschr Suppl** 1996;79:5S–8S

[Lugol's solution in endoscopic diagnosis of early esophageal cancer] Wang G, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jul;75(7):417–8, 446 (Eng. Abstr.) **(Chi)**

[Space–occupying lesions of the lacrimal gland in CT and MRI exemplified by 4 cases] Lemke AJ, et al. **Aktuelle Radiol** 1995 Nov;5(6):363–6 (Eng. Abstr.) **(Ger)**

[Differential diagnosis of focal liver lesions with MRI using the superparamagnetic contrast medium endorem] Vogl TJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S258–66 (Eng. Abstr.) **(Ger)**

[Role of microcolpohysteroscopy at an ambulatory center of level II preventive gynecologic oncology in the study of pre–neoplastic lesions of the uterine cervix] Vigada G, et al. **Minerva Ginecol** 1995 May;47(5):183–7 (Eng. Abstr.) **(Ita)**

[Iridological indices in cancerous and precancerous stomach diseases] Potebnia GP, et al. **Klin Khir** 1995;(9–10):29–31 **(Rus)**

[Iridological manifestations of tumorous and pretumorous diseases of the breast] Potebnia GP, et al. **Klin Khir** 1996; (1):34–6 **(Rus)**

[The differential possibilities of the laser correlational spectroscopic method in the diagnosis of different pathological processes encountered among the population of the Urals radiation trace] Akleev AV, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):829–35 (Eng. Abstr.) **(Rus)**

[A computer program for the rapid luminescent cytological diagnosis of precancer and cancer of the lip and mouth mucosa] Filiurin MD. **Stomatologiia (Mosk)** 1995;74(2):50–2 (Eng. Abstr.) **(Rus)**

DIET THERAPY

Inability of low– or high–fat diet to modulate late stages of colon carcinogenesis in Sprague–Dawley rats. Bird RP, et al. **Cancer Res** 1996 Jul 1;56(13):2896–9

DRUG THERAPY

Photodynamic therapy and lip vermilion dysplasia: a pilot study. Gregory GF, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):346–7

The role of photodynamic therapy in the management of oral cancer and precancer. Hopper C. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):71–2 (7 ref.)

Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)

Transforming growth factor beta 1–induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Müllauer L, et al. **Hepatology** 1996 Apr;23(4):840–7

Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188–94 (22 ref.)

NSAID chemoprevention of colorectal adenomas and oesophageal metaplasia [letter; comment] Morgan G. **J R Soc Med** 1996 Apr;89(4):237. Comment on: J R Soc Med 1995 Nov;88(11):625–8.

[Photodynamic therapy of small adenocarcinomas with methylene blue] Orth K, et al. **Chirurg** 1995 Dec; 66(12):1254–7 (Eng. Abstr.) **(Ger)**

[Photodynamic therapy of dysplasia and early cancer of the esophagus] Gossner L, et al. **Leber Magen Darm** 1996 May; 26(3):132, 135–7 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern. Dombrowski F, et al. **Am J Pathol** 1996 Apr;148(4):1249–56

Studies of the activities of lysosomal enzymes in serum and buccal pouch tissue of hamsters during 7,12–dimethylbenz[a]anthracene–induced carcinogenesis. Balasubramanian S, et al. **Cancer Lett** 1996 Mar 19; 101(1):9–14

Increased telomerase activity in mouse skin premalignant progression. Bednarek A, et al. **Cancer Res** 1995 Oct 15; 55(20):4566–9

Overexpression of int–5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Tekmal RR, et al. **Cancer Res** 1996 Jul 15;56(14):3180–5

The role of glutathione S–transferases in head and neck squamous cell carcinogenesis. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):349–54 (63 ref.)

Influence of proliferative stimulation on the activity of rat intestinal diamine oxidase. Schwelberger HG, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S66–7

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c–src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2–11

Effect of fish oil on the development of AOM–induced glutathione S–transferase placental form positive hepatocellular foci in male F344 rats. Sugie S, et al. **Nutr Cancer** 1995;24(2):187–95

[Enzymic spectrum of preneoplastic and neoplastic changes induced by 1,2–dimethylhydrazine in mouse kidneys] Ahn IS, et al. **Arkh Patol** 1995 Nov–Dec;57(6):52–7 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Gastric premalignancy and cancer screening in high–risk patients. Yoshida S, et al. **Am J Gastroenterol** 1996 May; 91(5):839–43 (24 ref.)

Forty years of repeated screening: the significance of carcinoma in situ. Morrison BJ, et al. **Br J Cancer** 1996 Sep;74(5):814–9

Physical activity, obesity, and risk of colorectal adenoma in women (United States). Giovannucci E, et al. **Cancer Causes Control** 1996 Mar;7(2):253–63

Prevalence of precancerous lesions of the stomach in Venezuela. Muñoz N, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):41–6

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

Gastrointestinal cancer: epidemiological data and premalignant lesions. Hertan HI, et al. **Gastroenterologist** 1995 Sep;3(3):199–219 (189 ref.)

Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241–3 (17 ref.)

Prevalence of skin neoplasms among the atomic bomb survivors. Yamada M, et al. **Radiat Res** 1996 Aug; 146(2):223–6

[Prevalence of Helicobacter pylori infection in stomach carcinoma] Hatz RA, et al. **Chirurg** 1996 Apr;67(4):403–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Lymphoma induced in mice chronically exposed to very strong low-frequency electromagnetic field. Fam WZ, et al. **Cancer Lett** 1996 Aug 2;105(2):257–69

Hormone dependent and independent mammary tumor development form N-methyl-N-nitrosourea-treated rat mammary epithelial cell xenografts in the nude mouse: multiple pathways and H-ras activation. Hwang SI, et al. **Cancer Lett** 1996 Mar 19;101(1):123–34

Inability of low- or high-fat diet to modulate late stages of colon carcinogenesis in Sprague-Dawley rats. Bird RP, et al. **Cancer Res** 1996 Jul 1;56(13):2896–9

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al.
Cold Spring Harb Symp Quant Biol 1994;59:577–83 (58 ref.)

Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Tytgat GN, et al.
Eur J Cancer 1995 Jul-Aug;31A(7–8):1174–7 (41 ref.)

Case-control study of oral dysplasia and risk habits among patients of a dental hospital. Kulasegaram R, et al.
Eur J Cancer B Oral Oncol 1995 Jul;31B(4):227–31

Intra-oral cancers in Scotland. Yewe-Dyer MR.
Health Bull (Edinb) 1995 Sep;53(5):311–3

Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940–7 (90 ref.)

Modifying influence of swine-serum-induced liver fibrosis on development of preneoplastic lesions in rat liver. Wada S, et al. **Jpn J Cancer Res** 1996 Mar;87(3):240–6

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185–92 (50 ref.)

Premalignant conditions of the small intestine. Ryan JC.
Semin Gastrointest Dis 1996 Apr;7(2):88–93 (72 ref.)

[Diet and precancerous gastric lesions: preliminary results of a sampling study of homogeneous population] Spaziani E, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):265–8 (Eng. Abstr.) **(Ita)**

GENETICS

Use of genetic markers during endoscopic screening and follow-up of gastrointestinal precancerous lesions. Van Laethem JL. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):187–92

Genetic markers and premalignancy. Grandjouan S.
Am J Gastroenterol 1996 May;91(5):844–6 (31 ref.)

Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilation. Tomono H, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1211–4

Somatic genetic changes in lung cancer and precancerous lesions. Sundaresan V, et al. **Ann Oncol** 1995;6 Suppl 1:27–31; discussion 31–2 (14 ref.)

DNA ploidy, P53 expression, and cellular proliferation in normal epithelium and squamous dysplasia of non-cancerous and cancerous human oesophagi. Itakura Y, et al. **Anticancer Res** 1996 Jan-Feb;16(1):201–8

Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. Miller FR, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1765–9

Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Smith AL, et al.
Br J Cancer 1996 Jan;73(2):203–9

Flow cytometric DNA content analysis on squamous cell carcinomas according to the preceding lesions. Tamura A, et al. **Br J Dermatol** 1996 Jan;134(1):40–3

Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)

Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Semba S, et al.
Cancer 1996 Apr 15;77(8 Suppl):1620–7

p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Wang LD, et al. **Cancer** 1996 Apr 1; 77(7):1244–9

Genetic progression model for head and neck cancer: implications for field cancerization. Califano J, et al.
Cancer Res 1996 Jun 1;56(11):2488–92

Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2'-dimethyl-4-aminobiphenyl. Feng Y, et al.
Cancer Res 1996 Feb 1;56(3):527–31

Different genetic susceptibility to aberrant crypts and colon adenomas in mice. Moen CJ, et al. **Cancer Res** 1996 May 15;56(10):2382–6

Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Müller JR, et al. **Cancer Res** 1996 Jan 15;56(2):419–23

X chromosome inactivation in the normal female genital tract: implications for identification of neoplasia. Mutter GL, et al. **Cancer Res** 1995 Nov 1;55(21):5080–4

Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Roz L, et al. **Cancer Res** 1996 Mar 15;56(6):1228–31

Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Thiberville L, et al. **Cancer Res** 1995 Nov 15; 55(22):5133–9

Molecular genetic changes found in human lung cancer and its precursor lesions. Gazdar AF, et al.
Cold Spring Harb Symp Quant Biol 1994;59:565–72 (77 ref.)

Molecular genetics of dysplasia in ulcerative colitis. Benhattar J, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1171–3 (15 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al.
Eur J Cancer Prev 1996 Feb;5(1):5–17 (139 ref.)

Clonal analysis of precancerous lesion of hepatocellular carcinoma [comment] Aihara T, et al. **Gastroenterology** 1996 Aug;111(2):455–61. Comment on: Gastroenterology 1996 Aug;111(2):526–8.

Genetic mechanisms in esophageal carcinogenesis: frequent deletion of 3p and 17p in premalignant lesions. Shimada M, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):165–9

p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. Kim YT, et al. **Hum Pathol** 1996 Apr;27(4):389–95

Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Gomyo Y, et al. **Int J Cancer** 1996 May 29;66(5):594–9

Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. Kuo MY, et al.
J Oral Pathol Med 1995 Jul;24(6):255–60

Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. Jeevaratnam P, et al. **J Pathol** 1996 May; 179(1):20–5

p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. Kusama K, et al. **J Pathol** 1996 Apr;178(4):415–21

K-ras and p53 mutations in human colorectal aberrant crypt foci. Losi L, et al. **J Pathol** 1996 Mar;178(3):259–63

Expression of c-myc in altered hepatic foci induced in rats by various single doses of diethylnitrosamine and promotion by 0.05% phenobarbital. Deguchi T, et al.
Mol Carcinog 1995 Nov;14(3):152–9

Infrequent Ha-ras mutations and absence of Ki-ras, N-ras, and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions. Suzui M, et al. **Mol Carcinog** 1995 Dec; 14(4):294–8

Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Zörnig M, et al.
Oncogene 1995 Nov 16;11(10):2165–74

Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Berg RJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):274–8

Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Heselmeyer K, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):479–84

Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Ieda S, et al. **Surg Today** 1996;26(4):230–5

[Expression of ras and erbB2 in benign and malignant lesions of the stomach] Zhao A, et al.
Chung Hua Chung Liu Tsa Chih 1995 Sep;17(5):336–9 (Eng. Abstr.) **(Chi)**

[Multiple gene alterations involved in the processor of human gastric carcinogenesis] Lu Y, et al.
Chung Hua I Hsueh Tsa Chih 1995 Nov;75(11):679–82, 710–1 (Eng. Abstr.) **(Chi)**

[Multiple analysis for the c-Ha-ras activation and DNA content in human gastric precancerous lesions] Yu J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):739–42 (Eng. Abstr.) **(Chi)**

[Manifestation of tuberous sclerosis in the ENT area] Helling K, et al. **HNO** 1996 May;44(5):264–6 (Eng. Abstr.) **(Ger)**

[Precancerous lesion in colorectal cancer] Nagawa H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2043–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Fibronectin gene expression in preneoplastic states and female genital neoplasms] Wójcicka-Bartłomiejczyk B, et al. **Ginekol Pol** 1995 Aug;66(8):457–64 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Effect of serotype 2 and 3 Marek's disease vaccines on the development of avian leukosis virus-induced pre-neoplastic bursal follicles. Marsh JD, et al.
Avian Dis 1995 Oct-Dec;39(4):743–51

A comparative study on expression of mucin related antigens in preneoplastic and neoplastic rat colorectal mucosa. Baral R, et al. **Cancer Lett** 1996 Jul 19;105(1):15–22

Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Itzkowitz SH, et al. **Gastroenterology** 1996 Mar; 110(3):694–704

Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. Herold-Mende C, et al. **J Pathol** 1996 May;179(1):66–73

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2–11

METABOLISM

Changes in tRNA pattern in ethionine-induced rat putative preneoplastic hepatocyte nodules. Kanduc D, et al.
Biochem Mol Biol Int 1996 May;38(6):1191–7

Linear porokeratosis with multiple squamous cell carcinomas: study of p53 expression in porokeratosis and squamous cell carcinoma [letter] Sasaki S, et al. **Br J Dermatol** 1996 Jun; 134(6):1151–3

p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Wang LD, et al. **Cancer** 1996 Apr 1; 77(7):1244–9

Nitrite, N-nitroso compounds, and other analytes in physiological fluids in relation to precancerous gastric lesions. You WC, et al.
Cancer Epidemiol Biomarkers Prev 1996 Jan;5(1):47–52

Membrane and cytosolic protein phosphorylation patterns in the early stages of DEN-induced hepatocarcinogenesis in rats fed a high or low protein diet. La Porta CA, et al. **Cancer Lett** 1995 Nov 6;97(2):217–23

Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Kim YH, et al.
Cancer Res 1995 Dec 1;55(23):5603–10

Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Xu XC, et al. **Cancer Res** 1995 Dec 1; 55(23):5507–11

Expression of hepatocyte growth factor and c-met mRNAs during rat chemically induced hepatocarcinogenesis. Imai T, et al. **Carcinogenesis** 1996 Jan;17(1):19–24

Expression of CD44v6 is associated with cellular dysplasia in colorectal epithelial cells. Orzechowski HD, et al.
Eur J Cancer 1995 Nov;31A(12):2073–9

p53 expression in ulcerative colitis: a longitudinal study. Ilyas M, et al. **Gut** 1995 Dec;37(6):802–4

p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Wistuba II, et al. **Hum Pathol** 1996 Apr;27(4):360–5

Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Ren ZP, et al. **Int J Cancer** 1996 Jun 21; 69(3):174–9

Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. Chan WK, et al.
J Pathol 1995 Nov;177(3):241–6

Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. Furihata M, et al.
J Pathol 1996 Feb;178(2):133–9

In situ analysis of tissue dynamics and p53 expression in human gastric mucosa. Imatani A, et al. **J Pathol** 1996 May; 179(1):39–42

Expression of markers of differentiation in normal bronchial epithelium and bronchial dysplasia. Pendleton N, et al.
J Pathol 1996 Feb;178(2):146–50

BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. Ter Harmsel B, et al. **J Pathol** 1996 May; 179(1):26–30

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions [see comments] Weinstat-Saslow D, et al. **Nat Med** 1995 Dec;1(12):1257–60. Comment in: Nat Med 1995 Dec;1(12):1250–1.

The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Polkowski W, et al. **Surg Oncol** 1995 Jun;4(3):163–71

Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8. Niiya K, et al.
Thromb Haemost 1995 Dec;74(6):1511–5

[Various immunohistochemical markers of precancer and variants of prostate cancer] Romanenko AM, et al.
Arkh Patol 1995 Jul-Aug;57(4):38–41 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Bacteria in the aetio-pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)

NURSING

Educating women about early detection of gynecologic cancers using a brochure. Mahon SM.
Oncol Nurs Forum 1996 Apr;23(3):529–31

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem. Levine MS, et al.
Abdom Imaging 1995 Jul-Aug;20(4):291–8 (69 ref.)

Is keratoacanthoma a variant of squamous cell carcinoma. New insights into an old controversy ... soon? [editorial; comment] LeBoit PE. **Am J Dermatopathol** 1995 Aug; 17(4):319–20. Comment on: Am J Dermatopathol 1995 Aug;17(4):324–31. Comment on: Am J Dermatopathol 1995

Aug;17(4):332–4. Comment on: Am J Dermatopathol 1995 Aug;17(4):335–8.

Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship [see comments] Nzeako UC, et al. **Am J Gastroenterol** 1996 May;91(5):879–84. Comment in: Am J Gastroenterol 1996 May;91(5):836–7.

Nodular regenerative hyperplasia, dysplasia, and hepatocellular carcinoma [editorial; comment] Wanless IR. **Am J Gastroenterol** 1996 May;91(5):836–7. Comment on: Am J Gastroenterol 1996 May;91(5):879–84.

Expression of proliferating cell nuclear antigen in premalignant lesions of the larynx. Zhao R, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):36–44

MCF10AT: a model for the evolution of cancer from proliferative breast disease. Dawson PJ, et al. **Am J Pathol** 1996 Jan;148(1):313–9

Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern. Dombrowski F, et al. **Am J Pathol** 1996 Apr;148(4):1249–56

Expression of peptidyl–glycine alpha–amidating mono–oxygenase (PAM) enzymes in morphological abnormalities adjacent to pulmonary tumors. Martínez A, et al. **Am J Pathol** 1996 Aug;149(2):707–16

Evolution of neoplastic development in the liver of transgenic mice co–expressing c–myc and transforming growth factor–alpha. Santoni–Rugiu E, et al. **Am J Pathol** 1996 Aug;149(2):407–28

Detection of squamous neoplasia by fluorescence imaging comparing porfimer sodium fluorescence to tissue autofluorescence in the hamster cheek–pouch model. Pathak I, et al. **Am J Surg** 1995 Nov;170(5):423–6

Renal epithelial dysplasia [letter; comment] Dodd LG, et al. **Am J Surg Pathol** 1995 Nov;19(11):1335–7. Comment on: Am J Surg Pathol 1994 Nov;18(11):1117–24.

Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Kitamura H, et al. **Am J Surg Pathol** 1996 May;20(5):553–62

Comparison of nuclear area measurements carried out on normal and dysplastic oral smears. Cowpe JG, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):241–6

DNA ploidy, P53 expression, and cellular proliferation in normal epithelium and squamous dysplasia of non–cancerous and cancerous human oesophagi. Itakura Y, et al. **Anticancer Res** 1996 Jan–Feb;16(1):201–8

Studies of the inflammatory process and malignant potential of oral mucosal lichen planus. Kilpi A, et al. **Aust Dent J** 1996 Apr;41(2):87–90

Distribution of lymphoid nodules, aberrant crypt foci and tumours in the colon of carcinogen–treated rats. Cameron IL, et al. **Br J Cancer** 1996 Apr;73(7):893–8

Malignant transformation of monoclonal gammopathy of undetermined significance among out–patients of a community hospital in southeastern Netherlands. van de Poel MH, et al. **Br J Haematol** 1995 Sep;91(1):121–5

Actinic keratosis and dysplasia of the conjunctiva: a clinicopathological study of 45 cases. Mauriello JA Jr, et al. **Can J Ophthalmol** 1995 Oct;30(6):312–6

Clinical diagnosis and therapy of cutaneous melanoma in situ [letter] Massi D. **Cancer** 1996 Sep 1;78(5):1140–2

Atypical adenomatous hyperplasia and adenocarcinoma of the human lung: their heterology in form and analogy in immunohistochemical characteristics. Mori M, et al. **Cancer** 1996 Feb 15;77(4):665–74

Gastric epithelial dysplasia. How clinicopathologic background relates to management. Rugge M, et al. **Cancer** 1995 Aug 1;76(3):376–82

Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7–year follow–up. Seidman JD, et al. **Cancer** 1996 Jun 15;77(12):2529–37

Quantitative analysis of changes in cell proliferation and apoptosis during preneoplastic and neoplastic stages of hepatocarcinogenesis in rat. Kong J, et al. **Cancer Lett** 1996 Aug 2;105(2):241–8

Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Jovanovic AS, et al. **Cancer Res** 1996 Apr 15;56(8):1917–21

Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Otori K, et al. **Cancer Res** 1995 Nov 1; 55(21):4743–6

p53–independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Shibata MA, et al. **Cancer Res** 1996 Jul 1;56(13):2998–3003

Reversibility of promoter induced hepatic focal lesion growth in mice. Kolaja KL, et al. **Carcinogenesis** 1996 Jul; 17(7):1403–9

Changes of cellular morphology and nuclear DNA content in different nasopharyngeal epithelium from different patients. Zhao S, et al. **Chin Med J (Engl)** 1995 May; 108(5):377–82

Antigen retrieval: p53 staining in benign, pre–malignant and malignant tissues of the larynx. Tan LK, et al. **Clin Otolaryngol** 1996 Apr;21(2):147–50

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)

Precancerous and cancerous lesions of the oral cavity. Summerlin DJ. **Dermatol Clin** 1996 Apr;14(2):205–23 (22 ref.)

Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Fouret P, et al. **Diagn Mol Pathol** 1995 Jun;4(2):122–7

Natural history of aberrant crypt foci. A surgical approach. Shpitz B, et al. **Dis Colon Rectum** 1996 Jul;39(7):763–7

Histology of gastric antrum in intestinal–type gastric adenocarcinoma from Asir Central Hospital, Saudi Arabia. Morad NA. **East Afr Med J** 1995 Sep;72(9):577–8

Grading of dysplasia. Riddell RH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1169–70 (14 ref.)

Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Birchall MA, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):380–3

The relationship between vascularity and cell proliferation in human normal and pathological lesions of the oral cheek epithelium. Tipoe GL, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):24–31

Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Roa I, et al. **Gastroenterology** 1996 Jul;111(1):232–6

Inflammatory, preneoplastic, and neoplastic changes of the gastric mucosa. Examinations by the AgNORT–technique. Steininger H, et al. **Gen Diagn Pathol** 1995 May;141(1):15–9

K–ras gene mutation in gall bladder carcinomas and dysplasia. Ajiki T, et al. **Gut** 1996 Mar;38(3):426–9

Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Broomé U, et al. **Hepatology** 1995 Nov;22(5):1404–8

Pre–neoplastic lesions of the prostate. Parkinson MC. **Histopathology** 1995 Oct;27(4):301–11 (103 ref.)

Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Terada T, et al. **Histopathology** 1995 Oct; 27(4):333–9

Dysplasia in atypical liver nodes [letter; comment] Berman JJ, et al. **Hum Pathol** 1996 Feb;27(2):211–3. Comment on: Hum Pathol 1995 Aug;26(8):897–906.

Multifocal heterogeneity in villin and Ep–CAM expression in Barrett's esophagus. Kumble S, et al. **Int J Cancer** 1996 Mar 28;66(1):48–54

Radiation–induced apoptosis in normal and pre–neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Meyn RE, et al. **Int J Cancer** 1996 Feb 8;65(4):466–72

Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Scully RE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S9–15 (13 ref.)

Granulomatous slack skin: a possible precursor of Hodgkin's disease. DeGregorio R, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1044–7 (22 ref.)

Premalignant keratinocytic neoplasms. Schwartz RA. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):223–42 (399 ref.)

Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? Skender–Kalnenas TM, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1000–7

Pathology of ovarian cancer precursors. Scully RE. **J Cell Biochem Suppl** 1995;23:208–18 (23 ref.)

Histological classification of the neoplastic changes arising in ulcerative colitis: a new proposal in Japan. Konishi F, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:20–4

Colonoscopic diagnosis of dysplasia and early cancer in longstanding colitis. Nagasako K, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:36–9

Requirements of a cancer screening program to be scientifically credible. Riddell RH. **J Gastroenterol** 1995 Nov;30 Suppl 8:43–4

Implications of a diagnosis of dysplasia in ulcerative colitis. Riddell RH. **J Gastroenterol** 1995 Nov;30 Suppl 8:25–9

Results of cancer surveillance in ulcerative colitis. Suzuki K, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:40–2

Comparison of the proliferative capacity of adenomatous hyperplasia and well differentiated hepatocellular carcinoma. Yamashita A. **J Gastroenterol** 1996 Jun; 31(3):373–8

Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)

Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)

Oral white lesions with special reference to precancerous and tobacco– related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. Axéll T, et al. **J Oral Pathol Med** 1996 Feb;25(2):49–54 (3 ref.)

How important is tumour shape? Quantification of the epithelial–connective tissue interface in oral lesions using local connected fractal dimension analysis. Landini G, et al. **J Pathol** 1996 Jun;179(2):210–7

Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel–Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. Walther MM, et al. **J Urol** 1995 Dec; 154(6):2010–4; discussion 2014–5

Relationship of esophageal dysplasia to associated head and neck cancer in patients with esophageal carcinoma. Takiyama W, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):12–7

A biologically based model for the analysis of premalignant foci of arbitrary shape. Dewanji A, et al. **Math Biosci** 1996 Jul 1;135(1):55–68

Distribution of cytokeratin 19–positive biliary cells in cirrhotic nodules, hepatic borderline nodules (atypical adenomatous hyperplasia), and small hepatocellular carcinomas. Terada T, et al. **Mod Pathol** 1995 May; 8(4):371–9

Compensatory apoptosis in response to SV40 large T antigen expression in the liver. Allemand I, et al. **Oncogene** 1995 Dec 21;11(12):2583–90

Salivary gland duct involvement in oral epithelial dysplasia and squamous cell carcinoma. Daley TD, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):186–92

Boundary in the pathologic evaluation of premalignant prostatic lesions. Algaba F. **Pathol Res Pract** 1995 Sep; 191(9):856–9

Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Montironi R, et al. **Pathol Res Pract** 1995 Sep; 191(9):873–80

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)

The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Qian J, et al. **Pathol Res Pract** 1995 Sep; 191(9):860–7

Nephrogenic rest associated with a mesoblastic nephroma—what does it tell us? Vujanić GM, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):469–75

The effect of dieldrin and phenobarbital on preneoplastic hepatic lesion growth in male F344 rat and B6C3F1 mouse. Kolaja KL, et al. **Prog Clin Biol Res** 1995;391:409–23

Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. McNeal JE, et al. **Prostate** 1995 Nov;27(5):258–68

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185–92 (50 ref.)

Premalignant lesions of the stomach. Ho SB. **Semin Gastrointest Dis** 1996 Apr;7(2):61–73 (85 ref.)

Preneoplastic conditions of the liver. Riegler JL. **Semin Gastrointest Dis** 1996 Apr;7(2):74–87 (79 ref.)

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

Multiple occurrence of borderline hepatocellular nodules in human cirrhotic livers: possible multicentric origin of hepatocellular carcinoma. Terada T, et al. **Virchows Arch** 1995;427(4):379–83

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)

[Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions] Li H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):286–8 (Eng. Abstr.) **(Chi)**

[Focal nodular hyperplasia of the liver: assessment of diagnosis and treatment in 31 patients in 15 years] de Wilt JH, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):18–22 (Eng. Abstr.) **(Dut)**

[Histopathologic correlates of false–positive cytologic findings in the uterine cervix] Horn LC, et al. **Geburtshilfe Frauenheilkd** 1995 Aug;55(8):425–30 (Eng. Abstr.) **(Ger)**

[Early invasive cervix carcinoma—FIGO 1994] Pickel H, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):42–4 (Eng. Abstr.) **(Ger)**

[Diseases of the breast] Bässler R. **Pathologe** 1996 Jan; 17(1):92–106 (23 ref.) **(Ger)**

[Mucin histochemical analysis of mucin–forming carcinomas, metaplasias of the urothelium and in persistent urachus] Ebel K, et al. **Pathologe** 1996 May;17(3):208–12 (Eng. Abstr.) **(Ger)**

[Proliferation kinetics of bronchioloalveolar tumorlets] Theile A, et al. **Pathologe** 1996 Mar;17(2):163–70 (Eng. Abstr.) **(Ger)**

[The malignant transformation of leukoplakia of the oral cavity. A review of the literature and clinical case reports] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):291–300 (62 ref.) (Eng. Abstr.) **(Ita)**

[Characteristics of early carcinomas and precancerous lesions in the urinary bladder] Fukushima S, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2067–72 (Eng. Abstr.) **(Jpn)**

[Reevaluation of preneoplastic lung lesions in lung carcinoma? In bronchial carcinoma?] Kato H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2048–54 (32 ref.) (Eng. Abstr.) **(Jpn)**

[New concepts on precancerous lesions of the stomach] Mai M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2029–37 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Reevaluation of precancerous lesion of squamous cell carcinoma] Sumiyoshi K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2038–42 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Precancerous stages of hepatocellular carcinoma] Tanikawa

K. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2055–61 (29 ref.) (Eng. Aostr.) **(Jpn)**

[Reevaluation of precancerous lesions of the skin] Tsuchida T, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2062–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Liver cell dysplasia] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):273–6 (18 ref.) **(Jpn)**

[Analysis of seven year prophylactic examinations of uterine cervix carcinoma in women living in the town of Kielce] Malarewicz A, et al. **Ginekol Pol** 1995 Apr;66(4):211–5 (Eng. Abstr.) **(Pol)**

[Concepts related to the course of gastric cancer] Espejo Romero H, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S46–70 (32 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Santoni-Rugiu E, et al. **Am J Pathol** 1996 Aug;149(2):407–28

Menstrual cycle chronobiology: is it important in breast cancer screening and therapy? Bjarnason GA. **Lancet** 1996 Feb 10;347(8998):345–6

The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Chemoprevention of mammary preneoplasia. In vitro effects of a green tea polyphenol. Araki R, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:215–22

Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Heitmiller RF, et al. **Ann Surg** 1996 Jul;224(1):66–71

Inhibition of the development of rat liver preneoplastic lesions by verapamil and dexverapamil. Ghia M, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1739–41

Chemoprevention of diethylnitrosamine-induced liver foci and hepatocellular adenomas in C3H mice. Pereira MA. **Anticancer Res** 1995 Sep-Oct;15(5B):1953–6

Effect of potato starch, cornstarch and sucrose on aberrant crypt foci in rats exposed to azoxymethane. Thorup I, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2101–5

In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Moriya K, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):217–23

Effects of dietary beta-carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine-treated rats. Appel MJ, et al. **Carcinogenesis** 1996 Jul;17(7):1411–6

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Endoh T, et al. **Carcinogenesis** 1996 Mar; 17(3):467–75

Inhibitory effects of d-limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Kawamori T, et al. **Carcinogenesis** 1996 Feb; 17(2):369–72

Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats. Onogi N, et al. **Carcinogenesis** 1996 Jun;17(6):1291–6

Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha, 25-dihydroxyvitamin D3. Otoshi T, et al. **Carcinogenesis** 1995 Sep;16(9):2091–7

Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Pereira MA, et al. **Carcinogenesis** 1996 Feb;17(2):373–6

Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Simile MM, et al. **Carcinogenesis** 1996 Jul;17(7):1533–7

Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5-f]quinoline-induced DNA adducts and colonic aberrant crypts in the F344 rat. Xu M, et al. **Carcinogenesis** 1996 Jul;17(7):1429–34

Annual screening for oral cancer and precancer by invitation to 60-year-old residents of a city in Japan. Ikeda N, et al. **Community Dent Health** 1995 Sep;12(3):133–7

Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high-risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)

Antioxidants, Helicobacter pylori and stomach cancer in Venezuela. de Sanjosé S, et al. **Eur J Cancer Prev** 1996 Feb;5(1):57–62

Strengths and weaknesses of screening programmes for oral malignancies and potentially malignant lesions. Warnakulasuriya KA, et al. **Eur J Cancer Prev** 1996 Apr; 5(2):93–8 (33 ref.)

The influence of high and low molecular weight chitosan on colonic cell proliferation and aberrant crypt foci development in CF1 mice. Torzsas TL, et al. **Food Chem Toxicol** 1996 Jan;34(1):73–7

Wheat bran suppresses potato starch—potentiated colorectal tumorigenesis at the aberrant crypt stage in a rat model. Young GP, et al. **Gastroenterology** 1996 Feb;110(2):508–14

Human papillomaviruses and cervical screening [editorial] Etherington IJ, et al. **Genitourin Med** 1996 Jun;72(3):153–4

Building up a computerized follow-up register and information system for cervical cytology. Terpos AA, et al. **Int J Biomed Comput** 1995 Jun;39(3):277–85

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. Takahashi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):219–22

Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats. Charalambous D, et al. **J Gastroenterol Hepatol** 1996 Jan; 11(1):88–92

Chemoprevention of head and neck cancer. Voravud N. **J Med Assoc Thai** 1996 Mar;79(3):185–93 (65 ref.)

Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon. Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):549–54

Chemopreventive effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate, on rat oral carcinogenesis. Ohnishi M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):349–56

Dietary fiber and the chemopreventive modelation of colon carcinogenesis. Alabaster O, et al. **Mutat Res** 1996 Feb 19;350(1):185–97

Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Abdelali H, et al. **Nutr Cancer** 1995; 24(2):121–32

Dietary cholesterol inhibits the development of aberrant crypt foci in the colon. el-Sohemy A, et al. **Nutr Cancer** 1996;25(2):111–7

Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer. Kozacko MF, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2953–7

Effects of dietary n-3, n-6 and n-9 polyunsaturated fatty acids on benzo(a)pyrene-induced forestomach tumorigenesis in C57BL6J mice. Silva RA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):273–7

[Quality assurance by improved cooperation structures. The example of decentralized early detection mammography] Swart E, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):559–65 (Eng. Abstr.) **(Ger)**

[Early detection of colorectal carcinoma (letter)] Klapdor R. **Med Klin** 1996 May 15;91(5):320–1; discussion 321–2 **(Ger)**

RADIOGRAPHY

Dysplasia in ulcerative colitis: is radiography adequate for diagnosis? [see comments] Matsumoto T, et al. **Radiology** 1996 Apr;199(1):85–90. Comment in: Radiology 1996 Apr;199(1):28–30.

Congenital bile duct cyst: a premalignant lesion of the biliary tract associated with adenocarcinoma—a case report. Holzinger F, et al. **Z Gastroenterol** 1996 Jun;34(6):382–5

SURGERY

Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)

Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Sinclair RD, et al. **Australas J Dermatol** 1995 Aug;36(3):133–42 (60 ref.)

The integration of diagnostic tests and the role of outpatient surgery in the management of breast disease. Ranieri E, et al. **Int Surg** 1995 Apr-Jun;80(2):181–4

Transduodenal excision of premalignant duodenal lesions in patients with portal hypertension. Pruitt AL, et al. **J Clin Gastroenterol** 1995 Dec;21(4):334–5

Laparoscopic approaches in the management of patients with early gastric carcinomas. Kitano S, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):359–62

[Endoscopic mucosectomy for resection of early gastric cancer and precancerous lesions] Zhou L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):443–5 (Eng. Abstr.) **(Chi)**

[Laparoscopic gastrectomy. A case report] Ablassmaier B, et al. **Chirurg** 1996 Jun;67(6):643–7 (Eng. Abstr.) **(Ger)**

[Early squamous epithelial carcinoma of the esophagus—multicentricity, metastatic pattern and prognosis] Hölscher AH, et al. **Chirurg** 1996 Apr; 67(4):357–61 (Eng. Abstr.) **(Ger)**

[Sensible use of CO2 laser therapy on the lower genital tract of the woman] Hilgarth M, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):M27–34 **(Ger)**

[Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics] Kindermann G, et al. **Geburtshilfe Frauenheilkd** 1995 Dec; 55(12):687–94 (Eng. Abstr.) **(Ger)**

[Laser therapy of the skin] Hohenleutner U, et al. **HNO** 1995 Sep;43(9):557–71 (64 ref.) **(Ger)**

[Results of surgical therapy of early stomach cancer] Winkler M, et al. **Zentralbl Chir** 1995;120(10):795–9 (Eng. Abstr.) **(Ger)**

[Therapy of preinvasive vulvar neoplasia--standardized or individual?] Schnürch HG, et al. **Zentralbl Gynakol** 1996; 118(6):345–9 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons. Marley JJ, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):28–36

Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Yefenof E, et al. **Cancer Immunol Immunother** 1995 Dec; 41(6):389–96

Micronuclei and carcinogen DNA adducts as intermediate end points in nutrient intervention trial of precancerous lesions in the oral cavity. Prasad MP, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):155–9

ULTRASTRUCTURE

Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserine. Visser CJ, et al. **Br J Cancer** 1996 Jul;74(1):92–8

Changes in the number of silver-stained nucleolar organizer regions in the normal, preneoplastic, and neoplastic endometrium. Niwa K, et al. **Cancer Detect Prev** 1995; 19(5):436–40

Nuclear morphometry in experimental oral mucosal carcinogenesis. Rich AM, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):169–75

Grading of precancerous laryngeal lesions by multiparameter image analysis at separate epithelial layers. Dreyer T, et al. **J Pathol** 1995 Dec;177(4):385–93

VETERINARY

Preneoplastic and neoplastic lesions of rat hereditary renal cell tumors express markers of proximal and distal nephron. Wolf DC, et al. **Vet Pathol** 1995 Jul;32(4):379–86

VIROLOGY

Detection of human papillomavirus (HPV) types in precancerous and cancerous lesions of cervix in Indian women: a preliminary report. Menon MM, et al. **Indian J Cancer** 1995 Dec;32(4):154–9

Transgenic models for papillomavirus-associated multistep carcinogenesis. Kondoh G, et al. **Intervirology** 1995; 38(3-4):181–6

Epstein-Barr virus and nasopharyngeal cancer [letter; comment] Schuster V, et al. **N Engl J Med** 1996 Jan 11; 334(2):122–3. Comment on: N Engl J Med 1995 Sep 14;333(11):693–8.

PRECAUTIONS, UNIVERSAL see **UNIVERSAL PRECAUTIONS**

PRECEPTORSHIP

Using standardized students to educate preceptors [letter] Lang F, et al. **Acad Med** 1995 Oct;70(10):855–6

Communication as an essential part of program and institutional development. Lemon M, et al. **Acad Med** 1995 Oct;70(10):884–6

Second year general professional training for dentists: the West Midlands regional scheme one year on. Frame JW, et al. **Br Dent J** 1995 Oct 21;179(8 Spec No):309–10

VT2—a trainee's point of view. Sethi S. **Br Dent J** 1995 Oct 21;179(8 Spec No):311–2

Support of community preceptors: what do they need? Langlois JP. **Fam Med** 1995 Nov-Dec;27(10):641–5

Reactions of family medicine community preceptors to teaching medical students. Usatine RP, et al. **Fam Med** 1995 Oct;27(9):566–70

Benefits of training dietetics students in preprofessional practice programs: a comparison with dietetic internships. Gilbride JA, et al. **J Am Diet Assoc** 1996 Aug;96(8):758–63

Impact of preceptors on student attitudes toward supervised practice. Wolf KN, et al. **J Am Diet Assoc** 1996 Aug; 96(8):800–2

Questions asked by family physicians who want to serve as medical student preceptors. Sheets KJ, et al. **J Fam Pract** 1996 May;42(5):503–11

Ensuring clinical experiences: is managed care a threat? Sullivan EJ. **J Prof Nurs** 1995 Sep-Oct;11(5):262

Out of the classroom—into the exam room. Bell H. **Minn Med** 1995 Dec;78(12):10–6

University of Minnesota community rotations expose students to family practice. Benzie DP, et al. **Minn Med** 1995 Dec; 78(12):17–20

An investigation of the preceptor as potential mentor [letter] Beauchesne MA, et al. **Nurse Pract** 1996 Mar;21(3):155–6, 158–9

Volunteers sought to help train more generalists. Shoop GH. **Pa Med** 1995 Jun;98(6):24–6

[The practicability of preceptorship in the curriculum of medical education] Lin CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Mar; 12(3):167–73 (Eng. Abstr.) **(Chi)**

METHODS

Sharing the wealth: collaboration on practice readiness. Roche J, et al. **J Nurs Educ** 1995 Oct;34(7):333–6

PRECEPTORSHIP

ORGANIZATION & ADMINISTRATION

The effect of a senior preceptorship on the adaptive competencies of community college nursing students. Ridley MJ, et al. **J Adv Nurs** 1995 Jul;22(1):58–65

Faculty development of pediatric practitioners: complexities in teaching clinical precepting. Roberts KB, et al. **Pediatrics** 1996 Mar;97(3):389–93

STANDARDS

Using audiotapes to monitor student–preceptor interactions in a decentralized clerkship. Schwiebert P, et al. **Fam Med** 1996 Jan;28(1):24–8

The surgical clerkship: characteristics of the effective teacher. Sloan DA, et al. **Med Educ** 1996 Jan;30(1):18–23

TRENDS

Orientation and preceptorship: the new research clinician's lifeline. Hunsley SL. **J Neurosci Nurs** 1995 Jun;27(3):194–9

PRECIPITATING FACTORS

Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. Inouye SK, et al. **JAMA** 1996 Mar 20;275(11):852–7

PRECIPITATION

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

PRECIPITIN ASSAY, RADIOIMMUNE see **RADIOIMMUNOPRECIPITATION ASSAY**

PRECIPITIN TESTS

Quantitative determination of fibronectin (FN): evaluation of immunoturbidimetric and rate nephelometric techniques for FN assay in the different biologic materials. Mangraviti S, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec; 23(6):285–9

Detection of anti–neutrophil cytoplasmic antibodies by immunoprecipitation. Lucena–Fernandes F, et al. **Clin Invest Med** 1995 Jun;18(3):153–62

Effect of organic solvents on lysozyme–antilysozyme precipitin reaction. Ahmad A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jun;114(2):119–21

N–glycanase treatment of F(ab')2 derived from asymmetric murine IgG3 mAb determines the acquisition of precipitating activity. Mathov I, et al. **Mol Immunol** 1995 Oct;32(14–15):1123–30

Modification of cholinergic–mediated cellular transmembrane signals by the interaction of human chagasic IgG with cardiac muscarinic receptors. Goin JC, et al. **Neuroimmunomodulation** 1994 Sep–Oct;1(5):284–91

METHODS

A new method for the determination of the ABO blood type of semen by immunoblotting using anti–ABH antibodies following immunoprecipitation. Sato I, et al. **J Immunol Methods** 1995 Dec 27;188(2):229–37

An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. Steinitz M, et al. **J Immunol Methods** 1995 Nov 16; 187(1):171–7

Generation of oligonucleotides containing site–specific cyclobutane pyrimidine dimers and pyrimidine(6–4)pyrimidinone photoproducts by immunoprecipitation. Ghosh R, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4934–7

VETERINARY

Comparison of agar–gel precipitin responses among strains of fowl adenovirus using antigens prepared from chorioallantoic membranes and chicken kidney cell cultures. Takase K, et al. **J Vet Med Sci** 1995 Apr; 57(2):327–30

PRECIPITINS

CHEMISTRY

Structure of the N–linked oligosaccharides from tridacnin, a lectin found in the haemolymph of the giant clam Hippopus hippopus. Puanglarp N, et al. **Eur J Biochem** 1995 Sep 15;232(3):873–80

PRECONCEPTION CARE

see related
PRENATAL CARE

The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes. Czeizel AE, et al. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):175–84

The impact of a preconceptional health promotion program on intendedness of pregnancy. Moos MK, et al. **Am J Perinatol** 1996 Feb;13(2):103–8

Preconceptional and prenatal multivitamin–mineral supplement use in the 1988 National Maternal and Infant Health Survey. Yu SM, et al. **Am J Public Health** 1996 Feb;86(2):240–2

Preconception care: a means of prevention. Cefalo RC, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):403–16 (38 ref.)

Primary prevention of birth defects by periconceptional care, including multivitamin supplementation. Czeizel AE. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):417–30 (26 ref.)

ACOG technical bulletin. Preconceptional care. Number 205—May 1995. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Aug;50(2):201–7

Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337–74 (113 ref.)

A fertility diet for planning pregnancy. Wynn M, et al. **Nutr Health** 1995;10(3):219–38 (50 ref.)

[The preconception consultation: a good idea? (letter; comment)] Niermeijer MF. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2056–7. Comment on: Ned Tijdschr Geneeskd 1995 May 20;139(20):1045–6. **(Dut)**

PRECURSOR RNA see **RNA PRECURSORS**

PREDATORY BEHAVIOR

Field observation of a group of Geoffroy's marmosets mobbing a Margay cat. Passamani M. **Folia Primatol (Basel)** 1995;64(3):163–6

Laboratory studies of antipredator behavior in the Mongolian gerbil (Meriones unguiculatus): factors affecting response attenuation with repeated presentations. Ellard CG. **J Comp Psychol** 1996 Jun;110(2):155–63

Cannibalism and predation behaviour of the blowfly, Chrysomyia albiceps (Wiedemann) larvae (Diptera: Calliphoridae). Omar AH. **J Egypt Soc Parasitol** 1995 Dec; 25(3):729–43

Evolutionary dynamics of predator–prey systems: an ecological perspective. Marrow P, et al. **J Math Biol** 1996; 34(5–6):556–78

The structural stability of a three–species food chain model. Eisenberg JN, et al. **J Theor Biol** 1995 Oct 21;176(4):501–10

A predator–prey model with optimal suppression of reproduction in the prey. Gyllenberg M, et al. **Math Biosci** 1996 Jun;134(2):119–52

Qualitative analysis of Kolmogorov–type models of predator–prey systems. Huang L, et al. **Math Biosci** 1995 Nov;130(1):85–97

Boldness and predator deterrence: a critique of Godin & Davis. Milinski M, et al. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):103–5; discussion 107–12

PHYSIOLOGY

Predatory aggression in male mice selectively bred for isolation–induced intermale aggression. Sandnabba NK. **Behav Genet** 1995 Jul;25(4):361–6

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109–21 (56 ref.)

The prey consumption and prey preference of the larvae of the mosquito Culex (Lutzia) raptor on the larvae of Culex quinquefasciatus. Thangam TS, et al. **Experientia** 1996 Apr 15;52(4):380–2

The kinematics and mechanism of prey capture in the African pig–nosed frog (Hemisus marmoratum): description of a radically divergent anuran tongue. Ritter D, et al. **J Exp Biol** 1995 Sep;198 (Pt 9):2025–40

Predatory aggression induced by hypothalamic stimulation: modulation by midbrain periaqueductal gray (PAG). Manchanda SK, et al. **Neurobiology (Bp)** 1995; 3(3–4):405–17

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

PREDIABETIC STATE

BLOOD

Elevated serum levels of macrophage–derived cytokines precede and accompany the onset of IDDM. Hussain MJ, et al. **Diabetologia** 1996 Jan;39(1):60–9

Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Mykkänen L, et al. **Diabetologia** 1995 Oct;38(10):1176–82

Fasting proinsulin and 2–h post–load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Nijpels G, et al. **Diabetologia** 1996 Jan;39(1):113–8

GENETICS

Altered insulin receptor messenger ribonucleic acid splicing in liver is associated with deterioration of glucose tolerance in the spontaneously obese and diabetic rhesus monkey: analysis of controversy between monkey and human studies. Huang Z, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1552–6

IMMUNOLOGY

Autoimmunity to the GM2–1 islet ganglioside before and at the onset of type I diabetes. Dotta F, et al. **Diabetes** 1996 Sep;45(9):1193–6

ICA512 autoantibody radioassay. Gianani R, et al. **Diabetes** 1995 Nov;44(11):1340–4

Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Bonifacio E, et al. **Diabetologia** 1995 Jul;38(7):816–22

Elevated serum levels of macrophage–derived cytokines precede and accompany the onset of IDDM. Hussain MJ, et al. **Diabetologia** 1996 Jan;39(1):60–9

Homing of lymphocytes into islets of Langerhans in prediabetic non–obese diabetic mice is not restricted to autoreactive T cells. Faveeuw C, et al. **Int Immunol** 1995 Dec;7(12):1905–13

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin–dependent diabetes. Rudy G, et al. **Mol Med** 1995 Sep;1(6):625–33

The 37/40–kilodalton autoantigen in insulin–dependent diabetes mellitus is the putative tyrosine phosphatase IA–2. Passini N, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9412–6

PATHOLOGY

Homing of lymphocytes into islets of Langerhans in prediabetic non–obese diabetic mice is not restricted to autoreactive T cells. Faveeuw C, et al. **Int Immunol** 1995 Dec;7(12):1905–13

PHYSIOPATHOLOGY

Prediabetic blood pressure and familial predisposition to renal disease in Pima Indians with non–insulin–dependent diabetes mellitus. Nelson RG, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):212–4

SURGERY

Expression of cytokines during rejection of fetal pig islet xenografts in nonobese diabetic mice. Kovarik J, et al. **Transplant Proc** 1996 Apr;28(2):811

THERAPY

Intranasal administration of insulin peptide B: 9–23 protects NOD mice from diabetes. Daniel D, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:371–2

PREDICTIVE VALUE OF TESTS

see related
FALSE NEGATIVE REACTIONS
FALSE POSITIVE REACTIONS

Accuracy and predictive values in clinical decision–making. Eisenberg MJ. **Cleve Clin J Med** 1995 Sep–Oct;62(5):311–6

To test or not to test: where is the truth? [letter] Gilseth M. **J Clin Oncol** 1996 Apr;14(4):1406–7

Cessation of follow–up tests with limited utility: a patient's perspective [letter] Loprinzi CL. **J Clin Oncol** 1996 Apr; 14(4):1406

Electrocardiographic diagnosis of acute myocardial infarction in the presence of left bundle–branch block [letter; comment] Ackermann RJ, et al. **N Engl J Med** 1996 Jul 11;335(2):131–2; discussion 133. Comment on: N Engl J Med 1996 Feb 22;334(8):481–7.

Bayesian imputation of predictive values when covariate information is available and gold standard diagnosis is unavailable. Epstein LD, et al. **Stat Med** 1996 Mar 15; 15(5):463–76

On the sample size for one–sided equivalence of sensitivities based upon McNemar's test. Lu Y, et al. **Stat Med** 1995 Aug 30;14(16):1831–9

Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute rejection of renal allografts. Copin MC, et al. **Transpl Immunol** 1995 Sep;3(3):229–39

[The ROC curve in the measurement of the diagnostic value of tests] Forsström JJ. **Duodecim** 1995;111(3):237–44 (41 ref.) **(Fin)**

[Predictive value of Calprotect Phical (letter)] Bolann BJ, et al. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3855 **(Nor)**

[Principles of priorities in health care and predictive tests discussed at a Scandinavian ethics meeting] Oldinger E. **Nord Med** 1995;110(12):323–4 **(Swe)**

PREDISPOSING FACTORS see **CAUSALITY**

PREDNISOLONE

ADMINISTRATION & DOSAGE

Double–blind, placebo–controlled study of cyclosporin A as a corticosteroid–sparing agent in corticosteroid–dependent asthma. Lock SH, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):509–14

Adjuvant high–dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Beckers RC, et al. **Br J Dermatol** 1995 Aug;133(2):289–93

An N–of–1 trial for treatment of hyperemesis gravidarum. Magee LA, et al. **Br J Obstet Gynaecol** 1996 May;

103(5):478–80
Withdrawal of corticosteroid therapy after acute asthma attacks. **Can Med Assoc J** 1995 Nov 15;153(10):1471, 1473 **(Eng, Fre)**
Long-term cyclosporin in steroid-dependent nephrotic syndrome. Yoshikawa N, et al. **Contrib Nephrol** 1995; 114:19–27
Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? Kirwan JR, et al. **Drugs Aging** 1996 Mar;8(3):157–61 (16 ref.)
Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. Sheen IS, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):143–7
Treatment of Kawasaki disease with corticosteroid [letter] Shinohara M, et al. **J Pediatr** 1996 Sep;129(3):483–4; discussion 484–5
Perioperative steroid cover. Levy A. **Lancet** 1996 Mar 30; 347(9005):846–7
Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study. Lu SY, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):705–9
Pleural effusion in ankylosing spondylitis; successful treatment with intra-pleural steroid administration. Tanaka H, et al. **Respir Med** 1995 Aug;89(7):509–11
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment [see comments] Gibson GJ, et al. **Thorax** 1996 Mar;51(3):238–47. Comment in: Thorax 1996 Mar;51(3):229–30.
[Anti-Jo-1-positive polymyositis with interstitial alveolitis and pericardial effusion. Overview of 3 years treatment] Krajnc I. **Wien Klin Wochenschr** 1995;107(19):590–2 (Eng. Abstr.) **(Ger)**
[Steroid-responsive sensorineural hearing loss with low tone loss] Toriya R, et al. **Fukuoka Igaku Zasshi** 1995 Nov; 86(11):417–23 (Eng. Abstr.) **(Jpn)**
[Acute pulmonary disease in systemic lupus erythematosus successfully treated with prednisolone pulse therapy] Kashiwabara K, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Jan; 34(1):106–10 (Eng. Abstr.) **(Jpn)**
[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al.
Nippon Naika Gakkai Zasshi 1995 Nov 10;84(11):1865–9 (5 ref.) **(Jpn)**
[Association of precore mutant HBV with HBe-seroconversion] Daikoku M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:201–4 **(Jpn)**
[Corticosteroid withdrawal therapy for hepatitis B] Kumada H. **Nippon Rinsho** 1995 Oct;53 Suppl:635–9 **(Jpn)**
[Evaluation in long term observation of corticosteroid withdrawal therapy for chronic hepatitis type B] Yano M. **Nippon Rinsho** 1995 Oct;53 Suppl:640–2 **(Jpn)**
[Secondary gastrointestinal amyloidosis: successful treatment with TPN, prednisolone and colchicine therapy. Report of a case] Muramatsu S, et al.
Nippon Shokakibyo Gakkai Zasshi 1995 Oct;92(10):1770–5 **(Jpn)**
[Experience in the use of lymphatic infusion preparations in multimodal treatment of patients with giant lung abscess] Opanasenko NS. **Klin Khir** 1996;(1):25–7 **(Rus)**

ADVERSE EFFECTS

Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Sato A, et al. **Am J Hypertens** 1995 Aug; 8(8):823–8
Osteoporosis in steroid-dependent asthma. Villareal MS, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):369–72
Budesonide or prednisolone in active Crohn's disease [editorial] Baert F, et al. **Ann Med** 1995 Dec;27(6):631
Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids [see comments] Leibowitz HM, et al. **Arch Ophthalmol** 1996 Aug; 114(8):933–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1000–1.
Polymyalgia rheumatica and giant cell arteritis [letter; comment] Myles AB. **BMJ** 1995 Nov 4;311(7014):1232. Comment on: BMJ 1995 Aug 12;311(7002):455.
Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Walsh LJ, et al. **BMJ** 1996 Aug 10;313(7053):344–6
Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Carpani de Kaski M, et al. **Gut** 1995 Nov;37(5):613–6
Hospital acquired pulmonary nocardiosis complicating polymyositis. Gupta D, et al. **J Assoc Physicians India** 1995 Sep;43(9):641–2
Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Ratcliffe PJ, et al. **Lancet** 1996 Sep 7;348(9028):643–8
Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Deodhar AA, et al. **N Engl J Med** 1995 Dec 7;333(23):1569–70. Comment on: N Engl J Med 1995 Jul 20;333(3):142–6.
Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Fries JF, et al. **N Engl J Med** 1995 Dec 7;333(23):1569; discussion 1570. Comment on: N Engl J Med 1995 Jul 20;333(3):142–6.
Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate [see comments] Morice AH, et al. **Thorax** 1995 Nov;50(11):1221–2. Comment in: Thorax 1995 Nov;50(11):1222–3.
Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation. Höfle G, et al. **Thyroid** 1995 Dec;5(6):477–80
Clinical analysis of steroid glaucoma. Kong L, et al.
Yen Ko Hsueh Pao 1995 Mar;11(1):53–6
[Using a lipid clearing drug to prevent osteocytes damage of the femoral head in steroid-treated rabbits] Zhou M, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):13–6 (Eng. Abstr.) **(Chi)**
[Acute myopathy in an asthmatic patient treated with corticoids and muscle relaxants in the intensive care unit] Sangla I, et al. **Presse Med** 1996 Feb 24;25(7):284–6 (Eng. Abstr.) **(Fre)**
[Acute exacerbation by reactivation of HBV in steroid withdrawal therapy] Arase Y. **Nippon Rinsho** 1995 Oct;53 Suppl:522–6 (6 ref.) **(Jpn)**
[Effect of human PTH on steroid-induced osteopenia: a histomorphometric study of decalcified and undecalcified trabecular bone sections in rat] Unoki E.
Nippon Seikeigeka Gakkai Zasshi 1995 Oct;69(10):1064–75 (Eng. Abstr.) **(Jpn)**
[Generalized cryptococcosis in secondary immunodeficiency induced by long-term steroid therapy (on the 100th anniversary of the day of first discovery in 1894)] Khmelynitski i OK, et al. **Arkh Patol** 1995 Nov–Dec; 57(6):66–70 (Eng. Abstr.) **(Rus)**
[A case of steroid tuberculosis in systemic scleroderma] Kazak TI, et al. **Probl Tuberk** 1996;(2):57–8 **(Rus)**
[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis] Tsurko VV, et al. **Ter Arkh** 1995; 67(7):71–4 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Subcellular pathologic features of glucocorticoid-induced hepatopathy in dogs. Rutgers HC, et al. **Am J Vet Res** 1995 Jul;56(7):898–907
The effects of corticosteroids of adenoviral replication. Romanowski EG, et al. **Arch Ophthalmol** 1996 May; 114(5):581–5
Non-surgical management of the carpal tunnel syndrome [letter] Myles AB, et al. **Br J Rheumatol** 1995 Sep; 34(9):890–1
Contact sensitivity to 5 different ingredients of a topical medicament (Imacort cream). Brand CU, et al.
Contact Dermatitis 1995 Aug;33(2):137
Alpha-crystallin acting as a molecular chaperone protects catalase against steroid-induced inactivation. Hook DW, et al. **FEBS Lett** 1996 Mar 18;382(3):281–4
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Kaspers GJ, et al.
Med Pediatr Oncol 1996 Aug;27(2):114–21
Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16 alpha-alkoxycarbonyl-17-deoxyprednisolone derivatives. Yoon KJ, et al. **Steroids** 1995 Jul;60(7):445–51
[Does lung maturation therapy with 16-methylene-prednisolone modify maternal infection parameters in threatened premature labor?] Winkler M, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):317–21 (Eng. Abstr.) **(Ger)**
[Prednisolone acetate reference standard (Control 941) of the National Institute of Health Sciences] Kitajima A, et al. **Eisei Shikenjo Hokoku** 1995;(113):107–10 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Improved HPLC method for simultaneous analysis of cortisol, 11-deoxycortisol, prednisolone, methylprednisolone, and dexamethasone in serum and urine. McWhinney BC, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):979–81

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

PHARMACOKINETICS

Combined effect of d-limonene pretreatment and temperature on the rat skin permeation of lipophilic and hydrophilic drugs. Ohara N, et al. **Biol Pharm Bull** 1995 Mar; 18(3):439–42
Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. Chen CL, et al. **Chin J Physiol** 1995; 38(1):1–6
The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Harris RZ, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):429–35
Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. Homma M, et al. **J Pharm Pharmacol** 1995 Aug;47(8):687–92
Topographic distribution of prednisolone in the lens after organ culture. Kojima M, et al. **Ophthalmic Res** 1995;27 Suppl 1:25–33
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Möllmann H, et al. **Pharm Res** 1995 Jul; 12(7):1096–100
Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Rohatagi S, et al.
Pharmazie 1995 Sep;50(9):610–3
Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)
[Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog] Kietzmann M, et al.
DTW Dtsch Tierarztl Wochenschr 1996 Jan;103(1):14–6 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Breese EJ, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):547–52
Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recombinant alpha-interferon with steroid priming. Guan R, et al.
Aliment Pharmacol Ther 1995 Oct;9(5):535–40
In vitro culture with prednisolone increases BCL-2 protein expression in adult acute lymphoblastic leukemia cells. Tosi P, et al. **Am J Hematol** 1996 Apr;51(4):261–4
Recovery of corticosteroid-induced changes in contractile properties and morphology of rat diaphragm. Dekhuijzen PN, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):769–75
In vivo effect of prednisolone on release of leukotriene C4 in eosinophils obtained from asthmatic patients. Shindo K, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):869–74
In vivo effect of prednisolone on release of leukotriene B4 from neutrophils from asthmatic patients. Shindo K, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):759–63
Modulation by prednisolone of calcium handling in skeletal muscle cells. Metzinger L, et al. **Br J Pharmacol** 1995 Dec; 116(7):2811–6
Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Taborda-Barata L, et al.
Clin Exp Allergy 1996 Jan;26(1):68–78
Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells. Shimojo M, et al. **Endocr J** 1995 Oct; 42(5):629–36
Concomitant use of prostaglandin E1 and prednisolone; inhibition of superoxide anion production by polymorphonuclear leucocytes. Miyata M, et al.
Fukushima J Med Sci 1995 Jun;41(1):15–28
TNF-alpha participates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice. Nagai H, et al. **Inflamm Res** 1996 Mar;45(3):136–40
Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model. Oluyomi AO, et al. **Inflamm Res** 1995 Aug;44(8):350–6
Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone. Towbin H, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S160–1
In vivo effects of various therapies on complement-sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria. Shichishima T, et al. **Int J Hematol** 1996 Jun;63(4):291–302
Lipocortin-1 distribution in bronchoalveolar lavage from healthy human lung: effect of prednisolone. Smith SF, et al. **J Appl Physiol** 1995 Jul;79(1):121–8
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Ito C, et al. **J Clin Oncol** 1996 Aug;14(8):2370–6
Prednisolone blocks extreme intermale social aggression in seizure-induced, brain-damaged rats: implications for the amygdaloid central nucleus, corticotrophin-releasing factor, and electrical seizures. Bedard AW, et al.
Psychol Rep 1995 Aug;77(1):3–9
Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)
[Determination of individual sensitivity of peripheral blood lymphocytes to cytostatic agents and hormones] Rakitanskaia IA, et al. **Klin Lab Diagn** 1995 Sep–Oct; (5):23–4 **(Rus)**

THERAPEUTIC USE

Long-term corticosteroid therapy for gastric antral vascular ectasia [letter] Suzuki T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1873–4
High-dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura [letter] Saito N, et al.
Am J Hematol 1996 Feb;51(2):173–4
Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. Vanherweghem JL, et al.
Am J Kidney Dis 1996 Feb;27(2):209–15
Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Foster CS, et al. **Am J Ophthalmol** 1996 Aug;122(2):171–82
Prednisolone treatment in asthma. Reduction in the numbers

of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Bentley AM, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):551-6

Is the time for steroids in treatment of asthma over? [letter] Kanwar BA, et al. **Am J Respir Crit Care Med** 1996 Sep; 154(3 Pt 1):823-4

Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):557-60

Eosinophil activity reflects clinical status in patients with asthma before and during a prednisolone course. Skedinger M, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):250-5

Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Krogsgaard MR, et al. **Ann Rheum Dis** 1996 Feb;55(2):143-6

Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Stichtenoth DO, et al. **Ann Rheum Dis** 1995 Oct; 54(10):820-4

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607-27 (87 ref.)

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109-12 (19 ref.)

Systemic steroids and eczematized Darier's disease [letter; comment] Gordon PM, et al. **Br J Dermatol** 1995 Sep; 133(3):492. Comment on: Br J Dermatol 1994 Nov;131(5):713-6.

Effects of allopurinol and steroids on inflammation and oxidative tissue damage in experimental lens induced uveitis: a biochemical and morphological study. Augustin AJ, et al. **Br J Ophthalmol** 1996 May;80(5):451-7

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Maillefert JF, et al. **Br J Rheumatol** 1996 May;35(5):430-5

Prednisolone non-compliance and its related factors in patients with systemic lupus erythematosus. Lin WS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct; 56(4):244-51

Lymphocytic hypophysitis [letter] Cohen R, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):769

Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Robinson DS, et al. **Clin Exp Allergy** 1995 Nov;25(11):1118-27

Immunosuppression in rapidly progressive Henoch-Schoenlein nephritis [letter] Worth DP. **Clin Nephrol** 1996 Feb;45(2):135-6

Large vessel vasculitis without temporal artery involvement: isolated form of giant cell arteritis? Lambert M, et al. **Clin Rheumatol** 1996 Mar;15(2):174-80

Cyclosporin in steroid-resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73-7 (32 ref.)

Corticosteroid treatment does not improve the results of intrauterine insemination in male subfertility caused by antisperm antibodies. Grigoriou O, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):227-30

Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits [letter] Kulkarni PS, et al. **Exp Eye Res** 1995 Dec;61(6):767-8

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Modigliani R, et al. **Gastroenterology** 1996 Mar;110(3):688-93

A controlled double blind study of azathioprine in the management of Crohn's disease. Candy S, et al. **Gut** 1995 Nov;37(5):674-8

Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Kjeldsen J, et al. **Gut** 1995 Dec;37(6):805-10

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Lee FI, et al. **Gut** 1996 Feb;38(2):229-33

A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Chayama K, et al. **Hepatology** 1996 May;23(5):953-7

Ovarian autoimmunity and corticotherapy in an in-vitro fertilization attempt. Barbarino-Monnier P,, et al. **Hum Reprod** 1995 Aug;10(8):2006-7

Therapeutic uses of methyl prednisolone. Mondal T, et al. **Indian Pediatr** 1995 Jul;32(7):787-93 (26 ref.)

Combined treatment with ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to) plus prednisolone on adjuvant-induced arthritis in Lewis rat. Harigai E, et al. **Int J Immunopharmacol** 1995 May;17(5):411-8

Steroid pulse therapy in lupus cystitis [see comments] Segawa C, et al. **Intern Med** 1996 Feb;35(2):155-8. Comment in: Intern Med 1996 Feb;35(2):87-8.

The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid-resistant bronchial asthma. Sousa AR, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):698-706

Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome? Singh NK, et al. **J Assoc Physicians India** 1996 Jan;44(1):22-4

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582-6 (22 ref.)

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. Adcock IM, et al. **J Exp Med** 1995 Dec 1;182(6):1951-8

Corticosteroids for the management of ulcerative colitis. Oshitani N, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:118-20

Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. Tynell E, et al. **J Infect Dis** 1996 Aug;174(2):324-31

Nonsurgical management of surgical otitis media with effusion. Rosenfeld RM. **J Laryngol Otol** 1995 Sep; 109(9):811-6

Effects of prednisolone and dexamethasone on alkali burns of the esophagus in rabbit. Bautista A, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):275-83

An empirical model of hyperopic shift with corticosteroid modulation and refractive power prediction after photorefractive keratectomy. Wang W, et al. **J Refract Surg** 1995 May-Jun;11(3 Suppl):S314-8

Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids [see comments] Gudbjörnsson B, et al. **J Rheumatol** 1996 Apr;23(4):596-602 . Comment in: J Rheumatol 1996 Apr;23(4):577-81.

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. Krogsgaard MR, et al. **J Rheumatol** 1995 Sep;22(9):1660-2

Extratemporal facial nerve paralysis after blunt trauma. Simo R, et al. **J Trauma** 1996 Feb;40(2):306-7

Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia. Kaspers GJ, et al. **Leukemia** 1996 Apr;10(4):675-81

Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Porter D. **N Engl J Med** 1995 Dec 7; 333(23):1569; discussion 1570. Comment on: N Engl J Med 1995 Jul 20;333(3):142-6.

Successful trial of steroids in two haemodialysis patients with inflammatory disease and anaemia unresponsive to recombinant erythropoietin [letter] Tzanakis I, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):400-1

Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Chan TM, et al. **Nephron** 1995;71(3):321-7

Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Kobayashi Y, et al. **Nephron** 1996;72(2):237-42

Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids. Jude EB, et al. **Postgrad Med J** 1996 Aug; 72(850):489-91

Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. D'Ercole C, et al. **Prenat Diagn** 1995 Dec; 15(12):1171-5

Pulmonary amyloidosis: treatment with laser therapy and systemic steroids. Nugent AM, et al. **Respir Med** 1996 Aug; 90(7):433-5

Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Galarza I, et al. **Thorax** 1995 Dec; 50(12):1305-7

Compliance with oral corticosteroids during steroid trials in chronic airways obstruction. Hatton MQ, et al. **Thorax** 1996 Mar;51(3):323-4

Conversion of cyclosporine to azathroprine in renal transplant recipients. Bassiri A, et al. **Transplant Proc** 1995 Oct;27(5):2691

Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy. Kehinde EO, et al. **Transplant Proc** 1996 Jun;28(3):1449-50

Withdrawal or reduction of steroids based on pharmacodynamics assessed by antilymphocyte action after renal transplantation. Kozaki K, et al. **Transplant Proc** 1996 Jun;28(3):1300-1

Retrospective study of cyclosporine-prednisolone versus cyclosporine-azathioprine-prednisolone immunosuppression in living donor kidney transplantation. Reissi D, et al. **Transplant Proc** 1995 Oct;27(5):2685-6

High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression. Sakhuja V, et al. **Transplant Proc** 1995 Oct;27(5):2728-30

[Specific respiratory manifestations associated with hemorrhagic rectocolitis. Analysis of a case and review of the literature] Lagier E, et al. **Gastroenterol Clin Biol** 1996;20(4):397-400 (28 ref.) (Eng. Abstr.) **(Fre)**

[Study on a predictive marker for evaluating the effectiveness of steroid therapy in IgA nephropathy-significance of extracapillary changes] Yamamoto S, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb;38(2):74-83 (Eng. Abstr.) **(Jpn)**

[Primary myelofibrosis with positive coombs' test responding to prednisolone] Yumoto Y, et al. **Rinsho Ketsueki** 1996 Mar;37(3):255-9 (Eng. Abstr.) **(Jpn)**

TOXICITY

In vivo morphological changes in rat lenses induced by the administration of prednisolone after subliminal X-irradiation. A preliminary report. Shui YB, et al. **Ophthalmic Res** 1995;27(3):178-86

PREDNISOLONE, TOPICAL

ADVERSE EFFECTS

Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Bircher AJ, et al. **Acta Derm Venereol** 1995 Nov;75(6):490-3 (38 ref.)

PREDNISONE

ADMINISTRATION & DOSAGE

Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Książek J, et al. **Acta Paediatr** 1995 Aug;84(8):889-93

A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study. Hogg RJ. **Am J Kidney Dis** 1995 Nov; 26(5):792-6

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Noonan M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1467-73

Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Liang GC, et al. **Arthritis Rheum** 1996 Jan;39(1):171-4 (15 ref.)

Pustular psoriasis of pregnancy. Lee SH, et al. **Australas J Dermatol** 1995 Nov;36(4):199-200

Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis [see comments] Lê Thi Huong D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):9-16. Comment in: Clin Exp Rheumatol 1996 Jan-Feb;14(1):1-4.

Steroids in acute asthma: oral or nebulized? Singhi S. **Indian Pediatr** 1996 Mar;33(3):262-3

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Sangfelt O, et al. **Int J Cancer** 1995 Oct 9; 63(2):190-2

Use of supplemental steroids in patients having orthopaedic operations. Friedman RJ, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1801-6

Nontapering versus tapering prednisone in acute exacerbations of asthma: a pilot trial. Verbeek PR, et al. **J Emerg Med** 1995 Sep-Oct;13(5):715-9

Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. Kobashigawa JA, et al. **J Heart Lung Transplant** 1995 Sep-Oct;14(5):963-7

Treatment of hemangiomas of infants with high doses of prednisone. Sadan N, et al. **J Pediatr** 1996 Jan;128(1):141-6

Short term effect of methotrexate in severe steroid-dependent asthma. Kanzow G, et al. **Lung** 1995;173(4):223-31

Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Roccatello D, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2054-9

Prehospital management of asthmatic children [letter; comment] Perry RF, et al. **Pediatr Emerg Care** 1996 Feb; 12(1):71-2. Comment on: Pediatr Emerg Care 1995 Aug;11(4):217-9.

Steroids and asthma [letter] Van Ditzhuyzen O, et al. **Pediatrics** 1996 Jul;98(1):169; discussion 169-70

Steroids and asthma [letter] Weinberger M. **Pediatrics** 1996 Jul;98(1):168-9; discussion 169-70

Perforation of the stomach during laparoscopic Nissen fundoplication in a patient on chronic corticosteroid therapy [letter] Helling TS. **Surg Endosc** 1995 Oct; 9(10):1146

Single dose of prednisone does not induce amphetamine-like subjective effects in healthy subjects. Warot D, et al. **Therapie** 1995 Jul-Aug;50(4):307-12

Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Hilbrands LB, et al. **Transplantation** 1996 Apr 15;61(7):1038-46

[Treatment of ocular inflammatory disease with glucocorticoids and cyclophosphamide pulses] Cuchacovich M, et al. **Rev Med Chil** 1995 Jul;123(7):865-73 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Pichette V, et al. **Am J Kidney Dis** 1996 Jul;28(1):105-14

Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis [letter; comment] Roger L. **Am J Med** 1995 Dec;99(6):692-4. Comment on: Am J Med 1994 Feb;96(2):115-23.

Bilateral exudative retinal detachment complicating systemic corticosteroid therapy in the presence of renal failure. Desatnik HR, et al. **Am J Ophthalmol** 1996 Sep; 122(3):432-4

Greater risk of incisional hernia with morbidly obese than

steroid-dependent patients and low recurrence with prefascial polypropylene mesh. Sugerman HJ, et al. **Am J Surg** 1996 Jan;171(1):80–4

Corticosteroid-induced suicide attempt [letter] Uva JL. **Ann Emerg Med** 1996 Sep;28(3):376–7

Testosterone treatment of men treated with glucocorticoids [editorial; comment] Odell WD. **Arch Intern Med** 1996 Jun 10;156(11):1133–4. Comment on: Arch Intern Med 1996 Jun 10;156(11):1173–7.

Oral prednisone as a risk factor for infections in children with asthma. Grant CC, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):58–63

Bone density loss during treatment of chronic GVHD. Stern JM, et al. **Bone Marrow Transplant** 1996 Mar;17(3):395–400

The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Pons F, et al. **Br J Rheumatol** 1995 Aug;34(8):742–6

Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Saito JK, et al. **Calcif Tissue Int** 1995 Aug;57(2):115–9

Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Lems WF, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):293–7

Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Hricik DE, et al. **Clin Transplant** 1995 Oct;9(5):419–23

Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. Paz-Pacheco E, et al. **J Bone Miner Res** 1995 Nov;10(11):1713–8

Muscle glycogen of steroid myopathy patients [letter] Schliselfeld LH, et al. **J Neurol Sci** 1996 Mar; 136(1–2):192–5

Steroid therapy can modulate gut barrier function, host defense, and survival in thermally injured mice. Gianotti L, et al. **J Surg Res** 1996 Apr;62(1):53–8

Cytotoxic therapy and side effect in childhood. Inaba S. **J Toxicol Sci** 1995 Sep;20(4):485–6

Nocturnal growth hormone (GH) secretion and GH response to clonidine provocation in children before and after long-term prednisone therapy. Soliman AT, et al. **J Trop Pediatr** 1995 Dec;41(6):344–7

Non-ketotic hyperosmolar coma complicating steroid treatment in childhood nephrosis. Yang JY, et al. **Pediatr Nephrol** 1995 Oct;9(5):621–2

Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Van Dongen-Melman JE, et al. **Pediatr Res** 1995 Jul;38(1):86–90

Fatal Cytomegalovirus pneumonia in a patient receiving corticosteroids and methotrexate for mixed connective tissue disease. Wallace JR, et al. **South Med J** 1996 Jul; 89(7):726–8

[Tumor lysis syndrome in chronic lymphoid leukemia treated with chlorambucil and prednisone (letter)] Alliot C, et al. **Presse Med** 1995 Sep 2–9;24(25):1178 **(Fre)**

ANALOGS & DERIVATIVES

Tuberculous peritonitis complicating corticosteroid therapy for acute alcoholic hepatitis [letter] Korula J. **Dig Dis Sci** 1995 Oct;40(10):2119–20

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetic interactions between zileuton and prednisone. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:105–11

Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Jonkers RE, et al. **Eur J Clin Pharmacol** 1995;49(1–2):37–44

PHARMACOLOGY

The influence of encortone on changes of some parameters of parotid serous cells of female white rats of Wistar breed. Zarębska A. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:51–6

Modulation of alpha-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers. Hendrix CW, et al. **Antiviral Res** 1995 Oct; 28(2):121–31

Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Lanza L, et al. **Clin Exp Immunol** 1996 Mar;103(3):482–90

Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Lems WF, et al. **Clin Rheumatol** 1995 Jul; 14(4):420–4

A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. Howland WC 3rd, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):32–8

The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Hilbrands LB, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2073–81

[Effects of prednisone and azathioprine treatment on oligoclonal IGG in the cerebrospinal fluid of multiple sclerosis patients. Preliminary communication] Losy J, et al. **Neurol Neurochir Pol** 1996 Mar-Apr;30(2):201–11 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Skinner M, et al. **Am J Med** 1996 Mar;100(3):290–8

Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Smith MC, et al. **Am J Med** 1996 Jul;101(1):41–8

Case reports: continuous corticosteroids for refractory poorly differentiated lymphocytic lymphoma. Newcom SR. **Am J Med Sci** 1996 Sep;312(3):136–7

Inspiratory muscle strength and endurance in steroid-dependent asthma. Perez T, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):610–5

Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Thompson WH, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):407–12

Pulmonary valvular stenosis associated with Takayasu's Disease. Favorable response to corticosteroids. A case report. Rangel A, et al. **Angiology** 1996 Jul;47(7):717–24

Outpatient management of acute urticaria: the role of prednisone [see comments] Pollack CV Jr, et al. **Ann Emerg Med** 1995 Nov;26(5):547–51. Comment in: Ann Emerg Med 1996 Apr;27(4):527–8.

Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Scarfone RJ, et al. **Ann Emerg Med** 1995 Oct;26(4):480–6

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley RJ, et al. **Ann Intern Med** 1996 Sep 1;125(5):376–83

Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Adour KK, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):371–8

Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Whitley RJ, et al. **Antiviral Res** 1996 Jan;29(1):67–8

A prognostic index for multiple myeloma. Grignani G, et al. **Br J Cancer** 1996 May;73(9):1101–7

Oral prednisone in the treatment of acne agminata. Uesugi Y, et al. **Br J Dermatol** 1996 Jun;134(6):1098–100

Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Meakin JW, et al. **Breast Cancer Res Treat** 1996;37(1):11–9

Giant cell arteritis: diagnosis and management. Kachroo A, et al. **Bull Rheum Dis** 1996 Aug;45(5):2–5

Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Benyounes B, et al. **Chest** 1996 Jul;110(1):284–6

Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Wyser C, et al. **Chest** 1996 Aug;110(2):333–8

Interleukin-6 activity in dogs with juvenile polyarteritis syndrome: effect of corticosteroids. Hogenesch H, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):107–10

Concentrations of interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for tuberculous meningitis. Donald PR, et al. **Clin Infect Dis** 1995 Oct;21(4):924–9

Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Talati SJ, et al. **Clin Nucl Med** 1995 Nov;20(11):995–7

Henoch-Schonlein purpura associated with coxsackie-virus B1 infection [letter] Costa MM, et al. **Clin Rheumatol** 1995 Jul;14(4):488–90

Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Pedrosa MC, et al. **Clin Transplant** 1995 Aug;9(4):322–5

The treatment of infantile spasms by paediatric neurologists in the UK and Ireland [letter] Appleton RE. **Dev Med Child Neurol** 1996 Mar;38(3):278–9

Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Généreau T, et al. **Dig Dis Sci** 1996 Apr; 41(4):684–8

Effect of systemic steroids on ileal pouch-anal anastomosis in patients with ulcerative colitis. Ziv Y, et al. **Dis Colon Rectum** 1996 May;39(5):504–8

Current concepts in the diagnosis and treatment of sudden sensorineural hearing loss. Schweinfurth JM, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):117–21

The effect of intermittent steroid therapy on anti-sperm antibody levels. Keane D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):75–9

Use of corticosteroids in the prevention of post-ERCP pancreatitis. Weiner GR, et al. **Gastrointest Endosc** 1995 Dec;42(6):579–83

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):893–9 (25 ref.)

IVIG, anti-D or oral prednisolone in acute ITP? **Indian Pediatr** 1995 Feb;32(2):263–4

Oral prednisone therapy in experimental rhinovirus infections. Gustafson LM, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):1009–14

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. Conti A, et al. **J Endocrinol Invest** 1996 Feb;19(2):127–30

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Calleja JL, et al. **J Hepatol** 1996 Mar;24(3):308–12

The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group. Beck RW, et al. **J Neuroophthalmol** 1995 Sep;15(3):131–5

Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. Suastegui Roman RA, et al. **J Neurosurg** 1996 Apr; 84(4):629–33

Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome. de Asis ML, et al. **J Pediatr** 1995 Oct;127(4):663–5

A new surgical complication related to corticosteroids in a patient with Henoch-Schönlein purpura. van den Broek RW, et al. **J Pediatr Surg** 1995 Sep;30(9):1341–3

Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov-Dec;15(6):463–9

What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? Criswell LA, et al. **J Rheumatol** 1995 May;22(5):829–35

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. Ferraccioli G, et al. **J Rheumatol** 1996 Apr;23(4):624–8

Cytotoxic therapy and side effect in childhood. Inaba S. **J Toxicol Sci** 1995 Sep;20(4):485–6

Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Hunt LW, et al. **Mayo Clin Proc** 1996 Apr;71(4):361–8

Immunosuppressive therapy for myocarditis [letter; comment] Cunnion RE, et al. **N Engl J Med** 1995 Dec 21;333(25):1713; discussion 1714. Comment on: N Engl J Med 1995 Aug 3;333(5):269–75.

Disseminated histoplasmosis in a haemodialysis patient on immunosuppression after graft failure. Smak Gregoor PJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):542–4

Low-dose, short-term oral prednisone in the treatment of carpal tunnel syndrome. Herskovitz S, et al. **Neurology** 1995 Oct;45(10):1923–5

Reversible dementia and chorea in a young woman with the lupus anticoagulant. Van Horn G, et al. **Neurology** 1996 Jun;46(6):1599–603

MRI in Graves orbitopathy: recognition of enlarged muscles and prediction of steroid response. Polito E, et al. **Ophthalmologica** 1995;209(4):182–6

In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Guaydier-Souquières G, et al. **Osteoporos Int** 1996;6(2):171–7

Randomized trial of the efficacy of trimethoprim-sulfamethoxazole and prednisone in preventing post-tympanostomy tube morbidity. Daly KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1068–74

Treatment of childhood steroid-resistant nephrotic syndrome with pulse methylprednisolone and cyclophosphamide [letter] Sa GA, et al. **Pediatr Nephrol** 1996 Apr;10(2):250

High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randonized, blinded study. Baram TZ, et al. **Pediatrics** 1996 Mar;97(3):375–9

Steroids and asthma [letter] DeMasi JM. **Pediatrics** 1996 Jul; 98(1):169; discussion 169–70

Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Park CL, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):196–200

Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Neumann R, et al. **Retina** 1995;15(3):201–12

The quest for the ideal therapy for giant cell arteritis [letter; comment] Gonzalez-Gay MA. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7–8):539. Comment on: Rev Rhum Ed Fr 1994;61(7–8):485–90.

Immunosuppressive protocols at transplantation centers in Turkey. Haberal M, et al. **Transplant Proc** 1995 Oct; 27(5):2776–7

Triple therapy with cyclosporine A in kidney transplant patients. Matl I, et al. **Transplant Proc** 1995 Oct;27(5):2573

Donor-specific transfusions have long-term beneficial effects for human renal allografts. Flye MW, et al. **Transplantation** 1995 Dec 27;60(12):1395–401

A randomized prospective trial of steroid withdrawal after liver transplantation. McDiarmid SV, et al. **Transplantation** 1995 Dec 27;60(12):1443–50

Steroid-resistant asthma. Leung DY. **West J Med** 1995 Oct; 163(4):367–8

[Effects of thymectomy and glucocorticoid therapy on peripheral lymphocytes in myasthenia gravis] Huang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):514–7 (Eng. Abstr.) **(Chi)**

[For the present Duchenne' disease should not be treated with prednisone] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1109–11 (21 ref.) **(Dut)**

[Local corticosteroid therapy in a severe form of pemphigoid gestationis (letter)] Guillaume JC, et al. **Ann Dermatol Venereol** 1996;123(1):31 **(Fre)**

PREDNISONE

[Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant] Pilorget H, et al. **Arch Pediatr** 1996 Jan;3(1):40–3 (Eng. Abstr.) **(Fre)**

[Ulcerated necrobiosis lipoidica associated with insulin–dependent diabetes mellitus. Beneficial effect of corticosteroid therapy by oral administration] Hocqueloux L, et al. **Presse Med** 1996 Jan 6–13;25(1):25–7 (Eng. Abstr.) **(Fre)**

[Efficacy of steroid therapy in a case of hepatic hemangioendothelioma in childhood] Repetto T, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):213–5 (Eng. Abstr.) **(Ita)**

[Evaluation of the efficacy of levamisole in corticosteroid–dependent nephrotic syndrome in children] Książek J, et al. **Pediatr Pol** 1995 Dec;70(12):1037–42 (Eng. Abstr.) **(Pol)**

[Evaluation of the usefulness of bronchoalveolar lavage for prognosing and monitoring the treatment of patients with chronic allergic alveolitis] Jastrzębski D, et al. **Pneumonol Alergol Pol** 1996;64(3–4):157–64 (Eng. Abstr.) **(Pol)**

[A clinico–morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Ratner MIa, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):32–5 (Eng. Abstr.) **(Rus)**

[Autoimmune hemolytic anemia associated with Castleman's disease. Response of both diseases to glucocorticoid treatment (letter; comment)] Gómez–Espuch J, et al. **Med Clin (Barc)** 1996 May 4;106(17):677–8. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):638–9. **(Spa)**

[Comparative study of the effectiveness of 2 oral corticoids in the control of severe crisis of bronchial asthma: deflazacort and prednisone] Chapela R. **Rev Alerg Mex** 1995 Jul–Aug;42(4):64–8 (Eng. Abstr.) **(Spa)**

[Comparison of 2 treatment strategies with prednisone and interferon in chronic hepatitis B] Gómez Camacho F, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):185–90 (Eng. Abstr.) **(Spa)**

[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy] Marco P, et al. **Sangre (Barc)** 1995 Oct;40(5):389–92 (Eng. Abstr.) **(Spa)**

PRE–ECLAMPSIA

Preeclampsia and hypertensive disorders of pregnancy. Zamorski MA, et al. **Am Fam Physician** 1996 Apr; 53(5):1595–610 (32 ref.)

Low cyclic guanosine monophosphate levels in the amniotic fluid of pre–eclamptic pregnancies. Rizzo G, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):834–7

Pre–eclampsia. Mathai M. **Ceylon Med J** 1996 Mar;41(1):7–9

Free amino acid concentrations in normal and abnormal third trimester placental villi. Morris NH, et al. **Eur J Clin Invest** 1995 Oct;25(10):796–8

Preeclampsia: not simply pregnancy–induced hypertension. Roberts JM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):25–8, 31–6 (7 ref.)

Fetal biophysical profile and vibratory acoustic stimulation in high–risk pregnancies. Petrović O, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):11–5

Pre–eclampsia [editorial] Mathai M. **Natl Med J India** 1995 Sep–Oct;8(5):201–3

Postpartum tubal ligation after pregnancy complicated by preeclampsia or gestational hypertension. Vincent RD Jr, et al. **Obstet Gynecol** 1996 Jul;88(1):119–22

[Progresses in prenatal medicine in China, 1995] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):748–9 (0 ref.) **(Chi)**

[Severe preeclampsia. Analysis of a case with fatal outcome] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):192–5 (Eng. Abstr.) **(Fre)**

BLOOD

Plasma platelet aggregating factor and platelet aggregation studies in pre–eclampsia. Ahlawat S, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):428–31

Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre–eclampsia. Schneider F, et al. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):40–4

Pregnancy associated alpha–glycoprotein (SP–III) in Nigerian pregnant women. Onyemelukwe GC, et al. **Afr J Med Med Sci** 1995 Mar;24(1):17–20

Mechanical stress eliminates the effects of plasma from patients with preeclampsia on endothelial cells. Baker PN, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):730–6

Plasma P selectin (GMP–140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Halim A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):272–7

Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Hubel CA, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):975–82

Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Lyall F, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):714–8

Fetal ionized magnesium levels parallel maternal levels during magnesium sulfate therapy for preeclampsia. Mason BA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):213–7

Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Muller F, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):37–40

Endothelial dysfunction yes, cytotoxicity no! [letter; comment] Roberts JM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):978–9. Comment on: Am J Obstet Gynecol 1995 Jan;172(1 Pt 1):196–201.

Plasma and placental calcitonin gene–related peptide in pregnancies complicated by severe preeclampsia. Schiff E, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1405–9

Endothelial cell proliferation is suppressed by plasma but not serum from women with preeclampsia. Smárason AK, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):787–93

Preeclampsia: the effects of serum on endothelial cell prostacyclin, endothelin, and cell membrane integrity. Zammit VC, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):737–43

NOS expression is increased in endothelial cells exposed to plasma from women with preeclampsia. Davidge ST, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1106–12

Platelet sensitivity to prostaglandin E1 inhibition is reduced in pre–eclampsia but not in nonproteinuric gestational hypertension. Torres PJ, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):19–24

Insulin–like growth factor–binding protein 1 and insulin–like growth factor–binding protein 3 in pre–eclampsia. Wang HS, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):654–9

The concentration of plasma atrial natriuretic peptide in normotensive and preeclamptic pregnancies. Senöz S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):173–7

Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Nobunaga T, et al. **Gynecol Obstet Invest** 1996;41(3):189–93

Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Baker PN, et al. **Hypertension** 1996 Jan;27(1):56–61

Plasma glucose and pre–eclampsia. Khan KS, et al. **Int J Gynaecol Obstet** 1996 May;53(2):111–6

Brain natriuretic peptide and cyclic guanosine–3',5' monophosphate in pre–eclampsia. Lauria MR, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):128–31

Mean platelet volume of normal pregnant women and severe preeclamptic women in Siriraj Hospital. Boriboonhirunsarn D, et al. **J Med Assoc Thai** 1995 Nov;78(11):586–9

Vasospastic action of serotonin on the umbilical artery in normal and preeclamptic patients. Taniguchi K. **J Obstet Gynaecol** 1995 Feb;21(1):37–42

Soluble tumor necrosis factor receptors and soluble interleukin–6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre–eclamptic pregnancies. Opsjøn SL, et al. **J Reprod Immunol** 1995 Jul; 29(2):119–34

Serum from patients with severe preeclampsia is not cytotoxic to endothelial cells. Kupferminc MJ, et al. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):89–92

Relationship between elevated lipid peroxides, vitamin E deficiency and hypertension in preeclampsia. Jain SK, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):33–8

The comparative value of interleukin–4 in sera of women with preeclampsia and cord sera. Omu AE, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):688–91

Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Baker PN, et al. **Obstet Gynecol** 1995 Nov;86(5):815–21

Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Hsu CD, et al. **Obstet Gynecol** 1995 Dec;86(6):897–9

Soluble tumor necrosis factor receptors and interleukin–6 levels in patients with severe preeclampsia. Kupferminc MJ, et al. **Obstet Gynecol** 1996 Sep;88(3):420–7

Comparison of age distribution of umbilical cord erythrocytes in preeclampsia versus uncomplicated pregnancy. Lurie S. **Obstet Gynecol** 1996 Aug;88(2):180–3

Hypertension in pregnancy: changes in activin A maternal serum concentration. Petraglia F, et al. **Placenta** 1995 Jul; 16(5):447–54

Epidural analgesia in a preeclamptic parturient after normalization of a prolonged bleeding time with DDAVP. Fragneto RY, et al. **Reg Anesth** 1995 Sep–Oct;20(5):448–51

Comparison of thrombelastography with common coagulation tests in preeclamptic and healthy parturients. Wong CA, et al. **Reg Anesth** 1995 Nov–Dec;20(6):521–7

Concentrations of corticotrophin–releasing hormone in the umbilical–cord blood of pregnancies complicated by pre–eclampsia. Goland RS, et al. **Reprod Fertil Dev** 1995; 7(5):1227–30

Lower circulating insulin–like growth factor I and 1,25–dihydroxyvitamin D levels in preeclampsia. Halhali A, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):259–66

Flow cytometric detection of activated platelets in pregnant women prior to the development of pre–eclampsia. Janes SL, et al. **Thromb Haemost** 1995 Oct;74(4):1059–63

[Changes in plasma endothelin–1 and lipid peroxidate levels and amount of superoxidate dismutase in red blood cell in patients with pregnancy–induced hypertension] Liang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr; 31(4):220–2 (Eng. Abstr.) **(Chi)**

[The preliminary study of insulin resistance in pregnancy induced hypertension] Zhang K, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):467–70 (Eng. Abstr.) **(Chi)**

[Estriol and human placental lactogen as risk indicators in pregnancies of diabetic and hypertensive patients] Günter HH, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug; 199(4):142–7 (Eng. Abstr.) **(Ger)**

[Complications in HELLP syndrome due to peripartal hemostatic disorder] Tanner B, et al. **Zentralbl Gynakol** 1996;118(4):213–20 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Pre–eclampsia–like conditions produced by nitric oxide inhibition: effects of L–arginine, D–arginine and steroid hormones. Buhimschi I, et al. **Hum Reprod** 1995 Oct; 10(10):2723–30

COMPLICATIONS

Preeclampsia and postpartum renal failure: examples of pregnancy–induced microangiopathy [editorial] Ferris TF. **Am J Med** 1995 Oct;99(4):343–7

The need for seizure prophylaxis in preeclampsia is still unresolved [letter; comment] Burrows RF, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):800–1. Comment on: Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):929–35.

The feasibility of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy [see comments] Burrows RF, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):929–35. Comment in: Am J Obstet Gynecol 1996 Feb;174(2):800–1.

Neonatal outcome after preterm delivery for preeclampsia [letter; comment] Rigo JJr, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1080–1. Comment on: Am J Obstet Gynecol 1995 Jun;172(6):1785–8; discussion 1788–92.

A pre–eclamptic with coarctation of the aorta. Matthews PC, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):358

Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)

Spontaneous ruptured subcapsular liver hematoma associated with pregnancy. A case report. Sherbahn R. **J Reprod Med** 1996 Feb;41(2):125–8

Posterior leucoencephalopathy syndrome [letter; comment] Williams EJ, et al. **Lancet** 1996 Jun 1;347(9014):1556–7. Comment on: Lancet 1996 Apr 13;347(9007):988.

Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta–analysis. Ananth CV, et al. **Obstet Gynecol** 1996 Aug;88(2):309–18

Histochemical evaluation of placental angiotensinase A in pre–eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational proteinuric hypertension. Neudeck H, et al. **Placenta** 1996 Mar–Apr; 17(2–3):155–63

[Management of HELLP syndrome before 32 weeks of amenorrhea. 22 cases] Audibert F, et al. **Presse Med** 1996 Feb 17;25(6):235–9 (Eng. Abstr.) **(Fre)**

[Effect of preeclampsia on neonatal morbidity] Beke A, et al. **Orv Hetil** 1995 Sep 10;136(37):1999–2003 (Eng. Abstr.) **(Hun)**

[Preeclamptic liver disease] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):575–7 (12 ref.) **(Jpn)**

[Comprehensive laboratory diagnosis of intravascular blood coagulation syndrome in late gestosis] Lukinova NI, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):99–103 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Imaging techniques in an eclamptic patient–demonstration of spinal cord lesion using MRI. Rabinerson D, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):758–61

Daily antenatal testing in women with severe preeclampsia. Chari RS, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1207–10

The angiotensin sensitivity test and low–dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Kyle PM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):865–72

Urinary calcium to creatinine ratio for predicting preeclampsia. Ozcan T, et al. **Am J Perinatol** 1995 Sep; 12(5):349–51

Pressor response to cycle ergometry in the midtrimester of pregnancy: can it predict preeclampsia? Watson WJ, et al. **Am J Perinatol** 1995 Jul;12(4):265–7

Biochemical prediction of pre–eclampsia [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 May;103(5):xxii. Comment on: Br J Obstet Gynaecol 1996 May;103(5):421–6.

K4 or K5 [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Sep;103(9):vii. Comment on: Br J Obstet Gynaecol 1996 Sep;103(9):862–3.

The definition of pre–eclampsia [letter; comment] Penny J, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):192–3. Comment on: Br J Obstet Gynaecol 1995 Jul;102(7):586–7.

Liver disease in preeclampsia [clinical conference] Byrd DE, et al. **Gastroenterologist** 1996 Mar;4(1):65–9

Twenty four–hour ambulatory blood pressure monitoring in women with pre–eclampsia. Bellomo G, et al. **J Hum Hypertens** 1995 Aug;9(8):617–21

Vascular sounds in hypertensive pregnancy [letter; comment] Pirie AM, et al. **Lancet** 1996 Mar 2;347(9001):618–9. Comment on: Lancet 1996 Jan 20;347(8995):139–42.

Preventing pre-eclampsia. Roberts JM. **Lancet** 1996 Aug 3; 348(9023):281-2

Atypical presentation of preeclampsia in high-order multifetal gestations. Hardardottir H, et al. **Obstet Gynecol** 1996 Mar;87(3):370-4

Urinary calcium in asymptomatic primigravidas who later developed preeclampsia. Suarez VR, et al. **Obstet Gynecol** 1996 Jan;87(1):79-82

Determination of mineral, parathyroid hormone, and 6-keto-prostaglandin-F1 alpha levels in pregnant women with hypertension and pre-eclampsia. Sulaiman S, et al. **Singapore Med J** 1995 Dec;36(6):637-40

[Pre-eclampsia in the first half of pregnancy: an unknown problem?] van Hoven M, et al. **Ned Tijdschr Geneeskd** 1996 May 4;140(18):961-3 **(Dut)**

[Kallikrein (urine) in pregnancy-induced hypertension] Schröcksnadel H, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):580-2 (Eng. Abstr.) **(Ger)**

[Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values] Kolben M, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:126-31 (Eng. Abstr.) **(Ger)**

[Increased serum level of c-erbB-2-coded protein p105 in patients with pre-eclampsia] Meden H, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:157-60 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Definition and treatment of severe preeclampsia [letter; comment] Nisell H, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):852-3. Comment on: Acta Obstet Gynecol Scand 1995 Mar;74(3):181-5.

Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313-5 (18 ref.)

Fetal ionized magnesium levels parallel maternal levels during magnesium sulfate therapy for preeclampsia. Mason BA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):213-7

Favorable hemodynamic effects of magnesium sulfate in preeclampsia. Scardo JA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1249-53

Platelet response to vasopressin in preeclampsia [letter] van der Post J, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1897-8

Management of pre-eclampsia [letter; comment] Ward JE, et al. **Br J Anaesth** 1996 Jun;76(6):889-90. Comment on: Br J Anaesth 1996 Jan;76(1):133-48.

Use of misoprostol (prostaglandin E1 methyl analogue) to expedite delivery in severe preeclampsia remote from term. Del Valle GO, et al. **J Matern Fetal Med** 1996 Jan-Feb; 5(1):39-40

Magnesium and eclampsia [letter] Duley L. **Lancet** 1995 Nov 18;346(8986):1365

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115-22 (45 ref.)

The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Lees C, et al. **Obstet Gynecol** 1996 Jul; 88(1):14-9

The role of the vascular endothelium in the contractile responses of human chorionic plate artery in pre-eclampsia to prostaglandin F2 alpha, 5-hydroxytryptamine, and potassium chloride. Ezimokhai M, et al. **Res Exp Med (Berl)** 1995;195(3):171-82

[Effect of ritodrine hydrochloride on uterine and umbilical blood flow in patients with preeclampsia and IUGR] Kumazawa T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):939-45 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Immunohistochemical characterization of placental nitric oxide synthase expression in preeclampsia. Ghabour MS, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):687-94

Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels: high risk for maternal death. Catanzarite VA, et al. **Am J Perinatol** 1995 Sep;12(5):310-3

Nitric oxide synthase activities in placental tissue from normotensive, pre-eclamptic and growth retarded pregnancies. Morris NH, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):711-4

Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies. Rutherford RA, et al. **Br J Pharmacol** 1995 Dec;116(8):3099-109

Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. Wang Y, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):179-84

Nitric oxide synthase activity in placentae from women with pre-eclampsia. Conrad KP, et al. **Placenta** 1995 Dec; 16(8):691-9

Increased immunohistochemical expression of neutral metalloendopeptidase (enkephalinase; EC 3.4.24.11) in villi of the human placenta with pre-eclampsia. Li XM, et al. **Placenta** 1995 Jul;16(5):435-45

Histochemical evaluation of placental angiotensinase A in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational proteinuric hypertension. Neudeck H, et al. **Placenta** 1996 Mar-Apr; 17(2-3):155-63

Effect of asymmetric dimethyl arginine on nitric oxide synthase activity in normal and pre-eclamptic placentae. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1581-4

EPIDEMIOLOGY

Case-control study of maternal blood group and severe pre-eclampsia. Spinillo A, et al. **J Hum Hypertens** 1995 Aug;9(8):623-5

Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. Ananth CV, et al. **Obstet Gynecol** 1996 Aug;88(2):309-18

[Adolescent pregnancy and the development of pre-eclampsia--eclampsia] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1994;33(2):8-9 (Eng. Abstr.) **(Bul)**

[Prenatal biopsychosocial risk and preeclampsia] Herrera JA, et al. **Aten Primaria** 1995 Nov 30;16(9):552-5 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Underlying disorders associated with severe early-onset preeclampsia. Dekker GA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1042-8

Recent advances in the aetiology and management of pre-eclampsia. Scott A, et al. **Br J Hosp Med** 1996 Apr 17-30;55(8):476-8 (18 ref.)

Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Sattar N, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):614-20 (57 ref.)

Serum lipids in early pregnancy and risk of pre-eclampsia. van den Elzen HJ, et al. **Br J Obstet Gynaecol** 1996 Feb; 103(2):117-22

Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception [letter; comment] Robillard PY, et al. **Lancet** 1996 Mar 2;347(9001):619. Comment on: Lancet 1994 Oct 8;344(8928):973-5.

Malaria associated pre-eclampsia in Senegal [letter] Sartelet H, et al. **Lancet** 1996 Apr 20;347(9008):1121

Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Nugent CE, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):829-31

Advanced triploid pregnancy and preeclampsia. Sorem KA, et al. **South Med J** 1995 Nov;88(11):1144-5

Lighting and fattening--evolving concepts in the pathogenesis of preeclampsia [editorial; comment] Taylor RN. **West J Med** 1996 Apr;164(4):359-61 (12 ref.). Comment on: West J Med 1996 Apr;164(4):315-20.

[The role of nitric oxide in the pathogenesis of pregnancy induced hypertension] Li A, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):52-4 (17 ref.) **(Chi)**

-Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93-6 (18 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Chen G, et al. **Clin Exp Immunol** 1996 Apr;104(1):154-9

[A case-control study of pregnancy-induced hypertension with a genetic predisposition: association of a molecular variant of angiotensinogen in the Japanese women] Kobashi G. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):649-57 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Histochemical demonstration of interleukin-2 in decidua cells of patients with preeclampsia. Hara N, et al. **Am J Reprod Immunol** 1995 Jul;34(1):44-51

Pre-eclampsia: physiology and immunological aspects. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):85-97 (163 ref.)

Immunoglobulin G and complement C3 levels in pregnancy induced hypertension. Ramdenee GR, et al. **Indian Pediatr** 1995 Feb;32(2):179-83

[Study of the relationship between complement activation and vascular endothelial damage in pregnancy induced hypertension] Zheng Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):152-5 (Eng. Abstr.) **(Chi)**

[Role of autoantibody in preeclampsia] Yamamoto T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):146-51 (Eng. Abstr.) **(Jpn)**

METABOLISM

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432-8 (34 ref.)

Resistance to insulin-mediated glucose uptake and hyperinsulinemia in women who had preeclampsia during pregnancy. Fuh MM, et al. **Am J Hypertens** 1995 Jul; 8(7):768-71

Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia. Davidge ST, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1008-13

Secretion of prostaglandins and endothelin-1 by decidual endothelial cells from normal and preeclamptic pregnancies: comparison with human umbilical vein endothelial cells. Gallery ED, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1557-62

Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Many A, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):288-91 (60 ref.)

The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia. Orpana AK, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1056-60

Systemic and fetal-maternal nitric oxide synthesis in normal pregnancy and pre-eclampsia. Boccardo P, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):879-86

Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine. López-Jaramillo P, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):33-8

Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia [letter; comment] Meekins JW. **Br J Obstet Gynaecol** 1995 Oct;102(10):842-3. Comment on: Br J Obstet Gynaecol 1995 Jan;102(1):20-5.

Comparative study of sodium nitroprusside induced vasodilation of human placental veins from premature and full-term normotensive and preeclamptic pregnancy. Bobier HS, et al. **Can J Physiol Pharmacol** 1995 Aug; 73(8):1118-22

Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Kalenga MK, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):429-33

Altered release of endothelin-1,2 and thromboxane B2 from trophoblastic cells in pre-eclampsia. Cervar M, et al. **Eur J Clin Invest** 1996 Jan;26(1):30-7

Atrial natriuretic peptide (ANP) in preeclampsia-like syndrome in a rat model. Casper FW, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):292-6

Human mannan binding protein in pre-eclampsia. Kilpatrick DC. **Immunol Lett** 1996 Mar;49(3):175-7

Increased amniotic fluid divalent cation concentration in preeclampsia. Weiss M, et al. **J Basic Clin Physiol Pharmacol** 1995;6(1):71-7

Depressed sodium-calcium exchange in human umbilical arteries from women with preeclampsia. Sato K, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):328-32

The imbalance of plasminogen activators and inhibitor in preeclampsia. Gao M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):9-16

The role of nitric oxide metabolites during pregnancy. Begum S, et al. **Kobe J Med Sci** 1996 Apr;42(2):131-41

Base deficit and oxygen transport in severe preeclampsia. Wheeler TC, et al. **Obstet Gynecol** 1996 Mar;87(3):375-9

The effect of pre-eclampsia on human placental corticotrophin-releasing hormone content and processing [published erratum appears in Placenta 1995 Sep;16(6):567] Goland RS, et al. **Placenta** 1995 Jun;16(4):375-82

Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Lyall F, et al. **Placenta** 1995 Oct; 16(7):579-87

[Population pharmacokinetics/pharmacodynamics of magnesium sulfate in pregnancy induced hypertensive gravidas treated with the drug] Rui JZ, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):81-5 (Eng. Abstr.) **(Chi)**

[Diabetes and pregnancy] Van Assche FA. **Verh K Acad Geneeskd Belg** 1996;58(1):11-6; discussion 16-8 (Eng. Abstr.) **(Dut)**

MORTALITY

Pre-eclampsia and maternal mortality--a universal problem [editorial] Anthony J. **S Afr Med J** 1996 May;86(5):513

PATHOLOGY

Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. Dani R, et al. **Am J Gastroenterol** 1996 Feb;91(2):292-4

Hypertension, proteinuria, and hypocomplementemia in a multigravida [clinical conference] Hou S, et al. **Am J Kidney Dis** 1996 Feb;27(2):292-8

Placental pathologic features of preterm preeclampsia. Salafia CM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1097-105

Glomerular inflammation in pregnant rats after infusion of low dose endotoxin. An immunohistological study in experimental pre-eclampsia. Faas MM, et al. **Am J Pathol** 1995 Nov;147(5):1510-8

A morphometric study of preeclamptic nephropathy with focal segmental glomerulosclerosis. Lee HS, et al. **Clin Nephrol** 1995 Jul;44(1):14-21

Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. Genbacev O, et al. **J Clin Invest** 1996 Jan 15;97(2):540-50

Maternal/fetal death. Avery JK. **J Tenn Med Assoc** 1996 Feb;89(2):51-2

[Study of the relationship between complement activation and vascular endothelial damage in pregnancy induced hypertension] Zheng Y, et al.

Chung Hua Fu Chan Ko Tsa Chih 1996 Mar;31(3):152–5 (Eng. Abstr.) **(Chi)**

[Secretion of endothelin–1 by trophoblast cells and binding of endothelin–1 to trophoblast membranes in healthy and pre–eclampsia pregnancies] Cervar M, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:42–5 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Central and peripheral hemodynamics in severe preeclampsia. Yang JM, et al. **Acta Obstet Gynecol Scand** 1996 Feb; 75(2):120–6

Effects of selected vasoconstrictor agonists on isolated omental artery from premenopausal nonpregnant women and from normal and preeclamptic pregnant women. Belfort MA, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):687–93

Effects of estradiol–17 beta and progesterone on isolated human omental artery from premenopausal nonpregnant women and from normotensive and preeclamptic pregnant women. Belfort MA, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):246–53

Is fetal neurologic and physical development accelerated in preeclampsia? Chari RS, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):829–32

Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. de Groot CJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):24–9

Absence of relaxation to lactate in human placental vessels of pregnancies with severe preeclampsia. Figueroa R, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1800–6

Effect of serum on secretion of prostacyclin and endothelin–1 by decidual endothelial cells from normal and preeclamptic pregnancies. Gallery ED, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):918–23

Attachment and differentiation in vitro of trophoblast from normal and preeclamptic human placentas. Pijnenborg R, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):30–6

The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Yoneyama Y, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):267–71

Serotonin in pre–eclampsia [letter; comment] Gajraj NM, et al. **Br J Anaesth** 1996 May;76(5):748–9. Comment on: Br J Anaesth 1996 Jan;76(1):133–48.

Maternal and uteroplacental haemodynamic state in pre–eclamptic patients during spinal anaesthesia for Caesarean section. Karinen J, et al. **Br J Anaesth** 1996 May; 76(5):616–20

Recent developments in the pathophysiology and management of pre–eclampsia [see comments] Mushambi MC, et al. **Br J Anaesth** 1996 Jan;76(1):133–48 (146 ref.) . Comment in: Br J Anaesth 1996 May;76(5):748–9. Comment in: Br J Anaesth 1996 Jun;76(6):889–90.

Nitric oxide, the endothelium, pregnancy and pre–eclampsia. Morris NH, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):4–15 (152 ref.)

Blood pressure and renal function seven years after pregnancy complicated by hypertension. Nisell H, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):876–81

Oscilometric blood pressure measurements in severe pre–eclampsia: validation of SpaceLabs 90207 [letter; comment] Pirie AM, et al. **Br J Obstet Gynaecol** 1996 Jul; 103(7):721–2. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):171–3.

Oscillometric blood pressure measurements in severe pre–eclampsia: validation of the SpaceLabs 90207 [see comments] Shennan A, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):171–3. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):721–2.

Hypertensive and normal pregnancy: a longitudinal study of blood pressure, distensibility of dorsal hand veins and the ratio of the stable metabolites of thromboxane A2 and prostacyclin in plasma. Smith AJ, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):900–6

The relation of parathyroid function to pregnancy–induced hypertension. Wang W, et al. **Chin Med J (Engl)** 1995 Aug; 108(8):576–8

The physiology of pre–eclampsia. Brown MA. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):781–91 (85 ref.)

Pre–eclampsia: physiology and immunological aspects. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):85–97 (163 ref.)

Nitric oxide and prostaglandin systems inhibition on the isolated perfused human placenta from normal and preeclamptic pregnancies. González C, et al. **Gynecol Obstet Invest** 1995;40(4):244–8

Ophthalmic artery velocimetry in preeclampsia. Hata T, et al. **Gynecol Obstet Invest** 1995;40(1):32–5

Cerebral magnetic resonance angiographic findings in severe preeclampsia. Matsuda Y, et al. **Gynecol Obstet Invest** 1995; 40(4):249–52

Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre–eclampsia. Gilabert J, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:121–31 (83 ref.)

Invited editorial on "effect of altitude on uterine artery blood flow during normal pregnancy" and "alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude" [editorial; comment] Clark KE. **J Appl Physiol** 1995 Jul;79(1):5–6. Comment on: J Appl Physiol 1995 Jul;79(1):7–14. Comment on: J Appl Physiol 1995 Jul;79(1):15–22.

Alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude [see comments] Zamudio S, et al. **J Appl Physiol** 1995 Jul; 79(1):15–22. Comment in: J Appl Physiol 1995 Jul;79(1):5–6.

Pre–eclampsia does not alter the response to endothelin–1 in human omental artery. Vedernikov YP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S233–5

A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre–eclampsia. Visser W, et al. **J Hypertens** 1995 Jul;13(7):791–5

Blood pressure changes in normotensive women readmitted in the postpartum period with severe preeclampsia/eclampsia. Atterbury JL, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):201–5

Transcranial Doppler findings of cerebral vasospasm in preeclampsia. Hansen WF, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):194–200

Automated 24–hour ambulatory blood pressure monitoring in preeclampsia. Montan S, et al. **J Perinat Med** 1995; 23(5):353–8

Neonatal outcome of premature infants of mothers with preeclampsia. Shah DM, et al. **J Perinatol** 1995 Jul–Aug; 15(4):264–7

Increased placental antifibrinolytic potential and fibrin deposits in pregnancy–induced hypertension and preeclampsia. Kanfer A, et al. **Lab Invest** 1996 Jan; 74(1):253–8

Pre–eclampsia: excessive activation of a G protein–associated receptor? Coffey CG. **Med Hypotheses** 1995 May; 44(5):406–8

Pre–eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414–8 (46 ref.)

Diurnal blood pressure difference in the assessment of preeclampsia. Halligan A, et al. **Obstet Gynecol** 1996 Feb; 87(2):205–8

Cerebral palsy in very low birth weight infants, pre–eclampsia and magnesium sulphate [letter; comment] Blair E, et al. **Pediatrics** 1996 May;97(5):780–2. Comment on: Pediatrics 1995 Feb;95(2):263–9.

Pre–eclampsia and CVPs [letter] Anthony J, et al. **S Afr Med J** 1996 Mar;86(3):273

Changes observed in Doppler studies of the fetal circulation in pregnancies complicated by pre–eclampsia or the delivery of a small–for–gestational–age baby. I. Cross–sectional analysis. Harrington K, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):19–28

Preeclampsia. Still an enigma [see comments] Duda J. **West J Med** 1996 Apr;164(4):315–20 (75 ref.). Comment in: West J Med 1996 Apr;164(4):359–61.

[Uteroplacental blood flow monitoring by color Doppler flow imaging in pregnancy induced hypertension] Qiao F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):337–9 (Eng. Abstr.) **(Chi)**

[Pre–eclampsia and HELLP syndrome] Vial Y, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):267–71 **(Fre)**

[The role of vascular nitric oxide (NO) in the pathomechanism of pre–eclampsia] Visontai ZZ, et al. **Orv Hetil** 1995 Nov 19;136(47):2547–51 (50 ref.) (Eng. Abstr.) **(Hun)**

[Usefulness of standard clotting and fibrinolysis tests for evaluation of hemostatic balance in women during the III trimester of pregnancy with slight and moderate preeclampsia] Starzewski J, et al. **Przegl Lek** 1996; 53(2):83–7 (Eng. Abstr.) **(Pol)**

[Compliance of the lung–thorax system in pregnancy complicated by pre–eclampsia] Zil'ber AP, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):12–5 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

The angiotensin sensitivity test and low–dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Kyle PM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):865–72

The pharmacological prevention of pre–eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)

Prefer diazepam for initial control of pre–eclamptic fits [letter; comment] [see comments] Fox R, et al. **BMJ** 1995 Nov 25;311(7017):1433. Comment on: BMJ 1995 Sep 16;311(7007):702–3. Comment in: BMJ 1996 Mar 9;312(7013):639.

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré–eclampsia com Aspirina) Collaborative Group [see comments] **Br J Obstet Gynaecol** 1996 Jan; 103(1):39–47. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):719–20.

Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. **Br J Obstet Gynaecol** 1995 Nov;102(11):861–8

Prediction of pre–eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin [see comments] Bower SJ, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):625–9 Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Where next for prophylaxis against pre–eclampsia? [see comments] Pipkin FB, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):603–7. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Calcium supplementation during pregnancy. Melnikow JA. **J Fam Pract** 1996 Aug;43(2):115–6

Effect of calcium supplementation on pregnancy–induced hypertension and preeclampsia: a meta–analysis of randomized controlled trials [see comments] Bucher HC, et al. **JAMA** 1996 Apr 10;275(14):1113–7. Comment in: JAMA 1996 Apr 10;275(14):1128–9.

Are non–diabetic women with abnormal glucose screening test at increased risk of pre–eclampsia, macrosomia and caesarian birth? Khan KS, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):176–9

[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**

[Should nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Uzan S, et al. **Contracept Fertil Sex** 1996 Apr;24(4):262–3 **(Fre)**

[Uterine velocimetry and vascular pregnancy pathologies prevented with low–dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

–Is prevention of pre–eclampsia with low dosage aspirin possible? Critical assessment of available studies– Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Transient blindness in a preeclamptic patient secondary to cerebral edema. Shieh T, et al. **Hawaii Med J** 1996 Jul; 55(7):116–7

THERAPY

Recent developments in the pathophysiology and management of pre–eclampsia [see comments] Mushambi MC, et al. **Br J Anaesth** 1996 Jan;76(1):133–48 (146 ref.) . Comment in: Br J Anaesth 1996 May;76(5):748–9. Comment in: Br J Anaesth 1996 Jun;76(6):889–90.

Management of severe preeclampsia. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):110–3

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)

[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) **(Fre)**

[Indications for pregnancy termination in cases of pre–eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

ULTRASONOGRAPHY

Uterine Doppler wave form and the prediction of the recurrence of pre–eclampsia and intra–uterine growth retardation in patients treated with low–dose aspirin. Haddad B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):179–83

The value of Doppler study of the umbilical artery in predicting perinatal outcome in pre–eclamptic patients. Rocca MM, et al. **J Obstet Gynaecol** 1995 Oct;21(5):427–31

Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre–eclampsia, placental abruption or delivery of a small–for–gestational–age baby. Harrington K, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):182–8

[Uterine velocimetry and vascular pregnancy pathologies prevented with low–dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Standards in perinatal medicine—Doppler ultrasound in pregnancy] **Geburtshilfe Frauenheilkd** 1996 May; 56(5):M69–73 **(Ger)**

URINE

Lysosomal enzymuria in preeclampsia. Jackson DW, et al. **Am J Kidney Dis** 1996 Jun;27(6):826–33

Early prediction of pre–eclampsia by measurement of kallikrein and creatinine on a random urine sample [see comments] Millar JG, et al. **Br J Obstet Gynaecol** 1996 May;103(5):421–6. Comment in: Br J Obstet Gynaecol 1996 May;103(5):xxii.

[Urinary proteins during pregnancy in women with and without pregnancy induced hypertension] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):395–7 (Eng. Abstr.) **(Chi)**

PREENING see **GROOMING**

PRE-EXCITATION, MAHAIM-TYPE

COMPLICATIONS

Preexcitation in hypertrophic cardiomyopathy: a case of a fasciculoventricular Mahaim fiber. Stellbrink C, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1717-20

SURGERY

[Electrophysiologic findings and high frequency catheter ablation in atriofascicular and nodoventricular pathways ("Mahaim bundles")] Kottkamp H, et al. **Z Kardiol** 1995; 84 Suppl 2:153-62 (Eng. Abstr.) **(Ger)**

PRE-EXCITATION SYNDROMES

DIAGNOSIS

ECG of the month. Electrical bridges. Ventricular preexcitation. Martinez-Lopez JI. **J La State Med Soc** 1996 Jan;148(1):3-6

Use of double ventricular extrastimulation to determine the preexcitation index in atrioventricular nodal reentrant tachycardia. Wagshal AB, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2041-52

["Malignant Kent" arrhythmia, clinical case and literature review] Baroud I, et al. **Rev Med Brux** 1996 Apr;17(2):51-6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Electrocardiogram in pre-excitation] Oreto G, et al. **G Ital Cardiol** 1996 Mar;26(3):303-22 (55 ref.) **(Ita)**

[Electrocardiographic Holter monitoring in patients with ventricular pre-excitation: possibilities of its uses and pitfalls] Jurkovičová O, et al. **Vnitr Lek** 1995 Sep; 41(9):629-36 (21 ref.) (Eng. Abstr.) **(Slo)**

PATHOLOGY

Mahaim, Kent and abnormal atrioventricular conduction. Anderson RH, et al. **Cardiovasc Res** 1996 Apr;31(4):480-91 (44 ref.)

PHYSIOPATHOLOGY

Electrocardiographic and clinical precursors of ventricular fibrillation: chain of events. Bayés-Genís A, et al. **J Cardiovasc Electrophysiol** 1995 May;6(5):410-7 (47 ref.)

Regular wide QRS complex tachycardia during atrial fibrillation in a patient with preexcitation syndrome: a case report. Gatzoulis K, et al. **J Cardiovasc Electrophysiol** 1995 Jun;6(6):493-7

Transient T wave abnormalities after cessation of ventricular preexcitation: memory of what? Surawicz B. **J Cardiovasc Electrophysiol** 1996 Jan;7(1):51-9

The JT interval as a depolarization independent measurement of repolarization: lessons from catheter ablation of the Wolff-Parkinson-White syndrome. Salim MA, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2158-62

[Analysis of arrhythmias using Holter electrocardiographic monitoring in patients with ventricular preexcitation] Jurkovičová O, et al. **Bratisl Lek Listy** 1995 Aug; 96(8):420-9 (Eng. Abstr.) **(Slo)**

PREFERRED PROVIDER ORGANIZATIONS

PPOs: are they good for ASHA members? Task Force on Treatment Outcome and Cost Effectiveness. Kreb RA, et al. **ASHA** 1995 Nov-Dec;37(11-12):39-41

Infertility treatment dropout and insurance coverage. Gleicher N, et al. **Obstet Gynecol** 1996 Aug;88(2):289-93

LEGISLATION & JURISPRUDENCE

Physician-run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59-65 (20 ref.)

Any-willing-provider and freedom-of-choice laws: an economic assessment. Hellinger FJ. **Health Aff (Millwood)** 1995 Winter;14(4):297-302

Contract analysis. A guide to participating provider agreements. Volland L, et al. **N Y State Dent J** 1996 May; 62(5):36-41

ORGANIZATION & ADMINISTRATION

Managed care contracting/capitation. Reardon TM. **Ann Thorac Surg** 1995 Nov;60(5):1500-8 (0 ref.)

PREFRONTAL CORTEX

Planning and script analysis following prefrontal lobe lesions. Sirigu A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:277-88 (18 ref.)

ANATOMY & HISTOLOGY

Architecture of the prefrontal cortex and the central executive. Goldman-Rakic PS. **Ann N Y Acad Sci** 1995 Dec 15;769:71-83 (37 ref.)

Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Rajkowska G, et al. **Cereb Cortex** 1995 Jul-Aug;5(4):307-22

Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. Rajkowska G, et al. **Cereb Cortex** 1995 Jul-Aug;5(4):323-37

Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys. Carmichael ST, et al. **J Comp Neurol** 1995 Dec 25;363(4):615-641

Sensory and premotor connections of the orbital and medial prefrontal cortex of macaque monkeys. Carmichael ST, et al. **J Comp Neurol** 1995 Dec 25;363(4):642-664

Intrinsic circuit organization of the major layers and sublayers of the dorsolateral prefrontal cortex in the rhesus monkey. Kritzer MF, et al. **J Comp Neurol** 1995 Aug 14; 359(1):131-43

Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499-510 (155 ref.)

CHEMISTRY

Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. Rosenberg DR, et al. **J Comp Neurol** 1995 Jul 31;358(3):383-400

Patterns of convergence and segregation in the medial nucleus accumbens of the rat: relationships of prefrontal cortical, midline thalamic, and basal amygdaloid afferents. Wright CI, et al. **J Comp Neurol** 1995 Oct 23; 361(3):383-403

CYTOLOGY

Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Akbarian S, et al. **Arch Gen Psychiatry** 1996 May;53(5):425-36

Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Selemon LD, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):805-18; discussion 819-20

Synaptology of prefrontal cortical projections to the basolateral amygdala: an electron microscopic study in the rat. Brinley-Reed M, et al. **Neurosci Lett** 1995 Dec 29; 202(1-2):45-8

Prefrontal cortex projections to the basilar pons in rhesus monkey: implications for the cerebellar contribution to higher function. Schmahmann JD, et al. **Neurosci Lett** 1995 Oct 27;199(3):175-8

DRUG EFFECTS

Fetal alcohol exposure alters the induction of immediate early gene mRNA in the rat prefrontal cortex after an alternation task. Nagahara AH, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1389-97

L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Carey RJ, et al. **Biol Psychiatry** 1995 Nov 15;38(10):669-76

Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255-62

Left and right 6-hydroxydopamine lesions of the medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral response to stress. Carlson JN, et al. **Brain Res** 1996 Mar 4;711(1-2):1-9

Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat. Herremans AH, et al. **Brain Res** 1996 Mar 4; 711(1-2):102-11

Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum. King D, et al. **Brain Res** 1995 Jul 10; 685(1-2):117-28

Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex. Stephans SE, et al. **Brain Res** 1995 Nov 27;700(1-2):99-106

In vivo stimulated dopamine release in the nucleus accumbens: modulation by the prefrontal cortex. Thompson TL, et al. **Brain Res** 1995 Jul 17;686(1):93-8

Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Gudelsky GA. **Eur J Pharmacol** 1995 Nov 24;286(3):223-8

Excitatory responses evoked in prefrontal cortex by mediodorsal thalamic nucleus stimulation: influence of anaesthesia. Pirot S, et al. **Eur J Pharmacol** 1995 Oct 4; 285(1):45-54

Pentobarbital differentially inhibits N-methyl-D-aspartate and kainate-stimulated [3H]noradrenaline overflow in rat cortical slices. Brown LM. **Gen Pharmacol** 1995 Nov; 26(7):1603-6

Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. Kusumi I, et al. **J Neural Transm Gen Sect** 1995;101(1-3):231-5

Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. Iyer RN, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):40-7

Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission. Pan WH, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):725-31

Alterations in locomotor activity after microinjections of GBR-12909, selective dopamine antagonists or neurotensin into the medial prefrontal cortex. Radcliffe RA, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1467-76

Effects of prenatal cocaine exposure in the prefrontal cortex of the rat. A morphometric evaluation. Xavier MR, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):99-110

Influence of lipid peroxidation on [3H]ketanserin binding to 5-HT2 prefrontal cortex receptors. Rego AC, et al. **Neurochem Int** 1995 Dec;27(6):489-96

Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. See RE, et al. **Neuroreport** 1995 Sep 11;6(13):1795-8

Local injection of bicuculline into area 8 and area 6 of the rhesus monkey induces deficits in performance of a visual discrimination GO/NO-GO task. Oishi T, et al. **Neurosci Res** 1995 May;22(2):163-77

Systemic morphine and local opioid effects on neuronal activity in the medial prefrontal cortex. Giacchino JL, et al. **Neuroscience** 1996 Feb;70(4):941-9

Anesthetics decreased the microdialysis extraction fraction of norepinephrine but not dopamine in the medial prefrontal cortex. Pan WH, et al. **Synapse** 1995 Sep; 21(1):85-92

ENZYMOLOGY

Retinoid dysregulation may result in abnormal expression of glutamic acid decarboxylase in schizophrenia [letter; comment] Goodman AB. **Arch Gen Psychiatry** 1996 Jul; 53(7):653. Comment on: Arch Gen Psychiatry 1995 Apr;52(4):258-66; discussion 267-78.

Dendritic spine density of NADPH diaphorase reactive neurons in the medial prefrontal cortex (mPFC) of the rat. Gabbott PL, et al. **Brain Res** 1995 Nov 6;698(1-2):253-8

Differential expression of NADPH diaphorase in functionally distinct prefrontal cortices in the rhesus monkey. Dombroski SM, et al. **Neuroscience** 1996 May;72(1):49-62

GROWTH & DEVELOPMENT

Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Anderson SA, et al. **Neuroscience** 1995 Jul;67(1):7-22

INJURIES

D1-class dopamine receptor involvement in the behavioral recovery from prefrontal cortical injury. Vargo JM, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):39-48

Preserved speech abilities and compensation following prefrontal damage. Buckner RL, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1249-53

Time-dependent changes in dopamine agonist-induced striatal Fos immunoreactivity are related to sensory neglect and its recovery after unilateral prefrontal cortex injury. Vargo JM, et al. **Synapse** 1995 Aug;20(4):305-15

METABOLISM

Prefrontal levels of 5-HIAA, but not dopamine, predict alcohol consumption in male Wistar rats following 6-OHDA lesions. Deckel AW, et al. **Alcohol** 1995 Nov-Dec;12(6):563-8

Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Akbarian S, et al. **Brain Res** 1995 Nov 20;699(2):297-304

Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Arango V, et al. **Brain Res** 1995 Aug 7; 688(1-2):121-33

Co-localisation of NADPH diaphorase activity and GABA immunoreactivity in local circuit neurones in the medial prefrontal cortex (mPFC) of the rat. Gabbott PL, et al. **Brain Res** 1995 Nov 20;699(2):321-8

Alterations in GABAA receptor binding in the prefrontal cortex following exposure to chronic stress. Gruen RJ, et al. **Brain Res** 1995 Jun 26;684(1):112-4

Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. Pan WH, et al. **Brain Res** 1995 Jul 24;686(2):249-53

Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Sumiyoshi T, et al. **Brain Res** 1996 Feb 5;708(1-2):209-14

Organophosphorus compounds preferentially affect second messenger systems coupled to M2/M4 receptors in rat frontal cortex. Ward TR, et al. **Brain Res Bull** 1996; 39(1):49-55

GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Akbarian S, et al. **Cereb Cortex** 1995 Nov-Dec; 5(6):550-60

Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Merchant KM, et al. **Cereb Cortex** 1996 Jul-Aug; 6(4):561-70

Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. Mann JJ, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):418-26

Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. Galva MD, et al. **J Neural Transm Gen Sect** 1995;

101(1-3):83-94
Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. Kusumi I, et al. **J Neural Transm Gen Sect** 1995;101(1-3):231-5
Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. Jedema HP, et al. **J Neurochem** 1996 Apr;66(4):1448-53
Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat. Goldstein LE, et al. **J Neurosci** 1996 Aug 1;16(15):4787-98
Dye coupling between pyramidal neurons in developing rat prefrontal and frontal cortex is reduced by protein kinase A activation and dopamine. Rörig B, et al. **J Neurosci** 1995 Nov;15(11):7386-400
Concentration-dependent dual action of locally applied N-methyl-D-aspartate on extracellular dopamine in the rat prefrontal cortex in vivo. Feenstra MG, et al. **Neurosci Lett** 1995 Dec 8;201(2):175-8
Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Kolachana BS, et al. **Neuroscience** 1995 Dec;69(3):859-68
Age-related changes in diurnal acetylcholine release in the prefrontal cortex of male rats as measured by microdialysis. Mitsushima D, et al. **Neuroscience** 1996 May;72(2):429-34
Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats. Hernandez L, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):581-9
Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. Rada PV, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):809-16
Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate abstinence. Bassareo V, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):202-5
Anesthetics decreased the microdialysis extraction fraction of norepinephrine but not dopamine in the medial prefrontal cortex. Pan WH, et al. **Synapse** 1995 Sep; 21(1):85-92

PATHOLOGY

Synaptophysin immunoreactivity is stable 36 h postmortem. Liu X, et al. **Dementia** 1995 Jul-Aug;6(4):211-7
Human prefrontal lesions increase distractibility to irrelevant sensory inputs. Chao LL, et al. **Neuroreport** 1995 Aug 21; 6(12):1605-10
Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Daviss SR, et al. **Psychiatry Res** 1995 Nov 29;59(1-2):81-96

PHYSIOLOGY

No-go potential in the prefrontal cortex and electrical stimulation of its loci in monkeys. Sasaki K. **Adv Neurol** 1995;67:131-41 (20 ref.)
Effects of ibotenic acid lesions of the ventral striatum and the medial prefrontal cortex on ethanol consumption in the rat. Hansen S, et al. **Alcohol** 1995 Sep-Oct; 12(5):397-402
On some functions of the human prefrontal cortex. Damasio AR. **Ann N Y Acad Sci** 1995 Dec 15;769:241-51 (32 ref.)
Neuronal models of prefrontal cortical functions. Dehaene S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:305-19 (37 ref.)
Temporal processing. Fuster JM. **Ann N Y Acad Sci** 1995 Dec 15;769:173-81 (19 ref.)
Similarities and distinctions among current models of prefrontal cortical functions. Grafman J. **Ann N Y Acad Sci** 1995 Dec 15;769:337-68 (116 ref.)
A model of the dynamics of prefrontal cortico-thalamo-basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375-80 (22 ref.)
Types of planning: can artificial intelligence yield insights into prefrontal function? Hendler JA. **Ann N Y Acad Sci** 1995 Dec 15;769:265-76 (45 ref.)
Forms of reasoning: insight into prefrontal functions? Holyoak KJ, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:253-63 (55 ref.)
A computer model of prefrontal cortex function. Levinson R. **Ann N Y Acad Sci** 1995 Dec 15;769:381-8 (9 ref.)
Procedural learning and prefrontal cortex. Pascual-Leone A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:61-70 (20 ref.)
Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Reinsel RA, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:393-7
Memory and the prefrontal cortex. Shimamura AP. **Ann N Y Acad Sci** 1995 Dec 15;769:151-9 (44 ref.)
The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448-55 (130 ref.)
A comparison of the effects of frontal cortical and thalamic lesions on measures of spatial learning and memory in the rat. Harrison LM, et al. **Behav Brain Res** 1996 Feb; 75(1-2):195-206
Effects of lesions to amygdala, ventral subiculum, medial prefrontal cortex, and nucleus accumbens on the reaction to novelty: implication for limbic-striatal interactions. Burns LH, et al. **Behav Neurosci** 1996 Feb;110(1):60-73
Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Morgan MA, et al. **Behav Neurosci** 1995 Aug;109(4):681-8
Functional differences between the prelimbic and anterior cingulate regions of the rat prefrontal cortex. Seamans JK, et al. **Behav Neurosci** 1995 Dec;109(6):1063-73
Functional lateralization of the prefrontal cortex during traditional frontal lobe tasks. Van Horn JD, et al. **Biol Psychiatry** 1996 Mar 15;39(6):389-99
Lesions of the medial prefrontal cortex and sexual behavior in the male rat. Agmo A, et al. **Brain Res** 1995 Oct 23; 696(1-2):177-86
Central nervous stimulants facilitate sexual behavior in male rats with medial prefrontal cortex lesions. Agmo A, et al. **Brain Res** 1995 Oct 23;696(1-2):187-93
Left and right 6-hydroxydopamine lesions of the medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral response to stress. Carlson JN, et al. **Brain Res** 1996 Mar 4;711(1-2):1-9
Prefrontal cortical mediation of rats' place learning in a modified water maze. Mogensen J, et al. **Brain Res Bull** 1995;38(5):425-34
The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Tanila H, et al. **Brain Res Bull** 1996;40(2):117-9
Activation of human prefrontal cortex during spatial and nonspatial working memory tasks measured by functional MRI. McCarthy G, et al. **Cereb Cortex** 1996 Jul-Aug; 6(4):600-11
Changes in limbic and prefrontal functional interactions in a working memory task for faces. McIntosh AR, et al. **Cereb Cortex** 1996 Jul-Aug;6(4):571-84
Prefrontal alterations during memory processing in aging. Nielsen-Bohlman L, et al. **Cereb Cortex** 1995 Nov-Dec; 5(6):541-9
Subdural potentials at orbitofrontal and mesial prefrontal areas accompanying anticipation and decision making in humans: a comparison with Bereitschaftspotential. Ikeda A, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 98(3):206-12
Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. Banks KE, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):157-67
Topographically specific hippocampal projections target functionally distinct prefrontal areas in the rhesus monkey. Barbas H, et al. **Hippocampus** 1995;5(6):511-33
Synaptic reorganisation of the mediodorsal thalamic nucleus in adult rat following chronic prefrontal cortical lesions. Négyessy L, et al. **J Hirnforsch** 1995;36(3):433-41
The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. Karreman M, et al. **J Neurochem** 1996 Feb; 66(2):589-98
Dissociation of human prefrontal cortical areas across different speech production tasks and gender groups. Buckner RL, et al. **J Neurophysiol** 1995 Nov;74(5):2163-73
Lateralization of prefrontal activation during internal mental calculation: a functional magnetic resonance imaging study. Burbaud P, et al. **J Neurophysiol** 1995 Nov;74(5):2194-200
Information coding in the rodent prefrontal cortex. I. Single-neuron activity in orbitofrontal cortex compared with that in pyriform cortex. Schoenbaum G, et al. **J Neurophysiol** 1995 Aug;74(2):733-50
Information coding in the rodent prefrontal cortex. II. Ensemble activity in orbitofrontal cortex. Schoenbaum G, et al. **J Neurophysiol** 1995 Aug;74(2):751-62
A comparison of the effects of medial prefrontal, cingulate cortex, and cingulum bundle lesions on tests of spatial memory: evidence of a double dissociation between frontal and cingulum bundle contributions. Aggleton JP, et al. **J Neurosci** 1995 Nov;15(11):7270-81
NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. Verma A, et al. **J Neurosci** 1996 Jan;16(1):373-9
The neural basis of the central executive system of working memory. D'Esposito M, et al. **Nature** 1995 Nov 16; 378(6554):279-81
Dissociation in prefrontal cortex of affective and attentional shifts. Dias R, et al. **Nature** 1996 Mar 7;380(6569):69-72
Reward expectancy in primate prefrontal neurons [see comments] Watanabe M. **Nature** 1996 Aug 15; 382(6592):629-32. Comment in: Nature 1996 Aug 15;382(6592):579.
Lateralized effect of rapid-rate transcranial magnetic stimulation of the prefrontal cortex on mood. Pascual-Leone A, et al. **Neurology** 1996 Feb;46(2):499-502
Cerebral bases of consciousness: a historical view. Markowitsch HJ. **Neuropsychologia** 1995 Sep;33(9):1181-92
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. George MS, et al. **Neuroreport** 1995 Oct 2;6(14):1853-6
Inhibition of hippocampoprefrontal cortex excitatory responses by the mesocortical DA system. Jay TM, et al. **Neuroreport** 1995 Oct 2;6(14):1845-8
Functional role of the prefrontal cortex in retrieval of memories: a PET study. Kapur S, et al. **Neuroreport** 1995 Oct 2;6(14):1880-4
Prefrontal neurones sensitive to increased visual attention in the monkey. Lecas JC. **Neuroreport** 1995 Dec 29;7(1):305-9
Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499-510 (155 ref.)
Pain-related cerebral potentials in patients with frontal or parietal lobe lesions. Daum I, et al. **Neurosci Lett** 1995 Sep 8;197(2):137-40
Non-dominant dorsal-prefrontal activation during chess problem solution evidenced by single photon emission computerized tomography (SPECT). Onofrj M, et al. **Neurosci Lett** 1995 Oct 6;198(3):169-72
Cognitive potentials: ipsilateral corticocortical interconnections in prefrontal human cortex ablations. Zappoli R, et al. **Neurosci Lett** 1995 Jun 30;193(2):140-4
Responses of the medial prefrontal cortex to stimulation of the amygdala in the rat: a study with laminar field potential recording. Matsuda Y, et al. **Neurosci Res** 1995 Oct; 23(3):281-8
Ventrolateral orbital cortex and periaqueductal gray stimulation-induced effects on on- and off-cells in the rostral ventromedial medulla in the rat. Hutchison WD, et al. **Neuroscience** 1996 Jan;70(2):391-407
Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-D-aspartate antagonists. Wolf ME, et al. **Neuroscience** 1995 Nov;69(2):417-39
Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self-administration under a progressive ratio schedule of reinforcement. McGregor A, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):5-9
Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Murphy BL, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1325-9
Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Swerdlow NR, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):27-34
Functional brain imaging studies of cortical mechanisms for memory. Ungerleider LG. **Science** 1995 Nov 3; 270(5237):769-75 (94 ref.)
Power spectral analysis of electroencephalographic desynchronization induced by cocaine in rats: correlation with evaluation of noradrenergic neurotransmission at the medial prefrontal cortex. Chang AY, et al. **Synapse** 1995 Oct;21(2):149-57
Electrochemical evidence of increased dopamine transmission in prefrontal cortex and nucleus accumbens elicited by ventral tegmental mu-opioid receptor activation in freely behaving rats. Noel MB, et al. **Synapse** 1995 Oct; 21(2):110-22
[The role of the head of the caudate nucleus and the orbital cortex in the neuronal activity of the tectum mesencephali in the food reflex in cats] Driagin IuM. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):180-4 **(Rus)**
[The effects of the orbital cortex on the neuronal activity of the tegmentum mesencephali in a food reflex in cats] Driagin IuM. **Fiziol Zh Im I M Sechenova** 1995 Apr; 81(4):76-82 (Eng. Abstr.) **(Rus)**
[The neurophysiological correlates of improvement in the cognitive characteristics of monkeys with modification of the NMDA-ergic structures of the prefrontal cortex] Dudkin KN, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan; 81(1):32-9 (Eng. Abstr.) **(Rus)**
[The dynamic impulse activity of the neocortical neurons in monkeys with the task of visual recognition after short-term oxygen starvation] Dudkin KN, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):62-70 (Eng. Abstr.) **(Rus)**
[The corticostriatal mechanisms of behavior] Suvorov NF, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):1-12 (Eng. Abstr.) **(Rus)**
[Effect of stimulation of the peripheral pathways and somatosensory cortex on the neuronal activity of the medial wall of the prefrontal cortex in the white rat] Tsytsarev VIu, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):45-51 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Prefrontal neuropsychological impairment and illness duration in schizophrenia: a study of 204 patients in Hong Kong. Chen EY, et al. **Acta Psychiatr Scand** 1996 Feb; 93(2):144-50
Cognitive functioning in "diffuse" pathology. Role of prefrontal and limbic structures. Boller F, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:23-39 (51 ref.)
Experimental approach to prefrontal functions in humans. Dubois B, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:41-60 (65 ref.)
Glucose metabolism in murderers [letter; comment] Ladds B, et al. **Biol Psychiatry** 1995 Sep 1;38(5):342-3. Comment on: Biol Psychiatry 1994 Sep 15;36(6):365-73.
Bipolar affective disorder minus left prefrontal cortex equals schizophrenia. Pang A, et al. **Br J Psychiatry** 1996 May; 168(5):647-50
Schizophrenia: a disconnection syndrome? Friston KJ, et al. **Clin Neurosci** 1995;3(2):89-97 (61 ref.)
Selective impairments in managerial knowledge following pre-frontal cortex damage. Sirigu A, et al. **Cortex** 1995

Jun;31(2):301-16
The Cognitive Bias Task and lateralized frontal lobe functions in males. Podell K, et al.
J Neuropsychiatry Clin Neurosci 1995 Fall;7(4):491-501
Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Akbarian S, et al. **J Neurosci** 1996 Jan;16(1):19-30
Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Pascual-Leone A, et al. **Lancet** 1996 Jul 27;348(9022):233-7
Wisconsin Card Sorting Test performance in obsessive-compulsive disorder: no evidence for involvement of dorsolateral prefrontal cortex. Abbruzzese M, et al. **Psychiatry Res** 1995 Sep 8;58(1):37-43
The functional architecture of the prefrontal cortex and schizophrenia [editorial] Lewis DA, et al. **Psychol Med** 1995 Sep;25(5):887-94 (80 ref.)
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Keefe RS, et al. **Schizophr Res** 1995 Sep;17(1):25-33
[Frontal lobe dysfunction and depressive state: relation to endogenous character of depression] Moreaud O, et al. **Encephale** 1996 Jan-Feb;22(1):47-51 (Eng. Abstr.) **(Fre)**
[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 May-Jun;24(3):148-55 (49 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. Mann JJ, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):418-26
A positron emission tomography study of the short-term maintenance of verbal information. Fiez JA, et al. **J Neurosci** 1996 Jan 15;16(2):808-22
The functional anatomy of remembered saccades: a PET study. O'Sullivan EP, et al. **Neuroreport** 1995 Nov 13; 6(16):2141-4
Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Andreasen NC, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9985-90
Preserved speech abilities and compensation following prefrontal damage. Buckner RL, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1249-53

ULTRASTRUCTURE

Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy. Smiley JF, et al. **J Comp Neurol** 1996 Apr 8;367(3):431-43
Ultrastructural associations between dopamine terminals and local circuit neurons in the monkey prefrontal cortex: a study of calretinin-immunoreactive cells. Sesack SR, et al. **Neurosci Lett** 1995 Nov 10;200(1):9-12

PREGNADIENEDIOLS

ADMINISTRATION & DOSAGE

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Drouin M, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):153-60
Once-a-day topical corticosteroids. **Drug Ther Bull** 1995 Mar;33(3):21-2 (15 ref.)

CHEMICAL SYNTHESIS

An unusual rearrangement product formed during production of mometasone furoate (Sch 32088). Puar MS, et al. **Steroids** 1995 Sep;60(9):612-4

PHARMACOLOGY

Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids. Visscher HW, et al. **Eur J Clin Pharmacol** 1995;48(2):123-5

PREGNADIENES

ADVERSE EFFECTS

Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids [see comments] Leibowitz HM, et al. **Arch Ophthalmol** 1996 Aug; 114(8):933-7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1000-1.

THERAPEUTIC USE

Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Foster CS, et al. **Am J Ophthalmol** 1996 Aug;122(2):171-82
Corticosteroid therapy of eye disease. Fifty years later [editorial; comment] Raizman M. **Arch Ophthalmol** 1996 Aug;114(8):1000-1 (25 ref.). Comment on: Arch Ophthalmol 1996 Aug;114(8):933-7.

PREGNANCY

see related
PRENATAL CARE
PSEUDOPREGNANCY

Spectrum of cytologic changes in pregnancy. A review of 100 abnormal cervicovaginal smears, with emphasis on diagnostic pitfalls. Pisharodi LR, et al. **Acta Cytol** 1995 Sep-Oct;39(5):905-8
Successful treatment of a combined interstitial and intrauterine pregnancy after tubal embryo transfer (TET). Chen SU, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):752-5
Conservative versus radical surgery for tubal pregnancy. A review. Clausen I. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):8-12 (44 ref.)
Effect of dehydroepiandrosterone sulfate on fetal middle cerebral artery flow velocity waveforms in term pregnancy. Hata T, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):343-6
Coexistence of bilateral tubal and intrauterine pregnancy. Jønler M, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):750-2
Fetal fibronectin and microorganisms in vaginal fluid of healthy pregnant women. Rossel Goffeng A, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):520-5
Cancer incidence for children born in a smelting community. Wulff M, et al. **Acta Oncol** 1996;35(2):179-83
Drug utilization study during pregnancy. Abdul Hadi B, et al. **Acta Pharm Hung** 1995 May;65(3):69-75
Smoking cessation in pregnancy: the effect of hypnosis in a randomized study. Valbø A, et al. **Addict Behav** 1996 Jan-Feb;21(1):29-35
Sexual activity during and after pregnancy. Adinma JI. **Adv Contracept** 1996 Mar;12(1):53-61
Clinical problems and counseling for single-parent families. Meurer JR, et al. **Am Fam Physician** 1996 Sep 1;54(3):864, 867-70
National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Gaughan WJ, et al. **Am J Kidney Dis** 1996 Aug;28(2):266-9
Impact of health education during pregnancy on behavior and utilization of health resources. Latin American Network for Perinatal and Reproductive Research. Belizán JM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):894-9
Spontaneous hair hyperpigmentation in response to vitamin intake in pregnancy--a clue for homocystinuria [letter] Reish O, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1640-1
Effect of dehydroepiandrosterone sulfate on maternal cardiac function in term pregnancy. Hata T, et al. **Am J Perinatol** 1996 Jan;13(1):11-3
Maternal smoking during pregnancy and the risk of congenital urinary tract anomalies. Li DK, et al. **Am J Public Health** 1996 Feb;86(2):249-53
Sexuality in Nigerian pregnant women: perceptions and practice. Adinma JI. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):290-3
Pregnancy, abortion and the dangers of prescribing vitamin A analogs in Australia [letter] Lipson T. **Australas J Dermatol** 1996 May;37(2):114-5
Pregnant women receiving benefit in Britain eat badly [news] Claxton R. **BMJ** 1995 Nov 25;311(7017):1390
Pregnant women should wear seat belts [letter] Griffiths M. **BMJ** 1995 Dec 2;311(7018):1501
Radiological standards for primary dental care [letter; comment] D'Cruz L. **Br Dent J** 1995 Nov 11;179(9):328. Comment on: Br Dent J 1995 Jun 24;178(12):454-60.
A longitudinal study of the cervix in pregnancy using transvaginal ultrasound. Cook CM, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):16-8
Successful pregnancy after treatment of stage III bilateral ovarian dysgerminoma. Hudson CN, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1015-6
Sonographic screening for urinary tract abnormalities in patients with Schistosoma haematobium infection: pitfalls in examining pregnant women. Richter J, et al. **Bull World Health Organ** 1996;74(2):217-21
Reproductive history and prognosis in patients with operable breast cancer [letter; comment] Brower ST, et al. **Cancer** 1995 Aug 1;76(3):531-3. Comment on: Cancer 1994 Sep 1;74(5):1591-4.
Breast cancer in Swedish women before age 50: evidence of a dual effect of completed pregnancy. Leon DA, et al. **Cancer Causes Control** 1995 Jul;6(4):283-91
Inhibitory potential of pregnancy and lactation on mammary carcinogenesis induced by a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, in Sprague-Dawley rats. Kimura J, et al. **Cancer Lett** 1996 Mar 19;101(1):73-8
Double failed female sterilisation [letter] Sirisena J, et al. **Ceylon Med J** 1995 Dec;40(4):168
Pregnancy achieved after treatment in a case of endometrial ossification. A case report and literature review. Liu Q, et al. **Chin Med J (Engl)** 1995 Oct;108(10):793-5
Synchronous intrauterine and ectopic pregnancy. A report on two cases. Grampa M, et al. **Clin Exp Obstet Gynecol** 1995;22(4):339-40
Exercise during pregnancy and pregnancy outcome. Tanji J. **Clin J Sport Med** 1995 Oct;5(4):267
Pregnancy in patients with cystic fibrosis. Hilman BC, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):70-86 (54 ref.)
Pregnancy following treatment of an adolescent with Yolk sac tumour. Tesic M, et al. **Eur J Gynaecol Oncol** 1996; 17(1):55-8
Benzodiazepine use during pregnancy: a prospective study [letter] Courtens W, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):181-2
Prognosis of fertility after surgical closure of vesicouterine fistula. Lotocki W, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):87-90
Evaluation of serum CA 125 concentrations as predictors of pregnancy with human in vitro fertilization. Miller KA, et al. **Fertil Steril** 1996 Jun;65(6):1184-9
In-vitro fertilization pregnancies and perinatal health in Finland 1991-1993. Gissler M, et al. **Hum Reprod** 1995 Jul; 10(7):1856-61
Pregnancy following intracytoplasmic sperm injection (ICSI) of a single oocyte in a natural cycle. Norman RJ, et al. **Hum Reprod** 1995 Jul;10(7):1626-7
In-vitro fertilization: the experience of treatment, pregnancy and delivery. van Balen F, et al. **Hum Reprod** 1996 Jan; 11(1):95-8
Cervical pregnancy: three case reports and a review of the literature. Van de Meerssche M, et al. **Hum Reprod** 1995 Jul;10(7):1850-5 (42 ref.)
Pregnancies following pre-conception diagnosis of common aneuploidies by fluorescent in-situ hybridization. Verlinsky Y, et al. **Hum Reprod** 1995 Jul;10(7):1923-7
Changes in health behaviors made by pregnant substance users. Higgins PG, et al. **Int J Addict** 1995 Aug; 30(10):1323-33
Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug;40(4):175-86 (67 ref.)
Vitamin A supplementation during pregnancy. **Int J Gynaecol Obstet** 1995 Dec;51(3):286-7
Guidelines for diagnostic imaging during pregnancy. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Dec;51(3):288-91
Combined intra-uterine and cervical pregnancy treated successfully with methotrexate. Bratta FG, et al. **Int J Gynaecol Obstet** 1996 May;53(2):173-4
Childbearing motivation and its measurement. Miller WB. **J Biosoc Sci** 1995 Oct;27(4):473-87
Transvaginal sonography of the yolk sac in normal and abnormal pregnancy. Stampone C, et al. **J Clin Ultrasound** 1996 Jan;24(1):3-9
Factors related to planned and unplanned pregnancies. Rosenfeld JA, et al. **J Fam Pract** 1996 Aug;43(2):161-6
Medicaid costs of live births from unintended pregnancies in Florida. Hopkins RS, et al. **J Fla Med Assoc** 1995 Aug; 82(8):540-3
Balancing judicial interests in HIV cases: Part 2, Issues for nurse administrators. Zachary MK. **J Nurs Adm** 1995 Nov; 25(11):9-14
Use of the Cytobrush for Papanicolaou smear screens in pregnant women. Foster JC, et al. **J Nurse Midwifery** 1996 May-Jun;41(3):211-7
Pregnancy following renal transplantation: the experience in Hong Kong. To WW, et al. **J Obstet Gynaecol** 1995 Jun; 21(3):263-7
Time to pregnancy among women occupationally exposed to lead. Sallmén M, et al. **J Occup Environ Med** 1995 Aug; 37(8):931-4
Spontaneous pregnancy in women awaiting oocyte donation. Sauer MV. **J Reprod Med** 1995 Sep;40(9):630-2
Assessment of luteal blood flow in normal early pregnancy. Alcázar JL, et al. **J Ultrasound Med** 1996 Jan;15(1):53-6
In vitro fertilization improves pregnancy rates for sperm obtained by rectal probe ejaculation. Matthews GJ, et al. **J Urol** 1996 Jun;155(6):1934-7
Prepregnant weight in relation to risk of neural tube defects [see comments] Werler MM, et al. **JAMA** 1996 Apr 10; 275(14):1089-92. Comment in: JAMA 1996 Apr 10;275(14):1127-8.
Pregnancies after endolymphatic therapy of residual retroperitoneal Hodgkin lymphoma. Hirnle P, et al. **Lymphology** 1995 Jun;28(2):73-7
Magnetic resonance imaging in pregnancy. Colletti PM, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):291-307 (53 ref.)
Pregnancy and the safety of magnetic resonance imaging. Kanal E. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):309-17 (74 ref.)
Case records of the Massachusetts General Hospital. Case 3-1996. Severe abdominal pain during early pregnancy in a woman with previous infertility [clinical conference] **N Engl J Med** 1996 Jan 25;334(4):255-60
When an employee becomes pregnant. Employer's rights and responsibilities. Plunkett LR. **N Y State Dent J** 1996 Jan; 62(1):9-11
Seat belts and pregnancy [letter] Insull BJ. **N Z Med J** 1995 Nov 10;108(1011):466
Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. Leversha AM, et al. **N Z Med J** 1995 Oct 27;108(1010):428-30
Successful pregnancy in a hemodialysis patient treated with erythropoietin [letter] Amoedo ML, et al. **Nephron** 1995; 70(2):262-3
Effects of fetal number and multifetal reduction on length

of in vitro fertilization pregnancies. Haning RV Jr, et al. **Obstet Gynecol** 1996 Jun;87(6):964–8

A randomized controlled trial of smoking cessation intervention in pregnancy in an academic clinic. Hartmann KE, et al. **Obstet Gynecol** 1996 Apr;87(4):621–6

A guest editorial: pregnancy in the twenty-first century: woman, nurturer, parent, judge [editorial] Gates EA. **Obstet Gynecol Surv** 1996 Jan;51(1):1–2

The Role of General Practice in Maternity Care. Royal College of General Practitioners. Report of the RCGP Maternity Care Group. **Occas Pap R Coll Gen Pract** 1995 Nov;(72):1–14 (24 ref.)

Twin pregnancy following in vitro fertilisation coinciding with laryngeal cancer. Pytel J, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Jul–Aug; 57(4):232–4

Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Van Marter LJ, et al. **Pediatrics** 1996 May;97(5):658–63

Pregnancy after abdominoplasty [letter] Menz P. **Plast Reconstr Surg** 1996 Aug;98(2):377–8

Successful pregnancy following aplastic anaemia. Leong KW, et al. **Postgrad Med J** 1995 Oct;71(840):625–7

Youth beliefs and knowledge about the risks of drinking while pregnant. MacKinnon DP, et al. **Public Health Rep** 1995 Nov–Dec;110(6):754–63

The Social Support Apgar: instrument development and testing. Norwood SL. **Res Nurs Health** 1996 Apr; 19(2):143–52

New experiments underscore warnings on maternal drinking [news] Braun S. **Science** 1996 Aug 9;273(5276):738–9

Working conditions, maternity legislation, and preterm birth. Berkowitz GS, et al. **Semin Perinatol** 1995 Aug;19(4):272–8 (40 ref.)

The influence of fetal and maternal factors on the distribution of birthweight. Cogswell ME, et al. **Semin Perinatol** 1995 Jun;19(3):222–40 (58 ref.)

Pregnancy in renal transplantation recipients: outcome and complications in 44 pregnancies. al Hassani MK, et al. **Transplant Proc** 1995 Oct;27(5):2585

Influence of pregnancy on graft function after renal transplantation. Nojima M, et al. **Transplant Proc** 1996 Jun; 28(3):1582–5

Aetiology of vaginal infections in pregnant and non-pregnant women in Barbados. Levett PN. **West Indian Med J** 1995 Sep;44(3):96–8

Self-medication during pregnancy [letter] Clavijo HA, et al. **World Health Forum** 1995;16(4):403–4

Sudan: situational analysis of maternal health in Bara District, North Kordofan. Campbell M, et al. **World Health Stat Q** 1995;48(1):60–6

[Pregnancy is a natural phenomenon! What about the risk factors? (letter)] Philip J. **Ugeskr Laeger** 1995 Dec 18; 157(51):7154–5 **(Dan)**

[Violence towards pregnant women] Rasmussen KL, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2373–6 (35 ref.) (Eng. Abstr.) **(Dan)**

[Comparison between various methods of pregnancy screening during a large-scale ivermectin treatment in Cameroon] Chippaux JP, et al. **Bull Soc Pathol Exot** 1995; 88(3):129–33 (Eng. Abstr.) **(Fre)**

[A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro] Daya S, et al. **Contracept Fertil Sex** 1995 Dec;23(12):766–71 (Eng. Abstr.) **(Fre)**

[Intrauterine and extrauterine pregnancy association: apropos of 2 cases in gynecological and obstetrical clinical medicine] Diallo D, et al. **Dakar Med** 1994;39(2):165–8 (Eng. Abstr.) **(Fre)**

[Travel and pregnancy] Charles G, et al. **Med Trop (Mars)** 1995;55(3):199–200 **(Fre)**

[Pregnancy during substitutive treatment for premature menopause (letter)] Helie C, et al. **Presse Med** 1996 Jan 27;25(3):128 **(Fre)**

[Simultaneous intrauterine and extrauterine pregnancy in the presence of inert intrauterine device: a case report] Akpadza K, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep; 90(7–9):360–1 (Eng. Abstr.) **(Fre)**

[Concerning the article: Simultaneous intrauterine and extrauterine pregnancy in the presence of an inert intrauterine device (letter)] Delarue T. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):560 **(Fre)**

[The fate of women reflected in classical literature] Lauritzen C. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M96–105 **(Ger)**

[Uncomplicated second pregnancy following acute pregnancy fatty liver (letter)] Zürcher K. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1224 **(Ger)**

[Underwater diving during pregnancy] Revel A, et al. **Harefuah** 1995 Jun 1;128(11):707–10 (28 ref.) **(Heb)**

[Effect of pregnancy and delivery on genuine stress incontinence] Zilberman B, et al. **Harefuah** 1995 Jul; 129(1–2):43–6 (21 ref.) **(Heb)**

[The influence of pregnancy and delivery on the climacteric symptoms] Kubota T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):1–8 (Eng. Abstr.) **(Jpn)**

[Occurrence of Bacteroides fragilis strains in full term and post term pregnancies] Leszczyński P, et al. **Ginekol Pol** 1995 Jun;66(6):324–9 (Eng. Abstr.) **(Pol)**

[Promotion of mother–infant health: a comparative study of legislation of pregnancy protection] Mas Pons R, et al. **Aten Primaria** 1995 Sep 30;16(5):246–50, 252 (Eng. Abstr.) **(Spa)**

[Usefulness of the Granada culture media in the detection of pregnant women carrying Streptococcus agalactiae (letter)] Juncosa T, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):572–3 **(Spa)**

[Occurrence of pregnancy after microsurgical treatment of sterile patients with tubo-ovarian adhesive diseases] Lopez-Ortiz CS, et al. **Ginecol Obstet Mex** 1996 Jun; 64:256–60 (Eng. Abstr.) **(Spa)**

[The logic of a traditional health belief: solar eclipse and pregnancy in Ocuituco, Mexico] Castro R. **Salud Publica Mex** 1995 Jul–Aug;37(4):329–38 (Eng. Abstr.) **(Spa)**

[The importance of preventing smoking by women. Especially, smoking during pregnancy!] Cnattingius S, et al. **Lakartidningen** 1995 Dec 6;92(49):4677–8 **(Swe)**

[EU regulations for the protection of pregnant and breast-feeding employees] Ahlborg G Jr. **Nord Med** 1996 May;111(5):155 **(Swe)**

BLOOD

Hemoglobin concentration in pregnant women. Experience from Moshi, Tanzania. Bergsjo P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):241–4

Relaxin is not related to symptom-giving pelvic girdle relaxation in pregnant women. Hansen A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):245–9

Prorenin and active renin in human fetal circulation. Lenz T. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):291–3

Immunoelectrophoretic differentiation of alpha-fetoprotein in disorders with elevated serum alpha-fetoprotein levels or during pregnancy. Chen RJ, et al. **Acta Oncol** 1995; 34(7):931–5

Pregnancy associated alpha-glycoprotein (SP-III) in Nigerian pregnant women. Onyemelukwe GC, et al. **Afr J Med Med Sci** 1995 Mar;24(1):17–20

Effects of weekly iron supplementation on pregnant Indonesian women are similar to those of daily supplementation [see comments] Ridwan E, et al. **Am J Clin Nutr** 1996 Jun;63(6):884–90. Comment in: Am J Clin Nutr 1996 Jun;63(6):853–5.

Adverse effect of pregnancy on high density lipoprotein (HDL) cholesterol in young adult women. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Lewis CE, et al. **Am J Epidemiol** 1996 Aug 1; 144(3):247–54

Physiological neutrophilia is associated with elevated serum level of macrophage colony-stimulating factor (M-CSF) [letter; comment] Hatake K, et al. **Am J Hematol** 1996 May; 52(1):66. Comment on: Am J Hematol 1995 Apr;48(4):288.

Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Brancazio LR, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1240–5

Prenatal diagnosis by use of fetal cells isolated from maternal blood [letter; comment] de la Cruz F, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1354–5. Comment on: Am J Obstet Gynecol 1995 Mar;172(3):1064–5.

Fetal RhD genotyping in fetal cells flow sorted from maternal blood. Geifman-Holtzman O, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):818–22

The origin of alpha-fetoprotein in first-trimester anembryonic pregnancies. Jauniaux E, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1742–8

Plasma and placental calcitonin gene-related peptide in pregnancies complicated by severe preeclampsia. Schiff E, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1405–9

Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Simpson JL, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1742–8

Enrichment of fetal trophoblast cells from the maternal peripheral blood followed by detection of fetal deoxyribonucleic acid with a nested X/Y polymerase chain reaction. van Wijk IJ, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):871–8

Routine measurements of umbilical artery lactate levels in the prediction of perinatal outcome. Westgren M, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1416–22

Relationship between erythrocyte deformability and hematocrit in maternal and cord blood [letter] Lurie S. **Am J Perinatol** 1996 May;13(4):255

Increased blood lead and decreased calcium levels during pregnancy: a prospective study of Swedish women living near a smelter. Lagerkvist BJ, et al. **Am J Public Health** 1996 Sep;86(9):1247–52

Soluble tumor necrosis factor receptor in serum and urine throughout normal pregnancy and at delivery. Arntzen KJ, et al. **Am J Reprod Immunol** 1995 Sep;34(3):163–9

Comparative analysis of the immunophenotypes of decidual and peripheral blood large granular lymphocytes and T cells during early human pregnancy. Geiselhart A, et al. **Am J Reprod Immunol** 1995 Apr;33(4):315–22

Riboflavin and pyridoxine status in a group of pregnant Mexican women. Tovar AR, et al. **Arch Med Res** 1996 Summer;27(2):195–200

An antibody specific to N-terminal amino acid sequence of human maternal serum cystine aminopeptidase and its applications. Watanabe Y, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):653–8

Identification of an alanine aminopeptidase in human maternal serum as a membrane-bound aminopeptidase N. Watanabe Y, et al. **Biol Chem Hoppe Seyler** 1995 Jul; 376(7):397–400

Maternal and neonatal plasma transthyretin (prealbumin) concentrations and birth weight of newborn infants. Jain SK, et al. **Biol Neonate** 1995;68(1):10–4

Umbilical cord osteocalcin in normal pregnancies and pregnancies complicated by fetal growth retardation or diabetes mellitus. Verhaeghe J, et al. **Biol Neonate** 1995; 68(6):377–83

Blood lead dynamics of lead-exposed pregnant women and its effects on fetus development. Wan BJ, et al. **Biomed Environ Sci** 1996 Mar;9(1):41–5

A case-control study of cryptorchidism and maternal hormone concentrations in early pregnancy. Key TJ, et al. **Br J Cancer** 1996 Mar;73(5):698–701

Activated protein C sensitivity ratio in pregnant women at delivery. Mathonnet F, et al. **Br J Haematol** 1996 Jan; 92(1):244–6

Maternal essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid status. Al MD, et al. **Br J Nutr** 1995 Jul; 74(1):55–68

Coagulation and fibrinolysis in smoking and nonsmoking pregnant women. Mercelina-Roumans PE, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):789–94

Serum lipids in early pregnancy and risk of pre-eclampsia. van den Elzen HJ, et al. **Br J Obstet Gynaecol** 1996 Feb; 103(2):117–22

Blood folic acid and vitamin B12 in relation to neural tube defects. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):319–24 (16 ref.)

Substrate and hormonal responses during exercise classes at selected stages of pregnancy. Bonen A, et al. **Can J Appl Physiol** 1995 Dec;20(4):440–51

Triple-marker screening for Down syndrome [letter; comment] Farrell SA, et al. **Can Med Assoc J** 1996 Aug 1;155(3):271–2; discussion 272–3. Comment on: Can Med Assoc J 1996 Feb 15;154(4):465–79.

Triple-marker screening for Down syndrome [letter; comment] Viner G. **Can Med Assoc J** 1996 Aug 1; 155(3):272; discussion 272–3. Comment on: Can Med Assoc J 1996 Feb 15;154(4):465–79.

Midtrimester human chorionic gonadotropin levels: normal reference values in Chinese pregnant women. Hsu JJ, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):240–7

The source of endogenous digitalis-like substance in normal pregnancy. Gao S, et al. **Chin Med J (Engl)** 1995 Dec; 108(12):932–4

Plasma carnitine concentrations in pregnancy, cord blood, and neonates and children. Winter SC, et al. **Clin Chim Acta** 1995 Dec 15;243(1):87–93

Mood and hormonal changes during late pregnancy and puerperium. Asher I, et al. **Clin Exp Obstet Gynecol** 1995; 22(4):321–5

Pregnancy outcomes in women without gestational diabetes mellitus related to the maternal glucose level. Is there a continuum of risk? Moses RG, et al. **Diabetes Care** 1995 Dec;18(12):1527–33

Maternal serum triglyceride, glucose tolerance, and neonatal birth weight ratio in pregnancy. Nolan CJ, et al. **Diabetes Care** 1995 Dec;18(12):1550–6

The composition of individual molecular species of plasma phosphatidylcholine in human pregnancy. Postle AD, et al. **Early Hum Dev** 1995 Aug 30;43(1):47–58

Relaxin levels in amniotic fluid, extraembryonic coelomic fluid and maternal serum in early human pregnancy. Wathen NC, et al. **Early Hum Dev** 1995 Aug 30;43(1):71–4

Feasibility of collecting maternal blood and hair samples in a case-control study of congenital anomalies [letter; comment] Takahashi ER, et al. **Epidemiology** 1995 Jul; 6(4):469. Comment on: Epidemiology 1996 Jan;7(1):110.

Platelet count and platelet indices at various stages of normal pregnancy in smoking and non-smoking women. Mercelina-Roumans PE, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):267–9

The reticulocyte count and its subfractions in smoking and non-smoking pregnant women. Mercelina-Roumans PE, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):263–5

Serum concentration of endogenous G-CSF in women during the menstrual cycle and pregnancy. Makinoda S, et al. **Eur J Clin Invest** 1995 Nov;25(11):877–9

Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga-Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)

Changes of some vitamin levels during and after normal pregnancy. Bruinse HW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):31–7

Changes of erythrocyte microrheology during normal pregnancy and after delivery. Lukačín S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):125–8

Unmeasurable relaxin concentrations in repeated pregnancies after embryo transfer. Petersen LK, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):255–7

Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancies. Rebelo I, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):189–94

The concentration of plasma atrial natriuretic peptide in

normotensive and preeclamptic pregnancies. Senöz S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):173–7

Serum levels of insulin–like growth factor–binding protein–3 in normal pregnancy. Wang HS, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):157–60

Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening. Heinonen S, et al. **Fertil Steril** 1996 Sep; 66(3):398–403

Maternal age–dependent and sex–related changes of gestational serum alpha–fetoprotein. Szabó M, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):368–72

Fibronectin in the plasma during pregnancy and parturition. Cunze T, et al. **Gynecol Obstet Invest** 1996;41(3):183–8

Changes in platelet volume and count during pregnancy: a longitudinal study [letter] Lurie S. **Gynecol Obstet Invest** 1995;40(1):71–2

Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Nobunaga T, et al. **Gynecol Obstet Invest** 1996;41(3):189–93

Plasma granulocyte colony stimulating factor concentrations in pregnant women. Umesaki N, et al. **Gynecol Obstet Invest** 1995;40(1):5–7

Fetal cells in maternal blood: recovery by charge flow separation. Wachtel SS, et al. **Hum Genet** 1996 Aug; 98(2):162–6

Why is there a peak of human chorionic gonadotrophin (HCG) in early pregnancy? Chard T, et al. **Hum Reprod** 1995 Jul;10(7):1837–40 (61 ref.)

Effect of ovulation induction on uterine blood flow and oestradiol and progesterone concentrations in early pregnancy. Dickey RP, et al. **Hum Reprod** 1995 Nov; 10(11):2875–9

beta 2–Glycoprotein I–dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Katano K, et al. **Hum Reprod** 1996 Mar; 11(3):509–12

Nucleated erythrocytes in maternal blood: quantity and quality of fetal cells in enriched populations. Reading JP, et al. **Hum Reprod** 1995 Sep;10(9):2510–5

Vitamin B1, B2 and B6 during the course of pregnancy of rural and urban women in northeast Thailand. Pongpaew P, et al. **Int J Vitam Nutr Res** 1995;65(2):111–6

Fat intake of women during normal pregnancy: relationship with maternal and neonatal essential fatty acid status. Al MD, et al. **J Am Coll Nutr** 1996 Feb;15(1):49–55

Serum ionized magnesium and other electrolytes in the antenatal period of human pregnancy. Handwerker SM, et al. **J Am Coll Nutr** 1996 Feb;15(1):36–43

Factors related to early pregnancy recognition in the woman. Behr B, et al. **J Assist Reprod Genet** 1995 Apr;12(4):278–82

The predictive value of serum progesterone and 17–OH progesterone levels on in vitro fertilization outcome. Levy MJ, et al. **J Assist Reprod Genet** 1995 Mar;12(3):161–6

Progesterone concentration as a predictor of pregnancy normalcy is the most useful when hCG levels are less than 2000 mIU/mL. Long CA, et al. **J Assist Reprod Genet** 1995 Mar;12(3):195–7

Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. Paoletti AM, et al. **J Assist Reprod Genet** 1995 Apr;12(4):263–8

Basal serum follicle stimulating hormone (FSH) and estradiol levels as predictors of pregnancy in unstimulated donor insemination cycles. Witt BR, et al. **J Assist Reprod Genet** 1995 Mar;12(3):157–60

High maternal serum chorionic gonadotropin level in Downs' syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts. Eldar–Geva T, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3528–31

The free form of insulin–like growth factor I increases in circulation during normal human pregnancy. Hasegawa T, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3284–6

Measurement of circulating inhibin forms during the establishment of pregnancy. Illingworth PJ, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1471–5

Soluble interleukin–6 (IL–6) receptor in the sera of pregnant women forms a complex with IL–6 and augments human chorionic gonadotropin production by normal human trophoblasts through binding to the IL–6 signal transducer. Matsuzaki N, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2912–7

Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. Muttukrishna S, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3328–34

Immunoradiometric assay for follistatin: serum immunoreactive follistatin levels in normal adults and pregnant women. Wakatsuki M, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):630–4

Lipoproteins in pregnant women before and during delivery: influence on neonatal haemorheology. Uberos–Fernández J, et al. **J Clin Pathol** 1996 Feb;49(2):120–3

Circulating levels of IGF–I and IGF–binding protein–1 throughout pregnancy: relation to birthweight and maternal weight. Hills FA, et al. **J Endocrinol** 1996 Feb; 148(2):303–9

Insulin–like growth factor–I and insulin–like growth factor–binding protein–1 in Taiwanese women during normal pregnancy. Wang HS, et al. **J Formos Med Assoc** 1995 Nov;94(11):698–701

Serum ferritin and selective iron prophylaxis in pregnancy? [letter] Sandstad B, et al. **J Intern Med** 1996 Jul; 240(1):47–50

Erythrocyte deformability of nonpregnant, pregnant, and fetal blood. Eguchi K, et al. **J Perinat Med** 1995;23(4):301–6

Changes in blood manganese levels during pregnancy in iron supplemented and non supplemented women. Tholin K, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):13–7

Folate levels and neural tube defects. Implications for prevention [see comments] Daly LE, et al. **JAMA** 1995 Dec 6;274(21):1698–702. Comment in: JAMA 1995 Dec 6;274(21):1717–8. Comment in: JAMA 1996 Jun 5;275(21):1635–6.

Maternal folate status and risk of neural tube defects [letter; comment] Kirke PN, et al. **Lancet** 1996 Jul 6;348(9019):67–8 . Comment on: Lancet 1996 May 11;347(9011):1336.

Plasma alpha– and gamma–tocopherol have different pattern during normal human pregnancy. Al Senaidy AM. **Mol Cell Biochem** 1996 Jan 12;154(1):71–5

Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. Aitken DA, et al. **N Engl J Med** 1996 May 9;334(19):1231–6

CRH, a placental clock and preterm labour [comment] Challis JR. **Nat Med** 1995 May;1(5):416. Comment on: Nat Med 1995 May;1(5):460–3.

A placental clock controlling the length of human pregnancy [see comments] McLean M, et al. **Nat Med** 1995 May; 1(5):460–3. Comment in: Nat Med 1995 May;1(5):416.

Is an elevated circulating maternal homocysteine concentration a risk factor for neural tube defects? Ubbink JB. **Nutr Rev** 1995 Jun;53(6):173–5 (14 ref.)

Blood gas analysis of placental and uterine blood during cesarean delivery. Fujikura T, et al. **Obstet Gynecol** 1996 Jan;87(1):133–6

Use of the Centers for Disease Control and Prevention childhood lead poisoning risk questionnaire to predict blood lead elevations in pregnant women [letter; comment] Gemmel DJ. **Obstet Gynecol** 1996 Jul;88(1):159–60. Comment on: Obstet Gynecol 1996 Feb;87(2):209–12.

Third–trimester arterial blood gas and acid base values in normal pregnancy at moderate altitude. Hankins GD, et al. **Obstet Gynecol** 1996 Sep;88(3):347–50

Decreased plasma tryptophan in pregnancy. Schröcksnadel H, et al. **Obstet Gynecol** 1996 Jul;88(1):47–50

Use of the Centers for Disease Control and Prevention childhood lead poisoning risk questionnaire to predict blood lead elevations in pregnant women [see comments] Stefanak MA, et al. **Obstet Gynecol** 1996 Feb;87(2):209–12 . Comment in: Obstet Gynecol 1996 Jul;88(1):159–60.

Development of a model system to compare cell separation methods for the isolation of fetal cells from maternal blood. Bianchi DW, et al. **Prenat Diagn** 1996 Apr;16(4):289–98

Alpha–fetoprotein elevation in maternal serum after percutaneous umbilical blood sampling (PUBS) [letter] Buscaglia M, et al. **Prenat Diagn** 1996 Apr;16(4):375–6

Triploidy, imprinting, and hCG levels in maternal serum screening [letter] Eiben B, et al. **Prenat Diagn** 1996 Apr; 16(4):377–8

The time of appearance and disappearance of fetal DNA from the maternal circulation. Thomas MR, et al. **Prenat Diagn** 1995 Jul;15(7):641–6

Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Mizutani S, et al. **Regul Pept** 1995 Nov 10;59(3):371–8

Serum selenium levels during normal pregnancy in healthy Spanish women. Navarro M, et al. **Sci Total Environ** 1996 Jul 30;186(3):237–42

Maternal serum amylase and lipase profiles in pregnancy: determinations in both once–sampled and multisampled patient cohorts. Xydas NP, et al. **South Med J** 1996 Feb; 89(2):199–203

Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy. Horn EH, et al. **Thromb Haemost** 1996 Feb;75(2):346–51

Guidelines for blood grouping and red cell antibody testing during pregnancy. British Committee for Standards in Haematology, Blood Transfusion Task Force. **Transfus Med** 1996 Mar;6(1):71–4

Prenatal fetal sex determination from maternal peripheral blood using polymerase chain reaction. Yang YH, et al. **Yonsei Med J** 1995 Sep;36(4):361–6

[The effect of the diet on the iron status and incidence of anemia in pregnant women] Ivanova L, et al. **Akush Ginekol (Sofiia)** 1995;34(1):6–8 (Eng. Abstr.) **(Bul)**

[Serum zinc and its relation to diet during late pregnancy] Ivanova L, et al. **Akush Ginekol (Sofiia)** 1995;34(3):17–9 (Eng. Abstr.) **(Bul)**

[Changes in the level of lipid peroxidation in healthy pregnant women] Pentieva K, et al. **Akush Ginekol (Sofiia)** 1995; 34(3):19–21 (Eng. Abstr.) **(Bul)**

[Dynamics of blood lead level in exposed workers and its effects on fetal constitutional development] Wan B, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):267–9 (Eng. Abstr.) **(Chi)**

[The prevalence of anti–hepatitis C antibodies in pregnant women and blood donors in Bénin] Develoux M, et al. **Bull Soc Pathol Exot** 1995;88(3):115–6 (Eng. Abstr.) **(Fre)**

[Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis] Simpson JL, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):445–50 (64 ref.) (Eng. Abstr.) **(Fre)**

[Maternal and fetal retinoid assay. Two case reports of isotretinoin (Roaccutane) exposure] Pons JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):274–6 (Eng. Abstr.) **(Fre)**

[Atrial natriuretic peptide in normotensive pregnancy: concentrations in physical stress, pre– and postpartal and in the umbilical cord] Günter HH, et al. **Zentralbl Gynakol** 1995;117(11):592–7 (Eng. Abstr.) **(Ger)**

[Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins] Ellenbogen A, et al. **Harefuah** 1995 Dec 1;129(11):455–6, 536 (Eng. Abstr.) **(Heb)**

[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy–-comparing normal pregnancy and toxemia of pregnancy] Murakami M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):177–83 (Eng. Abstr.) **(Jpn)**

[A study on the maternal plasma C21 steroids concentration during pregnancy] Oku M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar;48(3):163–9 (Eng. Abstr.) **(Jpn)**

[Comparison of prolactin levels in first, second and multiple physiological pregnancy] Jagiełło–Wójtowicz E, et al. **Ginekol Pol** 1995 Jul;66(7):397–401 (Eng. Abstr.) **(Pol)**

[Magnesium concentration in serum of pregnant women in selected pathologic states of pregnancy] Roszyk A. **Ginekol Pol** 1996 Mar;67(3):109–13 (Eng. Abstr.) **(Pol)**

[C–reactive protein in normal pregnancy] Szpakowski M, et al. **Ginekol Pol** 1996 Jan;67(1):17–20 (Eng. Abstr.) **(Pol)**

[Frequency of pregnant HBsAg carriers in a Brazilian community] Duarte G, et al. **Bol Oficina Sanit Panam** 1996 Mar;120(3):189–97 (Eng. Abstr.) **(Por)**

[Extracellular DNA in the blood of pregnant women] Kazakov VI, et al. **Tsitologiia** 1995;37(3):232–6 (Eng. Abstr.) **(Rus)**

[Effects of multivitamin preparations enriched with Fe, Zn and Se on the selenium status of pregnant women] Shagova MV, et al. **Vopr Pitan** 1995;(5):17–9 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Density of lumbar cerebrospinal fluid in pregnant and nonpregnant humans. Richardson MG, et al. **Anesthesiology** 1996 Aug;85(2):326–30

CSF progesterone concentrations in pregnancy [letter; comment] Baliga N. **Br J Anaesth** 1996 Jun;76(6):886. Comment on: Br J Anaesth 1995 Dec;75(6):683–7.

Cerebrospinal fluid progesterone in pregnant women [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Dec; 75(6):683–7. Comment in: Br J Anaesth 1996 Jun;76(6):886.

DRUG EFFECTS

Measurement of exposure to environmental tobacco smoke in pregnant women. O'Connor TZ, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1315–21

Use of antithrombotic agents during pregnancy. Ginsberg JS, et al. **Chest** 1995 Oct;108(4 Suppl):305S–311S (53 ref.)

"Moderate" drinking during pregnancy: cause for concern? Abel EL. **Clin Chim Acta** 1996 Mar 15;246(1–2):149–54 (15 ref.)

Mild maternal drinking and pregnancy outcome: perceived versus true risks. Koren G, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):155–62

Termination of early pregnancy (up to and after 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. Aubény E, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 2:85–91

[The use of drugs in pregnant and nursing women with dermatologic diseases] Miteva L, et al. **Akush Ginekol (Sofiia)** 1995;34(2):42–6 (20 ref.) **(Bul)**

ETHNOLOGY

The traditional humoral food habits of pregnant Vietnamese–Australian women and their effect on birth weight. Mitchell J, et al. **Aust J Public Health** 1995 Dec; 19(6):629–33

Racial and ethnic correlates of tobacco, alcohol and illicit drug use in a pregnant population. Wiemann CM, et al. **J Reprod Med** 1995 Aug;40(8):571–8

Determinants of gestational weight gain outside the recommended ranges among black and white women. Caulfield LE, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):760–6

Pregnancy and delivery practices and beliefs of Ethiopian immigrant women in Israel. Granot M, et al. **West J Nurs Res** 1996 Jun;18(3):299–313

[Pregnancy in older allochthonous women] van Selm GM, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1716–9 **(Dut)**

GENETICS

Detection of oxytocin receptor in endocervical scrapings during pregnancy. Kubota Y, et al. **Adv Exp Med Biol** 1995; 395:489–90

Gestational drive and the green–bearded placenta. Haig D. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6547–51

[The phenomenon of premature chromatid disjunction in the

tissues of human embryos in vivo, in vitro and in pregnant women] Lozynska MR, et al. **Tsitol Genet** 1995 Sep–Oct; 29(5):23–8 (Eng. Abstr.) **(Ukr)**

IMMUNOLOGY

The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Filbey D, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):687–92

Naturally occurring insulin autoantibodies in neonates of normal pregnancies and their relationship to insulinemia and birth weight. Wellik SR, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1878–84

GRO alpha in the fetomaternal and amniotic fluid compartments during pregnancy and parturition. Cohen J, et al. **Am J Reprod Immunol** 1996 Jan;35(1):23–9

Comparative analysis of the immunophenotypes of decidual and peripheral blood large granular lymphocytes and T cells during early human pregnancy. Geiselhart A, et al. **Am J Reprod Immunol** 1995 Apr;33(4):315–22

The expression of a progesterone–induced immunomodulatory protein in pregnancy lymphocytes. Szekeres–Bartho J, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):342–8

Maternal–fetal immunology and autoimmune disease: is some autoimmune disease auto–alloimmune or allo–autoimmune? Nelson JL. **Arthritis Rheum** 1996 Feb;39(2):191–4

Production of interferons in human placental trophoblast subpopulations and their possible roles in pregnancy. Aboagye–Mathiesen G, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):650–9

Time course analysis of alpha+ beta+ T cell clones during normal pregnancy. Höger TA, et al. **Eur J Immunol** 1996 Apr;26(4):834–8

Antibodies to oxidized low–density lipoprotein and to cardiolipin in nonpregnant and pregnant women with habitual abortion. Tulppala M, et al. **Fertil Steril** 1995 Nov; 64(5):947–50

Antibodies to cytokeratins bind to epitopes in human uterine smooth muscle cells in normal and pathological pregnancies. Stiemer B, et al. **Histopathology** 1995 Nov; 27(5):407–14

beta 2–Glycoprotein I–dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Katano K, et al. **Hum Reprod** 1996 Mar; 11(3):509–12

Materno–fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)

Soluble interleukin–6 (IL–6) receptor in the sera of pregnant women forms a complex with IL–6 and augments human chorionic gonadotropin production by normal human trophoblasts through binding to the IL–6 signal transducer. Matsuzaki N, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2912–7

Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? Pop VJ, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3561–6

Toxoplasma IgG. & IgM. antibodies. A case control study. Attia RA, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):877–82

The effect of pregnancy on polymorphonuclear leukocyte function. Crouch SP, et al. **J Immunol** 1995 Dec 1; 155(11):5436–43

CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy–induced immune depression in uninfected and HIV–infected women. Rich KC, et al. **J Infect Dis** 1995 Nov; 172(5):1221–7

Serum interleukin–2 and soluble interleukin–2 receptor in gestational trophoblastic diseases. Shaarawy M, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):39–46

Rubella in mothers [letter] [see comments] Rushworth RL, et al. **Lancet** 1996 May 4;347(9010):1262. Comment in: Lancet 1996 Jul 27;348(9022):267–8.

Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lynch AM, et al. **Lupus** 1995 Oct;4(5):365–9

Cancer: a biological problem without any natural immunological solution? A unified theory, with implications for grafts, pregnancy and tumour immunoprophylaxis. Manzo G. **Med Hypotheses** 1995 Oct; 45(4):317–24

Assessment of rubella immunity in women born in 1959–74 in a solo rural general practice. Janes R. **N Z Med J** 1995 Sep 22;108(1008):384–5

Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

Immunosuppressive properties of plasma and lymphocytes from the human retroplacental blood. Xiao L, et al. **Scand J Immunol** 1996 Sep;44(3):299–304

Critical review of protease–treated red cell tests for the detection of irregular blood group antibodies during pregnancy [letter] Jemmolo G, et al. **Vox Sang** 1995; 69(2):144

[Natural cytotoxicity of CD16+ lymphocytes in women with selected states of pregnancy pathology] Kamiński K, et al. **Ginekol Pol** 1995 Apr;66(4):193–7 (Eng. Abstr.) **(Pol)**

[The functional activity of the lymphoid cell population in the decidua in the late period of pregnancy] Repina MA, et al. **Morfologiia** 1994 Jul–Dec;107(7–12):155–8 (Eng. Abstr.) **(Rus)**

[The serum markers in the pregnant population of the basic health area of El Natahoyo (Gijón)] Menéndez MT, et al. **Aten Primaria** 1996 Jun 15;18(1):17–21 (Eng. Abstr.) **(Spa)**

[Prevalence of rubella virus antibodies in pregnant women in two zones of Valle de Mexico] Bustamante–Calvillo ME, et al. **Ginecol Obstet Mex** 1996 Mar;64:114–6 (Eng. Abstr.) **(Spa)**

METABOLISM

Detection of oxytocin receptor in endocervical scrapings during pregnancy. Kubota Y, et al. **Adv Exp Med Biol** 1995; 395:489–90

Immunolocalization of progesterone–induced uterine protein–1 in human endometrium during the menstrual cycle and in the placenta throughout gestation. Sharpe–Timms KL, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1569–78

Aspects of metabolism in normal and gestational diabetic pregnancy. Johnston DG, et al. **Biochem Soc Trans** 1995 Aug;23(3):512–6 (20 ref.)

Unexpected relationship between fat mass and basal metabolic rate in pregnant women. Bronstein MN, et al. **Br J Nutr** 1996 May;75(5):659–68

Systemic and fetal–maternal nitric oxide synthesis in normal pregnancy and pre–eclampsia. Boccardo P, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):879–86

Nitric oxide, the endothelium, pregnancy and pre–eclampsia. Morris NH, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):4–15 (152 ref.)

Garlic ingestion by pregnant women alters the odor of amniotic fluid. Mennella JA, et al. **Chem Senses** 1995 Apr; 20(2):207–9

Glucose metabolism assessment in pregnancy. Garner PR. **Clin Biochem** 1995 Oct;28(5):499–502 (18 ref.)

Steroids in human intrauterine fluids of early pregnancy. Atkinson G, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):435–40

Calcium homeostasis in pregnancy. Hosking DJ. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):1–6 (45 ref.)

Prostaglandin–metabolizing enzymes during pregnancy: characterization of NAD(+)–dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450–dependent prostaglandin omega–hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)

A relationship between impaired fetal growth and reduced muscle glycolysis revealed by 31P magnetic resonance spectroscopy. Taylor DJ, et al. **Diabetologia** 1995 Oct; 38(10):1205–12

Relaxin levels in amniotic fluid, extraembryonic coelomic fluid and maternal serum in early human pregnancy. Wathen NC, et al. **Early Hum Dev** 1995 Aug 30;43(1):71–4

Expression of oxytocin receptor in human pregnant myometrium. Kimura T, et al. **Endocrinology** 1996 Feb; 137(2):780–5

Report on the working group on energy requirements for pregnancy and lactation. Allen LH, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S190–1

Energy requirements of pregnant and lactating women. Prentice AM, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S82–110; discussion S10–1 (114 ref.)

Different energy metabolite pattern between uterine smooth muscle and striated rectus muscle in term pregnant women. Steingrímsdóttir T, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):241–5

Energy requirements of pregnancy for healthy Dutch women. van Raaij JM. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):7–13 (12 ref.)

Lactose metabolism and time to pregnancy. Herrinton LJ, et al. **Fertil Steril** 1996 Sep;66(3):384–8

Angiotensin II receptor characteristics and subtype expression in uterine arteries and myometrium during pregnancy. Cox BE, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):49–58

Glucose homeostasis during spontaneous labor in normal human pregnancy. Maheux PC, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):209–15

Placental corticotrophin–releasing hormone: there by accident or design? Perkins AV, et al. **J Endocrinol** 1995 Dec;147(3):377–81

Some aspects of neonatal essential fatty acid status are altered by linoleic acid supplementation of women during pregnancy. Al MD, et al. **J Nutr** 1995 Nov;125(11):2822–30

Adenylyl cyclase activity in human decidua and myometrium during pregnancy and labour. Miyazaki K, et al. **J Reprod Fertil** 1995 Sep;105(1):141–5

The role of nitric oxide metabolites during pregnancy. Begum S, et al. **Kobe J Med Sci** 1996 Apr;42(2):131–41

Glucose and lactate kinetics during a short exercise bout in pregnancy. Cowett RM, et al. **Metabolism** 1996 Jun; 45(6):753–8

Insulin receptor binding from mid–term and full–term placentas of patients with gestational diabetes mellitus and normal pregnant women. al–Attas OS. **Mol Cell Biochem** 1995 Oct 4;151(1):27–31

Selenium in human lactation. Sanz Alaejos M, et al. **Nutr Rev** 1995 Jun;53(6):159–66 (101 ref.)

Bone turnover and mineral metabolism in the last trimester of pregnancy: effect of multiple gestation. Okah FA, et al. **Obstet Gynecol** 1996 Aug;88(2):168–73

Fuel metabolism in pregnancy and in gestational diabetes mellitus. Boden G. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):1–10 (53 ref.)

Volume–activated release of D–aspartate from human placental tissue [letter] Shennan DB, et al. **Placenta** 1996 Mar–Apr;17(2–3):189–90

Expression pattern of cytokines in the different compartments of the feto–maternal unit under various conditions. Stallmach T, et al. **Reprod Fertil Dev** 1995;7(6):1573–80

Parathyroid hormone–related protein (PTHrP) concentrations in human amniotic fluid during gestation and at the time of labour. Wlodek ME, et al. **Reprod Fertil Dev** 1995;7(6):1509–13

Maternal serum amylase and lipase profiles in pregnancy [letter] Saade GR. **South Med J** 1996 Jul;89(7):741

[The evaluation of energy balance in pregnancy] Angelova K, et al. **Akush Ginekol (Sofiia)** 1995;34(2):13–6 (Eng. Abstr.) **(Bul)**

[Corticotropin–releasing hormone in pregnancy] Sun G. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):270–2 (10 ref.) **(Chi)**

[Regular vitamin A supplements are safe for pregnant women who consume few liver products] van den Berg H, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):192–5 (Eng. Abstr.) **(Dut)**

[A study of interleukin–6 and soluble interleukin–6 receptors during pregnancy and delivery] Ishizaki S. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1230–6 (Eng. Abstr.) **(Jpn)**

[Activity of superoxide dismutase and its isoenzyme during normal pregnancy] Królak B, et al. **Ginekol Pol** 1996 Apr; 67(4):165–8 (Eng. Abstr.) **(Pol)**

[Changes in levels of human placenta lactogen (hPL), progesterone, and estriol in blood serum and estrogens in urine during gestational diabetes mellitus] Olszewski J, et al. **Ginekol Pol** 1995 Mar;66(3):145–50 (Eng. Abstr.) **(Pol)**

[Mercury in the hair of pregnant and lactating Chilean mothers] Bruhn CG, et al. **Bol Oficina Sanit Panam** 1995 Nov;119(5):405–14 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Effects of endothelin–1 and the ETA receptor antagonist BQ–123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)

Timing and patterns of exposures during pregnancy and their implications for study methods. Hertz–Picciotto I, et al. **Am J Epidemiol** 1996 Mar 15;143(6):597–607

"Physiologic" intracellular acidosis in pregnancy. Bardicef O, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):879–80

Diurnal variation in angiotensin sensitivity in pregnancy. Delemarre FM, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):259–61

A critique of the new recommendations for weight gain in pregnancy. Johnson JW, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):254–8 (25 ref.)

Cervical ripening in humans: potential roles of estrogen, progesterone, and insulin–like growth factor–I. Stjernholm Y, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1065–71

Use of cardiac index in pregnancy: is it justified? van Oppen AC, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):923–8

Maternal and fetal responses to low–impact aerobic dance. McMurray RG, et al. **Am J Perinatol** 1995 Jul;12(4):282–5

Maternal prepregnant weight and weight gain: relationship to placental microstructure and morphometric oxygen diffusion capacity. Stevens–Simon C, et al. **Am J Perinatol** 1995 Nov;12(6):407–12

Effect of oral protein loading on renal hemodynamics in human pregnancy. Barron WM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R888–95

Effect of atrial natriuretic peptide on renal hemodynamics and sodium excretion during human pregnancy. Irons DW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F239–42

Renal reserve during human pregnancy. Sturgiss SN, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F16–20

Thyroid function studies in normal pregnant Tanzanian women. Kabyemela EA, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):58–61

Sleeping habits of pregnant women: a questionnaire study. Fujino Y, et al. **Appl Human Sci** 1995 Nov;14(6):305–7

Second trimester colour Doppler imaging of the uterine artery: reproducibility of the resistance index. Yan YL, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):254–6

Maternal recognition of pregnancy. Roberts RM, et al. **Biol Reprod** 1996 Feb;54(2):294–302 (80 ref.)

Maternal nutrition in early and late pregnancy in relation to placental and fetal growth. Godfrey K, et al. **BMJ** 1996 Feb 17;312(7028):410–4

The thermic effect of food in normal–weight and overweight pregnant women. Bronstein MN, et al. **Br J Nutr** 1995 Aug;74(2):261–75

Blood pressure measurement in pregnancy [see comments] de Swiet M, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):862–3 (12 ref.). Comment in: Br J Obstet Gynaecol 1996 Sep;103(9):vii.

Effects of fish oil supplementation in late pregnancy on blood pressure: a randomised controlled trial. Salvig JD, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):529–33

Mesenteric arterial function in the rat in pregnancy: role of

sympathetic and sensory-motor perivascular nerves, endothelium, smooth muscle, nitric oxide and prostaglandins. Ralevic V, et al. **Br J Pharmacol** 1996 Apr; 117(7):1463–70

Maternal rectal temperature and fetal heart rate responses to upright cycling in late pregnancy. O'Neill ME. **Br J Sports Med** 1996 Mar;30(1):32–5

Dye-coupling between term pregnant human myometrial cells before labor: carboxyfluorescein versus lucifer yellow. Ciray HN, et al. **Cell Biol Int** 1995 Jul;19(7):609–17

Regulation of breathing and perception of dyspnea in healthy pregnant women. García-Río F, et al. **Chest** 1996 Aug; 110(2):446–53

Control mechanisms for physiological hypertrophy of pregnancy. Mone SM, et al. **Circulation** 1996 Aug 15; 94(4):667–72

Role of the pulmonary circulation in the distribution of human fetal cardiac output during the second half of pregnancy. Rasanen J, et al. **Circulation** 1996 Sep 1; 94(5):1068–73

The maternal hypothalamic-pituitary-adrenal axis in the third trimester of human pregnancy. Magiakou MA, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):419–28

Nausea, vomiting and thyroid function before and after induced abortion in normal pregnancy. Aprierto U, et al. **Clin Exp Obstet Gynecol** 1996;23(1):18–20

Normal cardiopulmonary physiology during pregnancy. Crapo RO. **Clin Obstet Gynecol** 1996 Mar;39(1):3–16 (54 ref.)

Relaxin used to produce the cervical ripening of labor. Weiss G. **Clin Obstet Gynecol** 1995 Jun;38(2):293–300 (16 ref.)

Maternal adaptation to pregnancy. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):420–6 (55 ref.)

Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)

Nutrition in pregnancy. Proceedings of an international workshop. Eindhoven, The Netherlands, 25 November 1994. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):1–78

A computerized diagnostic system for the interpretation of umbilical artery blood flow velocity waveforms. Beksaç MS, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):37–42

Autonomic cardiovascular control in pregnancy. Ekholm EM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):29–36 (75 ref.)

Urinary cGMP levels during pregnancy with and without uterine contractions. Francoual J, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):17–9

Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)

Essential fatty acids in pregnancy and early human development. Hornstra G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):57–62 (35 ref.)

Iron supplementation during pregnancy. Roodenburg AJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):65–71 (66 ref.)

Low sodium diet in pregnancy: effects on maternal nutritional status. van der Maten GD. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):63–4

Regulation of corpus luteum function in early human pregnancy. Hagström HG, et al. **Fertil Steril** 1996 Jan; 65(1):81–6

Tobacco smoking (up to 10 cigarettes daily) and lung functions in pregnant women. Kostianev S, et al. **Folia Med (Plovdiv)** 1994;36(3):21–5

Nitric oxide and prostaglandin systems inhibition on the isolated perfused human placenta from normal and preeclamptic pregnancies. González C, et al. **Gynecol Obstet Invest** 1995;40(4):244–8

Flow velocity waveforms of the uterine artery in pregnancy: transvaginal versus transabdominal approach. Jaffa AJ, et al. **Gynecol Obstet Invest** 1995;40(2):80–3

The pregnant worker: how much is too much? Assessing safe activity levels. Feinberg JS, et al. **Hawaii Med J** 1996 May;55(5):85–6 (15 ref.)

Pregnancy-induced alterations of relaxation in response to magnesium in the rat aorta may be due to plasma-borne agents. Ezimokhai M, et al. **Heart Vessels** 1995; 10(4):197–203

Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Bacq Y, et al. **Hepatology** 1996 May;23(5):1030–4

Immuno-endocrine interactions in early pregnancy. Chaouat G, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:55–9 (45 ref.)

Effect of ovulation induction on uterine blood flow and oestradiol and progesterone concentrations in early pregnancy. Dickey RP, et al. **Hum Reprod** 1995 Nov; 10(11):2875–9

The role of relaxin in the pregnancy associated reduction in plasma osmolality. Johnson MR, et al. **Hum Reprod** 1996 May;11(5):1105–8

Spontaneous pregnancy after previous pregnancy by oocyte donation due to premature ovarian failure [letter] Sheu BC, et al. **Hum Reprod** 1996 Jun;11(6):1359–60

Changes in activity of superoxide dismutase in the human endometrium throughout the menstrual cycle and in early pregnancy. Sugino N, et al. **Hum Reprod** 1996 May; 11(5):1073–8

Effects of long-term nitric oxide synthesis inhibition on plasma volume expansion and fetal growth in the pregnant rat. Salas SP, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1019–23

Growth factors in pregnancy. Cooper JC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):197–203 (22 ref.)

Attempted weight loss during pregnancy. Cogswell ME, et al. **Int J Obes Relat Metab Disord** 1996 Apr;20(4):373–5

Timing of weight gain during pregnancy: promoting fetal growth and minimizing maternal weight retention. Muscati SK, et al. **Int J Obes Relat Metab Disord** 1996 Jun; 20(6):526–32

A food frequency questionnaire can detect pregnancy-related changes in diet. Brown JE, et al. **J Am Diet Assoc** 1996 Mar;96(3):262–6

Invited editorial on "effect of altitude on uterine artery blood flow during normal pregnancy" and "alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude" [editorial; comment] Clark KE. **J Appl Physiol** 1995 Jul;79(1):5–6. Comment on: J Appl Physiol 1995 Jul;79(1):7–14. Comment on: J Appl Physiol 1995 Jul;79(1):15–22.

Effect of altitude on uterine artery blood flow during normal pregnancy [see comments] Zamudio S, et al. **J Appl Physiol** 1995 Jul;79(1):7–14. Comment in: J Appl Physiol 1995 Jul;79(1):5–6.

Color-Doppler velocimetry of uterine arteries in pregnant and nonpregnant patients during multiovulation induction for IVF. Levi-Setti PE, et al. **J Assist Reprod Genet** 1995 Aug;12(7):413–7

Fertilization and pregnancies following intracytoplasmic injection of testicular spermatozoa. Obruca A, et al. **J Assist Reprod Genet** 1995 Oct;12(9):627–31

Luteal estrogen is not required for the establishment of pregnancy in the human. Zegers-Hochschild F, et al. **J Assist Reprod Genet** 1995 Mar;12(3):224–8

Effect of corticotropin-releasing factor-binding protein on prostaglandin release from cultured maternal decidua and on contractile activity of human myometrium in vitro. Petraglia F, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3073–6

Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium: a longitudinal study. Yamaga A, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):752–6

Hepatic venous Doppler waveforms: changes in pregnancy. Roobottom CA, et al. **J Clin Ultrasound** 1995 Oct; 23(8):477–82

Characteristics of a reversed circadian blood pressure rhythm in pregnant women with hypertension. Olofsson P. **J Hum Hypertens** 1995 Jul;9(7):565–70

Point of diminishing returns: when does gestational weight gain cease benefiting birthweight and begin adding to maternal obesity? Luke B, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):168–73

Do receptors get pregnant too? Adrenergic receptor alterations in human pregnancy. Smiley RM, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):106–14 (60 ref.)

Changes of bone mineral density in pregnant and postpartum women. Matsumoto I, et al. **J Obstet Gynaecol** 1995 Oct; 21(5):419–25

Biochemical events in cervical ripening dilatation during pregnancy and parturition. Osmers RG, et al. **J Obstet Gynaecol** 1995 Apr;21(2):185–94

Blood pressure measurement during pregnancy: auscultatory versus oscillatory methods. Green LA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):155–9

Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474–85 (47 ref.)

Pregnancy after the fontan procedure for tricuspid atresia. A case report. Lao TT, et al. **J Reprod Med** 1996 Apr; 41(4):287–90

Duration and variability of normal pregnancy. Implications for clinical practice. Mongelli M, et al. **J Reprod Med** 1995 Sep;40(9):645–8

Maternal right hypogastric artery blood flow during normal pregnancy and 6 weeks postpartum. Veille JC, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):191–8

Corpus luteum blood flow in normal and abnormal early pregnancy: evaluation with transvaginal color and pulsed Doppler sonography [letter; comment] Applebaum M. **J Ultrasound Med** 1995 Oct;14(10):756. Comment on: J Ultrasound Med 1994 Dec;13(12):971–5.

The fourth sound of Korotkoff in pregnancy: a myth? [letter; comment] Franx A, et al. **Lancet** 1996 Mar 23;347(9004):841 . Comment on: Lancet 1996 Jan 20;347(8995):139–42.

Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry [see comments] Shennan A, et al. **Lancet** 1996 Jan 20; 347(8995):139–42. Comment in: Lancet 1996 Jan 20:347(8995):135–6. Comment in: Lancet 1996 Mar 2;347(9001):618–9. Comment in: Lancet 1996 Mar 23;347(9004):841.

Diagnosis of early pregnancy and early complications. Cartwright PS. **Med Clin North Am** 1995 Nov; 79(6):1319–35 (33 ref.)

Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68–72 (73 ref.)

Lead mobilisation during pregnancy [letter] Gulson BL, et al. **Med J Aust** 1995 Oct 16;163(8):447

Pregnancy, lactation, and menopause: how physiology and gender affect the toxicity of chemicals. Roberts JS, et al. **Mt Sinai J Med** 1995 Oct;62(5):343–55 (66 ref.)

Factors related to body weight changes during and after pregnancy: the Stockholm Pregnancy and Weight Development Study. Ohlin A, et al. **Obes Res** 1996 May; 4(3):271–6

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Differences between office and 24-hour ambulatory blood pressure measurement during pregnancy. Churchill D, et al. **Obstet Gynecol** 1996 Sep;88(3):455–61

Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Coulson CC, et al. **Obstet Gynecol** 1996 Apr;87(4):610–2

The effects of maternal position and cardiac output on intrapulmonary shunt in normal third-trimester pregnancy. Hankins GD, et al. **Obstet Gynecol** 1996 Sep;88(3):327–30

The hemodynamic effects of maternal hypo- and hyperoxygenation in healthy term pregnancies. Polvi HJ, et al. **Obstet Gynecol** 1995 Nov;86(5):795–9

Cardiac output in normal pregnancy: a critical review. van Oppen AC, et al. **Obstet Gynecol** 1996 Feb;87(2):310–8 (81 ref.)

A longitudinal study of maternal hemodynamics during normal pregnancy. van Oppen AC, et al. **Obstet Gynecol** 1996 Jul;88(1):40–6

Impact of the L-arginine/nitric oxide system in pregnancy. Neri I, et al. **Obstet Gynecol Surv** 1995 Dec;50(12):851–8 (64 ref.)

Analysing the relationship between maternal weight gain and birthweight: exploration of four statistical issues. Selvin S, et al. **Paediatr Perinat Epidemiol** 1996 Apr;10(2):220–34

Maternal body mass, proportional weight gain, and fetal growth in parous women. Shepard MJ, et al. **Paediatr Perinat Epidemiol** 1996 Apr;10(2):207–19

Somatostatin levels during infancy, pregnancy, and lactation: a review. Goldstein A, et al. **Peptides** 1995;16(7):1321–6 (63 ref.)

Structure and function of the abdominal muscles in primigravid subjects during pregnancy and the immediate postbirth period. Gilleard WL, et al. **Phys Ther** 1996 Jul; 76(7):750–62

Dipeptide transport in brush-border membrane vesicles (BBMV) prepared from human full-term placentae. Meredith D, et al. **Placenta** 1996 Mar–Apr;17(2–3):173–9

Immunohistochemical localization of vascular endothelial growth factor in the human placenta. Shiraishi S, et al. **Placenta** 1996 Mar–Apr;17(2–3):111–21

Early amniocentesis at 10–12 weeks' gestation. Diaz Vega M, et al. **Prenat Diagn** 1996 Apr;16(4):307–12

Priorities for nutrition interventions in reproductive health: a bilateral agency perspective. Davidson FR. **Proc Nutr Soc** 1995 Jul;54(2):361–6 (19 ref.)

The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329–43 (97 ref.)

The struggle within. Conflict between fetus and mother may trouble pregnancy [news] Horgan J. **Sci Am** 1995 Dec; 273(6):25–6

Renal reserve in pregnancy. Gaboury CL, et al. **Semin Nephrol** 1995 Sep;15(5):449–53 (27 ref.)

Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504–11 (51 ref.)

Individual nutrient effects on length of gestation and pregnancy outcome. Murtaugh MA, et al. **Semin Perinatol** 1995 Jun;19(3):197–210 (138 ref.)

Reduction of food intake during pregnancy in rural south India. Hutter I. **Trop Med Int Health** 1996 Jun;1(3):399–405

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

Korotkoff's sounds in pregnancy. Quinn M. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):58–61

The electrocardiogram of pregnant Nigerian women. Edemeka DB, et al. **West Afr J Med** 1995 Oct–Dec; 14(4):227–32

[Pregnancy and labor under new urodynamic conditions] Kutsarev I, et al. **Khirurgiia (Sofiia)** 1994;47(3):15–6 **(Bul)**

[Orogenital sex and pregnancy (letter)] Ramsay T. **Duodecim** 1995;111(2):188–9 **(Fin)**

[Physiological review of the mammary gland development during pregnancy] Merviel P, et al. **Contracept Fertil Sex** 1996 Mar;24(3):218–22 (25 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**

[Is the length of gestation a multiple of a fundamental cycle?] Kotoujansky J, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):486–93 (Eng. Abstr.) **(Fre)**

[Vaginal environment. The vaginal climate and its variations] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):471–80 (8 ref.) (Eng. Abstr.) **(Fre)**

[Effect of pregnancy and labor on serotonin metabolism] du Bois A, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;

55(9):500–4 (Eng. Abstr.) **(Ger)**

[Normal values for relative Doppler indices. A/B ratio, resistance index and pulsatility index of the uterine artery and umbilical artery in normal pregnancy. A longitudinal study] Hüneke B, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):616–22 (Eng. Abstr.) **(Ger)**

[Bioelectric profiles and nutritional status in pregnancy: protocol of a multicentric project to measure bioimpedance in pregnancy] Mele MC, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):25–33 (23 ref.) (Eng. Abstr.) **(Ita)**

[Differentiation of extravillous trophoblast during normal pregnancy] Sasagawa M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May; 48(5):315–20 (Eng. Abstr.) **(Jpn)**

[The respiratory system in pregnancy] Buchacz P, et al. **Ginekol Pol** 1995 Jun;66(6):347–50 (48 ref.) (Eng. Abstr.) **(Pol)**

[Effect of blood flow velocity on umbilical vessels in twin pregnancy] Gąsior W, et al. **Ginekol Pol** 1995 Aug; 66(8):477–9 (Eng. Abstr.) **(Pol)**

[Usefulness of vaginal ultrasonography for evaluation of cervix sufficiency in pregnancy] Marianowski J, et al. **Ginekol Pol** 1995 Jul;66(7):391–6 (Eng. Abstr.) **(Pol)**

[Uncomplicated course of pregnancy after previous ligation of both internal iliac arteries and left ovarian artery] Szramik Z, et al. **Ginekol Pol** 1996 Jan;67(1):45–7 (Eng. Abstr.) **(Pol)**

[Objective evaluation of physical exertion in pregnant women based on long–term recording of heart action. Results of a pilot study] Makowiec–Dąbrowska T, et al. **Med Pr** 1996; 47(3):233–9 (Eng. Abstr.) **(Pol)**

[Functional activity of the hypophyseal–thyroid system in pregnant women under conditions of the town of Khabarovska] Uchakina RV, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):85–91 **(Rus)**

[The laboratory support of the gestational process] Kulakov VI. **Klin Lab Diagn** 1995 Nov–Dec;(6):42–6 **(Rus)**

[The dynamics of the physical work capacity of women during pregnancy] Osipov VG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):33–4 **(Rus)**

PSYCHOLOGY

Perceptions of pregnant/parenting teens: reframing issues for an integrated approach to pregnancy problems. Rodriquez C Jr, et al. **Adolescence** 1995 Fall;30(119):685–706

Use of decision analysis to evaluate patients' choices of diagnostic prenatal test. Verp MS, et al. **Am J Med Genet** 1995 Sep 25;58(4):337–44

The relationship between pregnancy and sexual risk taking. Wilson TE, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):1033–6

Services for homeless pregnant women: lessons from the field. Weinreb L, et al. **Am J Orthopsychiatry** 1995 Oct; 65(4):492–501

The impact of a preconceptional health promotion program on intendedness of pregnancy. Moos MK, et al. **Am J Perinatol** 1996 Feb;13(2):103–8

Antenatal psychosocial risk factors associated with adverse postpartum family outcomes. Wilson LM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):785–99

Delusion of pregnancy in psychotic depression and ECT response [letter] Bernardo M, et al. **Convuls Ther** 1996 Mar; 12(1):39–40

What causes the excess left–handedness in twins? [letter; comment] James WH. **Early Hum Dev** 1995 Aug 30; 43(1):95. Comment on: Early Hum Dev 1994 Dec 16;40(1):23–7.

Breastfeeding duration: prenatal intentions and postnatal practices. Lawson K, et al. **J Adv Nurs** 1995 Nov; 22(5):841–9

The effect of the amount of feedback on anxiety levels during ultrasound scanning. Zlotogorski Z, et al. **J Clin Ultrasound** 1996 Jan;24(1):21–4

Maternal anxiety during pregnancy: effect on fetal behavior at 38 to 40 weeks of gestation. Groome LJ, et al. **J Dev Behav Pediatr** 1995 Dec;16(6):391–6

Validating a model developed to predict prenatal care utilization. Campbell JD, et al. **J Fam Pract** 1995 Nov; 41(5):457–64

The essence of nurse–midwifery care. The woman's story. Kennedy HP. **J Nurse Midwifery** 1995 Sep–Oct;40(5):410–7

Prenatal and postnatal attachment: a modest correlation. Müller ME. **J Obstet Gynecol Neonatal Nurs** 1996 Feb; 25(2):161–6

Pregnancy decision making as a significant life event: a commitment approach. Lydon J, et al. **J Pers Soc Psychol** 1996 Jul;71(1):141–51

Perceived need for treatment among pregnant and nonpregnant women arrestees. Baldwin DM, et al. **J Psychoactive Drugs** 1995 Oct–Dec;27(4):389–99

The abortion decision: reasons and ambivalence. Allanson S, et al. **J Psychosom Obstet Gynaecol** 1995 Sep; 16(3):123–36

Motives for having or not having children: a comparison between questionnaire and interview methods. Wikman M, et al. **J Psychosom Obstet Gynaecol** 1995 Dec;16(4):171–80

Factors relating to smoking and pregnancy in the North Western Region. Forrest D, et al. **J Public Health Med** 1995 Jun;17(2):205–10

Life after birth. Blumfield W. **J R Soc Health** 1996 Jun; 116(3):176–9

Gender roles and alcohol abuse across the transition to parenthood. Richman JA, et al. **J Stud Alcohol** 1995 Sep; 56(5):553–7

Failure to address the psychosocial benefit of prenatal sonography: another failing of the RADIUS Study. Routine Antenatal Diagnostic Imaging with Ultrasound [letter] Persutte WH. **J Ultrasound Med** 1995 Oct; 14(10):795–6

Adaptation to pregnancy and motherhood among subfecund and fecund primiparous women. Halman LJ, et al. **Matern Child Nurs J** 1995 Jul–Sep;23(3):90–100

The production of authoritative knowledge in American prenatal care. Browner CH, et al. **Med Anthropol Q** 1996 Jun;10(2):141–56

The social production of authoritative knowledge in pregnancy and childbirth. Davis–Floyd R, et al. **Med Anthropol Q** 1996 Jun;10(2):111–20

Intuition as authoritative knowledge in midwifery and homebirth. Davis–Floyd R, et al. **Med Anthropol Q** 1996 Jun;10(2):237–69

Authoritative knowledge and birth territories in contemporary Japan. Fiedler DC. **Med Anthropol Q** 1996 Jun;10(2):195–212

Intuition and the emergence of midwifery as authoritative knowledge. Gaskin IM. **Med Anthropol Q** 1996 Jun; 10(2):295–8

Fetal ultrasound imaging and the production of authoritative knowledge in Greece. Georges E. **Med Anthropol Q** 1996 Jun;10(2):157–75

Authority and authoritative knowledge in American birth. Hays BM. **Med Anthropol Q** 1996 Jun;10(2):291–4

Fetal rights versus the female body: contested domains. Heriot MJ. **Med Anthropol Q** 1996 Jun;10(2):176–94

Maternal health, war, and religious tradition: authoritative knowledge in Pujehun District, Sierra Leone. Jambai A, et al. **Med Anthropol Q** 1996 Jun;10(2):270–86

Ways of knowing about birth in three cultures. Sargent C, et al. **Med Anthropol Q** 1996 Jun;10(2):213–36

"Women come here on their own when they need to": prenatal care, authoritative knowledge, and maternal health in Oaxaca. Sesia PM. **Med Anthropol Q** 1996 Jun; 10(2):121–40

Telephone support for pregnant women: outcome in late pregnancy. Bullock LF, et al. **N Z Med J** 1995 Nov 24; 108(1012):476–8

Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

Firstborns' behaviors during a mother's second pregnancy. Gottlieb LN, et al. **Nurs Res** 1995 Nov–Dec;44(6):356–62

Smoking in pregnancy: a way to cope with excessive workload? Wergeland E, et al. **Scand J Prim Health Care** 1996 Mar;14(1):21–8

Identification and care of problems associated with alcohol ingestion in pregnancy. Hankin JR, et al. **Semin Perinatol** 1995 Aug;19(4):286–92 (24 ref.)

Smoking cessation interventions for pregnant women: review and future directions. O'Campo P, et al. **Semin Perinatol** 1995 Aug;19(4):279–85 (37 ref.)

Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)

Inclusion of psychosocial conditions in clinical practice and the problem of medicalization. Førde R. **Theor Med** 1996 Jun;17(2):151–61

Guinea–Bissau: what women know about the risks—an anthropological study. Oosterbaan MM, et al. **World Health Stat Q** 1995;48(1):39–43

[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:116–9 (22 ref.) **(Fre)**

[Psychology of the desire for children in men and women] Frick–Bruder V, et al. **Geburtshilfe Frauenheilkd** 1994 Nov; 54(11):M142–6 **(Ger)**

[Couple relationship dynamics in transition to parenthood] Simoni H, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr;46(3–4):124–30 (Eng. Abstr.) **(Ger)**

[Fear as a risk factor in perinatology] Zdziennicki A. **Wiad Lek** 1994 Sep;47(17–18):698–9 (21 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

[Protection from ionizing radiation for pregnant workers] Campos Venuti G, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):194–6 (15 ref.) **(Ita)**

STATISTICS & NUMERICAL DATA

Vaginal douching and reduced fertility. Baird DD, et al. **Am J Public Health** 1996 Jun;86(6):844–50

Exercise during pregnancy among US women. Zhang J, et al. **Ann Epidemiol** 1996 Jan;6(1):53–9

The sperm stress test: a novel test that predicts pregnancy in assisted reproductive technologies. Alvarez JG, et al. **Fertil Steril** 1996 Feb;65(2):400–5

The effect of assisted hatching on pregnancy rates after frozen embryo transfer. Check JH, et al. **Fertil Steril** 1996 Feb;65(2):254–7

An improvement in the embryo quality and pregnancy rate by the pulsatile administration of human menopausal gonadotropin in patients with previous unsuccessful in vitro fertilization attempts. Jinno M, et al. **Fertil Steril** 1996 Feb; 65(2):382–6

Counting the changes in childbirth: trends and gaps in national statistics [editorial] Smith JP. **J Adv Nurs** 1995 Oct;22(4):619

Intracytoplasmic sperm injection: a treatment for extreme oligospermia [see comments] Gil–Salom M, et al. **J Urol** 1996 Sep;156(3):1001–4. Comment in: J Urol 1996 Sep;156(3):1013.

From the Institute of Medicine. Brown SS, et al. **JAMA** 1995 Nov 1;274(17):1332

Prevalence of violence against pregnant women. Gazmararian JA, et al. **JAMA** 1996 Jun 26;275(24):1915–20 (38 ref.)

Decreased fertility in Britain compared with Finland. Joffe M. **Lancet** 1996 Jun 1;347(9014):1519–22

Pregnancy and the timing of intercourse [letter; comment] Hilgers TW. **N Engl J Med** 1996 May 9;334(19):1267; discussion 1267–8. Comment on: N Engl J Med 1995 Dec 7;333(23):1517–21.

Prevalence of smoking in early pregnancy by census area: measured by anonymous cotinine testing of residual antenatal blood samples. Tappin DM, et al. **N Z Med J** 1996 Mar 22;109(1018):101–3

The relationship of early follicular phase serum LH and pregnancy rates in women with regular menses. Check JH, et al. **Obstet Gynecol** 1996 Feb;87(2):291–6

Pregnancy rates among women infected with human immunodeficiency virus. Adult/Adolescent HIV Spectrum of Disease Project Group. Chu SY, et al. **Obstet Gynecol** 1996 Feb;87(2):195–8

Effect of age on intrauterine insemination with frozen donor sperm. Kang BM, et al. **Obstet Gynecol** 1996 Jul;88(1):93–8

Patterns of reproduction among the Fang of Nsork (Equatorial Guinea): pregnancies, abortions and child spacing. Sainz de la Maza Kaufmann M, et al. **Rev Biol Trop** 1994 Apr–Aug;42(1–2):315–8

Health aspects of pregnancy and childbirth: United States, 1982–88. Chandra A. **Vital Health Stat 23** 1995 Aug; (18):1–74

[Obstetrical observations of single–parent pregnancies (based on data from the Clinique Universitaire de Gynecologie, d'Obstétrique et de la Reproduction in the city of Besançon, France)] Zheliazkova E, et al. **Akush Ginekol (Sofiia)** 1995; 34(3):14–6 (Eng. Abstr.) **(Bul)**

[Pregnancy after diagnosis of menopause] Jamin C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):677–81 (55 ref.) (Eng. Abstr.) **(Fre)**

[Reproductive histories of coastal and inland women with and without exposure to methylmercury in Kumamoto] Inaoka T, et al. **Nippon Eiseigaku Zasshi** 1995 Oct; 50(4):861–6 (Eng. Abstr.) **(Jpn)**

URINE

6–sulfatoxymelatonin levels in pregnant women during workplace and nonworkplace stresses: a potential biologic marker of sympathetic activity. Katz VL, et al. **Am J Perinatol** 1995 Jul;12(4):299–302

Soluble tumor necrosis factor receptor in serum and urine throughout normal pregnancy and at delivery. Arntzen KJ, et al. **Am J Reprod Immunol** 1995 Sep;34(3):163–9

Increased urine chromium excretion in normal pregnancy [letter] Morris B, et al. **Clin Chem** 1995 Oct;41(10):1544–5

Increased aldosterone–18–glucuronide/tetrahydroaldosterone ratios in pregnancy. Wacker J, et al. **Endocr Res** 1995 Feb–May; 21(1–2):197–202

[Urinary proteins during pregnancy in women with and without pregnancy induced hypertension] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):395–7 (Eng. Abstr.) **(Chi)**

[Hydroxyproline urine excretion—potential marker of cervical ripening?] Rechberger T, et al. **Ginekol Pol** 1996 Jan;67(1):24–7 (Eng. Abstr.) **(Pol)**

PREGNANCY, ABDOMINAL

Feticide followed by successful removal of pregnancy products in early abdominal pregnancy. Qureshi RN, et al. **J Obstet Gynaecol** 1995 Feb;21(1):13–6

[Term abdominal pregnancy with delivery of a living child. Two case reports] Diouf A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):212–5 (Eng. Abstr.) **(Fre)**

[Primary hepatic pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):523–5 (14 ref.) **(Jpn)**

[Recurrent abdominal pregnancy. A case report] Simón Pereira LA, et al. **Ginecol Obstet Mex** 1995 Nov;63:474–7 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Unusual presentation of abdominal pregnancy. Shava J, et al. **Cent Afr J Med** 1995 Sep;41(9):293–4

Placental abruption in association with advanced abdominal pregnancy. A case report. Yu S, et al. **J Reprod Med** 1995 Oct;40(10):731–5

DIAGNOSIS

Primary abdominal pregnancy: disregarding clinical features leads to misdiagnosis [letter; comment] Persad PS, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):296–7. Comment

on: Am J Obstet Gynecol 1995 May;172(5):1603–4.
Amniotic fluid alpha fetoprotein (AFAFP) and maternal serum alpha fetoprotein (MSAFP) in abdominal pregnancies: correlation with extent and site of placental implantation and clinical implications. Shumway JB, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):120–3
Antenatal diagnosis of a late abdominal pregnancy using ultrasound and magnetic resonance imaging: a case report of successful outcome. Hall JM, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):289–92

SURGERY

Placental abruption in association with advanced abdominal pregnancy. A case report. Yu S, et al. **J Reprod Med** 1995 Oct;40(10):731–5
Sonographic follow–up of a placenta left in situ after delivery of the fetus in an abdominal pregnancy. Bajo JM, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):285–8

PREGNANCY, ADOLESCENT see **PREGNANCY IN ADOLESCENCE**

PREGNANCY, ANIMAL

see related
ANIMALS, NEWBORN

Cervical ripening. A rat model for investigation of contractile and passive biomechanical properties, with focus on antigestagens, eosinophil granulocytes and mast cells. Knudsen UB. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):88–9
Impact of early growth retardation on glucoregulatory control and insulin action in mature rats. Holness MJ. **Am J Physiol** 1996 Jun;270(6 Pt 1):E946–54
[Immigration of a pregnant female in an alpine marmot family group: behavioural and genetic data] Goossens B, et al. **C R Acad Sci III** 1996 Mar;319(3):241–6
The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats. Chu ZM, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):481–3
Maternal high calcium diet fails to reverse rickets in the osteosclerotic mouse. Lester DR Jr, et al. **Clin Orthop** 1996 Sep;(330):271–80
The SV40 T–antigen induces premature apoptotic mammary gland involution during late pregnancy in transgenic mice. Tzeng YJ, et al. **FEBS Lett** 1996 Feb 19;380(3):215–8
The visual appearance and somatic cell count of mammary secretions collected from primigravid heifers during gestation and early postpartum. Hallberg JW, et al. **J Dairy Sci** 1995 Jul;78(7):1629–36
Patterns of prenatal survival in the common marmoset (Callithrix jacchus). Jaquish CE, et al. **J Med Primatol** 1996 Jan;25(1):57–63
Dual regulation of luteal progesterone production by androstenedione during spontaneous and RU486–induced luteolysis in pregnant rats. Tellería CM, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):385–93
Ultrastructural and morphometrical studies on the endothelial cells of arteries supplying the abdomino–inguinal mammary gland of rats during the reproductive cycle. Abdul Awal M, et al. **J Vet Med Sci** 1996 Jan;58(1):29–34
Early embryonic development in vitro and embryo transfer in the cat. Kanda M, et al. **J Vet Med Sci** 1995 Aug; 57(4):641–6
Validity of retrograde corpora lutea of pregnancy as an index of past gestation in Sika deer, Cervus nippon. Kita I, et al. **J Vet Med Sci** 1995 Dec;57(6):1029–33
Susceptibility of fetal, virgin, pregnant and lactating rats for the induction of mammary tumors by gamma rays. Inano H, et al. **Radiat Res** 1996 Jun;145(6):708–13
Localization of neutral endopeptidase in the ovine uterus and conceptus during the oestrous cycle and early pregnancy. Riley SC, et al. **Reprod Fertil Dev** 1995;7(1):27–33
Presence of antigen and antibodies in serum and genital discharges of heifers after experimental intrauterine inoculation with Leptospira interrogans serovar hardjo. Dhaliwal GS, et al. **Res Vet Sci** 1996 Mar;60(2):157–62
Pregnancy diagnosis by ultrasound [letter] Hollands C. **Vet Rec** 1995 Aug 5;137(6):152
[Study of pregnancy and pseudopregnancy in goats] Hesselink JW. **Tijdschr Diergeneeskd** 1996 Jan 15; 121(2):51–2 **(Dut)**
[Cow pregnancy yes or no?] Pieterse MC. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):53 **(Dut)**
[Chronic and acute effect of cycletanine in NO–dependent hypertensive pregnant rats] Van Overloop B, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1223–7 (Eng. Abstr.) **(Fre)**
[The determinants of cardiac failure in utero: the case of fetal tachycardia (letter)] Azancot A. **Arch Pediatr** 1996; 3 Suppl 1:354s–355s **(Fre)**
[Preimplantation diagnosis of delta F508 mutation of mucoviscidosis in transgenic mice] Ji YZ, et al. **Presse Med** 1995 Sep 16;24(26):1193–7 (Eng. Abstr.) **(Fre)**
[Consequences of a surgical correction of an insufficient closure of the vulva on genital flora and conception rate in mares] Heilkenbrinker T, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):183–7 (Eng. Abstr.) **(Ger)**
[Care of pregnancy and prevention of lamb diseases in goats] Elze K, et al. **Tierarztl Prax** 1995 Dec;23(6):559–64 (Eng. Abstr.) **(Ger)**
[Control of ovulation in the mare with Ovuplant (short–term release of the GnRH analog deslorelin acetate). Overview of investigations from 1990 to 1994] Jöchle W. **Tierarztl Prax** 1995 Aug;23(4):381–93 (Eng. Abstr.) **(Ger)**
[Effect of the beta receptor blockader carazolol on the dropping and retention of the placenta in the camel (C. dromedarius)] Nasr MT, et al. **Tierarztl Prax** 1996 Jun; 24(3):319–21 (Eng. Abstr.) **(Ger)**

BLOOD

Effect of pregnancy on plasma phenobarbital concentrations in rats. Moriyama M, et al. **Acta Med Okayama** 1995 Oct; 49(5):237–40
Inhibition of stimulated and basal ACTH by cortisol during ovine pregnancy. Keller–Wood M. **Am J Physiol** 1996 Jul; 271(1 Pt 2):R130–6
Comparison of maternal blood and fetal liver selenium concentrations in cattle in California. Kirk JH, et al. **Am J Vet Res** 1995 Nov;56(11):1460–4
9,13–Di–cis–retinoic acid is the major circulating geometric isomer of retinoic acid in the periparturient period. Horst RL, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):235–9
Peripheral cortisol levels throughout gestation in the cow: effect of stage of gestation and foetal number. Patel OV, et al. **Br Vet J** 1996 Jul;152(4):425–32
Hematological and serum biochemical values in pregnant and postpartum females of the squirrel monkey (Saimiri sciureus). Suzuki T, et al. **Exp Anim** 1996 Jan;45(1):39–43
Characterization of the insulin–like growth factor (IGF) axis in the serum of maternal and fetal macaques (Macaca mulatta and Macaca fascicularis). Tarantal AF, et al. **Growth Regul** 1995 Dec;5(4):190–8
Effect of the H1–antagonist bromadryl on mast cells in pregnant rats ex vivo. Drábiková K, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S36–7
Hormonal indicators of pregnancy in llamas and alpacas. Bravo PW, et al. **J Am Vet Med Assoc** 1996 Jun 15; 208(12):2027–30
Acute shifts in relaxin, progesterone, prolactin, and growth hormone secretion in Chinese Meishan gilts during late pregnancy and after hysterectomy. Dlamini BJ, et al. **J Anim Sci** 1995 Dec;73(12):3732–42
Changes in plasma beta–cell tropin concentrations during pregnancy in rats. Davenport M, et al. **J Endocrinol** 1995 Jul;146(1):177–82
Moderate food restriction abolishes the pregnancy–associated rise in serum growth hormone and decreases serum insulin–like growth factor–I (IGF–I) concentrations without altering IGF–I mRNA expression in rats. Monaco MH, et al. **J Nutr** 1996 Feb;126(2):544–53
Sex steroid levels throughout gestation in cows carrying normal and malformed fetuses. Patel OV, et al. **J Vet Med Sci** 1995 Aug;57(4):659–63
Application of anti–bovine CD2 monoclonal antibody to the rosette inhibition test for detection of early pregnancy factor in cattle. Yoshioka K, et al. **J Vet Med Sci** 1995 Aug;57(4):721–5
Serum chemistry of bowhead whales (Balaena mysticetus). Heidel JR, et al. **J Wildl Dis** 1996 Jan;32(1):75–9
The maternal leucocyte response to the endometrial cups in horses is correlated with the developmental stages of the invasive trophoblast cells. Grünig G, et al. **Placenta** 1995 Sep;16(6):539–59
Peripheral plasma progesterone concentrations in pregnant and non–pregnant greyheaded flying–foxes (Pteropus poliocephalus) and little red flying–foxes (P. scapulatus). Towers PA, et al. **Reprod Fertil Dev** 1995;7(5):1163–76
Plasma progesterone, oestradiol–17 beta, oestrone sulphate, corticosteroids and a metabolite of PGF2 alpha: evolution throughout pregnancy, before, during and after parturition in buffalo cows. Eissa HM, et al. **Vet Res** 1995;26(4):310–8
[Concentrations of metabolically relevant parameters in the blood of highly pregnant ewes] Hamadeh ME, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar;109(3):81–6 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Progesterone suppression of activation of supraoptic nucleus (SON) neurones in late pregnancy in the rat. Antonijevic I, et al. **Adv Exp Med Biol** 1995;395:195–6
Effects of alcohol on blastocyst implantation site blood flow in the rat. Mitchell JA, et al. **Alcohol Alcohol** 1996 Jan; 31(1):81–7
Perinatal maternal ethanol effects on pregnant mice and on offspring viability and growth: influences of exposure time and weaning diet. Middaugh LD, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1351–8
Cocaine's effect on plasma oxytocin concentrations in the baboon during late pregnancy. Morgan MA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1026–7
Effect of diethylstilbestrol or zeranol on fetal development, gestation duration, and number of offspring in NMRI mice. Pérez–Martínez C, et al. **Am J Vet Res** 1995 Dec; 56(12):1615–9
Hemodynamic effects of intravenous isoproterenol versus epinephrine in the chronic maternal–fetal sheep preparation. Marcus MA, et al. **Anesth Analg** 1996 May; 82(5):1023–6
Cocaine transiently impairs maternal behavior in the rat. Vernotica EM, et al. **Behav Neurosci** 1996 Apr; 110(2):315–23
Effect of IFN–gamma administration in virgin and pregnant mice: distribution of lymphoid and myeloid cells in the spleen. Athanassakis I, et al. **Eur Cytokine Netw** 1995 May–Jun;6(3):167–76
Mifepristone (RU 486) induces parturition in primiparous beef heifers and reduces incidence of dystocia. Dlamini BJ, et al. **J Anim Sci** 1995 Nov;73(11):3421–6
Abortifacient response and plasma vasoconstrictive activity after feeding needles from ponderosa pine trees to cattle and sheep. Short RE, et al. **J Anim Sci** 1995 Jul; 73(7):2102–4
Pregnancy terminating effect of Jatropha curcas in rats. Goonasekera MM, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):117–23
Effects of angiotensin II in fetal sheep and modification of its actions by indomethacin. Stevenson KM, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):147–58
Can the mechanisms of aluminum neurotoxicity be integrated into a unified scheme? Strong MJ, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):599–613
Interactive effects of prenatal cocaine and nicotine exposure on maternal toxicity, postnatal development and behavior in the rat. Sobrian SK, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):121–43
Prenatal cocaine exposure revealed minimal postnatal changes in rat striatal dopamine D2 receptor sites and mRNA levels in the offspring. Stadlin A, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):67–76
Effects of prenatal cocaine exposure in the prefrontal cortex of the rat. A morphometric evaluation. Xavier MR, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):99–110
Studies on the reproductive effects of Fusarium moniliforme culture material in rats and the biodistribution of [14C] fumonisin B1 in pregnant rats. Voss KA, et al. **Nat Toxins** 1996;4(1):24–33
CRF administered to pregnant rats alters offspring behavior and morphology. Williams MT, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):161–7
Combined effects of caffeine and malnutrition on the development of the trigeminal nuclear center: autoradiographic and biochemical studies. Saito T, et al. **Physiol Behav** 1995 Oct;58(4):769–74
Effect of insulin on endocrine pancreas function during late pregnancy in the rat. Wijkstra S, et al. **Physiol Behav** 1995 Sep;58(3):445–50
Neonatal mouse hip joint and hindlimb anomalies induced by prenatal exposure to Ara–C. Chiba K, et al. **Reprod Toxicol** 1996 May–Jun;10(3):215–9
Vanadium: a review of the reproductive and developmental toxicity. Domingo JL. **Reprod Toxicol** 1996 May–Jun; 10(3):175–82 (61 ref.)
Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. Kato I, et al. **Reprod Toxicol** 1996 May–Jun;10(3):209–14
Dose– (and time–) dependent blockade of pregnancy in Sprague–Dawley rats administered ammonium dinitramide in drinking water. Kinkead ER, et al. **Toxicol Ind Health** 1996 Jan–Feb;12(1):59–67
Maternal reproductive effects of oral salicylic acid in Sprague–Dawley rats. Davis DP, et al. **Toxicol Lett** 1996 Mar;84(3):135–41
Embryotoxicity of orally administered chromium in mice: exposure during the period of organogenesis. Junaid M, et al. **Toxicol Lett** 1996 Mar;84(3):143–8
Chromium fetotoxicity in mice during late pregnancy. Junaid M, et al. **Vet Hum Toxicol** 1995 Aug;37(4):320–3
Effects on reproduction in female offspring from Sprague–Dawley rats fed 10% snakeweed (Gutierrezia microcephala) throughout pregnancy and concurrent treatment with safflower oil. Staley EC, et al. **Vet Hum Toxicol** 1995 Oct;37(5):440–2
[Reproductive and developmental toxicity studies of calcipotriol (MC903): (4)—A perinatal and postnatal study in rats by subcutaneous administration] Uchiyama H, et al. **J Toxicol Sci** 1996 Jul;21 Suppl 2:439–55 (Eng. Abstr.) **(Jpn)**
[The effect of calcium antagonists, partusisten, oxytocin and prostenon on uterine contractile activity in pregnant rats] Korkhov VV, et al. **Eksp Klin Farmakol** 1995 Nov–Dec; 58(6):40–1 (Eng. Abstr.) **(Rus)**
[The corrective properties of glycine in alcoholic intoxication in the fetal period of pregnancy] Sheveleva GA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):27–9 (Eng. Abstr.) **(Rus)**

GENETICS

A search for quantitative trait loci for ovulation rate in cattle. Blattman AN, et al. **Anim Genet** 1996 Jun;27(3):157–62
Stathmin gene expression in mammary gland and in Nb2 cells. Puissant C, et al. **Biol Cell** 1995;85(2–3):109–15

IMMUNOLOGY

Influence of the perinatal period on bovine interferon production. Kandefer–Szerszeń M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):307–11
In vitro and in vivo interferon production by bovine colostral leukocytes. Kandefer–Szerszeń M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):190–2

The role of perforin-expression by granular metrial gland cells in pregnancy. Stallmach T, et al. **Eur J Immunol** 1995 Dec;25(12):3342-8

Prenatal alcohol exposure selectively suppresses cell-mediated but not humoral immune responsiveness. Gottesfeld Z, et al. **Int J Immunopharmacol** 1995 Mar; 17(3):247-54

Quantitative analysis of intraepithelial large granular lymphocyte distribution and maternofetal cellular interactions in the synepitheliochorial placenta of the deer. Lee CS, et al. **J Anat** 1995 Oct;187 (Pt 2):445-60

Protection against mortality due to Vibrio cholerae infection in infant rabbits caused by immunization of mothers with cholera protective antigen. Sciortino CV. **J Diarrhoeal Dis Res** 1996 Mar;14(1):16-26

Anti-human gonadotropin antibodies generated during in vitro fertilization (IVF)-related cycles: effect on fertility of rhesus macaques. Iliff SA, et al. **J Med Primatol** 1995 Jan;24(1):7-11

Evaluation of immune parameters and lymphocyte production of prolactin-immunoreactive proteins after chronic administration of cocaine to pregnant rats. Masten SA, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1090-6

Cellular immune responses in the pig uterus during pregnancy. Bischof RJ, et al. **J Reprod Immunol** 1995 Jul; 29(2):161-78

Immunosuppressive activity of a porcine high-molecular weight uterine macromolecule is associated with transforming growth factor-beta. Segerson EC. **J Reprod Immunol** 1995 May;29(1):47-60

Antibody-dependent cellular cytotoxic activity of cells in the rat metrial gland in pregnancy. Peel S, et al. **Scand J Immunol** 1996 Jan;43(1):16-22

T cell awareness of paternal alloantigens during pregnancy. Tafuri A, et al. **Science** 1995 Oct 27;270(5236):630-3

METABOLISM

Differential expression of CD44 in rabbit uterine epithelium during early pregnancy. Hohn HP, et al. **Acta Anat (Basel)** 1995;152(3):185-94

Myometrial arginase activity increases with advancing pregnancy in the guinea pig. Weiner CP, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):779-82

Suppression of circulating calcitriol and duodenal active Ca transport by ketoconazole in pregnant rats. Boass A, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E934-9

Tissue specific expression of vascular smooth muscle angiotensin II receptor subtypes during ovine pregnancy. Cox BE, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H212-21

Interaction between nitric oxide and prostaglandin E2 pathways in pregnant rat uteri. Dong YL, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E471-6

Endothelial vasodilator production by uterine and systemic arteries. I. Effects of ANG II on PGI2 and NO in pregnancy. Magness RR, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1914-23

Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. Omer S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F194-7

Phospholipase A2 activity is increased in guinea pig uterine cervix in late pregnancy and at parturition. Rajabi MR, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E940-7

Pregnancy and ephedrine increase the release of nitric oxide in ovine uterine arteries. Li P, et al. **Anesth Analg** 1996 Feb;82(2):288-93

Study on the energy and protein metabolism in horses. Burlacu GH, et al. **Arch Tierernahr** 1993;45(2):173-85

Hormonal influences on beta-lactoglobulin transgene expression inferred from chromatin structure. Whitelaw CB. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):121-5

Impairment of the liver insulin receptor autoactivation cascade at full-term pregnancy in the rat. Martinez C, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):523-9

OZF gene expression in growing mouse and rabbit mammary gland and in rabbit mammary cells and Nb2 cells under prolactin action. Puissant C, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):543-52

Expression of rat microsomal epoxide hydrolase during pregnancy. Kim SG. **Biochem Pharmacol** 1995 Nov 9; 50(10):1593-7

The pregnant ovine endometrium constitutively expresses and secretes a highly stable bombesin-like peptide, which shares C-terminal sequence but differs structurally from gastrin-releasing peptide. Giraud A, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):189-97

Identification of 14-hydroxy-4,14-retro-retinol as an in vivo metabolite of vitamin A. Tzimas G, et al. **Biochim Biophys Acta** 1996 May 31;1301(1-2):1-6

Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroid-treated ewes and during the estrous cycle and early pregnancy. Hampton AL, et al. **Biol Reprod** 1995 Aug;53(2):302-11

Serum clearance and urinary excretion of pteroylmonoglutamic acid in gestating and lactating dairy cows. Girard CL, et al. **Br J Nutr** 1995 Dec;74(6):857-65

Protein utilization, growth and survival in essential-fatty-acid-deficient rats. Henry CJ, et al. **Br J Nutr** 1996 Feb;75(2):237-48

In situ analysis of estrogen receptor mRNA expression in the brain of female rats during pregnancy. Wagner CK, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):127-35

Carbohydrate-lipid interactions during gestation and their control by insulin. Herrera E, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2499-519 (74 ref.)

Alkaline phosphatase distribution in the plasma membrane of uterine epithelial cells is markedly altered during early pregnancy in the rat. Bucci M, et al. **Cell Biol Int** 1995 Nov;19(11):921-8

Disaccharidase activities in pregnant and lactating rats. Prieto RM, et al. **Comp Biochem Physiol A Physiol** 1994 Nov; 109(3):741-7

Changes in intestinal alpha-methyl-D-glucoside uptake due to pregnancy and lactation in rats. Prieto RM, et al. **Digestion** 1996;57(1):16-21

The insulin-like growth factor-II/mannose-6-phosphate receptor is present in fetal bovine tissues throughout gestation. Pfuender M, et al. **Domest Anim Endocrinol** 1995 Oct;12(4):317-24

The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. Gordon JD, et al. **Drug Metab Dispos** 1995 Dec; 23(12):1383-9

Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey. Sandberg JA, et al. **Drug Metab Dispos** 1995 Aug; 23(8):881-4

A cDNA encoding a new member of the rat placental lactogen family, PL-I mosaic (PL-Im). Hirosawa M, et al. **Endocr J** 1994 Aug;41(4):387-97

Oxytocin receptor gene expression in the rat uterus during pregnancy and the estrous cycle and in response to gonadal steroid treatment. Larcher A, et al. **Endocrinology** 1995 Dec;136(12):5350-6

Connexin-26 and connexin-43 are differentially expressed and regulated in the rat myometrium throughout late pregnancy and with the onset of labor. Orsino A, et al. **Endocrinology** 1996 May;137(5):1545-53

Estrogen regulates the stage-specific expression of kidney androgen-regulated protein in rat uterus during reproductive cycle and pregnancy. Runic R, et al. **Endocrinology** 1996 Feb;137(2):729-37

Characterization of oxytocin receptor expression and distribution in the pregnant sheep uterus. Wu WX, et al. **Endocrinology** 1996 Feb;137(2):722-8

Estrogen and progesterone receptors, cell proliferation, and c-fos expression in the ovine uterus during early pregnancy. Zheng J, et al. **Endocrinology** 1996 Jan;137(1):340-8

Expression of the gene for the receptor of gonadotropin-releasing hormone in the rat mammary gland. Levi LN, et al. **FEBS Lett** 1996 Jan 29;379(2):186-90

Toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats including placental and lactational transfer to fetuses and neonates. Li X, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):70-6

Calbindin-D9k expression in the pregnant cow uterus and placenta. Reiswig JD, et al. **Histochem Cell Biol** 1995 Aug; 104(2):169-74

Zidovudine kinetics in the pregnant baboon. Garland M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):117-27

Lectin histochemistry of pregnant rat uterine tissues. Peel S, et al. **J Anat** 1996 Feb;188 (Pt 1):197-205

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804-19 (117 ref.)

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820-33 (81 ref.)

Cardiac enzyme activities in fetal and adult pregnant and nonpregnant sheep exposed to high-altitude hypoxemia. Ohtsuka T, et al. **J Appl Physiol** 1995 Oct;79(4):1286-9

Molecular basis of the soluble and membrane-bound forms of the murine leukemia inhibitory factor receptor alpha-chain. Expression in normal, gestating, and leukemia inhibitory factor nullizygous mice. Owczarek CM, et al. **J Biol Chem** 1996 Mar 8;271(10):5495-504

Mouse uterus peptidylarginine deiminase is expressed in decidual cells during pregnancy. Arai T, et al. **J Cell Biochem** 1995 Jul;58(3):269-78

Suppression of maternal adrenal dehydroepiandrosterone and dehydroepiandrosterone sulfate production by estrogen during baboon pregnancy. Albrecht ED, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3201-8

Amniotic and allantoic fluid concentrations of thyroxine, 3,3',5'-tri-iodothyronine, 3,3'-di-iodothyronine and 3',5'-di-iodothyronine in the pig during the period of gestation. Brzezińska-Slebodzińska E, et al. **J Endocrinol** 1995 Nov;147(2):245-51

Different molecular and messenger ribonucleic acid forms of insulin-like growth factor-binding protein-3 in the pregnant baboon (Papio anubis). Gargosky SE, et al. **J Endocrinol** 1995 Dec;147(3):449-61

Characterization of protein production by caprine placental membranes: identification and immunolocalization of retinol-binding protein. Liu KH, et al. **J Endocrinol** 1995 Sep;146(3):527-34

IGF-II and IGF-binding proteins increase dramatically during rabbit pregnancy. Nason KS, et al. **J Endocrinol** 1996 Jan;148(1):121-30

Inhibition of mouse placental lactogen-II release from placental cells by interleukin-1 after mid-pregnancy. Yamaguchi M, et al. **J Endocrinol** 1995 Dec;147(3):423-9

Localization of NADPH diaphorase in the mouse uterus during the first half of pregnancy and during an artificially induced decidual cell reaction. Moorhead CS, et al. **J Histochem Cytochem** 1995 Oct;43(10):1053-60

Expression of mouse alpha-macroglobulins, lipoprotein receptor-related protein, LDL receptor, apolipoprotein E, and lipoprotein lipase in pregnancy. Overbergh L, et al. **J Lipid Res** 1995 Aug;36(8):1774-86

Cloning of rabbit prolactin cDNA and prolactin gene expression in the rabbit mammary gland. Gabou L, et al. **J Mol Endocrinol** 1996 Feb;16(1):27-37

Changes in pro-opiomelanocortin and pre-proenkephalin mRNA levels in the ovine brain during pregnancy, parturition and lactation and in response to oestrogen and progesterone. Broad KD, et al. **J Neuroendocrinol** 1993 Dec;5(6):711-9

Ribonucleic acid nucleotides in maternal and fetal tissues derive almost exclusively from synthesis de novo in pregnant mice. Boza JJ, et al. **J Nutr** 1996 Jul; 126(7):1749-58

Choline distribution and metabolism in pregnant rats and fetuses are influenced by the choline content of the maternal diet. Garner SC, et al. **J Nutr** 1995 Nov; 125(11):2851-8

Pregnancy and lactation are associated with diminished concentrations of choline and its metabolites in rat liver. Zeisel SH, et al. **J Nutr** 1995 Dec;125(12):3049-54

Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism. Khac LD, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):130-6

Concentrations of Na+ and Cl- in transplacental ultrafiltrate in sheep. Faber JJ, et al. **J Physiol (Lond)** 1995 Aug 15; 487 (Pt 1):159-67

Atrial natriuretic factor release during pregnancy in rats. Zhang Y, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):509-14

Whole-body retention and fetal uptake of 65Zn in pregnant mice fed a Zn-deficient diet. Matsusaka N, et al. **J Radiat Res (Tokyo)** 1995 Sep;36(3):196-202

Differential metabolism of exogenous platelet-activating factor by glandular epithelial and stromal cells of rabbit endometrium. Kudolo GB, et al. **J Reprod Fertil** 1995 Nov; 105(2):315-24

Premating and gestational effects of maternal nutrition on secondary sex ratio in house mice. Meikle DB, et al. **J Reprod Fertil** 1995 Nov;105(2):193-6

A novel uterine protein that associates with the embryonic capsule in equids. Stewart F, et al. **J Reprod Fertil** 1995 Sep;105(1):65-70

Molecular cloning of cDNA for equine ovarian inhibin/activin beta A subunit. Yoshida S, et al. **J Vet Med Sci** 1995 Jun;57(3):469-73

Diagnosing pregnancy in free-ranging elk using fecal steroid metabolites. White PJ, et al. **J Wildl Dis** 1995 Oct; 31(4):514-22

Angiotensin II receptor subtypes in the adrenals of pregnant rats. Forcier I, et al. **Mol Cell Endocrinol** 1995 Oct 30; 114(1-2):177-86

Leukemia inhibitory factor, LIF receptor, and gp130 in the mouse uterus during early pregnancy. Yang ZM, et al. **Mol Reprod Dev** 1995 Dec;42(4):407-14

Maternal-fetal pharmacokinetics: summary and future directions. Szeto HH. **NIDA Res Monogr** 1995;154:203-17 (36 ref.)

New approaches for drug and kinetic analysis in the maternal-fetal unit. Tonn GR, et al. **NIDA Res Monogr** 1995;154:175-202 (43 ref.)

Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats. Huang CS, et al. **Pharm Res** 1995 Nov;12(11):1647-51

Liver alcohol dehydrogenase activity and ethanol levels during chronic ethanol intake in pregnant rats and their offspring. Través C, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):93-9

Localization and quantitation of angiotensin AT1 and AT2 receptors in the pregnant and non-pregnant sheep uterus. Moeller I, et al. **Regul Pept** 1996 Mar 22;61(3):213-8

Sulfated glycoprotein-1 (SGP-1) expression in ovine endometrium during the oestrous cycle and early pregnancy. Spencer TE, et al. **Reprod Fertil Dev** 1995; 7(5):1053-60

Comparative disposition, receptor affinity, and teratogenic activity of sulfon arotinoids. Willhite CC, et al. **Teratology** 1995 Sep;52(3):169-75

Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. Welsch F, et al. **Toxicol Lett** 1995 Dec;82-83:539-47

[Molecules of the family of aspartic proteinases in the placenta of ruminants: hormones or proteins?] Beckers JF, et al. **Bull Mem Acad R Med Belg** 1994;149(8-11):355-64; discussion 364-7 (Eng. Abstr.) **(Fre)**

[Energy and nitrogen metabolism of pregnant and lactating sows and suckling piglets. 3. Chemical composition and energy content of the animal body fractions as well as portions of the animal body fractions of empty body of nonpregnant, pregnant and lactating sows] Beyer M, et al. **Arch Tierernahr** 1993;45(1):13-34 (Eng. Abstr.) **(Ger)**

[The redistribution of calcium ions and organic substances in pregnant rats under extreme conditions] Natochin IuV, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):65-71 (Eng. Abstr.) **(Rus)**

[Effects of cold on triiodothyronine metabolism in the pregnant rat] Blanco MR, et al. **Medicina (B Aires)** 1991; 51(6):539–43 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Pharmacological evidence for an oxytocin-like hormone in early pregnancy corpus luteum in sheep. Marnet PG, et al. **Adv Exp Med Biol** 1995;395:545–6

Changes in rat cervical collagen during gestation and after antiprogesterone treatment as measured in vivo with light-induced autofluorescence. Glassman W, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1550–6

Effect of pregnancy on activation of central pathways following atrial distension. Deng Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R552–6

Pregnancy enhances the pressor response to thromboxane analogues in rabbits. Losonczy G, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R720–5

Contraction and endothelium-dependent relaxation in mesenteric microvessels from pregnant rats. Pascoal IF, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1899–904

Reversion of insulin resistance in the rat during late pregnancy by 72-h glucose infusion. Ramos P, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E858–63

Body temperature response to IL-1 beta in pregnant rats. Simrose RL, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1179–82

Changes in transcripts encoding calcium channel subunits of rat myometrium during pregnancy. Tezuka N, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1008–17

Morphological changes in the smooth muscle cells of the mouse lower oviduct during pregnancy and post-partum. Faussone-Pellegrini MS, et al. **Arch Histol Cytol** 1995 Aug; 58(3):293–301

Lateral habenula neurons are necessary for the hormonal onset of maternal behavior and for the display of postpartum estrus in naturally parturient female rats. Matthews-Felton T, et al. **Behav Neurosci** 1995 Dec; 109(6):1172–88

Glucose and insulin tolerance tests in the rat on different days of gestation. Muñoz C, et al. **Biol Neonate** 1995; 68(4):282–91

Isolation and characterization of a 30-kDa endometrial glycoprotein synthesized during the estrous cycle and early pregnancy of the pig. Geisert RD, et al. **Biol Reprod** 1995 Nov;53(5):1038–50

Parturition in the rabbit is compromised by daytime nursing: the role of oxytocin. Hudson R, et al. **Biol Reprod** 1995 Sep;53(3):519–24

Studies on the role of plasminogen activators and plasminogen activator inhibitor type-1 in rat corpus luteum of pregnancy. Liu YX, et al. **Biol Reprod** 1995 Nov; 53(5):1131–8

Epithelial lining of the sheep ampulla oviduct undergoes pregnancy-associated morphological changes in secretory status and cell height. Murray MK. **Biol Reprod** 1995 Sep; 53(3):653–63

Patterns of relaxin and steroids in the reproductive cycle of the common marmoset (Callithrix jacchus): effects of prostaglandin F2 alpha on relaxin and progesterone secretion during pregnancy. Steinetz BG, et al. **Biol Reprod** 1995 Oct;53(4):834–9

Increased sensitivity of rat myometrium to the contractile effect of platelet activating factor before delivery. Kim BK, et al. **Br J Pharmacol** 1995 Aug;115(7):1211–4

Effect of zinc deficiency induced before and during pregnancy on the survival of female rats and their pups. Braga-Costa TM, et al. **Braz J Med Biol Res** 1995 May; 28(5):569–74

High intensity exercise during pregnancy of rats. Effects on mother and offspring. Denadai BS, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):727–40

Suboptimal protein nutrition in early life later influences insulin action in pregnant rats. Holness MJ, et al. **Diabetologia** 1996 Jan;39(1):12–21

Renal oxytocin receptor messenger ribonucleic acid: characterization and regulation during pregnancy and in response to ovarian steroid treatment. Breton C, et al. **Endocrinology** 1996 Jul;137(7):2711–7

Proliferation of microvascular endothelial cells in the primate corpus luteum during the menstrual cycle and simulated early pregnancy. Christenson LK, et al. **Endocrinology** 1996 Jan;137(1):367–74

Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide. Escalada J, et al. **Endocrinology** 1996 Feb; 137(2):631–7

Effect of androstenedione administration on the maternal hypothalamo-pituitary-adreno-placental axis in the pregnant rhesus monkey. Giussani DA, et al. **Endocrinology** 1996 Feb;137(2):608–14

Monoclonal antibodies specific for rat relaxin. IX. Evidence that endogenous relaxin promotes growth of the vagina during the second half of pregnancy in rats. Zhao S, et al. **Endocrinology** 1996 Feb;137(2):425–30

Identical triplets in a thoroughbred mare [see comments] Meadows SJ, et al. **Equine Vet J** 1995 Sep;27(5):394–7. Comment in: Equine Vet J 1995 Sep;27(5):321.

Monozygotic triplets in the mare [editorial; comment] Short RV. **Equine Vet J** 1995 Sep;27(5):321. Comment on: Equine Vet J 1995 Sep;27(5):394–7.

The basal plasma membrane and lamina densa of uterine epithelial cells are both altered during early pregnancy and by ovarian hormones in the rat. Shion YL, et al. **Eur J Morphol** 1995 Jul;33(3):257–64

Effect of pregnancy on vasopressin-mediated responses in guinea-pig uterine arteries with intact and denuded endothelium. Jovanović A, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):101–11

Effects of nifedipine and Bay K 8644 on myotropic responses in aortic rings of pregnant rats. Roy B, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):1–9

The effects of pregnancy and parturition on the substance P content of the rat uterus: uterine growth is accompanied by hypertrophy of its afferent innervation. Amira S, et al. **Exp Physiol** 1995 Jul;80(4):645–50

Impact of gestational age on the catecholamine responses of the fetal sheep adrenal to cholinergic stimulation in vitro. Butler TG, et al. **Exp Physiol** 1995 Sep;80(5):767–77

Cardiovascular responses to heat stress in late gestation fetal sheep. Walker DW, et al. **Exp Physiol** 1995 Sep; 80(5):755–66

A new approach to the areolar structures in the pig placenta: histochemistry and development of mucous areolae. Bielańska-Osuchowska Z, et al. **Folia Histochem Cytobiol** 1995;33(2):95–101

Length of estrous cycle and gestation in the Arabian oryx (Oryx leucoryx) and the importance of the male presence for induction of postpartum estrus. Sempéré AJ, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):235–41

Pregnancy-induced alterations of relaxation in response to magnesium in the rat aorta may be due to plasma-borne agents. Ezimokhai M, et al. **Heart Vessels** 1995; 10(4):197–203

Independent modulation of galactose-specific receptor expression in rat liver cells. Massimi M, et al. **Hepatology** 1995 Dec;22(6):1819–28

Growth factors in pregnancy. Cooper JC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):197–203 (22 ref.)

Glomerular hemodynamic effects of late pregnancy in rats with experimental membranous glomerulonephropathy. Baylis C, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1197–201

Evaluation of the benefits of the timing of pregnancy testing by transrectal palpation in dairy cattle. Thompson JA, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1462–5

Glucose tolerance of pregnant sows is related to postnatal pig mortality. Kemp B, et al. **J Anim Sci** 1996 Apr; 74(4):879–85

The effect of ewe body condition at lambing on colostral immunoglobulin G concentration and lamb performance. al-Sabbagh TA, et al. **J Anim Sci** 1995 Oct;73(10):2860–4

Influence of energy or protein supplementation during midpregnancy on forage intake of ewes grazing Montana winter range. Soder KJ, et al. **J Anim Sci** 1995 Oct; 73(10):2853–9

Calving intervals in beef cows at 2, 3, and 4 years of age when breeding is not restricted after calving. Werth LA, et al. **J Anim Sci** 1996 Mar;74(3):593–6

Responses of porcine corpora lutea to somatotropin administration during pregnancy. Yuan W, et al. **J Anim Sci** 1996 Apr;74(4):873–8

Growth and accretion of energy and protein in the gravid uterus during late pregnancy in Holstein cows. Bell AW, et al. **J Dairy Sci** 1995 Sep;78(9):1954–61

Accounting for the peripartum loss of granulated metrial gland cells, a natural killer cell population, from the pregnant mouse uterus. Delgado SR, et al. **J Leukoc Biol** 1996 Feb;59(2):262–9

Moderate copper deprivation during gestation and lactation affects dentate gyrus and hippocampal maturation in immature male rats. Hunt CD, et al. **J Nutr** 1995 Oct; 125(10):2700–10

The effects of anaemia on heart, placenta and body weight, and blood pressure in fetal and neonatal rats. Crowe C, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):515–9

Analysis of bursting responses of oxytocin neurones in the rat in late pregnancy, lactation and after weaning. Jiang QB, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):237–48

Changes in secretory status, cell height and percentage ciliation of epithelial lining of sheep fimbria oviduct during early pregnancy. Murray MK. **J Reprod Fertil** 1996 Mar; 106(2):173–83

Developmental regulation and partial characterization of growth factors in the bovine mammary gland. Talhouk RS, et al. **J Reprod Fertil** 1996 Mar;106(2):221–30

The effects of low dietary copper intake during pregnancy on physiological fluids and reproductive performance of first-litter gilts. Cao J, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):18–27

Morphometrical changes of the arterial walls of main arteries from heart to the abdomino-inguinal mammary glands of rat from virgin through pregnancy, lactation and post-weaning. Awal MA, et al. **J Vet Med Sci** 1995 Apr; 57(2):251–6

Monitoring reproductive status by fecal progesterone analysis in ruminants. Hirata S, et al. **J Vet Med Sci** 1995 Oct; 57(5):845–50

Macroscopic observations of mammary glands and teats of Japanese serows, Capricornis crispus, with special reference to past gestation. Kita I, et al. **J Vet Med Sci** 1995 Jun; 57(3):447–51

The effects of xylazine on intrauterine pressure, uterine blood flow, maternal and fetal cardiovascular and pulmonary function in pregnant goats. Sakamoto H, et al. **J Vet Med Sci** 1996 Mar;58(3):211–7

Glomerular hemodynamic responses to pregnancy in rats with severe reduction of renal mass. Deng A, et al. **Kidney Int** 1995 Jul;48(1):39–44

Characteristic changes in sleep patterns during pregnancy in rats. Nishina H, et al. **Neurosci Lett** 1996 Jan 12; 203(1):5–8

Aggression in the lactating female rat: the normal decline is not dependent on the physical development of the pups. Albert DJ, et al. **Physiol Behav** 1995 Sep;58(3):477–81

Changes in pain threshold during the reproductive cycle of the female rat. Cruz Y, et al. **Physiol Behav** 1996 Mar; 59(3):543–7

Strange-male-induced pregnancy disruption in mice: reduction of vulnerability by 17 beta-estradiol antibodies. de Catanzaro D, et al. **Physiol Behav** 1995 Aug;58(2):401–4

Strange-male-induced pregnancy disruption in mice: potentiation by administration of 17 beta-estradiol to castrated males. De Catanzaro D, et al. **Physiol Behav** 1995 Aug;58(2):405–7

Effect of constant light on parturition and postpartum reproduction in the rat. Rowland DL, et al. **Physiol Behav** 1995 Sep;58(3):567–72

Measurement of physiological parameters and activity in a Mongolian gerbil during gravidity and lactation with an implanted transmitter. Weinandy R, et al. **Physiol Behav** 1995 Oct;58(4):811–4

Keratinocyte growth factor and its receptor in the rhesus macaque placenta during the course of gestation. Izumi S, et al. **Placenta** 1996 Mar-Apr;17(2–3):123–35

Whole-body fuel selection: 'reproduction'. Robinson JJ, et al. **Proc Nutr Soc** 1995 Mar;54(1):283–99 (108 ref.)

Increase of aldosterone secretion in adrenal cortex suspensions derived from pregnant rats. Brochu M, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):147–52

Pregnancy-related alterations of vascular responses in rat. Bobadilla LR, et al. **Proc West Pharmacol Soc** 1995;38:67–8

Does continuous intravenous infusion of low-concentration epinephrine impair uterine blood flow in pregnant ewes? Norris MC, et al. **Reg Anesth** 1995 May-Jun;20(3):206–11

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313–8 (31 ref.)

Recording and analysis of uterine activity in pregnant guinea-pigs. Schellenberg JC, et al. **Reprod Fertil Dev** 1995; 7(5):1261–7

Production of twin calves with in vitro fertilised embryos: effects on the reproductive performance of dairy cows. McEvoy JD, et al. **Vet Rec** 1995 Jun 24;136(25):627–32

Variation factors of pregnancy rates after oestrus synchronization treatment in French Charolais beef cows. Ponsart C, et al. **Vet Res** 1996;27(3):227–39

Course of pregnancy, steroid hormone levels and maturation process of placentomes after oestrone infusion in cows near term. Janowski T, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):345–50

Embryo survival following non-surgical embryo recovery in superovulated dairy heifers. López-Gatius F. **Zentralbl Veterinarmed A** 1995 Apr;42(2):105–10

[A decrease in blood flow and incorporation of 45Ca and 3H-proline in the bones in pregnant female rats] Kapitola J, et al. **Sb Lek** 1995;96(4):313–8 (Eng. Abstr.) **(Cze)**

[Food intake of dairy cows and heifers in late pregnancy during feeding of maize silage] Kirchgessner M, et al. **Arch Tierernahr** 1995;48(4):367–79 (Eng. Abstr.) **(Ger)**

[Changes in certain indicators of the functional status of the rabbit fetus depending on the dam's body position] Nazarova LA, et al. **Biull Eksp Biol Med** 1996 Jan; 121(1):33–5 **(Rus)**

[The effect of water deprivation on the mother-fetus system at different stages of pregnancy in rats] Serova LV, et al. **Zh Evol Biokhim Fiziol** 1995 Sep-Dec;31(5–6):611–7 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Nest defense and survival of offspring in highly aggressive wild Canadian female house mice. Vom Saal FS, et al. **Physiol Behav** 1995 Oct;58(4):669–78

PREGNANCY-ASSOCIATED ALPHA 2-GLOBULINS see **PREGNANCY ZONE PROTEINS**

PREGNANCY-ASSOCIATED ALPHA 2-GLYCOPROTEINS see **PREGNANCY ZONE PROTEINS**

PREGNANCY-ASSOCIATED ALPHA 2-MACROGLOBULINS see **PREGNANCY ZONE PROTEINS**

PREGNANCY-ASSOCIATED ALPHA-PLASMA PROTEIN

ANALYSIS

First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Krantz DA, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):612–6

Trophoblast antigen levels in the first trimester of a trisomy

22 pregnancy. Wheeler DM, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Jun;66(2):197–9

Pregnancy–associated plasma protein A (PAPP–A): measurement by highly sensitive and specific enzyme immunoassay, importance of first–trimester serum determinations, and stability studies. Bersinger NA, et al. **Reprod Fertil Dev** 1995;7(6):1419–23

GENETICS

Complete cDNA sequence of the preproform of human pregnancy–associated plasma protein–A. Evidence for expression in the brain and induction by cAMP. Haaning J, et al. **Eur J Biochem** 1996 Apr 1;237(1):159–63

Gene expression of human pregnancy–associated plasma protein–A in placenta from trisomic pregnancies. Brizot ML, et al. **Placenta** 1996 Jan;17(1):33–6

ISOLATION & PURIFICATION

[Isolation and purification of pregnancy–associated plasma protein A] Suzuki Y, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Jan;48(1):17–24 (Eng. Abstr.) **(Jpn)**

METABOLISM

A sensitive enzyme immunoassay for pregnancy–associated plasma protein A (PAPP–A): a possible first trimester method of screening for Down syndrome and other trisomies. Bersinger NA, et al. **Arch Gynecol Obstet** 1995; 256(4):185–92

PHARMACOLOGY

Interaction of human pregnancy–associated plasma protein–A with serine proteinases. Zorin NA, et al.
Clin Chim Acta 1995 Jul 31;239(1):47–55

PREGNANCY COMPLICATIONS

see related
PREGNANCY, PROLONGED

Pregnancy does not offer protection against Zollinger–Ellison syndrome. Ezeh UO, et al.
Acta Obstet Gynecol Scand 1996 Mar;75(3):302–4

Validity of self–reported smoking habits in pregnancy: a saliva cotinine analysis. Parazzini F, et al.
Acta Obstet Gynecol Scand 1996 Apr;75(4):352–4

Transient osteoporosis of the hip in pregnancy complicated by femoral neck fracture: a case report. Junk S, et al.
Acta Orthop Scand 1996 Feb;67(1):69–70

Thyroid disease during pregnancy. Bishnoi A, et al.
Am Fam Physician 1996 Jan;53(1):215–20 (19 ref.)

Maternal asthma and idiopathic preterm labor. Kramer MS, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1078–88

Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Brandt LJ, et al. **Am J Gastroenterol** 1995 Nov;90(11):1918–22

Rapidly reversible acute renal failure from ureteral obstruction in pregnancy. Jena M, et al.
Am J Kidney Dis 1996 Sep;28(3):457–60 (22 ref.)

Prenatal diagnosis of osteochondrodysplasias in high risk pregnancy. Gordienko IYu, et al. **Am J Med Genet** 1996 May 3;63(1):90–7

Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. Coverdale JH, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):169–73 (25 ref.)

Activated protein C resistance and pregnancy complications [letter] Grisaru D, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):801–2

Headaches in women, including women who are pregnant. Paulson GW. **Am J Obstet Gynecol** 1995 Dec; 173(6):1734–41 (53 ref.)

Trauma in pregnancy: the role of interpersonal violence. Poole GV, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1873–7; discussion 1877–8

Gastrointestinal hemorrhage during pregnancy in a patient with a history of vertical–banded gastroplasty. Ramirez MM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1630–1

Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision–analytic approach. Rouse DJ, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1357–63

Further insights into autoimmune thrombocytopenia in pregnancy [letter; comment] Skupski DW, et al.
Am J Obstet Gynecol 1996 Jun;174(6):1944–6. Comment on: Am J Obstet Gynecol 1995 Aug;173(2):479–82.

Pregnancy outcomes and health care use: effects of abuse. Webster J, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):760–7

Myocardial infarction and coronary artery dissection during pregnancy associated with type IV Ehlers–Danlos syndrome. Athanassiou AM, et al. **Am J Perinatol** 1996 Apr;13(3):181–3

Congenital genitourinary tract abnormalities following cocaine exposure in utero. Battin M, et al.
Am J Perinatol 1995 Nov;12(6):425–8

In utero treatment of fetal goitrous hypothyroidism caused by maternal Graves' disease. Hadi HA, et al.
Am J Perinatol 1995 Nov;12(6):455–8

Prenatal diagnosis and management of fetal goiter caused by maternal Grave's disease. Hadi HA, et al.
Am J Perinatol 1995 Jul;12(4):240–2

Alpha 1–antitrypsin deficiency and pregnancy. Kuller JA, et al. **Am J Perinatol** 1995 Sep;12(5):303–5

Cocaine is associated with intrauterine fetal death in women with suspected preterm labor. Martinez A, et al.
Am J Perinatol 1996 Apr;13(3):163–6

Gallbladder perforation in pregnancy. Petrozza JC, et al.
Am J Perinatol 1995 Sep;12(5):339–41

Maternal, placental, and neonatal associations with early germinal matrix/intraventricular hemorrhage in infants born before 32 weeks' gestation. Salafia CM, et al.
Am J Perinatol 1995 Nov;12(6):429–36

Hyperreactio luteinalis associated with pregnancy: a case report and review of the literature. Schnorr JA Jr, et al.
Am J Perinatol 1996 Feb;13(2):95–7 (6 ref.)

Effect measures for behavioral factors adversely affecting fetal growth. Spinillo A, et al. **Am J Perinatol** 1996 Feb; 13(2):119–23

Pregnancy in a patient with Goodpasture syndrome and renal transplantation. Wells SR, et al. **Am J Perinatol** 1996 Feb; 13(2):79–80

Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Milberger S, et al. **Am J Psychiatry** 1996 Sep; 153(9):1138–42

Moderate prenatal alcohol exposure and psychomotor development at preschool age [see comments] Larroque B, et al. **Am J Public Health** 1995 Dec;85(12):1654–61. Comment in: Am J Public Health 1995 Dec;85(12):1614–5.

Intrauterine growth retardation and premature delivery: the influence of maternal smoking and psychosocial factors. Nordentoft M, et al. **Am J Public Health** 1996 Mar; 86(3):347–54

The diagnosis and management of breast problems during pregnancy and lactation. Scott–Conner CE, et al.
Am J Surg 1995 Oct;170(4):401–5 (47 ref.)

Anaesthesia for caesarean section in a patient with Klippel–Feil syndrome. The use of a microspinal catheter. Dresner MR, et al. **Anaesthesia** 1995 Sep;50(9):807–9

Arnold–chiari malformation in pregnancy. Semple DA, et al. **Anaesthesia** 1996 Jun;51(6):580–2

The Bullard laryngoscope for emergency airway management in a morbidly obese parturient. Cohn AI, et al. **Anesth Analg** 1995 Oct;81(4):872–3

Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94–7 (12 ref.)

Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Keilson LM, et al. **Ann Intern Med** 1996 Feb 15; 124(4):425–8

Morning sickness: impact on offspring salt preference. Crystal SR, et al. **Appetite** 1995 Dec;25(3):231–40

Maternal HIV and drug use: effect on health and social morbidity. Mok JY, et al. **Arch Dis Child** 1996 Mar; 74(3):210–4

The Kleihauer–Betke test. Clinical utility, indication, and correlation in patients with placental abruption and cocaine use. Emery CL, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1032–7

Pregnancy in spinal cord injured women. Baker ER, et al. **Arch Phys Med Rehabil** 1996 May;77(5):501–7 (67 ref.)

Asphyxia. Mac Donald D.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):579–94 (65 ref.)

Effect of subadequate maternal vitamin–A status on placental transfer of retinol and beta–carotene to the human fetus. Dimenstein R, et al. **Biol Neonate** 1996;69(4):230–4

Maternal obesity and body composition of the neonate. Silliman K, et al. **Biol Neonate** 1995;68(6):384–93

Pregnancy in women with cystic fibrosis [editorial] Edenborough FP, et al. **BMJ** 1995 Sep 30;311(7009):822–3

Fetal homicide charge for drinking while pregnant [news] Macready N. **BMJ** 1996 Sep 14;313(7058):645

Heterotopic pregnancy associated with assisted conception. Boulos AN, et al. **Br J Hosp Med** 1995 Oct 4–17; 54(7):349–50

Selenium deficiency and miscarriage: a possible link? Barrington JW, et al. **Br J Obstet Gynaecol** 1996 Feb; 103(2):130–2

Pregnancy, the puerperium, hormones and multiple sclerosis [letter; comment] James WH. **Brain** 1995 Dec;118 (Pt 6):1617–8. Comment on: Brain 1995 Feb;118 (Pt 1):253–61.

Multiple cardiac masses diagnosed with prenatal ultrasonography in the fetus of a woman with tuberous sclerosis. Goh RH, et al. **Can Assoc Radiol J** 1995 Dec; 46(6):461–4

Carbon monoxide poisoning in pregnancy.
Can Fam Physician 1996 May;42:854–5

The fetus as a passive smoker. Koren G.
Can Fam Physician 1996 Jul;42:1301–3 (15 ref.)

Acute and chronic lung allograft rejection during pregnancy. Donaldson S, et al. **Chest** 1996 Jul;110(1):293–6

Obstetric complications in pulmonary and critical care medicine. Rizk NW, et al. **Chest** 1996 Sep;110(3):791–809 (196 ref.)

Prenatal evaluation of congenital heart disease in high–risk pregnancies. Giancotti A, et al.
Clin Exp Obstet Gynecol 1995;22(3):225–9

Screening for coeliac disease as a possible maternal risk factor for neural tube defect. Dickey W, et al. **Clin Genet** 1996 Feb;49(2):107–8

Reversible renal failure due to the antiphospholipid antibody syndrome, pre–eclampsia and renal thrombotic microangiopathy. Kon SP, et al. **Clin Nephrol** 1995 Oct; 44(4):271–3

Diagnostic imaging of the lung during pregnancy. Diethelm L, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):36–55 (41 ref.)

Cushing's disease and pregnancy: report of six cases. Chico A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):143–6 (20 ref.)

The grand multipara. Goldman GA, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Aug;61(2):105–9

Biochemical and Doppler predictors of poor perinatal outcome in a fetus with four umbilical vessels. Martinez JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):145–7

Wilson's disease in pregnancy. Nunns D, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Sep;62(1):141–3

A retrospective study of 11 pregnant women with thermal injuries. Unsür V, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Jan;64(1):55–8

Pelvic kidney: a rare cause of obstetrical obstruction. Zwertbroek W, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Nov;63(1):95–6

Sonographic prenatal diagnosis of ambiguous genitalia. Sivan E, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):311–4

Prepregnancy headache and the well–being of mother and newborn. Aromaa M, et al. **Headache** 1996 Jul–Aug; 36(7):409–15

A fertile woman with Kartagener's syndrome and three consecutive pregnancies [letter] Eliyahu S, et al.
Hum Reprod 1996 Mar;11(3):683

Nephrotic syndrome and periodic fever in pregnancy [letter] Ersan F, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):59–60

Great grand multiparity—beyond the 10th delivery. Kaplan B, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):17–9

Pregnancy following rupture of the pregnant uterus. Soltan MH, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):37–42

Myotonic dystrophy in pregnancy [letter] Vendola N, et al.
Int J Gynaecol Obstet 1995 Sep;50(3):297–8

Myasthenia gravis beginning during pregnancy, partum or puerperium: a distinct clinical entity [editorial] León F.
Invest Clin 1995 Sep;36(3):99–100

Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168–76 (89 ref.)

Exercise dependence in a pregnant runner. Spieker MR.
J Am Board Fam Pract 1996 Mar–Apr;9(2):118–21

Simultaneous bilateral facial palsy in pregnancy. Jessen MR, et al. **J Am Osteopath Assoc** 1996 Jan;96(1):55–7

Pruritic urticarial papules and plaques of pregnancy [letter] Bernstein SE, et al. **J Am Podiatr Med Assoc** 1995 Oct; 85(10):560

Glomerular hemodynamic effects of late pregnancy in rats with experimental membranous glomerulonephropathy. Baylis C, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1197–201

Neurologic and ophthalmologic findings in children exposed to cocaine in utero. Tsay CH, et al. **J Child Neurol** 1996 Jan;11(1):25–30

Major conduction anesthesia in a patient with Klippel–Trenaunay Syndrome. Gaiser RR, et al.
J Clin Anesth 1995 Jun;7(4):316–9

Recurrence of acute fatty liver of pregnancy. Visconti M, et al. **J Clin Gastroenterol** 1995 Oct;21(3):243–5

Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603–6 (52 ref.)

Exploring the genetic role of the HLA–DPB1 locus in Chileans with intrahepatic cholestasis of pregnancy. Mella JG, et al. **J Hepatol** 1996 Mar;24(3):320–3

In–utero cocaine exposure and neonatal intestinal perforation: a case report. The' TG, et al. **J Natl Med Assoc** 1995 Dec; 87(12):889–91

Examining separated symphysis pubis. Davidson MR.
J Nurse Midwifery 1996 May–Jun;41(3):259–62 (15 ref.)

Effect of bronchial asthma on the course of pregnancy, labour and perinatal outcome. Jana N, et al.
J Obstet Gynaecol 1995 Jun;21(3):227–32

Pregnancy, labor and delivery in a woman with a damaged spinal cord. Yaginuma Y, et al. **J Obstet Gynaecol** 1995 Jun;21(3):277–9

Landry–Guillain–Barre–Strohl syndrome in pregnancy. Yaginuma Y, et al. **J Obstet Gynaecol Res** 1996 Feb; 22(1):47–9

The discomforts of pregnancy. Davis DC.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):73–81 (40 ref.)

Validity aspects of exposure and outcome data in reproductive studies. Hemminki K, et al.
J Occup Environ Med 1995 Aug;37(8):903–7

Antenatal and intrapartum factors associated with sudden infant death syndrome in the New Zealand Cot Death Study. Stewart AJ, et al. **J Paediatr Child Health** 1995 Oct;31(5):473–8

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al.
J Perinatol 1995 Nov–Dec;15(6):510–3 (7 ref.)

First–trimester pancreatitis. Maternal and neonatal outcome. Legro RS, et al. **J Reprod Med** 1995 Oct;40(10):689–95

Adrenal pseudocyst in pregnancy. A case report. Trauffer PM, et al. **J Reprod Med** 1996 Mar;41(3):195–7

Acute obstructive uropathy in a gravid patient with pelvic injuries: case report. DeLuca L, et al. **J Trauma** 1996 Sep; 41(3):556–7

The influence of maternal iron deficiency anaemia on the haemoglobin concentration of the infant. Türkay S, et al. **J Trop Pediatr** 1995 Dec;41(6):369–71

Pregnancy in a patient with an ileal substitute bladder followed by severe destabilization of the pelvic support. Schilling A, et al. **J Urol** 1996 Apr;155(4):1389–90

Are non-diabetic women with abnormal glucose screening test at increased risk of pre-eclampsia, macrosomia and caesarian birth? Khan KS, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):176–9

Congenital cataracts and maternal vitamin D deficiency [letter] Blau EB. **Lancet** 1996 Mar 2;347(9001):626

Influence of pregnancy on the course of primary chronic glomerulonephritis. Jungers P, et al. **Lancet** 1995 Oct 28; 346(8983):1122–4

Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Murphy DJ, et al. **Lancet** 1995 Dec 2;346(8988):1449–54

Pregnancy-associated osteoporosis. Rizzoli R, et al. **Lancet** 1996 May 11;347(9011):1274–6

Pregnancy-associated osteoporosis [letter] Smith R, et al. **Lancet** 1996 Aug 10;348(9024):402–3

Peripartum Bell's palsy [letter] Steiner I, et al. **Lancet** 1996 Apr 20;347(9008):1121–2

Pneumonitis in a lupus twin pregnancy: a case report. Comer M, et al. **Lupus** 1996 Apr;5(2):146–8

Factors associated with fetal losses in severe systemic lupus erythematosus. Martínez-Rueda JO, et al. **Lupus** 1996 Apr; 5(2):113–9

Trauma in pregnancy and cerebral palsy: is there a link? Gilles MT, et al. **Med J Aust** 1996 Apr 15;164(8):500–1

Chronic recurrent pancreatitis in pregnancy. Paternoster DM, et al. **Minerva Ginecol** 1995 Dec;47(12):561–4

Case records of the Massachusetts General Hospital. Case 3–1996. Severe abdominal pain during early pregnancy in a woman with previous infertility [clinical conference] **N Engl J Med** 1996 Jan 25;334(4):255–60

Pregnancy and renal disease [editorial; comment] Epstein FH. **N Engl J Med** 1996 Jul 25;335(4):277–8. Comment on: N Engl J Med 1996 Jul 25;335(4):226–32.

Outcome of pregnancy in women with moderate or severe renal insufficiency [see comments] Jones DC, et al. **N Engl J Med** 1996 Jul 25;335(4):226–32. Comment in: N Engl J Med 1996 Jul 25;335(4):277–8.

Liver disease in pregnancy. Knox TA, et al. **N Engl J Med** 1996 Aug 22;335(8):569–76 (60 ref.)

Court ordered obstetric intervention: a commentary. Brenner B, et al. **N Z Med J** 1995 Oct 27;108(1010):431–2

FBI investigates radiation exposure claims [news] Appel A. **Nature** 1995 Oct 19;377(6550):568

Repeated successful pregnancies after kidney transplantation in 102 women (Report by the EDTA Registry). Ehrich JH, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1314–7

Second attack of acute tubulointerstitionephritis induced by cefataxim and pregnancy [letter] Grčevska L, et al. **Nephron** 1996;72(2):354–5

Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)

Abuse during pregnancy: associations with maternal health and infant birth weight. McFarlane J, et al. **Nurs Res** 1996 Jan-Feb;45(1):37–42

Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

Pregnancy in patients with preexisting transverse myelitis. Berghella V, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):809–12

The effect of maternal obesity on the accuracy of fetal weight estimation [letter; comment] Rossavik IK. **Obstet Gynecol** 1995 Nov;86(5):867. Comment on: Obstet Gynecol 1995 Jul;86(1):102–7.

Lower urinary tract dysfunction in pregnancy: a review. Mikhail MS, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):675–83 (99 ref.)

Pemphigus vulgaris and pregnancy. Ruach M, et al. **Obstet Gynecol Surv** 1995 Oct;50(10):755–60 (48 ref.)

Endometriosis of the appendix with decidual polyp formation: a rare cause of acute appendicitis during pregnancy. Silvestrini IE, et al. **P R Health Sci J** 1995 Sep;14(3):223–5

Long-term effects of gestational protein malnutrition on postnatal growth, insulin-like growth factor (IGF)-I, and IGF-binding proteins in rat progeny. Muaku SM, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):649–55

Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. D'Ercole C, et al. **Prenat Diagn** 1995 Dec; 15(12):1171–5

Effect of surgically induced endometriosis on pregnancy and effect of pregnancy and lactation on endometriosis in mice. Cummings AM, et al. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):332–7

Effect of maternal undernutrition in early gestation on the development of fetal myofibres in the guinea-pig. Dwyer CM, et al. **Reprod Fertil Dev** 1995;7(5):1285–92

Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):411–25 (109 ref.)

Gastrointestinal motility disorders in pregnancy. Torbey CF, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):203–16 (138 ref.)

Perceptions of risk during pregnancy amongst urban women in northeast Brazil. Atkinson SJ, et al. **Soc Sci Med** 1995 Dec;41(11):1577–86

Antiphospholipid syndrome associated with seizures. Milstone A, et al. **South Med J** 1996 Jul;89(7):738–40

Uterine pyomyoma as a complication of pregnancy in an intravenous drug user. Prahlow JA, et al. **South Med J** 1996 Sep;89(9):892–5

Acute cholecystitis with calculous biliary duct obstruction in the gravid patient. Management by ERCP, papillotomy, stone extraction, and laparoscopic cholecystectomy. Friedman RL, et al. **Surg Endosc** 1995 Aug;9(8):910–3

Hyperparathyroidism and pancreatitis during pregnancy. Inabnet WB, et al. **Surgery** 1996 Jun;119(6):710–3 (32 ref.)

Adult congenital lobar emphysema in pregnancy. Critchley PS, et al. **Thorax** 1995 Aug;50(8):909–10

National Transplantation Pregnancy Registry (NTPR): cyclosporine dosing and pregnancy outcome in female renal transplant recipients. Armenti VT, et al. **Transplant Proc** 1996 Aug;28(4):2111–2

Renal transplantation one week after conception. Miller BW, et al. **Transplantation** 1995 Dec 15;60(11):1353–4

A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). Yoshimura N, et al. **Transplantation** 1996 May 27;61(10):1552–3

Spurious urinary calculosis in pregnancy. Khan MS, et al. **Ulster Med J** 1995 Apr;64(1):108–10

Xanthogranulomatous pyelonephritis in a pregnant woman: a case report and review of the literature. Figueroa AJ, et al. **Urology** 1996 Aug;48(2):294–7 (14 ref.)

Rarity of FLP should be noted [letter] Williams MS. **Wis Med J** 1996 Jun;95(6):334

[Addison's disease in pregnancy: a report of six cases] Xia Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr; 31(4):226–8 (Eng. Abstr.) **(Chi)**

[Systemic lupus erythematosus during pregnancy] Christensen H. **Ugeskr Laeger** 1996 Jan 22;158(4):431–3 (Eng. Abstr.) **(Dan)**

[Pregnancy is a natural phenomenon! What about the risk factors? (letter)] Philip J. **Ugeskr Laeger** 1995 Dec 18; 157(51):7154–5 **(Dan)**

[Fatal arrhythmia following administration of suxamethonium in a postpartum woman subsequently found to have dystrophia myotonica] Rozendaal FW, et al. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1317–9 (Eng. Abstr.) **(Dut)**

[Question of the month: should direct immunofluorescence be performed in every case of papulous or pruriginous gestational dermatosis?] **Ann Dermatol Venereol** 1996; 123(1):60–2 **(Fre)**

[Facial involvement in papulous, prurient and urticarial skin disease in pregnancy] Estève E, et al. **Ann Dermatol Venereol** 1996;123(2):122–3 **(Fre)**

[Local corticosteroid therapy in a severe form of pemphigoid gestationis (letter)] Guillaume JC, et al. **Ann Dermatol Venereol** 1996;123(1):31 **(Fre)**

[Primary hyperparathyroidism and pregnancy] Matejka G, et al. **Ann Endocrinol (Paris)** 1996;57(1):77–80 (Eng. Abstr.) **(Fre)**

[Pregnancy and the child of a mother with phenylketonuria] Abadie V, et al. **Arch Pediatr** 1996 May;3(5):489–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Cocaine and pregnancy: a disturbing association with the increase of addiction (letter)] Ferraro R, et al. **Arch Pediatr** 1995 Oct;2(10):1018–9 **(Fre)**

[Central serous chorioretinopathy in a pregnant woman] Khairallah M, et al. **J Fr Ophtalmol** 1996;19(3):216–21 (14 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic value of a single umbilical artery. 87 cases] Blache G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):522–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Prolonged pregnancy. Review of the literature] Boisselier P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):739–46 (52 ref.) (Eng. Abstr.) **(Fre)**

[Association of Takayasu's arteritis, pregnancy and Still's disease] Fignon A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):747–50 (13 ref.) (Eng. Abstr.) **(Fre)**

[Effects of smoking during pregnancy on the fetus and infant: an objective review or a biased point of view? (letter)] Kaminski M. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(4):424–5 **(Fre)**

[Myasthenia and pregnancy. Two case reports] Lucot JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):179–85 (19 ref.) (Eng. Abstr.) **(Fre)**

[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**

[Is water hepatotoxic?] Cordonnier C, et al. **Rev Med Interne** 1996;17 Suppl 2:255s–257s **(Fre)**

[Drug addiction: pregnancy and newborn infant] Lambotte R, et al. **Rev Med Liege** 1996 Feb;51(2):154–9 **(Fre)**

[Uncomplicated second pregnancy following acute pregnancy fatty liver (letter)] Zürcher K. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1224 **(Ger)**

[Pregnancy-associated osteoporosis] Ohana N, et al. **Harefuah** 1996 Mar 1;130(5):344–6 (32 ref.) **(Heb)**

[HELP syndrome and anesthetic management] Kinouchi K, et al. **Masui** 1996 May;45(5):617–23 (Eng. Abstr.) **(Jpn)**

[Puerperal secondary pulmonary hypertension in a patient with mixed connective tissue disease] Watanabe R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):883–7 (Eng. Abstr.) **(Jpn)**

[Obesity in pregnancy and delivery] Yamamoto T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:553–8 (21 ref.) **(Jpn)**

[Pregnancy and antiphospholipid syndrome] Aoki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):852–62 (27 ref.) **(Jpn)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

[A case of beta 2-glycoprotein I-independent antiphospholipid syndrome] Ozawa N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1079–82 **(Jpn)**

[A case report of congenital liver fibrosis tolerated 3 normal deliveries] Yonekawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):201–5 (10 ref.) **(Jpn)**

[Idiopathic acute fatty liver of pregnancy: IAFLP] Ibe T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):24–7 (23 ref.) **(Jpn)**

[Liver disease in pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):400–2 (12 ref.) **(Jpn)**

[Spontaneous rupture of an endometriotic cyst in pregnancy near term] Bieńkiewicz A, et al. **Ginekol Pol** 1996 Mar; 67(3):160–2 (Eng. Abstr.) **(Pol)**

[Pregnancy course in women with terminal kidney failure treated with hemodialysis] Gumprecht J, et al. **Ginekol Pol** 1995 Jul;66(7):425–9 (36 ref.) (Eng. Abstr.) **(Pol)**

[A case of acute renal failure in pregnancy complicated by Henoch-Schoenlein purpura requiring hemodialysis therapy] Muszytowski M, et al. **Ginekol Pol** 1996 Jan; 67(1):42–4 (Eng. Abstr.) **(Pol)**

[Hyperthyreosis during pregnancy. Case reports] Pisarek-Miedzińska D, et al. **Ginekol Pol** 1996 Mar; 67(3):157–9 (Eng. Abstr.) **(Pol)**

[Lupus pregnancy, its effect on the course of lupus nephritis and the evaluation of fetal loss frequency] Rychlewska B, et al. **Ginekol Pol** 1995 Jun;66(6):313–7 (Eng. Abstr.) **(Pol)**

[Evaluation of the course of pregnancy and the newborn state in women with bronchial asthma] Wszelaki-Lass E, et al. **Ginekol Pol** 1995 Dec;66(12):670–3 (Eng. Abstr.) **(Pol)**

[The effect of pregnancy on the course of ankylosing spondylitis] Jajić Z, et al. **Reumatizam** 1995;42(1):11–4 (Eng. Abstr.) **(Scr)**

[Recurrent intrahepatic cholestasis in pregnancy] Cirić S, et al. **Vojnosanit Pregl** 1995 Sep-Oct;52(5):509–12 (Eng. Abstr.) **(Scr)**

[Outcome of pregnancy in patients with transplants with and without cyclosporin therapy] González Z, et al. **Bol Asoc Med P R** 1995 May-Jun;87(5–6):109–10 **(Spa)**

[Acute hyperlipemic pancreatitis and pregnancy (letter)] Girona Torres E, et al. **Gastroenterol Hepatol** 1996 Feb; 19(2):79–80 **(Spa)**

[5th National Congress on Obstetrics and Gynecology. 6–10 November 1994. Abstracts] **Ginecol Obstet Mex** 1994 Nov; 62 Suppl 1:1–95 **(Spa)**

[Progressive systemic sclerosis and pregnancy] Argueta Zuñiga M, et al. **Ginecol Obstet Mex** 1996 Feb;64:76–8 (Eng. Abstr.) **(Spa)**

[Asthma and pregnancy] Gazca Aguilar A, et al. **Ginecol Obstet Mex** 1995 Nov;63:460–6 (Eng. Abstr.) **(Spa)**

[Spontaneous hepatic rupture during pregnancy. Report of a case. Review of the literature] Villarreal Peral C, et al. **Ginecol Obstet Mex** 1995 Sep;63:395–7 (9 ref.) (Eng. Abstr.) **(Spa)**

[Pulmonary hypoplasia of the newborn infant in a pregnancy complicated with ovular premature rupture and oligohydramnios] Aspillaga C, et al. **Rev Chil Obstet Ginecol** 1995;60(2):131–4 (Eng. Abstr.) **(Spa)**

[Pustular psoriasis in pregnancy] Perucca E, et al. **Rev Chil Obstet Ginecol** 1995;60(2):125–7 (Eng. Abstr.) **(Spa)**

[Liver cirrhosis and pregnancy] Roncone E, et al. **Rev Chil Obstet Ginecol** 1994;59(5):383–6; discussion 386–7 (Eng. Abstr.) **(Spa)**

[Anesthesia for cesarean delivery in a case of myotonia congenita] Arcas M, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):147–9 (Eng. Abstr.) **(Spa)**

[Primary hyperparathyroidism and gestation. Report of a case] Cristóbal I, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):150 **(Spa)**

[Cesarean section in a myasthenia gravis patient (letter)] Facorro E, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):115 **(Spa)**

[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

BLOOD

Serum transferrin receptor concentrations in women with mild malnutrition. Kuvibidila S, et al. **Am J Clin Nutr** 1996 Apr;63(4):596–601

Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. I. Effects on physical growth at age 5 years. Eskenazi B, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S10–8

Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure.

II. Effects on neurodevelopment at age 5 years. Eskenazi B, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S19–29

Long-term outcome of mothers of children with complete congenital heart block. Press J, et al. **Am J Med** 1996 Mar; 100(3):328–32

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211–6 (13 ref.)

Peripheral joint laxity increases in pregnancy but does not correlate with serum relaxin levels. Schauberger CW, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):667–71

Routine measurements of umbilical artery lactate levels in the prediction of perinatal outcome. Westgren M, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1416–22

Pregnancy and estrogen-induced panic [letter; comment] Griez EJ, et al. **Am J Psychiatry** 1995 Nov;152(11):1688 . Comment on: Am J Psychiatry 1994 Aug;151(8):1246.

Phenytoin serum concentration monitoring during pregnancy and puerperium in Mexican epileptic women. Rodriguez-Palomares C, et al. **Arch Med Res** 1995 Winter; 26(4):371–7

Umbilical cord dopamine beta-hydroxylase, chromogranin A and met-enkephalin after conditions associated with chronic intrauterine stress. Van Reempts PJ, et al. **Biol Neonate** 1996;69(1):22–9

Maternal smoking and fetal carboxyhaemoglobin and blood gas levels [letter; comment] Yoong WC. **Br J Obstet Gynaecol** 1996 Jul;103(7):721. Comment on: Br J Obstet Gynaecol 1996 Jan;103(1):78–82.

Lead risk during pregnancy. **Can Fam Physician** 1996 Mar; 42:414–6

Astute readers help [letter] Lai S. **Can Fam Physician** 1996 Jul;42:1288

Serum concentrations of osteocalcin in pregnant women with multinodular thyroid goiter undergoing treatment with levothyroxine. Letizia C, et al. **Endocr Res** 1995 Aug; 21(3):645–52

Biochemical assessment of nutritional status in pre- and post-natal Turkish women and outcome of pregnancy. Açkurt F, et al. **Eur J Clin Nutr** 1995 Aug;49(8):613–22

Familial dysalbuminemic hyperthyroxinemia in pregnancy. Sachmechi I, et al. **Eur J Endocrinol** 1995 Dec; 133(6):729–31

Measurement of circulating inhibin forms during the establishment of pregnancy. Illingworth PJ, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1471–5

Carpal tunnel syndrome during pregnancy: prevalence and blood level of pyridoxine. Atisook R, et al. **J Med Assoc Thai** 1995 Aug;78(8):410–4

Pregnancy outcome in women with low midtrimester maternal serum unconjugated estriol. Santolaya-Forgas J, et al. **J Reprod Med** 1996 Feb;41(2):87–90

Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. Petri M, et al. **J Rheumatol** 1995 Jul;22(7):1365–8

Deletion of E and e antigens in a pregnant woman [letter] Cotorruelo C, et al. **Transfusion** 1996 Feb;36(2):191

[Magnesium concentration in serum of pregnant women in selected pathologic states of pregnancy] Roszyk A. **Ginekol Pol** 1996 Mar;67(3):109–13 (Eng. Abstr.) **(Pol)**

[The preliminary results of a study of the role of endogenous nitric oxide in pregnant women with chronic glomerulonephritis, hypertension and puerperal eclampsia] Zozulia OV, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct; (5):23–5 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Toxic hepatitis: a rare complication associated with the use of ritodrine during pregancy. De Arcos F, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):340–2

Smoking habits among pregnant women in a Norwegian county 1987–1994. Eriksson KM, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):355–9

Deferoxamine treatment for acute iron intoxication in pregnancy. Khoury S, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):756–7

Zidovudine as an immunomodulatory agent. Urso P, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S103–12

Bone density studies in pregnant women receiving heparin. Shefras J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):171–4

Night sedation in pregnancy--inappropriate prescribing [letter] Phelan H, et al. **Ir Med J** 1993 May;86(3):107

Metobromuron/metolachlor ingestion with late onset methemoglobinemia in a pregnant woman successfully treated with methylene blue. Yang CC, et al. **J Toxicol Clin Toxicol** 1995;33(6):713–6

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381–90 (40 ref.)

Cocaine-associated rhabdomyolysis causing renal failure in pregnancy. Lampley EC, et al. **Obstet Gynecol** 1996 May; 87(5 Pt 2):804–6

[Vitamin A in pregnancy] Olsen J, et al. **Ugeskr Laeger** 1996 May 27;158(22):3171–2 **(Dan)**

[Folic acid and pregnancy--certain knowledge, uncertain practice] Vollset SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):217–8 **(Nor)**

[A study of smoking habits among pregnant women. Most pregnant smokers are in the lower social groups] Holm LE, et al. **Lakartidningen** 1996 Apr 3;93(14):1343–8 **(Swe)**

[Smoking during pregnancy is harmful for the child] Olausson PO, et al. **Lakartidningen** 1995 Dec 6; 92(49):4707–9 **(Swe)**

DIAGNOSIS

Gravid uterine dehiscence: MR findings. Hamrick-Turner JE, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):486–8

Abdominopelvic MR imaging in the nonobstetric evaluation of pregnant patients. Forstner R, et al. **AJR Am J Roentgenol** 1996 May;166(5):1139–44

Early occurrence of acute fatty liver in pregnancy. Buytaert IM, et al. **Am J Gastroenterol** 1996 Mar;91(3):603–4

A study of eight medical centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal outcome with comparison control groups. Cappell MS, et al. **Am J Gastroenterol** 1996 Feb;91(2):348–54

Sturge-Weber syndrome in pregnancy. Dolkart LA, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):969–71

A comparison between two screening methods for detection of microproteinuria. Higby K, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1111–4

Second-trimester echogenic bowel and intraamniotic bleeding: association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 nm. Sepulveda W, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):839–42

Idiopathic rapidly progressive (crescentic) glomerulonephritis in pregnancy. Dolkart LA, et al. **Am J Perinatol** 1996 May;13(4):199–201

Acute manic episodes in pregnancy [clinical conference] Finnerty M, et al. **Am J Psychiatry** 1996 Feb;153(2):261–3

Gestational diabetes complicated by severe hypertriglyceridemia and acute pancreatitis. Bar-David J, et al. **Arch Gynecol Obstet** 1996;258(2):101–4

Diastasis of the pubic symphysis [letter] McIntosh JM. **Br J Gen Pract** 1994 Sep;44(386):428

Obstetric complications in schizophrenia [letter; comment] Mortensen PB, et al. **Br J Psychiatry** 1995 Nov; 167(5):695–6; discussion 696–7. Comment on: Br J Psychiatry 1995 Jun;166(6):734–41.

Obstetric complications in schizophrenia [letter; comment] Rifkin L, et al. **Br J Psychiatry** 1995 Nov;167(5):694–5; discussion 696–7. Comment on: Br J Psychiatry 1995 Jun;166(6):734–41.

Demographic and obstetric risk factors for postnatal psychiatric morbidity. Warner R, et al. **Br J Psychiatry** 1996 May;168(5):607–11

Multicystic renal dysplasia diagnosed in the antenatal period [letter] Robson WL, et al. **Br J Urol** 1996 Mar;77(3):478

Dermatomyositis in pregnancy. Solomon JE, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):83–6

Impaired glucose tolerance of pregnancy by WHO and NDDG criteria National Diabetes Data Group [letter; comment] Ryan EA. **Diabetes Care** 1995 Jul;18(7):1076–7 . Comment on: Diabetes Care 1994 Nov;17(11):1264–8.

Hyperreactio luteinalis masquerading as an ovarian neoplasm in a triplet pregnancy. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):177–80

Assessment of painful ureterohydronephrosis during pregnancy by MR urography. Roy C, et al. **Eur Radiol** 1996;6(3):334–8

Missed opportunities for intervening in the lives of pregnant women addicted to alcohol or other drugs. Gehshan S. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):160–3

Adult Arnold-Chiari malformation: a postpartum case presentation. O'Reilly SA, et al. **J Am Osteopath Assoc** 1995 Oct;95(10):607–9

Symptomatic adrenal pseudocyst. Moons P, et al. **J Belge Radiol** 1996 Feb;79(1):23–5

Puerperal psychosis mimicking eclampsia. Ranzini AC, et al. **J Matern Fetal Med** 1996 Jan–Feb;5(1):36–8

Case report: torsion of a gravid horn of a didelphic uterus. Achanna S, et al. **J Obstet Gynaecol Res** 1996 Apr; 22(2):107–9

Prediction of neonatal hyperthyroidism in infants born to mothers with Graves disease. Skuza KA, et al. **J Pediatr** 1996 Feb;128(2):264–8

Air transport of obstetric critical care patients to tertiary centers. Elliott JP, et al. **J Reprod Med** 1996 Mar; 41(3):171–4

Primary hyperaldosteronism in pregnancy. A case report. Solomon CG, et al. **J Reprod Med** 1996 Apr;41(4):255–8

Diagnosis and treatment of ureteral calculi during pregnancy with rigid ureteroscopes. Scarpa RM, et al. **J Urol** 1996 Mar;155(3):875–7

Ureteroscopy in pregnancy [see comments] Ulvik NM, et al. **J Urol** 1995 Nov;154(5):1660–3. Comment in: J Urol 1995 Nov;154(5):1664.

Fast imaging MR assessment of ureterohydronephrosis during pregnancy. Roy C, et al. **Magn Reson Imaging** 1995; 13(6):767–72

Diagnosis of early pregnancy and early complications. Cartwright PS. **Med Clin North Am** 1995 Nov; 79(6):1319–35 (33 ref.)

Liver disease in pregnancy. Wolf JL. **Med Clin North Am** 1996 Sep;80(5):1167–87 (86 ref.)

Second trimester uterine atony imitating ectopic pregnancy: magnetic resonance diagnosis. Wax JR, et al. **Mil Med** 1995 Oct;160(10):534–5

Loss prevention case of the month. Difficult diagnosis. Avery JK. **Tenn Med** 1996 Jul;89(7):244–5

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302–13 (68 ref.)

[Maternal hyperphenylalaninemia in a population of healty Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring] Hyánek J, et al. **Cas Lek Cesk** 1996 Jan 17;135(2):50–3 (Eng. Abstr.) **(Cze)**

[Pitfalls in cytologic diagnosis of thyroid disease associated with pregnancy] Dušková J, et al. **Cesk Patol** 1995 Dec; 31(4):114–8 (Eng. Abstr.) **(Cze)**

[Risks in examining pregnant women with magnetic resonance and other imaging modalities] Hušák V, et al. **Ceska Gynekol** 1995 Dec;60(6):301–3 **(Cze)**

[Intestinal obstruction and pregnancy] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):297–300 (10 ref.) (Eng. Abstr.) **(Fre)**

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Hip diseases in pregnancy] Hettfleisch J, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):657–60 (Eng. Abstr.) **(Ger)**

[Rheumatic diseases in pregnancy—problems from the viewpoint of the gynecologist] Heyl W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M121–4 (21 ref.) **(Ger)**

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

[Assessment of degree of edema by means of bioelectrical impedance during pregnancy] Arisawa M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):25–31 (Eng. Abstr.) **(Jpn)**

[Nephrologic analysis of 94 women with diagnosed "primary" gestosis] Kuska J, et al. **Ginekol Pol** 1995 Nov; 66(11):609–13 (Eng. Abstr.) **(Pol)**

[Results of fetal monitoring in pregnancy with enzymatic and neuroendocrinologic risk factors] Pabian W, et al. **Ginekol Pol** 1996 Apr;67(4):169–75 (Eng. Abstr.) **(Pol)**

[The organizational forms for the early detection and prevention of acute pyelonephritis and dispensary care for pregnant women] Dovlatian AA, et al. **Akush Ginekol (Mosk)** 1995;(6):49–53 **(Rus)**

[Diagnosis of chorea gravidarum] Likhachev SA, et al. **Klin Med (Mosk)** 1995;73(6):64 **(Rus)**

[The results of the nephrological examination of women with a history of nephropathy in pregnancy] Zozulia OV, et al. **Klin Med (Mosk)** 1995;73(3):83–5 **(Rus)**

[Factors related to the recognition of alarm signals during pregnancy] Ortigosa-Corona E, et al. **Ginecol Obstet Mex** 1996 Feb;64:90–5 (24 ref.) (Eng. Abstr.) **(Spa)**

[Diagnosis of Cushing's disease in pregnancy] Manzanares JM, et al. **Med Clin (Barc)** 1995 Dec 2;105(19):744–7 (Eng. Abstr.) **(Spa)**

[Primigravida with rapid evolved liver insufficiency in third trimester pregnancy (clinical conference)] **Rev Clin Esp** 1995 Nov;195(11):801–6 **(Spa)**

[Acute fatty liver in pregnancy. A diagnosis to be considered] Bértoli F, et al. **Rev Med Panama** 1995 Jan–May; 20(1–2):9–19 (Eng. Abstr.) **(Spa)**

DIET THERAPY

Pregnant woman with Crohn's disease maintained on oral hyperalimentation. Matsubayashi S, et al. **Nutrition** 1995 May–Jun;11(3):300–1

DRUG THERAPY

The pharmacokinetics of oral and intramuscular administration of dexamethasone in late pregnancy. Elliott CL, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):213–6

Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease. Wenzl R, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):298–9

Low or high doses of spironolactone for treatment of maternal Bartter's syndrome [letter; comment] Rigó J Jr, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):297. Comment on: Am J Obstet Gynecol 1995 May;172(5):1655–6.

Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Vutyavanich T, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):881–4

Asthma treatment in pregnancy: a randomized controlled study. Wendel PJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):150–4

The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1292–6

Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Altshuler LL, et al. **Am J Psychiatry** 1996 May;153(5):592–606

Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Buchanan NM, et al. **Ann Rheum Dis** 1996 Jul;55(7):486–8

Effects of immunosuppressive drugs during pregnancy. Bermas BL, et al. **Arthritis Rheum** 1995 Dec;38(12):1722–32 (107 ref.)

Pustular psoriasis of pregnancy. Lee SH, et al. **Australas J Dermatol** 1995 Nov;36(4):199–200

Retinol in addition to retinoic acid is required for successful gestation in vitamin A–deficient rats. Wellik DM, et al. **Biol Reprod** 1995 Dec;53(6):1392–7

Dermatomyositis presenting in pregnancy. Harris A, et al. **Br J Dermatol** 1995 Nov;133(5):783–5

Angiolymphoid hyperplasia with eosinophilia: successful treatment with indomethacin farnesil [letter] Nomura K, et al. **Br J Dermatol** 1996 Jan;134(1):189–90

Management of epilepsy in pregnancy: therapeutic aspects. Rutherford JM, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):620–2

Suspected congenital sertraline dependence [letter] Kent LS, et al. **Br J Psychiatry** 1995 Sep;167(3):412–3

Antidepressants in pregnancy and breastfeeding [letter] Ratan DA, et al. **Br J Psychiatry** 1995 Dec;167(6):824

Safe use of iodized oil to prevent iodine deficiency in pregnant women. A statement by the World Health Organization. **Bull World Health Organ** 1996;74(1):1–3

Administration of iodized oil during pregnancy: a summary of the published evidence. Delange F. **Bull World Health Organ** 1996;74(1):101–8 (74 ref.)

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

The antiphospholipid syndrome. Edelman PL. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):427–31

Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Davies MH, et al. **Gut** 1995 Oct;37(4):580–4

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334–46 (108 ref.)

Effects of third trimester fluoxetine exposure on the newborn. Goldstein DJ. **J Clin Psychopharmacol** 1995 Dec; 15(6):417–20

Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants. Azizi F. **J Pediatr** 1996 Jun;128(6):855–8

Guidelines for anticoagulation therapy in pregnancy. Ryan K, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):133–6 (4 ref.)

Levodopa in pregnancy [letter] von Graevenitz KS, et al. **Mov Disord** 1996 Jan;11(1):115–6

Birth outcomes in pregnant women taking fluoxetine [see comments] Chambers CD, et al. **N Engl J Med** 1996 Oct 3;335(14):1010–5. Comment in: N Engl J Med 1996 Oct 3;335(14):1056–8.

Treatment depression in pregnancy [editorial; comment] Robert E. **N Engl J Med** 1996 Oct 3;335(14):1056–8. Comment on: N Engl J Med 1996 Oct 3;335(14):1010–15.

Effect of diltiazem and methyldopa on gestation-related renal complications in rats with adriamycin nephrosis. Relationship to glomerular prostanoid synthesis. Podjarny E, et al. **Nephrol Dial Transplant** 1995;10(9):1598–602

Reproductive and developmental toxicity of aluminum: a review. Domingo JL. **Neurotoxicol Teratol** 1995 Jul–Aug; 17(4):515–21 (59 ref.)

Medications Development for the Treatment of Pregnant Addicts and their Infants. Proceedings of a meeting. August 26–27, 1993. **NIDA Res Monogr** 1995;149:1–235

Clinical trials of pharmacologic treatments in pregnant women—methodologic considerations. Schottenfeld RS. **NIDA Res Monogr** 1995;149:201–23

Overview: medications development for the treatment of drug abuse. Vocci F, et al. **NIDA Res Monogr** 1995; 149:4–15

Testing medications for the treatment of addiction in pregnancy: one reviewer's opinion. Wright C. **NIDA Res Monogr** 1995;149:231–5

Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial [letter; comment] Beckmann CR. **Obstet Gynecol** 1996 Mar;87(3):479–80. Comment on: Obstet Gynecol 1995 Oct;86(4 Pt 1):560–4.

Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Dulitzki M, et al. **Obstet Gynecol** 1996 Mar;87(3):380–3

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

Successful treatment of recurrent non-immune hydrops secondary to fetal hyperthyroidism. Treadwell MC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):838–40

Paralytic ileus in a fetus-neonate after maternal intake of benzodiazepine. Haeusler MC, et al. **Prenat Diagn** 1995 Dec;15(12):1165–7

Drug delivery during pregnancy: evaluation in vitro of new drugs. Dancis J, et al. **Reprod Fertil Dev** 1995;7(6):1485–9 (33 ref.)

Bendectin/diclectin for morning sickness: a Canadian follow-up of an American tragedy [editorial] Ornstein M, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):1–6

Treatment of migraine during pregnancy and lactation. Miles CB. **S D J Med** 1995 Nov;48(11):373–7 (24 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

Acute asthma during pregnancy. Stenius-Aarniala BS, et al. **Thorax** 1996 Apr;51(4):411–4

[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

[Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy] Lainé-Cessac P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):537–42 (Eng. Abstr.) **(Fre)**

A 2-year evaluation of questions concerning "Drugs—Pregnancy" at the CRPV in Nantes March 1992—March 1994] Chiffoleau A, et al. **Therapie** 1995 Sep-Oct;50(5):429–38 (Eng. Abstr.) **(Fre)**

[Neonatal toxicity of naphazoline administrated during pregnancy (letter)] Dageville C, et al. **Therapie** 1995 Sep-Oct;50(5):472–3 **(Fre)**

[Evaluation of reports on "pregnancy and drugs" received during a period of 39 months by the Regional Pharmacovigilance Center, Lorraine (Nancy) (letter)] Hanesse B, et al. **Therapie** 1995 Sep-Oct;50(5):471–2 **(Fre)**

[Treatment of constipation in pregnant women. A multicenter study in a gynecological practice] Müller M, et al. **Schweiz Med Wochenschr** 1995 Sep 9;125(36):1689–93 (Eng. Abstr.) **(Ger)**

[Pharmacologic principles of drug prescribing in pregnancy] Estler CJ. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):743–8 (18 ref.) (Eng. Abstr.) **(Ger)**

–Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy– Rudi J, et al. **Z Gastroenterol** 1996 Mar;34(3):188–91 (Eng. Abstr.) **(Ger)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

[Treatment of Basedow-Graves disease in pregnancy] Konrády A. **Orv Hetil** 1995 Dec 10;136(50):2721–5 (Eng. Abstr.) **(Hun)**

[The protective action of limontar in pregnant animals with acute hypoxic hypoxia] Korneev AA, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):34–6 (Eng. Abstr.) **(Rus)**

[The successful therapy of an exacerbation of mesangioproliferative nephritis during pregnancy] Nikiforova OV, et al. **Ter Arkh** 1995;67(10):69–70 **(Rus)**

ECONOMICS

Weight excess before pregnancy: complications and cost. Galtier-Dereure F, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):443–8

ENZYMOLOGY

Glucose homeostasis in adulthood and in pregnancy in a patient with hepatic glycogen synthetase deficiency. Byrne BM, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):931–3

EPIDEMIOLOGY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454–8 (29 ref.)

Maternal risk factors for preterm birth and low birthweight in Cape Verde. Wessel H, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):360–6

Celiac disease and pregnancy outcome. Ciacci C, et al. **Am J Gastroenterol** 1996 Apr;91(4):718–22

Factors adversely affecting pregnancy outcome in the military. Magann EF, et al. **Am J Perinatol** 1995 Nov; 12(6):462–6

The relation of maternal complications to outcomes in very low birthweight infants in an era of changing neonatal care. Palta M, et al. **Am J Perinatol** 1996 Feb;13(2):109–14

Changes in perinatal cocaine use in an inner-city hospital, 1988 to 1992. McCalla S, et al. **Am J Public Health** 1995 Dec;85(12):1695–7

Violence and substance use among North Carolina pregnant women. Martin SL, et al. **Am J Public Health** 1996 Jul; 86(7):991–8

The prevalence and correlates of anaemia among young children and women of childbearing age in Al Ain, United Arab Emirates. Hossain MM, et al. **Ann Trop Paediatr** 1995 Sep;15(3):227–35

High rates of violence, crime, academic problems, and behavioral problems in males with both early neuromotor deficits and unstable family environments. Raine A, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):544–9

Schizophrenia after prenatal famine. Further evidence. Susser E, et al. **Arch Gen Psychiatry** 1996 Jan;53(1):25–31

The effect of social deprivation on birthweight, excluding physiological and pathological effects. Wilcox MA, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):918–24

Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Ruiz-Irastorza G, et al. **Br J Rheumatol** 1996 Feb; 35(2):133–8

Snoring in pregnancy. Disease or not? [editorial; comment] Littner MR. **Chest** 1996 Apr;109(4):859–61. Comment on: Chest 1996 Apr;109(4):885–9.

Self-reported snoring in pregnancy. Association with fetal outcome [see comments] Loube DI, et al. **Chest** 1996 Apr; 109(4):885–9. Comment in: Chest 1996 Apr;109(4):859–61.

Association of drug abuse and child abuse. Jaudes PK, et al. **Child Abuse Negl** 1995 Sep;19(9):1065–75

Pregnancy outcomes in a prospective matched control study of pregnancy and renal disease. Holley JL, et al. **Clin Nephrol** 1996 Feb;45(2):77–82

Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165–71 (34 ref.)

Perinatal outcomes and family practice [letter; comment] Krall MA. **J Am Board Fam Pract** 1996 Mar–Apr; 9(2):152–3. Comment on: J Am Board Fam Pract 1995 Nov–Dec;8(6):440–7.

Validation of the Danish Birth Registration. Kristensen J, et al. **J Clin Epidemiol** 1996 Aug;49(8):893–7

Carpal tunnel syndrome during pregnancy: prevalence and blood level of pyridoxine. Atisook R, et al. **J Med Assoc Thai** 1995 Aug;78(8):410–4

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)

Maternal and neonatal morbidity associated with in vitro fertilization. Tallo CP, et al. **J Pediatr** 1995 Nov; 127(5):794–800

Obstetric physicians: are they needed? The workload of a medical complications in pregnancy clinic. Nelson-Piercy C, et al. **J R Coll Physicians Lond** 1996 Mar–Apr; 30(2):150–4

Maternal health in developing countries [letter; comment] Harrison KA, et al. **Lancet** 1996 Feb 10;347(8998):400. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1711.

Randomised controlled trial of a reduced-visits programme of antenatal care in Harare, Zimbabwe. Munjanja SP, et al. **Lancet** 1996 Aug 10;348(9024):364–9

Term and postterm low-risk pregnancies: management schemes for the reduction of high rates of cesarean section. Mancuso S, et al. **Minerva Ginecol** 1996 Mar;48(3):95–8

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

The effect of human immunodeficiency virus infection and drug use on birth characteristics. Johnstone FD, et al. **Obstet Gynecol** 1996 Sep;88(3):321–6

Singleton pregnancy after in vitro fertilization: expectations and outcome. Verlaenen H, et al. **Obstet Gynecol** 1995 Dec; 86(6):906–10

Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein. Wenstrom KD, et al. **Obstet Gynecol** 1996 Feb;87(2):213–6

The relationship between idiopathic mental retardation and maternal smoking during pregnancy. Drews CD, et al. **Pediatrics** 1996 Apr;97(4):547–53

Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Soma H, et al. **Reprod Fertil Dev** 1995;7(6):1533–8

Pregnancy-related sickness absence among employed women in a Swedish county. Alexanderson K, et al. **Scand J Work Environ Health** 1995 Jun;21(3):191–8

Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)

Pica in a rural obstetric population. Smulian JC, et al. **South Med J** 1995 Dec;88(12):1236–40

Self-reported symptoms of gynecological morbidity and their treatment in south India. Bhatia JC, et al. **Stud Fam Plann** 1995 Jul–Aug;26(4):203–16

Issues in measuring maternal morbidity: lessons from the Philippines Safe Motherhood Survey Project. Stewart MK, et al. **Stud Fam Plann** 1996 Jan–Feb;27(1):29–35

Pregnancy in renal transplantation recipients: outcome and complications in 44 pregnancies. al Hassani MK, et al. **Transplant Proc** 1995 Oct;27(5):2585

Influence of pregnancy on graft function after renal transplantation. Nojima M, et al. **Transplant Proc** 1996 Jun; 28(3):1582–5

Multiple birth concordance of street drug assays of meconium analysis. Lewis D, et al. **Vet Hum Toxicol** 1995 Aug; 37(4):318–9

[Pregnancy and labor in 335 cases of high multiparity] Slavelkov S, et al. **Akush Ginekol (Sofiia)** 1995;34(3):4–6 (Eng. Abstr.) **(Bul)**

[Reproductive histories of coastal and inland women with and without exposure to methylmercury in Kumamoto] Inaoka T, et al. **Nippon Eiseigaku Zasshi** 1995 Oct; 50(4):861–6 (Eng. Abstr.) **(Jpn)**

ETHNOLOGY

Physical abuse, smoking, and substance use during pregnancy: prevalence, interrelationships, and effects on birth weight. McFarlane J, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):313–20

ETIOLOGY

Perimortem cesarean section: case reports and recommendations. Lanoix R, et al. **Acad Emerg Med** 1995 Dec;2(12):1063–7

Maternal and perinatal implications of the use of human recombinant erythropoietin. Braga J, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):449–3

The hazards of reproduction in space. Sullivan R. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):372–7 (72 ref.)

Elevated umbilical erythropoietin levels during labor in newborns of smoking mothers. Bili H, et al. **Am J Perinatol** 1996 Feb;13(2):85–7

Pregnancy and corneal allograft rejection [letter] Fulton JC, et al. **Arch Ophthalmol** 1996 Jun;114(6):765

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Sanders JE, et al. **Blood** 1996 Apr 1;87(7):3045–52

Pregnancies in a woman with a vesico-uterine fistula following lower segment caesarean section. Allenby K, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):87–9

A successful pregnancy in a patient with homocystinuria and a previous near-fatal postpartum cavernous sinus thrombosis. Calvert SM, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):751–2

Velamentous umbilical cord insertion may be suspected from maternal serum alpha-fetoprotein and hCG. Heinonen S, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):209–13

Management of female genital mutilation: the Northwick Park Hospital experience. McCaffrey M, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):787–90

Complications of pregnancy after infertility treatment: awareness and prevention [letter; comment] Rai RS, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):191–2. Comment on: Br J Obstet Gynaecol 1995 Jul;102(7):520–4.

Flatfeet in pregnancy [letter] Bohemen EK, et al. **Br J Rheumatol** 1996 Apr;35(4):396–7

Non-traumatic rupture of the urinary tract during pregnancy. Wolff JM, et al. **Br J Urol** 1995 Nov;76(5):645–8

Pulmonary edema in a woman following fetal surgery. DiFederico EM, et al. **Chest** 1996 Apr;109(4):1114–7

Acute respiratory failure in pregnancy. Deblieux PM, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):143–52 (14 ref.)

Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)

Rupture of pregnant uterus in Shashemene General Hospital, south Shoa, Ethiopia (a three year study of 37 cases). Chamiso B. **Ethiop Med J** 1995 Oct;33(4):251–7

Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Ben-Chetrit A, et al. **Hum Reprod** 1995 Nov;10(11):3057–60 (34 ref.)

Uterine rupture during pregnancy after laparoscopic myomectomy. Dubuisson JB, et al. **Hum Reprod** 1995 Jun; 10(6):1475–7

Pregnancy-induced Cushing's syndrome in multiple pregnancies. Wallace C, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):15–21

A case of sarcoidosis which relapsed twice after successive parturitions. Kishimoto S, et al. **J Dermatol** 1995 Dec; 22(12):953–7

Hip, knee, and foot pain during pregnancy and the postpartum period. Vullo VJ, et al. **J Fam Pract** 1996 Jul; 43(1):63–8

Massive rectal bleeding in pregnancy: a case report. Byrne DJ, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):396

Severe maternal and fetal electrolyte imbalance in pregnancy after gastric surgery for morbid obesity. A case report. Weissman A, et al. **J Reprod Med** 1995 Nov;40(11):813–6

Gas embolism in obstetrics and gynecology. A review. Weissman A, et al. **J Reprod Med** 1996 Feb;41(2):103–11 (89 ref.)

Risk profile of pregnant mothers in Kelantan. Zulkifli A, et al. **Med J Malaysia** 1995 Dec;50(4):359–64

Pregnancy outcome following genetic amniocentesis at 11–14 versus 16–19 weeks' gestation. Brumfield CG, et al. **Obstet Gynecol** 1996 Jul;88(1):114–8

Pregnancy-associated osteoporosis. Smith R, et al. **QJM** 1995 Dec;88(12):865–78

Kock pouch dysfunction during pregnancy. Management of a case. Curtis RD, et al. **Surg Endosc** 1996 Jul;10(7):755–7

[Deviatio ileopancreatica a modo Scopinaro and intrauterine fetal hypotrophy] Tsenov A, et al. **Akush Ginekol (Sofiia)** 1994;33(2):45–7 **(Bul)**

[Pelvic pain caused by pregnancy (letter)] Pel M. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2586–7 **(Dut)**

[Does coitus have an effect on the course of pregnancy?] Kurki T. **Duodecim** 1994;110(18):1681–5 (32 ref.) **(Fin)**

[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**

[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Ileus in late pregnancy--sequela of follicle puncture within the scope of in vitro fertilization?] Bung P, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):252–3 (Eng. Abstr.) **(Ger)**

[Continent urinary diversion and pregnancy] Voges GE, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):711–5 (Eng. Abstr.) **(Ger)**

[Current aspects of gynecology and obstetrics (editorial)] Ludwig H. **Ther Umsch** 1996 Jun;53(6):429–30 **(Ger)**

[Emergencies in obstetrics] Ludwig H. **Ther Umsch** 1996 Jun; 53(6):477–96 (54 ref.) (Eng. Abstr.) **(Ger)**

[A rare cause of uterine rupture during pregnancy] Poli M, et al. **Minerva Ginecol** 1995 Sep;47(9):391–2 **(Ita)**

[Acute abdomen in pregnancy. Diagnosis of surgical causes] Bøe HA, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):600–3 (Eng. Abstr.) **(Nor)**

[A case of large bowel injury with a safety belt in a pregnant woman] Gwoździewicz J, et al. **Wiad Lek** 1994 Oct; 47(19–20):794–5 (Eng. Abstr.) **(Pol)**

[Risk of radiologic examinations during pregnancy] Ramos HV. **Acta Med Port** 1996 Jan;9(1):49–53 (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Immunologic evaluation of a neonate born to an immunosuppressed kidney transplant recipient. Ersay A, et al. **Am J Perinatol** 1995 Nov;12(6):413–5

Pregnancy and warm autoantibodies: a case report. Gerson A, et al. **Am J Perinatol** 1996 Jan;13(1):19–20

IL-6 and G-CSF levels in amniotic fluid during the second trimester in normal and abnormal pregnancies. Weimann E, et al. **Arch Gynecol Obstet** 1995;256(3):125–30

Essential edema-proteinuria-hypertension (EPH) gestosis and gestosis superimposing pre-existing renal disease: comparison of cellular immunity parameters. Malinowski A, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5–6):387–91

Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Nelson JL. **Arthritis Rheum** 1996 Feb;39(2):191–4

Pregnancy, schizophrenia and rheumatoid arthritis [letter; comment] Rafter GW. **Br J Rheumatol** 1996 Jun;35(6):603 . Comment on: Br J Rheumatol 1995 Jan;34(1):1–3.

The effects of pregnancy on autoimmune diseases. Buyon JP, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):99–104 (57 ref.)

Antibodies to cytokeratins bind to epitopes in human uterine smooth muscle cells in normal and pathological pregnancies. Stiemer B, et al. **Histopathology** 1995 Nov; 27(5):407–14

Anesthesia with antiphospholipid antibodies: anesthetic management of a parturient with lupus anticoagulant and anticardiolipin antibody. Fahy BG, et al. **J Clin Anesth** 1996 Feb;8(1):49–53

The antiphospholipid-protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S–100S (186 ref.)

Amniotic fluid levels of CA 19.9 and CA 15.3 in normal and Down's syndrome pregnancies. Noci I, et al. **J Perinat Med** 1995;23(3):237–41

Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. Tseng CE, et al. **J Rheumatol** 1996 May;23(5):925–32

Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)

Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lynch AM, et al. **Lupus** 1995 Oct;4(5):365–9

Obstetric outcome in systemic lupus erythematosus. Lima F, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):184–92 (43 ref.)

Severe hemolytic disease of the newborn due to anti-Js(b). Gordon MC, et al. **Vox Sang** 1995;69(2):140–1

A quantitative assay for subclassing IgG alloantibodies implicated in hemolytic disease of the newborn. Thomas NC, et al. **Vox Sang** 1995;69(2):120–5

[Intrauterine management of Rh-alloimmunization] Intödy Z, et al. **Orv Hetil** 1996 Mar 31;137(13):675–9 (Eng. Abstr.) **(Hun)**

[Deficiency of maternal recognition of fetal-placental antigens in pregnancy complicated by idiopathic growth retardation] Dudarewicz L, et al. **Ginekol Pol** 1995 Sep; 66(9):498–501 (Eng. Abstr.) **(Pol)**

[Natural cytotoxicity of CD16+ lymphocytes in women with selected states of pregnancy pathology] Kamiński K, et al. **Ginekol Pol** 1995 Apr;66(4):193–7 (Eng. Abstr.) **(Pol)**

METABOLISM

Folic acid absorption in women with a history of pregnancy with neural tube defect [see comments] Davis BA, et al. **Am J Clin Nutr** 1995 Oct;62(4):782–4. Comment in: Am J Clin Nutr 1996 Jun;63(6):976–7.

Maternal smoking and fetal carboxyhaemoglobin and blood gas levels [see comments] Soothill PW, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):78–82. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):721.

Expression pattern of cytokines in the different compartments of the feto-maternal unit under various conditions. Stallmach T, et al. **Reprod Fertil Dev** 1995;7(6):1573–80

MORTALITY

Spontaneous rupture of the spleen. A fatal complication of pregnancy. McCormick GM 2nd, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):132–4 (15 ref.)

Obstetric patients treated in intensive care units and maternal mortality. Regional Teams for the Survey. Bouvier-Colle MH, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):121–5

Public health ... mothers at risk --news-- **Hosp Health Netw** 1996 Sep 5;70(17):11

Trends in maternal mortality in Saudi Arabia. al-Meshari A, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):25–32

Pregnancy-related mortality in the United States, 1987–1990. Berg CJ, et al. **Obstet Gynecol** 1996 Aug;88(2):161–7

NURSING

Crack cocaine and pregnancy. Kearney MH. **Am J Nurs** 1996 Mar;96(3):17, 19

Emergency! Renal calculi. Ruth-Sahd LA. **Am J Nurs** 1995 Nov;95(11):50

Home care of the battered pregnant woman: one battered woman's pregnancy. Christian A. **J Obstet Gynecol Neonatal Nurs** 1995 Nov-Dec; 24(9):836–42

PATHOLOGY

Spectrum of cytologic changes in pregnancy. A review of 100 abnormal cervicovaginal smears, with emphasis on diagnostic pitfalls. Pisharodi LR, et al. **Acta Cytol** 1995 Sep-Oct;39(5):905–8

Study of the liver changes occurring in pre-eclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. Dani R, et al. **Am J Gastroenterol** 1996 Feb;91(2):292–4

Histologic evidence of old intrauterine bleeding is more frequent in prematurity. Salafia CM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1065–70

Pruritic urticarial papules and plaques of pregnancy (polymorphic eruption of pregnancy): two unusual cases. Vaughan Jones SA, et al. **Br J Dermatol** 1996 Jul; 135(1):102–5

Localized endometrial proliferations associated with pregnancy: clinical and histopathologic features of 11 cases. Genest DR, et al. **Hum Pathol** 1995 Nov;26(11):1233–40

Subcutaneous and superficial granuloma pyogenicum. Park YH, et al. **Int J Dermatol** 1996 Mar;35(3):205–6 (9 ref.)

Solitary reticulohistiocytoma in pregnancy: immunohistochemical and ultrastructural study of a case with unusual immunophenotype. Hunt SJ, et al. **J Cutan Pathol** 1995 Apr;22(2):177–81

Recurrent hemolytic uremic syndrome in a renal transplant patient during pregnancy. Sølling J, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):507–10

Multicentric renal angiomyolipoma associated with pulmonary lymphangioleiomyomatosis: case report, with histologic, immunohistochemical, and DNA content analyses. Tawfik O, et al. **Urology** 1996 Sep;48(3):476–80

[Polypoid cystitis in pregnant diabetic] Estébanez Zarranz MJ, et al. **Actas Urol Esp** 1995 Apr;19(4):333–6 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Relaxin is not related to symptom-giving pelvic girdle relaxation in pregnant women. Hansen A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):245–9

Chronological changes in subjective symptoms during pregnancy in nulliparous and multiparous women. Oga M, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):784–7

Facial nerve palsy during pregnancy. Danielides V, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):131–5

Umbilical artery Doppler velocimetry: clinical utility in high-risk pregnancies. Divon MY. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):10–4 (36 ref.)

Quantitative echocardiographic assessment of left ventricular function in critically ill obstetric patients: a comparative study. Rokey R, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1148–52

A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Rossiter JP, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1599–606

Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Rogers RG, et al. **Am J Perinatol** 1995 Jul;12(4):262–4

Effects of obesity on pregnant women: maternal hemodynamic change. Tomoda S, et al. **Am J Perinatol** 1996 Feb;13(2):73–8

Effect of chronic hypoxia on myometrial responsiveness in the pregnant rat. Rhee JW, et al. **Am J Physiol** 1996 Mar; 270(3 Pt 1):E477–82

Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy. Walsh JW, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G506–14

Nocturnal hypoxaemia in late pregnancy. Bourne T, et al. **Br J Anaesth** 1995 Dec;75(6):678–82

The thermic effect of food in normal-weight and overweight pregnant women. Bronstein MN, et al. **Br J Nutr** 1995 Aug;74(2):261–75

Changes in bone density and biochemical markers of bone turnover in pregnancy-associated osteoporosis. Khastgir G, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):716–8

Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Ruiz-Irastorza G, et al. **Br J Rheumatol** 1996 Feb; 35(2):133–8

Anaesthetic management of labour and delivery in the parturient with mitochondrial myopathy. Rosaeg OP, et al. **Can J Anaesth** 1996 Apr;43(4):403–7

Regulation of breathing and perception of dyspnea in healthy pregnant women. García-Río F, et al. **Chest** 1996 Aug; 110(2):446–53

Transient osteoporosis of the hip in pregnancy: natural history of changes in bone mineral density. Funk JL, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):373–82

Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)

Timing of prenatal starvation in women and birth weight in their first and second born offspring: the Dutch Famine Birth Cohort study. Lumey LH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):23–30

The effect of normal childbirth on eyes with abnormalities predisposing to rhegmatogenous retinal detachment. Landau D, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Sep;233(9):598–600

Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Monte MJ, et al. **Hepatology** 1996 May;23(5):1208–17

Psoriasis and pregnancy: hormone and immune system interaction. Boyd AS, et al. **Int J Dermatol** 1996 Mar; 35(3):169–72

Weight excess before pregnancy: complications and cost. Galtier-Dereure F, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):443–8

Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. Clifton VL, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2888–93

The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. de Zegher F, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3127–30

Subchorionic hematomas in early pregnancy: clinical outcome and blood flow patterns. Kurjak A, et al. **J Matern Fetal Med** 1996 Jan–Feb;5(1):41–4

Point of diminishing returns: when does gestational weight gain cease benefiting birthweight and begin adding to maternal obesity? Luke B, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):168–73

Amyotrophic lateral sclerosis and pregnancy. Vincent O, et al. **J Neurol Sci** 1995 May;129 Suppl:42–3

Maternal glucocorticoid secretion mediates long-term effects of prenatal stress. Barbazanges A, et al. **J Neurosci** 1996 Jun 15;16(12):3943–9

Insulin sensitivity in adult female rats subjected to malnutrition during the perinatal period. Holemans K, et al. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):71–7

Amniotic fluid epidermal growth factor levels in normal and abnormal pregnancies. Varner MW, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):17–9

Effects of CO2 pneumoperitoneum in pregnant ewes. Curet MJ, et al. **J Surg Res** 1996 Jun;63(1):339–44

Effect of recurrent pregnancies on the evolution of adriamycin nephropathy. Pomeranz M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2049–53

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Pregnancy complications and birth outcomes in obese and normal-weight women: effects of gestational weight change. Edwards LE, et al. **Obstet Gynecol** 1996 Mar; 87(3):389–94

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1–27 (166 ref.)

[Pelvic pain and pregnancy (letter)] Driessen F. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):278–9 **(Dut)**

[Pelvic pain and pregnancy] Engelen MJ, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1961–4 **(Dut)**

[Pelvic pain caused by pregnancy; a new disease?] Mens JM. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1964–6 (11 ref.) **(Dut)**

[Minor symptoms in family practice; chloasma or 'pregnancy mask' (see comments)] van Stralen-Bohlmann A, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1971–4 (17 ref.) . Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2513–4. Comment in: Ned Tijdschr Geneeskd 1995 Dec 23;139(51):2698. **(Dut)**

[The activation of lupus in pregnancy and its successful immunological treatment] Tulokas S. **Duodecim** 1994; 110(23–24):2223–6 **(Fin)**

[When children "have children"—reproduction biological problems in girls between 11 and 15 years of age] Plöckinger B, et al. **Geburtshilfe Frauenheilkd** 1996 May; 56(5):248–51 (Eng. Abstr.) **(Ger)**

[Comparison of fetal circulatory responses during maternal bleeding and fetal bleeding] Yoshihara H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):9–16 (Eng. Abstr.) **(Jpn)**

[Preservation of gonadotrophic function and pregnancy in Sheehan's syndrome: a case report and review of the literature] Vieira HB, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):135–8 (17 ref.) (Eng. Abstr.) **(Por)**

[Characteristics of adaptive reactions of pregnant women with chronic inflammatory gynecologic diseases and in their newborn in the early neonatal period] Krylov VI, et al. **Akush Ginekol (Mosk)** 1995;(4):24–6 (Eng. Abstr.) **(Rus)**

[The indices of the physiological maturity of the progeny under conditions of chronic cholestatic lesions of the liver in the mother] Briukhin GV. **Morfologiia** 1995;108(1):35–8 (Eng. Abstr.) **(Rus)**

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70–4 (23 ref.) **(Spa)**

[Absent or reverse diastolic umbilical flow] Guerra F, et al. **Rev Chil Obstet Ginecol** 1995;60(2):101–7 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Does magnesium sulfate affect the length of labor induction in women with pregnancy-associated hypertension? Atkinson MW, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1219–22

Vitamin B1 and B6 substitution in pregnancy for leg cramps [letter; comment] Avşar AF, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):233–4. Comment on: Am J Obstet Gynecol 1995 Jul;173(1):175–80.

Smoking cessation counseling during routine public prenatal care [letter; comment] Haddow JE, et al. **Am J Public Health** 1995 Oct;85(10):1451–2. Comment on: Am J Public Health 1995 Feb;85(2):217–22.

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group [see comments] **Br J Obstet Gynaecol** 1996 Jan; 103(1):39–47. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):719–20.

Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)

Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56–69 (44 ref.)

Multifetal pregnancies. Smith-Levitin M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):465–71 (52 ref.)

Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787–93 (34 ref.)

Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy [editorial; comment] Elkayam UR. **J Am Coll Cardiol** 1996 Jun;27(7):1704–6. Comment on: J Am Coll Cardiol 1996 Jun;27(7):1698–703.

Efforts to reduce perinatal mortality, HIV, and drug addiction: surveys of the states. Chavkin W, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):164–6

The employability of pregnant and breastfeeding servicewomen. Croft AM. **J R Army Med Corps** 1995 Oct; 141(3):134–41

Are non-diabetic women with abnormal glucose screening test at increased risk of pre-eclampsia, macrosomia and caesarian birth? Khan KS, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):176–9

NHMRC recommendations on abstinence from alcohol in pregnancy. National Health and Medical Research Council [letter] Holman CD, et al. **Med J Aust** 1996 Jun 3; 164(11):699

Telephone support for pregnant women: outcome in late pregnancy. Bullock LF, et al. **N Z Med J** 1995 Nov 24; 108(1012):476–8

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

Abuse during pregnancy: frequency, severity, perpetrator, and risk factors of homicide. McFarlane J, et al. **Public Health Nurs** 1995 Oct;12(5):284–9

Addressing battering during pregnancy: reducing low birth weight and ongoing abuse. Campbell JC. **Semin Perinatol** 1995 Aug;19(4):301–6 (37 ref.)

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176–84 (54 ref.)

Maternal health and safe motherhood: findings from concluded research studies. **World Health Stat Q** 1995; 48(1):2–3

[Summary of National Symposium on Improving Quality of Obstetric Care for Safe Motherhood] Xing S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):134–71 **(Chi)**

[Vitamin supplementation for pregnant women] Marpeau L. **Contracept Fertil Sex** 1996 Mar;24(3):188–90 **(Fre)**

[Wanting a child in Hashimoto thyroiditis with hypothyreosis] Gärtner R. **Dtsch Med Wochenschr** 1996 May 3;121(18):608 **(Ger)**

[Thyroid gland dysfunctions and disorders in pregnancy and puerperium. Prevention, diagnosis and therapy] Bohnet HG, et al. **Geburtshilfe Frauenheilkd** 1995 Nov; 55(11):M134–6 **(Ger)**

[Folic acid in pregnancy] Teichmann A, et al. **Med Monatsschr Pharm** 1995 Nov;18(11):333–4 **(Ger)**

[Prevention and treatment of hemorrhage in obstetrical hospitals] Zarubina EN, et al. **Akush Ginekol (Mosk)** 1995; (4):19–22 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

The relationship between psychological distress during pregnancy and birth weight for gestational age. Hedegaard M, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):32–9

Possible influence of expatriation on perinatal outcome. Kuvacic I, et al. **Acta Obstet Gynecol Scand** 1996 Apr; 75(4):367–71

Risks associated with childbearing in schizophrenia. Trixler M, et al. **Acta Psychiatr Belg** 1995 May–Jun;95(3):159–62

Effect of pregnancy on three patients with bipolar disorder. Sharma V, et al. **Ann Clin Psychiatry** 1995 Mar;7(1):39–42

Correlates of multigravida women's binge drinking during pregnancy. A longitudinal study. Pascoe JM, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1325–9

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113–22 (69 ref.). Comment in: Behav Med 1996 Fall;21(3):123–9.

Childhood abuse and suicidality in obstetrics patients in a hospital-based urban prenatal clinic. Farber EW, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):56–60

Drug-taking behaviours of pregnant substance abusers in treatment. Higgins PG, et al. **J Adv Nurs** 1995 Sep; 22(3):425–32

Self-esteem of pregnant substance abusers. Higgins PG, et al. **Matern Child Nurs J** 1995 Jul–Sep;23(3):75–81

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

Obsessive-compulsive disorder limited to pregnancy. Iancu I, et al. **Psychother Psychosom** 1995;64(2):109–12

Health consequences of severe life events for pregnancy. Rostad B, et al. **Scand J Prim Health Care** 1995 Jun; 13(2):99–104

Psychosocial factors and heavy smoking during pregnancy among parous Scandinavian women. Thue E, et al. **Scand J Prim Health Care** 1995 Sep;13(3):182–7

A grounded theory of balancing alcohol recovery and pregnancy. Brudenell I. **West J Nurs Res** 1996 Aug; 18(4):429–40

[Psychological stress and pregnancy outcome (editorial)] Henriksen TB, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2365 **(Dan)**

[Psychiatric emergencies and pregnancy] Rais M. **Rev Med Suisse Romande** 1996 Apr;116(4):291–4 **(Fre)**

[Psychiatric diseases and pregnancy] Fuchs U. **Gynakologe** 1995 Dec;28(6):440–5 (16 ref.) **(Ger)**

[Maternal instinct in women with complicated pregnancy] Reroń A. **Ginekol Pol** 1995 Jan;66(1):13–8 (Eng. Abstr.) **(Pol)**

[Fear as a risk factor in perinatology] Zdziennicki A. **Wiad Lek** 1994 Sep;47(17–18):698–9 (21 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Radiologic management of abdominal trauma in pregnancy. Goldman SM, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):763–7 (33 ref.)

REHABILITATION

Behavioral treatment of cocaine-dependent pregnant women and TB-exposed patients. Elk R, et al. **Addict Behav** 1995 Jul–Aug;20(4):533–42

Attitude toward recovery and completion of a substance abuse treatment program. Britt GC, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):349–53

Methadone use during pregnancy. Jarvis MA, et al. **NIDA Res Monogr** 1995;149:58–77

SURGERY

Successful conservative management of placenta percreta with rectal involvement in a primigravida. Lee LC, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):839–41

Ovarian hyperstimulation syndrome (OHSS) in pregnancy not associated with ovulation induction. Regi A, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):599–600

Endoscopic management of spontaneous bile duct perforation and bile peritonitis complicating term pregnancy. Thaggard WG, et al. **Am J Gastroenterol** 1995 Nov;90(11):2054–5

Laparoscopic surgery during pregnancy. Amos JD, et al. **Am J Surg** 1996 Apr;171(4):435–7

Sigmoid volvulus in pregnancy. Lord SA, et al. **Am Surg** 1996 May;62(5):380–2

Anaesthetic considerations for a possible malignant hyperthermia susceptible fetus [letter] Hersch PE, et al. **Anaesthesia** 1996 Jan;51(1):99

Neostigmine, atropine, and glycopyrrolate: does neostigmine cross the placenta? Clark RB, et al. **Anesthesiology** 1996 Feb;84(2):450–2

Problematic renal calculi presenting during pregnancy. Fligelstone LJ, et al. **Ann R Coll Surg Engl** 1996 Mar; 78(2):142–5

Surveyed use of fetal and uterine monitoring during maternal surgery. Kendrick JM, et al. **AORN J** 1995 Sep;62(3):386–9, 391–2

Laparoscopy during pregnancy. Curet MJ, et al. **Arch Surg** 1996 May;131(5):546–50; discussion 550–1

Pregnancies complicated by acute appendicitis. To WW, et al. **Aust N Z J Surg** 1995 Nov;65(11):799–803

Anaesthetic dilemma: half a spinal is better than none. Smith AF, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12; 54(10):513–4

A comparative study of caesarean deliveries by assistant medical officers and obstetricians in Mozambique. Pereira C, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):508–12

Management of acute hydronephrosis in pregnancy by ureteral stenting. Zwergel T, et al. **Eur Urol** 1996; 29(3):292–7

Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

Management of choledocholithiasis during pregnancy: a new protocol in the laparoscopic era. Liberman MA, et al. **J Laparoendosc Surg** 1995 Dec;5(6):399–403

Laparoscopic surgery in pregnancy: report on two cases. Posta CG. **J Laparoendosc Surg** 1995 Jun;5(3):203–5

Carpal tunnel syndrome in pregnancy: indications for early surgery. Stahl S, et al. **J Neurol Sci** 1996 Mar; 136(1–2):182–4

Obstetric management of incompetent cervix and bulging fetal membranes. Schorr SJ, et al. **J Reprod Med** 1996 Apr; 41(4):235–8

Management of spontaneous pneumothorax during pregnancy: case report and review of the literature. VanWinter JT, et al. **Mayo Clin Proc** 1996 Mar; 71(3):249–52 (27 ref.)

Surgical management of pseudotumor cerebri in pregnancy: case report. Shapiro S, et al. **Neurosurgery** 1995 Oct; 37(4):829–31

Pipkin type IV fracture treated surgically during pregnancy. Ebraheim NA, et al. **Orthopedics** 1996 Apr;19(4):350–3

Laparoscopic cholecystectomy in pregnancy. A safe option during the second trimester? Martin IG, et al. **Surg Endosc** 1996 May;10(5):508–10

Laparoscopic cholecystectomy during pregnancy. Review of anesthetic management, surgical considerations. Steinbrook RA, et al. **Surg Endosc** 1996 May;10(5):511–5

Laparoscopic cholecystectomy in pregnancy. A report of 6 cases and review of the literature. Wishner JD, et al. **Surg Endosc** 1996 Mar;10(3):314–8 (29 ref.)

Laparoscopic cholecystectomy during pregnancy. Lanzafame RJ. **Surgery** 1995 Oct;118(4):627–31; discussion 631–3 (28 ref.)

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Trauma in the last trimester of pregnancy] Prokop A, et al. **Unfallchirurg** 1996 Jun;99(6):450–3 (11 ref.) (Eng. Abstr.) **(Ger)**

[Experience with autologous transfusion in obstetrics] Palin S, et al. **Minerva Ginecol** 1995 May;47(5):231–7 (Eng. Abstr.) **(Ita)**

[Incidence and indication for cesarean section at the Central Military Hospital of Mexico] Olivares Morales AS, et al. **Ginecol Obstet Mex** 1996 Feb;64:79–84 (Eng. Abstr.) **(Spa)**

[Fetal endoscopic surgery in a case of twin pregnancy complicated by reversed arterial perfusion sequence (TRAP sequence)] Quintero R, et al. **Rev Chil Obstet Ginecol** 1995;60(2):112–6; discussion 116–7 (Eng. Abstr.) **(Spa)**

THERAPY

Abdominal trauma in the pregnant patient. Hill DA, et al. **Am Fam Physician** 1996 Mar;53(4):1269–74

Successful use of recombinant human erythropoietin in a pregnant woman with lupus nephritis. Kontessis PS, et al. **Am J Kidney Dis** 1995 Nov;26(5):781–4

Management and outcome of pregnant women with interstitial and restrictive lung disease. Boggess KA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1007–14

Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. O'Brien B, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):708–15

The management of a persistent adnexal mass in pregnancy. Platek DN, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1236–40

Treatment of pregnancy-related illnesses. Prevost RR. **Am Pharm** 1995 Oct;NS35(10):25–32 (14 ref.)

Problematic renal calculi presenting during pregnancy [letter] Thompson T, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):399

Guillain-Barré syndrome in pregnancy—two case reports and a discussion on management. Bolik A, et al. **Arch Gynecol Obstet** 1995;256(4):199–203

Obstetric emergencies: their practical management. Molloy BG. **Aust Fam Physician** 1995 Oct;24(10):1943–7; quiz 1950

Multicentre trials in obstetrics and gynaecology. Smaller explanatory trials are required [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Jul;103(7):599–602. Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):603–7. Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):625–9.

Obstetrics and gynaecology in the developing world. Lunan CB. **Br J Obstet Gynaecol** 1996 Jun;103(6):491–3

Management of ureteric calculi during pregnancy by ureteroscopy and laser lithotripsy. Carringer M, et al. **Br J Urol** 1996 Jan;77(1):17–20

Systemic supply to a pulmonary arteriovenous malformation: potential explanation for recurrence. Wispelaere JFD, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):285–7

The practical management of thyroid disease in pregnancy. **Drug Ther Bull** 1995 Oct;33(10):75–7

Obstetric patients treated in intensive care units and maternal mortality. Regional Teams for the Survey. Bouvier-Colle MH, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):121–5

Normal pregnancy in primary alveolar hypoventilation treated with nocturnal nasal intermittent positive pressure ventilation. Pieters T, et al. **Eur Respir J** 1995 Aug; 8(8):1424–7

Ureteral drainage with double-J catheters in obstructive uropathy during pregnancy. A report of 3 cases. Vendola N, et al. **Gynecol Obstet Invest** 1995;40(4):274–5

Maintenance of effects in the nonmedical treatment of headaches during pregnancy. Scharff L, et al. **Headache** 1996 May;36(5):285–90

Themes and variations among seven comprehensive perinatal drug and alcohol abuse treatment models. Clayson Z, et al. **Health Soc Work** 1995 Aug;20(3):234–8

ACOG criteria set. Initial maternal--fetal assessment following acute abdominal trauma. Number 12—November 1995. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Apr;53(1):93–4

Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. Roti E, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1679–82 (15 ref.)

The maternal-fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR. **J Contemp Health Law Policy** 1996 Spring;12(2):637–73 (255 ref.)

Chiropractic care, including craniosacral therapy, during pregnancy: a static-group comparison of obstetric interventions during labor and delivery. Phillips CJ, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):525–9

Gallbladder disease in pregnancy. Davis A, et al. **J Reprod Med** 1995 Nov;40(11):759–62

Periurethral collagen injection and pregnancy. Carr LK, et al. **J Urol** 1996 Mar;155(3):1037

Diagnosis and treatment of ureteral calculi during pregnancy with rigid ureteroscopes. Scarpa RM, et al. **J Urol** 1996 Mar;155(3):875–7

Ureteroscopy in pregnancy [see comments] Ulvik NM, et al. **J Urol** 1995 Nov;154(5):1660–3. Comment in: J Urol 1995 Nov;154(5):1664.

Clinical management of drug dependency in pregnancy. Woods JR Jr. **NIDA Res Monogr** 1995;149:39–57

Bed rest and high-risk pregnancy. Differentiating the effects of diagnosis, setting, and treatment. Maloni JA. **Nurs Clin North Am** 1996 Jun;31(2):313–25 (35 ref.)

Endoscopic management of biliary disease during pregnancy. Nesbitt TH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):806–9

Acute spinal cord injury and neurogenic shock in pregnancy. Gilson GJ, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):556–60 (11 ref.)

Nonpharmacological management of headaches during pregnancy. Marcus DA, et al. **Psychosom Med** 1995 Nov-Dec;57(6):527–35

Treatment of pneumothorax during pregnancy. Levine AJ, et al. **Thorax** 1996 Mar;51(3):338–9:discussion 340–1

Resolution of hyperthyroidism in a pregnant woman with toxic thyroid nodule by percutaneous ethanol injection. Cortelazzi D, et al. **Thyroid** 1995 Dec;5(6):473–5

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314–26 (87 ref.)

[Obstetric complications and medical and surgical complication: intensive care and management. A symposium summary] **Chung Hua I Hsueh Tsa Chih** 1995 Aug;75(8):455–8 **(Chi)**

[Pregnancy in a hemodialysis patient] van der Wal HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):667–9 (Eng. Abstr.) **(Dut)**

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

[Intravenous use of nitroglycerin in obstetrical emergencies. 9 cases of version by internal manipulations (letter)] Dufour P, et al. **Presse Med** 1996 May 25;25(18):865 **(Fre)**

[Pharma clinics: how I treat... Inflammatory intestinal diseases and pregnancy] Belaiche J. **Rev Med Liege** 1995 Nov;50(11):449–50 **(Fre)**

[Injury and pregnancy] Béguin F. **Rev Med Suisse Romande** 1996 Apr;116(4):285–6 **(Fre)**

[Preventable medical treatment errors in gynecology and obstetrics. Conclusions of the Expert Committee for Medical Treatment Errors of the North-Rhine Medical Group] Fitting W. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):M87–90 **(Ger)**

[Pregnancy and labor in idiopathic thrombocytopenic purpura] Tampakoudis P, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):583–6 (Eng. Abstr.) **(Ger)**

[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone] Feist E, et al. **Z Rheumatol** 1996 Mar–Apr; 55(2):127–32 (Eng. Abstr.) **(Ger)**

[Pregnancy care in drug-dependent patients under the charge of SERT (Public Service for the Treatment of Drug Addiction) of Massa-Carrara. The prevention of fetal damages and premature labor] Damone R, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):86–8 **(Ita)**

[Acute kidney failure associated with pregnancy and delivery] Niemczyk S, et al. **Ginekol Pol** 1995 May; 66(5):305–8 (Eng. Abstr.) **(Pol)**

[Myasthenic crisis during pregnancy: case report and literature survey] Kwieciński H, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):50–2 (14 ref.) (Eng. Abstr.) **(Pol)**

[Methods of gravitational surgery on the blood in obstetrics and gynecology] Abubakirova AM, et al. **Akush Ginekol (Mosk)** 1995;(5):40–3 (45 ref.) **(Rus)**

ULTRASONOGRAPHY

Prenatal diagnosis of epignathus causing acute polyhydramnios. Ekici E, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):498–501

The clinical significance of ultransonographically detected subchorionic hemorrhages. Ball RH, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):996–1002

Amnion rupture in the second trimester. Hewitt B, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):323–5

Transvaginal ultrasound in the management of women with suspected cervical incompetence [see comments] Fox R, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):921–4. Comment in: Br J Obstet Gynaecol 1996 Sep;103(9):viii.

Routine obstetric ultrasound examinations in South Africa: cost and effect on perinatal outcome—a prospective randomised controlled trial. Geerts LT, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):501–7

Diagnosis of acute ureteral calculous obstruction in pregnant women using colour and pulsed Doppler sonography. Haddad MC, et al. **Clin Radiol** 1995 Dec;50(12):864–6

Ultrasound and Doppler in the diagnosis of ovarian torsion. Davis LG, et al. **Eur J Radiol** 1995 Jul;20(2):133–6

Early fetal circulation in pregnancies complicated by retroplacental hematoma. Rizzo G, et al. **J Clin Ultrasound** 1995 Nov-Dec;23(9):525–9

Role of transvaginal sonography in pelvic scan for female reproductive system. Das KK, et al. **J Indian Med Assoc** 1995 Aug;93(8):301–4, 309

Subchorionic placental cyst: a cause of fetal growth retardation—ultrasound and color-flow Doppler diagnosis and follow-up. Raga F, et al. **J Natl Med Assoc** 1996 May; 88(5):285–8

Use of ultrasonography for the evaluation of pregnant trauma patients. Ma OJ, et al. **J Trauma** 1996 Apr;40(4):665–8

The significance of high umbilical venous blood flow measurements in a high-risk population. Challis DE, et al. **J Ultrasound Med** 1995 Dec;14(12):907–12

Doppler sonography in the diagnosis of antepartum pyelonephritis: value of intrarenal resistive index measurements. Keogan MT, et al. **J Ultrasound Med** 1996 Jan;15(1):13–7

Perinatal diagnostic evaluation of velamentous umbilical cord insertion: clinical, Doppler, and ultrasonic findings. Heinonen S, et al. **Obstet Gynecol** 1996 Jan;87(1):112–7

First-trimester ultrasound: the essentials. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):2–14 (64 ref.)

Sonography of pregnancies with first-trimester bleeding and a viable embryo: a study of prognostic indicators by logistic regression analysis. Falco P, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):165–9

Urinary calculus in pregnancy. Silver DA, et al. **Urology** 1996 Jun;47(6):920

[Changes in the position of the urethra and bladder neck during pregnancy and after delivery] Martan A, et al. **Ceska Gynekol** 1996 Feb;61(1):35–9 (Eng. Abstr.) **(Cze)**

[A case of detection of pulmonary sequestration during the early stage of pregnancy and subsequent successful therapy] Hajdú H, et al. **Orv Hetil** 1996 May 5;137(18):975–8 (Eng. Abstr.) **(Hun)**

[Malignant sacrococcygeal teratoma: report of a case of "explosive" intrauterine growth] Battaglino F, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):95–8 (Eng. Abstr.) **(Ita)**

[Syndrome of the abdominal rectus muscle monitored ultrasonographically during pregnancy] Nowocień B, et al. **Ginekol Pol** 1995 Nov;66(11):649–50 (Eng. Abstr.) **(Pol)**

[A case of Prune Belly Syndrome. Prenatal diagnosis] Montoya S, et al. **Ginecol Obstet Mex** 1995 Sep;63:382–4 (Eng. Abstr.) **(Spa)**

URINE

[Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)] Radici E, et al. **Minerva Ginecol** 1996 Jan–Feb; 48(1–2):5–9 (Eng. Abstr.) **(Ita)**

VETERINARY

Effect of overcrowding on claw health in first-calved Friesian heifers. Leonard FC, et al. **Br Vet J** 1996 Jul; 152(4):459–72

Cecal impaction in a cow. Desrochers A, et al. **Can Vet J** 1995 Jul;36(7):430–1

Prevalence of lesions associated with subclinical laminitis in first-lactation cows from herds with high milk production. Smilie RH, et al. **J Am Vet Med Assoc** 1996 May 1; 208(9):1445–51

Use of performance ratios to calculate the economic impact of thin cows in a beef cattle herd. Wikse SE, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1292–7

Lead poisoning and toxicokinetics in a heifer and fetus treated with CaNa2 EDTA and thiamine. O'Hara TM, et al. **J Vet Diagn Invest** 1995 Oct;7(4):531–7

[A horse with chronic eosinophilic enteritis] van der Kolk JH, et al. **Tijdschr Diergeneeskd** 1995 Dec 1;120(23):680–2 (Eng. Abstr.) **(Dut)**

[Intestinal perforation in a llama mare following rectal palpation (veterinary expert opinion)] Steffen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):330–1 (Eng. Abstr.) **(Ger)**

[Iodine deficiency in goats as a cause of congenital goiter

in kids] Bíreš J, et al. **Vet Med (Praha)** 1996 May; 41(5):133–8 (Eng. Abstr.) **(Slo)**

VIROLOGY

Mother–to–infant transmission of hepatitis C virus: a prospective study. Matsubara T, et al. **Eur J Pediatr** 1995 Dec;154(12):973–8

PREGNANCY COMPLICATIONS, CARDIOVASCULAR

Severely impaired fetal growth is preceded by maternal hemodynamic maladaptation in very early pregnancy. Duvekot JJ, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):693–7

Preeclampsia and hypertensive disorders of pregnancy. Zamorski MA, et al. **Am Fam Physician** 1996 Apr; 53(5):1595–610 (32 ref.)

Peripartum cardiomyopathy. Lampert MB, et al. **Am Heart J** 1995 Oct;130(4):860–70 (80 ref.)

Emergency! Thoracic aortic dissection. Ortiz AC. **Am J Nurs** 1996 Jun;96(6):50

Monitored outpatient management of mild gestational hypertension remote from term in teenage pregnancies. Barton JR, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1865–8

Spontaneous uterine rupture and hemoperitoneum in the first trimester. Dibbs KI, et al. **Am J Perinatol** 1995 Nov; 12(6):439–41

Endocardial fibroelastosis: an unusual cause of pulmonary hypertension in pregnancy. Mandel RI, et al. **Am J Perinatol** 1995 Sep;12(5):319–21

Infiltration anaesthesia in the management of Caesarean section in a patient with peripartum cardiomyopathy [letter] Mellor DJ, et al. **Anaesthesia** 1996 Apr;51(4):409

Magnesium sulfate adversely affects fetal lamb survival and blocks fetal cerebral blood flow response during maternal hemorrhage. Reynolds JD, et al. **Anesth Analg** 1996 Sep; 83(3):493–9

Acute myocardial infarction during pregnancy and puerperium: a review. Badui E, et al. **Angiology** 1996 Aug; 47(8):739–56 (128 ref.)

Effects of maternal hypertension in very–low–birth–weight infants. Kim CR, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):686–91

Elective forceps delivery and extradural anaesthesia in a primigravida with portal hypertension and oesophageal varices. Heriot JA, et al. **Br J Anaesth** 1996 Feb;76(2):325–7

Pregnancy complicated by aortic dissection: caesarean delivery during extradural anaesthesia. Jayaram A, et al. **Br J Anaesth** 1995 Sep;75(3):358–60

Pregnancy and heart disease. Oakley CM. **Br J Hosp Med** 1996 Apr 3–16;55(7):423–6 (15 ref.)

Perinatal morbidity in chronic hypertension. McCowan LM, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):123–9

Anaesthetic management for caesarean section in a patient with Kawasaki disease. Alam S, et al. **Can J Anaesth** 1995 Nov;42(11):1024–6

Splenic avulsion in a pregnant patient with vomiting. Nguyen N, et al. **Can J Surg** 1995 Oct;38(5):464–5

Deep venous thrombosis and pulmonary embolism. Brown HL, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):87–100 (70 ref.)

Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small–for–gestational–age births. Ananth CV, et al. **Epidemiology** 1995 Jul;6(4):391–5

Multiple and massive arteriovenous malformations in pregnancy. Geary M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):147–50

Pulmonary hypertension, cardiac disease and pregnancy. Tahir H. **Int J Gynaecol Obstet** 1995 Nov;51(2):109–13

The relationship of sonographic placental grading, biochemical pulmonary maturity and neonatal outcome in pregnancy–induced hypertension. Jana N, et al. **J Indian Med Assoc** 1995 Jul;93(7):262–5

Neonatal neutropenia and thrombocytopenia following maternal hypertension. Fraser SH, et al. **J Paediatr Child Health** 1996 Feb;32(1):31–4

Early neonatal complications after elective preterm delivery in hypertensive pregnancies. Spinillo A, et al. **J Perinat Med** 1995;23(3):175–81

Two successful vaginal deliveries in a heart transplant recipient. Eskandar M, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):880

Perinatal outcome in growth–restricted fetuses: do hypertensive and normotensive pregnancies differ? Piper JM, et al. **Obstet Gynecol** 1996 Aug;88(2):194–9

Postpartum tubal ligation after pregnancy complicated by preeclampsia or gestational hypertension. Vincent RD Jr, et al. **Obstet Gynecol** 1996 Jul;88(1):119–22

Third successful pregnancy and delivery in a patient with permanent junctional reciprocating tachycardia. Yartseva I, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1956–8

Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. Shovlin CL, et al. **QJM** 1995 Dec;88(12):879–87

Fetal growth retardation and increased placental weight in the spontaneously hypertensive rat. Johnston BM. **Reprod Fertil Dev** 1995;7(3):639–45

[Clinical analysis of 62 pregnant women complicated with organic heart diseases] Liu T, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):146–8 (Eng. Abstr.) **(Chi)**

[Analysis for 13 term deliveries after cardiac valve replacement and percutaneous transluminal mitral commissuroplasty] Wang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):12–4 (Eng. Abstr.) **(Chi)**

[Case report 8. Management of the first labor stage in a heart patient without CTG monitoring and without the presence of a physician] **Ceska Gynekol** 1995 Dec;60(6):315–6 **(Cze)**

[Prevention, diagnosis and therapy of thromboembolic complications and disseminated intravascular coagulation in obstetrics] Malý M, et al. **Ceska Gynekol** 1995 Aug; 60(4):217–8 **(Cze)**

[Critical pulmonary edema following cesarean section] Puura A, et al. **Duodecim** 1995;111(3):249–52 **(Fin)**

[Cesarean section and left ventricular failure caused by coronary artery disease: anesthetic management] Guevara–Olivari N, et al. **Ann Fr Anesth Reanim** 1995; 14(5):421–5 (Eng. Abstr.) **(Fre)**

[Post–partum cardiomyopathy: medical aspects, role of heart transplantation] Bertrand E. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1635–40 (42 ref.) (Eng. Abstr.) **(Fre)**

[Aortic dissection and pregnancy. Apropos of a case] Helms E, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):397–9 (Eng. Abstr.) **(Fre)**

[Cerebral venous thrombosis and arterial infarction in pregnancy and puerperium. A series of 60 cases] Ben Hamouda–M'Rad I, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):563–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Acute anterior myocardial infarction in a patient with left atrial myxoma during pregnancy] Manfredini R, et al. **G Ital Cardiol** 1995 Nov;25(11):1419–24 (Eng. Abstr.) **(Ita)**

[Infants born to hypertensive mothers: a clinical–epidemiological study] Manganaro R, et al. **Minerva Ginecol** 1996 Mar;48(3):73–6 (Eng. Abstr.) **(Ita)**

[A case–control study of pregnancy–induced hypertension with a genetic predisposition: association of a molecular variant of angiotensinogen in the Japanese women] Kobashi G. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):649–57 (Eng. Abstr.) **(Jpn)**

[Anesthesia for cesarean section in a patient with intracranial A–V malformation] Terao M, et al. **Masui** 1995 Dec; 44(12):1700–2 (Eng. Abstr.) **(Jpn)**

[Massive hemoptysis caused by disruption of a bronchial aneurysm diagnosed by microscopic examination of the resected lung] Nakamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):721–5 (Eng. Abstr.) **(Jpn)**

[Clinical study on the intracranial arteriovenous malformation associated with pregnancy] Fujita K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1359–64 (Eng. Abstr.) **(Jpn)**

[Supraventricular tachycardia during pregnancy: incidence and therapeutic management (letter)] Rodríguez Blanco VM, et al. **An Med Interna** 1996 Mar;13(3):151–2 **(Spa)**

BLOOD

Hemoglobin concentration in pregnant women. Experience from Moshi, Tanzania. Bergsjo P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):241–4

Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre–eclampsia. Schneider F, et al. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):40–4

Effects of low–dose aspirin therapy on plasma levels of polyunsaturated fatty acids: a preliminary investigation. McCoy MC, et al. **Am J Perinatol** 1995 Sep;12(5):371–4

Lipoprotein levels in patients with pregnancy induced hypertension. Uslu A, et al. **Arch Gynecol Obstet** 1996; 258(1):21–4

Platelet sensitivity to prostaglandin E1 inhibition is reduced in pre–eclampsia but not in nonproteinuric gestational hypertension. Torres PJ, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):19–24

Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Nobunaga T, et al. **Gynecol Obstet Invest** 1996;41(3):189–93

High levels of corticotropin–releasing factor (CRF) are inversely correlated with low levels of maternal CRF–binding protein in pregnant women with pregnancy–induced hypertension. Petraglia F, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):852–6

Second and early third trimester atrial natriuretic peptide (ANP) levels in pregnancies subsequently complicated by hypertension. Chung TK, et al. **J Obstet Gynaecol** 1995 Oct;21(5):515–20

Erythrocyte insulin and insulin–like growth factor–I receptor tyrosine kinase activity in hypertension in pregnancy. Sowers JR, et al. **Metabolism** 1995 Oct;44(10):1308–13

Relationship between elevated lipid peroxides, vitamin E deficiency and hypertension in preeclampsia. Jain SK, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):33–8

Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Hsu CD, et al. **Obstet Gynecol** 1995 Dec;86(6):897–9

Hypertension in pregnancy: changes in activin A maternal serum concentration. Petraglia F, et al. **Placenta** 1995 Jul; 16(5):447–54

[Concentration of lipids and lipoproteins in serum of women with pregnancy induced hypertension] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):72–5 (Eng. Abstr.) **(Pol)**

[Concentration of lipids and lipoproteins in serum of pregnant women with primary hypertension] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):69–71 (Eng. Abstr.) **(Pol)**

[Kidney function in pregnant women with arterial hypertension] Banaczek Z. **Ginekol Pol** 1995 Jan;66(1):5–8 (Eng. Abstr.) **(Pol)**

[The effect of hypertension severity in pregnant women and during birth on renal function] Banaczek Z. **Ginekol Pol** 1995 Jan;66(1):9–12 (Eng. Abstr.) **(Pol)**

[Increased cholesterol in red cell membranes in women with pregnancy induced hypertension] Jendryczko A, et al. **Ginekol Pol** 1996 Feb;67(2):65–9 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease [letter; comment] Schwingl PJ. **Br J Obstet Gynaecol** 1996 Jan;103(1):93–4 . Comment on: Br J Obstet Gynaecol 1995 Feb;102(2):153–9.

DIAGNOSIS

Microalbuminuria as an early predictor of hypertensive complications in pregnant women at high risk. Bar J, et al. **Am J Kidney Dis** 1996 Aug;28(2):220–5

Pregnancy complicated by cerebral venous thrombosis in Behçet's disease. Wechsler B, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1627–9

Pregnancy–induced hypertension or a normal variant? [letter] O'Hanlon J. **Anaesthesia** 1995 Nov;50(11):1014

The risks of delay in diagnosis of breathlessness in pregnancy [see comments] Morley CA, et al. **BMJ** 1995 Oct 21; 311(7012):1083–4. Comment in: BMJ 1996 Feb 10;312(7027):376.

Measuring diastolic blood pressure in pregnancy [editorial] Rubin P. **BMJ** 1996 Jul 6;313(7048):4–5

Microalbuminuria: a predictor of pregnancy–induced hypertension. Das V, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):928–30

K4 or K5 [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Sep;103(9):vii. Comment on: Br J Obstet Gynaecol 1996 Sep;103(9):862–3.

Fetal heart rate monitoring by telephone during pregnancy—opinion of users and non–users of a new technology. Blondel B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):23–7

Peripartum cardiomyopathy complicating severe aortic stenosis. Purcell IF, et al. **Int J Cardiol** 1995 Nov 24; 52(2):163–5; discussion 165–6

Twenty four–hour ambulatory blood pressure monitoring in women with pre–eclampsia. Bellomo G, et al. **J Hum Hypertens** 1995 Aug;9(8):617–21

Rupture of the external iliac artery during pregnancy: a case of type IV Ehlers–Danlos syndrome. Brees CK, et al. **J Ky Med Assoc** 1995 Dec;93(12):553–5

Validity in nulliparas of increased beta–human chorionic gonadotrophin at mid–term for predicting pregnancy–induced hypertension complicated with proteinuria and intrauterine growth retardation. Vaillant P, et al. **Nephron** 1996;72(4):557–63

Determination of mineral, parathyroid hormone, and 6–keto–prostaglandin–F1 alpha levels in pregnant women with hypertension and pre–eclampsia. Sulaiman S, et al. **Singapore Med J** 1995 Dec;36(6):637–40

[Aggravation of supraventricular tachycardia symptoms during pregnancy] Huikuri H, et al. **Duodecim** 1995; 111(4):351–4 **(Fin)**

[Pulmonary embolism and pregnancy: report of a case; review of the literature] Blondel S, et al. **J Mal Vasc** 1995; 20(4):317–22 (20 ref.) (Eng. Abstr.) **(Fre)**

[Emergencies in obstetrics. Pulmonary embolism] Extermann P. **Rev Med Suisse Romande** 1996 Apr;116(4):287 **(Fre)**

[Hypertension in pregnancy] Wight E. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1446–8 (Eng. Abstr.) **(Ger)**

[Arterial hypertension in pregnancy (editorial)] Morgado V. **Acta Med Port** 1996 Jan;9(1):3–5 **(Por)**

[Pregnancy outcomes in women with a pathological weight gain, vascular dysfunction, transitory edemas and transient proteinuria] Lipatov IS, et al. **Akush Ginekol (Mosk)** 1995; (6):16–8 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Anticoagulant therapy in pregnancy. Report of 54 cases. Lecuru f, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):217–21

Does magnesium sulfate affect the length of labor induction in women with pregnancy–associated hypertension? Atkinson MW, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1219–22

Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo–controlled study. Wide–Swensson DH, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):872–8

Accidental nicardipine overdosage without serious maternal or neonatal consequence. Aya AG, et al. **Anaesth Intensive Care** 1996 Feb;24(1):99–101

Adenosine use in a pregnant patient with supraventricular tachycardia [letter] Hagley MT, et al.

Ann Pharmacother 1995 Sep;29(9):938

Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin. Macklon NS, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):672-5

Use of esmolol in a parturient with hypertrophic obstructive cardiomyopathy. Fairley CJ, et al. **Br J Anaesth** 1995 Dec; 75(6):801-4

Deep vein thrombosis in pregnancy and heparin hypersensitivity. Ojukwu C, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):934-6

Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Räsänen J, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):195-201

Calcium supplementation during pregnancy. Melnikow JA. **J Fam Pract** 1996 Aug;43(2):115-6

Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. Jegasothy R, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):21-4

Use of intravenous adenosine triphosphate (ATP) to terminate supraventricular tachycardia in a pregnant woman with Wolff-Parkinson-White syndrome. Kanai M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):95-9

Choice of antihypertensive therapy during pregnancy [letter] Casele HL, et al. **JAMA** 1996 Sep 11;276(10):780

Anticoagulants during pregnancy. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Jan-Feb;20(1):56

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257-65 (93 ref.)

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115-22 (45 ref.)

A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Morris JM, et al. **Obstet Gynecol** 1996 Jan;87(1):74-8

Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Turrentine MA, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):534-41 (52 ref.)

Intraplatelet free calcium and calcium-regulating hormones in plasma are not related to the antihypertensive effect of nifedipine in hypertensive pregnancy. Manninen A, et al. **Pharmacol Toxicol** 1995 Nov;77(5):327-32

Use of urokinase in pregnancy. Two success stories. La Valleur J, et al. **Postgrad Med** 1996 May;99(5):269-70, 272-3

ACE inhibitors in pregnancy--how to avoid the sting in the tail [editorial] Opie LH. **S Afr Med J** 1996 Apr;86(4):326-7

[Thrombolytic therapy with rt-PA for thrombosis of tricuspid valve prosthesis during pregnancy] Azzano O, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):267-70 (Eng. Abstr.) **(Fre)**

[Low-molecular-weight heparin in the prevention of thromboembolism in pregnant thrombophilic patients] Boda Z, et al. **Orv Hetil** 1996 Jan 28;137(4):183-5 (Eng. Abstr.) **(Hun)**

[The role of heparin sulfate in the treatment of pregnant women with circulatory deficiency syndrome] Palmeri MA, et al. **Minerva Ginecol** 1996 Mar;48(3):119-23 (Eng. Abstr.) **(Ita)**

[Changes in cardiohemodynamic indicators during use of verapamil for preventing and treating hypertensive complications of pregnancy] Gromyko GL. **Biull Eksp Biol Med** 1995 Nov;120(11):547-50 **(Rus)**

ECONOMICS

A comparative study of obstetric outcome of patients with pregnancy induced hypertension: economic considerations. Omu AE, et al. **Acta Obstet Gynecol Scand** 1996 May; 75(5):443-8

ENZYMOLOGY

Placental Na+, K+ activated ATP-ase activity in SHRSP in connection with pregnancy induced hypertension and intra-uterine growth retardation. Fuchi I, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S283-5

Nitric oxide synthase activity in placentae from women with pre-eclampsia. Conrad KP, et al. **Placenta** 1995 Dec; 16(8):691-9

[Decreased activity of oxidoreductases in erythrocytes and blood platelets from venous and umbilical blood of women with pregnancy-induced hypertension] Jendryczko A, et al. **Ginekol Pol** 1995 Dec;66(12):656-9 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Hypertensive disorders of pregnancy and stillbirth in North Carolina, 1988 to 1991. Ananth CV, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):788-93

Incidence of pregnancy-induced hypertension among gestational diabetics. Schaffir JA, et al. **Am J Perinatol** 1995 Jul;12(4):252-4

First trimester biological markers for the prediction of pregnancy-induced hypertension. Tomoda S, et al. **Am J Perinatol** 1996 Feb;13(2):89-93

Prevalence of hypertension among women in rural Zimbabwe: a comparison of pregnant and non-pregnant women. Sparks BT, et al. **Cent Afr J Med** 1996 Apr; 42(4):93-7

Epidemiology of low birth weight in an industrial area in India. Misra M, et al. **J Trop Pediatr** 1995 Dec;41(6):374-6

Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. Ananth CV, et al. **Obstet Gynecol** 1996 Aug;88(2):309-18

Maternal hypertension and associated pregnancy complications among African-American and other women in the United States. Samadi AR, et al. **Obstet Gynecol** 1996 Apr;87(4):557-63

[Hypertension associated with pregnancy. Epidemiologic study of 311 consecutive cases] Machado MH, et al. **Acta Med Port** 1996 Jan;9(1):7-14 (Eng. Abstr.) **(Por)**

[Prenatal biopsychosocial risk and preeclampsia] Herrera JA, et al. **Aten Primaria** 1995 Nov 30;16(9):552-5 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Ruptured subcapsular hepatic haematoma secondary to "HELLP syndrome". Majerus B, et al. **Acta Chir Belg** 1995 Nov-Dec;95(6):251-3

Pregnancy related changes in some cardiovascular risk factors. Berge LN, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):439-42

The supine hypotensive syndrome. 1960 [classical article] Holmes F. **Anaesthesia** 1995 Nov;50(11):972-7

Metoclopramide exaggerates stress-induced tachycardia in pregnant sheep. Eisenach JC, et al. **Anesth Analg** 1996 Mar; 82(3):607-11

Cardiac arrest at induction of anaesthesia for Caesarean section [letter] Wilson JA. **Br J Anaesth** 1996 Feb; 76(2):332-3

Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Brenner B, et al. **Br J Haematol** 1996 Jul;94(1):166-7

Maternal congenital heart disease and pregnancy outcome. Chia YT, et al. **J Obstet Gynaecol Res** 1996 Apr; 22(2):185-91

Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception [letter; comment] Robillard PY, et al. **Lancet** 1996 Mar 2;347(9001):619. Comment on: Lancet 1994 Oct 8;344(8928):973-5.

Pregnancy and the risk of stroke. Kittner SJ, et al. **N Engl J Med** 1996 Sep 12;335(11):768-74

Acute pulmonary oedema in late pregnancy. O'Mahony D, et al. **Postgrad Med J** 1995 Sep;71(839):571-3

When is hypertension a cause for concern? Redman C. **Practitioner** 1996 Apr;240(1561):264-8 (0 ref.)

[Rendu-Osler-Weber disease and intracranial hemorrhage during pregnancy. A case report] Gillard P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):294-6 (Eng. Abstr.) **(Fre)**

[Significance of doppler ultrasound examination in successful termination of pregnancy with arterial hypertension in the course of chronic proliferative glomerulonephritis] Mizgiert W, et al. **Ginekol Pol** 1995 May;66(5):297-301 (Eng. Abstr.) **(Pol)**

[The role of endothelial dysfunction in the genesis of hypertensive states in pregnant women] Supriaga OM. **Akush Ginekol (Mosk)** 1995;(6):5-9 (40 ref.) **(Rus)**

[The effect of blood loss on hemostatic regulation by the lungs in puerperae with gestoses complicated by acute kidney failure] Muradov MK, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):33-6 **(Rus)**

IMMUNOLOGY

Studies of natural killer cells in pregnancy-induced hypertension. Peraçoli JC, et al. **Braz J Med Biol Res** 1995 Jun;28(6):655-61

Immunoglobulin G and complement C3 levels in pregnancy induced hypertension. Ramdenee GR, et al. **Indian Pediatr** 1995 Feb;32(2):179-83

Successful pregnancy in a Churg-Strauss syndrome patient with a history of intrauterine fetal death. Ogasawara M, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):200-2

Anticardiolipin antibodies and cardiovascular disease [letter; comment] Nelson-Piercy C, et al. **J R Soc Med** 1996 Feb; 89(2):119. Comment on: J R Soc Med 1995 Aug;88(8):433-6.

Relationship between lupus anticoagulant (LAC) and pregnancy-induced hypertension. Matsumoto T, et al. **Reprod Fertil Dev** 1995;7(6):1569-71

METABOLISM

Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Bourget P, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):233-41

Epidermal growth factor receptors in placentae and fetal membranes from hypertension-complicated pregnancies. Ferrandina G, et al. **Hum Reprod** 1995 Jul;10(7):1845-9

Dynamic parameters of maternal amino acid metabolism and fetal growth. Hod M, et al. **Isr J Med Sci** 1996 Jul; 32(7):530-6

Placental prostanoid release in severe intrauterine growth retardation. Sorem KA, et al. **Placenta** 1995 Sep; 16(6):503-15

Alterations of intrauterine eicosanoid production in pregnancy-induced hypertension: decreased production of 12-hydroxyeicosatetraenoic acid in the placenta. Arbogast E, et al. **Prostaglandins** 1996 Feb;51(2):125-37

Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504-11 (51 ref.)

MORTALITY

Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Jónsdóttir LS, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):772-6

PATHOLOGY

Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Cusick W, et al. **Am J Reprod Immunol** 1995 Sep;34(3):141-7

Placental bed lesions and infant birth weight in hypertensive pregnant women. Ramos JG, et al. **Braz J Med Biol Res** 1995 Apr;28(4):447-55

Studies on pregnancy hypertension and IUGR-SFD: effects of drugs on the blood vessels in the placenta of pregnant SHRSP. Fuchi I, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S286-7

Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611-29 (73 ref.)

Morpho-functional modifications of human syncytiotrophoblast plasma membrane during pregnancy induced hypertension. Biagini G, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):15-20

PHYSIOPATHOLOGY

Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Lee SH, et al. **Am J Cardiol** 1995 Oct 1;76(10):675-8

Blood pressure and renal function seven years after pregnancy complicated by hypertension. Nisell H, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):876-81

Hypertensive and normal pregnancy: a longitudinal study of blood pressure, distensibility of dorsal hand veins and the ratio of the stable metabolites of thromboxane A2 and prostacyclin in plasma. Smith AJ, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):900-6

Invited editorial on "effect of altitude on uterine artery blood flow during normal pregnancy" and "alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude" [editorial; comment] Clark KE. **J Appl Physiol** 1995 Jul;79(1):5-6. Comment on: J Appl Physiol 1995 Jul;79(1):7-14. Comment on: J Appl Physiol 1995 Jul;79(1):15-22.

Alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude [see comments] Zamudio S, et al. **J Appl Physiol** 1995 Jul; 79(1):15-22. Comment in: J Appl Physiol 1995 Jul;79(1):5-6.

Characteristics of a reversed circadian blood pressure rhythm in pregnant women with hypertension. Olofsson P. **J Hum Hypertens** 1995 Jul;9(7):565-70

Apparatus for home monitoring of pregnant hypertensive patients. Hon EH, et al. **J Matern Fetal Med** 1996 Jan-Feb; 5(1):45-9

Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Kanfer A, et al. **Lab Invest** 1996 Jan; 74(1):253-8

The semantics of pressure [comment] Mathews D. **Lancet** 1996 Jan 20;347(8995):135-6. Comment on: Lancet 1996 Jan 20;347(8995):139-42.

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414-8 (46 ref.)

The pregnant patient with an intracranial arteriovenous malformation. Cesarean or vaginal delivery using regional or general anesthesia? Sharma SK, et al. **Reg Anesth** 1995 Sep-Oct;20(5):455-8

[Hypertension and pregnancy. Diagnosis, physiopathology and treatment] Fournier A, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2273-98 (145 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in patients with congenital heart defect] Schlemmer M. **Wien Klin Wochenschr** 1995;107(20):608-12 (20 ref.) (Eng. Abstr.) **(Ger)**

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep-Oct;199(5):195-8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Blood circulation in retarded and normal offspring of hypertonic pregnant women] Jakobovits A, et al. **Orv Hetil** 1996 Apr 14;137(15):793-7 (46 ref.) (Eng. Abstr.) **(Hun)**

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70-4 (23 ref.) **(Spa)**

PREVENTION & CONTROL

Heparin levels to guide thromboembolism prophylaxis during pregnancy. Barbour LA, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1869-73

Hereditary angioedema: prophylaxis management in the puerperium [letter] Hawthorne LA, et al. **Anaesthesia** 1996 Mar;51(3):283-4

Thrombosis and embolism. Horn EH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):595-618 (95 ref.)

Obstetric thromboprophylaxis. Nelson-Piercy C. **Br J Hosp Med** 1996 Apr 3-16;55(7):404-8

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [letter; comment] Goffinet F, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):719-20. Comment on: Br J Obstet Gynaecol 1996 Jan;103(1):39-47.

Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses [see comments] Salazar E, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1698-703 . Comment in: J Am Coll Cardiol 1996 Jun;27(7):1704-6.

Prevention of pregnancy-induced hypertension by calcium dietary supplement: a preliminary report. Tomoda S, et al. **J Obstet Gynaecol** 1995 Jun;21(3):281-8

Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials [see comments] Bucher HC, et al. **JAMA** 1996 Apr 10;275(14):1113-7. Comment in: JAMA 1996 Apr 10;275(14):1128-9.

Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68-72 (73 ref.)

[Cholesterol levels in young men and women planning conception] Czeizel E, et al. **Orv Hetil** 1996 Jan 21; 137(3):125-8 (Eng. Abstr.) **(Hun)**

SURGERY

Umbilical artery flow velocity during maternal cardiopulmonary bypass. Goldstein I, et al. **Ann Thorac Surg** 1995 Oct;60(4):1116-8

Traumatic rupture of the thoracic aorta during the second trimester of pregnancy. Lemermeyer G, et al. **Ann Thorac Surg** 1996 May;61(5):1541-3

Cardiopulmonary bypass during pregnancy. Parry AJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1865-9 (47 ref.)

Cardiopulmonary bypass in pregnancy. Pomini F, et al. **Ann Thorac Surg** 1996 Jan;61(1):259-68 (65 ref.)

The long-term outcome of proximal vein thrombosis during pregnancy is not improved by the addition of surgical thrombectomy to anticoagulant treatment. Törngren S, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):31-6

Laparoscopic unwinding of hyperstimulated ischaemic ovaries during the second trimester of pregnancy. Levy T, et al. **Hum Reprod** 1995 Jun;10(6):1478-80

Intrauterine pregnancy and aortic valve replacement [clinical conference] Paulus DA, et al. **J Clin Anesth** 1995 Jun; 7(4):338-46

[Cesarean section in severe double valvular disease] Ilkjaer S, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2552-3 (Eng. Abstr.) **(Dan)**

[Heart surgery with extracorporeal circulation in pregnant women. Analysis of materno-fetal outcome (see comments)] Born D, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):207-11 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Mar;64(3):263-4. **(Por)**

[Heart surgery with extracorporeal circulation in pregnant women (editorial; comment)] Grinberg M, et al. **Arq Bras Cardiol** 1995 Mar;64(3):263-4. Comment on: Arq Bras Cardiol 1995 Mar;64(3):207-11. **(Por)**

THERAPY

ACOG report addresses hypertension in pregnancy. **Am Fam Physician** 1996 Sep 1;54(3):1112, 1115

Treatment of arrhythmias during pregnancy. Page RL. **Am Heart J** 1995 Oct;130(4):871-6 (50 ref.)

Spontaneous hepatic hemorrhage associated with pregnancy. Treatment by hepatic arterial interruption. Stain SC, et al. **Ann Surg** 1996 Jul;224(1):72-8

Primary angioplasty using a urokinase-coated hydrogel balloon in acute myocardial infarction during pregnancy. Glazier JJ, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):216-9

Interventional cardiology in pregnancy. Presbitero P, et al. **Eur Heart J** 1996 Feb;17(2):182-8 (104 ref.)

Care of the patient with severe pregnancy induced hypertension. Walker JJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):127-35 (34 ref.)

ACOG technical bulletin. Hypertension in pregnancy. Number 219--January 1996 (replaces no. 91, February 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 May;53(2):175-83

The expanded role of coronary angioplasty during pregnancy. Mardini AH, et al. **J Tenn Med Assoc** 1995 Nov;88(11):423-4

Venous thromboembolism during pregnancy. Toglia MR, et al. **N Engl J Med** 1996 Jul 11;335(2):108-14 (70 ref.)

Acute myocardial infarction in pregnancy with subsequent medical and surgical management. Garry D, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):802-4

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):205-20 (38 ref.)

[Balloon mitral valve commissurotomy in pregnancy] Burger W, et al. **Dtsch Med Wochenschr** 1996 Mar 8; 121(10):299-302 (Eng. Abstr.) **(Ger)**

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561-6 (45 ref.) (Eng. Abstr.) **(Hun)**

[Hypertension in pregnancy: management protocols and pregnancy outcome followed at our ambulatory service] Frusca T, et al. **Minerva Ginecol** 1995 May;47(5):215-22 (Eng. Abstr.) **(Ita)**

[Complete heart block treated with electrotherapy in a 30-year-old pregnant women with Kearns-Sayre syndrome] Sworczak K, et al. **Pol Arch Med Wewn** 1995 Sep;94(3):267-74 (Eng. Abstr.) **(Pol)**

[Vulvar varices] Labaš P, et al. **Ceska Gynekol** 1995 Aug; 60(4):200-1 (Eng. Abstr.) **(Slo)**

[Treatment of cardiac arrhythmias during pregnancy] Rodríguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29-36 (125 ref.) **(Spa)**

ULTRASONOGRAPHY

Vasa praevia: second trimester diagnosis using colour flow imaging. Daly-Jones E, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):284-6

Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. Desai DK, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):523-8

Prenatal diagnosis of tetralogy of Fallot with absent pulmonary valve. Rane HS, et al. **Indian Heart J** 1995 Jul-Aug;47(4):375-7

Congenital left ventricular aneurysm causing hydrops fetalis: prenatal diagnosis with color Doppler ultrasonography. Sepulveda W, et al. **J Ultrasound Med** 1996 Apr; 15(4):327-31

Abnormal umbilical artery Doppler waveforms and cord blood corticotropin-releasing hormone. Giles WB, et al. **Obstet Gynecol** 1996 Jan;87(1):107-11

Subchorionic hemorrhage in first-trimester pregnancies: prediction of pregnancy outcome with sonography. Bennett GL, et al. **Radiology** 1996 Sep;200(3):803-6

[Pregnancy in Takayasu arteritis] Bloechle M, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):116-9 (Eng. Abstr.) **(Ger)**

[Ultrasonographic evaluation of pelvis minor and lower extremity veins during pregnancy and puerperium] Stefańczyk L, et al. **Ginekol Pol** 1996 Feb;67(2):82-7 (Eng. Abstr.) **(Pol)**

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649-56 (110 ref.)

Increased aldosterone-18-glucuronide/tetrahydroaldosterone ratios in pregnancy. Wacker J, et al. **Endocr Res** 1995 Feb-May; 21(1-2):197-202

Use of the protein/creatinine ratio of a single voided urine specimen in the evaluation of suspected pregnancy-induced hypertension. Young RA, et al. **J Fam Pract** 1996 Apr; 42(4):385-9

PREGNANCY COMPLICATIONS, HEMATOLOGIC

A case of pregnancy associated with cyclic neutropenia. Yoshida Y, et al. **Acta Obstet Gynecol Scand** 1995 Nov; 74(10):836-8

Prenatal diagnosis of intracranial hemorrhage secondary to maternal idiopathic thrombocytopenic purpura: a case report. Tampakoudis P, et al. **Am J Perinatol** 1995 Jul; 12(4):268-70

Epidural caesarean section in a patient with congenital antithrombin III deficiency. Rowbottom SJ. **Anaesth Intensive Care** 1995 Aug;23(4):493-5

The cocaine-abusing parturient is not at an increased risk for thrombocytopenia. Gershon RY, et al. **Anesth Analg** 1996 Apr;82(4):865-6

Failure of immunoglobulins to prevent neonatal thrombocytopenia in mothers with immunothrombocytopenic purpura. Zuppa AA, et al. **Biol Neonate** 1995;67(6):450-2

Sickle cell disease and pregnancy. Koshy M. **Blood Rev** 1995 Sep;9(3):157-64 (60 ref.)

Megaloblastic anemia in pregnancy. Campbell BA. **Clin Obstet Gynecol** 1995 Sep;38(3):455-62 (44 ref.)

Thalassemia in pregnancy. Kilpatrick SJ, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):485-96 (62 ref.)

Hemolytic anemias in pregnancy. Leduc L. **Clin Obstet Gynecol** 1995 Sep;38(3):463-71 (44 ref.)

Management of disseminated intravascular coagulopathy. Richey ME, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):514-20 (19 ref.)

Inherited disorders of coagulation in pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):497-513 (81 ref.)

Pregnancy complicated by sickle hemoglobinopathy. Rust OA, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):472-84 (42 ref.)

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535-46 (26 ref.)

Iron deficiency anemia in pregnancy. Schwartz WJ 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):443-54 (45 ref.)

Management of the obstetric patient with thrombocytopenia. Sullivan CA, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):521-34 (39 ref.)

Management of the Rh-sensitized mother. Gollin YG, et al. **Clin Perinatol** 1995 Sep;22(3):545-59 (45 ref.)

Anemia of pregnancy. Mani S, et al. **Clin Perinatol** 1995 Sep; 22(3):593-607 (41 ref.)

Anaemia in pregnancy: perceptions of patients in Dar-es-Salaam. Massawe S, et al. **East Afr Med J** 1995 Aug;72(8):498-503

Essential thrombocythemia and pregnancy [letter; comment] Pardini S, et al. **Haematologica** 1995 Jul-Aug;80(4):392-3 . Comment on: Haematologica 1994 Jul-Aug;79(4):360-3.

Successful pregnancy in a patient with hemolytic-uremic syndrome during the second trimester of pregnancy. Martínez-Román S, et al. **J Reprod Med** 1996 Mar; 41(3):211-4

Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Smith JA, et al. **Obstet Gynecol** 1996 Feb;87(2):199-204

[Prevention, diagnosis and therapy of thromboembolic complications and disseminated intravascular coagulation in obstetrics] Malý M, et al. **Ceska Gynekol** 1995 Aug; 60(4):217-8 **(Cze)**

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860-2 (9 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child] Zahner J, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1517-23 (55 ref.) **(Ger)**

[Hereditary antithrombin III deficiency. Report of an obstetric case and review of the literature] Leal-Tijerina G, et al. **Ginecol Obstet Mex** 1996 Apr;64:177-83 (18 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Pregnancy associated alpha-glycoprotein (SP-III) in Nigerian pregnant women. Onyemelukwe GC, et al. **Afr J Med Med Sci** 1995 Mar;24(1):17-20

Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Hirsch DR, et al. **Am Heart J** 1996 Jun; 131(6):1145-8

Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia [see comments] Shpilberg O, et al. **Br J Haematol** 1996 Feb;92(2):491-3. Comment in: Br J Haematol 1996 Jun 2;93(4):977.

Optimal haematocrit and haemoglobin S levels in pregnant women with sickle cell disease. Howard RJ, et al. **Clin Lab Haematol** 1995 Jun;17(2):157-61

Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Janes SL, et al. **Thromb Haemost** 1995 Oct;74(4):1059-63

[The effect of the diet on the iron status and incidence of anemia in pregnant women] Ivanova L, et al. **Akush Ginekol (Sofiia)** 1995;34(1):6-8 (Eng. Abstr.) **(Bul)**

[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy--comparing normal pregnancy and toxemia of pregnancy] Murakami M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):177-83 (Eng. Abstr.) **(Jpn)**

[Comprehensive laboratory diagnosis of intravascular blood coagulation syndrome in late gestosis] Lukinova NI, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):99-103 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Thrombocytopenia in pregnant women who use cocaine. Kain ZN, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):885-90

Effective treatment of drug-induced agranulocytosis using recombinant human granulocyte colony stimulating factor in pregnancy. Fujiwaki R, et al. **Gynecol Obstet Invest** 1995; 40(4):276-7

[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691-6 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Diagnosis of APC Resistance during pregnancy [letter] Cumming AM, et al. **Br J Haematol** 1996 Mar;92(4):1026-9

Prenatal diagnosis of hematologic disorders. Phillips OP, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):558-72 (30 ref.)

Screening for anemia in pregnancy with copper sulfate densitometry. Pistorius LR, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):33-6

Sickle cell thalassemia in pregnancy: a case report. Carpani G, et al. **J Matern Fetal Med** 1996 Jan-Feb;5(1):28-30 -Case report of clinical and pathophysiological similarities of Moschkowitz disease and HELLP syndrome- Kaiser C, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):101-4 (Eng. Abstr.) **(Ger)**

[Beta-thalassemia and pregnancy: 2 rare cases] Fistarol M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):29-32 (Eng. Abstr.) **(Ger)**

[Reversible cerebral MRI findings in acute microangiopathic hemolytic anemia] Horn M, et al. **Nervenarzt** 1996 Jun; 67(6):502-5 (Eng. Abstr.) **(Ger)**

PREGNANCY COMPLICATIONS, HEMATOLOGIC

DRUG THERAPY

Refractory thrombotic thrombocytopenic purpura treated with cyclosporine [letter] Bachman WR, et al. **Am J Hematol** 1996 Jan;51(1):93–4

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta–thalassemia patients during pregnancy [letter] Bourantas K, et al. **Eur J Haematol** 1996 May;56(5):326–8

Treating the anaemia of a pregnancy with heterozygous beta thalassaemia with recombinant human erythropoietin (r–HuEPO) [letter] Juncà J, et al. **Eur J Haematol** 1995 Oct;55(4):277–8

Effective treatment of drug–induced agranulocytosis using recombinant human granulocyte colony stimulating factor in pregnancy. Fujiwaki R, et al. **Gynecol Obstet Invest** 1995; 40(4):276–7

Danazol for thrombocytopenia in pregnancy with underlying systemic lupus erythematosus. Insiripong S, et al. **J Med Assoc Thai** 1996 May;79(5):330–2

Vincristine for refractory autoimmune thrombocytopenic purpura in pregnancy. A case report. Gross Z, et al. **J Reprod Med** 1995 Oct;40(10):739–42

Anticoagulants during pregnancy. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):56

Erythropoietin treatment of erythropoietin–deficient anemia without renal disease during pregnancy. Harris SA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):812–4

The effects of long–term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Douketis JD, et al. **Thromb Haemost** 1996 Feb;75(2):254–7

[Iron and pregnancy] Beaufrère B, et al. **Arch Pediatr** 1995 Dec;2(12):1209–18 (65 ref.) (Eng. Abstr.) **(Fre)**

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Thrombotic risk during pregnancy and puerperium in women with APC–resistance—effective subcutaneous heparin prophylaxis in a pregnant patient [letter] De Stefano V, et al. **Thromb Haemost** 1995 Aug;74(2):793–4

ETIOLOGY

Factor XI deficiency in a Bedouin family [letter] Hatskelzon L, et al. **Am J Hematol** 1996 Jun;52(2):121

Arg506–Gln mutation in factor V and risk of thrombosis during pregnancy. Bokarewa MI, et al. **Br J Haematol** 1996 Feb;92(2):473–8

Severe recurrent epistaxis causing antepartum fetal distress [letter] Braithwaite JM, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):197–8

Successful pregnancy following aplastic anaemia. Leong KW, et al. **Postgrad Med J** 1995 Oct;71(840):625–7

The aetiology of anaemia in pregnancy in West Africa. van den Broek N. **Trop Doct** 1996 Jan;26(1):5–7 (16 ref.)

[A case of citrullinemia repeatedly induced by pregnancy] Ohta N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May;48(5):351–4 **(Jpn)**

IMMUNOLOGY

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti–D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777–83 (30 ref.)

Antiplatelet antibody testing in thrombocytopenic pregnant women. Lescale KB, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):1014–8

Chorionic villus sampling and materno–fetal transfusions: an immunological pathogenesis of vascular disruptive syndromes? Los FJ, et al. **Prenat Diagn** 1996 Mar; 16(3):193–8

[Neonatal alloimmune thrombocytopenia. Diagnosis and follow–up in pregnancy] Husebekk A, et al. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1219–22 (Eng. Abstr.) **(Nor)**

PATHOLOGY

Placental histomorphometry and morphometric diffusing capacity of the villous membrane in pregnancies complicated by maternal iron–deficiency anemia. Reshetnikova OS, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):724–7

PHYSIOPATHOLOGY

Intra–amniotic maternal hemorrhage in preterm labor: a case report. Kurata H, et al. **J Perinat Med** 1995;23(3):229–32

PREVENTION & CONTROL

Anthelmintic therapy and iron supplementation of pregnant women [letter; comment] Pawlowski ZS. **Am J Clin Nutr** 1995 Nov;62(5):1023–4. Comment on: Am J Clin Nutr 1994 Aug;60(2):286–92.

Iron supplementation during pregnancy: is it effective? [editorial; comment] Yip R. **Am J Clin Nutr** 1996 Jun; 63(6):853–5. Comment on: Am J Clin Nutr 1996 Jun;63(6):884–90.

Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107–11 (54 ref.)

Operational problems of an iron supplementation programme for pregnant women: an assessment of UNRWA experience. Pappagallo S, et al. **Bull World Health Organ** 1996;74(1):25–33

Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317–9 (22 ref.)

Impact of nutritional supplements on hematological profile of pregnant women. Chawla PK, et al. **Indian Pediatr** 1995 Aug;32(8):876–80

ACOG technical bulletin. Hemoglobinopathies in pregnancy. Number 220—February 1996 (replaces no. 185, October 1993). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 May;53(2):184–94

Screening criteria for beta thalassaemia trait in pregnant women. Rogers M, et al. **J Clin Pathol** 1995 Nov; 48(11):1054–6

Guidelines for dietary supplementation of pregnant women in a Rwandan refugee camp. Duckett JR. **J R Army Med Corps** 1996 Feb;142(1):13–4

Rho (D) immune globulin i.v. for prevention of Rh isoimmunization and for treatment of ITP. **Med Lett Drugs Ther** 1996 Jan 19;38(966):6–8

The role of discriminant functions in screening for beta–thalassaemia traits during pregnancy. Yeo GS, et al. **Singapore Med J** 1995 Dec;36(6):615–8

Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Bauer KA. **Thromb Haemost** 1995 Jul;74(1):94–100 (93 ref.)

[Are there grounds for iron supplementation? (letter)] Hemminki E. **Duodecim** 1994;110(19):1812–3; discussion 1814–5 **(Fin)**

[Mothers and iron (letter)] Pakkala S. **Duodecim** 1994; 110(19):1811–2; discussion 1814–5 **(Fin)**

[Iron prophylaxis and maternal hematological levels during pregnancy] Siimes MA, et al. **Duodecim** 1994; 110(14):1329–32 **(Fin)**

RADIOGRAPHY

[Recurrent thromboses in a 32–year–old pregnant patient with permanent vena cava filter] Kröger K, et al. **Vasa** 1995;24(4):385–8 (Eng. Abstr.) **(Ger)**

THERAPY

Childbearing age patients with essential thrombocythemia: should they be placed on interferon? [letter] Díez–Martín JL, et al. **Am J Hematol** 1996 Aug;52(4):331–2

Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies. Ezra Y, et al. **Am J Hematol** 1996 Jan; 51(1):1–6 (21 ref.)

Advantages of larger volume, less frequent intrauterine red blood cell transfusions for maternal red cell alloimmunization. Inglis SR, et al. **Am J Perinatol** 1996 Jan;13(1):27–33

Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Mokrzycki MH, et al. **Blood Purif** 1995;13(5):271–82 (100 ref.)

Platelet storage pool deficiency in pregnancy. Edozien LC, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):220

Pregnancy in women with essential thrombocythaemia [letter; comment] Frezzato M, et al. **Br J Haematol** 1996 Jun 2;93(4):977. Comment on: Br J Haematol 1996 Feb;92(2):491–3.

Platelet counts during pregnancy in essential thrombocythaemia treated with recombinant alpha–interferon [letter] Pulik M, et al. **Br J Haematol** 1996 May;93(2):495

Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Howard RJ, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):947–51

Transfusion therapy in pregnancy. Naef RW 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):547–57 (29 ref.)

Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon–alpha 2a. Milano V, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):74–8 (30 ref.)

Treatment of essential thrombocythemia during pregnancy with interferon–alpha. Delage R, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):814–7 (15 ref.)

Implementation of the rhesus prevention programme: a prospective study [see comments] Ghosh S, et al. **Scott Med J** 1994 Oct;39(5):147–9. Comment in: Scott Med J 1994 Oct;39(5):138.

Anti–D (again!)—tell me the old, old story... [comment] Mitchell R. **Scott Med J** 1994 Oct;39(5):138. Comment on: Scott Med J 1994 Oct;39(5):147–9.

[Willebrand's disease and pregnancy. Fifteen cases] Depret–Mosser S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):405–10 (Eng. Abstr.) **(Fre)**

[Blood transfusion in benign obstetric–gynecologic disorders] Barbieri F, et al. **Minerva Ginecol** 1995 Sep;47(9):365–8 (Eng. Abstr.) **(Ita)**

[The management of pregnancy with hereditary spherocytosis] Yamada H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):73–6 **(Jpn)**

PREGNANCY COMPLICATIONS, INFECTIOUS

Measles in pregnancy. Kamaci M, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):307–9

Characteristics of pregnant HIV–1 infected women in Europe. European Collaborative Study. Thorne C, et al. **AIDS Care** 1996 Feb;8(1):33–42

Consumer campaign is directed at women with HIV or AIDS [news] **Am Fam Physician** 1996 Feb 1;53(2):466

Comparison of methods of estimating the mother–to–child transmission rate of human immunodeficiency virus type 1 (HIV–1). New York City Perinatal HIV Transmission Collaborative Study Group. Matheson PB, et al. **Am J Epidemiol** 1995 Oct 1;142(7):714–8

The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Meis PJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1231–5

Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Regan JA, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1354–60

Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type–1. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):42–9

Maternal HIV infection, drug use, and growth of uninfected children in their first 3 years. Ross A, et al. **Arch Dis Child** 1995 Dec;73(6):490–5

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1–19 (166 ref.)

Listeria septicaemia in a young healthy pregnant woman. Kurup A, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):316–7

Recent advances in obstetrics. Transmission of HIV from mother to infant depends on many factors [letter; comment] [see comments] Berer M. **BMJ** 1996 Feb 10; 312(7027):379–80. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

Anaesthetic management of caesarean section in a patient with active recurrent genital herpes and AIDS–related dementia. Birnbach DJ, et al. **Br J Anaesth** 1995 Nov; 75(5):639–41

The management of recurrent genital herpes infection in pregnancy: a postal survey of obstetric practice [letter] Jolly J. **Br J Obstet Gynaecol** 1996 Jul;103(7):722–3

Tuberculosis during pregnancy. Addis A, et al. **Can Fam Physician** 1996 Aug;42:1461–2

Lower lung field tuberculosis in Yaounde, Cameroon. Kuaban C, et al. **Cent Afr J Med** 1996 Mar;42(3):62–5

Kaposi's sarcoma in a two week old infant born to a mother with Kaposi's sarcoma/AIDS. McCarty KA, et al. **Cent Afr J Med** 1995 Oct;41(10):330–1

The value of placental pathology in studies of spontaneous prematurity. Salafia CM, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):89–98

Prenatal stroke associated with maternal parvovirus infection [letter] Craze JL, et al. **Dev Med Child Neurol** 1996 Jan; 38(1):84–5

Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood–onset IDDM. Dahlquist G, et al. **Diabetologia** 1995 Nov;38(11):1371–3

Varicella and pregnancy. Dufour P, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):119–23

The management of pregnancy and delivery in HIV–infected women in Europe. Scaravelli G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):7–13

HIV infection and maternal outcome of pregnancy in Mozambican women: a case–control study [letter] Bergström S, et al. **Genitourin Med** 1995 Oct;71(5):323–4

Infectious processes: an infrequent cause of first trimester spontaneous abortions. Simpson JL, et al. **Hum Reprod** 1996 Mar;11(3):668–72

Pregnancy and leprosy neuropathy. Duncan ME. **Indian J Lepr** 1996 Jan–Mar;68(1):23–34 (34 ref.)

Experimental genital mycoplasmosis: time of infection influences pregnancy outcome. Brown MB, et al. **Infect Immun** 1996 Jun;64(6):2315–21

Pregnancy failure following vaginal infection of sheep with Chlamydia psittaci prior to breeding. Papp JR, et al. **Infect Immun** 1996 Apr;64(4):1116–25

The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi. Taha TE, et al. **Int J Epidemiol** 1995 Oct; 24(5):1022–9

Granuloma inguinale in association with pregnancy and HIV infection. Hoosen AA, et al. **Int J Gynaecol Obstet** 1996 May;53(2):133–8

Maternal brain death during pregnancy. Vives A, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):67–9

Acceptability of interventions to reduce mother–to–child transmission of HIV–1 in west Africa. Cartoux M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):290–2

Cesarean deliveries and maternal–infant HIV transmission: results from a prospective study in South Africa. Kuhn L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):478–83

Prenatal care and birth outcomes of a cohort of HIV–infected women. Turner BJ, et al.

J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12(3):259–67

Recent advances in pediatric HIV. Menard J, et al. **J Ark Med Soc** 1995 Sep;92(4):165–8

Double viral infection during pregnancy. Brid NS, et al. **J Assoc Physicians India** 1995 Apr;43(4):288

Congenital anomalies following maternal varicella infection during early pregnancy. Huang YC, et al. **J Formos Med Assoc** 1996 May;95(5):393–5

A study by means of a new assay of the relationship between an outbreak of erythema infectiosum and non–immune hydrops fetalis caused by human parvovirus B19. Yaegashi N, et al. **J Infect** 1995 Nov;31(3):195–200

Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection. Langston C, et al. **J Infect Dis** 1995 Dec;172(6):1451–60

Laboratory diagnosis of infection status in infants perinatally exposed to human immunodeficiency virus type 1 [see comments] Paul MO, et al. **J Infect Dis** 1996 Jan; 173(1):68–76. Comment in: J Infect Dis 1996 Jul;174(1):244–5.

How much paediatric HIV infection could be prevented by antenatal HIV testing? Dunn DT, et al. **J Med Screen** 1995; 2(1):35–40

Mother–to–infant transmission of hepatitis C virus in human immunodeficiency virus–coinfected mother: a case report. Koseki S, et al. **J Obstet Gynaecol Res** 1996 Apr; 22(2):139–42

Human parvovirus B19 in pregnancy. Finch CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):495–8 (20 ref.)

Group B streptococcus during the perinatal period. Shermer RH. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):562–6 (21 ref.)

Sepsis during pregnancy. Simpson KR. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):550–6 (26 ref.)

Intra–uterine varicella or herpes zoster and childhood deafness [letter] Mutton PE. **J Paediatr Child Health** 1995 Oct;31(5):483

Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group. Moye J Jr, et al. **J Pediatr** 1996 Jan;128(1):58–69

Risk factors for HIV infection overlooked in routine antenatal care [see comments] Hawken J, et al. **J R Soc Med** 1995 Nov;88(11):634–6. Comment in: J R Soc Med 1996 Mar;89(3):180.

Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses. Hutto C, et al. **J Virol** 1996 Jun;70(6):3589–98

Crohn's disease after in–utero measles virus exposure. Ekbom A, et al. **Lancet** 1996 Aug 24;348(9026):515–7

Vertical transmission of hepatitis G [letter] [see comments] Feucht HH, et al. **Lancet** 1996 Mar 2;347(9001):615–6. Comment in: Lancet 1996 Apr 20;347(9008):1116.

Mechanism of vertical transmission of hepatitis G [letter; comment] Lin HH, et al. **Lancet** 1996 Apr 20; 347(9008):1116. Comment on: Lancet 1996 Mar 2;347(9001):615–6.

Bacterial vaginosis and preterm birth [letter; comment] Bloom BS, et al. **N Engl J Med** 1996 May 16;334(20):1338–9 . Comment on: N Engl J Med 1995 Dec 28;333(26):1737–42.

Association between bacterial vaginosis and preterm delivery of a low–birth–weight infant. The Vaginal Infections and Prematurity Study Group [see comments] Hillier SL, et al. **N Engl J Med** 1995 Dec 28;333(26):1737–42. Comment in: N Engl J Med 1995 Dec 28;333(26):1772–4. Comment in: N Engl J Med 1996 May 16;334(20):1337–8; discussion 1338–9. Comment in: N Engl J Med 1996 May 16;334(20):1338–9.

Reducing mother–to–infant transmission of HIV — the door remains open [editorial; comment] Landers DV, et al. **N Engl J Med** 1996 Jun 20;334(25):1664–5. Comment on: N Engl J Med 1996 Jun 20;334(25):1619–23.

Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study [see comments] Landesman SH, et al. **N Engl J Med** 1996 Jun 20; 334(25):1617–23. Comment in: N Engl J Med 1996 Jun 20;334(25):1664–5.

Herpes zoster during pregnancy: a case report. Janes R. **N Z Med J** 1995 Oct 27;108(1010):432–3

Neonatal herpes simplex virus (HSV) infections. Harrison CJ. **Nebr Med J** 1995 Oct;80(10):311–5

A fatal case of congenital cytomegalic inclusion disease following recurrent maternal infection. Portolani M, et al. **New Microbiol** 1995 Oct;18(4):427–8

Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidémiologie Clinique Du SIDA en Aquitaine. Hocke C, et al. **Obstet Gynecol** 1995 Dec; 86(6):886–91

Ureaplasma urealyticum infection of the placenta in pregnancies that ended prematurely. Kundsin RB, et al. **Obstet Gynecol** 1996 Jan;87(1):122–7

Lues–lues: maternal and fetal considerations of syphilis. Ray JG. **Obstet Gynecol Surv** 1995 Dec;50(12):845–50 (30 ref.)

Maternal Lyme disease and congenital malformations: a cord blood serosurvey in endemic and control areas. Williams CL, et al. **Paediatr Perinat Epidemiol** 1995 Jul;9(3):320–30

Papulosquamous plaques in a mother and newborn son [clinical conference] Johnson ML, et al. **Pediatr Dermatol** 1995 Sep;12(3):281–4

AIDS–resembling disease in a non–HIV–infected African born to an HIV–positive mother. Irova T, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):495–8

High efficiency of vertical transmission of hepatitis C virus among babies born to human immunodeficiency virus–negative women [letter] Maccabruni A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):921–2

Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

Vocal cord paralysis as a presentation of intrauterine infection with varicella–zoster virus. Randel RC, et al. **Pediatrics** 1996 Jan;97(1):127–8

HIV in pregnancy—a policy needed [letter] Anthony J, et al. **S Afr Med J** 1995 Sep;85(9):936

Fatal disseminated herpes simplex in pregnancy with maternal and neonatal death. Gelven PL, et al. **South Med J** 1996 Jul;89(7):732–4

[Infection and monitoring in obstetrics (editorial)] Yue J. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):451–3 **(Chi)**

[Investigation of cervical Chlamydia trachomatis infection in gynecologic outpatients] Gao ZY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug; 16(4):211–2 (Eng. Abstr.) **(Chi)**

[Neurologic manifestations in a child of a mother with gestational herpes] Berthier M, et al. **Arch Pediatr** 1996 May;3(5):460–2 (Eng. Abstr.) **(Fre)**

[Neonatal pericarditis of benign outcome during maternofetal group B streptococcus infection (letter)] Chalumeau M, et al. **Arch Pediatr** 1996 Feb;3(2):187–8 **(Fre)**

[HIV transmission from mother to child: risk factors, period, prevention. Groupe Français d'études de l'infection VIH du nouveau–né] Mayaux MJ. **Arch Pediatr** 1996;3 Suppl 1:17s–19s **(Fre)**

[Treatment with recombinant interferon alfa–2a and pregnancy in a patient with chronic viral hepatitis C (letter)] Masbou J, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):961–2 **(Fre)**

[Pregnant women with HIV infection: medical decision] Ciraru–Vigneron N. **Presse Med** 1996 May 25; 25(18):847–52 (29 ref.) (Eng. Abstr.) **(Fre)**

[Human immunodeficiency virus infection in pregnancy. General aspects] d'Ercole C, et al. **Presse Med** 1996 Jan 20;25(2):77–80 (24 ref.) (Eng. Abstr.) **(Fre)**

[The effect of birth–specific factors on the transfer of the HIV–1 virus from mother to child (news)] Mörike EM. **Dtsch Med Wochenschr** 1996 Aug 16;121(33):A11 **(Ger)**

[Herpetic eczema in pregnancy] Wollenberg A, et al. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1395–8 (Eng. Abstr.) **(Ger)**

[HIV and pregnancy] Rudin C, et al. **Schweiz Med Wochenschr** 1995 Dec 2;125(48):2322–9 (Eng. Abstr.) **(Ger)**

[Isolation of Brucella melitensis biovar 2 from the human milk] Casalinuovo F, et al. **Ann Ig** 1995 Mar–Apr;7(2):91–5 **(Ita)**

[Neuropsychological development of children born to HIV–positive mothers] Piazza F, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):331–3 (Eng. Abstr.) **(Ita)**

[Congenital rubella: a case of particular radiological value] Gugliantini P, et al. **Radiol Med (Torino)** 1995 Oct; 90(4):513–6 **(Ita)**

[A case of miliary tuberculosis during pregnancy in a patient on hemodialysis] Shishido S, et al. **Kekkaku** 1995 Aug; 70(8):473–6 (Eng. Abstr.) **(Jpn)**

[Infectious diseases of the female reproductive system (editorial)] Kulakov VI, et al. **Akush Ginekol (Mosk)** 1995; (4):3–6 **(Rus)**

[Clinical aspects, diagnosis and treatment of intrauterine infections] Simakova MG, et al. **Akush Ginekol (Mosk)** 1995;(4):7–10 (54 ref.) **(Rus)**

[Bacteremia caused by Campylobacter jejuni associated with spontaneous abortion (letter)] Saavedra JM, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):61–2 **(Spa)**

[Current concepts on the course of pregnancies complicated by tuberculosis] Ambriz–Lopez R, et al. **Ginecol Obstet Mex** 1996 Jun;64:272–7 (30 ref.) (Eng. Abstr.) **(Spa)**

[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

[Parasitic and viral marker detection in pregnant adolescents and their newborn infants at risk] Contreras MC, et al. **Rev Chil Obstet Ginecol** 1995;60(2):85–9 (Eng. Abstr.) **(Spa)**

[Bacterial vaginosis II. Related pathology and therapy] Oyarzún E, et al. **Rev Chil Obstet Ginecol** 1995;60(2):135–42 (43 ref.) **(Spa)**

BLOOD

Fetal haematological response to intra–uterine infection in preterm prelabour amniorrhexis. Carroll SG, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):279–85

Serum vitamin A and beta–carotene levels in pregnant women infected with human immunodeficiency virus–1. Phuapradit W, et al. **Obstet Gynecol** 1996 Apr;87(4):564–7

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother–to–child transmission. Fang G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12100–4

[The HIV–1 RNA serum level and the risk of perinatal HIV–1 transmission (news)] Mörike EM. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):A7 **(Ger)**

DIAGNOSIS

The need and value of routine screening of all pregnant women for hepatitis B surface antigen. Capar M, et al. **Acta Med Croatica** 1995;49(4–5):161–4

An isolated case of Q–fever during pregnancy. Kaplan B, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):848–9

The sensitivity of HIV–1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra–uterine and intra–partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)

Correlates of acceptance of HIV testing and post–test counseling in the obstetrical setting. Sorin MD, et al. **AIDS Educ Prev** 1996 Feb;8(1):72–85

Prenatal screening for group B Streptococcus. II. Impact of antepartum screening and prophylaxis on neonatal care. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):842–6

Physician attitudes toward human immunodeficiency virus testing in pregnancy. Segal AI. **Am J Obstet Gynecol** 1996 Jun;174(6):1750–5; discussion 1755–6

Hepatitis E: an overview. Mast EE, et al. **Annu Rev Med** 1996;47:257–66 (55 ref.)

A matter of trust: mandatory HIV testing [letter; comment] Laraque D, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):556–7. Comment on: Arch Pediatr Adolesc Med 1995 May;149(5):581–2.

Evaluation of a rapid enzyme immunoassay for detection of genital colonization of group B streptococci in pregnant women: own experience and review. Hordnes K, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):251–3

Voluntary, named testing for HIV in a community based antenatal clinic: a pilot study. Chrystie IL, et al. **BMJ** 1995 Oct 7;311(7010):928–31

Descriptive survey of antenatal HIV testing in London: policy, uptake, and detection. MacDonagh SE, et al. **BMJ** 1996 Aug 31;313(7056):532–3

Lower genital tract swabs in the prediction of intrauterine infection in preterm prelabour rupture of the membranes. Carroll SG, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):54–9

Hepatitis C virus infection in pregnancy. Floreani A, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):325–9

Bacterial 16S rDNA polymerase chain reaction in the detection of intra–amniotic infection. Jalava J, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):664–9

Chronic Q fever of pregnancy presenting as Coxiella burnetii placentitis: successful outcome following therapy with erythromycin and rifampin. Bental T, et al. **Clin Infect Dis** 1995 Nov;21(5):1318–21

Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120–42 (87 ref.)

Cytodiagnosis of parvovirus B19 infection from ascites fluid of hydrops fetalis: report of a case. Iwa N, et al. **Diagn Cytopathol** 1995 Aug;13(2):139–41

Efficacy of a universal screening program for the prevention of neonatal group B streptococcal disease. de Cueto M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):810–2

Maternal assessment in the prediction of intrauterine infection in preterm prelabor amniorrhexis. Carroll SG, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):290–6

Diagnostic efficacy of chlamydial antibodies in cervical secretions from pregnant women and adolescent girls. Thejls H, et al. **Genitourin Med** 1995 Dec;71(6):370–4

Schizotypy and maternal exposure to influenza and to cold temperature: the Mauritius study. Venables PH. **J Abnorm Psychol** 1996 Feb;105(1):53–60

Prevalence of hepatitis B e antigen in pregnant women and patients with liver disease. Gill HH, et al. **J Assoc Physicians India** 1995 Apr;43(4):247–8

Automated microneutralization: method and comparison with western blot for type–specific detection of herpes simplex antibodies in two pregnant populations. Garland SM, et al. **J Virol Methods** 1995 Nov;55(3):285–94

HIV and the paediatrician as the child's advocate. Duke C, et al. **Lancet** 1996 Jul 27;348(9022):247–9

Uriscreen, a rapid enzymatic urine screening test: useful predictor of significant bacteriuria in pregnancy. Hagay Z, et al. **Obstet Gynecol** 1996 Mar;87(3):410–3

Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost–effectiveness and cost–benefit analysis [letter; comment] Nunns D. **Obstet Gynecol** 1995 Nov;86(5):867–8. Comment on: Obstet Gynecol 1995 Jul;86(1):119–23.

Toxoplasmosis diagnosis in pregnant women infected with human immunodeficiency virus I [letter] Hassl A, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1016–7

Fetal hydrops secondary to human parvovirus infection in early pregnancy. Petrikovsky BM, et al. **Prenat Diagn** 1996 Apr;16(4):342–4

Varicella during pregnancy. Maternal and fetal effects. Katz VL, et al. **West J Med** 1995 Nov;163(5):446–50

[Serious urinary infections and pregnancy] Njeh M, et al. **Ann Urol (Paris)** 1996;30(3):147–50 (Eng. Abstr.) **(Fre)**

[Maternal–fetal HIV infection diagnosed in a 12 year–old child (letter)] Dageville C, et al. **Arch Pediatr** 1996 Mar; 3(3):290–1 **(Fre)**

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) **(Ger)**

[Initial manifestation of tuberculoid leprosy in pregnancy. Guidelines for diagnosis and therapy] Neuer A, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):156–60 (Eng. Abstr.) **(Ger)**

[Preconceptional screening of sexually transmittable diseases (letter)] Gasztonyi Z. **Orv Hetil** 1996 Jan 14;137(2):99–100 **(Hun)**

[Frequency and mode of use of testing for HIV infection in women hospitalized for childbirth] Puro V, et al. **Minerva Ginecol** 1995 Oct;47(10):439–45 (Eng. Abstr.) **(Ita)**

[Early neonatal manifestations of group B Streptococcus infection: case series and preventive strategy] Moscatelli P, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):427–9 (Eng. Abstr.) **(Ita)**

[Infection with parvovirus B19 in pregnant women] Oszukowski P, et al. **Ginekol Pol** 1996 Mar;67(3):114–6 (Eng. Abstr.) **(Pol)**

[The achievements and tasks of clinical microbiology in obstetrics and neonatology] Ankirskaia AS. **Klin Lab Diagn** 1996 Jan–Feb;(1):23–6 **(Rus)**

DRUG THERAPY

Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Joesoef MR, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1527–31

Prenatal screening for group B Streptococcus. I. Impact of antepartum screening on antenatal prophylaxis and intrapartum care. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):837–41

Cryptococcal meningitis in pregnancy. Chen CP, et al. **Am J Perinatol** 1996 Jan;13(1):35–6

Acyclovir in chickenpox [letter] Jenks PJ, et al. **Arch Dis Child** 1996 Feb;74(2):184

Treatment of erythema migrans in pregnancy. Maraspin V, et al. **Clin Infect Dis** 1996 May;22(5):788–93

Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120–42 (87 ref.)

The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)

Treating sexually transmitted diseases in pregnancy. Vetter K. **Curr Probl Dermatol** 1996;24:164–73 (36 ref.)

Successful empiric treatment of HSV hepatitis in pregnancy. Case report and review of the literature. Glorioso DV, et al. **Dig Dis Sci** 1996 Jun;41(6):1273–5

The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)

Guidelines for the use of zidovudine in pregnant women with HIV infection. De Santis M, et al. **Drugs** 1995 Jul;50(1):43–7 (34 ref.)

Antibacterial agents in pregnancy. Korzeniowski OM. **Infect Dis Clin North Am** 1995 Sep;9(3):639–51 (65 ref.)

Nosocomial Torulopsis glabrata fungemia with shock in a pregnant woman successfully treated with high doses of fluconazole and delivery of healthy child [letter] Krcmery S, et al. **J Chemother** 1995 Jun;7(3):253

Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties [see comments] Fiscus SA, et al. **JAMA** 1996 May 15;275(19):1483–8. Comment in: JAMA 1996 May 15;275(19):1514–5. Comment in: JAMA 1996 Aug 21;276(7):527–8.

Cost–effectiveness of short–course zidovudine to prevent perinatal HIV type 1 infection in a sub–Saharan African Developing country setting. Mansergh G, et al. **JAMA** 1996 Jul 10;276(2):139–45

Preventing perinatal HIV infection. How far have we come? [editorial; comment] Simonds RJ, et al. **JAMA** 1996 May 15;275(19):1514–5. Comment on: JAMA 1996 May 15;275(19):1483–8. Comment on: JAMA 1996 May 15;275(19):1504–6.

Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center [see comments] Wiznia AA, et al. **JAMA** 1996 May 15;275(19):1504–6. Comment in: JAMA 1996 May 15;275(19):1514–5.

World AIDS Day: what progress since last year? [editorial] Cooper DA. **Med J Aust** 1995 Dec 4–18;163(11–12):566

Preterm delivery and low birth weight--a dire legacy [editorial; comment] Hack M, et al. **N Engl J Med** 1995 Dec 28;333(26):1772–4. Comment on: N Engl J Med 1995 Dec 28;333(26):1732–6. Comment on: N Engl J Med 1995 Dec 28;1737–42. Comment on: N Engl J Med 1995 Dec 28;333(26):1744–9.

Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis [see comments] Hauth JC, et al. **N Engl J Med** 1995 Dec 28; 333(26):1732–6. Comment in: N Engl J Med 1995 Dec 28;333(26):1772–4. Comment in: N Engl J Med 1996 May 16;334(20):1337–8; discussion 1338–9.

Bacterial vaginosis and preterm birth [letter; comment] McGregor JA, et al. **N Engl J Med** 1996 May 16; 334(20):1337–8; discussion 1338–9. Comment on: N Engl J Med 1995 Dec 28;333(26):1732–6. Comment on: N Engl J Med 1995 Dec 28;333(26):1737–42.

Acyclovir suppression to prevent cesarean delivery after first–episode genital herpes. Scott LL, et al. **Obstet Gynecol** 1996 Jan;87(1):69–73

Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta–analysis. Turrentine MA, et al. **Obstet Gynecol** 1995 Dec;86(6):1021–5

Acyclovir suppression to prevent cesarean delivery after first–episode genital herpes [letter] Watts H, et al. **Obstet Gynecol** 1996 Jun;87(6):1064–5

Severe psittacosis during pregnancy and suppression of antibody response with early therapy. Khatib R, et al. **Scand J Infect Dis** 1995;27(5):519–21

AZT trial in Thailand [letter; comment] Lallemant M, et al. **Science** 1995 Nov 10;270(5238):899–900. Comment on: Science 1995 Aug 4;269(5224):624–6.

Guarding against premature birth [news] Roush W. **Science** 1996 Jan 12;271(5246):139–40

Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov–Dec; 22(6):370–6 (84 ref.)

[Clinical observation on perinatal Chlamydia trachomata infection] Huo X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):460–2 (Eng. Abstr.) **(Chi)**

[Early hematological consequences in infants born to HIV seropositive mothers treated with zidovudine during pregnancy (letter)] Tricoire J, et al. **Arch Pediatr** 1995 Aug; 2(8):800–1 **(Fre)**

ECONOMICS

Economic impact of treatment of HIV–positive pregnant women and their newborns with zidovudine. Implications for HIV screening. Mauskopf JA, et al. **JAMA** 1996 Jul 10;276(2):132–8

Management of the presumed susceptible varicella (chickenpox)–exposed gravida: a cost–effectiveness/cost–benefit analysis. Rouse DJ, et al. **Obstet Gynecol** 1996 Jun;87(6):932–6

[Medical costs associated with the risk of maternal–fetal contamination by HIV. Results of a prospective survey] Seror V, et al. **Arch Pediatr** 1995 Oct;2(10):957–64 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Seroprevalences of Toxoplasma, malaria, rubella, cytomegalovirus, HIV and treponemal infections among pregnant women in Cotonou, Republic of Benin. Rodier MH, et al. **Acta Trop** 1995 Aug;59(4):271–7

Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. Bloland PB, et al. **AIDS** 1995 Jul;9(7):721–6

HIV infection among antenatal women in Zambia, 1990–1993 [letter] Fylkesnes K, et al. **AIDS** 1996 May;10(5):555–6

Use of multiple reporting sources for perinatal hepatitis B surveillance and follow–up. Ikeda RM, et al. **Am J Epidemiol** 1995 Oct 1;142(7):765–70

Maternal influenza, obstetric complications, and schizophrenia. Wright P, et al. **Am J Psychiatry** 1995 Dec; 152(12):1714–20

Primary varicella in adults: pneumonia, pregnancy, and hospital admission. Baren JM, et al. **Ann Emerg Med** 1996 Aug;28(2):165–9

The European Collaborative Study: clinical and immunological characteristics of HIV 1–infected pregnant women. Thorne C, et al. **Br J Obstet Gynaecol** 1995 Nov; 102(11):869–75

Prevalence of HIV infection among pregnant women in Newfoundland. Ratnam S, et al. **Can Med Assoc J** 1996 Apr 1;154(7):1027–32

Measles virus haemagglutination–inhibition antibodies among pregnant and non–pregnant women in the vaccine era in Harare, Zimbabwe. Obi CL, et al. **Cent Afr J Med** 1996 May;42(5):135–8

Schistosomiasis and hepatitis B infection in pregnancy: implications for vaccination against hepatitis B. Patana M, et al. **Cent Afr J Med** 1995 Sep;41(9):288–92

Epidemiology of HIV infection in women and newborns. Gwinn M, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):292–304 (22 ref.)

Substance abuse and HIV pregnancy. Sprauve ME. **Clin Obstet Gynecol** 1996 Jun;39(2):316–32 (98 ref.)

Seroprevalence of human immunodeficiency virus infection and its association with syphilis seropositivity among antenatal clinic attenders at Debretabor Rural Hospital, Ethiopia. Kidan KG, et al. **East Afr Med J** 1995 Sep; 72(9):579–83

Sentinel surveillance and cross sectional survey on HIV infection prevalence: a comparative study. Kwesigabo G, et al. **East Afr Med J** 1996 May;73(5):298–302

Hepatitis B virus infection among pregnant women in Zambia. Oshitani H, et al. **East Afr Med J** 1995 Dec; 72(12):813–5

High prevalence of human T–lymphotropic virus (HTLV) infection in pregnant women in southern France [letter] Vignoli C, et al. **Eur J Epidemiol** 1995 Feb;11(1):93–4

Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? A prospective cohort study from Kigali, Rwanda, 1992–1993. The Pregnancy and HIV (EGE) Group. Leroy V, et al. **Genitourin Med** 1995 Aug;71(4):207–11

Coinfection with chlamydia and gonorrhoea among pregnant women and bacterial vaginosis. Joesoef MR, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):61–4

Rubella in pregnancy in Israel: 15 years of follow–up and remaining problems. Fogel A, et al. **Isr J Med Sci** 1996 May;32(5):300–5

Characteristics of HIV–infected pregnant women in the Bahamas. Gomez MP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):400–5

Temporal and geographical trends of anti–HIV–1 antibodies screening among newborns in Italy, 1990–1993. Italian Collaborative Study Group for HIV Prevalence in Newborns. Ippolito G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):63–8

Seroprevalence of HIV–1 among pregnant women at Recife, northeastern Brazil [letter] Souza E da S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):486–7

Low HTLV–I/II seroprevalence in pregnant women in Congo and a geographic cluster of an HTLV–like indeterminate western blot pattern [letter] Tuppin P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):105–7

Serotypes, genotypes and levels of hepatitis C viremia in pregnant women in Taiwan. Lin HH, et al. **J Formos Med Assoc** 1996 Jun;95(6):429–34

Effect of pregnancy on the risk of developing active tuberculosis. Espinal MA, et al. **J Infect Dis** 1996 Feb; 173(2):488–91

Biological agents and pregnancy. Ekblad U. **J Occup Environ Med** 1995 Aug;37(8):962–5

Maternal and neonatal prevalence of toxoplasma and cytomegalovirus (CMV) antibodies and hepatitis–B antigens in an Egyptian rural area. el–Nawawy A, et al. **J Trop Pediatr** 1996 Jun;42(3):154–7

High syphilis and low but rising HIV seroprevalence rates in Madagascar [letter] Behets FM, et al. **Lancet** 1996 Mar 23;347(9004):831

HIV prevalence among pregnant women in Kigali, Rwanda [letter] Leroy V, et al. **Lancet** 1995 Dec 2;346(8988):1488–9

Anti–HCV prevalence and risk factors analysis in pregnant women in central Brazil. Martins RM, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):11

HIV infection in women and children. Schwebke KE, et al. **Minn Med** 1995 Nov;78(11):35–9

Pregnancy rates among women infected with human immunodeficiency virus. Adult/Adolescent HIV Spectrum of Disease Project Group. Chu SY, et al. **Obstet Gynecol** 1996 Feb;87(2):195–8

The effect of human immunodeficiency virus infection and drug use on birth characteristics. Johnstone FD, et al. **Obstet Gynecol** 1996 Sep;88(3):321–6

Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115–24 (52 ref.)

Latest figures on HIV pregnancies [news] **S Afr Med J** 1995 Jul;85(7):610–1

Decline of herpes simplex virus type 2 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. Persson K, et al. **Scand J Infect Dis** 1995;27(3):195–9

Screening for Chlamydia trachomatis infection in pregnant women in Martinique. Chout RT, et al. **Sex Transm Dis** 1995 Jul–Aug;22(4):221–7

[Occurrence of toxoplasmosis in pregnant women in Denmark. A study of 5.402 pregnant women] Lebech M, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5242–5 (Eng. Abstr.) **(Dan)**

[Medical costs associated with the risk of maternal–fetal contamination by HIV. Results of a prospective survey] Seror V, et al. **Arch Pediatr** 1995 Oct;2(10):957–64 (Eng. Abstr.) **(Fre)**

[HIV infection in pregnant women in Dakar (Senegal)] Diouf A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):283–7 (Eng. Abstr.) **(Fre)**

[Prevalence of hepatitis B viral markers in a population of pregnant women in Brazzaville (Congo)] Itoua–Ngaporo A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):534–6 (Eng. Abstr.) **(Fre)**

[Cytomegalovirus infections during pregnancy] de Sarcus B. **Presse Med** 1996 Feb 10;25(5):211–2 (Eng. Abstr.) **(Fre)**

[Pregnancies in HIV infected women in Switzerland] Biedermann K, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):447–55 (Eng. Abstr.) **(Ger)**

[Prevalence of hepatitis B in pregnancy and selective screening] Niesert S, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):283–6 (Eng. Abstr.) **(Ger)**

[Prevalence of group B beta–hemolytic Streptococcus colonization in a sample of 23,312 pregnant women and newborn infants] Bagnani A, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):295–7 (Eng. Abstr.) **(Ita)**

[Chlamydia trachomatis infection and risk factors in pregnant women] Amaral MG, et al. **Rev Assoc Med Bras** 1995 May–Jun;41(3):193–6 (Eng. Abstr.) **(Por)**

[Seroepidemiology for the hepatitis B virus (HBV) in pregnant women/parturients and its transmission to newborns in Goiânia, GO. Cardosa D das D, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):349–53 (Eng. Abstr.) **(Por)**

[Urogenital mycoplasmosis and Mycoplasma carriage during pregnancy and in inflammatory processes of the genitalia

in workers in the electronics industry] Prozorovskiĭ SV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):93–6 (Eng. Abstr.) **(Rus)**

[Prevalence of hepatitis C virus antibodies in pregnant women in Santiago (letter)] Quero MS, et al. **Rev Med Chil** 1995 Jul;123(7):907–8 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar–Apr;111(2):104–13 (15 ref.). Comment in: Public Health Rep 1996 Mar–Apr;111(2):114–5.

ETIOLOGY

The incidence of complications after caesarean section in 156 HIV–positive women. Semprini AE, et al. **AIDS** 1995 Aug; 9(8):913–7

Ovine Chlamydiosis in pregnancy. Flanagan PG, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):382–5

Sepsis due to Clostridium perfringens after second–trimester amniocentesis [letter] Hovav Y, et al. **Clin Infect Dis** 1995 Jul;21(1):235–6

Brucellar bacteremia in pregnancy [letter] Oscherwitz SL. **Clin Infect Dis** 1995 Sep;21(3):714–5

The effect of an in–vitro fertilization pregnancy on a woman with genital tuberculosis. Gull I, et al. **Hum Reprod** 1995 Nov;10(11):3052–4

Preterm labor: emerging role of genital tract infections. Andrews WW, et al. **Infect Agents Dis** 1995 Dec; 4(4):196–211 (185 ref.)

[Clostridium perfringens septicemia associated with foodborne toxic infection and abortion] Lantelme P, et al. **Ann Fr Anesth Reanim** 1995;14(4):359–61 (Eng. Abstr.) **(Fre)**

[New strategies in the treatment of chronic viral hepatitis (news)] Manns M, et al. **Internist (Berl)** 1995 Dec; 36(12):1201 **(Ger)**

[Infective endocarditis associated with pregnancy] Jorge S do C, et al. **Arq Bras Cardiol** 1995 Apr;64(4):319–22 (Eng. Abstr.) **(Por)**

[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**

[Factors facilitating the development of tuberculosis in pregnant women and puerperae and the role in their examination of contact film thermal indication] Fisher Iula, et al. **Akush Ginekol (Mosk)** 1995;(6):40–3 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

A prospective study of antibodies against parvovirus B19 in pregnancy. Skjöldebrand–Sparre L, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):336–9

HIV infection in women: immunological markers and the influence of pregnancy. Brettle RP, et al. **AIDS** 1995 Oct; 9(10):1177–84

HIV–1 and immunological changes during pregnancy: a comparison between HIV–1–seropositive and HIV–1–seronegative women in Nairobi, Kenya. Temmerman M, et al. **AIDS** 1995 Sep;9(9):1057–60

Amniotic fluid interleukin–10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Greig PC, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1223–7

Hepatitis B surface antigenaemia in Ilorin, Kwara State, Nigeria. Bada AS, et al. **Cent Afr J Med** 1996 May; 42(5):139–41

Relationships between humoral factors in HIV–1–infected mothers and the occurrence of HIV infection in their infants. Mabondzo A, et al. **Clin Exp Immunol** 1995 Dec; 102(3):476–80

Chlamydia trachomatis seropositivity during pregnancy is associated with perinatal complications. Gencay M, et al. **Clin Infect Dis** 1995 Aug;21(2):424–6

Vertical transmission of hepatitis C virus in low–risk pregnant women. Pipan C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):116–20

Listeria monocytogenes infection in pregnant mice: abnormalities in the function of non–adherent accessory light density dendritic cells. Klink M, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):143–52

Cytokine patterns during progression to AIDS in children with perinatal HIV infection. Hyjek E, et al. **J Immunol** 1995 Oct 15;155(8):4060–71

CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy–induced immune depression in uninfected and HIV–infected women. Rich KC, et al. **J Infect Dis** 1995 Nov; 172(5):1221–7

Seroprevalence of HBV (anti–HBc, HBsAg and anti–HBs) and HDV infections among 9006 women at delivery. Bart PA, et al. **Liver** 1996 Apr;16(2):110–6

Suppression of anti–Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women's vulnerability to vaginal candidiasis. Nohmi T, et al. **Microbiol Immunol** 1995;39(6):405–9

High incidence of congenital rubella syndrome after a rubella outbreak. Mellinger AK, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):573–8

Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection. Gratacós E, et al. **Prenat Diagn** 1995 Dec; 15(12):1109–13

Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA–DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence–based typing method. Winchester R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12374–8

[Prevalence of hepatitis B viral markers in a population of pregnant women in Brazzaville (Congo)] Itoua–Ngaporo A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):534–6 (Eng. Abstr.) **(Fre)**

[The interferon status and cellular immunity of pregnant women with viral hepatitis B] Akhmedova MD, et al. **Ter Arkh** 1995;67(11):7–10 (Eng. Abstr.) **(Rus)**

[Immunity to rubella in pregnant women in the health area of Toledo (letter)] Muñoz González F, et al. **Aten Primaria** 1996 May 31;17(9):596–7 **(Spa)**

METABOLISM

Intrauterine infection and the effects of inflammatory mediators on prostaglandin production by myometrial cells from pregnant women. Pollard JK, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):682–6

Disposition of ornidazole and its metabolites during pregnancy. Bourget P, et al. **J Antimicrob Chemother** 1995 May;35(5):691–6

Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [letter] Acosta EP, et al. **J Infect Dis** 1996 Sep;174(3):673

Botulism in a pregnant women [letter] Robin L, et al. **N Engl J Med** 1996 Sep 12;335(11):823–4

MICROBIOLOGY

Gestational pyelonephritis––associated Escherichia coli isolates represent a nonrandom, closely related population. Hart A, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):983–9

Detection of Chlamydia trachomatis and Trichomonas vaginalis by polymerase chain reaction in introital specimens from pregnant women. Witkin SS, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):165–7

Chlamydial antibodies in women who suffer miscarriage. Osser S, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):137–41

Group B streptococcal meningitis in a pregnant woman before the onset of labor. Braun TI, et al. **Clin Infect Dis** 1995 Oct;21(4):1042–3

The role of bacterial vaginosis and vaginal bacteria in amniotic fluid infection in women in preterm labor with intact fetal membranes. Hillier SL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S276–8

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

Rapid detection of group B streptococcal antigen from vaginal specimens using a new Optical ImmunoAssay technique. Park CH, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):125–8

Bacteremia and chorioamnionitis due to cryptic genospecies of Haemophilus Influenzae biotype I. Gill MV, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1088–90

Vertical transmission of Citrobacter diversus documented by DNA fingerprinting. Harvey BS, et al. **Infect Control Hosp Epidemiol** 1995 Oct;16(10):564–9

Intrauterine death and infections during pregnancy. Moyo SR, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):211–8

Actinobacillus actinomycetemcomitans septicemia during pregnancy [letter] Shalini S, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):57–8

Pasteurella multocida––an uncommon cause of obstetric and gynaecological sepsis. Riley UB, et al. **J Infect** 1995 Jul; 31(1):51–3

Bacterial vaginosis in pregnancy: distribution of bacterial species in different gram–stain categories of the vaginal flora. Rosenstein IJ, et al. **J Med Microbiol** 1996 Aug; 45(2):120–6

Prevalence, genotypes and antibody titer of hepatitis C virus in pregnant women in Taiwan. Lin HH, et al. **J Obstet Gynaecol** 1995 Dec;21(6):557–62

A prospective study on the relationship between intrapartum maternal group–B streptococcal concentration and signs of infection in neonates. Itakura A, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):101–5

Genital infections in the aetiology of late fetal death: an incident case–referent study. Osman NB, et al. **J Trop Pediatr** 1995 Oct;41(5):258–66

An incident case–referent study of threatening preterm birth and genital infection. Osman NB, et al. **J Trop Pediatr** 1995 Oct;41(5):267–72

Monomicrobial necrotizing fasciitis complicating pregnancy and puerperium. McHenry CR, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):823–6

[Progresses in prenatal medicine in China, 1995] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):748–9 (0 ref.) **(Chi)**

[Genital infections as a cause of abortion in the first trimester of pregnancy. Review of the literature] Capuzzo E, et al. **Minerva Ginecol** 1995 Dec;47(12):557–60 (15 ref.) (Eng. Abstr.) **(Ita)**

[Obligate anaerobic microbes in obstetric and gynecologic diseases] Kulakov VI, et al. **Vestn Ross Akad Med Nauk** 1996;(2):26–9 (Eng. Abstr.) **(Rus)**

[Mycoplasma infections] Silva S, et al. **Rev Chil Obstet Ginecol** 1994;59(6):485–91 (25 ref.) **(Spa)**

PARASITOLOGY

Detection of Chlamydia trachomatis and Trichomonas vaginalis by polymerase chain reaction in introital specimens from pregnant women. Witkin SS, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):165–7

PATHOLOGY

Maternal varicella during pregnancy: correlation of maternal history and fetal outcome with placental histopathology. Qureshi F, et al. **Hum Pathol** 1996 Feb;27(2):191–5

Murine granulated metrial gland cells are susceptible to Chlamydia psittaci infection in vivo. Sánchez J, et al. **Infect Immun** 1996 Sep;64(9):3897–900

PHYSIOPATHOLOGY

Infant mortality and maternal vitamin A deficiency during human immunodeficiency virus infection. Semba RD, et al. **Clin Infect Dis** 1995 Oct;21(4):966–72

Behaviour of a high–temperature–requirement A (HtrA) deletion mutant of Brucella abortus in goats. Elzer PH, et al. **Res Vet Sci** 1996 Jan;60(1):48–50

PREVENTION & CONTROL

A family planning intervention to reduce vertical transmission of HIV in Rwanda. King R, et al. **AIDS** 1995 Jul;9 Suppl 1:S45–51

Unconventional conceptions and HIV. Macaulay L, et al. **AIDS Care** 1995;7(3):261–76

Vertical transmission of HIV––a rediscussion of testing. Macquart–Moulin G, et al. **AIDS Care** 1995;7(5):657–62

The cost–effectiveness of human immunodeficiency virus screening in pregnancy. Ecker JL. **Am J Obstet Gynecol** 1996 Feb;174(2):716–21

The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Lewis R, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1329–33

Infectious diseases. Gilbert GL. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):529–43 (63 ref.)

Risk assessment and other screening options for gonorrhoea and chlamydial infections in women attending rural Tanzanian antenatal clinics. Mayaud P, et al. **Bull World Health Organ** 1995;73(5):621–30

Chickenpox during pregnancy. Small but real risk. Koren G. **Can Fam Physician** 1995 Sep;41:1477–8

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Vaginal and cervical pH in bacterial vaginosis and cervicitis during pregnancy. Sagawa T, et al. **Hokkaido Igaku Zasshi** 1995 Nov;70(6):839–46

Antenatal attenders and HIV testing [letter; comment] Kell P, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):299; discussion 300. Comment on: Int J STD AIDS 1994 Nov–Dec;5(6):400–4.

Using HIV/AIDS surveillance to monitor public health efforts to reduce perinatal transmission of HIV [letter] Wortley PM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):205–6

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May–Jun;5(3):100–5 (26 ref.)

Use of anonymous newborn serosurveys to evaluate antenatal HIV screening programmes [see comments] Holland FJ, et al. **J Med Screen** 1994 Jul;1(3):176–9. Comment in: J Med Screen 1994 Jul;1(3):143.

Why screen for HIV infection in pregnancy? [editorial; comment] Newell ML. **J Med Screen** 1994 Jul;1(3):143. Comment on: J Med Screen 1994 Jul;1(3):176–9.

HIV screening and treatment in pregnancy. Ross EL. **J Miss State Med Assoc** 1996 Aug;37(8):706–7

Risk factors for HIV infection overlooked in routine antenatal care [letter; comment] Arnott MA, et al. **J R Soc Med** 1996 Mar;89(3):180. Comment on: J R Soc Med 1995 Nov;88(11):634–6.

Preventing perinatal HIV transmission [letter] Goldstein PJ, et al. **JAMA** 1996 Sep 11;276(10):779–80

A piece of my mind. Shadow bands. Lyons SF. **JAMA** 1996 Jul 10;276(2):98

Pediatric HIV disease, zidovudine in pregnancy, and unblinding heelstick surveys. Reframing the debate on prenatal HIV testing [see comments] Minkoff H, et al. **JAMA** 1995 Oct 11;274(14):1165–8. Comment in: JAMA 1996 Feb 7;275(5):357–8.

HIV counseling and testing of pregnant women [letter] Phillips KA, et al. **JAMA** 1996 Jul 24–31;276(4):283–4

HIV testing among women aged 18–44 years––United States, 1991 and 1993. **MMWR Morb Mortal Wkly Rep** 1996 Aug 30;45(34):733–7

Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1996 May 31;45(RR–7):1–24

U.S. Public Health Service recommendations for human

immunodeficiency virus counseling and voluntary testing for pregnant women. **MMWR Morb Mortal Wkly Rep** 1995 Jul 7;44(RR-7):1-15

Adjunctive antibiotic treatment in preterm labor and neonatal morbidity: a meta-analysis. Egarter C, et al. **Obstet Gynecol** 1996 Aug;88(2):303-9

Management of the presumed susceptible varicella (chickenpox)-exposed gravida: a cost-effectiveness/cost-benefit analysis. Rouse DJ, et al. **Obstet Gynecol** 1996 Jun;87(6):932-6

Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115-24 (52 ref.)

Hepatitis B virus serology in pregnant women: transmittal of results from obstetricians to pediatricians in California. Rosenthal P, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):927-31

Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention. Gorsky RD, et al. **Public Health Rep** 1996 Jul-Aug;111(4):335-41

For children's sake. New law mandates HIV testing of pregnant patients. Grimes RM, et al. **Tex Med** 1996 Jan; 92(1):36-40

[Development and evaluation of screening algorithms for sexually transmitted diseases in pregnant women at Libreville, Gabon] Bourgeois A, et al. **Sante** 1996 Mar-Apr; 6(2):115-21 (Eng. Abstr.) **(Fre)**

[Attitudes to counseling related to HIV infection screening in Bobo-Dioulasso, Burkina Faso] Cartoux M, et al. **Sante** 1996 Jan-Feb;6(1):7-10 (Eng. Abstr.) **(Fre)**

[Prevention of infection and therapy of premature labor] Martius J. **Arch Gynecol Obstet** 1995;257(1-4):451-7 (35 ref.) **(Ger)**

[Guidelines for managing HBV, HCV, and HIV infections in obstetrics] Aspöck C, et al. **Wien Klin Wochenschr** 1995; 107(20):595-7 **(Ger)**

[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov-Dec;199(6):253-6 (24 ref.) **(Ger)**

[Obstetric prevention of neonatal infections caused by group B beta-hemolytic Streptococcus] Diani F, et al. **Pediatr Med Chir** 1995 Jul-Aug;17(4):307-9 (Eng. Abstr.) **(Ita)**

[Perinatal HBV infection and prevention of neonatal HBV infection] Fujisawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:342-9 **(Jpn)**

PSYCHOLOGY

The consequences of a positive prenatal HIV antibody test for women. Lester P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):341-9

RADIOGRAPHY

[Tuberculosis and pregnancy] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):863-6 (Eng. Abstr.) **(Fre)**

SURGERY

Acute flexor tenosynovitis in association with Clostridium difficile infection: a case report. Wright TW, et al. **J Hand Surg [Am]** 1996 Mar;21(2):304-6

[The treatment of neglected cases of condylomata acuminata in pregnant women with the Nd:Yag laser] Buzalov S, et al. **Akush Ginekol (Sofiia)** 1995;34(2):38-9 (Eng. Abstr.) **(Bul)**

[A rare case of appendicitis in pregnancy] Dębniak B, et al. **Ginekol Pol** 1996 Jan;67(1):37-9 (Eng. Abstr.) **(Pol)**

[Use of CO2 laser in the treatment of condylomata acuminata of the anogenital region in pregnant women] Woźniak J, et al. **Ginekol Pol** 1995 Feb;66(2):103-7 (Eng. Abstr.) **(Pol)**

THERAPY

The management of recurrent genital herpes infection in pregnancy: a postal survey of obstetric practice [see comments] Brocklehurst P, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):791-7. Comment in: Br J Obstet Gynaecol 1996 May;103(5):485-6.

The management of recurrent genital herpes infection in pregnancy: a postal survey of obstetric practice [letter; comment] Yoong WC. **Br J Obstet Gynaecol** 1996 May; 103(5):485-6. Comment on: Br J Obstet Gynaecol 1995 Oct;102(10):791-7.

Successful management of a serious group A streptococcal infection during the third trimester of pregnancy. Nyberg SL, et al. **Clin Infect Dis** 1995 Oct;21(4):1058-9

Management of HIV infection for the childbearing age woman. Bardeguez AD. **Clin Obstet Gynecol** 1996 Jun; 39(2):344-60 (107 ref.)

Common ethical dilemmas encountered in the management of HIV-infected women and newborns. Chervenak FA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):411-9 (16 ref.)

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107-19 (79 ref.)

Guidelines for management of the HIV infected pregnant woman. Mississippi State Medical Association. **J Miss State Med Assoc** 1996 Aug;37(8):708

Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474-85 (47 ref.)

Botulism and pregnancy [letter] Polo JM, et al. **Lancet** 1996 Jul 20;348(9021):195

Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-benefit analysis [letter; comment] Nunns D. **Obstet Gynecol** 1995 Nov;86(5):867-8. Comment on: Obstet Gynecol 1995 Jul;86(1):119-23.

Successful pregnancy complicated by peritonitis in a 35- year old CAPD patient. Tison A, et al. **Perit Dial Int** 1996;16 Suppl 1:S489-91

Sexual infections in the antenatal patient. Priestley C, et al. **Practitioner** 1995 Sep;239(1554):552-7 (6 ref.)

Chickenpox in pregnancy: how dangerous? Venkatesan P. **Practitioner** 1996 Apr;240(1561):256-9 (5 ref.)

Social interventions in the care of human immunodeficiency virus (HIV)-infected pregnant women. Levine C, et al. **Semin Perinatol** 1995 Aug;19(4):323-9

[Lethal, non-menstrual toxic shock syndrome associated with Staphylococcus aureus sepsis] Raumanns J, et al. **Anaesthesist** 1995 Dec;44(12):869-74 (Eng. Abstr.) **(Ger)**

VETERINARY

Comparison among strains of porcine reproductive and respiratory syndrome virus for their ability to cause reproductive failure. Mengeling WL, et al. **Am J Vet Res** 1996 Jun;57(6):834-9

Pathogenesis of plaque variants of porcine reproductive and respiratory syndrome virus in pregnant sows. Park BK, et al. **Am J Vet Res** 1996 Mar;57(3):320-3

Classical swine fever in wild boar (Sus scrofa)--experimental infections and viral persistence. Depner KR, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct;102(10):381-4

Financial evaluation of vaccination and testing alternatives for control of parvovirus-induced reproductive failure in swine. Gardner IA, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):863-9

What is your diagnosis? Right maxillary sinusitis or sinus cyst in a cow. Miller M, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):829-30

Abortion in a mare associated with Corynebacterium pseudotuberculosis infection. Poonacha KB, et al. **J Vet Diagn Invest** 1995 Oct;7(4):563-4

Investigation of the pathogenesis of transplacental transmission of Aleutian mink disease parvovirus in experimentally infected mink. Broll S, et al. **J Virol** 1996 Mar;70(3):1455-66

Leptospira interrogans exposure in free-ranging elk in Washington. Bender LC, et al. **J Wildl Dis** 1996 Jan; 32(1):121-4

Brucellosis in captive bison [letter; comment] Meyer ME, et al. **J Wildl Dis** 1995 Jan;31(1):106-14. Comment on: J Wildl Dis 1990 Jul;26(3):360-71.

Pathogenesis of intrauterine infections with bovine viral diarrhea virus. Moennig V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):477-87 (51 ref.)

Distribution of bluetongue virus in tissues of experimentally infected pregnant dogs as determined by in situ hybridization. Brown CC, et al. **Vet Pathol** 1996 May; 33(3):337-40

Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Brownlie J, et al. **Vet Rec** 1995 Jul 15;137(3):58-62

Neospora abortion in cattle in Ireland [letter] Collery PM. **Vet Rec** 1995 Jun 10;136(23):595

Application of an equine herpesvirus 1 (EHV1) type-specific ELISA to the management of an outbreak of EHV1 abortion. Drummer HE, et al. **Vet Rec** 1995 Jun 10; 136(23):579-81

Peste des petits ruminants in goats in India. Kulkarni DD, et al. **Vet Rec** 1996 Feb 24;138(8):187-8

Concurrent bovine viral diarrhoea virus and Salmonella typhimurium DT104 infection in a group of pregnant dairy heifers. Penny CD, et al. **Vet Rec** 1996 May 18; 138(20):485-9

Brain malformations in ovine fetuses associated with the cytopathogenic biotype of bovine viral-diarrhoea virus. Gruber AD, et al. **Zentralbl Veterinarmed [B]** 1995 Sep; 42(7):443-7

Variation in neuropathogenicity in sheep fetuses transplacentally infected with non-cytopathogenic and cytopathogenic biotypes of bovine-virus diarrhoea virus. Hewicker-Trautwein M, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):557-67

Histopathological and immunofluorescent studies on transplacental infection in experimentally induced abortion by equine arteritis virus. Wada R, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):65-74

VIROLOGY

An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Katz VL, et al. **Am J Perinatol** 1996 Jan;13(1):43-5

Parvovirus associated fetal hydrops: reversal of pregnancy induced proteinuric hypertension by in utero fetal transfusion. Duthie SJ, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1011-3

The influence of a maternal chronic hepatitis B virus infection on the repertoire of transcribed T-cell receptor beta chain variable region genes in human cord blood. Abbott WG, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1034-9

Mother-to-child transmission of human immunodeficiency virus type 1 in Nairobi [letter; comment] Dunn D, et al. **J Infect Dis** 1995 Nov;172(5):1418-9. Comment on: J Infect Dis 1994 Nov;170(5):1134-40.

Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. Harrison CJ, et al. **J Infect Dis** 1995 Nov;172(5):1212-20

CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. Rich KC, et al. **J Infect Dis** 1995 Nov; 172(5):1221-7

Use of polymerase chain reaction and quantitative antibody tests in children born to human immunodeficiency virus-1-infected mothers. Newell ML, et al. **J Med Virol** 1995 Dec;47(4):330-5

Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. Amedee AM, et al. **J Virol** 1995 Dec;69(12):7982-90

Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program. Buonaguro L, et al. **J Virol** 1995 Dec;69(12):7971-81

Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. O'Neil LL, et al. **J Virol** 1996 May;70(5):2894-901

Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load [see comments] Dickover RE, et al. **JAMA** 1996 Feb 28;275(8):599-605. Comment in: JAMA 1996 Feb 28;275(8):640-1.

Quantifying HIV [editorial; comment] Landesman SH, et al. **JAMA** 1996 Feb 28;275(8):640-1. Comment on: JAMA 1996 Feb 28;275(8):599-605.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. Mayaux MJ, et al. **JAMA** 1996 Feb 28;275(8):606-10

A maternal risk factor for mother-to-child HTLV-I transmission: viral antigen-producing capacities in culture of peripheral blood and breast milk cells. Yoshinaga M, et al. **Jpn J Cancer Res** 1995 Jul;86(7):649-54

HIV quantification: useful for prediction of vertical transmission? [letter; comment] Zöllner B, et al. **Lancet** 1996 Mar 30;347(9005):899. Comment on: Lancet 1996 Jan 13;347(8994):71-3.

Mother-to-baby transmission of hepatitis G virus. Moaven LD, et al. **Med J Aust** 1996 Jul 15;165(2):84-5

Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Brown ZA, et al. **Obstet Gynecol** 1996 Apr;87(4):483-8

Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Prazuck T, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):940-7

Cytomegalovirus in the perfused human term placenta in vitro. Mühlemann K, et al. **Placenta** 1995 Jun;16(4):367-73

Changing face of HIV/AIDS care--mother-fetal and maternal-child HIV transmission. Frascino RJ. **West J Med** 1995 Oct;163(4):368-9

[Detection of intrauterine transmission of human cytomegalovirus by nested polymerase chain reaction] Huang H, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):454-6 (Eng. Abstr.) **(Chi)**

[Clinical observation on vertical transmission of human papillomavirus] Xu S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):457-9 (Eng. Abstr.) **(Chi)**

[HIV and family planning] Vartti AM. **Duodecim** 1994; 110(19):1765-9 (27 ref.) **(Fin)**

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520-4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Rubella and pregnancy: fetal infection without embryonal or fetal pathology. A case report] Chapeau J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):622-3 (Eng. Abstr.) **(Fre)**

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618-21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416-9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Transmission of human immunodeficiency virus to the fetus during pregnancy] d'Ercole C, et al. **Presse Med** 1996 Jan 27;25(3):119-25 (41 ref.) (Eng. Abstr.) **(Fre)**

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352-7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Prevalence of hepatitis E virus antibodies in pregnant women in the Paris region: serological considerations (letter)] Pillot J, et al. **Presse Med** 1995 Sep 23;24(27):1271 **(Fre)**

[Comparative study of the placenta from HIV+ mothers. Ultrastructural analysis] Villegas-Castrejon H, et al. **Ginecol Obstet Mex** 1996 Apr;64:167-76 (Eng. Abstr.) **(Spa)**

PREGNANCY COMPLICATIONS, NEOPLASTIC

Malignant myxoid sarcoma of the Bartholin gland in pregnancy. Fried-Oginski W, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1633-5

Successful pregnancy in association with Zollinger-Ellison syndrome. Harper MA, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):863-4

Clinical significance of neurofibromatosis in pregnancy. Hadi HA. **Am J Perinatol** 1995 Nov;12(6):459-61 (11 ref.)

Medical pregnancy termination in the presence of a massive uterine fibroid. Fenwick DK, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):332-3

Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer. Lawal AH, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):931-2

Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy-associated malignancies [letter; comment] Rodriguez JM. **Cancer** 1995 Nov 1; 76(9):1678-9. Comment on: Cancer 1995 Jun 1;75(11):2669-76.

Development of melanoma throughout two close pregnancies. Case report. Diaferia A, et al. **Clin Exp Obstet Gynecol** 1995;22(3):220-4

Clinical and ultrasonographic implications of uterine leiomyomatosis in pregnancy. Piazze Garnica J, et al. **Clin Exp Obstet Gynecol** 1995;22(4):293-7

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535-46 (26 ref.)

Colposcopy monitoring in pregnancy complicated by CIN and early cervical cancer. Madej JG Jr. **Eur J Gynaecol Oncol** 1996;17(1):59-65

Vulvar syringoma exacerbated during pregnancy. Turan C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):141-2

A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Rodriguez-Cuevas S, et al. **Eur J Surg Oncol** 1995 Dec;21(6):692

Metastatic cerebral choriocarcinoma coexistent with a viable pregnancy. Dana A, et al. **Gynecol Oncol** 1996 Apr; 61(1):147-9

Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309-13

Krukenberg tumor complicated by pregnancy. Mackey JR, et al. **Gynecol Oncol** 1996 Apr;61(1):153-5

Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. Niwa K, et al. **Gynecol Oncol** 1995 Dec;59(3):398-400

Partial hydatidiform mole and hypertension associated with a live fetus--variable presentation in two cases. Nwosu EC, et al. **Hum Reprod** 1995 Sep;10(9):2459-62

Serous cystadenocarcinoma and ovarian teratoma during pregnancy [letter] Angel-Müller E, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):55-6

Pregnancy outcome among long-term survivors with acute leukemia. Kawamura S, et al. **Int J Hematol** 1995 Oct; 62(3):157-61

Traumatic origin of a meningioma? Betz P, et al. **Int J Legal Med** 1995;107(6):326-8

Phaeochromocytoma in pregnancy: a case report. Atan A, et al. **Int Urol Nephrol** 1996;28(1):11-3

Cesarean section in a pregnant patient with an anterior mediastinal mass and failed supradiaphragmatic irradiation. Martin WJ. **J Clin Anesth** 1995 Jun;7(4):312-5

Cervical intraepithelial neoplasia in pregnancy. Harper DM, et al. **J Fam Pract** 1996 Jan;42(1):79-83 (27 ref.)

Fetal and neonatal haemodilution associated with multiple placental chorioangioma: case report. Montan S, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):43-6

Cerebellar hemangioblastoma complicating pregnancy. A case report. Nathan L, et al. **J Reprod Med** 1995 Sep; 40(9):662-4

Liver haemangioma and pregnancy [letter] Fouchard I, et al. **Lancet** 1996 Jun 15;347(9016):1694

Cavernous haemangioma of the liver and pregnancy [letter] Malaguarnera M, et al. **Lancet** 1996 Mar 16;347(9003):772

Lung cancer during pregnancy [editorial; comment] Bitar RJ, et al. **Mayo Clin Proc** 1995 Nov;70(11):1130. Comment on: Mayo Clin Proc 1995 Apr;70(4):384-7.

Lung cancer during pregnancy [letter; comment] Cone LA, et al. **Mayo Clin Proc** 1995 Nov;70(11):1130. Comment on: Mayo Clin Proc 1995 Apr;70(4):384-7.

Simultaneous choriocarcinoma in mother and newborn infant. Picton SV, et al. **Med Pediatr Oncol** 1995 Dec; 25(6):475-8

Myomas and pregnancy. Phelan JP. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):801-5 (28 ref.)

Cancer in pregnancy: a review of the literature. Part I. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):125-34 (185 ref.)

Cancer in pregnancy: a review of the literature. Part II. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):135-42 (185 ref.)

Leukemia during pregnancy. Ramirez-Smiley M, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1363-8 (16 ref.)

Breast cancer in pregnancy and lactation. DiFronzo LA, et al. **Surg Clin North Am** 1996 Apr;76(2):267-78 (45 ref.)

[Breast cancer during pregnancy] Merviel P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):266-75 (51 ref.) (Eng. Abstr.) **(Fre)**

[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543-8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Ovarian cancer and pregnancy] Ayoubi J, et al. **Rev Fr Gynecol Obstet** 1995 Jul-Sep;90(7-9):335-41 (Eng. Abstr.) **(Fre)**

[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435-41 (18 ref.) (Eng. Abstr.) **(Fre)**

[Malignant melanoma and pregnancy] Rozen A, et al. **Harefuah** 1996 Apr 15;130(8):555-7 (17 ref.) **(Heb)**

[Acute anterior myocardial infarction in a patient with left atrial myxoma during pregnancy] Manfredini R, et al. **G Ital Cardiol** 1995 Nov;25(11):1419-24 (Eng. Abstr.) **(Ita)**

[2 fatal cases of acute myeloid leukemia (M3, M4) during pregnancy] Aragona M, et al. **Pathologica** 1995 Apr; 87(2):125-34 (Eng. Abstr.) **(Ita)**

[Carcinoid syndrome in a pregnant woman. Case report] Szczurowicz A, et al. **Ginekol Pol** 1995 Jan;66(1):59-60 (Eng. Abstr.) **(Pol)**

[Features of tumor growth in pregnant rats] Shelepov VP, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):640-1 **(Rus)**

[Pregnancy, breast cancer and tumor infarction] Vera-Sempere FJ, et al. **An Med Interna** 1996 Jan; 13(1):31-3 (Eng. Abstr.) **(Spa)**

[Gestational trophoblastic tumors (letter)] Ayala AR. **Ginecol Obstet Mex** 1996 Feb;64:51 **(Spa)**

[Hematologic neoplasms and pregnancy] Tartas N, et al. **Medicina (B Aires)** 1995;55(2):155-8 (Eng. Abstr.) **(Spa)**

[Complicated placental chorioangioma: infrequent cause of premature labor] Enríquez R, et al. **Rev Chil Obstet Ginecol** 1994;59(5):390-2 (Eng. Abstr.) **(Spa)**

[Cystic hygroma. Antenatal diagnosis and clinical management] Ruiz M, et al. **Rev Chil Obstet Ginecol** 1994; 59(6):428-33; discussion 433-4 (Eng. Abstr.) **(Spa)**

[A case of acute leukemia and pregnancy] Oviedo de Albiero MM, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995; 53(1):33-5 **(Spa)**

DIAGNOSIS

Term delivery after hepatocellular carcinoma resection in previous pregnancy. Hsieh TT, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):77-8

Large cervical adenomyoma occurring in a first-trimester gravid uterus: radiologic-pathology correlation. Athas JM, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):514-5

Ballantyne syndrome caused by a large placental chorioangioma. Dorman SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1632-3

Parovarian borderline malignancy in pregnancy. Fine BA, et al. **Arch Gynecol Obstet** 1996;258(2):105-8

Colposcopy and directed biopsy reliability during pregnancy: a cohort study. Baldauf JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):31-6

Gastric carcinoma presenting as a Krukenberg tumor in the 24th week of gestation. Tamussino K, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):251-2

Twin pregnancies with complete hydatidiform mole and coexisting fetus: use of fluorescent in situ hybridization to evaluate placental X- and Y-chromosomal content. Choi-Hong SR, et al. **Hum Pathol** 1995 Nov; 26(11):1175-80

Primary care equals primary responsibility. Avery JK. **J Ark Med Soc** 1996 Jan;92(8):399

A twin pregnancy with a hydatidiform mole and an alive, coexistent baby after in vitro fertilization and embryo transfer. Cheng PJ, et al. **J Assist Reprod Genet** 1995 Jul; 12(6):389-92

Case report. Antenatal diagnosis of chorioangioma of the placenta: MR features. Mochizuki T, et al. **J Comput Assist Tomogr** 1996 May-Jun;20(3):413-6

Pheochromocytoma in pregnancy: a case report. Kunthonkitidej K. **J Med Assoc Thai** 1996 Apr; 79(4):258-62

Liver haemangioma and pregnancy [letter] Itai Y. **Lancet** 1996 Jun 15;347(9016):1693-4

The changing clinical presentation of complete molar pregnancy. Soto-Wright V, et al. **Obstet Gynecol** 1995 Nov;86(5):775-9

[Breast cancer during pregnancy. Epidemiology--diagnosis--prognosis] Gorins A, et al. **Contracept Fertil Sex** 1996 Feb;24(2):153-6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Pyoderma gangrenosum as a precursor of myeloid leukemia] Maier H, et al. **Hautarzt** 1995 Sep;46(9):647-50 (Eng. Abstr.) **(Ger)**

[Leiomyosarcoma of the stomach] Walther H, et al. **Leber Magen Darm** 1996 Mar;26(2):104, 107-8 (Eng. Abstr.) **(Ger)**

[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al. **Strahlenther Onkol** 1995 Sep;171(9):539-42 (16 ref.) (Eng. Abstr.) **(Ger)**

[Pseudosarcoma botryoides during pregnancy] Lasso de la Vega J, et al. **Rev Med Panama** 1995 Jan-May;20(1-2):45-9 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin [letter] Lin CP, et al. **Am J Hematol** 1996 Mar;51(3):251-2

Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid [letter] Nakamura K, et al. **Ann Hematol** 1995 Nov;71(5):263-4

Cis-platinum neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervix. Giacalone PL, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):932-4

VACOP-B chemotherapy for high grade non-Hodgkin's lymphoma in pregnancy. Rodriguez JM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):319-20

Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy. Shanis BS, et al. **Gynecol Endocrinol** 1996 Apr;10(2):91-4

Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Jones WB, et al. **Gynecol Oncol** 1996 Apr;61(1):126-30

Sinusoidal fetal heart rate pattern during chemotherapy in a pregnant woman with acute myelogenous leukemia. Hsu KF, et al. **J Formos Med Assoc** 1995 Sep;94(9):562-5

Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient. Goldwasser F, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):173-6

Perceived concerns of pregnant women with breast cancer treated with chemotherapy. Bandyk EA, et al. **Oncol Nurs Forum** 1995 Jul;22(6):975-7

[A clinical analysis of 15 cases of acute leukemia complicating pregnancy] Hou Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):260-2 (Eng. Abstr.) **(Chi)**

EPIDEMIOLOGY

Cancers coinciding with childbearing: delayed diagnosis during pregnancy? Lambe M, et al. **BMJ** 1995 Dec 16; 311(7020):1607-8

A case-control study of Hodgkin's disease and pregnancy. Zwitter M, et al. **Br J Cancer** 1996 Jan;73(2):246-51

[Breast cancer during pregnancy. Epidemiology--diagnosis--prognosis] Gorins A, et al. **Contracept Fertil Sex** 1996 Feb;24(2):153-6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Hydatidiform mole. Clinical aspects, incidence and risk factors] Quiñonez Zarza C. **Ginecol Obstet Mex** 1995 Sep; 63:391-4 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pregnancy and fibroids causing simultaneous urinary retention and ureteric obstruction. Monga AK, et al. **Br J Urol** 1996 Apr;77(4):606-7

METABOLISM

Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Huynh H, et al. **Cancer Res** 1996 Aug 15; 56(16):3651-4

PATHOLOGY

Central nervous system involvement in gestational trophoblastic neoplasia. Ayhan A, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):548-50

Agminated Spitz nevi occurring within a congenital speckled lentiginous nevus. Aloi F, et al. **Am J Dermatopathol** 1995 Dec;17(6):594-8

Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Anderson BO, et al. **Ann Surg Oncol** 1996 Mar;3(2):204-11

Bilateral primary breast lymphoma in pregnancy: a case report and literature review. Kirkpatrick AW, et al. **Can J Surg** 1996 Aug;39(4):333-5 (26 ref.)

Pregnancy-associated lymphomas. A clinicopathologic study. Gelb AB, et al. **Cancer** 1996 Jul 15;78(2):304-10

Acute promyelocytic leukemia and pregnancy. A case report. Hoffman MA, et al. **Cancer** 1995 Dec 1;76(11):2237-41 (32 ref.)

Multilocular renal cyst: a diagnostic pitfall on fine-needle aspiration cytology: case report. Morgan C, et al. **Diagn Cytopathol** 1995 Jul;13(1):66-70

Breast cancer during pregnancy and lactation in Zaria, Nigeria. Hassan I, et al. **East Afr Med J** 1995 May; 72(5):280-2

Virilizing stromal Leydig cell tumor (Leydig cell-containing thecoma) of the ovary in pregnancy. A case report with extensive immunohistochemical investigation of the tumor cells. Horny HP, et al. **Gen Diagn Pathol** 1995 May; 141(1):57-60

Langerhans' cells and L1 antigen expression in normal and abnormal squamous epithelium of the cervical transformation zone. Poppe WA, et al. **Gynecol Obstet Invest** 1996;41(3):207-13

Benign cervical leiomyoma leading to disseminated fatal malignancy. O'Connell MP, et al. **Gynecol Oncol** 1996 Jul; 62(1):119-22 (5 ref.)

Teratoma of the placenta. Jaswal TS, et al. **J Indian Med Assoc** 1995 Sep;93(9):362, 345

Management of a carcinoma of the tongue during pregnancy:

report of case. Lasaridis N, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):221–4 (16 ref.)

Massive metastases from a lobular breast carcinoma from an unknown primary during pregnancy. A case report. Torné A, et al. **J Reprod Med** 1995 Sep;40(9):676–80

Breast cancer during pregnancy: quantifying the risk of treatment delay. Nettleton J, et al. **Obstet Gynecol** 1996 Mar;87(3):414–8

Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Nugent CE, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):829–31

Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. Hardman WJ 3rd, et al. **South Med J** 1996 Mar;89(3):291–4 (22 ref.)

Uterine pyomyoma as a complication of pregnancy in an intravenous drug user. Prahlow JA, et al. **South Med J** 1996 Sep;89(9):892–5

Monomorphic (basal cell) salivary adenoma of ovary: report of a case. Russell P, et al. **Ultrastruct Pathol** 1995 Sep–Oct; 19(5):431–8

[Spontaneous uterine rupture in the 18th week of pregnancy in a primigravida patient with adenomyosis] Mueller MD, et al. **Zentralbl Gynakol** 1996;118(1):42–4 (Eng. Abstr.) **(Ger)**

[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

[Rapidly growing renal angiomyolipoma associated with pregnancy (letter; comment)] Fariña LA. **Actas Urol Esp** 1995 May;19(5):425–7. Comment on: Actas Urol Esp 1994 Jul–Aug;18(7):755–7. **(Spa)**

PHYSIOPATHOLOGY

Preferred genetic evolutionary sequences in human breast cancer: a case study. Shackney SE, et al. **Cytometry** 1995 Sep 1;21(1):6–13

[Fibroma in pregnancy] Struzziero E, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):15–6 (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Rapid recurrence of craniopharyngioma during pregnancy with recovery of vision: a case report. Maniker AH, et al. **Surg Neurol** 1996 Apr;45(4):324–7

RADIOTHERAPY

Mantle irradiation for Hodgkin's disease during pregnancy: safe and practical? [editorial; comment] Byram D. **Australas Radiol** 1996 May;40(2):101–3 (30 ref.). Comment on: Australas Radiol 1996 May;40(2):146–8.

Radiotherapy for Hodgkin's disease in pregnancy [see comments] Leung JT, et al. **Australas Radiol** 1996 May; 40(2):146–8. Comment in: Australas Radiol 1996 May;40(2):101–3.

SURGERY

Surgery for pancreatic tumors during pregnancy: a case report and review of the literature. Sciscione AC, et al. **Am J Perinatol** 1996 Jan;13(1):21–5 (28 ref.)

Juvenile laryngeal papillomatosis from an HPV-positive mother. A case report. Alberico S, et al. **Clin Exp Obstet Gynecol** 1995;22(3):243–6

Myomectomy during pregnancy and caesarean section. Michalas SP, et al. **Hum Reprod** 1995 Jul;10(7):1869–70

Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

Surgical management of breast masses in pregnant women. Collins JC, et al. **J Reprod Med** 1995 Nov;40(11):785–8

Laparoscopic removal of a dermoid cyst in pregnancy. A case report. Della Badia CR, et al. **J Reprod Med** 1995 Nov;40(11):797–9

Recurrent left atrial myxoma in a patient with a twin fetus pregnancy. Nakata S, et al. **Jpn Circ J** 1996 Feb;60(2):130–2

Successful excision of a giant acoustic neuroma in the third trimester of pregnancy. Thacker JG, et al. **Scott Med J** 1995 Aug;40(4):117–8

[Therapy of ovarian carcinoma in pregnancy] Rob L, et al. **Ceska Gynekol** 1996 Apr;61(2):99–101 **(Cze)**

[Ovarian tumors and pregnancy] Hahn U, et al. **Zentralbl Gynakol** 1996;118(6):334–5 (Eng. Abstr.) **(Ger)**

THERAPY

The management of urological malignancies during pregnancy. Loughlin KR. **Br J Urol** 1995 Nov;76(5):639–44 (60 ref.)

Cervical carcinoma and pregnancy. A national patterns of care study of the American College of Surgeons. Jones WB, et al. **Cancer** 1996 Apr 15;77(8):1479–88

Pregnancy during alpha-interferon therapy in patients with advanced Hodgkin's disease [letter] Ferrari VD, et al. **Eur J Cancer** 1995 Nov;31A(12):2121–2

Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum [letter] Haggstrom J, et al. **Eur J Haematol** 1996 Jul;57(1):101–2

Two cases of breast cancer in young women. **Eur J Surg Oncol** 1996 Feb;22(1):108–13

Stage I squamous cell cervical carcinoma in pregnancy: planned delay in therapy awaiting fetal maturity. Sorosky JI, et al. **Gynecol Oncol** 1995 Nov;59(2):207–10

Breast cancer during pregnancy: quantifying the risk of treatment delay. Nettleton J, et al. **Obstet Gynecol** 1996 Mar;87(3):414–8

[Hydatidiform mole and live fetus—a happy ending in a hopeless pregnancy] Suvanto-Luukkonen E, et al. **Duodecim** 1995;111(3):245–8 **(Fin)**

[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):174–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) **(Ger)**

[Breast cancer during pregnancy] Jereczek B. **Ginekol Pol** 1995 Aug;66(8):480–3 (24 ref.) (Eng. Abstr.) **(Pol)**

[Leukemia and pregnancy. Review apropos of a clinical case] Perucca E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):118–23; discussion 123–4 (13 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Choriocarcinoma following term pregnancy by transvaginal color Doppler ultrasound. A two case report. Cormio G, et al. **Eur J Gynaecol Oncol** 1996;17(2):151–3

Prenatal diagnosis of a grade IV sacrococcygeal teratoma. Shipp TD, et al. **J Ultrasound Med** 1996 Feb;15(2):175–7

Large placental hemangioma diagnosed by ultrasonography—a case report. Lisboa Bittencourt A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1033–5

B-mode color sonographic images in obstetrics and gynecology: preliminary report. Dambrosio F, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):208–15

[The volumetric changes of uterine myomas in pregnancy] Rosati P. **Radiol Med (Torino)** 1995 Sep;90(3):269–71 (Eng. Abstr.) **(Ita)**

VETERINARY

Uterine carcinomas in mother cats after intrafetal inoculation of allogeneic tumor cells (K248 C and P). Minke JM, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3–4):361–6

VIROLOGY

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

PREGNANCY COMPLICATIONS, PARASITIC

Transplacental transmission of Plasmodium falciparum in rural Malawi. Redd SC, et al. **Am J Trop Med Hyg** 1996; 55(1 Suppl):57–60

The effect of chronic intestinal parasitic infection on maternal and perinatal outcome. Weigel MM, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):9–17

Wistar rat-Plasmodium berghei model does not approximate human congenital malaria. Fischer PR. **J Parasitol** 1996 Aug;82(4):635–7

Malaria as factor in low birthweight in Zaire [letter; comment] Brabin BJ, et al. **Lancet** 1996 Feb 24; 347(9000):552. Comment on: Lancet 1995 Dec 2;346(8988):1493–4.

Malaria associated pre-eclampsia in Senegal [letter] Sartelet H, et al. **Lancet** 1996 Apr 20;347(9008):1121

The consequences of malaria infection in pregnant women and their infants. Chimsuku L, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:1–2

Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. D'Ercole C, et al. **Prenat Diagn** 1995 Dec; 15(12):1171–5

[Congenital Chagas disease in the city of Santa Fé. Diagnosis and treatment] Streiger M, et al. **Medicina (B Aires)** 1995; 55(2):125–32 (Eng. Abstr.) **(Spa)**

BLOOD

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Antenatal diagnosis of congenital toxoplasmosis: evaluation of the biological parameters in a cohort of 286 patients. Pratlong F, et al. **Br J Obstet Gynaecol** 1996 Jun; 103(6):552–7

Pinworms in pregnancy. Hamblin J, et al. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):321–4 (15 ref.)

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

[Congenital toxoplasmosis retinochoroiditis after primary infection of the mother in pregnancy] Kuchar A, et al. **Ophthalmologe** 1996 Apr;93(2):190–3 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of toxoplasmosis infections in pregnancy at the Rostock University Gynecologic Clinic 1986–1994] Briese V, et al. **Zentralbl Gynakol** 1995; 117(11):578–84 (Eng. Abstr.) **(Ger)**

[Prevalence of Toxoplasma gondii antibodies in a population of pregnant women in Cuba] González-Morales T, et al. **Gac Med Mex** 1995 Sep–Dec;131(5–6):499–503 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):50–6

Treating sexually transmitted diseases in pregnancy. Vetter K. **Curr Probl Dermatol** 1996;24:164–73 (36 ref.)

The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)

Visceral leishmaniasis during pregnancy treated with megluimine antimoniate. Utili R, et al. **Infection** 1995 May–Jun;23(3):182–3

Hypoglycemia after oral quinine administration [letter] Kochar DK, et al. **J Assoc Physicians India** 1995 Sep; 43(9):654, 657

[Value of prevention of congenital toxoplasmosis] Douche C, et al. **J Fr Ophtalmol** 1996;19(5):330–4 (Eng. Abstr.) **(Fre)**

ECONOMICS

Cost-benefit analysis of screening for toxoplasmosis during pregnancy. Lappalainen M, et al. **Scand J Infect Dis** 1995; 27(3):265–72

EPIDEMIOLOGY

Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. Bloland PB, et al. **AIDS** 1995 Jul;9(7):721–6

Malaria in the pregnant African woman: epidemiology, practice, research, and policy. Foster SO. **Am J Trop Med Hyg** 1996;55(1 Suppl):1

The effect of placental malaria infection on perinatal mortality in rural Malawi. McDermott JM, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):61–5

Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):24–32

Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996; 55(1 Suppl):17–23

Seroprevalence of syphilis amongst pregnant women attending antenatal clinics in a rural hospital in north west Ethiopia. Azeze B, et al. **Genitourin Med** 1995 Dec; 71(6):347–50

Toxoplasma infection and pathological outcome of pregnancy. Djurković-Djaković O. **Gynecol Obstet Invest** 1995;40(1):36–41

Prevalence of malaria among pregnant and non-pregnant women of district Jabalpur, Madhya Pradesh. Singh N, et al. **Indian J Malariol** 1995 Mar;32(1):6–13

Transplacental passage of Plasmodium falciparum and seroevaluation of newborns in northern Nigeria. Egwunyenga OA, et al. **J Commun Dis** 1995 Jun; 27(2):77–83

Incidence of anti-Toxoplasma antibodies in women with high-risk pregnancy and habitual abortions. Galván Ramírez M de la L, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):333–7

Hookworm infection in pregnancy. Bundy DA, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):521–2

[Seroprevalence of toxoplasmosis in Dakar (Senegal) in 1993: study of women in their reproductive years] Diallo S, et al. **Sante** 1996 Mar–Apr;6(2):102–6 (Eng. Abstr.) **(Fre)**

[Chagas disease in northern Chile. Serological prevalence in pregnant women of the city of Antofagasta, 1991–1993] Arancibia AM, et al. **Bol Chil Parasitol** 1995 Jan–Jun; 50(1–2):45–7 (Eng. Abstr.) **(Spa)**

[Toxoplasmosis in pregnancy: new diagnostic techniques] Rodriguez JC, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):145–9 (Eng. Abstr.) **(Spa)**

[Prevalence of toxoplasmosis in pregnant women of the province of La Habana] Martinez Sanchez R, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep–Oct;36(5):445–50 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Kapperud G, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):405–12

Risk factors for recent toxoplasma infection in pregnant women in Naples. Buffolano W, et al. **Epidemiol Infect** 1996 Jun;116(3):347–51

[Toxoplasmosis as a risk factor in pregnant women after renal transplantation] Ejmocka-Ambroziak A, et al. **Wiad Lek** 1994 Sep;47(17–18):700–1 (9 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Malaria and pregnancy in Cameroonian primigravidae: humoral and cellular immune responses to Plasmodium falciparum blood-stage antigens. Fievet N, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):612–7

Maternal Trypanosoma cruzi-specific antibodies and worsening of acute infection in mouse offspring. Marques de Araujo S, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):13–7

Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines. Krishnan L, et al. **J Immunol** 1996 Jan 15;156(2):644–52

T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells. Krishnan L, et al. **J Immunol** 1996 Jan 15;156(2):653–62

Pregnancy, immunosuppression and reactivation of latent toxoplasmosis. Biedermann K, et al. **J Perinat Med** 1995; 23(3):191–203

Detection by enzyme immunosorbent assay of Toxoplasma gondii IgG antibodies in dried blood spots on PKU-filter paper from newborns. Lebech M, et al. **Scand J Infect Dis** 1995;27(3):259–63

A longitudinal study of malaria infection, morbidity and antibody titres in infants of a rural community in Ghana. Akanmori BD, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):560–1

[Immunological interactions between malaria and pregnancy] Deloron P, et al. **Med Trop (Mars)** 1995;55(4 Suppl):67–8 (11 ref.) **(Fre)**

PARASITOLOGY

Malaria parasite density in pregnant women of district Jabalpur, Madhya Pradesh. Singh N, et al. **Indian J Malariol** 1996 Mar;33(1):41–7

Images in clinical medicine. Placental malaria. Miller IJ, et al. **N Engl J Med** 1996 Jul 11;335(2):98

Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta [see comments] Fried M, et al. **Science** 1996 Jun 7;272(5267):1502–4. Comment in: Science 1996 Jun 7;272(5267):1416–7.

Malaria hideout found in new mothers [news; comment] Williams N. **Science** 1996 Jun 7;272(5267):1416–7. Comment on: Science 1996 Jun 7;272(5267):1502–4.

[Fasciola hepatica—a unusual cause of acute cholecystitis with cholestatic jaundice] Riedtmann HJ, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1642–8 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Abortions, fetal death, and stillbirths in pregnant pygmy goats inoculated with tachyzoites of Neospora caninum. Lindsay DS, et al. **Am J Vet Res** 1995 Sep;56(9):1176–80

PREVENTION & CONTROL

Anthelmintic therapy and iron supplementation of pregnant women [letter; comment] Pawlowski ZS. **Am J Clin Nutr** 1995 Nov;62(5):1023–4. Comment on: Am J Clin Nutr 1994 Aug;60(2):286–92.

Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. Cot M, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):581–5

Protection of young rats from acute Trypanosoma cruzi infection by interferon-gamma given to their mothers during pregnancy. Davila HO, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):660–4

Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine-pyrimethamine. Schultz LJ, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):87–94

Infant and second-year mortality in rural Malawi: causes and descriptive epidemiology. Slutsker L, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):77–81

The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):33–41

Developing effective strategies for malaria prevention programs for pregnant African women. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):95–100

The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):2–7

Perception and utilisation of malaria prophylaxis among pregnant women in Dar es Salaam, Tanzania. Mnyika KS, et al. **East Afr Med J** 1995 Jul;72(7):431–5

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May–Jun;5(3):100–5 (26 ref.)

THERAPY

Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi: The Mangochi Malaria Research Project. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):8–16

VETERINARY

A study on the prevention of prenatal and galactogenic Toxocara canis infections in pups by treatment of infected bitches with ivermectin or doramectin. Epe C, et al. **Appl Parasitol** 1995 May;36(2):115–23

The effect of ivermectin treatment of late pregnant dairy cows in south-west Victoria on subsequent milk production and reproductive performance [published erratum appears in Aust Vet J 1995 Sep;72(9):360] Walsh A, et al. **Aust Vet J** 1995 Jun;72(6):201–7

The effect of experimental infection of Boran cattle in early and mid-pregnancy with Trypanosoma vivax. Okech G, et al. **Br Vet J** 1996 Jul;152(4):441–51

Suspected in utero infection in a boran heifer experimentally infected with Trypanosoma vivax. Okech G, et al. **Br Vet J** 1996 Jan;152(1):105–7

Investigation of pregnancy losses in beef cattle herds associated with Neospora sp. infection. Hoar BR, et al. **Can Vet J** 1996 Jun;37(6):364–6

Neospora species infection in a herd of dairy cattle. Björkman C, et al. **J Am Vet Med Assoc** 1996 May 1;208(9):1441–4

Fetal loss in BALB/C mice infected with Neospora caninum. Long MT, et al. **J Parasitol** 1996 Aug;82(4):608–11

Persistence of Tritrichomonas foetus in naturally infected cows and heifers in Argentina. Mancebo OA, et al. **Vet Parasitol** 1995 Aug;59(1):7–11

Disposition of diminazene aceturate (Berenil) in trypanosome-infected pregnant and lactating cows. Mdachi RE, et al. **Vet Parasitol** 1995 Jun;58(3):215–25

Ovine toxoplasmosis: seroconversion during pregnancy and lamb birth rate in Uruguayan sheep flocks. Savio E, et al. **Vet Parasitol** 1995 Dec;60(3–4):241–7

Lesions of neonatally induced toxoplasmosis in cats. Dubey JP, et al. **Vet Pathol** 1996 May;33(3):290–5

PREGNANCY, ECTOPIC

Successful treatment of a combined interstitial and intrauterine pregnancy after tubal embryo transfer (TET). Chen SU, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):752–5

Is the fibroid a uterus? Koong DK, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):332–4

Spontaneous conception and intrauterine pregnancy in a symptomatic missed abortion of ectopic pregnancy conceived in the previous cycle. Kobayashi F, et al. **Hum Reprod** 1996 Jun;11(6):1347–9

Cervical pregnancy: three case reports and a review of the literature. Van de Meerssche M, et al. **Hum Reprod** 1995 Jul;10(7):1850–5 (42 ref.)

Recurrent cervical pregnancy after assisted reproduction by intrafallopian transfer. Qasim SM, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):831–2

[Cervical pregnancy] Smeral P. **Ceska Gynekol** 1995 Dec; 60(6):305–6 **(Cze)**

BLOOD

Failure of creatine kinase to predict ectopic pregnancy. Korhonen J, et al. **Fertil Steril** 1996 May;65(5):922–4

Serum creatine kinase does not predict ectopic pregnancy. Vandermolen DT, et al. **Fertil Steril** 1996 May;65(5):916–21

CHEMICALLY INDUCED

Ectopic pregnancies in subjects on progestin-only pills [letter; comment] Netter A. **Fertil Steril** 1996 May; 65(5):1078–9. Comment on: Fertil Steril 1995 Jan;63(1):30–3.

COMPLICATIONS

Clinical presentation of ectopic pregnancy in Transkei, South Africa. Amoko DH, et al. **East Afr Med J** 1995 Dec; 72(12):770–3

Reproductive potential after an ectopic pregnancy. al-Nuaim L, et al. **Fertil Steril** 1995 Nov;64(5):942–6

Fertility after ectopic pregnancy: first results of a population-based cohort study in france. Job-Spira N, et al. **Hum Reprod** 1996 Jan;11(1):99–104

Adenomyosis in a rudimentary uterine horn with intrauterine fetal death: a case report. Numa F, et al. **J Obstet Gynaecol** 1995 Jun;21(3):289–92

[Hemorrhagic shock—an emergency in extrauterine pregnancy] Elvedi-Gašparović V, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:37–40 (Eng. Abstr.) **(Scr)**

DIAGNOSIS

Ectopic pregnancy—Part I: Clinical and laboratory diagnosis. Brennan DF. **Acad Emerg Med** 1995 Dec;2(12):1081–9 (82 ref.)

Ectopic pregnancy—Part II: Diagnostic procedures and imaging. Brennan DF. **Acad Emerg Med** 1995 Dec; 2(12):1090–7 (76 ref.)

Ectopic pregnancy: prospective study with improved diagnostic accuracy. Kaplan BC, et al. **Ann Emerg Med** 1996 Jul;28(1):10–7

Prenatal diagnosis of extra-amniotic pregnancy. Leung KY, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1013–5

Synchronous intrauterine and ectopic pregnancy. A report on two cases. Grampa M, et al. **Clin Exp Obstet Gynecol** 1995;22(4):339–40

Ectopic pregnancy. Duchatel FC. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):472–6 (34 ref.)

Clinical presentation of ectopic pregnancy in Transkei, South Africa. Amoko DH, et al. **East Afr Med J** 1995 Dec; 72(12):770–3

A magnetic resonance imaging approach for the diagnosis of a triplet cornual pregnancy. Bassil S, et al. **Fertil Steril** 1995 Nov;64(5):1029–31

Failure of creatine kinase to predict ectopic pregnancy. Korhonen J, et al. **Fertil Steril** 1996 May;65(5):922–4

Single serum progesterone as a screen for ectopic pregnancy: exchanging specificity and sensitivity to obtain optimal test performance. McCord ML, et al. **Fertil Steril** 1996 Oct; 66(4):513–6

Evaluation of serum creatine kinase levels in ectopic pregnancy. Qasim SM, et al. **Fertil Steril** 1996 Feb; 65(2):443–5

Endometrial stripe thickness as a predictor of ectopic pregnancy. Spandorfer SD, et al. **Fertil Steril** 1996 Sep; 66(3):474–7

Serum creatine kinase does not predict ectopic pregnancy. Vandermolen DT, et al. **Fertil Steril** 1996 May;65(5):916–21

The prediction of ectopic pregnancy after in-vitro fertilization and embryo transfer. Marcus SF, et al. **Hum Reprod** 1995 Aug;10(8):2165–8

Suspected ectopic pregnancy. What to do when human chorionic gonadotropin levels are below the discriminatory zone. Ankum WM, et al. **J Reprod Med** 1995 Jul; 40(7):525–8

Second trimester uterine atony imitating ectopic pregnancy: magnetic resonance diagnosis. Wax JR, et al. **Mil Med** 1995 Oct;160(10):534–5

[Hemothorax and ectopic pregnancy] Madsen EM, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4524–5 (Eng. Abstr.) **(Dan)**

[Atypical last menstruation: extrauterine pregnancy in the differential diagnosis] de Groot CJ, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1341–3 **(Dut)**

[Diagnosis and treatment of extrauterine pregnancy in The Netherlands] Mol BW, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1358–61 (Eng. Abstr.) **(Dut)**

[Ovarian pregnancy apropos of 2 cases] Cissé CT, et al. **Dakar Med** 1994;39(1):69–75 (Eng. Abstr.) **(Fre)**

[Intrauterine and extrauterine pregnancy association: apropos of 2 cases in gynecological and obstetrical clinical medicine] Diallo D, et al. **Dakar Med** 1994;39(2):165–8 (Eng. Abstr.) **(Fre)**

[Validity of instrumental tests, individual and combined, in the rapid diagnosis of extra-uterine pregnancy] D'Amato B, et al. **Minerva Ginecol** 1995 May;47(5):189–91 (Eng. Abstr.) **(Ita)**

[Current state of conservative management of ectopic pregnancy] Marin Cantu VA, et al. **Ginecol Obstet Mex** 1996 Mar;64:123–30 (49 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Stika CS, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1840–6; discussion 1846–8

Medical management should be routinely used as primary therapy for ectopic pregnancy. Stovall TG. **Clin Obstet Gynecol** 1995 Jun;38(2):346–52 (28 ref.)

Methotrexate: local versus intramuscular [letter; comment] Cohen DR, et al. **Fertil Steril** 1996 Jan;65(1):206–7. Comment on: Fertil Steril 1994 Nov;62(5):943–7.

Ectopic pregnancy: histopathology and assessment of cell proliferation with and without methotrexate treatment. Floridon C, et al. **Fertil Steril** 1996 Apr;65(4):730–8

A case of cervical pregnancy treated with methotrexate. Camli L, et al. **Gynecol Obstet Invest** 1995;40(3):213–4

Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Corsan GH, et al. **Hum Reprod** 1995 Oct;10(10):2719–22

Combined intra-uterine and cervical pregnancy treated successfully with methotrexate. Bratta FG, et al. **Int J Gynaecol Obstet** 1996 May;53(2):173–4

Chronic ectopic pregnancy after clinically successful methotrexate treatment of ectopic pregnancy. Dunn RC, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):247–9

A new approach to methotrexate and lipiodol suspensions for ectopic pregnancy: preliminary in vitro and animal experiments. Fujishita A, et al. **J Obstet Gynaecol** 1995 Oct;21(5):529–35

Methotrexate for nonsurgical treatment of ectopic pregnancy: nursing implications. Maiolatesi CR, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr;25(3):205–8 (16 ref.)

Methotrexate therapy for ectopic pregnancy in adolescents. McCord ML, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):71–3

Treatment of ectopic pregnancy with single-dose methotrexate in a patient with an intrauterine device. A case report. Sites CK. **J Reprod Med** 1995 Nov; 40(11):800–2

Methotrexate and angiographic embolization for conservative treatment of cervical pregnancy. Marston LM, et al. **South Med J** 1996 Feb;89(2):246–8

High dose methotrexate infusion with leucovorin rescue for treatment of ectopic pregnancy [see comments] Larson DM, et al. **Wis Med J** 1995 Dec;94(12):664–7. Comment in: Wis Med J 1995 Dec;94(12):668–9.

The time has come for the medical management of ectopic pregnancy [comment] Schink JC. **Wis Med J** 1995 Dec; 94(12):668–9. Comment on: Wis Med J 1995 Dec;94(12):664–7.

[Current indications for medical treatment of ectopic

pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552–7 (41 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

[Laparoscopic surgery versus laparotomy in extrauterine pregnancy: an analysis of the cost–benefit relationship] **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1340 **(Ger)**

EPIDEMIOLOGY

Past contraceptive method use and risk of ectopic pregnancy. Parazzini F, et al. **Contraception** 1995 Aug;52(2):93–8

IUD use and the risk of ectopic pregnancy: a meta-analysis of case–control studies [see comments] Xiong X, et al. **Contraception** 1995 Jul;52(1):23–34. Comment in: Contraception 1995 Nov;52(5):321–2.

Ectopic pregnancy and seasonality [letter] Lund VE, et al. **Hum Reprod** 1996 Mar;11(3):683–4

Induced abortions and risk of ectopic pregnancy. Parazzini F, et al. **Hum Reprod** 1995 Jul;10(7):1841–4

Risk factors for ectopic pregnancy after in vitro fertilization and embryo transfer. Ribič–Pucelj M, et al. **J Assist Reprod Genet** 1995 Oct;12(9):594–8

Ectopic pregnancy falls in Finland [letter] Mäkinen J. **Lancet** 1996 Jul 13;348(9020):129–30

Previous cesarean delivery and the risk of ectopic pregnancy. Kendrick JS, et al. **Obstet Gynecol** 1996 Feb;87(2):297–301 (19 ref.)

[Epidemiology of ectopic pregnancy: incidence and risk factors] Coste J, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):135–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Ectopic pregnancy. The "epidemic" seems to be over] Thorburn J. **Lakartidningen** 1995 Dec 6;92(49):4701–6 (Eng. Abstr.) **(Swe)**

ETHNOLOGY

Ectopic pregnancy: a nursing approach to excess risk among minority women. Bernstein J. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):803–10 (71 ref.)

ETIOLOGY

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307–10 (12 ref.)

Past contraceptive method use and risk of ectopic pregnancy. Parazzini F, et al. **Contraception** 1995 Aug;52(2):93–8

IUDs and ectopic pregnancy [letter; comment] Sivin I. **Contraception** 1995 Nov;52(5):321–2. Comment on: Contraception 1995 Jul;52(1):23–34.

IUD use and the risk of ectopic pregnancy: a meta-analysis of case–control studies [see comments] Xiong X, et al. **Contraception** 1995 Jul;52(1):23–34. Comment in: Contraception 1995 Nov;52(5):321–2.

Risk factors for ectopic pregnancy: a meta-analysis. Ankum WM, et al. **Fertil Steril** 1996 Jun;65(6):1093–9

Luteal phase defects and tubal transport [letter; comment] Jakobovits AA, et al. **Fertil Steril** 1996 Jan;65(1):204–5. Comment on: Fertil Steril 1995 Jan;63(1):30–3.

Heterotopic pregnancies after controlled ovarian hyperstimulation and assisted reproductive techniques. Wu MY, et al. **J Formos Med Assoc** 1995 Oct;94(10):600–4

Isthmico–cervical ectopic pregnancy following caesarean section. Hingorani SR, et al. **J Postgrad Med** 1994 Jan–Mar; 40(1):33–5

Cornual heterotopic pregnancy and cornual resection after in vitro fertilization/embryo transfer. A report of two cases. Loret de Mola JR, et al. **J Reprod Med** 1995 Aug; 40(8):606–10

[Ectopic pregnancy: factors related to ovum anomalies?] Bouyer J, et al. **Rev Epidemiol Sante Publique** 1996 Apr; 44(2):101–10 (48 ref.) (Eng. Abstr.) **(Fre)**

[Concerning the article: Simultaneous intrauterine and extrauterine pregnancy in the presence of an inert intrauterine device (letter)] Delarue T. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):560 **(Fre)**

GENETICS

Cytogenetic study employing chorionic villi in ectopic pregnancy. Han SS, et al. **Yonsei Med J** 1995 Nov; 36(5):438–47

IMMUNOLOGY

Decidual natural killer cytotoxicity decreased in normal pregnancy but not in anembryonic pregnancy and recurrent spontaneous abortion. Chao KH, et al. **Am J Reprod Immunol** 1995 Nov;34(5):274–80

MICROBIOLOGY

Chlamydia trachomatis and ectopic pregnancy: retrospective analysis of salpingectomy specimens, endometrial biopsies, and cervical smears. Lan J, et al. **J Clin Pathol** 1995 Sep; 48(9):815–9

Chlamydial serology among patients with tubal factor infertility and ectopic pregnancy in Alexandria, Egypt. Mehanna MT, et al. **Sex Transm Dis** 1995 Sep–Oct; 22(5):317–21

PATHOLOGY

Follow up and outcome of isthmic pregnancy located in a previous caesarean section scar. Herman A, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):839–41

Ectopic pregnancy: histopathology and assessment of cell proliferation with and without methotrexate treatment. Floridon C, et al. **Fertil Steril** 1996 Apr;65(4):730–8

Endometrial stripe thickness as a predictor of ectopic pregnancy. Spandorfer SD, et al. **Fertil Steril** 1996 Sep; 66(3):474–7

Laparoscopic removal of an abdominal pregnancy adherent to the appendix after ovulation induction with human menopausal gonadotrophin. Ben–Rafael Z, et al. **Hum Reprod** 1995 Jul;10(7):1804–5

Second trimester ovarian pregnancy [letter] Evrüke C, et al. **Int J Gynaecol Obstet** 1996 May;53(2):167–9

[Contemporary biopsy for diagnosis of abortion residues: preliminary experience] Hott H, et al. **Rev Chil Obstet Ginecol** 1995;60(1):38–42 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Reproductive potential after an ectopic pregnancy. al–Nuaim L, et al. **Fertil Steril** 1995 Nov;64(5):942–6

SURGERY

Previous ectopic pregnancy should be considered a contraindication for microsurgery. Strandell A, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):394–9

Operative management of ectopic pregnancy: a cost analysis. Foulk RA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):90–6

Randomized study of antibiotic prophylaxis for general and gynaecological surgery from a single centre in rural Africa. Reggiori A, et al. **Br J Surg** 1996 Mar;83(3):356–9

Laparoscopic management of ectopic pregnancy. Grainger DA, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):277–82 (58 ref.)

Ectopic pregnancy and laparoscopy: review of 1197 patients treated by salpingectomy or salpingotomy. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):61–7 (62 ref.)

Is removal of the tube mandatory after coagulation in ectopic pregnancies. Oettinger M, et al. **Gynecol Obstet Invest** 1995; 40(1):8–10

Laparoscopic removal of an abdominal pregnancy adherent to the appendix after ovulation induction with human menopausal gonadotrophin. Ben–Rafael Z, et al. **Hum Reprod** 1995 Jul;10(7):1804–5

Salpingectomy – the laparoscopic surgical choice for ectopic pregnancy. Dubuisson JB, et al. **Hum Reprod** 1996 Jun; 11(6):1199–203

Bilateral tubal pregnancy treated with laparoscopy [letter] Takeuchi K, et al. **Int J Gynaecol Obstet** 1995 Dec; 51(3):259–60

[Laparoscopic surgery in ectopic pregnancy] Rachev E, et al. **Akush Ginekol (Sofiia)** 1995;34(1):35–6 (Eng. Abstr.) **(Bul)**

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

[Introduction of laparoscopic surgery in extrauterine pregnancy] Rempen A. **Geburtshilfe Frauenheilkd** 1995 Jul; 55(7):357–64 (28 ref.) (Eng. Abstr.) **(Ger)**

[The clinical picture of endoscopically treated extrauterine pregnancy. Postoperative follow–up of 677 endoscopically operated extrauterine pregnancies 1983–1993] Zöckler R, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):365–8 (Eng. Abstr.) **(Ger)**

[Endoscopic surgery in ectopic pregnancy. Analysis of 105 cases] Duque G, et al. **Rev Chil Obstet Ginecol** 1995; 60(1):12–6 (Eng. Abstr.) **(Spa)**

THERAPY

Current trends in the treatment of ectopic pregnancy. Boni T, et al. **Clin Exp Obstet Gynecol** 1995;22(3):198–201

Ectopic pregnancy. Duchatel FC. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):472–6 (34 ref.)

Heterotopic pregnancy in a woman without previous ovarian hyperstimulation: ultrasound diagnosis and management. Zullo F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):193–5

Successful treatment of an advanced interstitial pregnancy by sequential systemic and local administration of methotrexate. Hoek A, et al. **Hum Reprod** 1995 Jul; 10(7):1864–5

Non–surgical treatment of ectopic pregnancy in the sole remaining tube. Parrilla JJ, et al. **Hum Reprod** 1995 Jul; 10(7):1866–8

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):175–86 (67 ref.)

Enhanced magnetic resonance imaging in monitoring of conservative treatment of cervical pregnancy. Takashima M, et al. **J Obstet Gynaecol** 1995 Dec;21(6):545–50

Treatment of the small unruptured ectopic pregnancy: a cost analysis of methotrexate versus laparoscopy. Alexander JM, et al. **Obstet Gynecol** 1996 Jul;88(1):123–7

Methotrexate and angiographic embolization for conservative treatment of cervical pregnancy. Marston LM, et al. **South Med J** 1996 Feb;89(2):246–8

[Diagnosis and treatment of extrauterine pregnancy in The Netherlands] Mol BW, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1358–61 (Eng. Abstr.) **(Dut)**

[Fertility after ectopic pregnancy. Results of the first three years of the Auvergne Registry] Bouyer J, et al. **Contracept Fertil Sex** 1996 Jun;24(6):475–81 (Eng. Abstr.) **(Fre)**

[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al. **Contracept Fertil Sex** 1996 Apr;24(4):297–302 (36 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Ultrasonographic examination by emergency physicians of patients at risk for ectopic pregnancy. Mateer JR, et al. **Acad Emerg Med** 1995 Oct;2(10):867–73

Emergency medicine physicians saving time with ultrasound. Durham B. **Am J Emerg Med** 1996 May;14(3):309–13

Outcome analysis of a protocol including bedside endovaginal sonography in patients at risk for ectopic pregnancy. Mateer JR, et al. **Ann Emerg Med** 1996 Mar; 27(3):283–9

Clinician's approach to ectopic pregnancy. Emerson DS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):199–222 (77 ref.)

Heterotopic pregnancy in a woman without previous ovarian hyperstimulation: ultrasound diagnosis and management. Zullo F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):193–5

Ultrasonographic "endometrial three–layer" pattern: a unique finding in ectopic pregnancy. Lavie O, et al. **J Clin Ultrasound** 1996 May;24(4):179–83

Conserving fertility with early management of cervical pregnancy. A case report. Kligman I, et al. **J Reprod Med** 1995 Oct;40(10):743–6

Ectopic pregnancy: ultrasonographic diagnosis and interpretive pitfalls. Hertzberg BS, et al. **South Med J** 1995 Dec;88(12):1191–8

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

[Cervical pregnancy. Contribution of ultrasonography to diagnosis and therapeutic management] Guerrier C, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):352, 355–9 (Eng. Abstr.) **(Fre)**

[Diagnostic reliability of vaginal ultrasound in ectopic pregnancy] Hopp H, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):666–70 (Eng. Abstr.) **(Ger)**

[The role of transvaginal ultrasonography in early diagnosis of ectopic ovarian pregnancy] Kowalczyk D, et al. **Ginekol Pol** 1996 Feb;67(2):91–3 (Eng. Abstr.) **(Pol)**

PREGNANCY, FIRST TRIMESTER see **PREGNANCY TRIMESTER, FIRST**

PREGNANCY, HIGH-RISK

see related

PREGNANCY COMPLICATIONS

Amniotic fluid index and perinatal morbidity. Dizon–Townson D, et al. **Am J Perinatol** 1996 May; 13(4):231–4

The NST–EXPERT project: the need to evolve. Alonso–Betanzos A, et al. **Artif Intell Med** 1995 Aug; 7(4):297–313 (40 ref.)

Preconception care: a means of prevention. Cefalo RC, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):403–16 (38 ref.)

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré–eclampsia com Aspirina) Collaborative Group [see comments] **Br J Obstet Gynaecol** 1996 Jan; 103(1):39–47. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):719–20.

Detection of fetal fibronectin as a predictor of preterm delivery in high risk asymptomatic pregnancies. Leeson SC, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):48–53

Detection of fetal fibronectin as a predictor of preterm delivery in high risk asymptomatic pregnancies [letter] Owen P. **Br J Obstet Gynaecol** 1996 Sep;103(9):937

Pregnancy outcomes in a prospective matched control study of pregnancy and renal disease. Holley JL, et al. **Clin Nephrol** 1996 Feb;45(2):77–82

Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small–for–gestational–age births. Ananth CV, et al. **Epidemiology** 1995 Jul;6(4):391–5

High delivery intervention rates in nulliparous women over age 35. Ezra Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):203–7

A multicentre collaborative study of the care of mothers and infants with a comprehensive MCH care package utilizing high risk approach strategy at primary health centres: summary, conclusions and recommendations. Maitra K, et al. **Indian Pediatr** 1995 Jan;32(1):67–72

Military pregnancies and adverse perinatal outcome. Magann EF, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):19–24

Liver transplantation and pregnancy [letter] Paternoster DM, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):199–200

Fetal biophysical profile and vibratory acoustic stimulation

in high-risk pregnancies. Petrović O, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):11-5

Framing the debate: can prenatal care help to reduce the black-white disparity in infant mortality? Rowley DL. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):187-93 (119 ref.)

The value of Doppler study of the umbilical artery in predicting perinatal outcome in pre-eclamptic patients. Rocca MM, et al. **J Obstet Gynaecol** 1995 Oct;21(5):427-31

Perinatal nurse practitioners and health care reform. Gennaro S, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):597-601

Pregnancy after cardiac transplantation: principles of nursing care. Jordan E, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):131-5 (15 ref.)

Genetics casebook. Duplication-deletion syndromes. Day-Salvatore DL, et al. **J Perinatol** 1995 Jul-Aug; 15(4):333-7

Natal status of infants of cocaine users and control subjects: a prospective comparison. Hurt H, et al. **J Perinatol** 1995 Jul-Aug;15(4):297-304

Comparison of umbilical Doppler velocimetry, nonstress testing, and biophysical profile in pregnancies complicated by diabetes. Bracero LA, et al. **J Ultrasound Med** 1996 Apr;15(4):301-8

Risk of neural tube defect-affected pregnancies among obese women [see comments] Shaw GM, et al. **JAMA** 1996 Apr 10;275(14):1093-6. Comment in: JAMA 1996 Apr 10;275(14):1127-8.

Bed rest and high-risk pregnancy. Differentiating the effects of diagnosis, setting, and treatment. Maloni JA. **Nurs Clin North Am** 1996 Jun;31(2):313-25 (35 ref.)

A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327-32 (11 ref.)

Use of ultrasonography in the home care of high-risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305-12 (17 ref.)

The epidemiology of placental features: associations with gestational age and neonatal outcome. Beebe LA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):771-8

Efficacy of fetal echocardiography and yield by risk category. Buskens E, et al. **Obstet Gynecol** 1996 Mar; 87(3):423-8

Varicella vaccine and susceptible pregnant mothers [letter; comment] Kan BD, et al. **Pediatrics** 1996 Mar;97(3):441. Comment on: Pediatrics 1995 May;95(5):791-6.

Complications of cordocentesis in high-risk pregnancies: effects on fetal loss or preterm delivery. Bernaschek G, et al. **Prenat Diagn** 1995 Nov;15(11):995-1000

Client characteristics associated with not keeping appointments for public health nursing home visits. Josten LE, et al. **Public Health Nurs** 1995 Oct;12(5):305-11

Strategy of risk approach in antenatal care: evaluation of the referral compliance [letter; comment] Akalin MZ, et al. **Soc Sci Med** 1995 Aug;41(4):595-6. Comment on: Soc Sci Med 1995 Feb;40(4):529-35.

First-trimester ultrasound screening for chromosomal defects. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):216-26 (58 ref.)

Training traditional birth attendants in Nigeria--the pictorial method. Matthews MK, et al. **World Health Forum** 1995; 16(4):409-13

[Pregnancy after hepatic transplantation: what is the maternal risk?] Pruvot FR, et al. **Gastroenterol Clin Biol** 1996; 20(5):457-61 (Eng. Abstr.) **(Fre)**

[Planned pregnancy program in systemic lupus erythematosus] Lê Thi Huong D, et al. **Presse Med** 1996 Apr 27;25(15):711-7 (Eng. Abstr.) **(Fre)**

[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417-22 (25 ref.) (Eng. Abstr.) **(Fre)**

[Quality of health services in Africa : example of dystocia prenatal screening in Nioki (Zaire)] Fournier P, et al. **Sante** 1996 Mar-Apr;6(2):107-14 (Eng. Abstr.) **(Fre)**

[Twins and multiple pregnancy] Arabin B, et al. **Arch Gynecol Obstet** 1995;257(1-4):394-403 (40 ref.) **(Ger)**

[The desire for children in Werlhof's disease] Kiefel V. **Dtsch Med Wochenschr** 1996 Aug 2;121(31-32):999 **(Ger)**

[Should maternal guidelines be improved?] Behrens O, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M129-31 **(Ger)**

[Detection of erythropoietin in amniotic fluid] Büscher U, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):243-7 (Eng. Abstr.) **(Ger)**

[Clinical results of pulse oximetry sub partu for measuring fetal arterial oxygen saturation] Butterwegge M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):634-41 (Eng. Abstr.) **(Ger)**

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605-15 (127 ref.) (Eng. Abstr.) **(Ger)**

[Quality of prenatal data in the Hessian Perinatal Registry. A comparison with data from maternal health record and results of a pregnancy survey] Jahn A, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):132-8 (Eng. Abstr.) **(Ger)**

-Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93-6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Joint recommendation of the Professional Diabetes and Pregnancy Group, the German Diabetes Society, the German Society of Gynecology and Obstetrics, the German-Austrian Society of Neonatology and Pediatric Intensive Care Medicine and the German Society of Perinatal Medicine for managing newborn infants of diabetic mothers] **Z Geburtshilfe Neonatol** 1996 Mar-Apr; 200(2):79 **(Ger)**

[Doppler ultrasound and prenatal care] Gonser M. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):69-71 **(Ger)**

[Legal problems in transportation of pregnant patients in premature labor from the viewpoint of basic and defined management] Ratzel R. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):126-7 **(Ger)**

[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone] Feist E, et al. **Z Rheumatol** 1996 Mar-Apr; 55(2):127-32 (Eng. Abstr.) **(Ger)**

[Prematurity, low birth weight and the interval between pregnancies] Ochoa Sangrador C, et al. **An Esp Pediatr** 1996 Jul;45(1):67-70 (Eng. Abstr.) **(Spa)**

BLOOD

Unexplained elevated maternal serum alpha-fetoprotein in singleton pregnancies as a predictor of fetal risk. Akinbiyi AA. **Int J Gynaecol Obstet** 1996 Apr;53(1):17-21

[Pregnancy and labor in idiopathic thrombocytopenic purpura] Tampakoudis P, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):583-6 (Eng. Abstr.) **(Ger)**

[Estriol and human placental lactogen as risk indicators in pregnancies of diabetic and hypertensive patients] Günter HH, et al. **Z Geburtshilfe Neonatol** 1995 Jul-Aug; 199(4):142-7 (Eng. Abstr.) **(Ger)**

[The course of pregnancy and fetal outcome in diabetic patients with anamnestic fetal death] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul-Aug;199(4):163-6 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Rheumatic diseases in pregnancy--problems from the viewpoint of the gynecologist] Heyl W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M121-4 (21 ref.) **(Ger)**

PHYSIOLOGY

Accuracy of the umbilical arteries Doppler flow velocity waveforms in detecting adverse perinatal outcomes in a high-risk population. Todros T, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):113-9

[Doppler sonography of the ductus venosus in high risk pregnancies at 23 and 26 weeks] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):661-3 (Eng. Abstr.) **(Ger)**

[Pregnancy in patients with congenital heart defect] Schlemmer M. **Wien Klin Wochenschr** 1995;107(20):608-12 (20 ref.) (Eng. Abstr.) **(Ger)**

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep-Oct;199(5):195-8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Results of fetal monitoring in pregnancy with enzymatic and neuroendocrinologic risk factors] Pabian W, et al. **Ginekol Pol** 1996 Apr;67(4):169-75 (Eng. Abstr.) **(Pol)**

PREGNANCY IN ADOLESCENCE

Towards regional equality in family planning: teenage pregnancies and abortions in Finland from 1976 to 1993. Kosunen EA, et al. **Acta Obstet Gynecol Scand** 1996 Jul; 75(6):540-7

Maternal risk factors for preterm birth and low birthweight in Cape Verde. Wessel H, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):360-6

Monitored outpatient management of mild gestational hypertension remote from term in teenage pregnancies. Barton JR, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1865-8

Preoperative pregnancy testing in adolescents [see comments] Azzam FJ, et al. **Anesth Analg** 1996 Jan;82(1):4-7. Comment in: Anesth Analg 1996 Jan;82(1):1-3. Comment in: Anesth Analg 1996 Aug;83(2):438-9. Comment in: Anesth Analg 1996 Aug;83(2):439. Comment in: Anesth Analg 1996 Aug;83(2):439-40.

Preoperative pregnancy testing [letter; comment] Cartabuke RS. **Anesth Analg** 1996 Aug;83(2):436. Comment on: Anesth Analg 1996 Jan;82(1):1-3.

Medical ethics and legal standards [editorial; comment] [see comments] Duncan PG, et al. **Anesth Analg** 1996 Jan; 82(1):1-3. Comment on: Anesth Analg 1996 Jan;82(1):4-7. Comment in: Anesth Analg 1996 Aug;83(2):436. Comment in: Anesth Analg 1996 Aug;83(2):438-9. Comment in: Anesth Analg 1996 Aug;83(2):439-40. Comment in: Anesth Analg 1996 Aug;83(2):440-1.

Teenage parents and their offspring. Kaufman J. **Ann N Y Acad Sci** 1996 Jun 18;789:17-30

Pregnant teenagers and contraception. Contraceptive failure may be a major factor in teenage pregnancy [letter; comment] Williams ES. **BMJ** 1995 Sep 23;311(7008):806-7. Comment on: BMJ 1995 Jun 24;310(6995):1644.

Physicians' responsibility toward birth control [letter] De Marco TJ. **Can Fam Physician** 1995 Dec;41:2085

Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525-31 (42 ref.)

The younger sisters of childbearing adolescents: their attitudes, expectations, and behaviors. East PL. **Child Dev** 1996 Apr;67(2):267-82

Experience with side effects and health risks associated with Norplant implant use in adolescents. Rosenthal SL, et al. **Contraception** 1995 Nov;52(5):283-5

Further evidence of reproductive immaturity among gynecologically young pregnant adolescents. Stevens-Simon C, et al. **Fertil Steril** 1995 Dec; 64(6):1109-12

Outreach. Practice parenting. Hudson T. **Hosp Health Netw** 1996 Sep 5;70(17):68

Outreach. Pregnant teens get the "Baby Blues". Nordhaus-Bike A. **Hosp Health Netw** 1996 May 5;70(9):60

Adolescent and adult mothers' perceptions of hazardous situations for their children. McClure-Martinez K, et al. **J Adolesc Health** 1996 Mar;18(3):227-31

Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168-76 (89 ref.)

Teenage abortion in Germany: with reference to the legal system in the United States. Belling DW, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):475-502 (128 ref.)

Adolescents' use of levonorgestrel implants for contraception. Spaulding C. **J Fam Pract** 1996 Apr; 42(4):349

Adolescent parenting: outcomes and maternal perceptions. Thompson PJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):713-8

The coincident diagnosis of pelvic inflammatory disease and pregnancy: are they compatible? Acquavella AP, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):129-32

Methotrexate therapy for ectopic pregnancy in adolescents. McCord ML, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):71-3

Opposing opinions on abstinence programs for adolescents. Weed SE, et al. **J Pediatr Adolesc Gynecol** 1996 Aug; 9(3):165-8

An overview of adolescent pregnancy. Yordan EE, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):111-8 (46 ref.)

Sequelae of premature sexual life [comment] Creatsas G. **J R Soc Med** 1995 Jul;88(7):369-71 (12 ref.). Comment on: J R Soc Med 1995 Jul;88(7):384-8.

Benefits from a teen pregnancy program: neonatal outcomes potential cost savings. Blackhurst DW, et al. **J S C Med Assoc** 1996 May;92(5):209-15

Adolescent pregnancy [letter] Cheng L, et al. **JAMA** 1996 Jul 24-31;276(4):282; discussion 283

Adolescent pregnancy [letter] Donohoe MT. **JAMA** 1996 Jul 24-31;276(4):282; discussion 283

Adolescent pregnancy [letter] Fitch JT, et al. **JAMA** 1996 Jul 24-31;276(4):282-3

Pregnancy in adolescence [editorial; comment] Litt IF. **JAMA** 1996 Apr 3;275(13):1030. Comment on: JAMA 1996 Apr 3;275(13):989-94.

A piece of my mind. Shadow bands. Lyons SF. **JAMA** 1996 Jul 10;276(2):98

Adolescents with negative pregnancy test results. An accessible at-risk group. Zabin LS, et al. **JAMA** 1996 Jan 10;275(2):113-7

Teenage pregnancies in Kansas, 1980-1993 [news] Sommer K. **Kans Med** 1995 Fall;96(3):149-50

Helping postpartum rural adolescents visualize future goals. Walsh SM, et al. **MCN Am J Matern Child Nurs** 1995 Sep-Oct;20(5):276-9

Public policy and adolescent pregnancy: a reexamination of the issues. Montessoro AC, et al. **Nurs Outlook** 1996 Jan-Feb;44(1):31-6 (18 ref.)

Adolescence and very low birth weight infants: a disproportionate association [letter] Kirby RS. **Obstet Gynecol** 1996 Jun;87(6):1060-1

Adolescence and very low birth weight infants: a disproportionate association. Miller HS, et al. **Obstet Gynecol** 1996 Jan;87(1):83-8

Male adolescents involved in pregnancy: associated health risk and problem behaviors. Spingarn RW, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):262-8

Parental consent for a minor's abortion [letter] Casner PD. **Pharos** 1996 Spring;59(2):44-5; discussion 46

Parental consent for a minor's abortion [letter] Dickstein LJ. **Pharos** 1996 Spring;59(2):44; discussion 46

Parental consent for a minor's abortion [letter] Fleming TN. **Pharos** 1996 Spring;59(2):44; discussion 46

Parental consent for a minor's abortion [letter] Herrington P. **Pharos** 1996 Spring;59(2):45; discussion 46

Parental consent for a minor's abortion [letter] Karlin E. **Pharos** 1996 Spring;59(2):45; discussion 46

Parental consent for a minor's abortion [letter] Nallin EP. **Pharos** 1996 Spring;59(2):46

Parental consent for a minor's abortion [letter] Saberman J. **Pharos** 1996 Spring;59(2):45; discussion 46

Translating research into MCH service: comparison of a pilot project and a large-scale resource mothers program. Rogers MM, et al. **Public Health Rep** 1995 Sep-Oct; 110(5):563-9; discussion 562

A better way of approaching adolescent pregnancy [letter; comment] Barzelatto J. **Soc Sci Med** 1996 Mar;42(5):785.

Comment on: Soc Sci Med 1995 Nov;41(9):1203-5.
Exploring the relationship between purpose in life and African American adolescents' use of prenatal care services. Spence SA, et al. **Soc Work Health Care** 1995; 22(2):43-53
Drugs, poverty, pregnancy, and foster care in Los Angeles, California, 1989 to 1991. Lewis MA, et al. **West J Med** 1995 Nov;163(5):435-40
[Ultrasonic screening of pregnant teenagers] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1995;34(2):11-3 (Eng. Abstr.) **(Bul)**
[Compare stress and social support between adolescent and adult pregnant women during third trimester] Chen HM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Mar; 12(3):183-92 (Eng. Abstr.) **(Chi)**
[Evolution of pregnancy in adolescents of Catalonia (1987-1992)] Armelles M, et al. **Aten Primaria** 1995 Nov 15;16(8):469-72 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

The effects of childhood sexual abuse on minority adolescent mothers. Esparza DV, et al.
J Obstet Gynecol Neonatal Nurs 1996 May;25(4):321-8
Racial disparity in pregnancy outcomes: analysis of black and white teenage pregnancies. Taylor GB, et al.
J Perinatol 1995 Nov-Dec;15(6):480-3
Acculturation, perceived social support, and self-esteem in primigravida Puerto Rican teenagers. Orshan SA.
West J Nurs Res 1996 Aug;18(4):460-73

PHYSIOLOGY

Weight gain, nutrition, and pregnancy outcome: findings from the Camden study of teenage and minority gravidas. Scholl TO, et al. **Semin Perinatol** 1995 Jun;19(3):171-81
[When children "have children"--reproduction biological problems in girls between 11 and 15 years of age] Plöckinger B, et al. **Geburtshilfe Frauenheilkd** 1996 May; 56(5):248-51 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Perceptions of pregnant/parenting teens: reframing issues for an integrated approach to pregnancy problems. Rodriquez C Jr, et al. **Adolescence** 1995 Fall;30(119):685-706
Depressive symptoms, stress, and social support in pregnant and postpartum adolescents. Barnet B, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):64-9
Are adolescents who report prior sexual abuse at higher risk for pregnancy? Rainey DY, et al. **Child Abuse Negl** 1995 Oct;19(10):1283-8
Associations among adult attachment representations, maternal sensitivity, and infant-mother attachment in a sample of adolescent mothers. Ward MJ, et al.
Child Dev 1995 Feb;66(1):69-79
Durations of adolescent sexual relationships before and after conception. Toledo-Dreves V, et al. **J Adolesc Health** 1995 Sep;17(3):163-72
The effects of childhood sexual abuse on minority adolescent mothers. Esparza DV, et al.
J Obstet Gynecol Neonatal Nurs 1996 May;25(4):321-8
Teenage pregnancy: a comparative study of teenagers choosing termination of pregnancy or antenatal care [see comments] Pearson VA, et al. **J R Soc Med** 1995 Jul; 88(7):384-8. Comment in: J R Soc Med 1995 Jul;88(7):369-71.
Teaching pregnant adolescents to cope with environmental smoke. Winkelstein ML.
MCN Am J Matern Child Nurs 1995 Jan-Feb;20(1):38-42
Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65-82 (53 ref.)
Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255-90 (70 ref.)
The development of attachment behaviors in pregnant adolescents. Bloom KC. **Nurs Res** 1995 Sep-Oct; 44(5):284-9
Linkages between sexual risk taking, substance use, and AIDS knowledge among pregnant adolescents and young mothers. Koniak-Griffin D, et al. **Nurs Res** 1995 Nov-Dec; 44(6):340-6
Association between postpartum substance use and depressive symptoms, stress, and social support in adolecent mothers. Barnet B, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):659-66
Maternal characteristics of adolescent mothers and older mothers of infants. Camp BW. **Psychol Rep** 1995 Dec;77(3 Pt 2):1152-4
[Social psychological studies of pregnant adolescents] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1995; 34(3):9-12 (Eng. Abstr.) **(Bul)**
[Abortions on demand in adolescents] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1994;33(2):20-3 (Eng. Abstr.) **(Bul)**
[Body image, cognition, behavior and social support of married pregnant adolescents during the third trimester] Chen HM, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 Jun; 12(6):370-80 (Eng. Abstr.) **(Chi)**

STATISTICS & NUMERICAL DATA

The ages of fathers in California adolescent births, 1993. Males M, et al. **Am J Public Health** 1996 Apr;86(4):565-8
Teenage pregnancy in the United Kingdom in the 1990s: the implications for primary care. Jacobson LD, et al.
Fam Pract 1995 Jun;12(2):232-6 (60 ref.)
Adolescent pregnancy in Europe. Creatsas GC.
Int J Fertil Menopausal Stud 1995;40 Suppl 2:80-4
Follow-up of pregnant teens at a hospital-based clinic. Forman SF, et al. **J Adolesc Health** 1995 Sep;17(3):193-7
From the Centers for Disease Control and Prevention. State-specific pregnancy and birth rates among teenagers--United States, 1991-1992. **JAMA** 1995 Nov 15; 274(19):1501-2
Pregnancy, abortion, and birth rates among US adolescents--1980, 1985, and 1990 [see comments] Spitz AM, et al. **JAMA** 1996 Apr 3;275(13):989-94. Comment in: JAMA 1996 Apr 3;275(13):1030.
The health of Australia's mothers and babies [letter] Grover SR, et al. **Med J Aust** 1996 Jul 1;165(1):60
Births to teenagers: trends and obstetric outcomes. Amini SB, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):668-74
Effect of maternal age on birth outcomes among young adolescents. Cooper LG, et al. **Soc Biol** 1995 Spring-Summer;42(1-2):22-35
A better way of approaching adolescent pregnancy [editorial] [see comments] Battin MP. **Soc Sci Med** 1995 Nov; 41(9):1203-5. Comment in: Soc Sci Med 1996 Mar;42(5):785.
[The perinatal results in underage mothers] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1995;34(3):12-4 (Eng. Abstr.) **(Bul)**
[Adolescent pregnancy and the development of pre-eclampsia--eclampsia] Porozhanova V, et al.
Akush Ginekol (Sofiia) 1994;33(2):8-9 (Eng. Abstr.) **(Bul)**

PREGNANCY IN DIABETES

see related
DIABETES, GESTATIONAL

Long-term prognosis of infants of diabetic mothers. Relationship between metabolic disorders in newborns and adult offspring. Přibylová H, et al. **Acta Diabetol** 1996 Mar; 33(1):30-4
The influence of glucose tolerance tests on subsequent carbohydrate metabolism in pregnancy. Fung HY, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):347-51
Prediction of fetal lung maturity in infants of diabetic mothers using the FLM S/A and disaturated phosphatidylcholine tests. Tanasijevic MJ, et al. **Am J Clin Pathol** 1996 Jan; 105(1):17-22
The expanding clinical phenotype of the tRNA(Leu(UUR)) A-->G mutation at np 3243 of mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Feigenbaum A, et al. **Am J Med Genet** 1996 Apr 24;62(4):404-9
Pregnancy outcomes in the Diabetes Control and Complications Trial. **Am J Obstet Gynecol** 1996 Apr; 174(4):1343-53
Prevention of diabetes-associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. Hagay ZJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1036-41
Does pregnancy increase the risk for development and progression of diabetic nephropathy? Miodovnik M, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1180-9; discussion 1189-91
Cardiac and venous blood flow in fetuses of insulin-dependent diabetic mothers: evidence of abnormal hemodynamics in early gestation. Rizzo G, et al.
Am J Obstet Gynecol 1995 Dec;173(6):1775-81
Picture of the month. Femoral hypoplasia-unusual facies syndrome. Giacoia GP, et al.
Arch Pediatr Adolesc Med 1996 Jul;150(7):761-2
Insulin-dependent diabetes mellitus presenting as diabetic ketoacidosis in pregnancy. Ko GT, et al.
Aust N Z J Obstet Gynaecol 1995 Aug;35(3):321-2
Effects of hypoglycaemia on fetal heart activity and umbilical artery Doppler velocity waveforms in pregnant women with insulin-dependent diabetes mellitus. Björklund AO, et al. **Br J Obstet Gynaecol** 1996 May;103(5):413-20
Does early growth delay occur in diabetic pregnancy [letter; comment] Pedersen JF, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):936. Comment on: Br J Obstet Gynaecol 1995 Mar;102(3):224-7.
Long-term effects of pregnancy on diabetic complications. Kaaja R, et al. **Diabet Med** 1996 Feb;13(2):165-9
Outcome of pregnancy in patients with insulin-dependent diabetes mellitus and nephropathy with moderate renal impairment. Mackie AD, et al. **Diabet Med** 1996 Jan; 13(1):90-6
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood. Roll U, et al. **Diabetes** 1996 Jul;45(7):967-73
Feasibility and acceptability of a proposed infant feeding intervention trial for the prevention of type I diabetes. Gerstein HC, et al. **Diabetes Care** 1995 Jul;18(7):940-2
Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al.
Diabetes Care 1996 May;19(5):514-41 (324 ref.)
Birth defects in diabetic pregnancies: where do we go from here? Buchanan TA. **Eur J Endocrinol** 1996 Apr; 134(4):395-7
Effects of maternal diabetes on fetal expression of insulin-like growth factor and insulin-like growth factor binding protein mRNAs in the rat. Streck RD, et al.
J Endocrinol 1995 Nov;147(2):R5-8
Doppler ultrasound characteristics of fetal nasal flow in pregnancies complicated by diabetes mellitus. Badalian SS, et al. **J Matern Fetal Med** 1996 Jul-Aug;5(4):206-10
Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar-Apr;5(2):85-8 (12 ref.)
Use of color Doppler to study the breathing patterns of fetuses of mothers with diabetes. Wyse LJ, et al.
J Matern Fetal Med 1996 Jul-Aug;5(4):174-81
Outcome of amniotic fluid analysis and neonatal respiratory status in diabetic and nondiabetic pregnancies. Piper JM, et al. **J Reprod Med** 1995 Nov;40(11):780-4
Comparison of umbilical Doppler velocimetry, nonstress testing, and biophysical profile in pregnancies complicated by diabetes. Bracero LA, et al. **J Ultrasound Med** 1996 Apr;15(4):301-8
Blood flow velocity waveforms of the fetal middle cerebral artery in pregnancies complicated by diabetes mellitus. Ishimatsu J, et al. **Kurume Med J** 1995;42(3):161-6
Type I diabetes and pregnancy [letter; comment] Lowy C. **Lancet** 1995 Oct 7;346(8980):966-7. Comment on: Lancet 1995 Jul 15;346(8968):157-61.
What happens to the offspring of diabetic pregnancies? Doshier S. **MCN Am J Matern Child Nurs** 1995 Jan-Feb; 20(1):25-33
Evolution and natural history of diabetic retinopathy during pregnancy. Srivatsa LP. **Metab Pediatr Syst Ophthalmol** 1994;17(1-4):19-28
Sonographic prediction of shoulder dystocia in infants of diabetic mothers. Cohen B, et al. **Obstet Gynecol** 1996 Jul; 88(1):10-3
Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Gordon M, et al. **Obstet Gynecol** 1996 Mar;87(3):401-9
Use of the TDx-FLM assay in evaluating fetal lung maturity in an insulin-dependent diabetic population. The Diabetes and Fetal Maturity Study Group. Livingston EG, et al. **Obstet Gynecol** 1995 Nov;86(5):826-9
Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al.
Obstet Gynecol Clin North Am 1996 Mar;23(1):259-77 (105 ref.)
Fetal surveillance and timing of delivery in pregnancy complicated by diabetes mellitus. Landon MB, et al.
Obstet Gynecol Clin North Am 1996 Mar;23(1):109-23
Prenatal diagnosis and prevention of diabetic embryopathy. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):11-28
The pathogenesis of diabetes-associated congenital malformations. Reece EA, et al.
Obstet Gynecol Clin North Am 1996 Mar;23(1):29-45 (144 ref.)
The infant of the diabetic mother. Tyrala EE.
Obstet Gynecol Clin North Am 1996 Mar;23(1):221-41 (89 ref.)
Increased muscularization of small pulmonary arteries in preterm infants of diabetic mothers: a morphometric study in noninflated, noninjected, routinely fixed lungs. Colpaert C, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct; 15(5):689-705
Interactive effects of alcohol and diabetes during pregnancy on the rat fetus. Lin Y, et al.
Teratog Carcinog Mutagen 1995;15(3):147-53
Pregnancy after pancreas transplantation: report of four new cases and review of the literature. Barrou B, et al.
Transplant Proc 1995 Dec;27(6):3043-4 (2 ref.)
Should an echocardiographic scan be done routinely for infants of diabetic mothers? Vural M, et al.
Turk J Pediatr 1995 Oct-Dec;37(4):351-6
[Diabetes and pregnancy] Omori Y.
Nippon Naika Gakkai Zasshi 1996 Mar 10;85(3):379-83 (8 ref.) **(Jpn)**
[Retinopathy and perinatal outcome in diabetic pregnancy] Sameshima H, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Oct; 47(10):1048-54 (Eng. Abstr.) **(Jpn)**
[Characteristics of hemodynamics in cardiomyopathies of newborn infants of diabetic mothers] Medvenskaia VV.
Akush Ginekol (Mosk) 1995;(4):32-4 (Eng. Abstr.) **(Rus)**
[Macrosomia and death. Relationship with maternal diabetes] Forsbach G, et al. **Ginecol Obstet Mex** 1995 Dec; 63:499-501 (Eng. Abstr.) **(Spa)**
[Prevalence of dental caries, gingivitis and periodontal disease in pregnant diabetic women] López-Pérez R, et al.
Salud Publica Mex 1996 Mar-Apr;38(2):101-9 (Eng. Abstr.) **(Spa)**

BLOOD

Clinically significant interference by haemoglobin F during pregnancy with the measurement of HbA1 using the Corning agar electroendosmotic technique. Knapp ML, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):151-3
Density distribution of erythrocytes in class A2 (insulin requiring) gestational diabetes. Lurie S.
Arch Gynecol Obstet 1996;258(2):65-8
Umbilical cord osteocalcin in normal pregnancies and pregnancies complicated by fetal growth retardation or

diabetes mellitus. Verhaeghe J, et al. **Biol Neonate** 1995; 68(6):377–83

Serum levels of insulin–like growth factor–1 in first trimester of diabetic pregnancy: relation to early growth delay. Pedersen JF, et al. **Br J Obstet Gynaecol** 1995 Nov; 102(11):927–8

Diabetes and experimental pregnancy in rats: course of maternal blood glucose levels and its repercussions on the blood glucose levels and pancreas of newborn pups. Rudge MV, et al. **Braz J Med Biol Res** 1995 Feb;28(2):219–25

The comparison of 50 grams glucose challenge test, HbA1c and fructosamine levels in diagnosis of gestational diabetes mellitus. Uncu G, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):230–4

Is macrosomia associated with poor glycaemic control in diabetic pregnancy? Page RC, et al. **Diabet Med** 1996 Feb; 13(2):170–4

Accuracy of blood glucose meters in pregnant subjects with diabetes [letter] Stenger P, et al. **Diabetes Care** 1996 Mar; 19(3):268–9

Similarity of insulin–dependent diabetics' and non–insulin–dependent diabetics' levels of beta–hCG and unconjugated estriol with controls: no need to adjust as with alpha–fetoprotein. Evans MI, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):20–2

Method–dependent increase in lipoprotein(a) in insulin–dependent diabetes mellitus during pregnancy. Pekelharing HL, et al. **Metabolism** 1995 Dec; 44(12):1606–11

Glucose monitoring and insulin therapy during pregnancy. Homko CJ, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):47–74 (95 ref.)

[Estriol and human placental lactogen as risk indicators in pregnancies of diabetic and hypertensive patients] Günter HH, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug; 199(4):142–7 (Eng. Abstr.) **(Ger)**

[Influence of non–diabetic pregnancy on fructosamine and HbA1c concentration] Günter HH, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):148–55 (Eng. Abstr.) **(Ger)**

[The course of pregnancy and fetal outcome in diabetic patients with anamnestic fetal death] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):163–6 (Eng. Abstr.) **(Ger)**

[Changes in levels of chorionic gonadotrophin (hCG) and its subunit alpha and beta in pregnancy complicated by diabetes (GDM)] Olszewski J, et al. **Ginekol Pol** 1995 Feb; 66(2):80–4 (Eng. Abstr.) **(Pol)**

[The importance of study of the hemostatic system for the management of pregnant women with diabetes mellitus] Petrukhin VA, et al. **Klin Lab Diagn** 1995 Nov–Dec; (6):87–9 **(Rus)**

COMPLICATIONS

Perinatal morbidity and mortality in offspring of diabetic mothers in Qatif, Saudi Arabia. al–Dabbous IA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):165–9

Patterns of referral and examination for retinopathy in pregnant women with diabetes by primary care physicians [see comments] Marrero DG, et al. **Ophthalmic Epidemiol** 1995 Jun;2(2):93–8. Comment in: Ophthalmic Epidemiol 1995 Jun;2(2):57–8.

[Diabetic retinopathy and pregnancy] Veougstraete C. **Bull Soc Belge Ophtalmol** 1995;256:33–41 (39 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis of three caudal regression syndromes associated with maternal diabetes] Houfflin V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):389–95 (40 ref.) (Eng. Abstr.) **(Fre)**

[Polypoid cystitis in pregnant diabetic] Estébanez Zarranz MJ, et al. **Actas Urol Esp** 1995 Apr;19(4):333–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Gestational diabetes complicated by severe hypertriglyceridemia and acute pancreatitis. Bar–David J, et al. **Arch Gynecol Obstet** 1996;258(2):101–4

Impaired glucose tolerance of pregnancy by WHO and NDDG criteria National Diabetes Data Group [letter; comment] Ryan EA. **Diabetes Care** 1995 Jul;18(7):1076–7 . Comment on: Diabetes Care 1994 Nov;17(11):1264–8.

Severe axial mesodermal dysplasia spectrum in an infant of a diabetic mother. Depraetere M, et al. **Genet Couns** 1995; 6(4):303–7

[Risk groups of newborn infants of diabetic mothers in relation to their somatic outcome and maternal diabetic metabolic status in pregnancy] Stiete H, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):156–62 (Eng. Abstr.) **(Ger)**

[Diabetic nephropathy and pregnancy] Paternoster DM, et al. **Minerva Ginecol** 1995 Sep;47(9):393–9 (Eng. Abstr.) **(Ita)**

[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**

[Use of fructosamine serum level measurements for diagnosis of insulin–dependent diabetic in pregnancy] Strojek K, et al. **Ginekol Pol** 1995 Nov;66(11):605–8 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Fetal size at birth in relation to quality of blood glucose control in pregnancies complicated by pregestational diabetes mellitus. Persson B, et al. **Br J Obstet Gynaecol** 1996 May;103(5):427–33

Congenital malformations in pregnancies complicated by NIDDM. Towner D, et al. **Diabetes Care** 1995 Nov; 18(11):1446–51

[Effect of insulin therapy on duration of pregnancy in women with diabetes] Kaim I. **Ginekol Pol** 1995 Jun;66(6):318–23 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Phosphotyrosine protein phosphatases and diabetic pregnancy: an association between low molecular weight acid phosphatase and degree of glycemic control. Gloria–Bottini F, et al. **Experientia** 1996 Apr 15;52(4):340–3

EPIDEMIOLOGY

Diabetes in pregnancy in Pakistani women: prevalence and complications in an indigenous south Asian community. Ahkter J, et al. **Diabet Med** 1996 Feb;13(2):189–91

The epidemiology of diabetes and pregnancy in the U.S., 1988. Engelgau MM, et al. **Diabetes Care** 1995 Jul; 18(7):1029–33

Diabetes in pregnancy. Bassaw B, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):5–9

Assessing the risk of gestational diabetes in twin gestation. Henderson CE, et al. **J Natl Med Assoc** 1995 Oct; 87(10):757–8

Women with diabetes during pregnancy: sociodemographics, outcomes, and costs of care. York R, et al. **Public Health Nurs** 1995 Oct;12(5):290–3

[Diabetes screening in pregnant patients with different risk factors. Benefits, therapeutic success, consequences (see comments)] Stoz F, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):138–41 (Eng. Abstr.). Comment in: Z Geburtshilfe Neonatol 1995 Jul–Aug;199(4):176–7. **(Ger)**

[Evaluation of a seven year period of managing pregnancies complicated by diabetes mellitus] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):76–9 (Eng. Abstr.) **(Pol)**

GENETICS

Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Silverman BL, et al. **Diabetes Care** 1995 May;18(5):611–7

Mutation in the mitochondrial tRNA(leu) at position 3243 and spontaneous abortions in Japanese women attending a clinic for diabetic pregnancies. Yanagisawa K, et al. **Diabetologia** 1995 Jul;38(7):809–15

IMMUNOLOGY

Lessons learned from the non–obese diabetic mouse II: Amelioration of pancreatic autoimmune isograft rejection during pregnancy. Chen HM, et al. **Am J Perinatol** 1996 May;13(4):249–54

METABOLISM

Prenatal and perinatal influences on long–term psychomotor development in offspring of diabetic mothers. Rizzo TA, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1753–8

Long–term consequences in offspring of diabetes in pregnancy: studies with syngeneic islet–transplanted streptozotocin–diabetic rats. Ryan EA, et al. **Endocrinology** 1995 Dec;136(12):5587–92

Amniotic fluid insulin and C peptide levels in diabetic and nondiabetic women during early pregnancy. Fallucca F, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):137–9

Increased natriuretic peptides in fetal hearts of diabetic rats. Mulay S, et al. **J Endocrinol** 1995 Aug;146(2):255–9

Insulin–like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies. Roth S, et al. **J Soc Gynecol Investig** 1996 Mar–Apr; 3(2):78–84

Metabolic management of diabetes during labor and delivery. Isseh N, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):175–80

Dexamethasone enhances surfactant protein gene expression in streptozotocin–induced immature rat lungs. Rayani HH, et al. **Pediatr Res** 1995 Dec;38(6):870–7

Yolk sac concentration of prostaglandin E2 in diabetic pregnancy: further clues to the etiology of diabetic embryopathy. Schoenfeld A, et al. **Prostaglandins** 1995 Sep; 50(3):121–6

Transport and metabolism of adenosine in diabetic human placenta. Osses N, et al. **Reprod Fertil Dev** 1995; 7(6):1499–503

[Concentration of magnesium in the amniotic fluid of a patient with diabetes] Doraczynska E, et al. **Ginekol Pol** 1995 Dec;66(12):653–5 (Eng. Abstr.) **(Pol)**

MORTALITY

[Diabetes and pregnancy] Biesenbach G. **Wien Klin Wochenschr** 1996;108(10):281–8 (65 ref.) (Eng. Abstr.) **(Ger)**

NURSING

A model of home care for high–risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327–32 (11 ref.)

PATHOLOGY

Diabetes in pregnancy: uterine blood flow and embryonic development in the rat. Wentzel P, et al. **Pediatr Res** 1995 Oct;38(4):598–606

PHYSIOPATHOLOGY

Renal growth during pregnancy in insulin–dependent diabetic women. A prospective study of renal volume and clinical variables. Lauszus FF, et al. **Acta Diabetol** 1995 Dec; 32(4):225–9

Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Kjos SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1532–9

A random single Doppler study of the umbilical artery in the evaluation of pregnancies complicated by diabetes. Ben–Ami M, et al. **Am J Perinatol** 1995 Nov;12(6):437–8

Guessing the weight of the baby [comment] Hall MH. **Br J Obstet Gynaecol** 1996 Aug;103(8):734–6 (24 ref.). Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):747–54.

Effects of maternal diabetes on blood pressure and glucose tolerance in offspring of spontaneously hypertensive rats: relation to birth weight. Iwase M, et al. **Clin Sci (Colch)** 1995 Sep;89(3):255–60

Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Chew EY, et al. **Diabetes Care** 1995 May; 18(5):631–7

The influence of pregnancy on IDDM complications. Hemachandra A, et al. **Diabetes Care** 1995 Jul;18(7):950–4

Iohexol clearance for assessment of glomerular filtration rate in diabetic pregnancy. Olofsson P, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):63–7

Effect of maternal diabetes on longevity in offspring of spontaneously hypertensive rats. Iwase M, et al. **Gerontology** 1995;41(4):181–6

A case of severe diabetic retinopathy in pregnancy. Nwosu EC, et al. **Hum Reprod** 1995 Sep;10(9):2463–4

Is there a correlation between aortic Doppler velocimetric findings in diabetic pregnant women and fetal outcome? Reece EA, et al. **J Ultrasound Med** 1996 Jun;15(6):437–40

Counterregulatory hormonal responses to hypoglycemia during pregnancy. Rosenn BM, et al. **Obstet Gynecol** 1996 Apr;87(4):568–74

Diabetic retinopathy in pregnancy. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):161–71

Study of lens autofluorescence by fluorophotometry in pregnant patients with diabetes. Beneyto P, et al. **Ophthalmology** 1996 May;103(5):822–6

Circulatory and metabolic effects of hypoxia in the hyperinsulinemic ovine fetus. Stonestreet BS, et al. **Pediatr Res** 1995 Jul;38(1):67–75

Diabetes in pregnancy: uterine blood flow and embryonic development in the rat. Wentzel P, et al. **Pediatr Res** 1995 Oct;38(4):598–606

[Abnormal glucose tolerance and insulin resistance after diabetes in pregnancy] Paulus WE, et al. **Zentralbl Gynakol** 1995;117(8):417–22 (Eng. Abstr.) **(Ger)**

[Comparison of Doppler examination results for utero–placental blood flow and plate–villous index—morphologic determinant of placental barrier in pregnant patients with diabetes] Preis K, et al. **Ginekol Pol** 1995 Jul;66(7):386–90 (Eng. Abstr.) **(Pol)**

[The clinical course of the early neonatal period in the newborn infants of mothers with diabetes mellitus] Znamenskaia TK. **Vrach Delo** 1995 Jan–Feb;(1–2):140–2 **(Rus)**

PREVENTION & CONTROL

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

Metabolic management of diabetes during labor and delivery. Isseh N, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):175–80

Screening and diagnosis for gestational diabetes mellitus among Chippewa women in northern Minnesota. Rith–Najarian SJ, et al. **Minn Med** 1996 May;79(5):21–5

PSYCHOLOGY

Affect in diabetic women during pregnancy and postpartum. York R, et al. **Nurs Res** 1996 Jan–Feb;45(1):54–6

THERAPY

Short–term cost benefit of pre–conception care for diabetes [letter] Elixhauser A, et al. **Diabetes Care** 1996 Apr; 19(4):384

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):205–20 (38 ref.)

Diabetic nephropathy and pregnancy. Kitzmiller JL, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):173–203 (192 ref.)

Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Whiteman VE, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):87–107 (90

ref.)
[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**
[Joint recommendation of the Professional Diabetes and Pregnancy Group, the German Diabetes Society, the German Society of Gynecology and Obstetrics, the German–Austrian Society of Neonatology and Pediatric Intensive Care Medicine and the German Society of Perinatal Medicine for managing newborn infants of diabetic mothers] **Z Geburtshilfe Neonatol** 1996 Mar–Apr; 200(2):79 **(Ger)**
[Monitoring the pregnant diabetic patient] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):132–7 (41 ref.) (Eng. Abstr.) **(Ger)**
[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**
[Diabetes mellitus complicating pregnancy] Penza G, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):26–8 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Fetal cardiac hypertrophy and cardiac function in diabetic pregnancies. Gandhi JA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1132–6
Clinical and ultrasound prediction of macrosomia in diabetic pregnancy [see comments] Johnstone FD, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):747–54. Comment in: Br J Obstet Gynaecol 1996 Aug;103(8):734–6.

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

PREGNANCY MAINTENANCE

PHYSIOLOGY

Disruption of early pregnancy by direct and indirect exposure to novel males in mice: comparison of influences of preputialectomized and intact males. de Catanzaro D, et al. **J Reprod Fertil** 1996 Mar;106(2):269–74

PREGNANCY, MULTIPLE

see related
PREGNANCY REDUCTION, MULTIFETAL

Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Mathur RS, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3–4):233–5 (15 ref.)
Multifetal pregnancy reduction [letter; comment] Aznar J. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):90–1. Comment on: Acta Obstet Gynecol Scand 1994 May;73(5):403–6.
Acardius (acardius acephalus). Jønler M, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):412–4
Prolongation of pregnancy and survival of both twins after preterm premature rupture of membrane of twin A and 19 weeks' gestation. Wu MY, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):299–302
Heterotopic pregnancy after in vitro fertilization. Sucov A, et al. **Am J Emerg Med** 1995 Nov;13(6):641–3
The current status of multifetal pregnancy reduction. Berkowitz RL, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1265–72 (39 ref.)
Delivery of the nonvertex second twin: breech extraction versus external cephalic version. Chauhan SP, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1015–20
Multifetal pregnancy reduction: evaluation of fetal growth in the remaining twins. Depp R, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1233–8; discussion 1238–40
Cerebellar growth in normal and growth-restricted fetuses of multiple gestations. Goldstein I, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1343–8
Etiology and outcome of extremely low-birth-weight infants. Iannucci TA, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1896–900; discussion 1900–2
The clinical outcome of preterm premature rupture of membranes in twin versus singleton pregnancies. Bianco AT, et al. **Am J Perinatol** 1996 Apr;13(3):135–8
Delayed delivery of a triplet pregnancy without surgical intervention: a case report. Ziegler WF, et al. **Am J Perinatol** 1996 Apr;13(3):191–3
Recent trends in the incidence of multiple births and associated mortality in England and Wales. Dunn A, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul;75(1):F10–9
Delayed-interval delivery in a quadruplet pregnancy: the use of transperineal ultrasound and cervical cerclage. Flynn A, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):280–2
Hydrops foetalis in dwarf calves associated with twinning. Harper PA, et al. **Aust Vet J** 1995 Jun;72(6):236–8
Twin births to mothers who are twins: a registry based study. Lichtenstein P, et al. **BMJ** 1996 Apr 6;312(7035):879–81
Rates of triplet pregnancies in Western Australia may be beginning to fall [letter] Watson L, et al. **BMJ** 1996 Sep 7;313(7057):625–6
In vitro fertilisation and gamete intrafallopian transfer: an integrative analysis of research, 1987–1992 [letter; comment] Jenkins JM. **Br J Obstet Gynaecol** 1995 Oct; 102(10):844. Comment on: Br J Obstet Gynaecol 1995 Apr;102(4):317–25.
Pregnancy with stillbirth of both twins. Rydhstroem H. **Br J Obstet Gynaecol** 1996 Jan;103(1):25–32
Yolk sac number, size and morphologic features in monochorionic monoamniotic twin pregnancy. Levi CS, et al. **Can Assoc Radiol J** 1996 Apr;47(2):98–100
Umbilical veins in dichorionic twins. A morpho-functional assessment. Cester N, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):183–97 (34 ref.)
Triplet pregnancy and fetal reduction counselling. Mantzavinos T, et al. **Clin Exp Obstet Gynecol** 1996; 23(1):48–50
Intrapartum management of multiple gestations. Houlihan C, et al. **Clin Perinatol** 1996 Mar;23(1):91–116 (92 ref.)
Multifetal pregnancies. Smith-Levitin M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):465–71 (52 ref.)
Is multiple pregnancy an unavoidable complication of ovulation induction? The case for pulsatile GnRH. Filicori M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S19–21
Multiple pregnancies: the price to pay. Salat-Baroux J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S17–8
Hyperreactio luteinalis masquerading as an ovarian neoplasm in a triplet pregnancy. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):177–80
Multifetal reduction of high-order multiple pregnancy: comparison of obstetrical outcome with nonreduced twin gestations. Alexander JM, et al. **Fertil Steril** 1995 Dec; 64(6):1201–3
A magnetic resonance imaging approach for the diagnosis of a triplet cornual pregnancy. Bassil S, et al. **Fertil Steril** 1995 Nov;64(5):1029–31
Experience with transvaginal ultrasound-guided aspiration of supernumerary follicles for the prevention of multiple pregnancies after ovulation induction and intrauterine insemination. De Geyter C, et al. **Fertil Steril** 1996 Jun; 65(6):1163–8
Pregnancy outcome after early amniotic fluid leakage after transabdominal multifetal reduction [see comments] Lipitz S, et al. **Fertil Steril** 1996 May;65(5):1055–8. Comment in: Fertil Steril 1996 May;65(6):909–11.
A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on-going IVF–ET twin pregnancy. Bar-Hava I, et al. **Gynecol Endocrinol** 1995 Dec;9(4):295–8
Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism. Farina G, et al. **Haematologica** 1995 Jul–Aug;80(4):335–7
Twin pregnancies with complete hydatidiform mole and coexisting fetus: use of fluorescent in situ hybridization to evaluate placental X- and Y-chromosomal content. Choi-Hong SR, et al. **Hum Pathol** 1995 Nov; 26(11):1175–80
Monozygotic triplet pregnancy following transfer of frozen-thawed embryos. Belaisch-Allart J, et al. **Hum Reprod** 1995 Nov;10(11):3064–6
Trizygotic quadruplet pregnancy following in-vitro fertilization: an additional factor against replacement of three embryos in young patients? Biljan MM, et al. **Hum Reprod** 1995 Aug;10(8):2169–70
Multiple births in couples with infertility problems [letter; comment] Garel M, et al. **Hum Reprod** 1995 Oct; 10(10):2748–9. Comment on: Hum Reprod 1995 May;10(5):1079–84.
Multiple births in couples with infertility problems [letter; comment] Hecht BR. **Hum Reprod** 1995 Oct;10(10):2749; discussion 2750. Comment on: Hum Reprod 1995 May;10(5):1079–84.
Spontaneous conception and intrauterine pregnancy in a symptomatic missed abortion of ectopic pregnancy conceived in the previous cycle. Kobayashi F, et al. **Hum Reprod** 1996 Jun;11(6):1347–9
Multiple births in couples with infertility problems [letter] Leiblum S, et al. **Hum Reprod** 1995 Oct;10(10):2750
What factors predetermine the risk of having a high-order multiple pregnancy with gamete intra-fallopian transfer? Nadkarni P, et al. **Hum Reprod** 1996 Mar;11(3):655–9
Delayed interval delivery in quadruplets. Olatunbosun OA, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):287–90
Bilateral tubal pregnancy treated with laparoscopy [letter] Takeuchi K, et al. **Int J Gynaecol Obstet** 1995 Dec; 51(3):259–60
Fetal fibronectin as a screening test for premature delivery in multiple pregnancies. Tolino A, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):3–7
Theriogenology question of the month. Placental insufficiency, probably the result of twin fetuses. Wolfsdorf K. **J Am Vet Med Assoc** 1996 Jan 15;208(2):201–2
A twin pregnancy with a hydatidiform mole and an alive, coexistent baby after in vitro fertilization and embryo transfer. Cheng PJ, et al. **J Assist Reprod Genet** 1995 Jul; 12(6):389–92
Early first-trimester ultrasound provides a window through which the chorionicity of twins can be diagnosed in an in vitro fertilization (IVF) population. Copperman AB, et al. **J Assist Reprod Genet** 1995 Nov;12(10):693–7
Pregnancy-induced Cushing's syndrome in multiple pregnancies. Wallace C, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):15–21
Prenatal prediction of neonatal growth status in twins using individualized growth assessment. Deter RL, et al. **J Clin Ultrasound** 1996 Feb;24(2):53–9
A twin gestation complicated by gastroschisis in both twins. Fuentes A, et al. **J Clin Ultrasound** 1996 Jan;24(1):48–50
Determinants of multiple pregnancies in in vitro fertilization other than number of transferred embryos. Suchartwatnachai C, et al. **J Med Assoc Thai** 1995 Sep; 78(9):481–6
Assessing the risk of gestational diabetes in twin gestation. Henderson CE, et al. **J Natl Med Assoc** 1995 Oct; 87(10):757–8
Role of color flow Doppler ultrasonography in diagnosing velamentous insertion of the umbilical cord and vasa previa. A report of two cases. Raga F, et al. **J Reprod Med** 1995 Nov;40(11):804–8
Multifetal reduction in high-order gestations: a nonelective procedure? [editorial; comment] Simpson JL, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):1–2. Comment on: J Soc Gynecol Investig 1996 Jan–Feb;3(1):23–6.
Prenatal diagnosis of frontonasal dysplasia (median cleft syndrome). Frattarelli JL, et al. **J Ultrasound Med** 1996 Jan;15(1):81–3
Effect of indomethacin on individual amniotic fluid indices in multiple gestations. Hill LM, et al. **J Ultrasound Med** 1996 May;15(5):395–9
Early diagnosis of conjoined twins in triplet pregnancy after in vitro fertilization and assisted hatching. Skupski DW, et al. **J Ultrasound Med** 1995 Aug;14(8):611–5
Date of delivery in multifetal pregnancies [letter] Luke B. **JAMA** 1996 Aug 14;276(6):452
Reestimating date of delivery in multifetal pregnancies. Minakami H, et al. **JAMA** 1996 May 8;275(18):1432–4
Recurrent left atrial myxoma in a patient with a twin fetus pregnancy. Nakata S, et al. **Jpn Circ J** 1996 Feb;60(2):130–2
Atypical presentation of preeclampsia in high-order multifetal gestations. Hardardottir H, et al. **Obstet Gynecol** 1996 Mar;87(3):370–4
Outcome of twin pregnancies reduced from triplets compared with nonreduced twin gestations. Lipitz S, et al. **Obstet Gynecol** 1996 Apr;87(4):511–4
Evaluation of the twin peak or lambda sign in determining chorionicity in multiple pregnancy. Wood SL, et al. **Obstet Gynecol** 1996 Jul;88(1):6–9
Echogenic material in the fetal gallbladder in a surviving monochorionic twin. Sepulveda W, et al. **Pediatr Radiol** 1996;26(2):129–30
Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free-beta hCG and AFP. Barnabei VM, et al. **Prenat Diagn** 1995 Dec;15(12):1131–4
Selective termination of an abnormal fetus in multiple gestations [letter; comment] Berkowitz RL. **Prenat Diagn** 1995 Nov;15(11):1085–7. Comment on: Prenat Diagn 1995 Apr;15(4):386–7.
Twin delivery after a caesarean section — always a section? [letter] Essel JK, et al. **S Afr Med J** 1996 Mar;86(3):279–80
Accuracy of ultrasound estimation of fetal weight in multiple pregnancies. Lynch L, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):349–52
Multiple birth concordance of street drug assays of meconium analysis. Lewis D, et al. **Vet Hum Toxicol** 1995 Aug; 37(4):318–9
[Difficulties in the obstetrical management of the delivery of twins] Pranchev N. **Akush Ginekol (Sofiia)** 1995;34(3):69 (Eng. Abstr.) **(Bul)**
[Clinical use of selective reduction in multifetal pregnancies] Fang Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug; 75(8):459–62, 509 (Eng. Abstr.) **(Chi)**
[Multiple pregnancies. FIVNAT] **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):494–7 (Eng. Abstr.) **(Fre)**
[Monozygotic triplet pregnancy after transfer of frozen embryos] Belaïsch-Allart J, et al. **Contracept Fertil Sex** 1995 Dec;23(12):758–60 (Eng. Abstr.) **(Fre)**
[Is hyaline membrane disease more frequent in multiple pregnancies? (letter)] Chevrel J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):651 **(Fre)**
[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Unusual twin pregnancy: one in the pseudo-unicornate uterus and the other in the rudimentary uterine horn. Discussion on the diagnosis and management during pregnancy] Opinel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):549–52 (Eng. Abstr.) **(Fre)**
[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57–61 (39 ref.) **(Fre)**
[Labor and delivery in twin pregnancy] Wirthner D, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):255–60 (49 ref.) **(Fre)**
[Twins and multiple pregnancy] Arabin B, et al. **Arch Gynecol Obstet** 1995;257(1–4):394–403 (40 ref.) **(Ger)**
-Interruption of umbilical blood flow in an acardiac twin by endoscopic laser coagulation- Hecher K, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):97–100 (Eng. Abstr.) **(Ger)**

[Triplet pregnancy after intracytoplasmic sperm injections] Küpker W, et al. **Geburtshilfe Frauenheilkd** 1995 Sep; 55(9):536–9 (Eng. Abstr.) **(Ger)**

[Antenatal diagnosis of acardius amorphous] Yura S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1381–4 **(Jpn)**

[Triplet and quadruplet pregnancy: management and perinatal outcome] González P, et al. **Rev Chil Obstet Ginecol** 1994;59(5):361–5 (Eng. Abstr.) **(Spa)**

[Biophysical profile in twin pregnancy: prospective study] Medina D, et al. **Rev Chil Obstet Ginecol** 1994;59(5):343–8 (Eng. Abstr.) **(Spa)**

BLOOD

Peripheral cortisol levels throughout gestation in the cow: effect of stage of gestation and foetal number. Patel OV, et al. **Br Vet J** 1996 Jul;152(4):425–32

Predictive value of hCG level 14 days after embryo transfer. Guth B, et al. **J Assist Reprod Genet** 1995 Jan;12(1):13–4

Unexplained elevated maternal serum alpha-fetoprotein levels and pregnancy outcome in twins. Hong S, et al. **Obstet Gynecol** 1996 Sep;88(3):337–42

GENETICS

A search for quantitative trait loci for ovulation rate in cattle. Blattman AN, et al. **Anim Genet** 1996 Jun;27(3):157–62

METABOLISM

Ultrasonographic measurement of amniotic fluid volume in normal diamniotic twin pregnancies. Chau AC, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1003–7

Maternal undernutrition during late pregnancy in sheep. Its relationship to maternal condition, gestation length, hepatic physiology and glucose metabolism. West HJ. **Br J Nutr** 1996 Apr;75(4):593–605

Pregnant woman with Crohn's disease maintained on oral hyperalimentation. Matsubayashi S, et al. **Nutrition** 1995 May-Jun;11(3):300–1

Bone turnover and mineral metabolism in the last trimester of pregnancy: effect of multiple gestation. Okah FA, et al. **Obstet Gynecol** 1996 Aug;88(2):168–73

PHYSIOLOGY

Identical triplets in a thoroughbred mare [see comments] Meadows SJ, et al. **Equine Vet J** 1995 Sep;27(5):394–7. Comment in: Equine Vet J 1995 Sep;27(5):321.

Monozygotic triplets in the mare [editorial; comment] Short RV. **Equine Vet J** 1995 Sep;27(5):321. Comment on: Equine Vet J 1995 Sep;27(5):394–7.

Differential fertility of mothers of twins and mothers of singletons: study in Limon, Costa Rica. Madrigal L. **Hum Biol** 1995 Oct;67(5):779–87

The intrauterine ponderal index in relation to birth weight discordance in twin gestations. Blickstein I, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):253–5

Maternal weight gains in ideal twin outcomes. Luke B, et al. **J Am Diet Assoc** 1996 Feb;96(2):178–81

Maternal weight gain patterns and birth weight outcome in twin gestation. Lantz ME, et al. **Obstet Gynecol** 1996 Apr; 87(4):551–6

Normal values for amniotic fluid index during uncomplicated twin pregnancy. Porter TF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):699–702

Production of twin calves with in vitro fertilised embryos: effects on the reproductive performance of dairy cows. McEvoy JD, et al. **Vet Rec** 1995 Jun 24;136(25):627–32

[Spontaneous abortion of one twin and later spontaneous delivery of the surviving twin] Kouam L, et al. **Zentralbl Gynakol** 1995;117(11):604–7 (Eng. Abstr.) **(Ger)**

[Effect of blood flow velocity on umbilical vessels in twin pregnancy] Gąsior W, et al. **Ginekol Pol** 1995 Aug; 66(8):477–9 (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Accommodating a twin pregnancy: maternal processes. Van der Zalm JE. **Acta Genet Med Gemellol (Roma)** 1995; 44(2):117–33

Attitudes of in vitro fertilization and intrauterine insemination couples toward multiple gestation pregnancy and multifetal pregnancy reduction. Goldfarb J, et al. **Fertil Steril** 1996 Apr;65(4):815–20

Multifetal pregnancy reduction. A review of an evolving technology and its psychosocial implications. Ormont MA, et al. **Psychosomatics** 1995 Nov-Dec;36(6):522–30 (29 ref.)

[Fate of supernumerary embryos and risk of multiple pregnancy in in-vitro fertilization: attitude of involved couples] Laruelle C, et al. **Rev Med Brux** 1996 Jun; 17(3):115–9 (Eng. Abstr.) **(Fre)**

[31 years experiences with triplets. 13 years self-help for parents with the ABC Club e.V., International Triplet and Multiple Birth Initiative] Grützner-Könnecke H. **Geburtshilfe Frauenheilkd** 1995 Aug;55(8):M88–9 **(Ger)**

[Pregnancy, labor and partnership in a family with an IVF child] Pastor VS, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):M83–7 (45 ref.) **(Ger)**

STATISTICS & NUMERICAL DATA

The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes. Czeizel AE, et al. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):175–84

What proportion of multiple births are due to ovulation induction? A register-based study in Italy. Corchia C, et al. **Am J Public Health** 1996 Jun;86(6):851–4

Assisted reproductive technologies: estimates of their contribution to multiple births and newborn hospital days in the United States. Wilcox LS, et al. **Fertil Steril** 1996 Feb;65(2):361–6 (25 ref.)

Are 'natural' twinning rates continuing to decline? James WH. **Hum Reprod** 1995 Nov;10(11):3042–4

Twins and other multiples: progress with a price [editorial] Keith LG. **Int J Gynaecol Obstet** 1995 Nov;51(2):105–8

Excess males in preterm birth: interactions with gestational age, race, and multiple birth. Cooperstock M, et al. **Obstet Gynecol** 1996 Aug;88(2):189–93

Incidence of multiple ovulation and multiple pregnancy in mares. Newcombe JR. **Vet Rec** 1995 Jul 29;137(5):121–3

PREGNANCY OUTCOME

Pregnancy outcome after laser surgery for cervical intraepithelial neoplasia. Forsmo S, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):139–43

Possible influence of expatriation on perinatal outcome. Kuvacic I, et al. **Acta Obstet Gynecol Scand** 1996 Apr; 75(4):367–71

Accuracy of the umbilical arteries Doppler flow velocity waveforms in detecting adverse perinatal outcomes in a high-risk population. Todros T, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):113–9

Fetal congenital diaphragmatic hernia: accuracy of sonography in the diagnosis and prediction of the outcome after birth. Guibaud L, et al. **AJR Am J Roentgenol** 1996 May;166(5):1195–202

Dietary and serum folate: their influence on the outcome of pregnancy. Scholl TO, et al. **Am J Clin Nutr** 1996 Apr; 63(4):520–5

Epidemiology of preterm delivery in two birth cohorts with an interval of 20 years. Olsën P, et al. **Am J Epidemiol** 1995 Dec 1;142(11):1184–93

A study of eight medical centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal outcome with comparison control groups. Cappell MS, et al. **Am J Gastroenterol** 1996 Feb;91(2):348–54

Correlations of placental vascular anatomy and clinical outcomes in 69 monochorionic twin pregnancies. Machin G, et al. **Am J Med Genet** 1996 Jan 22;61(3):229–36

Pregnancy outcomes in the Diabetes Control and Complications Trial. **Am J Obstet Gynecol** 1996 Apr; 174(4):1343–53

Monitored outpatient management of mild gestational hypertension remote from term in teenage pregnancies. Barton JR, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1865–8

The impact of the Women, Infants and Children Food Supplement Program on birth outcome. Brown HL, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1279–83

On intrapartum fetal monitoring. Cibils LA. **Am J Obstet Gynecol** 1996 Apr;174(4):1382–9 (71 ref.)

Successful pregnancy in association with Zollinger-Ellison syndrome. Harper MA, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):863–4

Etiology and outcome of extremely low-birth-weight infants. Iannucci TA, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1896–900; discussion 1900–2

Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum alpha-fetoprotein levels. Konchak PS, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1115–9

Employment, exertion, and pregnancy outcome: assessment by kilocalories expended each day. Magann EF, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):182–7

The obstetric outcome of in vitro fertilization and embryo transfer in women with congenital uterine malformation. Marcus S, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):85–9

Perinatal outcome in relation to second-stage duration. Menticoglou SM, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):906–12

Vaginal birth after cesarean section in twin gestation. Miller DA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):194–8

Trauma in pregnancy: the role of interpersonal violence. Poole GV, et al. **Am J Obstet Gynecol** 1996 Jun; 174(6):1873–7; discussion 1877–8

Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Regan JA, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1354–60

Obstetric outcome after failed termination of pregnancy--a report of two cases. Ricciotti HA, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1619–20

Neonatal outcome after preterm delivery for preeclampsia [letter; comment] Rigo JJr, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1080–1. Comment on: Am J Obstet Gynecol 1995 Jun;172(6):1785–8; discussion 1788–92.

Head entrapment and neonatal outcome by mode of delivery in breech deliveries from twenty-four to twenty-seven weeks of gestation. Robertson PA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1171–6

Maternal and neonatal outcome of 846 term singleton breech deliveries: seven-year experience at a single center. Schiff E, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):18–23

Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Schleifer RA, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1152–6

Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Simpson JL, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1742–8

Pregnancy outcomes and health care use: effects of abuse. Webster J, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):760–7

Fetal macrosomia: does antenatal prediction affect delivery route and birth outcome? Weeks JW, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1215–9

A random single Doppler study of the umbilical artery in the evaluation of pregnancies complicated by diabetes. Ben-Ami M, et al. **Am J Perinatol** 1995 Nov;12(6):437–8

The clinical outcome of preterm premature rupture of membranes in twin versus singleton pregnancies. Bianco AT, et al. **Am J Perinatol** 1996 Apr;13(3):135–8

Correlation of fetal heart rate decelerations following acoustic stimulation with perinatal outcome. Dunston-Boone G, et al. **Am J Perinatol** 1995 Sep; 12(5):342–6

Clinical significance of neurofibromatosis in pregnancy. Hadi HA. **Am J Perinatol** 1995 Nov;12(6):459–61 (11 ref.)

Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Rogers RG, et al. **Am J Perinatol** 1995 Jul;12(4):262–4

Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):50–6

The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):2–7

The fetus comes of age [editorial] Holdcroft A. **Anaesthesia** 1995 Nov;50(11):925–7

Fetal morbidity in herpes gestationis [letter] Mascaró JM Jr, et al. **Arch Dermatol** 1995 Oct;131(10):1209–10

Outcome of triplet pregnancies [letter] Cooke R. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F197

Recent trends in the incidence of multiple births and associated mortality in England and Wales. Dunn A, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul;75(1):F10–9

Laser 'miniconisation' and the outcome of subsequent pregnancy. Békássy Z, et al. **Arch Gynecol Obstet** 1996; 258(2):75–9

The outcome of pregnancy in an immigrant Ethiopian population in Israel. Segal S, et al. **Arch Gynecol Obstet** 1996;258(1):43–6

Obstetric health services in Far North Queensland: is choice an option? Fitzpatrick JM. **Aust J Public Health** 1995 Dec; 19(6):580–8

Maternal nutrition and obstetric outcome. Steegers-Theunissen BP. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):431–43 (65 ref.)

How can new behavioral knowledge and proven aids to treatment enter the teaching and practice of obstetrics? [comment] Good RS, et al. **Behav Med** 1995 Fall; 21(3):123–9. Comment on: Behav Med 1995 Fall;21(3):101–12. Comment on: Behav Med 1995 Fall;21(3):113–22.

Successful pregnancy after allogeneic bone marrow transplantation following conditioning including a 10-Gy single exposure total body irradiation [letter; comment] Milpied N, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):467. Comment on: Bone Marrow Transplant 1995 Apr;15(4):637–8.

Fertility, reproductive outcomes, and health of offspring, of patients treated for Hodgkin's disease: an investigation including chromosome examinations. Swerdlow AJ, et al. **Br J Cancer** 1996 Jul;74(2):291–6

Umbilical coiling index: is it a marker for the foetus at risk? Ercal T, et al. **Br J Clin Pract** 1996 Jul-Aug;50(5):254–6

Obstetric outcome of pregnancies resulting from embryos biopsied for pre-implantation diagnosis of inherited disease. Soussis I, et al. **Br J Obstet Gynaecol** 1996 Aug; 103(8):784–8

Maternal anthropometry and pregnancy outcomes. A WHO Collaborative Study. **Bull World Health Organ** 1995;73 Suppl:1–98

Carbon monoxide poisoning in pregnancy. **Can Fam Physician** 1996 May;42:854–5

Effect of taurine deficiency on tissue taurine concentrations and pregnancy outcome in the rat. Gottschall-Pass KT, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1130–5

Self-reported snoring in pregnancy. Association with fetal outcome [see comments] Loube DI, et al. **Chest** 1996 Apr; 109(4):885–9. Comment in: Chest 1996 Apr;109(4):859–61.

Prospective studies on the relationship between the 50 g glucose challenge test and pregnant outcome. Sun B, et al. **Chin Med J (Engl)** 1995 Dec;108(12):910–3

Pregnancy following in vitro fertilization and embryo transfer by microsurgical epididymal sperm aspiration from a patient with congenital absence of the vas deferens: a case report. Tzeng CR, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb;57(2):161–4

Mild maternal drinking and pregnancy outcome: perceived

versus true risks. Koren G, et al. **Clin Chim Acta** 1996 Mar 15;246(1-2):155-62

Postmaturity: how far is it a clinical entity in its own right? Carlomagno G, et al. **Clin Exp Obstet Gynecol** 1996; 23(1):41-7

Exercise during pregnancy and pregnancy outcome. Tanji J. **Clin J Sport Med** 1995 Oct;5(4):267

Pregnancy in patients with cystic fibrosis. Hilman BC, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):70-86 (54 ref.)

Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56-69 (44 ref.)

Pregnancy outcomes in women without gestational diabetes mellitus related to the maternal glucose level. Is there a continuum of risk? Moses RG, et al. **Diabetes Care** 1995 Dec;18(12):1527-33

Surgical management of female infertility in Ilorin, Nigeria [see comments] Anate M, et al. **East Afr Med J** 1995 Jul; 72(7):411-4. Comment in: East Afr Med J 1995 Jul;72(7):409-10.

Return of fertility after an IUD removal for planned pregnancy: a six year prospective study. Tadesse E. **East Afr Med J** 1996 Mar;73(3):169-71

Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165-71 (34 ref.)

Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. Ananth CV, et al. **Epidemiology** 1995 Jul;6(4):391-5

Breech delivery and foetal outcome: a review of 291 cases. Mekbib TA. **Ethiop Med J** 1995 Jul;33(3):175-82

Biochemical assessment of nutritional status in pre- and post-natal Turkish women and outcome of pregnancy. Açkurt F, et al. **Eur J Clin Nutr** 1995 Aug;49(8):613-22

Reproductive outcome after hysteroscopic metroplasty. Colacurci N, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):147-50

Stretching of the cervix and stripping of the membranes at term: a randomised controlled study. Goldenberg M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):129-32

Breech presentation and cesarean section in term nulliparous women. Leiberman JR, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Aug;61(2):111-5

Fertility and pregnancy outcome after myomectomy in sterility patients. Sudik R, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Apr;65(2):209-14

A retrospective study of 11 pregnant women with thermal injuries. Unsür V, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Jan;64(1):55-8

Feedback of obstetrical outcomes as an educational tool [letter] Fox CH, et al. **Fam Med** 1995 Sep;27(8):486-7

Multifetal reduction of high-order multiple pregnancy: comparison of obstetrical outcome with nonreduced twin gestations. Alexander JM, et al. **Fertil Steril** 1995 Dec; 64(6):1201-3

Effect of abnormal hypo-osmotic swelling test on fertilization rate and pregnancy outcome in in vitro fertilization cycles. Biljan MM, et al. **Fertil Steril** 1996 Sep;66(3):412-6

Comparisons of pregnancy loss patterns after intracytoplasmic sperm injection and other assisted reproductive technologies. Coulam CB, et al.
Fertil Steril 1996 Jun;65(6):1157-62

Successful pregnancy outcome after cryopreservation of all fresh embryos with subsequent transfer into an unstimulated cycle. Frederick JL, et al. **Fertil Steril** 1995 Nov; 64(5):987-90

Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Licciardi FL, et al. **Fertil Steril** 1995 Nov;64(5):991-4

Pregnancy outcome after early amniotic fluid leakage after transabdominal multifetal reduction [see comments] Lipitz S, et al. **Fertil Steril** 1996 May;65(5):1055-8. Comment in: Fertil Steril 1996 May;65(6):909-11.

Pregnancy and birth after intracytoplasmic sperm injection of in vitro matured germinal-vesicle stage oocytes: case report. Nagy ZP, et al. **Fertil Steril** 1996 May;65(5):1047-50

Outcome of ovum donation in Turner's syndrome patients. Press F, et al. **Fertil Steril** 1995 Nov;64(5):995-8

Successful establishment of pregnancy by superovulation and intrauterine insemination with sperm recovered by a modified Hotchkiss procedure from a patient with retrograde ejaculation. Ranieri DM, et al. **Fertil Steril** 1995 Nov;64(5):1039-42

Outcome of urological abnormalities prenatally diagnosed by ultrasound. Podevin G, et al. **Fetal Diagn Ther** 1996 May-Jun;11(3):181-90

HIV infection and maternal outcome of pregnancy in Mozambican women: a case-control study [letter] Bergström S, et al. **Genitourin Med** 1995 Oct;71(5):323-4

Polycystic ovarian syndrome: pregnancy outcome following in vitro fertilization-embryo transfer. Alcalay M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):119-23

Evaluation of a new embryo-grading system to predict pregnancy rates following in vitro fertilization. Hoover L, et al. **Gynecol Obstet Invest** 1995;40(3):151-7

When is the optimal time for delivery?—Purely from the fetuses' perspective. Minakami H, et al.
Gynecol Obstet Invest 1995;40(3):174-8

Prepregnancy headache and the well-being of mother and newborn. Aromaa M, et al. **Headache** 1996 Jul-Aug; 36(7):409-15

Maternal varicella during pregnancy: correlation of maternal history and fetal outcome with placental histopathology. Qureshi F, et al. **Hum Pathol** 1996 Feb;27(2):191-5

Outcome of pregnancy in women with recurrent spontaneous abortion following immunotherapy with allogeneic lymphocytes. Agrawal S, et al. **Hum Reprod** 1995 Sep; 10(9):2280-4

Ovarian autoimmunity and corticotherapy in an in-vitro fertilization attempt. Barbarino-Monnier P, et al.
Hum Reprod 1995 Aug;10(8):2006-7

Nurses performing embryo transfer: successful outcome of in-vitro fertilization. Barber D, et al. **Hum Reprod** 1996 Jan;11(1):105-8

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Clark AM, et al. **Hum Reprod** 1995 Oct;10(10):2705-12

Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile? Corsan G, et al. **Hum Reprod** 1996 May;11(5):1109-12

Implantation failure and immunotherapy. Coulam CB.
Hum Reprod 1995 Jun;10(6):1338-40

Outcome of intracytoplasmic sperm injection with testicular spermatozoa in obstructive and non-obstructive azoospermia. Devroey P, et al. **Hum Reprod** 1996 May; 11(5):1015-8

Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Farhi J, et al. **Hum Reprod** 1995 Oct;10(10):2576-8

Pregnancy and lifestyle study: the long-term use of the contraceptive pill and the risk of age-related miscarriage. Ford JH, et al. **Hum Reprod** 1995 Jun;10(6):1397-402

Results of IVF in patients with endometriosis: the severity of the disease does not affect outcome, or the incidence of miscarriage. Geber S, et al. **Hum Reprod** 1995 Jun; 10(6):1507-11

Reproductive outcome following hysteroscopic management of intrauterine septum and adhesions. Goldenberg M, et al. **Hum Reprod** 1995 Oct;10(10):2663-5

Pregnancy outcome after multifetal pregnancy reduction to twins compared with spontaneously conceived twins. Groutz A, et al. **Hum Reprod** 1996 Jun;11(6):1334-6

Fertility after ectopic pregnancy: first results of a population-based cohort study in france. Job-Spira N, et al. **Hum Reprod** 1996 Jan;11(1):99-104

Successful pregnancy outcome in a renal transplant patient following in-vitro fertilization. Lockwood GM, et al.
Hum Reprod 1995 Jun;10(6):1528-30

Autoantibodies and antisperm antibodies in sera and follicular fluids of infertile patients; relation to reproductive outcome after in-vitro fertilization. Nip MM, et al. **Hum Reprod** 1995 Oct;10(10):2564-9

Pregnancy and birth after intracytoplasmic sperm injection with spermatozoa from a patient with tail stump syndrome. Stalf T, et al. **Hum Reprod** 1995 Aug;10(8):2112-4

The outcome of intracytoplasmic sperm injection is unrelated to 'strict criteria' sperm morphology. Svalander P, et al.
Hum Reprod 1996 May;11(5):1019-22

Potential effects of Omeprazole in pregnancy [letter] Tsirigotis M, et al. **Hum Reprod** 1995 Aug;10(8):2177-8

Obstetric and perinatal outcome of pregnancies following intracytoplasmic sperm injection. Wennerholm UB, et al.
Hum Reprod 1996 May;11(5):1113-9

Obstetric outcome of 424 pregnancies after intracytoplasmic sperm injection. Wisanto A, et al. **Hum Reprod** 1995 Oct; 10(10):2713-8

Immunoglobulin G and complement C3 levels in pregnancy induced hypertension. Ramdenee GR, et al.
Indian Pediatr 1995 Feb;32(2):179-83

Diabetes in pregnancy. Bassaw B, et al.
Int J Gynaecol Obstet 1995 Jul;50(1):5-9

Granuloma inguinale in association with pregnancy and HIV infection. Hoosen AA, et al. **Int J Gynaecol Obstet** 1996 May;53(2):133-8

Great grand multiparity—beyond the 10th delivery. Kaplan B, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):17-9

Prediction of early pregnancy outcomes. Lin YS, et al.
Int J Gynaecol Obstet 1995 Oct;51(1):33-8

The outcome of placenta accreta in Kuwait (1981-1993). Makhseed M, et al. **Int J Gynaecol Obstet** 1995 Aug; 50(2):139-44

Determinants of pregnancy outcome in patients with gestational diabetes. Nasrat H, et al.
Int J Gynaecol Obstet 1996 May;53(2):117-23

Fetal biophysical profile and vibratory acoustic stimulation in high-risk pregnancies. Petrović O, et al.
Int J Gynaecol Obstet 1995 Jul;50(1):11-5

Pregnancy following rupture of the pregnant uterus. Soltan MH, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):37-42

Pulmonary hypertension, cardiac disease and pregnancy. Tahir H. **Int J Gynaecol Obstet** 1995 Nov;51(2):109-13

Pregnancy outcome among long-term survivors with acute leukemia. Kawamura S, et al. **Int J Hematol** 1995 Oct; 62(3):157-61

Neonatal outcome and obstetric complications in women with gestational diabetes: effects of maternal body mass index. Di Cianni G, et al.
Int J Obes Relat Metab Disord 1996 May;20(5):445-9

Rubella in pregnancy in Israel: 15 years of follow-up and remaining problems. Fogel A, et al. **Isr J Med Sci** 1996 May;32(5):300-5

Prenatal care and birth outcomes of a cohort of HIV-infected women. Turner BJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12(3):259-67

Perinatal outcomes: a comparison between family physicians and obstetricians [see comments] Deutchman ME, et al. **J Am Board Fam Pract** 1995 Nov-Dec;8(6):440-7. Comment in: J Am Board Fam Pract 1995 Nov-Dec;8(6):494-6. Comment in: J Am Board Fam Pract 1996 Mar-Apr;9(2):152-3.

Pregnancy outcomes after the Fontan repair. Canobbio MM, et al. **J Am Coll Cardiol** 1996 Sep;28(3):763-7

Maternal weight gains in ideal twin outcomes. Luke B, et al. **J Am Diet Assoc** 1996 Feb;96(2):178-81

Not all prenatal care is appropriate care. Atrash HK.
J Am Med Wom Assoc 1995 Sep-Oct;50(5):144-6

Employment-related physical activity and pregnancy outcome. Berkowitz GS. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):167-9, 174 (33 ref.)

Parental care and women's health [editorial] Chavkin W.
J Am Med Wom Assoc 1995 Sep-Oct;50(5):143

Heterogeneity between women who received prenatal care in the third trimester and those who received no prenatal care. Elam-Evans LD, et al. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):175-7

Prenatal care—the good, the bad, and the ugly. Marks JS.
J Am Med Wom Assoc 1995 Sep-Oct;50(5):146

Prenatal WIC participation related to Medicaid cost savings and infant health outcomes. **J Ark Med Soc** 1995 Nov; 92(6):297-9

The first pregnancy in a transport-intracytoplasmic sperm injection (T-ICSI) scheme. Anyaegbunam W, et al.
J Assist Reprod Genet 1995 Jul;12(6):396-8

Families created through ovum donation: a preliminary investigation of obstetrical outcome and psychosocial adjustment. Applegarth L, et al. **J Assist Reprod Genet** 1995 Oct;12(9):574-80

Screening of maternal sera using a mouse embryo culture assay is not predictive of human embryo development or IVF outcome. Clarke RN, et al. **J Assist Reprod Genet** 1995 Jan;12(1):20-5

Predictive value of hCG level 14 days after embryo transfer. Guth B, et al. **J Assist Reprod Genet** 1995 Jan;12(1):13-4

Successful delivery at age 61: report of a case as a result of oocyte donation. Sposetti R. **J Assist Reprod Genet** 1995 Oct;12(9):658-60

Transvaginal sonography of the yolk sac in normal and abnormal pregnancy. Stampone C, et al.
J Clin Ultrasound 1996 Jan;24(1):3-9

Significance of nuchal cord. Dhar KK, et al.
J Indian Med Assoc 1995 Dec;93(12):451-3

Effect of prenatal care on obstetrical outcome. Amini SB, et al. **J Matern Fetal Med** 1996 May-Jun;5(3):142-50

Logistic regression generated probability estimates for trisomy 21 outcomes from serum alpha fetoprotein and beta human chorionic gonadotrophin: simplification with increased specificity. Evans MI, et al.
J Matern Fetal Med 1996 Jan-Feb;5(1):1-6

Subchorionic hematomas in early pregnancy: clinical outcome and blood flow patterns. Kurjak A, et al.
J Matern Fetal Med 1996 Jan-Feb;5(1):41-4

Emergent cervical cerclage: predictors of success or failure. Latta RA, et al. **J Matern Fetal Med** 1996 Jan-Feb; 5(1):22-7

Maternal congenital heart disease and pregnancy outcome. Chia YT, et al. **J Obstet Gynaecol Res** 1996 Apr; 22(2):185-91

Successful pregnancy after intracytoplasmic injection of a single testicular spermatozoon into a human oocyte: a case report. Suganuma N, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):111-7

Pregnancy outcomes among active and sedentary primiparous women. Horns PN, et al.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):49-54

Adolescent parenting: outcomes and maternal perceptions. Thompson PJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):713-8

Reproductive effects of chemical exposures in health professions. Ahlborg G Jr, et al. **J Occup Environ Med** 1995 Aug;37(8):957-61

Physical work load and pregnancy outcome. Ahlborg G Jr.
J Occup Environ Med 1995 Aug;37(8):941-4

Biological agents and pregnancy. Ekblad U.
J Occup Environ Med 1995 Aug;37(8):962-5

Magnetic fields of video display terminals and pregnancy outcome. Lindbohm ML, et al. **J Occup Environ Med** 1995 Aug;37(8):952-6 (30 ref.)

Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908-14 (48 ref.)

Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935-40 (27 ref.)

Female noise exposure, shift work, and reproduction. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):945-50 (31 ref.)

The outcome of post-term pregnancy. A comparative study. Kaplan B, et al. **J Perinat Med** 1995;23(3):183-9

Good fetal outcome following prolonged indomethacin induced anhydramnios. Case report. Shen O, et al.
J Perinat Med 1995;23(3):233-6

Natal status of infants of cocaine users and control subjects: a prospective comparison. Hurt H, et al. **J Perinatol** 1995 Jul-Aug;15(4):297-304

Martial status and military occupational specialty: neither factor has a selective adverse effect on pregnancy outcome. Magann EF, et al. **J Perinatol** 1995 Sep–Oct;15(5):372–4

Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. Paarlberg KM, et al. **J Psychosom Res** 1995 Jul;39(5):563–95 (136 ref.)

Perinatal death: worse obstetric and neonatal outcome in a subsequent pregnancy. Crowther ME. **J R Army Med Corps** 1995 Jun;141(2):92–7

Leuprolide acetate for inducing ovulation in women undergoing ovarian stimulation. diDonato P, et al. **J Reprod Med** 1995 Oct;40(10):715–6

Pregnancy after the fontan procedure for tricuspid atresia. A case report. Lao TT, et al. **J Reprod Med** 1996 Apr; 41(4):287–90

First–trimester pancreatitis. Maternal and neonatal outcome. Legro RS, et al. **J Reprod Med** 1995 Oct;40(10):689–95

Hysteroscopically detected asymptomatic müllerian anomalies. Prevalence and reproductive implications. Maneschi F, et al. **J Reprod Med** 1995 Oct;40(10):684–8

Successful pregnancy in a patient with hemolytic–uremic syndrome during the second trimester of pregnancy. Martínez–Román S, et al. **J Reprod Med** 1996 Mar; 41(3):211–4

Spontaneous pregnancies despite failed attempts at ovulation induction in a woman with latrogenic premature ovarian failure. Menashe Y, et al. **J Reprod Med** 1996 Mar; 41(3):207–10

Pregnancy in women under 35 with elevated early follicular phase follicle–stimulating hormone levels. A report of five cases. Rose BI. **J Reprod Med** 1996 Mar;41(3):201–4

Pregnancy outcome in women with low midtrimester maternal serum unconjugated estriol. Santolaya–Forgas J, et al. **J Reprod Med** 1996 Feb;41(2):87–90

Benefits from a teen pregnancy program: neonatal outcomes potential cost savings. Blackhurst DW, et al. **J S C Med Assoc** 1996 May;92(5):209–15

Correlation of serum cytokine and adhesion molecule determinations with pregnancy outcome. Schust DJ, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):259–61

Comparison of umbilical Doppler velocimetry, nonstress testing, and biophysical profile in pregnancies complicated by diabetes. Bracero LA, et al. **J Ultrasound Med** 1996 Apr;15(4):301–8

The clinical implications of early diastolic notch in third trimester Doppler waveform analysis of the uterine artery. Park YW, et al. **J Ultrasound Med** 1996 Jan;15(1):47–51

Effect of frequency of prenatal care visits on perinatal outcome among low–risk women. A randomized controlled trial [see comments] McDuffie RS Jr, et al. **JAMA** 1996 Mar 20;275(11):847–51. Comment in: JAMA 1996 Jul 10;276(2):101.

Frequency of prenatal care visits and perinatal outcome [letter; comment] Zalar RW. **JAMA** 1996 Jul 10;276(2):101 . Comment on: JAMA 1996 Mar 20;275(11):847–51.

Randomised controlled trial of a reduced–visits programme of antenatal care in Harare, Zimbabwe. Munjanja SP, et al. **Lancet** 1996 Aug 10;348(9024):364–9

Methodologic issues in the study of second malignant neoplasms and pregnancy outcomes. Robison LL. **Med Pediatr Oncol Suppl** 1996;1:41–4

Birth outcomes in pregnant women taking fluoxetine [see comments] Chambers CD, et al. **N Engl J Med** 1996 Oct 3;335(14):1010–5. Comment in: N Engl J Med 1996 Oct 3;335(14):1056–8.

Pregnancy and renal disease [editorial; comment] Epstein FH. **N Engl J Med** 1996 Jul 25;335(4):277–8. Comment on: N Engl J Med 1996 Jul 25;335(4):226–32.

Association between bacterial vaginosis and preterm delivery of a low–birth–weight infant. The Vaginal Infections and Prematurity Study Group [see comments] Hillier SL, et al. **N Engl J Med** 1995 Dec 28;333(26):1737–42. Comment in: N Engl J Med 1995 Dec 28;333(26):1772–4. Comment in: N Engl J Med 1996 May 16;334(20):1337–8; discussion 1338–9. Comment in: N Engl J Med 1996 May 16;334(20):1338–9.

Outcome of pregnancy in women with moderate or severe renal insufficiency [see comments] Jones DC, et al. **N Engl J Med** 1996 Jul 25;335(4):226–32. Comment in: N Engl J Med 1996 Jul 25;335(4):277–8.

Treatment depression in pregnancy [editorial; comment] Robert E. **N Engl J Med** 1996 Oct 3;335(14):1056–8. Comment on: N Engl J Med 1996 Oct 3;335(14):1010–15.

Normal pregnancy after renal transplantation [letter] Vergoulas G, et al. **Nephrol Dial Transplant** 1995; 10(5):717–8

Maternal risk factors in fetal alcohol syndrome: provocative and permissive influences. Abel EL, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):445–62 (327 ref.)

The effect of chronic cocaine exposure during pregnancy on maternal and infant outcomes in the rhesus monkey. Morris P, et al. **Neurotoxicol Teratol** 1996 Mar–Apr; 18(2):147–54

Hyperechogenic fetal bowel and elevated serum alpha–fetoprotein: a poor fetal prognosis. Achiron R, et al. **Obstet Gynecol** 1996 Sep;88(3):368–71

Elevated second–trimester maternal serum hCG alone or in combination with elevated alpha–fetoprotein. Benn PA, et al. **Obstet Gynecol** 1996 Feb;87(2):217–22

Pregnancy in patients with preexisting transverse myelitis. Berghella V, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):809–12

Pregnancy outcome at age 40 and older. Bianco A, et al. **Obstet Gynecol** 1996 Jun;87(6):917–22

Intentional delivery versus expectant management with preterm ruptured membranes at 30–34 weeks' gestation [letter; comment] Boulvain M. **Obstet Gynecol** 1996 May; 87(5 Pt 1):798–9. Comment on: Obstet Gynecol 1995 Dec;86(6):875–9.

Pregnancy outcome following genetic amniocentesis at 11–14 versus 16–19 weeks' gestation. Brumfield CG, et al. **Obstet Gynecol** 1996 Jul;88(1):114–8

Intentional delivery versus expectant management with preterm ruptured membranes at 30–34 weeks' gestation [see comments] Cox SM, et al. **Obstet Gynecol** 1995 Dec; 86(6):875–9. Comment in: Obstet Gynecol 1996 May;87(5 Pt 1):798–9.

Pregnancy complications and birth outcomes in obese and normal–weight women: effects of gestational weight change. Edwards LE, et al. **Obstet Gynecol** 1996 Mar; 87(3):389–94

Two successful vaginal deliveries in a heart transplant recipient. Eskandar M, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):880

Acute myocardial infarction in pregnancy with subsequent medical and surgical management. Garry D, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):802–4

Perinatal outcome and long–term follow–up associated with modern management of diabetic nephropathy. Gordon M, et al. **Obstet Gynecol** 1996 Mar;87(3):401–9

Perinatal diagnostic evaluation of velamentous umbilical cord insertion: clinical, Doppler, and ultrasonic findings. Heinonen S, et al. **Obstet Gynecol** 1996 Jan;87(1):112–7

Unexplained elevated maternal serum alpha–fetoprotein levels and pregnancy outcome in twins. Hong S, et al. **Obstet Gynecol** 1996 Sep;88(3):337–42

Effect of age on intrauterine insemination with frozen donor sperm. Kang BM, et al. **Obstet Gynecol** 1996 Jul;88(1):93–8

Expectant management of twin pregnancies discordant for anencephaly. Lipitz S, et al. **Obstet Gynecol** 1995 Dec; 86(6):969–72

Outcome of twin pregnancies reduced from triplets compared with nonreduced twin gestations. Lipitz S, et al. **Obstet Gynecol** 1996 Apr;87(4):511–4

Prolonged labor in nulliparas: lessons from the active management of labor. Malone FD, et al. **Obstet Gynecol** 1996 Aug;88(2):211–5

Outcome of twin gestations complicated by a single anomalous fetus. Malone FD, et al. **Obstet Gynecol** 1996 Jul;88(1):1–5

Adverse pregnancy outcome after a false–positive screen for Down syndrome using multiple markers [letter; comment] Marcotte MP. **Obstet Gynecol** 1995 Dec;86(6):1035–6. Comment on: Obstet Gynecol 1995 Aug;86(2):255–8.

Maternal and perinatal outcome of patients with preterm labor and meconium–stained amniotic fluid. Mazor M, et al. **Obstet Gynecol** 1995 Nov;86(5):830–3

Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Smith JA, et al. **Obstet Gynecol** 1996 Feb;87(2):199–204

Singleton pregnancy after in vitro fertilization: expectations and outcome. Verlaenen H, et al. **Obstet Gynecol** 1995 Dec; 86(6):906–10

Serial hematologic changes and pregnancy outcome. Whittaker PG, et al. **Obstet Gynecol** 1996 Jul;88(1):33–9

Race, perinatal outcome, and amniotic infection. Fiscella K. **Obstet Gynecol Surv** 1996 Jan;51(1):60–6 (54 ref.)

Health of children born to medical radiographers. Roman E, et al. **Occup Environ Med** 1996 Feb;53(2):73–9

Reproductive risk factors for epilepsy among ten–year–old children in metropolitan Atlanta. Kuenneth CA, et al. **Paediatr Perinat Epidemiol** 1996 Apr;10(2):186–96

Prenatal pediatrics: traditional specialty definitions no longer apply. Nichols VG, et al. **Pediatrics** 1996 May;97(5):729–32

Antenatal phenobarbital therapy and neonatal outcome. I: Effect on intracranial hemorrhage. Shankaran S, et al. **Pediatrics** 1996 May;97(5):644–8

The prognostic factors in the prenatal diagnosis of the echogenic fetal lung. Barret J, et al. **Prenat Diagn** 1995 Sep;15(9):849–53

Mosaicism for trisomy 12: four cases with varying outcomes. Bischoff FZ, et al. **Prenat Diagn** 1995 Nov;15(11):1017–26

A 10–year survey, 1980–1990, of prenatally diagnosed small supernumerary marker chromosomes, identified by FISH analysis. Outcome and follow–up of 14 cases diagnosed in a series of 12,699 prenatal samples. Brøndum–Nielsen K, et al. **Prenat Diagn** 1995 Jul;15(7):615–9

Pregnancy outcome after transcervical CVS with a flexible biopsy forceps: evaluation of risk factors. Lunshof S, et al. **Prenat Diagn** 1995 Sep;15(9):809–16

Prenatal lead exposure and the pregnancy outcome. A case–control study in southern Poland. Pietrzyk JJ, et al. **Przegl Lek** 1996;53(4):342–7

Subchorionic hemorrhage in first–trimester pregnancies: prediction of pregnancy outcome with sonography. Bennett GL, et al. **Radiology** 1996 Sep;200(3):803–6

Fetal liver calcifications: sonographic appearance and postnatal outcome. Stein B, et al. **Radiology** 1995 Nov; 197(2):489–92

Drinking water source and reproductive outcomes in Sprague–Dawley rats. Uriu–Hare JY, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):549–61

A strategy to promote research–based nursing care: effects on childbirth outcomes. Hodnett ED, et al. **Res Nurs Health** 1996 Feb;19(1):13–20

Perinatal outcome among the offspring of employees and people living around a Swedish smelter. Wulff M, et al. **Scand J Work Environ Health** 1995 Aug;21(4):277–82

Home visits during pregnancy: consequences on pregnancy outcome, use of health services, and women's situations. Blondel B, et al. **Semin Perinatol** 1995 Aug;19(4):263–71

Individual nutrient effects on length of gestation and pregnancy outcome. Murtaugh MA, et al. **Semin Perinatol** 1995 Jun;19(3):197–210 (138 ref.)

Weight gain, nutrition, and pregnancy outcome: findings from the Camden study of teenage and minority gravidas. Scholl TO, et al. **Semin Perinatol** 1995 Jun;19(3):171–81

Effect of maternal age on birth outcomes among young adolescents. Cooper LG, et al. **Soc Biol** 1995 Spring–Summer;42(1–2):22–35

National Transplantation Pregnancy Registry (NTPR): cyclosporine dosing and pregnancy outcome in female renal transplant recipients. Armenti VT, et al. **Transplant Proc** 1996 Aug;28(4):2111–2

Computer analysis of the early diastolic notch in Doppler sonograms of the uterine arteries. Loupas T, et al. **Ultrasound Med Biol** 1995;21(8):1001–11

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

Fetal heart screening in low–risk pregnancies. Rustico MA, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):313–9

Selected clinical perspectives in the United States. Collection of clinical data on assisted reproduction. Zarutskie P. **Womens Health Issues** 1996 May–Jun;6(3):131–4; discussion 138–40

[The outcome of delivery in the breech presentation at the Stara Zagora Obstetrics and Gynecology Clinic during 1990–1992] Lazarov L, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):4–7 (Eng. Abstr.) **(Bul)**

[The large fetus—its obstetrical management and the results] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1995;34(2):7–9 (Eng. Abstr.) **(Bul)**

[The perinatal results in underage mothers] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1995;34(3):12–4 (Eng. Abstr.) **(Bul)**

[Epidemiological studies on risk for adverse pregnancy outcomes in women neighboring a petrochemical works] Chen Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):209–12 (Eng. Abstr.) **(Chi)**

[Systemic lupus erythematosus during pregnancy] Christensen H. **Ugeskr Laeger** 1996 Jan 22;158(4):431–3 (Eng. Abstr.) **(Dan)**

[The significance of psychosocial stress for pregnancy course and fetal development] Hansen D, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2369–72 (Eng. Abstr.) **(Dan)**

[Psychological stress and pregnancy outcome (editorial)] Henriksen TB, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2365 **(Dan)**

[Pregnancy in a hemodialysis patient] van der Wal HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):667–9 (Eng. Abstr.) **(Dut)**

[Questions about the future of the child] David G. **Bull Acad Natl Med** 1995 Nov;179(8):1751–7 (21 ref.) (Eng. Abstr.) **(Fre)**

[Human embryo cryopreservation: current state in France (1985–1993). French Federation of IVF Biologists] **Contracept Fertil Sex** 1996 Mar;24(3):229–32 (Eng. Abstr.) **(Fre)**

[Multiple pregnancies. FIVNAT] **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):494–7 (Eng. Abstr.) **(Fre)**

[French in vitro fertilization registry. 1994 report] **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):490–3 (Eng. Abstr.) **(Fre)**

[Fertility after ectopic pregnancy. Results of the first three years of the Auvergne Registry] Bouyer J, et al. **Contracept Fertil Sex** 1996 Jun;24(6):475–81 (Eng. Abstr.) **(Fre)**

[Reproductive mishaps and infertility in women exposed to DES in utero. A retrospective study of 258 exposed women and 50 unexposed siblings] Cabau A, et al. **Contracept Fertil Sex** 1996 Apr;24(4):253–8 **(Fre)**

[Influence of infertility etiology and follicular stimulation protocols on pregnancy outcomes by in vitro fertilization] Merviel P, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):157–62 (Eng. Abstr.) **(Fre)**

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic value of a single umbilical artery. 87 cases] Blache G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):522–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy] Lainé–Cessac P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):537–42 (Eng. Abstr.) **(Fre)**

[Spontaneous pregnancies in couples after failed or successful in vitro fertilization] Vardon D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):811–5 (Eng. Abstr.) **(Fre)**

[Pregnancy after transposition and repositioning of the

ovaries in a patient with clear-cell adenocarcinoma] Gerbaulet A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):534-8 (Eng. Abstr.) **(Fre)**

[Quality of prenatal data in the Hessian Perinatal Registry. A comparison with data from maternal health record and results of a pregnancy survey] Jahn A, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):132-8 (Eng. Abstr.) **(Ger)**

[The course of pregnancy and fetal outcome in diabetic patients with anamnestic fetal death] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul-Aug;199(4):163-6 (Eng. Abstr.) **(Ger)**

[Progress of labor and neonatal morbidity in primiparity with breech presentation] Perl FM, et al. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):56-60 (Eng. Abstr.) **(Ger)**

[Administration of pethidine in labor with meconium contaminated amniotic fluid: effect on fetal outcome and respiratory disorders] Riehn A, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):103-6 (Eng. Abstr.) **(Ger)**

[Thoughts and observations on the "E-E-time" in emergency cesarean section] Roemer VM, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):92-8 **(Ger)**

[Para-spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):99-102 (Eng. Abstr.) **(Ger)**

[Risk groups of newborn infants of diabetic mothers in relation to their somatic outcome and maternal diabetic metabolic status in pregnancy] Stiete H, et al. **Z Geburtshilfe Neonatol** 1995 Jul-Aug;199(4):156-62 (Eng. Abstr.) **(Ger)**

[Doppler sonographic flow measurements of the middle cerebral artery in end-diastolic zero flow in the umbilical arteries in relation to fetal outcome] Ulrich S, et al. **Z Geburtshilfe Neonatol** 1996 Jan-Feb;200(1):21-4 (Eng. Abstr.) **(Ger)**

[Hypertension in pregnancy: management protocols and pregnancy outcome followed at our ambulatory service] Frusca T, et al. **Minerva Ginecol** 1995 May;47(5):215-22 (Eng. Abstr.) **(Ita)**

[Pregnancy outcome in long-term survivors with adult acute leukemia, malignant lymphoma and breast cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):821-6 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Prenatal detection of the growth-retarded fetuses with a serious risk of adverse perinatal outcome by uterine artery Doppler flow velocimetry: a prospective study] Iwata M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1365-70 (Eng. Abstr.) **(Jpn)**

[Retinopathy and perinatal outcome in diabetic pregnancy] Sameshima H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1048-54 (Eng. Abstr.) **(Jpn)**

[Evaluation of a seven year period of managing pregnancies complicated by diabetes mellitus] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):76-9 (Eng. Abstr.) **(Pol)**

[Effect of electro-conization involving the vaginal part of the uterine cervix on cervical mucus parameters] Hajdasz P. **Ginekol Pol** 1995 Aug;66(8):473-6 (Eng. Abstr.) **(Pol)**

[Effect of insulin therapy on duration of pregnancy in women with diabetes] Kaim I. **Ginekol Pol** 1995 Jun;66(6):318-23 (Eng. Abstr.) **(Pol)**

[Lupus pregnancy, its effect on the course of lupus nephritis and the evaluation of fetal loss frequency] Rychlewska B, et al. **Ginekol Pol** 1995 Jun;66(6):313-7 (Eng. Abstr.) **(Pol)**

[Fertility of women after microsurgical resection of intraperitoneal adhesions of uterine adnexa] Starczewski A, et al. **Ginekol Pol** 1995 Aug;66(8):469-72 (Eng. Abstr.) **(Pol)**

[Uncomplicated course of pregnancy after previous ligation of both internal iliac arteries and left ovarian artery] Szramik Z, et al. **Ginekol Pol** 1996 Jan;67(1):45-7 (Eng. Abstr.) **(Pol)**

[Evaluation of the course of pregnancy and the newborn state in women with bronchial asthma] Wszelaki-Lass E, et al. **Ginekol Pol** 1995 Dec;66(12):670-3 (Eng. Abstr.) **(Pol)**

[Diabetes mellitus complicating pregnancy] Penza G, et al. **Pol Tyg Lek** 1996 Jan;51(1-5):26-8 (Eng. Abstr.) **(Pol)**

[Pregnancy after heart transplantation] Almeida DR, et al. **Arq Bras Cardiol** 1995 Sep;65(3):237-42 (41 ref.) (Eng. Abstr.) **(Por)**

[Heart surgery with extracorporeal circulation in pregnant women. Analysis of materno-fetal outcome (see comments)] Born D, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):207-11 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Mar;64(3):263-4. **(Por)**

[Pregnancy outcomes in women with a pathological weight gain, vascular dysfunction, transitory edemas and transient proteinuria] Lipatov IS, et al. **Akush Ginekol (Mosk)** 1995; (6):16-8 (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of immunotherapy and prediction of pregnancy outcomes on the basis of parameters of cellular immunity in women with habitual abortion] Mil'ko-Chernomorets IuV, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):46 **(Rus)**

[Possibilities of preserving reproductive function after therapy for early malignancies of the cervix uteri, endometrium and ovaries] Chissov VI, et al. **Vopr Onkol** 1996;42(2):107-11 (Eng. Abstr.) **(Rus)**

[Triplet and quadruplet pregnancy: management and perinatal outcome] González P, et al. **Rev Chil Obstet Ginecol** 1994;59(5):361-5 (Eng. Abstr.) **(Spa)**

ECONOMICS

Multiple pregnancies: the price to pay. Salat-Baroux J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S17-8

EPIDEMIOLOGY

Effect of United States residence on birth outcomes among Mexican immigrants: an exploratory study. Guendelman S, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S30-8

Exercise, employment, other daily activities, and adverse pregnancy outcomes. Schramm WF, et al. **Am J Epidemiol** 1996 Feb 1;143(3):211-8

Celiac disease and pregnancy outcome. Ciacci C, et al. **Am J Gastroenterol** 1996 Apr;91(4):718-22

Factors adversely affecting pregnancy outcome in the military. Magann EF, et al. **Am J Perinatol** 1995 Nov; 12(6):462-6

Small for gestational age fetus and neonatal outcome: reevaluation of the relationship. Ott WJ. **Am J Perinatol** 1995 Nov;12(6):396-400

Maternity waiting shelters and pregnancy outcome: experience from a rural area in Zimbabwe. Tumwine JK, et al. **Ann Trop Paediatr** 1996 Mar;16(1):55-9

Obstetric experience of female medical practitioners as patients. Evans S. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):282-5

Pregnancy outcomes in a prospective matched control study of pregnancy and renal disease. Holley JL, et al. **Clin Nephrol** 1996 Feb;45(2):77-82

Trend of birthweights of African newborns: an overview. Airede AK. **East Afr Med J** 1996 Apr;73(4):271-5 (48 ref.)

Drinking water and pregnancy outcome in central North Carolina: source, amount, and trihalomethane levels. Savitz DA, et al. **Environ Health Perspect** 1995 Jun;103(6):592-6

Are seasonal preferences in pregnancy planning a source of bias in studies of seasonal variation in reproductive outcomes? The European Study Group on Infertility and Subfecundity. Basso O, et al. **Epidemiology** 1995 Sep; 6(5):520-4

Feasibility of collecting maternal hair samples in studies of reproductive and perinatal outcomes [letter; comment] Marcoux S, et al. **Epidemiology** 1996 Jan;7(1):110. Comment on: Epidemiology 1995 Jul;6(4):469.

Perinatal morbidity and mortality in offspring of diabetic mothers in Qatif, Saudi Arabia. al-Dabbous IA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):165-9

Toxoplasma infection and pathological outcome of pregnancy. Djurković-Djaković O. **Gynecol Obstet Invest** 1995;40(1):36-41

Military pregnancies and adverse perinatal outcome. Magann EF, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):19-24

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170-6 (30 ref.)

Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine [editorial; comment] Dottorini ME. **J Nucl Med** 1996 Apr;37(4):612-5 . Comment on: J Nucl Med 1996 Apr;37(4):606-12.

Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients [see comments] Schlumberger M, et al. **J Nucl Med** 1996 Apr;37(4):606-12. Comment in: J Nucl Med 1996 Apr;37(4):612-5.

Outcomes of 11,788 planned home births attended by certified nurse-midwives. A retrospective descriptive study. Anderson RE, et al. **J Nurse Midwifery** 1995 Nov-Dec; 40(6):483-92

Births to teenagers: trends and obstetric outcomes. Amini SB, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):668-74

The epidemiology of placental features: associations with gestational age and neonatal outcome. Beebe LA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):771-8

Efficiency of lower threshold criteria for the diagnosis of gestational diabetes. Berkus MD, et al. **Obstet Gynecol** 1995 Dec;86(6):892-6

Perinatal outcome in growth-restricted fetuses: do hypertensive and normotensive pregnancies differ? Piper JM, et al. **Obstet Gynecol** 1996 Aug;88(2):194-9

Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein. Wenstrom KD, et al. **Obstet Gynecol** 1996 Feb;87(2):213-6

Women with diabetes during pregnancy: sociodemographics, outcomes, and costs of care. York R, et al. **Public Health Nurs** 1995 Oct;12(5):290-3

Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211-21 (46 ref.)

[The future of peri- and neonatal data (editorial)] Rauskolb R. **Z Geburtshilfe Neonatol** 1995 Nov-Dec;199(6):235 **(Ger)**

ETHNOLOGY

Pregnancy outcomes of US-born and foreign-born Japanese Americans. Alexander GR, et al. **Am J Public Health** 1996 Jun;86(6):820-4

Acculturation and low-birthweight infants among Latino women: a reanalysis of HHANES data with structural equation models [see comments] Cobas JA, et al. **Am J Public Health** 1996 Mar;86(3):394-6. Comment in: Am J Public Health 1996 Mar;86(3):303-5.

Adverse pregnancy outcomes: differences between US- and foreign-born women in major US racial and ethnic groups. Singh GK, et al. **Am J Public Health** 1996 Jun;86(6):837-43

Preterm delivery among women in the South Carolina Medicaid High Risk Channeling Project. Schulman ED. **J Health Care Poor Underserved** 1995;6(3):352-67

Racial disparity in pregnancy outcomes: analysis of black and white teenage pregnancies. Taylor GB, et al. **J Perinatol** 1995 Nov-Dec;15(6):480-3

Pregnancy outcomes in urban aboriginal women [see comments] de Costa C, et al. **Med J Aust** 1996 May 6; 164(9):523-6. Comment in: Med J Aust 1996 May 6;164(9):516-7.

Pregnancy outcomes of Australian aboriginals and Torres Strait Islanders [editorial; comment] O'Connor MC, et al. **Med J Aust** 1996 May 6;164(9):516-7. Comment on: Med J Aust 1996 May 6;164(9):523-6.

Determinants of gestational weight gain outside the recommended ranges among black and white women. Caulfield LE, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):760-6

Racial-ethnic differences in prenatal diagnostic test use and outcomes: preferences, socioeconomics, or patient knowledge? Kuppermann M, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):675-82

Effects of sustained nurse/mother contact on infant outcomes among low-income African-American families. Barnes-Boyd C. **Public Health Nurs** 1995 Dec;12(6):378-85

Ethnic disparity in the performance of prenatal nutrition risk assessment among Medicaid-eligible women. Fuentes-Afflick E, et al. **Public Health Rep** 1995 Nov-Dec; 110(6):764-73

The influence of race and previous pregnancy outcome on outcomes in the current pregnancy. Gardner MO, et al. **Semin Perinatol** 1995 Jun;19(3):191-6 (23 ref.)

GENETICS

The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Hook EB, et al. **Am J Hum Genet** 1995 Oct;57(4):875-81

Current topic: HLA and reproduction: lessons from studies in the Hutterites. Ober C. **Placenta** 1995 Oct;16(7):569-77

PSYCHOLOGY

Controlled prospective study on the mental health of women following pregnancy loss. Janssen HJ, et al. **Am J Psychiatry** 1996 Feb;153(2):226-30

Strange-male-induced pregnancy disruption in mice: potentiation by administration of 17 beta-estradiol to castrated males. De Catanzaro D, et al. **Physiol Behav** 1995 Aug;58(2):405-7

Strange-male-induced pregnancy disruption in mice: reduction of vulnerability by 17 beta-estradiol antibodies. de Catanzaro D, et al. **Physiol Behav** 1995 Aug;58(2):401-4

PREGNANCY, PROLONGED

Prolongation of pregnancy and survival of both twins after preterm premature rupture of membrane of twin A and 19 weeks' gestation. Wu MY, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):299-302

Assessment of the post-term pregnancy. McMahon MJ, et al. **Am Fam Physician** 1996 Aug;54(2):631-6, 641-2

Efficacy of outpatient induction with low-dose intravaginal prostaglandin E2: a randomized, double-blind, placebo-controlled trial. O'Brien JM, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1855-9

Prognostic value of biophysical profile score in post-date pregnancy. Bresadola M, et al. **Clin Exp Obstet Gynecol** 1995;22(4):330-8

Bias in studies of preterm and postterm delivery due to ultrasound assessment of gestational age. Henriksen TB, et al. **Epidemiology** 1995 Sep;6(5):533-7

ACOG criteria set. Postterm pregnancy. Number 10--August 1995. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Apr;53(1):89-90

Predictive value of amniotic fluid index for oligohydramnios in patients with prolonged pregnancies. O'Reilly-Green CP, et al. **J Matern Fetal Med** 1996 Jul-Aug;5(4):218-26

The outcome of post-term pregnancy. A comparative study. Kaplan B, et al. **J Perinat Med** 1995;23(3):183-9

Stripping of membranes as a safe method to reduce prolonged pregnancies. Berghella V, et al. **Obstet Gynecol** 1996 Jun; 87(6):927-31

Doppler study of the fetal cardiac function in prolonged pregnancies. Weiner Z, et al. **Obstet Gynecol** 1996 Aug; 88(2):200-2

[Management of prolonged pregnancy in Denmark. A questionnaire study] Stornes I. **Ugeskr Laeger** 1996 Jan 22; 158(4):422-4 (Eng. Abstr.) **(Dan)**

[Prolonged pregnancy. Review of the literature] Boisselier P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):739-46 (52 ref.) (Eng. Abstr.) **(Fre)**

[Is induced labor justified in diabetes, macrosomia and

prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**

[Postterm pregnancy—importance of this problem in modern obstetrics] Chazan B, et al. **Ginekol Pol** 1996 Mar; 67(3):148–56 (20 ref.) (Eng. Abstr.) **(Pol)**

[Randomized comparative study of induced labor with oxytocin and misoprostol in prolonged pregnancies] Echeverría E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):108–11 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Term and postterm low-risk pregnancies: management schemes for the reduction of high rates of cesarean section. Mancuso S, et al. **Minerva Ginecol** 1996 Mar;48(3):95–8

GENETICS

Gene expression of fatty acid synthesizing enzymes in fetal rat lung in prolonged pregnancy. Walther FJ, et al. **Biol Neonate** 1995;68(2):128–34

IMMUNOLOGY

[Level of antifibrinogen antibodies in newborns and women during the postpartum period] Kondera-Anasz Z. **Ginekol Pol** 1995 Dec;66(12):674–80 (Eng. Abstr.) **(Pol)**

METABOLISM

[The studies of the estrogen and progesterone receptor levels in the placenta, fetal membrane, uteroplacental bed and myometrium in patients with prolonged pregnancy] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep; 30(9):536–8 (Eng. Abstr.) **(Chi)**

[Fetal metabolism in post term pregnancy based on biochemical investigations of amniotic fluid. IV. Ion composition] Wójcicka-Jagodzińska J, et al. **Ginekol Pol** 1995 May;66(5):253–6 (Eng. Abstr.) **(Pol)**

[Fetal metabolism in post-term pregnancy based on biochemical examinations of amniotic fluid. V. Glucose, bilirubin, H+ ions, hormones and tests of lung maturation] Wójcicka-Jagodzińska J, et al. **Ginekol Pol** 1995 May; 66(5):257–61 (Eng. Abstr.) **(Pol)**

PREGNANCY PROTEINS

ANALYSIS

Immunolocalization of progesterone-induced uterine protein-1 in human endometrium during the menstrual cycle and in the placenta throughout gestation. Sharpe-Timms KL, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1569–78

Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Kämäräinen M, et al. **Am J Pathol** 1996 May; 148(5):1435–43

CREB-1 and CREB-2 immunoreactivity in the rat brain. Ferrer I, et al. **Brain Res** 1996 Mar 11;712(1):159–64

Correlation of serum and follicular fluid concentrations of placental protein 14 and CA-125 in in vitro fertilization-embryo transfer patients. Chryssikopoulos A, et al. **Fertil Steril** 1996 Oct;66(4):599–603

The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology. Dalton CF, et al. **Hum Reprod** 1995 Oct;10(10):2680–4

Biochemical and topological analysis of adult T-cell leukaemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. Kobayashi F, et al. **Hum Reprod** 1995 Jun;10(6):1603–8

Enzyme-linked immunosorbent assay for ovine interferon-tau. Zhu D, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):147–50

Immunocytochemical localization of endometrial proteins [letter; comment] Fazleabas AT. **Placenta** 1995 Jun; 16(4):401. Comment on: Placenta 1994 Oct;15(7):701–8.

Immunocytochemical localization of thioredoxin in human trophoblast and decidua. Perkins AV, et al. **Placenta** 1995 Oct;16(7):635–42

[Polymorphism of placental alkaline phosphatase on the level of DNA and protein in the Mordovian population] Bekman G, et al. **Genetika** 1996 Mar;32(3):420–4 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Glycoproteins of the aspartyl proteinase gene family secreted by the developing placenta. Roberts RM, et al. **Adv Exp Med Biol** 1995;362:231–40

Expression and purification of bovine trophoblast protein-1 (bTP-1) in Escherichia coli. Grewal TS, et al. **Ann N Y Acad Sci** 1996 May 15;782:264–71

Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Birkenhäger R, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):703–7

The production of placental protein 14 by human uterine tubal epithelial cells in culture. Laird SM, et al. **Hum Reprod** 1995 Jun;10(6):1346–51

Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Viglietto G, et al. **Oncogene** 1996 Aug 1; 13(3):577–87

Long-term effects of calcium availability on prolactin and protein synthesis in human decidual cells. Couderc B, et al. **Placenta** 1995 Sep;16(6):527–37

A pregnancy-specific glycoprotein is expressed in the brain and serves as a receptor for mouse hepatitis virus. Chen DS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12095–9

BLOOD

Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predicts success or miscarriage. Coulam CB, et al. **Am J Reprod Immunol** 1995 Oct;34(4):219–24

The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):342–8

Serum levels of endometrial proteins during transcervical resection of the endometrium. Hahn RG, et al. **Br J Obstet Gynaecol** 1996 May;103(5):442–5

Endometrial and placental protein markers and ovarian steroids in serum during in-vitro fertilization cycles. Bersinger NA, et al. **Hum Reprod** 1995 Aug;10(8):2149–54

Relationships between the uterine environment and maternal plasma concentrations of insulin-like growth factor binding protein-1 and placental protein 14 in early pregnancy. Wheeler T, et al. **Hum Reprod** 1995 Oct;10(10):2700–4

[Value of serum placental protein 14 determination in differential diagnosis of abnormal early pregnancy] Römer T, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):490–2 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. Dell A, et al. **J Biol Chem** 1995 Oct 13;270(41):24116–26

GENETICS

Mapping of murine YACs containing the genes Cea2 and Cea4 after B1-PCR amplification and FISH-analysis. Rettenberger G, et al. **Chromosome Res** 1995 Dec; 3(8):473–8

Analyses of cis-acting and trans-acting elements that are crucial to sustain pregnancy-specific glycoprotein gene expression in different cell types. Koritschoner NP, et al. **Eur J Biochem** 1996 Mar 1;236(2):365–72

Cloning of a new member of the insulin gene superfamily (INSL4) expressed in human placenta. Chassin D, et al. **Genomics** 1995 Sep 20;29(2):465–70

Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Mattei MG, et al. **Genomics** 1996 Feb 15; 32(1):168–9

Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Miyagi Y, et al. **Genomics** 1996 Jul 1; 35(1):267–8

Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. King A, et al. **J Immunol** 1996 Mar 15;156(6):2068–76

Frequent ectopic expression of a placenta-specific gene at high levels in BALB/c mouse mammary carcinomas. VanHouten JN, et al. **Oncogene** 1996 May 16;12(10):2241–5

A bifunctional vector suitable for both site-directed mutagenesis and recombinant expression of interferon-tau in Escherichia coli. Li J, et al. **Protein Expr Purif** 1995 Aug;6(4):401–7

[mRNA expression and protein localization of placental tissue protein 11, 12, 19 in gynecologic malignant tumors] Yudate T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1248–54 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):342–8

ISOLATION & PURIFICATION

Dynorphin A(1-8) in human placenta: amino acid sequence determined by tandem mass spectrometry. Agbas A, et al. **Peptides** 1995;16(4):623–7

METABOLISM

Anti-adhesive glycosylation of fibronectin-like molecules in human placental matrix-type fibrinoid. Frank HG, et al. **Histochem Cell Biol** 1995 Oct;104(4):317–29

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. Cao Y, et al. **J Biol Chem** 1996 Feb 9;271(6):3154–62

A motif in PSG11s mediates binding to a receptor on the surface of the promonocyte cell line THP-1. Rutherfurd KJ, et al. **Mol Endocrinol** 1995 Oct;9(10):1297–305

Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Viglietto G, et al. **Oncogene** 1995 Oct 19; 11(8):1569–79

Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Subramaniam PS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12270–4

Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al. **Reprod Fertil Dev** 1995;7(6):1431–6 (26 ref.)

Human placental tissue factor: protease susceptibility of extracellular and cytoplasmic domains. Whittle SM, et al. **Thromb Res** 1995 Sep 15;79(5–6):451–9

PHARMACOLOGY

Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Birkenhäger R, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):703–7

Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Petersen LC, et al. **Biochemistry** 1996 Jan 9;35(1):266–72

Ovine interferon tau suppresses transcription of the estrogen receptor and oxytocin receptor genes in the ovine endometrium. Spencer TE, et al. **Endocrinology** 1996 Mar; 137(3):1144–7

Ovine interferon-tau inhibits estrogen receptor up-regulation and estrogen-induced luteolysis in cyclic ewes. Spencer TE, et al. **Endocrinology** 1995 Nov;136(11):4932–44

Anti-HIV potential of a new interferon, interferon-tau (trophoblastin). Dereuddre-Bosquet N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):241–6

Effect of pregnancy-specific protein B on luteal cell progesterone, prostaglandin, and oxytocin production during two stages of the bovine estrous cycle. Del Vecchio RP, et al. **J Anim Sci** 1995 Sep;73(9):2662–8

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. Cao Y, et al. **J Biol Chem** 1996 Feb 9;271(6):3154–62

Effect of bovine interferon-tau on body temperature and plasma progesterone concentrations in cyclic dairy cows. Meyer MD, et al. **J Dairy Sci** 1995 Jul;78(7):1470–6

Extension of corpus luteum lifespan and reduction of uterine secretion of prostaglandin F2 alpha of cows in response to recombinant interferon-tau. Meyer MD, et al. **J Dairy Sci** 1995 Sep;78(9):1921–31

Intrauterine injection of ovine interferon-tau alters oestrogen receptor and oxytocin receptor expression in the endometrium of cyclic ewes. Spencer TE, et al. **J Mol Endocrinol** 1995 Oct;15(2):203–20

Bovine luteal cell production in vitro of prostaglandin E2, oxytocin and progesterone in response to pregnancy-specific protein B and prostaglandin F2 alpha. Del Vecchio RP, et al. **J Reprod Fertil** 1996 May; 107(1):131–6

Prostaglandin F2 alpha, progesterone and oxytocin production by cultured bovine luteal cells treated with prostaglandin E2 and pregnancy-specific protein B. Del Vecchio RP, et al. **Prostaglandins** 1995 Sep;50(3):137–50

PHYSIOLOGY

Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Kämäräinen M, et al. **Am J Pathol** 1996 May; 148(5):1435–43

Ovine interferon-tau regulates expression of endometrial receptors for estrogen and oxytocin but not progesterone. Spencer TE, et al. **Biol Reprod** 1995 Sep;53(3):732–45

High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris. Van Heeke G, et al. **J Interferon Cytokine Res** 1996 Feb; 16(2):119–26

Does the amniotic fluid protein absorption contribute significantly to the fetal weight? Cheng W, et al. **J Paediatr Child Health** 1996 Feb;32(1):39–41

Recent advances in placental peptide research: workshop report. Mizutani S, et al. **Reprod Fertil Dev** 1995; 7(6):1443–50

SECRETION

Secretion of biologically active interferon tau by in vitro-derived bovine trophoblastic tissue. Stojkovic M, et al. **Biol Reprod** 1995 Dec;53(6):1500–7

THERAPEUTIC USE

In vivo immunosuppressive effects of recombinant ovine interferon-tau (trophoblastin): r.oTP (r.oIFN-tau) inhibits local GVH reaction in mice (PLN assay), prevents fetal resorptions, and favors embryo survival and implantation in the CBA/J x DBA/2 mice combination. Assal-Meliani A, et al. **Am J Reprod Immunol** 1995 Mar;33(3):267–75

TOXICITY

Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Subramaniam PS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12270–4

PREGNANCY RATE

Does hyperandrogenism explain lower in vitro fertilization (IVF) success rates in smokers? Gustafson O, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):149–56

Some factors influencing pregnancy rate and subsequent litter size in primiparous sows. Sterning M, et al. **Acta Vet Scand** 1995;36(3):353–65

Calving rates in a tropical beef herd after treatment with a synthetic progestagen, norgestomet, or a prostaglandin analogue, cloprostenol. Frisch JE, et al. **Aust Vet J** 1996 Mar;73(3):98–102

Italy's fertility rate falls as women reject childbearing [news] Evans L. **BMJ** 1996 Mar 2;312(7030):530

The TCu 380A IUD and the frameless IUD "the FlexiGard": interim three-year data from an international multicenter trial. UNDP, UNFPA, and WHO Special Programme of Research, Development and Research Training in Human Reproduction, World Bank: IUD Research Group. **Contraception** 1995 Aug;52(2):77–83

Effectiveness of Norplant implants through seven years: a large-scale study in China. Gu S, et al. **Contraception** 1995 Aug;52(2):99–103

Fertility and pregnancy outcome after myomectomy in sterility patients. Sudik R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):209–14

Pregnancy rates after communal growth of preimplantation human embryos in vitro. Almagor M, et al. **Fertil Steril** 1996 Sep;66(3):394–7

Comparison of sperm parameters, in vitro fertilization results, and subsequent pregnancy rates using sequential ejaculates, collected two hours apart, from oligoasthenozoospermic men. Barash A, et al. **Fertil Steril** 1995 Nov;64(5):1008–11

Effect of abnormal hypo-osmotic swelling test on fertilization rate and pregnancy outcome in in vitro fertilization cycles. Biljan MM, et al. **Fertil Steril** 1996 Sep;66(3):412–6

Successful pregnancy outcome after cryopreservation of all fresh embryos with subsequent transfer into an unstimulated cycle. Frederick JL, et al. **Fertil Steril** 1995 Nov; 64(5):987–90

The effect of antioxidant treatment on human spermatozoa and fertilization rate in an in vitro fertilization program. Geva E, et al. **Fertil Steril** 1996 Sep;66(3):430–4

Lactose metabolism and time to pregnancy. Herrinton LJ, et al. **Fertil Steril** 1996 Sep;66(3):384–8

Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Licciardi FL, et al. **Fertil Steril** 1995 Nov;64(5):991–4

The effect of sperm parameters on the outcome of intracytoplasmic sperm injection. Mansour RT, et al. **Fertil Steril** 1995 Nov;64(5):982–6

Reproductive potential after an ectopic pregnancy. al-Nusim L, et al. **Fertil Steril** 1995 Nov;64(5):942–6

Intracytoplasmic sperm injection: achievement of high pregnancy rates in couples with severe male factor infertility is dependent primarily upon female and not male factors. Oehninger S, et al. **Fertil Steril** 1995 Nov; 64(5):977–81

Outcome of ovum donation in Turner's syndrome patients. Press F, et al. **Fertil Steril** 1995 Nov;64(5):995–8

Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome? Senöz S, et al. **Gynecol Endocrinol** 1995 Jun;9(2):91–6

Relationship of endometrial thickness and echo patterns on pregnancy rates in patients with luteal phase defects. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):101–7

Pregnancies after testicular sperm extraction and intracytoplasmic sperm injection in non-obstructive azoospermia. Devroey P, et al. **Hum Reprod** 1995 Jun; 10(6):1457–60

Background pregnancy rates in an infertile population. Gleicher N, et al. **Hum Reprod** 1996 May;11(5):1011–2

Cryopreservation: the problem of evaluation. Jones HW Jr, et al. **Hum Reprod** 1995 Aug;10(8):2136–8

The use of intra-endometrial embryo transfer for increasing the pregnancy rate. Nakayama T, et al. **Hum Reprod** 1995 Jul;10(7):1833–6

Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Scott RT, et al. **Hum Reprod** 1995 Jul;10(7):1706–10

Evaluation of the Tru-Trax cervical mucus penetration test in predicting fertilization and pregnancy rates in in-vitro fertilization. Sharara FI, et al. **Hum Reprod** 1995 Jun; 10(6):1481–5

Two instead of three embryo transfer in in-vitro fertilization. Tasdemir M, et al. **Hum Reprod** 1995 Aug;10(8):2155–8

Differential impact on pregnancy rate of selective salpingography, tubal catheterization and wire-guide recanalization in the treatment of proximal fallopian tube obstruction. Woolcott R, et al. **Hum Reprod** 1995 Jun; 10(6):1423–6

Sperm morphology using strict criteria after Percoll density separation: influence on cleavage and pregnancy rates after in-vitro fertilization. Yue Z, et al. **Hum Reprod** 1995 Jul; 10(7):1781–5

Estrous length, pregnancy rate, gestation and parturition lengths, litter size, and juvenile mortality in the domestic cat. Root MV, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct; 31(5):429–33

Plasma and milk urea nitrogen in relation to pregnancy rate in lactating dairy cattle. Butler WR, et al. **J Anim Sci** 1996 Apr;74(4):858–65

Effect of norgestomet treatment after insemination on the calving rate of postpartum suckled beef cows. Favero RJ, et al. **J Anim Sci** 1995 Nov;73(11):3230–4

Effect of a gonadotropin-releasing hormone agonist on follicle recruitment and pregnancy rate in cattle. Schmitt EJ, et al. **J Anim Sci** 1996 Jan;74(1):154–61

Calf production by Angus-Hereford and Brahman-Hereford cows on two native rangeland forage systems. Sims PL, et al. **J Anim Sci** 1995 Oct;73(10):2893–902

Fate of the dominant follicle, embryonal survival, and pregnancy rates in dairy cattle treated with prostaglandin F2 alpha and progestins in the absence or presence of a functional corpus luteum. Smith MW, et al. **J Anim Sci** 1995 Dec;73(12):3743–51

The first pregnancy in a transport-intracytoplasmic sperm injection (T-ICSI) scheme. Anyaegbunam W, et al. **J Assist Reprod Genet** 1995 Jul;12(6):396–8

Cumulative birth rates following cryopreservation of all embryos in stimulated in vitro fertilization (IVF) cycles. Bergh C, et al. **J Assist Reprod Genet** 1995 Mar;12(3):191–4

A seasonal effect on pregnancy rates in an in vitro fertilization program. Chamoun D, et al. **J Assist Reprod Genet** 1995 Oct;12(9):585–9

Sperm stimulants can improve fertilization rates in male-factor cases undergoing IVF to the same extent as micromanipulation by partial zona dissection (PZD) or subzonal sperm insemination (SUZI): a randomized controlled study. Edirisinghe WR, et al. **J Assist Reprod Genet** 1995 May;12(5):312–8

Effect of varicocelectomy on sperm parameters and pregnancy rate in patients with subclinical varicocele: a randomized prospective controlled study [see comments] Yamamoto M, et al. **J Urol** 1996 May;155(5):1636–8. Comment in: J Urol 1996 May;155(5):1643.

How effective are contraceptives? The determination and measurement of pregnancy rates. Potter LS. **Obstet Gynecol** 1996 Sep;88(3 Suppl):13S–23S (51 ref.)

Measuring contraceptive effectiveness: a conceptual framework. Steiner M, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):24S–30S

[A novel method of ovarian stimulation for in vitro fertilization (bromocriptine-rebound method) increases developmental potential of oocytes and pregnancy rate] Jinno M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec;47(12):1337–44 (Eng. Abstr.) **(Jpn)**

PREGNANCY REDUCTION, MULTIFETAL

The current status of multifetal pregnancy reduction. Berkowitz RL, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1265–72 (39 ref.)

Multifetal pregnancy reduction: evaluation of fetal growth in the remaining twins. Depp R, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1233–8; discussion 1238–40

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Shulman LP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1072–4

From twin to singleton [editorial] Berkowitz RL. **BMJ** 1996 Aug 17;313(7054):373–4

Selective abortions hit the headlines [news] Dyer C. **BMJ** 1996 Aug 17;313(7054):380

Expectant management of twin pregnancy with single fetal death [letter; comment] Arayomi JO, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):842. Comment on: Br J Obstet Gynaecol 1995 Jan;102(1):26–30.

Triplet pregnancy and fetal reduction counselling. Mantzavinos T, et al. **Clin Exp Obstet Gynecol** 1996; 23(1):48–50

Pregnancy outcome after multifetal pregnancy reduction to twins compared with spontaneously conceived twins. Groutz A, et al. **Hum Reprod** 1996 Jun;11(6):1334–6

Three ethically justified indications for selective termination in multifetal pregnancy: a practical and comprehensive management strategy. Chervenak FA, et al. **J Assist Reprod Genet** 1995 Sep;12(8):531–6

International, collaborative experience of 1789 patients having multifetal pregnancy reduction: a plateauing of risks and outcomes [see comments] Evans MI, et al. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):23–6. Comment in: J Soc Gynecol Investig 1996 Jan-Feb;3(1):1–2.

Multifetal reduction in high-order gestations: a nonelective procedure? [editorial; comment] Simpson JL, et al. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):1–2. Comment on: J Soc Gynecol Investig 1996 Jan-Feb;3(1):23–6.

Effects of fetal number and multifetal reduction on length of in vitro fertilization pregnancies. Haning RV Jr, et al. **Obstet Gynecol** 1996 Jun;87(6):964–8

Outcome of twin pregnancies reduced from triplets compared with nonreduced twin gestations. Lipitz S, et al. **Obstet Gynecol** 1996 Apr;87(4):511–4

Preterm delivery after selective termination in twin pregnancies. Lynch L, et al. **Obstet Gynecol** 1996 Mar; 87(3):366–9

Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Nugent CE, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):829–31

Selective termination of an abnormal fetus in multiple gestations [letter; comment] Berkowitz RL. **Prenat Diagn** 1995 Nov;15(11):1085–7. Comment on: Prenat Diagn 1995 Apr;15(4):386–7.

Multifetal pregnancy reduction [letter] Nelson TK. **Psychosomatics** 1996 Jul-Aug;37(4):398–9

Anti-life mentality in medical circles [editorial] de Muelenaere CW. **S Afr Med J** 1995 Nov;85(11):1147–50

[Clinical use of selective reduction in multifetal pregnancies] Fang Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug; 75(8):459–62, 509 (Eng. Abstr.) **(Chi)**

[Fate of supernumerary embryos and risk of multiple pregnancy in in-vitro fertilization: attitude of involved couples] Laruelle C, et al. **Rev Med Brux** 1996 Jun; 17(3):115–9 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Multifetal reduction of high-order multiple pregnancy: comparison of obstetrical outcome with nonreduced twin gestations. Alexander JM, et al. **Fertil Steril** 1995 Dec; 64(6):1201–3

Pregnancy outcome after early amniotic fluid leakage after transabdominal multifetal reduction [see comments] Lipitz S, et al. **Fertil Steril** 1996 May;65(5):1055–8. Comment in: Fertil Steril 1996 May;65(6):909–11.

INSTRUMENTATION

-Interruption of umbilical blood flow in an acardiac twin by endoscopic laser coagulation- Hecher K, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):97–100 (Eng. Abstr.) **(Ger)**

METHODS

Intracardiac fibrin adhesive for selective fetocide in twin pregnancy: report of three cases. Dumler EA, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):213–5

PSYCHOLOGY

Attitudes of in vitro fertilization and intrauterine insemination couples toward multiple gestation pregnancy and multifetal pregnancy reduction. Goldfarb J, et al. **Fertil Steril** 1996 Apr;65(4):815–20

Multifetal pregnancy reduction. A review of an evolving technology and its psychosocial implications. Ormont MA, et al. **Psychosomatics** 1995 Nov-Dec;36(6):522–30 (29 ref.)

PREGNANCY, SECOND TRIMESTER see PREGNANCY TRIMESTER, SECOND

PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEIN

ANALYSIS

Maternal serum Schwangerschafts protein-1 (SP1) and fetal chromosomal abnormalities at 10-13 weeks' gestation. Brizot ML, et al. **Early Hum Dev** 1995 Aug 30;43(1):31–6

The expression of trophoblastic cell markers by lung carcinomas. Boucher LD, et al. **Hum Pathol** 1995 Nov; 26(11):1201–6

[Changes in the level of serum trophoblastic beta 1-globulin in threatened abortion] Shmagel' KV, et al. **Akush Ginekol (Mosk)** 1995;(6):22–5 (Eng. Abstr.) **(Rus)**

[Use of a mathematical model to establish normal serum parameters characterizing the function of the fetoplacental complex] Shmagel' KV. **Klin Lab Diagn** 1995 May-Jun; (3):28–32 (Eng. Abstr.) **(Rus)**

SECRETION

The role of pregnancy-specific beta-1 glycoprotein (SP1) in assessing the human blastocyst quality in vitro. Saith RR, et al. **Hum Reprod** 1996 May;11(5):1038–42

PREGNANCY, TEENAGE see PREGNANCY IN ADOLESCENCE

PREGNANCY TESTS

Preoperative pregnancy testing in adolescents [see comments] Azzam FJ, et al. **Anesth Analg** 1996 Jan;82(1):4–7. Comment in: Anesth Analg 1996 Jan;82(1):1–3. Comment in: Anesth Analg 1996 Aug;83(2):438–9. Comment in: Anesth Analg 1996 Aug;83(2):439. Comment in: Anesth Analg 1996 Aug;83(2):439–40.

The cost of preoperative pregnancy testing [letter; comment] Battit GE. **Anesth Analg** 1996 Aug;83(2):439. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

Preoperative pregnancy testing [letter; comment] Cartabuke RS. **Anesth Analg** 1996 Aug;83(2):436. Comment on: Anesth Analg 1996 Jan;82(1):1–3.

Medical ethics and legal standards [editorial; comment] [see comments] Duncan PG, et al. **Anesth Analg** 1996 Jan; 82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7. Comment in: Anesth Analg 1996 Aug;83(2):436. Comment in: Anesth Analg 1996 Aug;83(2):438–9. Comment in: Anesth Analg 1996 Aug;83(2):439–40. Comment in: Anesth Analg 1996 Aug;83(2):440–1.

Preoperative pregnancy testing in adolescents [letter; comment] Malviya S, et al. **Anesth Analg** 1996 Mar; 82(3):673. Comment on: Anesth Analg 1995 Sep;81(3):661.

Preoperative pregnancy testing revisited [letter; comment] Mesrobian JR. **Anesth Analg** 1996 Aug;83(2):440–1. Comment on: Anesth Analg 1996 Jan;82(1):1–3.

Preoperative pregnancy testing: "justice and testing for all" [letter; comment] Twersky RS, et al. **Anesth Analg** 1996 Aug;83(2):438–9. Comment on: Anesth Analg 1996 Jan;82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

Preoperative pregnancy testing in ambulatory surgery [letter; comment] Lewis I, et al. **Anesthesiology** 1996 May; 84(5):1259–60; discussion 1261. Comment on: Anesthesiology 1995 Oct;83(4):690–3.

Preoperative pregnancy testing in ambulatory surgery. Incidence and impact of positive results [see comments] Manley S, et al. **Anesthesiology** 1995 Oct;83(4):690–3. Comment in: Anesthesiology 1996 May;84(5):1259–60; discussion 1261. Comment in: Anesthesiology 1996 May;84(5):1260; discussion 1261. Comment in: Anesthesiology 1996 May;84(5):1260–1.

Preoperative pregnancy testing in ambulatory surgery [letter; comment] Rosenberg MK. **Anesthesiology** 1996 May; 84(5):1260; discussion 1261. Comment on: Anesthesiology 1995 Oct;83(4):690–3.

Preoperative pregnancy testing in ambulatory surgery [letter; comment] Zeig NJ, et al. **Anesthesiology** 1996 May; 84(5):1260–1. Comment on: Anesthesiology 1995 Oct;83(4):690–3.

Predictive value of hCG level 14 days after embryo transfer. Guth B, et al. **J Assist Reprod Genet** 1995 Jan;12(1):13–4

Emergency department pregnancy testing. Olshaker JS. **J Emerg Med** 1996 Jan–Feb;14(1):59–65 (75 ref.)

Preovulatory sonographic uterine receptivity index (SURI): usefulness as an indicator of pregnancy in women undergoing assisted reproductive treatments. Serafini P, et al. **J Ultrasound Med** 1995 Oct;14(10):751–5

Value of preoperative pregnancy test in risk management [letter] Gazvani MR, et al. **Lancet** 1996 May 4; 347(9010):1271

Value of preoperative pregnancy test in risk management [letter] Wagman H. **Lancet** 1996 Jun 15;347(9016):1695–6

[Comparison between various methods of pregnancy screening during a large-scale ivermectin treatment in Cameroon] Chippaux JP, et al. **Bull Soc Pathol Exot** 1995; 88(3):129–33 (Eng. Abstr.) **(Fre)**

ECONOMICS

The cost of preoperative pregnancy testing [letter; comment] Kettler RE. **Anesth Analg** 1996 Aug;83(2):439–40. Comment on: Anesth Analg 1996 Jan;82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

STANDARDS

Uses and misuses of serum hCG—a clinical audit. Magnay JL, et al. **Br J Biomed Sci** 1995 Mar;52(1):26–30

STATISTICS & NUMERICAL DATA

Adolescents with negative pregnancy test results. An accessible at-risk group. Zabin LS, et al. **JAMA** 1996 Jan 10;275(2):113–7

VETERINARY

Evaluation of the benefits of the timing of pregnancy testing by transrectal palpation in dairy cattle. Thompson JA, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1462–5

Application of anti-bovine CD2 monoclonal antibody to the rosette inhibition test for detection of early pregnancy factor in cattle. Yoshioka K, et al. **J Vet Med Sci** 1995 Aug;57(4):721–5

Pregnancy detection in bighorn sheep (Ovis canadensis) using a fecal-based enzyme immunoassay. Borjesson DL, et al. **J Wildl Dis** 1996 Jan;32(1):67–74

Diagnosing pregnancy in free-ranging elk using fecal steroid metabolites. White PJ, et al. **J Wildl Dis** 1995 Oct; 31(4):514–22

Animal transport proposals 'less than satisfactory' [news] **Vet Rec** 1996 Jan 20;138(3):50–1

[Cow pregnancy yes or no?] Pieterse MC. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):53 **(Dut)**

PREGNANCY, THIRD TRIMESTER see **PREGNANCY TRIMESTER, THIRD**

PREGNANCY TOXEMIAS

BLOOD

D-Dimer in intra-uterine growth retardation and gestational hypertension. Francalanci I, et al. **Thromb Res** 1995 Oct 1;80(1):89–92

[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy—comparing normal pregnancy and toxemia of pregnancy] Murakami M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):177–83 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

A hypertensive parturient with a supraventricular tachycardia. Lima J, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):625–6

Retinal pigment epithelium tear following toxemia of pregnancy. Menchini U, et al. **Eur J Ophthalmol** 1995 Apr–Jun;5(2):139–41

[Effect of preeclampsia on neonatal morbidity] Beke A, et al. **Orv Hetil** 1995 Sep 10;136(37):1999–2003 (Eng. Abstr.) **(Hun)**

DIAGNOSIS

[A study for predicting toxemia of pregnancy by the diastolic notch in pulsed Doppler flow velocity waveforms of the uterine arteries—quantitative analysis of the diastolic notch as uterine arterial index (UTAI)] Sato H. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1055–62 (Eng. Abstr.) **(Jpn)**

[The diagnostic characteristics of late toxicosis in pregnant women with hypertension and chronic kidney diseases] Rogov VA, et al. **Ter Arkh** 1995;67(10):65–9 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Improvement of a toxaemic pregnancy with molsidomine, a nitric oxide donor [letter] Boulanger H, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):391–2

EPIDEMIOLOGY

China: epidemiology of pregnancy-induced hypertension. Jiang D. **World Health Stat Q** 1995;48(1):8–10

ETIOLOGY

[Immunologic aspects on the etiology of pregnancy toxemia] Buitron Garcia RG, et al. **Ginecol Obstet Mex** 1996 Mar; 64:131–4 (Eng. Abstr.) **(Spa)**

METABOLISM

Maternal undernutrition during late pregnancy in sheep. Its relationship to maternal condition, gestation length, hepatic physiology and glucose metabolism. West HJ. **Br J Nutr** 1996 Apr;75(4):593–605

THERAPY

[Clinical effectiveness of enterosorbents in patients with chronic bronchitis and gestational toxicosis] Provotorov VM, et al. **Klin Med (Mosk)** 1996;74(1):48–50 (Eng. Abstr.) **(Rus)**

VETERINARY

Aqueous humour and cerebrospinal fluid collected at necropsy as indicators of ante mortem serum 3-OH butyrate concentration in pregnant sheep. Scott PR, et al. **Br Vet J** 1995 Jul–Aug;151(4):459–61

PREGNANCY TRIMESTER, FIRST

Recommendation to avoid all drugs during first trimester is unrealistic [letter] Czeizel AE. **BMJ** 1996 Aug 17; 313(7054):424–5

Electron-microscopic immunolabelling of vasoactive substances in human umbilical endothelial cells and their actions in early and late pregnancy. Sexton AJ, et al. **Cell Tissue Res** 1996 Apr;284(1):167–75

Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. Forest JC, et al. **Clin Biochem** 1995 Aug;28(4):443–9

The spectrum of first-trimester ultrasound findings. Sohaey R, et al. **Curr Probl Diagn Radiol** 1996 Mar–Apr; 25(2):54–75 (93 ref.)

Experience with early amniocentesis. Sundberg K, et al. **J Perinat Med** 1995;23(3):149–58 (35 ref.)

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227–40 (44 ref.). Comment in: Prenat Diagn 1995 Dec;15(3):1209–13.

Early amniocentesis: a clinical review. Wilson RD. **Prenat Diagn** 1995 Dec;15(13):1259–73 (97 ref.)

[Early amniocentesis in prenatal diagnosis] Pawłowska B, et al. **Ginekol Pol** 1995 May;66(5):262–6 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Immunomorphologic studies of human decidua-associated lymphoid cells in normal early pregnancy. Mincheva-Nilsson L, et al. **Adv Exp Med Biol** 1995; 371A:367–71

Characteristics of perforin expressing lymphocytes within the first trimester decidua of human pregnancy. Rukavina D, et al. **Am J Reprod Immunol** 1995 May;33(5):394–404

PHYSIOLOGY

Effect of 1st-trimester loss on restoration of the hypothalamic-pituitary-ovarian axis. Elkas JC, et al. **Gynecol Obstet Invest** 1995;40(4):257–60

The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. Docherty SM, et al. **Hum Reprod** 1996 Jun;11(6):1157–61 (38 ref.)

PREGNANCY TRIMESTER, SECOND

Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. Forest JC, et al. **Clin Biochem** 1995 Aug;28(4):443–9

Normal testicular histology in a mid-trimester 49,XXXXY fetus [letter] Fryns JP, et al. **Clin Genet** 1995 Jun;47(6):331

BLOOD

Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. Piggott M, et al. **J Med Screen** 1994 Jan;1(1):45–9

Choice of serum markers in antenatal screening for Down's syndrome. Wald NJ, et al. **J Med Screen** 1994 Apr; 1(2):117–20

Pregnancy outcome in women with low midtrimester maternal serum unconjugated estriol. Santolaya-Forgas J, et al. **J Reprod Med** 1996 Feb;41(2):87–90

PHYSIOLOGY

Glycosaminoglycan accumulation in amniotic fluid during early pregnancy. Sloan R, et al. **Biochem Soc Trans** 1996 Feb;24(1):103S

PREGNANCY TRIMESTER, THIRD

Electron-microscopic immunolabelling of vasoactive substances in human umbilical endothelial cells and their actions in early and late pregnancy. Sexton AJ, et al. **Cell Tissue Res** 1996 Apr;284(1):167–75

BLOOD

Brain natriuretic peptide and cyclic guanosine-3',5' monophosphate in pre-eclampsia. Lauria MR, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):128–31

Association of endogenous steroid levels with high and low density lipoprotein concentrations in the human maternal-fetoplacental unit at term. Nayar S, et al. **J Reprod Med** 1996 Feb;41(2):91–8

Maternal plasma and amniotic fluid cortisol and progesterone concentrations between women with and without term labor. A comparison. Ohana E, et al. **J Reprod Med** 1996 Feb;41(2):80–6

[Concentration of lipids and lipoproteins in serum of pregnant women with primary hypertension] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):69–71 (Eng. Abstr.) **(Pol)**

[Concentration of lipids and lipoproteins in serum of women with pregnancy induced hypertension] Banaczek Z, et al. **Ginekol Pol** 1995 Feb;66(2):72–5 (Eng. Abstr.) **(Pol)**

METABOLISM

[Fetal metabolism in post term pregnancy based on biochemical investigations of amniotic fluid. IV. Ion composition] Wójcicka-Jagodzińska J, et al. **Ginekol Pol** 1995 May;66(5):253–6 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Amniotic fluid epidermal growth factor levels in normal and abnormal pregnancies. Varner MW, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):17–9

[Evaluation of the usefulness and reference values for the amniotic fluid index in normal pregnancy between 30 and 42 weeks of gestation] Heimrath J, et al. **Ginekol Pol** 1995 Feb;66(2):85–8 (Eng. Abstr.) **(Pol)**

PREGNANCY, TUBAL

Coexistence of bilateral tubal and intrauterine pregnancy. Jønler M, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):750–2

Gynaecological emergency in surgical theatre. A case report. Konar HL. **Clin Exp Obstet Gynecol** 1996;23(1):26–8

[Simultaneous intrauterine and extrauterine pregnancy in the presence of inert intrauterine device: a case report] Akpadza K, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep; 90(7–9):360–1 (Eng. Abstr.) **(Fre)**

BLOOD

Placental isoferritin patterns during normal first trimester and tubal gestations. Maymon R, et al. **Hum Reprod** 1995 Sep; 10(9):2445–7

COMPLICATIONS

[Ectopic molar pregnancy. Two cases in sixteen years] Diouf A, et al. **Contracept Fertil Sex** 1995 Nov;23(11):674–6 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Heterotopic pregnancy after in vitro fertilization. Sucov A, et al. **Am J Emerg Med** 1995 Nov;13(6):641–3

Maternal serum creatine kinase: a possible predictor of tubal pregnancy? [letter; comment] García-Velasco JA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):238–40. Comment on: Am J Obstet Gynecol 1993 Nov;169(5):1149–50.

False-negative laparoscopy: a pitfall in the diagnosis of early ectopic pregnancy. Edozien LC, et al. **Br J Clin Pract** 1995 Nov–Dec;49(6):326–7

Two-step diagnosis of bilateral ectopic pregnancy after in vitro fertilization. Hugues J, et al. **J Assist Reprod Genet** 1995 Aug;12(7):460–2

Case records of the Massachusetts General Hospital. Case 3–1996. Severe abdominal pain during early pregnancy in a woman with previous infertility [clinical conference]

N Engl J Med 1996 Jan 25;334(4):255–60

[Value of serum placental protein 14 determination in differential diagnosis of abnormal early pregnancy] Römer T, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):490–2 (Eng. Abstr.) **(Ger)**

[Undetected tubal pregnancy in gynecologic practice. A case from expert witness files] Beck L, et al. **Gynakologe** 1995 Oct;28(5):389–90 **(Ger)**

[The role of comprehensive examination and laparoscopy in the surgical treatment of tubal pregnancy] Zurabiani ZR, et al. **Akush Ginekol (Mosk)** 1995;(5):20–3 (Eng. Abstr.) **(Rus)**

[Current state of conservative management of ectopic pregnancy] Marin Cantu VA, et al. **Ginecol Obstet Mex** 1996 Mar;64:123–30 (49 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Recurrent tubal pregnancy after a intra-tubal injection of methotrexate. Analysis of an case report with a histological tubal study] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):482–4 (Eng. Abstr.) **(Fre)**

[Histopathologic findings of the trophoblast and tubal wall after medicamentous therapy of tubal pregnancies] Klein M, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):671–3 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Salpingitis and tubal pregnancy in materials from the Clinics of the Surgical Gynecological Academy of Medicine in Lublin in the years 1978–1988] Semczuk M, et al. **Ginekol Pol** 1995 Sep;66(9):507–12 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Severe ovarian hyperstimulation syndrome and combined intrauterine and tubal pregnancy after in-vitro fertilization and embryo transfer. Moosburger D, et al. **Hum Reprod** 1996 Jan;11(1):68–9

[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Proliferative activity in ectopic trophoblastic tissue. Klein M, et al. **Hum Reprod** 1995 Sep;10(9):2441–4

[Recurrent tubal pregnancy after a intra-tubal injection of methotrexate. Analysis of an case report with a histological tubal study] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):482–4 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Brain water intoxication and CT hypolucencies in ovarian hyperstimulation syndrome complicating gametes intrafallopian transfer (GIFT) and tubal pregnancy [letter] Onofrj M, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):233–4

REHABILITATION

[Tubal pregnancy: the experience of early rehabilitative treatment] Strugatskil VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):21–2 (Eng. Abstr.) **(Rus)**

SURGERY

Conservative versus radical surgery for tubal pregnancy. A review. Clausen I. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):8–12 (44 ref.)

Disseminated implantation of peritoneal trophoblastic tissue secondary to laparoscopic removal of a tubal pregnancy. Sjøgren P, et al. **Acta Obstet Gynecol Scand** 1996 Apr; 75(4):408–9

Previous ectopic pregnancy should be considered a contraindication for microsurgery. Strandell A, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):394–9

For tubal pregnancy, surgical treatment is usually best. Gomel V. **Clin Obstet Gynecol** 1995 Jun;38(2):353–61 (48 ref.)

Cost-benefit analysis of laparoscopic adnexectomy. Tintara H, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):21–5

Is salpingostomy the surgical treatment of choice for unruptured tubal pregnancy? Rulin MC. **Obstet Gynecol** 1995 Dec;86(6):1010–3

[Results of endoscopic treatment of tubal pregnancy] Sopanen T, et al. **Duodecim** 1994;110(6):569–73 **(Fin)**

[Radical laparoscopic surgery of ectopic pregnancy: results from a continuous series of 383 interventions] Dubuisson JB, et al. **Contracept Fertil Sex** 1996 Feb;24(2):140–6 (36 ref.) (Eng. Abstr.) **(Fre)**

[The role of comprehensive examination and laparoscopy in the surgical treatment of tubal pregnancy] Zurabiani ZR, et al. **Akush Ginekol (Mosk)** 1995;(5):20–3 (Eng. Abstr.) **(Rus)**

THERAPY

Unsuccessful treatment of tubal pregnancy by shock wave lithotripsy. Egarter C, et al. **Arch Gynecol Obstet** 1995; 256(4):205–7

PREGNANCY, UNWANTED

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311–8 (30 ref.)

Condom failure is on the increase [news] Carnall D. **BMJ** 1996 Apr 27;312(7038):1059

Pregnant teenagers and contraception. The needs of older women are just as great [letter; comment] [see comments] Randall S, et al. **BMJ** 1995 Sep 23;311(7008):807. Comment on: BMJ 1995 Jun 24;310(6995):1644. Comment in: BMJ 1995 Sep 23;311(7008):762–3.

Consensus statement on emergency contraception. **Contraception** 1995 Oct;52(4):211–3 (6 ref.)

Medicaid costs of live births from unintended pregnancies in Florida. Hopkins RS, et al. **J Fla Med Assoc** 1995 Aug; 82(8):540–3

Unintended pregnancy. **Nurse Pract** 1995 Nov;20(11 Pt 1):76–9

[Liability in failed sterilization from the legal viewpoint] Franzki H. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):676–8 (Eng. Abstr.) **(Ger)**

[Legal liability in failed sterilization from the physician's viewpoint] Hammerstein J. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):678–81; discussion 681–3 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787–90 (24 ref.)

Teenage pregnancy: a comparative study of teenagers choosing termination of pregnancy or antenatal care [see comments] Pearson VA, et al. **J R Soc Med** 1995 Jul; 88(7):384–8. Comment in: J R Soc Med 1995 Jul;88(7):369–71.

The influence of abuse on pregnancy intention. Campbell JC, et al. **Womens Health Issues** 1995 Winter;5(4):214–23

PREGNANCY ZONE PROTEINS

ANALYSIS

Immunolocalization of 91 kDa ascitic protein in the human placenta. Kami K, et al. **Okajimas Folia Anat Jpn** 1995 Oct;72(4):227–34

BIOSYNTHESIS

Glycoproteins of the aspartyl proteinase gene family secreted by the developing placenta. Roberts RM, et al. **Adv Exp Med Biol** 1995;362:231–40

ISOLATION & PURIFICATION

[Molecules of the family of aspartic proteinases in the placenta of ruminants: hormones or proteins?] Beckers JF, et al. **Bull Mem Acad R Med Belg** 1994;149(8–11):355–64; discussion 364–7 (Eng. Abstr.) **(Fre)**

METABOLISM

Pregnancy associated alpha-glycoprotein (SP-III) in Nigerian pregnant women. Onyemelukwe GC, et al. **Afr J Med Med Sci** 1995 Mar;24(1):17–20

Preparation and characterization of a C-terminal fragment of pregnancy zone protein corresponding to the receptor-binding peptide from human alpha 2-macroglobulin. Jensen PE, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):254–8

Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. Valnickova Z, et al. **J Biol Chem** 1996 May 31;271(22):12937–43

PREGNANEDIOL

ANALOGS & DERIVATIVES

Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm. Kassam A, et al. **Environ Health Perspect** 1996 Apr;104(4):408–13

Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Baird DD, et al. **Epidemiology** 1995 Sep;6(5):547–50

Pregnancy detection in bighorn sheep (Ovis canadensis) using a fecal-based enzyme immunoassay. Borjesson DL, et al. **J Wildl Dis** 1996 Jan;32(1):67–74

URINE

Predictors of ovarian steroid secretion in reproductive-age women. Westhoff C, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):381–8

[Pregnanediol (P2)] Kambegawa A. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:576–9 (11 ref.) **(Jpn)**

PREGNANEDIONES

BLOOD

Women with steroid 5 alpha-reductase 2 deficiency have normal concentrations of plasma 5 alpha-dihydroprogesterone during the luteal phase. Milewich L, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3136–9

CHEMICAL SYNTHESIS

Antiandrogen. III. 11-oxapregnane steroids. Takegawa S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):746–8

CHEMISTRY

Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation. Mavromoustakos T, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):257–64

PHARMACOLOGY

Preemptive analgesic effects of steroid anesthesia with alphaxalone in the rat formalin test. Evidence for differential GABA(A) Receptor modulation in persistent nociception. Gilron I, et al. **Anesthesiology** 1996 Mar; 84(3):572–9

Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Akhondzadeh S, et al. **Brain Res** 1995 Apr 24;677(2):311–8

Failure of the steroid anaesthetic alphaxalone to inhibit CRF-induced ACTH secretion in rats in the fast feedback time domain. Hinz B, et al. **Pharmazie** 1996 Jun;51(6):433–4

PREGNANES

ADMINISTRATION & DOSAGE

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

CHEMISTRY

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

ISOLATION & PURIFICATION

New polyoxypregnane ester derivatives from Leptadenia hastata. Aquino R, et al. **J Nat Prod** 1996 Jun;59(6):555–64

PHARMACOLOGY

Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. Schoonen WG, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):423–37

Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. Schoonen WG, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):439–44

The hyperphagic effect of 3 alpha-hydroxylated pregnane steroids in male rats. Chen SW, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):777–82

The effect of menopause and hormone replacement therapy on bone alkaline phosphatase. Alexandersen P, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):571–6

TOXICITY

Functional, biochemical, and morphological hepatobiliary effects in rats chronically exposed to a steroidal antiandrogen. Descotes G, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):23–33

PREGNANETRIOL

ANALOGS & DERIVATIVES

Urinary pregnanetriol-3-glucuronide in children: age-related change and application to the management of 21-hydroxylase deficiency. Yang Y, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):107–13

15 beta-hydroxysteroids (Part IV). Steroids of the human perinatal period: the synthesis of 3 alpha,15 beta,17 alpha-trihydroxy-5 alpha-pregnan-20-one and its A/B-ring configurational isomers. Reeder AY, et al. **Steroids** 1995 Dec;60(12):796–801

URINE

[Pregnanetriol (P3)] Kambegawa A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:580–3 (11 ref.) **(Jpn)**

PREGNANOLONE

ADMINISTRATION & DOSAGE

Comparison of eltanolone and propofol on a pressure-volume analysis of the heart. Mulier JP, et al. **Anesth Analg** 1996 Aug;83(2):233-7

EEG analysis and pharmacodynamic modelling after intravenous bolus injection of eltanolone (pregnanolone). Hering W, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):407-15

Chronic neurosteroid treatment decreases the efficacy of benzodiazepine ligands and neurosteroids at the gamma-aminobutyric acidA receptor complex in mammalian cortical neurons. Yu R, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):784-9

ANALOGS & DERIVATIVES

Neurosteroid analogues. 3. The synthesis and electrophysiological evaluation of benz[e]indene congeners of neuroactive steroids having the 5 beta-configuration. Han M, et al. **J Med Chem** 1995 Oct 27;38(22):4548-56

3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor. Hawkinson JE, et al. **Mol Pharmacol** 1996 May; 49(5):897-906

ANTAGONISTS & INHIBITORS

Flumazenil blocks the anxiolytic action of allopregnanolone. Fernández-Guasti A, et al. **Eur J Pharmacol** 1995 Jul 25; 281(1):113-5

METABOLISM

Allopregnanolone concentration in hippocampus of prepubertal rats and female rats throughout estrous cycle. Palumbo MA, et al. **J Endocrinol Invest** 1995 Dec; 18(11):853-6

Influence of the estrus cycle on the discrimination of apparent neuroactive steroid site subtypes on the gamma-aminobutyric acidA receptor complex in the rat. McCauley LD, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1412-7

PHARMACOLOGY

In vitro effects of eltanolone on rat myocardium. Riou B, et al. **Anesthesiology** 1995 Oct;83(4):792-8

Concentration-effect relationships of eltanolone given as a bolus dose or constant rate intravenous infusion to healthy male volunteers. Wessén A, et al. **Anesthesiology** 1996 Jun; 84(6):1317-26

Allopregnanolone acts as an inhibitory modulator on alpha1- and alpha6-containing GABA-A receptors. Hauser CA, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):531-6

Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Akhondzadeh S, et al. **Brain Res** 1995 Apr 24;677(2):311-8

The neurosteroid 3 alpha, 5 apha-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Frye CA. **Brain Res** 1995 Oct 23;696(1-2):113-20

Chronic neurosteroid treatment attenuates single cell GABAA response and its potentiation by modulators in cortical neurons. Yu R, et al. **Brain Res** 1996 Jan 8; 706(1):160-2

Sex steroids and memory. **Ciba Found Symp** 1995;191:113-21

EEG analysis and pharmacodynamic modelling after intravenous bolus injection of eltanolone (pregnanolone). Hering W, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):407-15

Infusions of diazepam and allopregnanolone into the midbrain central gray facilitate open-field behavior and sexual receptivity in female rats. McCarthy MM, et al. **Horm Behav** 1995 Sep;29(3):279-95

Rise in intracellular calcium via a nongenomic effect of allopregnanolone in fetal rat hypothalamic neurons. Dayanithi G, et al. **J Neurosci** 1996 Jan;16(1):130-6

Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. Brewster ME, et al. **J Pharm Sci** 1995 Oct;84(10):1154-9

Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone. Cheney DL, et al. **Neuroreport** 1995 Aug 21;6(12):1697-700

Neuroactive steroids modulate GABA inhibition of hypothalamic somatostatin release. Tapia-Arancibia L, et al. **Neuroreport** 1995 Oct 2;6(14):1927-31

Allopregnanolone potentiates a GABA-withdrawal syndrome in the rat cerebral cortex. Calixto E, et al. **Neurosci Lett** 1995 Aug 4;195(2):73-6

PHYSIOLOGY

Interaction between 17 beta-oestradiol and 3 alpha-hydroxy-5 alpha-pregnane-20-one in the control of neuronal excitability in slices from the CA1 hippocampus in vitro of guinea-pigs and rats. Landgren S, et al. **Acta Physiol Scand** 1995 Jun;154(2):165-76

Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. Genazzani AR, et al. **Eur J Endocrinol** 1995 Sep; 133(3):375-80

PREGNANT MARE'S SERUM see **GONADOTROPINS, EQUINE**

PREGNATRIENES

Successful in vitro purging of leukemic blasts from marrow by cortivazol, a pyrazolosteroid: a preclinical study for autologous transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Juneja HS, et al. **Leukemia** 1995 Oct;9(10):1771-8

ADMINISTRATION & DOSAGE

The effect of lazaroid (U74500A), a novel inhibitor of lipid peroxidation, on 24-hour heart preservation. A study based on a working model using cross-circulated blood-perfused rabbit hearts. Nishida T, et al. **Transplantation** 1996 Jan 27;61(2):194-9

Lazaroid U-74389G for 48-hour canine liver preservation. Todo S, et al. **Transplantation** 1996 Jan 27;61(2):189-94

[Cortisone injection into the sacroiliac joint] Bellaïche L. **Ann Radiol (Paris)** 1995;38(4):192-5 (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

An unusual rearrangement product formed during production of mometasone furoate (Sch 32088). Puar MS, et al. **Steroids** 1995 Sep;60(9):612-4

PHARMACOKINETICS

Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Fleishaker JC, et al. **Eur J Clin Pharmacol** 1996;50(1-2):139-45

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. Fleishaker JC, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):991-8

Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. Wienkers LC, et al. **J Pharmacol Exp Ther** 1996 May;277(2):982-90

PHARMACOLOGY

Donor lazaroid pretreatment improves viability of livers harvested from non-heart-beating rats. Xu HS, et al. **Am J Surg** 1996 Jan;171(1):113-6; discussion 116-7

Traumatic neuronal injury in cortical cell culture is attenuated by 21-aminosteroids. Regan RF, et al. **Brain Res** 1995 Jun 5;682(1-2):144-50

The 21-aminosteroid U-74389F increases the number of glial fibrillary acidic protein-expressing astrocytes in the spinal cord of control and Wobbler mice. Gonzalez Deniselle MC, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):61-72

Influence of the 21-aminosteroid U74389F on ischemia-reperfusion injury in the rat. Paroni R, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):737-42

Protective effects of lazaroid U74389F (16-desmethyl tirilazad) on endrin-induced lipid peroxidation and DNA damage in brain and liver and regional distribution of catalase activity in rat brain. Bagchi M, et al. **Free Radic Biol Med** 1995 Dec;19(6):867-72

21-aminosteroid and 2-(aminomethyl)chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Shi F, et al. **Free Radic Biol Med** 1995 Sep;19(3):349-57

Hydrogen peroxide induces 21-aminosteroid-inhibitable F2-isoprostane production and cytolysis in renal tubular epithelial cells. Salahudeen A, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1300-3

Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. Smith SL, et al. **J Neurosurg** 1996 Feb;84(2):229-33

Effects of methylprednisolone and 21-aminosteroids on mitogen-induced interleukin-6 and tumor necrosis factor-alpha production in human peripheral blood mononuclear cells. Buttgereit F, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):850-3

Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidation. Campo GM, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):333-40

The 21-aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation. Wang Y, et al. **J Pharmacol Exp Ther** 1996 May;277(2):714-20

The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. Yue G, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):265-70

Effects of an antioxidant in a rabbit model of tourniquet-induced skeletal muscle ischemia-reperfusion injury. Mohler LR, et al. **J Surg Res** 1996 Jan;60(1):23-8

The antioxidant, U74389, ameliorates the depression of vascular reactivity caused by lipopolysaccharide. Loegering DJ, et al. **Life Sci** 1995;57(20):PL321-6

Vascular effects of the 21-aminosteroid tirilazad mesylate: protection against oxidant stress. McKenna R, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):279-92

Constitutive repression and nuclear factor I-dependent hormone activation of the mouse mammary tumor virus promoter in Saccharomyces cerevisiae. Chávez S, et al. **Mol Cell Biol** 1995 Dec;15(12):6987-98

Synergistic renal protection by combining alkaline-diuresis with lipid peroxidation inhibitors in rhabdomyolysis: possible interaction between oxidant and non-oxidant mechanisms. Salahudeen AK, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):635-42

Lazaroids protect isolated rat pancreatic acinar cells against damage induced by free radicals. Niederau C, et al. **Pancreas** 1995 Aug;11(2):107-21

Protective effects of tirilazad mesylate in a cellular model of peroxynitrite toxicity. Fici GJ, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):357-71

Tirilazad does not protect rat brain from brachytherapy-induced injury. Bernstein M, et al. **Surg Neurol** 1996 May;45(5):482-9

Effects of superoxide dismutase and U74389G on acute trimethyltin-induced cochlear dysfunction. Clerici WJ. **Toxicol Appl Pharmacol** 1996 Feb;136(2):236-42

Lazaroid U74500A enhances donor lung preservation in the rat transplant model. Du Z, et al. **Transplant Proc** 1995 Dec;27(6):3574-7

Impact of Lazaroid U74006F on ischemia and reperfusion injury of islets after transplantation in the rat. Shapiro AM, et al. **Transplant Proc** 1996 Feb;28(1):85-6

Cardioprotective effects of the lazaroid U74389G following cold preservation and transplantation of rat hearts. Duguay P, et al. **Transplantation** 1996 Apr 15;61(7):1023-8

THERAPEUTIC USE

Effects of U-74389G, a novel 21-aminosteroid, on small intestinal ischemia and reperfusion injury in horses. Vatistas NJ, et al. **Am J Vet Res** 1996 May;57(5):762-70

Tirilazad prevention of reperfusion edema after focal ischemia in cynomolgus monkeys. Boisvert DP, et al. **Can J Neurol Sci** 1996 Feb;23(1):46-52

Lazaroids. CNS pharmacology and current research. Clark WM, et al. **Drugs** 1995 Dec;50(6):971-83 (64 ref.)

Effects of the lazaroid U74389G (21 aminosteroid) on skeletal muscle reperfusion injury in rabbits. Hoballah JJ, et al. **Int Angiol** 1996 Mar;15(1):61-6

The lazaroid U74389G protects normal brain from stereotactic radiosurgery-induced radiation injury. Buatti JM, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1; 34(3):591-7

Tirilazad and subarachnoid hemorrhage [letter] Astrup J, et al. **J Neurosurg** 1996 Jun;84(6):1078-9

Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. Kassell NF, et al. **J Neurosurg** 1996 Feb; 84(2):221-8

Lack of effect of postinjury treatment with methylprednisolone or tirilazad mesylate on the increase in eicosanoid levels in the acutely injured cat spinal cord. Hall ED, et al. **J Neurotrauma** 1995 Jun;12(3):245-56

Pitfalls and advances from the international tirilazad trial in moderate and severe head injury. Marshall LF, et al. **J Neurotrauma** 1995 Oct;12(5):929-32

Attenuation of multiple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G. Remmers D, et al. **J Surg Res** 1996 May;62(2):278-83

Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis. Orozco J, et al. **Neurol Res** 1995 Dec; 17(6):423-5

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105-12 (37 ref.)

Amelioration of impaired cerebral metabolism after severe acidotic ischemia by tirilazad posttreatment in dogs. Kim H, et al. **Stroke** 1996 Jan;27(1):114-21

[Duchenne Boulogne myopathy and free radicals; potential value of lazaroids in the treatment of this disease] Poindron P, et al. **C R Seances Soc Biol Fil** 1995;189(6):1199-217 **(Fre)**

TOXICITY

Tirilazad mesylate--effects of the 21-aminosteroid on the lymphoid system of laboratory animals: a comparison with the glucocorticoid methylprednisolone. Jackson TA, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):246-57

PREGNENEDIONES

ADMINISTRATION & DOSAGE

Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Svedmyr J, et al. **Acta Paediatr** 1995 Aug;84(8):884-8

Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Wennergren G, et al. **Acta Paediatr** 1996 Feb;85(2):183-9

Effects of "systemic" budesonide concentrations on in vitro allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Oddera S, et al. **Allergy** 1995 May;50(5):397-404

Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Cockcroft DW, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1485-9

Nocturnal cortisol secretion in healthy adults before and after

inhalation of budesonide. Nikolaizik WH, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):97–101

Withdrawal of corticosteroid therapy after acute asthma attacks. **Can Med Assoc J** 1995 Nov 15;153(10):1471, 1473 **(Eng, Fre)**

A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Pauwels RA, et al. **Chest** 1996 Jul;110(1):53–7

Inhaled budesonide therapy for patients with stable COPD [see comments] Weiner P, et al. **Chest** 1995 Dec; 108(6):1568–71. Comment in: Chest 1995 Dec;108(6):1486–7.

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler (P-MDI) [letter] Fuller RW, et al. **Eur Respir J** 1995 Dec;8(12):2194–5

Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Kharitonov SA, et al. **Eur Respir J** 1996 Feb;9(2):196–201

Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide. Knutsson PU, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):655–61

Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. de Jong EM, et al. **J Dermatol Sci** 1995 May; 9(3):185–94

Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. Nolen H 3rd, et al. **J Pharm Sci** 1995 Jun;84(6):677–81

Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. Di Munno O, et al. **J Rheumatol** 1995 Aug;22(8):1492–8

Inhaled steroids in the treatment of pertussis [letter] Winrow AP. **Pediatr Infect Dis J** 1995 Oct;14(10):922

Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Malo JL, et al. **Respir Med** 1995 Sep;89(8):537–43

Effects of plain and controlled-ileal-release budesonide formulations in experimental ileitis. Boyd AJ, et al. **Scand J Gastroenterol** 1995 Oct;30(10):974–81

In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. Everard ML, et al. **Thorax** 1996 Jan;51(1):75–7

Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients. Meijer RJ, et al. **Thorax** 1996 Apr;51(4):433–4

Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Weiner P, et al. **Thorax** 1995 Dec;50(12):1270–3

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Effects of inhalation of a glucocorticoid using metered-dose propellant gas aerosol and Turbohaler—a roentgen pilot study] Vogel H, et al. **Pneumologie** 1995 Oct;49(10):559–60 **(Ger)**

[The effect of the Russian inhalant glucocorticosteroid budesonide on bronchial inflammation and hyperreactivity during the long-term treatment of bronchial asthma patients] Sutochnikova OA, et al. **Ter Arkh** 1996; 68(3):48–50 (Eng. Abstr.) **(Rus)**

[Comparative study] of beclomethasone and budesonide, with same posology (400 micrograms every 12 hours), in the control of cortico-dependent intrinsic asthma] Hernández J, et al. **Allergol Immunopathol (Madr)** 1995 Sep-Oct; 23(5):193–201 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Linear growth of very young asthmatic children treated with high-dose nebulized budesonide. Reid A, et al. **Acta Paediatr** 1996 Apr;85(4):421–4

Budesonide patch testing [letter] Rietschel RL. **Arch Dermatol** 1995 Dec;131(12):1466–7

Erythema-multiforme-like contact dermatitis from budesonide. Stingeni L, et al. **Contact Dermatitis** 1996 Feb; 34(2):154–5

Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Roy A, et al. **Eur Respir J** 1996 Feb;9(2):226–31

Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Hanania NA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):571–9

Reactions to other corticosteroids in patients with positive patch test reactions to budesonide. Wilkinson M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):963–8

Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. Packe GE, et al. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):128–32

[Budesonide (letter)] Schäkel K, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1490 **(Ger)**

[Toxic epidermal necrolysis in a patient treated with high doses of deflazacort (letter)] Navarro Llanos A, et al. **Med Clin (Barc)** 1996 Apr 20;106(15):599 **(Spa)**

[Depression in a child treated with Pulmicort Turbuhaler] **Lakartidningen** 1996 May 22;93(21):2083 **(Swe)**

BLOOD

Sensitive high-performance liquid chromatographic assay method for the determination of guggulsterone in serum. Singh SK, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):173–6

CHEMICAL SYNTHESIS

New steroidal diazo ketones as potential photoaffinity labeling reagents for the mineralocorticoid receptor: synthesis and biological activities. Davioud E, et al. **J Med Chem** 1996 Jul 5;39(14):2860–4

IMMUNOLOGY

Short courses of high-dose inhaled budesonide and serum IgG subclass levels in healthy volunteers. Van Schoor J, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):113–8

PHARMACOKINETICS

The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Barry PW, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):76–8

Pharmacokinetics and pharmacodynamics of cloprednol. Möllmann H, et al. **Int J Clin Pharmacol Ther** 1996 Jan; 34(1):1–5

Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Möllmann H, et al. **Pharm Res** 1995 Jul; 12(7):1096–100

PHARMACOLOGY

Allergen-induced late airways reactions in the pig. Influence of endogenous and exogenous glucocorticoids. Fornhem C. **Acta Physiol Scand Suppl** 1995;631:1–48

Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge. Hilberg O. **Allergy** 1995 Aug;50(8):683–8

Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Nikolaizik WH, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):97–101

Budesonide or prednisolone in active Crohn's disease [editorial] Baert F, et al. **Ann Med** 1995 Dec;27(6):631

Calving rates in a tropical beef herd after treatment with a synthetic progestagen, norgestomet, or a prostaglandin analogue, cloprostenol. Frisch JE, et al. **Aust Vet J** 1996 Mar;73(3):98–102

Progestin-induced puberty and secretion of luteinizing hormone in heifers. Anderson LH, et al. **Biol Reprod** 1996 May;54(5):1025–31

Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. van den Berg HW, et al. **Br J Cancer** 1996 Feb;73(4):477–81

Reduced levels of cathepsin D associated with tamoxifen resistance and estrogen independence in the ZR-75-1 human breast cancer cell line. Long BJ, et al. **Cancer Lett** 1996 Feb 6;99(2):233–8

The pathophysiology and treatment of rhinitis medicamentosa. Graf P, et al. **Clin Otolaryngol** 1995 Jun; 20(3):224–9

Inhibition of 5 alpha-reductase activity impairs the testosterone-dependent restoration of spermiogenesis in adult rats. O'Donnell L, et al. **Endocrinology** 1996 Jul; 137(7):2703–10

An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Lönnebo A, et al. **Eur J Clin Pharmacol** 1996;49(6):459–63

The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs. Stevens WH, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):251–7

The effect of high-dose inhaled budesonide on lipid profile in asthmatic patients. Yavuz O, et al. **Gen Pharmacol** 1996 Jan;27(1):89–90

Effect of norgestomet treatment after insemination on the calving rate of postpartum suckled beef cows. Favero RJ, et al. **J Anim Sci** 1995 Nov;73(11):3230–4

Effect of a gonadotropin-releasing hormone agonist on follicle recruitment and pregnancy rate in cattle. Schmitt EJ, et al. **J Anim Sci** 1996 Jan;74(1):154–61

Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. McKay DM, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):403–10

Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. Fuglsang G, et al. **Pediatr Allergy Immunol** 1995 May;6(2):103–8

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Clark DJ, et al. **Thorax** 1996 Mar;51(3):262–6

Effects of topical budesonide on epithelial restitution in vivo in guinea pig trachea. Erjefält JS, et al. **Thorax** 1995 Jul; 50(7):785–92

[Control of reproduction in the female Ndama cow by Norgestomet (CRESTAR)] Diop PE, et al. **Dakar Med** 1994;39(2):129–34 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190–4

Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Wennergren G, et al. **Acta Paediatr** 1996 Feb;85(2):183–9

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Lémann M, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):557–62

Inhaled steroids treatment and withdrawal in asthmatic children. Farrero E, et al. **Allergol Immunopathol (Madr)** 1995 Jul-Aug;23(4):182–8

Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Autio P, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1172–5

Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. de Jong JW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):70–5

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Pedersen B, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1519–29

Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Krogsgaard MR, et al. **Ann Rheum Dis** 1996 Feb;55(2):143–6

Anti-inflammatory therapy reduces wheezing after bronchiolitis. Reijonen T, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):512–7

Effect of inhaled corticosteroids on bronchial hyperresponsiveness in patients with mild asthma. Wongtim S, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):81–5

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol [see comments] Kalra S, et al. **Chest** 1996 Apr;109(4):953–6. Comment in: Chest 1996 Apr;109(4):862–4.

Effect of early vs late intervention with inhaled corticosteroids in asthma [see comments] Selroos O, et al. **Chest** 1995 Nov;108(5):1228–34. Comment in: Chest 1995 Nov;108(5):1188–90.

Treat patients who have nocturnal asthma with anti-inflammatory drugs first [letter; comment] Wempe JB, et al. **Chest** 1996 Apr;109(4):1130. Comment on: Chest 1995 Feb;107(2):406–12.

Transient osteoporosis of the hip: successful response to deflazacort. Carmona-Ortells L, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):653–5

GISC protocol experience in the treatment of essential mixed cryoglobulinaemia. Pioltelli P, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S187–90

A comparison of the efficacy and patient acceptability of budesonide and beclomethasone dipropionate aqueous nasal sprays in patients with perennial rhinitis. Adamopoulos G, et al. **Clin Otolaryngol** 1995 Aug;20(4):340–4

The pathophysiology and treatment of rhinitis medicamentosa. Graf P, et al. **Clin Otolaryngol** 1995 Jun; 20(3):224–9

Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Markham A, et al. **Drugs** 1995 Aug; 50(2):317–33 (68 ref.)

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

The psychological factors associated with poor compliance with treatment in asthma. Bosley CM, et al. **Eur Respir J** 1995 Jun;8(6):899–904

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Greenberg GR, et al. **Gastroenterology** 1996 Jan; 110(1):45–51

Nebulized steroids for mild-to-moderate croup. **Indian Pediatr** 1995 Mar;32(3):395–6

Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. de Blic J, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):14–20

Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. Volovitz B, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):874–8

Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. Bagnasco M, et al. **J Endocrinol Invest** 1995 Apr;18(4):305–7

The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children. Pichaipat V, et al. **J Med Assoc Thai** 1995 Oct;78(10):505–8

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. Krogsgaard MR, et al. **J Rheumatol** 1995 Sep;22(9):1660–2

Inhaled steroids and psoriasis [letter] Harries M. **Lancet** 1995 Dec 9;346(8989):1567

Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Geelhoed GC, et al. **Pediatr Pulmonol** 1995 Dec;20(6):355–61

Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup. Fitzgerald D, et al. **Pediatrics** 1996 May;97(5):722–5

The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup. Klassen TP, et al. **Pediatrics** 1996 Apr;97(4):463–6

[Vascular hyperfragility in systemic lupus erythematosus treated with low doses of cortisone] Longo F, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):535-7 (Eng. Abstr.) **(Ita)**

[Assessment of respiratory function in patients with chronic obstructive pulmonary diseases treated with budesonide] Kozak-Szkopek E. **Pneumonol Alergol Pol** 1995; 63(9-10):532-8 (Eng. Abstr.) **(Pol)**

[Comparative study of the effectiveness of 2 oral corticoids in the control of severe crisis of bronchial asthma: deflazacort and prednisone] Chapela R. **Rev Alerg Mex** 1995 Jul-Aug;42(4):64-8 (Eng. Abstr.) **(Spa)**

PREGNENES

CHEMISTRY

A comparative structural study on the steroids [1,2,5]oxadiazolo[3',4':3,4]-5 alpha-pregn-16-en-20-one oxime (HS998), [1,2,5]oxadiazolo[3,4':3,4]-5 beta-pregn-16-en-20-one (HS973) by NMR, molecular modeling, and X-ray investigations. Kayser F, et al. **Steroids** 1995 Oct;60(10):713-9

PREGNENOLONE

ANALOGS & DERIVATIVES

Indomethacin, esculetin and nordihydroguaiaretic acid modify arachidonate biosynthesis in rat adrenocortical cells. de Gómez Dumm NT, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):155-64

BIOSYNTHESIS

15-lipoxygenase metabolite(s) of arachidonic acid mediates adrenocorticotropin action in bovine adrenal steroidogenesis. Yamazaki T, et al. **Endocrinology** 1996 Jul; 137(7):2670-5

Steroid production by equine fetal gonads: a speculative view [editorial; comment] Raeside JI. **Equine Vet J** 1995 Sep; 27(5):324-5. Comment on: Equine Vet J 1995 Sep;27(5):334-40. Comment on: Equine Vet J 1995 Sep;27(5):342-7.

Cholera toxin directly stimulates pregnenolone generation with increasing Ca2+ efflux in bovine adrenocortical mitochondria. Nishikawa T, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):203-8

BLOOD

[Pregnenolone] Nakamura S, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:464-6 (7 ref.) **(Jpn)**

[A study on the maternal plasma C21 steroids concentration during pregnancy] Oku M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar;48(3):163-9 (Eng. Abstr.) **(Jpn)**

METABOLISM

Environmental temperature and cryptorchidism: effects on pregnenolone-sulfatase of mice testicular tissue. Valencia-Sánchez A, et al. **Arch Androl** 1996 May-Jun; 36(3):233-8

Formation of pregnenolone- and dehydroepiandrosterone-fatty acid esters by lecithin-cholesterol acyltransferase in human plasma high density lipoproteins. Lavallée B, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):306-12

Thyroid hormone induces the generation of a novel putative protein in piscine ovarian follicle that stimulates the conversion of pregnenolone to progesterone. Bhattacharya S, et al. **Eur J Endocrinol** 1996 Jan;134(1):128-35

The role of pregnenolone-metabolizing enzymes in the regulation of oestradiol biosynthesis during development of the first wave dominant follicle in the cow. Carrière PD, et al. **J Endocrinol** 1996 May;149(2):233-42

Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone. Cheney DL, et al. **Neuroreport** 1995 Aug 21;6(12):1697-700

Effect of phospholipids and organic solvents on the formation of 5,16-androstadien-3 beta-ol from pregnenolone in adrenal and testicular microsomes. Meadus WJ, et al. **Steroids** 1995 May;60(5):395-400

PHARMACOLOGY

The effects of pregnenolone sulfate and ethylestrenol on retention of a passive avoidance task. Isaacson RL, et al. **Brain Res** 1995 Aug 14;689(1):79-84

Male preference for the odors of estrous female mice is reduced by the neurosteroid pregnenolone sulfate. Kavaliers M, et al. **Brain Res** 1995 Jun 5;682(1-2):222-6

Sex steroids and memory. **Ciba Found Symp** 1995;191:113-21

Modulation of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in the equine placenta by pregnenolone and progesterone metabolites [see comments] Chavatte PM, et al. **Equine Vet J** 1995 Sep;27(5):342-7. Comment in: Equine Vet J 1995 Sep;27(5):324-5.

Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. Brewster ME, et al. **J Pharm Sci** 1995 Oct;84(10):1154-9

Inactivation of Escherichia coli-expressed rabbit cytochrome P-450 2C enzymes by 17 beta-substituted steroids. Klekotka PA, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1450-5

Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone. Cheney DL, et al. **Neuroreport** 1995 Aug 21;6(12):1697-700

Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Flood JF, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10806-10

THERAPEUTIC USE

Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. Muto M, et al. **J Dermatol** 1995 Oct; 22(10):770-2

PREGNENOLONE CARBONITRILE

PHARMACOLOGY

A novel cis-acting element in a liver cytochrome P450 3A gene confers synergistic induction by glucocorticoids plus antiglucocorticoids. Quattrochi LC, et al. **J Biol Chem** 1995 Dec 1;270(48):28917-23

PREHOSPITAL EMERGENCY CARE see **EMERGENCY MEDICAL SERVICES**

PREIMPLANTATION PHASE

Identification of calcium flux in single preimplantation mouse embryos with the calcium-sensitive vibrating probe. Keefe D, et al. **Biol Bull** 1995 Oct-Nov;189(2):200

Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Sharkey AM, et al. **Biol Reprod** 1995 Oct;53(4):974-81

Fertilization in vitro of mouse ova from inbred and outbred strains: complete preimplantation embryo development in glucose-supplemented KSOM. Summers MC, et al. **Biol Reprod** 1995 Aug;53(2):431-7

Update in preimplantation genetic diagnosis: successes, advances, and problems. Grifo JA, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):135-8 (31 ref.)

Differential expression of the full-length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst. Tong BJ, et al. **Endocrinology** 1996 Apr;137(4):1492-6

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7-10 (23 ref.)

Embryonic human leukocyte antigen-G expression: possible implications for human preimplantation development. Jurisicova A, et al. **Fertil Steril** 1996 May;65(5):997-1002

Expression of transcription regulating genes in human preimplantation embryos. Abdel-Rahman B, et al. **Hum Reprod** 1995 Oct;10(10):2787-92

Proliferation of blastomeres from biopsied cleavage stage human embryos in vitro: an alternative to blastocyst biopsy for preimplantation diagnosis. Geber S, et al. **Hum Reprod** 1995 Jun;10(6):1492-6

Associations between ultrasound indices of follicular blood flow, oocyte recovery and preimplantation embryo quality. Nargund G, et al. **Hum Reprod** 1996 Jan;11(1):109-13

Selected papers from the 5th annual meeting of the International Working Group on Preimplantation Genetics. Hamburg, Germany, June 28, 1995. **J Assist Reprod Genet** 1996 Feb;13(2):87-192

Regulation of preimplantation development of mouse embryos: effects of inhibition of myosin light-chain kinase, a Ca2+/calmodulin-dependent enzyme. Kabir N, et al. **J Exp Zool** 1996 Feb 1;274(2):101-10

Clinical experience with preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Prenat Diagn** 1996 Feb;16(2):137-42

Characterization of glucose transport in preimplantation mouse embryos. Gardner HG, et al. **Reprod Fertil Dev** 1995; 7(1):41-50

[Apropos of the diagnosis of preimplantation in transgenic mice (letter; comment)] Huriet C. **Presse Med** 1996 Feb 17;25(6):261. Comment on: Presse Med 1995 Sep 16;24(26):261. **(Fre)**

[Preimplantation diagnosis of delta F508 mutation of mucoviscidosis in transgenic mice] Ji YZ, et al. **Presse Med** 1995 Sep 16;24(26):1193-7 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effect of anordrin on the development of mouse preimplantation embryos in vitro. Juneja SC, et al. **J Assist Reprod Genet** 1996 Apr;13(4):356-62

GENETICS

Preimplantation genetic testing for Huntington disease and certain other dominantly inherited disorders. Schulman JD, et al. **Clin Genet** 1996 Feb;49(2):57-8

Transient expression of translation initiation factor eIF-4C during the 2-cell stage of the preimplantation mouse embryo: identification by mRNA differential display and the role of DNA replication in zygotic gene activation. Davis W Jr, et al. **Dev Biol** 1996 Mar 15;174(2):190-201

Expression of SGP-1 mRNA in preimplantation mouse embryos. Cao QP, et al. **Dev Genet** 1995;17(3):263-71

Expression of X-linked genes in androgenetic, gynogenetic, and normal mouse preimplantation embryos. Latham KE, et al. **Dev Genet** 1995;17(3):212-22

Identification of genes showing altered expression in preimplantation and early postimplantation parthenogenetic embryos. Mann M, et al. **Dev Genet** 1995; 17(3):223-32

Interleukin gene expression in mouse preimplantation development. Gerwin N, et al. **Dev Immunol** 1995; 4(3):169-79

Gene transfer and expression in mouse preimplantation embryos by recombinant adenovirus vector. Tsukui T, et al. **Mol Reprod Dev** 1995 Nov;42(3):291-7

IMMUNOLOGY

Preimplantation factor (PIF) predicts subsequent pregnancy loss. Coulam CB, et al. **Am J Reprod Immunol** 1995 Aug; 34(2):88-92

Interleukin gene expression in mouse preimplantation development. Gerwin N, et al. **Dev Immunol** 1995; 4(3):169-79

HLA-G expression during preimplantation human embryo development. Jurisicova A, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):161-5

[Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576-80 (50 ref.) (Eng. Abstr.) **(Fre)**

[Regulation by maternally derived cytokines of pre-implantation development and uterine receptiveness] Stewart CL, et al. **Contracept Fertil Sex** 1995 Sep; 23(9):555-61 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Immune interferon gamma inhibits translational mobility of a plasma membrane protein in preimplantation stage mouse embryos: a T-helper 1 mechanism for immunologic reproductive failure. Polgár K, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):282-7

Fine structural cytochemical and immunocytochemical analysis of nucleic acids and ribonucleoprotein distribution in nuclei of pig oocytes and early preimplantation embryos. Kopecny V, et al. **Chromosoma** 1996 Jun;104(8):561-74

Ezrin becomes restricted to outer cells following asymmetrical division in the preimplantation mouse embryo. Louvet S, et al. **Dev Biol** 1996 Aug 1;177(2):568-79

Translocation of active mitochondria during hamster preimplantation embryo development studied by confocal laser scanning microscopy. Barnett DK, et al. **Dev Dyn** 1996 Jan;205(1):64-72

Multiple members of the connexin gene family participate in preimplantation development of the mouse. Davies TC, et al. **Dev Genet** 1996;18(3):234-43

Transient release of calcium from inositol 1,4,5-trisphosphate-specific stores regulates mouse preimplantation development. Stachecki JJ, et al. **Development** 1996 Aug;122(8):2485-96

Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Pellicer A, et al. **Fertil Steril** 1996 Jun;65(6):1190-5

[The rapid assessment of the morphofunctional status of preimplantation mouse embryos at the moment of explantation during cultivation and development in vitro] Bogoliubova NA, et al. **Tsitologiia** 1995;37(3):202-7 (Eng. Abstr.) **(Rus)**

PREJUDICE

Salary inequities and health care costs [letter] Mutha S, et al. **Acad Med** 1995 Oct;70(10):853-4

Trends in heterosexual tertiary students' knowledge of HIV and intentions to avoid people who might have HIV. Van de Ven P, et al. **AIDS Care** 1996 Feb;8(1):43-53

Killing in the name of healing: the active role of the German medical profession during the Third Reich. Ernst E. **Am J Med** 1996 May;100(5):579-81

Women abuse drugs, too [letter] Coffey C. **Am J Nurs** 1996 Apr;96(4):20-1

Statement: nondiscrimination and inclusion regarding members of the occupational therapy professional community. American Occupational Therapy Association. Hansen R, et al. **Am J Occup Ther** 1995 Nov-Dec; 49(10):1009

Teaching sensitivity to cultural issues in women's health care in a community hospital setting. Leppert PC, et al. **Am J Prev Med** 1996 Mar-Apr;12(2):69-70

Sexism and heterosexism in the diagnostic interview for borderline patients? [letter] Zucker KJ. **Am J Psychiatry** 1996 Jul;153(7):966

Medicine and the Holocaust [letter] Gelles JM. **Ann Intern Med** 1995 Dec 15;123(12):964; discussion 964-5

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470-82 (58 ref.)

Miscoding of mental health diagnoses and stigmatization [letter; comment] Devitt N. **Arch Fam Med** 1995 Nov; 4(11):917. Comment on: Arch Fam Med 1994 Apr;3(4):319-20.

Gender differences in device therapy for malignant ventricular arrhythmias. Horton HL, et al. **Arch Intern Med** 1995 Nov 27;155(21):2342-5

PREJUDICE

George Adlington Syme Oration. The International Year of Tolerance: its challenge to Australia. Wilson R. **Aust N Z J Surg** 1995 Dec;65(12):833–7

Black and Asian nurses in the NHS report harassment [news] Beecham L. **BMJ** 1995 Nov 11;311(7015):1247

Flaws in agist arguments. Philosopher acquiesces to prevailing social mores [letter; comment] Bytheway B. **BMJ** 1995 Sep 16;311(7007):752; discussion 752–3. Comment on: BMJ 1995 May 6;310(6988):1179–82.

The GMC, racism, and complaints against doctors [editorial] Godlee F. **BMJ** 1996 May 25;312(7042):1314–5

South Africa's health. Apartheid cut both ways [letter; comment] Graham BJ. **BMJ** 1995 Oct 7;311(7010):947; discussion 948. Comment on: BMJ 1995 Apr 29;310(6987):1119–22.

South African Medical Association colluded with apartheid [letter; comment] Lawrence RA. **BMJ** 1995 Oct 14; 311(7011):1026. Comment on: BMJ 1995 Jul 15;311(6998):148.

Flaws in agist arguments. Doctors need pragmatic strategies [letter; comment] Lilford RJ. **BMJ** 1995 Sep 16; 311(7007):752; discussion 752–3. Comment on: BMJ 1995 May 6;310(6988):1179–82.

Survey of HIV patients' views on confidentiality and non–discrimination policies in general practice. Shaw M, et al. **BMJ** 1996 Jun 8;312(7044):1463–4

Life's unfair [letter] Wilkins J. **BMJ** 1996 Feb 10; 312(7027):381

Perceived antecedents of emotional reactions in inter–ethnic relations. Dijker AJ, et al. **Br J Soc Psychol** 1996 Jun;35 (Pt 2):313–29

Manners of expressing negative and sympathetic attitudes towards the unemployed. McFadyen RG, et al. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):303–23

Many voices—sociocultural results of the ethnocultural communities facing AIDS study in Canada. Singer SM, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S26–32, S28–35 **(Eng, Fre)**

Residents' experiences of abuse, discrimination and sexual harassment during residency training. McMaster University Residency Training Programs [see comments] Cook DJ, et al. **Can Med Assoc J** 1996 Jun 1;154(11):1657–65. Comment in: Can Med Assoc J 1996 Jun 1;154(11):1705–8.

Do Canadian female surgeons feel discriminated against as women? Ferris LE, et al. **Can Med Assoc J** 1996 Jan 1; 154(1):21–7

Isolation, excessive time demands and sexism face female MDs, CMA workshop told. MacLeod K. **Can Med Assoc J** 1996 Mar 1;154(5):708–9

Electroconvulsive therapy: problems and prejudices. Jackson J. **Convuls Ther** 1995 Sep;11(3):179–81

The value of curiosity and naiveté for the cross–cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)

The aging semantic differential: a confirmatory factor analysis. Intrieri RC, et al. **Gerontologist** 1995 Oct; 35(5):616–21

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov–Dec;24(6):427–35 (64 ref.)

Domestic violence [letter; comment] Uzych L. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):18. Comment on: Hosp Pract (Off Ed) 1995 Oct 15;30(10):45–52; discussion 52–3.

Culture, age and gender: effects on quality of predicted self and colleague reactions. Greipp ME. **Int J Nurs Stud** 1996 Feb;33(1):83–97

Myth and madness: a report of a psychoanalytic study of antisemitism. Ostow M. **Int J Psychoanal** 1996 Feb;77 (Pt 1):15–31

Stigma and psychiatric disorder in Israeli society [letter] **Isr J Psychiatry Relat Sci** 1996;33(1):68–71

Stigma and psychiatric disorder—a commentary [letter] Katzenelson–Bank D. **Isr J Psychiatry Relat Sci** 1996; 33(2):137–8

The consequences of a positive prenatal HIV antibody test for women. Lester P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):341–9

HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)

Choosing without losing: resisting medical heterosexism. Scarce M. **J Am Coll Health** 1995 Nov;44(3):135–6

Reply to Whitehouse and Deal editorial [letter; comment] Dick EG. **J Am Geriatr Soc** 1996 Jun;44(6):734–7. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1314–5.

Measurement and correlates of internalized homophobia: a factor analytic study. Ross MW, et al. **J Clin Psychol** 1996 Jan;52(1):15–21

Discrimination and abuse experienced by general internists in Canada. Cook DJ, et al. **J Gen Intern Med** 1995 Oct; 10(10):565–72

These sorts of people don't do very well': race and allocation of health care resources. Lowe M, et al. **J Med Ethics** 1995 Dec;21(6):356–60

Dismantling discrimination in dental education. Dummett CO. **J Natl Med Assoc** 1996 Jul;88(7):454–9

Employment discrimination experiences of registered nurses. Swart JC, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):37–43

Balancing judicial interests in HIV cases: Part 2, Issues for nurse administrators. Zachary MK. **J Nurs Adm** 1995 Nov; 25(11):9–14

Heterosexism in nursing education. Gray DP, et al. **J Nurs Educ** 1996 May;35(5):204–10 (12 ref.)

Stigma: baccalaureate nursing students' attitudes toward persons living with AIDS. Leasure R, et al. **J Nurs Educ** 1996 May;35(5):234–6

Undermining prejudice: the other epidemic [editorial] Tanner CA. **J Nurs Educ** 1996 May;35(5):195

The prejudiced personality, racism, and anti–Semitism: the PR scale forty years later. Dunbar E. **J Pers Assess** 1995 Oct;65(2):270–7

Variability in automatic activation as an unobtrusive measure of racial attitudes: a bona fide pipeline? Fazio RH, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1013–27

Influence of prototypes on perceptions of prejudice. Inman ML, et al. **J Pers Soc Psychol** 1996 Apr;70(4):727–39

"Nursism": an age old concern. Lewenson S. **J Prof Nurs** 1995 Sep–Oct;11(5):260

His and her individualisms? Sex bias and individualism in psychologists' responses to case vignettes. Fowers BJ, et al. **J Psychol** 1996 Mar;130(2):159–74

The great insanity [letter] Cohen SI, et al. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):448–9

Discrimination against men in infertility treatment. Birenbaum–Carmeli D, et al. **J Reprod Med** 1995 Aug; 40(8):590–4

Collective identity and intergroup prejudice among Jewish and Arab students in the United States. Ruttenberg J, et al. **J Soc Psychol** 1996 Apr;136(2):209–20

Subtle prejudice against women in The Netherlands. Vrugt AJ, et al. **J Soc Psychol** 1995 Oct;135(5):601–6

Career development for women in academic medicine: Multiple interventions in a department of medicine. Fried LP, et al. **JAMA** 1996 Sep 18;276(11):898–905

Natural law, human dignity and alcohol. Rougé D, et al. **Med Law** 1995;14(7–8):543–6

Crimes against genetics [editorial; comment] **Nat Genet** 1995 Nov;11(3):223–4. Comment on: Nat Genet 1995 Nov;11(3):233–4. Comment on: Nat Genet 1995 Nov;11(3):241–7.

Genes and discrimination [editorial] [see comments] Culliton BJ. **Nat Med** 1995 May;1(5):385. Comment in: Nat Med 1995 Aug;1(8):720.

Are cancer patients subject to employment discrimination? Rothstein MA, et al. **Oncology (Huntingt)** 1995 Dec; 9(12):1303–6; discussion 1311–2, 1315

Body stereotyping and stigmatization of obese persons by first graders. Goldfield A, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):909–10

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147–50 (8 ref.)

Formative research in the Meena Communication Initiative. Aghi M, et al. **Promot Educ** 1996 Jun;3(2):24–7, 46

Age and health bias in practicing clinical psychologists. James JW, et al. **Psychol Aging** 1995 Dec;10(4):610–6

Prejudice toward persons living with a fatal illness. Dukes RL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1107–14

HIV/AIDS activists want blacklist for discriminators [news] van der Linde I. **S Afr Med J** 1994 Dec;84(12):11

Environmental integrity, racism, health. Westra L. **Sci Total Environ** 1996 May 17;184(1–2):57–66

Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303–15 (79 ref.)

Attitudes towards people with HIV: are they as stigmatizing as people with HIV perceive them to be? Green G. **Soc Sci Med** 1995 Aug;41(4):557–68

Supervisor personal liability for ADA discrimination. Emerging issues for hospital administrators and physicians. Blanck PD, et al. **Spine** 1995 Jul 1;20(13):1528–32

Clean hand—dirty hand [editorial] Brink PJ. **West J Nurs Res** 1996 Apr;18(2):118–9

[Contemporary thoughts of a psychoanalyst. On some hidden consequences of "coping with the past" in relation to the national socialism era] Speidel H. **Z Psychosom Med Psychoanal** 1996;42(2):179–89 (Eng. Abstr.) **(Ger)**

[Increased mortality after acute myocardial infarction in women: treatment bias or a different disease? (editorial)] Behar S. **Harefuah** 1995 Nov 1;129(9):325–7 **(Heb)**

[The right to work and the non–discrimination of individuals infected with the human immunodeficiency virus, HIV/AIDS. The fitness test (editorial)] Torgal J. **Acta Med Port** 1995 Jul–Aug;8(7–8):401–4 **(Por)**

[Ethnopsychology: a corrector project (editorial)] Vilanova AR. **Acta Psiquiatr Psicol Am Lat** 1995 May;41(2):101–2 **(Spa)**

[Violence and sexism in television cartoons for children. Analysis of the contents] Prieto Rodríguez MA, et al. **Aten Primaria** 1996 Apr 15;17(6):382–8 (Eng. Abstr.) **(Spa)**

[Care according to patient gender in emergency services: different or unequal?] Ruiz T, et al. **Gac Sanit** 1995 Mar–Apr;9(47):76–83 (Eng. Abstr.) **(Spa)**

[Instruction and equality in medical research. Sex–related obstacles after equal education] Hultman CM, et al. **Lakartidningen** 1995 Nov 22;92(47):4452, 4455–6, 4461 **(Swe)**

[Nobody will be punished for one's own hereditary disposition. Genetic information should be protected by law] Lindblom A, et al. **Lakartidningen** 1996 Mar 6; 93(10):908–10 **(Swe)**

PREKALLIKREIN

see related
COAGULANTS

ANALYSIS

[Fletcher factor, Fitzgerald factor] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:167–70 (10 ref.) **(Jpn)**

METABOLISM

Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. Herwald H, et al. **J Biol Chem** 1996 May 31;271(22):13061–7

Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Imamura T, et al. **Lab Invest** 1996 May;74(5):861–70

[Elevated plasma prekallikrein level in patients with diabetes] Ciechanowicz A, et al. **Pol Arch Med Wewn** 1995 Aug; 94(2):105–11 (Eng. Abstr.) **(Pol)**

PRELEUKEMIA

COMPLICATIONS

Myelodysplastic syndrome presenting as cutaneous vasculitis. O'Donnell BF, et al. **Clin Exp Dermatol** 1995 Sep; 20(5):439–42

DIAGNOSIS

Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia. Vervoordeldonk SF, et al. **Br J Haematol** 1996 Mar; 92(4):922–8

GENETICS

BCR rearrangement without juxtaposition of ABL in pre–T acute lymphoblastic leukaemia. Fossâ A, et al. **Br J Haematol** 1996 May;93(2):403–5

Specific N–ras mutation in bone marrow within 48 H of 7,12–dimethylbenz[a]anthracene treatment in Huggins–Sugiyama rat leukemogenesis. Osaka M, et al. **Mol Carcinog** 1996 Jul;16(3):126–31

IMMUNOLOGY

In vitro modulation of preleukemic AKR mouse macrophage function by bacterial immunomodulators. Burek B, et al. **Immunol Lett** 1995 Mar;45(3):185–8

PATHOLOGY

Progression of a myelodysplastic syndrome to pre–B acute lymphoblastic leukemia: a case report and cell lineage study. Abruzzese E, et al. **Ann Hematol** 1996 Jul;73(1):35–8

Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells. Sawada K, et al. **Blood** 1996 Jul 1; 88(1):319–27

Gelatinous degeneration presenting as a preleukaemic syndrome. Arranz R, et al. **J Clin Pathol** 1996 Jun; 49(6):512–4

Acute lymphoblastic leukemia following preleukemic syndromes in adults. Escudier SM, et al. **Leukemia** 1996 Mar;10(3):473–7

PREMARIN see **ESTROGENS, CONJUGATED**

PREMARITAL EXAMINATIONS

Premarital screening of hemoglobinopathies: a pilot study in Turkey. Altay C, et al. **Hum Hered** 1996 Mar–Apr; 46(2):112–4

Pre–marital genetic counselling to consanguineous couples: attitudes, beliefs and decisions among counselled, noncounselled and unrelated couples in Israel. Shiloh S, et al. **Soc Sci Med** 1995 Nov;41(9):1301–10

PREMATURE ATRIAL BEATS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE ATRIAL CONTRACTIONS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE BEATS see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE CARDIAC COMPLEXES see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE SUPRAVENTRICULAR BEATS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE VENTRICULAR BEATS see **VENTRICULAR PREMATURE COMPLEXES**

PREMATURE VENTRICULAR CONTRACTIONS see **VENTRICULAR PREMATURE COMPLEXES**

PREMEDICAL EDUCATION see **EDUCATION, PREMEDICAL**

PREMEDICATION

see related
ANTIBIOTIC PROPHYLAXIS
PREANESTHETIC MEDICATION

Is preoperative ketorolac a useful adjunct to regional anesthesia for inguinal herniorrhaphy? Ben-David B, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):358–63

Premedication with sublingual buprenorphine for out-patient arthroscopy: reduced need for postoperative pethidine but higher incidence of nausea. Juhlin-Dannfelt M, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):633–6

What is the risk of reaction on repeat exposure to contrast material, and how should the patients be premedicated? Dyer R, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1543

Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Darbar D, et al. **Am J Cardiol** 1996 Jun 15;77(15):1351–5

Chest tube removal practices in critical care units in the United States. Kinney MR, et al. **Am J Crit Care** 1995 Nov;4(6):419–24

Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team. Kanda Y, et al. **Am J Hematol** 1996 Apr;51(4):265–8

The ovarian dysgenesis normally induced by neonatal thymectomy is prevented by the prior administration of estrogen. Chapman JC, et al. **Am J Reprod Immunol** 1995 Sep;34(3):195–9

The effect of oral cisapride premedication on fasting gastric volumes. Kluger MT, et al. **Anaesth Intensive Care** 1995 Dec;23(6):687–90

Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. Paech MJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):548–54

Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial. Koivuranta MK, et al. **Anaesthesia** 1996 Jan;51(1):52–55

How much droperidol in combination with PCA morphine? [letter] Morrow BC, et al. **Anaesthesia** 1996 Jan;51(1):92

Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy. Hannibal K, et al. **Anesth Analg** 1996 Aug;83(2):376–81

Preoperative oral ondansetron for pediatric tonsillectomy. Rose JB, et al. **Anesth Analg** 1996 Mar;82(3):558–62

Cytokine and hormonal changes after cholecystectomy. Effect of ibuprofen pretreatment. Chambrier C, et al. **Ann Surg** 1996 Aug;224(2):178–82

Steroid administration in heart and heart-lung transplantation: is the timing adequate? Wan S, et al. **Ann Thorac Surg** 1996 Feb;61(2):674–8

Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Meltzer HY, et al. **Biol Psychiatry** 1995 Sep 1;38(5):310–8

Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Fibbe WE, et al. **Blood** 1995 Nov 1;86(9):3308–13

Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF [letter; comment] Husson B, et al. **Blood** 1996 Apr 15;87(8):3526–8. Comment on: Blood 1995 May 1;85(9):2619–26.

Potentiation of neutrophil functions with administration of granulocyte colony-stimulating factor to donors for granulocyte transfusions [letter; comment] Katoh M, et al. **Blood** 1996 Apr 15;87(8):3524–5. Comment on: Blood 1993 Jun 1;81(11):2866–71.

Dose of propofol for laryngeal mask airway insertion in children: effect of premedication with midazolam. Martlew RA, et al. **Br J Anaesth** 1996 Feb;76(2):308–9

Preoperative infusion of amino acids prevents postoperative hypothermia. Selldén E, et al. **Br J Anaesth** 1996 Feb; 76(2):227–34

Effects of clonidine premedication on the pressor response to alpha-adrenergic agonists. Tanaka M, et al. **Br J Anaesth** 1995 Nov;75(5):593–7

Dimenhydrinate pretreatment in patients receiving intra-arterial ioxaglate: effect on nausea and vomiting. Smith DC, et al. **Can Assoc Radiol J** 1995 Dec;46(6):449–53

Oral clonidine premedication reduces vomiting in children after strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1995 Nov;42(11):977–81

Ranitidine suspension or famotidine resoriblette and gastric fluid volume and pH. Oikkonen M, et al. **Can J Anaesth** 1995 Sep;42(9):793–6

A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy. Maltais F, et al. **Chest** 1996 May;109(5):1195–8

Antibiotic prophylaxis and head and neck surgery—what about pulmonary complications? [editorial] Morton RP. **Clin Otolaryngol** 1996 Apr;21(2):97–8

Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients. Jazzar A, et al. **Clin Transplant** 1995 Aug;9(4):334–9

Decreased left ventricular contractility during porcine endotoxemia is not prevented by ibuprofen. Herbertson MJ, et al. **Crit Care Med** 1996 May;24(5):815–9

Pharmacokinetics of temazepam in male surgical patients. Indalo AA, et al. **East Afr Med J** 1995 Aug;72(8):483–5

Effect of colonoscopy premedication containing diazepam and pethidine on the release of mast cell mediators in gut mucosal samples. Raithel M, et al. **Endoscopy** 1995 Aug; 27(6):415–23

Pre-emptive versus post-surgical administration of ketorolac for hysterectomy. Parke TJ, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):549–53

In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide [see comments] Ezzat S, et al. **Eur J Endocrinol** 1995 Dec; 133(6):686–90. Comment in: Eur J Endocrinol 1995 Dec;133(6):675–7.

Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis? [letter] Lyytikäinen O, et al. **Eur J Haematol** 1996 Mar; 56(3):188–9

Infection after laparoscopic cholecystectomy: are antibiotics really necessary? Watkin DS, et al. **Eur J Surg** 1995 Jul; 161(7):509–11

A pre-operative mydriatic regime using a single application of tropicamide Novel Ophthalmic Delivery System and guttae phenylephrine 10%. Patel CK, et al. **Eye** 1995;9 (Pt 3):337–40

Intravenous antispasmodic and patient-controlled analgesia are of benefit for screening flexible sigmoidoscopy. Saunders BP, et al. **Gastrointest Endosc** 1995 Aug; 42(2):123–7

Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy [letter] Jayaweera D, et al. **Genitourin Med** 1995 Dec; 71(6):414–5

Why use Buscopan during diagnostic upper gastrointestinal endoscopy? [letter] Chopra K, et al. **Gut** 1996 Mar;38(3):473

Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Mikkelsen AL, et al. **Gynecol Obstet Invest** 1995; 40(2):125–8

Sumatriptan prophylaxis for postelectroconvulsive therapy headaches. DeBattista C, et al. **Headache** 1995 Sep; 35(8):502–3

Perioperative benzimidazole therapy in human hydatid liver disease. Tsimoyiannis EC, et al. **Int Surg** 1995 Apr-Jun; 80(2):131–3

Effect of cyclooxygenase inhibition in a canine model of unilateral pulmonary occlusion and reperfusion. Segiet W, et al. **Intensive Care Med** 1995 Oct;21(10):817–25

Case against antibiotic prophylaxis for endocarditis and prosthesis infection in dermatologic procedures involving uninfected skin [letter; comment] George PM. **J Am Acad Dermatol** 1996 Jan;34(1):153–4. Comment on: J Am Acad Dermatol 1995 Feb;32(2 Pt 1):155–76; quiz 177–80.

Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. Bianconi L, et al. **J Am Coll Cardiol** 1996 Sep;28(3):700–6

Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? [letter; comment] Letac B. **J Am Coll Cardiol** 1996 Jan;27(1):251–2. Comment on: J Am Coll Cardiol 1995 May;25(6):1354–61.

Pretreatment of human myocardium with adenosine during open heart surgery. Lee HT, et al. **J Card Surg** 1995 Nov; 10(6):665–76

Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions [letter] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):481–2

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Kemp G, et al. **J Clin Oncol** 1996 Jul;14(7):2101–12

Safety profile of single-dose dexamethasone premedication for paclitaxel [letter] Parikh B, et al. **J Clin Oncol** 1996 Jul;14(7):2189–90

Natural premedication for mast cell proliferative disorders [letter] Yaniv R, et al. **J Ethnopharmacol** 1995 Apr; 46(1):71–2

Lack of effect of 6 g inositol treatment of post-ECT cognitive function in humans. Levine J, et al. **J Psychiatr Res** 1995 Nov-Dec;29(6):487–9

Same-day Dilapan insertion before second-trimester dilatation and evacuation for a fetal anomaly or death. Patsner B. **J Reprod Med** 1996 Feb;41(2):71–2

Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas. Hansen PB, et al. **Leuk Lymphoma** 1995 Nov;19(5-6):453–60

Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Adler CH, et al. **Mov Disord** 1996 Jan;11(1):79–81

A randomized trial of two preparations of vaginal prostaglandin for pre-induction cervical ripening. Murray HG, et al. **Obstet Gynecol** 1995 Dec;86(6):880–5

Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Roberts CW. **Ophthalmology** 1996 Apr;103(4):636–9

Central sensitization as a result of surgical pain: investigation of the pre-emptive value of pethidine for ovariohysterectomy in the rat. Lascelles BD, et al. **Pain** 1995 Aug;62(2):201–12

Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma. Bovo G, et al. **Pathologica** 1995 Apr;87(2):135–8

Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Perkins SW, et al. **Plast Reconstr Surg** 1996 Sep;98(3):427–33; discussion 434–5

Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Lukkarinen O, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):33–6

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)

Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Rose PG. **Semin Oncol** 1996 Aug;23(4 Suppl 8):83–9

Guidelines for the administration of amifostine. Schuchter LM. **Semin Oncol** 1996 Aug;23(4 Suppl 8):40–3

Histopathological effects of androgen deprivation in prostatic cancer. Civantos F, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):22–31

Preoperative disseminated intravascular coagulation (DIC) associated with aortic aneurysm—does it need to be corrected before surgery? Oba J, et al. **Surg Today** 1995; 25(12):1011–4

[Prevention of urinary infections as a complication in endoscopic surgery] Rovný R, et al. **Rozhl Chir** 1995 Nov; 74(7):361–2 (Eng. Abstr.) **(Cze)**

[Survey on the practice of antibiotic prophylaxis of infective endocarditis by dentists] Bennis A, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):713–8 (Eng. Abstr.) **(Fre)**

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

[The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema] Mohr M, et al. **Anaesthesist** 1996 Jul; 45(7):626–30 (Eng. Abstr.) **(Ger)**

[Multidimensional psychometric assessment of preoperative mood. Effects of zolpidem compared to phenobarbital combined with promethazine as premedication] Uhlig T, et al. **Anaesthesist** 1995 Sep;44(9):634–42 (Eng. Abstr.) **(Ger)**

[Acceptability of high colonoscopy using different premedication—a comparison of the effect of midazolam versus midazolam and pethidine from the viewpoint of the patient and the physician] Ehrle UB, et al. **Z Gastroenterol** 1995 Dec;33(12):704–8 (Eng. Abstr.) **(Ger)**

[Hormonal premedication in endometrium ablation—results of a prospective comparative study] Römer T, et al. **Zentralbl Gynakol** 1996;118(5):291–4 (Eng. Abstr.) **(Ger)**

METHODS

Effects of chemical pretreatment on posttraumatic cortical edema in the rat. Biros MH, et al. **Am J Emerg Med** 1996 Jan;14(1):27–32

Intravenous calcium chloride in the conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm. O'Brien JF, et al. **Am J Emerg Med** 1996 Jan; 14(1):50–2

No support for intravenous lidocaine airway reflex suppression during rapid sequence intubation [letter] [see comments] Zemenick RB. **Ann Emerg Med** 1995 Nov; 26(5):660. Comment in: Ann Emerg Med 1996 Apr;27(4):528–9.

A comparison of two skin preps used in cardiac surgical procedures. Hagen KS, et al. **AORN J** 1995 Sep; 62(3):393–402

The effect of intravenous dexamethasone in pediatric adenotonsillectomy. April MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):117–20

Rapid sequence intubation in the emergency department. Dufour DG, et al. **J Emerg Med** 1995 Sep-Oct;13(5):705–10

[Randomized study of sulprostone versus misoprostol in the cervical preparation before elective abortion in nulliparous women] Schaub B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):505–10 (Eng. Abstr.) **(Fre)**

VETERINARY

Gastro-oesophageal reflux during anaesthesia in the dog: the effect of preoperative fasting and premedication. Galatos AD, et al. **Vet Rec** 1995 Nov 4;137(19):479–83

PREMENOPAUSE

Plasma lipoprotein profile and lipolytic activities in response to the substitution of lean white fish for other animal protein sources in premenopausal women. Gascon A, et al. **Am J Clin Nutr** 1996 Mar;63(3):315–21

PREMENOPAUSE

Association of bone mineral density and sex hormone levels with osteoarthritis of the hand and knee in premenopausal women. Sowers MF, et al. **Am J Epidemiol** 1996 Jan 1; 143(1):38–47

Re: "Risk of premenopausal breast cancer and use of electric blankets" and "Use of electric blankets and risk of postmenopausal breast cancer" [letter; comment] Wertheimer N, et al. **Am J Epidemiol** 1995 Dec 15; 142(12):1344–5. Comment on: Am J Epidemiol 1994 Dec 1;140(11):974–9. Comment on: Am J Epidemiol 1991 Jul 15;134(2):180–5.

Effects of estradiol–17 beta and progesterone on isolated human omental artery from premenopausal nonpregnant women and from normotensive and preeclamptic pregnant women. Belfort MA, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):246–53

Effects of selected vasoconstrictor agonists on isolated omental artery from premenopausal nonpregnant women and from normal and preeclamptic pregnant women. Belfort MA, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):687–93

Ovarian cysts in premenopausal and postmenopausal tamoxifen–treated women with breast cancer. Shushan A, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):141–4

Breast cancer: screening in premenopausal women: current recommendations and opportunities for research. Mettlin C, et al. **Ann Med** 1995 Aug;27(4):461–5 (15 ref.)

The effect of systemic lupus erythematosus and long–term steroid therapy on bone mass in pre–menopausal women. Pons F, et al. **Br J Rheumatol** 1995 Aug;34(8):742–6

A case–control study of reproductive variables, alcohol, and smoking in premenopausal bilateral breast cancer. Haile RW, et al. **Breast Cancer Res Treat** 1996;37(1):49–56

The use of questionnaire data to classify peri– and premenopausal status. Cooper GS, et al. **Epidemiology** 1995 Nov;6(6):625–8

The indirect association of lactation with subsequent perimenopausal body weight. Rush D, et al. **Eur J Clin Nutr** 1996 Jan;50(1):12–6

Trans–vaginal ultrasound examination of ovarian masses in premenopausal women. Botta G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):37–41

Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin–releasing hormone agonist–treated females. Brosens I, et al. **Fertil Steril** 1996 Sep;66(3):376–9

Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre– and postmenopausal women. Strigini FA, et al. **Gynecol Oncol** 1996 Apr;61(1):68–72

Body size indices and breast cancer risk before and after menopause. Franceschi S, et al. **Int J Cancer** 1996 Jul 17; 67(2):181–6

The perimenopause: a critical time in a woman's life. Sulak PJ. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):85–9 (18 ref.)

ACOG technical bulletin. Health maintenance for perimenopausal women. Number 210—August 1995. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Nov;51(2):171–81

Duration and reintroduction of adjuvant chemotherapy for node–positive premenopausal breast cancer patients. International Breast Cancer Study Group. **J Clin Oncol** 1996 Jun;14(6):1885–94

Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Lichtman R. **J Nurse Midwifery** 1996 May–Jun;41(3):195–210 (109 ref.)

Discomforts of the perimenopause. LeBoeuf FJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):173–80 (29 ref.)

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. Lien EA, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):229–31

Sensitivity and specificity of sonohysterography for the evaluation of the uterine cavity in perimenopausal patients. Wolman I, et al. **J Ultrasound Med** 1996 Apr;15(4):285–8

Comparison of the clinicopathological characteristics of premenopausal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. Yasumizu T, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):152–6

The perimenopause and contraception. Shaaban MM. **Maturitas** 1996 Mar;23(2):181–92 (77 ref.)

Spinal bone mineral loss in estrogen–replete, calcium–replete premenopausal women. Citron JT, et al. **Osteoporos Int** 1995;5(4):228–33

The association between vitamin D receptor gene polymorphisms and bone mineral density at the spine, hip and whole–body in premenopausal women. Salamone LM, et al. **Osteoporos Int** 1996;6(1):63–8

Prevention of cardiovascular risk factor elevations in healthy premenopausal women. Simkin–Silverman L, et al. **Prev Med** 1995 Sep;24(5):509–17

Alcohol dependence, smoking status, reproductive characteristics, and bone mineral density in premenopausal women. Clark K, et al. **Res Nurs Health** 1996 Oct; 19(5):399–408

[Vertebral bone loss in perimenopause. Results of a 7–year longitudinal study] Pouillès JM, et al. **Presse Med** 1996 Feb 24;25(7):277–80 (Eng. Abstr.) **(Fre)**

BLOOD

Relation of energy, fat, and fiber intakes to plasma concentrations of estrogens and androgens in premenopausal women. Dorgan JF, et al. **Am J Clin Nutr** 1996 Jul;64(1):25–31

Plasma lipids and lipoprotein alterations in tamoxifen–treated breast cancer women in relation to the menopausal status. Ilanchezhian S, et al. **Cancer Biochem Biophys** 1995 Nov; 15(2):83–90

Plasma homocysteine and menopausal status. Wouters MG, et al. **Eur J Clin Invest** 1995 Nov;25(11):801–5

The effect of surgical castration on lipid metabolism in premenopausal and postmenopausal women. Goldman GA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun; 66(2):133–6

The effects of hormone replacement therapy on plasma vitamin E levels in post–menopausal women. Wu J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):151–4

An amplitude–specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. van den Berg G, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2460–7

Hormone levels during dietary changes in premenopausal African–American women [see comments] Woods MN, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1369–74. Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1332–3.

[Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma] Pavić S, et al. **Med Pregl** 1995;48(5–6):159–61 (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

Effect of tamoxifen on bone mineral density measured by dual–energy x–ray absorptiometry in healthy premenopausal and postmenopausal women. Powles TJ, et al. **J Clin Oncol** 1996 Jan;14(1):78–84

[Variability of bone response to hormone replacement therapy] Ruiz JC, et al. **Rev Fr Gynecol Obstet** 1995 May–Jun;90(5–6):263–4, 267–74 (Eng. Abstr.) **(Fre)**

METABOLISM

Selective responses of hormones involved in carbohydrate and lipid metabolism and properties of erythrocyte membranes during the menstrual cycle in premenopausal women consuming moderate amounts of alcohol. Bhathena SJ, et al. **Am J Clin Nutr** 1995 Oct;62(4):751–6

Acute biochemical variations induced by two different calcium salts in healthy perimenopausal women. Gonnelli S, et al. **Calcif Tissue Int** 1995 Sep;57(3):175–7

Bone mass and metabolism in women aged 45–55. Garton M, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):563–70

Gonadotropins and gonadotropin receptors during the perimenopause. Vihko KK, et al. **Eur J Endocrinol** 1996 Mar;134(3):357–61

Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. Garnero P, et al. **J Bone Miner Res** 1995 Sep;10(9):1283–8

Calcium bioavailability from bovine milk and dairy products in premenopausal women using intrinsic and extrinsic labeling techniques. Nickel KP, et al. **J Nutr** 1996 May; 126(5):1406–11

Lipid and carbohydrate metabolic risk markers for coronary heart disease and blood pressure in healthy non–obese premenopausal women of different racial origins in the United Kingdom. Proudler AJ, et al. **Metabolism** 1996 Mar; 45(3):328–33

PHYSIOLOGY

Evaluation of bone density with peripheral quantitative computed tomography in healthy premenopausal, perimenopausal, and postmenopausal women. Hernández ER, et al. **Age Ageing** 1995 Sep;24(5):447–50

Prediction of fractures in perimenopausal women: a comparison of dual energy x ray absorptiometry and broadband ultrasound attenuation. Stewart A, et al. **Ann Rheum Dis** 1996 Feb;55(2):140–2

Insulin resistance and sympathetic nervous system activity in hypertensive and normotensive premenopausal women. Nordby G, et al. **Blood Press** 1995 Sep;4(5):287–92

Ovulatory premenopausal women lose cancellous spinal bone: a five year prospective study. Prior JC, et al. **Bone** 1996 Mar;18(3):261–7

Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S–55S (30 ref.)

Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Jäger W, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):279–87

Methylergometrine–induced myocardial ischemia in a previously asymptomatic premenopausal woman [letter] Oneglia C, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):631–2

Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Gebbie AE, et al. **Contraception** 1995 Oct;52(4):221–2

Differential effects on bone density of progestogen–only methods for contraception in premenopausal women. Naessen T, et al. **Contraception** 1995 Jul;52(1):35–9

Effects of calcium and exercise on bone mineral density in premenopausal women with osteoporosis. Holmes–Walker J, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):323–6

Long–term effect of vaginal deliveries on anorectal function in normal perimenopausal women. Ryhammer AM, et al. **Dis Colon Rectum** 1996 Aug;39(8):852–9

Cyclical tumour variations in premenopausal women with early breast cancer. Badwe RA, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2181–4

Body composition and bone mineral density in premenopausal and early perimenopausal women. Salamone LM, et al. **J Bone Miner Res** 1995 Nov; 10(11):1762–8

Transmenopausal change of trabecular bone density and structural pattern assessed by peripheral quantitative computed tomography in Japanese women. Takagi Y, et al. **J Bone Miner Res** 1995 Nov;10(11):1830–4

Effect of sodium valproate on luteinizing hormone secretion in pre– and postmenopausal women and its modulation by naloxone infusion. Popovic V, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2520–4

Sex steroids, bone mass, and bone loss. A prospective study of pre–, peri–, and postmenopausal women. Slemenda C, et al. **J Clin Invest** 1996 Jan 1;97(1):14–21

Bone mineral density in premenopausal anovulatory women. Park KH, et al. **J Obstet Gynaecol** 1995 Feb;21(1):89–97

Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Adami S, et al. **Osteoporos Int** 1996;6(1):8–13

Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women [letter; comment] Parfitt AM. **Osteoporos Int** 1995;5(4):283. Comment on: Osteoporos Int 1994 May;4(3):123–8.

[Bone mineral density of the lumbar spine and its relation to biological and lifestyle factors in middle–aged and aged Japanese women (Part 3). Relationships of physical fitness and lifestyle factors to bone mineral density in premenopausal and postmenopausal women] Kajita E, et al. **Nippon Eiseigaku Zasshi** 1995 Oct;50(4):893–900 (Eng. Abstr.) **(Jpn)**

[Thyroid function and menopausal status in benign and malignant breast diseases] Pavić Z, et al. **Med Pregl** 1995; 48(7–8):231–3 (Eng. Abstr.) **(Scr)**

[Relationship between blood levels of sex hormone binding globulin, testosterone levels in blood and saliva and body morphology in premenopausal women] Navarro MA, et al. **Med Clin (Barc)** 1996 Mar 23;106(11):405–8 (Eng. Abstr.) **(Spa)**

URINE

Characterization of reproductive hormonal dynamics in the perimenopause. Santoro N, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1495–501

PREMENSTRUAL SYNDROME

Premenstrual syndrome: diagnosis and treatment. Trott A, et al. **Del Med J** 1996 Jul;68(7):357–63

A clinician's guide to the premenstrual syndrome. Barnhart KT, et al. **Med Clin North Am** 1995 Nov;79(6):1457–72 (73 ref.)

Rethinking the label: who benefits from the PMS construct? Gurevich M. **Women Health** 1995;23(2):67–98 (102 ref.)

BLOOD

Low plasma gamma–aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Halbreich U, et al. **Am J Psychiatry** 1996 May; 153(5):718–20

DIAGNOSIS

Dependency on progesterone in woman with self–diagnosed premenstrual syndrome [letter] Keefe DL, et al. **Lancet** 1996 Apr 27;347(9009):1182

Personality traits in LLPDD and normal controls during follicular and luteal menstrual–cycle phases. Parry BL, et al. **Psychol Med** 1996 Jan;26(1):197–202

Comparative analysis of three PMS assessment instruments—the identification of premenstrual syndrome with core symptoms. Thys–Jacobs S, et al. **Psychopharmacol Bull** 1995;31(2):389–96

Personality factors in women with premenstrual syndrome. Freeman EW, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):453–9

DRUG THERAPY

Treatment of premenstrual syndrome by spironolactone: a double–blind, placebo–controlled study. Wang M, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):803–8

Successful estradiol treatment of psychotic symptoms in the premenstrual phase: a case report. Korhonen S, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):237–8

Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Magill PJ. **Br J Gen Pract** 1995 Nov; 45(400):589–93

Is evening primrose oil of value in the treatment of premenstrual syndrome? Budeiri D, et al.

Control Clin Trials 1996 Feb;17(1):60–8

Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. Baker ER, et al. **J Assist Reprod Genet** 1995 Mar;12(3):205–9

Fluvoxamine for premenstrual dysphoric disorder: a pilot study. Freeman EW, et al. **J Clin Psychiatry** 1996;57 Suppl 8:56–9; discussion 60

Sertraline versus desipramine in the treatment of premenstrual syndrome: an open–label trial. Freeman EW, et al. **J Clin Psychiatry** 1996 Jan;57(1):7–11

Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency [see comments] van Leusden HA. **Lancet** 1995 Dec 2;346(8988):1443–4. Comment in: Lancet 1996 Jan 13;347(8994):122. Comment in: Lancet 1996 Feb 17;347(8999):470–1.

Fluoxetine for premenstrual dysphoria [letter; comment] Edbril SD. **N Engl J Med** 1995 Oct 26;333(17):1152–3. Comment on: N Engl J Med 1995 Jun 8;332(23):1529–34.

Norethisterone enantate in the treatment of premenstrual syndrome. Gunston KD. **S Afr Med J** 1995 Sep;85(9):851–2

EPIDEMIOLOGY

Greater alcohol use in women with PMS [letter; comment] Ragan PW. **Am J Psychiatry** 1995 Oct;152(10):1539–40. Comment on: Am J Psychiatry 1994 Oct;151(10):1503–4.

Do premenstrual pain and edema exhibit seasonal variability? Marbach JJ, et al. **Psychosom Med** 1995 Nov–Dec; 57(6):536–40

–Assessment of the prevalence of pre– and perimenstrual symptoms in female personnel of a university clinic– Gaulrapp K, et al. **Gynakol Geburtshilfliche Rundsch** 1995; 35(4):199–208 (Eng. Abstr.) **(Ger)**

[Premenstrual dysphoric disorder: an epidemiological study] de la Gándara Martín JJ, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 May–Jun;24(3):111–7 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Serotonin and premenstrual dysphoric disorder [letter; comment] Brzezinski A. **Lancet** 1996 Feb 17; 347(8999):470–1. Comment on: Lancet 1995 Dec 2;346(8988):1443–4.

GENETICS

Genetic and environmental factors in premenstrual symptom reporting and its relationship to depression and a general neuroticism trait. van den Akker OB, et al.
J Psychosom Res 1995 May;39(4):477–87

HISTORY

The premenstrual syndrome: a brief history. Richardson JT. **Soc Sci Med** 1995 Sep;41(6):761–7

PATHOLOGY

[The pathological mechanisms of the intermenstrual pain syndrome] Bilak NP, et al. **Akush Ginekol (Mosk)** 1995; (6):29–34 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Electrophysiological findings during the menstrual cycle in women with and without late luteal phase dysphoric disorder: relationship to risk for alcoholism? Ehlers CL, et al. **Biol Psychiatry** 1996 Apr 15;39(8):720–32

Catamenial epilepsy: gynecological and hormonal implications. Five case reports. Rodriguez Macias KA. **Gynecol Endocrinol** 1996 Apr;10(2):139–42

Decreased central opioid activity in premenstrual syndrome: luteinizing hormone response to naloxone. Rapkin AJ, et al. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):93–8

Thyroid axis function during the menstrual cycle in women with premenstrual syndrome. Girdler SS, et al.
Psychoneuroendocrinology 1995;20(4):395–403

PSYCHOLOGY

Menstrual phase–independent retrieval deficit in women with PMS. Keenan PA, et al. **Biol Psychiatry** 1995 Sep 15; 38(6):369–77

Suicidal ideas during premenstrual phase. Chaturvedi SK, et al. **J Affect Disord** 1995 Jun 8;34(3):193–9

Premenstrual tension among hysterectomized women. Braiden V, et al. **J Psychosom Obstet Gynaecol** 1995 Sep; 16(3):145–51

Distribution of positive moods in women with the premenstrual syndrome and in normal women. Metcalf MG, et al. **J Psychosom Res** 1995 Jul;39(5):609–18

Premenstrual syndrome [letter; comment] Cohen SI.
Lancet 1996 Jan 13;347(8994):122. Comment on: Lancet 1995 Dec 2;346(8988):1443–4.

Premenstrual syndrome [letter; comment] Metcalf MG.
Psychol Med 1995 May;25(3):657–8. Comment on: Psychol Med 1993;Suppl 24:1–47.

The inter–relationship of premenstrual symptoms. Mira M, et al. **Psychol Med** 1995 Sep;25(5):947–55

Comparative analysis of three PMS assessment instruments––the identification of premenstrual syndrome with core symptoms. Thys–Jacobs S, et al.
Psychopharmacol Bull 1995;31(2):389–96

Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Johnson WG, et al. **Psychosom Med** 1995 Jul–Aug; 57(4):324–30

The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)

Stress responsivity in exercisers and non–exercisers during different phases of the menstrual cycle. Choi PY, et al.
Soc Sci Med 1995 Sep;41(6):769–77

What is this news on the menstrual cycle and premenstrual syndrome? Introduction. Choi PY. **Soc Sci Med** 1995 Sep; 41(6):759–60

The menstrual cycle, science and femininity: assumptions underlying menstrual cycle research. Nicolson P.
Soc Sci Med 1995 Sep;41(6):779–84 (64 ref.)

Theory and methodology in premenstrual syndrome research. Walker A. **Soc Sci Med** 1995 Sep;41(6):793–800 (56 ref.)

[Psychological aspects of the premenstrual syndrome] Ben–Zion IZ, et al. **Harefuah** 1995 Dec 1;129(11):512–5 (15 ref.) **(Heb)**

[Premenstrual dysphoric disorder: an epidemiological study] de la Gándara Martín JJ, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 May–Jun;24(3):111–7 (10 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

ACOG committee opinion. Premenstrual syndrome. Number 155—April 1995 (replaces no. 66, January 1989) Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Jul;50(1):80–4

Fluoxetine for premenstrual dysphoria [letter; comment] Prior JC, et al. **N Engl J Med** 1995 Oct 26;333(17):1152; discussion 1153. Comment on: N Engl J Med 1995 Jun 8;332(23):1529–34.

PREMENSTRUAL TENSION see **PREMENSTRUAL SYNDROME**

PREMOLAR see **BICUSPID**

PRENALTEROL

ANALYSIS

Polarographic determination of prenalterol hydrochloride through treatment with nitrous acid. Aly FA, et al.
J Pharm Biomed Anal 1995 Aug;13(9):1127–31

PRENATAL CARE

Vertical transmission of HIV—a rediscussion of testing. Macquart–Moulin G, et al. **AIDS Care** 1995;7(5):657–62

Timing and patterns of exposures during pregnancy and their implications for study methods. Hertz–Picciotto I, et al.
Am J Epidemiol 1996 Mar 15;143(6):597–607

Impact of health education during pregnancy on behavior and utilization of health resources. Latin American Network for Perinatal and Reproductive Research. Belizán JM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):894–9

The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Lewis R, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1329–33

Prenatal screening for group B Streptococcus. II. Impact of antepartum screening and prophylaxis on neonatal care. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):842–6

Prenatal screening for group B Streptococcus. I. Impact of antepartum screening on antenatal prophylaxis and intrapartum care. Mercer BM, et al.
Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):837–41

Maternal prepregnant weight and weight gain: relationship to placental microstructure and morphometric oxygen diffusion capacity. Stevens–Simon C, et al.
Am J Perinatol 1995 Nov;12(6):407–12

Preconceptional and prenatal multivitamin–mineral supplement use in the 1988 National Maternal and Infant Health Survey. Yu SM, et al. **Am J Public Health** 1996 Feb;86(2):240–2

Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996; 55(1 Suppl):17–23

Descriptive survey of antenatal HIV testing in London: policy, uptake, and detection. MacDonagh SE, et al.
BMJ 1996 Aug 31;313(7056):532–3

Antenatal care on trial [editorial; comment] [see comments] Neilson J. **BMJ** 1996 Mar 2;312(7030):524–5. Comment on: BMJ 1996 Mar 2;312(7030):546–53. Comment on: BMJ 1995 Mar 2;312(7030):554–9. Comment in: BMJ 1996 Jul 20;313(7050):168; discussion 169.

Vitamins in early pregnancy [editorial] Smithells D. **BMJ** 1996 Jul 20;313(7050):128–9

Canadian doctors withdraw prenatal care [news] Spurgeon D. **BMJ** 1996 Aug 31;313(7056):511

Active management of labour [editorial] Thornton JG.
BMJ 1996 Aug 17;313(7054):378

Periconceptual folate supplementation [letter] Gillies A, et al. **Br J Gen Pract** 1996 Apr;46(405):254

Women's views of their first antenatal visit [letter] Hirst J, et al. **Br J Gen Pract** 1996 May;46(406):319

Folic acid in pregnancy [letter] Phull E, et al.
Br J Gen Pract 1995 Dec;45(401):688

A multicentre comparative study of 17 experts and an intelligent computer system for managing labour using the cardiotocogram [see comments] Keith RD, et al.
Br J Obstet Gynaecol 1995 Sep;102(9):688–700. Comment in: Br J Obstet Gynaecol 1996 May;103(5):489–90.

The active mismanagement of labour [comment] Oláh KS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):729–31 (12 ref.). Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):763–8. Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):769–75.

Antenatal serology testing in pregnancy [see comments] Whittle MJ. **Br J Obstet Gynaecol** 1996 Mar;103(3):195–6 . Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):720–1.

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Antenatal Care. Bréart G. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):417–9 (10 ref.)

Variability in diagnostic evaluation and criteria for gestational diabetes. Solomon CG, et al. **Diabetes Care** 1996 Jan;19(1):12–6

Evaluation of a program for prenatal care case management. Piper JM, et al. **Fam Plann Perspect** 1996 Mar–Apr; 28(2):65–8

Childhood abuse and suicidality in obstetrics patients in a hospital–based urban prenatal clinic. Farber EW, et al.
Gen Hosp Psychiatry 1996 Jan;18(1):56–60

Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? [letter] L'Herminez M, et al. **Genitourin Med** 1996 Apr;72(2):148

Intervention model for substance–using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113–8 (69 ref.)

Recent advances in the management of Rh hemolytic disease of the newborn (HDN). Gupte SC. **Indian J Med Sci** 1995 Mar;49(3):66–72

Maternal care receptivity and its relation to perinatal and neonatal mortality. A rural study. Bhardwaj N, et al.
Indian Pediatr 1995 Apr;32(4):416–23

Development, refinement and future usage of the scale: "attitudes toward learning in pregnancy". Jackson MS, et al. **Int J Nurs Stud** 1996 Feb;33(1):37–46

Prenatal care and birth outcomes of a cohort of HIV–infected women. Turner BJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12(3):259–67

Access and outcomes of obstetric care [letter] Sonis J.
J Am Board Fam Pract 1996 Jan–Feb;9(1):72–3

Prenatal nutrition counseling: two caveats [letter; comment] Ellison GT, et al. **J Am Diet Assoc** 1996 May;96(5):448–50 . Comment on: J Am Diet Assoc 1985 Jan;85(1):40–5.

Parental care and women's health [editorial] Chavkin W.
J Am Med Wom Assoc 1995 Sep–Oct;50(5):143

Missed opportunities for intervening in the lives of pregnant women addicted to alcohol or other drugs. Gehshan S.
J Am Med Wom Assoc 1995 Sep–Oct;50(5):160–3

Physician ability to predict appointment–keeping behavior of prenatal patients. Feierabend RH. **J Fam Pract** 1996 May;42(5):482–6

Iron prophylaxis in pregnancy. French L. **J Fam Pract** 1996 Jan;42(1):24–5

Effect of prenatal care on obstetrical outcome. Amini SB, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):142–50

Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):85–8 (12 ref.)

Promoting healthy parenting through prenatal education [editorial] Clay LS. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):397–8

Preparing couples for home birth. Practical suggestions. Dancy RB, et al. **J Nurse Midwifery** 1995 Nov–Dec; 40(6):522–8

Home care of the battered pregnant woman: one battered woman's pregnancy. Christian A.
J Obstet Gynecol Neonatal Nurs 1995 Nov–Dec; 24(9):836–42

The effect of a comprehensive prematurity prevention program on the number of admissions to the neonatal intensive care unit. Joffe GM, et al. **J Perinatol** 1995 Jul–Aug;15(4):305–9

Benefits from a teen pregnancy program: neonatal outcomes potential cost savings. Blackhurst DW, et al.
J S C Med Assoc 1996 May;92(5):209–15

Coverage and quality of natal and postnatal care: women's perceptions, Saudi Arabia. Baldo MH, et al.
J Trop Pediatr 1995;41 Suppl 1:30–7

Progress toward elimination of neonatal tetanus— Egypt, 1988–1994. From the Centers for Disease Control.
JAMA 1996 Mar 6;275(9):679–80

From the Centers for Disease Control and Prevention. Knowledge and use of folic acid by women of childbearing age—United States, 1995. **JAMA** 1995 Oct 18;274(15):1190

A piece of my mind. Shadow bands. Lyons SF. **JAMA** 1996 Jul 10;276(2):98

US specialists object to AMA's call for mandatory HIV testing [news] Rovner J. **Lancet** 1996 Aug 3;348(9023):330

Midwife–managed care [comment] Wagner M. **Lancet** 1996 Jul 27;348(9022):208. Comment on: Lancet 1996 Jul 27;348(9022):213–8.

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec;

20(6):346 (9 ref.)
The production of authoritative knowledge in American prenatal care. Browner CH, et al. **Med Anthropol Q** 1996 Jun;10(2):141–56
"Women come here on their own when they need to": prenatal care, authoritative knowledge, and maternal health in Oaxaca. Sesia PM. **Med Anthropol Q** 1996 Jun; 10(2):121–40
Continuity of care by a midwife team versus routine care during pregnancy and birth: a randomised trial [letter] Boland CM. **Med J Aust** 1996 Jul 1;165(1):61
Pregnancy outcomes in urban aboriginal women [see comments] de Costa C, et al. **Med J Aust** 1996 May 6; 164(9):523–6. Comment in: Med J Aust 1996 May 6;164(9):516–7.
Pregnancy outcomes of Australian aboriginals and Torres Strait Islanders [editorial; comment] O'Connor MC, et al. **Med J Aust** 1996 May 6;164(9):516–7. Comment on: Med J Aust 1996 May 6;164(9):523–6.
Screening and diagnosis for gestational diabetes mellitus among Chippewa women in northern Minnesota. Rith-Najarian SJ, et al. **Minn Med** 1996 May;79(5):21–5
Progress toward elimination of neonatal tetanus—Egypt, 1988–1994. **MMWR Morb Mortal Wkly Rep** 1996 Feb 2; 45(4):89–92
The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation. Thorp JA, et al. **Obstet Gynecol** 1995 Dec;86(6):982–9
The Role of General Practice in Maternity Care. Royal College of General Practitioners. Report of the RCGP Maternity Care Group. **Occas Pap R Coll Gen Pract** 1995 Nov;(72):1–14 (24 ref.)
Barriers to prevention of perinatal group B streptococcal disease. Jafari HS, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):662–7
Prenatal dexamethasone and exogenous surfactant therapy: surface activity and surfactant components in airway specimens. Kari MA, et al. **Pediatr Res** 1995 Nov; 38(5):676–84
Gestational diabetes: ensuring a successful outcome. Davidson JA, et al. **Postgrad Med** 1996 Mar;99(3):165–72 (14 ref.)
Preventive care in pregnancy. Morrow CE. **Prim Care** 1995 Dec;22(4):755–84 (93 ref.)
Improving postpartum marital relationships. Kermeen P. **Psychol Rep** 1995 Jun;76(3 Pt 1):831–4
Ethnic disparity in the performance of prenatal nutrition risk assessment among Medicaid-eligible women. Fuentes-Afflick E, et al. **Public Health Rep** 1995 Nov–Dec; 110(6):764–73
Health aspects of pregnancy and childbirth: United States, 1982–88. Chandra A. **Vital Health Stat 23** 1995 Aug; (18):1–74
WAPC position statement. Human immunodeficiency virus (HIV) education and testing in the perinatal period. Wisconsin Association for Perinatal Care. **Wis Med J** 1996 Jan;95(1):30–5
[Obstetric quality investigation on urban and rural area in China] Xiang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):138–41 (Eng. Abstr.) **(Chi)**
[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[[Initial results of "preventive self-care by pregnant patients" for prevention of premature labor] Saling E, et al. **Arch Gynecol Obstet** 1995;257(1–4):178–85 **(Ger)**
[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):129–35 (8 ref.) **(Ger)**
[Should maternal guidelines be improved?] Behrens O, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M129–31 **(Ger)**
[Diabetes screening in pregnant patients with different risk factors. Benefits, therapeutic success, consequences (see comments)] Stoz F, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):138–41 (Eng. Abstr.). Comment in: Z Geburtshilfe Neonatol 1995 Jul–Aug;199(4):176–7. **(Ger)**
[Pregnancy care in drug-dependent patients under the charge of SERT (Public Service for the Treatment of Drug Addiction) of Massa-Carrara. The prevention of fetal damages and premature labor] Damone R, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):86–8 **(Ita)**
[Pregnancy care: protocols and guidelines in Italy] Dubini V, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):63–5 **(Ita)**
[Postterm pregnancy—importance of this problem in modern obstetrics] Chazan B, et al. **Ginekol Pol** 1996 Mar; 67(3):148–56 (20 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Short-term cost benefit of pre-conception care for diabetes [letter] Elixhauser A, et al. **Diabetes Care** 1996 Apr; 19(4):384
Weight excess before pregnancy: complications and cost. Galtier-Dereure F, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):443–8

HISTORY

Dr Grantly Dick-Read [letter; comment] Allen V. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F197–8 . Comment on: Arch Dis Child 1994 Sep;71(2):F145–6.
Soranus of Ephesus (circa AD 98–138) and perinatal care in Roman times. Dunn PM. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F51–2

LEGISLATION & JURISPRUDENCE

Prenatal care and public policy: lessons for promoting women's health. Hughes DC, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):156–9, 163 (32 ref.)
For children's sake. New law mandates HIV testing of pregnant patients. Grimes RM, et al. **Tex Med** 1996 Jan; 92(1):36–40

METHODS

Smoking cessation counseling during routine public prenatal care [letter; comment] Haddow JE, et al. **Am J Public Health** 1995 Oct;85(10):1451–2. Comment on: Am J Public Health 1995 Feb;85(2):217–22.
Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Harris H, et al. **Br J Gen Pract** 1996 Apr; 46(405):225–7
Risk assessment and other screening options for gonorrhoea and chlamydial infections in women attending rural Tanzanian antenatal clinics. Mayaud P, et al. **Bull World Health Organ** 1995;73(5):621–30
Antenatal period: an educational opportunity. Verma M, et al. **Indian Pediatr** 1995 Feb;32(2):171–7
Antenatal attenders and HIV testing [letter; comment] Kell P, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):299; discussion 300. Comment on: Int J STD AIDS 1994 Nov–Dec;5(6):400–4.
Screening criteria for beta thalassaemia trait in pregnant women. Rogers M, et al. **J Clin Pathol** 1995 Nov; 48(11):1054–6
Risk factors for HIV infection overlooked in routine antenatal care [letter; comment] Arnott MA, et al. **J R Soc Med** 1996 Mar;89(3):180. Comment on: J R Soc Med 1995 Nov;88(11):634–6.
Risk factors for HIV infection overlooked in routine antenatal care [see comments] Hawken J, et al. **J R Soc Med** 1995 Nov;88(11):634–6. Comment in: J R Soc Med 1996 Mar;89(3):180.
Alternative prenatal care. Impact of reduced visit frequency, focused visits and continuity of care. Binstock MA, et al. **J Reprod Med** 1995 Jul;40(7):507–12
A rapid community based health evaluation of pregnant women in low socioeconomic settlements of Karachi. Fikree FF, et al. **JPMA J Pak Med Assoc** 1995 Jul; 45(7):170–3
Randomised controlled trial of a reduced-visits programme of antenatal care in Harare, Zimbabwe. Munjanja SP, et al. **Lancet** 1996 Aug 10;348(9024):364–9
Randomised, controlled trial of efficacy of midwife-managed care [see comments] Turnbull D, et al. **Lancet** 1996 Jul 27;348(9022):213–8. Comment in: Lancet 1996 Jul 27;348(9022):208.
Enhancing perinatal outcome in homeless women: the challenge of providing comprehensive health care. Beal AC, et al. **Semin Perinatol** 1995 Aug;19(4):307–13 (19 ref.)
Home visits during pregnancy: consequences on pregnancy outcome, use of health services, and women's situations. Blondel B, et al. **Semin Perinatol** 1995 Aug;19(4):263–71
Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)
Social interventions in the care of human immunodeficiency virus (HIV)-infected pregnant women. Levine C, et al. **Semin Perinatol** 1995 Aug;19(4):323–9
Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)
Inclusion of psychosocial conditions in clinical practice and the problem of medicalization. Førde R. **Theor Med** 1996 Jun;17(2):151–61
[Monitoring the pregnant diabetic patient] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):132–7 (41 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Improving access to prenatal care in Vermont. Carney JK, et al. **Am J Public Health** 1996 Jun;86(6):880–1
Prenatal hospitalization and compliance with guidelines for prenatal care. Haas JS, et al. **Am J Public Health** 1996 Jun;86(6):815–9
De Madres a Madres: an access model for primary care. McFarlane J. **Am J Public Health** 1996 Jun;86(6):879–80
Pattern of prenatal care and infant immunization status in a comprehensive adolescent-oriented maternity program. Stevens-Simon C, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):829–33
Reduced schedule of antenatal visits. Attention should be paid to what women want [letter; comment] Hinshaw K, et al. **BMJ** 1996 Jul 20;313(7050):168; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):524–5. Comment on: BMJ 1996 Mar 2;312(7030):546–53.
Reduced schedule of antenatal visits. Differences in psychosocial outcomes between groups were not large [letter; comment] O'Connell T. **BMJ** 1996 Jul 20; 313(7050):167; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.
A randomised controlled trial comparing two schedules of antenatal visits: the antenatal care project [see comments] Sikorski J, et al. **BMJ** 1996 Mar 2;312(7030):546–53. Comment in: BMJ 1996 Mar 2;312(7030):524–5. Comment in: BMJ 1996 Jul 20;313(7050):167; discussion 169. Comment in: BMJ 1996 Jul 20;313(7050):167–8; discussion 169. Comment in: BMJ 1996 Jul 20;313(7050):168; discussion 169.
Reduced schedule of antenatal visits. Effect of fewer visits on postnatal depression is important [letter; comment] Tincello D. **BMJ** 1996 Jul 20;313(7050):167–8; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.
Should obstetricians see women with normal pregnancies? A multicentre randomised controlled trial of routine antenatal care by general practitioners and midwives compared with shared care led by obstetricians [see comments] Tucker JS, et al. **BMJ** 1996 Mar 2; 312(7030):554–9. Comment in: BMJ 1996 Mar 2;312(7030):524–5.
Reduced schedule of antenatal visits. Study ignored influence of parity on women's needs [letter; comment] Vause S, et al. **BMJ** 1996 Jul 20;313(7050):167; discussion 169. Comment on: BMJ 1996 Mar 2;312(7030):546–53.
Outreach. Pregnant teens get the "Baby Blues". Nordhaus-Bike A. **Hosp Health Netw** 1996 May 5;70(9):60
Baby love and budget relief: some promising practices in prenatal managed care in Medicaid. Armstead RC, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):178–81
Prenatal care in developing counties: the World Health Organization technical working group on antenatal care. Berg CJ. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):182–6
Family planning: an essential component of prenatal care. Klerman LV, et al. **J Am Med Wom Assoc** 1995 Sep–Oct; 50(5):147–51 (31 ref.)
Framing the debate: can prenatal care help to reduce the black-white disparity in infant mortality? Rowley DL. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):187–93 (119 ref.)
The importance of extreme prematurity and low birthweight to US neonatal mortality patterns: implications for prenatal care and women's health. Wise PH, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):152–5
Transforming prenatal care: reflections on the past and present with implications for the future. Maloni JA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):17–23 (51 ref.)
Local responses to expanded Medicaid coverage for pregnant women. Dubay LC, et al. **Milbank Q** 1995;73(4):535–63
The prenatal visit. American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. **Pediatrics** 1996 Jan;97(1):141–2
[The organizational forms for the early detection and prevention of acute pyelonephritis and dispensary care for pregnant women] Dovlatian AA, et al. **Akush Ginekol (Mosk)** 1995;(6):49–53 **(Rus)**

STANDARDS

Content of prenatal care during the initial workup. Peoples-Sheps MD, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):220–6
Voluntary, named testing for HIV in a community based antenatal clinic: a pilot study. Chrystie IL, et al. **BMJ** 1995 Oct 7;311(7010):928–31
Addressing the patient's agenda in the reorganization of antenatal and infant health care: experience in one general practice. Mellor J, et al. **Br J Gen Pract** 1995 Aug; 45(397):423–5
The effectiveness of antenatal care in preventing intrauterine growth retardation and low birth weight due to preterm delivery. Coria-soto IL, et al. **Int J Qual Health Care** 1996 Feb;8(1):13–20
Not all prenatal care is appropriate care. Atrash HK. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):144–6
Heterogeneity between women who received prenatal care in the third trimester and those who received no prenatal care. Elam-Evans LD, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):175–7
Prenatal care—the good, the bad, and the ugly. Marks JS. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):146
Effect of frequency of prenatal care visits on perinatal outcome among low-risk women. A randomized controlled trial [see comments] McDuffie RS Jr, et al. **JAMA** 1996 Mar 20;275(11):847–51. Comment in: JAMA 1996 Jul 10;276(2):101.
U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. **MMWR Morb Mortal Wkly Rep** 1995 Jul 7;44(RR-7):1–15
Implementation of the rhesus prevention programme: a prospective study [see comments] Ghosh S, et al. **Scott Med J** 1994 Oct;39(5):147–9. Comment in: Scott Med J 1994 Oct;39(5):138.
Can what counts be counted? Reflections on the content, costs, benefits, and impacts of prenatal care. Ion HW. **Womens Health Issues** 1995 Fall;5(3):143–52

STATISTICS & NUMERICAL DATA

A statewide, toll-free telephone service to improve obstetric care. Rayburn WF, et al. **J Okla State Med Assoc** 1995 Aug;88(8):342–4

TRENDS

Prenatal care: an update and future trends. Groutz A, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):452–60 (83 ref.)

State of South Dakota's child: 1995. Wilson AL. **S D J Med** 1996 Jan;49(1):9–16

Prenatal care in the United States, 1980–94. Lewis CT, et al. **Vital Health Stat 21** 1996 Jul;(54):1–17

Prenatal care: will the past predict the future? [editorial] Peoples-Sheps MD. **Womens Health Issues** 1996 Jul–Aug; 6(4):235–6

UTILIZATION

The impact of extended maternity services on prenatal care use among Medicaid women. Farrow DC, et al. **Am J Prev Med** 1996 Mar–Apr;12(2):103–7

Prenatal and delivery care and childhood immunization in Guatemala: do family and community matter? Pebley AR, et al. **Demography** 1996 May;33(2):231–47

Validating a model developed to predict prenatal care utilization. Campbell JD, et al. **J Fam Pract** 1995 Nov; 41(5):457–64

Prenatal care use in nonmetropolitan and metropolitan America: racial/ethnic differences. Clarke LL, et al. **J Health Care Poor Underserved** 1995;6(4):410–33

Antenatal care, attitudes, and practices. Baldo MH, et al. **J Trop Pediatr** 1995;41 Suppl 1:21–9

Frequency of prenatal care visits and perinatal outcome [letter; comment] Zalar RW. **JAMA** 1996 Jul 10;276(2):101 . Comment on: JAMA 1996 Mar 20;275(11):847–51.

Adequacy of prenatal-care utilization—California, 1989–1994. **MMWR Morb Mortal Wkly Rep** 1996 Aug 2; 45(30):653–6

A review of problems of universal access to prenatal care. York R, et al. **Nurs Clin North Am** 1996 Jun;31(2):279–92 (40 ref.)

Access to physicians, obstetric care use, and adequacy of prenatal care for Medicaid patients in Maine: 1985–1989. Deprez RD, et al. **Obstet Gynecol** 1996 Sep;88(3):443–50

Trends in the percentage of women who received no prenatal care in the United States, 1980–1992: contributions of the demographic and risk effects. Elam-Evans LD, et al. **Obstet Gynecol** 1996 Apr;87(4):575–80

Characteristics of pregnant women, utilization, and satisfaction with prenatal services in St. Petersburg, Russia. Dennis LI, et al. **Public Health Nurs** 1995 Dec;12(6):374–7

A population-based survey of obstetric practices among rural women in the Bizana district, Transkei. O'Mahony D, et al. **S Afr Med J** 1995 Nov;85(11):1168–71

Exploring the relationship between purpose in life and African American adolescents' use of prenatal care services. Spence SA, et al. **Soc Work Health Care** 1995; 22(2):43–53

Prenatal care in the United States, 1980–94. Lewis CT, et al. **Vital Health Stat 21** 1996 Jul;(54):1–17

Does universal health care coverage mean universal accessibility? Examining the Canadian experience of poor, prenatal women. Morton AM, et al. **Womens Health Issues** 1995 Fall;5(3):139–42

[Pregnancy care: an epidemiological evaluation] Di Lallo D. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):60–2 **(Ita)**

PRENATAL DIAGNOSIS

see related
GENETIC COUNSELING

Prenatal diagnosis of choroideremia. Schwartz M, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):33–6

Issues associated with prenatal testing for fetal abnormalities [letter; comment] Reid JR IV. **Am Fam Physician** 1996 Jun;53(8):2435, 2439–40. Comment on: Am Fam Physician 1995 Dec;52(8):2173–4, 2177. Comment on: Am Fam Physician 1995 Dec;52(8):2277–83, 2285–6.

Prenatal diagnosis: more than meets the eye [editorial; comment] [see comments] Zamorski MA. **Am Fam Physician** 1995 Dec;52(8):2173–4, 2177. Comment on: Am Fam Physician 1995 Dec;52(8):2277–83, 2285–6. Comment in: Am Fam Physician 1996 Jun;53(8):2435, 2439–40.

Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989–1991. Velie EM, et al. **Am J Epidemiol** 1996 Sep 1;144(5):473–9

Prenatal diagnosis of 45,X/46,XX [letter] Hsu LY. **Am J Hum Genet** 1996 Mar;58(3):634–6

Aneuploidy among prenatally detected neural tube defects. Hume RF Jr, et al. **Am J Med Genet** 1996 Jan 11; 61(2):171–3

Epidemiology of osteochondrodysplasias: changing trends due to advances in prenatal diagnosis. Rasmussen SA, et al. **Am J Med Genet** 1996 Jan 2;61(1):49–58

Reports on the clinical use of fetal biophysical testing: shouldn't they take into consideration the important results from the studies on validity and efficacy? [letter; comment] Bernardes J, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1636–7. Comment on: Am J Obstet Gynecol 1995 Feb;172(2 Pt 1):486–92.

Prenatal diagnosis by use of fetal cells isolated from maternal blood [letter; comment] de la Cruz F, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1354–5. Comment on: Am J Obstet Gynecol 1995 Mar;172(3):1064–5.

Integration of genetics and ultrasonography in prenatal diagnosis: just looking is not enough. Evans MI, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1925–31; discussion 1931–3

Prenatal cytogenetic abnormalities: correlations of structural rearrangements and ultrasonographically detected fetal anomalies. Hume RF Jr, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1334–6

Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study. Kellner LH, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1306–9

Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Kjos SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1532–9

First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Krantz DA, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):612–6

Chorionic villus sampling safety. Report of World Health Organization/EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, Tel-Aviv, Israel, May 21, 1994. Kuliev A, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):807–11

Rapid aneuploid diagnosis of high-risk fetuses by fluorescence in situ hybridization. Lapidot-Lifson Y, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):886–90

Detection of viral deoxyribonucleic acid in the amniotic fluid of low-risk pregnancies by polymerase chain reaction. McLean LK, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1282–6

Prenatal diagnosis of congenital cytomegalovirus infection with abnormal triple-screen results and hyperechoic fetal bowel. Peters MT, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):953–4

Nicked free beta-subunit of human chorionic gonadotropin: a potential new marker for Down syndrome screening. Rotmensch S, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):609–11

Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach. Rouse DJ, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1357–63

Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction: a study of 34 cases diagnosed in fetuses. Tanemura M, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):578–82

Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old [see comments] Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1287–92. Comment in: Am J Obstet Gynecol 1996 Jun;174(6):1941–2.

The influence of maternal weight on human chorionic gonadotropin in the multiple-marker screening test for fetal Down syndrome. Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1297–300

Differences in practice patterns between obstetricians and family physicians: use of serum screening. Yankowitz J, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1361–5

Prenatal detection of the separation of the great toe, toe syndactyly, and large bilateral choroid plexus cysts in a fetus with trisomy 18. Chen CP, et al. **Am J Perinatol** 1996 May;13(4):203–5

Prenatal diagnosis and management of fetal goiter caused by maternal Grave's disease. Hadi HA, et al. **Am J Perinatol** 1995 Jul;12(4):240–2

Prenatal diagnosis of intracranial hemorrhage secondary to maternal idiopathic thrombocytopenic purpura: a case report. Tampakoudis P, et al. **Am J Perinatol** 1995 Jul; 12(4):268–70

Molecular diagnosis of Duchenne muscular dystrophy in Singapore. Low PS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):84–9 (18 ref.)

The effects of gestation dating on the calculation of patient specific risks in Down's syndrome screening. Bishop J, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):464–77

Prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization on uncultured amniotic cells: experience with 630 samples. Mercier S, et al. **Ann Genet** 1995;38(3):151–7

Absence of detectable alpha 6 integrin in pyloric atresia-junctional epidermolysis bullosa syndrome. Application for prenatal diagnosis in a family at risk for recurrence. Shimizu H, et al. **Arch Dermatol** 1996 Aug; 132(8):919–25

A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies. Bersinger NA, et al. **Arch Gynecol Obstet** 1995; 256(4):185–92

Histology of fetal eyes with oculocutaneous albinism. Akeo K, et al. **Arch Ophthalmol** 1996 May;114(5):613–6

Antenatal screening for carriers of hepatitis B virus [editorial; comment] [see comments] Boxall EH. **BMJ** 1995 Nov 4; 311(7014):1178–9. Comment on: BMJ 1995 Nov 4;311(7014):1197–9. Comment on: BMJ 1995 Nov 4;311(7014):1200–2. Comment in: BMJ 1996 Feb 24;312(7029):507.

Ethnic differences in outcome of serum screening for Down's syndrome. Differences in median values may account for differences in false positive rates [letter; comment] Ford C, et al. **BMJ** 1996 Apr 20;312(7037):1040–1. Comment on: BMJ 1996 Jan 13;312(7023):94–5.

Ethnic differences in the outcome of serum screening for Down's syndrome [see comments] Gilbert L, et al. **BMJ** 1996 Jan 13;312(7023):94–5. Comment in: BMJ 1996 Apr 20;312(7037):1040–1. Comment in: BMJ 1996 Apr 30;312(7037):1041.

Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis [see comments] Grosheide PM, et al. **BMJ** 1995 Nov 4;311(7014):1197–9 . Comment in: BMJ 1995 Nov 4;311(7014):1178–9.

Ethnic differences in outcome of serum screening for Down's syndrome. For appreciable ethnic differences in false positive rates, use different cut off points [letter; comment] Holloway PJ, et al. **BMJ** 1996 Apr 20;312(7037):1041. Comment on: BMJ 1996 Jan 13;312(7023):94–5.

Cost effectiveness of antenatal screening for cystic fibrosis. Counselors do not have to be genetic nurse specialists [letter; comment] Kent P. **BMJ** 1996 Apr 6;312(7035):908; discussion 910. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

Information about prenatal testing does not necessarily increase uptake [letter; comment] Moore WM. **BMJ** 1996 Feb 24;312(7029):508. Comment on: BMJ 1995 Oct 28;311(7013):1127–30.

Decision analysis and screening for Down's syndrome. Estimate of uptake of amniocentesis is overoptimistic [letter; comment] Murray D, et al. **BMJ** 1995 Nov 18; 311(7016):1371; discussion 1372–3. Comment on: BMJ 1995 Aug 5;311(7001):351–6.

Decision analysis and screening for Down's syndrome. Not using age specific values invalidates study [letter; comment] Spencer K. **BMJ** 1995 Nov 18;311(7016):1371–2; discussion 1372–3. Comment on: BMJ 1995 Aug 5;311(7001):351–6.

Ethnic differences in outcome of serum screening for Down's syndrome. Median values and maternal weight specific to the ethnic group should be used [letter; comment] Spencer K. **BMJ** 1996 Apr 20;312(7037):1041. Comment on: BMJ 1996 Jan 13;312(7023):94–5.

A randomised trial of three methods of giving information about prenatal testing [see comments] Thornton JG, et al. **BMJ** 1995 Oct 28;311(7013):1127–30. Comment in: BMJ 1996 Feb 24;312(7029):508.

Prenatal and postnatal prevalence of Turner's syndrome. Data presented were insufficient to challenge specificity of prenatal diagnosis [letter; comment] van der Sijs-Bos CJ, et al. **BMJ** 1996 Jul 6;313(7048):47–8. Comment on: BMJ 1996 Jan 6;312(7022):16–21.

Decision analysis and screening for Down's syndrome. Testing should be in all women [letter; comment] Wald NJ, et al. **BMJ** 1995 Nov 18;311(7016):1372–3. Comment on: BMJ 1995 Aug 5;311(7001):351–6.

HTLV-I screening in Britain. Antenatal screening is important [letter; comment] Weber JN, et al. **BMJ** 1996 Mar 16;312(7032):706. Comment on: BMJ 1995 Nov 18;311(7016):1313–4.

Antenatal diagnosis of congenital heart disease and Down's syndrome: the potential effect on the practice of paediatric cardiology. Abu-Harb M, et al. **Br Heart J** 1995 Aug; 74(2):192–8

The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability [letter; comment] Danielian PJ. **Br J Obstet Gynaecol** 1996 Apr;103(4):391. Comment on: Br J Obstet Gynaecol 1995 May;102(5):364–9.

Screening for fetal trisomy in twin pregnancy [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Sep; 103(9):viii. Comment on: Br J Obstet Gynaecol 1996 Sep;103(9):887–90.

Prenatal diagnosis of extra-amniotic pregnancy. Leung KY, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1013–5

Antenatal diagnosis of congenital toxoplasmosis: evaluation of the biological parameters in a cohort of 286 patients. Pratlong F, et al. **Br J Obstet Gynaecol** 1996 Jun; 103(6):552–7

Prenatal diagnosis of fetal subdural haematomas. Sohda S, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):89–90

Case: responding to a request for genetic testing that is still in the lab. Biesecker LG, et al. **Camb Q Healthc Ethics** 1995 Summer;4(3):387–400

Transparent women, visible genes, and new conceptions of disease. Hubbard R. **Camb Q Healthc Ethics** 1995 Summer; 4(3):291–5

The day-to-day realities: commentary on the new eugenics and medicalized reproduction. Sher G, et al. **Camb Q Healthc Ethics** 1995 Summer;4(3):313–5

The road that I see: implications of new reproductive technologies. Steel KO. **Camb Q Healthc Ethics** 1995 Summer;4(3):351–4

The new eugenics and medicalized reproduction. Testart J. **Camb Q Healthc Ethics** 1995 Summer;4(3):304–12

Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination [see comments] Dick PT. **Can Med Assoc J** 1996 Feb 15; 154(4):465–79. Comment in: Can Med Assoc J 1996 Aug 1;155(3):271–2; discussion 272–3. Comment in: Can Med Assoc J 1996 Aug 1;155(3):272; discussion 272–3.

Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. Forest JC, et al. **Clin Biochem** 1995 Aug;28(4):443–9

Maternal serum screening for fetal Down's syndrome, a retrospective study. Lemay C, et al. **Clin Chim Acta** 1995 Jul 14;238(2):151–62

Prenatal diagnosis of heterozygous deficiency of the second component of complement. Sullivan KE, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):606–7

Screening for Down's syndrome [comment] Chard T. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):15. Comment on: Clin Endocrinol (Oxf) 1996 Jan;44(1):17–21.

Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A [see comments] Wallace EM, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):17–21. Comment in: Clin Endocrinol (Oxf) 1996 Jan;44(1):15.

Early management and post-natal investigation of pre-natally diagnosed hydronephrosis [letter] Lindsell DR, et al. **Clin Radiol** 1996 Sep;51(9):666–7

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594–6 (17 ref.)

Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital: a two year prospective study. Viljoen D, et al. **East Afr Med J** 1996 May;73(5):327–9

Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga-Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7–10 (23 ref.)

Shoulder dystocia—is it predictable? Geary M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):15–8

Maternal serum markers for fetal trisomy 21 screening. Muller F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):3–6 (30 ref.)

Haemangioendothelioma in a preterm infant associated with highly elevated alpha-fetoprotein [letter] Lehrnbecher T, et al. **Eur J Pediatr** 1996 May;155(5):423–4

A family with combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cells. Levade T, et al. **Eur J Pediatr** 1995 Aug;154(8):643–8

Gastroschisis in the decade of prenatal diagnosis: 1983–1993. Haddock G, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):18–22

Prenatal diagnosis of thrombocytopenia-absent radius syndrome. Boute O, et al. **Fetal Diagn Ther** 1996 May–Jun; 11(3):224–30

Cardiac defects in 1st-trimester fetuses with trisomy 18. Hyett JA, et al. **Fetal Diagn Ther** 1995 Nov–Dec; 10(6):381–6

Impact of abnormal second-trimester maternal serum single, double, and triple screening on patient choices about prenatal diagnosis. Lowry DL, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):286–9

Dandy–Walker malformation in a fetus with pentasomy X (49,XXXXX) prenatally diagnosed by fluorescence in situ hybridization technique. Myles TD, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):333–36

Antenatal diagnosis and surgical management of congenital cystic adenomatoid malformation of the lung. Taguchi T, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):400–7

HLA-G mRNA forms in human trophoblasts and peripheral blood lymphocytes: potential use in prenatal diagnosis. Moreau P, et al. **Folia Biol (Praha)** 1994;40(6):431–8

Implications of prenatal diagnosis of sickle cell disease. de Montalembert M, et al. **Genet Couns** 1996;7(1):9–15

Fetal privacy and confidentiality. Botkin JR. **Hastings Cent Rep** 1995 Sep–Oct;25(5):32–9

Society's diseases. Morejon DP, et al. **Hastings Cent Rep** 1996 May–Jun;26(3):21; discussion 21–2

Outcome of isolated congenital complete heart block diagnosed in utero. Groves AM, et al. **Heart** 1996 Feb; 75(2):190–4

Advances in the prenatal and molecular diagnosis of the hemoglobinopathies and thalassemias. Embury SH. **Hemoglobin** 1995 Sep;19(5):237–61 (125 ref.)

Uniparental disomy in humans: development of an imprinting map and its implications for prenatal diagnosis. Ledbetter DH, et al. **Hum Mol Genet** 1995;4 Spec No:1757–64 (100 ref.)

Preimplantation diagnosis in disease control, not eugenics. Schulman JD, et al. **Hum Reprod** 1996 Mar;11(3):463–4

Fetoscopy, fetal-tissue sampling and the ESHRE guidelines on prenatal diagnosis [letter] Simpson JL, et al. **Hum Reprod** 1996 Mar;11(3):682

ACOG technical bulletin. Hemoglobinopathies in pregnancy. Number 220—February 1996 (replaces no. 185, October 1993). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 May;53(2):184–94

The effects of in utero diagnostic X-irradiation on the development of preschool-age children. Ornoy A, et al. **Isr J Med Sci** 1996 Feb;32(2):112–5

Selected papers from the 5th annual meeting of the International Working Group on Preimplantation Genetics. Hamburg, Germany, June 28, 1995. **J Assist Reprod Genet** 1996 Feb;13(2):87–192

Preimplantation genetic diagnosis [editorial] Verlinsky Y. **J Assist Reprod Genet** 1996 Feb;13(2):87–9

Gene dosage in capillary electrophoresis: pre-natal diagnosis of Down's syndrome. Gelfi C, et al. **J Chromatogr A** 1995 Dec 22;718(2):405–12

Use of PCR for prenatal and postnatal diagnosis of congenital rubella. Bosma TJ, et al. **J Clin Microbiol** 1995 Nov; 33(11):2881–7

Chest wall hamartoma diagnosed prenatally using ultrasonography and computed tomography. Masuzaki H, et al. **J Clin Ultrasound** 1996 Feb;24(2):83–5

Usefulness of ultrasonography and magnetic resonance imaging for prenatal diagnosis of fetal teratoma of the neck. Tsuda H, et al. **J Clin Ultrasound** 1996 May;24(4):217–9

First-trimester enzyme exclusion of Farber disease using a micromethod with [3H]ceramide. Akhunov VS, et al. **J Inherit Metab Dis** 1995;18(5):616–9

Prenatal diagnosis of Menkes disease by mutation analysis. Das S, et al. **J Inherit Metab Dis** 1995;18(3):364–5

Prenatal diagnosis for Canavan disease: the use of DNA markers. Matalon R, et al. **J Inherit Metab Dis** 1995; 18(2):215–7

Prenatal diagnosis and therapy for a patient with vitamin B12-responsive methylmalonic acidaemia. Soda H, et al. **J Inherit Metab Dis** 1995;18(3):295–8

Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization. McDuffie RS Jr, et al. **J Matern Fetal Med** 1996 Mar–Apr; 5(2):70–3

Prenatal diagnosis: whose right? Heyd D. **J Med Ethics** 1995 Oct;21(5):292–7

Direct marketing of cystic fibrosis carrier screening: commercial push or population need? [letter] Cuckle H, et al. **J Med Genet** 1995 Sep;32(9):758

Adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination. Decruyenaere M, et al. **J Med Genet** 1995 Oct;32(10):799–804; discussion 805

Use of type VII collagen gene (COL7A1) markers in prenatal diagnosis of recessive dystrophic epidermolysis bullosa. Dunnill MG, et al. **J Med Genet** 1995 Sep;32(9):749–50

Reply to the commentary on Decruyenaere et al "adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination" [letter] Evers-Kiebooms G, et al. **J Med Genet** 1995 Oct;32(10):836

Recurrence of DiGeorge syndrome: prenatal detection by FISH of a molecular 22q11 deletion. Van Hemel JO, et al. **J Med Genet** 1995 Aug;32(8):657–8

Impact of prenatal screening and diagnosis on the epidemiology of structural congenital anomalies. Chi LH, et al. **J Med Screen** 1995;2(2):67–70

Population based prenatal screening for the fragile X syndrome. Palomaki GE. **J Med Screen** 1994 Jan;1(1):65–72

Choice of serum markers in antenatal screening for Down's syndrome. Wald NJ, et al. **J Med Screen** 1994 Apr; 1(2):117–20

Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. Revello MG, et al. **J Med Virol** 1995 Dec;47(4):462–6

Chorionic villus sampling: clinical experience of the initial 750 cases. Yang YH, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):143–9

Prenatal diagnosis by analysis of fetal cells in maternal blood. Bianchi DW. **J Pediatr** 1995 Dec;127(6):847–56 (91 ref.)

Impact of antenatal diagnosis on incidence and prognosis in abdominal wall defects. Fisher R, et al. **J Pediatr Surg** 1996 Apr;31(4):538–41

Induced cardioversion of fetal flutter by artificial rupture of membranes at term. Hourvitz A, et al. **J Perinat Med** 1995;23(5):403–7

Antenatally diagnosed neonatal craniopharyngioma. Kültürsay N, et al. **J Perinatol** 1995 Sep–Oct;15(5):426–8

Pitfalls in the diagnosis of nonconjoined monoamniotic twins. Strohbehn K, et al. **J Perinatol** 1995 Nov–Dec;15(6):484–93 (56 ref.)

Prenatal diagnosis of partial trisomy through in situ hybridization on amniocytes with whole chromosome and centromere-specific DNA probes. A case report. Blancato JK, et al. **J Reprod Med** 1995 Jul;40(7):537–9

Romano-Ward syndrome diagnosed as moderate fetal bradycardia. A case report. Vigliani M. **J Reprod Med** 1995 Oct;40(10):725–8

A 35-year-old pregnant woman considering maternal serum screening and amniocentesis. Mennuti M. **JAMA** 1996 May 8;275(18):1440–6

Familial pericentric inversion incidentally detected at prenatal diagnosis. Uehara S, et al. **Jpn J Hum Genet** 1995 Sep;40(3):259–63

Application of natural and amplification-created restriction sites in prenatal and preimplantation diagnosis of beta-thalassemia. Kuo PL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):496–506

Prenatal screening for cystic fibrosis: 5 years' experience reviewed [see comments] Brock DJ. **Lancet** 1996 Jan 20; 347(8995):148–50. Comment in: Lancet 1996 Apr 6;347(9006):969.

False-negative results in Down's syndrome screening [letter] [see comments] Cavalli P. **Lancet** 1996 Apr 6; 347(9006):965–6. Comment in: Lancet 1996 Jun 1;347(9014):1553. Comment in: Lancet 1996 Jun 1;347(9014):1553–4.

Computer software programs and Down's syndrome risk calculations [letter; comment] Eiben B, et al. **Lancet** 1996 Jun 1;347(9014):1553–4. Comment on: Lancet 1996 Apr 6;347(9006):965–6.

Sex chromosome abnormalities after intracytoplasmic sperm injection [letter; comment] Govaerts I, et al. **Lancet** 1995 Oct 21;346(8982):1095–6. Comment on: Lancet 1995 Sep 16;346(8977):773.

Cystic fibrosis screening policies [letter; comment] Hall MH, et al. **Lancet** 1996 Apr 6;347(9006):969. Comment on: Lancet 1996 Jan 20;347(8995):148–50.

Sex chromosome abnormalities after intracytoplasmic sperm injection [letter; comment] Hoegerman SF, et al. **Lancet** 1995 Oct 21;346(8982):1095. Comment on: Lancet 1995 Sep 16;346(8977):773.

Computer software programs and Down's syndrome risk calculations [letter; comment] Knight GJ, et al. **Lancet** 1996 Jun 1;347(9014):1553. Comment on: Lancet 1996 Apr 6;347(9006):965–6.

Sex chromosome abnormalities after intracytoplasmic sperm injection [letter; comment] Liebaers I, et al. **Lancet** 1995 Oct 21;346(8982):1095. Comment on: Lancet 1995 Sep 16;346(8977):773.

Prenatal diagnosis of Batten's disease. Munroe PB, et al. **Lancet** 1996 Apr 13;347(9007):1014–5

Sex chromosome abnormalities after intracytoplasmic sperm injection [letter; comment] Tesarik J. **Lancet** 1995 Oct 21; 346(8982):1096. Comment on: Lancet 1995 Sep 16;346(8977):773.

Erroneous genetic risk assessment of Alport syndrome [letter] Turco AE, et al. **Lancet** 1995 Nov 4;346(8984):1237

Selective abortion after prenatal diagnosis. Schubert-Lehnhardt V. **Med Law** 1996;15(1):75–81

When is prenatal diagnosis 'eugenics'? [news] **Nature** 1995 Dec 7;378(6557):549

Perinatal approach to skeletal dysplasia. MacDonald MR, et al. **Nebr Med J** 1995 Nov;80(11):334–5

Antenatal diagnosis of vein of Galen aneurysmal malformation: MR study of fetal brain and postnatal follow-up. Campi A, et al. **Neuroradiology** 1996 Jan; 38(1):87–90

Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group. Hsu JJ, et al. **Obstet Gynecol** 1996 Jun;87(6):943–7

An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Lancaster JM, et al. **Obstet Gynecol** 1996 Feb;87(2):306–9

Intrauterine diagnosis of sex chromosome aneuploidy. Linden MG, et al. **Obstet Gynecol** 1996 Mar;87(3):468–75 (51 ref.)

Prenatal diagnosis and prevention of diabetic embryopathy. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):11–28

Prenatal diagnosis of hemoglobinopathies in Turkey: Hacettepe experience. Gürgey A, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):163–6

Prenatal MRI diagnosis of fetal cerebral tuberous sclerosis. Sonigo P, et al. **Pediatr Radiol** 1996;26(1):1–4

First trimester prenatal diagnosis of Smith-Lemli-Opitz syndrome (7-dehydrocholesterol reductase deficiency). Mills K, et al. **Pediatr Res** 1996 May;39(5):816–9

Prenatal diagnosis of organic acidemias based on amniotic fluid levels of acylcarnitines. Shigematsu Y, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):680–4

Prenatal pediatrics: traditional specialty definitions no longer apply. Nichols VG, et al. **Pediatrics** 1996 May;97(5):729–32

Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990–1991. Roberts HE, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):880–3

Current awareness in prenatal diagnosis. **Prenat Diagn** 1995 Nov;15(11):1091–8

Current awareness in prenatal diagnosis. **Prenat Diagn** 1996 Mar;16(3):281–8

Current awareness in prenatal diagnosis. **Prenat Diagn** 1996 Feb;16(2):185–92

Current awareness in prenatal diagnosis. **Prenat Diagn** 1995 Sep;15(9):881–8

Current awareness in prenatal diagnosis. **Prenat Diagn** 1996 Apr;16(4):379–86

Current awareness in prenatal diagnosis. **Prenat Diagn** 1995 Dec;15(12):1199–206

Current awareness in prenatal diagnosis. **Prenat Diagn** 1995 Oct;15(10):985–92

Current awareness in prenatal diagnosis. **Prenat Diagn** 1995 Jul;15(7):683–90

Selective termination of an abnormal fetus in multiple gestations [letter; comment] Berkowitz RL. **Prenat Diagn** 1995 Nov;15(11):1085–7. Comment on: Prenat Diagn 1995 Apr;15(4):386–7.

A 10-year survey, 1980–1990, of prenatally diagnosed small supernumerary marker chromosomes, identified by FISH analysis. Outcome and follow-up of 14 cases diagnosed in a series of 12,699 prenatal samples. Brøndum-Nielsen K, et al. **Prenat Diagn** 1995 Jul;15(7):615–9

Two-analyte assay for Down syndrome screening [letter] Cavalli P. **Prenat Diagn** 1995 Jul;15(7):680–1

Prenatal diagnosis of partial monosomy 3p and partial trisomy 2p in a fetus associated with shortening of the long bones and a single umbilical artery. Chen CP, et al. **Prenat Diagn** 1996 Mar;16(3):270–5

Elevated mid-trimester hCG and maternal lupus anticoagulant. Clark F, et al. **Prenat Diagn** 1995 Nov; 15(11):1035–9

Down's syndrome screening using urine beta-core fragment test: choice of immunoassay [letter] Cole LA. **Prenat Diagn** 1995 Jul;15(7):679–80

Improved parameters for risk estimation in Down's syndrome screening. Cuckle H. **Prenat Diagn** 1995 Nov; 15(11):1057–65

Urinary multiple marker screening for Down's syndrome. Cuckle HS, et al. **Prenat Diagn** 1995 Aug;15(8):745–51

Posting maternal blood samples for free beta-human chorionic gonadotrophin testing [letter] Cuckle HS, et al. **Prenat Diagn** 1995 Sep;15(9):879–80

Prenatal diagnosis of Rambam–Hasharon syndrome. Frydman M, et al. **Prenat Diagn** 1996 Mar;16(3):266–9

Cytogenetic analysis of fetal chondrocytes: a comparative study. Gelman–Kohan Z, et al. **Prenat Diagn** 1996 Feb; 16(2):165–8

Difficulties in prenatal detection of mosaic trisomy 8 [letter] Hanna JS, et al. **Prenat Diagn** 1995 Dec;15(12):1196–7

Infantile hypophosphatasia: successful prenatal assessment by testing for tissue–non–specific alkaline phosphatase isoenzyme gene mutations. Henthorn PS, et al. **Prenat Diagn** 1995 Nov;15(11):1001–6

Prenatal analysis of the insulin receptor gene in a family with leprechaunism. Krook A, et al. **Prenat Diagn** 1995 Jul; 15(7):669–71

Prenatal analysis of the insulin receptor gene in a family with leprechaunism. Longo N, et al. **Prenat Diagn** 1995 Nov; 15(11):1070–4

Prenatal diagnosis of mosaic tetrasomy 12p/trisomy 12p by fluorescent in situ hybridization in amniotic fluid cells: a case report of Pallister–Killian syndrome. Los FJ, et al. **Prenat Diagn** 1995 Dec;15(12):1155–9

Genetic basis of lethal junctional epidermolysis bullosa in an affected fetus: implications for prenatal diagnosis in one family. McGrath JA, et al. **Prenat Diagn** 1995 Jul; 15(7):647–54

Crown–rump length in aneuploid fetuses: implications for first–trimester biochemical screening for aneuploidies. Macintosh MC, et al. **Prenat Diagn** 1995 Aug;15(8):691–4

Prenatal diagnosis of Charcot–Marie–Tooth disease type 1A (CMT1A) using molecular genetic techniques. Navon R, et al. **Prenat Diagn** 1995 Jul;15(7):633–40

Prenatal diagnostic testing for familial dysautonomia using linked genetic markers. Oddoux C, et al. **Prenat Diagn** 1995 Sep;15(9):817–26

Risk–based prenatal screening for trisomy 18 using alpha–fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Palomaki GE, et al. **Prenat Diagn** 1995 Aug;15(8):713–23

Prenatal diagnosis of Marfan syndrome: identification of a fibrillin–1 mutation in chorionic villus sample. Rantamäki T, et al. **Prenat Diagn** 1995 Dec;15(12):1176–81

The effect of thermal instability of intact human chorionic gonadotropin (ihCG) on the application of its free beta–subunit (free beta hCG) as a serum marker in Down syndrome screening. Sancken U, et al. **Prenat Diagn** 1995 Aug;15(8):731–8

Prenatal diagnosis of trisomy 9. Six cases and a review of the literature. Saura R, et al. **Prenat Diagn** 1995 Jul; 15(7):609–14 (25 ref.)

Active cascade cystic fibrosis screening [letter; comment] Super M, et al. **Prenat Diagn** 1995 Nov;15(11):1082–3. Comment on: Prenat Diagn 1994 Dec;14(13):1243–52.

Maternal platelet size as a marker for fetal trisomies 18 and 13. Thilaganathan B, et al. **Prenat Diagn** 1995 Jul; 15(7):605–8

In utero diagnosis and treatment of fetal goitrous hypothyroidism, caused by maternal use of propylthiouracil. Van Loon AJ, et al. **Prenat Diagn** 1995 Jul;15(7):599–604

A chromosome 21–specific cosmid cocktail for the detection of chromosome 21 aberrations in interphase nuclei. van Opstal D, et al. **Prenat Diagn** 1995 Aug;15(8):705–11

Prenatal identification of i(Yp) by molecular cytogenetic analysis. Wang BB, et al. **Prenat Diagn** 1995 Dec; 15(12):1115–9

A case of paternal uniparental disomy for chromosome 11. Webb A, et al. **Prenat Diagn** 1995 Aug;15(8):773–7

Effect of gravidity and parity on the parameters used in serum screening for trisomy 21 [letter] Zimmermann R, et al. **Prenat Diagn** 1995 Aug;15(8):781–2

Elevated alpha–fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester? Zimmermann R, et al. **Prenat Diagn** 1995 Dec;15(12):1121–4

Prenatal molecular diagnosis of Gaucher disease. Zimran A, et al. **Prenat Diagn** 1995 Dec;15(12):1185–8

Pregnancy–associated plasma protein A (PAPP–A): measurement by highly sensitive and specific enzyme immunoassay, importance of first–trimester serum determinations, and stability studies. Bersinger NA, et al. **Reprod Fertil Dev** 1995;7(6):1419–23

Screening for Down syndrome in the first trimester. Powell KJ, et al. **Reprod Fertil Dev** 1995;7(6):1413–7 (54 ref.)

Prenatal screening for Down syndrome and neural tube defects [letter] Smart RD, et al. **S Afr Med J** 1996 Feb; 86(2):182–3

Acceptability of prenatal diagnosis of sickle cell anaemia (SCA) by female patients and parents of SCA patients in Nigeria. Durosinmi MA, et al. **Soc Sci Med** 1995 Aug; 41(3):433–6

Healing fictions': stories of choosing in the aftermath of the detection of fetal anomalies. Sandelowski M, et al. **Soc Sci Med** 1996 Feb;42(3):353–61

Prenatal diagnosis and screening of common genetic diseases in Hong Kong. Chan V, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:1–2

Prenatal diagnosis and cytogenetics. Romyanan O. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:89–91

Prenatal diagnosis for beta–thalassemia syndromes using HRP–labeled oligonucleotide probes at Siriraj Hospital. Winichagoon P, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:282–6

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302–13 (68 ref.)

Biochemical and ultrasound screening for Down's syndrome: rivals or partners? Cuckle H. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):236–8

Evidence of effectiveness and fetal investigation: trials and tribulations [editorial] Maulik D. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):305–6

Prevalence of fetal facial cleft at different stages of pregnancy. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):327–9 (11 ref.)

[Study on evaluation of fetal scalp tissue pH value during labor] Li W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):149–51 (Eng. Abstr.) (Chi)

[Direct genotyping and antenatal diagnosis of deletional alpha–thalassemia of the southeast Asian type by polymerase chain reaction technique] Zhong M, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):597–9 (Eng. Abstr.) (Chi)

[Analysis of beta–thalassemia mutations and prenated diagnosis in Chengdu population] Liu B, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):361–6 (Eng. Abstr.) (Chi)

[The first case of leukocyte integrin deficiency syndrome in the Czech Republic and successful prenatal diagnosis in the affected family] Král V, et al. **Cas Lek Cesk** 1996 Mar 6;135(5):154–8 (Eng. Abstr.) (Cze)

[Screening for Down's syndrome—results of a 3–year study] Kimlová I, et al. **Ceska Gynekol** 1996 Apr;61(2):75–8 (Eng. Abstr.) (Cze)

[The role of prenatal diagnosis on the decreasing incidence of congenital defects in the pediatric population in the Czech Republic 1988–1994] Sipek A, et al. **Ceska Gynekol** 1996 Feb;61(1):59–70 (Cze)

[Prenatal screening for abnormalities and chromosomal disorders (editorial)] Brandt NJ, et al. **Ugeskr Laeger** 1996 Feb 26;158(9):1197 (Dan)

[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and disadvantages of screening and diagnostic methods] Nørgaard–Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) (Dan)

[Molecular biology and prenatal diagnosis] Schwartz M. **Ugeskr Laeger** 1995 Oct 9;157(41):5703–6 (Dan)

[Serum screening for fetal Down syndrome in pregnant women with an indication for prenatal diagnosis because of age: fewer amniocenteses] Kornman LH, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1840–4 (Eng. Abstr.) (Dut)

–Screening for toxoplasmosis in pregnancy– Extermann P. **Arch Gynecol Obstet** 1995;256 Suppl:S170–2 (10 ref.) (Fre)

–Toxoplasmosis in pregnancy: arguments in favor of systematic screening in Switzerland– Hohlfeld P. **Arch Gynecol Obstet** 1995;256 Suppl:S165–9 (26 ref.) (Fre)

[Rubella and pregnancy: fetal infection without embryonal or fetal pathology. A case report] Chapeau J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):622–3 (Eng. Abstr.) (Fre)

–Prenatal diagnosis of brain damage in the fetus– Dürig P. **Arch Gynecol Obstet** 1995;256 Suppl:S43–9 (46 ref.) (Ger)

[Prenatal diagnosis as ethical problem field] Honnefelder L. **Arch Gynecol Obstet** 1995;257(1–4):493–8 (Ger)

–Increased AFP values– Zimmermann R. **Arch Gynecol Obstet** 1995;256 Suppl:S173–7 (Ger)

[Should maternal guidelines be improved?] Behrens O, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M129–31 (Ger)

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) (Ger)

[Intrauterine diagnosis and therapy of fetal arrhythmias] Gembruch U, et al. **Gynakologe** 1995 Oct;28(5):329–45 (69 ref.) (Ger)

[Observations on ethics in prenatal diagnosis from the viewpoint of the pediatrician] Lenard HG. **Gynakologe** 1995 Oct;28(5):384–8 (Ger)

[Diagnostic–therapeutic concept in hydrocephalus] Voigt HJ. **Gynakologe** 1995 Oct;28(5):346–55 (27 ref.) (Ger)

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) (Ger)

[Erythropoietin as a biochemical parameter for fetal hypoxia] Fahnenstich H, et al. **Klin Padiatr** 1995 Nov–Dec; 207(6):326–30 (Eng. Abstr.) (Ger)

[The MRI in pre– and postnatal diagnosis of congenital sacrococcygeal teratoma] Bachmann G, et al. **Radiologe** 1995 Aug;35(8):504–7 (Eng. Abstr.) (Ger)

[Pregnancy termination after prenatal diagnosis—data of the Styrian malformation register (1985–1992)] Häusler MC, et al. **Wien Klin Wochenschr** 1996;108(6):169–74 (Eng. Abstr.) (Ger)

[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):253–6 (24 ref.) (Ger)

[Vein of Galen malformation: prenatal diagnosis and noninvasive procedure] Goelz R, et al. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):72–5 (Eng. Abstr.) (Ger)

[Pre– and postpartum management of hypoplastic left heart syndrome (letter)] Kattner. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):75 (Ger)

[Triple test: problem or enhancement of prenatal diagnosis (editorial)] Rauskolb R, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):91 (Ger)

[Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index (letter)] Reynolds T, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun; 199(3):128–9 (Ger)

[Prenatal diagnosis of lysosomal diseases] Owada M, et al. **Nippon Rinsho** 1995 Dec;53(12):2926–32 (22 ref.) (Jpn)

[DNA diagnosis for short limb dwarfism, possibility of prenatal diagnosis for achondroplasia] Komori S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):229–32 (Jpn)

[A case of trisomy 19 pseudomosaicism—originated an extra fetal organ] Yamada N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1378–80 (Jpn)

[Antenatal diagnosis of acardius amorphous] Yura S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1381–4 (Jpn)

[Carrier detection and prenatal diagnosis for hemophilia A using the inversion analysis of the factor VIII gene] Okamoto Y, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1252–6 (Eng. Abstr.) (Jpn)

[Contents of alpha–fetoprotein in the blood of pregnant women as a criterion of the presence of congenital heart defects in the fetus] Vakharlovskiĭ VG, et al. **Akush Ginekol (Mosk)** 1995;(4):22–4 (Eng. Abstr.) (Rus)

[Chromosomal mosaicism of extraembryonic cell membrane, detected during prenatal diagnosis] Zolotukhina TV, et al. **Genetika** 1995 Sep;31(9):1317–21 (Eng. Abstr.) (Rus)

[The antenatal diagnosis of fetal Rh classification] Bykova E, et al. **Klin Lab Diagn** 1995 Nov–Dec;(6):83–4 (Rus)

[Newborn infants diagnosed prenatally with uropathies] García Mérida M, et al. **An Esp Pediatr** 1996 Jun; 44(6):581–4 (Eng. Abstr.) (Spa)

[Multidisciplinary assessment of the fetus with hydrocephalus: study protocol and results] Leis MT, et al. **Ginecol Obstet Mex** 1996 Apr;64:154–60 (Eng. Abstr.) (Spa)

[Prenatal diagnosis] **Rev Chil Obstet Ginecol** 1994; 59(6):403–15 (Spa)

ADVERSE EFFECTS

Recent advances in obstetrics. Testing for Down's syndrome carries too much stress [letter; comment] [see comments] Warner D. **BMJ** 1996 Feb 10;312(7027):379. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

ECONOMICS

Cost effectiveness of antenatal screening for cystic fibrosis. Realistic cost must be established for genetic counselling in two step screening [letter; comment] Brock DJ. **BMJ** 1996 Apr 6;312(7035):908; discussion 910. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

Cost effectiveness of antenatal screening for cystic fibrosis [see comments] Cuckle HS, et al. **BMJ** 1995 Dec 2; 311(7018):1460–3; discussion 1463–4. Comment in: BMJ 1996 Apr 6;312(7035):908; discussion 910. Comment in: BMJ 1996 Apr 6;312(7035):908–9; discussion 910. Comment in: BMJ 1996 Apr 6;312(7035):909; discussion 910. Comment in: BMJ 1996 Apr 6;312(7035):909–10.

Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening would be easier for many centres [letter; comment] Doherty RA, et al. **BMJ** 1996 Apr 6; 312(7035):909; discussion 910. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening should be preferred for medical reasons [letter; comment] Morris J. **BMJ** 1996 Apr 6; 312(7035):908–9; discussion 910. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

Decision analysis and screening for Down's syndrome. Costs were overestimated [letter; comment] Reynolds TM. **BMJ** 1995 Nov 18;311(7016):1372; discussion 1372–3. Comment on: BMJ 1995 Aug 5;311(7001):351–6.

Methods used in economic evaluations of prenatal screening are disputed [letter] Torgerson DJ, et al. **BMJ** 1996 Aug 3;313(7052):303

Cost effectiveness of antenatal screening for cystic fibrosis. Authors should have used marginal analysis [letter; comment] Torgerson DJ. **BMJ** 1996 Apr 6;312(7035):909; discussion 910. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

Marginal costs and benefits [see comments] Torgerson DJ,

et al. **BMJ** 1996 Jan 6;312(7022):35–6. Comment in: BMJ 1996 Apr 20;312(7037):1041–2.

When marginal costs and benefits should be used in screening [letter; comment] Wald N, et al. **BMJ** 1996 Apr 20; 312(7037):1041–2. Comment on: BMJ 1996 Jan 6;312(7022):35–6.

Cost effectiveness of antenatal screening for cystic fibrosis. Study might be better described as a cost description of screening [letter; comment] Walters S. **BMJ** 1996 Apr 6; 312(7035):909–10. Comment on: BMJ 1995 Dec 2;311(7018):1460–3; discussion 1463–4.

The impact of maternal age on the cost effectiveness of Down's syndrome screening. Torgerson DJ. **Br J Obstet Gynaecol** 1996 Jun;103(6):581–3

Willingness to pay for antenatal carrier screening for cystic fibrosis. Donaldson C, et al. **Health Econ** 1995 Nov–Dec; 4(6):439–52

Prenatal screening vouchers. Lilford RJ, et al. **J R Soc Med** 1996 Mar;89(3):130–1

INSTRUMENTATION

An expert diagnostic system based on neural networks and image analysis techniques in the field of automated cytogenetics. Beksaç MS, et al. **Technol Health Care** 1996 Mar;3(4):217–29

METHODS

Quantitative and functional asessment of anti–RhD: a comparative study of non–invasive methods in antenatal prediction of Rh hemolytic disease. Filbey D, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):102–7

Contemporary approaches to prenatal diagnosis [see comments] Kuller JA, et al. **Am Fam Physician** 1995 Dec; 52(8):2277–83, 2285–6. Comment in: Am Fam Physician 1995 Dec;52(8):2173–4, 2177. Comment in: Am Fam Physician 1996 Jun;53(8):2435, 2439–40.

Is the 15–in situ clone protocol necessary to detect amniotic fluid mosaicism? Cheng EY, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1025–30

Maternal serum screening should not replace amniocentesis [letter] Hsu LY, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):977–8

Accuracy of prenatal determination of RhD type status by polymerase chain reaction with amniotic cells. Lighten AD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1182–5

Prenatal maternal dried blood screening with alpha–fetoprotein and free beta–human chorionic gonadotropin for open neural tube defect and Down syndrome. Macri JN, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):566–72

How frequently should the amniotic fluid index be performed during the course of antepartum testing? Wing DA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):33–6

The NST–EXPERT project: the need to evolve. Alonso–Betanzos A, et al. **Artif Intell Med** 1995 Aug; 7(4):297–313 (40 ref.)

Assay used in serum screening for Down's syndrome may depend on ethnic make up of population [letter] Gilbert L, et al. **BMJ** 1996 Aug 3;313(7052):297

Prenatal and postnatal prevalence of Turner's syndrome: a registry study [see comments] Gravholt CH, et al. **BMJ** 1996 Jan 6;312(7022):16–21. Comment in: BMJ 1996 Apr 27;312(7038):1100; discussion 1100–1. Comment in: BMJ 1996 Apr 27;312(7038):1100–1. Comment in: BMJ 1996 Jul 6;313(7048):47–8.

Programme for preventing perinatal hepatitis B infection through screening of pregnant women and immunisation of infants of infected mothers in The Netherlands, 1989–92. National Hepatitis B Steering Committee [see comments] Grosheide PM, et al. **BMJ** 1995 Nov 4;311(7014):1200–2 . Comment in: BMJ 1995 Nov 4;311(7014):1178–9.

Quadruple test is available for Down's syndrome [news] Wise J. **BMJ** 1996 Aug 17;313(7054):380

A whole blood assay for platelet HPA1 (PLA1) phenotyping applicable to large–scale screening. Bessos H, et al. **Br J Haematol** 1996 Jan;92(1):221–5

Rapid diagnosis of beta–thalassaemia by mutagenically separated polymerase chain reaction (MS–PCR) and its application to prenatal diagnosis. Chang JG, et al. **Br J Haematol** 1995 Nov;91(3):602–7

The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. Denomme GA, et al. **Br J Haematol** 1995 Nov;91(3):742–6

Fetal malformations diagnosed antenatally 1: General principles. Sprigg A. **Br J Hosp Med** 1995 Oct 18–31; 54(8):387–90

First trimester fetal nuchal translucency: problems with screening the general population 1 & 2 [letter] Braithwaite JM, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1018–9

Antenatal screening for cystic fibrosis. Cuckle H, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):795–9

Non–invasive prenatal diagnosis by isolation of both trophoblasts and fetal nucleated red blood cells from the peripheral blood of pregnant women. Durrant L, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):219–22

Maternal urinary free beta–subunit of human chorionic gonadotrophin: creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. Hayashi M, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):577–80

Biochemical screening for Down's syndrome [letter] James M, et al. **Br J Obstet Gynaecol** 1996 May;103(5):486–7

The usefulness of hCG and unconjugated oestriol in prenatal diagnosis of trisomy 18. Leporrier N, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):335–8

Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy [letter; comment] Page IJ. **Br J Obstet Gynaecol** 1995 Sep;102(9):758; discussion 759–60. Comment on: Br J Obstet Gynaecol 1994 Sep;101(9):782–6.

Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Pandya PP, et al. **Br J Obstet Gynaecol** 1995 Dec; 102(12):957–62

Obstetric outcome of pregnancies resulting from embryos biopsied for pre–implantation diagnosis of inherited disease. Soussis I, et al. **Br J Obstet Gynaecol** 1996 Aug; 103(8):784–8

Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 May;103(5):407–12

Short communication: MR imaging of fetal brain abnormalities using a HASTE sequence. Tsuchiya K, et al. **Br J Radiol** 1996 Jul;69(823):668–70

Growth of the tibia and fibula bones in human fetuses. Cupello AJ, et al. **Bull Assoc Anat (Nancy)** 1995 Sep; 79(246):17–20

Triple–marker screening for Down syndrome [letter; comment] Farrell SA, et al. **Can Med Assoc J** 1996 Aug 1;155(3):271–2; discussion 272–3. Comment on: Can Med Assoc J 1996 Feb 15;154(4):465–79.

Triple–marker screening for Down syndrome [letter; comment] Viner G. **Can Med Assoc J** 1996 Aug 1; 155(3):272; discussion 272–3. Comment on: Can Med Assoc J 1996 Feb 15;154(4):465–79.

Cordocentesis: a useful method for prenatal diagnosis. Xiang Y, et al. **Chin Med J (Engl)** 1996 Apr;109(4):291–4

Preimplantation diagnosis by whole–genome amplification, PCR amplification, and solid–phase minisequencing of blastomere DNA. Paunio T, et al. **Clin Chem** 1996 Sep; 42(9):1382–90

Detection of alpha–thalassemia–1 (Southeast Asian type) and its application for prenatal diagnosis. Winichagoon P, et al. **Clin Genet** 1995 Jun;47(6):318–20

Prenatal diagnosis of hematologic disorders. Phillips OP, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):558–72 (30 ref.)

Maternal serum screening for birth defects: results of a Connecticut regional program. Benn PA, et al. **Conn Med** 1996 Jun;60(6):323–7

Case report: unusually high rates of aneuploid embryos in a 28–year old woman with incontinentia pigmenti. Munné S, et al. **Cytogenet Cell Genet** 1996;72(1):43–5

Prenatal diagnosis of a (X;X) translocation by fluorescence in situ hybridization and laser scanning image cytometry. Tachdjian G, et al. **Fetal Diagn Ther** 1995 Nov–Dec; 10(6):387–92

Invasive prenatal procedures: is 'backup' tissue sampling indicated? Meagher S, et al. **Gynecol Obstet Invest** 1995; 40(2):94–6

Non–invasive early prenatal molecular diagnosis using retrieved transcervical trophoblast cells. Massari A, et al. **Hum Genet** 1996 Feb;97(2):150–5

Analysis of sex and delta F508 in single amniocytes using primer extension preamplification. Schaaff F, et al. **Hum Genet** 1996 Aug;98(2):158–61

Simultaneous amplification of the two most frequent mutations of infantile Tay–Sachs disease in single blastomeres. Sermon K, et al. **Hum Reprod** 1995 Aug; 10(8):2214–7

Prenatal diagnosis of genetic disorders. Kulkarni ML, et al. **Indian Pediatr** 1995 Nov;32(11):1229–38 (28 ref.)

The diagnosis of foetal distress: a challenge to midwives. Mead M. **J Adv Nurs** 1996 May;23(5):975–83 (73 ref.)

Clinical application of FISH for sex determination of embryos in preimplantation diagnosis of X–linked diseases. Coonen E, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):133–6

Allelic dropout caused by allele–specific amplification failure in single–cell PCR of the cystic fibrosis delta F508 deletion. Dreesen JC, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):112–4

Fluorescent PCR: a new technique for PGD of sex and single–gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

Polymerase chain reaction amplification specificity: incidence of allele dropout using different DNA preparation methods for heterozygous single cells. Gitlin SA, et al. **J Assist Reprod Genet** 1996 Feb;13(2):107–11

Detection of chromosomal abnormalities in human preimplantation embryos using FISH. Harper JC, et al. **J Assist Reprod Genet** 1996 Feb;13(2):137–9

Identifying the sex of human preimplantation embryos in X–linked disease: amplification efficiency of a Y–specific alphoid repeat from single blastomeres with two lysis protocols. Kontogianni EH, et al. **J Assist Reprod Genet** 1996 Feb;13(2):125–32

Reduction in signal overlap results in increased FISH efficiency: implications for preimplantation genetic diagnosis. Munné S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):149–56

Reduced allele dropout in single–cell analysis for preimplantation genetic diagnosis of cystic fibrosis. Ray PF, et al. **J Assist Reprod Genet** 1996 Feb;13(2):104–6

Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). Rechitsky S, et al. **J Assist Reprod Genet** 1996 Feb;13(2):115–24

Prenatal diagnosis of X linked lymphoproliferative disease using multiplex polymerase chain reaction [letter] Schuster V, et al. **J Med Genet** 1995 Sep;32(9):756–7

Rapid chromosome analysis and prenatal diagnosis using fluid from the cystic hygroma, hydrothorax and isolated ascites: new source for chromosome analysis. Yang YH, et al. **J Obstet Gynaecol** 1995 Oct;21(5):443–50

Triple test for prenatal detection of Edwards syndrome (trisomy 18). Sinosich MJ, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):57–60

Preimplantation genetic diagnosis of beta–thalassaemia major [letter] Ray PF, et al. **Lancet** 1996 Jun 15;347(9016):1696

Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. Aitken DA, et al. **N Engl J Med** 1996 May 9;334(19):1231–6

Marfan syndrome as a paradigm for transcript–targeted preimplantation diagnosis of heterozygous mutations. Eldadah ZA, et al. **Nat Med** 1995 Aug;1(8):798–803

Prenatal detection of Down syndrome. Smith CV. **Nebr Med J** 1995 Aug;80(8):268–70

Polymorphisms in the alanine:glyoxylate aminotransferase gene and their application to the prenatal diagnosis of primary hyperoxaluria type 1. Rumsby G, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:30–2

Prenatal diagnosis of Duchenne muscular dystrophy using a single fetal nucleated erythrocyte in maternal blood. Sekizawa A, et al. **Neurology** 1996 May;46(5):1350–3

Prenatal diagnosis of the fetal RhD blood type using a single fetal nucleated erythrocyte from maternal blood. Sekizawa A, et al. **Obstet Gynecol** 1996 Apr;87(4):501–5

What are the present possibilities for the prenatal diagnosis of primary hyperoxaluria? Danpure CJ. **Pediatr Nephrol** 1996 Apr;10(2):190 (7 ref.)

Prenatal diagnosis of glycogen storage disease type II: enzyme assay or mutation analysis? Kleijer WJ, et al. **Pediatr Res** 1995 Jul;38(1):103–6

Non– or minimally invasive prenatal diagnostic tests on maternal blood samples or transcervical cells. Adinolfi M. **Prenat Diagn** 1995 Oct;15(10):889–96 (79 ref.)

Detection of fetal cells in transcervical samples and prenatal diagnosis of chromosomal abnormalities. Adinolfi M, et al. **Prenat Diagn** 1995 Oct;15(10):943–9

Clinical experience with preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Prenat Diagn** 1996 Feb;16(2):137–42

Multiple–marker screen positive results in Noonan syndrome [letter] Aranguren G, et al. **Prenat Diagn** 1996 Feb; 16(2):183–4

Effect of gravidity on maternal serum markers for Down's syndrome. Barkai G, et al. **Prenat Diagn** 1996 Apr; 16(4):319–22

Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free–beta hCG and AFP. Barnabei VM, et al. **Prenat Diagn** 1995 Dec;15(12):1131–4

Development of a model system to compare cell separation methods for the isolation of fetal cells from maternal blood. Bianchi DW, et al. **Prenat Diagn** 1996 Apr;16(4):289–98

Detection of low–grade mosaicism in fetal cells isolated from maternal blood. Bischoff FZ, et al. **Prenat Diagn** 1995 Dec; 15(12):1182–4

Prenatal aspects of giant fetal cranial haemangio–endothelioma. Boulot P, et al. **Prenat Diagn** 1996 Apr;16(4):357–9

Immunohistochemical characterization of cells retrieved by transcervical sampling in early pregnancy. Bulmer JN, et al. **Prenat Diagn** 1995 Dec;15(12):1143–53

Prenatal diagnosis of cystic fibrosis in a highly heterogeneous population. Casals T, et al. **Prenat Diagn** 1996 Mar; 16(3):215–22

Assessment of serum levels of alpha–1–microglobulin, beta–2–microglobulin, and retinol binding protein in the fetal blood. A method for prenatal evaluation of renal function. Cobet G, et al. **Prenat Diagn** 1996 Apr; 16(4):299–305

A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid. Grenier A, et al. **Prenat Diagn** 1996 Mar;16(3):239–42

Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free alpha and free beta–hCG. Hackshaw AK, et al. **Prenat Diagn** 1995 Dec;15(12):1125–30

Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease. Heinonen S, et al. **Prenat Diagn** 1996 Mar;16(3):207–13

Prenatal diagnosis of X–linked myotubular myopathy: strategies using new and tightly linked DNA markers. Hu LJ, et al. **Prenat Diagn** 1996 Mar;16(3):231–7

Prenatal diagnosis of adrenoleukodystrophy by means of mutation analysis. Imamura A, et al. **Prenat Diagn** 1996 Mar;16(3):259–61

Uterine cavity lavage: adding FISH to conventional cytogenetics for embryonic sexing and diagnosing common chromosomal aberrations. Ishai D, et al. **Prenat Diagn** 1995 Oct;15(10):961–5

Early prenatal diagnosis of Fanconi anaemia in a twin pregnancy, using DNA analysis. Kwee ML, et al. **Prenat Diagn** 1996 Apr;16(4):345–8

The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Liu YC, et al. **Prenat Diagn** 1996 Apr;16(4):363–5 (8 ref.)

Prenatal diagnosis of Blackfan–Diamond syndrome: case report and review of the literature. McLennan AC, et al. **Prenat Diagn** 1996 Apr;16(4):349–53 (15 ref.)

Molecular prenatal diagnosis of 3–hydroxy–3–methylglutaryl CoA lyase deficiency. Mitchell GA, et al. **Prenat Diagn** 1995 Aug;15(8):725–9

Fetal hydrops secondary to human parvovirus infection in early pregnancy. Petrikovsky BM, et al. **Prenat Diagn** 1996 Apr;16(4):342–4

Prenatal screening for haemoglobin disorders [see comments] Petrou M, et al. **Prenat Diagn** 1995 Dec;15(13):1275–95 (60 ref.). Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Methods for the transcervical collection of fetal cells during the first trimester of pregnancy. Rodeck C, et al. **Prenat Diagn** 1995 Oct;15(10):933–42

Isolation of fetal cells from transcervical samples by micromanipulation: molecular confirmation of their fetal origin and diagnosis of fetal aneuploidy. Tutschek B, et al. **Prenat Diagn** 1995 Oct;15(10):951–60

Prenatal diagnosis of beta–thalassaemia and sickle cell anaemia in Turkey. Tüzmen S, et al. **Prenat Diagn** 1996 Mar;16(3):252–8

Prenatal screening for Down's syndrome using inhibin–A as a serum marker. Wald NJ, et al. **Prenat Diagn** 1996 Feb; 16(2):143–53

Prenatal diagnosis of X–linked spinal and bulbar muscular atrophy in a Greek family. Yapijakis C, et al. **Prenat Diagn** 1996 Mar;16(3):262–5

Antenatal screening for Down syndrome. Wald NJ. **Prog Clin Biol Res** 1995;393:27–42 (25 ref.)

A simple non radioactive method for detecting beta–thalassemia/hbe disease: application to prenatal diagnosis. Fucharoen S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:278–81

Prenatal diagnosis of Hb Bart's hydrops fetalis by PCR technique: Pramongkutklao experience. Torcharus K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:287–90

Evaluation of intrauterine growth retardation in the fetus and neonate: are simple–minded methods good enough? [editorial] Deter RL. **Ultrasound Obstet Gynecol** 1995 Sep; 6(3):161–3

Impact of prenatal mid–trimester screening on the prevalence of fetal structural anomalies: a prospective epidemiological study. Papp Z, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):320–6

[Serum screening in pregnant women for Down syndrome and open neural–tube defects; testing against the Health Council criteria for genetic screening (see comments)] Wildhagen MF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13; 140(2):85–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):506–7; discussion 507–8. **(Dut)**

[Prenatal diagnosis of cutaneous genetic diseases by the study of fetal DNA] Hovnanian A, et al. **Ann Dermatol Venereol** 1995;122(4):173–85 (151 ref.) (Eng. Abstr.) **(Fre)**

[What method of sampling is best for prenatal diagnosis of genetic diseases? (editorial)] Dumez Y. **Arch Pediatr** 1995 Aug;2(8):719–21 **(Fre)**

[Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis] Simpson JL, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):445–50 (64 ref.) (Eng. Abstr.) **(Fre)**

[Prediction of prematurity by oncofetal fibronectin. Prospective cohort study] Irion O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):624–9 (Eng. Abstr.) **(Fre)**

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Rational use of fetal fibronectin in the evaluation of premature labor risk] Rozenberg P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):288–93 (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the fetus. Contribution to antenatal diagnosis] Garel C, et al. **Presse Med** 1996 Mar 16;25(9):452–6 (23 ref.) (Eng. Abstr.) **(Fre)**

[Development and evaluation of screening algorithms for sexually transmitted diseases in pregnant women at Libreville, Gabon] Bourgeois A, et al. **Sante** 1996 Mar–Apr; 6(2):115–21 (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis—current aspects] Schmidt W. **Arch Gynecol Obstet** 1995;257(1–4):190–4 **(Ger)**

[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302–14 (93 ref.) **(Ger)**

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

[Noninvasive prenatal diagnosis of fetal cells in maternal blood] Tutschek B, et al. **Gynakologe** 1995 Oct; 28(5):289–301 (74 ref.) **(Ger)**

[Prenatal diagnosis] Miny P, et al. **Ther Umsch** 1995 Dec; 52(12):792–800 (Eng. Abstr.) **(Ger)**

[Prenatal diagnosis of abnormalities of the urinary tract] Vilits P, et al. **Wien Klin Wochenschr** 1995;107(23):736–8 (Eng. Abstr.) **(Ger)**

[Analysis of five mutations of cystic fibrosis occurring in the Hungarian population] Németh K, et al. **Orv Hetil** 1996 Apr 28;137(17):899–903 (Eng. Abstr.) **(Hun)**

[Fluorescence in situ hybridization in prenatal diagnosis. First experiences] Tardy E, et al. **Orv Hetil** 1996 Mar 10; 137(10):523–6 (Eng. Abstr.) **(Hun)**

[Validity of instrumental tests, individual and combined, in the rapid diagnosis of extra–uterine pregnancy] D'Amato B, et al. **Minerva Ginecol** 1995 May;47(5):189–91 (Eng. Abstr.) **(Ita)**

[Pharmacologic induction of fetal immobilization for prenatal diagnostic–therapeutic procedures] Greco P, et al. **Minerva Ginecol** 1995 May;47(5):207–10 (Eng. Abstr.) **(Ita)**

[The use of the screening of maternal serum factors for the prenatal diagnosis of fetal developmental defects and chromosomal diseases] Arbuzova SB, et al. **Tsitol Genet** 1995 Jul–Aug;29(4):44–7 (Eng. Abstr.) **(Rus)**

[Blood markers in the prenatal diagnosis of Down's syndrome: the triple test] Ortega–Benito JM. **Med Clin (Barc)** 1995 Sep 9;105(7):264–8 (32 ref.) **(Spa)**

PSYCHOLOGY

Use of decision analysis to evaluate patients' choices of diagnostic prenatal test. Verp MS, et al. **Am J Med Genet** 1995 Sep 25;58(4):337–44

Serum screening for Down's syndrome. Creates stress for carers and parents [letter; comment] Bunn A, et al. **BMJ** 1996 Apr 13;312(7036):974–5. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment on: BMJ 1996 Feb 10;312(7027):379. Comment on: BMJ 1996 Feb 10;312(7027):379–80.

The consequences of a positive prenatal HIV antibody test for women. Lester P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):341–9

Questions of parental anxiety [editorial; comment] Ferguson–Smith MA. **Prenat Diagn** 1995 Dec; 15(13):1209–13. Comment on: Prenat Diagn 1995 Dec;15(13):1215–26. Comment on: Prenat Diagn 1995 Dec;15(13):1227–40. Comment on: Prenat Diagn 1995 Dec;15(13):1241–57. Comment on: Prenat Diagn 1995 Dec;15(13):1275–95. Comment on: Prenat Diagn 1995 Dec;15(13):1297–302. Comment on: Prenat Diagn 1995 Dec;15(13):1303–11.

Towards informed decisions about prenatal testing: a review [see comments] Marteau TM. **Prenat Diagn** 1995 Dec; 15(13):1215–26 (75 ref.). Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

STANDARDS

Prenatal and postnatal prevalence of Turner's syndrome. No reason to doubt standard of prenatal diagnosis [comment] Hahnemann JM, et al. **BMJ** 1996 Apr 27;312(7038):1100–1 . Comment on: BMJ 1996 Jan 6;312(7022):16–21.

Prenatal testing leads to row in The Netherlands [news] Sheldon T. **BMJ** 1995 Nov 4;311(7014):1187

Clinical ethics committee. Thornton JG, et al. **BMJ** 1995 Sep 9;311(7006):667–9

[Quality of health services in Africa : example of dystocia prenatal screening in Nioki (Zaire)] Fournier P, et al. **Sante** 1996 Mar–Apr;6(2):107–14 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Recent advances in obstetrics. Figures on screening for Down's syndrome are inaccurate [letter; comment] [see comments] Kennard A, et al. **BMJ** 1996 Feb 10; 312(7027):379. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

Preimplantation diagnosis of inherited disease by embryo biopsy: an update of the world figures. Harper JC. **J Assist Reprod Genet** 1996 Feb;13(2):90–5

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)

Decision making with respect to diagnostic testing: a method of valuing the benefits of antenatal screening. Cairns J, et al. **Med Decis Making** 1996 Apr–Jun;16(2):161–8

The association between small size for gestational age and perinatal and neonatal death in a UK Regional Health Authority. de Courcy–Wheeler RH, et al. **Paediatr Perinat Epidemiol** 1995 Oct;9(4):431–40

TRENDS

The development of magnetic resonance imaging in obstetrics. Duncan KR. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):178–81 (20 ref.)

UTILIZATION

Prenatal screening for Down's syndrome in Maine, 1980 to 1993 [letter] Palomaki GE, et al. **N Engl J Med** 1996 May 23;334(21):1409–10

VETERINARY

Prenatal testing for caprine N–acetylglucosamine–6–sulphatase deficiency and sex identification. Leipprandt JR, et al. **J Inherit Metab Dis** 1995;18(5):647–8

PRENATAL DIAGNOSIS, ULTRASONIC see **ULTRASONOGRAPHY, PRENATAL**

PRENATAL EXPOSURE DELAYED EFFECTS

see related
MATERNAL EXPOSURE
PATERNAL EXPOSURE

Amphetamine addiction during pregnancy: 14–year follow–up of growth and school performance. Cernerud L, et al. **Acta Paediatr** 1996 Feb;85(2):204–8

No association between prenatal exposure to influenza and autism. Dassa D, et al. **Acta Psychiatr Scand** 1995 Aug; 92(2):145–9

Effect of chronic maternal ethanol administration on glutamate and N–methyl–D–aspartate binding sites in the hippocampus of the near–term fetal guinea pig. Abdollah S, et al. **Alcohol** 1995 Jul–Aug;12(4):377–82

Prenatal alcohol exposure and the effects of environmental enrichment on hippocampal dendritic spine density. Berman RF, et al. **Alcohol** 1996 Mar–Apr;13(2):209–16

Early handling can attenuate adverse effects of fetal ethanol exposure. Weinberg J, et al. **Alcohol** 1995 Jul–Aug; 12(4):317–27

Effects of prenatal ethanol exposure and stress in adulthood on lymphocyte populations in rats. Giberson PK, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1286–94

Autistic behaviors in offspring of mothers abusing alcohol and other drugs: a series of case reports. Harris SR, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):660–5

Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. I. Effects on physical growth at age 5 years. Eskenazi B, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S10–8

Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. II. Effects on neurodevelopment at age 5 years. Eskenazi B, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S19–29

Bias caused by migration in case–control studies of prenatal risk factors for childhood and adult diseases. Jones ME, et al. **Am J Epidemiol** 1996 Apr 15;143(8):823–31

Gravid health status, medication use, and risk of neuroblastoma. Michalek AM, et al. **Am J Epidemiol** 1996 May 15;143(10):996–1001

Prospective study of noise exposure during pregnancy on birth weight. Wu TN, et al. **Am J Epidemiol** 1996 Apr 15;143(8):792–6

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

Renal dysplasia associated with in utero exposure to gentamicin and corticosteroids. Hulton SA, et al. **Am J Med Genet** 1995 Jul 31;58(1):91–3

Age at menarche among diethylstilbestrol granddaughters. Wilcox AJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):835–6

Vestibular dysfunction in a child with embryonic exposure to accutane. Westerman ST, et al. **Am J Otol** 1994 May; 15(3):400–3

Cardiovascular effects of cocaine in neonates exposed prenatally. Tuboku–Metzger AJ, et al. **Am J Perinatol** 1996 Jan;13(1):1–4

Moderate prenatal alcohol exposure and psychomotor development at preschool age [see comments] Larroque B, et al. **Am J Public Health** 1995 Dec;85(12):1654–61. Comment in: Am J Public Health 1995 Dec;85(12):1614–5.

Prenatal cocaine alters diaphragmatic EMG responses to hypoxia in developing swine. Moss IR, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1961–6

Estrogen receptor (ER) and its messenger ribonucleic acid expression in the genital tract of female mice exposed neonatally to tamoxifen and diethylstilbestrol. Sato T, et al. **Anat Rec** 1996 Mar;244(3):374–85

Evolution of somatic and germ cell populations after busulfan treatment in utero or neonatal cryptorchidism in the rat. Boujrad N, et al. **Andrologia** 1995 Jul–Aug;27(4):223–8

Fetal exposure to involuntary maternal smoking and childhood respiratory disease. Barber K, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):427–30

Early life affects the risk of developing breast cancer. Hilakivi–Clarke L, et al. **Ann N Y Acad Sci** 1995 Sep 30; 768:327–30

Morning sickness: impact on offspring salt preference. Crystal SR, et al. **Appetite** 1995 Dec;25(3):231–40

Maternal HIV and drug use: effect on health and social morbidity. Mok JY, et al. **Arch Dis Child** 1996 Mar; 74(3):210–4

Maternal HIV infection, drug use, and growth of uninfected children in their first 3 years. Ross A, et al. **Arch Dis Child** 1995 Dec;73(6):490–5

Neurobehavioral development of CD–1 mice after combined gestational and postnatal exposure to ozone. Dell'Omo G, et al. **Arch Toxicol** 1995;69(9):608–16

Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)

Prenatal cocaine exposure affects the acoustic startle response in adult rat. Hughes HE, et al. **Behav Brain Res** 1996 Feb; 75(1–2):83–90

Effects of perinatal testosterone on handedness of gerbils:

support for part of the Geschwind–Galaburda hypothesis. Clark MM, et al. **Behav Neurosci** 1996 Apr;110(2):413–7

Effects of prenatal exposure to cocaine on Morris water maze performance in adult rats. Heyser CJ, et al. **Behav Neurosci** 1995 Aug;109(4):734–43

Neurochemical effects of a 20 kHz magnetic field on the central nervous system in prenatally exposed mice. Dimberg Y. **Bioelectromagnetics** 1995;16(4):263–7

Lung hypoplasia and surfactant system immaturity induced in the fetal rat by prenatal exposure to nitrofen. Alfanso LF, et al. **Biol Neonate** 1996;69(2):94–100

Affective disorders in Holland after prenatal exposure to the 1957 A2 influenza epidemic. Brown AS, et al. **Biol Psychiatry** 1995 Aug 15;38(4):270–3

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. **Br J Obstet Gynaecol** 1995 Nov;102(11):861–8

Diet in pregnancy and the offspring's blood pressure 40 years later. Campbell DM, et al. **Br J Obstet Gynaecol** 1996 Mar; 103(3):273–80

Obstetric complications in schizophrenia [letter; comment] Mortensen PB, et al. **Br J Psychiatry** 1995 Nov; 167(5):695–6; discussion 696–7. Comment on: Br J Psychiatry 1995 Jun;166(6):734–41.

Antidepressants in pregnancy and breastfeeding [letter] Ratan DA, et al. **Br J Psychiatry** 1995 Dec;167(6):824

Obstetric complications in schizophrenia [letter; comment] Rifkin L, et al. **Br J Psychiatry** 1995 Nov;167(5):694–5; discussion 696–7. Comment on: Br J Psychiatry 1995 Jun;166(6):734–41.

Maternal serum human chorionic gonadotrophin during early pregnancy resulting in boys with hypospadias or cryptorchidism. Kiely EA, et al. **Br J Urol** 1995 Sep; 76(3):389–92

Mental rotation at 7 years: relations with prenatal testosterone levels and spatial play experiences. Grimshaw GM, et al. **Brain Cogn** 1995 Oct;29(1):85–100

Talents and disorders: relationships among handedness, sex, and college major. Martino G, et al. **Brain Cogn** 1995 Oct; 29(1):66–84

Cholinergic denervation–like changes in rat hippocampus following developmental lead exposure. Bielarczyk H, et al. **Brain Res** 1996 Feb 5;708(1–2):108–15

Prenatal stress in rats facilitates amphetamine–induced sensitization and induces long–lasting changes in dopamine receptors in the nucleus accumbens. Henry C, et al. **Brain Res** 1995 Jul 10;685(1–2):179–86

Prenatal exposure to morphine alters brain mu opioid receptor characteristics in rats. Rimanóczy A, et al. **Brain Res** 1995 Sep 4;690(2):245–8

Alterations of the thalamo–cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl–L–carnitine. Santarelli M, et al. **Brain Res** 1995 Nov 6;698(1–2):241–7

Effects of an every other day rapid kindling procedure in prenatally protein malnourished rats. Shultz PL, et al. **Brain Res** 1995 Jun 5;682(1–2):35–40

Long–term effects of prenatal stress and handling on metabolic parameters: relationship to corticosterone secretion response. Vallée M, et al. **Brain Res** 1996 Mar 18;712(2):287–92

Intrauterine cocaine exposure of rabbits: persistent elevation of GABA–immunoreactive neurons in anterior cingulate cortex but not visual cortex. Wang XH, et al. **Brain Res** 1995 Aug 14;689(1):32–46

Loss of neonatal hypoxia tolerance after prenatal nicotine exposure: implications for sudden infant death syndrome. Slotkin TA, et al. **Brain Res Bull** 1995;38(1):69–75

Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepinephrine release in male offspring. Jones AP, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):127–31

Long–term consequences of prenatal cocaine exposure on biogenic amines in the brains of mice: the role of sex. Miller MW, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):22–8

Age–related mu–, delta–and kappa–opioid ligands in respiratory–related brain regions of piglets: effect of prenatal cocaine. Zhang C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):188–93

Prenatal morphine exposure differentially alters expression of opioid peptides in striatum of newborns. Tempel A, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):227–32

Is perinatal picrotoxin anxiogenic? Silva MR, et al. **Braz J Med Biol Res** 1995 Jun;28(6):663–6

Safety of tetanus toxoid in pregnant women: a hospital–based case–control study of congenital anomalies. Silveira CM, et al. **Bull World Health Organ** 1995;73(5):605–8

Ethanol neurobehavioural teratogenesis and the role of L–glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209–23 (175 ref.)

Cigarette smoking during pregnancy. Stewart DE, et al. **Can J Psychiatry** 1995 Dec;40(10):603–7

Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Boyd J, et al. **Cancer** 1996 Feb 1;77(3):507–13

A case–control study of maternal risk factors for thyroid cancer in young women (California, United States). Paoff K, et al. **Cancer Causes Control** 1995 Sep;6(5):389–97

Effect of stage of development on frequency and pathogenesis of kidney tumors induced in Noble (Nb) rats exposed prenatally or neonatally to N–nitrosoethylurea. Diwan BA, et al. **Carcinogenesis** 1995 Sep;16(9):2023–8

Nonuniform alteration of dendritic development in the cerebral cortex following prenatal cocaine exposure. Jones L, et al. **Cereb Cortex** 1996 May–Jun;6(3):431–45

The developmental outcome of children born to heroin–dependent mothers, raised at home or adopted. Ornoy A, et al. **Child Abuse Negl** 1996 May;20(5):385–96

Prenatally drug–exposed children in out–of–home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan–Feb;75(1):19–34 (30 ref.)

Quantitative EEG characteristics of children exposed in utero to cocaine. Prichep LS, et al. **Clin Electroencephalogr** 1995 Jul;26(3):166–72

Developmental neurotoxicity to methamphetamines. Weissman AD, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):372–4

Time of onset of necrotizing enterocolitis in newborn infants with known prenatal cocaine exposure. Lopez SL, et al. **Clin Pediatr (Phila)** 1995 Aug;34(8):424–9

Perinatal astemizole exposure in the rat throughout gestation: long–term behavioral and anatomic effects associated with reproduction. Almeida RG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jun;114(2):123–7

Pre– and postnatal effects of chronic maternal hypoxia on substance–P immunoreactivity in rabbit brainstem regions. Gingras JL, et al. **Dev Neurosci** 1995;17(5–6):350–6

Prenatal stress alters immune function in the offspring of rats. Klein SL, et al. **Dev Psychobiol** 1995 Sep;28(6):321–36

Effects of altered olfactory experiences on the development of infant rats' responses to odors. Terry LM, et al. **Dev Psychobiol** 1996 May;29(4):353–77

Cardiac and respiratory patterns during sleep in cocaine–exposed neonates. Regalado MG, et al. **Early Hum Dev** 1996 Mar 22;44(3):187–200

Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring. Migliaccio S, et al. **Endocrinology** 1996 May;137(5):2118–25

Fertility in mice after prenatal exposure to benzo[a]pyrene and inorganic lead. Kristensen P, et al. **Environ Health Perspect** 1995 Jun;103(6):588–90

Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Sharpe RM, et al. **Environ Health Perspect** 1995 Dec; 103(12):1136–43

The risk of childhood cancer from intrauterine and preconceptional exposure to ionizing radiation. Wakeford R. **Environ Health Perspect** 1995 Nov;103(11):1018–25 (84 ref.)

Perinatal risk factors and schizophrenia: selective review and methodological concerns. McNeil TF. **Epidemiol Rev** 1995; 17(1):107–12 (46 ref.)

Perinatal factors and risk of breast cancer. Sanderson M, et al. **Epidemiology** 1996 Jan;7(1):34–7

The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age. Windham GC, et al. **Epidemiology** 1995 Nov;6(6):591–7

Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds. Phillips NK, et al. **Epilepsia** 1996 Oct;37(10):991–9

Comments on Takei et al.: Prenatal exposure to influenza epidemics and the risk of mental retardation [letter; comment] Bromet E. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):261–2; discussion 263–6. Comment on: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):255–9.

Comments on Takei et al.: Prenatal exposure to influenza epidemics and the risk of mental retardation [letter; comment] Crow TJ. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):260–1; discussion 263–6. Comment on: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):255–9.

Comments on Takei et al.: Prenatal exposure to influenza epidemics and the risk of mental retardation [letter; comment] Jablensky A. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):262–3; discussion 263–6. Comment on: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):255–9.

Prenatal exposure to influenza epidemics and risk of mental retardation [see comments] Takei N, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):255–9. Comment in: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):260–1; discussion 263–6. Comment in: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):261–2; discussion 263–6. Comment in: Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):262–3; discussion 263–6.

Underfeeding of rat mothers during the first two trimesters of gestation does not alter insulin action and insulin secretion in the progeny. Portha B, et al. **Eur J Endocrinol** 1995 Oct;133(4):475–82

Prenatal exposure to diethylstilbestrol and the mother–daughter relationship. Cahen F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):181–7

Timing of prenatal starvation in women and birth weight in their first and second born offspring: the Dutch Famine Birth Cohort study. Lumey LH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):23–30

Effects of gestational or neonatal treatment with alpha–difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry. Sparapani M, et al. **Exp Brain Res** 1996 Mar;108(3):433–40

Evaluation of the developmental neuroendocrine and reproductive toxicology of aluminium. Agarwal SK, et al. **Food Chem Toxicol** 1996 Jan;34(1):49–53

Effect of Spirulina maxima consumption on reproduction and peri– and postnatal development in rats. Salazar M, et al. **Food Chem Toxicol** 1996 Apr;34(4):353–9

Prenatal exposure of Balb/c mice to ochratoxin A: effects on the immune system in the offspring. Thuvander A, et al. **Food Chem Toxicol** 1996 Jun;34(6):547–54

Cataractogenesis in rats induced by in utero exposure to RG 12915, a 5–HT3 antagonist. Lerman SA, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):270–6

Assessment of offspring development and behavior following gestational exposure to inhaled methanol in the rat. Stanton ME, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):100–10

Effect of prenatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone level in adult rats. Pap E, et al. **Gen Pharmacol** 1995 Mar; 26(2):365–7

Effect of testosterone administration, pre– and postnatally, on the immune system of rats. Konstadoulakis MM, et al. **Horm Metab Res** 1995 Jun;27(6):275–8

Effect of prenatal undernutrition and phenobarbitone administration on discrimination learning and passive avoidance behaviour in rats. Jaiswal AK, et al. **Indian J Exp Biol** 1996 Feb;34(2):118–23

Rat fetal and postnatal development after treatment in utero with histamine H1 antagonists. Sturman G, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S74–5

Maternal and perinatal factors associated with non–Hodgkin's lymphoma among children. Adami J, et al. **Int J Cancer** 1996 Mar 15;65(6):774–7

Increased risk of cancer in the descendants of Syrian hamsters exposed prenatally to diethylnitrosamine (DEN). Mohr U, et al. **Int J Cancer** 1995 Sep 27;63(1):86–91

Prenatal alcohol exposure selectively suppresses cell–mediated but not humoral immune responsiveness. Gottesfeld Z, et al. **Int J Immunopharmacol** 1995 Mar; 17(3):247–54

Effect of chronic cadmium exposure on VEP and EEG spectral components. Yargicoglu P, et al. **Int J Neurosci** 1996 Apr;85(3–4):173–84

Long–term effects on tumour incidence and survival from 241Am exposure of the BALB/c mouse in utero and during adulthood. van den Heuvel R, et al. **Int J Radiat Biol** 1995 Dec;68(6):679–86

Apnea and vomiting in an infant due to cocaine exposure. Okoruwa E, et al. **Iowa Med** 1995 Nov;85(11):449–50

The effects of in utero diagnostic X–irradiation on the development of preschool–age children. Ornoy A, et al. **Isr J Med Sci** 1996 Feb;32(2):112–5

No confirmation of Geschwind's hypothesis of associations between reading disability, immune disorders, and motor preference in ADHD. Biederman J, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):545–52

Schizotypy and maternal exposure to influenza and to cold temperature: the Mauritius study. Venables PH. **J Abnorm Psychol** 1996 Feb;105(1):53–60

Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371–7 (50 ref.)

Smoking triggers cleft palate development [news] **J Am Dent Assoc** 1995 Sep;126(9):1212, 1214

Effects of prenatal androgenization and postnatal steroid treatment on growth hormone, insulin–like growth factor I and II, insulin, thyroxine, and triidothyronine concentrations in beef heifers. Aldrich SL, et al. **J Anim Sci** 1996 Feb;74(2):420–8

Parturition and periparturient reproductive and metabolic hormone concentrations in prenatally androgenized beef heifers. Aldrich SL, et al. **J Anim Sci** 1995 Dec; 73(12):3712–8

Acute prenatal androgen treatment increases birth weights and growth rates in lambs. Gill JW, et al. **J Anim Sci** 1995 Sep;73(9):2600–8

The effects of in utero exposure of lambs to a beta–adrenergic agonist on prenatal and postnatal muscle growth, carcass cutability, and meat tenderness. Shackelford SD, et al. **J Anim Sci** 1995 Oct;73(10):2986–93

Chronic prenatal cocaine retards maturation of state and of respiratory patterns in swine. Moss IR, et al. **J Appl Physiol** 1995 Aug;79(2):567–74

Effect of prenatal and postnatal exposure to lead on kidney function in male and female rats. Vyskocil A, et al. **J Appl Toxicol** 1995 Jul–Aug;15(4):327–8

Brief report: genetic, prenatal, and immunologic factors. Smalley SL, et al. **J Autism Dev Disord** 1996 Apr; 26(2):195–8 (16 ref.)

Self–reported allergy, infection, and autoimmune diseases among men and women exposed in utero to diethylstilbestrol. Baird DD, et al. **J Clin Epidemiol** 1996 Feb;49(2):263–6

Hematological variables in cord blood of neonates of smoking and nonsmoking mothers. Mercelina–Roumans PE, et al. **J Clin Epidemiol** 1996 Apr;49(4):449–54

Handedness and other laterality indices in women prenatally exposed to DES. Scheirs JG, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):725–30

Effects of third trimester fluoxetine exposure on the newborn. Goldstein DJ. **J Clin Psychopharmacol** 1995 Dec; 15(6):417–20

Influence of prenatal ethanol exposure on cholinergic development in the rat striatum. Heaton MB, et al. **J Comp Neurol** 1996 Jan 1;364(1):113–20

Influence of chronic prenatal ethanol on cholinergic neurons of the septohippocampal system. Swanson DJ, et al. **J Comp Neurol** 1996 Jan 1;364(1):104–12

Prenatal auditory experience directs species-typical perceptual responsiveness in bobwhite quail chicks (Colinus virginianus). McBride T, et al. **J Comp Psychol** 1995 Sep; 109(3):321–9

The developmental implications of prenatal and/or postnatal crack cocaine exposure in preschool children: a preliminary report. Bender SL, et al. **J Dev Behav Pediatr** 1995 Dec; 16(6):418–24; discussion 425–30

Is there an association between season of birth and reading disability? Flynn JM, et al. **J Dev Behav Pediatr** 1996 Feb; 17(1):22–6

Crack cocaine exposure in preschool children: focusing on the relevant issues. Walsh KK, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):107–8

Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603–6 (52 ref.)

Does peace prevent homosexuality? Schmidt G, et al. **J Homosex** 1995;28(3–4):269–75

Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. Shu XO, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):24–31

In-utero cocaine exposure and neonatal intestinal perforation: a case report. The' TG, et al. **J Natl Med Assoc** 1995 Dec; 87(12):889–91

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)

Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine [editorial; comment] Dottorini ME. **J Nucl Med** 1996 Apr;37(4):612–5 . Comment on: J Nucl Med 1996 Apr;37(4):606–12.

Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients [see comments] Schlumberger M, et al. **J Nucl Med** 1996 Apr;37(4):606–12. Comment in: J Nucl Med 1996 Apr;37(4):612–5.

Maternal protein restriction influences the programming of the rat hypothalamic-pituitary-adrenal axis. Langley-Evans SC, et al. **J Nutr** 1996 Jun:126(6):1578–85

Cleft palate, mortality and morbidity in infants of substance abusing mothers. Thomas DB. **J Paediatr Child Health** 1995 Oct;31(5):457–60

Increased blood pressure in neonates and infants whose mothers smoked during pregnancy. Beratis NG, et al. **J Pediatr** 1996 Jun;128(6):806–12

Favism in a female newborn infant whose mother ingested fava beans before delivery. Corchia C, et al. **J Pediatr** 1995 Nov;127(5):807–8 (8 ref.)

Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. Levy HL, et al. **J Pediatr** 1996 Jun; 128(6):770–5

Deficient hypoxia awakening response in infants of smoking mothers: possible relationship to sudden infant death syndrome. Lewis KW, et al. **J Pediatr** 1995 Nov; 127(5):691–9

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241–3 (23 ref.)

Case study of the home health management of a child with congenital anomalies associated with prenatal cocaine abuse. Johnson MO, et al. **J Pediatr Nurs** 1995 Dec; 10(6):375–82

Effect of maternal illicit drug use on the mortality of very low birth weight infants. Beeram MR, et al. **J Perinatol** 1995 Nov–Dec;15(6):456–60; quiz 461–2

Perinatal methadone exposure produces physical dependence and altered behavioral development in the rat. Kunko PM, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1344–51

The effects of chronic amphetamine treatment on prenatal ethanol-induced changes in dopamine receptor function: electrophysiological findings. Shen RY, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1054–60

Maternal exposure to influenza and risk of schizophrenia: a 22 year study from The Netherlands. Takei N, et al. **J Psychiatr Res** 1995 Nov–Dec;29(6):435–45

Long term effects of prenatal exposure to low level gamma rays on spontaneous circadian motor activity of male mice. Minamisawa T, et al. **J Radiat Res (Tokyo)** 1995 Sep; 36(3):179–84

Effects of prenatal exposure to low-dose beta radiation from tritiated water on the neurobehavior of mice. Wang B, et al. **J Radiat Res (Tokyo)** 1995 Jun;36(2):103–11

Association of disproportionate growth of fetal rats in late gestation with raised systolic blood pressure in later life. Langley-Evans SC, et al. **J Reprod Fertil** 1996 Mar; 106(2):307–12

Preterm betamethasone treatment of fetal sheep: outcome after term delivery. Jobe AH, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):250–8

Morphometry on proximal tubule of the kidney in rat pups from uninephrectomized mothers. Okada T, et al. **J Vet Med Sci** 1995 Jun;57(3):415–7

In utero exposure to phenobarbital and intelligence deficits in adult men. Reinisch JM, et al. **JAMA** 1995 Nov 15; 274(19):1518–25

Premenopausal breast cancer after in-utero exposure to stilboestrol [letter] Huckell C, et al. **Lancet** 1996 Aug 3; 348(9023):331

Effects of diazepam and cyclohexyladenosine on open-field behavior in rats perinatally exposed to caffeine. Fisher CE, et al. **Life Sci** 1996;58(8):701–9

Effects of in utero exposure to 4.7 T MR imaging conditions on fetal growth and testicular development in the mouse. Carnes KI, et al. **Magn Reson Imaging** 1996;14(3):263–74

Carbon monoxide--does fetal exposure cause sudden infant death syndrome? Hutter CD, et al. **Med Hypotheses** 1996 Jan;46(1):1–4

Lead mobilisation during pregnancy [letter] Gulson BL, et al. **Med J Aust** 1995 Oct 16;163(8):447

Effects of prenatal cocaine exposure in the photoreceptor cells of the rat retina. Silva-Araújo A, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):77–86

Effects of prenatal cocaine exposure in the retinal ganglion cell layer of the rat. A morphometric analysis. Silva-Araújo A, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):87–97

Interactive effects of prenatal cocaine and nicotine exposure on maternal toxicity, postnatal development and behavior in the rat. Sobrian SK, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):121–43

Prenatal cocaine exposure revealed minimal postnatal changes in rat striatal dopamine D2 receptor sites and mRNA levels in the offspring. Stadlin A, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):67–76

Effects of prenatal cocaine exposure in the prefrontal cortex of the rat. A morphometric evaluation. Xavier MR, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):99–110

Intellectual impairment in children exposed to polychlorinated biphenyls in utero. Jacobsen JL, et al. **N Engl J Med** 1996 Sep 12;335(11):783–9

The effect of ethanol on HSP70 in cultured rat glial cells and in brain areas of rat pups exposed to ethanol in utero. Holownia A, et al. **Neurochem Res** 1995 Jul;20(7):875–8

Prenatal exposure to cocaine selectively disrupts motor responding to D-amphetamine in young and mature rabbits. Simansky KJ, et al. **Neuropharmacology** 1996 Jan; 35(1):71–8

Maternal exposure to polychlorinated biphenyls inhibits long-term potentiation in the visual cortex of adult rats. Altmann L, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):53–6

Prenatal corticosterone increases spontaneous and d-amphetamine induced locomotor activity and brain dopamine metabolism in prepubertal male and female rats. Diaz R, et al. **Neuroscience** 1995 May;66(2):467–73

Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats. Acuff-Smith KD, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):199–215

Magnetic resonance imaging and spectroscopy in fetal ethanol exposed Macaca nemestrina. Astley SJ, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):523–30

Effects of prenatal ethanol exposure on dopamine systems in C57BL/6J mice. Boggan WO, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):41–8

Prenatal ethanol exposure in rats: long-lasting effects on learning. Clausing P, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):545–52

Prenatal coexposure to metallic mercury vapour and methylmercury produce interactive behavioural changes in adult rats. Fredriksson A, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):129–34

Effects of prenatal maternal ethanol on male offspring progressive-ratio performance and response to amphetamine. Gentry GD, et al. **Neurotoxicol Teratol** 1995 Nov–Dec;17(6):673–7

Effects of prenatal cocaine exposure on haloperidol-induced increases in prolactin release and dopamine turnover in weanling, periadolescent, and adult offspring. Goodwin GA, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):507–14

Validation of automated behavioral test systems. Henck JW, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):189–97

Prenatal dexamethasone or stress but not ACTH or corticosterone alter sexual behavior in male rats. Holson RR, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):393–401

Development of infants born to cocaine-abusing women: biologic/maternal influences. Howard J, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):403–11

Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat. Hutchings DE, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):419–23

Prenatal cocaine exposure affects social behavior in Sprague-Dawley rats. Johns JM, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):569–76

The effects of lead on otoacoustic emissions and auditory evoked potentials in monkeys. Lasky RE, et al. **Neurotoxicol Teratol** 1995 Nov–Dec;17(6):633–44

The effect of chronic cocaine exposure during pregnancy on maternal and infant outcomes in the rhesus monkey. Morris P, et al. **Neurotoxicol Teratol** 1996 Mar–Apr; 18(2):147–54

The effect of chronic cocaine exposure during pregnancy on the acquisition of operant behaviors by rhesus monkey offspring. Morris P, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):155–66

Effects of prenatal ethanol exposure and early experience on home-cage and open-field activity in mice. Mothes HK, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):59–65

In utero lead exposure in squirrel monkeys: motor effects seen with schedule-controlled behavior. Newland MC, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):33–40

Medium and long-term behavioral effects in mice of extended gestational exposure to ozone. Petruzzi S, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):463–70

Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Richardson GA, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):479–87

Neurotoxicity of sodium fluoride in rats [letter] Ross JF, et al. **Neurotoxicol Teratol** 1995 Nov–Dec;17(6):685–8

Effects of prenatal cocaine exposure on postnatal growth patterns of male Wistar rats. Silva MC, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):471–7

The effects of cocaine exposure prior to and during pregnancy in rats fed low or adequate protein diets. Tonkiss J, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):593–600

Prenatal cocaine but not prenatal malnutrition affects foster mother-pup interactions in rats. Tonkiss J, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):601–8

Prenatal exposure to sodium phenytoin in rats induces complex maze learning deficits comparable to those induced by exposure to phenytoin acid at half the dose. Vorhees CV, et al. **Neurotoxicol Teratol** 1995 Nov–Dec; 17(6):627–32

Prenatal haloperidol reduces the number of active midbrain dopamine neurons in rat offspring. Zhang J, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):49–57

Biological Mechanisms and Perinatal Exposure to Abused Drugs. Proceedings of a meeting. May 25–26, 1994. **NIDA Res Monogr** 1995;158:1–236

Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)

Smoking in pregnancy as a risk factor for long-term mortality in the offspring. Hofvendahl EA. **Paediatr Perinat Epidemiol** 1995 Oct;9(4):381–90

Children's passive and prenatal exposure to cigarette smoke. Byrd RS, et al. **Pediatr Ann** 1995 Dec;24(12):640–2, 644–5 (37 ref.)

Transient dystonia of infancy, a result of intrauterine cocaine exposure? Beltran RS, et al. **Pediatr Neurol** 1995 May; 12(4):354–6

Immunologic effects of background prenatal and postnatal exposure to dioxins and polychlorinated biphenyls in Dutch infants. Weisglas-Kuperus N, et al. **Pediatr Res** 1995 Sep; 38(3):404–10

Neurological correlates of fetal cocaine exposure: transient hypertonia of infancy and early childhood. Chiriboga CA, et al. **Pediatrics** 1995 Dec;96(6):1070–7

Effects of polychlorinated biphenyl/dioxin exposure and feeding type on infants' mental and psychomotor development. Koopman-Esseboom C, et al. **Pediatrics** 1996 May;97(5):700–6

Effects of in utero substance exposure on infant neurobehavior. Napiorkowski B, et al. **Pediatrics** 1996 Jul; 98(1):71–5

Methylene blue-induced phototoxicity: an unrecognized complication. Porat R, et al. **Pediatrics** 1996 May; 97(5):717–21 (19 ref.)

Cocaine-exposed preterm neonates show behavioral and hormonal differences. Scafidi FA, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):851–5

Antenatal phenobarbital therapy and neonatal outcome. II: Neurodevelopmental outcome at 36 months. Shankaran S, et al. **Pediatrics** 1996 May;97(5):649–52

Late dose-response effects of prenatal cocaine exposure on newborn neurobehavioral performance. Tronick EZ, et al. **Pediatrics** 1996 Jul;98(1):76–83

Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Van Marter LJ, et al. **Pediatrics** 1996 May;97(5):658–63

Neurochemical and neurobehavioral effects of repeated gestational exposure to chlorpyrifos in maternal and developing rats. Chanda SM, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):771–6

Prenatal naltrexone facilitates male sexual behavior in the rat. Cohen E, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):183–8

Elicitation and modification of the rabbit's nictitating membrane reflex following prenatal exposure to cocaine. Romano AG, et al. **Pharmacol Biochem Behav** 1996 Apr; 53(4):857–62

Intrauterine exposure to cocaine produces a modality-specific acceleration of classical conditioning in adult rabbits. Romano AG, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):415–20

Effects of dietary gamma-linolenic acid and prenatal ethanol on mouse brain and behavior. Wainwright PE, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):843–52

Play behavior and stress responsivity in periadolescent offspring exposed prenatally to cocaine. Wood RD, et al.

Pharmacol Biochem Behav 1995 Oct;52(2):367–74

Maternal ingestion of ortho–aminoacetophenone during gestation affects intake by offspring. Nolte DL, et al. **Physiol Behav** 1995 Nov;58(5):925–8

Prenatal cocaine produces dose–dependent suppression of prolactin and growth hormone in neonatal rats. Smith RF, et al. **Physiol Behav** 1995 Sep;58(3):619–23

Effects of prenatal ultrasound exposure on adult offspring behavior in the Wistar rat. Jensh RP, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):171–9

Prenatal lead exposure and the pregnancy outcome. A case–control study in southern Poland. Pietrzyk JJ, et al. **Przegl Lek** 1996;53(4):342–7

Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. Trautman PD, et al. **Psychoneuroendocrinology** 1995; 20(4):439–49

Irreversible impairment of active avoidance behavior in rats prenatally exposed to mild concentrations of carbon monoxide. De Salvia MA, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):66–71

Effects of prenatal diazepam on two–way avoidance behavior, swimming navigation and brain levels of benzodiazepine–like molecules in male Roman high– and low–avoidance rats. Driscoll P, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):51–7

A comparison of behavioural effects of prenatally administered oxazepam in mice exposed to open–fields in the laboratory and the real world. Fiore M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):72–7

Behavioural consequences of maternal exposure to natural cannabinoids in rats. Navarro M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):1–14 (110 ref.)

Limited changes of mouse maternal care after prenatal oxazepam: dissociation from pup–related stimulus perception. Petruzzi S, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):58–65

Alterations in hippocampal hemicholinium–3 binding and related behavioural and biochemical changes after prenatal phenobarbitone exposure. Zahalka EH, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):44–50

Sustained alterations in postnatal respiratory function following sub–optimal intrauterine conditions. Harding R. **Reprod Fertil Dev** 1995;7(3):431–41 (67 ref.)

Postnatal consequences of chronic intrauterine compromise. Henderson–Smart DJ. **Reprod Fertil Dev** 1995;7(3):559–65 (44 ref.)

Neonatal mouse hip joint and hindlimb anomalies induced by prenatal exposure to Ara–C. Chiba K, et al. **Reprod Toxicol** 1996 May–Jun;10(3):215–9

Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. Kato I, et al. **Reprod Toxicol** 1996 May–Jun;10(3):209–14

Effects of postnatal exposure to cocaine on the development of the rat corpus callosum. Ojima K, et al. **Reprod Toxicol** 1996 May–Jun;10(3):221–5

Reanalysis of dose–response data from the Iraqi methylmercury poisoning episode. Crump K, et al. **Risk Anal** 1995 Aug;15(4):523–32

Prenatal development of monozygotic twins and concordance for schizophrenia. Davis JO, et al. **Schizophr Bull** 1995;21(3):357–66

Time trends in schizophrenia: changes in obstetric risk factors with industrialization. Warner R. **Schizophr Bull** 1995; 21(3):483–500 (160 ref.)

Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Cotter D, et al. **Schizophr Res** 1995 Aug 15;16(3):233–41

Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

Alzheimer's disease: preliminary study of spatial distribution at birth place. Jean H, et al. **Soc Sci Med** 1996 Mar; 42(6):871–8

Effects of prenatal alcohol exposure on the postnatal morphology of the rat oculomotor nucleus. Burrows RC, et al. **Teratology** 1995 May;51(5):318–28

Autonomic and behavioral thermoregulation in golden hamsters exposed perinatally to dioxin. Gordon CJ, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):120–5

Developmental exposure to ozone induces subtle changes in swimming navigation of adult mice. Dell'Omo G, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):91–9

Variations in peroxisomal catalase of neonatal rat hepatocyte subpopulations. Effect of pre– and postnatal exposure to alcohol. Tolosa D, et al. **Virchows Arch** 1995;427(3):309–15

[Assessment of risk factors and prevention of psychosis (letter)] Hadders–Algra M. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1740–1 **(Dut)**

[Reproductive mishaps and infertility in women exposed to DES in utero. A retrospective study of 258 exposed women and 50 unexposed siblings] Cabau A, et al. **Contracept Fertil Sex** 1996 Apr;24(4):253–8 **(Fre)**

[Childhood psychoses and organic pathology: results of a study of 144 cases] Rohmer JG, et al. **Encephale** 1995 Jul–Aug;21(4):307–16 (Eng. Abstr.) **(Fre)**

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Fetal environment and coronary ischemia risk: review of the literature with particular reference to syndrome X] Lehingue Y. **Rev Epidemiol Sante Publique** 1996 Jun; 44(3):262–77 (57 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy after transposition and repositioning of the ovaries in a patient with clear–cell adenocarcinoma] Gerbaulet A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):534–8 (Eng. Abstr.) **(Fre)**

[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**

[Comment on F. Stoz et al.: is general amalgam prohibition justified? (letter; comment)] Drasch G. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):176–7. Comment on: Z Geburtshilfe Neonatol 1995 Jul–Aug;199(4):138–41. **(Ger)**

[4 1/2 years later: Mannheim risk children of preschool age] Laucht M, et al. **Z Kinder Jugenpsychiatr** 1996 Jun; 24(2):67–81 (Eng. Abstr.) **(Ger)**

[Tobacco smoking––a risk factor for intrauterine growth retardation, preterm delivery and low birth weight] Kalinka J, et al. **Ginekol Pol** 1996 Feb;67(2):75–81 (Eng. Abstr.) **(Pol)**

[Effect of smoking in the families of newborn infants on levels of immunoglobulin E in cord blood] Oldak E. **Pediatr Pol** 1995 Sep;70(9):723–6 (Eng. Abstr.) **(Pol)**

[Fetal alcohol syndrome: neurobehavioral effects of prenatal alcohol exposure] Tyra TL. **Psychiatr Pol** 1995 Sep–Oct; 29(5):697–708 (Eng. Abstr.) **(Pol)**

[Change in plasma morphine level and pain sensitivity in prenatally morphinized rats] Chobanov NG, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):273–5 **(Rus)**

[Piracetam as a corrector of long–term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy] Trofimov SS, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):435–7 **(Rus)**

[The transplacental transport and effect of morphine administered in the prenatal period on its level in adult rats] Bolko SS, et al. **Eksp Klin Farmakol** 1995 Nov–Dec; 58(6):42–4 (Eng. Abstr.) **(Rus)**

[The correction with nooglutil and L–pyroglutamyl–D–alanine amide of cognitive disorders in rats due to intrauterine hypoxia] Trofimov SS, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):10–3 (Eng. Abstr.) **(Rus)**

[Population profile of brain asymmetry in rats after intra–amniotic administration of vasopressin] Klement'ev BI, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):104–9 (Eng. Abstr.) **(Rus)**

[Assessment of radioactive irradiation of Kamensk–Uralski inhabitants and its impact on their descendants' health] Riabova NV, et al. **Gig Sanit** 1996 Mar–Apr;(2):28–31 (Eng. Abstr.) **(Rus)**

[The characteristics of the structural development of the thymus and spleen in the progeny of white rats exposed to pyrogenal action during pregnancy] Bandazhevskil IuI, et al. **Morfologiia** 1994 Apr–Jun;106(4–6):9–17 (Eng. Abstr.) **(Rus)**

[The consequences for the first–generation progeny of Wistar rats of the irradiation of both parents with a background of mexamine use] Nefëdov IIu, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):773–7 (Eng. Abstr.) **(Rus)**

[The functional–structural characteristics of the neurons in cultured explants of the cerebral cortex of rats subjected to immobilization–cold exposure in the prenatal developmental period] Gusaruk LR, et al. **Tsitologiia** 1995; 37(7):579–85 (Eng. Abstr.) **(Rus)**

[The cytogenetic reaction of the lymphocytes to in–vitro irradiation in children born to patients after antitumor radio– and chemotherapy] Vorobtsova IE, et al. **Tsitologiia** 1995;37(5–6):449–57 (Eng. Abstr.) **(Rus)**

[The behavioral development of rats with prenatal hypoinsulinemia] Shvyrkova NA, et al. **Zh Vyssh Nerv Deist Im I P Pavlova** 1995 Nov–Dec; 45(6):1190–7 (Eng. Abstr.) **(Rus)**

[Effects of ethanol on thyroid gland development] Matavulj M, et al. **Med Pregl** 1994;47(9–10):314–9 (Eng. Abstr.) **(Scr)**

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**

PRENEOPLASTIC CONDITIONS see **PRECANCEROUS CONDITIONS**

PRENIDATION PHASE see **PREIMPLANTATION PHASE**

PRENYLAMINE

PHARMACOLOGY

[Effects of calcium channel blockers on electrical and mechanical responses of rat phrenic nerve–diaphragm preparations] Zupko I, et al. **Acta Pharm Hung** 1995 Jul; 65(4):127–31 (Eng. Abstr.) **(Hun)**

PRENYLTRANSFERASE see **DIMETHYLALLYLTRANSFERASE**

PREOPERATIVE CARE

Statistical aspects in studies of preoperative fluid intake and gastric content. Søreide E, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):738–43

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Outcome analysis of preoperative embolization with N–butyl cyanoacrylate in cerebral arteriovenous malformations. DeMeritt JS, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1801–7

Preoperative grading of glioma malignancy with thallium–201 single–photon emission CT: comparison with conventional CT. Källén K, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):925–32

Dipyridamole technetium 99m sestamibi myocardial tomography for preoperative cardiac risk stratification before major or minor nonvascular surgery. Stratmann HG, et al. **Am Heart J** 1996 Sep;132(3):536–41

Is ERCP necessary for symptomatic gallbladder stone patients before laparoscopic cholecystectomy? Changchien CS, et al. **Am J Gastroenterol** 1995 Dec;90(12):2124–7

Cyclosporin use in the precolectomy chronic ulcerative colitis patient: a community experience and its relationship to prospective and controlled clinical trials.Pacific Northwest Gastroenterology Society [see comments] Kozarek R, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2093–6. Comment in: Am J Gastroenterol 1995 Dec;90(12):2093–6.

Selective endoscopic retrograde cholangiography and preoperative bile duct stone removal in patients scheduled for laparoscopic cholecystectomy: a prospective study. Santucci L, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1326–30

A convenient method for preoperative templating. Jay VP, et al. **Am J Orthop** 1995 Oct;24(10):792

Physician survey on the care of children with tracheotomies. Woolley AL, et al. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):50–3

Conservation of blood during cardiovascular surgery. Cooley DA. **Am J Surg** 1995 Dec;170(6A Suppl):53S–59S

Preoperative saline loading improves outcome after elective, noncardiac surgical procedures. Garrison RN, et al. **Am Surg** 1996 Mar;62(3):223–31

Preoperative thyroid ultrasonography and fine–needle aspiration cytology in ectopic thyroid. Wang CY, et al. **Am Surg** 1995 Dec;61(12):1029–31

Precholecystectomy esophagogastroduodenoscopy: is it of value? Yavorski CC, et al. **Am Surg** 1995 Dec;61(12):1032–4

Should we keep the anaesthetic room? [letter; comment] [see comments] Claxton AR. **Anaesthesia** 1995 Dec;50(12):1095 . Comment on: Anaesthesia 1992 Dec;47(12):1021–2. Comment in: Anaesthesia 1996 May;51(5):509.

Pre–operative hypertension; do we postpone surgery too readily? [letter] Galizia EJ. **Anaesthesia** 1996 May; 51(5):500–1

Acute exacerbation of depression after discontinuation of monoamine oxidase inhibitor prior to cardiac surgery. Abdi S, et al. **Anesth Analg** 1996 Sep;83(3):656–7

The cost of preoperative pregnancy testing [letter; comment] Battit GE. **Anesth Analg** 1996 Aug;83(2):439. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

Preoperative pregnancy testing [letter; comment] Cartabuke RS. **Anesth Analg** 1996 Aug;83(2):436. Comment on: Anesth Analg 1996 Jan;82(1):1–3.

Preoperative pregnancy testing in adolescents [letter; comment] Malviya S, et al. **Anesth Analg** 1996 Mar; 82(3):673. Comment on: Anesth Analg 1995 Sep;81(3):661.

Preoperative pregnancy testing revisited [letter; comment] Mesrobian JR. **Anesth Analg** 1996 Aug;83(2):440–1. Comment on: Anesth Analg 1996 Jan;82(1):1–3.

The Amsterdam Preoperative Anxiety and Information Scale (APAIS) [see comments] Moerman N, et al. **Anesth Analg** 1996 Mar;82(3):445–51. Comment in: Anesth Analg 1996 Mar;82(3):443–4.

How much do they really want to know? Preoperative patient interviews and the anesthesiologist [editorial; comment] Roizen MF, et al. **Anesth Analg** 1996 Mar; 82(3):443–4. Comment on: Anesth Analg 1996 Mar;82(3):445–51.

Preoperative pregnancy testing: "justice and testing for all" [letter; comment] Twersky RS, et al. **Anesth Analg** 1996 Aug;83(2):438–9. Comment on: Anesth Analg 1996 Jan;82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

Video as a patient teaching tool: does it add to the preoperative anesthetic visit? Zvara DA, et al. **Anesth Analg** 1996 May;82(5):1065–8

Development and effectiveness of an anesthesia preoperative evaluation clinic in a teaching hospital [see comments] Fischer SP. **Anesthesiology** 1996 Jul;85(1):196–206. Comment in: Anesthesiology 1996 Jul;85(1):1–3.

Postoperative management strategies may obviate the need for most preoperative cardiac testing [letter] Rosenfeld BA, et al. **Anesthesiology** 1996 May;84(5):1266–8

Echocardiography for assessing cardiac risk in patients having noncardiac surgery. Study of Perioperative Ischemia Research Group. Halm EA, et al.

Ann Intern Med 1996 Sep 15;125(6):433–41

Medical audit: the role of an orthopaedic preoperative clinic. West R, et al. **Ann R Coll Surg Engl** 1995 May;77(3 Suppl):134–5

Preoperative chemoradiotherapy for rectal cancer [letter; comment] Hoffman JP. **Ann Surg** 1996 Jul;224(1):109–10. Comment on: Ann Surg 1995 Jun;221(6):778–86; discussion 786–7.

Pre–operative management for surgery of pheochromocytoma. Májek M, et al. **Ann Urol (Paris)** 1996; 30(1):20–4

Generalizability of the Preoperative Self–Efficacy Scale. Oetker–Black SL. **Appl Nurs Res** 1996 Feb;9(1):40–4

Variations in preoperative medical testing in healthy cataract surgery patients [editorial; comment] Obstbaum SA. **Arch Ophthalmol** 1995 Oct;113(10):1241–2. Comment on: Arch Ophthalmol 1995 Oct;113(10):1248–56.

Preoperative vascular imaging for the fibular osteocutaneous flap. Carroll WR, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):708–12

The clinical usefulness of the preoperative bleeding time. Gewirtz AS, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):353–6

Preoperative "chemoradiation" for stages II and III rectal carcinoma. Stryker SJ, et al. **Arch Surg** 1996 May; 131(5):514–8; discussion 518–9

Rheological properties of commonly used plasma substitutes during preoperative normovolaemic acute haemodilution. Freyburger G, et al. **Br J Anaesth** 1996 Apr;76(4):519–25

Preoxygenation—the importance of a good face mask seal [see comments] McGowan P, et al. **Br J Anaesth** 1995 Dec; 75(6):777–8. Comment in: Br J Anaesth 1996 May;76(5):748.

Preoperative fasting for paediatric anaesthesia [letter; comment] Stack CG, et al. **Br J Anaesth** 1995 Sep;75(3):375 . Comment on: Br J Anaesth 1995 Mar;74(3):349.

Perioperative changes in alpha 1–acid glycoprotein concentrations [letter; comment] Tucker GT. **Br J Anaesth** 1996 Jul;77(1):130. Comment on: Br J Anaesth 1996 Mar;76(3):365–8.

A 55–year–old man with chronic liver disease and coagulation abnormalities. Anderson C. **Cleve Clin J Med** 1995 Nov–Dec;62(6):372–3

The preoperative bleeding time test: assessing its clinical usefulness. Gewirtz AS, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):379–82 (41 ref.)

Perioperative care of the elderly patient: special considerations. Miller DL. **Cleve Clin J Med** 1995 Nov–Dec;62(6):383–90

Use of preoperative autologous blood donations and erythropoietin for treatment of giant cell tumor of the ischium. Matsumoto K, et al. **Clin Orthop** 1996 May; (326):246–9

Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76–96 (89 ref.)

Preoperative assessment of the patient with cardiac disease. Mangano DT. **Curr Opin Cardiol** 1995 Sep;10(5):530–42 (121 ref.)

Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Coley CM, et al. **Curr Probl Cardiol** 1996 May;21(5):289–382 (325 ref.)

Endorectal ultrasound of T3 and T4 rectal cancers after preoperative chemoradiation. Williamson PR, et al. **Dis Colon Rectum** 1996 Jan;39(1):45–9

Surgical management of patients with severe anaemia due to acute blood loss: a case for withholding perioperative blood transfusion. Elechi EN, et al. **East Afr Med J** 1995 Jun;72(6):343–4

Preoperative ERCP in the management of common bile duct stones before laparoscopic cholecystectomy. Kum CK, et al. **Eur J Surg** 1996 Mar;162(3):205–10

The impact of preoperative gonadotropin–releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Muzii L, et al. **Fertil Steril** 1996 Jun; 65(6):1235–7

Preoperative preparation prior to colorectal surgery [letter] Wexner SD. **Gastrointest Endosc** 1996 May;43(5):530–1

Cell biological evaluation of biliary drainage prior to hepatectomy in obstructive jaundice. Ido M, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):308–16

Preoperative biliary drainage in obstructive jaundice. Kawarada Y, et al. **Hepatogastroenterology** 1995 Jul–Aug; 42(4):300–7

Detection of neopterin, interleukin–6 and acute–phase proteins as parameters of potential monocyte activation in preoperative patients. Haupt W, et al. **Infection** 1995 Sep–Oct;23(5):263–6

Computerization of the preoperative anesthesia interview. Vitkun SA, et al. **Int J Clin Monit Comput** 1995 May; 12(2):71–6

What are the risks of cystectomy and the advances in perioperative care? Montie JE, et al. **Int J Urol** 1995 Jun; 2 Suppl 2:89–104 (78 ref.)

Patient's evaluation and recall of the preoperative anaesthetic visit. Ali S, et al. **Ir Med J** 1996 Mar–Apr;89(2):74–5

Is there a need for diagnostic upper gastrointestinal endoscopy before cholecystectomy? Niv Y, et al. **Isr J Med Sci** 1995 Sep;31(9):536–9

Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Eagle KA, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):910–48

Phase I–II randomized study on prehepatectomy recombinant interleukin–2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. Elias D, et al. **J Am Coll Surg** 1995 Oct;181(4):303–10

Preoperative geriatric assessment [letter; comment] Cefalu CA. **J Am Geriatr Soc** 1996 Mar;44(3):333. Comment on: J Am Geriatr Soc 1995 Jul;43(7):811–21.

Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report. Kim SB, et al. **J Korean Med Sci** 1995 Apr;10(2):111–20

The utility of pre–operative abdominal computerized tomography scanning in colorectal surgery. Isbister WH, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):232–4

Outpatient echocardiography as a predictor of perioperative cardiac morbidity after peripheral vascular surgical procedures. Ouriel K, et al. **J Vasc Surg** 1995 Dec; 22(6):671–7; discussion 678–9

Preoperative cardiac evaluation and perioperative monitoring for noncardiac vascular surgery [letter; comment] Ramsay J, et al. **JAMA** 1995 Dec 6;274(21):1671; discussion 1672 . Comment on: JAMA 1995 Jun 28;273(24):1919–25.

Value of preoperative pregnancy test in risk management [letter] Gazvani MR, et al. **Lancet** 1996 May 4; 347(9010):1271

Value of preoperative pregnancy test in risk management [letter] Wagman H. **Lancet** 1996 Jun 15;347(9016):1695–6

Effect of Doppler echocardiography on utilization of hemodynamic cardiac catheterization in the preoperative evaluation of aortic stenosis [see comments] Roger VL, et al. **Mayo Clin Proc** 1996 Feb;71(2):141–9. Comment in: Mayo Clin Proc 1996 Jul;71(7):721.

Preoperative assessment and postoperative management of the elderly surgical patient [see comments] Finucane P, et al. **Med J Aust** 1995 Sep 18;163(6):328–30. Comment in: Med J Aust 1996 Mar 18;164(6):383–4.

Preoperative assessment of patients with known or suspected coronary disease. Mangano DT, et al. **N Engl J Med** 1995 Dec 28;333(26):1750–6 (55 ref.)

Clinical evaluation and noninvasive electroencephalography. Preoperative evaluation. Cascino GD. **Neuroimaging Clin N Am** 1995 Nov;5(4):547–58 (58 ref.)

Preoperative investigations. Hannallah RS. **Paediatr Anaesth** 1995;5(5):325–9 (17 ref.)

The preoperative management of the child with a heart murmur. McEwan AI, et al. **Paediatr Anaesth** 1995; 5(3):151–6 (28 ref.)

Surgically significant nutritional supplements. Petry JJ. **Plast Reconstr Surg** 1996 Jan;97(1):233–40 (70 ref.)

Preoperative cardiac evaluation. Assessing risk before noncardiac surgery. Almany SL, et al. **Postgrad Med** 1995 Oct;98(4):171–4, 180–2 (12 ref.)

Preoperative estimate of extent of disease in T1c: how well can we predict? Austenfeld MS. **Semin Urol Oncol** 1995 Aug;13(3):176–80 (42 ref.)

Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double–blind randomized study. Heiss MM, et al. **Surgery** 1996 May;119(5):523–7

Role of preoperative iodocholesterol scintiscanning in patients undergoing adrenalectomy for Cushing's syndrome. Yu KC, et al. **Surgery** 1995 Dec;118(6):981–6; discussion 986–7

Correct preoperative localization: does it permit a change in operative strategy for primary hyperparathyroidism? Zmora O, et al. **Surgery** 1995 Dec;118(6):932–5

Soluble fibrin in plasma before and after surgery for benign and malignant colorectal disease. Iversen LH, et al. **Thromb Res** 1995 Sep 15;79(5–6):471–81

Consensus conference on autologous transfusion. Preoperative autologous donation. Thomas MJ, et al. **Transfusion** 1996 Jul;36(7):633–9 (94 ref.)

The necessity of voiding cystourethrogram in the pretransplant urologic evaluation. Shandera KC, et al. **Urology** 1996 Feb;47(2):198–200

Pre–operative autologous blood donations. A five–year experience in Trinidad and Tobago. Charles W, et al. **West Indian Med J** 1995 Sep;44(3):91–2

[Blood autotransfusion in vascular surgery (predeposited blood)] Georgiev G, et al. **Khirurgiia (Sofiia)** 1995; 48(1):97–102 (Eng. Abstr.) **(Bul)**

[Preoperative drainage of the biliary tract in patients with obstructive jaundice] Válek V, et al. **Rozhl Chir** 1995 Aug; 74(5):235–8 (Eng. Abstr.) **(Cze)**

[Preoperative internal medicine consultation. I. General aspects and management in diabetes mellitus and obstructive lung disease (letter; comment)] Jaspers CA, et al. **Ned Tijdschr Geneeskd** 1995 Sep 2;139(35):1801. Comment on: Ned Tijdschr Geneeskd 1995 May 20;139(20):1019–23. **(Dut)**

[Preoperative evaluation of coronary circulation] Demeure D, et al. **Ann Fr Anesth Reanim** 1996;15(3):284–94 (Eng. Abstr.) **(Fre)**

[When, in which patients and for what surgical procedures should programmed autologous transfusion be considered? Which quantitative benefit should be expected?] Laxenaire MC, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:32–8 **(Fre)**

[Perioperative artificial nutrition programmed for the adult surgical patient. Saint–Mandé, December 16, 1994: The Francophone Society of Enteral and Parenteral Nutrition and the French Society of Anesthesia and Resuscitation] **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):310–9 (0 ref.) **(Fre)**

[Coronary assessment and surgery for aortic aneurysm: a pragmatic attitude] Watelet J, et al. **J Mal Vasc** 1996;21 Suppl A:1–9 (Eng. Abstr.) **(Fre)**

[Preoperative fasting and prevention of aspiration from the legal medicine viewpoint] Püschel K. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):248–50 **(Ger)**

[Conventional and new measures for prevention of aspiration] Roewer N. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):257–60 **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

[Dental treatment before radiotherapy of carcinoma of the mouth floor] Weischer T, et al. **Fortschr Kiefer Gesichtschir** 1995;40:170–2 (Eng. Abstr.) **(Ger)**

[Effect of orthograde intestinal irrigation with Prepacol and polyethyleneglycol solution on duration of postoperative ileus after colorectal resections] Gründel K, et al. **Langenbecks Arch Chir** 1996;381(3):160–4 (Eng. Abstr.) **(Ger)**

[Perioperative use of noninvasive ventilation] Karg O, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:38–40 (Eng. Abstr.) **(Ger)**

[An absent correlation between antioxidant blood concentrations and the remission response of preoperatively treated breast carcinomas] Hartmann A, et al. **Strahlenther Onkol** 1996 Aug;172(8):434–8 (Eng. Abstr.) **(Ger)**

[Preoperative regional therapy for extremity sarcoma] Schmitt G. **Strahlenther Onkol** 1996 Jan;172(1):49–50 **(Ger)**

[Dentogenic sources of infection in patients with awaiting heart valve replacement] Krennmair G, et al. **Wien Klin Wochenschr** 1996;108(10):289–92 (Eng. Abstr.) **(Ger)**

[The necessity of mechanical bowel preparation in colo–rectal surgery (editorial)] Assalia A, et al. **Harefuah** 1996 Jan 1;130(1):23–4 **(Heb)**

[To the question of routine preoperative x–ray examination (letter)] Péter M. **Orv Hetil** 1996 Jan 14;137(2):99 **(Hun)**

[The preoperative staging of rectal cancer. A comparative assessment between endorectal echography and pelvic CT] Carrella G, et al. **G Chir** 1996 Apr;17(4):190–4 (Eng. Abstr.) **(Ita)**

[The recent trend in preoperative fasting] Kawasaki J, et al. **Masui** 1995 Aug;44(8):1154–8 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of preoperative treatment with recombinant human erythropoietin in patients undergoing hemodilutional autologous transfusion] Nakae Y, et al. **Masui** 1995 Oct; 44(10):1362–8 (Eng. Abstr.) **(Jpn)**

[Preoperative plasmapheresis for lung cancer with multiple myeloma] Tagawa T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1967–71 (Eng. Abstr.) **(Jpn)**

[Ambulatory surgery, preoperative anamnesis and clinical examination (letter)] Noess PA. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1258 **(Nor)**

[Ambulatory surgery—preoperative examinations] Raeder JC. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):497–9 (Eng. Abstr.) **(Nor)**

[Preparing patients with hematologic diseases for surgical interventions] Podolak–Dawidziak M, et al. **Pol Arch Med Wewn** 1995 May;93(5):390–4 (21 ref.) **(Pol)**

[Role of autotransfusion of pre–stored blood in benign prostate hyperplasia. Our experience] Mínguez Martínez R, et al. **Actas Urol Esp** 1995 Oct;19(9):686–91 (Eng. Abstr.) **(Spa)**

[Renal hydatidosis: importance of preoperative diagnosis] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Oct; 48(8):839–41 (Eng. Abstr.) **(Spa)**

[Preoperative assessment in adults] Halabe–Cherem J, et al. **Gac Med Mex** 1995 May–Jun;131(3):267–75; discussion 275–6 (Eng. Abstr.) **(Spa)**

[Analysis of preoperative reserve criteria and intraoperative transfusion of blood derivatives at an anesthesiology and recovery service] Ojeda R, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):286–9 (Eng. Abstr.) **(Spa)**

[Preanesthetic study revealing an endobronchial foreign body in an asthmatic patient (letter)] Pérez–Torres MC, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):115–7 **(Spa)**

ADVERSE EFFECTS

Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? [see comments] Harada T, et al. **Ann Surg** 1996 Jul;224(1):4–9. Comment in: Ann Surg 1996 Jul;224(1):1–3.

Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans [see comments] Sedman PC, et al. **Br J Surg** 1995 Dec; 82(12):1663–7. Comment in: Br J Surg 1996 May;83(5):713–4.

Hospital acquired pre–prostatectomy bacteriuria: risk factors and implications. Ibrahim AI. **East Afr Med J** 1996 Feb; 73(2):107–10

PREOPERATIVE CARE

ECONOMICS

Unnecessary preoperative investigations: evaluation and cost analysis. Allison JG, et al. **Am Surg** 1996 Aug;62(8):686–9

The cost of preoperative pregnancy testing [letter; comment] Kettler RE. **Anesth Analg** 1996 Aug;83(2):439–40. Comment on: Anesth Analg 1996 Jan;82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7.

Economic benefits attributed to opening a preoperative evaluation clinic for outpatients. Pollard JB, et al. **Anesth Analg** 1996 Aug;83(2):407–10

Cost–effective preoperative evaluation, operative treatment, and postoperative follow–up in the breast cancer patient. Cady B. **Surg Clin North Am** 1996 Feb;76(1):25–34

"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11–23 (42 ref.)

HISTORY

[Origins of preoperative fasting] Goerig M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):245–8 **(Ger)**

METHODS

Is systematic preoperative screening for muscle relaxant and latex allergy advisable? Porri F, et al. **Allergy** 1995 Apr; 50(4):374–7

Alternatives to allogeneic blood use in surgery: acute normovolemic hemodilution and preoperative autologous donation. D'Ambra MN, et al. **Am J Surg** 1995 Dec;170(6A Suppl):49S–52S

Blood management in orthopedic surgery. Sculco TP. **Am J Surg** 1995 Dec;170(6A Suppl):60S–63S

Is routine carotid screening for coronary surgery needed? Walker WA, et al. **Am Surg** 1996 Apr;62(4):308–10

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255–62 (63 ref.)

Preoperative dipyridamole thallium imaging and ambulatory electrocardiographic monitoring as a predictor of perioperative cardiac events and long–term outcome [see comments] Fleisher LA, et al. **Anesthesiology** 1995 Nov; 83(5):906–17. Comment in: Anesthesiology 1995 Nov;83(5):897–901.

Another simple method for ring removal [letter] Inoue S, et al. **Anesthesiology** 1995 Nov;83(5):1133–4

Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? [editorial; comment] Mangano DT. **Anesthesiology** 1995 Nov; 83(5):897–901 (11 ref.). Comment on: Anesthesiology 1995 Nov;83(5):906–17.

Is pre–operative patient assessment effective? A prospective trial of 100 patients. Banerjee AR, et al. **Ann R Coll Surg Engl** 1996 May;78(3 Suppl):119–21

Randomised study of sterile versus non–sterile urethral catheterisation. Carapeti EA, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):59–60

Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Lowy AM, et al. **Ann Surg** 1996 Feb;223(2):177–85

Preoperative two– and three–dimensional transesophageal echocardiographic assessment of heart tumors. Borges AC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1163–7

Effect of music on ambulatory surgery patients' preoperative anxiety. Augustin P, et al. **AORN J** 1996 Apr;63(4):750, 753–8

Preoperative technetium Tc 99m sestamibi imaging. Paving the way to minimal–access parathyroid surgery. Sofferman RA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr; 122(4):369–74

Laser skin resurfacing. Pre– and posttreatment guidelines. Lowe NJ, et al. **Dermatol Surg** 1995 Dec;21(12):1017–9

Preoperative strategies in the management of Wilms tumor. de Kraker J, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1275–85 (12 ref.)

Ultrasonographic monitoring of the effects of preoperative chemotherapy in osteosarcoma and Ewing's sarcoma. Kinoshita T, et al. **Int Orthop** 1995;19(5):312–4

Preoperative laboratory evaluation. Velanovich V. **J Am Coll Surg** 1996 Jul;183(1):79–87 (75 ref.)

Preoperative assessment of older adults [letter; comment] Rosenthal RA. **J Am Geriatr Soc** 1996 Feb;44(2):213–4. Comment on: J Am Geriatr Soc 1995 Jul;43(7):811–21.

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

Prognostic significance of preoperative MRI scans in glioblastoma multiforme. Hammoud MA, et al. **J Neurooncol** 1996 Jan;27(1):65–73

How to assess the nose for rhinoplasty. Willett JM. **J Otolaryngol** 1996 Feb;25(1):23–5 (5 ref.)

Presurgical integrated MRI/SPECT localization of the sensorimotor cortex in a patient with a low–grade astrocytoma in the rolandic area. Sabatini U, et al. **Neuroreport** 1995 Dec 29;7(1):105–8

The use of intraoperative autotransfusion as a second stage of autologous blood use in pediatric orthopaedic surgery. Flynn JM, et al. **P R Health Sci J** 1995 Dec;14(4):259–62

An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective. Temudom T, et al. **Pancreas** 1995 Oct;11(3):283–8

Evaluation and preparation of pediatric patients undergoing anesthesia. American Academy of Pediatrics. Section on Anesthesiology. **Pediatrics** 1996 Sep;98(3 Pt 1):502–8

The role of preoperative investigations in predicting difficult laparoscopic cholecystectomies. Results in 200 consecutive cases. Urbano D, et al. **Surg Endosc** 1996 Aug;10(8):791–3

Perioperative care in the elderly urologic patient. Smith R, et al. **Urol Clin North Am** 1996 Feb;23(1):27–41 (51 ref.)

[Effective preoperative studies in outpatient anesthesiology] Langemeijer JJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1723–6 (Eng. Abstr.) **(Dut)**

[Recommendations of the jury. Peri–operative artificial nutrition]. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:5–16 **(Fre)**

[Pre– and post–operative enteral nutrition in elective surgery in adults. Techniques, advantages and adverse effects] Beau P. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:121–6 (Eng. Abstr.) **(Fre)**

[Caloric and nitrogen intake during pre– and post–operative periods. method and duration] Cohen S, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:75–81 (Eng. Abstr.) **(Fre)**

[Role of new nitrogen substrates during peri–operative artificial nutrition in adults] Cynober L. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:102–6 (Eng. Abstr.) **(Fre)**

[Role of recombinant erythropoietin during the preoperative period] Janssens M, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:98–106 **(Fre)**

[How to assess preoperative nutritional status?] Melchior JC. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:19–26 (Eng. Abstr.) **(Fre)**

[Respective indications of enteral or parenteral nutrition during pre– and post–operative periods] Petit J, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:127–36 (Eng. Abstr.) **(Fre)**

[In which patients has the efficacy of preoperative artificial nutrition be proved?] Yakoun M. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:47–53 (Eng. Abstr.) **(Fre)**

[Blood salvage: a conditional safety] Andreassian B, et al. **J Mal Vasc** 1996;21 Suppl A:22–35 (48 ref.) (Eng. Abstr.) **(Fre)**

[Orthodontic pre– and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11–20 (19 ref.) **(Ger)**

[Preoperative radiochemotherapy in esophageal carcinoma] Stahl M. **Schweiz Rundsch Med Prax** 1996 Mar 5; 85(10):303–6 (Eng. Abstr.) **(Ger)**

[The effect of the irradiation technic on the success of preoperative radiotherapy in rectal carcinoma: the results of the Stockholm–I and –II studies] Fietkau R. **Strahlenther Onkol** 1995 Nov;171(11):664–5 **(Ger)**

[Preoperative measures in emergencies] Leutenegger A. **Swiss Surg** 1995;(3):148–51 (Eng. Abstr.) **(Ger)**

[Preparation of the patient to the surgical intervention: cognitive survey at the General Surgery Specialization School of the University of Milano] Foschi D, et al. **Minerva Chir** 1995 Sep;50(9 Suppl):119–28 **(Ita)**

[The value of preoperative thoracic CT. 19 patients with bronchial cancer surgically treated] Eggesbø HB, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2169–71 (Eng. Abstr.) **(Nor)**

[Preparation of suppurative wounds for autodermatoplasty with electrochemially activated solutions] Legchilo AN, et al. **Khirurgiia (Mosk)** 1996;(1):57–8 (Eng. Abstr.) **(Rus)**

[Our experience with the pre– and postoperative management of middle–aged and elderly patients undergoing a urological surgical intervention] Gorilovskii LM. **Ter Arkh** 1995;67(10):51–3 **(Rus)**

[The preoperative preparation of patients with liver cirrhosis complicated by a drug–resistant form of ascites] Pozdniakov AV. **Vestn Khir Im I I Grek** 1992 Nov–Dec; 149(11–12):383–4 **(Rus)**

[Preoperative plasma– and thrombocytapheresis in patients with ischemic heart disease] Shilov VV, et al. **Vestn Khir Im I I Grek** 1995;154(2):77–81 **(Rus)**

[Arterial surgery of the extremities without angiography. A simpler preoperative survey with color doppler] Karacagil S, et al. **Lakartidningen** 1995 Oct 4;92(40):3692–3 **(Swe)**

[The dynamics of the intoxication indices during the performance of the preoperative preparation of patients with disseminated progressive destructive pulmonary tuberculosis] Prystaĭko IaI. **Klin Khir** 1995;(6):11–3 **(Ukr)**

NURSING

Evaluating a revised self–efficacy scale for preoperative patients. Oetker–Black SL, et al. **AORN J** 1995 Aug; 62(2):244–6, 249–50

The pre– and postsurgical nursing of women with stress incontinence. Berglund AL, et al. **J Adv Nurs** 1996 Mar; 23(3):502–11

PSYCHOLOGY

Children's preoperative coping and its effects on postoperative anxiety and return to normal activity. LaMontagne LL, et al. **Nurs Res** 1996 May–Jun;45(3):141–7

STANDARDS

Do ophthalmologists, anesthesiologists, and internists agree about preoperative testing in healthy patients undergoing cataract surgery? [see comments] Bass EB, et al. **Arch Ophthalmol** 1995 Oct;113(10):1248–56. Comment in: Arch Ophthalmol 1995 Oct;113(10):1241–2.

Evaluating cardiac risk in noncardiac surgery patients. Bronson DL, et al. **Cleve Clin J Med** 1995 Nov–Dec; 62(6):391–400 (39 ref.)

Postoperative pulmonary complications: risk assessment, prevention, and treatment. Hayden SP, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):401–7 (27 ref.)

Preoperative screening: what tests are necessary? Jones T, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):374–8 (39 ref.)

Clinical aspects of the preanesthetic evaluation. Zambricki C. **Nurs Clin North Am** 1996 Sep;31(3):607–21

Should antibiotic prophylaxis be used routinely in clean surgical procedures: a tentative yes. Lewis RT, et al. **Surgery** 1995 Oct;118(4):742–6; discussion 746–7

[Plea for systematic preoperative tests] Cousin MT. **Cah Anesthesiol** 1996;44(1):81–5 **(Fre)**

[Value of selective prescription of preanesthetic laboratory tests] Mignonsin D, et al. **Cah Anesthesiol** 1996;44(1):13–7 (Eng. Abstr.) **(Fre)**

TRENDS

"Nulla per os [NPO] after midnight" reassessed. Dowling JL Jr. **R I Med** 1995 Dec;78(12):339–41

PREOPTIC AREA

ANATOMY & HISTOLOGY

The population of GnRH–containing neurons showing socially mediated size changes project to the pituitary in a teleost, Haplochromis burtoni. Bushnik TL, et al. **Brain Behav Evol** 1995;46(6):371–7

Chemical topography of efferent projections from the median preoptic nucleus to pontine monoaminergic cell groups in the rat. Zardetto–Smith AM, et al. **Neurosci Lett** 1995 Oct 27;199(3):215–9

CHEMISTRY

Microdialysis measurement of intracerebral somatostatin in the goat. Hashizume T, et al. **Domest Anim Endocrinol** 1995 Oct;12(4):363–70

Thyrotropin–releasing hormone hyperactivity in the preoptic area of spontaneously hypertensive rats. Garcia SI, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1105–10

CYTOLOGY

Medial preoptic area afferents to periaqueductal gray medullo–output neurons: a combined Fos and tract tracing study. Rizvi TA, et al. **J Neurosci** 1996 Jan;16(1):333–44

DRUG EFFECTS

The opposing effects of interleukin –1 beta microinjected into the preoptic hypothalamus and the ventromedial hypothalamus on nociceptive behavior in rats. Oka T, et al. **Brain Res** 1995 Nov 27;700(1–2):271–8

The role of norepinephrine in mediating luteinizing hormone release in response to blockade of kappa–opioid receptors in the medial preoptic area. Zhen S, et al. **Brain Res** 1995 Nov 6;698(1–2):121–9

Low doses of neurotensin in the preoptic area produce hyperthermia. Comparison with other brain sites and with neurotensin–induced analgesia. Benmoussa M, et al. **Brain Res Bull** 1996;39(5):275–9

Testosterone effects on the neuronal ultrastructure in the medial preoptic nucleus of male Japanese quail. Panzica GC, et al. **Brain Res Bull** 1996;39(5):281–92

The role of angiotensin AT1 receptors in the diuretic, natriuretic, kaliuretic and blood pressure responses induced by angiotensin II activation of the median preoptic nucleus in conscious rats. Ferreira–do–Vale C, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1097–101

Evidence that gonadal steroids modulate nitric oxide efflux in the medial preoptic area: effects of N–methyl–D–aspartate and correlation with luteinizing hormone secretion. Pu S, et al. **Endocrinology** 1996 May; 137(5):1949–55

Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: relationship with body temperature and hypothalamic–pituitary–adrenocortical axis activity. Linthorst AC, et al. **Eur J Neurosci** 1995 Dec 1; 7(12):2418–30

Estradiol modulation of neuron loss in the medial division of medial preoptic nucleus in rats during aging. Hsieh YL, et al. **Gerontology** 1996;42(1):18–24

Human placental lactogen infusions into the medial preoptic area stimulate maternal behavior in steroid–primed, nulliparous female rats. Bridges RS, et al. **Horm Behav** 1995 Jun;29(2):216–26

Effects of opioid peptides on the electrical activity of preoptic and hypothalamic neurons in the quail brain. Furukawa Y, et al. **J Exp Zool** 1995 Oct 1;273(2):96–103

Involvement of serotonin in the regulation of GnRH gene expression in the male rat brain. Li S, et al. **Neuropeptides** 1995 Jul;29(1):21–5

Effects of morphiceptin in the medial preoptic area on male sexual behavior. Matuszewich L, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):330–5

ENZYMOLOGY

Progesterone receptor immunoreactivity in aromatic L–amino acid decarboxylase–containing neurons of the guinea pig hypothalamus and preoptic area. Warembourg M, et al. **J Comp Neurol** 1996 Apr 15;367(4):477–90

Effects of testosterone and its metabolites on aromatase–immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)

METABOLISM

Characterization of progesterone–3–[125I–BSA] binding sites in the medial preoptic area and anterior hypothalamus. Caldwell JD, et al. **Brain Res** 1995 Sep 25;693(1–2):225–32

Testosterone effects on vasotocinergic innervation of sexually dimorphic medial preoptic nucleus and lateral septum during aging in male quail. Panzica GC, et al. **Brain Res** 1996 Mar 18;712(2):190–8

Dopamine release in the medial preoptic area during male copulatory behavior in rats. Sato Y, et al. **Brain Res** 1995 Sep 18;692(1–2):66–70

Cyclic and age–related changes in norepinephrine concentrations in the medial preoptic area and arcuate nucleus. Mohankumar PS, et al. **Brain Res Bull** 1995; 38(6):561–4

Evidence that gonadal steroids modulate nitric oxide efflux in the medial preoptic area: effects of N–methyl–D–aspartate and correlation with luteinizing hormone secretion. Pu S, et al. **Endocrinology** 1996 May; 137(5):1949–55

Increased fos expression in preoptic calcitonin gene–related peptide (CGRP) neurones following mating but not the luteinizing hormone surge in female rats. Herbison AE, et al. **J Neuroendocrinol** 1995 May;7(5):377–85

Extracellular dopamine in the medial preoptic area: implications for sexual motivation and hormonal control of copulation. Hull EM, et al. **J Neurosci** 1995 Nov; 15(11):7465–71

The developmental increase of the AT1A, but not the AT1B, receptor mRNA level at the preoptic area in spontaneously hypertensive rats. Komatus C, et al. **Life Sci** 1996; 58(14):1109–21

Preoptic neuronal circuit: atrial natriuretic peptide–containing neurons are sensitive to acute and chronic alterations in body fluid volume. Palkovits M, et al. **Miner Electrolyte Metab** 1995;21(6):423–7

Gonadal steroid hormone regulation of proopiomelanocortin gene expression in arcuate neurons that innervate the medial preoptic area of the rat. Cheung S, et al. **Neuroendocrinology** 1995 Sep;62(3):283–92

Preoptic rather than mediobasal hypothalamic amino acid neurotransmitter release regulates GnRH secretion during the estrogen–induced LH surge in the ovariectomized rat. Jarry H, et al. **Neuroendocrinology** 1995 Nov;62(5):479–86

Progesterone suppression of glutamic acid decarboxylase (GAD67) mRNA levels in the preoptic area: correlation to the luteinizing hormone surge. Unda R, et al. **Neuroendocrinology** 1995 Dec;62(6):562–70

Branching serotonergic and non–serotonergic projections from caudal brainstem to the medial preoptic area and the lumbar spinal cord, in the rat. Leanza G, et al. **Neurosci Lett** 1995 Nov 10;200(1):5–8

Prostaglandin–dependent c–Fos expression in the median preoptic nucleus of pigs subjected to restraint: correlation with hyperthermia. Vellucci SV, et al. **Neurosci Lett** 1995 Sep 22;198(1):49–51

PATHOLOGY

Estradiol modulation of neuron loss in the medial division of medial preoptic nucleus in rats during aging. Hsieh YL, et al. **Gerontology** 1996;42(1):18–24

Magnetic resonance imaging of NMDA–induced lesion of the medial preoptic area and changes in sleep, temperature and sex behaviour. Mohan Kumar V, et al. **Neurosci Res** 1996 Feb;24(3):207–14

PHYSIOLOGY

Involvement of opioid peptides of the preoptic area during electroacupuncture analgesia. Wu GC, et al. **Acupunct Electrother Res** 1995 Jan–Mar;20(1):1–6

Neuronal discharge of preoptic/anterior hypothalamic thermosensitive neurons: relation to NREM sleep. Alam MN, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1240–9

Preoptic/anterior hypothalamic neurons: thermosensitivity in rapid eye movement sleep. Alam MN, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1250–7

Effect of pregnancy on activation of central pathways following atrial distension. Deng Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R552–6

Halothane modulates thermosensitive hypothalamic neurons in rat brain slices. Farber NE, et al. **Anesthesiology** 1995 Dec;83(6):1241–53

Lateral habenula neurons are necessary for the hormonal onset of maternal behavior and for the display of postpartum estrus in naturally parturient female rats. Matthews–Felton T, et al. **Behav Neurosci** 1995 Dec; 109(6):1172–88

The effects of olfactory and somatosensory desensitization on Fos–like immunoreactivity in the brains of pup–exposed postpartum rats. Walsh CJ, et al. **Behav Neurosci** 1996 Feb; 110(1):134–53

Local preoptic/anterior hypothalamic warming alters spontaneous and evoked neuronal activity in the magno–cellular basal forebrain. Alam N, et al. **Brain Res** 1995 Oct 23;696(1–2):221–30

In vitro thermosensitivity of the midline thalamus. Travis KA, et al. **Brain Res** 1995 Jul 17;686(1):17–22

Dissociation of the restoration of copulatory behavior and the testicular morphology in old male rats with fetal brain grafting. Peng YI, et al. **Chin J Physiol** 1995;38(1):13–7

Thermoregulatory responses to thermal stimulation of the preoptic anterior hypothalamus in the red fox (Vulpes vulpes). Klir JJ, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):557–66

A lesion and neuroanatomical tract–tracing analysis of the role of the bed nucleus of the stria terminalis in retrieval behavior and other aspects of maternal responsiveness in rats. Numan M, et al. **Dev Psychobiol** 1996 Jan;29(1):23–51

The inhibitory effect of beta–endorphin on LH release in ovariectomized rats does not involve the preoptic GABAergic system. Jarry H, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):317–23

Differences in electrophysiological properties of angiotensinergic pathways from the subfornical organ to the median preoptic nucleus between normotensive Wistar–Kyoto and spontaneously hypertensive rats. Tanaka J, et al. **Exp Neurol** 1995 Aug;134(2):192–8

The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51–125 (287 ref.)

Progesterone–facilitated lordosis in medial preoptic area–lesioned, juvenile guinea pigs. Olster DH. **Horm Behav** 1995 Dec;29(4):519–30

Preoptic area lesions disrupt prolactin–induced parental feeding behavior in ring doves. Slawski BA, et al. **Horm Behav** 1995 Jun;29(2):248–66

The medial amygdaloid nucleus and medial preoptic area mediate steroidal control of sexual behavior in the male Syrian hamster. Wood RI, et al. **Horm Behav** 1995 Sep; 29(3):338–53

Effect of application of gamma amino butyric acid at the medial preoptic area on sleep–wakefulness. Chari DM, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):299–301

Effect of lateral hypothalamus lesions on the water and salt intake, and sodium and urine excretion induced by activation of the median preoptic nucleus in conscious rats. da Silva RK, et al. **J Auton Nerv Syst** 1995 Jun 25; 53(2–3):195–204

P–chlorophenylalanine facilitates copulatory behavior in septal lesioned but not in preoptic lesioned male rats. Kondo Y, et al. **J Neuroendocrinol** 1993 Dec;5(6):629–33

Formation of neurons in the sexually dimorphic anteroventral periventricular nucleus of the preoptic area of the rat: effects of prenatal treatment with testosterone propionate. Nishizuka M, et al. **J Neuroendocrinol** 1993 Oct;5(5):569–73

Regulation of GABA transporter activity and mRNA expression by estrogen in rat preoptic area. Herbison AE, et al. **J Neurosci** 1995 Dec;15(12):8302–9

Altered sexual partner preference in male ferrets given excitotoxic lesions of the preoptic area/anterior hypothalamus. Paredes RG, et al. **J Neurosci** 1995 Oct; 15(10):6619–30

Facilitation of the arterial baroreflex by the preoptic area in anaesthetized rats. Inui K, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):521–31

Differential control of proceptive and receptive components of female rat sexual behavior by the preoptic area. Sakuma Y. **Jpn J Physiol** 1995;45(2):211–28 (103 ref.)

A revised critical period for the sexual differentiation of the sexually dimorphic nucleus of the preoptic area in the rat. Davis EC, et al. **Neuroendocrinology** 1995 Dec;62(6):579–85

An interleukin–1–alpha–like neuronal system in the preoptic–hypothalamic region and its induction by bacterial lipopolysaccharide in concentrations which alter pituitary hormone release. Rettori V, et al. **Neuroimmunomodulation** 1994 Jul–Aug;1(4):251–8

Effects of hypothalamic lesions on the body temperature rhythm of the golden hamster. Osborne AR, et al. **Neuroreport** 1995 Nov 13;6(16):2187–92

Differential cellular localization of oestrogen receptor immunoreactivity and oxytocin mRNA and immunoreactivity in the rat preoptic area. Cruttwell CJ, et al. **Neurosci Lett** 1995 Nov 17;200(2):89–92

Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure. Giuliano F, et al. **Neurosci Lett** 1996 May 3;209(1):1–4

The nitric oxide synthase (NOS)–like immunoreactive extrahypophysial projections of the neurosecretory preoptic nucleus of the electric ray (elasmobranchs) suggest a neuroregulatory role for this nucleus. Pérez SE, et al. **Neurosci Lett** 1995 Aug 4;195(2):85–8

Naloxone and initial estrogen action to induce lordosis in ovariectomized rats: the effect of a cut between the septum and preoptic area. Torii M, et al. **Neurosci Lett** 1995 Aug 11;195(3):167–70

Prostaglandin D2 modulates sleep–related and noradrenaline–induced activity of preoptic and basal forebrain neurons in the rat. Osaka T, et al. **Neurosci Res** 1995 Oct;23(3):257–68

Activation of ventrolateral preoptic neurons during sleep. Sherin JE, et al. **Science** 1996 Jan 12;271(5246):216–9

[The restructuring of the neuronal activity of the lateral hypothalamic preoptic area during the development of sleep] Suntsova NV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep–Oct; 45(5):948–56 (Eng. Abstr.) **(Rus)**

SURGERY

Preoptic recess ablation selectively increases baroreflex sensitivity to angiotensin II in conscious rats. Bealer SL. **Peptides** 1995;16(7):1197–201

ULTRASTRUCTURE

Gonadal steroid hormones upregulate medial preoptic mu–opioid receptors in the rat. Zhou L, et al. **Eur J Pharmacol** 1995 May 24;278(3):271–4

The developmental increase of the AT1A, but not the AT1B, receptor mRNA level at the preoptic area in spontaneously hypertensive rats. Komatus C, et al. **Life Sci** 1996; 58(14):1109–21

PREOVULATORY PHASE see **FOLLICULAR PHASE**

PREPAID DENTAL CARE see **INSURANCE, DENTAL**

PREPAID GROUP HEALTH ORGANIZATIONS see **HEALTH MAINTENANCE ORGANIZATIONS**

PREPAID GROUP PRACTICE see **GROUP PRACTICE, PREPAID**

PREPAID HEALTH PLANS

see related
GROUP PRACTICE, PREPAID

ECONOMICS

Utah's Prepaid Mental Health Plan: the first year. Christianson JB, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):160–72

Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38–47 (15 ref.)

HISTORY

The Delaware Foundation for Health Care—history revisited [letter] Platt D. **Del Med J** 1995 Dec;67(12):634–5

Who will take care of the worker? The establishment of "Kupat Holim," the Workers' Sick Fund in Israel, 1911–1921. Shvarts S. **J Hist Med Allied Sci** 1995 Oct; 50(4):525–56

ORGANIZATION & ADMINISTRATION

The QSHP proposal: 10 questions most often asked. Grace TW, et al. **J Am Coll Health** 1995 Sep;44(2):43–9

PREPHENATE DEHYDRATASE

GENETICS

Cloning of m–fluorophenylalanine–resistant gene and mutational analysis of feedback–resistant prephenate dehydratase from Corynebacterium glutamicum. Chan MS, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):537–42

Molecular cloning with a pMEA300–derived shuttle vector and characterization of the Amycolatopsis methanolica prephenate dehydratase gene. Vrijbloed JW, et al. **J Bacteriol** 1995 Nov;177(22):6666–9

PREPHENATE DEHYDROGENASE

METABOLISM

Identification of active site residues of chorismate mutase–prephenate dehydrogenase from Escherichia coli. Christendat D, et al. **Biochemistry** 1996 Apr 9; 35(14):4468–79

PREPHENATE HYDRO–LYASE see **PREPHENATE DEHYDRATASE**

PREPROSTHETIC ORAL SURGERY see **SURGERY, ORAL, PREPROSTHETIC**

PRESBYCUSIS

Geriatric grand rounds: hearing impairment and functional independence [clinical conference] Swagerty DL Jr. **Kans Med** 1995 Fall;96(3):147–8, 151

Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul–Aug;10(3):593–607 (73 ref.)

ETIOLOGY

Age–related changes in auditory evoked potentials of gerbils.

PRESBYCUSIS

III. Low-frequency responses and repetition rate effects. Boettcher FA, et al. **Hear Res** 1995 Jul;87(1-2):208-19

GENETICS

Genetics of age-related hearing loss in mice. II. Strain differences and effects of caloric restriction on cochlear pathology and evoked response thresholds. Willott JF, et al. **Hear Res** 1995 Aug;88(1-2):143-55

PATHOLOGY

Quantitative evaluation of myelinated nerve fibres and hair cells in cochleae of humans with age-related high-tone hearing loss. Felder E, et al. **Hear Res** 1995 Nov; 91(1-2):19-32

Synaptic loss in the central nucleus of the inferior colliculus correlates with sensorineural hearing loss in the C57BL/6 mouse model of presbycusis. Kazee AM, et al. **Hear Res** 1995 Sep;89(1-2):109-20

PHYSIOPATHOLOGY

[Hearing impairment in quietude and noise; 2 different forms of expression of presbyacusis] Plomp R, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):14-9 (Eng. Abstr.) **(Dut)**

[Clinical application of distortion products of otoacoustic emissions in presbycusis] Nieschalk M, et al. **Laryngorhinootologie** 1996 Mar;75(3):129-34 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Presbycusis and phonemic regression. Tyberghein J. **Acta Otorhinolaryngol Belg** 1996;50(2):85-90

Development of a short scale for self-assessment of experiences of hearing loss. The hearing coping assessment. Andersson G, et al. **Scand Audiol** 1995;24(3):147-54

REHABILITATION

Hearing aids: value for money and health gain. Lamden KH, et al. **J Public Health Med** 1995 Dec;17(4):445-9

PRESBYOPIA

EPIDEMIOLOGY

Correlation between presbyopia, age and number of births of mothers in the Kumasi area of Ghana. Morny FK. **Ophthalmic Physiol Opt** 1995 Sep;15(5):463-6

ETIOLOGY

The aetiology of presbyopia: a summary of the role of lenticular and extralenticular structures. Gilmartin B. **Ophthalmic Physiol Opt** 1995 Sep;15(5):431-7 (82 ref.)

PATHOLOGY

[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3-9 (0 ref.) **(Ger)**

PSYCHOLOGY

Social skills training for depressed, visually impaired older adults. A treatment manual. Donohue B, et al. **Behav Modif** 1995 Oct;19(4):379-424

REHABILITATION

Broken down by age and sex. The optical correction of presbyopia revisited. Pointer JS. **Ophthalmic Physiol Opt** 1995 Sep;15(5):439-43

Varifocal contact lenses for the correction of presbyopia. Port M, et al. **Ophthalmic Physiol Opt** 1995 Sep; 15(5):457-61

Visual problems of the aging musician. Kadrmas EF, et al. **Surv Ophthalmol** 1996 Jan-Feb;40(4):338-41

SURGERY

Success of monovision in presbyopes: review of the literature and potential applications to refractive surgery. Jain S, et al. **Surv Ophthalmol** 1996 May-Jun;40(6):491-9 (67 ref.)

THERAPY

Small-diameter corneal inlay in presbyopic or pseudophakic patients. Keates RH, et al. **J Cataract Refract Surg** 1995 Sep;21(5):519-21

ULTRASONOGRAPHY

[Ultrasound biomicroscopy imaging of accommodative configuration changes in the presbyopic ciliary body] Bacskulin A, et al. **Ophthalmologe** 1996 Apr;93(2):199-203 (Eng. Abstr.) **(Ger)**

PRESBYTIS see **CERCOPITHECIDAE**

PRESCRIPTION FEES

Dental prescribing: minimising the cost to the patient and the NHS. Thornhill MH, et al. **Br Dent J** 1996 Feb 10; 180(3):111-5

An ethicist's commentary on the case of the veterinarian failing to prescribe prescription drugs and losing practice income. Rollin BE. **Can Vet J** 1996 Jun;37(6):330-1

Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure. Hughes D, et al. **Health Econ** 1995 May-Jun;4(3):213-20

Coping with the cost of prescription drugs. Strickland WJ, et al. **J Health Care Poor Underserved** 1996;7(1):50-62

A survey of physician knowledge of drug costs. Hoffman J, et al. **J Pain Symptom Manage** 1995 Aug;10(6):432-5

Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Collins RW, et al. **Prev Med** 1995 Jul;24(4):369-74

[Pharmaceutical expenditure in primary care according to the prescription source] Lomeña Villalobos JA, et al. **Aten Primaria** 1996 Jun 15;18(1):35-8 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Dispensing of medicines and professional fees [letter] Wray JG. **Vet Rec** 1996 May 18;138(20):503-4

TRENDS

Trends in the use of blood pressure lowering medications in Auckland, and associated costs, 1982-94. Trye P, et al. **N Z Med J** 1996 Jul 26;109(1026):270-2

[Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies] Brecht JG, et al. **Med Klin** 1995 Sep 15;90(9):541-6 **(Ger)**

PRESCRIPTION INSURANCE see **INSURANCE, PHARMACEUTICAL SERVICES**

PRESCRIPTIONS, DRUG

Minimizing prescribing errors in infants and children. Fox GN. **Am Fam Physician** 1996 Mar;53(4):1319-25

AMA house scrutinizes managed care prescription policies, decries payments to pharmacists for switches [news] **Am J Health Syst Pharm** 1995 Sep 15;52(18):1967, 1970

Handling the first dose of a questionable order. Aebi C. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2092-4

Do pharmacists need prescribing privileges to implement pharmaceutical care? [see comments] Carmichael JM. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1699-701. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

The key to pharmacist prescribing: collaboration. Galt KA. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1696-9

Effect of prescribing guidelines on the use of neuromuscular blocking agents. Gora-Harper ML, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1900-4

Pharmacists' duty to refrain from dispensing potentially addictive medication if necessary. Mullan K, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):308-10

Requirements for pharmacists dispensing ephedrine products. Stein GC. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1630

Pharmacist prescribing [editorial; comment] Talley CR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1635. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1616, 1620, 1623-4. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1693-5. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1699-701. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1732.

Prescribing medications: changing the paradigm for a changing health care system [see comments] Webb CE. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1693-5. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Obtaining prescribing authority for pharmacists: lessons learned [see comments] Wittenburg AS. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1616, 1620, 1623-4. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Collaborative drug therapy management [see comments] Zellmer WA. **Am J Health Syst Pharm** 1995 Aug 1; 52(15):1732. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Hanlon JT, et al. **Am J Med** 1996 Apr;100(4):428-37

Response to: 'a mother's perspective' [letter] Cooper MJ. **Am Pharm** 1995 Sep;NS35(9):4

Computer-generated prescription orders. Davis NM, et al. **Am Pharm** 1995 Sep;NS35(9):10

Prescribing authority: an examination of Ohio pharmacists' opinions. Desikan R, et al. **Am Pharm** 1995 Oct; NS35(10):19-23

Update on state prescribing authority. Flanagan ME. **Am Pharm** 1995 Oct;NS35(10):12-8

Drug use in the nursing home [letter] Tolle SW, et al. **Ann Intern Med** 1996 Mar 15;124(6):616

Inappropriate guilt over benzodiazepine prescription [letter; comment] Reynolds RD. **Arch Fam Med** 1996 Jan;5(1):9 . Comment on: Arch Fam Med 1995 Jul;4(7):576.

A guide to computer-generated prescriptions. Frank O, et al. **Aust Fam Physician** 1996 Jul;25(7):1162-3

A study of general practitioners' reasons for changing their prescribing behaviour. Armstrong D, et al. **BMJ** 1996 Apr 13;312(7036):949-52

Health ministers look at cross border prescriptions [news] Conradi P. **BMJ** 1995 Dec 9;311(7019):1524

Private prescribing of controlled drugs [letter; comment] Ford C. **BMJ** 1995 Sep 16;311(7007):755. Comment on: BMJ 1995 May 27;310(6991):1407.

Saudi Arabia curbs tranquilliser prescribing [news] Kandela P. **BMJ** 1996 Feb 3;312(7026):271

India's consumer groups call for more rational prescribing [news] Mudur G. **BMJ** 1996 Jan 13;312(7023):76

Information on sugar free medicines is readily available [letter; comment] Styles M. **BMJ** 1995 Sep 30;311(7009):879 . Comment on: BMJ 1995 Jul 15;311(6998):141-2.

Effects of fundholding on prescribing habits. Generic prescriptions are defined differently for dispensing practices [letter; comment] Willis T. **BMJ** 1996 Mar 30;312(7034):848 . Comment on: BMJ 1995 Dec 9;311(7019):1543-7.

Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study. Wilson RP, et al. **BMJ** 1996 Sep 7; 313(7057):595-9

Computer based prescribing [editorial] [see comments] Wyatt J, et al. **BMJ** 1995 Nov 4;311(7014):1181-2. Comment in: BMJ 1996 Feb 17;312(7028):445. Comment in: BMJ 1996 Feb 17;312(7028):445-6. Comment in: BMJ 1996 Feb 17;312(7028):446.

Dental prescribing [letter] Kravitz AS. **Br Dent J** 1996 May 25;180(10):366

Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed. Godwin M, et al. **Can Fam Physician** 1996 Jul; 42:1309-16

Do pharmaceutical representatives misuse their drug samples? Tong KL, et al. **Can Fam Physician** 1995 Aug; 41:1363-6

Strategies for improving prescribing practice [see comments] Anderson GM, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1013-7 (38 ref.). Comment in: Can Med Assoc J 1996 Jun 1;154(11):1620.

Variability in prescription drug utilization: issues for research. Anis AH, et al. **Can Med Assoc J** 1996 Mar 1;154(5):635-40

Facts about the fax: MDs advised to be cautious. Capen K. **Can Med Assoc J** 1995 Oct 15;153(8):1152-3

Regulated analgesics and pain control [letter; comment] Clark AJ, et al. **Can Med Assoc J** 1996 May 15;154(10):1472, 1474; discussion 1476-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Regulated analgesics and pain control [letter; comment] Goldman B. **Can Med Assoc J** 1996 May 15;154(10):1474; discussion 1476-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Regulated analgesics and pain control [letter; comment] Hagen NA, et al. **Can Med Assoc J** 1996 May 15; 154(10):1470, 1472. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Modifying prescribing of regulated analgesics [letter; comment] Hux JE. **Can Med Assoc J** 1996 Apr 1; 154(7):1005-6; discussion 1006-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Regulated analgesics and pain control [letter; comment] Jovey RD. **Can Med Assoc J** 1996 May 15;154(10):1476; discussion 1476-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Modifying prescribing of regulated analgesics [letter; comment] Murray M. **Can Med Assoc J** 1996 Apr 1; 154(7):1006; discussion 1006-7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31-9.

Modifying prescribing of regulated analgesics [letter] Panton WD. **Can Med Assoc J** 1996 Apr 1;154(7):1006; discussion 1006-7

Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. Tamblyn RM, et al. **Can Med Assoc J** 1996 Apr 15;154(8):1177-84

An ethicist's commentary on whether a veterinarian should write a prescription of a branded drug in return for a financial incentive. Rollin BE. **Can Vet J** 1996 Mar; 37(3):149

Oncologists and primary care physicians' attitudes toward pain control and morphine prescribing in France [see comments] Larue F, et al. **Cancer** 1995 Dec 1; 76(11):2375-82. Comment in: Cancer 1995 Dec 1;76(11):2181-5.

Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status. Potts M, et al. **Drug Saf** 1995 Dec;13(6):333-7

Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk? Benrimoj SI, et al. **Drugs Aging** 1995 Oct;7(4):255-65 (152 ref.)

Drug prescription in Italy. Maggini M, et al. **Eur J Clin Pharmacol** 1996;49(6):429-30 (7 ref.)

Optometrists threaten public safety with bill [letter] Miura CM. **Hawaii Med J** 1996 Jun;55(6):96

A comparison of alternative models of prescription drug utilization. Grootendorst PV. **Health Econ** 1995 May-Jun; 4(3):183-98

Rational drug therapy as evaluated from student's clinical case reports. Kohli K, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):400-2

A comparative study of prescribing pattern at different levels of health care delivery system in Bangalore district. Srishyla MV, et al. **Indian J Physiol Pharmacol** 1995 Jul;

39(3):247–51
Gender differences in medical presentation and detection of patients with a history of alcohol abuse or dependence. Amodei N, et al. **J Addict Dis** 1996;15(1):19–31
Avoiding prescribing errors: a systematic approach. Marek CL. **J Am Dent Assoc** 1996 May;127(5):617–23
Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. Boyter AC, et al. **J Antimicrob Chemother** 1995 Aug;36(2):403–9
The dentist and prescription drug abuse. Balevi B, et al. **J Can Dent Assoc** 1996 Jan;62(1):56–60
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. Mann RD, et al. **J Clin Epidemiol** 1996 Feb;49(2):247–50
Use of an automated prescription database to identify individuals with asthma. Osborne ML, et al. **J Clin Epidemiol** 1995 Nov;48(11):1393–7
Continued prescribing of inappropriate drugs in general practice. Britten N, et al. **J Clin Pharm Ther** 1995 Aug; 20(4):199–205
Influencing the prescribing behaviour of physicians: a metaevaluation. Pippalla RS, et al. **J Clin Pharm Ther** 1995 Aug;20(4):189–98
Using "literature" to evaluate new drugs. Felpel LP. **J Dent Educ** 1996 May;60(5):465–6
Prescription drug noncompliance: a clear and present danger. Olshaker JS. **J Emerg Med** 1996 Jan–Feb;14(1):87–9
Norplant prescribing in family practice. Steadman MS, et al. **J Fam Pract** 1996 Mar;42(3):267–72
Effect of physician gender on the prescription of estrogen replacement therapy. Seto TB, et al. **J Gen Intern Med** 1996 Apr;11(4):197–203
Community patterns of transdermal nicotine use and provider counseling [see comments] Swartz SH, et al. **J Gen Intern Med** 1995 Dec;10(12):656–62. Comment in: J Gen Intern Med 1995 Dec;10(12):697–9.
Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)
Report from the International Association for the Study of Pain Task Force on cancer pain. Portenoy RK. **J Pain Symptom Manage** 1996 Aug;12(2):93–6
Resisting the urge to prescribe [editorial; comment] Edwards KM. **J Pediatr** 1996 Jun;128(6):729–30. Comment on: J Pediatr 1996 Jun;128(6):757–64.
Measuring switchability and prescribability: when is average bioequivalence sufficient? Hauck WW, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):551–64
Preparing for prescriptive practice: Advanced practice psychiatric nursing and psychopharmacotherapy. Bailey KP. **J Psychosoc Nurs Ment Health Serv** 1996 Jan; 34(1):16–20
Perils of the power of prescriptive authority [editorial] Ryan JA. **J Psychosoc Nurs Ment Health Serv** 1996 Mar;34(3):8–9
Errors in drug prescribing. Ansari MZ, et al. **J Qual Clin Pract** 1995 Sep;15(3):183–90
Iatrogenic iodine toxicity [letter] Borron SW. **J Toxicol Clin Toxicol** 1996;34(5):531–3
Provision of prescription drug info mandated [news] Marwick C. **JAMA** 1996 Sep 25;276(12):935
Safe prescribing of methotrexate for rheumatoid arthritis [letter] Kirkham BW. **Med J Aust** 1995 Sep 4;163(5):278
Starting SSRI antidepressant therapy: its effect on tricyclic antidepressant and benzodiazepine prescribing [letter] Parkes AJ. **Med J Aust** 1996 Apr 15;164(8):509
A study of unclaimed prescriptions in Hospital Universiti Sains Malaysia (HUSM). Kamaruzaman WS. **Med J Malaysia** 1995 Dec;50(4):396–400
Quantitative comparison of human computer interaction for direct prescription entry systems. Endoh A, et al. **Medinfo** 1995;8 Pt 2:1101–5
Modeling drug information for a prescription-oriented knowledge base on drugs. Milstein C, et al. **Methods Inf Med** 1995 Sep;34(4):318–27
A general model of drug prescription. Séné B, et al. **Methods Inf Med** 1995 Sep;34(4):310–7
Differences between prescribed and dispensed medications. Gardner TL, et al. **N Z Med J** 1996 Mar 8;109(1017):69–72
Trends in antihypertensive prescribing. Penrose A, et al. **N Z Med J** 1996 Jan 26;109(1014):4–7
Prescriptive authority legislation in Arkansas [letter] Crall PT. **Nurse Pract** 1995 Oct;20(10):8, 10–1
Myth, mystique, and monopoly in the prescription of medicine [letter] Sutliff LS. **Nurse Pract** 1996 Mar; 21(3):153–5
Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25–30 (33 ref.)
Changing prescriptive authority of advanced practice nurses. Stempkowski L. **Oncol Nurs Forum** 1996 May;23(4):712
The efficacy of the Prescription of Gain/Output (POGO) in fitting hearing aids to mild and moderate sensorineural hearing losses. Thorpe S, et al. **S Afr J Commun Disord** 1994;41:65–72
Psychotropic medication usage at Lentegeur Hospital, Cape Town [letter] Chouler C, et al. **S Afr Med J** 1994 Dec; 84(12):877
Analysis of paediatric prescribing profiles in two health-funding systems. Rothberg AD, et al. **S Afr Med J** 1996 Jun;86(6):672–4
[Pattern of prescriptions for psychopharmaceuticals to first-admission schizophrenic patients in the county of Arhus] Lützhøft JH, et al. **Ugeskr Laeger** 1996 Apr 8; 158(15):2118–22 (Eng. Abstr.) (Dan)
[Registration in medical journals of prescriptions for strong analgesics prescribed by general practitioners] Sørensen HT, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5538–40 (Eng. Abstr.) (Dan)
[Pharmacotherapy: clinical practice (letter)] van Luijn JC. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):331 (Dut)
[The act of prescribing: a shadow zone in psychiatry] Henry A. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):471–3 (Fre)
[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study] Boissel JP, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1261–6 (Eng. Abstr.) (Fre)
[[Wallonian general physicians. Which prescriptions should be given to elderly persons over 75 years?] Franck J, et al. **Rev Med Liege** 1996 Feb;51(2):163–74 (47 ref.) (Fre)
[Factors influencing the prescribing of nootropic agents (letter)] Schüler P. **Dtsch Med Wochenschr** 1996 Mar 22; 121(12):391 (Ger)
[Factors influencing the prescribing of nootropic drugs. Results of a representative inquiry in Lower Saxony] Stoppe G, et al. **Dtsch Med Wochenschr** 1995 Nov 24; 120(47):1614–9 (Eng. Abstr.) (Ger)
[The "fate" of family practice prescriptions in the hospital. About 50%of prescriptions were changed] Tabache M. **Fortschr Med** 1995 Aug 30;113(24):342 (Ger)
[The prescription of psychopharmaceuticals in general medicine: gender differences] Maggini M, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):261–2 (Ita)
[Osteoporosis drugs prescribed on blue forms!] Halse J, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3050–1 (Eng. Abstr.) (Nor)
[Prescription drugs against osteoporosis (letter)] Medical JB. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3661–2 (Nor)
[Prescription for diazepam 5 mg tablets in Vestfold 1989 and 1995] Otterstad HK, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1331–3 (Eng. Abstr.) (Nor)
[Prescription of platelet antiaggregants in secondary prevention of ischemic heart disease] Calpe Climent AV, et al. **Aten Primaria** 1996 Mar 15;17(4):268–72 (Eng. Abstr.) (Spa)
[Drug prescriptions in general medicine clinics or drugs prescribed by primary care physicians? (letter; comment)] Costa Alcaraz AM, et al. **Aten Primaria** 1995 Oct 31; 16(7):454–5. Comment on: Aten Primaria 1995 Mar 31;15(5):286–8. (Spa)
[A descriptive study of long-term medication authorized in the health district of Lleñá (Badalona)] Díaz Barroso A, et al. **Aten Primaria** 1996 Mar 15;17(4):251–6 (Eng. Abstr.) (Spa)
[Analysis of prescriptions of antibiotics for acute respiratory infections at a health center (see comments)] Formento Tirado JA, et al. **Aten Primaria** 1995 Sep 30;16(5):281–4 (Eng. Abstr.). Comment in: Aten Primaria 1996 Apr 15;17(6):425–6. (Spa)
[Reflections on drug prescriptions arising from a pharmaco-epidemiological course] Mateos Campos R, et al. **Aten Primaria** 1996 May 15;17(8):527–30 (Spa)
[Prescription of antibiotics in acute respiratory infections (letter; comment)] Pérez Caballero MC, et al. **Aten Primaria** 1996 Apr 15;17(6):425–6. Comment on: Aten Primaria 1995 Sep 30;16(5):281–4. (Spa)
[Characteristics of drug acquisition in Morelia (Michoacán), Mexico] Vicencio Acevedo D, et al. **Bol Oficina Sanit Panam** 1995 Sep;119(3):236–42 (Eng. Abstr.) (Spa)
[Utilization of medication by the elderly in Argentine] Iñesta García A, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):315–27 (Eng. Abstr.) (Spa)
[Prescription rules for narcotics are too complicated (letter)] Almkvist H, et al. **Lakartidningen** 1996 Mar 13;93(11):987 (Swe)
[Safety in Swedish health care—a function of the number of signatures! (letter)] Asplund J. **Lakartidningen** 1996 Mar 13;93(11):988–9 (Swe)
[A new form for every fifth prescription!] Bergman U, et al. **Lakartidningen** 1996 May 15;93(20):1928–30 (Swe)
[Lists presented by eight drug committees compared. The number of preparations varies. Similar views on the most expensive drugs] Bergman U, et al. **Lakartidningen** 1996 Apr 10;93(15):1459–60 (Swe)
[New prescription forms counteract quality development (letter)] Brorsson A. **Lakartidningen** 1996 May 8; 93(19):1816 (Swe)
[A test for APC resistance prior to prescription of oral contraceptives? Discussion about screening should be based on facts] Dahlbäck B. **Lakartidningen** 1995 Nov 29; 92(48):4558, 4561 (Swe)
[The prescription registry must be used correctly: quality improvement—not a basis for sanctions] Eliasson G. **Lakartidningen** 1996 Mar 27;93(13):1197–8 (Swe)
[The new prescription form does not function in everyday care (letter)] Forsman B, et al. **Lakartidningen** 1996 Mar 13;93(11):988 (Swe)
[Who is prescribing what and at what cost?] Håkansson A, et al. **Lakartidningen** 1996 Mar 27;93(13):1189–90, 1195 (Swe)
[Free prescription right—a chimera? (letter)] Hoffmann M. **Lakartidningen** 1995 Nov 22;92(47):4405 (Swe)
[Indication for gastroscopy is not the problem. It may prevent medication without previous diagnosis!] Järhult J. **Lakartidningen** 1996 Jun 26;93(26–27):2518–20 (22 ref.) (Swe)
[A new prescription form introduced to prevent falsifications] Johnson K. **Lakartidningen** 1996 Feb 7;93(6):430 (Swe)
[Why are so many drugs prescribed? (letter)] Kihlander M, et al. **Lakartidningen** 1996 Apr 17;93(16):1512 (Swe)
[Who will choose patients' medication in the future? Independent information must be strengthened II] Liedholm H, et al. **Lakartidningen** 1996 Jun 12; 93(24):2315–7 (Swe)
[Who will direct the choice of drugs in the future? Independent drug information must be supported] Lindvall IH. **Lakartidningen** 1996 Apr 10;93(15):1403–5 (Swe)
[Prior to new drug approval: improve the routines of license prescriptions (see comments)] Lundberg B, et al. **Lakartidningen** 1996 Feb 14;93(7):597–600. Comment in: Lakartidningen 1996 Apr 10;93(15):1408, 1411. (Swe)
[Computerized drug prescription increases the benefits (letter)] Malmberg BG. **Lakartidningen** 1996 Aug 28; 93(34):2819–20 (Swe)
[Prescription rules for licensed drugs should not be simplified (letter; comment)] Rastad JA, et al. **Lakartidningen** 1996 Apr 10;93(15):1408, 1411. Comment on: Lakartidningen 1996 Feb 14;93(7):597–600. (Swe)
["Prescription reform" increases demands on physicians' integrity. County council must finance continuing education] Sjögreen J, et al. **Lakartidningen** 1996 Mar 27; 93(13):1196–7 (Swe)
[Too large supplies in medicine cabinets of the elderly. Prescription- and discount-systems should be revised] Skogsberg U, et al. **Lakartidningen** 1996 Mar 6;93(10):912, 915–6 (Swe)
[Signing the prescriptions reduces the risk of errors (letter)] Swartling PG. **Lakartidningen** 1996 Mar 20;93(12):1107–8 (Swe)
[Drug prescription may be influenced by active efforts (letter)] Wallén L, et al. **Lakartidningen** 1995 Oct 4; 92(40):3662 (Swe)
[Physicians should keep a record of their own antibiotic prescriptions! Over-prescribing should be obvious] Wilhelmson B. **Lakartidningen** 1996 Feb 21;93(8):700–4 (Swe)

CLASSIFICATION

GAO report on need for a third class: 'prove it'. Kibbe AH. **Am Pharm** 1995 Dec;NS35(12):48–9

ECONOMICS

Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. Stempel DA, et al. **Arch Fam Med** 1996 Jan;5(1):36–40
Specific therapeutic group age-sex related prescribing units (STAR-PUs): weightings for analysing general practices' prescribing in England [see comments] Lloyd DC, et al. **BMJ** 1995 Oct 14;311(7011):991–4. Comment in: BMJ 1996 Feb 10;312(7027):378.
Prescribing by general practitioner fundholders. Other factors probably explain differences in prescribing [letter; comment] Robinson E. **BMJ** 1996 Mar 30;312(7034):849. Comment on: BMJ 1993 Nov 6;307(6913):1186–9. Comment on: BMJ 1995 Nov 18;311(7016):1347–50.
The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme [see comments] Stewart-Brown S, et al. **BMJ** 1995 Dec 9; 311(7019):1543–7. Comment in: BMJ 1996 Mar 30;312(7034):848. Comment in: BMJ 1996 Mar 30;312(7034):848–9.
Prescribing by general practitioner fundholders. Longer study shows that costs rise again after initial savings [letter; comment] Trimble I, et al. **BMJ** 1996 Mar 30; 312(7034):848–9. Comment on: BMJ 1993 Nov 6;307(6913):1186–9. Comment on: BMJ 1995 Nov 18;311(7016):1347–50. Comment on: BMJ 1995 Dec 9;311(7019):1543–7.
Explaining variations in general practice prescribing costs per ASTRO-PU (age, sex, and temporary resident originated prescribing unit). Whynes DK, et al. **BMJ** 1996 Feb 24;312(7029):488–9
Effects of fundholding on prescribing habits. Results of similar study in Mersey were different [letter; comment] Wilson R, et al. **BMJ** 1996 Mar 30;312(7034):848. Comment on: BMJ 1995 Dec 9;311(7019):1543–7.
Alterations in prescribing by general practitioner fundholders: an observational study [see comments] Wilson RP, et al. **BMJ** 1995 Nov 18;311(7016):1347–50. Comment in: BMJ 1996 Mar 30;312(7034):848–9. Comment in: BMJ 1996 Mar 30;312(7034):849.
Dental prescribing: minimising the cost to the patient and the NHS. Thornhill MH, et al. **Br Dent J** 1996 Feb 10; 180(3):111–5
Influences on prescribing in non-fundholding general practices. Eccles MP, et al. **Br J Gen Pract** 1996 May; 46(406):287–90
Sharing resources to create a district drug formulary: a countywide controlled trial. Hill-Smith I. **Br J Gen Pract** 1996 May;46(406):271–75
Payment equity for prescription drugs [letter] Lexchin J.

Can Fam Physician 1996 Mar;42:404, 406
Opportunity lost: a frontline view of reference-based pricing [editorial] Woollard RF. **Can Med Assoc J** 1996 Apr 15; 154(8):1185–8
GP fundholding and the costs of prescribing. Whynes DK, et al. **J Public Health Med** 1995 Sep;17(3):323–9
Prescribing costs in general practice fundholding [letter; comment] Wilson R, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1710–1. Comment on: Lancet 1995 Oct 28;346(8983):1139–42.
Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs [letter; comment] Frey HS. **N Engl J Med** 1995 Nov 9;333(19):1289–90. Comment on: N Engl J Med 1995 Jun 15;332(24):1612–7.
Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs [letter; comment] Lehmann DF. **N Engl J Med** 1995 Nov 9;333(19):1289; discussion 1290. Comment on: N Engl J Med 1995 Jun 15;332(24):1612–7.
Reducing prescribing [letter] Harris J, et al. **N Z Med J** 1996 Jun 28;109(1024):243
Dispensing of medicines and professional fees [letter] Wray JG. **Vet Rec** 1996 May 18;138(20):503–4
[Usefulness of prescription of generic drugs for cost containment in pharmaceutics. Analysis in the Community of Navarra] Ansa Erice I, et al. **Aten Primaria** 1996 Apr 15;17(6):411–4 (Eng. Abstr.) **(Spa)**
[Factors determining costs of drug prescriptions in primary health care] Cabedo García VR, et al. **Aten Primaria** 1995 Oct 31;16(7):407–8, 410–2, 414–6 (Eng. Abstr.) **(Spa)**
[Should we assess the cost of a drug before prescribing it? (letter)] Giner Valero M, et al. **Aten Primaria** 1996 Feb 29;17(3):233–4 **(Spa)**

HISTORY

Progress of experimental studies on prescriptions designed by Zhang Zhongjing. Jiang T, et al.
J Tradit Chin Med 1996 Mar;16(1):55–64

STANDARDS

Policy to restrict use of i.v. bumetanide. Montgomery PA, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1802–4
Sterile cockpit. Davis NM, et al. **Am Pharm** 1995 Dec; NS35(12):11
The challenge of postal medicine [letter] Rothschild BM. **Ann Intern Med** 1996 Feb 15;124(4):454–5
Identifying inappropriate prescribing in the elderly: time to refocus [editorial] Plushner S, et al. **Ann Pharmacother** 1996 Jan;30(1):81–3
Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Bateman DN, et al. **Br J Gen Pract** 1996 Jan; 46(402):20–5 (12 ref.)
Effectiveness of notification and group education in modifying prescribing of regulated analgesics [see comments] Anderson JF, et al. **Can Med Assoc J** 1996 Jan 1;154(1):31–9. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1005–6; discussion 1006–7. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1006; discussion 1006–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1470, 1472. Comment in: Can Med Assoc J 1996 May 15;154(10):1472, 1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1476; discussion 1476–7.
Variability in prescription drug utilization: issues for research. Anis AH, et al. **Can Med Assoc J** 1996 Mar 1;154(5):635–40
Improving physician prescribing practices: bridge over troubled waters [editorial] MacLeod SM.
Can Med Assoc J 1996 Mar 1;154(5):675–7 (10 ref.)
Prescription writing in Gondar outpatient teaching hospital, Ethiopia. Desta Z, et al. **East Afr Med J** 1996 Feb; 73(2):115–9
Drug name confusion between patients and doctor [letter] Hisa T. **Int J Dermatol** 1996 Apr;35(4):303
The prescription as final common pathway. Avorn J.
Int J Technol Assess Health Care 1995 Summer; 11(3):384–90
Mismedicating the elderly—says who? [editorial] [see comments] Miller AE Jr. **J Fam Pract** 1995 Oct;41(4):331–6 . Comment in: J Fam Pract 1996 Apr;42(4):341–2.
AMA and USP seek physician assistance in preventing medication errors. **J Miss State Med Assoc** 1995 Dec; 36(11):383–5
Doctors should note reason for prescription [letter] Goldstein AO. **N C Med J** 1995 Dec;56(12):596
"Justifying nurse practitioner existence: hard facts to hard figures" [letter] [see comments] Mahoney D.
Nurse Pract 1995 Oct;20(10):8. Comment in: Nurse Pract 1995 Nov;20(11 Pt 1):8, 10.
Change in prescribing patterns of general practitioners in Italy before and after the Reform Drug Act. A case study of changes in the city of Turin. Rolle C, et al.
Pharm World Sci 1995 Sep 22;17(5):158–62
[The prescription as an aid for communication between physicians and pharmacists. A study of errors and insufficient information on prescriptions] Saanum DT, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2325–9 (Eng. Abstr.) **(Nor)**
[Computers and quality: a practical example (letter)] Alonso López FA, et al. **Aten Primaria** 1995 Sep 30;16(5):296 **(Spa)**

STATISTICS & NUMERICAL DATA

Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Menniti-Ippolito F, et al. **Acta Neurol Scand** 1995 Jul; 92(1):49–54
Pharmaco-epidemiological study of drug consumption in the preproductive age period. Majtás J, et al.
Acta Pharm Hung 1995 Jul;65(4):123–5
The menace of beta-lactamase production on antibiotic prescription in community acquired-infections in Nigeria. Oyelese AO, et al. **Afr J Med Med Sci** 1995 Jun; 24(2):125–30
Use of prescription psychotropic drugs among suicide victims in New York City. Marzuk PM, et al.
Am J Psychiatry 1995 Oct;152(10):1520–2
Self-poisonings with antidepressants and other psychotropics in an urban area of Sweden. Isacsson G, et al.
Ann Clin Psychiatry 1995 Sep;7(3):113–8
Prescribing habits of Peruvian physicians and factors influencing them. Zárate Cárdenas E, et al.
Bull Pan Am Health Organ 1995 Dec;29(4):328–37
Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cherny NJ, et al. **Cancer** 1995 Oct 1;76(7):1283–93
Paracetamol prescribing—an epidemic? Dawson KP, et al.
Fam Pract 1996 Apr;13(2):179–81
The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Gurwitz JH, et al. **Health Serv Res** 1995 Dec;30(5):672–85
Prescribing patterns in primary health care in Taiwan. Lai MS, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):437–41
Off-label drug use in human immunodeficiency virus disease. Brosgart CL, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 May 1;12(1):56–62
The pattern of topical corticosteroid prescribing in the United States, 1989–1991. Stern RS. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):183–6
An intervention on discharge polypharmacy. Smith DM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):416–9
Distribution of prescription drug exposures in the elderly: description and implications. Anderson G, et al.
J Clin Epidemiol 1996 Aug;49(8):929–35
Analyses of data quality in registries concerning diabetes mellitus—a comparison between a population based hospital discharge and an insulin prescription registry. Nielsen GL, et al. **J Med Syst** 1996 Feb;20(1):1–10
How common is heart failure? Evidence from PACT (prescribing analysis and cost) data in Nottingham. Clarke KW, et al. **J Public Health Med** 1995 Dec;17(4):459–64
The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures. Martin BC, et al. **Med Care** 1996 Jul;34(7):686–701
Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs. Banfi R, et al.
Pharm World Sci 1995 Jul 28;17(4):138–40
Who is using antihypertensive drugs? A prescription analysis from Finland. Wallenius S, et al.
Scand J Prim Health Care 1996 Mar;14(1):54–61
Retail pharmacies in developing countries: a behavior and intervention framework. Goel P, et al. **Soc Sci Med** 1996 Apr;42(8):1155–61
Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Nizami SQ, et al. **Soc Sci Med** 1996 Apr;42(8):1133–9
Factors influencing physicians' prescribing behaviour in the treatment of childhood diarrhoea: knowledge may not be the clue. Paredes P, et al. **Soc Sci Med** 1996 Apr; 42(8):1141–53
Improving physician prescribing patterns to treat rhinopharyngitis. Intervention strategies in two health systems of Mexico. Pérez-Cuevas R, et al. **Soc Sci Med** 1996 Apr;42(8):1185–94
Small group intervention vs formal seminar for improving appropriate drug use. Santoso B. **Soc Sci Med** 1996 Apr; 42(8):1163–8
[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al.
Encephale 1996 May-Jun;22(3):187–96 (68 ref.) (Eng. Abstr.) **(Fre)**
[Reflexions before the introduction of a drug prescription survey at hospitals] Goubier-Vial C, et al. **Therapie** 1996 Jan-Feb;51(1):57–66 (Eng. Abstr.) **(Fre)**
[Self-assessment of prescribing behavior of psychotropic drugs for children and adolescence. Results of a survey of established physicians] Trott GE, et al.
Psychiatr Prax 1995 Nov;22(6):235–9 (Eng. Abstr.) **(Ger)**
[Prescribed drugs and diagnoses in over 60-year-old persons exemplified by cardiovascular diseases. Follow-up studies using federal health insurance data] von Ferber L, et al. **Z Gerontol Geriatr** 1995 Nov-Dec;28(6):401–7 (Eng. Abstr.) **(Ger)**
[Reduction in prescription of B-preparations in general practice] Krokstad S, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3634–7 (Eng. Abstr.) **(Nor)**
[An analysis of long-term computerized prescriptions for those over and under 65 at a health center] Alonso López FA, et al. **Aten Primaria** 1996 May 31;17(9):555–8 (Eng. Abstr.) **(Spa)**
[Delegated prescription by specialists in primary care] Arroyo MP, et al. **Aten Primaria** 1995 Nov 30;16(9):538–44 (Eng. Abstr.) **(Spa)**
[Analysis of repeat prescriptions in chronic treatments at a health center] Castillo Alonso P, et al. **Aten Primaria** 1995 Nov 30;16(9):526–30 (Eng. Abstr.) **(Spa)**

VETERINARY

Dispensing medicines without first visiting the farm [letter] Baker RW. **Vet Rec** 1996 Feb 3;138(5):119
Dispensing medicines without first visiting the farm [letter] Borthwick BR, et al. **Vet Rec** 1996 Feb 3;138(5):118–9
Prescription of veterinary drugs in fish farming [letter] Grant A, et al. **Vet Rec** 1995 Aug 26;137(9):227–8
Prescription of veterinary drugs in fish farming [letter] Grave K, et al. **Vet Rec** 1995 Jul 8;137(2):51–2
Veterinary medicines [letter] Sanford J. **Vet Rec** 1995 Sep 30;137(14):356

PRESCRIPTIONS, NON-DRUG

Documentation of the hemodialysis prescription: a current evaluation [editorial] Lundin AP, et al.
Am J Kidney Dis 1996 May;27(5):759–61
Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45–51 (32 ref.)
The dialysis prescription: reuse. Maidment HJ, et al.
Am J Nephrol 1996;16(1):52–9 (73 ref.)
Preventing diabetic foot disease: lessons from the Medicare therapeutic shoe demonstration. Wooldridge J, et al.
Am J Public Health 1996 Jul;86(7):935–8
Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status. Potts M, et al. **Drug Saf** 1995 Dec;13(6):333–7
Order writing for parenteral nutrition by registered dietitians. Mueller CM, et al. **J Am Diet Assoc** 1996 Aug;96(8):764–8; quiz 769–70
Second opinion: a computer expert system designed to aid in the determination of spectacle lens prescriptions. Edlefsen DA, et al. **J Am Optom Assoc** 1995 Oct; 66(10):620–30
Orthotic prescription principles. Seleski S.
J Spinal Cord Med 1996 Apr;19(2):97–8
The role of the pediatrician in prescribing therapy services for children with motor disabilities. American Academy of Pediatrics Committee on Children With Disabilities.
Pediatrics 1996 Aug;98(2 Pt 1):308–10
A new method for prescribing exercise: three-point ratings of perceived exertion. Dunbar CC, et al.
Percept Mot Skills 1996 Feb;82(1):139–46
Targets in CAPD and APD prescription. Blake PG.
Perit Dial Int 1996;16 Suppl 1:S143–6 (17 ref.)
Peritoneal dialysis prescription for neonates. Fischbach M.
Perit Dial Int 1996;16 Suppl 1:S512–4 (23 ref.)
The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al.
Perit Dial Int 1996;16 Suppl 1:S147–52 (18 ref.)
Quality assurance of clinical transfusion practice by implementation of the privilege of blood prescription and computerized prospective audit of blood requests. Marconi M, et al. **Transfus Med** 1996 Mar;6(1):11–9

STANDARDS

Impaired delivery of dialysis: diagnosis and correction. Delmez JA, et al. **Am J Nephrol** 1996;16(1):29–34 (15 ref.)

PRESENTATION, BREECH see **BREECH PRESENTATION**

PRESENTATION, FETAL see **LABOR PRESENTATION**

PRESERVATION, BIOLOGICAL

see related
CRYOPROTECTIVE AGENTS
FIXATIVES

Guardians of the wax ... and the patient [editorial] Mills SE, et al. **Am J Clin Pathol** 1995 Oct;104(4):365–7
Trehalose metabolism—new horizons in technological applications. Panek AD. **Braz J Med Biol Res** 1995 Feb; 28(2):169–81 (98 ref.)
Effect of specimen storage on absolute CD4 counts. Kabengera S, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):232–4
Stability of urinary female reproductive hormones stored under various conditions. Kesner JS, et al.
Reprod Toxicol 1995 May-Jun;9(3):239–44

ADVERSE EFFECTS

Discriminating between preservation and reperfusion injury in human cardiac allografts using heart weight and left ventricular mass. Slater JP, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II223–7

METHODS

A new, stable preservation method for cytologic specimens for immunocytochemical analysis [letter] Okuyama T, et al. **Acta Cytol** 1996 Jul-Aug;40(4):853-4

Cryopreservation of teeth. Organizational aspects of a tissue bank for tooth tissues. Politis C, et al. **Acta Stomatol Belg** 1995 Dec;92(4):149-54

Storage and preservation of blood and urine for trace element analysis. A review. Subramanian KS. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):187-210 (96 ref.)

Long-term preservation of DNA in agarose gels using 70% ethanol. Jacobs D, et al. **Biotechniques** 1995 Dec; 19(6):892-4

Comparison of fresh versus sodium acetate acetic acid formalin preserved stool specimens for diagnosis of intestinal protozoal infections. Mank TG, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1076-81

Stability of polypeptide immunoreactants and polyvinyl alcohol as a blocking agent on polyester cloth during dry storage. Boyd S, et al. **Immunol Invest** 1995 Aug; 24(5):795-803

Comparison of preservation techniques for DNA extraction from hymenopterous insects. Dillon N, et al. **Insect Mol Biol** 1996 Feb;5(1):21-4

Improved technique for storage of tear microvolumes. Gilbard JP, et al. **Invest Ophthalmol Vis Sci** 1987 Feb; 28(2):401-3

Comparison of preservation media for storage of stool samples. Wasfy M, et al. **J Clin Microbiol** 1995 Aug; 33(8):2176-8

Protective effect of amiloride during hypothermic hyperkalemic preservation: a 31P NMR study in isolated pig hearts. Kupriyanov VV, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2237-48

Growth and storage of Agrobacterium. van Asma FM. **Methods Mol Biol** 1995;44:1-7

VETERINARY

Methods for permanent conservation of biological objects and anatomic preparations in synthetic resins. Vodenicharov A, et al. **Anat Histol Embryol** 1995 Dec; 24(4):233-6

PRESERVATION, FOOD see FOOD PRESERVATION

PRESERVATIVES, PHARMACEUTICAL

see related

ANTIOXIDANTS

[Stability of phenyl salicylate in alcoholic-aqueous solution] Miyatake N, et al. **Yakugaku Zasshi** 1996 Jan;116(1):65-70 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative--a double-blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782-4

Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Niemeijer NR, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):535-40

To preserve or not to preserve, is that the question? [editorial; comment] Wilson LA. **Br J Ophthalmol** 1996 Jul; 80(7):583-4. Comment on: Br J Ophthalmol 1996 Jul;80(7):588-91.

Thimerosal is a frequent sensitizer but is not in the standard series. Aberer W, et al. **Contact Dermatitis** 1995 Jun; 32(6):367-8

Methyldibromoglutaronitrile is an important contact allergen in The Netherlands. de Groot AC, et al. **Contact Dermatitis** 1996 Feb;34(2):118-20

No cross-sensitization between MCI/MI, benzisothiazolinone and octylisothiazolinone. Geier J, et al. **Contact Dermatitis** 1996 Feb;34(2):148-9

Patch testing with preservatives at St John's from 1982 to 1993. Jacobs MC, et al. **Contact Dermatitis** 1995 Oct; 33(4):247-54

Assessment of continuing sensitivity to MCI/MI (Kathon CG). Jacobs MC, et al. **Contact Dermatitis** 1995 Jul;33(1):69

Frequency of contact sensitivity to drugs and preservatives in patients with conjunctivitis. Rudzki E, et al. **Contact Dermatitis** 1995 Oct;33(4):270

Euxyl K 400: incidence of sensitization, patch test concentration and vehicle. Tosti A, et al. **Contact Dermatitis** 1995 Sep;33(3):193-5

Allergy to Unna boots in four patients. Praditsuwan P, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):906-8

Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Graf P. **Rhinology** 1996 Mar;34(1):9-13

[Replacement of preservation agent Kathon CG in cosmetics by Euxyl K 400; indeed out of the frying pan into the fire] de Groot AC. **Ned Tijdschr Geneeskd** 1995 Sep 9; 139(36):1850 **(Dut)**

[Source and clinical significance of allergy for thiomersal, an organic mercury compound] van 't Veen AJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):297-300 (31 ref.) **(Dut)**

[A new allergen dibromodicyanobutane. Report of a study in 310 patients January-December 1994] Vigan M, et al. **Ann Dermatol Venereol** 1996;123(5):322-4 (Eng. Abstr.) **(Fre)**

[Incidence of hypersensitivity to antibiotics and preservatives in eye drops] Rudzki E, et al. **Klin Oczna** 1995 Mar-Apr; 97(3-4):66-7 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Compatibility of a commercially available low-density polyethylene eye-drop container with antimicrobial preservatives and potassium ascorbate. Barnes AR. **J Clin Pharm Ther** 1995 Dec;20(6):341-4

PHARMACOLOGY

Evaluating the preservative effectiveness of RGP lens care solutions. Keeven J, et al. **CLAO J** 1995 Oct;21(4):238-41

The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light, scanning and transmission electron microscopy study. Braat JP, et al. **Clin Exp Allergy** 1995 Oct;25(10):957-65

Benzalkonium chloride inhibited the histamine release from rat peritoneal mast cells induced by bradykinin and GlcNAc oligomer-specific lectin Datura stramonium agglutinin, but heparin did not. Niitsuma A, et al. **Gen Pharmacol** 1996 Jan;27(1):123-8

The effect of topical cholinergic medications on human Tenon's capsule fibroblasts in tissue culture. Cunlife IA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug; 233(8):507-12

Ophthalmic preservatives as absorption promoters for ocular drug delivery. Sasaki H, et al. **J Pharm Pharmacol** 1995 Sep;47(9):703-7

Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Graf P, et al. **Laryngoscope** 1996 May;106(5 Pt 1):605-9

[Nisin, a potential preservative for topical preparations] Valenta C, et al. **Pharmazie** 1996 Feb;51(2):119-22 (Eng. Abstr.) **(Ger)**

POISONING

Mercury poisoning associated with hepatitis-B immunoglobulin [letter] Lowell JA, et al. **Lancet** 1996 Feb 17;347(8999):480

PRESSORECEPTORS

see related

BAROREFLEX

ANATOMY & HISTOLOGY

Barosensitive neurons in the rostral ventrolateral medulla of the rat in vivo: morphological properties and relationship to C1 adrenergic neurons. Lipski J, et al. **Neuroscience** 1995 Nov;69(2):601-18

CHEMISTRY

Synaptic interactions of substance P immunoreactive nerve terminals in the baro- and chemoreceptor reflexes of the cat. Gatti PJ, et al. **Brain Res** 1995 Sep 25;693(1-2):133-47

DRUG EFFECTS

Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Gratton JP, et al. **Am J Hypertens** 1995 Nov; 8(11):1121-7

Baroreceptor function is restored by antihypertensive therapy through lowering of blood pressure in adult SHR. Ichikawa M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S67-9

Biphasic pressor responses to norepinephrine in humans. Sato K, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):583-7

Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction. Marakas SA, et al. **Eur Heart J** 1995 Jul;16(7):914-21

Cardiovascular and respiratory changes following exposure to a synthetic toxin of Ptychodiscus brevis. Koley J, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):483-6

Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Benter IF, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1138-44

Comparison of early and late start of antihypertensive agents and baroreceptor reflexes. Kumagai K, et al. **Hypertension** 1996 Feb;27(2):209-18

Infrarenal aortic clamp hypertension is exacerbated by baroreceptor blockade. Giglia JS; et al. **J Surg Res** 1996 Aug;64(2):112-5

A noninvasive evaluation of baroreceptor sensitivity with the Valsalva maneuver and phenylephrine methods. Richter JP, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug;17(6):423-8

Effect of pentobarbital anesthesia on the pressor response to agonists in vivo in normal and endotoxemic rats. Hauser GJ, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov; 90(2):289-300

[Vasopressin facilitates aortic baroreceptor activity in the rat] Ma XY, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):394-400 (Eng. Abstr.) **(Chi)**

METABOLISM

Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Freeman K, et al. **Am J Hypertens** 1995 Sep; 8(9):863-9

PHYSIOLOGY

Comparison of two mechanical carotid baroreceptor stimulation techniques. Kardos A, et al. **Acta Physiol Hung** 1995;83(2):121-33

Central blood volume influences sympathetic sudomotor nerve traffic in warm humans. Dodt C, et al. **Acta Physiol Scand** 1995 Sep;155(1):41-51

An impaired carotid sinus distensibility and baroreceptor sensitivity alter autonomic activity in patients with effort angina associated with significant coronary artery disease. Tomiyama H, et al. **Am J Cardiol** 1996 Jul 15;78(2):225-7

Baroreceptor-induced inhibition of sympathetic neurons by GABA acting at a spinal site. Lewis DI, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1885-92

Complexity and "chaos" in blood pressure after baroreceptor denervation of conscious dogs. Wagner CD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1760-6

Renal sympathetic nerve activity after dexmedetomidine in nerve-intact and baroreceptor-denervated rabbits. Oku S, et al. **Anesth Analg** 1996 Sep;83(3):477-81

The effects of ketamine on renal sympathetic nerve activity and phrenic nerve activity in rabbits (with vagotomy) with and without afferent inputs from peripheral receptors. Sasao J, et al. **Anesth Analg** 1996 Feb;82(2):362-7

Dose-dependent increases in the renal sympathetic nerve activity during rapid increase in isoflurane concentration in intact, lower airway-deafferented, and baroreceptor-deafferented rabbits. Okamoto H, et al. **Anesthesiology** 1996 May;84(5):1196-204

Learning of physiological responses: II. Classical conditioning of the baroreflex. Dworkin BR, et al. **Behav Neurosci** 1995 Dec;109(6):1119-36

Effect of baroreceptor activation and systemic hypotension on plasma endothelin 1 and neuropeptide Y. Notarius CF, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1136-43

Demonstrable cardiac reinnervation after human heart transplantation by carotid baroreflex modulation of RR interval. Bernardi L, et al. **Circulation** 1995 Nov 15; 92(10):2895-903

New insights into the pathophysiology of carotid sinus syndrome. Tea SH, et al. **Circulation** 1996 Apr 1; 93(7):1411-6

Alteration of baroreceptor and chemoreceptor reflexes in spontaneously hypertensive rats. Ohta H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S60-1

Baroreceptors in the carotid sinus contribute to arterial baroreceptor reflexes in normotensive rats. Ohta H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S62-3

Influence of central command and ergoreceptors on the splanchnic circulation during isometric exercise. Duprez D, et al. **Eur J Appl Physiol** 1995;71(5):459-63

Heterogeneous responsiveness of the in situ rat vascular endothelial cells to mechanical stretching in vitro. Sugimoto K, et al. **Eur J Cell Biol** 1995 Sep;68(1):70-7

Orthostatic hypertension due to vascular adrenergic hypersensitivity. Benowitz NL, et al. **Hypertension** 1996 Jul;28(1):42-6

Effect of acute haemodilution on right atrial type-B receptor activity in anaesthetized cats. Bhunia S, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):216-22

Cardiopulmonary baroreflex function in nephrotic rats. Neahring JC, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2082-6

Carotid arterial hemodynamics in response to LBNP in normal subjects: methodological aspects. Pannier B, et al. **J Appl Physiol** 1995 Nov;79(5):1546-55

'Aortic baroreceptor' neurons in the nucleus tractus solitarius in rats: convergence of cardiovascular inputs as revealed by heartbeat-locked activity. Nosaka S, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1-2):69-80

Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. Merrill DC, et al. **J Clin Invest** 1996 Feb 15;97(4):1047-55

On the origin of low-frequency blood pressure variability in the conscious dog. Just A, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):215-23

Urinary bladder distension: its effects on carotid baroreceptor reflex left ventricular inotropic response in the dog. Ward J, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):857-68

A noninvasive evaluation of baroreceptor sensitivity with the Valsalva maneuver and phenylephrine methods. Richter JP, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug;17(6):423-8

Inhibition of catecholamine (noradrenaline, dopamine) release in the locus coeruleus and the hypothalamus by baroreceptor activation: identification of the involved baroreceptors. Schneider C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):291-6

Methods for studying intestinal sensitivity and compliance: in vitro studies of balloons and a barostat. Toma TP, et al. **Neurogastroenterol Motil** 1996 Mar;8(1):19–28

Expression of c–fos protein in the nucleus tractus solitarius in response to physiological activation of carotid baroreceptors. Dean C, et al. **Neuroscience** 1995 Nov; 69(1):249–57

Oxytocin antisense reduces salt intake in the baroreceptor–denervated rat. Morris M, et al. **Regul Pept** 1995 Oct 20;59(2):261–6

Baroreflex and chemoreflex control of fetal hormone secretion. Wood CE. **Reprod Fertil Dev** 1995;7(3):479–89 (94 ref.)

Effect of changes in airway surface liquid on laryngeal receptors and muscles. Sant'Ambrogio FB, et al. **Respir Physiol** 1995 Jul;101(1):31–9

Five–year follow–up of patients after thromboendarterectomy of the internal carotid artery: Relevance of baroreceptor sensitivity. Hirschl M, et al. **Stroke** 1996 Jul;27(7):1167–72

[Baroreflexes and congestive heart failure] Aumont MC, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):555–8 (Eng. Abstr.) **(Fre)**

[Dependence between the baroreceptor reflex and the variability of arterial pressure and period of cardiac contraction in rats in arterial hypertension] Gavrikov KE, et al. **Biull Eksp Biol Med** 1995 May;119(5):474–6 **(Rus)**

[The relationship of systemic pressor reactions to the initial (spontaneous) blood pressure level] Osadchil LI, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):89–99 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Observations on carotid sinus hypersensitivity from direct intraneural recordings of sympathetic nerve traffic. Luck JC, et al. **Am J Cardiol** 1996 Jun 15;77(15):1362–5

PRES– and orthostatic–induced heart–rate changes as markers of labile hypertension: magnitude and reliability measures. Rau H, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):105–15

Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Grassi G, et al. **Circulation** 1995 Dec 1;92(11):3206–11

Baroreceptor activity and the induction of sleep. Velden M, et al. **Percept Mot Skills** 1996 Feb;82(1):178

[Ischemic white matter lesions may be caused by the baroreceptor reflex are dysfunction] Obi T. **Rinsho Shinkeigaku** 1995 Aug;35(8):837–42 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Upregulation of imidazoline receptors in the medulla oblongata accounts for the enhanced hypotensive effect of clonidine in aortic barodenervated rats. el–Mas MM, et al. **Brain Res** 1995 Sep 11;691(1–2):195–204

Elastin and mechanoreceptor mechanisms with special reference to the mammalian carotid sinus. Kimani JK. **Ciba Found Symp** 1995;192:215–30; discussion 230–6 (68 ref.)

PRESSURE

see related
ATMOSPHERIC PRESSURE
BLOOD PRESSURE
MANOMETRY

Cold urticaria and delayed pressure urticaria in the same patient [letter] Valsecchi R, et al. **Acta Derm Venereol** 1996 Jan;76(1):89

Intramuscular pressures for monitoring different tasks and muscle conditions. Sejersted OM, et al. **Adv Exp Med Biol** 1995;384:339–50 (56 ref.)

Yield pressure: a new concept in the evaluation of GERD? Ismail T, et al. **Am J Gastroenterol** 1996 Mar;91(3):616–7

Cricoid pressure: are two hands better than one? Cook TM. **Anaesthesia** 1996 Apr;51(4):365–8

Effect of injection pressure on the success rate of peribulbar block. Gillart T, et al. **Anaesthesia** 1996 Aug;51(8):779–82

Compression therapy in painful piezogenic pedal papules. Böni R, et al. **Arch Dermatol** 1996 Feb;132(2):127–8

Kinetics of butyrylcholinesterase in reversed micelles under high pressure. Clery C, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):85–93

Induration of the diabetic foot pad: another risk factor for recurrent neuropathic plantar ulcers. Brink T. **Biomed Tech (Berl)** 1995 Jul–Aug;40(7–8):205–9

The pressure–flow relation in resting rat skeletal muscle perfused with pure erythrocyte suspensions. Sutton DW, et al. **Biorheology** 1995 Jan–Feb;32(1):29–42

Dependence of water conductivity on pressure and temperature in plant stems. Yamamoto R. **Biorheology** 1995 Jul–Aug;32(4):421–30

Cricoid pressure applied after placement of the laryngeal mask prevents gastric insufflation but inhibits ventilation. Asai T, et al. **Br J Anaesth** 1996 Jun;76(6):772–6

Effect of digital pressure on the neurovascular sheath during perivascular axillary block. Koschielniak–Nielsen ZJ, et al. **Br J Anaesth** 1995 Dec;75(6):702–6

Pressure effects on metabolism in tissues from mice (Mus muscalis) and freshwater mussel (Elliptio complanata). Cheney MA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):69–76

A comparison of the dynamic pedobarograph and EMED systems for measuring dynamic foot pressures. Quaney B, et al. **Foot Ankle Int** 1995 Sep;16(9):562–6

A system for the analysis of seat support surfaces using surface shape control and simultaneous measurement of applied pressures. Brienza DM, et al. **IEEE Trans Rehabil Eng** 1996 Jun;4(2):103–13

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197–219 (122 ref.)

Membranes as a target for stress adaptation. Russell NJ, et al. **Int J Food Microbiol** 1995 Dec;28(2):255–61

Acoustic radiation pressure in a three–dimensional lossy medium. Jiang ZY, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):741–7

Multiple mechanosensitive ion channels from Escherichia coli, activated at different thresholds of applied pressure. Berrier C, et al. **J Membr Biol** 1996 May;151(2):175–87

Correlation of measurements of pressure perception using the pressure–specified sensory device with electrodiagnostic testing. Tassler PL, et al. **J Occup Environ Med** 1995 Jul;37(7):862–6

Central compartment pressure monitoring following clubfoot release. Hanlon M, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):63–6

Effect of pressure on echocardiographic videodensity from sonicated albumin: an in vitro model. Gottlieb S, et al. **J Ultrasound Med** 1995 Feb;14(2):109–16

Application of pressure to biochemical equilibria: the other thermodynamic variable. Royer CA. **Methods Enzymol** 1995;259:357–77

Temporomandibular joint compression in coma. Wijdicks EF. **Neurology** 1996 Jun;46(6):1774

Circumferential pressure as a rapid method to assess intraosseous needle placement. Strausbaugh SD, et al. **Pediatr Emerg Care** 1995 Oct;11(5):274–6

High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697–706 (63 ref.)

Pressure antagonism of nitrous oxide depression of intracellular calcium in a neuroblastoma cell line. Resendes MC, et al. **Undersea Hyperb Med** 1996 Mar;23(1):27–30

[Treatment of keloids of the earlobe (see comments)] Vegter F, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1678–80 (18 ref.). Comment in: Ned Tijdschr Geneeskd 1995 Oct 14;139(41):2110–1. Comment in: Ned Tijdschr Geneeskd 1995 Nov 25;139(47):2453. **(Dut)**

[Intermittent impulse compression. An alternative in therapy of post–traumatic and postoperative edema] Stöckle U, et al. **Chirurg** 1996 May;67(5):539–45 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Veterinary and industrial high pressure injection injuries [editorial] Burke F, et al. **BMJ** 1996 Jun 8;312(7044):1436

Verrucous skin lesions on the feet in diabetic neuropathy [letter; comment] Gerbig AW, et al. **Br J Dermatol** 1995 Dec;133(6):1011–2. Comment on: Br J Dermatol 1994 Nov;131(5):747–8.

Immunohistological comparison of granulated cell proteins in induced immediate urticarial dermographism and delayed pressure urticaria lesions. McEvoy MT, et al. **Br J Dermatol** 1995 Dec;133(6):853–60

Dystrophic form of inherited epidermolysis bullosa in a dog (Akita Inu). Nagata M, et al. **Br J Dermatol** 1995 Dec; 133(6):1000–3

Hemodynamic effects of high–frequency oscillatory ventilation in severe pediatric respiratory failure. Gutiérrez JA, et al. **Intensive Care Med** 1995 Jun;21(6):505–10

Major vascular injury from high–pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165–7 (15 ref.)

[Delayed–pressure urticaria––analysis of 28 patients] Mijailović B, et al. **Vojnosanit Pregl** 1995 May–Jun; 52(3):237–40 (Eng. Abstr.) **(Ser)**

PRESSURE SORE see **DECUBITUS ULCER**

PRESSURE SUITS see **G SUITS**

PRESSURE ULCER see **DECUBITUS ULCER**

PRESYNAPTIC RECEPTORS see **RECEPTORS, PRESYNAPTIC**

PRESYNAPTIC TERMINALS

Quantitative morphological analysis of subicular terminals in the rat entorhinal cortex. van Haeften T, et al. **Hippocampus** 1995;5(5):452–9

Presynaptic dopaminergic deficits in Lesch–Nyhan disease [see comments] Ernst M, et al. **N Engl J Med** 1996 Jun 13;334(24):1568–72. Comment in: N Engl J Med 1996 Jun 13;334(24):1602–4.

Presynaptic Mechanisms of Neurotransmission. Proceedings of a meeting. San Diego, California, 9–11 November 1995. **Neuropharmacology** 1995 Nov;34(11):1343–587

CHEMISTRY

Identification of a 140 kDa protein of rat presynaptic terminal membranes encompassing the active zones. Stieber A, et al. **Brain Res** 1995 Nov 27;700(1–2):261–70

The sap47 gene of Drosophila melanogaster codes for a novel conserved neuronal protein associated with synaptic terminals. Reichmuth C, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):45–54

Dystrophin localization at presynapse in rat retina revealed by immunoelectron microscopy [see comments] Ueda H, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2318–22 . Comment in: Invest Ophthalmol Vis Sci 1996 Feb;37(2):255.

Synapsin I deficiency results in the structural change in the presynaptic terminals in the murine nervous system. Takei Y, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1789–800

Differential synaptic innervation of neurons in the internal and external segments of the globus pallidus by the GABA–and glutamate–containing terminals in the squirrel monkey. Shink E, et al. **J Comp Neurol** 1995 Jul 17;358(1):119–41

Synaptic innervation of midbrain dopaminergic neurons by glutamate–enriched terminals in the squirrel monkey. Smith Y, et al. **J Comp Neurol** 1996 Jan 8;364(2):231–53

Synaptic vesicle movements monitored by fluorescence recovery after photobleaching in nerve terminals stained with FM1–43. Henkel AW, et al. **J Neurosci** 1996 Jun 15; 16(12):3960–7

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2A–autoreceptors in rabbit atria and kidney. Limberger N, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):31–42

Localization and functional significance of the Na+/Ca2+ exchanger in presynaptic boutons of hippocampal cells in culture. Reuter H, et al. **Neuron** 1995 Nov;15(5):1077–84

Co–localization of angiotensin II and gamma–aminobutyric acid in axon terminals in the rat subfornical organ. Pickel VM, et al. **Neurosci Lett** 1995 Jun 30;193(2):89–92

Interaction between substance P–immunoreactive central terminals and gamma–aminobutyric acid–immunoreactive elements in synaptic glomeruli in the lamina II of the chicken spinal cord. Sakamoto H, et al. **Neurosci Res** 1995 Nov;23(4):335–43

DRUG EFFECTS

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

Parenterally administered 3–nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum. Bowyer JF, et al. **Brain Res** 1996 Mar 18;712(2):221–9

Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. Baumann MH, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):87–93

Presynaptic depression of inhibitory postsynaptic potentials by metabotropic glutamate receptors in rat hippocampal CA1 pyramidal cells. Jouvenceau A, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):131–9

Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. Urban R, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):29–37

Decreased monosynaptic GABAB–mediated inhibitory postsynaptic potentials in hippocampal CA1 pyramidal cells in the aged rat: pharmacological characterization and possible mechanisms. Billard JM, et al. **J Neurophysiol** 1995 Aug;74(2):539–46

Activation of GABAB receptors at individual release boutons of the crayfish opener neuromuscular junction produces presynaptic inhibition. Fischer Y, et al. **J Neurophysiol** 1996 Apr;75(4):1377–85

Nitric oxide is used as an orthograde cotransmitter at identified histaminergic synapses. Jacklet JW. **J Neurophysiol** 1995 Aug;74(2):891–5

The presynaptic alpha–2 autoreceptors in pig brain cortex are alpha–2A. Trendelenburg AU, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):462–7

Ethanol increases the activity of large conductance, Ca(2+)–activated K+ channels in isolated neurohypophysial terminals. Dopico AM, et al. **Mol Pharmacol** 1996 Jan;49(1):40–8

Sub–nanomolar concentrations of ciguatoxin–1 excite preganglionic terminals in guinea pig sympathetic ganglia. Hamblin PA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):236–46

pH–dependent modulation of N–methyl–D–aspartate receptor–mediated synaptic currents by histamine in rat hippocampus in vitro. Saybasili H, et al. **Neurosci Lett** 1995 Oct 27;199(3):225–7

Zn2+ potentiates steady–state ATP activated currents in rat nodose ganglion neurons by increasing the burst duration of a 35 pS channel. Wright JM, et al. **Neurosci Lett** 1995 Jul 7;193(3):177–80

Synthesis of an O–palmitoylated 44–residue peptide amide (PLTX II) blocking presynaptic calcium channels in Drosophila. Bódi J, et al. **Pept Res** 1995 Jul–Aug; 8(4):228–35

ENZYMOLOGY

Characterization of dual leucine zipper–bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane

depolarization via calcineurin. Mata M, et al. **J Biol Chem** 1996 Jul 12;271(28):16888–96

Carotid sinus nerve terminals which are tyrosine hydroxylase immunoreactive are found in the commissural nucleus of the tractus solitarius. Massari VJ, et al. **J Neurocytol** 1996 Mar;25(3):197–208

A presynaptic inositol-5-phosphatase. McPherson PS, et al. **Nature** 1996 Jan 25;379(6563):353–7

METABOLISM

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

Effects of aging on prejunctional control of neurotransmission in the rat. Docherty JR. **Ann N Y Acad Sci** 1996 Jun 15;786:264–73

Rate of Na+/Ca2+ exchange across the plasma membrane of synaptosomes measured using the fluorescence of chlorotetracycline. Implications to calcium homeostasis in synaptic terminals. García-Martín E, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):257–64

Direct demonstration of sulphonylurea-sensitive KATP channels on nerve terminals of the rat motor cortex. Lee K, et al. **Br J Pharmacol** 1995 Jun;115(3):385–7

Suppression of presynaptic calcium influx by metabotropic glutamate receptor agonists in neonatal rat hippocampus. Yoshino M, et al. **Brain Res** 1995 Oct 16;695(2):179–85

Abnormalities in brain serotonin concentration, high-affinity uptake, and tryptophan hydroxylase activity in severe-seizure genetically epilepsy-prone rats. Statnick MA, et al. **Epilepsia** 1996 Apr;37(4):311–21

Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Gatley SJ, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):141–9

Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Rongen GA, et al. **Hypertension** 1996 Apr;27(4):933–8

Glutamate-like immunoreactivity in synaptic terminals of the posterior cingulopontine pathway: a light and electron microscopic study in the rabbit. Azkue J, et al. **J Chem Neuroanat** 1995 Dec;9(4):261–9

The glutamate-enriched cortical and thalamic input to neurons in the subthalamic nucleus of the rat: convergence with GABA-positive terminals. Bevan MD, et al. **J Comp Neurol** 1995 Oct 23;361(3):491–511

Morphologically heterogeneous met-enkephalin terminals form synapses with tyrosine hydroxylase-containing dendrites in the rat nucleus locus coeruleus. Van Bockstaele EJ, et al. **J Comp Neurol** 1995 Dec 18;363(3):423–38

Presynaptic metabotropic glutamate receptors in adult and developing neurons: autoexcitation in the olfactory bulb. van den Pol AN. **J Comp Neurol** 1995 Aug 21; 359(2):253–71

Removal of extracellular chloride suppresses transmitter release from photoreceptor terminals in the mudpuppy retina. Thoreson WB, et al. **J Gen Physiol** 1996 May; 107(5):631–42

Evidence for presynaptic adenosine A2a receptors associated with norepinephrine release and their desensitization in the rat nucleus tractus solitarius. Barraco RA, et al. **J Neurochem** 1995 Oct;65(4):1604–11

Presynaptic nicotinic receptors stimulate increases in intraterminal calcium of chick sympathetic neurons in culture. Doležal V, et al. **J Neurochem** 1995 Oct; 65(4):1874–9

Clustering of gephyrin at GABAergic but not glutamatergic synapses in cultured rat hippocampal neurons. Craig AM, et al. **J Neurosci** 1996 May 15;16(10):3166–77

Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. Gereau RW 4th, et al. **J Neurosci** 1995 Oct;15(10):6879–89

PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. Hunt CA, et al. **J Neurosci** 1996 Feb 15;16(4):1380–8

Presynaptic glutamate levels in tonic and phasic motor axons correlate with properties of synaptic release. Shupliakov O, et al. **J Neurosci** 1995 Nov;15(11):7168–80

Hyperosmotic activation of transmitter release from presynaptic terminals onto retinal ganglion cells. Yu W, et al. **J Neurosci Methods** 1995 Nov;62(1–2):159–68

Presystemic bradykinin metabolism in sheep and rat nasal homogenates. Chung FY, et al. **J Pharm Sci** 1995 Jul; 84(7):794–8

GABAB receptor-mediated presynaptic inhibition in guinea-pig hippocampus is caused by reduction of presynaptic Ca2+ influx. Wu LG, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):649–57

Mediatophore and other presynaptic proteins. A cybernetic linking at the active zone. Dunant Y, et al. **J Physiol Paris** 1995;89(3):147–56 (68 ref.)

Subtype determination of presynaptic alpha 2-autoreceptors in the rabbit pulmonary artery and human saphenous vein. Molderings GJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):483–90

Regulation of intracellular [Ca2+] and GABA release by presynaptic GABAB receptors in rat cerebrocortical synaptosomes. Santos AE, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):397–406

The concept of calcium concentration microdomains in synaptic transmission. Llinás R, et al. **Neuropharmacology** 1995 Nov;34(11):1443–51

Detecting changes in calcium influx which contribute to synaptic modulation in mammalian brain slice. Sabatini BL, et al. **Neuropharmacology** 1995 Nov;34(11):1453–67

Co-localization of mu-opioid receptor-like and substance P-like immunoreactivities in axon terminals within the superficial layers of the medullary and spinal dorsal horns of the rat. Ding YQ, et al. **Neurosci Lett** 1995 Sep 22; 198(1):45–8

Presynaptic localization of mu-opioid receptor-like immunoreactivity in retinal axon terminals within the terminal nuclei of the accessory optic tract: a light and electron microscope study in the rat. Ding YQ, et al. **Neurosci Lett** 1995 Oct 20;199(2):139–42

ERK2-type mitogen-activated protein kinase (MAPK) and its substrates in postsynaptic density fractions from the rat brain. Suzuki T, et al. **Neurosci Res** 1995 Jun;22(3):277–85

High-resolution immunogold localization of AMPA type glutamate receptor subunits at synaptic and non-synaptic sites in rat hippocampus. Baude A, et al. **Neuroscience** 1995 Dec;69(4):1031–55

Synaptic expression of the high-affinity kainate receptor subunit KA2 in hippocampal cultures. Roche KW, et al. **Neuroscience** 1995 Nov;69(2):383–93

Immunocytochemical evidence for the presence of vasopressin in intermediate sized neurosecretory granules of solitary neurohypophyseal terminals in the homozygous Brattleboro rat. Sonnemans MS, et al. **Neuroscience** 1996 May;72(1):225–31

Role of the C2B domain of synaptotagmin in vesicular release and recycling as determined by specific antibody injection into the squid giant synapse preterminal. Fukuda M, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10708–12

The entry and clearance of Ca2+ at individual presynaptic active zones of hair cells from the bullfrog's sacculus. Issa NP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9527–32

Role of the C2A domain of synaptotagmin in transmitter release as determined by specific antibody injection into the squid giant synapse preterminal. Mikoshiba K, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10703–7

Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Wan FJ, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):433–41

Acetylcholine receptors: too many channels, too few functions [see comments] Sivilotti L, et al. **Science** 1995 Sep 22;269(5231):1681–2. Comment in: Science 1995 Sep 22;269(5231):1692–6.

Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine. Gatley SJ, et al. **Synapse** 1995 Jun; 20(2):137–44

PATHOLOGY

The role of remaining presynaptic terminals in the hippocampal CA1 after selective neuronal death: ischemia-induced glutamate efflux. Mitani A, et al. **Acta Neuropathol (Berl)** 1996;91(1):41–6

Adrenal medullary implants reduce transsynaptic degeneration in the spinal cord of rats following chronic constriction nerve injury. Hama AT, et al. **Exp Neurol** 1996 Jan;137(1):81–93

PHYSIOLOGY

The role of remaining presynaptic terminals in the hippocampal CA1 after selective neuronal death: ischemia-induced glutamate efflux. Mitani A, et al. **Acta Neuropathol (Berl)** 1996;91(1):41–6

Fatigue at the neuromuscular junction. Branch point vs. presynaptic vs. postsynaptic mechanisms. Sieck GC, et al. **Adv Exp Med Biol** 1995;384:83–100 (90 ref.)

Nucleus tractus solitarius efferent terminals synapse on neurons in the caudal ventrolateral medulla that project to the rostral ventrolateral medulla. Aicher SA, et al. **Brain Res** 1995 Sep 25;693(1–2):51–63

Synaptic interactions of substance P immunoreactive nerve terminals in the baro- and chemoreceptor reflexes of the cat. Gatti PJ, et al. **Brain Res** 1995 Sep 25;693(1–2):133–47

Enhanced release of acetylcholine in the rostral ventrolateral medulla of spontaneously hypertensive rats. Kubo T, et al. **Brain Res** 1995 Jul 17;686(1):1–9

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)

The basement membrane at the neuromuscular junction: a synaptic mediatrix. Carbonetto S, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):596–605 (64 ref.)

Expression of the unc-4 homeoprotein in Caenorhabditis elegans motor neurons specifies presynaptic input. Miller DM 3rd, et al. **Development** 1995 Sep;121(9):2877–86

Synaptic connections and putative functions of the dopaminergic innervation of the guinea pig cochlea. d'Aldin C, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):270–4

Postsynaptic targets of Purkinje cell terminals in the cerebellar and vestibular nuclei of the rat. De Zeeuw CI, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2322–33

Synaptic evoked potentials from regenerating dorsal root axons within fetal spinal cord tissue transplants. Houle JD, et al. **Exp Neurol** 1996 Jun;139(2):278–90

Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Umbriaco D, et al. **Hippocampus** 1995;5(6):605–20

Presynaptic excitability. Jackson MB. **Int Rev Neurobiol** 1995; 38:201–51 (296 ref.)

Two types of corticopulvinar terminations: round (type 2) and elongate (type 1). Rockland KS. **J Comp Neurol** 1996 Apr 22;368(1):57–87

Dual signalling by the adenosine A2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. Gubitz AK, et al. **J Neurochem** 1996 Jul; 67(1):374–81

Presynaptic NMDA receptors display physiological characteristics of homomeric complexes of NR1 subunits that contain the exon 5 insert in the N-terminal domain. Wang JK, et al. **J Neurochem** 1996 Feb;66(2):865–8

Synaptic contacts from nodes of Ranvier in the granular layer of the frog cerebellum. Kohno K, et al. **J Neurocytol** 1972 Oct;1(3):255–62

Depression of synaptic connections between identified motor neurons in the locust. Parker D. **J Neurophysiol** 1995 Aug; 74(2):529–38

Effective synaptic current and motoneuron firing rate modulation. Powers RK, et al. **J Neurophysiol** 1995 Aug; 74(2):793–801

Synaptic current kinetics in a solely AMPA-receptor-operated glutamatergic synapse formed by rat retinal ganglion neurons. Taschenberger H, et al. **J Neurophysiol** 1995 Sep;74(3):1123–36

Functional GABAergic synaptic connection in neonatal mouse barrel cortex. Agmon A, et al. **J Neurosci** 1996 Aug 1;16(15):4684–95

Presynaptic facilitation revisited: state and time dependence. Byrne JH, et al. **J Neurosci** 1996 Jan 15;16(2):425–35 (132 ref.)

Comparative study of pre- and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. File SE, et al. **J Neurosci** 1996 Aug 1;16(15):4810–5

Frequency and dendritic distribution of autapses established by layer 5 pyramidal neurons in the developing rat neocortex: comparison with synaptic innervation of adjacent neurons of the same class. Lübke J, et al. **J Neurosci** 1996 May 15;16(10):3209–18

Pharmacological characterization of presynaptic calcium currents underlying glutamatergic transmission in the avian auditory brainstem. Sivaramakrishnan S, et al. **J Neurosci** 1995 Oct;15(10):6576–85

Homeostasis of synaptic transmission in Drosophila with genetically altered nerve terminal morphology. Stewart BA, et al. **J Neurosci** 1996 Jun 15;16(12):3877–86

Functional correlation of NMDA receptor epsilon subunits expression with the properties of single-channel and synaptic currents in the developing cerebellum. Takahashi T, et al. **J Neurosci** 1996 Jul 15;16(14):4376–82

A quantitative analysis of presynaptic calcium dynamics that contribute to short-term enhancement. Tank DW, et al. **J Neurosci** 1995 Dec;15(12):7940–52

Calcium-dependent inactivation of calcium current in synaptic terminals of retinal bipolar neurons. von Gersdorff H, et al. **J Neurosci** 1996 Jan;16(1):115–22

Preparative methods for brain slices: a discussion. Aitken PG, et al. **J Neurosci Methods** 1995 Jun;59(1):139–49

The brain slice preparation: a tribute to the pioneer Henry McIlwain. Collingridge GL. **J Neurosci Methods** 1995 Jun; 59(1):5–9

Making the best of brain slices: comparing preparative methods. Lipton P, et al. **J Neurosci Methods** 1995 Jun; 59(1):151–6

A method of estimating the rate of miniature end-plate potential occurrences based on parametric time series modeling. Mino H, et al. **J Neurosci Methods** 1995 Dec; 63(1–2):93–101

Synaptic plasticity: stairway to memory. Jodar L, et al. **Jpn J Pharmacol** 1995 Aug;68(4):359–87 (285 ref.)

Patterns of presynaptic gene expression define two stages of synaptic differentiation. Lou XJ, et al. **Mol Cell Neurosci** 1995 Jun;6(3):252–62

Subclassification of presynaptic alpha 2-adrenoceptors: alpha 2D-autoreceptors in mouse brain. Limberger N, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):43–8

Synaptic transmission at single visualized hippocampal boutons. Liu G, et al. **Neuropharmacology** 1995 Nov; 34(11):1407–21

Descending noradrenergic neurones tonically suppress spinal presynaptic inhibition in rats. Hasegawa Y, et al. **Neuroreport** 1995 Dec 29;7(1):262–6

Polysynaptic neural pathways from low threshold trunk cutaneous afferents to tail motoneurons in the spinalized cat. Wada N, et al. **Neurosci Lett** 1995 Nov 10;200(1):49–52

Differences in dispersion of monkey optic nerve fibers according to their terminal layers in the lateral geniculate nucleus. Naito J. **Neurosci Res** 1995 Jun;22(3):347–50

Ca(2+)-dependent Cl- current at the presynaptic terminals of goldfish retinal bipolar cells. Okada T, et al. **Neurosci Res** 1995 Oct;23(3):297–303

Lack of evidence for P2X-purinoceptor involvement in fast synaptic responses in intact sympathetic ganglia isolated from guinea-pigs. Inokuchi H, et al. **Neuroscience** 1995 Nov;69(2):651–9

A neural tetraspanin, encoded by late bloomer, that facilitates

synapse formation [see comments] Kopczynski CC, et al. **Science** 1996 Mar 29;271(5257):1867–70. Comment in: Science 1996 Mar 29;271(5257):1807–5.
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors [see comments] McGehee DS, et al. **Science** 1995 Sep 22;269(5231):1692–6. Comment in: Science 1995 Sep 22;269(5231):1681–2.
LTP—a structural model to explain the inconsistencies [see comments] Edwards FA. **Trends Neurosci** 1995 Jun; 18(6):250–5. Comment in: Trends Neurosci 1995 Dec;18(12):519–20.

SECRETION

The neuronal exocytotic fusion machine: some new developments. Chapman ER, et al. **Neuropharmacology** 1995 Nov;34(11):1343–9 (64 ref.)
v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351–60 (63 ref.)
Quantal secretion recorded from visualized boutons. Warren D, et al. **Neurosci Lett** 1995 Jun 16;192(3):205–8
Probabilistic secretion of quanta at somatic motor–nerve terminals: the fusion-pore model, quantal detection and autoinhibition. Thomson PC, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Aug 29; 349(1328):197–214

ULTRASTRUCTURE

Evidence of synaptic contacts of nociceptive primary afferent central terminals on GABAergic interneurons in the substantia gelatinosa. Hiura A, et al. **Arch Histol Cytol** 1996 Mar;59(1):55–60
Electron microscopic evidence that axon terminals from the mediodorsal thalamic nucleus make direct synaptic contacts with callosal cells in the prelimbic cortex of the rat. Kuroda M, et al. **Brain Res** 1995 Apr 24;677(2):348–53
Association of dopaminergic terminals and neurons releasing nitric oxide in the rat striatum: an electron microscopic study using NADPH-diaphorase histochemistry and tyrosine hydroxylase immunohistochemistry. Fujiyama F, et al. **Brain Res Bull** 1996;40(2):121–7
A comparative ultrastructural study of primary afferents from the brachial and cervical plexuses to the external cuneate nucleus of gerbils. Lan CT, et al. **J Anat** 1995 Aug;187 (Pt 1):115–25
Quantitative analysis of synaptogenesis in the inner plexiform layer of macaque monkey fovea. Crooks J, et al.
J Comp Neurol 1995 Sep 18;360(2):349–62
"Satellite cells" and nerve terminals in the crayfish opener muscle visualized with fluorescent dyes. Harrington CC, et al. **J Comp Neurol** 1995 Oct 23;361(3):441–50
Ultrastructure of the synaptic terminals of the dorsal giant serotonin-IR neuron and deutocerebral commissure interneurons in the accessory and olfactory lobes of the crayfish. Sandeman RE, et al. **J Comp Neurol** 1995 Oct 30;361(4):617–32
An ultrastructural study of cuneocerebellar neurons and primary afferent terminals in the external cuneate nucleus of gerbils as revealed by retrograde and transganglionic transport of horseradish peroxidase. Lan CT, et al.
J Neurocytol 1995 Jun;24(6):465–77
Synaptic degenerative changes in human traumatic brain edema. An electron microscopic study of cerebral cortical biopsies. Castejòn OJ, et al. **J Neurosurg Sci** 1995 Mar; 39(1):47–65
Ultrastructural associations between dopamine terminals and local circuit neurons in the monkey prefrontal cortex: a study of calretinin-immunoreactive cells. Sesack SR, et al. **Neurosci Lett** 1995 Nov 10;200(1):9–12
Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Anderson SA, et al. **Neuroscience** 1995 Jul;67(1):7–22

PREVALENCE

The relationship between white matter low attenuation on brain CT and vascular risk factors: a memory clinic study. Amar K, et al. **Age Ageing** 1995 Sep;24(5):411–5
Behavior problems of residents with dementia in special care units. Wagner AW, et al. **Alzheimer Dis Assoc Disord** 1995 Fall;9(3):121–7
Alternative approaches for estimating prevalence in epidemiologic surveys with two waves of respondents. Brenner H. **Am J Epidemiol** 1995 Dec 1;142(11):1236–45
Internal validity analysis: a method for adjusting capture–recapture estimates of prevalence. Hook EB, et al. **Am J Epidemiol** 1995 Nov 1;142(9 Suppl):S48–52
Posttraumatic stress disorder in the National Comorbidity Survey. Kessler RC, et al. **Arch Gen Psychiatry** 1995 Dec; 52(12):1048–60
Sources of variability in prevalence rates of Alzheimer's disease. Corrada M, et al. **Int J Epidemiol** 1995 Oct; 24(5):1000–5 (37 ref.)
Estimation of prevalence rate ratios from cross-sectional data [letter; comment] Zocchetti C, et al. **Int J Epidemiol** 1995 Oct;24(5):1064–7. Comment on: Int J Epidemiol 1994 Apr;23(2):428–9.
The law of halves. Herman J. **J Clin Epidemiol** 1996 May; 49(5):595–8 (40 ref.)
On prevalence and incidence [editorial] Herman J. **Scand J Prim Health Care** 1995 Sep;13(3):161–2
Confidence limits for the population prevalence rate based on the negative binomial distribution. Lui KJ. **Stat Med** 1995 Jul 15;14(13):1471–7

PREVALENCE STUDIES see **CROSS-SECTIONAL STUDIES**

PREVENTION, PRIMARY see **PRIMARY PREVENTION**

PREVENTIVE DENTISTRY

see related
DENTAL CLINICS
HEALTH EDUCATION, DENTAL

[Analysis of activities of the preventive dentistry service in the Health Area 8 of the Valencia Autonomous Region] Llena Puy MC, et al. **Aten Primaria** 1996 Feb 29; 17(3):202–6 (Eng. Abstr.) **(Spa)**
[Evaluation of a 4-year dental hygiene preventive program of the Les Planes health district in Sant Joan Despí (Barcelona)] Pujol MT, et al. **Aten Primaria** 1996 May 15; 17(8):523–6 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

The prevalence of dental sealants in the US population: findings from NHANES III, 1988–1991. Selwitz RH, et al. **J Dent Res** 1996 Feb;75 Spec No:652–60

PREVENTIVE HEALTH SERVICES

see related
HEALTH PROMOTION
IMMUNIZATION

An ecological assessment of community-based interventions for prevention and health promotion: approaches to measuring community coalitions. Goodman RM, et al.
Am J Community Psychol 1996 Feb;24(1):33–61
The Washington Heights-Inwood Healthy Heart Program: a 6-year report from a disadvantaged urban setting. Shea S, et al. **Am J Public Health** 1996 Feb;86(2):166–71
Preventive health care [letter] Feldman W.
Arch Pediatr Adolesc Med 1996 Mar;150(3):330
Fair shares in health care? Ethnic and socioeconomic influences on recording of preventive care in selected inner London general practices. Healthy Eastenders Project [see comments] Atri J, et al. **BMJ** 1996 Mar 9;312(7031):614–7 . Comment in: BMJ 1996 Jul 6;313(7048):48.
Harnessing the strengths of the leprosy programme to control tuberculosis. Lockwood DN, et al. **BMJ** 1995 Sep 30; 311(7009):862–3
Vietnamese people in study may have had language difficulties [letter; comment] Nguyen-Van-Tam JS, et al. **BMJ** 1996 Jul 6;313(7048):48. Comment on: BMJ 1996 Mar 9;312(7031):614–7.
Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)
Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm. Marshall KG.
Can Med Assoc J 1996 Jul 15;155(2):169–76 (94 ref.)
Effectiveness of control programs for pneumonia among children in China and Fiji. Shimouchi A, et al.
Clin Infect Dis 1995 Dec;21 Suppl 3:S213–17
Computer system to improve delivery of preventive care [letter; comment] Dickey LL. **Fam Med** 1995 Nov-Dec; 27(10):630. Comment on: Fam Med 1995 Apr;27(4):260–6.
HMSA's HealthPass—a strategy for delivery of preventive services. Park G. **Hawaii Med J** 1995 Aug;54(8):697–703
Interpreting excess mortality in a prevention trial for older adults. Patrick DL, et al. **Int J Epidemiol** 1995;24 Suppl 1:S27–33
10-year educational programme aimed at rheumatic fever in two French Caribbean islands [see comments] Bach JF, et al. **Lancet** 1996 Mar 9;347(9002):644–8. Comment in: Lancet 1996 May 4;347(9010):1271–2.
Preventive health care in a multicultural society: are we culturally competent? [editorial] Walker PF.
Mayo Clin Proc 1996 May;71(5):519–21
Protecting Australian overseas travellers [letter] Jackson MS, et al. **Med J Aust** 1996 Jul 15;165(2):119–20
Not-for-profit health plans [letter] Harris RH Jr.
N Engl J Med 1996 Aug 8;335(6):438
The new edition of the Guide to Clinical Preventive Services. Wilson M, et al. **Pediatrics** 1996 May;97(5):733–5
Prevention—how much of it in our health care? [editorial; comment] **West Afr J Med** 1995 Apr-Jun;14(2):70–1. Comment on: West Afr J Med 1995 Apr-Jun;14(2):91–6. Comment on: West Afr J Med 1995 Apr-Jun;14(2):101–4.
Preventive care in emergency departments. Rodriguez RM.
West J Med 1996 Jan;164(1):68
Cardiovascular disease prevention projects in local public health agencies, Wisconsin, 1995. Watson L, et al.
Wis Med J 1995;94(8):449–54
[Parent and child care: medical efficacy]
Verloove-Vanhorick SP. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):874–8 (40 ref.) **(Dut)**
[Quality adjusted life years in assessment of preventive measures. Should blood donors be tested for HTLV-I/II infections?] Magnus P, et al. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1229–32 (Eng. Abstr.) **(Nor)**
[Towards a new policy for preventive work?] Røiseland A.
Tidsskr Nor Laegeforen 1996 Jun 20;116(16):1916–8 **(Nor)**
[The status and outlook of outfitting the military medical service with the technical materiel for prophylactic health purposes] Zhiliaev EG, et al. **Voen Med Zh** 1995 Jul; (7):15–21 **(Rus)**
[Difficulties in carrying out preventive activities in primary care] Aubá J, et al. **Aten Primaria** 1995 Oct 31;16(7):428–32 (Eng. Abstr.) **(Spa)**
[Prevention and health promotion in a client-provider model (editorial)] Kloppe P. **Aten Primaria** 1996 Mar 15; 17(4):237–8 **(Spa)**
[Preventive medical work is important but difficult. Shortage of time and information is main obstacle] Himmelmann L, et al. **Lakartidningen** 1996 Feb 21;93(8):694–9 **(Swe)**
[Follow-up of health status of young girls by primary health care. Preventive work is the target of the health care center in Lilla Edet] Olsson I. **Lakartidningen** 1996 Aug 7; 93(32–33):2719–20 **(Swe)**
[Preventive work requires more engagement (letter)] Swartz ME. **Lakartidningen** 1996 May 1;93(18):1710–1 **(Swe)**

ECONOMICS

The cost of comprehensive preventive medical services for adolescents. Gans JE, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1226–34 (52 ref.)
Prevention dollars and sense [editorial] Joffe A.
Arch Pediatr Adolesc Med 1995 Nov;149(11):1203–4
Costs of prevention. Place impossible political burden on local authorities [letter; comment] Connolly CK. **BMJ** 1996 Mar 16;312(7032):708. Comment on: BMJ 1995 Dec 9;311(7019):1520.
Costs of prevention. Prevention encompasses more than screening [letter; comment] Khaw KT. **BMJ** 1996 Mar 16; 312(7032):708. Comment on: BMJ 1995 Dec 9;311(7019):1520.
Payment and attendance at general practice preventive health examinations. Christensen B. **Fam Med** 1995 Sep; 27(8):531–4
Tuberculosis control in China [letter] Bogg L, et al.
Lancet 1996 Jun 15;347(9016):1702
Assessing the effectiveness of disease and injury prevention programs: costs and consequences.
MMWR Morb Mortal Wkly Rep 1995 Aug 18; 44(RR-10):1–10
Not-for-profit health plans [letter] Legorreta AP.
N Engl J Med 1996 Aug 8;335(6):438

LEGISLATION & JURISPRUDENCE

Prevention and government: health policy making in the United Kingdom and Germany. Freeman R.
J Health Polit Policy Law 1995 Fall;20(3):745–65

METHODS

Directly observed preventive therapy. Turning the tide against tuberculosis. Kohn MR, et al.
Arch Pediatr Adolesc Med 1996 Jul;150(7):727–9

ORGANIZATION & ADMINISTRATION

Preventing cardiovascular disease through community-based risk reduction: the Bootheel Heart Health Project. Brownson RC, et al. **Am J Public Health** 1996 Feb; 86(2):206–13
Victimization prevention programs for children: a follow-up. Finkelhor D, et al. **Am J Public Health** 1995 Dec; 85(12):1684–9
Prevention and the reforming U.S. health care system: changing roles and responsibilities for public health. Gordon RL, et al. **Annu Rev Public Health** 1996;17:489–509 (86 ref.)
Primary care physicians' use of office resources in the provision of preventive care. Dickey LL, et al.
Arch Fam Med 1996 Jul-Aug;5(7):399–404
An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Leininger LS, et al. **Arch Fam Med** 1996 Feb;5(2):108–15
Missed opportunities for vaccination and the delivery of preventive care. Ball TM, et al.
Arch Pediatr Adolesc Med 1996 Aug;150(8):858–61
Adolescent health: moving from prevention to promotion through a quality of life approach. Raphael D, et al.
Can J Public Health 1996 Mar-Apr;87(2):81–3
Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al.
Fam Pract 1996 Apr;13(2):182–93 (139 ref.)
Clinical paths. Prevention is the best medicine. Appleby C.
Hosp Health Netw 1996 Aug 20;70(16):40
Outreach. Preventive medicine that's more than shots and checkups. Speer TL. **Hosp Health Netw** 1996 Mar 20; 70(6):80
Alcohol-problem prevention research policy: the need for a phases research model. Holder H, et al.
J Public Health Policy 1995;16(3):324–46 (43 ref.)
From the Centers for Disease Control and Prevention. Prevention and managed care: organizations, purchasers of health care, and public health agencies. **JAMA** 1996 Jan 3;275(1):26–9
Prevention and managed care: opportunities for managed

care organizations, purchasers of health care, and public health agencies. **MMWR Morb Mortal Wkly Rep** 1995 Nov 17;44 Rr-14:1-12

The effect among older persons of a general preventive visit on three health behaviors: smoking, excessive alcohol drinking, and sedentary lifestyle. The Medicare Preventive Services Research Team. Burton LC, et al. **Prev Med** 1995 Sep;24(5):492-7

An evaluation of the future role of non-governmental organizations currently engaged in leprosy control in India. Vaz W, et al.
Southeast Asian J Trop Med Public Health 1995 Jun; 26(2):297-300

WomanKind: an innovative model of health care response to domestic abuse. Hadley SM, et al.
Womens Health Issues 1995 Winter;5(4):189-98

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224-32 (42 ref.)

[The intensification of the activities of sanatorium-type institutions] Vakhitov ShM, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1995 May-Jun; (3):25-6 **(Rus)**

STANDARDS

A study of patient satisfaction and adherence to preventive care practice guidelines [see comments] Weingarten SR, et al. **Am J Med** 1995 Dec;99(6):590-6. Comment in: Am J Med 1995 Dec;99(6):588-9.

Assessment of delivery of preventive health services. Hershey CO, et al. **Am J Med Qual** 1996 Summer;11(2):81-6

Developing evidence-based clinical practice guidelines: lessons learned by the US Preventive Services Task Force. Woolf SH, et al. **Annu Rev Public Health** 1996;17:511-38 (104 ref.)

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837-43 (61 ref.)

Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix [see comments] Parboosingh EJ, et al.
Can Med Assoc J 1996 Jun 15;154(12):1847-53 (18 ref.). Comment in: Can Med Assoc J 1996 Jun 15;154(12):1867-9.

Commentary on the new Guide to Clinical Preventive Services [see comments] Henry CA, et al.
Cleve Clin J Med 1996 May-Jun;63(3):141-6. Comment in: Cleve Clin J Med 1996 May-Jun;63(3):136.

Evaluation of preventive and health promotion activities in 166 primary care practices in Spain. The Coordinating Group For Prevention and Health Promotion in Primary Care in Spain. Brotons C, et al. **Fam Pract** 1996 Apr; 13(2):144-51

Competing HMOs collaborate to improve preventive services. Solberg LI, et al. **Jt Comm J Qual Improv** 1995 Nov;21(11):600-10

Bright futures. Brodell RD, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):965-6

[Are child health services really efficient? Resources can be allocated to exposed children] Sjönell G. **Lakartidningen** 1996 May 8;93(19):1808, 1811 **(Swe)**

STATISTICS & NUMERICAL DATA

Need and desire for preventive care measures in emergency department patients. Rodriguez RM, et al.
Ann Emerg Med 1995 Nov;26(5):615-20

Are Asian/Pacific Islander American women represented in women's health research? [letter] Yi JK.
Womens Health Issues 1996 Jul-Aug;6(4):237-8

TRENDS

Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Freudenberg N, et al. **Health Educ Q** 1995 Aug;22(3):290-306 (83 ref.)

Twentieth century paradigms that threaten both scientific and humane medicine in the twenty-first century. Feinstein AR. **J Clin Epidemiol** 1996 Jun;49(6):615-7

Today's physician, tomorrow's world [editorial] Walton TM Jr. **J Natl Med Assoc** 1995 Oct;87(10):739

[Preventive and after-care of elderly patients from the viewpoint of the established physician. Recommendations for new structures in ambulatory medical management of the elderly] Zeller W. **Fortschr Med** 1996 May 30; 114(15):191-2 **(Ger)**

[Prevention, standards and future developments in medical specialties--developments, deficits and outdated procedures in specialty fields. Working Group of Scientific Medical Specialty Societies, Dusseldorf]
Z Arztl Fortbild (Jena) 1996 Feb;90(1):51-8 **(Ger)**

UTILIZATION

Socioeconomic status and preventive health-care use by children in Spain. Navarro-Rubio MD, et al.
Am J Prev Med 1995 Jul-Aug;11(4):256-62

Evaluation of a health promotion demonstration program for the rural elderly. Lave JR, et al. **Health Serv Res** 1996 Aug;31(3):261-81

The tension between cost containment and the underutilization of effective health services. Bloom BS, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):1-8

The prevalence of clinical preventive services utilization by older women. Bergman-Evans B, et al. **Nurse Pract** 1996 Apr;21(4):88, 90, 99-100, passim

You can help promote use of mammogram benefit. Queenan E, et al. **Pa Med** 1995 Oct;98(10):26-8

The effects of a computer-assisted reminder system on patient compliance with recommended health maintenance procedures. Vincent EC, et al.
Proc Annu Symp Comput Appl Med Care 1995;:656-60

Barriers to the use of preventive health care services for children. Riportella-Muller R, et al. **Public Health Rep** 1996 Jan-Feb;111(1):71-7

Factors associated with participation in a preventive cardiology service by patients with coronary heart disease. Dignan MB, et al. **South Med J** 1995 Oct;88(10):1057-61

[Insufficient participation in prevention programs for infants by Turkish, Moroccan, Chinese and Vietnamese parents in large cities] Hirasing RA, et al.
Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2726-30 (Eng. Abstr.) **(Dut)**

[Knowledge of the utilization of preventive practices through a telephone survey] Berraondo I, et al. **Aten Primaria** 1996 Jul-Aug;18(3):131-4 (Eng. Abstr.) **(Spa)**

PREVENTIVE MEDICINE

see related
HEALTH PROMOTION

Clinical preventive medical specialist [letter] Koenig J.
Am J Prev Med 1996 Mar-Apr;12(2):71

Federal scene. Introducing Annals of Epidemiology Federal scene section. Snider DE, et al. **Ann Epidemiol** 1996 Jan; 6(1):1-3

Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321-36 (87 ref.)

The role of community health centers in providing preventive care to adolescents. Hedberg VA, et al.
Arch Pediatr Adolesc Med 1996 Jun;150(6):603-8

Beta-carotene, carotenoids, and disease prevention in humans. Mayne ST. **FASEB J** 1996 May;10(7):690-701 (70 ref.)

NIH research. An investment in prevention.
J Fla Med Assoc 1995 Oct;82(10):697-9

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ.
J Matern Fetal Med 1996 May-Jun;5(3):100-5 (26 ref.)

Head injury mechanisms and the concept of preventive management: a review and critical synthesis. Ommaya AK.
J Neurotrauma 1995 Aug;12(4):527-46 (101 ref.)

Population strategy for preventive medicine [letter; comment] Tunstall-Pedoe H. **J R Soc Med** 1996 Mar; 89(3):179. Comment on: J R Soc Med 1995 Nov;88(11):607-10.

New prevention guidelines called 'state of the art' [news] Voelker R. **JAMA** 1996 Feb 21;275(7):505

Will altruism endanger prevention? [news] Voelker R. **JAMA** 1996 May 15;275(19):1463-4

Counselling: the big gap in disease management in Pakistan [editorial] Akhtar T. **JPMA J Pak Med Assoc** 1995 Jun; 45(6):146-7

The potentiality and practicality of a 'salt-free' diet for the prevention and amelioration of human disorders. Leeming RA. **Med Hypotheses** 1996 Jan;46(1):45-51 (45 ref.)

Nutritional antioxidants: their role in disease prevention. Winterbourn CC. **N Z Med J** 1995 Nov 10;108(1011):447-9

[Practical attitude in the matter of screening in the general practitioner's office] Stibbe G, et al. **Rev Med Brux** 1995 Jul-Aug;16(4):330-1 **(Fre)**

[A call for combining pediatric preventive and curative health care in Israel] Urkin J. **Harefuah** 1996 Jan 15; 130(2):126-8 **(Heb)**

[General practitioner's participation in a health promotion project sponsored by the District. Analysis of some relevant individual variables] D'Alessandro D, et al. **Ann Ig** 1996 Mar-Apr;8(2):201-8 (Eng. Abstr.) **(Ita)**

["Memorial Klinger": food, wellbeing factors, and disease factors. Milano, April 8-9, 1994] **Minerva Chir** 1995 Sep; 50(9 Suppl):163-7 **(Ita)**

[A study of preventive medicine in relation to mental health among middle-management employees (Part 2)--effects of long working hours on lifestyles, perceived stress and working-life satisfaction among white-collar middle-management employees] Maruyama S, et al.
Nippon Eiseigaku Zasshi 1995 Oct;50(4):849-60 (Eng. Abstr.) **(Jpn)**

[Towards a new policy for preventive work?] Røiseland A.
Tidsskr Nor Laegeforen 1996 Jun 20;116(16):1916-8 **(Nor)**

[The role of preventive medicine in the system of ecological support for the Armed Forces] Zhiliaev EG, et al.
Voen Med Zh 1996 Apr;317(4):7-9 **(Rus)**

[The role of the general practitioner in the prevention and control of modern diseases] Planojević M. **Med Pregl** 1995; 48(7-8):213-5 **(Scr)**

[Preventive work requires more engagement (letter)] Swartz ME. **Lakartidningen** 1996 May 1;93(18):1710-1 **(Swe)**

EDUCATION

Adequacy of training in preventive medicine and public health: a national survey of residency graduates. Stein DH, et al. **Acad Med** 1996 Apr;71(4):375-80

Teaching preventive cardiology: the consultation clinic. Cable TA, et al. **Am J Prev Med** 1996 May-Jun;12(3):161-4

A survey of residency management training: general preventive medicine graduates. Cordes DH, et al.
Am J Prev Med 1996 May-Jun;12(3):172-6

Preventive medicine training and managed care: current status and models for the future. Dysinger WS.
Am J Prev Med 1996 May-Jun;12(3):145-50

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165-71 (24 ref.)

Training physicians to care for the underserved: preventive medicine residency-community health center linkages. Hill L, et al. **Am J Prev Med** 1996 May-Jun;12(3):156-60

Barriers to learning preventive medicine: student experiences in undergraduate medical education [letter] Jung P, et al.
Am J Prev Med 1996 May-Jun;12(3):141-2

Performance indicators for assessing competencies of preventive medicine residents [letter; comment] Kuhnen AE. **Am J Prev Med** 1995 Sep-Oct;11(5):349. Comment on: Am J Prev Med 1995 Jan-Feb;11(1):1-8.

Education and the future of preventive medicine [editorial] Patrick K, et al. **Am J Prev Med** 1996 May-Jun; 12(3):139-40

Putting prevention into practice. Impact of a multifaceted physician education program on preventive services in the inner city. Gemson DH, et al. **Arch Intern Med** 1995 Nov 13;155(20):2210-6

Preventive medicine indoctrination must begin at undergraduate level [letter; comment] Licciardone JC.
J Am Osteopath Assoc 1995 Oct;95(10):572, 574. Comment on: J Am Osteopath Assoc 1995 Apr;95(4):267-8, 271-5.

Medical schools, the social contract and population medicine: McMaster revisited. Coulter ID, et al.
J Manipulative Physiol Ther 1995 Oct;18(8):554-8 (25 ref.)

Why can't we educate doctors to practice preventive medicine? Cimino JA. **Prev Med** 1996 Jan-Feb;25(1):63-5

[Preventive medicine in the practitioner's office: necessary education] Pécoud A, et al. **Rev Med Suisse Romande** 1995 Aug;115(8):599-601 **(Fre)**

HISTORY

Finding a function for public health: disease theory or political philosophy? [comment] Hamlin C.
J Health Polit Policy Law 1995 Winter;20(4):1025-31. Comment on: J Health Polit Policy Law 1995 Winter;20(4):1001-24.

Miasma and "social factors" in disease causality: lessons from the nineteenth century [see comments] Tesh SN.
J Health Polit Policy Law 1995 Winter;20(4):1001-24. Comment in: J Health Polit Policy Law 1995 Winter;20(4):1025-31.

Civil war reenactors revere, learn from the past [news] Cole TB. **JAMA** 1996 Apr 17;275(15):1146-8

[Avicenna, a forerunner of hygiene and preventive medicine] Polizzi F. **Ann Ig** 1994 Jul-Dec;6(4-6):357-64 (Eng. Abstr.) **(Ita)**

METHODS

Preventive medicine: time for another Boston Tea Party [letter] Jameson MG. **Am J Prev Med** 1995 Jul-Aug; 11(4):213

[Operative methodology for risk prevention in the beauty culture sector] Baldini P, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2-3):223-4 **(Ita)**

ORGANIZATION & ADMINISTRATION

The preventive medicine manager: a new role for preventive medicine specialists in managed care. Bokor A, et al.
Am J Prev Med 1996 May-Jun;12(3):143-4

Preventive medicine training and managed care: current status and models for the future. Dysinger WS.
Am J Prev Med 1996 May-Jun;12(3):145-50

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165-71 (24 ref.)

An ounce of prevention... [editorial; comment] Clough JD.
Cleve Clin J Med 1996 May-Jun;63(3):136. Comment on: Cleve Clin J Med 1996 May-Jun;63(3):141-6.

Telepreventive medicine. Aaron DJ, et al. **MD Comput** 1996 Jul-Aug;13(4):335-8

Thetford plastics fire, October 1991: the role of a preventive medical team in chemical incidents. Baxter PJ, et al.
Occup Environ Med 1995 Oct;52(10):694-8

STANDARDS

Putting prevention into practice. Impact of a multifaceted physician education program on preventive services in the inner city. Gemson DH, et al. **Arch Intern Med** 1995 Nov 13;155(20):2210-6

STATISTICS & NUMERICAL DATA

Computer reminders to implement preventive care guidelines for hospitalized patients. Overhage JM, et al.
Arch Intern Med 1996 Jul 22;156(14):1551-6

Audit of preventive activities in 16 inner London practices using a validated measure of patient population, the 'active patient' denominator. Healthy Eastenders Project. Robson J, et al. **Br J Gen Pract** 1995 Sep;45(398):463-6

The delivery of immunizations and other preventive services

in private practices. Bordley WC, et al. **Pediatrics** 1996 Apr;97(4):467–73

TRENDS

Preventive medicine and public health. Foege WH. **JAMA** 1996 Jun 19;275(23):1846–7
Prevention into the 21st century. Frank AL. **Mt Sinai J Med** 1996 May–Sep;63(3–4):236–40
The future of preventive medicine. Council on Long Range Planning and Development. **Prev Med** 1996 Jan–Feb; 25(1):73–81 (65 ref.)
Accomplishments and prospects of epidemiology. Trichopoulos D. **Prev Med** 1996 Jan–Feb;25(1):4–6
Lifestyle medicine for the nineties [editorial] Wynder EL. **Prev Med** 1996 Jan–Feb;25(1):82–3
[Prevention, standards and future developments in medical specialties—epidemiology] Vosteen KH. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):515–25 **(Ger)**
[Prevention, standards and future developments in medical specialties—developments, deficits and outdated methods in medical specialties] Vosteen KHZ. **Z Arztl Fortbild (Jena)** 1996 May;90(3):249–58 **(Ger)**
[The vital tasks of preventive medicine] Chizh IM. **Voen Med Zh** 1996 May;317(5):4–14, 80 (Eng. Abstr.) **(Rus)**

PREVOTELLA

CLASSIFICATION

Comparison of the use of oligonucleotide probes, 4–methylumbelliferyl derivatives, and conventional methods for identifying Prevotella bivia. Rabe LK, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S195–7
Prevotella intermedia and Prevotella nigrescens serotypes, ribotypes and binding characteristics. Dahlén GG, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):89–95
Confirmation of the species Prevotella intermedia and Prevotella nigrescens. Frandsen EV, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):429–35
16S rRNA gene similarities indicate that Hallella seregens (Moore and Moore) and Mitsuokella dentalis (Haapsalo et al.) are genealogically highly related and are members of the genus Prevotella: emended description of the genus Prevotella (Shah and Collins) and description of Prevotella dentalis comb. nov. Willems A, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):832–6

DRUG EFFECTS

Resistance to beta–lactam antibiotics and beta–lactamase production of Bacteroides, Porphyromonas and Prevotella strains. Nagy E, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):287–99
Stoichiometry of pectin and glucose fermentation in Prevotella ruminicola. Marounek M, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):107–10
[In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria] Bland S, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):289–93 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The cellular location of Prevotella ruminicola beta–1,4–D–endoglucanase and its occurrence in other strains of ruminal bacteria. Gardner RG, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3288–92
A xylan hydrolase gene cluster in Prevotella ruminicola B(1)4: sequence relationships, synergistic interactions, and oxygen sensitivity of a novel enzyme with exoxylanase and beta–(1,4)–xylosidase activities. Gasparic A, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2958–64
Comparative studies of the IgA1 protease genes from Haemophilus influenzae, Neisseria gonorrhoeae, and Prevotella melaninogenica. Arzese A, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S169–71
Enzymatic profiles of Prevotella, Porphyromonas, and Bacteroides species obtained with the API ZYM system and Rosco diagnostic tablets. Durmaz B, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S192–4
Evaluation of S1 chromogenic cephalosporin beta–lactamase disk assay tested against gram–positive anaerobes, coagulase–negative staphylococci, Prevotella spp. and Enterococcus spp. Marshall SA, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):353–5
Expression of a cloned cellulase/xylanase gene from Prevotella ruminicola in Bacteroides vulgatus, Bacteroides uniformis and Prevotella ruminicola. Daniel AS, et al. **J Appl Bacteriol** 1995 Oct;79(4):417–24
Influence of 1,10–phenanthroline and its analogues, other chelators and transition metal ions on dipeptidase activity of the rumen bacterium, Prevotella ruminicola. Wallace RJ, et al. **J Appl Bacteriol** 1996 Jul;81(1):42–7

GENETICS

Use of a modified Bacteroides–Prevotella shuttle vector to transfer a reconstructed beta–1,4–D–endoglucanase gene into Bacteroides uniformis and Prevotella ruminicola B(1)4. Gardner RG, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):196–202
A xylan hydrolase gene cluster in Prevotella ruminicola B(1)4: sequence relationships, synergistic interactions, and oxygen sensitivity of a novel enzyme with exoxylanase and beta–(1,4)–xylosidase activities. Gasparic A, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2958–64
Prevotella intermedia and Prevotella nigrescens serotypes, ribotypes and binding characteristics. Dahlén GG, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):89–95
Cloning, sequencing, and characterization of a membrane–associated Prevotella ruminicola B(1)4 beta–glucosidase with cellodextrinase and cyanoglycosidase activities. Wulff–Strobel CR, et al. **J Bacteriol** 1995 Oct;177(20):5884–90
Structural organization of pRAM4, a cryptic plasmid from Prevotella ruminicola. Ogata K, et al. **Plasmid** 1996 Mar; 35(2):91–7

IMMUNOLOGY

Antibody response to Prevotella spp. in patients with ventilator–associated pneumonia. Grollier G, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):61–5

ISOLATION & PURIFICATION

Rapid differentiation of Prevotella intermedia and P. nigrescens by 16S rDNA PCR–RFLP. Milsom SE, et al. **J Med Microbiol** 1996 Jan;44(1):41–3
Characterisation of black–pigmented anaerobes isolated from diseased and healthy periodontal sites. Teanpaisan R, et al. **J Periodontal Res** 1995 Jul;30(4):245–51

METABOLISM

Role of phosphorolytic cleavage in cellobiose and cellodextrin metabolism by the ruminal bacterium Prevotella ruminicola. Lou J, et al. **Appl Environ Microbiol** 1996 May;62(5):1770–3
Interactions between Fibrobacter succinogenes, Prevotella ruminicola, and Ruminococcus flavefaciens in the digestion of cellulose from forages. Fondevila M, et al. **J Anim Sci** 1996 Mar;74(3):678–84
Use of sodium dodecyl sulfate polyacrylamide gel electrophoresis to measure degradation of soluble soybean proteins by Prevotella ruminicola GA33 or mixed ruminal microbes in vitro. Schwingel WR, et al. **J Anim Sci** 1996 Feb;74(2):475–82

PREVOTELLA INTERMEDIA

CHEMISTRY

Lipopolysaccharides of oral black pigmented bacteria and periodontal diseases. A novel immunomodulator different from endotoxin was extracted from Prevotella intermedia ATCC 25611 with hot phenol–water. Takada H, et al. **Prog Clin Biol Res** 1995;392:59–68

CLASSIFICATION

Prevotella intermedia and Prevotella nigrescens serotypes, ribotypes and binding characteristics. Dahlén GG, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):89–95
Confirmation of the species Prevotella intermedia and Prevotella nigrescens. Frandsen EV, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):429–35

DRUG EFFECTS

In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Miyake Y, et al. **J Periodontal Res** 1995 Jul; 30(4):290–3

GENETICS

Prevotella intermedia and Prevotella nigrescens serotypes, ribotypes and binding characteristics. Dahlén GG, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):89–95

IMMUNOLOGY

Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with peritonsillar cellulitis and abscess. Brook I, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S220–1
Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with infectious mononucleosis. Brook I, et al. **J Med Microbiol** 1996 Feb; 44(2):131–4
Influence of periodontal bacteria and disease status on V beta expression in T cells. Mathur A, et al. **J Periodontal Res** 1995 Sep;30(5):369–73

ISOLATION & PURIFICATION

Putative periodontal pathogens colonizing oral mucous membranes in denture–wearing subjects with a past history of periodontitis. Danser MM, et al. **J Clin Periodontol** 1995 Nov;22(11):854–9
The effect of a single mechanical treatment on the subgingival microflora in patients with HIV–associated gingivitis. Hofer D, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):180–7
The natural history of periodontal disease. The correlation of selected microbiological parameters with disease severity in Sri Lankan tea workers. Preus HR, et al. **J Clin Periodontol** 1995 Sep;22(9):674–8
Rapid differentiation of Prevotella intermedia and P. nigrescens by 16S rDNA PCR–RFLP. Milsom SE, et al. **J Med Microbiol** 1996 Jan;44(1):41–3
Bacterial colonization of the external and internal sulci and of cellulose membranes at time of retrieval. Novaes AB Jr, et al. **J Periodontol** 1995 Oct;66(10):864–9
Analytical performance of an immunologic–based periodontal bacterial test for simultaneous detection and differentiation of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia. Snyder B, et al. **J Periodontol** 1996 May;67(5):497–505

METABOLISM

Collagen–binding activity of Prevotella intermedia measured by a microtitre plate adherence assay. Grenier D. **Microbiology** 1996 Jun;142 (Pt 6):1537–41

PATHOGENICITY

Lipopolysaccharides of oral black pigmented bacteria and periodontal diseases. A novel immunomodulator different from endotoxin was extracted from Prevotella intermedia ATCC 25611 with hot phenol–water. Takada H, et al. **Prog Clin Biol Res** 1995;392:59–68

PHYSIOLOGY

Repopulation of periodontal pockets by microbial pathogens in the absence of supportive therapy. Shiloah J, et al. **J Periodontol** 1996 Feb;67(2):130–9
[Effects of the Prevotella intermedia culture filtrate and short–chain fatty acids on human polymorphonuclear neutrophil functions] Touyama M, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1348–55 (Eng. Abstr.) **(Jpn)**

PREVOTELLA MELANINOGENICA

DRUG EFFECTS

beta–Lactamase production and penicillin susceptibility among different ribotypes of Prevotella melaninogenica simultaneously colonizing the oral cavity. Könönen E, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S364–6

GROWTH & DEVELOPMENT

Effect of Bacteroides melaninogenicus culture supernatant and deconjugated bile salt on lipid absorption. Healy MJ, et al. **Dig Dis Sci** 1995 Nov;40(11):2456–9

PRIAPISM

Priapism: a historical and update review. Magoha GA. **East Afr Med J** 1995 Jun;72(6):399–401 (61 ref.)

CHEMICALLY INDUCED

Priapism associated with psychotropic drugs. Patel AG, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):315–9 (63 ref.)
Recurrent priapism as a side effect of zuclopenthixol decanoate. van Hemert AM, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):199–200
Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Kulmala RV, et al. **Int J Impot Res** 1995 Jun;7(2):131–6
Priapism associated with fluoxetine therapy: a case report. Javed MA. **JPMA J Pak Med Assoc** 1996 Feb;46(2):45–6
Risks of self–injection therapy for impotence [letter] Millard RJ, et al. **Med J Aust** 1996 Jul 15;165(2):117–8
[Erection disorders and priapism due to drugs] Meinhardt W, et al. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1871–3 (24 ref.) **(Dut)**
[Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto–prostatectomy] Llopis J, et al. **J Urol (Paris)** 1995;101(2):104–6 (Eng. Abstr.) **(Fre)**
[Stasis priapism secondary to PGE1: transformation into high–flow priapism] Negrín Díaz A, et al. **Actas Urol Esp** 1996 Mar;20(3):289–91 (Eng. Abstr.) **(Spa)**
[Priapism induced by vasoactive drugs] Allona Almagro A. **Arch Esp Urol** 1996 Apr;49(3):277–80 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Evolving concepts in the diagnosis and treatment of arterial high flow priapism. Hakim LS, et al. **J Urol** 1996 Feb; 155(2):541–8

DRUG THERAPY

Treatment of priapism during transurethral resection of the prostate. Quinney N, et al. **Br J Hosp Med** 1995 Oct 18–31; 54(8):393–4
Intracorporeal phenylephrine in the treatment of priapism [see comments] Muruve N, et al. **J Urol** 1996 Jan; 155(1):141–3. Comment in: J Urol 1996 Jan;155(1):147. Comment in: J Urol 1996 Aug;156(2 Pt 1):483.
Re: Intracorporeal phenylephrine in the treatment of priapism [letter; comment] Seftel AD. **J Urol** 1996 Aug;156(2 Pt 1):483. Comment on: J Urol 1996 Jan;155(1):141–3.
Managing intraoperative priapism [letter; comment] Corke PJ. **Reg Anesth** 1995 Nov–Dec;20(6):546. Comment on:

Reg Anesth 1994 Nov-Dec;19(6):423-8.
Intracavernous pharmacotherapy: treatment for the aging erectile response. Broderick GA. **Urol Clin North Am** 1996 Feb;23(1):111-26 (123 ref.)

ETIOLOGY

Priapism caused by a perineal abscess in a patient with Crohn's disease: CT findings. Alago W Jr, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1199-200
Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu-->Arg. Thuret I, et al. **Am J Hematol** 1996 Feb;51(2):133-6
High-flow priapism due to bilateral arteriosinusoidal fistulae. Göktaş S, et al. **Br J Urol** 1996 Jan;77(1):165-6
Selective embolization of bilateral arterial cavernous fistulas for posttraumatic penile arterial priapism. Lazinger M, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):281-4
Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278-80 (22 ref.)
Case report: high flow priapism diagnosed by colour Doppler flow mapping. Jarosz JM, et al. **Clin Radiol** 1995 Sep; 50(9):651-2
Aetiology of priapism in 207 patients. Kulmala R, et al. **Eur Urol** 1995;28(3):241-5
Haemoglobin SC disease presenting as a case of priapism to a GUM clinic. Rea AJ, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):361-2
Urinary symptoms in rabies [letter] Dutta JK. **J Assoc Physicians India** 1995 Jul;43(7):514, 517
Priapism as a presentation of hematological malignancy. Singh BP, et al. **J Assoc Physicians India** 1995 Apr; 43(4):297
Testosterone induced priapism in two adolescents with sickle cell disease. Slayton W, et al. **J Pediatr Endocrinol Metab** 1995 Jul-Sep;8(3):199-203
Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. Chakrabarty A, et al. **J Urol** 1996 Apr;155(4):1419-23
[Adverse effects: priapism caused by paroxetine] Bertholon F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):145-6; discussion 146-7 (Eng. Abstr.) **(Fre)**
[High flow priapism following a straddle-injury-induced arteriocavernosal fistula: a case report] Kuwahara M, et al. **Hinyokika Kiyo** 1995 Aug;41(8):625-8 (Eng. Abstr.) **(Jpn)**
[Klinefelter's syndrome as the only pathology associated with priapism. A clinical case] Fernández Fernández A, et al. **Arch Esp Urol** 1995 Nov;48(9):962-3 (4 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Priapism revealing ARG 506 to GLN factor V mutation. de Prost D, et al. **J Urol** 1996 Apr;155(4):1392

MICROBIOLOGY

Pediatric priapism associated with Mycoplasma pneumoniae. Hirshberg SJ, et al. **Urology** 1996 May;47(5):745-6

PHYSIOPATHOLOGY

Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. Chakrabarty A, et al. **J Urol** 1996 Apr;155(4):1419-23

PREVENTION & CONTROL

Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Virag R, et al. **Urology** 1996 May;47(5):777-81; discussion 781

SURGERY

A simple method of treating priapism in children. Ulman I, et al. **Br J Urol** 1996 Mar;77(3):460-1
[Priapism. Apropos of a case in a 10-year old child] Monote S, et al. **J Urol (Paris)** 1995;101(2):107-8 (Eng. Abstr.) **(Fre)**

THERAPY

High-flow priapism in a child: treatment with superselective embolization. Stock KW, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):290-2
ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838-40 (0 ref.). Comment in: **BMJ** 1996 Jul 13;313(7049):112; discussion 112-3.
An unusual case of priapism in a child: diagnosis and treatment. Jameson JS, et al. **Br J Urol** 1996 Mar; 77(3):462-3
Selective arterial embolization of idiopathic priapism. Cohen GS, et al. **Cardiovasc Intervent Radiol** 1996 Jan-Feb; 19(1):47-9
Selective embolization of bilateral arterial cavernous fistulas for posttraumatic penile arterial priapism. Lazinger M, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):281-4
Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278-80 (22 ref.)
Treatment of posttraumatic chronic high-flow priapisms by superselective embolization of cavernous artery with autologous clot. Kim SC, et al. **J Trauma** 1996 Mar; 40(3):462-5
Evolving concepts in the diagnosis and treatment of arterial high flow priapism. Hakim LS, et al. **J Urol** 1996 Feb; 155(2):541-8
Perineal abscess after embolization for high-flow priapism. Sandock DS, et al. **Urology** 1996 Aug;48(2):308-11
[Priapism in the adult: report of 15 cases] Ravery V, et al. **Prog Urol** 1995 Nov;5(5):697-700 (Eng. Abstr.) **(Fre)**

PRILOCAINE

EMLA prevents pain during local anesthesia for cataract surgery. Pappa X, et al. **Acta Anaesthesiol Belg** 1995; 46(2):75-8
The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Jones NC, et al. **Anaesthesia** 1996 May;51(5):446-8
Efficacy of the topical anesthetic cream, EMLA, in alleviating both needle insertion and injection pain. Raveh T, et al. **Ann Plast Surg** 1995 Dec;35(6):576-9
Prilocaine 3% is superior to a mixture of bupivacaine and lignocaine for peribulbar anaesthesia. Döpfmer UR, et al. **Br J Anaesth** 1996 Jan;76(1):77-80
Analgesic and anti-inflammatory effects of lignocaine-prilocaine (EMLA) cream in human burn injury. Pedersen JL, et al. **Br J Anaesth** 1996 Jun; 76(6):806-10
EMLA cream anaesthesia for frenuloplasty. Brough RJ, et al. **Br J Urol** 1995 Nov;76(5):653-4
EMLA during local anaesthetic vasectomy [letter; comment] Bryden AA, et al. **Br J Urol** 1995 Dec;76(6):813. Comment on: Br J Urol 1995 May;75(5):671.
Is lidocaine-prilocaine cream (EMLA) always useful for venous puncture in preoperative autologous blood donation? Vivien B, et al. **Can J Anaesth** 1996 Mar; 43(3):232-7
Is fasting necessary before prilocaine Bier's block? O'Sullivan I, et al. **J Accid Emerg Med** 1996 Mar;13(2):105-7
EMLA and venepuncture [letter; comment] Nott MR, et al. **J R Soc Med** 1995 Nov;88(11):664. Comment on: J R Soc Med 1995 May;88(5):264-7.
Urethral meatotomy in the office using topical EMLA cream for anesthesia. Cartwright PC, et al. **J Urol** 1996 Aug;156(2 Pt 2):857-8; discussion 858-9
Is intra-articular pethidine an alternative to local anaesthetics in arthroscopy? A double-blind study comparing prilocaine with pethidine. Ekblom A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):189-94
Regional variations in skin perfusion and skin thickness may contribute to varying efficacy of topical, local anaesthetics in neonates. Larsson BA, et al. **Paediatr Anaesth** 1996; 6(2):107-10
[Combined "3-in-1"/sciatic nerve block. Block effectiveness, serum level and side effects using 700 mg mepivacaine 1% without and with adrenaline and prilocaine 1%] Eifert B, et al. **Anaesthesist** 1996 Jan;45(1):52-8 (Eng. Abstr.) **(Ger)**
[Use of topical anesthesia--EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490-1 (26 ref.) **(Heb)**
[Efficacy of the EMLA cream in the reduction of pain caused by venipuncture in children premedicated with oral midazolam] Cassinello F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):360-3 (Eng. Abstr.) **(Spa)**
[EMLA: topical anesthesia of the skin. A step forward in pediatric anesthesia standards (editorial)] Santacana-Rillo E, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):353-4 **(Spa)**

ADMINISTRATION & DOSAGE

Morphine/prilocaine combination for intravenous regional anesthesia. Erciyes N, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):845-6
EMLA cream prior to insertion of elective epidurals. Elson JA, et al. **Anaesth Intensive Care** 1995 Jun;23(3):339-41
Myringotomy tube placement--another role for EMLA cream? [letter] Beerle BJ, et al. **Anesth Analg** 1996 Aug; 83(2):435
Randomised trial of topical versus sub-Tenon's local anaesthesia for small-incision cataract surgery. Manners TD, et al. **Eye** 1996;10 (Pt 3):367-70
Eutectic lidocaine/prilocaine 5% cream and patch may provide satisfactory analgesia for excisional biopsy or curettage with electrosurgery of cutaneous lesions. A randomized, controlled, parallel group study. Gupta AK, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):419-23
Preparation and stability testing of a hydrogel for topical analgesia. Nortier YL, et al. **Pharm World Sci** 1995 Nov 24;17(6):214-7
[Use of EMLA cream in premature and full-term newborn infants. Study of efficacy and tolerance] Gourrier E, et al. **Arch Pediatr** 1995 Nov;2(11):1041-6 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative--a double-blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782-4
Methemoglobinemia associated with prilocaine use in neonatal circumcision. Tse S, et al. **Am J Perinatol** 1995 Sep;12(5):331-2
Alkaline chemical ocular injury from Emla cream [letter] Brahma AK, et al. **Eye** 1995;9 (Pt 5):658-9
Methemoglobinemia in a renal transplant patient: case report. Hardwick FK, et al. **Pediatr Dent** 1995 Nov-Dec; 17(7):460-3
[Risk of methemoglobinemia after Emla application in premature infants (letter; comment)] Gourrier E, et al. **Arch Pediatr** 1995 Oct;2(10):1021-2. Comment on: Arch Pediatr 1995 Mar;2(3):291-2. **(Fre)**
[Cutaneous problems after application of EMLA in premature infants (letter)] Gourrier E, et al. **Arch Pediatr** 1996 Mar;3(3):289-90 **(Fre)**
[The use of pulse oximetry in prilocaine induced methemoglobinemia] Rudlof B, et al. **Anaesthesist** 1995 Dec;44(12):887-91 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Preparation and stability testing of a hydrogel for topical analgesia [letter] Boer Y. **Pharm World Sci** 1996 Apr; 18(2):85
Preparation and stability testing of a hydrogel for topical analgesia. Nortier YL, et al. **Pharm World Sci** 1995 Nov 24;17(6):214-7

PHARMACOKINETICS

Transpulmonary disposition of prilocaine, mepivacaine, and bupivacaine in humans in the course of epidural anaesthesia. Kietzmann D, et al. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):885-90

PHARMACOLOGY

Onset time of topical analgesia with EMLA 5%: no reduction with glyceryl trinitrate. Nott MR, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):17-20
Safety of lidocaine-prilocaine cream in the treatment of preterm neonates. Taddio A, et al. **J Pediatr** 1995 Dec; 127(6):1002-5

THERAPEUTIC USE

Does a local anaesthetic cream (EMLA) alleviate pain from heel-lancing in neonates? Larsson BA, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1028-31
Use of EMLA cream in the treatment of post-herpetic neuralgia. Litman SJ, et al. **J Clin Anesth** 1996 Feb; 8(1):54-7
A comparison of EMLA cream versus nitrous oxide for pediatric venous cannulation. Vetter TR. **J Clin Anesth** 1995 Sep;7(6):486-90
Evaluation of a new topical anesthetic agent: a pilot study. Lander J, et al. **Nurs Res** 1996 Jan-Feb;45(1):50-3

PRIMACLONE see PRIMIDONE

PRIMAQUINE

ADMINISTRATION & DOSAGE

Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. Arica B, et al. **J Microencapsul** 1995 Sep-Oct;12(5):469-85
[A preliminary study on the inhibitory action of target-primaqine on the exoerythrocytic forms of Plasmodium yoelii yoelii] Song J, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):117-9 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. Sin DD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):477-81

ANALOGS & DERIVATIVES

An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs. Fasanmade AA, et al. **Drug Metab Dispos** 1995 May;23(5):573-6
High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine. Dua VK, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):93-8

BLOOD

High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine. Dua VK, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):93-8

PHARMACOKINETICS

[Study of pharmacokinetics of liver targeting antimalarial agent neoglycoalbumin-primaquine conjugate (NGA-PQ) and primaquine phosphate in mouse] Li TL, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):721-5 (Eng. Abstr.) **(Chi)**

PRIMAQUINE

THERAPEUTIC USE

Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Safrin S, et al. **Ann Intern Med** 1996 May 1;124(9):792-802

Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Fryauff DJ, et al. **Lancet** 1995 Nov 4;346(8984):1190-3

PRIMARY CARE see PRIMARY HEALTH CARE

PRIMARY CARE PHYSICIANS see PHYSICIANS, FAMILY

PRIMARY HEALTH CARE

Revising the definition of the generalist physician. Altman DF. **Acad Med** 1995 Dec;70(12):1087-90

Evaluation of a rural-oriented primary care curriculum for internal medicine residents. Caudill TS, et al. **Acad Med** 1995 Oct;70(10):933

Should half of all medical school graduates enter primary care? Perceptions of faculty members at Jefferson Medical College. Gottlieb J, et al. **Acad Med** 1995 Dec; 70(12):1125-33

Medical school applicants' essays as predictors of primary care career choice. Hull AL, et al. **Acad Med** 1996 Jan; 71(1 Suppl):S37-9

The state of the literature on primary care specialty choice: where do we go from here? Meurer LN, et al. **Acad Med** 1996 Jan;71(1):68-77

Personal values and primary care specialty aspirations [letter] Schubot DB, et al. **Acad Med** 1995 Nov;70(11):952-3

Alcohol-related problems in primary care patients in Nigeria. Abiodun OA. **Acta Psychiatr Scand** 1996 Apr;93(4):235-9

Balint group training, "to balint" and detection of mental disorders in primary care [letter] García-Campayo J, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):319

Children with mental disorders in primary care: functional status and risk factors. Gureje O, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):310-4

Gynecologic care [editorial] Wellbery C. **Am Fam Physician** 1996 Mar;53(4):1041-2

Prescribing exercise for health: a simple framework for primary care [see comments] Will PM, et al. **Am Fam Physician** 1996 Feb 1;53(2):579-85 (16 ref.). Comment in: Am Fam Physician 1996 Feb 1;53(2):484-6.

Effectiveness of glaucoma screening by primary care physicians [letter] Woolf SH. **Am Fam Physician** 1996 Sep 15;54(4):1209-12

Prevention of depression with primary care patients: a randomized controlled trial. Muñoz RF, et al. **Am J Community Psychol** 1995 Apr;23(2):199-222

Most nephrologists are primary care providers for chronic dialysis patients: results of a national survey. Bender FH, et al. **Am J Kidney Dis** 1996 Jul;28(1):67-71

A multisite field test of the acceptability of physical activity counseling in primary care: project PACE. Long BJ, et al. **Am J Prev Med** 1996 Mar-Apr;12(2):73-81

Occurrence, recognition, and outcome of psychological disorders in primary care. Tiemens BG, et al. **Am J Psychiatry** 1996 May;153(5):636-44

Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Wessely S, et al. **Am J Psychiatry** 1996 Aug;153(8):1050-9

Evaluating primary care follow-up of breast cancer: methods and preliminary results of three studies. Grunfeld E, et al. **Ann Oncol** 1995;6 Suppl 2:47-52 (30 ref.)

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457-63 (65 ref.)

Comments of a consultant to primary care physicians [letter] Paulson GW. **Arch Fam Med** 1996 Jul-Aug;5(7):381-2

Violence, mental health, and substance abuse in patients who are seen in primary care settings. Wyshak G, et al. **Arch Fam Med** 1996 Sep;5(9):441-7

Intentional injury surveillance in a primary care pediatric setting. Sege R, et al. **Arch Pediatr Adolesc Med** 1996 Mar; 150(3):277-83

Educating nurses for primary psychiatric care: a South African perspective. Uys LR, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):348-53'

Shifting the balance from secondary to primary care [editorial] Coulter A. **BMJ** 1995 Dec 2;311(7018):1447-8

Evaluation of a primary care anticoagulant clinic. Reporting of results should be standardised [letter; comment] Fitzmaurice DA, et al. **BMJ** 1996 Jun 22; 312(7046):1609-10; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Evaluation of a primary care anticoagulant clinic. Authors did not present enough data [letter; comment] Fowlie PW. **BMJ** 1996 Jun 22;312(7046):1609. Comment on: BMJ 1996 Mar 2;312(7030):560.

Learning from primary care in developing countries [letter; comment] Gunasekera PC, et al. **BMJ** 1996 May 4; 312(7039):1161-2. Comment on: BMJ 1995 Oct 7;311(7010):891-2. Comment on: BMJ 1996 Jan 27;312(7025):249-50. Comment on: BMJ 1996 Jan 27;312(7025):250.

Primary care out of hours. Emergency centre in Midlothian is successful [letter; comment] Heaney D, et al. **BMJ** 1996 May 18;312(7041):1303-4. Comment on: BMJ 1996 Feb 10;312(7027):352-6.

Primary health care and adolescence [letter; comment] Kramer T, et al. **BMJ** 1995 Dec 2;311(7018):1500. Comment on: BMJ 1995 Sep 30;311(7009):825-6.

Primary health care and adolescence [editorial] [see comments] Macfarlane A, et al. **BMJ** 1995 Sep 30; 311(7009):825-6. Comment in: BMJ 1995 Dec 2;311(7018):1500.

Secondary prevention of coronary heart disease in primary care is cost effective [letter] McKnight A, et al. **BMJ** 1996 Aug 31;313(7056):563

Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. Paterson C. **BMJ** 1996 Apr 20;312(7037):1016-20

MYMOP, a patient generated measure of outcomes. Reliability of such instruments needs to be proved [letter] Ruta D, et al. **BMJ** 1996 Sep 7;313(7057):626-7

Balancing science and art in primary care research: past and present [editorial] Charlton R. **Br J Gen Pract** 1995 Dec; 45(401):639-40

Bereavement: a protocol for primary care. Charlton R, et al. **Br J Gen Pract** 1995 Aug;45(397):427-30 (49 ref.)

Preventing skin cancer [letter] Jones R. **Br J Gen Pract** 1995 Aug;45(397):443

Primary care research ethics. Jones R, et al. **Br J Gen Pract** 1995 Nov;45(400):623-6

The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting. Rosengren H, et al. **Br J Gen Pract** 1996 Mar;46(404):177-9

Clinical guidelines in primary care: a survey of general practitioners' attitudes and behaviour. Siriwardena AN. **Br J Gen Pract** 1995 Dec;45(401):643-7

Patient choice of general practice [letter] Taylor MB. **Br J Gen Pract** 1996 Mar;46(404):200

Comparison between primary care physiotherapy education/advice clinics and traditional hospital based physiotherapy treatment: a randomized trial. Worsfold C, et al. **Br J Gen Pract** 1996 Mar;46(404):165-8

New approach to primary medical care. Nine-point plan based on flawed analysis [editorial; comment] Lofsky S, et al. **Can Fam Physician** 1995 Nov;41:1831-6, 1840-6. Comment on: Can Fam Physician 1994 Sep;40:1523-30. **(Eng, Fre)**

New wine in old wineskins. Green Paper outlines rational new approach [editorial] Wedel RJ. **Can Fam Physician** 1995 Dec;41:2051-2, 2068-70 **(Eng, Fre)**

Essential surgery---respectable again [editorial] Lett RR, et al. **Can J Surg** 1995 Oct;38(5):398-9

Diagnosing the ills of our health care system [letter] Frew EM. **Can Med Assoc J** 1996 May 1;154(9):1316-7

The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Spengler M, et al. **Clin Invest Med** 1995 Aug;18(4):325-31

Primary care of children with HIV infection. Forsyth BW. **Curr Opin Pediatr** 1995 Oct;7(5):502-12 (57 ref.)

Primary health care in disasters: the NorAid system. Fjaer RB. **Disasters** 1995 Sep;19(3):264-8

Monitoring progress towards health for all by the year 2000: indicators from Iganga District, Uganda. Biritwum RB. **East Afr Med J** 1995 May;72(5):317-21

Using ICPC in a computer-based primary care information system. Klinkman MS, et al. **Fam Med** 1995 Jul-Aug; 27(7):449-56

Accuracy of on-site data entry in a rural primary care research network. Kreher NE, et al. **Fam Med** 1995 Jul-Aug;27(7):457-9

Ethnography: a stepwise approach for primary care researchers. Ventres WB, et al. **Fam Med** 1996 Jan; 28(1):52-6 (25 ref.)

Patients' evaluations of their consultations with primary health clinic doctors in the United Arab Emirates. Harrison A. **Fam Pract** 1996 Feb;13(1):59-66

A comparison of methods for measuring patient satisfaction with consultations in primary care. Kinnersley P, et al. **Fam Pract** 1996 Feb;13(1):41-51

DSM-IV primary care version: an opportunity for general hospital and consultation-liaison psychiatrists? [editorial] Pincus HA, et al. **Gen Hosp Psychiatry** 1995 Sep; 17(5):324-5

Geriatric assessment: making it work in primary care practice. Gudmundsson A, et al. **Geriatrics** 1996 Mar; 51(3):55-65

The role of nurses in the new health care marketplace [letter] Keepnews D. **Health Aff (Millwood)** 1995 Fall;14(3):280-1

Primary health care physicians' treatment of psychosocial problems: implications for social work. Gross R, et al. **Health Soc Work** 1996 May;21(2):89-95

Head count. When it comes to preparing for capitation, deft management skills are as important as number crunching. **Hosp Health Netw** 1996 Apr 20;70(8):67-8, 70, 72

The impact of primary health care services on under-five mortality in rural Niger. Magnani RJ, et al. **Int J Epidemiol** 1996 Jun;25(3):568-77

Economic considerations of primary care for the clinician. Fromer L. **Int J Fertil Menopausal Stud** 1996 Mar-Apr; 41(2):129-31

Measuring quality of life in Thai and US communities. Watanakij P, et al. **Int Nurs Rev** 1995 Jul-Aug;42(4):121-3

Public policy statement on primary medical care for HIV infected patients in addiction treatment: American Society of Addiction Medicine. **J Addict Dis** 1995;14(3):129-30

Community-oriented primary care programs. Bailey RN. **J Am Optom Assoc** 1995 Oct;66(10):631-3 (7 ref.)

Testing the field of vision: a primary responsibility [editorial] Classé JG. **J Am Optom Assoc** 1995 Nov;66(11):664-5

Cancer pain education: objectives for medical students and residents in primary care specialties. Palliative Oncology Education Section of the American Association for Cancer Education. **J Cancer Educ** 1996 Spring;11(1):7-10

Results of an office-based training program in clinical breast examination for primary care physicians. Benincasa TA, et al. **J Cancer Educ** 1996 Spring;11(1):25-31

Self-report disability in an international primary care study of psychological illness. Von Korff M, et al. **J Clin Epidemiol** 1996 Mar;49(3):297-303

Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76-82; discussion 83-5 (20 ref.)

Dental education and the primary oral health care clinic model. Ismail AI. **J Dent Educ** 1996 Jun;60(6):520-3

Public health medicine and primary care [letter] Gray DP. **J Epidemiol Community Health** 1996 Feb;50(1):108

The nature of primary care. Donaldson MS, et al. **J Fam Pract** 1996 Feb;42(2):113-6

Science and the future of primary care. Green LA. **J Fam Pract** 1996 Feb;42(2):119-22

Separating fad from fact: family medicine, primary care, and the role of health services research [editorial; comment] Grumbach K. **J Fam Pract** 1996 Jul;43(1):30-3. Comment on: J Fam Pract 1996 Jul;43(1):33-9. Comment on: J Fam Pract 1996 Jul;43(1):40-8.

What are the sciences of relationship-centered primary care. Inui TS. **J Fam Pract** 1996 Feb;42(2):171-7

Values and roles in primary care. Lamberts H, et al. **J Fam Pract** 1996 Feb;42(2):178-80

Sustained partnership in primary care [see comments] Leopold N, et al. **J Fam Pract** 1996 Feb;42(2):129-37. Comment in: J Fam Pract 1996 Jul;43(1):13.

Primary care research from a health system perspective. Nerenz DR. **J Fam Pract** 1996 Feb;42(2):186-91

Practice-based research networks: building the infrastructure of primary care research. Nutting PA. **J Fam Pract** 1996 Feb;42(2):199-203

Primary care: questions raised by a definition. Povar GJ. **J Fam Pract** 1996 Feb;42(2):124-8

Decision-making: a comparison of referral practice and primary care. Sox HC. **J Fam Pract** 1996 Feb;42(2):155-60

Primary care research: barriers and opportunities. Stange KC. **J Fam Pract** 1996 Feb;42(2):192-8

A framework for primary care research. Starfield B. **J Fam Pract** 1996 Feb;42(2):181-5

The difficult patient: prevalence, psychopathology, and functional impairment [see comments] Hahn SR, et al. **J Gen Intern Med** 1996 Jan;11(1):1-8. Comment in: J Gen Intern Med 1996 Jan;11(1):56-7.

Expert ratings of primary care goals and objectives. Robbins AS, et al. **J Gen Intern Med** 1995 Aug;10(8):429-35

Psychiatric screening in geriatric primary care: should it be for depression alone? Lish JD, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):141-53 (129 ref.)

Is cardiovascular screening in primary care worthwhile? Coope JR. **J Hum Hypertens** 1995 Oct;9(10):785-6 (20 ref.)

Genetics in primary care. Report on workshop of EC Concerted Action on Genetics Services in Europe (CAGSE) in association with the Royal College of GP Spring Meeting, Blackpool, UK, 28 April 1995. Harris R, et al. **J Med Genet** 1996 Apr;33(4):346-8

Primary health care nursing education in Canadian university schools of nursing. Tenn L. **J Nurs Educ** 1995 Nov; 34(8):350-8

Primary care for women. Assessment and management of headache. Barrett E. **J Nurse Midwifery** 1996 Mar-Apr; 41(2):117-24 (23 ref.)

Primary care for women. Management of common musculoskeletal disorders. Benetti MC, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):173-87 (40 ref.)

Primary care for women. Management of common respiratory problems. Mays M, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):139-54 (50 ref.)

Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):101-16 (55 ref.)

Primary care for women. Management and treatment of gastrointestinal disorders. Shaw B. **J Nurse Midwifery** 1996 Mar-Apr;41(2):155-72 (20 ref.)

Primary care for women. Comprehensive assessment and management of common mental health problems. Weintraub TA, et al. **J Nurse Midwifery** 1996 Mar-Apr; 41(2):125-38 (53 ref.)

Alexithymia in primary health care patients. Joukamaa M, et al. **J Psychosom Res** 1995 Oct;39(7):833-42

Primary or secondary care? What can economics contribute to evaluation at the interface? Scott A. **J Public Health Med** 1996 Mar;18(1):19-26

Turning to primary care [letter] Blaney D, et al. **Lancet** 1995 Dec 9;346(8989):1560

Turning to primary care [letter] Byrne S. **Lancet** 1995 Dec 9;346(8989):1561

Turning to primary care [letter] Carney TA. **Lancet** 1995 Dec 9;346(8989):1561

Turning to primary care [letter] Carpenter H. **Lancet** 1995 Dec 9;346(8989):1560–1

Recognition of common mental disorders in primary care in African countries: should "mental" be dropped? Patel V. **Lancet** 1996 Mar 16;347(9003):742–4

Community participation in health care [letter; comment] Waterston T. **Lancet** 1995 Sep 30;346(8979):907. Comment on: Lancet 1995 Aug 12;346(8972):421–4.

Primary care of the HIV patient: standard practice and new developments in the era of managed care. Kocurek K. **Med Clin North Am** 1996 Mar;80(2):375–410 (204 ref.)

Genetic screening and primary health care [editorial] Walpole IR. **Med J Aust** 1996 Apr 15;164(8):455–6

Implementation of a clinical workstation for general practice. Lovell NH, et al. **Medinfo** 1995;8 Pt 1:777

Schistosomiasis control in a primary health care system. Adbel Gawad el-Khoby T. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):303–6

A trial of increased access to primary care [letter] Adams WL. **N Engl J Med** 1996 Sep 19;335(12):897; discussion 897–8

A trial of increased access to primary care [letter] Corey GA. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

A trial of increased access to primary care [letter] Henley DE. **N Engl J Med** 1996 Sep 19;335(12):895; discussion 897–8

A trial of increased access to primary care [letter] Magill MK, et al. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

A trial of increased access to primary care [letter] Portnoi VA. **N Engl J Med** 1996 Sep 19;335(12):897; discussion 897–8

A trial of increased access to primary care [letter] Rich MW. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

A trial of increased access to primary care [letter] Snider GL, et al. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

A trial of increased access to primary care [letter] Starfield B, et al. **N Engl J Med** 1996 Sep 19;335(12):895–6; discussion 897–8

Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission [see comments] Weinberger M, et al. **N Engl J Med** 1996 May 30; 334(22):1441–7. Comment in: N Engl J Med 1996 May 30;334(22):1472–3.

Questions about the value of early intervention [editorial; comment] Welch HG. **N Engl J Med** 1996 May 30; 334(22):1472–3. Comment on: N Engl J Med 1996 May 30;334(22):1441–7.

Will increased primary care bring about increased medical access? [letter] Niederhoffer EC. **Nat Med** 1996 Sep; 2(9):948

Can we change the system? [editorial] Crosby LA. **Nebr Med J** 1996 Jul;81(7):183

Nebraska physicians and AIDS. Swindells S. **Nebr Med J** 1996 Jan;81(1):10–3

Child abuse prevention for former preterm infants in primary care follow-up [letter] Lawless JB. **Nurse Pract** 1995 Nov; 20(11 Pt 1):12, 14, 16

Recurrent aphthous stomatitis: primary care management. Petersen MJ, et al. **Nurse Pract** 1996 May;21(5):36–40, 42, 47 (32 ref.)

Primary care is a relationship. Sharp N. **Nurse Pract** 1996 May;21(5):134, 139–40

Patterns of referral and examination for retinopathy in pregnant women with diabetes by primary care physicians [see comments] Marrero DG, et al. **Ophthalmic Epidemiol** 1995 Jun;2(2):93–8. Comment in: Ophthalmic Epidemiol 1995 Jun;2(2):57–8.

Patterns of diabetic eye care by primary care physicians in the state of Indiana [see comments] Yung CW, et al. **Ophthalmic Epidemiol** 1995 Jun;2(2):85–91. Comment in: Ophthalmic Epidemiol 1995 Jun;2(2):57–8.

Diagnosing psychosocial problems. Kelleher KJ, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):899–901

Funding, franchising, and effective primary care [editorial; comment] Campion PD. **Postgrad Med J** 1996 Apr; 72(846):195. Comment on: Postgrad Med J 1996 Apr;72(846):201–6.

A model for adapting clinical guidelines for electronic implementation in primary care. Lobach DF. **Proc Annu Symp Comput Appl Med Care** 1995;:581–5

The SDDS-PC: a diagnostic aid for multiple mental disorders in primary care. Olfson M, et al. **Psychopharmacol Bull** 1995;31(2):415–20

Report from the First Roentgen Centennial Fellow. Franken EA Jr. **Radiology** 1995 Dec;197(3):857–8

Guidelines for the management of hypertension at primary health care level. Hypertension Society of Southern Africa, endorsed by the Medical Association of South Africa and the Medical Research Council. **S Afr Med J** 1995 Dec;85(12 Pt 2):1321–5

Essential drug list ready to go [news] **S Afr Med J** 1996 Feb;86(2):117

The role of culture in primary health care. Two case studies. Chipfakacha V. **S Afr Med J** 1994 Dec;84(12):860–2

Feed the children, not the parasites—an essential part of primary health care in South Africa [editorial] Fincham JE, et al. **S Afr Med J** 1996 Jun;86(6):647–9

Who promotes primary health care and why? [editorial] [see comments] Jeppe C. **S Afr Med J** 1995 Jul;85(7):634–6. Comment in: S Afr Med J 1995 Oct;85(10):1038–9.

Rationale for the hypertension guidelines for primary care in South Africa. Opie LH, et al. **S Afr Med J** 1995 Dec; 85(12 Pt 2):1325–8, 1330–1, 1334–5 passim

Who promotes primary health care and why? [letter; comment] Rabiner E. **S Afr Med J** 1995 Oct;85(10):1038–9 . Comment on: S Afr Med J 1995 Jul;85(7):634–6.

Decisional conflict in general practice: strategies of patient management. Di Caccavo A, et al. **Soc Sci Med** 1995 Aug; 41(3):347–53

Health promotion in primary care: physician–patient communication and decision making about prescription medications. Makoul G, et al. **Soc Sci Med** 1995 Nov; 41(9):1241–54

Primary health care: the basis for malaria control in Hubei, China. Li HF, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):29–33

Sustainability of schistosomiasis case detection based on primary health care. Engels D, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):599

Prevalence of blindness and visual impairment in the region of Ségou, Mali. A baseline survey for a primary eye care programme. Kortlang C, et al. **Trop Med Int Health** 1996 Jun;1(3):314–9

Infant/toddler oral health care: guidelines for the primary care physician. Veselicky LT, et al. **W V Med J** 1996 Jan–Feb;92(1):22–5

Prevention—how much of it in our health care? [editorial; comment] **West Afr J Med** 1995 Apr–Jun;14(2):70–1. Comment on: West Afr J Med 1995 Apr–Jun;14(2):91–6. Comment on: West Afr J Med 1995 Apr–Jun;14(2):101–4.

Factors associated with choosing a primary care career. Schieberl JL, et al. **West J Med** 1996 Jun;164(6):492–6

Proceedings of the 1995 Wisconsin Primary Care Research Forum. Wausau, Wisconsin, September 29–30, 1995. **Wis Med J** 1995 Dec;94(12):672–86

Women's narratives in primary care medical encounters. Borges S, et al. **Women Health** 1995;23(1):29–56

Research of the exploitation of human resources in blind prevention and primary eye care. Wei J, et al. **Yen Ko Hsueh Pao** 1995 Mar;11(1):1–4

[Diagnostic ultrasound imaging in municipal health care centers (editorial)] Kunnamo I. **Duodecim** 1994; 110(21):1971–3 (11 ref.) **(Fin)**

[The problem of recognizing depression in primary care] Poutanen O, et al. **Duodecim** 1995;111(5):419–26 **(Fin)**

[The general practitioner as physician of first contact with health problems] Tabenkin H, et al. **Harefuah** 1995 Nov 1;129(9):297–303, 368 (Eng. Abstr.) **(Heb)**

[Emergency treatment of stroke patients—what does the primary health care do?] Bugge P, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1893–6 (Eng. Abstr.) **(Nor)**

[ADP-based records in primary health care. Rationalization or reorganization?] Hofmann B, et al. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1470–3 (Eng. Abstr.) **(Nor)**

[What does the primary care physician now about his deceased patients? A study of deaths in a group practice] Kristoffersen JE. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):869–71 (Eng. Abstr.) **(Nor)**

[Perspectives of development and production of portable diagnostic devices for therapeutic and cardiological care] Kovner LG, et al. **Med Tekh** 1996 Mar–Apr;(2):20–1 (Eng. Abstr.) **(Rus)**

[Strategies for the detection of dyslipemias in primary care in La Rioja] Brea Hernando AJ, et al. **An Med Interna** 1996 May;13(5):227–31 (Eng. Abstr.) **(Spa)**

[Geriatrics seen from the primary care perspective] Morelo Negrete L, et al. **An Med Interna** 1995 Jul;12(7):329–32 (Eng. Abstr.) **(Spa)**

[Design of an information system for primary care. Task Force for the design of an information system for primary care] **Aten Primaria** 1996 Apr 30;17(7):449–56 (Eng. Abstr.) **(Spa)**

[Allocation of resources for the health care of diabetics. Panel of Experts, Ministry of Health and Consumption] **Aten Primaria** 1996 Apr 30;17(7):471–9 **(Spa)**

[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**

[Analysis of information sources in the journal, Atencion Primaria] Aleixandre R, et al. **Aten Primaria** 1996 Mar 31; 17(5):321–5 (Eng. Abstr.) **(Spa)**

[Ten years of the journal Atención Primaria (1984–1993): a bbibliometric and subject analysis] Aleixandre R, et al. **Aten Primaria** 1996 Feb 29;17(3):225–30 **(Spa)**

[Oral anticoagulation from the primary care perspective (letter; comment)] Alonso M, et al. **Aten Primaria** 1995 Nov 30;16(9):574. Comment on: Aten Primaria 1995 May 31;15(9):555–60. **(Spa)**

[Relationship between health care levels (editorial)] Alonso Fernández M, et al. **Aten Primaria** 1996 Mar 15; 17(4):239–40 **(Spa)**

[The follow-up of a patient cohort with arterial hypertension in primary care] Alonso Martínez MM, et al. **Aten Primaria** 1996 May 31;17(9):575–9 (Eng. Abstr.) **(Spa)**

[Delegated prescription by specialists in primary care] Arroyo MP, et al. **Aten Primaria** 1995 Nov 30;16(9):538–44 (Eng. Abstr.) **(Spa)**

[Difficulties in carrying out preventive activities in primary care] Aubá J, et al. **Aten Primaria** 1995 Oct 31;16(7):428–32 (Eng. Abstr.) **(Spa)**

[Care of women in primary health care (editorial)] Bailón Muñoz E, et al. **Aten Primaria** 1996 May 15;17(8):483–5 **(Spa)**

[Control of anticoagulation in primary care (letter; comment)] Caballero Martinez F, et al. **Aten Primaria** 1995 Nov 30; 16(9):574–5. Comment on: Aten Primaria 1995 May 31;15(9):555–60. **(Spa)**

[A health system that does not live up to expectations. A primary health care team attempt at an integrated approach to a case (letter)] Cárdenas Rodríguez M, et al. **Aten Primaria** 1996 Feb 29;17(3):232–3 **(Spa)**

[Proposal for a new classification of long-term treatment in primary health care] Carrillo Muñoz R, et al. **Aten Primaria** 1996 Jan;17(1):48–51 (Eng. Abstr.) **(Spa)**

[The diagnosis of mental disorders by the primary care physician] Chocrón Bentata L, et al. **Aten Primaria** 1996 Jun 15;18(1):22–6 (Eng. Abstr.) **(Spa)**

[Drug prescriptions in general medicine clinics or drugs prescribed by primary care physicians? (letter; comment)] Costa Alcaraz AM, et al. **Aten Primaria** 1995 Oct 31; 16(7):454–5. Comment on: Aten Primaria 1995 Mar 31;15(5):286–8. **(Spa)**

[The role of the primary care physician in AIDS (editorial)] da Pena Alvarez JM. **Aten Primaria** 1996 Jul–Aug; 18(3):103–4 **(Spa)**

[Analysis of the use of radiology in primary health care] Delgado Nicolás MA, et al. **Aten Primaria** 1996 Jan; 17(1):52–6 (Eng. Abstr.) **(Spa)**

[A descriptive study of long-term medication authorized in the health district of Lleida (Badalona)] Díaz Barroso A, et al. **Aten Primaria** 1996 Mar 15;17(4):251–6 (Eng. Abstr.) **(Spa)**

[Consultation by third parties in primary care of the aged] García del Campo MM, et al. **Aten Primaria** 1995 Dec; 16(10):607–10, 612–4 (Eng. Abstr.) **(Spa)**

[Characterization of the assistance work of the general/family physician] Gérvas J, et al. **Aten Primaria** 1995 Nov 15; 16(8):501–6 **(Spa)**

[Examinations and referrals at a health center: a study of associated factors] Gómez-Calcerrada Berrocal D, et al. **Aten Primaria** 1996 Mar 31;17(5):353–7 (Eng. Abstr.) **(Spa)**

[Analysis of research in primary health care in the Murcia region (1988–1992)] González Díaz M, et al. **Aten Primaria** 1995 Sep 15;16(4):203–6 (Eng. Abstr.) **(Spa)**

[Suitability of a tobacco dependence clinic in primary care] Granollers Mercader S, et al. **Aten Primaria** 1995 Oct 15; 16(6):331–6 (Eng. Abstr.) **(Spa)**

[Improvement in the quality of the interclinic referral note in regard to the information given] Huertas Zarco I, et al. **Aten Primaria** 1996 Mar 31;17(5):317–20 (Eng. Abstr.) **(Spa)**

[User satisfaction with primary care teams: related to doctor's training in the field of physician–patient relations] Iragüen Eguskiza P, et al. **Aten Primaria** 1995 Nov 15;16(8):485–90 (Eng. Abstr.) **(Spa)**

[Does the communication between primary and secondary levels function?] Irazábal Olabarrieta L, et al. **Aten Primaria** 1996 Apr 15;17(6):376–81 (Eng. Abstr.) **(Spa)**

[Influence of the journal Atención Primaria on family medicine in Mexico (letter)] Irigoyen Coria A, et al. **Aten Primaria** 1996 Apr 30;17(7):480 **(Spa)**

[Analysis of adverse drug reactions detected in a primary health care center] Joyanes A, et al. **Aten Primaria** 1996 Mar 15;17(4):262–7 (Eng. Abstr.) **(Spa)**

[Classification systems in case-mix groups in ambulatory care. Perspectives for our primary health care] Juncosa S, et al. **Aten Primaria** 1996 Jan;17(1):76–82 (34 ref.) **(Spa)**

[Prevention and health promotion in a client-provider model (editorial)] Kloppe P. **Aten Primaria** 1996 Mar 15; 17(4):237–8 **(Spa)**

[Referral from primary care to hospital emergency services (letter; comment)] León Vázquez F, et al. **Aten Primaria** 1995 Dec;16(10):649–50, 652. Comment on: Aten Primaria 1995 Jun 30;16(2):89–91. **(Spa)**

–Factors of dissatisfaction with health care. A Delphi study– Maderuelo Fernández JA, et al. **Aten Primaria** 1996 Mar 31;17(5):348–52 (Eng. Abstr.) **(Spa)**

[The degree of compliance with the radiology requests from primary care] Martínez A, et al. **Aten Primaria** 1996 Jun 15;18(1):32–4 (Eng. Abstr.) **(Spa)**

[Infectious diseases in primary care] Mendive Arbeloa JM, et al. **Aten Primaria** 1996 Jan;17(1):64–8 (Eng. Abstr.) **(Spa)**

[Clinical autopsy in primary care?] Monzón Muñoz FJ, et al. **Aten Primaria** 1996 Jun 15;18(1):40–3 **(Spa)**

[Collection of data on primary care activities by sampling] Ortiz Cervelló F, et al. **Aten Primaria** 1996 Apr 15; 17(6):369–75 (Eng. Abstr.) **(Spa)**

[Professional associations in general medicine] Ortún V, et al. **Aten Primaria** 1996 Mar 15;17(4):300–2 **(Spa)**

[Health services accessibility in the Murcia region] Palomar Rodríguez J, et al. **Aten Primaria** 1996 May 15;17(8):507–11 (Eng. Abstr.) **(Spa)**

[Additional question ("is there anything else...?") in primary

health care] Peláez Fernández C, et al. **Aten Primaria** 1996 Jan;17(1):12–6 (Eng. Abstr.) **(Spa)**

[Evaluation of the urinalysis of the diabetic patient in primary care] Piedra de la Llana F, et al. **Aten Primaria** 1996 Jun 15;18(1):28–31 (Eng. Abstr.) **(Spa)**

[An evaluation of the information sent from primary care with hospital emergencies (letter)] Porcel A, et al. **Aten Primaria** 1996 Jun 15;18(1):46–7 **(Spa)**

[Training of nurses in primary health care: international experience in community health] Rayón Valpuesta E, et al. **Aten Primaria** 1995 Sep 30;16(5):289–92 **(Spa)**

[Evaluation of an informative leaflet on AIDS/HIV infection aimed at primary health care professionals in Catalonia] Rodés A, et al. **Aten Primaria** 1996 Jan;17(1):4–10 (Eng. Abstr.) **(Spa)**

[Is clinical pharmacology important in primary health care? The Mallorca experience (letter)] Rodríguez Moreno C. **Aten Primaria** 1996 Jan;17(1):88, 90 **(Spa)**

[Discrepancies in primary care text (letter)] Rodríguez Moreno C, et al. **Aten Primaria** 1996 Apr 15;17(6):426–7 **(Spa)**

[Episode: concept and usefulness in primary care] Rosell M, et al. **Aten Primaria** 1995 Dec;16(10):633–8, 640 **(Spa)**

[Primary care research: attitude of family physicians trained at the Córdoba Teaching Unit] Ruiz Moral R, et al. **Aten Primaria** 1995 Oct 15;16(6):360–3 (Eng. Abstr.) **(Spa)**

[The Manual of the Primary Care Tutor (editorial)] Saura Llamas J. **Aten Primaria** 1996 Feb 29;17(3):177–8 **(Spa)**

[Primary care research in the Valencia community. Original articles published over a 4-year period (1990–1993)] Soler Torró JM, et al. **Aten Primaria** 1995 Oct 15;16(6):338–42 (Eng. Abstr.) **(Spa)**

[Prostate cancer screening in the primary care consultation (editorial)] Subías Loren PJ, et al. **Aten Primaria** 1996 May 31;17(9):545–6 **(Spa)**

[Role of the social worker in the primary care team: let's plan a dream (editorial)] Turabián JL. **Aten Primaria** 1995 Nov 30;16(9):513–4 **(Spa)**

[The Methadone Maintenance Program for intravenous heroin addicts. What information do primary care physicians have?] Velarde Mayol C, et al. **Aten Primaria** 1996 May 31;17(9):581–4 (Eng. Abstr.) **(Spa)**

[A comparison of the oral endoscopy reports requested by primary care and hospital care (letter)] Vergeles Blanca JM, et al. **Aten Primaria** 1996 Jun 15;18(1):45–6 **(Spa)**

[An operative primary health care services model including physicians and technicians] Santacruz J, et al. **Gac Med Mex** 1995 Sep–Dec;131(5–6):513–25 (Eng. Abstr.) **(Spa)**

[Professional perspective in primary health care reform: a qualitative approximation] Rodríguez R, et al. **Gac Sanit** 1995 Jul–Aug;9(49):237–43 (Eng. Abstr.) **(Spa)**

[Content analysis in the assessment of the new model of primary health care in the Valencian community] Rodríguez R, et al. **Gac Sanit** 1995 Jul–Aug;9(49):244–50 (Eng. Abstr.) **(Spa)**

[Demand and HIV testing prescription in primary care. Registry of the network of sentinel physicians from Castilla y León in 1991, 1992, and 1993] Vega Alonso AT, et al. **Gac Sanit** 1996 Jan–Feb;10(52):25–33 (Eng. Abstr.) **(Spa)**

[Relations between hospital and primary care. Experience at an internal medicine service] Criado-Montilla J, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):463–8 **(Spa)**

[Reflections on primary health care for adults] Parrochia E. **Rev Med Chil** 1995 Mar;123(3):390–3 **(Spa)**

[Education of psychologists and their role in primary health care] Durán-González LI, et al. **Salud Publica Mex** 1995 Sep–Oct;37(5):462–71 (Eng. Abstr.) **(Spa)**

[Utilization of health services by febrile patients in a malaria transmission area in Mexico] Leyva-Flores R, et al. **Salud Publica Mex** 1995 Sep–Oct;37(5):400–7 (Eng. Abstr.) **(Spa)**

[Unnecessary admissions to departments of internal medicine. The contact with primary health care must be improved] Bergstad B, et al. **Lakartidningen** 1996 Jun 12;93(24):2344–5 **(Swe)**

[Primary community care in Finland: no evident advantages for democracy and efficiency] Björkgren M, et al. **Lakartidningen** 1995 Nov 22;92(47):4396–8; discussion 4398, 4403 **(Swe)**

[Patients depending on interpreters need more resources] Carlander AC, et al. **Lakartidningen** 1996 Aug 28; 93(34):2854–6 **(Swe)**

[Should primary health care be highly specified? (letter)] Eckerman I. **Lakartidningen** 1996 Jun 12;93(24):2318 **(Swe)**

[Free of charge primary health care!] Lange N. **Lakartidningen** 1995 Nov 1;92(44):4070, 4075 **(Swe)**

[Extended guaranteed care. What are we going to do? (letter)] Löf R, et al. **Lakartidningen** 1996 Jan 31;93(5):342 **(Swe)**

[Orthopedics in primary health care (letter)] Rosenquist B. **Lakartidningen** 1996 Apr 17;93(16):1512 **(Swe)**

[9th Scandinavian Congress in General Medicine. Holistic health—the strong point in primary health care] Oldinger E. **Nord Med** 1995;110(8–9):226–7 **(Swe)**

CLASSIFICATION

[Utilization of computerized classification system of primary care: three years of experience] Leduc Y, et al. **Can Fam Physician** 1995 Aug;41:1338–45 (Eng. Abstr.) **(Fre)**

ECONOMICS

Cost comparison of psychiatric outpatient clinics based in hospitals and in primary care (general practice health center). Shah A. **Acta Psychiatr Scand** 1995 Jul;92(1):30–4

Health care costs of primary care patients with recognized depression. Simon GE, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):850–6

FHSAs and family health services. Scott H. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):291–2

A capitation primer for pediatricians. Wilson D, et al. **Curr Opin Pediatr** 1996 Apr;8(2):176–80

The community psychiatric nurse in primary care: an economic analysis. Gournay K, et al. **J Adv Nurs** 1995 Oct;22(4):769–78

Medicare costs in urban areas and the supply of primary care physicians [see comments] Mark DH, et al. **J Fam Pract** 1996 Jul;43(1):33–9. Comment in: J Fam Pract 1996 Jul;43(1):30–2.

Medicaid primary care services in New York State: partial capitation vs full capitation. Rosenthal TC, et al. **J Fam Pract** 1996 Apr;42(4):362–8

Health insurance does not guarantee access to primary care: a national study of physicians' acceptance of publicly insured patients. Cykert S, et al. **J Gen Intern Med** 1995 Jun;10(6):345–8

Assessing the quality of primary care: the use and importance of reimbursement data. Longo DR, et al. **J Health Care Finance** 1995 Summer;21(4):13–30

Showcasing primary care. Bell H. **Minn Med** 1995 Oct; 78(10):8–14, 58–60

A trial of increased access to primary care [letter] Burack JH. **N Engl J Med** 1996 Sep 19;335(12):897; discussion 897–8

[Analysis of the variability of primary care costs (see comments)] García Cardona F, et al. **Aten Primaria** 1995 Nov 15;16(8):473–8 (Eng. Abstr.). Comment in: Aten Primaria 1996 May 15;17(8):543–4. **(Spa)**

[Pharmaceutical expenditure in primary care according to the prescription source] Lomeña Villalobos JA, et al. **Aten Primaria** 1996 Jun 15;18(1):35–8 (Eng. Abstr.) **(Spa)**

HISTORY

Research and history [letter] Stokes T. **Fam Pract** 1996 Apr; 13(2):208

LEGISLATION & JURISPRUDENCE

Primary health care and severe mental illness: the need for national and state policy [editorial] Davis KE. **Health Soc Work** 1996 May;21(2):83–7

Primary care equals primary responsibility. Avery JK. **J Ark Med Soc** 1996 Jan;92(8):399

Effects of the German 1993 health reform law upon primary care practitioners' individual performance: results from an empirical study in sentinel practices. Hoopmann M, et al. **J Epidemiol Community Health** 1995 Aug;49 Suppl 1:33–6

[The Bremen primary examination program for refugees (I)] Mohammadzadeh Z. **Gesundheitswesen** 1995 Aug–Sep; 57(8–9):457–61 (Eng. Abstr.) **(Ger)**

[The Bremen primary examination program for refugees (II)] Mohammadzadeh Z. **Gesundheitswesen** 1995 Aug–Sep; 57(8–9):462–6 **(Ger)**

[Interdisciplinary cooperation in primary care of elderly patients—results of results with consequences for general practice] Schick B, et al. **Gesundheitswesen** 1996 Mar; 58(3):126–31 (Eng. Abstr.) **(Ger)**

MANPOWER

Family physician workforce reform: AAFP recommendations. Board of Directors, American Academy of Family Physicians [see comments] **Am Fam Physician** 1996 Jan;53(1):65–6, 71–2, 75, passim. Comment in: Am Fam Physician 1996 Jan;53(1):57–8.

The virtual health economy: telemedicine and the supply of primary care physicians in rural America. McCarthy D. **Am J Law Med** 1995;21(1):111–30 (176 ref.)

Medical education and health for all: dream, mirage or nemesis? [editorial; comment] Clarke R. **Aust J Public Health** 1995 Oct;19(5):439–40. Comment on: Aust J Public Health 1995 Oct;19(5):525.

Medical education and health for all [see comments] Shapiro M, et al. **Aust J Public Health** 1995 Oct;19(5):525. Comment in: Aust J Public Health 1995 Oct;19(5):439–40.

Retraining specialists for primary care. Scherger JE. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):24D–F, 24H

Medicare costs in urban areas and the supply of primary care physicians [see comments] Mark DH, et al. **J Fam Pract** 1996 Jul;43(1):33–9. Comment in: J Fam Pract 1996 Jul;43(1):30–2.

Balancing primary versus specialty care [see comments] Shi L. **J R Soc Med** 1995 Aug;88(8):428–32 (62 ref.). Comment in: J R Soc Med 1995 Aug;88(8):425.

Primary care: specialists or generalists. Gabriel SE. **Mayo Clin Proc** 1996 Apr;71(4):415–9 (62 ref.)

Planning the future of primary care in NC [letter; comment] Bean GO. **N C Med J** 1995 Dec;56(12):597. Comment on: N C Med J 1995 Aug;56(8):352–8. Comment on: N C Med J 1995 Aug;56(8):360–3.

Primary care physicians for North Carolina. How many are needed? Where will they come from? Can the need be met? [see comments] Kobrinski EJ, et al. **N C Med J** 1995 Aug; 56(8):352–8. Comment in: N C Med J 1995 Dec;56(12):597.

Volunteers sought to help train more generalists. Shoop GH. **Pa Med** 1995 Jun;98(6):24–6

Medical shortage designation. A federal intervention that works. Arrindell ER, et al. **West J Med** 1996 Jun; 164(6):537–8

Are you being counted? Feehan EB. **West J Med** 1996 Jun; 164(6):538–9

[The general practitioner on the first step in the Third World] Van Dormael M. **Ann Soc Belg Med Trop** 1995;75 Suppl 1:27–38 **(Fre)**

[The health district in primary health care and the community health officer] Tarsitani G, et al. **Ann Ig** 1994 Jul–Dec; 6(4–6):375–82 (Eng. Abstr.) **(Ita)**

[The development of a test for evaluating the knowledge of and attitudes on human immunodeficiency virus infection in primary health care professionals] Llobera Serentill A, et al. **Aten Primaria** 1996 May 31;17(9):564–9 (Eng. Abstr.) **(Spa)**

METHODS

Future provision of out of hours primary medical care: a survey with two general practitioner research networks [see comments] Lattimer V, et al. **BMJ** 1996 Feb 10; 312(7027):352–6. Comment in: BMJ 1996 May 18;312(7041):1303–4. Comment in: BMJ 1996 May 18;312(7041):1304. Comment in: BMJ 1996 Jun 22;312(7046):1610.

Developmental monitoring in primary care. Goldfarb CE, et al. **Can Fam Physician** 1996 Aug;42:1527–32, 1535–6 (22 ref.)

Battered women: how the primary care practitioner can help. Henry CA, et al. **Cleve Clin J Med** 1996 Jul–Aug; 63(4):199–201

The role of the primary care physician in the care of the terminally ill. Ogle KS, et al. **Clin Geriatr Med** 1996 May; 12(2):267–78

A prospective controlled trial of computerized decision support for lipid management in primary care. Hobbs FD, et al. **Fam Pract** 1996 Apr;13(2):133–7

Computerized assessment of common mental disorders in primary care: effect on clinical outcome. Lewis G, et al. **Fam Pract** 1996 Apr;13(2):120–6

Primary care of the adolescent patient. Faigel HC. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):127–33, 137–8, 144–8 (10 ref.)

Computerized knowledge bases in primary health care: a curse or a blessing for health promotion, prevention and patient quality?. Alendahl K, et al. **Medinfo** 1995;8 Pt 2:917–21

Chlamydia trachomatis infection among Hispanic women in the California–Mexico border area, 1993: establishing screening criteria in a primary care setting. Gunn RA, et al. **Sex Transm Dis** 1995 Nov–Dec;22(6):329–34

Pitfalls of patient education. Limited success of a program for back pain in primary care. Cherkin DC, et al. **Spine** 1996 Feb 1;21(3):345–55

[Family counseling in primary health care: a systemic approach] Jarabo Crespo Y, et al. **Aten Primaria** 1995 Nov 30;16(9):557–62 (27 ref.) **(Spa)**

[The approach to generalized pruritus in primary care] Sarrasqueta Sáenz P, et al. **Aten Primaria** 1996 May 31; 17(9):590–4 **(Spa)**

ORGANIZATION & ADMINISTRATION

De Madres a Madres: an access model for primary care. McFarlane J. **Am J Public Health** 1996 Jun;86(6):879–80

Comment: Deteriorating health in Russia—a place for community-based approaches [comment] Wyon JB. **Am J Public Health** 1996 Mar;86(3):321–3. Comment on: Am J Public Health 1996 Mar;86(3):307–16. Comment on: Am J Public Health 1996 Mar;86(3):313–20.

Nurses and physicians attempt to define collaboration and practice roles. Avery LH. **AORN J** 1995 Jul;62(1):107–10

Primary care physicians' use of office resources in the provision of preventive care. Dickey LL, et al. **Arch Fam Med** 1996 Jul–Aug;5(7):399–404

An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Leininger LS, et al. **Arch Fam Med** 1996 Feb;5(2):108–15

Primary care: restoring the jewel in the crown [editorial] Bogle I, et al. **BMJ** 1996 Jun 29;312(7047):1624–5

Integrating pharmacy into the primary care team. Freedom from the dispensary is essential [letter; comment] Bradley M. **BMJ** 1995 Sep 16;311(7007):753. Comment on: BMJ 1995 Jun 24;310(6995):1620–1.

Integrating pharmacy into the primary care team. "One stop clinic" has advantages for patients [letter; comment] Crowe G, et al. **BMJ** 1995 Sep 16;311(7007):753. Comment on: BMJ 1995 Jun 24;310(6995):1620–1.

Learning from primary care in developing countries. Innovations in developing countries have had worldwide relevance [letter; comment] [see comments] Cutting WA. **BMJ** 1996 Jan 27;312(7025):249–50. Comment on: BMJ 1995 Oct 7;311(7010):891–2. Comment in: BMJ 1996 May 4;312(7039):1161–2.

Creating a shared vision of out of hours care: using rapid appraisal methods to create an interagency, community oriented, approach to service development. Dale J, et al. **BMJ** 1996 May 11;312(7040):1206–10

UK government proposes changes to primary care [news] Dyer O. **BMJ** 1996 Jun 15;312(7045):1500

A primary care market? [editorial] Ham C. **BMJ** 1996 Jul 20;313(7050):127–8

Learning from primary care in developing countries. Authors overestimate role of barefoot doctors in China [letter; comment] [see comments] Jewell T. **BMJ** 1996 Jan 27; 312(7025):250. Comment on: BMJ 1995 Oct 7;311(7010):891–2. Comment in: BMJ 1996 May 4;312(7039):1161–2.

Primary health care led NHS: learning from developing countries [editorial] [see comments] Johnstone P, et al. **BMJ** 1995 Oct 7;311(7010):891–2. Comment in: BMJ 1996 Jan 27;312(7025):249–50. Comment in: BMJ 1996 Jan 27;312(7025):250. Comment in: BMJ 1996 May 4;312(7039):1161–2.

Learning from primary care in developing countries. Outreach programme in Kenya was based on extensive community participation [letter; comment] [see comments] Murray SA. **BMJ** 1996 Jan 27;312(7025):250. Comment on: BMJ 1995 Oct 7;311(7010):891–2. Comment in: BMJ 1996 May 4;312(7039):1161–2.

Research and development in primary care [letter] Caan W. **Br J Gen Pract** 1995 Aug;45(397):442

Primary care and the maelstrom of health care reform in the United States of America. Curtis P. **Br J Gen Pract** 1995 Aug;45(397):433–7 (36 ref.)

Facilitation projects [letter] Evans T, et al. **Br J Gen Pract** 1995 Aug;45(397):441–2

There is hope yet for the development of primary health care in deprived areas. Thomas P. **Br J Gen Pract** 1995 Nov;45(400):572–4

Structured management in primary care of patients with epilepsy [editorial; comment] White P. **Br J Gen Pract** 1996 Jan;46(402):3–4 (14 ref.). Comment on: Br J Gen Pract 1996 Jan;46(402):37–42.

GP fundholding: fact or fiction. Tod D. **Br J Hosp Med** 1995 Nov 1–14;54(9):471–2

Patient selection may be the key for the success of shared care for glaucoma [letter] Rao GP, et al. **Br J Ophthalmol** 1996 Apr;80(4):381

Doctors, nurses, and primary care [editorial] Flook N. **Can Fam Physician** 1995 Sep;41:1441–3, 1455–8 **(Eng, Fre)**

Home healthcare: the role of the primary care physician. Goldberg AI. **Compr Ther** 1995 Nov;21(11):633–8 (20 ref.)

Managed care, primary care, and quality for children. Reid RJ, et al. **Curr Opin Pediatr** 1996 Apr;8(2):164–70

Medical nostalgia: 'simple' medical care versus technology [editorial] Bleck E. **Dev Med Child Neurol** 1996 Jan; 38(1):1–2

Screening for social and environmental problems in a VA primary care setting. Cook CA, et al. **Health Soc Work** 1996 Feb;21(1):41–7

Caveat emptor. Scoping out the primary care practice game. Kaufman N. **Hosp Health Netw** 1995 Nov 5;69(21):38–9

How Medalia made primary care its cornerstone [interview by Christopher Serb] Rorem S. **Hosp Health Netw** 1995 Oct 5;69(19):12–3

Case study: practical tools for improving needs–based health management and technology assessment. The PHC MAP series. Wilson RG. **Int J Technol Assess Health Care** 1995 Fall;11(4):709–15

Primary health care progress in nursing citations. MacIntosh J, et al. **Int Nurs Rev** 1995 Jul–Aug;42(4):115–20 (13 ref.)

Linking quality improvement with primary health care. Sukati NA. **Int Nurs Rev** 1995 Jul–Aug;42(4):109–14, 124 (36 ref.)

Power and structure in primary care [editorial; comment] Weingarten MA. **Isr J Med Sci** 1996 Jul;32(7):570–2. Comment on: Isr J Med Sci 1996 Jul;32(7):545–50. Comment on: Isr J Med Sci 1996 Jul;32(7):551–4. Comment on: Isr J Med Sci 1996 Jul;32(7):555–60.

The primary care provider's role in caring for young people with chronic illness. Kelly A. **J Adolesc Health** 1995 Jul; 17(1):32–6

Short or long consultations? Primary care nurses' considerations in making appointments with general practitioners. Andersson SO, et al. **J Adv Nurs** 1995 Oct; 22(4):759–68

Primary health care team workshop: team members' perspectives. Long S. **J Adv Nurs** 1996 May;23(5):935–41

Decreased utilization of healthcare resources after initiating a model geriatrics primary managed care practice [letter] McDowell JG, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1134

Community health: the risks of confusion and complacency. Popay J. **J Epidemiol Community Health** 1996 Feb; 50(1):6–14

The changing interface of primary and specialty care. Lanier DC, et al. **J Fam Pract** 1996 Mar;42(3):303–5

Mental health services: critical component of integrated primary care and substance abuse treatment. Brach C, et al. **J Health Care Poor Underserved** 1995;6(3):322–41

Primary care for women revisited. Nurse–midwifery management of common health problems [editorial] Marchese T, et al. **J Nurse Midwifery** 1996 Mar–Apr; 41(2):80–2

Primary care for women. Health assessment, health promotion, and disease prevention services. Murphy PA. **J Nurse Midwifery** 1996 Mar–Apr;41(2):83–91

Primary care for women. Cultural competence in primary care services. Rorie JA, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):92–100

Primary care and the public health: general practitioners and health protection. Summerton N. **J Public Health Med** 1995 Sep;17(3):318–22

The Claxton Elementary School Health Program: merging perceptions and behaviors to identify problems. Landis SE, et al. **J Sch Health** 1995 Sep;65(7):250–4

Developing provider partnerships in the detection of oral cancer and the prevention of smokeless tobacco use. Messer NC, et al. **Md Med J** 1995 Oct;44(10):788–91

Primary managed care. More choice, less cost. Light DW. **Med Care** 1996 Sep;34(9):985–6

What makes quality assurance effective? Results from a randomized, controlled trial in 16 primary care group practices. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS29–39

Leadership for quality improvement in group practices. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS40–51

Outpatient geriatric evaluation and management. Results of a randomized trial. Toseland RW, et al. **Med Care** 1996 Jun;34(6):624–40

A shared computer–based problem–oriented patient record for the primary care team. Linnarsson R, et al. **Medinfo** 1995;8 Pt 2:1663

The SAPPHIRE toolkit: an interactive system for the evaluation of primary healthcare computing. Pitt M, et al. **Medinfo** 1995;8 Pt 2:1672

Beyond computer–based clinical reminders: improvement of the total service quality by small–group based organizational learning in primary care. Timpka T, et al. **Medinfo** 1995;8 Pt 1:559–63

Delivery of primary neurosurgical care in developing countries—scope for mutual cooperation. Pant B. **Neurol Med Chir (Tokyo)** 1996 May;36(5):326–9

Primary care neurologists [letter; comment] Fiedler KJ. **Neurology** 1996 Jun;46(6):1782; discussion 1783–4. Comment on: Neurology 1995 Jun;45(6):1052–61.

Primary care neurologists [letter; comment] Jaffe R. **Neurology** 1996 Jun;46(6):1782–3; discussion 1783–4. Comment on: Neurology 1995 Jun;45(6):1052–61.

Primary care neurologists [letter; comment] Menken M. **Neurology** 1996 Jun;46(6):1783; discussion 1783–4. Comment on: Neurology 1995 Jun;45(6):1052–61.

Nurse–managed primary care center. Newland JA, et al. **Nurs Clin North Am** 1996 Sep;31(3):471–86 (20 ref.)

Integrating nurse practitioner and nursing roles in a primary health care setting [letter] O'Cheskey S, et al. **Nurse Pract** 1995 Sep;20(9):10–2

Healthy villages. Browne D. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):30–2

Teamwork in rural practice. Cunningham WF, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):19–22 (45 ref.)

Clinical guidelines and their implementation. Forrest D, et al. **Postgrad Med J** 1996 Jan;72(843):19–22 (13 ref.)

The development of healthcare services for drug misusers and prostitutes. Morrison CL, et al. **Postgrad Med J** 1995 Oct;71(840):593–7

Prevention in practice. Alto WA. **Prim Care** 1995 Dec; 22(4):543–54

Community partnership primary care: a new paradigm for primary care. Courtney R. **Public Health Nurs** 1995 Dec; 12(6):366–73

New health care system can be built on expanded primary care [news] **Public Health Rep** 1996 Jul–Aug;111(4):291–2

SASPREN — a new development in family practice research in South Africa. Volmink J. **S Afr Med J** 1996 Mar; 86(3):239–41

Medical audit used for estimation of optimum level of outpatient care. Lindström K, et al. **Scand J Prim Health Care** 1995 Sep;13(3):175–81

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)

Hands–on training in health district management. De Brouwere V, et al. **World Health Forum** 1996;17(3):271–3

Reorienting health care in Africa—can the élite believe in equity? Einterz E. **World Health Forum** 1996;17(3):261–5

Health information for the grass roots. M'Jamtu–Sie N. **World Health Forum** 1996;17(3):277–82

Radical reforms for primary health care in New Zealand. Malcolm L. **World Health Forum** 1995;16(3):283–6

For better data, better utilized. Osibogun A, et al. **World Health Forum** 1996;17(3):274–6

Eye care by traditional healers [letter] Parmar RS, et al. **World Health Forum** 1996;17(3):292–3

[Primary health care in Ghana: no pay no cure?] Kyei–Faried S, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2321–5 **(Dut)**

[Development in primary care does not preclude the personal physician approach] Saarelma O. **Duodecim** 1995; 111(1):26–31 **(Fin)**

[Adequacy of health care services for young immigrant families] Gravel S, et al. **Can J Public Health** 1996 May–Jun;87(3):152–7 (Eng. Abstr.) **(Fre)**

[Vietnam: appropriate management of a pediatric hospital in the context of limited resources] Nguyen TN, et al. **Med Trop (Mars)** 1995;55(3):275–80 (Eng. Abstr.) **(Fre)**

[The health district in primary health care and the community health officer] Tarsitani G, et al. **Ann Ig** 1994 Jul–Dec; 6(4–6):375–82 (Eng. Abstr.) **(Ita)**

[The advantages and disadvantages of decentralizing team management (editorial)] Corrales Nadal A. **Aten Primaria** 1996 May 31;17(9):547–8 **(Spa)**

[Influence of the organizational model on user satisfaction] Delgado A, et al. **Aten Primaria** 1995 Oct 15;16(6):314–8, 320–1 (Eng. Abstr.) **(Spa)**

[Health care management: coordination of health care assistance levels] Aranaz Andrés JM, et al. **Med Clin (Barc)** 1996 Feb 10;106(5):182–4 **(Spa)**

[Clinical management: the great forgotten in primary health care? (letter)] Tamborero G, et al. **Med Clin (Barc)** 1996 Mar 9;106(9):357 **(Spa)**

[The myocardial infarction group: secondary prevention in primary health care for the aged is needed] Lind J. **Lakartidningen** 1996 Feb 7;93(6):436–43 **(Swe)**

STANDARDS

The quality of cervical cancer screening: a primary care perspective. Curtis P, et al. **Am J Med Qual** 1996 Spring; 11(1):11–7 (49 ref.)

Primary care as form or content? Mottur–Pilson C. **Am J Med Qual** 1995 Winter;10(4):177–82 (26 ref.)

Health care for persons with non–insulin–dependent diabetes mellitus. The German experience. Berger M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):153–5 (11 ref.)

Improving diabetes care in the primary health setting. The Indian Health Service experience. Gohdes D, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):149–52

Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Gerbert B, et al. **Arch Dermatol** 1996 Sep;132(9):1030–8

Evaluation of a primary care anticoagulant clinic. Issue of quality control was not addressed [letter; comment] Adlakha S, et al. **BMJ** 1996 Jun 22;312(7046):1609; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Minimum standards should be set for near patient testing [letter; comment] Crook M. **BMJ** 1996 May 4; 312(7039):1157. Comment on: BMJ 1996 Feb 3;312(7026):263–4.

Use of the consultation satisfaction questionnaire to examine patients' satisfaction with general practitioners and community nurses: reliability, replicability and discriminant validity. Poulton BC. **Br J Gen Pract** 1996 Jan; 46(402):26–31

Manipulative physiotherapy for spinal problems in primary care: outcomes of care. Bradshaw C, et al. **Br J Rheumatol** 1995 Nov;34(11):1070–3

Inflammatory back pain in primary care. Underwood MR, et al. **Br J Rheumatol** 1995 Nov;34(11):1074–7

Evaluation of preventive and health promotion activities in 166 primary care practices in Spain. The Coordinating Group For Prevention and Health Promotion in Primary Care in Spain. Brotons C, et al. **Fam Pract** 1996 Apr; 13(2):144–51

Improving patient quality of life with feedback to physicians about functional status. Rubenstein LV, et al. **J Gen Intern Med** 1995 Nov;10(11):607–14

Changing the health promotion behaviors of primary care physicians: lessons from two projects. Love RR. **Jt Comm J Qual Improv** 1995 Jul;21(7):339–43

A meta–analysis of nurse practitioners and nurse midwives in primary care. Brown SA, et al. **Nurs Res** 1995 Nov–Dec; 44(6):332–9

Working effectively with interpreters in the primary care setting. Poss JE, et al. **Nurse Pract** 1995 Dec;20(12):43–7 (9 ref.)

Oral anticoagulant treatment in a medical care district—a descriptive study. Jansson JH, et al. **Scand J Prim Health Care** 1995 Dec;13(4):268–74

[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?] Engebråten O, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2913–6 (Eng. Abstr.) **(Nor)**

[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996 Jan;17(1):24–32 (21 ref.) (Eng. Abstr.) **(Spa)**

[The necessary updating of primary care (editorial)] Moreu Orobitg F. **Aten Primaria** 1996 Jan;17(1):2–3 **(Spa)**

[Is private management of primary health services more efficient?] Sjönell G. **Lakartidningen** 1996 Aug 7; 93(32–33):2722–4 **(Swe)**

STATISTICS & NUMERICAL DATA

What influences physician practice behavior? An interview study of physicians who received consultative geriatric assessment recommendations [see comments] Maly RC, et al. **Arch Fam Med** 1996 Sep;5(9):448–54. Comment in: Arch Fam Med 1996 Sep;5(9):455–6.

Primary care involvement among hospitalized children. Perrin JM, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):479–86

Childhood immunizations in the emergency department [letter; comment] Yoshimoto CM. **Arch Pediatr Adolesc Med** 1996 May;150(5):559–60. Comment on: Arch Pediatr Adolesc Med 1995 Apr;149(4):393–7.

Assessing the outcome of making it easier for patients to change general practitioner: practice characteristics associated with patient movements. Thomas K, et al. **Br J Gen Pract** 1995 Nov;45(400):581–6

Epidemiology of mental disorders in primary care settings. Goldberg D. **Epidemiol Rev** 1995;17(1):182–90 (59 ref.)

Prescribing patterns in primary health care in Taiwan. Lai MS, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):437–41

Do primary care physicians screen patients about alcohol intake using the CAGE questions? Wenrich MD, et al. **J Gen Intern Med** 1995 Nov;10(11):631–4

Changes in the anthropometric status of rural African under-fives during a decade of primary health care. den Besten L, et al. **J Trop Med Hyg** 1995 Dec;98(6):361–6

Essential data set for computer management of distributed primary care services. Flygt C, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):331–41

How benzodiazepines are prescribed in a primary health care setting in Spain. Del Rio MC, et al. **Therapie** 1996 Mar–Apr;51(2):185–9

TRENDS

Shaking the kaleidoscope [editorial] Poole DL. **Health Soc Work** 1995 Aug;20(3):163–6

K. N. Rao Memorial Oration. Primary health care—developing leadership. Naidu GC. **Indian J Public Health** 1995 Apr–Jun;39(2):46–9

Managed care slowly makes inroads in Indiana. Neal TR. **Indiana Med** 1995 Sep–Oct;88(5):326–9

Primary health care and donor dependency: a case study of nongovernment assistance in Burkina Faso. Maclure R. **Int J Health Serv** 1995;25(3):539–58

Integrating a primary care role with allergy and immunology training. Schuller D, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):878–81

The future of community health trusts. Browning R. **J R Soc Health** 1996 Feb;116(1):44–6

The nursing profession—a changing role in a changing world. Higgins P. **J R Soc Health** 1996 Feb;116(1):51–6

Primary care at the centre [editorial; comment] Swales JD. **J R Soc Med** 1995 Aug;88(8):425. Comment on: J R Soc Med 1995 Aug;88(8):428–39.

Decision support in the United Kingdom for general practice: past, present, and future. Young AJ, et al. **Medinfo** 1995; 8 Pt 2:1025–9

Managed care and the future of primary care for adults with mental retardation. Birenbaum A. **Ment Retard** 1995 Oct; 33(5):334–7

Out of the classroom—into the exam room. Bell H. **Minn Med** 1995 Dec;78(12):10–6

Defining the NP role [letter] Henson RJ. **Nurse Pract** 1996 Apr;21(4):8, 13

Defining localities for health planning: a GIS approach. Bullen N, et al. **Soc Sci Med** 1996 Mar;42(6):801–16

Telemedicine: a physician extender in the delivery of primary pediatric care. Benjamin JT. **Va Med Q** 1996 Summer; 123(3):180–1

[The role of general practice within the public health care system] Steinkohl M. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):153–7 (Eng. Abstr.) **(Ger)**

[What are the possibilities for public health care in a system based on physicians' patient lists?] Grimsmo A, et al. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):275–7 (Eng. Abstr.) **(Nor)**

[The future of gatekeeping in Spain (letter; comment)] Castillejo i Peña J. **Aten Primaria** 1995 Nov 30;16(9):573–4 . Comment on: Aten Primaria 1995 Apr 30;15(7):418–20. **(Spa)**

[The primary care physician, the specialist, and the internist? (editorial) (see comments)] Manresa JM. **Med Clin (Barc)** 1995 Sep 30;105(10):374–6. Comment in: Med Clin (Barc) 1996 Mar 16;106(10):395. Comment in: Med Clin (Barc) 1996 Jun 8;107(2):76. **(Spa)**

[The primary care physician and the specialist. Students and professors? (letter; comment)] Turabián JL. **Med Clin (Barc)** 1996 Jun 8;107(2):76. Comment on: Med Clin (Barc) 1995 Sep 30;105(10):374–6. **(Spa)**

UTILIZATION

Black women receive less mammography even with similar use of primary care [see comments] Burns RB, et al. **Ann Intern Med** 1996 Aug 1;125(3):173–82. Comment in: Ann Intern Med 1996 Aug 1;125(3):237–9.

Repeat abortion and use of primary care health services. Westfall JM, et al. **Fam Plann Perspect** 1995 Jul–Aug; 27(4):162–5

Measuring the prevalence of diabetes mellitus in a Greek primary health care district. Lionis CD, et al. **Fam Pract** 1996 Feb;13(1):18–21

Frequent attenders [letter; comment] Neal RD. **Fam Pract** 1995 Sep;12(3):370. Comment on: Fam Pract 1994 Dec;11(4):424–30. Comment on: Fam Pract 1994 Dec;11(4):431–7.

Do primary care patients accept psychological treatments? Arean PA, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):22–7

Geographic variation in primary care visits in Iowa. Briggs LW, et al. **Health Serv Res** 1995 Dec;30(5):657–71

Health services use and mortality among older primary care patients with alcoholism. Callahan CM, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1378–83

Sustained partnerships [letter; comment] Thom D. **J Fam Pract** 1996 Jul;43(1):13. Comment on: J Fam Pract 1996 Feb;42(2):129–37.

Carpal tunnel syndrome. Effects of litigation on utilization of health care and physician workload. Kasdan ML, et al. **J Ky Med Assoc** 1996 Jul;94(7):287–90

Most common diseases treated in primary health care facilities in Lebanon. Adib SM, et al. **J Med Liban** 1995; 43(1):17–22

Emergency hospital visits for asthma [letter] Johnson P, et al. **Lancet** 1996 Aug 24;348(9026):556

The effects of having a regular doctor on access to primary care. Lambrew JM, et al. **Med Care** 1996 Feb;34(2):138–51

Out-of-hours attendance and outcomes for asthmatic patients at two primary care services. Kljakovic M, et al. **N Z Med J** 1996 Jul 12;109(1025):254–7

Headaches and the primary care pediatrician [editorial] Altemeier WA 3rd. **Pediatr Ann** 1995 Sep;24(9):446–7

Children's access to primary care: differences by race, income, and insurance status. Newacheck PW, et al. **Pediatrics** 1996 Jan;97(1):26–32

Role of primary care physicians in the care of epileptic patients. al-Shammari SA, et al. **Public Health** 1996 Jan; 110(1):47–8

Using nursing diagnoses to explain utilization in a Community Nursing Center. Coenen A, et al. **Res Nurs Health** 1996 Oct;19(5):441–5

[No difference in frequency of family practitioner consultation by Turkish, Surinam and Moroccan 0–14-year-old children from Dutch children, but difference in reason for contact] Versluis-van Winkel SY, et al. **Ned Tijdschr Geneeskd** 1996 May 4;140(18):980–4 (Eng. Abstr.) **(Dut)**

[The descriptive study of primary care in otorhinolaryngology] Benito JI, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):55–62 (Eng. Abstr.) **(Spa)**

[The frequency of the use of hospital emergency services: its relation to the use of primary care in a pediatric population] Sansa Pérez L, et al. **An Esp Pediatr** 1996 Feb; 44(2):105–8 (Eng. Abstr.) **(Spa)**

[Influence of age and sex on various types of utilization of the primary health care] Bellón Saameño JA, et al. **Gac Sanit** 1995 Nov–Dec;9(51):343–53 (Eng. Abstr.) **(Spa)**

PRIMARY NURSING CARE

Evaluation of nurse prescribing in a dermatology unit [letter] Cox NH, et al. **Br J Dermatol** 1995 Aug;133(2):340–1

Ability of a trained primary healthcare nurse to discriminate dementia from other psychogeriatric disorders. Sjöbeck B, et al. **Int Psychogeriatr** 1995 Spring;7(1):9–16

Hypertension 1996—simplified guidelines for primary care nurses and medical students. Opie LH. **S Afr Med J** 1996 Apr;86(4):357–8

METHODS

The role of the rheumatology nurse practitioner in primary care: an experiment in the further education of the practice nurse. Grahame R, et al. **Br J Rheumatol** 1996 Jun; 35(6):581–8

Primary care across clinical settings. Kelly M. **Nurs Clin North Am** 1996 Sep;31(3):465–70

ORGANIZATION & ADMINISTRATION

Teamwork. Primary nursing pioneers. Montague J. **Hosp Health Netw** 1995 Dec 5;69(23):56

How Finnish nurses changed over to primary nursing. Munnukka T, et al. **Int Nurs Rev** 1995 Nov–Dec; 42(6):187–91

Valuing authority/responsibility relationships. The essence of professional practice. Webb SS, et al. **J Nurs Adm** 1996 Feb;26(2):28–33

Patient outcomes for the chronically critically ill: special care unit versus intensive care unit [see comments] Rudy EB, et al. **Nurs Res** 1995 Nov–Dec;44(6):324–31. Comment in: Nurs Res 1995 Nov–Dec;44(6):323.

TRENDS

The nursing profession—a changing role in a changing world. Higgins P. **J R Soc Health** 1996 Feb;116(1):51–6

PRIMARY PREVENTION

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)

Extending the benefit of lipid-regulating therapy to primary prevention. Jones PH, et al. **Am J Cardiol** 1995 Sep 28; 76(9):118C–121C (17 ref.)

Prevalence and detection of HIV risk behavior in primary care: implications for clinical preventive services. Ward J, et al. **Am J Prev Med** 1995 Jul–Aug;11(4):224–30

Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378–83 (43 ref.)

Genes and agents: how to prioritize to prevent disease [editorial] Rylander R. **Arch Environ Health** 1995 Sep–Oct; 50(5):333–4

In the eye of the beholder. Hux JE, et al. **Arch Intern Med** 1995 Nov 27;155(21):2277–80

Put prevention into practice. A systematic approach to the delivery of clinical preventive services [editorial] McGinnis JM, et al. **Arch Intern Med** 1996 Jan 22;156(2):130–2

Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391–403 (16 ref.)

The road that I see: implications of new reproductive technologies. Steel KO. **Camb Q Healthc Ethics** 1995 Summer;4(3):351–4

Primary prevention of coronary heart disease in women. Meilahn EN, et al. **Cardiology** 1995;86(4):286–98 (134 ref.)

Epidemiology, prevention and screening for prostate cancer. Pavone-Macaluso M. **Eur Urol** 1996;29 Suppl 2:49–53 (21 ref.)

The most cost-effective health care. Fromer LM. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):46+7

Need for national hypertension control programme. Wasir HS. **Indian Heart J** 1995 Jul–Aug;47(4):409–10

Preventive health care for older women. Speroff L. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):64–8

Primary prevention of hepatocellular carcinoma. Yu SZ. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):674–82 (24 ref.)

Primary prevention means a change in business as usual [editorial] Albee GW. **J Nerv Ment Dis** 1996 Feb;184(2):67

Access to health care and preventable hospitalization [letter; comment] Jameson M. **JAMA** 1995 Dec 13;274(22):1759–60 . Comment on: JAMA 1995 Jul 26;274(4):305–11. Comment on: JAMA 1995 Jul 26;274(4):346–7.

Cancer prevention strategies for the future: risk identification and preventive intervention. Colditz GA, et al. **Milbank Q** 1995;73(4):621–51 (104 ref.)

Screening, health promotion, and prevention in women. Bowman MA, et al. **Prim Care** 1995 Dec;22(4):661–77 (98 ref.)

Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)

Health maintenance and prevention in the elderly. Gleich GS. **Prim Care** 1995 Dec;22(4):697–711 (50 ref.)

Screening, health promotion, and prevention in men. Horst T, et al. **Prim Care** 1995 Dec;22(4):679–95 (72 ref.)

Screening for disease, cost-effectiveness, and guidelines. Meyer DL. **Prim Care** 1995 Dec;22(4):591–9 (18 ref.)

Prevention in practice. Ethnic groups. Millar J, et al. **Prim Care** 1995 Dec;22(4):713–30 (27 ref.)

Prevention in adults. Molberg P. **Prim Care** 1995 Dec; 22(4):653–60 (21 ref.)

Preventive care in pregnancy. Morrow CE. **Prim Care** 1995 Dec;22(4):755–84 (93 ref.)

Preventive health care for children. Natarajan A, et al. **Prim Care** 1995 Dec;22(4):619–36 (33 ref.)

The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785–804 (43 ref.)

Preventive health care for infants birth to two years of age. Sand PO, et al. **Prim Care** 1995 Dec;22(4):601–18 (25 ref.)

Preventive health care for teenagers and young adults. Schaff EA, et al. **Prim Care** 1995 Dec;22(4):637–52 (27 ref.)

Role of Danish general practitioners in AIDS prevention. Sandbaek A, et al. **Scand J Prim Health Care** 1995 Dec; 13(4):307–15

Ethical aspects of prevention. Tomatis L. **Scand J Work Environ Health** 1995 Aug;21(4):245–51 (44 ref.)

The role of prevention. Johnson EM. **Subst Use Misuse** 1996 May;31(6):767–70

Prevention—how much of it in our health care? [editorial; comment] **West Afr J Med** 1995 Apr–Jun;14(2):70–1. Comment on: West Afr J Med 1995 Apr–Jun;14(2):91–6. Comment on: West Afr J Med 1995 Apr–Jun;14(2):101–4.

[Motivation for preventive care] Honzák R, et al. **Sb Lek** 1995;96(2):131–6 (Eng. Abstr.) **(Cze)**

[Prevention in family practice (editorial)] Christensen B. **Ugeskr Laeger** 1996 Aug 26;158(35):4886 **(Dan)**

[Does the cardiologists' report on lipids forget primary prevention? (letter)] Nordestgaard BG. **Ugeskr Laeger** 1996 Jun 10;158(24):3478–9 **(Dan)**

[Fewer unhealthy years: a utopia?] Mackenbach JP. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2076–7 **(Dut)**

[Immunization from a socio-scientific viewpoint] Streefland PH. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):6–8 **(Dut)**

[Cause of death of Amsterdam children who died abroad 1992–1993; possibilities for prevention (letter; comment)] Venneman W. **Ned Tijdschr Geneeskd** 1996 Jun 1; 140(22):1203. Comment on: Ned Tijdschr Geneeskd 1996 Apr 6;140(14):777–81. **(Dut)**

[Physical activity in childhood may have advantages even in older age (editorial)] Taimela S. **Duodecim** 1995; 111(3):216–8 **(Fin)**

[Risk factors and primary prevention (editorial)] Richard JL. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1559–60 **(Fre)**

[Chemoprevention of cancers, the point of view of health insurance] Benech JM, et al. **Bull Cancer (Paris)** 1995 Jul; 82 Suppl 3:230s–231s (Eng. Abstr.) **(Fre)**

[Medical chemoprevention of cancers. From the point of view of social sciences] Bourret P, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:224s–229s (Eng. Abstr.) **(Fre)**

[Methodology and legitimacy of French clinical trials in primary chemoprevention of cancers. The point of view

of the National Federation of French cancer centers] Eisinger F, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:232s–236s (Eng. Abstr.) **(Fre)**

[Primary prevention of colorectal cancer] Faivre J, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:172s–177s (Eng. Abstr.) **(Fre)**

[Is breast cancer prevention by tamoxifen possible?] Namer M, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:155s–167s (65 ref.) (Eng. Abstr.) **(Fre)**

[Should cancer prevention become a form of treatment? (editorial)] Pujol H. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:149s–150s **(Fre)**

[Public health problems related to chemoprevention of cancers] Schaffer P, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:213s–223s (Eng. Abstr.) **(Fre)**

[Cancer of the breast: primary prevention of breast cancer by tamoxifen, eligibility criteria, alternatives to English proposals] Serin D. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:168s–171s (Eng. Abstr.) **(Fre)**

[Health in the third age] Fung J, et al. **J Med Liban** 1995; 43(1):39–42 **(Fre)**

[Prevention, standards and future developments in medical specialties—prevention] Vosteen KH.
Z Arztl Fortbild (Jena) 1995 Dec;89(7):749–59 (0 ref.) **(Ger)**

[The treatment of hypercholesterolemia in primary and secondary prevention] Sirtori CR. **Ann Ital Med Int** 1995 Oct;10 Suppl:48S–52S (22 ref.) (Eng. Abstr.) **(Ita)**

[Serum C3 as a screening factor in the primary prevention of myocardial infarct] Muscari A, et al. **Cardiologia** 1995 Jul;40(7):507–14 (Eng. Abstr.) **(Ita)**

[The primary and secondary prevention of allergic diseases in the child "at risk" for atopy: a review of the literature and the authors' personal experience] Bruno G, et al.
Pediatr Med Chir 1995 May–Jun;17(3):199–207 (125 ref.) (Eng. Abstr.) **(Ita)**

[Quality in preventive and health promotion activities] Blomberg I. **Nord Med** 1995;110(10):246–9 (15 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Economic evaluation of HIV prevention programs. Holtgrave DR, et al. **Annu Rev Public Health** 1996; 17:467–88 (114 ref.)

Cost–effectiveness of alternative interventions for the prevention and treatment of coronary heart disease. Crowley S, et al. **Aust J Public Health** 1995 Aug; 19(4):336–46 (77 ref.)

Prophylaxis for stress–related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben–Menachem T, et al.
Crit Care Med 1996 Feb;24(2):338–45 (59 ref.)

Economic implications of IGT intervention: the case of a 'phantom alternative'? Gafni A. **Diabet Med** 1996;13(3 Suppl 2):S25–8

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden. Linholm L, et al.
J Epidemiol Community Health 1996 Apr;50(2):190–5

The cost–effectiveness of a multifactorial targeted prevention program for falls among community elderly persons. Rizzo JA, et al. **Med Care** 1996 Sep;34(9):954–69

Threshold analysis and programs for prevention of HIV infection. Holtgrave DR, et al. **Med Decis Making** 1995 Oct–Dec;15(4):311–7

EDUCATION

The role of schools in Healthy People 2000 [letter; comment] Heeb MA. **JAMA** 1995 Oct 18;274(15):1195–6. Comment on: JAMA 1995 Apr 12;273(14):1123–9.

LEGISLATION & JURISPRUDENCE

[The application of D.Lgs. 626/94 in USL (local health unit) enterprises and hospital enterprises: a proposal for organizing preventive activities. The Associazione Italiana di Medicina Preventiva dei Lavoratori della Sanità]
Med Lav 1995 Jul–Aug;86(4):352–9 **(Ita)**

METHODS

Does multiple risk factor reduction explain the reduction in fall rate in the Yale FICSIT Trial? Frailty and Injuries Cooperative Studies of Intervention Techniques. Tinetti ME, et al. **Am J Epidemiol** 1996 Aug 15;144(4):389–99

Promoting healthy eating: Contra Costa County's food policy [news] Cortes F, et al. **Am J Public Health** 1995 Oct; 85(10):1449–50

Epidemiology and prevention of breast cancer. Kelsey JL, et al. **Annu Rev Public Health** 1996;17:47–67 (65 ref.)

Pathways to suicide prevention. Murphy BM, et al.
Br J Hosp Med 1995 Jun 21–Jul 11;54(1):11–4 (18 ref.)

Strategy for controlling rheumatic fever/rheumatic heart disease, with emphasis on primary prevention: memorandum from a joint WHO/ISFC meeting.
Bull World Health Organ 1995;73(5):583–7

Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)

Nonlipid primary and secondary prevention strategies for coronary heart disease. Maron DJ. **Clin Cardiol** 1996 May; 19(5):419–23 (36 ref.)

Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? [editorial] Lynch HT.
Dis Colon Rectum 1996 Jan;39(1):109–10

The effect of hypo–allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)

Allergy prevention—an attainable objective? Hide DW.
Eur J Clin Nutr 1995 Sep;49 Suppl 1:S71–6 (23 ref.)

The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)

'Prevention programmes'—a dietetic minefield. Wolfe SP.
Eur J Clin Nutr 1995 Sep;49 Suppl 1:S92–9 (65 ref.)

Type II diabetes: a treatment approach for the older patient. Miller M. **Geriatrics** 1996 Aug;51(8):43–4, 47–9; quiz 50 (20 ref.)

Preventing falls: how to identify risk factors, reduce complications. Tideiksaar R. **Geriatrics** 1996 Feb; 51(2):43–6, 49–50, 53, quiz 54–5 (5 ref.)

Usefulness of the protection motivation theory in explaining hearing protection device use among male industrial workers. Melamed S, et al. **Health Psychol** 1996 May; 15(3):209–15

Epidemiology for prevention. Wall S. **Int J Epidemiol** 1995 Aug;24(4):655–64 (55 ref.)

Primary prevention of coronary artery disease. St. Pierre M, et al. **J Ark Med Soc** 1996 Jul;93(2):89–91 (14 ref.)

Role of physicians in preventing diarrhoea. Suresh K, et al.
J Indian Med Assoc 1995 Jun;93(6):245–7

Targeting lipid–lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Ramsay LE, et al. **Lancet** 1996 Aug 10;348(9024):387–8

European strategies in the war on cancer [letter] Tubiana M. **Lancet** 1996 Aug 17;348(9025):474

Computerized knowledge bases in primary health care: a curse or a blessing for health promotion, prevention and patient quality?. Alendahl K, et al. **Medinfo** 1995;8 Pt 2:917–21

Analysis of mediating variables in prevention and intervention research. MacKinnon DP.
NIDA Res Monogr 1994;139:127–53 (68 ref.)

Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)

Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus–infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Thea DM, et al. **Pediatrics** 1996 Jan;97(1):59–64

Cardiovascular risk–factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

Family violence: practical recommendations for physicians and the medical community. Buel SM, et al.
Womens Health Issues 1995 Winter;5(4):158–72 (24 ref.)

[Methods and intervention in populations with high–risk for cancer] Sancho–Garnier H. **Bull Cancer (Paris)** 1995 Jul; 82 Suppl 3:207s–212s (Eng. Abstr.) **(Fre)**

[Prophylaxis for travellers in Africa: new aspects (letter)] Monlun E, et al. **Med Trop (Mars)** 1995;55(4 Suppl):120 **(Fre)**

[The campaign against HIV and AIDS: widening the field of action (editorial)] Piot P, et al. **Sante** 1995 Sep–Oct; 5(5):271–3 **(Fre)**

ORGANIZATION & ADMINISTRATION

Community–based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre–Molina M, et al.
Annu Rev Public Health 1996;17:337–58 (121 ref.)

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)

Prevention in practice. Alto WA. **Prim Care** 1995 Dec; 22(4):543–54

Health promotion, health protection, and preventive services. Cooke BE. **Prim Care** 1995 Dec;22(4):555–64 (36 ref.)

[Familial hypercholesterolemia in eastern Quebec: a public health problem? The experience of the hyperlipidemia clinic of Chicoutimi] Gaudet D, et al. **Union Med Can** 1995 Sep;124(2):54–60 **(Fre)**

STANDARDS

Preventive therapies: weighing the pros and cons [editorial; comment] Laupacis A. **Can Med Assoc J** 1996 May 15; 154(10):1510–2. Comment on: Can Med Assoc J 1996 May 15;154(10):1493–9.

Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.). Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.

Commentary on the new Guide to Clinical Preventive Services [see comments] Henry CA, et al.
Cleve Clin J Med 1996 May–Jun;63(3):141–6. Comment in: Cleve Clin J Med 1996 May–Jun;63(3):136.

WHO warns of inadequate noncommunicable disease prevention [news] **Public Health Rep** 1996 Jul–Aug; 111(4):296–7

[Social inequalities and prevention: vaccination status of adolescents] De Spiegelaere M, et al.
Rev Epidemiol Sante Publique 1996 Jun;44(3):228–36 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Cancer occurrence and screening in family practice. A 20–year experience. Kiernan GN, et al. **J Fam Pract** 1996 Jul;43(1):49–55

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al.
Prev Med 1995 Nov;24(6):543–5 (26 ref.). Comment on: Prev Med 1995 Nov;24(6):546–2.

TRENDS

Physician performance of preventive care for women. Gill JM. **Del Med J** 1996 Jul;68(7):349–55

PRIMATE DISEASES

Simian immunodeficiency virus variants: threat of new lentiviruses. McClure HM, et al. **Am J Med Sci** 1996 Jan; 311(1):30–3 (46 ref.)

Experimental infection of cynomolgus macaques with Ebola–Reston filoviruses from the 1989–1990 U.S. epizootic. Jahrling PB, et al. **Arch Virol Suppl** 1996; 11:115–34

Benign prostatic hyperplasia in the nonhuman primate Leontopithecus. Ferreira BR, et al.
Folia Primatol (Basel) 1995;65(1):48–53

Persistent Epstein–Barr virus infection in the common marmoset (Callithrix jacchus). Cox C, et al.
J Gen Virol 1996 Jun;77 (Pt 6):1173–80

Mycobacterium kansasii infection in squirrel monkeys (Saimiri sciureus sciureus). Brammer DW, et al.
J Med Primatol 1995 Dec;24(4):231–5

Endocrine neoplasia in New World primates. Dias JL, et al. **J Med Primatol** 1996 Jan;25(1):34–41

Gastrin levels and gastric emptying times in rhesus monkeys with a history of acute gastric dilatation. Fanton JW, et al. **J Med Primatol** 1995 Dec;24(4):243–5

Patterns of prenatal survival in the common marmoset (Callithrix jacchus). Jaquish CE, et al. **J Med Primatol** 1996 Jan;25(1):57–63

Melanotic ependymoma in a Goeldi's marmoset (Callimico goeldii). Nichols DK, et al. **J Med Primatol** 1995 Jan; 24(1):49–51

Lipoprotein profiles and glucose tolerance in lean and obese chimpanzees. Steinetz BG, et al. **J Med Primatol** 1996 Jan; 25(1):17–25

Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Olobo JO, et al. **Vet Parasitol** 1995 Dec;60(3–4):199–212

DIAGNOSIS

Renal carcinoma in a chimpanzee (Pan troglodytes). Greenwood AG, et al. **Vet Rec** 1995 Oct 7;137(15):380–1

EPIDEMIOLOGY

The prevalence of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) increases with the duration of captivity. D'Hooghe TM, et al.
Acta Obstet Gynecol Scand 1996 Feb;75(2):98–101

Dental pathology in Pongo satyrus borneensis. Stoner KE.
Am J Phys Anthropol 1995 Nov;98(3):307–21

Is there an epidemic/epizootic of spondyloarthropathy in baboons? [letter] Rothschild BM, et al. **J Med Primatol** 1996 Jan;25(1):69–70

PATHOLOGY

Spontaneous lesions detected in the common cotton–eared marmosets (Callithrix jacchus). Okazaki Y, et al.
J Vet Med Sci 1996 Mar;58(3):181–90

TRANSMISSION

Cross–species transmission and recombination of 'AIDS' viruses. Sharp PM, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Jul 29; 349(1327):41–7

PRIMATE IMMUNODEFICIENCY VIRUSES see **IMMUNODEFICIENCY VIRUSES, PRIMATE**

PRIMATES

Sexual selection and ejaculatory frequencies in primates. Dixson AF. **Folia Primatol (Basel)** 1995;64(3):146–52

Investigation of species specificity using nine PCR–based human STR systems. Crouse CA, et al. **J Forensic Sci** 1995 Nov;40(6):952–6

13th annual symposium on nonhuman primate models for AIDS. Monterey, California, November 5–8, 1994. Abstracts. **J Med Primatol** 1995 Dec;24(4):169–229

Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. Warren JT, et al. **J Med Primatol** 1995 May;24(3):150–68

Provision for welfare of non–human primates used in biomedical research. Box HO, et al. **Lab Anim** 1995 Jul; 29(3):233–6

Guidelines and legal codes for the welfare of non–human primates in biomedical research. Poole TB. **Lab Anim** 1995

Jul;29(3):244–9
A composite estimate of primate phylogeny. Purvis A. **Philos Trans R Soc Lond B Biol Sci** 1995 Jun 29; 348(1326):405–21
Protopithecus: rediscovering the first fossil primate. Hartwig WC. **Pubbl Stn Zool Napoli II** 1995;17(3):447–60
More monkey business alleged at NYU [news] Stone R. **Science** 1996 Aug 23;273(5278):1040

ANATOMY & HISTOLOGY

Limb skeleton and locomotor adaptations of Apidium phiomense, an Oligocene anthropoid from Egypt. Fleagle JG, et al. **Am J Phys Anthropol** 1995 Jul;97(3):235–89
New notharctine (Primates, Adapiformes) skull from the Uintan (middle Eocene) of San Diego County, California. Gunnell GF. **Am J Phys Anthropol** 1995 Dec;98(4):447–70
Muscular and osseous anatomy of the primate anterior temporal fossa and the functions of the postorbital septum. Ross C. **Am J Phys Anthropol** 1995 Nov;98(3):275–306
Structural adaptations for gliding in mammals with implications for locomotor behavior in paromomyids. Runestad JA, et al. **Am J Phys Anthropol** 1995 Oct; 98(2):101–19
The vestibular nuclei of the rat project to the lateral part of the thalamic parafascicular nucleus (centromedian nucleus in primates). Shiroyama T, et al. **Brain Res** 1995 Dec 15;704(1):130–4
Variation and evolution of mammalian corticospinal somata with special reference to primates. Nudo RJ, et al. **J Comp Neurol** 1995 Jul 24;358(2):181–205
Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)
An evaluation of the use of multidimensional scaling for understanding brain connectivity. Goodhill GJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 May 30; 348(1325):265–80
Non-metric multidimensional scaling in the analysis of neuroanatomical connection data and the organization of the primate cortical visual system. Young MP, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 May 30; 348(1325):281–308
Chemical anatomy of primate basal ganglia. Parent A, et al. **Prog Neurobiol** 1995 Jun;46(2–3):131–97 (500 ref.)
Receptive field structure in the primate retina. Lee BB. **Vision Res** 1996 Mar;36(5):631–44 (97 ref.)

BLOOD

Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282–305 (115 ref.)

GENETICS

Molecular evolution of class I alcohol dehydrogenases in primates. Models for gene evolution and comparison of 3' untranslated regions of cDNAS. Cheung B, et al. **Adv Exp Med Biol** 1995;372:315–20
The involucrin gene and hominoid relationships. Green H, et al. **Am J Phys Anthropol** 1995 Oct;98(2):213–6; discussion 228–32
Learning to live with a trichotomy. Marks J. **Am J Phys Anthropol** 1995 Oct;98(2):211–3; discussion 218–24
When is ancient polymorphism a potential problem for molecular phylogenetics? Rogers J, et al. **Am J Phys Anthropol** 1995 Oct;98(2):216–8; discussion 224–8
The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1–29 (135 ref.)
Molecular anatomy of human chromosome 9: comparative mapping of the immunoglobulin processed pseudogene C epsilon 3 (IGHEP2) in primates. Tanabe H, et al. **Cytogenet Cell Genet** 1996;73(1–2):92–6
Increased microsatellite variability in Macaca mulatta compared to humans due to a large scale deletion/insertion event during primate evolution. Kayser M, et al. **Electrophoresis** 1995 Sep;16(9):1607–11
Inhibition of vitamin D receptor–retinoid X receptor–vitamin D response element complex formation by nuclear extracts of vitamin D–resistant New World primate cells. Arbelle JE, et al. **Endocrinology** 1996 Feb;137(2):786–9
Alu repeats: a source for the genesis of primate microsatellites. Arcot SS, et al. **Genomics** 1995 Sep 1; 29(1):136–44
Generation and reactivation of T-cell receptor A joining region pseudogenes in primates. Thiel C, et al. **Immunogenetics** 1996;43(1–2):57–62
Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13–31 (45 ref.)
Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33–62 (96 ref.)
Quantifying the degree of convergence in primate Mhc–DRB genes. O hUigin C. **Immunol Rev** 1995 Feb;143:123–40 (24 ref.)
Prediction of primate splice junction gene sequences with a cooperative knowledge acquisition system. Mephu Nguifo E, et al. **Ismb** 1993;1:292–300
Comparative sequence analysis of cytokine genes from human and nonhuman primates. Villinger F, et al. **J Immunol** 1995 Oct 15;155(8):3946–54
The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline. Yang AS, et al. **J Mol Biol** 1996 May 3;258(2):240–50
Polymorphism, monomorphism, and sequences in conserved microsatellites in primate species. Blanquer-Maumont A, et al. **J Mol Evol** 1995 Oct;41(4):492–7
Presence and abundance of CENP-B box sequences in great ape subsets of primate-specific alpha-satellite DNA. Haaf T, et al. **J Mol Evol** 1995 Oct;41(4):487–91
The role and amplification of the HS Alu subfamily founder gene. Shaikh TH, et al. **J Mol Evol** 1996 Jan;42(1):15–21
Mapping the homolog of the human Rb1 gene to chromosome 14 of higher primates. Verma RS, et al. **Mamm Genome** 1996 Aug;7(8):591–2
Tempo and mode of synonymous substitutions in mitochondrial DNA of primates. Adachi J, et al. **Mol Biol Evol** 1996 Jan;13(1):200–8
Mitochondrial DNA migration events in yeast and humans: integration by a common end-joining mechanism and alternative perspectives on nucleotide substitution patterns. Blanchard JL, et al. **Mol Biol Evol** 1996 Jul;13(6):893
Amylase gene structures in primates: retroposon insertions and promoter evolution. Samuelson LC, et al. **Mol Biol Evol** 1996 Jul;13(6):767–79
Gene conversion and natural selection in the evolution of X-linked color vision genes in higher primates. Zhou YH, et al. **Mol Biol Evol** 1996 Jul;13(6):780–3
Support for interordinal eutherian relationships with an emphasis on primates and their archontan relatives. Allard MW, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):78–88 (74 ref.)
Hominoid phylogeny estimated by model selection using goodness of fit significance tests. Czelusniak J, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):283–90
Epilogue: a personal account of the origins of a new paradigm. Goodman M. **Mol Phylogenet Evol** 1996 Feb; 5(1):269–82
Rates of nucleotide substitution in primates and rodents and the generation–time effect hypothesis. Li WH, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):182–7
Re: The questionable implications of the dopamine D4 receptor (DRD4) gene tree for primate phylogeny [letter] Ruvolo M, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):439–40
Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)
Behavior predicts genes structure in a wild primate group. Altmann J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):5797–801
Ancient single origin for Malagasy primates. Yoder AD, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5122–6
Primate brain evolution: genetic and functional considerations. Keverne EB, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22;263(1371):689–96
Mobilization of an ERV9 human endogenous retroviral element during primate evolution. Di Cristofano A, et al. **Virology** 1995 Oct 20;213(1):271–5

GROWTH & DEVELOPMENT

Anthropological considerations relevant to the maturation of the immune response in humans. Gill TJ 3rd. **Am J Reprod Immunol** 1995 Apr;33(4):277–81

IMMUNOLOGY

Detection of Ebola-Reston (Filoviridae) virus antibody by dot-immunobinding assay. Kalter SS, et al. **Lab Anim Sci** 1995 Oct;45(5):523–5

METABOLISM

Intestinal methanogenesis in primates--a genetic and evolutionary approach. Hackstein JH, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr;102(4):152–4

PARASITOLOGY

The Enterobiinae subfam. Nov. (Nematoda, Oxyurida) pinworm parasites of primates and rodents. Hugot JP, et al. **Int J Parasitol** 1996 Feb;26(2):147–59
Morphology and morphometrics of three oxyurids parasitic in primates with a description of Lemuricola microcebi n. sp. Hugot JP, et al. **Int J Parasitol** 1995 Sep; 25(9):1065–75

PHYSIOLOGY

New characters for the functional interpretation of primate scapulae and proximal humeri. Larson SG. **Am J Phys Anthropol** 1995 Sep;98(1):13–35
Open-loop simulations of the primate saccadic system using burst cell discharge from the superior colliculus. Das S, et al. **Biol Cybern** 1995 Nov;73(6):509–18
Evolution of the sweetness receptor in primates. I. Why does alitame taste sweet in all prosimians and simians, and aspartame only in Old World simians? Glaser D, et al. **Chem Senses** 1995 Oct;20(5):573–84
Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)
Sperm length and sperm competition in primates: a rebuttal of criticism [comment] Roldan ER, et al. **Folia Primatol (Basel)** 1995;64(4):225–8; discussion 229–30 . Comment on: Folia Primatol (Basel) 1993;61(4):221–7.
The neonatal period: a critical interval in male primate development. Mann DR, et al. **J Endocrinol** 1996 May; 149(2):191–7
Reanimation and engraftment of the asystolic primate heart [letter; comment] Chandra M. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):684. Comment on: J Thorac Cardiovasc Surg 1995 Jun;109(6):1097–10; discussion 1101–2.
Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499–510 (155 ref.)
Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)
Neocortex size and behavioural ecology in primates. Barton RA. **Proc R Soc Lond B Biol Sci** 1996 Feb 22; 263(1367):173–7
Primate brain evolution: genetic and functional considerations. Keverne EB, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22;263(1371):689–96
Colour vision as an adaptation to frugivory in primates. Osorio D, et al. **Proc R Soc Lond B Biol Sci** 1996 May 22;263(1370):593–9
The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Clarkson TB, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):189–98 (34 ref.)
[Result of a European-wide inquiry about the use of artificial UV radiation sources in zoo animal husbandry with special regard to the mammals (Primates/Simiae/monkeys)] Hofmann-Parisot M. **Berl Munch Tierarztl Wochenschr** 1995 May;108(5):185–91 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

VIROLOGY

Molecular phylogeny and dissemination of human T-cell lymphotropic virus type I viewed within the context of primate evolution and human migration. Yanagihara R, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S145–61

PRIMIDONE

ADVERSE EFFECTS

An acardiac acephalic monster following in-utero anti-epileptic drug exposure. Kutlay B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):245–8

BLOOD

[Primidone] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:928–30 (21 ref.) **(Jpn)**

PHARMACOKINETICS

An interpretation of 14C-urea and 14C-primidone extraction in isolated rabbit lungs. Audi SH, et al. **Ann Biomed Eng** 1996 May-Jun;24(3):337–51

THERAPEUTIC USE

Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Hermanns G, et al. **Epilepsia** 1996 Jul;37(7):675–9

PRIMIPARITY see **PARITY**

PRIMITIVE GUT see **GASTRULA**

PRIMITIVE STREAK see **GASTRULA**

PRINDOLOL see **PINDOLOL**

PRINTING

Acute changes in the EEG of workers exposed to mixtures of organic solvents. Muttray A, et al. **Int J Occup Med Environ Health** 1995;8(2):131–7
Malignant melanoma among lithographers. Nielsen H, et al. **Scand J Work Environ Health** 1996 Apr;22(2):108–11
IARC evaluates printing processes and printing inks, carbon black and some nitro compounds. Wilbourn J, et al. **Scand J Work Environ Health** 1996 Apr;22(2):154–6
[An experimental evaluation of the efficacy of 4 types of detergents for 3 types of dyes to which workers in color-printing plants are exposed] Terzaghi GF, et al. **Med Lav** 1996 Jan-Feb;87(1):44–50 (Eng. Abstr.) **(Ita)**
[Relationship between vibratory sense threshold and blood lead concentration in ceramic color workers and transfer printing manufacturers] Fukaya Y, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):748–53 (Eng. Abstr.) **(Jpn)**

ECONOMICS

BMJ should review its policy on reprints [letter] [see comments] Cummins D, et al. **BMJ** 1995 Oct 28;

311(7013):1169. Comment in: BMJ 1996 Feb 10;312(7027):381.

STATISTICS & NUMERICAL DATA

Cancer in printing workers in Denmark. Lynge E, et al. **Occup Environ Med** 1995 Nov;52(11):738–44

PRINZMETAL'S ANGINA see **ANGINA PECTORIS, VARIANT**

PRION DISEASES

see related
SLOW VIRUS DISEASES

Inflammatory diseases. **Curr Opin Neurol** 1995 Jun; 8(3):B73–83

Human prion diseases and neurodegeneration. Prusiner SB. **Curr Top Microbiol Immunol** 1996;207:1–17 (118 ref.)

The folding intermediate concept of prion protein formation and conformational links to infectivity. Safar J. **Curr Top Microbiol Immunol** 1996;207:69–76 (14 ref.)

A dreadful challenge [comment] Collee JG. **Lancet** 1996 Apr 6;347(9006):917–8. Comment on: Lancet 1996 Apr 6;347(9006):921–5. Comment on: Lancet 1996 Apr 6;347(9006):945–8.

A new variant of prion disease [comment] Collinge J, et al. **Lancet** 1996 Apr 6;347(9006):916–7. Comment on: Lancet 1996 Apr 6;347(9006):921–5. Comment on: Lancet 1996 Apr 6;347(9006):945–8.

Prion diseases. Tateishi J. **Microbiol Immunol** 1995; 39(12):923–8 (44 ref.)

[Human spongiform encephalopathies. Diseases caused by prions] Jørn N, et al. **Ugeskr Laeger** 1996 Jul 8; 158(28):4066–72 (40 ref.) (Eng. Abstr.) **(Dan)**

[Prion diseases (editorial)] Vorstrup S, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4061 **(Dan)**

[Fatal familial insomnia and prion diseases] Seilhean D, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):225–30 (61 ref.) (Eng. Abstr.) **(Fre)**

[Prion diseases in dementia] Kitamoto T. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):178–9 **(Jpn)**

[Infectious diseases—new and old, in new forms] Degré M. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2875–6 **(Nor)**

[The so-called prions (letter; comment)] O'Leary K, et al. **Medicina (B Aires)** 1995;55(2):183–4. Comment on: Medicina (B Aires) 1990;50(6):563–5. **(Spa)**

CHEMICALLY INDUCED

Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. Blakemore WF. **J Neurocytol** 1972 Dec;1(4):413–26

COMPLICATIONS

Fatal insomnia in a case of familial Creutzfeldt–Jakob disease with the codon 200(Lys) mutation. Chapman J, et al. **Neurology** 1996 Mar;46(3):758–61

DIAGNOSIS

Human prion diseases. Parchi P, et al. **Curr Opin Neurol** 1995 Aug;8(4):286–93 (55 ref.)

New diagnostic tests for prion diseases [editorial; comment] Collinge J. **N Engl J Med** 1996 Sep 26;335(13):963–5. Comment on: N Engl J Med 1996 Sep 26;335(13):924–30.

Preclinical test for prion diseases [letter] Schreuder BE, et al. **Nature** 1996 Jun 13;381(6583):563

[Conference at the Salpêtrière. April 1994 . Familial dementia and onirism in a 63-year-old woman] Laurent B, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):420–8 (50 ref.) **(Fre)**

[Transmissible spongiform encephalopathies—an unconventional contagious agent] Degré M. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3137–40 (32 ref.) (Eng. Abstr.) **(Nor)**

EPIDEMIOLOGY

Spongiform encephalopathies in mainland China [letter] Sun CK, et al. **Lancet** 1996 Aug 24;348(9026):544

ETIOLOGY

Transgenetics and neuropathology of prion diseases. DeArmond SJ, et al. **Curr Top Microbiol Immunol** 1996; 207:125–46 (80 ref.)

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

Pathogenesis of spongiform encephalopathies: an update. Aguzzi A. **Int Arch Allergy Immunol** 1996 Jun; 110(2):99–106 (67 ref.)

Leucoencephalopathy after inhalation of heroin: a case report [letter] Celius EG, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):694–5

Keeping an open mind about prions [news] Finkel E. **Lancet** 1996 Aug 3;348(9023):326

Putting prions to the test [news] Mestel R. **Science** 1996 Jul 12;273(5272):184–9

[Non-conventional infectious agents or PRIONS (editorial)] Hauw JJ, et al. **Ann Pathol** 1995;15(6):409–14 (54 ref.) **(Fre)**

GENETICS

Prions, beta-sheets and transmissible dementias: is there still something missing? Liberski PP. **Acta Neuropathol (Berl)** 1995;90(2):113–25 (202 ref.)

Prion disease with 144 base pair insertion in a Japanese family line. Oda T, et al. **Acta Neuropathol (Berl)** 1995;90(1):80–6

Is hereditary inclusion body myopathy a "familial prion disease" ? [letter] Cervenáková L, et al. **Ann Neurol** 1996 Jul;40(1):128

Hypokinesia and presenile dementia in a Dutch family with a novel insertion in the prion protein gene. van Gool WA, et al. **Brain** 1995 Dec;118 (Pt 6):1565–71

Fatal familial insomnia and familial Creutzfeldt–Jakob disease: a tale of two diseases with the same genetic mutation. Gambetti P. **Curr Top Microbiol Immunol** 1996; 207:19–25 (17 ref.)

Transgenetics of prion diseases. Prusiner SB. **Curr Top Microbiol Immunol** 1996;206:275–304 (134 ref.)

Transgenetics and gene targeting in studies of prion diseases. Scott MR, et al. **Curr Top Microbiol Immunol** 1996; 207:95–123 (134 ref.)

Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Telling GC, et al. **Genes Dev** 1996 Jul 15;10(14):1736–50

A prion disease with a novel 96-base pair insertional mutation in the prion protein gene. Campbell TA, et al. **Neurology** 1996 Mar;46(3):761–6

Fatal insomnia in a case of familial Creutzfeldt–Jakob disease with the codon 200(Lys) mutation. Chapman J, et al. **Neurology** 1996 Mar;46(3):758–61

Prion disease (PrP-A117V) presenting with ataxia instead of dementia. Mastrianni JA, et al. **Neurology** 1995 Nov; 45(11):2042–50

Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **Prog Brain Res** 1995; 105:15–22 (43 ref.)

Transmissibility of Creutzfeldt–Jakob disease and related disorders. Collins SJ, et al. **Sci Prog** 1995;78 (Pt 3):217–27 (30 ref.)

[Molecular genetics of familial and sporadic forms of human prion diseases] Laplanche JL, et al. **Ann Pharm Fr** 1995; 53(5):193–200 (76 ref.) (Eng. Abstr.) **(Fre)**

[Importance of genetic factors in pathogenesis of subacute spongiform viral encephalitis] Wierzba W, et al. **Postepy Hig Med Dosw** 1995;49(2):253–61 (22 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Williamson RA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7279–82

METABOLISM

Prion diseases and the 'protein only' hypothesis: a theoretical dynamic study. Laurent M. **Biochem J** 1996 Aug 15;318 (Pt 1):35–9

Hypokinesia and presenile dementia in a Dutch family with a novel insertion in the prion protein gene. van Gool WA, et al. **Brain** 1995 Dec;118 (Pt 6):1565–71

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

Western blot mapping of disease-specific amyloid in various animal species and humans with transmissible spongiform encephalopathies using a high-yield purification method. Beekes M, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2567–76

Misfolding the way to disease [news] Taubes G. **Science** 1996 Mar 15;271(5255):1493–5

PATHOLOGY

Spontaneous spongiform encephalopathy in a young adult rhesus monkey [letter] Bons N, et al. **Lancet** 1996 Jul 6; 348(9019):55

Detection of apoptosis in murine scrapie. Lucassen PJ, et al. **Neurosci Lett** 1995 Oct 6;198(3):185–8

[Consensus report: tissue handling in suspected Creutzfeldt–Jakob disease and other spongiform encephalopathies (prion diseases) in the human.European Union Biomed-1 Concerted Action] Budka H, et al. **Pathologe** 1996 Mar;17(2):171–5 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The 'infective' process in scrapie and human spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1995 Aug;45(2):214–8 (37 ref.)

Prion function and dysfunction: a structure-based scenario. Radulescu RT, et al. **Med Hypotheses** 1996 Mar;46(3):225–8

Prion disease (PrP-A117V) presenting with ataxia instead of dementia. Mastrianni JA, et al. **Neurology** 1995 Nov; 45(11):2042–50

PREVENTION & CONTROL

Opinion on possible ban on ruminant by-products in ruminant feeds [letter] Scott GC. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1958

Prions and hospital infections [letter] van Asten JA, et al. **Lancet** 1996 Apr 6;347(9006):966–7

TRANSMISSION

Tissue handling in suspected Creutzfeldt–Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Budka H, et al. **Brain Pathol** 1995 Jul; 5(3):319–22 (20 ref.)

Eye banking 1995: danger and opportunity [editorial; comment] Cavanagh HD. **Cornea** 1995 Nov;14(6):545–6. Comment on: Cornea 1995 Nov;14(6):547–53.

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.). Comment in: Cornea 1995 Nov;14(6):545–6.

BSE and farmworkers [letter] Shaw IC. **Lancet** 1995 Nov 18;346(8986):1365

Creutzfeldt–Jakob disease [letter] Verdrager J. **Lancet** 1996 Jun 15;347(9016):1704

Sleepless in Bologna: transmission of fatal familial insomnia. Aguzzi A, et al. **Trends Microbiol** 1996 Apr;4(4):129–31; discussion 131–2 (33 ref.)

[Prion disease in humans and animals] van Bekkum JG. **Tijdschr Diergeneeskd** 1996 Mar 15;121(6):166 **(Dut)**

[Allografts in otology. Potential risk of prion contamination. Current status of knowledge and legislation] Martin CH, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):241–3 (Eng. Abstr.) **(Fre)**

[Pros and cons of use of collagenated arterial prostheses] Barral X, et al. **J Mal Vasc** 1996;21 Suppl A:36–40 (11 ref.) (Eng. Abstr.) **(Fre)**

[Prions—pathogens of transmissible dementia in the human (editorial)] Schlicht HJ, et al. **Med Klin** 1995 Nov 15; 90(11):658–60 **(Ger)**

[Human prion diseases and experimental transmission] Tateishi J. **Uirusu** 1995 Jun;45(1):1–4 (13 ref.) **(Jpn)**

VETERINARY

Spongiform central nervous system myelinopathy in African dwarf goats. Obermaier G, et al. **J Comp Pathol** 1995 Nov; 113(4):357–72

Feline spongiform encephalopathy. BSAVA Scientific Committee [news] **J Small Anim Pract** 1996 Apr;37(4):198

Spontaneous spongiform encephalopathy in a young adult rhesus monkey [letter] Bons N, et al. **Lancet** 1996 Jul 6; 348(9019):55

[Prion disease in humans and animals] van Bekkum JG. **Tijdschr Diergeneeskd** 1996 Mar 15;121(6):166 **(Dut)**

VIROLOGY

Tubulovesicular structures (TVS): virus-like particles specific for all subacute spongiform virus encephalopathies—what are they really? Liberski PP. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):89–93 (18 ref.)

The nature of the scrapie agent: the virus theory. Narang H. **Proc Soc Exp Biol Med** 1996 Jul;212(3):208–24 (139 ref.)

Reflections on scrapie and related disorders, with consideration of the possibility of a viral aetiology. Darcel C. **Vet Res Commun** 1995;19(3):231–52 (130 ref.)

[Prions] Scheffer U. **Med Klin** 1995 Nov 15;90(11):653–7 (31 ref.) **(Ger)**

PRION PROTEINS see **PRIONS**

PRIONS

Altered GABA distribution in hamster brain is an early molecular consequence of infection by scrapie prions. Lu P, et al. **Brain Res** 1995 May 29;681(1–2):235–41

Evidence for two prions in yeast: [URE3] and [PSI] Wickner RB, et al. **Curr Top Microbiol Immunol** 1996;207:147–60 (39 ref.)

Experimental infection of cattle with the agents of transmissible mink encephalopathy and scrapie. Robinson MM, et al. **J Comp Pathol** 1995 Oct;113(3):241–51

Prions and hospital infections [letter] van Asten JA, et al. **Lancet** 1996 Apr 6;347(9006):966–7

Altered circadian activity rhythms and sleep in mice devoid of prion protein. Tobler I, et al. **Nature** 1996 Apr 18; 380(6575):639–42

Prions of yeast and heat-shock protein 104: 'coprion' and cure. Wickner RB. **Trends Microbiol** 1995 Oct;3(10):367–9 (21 ref.)

Molecular genetics and biophysics of prions. Prusiner SB. **Uirusu** 1995 Jun;45(1):5–42 (221 ref.)

[Prion-like cytoplasmic genetic determinants of the budding yeast: conformations and biological functions of protein] Ono B. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2320–8 (49 ref.) **(Jpn)**

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

ANALYSIS

Objective quantification of prion protein in spinal cords of cases of Creutzfeldt–Jakob disease. Sutherland K, et al. **Anal Cell Pathol** 1996 Jan;10(1):25–35

Diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Kretzschmar HA, et al. **Arch Neurol** 1996 Sep;53(9):913–20

Testing for prion protein does not confirm previously reported conjugal CJD [letter] Hainfellner JA, et al. **Lancet** 1996 Mar 2;347(9001):616–7

Ultrastructural immuno–localization of synthetic prion protein peptide antibodies in 87V murine scrapie. Jeffrey M, et al. **Neurodegeneration** 1996 Mar;5(1):101–9

Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non–transmissible brain amyloidoses. Liberski PP, et al. **Neurodegeneration** 1996 Mar;5(1):95–9

A quantitative and qualitative analysis of prion protein immunohistochemical staining in Creutzfeldt–Jakob disease using four anti prion protein antibodies. MacDonald ST, et al. **Neurodegeneration** 1996 Mar;5(1):87–94

Early pathologic and biochemical changes in Creutzfeldt–Jakob disease: study of brain biopsies. Castellani R, et al. **Neurology** 1996 Jun;46(6):1690–3

Absence of detectable infectivity in trachea of BSE–affected cattle. Taylor DM, et al. **Vet Rec** 1996 Feb 17;138(7):160–1

In situ hybridization and immunohistochemistry for prion protein (PrP) in bovine spongiform encephalopathy (BSE). Graber HU, et al. **Zentralbl Veterinarmed A** 1995 Sep; 42(7):453–9

ANTAGONISTS & INHIBITORS

Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Perovic S, et al. **Neurodegeneration** 1995 Dec;4(4):369–74

BIOSYNTHESIS

A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. Lehmann S, et al. **J Biol Chem** 1995 Oct 13;270(41):24589–97

Replication of scrapie in spleens of SCID mice follows reconstitution with wild–type mouse bone marrow. Fraser H, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1935–40

Unaltered susceptibility to BSE in transgenic mice expressing human prion protein [see comments] Collinge J, et al. **Nature** 1995 Dec 21–28;378(6559):779–83. Comment in: Nature 1995 Dec 21–28;378(6559):759. Comment in: Nature 1995 Dec 21–28;378(6559):761–2.

Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform. Lehmann S, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5610–4

BLOOD

PrP27–30 is a normal soluble prion protein fragment released by human platelets. Perini F, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):572–7

CHEMISTRY

Copper binding to the N–terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Hornshaw MP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):993–9

Structures of prion proteins and conformational models for prion diseases. Huang Z, et al. **Curr Top Microbiol Immunol** 1996;207:49–67

Disruption of prion rods generates 10–nm spherical particles having high alpha–helical content and lacking scrapie infectivity. Riesner D, et al. **J Virol** 1996 Mar;70(3):1714–22

NMR structure of the mouse prion protein domain PrP(121–321). Riek R, et al. **Nature** 1996 Jul 11; 382(6587):180–2

Cellular prion protein and GABAA receptors: no physical association? Kannenberg K, et al. **Neuroreport** 1995 Dec 29;7(1):77–80

Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Kaneko K, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11160–4

Putting prions to the test [news] Mestel R. **Science** 1996 Jul 12;273(5272):184–9

Support for the prion hypothesis for inheritance of a phenotypic trait in yeast [see comments] Patino MM, et al. **Science** 1996 Aug 2;273(5275):622–6. Comment in: Science 1996 Aug 2;273(5275):580.

Yeast prions: DNA–free genetics [news; comment] Vogel G. **Science** 1996 Aug 2;273(5275):580. Comment on: Science 1996 Aug 2;273(5275):622–6.

[Structure and functional similarity of yeast Sup35p and Ure2p proteins to mammalian prions] Kushnirov VV, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):750–5 (27 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Prion strains. Carlson GA. **Curr Top Microbiol Immunol** 1996; 207:35–47 (41 ref.)

Prion phylogeny revisited [letter; comment] Goldmann W, et al. **Nature** 1996 Jul 4;382(6586):32–3. Comment on: Nature 1996 Apr 25;380(6576):675.

DRUG EFFECTS

The UK epidemic of BSE: slow virus or chronic pesticide–initiated modification of the prion protein? Part 1: Mechanisms for a chemically induced pathogenesis/transmissibility. Purdey M. **Med Hypotheses** 1996 May;46(5):429–43

The UK epidemic of BSE: slow virus or chronic pesticide–initiated modification of the prion protein? Part 2: An epidemiological perspective. Purdey M. **Med Hypotheses** 1996 May;46(5):445–54

GENETICS

Prions, beta–sheets and transmissible dementias: is there still something missing? Liberski PP. **Acta Neuropathol (Berl)** 1995;90(2):113–25 (202 ref.)

Codon 219 polymorphism of PRNP in healthy Caucasians and Creutzfeldt–Jakob disease patients [letter] Petraroli R, et al. **Am J Hum Genet** 1996 Apr;58(4):888–9

SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. Perry RT, et al. **Am J Med Genet** 1995 Feb 27;60(1):12–8

Humanized prion protein knock–in by Cre–induced site–specific recombination in the mouse. Kitamoto T, et al. **Biochem Biophys Res Commun** 1996 May 24; 222(3):742–7

Identification of a promoter region in the rat prion protein gene. Saeki K, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):47–52

Hypokinesia and presenile dementia in a Dutch family with a novel insertion in the prion protein gene. van Gool WA, et al. **Brain** 1995 Dec;118 (Pt 6):1565–71

Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Telling GC, et al. **Cell** 1995 Oct 6; 83(1):79–90

Transgenetics and neuropathology of prion diseases. DeArmond SJ, et al. **Curr Top Microbiol Immunol** 1996; 207:125–46 (80 ref.)

Scanning for mutations in the human prion protein open reading frame by temporal temperature gradient gel electrophoresis. Wiese U, et al. **Electrophoresis** 1995 Oct; 16(10):1851–60

Prion protein (PrP) with amino–proximal deletions restoring susceptibility of PrP knockout mice to scrapie. Fischer M, et al. **EMBO J** 1996 Mar 15;15(6):1255–64

Propagation of the yeast prion–like [psi+] determinant is mediated by oligomerization of the SUP35–encoded polypeptide chain release factor. Paushkin SV, et al. **EMBO J** 1996 Jun 17;15(12):3127–34

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

Transient expression of tagged prion protein (PrP) in a neuronal cell line. Wightman LM, et al. **Gene Ther** 1994; 1 Suppl 1:S66

Interactions between wild–type and mutant prion proteins modulate neurodegeneration in transgenic mice. Telling GC, et al. **Genes Dev** 1996 Jul 15;10(14):1736–50

Human growth hormone–related iatrogenic Creutzfeldt–Jakob disease: search for a genetic susceptibility by analysis of the PRNP coding region. Jaegly A, et al. **Genomics** 1995 May 20;27(2):382–3

Genetic basis of Creutzfeldt–Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Windl O, et al. **Hum Genet** 1996 Sep;98(3):259–64

Sequence variation in intron of prion protein gene, crucial for complete diagnostic strategies [letter] Palmer MS, et al. **Hum Mutat** 1996;7(3):280–1

A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. Lehmann S, et al. **J Biol Chem** 1995 Oct 13;270(41):24589–97

Amino acid polymorphisms of PrP with reference to onset of scrapie in Suffolk and Corriedale sheep in Japan. Ikeda T, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2577–81

Spastic paraparesis and mutations in the prion protein gene [letter] Yamada M, et al. **J Neurol Sci** 1995 Dec; 134(1–2):215–6

Prion protein gene analysis in new variant cases of Creutzfeldt–Jakob disease [letter] Collinge J, et al. **Lancet** 1996 Jul 6;348(9019):56

Expression and targeting of Syrian hamster prion protein induced by heat shock in transgenic Drosophila melanogaster. Raeber AJ, et al. **Mech Dev** 1995 Jun; 51(2–3):317–27

Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Spudich S, et al. **Mol Med** 1995 Sep;1(6):607–13

Insoluble wild–type and protease–resistant mutant prion protein in brains of patients with inherited prion disease. Gabizon R, et al. **Nat Med** 1996 Jan;2(1):59–64

Phylogenesis of prion protein [letter] [see comments] Krakauer DC, et al. **Nature** 1996 Apr 25;380(6576):675. Comment in: Nature 1996 Jul 4;382(6586):32–3.

Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Sakaguchi S, et al. **Nature** 1996 Apr 11;380(6574):528–31

A prion disease with a novel 96–base pair insertional mutation in the prion protein gene. Campbell TA, et al. **Neurology** 1996 Mar;46(3):761–6

Prion analogues and twin studies in Parkinson's disease. Sommer SS, et al. **Neurology** 1996 Jan;46(1):273–5

Neuron–specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Race RE, et al. **Neuron** 1995 Nov; 15(5):1183–91

Serial MRI in early Creutzfeldt–Jacob disease with a point mutation of prion protein at codon 180. Ishida S, et al. **Neuroradiology** 1995 Oct;37(7):531–4

Hippocampal slices from prion protein null mice: disrupted Ca(2+)–activated K+ currents. Colling SB, et al. **Neurosci Lett** 1996 May 3;209(1):49–52

Vascular variant of prion protein cerebral amyloidosis with tau–positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Ghetti B, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):744–8

Prion–inducing domain of yeast Ure2p and protease resistance of Ure2p in prion–containing cells. Masison DC, et al. **Science** 1995 Oct 6;270(5233):93–5

[PSI] and [URE3] as yeast prions. Wickner RB, et al. **Yeast** 1995 Dec;11(16):1671–85 (79 ref.)

[Prions] Scheffer U. **Med Klin** 1995 Nov 15;90(11):653–7 (31 ref.) **(Ger)**

[Prions—pathogens of transmissible dementia in the human (editorial)] Schlicht HJ, et al. **Med Klin** 1995 Nov 15; 90(11):658–60 **(Ger)**

[A case of variant Gerstmann–Sträussler–Scheinker disease with the mutation of codon P105L] Kubo M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):873–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Detection of species specific epitopes of mouse and hamster prion proteins (PrPs) by anti–peptide antibodies. Yokoyama T, et al. **Arch Virol** 1996;141(3–4):763–9

Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Williamson RA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7279–82

ISOLATION & PURIFICATION

Semipreparative chromatographic method to purify the normal cellular isoform of the prion protein in nondenatured form. Pergami P, et al. **Anal Biochem** 1996 Apr 5;236(1):63–73

[ID–DLO designs preclinical test for scrapie. The Netherlands and England together fighting BSE (news)] Deleu S. **Tijdschr Diergeneeskd** 1996 Jul 15–Aug 1; 121(14–15):433–4 **(Dut)**

METABOLISM

Copper binding to the N–terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Hornshaw MP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):993–9

Recombinant prion protein rPrP27–30 from Syrian golden hamster reveals proteinase K sensitivity. Weiss S, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):173–9

Cell biology of the prion protein. Harris DA, et al. **Curr Top Microbiol Immunol** 1996;207:77–93 (42 ref.)

The folding intermediate concept of prion protein formation and conformational links to infectivity. Safar J. **Curr Top Microbiol Immunol** 1996;207:69–76 (14 ref.)

Patch–clamp analysis of synaptic transmission to cerebellar purkinje cells of prion protein knockout mice. Herms JW, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2508–12

Mutant and infectious prion proteins display common biochemical properties in cultured cells. Lehmann S, et al. **J Biol Chem** 1996 Jan 19;271(3):1633–7

Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. Petersen RB, et al. **J Biol Chem** 1996 May 24; 271(21):12661–8

Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. Beekes M, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1925–34

Replication of IFDO on a chemically defined medium. Burdon DW, et al. **J Med Microbiol** 1996 Jul;45(1):10–5

The abnormal isoform of the prion protein accumulates in late–endosome–like organelles in scrapie–infected mouse brain. Arnold JE, et al. **J Pathol** 1995 Aug;176(4):403–11

A single hamster PrP amino acid blocks conversion to protease–resistant PrP in scrapie–infected mouse neuroblastoma cells. Priola SA, et al. **J Virol** 1995 Dec; 69(12):7754–8

Accumulation of proteinase K–resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse–adapted strain of the Creutzfeldt–Jakob disease agent. Sakaguchi S, et al. **J Virol** 1995 Dec;69(12):7586–92

Prion protein released by platelets [letter] Perini F, et al. **Lancet** 1996 Jun 8;347(9015):1635–6

PATHOGENICITY

The association between PrP and infectivity in scrapie and BSE infected mouse brain. Somerville RA, et al. **Arch Virol** 1996;141(2):275–89

Interactions between wild–type and mutant prion proteins modulate neurodegeneration in transgenic mice. Telling GC, et al. **Genes Dev** 1996 Jul 15;10(14):1736–50

Pathogenesis of spongiform encephalopathies: an update. Aguzzi A. **Int Arch Allergy Immunol** 1996 Jun; 110(2):99–106 (67 ref.)

Disruption of prion rods generates 10–nm spherical particles having high alpha–helical content and lacking scrapie infectivity. Riesner D, et al. **J Virol** 1996 Mar;70(3):1714–22

The 'infective' process in scrapie and human spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1995

Aug;45(2):214–8 (37 ref.)
Prion function and dysfunction: a structure-based scenario. Radulescu RT, et al. **Med Hypotheses** 1996 Mar;46(3):225–8
Putting prions to the test [news] Mestel R. **Science** 1996 Jul 12;273(5272):184–9
Absence of detectable infectivity in trachea of BSE-affected cattle. Taylor DM, et al. **Vet Rec** 1996 Feb 17;138(7):160–1
Infectivity and host responses in Creutzfeldt-Jakob disease. Manuelidis L, et al. **Virology** 1996 Feb 1;216(1):46–59
[Non-conventional infectious agents or PRIONS (editorial)] Hauw JJ, et al. **Ann Pathol** 1995;15(6):409–14 (54 ref.) **(Fre)**
[Prions] Wieland S, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):949–52 **(Ger)**

PHARMACOLOGY

Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. Lledo PM, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2403–7

TOXICITY

Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Brown DR, et al. **Nature** 1996 Mar 28;380(6572):345–7
Cytotoxicity of prion protein peptide (PrP106–126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25–35. Hope J, et al. **Neurodegeneration** 1996 Mar;5(1):1–11

PRIORITIES, HEALTH see HEALTH PRIORITIES

PRISONERS

Anonymous HIV surveillance with risk factor elicitation at Scotland's largest prison, Barlinnie. Bird AG, et al. **AIDS** 1995 Jul;9(7):801–8
AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)
Foreign body in the foreskin of a former gulag prisoner [letter] Tanenbaun B, et al. **Am Fam Physician** 1996 Feb 15;53(3):865
Correlates of crack abuse among drug-using incarcerated women: psychological trauma, social support, and coping behavior. el-Bassel N, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):41–56
A prison release program for HIV-positive women: linking them to health services and community follow-up [letter] Flanigan TP, et al. **Am J Public Health** 1996 Jun; 86(6):886–7
Improving HIV/AIDS prevention in prisons is good public health policy [editorial; comment] Gaiter J, et al. **Am J Public Health** 1996 Sep;86(9):1201–3. Comment on: Am J Public Health 1996 Sep;86(9):1211–5.
Sexual behaviour of male inmates of a detention facility in Singapore: risks of intraprison human immunodeficiency virus transmission. Lee JT. **Ann Acad Med Singapore** 1995 Sep;24(5):685–90
Medical devices made into weapons by prisoners: an unrecognized risk. Hayden JW, et al. **Ann Emerg Med** 1995 Dec;26(6):739–42
Inmate security [letter] Hutson HR, et al. **Ann Emerg Med** 1996 Aug;28(2):247
Hepatitis C transmission through tattooing: a case report. Thompson SC, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):317–8
Shackling prisoners in hospital [editorial] [see comments] Dillner L. **BMJ** 1996 Jan 27;312(7025):200. Comment in: BMJ 1996 May 11;312(7040):1228.
Methadone maintenance reduces injecting in prison [letter] Dolan K, et al. **BMJ** 1996 May 4;312(7039):1162
Hunger strikes. Doctors do not have final decision on hunger strikers in prison [letter; comment] Feenan D. **BMJ** 1996 Feb 17;312(7028):444. Comment on: BMJ 1995 Oct 28;311(7013):1114–5.
Drug users and people with HIV infection need better care in prison [letter] Ford C. **BMJ** 1996 Jun 29;312(7047):1671
Drug use in prison. Methadone maintenance in prison needs to be evaluated [letter] Gore SM, et al. **BMJ** 1996 Aug 17;313(7054):429
Prison rights: mandatory drugs tests and performance indicators for prisons. Gore SM, et al. **BMJ** 1996 Jun 1; 312(7043):1411–3
Shackling prisoners in hospital. Is a breach of human rights [letter; comment] Holdstock D. **BMJ** 1996 May 11; 312(7040):1228. Comment on: BMJ 1996 Jan 27;312(7025):200.
Drug use in prison. Access to sterile injecting equipment is important [letter] Morrison CL, et al. **BMJ** 1996 Aug 17; 313(7054):429
Deaths in police custody are being analysed retrospectively [letter; comment] Norfolk G, et al. **BMJ** 1996 Apr 6; 312(7035):911. Comment on: BMJ 1996 Jan 6;312(7022):56.
Shackling prisoners in hospital. Causes problems for doctors [letter; comment] Pearce SJ. **BMJ** 1996 May 11; 312(7040):1228. Comment on: BMJ 1996 Jan 27;312(7025):200.
Shackling prisoners in hospital. Is unnecessary and avoidable [letter; comment] Philipp EE. **BMJ** 1996 May 11; 312(7040):1228. Comment on: BMJ 1996 Jan 27;312(7025):200.
Egyptian doctors held as prisoners of conscience [letter] Phillipson H. **BMJ** 1996 May 11;312(7040):1231
The prevalence of HIV-1 infection among inmates in Ontario, Canada. Calzavara LM, et al. **Can J Public Health** 1995 Sep-Oct;86(5):335–9
Voluntary anonymous linked study of the prevalence of HIV infection and hepatitis C among inmates in a Canadian federal penitentiary for women. Ford PM, et al. **Can Med Assoc J** 1995 Dec 1;153(11):1605–9
Prison deprivation and protein nutritional status of inmates of a developing community prison. Olubodun JO, et al. **Eur J Clin Nutr** 1996 Jan;50(1):58–60
Jail recidivism in a forensic case management program. Solomon P, et al. **Health Soc Work** 1995 Aug;20(3):167–73
Brainstem evoked potentials in three groups of prisoners after release from detention camp. Vrca A. **Int J Legal Med** 1996;108(5):259–61
HIV in UK prisons: a review of seroprevalence, transmission and patterns of risk [editorial] Curtis SP, et al. **Int J STD AIDS** 1995 Nov-Dec;6(6):387–91 (46 ref.)
Hearing loss in former prisoners of war of the Japanese. Grossman TW, et al. **J Am Geriatr Soc** 1996 Sep; 44(9):1089–92
Subtypes of incarcerated delinquents constructed via cluster analysis. Sorensen E, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):293–303
Jailed mothers: further explorations in public sector nursing. Osborne OH. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):23–8
Long-term health outcomes and medical effects of torture among US Navy prisoners of war in Vietnam [see comments] Nice DS, et al. **JAMA** 1996 Aug 7; 276(5):375–81. Comment in: JAMA 1996 Aug 7;276(5):416–7.
Bad news travels fast in Chile? [news] Duery L. **Lancet** 1996 Aug 31;348(9027):605
Preventing HIV transmission in prison: a tale of medical disobedience and Swiss pragmatism. Nelles J, et al. **Lancet** 1995 Dec 9;346(8989):1507–8
Forgotten imprisoned Syrian doctors [letter] [see comments] Phillipson H. **Lancet** 1995 Nov 4;346(8984):1232. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1711.
Release of Syrian doctors [letter; comment] Phillipson H. **Lancet** 1995 Dec 23–30;346(8991–8992):1711. Comment on: Lancet 1995 Nov 4;346(8984):1232.
Women as prisoners of war. Skelton WP 3rd, et al. **Mil Med** 1995 Nov;160(11):558–60
Physicians' experience and survival in patients with AIDS [letter; comment] Macher AM, et al. **N Engl J Med** 1996 Aug 1;335(5):350; discussion 350–1. Comment on: N Engl J Med 1996 Mar 14;334(11):729–31.
Jails, microbes, and the three-foot barrier [editorial; comment] Nelson JD. **N Engl J Med** 1996 Sep 19; 335(12):885–6. Comment on: N Engl J Med 1996 Sep 19;335(12):833–40.
Meningococcal disease in Los Angeles County, California, and among men in the county jails [see comments] Tappero JW, et al. **N Engl J Med** 1996 Sep 19;335(12):833–40. Comment in: N Engl J Med 1996 Sep 19;335(12):885–6.
The use of organs from executed prisoners in China [editorial] Briggs JD. **Nephrol Dial Transplant** 1996 Feb;11(2):238–40
Are malnutrition and stress risk factors for accelerated cognitive decline? A prisoner of war study. Sulway MR, et al. **Neurology** 1996 Mar;46(3):650–5
Suicide rates in Canadian prisons. Lester D. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1230
Commentary on TB testing of inmates [comment] Greifinger RB. **Public Health Rep** 1996 Jul-Aug;111(4):328–9. Comment on: Public Health Rep 1996 Jul-Aug;111(4):330–4.
Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)
Clinical challenges in the climate of prison. Prout C. **Trans Am Clin Climatol Assoc** 1995;107:287–294
Medical utility versus legal justice: a proposal for the ethical use of prisoner-donated organs. Callender CO, et al. **Transplant Proc** 1996 Feb;28(1):374
[Heroin abuse among Danish prisoners on remand. I. Prevalence related to form of administration] Andersen HS, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4749–53 (Eng. Abstr.) **(Dan)**
[Heroin abuse among Danish prisoners on remand. II. Consequences related to form of administration] Andersen HS, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4754–8 (Eng. Abstr.) **(Dan)**
[Anthropological medicine: myth and reality] Bataille M. **Acta Psychiatr Belg** 1995 Mar-Apr;95(2):57–69 (Eng. Abstr.) **(Fre)**
[The Social Protection Law] Floris M. **Acta Psychiatr Belg** 1995 Mar-Apr;95(2):70–81 (Eng. Abstr.) **(Fre)**
[HIV and hepatitis virus infections among prisoners and Police Forces in Rieti District, Italy] Bonaventura ME, et al. **Ann Ig** 1996 Mar-Apr;8(2):291–5 (Eng. Abstr.) **(Ita)**
[Treatment of hyperactivity and attention deficit with amphetamine. Experience with five adult prisoners] Stovner AM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):2002–5 (Eng. Abstr.) **(Nor)**
[Comparative study of the prevalence of hepatitis B virus infection and human immunodeficiency virus type 1 infection in the prison population between 1985 and 1992] del Olmo JA, et al. **Gastroenterol Hepatol** 1995 Oct; 18(8):405–9 (Eng. Abstr.) **(Spa)**
[Screening for HIV infection in prisons (letter)] Marco A, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):277–8 **(Spa)**

EDUCATION

The effects of peer education on STD and AIDS knowledge among prisoners in Mozambique. Vaz RG, et al. **Int J STD AIDS** 1996 Jan-Feb;7(1):51–4

HISTORY

Surgeon-superintendents on convict ships. Pearn J. **Aust N Z J Surg** 1996 Apr;66(4):253–6
Another physician on the front line in WWII [letter] Glomset D. **Iowa Med** 1995 Nov;85(11):442
[The history of the organization of medical care in Soviet prisoner-of-war camps] Nakhapetov BA. **Voen Med Zh** 1995 Mar;(3):71–4 **(Rus)**

LEGISLATION & JURISPRUDENCE

A different kind of "prisoner's dilemma". Schneiderman LJ, et al. **Camb Q Healthc Ethics** 1995 Fall;4(4):530–45
An unusual case of state-assisted prison suicide. Hayes LM. **Crisis** 1996;17(2):51–2
U.S. prisoners' access to experimental HIV therapies. Collins A, et al. **Minn Med** 1995 Nov;78(11):45–8

PSYCHOLOGY

Suicide and custody. Casale S. **AIDS Care** 1995;7 Suppl 2:S139–43
New York inmates' HIV risk behaviors: the implications for prevention policy and programs [see comments] Mahon N. **Am J Public Health** 1996 Sep;86(9):1211–5. Comment in: Am J Public Health 1996 Sep;86(9):1201–3.
Self-amputation of the ear: three men amputate four ears within five months. Alroe CJ, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):508–12
Treating mentally disordered prisoners. Solution to treating prisoners in hospital is financial [letter] Murray K, et al. **BMJ** 1995 Dec 16;311(7020):1641–2
Treating mentally disordered prisoners. Mental Health Act Commission should visit prisons [letter] Reeves RW. **BMJ** 1995 Dec 16;311(7020):1641
The psychopathology of incarcerated self-mutilators. Haines J, et al. **Can J Psychiatry** 1995 Nov;40(9):514–22
Prison suicide: an overview and guide to prevention (Part 3). Hayes LM. **Crisis** 1995;16(2):63–5
Psychopathy and dual-task performance under focusing conditions. Kosson DS. **J Abnorm Psychol** 1996 Aug; 105(3):391–400
Prevalence of HIV-related risk behaviors and STDs among incarcerated adolescents. Canterbury RJ, et al. **J Adolesc Health** 1995 Sep;17(3):173–7
Abuse histories among newly incarcerated women in a New York City jail. Richie BE, et al. **J Am Med Womens Assoc** 1996 May-Jul;51(3):111–4, 117
Test-retest evaluation of a four-subtest WAIS-R short form with young offenders. Thompson AP. **J Clin Psychol** 1995 May;51(3):410–4
Personality styles and dynamics of Alaska Native and nonnative incarcerated men. Glass MH, et al. **J Pers Assess** 1996 Jun;66(3):583–603
On fighting versus accepting stressful circumstances: primary and secondary control among HIV-positive men in prison. Thompson SC, et al. **J Pers Soc Psychol** 1996 Jun; 70(6):1307–17
Women offenders and reentry issues. Taylor SD. **J Psychoactive Drugs** 1996 Jan-Mar;28(1):85–93
Transgendered ... and taken to jail. Smith R. **J Psychosoc Nurs Ment Health Serv** 1995 Sep;33(9):44–6
Therapeutic communities in corrections and work release: some clinical and policy considerations. Inciardi JA, et al. **NIDA Res Monogr** 1994;144:259–67 (3 ref.)
Therapeutic communities in prison. Wexler HK, et al. **NIDA Res Monogr** 1994;144:181–208 (40 ref.)
Custodial status and self concepts of Nigerian inmates remanded to prison custody. Onyeneje EC, et al. **Percept Mot Skills** 1996 Feb;82(1):209–10
The extreme regressive reaction of a psychopath. Conacher GN, et al. **Psychiatr Q** 1996 Spring;67(1):1–10
A partial replication of Lippin (1990) using the Myers-Briggs type indicator with a sample of female prisoners. Long CK, et al. **Psychol Rep** 1995 Oct;77(2):467–72
Relationship between the Quick Test and WAIS-R in low-functioning criminal defendants. Simon MJ. **Psychol Rep** 1995 Dec;77(3 Pt 1):1001–2
Adaptation strategies and transient niches of one middle-class inmate in prison. Wooden WS, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):870
Exposure to serious family violence among incarcerated boys: its association with violent offending and potential mediating variables. Spaccarelli S, et al. **Violence Vict** 1995 Fall;10(3):163–82
[Risk factors in self-injurious behavior in a Swiss prison] Schaller G, et al. **Soz Praventivmed** 1996;41(4):249–56 (Eng. Abstr.) **(Fre)**
[Criteria for admission of drug dependent criminals for withdrawal treatment according to section 64 StGB with reference to the newest legal guidelines] Möller A, et al.

PRISONERS

Gesundheitswesen 1996 May;58(5):283–7 (Eng. Abstr.) **(Ger)**
[Physicians at the top security criminal institution in the country. Feeling of safety may rapidly turn to fear] Orn P. **Lakartidningen** 1996 Mar 20;93(12):1084–6 **(Swe)**

STATISTICS & NUMERICAL DATA

Female PCP-using jail detainees: proneness to violence and gender differences. Fishbein DH. **Addict Behav** 1996 Mar–Apr;21(2):155–72
Prison health: the breaking point. Berkman A. **Am J Public Health** 1995 Dec;85(12):1616–8
Prevalence of psychiatric disorders among incarcerated women. II. Convicted felons entering prison. Jordan BK, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):513–9
Prevalence of psychiatric disorders among incarcerated women. I. Pretrial jail detainees. Teplin LA, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):505–12
Prison rites: starting to inject inside. Gore SM, et al. **BMJ** 1995 Oct 28;311(7013):1135–6
Prevalence of psychiatric morbidity among remand prisoners in Scotland. Davidson M, et al. **Br J Psychiatry** 1995 Oct; 167(4):545–8
Screening prison inmates for mental disorder: an examination of the relationship between mental disorder and prison adjustment. DiCataldo F, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):573–85
Drug abuse and psychiatric comorbidity. Kokkevi A, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):329–37
Patterns of injecting and sharing in a Scottish prison. Shewan D, et al. **Drug Alcohol Depend** 1995 Oct;39(3):237–43
A cross-sectional seroprevalence survey for HIV-1 and high risk sexual behaviour of seropositives in a prison in India. Sundar M, et al. **Indian J Public Health** 1995 Jul–Sep; 39(3):116–8
Substance involvement among juvenile murderers: comparisons with older offenders based on interviews with prison inmates. Fendrich M, et al. **Int J Addict** 1995 Sep; 30(11):1363–82
The aging inmate. LaMere S, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Apr;34(4):25–9
Religiosity, criminality and types of offences of Jewish male prisoners. Ben-David S, et al. **Med Law** 1995; 14(7–8):509–19

PRISONER'S DILEMMA see **GAME THEORY**

PRISONS

Sexual behaviour and issues of HIV/AIDS prevention in an African prison [letter] Simooya O, et al. **AIDS** 1995 Dec; 9(12):1388–9
ASHP guidelines on pharmaceutical services in correctional facilities. American Society of Health-System Pharmacists. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1810–3
Correctional facilities guidelines [letter] Babb J. **Am J Health Syst Pharm** 1996 Feb 1;53(3):315, 320; discussion 320, 325
Correctional facilities guidelines [letter] Cason D, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):320; discussion 320, 325
Causes of death in Florida prisons: the dominance of AIDS [letter] Amankwaa AA. **Am J Public Health** 1995 Dec; 85(12):1710–1
The diversion of mentally ill persons from jails to community-based services: a profile of programs [see comments] Steadman HJ, et al. **Am J Public Health** 1995 Dec;85(12):1630–5. Comment in: Am J Public Health 1995 Dec;85(12):1611–3.
Jails and prisons—America's new mental hospitals [editorial; comment] Torrey EF. **Am J Public Health** 1995 Dec; 85(12):1611–3. Comment on: Am J Public Health 1995 Dec;85(12):1630–5.
Preventable disease in correctional facilities. Desmoteric foodborne outbreaks in the United States, 1974–1991. Cieslak PR, et al. **Arch Intern Med** 1996 Sep 9; 156(16):1883–8
Gone to the devil: the murals of Ile Royale hospital. Davidson AJ. **BMJ** 1995 Dec 23–30;311(7021):1713–4
Creating new criminals [editorial] McClintock T. **BMJ** 1995 Oct 21;311(7012):1037–8
TB infection and control in prisons [letter] St. John RK. **Can Med Assoc J** 1996 Jul 15;155(2):162–3
Telemedicine. A prison plugs in. Appleby C. **Hosp Health Netw** 1995 Nov 5;69(21):56, 58
The relationship between a medium secure environment and occupational stress in forensic psychiatric nurses. Kirby SD, et al. **J Adv Nurs** 1995 Nov;22(5):862–7
Prison life and the blood pressure of the inmates of a developing community prison. Olubodun J. **J Hum Hypertens** 1996 Apr;10(4):235–8
Serving time: psychiatric mental health nursing in corrections. Peternelj-Taylor CA, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):12–9 (35 ref.)
From the Centers for Disease Control and Prevention. HIV/AIDS education and prevention programs for adults in prisons and jails and juveniles in confinement facilities—United States, 1994. **JAMA** 1996 May 1; 275(17):1306–8
Hunger strike in Turkish prisons. Beynon J. **Lancet** 1996 Sep 14;348(9029):737
Tuberculosis in prisons [letter; comment] Coninx R, et al. **Lancet** 1995 Nov 4;346(8984):1238–9. Comment on: Lancet 1995 Oct 7;346(8980):948–9.
Tuberculosis in prisons—forgotten plague [see comments] Drobniewski F. **Lancet** 1995 Oct 7;346(8980):948–9. Comment in: Lancet 1995 Nov 4;346(8984):1238–9. Comment in: Lancet 1995 Nov 4;346(8984):1239.
Tuberculosis in prisons [letter; comment] Meux C. **Lancet** 1995 Nov 4;346(8984):1239. Comment on: Lancet 1995 Oct 7;346(8980):948–9.
Is a syringe exchange feasible in a prison setting? [letter] Dolan KA, et al. **Med J Aust** 1996 Apr 15;164(8):508
Is a syringe exchange feasible in a prison setting? [letter] Eyland SJ. **Med J Aust** 1996 Jul 1;165(1):59
HIV/AIDS education and prevention programs for adults in prisons and jails and juveniles in confinement facilities—United States, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Apr 5;45(13):268–71
Radiographic screening for tuberculosis in a large urban county jail [see comments] Puisis M, et al. **Public Health Rep** 1996 Jul–Aug;111(4):330–4. Comment in: Public Health Rep 1996 Jul–Aug;111(4):328–9.
AIDS clinic at the ACI. Khawaja M. **R I Med** 1995 Oct; 78(10):296–7
Prison health care [letter] Aginsky M, et al. **S Afr Med J** 1996 Jun;86(6):691–2
Work conditions and mental health among prison staff in France. Goldberg P, et al. **Scand J Work Environ Health** 1996 Feb;22(1):45–54
Clinical challenges in the climate of prison. Prout C. **Trans Am Clin Climatol Assoc** 1995;107:287–294
Terry and the fly. Thorburn KM. **West J Med** 1996 May; 164(5):457–8
Health care in correctional facilities. Thorburn KM. **West J Med** 1995 Dec;163(6):560–4 (47 ref.)
[Laryngeal tuberculosis in Antananarivo] Auregan G, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):90–4 (Eng. Abstr.) **(Fre)**
[Tuberculosis in the prison milieu at Antananarivo from 1990 to 1993] Auregan G, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):18–23 (Eng. Abstr.) **(Fre)**
[Physicians at the top security criminal institution in the country. Feeling of safety may rapidly turn to fear] Orn P. **Lakartidningen** 1996 Mar 20;93(12):1084–6 **(Swe)**

ECONOMICS

Options for recovery: promoting success among women mandated to treatment. Berkowitz G, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):31–8

HISTORY

Prisoner of war. Tankin LH. **Md Med J** 1995 Nov; 44(11):958–62

LEGISLATION & JURISPRUDENCE

Prison rights: mandatory drugs tests and performance indicators for prisons. Gore SM, et al. **BMJ** 1996 Jun 1; 312(7043):1411–3

ORGANIZATION & ADMINISTRATION

Jailed mothers: further explorations in public sector nursing. Osborne OH. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):23–8
Transgendered ... and taken to jail. Smith R. **J Psychosoc Nurs Ment Health Serv** 1995 Sep;33(9):44–6
The development of healthcare services for diabetic prisoners. MacFarlane IA. **Postgrad Med J** 1996 Apr; 72(846):214–7 (15 ref.)
[Working conditions, living conditions and physical health problems declared among penitentiary administration personnel in France] Goldberg P, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):200–13 (Eng. Abstr.) **(Fre)**

STANDARDS

Women's prison regime was "squalid and degrading" [news] Court C. **BMJ** 1996 Apr 13;312(7036):929
Environmental health issues in prisoner of war camps. Korte DV, et al. **Mil Med** 1995 Oct;160(10):483–6 (24 ref.)

STATISTICS & NUMERICAL DATA

Global spread of TB worrying trend for Canadian physicians. Cairney R. **Can Med Assoc J** 1996 Jan 15;154(2):236–8
Restricted patients in Scotland 1989–1995. Humphreys MS, et al. **Health Bull (Edinb)** 1996 Jul;54(4):344–7
Injury surveillance in correctional facilities—Michigan, April 1994–March 1995. **MMWR Morb Mortal Wkly Rep** 1996 Jan 26;45(3):69–72
Past and current drug use among Canadian correctional officers. Svenson LW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):977–8

PRISTINAMYCIN see **VIRGINIAMYCIN**

PRIVACY

see related
CONFIDENTIALITY

SELF DISCLOSURE

Teen's right to privacy vs. mother's right to know. Miya PA. **Am J Nurs** 1996 Mar;96(3):62
Consciousness, privacy, and information. Conrad D. **Biosystems** 1996;38(2–3):207–10
The rights of HIV infected healthcare workers [editorial; comment] Erridge P. **BMJ** 1996 Jun 29;312(7047):1625–6 . Comment on: BMJ 1996 Jun 29;312(7047):1679.
Genetic privacy: from the laboratory to the legislature. Andrews LB. **Genome Res** 1995 Oct;5(3):209–13 (17 ref.)
Caution guides genetic testing for hereditary cancer genes [news] Nelson NJ. **J Natl Cancer Inst** 1996 Jan 17; 88(2):70–2
Independent ethical review of studies involving personal medical records [letter] Wald N, et al. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):446
Public and private regulation of reproductive technologies. Byk C. **Med Law** 1995;14(3–4):215–9
Anonymity in peer review—time for a change? Clayson DB. **Regul Toxicol Pharmacol** 1995 Aug;22(1):101
[A Japanese version of inventory of orientation toward privacy] Yoshida K, et al. **Shinrigaku Kenkyu** 1996 Apr; 67(1):50–5 (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Privacy and autonomy in the physician-patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)
The public health information infrastructure. A national review of the law on health information privacy. Gostin LO, et al. **JAMA** 1996 Jun 26;275(24):1921–7
Corporate managed care [letter] Lebow R, et al. **N Engl J Med** 1996 Apr 18;334(16):1061; discussion 1062–3
[Human genetics and right to privacy. II] Martínez-Bullé Goyri VM. **Gac Med Mex** 1995 Sep–Dec;131(5–6):613–9 **(Spa)**
[The new genetics and the right to privacy] Velázquez A. **Gac Med Mex** 1995 May–Jun;131(3):367–72 **(Spa)**

PRIVACY ACT see **PRIVACY**

PRIVACY OF PATIENT DATA see **CONFIDENTIALITY**

PRIVATE ENTERPRISE see **PRIVATE SECTOR**

PRIVATE HOSPITALS see **HOSPITALS, PRIVATE**

PRIVATE PRACTICE

Quality of care among Jamaican private physicians offering family planning services. McDonald OP, et al. **Adv Contracept** 1995 Sep;11(3):245–54
Corporate takeover of medicine [letter] Guidera GG. **Am Fam Physician** 1995 Dec;52(8):2180
Compliance with primary prevention in private practice: creating a tobacco-free environment. Hovell MF, et al. **Am J Prev Med** 1995 Sep–Oct;11(5):288–93
A survey of the pattern of private general dental practice in Queensland, 1992. Spratley MH, et al. **Aust Dent J** 1995 Dec;40(6):392–6
Private prescribing of controlled drugs [letter; comment] Ford C. **BMJ** 1995 Sep 16;311(7007):755. Comment on: BMJ 1995 May 27;310(6991):1407.
BUPA's discretionary recognition of treatment. Psychosexual medicine is no longer recognised for benefit purposes [letter] Goodman RE. **BMJ** 1996 Feb 17;312(7028):447
BUPA moves into general practice [news] Kingman S. **BMJ** 1995 Oct 21;311(7012):1045
What is private practice? [letter] Cutler R. **Br Dent J** 1996 Jun 8;180(11):407
A model for the incorporation of intracytoplasmic sperm injection into a private practice in vitro fertilization program. Schoolcraft WB, et al. **Fertil Steril** 1996 Feb; 65(2):258–61
Hysterectomy: British National Health Service and private patients have very different experiences. Chapple A. **J Adv Nurs** 1995 Nov;22(5):900–6
Surgical audit in private practice. Wright JE. **J Qual Clin Pract** 1995 Sep;15(3):159–60
Physician specialty, systems of health care, and patient outcomes [editorial; comment] Fihn SD. **JAMA** 1995 Nov 8;274(18):1473–4. Comment on: JAMA 1995 Nov 8;274(18):1436–44.
Differences in work activities between private and community health centre GPs [letter; comment] Lake PB, et al. **Med J Aust** 1996 Jan 1;164(1):53–4. Comment on: Med J Aust 1995 Aug 21;163(4):187–90.
Results of 50 consecutive aneurysmectomies for abdominal aortic aneurysms at a private specialist centre. Leong YP, et al. **Med J Malaysia** 1995 Dec;50(4):330–3
Glaucoma care and conformance with preferred practice patterns. Examination of the private, community-based ophthalmologist. Hertzog LH, et al. **Ophthalmology** 1996 Jul;103(7):1009–13
"Fam-Med": an Internet list for small practices. Baldwin FD. **Pa Med** 1995 Nov;98(11):22–3
10 good reasons to stay independent. For private-practice physicians thinking about selling their practices. Orlowski SR. **Pa Med** 1995 Oct;98(10):11a–13a
Use of dreams in therapy: a survey of clinicians in private practice. Keller JW, et al. **Psychol Rep** 1995 Jun;76(3 Pt

2):1288–90
Perspectives on a neurosurgical practice. Cole HO. **Surg Neurol** 1996 Mar;45(3):301
Town versus gown. Besaw L. **Tex Med** 1995 Oct; 91(10):28–35
A practical approach to the evaluation and treatment of erectile dysfunction. A private practitioner's viewpoint. Baum N, et al. **Urol Clin North Am** 1995 Nov;22(4):865–77
[Heart surgery in private practice] Klingen G, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5541–4 (Eng. Abstr.) **(Dan)**
[The liberal ophthalmologists of the northern France and management of children with vision deficiencies] Defebvre MM, et al. **J Fr Ophtalmol** 1996;19(5):363–8 (Eng. Abstr.) **(Fre)**
[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78–88 (40 ref.) **(Fre)**
[Does the new Health Insurance Legislation lead to more competition? Consequences for physicians] Sommer JH. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2158–62 (Eng. Abstr.) **(Ger)**
[A general practitioner's dilemma—an odyssey directed by changing winds of politics] Carlsson B. **Lakartidningen** 1995 Nov 8;92(45):4157–8 **(Swe)**
[A physician in Gothenburg wanted to test something new. A private emergency call car improved quality of life] Orn P. **Lakartidningen** 1995 Nov 15;92(46):4292–3 **(Swe)**

ECONOMICS

Private practice: salvation or nemesis for the dental profession? [editorial] Landes DP. **Br Dent J** 1996 Feb 10; 180(3):82–3
Income generation in the NHS: opportunity or myth? Roddis MJ. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):67–8
The economic survival of pediatric practice. Hirsch AT. **Pediatrics** 1995 Oct;96(4 Pt 2):825–9; discussion 829–31
Limited private practice—the other issue [letter; comment] von Oppell UO, et al. **S Afr Med J** 1995 Sep;85(9):929. Comment on: S Afr Med J 1995 Aug;85(8):786–7. Comment on: S Afr Med J 1995 Aug;85(8):787–8. Comment on: S Afr Med J 1995 Aug;85(8):788–9.

LEGISLATION & JURISPRUDENCE

Public or private?... that is the question. Jerrold L. **Am J Orthod Dentofacial Orthop** 1996 Aug;110(2):231–2
Dentists lose state jury exemption. Are solo practitioners doomed? Plunkett LR. **N Y State Dent J** 1995 Nov; 61(9):12–4
Nurse practitioner private practice: three legal pitfalls to avoid. Buppert C. **Nurse Pract** 1996 Apr;21(4):32–4, 37
[Cooperation, community practice and practice community] Ratzel R. **Arch Gynecol Obstet** 1995;257(1–4):720–7 **(Ger)**

ORGANIZATION & ADMINISTRATION

Are emergency departments really a "safety net" for the medically indigent? Iserson KV, et al. **Am J Emerg Med** 1996 Jan;14(1):1–5
The "P–C" world of medicine: a commentary on the current medical scene. Griffen WO Jr. **Am Surg** 1996 Sep; 62(9):693–700
Solo or partnership. Urschel HC Jr. **Ann Thorac Surg** 1995 Nov;60(5):1473–5; discussion 1490–3
Is the problem private care or managed care? [letter; comment] Gregory B. **Can Med Assoc J** 1996 Jun 15; 154(12):1827; discussion 1828. Comment on: Can Med Assoc J 1996 Jan 15;154(2):142–3.
How solo physicians view their practices. Carlson B. **Indiana Med** 1996 May–Jun;89(3):250–4
Young physicians: taking charge in an era of change [interview by Karen Bouffard] Edelmann K. **Mich Med** 1996 May;95(5):26–9
A look at the private practice of the future. Nazarian LF. **Pediatrics** 1995 Oct;96(4 Pt 2):812–6
Limited private practice at academic hospitals — an 'in-house' group practice. Colborn RP, et al. **S Afr Med J** 1996 Mar;86(3):257–60

STANDARDS

Markers for primary care: missed opportunities to immunize and screen for lead and tuberculosis by private physicians serving large numbers of inner-city Medicaid-eligible children [see comments] Fairbrother G, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):785–90. Comment in: Pediatrics 1996 Jun;97(6 Pt 1):898–9.
[Quality assurance in coloscopy in private practice and the hospital. The Gastroenterology Quality Circle (GEQC) Munich] Heldwein W, et al. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1040–5 (Eng. Abstr.) **(Ger)**
[Care agreements in Orebro County (letter)] Baeckström P. **Lakartidningen** 1996 Jan 31;93(5):334 **(Swe)**
[We do not want neighbourhood microbiological laboratories! (letter)] Forsum U. **Lakartidningen** 1995 Dec 6;92(49):4673–4 **(Swe)**

STATISTICS & NUMERICAL DATA

The frequency and nature of skin conditions seen in a private dermatology practice in central Victoria, 1991–95. Kilkenny MF, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S50–3
Prediction of future high caries increments for children in a school dental service and in private practice. Imfeld TN, et al. **J Dent Educ** 1995 Oct;59(10):941–4
The delivery of immunizations and other preventive services in private practices. Bordley WC, et al. **Pediatrics** 1996 Apr;97(4):467–73

TRENDS

Visions of our health care future: is a parallel private system the answer? Gray C. **Can Med Assoc J** 1996 Apr 1; 154(7):1084–7
NHS waiting list have been a boon for private medicine in the UK [see comments] Richmond C. **Can Med Assoc J** 1996 Feb 1;154(3):378–81. Comment in: Can Med Assoc J 1996 Jul 1;155(1):20.
Betrayal by the surgeons [see comments] Light DW. **Lancet** 1996 Mar 23;347(9004):812–3. Comment in: Lancet 1996 May 18;347(9012):1404; discussion 1405. Comment in: Lancet 1996 May 18;347(9012):1404–5. Comment in: Lancet 1996 May 18;347(9012):1405.
A look at the private practice of the future. Nazarian LF. **Pediatrics** 1995 Oct;96(4 Pt 2):812–6

PRIVATE ROOMS see **PATIENTS' ROOMS**

PRIVATE SECTOR

The outlook for clinical research: impacts of federal funding restraint and private sector reconfiguration. Matherlee KR. **Acad Med** 1995 Dec;70(12):1065–72
NHS will be left with high risk, low profit services under private finance initiative [letter; comment] Bennett-Jones DN. **BMJ** 1996 Mar 23;312(7033):780. Comment on: BMJ 1995 Dec 2;311(7018):1450.
Private finance for the public good? [editorial] Dawson D, et al. **BMJ** 1996 Aug 10;313(7053):312
Clinical guidelines in the independent health care sector [editorial] Fairfield G, et al. **BMJ** 1996 Jun 22; 312(7046):1554–5
Private finance, public risk [editorial] [see comments] Ham C. **BMJ** 1995 Dec 2;311(7018):1450. Comment in: BMJ 1996 Mar 23;312(7033):780.
Private sector to fund new wave of NHS hospitals [news] Warden J. **BMJ** 1995 Dec 2;311(7018):1451
US physician warns Canadians about privatization [letter] [see comments] Gordon M. **Can Med Assoc J** 1996 Jan 15;154(2):142–3. Comment in: Can Med Assoc J 1996 Jun 15;154(12):1827; discussion 1828. Comment in: Can Med Assoc J 1996 Jun 15;154(12):1827–8.
Larger private-sector role in health care needed now, think tank warns. Lowry F. **Can Med Assoc J** 1996 Feb 15; 154(4):549–51
Private health care services [letter; comment] MacDonald IM. **Can Med Assoc J** 1995 Nov 15;153(10):1417. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1877–8.
Medical education and private institutions [letter] Sheriff DS. **J Indian Med Assoc** 1995 Mar;93(3):116–7
Ethics in academe. Oldaker S. **J Prof Nurs** 1995 Sep–Oct; 11(5):261
Assessment: the view from the private sector. Sawyer L. **J R Soc Health** 1995 Aug;115(4):258–60
Health of the public: The private-sector challenge. Showstack J, et al. **JAMA** 1996 Oct 2;276(13):1071–4
Private label insurance. Physician-run plans let doctors take the risk. Bouffard K. **Mich Med** 1996 May;95(5):20–1
Comments on POPULIS. 2. Health care data: government intervention or private cooperation? [comment] Musser JW. **Milbank Q** 1996;74(1):37–41. Comment on: Milbank Q 1996;74(1):3–31.
Comments on POPULIS. 3. Who has responsibility for a population's health? Nerenz DR. **Milbank Q** 1996; 74(1):43–9
Academic medical research: will collaboration with industry and national laboratories save it? [see comments] Eaton RP. **Pharos** 1995 Fall;58(4):2–4. Comment in: Pharos 1995 Fall;58(4):33.
Tobacco council and research [letter; comment] Mufson A, et al. **Science** 1996 May 31;272(5266):1247. Comment on: Science 1996 Apr 26;272(5261):488–94.
Depressive disorders: treatment patterns and costs of treatment in the private sector of the United States. Hu TW, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):224–30
[From in vitro fertilization to embryo transfers: evaluation of ten years of reproductive medical assistance in the private sector in France] Giacomini P, et al. **Contracept Fertil Sex** 1996 Apr;24(4):322–5 (Eng. Abstr.) **(Fre)**
[The insurance authority should be privatized (letter)] Vevatne T. **Tidsskr Nor Laegeforen** 1996 Mar 30; 116(9):1155 **(Nor)**
[Is private management of primary health services more efficient?] Sjönell G. **Lakartidningen** 1996 Aug 7; 93(32–33):2722–4 **(Swe)**

ECONOMICS

New BUPA scheme hits NHS patients [news] Tonks A. **BMJ** 1996 Jun 1;312(7043):1379
Implications of the development of managed health care in the South African private health care sector. Kinghorn AW. **S Afr Med J** 1996 Apr;86(4):335–8

ORGANIZATION & ADMINISTRATION

What restructuring means for nurses in Denmark. Stallknecht K, et al. **Int Nurs Rev** 1996 Jan–Feb;43(1):9–12
Independent sector home care: current issues and uncertainties. Leat D. **J R Soc Health** 1995 Oct; 115(5):326–9
Capabilities of public, voluntary and private dispensaries in basic health service provision. Ahmed AM, et al. **World Health Forum** 1996;17(3):257–60

STANDARDS

Public sector psychosocial nursing [editorial] Osborne OH. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):4–6

PRIVATIZATION

Privatising the NHS: dentistry paves the way [editorial] Shepherd JP, et al. **BMJ** 1996 Apr 13;312(7036):922–3
Is the problem private care or managed care? [letter; comment] Amato D. **Can Med Assoc J** 1996 Jun 15; 154(12):1827–8. Comment on: Can Med Assoc J 1996 Jan 15;154(2):142–3.
The benefits of privatization. Dirnfeld V. **Can Med Assoc J** 1996 Aug 15;155(4):407–10
The alluring myth of private medicine. Gordon M, et al. **Can Med Assoc J** 1996 Aug 15;155(4):404–6
Is the problem private care or managed care? [letter; comment] Gregory B. **Can Med Assoc J** 1996 Jun 15; 154(12):1827; discussion 1828. Comment on: Can Med Assoc J 1996 Jan 15;154(2):142–3.
Inside California's HMO market: a conversation with Leonard D. Schaeffer [interview by John K. Iglehart] Schaeffer LD. **Health Aff (Millwood)** 1995 Winter; 14(4):131–42
[Transformation of ownership in occupational health services] Durasiewicz Z. **Med Pr** 1995;46(3):255–62 (Eng. Abstr.) **(Pol)**
[Private health insurance leads to segregated care] Juhlin P. **Lakartidningen** 1995 Oct 4;92(40):3654, 3659 **(Swe)**

ECONOMICS

The public's stake in nonprofit health plan conversions [letter] Sherry ST, et al. **Health Aff (Millwood)** 1996 Summer; 15(2):317
Community financing or cost recovery: empowerment or social dumping? [editorial] Criel B, et al. **Trop Med Int Health** 1996 Jun;1(3):281–2

LEGISLATION & JURISPRUDENCE

["Privatization" of a radiologic hospital department. Decision of the German Federal Social Court of March 15, 1995] Rieger HJ. **Dtsch Med Wochenschr** 1995 Nov 24; 120(47):1636–8 **(Ger)**

ORGANIZATION & ADMINISTRATION

Plans to run private facility in public hospital draw some strong opposition in Alberta. Cairney R. **Can Med Assoc J** 1996 May 15;154(10):1543–4
[The basic organizational principles in the privatization of the state stomatological network] Ashurov GG. **Stomatologiia (Mosk)** 1995;74(3):77–9 **(Rus)**

TRENDS

The British health care reforms, the American health care revolution, and purchaser/provider contracts. Jost TS, et al. **J Health Polit Policy Law** 1995 Winter;20(4):885–908
Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191–214 (58 ref.)
Introducing a market to the United Kingdom's National Health Service. Maynard A, et al. **N Engl J Med** 1996 Feb 29;334(9):604–8
The role of pharmaceuticals in the privatization process in Vietnam's health-care system. Wolffers I. **Soc Sci Med** 1995 Nov;41(9):1325–32

PRIVILEGED COMMUNICATION see **CONFIDENTIALITY**

PRL-SECRETING PITUITARY ADENOMA see **PROLACTINOMA**

PRO PROFESSIONAL REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PROACCELERIN see **FACTOR V**

PROACTIVATOR CONVERTASE see **PROPERDIN FACTOR D**

PROADIFEN

PHARMACOLOGY

The role of nephrectomy and proadifen in blood pressure homeostasis following an acute kinin-induced hypotension in normotensive rats. Holte HR, et al. **Br J Pharmacol** 1996

PROADIFEN

Apr;117(7):1516–20

PROALBUMIN see PREALBUMIN

PROBABILISTIC MODELS see MODELS, STATISTICAL

PROBABILITY

Interpretation of bronchial brush specimens [letter; comment] Vollmer RT. **Am J Clin Pathol** 1995 Nov;104(5):603–4. Comment on: Am J Clin Pathol 1995 May;103(5):541–2. Comment on: Am J Clin Pathol 1995 May;103(5):588–93.

Error detection for genetic data, using likelihood methods. Ehm MG, et al. **Am J Hum Genet** 1996 Jan;58(1):225–34

Evaluation of the dispersional analysis method for fractal time series. Bassingthwaighte JB, et al. **Ann Biomed Eng** 1995 Jul–Aug;23(4):491–505

Model selection for extended quasi–likelihood models in small samples. Hurvich CM, et al. **Biometrics** 1995 Sep; 51(3):1077–84

Knowing about guessing and guessing about knowing: preschoolers' understanding of indeterminacy. Fay AL, et al. **Child Dev** 1996 Apr;67(2):689–716

DNA fingerprinting for forensic identification: some statistical issues. Majumder PP. **Electrophoresis** 1995 Sep; 16(9):1684–8

Statistical and genetic aspects of quality control for DNA identification. Morton NE, et al. **Electrophoresis** 1995 Sep; 16(9):1670–7 (30 ref.)

A chromosome–based method to infer IBD scores for missing and ambiguous markers. Gu C, et al. **Genet Epidemiol** 1995; 12(6):871–6

Variability of genotype–specific penetrance probabilities in the calculation of risk support intervals. Leal SM, et al. **Genet Epidemiol** 1995;12(6):859–62

Computing conditional recombination probabilities given marker information. Miller MB. **Genet Epidemiol** 1995; 12(6):883–8

Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep–Oct;4(5):355–71 (109 ref.)

Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. Krewski D, et al. **J Biopharm Stat** 1995 Nov;5(3):245–71

The meaning of kappa: probabilistic concepts of reliability and validity revisited. Guggenmoos–Holzmann I. **J Clin Epidemiol** 1996 Jul;49(7):775–82

Standard error and sample size determination for estimation of probabilities based on a test variable. White DB, et al. **J Clin Epidemiol** 1996 Apr;49(4):419–29

New statistical strategy for monitoring safety and efficacy in single–arm clinical trials. Thall PF, et al. **J Clin Oncol** 1996 Jan;14(1):296–303

The probability of unique solutions of sequencing by hybridization. Dyer M, et al. **J Comput Biol** 1994 Summer; 1(2):105–10

Method for calculation of probability of matching a bounded regular expression in a random data string. Sewell RF, et al. **J Comput Biol** 1995 Spring;2(1):25–31

The uncertain response in the bottlenosed dolphin (Tursiops truncatus). Smith JD, et al. **J Exp Psychol Gen** 1995 Dec; 124(4):391–408

Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. Inouye SK, et al. **JAMA** 1996 Mar 20;275(11):852–7

Clinical problem–solving: if at first you don't succeed [letter; comment] van den Ende J, et al. **N Engl J Med** 1996 Apr 4;334(14):919–20; discussion 920. Comment on: N Engl J Med 1995 Dec 7;333(23):1557–60.

Odds, risks and their relatives. Pagano M. **Nutrition** 1995 Sep–Oct;11(5):473

Calculating predictive performance: a user's note. Wu G. **Pharmacol Res** 1995 Jun;31(6):393–9

A probability database for decision–analytic models of coronary revascularization procedures. Murphy JF, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:72–6

De novo prediction of polypeptide conformations using dihedral probability grid Monte Carlo methodology. Evans JS, et al. **Protein Sci** 1995 Jun;4(6):1203–16

Building proteins from C alpha coordinates using the dihedral probability grid Monte Carlo method. Mathiowetz AM, et al. **Protein Sci** 1995 Jun;4(6):1217–32

Experimental quantiles of epidemiological indices in case–control studies with non–differential misclassification. Marinos AT, et al. **Stat Med** 1995 Jun 30;14(12):1291–306

Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilities. Roebruck P, et al. **Stat Med** 1995 Jul 30; 14(14):1583–94

[Helpful to bacterial identification: an alternative to probability calculation] Van Oystaeyen B. **Ann Biol Clin (Paris)** 1995;53(7–8):429–34 (Eng. Abstr.) **(Fre)**

PROBABILITY LEARNING

Testing models of decision making using confidence ratings in classification. Balakrishnan JD, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):615–33

Structural alignment in induction and similarity. Lassaline ME. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):754–70

Anticipation of coincidence, gender, and sports classification. Brady F. **Percept Mot Skills** 1996 Feb;82(1):227–39

To forget or not to forget: the effect of probability of test on directed forgetting. Golding JM, et al. **Q J Exp Psychol A** 1996 May;49(2):326–40

PROBABILITY THEORY

Predicting conditional probability distributions: a connectionist approach [letter] Weigend AS, et al. **Int J Neural Syst** 1995 Jun;6(2):109–18

PROBECID see PROBENECID

PROBENECID

PHARMACOLOGY

Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Jaehde U, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):532–41

Influence of probenecid on the renal excretion mechanisms of cefadroxil. Gimeno MJ, et al. **Drug Metab Dispos** 1996 Feb;24(2):270–2

On the relationship between the probenecid–sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance–associated protein (MRP). Versantvoort CH, et al. **Int J Cancer** 1995 Dec 11;63(6):855–62

Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. Pichette V, et al. **J Am Soc Nephrol** 1996 Feb;7(2):345–9

Effect of probenecid on 5–hydroxyindoleacetic acid in cisternal cerebrospinal fluid of rats with portacaval anastomosis. Bergeron M, et al. **Neurochem Res** 1995 Aug; 20(8):963–7

Systemic DL–kynurenine and probenecid pretreatment attenuates quinolinic acid–induced neurotoxicity in rats. Santamaría A, et al. **Neuropharmacology** 1996 Jan; 35(1):23–8

Effect of probenecid on the enantioselective pharmacokinetics of oxprenolol and its glucuronides in the rabbit. Laethem ME, et al. **Pharm Res** 1995 Dec; 12(12):1964–7

The effect of probenecid on the pharmacokinetics of zalcitabine in HIV–positive patients. Massarella JW, et al. **Pharm Res** 1996 Mar;13(3):449–52

Acetaminophen nephrotoxicity in the CD–1 mouse. II. Protection by probenecid and AT–125 without diminution of renal covalent binding. Emeigh Hart SG, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):161–9

THERAPEUTIC USE

An evidence based appraisal of the management of nontophaceous interval gout [editorial] [see comments] Ferraz MB. **J Rheumatol** 1995 Sep;22(9):1618–9 (26 ref.). Comment in: J Rheumatol 1995 Sep;22(9):1621–3.

PROBLEM–BASED LEARNING

An active–learning approach to basic clinical skills. Curry RH, et al. **Acad Med** 1996 Jan;71(1):41–4

Developing and evaluating the student assessment system in the preclinical problem–based curriculum at Sherbrooke. Des Marchais JE, et al. **Acad Med** 1996 Mar;71(3):274–83

Limiting tutorial–group size [letter] Dolmans DH, et al. **Acad Med** 1996 Jan;71(1):4

Exploratory factor analysis of students' ratings of a problem–based learning curriculum. Kalaian HA, et al. **Acad Med** 1996 Apr;71(4):390–2

Students' perceptions about their courses in problem–based–learning and conventional curricula. Kaufman DM, et al. **Acad Med** 1996 Jan;71(1 Suppl):S52–4

Development of clinical reasoning exercises in a problem–based curriculum. Neville AJ, et al. **Acad Med** 1996 Jan;71(1 Suppl):S105–7

Using faculty and student perceptions of group dynamics to develop recommendations for PBL training. Tipping J, et al. **Acad Med** 1995 Nov;70(11):1050–2

A model smoking–intervention curriculum for medical school. Usatine RP, et al. **Acad Med** 1996 Jan;71(1 Suppl):S96–8

Preparing students to participate in an active learning environment. Modell HI. **Am J Physiol** 1996 Jun;270(6 Pt 3):S69–77

Problem orientation is a new approach to surgical education. McGregor DB, et al. **Am J Surg** 1995 Dec;170(6):656–8; discussion 658–9

Adult learning theory, problem based learning, and paediatrics. David TJ, et al. **Arch Dis Child** 1995 Oct; 73(4):357–63

Self directed learning. Towle A, et al. **Arch Dis Child** 1996 Apr;74(4):357–9 (9 ref.)

Experiments with problem–based learning in oral biology. Aldred MJ. **Aust Dent J** 1995 Aug;40(4):252–3

Problem based learning at medical school. Some people think it's thrilling... [letter; comment] Farrow R. **BMJ** 1995 Dec 16;311(7020):1642–3. Comment on: BMJ 1995 Aug 5;311(7001):342–3.

Problem based learning at medical school ... but not all do [letter; comment] Morgan WK. **BMJ** 1995 Dec 16; 311(7020):1643. Comment on: BMJ 1995 Aug 5;311(7001):342–3.

Problem based learning at medical school ... and has been introduced successfully in Manchester [letter; comment] O'Neill PA. **BMJ** 1995 Dec 16;311(7020):1643. Comment on: BMJ 1995 Aug 5;311(7001):342–3.

Problem based learning at medical school. Problem based learning has been used for years in general practice in London... [letter; comment] Savage R, et al. **BMJ** 1995 Dec 16;311(7020):1643. Comment on: BMJ 1995 Aug 5;311(7001):342–3.

Self directed learning in the undergraduate dental curriculum. Fry H, et al. **Br Dent J** 1995 Nov 25;179(10):373–6

Self–directed learning [letter] Fry H, et al. **Br Dent J** 1996 Jan 20;180(2):52

Library faculty role in problem–based learning: facilitating small groups. Satterthwaite RK, et al. **Bull Med Libr Assoc** 1995 Oct;83(4):465–8

Using interactive video to add physical assessment data to computer–based patient simulations in nursing. White JE. **Comput Nurs** 1995 Sep–Oct;13(5):233–5

Problem–based learning in an undergraduate nursing programme: a case study. Andrews M, et al. **J Adv Nurs** 1996 Feb;23(2):357–65

Reflection and critical incident analysis: ethical and moral implications of their use within nursing and midwifery education. Rich A, et al. **J Adv Nurs** 1995 Dec;22(6):1050–7

Autonomy, problem–based learning, and the teaching of medical ethics. Parker M. **J Med Ethics** 1995 Oct; 21(5):305–10

Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)

A critical experiential teaching strategy: student and faculty participation in an AIDS walk. Patsdaughter CA, et al. **J Nurs Educ** 1996 May;35(5):223–6

Evidence–based medical education: the missing variable in the quality improvement equation. Chessare JB. **Jt Comm J Qual Improv** 1996 Apr;22(4):289–91

Crafting cases for problem–based learning: experience in a neuroscience course. Glick TH, et al. **Med Educ** 1996 Jan; 30(1):24–30

An electronic study guide for problem–based learning. Mooney GA, et al. **Med Educ** 1995 Nov;29(6):397–402

Integration of pharmacology into a problem–based learning curriculum for medical students. Sivam SP, et al. **Med Educ** 1995 Jul;29(4):289–96

The use of student journals in problem–based learning. Wetherell J, et al. **Med Educ** 1996 Mar;30(2):105–11

A problem–oriented, project organized, distance learning program in health informatics. Nøhr C, et al. **Medinfo** 1995; 8 Pt 2:1274–7

Medical informatics and problem–based learning in conjunction. Paterson GI, et al. **Medinfo** 1995;8 Pt 2:1149–53

Problem–based learning as a training modality in the occupational medicine curriculum. Felton JS. **Occup Med (Oxf)** 1996 Feb;46(1):5–11

Developing the role of the tutor/facilitator. Wetzel MS. **Postgrad Med J** 1996 Aug;72(850):474–7

Medical students: making a difference while learning. Epstein LC. **R I Med** 1995 Oct;78(10):302–3

The innovative medical curriculum of the University of Transkei Medical School. Part I. Problem–based learning [editorial] Iputo JE, et al. **S Afr Med J** 1996 Jun; 86(6):649–51

Controversies in community based education. Ogunbode O. **West Afr J Med** 1996 Jan–Mar;15(1):18–23 (15 ref.)

[Problem–based medical teaching] Tscherning T, et al. **Ugeskr Laeger** 1995 Nov 20;157(47):6567–71 (Eng. Abstr.) **(Dan)**

[Problem–oriented education, problem–based learning and activating teaching methods] Nikkarinen T, et al. **Duodecim** 1994;110(16):1548–55 (23 ref.) **(Fin)**

[Specialty Symposium of the Federal Medical Office "Problem–Oriented Learning in Medical Education, Graduate and Continuing Education" 9 to 10 September 1994, Würzburg] **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):329–442 **(Ger)**

["Information versus Communication" Workshop] Basler HD. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):437–8 **(Ger)**

[The pharmacotherapy circle—a promising way for improving quality in primary medical care] Bausch J. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):406–14 (Eng. Abstr.) **(Ger)**

["Teachers' Training Course"—evaluation of continuing studies for faculty in the field of ethics in medicine] Christ G, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):337–9 (Eng. Abstr.) **(Ger)**

[Health promotion and nutrition counseling for obese patients—a responsibility of medical care] Dittrich A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):382–5 (Eng. Abstr.) **(Ger)**

[Experiences in organization of medical graduate and continuing education in the new German country (Thüringen)] Dittrich C, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):349–54 (Eng. Abstr.) **(Ger)**

["The technique of problem–based learning—future of medical education curriculum?" Workshop] Falck–Ytter Y. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):440–1 **(Ger)**

[Case–oriented work in the quality circle] Gerlach FM, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):397–401 (Eng.

Abstr.) (Ger)
[Structured public health quality circle on the topic of diabetes management in general practice] Hartmann P, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):415–8 (Eng. Abstr.) (Ger)
[Does quality assurance modify clinical research, medical progress and medical graduate education in surgery?] Hupe K, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):359–63 (Eng. Abstr.) (Ger)
[The graduate education project in the new federal German lands "Diabetics—Management in General Practice"] Jörgens V, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):378–81 (Eng. Abstr.) (Ger)
[Professional development of media in general practice] Klein-Lange M, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):427–9 (Eng. Abstr.) (Ger)
[Report of experiences with quality circles] Mumenthaler M. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):424–5 (Ger)
[Initial experiences with the new environmental medicine course in graduate education] Nemitz B. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):346–8 (Eng. Abstr.) (Ger)
[The general practice course catalog—an attempt at quality assurance in graduate general practice education] Ollenschläger G, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):340–5 (Eng. Abstr.) (Ger)
[The "Patient Anxiety Seminar" as a graduate education program—effectiveness and use in general practice] Perkonigg A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):370–7 (Eng. Abstr.) (Ger)
[Systematic aspects of problem-based, case-related, practice-oriented, professional continuing education] Renschler HE. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):392–6 (Eng. Abstr.) (Ger)
[Problem-oriented learning at the Göttingen University. Report of a 1 week introductory conference ("sample course")] Sandholzer H, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):333–6 (Eng. Abstr.) (Ger)
[Graduate education in nutritional medicine in Germany—2 years after organization of the "Nutritional Medicine" teaching curriculum] Schauder P. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):386–91 (Eng. Abstr.) (Ger)
[Consensus as the basis of interdisciplinary graduate education curriculum] Sefrin P. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):364–6 (Eng. Abstr.) (Ger)
[General practice continuing education—initial experiences with problem-based learning in a continuing education program] Stiegler I, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):355–8 (Eng. Abstr.) (Ger)
["Knowledge versus action—quality circle work is different from traditional education" Workshop] Szecsenyi J, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):439–40 (Ger)
[Evaluation of a training program for moderators of panel doctor quality circles: a progress assessment] Szecsenyi J, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):419–23 (Eng. Abstr.) (Ger)
[Implementation and evaluation of quality circles in general practice] Tausch B, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):402–5 (Eng. Abstr.) (Ger)
[5 years experience with resuscitation courses] von Bose MJ, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):367–9 (Eng. Abstr.) (Ger)
[Applications of problem-based learning in the basic medical curriculum] Rendas AB, et al. **Acta Med Port** 1995 Jul–Aug;8(7–8):459–62 (Eng. Abstr.) (Por)

PROBLEM-ORIENTED MEDICAL RECORDS see **MEDICAL RECORDS, PROBLEM-ORIENTED**

PROBLEM SOLVING

see related
DECISION MAKING

Ratings of students' performances in a third-year internal medicine clerkship: a comparison between problem-based and lecture-based curricula. Richards BF, et al. **Acad Med** 1996 Feb;71(2):187–9
Developing a presentation and problem-solving station in a multistation standardized-patient examination. Rosebraugh CJ, et al. **Acad Med** 1996 Jan;71(1 Suppl):S102–4
How doctors learn: the role of clinical problems across the medical school-to-practice continuum. Slotnick HB. **Acad Med** 1996 Jan;71(1):28–34
Cross-task cross talk in memory and perception. Dutta A, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):49–62
Speed-accuracy decomposition yields a sudden insight into all-or-none information processing. Kounios J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):229–41
Accessing intuition through imagery for stress management, creative problem solving, and diagnosis [letter; comment] Burk DL Jr. **AJR Am J Roentgenol** 1996 May; 166(5):1231–2. Comment on: AJR Am J Roentgenol 1995 Oct;165(4):755–64.
The deaf child and solving problems of arithmetic. The importance of comprehensive reading. Serrano Pau C. **Am Ann Deaf** 1995 Jul;140(3):287–90
Process for preventing or identifying and resolving problems in drug therapy. Robertson KE. **Am J Health Syst Pharm** 1996 Mar 15;53(6):639–50
Quality circles as problem-solving tools in perioperative settings. Tuttle D. **AORN J** 1996 Mar;63(3):625, 628–9
Complete denture problem solving: a survey. Lechner SK, et al. **Aust Dent J** 1995 Dec;40(6):377–80
Relations between problem orientation and optimism, pessimism, and trait affectivity: a construct validation study. Chang EC, et al. **Behav Res Ther** 1996 Feb; 34(2):185–94
Impairments of discourse abilities and executive functions in traumatically brain-injured adults. Coelho CA, et al. **Brain Inj** 1995 Jul;9(5):471–7
Comparative conflict resolution patterns among parent-teen dyads of four ethnic groups in Hawaii. Hartz DT. **Child Abuse Negl** 1995 Jun;19(6):681–9
Depression and maltreatment as predictors of social competence and social problem-solving skills in school-age children. Levendosky AA, et al. **Child Abuse Negl** 1995 Oct;19(10):1183–95
Children's help-seeking behaviour. Westcott HL, et al. **Child Care Health Dev** 1995 Jul;21(4):255–70
Parent-child relationships, family problems-solving behavior, and sibling relationship quality: the moderating role of sibling temperaments. Brody GH, et al. **Child Dev** 1996 Jun;67(3):1289–300
The dynamics of preschoolers' categorization choices. Deák GO, et al. **Child Dev** 1996 Jun;67(3):740–67
Maternal working models of attachment, marital adjustment, and the parent-child relationship. Eiden RD, et al. **Child Dev** 1995 Oct;66(5):1504–18
Knowing about guessing and guessing about knowing: preschoolers' understanding of indeterminacy. Fay AL, et al. **Child Dev** 1996 Apr;67(2):689–716
Interaction style, problem-solving behavior, and family problem-solving effectiveness. Rueter MA, et al. **Child Dev** 1995 Feb;66(1):98–115
Waiting to use a symbol: the effects of delay on children's use of models. Uttal D, et al. **Child Dev** 1995 Dec; 66(6):1875–89
Context and development in family problem solving with preadolescent children. Vuchinich S, et al. **Child Dev** 1996 Jun;67(3):1276–88
Human errors in fatal and serious occupational accidents in Finland. Salminen S, et al. **Ergonomics** 1996 Jul;39(7):980–8
Who's got the power? Gender differences in partners' perceptions of influence during marital problem-solving discussions. Ball FL, et al. **Fam Process** 1995 Sep; 34(3):303–21
Ethics as design. Doing justice to moral problems. Whitbeck C. **Hastings Cent Rep** 1996 May–Jun;26(3):9–16
Beyond problem-solving [editorial] Berczeller PH. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):9, 12
Problem-focused coping in HIV-infected mothers in relation to self-efficacy, uncertainty, social support, and psychological distress. Sharts-Hopko NC, et al. **Image J Nurs Sch** 1996 Summer;28(2):107–11
Theoretical and empirical considerations of resourcefulness. Zauszniewski JA. **Image J Nurs Sch** 1995 Fall;27(3):177–80 (31 ref.)
Categorisation of the patient's medical condition—an analysis of nursing judgement. Crow R, et al. **Int J Nurs Stud** 1995 Oct;32(5):413–22
Information sources used in decision making: considerations for simulation development. Lamond D, et al. **Int J Nurs Stud** 1996 Feb;33(1):47–57
Social problem solving: a moderator of the relation between negative life stress and depression symptoms in children. Goodman SH, et al. **J Abnorm Child Psychol** 1995 Aug; 23(4):473–85
Poor interpersonal problem solving as a mechanism of stress generation in depression among adolescent women. Davila J, et al. **J Abnorm Psychol** 1995 Nov;104(4):592–600
Problem-based learning in an undergraduate nursing programme: a case study. Andrews M, et al. **J Adv Nurs** 1996 Feb;23(2):357–65
Exploring the process of data acquisition: methodological challenges encountered and strategies employed. Roberts J, et al. **J Adv Nurs** 1996 Feb;23(2):366–72
Artificial neural networks can distinguish novice and expert strategies during complex problem solving. Stevens RH, et al. **J Am Med Inform Assoc** 1996 Mar–Apr;3(2):131–8
Use of effective questioning to enhance the cognitive abilities of students. Sachdeva AK. **J Cancer Educ** 1996 Spring; 11(1):17–24
Calculation and number processing in mild Alzheimer's disease. Deloche G, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):634–9
Wayfinding in dementia of the Alzheimer type: planning abilities. Passini R, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):820–32
Use of social information in the problem solving of orangutans (Pongo pygmaeus) and human children (Homo sapiens). Call J, et al. **J Comp Psychol** 1995 Sep; 109(3):308–20
Manual laterality in chimpanzees (Pan troglodytes) in complex tasks. Colell M, et al. **J Comp Psychol** 1995 Sep; 109(3):298–307
Social learning in the golden hamster (Mesocricetus auratus). Prato Previde E, et al. **J Comp Psychol** 1996 Jun; 110(2):203–8
Attributions and behavior in functional and dysfunctional marriages. Bradbury TN, et al. **J Consult Clin Psychol** 1996 Jun;64(3):569–76
The longitudinal impact of demand and withdrawal during marital conflict. Heavey CL, et al. **J Consult Clin Psychol** 1995 Oct;63(5):797–801
Children's analogical problem solving: the effects of superficial, structural, and procedural similarity. Chen Z. **J Exp Child Psychol** 1996 Aug;62(3):410–31
Reasoning from memory: a lifespan inquiry into the necessity of remembering when reasoning about class inclusion. Howe ML, et al. **J Exp Child Psychol** 1996 Feb;61(1):1–42
Valuing of identity, distribution of attention, and perceptual salience in free and rule-governed classifications. Odom RD, et al. **J Exp Child Psychol** 1996 Mar;61(2):173–89
Performance demands in the selection of objects for counting. Towse JN, et al. **J Exp Child Psychol** 1996 Feb;61(1):67–79
Structural alignment in induction and similarity. Lassaline ME. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):754–70
Category-based predictions: influence of uncertainty and feature associations. Ross BH, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):736–53
Cognitive sequence knowledge: what is learned? Wenger JL, et al. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):599–619
Community program planning: a clinical outcome. Kuennen J, et al. **J Nurs Educ** 1995 Nov;34(8):387–9
Repressive emotional discreteness after failure. Egloff B, et al. **J Pers Soc Psychol** 1996 Jun;70(6):1318–26
Perceiving interpersonal conflict and reacting to it: the case for agreeableness. Graziano WG, et al. **J Pers Soc Psychol** 1996 Apr;70(4):820–35
Major life events and minor stressors: identifying mediational links in the stress process. Pillow DR, et al. **J Pers Soc Psychol** 1996 Feb;70(2):381–94
Critical thinking skills of baccalaureate nursing students. Saucier BL. **J Prof Nurs** 1995 Nov–Dec;11(6):351–7
Does high 'action-proneness' make people more vulnerable to chronic fatigue syndrome? A controlled psychometric study. Van Houdenhove B, et al. **J Psychosom Res** 1995 Jul;39(5):633–40
Instructive errors—an invitation [editorial] Swales JD. **J R Soc Med** 1995 Dec;88(12):665
Problem solving and coping strategies in persons with spinal cord injury who have and do not have a family history of alcoholism. Schandler SL, et al. **J Spinal Cord Med** 1996 Apr;19(2):78–86
Basic medical research as a means of solving national health problems. Iqbal MP, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):250–2
The relationship between resource constraints and physician problem solving. Implications for improving the process of care. Lescoe-Long MA, et al. **Med Care** 1996 Sep; 34(9):931–53
Clinical problem-solving using video simulation: an investigation. Roberts JD, et al. **Med Educ** 1995 Sep; 29(5):347–54
Spontaneous mnemonic strategies used by older and younger adults to remember proper names. Brooks JO 3rd, et al. **Memory** 1993 Dec;1(4):393–407
Hindsight bias and the misinformation effect: separating blended recollections from other recollection types. Pohl RF, et al. **Memory** 1995 Mar;3(1):21–55
Exploring the macrostructure of children's central conceptual structures in the domains of number and narrative. Case R, et al. **Monogr Soc Res Child Dev** 1996; 61(1–2):59–82
Evaluating the breadth and depth of training effects when central conceptual structures are taught. Griffin S, et al. **Monogr Soc Res Child Dev** 1996;61(1–2):83–102
Exploring the microstructure of children's central conceptual structures in the domain of number. Okamoto Y, et al. **Monogr Soc Res Child Dev** 1996;61(1–2):27–58
Learning to commit or avoid the base-rate error. Goodie AS, et al. **Nature** 1996 Mar 21;380(6571):247–9
Solution of an insight problem at different age levels. Antonietti A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1215–8
Mental activity, health, and life-satisfaction. Delin CR, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):944–6
Collaborative referencing in elderly women. Filer L, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):995–1000
Comparison of visual-motor performance and nonverbal reasoning among child and adolescent patients in an urban psychiatric hospital. Frey PD. **Percept Mot Skills** 1996 Feb; 82(1):179–84
Relationships among gender, cognitive style, academic major, and performance on the Piaget water-level task. Hammer RE, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):771–8
Digit and shape memory function in soroban learners: are soroban learners superior in general? Kawakami A. **Percept Mot Skills** 1995 Aug;81(1):75–80
Acceptable levels of tonal and broad-band repetitive and continuous sounds during the performance of nonauditory tasks. Landström U, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):803–16
An experimental test of "the mozart effect": does listening to his music improve spatial ability? Newman J, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1379–87
EEG correlates of enhanced spatial performance following exposure to music. Rideout BE, et al. **Percept Mot Skills** 1996 Apr;82(2):427–32
Redundant leading and following zeros in comparative numerical judgment. Takayanagi S, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):819–29

PROBLEM SOLVING

A comparison of rats and mice in a swimming pool place task and matching to place task: some surprising differences. Whishaw IQ. **Physiol Behav** 1995 Oct; 58(4):687–93

Cue recognition and cue elaboration in learning from examples. Zhu X, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1346–51

Everyday problem solving in older adults: observational assessment and cognitive correlates. Diehl M, et al. **Psychol Aging** 1995 Sep;10(3):478–91

On the mechanisms of plasticity in young and older adults after instruction in the method of loci: evidence for an amplification model. Verhaeghen P, et al. **Psychol Aging** 1996 Mar;11(1):164–78

Exploring 'theory of mind' in people with schizophrenia. Frith CD, et al. **Psychol Med** 1996 May;26(3):521–30

Listening to Mozart may not enhance performance on the revised Minnesota Paper Form Board Test. Carstens CB, et al. **Psychol Rep** 1995 Aug;77(1):111–4

Perceived problem-solving and vocational identity: implication for nontraditional premedical students. Henry P. **Psychol Rep** 1996 Jun;78(3 Pt 1):843–7

Delayed matching to complex samples and the formation of stimulus classes in children. Maguire RW, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1059–76

A study of planning and mathematics instruction for students with learning disabilities. Naglieri JA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1343–54

Learning set spatial navigation performance in three mouse strains. Petrie BF. **Psychol Rep** 1995 Dec;77(3 Pt 2):1339–42

Bias in conditional inference: implications for mental models and mental logic. Evans JS, et al. **Q J Exp Psychol A** 1995 Aug;48(3):644–70

Testing the mental model theory of propositional reasoning. Klauer KC, et al. **Q J Exp Psychol A** 1995 Aug; 48(3):671–87

Response to Mathias and Nettelbeck on the structure of competence: need for theory-based methods to test theory-based questions. Greenspan S, et al. **Res Dev Disabil** 1996 Mar–Apr;17(2):145–52; discussion 153–60

Interpersonal problem solving and information processing in schizophrenia. Corrigan PW, et al. **Schizophr Bull** 1995; 21(3):395–403

Situational familiarity and feature recognition in schizophrenia. Corrigan PW, et al. **Schizophr Bull** 1996; 22(1):153–61

Durable improvements in Wisconsin Card Sorting Test performance in schizophrenic patients. Vollema MG, et al. **Schizophr Res** 1995 Aug 15;16(3):209–15

Scaffolded instruction and the remediation of Wisconsin Card Sorting Test deficits in chronic schizophrenia. Young DA, et al. **Schizophr Res** 1995 Aug 15;16(3):199–207

Problem solving, stress, and coping in adolescent suicide attempts. Wilson KG, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):241–52

Conflict resolution strategies and marital distress as mediating factors in the link between witnessing interparental violence and wife battering. Choice P, et al. **Violence Vict** 1995 Summer;10(2):107–19

Breastfeeding kinetics. A problem-solving approach to breastfeeding difficulties. Livingstone V. **World Rev Nutr Diet** 1995;78:28–54 (59 ref.)

[Inductive reasoning and intelligence test performance—analysis of the manner of the effect of 2 thought training methods for children] Hager W, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Oct;44(8):296–302 (Eng. Abstr.) **(Ger)**

[Cognitive load and listener orientation in monologue instruction] Rossnagel C. **Z Exp Psychol** 1995;42(1):94–110 (Eng. Abstr.) **(Ger)**

[Priming effects in picture problems: preliminary solutions] Wippich W, et al. **Z Exp Psychol** 1995;42(2):324–52 (Eng. Abstr.) **(Ger)**

[Effect of mood and analytic and intuitive judgement tendencies in the "false-fame" effect] Hänze M. **Z Psychol Z Angew Psychol** 1996;204(2):149–66 (Eng. Abstr.) **(Ger)**

[Training of ethical problem-solving. Support for terminal care personnel] Bolinder G, et al. **Lakartidningen** 1995 Nov 8;92(45):4191–2, 4195 **(Swe)**

DRUG EFFECTS

A comparison of kainic acid plus colchicine and ibotenic acid-induced hippocampal formation damage on four configural tasks in rats. Alvarado MC, et al. **Behav Neurosci** 1995 Dec;109(6):1052–62

Problem solving following neonatal exposure to cocaine, ethanol, or cocaine/ethanol in combination in rats. Barron S, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):197–203

PHYSIOLOGY

Some prerequisites for a study of the evolution of cognition in the animal kingdom. Gervet J, et al. **Acta Biotheor** 1996 Mar;44(1):37–57

Cerebral blood flow changes in limbic regions induced by unsolvable anagram tasks. Schneider F, et al. **Am J Psychiatry** 1996 Feb;153(2):206–12

Rats with fimbria-fornix lesions can acquire and retain a visual-tactile transwitching (configural) task. Whishaw IQ, et al. **Behav Neurosci** 1995 Aug;109(4):607–12

Lesions of rat perirhinal cortex exacerbate the memory deficit observed following damage to the fimbria-fornix. Wiig KA, et al. **Behav Neurosci** 1995 Aug;109(4):620–30

Mental rotation at 7 years: relations with prenatal testosterone levels and spatial play experiences. Grimshaw GM, et al. **Brain Cogn** 1995 Oct;29(1):85–100

Selective impairment for simple division. Cipolotti L, et al. **Cortex** 1995 Sep;31(3):433–49

An iterative approach to the solution of the inverse problem. Srebro R. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 98(4):349–62

Planning and spatial working memory: a positron emission tomography study in humans. Owen AM, et al. **Eur J Neurosci** 1996 Feb;8(2):353–64

Physiological response in healthy subjects and in patients after myocardial infarction, elicited by a new computerised version of the Raven Coloured PM 47 as a mental stress test. Pruneti CA, et al. **Funct Neurol** 1995 Jul–Oct; 10(4–5):195–201

Executive functions of the frontal lobes: psychometric properties of a self-rating scale. Coolidge FL, et al. **Psychol Rep** 1995 Aug;77(1):24–6

[The effect of different masking noises on psychophysiological tasks] Tsaneva L, et al. **Probl Khig** 1995;20:109–15 (Eng. Abstr.) **(Bul)**

[The solving of the Revecz–Krushinskil test by Norway rats] Pleskacheva MG, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):701–15 (Eng. Abstr.) **(Rus)**

[The capacity for transitive inference in birds: the solving of the Gillan test by Corvidae and pigeons] Zorina ZA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):716–22 (Eng. Abstr.) **(Rus)**

PROBUCOL

Quenching of reactive oxidative species by probucol and comparison with other antioxidants. Bisby RH, et al. **Free Radic Biol Med** 1996;20(3):411–20

ADVERSE EFFECTS

Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Reinoehl J, et al. **Am Heart J** 1996 Jun;131(6):1184–91

Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Kajinami K, et al. **Atherosclerosis** 1996 Feb;120(1–2):181–7

Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol. Murphy MJ, et al. **Postgrad Med J** 1995 Aug;71(838):498–500

ANALOGS & DERIVATIVES

MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect. Sheetz MJ. **J Lipid Res** 1995 Dec;36(12):2609–21

[A probucol analog protects lipoproteins from oxidation better than does probucol] Dmitriev LF, et al. **Biull Eksp Biol Med** 1995 May;119(5):491–3 **(Rus)**

PHARMACOLOGY

Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Kaneko M, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1047–51

Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Ishizaka N, et al. **Atherosclerosis** 1995 Nov; 118(1):53–6

Probucol, but not MaxEPA fish oil, inhibits mononuclear cell adhesion to the aortic intima in the rat model of atherosclerosis. Barbeau ML, et al. **Biochem Cell Biol** 1995 May–Jun;73(5–6):283–8

Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation. Hanna AN, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1627–33

Inhibitory effect of probucol on nephrotoxicity induced by ferric nitrilotriacetate (Fe-NTA) in rats. Qin X, et al. **Carcinogenesis** 1995 Oct;16(10):2549–52

Inhibitory effect of probucol on benzo[alpha]pyrene induced lung tumorigenesis. Zarkovic M, et al. **Carcinogenesis** 1995 Oct;16(10):2599–601

Effect of probucol, an oral hypocholesterolaemic agent, on acute tobacco smoke inhalation in rats. Ishizaki T, et al. **Clin Sci (Colch)** 1996 Jun;90(6):517–23

Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits. Andersen HO, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1561–71

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Singal PK, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1055–63 (80 ref.)

Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. Mantha SV, et al. **Life Sci** 1996;58(6):503–9

[A probucol analog protects lipoproteins from oxidation better than does probucol] Dmitriev LF, et al. **Biull Eksp Biol Med** 1995 May;119(5):491–3 **(Rus)**

[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep–Oct; 41(5):2–8 (80 ref.) **(Rus)**

THERAPEUTIC USE

Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Watanabe K, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):23–9

Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. O'Keefe JH Jr, et al. **Am J Cardiol** 1996 Mar 15;77(8):649–52

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Chang MY, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1631–40

Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Tomochika Y, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):955–62

Probucol normalizes cholesteryl ester transfer in IDDM. Bagdade JD, et al. **Diabetes Care** 1995 Oct;18(10):1341–6

High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. Saku K, et al. **Eur J Clin Pharmacol** 1995; 48(3–4):209–15

Probucol prevents the progression of fatty liver in MSG obese mice. Yoshida T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):119–22

Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients [letter] de Lorgeril M, et al. **J Heart Lung Transplant** 1996 May;15(5):539–40

Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Lee YJ, et al. **Jpn Heart J** 1996 May;37(3):327–32

Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis [letter] Ogawa M, et al. **Nephron** 1995;70(3):376–7

The protective effect of probucol on adriamycin nephrosis in the rat. Futenma A, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):616–21

Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Kaul N, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):551–4

PROCAINAMIDE

ADVERSE EFFECTS

Interference with anticoagulation monitoring by procainamide-induced lupus anticoagulant. Metzdorff MT, et al. **Ann Thorac Surg** 1996 Mar;61(3):994–5

Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus. Starkebaum G, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):112–9

Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Abe H, et al. **Jpn Heart J** 1995 Jul;36(4):483–7

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

[A case of primary antiphospholipid antibody syndrome associated with procainamide induced systemic lupus erythematosus] Muramatsu M, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1736–8 **(Jpn)**

ANALOGS & DERIVATIVES

Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects. Stambler BS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1679–84

Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. Yamada A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):159–66

Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Ishii Y, et al. **Jpn J Pharmacol** 1995 Jun;68(2):175–82

Kinetics and dynamics of sematilide. Shi J, et al. **Ther Drug Monit** 1995 Oct;17(5):437–44

BLOOD

[Procainamide] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:954–6 (8 ref.) **(Jpn)**

DIAGNOSTIC USE

Noninvasive diagnosis of cardiac allograft rejection: the effect of procainamide. Everett JE, et al. **J Invest Surg** 1995 May–Jun;8(3):195–201

METABOLISM

Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE, et al. **J Clin Pharmacol** 1995 Sep;35(9):902–10

PHARMACOKINETICS

pH-dependent transport of procainamide in cultured renal epithelial monolayers of OK cells: consistent with nonionic

diffusion. Dudley AJ, et al. **Br J Pharmacol** 1995 Sep; 116(1):1685–91

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

PHARMACOLOGY

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part I. Propofol anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1995 Mar–Apr;47(2):143–52

THERAPEUTIC USE

Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia [see comments] Gorgels AP, et al. **Am J Cardiol** 1996 Jul 1; 78(1):43–6. Comment in: Am J Cardiol 1996 Jul 1;78(1):82–3.

Lidocaine and sustained monomorphic ventricular tachycardia: fact or fiction [editorial; comment] Josephson ME. **Am J Cardiol** 1996 Jul 1;78(1):82–3. Comment on: Am J Cardiol 1996 Jul 1;78(1):43–6.

Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Stambler BS, et al. **Am J Cardiol** 1996 May 1;77(11):960–6

Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Abe H, et al. **Jpn Heart J** 1995 Jul;36(4):483–7

PROCAINE

[The use of an analgin-novocaine-platyphylline mixture for arresting the pain attack and treating trigeminal neuralgia] Sheshelovskiĭ EG, et al. **Stomatologiia (Mosk)** 1996;75(1):44 **(Rus)**

ANALOGS & DERIVATIVES

Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates. Tobias JD, et al. **Can J Anaesth** 1996 Jan;43(1):69–72

Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Zhang JG, et al. **Hum Exp Toxicol** 1996 Jan;15(1):59–63

Anaesthetic management of the child with myotonic dystrophy: epidural anaesthesia as an alternative to general anaesthesia. Tobias JD. **Paediatr Anaesth** 1995;5(5):335–8

Topical ophthalmic anaesthesia for severe facial pain due to recurrent head and neck carcinoma [letter] Blackwell N, et al. **Palliat Med** 1995 Jul;9(3):255–6

BLOOD

Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. Harkins JD, et al. **Equine Vet J** 1996 Mar;28(2):121–5

CHEMISTRY

Use of the derivatizing agent 4-aminobenzoic acid 2-(diethylamino)ethyl ester for high-sensitivity detection of oligosaccharides by electrospray ionization mass spectrometry. Yoshino K, et al. **Anal Chem** 1995 Nov 1; 67(21):4028–31

PHARMACOKINETICS

Research on soft-tissue expander permeability to metronidazole and procaine. Zhan W, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1416–9

Phonophoretic permeation of procaine hydrochloride through an MDCK cell monolayer Hehn B, et al. **Pharmazie** 1996 May;51(5):341–5 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Ketter TA, et al. **Arch Gen Psychiatry** 1996 Jan;53(1):59–69

Determination of highest no effect dose (HNED) for local anaesthetic responses to procaine, cocaine, bupivacaine and benzocaine. Harkins JD, et al. **Equine Vet J** 1996 Jan; 28(1):30–7

Comparison of the reinforcing efficacy of cocaine and procaine in rhesus monkeys responding under a progressive-ratio schedule. Woolverton WL. **Psychopharmacology (Berl)** 1995 Aug;120(3):296–302

[The effect of inhibitors of sodium permeability (novocaine and tetrodotoxin) on the trace depolarization of myelinated nerve fibers] Katalymov LL. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):127–33 (Eng. Abstr.) **(Rus)**

[The reflex and direct actions of novocaine on the rhythm of the heart beats in rats in early postnatal ontogeny] Kulaev BS, et al. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb; 31(1):38–43 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Procaine is effective for minimizing postischemic ventricular fibrillation in cardiac surgery. Sellevold OF, et al. **Anesth Analg** 1995 Nov;81(5):932–8

URINE

Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. Harkins JD, et al. **Equine Vet J** 1996 Mar;28(2):121–5

PROCAINE AMIDE see **PROCAINAMIDE**

PROCARBAZINE

ADVERSE EFFECTS

Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy. Cespedes RD, et al. **Urology** 1995 Nov; 46(5):688–91

PHARMACOLOGY

Further studies on the ex-vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide-sensitive amine oxidase and monoamine oxidase activities. Holt A, et al. **J Pharm Pharmacol** 1995 Oct;47(10):837–45

TOXICITY

[Protection from procarbazine induced testicular toxicity by gonadal steroid hormones] Ye W, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):204–9 (Eng. Abstr.) **(Chi)**

PROCATEROL

ADMINISTRATION & DOSAGE

Effect of paper spacer (spader) in conjunction with procaterol metered dose inhaler in the treatment of acute asthma. Charoenratanakul S, et al. **J Med Assoc Thai** 1996 Mar;79(3):149–53

PHARMACOLOGY

A beta 2-agonist, procaterol, inhibits basophil migration. Yamaguchi M, et al. **J Asthma** 1995;32(2):125–30

[Effects of a beta 2-agonist, sodium cromoglycate, and an anticholinergic agent on hyperventilation-induced bronchoconstriction in sensitized rabbits] Suguro H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):856–61 (Eng. Abstr.) **(Jpn)**

PROCESS ASSESSMENT (HEALTH CARE)

Process for preventing or identifying and resolving problems in drug therapy. Robertson KE. **Am J Health Syst Pharm** 1996 Mar 15;53(6):639–50

The management of febrile seizures in the Mersey Region. Sweeney A, et al. **Dev Med Child Neurol** 1996 Jul; 38(7):578–84

Assessment methods for rehabilitation. Biefang S, et al. **Int J Rehabil Res** 1995 Sep;18(3):201–13 (47 ref.)

Do the national performance tables really indicate the performance of accident and emergency departments? Edhouse JA, et al. **J Accid Emerg Med** 1996 Mar; 13(2):123–6

Busy doing nothing: activity and interaction levels amongst differing populations of elderly patients. Nolan M, et al. **J Adv Nurs** 1995 Sep;22(3):528–38

Survey of career satisfaction with the quality of care delivered to in-patients suffering from dementia. Simpson RG, et al. **J Adv Nurs** 1995 Sep;22(3):517–27

Process analysis improves quality and volume of nutrition screenings. Brown DM. **J Am Diet Assoc** 1996 Apr; 96(4):381–3

Processes of care. Comparisons of certified nurse-midwives and obstetricians. Oakley D, et al. **J Nurse Midwifery** 1995 Sep–Oct;40(5):399–409

Toward optimal laboratory use. Problems in laboratory testing in primary care [see comments] Nutting PA, et al. **JAMA** 1996 Feb 28;275(8):635–9. Comment in: JAMA 1996 Jul 17;276(3):197.

Confusion of levels in monitoring outcomes and/or process. Long AF, et al. **Lancet** 1996 Jun 8;347(9015):1572

Validity and reliability of an oncology critical care patient acuity tool. Marsee VD, et al. **Oncol Nurs Forum** 1995 Jul;22(6):967–71

ORGANIZATION & ADMINISTRATION

Variability in clinical systems: applying modern quality control methods to health care. Banks NJ, et al. **Jt Comm J Qual Improv** 1995 Aug;21(8):407–19

PROCETOFEN

ADMINISTRATION & DOSAGE

[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias] Vaverková H, et al. **Vnitr Lek** 1996 Apr; 42(4):239–45 (Eng. Abstr.) **(Cze)**

[The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels] Perova NV, et al. **Ter Arkh** 1996;68(1):71–6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol. Murphy MJ, et al. **Postgrad Med J** 1995 Aug;71(838):498–500

PHARMACOLOGY

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Guérin M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):763–72

Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Arnaiz SL, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):175–80

Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Berthou L, et al. **Eur J Biochem** 1995 Aug 15;232(1):179–87

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. Berthou L, et al. **J Clin Invest** 1996 Jun 1; 97(11):2408–16

THERAPEUTIC USE

Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Collinson PO, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):159–61

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. Steinmetz A, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):563–70

Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients [letter] de Lorgeril M, et al. **J Heart Lung Transplant** 1996 May;15(5):539–40

[Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul;106(1):41–50 (Eng. Abstr.) **(Jpn)**

[Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):51–60 (Eng. Abstr.) **(Jpn)**

[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al. **Rev Clin Esp** 1995 Dec;195(12):817–9 (46 ref.) **(Spa)**

PROCHLORPERAZINE

ADVERSE EFFECTS

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)

PHARMACOKINETICS

The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Webb MS, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):147–55

PHARMACOLOGY

Metoclopramide and prochlorperazine do not decrease propofol hypnotic requirements. Ali PB, et al. **Anaesthesia** 1995 Nov;50(11):990–1

THERAPEUTIC USE

Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Jones J, et al. **Am J Emerg Med** 1996 May; 14(3):262–4

Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache [see comments] Coppola M, et al. **Ann Emerg Med** 1995 Nov;26(5):541–6 . Comment in: Ann Emerg Med 1996 Apr;27(4):529–30.

Prochlorperazine or metoclopramide? [letter; comment] Ducharme J, et al. **Ann Emerg Med** 1996 Apr;27(4):529–30 . Comment on: Ann Emerg Med 1995 Nov;26(5):541–6.

Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Gilbert CJ, et al. **Cancer** 1995 Dec 1;76(11):2330–7

Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Light RW, et al. **Chest** 1996 Apr; 109(4):975–81

PROCOLLAGEN

ANALYSIS

Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Sharif M, et al. **Ann Rheum Dis** 1996 Jan;55(1):47–51

Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis. Milman N, et al. **APMIS** 1995 Oct;103(10):749–54

Immuno–electron–microscopic localization of types III pN–collagen and IV collagen, laminin and tenascin in developing and adult human spleen. Liakka A, et al. **Cell Tissue Res** 1995 Oct;282(1):117–27

Aminoterminal propeptide of type III procollagen: a marker of hepatic fibrosis after bile duct obstruction in the monkey. Ruf G, et al. **Hepatogastroenterology** 1996 Jan–Feb; 43(7):121–6

Maturation of collagen fibrils in the corneal stroma results in masking of tyrosine–rich region of type V procollagen. Peter□ DM, et al. **Invest Ophthalmol Vis Sci** 1996 Sep; 37(10):2047–59

Intracellular interaction of collagen–specific stress protein HSP47 with newly synthesized procollagen. Satoh M, et al. **J Cell Biol** 1996 Apr;133(2):469–83

Procollagen–I and collagen–I in the serum and dialysate of CAPD patients: changes over time. Digenis GE, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):371–4

[Collagen, procollagen peptide] Mizuta T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:182–5 (16 ref.) **(Jpn)**

BIOSYNTHESIS

Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Kauppila S, et al. **Am J Pathol** 1996 Feb;148(2):539–48

Creation of a system for the assembly and expression of DNA constructs encoding novel recombinant human procollagen II. Arnold WV, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:204–5

Characterization of recombinant human collagen II with Arg519–to–Cys substitution. Fertala A, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:251–3

A 47–bp sequence of the first intron of the mouse pro alpha 1(II) collagen gene is sufficient to direct chondrocyte Expression. Lefebvre V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:284–7

The c–propeptide of type II procollagen binds to the enhancer region of the type II procollagen gene and regulates its transcription. Nakata K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:307–8

Localization of type IIA procollagen during chondrogenesis. Oganesian A, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:311–3

mRNA encoding a novel growth regulatory factor is coexpressed with type II procollagen during chondrogenesis. Sandell LJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:325–7

Separable regulatory elements from pro–alpha 2 (XI) collagen gene drive distinct patterns of cartilage–specific expression in transgenic mice. Tsumaki N, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:340–2

Antisense oligonucleotide inhibits the expression of procollagen type III gene in mouse fibroblasts. Kitamura Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):849–54

Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4–hydroxy–2,3–nonenal and other 4–hydroxy–2,3–alkenals is related to their molecular structure. Parola M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):261–4

Type I procollagen production and cell proliferation is mediated by transforming growth factor–beta in a model of hepatic fibrosis. Eghbali–Fatourechi G, et al. **Endocrinology** 1996 May;137(5):1894–903

Reverse transcription–polymerase chain reaction detection of collagen transcripts in healing human wounds. Hopkinson I, et al. **Eur J Clin Invest** 1995 Jul;25(7):539–42

Changes in collagen metabolism in response to endothelin–1: evidence for fibroblast heterogeneity. Dawes KE, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):229–38

The transcriptional activity of the CCAAT–binding factor CBF is mediated by two distinct activation domains, one in the CBF–B subunit and the other in the CBF–C subunit. Coustry F, et al. **J Biol Chem** 1996 Jun 14;271(24):14485–91

Characterization of human type III collagen expressed in a baculovirus system. Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4–hydroxylase subunit. Lamberg A, et al. **J Biol Chem** 1996 May 17;271(20):11988–95

Stimulation of alpha 1 (I) procollagen gene expression in NIH–3T3 cells by the human T cell leukemia virus type 1 (HTLV–1) Tax gene. Muñoz E, et al. **J Clin Invest** 1995 Nov;96(5):2413–20

Upregulation of collagen type I gene expression in the ventricular myocardium of thyroidectomized male and female rats. Klein LE, et al. **J Mol Cell Cardiol** 1996 Jan; 28(1):33–42

Platelet–derived growth factor is a cofactor in the induction of 1 alpha(I) procollagen expression by transforming growth factor–beta 1 in smooth muscle cells. Halloran BG, et al. **J Vasc Surg** 1996 May;23(5):767–73; discussion 774

Identification of a minimal sequence of the mouse pro–alpha 1(I) collagen promoter that confers high–level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Rossert JA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1027–31

BLOOD

Serum concentrations of procollagen type III aminoterminal peptide in growing dogs with hip dysplasia. Madsen JS, et al. **Acta Vet Scand** 1995;36(1):157–60

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Díez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D–17D (36 ref.)

The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Høst NB, et al. **Am J Cardiol** 1995 Nov 1;76(12):869–73

Evaluation of procollagen–III peptide as a marker for veno–occlusive disease after bone marrow transplantation. Schuler U, et al. **Ann Hematol** 1996 Jul;73(1):25–8

Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy–and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Tähtelä R, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2289–93

Evidence for McKusick's hypothesis of deficient collagen cross–linking in patients with homocystinuria. Lubec B, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):159–62

Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Kubo T, et al. **Bone** 1995 Oct;17(4):397–401

Changes in the carboxyl–terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. Pedersen BJ, et al. **Bone** 1995 Jul; 17(1):91–5

Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate–treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Oogarah PK, et al. **Br J Dermatol** 1995 Oct;133(4):512–8

The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate–induced hepatic damage in psoriasis patients. vanDooren–Greebe RJ, et al. **Br J Dermatol** 1996 Mar;134(3):481–7

Biochemical bone markers compared with bone density measurement by dual energy X–ray absorptiometry. Lotz J, et al. **Calcif Tissue Int** 1995 Oct;57(4):253–7

Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Díez J, et al. **Circulation** 1996 Mar 1;93(5):1026–32

Diagnostic accuracy of hyaluronan and type III procollagen amino–terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Guéchot J, et al. **Clin Chem** 1996 Apr;42(4):558–63

Immunoassay for intact amino–terminal propeptide of human type I procollagen. Melkko J, et al. **Clin Chem** 1996 Jun; 42(6 Pt 1):947–54

Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone [letter] Sharp CA, et al. **Clin Chem** 1996 Jul;42(7):1121–2

Comparison between serum levels of bone alkaline phosphatase and the carboxy–terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. Withold W, et al. **Clin Chim Acta** 1995 Aug 14;239(2):143–51

Type III procollagen N–peptide correlates with beta–2–microglobulin in myelomatosis. Hasselbalch HC, et al. **Clin Lab Haematol** 1995 Sep;17(3):237–41

Ginseng therapy in non–insulin–dependent diabetic patients. Sotaniemi EA, et al. **Diabetes Care** 1995 Oct;18(10):1373–5

Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours. Comparison with the results of 99mTc–methylene bisphosphonate bone scintigraphy. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):479–85

Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):193–7

Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Diot E, et al. **Eur Respir J** 1995 Sep;8(9):1559–65

Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer? Perachino M, et al. **Eur Urol** 1996;29(3):366–9

Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Kjeldsen J, et al. **Gut** 1995 Dec;37(6):805–10

Increased degradation of type I collagen in patients with inflammatory bowel disease. Silvennoinen J, et al. **Gut** 1996 Feb;38(2):223–8

Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Ishibashi K, et al. **Hepatology** 1996 Jul;24(1):27–31

Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. Santi I, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):107–12

Carboxy–terminal propeptide of human type I collagen and pyridinium cross–links as markers of bone growth in infants 1 to 18 months of age. Lieuw–A–Fa M, et al. **J Bone Miner Res** 1995 Jun;10(6):849–53

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. Conti A, et al. **J Endocrinol Invest** 1996 Feb;19(2):127–30

Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross–linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):157–63

Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone. Joffe P, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1912–7

Changes in serum type I and III procollagen levels in children with chronic renal failure. Cinaz P, et al. **Nephron** 1996; 72(2):189–91

Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Pedersen BJ, et al. **Osteoporos Int** 1995;5(6):472–7

Serum amino–terminal propeptide of type III procollagen levels in chronic pancreatitis. Navarro S, et al. **Pancreas** 1996 Mar;12(2):153–8

Prognostic value of serum hyaluronic acid and type I and III procollagen propeptides in extrahepatic biliary atresia. Trivedi P, et al. **Pediatr Res** 1995 Oct;38(4):568–73

Procollagen–I and collagen–I in the serum and dialysate of CAPD patients: changes over time. Digenis GE, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):371–4

Serum procollagen type I carboxyterminal propeptide in CAPD and hemodialysis patients. Gerakis A, et al. **Perit Dial Int** 1996;16 Suppl 1:S309–11

Aminopropeptide of human procollagen type I: a marker for the identification of blood from children in the mosquito blood meal. Bødker R, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):449–53

[Detection of serum procollagen III peptide in tuberculous patients] Yi S, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):215–7, 254–5 (Eng. Abstr.) **(Chi)**

[Procollagen III and laminin in chronic viral hepatopathies] Montalto G, et al. **Presse Med** 1996 Jan 20;25(2):59–62 (Eng. Abstr.) **(Fre)**

[Effect of GH/IGF–I deficiency on bone and collagen turnover in children and adults with GH deficiency] Sartorio A, et al. **Minerva Endocrinol** 1995 Jun;20(2):135–40 (Eng. Abstr.) **(Ita)**

[Procollagen type I C–propeptide in kidney transplant recipients] Vaccaro F, et al. **Minerva Med** 1996 Jun; 87(6):269–73 (Eng. Abstr.) **(Ita)**

CHEMISTRY

Biosynthesis of recombinant human pro–alpha 1(III) chains in a baculovirus expression system: production of disulphide–bonded and non–disulphide–bonded species containing full–length triple helices. Tomita M, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):847–53

Regulation of extracellular matrix deposition by the C–propeptide domain of fibrillar collagens. Davies D, et al. **Biochem Soc Trans** 1995 Nov;23(4):516S

Endoplasmic reticulum protein Hsp47 binds specifically to the N–terminal globular domain of the amino–propeptide of the procollagen I alpha 1 (I)–chain. Hu G, et al. **J Cell Biochem** 1995 Nov;59(3):350–67

DRUG EFFECTS

Glucocorticoids inhibit the synthesis rate of type III collagen, but do not affect the hepatic clearance of its aminoterminal propeptide (PIIINP). Hansen M, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):543–8

GENETICS

A 47–bp sequence of the first intron of the mouse pro alpha 1(II) collagen gene is sufficient to direct chondrocyte Expression. Lefebvre V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:284–7

The c–propeptide of type II procollagen binds to the enhancer region of the type II procollagen gene and regulates its transcription. Nakata K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:307–8

Separable regulatory elements from pro–alpha 2 (XI) collagen gene drive distinct patterns of cartilage–specific expression in transgenic mice. Tsumaki N, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:340–2

Stickler syndrome. A mutation in the nonhelical 3' end of type II procollagen gene. Ahmad NN, et al. **Arch Ophthalmol** 1995 Nov;113(11):1454–7

Transcriptional activation of the alpha 1(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Hitraya EG, et al. **Arthritis Rheum** 1996 Aug; 39(8):1347–54

Substitutions of aspartic acid for glycine–220 and of arginine for glycine–664 in the triple helix of the pro alpha 1(I) chain of type I procollagen produce lethal osteogenesis imperfecta and disrupt the ability of collagen fibrils to incorporate crystalline hydroxyapatite. Culbert AA, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):815–20

Differential regulation of transcription and transcript stability of pro–alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic

scleroderma. Eckes B, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):549–54

Biosynthesis of recombinant human pro-alpha 1(III) chains in a baculovirus expression system: production of disulphide-bonded and non-disulphide-bonded species containing full-length triple helices. Tomita M, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):847–53

Differential effects of tumor necrosis factor-alpha on the expression of fibronectin and collagen genes in cultured bovine endothelial cells. Yao J, et al. **Cell Mol Biol Res** 1995;41(1):17–28

Gly802Asp substitution in the pro alpha 2(I) collagen chain in a family with recurrent osteogenesis imperfecta due to paternal mosaicism. Lund AM, et al. **Eur J Hum Genet** 1996;4(1):39–45

Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Gurujeyalakshmi G, et al. **Exp Lung Res** 1995 Sep-Oct;21(5):791–808

Distribution of ApoBII, MCT118 (D1S80), YNZ22 (D17S30), and COL2A1 Amp-FLPs (amplified fragment length polymorphisms) in Caucasoid population of Slovakia. Kádasi L, et al. **Gene Geogr** 1994 Aug;8(2):121–7

The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Sakaida I, et al. **Hepatology** 1996 Apr;23(4):755–63

Deletion of a Gly-Pro-Pro repeat in the pro alpha2(I) chain of procollagen I in a family with dominant osteogenesis imperfecta type IV. Lund AM, et al. **Hum Genet** 1996 Mar; 97(3):287–90

Mutation in the carboxy-terminal propeptide of the Pro alpha 1(I) chain of type I collagen in a child with severe osteogenesis imperfecta (OI type III): possible implications for protein folding. Oliver JE, et al. **Hum Mutat** 1996; 7(4):318–26

Aberrant splicing of the type III procollagen mRNA leads to intracellular degradation of the protein in a patient with Ehlers-Danlos type IV. Thakker-Varia S, et al. **Hum Mutat** 1995;6(2):116–25

Direct sequencing of PCR products derived from cDNAs for the pro alpha 1 and pro alpha 2 chains of type I procollagen as a screening method to detect mutations in patients with osteogenesis imperfecta. Zhuang J, et al. **Hum Mutat** 1996;7(2):89–99

The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit. Coustry F, et al. **J Biol Chem** 1996 Jun 14;271(24):14485–91

Extensive alternative splicing within the amino-propeptide coding domain of alpha2(XI) procollagen mRNAs. Expression of transcripts encoding truncated pro-alpha chains. Lui VCH, et al. **J Biol Chem** 1996 Jul 12; 271(28):16945–51

Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. Mukhopadhyay K, et al. **J Biol Chem** 1995 Nov 17;270(46):27711–9

Bone fragility in transgenic mice expressing a mutated gene for type I procollagen (COL1A1) parallels the age-dependent phenotype of human osteogenesis imperfecta. Pereira RF, et al. **J Bone Miner Res** 1995 Dec; 10(12):1837–43

Glucocorticoids coordinately regulate type I collagen pro alpha 1 promoter activity through both the glucocorticoid and transforming growth factor beta response elements: a novel mechanism of glucocorticoid regulation of eukaryotic genes. Meisler N, et al. **J Cell Biochem** 1995 Nov;59(3):376–88

A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice. Bou-Gharios G, et al. **J Cell Biol** 1996 Sep;134(5):1333–44

New prolyl 4-hydroxylase inhibitor reduces procollagen gene expression and enzyme-altered lesions in rat liver cirrhosis. Sakaida I, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S63–4

Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen. Cole WG, et al. **J Med Genet** 1996 Mar;33(3):193–6

Procollagen gene expression is down-regulated by taurine and niacin at the transcriptional level in the bleomycin hamster model of lung fibrosis. Gurujeyalakshmi G, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1152–7

Similarities of in situ mRNA expression between gelatinase A (MMP-2) and type I procollagen in human gastrointestinal carcinoma: comparison with granulation tissue reaction. Ohtani H, et al. **Jpn J Cancer Res** 1995 Sep;86(9):833–9

The complete cDNA coding sequence for the mouse pro alpha 1(I) chain of type I procollagen. Li SW, et al. **Matrix Biol** 1995 Jul;14(7):593–5

Evidence for three major transcription activation elements in the proximal mouse proalpha2(I) collagen promoter. Hasegawa T, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3253–60

Identification of a minimal sequence of the mouse pro-alpha 1(I) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Rossert JA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1027–31

Reduced levels of alpha1(XI) procollagen mRNA in SV40-transformed cells. Sompayrac L, et al. **Virology** 1996 Apr 15;218(2):412–6

[Skin expansion and skin growth. Molecular proof of collagen synthesis in long-term skin expansion] Preyer S. **HNO** 1996 Mar;44(3):117 **(Ger)**

[Identification of procollagen mRNA in chronic active hepatitis B] Gillessen A, et al. **Z Gastroenterol** 1993 Feb; 31 Suppl 2:28–9 (Eng. Abstr.) **(Ger)**

METABOLISM

Collagen propeptides as indicators of collagen assembly. Risteli J, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:183–8 (18 ref.)

Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication of transforming growth factor-beta as a mediator of fibrosis. Mariani TJ, et al. **Am J Pathol** 1996 Jan; 148(1):151–64

Type-III procollagen assembly in semi-intact cells: chain association, nucleation and triple-helix folding do not require formation of inter-chain disulphide bonds but triple-helix nucleation does require hydroxylation. Bulleid NJ, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):195–202

Regulation of extracellular matrix deposition by the C-propeptide domain of fibrillar collagens. Davies D, et al. **Biochem Soc Trans** 1995 Nov;23(4):516S

Age related changes in biochemical markers of bone metabolism in horses. Price JS, et al. **Equine Vet J** 1995 May;27(3):201–7

Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells. Graham MF, et al. **Gastroenterology** 1995 Nov; 109(5):1454–61

Aberrant splicing of the type III procollagen mRNA leads to intracellular degradation of the protein in a patient with Ehlers-Danlos type IV. Thakker-Varia S, et al. **Hum Mutat** 1995;6(2):116–25

Collagen metabolism in obesity: the effect of weight loss. Rasmussen MH, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):659–63

Triple helix formation of procollagen type I can occur at the rough endoplasmic reticulum membrane. Beck K, et al. **J Biol Chem** 1996 Aug 30;271(35):21566–73

Assembly in vitro of thin and thick fibrils of collagen II from recombinant procollagen II. The monomers in the tips of thick fibrils have the opposite orientation from monomers in the growing tips of collagen I fibrils. Fertala A, et al. **J Biol Chem** 1996 Jun 21;271(25):14864–9

Endoplasmic reticulum protein Hsp47 binds specifically to the N-terminal globular domain of the amino-propeptide of the procollagen I alpha 1 (I)-chain. Hu G, et al. **J Cell Biochem** 1995 Nov;59(3):350–67

Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. Bruckner-Tuderman L, et al. **J Cell Biol** 1995 Oct;131(2):551–9

Ultrastructural localization of the C-propeptide released from type II procollagen in fetal bovine growth plate cartilage. Lee ER, et al. **J Histochem Cytochem** 1996 May; 44(5):433–43

Prolyl hydroxylation regulates intracellular procollagen degradation in cultured rat cardiac fibroblasts. Eleftheriades EG, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1459–73

Evidence for proteolytic processing of a cuticle collagen in a plant-parasitic nematode. Ray C, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):243–6

The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Li SW, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5127–30

BMP-1: resurrection as procollagen C-proteinase [comment] Reddi AH. **Science** 1996 Jan 26;271(5248):463. Comment on: Science 1996 Jan 19;271(5247):360–2.

[Determination of procollagen III levels in serum and broncho-alveolar lavage fluid in patients with interstitial lung disease and its clinical significance] Chen B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May;34(5):312–4 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23 ref.)

PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE

BIOSYNTHESIS

Transforming growth factor beta 1 influences lysyl hydroxylation of collagen I and reduces steady-state levels of lysyl hydroxylase mRNA in human osteoblast-like cells. Seitzer U, et al. **Eur J Clin Invest** 1995 Dec;25(12):959–66

GENETICS

Rat lysyl hydroxylase: molecular cloning, mRNA distribution and expression in a baculovirus system. Armstrong LC, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):93–102

METABOLISM

Site-directed mutagenesis of human lysyl hydroxylase expressed in insect cells. Identification of histidine residues and an aspartic acid residue critical for catalytic activity. Pirskanen A, et al. **J Biol Chem** 1996 Apr 19; 271(16):9398–402

The expression of a functional, secreted human lysyl hydroxylase in a baculovirus system. Krol BJ, et al. **J Invest Dermatol** 1996 Jan;106(1):11–6

SECRETION

The expression of a functional, secreted human lysyl hydroxylase in a baculovirus system. Krol BJ, et al. **J Invest Dermatol** 1996 Jan;106(1):11–6

PROCOLLAGEN-PROLINE DIOXYGENASE

ANTAGONISTS & INHIBITORS

The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Sakaida I, et al. **Hepatology** 1996 Apr;23(4):755–63

New prolyl 4-hydroxylase inhibitor reduces procollagen gene expression and enzyme-altered lesions in rat liver cirrhosis. Sakaida I, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S63–4

BIOSYNTHESIS

Characterization of human type III collagen expressed in a baculovirus system. Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4-hydroxylase subunit. Lamberg A, et al. **J Biol Chem** 1996 May 17;271(20):11988–95

BLOOD

[Prolyl hydroxylase] Yamada S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:383–5 (11 ref.) **(Jpn)**

CHEMISTRY

ERp60 does not substitute for protein disulphide isomerase as the beta-subunit of prolyl 4-hydroxylase. Koivunen P, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):599–605

Co-expression of the alpha subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes. Soluble alpha-subunit-BiP complexes have no prolyl 4-hydroxylase activity. Veijola J, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):613–8

GENETICS

Co-expression of the alpha subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes. Soluble alpha-subunit-BiP complexes have no prolyl 4-hydroxylase activity. Veijola J, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):613–8

ISOLATION & PURIFICATION

Purification and initial characterization of proline 4-hydroxylase from Streptomyces griseoviridus P8648: a 2-oxoacid, ferrous-dependent dioxygenase involved in etamycin biosynthesis. Lawrence CC, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):185–91

METABOLISM

Intracellular dissociation and reassembly of prolyl 4-hydroxylase:the alpha-subunits associated with the immunoglobulin-heavy-chain binding protein (BiP) allowing reassembly with the beta-subunit. John DC, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):659–65

Purification and initial characterization of proline 4-hydroxylase from Streptomyces griseoviridus P8648: a 2-oxoacid, ferrous-dependent dioxygenase involved in etamycin biosynthesis. Lawrence CC, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):185–91

Baculovirus expression of two protein disulphide isomerase isoforms from Caenorhabditis elegans and characterization of prolyl 4-hydroxylases containing one of these polypeptides as their beta subunit. Veijola J, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):721–9

Age-related alteration of proline hydroxylase and collagen-binding heat shock protein (HSP47) expression in human fibroblasts. Miyaishi O, et al. **Mech Ageing Dev** 1995 Nov 3;85(1):25–36

PROCOLOBUS see **COLOBUS**

PROCONVERTIN see **FACTOR VII**

PROCTITIS

CHEMICALLY INDUCED

Glutaraldehyde proctitis. Babb RR, et al. **West J Med** 1995 Nov;163(5):477–8

COMPLICATIONS

[Proctology and human immunodeficiency virus] Puy-Montbrun T. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B145–9 **(Fre)**

DIAGNOSIS

Radiation proctitis: a review. Babb RR. **Am J Gastroenterol** 1996 Jul;91(7):1309–11 (31 ref.)

Necrotizing fasciitis: two cases in a single family. Gilliland R, et al. **Ulster Med J** 1996 May;65(1):89–90

[Case for diagnosis. Streptococcus group A proctitis] Grosieux C, et al. **Ann Dermatol Venereol** 1995; 122(6–7):441–2 **(Fre)**

[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110–4 (20 ref.) **(Ger)**

DRUG THERAPY

Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. al-Sabbagh R, et al. **Am J Gastroenterol** 1996 Sep;91(9):1814–6

Formalin instillation for refractory radiation-induced hemorrhagic proctitis. Report of 16 patients. Saclarides TJ, et al. **Dis Colon Rectum** 1996 Feb;39(2):196–9

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Biswal BM, et al. **Radiother Oncol** 1995 Jun;35(3):212–5

ETIOLOGY

[Treatment of rectal hemorrhage secondary to radiation proctitis] Fayemendy L, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):65–7 **(Fre)**

MICROBIOLOGY

[Perianal infection caused by group A beta-hemolytic Streptococcus on children] Putto-Laurila A, et al. **Duodecim** 1995;111(4):361–4 **(Fin)**

PHYSIOPATHOLOGY

Influence of bradykinin in gastrointestinal disorders and visceral pain induced by acute or chronic inflammation in rats. Julia V, et al. **Dig Dis Sci** 1995 Sep;40(9):1913–21

SURGERY

Perineal excision of the rectum. Poppen B, et al. **Br J Surg** 1996 Mar;83(3):366–7

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222–8 (28 ref.) (Eng. Abstr.) **(Ger)**

[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martín S, et al. **Rev Med Chil** 1995 Mar;123(3):321–5 (15 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Imaging of peri-anal and perirectal abscesses and fistulae using endoluminal ultrasound diagnosis] Graf D, et al. **Swiss Surg** 1995;(6):294–7; discussion 297 (Eng. Abstr.) **(Ger)**

PROCTOCOLECTOMY, RESTORATIVE

Restorative proctocolectomy: morphological and functional study with coronal CT. Pizzamiglio M, et al. **Abdom Imaging** 1996 May–Jun;21(3):261–5

The results and failures of creating a pelvic reservoir in oncology (surgery, urology). Baradnay G, et al. **Acta Chir Hung** 1995–96;35(1–2):119–27

Greater risk of incisional hernia with morbidly obese than steroid-dependent patients and low recurrence with prefascial polypropylene mesh. Sugerman HJ, et al. **Am J Surg** 1996 Jan;171(1):80–4

Functional outcome of the double stapled ileoanal reservoir in patients more than 60 years of age. Reissman P, et al. **Am Surg** 1996 Mar;62(3):178–83

Long-term results after colectomy and ileoanal pull-through procedure in children. Fonkalsrud EW. **Arch Surg** 1996 Aug;131(8):881–5; discussion 885–6

Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Hurst RD, et al. **Arch Surg** 1996 May; 131(5):497–500; discussion 501–2

High dose loperamide suppositories: a novel approach for improving clinical function after restorative proctocolectomy. Levitt MD, et al. **Aust N Z J Surg** 1995 Dec;65(12):881–3

Total colectomy and "J" pouch ileo-anal pull through without temporary diverting ileostomy in the management of ulcerative colitis. Ortiz VN, et al. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):46–8

Effect of terminal ileal transposition on intestinal absorption following proctocolectomy. Hotokezaka M, et al. **Br J Surg** 1996 Apr;83(4):486–92

Substance P—an underlying factor for pouchitis? Prospective study of substance P- and vasoactive intestinal polypeptide-immunoreactive innervation and mast cells. Keränen U, et al. **Dig Dis Sci** 1996 Aug;41(8):1665–71

Substance P- and vasoactive intestinal polypeptide-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Keränen U, et al. **Dig Dis Sci** 1996 Aug; 41(8):1658–64

Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis: report of a case. Church JM, et al. **Dis Colon Rectum** 1996 May;39(5):584–6

Conversion of the failing ileoanal pouch to reservoir-ileostomy rather than to ileostomy alone. Ecker KW, et al. **Dis Colon Rectum** 1996 Sep;39(9):977–80

Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Sagar PM, et al. **Dis Colon Rectum** 1996 Aug;39(8):893–8

Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Ståhlberg D, et al. **Dis Colon Rectum** 1996 Sep;39(9):1012–8

Effect of systemic steroids on ileal pouch-anal anastomosis in patients with ulcerative colitis. Ziv Y, et al. **Dis Colon Rectum** 1996 May;39(5):504–8

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1154–9 (45 ref.)

Restorative compared with conventional proctocolectomy for the treatment of ulcerative colitis. Mikkola K, et al. **Eur J Surg** 1996 Apr;162(4):315–9

Ileal pouch-anal anastomosis for ulcerative colitis and polyposis coli: is the risk of carcinoma formation conclusively averted? Giebel GD, et al. **Eur J Surg Oncol** 1996 Aug;22(4):372–6

Pouchitis and neoplasia in the pelvic ileal reservoir [editorial] Shepherd NA. **Gastroenterology** 1995 Oct;109(4):1381–3

Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. Veress B, et al. **Gastroenterology** 1995 Oct;109(4):1090–7

Breath hydrogen analysis in patients with ileoanal pouch anastomosis. Bruun E, et al. **Gut** 1995 Aug;37(2):256–9

Leucocyte typing, cytokine expression, and epithelial turnover in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Goldberg PA, et al. **Gut** 1996 Apr;38(4):549–53

The perfect pelvic pouch—what makes the difference? Lewis WG, et al. **Gut** 1995 Oct;37(4):552–6

Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Merrett MN, et al. **Gut** 1996 Mar;38(3):362–4

Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation. Rowley S, et al. **Gut** 1995 Dec;37(6):845–7

Outcome of restorative proctocolectomy with ileal reservoir for ulcerative colitis: comparison of distal colitis with more proximal disease. Samarasekera DN, et al. **Gut** 1996 Apr; 38(4):574–7

Stapled ileal pouch-anal anastomosis with resection of the anal transition zone [see comments] Braun J, et al. **Int J Colorectal Dis** 1995;10(3):142–7. Comment in: Int J Colorectal Dis 1995;10(4):234.

A case of pneumatosis coli managed by restorative proctectomy and ileal pouch-anal anastomosis. Woodward A, et al. **Int J Colorectal Dis** 1995;10(3):181–2

Urinary immunoglobulins in patients with continent urinary reservoirs and ileal conduits. Terai A, et al. **Int J Urol** 1995 Jul;2(3):166–71

Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. Aitola P, et al. **J Clin Pathol** 1995 Jul;48(7):645–7

Total colectomy and ileorectal anastomosis in ulcerative colitis. Saito Y, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:131–4

Ileoanal anastomosis and ileoanal canal anastomosis in Japan: comparative retrospective study. Utsunomiya J, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:128–30

Restorative proctocolectomy for ulcerative colitis in children—is the J-pouch better than straight pull-through? Rintala RJ, et al. **J Pediatr Surg** 1996 Apr;31(4):530–3

Restorative proctocolectomy for Chagasic megacolon. MacSweeney ST, et al. **J R Soc Med** 1995 Aug;88(8):479P

Reconstruction and diversion [editorial; comment] Miller KS. **J Urol** 1996 May;155(5):1589–90. Comment on: J Urol 1996 May;155(5):1579–84. Comment on: J Urol 1996 May;155(5):1585–8. Comment on: J Urol 1996 May;155(5):1693–5.

Ileal pouch/anal anastomosis for Crohn's disease. Panis Y, et al. **Lancet** 1996 Mar 30;347(9005):854–7

Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Kartheuser AH, et al. **Mayo Clin Proc** 1996 Aug; 71(8):748–56

Intestinal intraluminal continuity is a prerequisite for the distal bowel motility response to feeding. Hallgren T, et al. **Scand J Gastroenterol** 1995 Jun;30(6):554–61

Clinical and physiological aspects of ileal pouch-anal anastomosis. Salemans JM, et al. **Scand J Gastroenterol Suppl** 1995;212:3–12 (98 ref.)

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov–Dec; 11(6):423–7 (27 ref.)

Kock pouch dysfunction during pregnancy. Management of a case. Curtis RD, et al. **Surg Endosc** 1996 Jul;10(7):755–7

Comparison of the functional results of ileorectostomy and ileal pouch-anal anastomosis following total colectomy. Nagy A. **Surg Today** 1996;26(5):377–80

Sacral nerve terminal motor latency after ileal J pouch-anal anastomosis for ulcerative colitis. Tomita R, et al. **Surg Today** 1995;25(11):946–9

Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Kartheuser AH, et al. **Surgery** 1996 Jun; 119(6):615–23

[Results of ileoanal reservoir surgery] Boné J, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2105–8 (Eng. Abstr.) **(Dan)**

[Ulcerative colitis—pouch or bag? (editorial)] Sørensen FH. **Ugeskr Laeger** 1996 Apr 8;158(15):2099 **(Dan)**

[Continent ileostomy following discontinuation of ileoanal anastomosis with ileum reservoir; good results in 7 patients] Kortmann BA, et al. **Ned Tijdschr Geneeskd** 1996 May 4; 140(18):984–7 (Eng. Abstr.) **(Dut)**

[Ileo-anal anastomosis in Crohn disease] Panis Y, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):77–8 **(Fre)**

[True and false local recurrence after continence resection for rectal carcinoma—the evaluation and the mesorectum] Stelzner F. **Chirurg** 1996 Jun;67(6):611–20 (Eng. Abstr.) **(Ger)**

[Restorative proctocolectomy for ulcerative colitis and familial polyposis] Sofer D, et al. **Harefuah** 1995 Sep; 129(5–6):176–9, 223 (Eng. Abstr.) **(Heb)**

[Restorative proctocolectomy. A morphological-functional study by computed tomography with coronal scans] Pavone P, et al. **Radiol Med (Torino)** 1995 Sep;90(3):244–9 (Eng. Abstr.) **(Ita)**

[The 3rd national workshop on defecography: the functional radiology of (neo) rectal ampullae (ileal reservoir, colo-anal anastomosis, continent perineal colostomy)] Piloni V, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):66–72 (34 ref.) (Eng. Abstr.) **(Ita)**

[Experience with incontinent urinary diversion—review of 31 ureterocutaneostomies, 101 ileal conduits and 107 colonic conduits] Hoshinaga K, et al. **Hinyokika Kiyo** 1995 Nov;41(11):903–8 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Zins BJ, et al. **Am J Gastroenterol** 1995 Dec;90(12):2177–81

Pouch-anal cancer after restorative proctocolectomy for familial adenomatous polyposis. von Herbay A, et al. **Am J Surg Pathol** 1996 Aug;20(8):995–9

Effect of epidural analgesia on postoperative ileus after ileal pouch-anal anastomosis. Kanazi GE, et al. **Am Surg** 1996 Jun;62(6):499–502

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

Carcinoma in an ileoanal pouch after restorative proctocolectomy for familial adenomatous polyposis. Bassuini MM, et al. **Br J Surg** 1996 Apr;83(4):506

Salvage surgery for ileal pouch outlet obstruction. Herbst F, et al. **Br J Surg** 1996 Mar;83(3):368–71

Results from pouch salvage. Korsgen S, et al. **Br J Surg** 1996 Mar;83(3):372–4

Complications of the ileal pouch: is the pouchogram a useful predictor? Malcolm PN, et al. **Clin Radiol** 1995 Sep; 50(9):613–7

Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Aisenberg J, et al. **Dig Dis Sci** 1995 Sep;40(9):1866–72

Sexual function following restorative proctocolectomy in women. Bambrick M, et al. **Dis Colon Rectum** 1996 Jun; 39(6):610–4

Comparison of relative risks of urinary stone formation after surgery for ulcerative colitis: conventional ileostomy vs. J-pouch. A comparative study. Christie PM, et al. **Dis Colon Rectum** 1996 Jan;39(1):50–4

Paradoxical puborectalis contraction in patients after pelvic pouch construction. Hull TL, et al. **Dis Colon Rectum** 1995 Nov;38(11):1144–6

Simple radiographic evaluation of ileoanal pouch volume. Schmidt CM, et al. **Dis Colon Rectum** 1996 Jan;39(1):66–73

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Penna C, et al. **Gut** 1996 Feb;38(2):234–9

Nonsurgical management strategies for the functional complications of ileocolonic continent urinary reservoirs. Hartenbach EM, et al. **Gynecol Oncol** 1995 Dec; 59(3):358–63

Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Mannel RS, et al.

Gynecol Oncol 1995 Dec;59(3):376–8

Complications of the afferent antireflux valve mechanism in the Kock ileal reservoir [see comments] Stein JP, et al. **J Urol** 1996 May;155(5):1579–84. Comment in: J Urol 1996 May;155(5):1589–90.

[Current concept and problems of urinary diversion. 2. Selection of operation: reservoir] Kanimoto Y, et al. **Hinyokika Kiyo** 1995 Nov;41(11):909–14 (Eng. Abstr.) **(Jpn)**

[Postoperative complications of self-catheterizable continent urinary diversions (Kock, Indiana, and appendiceal Mainz pouch) and patient care] Okada Y, et al. **Hinyokika Kiyo** 1995 Nov;41(11):947–52 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Use of a suture holder facilitates transanal anastomosis. Hirata K, et al. **Dis Colon Rectum** 1996 Jun;39(6):700–1

The use of an ileostomy connector to diminish the frequency of defecation prior to ileostomy closure in patients with a pelvic pouch. Maeda K, et al. **Surg Today** 1995; 25(7):657–61

METHODS

Stapled ileal pouch anal anastomoses are safer than handsewn anastomoses in patients with ulcerative colitis. Ziv Y, et al. **Am J Surg** 1996 Mar;171(3):320–3

The single-stapled ileo pouch anal anastomosis: a reasonable compromise. Senagore AJ, et al. **Am Surg** 1996 Jul; 62(7):535–9

Pelvic pouch–anal anastomoses: pros and cons about omission of mucosectomy and loop ileostomy. A study of 60 patients. Gullberg K, et al. **Ann Chir** 1995;49(6):527–33

Randomized comparison of straight and colonic J pouch anastomosis after low anterior resection. Hallböök O, et al. **Ann Surg** 1996 Jul;224(1):58–65

Laser Doppler blood flow measurement in rectal resection for carcinoma--comparison between the straight and colonic J pouch reconstruction. Hallböök O, et al. **Br J Surg** 1996 Mar;83(3):389–92

Prospective randomized controlled study of clinical function and anorectal physiology after low anterior resection: comparison of straight and colonic J pouch anastomoses. Ho YH, et al. **Br J Surg** 1996 Jul;83(7):978–80

Adenomatous polyps in the anal transitional zone after ileal pouch–anal anastomosis for familial adenomatous polyposis: treatment by transanal mucosectomy and ileal pouch advancement. Malassagne B, et al. **Br J Surg** 1995 Dec;82(12):1634

Colonic pouches in the treatment of low rectal cancer. Seow-Choen F. **Br J Surg** 1996 Jul;83(7):881–2

Clinical and physiological evaluation of anorectal eversion during restorative proctocolectomy. Williamson ME, et al. **Br J Surg** 1995 Oct;82(10):1391–4

Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)

Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size. Hida J, et al. **Dis Colon Rectum** 1996 Sep;39(9):986–91

Does eversion of the anorectum during restorative proctocolectomy influence functional outcome? Miller AS, et al. **Dis Colon Rectum** 1996 May;39(5):489–93

Effect of rectosigmoid stump length on restorative proctocolectomy after subtotal colectomy. Ozuner G, et al. **Dis Colon Rectum** 1995 Oct;38(10):1039–42

Selective preservation of the anal transition zone in ileoanal pouch procedures. Pricolo VE, et al. **Dis Colon Rectum** 1996 Aug;39(8):871–7

New technique for creation of stapled ileal J-pouch [letter] Martini MA, et al. **Int J Colorectal Dis** 1995;10(4):235–6

Stapled ileal pouch–anal anastomosis with resection of the anal transition zone [letter; comment] Thompson-Fawcett M, et al. **Int J Colorectal Dis** 1995;10(4):234. Comment on: Int J Colorectal Dis 1995;10(3):142–7.

Functional results of the double-stapled ileoanal reservoir. Reissman P, et al. **J Am Coll Surg** 1995 Nov;181(5):444–50

Inverted U-pouch ileal reservoir: a technique for conversion of straight ileoanal pull-through. Prasad ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1361–2

Complications of the afferent antireflux valve mechanism in the Kock ileal reservoir [see comments] Stein JP, et al. **J Urol** 1996 May;155(5):1579–84. Comment in: J Urol 1996 May;155(5):1589–90.

Anatomic basis of mesenteric elongation for ileo–anal anastomosis with J-shaped reservoir: comparison of two techniques of vascular section. Wind P, et al. **Surg Radiol Anat** 1996;18(1):11–6

The use of an ileostomy connector to diminish the frequency of defecation prior to ileostomy closure in patients with a pelvic pouch. Maeda K, et al. **Surg Today** 1995; 25(7):657–61

[Surgery for ulcerative colitis. Treatment with proctocolectomy, stapled ileum-J-pouch, stapled pouch–anal anastomosis and temporary ileostomy] Vinge OD, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2101–4 (Eng. Abstr.) **(Dan)**

[Surgical treatment of ulcero-hemorrhagic rectocolitis] Dozois RR, et al. **Ann Chir** 1995;49(7):628–36 (60 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Long-term causes of death following ileal pouch–anal anastomosis. Kollmorgen CF, et al. **Dis Colon Rectum** 1996 May;39(5):525–8

STANDARDS

A formal model for quality assurance in coloproctologic surgery. Pezzè M, et al. **Medinfo** 1995;8 Pt 2:1037–41

PROCTOCOLITIS

COMPLICATIONS

[Hepatic amebiasis and hemorrhagic rectocolitis: an accidental association? (letter)] Moliner S, et al. **Med Trop (Mars)** 1995;55(2):183–4 **(Fre)**

ENZYMOLOGY

[Adenomatous and inflammatory colorectal polyps: antioxidative enzyme activity in the colon] Beňo I, et al. **Cas Lek Cesk** 1996 Apr 3;135(7):208–10 (Eng. Abstr.) **(Slo)**

MICROBIOLOGY

Hemorrhagic proctosigmoiditis and Blastocystis hominis infection [letter] Carrascosa M, et al. **Ann Intern Med** 1996 Jan 15;124(2):278–9

PROCTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

PROCTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

PROCTOLOGY see **COLON AND RECTAL SURGERY (SPECIALTY)**

PROCTOSCOPY

Utility of endoscopic ultrasonography in rectal carcinoid tumors [letter; comment] Hokama A, et al. **Am J Gastroenterol** 1996 Jun;91(6):1289–90. Comment on: Am J Gastroenterol 1994 Apr;89(4):645.

Cancer of the rectum--palliative endoscopic treatment. Rupp KD, et al. **Eur J Surg Oncol** 1995 Dec;21(6):644–7

Diagnostic utility of endoscopic ultrasonography for preoperative rectal cancer staging estimation. Kaneko K, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):30–5

Rectal exploration in rectal cancer. Double contrast enema vs rectoscopy: a comparison of present diagnostic accuracy. De Franco A, et al. **Rays** 1995 Jan-Mar;20(1):21–35 **(Eng, Ita)**

Local excision of rectal tumours with transanal endoscopic microsurgery. Stipa S, et al. **Tumori** 1995 May-Jun;81(3 Suppl):50–6

Improvement of colo-rectal cancer surgery following introduction of endoscopical approach. Taschieri AM, et al. **Tumori** 1995 May-Jun;81(3 Suppl):57–9

[The role of ultrasonic endoscopy in the examination of post-obstetrical anal incontinence] Roseau G. **Contracept Fertil Sex** 1995 Dec;23(12):752–7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Rectal prolapse--choice of procedure and minimal invasive possibilities] Köckerling F, et al. **Chirurg** 1996 May; 67(5):471–82 (38 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Iatrogenic injuries of the rectum] Ilijevski N, et al. **Vojnosanit Pregl** 1995 Jul-Aug;52(4):407–10 **(Scr)**

INSTRUMENTATION

Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. Meyenberger C, et al. **Endoscopy** 1995 Sep;27(7):469–79

Is transanal endoscopic microsurgery (TEM) a valid treatment for rectal tumors? Lezoche E, et al. **Surg Endosc** 1996 Jul;10(7):736–41

[Current proctology--modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205–12 (33 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Videoendoscopic anoscopy: a new technique for examining the anal canal. Lazas DJ, et al. **Gastrointest Endosc** 1995 Oct;42(4):351–4

[Transanal endoscopic microsurgery for local excision of rectal neoplasms] Madhala O, et al. **Harefuah** 1995 Oct; 129(7–8):236–7, 295 (Eng. Abstr.) **(Heb)**

PROCTOSIGMOIDITIS see **PROCTOCOLITIS**

PROCTOSIGMOIDOSCOPY see **SIGMOIDOSCOPY**

PROCYCLIDINE

THERAPEUTIC USE

Paradoxical autonomic response to procyclidine in the neuroleptic malignant syndrome. Balzan MV. **Can J Neurol Sci** 1995 Aug;22(3):244–6

PRODIGIOSIN

ANALOGS & DERIVATIVES

Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants. Magae J, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):86–90

redD and actII-ORF4, pathway-specific regulatory genes for antibiotic production in Streptomyces coelicolor A3(2), are transcribed in vitro by an RNA polymerase holoenzyme containing sigma hrdD. Fujii T, et al. **J Bacteriol** 1996 Jun;178(11):3402–5

PRODIGIOZAN

PHARMACOLOGY

[The effect of pyrimidines, levamisole and prodigiozan on the antigen-specific regulation of delayed hypersensitivity in relation to the age and strain of the mice] Gaĭnutdinova DT, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):45–7 (Eng. Abstr.) **(Rus)**

[Prodigiozan modulation of the specific activity of antidepressants] Sibiriak SV, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):9–12 (Eng. Abstr.) **(Rus)**

PRODRUGS

Minireview: nucleotide prodrugs. Jones RJ, et al. **Antiviral Res** 1995 May;27(1–2):1–17 (119 ref.)

Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. Nolen H 3rd, et al. **J Pharm Sci** 1995 Jun;84(6):677–81

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Balzarini J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7295–9

ADMINISTRATION & DOSAGE

Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Benatti U, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):20–5

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281–7

ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Blakey DC, et al. **Cancer Res** 1996 Jul 15;56(14):3287–92

Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Millward MJ, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2409–11

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Chabot GG, et al. **J Clin Oncol** 1996 Jul; 14(7):2020–30

Antibody-enzyme conjugates for cancer therapy. Melton RG, et al. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):153–65 (85 ref.)

Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Gambacciani M, et al. **Osteoporos Int** 1995; 5(6):467–71

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Fick J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11071–5

ADVERSE EFFECTS

Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. Uematsu T, et al. **J Clin Pharmacol** 1996 May;36(5):439–51

A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity. Smit BJ, et al. **S Afr Med J** 1995 Sep;85(9):865–70

CHEMICAL SYNTHESIS

Ether, carbonate and urethane deoxynucleoside derivatives as prodrugs. Hammer K, et al. **Acta Chem Scand** 1996 Jul; 50(7):609–22

Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins. Hay MP, et al. **Anticancer Drug Des** 1996 Jul;11(5):383–402

Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate. Pignatello R, et al. **Anticancer Drug Des** 1996 Apr;11(3):253–64

Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. Roth T, et al. **Anticancer Drug Des** 1995 Dec;

10(8):655–66
Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation. Seymour LW, et al. **Anticancer Drug Des** 1996 Jul;11(5):351–65
Synthesis and biodistribution of [4–14C]–5–bromo–6–methoxy–5,6–dihydro–prodrug derivatives of 5–ethyl–2'–deoxyuridine. Cheraghali AM, et al. **Drug Des Discov** 1994 Jul;12(1):53–61
New mustard prodrugs for antibody–directed enzyme prodrug therapy: alternatives to the amide link. Dowell RI, et al. **J Med Chem** 1996 Mar 1;39(5):1100–5
Lipophilic, acid–stable, adenosine deaminase–activated anti–HIV prodrugs for central nervous system delivery. 3. 6–Amino prodrugs of 2'–beta–fluoro–2',3'–dideoxyinosine. Driscoll JS, et al. **J Med Chem** 1996 Apr 12;39(8):1619–25
Synthesis, X–ray crystallography, and pharmacokinetics of novel azomethine prodrugs of (R)–alpha–methylhistamine: highly potent and selective histamine H3 receptor agonists. Krause M, et al. **J Med Chem** 1995 Sep 29;38(20):4070–9
Discovery of the hemifumarate and (alpha–L–alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group. Robinson RP, et al. **J Med Chem** 1996 Jan 5;39(1):10–8
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody–directed enzyme prodrug therapy (ADEPT). Springer CJ, et al. **J Med Chem** 1995 Dec 22;38(26):5051–65
N–succinimidyl ester of ofloxacin—a novel prodrug. Dobias J, et al. **Pharmazie** 1995 Aug;50(8):563

CHEMISTRY

Prodrugs of anthracycline antibiotics suited for tumor–specific activation. Azoulay M, et al. **Anticancer Drug Des** 1995 Sep;10(6):441–50
Effects of pH, temperature, and chemical structure on the stability of S–(purin–6–yl)–L–cysteine: evidence for a novel molecular rearrangement mechanism to yield N–(purin–6–yl)–L–cysteine. Elfarra AA, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):654–8
Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines. Alexander J, et al. **J Med Chem** 1996 Jan 19;39(2):480–6
Evidence for a carbocation intermediate during conversion of bipinnatin–A and –C into irreversible inhibitors of nicotinic acetylcholine receptors. Hyde EG, et al. **J Med Chem** 1995 Nov 10;38(23):4704–9
Hypoxia–selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Tercel M, et al. **J Med Chem** 1996 Mar 1;39(5):1084–94
Esters of L–dopa: structure–hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism. Brunner–Guenat M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):861–9
Prodrugs revisited: the "ad hoc" approach as a complement to ligand design. Testa B, et al. **Med Res Rev** 1996 May; 16(3):233–41 (17 ref.)
Hydroxypropyl–beta–cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Jarho P, et al. **Pharm Res** 1995 Sep;12(9):1371–5
Hydrolysis of the prodrug, 2',3',5'–triacetyl–6–azauridine. Riley CM, et al. **Pharm Res** 1995 Sep;12(9):1361–70

METABOLISM

Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. Kratochwil NA, et al. **Anticancer Drug Des** 1996 Mar;11(2):155–71
Site–specific prodrug activation by antibody–beta–lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Meyer DL, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):440–6
Enantioselective release of 5–fluorouracil from N–(2–hydroxypropyl)methacrylamide–based copolymers via lysosomal enzymes. Putnam D, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):483–92
Partial purification and characterization of an esterase acting on the anticancer pro–drugs, 7–ethylcamptothecin derivatives. Fujita Y, et al. **Biol Pharm Bull** 1995 May; 18(5):648–52
Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Takahashi K, et al. **Biol Pharm Bull** 1995 Oct;18(10):1401–4
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Hoganson DK, et al. **Cancer Res** 1996 Mar 15;56(6):1315–23
The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Senter PD, et al. **Cancer Res** 1996 Apr 1;56(7):1471–4
Hypoxia–activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing. Wilson WR, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):881–5
Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1–40 (200 ref.)
Metabolism of Zidovudine. Veal GJ, et al. **Gen Pharmacol** 1995 Nov;26(7):1469–75 (54 ref.)
Genetic delivery of enzymes for cancer therapy. Deonarain MP, et al. **Gene Ther** 1995 Jun;2(4):235–44 (76 ref.)
Metabolism of dopamine prodrug, docarpamine. Yoshikawa M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S211–3
Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: in vivo micropuncture studies. Smith DE, et al. **J Pharm Sci** 1995 Oct;84(10):1147–50
Synthesis and biological properties of gamma–glutamyl–dermorphin, a prodrug. Misicka A, et al. **Life Sci** 1996;58(11):905–11
Vitamin K prodrugs: 2. water–soluble prodrugs of menahydroquinone–4 for systemic site–specific delivery. Takata J, et al. **Pharm Res** 1995 Dec;12(12):1973–9
Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. TenHoor CN, et al. **Pharm Res** 1995 Nov;12(11):1806–9
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Branch RA, et al. **Pharmacogenetics** 1995;5 Spec No:S97–102 (26 ref.)
Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Yokoi T, et al. **Pharmacogenetics** 1995;5 Spec No:S65–9

PHARMACOKINETICS

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)
Disposition of S–1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl–14C]S–1108 in rats and dogs. Mizojiri K, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1445–53
New potent azomethine prodrugs of the histamine H3–receptor agonist (R)–alpha–methylhistamine containing a heteroarylphenyl partial structure. Krause M, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):209–15
Bioavailability of cefpodoxime proxetil with co–administered acetylcysteine. Kees F, et al. **Arzneimittelforschung** 1996 Apr;46(4):435–8
Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Bijsterbosch MK, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):113–21
Pharmacokinetic analysis of the microscopic distribution of enzyme–conjugated antibodies and prodrugs: comparison with experimental data. Baxter LT, et al. **Br J Cancer** 1996 Feb;73(4):447–56
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Patterson AV, et al. **Br J Cancer** 1995 Nov;72(5):1144–50
Plasma clearance of an antibody—enzyme conjugate in ADEPT by monoclonal anti–enzyme: its effect on prodrug activation in vivo. Rogers GT, et al. **Br J Cancer** 1995 Dec;72(6):1357–63
Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra– and intracellular pH and drug uptake. Skarsgard LD, et al. **Br J Cancer** 1995 Dec; 72(6):1479–86
Activation of chemically diverse procarcinogens by human cytochrome P–450 1B1. Shimada T, et al. **Cancer Res** 1996 Jul 1;56(13):2979–84
Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. Yamazaki H, et al. **Carcinogenesis** 1995 Sep; 16(9):2167–70
Clinical pharmacokinetics of molsidomine. Rosenkranz B, et al. **Clin Pharmacokinet** 1996 May;30(5):372–84
Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Kostis JB, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):660–5
Synthesis and biodistribution of [4–14C]–5–bromo–6–methoxy–5,6–dihydro–prodrug derivatives of 5–ethyl–2'–deoxyuridine. Cheraghali AM, et al. **Drug Des Discov** 1994 Jul;12(1):53–61
Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey. Krasny HC, et al. **Drug Metab Dispos** 1995 Nov;23(11):1242–7
Metabolism of promutagens catalyzed by Drosophila melanogaster CYP6A2 enzyme in Saccharomyces cerevisiae. Saner C, et al. **Environ Mol Mutagen** 1996; 27(1):46–58
Prodrug versus drug effects of 150 micrograms desogestrel or 3–keto–desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3–keto–desogestrel. Kuhl H, et al. **Horm Res** 1995;44(3):126–32
A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. Breslin E, et al. **J Clin Pharmacol** 1996 May;36(5):414–21
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single–dose oral and intravenous administration. Bullingham R, et al. **J Clin Pharmacol** 1996 Apr;36(4):315–24
Pharmacokinetics and safety of a novel, long–acting, prodrug–type potassium channel opener, Y–27152, in healthy volunteers. Uematsu T, et al. **J Clin Pharmacol** 1996 May;36(5):439–51
Drug delivery systems. 2. Camptothecin 20–O–poly(ethylene glycol) ester transport forms. Greenwald RB, et al. **J Med Chem** 1996 May 10;39(10):1938–40
Cyclization–activated prodrugs: N–(substituted 2–hydroxyphenyl and 2–hydroxypropyl)carbamates based on ring–opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. Vigroux A, et al. **J Med Chem** 1995 Sep 29;38(20):3983–94
In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5–halo–y–methoxy(or ethoxy)–5,6–dihydro–3'–azido–3'–deoxythymidine diastereomers as potential prodrugs of 3'–azido–3'–deoxythymidine. Wang L, et al. **J Med Chem** 1996 Feb 16;39(4):826–33
Distribution of salicylate in pigmented rabbit ocular tissues after application of a prodrug, sodium monomethyl trisilanol orthohydroxybenzoate: in vivo and ex vivo studies. Chanalet L, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):83–94
Sulfobutyl ether beta–cyclodextrin (SBE–beta–CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. Järvinen T, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):95–106
Accumulation of 5–ethyl–2'–deoxyuridine and its 5,6–dihydro prodrugs in murine lung and its potential clinical application. Cheraghali AM, et al. **J Pharm Pharmacol** 1995 Jul;47(7):595–600
Enhanced oral bioavailability of DDI after administration of 6–Cl–ddP, an adenosine deaminase–activated prodrug, to chronically catheterized rats. Anderson BD, et al. **Pharm Res** 1995 Aug;12(8):1126–33
Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Aungst BJ, et al. **Pharm Res** 1995 May;12(5):763–7
pGlu–L–Dopa–Pro: a tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion. Bai JP. **Pharm Res** 1995 Jul; 12(7):1101–4
Theoretical design of prodrug–enhancer combination based on a skin diffusion model: prediction of permeation of acyclovir prodrugs treated with 1–geranylazacycloheptan–2–one. Bando H, et al. **Pharm Res** 1996 Mar;13(3):427–32
Species dependent esterase activities for hydrolysis of an anti–HIV prodrug glycovir and bioavailability of active SC–48334. Cook CS, et al. **Pharm Res** 1995 Aug; 12(8):1158–64
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Möllmann H, et al. **Pharm Res** 1995 Jul; 12(7):1096–100
Clinical pharmacokinetics of new antiepileptic drugs. Walker MC, et al. **Pharmacol Ther** 1995;67(3):351–84 (164 ref.)
Terbutaline prodrugs and oral beta 2–agonist therapy. Svensson LA. **Pharmacol Toxicol** 1995;77 Suppl 3:30–3
Cyp1a2(–/–) null mutant mice develop normally but show deficient drug metabolism. Liang HC, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1671–6
Morphological characterisation of the cell–growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. Albrecht CF, et al. **S Afr Med J** 1995 Sep;85(9):853–60
[Pharmacokinetic and clinical studies of S–1108 in the pediatric field. Pediatric Study Group of S–1108.] Fujii R, et al. **Jpn J Antibiot** 1995 Jul;48(7):921–41 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Sulphasalazine treatment and the colorectal mucosa–associated flora in ulcerative colitis. Hartley MG, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):157–63
Short–term hemodynamic, anti–ischemic, and antianginal effects of pirsidomine, a new sydnonimine. Stengele E, et al. **Am J Cardiol** 1996 May 1;77(11):937–41
Antiviral effect in human cytomegalovirus–infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. Shakiba S, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1383–5
A precursor of the nitric oxide donor SIN–1 modulates the stress protein heme oxygenase–1 in rat liver. Motterlini R, et al. **Biochem Biophys Res Commun** 1996 Aug 5; 225(1):167–72
5–(m–Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'–tri–O–acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. Ashour OM, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1601–11
Characterization of novel anthracycline prodrugs activated by human beta–glucuronidase for use in antibody–directed enzyme prodrug therapy. Houba PH, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):455–63
Maintenance of hepatic glutathione homeostasis and prevention of acetaminophen–induced cataract in mice by L–cysteine prodrugs. Rathbun WB, et al. **Biochem Pharmacol** 1996 May 3;51(9):1111–6
Triazolines—XXVII. delta2–1,2,3–triazoline anticonvulsants: novel 'built–in' heterocyclic prodrugs with a unique 'dual–action' mechanism for impairing excitatory amino acid L–glutamate neurotransmission. Kadaba PK, et al. **Bioorg Med Chem** 1996 Feb;4(2):165–78
Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra– and intracellular pH and drug uptake. Skarsgard LD, et al. **Br J Cancer** 1995 Dec; 72(6):1479–86
The effect of HN–65021 on responses to angiotensin II in

human forearm vasculature. Cockcroft JR, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):591–3

Effect of 17beta-estradiol–bisphosphonate conjugates, potential bone-seeking estrogen pro–drugs, on 17beta–estradiol serum kinetics and bone mass in rats. Bauss F, et al. **Calcif Tissue Int** 1996 Sep;59(3):168–73

Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Chen L, et al. **Cancer Res** 1996 Mar 15;56(6):1331–40

Potentiation of enediyne–induced apoptosis and differentiation by Bcl–2. Cortazzo M, et al. **Cancer Res** 1996 Mar 15;56(6):1199–203

Synthesis and anti–HIV activity of steroidal prodrugs of 3'–azido–3'–deoxythymidine (AZT). Balagopala MI, et al. **Cell Mol Biol (Noisy–le–grand)** 1995;41 Suppl 1:S1–7

Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens. Speciale A, et al. **Chemotherapy** 1996 Jan–Feb; 42(1):1–10

AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt–loaded Dahl salt–sensitive rats. Sugimoto K, et al. **Clin Exp Pharmacol Physiol** 1996 Apr; 23(4):282–6

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al. **Drugs Exp Clin Res** 1995;21(3):85–8

Mutagenic synergy between paraoxon and plant–activated m–phenylenediamine or 2–acetoxyacetylaminofluorene. Gichner T, et al. **Environ Mol Mutagen** 1996;27(1):59–66

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Bridgewater JA, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2362–70

Prevention of naphthalene–induced cataract and hepatic glutathione loss by the L–cysteine prodrugs, MTCA and PTCA. Rathbun WB, et al. **Exp Eye Res** 1996 Apr; 62(4):433–41

The effect on ephedrine prodrugs on locomotor activity in rats. Walker RB, et al. **Gen Pharmacol** 1996 Jan; 27(1):109–11

Suppression of noradrenaline spillover by the dopamine prodrug gamma–L–glutamyl–L–dopa: a central effect? McGrath BP, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S113–8

Lack of interaction between valaciclovir, the L–valyl ester of acyclovir, and Maalox antacid. de Bony F, et al. **J Antimicrob Chemother** 1996 Feb;37(2):383–7

A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. Breslin E, et al. **J Clin Pharmacol** 1996 May;36(5):414–21

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. Thackray AM, et al. **J Infect Dis** 1996 Feb;173(2):291–9

Synthesis of novel Se–substituted selenocysteine derivatives as potential kidney selective prodrugs of biologically active selenol compounds: evaluation of kinetics of beta–elimination reactions in rat renal cytosol. Andreadou I, et al. **J Med Chem** 1996 May 10;39(10):2040–6

Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha–phosphonosulfonic acid moiety. Dickson JK Jr, et al. **J Med Chem** 1996 Feb 2;39(3):661–4

Drug delivery systems: water soluble taxol 2'–poly(ethylene glycol) ester prodrugs–design and in vivo effectiveness. Greenwald RB, et al. **J Med Chem** 1996 Jan 19;39(2):424–31

Augmentation of human and rat lenticular glutathione in vitro by prodrugs of gamma–L–glutamyl–L–cysteine. Nagasawa HT, et al. **J Med Chem** 1996 Apr 12; 39(8):1676–81

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Weller T, et al. **J Med Chem** 1996 Aug 2;39(16):3139–47

Esters of L–dopa: structure–hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism. Brunner–Guenat M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):861–9

The cobalt(III)–insulin hexamer is a prolonged–acting insulin prodrug. Kurtzhals P, et al. **J Pharm Sci** 1995 Oct; 84(10):1164–8

Properties of ABT–299, a prodrug of A–85783, a highly potent platelet activating factor receptor antagonist. Albert DH, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1595–606

Targeting 6–thioguanine to the kidney with S–(guanin–6–yl)–L–cysteine. Elfarra AA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1298–304

Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood–brain barrier permeability. Greene DL, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1366–75

ABT–431: the diacetyl prodrug of A–86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. Shiosaki K, et al. **J Pharmacol Exp Ther** 1996 Jan; 276(1):150–60

Modulation of glutathione by a cysteine pro–drug enhances in vivo tumor response. Wang T, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1169–73

Hydrolysis of RRR–alpha–tocopheryl acetate (vitamin E acetate) in the skin and its UV protecting activity (an in vivo study with the rat). Beijersbergen van Henegouwen GM, et al. **J Photochem Photobiol B** 1995 Jul;29(1):45–51

Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. Elger W, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):395–403

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Manome Y, et al. **Nat Med** 1996 May;2(5):567–73

Acyloxymethyl as a drug protecting group. Part 3. Tertiary O–amidomethyl esters of penicillin G: chemical hydrolysis and anti–bacterial activity. Moreira R, et al. **Pharm Res** 1996 Jan;13(1):70–5

Derivatives of Dexanabinol. I. Water–soluble salts of glycinate esters. Pop E, et al. **Pharm Res** 1996 Jan; 13(1):62–9

Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. Magnani M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4403–8

Toward antibody–directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Wentworth P, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):799–803

Gemcitabine: metabolism, mechanisms of action, and self–potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3–10 (26 ref.)

THERAPEUTIC USE

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Ann Neurol** 1996 Mar;39(3):400–4

Antipneumocystis activity of 17C91, a prodrug of atovaquone. Comley JC, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2217–9

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Thackray AM, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):846–51

Antibody–directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Blakey DC, et al. **Biochem Soc Trans** 1995 Nov;23(4):1047–50

Anti–tumour effects of an antibody–carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC, et al. **Br J Cancer** 1995 Nov;72(5):1083–8

Plasma clearance of an antibody—enzyme conjugate in ADEPT by monoclonal anti–enzyme: its effect on prodrug activation in vivo. Rogers GT, et al. **Br J Cancer** 1995 Dec;72(6):1357–63

Angiolymphoid hyperplasia with eosinophilia: successful treatment with indomethacin farnesil [letter] Nomura K, et al. **Br J Dermatol** 1996 Jan;134(1):189–90

Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5–fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Trinh QT, et al. **Cancer Res** 1995 Nov 1;55(21):4808–12

Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Gooch WM 3rd, et al. **Clin Ther** 1995 Sep–Oct;17(5):838–51

Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis. Henry D, et al. **Clin Ther** 1995 Sep–Oct;17(5):861–74

Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active–controlled, double–blind multicentre trial in patients with congestive heart failure. Widimský J, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):95–102

Gene therapy for cancer using tumour–specific prodrug activation. Harris JD, et al. **Gene Ther** 1994 May;1(3):170–5

A monoclonal antibody against human beta–glucuronidase for application in antibody–directed enzyme prodrug therapy. Haisma HJ, et al. **Hybridoma** 1995 Aug; 14(4):377–82

A double–blind randomized trial comparing the efficacy and safety of a 5–day course of cefotiam hexetil with that of a 10–day course of penicillin V in adult patients with pharyngitis caused by group A beta–haemolytic streptococci. Carbon C, et al. **J Antimicrob Chemother** 1995 Jun;35(6):843–54

Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group. Gehanno P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:105–14

Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained–release verapamil. Abernethy DR, et al. **J Clin Pharmacol** 1995 Aug; 35(8):794–9

Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated–5–fluorocytosine. Haberkorn U, et al. **J Nucl Med** 1996 Jan;37(1):87–94

Patient–initiated, twice–daily oral famciclovir for early recurrent genital herpes. A randomized, double–blind multicenter trial. Canadian Famciclovir Study Group. Sacks SL, et al. **JAMA** 1996 Jul 3;276(1):44–9

Valacyclovir. **Med Lett Drugs Ther** 1996 Jan 5;38(965):3–4

Interaction of indometacin farnesil, a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis. Hirohata S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr; 19(2):136–44

Immunoliposomes as enzyme–carriers (immuno–enzymosomes) for antibody–directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Vingerhoeds MH, et al. **Pharm Res** 1996 Apr;13(4):604–10

Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Holm S, et al. **Scand J Infect Dis** 1995;27(3):221–8

Treatment of acute maxillary sinusitis—comparing cefpodoxime proxetil with amoxicillin. von Sydow C, et al. **Scand J Infect Dis** 1995;27(3):229–34

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)

Prodrugs in cancer chemotherapy. Connors TA, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):501–11 (76 ref.)

[Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil] Vyhnánek F, et al. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):68–70 (Eng. Abstr.) **(Cze)**

[Influence of intratumor administration of OK–432 on the tumor selectivity of 5'–DFUR] Ogawa K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2095–100 (Eng. Abstr.) **(Jpn)**

[A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double–blind method] Saito A, et al. **Jpn J Antibiot** 1996 Feb;49(2):144–74 (Eng. Abstr.) **(Jpn)**

TOXICITY

Cytotoxic evaluation of some N–acyl and N–acyloxy analogues of 3,5–bis(arylidene)–4–piperidones. Dimmock JR, et al. **Drug Des Discov** 1994 Jul;12(1):19–28

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al. **Drugs Exp Clin Res** 1995;21(3):85–8

Structural requirements for mutagenicity of flavonoids upon nitrosation. A structure–activity study. Rueff J, et al. **Mutagenesis** 1995 Jul;10(4):325–8

PRODUCT CONTAINERS see PRODUCT PACKAGING

PRODUCT LABELING

The Physicians' Desk Reference. Problems and possible improvements. Cohen JS, et al. **Arch Intern Med** 1996 Jul 8;156(13):1375–80

FDA labeling requirements for disinfection of endoscopes: a counterpoint [letter; comment] Gurevich I. **Infect Control Hosp Epidemiol** 1995 Sep;16(9):496–7; discussion 497–8. Comment on: Infect Control Hosp Epidemiol 1995 Apr;16(4):231–5.

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Jul 3;276(1):14

Smoke them out [letter] James WH. **Nature** 1996 May 30; 381(6581):363

METHODS

Interaction of signal word and colour on warning labels: differences in perceived hazard and behavioural compliance. Braun CC, et al. **Ergonomics** 1995 Nov; 38(11):2207–20

An examination of consumer advisement warning information embedded within written instructions: implications for memory and behaviour. Fuller JK, et al. **Ergonomics** 1995 Nov;38(11):2238–49

STANDARDS

Warning signal words: connoted strength and understandability by children, elders, and non–native English speakers. Wogalter MS, et al. **Ergonomics** 1995 Nov;38(11):2188–206

PRODUCT LABELING, DRUG see DRUG LABELING

PRODUCT LABELING, FOOD see FOOD LABELING

PRODUCT LINE MANAGEMENT

STANDARDS

How a three–campus heart service line improves clinical processes and outcomes. Frommater D, et al. **Jt Comm J Qual Improv** 1995 Jun;21(6):263–76

TRENDS

Differentiation and specialization in the California hospital industry 1983 to 1988. Zwanziger J, et al. **Med Care** 1996 Apr;34(4):361–72

PRODUCT PACKAGING

Hidden sharps [letter] Pandya KS, et al. **Anaesthesia** 1996 May;51(5):515

Cigarette packaging appeals to teens [news] **J Am Dent Assoc** 1995 Dec;126(12):1604

Development and evaluation of a shipping system for platelet components. George VM, et al. **Transfusion** 1996 Apr; 36(4):335–8

METHODS

Conversion of pipet-tip boxes into secure storage containers for microcentrifuge tubes. Hendry IR, et al. **Biotechniques** 1996 May;20(5):812

STANDARDS

Recommended practices for selection and use of packaging systems. Association of Operating Room Nurses. **AORN J** 1996 May;63(5):949–53

Paraffin (kerosene) poisoning in South Africa—some errors in a poster designed for black viewers [editorial] de Wet B, et al. **S Afr Med J** 1994 Nov;84(11):722–3

PRODUCT RECYCLING see **EQUIPMENT REUSE**

PRODUCT SURVEILLANCE, POSTMARKETING

Safety product evaluation: six years of experience. Simpkins SM, et al. **Am J Infect Control** 1995 Oct;23(5):317–22

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)

A successful device tracking program. Weed P. **AORN J** 1995 Aug;62(2):260–1, 264–5

Nothing to whoop about [comment] Brown GW. **Arch Pediatr Adolesc Med** 1996 May;150(5):461–3; discussion 464–5. Comment on: Arch Pediatr Adolesc Med 1996 May;150(5):457–60.

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment [see comments] Rosenthal S, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):457–60. Comment in: Arch Pediatr Adolesc Med 1996 May;150(5):461–3.

Informed consent to postmarketing research. Patients may feel pressured to participate [letter] Cox NH. **BMJ** 1995 Sep 9;311(7006):692

Third generation oral contraceptives. Postmarketing surveillance does not catch all adverse events [letter; comment] O'Brien P. **BMJ** 1996 Mar 2;312(7030):577. Comment on: BMJ 1995 Dec 16;311(7020):1639.

Before and after triazolam: changes in the consumption of hypnotics in Spain [letter] Martín Arias LH, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):289–90

The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Spengler M, et al. **Clin Invest Med** 1995 Aug;18(4):325–31

Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China. Li JT, et al. **Drugs** 1995;49 Suppl 2:474–6

Surveillance of adverse reactions due to ciprofloxacin in Japan. Matsuno K, et al. **Drugs** 1995;49 Suppl 2:495–6

European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. Lawson DH, et al. **Eur J Clin Pharmacol** 1995;49(1–2):73–9

The place of scientific publications in the evaluation of a clinical success [letter] Bouchard P. **J Periodontol** 1996 Apr;67(4):461

Loop electrosurgical excision in the peritoneal cavity. Preliminary experience with the rat model. Munro MG, et al. **J Reprod Med** 1996 Mar;41(3):143–8

ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). Fries JF. **J Rheumatol** 1995 May;22(5):995–7

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Feb 28;275(8):585

The relevance of searching for effects under a clinical-trial lamppost: a key issue. Rittenhouse BE. **Med Decis Making** 1995 Oct–Dec;15(4):348–57

Postmarketing surveillance with computer-based patient records. Vlug AE, et al. **Medinfo** 1995;8 Pt 1:327–30

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):517–8

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):387–90

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1975

STIMAREC report. Godin JF, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1728

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7–17 (14 ref.)

Performance of implantable defibrillator pacing/sensing lead adapters. Sgarbossa EB, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):811–4

The role of pharmacists in the recruitment of a cohort for postmarketing surveillance. A case study of acitretin in The Netherlands. Sturkenboom MC, et al. **Pharm World Sci** 1995 Jul 28;17(4):126–32

[Post-marketing surveillance (letter)] de Koning GH, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1202 **(Dut)**

[Post-marketing surveillance (letter)] Leufkens HG, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1201–2; discussion 1202 **(Dut)**

[Post-marketing surveillance (letter; comment)] Offerhaus L. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1201; discussion 1202. Comment on: Ned Tijdschr Geneeskd 1996 Mar 16;140(11):620–1. **(Dut)**

[Effects of the medical products legislation on roentgen services] Ewen K, et al. **Aktuelle Radiol** 1995 Sep; 5(5):331–4 (Eng. Abstr.) **(Ger)**

[Check list for publications on drug treatment studies] Selbmann HK. **Fortschr Med** 1996 Apr 10;114(10):123–4 **(Ger)**

[Clinical usefulness of drug surveillance studies (letter; comment)] Soto Alvarez J. **Aten Primaria** 1995 Oct 31; 16(7):455–6. Comment on: Aten Primaria 1995 May 15;15(8):516–8. **(Spa)**

[Drug surveillance within the pharmaceutical industry: present and future] Soto J, et al. **Med Clin (Barc)** 1996 May 4;106(17):665–9 (31 ref.) **(Spa)**

ECONOMICS

[Post-marketing surveillance (letter) (see comments)] Roos JC. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):620–1. Comment in: Ned Tijdschr Geneeskd 1996 Jun 1;140(22):1201; discussion 1202. **(Dut)**

METHODS

Development of a new qualitative test for fit testing respirators [see comments] Mullins HE, et al. **Am Ind Hyg Assoc J** 1995 Nov;56(11):1068–73. Comment in: Am Ind Hyg Assoc J 1996 Jun;57(6):576, 578–80.

STANDARDS

Informed consent to postmarketing research. British rules outlaw disguised promotion of drugs [letter] Wells F. **BMJ** 1995 Sep 9;311(7006):692

Postmarket surveillance to determine nutritional impact of macronutrient substitutes. Cheney M. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 2):S22–4; discussion S31–7

The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes. Forbes AL. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 2):S20–1; discussion S31–7

PRODUCTIVITY see **EFFICIENCY**

PRODUCTIVITY, ORGANIZATIONAL see **EFFICIENCY, ORGANIZATIONAL**

PROENZYMES see **ENZYME PRECURSORS**

PROERYTHROBLASTS see **ERYTHROBLASTS**

PROESTRUS

The brain histamine (HA) and pituitary luteinizing hormone (LH) levels in female rats anesthetized with ether on proestrus. Kim CY, et al. **Exp Anim** 1996 Apr;45(2):175–7

Effect of hypothyroidism on the pituitary-gonadal axis in the adult female rat. Mattheij JA, et al. **J Endocrinol** 1995 Jul;146(1):87–94

DRUG EFFECTS

One day estrous cycle shortening induced by antiprogestagen RU486 administration in proestrus to 4-day cyclic rats. Tébar M, et al. **Rev Esp Fisiol** 1995 Jun;51(2):85–91

PHYSIOLOGY

Decreased gonadotropin-releasing hormone neurosecretory response to glutamate agonists in middle-aged female rats on proestrus afternoon: a possible role in reproductive aging? Zuo Z, et al. **Endocrinology** 1996 Jun;137(6):2334–8

A relative depletion of luteinizing hormone-releasing hormone was observed in the median eminence of young but not middle-aged rats on the evening of proestrus. Rubin BS, et al. **Neuroendocrinology** 1995 Sep;62(3):259–69

PROFESSIONAL AUTONOMY

Physician assistants in control: ED mayhem [letter] Hall GJ. **Am J Emerg Med** 1996 May;14(3):338–9

Do pharmacists need prescribing privileges to implement pharmaceutical care? [see comments] Carmichael JM. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1699–701. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

The key to pharmacist prescribing: collaboration. Galt KA. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1696–9

Pharmacist prescribing [editorial; comment] Talley CR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1635. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1616, 1620, 1623–4. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1693–5. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1699–701. Comment on: Am J Health Syst Pharm 1995 Aug 1;52(15):1732.

Prescribing medications: changing the paradigm for a changing health care system [see comments] Webb CE. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1693–5. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Obtaining prescribing authority for pharmacists: lessons learned [see comments] Wittenburg AS. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1616, 1620, 1623–4. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

Collaborative drug therapy management [see comments] Zellmer WA. **Am J Health Syst Pharm** 1995 Aug 1; 52(15):1732. Comment in: Am J Health Syst Pharm 1995 Aug 1;52(15):1635.

The power of physicians: autonomy and balance in a changing system. Friedman E. **Am J Med** 1995 Dec; 99(6):579–86

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May–Jun;12(3):165–71 (24 ref.)

Professionalization of nurse practitioners. Bullough B. **Annu Rev Nurs Res** 1995;13:239–65 (106 ref.)

Feminism and nursing. Chinn PL. **Annu Rev Nurs Res** 1995; 13:267–89 (110 ref.)

Nursing research in Israel. Golander H, et al. **Annu Rev Nurs Res** 1996;14:207–24 (41 ref.)

The evolution of nursing research in Brazil. Mendes IA, et al. **Annu Rev Nurs Res** 1996;14:225–42 (68 ref.)

Evolution and vision [letter] Stonnington HH. **Arch Phys Med Rehabil** 1996 Jul;77(7):734

Doctors, nurses, and primary care [editorial] Flook N. **Can Fam Physician** 1995 Sep;41:1441–3, 1455–8 **(Eng, Fre)**

Value of certification [letter] Livingston M. **Can Fam Physician** 1996 Apr;42:616

Global physician budgets as common-property resources: some implications for physicians and medical associations. Hurley J, et al. **Can Med Assoc J** 1996 Apr 15;154(8):1161–8

Leaps of faith. Panum P. **Hosp Health Netw** 1996 Jun 20; 70(12):32–3

A giant step backward [letter] Adelman DS. **Image J Nurs Sch** 1996 Summer;28(2):91

Professional nursing in Brazil. Oguisso T. **Int Nurs Rev** 1996 May–Jun;43(3):81–4

The internationalization of professional regulation. Robinson J. **Int Nurs Rev** 1995 Nov–Dec;42(6):183–6

Pakistani nurses' vision for change. Zindani N. **Int Nurs Rev** 1996 May–Jun;43(3):85–8; 94

Second nursing symposium: 'Routes from Research to Reality' held at University College of St Martin, Lancaster, England, 7 April 1995. **J Adv Nurs** 1996 Jan;23(1):213–4

Critical care nurse satisfaction with levels of involvement in clinical decisions. Bucknall T, et al. **J Adv Nurs** 1996 Mar;23(3):571–7

Deputed power of medical control: the hidden message in the ritual of oral shift reports. Ekman I, et al. **J Adv Nurs** 1995 Nov;22(5):1006–11

The development of community psychiatric nursing: a professional project? Godin P. **J Adv Nurs** 1996 May; 23(5):925–34 (60 ref.)

Conflict, enactment, empowerment: conditions of independent therapeutic nursing intervention. Kubsch SM. **J Adv Nurs** 1996 Jan;23(1):192–200

The role of nursing journals in the advancement of professional nursing. Smith JP. **J Adv Nurs** 1996 Jan; 23(1):12–6 (7 ref.)

Nursing theory: everything the artist spits is art? Timpson J. **J Adv Nurs** 1996 May;23(5):1030–6 (65 ref.)

Zoapathy—a managed care caveat [comment] Tidwell TJ. **J Med Assoc Ga** 1996 Jan;85(1):37–8. Comment on: J Med Assoc Ga 1996 Jan;85(1):49–51.

Valuing authority/responsibility relationships. The essence of professional practice. Webb SS, et al. **J Nurs Adm** 1996 Feb;26(2):28–33

Advanced practice nurses [letter; comment] Williams K. **J Nurs Adm** 1996 Mar;26(3):7–8. Comment on: J Nurs Adm 1995 May;25(5):64–70.

The independent practice association [letter; comment] De Wolf W, et al. **JAMA** 1995 Dec 13;274(22):1761. Comment on: JAMA 1995 Jun 28;273(24):1937–42.

Nursing, medicine, quackery, and health care reform, 1844–1994. Rafferty AM. **Nurs Res** 1996 May–Jun; 45(3):190–1

Articulating the nursing in the nurse practitioner: can we? Should we? [letter] Yasuda C. **Nurse Pract** 1995 Dec; 20(12):10, 12

Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25–30 (33 ref.)

Changing prescriptive authority of advanced practice nurses. Stempkowski L. **Oncol Nurs Forum** 1996 May;23(4):712

Lessons to be learned [letter; comment] Peabody TD. **Pharos** 1995 Fall;58(4):35–6. Comment on: Pharos 1995 Winter;58(1):16–8.

Defining the PTA's roles. Amborse-Walsh L. **Phys Ther** 1996 Apr;76(4):410–3

Be not content to "sleep and feed" [letter] Holmes JA. **Phys Ther** 1996 Jun;76(6):664–6

When thoughtfulness dies [editorial] Rothstein JM. **Phys Ther** 1996 Apr;76(4):342–3
Demarcation and transformation within homoeopathic knowledge. A strategy of professionalization. Cant S, et al. **Soc Sci Med** 1996 Feb;42(4):579–88

PROFESSIONAL COMPETENCE

Professional competencies in the changing health care system: physicians' views on the importance and adequacy of formal training in medical school. Finocchio LJ, et al. **Acad Med** 1995 Nov;70(11):1023–8
Grassroots, "bottom-up" strategies for a successful academic career. Gruber N, et al. **Acad Med** 1996 Mar;71(3):218–9
Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)
Examining what residents look for in their role models. Wright S. **Acad Med** 1996 Mar;71(3):290–2
Critical care nurses' knowledge of pulmonary artery catheters. Burns D, et al. **Am J Crit Care** 1996 Jan; 5(1):49–54
Enhancing support for the graduate nurse. McHugh M, et al. **Am J Nurs** 1996 Jun;96(6):57–62
Power, professionalism, and patient advocacy. Flynn MB. **Am J Surg** 1995 Nov;170(5):407–9
Assessing third-year medical students' knowledge of and exposure to cleft palate before and after plastic surgery rotation. Vallino LD, et al. **Ann Plast Surg** 1996 Apr; 36(4):380–7
Family therapy skills for general practitioners. Jackson L, et al. **Aust Fam Physician** 1996 Aug;25(8):1265–7, 1269–71
Depiction of coroners more pulp fiction than fact [letter; comment] Pilley SF. **Can Med Assoc J** 1995 Oct 1; 153(7):886, 888. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1869–70.
Bioethics for clinicians [editorial; comment] Singer PA. **Can Med Assoc J** 1996 Jul 15;155(2):189–90. Comment on: Can Med Assoc J 1996 Jul 15;155(2):177–80.
The doctor, the patient: a first-year course for personal and professional growth. Davies SM, et al. **Fam Med** 1995 Jul–Aug;27(7):444–8
Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)
Participation in continuing professional education in nursing: findings of an interview study. Barriball KL, et al. **J Adv Nurs** 1996 May;23(5):999–1007
Is the professional code still the cornerstone of clinical nursing practice? Esterhuizen P. **J Adv Nurs** 1996 Jan; 23(1):25–31 (39 ref.)
Implementing change in nurses' professional behaviours: limitations of the cognitive approach. Lima–Basto M. **J Adv Nurs** 1995 Sep;22(3):480–9
Competence in aspects of behavioral treatment and consultation: implications for service delivery and graduate training. McGimsey JF, et al. **J Appl Behav Anal** 1995 Fall; 28(3):301–15
Professionalism—where are all the heroes? DeRosa GP. **J Bone Joint Surg Am** 1996 Sep;78(9):1295–9
Information on death certificates: cause for concern? James DS, et al. **J Clin Pathol** 1996 Mar;49(3):213–6
Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. Barber JP, et al. **J Consult Clin Psychol** 1996 Jun;64(3):619–22
Experienced and inexperienced health care workers' beliefs about challenging behaviours. Hastings RP, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):474–83
The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov–Dec;11(6):332–8 (22 ref.)
Public policy. The urge to merge—will quality survive? Kjervik DK. **J Prof Nurs** 1996 Jul–Aug;12(4):195
Professional practice. The essence of nursing—creative compassion. Koerner J. **J Prof Nurs** 1995 Nov–Dec; 11(6):317, 366
A call to authenticity—Part 1. Koerner JE. **J Prof Nurs** 1996 Jul–Aug;12(4):193
Professional image: enhanced or inhibited by attire? Newton M, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):240–4
Presentation format in analogue studies: effects on participants' evaluation. Johnson ME, et al. **J Psychol** 1996 May;130(3):341–9
[What are the criteria for the choice of future professors of pediatrics? (editorial)] Bougnères PF, et al. **Arch Pediatr** 1995 Sep;2(9):831–2 **(Fre)**
[letter] Poerio M. **Acta Otorhinolaryngol Ital** 1995 Oct; 15(5):400 **(Ita)**
[The practical clinical game and discussion as active teaching methods in the training of the future physician] Gusev EI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):96–8 **(Rus)**
[Validation of a test of neurological knowledge for general practitioners] Casabella B, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):33–8 (Eng. Abstr.) **(Spa)**

STANDARDS

A guideline for competency of the critical care nurse. Scribante J, et al. **Am J Crit Care** 1996 May;5(3):217–26
The need for death investigator training. Smith SR. **Am J Forensic Med Pathol** 1995 Jun;16(2):181
Pennsylvanians for merit selection. Marks LA, et al. **Pa Med** 1995 Nov;98(11):35
Prospective multicentre study of the accuracy of surgery for horizontal strabismus. Baker JD. **Surv Ophthalmol** 1996 Mar–Apr;40(5):421–2

PROFESSIONAL CORPORATIONS

What's in a name? Everything and nothing [editorial] Goldwyn RM. **Plast Reconstr Surg** 1996 Feb;97(2):427
Getting organized. Pros and cons of business structures for medical practice. Stern MZ. **Tex Med** 1995 Sep;91(9):24–6

ECONOMICS

A new approach to health system reform: seizing the moral high ground. Silverman JS. **Pa Med** 1995 Jun;98(6):28–30

LEGISLATION & JURISPRUDENCE

Good things don't always come to those who wait. Berg RN. **J Med Assoc Ga** 1995 Sep;84(7):329–30
Who's the boss? Ortolon K. **Tex Med** 1996 Jun;92(6):30–2

ORGANIZATION & ADMINISTRATION

Visits to three POs provide valuable information. Wolff TM. **Mich Med** 1995 Aug;94(8):12–5

PROFESSIONAL-FAMILY RELATIONS

Nurses do matter. Aerni S. **Am J Nurs** 1996 May;96(5):80
When a loved one is dying: families talk about nursing care. Czerwiec M. **Am J Nurs** 1996 May;96(5):32–6
When a baby dies. Diaz MR. **Am J Nurs** 1995 Nov; 95(11):54–6
For Joey's sake. Edinburgh LD. **Am J Nurs** 1995 Oct; 95(10):88
'The daughter is a nurse'. McConnell EA. **Am J Nurs** 1996 Jan;96(1):46–7
Alma: coping with culture, poverty, and disability. Blanche EI. **Am J Occup Ther** 1996 Apr;50(4):265–76
An exploratory study of how occupational therapists develop therapeutic relationships with family caregivers. Clark CA, et al. **Am J Occup Ther** 1995 Jul–Aug;49(7):587–94
The spiritual needs of pediatric patients and their families. Fina DK. **AORN J** 1995 Oct;62(4):556–64
Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)
The undoing of a diagnosis. The effect of a misdiagnosis of a disease. Barbero GJ. **Arch Pediatr Adolesc Med** 1995 Dec; 149(12):1341–4
Making time count. Blosser J. **ASHA** 1996 Winter;38(1):40–1
Preassessment planning with caregivers. Crais ER. **ASHA** 1996 Winter;38(1):38–9
Reaching families through technology. Gillette Y. **ASHA** 1996 Winter;38(1):42–5
Forming a therapeutic alliance with older adults. Hooper CR. **ASHA** 1996 Winter;38(1):43–5
A clinician with a family member with schizophrenia: a case report. Hough G. **Bull Menninger Clin** 1995 Summer; 59(3):345–56
The helping alliance in work with families where children have been abused or neglected [editorial; comment] Jones DP. **Child Abuse Negl** 1996 Apr;20(4):345–7. Comment on: Child Abuse Negl 1996 Apr;20(4):349–61.
Elizabeth and Alexandra's story. Astelm J. **Child Care Health Dev** 1995 Nov;21(6):369–75
Electroconvulsive therapy patient/family education. Dillon P. **Convuls Ther** 1995 Sep;11(3):188–91
Family involvement in medical decision making. Reust CE, et al. **Fam Med** 1996 Jan;28(1):39–45
Reconceiving the family. The process of consent in medical decisionmaking. Kuczewski MG. **Hastings Cent Rep** 1996 Mar–Apr;26(2):30–7
Scottish neonatal intensive care units; a study of staff and parental attitudes. Reid M, et al. **Health Bull (Edinb)** 1995 Sep;53(5):314–25
Management of the angry parents of severely ill children. Sardesai U, et al. **Indian Pediatr** 1995 Jan;32(1):123–7
Splitting on a pediatric consult liaison service. Robertson JM, et al. **Int J Psychiatry Med** 1996;26(1):93–104
A study of the attitudes of nurses to parental involvement in the initial child-protection conference, and their preparation for it. Bell M. **J Adv Nurs** 1995 Aug;22(2):250–7
Partnership nursing: influences on involvement of informal carers. Casey A. **J Adv Nurs** 1995 Dec;22(6):1058–62
Survey of career satisfaction with the quality of care delivered to in-patients suffering from dementia. Simpson RG, et al. **J Adv Nurs** 1995 Sep;22(3):517–27
Collaboration between research professional and consumer. Schopler E. **J Autism Dev Disord** 1996 Apr;26(2):277–80
Home. Valdini AF. **J Fam Pract** 1996 Aug;43(2):192–4
Family centered intrapartum care: revisiting an old concept. Tomlinson PS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):331–7
Life-threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219–23 (7 ref.)
Pediatrician's communication style: relationship to parent's perceptions and behaviors. Worchel FF, et al. **J Pediatr Psychol** 1995 Oct;20(5):633–44
How parents describe caring behaviors of nurses in pediatric intensive care. Vincent JL, et al. **MCN Am J Matern Child Nurs** 1996 Jul–Aug;21(4):197–201
Donation of heart valve tissue: seeking consent and meeting the needs of donor families. Haire MC, et al. **Med J Aust** 1996 Jan 1;164(1):28–31
When you don't know what to say, don't say anything [letter] Lucey DT. **N C Med J** 1995 Sep;56(9):414
Pediatric dentists' attitudes regarding parental presence during dental procedures. Marcum BK, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):432–6
Pediatric care for children whose parents are gay or lesbian. Perrin EC, et al. **Pediatrics** 1996 May;97(5):629–35
A survivor's tale [see comments] Cutler SB. **Pharos** 1996 Spring;59(2):37–40. Comment in: Pharos 1996 Spring;59(2):41.
Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137–40 (33 ref.)
What's a psychiatrist to do? [letter; comment] Berman LH. **Psychiatr Serv** 1995 Nov;46(11):1194. Comment on: Psychiatr Serv 1995 Aug;46(8):757–8.
Measuring therapeutic interactions: research and clinical applications. Weissmark MS, et al. **Psychiatry** 1995 May; 58(2):173–88
Pediatric critical care social work: clinical practice with parents of critically ill children. Dungan SS, et al. **Soc Work Health Care** 1995;21(1):69–80
Parent and professional perceptions about stress and coping strategies during a child's lengthy hospitalization. Horn JD, et al. **Soc Work Health Care** 1995;21(1):107–27
Organ and tissue procurement rates improve after professional healthcare education by hospital development coordinators and time sensitive requesting. Cumberland BG, et al. **Transplant Proc** 1995 Oct;27(5):2957–8
[Presence of parents in pediatric imaging] Schmit P, et al. **J Radiol** 1996 Jan;77(1):60–3 (Eng. Abstr.) **(Fre)**
[Conflicts between parenteral expectations and children's needs in child guidance clinics] Salgo L. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):359–65 (Eng. Abstr.) **(Ger)**
[Family situation of home care givers] Steffens MC, et al. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):75–94 (Eng. Abstr.) **(Ger)**
[Deficient care of children with functional disabilities. Insecure relationship between child health services and parents] Janson S, et al. **Lakartidningen** 1996 May 22; 93(21):2057–60 **(Swe)**

PROFESSIONAL IMPAIRMENT

Substance abuse in the perioperative setting. Dillmann JM. **AORN J** 1995 Jul;62(1):111–2
Drink, drugs and dentistry—are you at risk? **Br Dent J** 1996 May 25;180(10):392–3
Four years experience of a hospital's impaired physician committee. Schwartz RP, et al. **J Addict Dis** 1995; 14(2):13–21
Attitudes and perceptions of nursing students toward chemically impaired nurses: implications for nursing education. Wennerstrom PA, et al. **J Nurs Educ** 1996 May; 35(5):237–9
Policy and guidelines for prevention and management of substance abuse in the nursing education community. American Association of Colleges of Nursing. **J Prof Nurs** 1996 Jul–Aug;12(4):253–7
Helping the helper [letter] Combs J. **J Psychosoc Nurs Ment Health Serv** 1996 Mar;34(3):10
Interventions in response to chemically dependent nurses: effect of context and interpretation. Torkelson DJ, et al. **Res Nurs Health** 1996 Apr;19(2):153–62

LEGISLATION & JURISPRUDENCE

Consultation when the patient terminates an impaired treatment. Abarbanel A. **Am J Psychoanal** 1995 Dec; 55(4):347–63; discussion 365–7
Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425–35 (62 ref.)

PROFESSIONAL LIABILITY see LIABILITY, LEGAL

PROFESSIONAL-PATIENT RELATIONS

see related

TRUTH DISCLOSURE

What I learned on my sabbatical [see comments] Barnard D. **Acad Med** 1996 Mar;71(3):257. Comment in: Acad Med 1996 Mar;71(3):256.
Alcohol, other drugs, and what we gain from our patients [editorial] Edwards G. **Addiction** 1995 Aug;90(8):1021–3
Making a difference for patients, one pharmacist at a time. Raehl CL. **Am J Health Syst Pharm** 1995 Aug 1; 52(15):1663–6, 1675
A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Hanlon JT, et al. **Am J Med** 1996 Apr;100(4):428–37
Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

PROFESSIONAL-PATIENT RELATIONS

Are you a fraud? Am I a fraud? Is PM&R a fraud? [editorial] Meier RH 3rd. **Am J Phys Med Rehabil** 1996 Jan-Feb; 75(1):2

The consultant's role when the analyst terminates therapy. Elkind SN. **Am J Psychoanal** 1995 Dec;55(4):331-46; discussion 365-7

Understanding and differentiating clients' positive feelings in psychotherapy. Chance SE, et al. **Am J Psychother** 1995 Fall;49(4):514-25 (23 ref.)

Interactional obstacles to empathic relating in the psychotherapy of narcissistic disorders. Ivey G. **Am J Psychother** 1995 Summer;49(3):350-70

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787-90 (24 ref.)

Professional psychology and deaf people. The emergence of a discipline. Pollard RQ Jr. **Am Psychol** 1996 Apr; 51(4):389-96

Patient-therapist interaction in the behavioral treatment of panic disorder with agoraphobia. Keijsers GP, et al. **Behav Modif** 1995 Oct;19(4):491-517

Treat patients with kindness during magnetic resonance imaging [letter] Duncan K, et al. **BMJ** 1996 Jun 1; 312(7043):1421

Power, boundaries, intersubjectivity. Owen IR. **Br J Med Psychol** 1995 Jun;68 (Pt 2):97-107

Helen Bramson: treatment after sexual abuse by a mental health practitioner. Wohlberg JW, et al. **Bull Menninger Clin** 1996 Winter;60(1):52-61

Managed mental health care: conflicts of interest in the provider/client relationship. Backlar P. **Community Ment Health J** 1996 Apr;32(2):101-6

Case manager alliance with clients in an older cohort. Draine J, et al. **Community Ment Health J** 1996 Apr;32(2):125-34

Helping cancer patients disclose their concerns. Maguire P, et al. **Eur J Cancer** 1996 Jan;32A(1):78-81

Sampling communicative behaviours in children with intellectual disability in structured and unstructured situations. Iacono TA, et al. **Eur J Disord Commun** 1996; 31(2):106-20

The understanding and use of counselling by speech and language therapists at different levels of experience. Parkinson K, et al. **Eur J Disord Commun** 1996;31(2):140-52

A self psychologist in couplesland: multisubjective approach to transference and countertransference-like phenomena in marital relationships. Livingston MS. **Fam Process** 1995 Dec;34(4):427-39 (26 ref.)

Patients' threats. Expanded definition of assault. Flannery RB Jr, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):451-3

Changing the way we talk with elders: promoting health using the communication enhancement model. Ryan EB, et al. **Int J Aging Hum Dev** 1995;41(2):89-107

Therapist sexual feelings in hypnotherapy: managing therapeutic boundaries in hypnotic work. Adrian C. **Int J Clin Exp Hypn** 1996 Jan;44(1):20-32

Intersubjectivity in psychoanalysis: a critical review. Dunn J. **Int J Psychoanal** 1995 Aug;76 (Pt 4):723-38 (90 ref.)

The mutual search for self in the analytic dyad. Fabricius J. **Int J Psychoanal** 1995 Jun;76 (Pt 3):577-89

The infantile in the analytic relationship. Guignard F. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1083-93

A particular perspective on impasses in the clinical situation: further reflections on psychoanalytic listening. Schwaber EA. **Int J Psychoanal** 1995 Aug;76 (Pt 4):711-22

Using video and conversational analysis to train staff working with people with learning disabilities. Couchman W. **J Adv Nurs** 1995 Dec;22(6):1112-9

The role of technology in patient care [comment] Beardsley RS. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):315. Comment on: J Am Pharm Assoc (Wash) 1996 May;NS36(5):309-14.

Enactments of boundary violations. Panel report. **J Am Psychoanal Assoc** 1995;43(3):853-68

Desire and the female analyst. Schaverien J. **J Anal Psychol** 1996 Apr;41(2):261-87 (91 ref.)

Transforming or vampiric? When care-providers share their subjective realities with their patients [comment] Howe EG. **J Clin Ethics** 1995 Summer;6(2):98-111. Comment on: J Clin Ethics 1995 Summer;6(2):112-27.

Keeping care in health care reform. Imperato PJ. **J Community Health** 1996 Jun;21(3):155-8

The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Krupnick JL, et al. **J Consult Clin Psychol** 1996 Jun;64(3):532-9

The resolution of ruptures in the therapeutic alliance. Safran JD, et al. **J Consult Clin Psychol** 1996 Jun;64(3):447-58

The interaction of the alliance and therapy microprocess: a sequential analysis. Sexton HC, et al. **J Consult Clin Psychol** 1996 Jun;64(3):471-80

Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295-305 (43 ref.)

Experienced and inexperienced health care workers' beliefs about challenging behaviours. Hastings RP, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):474-83

Women, providers, and control. Rothman BK. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr;25(3):253-6

The promise of intimacy and the fear of our own undoing. Barnard D. **J Palliat Care** 1995 Winter;11(4):22-6

Presentation format in analogue studies: effects on participants' evaluation. Johnson ME, et al. **J Psychol** 1996 May;130(3):341-9

The Hippocratic Oath: a code for physicians, not a Pythagorean manifesto. Prioreschi P. **Med Hypotheses** 1995 Jun;44(6):447-62 (122 ref.)

The rehabilitation relationship. Horowitz R, et al. **New Dir Ment Health Serv** 1995 Winter;(68):21-32

Speaking tubes for bedside use [letter] Cantrell H. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):506

On priorities [editorial; comment] Barondess JA. **Pharos** 1996 Spring;59(2):41. Comment on: Pharos 1996 Spring;59(2):20-1. Comment on: Pharos 1996 Spring;59(2):30-3. Comment on: Pharos 1996 Spring;59(2):37-40.

A survivor's tale [see comments] Cutler SB. **Pharos** 1996 Spring;59(2):37-40. Comment in: Pharos 1996 Spring;59(2):41.

The politics of diagnostic identity. Brooks ER. **Psychiatr Serv** 1995 Oct;46(10):1013-4

Therapeutic alliance and outcome in a VA intensive case management program. Neale MS, et al. **Psychiatr Serv** 1995 Jul;46(7):719-21

Cost-effective communication skills training for state hospital employees. Smoot SL, et al. **Psychiatr Serv** 1995 Aug; 46(8):819-22

Erotic transference in the male adolescent-female analyst dyad. Atkinson S, et al. **Psychoanal Study Child** 1995; 50:171-86

Termination in child analysis. A child-led process? Fabricius J, et al. **Psychoanal Study Child** 1995;50:205-26

Communication issues in breast imaging. D'Orsi CJ, et al. **Radiol Clin North Am** 1995 Nov;33(6):1231-45 (31 ref.)

From another place and time. Little MA, et al. **Radiol Technol** 1995 Sep-Oct;67(1):78

[Establishing a healing relationship in a nonverbal manner. Psychotherapy series, 13: Music therapy] Timmermann T. **Fortschr Med** 1996 May 30;114(15):14, 16 **(Ger)**

[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201-5 (18 ref.) (Eng. Abstr.) **(Ger)**

[The dream as a relationship paradigm] Hölzer M, et al. **Psychother Psychosom Med Psychol** 1996 Mar-Apr; 46(3-4):116-23 (Eng. Abstr.) **(Ger)**

[Quality of the therapeutic relationship: do common factors in psychotherapy correspond with common characteristics of psychotherapists? SPR Collaborative Research Network] Orlinsky DE, et al. **Psychother Psychosom Med Psychol** 1996 Mar-Apr; 46(3-4):102-10 (Eng. Abstr.) **(Ger)**

[Communication barriers with the HIV+ patient perceived by health personnel] Contreras Tejera A, et al. **Gac Sanit** 1995 Mar-Apr;9(47):91-100 (Eng. Abstr.) **(Spa)**

PROFESSIONAL PRACTICE

see related
PRACTICE MANAGEMENT, DENTAL
PRACTICE MANAGEMENT, MEDICAL

Professionalism in the community pharmacy setting [letter] Odedina FT. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1572

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412-5 (18 ref.)

Concordance between retina specialists and a preferred practice pattern in treatment and follow-up criteria for diabetic retinopathy. The Mexico City Diabetes Study Retinopathy Group. González ME, et al. **Arch Med Res** 1996 Summer;27(2):205-11

Desirable performance standards for imprecision and bias in alternate sites. The views of laboratory professionals. Fraser CG, et al. **Arch Pathol Lab Med** 1995 Oct; 119(10):909-13

Pediatric rheumatology in adult rheumatology practices in Washington state. Sherry DD, et al. **Arthritis Rheum** 1996 Jul;39(7):1218-21

Pediatric dental practice: the number of your employees is increasing. Waldman HB. **ASDC J Dent Child** 1995 Sep-Oct;62(5):356-9

Profession in crisis? Redefining clinical engineering. Kasti M. **Biomed Instrum Technol** 1995 Jul-Aug;29(4):361-2

Only doing my duty? [editorial] Adshead G. **BMJ** 1995 Oct 14;311(7011):965-6

Relief workers need professionalism [news] Dillner L. **BMJ** 1995 Oct 7;311(7010):895

Doctors in Britain urged to practise effectively [news] Dillner L. **BMJ** 1996 Jan 20;312(7024):143-4

Nurses taking on junior doctors' work: a confusion of accountability. Dowling S, et al. **BMJ** 1996 May 11; 312(7040):1211-4

Over the counter drugs [editorial; comment] [see comments] Kennedy JG. **BMJ** 1996 Mar 9;312(7031):593-4. Comment on: BMJ 1996 Mar 9;312(7031):617-8. Comment on: BMJ 1996 Mar 9;312(7031):629-32. Comment in: BMJ 1996 Jul 13;313(7049):116.

Work in the European Union. Klemperer F. **BMJ** 1996 Mar 2;312(7030):567-70

Current practice and complications of temporary transvenous cardiac pacing. Murphy JJ. **BMJ** 1996 May 4; 312(7039):1134

Over the counter drugs. Both doctors and pharmacists should prescribe better [letter] Po AL, et al. **BMJ** 1996 Jul 13; 313(7049):115

Clinical practice and medical research: bridging the divide between the two cultures. Owen P. **Br J Gen Pract** 1995 Oct;45(399):557-60

Labour and delivery of 'normal' primiparous women: analysis of routinely collected data. Middle C, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):970-7

Obstetric pelvimetry in the UK: an appraisal of current practice. Morrison JJ, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):748-50

Comparison of single reading with double reading of mammograms, and change in effectiveness with experience. Warren RM, et al. **Br J Radiol** 1995 Sep;68(813):958-62

No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Oxman AD, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1423-31

Family physicians: what do we do? [letter] Rapoport D. **Can Med Assoc J** 1996 Jul 1;155(1):12-3

Preregistration and post graduate practice training period. FDI Working Group. **Int Dent J** 1995 Apr;45(2):141-59

The professional paradigm of qualified psychiatric nurses. Lindström UA. **J Adv Nurs** 1995 Oct;22(4):655-62

Developing direction for your practice. Palazzolo C, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):356-8

Functions of veterinary colleges and orientations of professional practice in the Americas. Rivas AL, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1630-5

Physicians' prevention-related practice behaviors in treating adult patients with asthma: results of a national survey [corrected and republished in J Asthma 1995;32(4):309-18] Wolle JM, et al. **J Asthma** 1995;32(2):131-40

Review of clinical activity by microbiologists. Balfour A. **J Clin Pathol** 1996 May;49(5):429-31

Career pathways and current practice patterns of clinical and counseling psychologists: a follow-up study of former interns. Stedman JM, et al. **J Clin Psychol** 1995 May; 51(3):441-8

Gender and the transition into practice. Solomon ES, et al. **J Dent Educ** 1995 Aug;59(8):836-40

What are the implications for the community of the discrepancy between the theory and practice of BP control? Jackson R. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S25-8 (8 ref.)

Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29-31 (13 ref.)

Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19-23 (17 ref.)

Women in oral and maxillofacial surgery: factors affecting career choices, attitudes, and practice characteristics. Risser MJ, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):753-7

Professional practice. Feel free. Koerner J. **J Prof Nurs** 1996 Mar-Apr;12(2):66

Management of seizures in the elderly: a survey of UK geriatricians. Stolarek IH, et al. **J R Soc Med** 1995 Dec; 88(12):686-9

A piece of my mind. A cyberday in the life. Bates DW, et al. **JAMA** 1996 Mar 13;275(10):753-4

Right of overseas doctors to practise in the UK [letter] [see comments] Attanasio AE. **Lancet** 1996 Jan 6;347(8993):62 . Comment in: Lancet 1996 Feb 24;347(9000):545.

Right of overseas doctors to practise in UK [letter; comment] Lowry S. **Lancet** 1996 Feb 24;347(9000):545. Comment on: Lancet 1996 Jan 6;347(8993):62.

Focused professional education: a response to physicians' individual educational needs. Kowalewski EJ, et al. **Md Med J** 1996 Jul;45(7):564-8

Empowering physicians for the future. Zako LR. **Mich Med** 1995 Nov;94(11):18-23

Is it time to consider a liability shield? Kenny R. **N J Med** 1995 Dec;92(12):799-802

Dentistry, self-esteem and criticism. Davidove DM. **N Y State Dent J** 1996 Apr;62(4):43-5

Caring advanced nursing practice [letter] Martin SR. **Nurse Pract** 1995 Nov;20(11 Pt 1):16, 21, 23 (29 ref.)

Prescribing in the elderly. Walley T, et al. **Postgrad Med J** 1995 Aug;71(838):466-71

Clinical practice, measurement and information technology [editorial] Andrews G, et al. **Psychol Med** 1995 May; 25(3):443-6

The simulated patient [comment] Lerman LG. **Public Health Rep** 1996 Mar-Apr;111(2):133-4. Comment on: Public Health Rep 1996 Mar-Apr;111(2):129-32.

Ultrasonography and the surgeon [editorial] Deziel DJ. **Surg Endosc** 1996 Jun;10(6):615-6

Is how you look important? Ausman JI. **Surg Neurol** 1996 May;45(5):490-1

24-hour service [letter; comment] Ellis RN. **Vet Rec** 1995 Sep 16;137(12):299. Comment on: Vet Rec 1995 Sep 2;137(10):249-50.

[Professional practice in stage I melanoma. A national survey of dermatologists] Poisson-Salomon AS, et al. **Ann Dermatol Venereol** 1995;122(5):259-62 **(Fre)**

[Spiritual ethical principles of surgical professional practice and imparting them to younger generations] Müller-Osten W. **Chirurg** 1995 Aug;66(8):suppl 172-5 **(Ger)**

[Errors and culprits (editorial)] Caeiro T. **Medicina (B Aires)** 1995;55(3):276 **(Spa)**

ECONOMICS

The "business" of medicine: hippocratic or hypocritical? Schuller DE. **Ann Allergy Asthma Immunol** 1996 Jul; 77(1):28–32

Issues to consider when buying or selling a veterinary practice. Matthew B. **Can Vet J** 1995 Oct;36(10):654–7 **(Eng, Fre)**

Advertising. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):228–34

HISTORY

Wouldn't Charles Prentice be pleased? [editorial] Classé JG. **J Am Optom Assoc** 1995 Sep;66(9):528

LEGISLATION & JURISPRUDENCE

Belgian doctors' freedom to be guaranteed [news] Sheldon T. **BMJ** 1996 Apr 20;312(7037):993

Optometrists threaten public safety with bill [letter] Miura CM. **Hawaii Med J** 1996 Jun;55(6):96

Nursing practice in Canada: the influence of current and proposed legislation. Hadley M. **J Adv Nurs** 1995 Dec; 22(6):1210–17

The legal implications of clinical practice guidelines. Keyes GG. **J Am Dent Assoc** 1996 Jun;127(6):795–800

Restrictive covenants: recent cases, court modification, and statutory provisions. Hannah HW. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1825–6

Consumer Protection Act and the medical profession. Kumaraswami TM. **J Indian Med Assoc** 1995 Mar; 93(3):112, 104

Noncompetition agreements in Kentucky health care. Dolson SW. **J Ky Med Assoc** 1996 Apr;94(4):154–8

Physicians must provide auxiliary aids/services to assure effective communication with hearing impaired patients. McGraw S, et al. **Mich Med** 1995 Aug;94(8):10–1

The Hanlester decision: intent is significant in anti-kickback law analysis. **Wis Med J** 1995 Nov;94(11):633–5

[Changes in the functional scope of a chief physician] Rieger HJ. **Dtsch Med Wochenschr** 1996 Feb 16;121(7):217–8 **(Ger)**

ORGANIZATION & ADMINISTRATION

Iowa physicians and community hospitals ... bound by common interests. Parker C. **Iowa Med** 1995 Oct; 85(10):404–7

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

Professional dynamics and the changing nature of medical work. Hafferty FW, et al. **J Health Soc Behav** 1995;Spec No:132–53 (130 ref.)

Guidelines for developing a nurse practitioner practice. Shay LE, et al. **Nurse Pract** 1996 Jan;21(1):72–81

The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1–10 (33 ref.)

24-hour service [letter; comment] Brown DJ. **Vet Rec** 1995 Sep 16;137(12):299. Comment on: Vet Rec 1995 Sep 2;137(10):249–50.

STANDARDS

Improper treatment of anaphylaxis. Knight A. **Allergy** 1996 Jan;51(1):67

Quality and professionalism in health care: a review of current initiatives in the NHS. Taylor D. **BMJ** 1996 Mar 9;312(7031):626–9

Nursing and the biological sciences [editorial] Clarke M. **J Adv Nurs** 1995 Sep;22(3):405–6

Dentistry as a business [letter] Enright CM. **J Am Dent Assoc** 1996 Feb;127(2):160

Analysis of necropsy request behaviour of clinicians. Start RD, et al. **J Clin Pathol** 1996 Jan;49(1):29–33

A professional challenge: nurses and smoking. Mundt MH, et al. **J Community Health Nurs** 1995;12(3):139–46

Physician malpractice: does the past predict the future? Taragin MI, et al. **J Gen Intern Med** 1995 Oct;10(10):550–6

Price competition, professional cooperation and standards. Arnold PC. **Med J Aust** 1996 Sep 2;165(5):272–3

If you want mediocre care, fail to reward people for giving excellent care [editorial] Spaeth GL. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):511–2

Analysis of the practice of nutrition support pharmacy specialists. Holcombe BJ, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):806–13

The legitimacy of clinical knowledge: towards a medical epistemology embracing the art of medicine. Malterud K. **Theor Med** 1995 Jun;16(2):183–98

Front-line management of pulmonary tuberculosis: an analysis of tuberculosis and treatment practices in urban Sindh, Pakistan [see comments] Marsh D, et al. **Tuber Lung Dis** 1996 Feb;77(1):86–92. Comment in: Tuber Lung Dis 1996 Feb;77(1):2–3.

Professionalism behaviors of hospital nurse executives and middle managers in 10 western states. Adams D, et al. **West J Nurs Res** 1996 Feb;18(1):77–88

[Annual report Veterinary Disciplinary Tribunal and Professional Board 1994. Attention to communication and reception of complaints is necessary] van Egmond S. **Tijdschr Diergeneeskd** 1995 Oct 15;120(20):596–9 **(Dut)**

STATISTICS & NUMERICAL DATA

Anaesthesia for exodontia in young children—a snapshot survey of European practice [letter] Davies MW, et al. **Anaesthesia** 1996 Jul;51(7):713

Insertion methods of the laryngeal mask airway. A survey of current practice in Wales. Dingley J, et al. **Anaesthesia** 1996 Jun;51(6):596–9

A national survey of screening for congenital dislocation of the hip. Dezateux C, et al. **Arch Dis Child** 1996 May; 74(5):445–8

Comparison of activity level and service intensity of male and female physicians in five fields of medicine in Ontario [see comments] Woodward CA, et al. **Can Med Assoc J** 1995 Oct 15;153(8):1097–106. Comment in: Can Med Assoc J 1996 Feb 1;154(3):303. Comment in: Can Med Assoc J 1996 Feb 15;154(4):446; discussion 446, 448.

Variation in angiographic practice and technique amongst interventional radiologists in the UK: assessment by postal questionnaire. Roobottom CA, et al. **Clin Radiol** 1995 Oct; 50(10):705–9

Dentist service rates and distribution of practice styles over time. Brennan DS, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):145–51

A survey of ethical dilemmas and practical problems encountered by practicing dentists. Kress GC, et al. **J Am Dent Assoc** 1995 Nov;126(11):1554–62

A survey of the current methods used in the UK to assess pituitary function. Davies MJ, et al. **J R Soc Med** 1996 Mar;89(3):159P–64P

Practice areas and settings of social workers in mental health. Gibelman M, et al. **Psychiatr Serv** 1995 Dec;46(12):1237

Employment settings of psychologists. Kohout JL. **Psychiatr Serv** 1995 Nov;46(11):1115

Psychiatrists' patients. Koran LM. **Psychiatr Serv** 1995 Sep; 46(9):873

[Woman physician in general practice] Leifels-Fischer B. **Arch Gynecol Obstet** 1995;257(1–4):709–12 **(Ger)**

TRENDS

Pharmacy's transition to a proactive practice mode. Poole TA. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2821–4

Our journey together. Evert MM. **Am J Occup Ther** 1995 Nov–Dec;49(10):1065–7

Acid-base management during cardiopulmonary bypass. Current trends in the United Kingdom. Goldsack C, et al. **Anaesthesia** 1996 Apr;51(4):396–8

Rho Chi Lecture Award. Is something broken that requires fixing? Bachmann KA. **Ann Pharmacother** 1995 Nov; 29(11):1156–9

Presidential inaugural address 1995—conquering challenges, creating successes. Jarnagin DE. **J Am Optom Assoc** 1995 Sep;66(9):581–3

A comparison of TPA/DPA certification and access to care in North Carolina, Missouri, and Illinois. Wingert TA, et al. **J Am Optom Assoc** 1995 Aug;66(8):466–70

Managing for the future. Feyerherm A, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):678–81

Professional or commercial [editorial] Landrum SE. **J Ark Med Soc** 1996 Jan;92(8):388–9

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)

Survival of the fittest [letter] Crowley WJ Jr. **Mo Med** 1995 Sep;92(9):562

Integrating lasers into clinical practice. Rounds RS, et al. **Optom Clin** 1995;4(4):125–40 (10 ref.)

Some observations on ophthalmology and contemporary patient care. Curran RE. **R I Med** 1995 Dec;78(12):337–8

[The veterinarian after the year 2002 (letter)] De Kruif A. **Tijdschr Diergeneeskd** 1995 Oct 1;120(19):566–7 **(Dut)**

PROFESSIONAL PRACTICE LOCATION

Sex differences among physicians in rural practice [letter; comment] Peloso PM. **Can Med Assoc J** 1996 Feb 1; 154(3):303. Comment on: Can Med Assoc J 1995 Oct 15;153(8):1097–106.

The paediatric oncology community nurse specialist: the influence of employment location and funders on models of practice. Hunt JA. **J Adv Nurs** 1995 Jul;22(1):126–33

Practice characteristics and performance of primary care practitioners. Hargraves JL, et al. **Med Care** 1996 Sep;34(9 Suppl):SS67–76

Recruitment to rural practice. Macleod JA. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):43–5

Have we got a deal for you, doc. Small towns recruiting big time to lure physicians to rural Texas. BeSaw L. **Tex Med** 1995 Aug;91(8):13–6

LEGISLATION & JURISPRUDENCE

New physicians, unlike new mechanics, find pay and location restricted [letter] MacDonald P. **Can Med Assoc J** 1996 May 1;154(9):1315–6

STATISTICS & NUMERICAL DATA

Factors influencing retention of rural Pennsylvania family physicians [see comments] Forti EM, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):469–74. Comment in: J Am Board Fam Pract 1995 Nov–Dec;8(6):496–9.

Dentists' work location in relation to their origin. Sjöström O. **Swed Dent J** 1996;20(1–2):69–73

TRENDS

Beyond retention: National Health Service Corps participation and subsequent practice locations of a cohort of rural family physicians. Rosenblatt RA, et al. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):23–30

The geographic and temporal patterns of residency-trained family physicians: University of Washington Family Practice Residency Network. West PA, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):100–8

Migration of obstetrician-gynecologists into and out of rural areas, 1985–1990. Ricketts TC, et al. **Med Care** 1996 May; 34(5):428–38

PROFESSIONAL REVIEW ORGANIZATIONS

The Residency Review Committee for Ophthalmology [editorial] Lessell S. **Arch Ophthalmol** 1996 Aug; 114(8):1002–4

Setting up interdepartmental peer review. The British Thoracic Society's scheme. Page RL, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):319–24

Changing health care practices in Medicare's Health Care Quality Improvement Program. Jencks SF. **Jt Comm J Qual Improv** 1995 Jul;21(7):343–7

KePRO prepares for new national cooperative project. Harrop DE. **Pa Med** 1995 Nov;98(11):28

KePRO project sheds light on anticoagulation in atrial fibrillation. Whittle J. **Pa Med** 1995 Dec;98(12):30–1

A word from WIPRO. Hospitals working on improving use of prophylactic antibiotics. Blustein J, et al. **Wis Med J** 1996 Jun;95(6):394–6

ORGANIZATION & ADMINISTRATION

KePRO's principal clinical coordinator. Harrop DE. **Pa Med** 1995 Jul;98(7):20

TRENDS

The origins and evolution of peer review organizations. Dettmann FG. **Jt Comm J Qual Improv** 1995 Jul; 21(7):322–4

Emerging themes in efforts to improve the quality of health care: overview. Greer AL, et al. **Jt Comm J Qual Improv** 1995 Jul;21(7):319–21

Notes from the field: changing peer review. Wolff M. **Jt Comm J Qual Improv** 1995 Jul;21(7):360–5

PROFESSIONAL STAFF COMMITTEES

see related
UTILIZATION REVIEW

Junior Doctors Committee has achieved much recently [letter] Smith S. **BMJ** 1996 Aug 10;313(7053):367

What we want. Part 4: Case reports and committee reports [editorial] Leduc CP. **Can Fam Physician** 1996 Apr; 42:592–3, 604–6 **(Eng, Fre)**

IRBs and hospital ethics advisory boards [letter] Seibel MM. **Fertil Steril** 1996 Oct;66(4):671

Institutional review boards. A net too thin. Palca J. **Hastings Cent Rep** 1996 May–Jun;26(3):4

Public policy statement on mutually accepted sanctions by State Boards of Medical Examiners. **J Addict Dis** 1995; 14(2):98–9

Four years experience of a hospital's impaired physician committee. Schwartz RP, et al. **J Addict Dis** 1995; 14(2):13–21

The value of the medical examiner as a member of the multidisciplinary trauma morbidity–mortality committee. Lozen YM, et al. **J Trauma** 1995 Dec;39(6):1054–7

[Scientific aspects of the organization of congresses. The scientific committee (editorial)] Gómez de la Cámara A. **Aten Primaria** 1995 Nov 30;16(9):511–2 **(Spa)**

[Informed consent and the approval of evaluation committees in Mexican medical research] López-de-la-Peña XA. **Rev Invest Clin** 1995 Sep–Oct;47(5):399–404 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Mental health tribunals [letter; comment] Crimlisk H, et al. **Br J Psychiatry** 1995 Jul;167(1):116–7. Comment on: Br J Psychiatry 1993 Jan;162:14–22.

ORGANIZATION & ADMINISTRATION

Member responsibilities on a nursing research committee. Martin PA. **Appl Nurs Res** 1996 Aug;9(3):154–7 (15 ref.)

Section of researchers. College of Family Physicians of Canada. Labrecque M. **Can Fam Physician** 1995 Aug; 41:1378–80 **(Eng, Fre)**

Battling environmental concerns. How physicians and hospitals can work together [editorial] Rosen DC. **Can Fam Physician** 1996 Mar;42:390–1, 400–2 **(Eng, Fre)**

From the Food and Drug Administration. Nightingale SL. **JAMA** 1995 Dec 27;274(24):1903

The institutional review board and beyond: future challenges to the ethics of human experimentation. Edgar H, et al. **Milbank Q** 1995;73(4):489–506

PROFESSIONAL STANDARDS REVIEW ORGANIZATIONS see **PROFESSIONAL REVIEW ORGANIZATIONS**

PROFIBRINOLYSIN see **PLASMINOGEN**

PROFLAVINE

Comparison of an intercalating dye and an intercalant–enzyme conjugate for DNA detection in a microtiter–based assay. Kolakowski B, et al. **Anal Chem** 1996 Apr 1;68(7):1197–200

PHARMACOLOGY

Haematoporphyrin and proflavine–sensitized photoinactivation of Salmonella dublin. Kussovski V, et al. **Cytobios** 1995;84(338–339):157–69

PROGENITOR CELLS see **STEM CELLS**

PROGENITOR CELLS, ERYTHROPOIETIC see **ERYTHROID PROGENITOR CELLS**

PROGENITOR CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

PROGERIA

CONGENITAL

Clinical variability in neonatal progeroid syndrome [letter] Hou JW, et al. **Am J Med Genet** 1995 Aug 28;58(2):195–6

GENETICS

On signal sequence polymorphisms and diseases of distribution. Rosenblum JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4471–3

METABOLISM

Atherogenic change in the thoracic aorta of the senescence–accelerated mouse. Yagi K, et al. **Atherosclerosis** 1995 Dec;118(2):233–6

PATHOLOGY

The Wiedemann–Rautenstrauch neonatal progeroid syndrome: a case report and review of the literature. Bitoun P, et al. **Clin Dysmorphol** 1995 Jul;4(3):239–45

[Neuropathological findings in a case of Hutchinson–Gilford progeria syndrome] Tanaka S, et al. **No To Hattatsu** 1995 Sep;27(5):407–9 **(Jpn)**

PROGERIA, ADULT see **WERNER'S SYNDROME**

PROGESTATIONAL HORMONE ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTATIONAL HORMONES

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

[35 years of estrogen–progestagen pills: where is the vascular risk?] Gaspard U. **Rev Med Liege** 1996 Jan;51(1):133–8 (15 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Low–dose progestogen contraception and the nursing mother. Toddywalla VS, et al. **Adv Contracept** 1995 Dec; 11(4):285–94

Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Nachtigall LE. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):993–7 (15 ref.)

Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Dallongeville J, et al. **Atherosclerosis** 1995 Nov;118(1):123–33

Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. **BMJ** 1996 Feb 24; 312(7029):473–8

Protective effect depot progestogens against uterine leiomyoma [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Sep;103(9):vii–viii. Comment on: Br J Obstet Gynaecol 1996 Sep;103(9):909–14.

The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Norris LA, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):261–7

Hormones and breast and endometrial cancers: preventive strategies and future research. Hulka BS, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:185–9 (49 ref.)

Rationale for estrogen with interrupted progestin as a new low–dose hormonal replacement therapy. Casper RF, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):225–34 (79 ref.)

Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):243–54 (83 ref.)

[Estrogen–gestagen substitution in geriatric gynecology. Long–term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**

[Gestagens and hormone substitution] Klinger G. **Zentralbl Gynakol** 1995;117 Suppl:25–9 (0 ref.) **(Ger)**

[Hormone therapy of endometriosis—principles and clinical aspects of gestagen treatment] Köhler G. **Zentralbl Gynakol** 1995;117 Suppl:6–13 (46 ref.) **(Ger)**

[The role of gestagens in prevention and therapy of endometrial hyperplasia] Römer T. **Zentralbl Gynakol** 1995; 117 Suppl:14–8 (10 ref.) **(Ger)**

[Gestagens and corpus luteum insufficiency] Rothe K. **Zentralbl Gynakol** 1995;117 Suppl:2–5 (24 ref.) **(Ger)**

ADVERSE EFFECTS

Low–dose progestogen contraception and the nursing mother. Toddywalla VS, et al. **Adv Contracept** 1995 Dec; 11(4):285–94

Menopause, postmenopausal estrogen preparations, and the risk of adult–onset asthma. A prospective cohort study. Troisi RJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1183–8

Ectopic pregnancies in subjects on progestin–only pills [letter; comment] Netter A. **Fertil Steril** 1996 May; 65(5):1078–9. Comment on: Fertil Steril 1995 Jan;63(1):30–3.

Hormone replacement therapy and breast cancer risk. Melnikow J. **J Fam Pract** 1995 Nov;41(5):501–2

Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see comments] **Lancet** 1995 Dec 16;346(8990):1582–8. Comment in: Lancet 1995 Dec 16;346(8990):1570. Comment in: Lancet 1996 Feb 24;347(9000):546–8. Comment in: Lancet 1996 Feb 24;347(9000):548–9. Comment in: Lancet 1996 Feb 24;347(9000):549.

Enhancement by factor V Leiden mutation of risk of deep–vein thrombosis associated with oral contraceptives containing a third–generation progestagen [see comments] Bloemenkamp KW, et al. **Lancet** 1995 Dec 16; 346(8990):1593–6. Comment in: Lancet 1995 Dec 16;346(8990):1570. Comment in: Lancet 1996 Feb 10;347(8998):396–7. Comment in: Lancet 1996 Feb 24;347(9000):546–8. Comment in: Lancet 1996 Feb 24;347(9000):548–9. Comment in: Lancet 1996 Feb 24;347(9000):549.

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components [see comments] Jick H, et al. **Lancet** 1995 Dec 16;346(8990):1589–93. Comment in: Lancet 1995 Dec 16;346(8990):1570. Comment in: Lancet 1996 Feb 24;347(9000):546–8. Comment in: Lancet 1996 Feb 24;347(9000):548–9. Comment in: Lancet 1996 Feb 24;347(9000):549.

[Gestagen therapy and reactive psychosis] **Ugeskr Laeger** 1996 Apr 29;158(18):2561 **(Dan)**

[Use of progestagens] Schaefers–Okkens AC, et al. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):335–7 **(Dut)**

[Beware: progestins elevate body temperature! (editorial)] Piette AM. **Rev Med Interne** 1995;16(11):813–4 **(Fre)**

AGONISTS

Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Heikinheimo O, et al. **Contraception** 1996 Jan;53(1):55–64

ANALOGS & DERIVATIVES see PROGESTATIONAL HORMONES, SYNTHETIC

ANALYSIS

[Determination of naturally occurring sex steroid hormones (androgens and progestagens) in beef] Hartwig M, et al. **Z Lebensm Unters Forsch** 1995 Dec;201(6):533–6 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Cervical ripening. A rat model for investigation of contractile and passive biomechanical properties, with focus on antigestagens, eosinophil granulocytes and mast cells. Knudsen UB. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):88–9

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)

Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception. Katkam RR, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):779–87

The endocrine prevention of breast cancer. Spicer DV, et al. **Cancer Invest** 1995;13(5):495–504 (72 ref.)

Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)

Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Heikinheimo O, et al. **Contraception** 1996 Jan;53(1):55–64

Reversibility of antigestagenic action of antiprogestin onapristone by exogenous progestagens during early pregnancy in guinea pig. Singh MM, et al. **Contraception** 1995 Sep;52(3):187–93

Two types of anti–progestins have distinct effects on site–specific phosphorylation of human progesterone receptor. Beck CA, et al. **J Biol Chem** 1996 Jan 12; 271(2):1209–17

Antiprogestin and/or gonadotropin–releasing hormone agonist for endometriosis treatment and bone maintenance: a 1–year primate study. Grow DR, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1933–9

One day estrous cycle shortening induced by antiprogestagen RU486 administration in proestrus to 4–day cyclic rats. Tébar M, et al. **Rev Esp Fisiol** 1995 Jun;51(2):85–91

Molecular identification of steroid analogs with dissociated antiprogestin activities. Wehle H, et al. **Steroids** 1995 May; 60(5):368–74

[Determination of the progesterone antagonist lilopristone in serum by RP–HPLC] Yu C, et al. **Yao Hsueh Hsueh Pao** 1995;30(6):449–53 (Eng. Abstr.) **(Chi)**

[Multiple usages for antiprogestins] Heikinheimo O. **Duodecim** 1994;110(10):1001–8 (39 ref.) **(Fin)**

BIOSYNTHESIS

Corticotropin releasing factor decidualizes human endometrial stromal cells in vitro. Interaction with progestin. Ferrari A, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5–6):251–5

BLOOD

A retrospective study of increased plasma progestagen concentrations in compromised neonatal foals. Rossdale PD, et al. **Reprod Fertil Dev** 1995;7(3):567–75

PHARMACOLOGY

Effect of progestin treatment on estradiol–and growth factor–stimulated breast cancer cell lines. Cappelletti V, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2551–5

Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Chen YH, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):651–9

Norgestimate. Corson SL. **Clin Obstet Gynecol** 1995 Dec; 38(4):841–8 (25 ref.)

The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Harris RZ, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):429–35

Differential effects on bone density of progestogen–only methods for contraception in premenopausal women. Naessen T, et al. **Contraception** 1995 Jul;52(1):35–9

Reversibility of antigestagenic action of antiprogestin onapristone by exogenous progestagens during early pregnancy in guinea pig. Singh MM, et al. **Contraception** 1995 Sep;52(3):187–93

Comparative pharmacology of newer progestogens. Kuhl H. **Drugs** 1996 Feb;51(2):188–215 (121 ref.)

Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Perusquía M, et al. **Gen Pharmacol** 1996 Jan;27(1):181–5

Growth inhibition by anti–estrogens and progestins in TGF–beta–resistant and –sensitive breast–tumor cells. Kalkhoven E, et al. **Int J Cancer** 1996 Mar 1;65(5):682–7

Fate of the dominant follicle, embryonal survival, and pregnancy rates in dairy cattle treated with prostaglandin F2 alpha and progestins in the absence or presence of a functional corpus luteum. Smith MW, et al. **J Anim Sci** 1995 Dec;73(12):3743–51

Progestin regulation of interleukin–8 mRNA levels and protein synthesis in human endometrial stromal cells. Arici A, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):71–6

Lack of estrogenic potential of progesterone– or 19–nor–progesterone–derived progestins as opposed to testosterone or 19–nor–testosterone derivatives on endometrial Ishikawa cells. Botella J, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):77–84

Progestins and danazol effect on cell–to–cell adhesion, and E–cadherin and alpha– and beta–catenin mRNA expressions. Fujimoto J, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5–6):275–82

New insights in the molecular mechanism of progestin–induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. Mol JA, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):67–71 (44 ref.)

Normal uterine arterial blood flow in postmenopausal women assessed by transvaginal color Doppler sonography: the effect of hormone replacement therapy. Bonilla–Musoles F, et al. **J Ultrasound Med** 1995 Jul;14(7):497–501

Transvaginal color Doppler assessment of endometrial status in normal postmenopausal women: the effect of hormone replacement therapy. Bonilla–Musoles F, et al. **J Ultrasound Med** 1995 Jul;14(7):503–7

Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG–M cells in vitro. Ueda M, et al. **Jpn J Cancer Res** 1996 May; 87(5):524–33

Ring A reduced progestins potently stimulate estrous behavior in rats: paradoxical effect through the progesterone receptor. Beyer C, et al. **Physiol Behav** 1995 Nov;58(5):985–93

Androgen and progestagen effects on plasma lipids. Bagatell CJ, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):255–71 (125 ref.)

Evidence of asynchrony in the onset of signs of oestrus in zebu cattle treated with a progestogen ear implant. Medrano EA, et al. **Res Vet Sci** 1996 Jan;60(1):51–4

Anabolic effects of progestogens in bone remodelling. Stěpán JJ, et al. **Sb Lek** 1995;96(4):293–7

[The development of the thymus gland in rat embryogenesis with progesterone administration] Churilova NI. **Morfologiia** 1994 Jul–Dec;107(7–12):82–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)

Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Sturdee DW. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):22–8 (31 ref.)

STANDARDS

Progestogens in estrogen–replacement therapy. Gambrell RD Jr. **Clin Obstet Gynecol** 1995 Dec;38(4):890–901 (43 ref.)

THERAPEUTIC USE

Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. Aston K, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):835–7

Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80–6 (49 ref.)

Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta–analyses of published randomised controlled trials. Martin–Hirsch PL, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):201–7

The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)

Hormonal anti–implantation agents: antiprogestins. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:140–50

Gonadotropin–releasing hormone (GnRH) agonists and estrogen/progestin replacement for the treatment of hirsutism: evaluating the results [editorial; comment] Rittmaster RS. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3403–5. Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3406–11.

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial [see comments] **JAMA** 1996 Feb 7;275(5):370–5. Comment in: JAMA 1996 Jun 26;275(24):1880–1.

Hormone replacement therapy and breast cancer risk [letter; comment] Campagnoli C, et al. **JAMA** 1996 Apr 17; 275(15):1159–60. Comment on: JAMA 1995 Jul 12;274(2):137–42.

Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. Grodstein F, et al. **N Engl J Med** 1996 Aug 15;335(7):453–61

A peppy response to PEPI results. Finnegan LP, et al. **Nat Med** 1995 Mar;1(3):205–6

Hormone replacement therapy: estrogen after menopause. Gibaldi M. **Pharmacotherapy** 1996 May–Jun;16(3):366–75

[Significance of gestagens in the prevention and therapy of postmenopausal osteoporosis] Stěpán J. **Ceska Gynekol** 1995 Oct;60(5):237–9 **(Cze)**

[Progestagen contraceptives] Cohen J. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):442–4 **(Fre)**

[Progestins and osteoporosis. Does progestin contribute to the effectiveness of estrogen replacement therapy in menopause?] Lopes P. **Rev Fr Gynecol Obstet** 1995 May–Jun;90(5–6):307–8 (17 ref.) **(Fre)**

[Gestagens and breast diseases] Lober R. **Zentralbl Gynakol** 1995;117 Suppl:19–24 (27 ref.) **(Ger)**

PROGESTATIONAL HORMONES, SYNTHETIC

see related
ANTINEOPLASTIC AGENTS, HORMONAL
CONTRACEPTIVE AGENTS, FEMALE
CONTRACEPTIVES, ORAL, SYNTHETIC

Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):736–42 (51 ref.)

ADMINISTRATION & DOSAGE

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Introduction. Bush TL, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):1S–2S

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Espeland MA, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):3S–19S

Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Johnson S, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):20S–35S

Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions. Miller VT, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):54S–65S

Physical and laboratory measurements in the PEPI Trial Postmenopausal Estrogen/Progestin Interventions. Wood PD, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):36S–53S

Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Barbosa I, et al. **Fertil Steril** 1996 Apr;65(4):724–9

Progestogen pretreatment in the short–term protocol does not affect the prognostic value of the oestradiol flare–up in response to a GnRH agonist. Cédrin–Durnerin I, et al. **Hum Reprod** 1995 Nov;10(11):2904–8

[Contraception with levonorgestrel subdermal implants. A Tunisian study] Hamzaoui R, et al. **Presse Med** 1996 Jun 29;25(23):1063–5 (Eng. Abstr.) **(Fre)**

[Depot gestagens] Zahradnik HP. **Arch Gynecol Obstet** 1995; 257(1–4):536–41 (9 ref.) **(Ger)**

[Hormonal premedication in endometrium ablation––results of a prospective comparative study] Römer T, et al. **Zentralbl Gynakol** 1996;118(5):291–4 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Short– and long–term effects on lipid metabolism of oral contraceptives containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel or 3–keto–desogestrel. Kuhl H, et al. **Horm Res** 1995;44(3):121–5

Progestogens and Cushing's syndrome. Harte C, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):274–5

Drug–induced progesterone dermatitis [letter; comment] Fisher DA. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):863–4 . Comment on: J Am Acad Dermatol 1995 Feb;32(2 Pt 2):333–8.

Estrogen–progestin therapy and coronary heart disease in radiation–induced rectal telangiectases. Niv Y, et al. **J Clin Gastroenterol** 1995 Dec;21(4):295–7

Discovery of novel intracellular receptor modulating drugs. Jones TK, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):61–6 (26 ref.)

Safety of combined oral contraceptive pills [letter; comment] Cramer DW. **Lancet** 1996 Feb 24;347(9000):546–8. Comment on: Lancet 1995 Dec 16;346(8990):1582–8. Comment on: Lancet 1995 Dec 16;346(8990):1589–93. Comment on: Lancet 1995 Dec 16;346(8990):1593–6.

Safety of combined oral contraceptive pills [letter; comment] de Lignieres B. **Lancet** 1996 Feb 24;347(9000):548–9. Comment on: Lancet 1995 Dec 16;346(8990):1582–8. Comment on: Lancet 1995 Dec 16;346(8990):1589–93. Comment on: Lancet 1995 Dec 16;346(8990):1593–6.

UK "pill scare" led to abortion increase [news] Ramsay S. **Lancet** 1996 Apr 20;347(9008):1109

Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. Selman PJ, et al. **Vet Q** 1995 Dec; 17(4):128–33

[Inflammatory disease of the upper digestive tract probably due to a synthetic progestational agent (letter)] Daghfous R, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):853–4 **(Fre)**

[Metrorrahgia induced by topical application of medroxyprogesterone. Is it worth it? (letter)] Martín Arias L, et al. **Med Clin (Barc)** 1996 Mar 9;106(9):356 **(Spa)**

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

DIAGNOSTIC USE

Relationship between sonographic endometrial thickness and progestin–induced withdrawal bleeding. Nakamura S, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):722–5

PHARMACOKINETICS

Prodrug versus drug effects of 150 micrograms desogestrel or 3–keto–desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3–keto–desogestrel. Kuhl H, et al. **Horm Res** 1995;44(3):126–32

PHARMACOLOGY

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Gilabert J, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1849–54

In vitro molecular assessment of the mechanisms of action of 19–nor progestins used as contragestational agents. Pasapera AM, et al. **Arch Med Res** 1995;26 Spec No:S203–7

Progestin–induced puberty and secretion of luteinizing hormone in heifers. Anderson LH, et al. **Biol Reprod** 1996 May;54(5):1025–31

Expression of receptors for epidermal growth factor and insulin–like growth factor I by ZR–75–1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin–like growth factor I receptor expression. van den Berg HW, et al. **Br J Cancer** 1996 Feb;73(4):477–81

Effects of exogenous female sex–steroid hormones on lymphocyte beta 2–adrenoceptors in normal females. Tan KS, et al. **Br J Clin Pharmacol** 1996 May;41(5):414–6

Reduced levels of cathepsin D associated with tamoxifen resistance and estrogen independence in the ZR–75–1 human breast cancer cell line. Long BJ, et al. **Cancer Lett** 1996 Feb 6;99(2):233–8

Gestodene–containing contraceptives. Kuhl H, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):829–40 (32 ref.)

Desogestrel. Stone SC. **Clin Obstet Gynecol** 1995 Dec; 38(4):821–8 (39 ref.)

Androgen levels in women using a single implant of nomegestrol acetate. Barbosa I, et al. **Contraception** 1996 Jan;53(1):37–40

The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Barbosa I, et al. **Contraception** 1995 Aug;52(2):111–4

Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Heikinheimo O, et al. **Contraception** 1996 Jan;53(1):55–64

A comparative study of one–year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Moore LL, et al. **Contraception** 1995 Oct;52(4):215–9

The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome. Carranza–Lira S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):161–4

Exaggerated effects of progestogen on uterine artery pulsatility index in Turner's syndrome patients receiving hormone replacement therapy. Biljan MM, et al. **Fertil Steril** 1995 Dec;64(6):1104–8

Cardiovascular risk factors and combined estrogen–progestin replacement therapy: a placebo–controlled study with nomegestrol acetate and estradiol. Conard J, et al. **Fertil Steril** 1995 Nov;64(5):957–62

Low dose megestrol increases serum albumin in malnourished dialysis patients. Lien YH, et al. **Int J Artif Organs** 1996 Mar;19(3):147–50

Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann A. **Int J Fertil Menopausal Stud** 1995;40 Suppl 2:98–104

Ultrasonographic monitoring of ovarian follicles in women using norethisterone for contraception. Chitlange SM, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):31–4

Effect of norgestomet treatment after insemination on the calving rate of postpartum suckled beef cows. Favero RJ, et al. **J Anim Sci** 1995 Nov;73(11):3230–4

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced–stage non–hormone–sensitive cancer: a placebo–controlled multicenter study. Simons JP, et al. **J Clin Oncol** 1996 Apr; 14(4):1077–84

Modulation of cardiac M2 muscarinic receptor binding by progesterone–related steroids. Wilkinson M, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1831–9

Effect of chlormadinone acetate–pellet implantation on the volume of prostate, peripheral blood levels of sex hormones and semen quality in the dog. Shimizu M, et al. **J Vet Med Sci** 1995 Jun;57(3):395–9

Safety of combined oral contraceptive pills [letter; comment] Plu–Bureau G, et al. **Lancet** 1996 Feb 24;347(9000):549. Comment on: Lancet 1995 Dec 16;346(8990):1582–8. Comment on: Lancet 1995 Dec 16;346(8990):1589–93. Comment on: Lancet 1995 Dec 16;346(8990):1593–6.

Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Pap E, et al. **Reprod Fertil Dev** 1995;7(5):1249–51

[The effect of estradiol, norethisterone and testosterone on regional circulation and relative weight of the testes, ovaries and uterus in rats] Kapitola J, et al. **Sb Lek** 1994; 95(3):189–98 (Eng. Abstr.) **(Cze)**

[Thyroid and ovarian hormones in ewes treated with gestagens and PMSG in the spring season] Bekeová E, et al. **Vet Med (Praha)** 1995 Nov;40(11):345–52 (Eng. Abstr.) **(Slo)**

[The desogestrel–ethinyl estradiol combination and overweight: current data] Rubio Lotvin B. **Ginecol Obstet Mex** 1995 Nov;63:483–6 (Eng. Abstr.) **(Spa)**

STANDARDS

The progestin–only pills and the levonorgestrel–releasing IUD: two progestin–only contraceptives. Chi IC. **Clin Obstet Gynecol** 1995 Dec;38(4):872–89 (71 ref.)

A twelve–month comparative clinical investigation of two low–dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Endrikat J, et al. **Contraception** 1995 Oct;52(4):229–35

Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Gebbie AE, et al. **Contraception** 1995 Oct;52(4):221–2

THERAPEUTIC USE

Progesterone antagonist RU 486 has bone-sparing effects in ovariectomized rats. Barengolts EI, et al. **Bone** 1995 Jul; 17(1):21–5

Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Muñoz-Torres M, et al. **Calcif Tissue Int** 1995 Aug;57(2):94–6

Added effect of progestogens on bone mineral density response to oestrogen [letter] Evans SF, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):123–4

A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clinton OP, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):251–6

Auditory cerebral lateralization following cross-gender hormone therapy. Cohen H, et al. **Cortex** 1995 Sep; 31(3):565–73

Chlormadinone acetate as a possible effective agent for congenital adrenal hyperplasia to suppress elevated ACTH and antagonize masculinization. Kageyama Y, et al. **Endocr J** 1995 Aug;42(4):505–8

Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Onu PE. **Eur Urol** 1995;28(3):229–35

Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Erenus M, et al. **Fertil Steril** 1996 Aug; 66(2):216–9

Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Kiilholma P, et al. **Fertil Steril** 1995 Nov; 64(5):903–8

Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Tranquilli AL, et al. **Gynecol Endocrinol** 1995 Jun; 9(2):137–41

Low dose megestrol increases serum albumin in malnourished dialysis patients. Lien YH, et al. **Int J Artif Organs** 1996 Mar;19(3):147–50

Norethindrone—a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug; 40(4):207–23 (64 ref.)

Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study. **Thromb Haemost** 1996 Mar;75(3):476–80

Diffuse severe digestive angiodysplasia in Bernard-Soulier syndrome. Improvement of bleeding by oestroprogestative therapy [letter] Bellucci S, et al. **Thromb Haemost** 1995 Dec;74(6):1610–2

[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**

[Synthetic progestational hormones in the treatment of neoplastic cachexia] Freyer G, et al. **Rev Med Interne** 1996; 17(1):79–84 (21 ref.) (Eng. Abstr.) **(Fre)**

[Regression of functional cysts: high dosage ovulation inhibitor and gestagen therapy has no added effect] Graf M, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):387–92 (Eng. Abstr.) **(Ger)**

[Enzyme therapy in treatment of mastopathy. A randomized double-blind clinical study] Rammer E, et al. **Wien Klin Wochenschr** 1996;108(6):180–3 (Eng. Abstr.) **(Ger)**

[Double-blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate] Blümel JE, et al. **Rev Chil Obstet Ginecol** 1994; 59(5):354–60 (Eng. Abstr.) **(Spa)**

TOXICITY

Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate. Martelli A, et al. **Carcinogenesis** 1996 Mar;17(3):551–4

Comparative study of DNA repair induced by cyproterone acetate, chiormadinone acetate and megestrol acetate in primary cultures of human and rat .hepatocytes. Martelli A, et al. **Carcinogenesis** 1996 May;17(5):1153–6

Genotoxicity evaluation of norethisterone acetate. Dhillon VS, et al. **Mutat Res** 1996 Jan;367(1):1–10

PROGESTERONE

see related
RECEPTORS, PROGESTERONE

Clearing up confusion over yams and progesterone [letter] Dentali S. **Altern Ther Health Med** 1996 Jul;2(4):19–20

Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Cappelletti V, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2551–5

The effect of ICI 164384 and beta-interferon on the growth and steroid receptor profile of breast cancer cell lines. Coradini D, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2557–61

Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action. Di Monaco M, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2581–4

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

Dependency on progesterone in woman with self-diagnosed premenstrual syndrome [letter] Keefe DL, et al. **Lancet** 1996 Apr 27;347(9009):1182

ADMINISTRATION & DOSAGE

Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Magill PJ. **Br J Gen Pract** 1995 Nov; 45(400):589–93

Progesterone administration to ovariectomized rats reduces water and salt intake induced by central administration of angiotensin II. do-Vale CF, et al. **Braz J Med Biol Res** 1995 Sep;28(9):999–1002

Micronized progesterone: vaginal and oral uses. Simon JA. **Clin Obstet Gynecol** 1995 Dec;38(4):902–14 (41 ref.)

Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Cicinelli E, et al. **Fertil Steril** 1996 Apr;65(4):860–2

Antiproliferative effects of low-dose micronized progesterone. Kim S, et al. **Fertil Steril** 1996 Feb; 65(2):323–31

The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study. Stovall DW, et al. **Fertil Steril** 1996 May;65(5):986–91

Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Bolaji II, et al. **Gynecol Endocrinol** 1996 Feb; 10(1):41–7

Administration of unmodified progesterone by nasal spray in fertile women. Cicinelli E, et al. **Gynecol Endocrinol** 1995 Dec;9(4):289–93

Efficacy of oral micronized progesterone in the treatment of luteal phase defects. Frishman GN, et al. **J Reprod Med** 1995 Jul;40(7):521–4

Progesterone enhancement of stomach tumor development in SD rats treated with N-methyl-N'-nitro-N-nitrosoguanidine. Ando Y, et al. **Jpn J Cancer Res** 1995 Oct;86(10):924–8

Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Suvanto-Luukkonen E, et al. **Maturitas** 1995 Nov;22(3):255–62

[Supplementation of estrogen and progesterone to postmenopausal women] Philip J, et al. **Ugeskr Laeger** 1996 May 20;158(21):2998 **(Dan)**

[The influence of modified sequential therapy on lipid metabolism in postmenopausal women] b1anosz S, et al. **Ginekol Pol** 1995 May;66(5):284–8 (Eng. Abstr.) **(Pol)**

[Evaluation of selected parameters of collagen metabolism in rats after implantation of copolymer d,l-lactide and E-caprolacton with cortisol and progesterone] Nowak M, et al. **Polim Med** 1995;25(3–4):25–35 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones. A case report. Ryu SJ, et al. **Angiology** 1996 Mar; 47(3):299–303

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

Withdrawal from the endogenous steroid progesterone results in GABAA currents insensitive to benzodiazepine modulation in rat CA1 hippocampus. Costa AM, et al. **J Neurophysiol** 1995 Jul;74(1):464–9

[Hepatic cytolysis caused by tocolytic treatment using micronized natural progesterone] Magnin G, et al. **Presse Med** 1996 Jan 27;25(3):102–5 (Eng. Abstr.) **(Fre)**

[Steroid-induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449–52 (21 ref.) **(Jpn)**

ANALOGS & DERIVATIVES

Biotin-labelled and photoactivatable aldosterone and progesterone derivatives as ligands for affinity chromatography, fluorescence immunoassays and photoaffinity labelling. Eisen C, et al. **Eur J Biochem** 1996 Apr 15;237(2):514–8

Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells. Botella J, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):77–84

Specific inhibition of the last steps of aldosterone biosynthesis by 18-vinylprogesterone in bovine adrenocortical cells. Defaye G, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):141–7

6 alpha-[18F]fluoroprogesterone: synthesis via halofluorination-oxidation, receptor binding and tissue distribution. Choe YS, et al. **Nucl Med Biol** 1995 Jul; 22(5):635–42

Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. Selman PJ, et al. **Vet Q** 1995 Dec; 17(4):128–33

ANALYSIS

Concentrations of tumor necrosis factor alpha and progesterone within the bovine corpus luteum sampled by continuous-flow microdialysis during luteolysis in vivo. Shaw DW, et al. **Biol Reprod** 1995 Oct;53(4):847–54

The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability [letter; comment] Danielian PJ. **Br J Obstet Gynaecol** 1996 Apr;103(4):391. Comment on: Br J Obstet Gynaecol 1995 May;102(5):364–9.

Folliculocentesis: a novel research technique to investigate the intrafollicular endocrine microenvironment. Ahmed Ebbiary NA, et al. **Hum Reprod** 1995 Sep;10(9):2325–33

Maternal plasma and amniotic fluid cortisol and progesterone concentrations between women with and without term labor. A comparison. Ohana E, et al. **J Reprod Med** 1996 Feb;41(2):80–6

Monitoring reproductive status by fecal progesterone analysis in ruminants. Hirata S, et al. **J Vet Med Sci** 1995 Oct; 57(5):845–50

Gonadotrophin releasing hormone treatment of Holstein cows with follicular cysts monitored by skim milk progesterone determination. Eissa HM, et al. **Vet Med (Praha)** 1996 Jan;41(1):1–5

[Biochemical basis for detection of estrogen and progesterone receptors in breast tumors using immunohistochemistry] Goussard J. **Ann Pathol** 1996;16(2):91–7 (41 ref.) **(Fre)**

[Examination of 17 beta-estradiol and progesterone levels in peritoneal fluid and blood serum of women with endometriosis] Skrzypczak J, et al. **Ginekol Pol** 1995 Sep; 66(9):523–8 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Anti-idiotypic immunization against progesterone [letter] Wang MW, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):386–8

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115–9 (42 ref.)

An exchange of ideas and "boutades" [letter] Brosens I. **Fertil Steril** 1996 Oct;66(4):669–70

Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Kettel LM, et al. **Fertil Steril** 1996 Jan;65(1):23–8

Blockade of ovulation in rabbits by RU-486, a competitive progesterone antagonist. Kanayama K, et al. **J Vet Med Sci** 1996 Mar;58(3):275–6

Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Karalis K, et al. **Nat Med** 1996 May;2(5):556–60

[Antiprogesterones—new prospects in induced abortion] Karag'ozov I, et al. **Akush Ginekol (Sofiia)** 1994;33(2):47–9 **(Bul)**

BIOSYNTHESIS

The effect of transforming growth factor-beta on steroidogenesis and expression of key steroidogenic enzymes with a human ovarian thecal-like tumor cell model. Carr BR, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1109–16; discussion 1116–7

Opioids modulate progesterone production in prepubertal Bunaji heifers. Gazal OS, et al. **Biol Reprod** 1995 Nov; 53(5):1075–80

Angiotensin II interferes with steroidogenesis in porcine granulosa cells. Li XM, et al. **Biol Reprod** 1995 Oct; 53(4):791–9

Four-day-old bovine corpus luteum: progesterone production and identification of matrix metalloproteinase activity in vitro. Tsang PC, et al. **Biol Reprod** 1995 Nov; 53(5):1160–8

Differential regulation of progesterone and estradiol production by mouse cumulus and mural granulosa cells by A factor(s) secreted by the oocyte. Vanderhyden BC, et al. **Biol Reprod** 1995 Dec;53(6):1243–50

Regulation of insulin-like growth factor-I and progesterone synthesis by insulin and growth hormone in the ovine ovary. Wathes DC, et al. **Biol Reprod** 1995 Oct;53(4):882–9

Steroid production after in vitro transcription, translation, and mitochondrial processing of protein products of complementary deoxyribonucleic acid for steroidogenic acute regulatory protein. King SR, et al. **Endocrinology** 1995 Nov;136(11):5165–76

Interleukin-1 beta stimulates sphingomyelin hydrolysis in cultured granulosa cells: evidence for a regulatory role of ceramide on progesterone and prostaglandin biosynthesis. Santana P, et al. **Endocrinology** 1996 Jun;137(6):2480–9

Steroid production by equine fetal gonads: a speculative view [editorial; comment] Raeside JI. **Equine Vet J** 1995 Sep; 27(5):324–5. Comment on: Equine Vet J 1995 Sep;27(5):334–40. Comment on: Equine Vet J 1995 Sep;27(5):342–7.

Thyroid hormone induces the generation of a novel putative protein in piscine ovarian follicle that stimulates the conversion of pregnenolone to progesterone. Bhattacharya S, et al. **Eur J Endocrinol** 1996 Jan;134(1):128–35

Autologous granulosa cell coculture demonstrates zygote suppression of granulosa cell steroidogenesis. Seifer DB, et al. **Fertil Steril** 1996 Sep;66(3):425–9

Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Zanagnolo V, et al. **Fertil Steril** 1996 May;65(5):1036–43

The cytoskeleton proteins and LH-regulated steroidogenesis of porcine luteal cells. Gregoraszczuk EL, et al. **Folia Histochem Cytobiol** 1996;34(1):35–9

A patient with a progesterone-producing adrenal adenoma who presented with primary amenorrhea. van Zonneveld P, et al. **Gynecol Endocrinol** 1995 Sep;9(3):189–94

Somatostatin action on rat ovarian steroidogenesis. Andreani CL, et al. **Hum Reprod** 1995 Aug;10(8):1968–73

Effects of growth hormone releasing hormone on rat ovarian steroidogenesis. Hugues JN, et al. **Hum Reprod** 1996 Jan; 11(1):50–4

Augmentation by thyroxine of human granulosa cell gonadotrophin-induced steroidogenesis. Wakim AN, et al. **Hum Reprod** 1995 Nov;10(11):2845–8

Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. van Agthoven T, et al. **Int J Cancer** 1995 Dec 11; 63(6):790–3

Epidermal growth factor (EGF) receptor localization in cultured human granulosa lutein cells and the stimulation of progesterone production by EGF and transforming growth factor-alpha (TGF-alpha). Tekpetey FR, et al. **J Assist Reprod Genet** 1995 Nov;12(10):720–7

Influence of thyroxine on human granulosa cell steroidogenesis in vitro. Wakim AN, et al. **J Assist Reprod Genet** 1995 Apr;12(4):274–7

Reduced preovulatory granulosa cell steroidogenesis in women with endometriosis. Harlow CR, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):426–9

Monoclonal antibodies specific for the binding site on the LH receptor alter progesterone production in cultured granulosa cells. Nau EA, et al. **J Endocrinol** 1996 Jul; 150(1):9–16

Functional luteolysis in response to hydrogen peroxide in human luteal cells. Vega M, et al. **J Endocrinol** 1995 Oct; 147(1):177–82

A comparative study of progesterone synthesis by term human fetal amnion and chorion. Gunasegaram R, et al. **J Perinat Med** 1995;23(5):371–7

Stimulation of rat granulosa cell progesterone production but not other differentiated functions by a splenocyte-derived factor. Ness JM, et al. **J Reprod Fertil** 1995 Sep; 105(1):125–33

Tumor necrosis factor-alpha affects in vitro hormone production by JEG-3 choriocarcinoma cell cultures. Pedersen AM, et al. **J Reprod Immunol** 1995 May; 29(1):69–80

Organization of 3 beta-hydroxysteroid dehydrogenase/isomerase and cytochrome P450scc into a catalytically active molecular complex in bovine adrenocortical mitochondria. Cherradi N, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):507–14

The possible involvement of LH/hCG induced mitochondrial proteins in the regulation of steroidogenesis in bovine luteal cells. Mittre H, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3–4):233–8

Dual regulation of luteal progesterone production by androstenedione during spontaneous and RU486-induced luteolysis in pregnant rats. Tellería CM, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):385–93

Differential effects of oxytocin on steroid production by bovine granulosa cells. Berndtson AK, et al. **Mol Cell Endocrinol** 1996 Feb 5;116(2):191–8

Hydrogen peroxide suppresses low-density lipoprotein (LDL) uptake and LDL-supported steroidogenesis by porcine luteal cells. Brannian JD, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):213–8

Growth hormone amplifies insulin-like growth factor I induced progesterone accumulation and P450scc mRNA expression. Xu YP, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):199–206

Comparison of growth hormone and insulin-like growth factor-I regulation of estradiol and progesterone production in human luteinized granulosa cells. Foster CM, et al. **Pediatr Res** 1995 Nov;38(5):763–7

Adhesion proteins increase cellular attachment, follicle-stimulating hormone receptors, and progesterone production in cultured porcine granulosa cells. Sites CK, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):78–83

Arachidonic acid inhibits hCG-stimulated progesterone production by corpora lutea of primates: potential mechanism of action. Ciereszko RE, et al. **Prostaglandins** 1995 Aug;50(2):103–19

Prostaglandin F2 alpha, progesterone and oxytocin production by cultured bovine luteal cells treated with prostaglandin E2 and pregnancy-specific protein B. Del Vecchio RP, et al. **Prostaglandins** 1995 Sep;50(3):137–50

Interactions between large and small luteal cells collected during the mid- or late-luteal stages of the bovine oestrous cycle. Del Vecchio RP, et al. **Reprod Fertil Dev** 1995; 7(1):35–40

[The effects of synthetic oligopeptides on progesterone production in corpus luteum cell of rat and their mechanism of action] Wang N. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):237–9 (Eng. Abstr.) **(Chi)**

[Suppressive effect of Gossypol, Gossypolone and serum from Gossypol treated rats on steroidogenesis in cultured porcine granulosa cells] Ohmura H. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):181–9 (Eng. Abstr.) **(Jpn)**

[The effect of TNF-alpha (tumor necrosis factor-alpha) on progesterone synthesis in vitro by cells from ovarian follicular fluid in women] Putowski L, et al. **Ginekol Pol** 1995 Jun;66(6):330–4 (Eng. Abstr.) **(Pol)**

[The nuclei of the follicular cells regulate steroidogenesis stimulated by a pituitary suspension in the follicles of the common frog in vitro] Skoblina MN, et al. **Ontogenez** 1995 Nov–Dec;26(6):446–52 (Eng. Abstr.) **(Rus)**

BLOOD

Concentrations of progesterone during storage of whole blood from llama (Lama glama): effects of anticoagulants, storage time and temperature. Abal MA, et al. **Acta Vet Scand** 1996;37(1):123–5

Prostaglandin F2 alpha metabolite and progesterone profiles in post-partum cows with retained foetal membranes. Bekana M, et al. **Acta Vet Scand** 1996;37(2):171–85

Comparison of single serum progesterone and endometrial biopsy for confirmation of ovulation in infertile Nigerian women. Ilesanmi AO, et al. **Afr J Med Med Sci** 1995 Mar; 24(1):97–101

Predictors of ovarian steroid secretion in reproductive-age women. Westhoff C, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):381–8

Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Paganini-Hill A, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):897–902

Serum binding of steroid tracers and its possible effects on direct steroid immunoassay. Micallef JV, et al. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):566–74

Maternal plasma and amniotic fluid 17 beta-estradiol, progesterone and cortisol concentrations in women with successfully and unsuccessfully treated preterm labor. Mazor M, et al. **Arch Gynecol Obstet** 1996;258(2):89–96

Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats. Kang YJ, et al. **Biochem Pharmacol** 1996 Feb 23; 51(4):567–70

Serum progesterone and prognosis in operable breast cancer. Mohr PE, et al. **Br J Cancer** 1996 Jun;73(12):1552–5

Effects of treatment with buserelin on plasma concentrations of oestradiol and progesterone and cycle length in the cow. Mann GE, et al. **Br Vet J** 1995 Jul–Aug;151(4):427–32

Behavior and progesterone levels in Callithrix jacchus females. Alencar AI, et al. **Braz J Med Biol Res** 1995 May; 28(5):591–5

Validity for epidemiological studies of long-term cryoconservation of steroid and protein hormones in serum and plasma. Bolelli G, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):509–13

Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Lu LJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):63–70

In vivo and in vitro effects of graded doses of the pesticide heptachlor on female sex steroid hormone production in rats. Oduma JA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):191–6

Serial measurement of peripheral oestrogen and progesterone concentrations in oestrous mares to determine optimum mating time and diagnose ovulation. Allen WR, et al. **Equine Vet J** 1995 Nov;27(6):460–4

Elevated progesterone levels in the late follicular phase do not predict success of in vitro fertilization-embryo transfer. Abuzeid MI, et al. **Fertil Steril** 1996 May;65(5):981–5

Premature progesterone elevation does not alter oocyte quality in in vitro fertilization. Fanchin R, et al. **Fertil Steril** 1996 Jun;65(6):1178–83

Single serum progesterone as a screen for ectopic pregnancy: exchanging specificity and sensitivity to obtain optimal test performance. McCord ML, et al. **Fertil Steril** 1996 Oct; 66(4):513–6

Effect of acute captivity stress on plasma concentrations of corticosterone and sex steroids in female whistling frogs, Litoria ewingi. Coddington EJ, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):33–8

Circulating levels of prolactin and progesterone in a wild population of red kangaroos (Macropus rufus) Marsupialia: Macropodidae. Muths E, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):317–22

Effect of prenatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone level in adult rats. Pap E, et al. **Gen Pharmacol** 1995 Mar; 26(2):365–7

Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):139–40

Endometrial and placental protein markers and ovarian steroids in serum during in-vitro fertilization cycles. Bersinger NA, et al. **Hum Reprod** 1995 Aug;10(8):2149–54

Serum progesterone at the time of human chorionic gonadotrophin does not predict pregnancy in in-vitro fertilization and embryo transfer. Bustillo M, et al. **Hum Reprod** 1995 Nov;10(11):2862–7

Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Corsan GH, et al. **Hum Reprod** 1995 Oct;10(10):2719–22

Effect of ovulation induction on uterine blood flow and oestradiol and progesterone concentrations in early pregnancy. Dickey RP, et al. **Hum Reprod** 1995 Nov; 10(11):2875–9

Atrial natriuretic peptide, oestradiol and progesterone in women undergoing spontaneous and gonadotrophin-stimulated ovulatory cycles. Yeko TR, et al. **Hum Reprod** 1995 Nov;10(11):2872–4

Prediction of early pregnancy outcomes. Lin YS, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):33–8

Hormonal indicators of pregnancy in llamas and alpacas. Bravo PW, et al. **J Am Vet Med Assoc** 1996 Jun 15; 208(12):2027–30

Effects of energy source in the diet on reproductive hormones and insulin during lactation and subsequent estrus in multiparous sows. Kemp B, et al. **J Anim Sci** 1995 Oct; 73(10):3022–9

Endocrine and ovarian responses to exogenous estradiol-17 beta in 6-month-old heifers previously immunized against growth hormone-releasing factor. Schoppee PD, et al. **J Anim Sci** 1995 Jul;73(7):2071–8

Relationship between circulating progesterone and conception at the first postpartum estrus in young primiparous beef cows. Werth LA, et al. **J Anim Sci** 1996 Mar;74(3):616–9

Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions. Babalioğlu R, et al. **J Assist Reprod Genet** 1996 Apr;13(4):306–9

The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome. Levy MJ, et al. **J Assist Reprod Genet** 1995 Mar;12(3):161–6

Progesterone concentration as a predictor of pregnancy normalcy is the most useful when hCG levels are less than 2000 mIU/mL. Long CA, et al. **J Assist Reprod Genet** 1995 Mar;12(3):195–7

The effects of hexachlorobenzene on circulating levels of adrenal steroids in the ovariectomized rat. Foster WG, et al. **J Biochem Toxicol** 1995 Jun;10(3):129–35

Mode of pulsatile follicle-stimulating hormone secretion in gonadal hormone-sufficient and -deficient women--a clinical research center study. Booth RA Jr, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3208–14

Effect of bovine interferon-tau on body temperature and plasma progesterone concentrations in cyclic dairy cows. Meyer MD, et al. **J Dairy Sci** 1995 Jul;78(7):1470–6

The effect of constant light on the concentration of catecholamines of the hypothalamus and adrenal glands, circulatory hadrenocorticotropin hormone and progesterone. Ivanišević-Milovanović OK, et al. **J Endocrinol Invest** 1995 May;18(5):378–83

The association between basal body temperature, plasma progesterone and the oestrous cycle in a marsupial, the Tasmanian bettong (Bettongia gaimardi). Rose RW, et al. **J Reprod Fertil** 1996 Jan;106(1):67–71

Reptilian (Chrysemys picta) hepatic progesterone receptors: relationship to plasma steroids and the vitellogenic cycle. Giannoukos G, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):93–106

Effects of splenectomy on luteolysis in pseudopregnant rabbits. Nariai K, et al. **J Vet Med Sci** 1995 Jun;57(3):503–5

Sex steroid levels throughout gestation in cows carrying normal and malformed fetuses. Patel OV, et al. **J Vet Med Sci** 1995 Aug;57(4):659–63

Cyclical variation in paroxysmal supraventricular tachycardia in women. Rosano GM, et al. **Lancet** 1996 Mar 23;347(9004):786–8

Menstrual cycle affects functional cerebral asymmetries. Rode C, et al. **Neuropsychologia** 1995 Jul;33(7):855–65

Effects of sex-linked imperfect albinism (sal-s) in the chicken on the relationships of plasma concentrations of progesterone and 17 beta-estradiol with egg production. Su H, et al. **Poult Sci** 1996 Jan;75(1):13–9

Influence of progesterone levels on prostaglandin concentrations in isolated uterine tissue and incubation medium from pseudopregnant rats. Motta A, et al. **Prostaglandins** 1995 Oct;50(4):213–23

Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Pap E, et al. **Reprod Fertil Dev** 1995;7(5):1249–51

Peripheral plasma progesterone concentrations in pregnant and non-pregnant greyheaded flying-foxes (Pteropus poliocephalus) and little red flying-foxes (P. scapulatus). Towers PA, et al. **Reprod Fertil Dev** 1995;7(5):1163–76

Alterations in circulating ovarian steroids in hexachlorobenzene-exposed monkeys. Foster WG, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):541–8

The measurement of progesterone in serum by a non-competitive idiometric assay. Barnard G, et al. **Steroids** 1995 Dec;60(12):824–9

Serum biochemical changes associated with cystic ovarian degeneration in pigs after atrazine treatment. Gojmerac T, et al. **Toxicol Lett** 1996 Apr;85(1):9–15

A possible linkage between gonadal hormones, serum and uterine levels of IgG of dairy cows. Brenner J, et al.

Vet Immunol Immunopathol 1995 Jul;47(1–2):179–84

Endometrial dating correlated with multiple luteal progesterone levels in confirming ovulation and luteal function in infertile Nigerian women. Ilesanmi AO. **West Afr J Med** 1995 Jul–Sep;14(3):152–6

Course of pregnancy, steroid hormone levels and maturation process of placentomes after oestrone infusion in cows near term. Janowski T, et al. **Zentralbl Veterinaermed A** 1995 Jul;42(5):345–50

[Serum levels of prolactin, progesterone and estradiol in nursing mothers] Nedkova V, et al. **Akush Ginekol (Sofiia)** 1995;34(3):22–3 (Eng. Abstr.) **(Bul)**

[Impact of placental hormone withdrawal on postpartum depression] Chang J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):342–4 (Eng. Abstr.) **(Chi)**

[The effect of experimental metabolic stress on ovulation and blood progesterone levels in cows] Vinkler A, et al. **Vet Med (Praha)** 1996 Mar;41(3):65–9 (Eng. Abstr.) **(Cze)**

[Folliculogenesis and endocrinology of superovulated Gobra cow] Diop PE, et al. **Dakar Med** 1994;39(2):213–22 (Eng. Abstr.) **(Fre)**

[Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins] Ellenbogen A, et al. **Harefuah** 1995 Dec 1;129(11):455–6, 536 (Eng. Abstr.) **(Heb)**

[Progesterone] Yoshimi T, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:573–5 (8 ref.) **(Jpn)**

[Thyroid and ovarian hormones in ewes treated with gestagens and PMSG in the spring season] Bekeová E, et al. **Vet Med (Praha)** 1995 Nov;40(11):345–52 (Eng. Abstr.) **(Slo)**

CEREBROSPINAL FLUID

CSF progesterone concentrations in pregnancy [letter; comment] Baliga N. **Br J Anaesth** 1996 Jun;76(6):886. Comment on: Br J Anaesth 1995 Dec;75(6):683–7.

Cerebrospinal fluid progesterone in pregnant women [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Dec; 75(6):683–7. Comment in: Br J Anaesth 1996 Jun;76(6):886.

CONTRAINDICATIONS

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

DEFICIENCY

Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. Jussofie A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):196–204

DIAGNOSTIC USE

Transvaginal sonography and progesterone challenge for identifying endometrial pathology in postmenopausal women. Malinova M, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):49–53

[A comparative study of the potentials of a cytological method, the progesterone test and echography in the early detection of endometrial carcinoma in women in the postmenopause] Ivanov S, et al. **Akush Ginekol (Sofiia)** 1994;33(2):31–2 (Eng. Abstr.) **(Bul)**

GENETICS

Differential gene regulation by estrogen and progesterone in the primate endometrium. Ace CI, et al. **Mol Cell Endocrinol** 1995 Nov 30;115(1):95–103

IMMUNOLOGY

Anti-idiotypic immunization against progesterone [letter] Wang MW, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):386–8

Progesterone-induced urticaria—need it be autoimmune? Wilkinson SM, et al. **Br J Dermatol** 1995 Nov;133(5):792–4

Functional expression of a single-chain anti-progesterone antibody fragment in the cytoplasm of a mutant Escherichia coli. He M, et al. **Nucleic Acids Res** 1995 Oct 11; 23(19):4009–10

METABOLISM

Effects of guanethidine-induced sympathectomy on the spermatogenic and steroidogenic testicular functions of prepubertal to mature rats. Carvalho TL, et al. **Andrologia** 1996 Mar–Apr;28(2):117–22

Identification and partial characterization of cytosolic progesterone-binding sites in the filamentous fungus Rhizopus nigricans. Lenasi H, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):80–6

Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Trapp T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):286–91

Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Barnes KM, et al. **Biochemistry** 1996 Apr 16;35(15):4820–7

Progesterone concentrations in serum, follicular fluid, and oviductal fluid of the golden hamster during the periovulatory period. Libersky EA, et al. **Biol Reprod** 1995 Sep;53(3):477–82

Relationship of circulating steroid hormones, luteal luteinizing hormone receptor and progesterone concentration, and embryonic mortality during early embryogenesis in the domestic cat. Swanson WF, et al. **Biol Reprod** 1995 Nov;53(5):1022–9

Characterization of progesterone-3-[125I-BSA] binding sites in the medial preoptic area and anterior hypothalamus. Caldwell JD, et al. **Brain Res** 1995 Sep 25;693(1–2):225–32

The effect of cytochrome b5 on progesterone metabolism in the ovine adrenal. Swart P, et al. **Endocr Res** 1995 Feb–May;21(1–2):297–306

Binding of [3H]progesterone to the human progesterone receptor: differences between individual and mixed isoforms. Carbajo P, et al. **Endocrinology** 1996 Jun; 137(6):2339–46

Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Meyer C, et al. **Eur J Biochem** 1996 Aug 1;239(3):726–31

Insulin-like growth factor (IGF)-I and IGF-II stimulate progesterone production by human luteal cells: role of IGF-I as mediator of growth hormone action. Apa R, et al. **Fertil Steril** 1996 Aug;66(2):235–9

Progesterone concentrations—physiologic or pharmacologic? [letter; comment] Spicer DV, et al. **Fertil Steril** 1996 May;65(5):1077–8. Comment on: Fertil Steril 1995 Apr;63(4):785–91.

Endometriosis and polycystic ovary syndrome: enhanced stimulatory effect of peritoneal fluid on progesterone release from human granulosa-lutein cells. Whitehead SA, et al. **Fertil Steril** 1996 Sep;66(3):487–9

Inhibitory effect of transferrin on progesterone production in the granulosa cell of humans in vivo and porcine granulosa cell in vitro. Kawano Y, et al. **Gynecol Obstet Invest** 1995;40(1):1–4

Action of leukotriene B4 in human granulosa cells in vitro. Rabe T, et al. **Hum Reprod** 1995 Jul;10(7):1881–4

Effect of pregnancy-specific protein B on luteal cell progesterone, prostaglandin, and oxytocin production during two stages of the bovine estrous cycle. Del Vecchio RP, et al. **J Anim Sci** 1995 Sep;73(9):2662–8

Hormone release from cultured luteinized-granulosa cells mimics differences seen in vivo in patients undergoing IVF-ET. Prien SD, et al. **J Assist Reprod Genet** 1995 Mar; 12(3):180–6

Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6. Born SL, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):957–63

Influence of the estrus cycle on the discrimination of apparent neuroactive steroid site subtypes on the gamma-aminobutyric acidA receptor complex in the rat. McCauley LD, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1412–7

Bovine luteal cell production in vitro of prostaglandin E2, oxytocin and progesterone in response to pregnancy-specific protein B and prostaglandin F2 alpha. Del Vecchio RP, et al. **J Reprod Fertil** 1996 May; 107(1):131–6

Effects of insulin-like growth factor I and interactions with transforming growth factor alpha and LH on proliferation of chicken granulosa cells and production of progesterone in culture. Onagbesan OM, et al. **J Reprod Fertil** 1995 Jul; 104(2):259–65

Biotransformation XXXIX. Metabolism of testosterone, androstenedione, progesterone and testosterone derivatives in Absidia coerulea culture. Brzezowska E, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5–6):357–62

Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Smith DF, et al. **Mol Cell Biol** 1995 Dec;15(12):6804–12

Effect of protein kinase C modulation on gonadotrophin-induced granulosa cell steroidogenesis. He H, et al. **Reprod Fertil Dev** 1995;7(1):83–95

[Relation between progesterone and pathogenesis of uterine leiomyomas] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):184–5 (13 ref.) **(Chi)**

[The effect of postnatal sympathectomy on the production and receptor binding of sex steroids in female rats during puberty] Savchenko ON, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):26–32 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Cicinelli E, et al. **Fertil Steril** 1996 Apr;65(4):860–2

Oral administration of micronized progesterone: a review and more experience. McAuley JW, et al. **Pharmacotherapy** 1996 May–Jun;16(3):453–7

[The erythrocytic pathway of the metabolic transformations of sex hormones] Petrenko IuM, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):36–40 **(Rus)**

PHARMACOLOGY

Effects of estradiol and interaction with progesterone or oxytocin on term human myometrial contractile activity. Fu X, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):13–8

Progesterone suppression of activation of supraoptic nucleus (SON) neurones in late pregnancy in the rat. Antonijevic I, et al. **Adv Exp Med Biol** 1995;395:195–6

Effects of estradiol-17 beta and progesterone on isolated human omental artery from premenopausal nonpregnant women and from normotensive and preeclamptic pregnant women. Belfort MA, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):246–53

The effect of specific hormones on fibrinolysis in pregnancy. Houlihan CM, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):168–72

Constitutive secretion of interleukin-6 by human decidual stromal cells in culture. Regulatory effect of progesterone. Montes MJ, et al. **Am J Reprod Immunol** 1995 Sep; 34(3):188–94

The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):342–8

Induction of M-CSF receptor and its mRNA, and activation of tyrosine kinase in peripheral monocytes by oestradiol-17 beta and progesterone. Fujimoto J, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):399–404

Progesterone and beta-estradiol influence the cell density-dependent distribution of cyclic nucleotides across the cell membrane of human C4-I cells (squamous carcinoma of the uterine cervix) by a non-genomic mechanism. Orbo A, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):1905–9

Effect of estrogen and progesterone on the expression of hepatic and extrahepatic sterol 27-hydroxylase in baboons (Papio sp). Kushwaha RS, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1088–94

Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Hanke H, et al. **Atherosclerosis** 1996 Mar;121(1):129–38

Progesterone stimulates GABA uptake in human spermatozoa. Aanesen A, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):88–93

Reducing PIP2 hydrolysis, Ins(1,4,5)P3 receptor availability, or calcium gradients inhibits progesterone-stimulated Xenopus oocyte maturation. Han JK, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):931–9

Estrogen receptor activation factor (E-RAF) of the rat uterus: hormonal control. Prem Kumar M, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1207–15

Effects of progesterone on in vitro sperm capacitation and egg penetration in the golden hamster. Libersky EA, et al. **Biol Reprod** 1995 Sep;53(3):483–7

Effect of in vivo gonadotropin treatment on the ability of progesterone, estrogen, and cyclic adenosine 5'-monophosphate to inhibit insulin-dependent granulosa cell mitosis in vitro. Luciano AM, et al. **Biol Reprod** 1995 Sep;53(3):664–9

Behavioral effects of interleukin-1 beta: modulation by gender, estrus cycle, and progesterone. Avitsur R, et al. **Brain Behav Immun** 1995 Sep;9(3):234–41

In vivo evidence for progesterone dependent decreases in serotonin release in the hypothalamus and midbrain central grey: relation to the induction of lordosis. Farmer CJ, et al. **Brain Res** 1996 Mar 4;711(1–2):84–92

Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes. Melcangi RC, et al. **Brain Res** 1996 Mar 4;711(1–2):10–5

Developmental and regional changes in brain norepinephrine levels in diabetic C57BL/KsJ mice: effects of estradiol and progesterone. Garris DR. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):314–9

Specific subunit mRNAs of the GABAA receptor are regulated by progesterone in subfields of the hippocampus. Weiland NG, et al. **Brain Res Mol Brain Res** 1995 Sep; 32(2):271–8

Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by beta-estradiol, progesterone, and dexamethasone. Aziz KE, et al. **Cell Immunol** 1996 Jan 10;167(1):79–85

A progesterone-induced protein increases the synthesis of asymmetric antibodies. Kelemen K, et al. **Cell Immunol** 1996 Jan 10;167(1):129–34

Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. Quantification of cellular proliferation by bromodeoxyuridine. Hanke H, et al. **Circulation** 1996 Jul 15;94(2):175–81

Effect of peripheral concentrations of progesterone on follicular growth and fertility in ewes. Johnson SK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):69–79

Influence of progesterone and its antagonist mifepristone (RU 486) on collagen content in uterine cervix in pregnant rats. Bieńkiewicz A. **Endocr Res** 1995 Aug;21(3):615–22

Inhibin is present in the corpus luteum of pseudopregnant rats and can interact with progesterone to inhibit resumption of estrous cycles. Foreman D, et al. **Endocr Res** 1995 Aug;21(3):595–614

Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Falany JL, et al. **Endocrinology** 1996 Apr;137(4):1395–401

Requirement for transglutaminase in progesterone-induced decidualization of human endometrial stromal cells. Fujimoto M, et al. **Endocrinology** 1996 Mar;137(3):1096–101

Progesterone diminishes the sensitivity of gonadotropin-releasing hormone-stimulated luteinizing hormone (LH) release and protects an LH pool from desensitization: actions opposed by cholera toxin. Janovick JA, et al. **Endocrinology** 1996 May;137(5):1823-7

Glycoprotein hormone alpha-subunit functions synergistically with progesterone to stimulate differentiation of cultured human endometrial stromal cells to decidualized cells: a novel role for free alpha-subunit in reproduction. Moy E, et al. **Endocrinology** 1996 Apr; 137(4):1332-9

Neuropeptide Y Y2 receptors in hypothalamic neuroendocrine areas are up-regulated by estradiol and decreased by progesterone cotreatment in the ovariectomized rat. Parker SL, et al. **Endocrinology** 1996 Jul;137(7):2896-900

Examination of steroid-induced changes in LHRH gene transcription using 33P-and 35S-labeled probes specific for intron 2. Petersen SL, et al. **Endocrinology** 1996 Jan; 137(1):234-9

Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells [letter; comment] Pike MC, et al. **Endocrinology** 1996 Apr;137(4):1505-6. Comment on: Endocrinology 1995 Jan;136(1):164-71.

The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Souque A, et al. **Endocrinology** 1995 Dec;136(12):5651-8

Progesterone inhibits superoxide radical production by mononuclear phagocytes in pseudopregnant rats. Sugino N, et al. **Endocrinology** 1996 Feb;137(2):749-54

Modulation of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in the equine placenta by pregnenolone and progesterone metabolites [see comments] Chavatte PM, et al. **Equine Vet J** 1995 Sep;27(5):342-7. Comment in: Equine Vet J 1995 Sep;27(5):324-5.

Inhibition of bovine cytochrome P-450(11 beta) by 18-unsaturated progesterone derivatives. Delorme C, et al. **Eur J Biochem** 1995 Aug 15;232(1):247-56

High-dose progesterone infusion in healthy males: evidence against antiglucocorticoid activity of progesterone. Allolio B, et al. **Eur J Endocrinol** 1995 Dec;133(6):696-700

Changes in prostaglandin synthesis and metabolism associated with labour, and the influence of dexamethasone, RU 486 and progesterone. Brennand JE, et al. **Eur J Endocrinol** 1995 Nov;133(5):527-33

Progesterone together with estradiol promotes luteinizing hormone beta-subunit mRNA stability in rat pituitary cells cultured in vitro. Park D, et al. **Eur J Endocrinol** 1996 Feb;134(2):236-42

Progesterone does not alter sympathetic activity in tissues involved in energy balance. Puerta M, et al. **Eur J Endocrinol** 1996 Apr;134(4):508-12

The basal plasma membrane and lamina densa of uterine epithelial cells are both altered during early pregnancy and by ovarian hormones in the rat. Shion YL, et al. **Eur J Morphol** 1995 Jul;33(3):257-64

Regulation of bile acid synthesis by estradiol and progesterone in primary cultures of rat hepatocytes. Chico Y, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):137-44

Effects of female sex hormones on polyamine-oxidizing enzyme activities and polyamine concentrations in immature rat uterus and liver. Dimitrov O, et al. **Experientia** 1996 Aug 15;52(8):795-8

Effect of progesterone and estradiol benzoate on superoxide dismutase activity in the brain of male rats. Pajović S, et al. **Experientia** 1996 Mar 15;52(3):221-4

Progesterone, impedance to blood flow, and luteal inadequacy? [letter; comment] Check JH. **Fertil Steril** 1996 Feb;65(2):454-5. Comment on: Fertil Steril 1995 Jul;64(1):76-80.

Luteal support with both estradiol and progesterone after clomiphene citrate stimulation for in vitro fertilization. Hurd WW, et al. **Fertil Steril** 1996 Oct;66(4):587-92

Intracellular calcium measurements in individual human sperm demonstrate that the majority can respond to progesterone [see comments] Plant A, et al. **Fertil Steril** 1995 Dec;64(6):1213-5. Comment in: Fertil Steril 1996 Jun;65(6):1265-7.

Progesterone-induced acrosome reaction: one receptor is not enough [letter; comment] Tesarik J. **Fertil Steril** 1996 Jun; 65(6):1265-7. Comment on: Fertil Steril 1995 Dec;64(6):1213-5.

Progesterone induces human sperm chemotaxis. Villanueva-Díaz C, et al. **Fertil Steril** 1995 Dec; 64(6):1183-8

Radioligand and immunochemical studies of turtle oviduct progesterone and estrogen receptors: correlations with hormone treatment and oviduct contractility. Giannoukos G, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):63-75

Effects of progesterone on the ultrastructure of the golden hamster parathyroid gland. Emura S, et al. **Histol Histopathol** 1995 Oct;10(4):907-11

Human placental lactogen infusions into the medial preoptic area stimulate maternal behavior in steroid-primed, nulliparous female rats. Bridges RS, et al. **Horm Behav** 1995 Jun;29(2):216-26

Progesterone does not potentiate the acrosome reaction in human spermatozoa: flow cytometric analysis using CD46 antibody. Carver-Ward JA, et al. **Hum Reprod** 1996 Jan; 11(1):121-6

Progesterone-induced immunosuppression is not mediated through the progesterone receptor. Schust DJ, et al. **Hum Reprod** 1996 May;11(5):980-5

Acrosome reaction induced in a limited population of human spermatozoa by progesterone (Ca(2+)-dependent) and ATP (Ca(2+)-independent). Tomiyama T, et al. **Hum Reprod** 1995 Aug;10(8):2052-5

Steroidal and growth factor regulation of [3H]thymidine incorporation by cultured endosalpingeal cells of the bovine oviduct. Tiemann U, et al. **In Vitro Cell Dev Biol Anim** 1995 Sep;31(8):640-5

Effects of progesterone on human spermatozoa prepared for in-vitro fertilization. Emiliozzi C, et al. **Int J Androl** 1996 Feb;19(1):39-47

In vitro fertilization and the effect of progesterone and 17 alpha-hydroxyprogesterone on acrosome reaction of mouse epididymal spermatozoa. Kholkute SK, et al. **Int J Androl** 1995 Jun;18(3):146-50

Evaluation of response to hormonal therapy in prepubertal gilts of different genetic lines. Tilton SL, et al. **J Anim Sci** 1995 Oct;73(10):3062-8

Is median thoracic artery a target organ artery for estradiol and progesterone? A comparison with uterine artery. Guis F, et al. **J Assist Reprod Genet** 1995 Aug;12(7):399-405

Application of a chromogenic bioassay procedure for the measurement of the proliferation of endothelial cells in vitro under the influence of the effects of steroid hormones and growth factors. Drummond AE, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3-4):123-34

Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. Balbín M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15175-81

Cellular factors binding to a novel cis-acting element mediate steroid hormone responsiveness of mouse mammary tumor virus promoter. Lee KI, et al. **J Biol Chem** 1995 Oct 13; 270(41):24502-8

Progesterone inhibits cholesterol biosynthesis in cultured cells. Accumulation of cholesterol precursors. Metherall JE, et al. **J Biol Chem** 1996 Feb 2;271(5):2627-33

Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s). Zhang X, et al. **J Biol Chem** 1996 Jun 21; 271(25):14825-33

Properties and regulation of 17 beta-hydroxysteroid oxidoreductase of OVCAR-3, CAOV-3, and A431 cells: effects of epidermal growth factor, estradiol, and progesterone. Blomquist CH, et al. **J Cell Biochem** 1995 Dec;59(4):409-17

Role of progesterone and nonsteroidal ovarian factors in regulating gonadotropin-releasing hormone self-priming in vitro. Byrne B, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1454-9

Progesterone stimulates the induction of human endometrial CD56+ lymphocytes in an in vitro culture system. Inoue T, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1502-7

Progesterone induces Ca++-dependent 3',5'-cyclic adenosine monophosphate increase in human sperm. Parinaud J, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1357-60

Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. McLaren J, et al. **J Clin Invest** 1996 Jul 15;98(2):482-9

Female sex hormone stimulates cultured human keratinocyte proliferation and its RNA- and protein-synthetic activities. Urano R, et al. **J Dermatol Sci** 1995 May;9(3):176-84

Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages. Miller L, et al. **J Leukoc Biol** 1996 Mar; 59(3):442-50

Sex hormone effects on Phialophora verrucosa in vitro and characterization of progesterone receptors. Hernández-Hernández F, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):235-9

Differential effects of estrogen and progesterone on levels of POMC mRNA levels in the arcuate nucleus: relationship to the timing of LH surge release. Petersen SL, et al. **J Neuroendocrinol** 1993 Dec;5(6):643-8

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. Bergeron R, et al. **J Neurosci** 1996 Feb 1;16(3):1193-202

Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle: effects of estrogen and progesterone. Gibbs RB. **J Neurosci** 1996 Feb 1;16(3):1049-55

Effects of progesterone on the metabolism of cancellous bone in young oophorectomized rats. Fujimaki T, et al. **J Obstet Gynaecol** 1995 Feb;21(1):31-6

Effects of sex hormones on protein and collagen content of the temporomandibular joint disc of the rat. Abubaker AO, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):721-7; discussion 727-8

Lack of effect of hormonal treatment and smoking on cytokeratin expression in buccal mucosa. Leimola-Virtanen R, et al. **J Oral Pathol Med** 1995 Jul;24(6):251-4

Inactivation of Escherichia coli-expressed rabbit cytochrome P-450 2C enzymes by 17 beta-substituted steroids. Klekotka PA, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1450-5

Effects of exogenous oxytocin and progesterone on GnRH-induced short luteal phases in anoestrous ewes. Beard AP, et al. **J Reprod Fertil** 1996 Jan;106(1):55-61

Progesterone and dexamethasone inhibition of uterine epithelial cell proliferation: studies with antiprogesterone compounds in the neonatal mouse. Bigsby RM, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):253-7

The tissue distribution of porcine 17 beta-estradiol dehydrogenase and its induction by progesterone. Kaufmann M, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5-6):535-9

Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells. Sömjen D, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):211-7

Activity of progesterone and anti-progestins in a rat mammary primary cell culture system. Taylor JA, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):117-21

The relaxant effect of sex steroids in rat myometrium is independent of the gamma-amino butyric acid system. Perusquía M, et al. **Life Sci** 1996;58(11):913-26

Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture. Sone H, et al. **Life Sci** 1996;59(1):21-5

Sequential estrogen and progesterone (P) followed by P withdrawal increases the level of oxytocin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the male rat. Thomas A, et al. **Life Sci** 1996; 58(19):1615-20

Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women's vulnerability to vaginal candidiasis. Nohmi T, et al. **Microbiol Immunol** 1995;39(6):405-9

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497-506 (49 ref.)

Unusual steroid specificity of the cell surface progesterone receptor on human sperm. Blackmore PF, et al. **Mol Pharmacol** 1996 Apr;49(4):727-39

Further indications of the multicomponent nature of the acrosome reaction-inducing substance of human follicular fluid. Fehl P, et al. **Mol Reprod Dev** 1995 Sep;42(1):80-8

Progesterone suppression of glutamic acid decarboxylase (GAD67) mRNA levels in the preoptic area: correlation to the luteinizing hormone surge. Unda R, et al. **Neuroendocrinology** 1995 Dec;62(6):562-70

Region-specific effects of ovarian hormones on estrogen receptor immunoreactivity. DonCarlos LL, et al. **Neuroreport** 1995 Oct 23;6(15):2054-8

Gastric emptying and gastric-intestinal transit in rats with varying ovarian hormone status. Bond EF, et al. **Nurs Res** 1996 Jul-Aug;45(4):218-24

The role of ovarian hormones, age and mammary gland development in polyomavirus mammary tumorigenesis. Rondinelli RH, et al. **Oncogene** 1995 Nov 2;11(9):1817-27

Influence of 17 beta-estradiol and progesterone on rat ocular lens. Scharf J, et al. **Ophthalmic Res** 1995;27(4):197-201

Effect of hormones and antihormones on phospholipase A2 activity in human endometrial stromal cells. Periwal SB, et al. **Prostaglandins** 1996 Mar;51(3):191-201

SIV transmission. Monkey study prompts high-level public health response [news] Cohen J. **Science** 1996 May 10; 272(5263):805

Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. Butt TR, et al. **Transplant Proc** 1996 Apr; 28(2):979-80

Effects of gonadal steroids on the growth of human pituitary adenomas in vitro. Caronti B, et al. **Tumour Biol** 1995; 16(6):353-64

[Effect of progesterone on ovulation length and duration of the ovarian cycle induced by the male effect in the Barbarine ewe and the local Tunisian goat] Lassoued N, et al. **Reprod Nutr Dev** 1995;35(4):415-26 (Eng. Abstr.) **(Fre)**

[The composition of milk after artificial lactation induction in 12- to 19-month-old heifers] Kaskous S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Sep;108(9):333-8 (Eng. Abstr.) **(Ger)**

[The significance of reproductive hormones in regulating production of prostaglandin F2alpha by immunocompetent cells] Shirshev SV, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):178-80 **(Rus)**

[The development of the thymus gland in rat embryogenesis with progesterone administration] Churilova NI. **Morfologiia** 1994 Jul-Dec;107(7-12):82-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cervical ripening in humans: potential roles of estrogen, progesterone, and insulin-like growth factor-I. Stjernholm Y, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1065-71

Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy. Walsh JW, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G506-14

Regulation of placental corticotropin-releasing hormone by steroids. Possible implications in labor initiation. Karalis K, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:551-5

Modulation of vitellogenin II gene by estradiol and progesterone in the Japanese quail. Gupta S, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):181-5

Down-regulation by progesterone of CFTR expression in endometrial epithelial cells: a study by competitive

RT-PCR. Mularoni A, et al.
Biochem Biophys Res Commun 1995 Dec 26;217(3):1105–11

Pulsatile gonadotropin secretion determined by frequent sampling from the intercavernous sinus of the mare: possible modulatory role of progesterone during luteolysis. Silvia PJ, et al. **Biol Reprod** 1995 Aug;53(2):438–46

Follicular and luteal progesterone play different roles synchronizing pituitary and ovarian events in the 4-day cyclic rat. Tébar M, et al. **Biol Reprod** 1995 Nov; 53(5):1183–9

Mifepristone and ovarian function. Curry TE Jr, et al.
Clin Obstet Gynecol 1996 Jun;39(2):486–97 (64 ref.)

Role of progesterone in luteinizing hormone–induced fibronectin production and deposition by chicken granulosa cells in vitro. Asem EK, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995 Oct;112(2):247–55

Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. White MM, et al. **Endocr Rev** 1995 Dec;16(6):739–51 (172 ref.)

N–cadherin–mediated cell contact inhibits granulosa cell apoptosis in a progesterone–independent manner. Peluso JJ, et al. **Endocrinology** 1996 Apr;137(4):1196–203

Glutathione peroxidase activity in endometrium: effects of sex hormones and cancer. Ohwada M, et al.
Gynecol Oncol 1996 Feb;60(2):277–82

Arylsulphatase A activity and sulphatide concentration in the female rabbit oviduct are under physiological hormonal influence. Vitaioli L, et al. **Histochem J** 1996 Feb; 28(2):149–56

Progesterone–facilitated lordosis in medial preoptic area–lesioned, juvenile guinea pigs. Olster DH.
Horm Behav 1995 Dec;29(4):519–30

Progesterone modulation of anaphylactically induced ion transport in uterus and intestine. Harari Y, et al.
Int Arch Allergy Immunol 1995 Oct;108(2):134–41

Importance of bicarbonate to the progesterone–initiated human sperm acrosome reaction [published erratum appears in J Androl 1995 Sep–Oct;16(5):416] Sabeur K, et al. **J Androl** 1995 May–Jun;16(3):266–71

Effect of nutrition on embryonal mortality in gilts: association with progesterone. Jindal R, et al. **J Anim Sci** 1996 Mar; 74(3):620–4

Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. Feng Z, et al. **J Cell Biol** 1995 Nov;131(4):1095–103

Thrombospondin–1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. Iruela–Arispe ML, et al. **J Clin Invest** 1996 Jan 15;97(2):403–12

Anti–progesterone effects on maternal recognition and behaviour imprinted during first pregnancy in mice. Crombie DL, et al. **J Endocrinol** 1995 Nov;147(2):331–7

Diverse modes of action of progesterone and its metabolites. Mahesh VB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):209–19 (135 ref.)

Estrogen could control photoperiodic adjustment in seasonal affective disorder. Partonen T. **Med Hypotheses** 1995 Jul; 45(1):35–6

The extragenomic action of progesterone on human spermatozoa is influenced by redox regulated changes in tyrosine phosphorylation during capacitation. Aitken RJ, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):83–93

Amphiregulin is an implantation–specific and progesterone–regulated gene in the mouse uterus. Das SK, et al. **Mol Endocrinol** 1995 Jun;9(6):691–705

Second messenger signalling during hormone–induced Xenopus oocyte maturation. Cork RJ, et al. **Zygote** 1994 Nov;2(4):289–99 (101 ref.)

[Progesterone and its metabolites in central nervous system function] Camacho–Arroyo I, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):329–40 (118 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Alcohol inhibits epidermal growth factor–stimulated progesterone secretion from human granulosa cells. McKenzie PP, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1382–8

Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro. van Vliet AK, et al. **Biochim Biophys Acta** 1996 Jun 11; 1301(3):237–41

Dissociation of relaxin and progesterone secretion from the primate corpus luteum by acute administration of a 3 beta–hydroxysteroid dehydrogenase inhibitor during the menstrual cycle. Duffy DM, et al. **Biol Reprod** 1995 Aug; 53(2):447–53

Patterns of relaxin and steroids in the reproductive cycle of the common marmoset (Callithrix jacchus): effects of prostaglandin F2 alpha on relaxin and progesterone secretion during pregnancy. Steinetz BG, et al.
Biol Reprod 1995 Oct;53(4):834–9

Ovarian production of IL6 and its potential inhibitory effect on progesterone secretion in Cynomolgus fascicularis. Machelon V, et al. **C R Acad Sci III** 1995 Nov; 318(11):1111–8

Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21–hydroxylase deficiency. Holmes–Walker DJ, et al.
Clin Endocrinol (Oxf) 1995 Sep;43(3):291–6

Effects of pregnant human, nonpregnant human, and fetal bovine sera on human chorionic gonadotropin, estradiol, and progesterone release by cultured human trophoblast cells. Henson MC, et al. **Endocrinology** 1996 May; 137(5):2067–74

Intracellular regulation of progesterone secretion by the superoxide radical in the rat corpus luteum. Sawada M, et al. **Endocrinology** 1996 May;137(5):1580–4

Lipopolysaccharide inhibits rat ovarian thecal–interstitial cell steroid secretion in vitro. Taylor CC, et al.
Endocrinology 1995 Dec;136(12):5527–32

Effect of FSH on progesterone secretion by porcine large and small luteal cells isolated from early–developing corpora lutea. Gregoraszczuk EL.
Exp Clin Endocrinol Diabetes 1995;103(4):272–4

In vitro human growth hormone increases human chorionic gonadotropin and progesterone secretion by human placenta at term: evidence of a modulatory role by opioids. Di Simone N, et al. **Gynecol Endocrinol** 1995 Jun; 9(2):157–64

Somatostatin in physiological concentrations inhibits basal and enhances luteinizing hormone–stimulated progesterone release from human granulosa–luteal cells. Holst N, et al. **Hum Reprod** 1995 Jun;10(6):1363–6

Effects of enclomiphene and zuclomiphene on basal and gonadotrophin–stimulated progesterone secretion by isolated subpopulations of small and large ovine luteal cells. Opsahl MS, et al. **Hum Reprod** 1996 Jun;11(6):1250–5

An aminopeptidase inhibitor, bestatin, enhances progesterone and oestradiol secretion by porcine granulosa cells stimulated with follicle stimulating hormone in vitro. Tachibana T, et al. **Hum Reprod** 1996 Mar;11(3):497–502

Acute shifts in relaxin, progesterone, prolactin, and growth hormone secretion in Chinese Meishan gilts during late pregnancy and after hysterectomy. Dlamini BJ, et al.
J Anim Sci 1995 Dec;73(12):3732–42

Effects of growth hormone, prolactin, insulin–like growth factors, and gonadotropins on progesterone secretion by porcine luteal cells. Yuan W, et al. **J Anim Sci** 1996 Apr; 74(4):866–72

Photothermal effects on ovarian growth and function in the soft–shelled turtle Lissemys punctata punctata. Sarkar S, et al. **J Exp Zool** 1996 Jan 1;274(1):41–55

The effect of insulin and insulin–like growth factors on luteal progesterone secretion in the rabbit. Miller JB, et al.
J Soc Gynecol Investig 1996 Sep–Oct;3(5):262–6

Luteotropic effect of pregnant mare serum gonadotropin in cattle. Hirako M, et al. **J Vet Med Sci** 1995 Apr; 57(2):317–21

An in vitro bioassay for testing the direct effect of luteinizing hormone–releasing hormone agonists on progesterone secretion by rat ovarian cells. Chu YH, et al. **Life Sci** 1995; 57(22):2031–9

Assessment of tissue integrity, ultrastructure and steroidogenic activity of corpora lutea of the marmoset monkey, Callithrix jacchus, following in vitro microdialysis. Fehrenbach A, et al. **Tissue Cell** 1995 Aug; 27(4):467–81

[Effect of interleukin–2 and interleukin–6 on ovary in the ovulatory period—establishment of the new ovarian perfusion system and influence of interleukins on ovulation rate and steroid secretion] Mikuni M.
Hokkaido Igaku Zasshi 1995 Jul;70(4):561–72 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Prevention of human recombinant interleukin–1 beta (rhIL–1 beta) embryolethality with progesterone or indomethacin. Marks TA, et al. **Am J Reprod Immunol** 1995 Apr; 33(4):292–300

Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. Clifford K, et al. **BMJ** 1996 Jun 15;312(7045):1508–11

Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Roof RL, et al.
Exp Neurol 1996 Apr;138(2):246–51

Induction of artificial endometrial cycles with oestradiol implants and injectable progesterone: establishment of a viable pregnancy in a woman with 17–alpha–hydroxylase deficiency. Ben–Nun I, et al. **Hum Reprod** 1995 Sep; 10(9):2456–8

Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. Baker ER, et al. **J Assist Reprod Genet** 1995 Mar;12(3):205–9

Combined estrogen–progesterone therapy [letter; comment] Gosink BB. **J Ultrasound Med** 1995 Sep;14(9):660. Comment on: J Ultrasound Med 1993 Dec;12(12):737–41.

[Turner syndrome and digestive telangiectasis: an additional value of estrogen–progestational treatment (letter)] Vuillemin E, et al. **Gastroenterol Clin Biol** 1996;20(5):510–1 **(Fre)**

TOXICITY

The later administration of progesterone more rapidly activates dormant mouse mammary tumor cells initiated by 3'–methyl–4–dimethylaminoazobenzene. Yamamoto R, et al. **Cancer Lett** 1996 Feb 27;100(1–2):41–5

Effects of estrogen, progesterone, and methoxychlor on surgically induced endometriosis in rats. Cummings AM, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):287–90

Does progesterone potentiate the in vitro effect of cocaine on papillary myocardium in Long–Evans rats? Glantz JC, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):563–70

PROGESTERONE–BINDING GLOBULIN

PHARMACOLOGY

Further indications of the multicomponent nature of the acrosome reaction–inducing substance of human follicular fluid. Fehl P, et al. **Mol Reprod Dev** 1995 Sep;42(1):80–8

PROGESTERONE RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTERONE REDUCTASE

ANTAGONISTS & INHIBITORS

Type beta 1 transforming growth factor is an inhibitor of 3 beta–hydroxysteroid dehydrogenase isomerase in mouse adrenal tumor cell line Y1. Cherradi N, et al.
Endocr Res 1995 Feb–May;21(1–2):61–6

Differential effects of trilostane and cyanoketone on the 3 beta–hydroxysteroid dehydrogenase–isomerase reactions in androgen and 16–androstene biosynthetic pathways in the pig testis. Cooke GM. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):95–101

DEFICIENCY

[Congenital disorders of the bile acid metabolism (3 beta–hydroxy–delta 5–steroid dehydrogenase/isomerase deficiency, delta 4–3–oxosteroid 5 beta–reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):362–6 (23 ref.) **(Jpn)**

GENETICS

Angiotensin II interferes with steroidogenesis in porcine granulosa cells. Li XM, et al. **Biol Reprod** 1995 Oct; 53(4):791–9

Structure–function relationships and molecular genetics of the 3 beta–hydroxysteroid dehydrogenase gene family. Simard J, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):489–505

METABOLISM

Organization of 3 beta–hydroxysteroid dehydrogenase/isomerase and cytochrome P450scc into a catalytically active molecular complex in bovine adrenocortical mitochondria. Cherradi N, et al.
J Steroid Biochem Mol Biol 1995 Dec;55(5–6):507–14

Expression and characterization of isoforms of 3 beta–hydroxysteroid dehydrogenase/delta 5–>4–isomerase in the hamster. Rogerson FM, et al.
J Steroid Biochem Mol Biol 1995 Dec;55(5–6):481–7

Structure–function relationships and molecular genetics of the 3 beta–hydroxysteroid dehydrogenase gene family. Simard J, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):489–505

PROGESTIN ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTIN RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTINS see **PROGESTATIONAL HORMONES**

PROGESTINS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTOGENS see **PROGESTATIONAL HORMONES**

PROGESTOGENS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGLUMIDE

ANALOGS & DERIVATIVES

Duration of anti–cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally. Moriyoshi Y, et al. **J Gastroenterol** 1996 Apr;31(2):249–53

Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR–1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA. Sazaki N, et al. **J Gastroenterol** 1995 Oct; 30(5):599–606

Loxiglumide, L–364,718 and L–365,260 prevent the inhibition of spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rat peripherally administered with cholecystokinin–8S. Kimura I, et al.
Jpn J Pharmacol 1995 May;68(1):129–32

THERAPEUTIC USE

Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea. Piolti R, et al.
Eur Neurol 1995;35(6):344–8

Potentiation of placebo analgesia by proglumide [letter] Benedetti F, et al. **Lancet** 1995 Nov 4;346(8984):1231

[Treatment of duodenal ulcer with famotidine and proglumide] Tarabar D, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):563–7 (Eng. Abstr.) **(Ser)**

PROGLUMIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PROGNATHISM

PHYSIOPATHOLOGY

Bite forces before and after surgical correction of mandibular prognathism. Ellis E 3rd, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):176–81

[Condylar movement in patient with skeletal mandibular prognathism during maximum opening and closing movement before and after surgery] Fujisaki T. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):408–21 (Eng. Abstr.) **(Jpn)**

SURGERY

Surgical refinement of the operative procedure for a minor degree of mandibular prognathism. Satoh K, et al. **Plast Reconstr Surg** 1996 Sep;98(4):740–6

[Condylar movement in patient with skeletal mandibular prognathism during maximum opening and closing movement before and after surgery] Fujisaki T. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):408–21 (Eng. Abstr.) **(Jpn)**

PROGNOSIS

Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)

Risk and prognosis. Hofman A. **Neth J Med** 1995 Sep; 47(3):137–9

A reader's guide to the evaluation of prognostic studies. van Walraven C, et al. **Postgrad Med J** 1996 Jan;72(843):6–11 (7 ref.)

PROGNOSTIC NUTRITIONAL INDEX (PNI) see **NUTRITION ASSESSMENT**

PROGONOMA, MELANOTIC see **NEUROECTODERMAL TUMOR, MELANOTIC**

PROGRAM DEVELOPMENT

Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients. Domenech MI, et al. **Acta Diabetol** 1995 Oct;32(3):142–7

Physician involvement and assessment in the development of hospital oncology programs. Konski AA. **Am J Clin Oncol** 1996 Jun;19(3):311–6

Implementing the COACH relationship model: health promotion for mothers and children. Hanks C, et al. **ANS Adv Nurs Sci** 1995 Dec;18(2):57–66

A career ladder program designed by perioperative staff nurses. Day DS, et al. **AORN J** 1995 Nov;62(5):805–9

Developing competency-based perioperative orientation programs. Schramm CA, et al. **AORN J** 1995 Oct;62(4):579, 582–90

Irradiation for the prevention of foodborne diseases. **Bull Pan Am Health Organ** 1995 Sep;29(3):279–81

Measuring of impact of patient counseling in the outpatient pharmacy setting: development and implementation of the counseling models for the Kaiser Permanente/USC Patient Consultation Study. Johnson KA, et al. **Clin Ther** 1995 Sep–Oct;17(5):988–1002

Need for national hypertension control programme. Wasir HS. **Indian Heart J** 1995 Jul–Aug;47(4):409–10

Family training: supporting mothers and fathers in the transition to parenthood. Vehviläinen-Julkunen K. **J Adv Nurs** 1995 Oct;22(4):731–7

Development, implementation, and evaluation of a health promotion program in a college setting. Fisher SP, et al. **J Am Coll Health** 1995 Sep;44(2):81–3

Coeur en santé St-Henri—a heart health promotion programme in a low income, low education neighbourhood in Montreal, Canada: theoretical model and early field experience. Paradis G, et al. **J Epidemiol Community Health** 1995 Oct;49(5):503–12

An audit programme for central venous catheter-associated infections. Elliott TS, et al. **J Hosp Infect** 1995 Jul; 30(3):181–91

Student home care program: a real taste of home. Buls P, et al. **J Nurs Educ** 1995 Nov;34(8):372–4

Jailed mothers: further explorations in public sector nursing. Osborne OH. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):23–8

Bridging the "med-ed gap" for students with special health care needs: a model school liaison program. Koenning GM, et al. **J Sch Health** 1995 Aug;65(6):207–12

Development of a comprehensive treatment program for chemical dependency at Al Amal Hospital, Dammam. Abdel-Mawgoud M, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):369–76

From the Institute of Medicine. Brown SS, et al. **JAMA** 1995 Nov 1;274(17):1332

Cooperation between government and industry in combating a perceived emerging pandemic. The 1976 swine influenza vaccination program. Hilleman MR. **JAMA** 1996 Jan 17; 275(3):241–3

World Health Organization strategy for emerging infectious diseases. LeDuc JW. **JAMA** 1996 Jan 24–31;275(4):318–20

Inner-city asthma control campaign under way [news] Marwick C. **JAMA** 1995 Oct 4;274(13):1004

'Shoe leather therapy' is gaining on TB [news] Voelker R. **JAMA** 1996 Mar 13;275(10):743–4

Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. **MMWR Morb Mortal Wkly Rep** 1995 Sep 8; 44(RR-11):1–16

Community-level prevention of human immunodeficiency virus infection among high-risk populations: the AIDS Community Demonstration Projects. **MMWR Morb Mortal Wkly Rep** 1996 May 10; 45(RR-6):1–24

Guidelines for school health programs to promote lifelong healthy eating. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1996 Jun 14; 45(RR-9):1–41

Psychiatric diagnoses in North Carolina Physicians Health Program participants. Betts WC. **N C Med J** 1996 Jul–Aug; 57(4):214–5

Into the next century. A strategic plan for the North Carolina Physicians Health Program. Keith JF Jr. **N C Med J** 1996 Jul–Aug;57(4):243–5

A North Carolina Medical Board member looks at the North Carolina Physicians Health Program. Trado CE. **N C Med J** 1996 Jul–Aug;57(4):230–2

Reducing impediments to technology transfer in drug abuse programming. Brown BS. **NIDA Res Monogr** 1995; 155:169–85 (38 ref.)

Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225–45 (8 ref.)

Policy considerations for a realistic approach to hunger in Nigeria. Igbedioh SO. **Nutr Health** 1996;10(4):341–58

Coping with fear of long-term complications in diabetes mellitus: a model clinical program. Zettler A, et al. **Psychother Psychosom** 1995;64(3–4):178–84

Eye care knowledge and practices among Malawian traditional healers and the development of collaborative blindness prevention programmes. Courtright P. **Soc Sci Med** 1995 Dec;41(11):1569–75

Computer integrated drug prevention: a new approach to teach lower socioeconomic 5th and 6th grade Israeli children to say no to drugs. Gropper M, et al. **Soc Work Health Care** 1995;22(2):87–103

Establishing a Women's Cancer Control Program using a multi-county consortium. Gohre F, et al. **Wis Med J** 1995 Oct;94(10):556–7

The Wisconsin Women's Cancer Control Program: 1993–1995. Johnson GD, et al. **Wis Med J** 1995 Oct; 94(10):553–5

[Procedures for the implementation of a program for quality control and assurance in ultrasonography equipment] Lago P, et al. **Radiol Med (Torino)** 1996 Jun;91(6):781–8 (Eng. Abstr.) **(Ita)**

[The development of a state anticancer program] Sukhachev VIa. **Vopr Onkol** 1995;41(2):35–6 **(Rus)**

METHODS

Comparison of Department of Veterans Affairs pharmacy services in 1992 and 1994 with strategic-planning goals. Portner TS, et al. **Am J Health Syst Pharm** 1996 May 1; 53(9):1032–40

Community program planning: a clinical outcome. Kuennen J, et al. **J Nurs Educ** 1995 Nov;34(8):387–9

Developing a collaborative community partnership program in medical asepsis with tattoo studios. Bechtel GA, et al. **Public Health Nurs** 1995 Oct;12(5):348–52

STANDARDS

[Quality nursing: where are we headed? The importance of the development of nursing standards for a quality assurance management system] Sansoni J. **Ann Ig** 1994 Jul–Dec;6(4–6):409–16 (Eng. Abstr.) **(Ita)**

PROGRAM EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

PROGRAM EVALUATION

ELPAT program report: background and current status (April 1996). Environmental Lead Proficiency Analytical Testing. Esche CA, et al. **Am Ind Hyg Assoc J** 1996 Jul; 57(7):697–703

Policy evaluation: better living through research. Boden LI. **Am J Ind Med** 1996 Apr;29(4):346–52 (40 ref.)

Intervention research: GAO experiences. Grasso PG. **Am J Ind Med** 1996 Apr;29(4):362–6

Key issues in intervention research: a program evaluation perspective. Lipsey MW. **Am J Ind Med** 1996 Apr; 29(4):298–302

Description and evaluation of the Iowa Depression Awareness, Recognition, and Treatment Program. O'Hara MW, et al. **Am J Psychiatry** 1996 May;153(5):645–9

American College of Emergency Physicians: Research fellowship program evaluation. **Ann Emerg Med** 1995 Dec; 26(6):733–4

The asthma year in Swedish pharmacies: a nationwide information and pharmaceutical care program for patients with asthma. Lisper B, et al. **Ann Pharmacother** 1996 May; 30(5):455–60

How effective is an integrated approach to low vision rehabilitation? Two year follow up results from south Devon [see comments] Shuttleworth GN, et al. **Br J Ophthalmol** 1995 Aug;79(8):719–23. Comment in: Br J Ophthalmol 1995 Aug;79(8):715–6.

A longitudinal study of associates at the National Library of Medicine, 1957–1990. Carle DO. **Bull Med Libr Assoc** 1995 Jul;83(3):275–9

The 'family cap': a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul–Aug; 27(4):166–71 (41 ref.)

Antenatal period: an educational opportunity. Verma M, et al. **Indian Pediatr** 1995 Feb;32(2):171–7

Use of facility-based assessment in the evaluation of a comprehensive leprosy training program in Nepal. Roos BR, et al. **Int J Lepr Other Mycobact Dis** 1995 Dec; 63(4):552–8

Tri-State Regional Pulmonary Rehabilitation Survey. Program characteristics and practices. Weiser PC, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):197–208

Expert ratings of primary care goals and objectives. Robbins AS, et al. **J Gen Intern Med** 1995 Aug;10(8):429–35

The School Health Policies and Programs Study (SHPPS): rationale for a nationwide status report on school health programs. Kann L, et al. **J Sch Health** 1995 Oct;65(8):291–4

The School Health Policies and Programs Study (SHPPS): context, methods, general findings, and future efforts. Kolbe LJ, et al. **J Sch Health** 1995 Oct;65(8):339–43

Change and technology in nursing education. Zelmer AC. **Medinfo** 1995;8 Pt 2:1357–61

Evaluation of research-based nursing practice. Goode CJ. **Nurs Clin North Am** 1995 Sep;30(3):421–8

Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity [see comments] Stern JS, et al. **Obes Res** 1995 Nov;3(6):591–604. Comment in: Obes Res 1995 Nov;3(6):589–90.

Improving clinical evaluations of new eye care technologies [editorial] Ellwein LB. **Ophthalmology** 1996 Jan;103(1):3–4

Palliative care services: what needs assessment? Robbins MA, et al. **Palliat Med** 1995 Oct;9(4):287–93

Failure of current guidelines for cholesterol screening in urban African-American adolescents. Rifai N, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):383–8

Are learning objectives useful in evaluating medical school course and instructor performance? Martin LF, et al. **South Med J** 1995 Dec;88(12):1241–8

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Barry MJ, et al. **Urology** 1995 Oct;46(4):445–61

[Inequalities in maternal-child health: impact of an intervention] Díez E, et al. **Gac Sanit** 1995 Jul–Aug; 9(49):224–31 (Eng. Abstr.) **(Spa)**

ECONOMICS

Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Posnett J, et al. **Health Econ** 1996 Jan–Feb;5(1):13–23

METHODS

Preclinical course-evaluation methods at U.S. and Canadian medical schools. Abrahams MB, et al. **Acad Med** 1996 Apr; 71(4):371–4

A consumer-oriented model for evaluating computer-assisted instructional materials for medical education. Glenn J. **Acad Med** 1996 Mar;71(3):251–5

Use of a standardized-patient-based clinical performance examination as an outcome measure to evaluate medical school curricula. Richards BF, et al. **Acad Med** 1996 Jan; 71(1 Suppl):S49–51

Evaluating the performance of a pharmacy benefit management company. Stern CS. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1865–7

Client-centered approach to develop a seating clinic satisfaction questionnaire: a qualitative study. McComas J, et al. **Am J Occup Ther** 1995 Nov–Dec;49(10):980–5

The measurements and testing programme of the European Union in the field of biomedical analysis: reference materials and cooperation between European EQAS. Dirscherl C, et al. **Ann Ist Super Sanita** 1995;31(1):103–7

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837–43 (61 ref.)

Epidemiologic measures of impact of community health promotion projects [letter] Holman CD, et al. **Int J Epidemiol** 1996 Jun;25(3):687–8

Epidemiological measures of participation in community health promotion projects. Oddy WH, et al. **Int J Epidemiol** 1995 Oct;24(5):1013–21

A not quite as quick but much cleaner alternative to the Expanded Programme on Immunization (EPI) Cluster Survey design. Turner AG, et al. **Int J Epidemiol** 1996

Feb;25(1):198–203

Methodology. Errecart MT, et al. **J Sch Health** 1995 Oct; 65(8):295–301

Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51–85 (69 ref.)

Program evaluation and research at thresholds. Cook JA. **New Dir Ment Health Serv** 1995 Winter;(68):75–85

Assessment of tuberculosis: is 'rapid assessment' needed? [editorial] Arnadottir T. **Tuber Lung Dis** 1995 Oct; 76(5):375–6

Indicators and research methods for rapid assessment of a tuberculosis control programme: case study of a rural area in South Africa. Lee T, et al. **Tuber Lung Dis** 1995 Oct; 76(5):441–9

[DRGs and MDCs in the evaluation of surgical departments: the experience of Local Health Screening Unit No. 13 of the Veneto Region] Tasso S, et al. **Epidemiol Prev** 1995 Sep;19:254–8 (Eng. Abstr.) **(Ita)**

[Evaluation of "the ever changing" educational program] Mościcka M, et al. **Rocz Panstw Zakl Hig** 1995;46(4):417–26 (Eng. Abstr.) **(Pol)**

[An evaluation of the epidemiological surveillance system for infectious diseases in the Barcelona Olympic Games of 1992] Pañella H, et al. **Gac Sanit** 1995 Mar–Apr; 9(47):84–90 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Breaking the matches in a paired t-test for community interventions when the number of pairs is small. Diehr P, et al. **Stat Med** 1995 Jul 15;14(13):1491–504

TRENDS

The WHO Programme for the Prevention of Blindness [editorial] Thylefors BI. **Ophthalmic Epidemiol** 1994 Mar; 1(1):3–4

PROGRAM EVALUATION, NURSING see **NURSING EVALUATION RESEARCH**

PROGRAMMABLE IMPLANTABLE INSULIN PUMP see **INSULIN INFUSION SYSTEMS**

PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEMS see **INFUSION PUMPS, IMPLANTABLE**

PROGRAMMED INSTRUCTION

Self directed learning. Towle A, et al. **Arch Dis Child** 1996 Apr;74(4):357–9 (9 ref.)

One–session therapist directed exposure vs two forms of manual directed self–exposure in the treatment of spider phobia. Hellström K, et al. **Behav Res Ther** 1995 Nov; 33(8):959–65

Biotherapy module III. Interferons. Gantz S, et al. **Cancer Nurs** 1995 Dec;18(6):479–91; quiz 492–4

Biotherapy module. II. Overview of biotherapy. Tomaszewski JG, et al. **Cancer Nurs** 1995 Oct; 18(5):397–412; quiz 413–5

A randomized trial of self–help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. Curry SJ, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):1005–14

An electronic study guide for problem–based learning. Mooney GA, et al. **Med Educ** 1995 Nov;29(6):397–402

RAINBOW: one answer to training a whole nation in one area of nursing informatics? Wright G, et al. **Medinfo** 1995; 8 Pt 2:1353–6

[Development and evaluation of self–study material for smoking prevention education] Takahashi H, et al. **Nippon Koshu Eisei Zasshi** 1995 Jul;42(7):454–62 (Eng. Abstr.) **(Jpn)**

TRENDS

Role of distance learning in health manpower training. Dutta PK. **Indian J Public Health** 1995 Jan–Mar;39(1):16–9

PROGRAMMED INSTRUCTION, COMPUTERIZED see **COMPUTER–ASSISTED INSTRUCTION**

PROGRAMMED LEARNING see **PROGRAMMED INSTRUCTION**

PROGRAMMING LANGUAGES

Dynamic simulation using a graphical programming language. Valenta HL Jr. **Biomed Sci Instrum** 1996; 32:323–32

Teaching computer interfacing with virtual instruments in an object–oriented language. Gulotta M. **Biophys J** 1995 Nov;69(5):2168–73

DNASTAT: a Pascal unit for the statistical analysis of DNA and protein sequences. Kleffe J, et al. **Comput Appl Biosci** 1995 Aug;11(4):449–55

PROXIMAL: a database system for the efficient retrieval of genetic information. Ganguly S, et al. **Comput Biol Med** 1996 May;26(3):199–207

A PC program for unbiased and predictive linear and quadratic discriminant analysis. Grouven U, et al. **Comput Biol Med** 1995 Jul;25(4):425–30

A C+ + class library foundation for developing an electronic medical record. O'Kane KC, et al. **Comput Biol Med** 1995 Jul;25(4):415–23

Artificial intelligence programming with LabVIEW: genetic algorithms for instrumentation control and optimization. Moore JH. **Comput Methods Programs Biomed** 1995 Jun; 47(1):73–9

Protein topology prediction through parallel constraint logic programming. Clark DA, et al. **Ismb** 1993;1:83–91

PALM—a pattern language for molecular biology. Helgesen C, et al. **Ismb** 1993;1:172–80

Cellular segregation and engulfment simulations using the cell programming language. Agarwal P. **J Theor Biol** 1995 Sep 7;176(1):79–89

Palingol: a declarative programming language to describe nucleic acids' secondary structures and to scan sequence database. Billoud B, et al. **Nucleic Acids Res** 1996 Apr 15; 24(8):1395–403

Querying temporal clinical databases with different time granularities: the GCH–OSQL language. Combi C, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:326–30

A comparison of the temporal expressiveness of three database query methods. Das AK, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:331–7

Medical decision support: experience with implementing the Arden Syntax at the Columbia–Presbyterian Medical Center. Jenders RA, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:169–73

Using intermediate states to improve the ability of the Arden Syntax to implement care plans and reuse knowledge. Sherman EH, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:238–42

Bioinformatics. Working the Web with a virtual lab and some Java [news] Fischman J. **Science** 1996 Aug 2; 273(5275):591–3

Do Java users live dangerously? [news] Seife C. **Science** 1996 Aug 2;273(5275):592

PROGRANULOCYTIC LEUKEMIA see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PROGRESSION–FREE SURVIVAL see **DISEASE–FREE SURVIVAL**

PROGRESSIVE INTERSTITIAL PNEUMONIA OF SHEEP see **PNEUMONIA, PROGRESSIVE INTERSTITIAL, OF SHEEP**

PROGRESSIVE LENTICULAR DEGENERATION see **HEPATOLENTICULAR DEGENERATION**

PROGRESSIVE MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

PROGRESSIVE PATIENT CARE

Measuring outcomes in the postacute continuum. Kilgore KM. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC21–6

Transferring to adult health care: experiences of adolescents with cystic fibrosis. Russell MT, et al. **J Pediatr Nurs** 1996 Aug;11(4):262–8 (44 ref.)

ECONOMICS

Subacute care: evolution in search of value. Haffey WJ, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC2–4

Cost analysis of intermediate care versus intensive care for the neurosurgery patient. Cohen L, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):3, 18

ORGANIZATION & ADMINISTRATION

Toward a pediatric subacute care model: clinical and administrative features. Grebin B, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12 Suppl):SC16–20

The acute and long–term care interface. Integrating the continuum. Phillips–Harris C, et al. **Clin Geriatr Med** 1995 Aug;11(3):481–501 (24 ref.)

Reducing intensive care unit length of stay. A stepdown unit for first–day heart surgery patients. Cady N, et al. **J Nurs Adm** 1995 Dec;25(12):29–35

STANDARDS

Measuring patient and relative satisfaction with level or aggressiveness of care and involvement in care decisions in the context of life threatening illness. Guyatt GH, et al. **J Clin Epidemiol** 1995 Oct;48(10):1215–24

TRENDS

The high dependency unit: where to now? Edbrooke DL. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):161–2

PROGUANIL see **CHLOROGUANIDE**

PROINSULIN

BIOSYNTHESIS

Specific co–ordinated regulation of PC3 and PC2 gene expression with that of preproinsulin in insulin–producing beta TC3 cells. Schuppin GT, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):259–68

Glucose–regulated translational control of proinsulin biosynthesis with that of the proinsulin endopeptidases PC2 and PC3 in the insulin–producing MIN6 cell line. Skelly RH, et al. **Diabetes** 1996 Jan;45(1):37–43

Loss of ganciclovir sensitivity by exclusion of thymidine kinase gene from transplanted proinsulin–producing fibroblasts as a gene therapy model for diabetes. Yoshimoto K, et al. **Gene Ther** 1996 Mar;3(3):230–4

Effects of galanin on proinsulin mRNA and insulin biosynthesis in normal islets. Lindskog S, et al. **Regul Pept** 1995 Aug 22;58(3):135–9

BLOOD

Quantitative variation in obesity–related traits and insulin precursors linked to the OB gene region on human chromosome 7. Duggirala R, et al. **Am J Hum Genet** 1996 Sep;59(3):694–703

Proinsulin level in diabetes mellitus measured by a new immunochemiluminometric assay. Wu TJ, et al. **Ann Clin Lab Sci** 1995 Nov–Dec;25(6):467–74

Simple, sensitive microplate IRMAs for intact and des–31,32–proinsulin compared with HPLC and cellulose IRMAs. Mohamed–Ali V, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):977–9

Beta–cell function in hypopituitary adults before and during growth hormone treatment. Beshyah SA, et al. **Clin Sci (Colch)** 1995 Sep;89(3):321–8

Higher proinsulin and specific insulin are both associated with a parental history of diabetes in nondiabetic Mexican–American subjects. Haffner SM, et al. **Diabetes** 1995 Oct;44(10):1156–60

Are insulin and proinsulin independent risk markers for premature coronary artery disease ? Katz RJ, et al. **Diabetes** 1996 Jun;45(6):736–41

Increased molar proinsulin–to–insulin ratio in women with previous gestational diabetes does not predict later impairment of glucose tolerance. Hanson U, et al. **Diabetes Care** 1996 Jan;19(1):17–20

Hyperinsulinemia in nondiabetic Asian subjects using specific assays for insulin, intact proinsulin, and des–31, 32–proinsulin. Nagi DK, et al. **Diabetes Care** 1996 Jan; 19(1):39–42

Proinsulin immunoreactivity in recent–onset IDDM: the significance of insulin antibodies and insulin autoantibodies. Snorgaard O, et al. **Diabetes Care** 1996 Feb;19(2):146–50

Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment. Kumakura S, et al. **Diabetes Res Clin Pract** 1995 Aug;29(2):107–12

A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non–diabetic subjects. Haffner SM, et al. **Diabetologia** 1995 Nov;38(11):1328–36

Association of proinsulin–like molecules with lipids and fibrinogen in non–diabetic subjects—evidence against a modulating role for insulin. Mohamed–Ali V, et al. **Diabetologia** 1995 Sep;38(9):1110–6

Intra–individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Mooy JM, et al. **Diabetologia** 1996 Mar; 39(3):298–305

Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Mykkänen L, et al. **Diabetologia** 1995 Oct;38(10):1176–82

Fasting proinsulin and 2–h post–load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Nijpels G, et al. **Diabetologia** 1996 Jan;39(1):113–8

Proinsulin, C–peptide, and insulin in normal subjects during an 8–h hyperglycemic clamp. Hartling SG, et al. **Eur J Endocrinol** 1996 Feb;134(2):197–200

True insulin and intact proinsulin levels in acromegalic patients. Tavares EF, et al. **Eur J Endocrinol** 1996 May; 134(5):549–53

Plasma proinsulin–like component in insulinoma: a 25–year experience. Gorden P, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2884–7

Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin–dependent diabetes mellitus. Prigeon RL, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3295–8

Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. Seaquist ER, et al. **J Clin Invest** 1996 Jan 15;97(2):455–60

Are specific serum insulin levels low in impaired glucose tolerance and type II diabetes?: measurement with a radioimmunoassay blind to proinsulin, in the population of Wadena, Minnesota. Goetz FC, et al. **Metabolism** 1995 Oct;44(10):1371–6

No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. Petersen KR, et al. **Metabolism** 1996 Jul;45(7):833–7

Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Båvenholm P, et al. **Thromb Haemost** 1995 Apr;73(4):568–75

[Determination of plasma proinsulins, insulin and C–peptide] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(1–2):3–9 (59 ref.) (Eng. Abstr.) **(Fre)**

[Proinsulin] Sato Y, et al. **Nippon Rinsho** 1995 Mar;53 Su

Pt 2:616–8 (13 ref.) (Jpn)

CHEMISTRY

Sequence requirements for proinsulin processing at the B–chain/C–peptide junction. Kaufmann JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):869–74

GENETICS

Production of human insulin in an E. coli system with Met–Lys–human proinsulin as the expressed precursor. Chen JQ, et al. **Appl Biochem Biotechnol** 1995 Oct; 55(1):5–15

Formation of inclusion bodies may be the key factor for the stability of expressed products in E. coli. Wei G, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):895–901

Expression and folding of an interleukin–2–proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C–peptide and the N–terminal fused sequence. Castellanos–Serra LR, et al. **FEBS Lett** 1996 Jan 8;378(2):171–6

Hyperproinsulinemia in a three–generation Caucasian family due to mutant proinsulin (Arg65–His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription. Fehmann HC, et al. **Peptides** 1995;16(6):1149–52

IMMUNOLOGY

Sequence similarity between beta–cell autoantigens [letter] Rudy G, et al. **Immunol Today** 1995 Aug;16(8):406–7

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin–dependent diabetes. Rudy G, et al. **Mol Med** 1995 Sep;1(6):625–33

METABOLISM

Preparation of Tyr–C–peptide from genetically altered human insulin precursor. Sun H, et al. **Appl Biochem Biotechnol** 1995 Dec;55(3):167–74

Sequence requirements for proinsulin processing at the B–chain/C–peptide junction. Kaufmann JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):869–74

High affinity binding sites for proinsulin in human IM–9 lymphoblasts. Jehle PM, et al. **Diabetologia** 1996 Apr; 39(4):421–32

A removable spacer peptide in an alpha–factor–leader/insulin precursor fusion protein improves processing and concomitant yield of the insulin precursor in Saccharomyces cerevisiae. Kjeldsen T, et al. **Gene** 1996 Apr 17;170(1):107–12

Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. O'Rahilly S, et al. **N Engl J Med** 1995 Nov 23; 333(21):1386–90

PHARMACOKINETICS

Time–action profiles of the intermediate–acting insulin analogue des(64,65)–human proinsulin. Heinemann L, et al. **Diabete Metab** 1995 Dec;21(6):415–9

PHYSIOLOGY

Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Schrezenmeir J. **Experientia** 1996 May 15;52(5):426–32 (26 ref.)

Role of insulin and proinsulin in diabetic vascular disease. Wareham NJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):76–82 (56 ref.)

SECRETION

Insulin and proinsulin secretion in subjects with abnormal glucose tolerance and a mitochondrial tRNA(Leu(UUR)) mutation [letter] Walker M, et al. **Diabetes Care** 1995 Nov; 18(11):1507–9

Hyperproinsulinemia in a three–generation Caucasian family due to mutant proinsulin (Arg65–His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

PROJECTION

The return of the projected: some thoughts on paranoia and a recent trend in horror films. Benton RJ. **Psychoanal Rev** 1995 Dec;82(6):903–31

Authoritarianism and projection. Lewis CA, et al. **Psychol Rep** 1995 Oct;77(2):362

PROJECTIONS AND PREDICTIONS see **FORECASTING**

PROJECTIVE TECHNIQUES

Differentiation between patients with schizophrenia and borderline disorders in the Percept–genetic Object–Relation Test, PORT. Nilsson A. **Br J Med Psychol** 1995 Dec;68 (Pt 4):287–309

Verbal and nonverbal expressions of central deficits in schizophrenia. Goren AR, et al. **J Nerv Ment Dis** 1995 Nov;183(11):715–9

Size, detail, and line heaviness in children's drawings as correlates of emotional distress: (more) negative evidence. Joiner TE Jr, et al. **J Pers Assess** 1996 Aug;67(1):127–41

["Sceno–R": a revision of materials for the Sceno Test] Fliegner J. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul–Aug;44(6):215–21 (Eng. Abstr.) (Ger)

[Tools for a clinical assessment of patients' attitude toward their schizophrenic illness: 3. Examples of clinical experiments] Wciórka J. **Psychiatr Pol** 1996 May–Jun; 30(3):415–27 (Eng. Abstr.) (Pol)

STATISTICS & NUMERICAL DATA

Security of attachment in 8–12–year–olds: a revised version of the Separation Anxiety Test, its psychometric properties and clinical interpretation. Wright JC, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):757–74

Prediction of adolescent aggression by childhood personality measures: a comparison of projective procedures, self–report tests, and behavior ratings. Graybill D, et al. **J Clin Psychol** 1996 Jan;52(1):61–6

Relationships of objective and projective dependency scores to sex role orientation in college student participants. Bornstein RF, et al. **J Pers Assess** 1996 Jun;66(3):555–68

Correlations between the Hand Test Pathology score and Personality Assessment Inventory scales for pain clinic patients. George JM, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1377–8

Projective personality tests of children with inflammatory bowel disease. Krall V, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1341–2

PROKARYOTIC CELLS

In situ PCR for visualization of microscale distribution of specific genes and gene products in prokaryotic communities. Hodson RE, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4074–82

Phage RNA polymerase vectors that allow efficient gene expression in both prokaryotic and eukaryotic cells. He B, et al. **Gene** 1995 Oct 16;164(1):75–9

Determining divergence times of the major kingdoms of living organisms with a protein clock. Doolittle RF, et al. **Science** 1996 Jan 26;271(5248):470–7

Proteins 'clock' the origins of all creatures—great and small [news; comment] Morell V. **Science** 1996 Jan 26; 271(5248):448. Comment on: Science 1996 Jan 26;271(5248):446–7.

CYTOLOGY

[Evolution of cells] Maier UG, et al. **Naturwissenschaften** 1996 Mar;83(3):103–12 (54 ref.) (Eng. Abstr.) (Ger)

ENZYMOLOGY

NADPH–P–450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)

Two types of aminoacyl–tRNA synthetases could be originally encoded by complementary strands of the same nucleic acid. Rodin SN, et al. **Orig Life Evol Biosph** 1995 Dec;25(6):565–89

METABOLISM

Analysis and modeling of substrate uptake and product release by prokaryotic and eukaryotic cells. Krämer R. **Adv Biochem Eng Biotechnol** 1996;54:31–74 (147 ref.)

Fancy meeting you here! A fresh look at "prokaryotic" protein phosphorylation. Kennelly PJ, et al. **J Bacteriol** 1996 Aug;178(16):4759–64 (54 ref.)

L–arginine transport and metabolism in Giardia intestinalis support its position as a transition between the prokaryotic and eukaryotic kingdoms. Knodler LA, et al. **Microbiology** 1995 Sep;141 (Pt 9):2063–70

PHYSIOLOGY

[Oxidative damage repair of DNA in prokaryotes] Zastawny TH. **Postepy Biochem** 1996;42(1):31–41 (118 ref.) (Pol)

PROLACTIN

see related
HYPERPROLACTINEMIA
RECEPTORS, PROLACTIN

ANALOGS & DERIVATIVES

Glycosylated and non–glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Priou A, et al. **Clin Endocrinol (Oxf)** 1995 Aug; 43(2):213–7

Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. Goffin V, et al. **J Biol Chem** 1996 Jul 12;271(28):16573–9

ANALYSIS

Plasma and tumor prolactin in colorectal cancer patients. Ilan Y, et al. **Dig Dis Sci** 1995 Sep;40(9):2010–5

Detection of mammosomatotroph cells and identification of the coexistence of growth hormone and prolactin within the same secretory granules in these cells using confocal laser scanning microscopy. Kabuto M, et al. **Histochem Cell Biol** 1995 Nov;104(5):363–7

Levels of pro–opiomelanocortin and prolactin mRNA in the fetal sheep pituitary following hypoxaemia and glucocorticoid treatment in late gestation. Matthews SG, et al. **J Endocrinol** 1995 Oct;147(1):139–46

ANTAGONISTS & INHIBITORS

Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Lemus–Wilson A, et al. **Br J Cancer** 1995 Dec;72(6):1435–40

Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. Goth MI, et al. **Endocrinology** 1996 Jan;137(1):274–80

Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for interactions with dopamine through inhibitory coupling to calcium entry. Wang J, et al. **Endocrinology** 1996 Feb;137(2):587–94

[The treatment of pseudopregnancy in the bitch with prolactin inhibitors metergoline and bromocriptine] Grünau B, et al. **Tierarztl Prax** 1996 Apr;24(2):149–55 (Eng. Abstr.) (Ger)

BIOSYNTHESIS

Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Maskall DD, et al. **Biol Psychiatry** 1995 Aug 15;38(4):235–9

Prolactin is synthesized and secreted by the endometrium [letter] Peedicayil J. **Biol Psychiatry** 1995 Sep 15;38(6):417

Endocrine interaction between zinc and prolactin. An interpretative review. Brandão–Neto J, et al. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):139–49 (57 ref.)

Expression of prolactin gene in human decidua during pregnancy studied by in situ hybridization histochemistry. Tadokoro N, et al. **Endocr J** 1995 Aug;42(4):537–43

Retinoic acid induces expression of the transcription factor GHF–1/Pit–1 in pituitary prolactin– and growth hormone–producing cell lines. Sánchez–Pacheco A, et al. **Endocrinology** 1995 Dec;136(12):5391–8

RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium. Stewart EA, et al. **Fertil Steril** 1996 Jun;65(6):1119–24

TEF–1 transrepression in BeWo cells is mediated through interactions with the TATA–binding protein, TBP. Jiang SW, et al. **J Biol Chem** 1996 Apr 19;271(16):9510–8

Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol–primed pituitary cells. Lee SC, et al. **J Endocrinol** 1996 Jan;148(1):69–76

Cloning of rabbit prolactin cDNA and prolactin gene expression in the rabbit mammary gland. Gabou L, et al. **J Mol Endocrinol** 1996 Feb;16(1):27–37

Effects of morphine and naloxone on prolactin and growth hormone gene expression in the male rat pituitary gland. Dobado–Berrios PM, et al. **J Neuroendocrinol** 1993 Oct; 5(5):553–6

Ovine prolactin increases hepatic UDP–glucuronosyltransferase activity in ovariectomized rats. Luquita MG, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):921–5

Evaluation of immune parameters and lymphocyte production of prolactin–immunoreactive proteins after chronic administration of cocaine to pregnant rats. Masten SA, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1090–6

Evaluation of prolactin–like activity produced by concanavalin–A stimulated mouse splenocytes. Gala RR, et al. **Life Sci** 1995;57(18):1683–700

Site–specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression. Ngô V, et al. **Mol Cell Biol** 1996 Jul;16(7):3245–54

Long–term effects of calcium availability on prolactin and protein synthesis in human decidual cells. Couderc B, et al. **Placenta** 1995 Sep;16(6):527–37

BLOOD

Serum cortisol and prolactin levels in childhood paroxysmal disorders. Dirik E, et al. **Acta Paediatr Jpn** 1996 Apr; 38(2):118–20

D–fenfluramine–induced prolactin responses in postwithdrawal alcoholics and controls. Farren CK, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1578–82

Thyrotropin and prolactin responses to thyrotropin–releasing hormone in young men at high or low risk for alcoholism. Garbutt JC, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1133–40

Potential role of serum prolactin measurement in the diagnosis of late posttraumatic seizures. A case report. Hammond FM, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):304–6

Castration attenuates prolactin response but potentiates ACTH response to conditioned stress in the rat. Bingaman EW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R856–63

Responses to mCPP stimulation in depressed patients [letter; comment] Thakore JH. **Am J Psychiatry** 1995 Dec; 152(12):1833–4; discussion 1834–5. Comment on: Am J Psychiatry 1994 Nov;151(11):1626–30.

Effects of long–term zearalenone administration on spermatogenesis and serum luteinizing hormone, follicle–stimulating hormone, and prolactin values in male

rats. Milano GD, et al. **Am J Vet Res** 1995 Jul;56(7):954–8

Sera gonadotropins, testosterone, and prolactin levels in men with oligozoospermia or asthenozoospermia. Check JH, et al. **Arch Androl** 1995 Jul–Aug;35(1):57–61

Prolactin concentrations in preterm and term pregnancy and labour. Mazor M, et al. **Arch Gynecol Obstet** 1996; 258(2):69–74

Genetic analysis of the relationships between behavioral and neuroendocrine traits in Roman High and Low Avoidance rat lines. Castanon N, et al. **Behav Genet** 1995 Jul; 25(4):371–84

Prolactin and growth hormone in perinatal asphyxia. Varvarigou A, et al. **Biol Neonate** 1996;69(2):76–83

Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Baumann MH, et al. **Biol Psychiatry** 1995 Dec 1;38(11):751–5

Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia. Davila R, et al. **Biol Psychiatry** 1995 Aug 15;38(4):267–9

Clozapine does not elevate serum prolactin levels in healthy men. Lee HS, et al. **Biol Psychiatry** 1995 Dec 1; 38(11):762–4

Effect of pindolol pretreatment on MK–212–induced plasma cortisol and prolactin responses in normal men. Meltzer HY, et al. **Biol Psychiatry** 1995 Sep 1;38(5):310–8

D,L–fenfluramine challenge test: experience in nonpatient sample. Muldoon MF, et al. **Biol Psychiatry** 1996 May 1; 39(9):761–8

Effects of thyrotropin–releasing hormone administration on the electroconvulsive therapy induced prolactin responses and seizure time. Papakostas Y, et al. **Biol Psychiatry** 1996 Mar 15;39(6):444–7

Prolactin and cortisol responses to fenfluramine challenge in mania. Yatham LN. **Biol Psychiatry** 1996 Feb 15; 39(4):285–8

A symmetric analysis of paired rankings with application to temporal patterns of hormonal concentration. Huh MH, et al. **Biometrics** 1995 Dec;51(4):1361–71

Enhancement of the prolactin response to d–fenfluramine in drug–naive schizophrenic patients. Abel KM, et al. **Br J Psychiatry** 1996 Jan;168(1):57–60

Effect of valine on 5–HT–mediated prolactin release in healthy volunteers, and on mood in remitted depressed patients. Williamson DJ, et al. **Br J Psychiatry** 1995 Aug; 167(2):238–42

Effects of norethisterone acetate and tamoxifen on serum prolactin levels, uterine growth and on the presence of uterine immunoreactive prolactin in estradiol–treated ovariectomized rats. Spritzer PM, et al. **Braz J Med Biol Res** 1995 Jan;28(1):125–30

Re: Endocrine responses to fenfluramine challenge in chronic fatigue syndrome. Cleare AJ, et al. **Can J Psychiatry** 1996 Mar;41(2):129–31

Validity for epidemiological studies of long–term cryoconservation of steroid and protein hormones in serum and plasma. Bolelli G, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):509–13

Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia. Larrea F, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):591–600

Glycosylated and non–glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Priou A, et al. **Clin Endocrinol (Oxf)** 1995 Aug; 43(2):213–7

High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. St–Jean E, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):305–9

Thyrotropin–releasing hormone in critical illness: from a dopamine–dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Van den Berghe G, et al. **Crit Care Med** 1996 Apr;24(4):590–5

Pulsatile secretion of prolactin in laying and incubating turkey hens. Proudman JA, et al. **Domest Anim Endocrinol** 1996 May;13(3):277–82

Prolactin response to suckling and maintenance of postpartum amenorrhea among intensively breastfeeding Nepali women. Stallings JF, et al. **Endocr Res** 1996 Feb; 22(1):1–28

Effect of constant light on fetal and maternal prolactin rhythms in sheep. Parraguez VH, et al. **Endocrinology** 1996 Jun;137(6):2355–61

Serum prolactin in neonates with seizures. Legido A, et al. **Epilepsia** 1995 Jul;36(7):682–6

Prolactin levels in febrile and afebrile seizures. Sifianou P, et al. **Eur J Pediatr** 1995 Nov;154(11):925–7

Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL–IgG complex. Bonhoff A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(4):252–5

Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients. De Marinis L, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):67–71

Hormonal modulation of antioxidant enzyme activities in young and old rats. Bolzán AD, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):169–75

The relationship between plasma levels of gonadotropins, androgens, and prolactin in azoospermic men with their testicular spermatogenic pattern. Bar–On E, et al. **Fertil Steril** 1995 Nov;64(5):1043–5

The effect of routine breast examination on serum prolactin levels. Hammond KR, et al. **Fertil Steril** 1996 Apr; 65(4):869–70

Plasma prolactin and luteinizing hormone during termination and onset of photorefractoriness in intact and pinealectomized European starlings (Sturnus vulgaris). Chakraborty S. **Gen Comp Endocrinol** 1995 Aug; 99(2):185–91

Changes of thyrotropin–releasing hormone concentration in the brain and levels of prolactin and thyroxin in the serum during spawning migration of the chum salmon Oncorhynchus keta. Hamano K, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):275–81

The effect of ovariectomy on concentrations of plasma prolactin and LH and parental behavior in the domestic fowl. Lea RW, et al. **Gen Comp Endocrinol** 1996 Jan; 101(1):115–21

Circulating levels of prolactin and progesterone in a wild population of red kangaroos (Macropus rufus) Marsupialia: Macropodidae. Muths E, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):317–22

Plasma prolactin, cortisol, and thyroid responses of the brown trout (Salmo trutta) exposed to lethal and sublethal aluminium in acidic soft waters. Waring CP, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):377–85

Hormone testing in women with adult–onset amenorrhea. Laufer MR, et al. **Gynecol Obstet Invest** 1995;40(3):200–3

Hormonal responses of male gerbils to stimuli from their mate and pups. Brown RE, et al. **Horm Behav** 1995 Dec; 29(4):474–91

Stressors, including social conflict, decrease plasma prolactin in male golden hamsters. Huhman KL, et al. **Horm Behav** 1995 Dec;29(4):581–92

Influence of the presence of chicks on the ability to resume incubation behavior in domestic hens (Gallus domesticus). Richard–Yris MA, et al. **Horm Behav** 1995 Dec; 29(4):425–41

Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol–treated ovariectomized rats. Spritzer PM, et al. **Horm Metab Res** 1996 Apr;28(4):171–6

Gonadotrophins and prolactin rise after bilateral oophorectomy for benign conditions. Crosignani PG, et al. **Hum Reprod** 1995 Sep;10(9):2277–9

The effect of an ICV H3–agonist on plasma prolactin in portocaval shunted and sham operated rats. Fogel WA, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S56–7

Portocaval shunt, an H3–antagonist and plasma hormone levels. Fogel WA, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S52–3

Parturition and periparturient reproductive and metabolic hormone concentrations in prenatally androgenized beef heifers. Aldrich SL, et al. **J Anim Sci** 1995 Dec; 73(12):3712–8

Serum concentrations of luteinizing hormone, growth hormone, and prolactin in untreated and estradiol–treated ovariectomized ewes after immunoneutralization of hypothalamic neuropeptide Y. Malven PV, et al. **J Anim Sci** 1995 Jul;73(7):2105–12

Feed deprivation of mares: plasma metabolite and hormonal concentrations and responses to exercise. Sticker LS, et al. **J Anim Sci** 1995 Dec;73(12):3696–704

Factors related to early pregnancy recognition in the woman. Behr B, et al. **J Assist Reprod Genet** 1995 Apr;12(4):278–82

Serum prolactin in chronic hydrocephalus. Bhatty GB. **J Assoc Physicians India** 1995 Sep;43(9):605–7

Ethanol decreases nocturnal plasma levels of thyrotropin and growth hormone but not those of thyroid hormones or prolactin in man. Ekman AC, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2627–32

The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. Hattori N. **J Clin Endocrinol Metab** 1996 Feb;81(2):586–90

I have heard that buspirone regularly affects various blood tests. Is this so? Shader RI. **J Clin Psychopharmacol** 1996 Apr;16(2):194

Circulating levels of growth hormone, insulin–like growth factor–I and prolactin in normal, growth retarded and anencephalic human fetuses. Arosio M, et al. **J Endocrinol Invest** 1995 May;18(5):346–53

Monitoring treatment in tetrahydrobiopterin deficiency by serum prolactin. Spada M, et al. **J Inherit Metab Dis** 1996; 19(2):231–3

The 24–hour rhythms in plasma growth hormone, prolactin and thyroid stimulating hormone: effect of sleep deprivation. Sadamatsu M, et al. **J Neuroendocrinol** 1995 Aug;7(8):597–606

Overnight human plasma melatonin, cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery. von Treuer K, et al. **J Pineal Res** 1996 Jan;20(1):7–14

Response of prolactin to different photoperiods after surgical disconnection of the hypothalamus and pituitary in sheep fetuses. Houghton DC, et al. **J Reprod Fertil** 1995 Jul; 104(2):199–206

Effect of continuous infusion of thyrotrophin–releasing hormone on plasma prolactin and on ovarian activity in melatonin–treated ewes. Robinson JJ, et al. **J Reprod Fertil** 1996 May;107(1):17–22

Annual changes in serum concentrations of prolactin in captive male black bears (Ursus americanus). Tsubota T, et al. **J Reprod Fertil** 1995 Jul;104(2):187–91

Euprolactinemic Galactorrhea. Response of bioassayable prolactin to thyrotropin–releasing hormone. Ataya KM, et al. **J Reprod Med** 1996 Mar;41(3):156–60

No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. Buskila D, et al. **J Rheumatol** 1996 Apr;23(4):629–32

Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. McMurray RW, et al. **J Rheumatol** 1995 Aug;22(8):1577–80

Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. Patel DD, et al. **J Surg Oncol** 1996 Jun; 62(2):86–92

Early treatment of cryptorchidism, semen quality and testicular endocrinology. Taskinen S, et al. **J Urol** 1996 Jul;156(1):82–4

Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Reis FM, et al. **Life Sci** 1996;58(2):155–61

Intravenous administration of cholecystokinin (CCK) stimulates prolactin and growth hormone release in the pig. Parrott RF, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):529–33

Effect of parathyroidectomy on thyrotropic and lactotropic function in patients with renal osteopathy. Zofková I, et al. **Nephron** 1995;71(3):284–90

Size and charge heterogeneity of pituitary and plasma prolactin in the male rat. Briski KP, et al. **Neuroendocrinology** 1996 May;63(5):437–45

Steroid treatment fails to induce an afternoon luteinizing hormone or prolactin surge in rats exposed to short–term constant light at the time of ovariectomy. Sterner MR, et al. **Neuroendocrinology** 1995 Sep;62(3):231–7

Serum prolactin concentrations are elevated after syncope. Oribe E, et al. **Neurology** 1996 Jul;47(1):60–2

Reduced prolactin and cortisol responses to d–fenfluramine in depressed compared to healthy matched control subjects. Cleare AJ, et al. **Neuropsychopharmacology** 1996 May; 14(5):349–54

Permissive role of corticotropin–releasing factor in the acute stress–induced prolactin release in female rats. Akema T, et al. **Neurosci Lett** 1995 Sep 29;198(2):146–8

Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion. Lissoni P, et al. **Oncology** 1995 Nov–Dec;52(6):439–42

Increased prolactin level and pituitary adenoma as a cause of headache in two patients with sickle cell disease. Sabbagh R, et al. **Pediatr Hematol Oncol** 1996 Jan–Feb; 13(1):101–5

Prenatal cocaine produces dose–dependent suppression of prolactin and growth hormone in neonatal rats. Smith RF, et al. **Physiol Behav** 1995 Sep;58(3):619–23

Serotonin function in detoxified heroin abusers: prolactin and cortisol responses to fenfluramine challenge. Gerra G, et al. **Psychiatry Res** 1995 Sep 29;58(2):153–60

Time course of the corticosteroid–dopaminergic interaction during metyrapone and dexamethasone administration. Lupien S, et al. **Psychiatry Res** 1995 Sep 8;58(1):23–35

Pindolol pretreatment blocks stimulation by meta–chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Meltzer HY, et al. **Psychiatry Res** 1995 Sep 29;58(2):89–98

Acute stress markers in humans: response of plasma glucose, cortisol and prolactin to two examinations differing in the anxiety they provoke. Armario A, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):17–24

Multihormonal responses to apomorphine in mental illness. Mokrani MC, et al. **Psychoneuroendocrinology** 1995; 20(4):365–75

Hormonal responses to dl–fenfluramine challenge are not blunted in seasonal affective disorder. Yatham LN, et al. **Psychoneuroendocrinology** 1995;20(4):433–8

Effect of pindolol on the prolactin response to d–fenfluramine. Park SB, et al. **Psychopharmacology (Berl)** 1995 Apr;118(4):471–4

Serum levels of prolactin and alpha–melanotrophin and structure of the ovary during the reproductive cycle of Columba livia (domestic pigeon). Castagnino RA, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):5–10

Hyperprolactinemia in systemic lupus erythematosus? Ostendorf B, et al. **Scand J Rheumatol** 1996;25(2):97–102

Prolactin and rapid eye movement sleep regulation. Roky R, et al. **Sleep** 1995 Sep;18(7):536–42 (96 ref.)

Serum prolactin concentration in pseudopregnant and normally reproducing goats. Hesselink JW, et al. **Vet Rec** 1995 Aug 12;137(7):166–8

Determination of canine prolactin by use of a commercial heterologous enzymeimmunoassay kit. Høier R, et al. **Zentralbl Veterinarmed A** 1996 Apr;43(2):65–74

[Serum levels of prolactin, progesterone and estradiol in nursing mothers] Nedkova V, et al. **Akush Ginekol (Sofiia)** 1995;34(3):22–3 (Eng. Abstr.) **(Bul)**

[Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine] Eulry F, et al. **Ann Med Interne (Paris)** 1996;147(1):15–9 (Eng. Abstr.) **(Fre)**

[Maintenance of the relation between the pulsed secretion of hormones and the internal sleep structure in human

African trypanosomiasis] Brandenberger G, et al. **Bull Soc Pathol Exot** 1994;87(5):383–9 (Eng. Abstr.) **(Fre)**

[Correlation of skinfold thickness with bone density and estradiol, FSH and prolactin level in a sample of 231 women] Gruber D, et al. **Wien Klin Wochenschr** 1995; 107(20):622–5 (Eng. Abstr.) **(Ger)**

[Normalization of the prolactin values during alfa-interferon therapy: the considerations with a female patient with anti-HCV-positive chronic hepatitis and prolactin-secreting hypophyseal microadenoma] Zennaro R, et al. **Clin Ter** 1996 Apr;147(4):169–71 (Eng. Abstr.) **(Ita)**

[Prolactin (PRL)] Aono T, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:275–7 (8 ref.) **(Jpn)**

[Comparison of prolactin levels in first, second and multiple physiological pregnancy] Jagiełło-Wójtowicz E, et al. **Ginekol Pol** 1995 Jul;66(7):397–401 (Eng. Abstr.) **(Pol)**

[The linear correlation coefficient of serotonin and prolactin concentrations in plasma of women chronically exposed to carbon disulfide] Stanosz S, et al. **Med Pr** 1995; 46(3):235–8 (Eng. Abstr.) **(Pol)**

[The influence of recombinant human erythropoietin (rHu-EPO) on circadian rhythm of prolactin secretion in patients with chronic renal failure treated with hemodialysis] Moczulski D, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):32–40 (Eng. Abstr.) **(Pol)**

[Prolactin secretion in diabetic nephropathy of patients with diabetes mellitus type I (IDDM)] Zukowska-Szczechowska E, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):125–34 (Eng. Abstr.) **(Pol)**

[Repetitive transcranial magnetic stimulation: EEG, serum prolactin and cortisol studies in humans] Zyss T, et al. **Psychiatr Pol** 1995 Jul-Aug;29(4):513–27 (Eng. Abstr.) **(Pol)**

[The prolactin and thyrotropic hormone content of the blood plasma in neostriatal dysfunction] Iakimovskiĭ AF, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):108–14 (Eng. Abstr.) **(Rus)**

[Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma] Pavić S, et al. **Med Pregl** 1995;48(5–6):159–61 (Eng. Abstr.) **(Scr)**

[Serum and hypophyseal profiles of alpha-melanotropin and prolactin during the reproductive cycle of Leptodactylus ocellatus] Vivas AB, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):15–8 (Eng. Abstr.) **(Spa)**

[Analysis of the predictive value of prolactin concentration in the umbilical cord as an evaluation parameter for respiratory insufficiency in the newborn] García León JF, et al. **Ginecol Obstet Mex** 1995 Sep;63:372–6 (Eng. Abstr.) **(Spa)**

[Hormonal markers of stress in acute cerebrovascular pathology] Miralles F, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):979–82 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Amino acids in highly conserved regions near the C-terminus of rat prolactin (PRL) play critical roles similar to those in binding of human GH to the PRL receptor. Kato Y, et al. **Biochem Biophys Res Commun** 1996 May 15; 222(2):547–52

Studies on the microheterogeneity and in vitro activity of glycosylated and nonglycosylated recombinant human prolactin separated using a novel purification process. Price AE, et al. **Endocrinology** 1995 Nov;136(11):4827–33

Characterization of lactogen receptor-binding site 1 of human prolactin. Kinet S, et al. **J Biol Chem** 1996 Jun 14;271(24):14353–60

Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin. Maciejewski PM, et al. **J Biol Chem** 1995 Nov 17;270(46):27661–5

Size and charge heterogeneity of pituitary and plasma prolactin in the male rat. Briski KP, et al. **Neuroendocrinology** 1996 May;63(5):437–45

DRUG EFFECTS

Effect of estrogen and neuroleptics on prolactin secretion and immunoreactive prolactin cells. Oliveira MC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):521–5

Effects of cyclosporin treatment on prolactin pulsatility in chronic hyperprolactinemic male rats. Lafuente A, et al. **J Neuroimmunol** 1996 Mar;65(1):41–7

Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Cuttica CM, et al. **Minerva Endocrinol** 1995 Jun;20(2):141–4

GENETICS

Mechanisms of transcriptional activation of the promoter of the rainbow trout prolactin gene by GHF1/Pit1 and glucocorticoid. Argenton F, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):57–66

Identification of two prolactin cDNA sequences from a goldfish pituitary cDNA library. Chan YH, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):8–12

The tilapia prolactin I gene: evolutionary conservation of the regulatory elements directing pituitary-specific expression. Poncelet AC, et al. **DNA Cell Biol** 1996 Aug; 15(8):679–92

A PCR-derived, non-isotopic labeled prolactin cRNA probe suitable for in situ hybridization. Wu H, et al. **Endocr Res** 1995 Nov;21(4):793–802

Pituitary adenylate cyclase-activating polypeptide regulates prolactin promoter activity via a protein kinase A-mediated pathway that is independent of the transcriptional pathway employed by thyrotropin-releasing hormone. Coleman DT, et al. **Endocrinology** 1996 Apr;137(4):1276–85

Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide. Escalada J, et al. **Endocrinology** 1996 Feb; 137(2):631–7

Expression and localization of prolactin messenger ribonucleic acid in the human immune system. Wu H, et al. **Endocrinology** 1996 Jan;137(1):349–53

Localization of prolactin and its receptor messenger RNA in the human decidua. Tadokoro N, et al. **Experientia** 1995 Dec 18;51(12):1216–9

Cloning of the cDNAs coding for cat growth hormone and prolactin. Warren WC, et al. **Gene** 1996 Feb 12;168(2):247–9

The c-Jun delta-domain inhibits neuroendocrine promoter activity in a DNA sequence- and pituitary-specific manner. Farrow KN, et al. **J Biol Chem** 1996 Jul 19; 271(29):17139–46

TEF-1 transrepression in BeWo cells is mediated through interactions with the TATA-binding protein, TBP. Jiang SW, et al. **J Biol Chem** 1996 Apr 19;271(16):9510–8

GABP mediates insulin-increased prolactin gene transcription. Ouyang L, et al. **J Biol Chem** 1996 May 3; 271(18):10425–8

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon I, et al. **J Clin Invest** 1996 Jan 1; 97(1):187–95

A possible role for D8/PSF-A-like sequences in lactotroph versus somatotroph expression of the human prolactin gene. Leite V, et al. **J Endocrinol** 1996 Jun;149(3):473–83

Nicotine acts directly on pituitary GH3 cells to inhibit prolactin promoter activity. Coleman DT, et al. **J Neuroendocrinol** 1995 Oct;7(10):785–9

Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Brennan P, et al. **Lancet** 1996 Jul 13;348(9020):106–9 (40 ref.)

Site-specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression. Ngô V, et al. **Mol Cell Biol** 1996 Jul;16(7):3245–54

The D2 receptor: blocked transcription in GH3 cells and cellular pathways employed by D2A to regulate prolactin promoter activity. Fischberg DJ, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):129–37

The role of estrogen receptor in modulation of chromatin conformation in the 5' flanking region of the rat prolactin gene. Malayer JR, et al. **Mol Cell Endocrinol** 1995 Sep 22; 113(2):145–54

Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells. Mallo F, et al. **Mol Cell Endocrinol** 1995 Oct 30; 114(1–2):117–25

Constitutively active Gq-alpha stimulates prolactin promoter activity via a pathway involving Raf activity. Tian J, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):249–56

Dynamic monitoring and quantification of gene expression in single, living cells: a molecular basis for secretory cell heterogeneity. Castaño JP, et al. **Mol Endocrinol** 1996 May; 10(5):599–605

Pituitary-type transcription of the human prolactin gene in the absence of Pit-1. Gellersen B, et al. **Mol Endocrinol** 1995 Jul;9(7):887–901

Adenohypophysial allografts releasing prolactin decrease prolactin mRNA concentration in the host hamster's adenohypophysis in situ. Campbell GT, et al. **Neuroendocrinology** 1996 May;63(5):430–6

Ultrastructural modifications and changes in the expression of hormonal genes produced by indomethacin in the anterior pituitary gland of the rat. Romano LA, et al. **Neurol Res** 1995 Oct;17(5):389–92

Pituitary-specific chromatin structure of the rat prolactin distal enhancer element. Willis SD, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1065–72

Vasoactive intestinal peptide stimulates prolactin mRNA expression in turkey pituitary cells: effects of dopaminergic drugs. Xu M, et al. **Proc Soc Exp Biol Med** 1996 May; 212(1):52–62

IMMUNOLOGY

Biological activity and immunological reactivity of human prolactin mutants. Rhee HK, et al. **Endocrinology** 1995 Nov;136(11):4990–5

Anti-prolactin autoantibodies and hyperprolactinaemia [letter; comment] Olukoga AO, et al. **Eur J Endocrinol** 1995 Oct;133(4):463–4. Comment on: Eur J Endocrinol 1994 May;130(5):434–7. Comment on: Eur J Endocrinol 1994 May;130(5):438–45.

Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Bonhoff A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(4):252–5

Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Gutiérrez MA, et al. **Int Arch Allergy Immunol** 1996 Mar; 109(3):229–35

Prolactin, bromocriptine and autoimmune diseases. Buskila D, et al. **Isr J Med Sci** 1996 Jan;32(1):23–7

Occurrence of secretogranin II in the prolactin-immunoreactive neurons of the rat lateral hypothalamus: an in situ hybridization and immunocytochemical study. Griffond B, et al. **J Chem Neuroanat** 1995 Aug;9(2):113–9

Prolactin suppression enhances the effects of perioperative donor-specific blood transfusions on graft survival. Martinelli GP, et al. **J Surg Res** 1996 Aug;64(2):190–7

Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599–614 (173 ref.)

ISOLATION & PURIFICATION

Studies on the microheterogeneity and in vitro activity of glycosylated and nonglycosylated recombinant human prolactin separated using a novel purification process. Price AE, et al. **Endocrinology** 1995 Nov;136(11):4827–33

METABOLISM

The nuclear prolactin receptor: a 62-kDa chromatin-associated protein in rat Nb2 lymphoma cells. Rao YP, et al. **Arch Biochem Biophys** 1995 Oct 1; 322(2):506–15

Amino acids in highly conserved regions near the C-terminus of rat prolactin (PRL) play critical roles similar to those in binding of human GH to the PRL receptor. Kato Y, et al. **Biochem Biophys Res Commun** 1996 May 15; 222(2):547–52

Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia. Davila R, et al. **Biol Psychiatry** 1995 Aug 15;38(4):267–9

Effect of hormone depletion on cell survival in the EMR-86 rat mammary carcinoma. Wijsman JH, et al. **Br J Cancer** 1996 May;73(10):1210–5

Characterization of growth hormone-binding protein in cattle plasma: prolactin-binding activity and 24-hour profile. Massart S, et al. **Domest Anim Endocrinol** 1996 Jan; 13(1):47–57

Autocrine and/or paracrine action of vasoactive intestinal peptide on thyrotropin-releasing hormone induced prolactin release. Balsa JA, et al. **Endocrinology** 1996 Jan; 137(1):144–50

Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide. Escalada J, et al. **Endocrinology** 1996 Feb; 137(2):631–7

Ontogenesis of prolactin receptor gene expression in the rat olfactory system: potential roles for lactogenic hormones in olfactory development. Freemark M, et al. **Endocrinology** 1996 Mar;137(3):934–42

Prolactin (PRL) is a zinc-binding protein. I. Zinc interactions with monomeric PRL and divalent cation protection of intragranular PRL cysteine thiols. Lorenson MY, et al. **Endocrinology** 1996 Mar;137(3):809–16

Protein disulphide isomerase and a lumenal cyclophilin-type peptidyl prolyl cis-trans isomerase are in transient contact with secretory proteins during late stages of translocation. Klappa P, et al. **Eur J Biochem** 1995 Sep 15;232(3):755–64

Cyclosporin A inhibits the degradation of signal sequences after processing of presecretory proteins by signal peptidase. Klappa P, et al. **Eur J Biochem** 1996 Jul 15; 239(2):509–18

Uneven regional distributions of prolactin- and growth hormone-secreting cells and sexually dimorphic proportions of prolactin secretors in the adenohypophysis of adult chickens. Lopez ME, et al. **Gen Comp Endocrinol** 1995 Nov;100(2):246–54

Changes in the ultrastructural distribution of prolactin and growth hormone mRNAs in pituitary cells of female rats after estrogen and bromocriptine treatment, studied using in situ hybridization with biotinylated oligonucleotide probes. Matsuno A, et al. **Histochem Cell Biol** 1995 Jul; 104(1):37–45

Differential storage of prolactin, granins (Chromogranin B and secretogranin II), and constitutive secretory markers in rat pituitary GH4C1 cells. Gorr SU. **J Biol Chem** 1996 Feb 16;271(7):3575–80

Characterization of lactogen receptor-binding site 1 of human prolactin. Kinet S, et al. **J Biol Chem** 1996 Jun 14;271(24):14353–60

Identification of the major site of rat prolactin phosphorylation as serine 177. Wang YF, et al. **J Biol Chem** 1996 Feb 2;271(5):2462–9

Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. Pellegrini-Bouiller I, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3390–6

Blood prolactin concentrations affect prolactin transfer into goat milk: implications for maintenance of lactation. Forsyth IA, et al. **J Endocrinol** 1995 Sep;146(3):411–20

Effects of melatonin in vivo upon luteinizing hormone and prolactin releases induced by opiate receptor antagonists in adult male rats. Shacoori V, et al. **J Endocrinol Invest** 1996 Feb;19(2):76–82

Identification and localization of 23,000 and glycosylated rat prolactin in subcellular fractions of rat anterior pituitary and purified secretory granules. Bollengier F, et al. **J Neuroendocrinol** 1993 Dec;5(6):669–76

Effects of dehydroepiandrosterone (DHEA) on pituitary prolactin and arcuate nucleus neuron tyrosine hydroxylase mRNA levels in the rat. Garcia de Yebenes E, et al.

J Neuroendocrinol 1995 Aug;7(8):589–95

Regulation of granulosa cell–derived ovarian metalloproteinase inhibitor(s) by prolactin. Murray SC, et al. **J Reprod Fertil** 1996 May;107(1):103–8

A possible role for nitric oxide but not for prostaglandin E2 in basal and interleukin–1–beta–induced PRL release in vitro. Brunetti L, et al. **Life Sci** 1995 Mar 3; 56(15):PL277–83

Effects of the N–terminal cysteine mutation on prolactin expression and secretion in transfected cells. Morin A, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):59–73

Biological activity of phosphorylated and dephosphorylated bovine prolactin. Wicks JR, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):223–9

Transduction of prolactin's (PRL) growth signal through both long and short forms of the PRL receptor. Das R, et al. **Mol Endocrinol** 1995 Dec;9(12):1750–9

Alteration of dynorphin and secretogranin II in the prolactin immunoreactive neurons of the rat lateral hypothalamus upon osmotic stimulation. Grillon S, et al. **Neurosci Lett** 1996 Apr 12;208(1):33–6

Prolactin in the Cestodes, Taenia solium and Taenia hydatigena: an immunocytochemical study. Liu B, et al. **Okajimas Folia Anat Jpn** 1996 May;73(1):25–35

Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Liu X, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8831–5

[Interrelationship of prolactin concentration with levels of other hormones and with testicular ultrastructural morphometric indicators in the human fetus] Sukhorukov VS, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):654–6 **(Rus)**

PHARMACOLOGY

Histophysiological evidence for parathyroid mediation of estrogen– and prolactin–induced hypercalcemia in the toad Bufo melanostictus (Schneider). Akbarsha MA, et al. **Acta Physiol Hung** 1995;83(2):171–9

The effect of specific hormones on fibrinolysis in pregnancy. Houlihan CM, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):168–72

Prolactin inhibits corticoid–induced differentiation of active Na+ transport across cultured frog tadpole skin. Takada M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1326–31

Effect of exogenous prolactin on ultrastructure of pinealocyte in female pigs during puberty. Przybylska B, et al. **Arch Vet Pol** 1994;34(1–2):91–8

Prolactin induces switching of T–cell receptor gene expression from alpha to gamma in rat Nb2 pre–T lymphoma cells(1) Hosokawa Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):958–62

Activation of phosphatidylinositol 3–kinase by prolactin in Nb2 cells. al–Sakkaf KA, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):779–84

Synergistic gene expressions of cyclin E, cdk2, cdk5 and E2F–1 during the prolactin–induced G1/S transition in rat Nb2 pre–T lymphoma cells. Hosokawa Y, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):393–9

OZF gene expression in growing mouse and rabbit mammary gland and in rabbit mammary cells and Nb2 cells under prolactin action. Puissant C, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):543–52

KN–62, a calcium/calmodulin–dependent protein kinase II inhibitor, inhibits high potassium–stimulated prolactin secretion and intracellular calcium increases in anterior pituitary cells. Cui ZJ, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):343–7

Prolactin–induced regression of the rat corpus luteum: expression of monocyte chemoattractant protein–1 and invasion of macrophages. Bowen JM, et al. **Biol Reprod** 1996 May;54(5):1120–7

[14C]2–deoxyglucose uptake in the brain of the ring dove (Streptopelia risoria). I. Prolactin–induced uptake. Lea RW, et al. **Brain Res** 1995 Nov 27;700(1–2):129–36

Acute effect of prolactin on active calcium absorption in rats. Krishnamra N, et al. **Can J Physiol Pharmacol** 1995 Aug; 73(8):1185–9

In vitro characterization of prolactin–induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Janssen T, et al. **Cancer** 1996 Jan 1;77(1):144–9

Rapid activation of mitogen–activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells. Rao YP, et al. **Cell Growth Differ** 1995 Oct;6(10):1235–44

Prolactin induced analgesia is dependent on ATP sensitive potassium channels. Shewade DG, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):635–6

Effect of prolactin on the in vitro phagocytic capacity of macrophages. Ortega E, et al. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):139–46

Prolactin inhibits the increased cytokine gene expression in Kupffer cells following haemorrhage. Zhu XH, et al. **Cytokine** 1996 Feb;8(2):134–40

Insulin–like growth factors–I and –II, somatotropin, prolactin, and placental lactogen are not acute effectors of lipolysis in ruminants. Houseknecht KL, et al. **Domest Anim Endocrinol** 1996 May;13(3):239–49

Rapid induction of pim–1 expression by prolactin and interleukin–2 in rat Nb2 lymphoma cells. Buckley AR, et al. **Endocrinology** 1995 Dec;136(12):5252–9

Prolactin, proliferation, and protooncogenes [editorial] Horseman ND. **Endocrinology** 1995 Dec;136(12):5249–51

Biological activity and immunological reactivity of human prolactin mutants. Rhee HK, et al. **Endocrinology** 1995 Nov;136(11):4990–5

Postreceptor signalling of growth hormone and prolactin and their effects in the differentiated insulin–secreting cell line, INS–1. Sekine N, et al. **Endocrinology** 1996 May; 137(5):1841–50

Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin–treated islets in vitro: mechanisms for long term up–regulation of islets. Weinhaus AJ, et al. **Endocrinology** 1996 May; 137(5):1640–9

Effect of growth hormone, prolactin and insulin on the release of IL–1 alpha, IFN–gamma and IL–4 by staphylococcal enterotoxin A–stimulated splenocytes. Galdiero M, et al. **Eur Cytokine Netw** 1995 May–Jun; 6(3):187–94

Usefulness of recombinant human prolactin for treatment of poor puerperal lactation in a rat model. Yoneda N, et al. **Eur J Endocrinol** 1995 Nov;133(5):613–7

A MGF/STAT5 binding site is necessary in the distal enhancer for high prolactin induction of transfected rabbit alpha s1–casein–CAT gene transcription. Jolivet G, et al. **FEBS Lett** 1996 Jul 8;389(3):257–62

Prolactin and insulin regulate the release of IL–1–alpha and IFN–gamma from murine splenocytes activated with porins or LPS of Salmonella typhimurium. Vitiello M, et al. **Immunol Cell Biol** 1995 Oct;73(5):452–6

Prolactin–induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Gutiérrez MA, et al. **Int Arch Allergy Immunol** 1996 Mar; 109(3):229–35

Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Chakraborty A, et al. **Int J Cancer** 1996 Mar 28;66(1):65–9

Effects of growth hormone, prolactin, insulin–like growth factors, and gonadotropins on progesterone secretion by porcine luteal cells. Yuan W, et al. **J Anim Sci** 1996 Apr; 74(4):866–72

A novel heat shock response in prolactin–dependent Nb2 node lymphoma cells. Blake MJ, et al. **J Biol Chem** 1995 Dec 8;270(49):29614–20

Prolactin inhibits epidermal growth factor–induced Ras–MAPK signaling in mammary epithelial cells. Johnson JL, et al. **J Biol Chem** 1996 Aug 30;271(35):21574–8

Role of tyrosine phosphorylation in potassium channel activation. Functional association with prolactin receptor and JAK2 tyrosine kinase. Prevarskaya NB, et al. **J Biol Chem** 1995 Oct 13;270(41):24292–9

Nuclear accumulation of multiple protein kinases during prolactin–induced proliferation of Nb2 rat lymphoma cells. Ganguli S, et al. **J Cell Physiol** 1996 May;167(2):251–60

The effects of bromocriptine and prolactin on porphyrin biosynthesis and morphology in the female hamster harderian gland. Shah SW, et al. **J Comp Physiol [B]** 1996; 166(2):144–9

Prolactin– and testosterone–induced inhibition of LH secretion after orchidectomy: role of catecholaminergic neurones terminating in the diagonal band of Broca, medial preoptic nucleus and median eminence. Park SK, et al. **J Endocrinol** 1996 Feb;148(2):291–301

Comparison of Mauthner cell size in sexually developed and undeveloped male red–bellied newts. Matsumoto A, et al. **J Neurobiol** 1995 Sep;28(1):126–32

Intraventricular prolactin inhibits hypothalamic vasoactive–intestinal polypeptide–expression in doves. Saldanha CJ, et al. **J Neuroendocrinol** 1995 Nov;7(11):881–7

In vitro contraction of the canine corpus cavernosum penis by direct perfusion with prolactin or growth hormone. Ra S, et al. **J Urol** 1996 Aug;156(2 Pt 1):522–5

Prolactin specifically regulates citrate oxidation and m–aconitase of rat prostate epithelial cells. Liu Y, et al. **Metabolism** 1996 Apr;45(4):442–9

Growth hormone (GH) and prolactin (PRL) regulate IGFBP–3 gene expression in rat beta–cells. De W, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):43–50

Androgen–independent effects of prolactin on the different lobes of the immature rat prostate. Reiter E, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):113–22

Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL–responsive gene transcription. Ferrag F, et al. **Mol Endocrinol** 1996 Apr;10(4):451–60

Effects of centrally administered prolactin upon mammary contractility in anesthetized lactating rats. Morales MT, et al. **Neuroendocrinology** 1995 Aug;62(2):207–14

Influence of thyroxine and thyroxine with growth hormone and prolactin on splenocyte subsets and on the expression of interleukin–2 and prolactin receptors on splenocyte subsets of Snell dwarf mice. Gala RR. **Proc Soc Exp Biol Med** 1995 Nov;210(2):117–25

Characteristics of the prolactin stimulation of c–fos mRNA levels in mouse mammary gland explants. Rillema JA, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):142–6

Effects of gonadotrophins, growth hormone and prolactin on developmental competence of domestic cat oocytes matured in vitro. Schramm RD, et al. **Reprod Fertil Dev** 1995;7(5):1061–6

Protein kinase C is not necessary for beta–casein gene induction by prolactin in HC11 mouse mammary cells. Mitev V, et al. **Reprod Nutr Dev** 1995;35(4):437–42

[Phosphorylation of adrenal cortex proteins by protein kinase C induced by prolactin] Sautin IuIu, et al. **Biokhimiia** 1996 Jan;61(1):34–41 (Eng. Abstr.) **(Rus)**

[The effect of prolactin on DNA synthesis in cultured bovine granulosa cells] Lebedeva IIu, et al. **Tsitologiia** 1995; 37(3):220–6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213–38 (130 ref.)

Prolactin–mediated gene activation in mammary epithelial cells. Groner B, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):587–94 (73 ref.)

PTP1D is a positive regulator of the prolactin signal leading to beta–casein promoter activation. Ali S, et al. **EMBO J** 1996 Jan 2;15(1):135–42

The responsiveness of tuberoinfundibular dopaminergic neurons to prolactin feedback is diminished between early lactation and midlactation in the rat. Arbogast LA, et al. **Endocrinology** 1996 Jan;137(1):47–54

The role of prolactin and growth hormone in the regulation of casein gene expression and mammary cell survival: relationships to milk synthesis and secretion. Travers MT, et al. **Endocrinology** 1996 May;137(5):1530–9

Regulation of luteal function by luteinizing hormone and prolactin at different times of the luteal phase. Hinney B, et al. **Eur J Endocrinol** 1995 Dec;133(6):701–17

The role of prolactin in realization of estradiol action in the uterus of ovariectomized rats. Gunin AG. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):119–27

Preoptic area lesions disrupt prolactin–induced parental feeding behavior in ring doves. Slawski BA, et al. **Horm Behav** 1995 Jun;29(2):248–66

Prolactin and testosterone: their role in male sexual function. Carani C, et al. **Int J Androl** 1996 Feb;19(1):48–54

Growth of secondary hair follicles of the Cashmere goat in vitro and their response to prolactin and melatonin. Ibraheem M, et al. **J Anat** 1994 Aug;185 (Pt 1):135–42

Negative regulatory element involved in the hormonal regulation of GlcNAc–1–P transferase gene in mouse mammary gland. Ma J, et al. **J Biol Chem** 1996 May 10; 271(19):11197–203

Migratory fat deposition in European quail: a role for prolactin? Boswell T, et al. **J Endocrinol** 1995 Jul; 146(1):71–9

Inhibitory effect of increased photoperiod on wool follicle growth. Pearson AJ, et al. **J Endocrinol** 1996 Jan; 148(1):157–66

Bioactivity and immunoreactivity of rat pituitary prolactin submitted to various extraction procedures. Prada MI, et al. **J Endocrinol Invest** 1995 May;18(5):341–5

Relationship between 17–beta–estradiol and prolactin in the regulation of natural killer cell activity during progression of endometriosis. Provinciali M, et al. **J Endocrinol Invest** 1995 Sep;18(8):645–52

Manipulating melatonin in red deer (Cervus elaphus): differences in the response to food restriction and lactation on the timing of the breeding season and prolactin–dependent pelage changes. Heydon MJ, et al. **J Exp Zool** 1995 Sep 1;273(1):12–20

Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599–614 (173 ref.)

Pattern of prolactin diurnal secretion in normal humans: evidence for nonlinear dynamics. Papavasiliou SS, et al. **Neuroendocrinology** 1995 Nov;62(5):444–53

The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul–Aug;1(4):201–16 (182 ref.)

Prolactin increases CD4/CD8 cell ratio in thymus–grafted congenitally athymic nude mice. Gaufo GO, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4165–9

Age–related effects of ectopic pituitary transplants on the activation of Ames dwarf mouse lymphocytes in vitro. Esquifino AI, et al. **Proc Soc Exp Biol Med** 1996 Jan; 211(1):87–93

Effect of estrogen on hyperprolactinemia–induced glucose intolerance in SHN mice. Matsuda M, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):243–7

SECRETION

Individual lactotropes release prolactin in a temporally divergent and sexually dimorphic pattern. Castaño JP, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E814–9

Recording of a large–conductance chloride channel in normal rat lactotrophs. Fahmi M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E969–76

Effect of hypothalamic infusion of a dopamine D1 receptor antagonist on prolactin secretion in the ewe. Curlewis JD, et al. **Brain Res** 1995 Oct 30;697(1–2):48–52

Effect of estrogen and neuroleptics on prolactin secretion and immunoreactive prolactin cells. Oliveira MC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):521–5

Disruptions in the secretion of cortisol, prolactin, and certain cytokines in human African trypanosomiasis patients. Radomski MW, et al. **Bull Soc Pathol Exot** 1994;87(5):376–9

Reduction in the expression and action of transforming

growth factor beta 1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Pastorcic M, et al. **Cancer Res** 1995 Nov 1;55(21):4892-8

Structural and functional differences between prolactin cells from the inner and outer zones of the male rat anterior pituitary. Vila-Porcile E, et al. **Cell Tissue Res** 1996 May; 284(2):247-59

Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Ciccarelli E, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):67-71

Melatonin modifies prolactin release induced by opiate antagonists in male rats. Shacoori V, et al. **Endocr Res** 1995 Aug;21(3):545-53

Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Wera S, et al. **Endocr Res** 1995 Aug;21(3):623-33

Prolactin release after mating and genitosensory stimulation in females. Erskine MS. **Endocr Rev** 1995 Aug;16(4):508-28 (222 ref.)

Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion. Balsa JA, et al. **Endocrinology** 1996 Feb;137(2):508-13

Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. Goth MI, et al. **Endocrinology** 1996 Jan;137(1):274-80

Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness. Rots NY, et al. **Endocrinology** 1996 May;137(5):1678-86

Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Shah GV, et al. **Endocrinology** 1996 May;137(5):1814-22

A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. Torner L, et al. **Endocrinology** 1995 Dec;136(12):5454-60

Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for interactions with dopamine through inhibitory coupling to calcium entry. Wang J, et al. **Endocrinology** 1996 Feb;137(2):587-94

Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. Arvat E, et al. **Eur J Endocrinol** 1995 Sep;133(3):300-4

Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats. Tuominen RK, et al. **Eur J Endocrinol** 1996 Feb;134(2):209-14

Differential disappearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat. Rauhala P, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):69-77

Paracrine cell to cell interactions determine the effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vitro prolactin release from rat pituitary cells. Benter S, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(6):386-90

Differences in the nyctohemeral secretion of TSH and PRL in healthy euthyroid men. Dericks-Tan JS, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):145-50

Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Paoletti AM, et al. **Fertil Steril** 1995 Dec;64(6):1094-8

The myometrium of postmenopausal women produces prolactin in response to human chorionic gonadotropin and alpha-subunit in vitro. Stewart EA, et al. **Fertil Steril** 1995 Nov;64(5):972-6

Protein kinase-C mediates chicken vasoactive intestinal peptide stimulated prolactin secretion and gene expression in turkey primary pituitary cells. Sun S, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):289-97

Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity. Bussen S, et al. **Gynecol Endocrinol** 1996 Apr; 10(2):83-90

Partial uncoupling of luteinizing hormone and prolactin pulse coincidence in hyperandrogenemic women. Graf MA, et al. **Gynecol Endocrinol** 1995 Sep;9(3):239-45

No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration. Maraschini C, et al. **Gynecol Endocrinol** 1996 Feb;10(1):7-15

Stimulated thyrotropin and prolactin secretion in lactating and non-lactating women. Rossmanith WG, et al. **Gynecol Endocrinol** 1995 Sep;9(3):181-8

Twenty-four hour patterns of prolactin secretion during lactation and the relationship to suckling and the resumption of fertility in breast-feeding women. Tay CC, et al. **Hum Reprod** 1996 May;11(5):950-5

Acute shifts in relaxin, progesterone, prolactin, and growth hormone secretion in Chinese Meishan gilts during late pregnancy and after hysterectomy. Dlamini BJ, et al. **J Anim Sci** 1995 Dec;73(12):3732-42

Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. Arafah BM, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3507-12

Gender differences in the temporal organization of proclactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels- a clinical research center study. Waldstreicher J, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1483-7

Effects of gonadal steroids on the opioid regulation of LH and prolactin release in ovariectomized pony mares. Aurich C, et al. **J Endocrinol** 1995 Nov;147(2):195-202

Inverse control of growth hormone and prolactin secretion in clonidine-stimulated dairy cattle. Borromeo V, et al. **J Endocrinol** 1995 Aug;146(2):271-7

Pituitary lactotrope expresses transforming growth factor beta (TGF beta) type II receptor mRNA and protein and contains 125I-TGF beta 1 binding sites. De A, et al. **J Endocrinol** 1996 Apr;149(1):19-27

Prolactin release from subpopulations of rat lactotrophs in the presence and absence of dopamine. Hu L, et al. **J Endocrinol** 1996 Jan;148(1):113-20

Studies on the role of TRH and corticosterone in the regulation of prolactin and thyrotrophin secretion during lactation. van Haasteren GA, et al. **J Endocrinol** 1996 Feb; 148(2):325-36

Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone in juvenile obesity before and after hypocaloric diet. Guzzaloni G, et al. **J Endocrinol Invest** 1995 Sep;18(8):621-9

Prolactin and growth hormone mRNA and protein characterization in SMtTW rat pituitary tumours. Delhase M, et al. **J Mol Endocrinol** 1995 Dec;15(3):233-43

Effects of excitatory amino acid receptor agonists and antagonists on the secretion of melatonin, luteinizing hormone and prolactin in the ram. Kumar V, et al. **J Neuroendocrinol** 1993 Dec;5(6):649-54

Evidence that melatonin acts in the pituitary gland through a dopamine-independent mechanism to mediate effects of daylength on the secretion of prolactin in the ram. Lincoln GA, et al. **J Neuroendocrinol** 1995 Aug;7(8):637-43

Opposing neuroendocrine actions of the natriuretic peptides: C-type and A-type natriuretic peptides do not interact with the same hypothalamic cells controlling prolactin secretion. Samson WK, et al. **J Neuroendocrinol** 1995 Oct; 7(10):759-63

Disruption of reproductive rhythms and patterns of melatonin and prolactin secretion following bilateral lesions of the suprachiasmatic nuclei in the ewe. Scott CJ, et al. **J Neuroendocrinol** 1995 Jun;7(6):429-43

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. Inoue T, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):137-43

Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. Millan MJ, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):885-98

Control of Ca2+ entry into rat lactotrophs by thyrotrophin-releasing hormone. Carew MA, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):349-60

Vasoactive intestinal peptide increases the liberation of arachidonate from anterior pituitary cells in vitro. Judd AM. **Life Sci** 1995;57(18):1641-6

Lactotroph and somatotroph function in piglets reared in a constant hot environment. Matteri RL, et al. **Life Sci** 1996;58(8):711-7

Central administration of 8-OH-DPAT and mCPP stimulates prolactin secretion in ovariectomized, estrogen-treated rats: lack of an effect on tuberoinfundibular dopaminergic neuron activity. Pan JT, et al. **Life Sci** 1996;58(14):1189-94

Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Gutiérrez MA, et al. **Lupus** 1995 Oct;4(5):348-52

Pituitary PRL secretion induced by tetraethylammonium is inhibited by dopamine through D2 receptors. Wang X, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):153-7

Adenohypophysial allografts releasing prolactin decrease prolactin mRNA concentration in the host hamster's adenohypophysis in situ. Campbell GT, et al. **Neuroendocrinology** 1996 May;63(5):430-6

Different serotonin receptor types participate in 5-hydroxytryptophan-induced gonadotropins and prolactin release in the female infantile rat. Lacau-Mengido IM, et al. **Neuroendocrinology** 1996 May;63(5):415-21

Does melatonin act on dopaminergic pathways in the mediobasal hypothalamus to mediate effects of photoperiod on prolactin secretion in the ram? Lincoln GA, et al. **Neuroendocrinology** 1995 Nov;62(5):425-33

Pattern of prolactin diurnal secretion in normal humans: evidence for nonlinear dynamics. Papavasiliou SS, et al. **Neuroendocrinology** 1995 Nov;62(5):444-53

Mechanisms of altered prolactin secretion due to the administration of interleukin-1 beta into the brain ventricles of the rat. Rivier C. **Neuroendocrinology** 1995 Aug; 62(2):198-206

Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Taylor AD, et al. **Neuroendocrinology** 1995 Nov;62(5):530-42

Semicircadian rhythm of dopamine release in the mediobasal hypothalamus in awake rats during pseudopregnancy: evidence that a thyrotropin-releasing hormone analogue stimulates dopamine release and thereby inhibits prolactin secretion. Timmerman W, et al. **Neuroendocrinology** 1995 Nov;62(5):434-43

Inhibition of nitric oxide synthase in the hypothalamus blocks the increase in plasma prolactin induced by intraventricular injection of interleukin-1 alpha in the rat. Rettori V, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):116-20

Mammosomatotroph adenoma cells secrete both growth hormone and prolactin. Kojima Y, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):791-6

Repeated cocaine administration reduces 5-HT1A-mediated prolactin secretion in rats. Baumann MH, et al. **Neurosci Lett** 1995 Jun 23;193(1):9-12

Morphine-induced prolactin release precedes a down-regulation of prolactin receptors in the male rat choroid plexus and hypothalamus. Lai Z, et al. **Neurosci Res** 1995 Oct;23(3):313-6

Effects of prenatal cocaine exposure on haloperidol-induced increases in prolactin release and dopamine turnover in weanling, periadolescent, and adult offspring. Goodwin GA, et al. **Neurotoxicol Teratol** 1995 Jul-Aug;17(4):507-14

Prolonged effects of tumor necrosis factor-alpha on anterior pituitary hormone release. Harel G, et al. **Peptides** 1995; 16(4):641-5

Opioid and tachykinin neuropeptides in prolactin-secreting human pituitary adenomas. Zhu X, et al. **Peptides** 1995; 16(6):1097-107

Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Missale C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4240-5

Effects of luteinizing hormone-releasing hormone on pulsatile prolactin secretion in adult hyperprolactinemic female rats. Lafuente A, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):251-6

Dynamics of prolactin secretion from diethylstilbestrol-induced rat prolactinoma tissue in vitro. Maas DL, et al. **Proc Soc Exp Biol Med** 1995 Nov; 210(2):150-5

Cholinergic modulation of growth hormone, prolactin and thyroid stimulating hormone responses to thyrotropin-releasing hormone in normal aging. Giusti M, et al. **Recenti Prog Med** 1995 Sep;86(9):341-4

Temporal relationship between prolactin secretion and slow-wave electroencephalic activity during sleep. Spiegel K, et al. **Sleep** 1995 Sep;18(7):543-8

Copulsatile release of thyrotropin and prolactin in normal and hypothyroid subjects. Samuels MH, et al. **Thyroid** 1995 Oct;5(5):369-72

[The effect of diazepam and flumazenil on pulsatile secretion of prolactin and LH in women] Cepický P, et al. **Ceska Gynekol** 1996 Feb;61(1):16-9 (Eng. Abstr.) **(Cze)**

[Pituitary adenoma secreting prolactin. Results of their surgical treatment] Otten P, et al. **Neurochirurgie** 1996; 42(1):44-53 (Eng. Abstr.) **(Fre)**

[Normalization of the prolactin values during alfa-interferon therapy: the considerations with a female patient with anti-HCV-positive chronic hepatitis and prolactin-secreting hypophyseal microadenoma] Zennaro R, et al. **Clin Ter** 1996 Apr;147(4):169-71 (Eng. Abstr.) **(Ita)**

[Prolactin and female gonadal endocrine regulation] Takeya U. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):824-32 (28 ref.) **(Jpn)**

[Molecular forms of human growth hormone and prolactin, secreted by cultured pituitary tumor cells] Bulatov AA, et al. **Biokhimiia** 1995 Oct;60(10):1637-46 (Eng. Abstr.) **(Rus)**

[Characteristics of prolactin secretion in response to different degrees of lesions of the vestibular analyzer] Boĭko NV, et al. **Kosm Biol Aviakosm Med** 1991 Nov-Dec;25(6):46-8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. Ufearo CS, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):354-9

Prolactin: a novel and safe immunomodulating hormone for the treatment of immunodepression following severe hemorrhage. Zellweger R, et al. **J Surg Res** 1996 Jun; 63(1):53-8

Effect of prolactin, rIFN-gamma or rTNF-alpha in murine toxoplasmosis. Benedetto N, et al. **Pathol Biol (Paris)** 1995 May;43(5):395-400

PROLACTIN-PRODUCING PITUITARY ADENOMA see **PROLACTINOMA**

PROLACTIN RECEPTORS see **RECEPTORS, PROLACTIN**

PROLACTINOMA

see related
HYPERPROLACTINEMIA

CHEMICALLY INDUCED

Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. Serri O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3177-9 (12 ref.)

Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. Garcia MM, et al. **J Endocrinol Invest** 1995 Jun;18(6):450-5

COMPLICATIONS

Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Dombrowski RC, et al.

Ann Pharmacother 1995 Oct;29(10):999–1001

Hyperprolactinemia and reproductive disorders—a profile from north east. Choudhury SD, et al.
J Assoc Physicians India 1995 Sep;43(9):617–8

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al.
Neurol Med Chir (Tokyo) 1996 Apr;36(4):234–6

DIAGNOSIS

High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. St-Jean E, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):305–9

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al.
Neurol Med Chir (Tokyo) 1996 Apr;36(4):234–6

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9 (53 ref.) **(Dut)**

[Macroprolactinoma] von Werder K.
Dtsch Med Wochenschr 1996 Jul 26;121(30):962 **(Ger)**

DRUG THERAPY

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Missale C, et al. **Br J Cancer** 1995 Dec;72(6):1397–9

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma. Kamel N, et al. **Endocr J** 1995 Aug;42(4):581–6

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Delgrange E, et al. **Eur J Endocrinol** 1996 Apr;134(4):454–6

Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy. Shanis BS, et al.
Gynecol Endocrinol 1996 Apr;10(2):91–4

Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Colao A, et al. **Horm Res** 1995; 44(5):222–8

The effects of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone-deficient adults. Riedl M, et al.
J Am Soc Nephrol 1995 Nov;6(5):1434–8

Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. Stepien H, et al. **J Endocrinol** 1996 Jul;150(1):99–106

[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865–8 (10 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. Flanagan DE, et al.
Clin Endocrinol (Oxf) 1996 Jul;45(1):117–20

Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. Burgess JR, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1841–5

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon I, et al. **J Clin Invest** 1996 Jan 1; 97(1):187–95

PATHOLOGY

Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814–20 (43 ref.)

Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81–92 (83 ref.)

Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. Feigenbaum SL, et al.
J Clin Endocrinol Metab 1996 May;81(5):1711–9

MR volumetry for monitoring intramuscular bromocriptine treatment in macroprolactinomas. Benesch H, et al.
J Comput Assist Tomogr 1995 Nov–Dec;19(6):866–70

Calcified cystic pituitary prolactinoma. Kasantikul V, et al.
J Med Assoc Thai 1995 Sep;78(9):497–501

[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Leslie WD, et al.
Nucl Med Commun 1995 Aug;16(8):698–702

PSYCHOLOGY

Familial prolactinoma [letter; comment] Sobrinho LG.
Clin Endocrinol (Oxf) 1995 Oct;43(4):511. Comment on: Clin Endocrinol (Oxf) 1995 May;42(5):483–6.

SECRETION

Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Jin L, et al.
Am J Pathol 1996 Jun;148(6):2057–66

No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration. Maraschini C, et al.
Gynecol Endocrinol 1996 Feb;10(1):7–15

Dynamics of prolactin secretion from diethylstilbestrol-induced rat prolactinoma tissue in vitro. Maas DL, et al. **Proc Soc Exp Biol Med** 1995 Nov; 210(2):150–5

SURGERY

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Soule SG, et al.
Clin Endocrinol (Oxf) 1996 Jun;44(6):711–6

Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. Feigenbaum SL, et al.
J Clin Endocrinol Metab 1996 May;81(5):1711–9

Microprolactinomas: why requiem for surgery? Liuzzi A, et al. **J Endocrinol Invest** 1996 Mar;19(3):196–8

Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Massoud F, et al.
Surg Neurol 1996 Apr;45(4):341–6

[Pituitary adenoma secreting prolactin. Results of their surgical treatment] Otten P, et al. **Neurochirurgie** 1996; 42(1):44–53 (Eng. Abstr.) **(Fre)**

THERAPY

Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). Berezin M, et al.
J Endocrinol Invest 1995 Jun;18(6):436–41

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9 (53 ref.) **(Dut)**

[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(2):174–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) **(Ger)**

[Treatment of hypothalamic-pituitary tumors—experiences at Hiroshima University School of Medicine] Uozumi T.
Nippon Naibunpi Gakkai Zasshi 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**

PROLAPSE

Pelvic organ prolapse and stress urinary incontinence. Rush CB, et al. **Med Clin North Am** 1995 Nov;79(6):1473–9 (16 ref.)

PROLAPSED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

PROLIFERATING CELL NUCLEAR ANTIGEN

Proliferating cell nuclear antigen staining as a prognostic indicator in soft-tissue malignant fibrous histiocytoma. Sugiura H, et al. **Arch Orthop Trauma Surg** 1995; 114(5):248–52

Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. Antinheimo J, et al.
J Neuropathol Exp Neurol 1995 Nov;54(6):776–82

ANALYSIS

Estimation of growth fraction in fine needle aspirates from non-Hodgkin's lymphoma using anti-proliferating cell nuclear antigen: correlation with the Kiel classification. Schmitt FC, et al. **Acta Cytol** 1996 Mar–Apr;40(2):199–204

Proliferating cell nuclear antigen in tissues and organs of human embryos. Tauber Z, et al.
Acta Univ Palacki Olomuc Fac Med 1995;139:29–32

p53 protein and proliferating cell nuclear antigen in eccrine poroma and porocarcinoma. an immunohistochemical study. Tateyama H, et al. **Am J Dermatopathol** 1995 Oct; 17(5):457–64

Proliferation indices of vestibular schwannomas by Ki-67 and proliferating cell nuclear antigen. Szeremeta W, et al.
Am J Otol 1995 Sep;16(5):616–9

Expression of proliferating cell nuclear antigen in premalignant lesions of the larynx. Zhao R, et al.
Am J Otolaryngol 1996 Jan–Feb;17(1):36–44

Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen. Yu CC, et al. **Anal Cell Pathol** 1995 Jul;9(1):45–52

Prognostic significance of high expression of proliferating cell nuclear antigen in patients with intestinal metaplasia. Blasco-Olaetxea E, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):963–7

Modifications of interphasic NORs as a diagnostic parameter of atypical lesions of the female breast. Di Stefano D, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1953–61

Proliferating cell nuclear antigen (PCNA) as a prognostic factor for colorectal cancer. Kovac D, et al.
Anticancer Res 1995 Sep–Oct;15(5B):2301–2

Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? Choong PF, et al. **APMIS** 1995 Nov; 103(11):797–805

The association of vascular proliferation with HPV status and epithelial PCNA positivity in cervical intraepithelial lesions. Soini Y, et al. **APMIS** 1996 Mar;104(3):183–90

Proliferating cell nuclear antigen distribution in verrucous carcinoma of the skin. Noel JC, et al. **Br J Dermatol** 1995 Dec;133(6):868–73

Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder. Shiina H, et al.
Br J Urol 1995 Dec;76(6):708–13

Biological characteristics of inverted papilloma of the urinary bladder. Urakami S, et al. **Br J Urol** 1996 Jan;77(1):55–60

Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Haerslev T, et al.
Breast Cancer Res Treat 1996;37(2):101–13

Needle biopsy of hepatocellular carcinoma: assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. Group d'Etude et de Traitement du Carcinoma Hépatocellulaire. Chapel F, et al. **Cancer** 1996 Mar 1;77(5):864–71

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Heegaard S, et al. **Cancer** 1995 Nov 15;76(10):1809–13

Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Oka K, et al. **Cancer** 1996 Jun 1;77(11):2280–5

Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen. Suehiro T, et al. **Cancer** 1995 Aug 1;76(3):399–405

Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Yokogi H. **Cancer** 1996 Aug 15; 78(4):819–26

Comparison of rectal mucosal proliferation measured by proliferating cell nuclear antigen (PCNA) immunohistochemistry and whole crypt dissection. Murray SC, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov;4(7):715–20

Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Perry JE, et al. **Cancer Res** 1996 Apr 1;56(7):1539–44

Immunohistochemical study of seminiferous epithelium in adult bovine testis using monoclonal antibodies against Ki-67 protein and proliferating cell nuclear antigen (PCNA). Wrobel KH, et al. **Cell Tissue Res** 1996 Feb; 283(2):191–201

Detection of bromo-deoxyuridine- and proliferating cell nuclear antigen-immunoreactivities in tooth germ. Casasco A, et al. **Connect Tissue Res** 1995;32(1–4):63–70

Three parameter flow cytometric analysis for simultaneous detection of cytokeratin, proliferation associated antigens and DNA content. Schutte B, et al. **Cytometry** 1995 Oct 1;21(2):177–86

Relationship of plasma CCK to acinar cell regeneration in acute pancreatitis as studied by proliferating cell nuclear antigen. Sakagami J, et al. **Dig Dis Sci** 1996 Sep; 41(9):1828–37

Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor. Blasco-Olaetxea E, et al.
Eur J Cancer 1996 Mar;32A(3):444–6

Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Karlsson M, et al. **Eur J Cancer** 1996 Feb;32A(2):357–62

Prognostic evaluation of HPV-associated precancerous and microinvasive carcinoma of the oral cavity: combined use of nucleolar organiser regions (AgNOR) and proliferating cell nuclear antigen (PCNA). Donofrio V, et al.
Eur J Cancer B Oral Oncol 1995 May;31B(3):174–80

Proliferating cell nuclear antigen in benign breast diseases. Cardillo MR, et al. **Eur J Gynaecol Oncol** 1995;16(6):476–81

Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in archival samples of non-Hodgkin's lymphoma. Correlation with flow cytometry proliferation results [letter] Gómez-Arbonés X, et al.
Eur J Haematol 1996 Apr;56(4):252–3

Detection of nucleotide excision repair incisions in human fibroblasts by immunostaining for PCNA. Aboussekhra A, et al. **Exp Cell Res** 1995 Dec;221(2):326–32

Roles of XPG and XPF/ERCC1 endonucleases in UV-induced immunostaining of PCNA in fibroblasts. Miura M, et al. **Exp Cell Res** 1996 Jul 10;226(1):126–32

Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Vail DM, et al. **Exp Hematol** 1996 Jun;24(7):807–15

Proliferating cell nuclear antigen: contradictory results regarding its presence in the lens. Gan L, et al.
Graefes Arch Clin Exp Ophthalmol 1995 Dec;233(12):792–4

Prognostic factors in urachal adenocarcinoma. A study in 41 specimens of DNA status, proliferating cell-nuclear antigen immunostaining, and argyrophilic nucleolar-organizer region counts. Nakanishi K, et al. **Hum Pathol** 1996 Mar;27(3):240–7

Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Yang WI, et al. **Hum Pathol** 1996 Jan;27(1):70–6

c-myc oncogene expression and cell proliferation in mixed oligo-astrocytoma. Banerjee M, et al. **Int J Cancer** 1996 Mar 15;65(6):730–3

Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Sun XF, et al. **Int J Cancer** 1996 Feb 20;69(1):5–8

Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Amada S, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):134–42

The significance of PCNA and p53 protein in some oral tumors. Tsuji T, et al. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):221–5

Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Ogura K, et al. **Int J Urol** 1995 Nov;2(5):302–8

Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma. Ghazvini S, et al. **Invest Ophthalmol Vis Sci** 1995 Dec; 36(13):2762–7

PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma. Seregard S, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1451–8

Detection of proliferating cell nuclear antigen (PCNA) in canine and feline mammary tumours. Preziosi R, et al. **J Comp Pathol** 1995 Nov;113(4):301–13

Proliferative activity of mixed hyperplastic adenomatous polyp/serrated adenoma in the large intestine, measured by PCNA (proliferating cell nuclear antigen). Fujishima N. **J Gastroenterol** 1996 Apr;31(2):207–13

Proliferating cells in human eccrine and apocrine sweat glands. Morimoto Y, et al. **J Histochem Cytochem** 1995 Dec;43(12):1217–21

Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone. Park HR, et al. **J Korean Med Sci** 1995 Oct;10(5):360–7

Expression of EGF, EGFR and PCNA in laryngeal lesions. Wen QH, et al. **J Laryngol Otol** 1995 Jul;109(7):630–6

Expression of Ki-67 antigen and proliferative cell nuclear antigen in benign and malignant epithelial lesions of the larynx. Zidar N, et al. **J Laryngol Otol** 1996 May; 110(5):440–5

Proliferating cell nuclear antigen (PCNA) detection of cellular proliferation in hypothyroid and hyperthyroid rat hearts. Heron MI, et al. **J Mol Cell Cardiol** 1995 Jul; 27(7):1393–403

Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. Hoyt JW, et al. **J Neurooncol** 1995;24(2):163–9

Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression. Nakabayashi H, et al. **J Neurooncol** 1995;24(3):209–17

Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. Cobb MA, et al. **J Neurosurg** 1996 Jan;84(1):85–90

Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. Ishibashi M, et al. **J Nucl Med** 1995 Dec; 36(12):2201–6

Use of bromodeoxyuridine, proliferating cell nuclear antigen, and nucleolar organizer regions in the multiparametric assessment of proliferating potency in cervical intraepithelial neoplasia. Kaneko S, et al. **J Obstet Gynaecol** 1995 Apr;21(2):133–44

Proliferating cell nuclear antigen (PCNA) expression in oral squamous cell carcinomas. Tsai ST, et al. **J Oral Pathol Med** 1995 Aug;24(7):313–5

Immunohistochemical study of proliferating cell nuclear antigen in hepatocytes of biliary atresia: a parameter to predict clinical outcome. Hossain M, et al. **J Pediatr Surg** 1995 Sep;30(9):1297–301

Significance of proliferating cell nuclear antigen (PCNA) expression in gastric cancer in relation to lymph node metastasis. Isozaki H, et al. **J Surg Oncol** 1996 Feb; 61(2):106–10

Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. Okusa Y, et al. **J Surg Oncol** 1996 Aug; 62(4):253–7

Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Dabbs DJ. **Mod Pathol** 1995 Aug;8(6):637–42

Proliferating cell nuclear antigen immunohistochemistry in astrocytes in experimental Creutzfeldt-Jakob disease and in human kuru, Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker syndrome. Biernat W, et al. **Neurodegeneration** 1995 Jun;4(2):195–201

Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. Wang Y, et al. **Oncogene** 1996 Mar 7;12(5):1069–75

Prognostic evaluation of curatively resected locally advanced gastric cancer patients with preoperative downstaging chemotherapy assessed by histochemical and pharmacologic means. Nakano H, et al. **Oncology** 1995 Nov-Dec;52(6):474–82

Proliferating cell nuclear antigen staining in syndrome and nonsyndrome odontogenic keratocysts. el Murtadi A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):217–20

Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in exocrine pancreatic carcinomas. Iachino C, et al. **Pathologica** 1995 Feb;87(1):56–8

PCNA defined proliferative activity of epithelial tumor cells in adenomas of the colon. Bielicki D, et al. **Pol J Pathol** 1995;46(3):151–4

PCNA and protein P53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression. Kałuża J, et al. **Pol J Pathol** 1995; 46(3):155–61

Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. McNeal JE, et al. **Prostate** 1995 Nov;27(5):258–68

Expression of the proliferative cell nuclear antigen (PCNA) in adenocarcinoma of the gallbladder, and its relationship to prognosis. Hanada K, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):377–82

Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Oyama T, et al. **Surg Oncol** 1995;4(2):83–9

Expression of proliferating cell nuclear antigen-positive cells during compensatory renal growth in cyclosporine-treated rats. Yang CW, et al. **Transplant Proc** 1996 Jun;28(3):1377–8

Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Kindblom LG, et al. **Virchows Arch** 1995;427(1):19–26

Expression of proliferating cell nuclear antigen in basal cell carcinomas and in squamous cell carcinomas of canine skin: correlation with mitotic index and histological features. Maiolino P, et al. **Zentralbl Veterinarmed A** 1995 Jul; 42(5):339–43

[Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions] Li H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):286–8 (Eng. Abstr.) **(Chi)**

[Expression of proliferating cell nuclear antigen (PCNA) in premalignant lesions of laryngeal epithelium] Zhou G, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995; 30(4):206–8 (Eng. Abstr.) **(Chi)**

[Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations] Wu J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):603–7 (Eng. Abstr.) **(Chi)**

[Expression of proliferating cell nuclear antigen in the liver tissue of hepatitis B patients] Lang Z, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):731–4 (Eng. Abstr.) **(Chi)**

[Expression of PCNA and protooncogenes during experimental hepatocarcinogenesis in rats] Ruan Y, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Feb;25(1):39–40 (Eng. Abstr.) **(Chi)**

[The expression and significance of proliferating cell nuclear antigen/cyclin in cholangiocarcinoma and gallbladder carcinoma] Yang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):437–8 (Eng. Abstr.) **(Chi)**

[C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer] Schönborn I, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):566–71 (Eng. Abstr.) **(Ger)**

[Correlationship between proliferating cell nuclear antigen (PCNA) expression and clinicopathological factors in colorectal cancer] Shirono J, et al. **Nippon Geka Gakkai Zasshi** 1995 Dec;96(12):787–91 (Eng. Abstr.) **(Jpn)**

[Clinical significance of proliferating cell nuclear antigen (PCNA) and argyrophilic nucleolar organizer region (AgNOR) in testicular tumors] Ohyama C, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1543–51 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of the expression of proliferating cell nuclear antigen in astrocytic gliomas of the cerebral hemispheres] Korshunov AG, et al. **Arkh Patol** 1996 Mar-Apr;58(2):32–7 (Eng. Abstr.) **(Rus)**

[Study of the expression of proliferating cell nuclear antigen and p185 in non-small cell lung carcinoma] Alemany Monraval P, et al. **Arch Bronconeumol** 1996 Apr; 32(4):165–9 (Eng. Abstr.) **(Spa)**

[Analysis of proliferating cell nuclear antigen (PCNA) expression in 24 cases of primary non-small cell pulmonary carcinomas and correlation with survival] Castellano VM, et al. **Arch Bronconeumol** 1996 Mar;32(3):127–31 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Expression patterns of DNA replication enzymes and the regulatory factor DREF during Drosophila development analyzed with specific antibodies. Yamaguchi M, et al. **Biol Cell** 1995;85(2–3):147–55

bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Pollina L, et al. **Br J Cancer** 1996 Jan; 73(2):139–43

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Hamel NW, et al. **Gynecol Oncol** 1996 Aug;62(2):192–8

The relationship between mast cell infiltration and the expression of PCNA and EGFr in experimental hepatocellular carcinoma of liver and squamous cell carcinoma of stomach in rats. Ruan Y, et al. **J Tongji Med Univ** 1996;16(1):6

Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Shivakumar CV, et al. **Mol Cell Biol** 1995 Dec;15(12):6785–93

BLOOD

Proliferating cell nuclear antigen immunoreaction in adrenal tumors. Damiani D, et al. **Tumori** 1995 Jul-Aug;81(4):273–7

CHEMISTRY

Embryonic PCNA: a missing link? [letter] Kelman Z, et al. **Curr Biol** 1995 Jul 1;5(7):814

Tyrosine 114 is essential for the trimeric structure and the functional activities of human proliferating cell nuclear antigen. Jónsson ZO, et al. **EMBO J** 1995 Nov 15; 14(22):5745–51

Schizosaccharomyces pombe proliferating cell nuclear antigen mutations affect DNA polymerase delta processivity. Arroyo MP, et al. **J Biol Chem** 1996 Jul 5; 271(27):15971–80

Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Kelman Z, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3613–20 (41 ref.)

DIAGNOSTIC USE

Proliferating cell nuclear antigen in the determination of growth rates in acoustic neuromas. Wiet RJ, et al. **Am J Otol** 1994 May;15(3):294–8

DRUG EFFECTS

Cell proliferation in lung fibrosis-associated hyperplastic lesions. Nishikawa A, et al. **Hum Exp Toxicol** 1995 Sep; 14(9):701–5

Proliferating cell nuclear antigen [letter; comment] Mighell A. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):3–4. Comment on: Oral Surg Oral Med Oral Pathol 1994 Dec;78(6):748–54.

Comparison of acute hepatocellular proliferating cell nuclear antigen labeling indices and growth fractions, p34cdc2 kinases, and serum enzymes in carbon tetrachloride-treated rats. Monticello TM, et al. **Toxicol Pathol** 1995 Jul-Aug; 23(4):439–46

GENETICS

Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors [see comments] Cain CT, et al. **Am J Dermatopathol** 1995 Aug;17(4):324–31. Comment in: Am J Dermatopathol 1995 Aug;17(4):319–20.

Addition of calmodulin antagonists to NRK cells during G1 inhibits proliferating cell nuclear antigen expression. López-Girona A, et al. **Cell Calcium** 1995 Jul;18(1):30–40

Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1. Ball KL, et al. **Eur J Biochem** 1996 May 1;237(3):854–61

Identification of an essential cis-element near the transcription start site for transcriptional activation of the proliferating cell nuclear antigen gene. Huang DY, et al. **J Biol Chem** 1996 Jan 12;271(2):1218–25

Essential role of E2F recognition sites in regulation of the proliferating cell nuclear antigen gene promoter during Drosophila development. Yamaguchi M, et al. **J Biol Chem** 1995 Oct 20;270(42):25159–65

Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Shivakumar CV, et al. **Mol Cell Biol** 1995 Dec;15(12):6785–93

Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter. Labrie C, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3732–41

Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Morris GF, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):895–9

[C-erbB-2, PCNA and histomorphologic factors in breast carcinoma after oral contraceptive use] Schönborn I, et al. **Pathologe** 1996 May;17(3):202–7 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Chronic intestinal pseudoobstruction associated with autoantibodies against proliferating cell nuclear antigen.

Nojima Y, et al. **Arthritis Rheum** 1996 May;39(5):877–9
Determination of the epitope of an inhibitory antibody to proliferating cell nuclear antigen. Roos G, et al. **Exp Cell Res** 1996 Jul 10;226(1):208–13
Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in colorectal cancer. Nakae S, et al. **J Surg Oncol** 1995 Nov;60(3):149–53

ISOLATION & PURIFICATION

Prognostic implication of proliferative markers MIB–1 and PC10 in esophageal squamous cell carcinoma. Lam KY, et al. **Cancer** 1996 Jan 1;77(1):7–13
Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Tannapfel A, et al. **Cancer** 1996 Jan 1; 77(1):164–71

METABOLISM

Flow cytometric characterization of proliferation–associated nuclear antigen (p105) during the cell cycle in normal lymphocytes and promyelocytic leukemia cells (HL–60). Qiao L, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):183–8
Expression of activation markers of the rheumatoid arthritis synovial membrane: comment on the article by Qu et al [letter; comment] Kinne RW, et al. **Arthritis Rheum** 1995 Sep;38(9):1346–8. Comment on: Arthritis Rheum 1994 Feb;37(2):212–20.
The mammalian DNA polymerase delta—proliferating cell nuclear antigen—template–primer complex: molecular characterization by direct binding. McConnell M, et al. **Biochemistry** 1996 Jun 25;35(25):8268–74
Proliferating cell nuclear antigen marks the initiation of follicular growth in the rat. Oktay K, et al. **Biol Reprod** 1995 Aug;53(2):295–301
Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate–specific antigen and alpha 1–antichymotrypsin in human prostate cancer. Igawa M, et al. **Br J Urol** 1996 Jan;77(1):107–12
Biologic characteristics of esophageal epithelial dysplasia assessed by proliferating cell nuclear antigen. Koga Y, et al. **Cancer** 1996 Jan 15;77(2):237–44
Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival. Nakamura T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1741–6
Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Shindoh M, et al. **Cancer** 1995 Nov 1;76(9):1513–21
Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1. Peterson SR, et al. **Cancer Res** 1995 Oct 15;55(20):4651–7
Expression of proliferation–associated nuclear autoantigens, p330d/CENP–F and PCNA, in differentiation and in drug–induced growth inhibition using two–parameter flow cytometry. Báez A, et al. **Cell Prolif** 1996 Apr;29(4):183–96
Genesis and evolution of high–ploidy tumour cells evaluated by means of the proliferation markers p34(cdc2), cyclin B1, PCNA and 3[H]–thymidine. Baroja A, et al. **Cell Prolif** 1996 Feb;29(2):89–100
Subcellular distribution of p21 and PCNA in normal and repair–deficient cells following DNA damage. Li R, et al. **Curr Biol** 1996 Feb 1;6(2):189–99
Pan cycle expression of proliferating cell nuclear antigen in human colorectal cancer and its proliferative correlations. Sawtell RM, et al. **Cytometry** 1995 Sep 15;22(3):190–9
Human and plant proliferating–cell nuclear antigen have a highly conserved binding site for the p53–inducible gene product p21WAF1. Ball KL, et al. **Eur J Biochem** 1996 May 1;237(3):854–61
PCNA and p53 [letter] Mighell A. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):403–4
Specific association of cyclin–like uracil–DNA glycosylase with the proliferating cell nuclear antigen. Muller–Weeks SJ, et al. **Exp Cell Res** 1996 Aug 1;226(2):346–55
Interaction studies between the p21Cip1/Waf1 cyclin–dependent kinase inhibitor and proliferating cell nuclear antigen (PCNA) by surface plasmon resonance. Knibiehler M, et al. **FEBS Lett** 1996 Aug 5;391(1–2):66–70
EGF–R and PCNA expression in ovarian carcinomas—correlation with classic prognostic factors. Minguillon C, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):197–201
Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high–risk patients. Garzetti GG, et al. **Gynecol Oncol** 1996 Apr;61(1):16–21
p53 PCNA, and Ki–67 in hydropic molar and nonmolar placentas: an immunohistochemical study. Schammel DP, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):158–66
Proliferating cell nuclear antigen in ACTH–independent bilateral macronodular adrenal hyperplasia. Nomata K, et al. **Int J Urol** 1995 Jul;2(3):203–5
Schizosaccharomyces pombe proliferating cell nuclear antigen mutations affect DNA polymerase delta processivity. Arroyo MP, et al. **J Biol Chem** 1996 Jul 5; 271(27):15971–80
Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand–induced A431 cell growth inhibition. Fan Z, et al. **J Cell Biol** 1995 Oct;131(1):235–42
The overexpression of proliferating cell nuclear antigen in biliary cirrhosis in the rat and its relationship with epidermal growth factor receptor. Zimmermann H, et al. **J Hepatol** 1995 Oct;23(4):459–64
In vivo modulation of proliferating cell nuclear antigen in growth plate chondrocytes from normal, hypophysectomized, growth hormone–treated hypophysectomized rats: a comparative immunohistochemical study with image analysis. Tajima Y, et al. **J Histochem Cytochem** 1996 Jul;44(7):713–20
Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Del Giglio A, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):235–41
A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Chen J, et al. **Nucleic Acids Res** 1996 May 1;24(9):1727–33
Processing of branched DNA intermediates by a complex of human FEN–1 and PCNA. Wu X, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2036–43
Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA. Chen IT, et al. **Oncogene** 1995 Nov 16; 11(10):1931–7
Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Chen IT, et al. **Oncogene** 1996 Feb 1;12(3):595–607
Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Jakus J, et al. **Oncogene** 1996 Jun 6; 12(11):2369–76
The differentiation primary response gne MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21 WAF1/CIP1. Vairapandi M, et al. **Oncogene** 1996 Jun 20;12(12):2579–94
Association of tumor cell proliferation with lymph node metastasis in early gastric cancer. Maeda K, et al. **Oncology** 1996 Jan–Feb;53(1):1–5
Vesical urothelium proliferation in spinal cord injured persons: an immunohistochemical study of PCNA and MIB.1 labelling. van Velzen D, et al. **Paraplegia** 1995 Sep; 33(9):523–9
Proliferation and maturation indices in nephrogenic rests and Wilms tumor; the emergence of heterogeneity from dormant nodular renal blastema. Bove KE, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):223–44
Epidermal cell proliferative activity assessed by proliferating cell nuclear antigen (PCNA) decreases following immobilization–induced stress in male Syrian hamsters. Tsuchiya T, et al. **Psychoneuroendocrinology** 1996 Jan; 21(1):111–7
Characterization of X–ray–induced immunostaining of proliferating cell nuclear antigen in human diploid fibroblasts. Miura M, et al. **Radiat Res** 1996 Jan; 145(1):75–80
[Expression of proliferating cell nuclear antigen (PCNA) in renal cell carcinoma] Seki H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1475–82 (Eng. Abstr.) **(Jpn)**
[Comparative studies on the time course of proliferating cell nuclear antigen and bromodeoxyuridine staining pattern in regenerating rat liver cells] Sakiyama J, et al. **Rinsho Byori** 1996 Jan;44(1):61–6 (Eng. Abstr.) **(Jpn)**
[Expression of a proliferation associated–nuclear antigen defined by Ki–67 monoclonal antibody in childhood acute leukemia] Ito M, et al. **Rinsho Ketsueki** 1995 Aug; 36(8):713–9 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Effects of IL–3 and LPS on transcription factors involved in the regulation of IL–6 mRNA. Tuyt LM, et al. **Br J Haematol** 1996 Mar;92(3):521–9

PHYSIOLOGY

Stimulation of DNA polymerase gamma activity by proliferating cell nuclear antigen. Taguchi T, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):715–22
Heterologous expression of the human cyclin–dependent kinase inhibitor p21Cip1 in the fission yeast, Schizosaccharomyces pombe reveals a role for PCNA in the chk1+ cell cycle checkpoint pathway. Tournier S, et al. **Mol Biol Cell** 1996 Apr;7(4):651–62
Radiosurgery for acoustic neurinoma with rapid growth and relatively high staining indexes for proliferating cell nuclear antigen and MIB–1. Yamamoto M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):241–5
Requirement of proliferating cell nuclear antigen in RAD6–dependent postreplicational DNA repair. Torres–Ramos CA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9676–81

RADIATION EFFECTS

Cell proliferation in lung fibrosis–associated hyperplastic lesions. Nishikawa A, et al. **Hum Exp Toxicol** 1995 Sep; 14(9):701–5

PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

PROLINE

The proline–rich motif is necessary but not sufficient for prolactin receptor signal transduction. O'Neal KD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:282–4
Substitution at codon 269 (glutamine —> proline) of the leptin receptor (OB–R) cDNA is the only mutation found in the Zucker fatty (fa/fa) rat. Iida M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):597–604
Effect of serine O–glycosylation on cis–trans proline isomerization. Pao YL, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):157–62
Binding of the proline–rich region of the epithelial Na+ channel to SH3 domains and its association with specific cellular proteins. McDonald FJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):491–7
Kinetic analysis of cyclophilin–catalyzed prolyl cis/trans isomerization by dynamic NMR spectroscopy. Kern D, et al. **Biochemistry** 1995 Oct 17;34(41):13594–602
Role of proline residue in the channel–forming and catecholamine–releasing activities of the peptaibol, trichosporin–B–VIa. Nagaoka Y, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):31–6
Influence of proline–14 substitution on the secondary structure in a synthetic analogue of alamethicin. Brachais L, et al. **Biopolymers** 1995 Oct;36(4):547–58
Towards prediction of cognate complexes between the WW domain and proline–rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1–8 (53 ref.)
Systematic introduction of proline in a eukaryotic signal sequence suggests asymmetry within the hydrophobic core. Ryan P, et al. **J Biol Chem** 1995 Nov 17;270(46):27876–9
Contribution of proline residues in the membrane–spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function. Sheppard DN, et al. **J Biol Chem** 1996 Jun 21;271(25):14995–5001
Highly selective bradykinin agonists and antagonists with replacement of proline residues by N–methyl–D– and L–phenylalanine. Reissmann S, et al. **J Med Chem** 1996 Feb 16;39(4):929–36
Synthesis and physicochemical, biological, and pharmacological properties of new bile acids amidated with cyclic amino acids. Roda A, et al. **J Med Chem** 1996 May 24;39(11):2270–6
The proline–rich region of the GH receptor is essential for JAK2 phosphorylation, activation of cell proliferation, and gene transcription. Dinerstein H, et al. **Mol Endocrinol** 1995 Dec;9(12):1701–7
Specific interactions outside the proline–rich core of two classes of Src homology 3 ligands. Feng S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12408–15

ADMINISTRATION & DOSAGE

Dosing time with ascorbic acid and nitrate, gum and tobacco chewing, fasting, and other factors affecting N–nitrosoproline formation in healthy subjects taking proline with a standard meal. Mirvish SS, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):775–82
Proline is synthesized from glutamate during intragastric infusion but not during intravenous infusion in neonatal piglets. Murphy JM, et al. **J Nutr** 1996 Apr;126(4):878–86

ANALOGS & DERIVATIVES

Novel 2– and 5–azido–N–(diphenylcarbamoyl)proline methyl esters. Examples of a novel proline oxidation. Lynch VM, et al. **Acta Crystallogr C** 1995 Dec 15;51 (Pt 12):2598–601
The influence of proline analogs on bleomycin–induced lung injury in rats. Ledwożyw A. **Acta Physiol Hung** 1995; 83(2):195–202
EPR and laser flash photolysis studies of the reaction of nitric oxide with water soluble NO trap Fe(II)–proline–dithiocarbamate complex. Paschenko SV, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):577–84
Inhibition of NF kappa B activity by oxidative processes in intact cells mechanism of action of pyrolidine dithiocarbamate and diamide. Brennan P, et al. **Biochem Soc Trans** 1996 Feb;24(1):3S
Crilvastatin, a new 3–hydroxy–3–methylglutaryl–coenzyme A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats. Hajri T, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):131–6
Peptides containing the sulfonamide transition–state isostere: synthesis and structure of N–acetyl–tauryl–L–proline methylamide. Moree WJ, et al. **Int J Pept Protein Res** 1995 Jun;45(6):501–7
Role of oxoproline in the regulation of neutral amino acid transport across the blood–brain barrier. Lee WJ, et al. **J Biol Chem** 1996 Aug 9;271(32):19129–33
2–Substituted penems with amino acid–related side chains: synthesis and antibacterial activity of a new series of beta–lactam antibiotics. Altamura M, et al. **J Med Chem** 1995 Oct 13;38(21):4244–56
Synthesis of the four isomers of 4–aminopyrrolidine–2,4–dicarboxylate: identification of a potent, highly selective, and systemically–active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. Monn JA, et al. **J Med Chem** 1996 Jul 19;39(15):2990–3000
Distribution of the dipeptide transporter system along the

gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ-29852. Marino AM, et al. **J Pharm Sci** 1996 Mar;85(3):282-6

Alpha-methyl-proline restores normal levels of bone collagen Type I synthesis in ovariectomized rats. Lubec G, et al. **Life Sci** 1995;57(24):2245-52

Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate. Schoepp DD, et al. **Neuropharmacology** 1995 Aug;34(8):843-50

ANALYSIS

Cloning a cDNA from human NK/T cells which codes for a protein with high proline content. Chen J, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):19-22

Metchnikowin, a novel immune-inducible proline-rich peptide from Drosophila with antibacterial and antifungal properties. Levashina EA, et al. **Eur J Biochem** 1995 Oct 15;233(2):694-700

[Synthesis of stearoyl derivatives of proline-containing hydrophobic peptides] Iskhakova FKh, et al. **Bioorg Khim** 1995 Aug;21(8):596-603 (Eng. Abstr.) **(Rus)**

[Synthesis of octadecyl esters of hydrophobic proline-containing peptides] Iskhakova FKh, et al. **Bioorg Khim** 1995 Jul;21(7):517-23 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Database cloning human delta 1-pyrroline-5-carboxylate synthetase (P5CS) cDNA: a bifunctional enzyme catalyzing the first 2 steps in proline biosynthesis. Aral B, et al. **C R Acad Sci III** 1996 Mar;319(3):171-8

Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: a natural bypass of th proA step. Ankri S, et al. **J Bacteriol** 1996 Aug;178(15):4412-9

Proline is synthesized from glutamate during intragastric infusion but not during intravenous infusion in neonatal piglets. Murphy JM, et al. **J Nutr** 1996 Apr;126(4):878-86

Decreased cysteine and proline synthesis in parenterally fed, premature infants. Miller RG, et al. **J Pediatr Surg** 1995 Jul;30(7):953-7; discussion 957-8

Proline is biosynthesized from arginine in Staphylococcus aureus. Townsend DE, et al. **Microbiology** 1996 Jun;142 (Pt 6):1491-7

CHEMISTRY

Novel 2- and 5-azido-N-(diphenylcarbamoyl)proline methyl esters. Examples of a novel proline oxidation. Lynch VM, et al. **Acta Crystallogr C** 1995 Dec 15;51 (Pt 12):2598-601

Determination of amino acid isotope ratios by electrospray ionization-mass spectrometry. Goshe MB, et al. **Anal Biochem** 1995 Nov 1;231(2):387-92

Resolution of cis and trans isomers of peptides containing proline using capillary zone electrophoresis. Moore AW Jr, et al. **Anal Chem** 1995 Oct 1;67(19):3464-75

Isomerization of the Xaa-Pro peptide bond induced by ionic interactions of arginine. Tsikaris V, et al. **Biopolymers** 1996 Jun;38(6):673-82

Fungal metabolites. XX. Effect of proline residue on the structure of ion-channel-forming peptide, trichosporin B-VIa. Nagaoka Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1119-24

A model for transmembrane helix with a cis-proline in the middle. Iyer LK, et al. **FEBS Lett** 1995 Oct 23;374(1):21-4

Comparison of proline and N-methylnorleucine induced conformational equilibria in cyclic pentapeptides. Weisshoff H, et al. **FEBS Lett** 1996 Jun 3;387(2-3):201-7

Solution conformations of proline rings in proteins studied by NMR spectroscopy. Cai M, et al. **J Biomol NMR** 1995 Sep;6(2):123-8

Proline scanning mutagenesis of a molten globule reveals non-cooperative formation of a protein's overall topology. Schulman BA, et al. **Nat Struct Biol** 1996 Aug;3(8):682-7

Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Macias MJ, et al. **Nature** 1996 Aug 15;382(6592):646-9

A single point mutation decreases picrotoxinin sensitivity of the human GABA receptor rho 1 subunit. Enz R, et al. **Neuroreport** 1995 Jul 31;6(11):1569-72

Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. Li SC, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6676-81

Destabilizing effect of proline substitutions in two helical regions of T4 lysozyme: leucine 66 to proline and leucine 91 to proline. Gray TM, et al. **Protein Sci** 1996 Apr; 5(4):742-51

Pseudodipeptide analogs of the pyrokinin/PBAN (FXPRLa) insect neuropeptide family containing carbocyclic Pro-mimetic conformational components. Nachman RJ, et al. **Regul Pept** 1995 Jun 27;57(3):359-70

Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. Ciszak E, et al. **Structure** 1995 Jun 15;3(6):615-22

A potential proline-rich motif upstream of the immunoreceptor tyrosine-based activation motif in bovine leukemia virus gp30, Epstein-Barr virus LMP2A, herpesvirus papio LMP2A, and African horsesickness virus VP7 [letter] Cantor GH. **Virology** 1996 Jun 15;220(2):265-6

GENETICS

Comparison between thymidylate synthase B of Bacillus subtilis ATCC6633 and 168. Montorsi M, et al. **Biochem Mol Biol Int** 1995 May;35(6):1245-51

Cloning and characterization of cDNAs for novel proteins with glutamic acid-proline dipeptide tandem repeats. Geertman R, et al. **Biochim Biophys Acta** 1996 May 2; 1306(2-3):147-52

Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Jin X, et al. **Carcinogenesis** 1995 Sep;16(9):2205-8

cDNA cloning and sequence analysis of a novel calcium binding protein with oligoproline motif. Yu S, et al. **Cell Struct Funct** 1995 Aug;20(4):263-8

Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille). Bezeaud A, et al. **Eur J Biochem** 1995 Nov 15;234(1):140-7

Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: a natural bypass of th proA step. Ankri S, et al. **J Bacteriol** 1996 Aug;178(15):4412-9

Corrected gene assignments of Escherichia coli pro-mutations. Serebrijski I, et al. **J Bacteriol** 1995 Dec; 177(24):7261-4

Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants. Serebrijski I, et al. **J Bacteriol** 1995 Dec; 177(24):7255-60

IMMUNOLOGY

A biological function for the XP motif within the N terminus of major histocompatibility complex class II-associated peptides. Breloer M, et al. **Eur J Immunol** 1996 Aug; 26(8):1825-9

METABOLISM

Nature of the unfolded state of ribonuclease A: effect of cis-trans X-Pro peptide bond isomerization. Houry WA, et al. **Biochemistry** 1996 Sep 10;35(36):11719-33

Characterization of the slow folding reactions of trp aporepressor from Escherichia coli by mutational analysis of prolines and catalysis by a peptidyl-prolyl isomerase. Mann CJ, et al. **Biochemistry** 1995 Nov 7;34(44):14573-80

Substrates containing phosphorylated residues adjacent to proline decrease the cleavage by proline-specific peptidases. Kaspari A, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):147-53

Fast axonal transport rates are unchanged in 6- and 24-month F344 rats. Jacob JM. **Brain Res** 1995 Nov 13;699(1):154-6

Ser57 in the Na+/proline permease of Escherichia coli is critical for high-affinity proline uptake. Quick M, et al. **Eur J Biochem** 1996 Aug 1;239(3):732-6

Tannin interactions with a full-length human salivary proline-rich protein display a stronger affinity than with single proline-rich repeats. Charlton AJ, et al. **FEBS Lett** 1996 Mar 18;382(3):289-92

Post-transcriptional control and kinetic characterization of proline transport in germinating conidiospores of Aspergillus nidulans. Tazebay UH, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):27-37

A proline-rich TGF-beta-responsive transcriptional activator interacts with histone H3. Alevizopoulos A, et al. **Genes Dev** 1995 Dec 15;9(24):3051-66

Functional analysis of the PUT3 transcriptional activator of the proline utilization pathway in Saccharomyces cerevisiae. des Etages SA, et al. **Genetics** 1996 Apr; 142(4):1069-82

A novel proline, glycine: K+ symporter in midgut brush-border membrane vesicles from larval Manduca sexta. Bader AL, et al. **J Exp Biol** 1995 Dec;198 (Pt 12):2599-607

Prolyl hydroxylation regulates intracellular procollagen degradation in cultured rat cardiac fibroblasts. Eleftheriades EG, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1459-73

Identification of three proline-directed phosphorylation sites in the human androgen receptor. Zhou ZX, et al. **Mol Endocrinol** 1995 May;9(5):605-15

The regulation of L-proline transport by insulin-like growth factor-I in human osteoblast-like SaOS-2 cells. Kudo Y, et al. **Pflugers Arch** 1996 Jul;432(3):419-25

Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor. Konopka JB, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6764-9

Environmental and developmental signals modulate proline homeostasis: evidence for a negative transcriptional regulator. Verbruggen N, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8787-91

[A decrease in blood flow and incorporation of 45Ca and 3H-proline in the bones in pregnant female rats] Kapitola J, et al. **Sb Lek** 1995;96(4):313-8 (Eng. Abstr.) **(Cze)**

PHARMACOKINETICS

Analysis of intestinal perfusion data for highly permeable drugs using a numerical aqueous resistance--nonlinear regression method. Sinko PJ, et al. **Pharm Res** 1996 Apr; 13(4):570-6

PHARMACOLOGY

Regional hemodynamic changes and vasopressin release induced by intracisternal injection of L-proline in the conscious rat. Takemoto Y. **Jpn J Physiol** 1995; 45(5):743-58

Interaction between primary and secondary metabolism in Streptomyces coelicolor A3(2): role of pyrroline-5-carboxylate dehydrogenase. Smith DD, et al. **Microbiology** 1995 Jul;141 (Pt 7):1739-44

Identification of three proline-directed phosphorylation sites in the human androgen receptor. Zhou ZX, et al. **Mol Endocrinol** 1995 May;9(5):605-15

Mitigating the effects of halofuginone on skin strength by feeding L-proline to broiler chickens. Christensen KD, et al. **Poult Sci** 1995 Oct;74(10):1610-21

PHYSIOLOGY

The ATP-binding and ATPase activities of human papillomavirus type 16 E1 are significantly weakened by the absence of prolines in its ATP-binding domain. Raj K, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2949-56

Proline in a transmembrane helix compensates for cavities in the photosynthetic reaction center. Schiffer M, et al. **J Mol Biol** 1995 Sep 29;252(4):472-82

The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. Yalamanchili R, et al. **J Virol** 1996 Apr; 70(4):2468-73

THERAPEUTIC USE

The influence of proline analogs on bleomycin-induced lung injury in rats. Ledwożyw A. **Acta Physiol Hung** 1995; 83(2):195-202

Proline, ascorbic acid, or thioredoxin affect jaundice and mortality in Long Evans cinnamon rats. Hawkins RL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):509-15

PROLINE DEHYDROGENASE see **PROLINE OXIDASE**

PROLINE HYDROXYLASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROLINE OXIDASE

BIOSYNTHESIS

Regulatory region with putA gene of proline dehydrogenase that links to the lum and the lux operons in Photobacterium leiognathi. Lin JW, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):868-75

GENETICS

Isolation, DNA sequence analysis, and mutagenesis of a proline dehydrogenase gene (putA) from Bradyrhizobium japonicum. Straub PF, et al. **Appl Environ Microbiol** 1996 Jan;62(1):221-9

Regulatory region with putA gene of proline dehydrogenase that links to the lum and the lux operons in Photobacterium leiognathi. Lin JW, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):868-75

Expression of the putA gene encoding proline dehydrogenase from Rhodobacter capsulatus is independent of NtrC regulation but requires an Lrp-like activator protein. Keuntje B, et al. **J Bacteriol** 1995 Nov;177(22):6432-9

Characterization of a Rhizobium meliloti proline dehydrogenase mutant altered in nodulation efficiency and competitiveness on alfalfa roots. Jiménez-Zurdo JI, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):492-8

Environmental and developmental signals modulate proline homeostasis: evidence for a negative transcriptional regulator. Verbruggen N, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8787-91

PROLINE,2-OXOGLUTARATE 4-DIOXYGENASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROLINE-SPECIFIC TRNA see **RNA, TRANSFER, PRO**

PROLONGED-ACTION PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

PROLYL-LEUCYL-GLYCINAMIDE see **MSH RELEASE-INHIBITING HORMONE**

PROLYMPHOCYTIC LEUKEMIA see **LEUKEMIA, PROLYMPHOCYTIC**

PROM (PREGNANCY) see **FETAL MEMBRANES, PREMATURE RUPTURE**

PROMAZINE

PHARMACOKINETICS

The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. Daniel W, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):127-36

PROMEDOL

THERAPEUTIC USE

[A pharmacological analysis of the antiedematous action of GABA-ergic and opioidergic agents in craniocerebral trauma] Novikov VE, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):67-9 (Eng. Abstr.) **(Rus)**

PROMEGESTONE

PHARMACOLOGY

Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones. Buhimschi I, et al. **Hum Reprod** 1995 Oct; 10(10):2723-30

PROMESTONE see **PROMEGESTONE**

PROMETHAZINE

Intramuscular ketamine is superior to meperidine, promethazine, and chlorpromazine for pediatric emergency department sedation [see comments] Petrack EM, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):676-81. Comment in: Arch Pediatr Adolesc Med 1996 Jul;150(7):665-7.

[Plasma catecholamine level and clinical parameters--quality criteria for premedication in childhood] Burkhardt U, et al. **Anaesthesiol Reanim** 1995;20(4):88-96 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Tarkkila P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):983-6

[Topical antihistaminics. Is their use justified? (letter)] Palop V, et al. **Aten Primaria** 1996 Jun 15;18(1):47-8 **(Spa)**

ANALYSIS

Electron microscopic demonstration of intracelluar promethazine accumulation sites by a precipitation technique: application to the cerebellar cortex of the mouse. Müller T. **J Histochem Cytochem** 1996 May;44(5):531-5

POISONING

Promethazine toxicity in a seven-month-old Doberman pinscher. Staley EC, et al. **Vet Hum Toxicol** 1995 Jun; 37(3):243-4

THERAPEUTIC USE

Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Light RW, et al. **Chest** 1996 Apr; 109(4):975-81

Successful cancer therapy with promethazine: the rationale. Jones GR. **Med Hypotheses** 1996 Jan;46(1):25-9 (28 ref.)

Reappraisal of lytic cocktail/demerol, phenergan, and thorazine (DPT) for the sedation of children [letter; comment] Parks BR, et al. **Pediatrics** 1996 May; 97(5):779-80. Comment on: Pediatrics 1995 Apr;95(4):598-602.

[Multidimensional psychometric assessment of preoperative mood. Effects of zolpidem compared to phenobarbital combined with promethazine as premedication] Uhlig T, et al. **Anaesthesist** 1995 Sep;44(9):634-42 (Eng. Abstr.) **(Ger)**

URINE

A liquid chromatographic method for the determination of promethazine enantiomers in human urine and serum using solid-phase extraction and fluorescence detection. Ponder GW, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1161-6

PROMETRYNE

TOXICITY

Effect of s-triazine compounds on testosterone metabolism in the rat prostate. Kniewald J, et al. **J Appl Toxicol** 1995 May-Jun;15(3):215-8

PROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PROMOTER REGIONS (GENETICS)

see related

GENES, REPORTER

GATA transcription factors negatively regulate erythropoietin gene expression. Imagawa S, et al. **Acta Haematol** 1996;95(3-4):248-56

Tissue-specific expression and preliminary functional analysis of the 5' flanking regions of the human mitochondrial aldehyde dehydrogenase (ALDH2) gene. Dipple KM, et al. **Adv Exp Med Biol** 1995;372:123-30

Promoters of the mammalian class III alcohol dehydrogenase genes. Edenberg HJ, et al. **Adv Exp Med Biol** 1995; 372:295-300

DARPP-32 promoter directs transgene expression to renal thick ascending limb of loop of Henle. Blau S, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F564-70

Telokin expression is mediated by a smooth muscle cell-specific promoter. Herring BP, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1656-65

Analysis of promoter activity by polymerase chain reaction amplification of reporter gene mRNA. Kastenbauer S, et al. **Anal Biochem** 1996 Jan 1;233(1):137-9

A primer extension method for quantitation of in vitro synthesized mRNA transcripts directed by promoter elements containing multiple transcription initiation sites. Kosovsky MJ, et al. **Anal Biochem** 1995 Dec 10; 232(2):258-61

Transcriptional regulation of the human type X collagen gene expression. Beier F, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:209-11

Sequence elements within intron 1 of the human collagen X gene do not contribute to the regulation of gene expression. Chambers D, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:227-30

Regulation of antibody class switching to IgE: characterization of an IL-4-responsive region in the immunoglobulin heavy-chain germline epsilon promoter. Delphin S, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:123-35

Identification of an AP1-like response region for osteogenic protein-1 in type X collagen promoter. Harada S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:259-60

A URA3-promoter deletion in a pYES vector increases the expression level of a fungal lipase in Saccharomyces cerevisiae. Okkels JS. **Ann N Y Acad Sci** 1996 May 15; 782:202-7

Use of a modified tryptophanase promoter to direct high-level expression of foreign proteins in E. coli. Sitney KC, et al. **Ann N Y Acad Sci** 1996 May 15;782:297-310

Mutations in immunoglobulin V gene promoters may cause reduced germline transcription and diminished recombination frequencies. Stiernholm BJ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:116-20

cis-regulatory elements of the peroxidase gene in Arabidopsis thaliana involved in root-specific expression and responsiveness to high-salt stress. Wanapu C, et al. **Ann N Y Acad Sci** 1996 May 15;782:107-14

Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Lee CH, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1805-11

Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines. Mayer K, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1733-7

A DNA motif present in alpha V integrin promoter exhibits dual binding preference to distinct transcription factors. Sharma HW, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):1857-67

Cloning of a marine cyanobacterial promoter for foreign gene expression using a promoter probe vector. Sode K, et al. **Appl Biochem Biotechnol** 1996 Jun;59(3):349-60

Nondisruptive detection of activity of catabolic promoters of Pseudomonas putida with an antigenic surface reporter system. Cebolla A, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):214-20

Use of starvation promoters to limit growth and selectively enrich expression of trichloroethylene- and phenol-transforming activity in recombinant Escherichia coli [corrected] [published erratum appears in Appl Environ Microbiol 1995 Nov;61(11):4140] Matin A, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3323-8

The retinoblastoma gene product negatively regulates cellular or viral oncogene promoters in vivo. Salcedo M, et al. **Arch Med Res** 1995;26 Spec No:S157-62

Activation of gene transcription by IL-4, IL-13 and IFN-gamma through a shared DNA binding motif. Köhler I, et al. **Behring Inst Mitt** 1995 Jun;(96):78-86

How cytokines control immunoglobulin class switching. Lorenz M, et al. **Behring Inst Mitt** 1995 Jun;(96):97-102

Mechanisms of transcriptional activation of the promoter of the rainbow trout prolactin gene by GHF1/Pit1 and glucocorticoid. Argenton F, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):57-66

Antagonism of COUP-TF and PPAR alpha/RXR alpha on the activation of the malic enzyme gene promoter: modulation by 9-cis RA. Baes M, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):338-45

CTF/NF-1 binds the stage selector element of the human gamma-globin gene promoter. Bottardi S, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):874-80

Two nuclear proteins bind to the promoter P3 region of the human parathyroid hormone-related peptide gene. Bui TD, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):222-5

In vivo role of the Sp1 site neighboring sterol-responsive element-1 in controlling low-density lipoprotein receptor gene expression. Chang R, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):733-9

Promoter variation in the liver glucokinase is a risk factor for non-insulin-dependent diabetes mellitus. Chiu KC, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):614-8

Identification of trans-acting factors that interact with cis-acting elements present in the first nontranslated exon of the human apolipoprotein B gene. Chuang SS, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):553-62

Dbl expression driven by the neuron specific enolase promoter induces tumor formation in transgenic mice with a p53(+/-) genetic background. Colucci-D'Amato GL, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):762-70

The opposing effects of retinoic acid and phorbol esters converge to a common response element in the promoter of the rat cholesterol 7 alpha-hydroxylase gene (CYP7A). Crestani M, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):585-92

Negative and positive elements in the promoter region of the human apoferritin L gene. D'Agostino P, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):329-37

An Mse I RFLP in the human CTLA4 promotor. Deichmann K, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):817-8

The utility of fluorescent in vivo reporter genes in molecular cardiology. Doevendans PA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):352-8

Molecular cloning of the rat inducible nitric oxide synthase gene promoter. Eberhardt W, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):752-6

Androgen regulation of the rat keratinocyte growth factor (KGF/FGF7) promoter. Fasciana C, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):858-63

Characterization of a distal 5'-flanking region (-2010/-630) of human GM-CSF. Fiorentini P, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1015-22

Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene. Fuse N, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):702-7

Modulation of vitellogenin II gene by estradiol and progesterone in the Japanese quail. Gupta S, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):181-5

The aldolase A promoter in proliferating rat thymocytes is regulated by a cluster of SP1 sites and a distal modulator. Hermfisse U, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):997-1005

Cloning and characterization of mouse tec promoter. Honda H, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):422-6

Transcription of the rat angiotensin II type 2 receptor gene. Ichiki T, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):566-71

Characterization of the Duffy gene promoter: evidence for tissue-specific abolishment of expression in Fy(a-b-) of black individuals. Iwamoto S, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):852-9

Functional characterization of a 1,25-dihydroxyvitamin D3 receptor binding site found in the rat atrial natriuretic factor promoter. Kahlen JP, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):882-6

Identification of promoter in the 5'-flanking region of the E. coli thioredoxin-linked thiol peroxidase gene: evidence for the existence of oxygen-related transcriptional regulatory protein. Kim HK, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):641-6

Promoter usage determines tissue specific responsiveness of the rat acetyl-CoA carboxylase gene. Kim TS, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):647-53

Characterization of a protein that binds a negative regulatory element in the mammary-specific whey acidic protein promoter. Kolb AF, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1045-52

Molecular cloning and functional analysis of the rat mu opioid receptor gene promoter. Kraus J, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):591-7

Human leukocyte integrin CD18 promoter directs low levels of expression of a mutated human CD4 reporter gene in leukocytes of transgenic mice. Kwiatkowski BA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):601-6

Characterization of a silencer that modulates transcription of the human distal aldolase A promoter. Lupo A, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):69-77

HMG-I binds to GATA motifs: implications for an HPFH syndrome. Magis W, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):927-33

Differential activation of the murine laminin B1 gene promoter by RAR alpha, ROR alpha, and AP-1. Matsui T. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):405-10

An upstream positive regulatory element in human GM-CSF promoter is recognized by NF-kappa B/Rel family members. Musso M, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):64-72

Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-kappaB dependent mechanism. Nunokawa Y, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):347-52

Basal regulatory promoter elements of the hsp27 gene in human breast cancer cells. Oesterreich S, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):155-63

Activated lymphocytes induce promoter activity of the TCA3 gene in mast cells following cell-to-cell contact. Oh CK, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):510-4

Promoter structure of the mouse TATA-binding protein (TBP) gene. Ohbayashi T, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):275-80

Functional analysis of the human guanylin gene promoter.

Pardigol A, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):638–44

Both RNA polymerase III and RNA polymerase II accurately initiate transcription from a human U6 promoter in vitro. Park JS, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):934–40

Structure of the phenylalanine hydroxylase gene in Drosophila melanogaster and evidence of alternative promoter usage. Ruiz-Vázquez P, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):238–42

Identification of a promoter region in the rat prion protein gene. Saeki K, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):47–52

Molecular cloning and characterization of human bone morphogenic protein (BMP)-5 gene promoter. Sakaue M, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):768–72

Isolation of a genomic DNA fragment having negative vitamin D response element. Sakoda K, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):31–5

Hepatocyte nuclear factor 3beta participates in the transcriptional regulation of the thyroperoxidase promoter. Sato K, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):86–93

Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Scherer SJ, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):722–8

Characterization of the human nm23-H2 promoter region and localization of the microsatellite D17S396. Seifert M, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):910–4

The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Strauss BE, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):825–31

The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Strauss BE, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):333–40

Functional analysis of the preproendothelin-1 gene promoter in pulmonary epithelial cells and monocytes. Sun G, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):647–52

Nucleotide sequence of 5'-upstream region and expression of a silkworm gene encoding a new member of the attacin family. Taniai K, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):594–9

Gene product identification and promoter analysis of hig locus of plasmid Rts1. Tian QB, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):679–84

Functional characterization of the promoter region of the human phospholipid transfer protein gene. Tu AY, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):705–11

Long-PCR of the ANP gene and PCR-SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172–8

Inhibitory effect of tannic acid on human immunodeficiency virus promoter activity induced by 12-O-tetra decanoylphorbol-13-acetate in Jurkat T-cells. Uchiumi F, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):411–7

Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Wang C, et al. **Biochem Biophys Res Commun** 1995 Dec 5; 217(1):113–22

A SP1 binding site in the GC-rich region is essential for a core promoter activity of the human endothelial nitric oxide synthase gene. Wariishi S, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):729–35

Cell specific differences in DNase I hypersensitivity between the two promoters of the rat glucokinase gene. Williams CP, et al. **Biochem Biophys Res Commun** 1995 Oct 4; 215(1):272–9

Characterization of the murine PIG-A promoter region high constitutive PIG-A gene expression in brain. Yu J, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):497–503

The promoter structure of TGF-beta type II receptor revealed by "oligo-capping" method and deletion analysis. Yu YS, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):302–6

Tissue specific expression of testis angiotensin converting enzyme is not determined by the -32 nonconsensus TATA motif. Zhou Y, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):48–53

Transgenic mice expressing the human ornithine decarboxylase gene under the control of mouse metallothionein I promoter. Alhonen L, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):405–8

Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Böhm SK, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):835–43

Insulin upstream factor 1 and a novel ubiquitous factor bind to the human islet amyloid polypeptide/amylin gene promoter. Bretherton-Watt D, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):495–502

Temperature-dependence of open-complex formation at two Escherichia coli promoters with extended -10 sequences. Burns HD, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):305–11

Identification of the transcription factors NF-YA and NF-YB as factors A and B that bound to the promoter of the major histocompatibility complex class II gene I-A beta. Celada A, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):771–7

Identification of a functional promoter element in the 5'-flanking region of the rat cMG1/TIS11b gene. Corps AN, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):251–8

Identification of direct-repeat-binding protein 1 (DRP-1), a DNA-binding protein that binds specifically to the 'malic' enzyme gene promoter direct repeat element. Ford KG, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):901–4

Structural organization of the rat branched-chain 2-oxo-acid dehydrogenase kinase gene and partial characterization of the promoter-regulatory region. Huang Y, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):603–9

Cloning and analysis of the promoter region of the rat SM22 alpha gene. Kemp PR, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):1037–43

Cloning and characterization of the 5' end and promoter region of the chicken acetyl-CoA carboxylase gene. El Khadir-Mounier C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):613–9

Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Kim RH, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):219–26

Expression of laminin gamma 1 cultured hepatocytes involves repeated CTC and GC elements in the LAMC1 promoter. Levavasseur F, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):745–52

Pseudopregnancy induces the expression of hepatocyte nuclear factor-1 beta and its target gene aminopeptidase N in rabbit endometrium via the epithelial promoter. Olsen J, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):31–7

Characterization of cell-specific modulatory element in the murine ornithine decarboxylase promoter. Palvimo JJ, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):993–8

Identification of distal silencing elements in the murine interferon-A11 gene promoter. Roffet P, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):697–706

The homeodomain protein IPF-1/STF-1 is expressed in a subset of islet cells and promotes rat insulin 1 gene expression dependent on an intact E1 helix-loop-helix factor binding site. Serup P, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):997–1003

The lung enriched transcription factor TTF-1 and the ubiquitously expressed proteins Sp1 and Sp3 interact with elements located in the minimal promoter of the rat Clara cell secretory protein gene. Toonen RF, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):467–73

The organization of the human GSTP1-1 gene promoter and its response to retinoic acid and cellular redox status. Xia C, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):155–61

Differences in regulation of alpha 1(I) collagen promoter in vascular smooth muscle cells in transfection studies and transgenic mice. Bedalov A. **Biochem Mol Biol Int** 1995 Sep;37(1):159–66

Modulation of transcriptional activity of the chicken ovalbumin gene promoter in primary cultures of chicken oviduct cells: effects of putative regulatory elements in the 5'-flanking region. Park HM, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):811–6

Stimulation of atrial natriuretic factor promoter activity by Src and Ras in cultured neonatal rat ventricular myocytes. Gillespie-Brown J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):445S

Effect of pertussis toxin and PGE2 on the functioning of the IL-2 promoter in interleukin-1 treated EL4.NOB-1 thymoma cells. McCarthy LM, et al. **Biochem Soc Trans** 1996 Feb;24(1):82S

Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. Birnbaum MJ, et al. **Biochemistry** 1995 Dec 19;34(50):16503–8

HO. and DNase I probing of E sigma 70 RNA polymerase--lambda PR promoter open complexes: Mg2+ binding and its structural consequences at the transcription start site. Craig ML, et al. **Biochemistry** 1995 Dec 5; 34(48):15624–32

Interactions between RNA polymerase and the positive and negative regulators of transcription at the Escherichia coli gal operon. Dalma-Weiszhausz DD, et al. **Biochemistry** 1996 Mar 26;35(12):3735–45

Tissue factor gene transcription in serum-stimulated fibroblasts is mediated by recruitment of c-Fos into specific AP-1 DNA-binding complexes. Felts SJ, et al. **Biochemistry** 1995 Sep 26;34(38):12355–62

Purification and characterization of a DNA polymerase beta promoter initiator element-binding transcription factor from bovine testis. He F, et al. **Biochemistry** 1996 Feb 13; 35(6):1775–82

Major groove recognition elements in the middle of the T7 RNA polymerase promoter. Li T, et al. **Biochemistry** 1996 Mar 26;35(12):3722–7

Differential expression and butyrate response of human alkaline phosphatase genes are mediated by upstream DNA elements. Park C, et al. **Biochemistry** 1996 Jul 30; 35(30):9807–14

Simultaneous binding and bending of promoter DNA by the TATA binding protein: real time kinetic measurements. Parkhurst KM, et al. **Biochemistry** 1996 Jun 11; 35(23):7459–65

Mode of selectivity in cyclic AMP receptor protein-dependent promoters in Escherichia coli. Pyles EA, et al. **Biochemistry** 1996 Jan 30;35(4):1162–72

Steroidogenic factor 1-dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene. Sugawara T, et al. **Biochemistry** 1996 Jul 16;35(28):9052–9

Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Taylor AH, et al. **Biochemistry** 1996 Jun 25; 35(25):8281–8

Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter. Vigneswaran N, et al. **Biochemistry** 1996 Jan 30;35(4):1106–14

Characterization of the human and mouse Fli-1 promoter regions. Barbeau B, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):220–32

Identification of a thyroid-specific and cAMP-responsive enhancer in the upstream sequences of the human thyroglobulin promoter. Berg V, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):35–8

Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: regulation by TGF-beta. Bloom BB, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):243–8

Molecular cloning and sequence analysis of the rat liver carnitine octanoyltransferase cDNA, its natural gene and the gene promoter. Choi SJ, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):215–22

Multiple nosZ promoters and anaerobic expression of nos genes necessary for Pseudomonas stutzeri nitrous oxide reductase and assembly of its copper centers. Cuypers H, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):183–90

Isolation of strong promoters from Clavibacter xyli subsp. cynodontis using a promoter probe plasmid. Haapalainen M, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):130–4

An upstream region of the H2AZ gene promoter modulates promoter activity in different cell types. Hatch CL, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):59–62

Promoter analysis of the bovine gene for seminalplasmin. Herbers J, et al. **Biochim Biophys Acta** 1995 Sep 19; 1263(3):271–4

Promoter region of the rat phosphoribosylpyrophosphate synthetase-associated protein 39. Ishizuka T, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):34–7

Identification and characterization of two promoters of rat kallikrein-binding protein gene. Ma JX, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):285–93

Structural and functional analysis of the 5'-flanking region of the rat beta 2-adrenergic receptor gene. McGraw DW, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):135–8

Cloning, sequence and characterization of the human AMPD2 gene: evidence for transcriptional regulation by two closely spaced promoters. Mahnke-Zizelman DK, et al. **Biochim Biophys Acta** 1996 Aug 14;1308(2):122–32

Characterization of the human AMPD3 gene reveals that 5'exon useage is subject to transcriptional control by three tandem promoters and alternative splicing. Mahnke-Zizelman DK, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):75–92

Cell line-specific transcriptional activation of the promoter of the human guanylyl cyclase C/heat-stable enterotoxin/receptor gene. Mann EA, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):7–10

Trans-activation of the wheat histone H3 promoter by Gal4 DNA-binding domain (1–94) in plant cells. Nakayama T, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):281–4

Structural and functional analysis of the human phosphoenolpyruvate carboxykinase gene promoter. O'Brien RM, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):284–8

Lens-preferred activity of the -1809/+46 mouse alpha A-crystallin promoter in stably integrated chromatin. Sax CM, et al. **Biochim Biophys Acta** 1996 Feb 7; 1305(1–2):49–53

The promoter-proximal, unstable IB region of the atp mRNA of Escherichia coli: an independently degraded region that can act as a destabilizing element. Schramm HC, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):162–70

The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Serfling E, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):181–200 (244 ref.)

Sequence of the rat PB-inducible CYP2B1 promoter. Shaw PM, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):54–8

Regulation of the human poly(ADP-ribosyl) transferase promoter via alternative DNA racket structures. Schweiger M, et al. **Biochimie** 1995;77(6):480–5

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

Expression of a human insulin transgene in cholinergic neurons of the mouse medial habenula. Douhet P, et al. **Biol Cell** 1995;85(2–3):137–46

Evaluation of HBV promoters for use in hepatic gene therapy. Löser P, et al. **Biol Chem Hoppe Seyler** 1996 Mar; 377(3):187–93

Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Prösch S, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):195–201

Demonstration of tissue-specific promoters in nonprimate species that express aromatase P450 in placentae. Hinshelwood MM, et al. **Biol Reprod** 1995 Nov; 53(5):1151–9

Method for sequencing foreign genes expressed from the

polyhedrin promoter of recombinant baculoviruses. Herzberg IM, et al. **Biotechniques** 1995 Aug;19(2):176–8

Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Deveaux S, et al. **Blood** 1996 Jun 1;87(11):4678–85

Functional interaction of GATA1 with erythroid Krüppel-like factor and Sp1 at defined erythroid promoters. Gregory RC, et al. **Blood** 1996 Mar 1; 87(5):1793–801

Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites. Himmelmann A, et al. **Blood** 1996 Feb 1;87(3):1036–44

Use of a promoter-trap retrovirus to identify and isolate genes involved in differentiation of a myeloid progenitor cell line in vitro. Jonsson JI, et al. **Blood** 1996 Mar 1; 87(5):1771–9

Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Malik P, et al. **Blood** 1995 Oct 15;86(8):2993–3005

In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants. Pace BS, et al. **Blood** 1996 Aug 1;88(3):1079–83

The tissue-specific transcriptional regulation of the megakaryocytic glycoprotein IIb gene is controlled by interactions between a repressor and positive cis-acting elements. Prandini MH, et al. **Blood** 1996 Sep 15; 88(6):2062–70

The promoter and 5' flanking sequences controlling human B29 gene expression. Thompson AA, et al. **Blood** 1996 Jan 15;87(2):666–73

Polymorphic variation in the human protein C (PROC) gene promoter can influence transcriptional efficiency in vitro. Scopes D, et al. **Blood Coagul Fibrinolysis** 1995 Jun; 6(4):317–21

Functional analysis of an unusual length polymorphism in the human antithrombin III (AT3) gene promoter. Winter PC, et al **Blood Coagul Fibrinolysis** 1995 Oct;6(7):659–64

Erythroid-specific expression of human growth hormone affects bone morphology in transgenic mice. Saban J, et al. **Bone** 1996 Jan;18(1):47–52

A-793 G to A transition in the factor IX gene promoter is polymorphic in the Caucasian population. Rai HK, et al. **Br J Haematol** 1996 Feb;92(2):501–3

The helix-loop-helix transcription factor USF interacts with the basal promoter of human amyloid precursor protein. Bourbonnière M, et al. **Brain Res Mol Brain Res** 1996 Jan; 35(1–2):304–8

Heat shock factor-1 mediates the transcriptional activation of Alzheimer's beta-amyloid precursor protein gene in response to stress. Dewji NN, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):325–8

Identification of a negative regulatory element in the 5'-flanking region of the human dopamine beta-hydroxylase gene. Ishiguro H, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):251–61

Promoter elements and second messenger pathways involved in transcriptional activation of tyrosine hydroxylase by ionomycin. Nankova B, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):164–72

A herpes simplex virus-1 vector containing the rat tyrosine hydroxylase promoter directs cell type-specific expression of beta-galactosidase in cultured rat peripheral neurons. Oh YJ, et al. **Brain Res Mol Brain Res** 1996 Jan; 35(1–2):227–36

Spatial and temporal regulation of the rat calmodulin gene III directed by a 877-base promoter and 103-base leader segment in the mature and embryonal central nervous system of transgenic mice. Shimoda K, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1–2):61–70

Dependence on reporter gene of apparent activity in gene fusions of a Streptomyces griseus streptomycin biosynthesis promoter. Lindley HK, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):407–17

Identification of an RB-responsive region in the 5' untranslated region of the RB gene. Fujita T, et al. **Cancer Lett** 1996 Mar 29;101(2):149–57

Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Kim SH, et al. **Cancer Lett** 1996 Jan 2;98(2):199–205

Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. Ince TA, et al. **Cancer Res** 1996 May 1; 56(9):2021–4

Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Issa JP, et al. **Cancer Res** 1996 Aug 15; 56(16):3655–8

Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Mukhopadhyay D, et al. **Cancer Res** 1995 Dec 15; 55(24):6161–5

Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Webster NJ, et al. **Cancer Res** 1996 Jun 15;56(12):2781–8

Effect of sulphur mustard on the initiation and elongation of transcription. Masta A, et al. **Carcinogenesis** 1996 Mar; 17(3):525–32

Displacement of sequence-specific transcription factors from mitotic chromatin. Martínez-Balbás MA, et al. **Cell** 1995 Oct 6;83(1):29–38

A mammalian RNA polymerase II holoenzyme containing all components required for promoter-specific transcription initiation. Ossipow V, et al. **Cell** 1995 Oct 6;83(1):137–46

Function of E. coli RNA polymerase sigma factor sigma 70 in promoter-proximal pausing. Ring BZ, et al. **Cell** 1996 Aug 9;86(3):485–93

Base-specific recognition of the nontemplate strand of promoter DNA by E. coli RNA polymerase. Roberts CW, et al. **Cell** 1996 Aug 9;86(3):495–501

Induction of cell death in murine fibroblasts by a c-myc promoter binding protein. Ray RB. **Cell Growth Differ** 1995 Sep;6(9):1089–96

Regulation of ornithine decarboxylase mRNA levels in human breast cancer cells: pattern of expression and involvement of core enhancer promoter element. Wright PS, et al. **Cell Growth Differ** 1995 Sep;6(9):1097–102

Transactivation of cardiac MLC-2 promoter by MyoD in 10T1/2 fibroblast cells is independent of E-box requirement but depends upon new proteins that recognize MEF-2 site. Goswami SK, et al. **Cell Mol Biol Res** 1995; 41(3):199–205

Transcriptional repression of heterologous constitutive and inducible promoters by the negative element of the rabbit angiotensin-converting enzyme gene. Kessler SP, et al. **Cell Mol Biol Res** 1995;41(6):595–602

Tissue-specific, temporally regulated expression mediated by the proximal ovine beta-lactoglobulin promoter in transgenic mice. Webster J, et al. **Cell Mol Biol Res** 1995; 41(1):11–5

Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Bartlett RJ, et al. **Cell Transplant** 1996 May–Jun;5(3):411–9

Identification of dioxin-responsive elements (DREs) in the 5' regions of putative dioxin-inducible genes. Lai ZW, et al. **Chem Biol Interact** 1996 Mar 25;100(2):97–112

Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7–17; discussion 17–23 (45 ref.)

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237–53; discussion 253–8 (49 ref.)

Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Rosenwasser LJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:74–8; discussion 95–6

Eukaryotic promoter recognition by binding sites for transcription factors. Kondrakhin YV, et al. **Comput Appl Biosci** 1995 Oct;11(5):477–88

A two-reporter gene system for the analysis of bi-directional transcription from the divergent MAL6T-MAL6S promoter in Saccharomyces cerevisiae. Bell PJ, et al. **Curr Genet** 1995 Oct;28(5):441–6

Characterization of the "promoter region" of the enolase-encoding gene enol from the anaerobic fungus Neocallimastix frontalis: sequence and promoter analysis. Fischer M, et al. **Curr Genet** 1995 Jun;28(1):80–6

NRE, the major nitrogen regulatory protein of Penicillium chrysogenum, binds specifically to elements in the intergenic promoter regions of nitrate assimilation and penicillin biosynthetic gene clusters. Haas H, et al. **Curr Genet** 1995 Jul;28(2):177–83

Endoglucanase II (EGII) of Penicillium janthinellum: cDNA sequence, heterologous expression and promotor analysis. Mernitz G, et al. **Curr Genet** 1996 Apr;29(5):490–5

Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205–16 (103 ref.)

A method for easy isolation of promoter fragments from promoter-probe libraries of filamentous fungi. Weltring KM. **Curr Genet** 1995 Jul;28(2):190–6

Start-specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173–87 (64 ref.)

Characterization of polymorphisms of an interleukin 1 receptor type 1 gene (IL1R1) promotor region (P2) and their relation to insulin-dependent diabetes mellitus (IDDM). The Danish Study Group of Diabetes in Childhood. Bergholdt R, et al. **Cytokine** 1995 Oct; 7(7):727–33

Two cis elements collaborate to spatially repress transcription from a sea urchin promoter. Frudakis TN, et al. **Dev Biol** 1995 Nov;172(1):230–41

Analysis of regulatory elements of the developmentally controlled chorion s15 promoter in transgenic Drosophila. Mariani BD, et al. **Dev Biol** 1996 Feb 25;174(1):115–24

Characterization of the SpHE promoter that is spatially regulated along the animal-vegetal axis of the sea urchin embryo. Wei Z, et al. **Dev Biol** 1995 Sep;171(1):195–211

Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-beta 1 chimeric gene. Zhou L, et al. **Dev Biol** 1996 May 1;175(2):227–38

Analysis of the promoter region of the Streptococcus mutans mannitol PTS operon. Honeyman AL, et al. **Dev Biol Stand** 1995;85:383–6

Environmentally regulated promoters in Lactococci. Israelsen H, et al. **Dev Biol Stand** 1995;85:443–8

Developmental alteration of the chromatin state at promoter/replication origin region of the aldolase B locus precedes transcriptional activation in the liver. Ito K, et al. **Dev Genet** 1995;17(4):312–8

Spatial expression of the hsr-omega (93D) gene in different tissues of Drosophila melanogaster and identification of promoter elements controlling its developmental expression. Mutsuddi M, et al. **Dev Genet** 1995;17(4):303–11

Posterior stripe expression of hunchback is driven from two promoters by a common enhancer element. Margolis JS, et al. **Development** 1995 Sep;121(9):3067–77

The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Moessler H, et al. **Development** 1996 Aug;122(8):2415–25

Mesoderm and endoderm differentiation in animal cap explants: identification of the HNF4-binding site as an activin A responsive element in the Xenopus HNF1alpha promoter. Weber H, et al. **Development** 1996 Jun; 122(6):1975–84

Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Ohagi S, et al. **Diabetes** 1996 Jul;45(7):897–901

A variation at position -30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Stone LM, et al. **Diabetes** 1996 Apr;45(4):422–8

Expression of the human T-cell receptor V beta 5.3 in Escherichia coli by thermal induction of the trc promoter: nucleotide sequence of the lacIts gene. Adari H, et al. **DNA Cell Biol** 1995 Nov;14(11):945–50

Characterization of the rat A2a adenosine receptor gene. Chu YY, et al. **DNA Cell Biol** 1996 Apr;15(4):329–37

Tissue-specific alternative promoters regulate the expression of the two sarco/endoplasmic reticulum Ca-ATPase isoforms from Artemia franciscana. Escalante R, et al. **DNA Cell Biol** 1995 Oct;14(10):893–900

Isolation and analysis of inducibility of the rat N-methylpurine-DNA glycosylase promoter. Grombacher T, et al. **DNA Cell Biol** 1996 Jul;15(7):581–8

Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1. Lee YI, et al. **DNA Cell Biol** 1996 Feb;15(2):99–104

Promoters for the human beta-hexosaminidase genes, HEXA and HEXB. Norflus F, et al. **DNA Cell Biol** 1996 Feb; 15(2):89–97

Promoter binding factors regulating cyclin B transcription in the sea urchin embryo. Thatcher JD, et al. **DNA Cell Biol** 1995 Oct;14(10):869–81

Computer assisted promoter analysis of a human sperm specific nucleoprotein gene cluster. Nelson JE, et al. **DNA Seq** 1995;5(6):329–37

Human renin 5'-flanking DNA to nucleotide-2750. Smith DL, et al. **DNA Seq** 1995;5(5):319–21

The rat hepatic leukemia factor (HLF) gene encodes two transcriptional activators with distinct circadian rhythms, tissue distributions and target preferences. Falvey E, et al. **EMBO J** 1995 Sep 1;14(17):4307–17

The two PAR leucine zipper proteins, TEF and DBP, display similar circadian and tissue-specific expression, but have different target promoter preferences. Fonjallaz P, et al. **EMBO J** 1996 Jan 15;15(2):351–62

Activation of the IL-2 gene promoter by HTLV-I tax involves induction of NF-AT complexes bound to the CD28-responsive element. Good L, et al. **EMBO J** 1996 Jul 15;15(14):3744–50

A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains. Goppelt A, et al. **EMBO J** 1996 Jun 17;15(12):3105–16

The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation. Gstaiger M, et al. **EMBO J** 1996 Jun 3;15(11):2781–90

Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. Hill CS, et al. **EMBO J** 1995 Oct 16;14(20):5037–47

Opening of an RNA polymerase II promoter occurs in two distinct steps and requires the basal transcription factors IIE and IIH. Holstege FC, et al. **EMBO J** 1996 Apr 1; 15(7):1666–77

DNA twist, flexibility and transcription of the osmoregulated proU promoter of Salmonella typhimurium. Jordi BJ, et al. **EMBO J** 1995 Nov 15;14(22):5690–700

RNA polymerase alpha subunit binding site in positively controlled promoters: a new model for RNA polymerase-promoter interaction and transcriptional activation in the Escherichia coli ada and aidB genes. Landini P, et al. **EMBO J** 1995 Sep 1;14(17):4329–35

Activation and repression of transcription at two different phage phi29 promoters are mediated by interaction of the same residues of regulatory protein p4 with RNA polymerase. Monsalve M, et al. **EMBO J** 1996 Jan 15; 15(2):383–91

Combinatorial interplay of promoter elements constitutes the minimal determinants for light and developmental control of gene expression in Arabidopsis. Puente P, et al. **EMBO J** 1996 Jul 15;15(14):3732–43

Role of the duplicated CCAAT box region in gamma-globin gene regulation and hereditary persistence of fetal

haemoglobin. Ronchi A, et al. **EMBO J** 1996 Jan 2; 15(1):143–9

Conserved function of anopheles gambiae midgut-specific promoters in the fruitfly. Skavdis G, et al. **EMBO J** 1996 Jan 15;15(2):344–50

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905–13 (100 ref.)

Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Van Lint C, et al. **EMBO J** 1996 Mar 1;15(5):1112–20

Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. Ye BH, et al. **EMBO J** 1995 Dec 15;14(24):6209–17

Haplotype analysis of CYP11B2. White PC, et al. **Endocr Res** 1995 Feb–May;21(1–2):437–42

Constitutively active G(S) alpha-subunits stimulate Pit-1 promoter activity via a protein kinase A-mediated pathway acting through deoxyribonucleic acid binding sites both for Pit-1 and for adenosine 3',5'-monophosphate response element-binding protein. Gaiddon C, et al. **Endocrinology** 1996 Apr;137(4):1286–91

Regulation of glucose transporters in cultured rat adipocytes: synergistic effect of insulin and dexamethasone on GLUT4 gene expression through promoter activation. Hajduch E, et al. **Endocrinology** 1995 Nov;136(11):4782–9

Cis-regulatory elements conferring cyclic 3',5'-adenosine monophosphate responsiveness of the progesterone receptor gene in transfected rat granulosa cells. Park-Sarge OK, et al. **Endocrinology** 1995 Dec;136(12):5430–7

Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. Southby J, et al. **Endocrinology** 1996 Apr;137(4):1349–57

Induction of chinook salmon growth hormone promoter activity by the adenosine 3',5'-monophosphate (cAMP)-dependent pathway involves two cAMP-response elements with the CGTCA motif and the pituitary-specific transcription factor Pit-1. Wong AO, et al. **Endocrinology** 1996 May;137(5):1775–84

A member of the CTF/NF-1 transcription factor family regulates murine growth hormone receptor gene promoter activity. Zou L, et al. **Endocrinology** 1995 Nov; 136(11):5236–9

The transcription factor AP-1 binds to the human interleukin 1 alpha promoter. Bailly S, et al. **Eur Cytokine Netw** 1996 Apr–Jun;7(2):125–8

A positive regulatory sequence of hepatitis B viral small X promoter. Chol CY, et al. **Eur J Biochem** 1996 Aug 1; 239(3):579–87

CCAAT/enhancer-binding protein beta (C/EBP beta) binds and activates while hepatocyte nuclear factor-4 (HNF-4) does not bind but represses the liver-type arginase promoter. Chowdhury S, et al. **Eur J Biochem** 1996 Mar 1;236(2):500–9

A (G+C)-rich motif in the aldolase C promoter functions as a constitutive transcriptional enhancer element. Cibelli G, et al. **Eur J Biochem** 1996 Apr 1;237(1):311–7

Identification of a functional cAMP response element in the secretogranin II gene. Cibelli G, et al. **Eur J Biochem** 1996 Feb 15;236(1):171–9

A silencer and an adjacent positive element interact to modulate the activity of the human insulin promoter. Clark AR, et al. **Eur J Biochem** 1995 Sep 1;232(2):627–32

Differential binding of cAMP-responsive-element (CRE)-binding protein-1 and activating transcription factor-2 to a CRE-like element in the human tissue-type plasminogen activator (t-PA) gene promoter correlates with opposite regulation of t-PA by phorbol ester in HT-1080 and HeLa cells. Costa M, et al. **Eur J Biochem** 1996 May 1;237(3):532–8

A regulatory domain within the virus-response element of the interferon alpha 1 gene acts as a transcriptional repressor sequence and determinant of cell-specific gene expression. Dent CL, et al. **Eur J Biochem** 1996 Mar 15; 236(3):895–903

The caudal-type homeobox protein Cdx-2 binds to the colon promoter of the carbonic anhydrase 1 gene. Drummond F, et al. **Eur J Biochem** 1996 Mar 1;236(2):670–81

The characterisation of the 5' regulatory region of a temperature-induced myosin-heavy-chain gene associated with myotomal muscle growth in the carp. Gauvry L, et al. **Eur J Biochem** 1996 Mar 15;236(3):887–94

A 30-kDa host protein binds to two very-late baculovirus promoters. Jain A, et al. **Eur J Biochem** 1996 Jul 15; 239(2):384–90

Characterization of the core promoter of the Na+/K(+)-ATPase alpha 1 subunit gene. Elements required for transcription by RNA polymerase II and RNA polymerase III in vitro. Kawakami K, et al. **Eur J Biochem** 1996 Apr 15;237(2):440–6

Analyses of cis-acting and trans-acting elements that are crucial to sustain pregnancy-specific glycoprotein gene expression in different cell types. Koritschoner NP, et al. **Eur J Biochem** 1996 Mar 1;236(2):365–72

Motifs resembling hepatocyte nuclear factor 1 and activator protein 3 mediate the tissue specificity of the human plasminogen gene. Meroni G, et al. **Eur J Biochem** 1996 Mar 1;236(2):373–82

Conserved regulation of the Hansenula polymorpha MOX promoter in Saccharomyces cerevisiae reveals insights in the transcriptional activation by Adr1p. Pereira GG, et al. **Eur J Biochem** 1996 May 15;238(1):181–91

Characterization of the human alpha 1(VI) collagen promoter and its comparison with human alpha 2(VI) promoters. Saitta B, et al. **Eur J Biochem** 1995 Dec 1;234(2):542–9

Regulation of expression of the rat serine protease inhibitor 2.3 gene by glucocorticoids and interleukin-6. A complex and unusual interplay between positive and negative cis-acting elements. Simar-Blanchet AE, et al. **Eur J Biochem** 1996 Mar 1;236(2):638–48

Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Gaetano C, et al. **Eur J Cancer** 1995;31A(4):447–52

TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Manus RM, et al. **Eur J Immunol** 1996 Sep;26(9):2113–8

Differential promoter activity in benign and malignant human cells of skin origin. Artuc M, et al. **Exp Dermatol** 1995 Oct;4(5):317–21

Epidermal growth factor and platelet-derived growth factor regulate the activity of the insulin-like growth factor I gene promoter. Li S, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):195–206

A plasmid shuttle vector bearing an rRNA promoter is extrachromosomally maintained in Crithidia fasciculata. Biebinger S, et al. **Exp Parasitol** 1996 Jul;83(2):252–8

Regulation of gene expression by alternative promoters. Ayoubi TA, et al. **FASEB J** 1996 Mar;10(4):453–60 (41 ref.)

Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. Shen J, et al. **FASEB J** 1995 Dec;9(15):1623–31

Modulation of Tax and PKA-mediated expression of HTLV-I promoter via cAMP response element binding and modulator proteins CREB and CREM. Bodor J, et al. **FEBS Lett** 1995 Dec 27;377(3):413–8

Granulocyte colony-stimulating factor induces the binding of STAT1 and STAT3 to the IFNgamma response region within the promoter of the Fc(gamma)RI/CD64 gene in human neutrophils. Bovolenta C, et al. **FEBS Lett** 1996 May 20;386(2–3):239–42

Transcriptional repression by methylation: cooperativity between a CpG cluster in the promoter and remote CpG-rich regions. Hug M, et al. **FEBS Lett** 1996 Feb 5; 379(3):251–4

DNA methylation in the promoter of ribosomal RNA genes in human cells as determined by genomic sequencing. Kochanek S, et al. **FEBS Lett** 1996 Jun 17;388(2–3):192–4

Helix-loop-helix transcription factors regulate Id2 gene promoter activity. Neuman K, et al. **FEBS Lett** 1995 Oct 30;374(2):279–83

Promoter and expression studies on an Arabidopsis thaliana dehydrin gene. Rouse DT, et al. **FEBS Lett** 1996 Mar 4; 381(3):252–6

Characterization and functional dissection of the galectin-1 gene promoter. Salvatore P, et al. **FEBS Lett** 1995 Oct 9;373(2):159–63

Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. Schäfer D, et al. **FEBS Lett** 1996 Aug 5;391(1–2):35–8

Stable expression of insect GABA receptors in insect cell lines. Promoters for efficient expression of Drosophila and mosquito Rdl GABA receptors in stably transformed mosquito cell lines. Shotkoski F, et al. **FEBS Lett** 1996 Feb 19;380(3):257–62

Cell type specific regulation of COUP-TF II promoter activity. Soosaar A, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):95–100

Isolation of promoters from Brevibacterium flavum strain MJ233C and comparison of their gene expression levels in B. flavum and Escherichia coli. Zupancic TJ, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):121–6

An element upstream from the human delta-globin-encoding gene specifically enhances beta-globin reporter gene expression in murine erythroleukemia cells. Acuto S, et al. **Gene** 1996 Feb 12;168(2):237–41

Temporal and tissue-specific expression of the MET ORF driven by the complete transcriptional unit of human A1AT gene in transgenic mice. Amicone L, et al. **Gene** 1995 Sep 11;162(2):323–8

Expression of the mitochondrial RNase P RNA subunit-encoding gene from a variant promoter sequence in Saccharomyces cerevisiae. Biswas TK. **Gene** 1996 Apr 17;170(1):23–30

Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Burcelin R, et al. **Gene** 1995 Oct 27;164(2):305–10

The citrate synthase-encoding gene of Rickettsia prowazekii is controlled by two promoters. Cai J, et al. **Gene** 1995 Sep 22;163(1):115–9

Sequence, initial functional analysis and protein-DNA binding sites of the mouse beta B2-crystallin-encoding gene. Chambers C, et al. **Gene** 1995 Dec 12;166(2):287–92

The bovine DNA polymerase beta promoter: cloning, characterization and comparison with the human core promoter. Chen KH, et al. **Gene** 1995 Oct 27;164(2):323–7

Characterization of the promoter of the human KAL gene, responsible for the X-chromosome-linked Kallmann syndrome. Cohen-Salmon M, et al. **Gene** 1995 Oct 27; 164(2):235–42

Cloning and characterization of the promoter for murine 84-kDa heat-shock protein. Dale EC, et al. **Gene** 1996 Jun 26;172(2):279–84

Sequence of a chicken erythroblast mono(ADP-ribosyl)transferase-encoding gene and its upstream region. Davis T, et al. **Gene** 1995 Oct 27; 164(2):371–2

Transcription of the region encoding the ferric dicitrate-transport system in Escherichia coli: similarity between promoters for fecA and for extracytoplasmic function sigma factors. Enz S, et al. **Gene** 1995 Sep 22; 163(1):13–8

Identification and expression of a homologue of the murine HoxA5 gene in the Mexican axolotl (Ambystoma mexicanum). Gaur A, et al. **Gene** 1995 Sep 11;162(2):249–53

Isolation and characterization of the promoter of the human 5'-nucleotidase (CD73)-encoding gene. Hansen KR, et al. **Gene** 1995 Dec 29;167(1–2):307–12

Promoter region of the mouse cyclin-dependent kinase 5-encoding gene. Ishizuka T, et al. **Gene** 1995 Dec 12; 166(2):267–71

The zebrafish Fgf-3 gene: cDNA sequence, transcript structure and genomic organization. Kiefer P, et al. **Gene** 1996 Feb 12;168(2):211–5

Sequence and unusual 3' flanking region of the rat tRNA[Ser]Sec gene. Kolker JD, et al. **Gene** 1995 Oct 27; 164(2):375–6

Structure and regulation of the gene encoding avian inhibitor of nuclear factor kappa B-alpha. Krishnan VA, et al. **Gene** 1995 Dec 12;166(2):261–6

An autonomously replicating eukaryotic expression vector with a tetracycline-responsive promoter. Lang Z, et al. **Gene** 1996 Feb 12;168(2):169–71

Positive regulation of human alpha 1 (I) collagen promoter activity by transcription factor Sp1. Li L, et al. **Gene** 1995 Oct 27;164(2):229–34

Cloning and characterization of three Aspergillus niger promoters. Luo X. **Gene** 1995 Sep 22;163(1):127–31

Construction of a CUP1 promoter-based vector to modulate gene expression in Saccharomyces cerevisiae. Mascorro-Gallardo JO, et al. **Gene** 1996 Jun 12; 172(1):169–70

The DRE sequence TATCGATA, a putative promoter-activating element for Drosophila melanogaster cell-proliferation-related genes. Matsukage A, et al. **Gene** 1995 Dec 12;166(2):233–6

A 28-bp negative element with multiple factor-binding activity controls expression of the vimentin-encoding gene. Moura-Neto V, et al. **Gene** 1996 Feb 12;168(2):261–6

A novel insertion sequence (IS)-like element of the thermophilic bacterium PS3 promotes expression of the alanine carrier protein-encoding gene. Murai N, et al. **Gene** 1995 Sep 22;163(1):103–7

Identification of three transcriptional regulatory elements in the rat mitochondrial benzodiazepine receptor-encoding gene. Oberto A, et al. **Gene** 1995 Dec 29;167(1–2):255–60

Comparison of the promoter proximal regions of the toxin-co-regulated tcp gene cluster in classical and El Tor strains of Vibrio cholerae O1. Ogierman MA, et al. **Gene** 1996 Apr 17;170(1):9–16

Upstream promoter elements are sufficient for selenocysteine tRNA[Ser]Sec gene transcription and to determine the transcription start point. Park JM, et al. **Gene** 1995 Aug 30;162(1):13–9

VTR expression cassettes for engineering conditional phenotypes in Pseudomonas: activity of the Pu promoter of the TOL plasmid under limiting concentrations of the XylR activator protein. Pérez-Martín J, et al. **Gene** 1996 Jun 12;172(1):81–6

Efficiency of different viral promoters in directing gene expression in mammalian cells: effect of 3'-untranslated sequences. Rotondaro L, et al. **Gene** 1996 Feb 12; 168(2):195–8

A tightly regulated expression system in Escherichia coli with SP6 RNA polymerase. Sagawa H, et al. **Gene** 1996 Feb 2;168(1):37–41

Functional analysis of a mosquito gamma-aminobutyric acid receptor gene promoter. Shotkoski F, et al. **Gene** 1996 Feb 12;168(2):127–33

Sequence of the promoter region of the mouse gene encoding ornithine aminotransferase. Shull JD, et al. **Gene** 1995 Sep 11;162(2):275–7

pHIVTATA-CAT, a versatile vector to study transcriptional regulatory elements in mammalian cells. Thiel G, et al. **Gene** 1996 Feb 12;168(2):173–6

Regulation of tcp genes in classical and El Tor strains of Vibrio cholerae O1. Thomas S, et al. **Gene** 1995 Dec 1; 166(1):43–8

Structure and chromosomal location of the mouse medium-chain acyl-CoA dehydrogenase-encoding gene and its promoter. Tolwani RJ, et al. **Gene** 1996 May 8; 170(2):165–71

Characterization of the human XPA promoter. Topping RS, et al. **Gene** 1995 Dec 12;166(2):341–2

Mode of activation of the GC box/Sp1-dependent promoter of the human NADH-cytochrome b5 reductase-encoding gene. Toyoda A, et al. **Gene** 1995 Oct 27;164(2):351–5

cis-regulatory elements within the proximal promoter of the rat gene encoding corticosteroid-binding globulin. Underhill DA, et al. **Gene** 1995 Sep 11;162(2):205–11

Cloning and transcription factor-binding sites of the human c-rel proto-oncogene promoter. Viswanathan M, et al. **Gene** 1996 May 8;170(2):271-6

Isolation and characterization of the 5'-flanking sequence of the human ocular lens MIP gene. Wang XY, et al. **Gene** 1995 Dec 29;167(1-2):321-5

p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites. Jackson P, et al. **Gene Expr** 1995;5(1):19-33

Defective herpes simplex virus vectors for the study of promoter and gene function in the CNS. New KC, et al. **Gene Ther** 1994;1 Suppl 1:S79

A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Vile R, et al. **Gene Ther** 1994 Sep;1(5):307-16

An AAV promoter-driven neuropeptide Y gene delivery system using Sendai virosomes for neurons and rat brain. Wu P, et al. **Gene Ther** 1996 Mar;3(3):246-53

Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins. Alexandre C, et al. **Genes Dev** 1996 Aug 15;10(16):2003-13

Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-box-deficient promoters. Burke TW, et al. **Genes Dev** 1996 Mar 15;10(6):711-24

Sequence-specific DNA binding of the B-cell-specific coactivator OCA-B. Cepek, KL, et al. **Genes Dev** 1996 Aug 15;10(16):2079-88

CIF, an essential cofactor for TFIID-dependent initiator function. Kaufmann J, et al. **Genes Dev** 1996 Apr 1; 10(7):873-86

Multiprotein transcription factor UAF interacts with the upstream element of the yeast RNA polymerase I promoter and forms a stable preinitiation complex. Keys DA, et al. **Genes Dev** 1996 Apr 1;10(7):887-903

Promoter specificity mediates the independent regulation of neighboring genes. Merli C, et al. **Genes Dev** 1996 May 15;10(10):1260-70

HSF access to heat shock elements in vivo depends critically on promoter architecture defined by GAGA factor, TFIID, and RNA polymerase II binding sites. Shopland LS, et al. **Genes Dev** 1995 Nov 15;9(22):2756-69

CLN3, not positive feedback, determines the timing of CLN2 transcription in cycling cells. Stuart D, et al. **Genes Dev** 1995 Nov 15;9(22):2780-94

Nucleotide polymorphism in the 5' promoter region of esterase 6 in Drosophila melanogaster and its relationship to enzyme activity variation. Odgers WA, et al. **Genetics** 1995 Sep;141(1):215-22

Sequences required for paramutation of the maize b gene map to a region containing the promoter and upstream sequences. Patterson GI, et al. **Genetics** 1995 Aug; 140(4):1389-406

Hot spots of recombination in fission yeast: inactivation of the M26 hot spot by deletion of the ade6 promoter and the novel hotspot ura4-aim. Zahn-Zabal M, et al. **Genetics** 1995 Jun;140(2):469-78

An efficient method for isolating putative promoters and 5'-transcribed sequences from large genomic clones. Mortlock DP, et al. **Genome Res** 1996 Apr;6(4):327-35

Genomic organization and 5'-flanking DNA sequence of the murine stomatin gene (Epb72). Gallagher PG, et al. **Genomics** 1996 Jun 15;34(3):410-2

Genomic organization, promoter analysis, and chromosomal localization of the gene for the mouse glial high-affinity glutamate transporter Slc1a3. Hagiwara T, et al. **Genomics** 1996 May 1;33(3):508-15

The human TAX1 gene encoding the axon-associated cell adhesion molecule TAG-1/axonin-1: genomic structure and basic promoter. Kozlov SV, et al. **Genomics** 1995 Nov 20;30(2):141-8

Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Lamerdin JE, et al. **Genomics** 1996 Jun 15;34(3):399-409

Human gene for the large subunit of ribonucleotide reductase (RRM1): functional analysis of the promoter. Parker NJ, et al. **Genomics** 1995 May 20;27(2):280-5

Cloning and characterization of the mouse glucokinase gene locus and identification of distal liver-specific DNase I hypersensitive sites. Postic C, et al. **Genomics** 1995 Oct 10;29(3):740-50

Conservation of position and sequence of a novel, widely expressed gene containing the major human alpha-globin regulatory element. Vyas P, et al. **Genomics** 1995 Oct 10; 29(3):679-89

Genomic structure and chromosomal localization of the mouse CDEI-binding protein CDEBP (APLP2) gene and promoter sequences. Yang Y, et al. **Genomics** 1996 Jul 1; 35(1):24-9

Cytokine inhibition of the hepatitis B virus core promoter. Romero R, et al. **Hepatology** 1996 Jan;23(1):17-23

A collagen enhancer-promoter construct in transgenic mice is markedly stimulated by ethanol administration. Walton CM, et al. **Hepatology** 1996 Feb;23(2):310-5

The human insulin-like growth factor-II promoter P1 is not restricted to liver: evidence for expression of P1 in other tissues and for a homologous promoter in baboon liver. Jin IH, et al. **Horm Metab Res** 1995 Oct;27(10):447-9

Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Joki T, et al. **Hum Gene Ther** 1995 Dec;6(12):1507-13

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Pang S, et al. **Hum Gene Ther** 1995 Nov;6(11):1417-26

Evaluation of G-to-A substitution in the apolipoprotein A-I gene promoter as a determinant of high-density lipoprotein cholesterol level in subjects with and without cholesteryl ester transfer protein deficiency. Akita H, et al. **Hum Genet** 1995 Nov;96(5):521-6

A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Braun A, et al. **Hum Genet** 1996 May;97(5):688-9

Isolation and characterization of the human mismatch repair gene hMSH2 promoter region. Scherer SJ, et al. **Hum Genet** 1996 Jan;97(1):114-6

Conservation of a maternal-specific methylation signal at the human IGF2R locus. Smrzka OW, et al. **Hum Mol Genet** 1995 Oct;4(10):1945-52

A mutation (T-45C) in the promoter region of the low-density-lipoprotein (LDL)-receptor gene is associated with a mild clinical phenotype in a patient with heterozygous familial hypercholesterolaemia (FH). Sun XM, et al. **Hum Mol Genet** 1995 Nov;4(11):2125-9

A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element? Tee MK, et al. **Hum Mol Genet** 1995 Nov;4(11):2109-16

An LDL receptor promoter mutation in a heterozygous FH patient with dramatically skewed ratio between the two allelic mRNA variants. Jensen LG, et al. **Hum Mutat** 1996; 7(1):82-4

Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980-1008 (116 ref.)

Regulation of the c-fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2-4):137-42 (14 ref.)

Cloning and partial characterization of the mouse B7-1 promoter. Antonia SJ, et al. **Immunogenetics** 1996; 43(4):234-7

A polymorphic dinucleotide repeat in the human IL-10 promoter. Eskdale J, et al. **Immunogenetics** 1995; 42(5):444-5

Bop: a new T-cell-restricted gene located upstream of and opposite to mouse CD8b. Hwang I, et al. **Immunogenetics** 1995;42(5):353-61

Promoter region of mouse Tcrg genes. Ishimi Y, et al. **Immunogenetics** 1996;43(1-2):68-71

Characterization of the mouse CD8 beta chain-encoding gene promoter region. Kawachi Y, et al. **Immunogenetics** 1996;44(5):358-65

The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Lee DM, et al. **Immunogenetics** 1996;44(2):108-14

Identification of C to T mutation at position -236 bp in the human NRAMP1 gene promoter. Lewis LA, et al. **Immunogenetics** 1996;44(4):309-11

The function of the octamer-binding site in the DRA promoter. Voliva CF, et al. **Immunogenetics** 1996; 43(1-2):20-6

Molecular analysis of the promoter region of the gene encoding the beta-amyloid precursor protein. Lahiri DK. **Indian J Biochem Biophys** 1995 Dec;32(6):329-35

Cloning and characterization of mycobacteriophage I3 promoters. Ramesh G, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):361-7

Cloning and characterization of mycobacteriophage I3 promoters. Ramesh GR, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):83

Pertussis toxin export genes are regulated by the ptx promoter and may be required for efficient translation of ptx mRNA in Bordetella pertussis. Baker SM, et al. **Infect Immun** 1995 Oct;63(10):3920-6

Evidence for a CD40 response element, distinct from the IL-4 response element, in the germline epsilon promoter. Fujita K, et al. **Int Immunol** 1995 Sep;7(9):1529-33

Mutated human Kirsten ras, driven by a thyroglobulin promoter, induces a growth advantage and partially dedifferentiates rat thyroid epithelial cells in vitro. Monaco C, et al. **Int J Cancer** 1995 Nov 27;63(5):757-60

Mutations in the core promoter/enhancer II regions of naturally occurring hepatitis B virus variants and analysis of the effects on transcription activities. Nishizono A, et al. **Intervirology** 1995;38(5):290-4

An antisense promoter within the hepatitis B virus X gene. Velhagen I, et al. **Intervirology** 1995;38(3-4):127-33

Recognising promoter sequences using an artificial immune system. Cooke DE, et al. **Ismb** 1995;3:89-97

Investigations of Escherichia coli promoter sequences with artificial neural networks: new signals discovered upstream of the transcriptional startpoint. Pedersen AG, et al. **Ismb** 1995;3:292-9

Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. Dubé JY, et al. **J Androl** 1995 Jul-Aug;16(4):304-11

A study of mycobacterial transcriptional apparatus: identification of novel features in promoter elements. Bashyam MD, et al. **J Bacteriol** 1996 Aug;178(16):4847-53

Analysis of CRP-CytR interactions at the Escherichia coli udp promoter. Brikun I, et al. **J Bacteriol** 1996 Mar; 178(6):1614-22

Resection and mutagenesis of the acid pH-inducible P2 promoter of the Agrobacterium tumefaciens virG gene. Chang CH, et al. **J Bacteriol** 1996 Aug;178(15):4717-20

Transcription of the glutamyl-tRNA reductase (hemA) gene in Salmonella typhimurium and Escherichia coli: role of the hemA P1 promoter and the arcA gene product. Choi P, et al. **J Bacteriol** 1996 Feb;178(3):638-46

G1n3p is capable of binding to UAS(NTR) elements and activating transcription in Saccharomyces cerevisiae. Cunningham TS, et al. **J Bacteriol** 1996 Jun;178(12):3470-9

Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. de Ruyter PG, et al. **J Bacteriol** 1996 Jun;178(12):3434-9

Analysis of Fur binding to operator sequences within the Neisseria gonorrhoeae fbpA promoter. Desai PJ, et al. **J Bacteriol** 1996 Aug;178(16):5020-3

Functional analysis of the major outer membrane protein gene promoters of Chlamydia trachomatis. Douglas AL, et al. **J Bacteriol** 1995 Nov;177(21):6286-9

Expression from the nifB promoter of Azotobacter vinelandii can be activated by NifA, VnfA, or AnfA transcriptional activators. Drummond M, et al. **J Bacteriol** 1996 Feb; 178(3):788-92

Analysis of the spacer DNA between the cyclic AMP receptor protein binding site and the lac promoter. Flatow U, et al. **J Bacteriol** 1996 Apr;178(8):2436-9

Expression of the TOL plasmid xylS gene in Pseudomonas putida occurs from a alpha 70-dependent promoter or from alpha 70- and alpha 54-dependent tandem promoters according to the compound used for growth. Gallegos MT, et al. **J Bacteriol** 1996 Apr;178(8):2356-61

In vitro binding of the Salmonella dublin virulence plasmid regulatory protein SpvR to the promoter regions of spvA and spvR. Grob P, et al. **J Bacteriol** 1996 Apr; 178(7):1813-20

Genetic analysis of the interaction between Vibrio cholerae transcription activator ToxR and toxT promoter DNA. Higgins DE, et al. **J Bacteriol** 1996 Feb;178(4):1080-7

Characterization of a late promoter from the Streptomyces temperate phage phi C31. Howe CW, et al. **J Bacteriol** 1996 Apr;178(7):2127-30

Regulatory factors acting at the bacteriophage Mu middle promoter. Kahmeyer-Gabbe M, et al. **J Bacteriol** 1996 Mar; 178(6):1585-92

Promoter analysis of the Xanthomonas campestris pv. campestris gum operon directing biosynthesis of the xanthan polysaccharide. Katzen F, et al. **J Bacteriol** 1996 Jul;178(14):4313-8

Genetic analysis of the Mycobacterium smegmatis rpsL promoter. Kenney TJ, et al. **J Bacteriol** 1996 Jun; 178(12):3564-71

Promoters controlling expression of the alternative nitrogenase and the molybdenum uptake system in Rhodobacter capsulatus are activated by NtrC, independent of sigma54, and repressed by molybdenum. Kutsche M, et al. **J Bacteriol** 1996 Apr;178(7):2010-7

The complex bet promoters of Escherichia coli: regulation by oxygen (ArcA), choline (BetI), and osmotic stress. Lamark T, et al. **J Bacteriol** 1996 Mar;178(6):1655-62

Role of curved DNA in binding of Escherichia coli RNA polymerase to promoters. Nickerson CA, et al. **J Bacteriol** 1995 Oct;177(20):5756-61

The binding site of the IclR repressor protein overlaps the promoter of aceBAK. Pan B, et al. **J Bacteriol** 1996 Jul; 178(13):3982-4

Transcriptional regulation of the Bacillus subtilis menp1 promoter. Qin X, et al. **J Bacteriol** 1996 Feb;178(3):705-13

Effects of H-NS and potassium glutamate on sigmaS- and sigma70-directed transcription in vitro from osmotically regulated P1 and P2 promoters of proU in Escherichia coli. Rajkumari K, et al. **J Bacteriol** 1996 Jul;178(14):4176-81

In vitro analysis of the interactions between the PocR regulatory protein and the promoter region of the cobalamin biosynthetic (cob) operon of Salmonella typhimurium LT2. Rondon MR, et al. **J Bacteriol** 1996 Apr;178(8):2196-203

Delineation of AbrB-binding sites on the Bacillus subtilis spo0H, kinB, ftsAZ, and pbpE promoters and use of a derived homology to identify a previously unsuspected binding site in the bsuB1 methylase promote. Strauch MA. **J Bacteriol** 1995 Dec;177(23):6999-7002

Growth phase-dependent transcription of the sigma(54)-dependent Po promoter controlling the Pseudomonas-derived (methyl)phenol dmp operon of pVI150. Sze CC, et al. **J Bacteriol** 1996 Jul;178(13):3727-35

sigma E changed to sigma B specificity by amino acid substitutions in its -10 binding region. Tatti KM, et al. **J Bacteriol** 1995 Nov;177(22):6506-9

Regulatory proteins and cis-acting elements involved in the transcriptional control of Rhizobium etli reiterated nifH genes. Valderrama B, et al. **J Bacteriol** 1996 Jun; 178(11):3119-26

Spacing requirements for transcription activation by Escherichia coli FNR protein. Wing HJ, et al. **J Bacteriol** 1995 Dec;177(23):6704-10

Sequences in the -35 region of Escherichia coli rpoS-dependent genes promote transcription by E sigma S. Wise A, et al. **J Bacteriol** 1996 May;178(10):2785-93

Genetic and topological analyses of the bop promoter of

Halobacterium halobium: stimulation by DNA supercoiling and non-B-DNA structure. Yang CF, et al. **J Bacteriol** 1996 Feb;178(3):840-5

Site-directed mutational analysis of the osmotically regulated proU promoter of Salmonella typhimurium. Zhang X, et al. **J Bacteriol** 1996 Jun;178(11):3377-9

Structure modification induced in the narG promoter by binding of integration host factor and NARL-P. Zhang X, et al. **J Bacteriol** 1996 Jul;178(13):3971-3

Activation of smooth muscle alpha-actin promoter in ras-transformed cells by treatments with antimitotic agents: correlation with stimulation of SRF:SRE mediated gene transcription. Kumar CC, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1285-92

Expression of rat cathepsin D cDNA in Saccharomyces cerevisiae: implications for intracellular targeting of cathepsin D to vacuoles. Nishimura Y, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):168-77

Structure and promoter analysis of the cytochrome P-450 aromatase gene of the teleost fish, medaka (Oryzias latipes). Tanaka M, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):719-25

Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decarboxylase gene is regulated by hepatocyte nuclear factor 1. Aguanno A, et al. **J Biol Chem** 1996 Feb 23;271(8):4528-38

Promoter structure and transcriptional activation of the murine TSG-14 gene encoding a tumor necrosis factor/interleukin-1-inducible pentraxin protein. Altmeyer A, et al. **J Biol Chem** 1995 Oct 27;270(43):25584-90

Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. Armesilla AL, et al. **J Biol Chem** 1996 Mar 29;271(13):7781-7

Characterization of the promoter region of the human transforming growth factor-beta type II receptor gene. Bae HW, et al. **J Biol Chem** 1995 Dec 8;270(49):29460-8

Multiple Sp1 binding sites in the cardiac/slow twitch muscle sarcoplasmic reticulum Ca2+-ATPase gene promoter are required for expression in Sol8 muscle cells. Baker DL, et al. **J Biol Chem** 1996 Mar 8;271(10):5921-8

Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. Balbín M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15175-81

Multiple promoters regulate tissue-specific expression of the human NPY-Y1 receptor gene. Ball HJ, et al. **J Biol Chem** 1995 Nov 10;270(45):27272-6

Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. Bastian LS, et al. **J Biol Chem** 1996 Aug 2;271(31):18554-60

Characterization of the Xenopus rhodopsin gene. Batni S, et al. **J Biol Chem** 1996 Feb 9;271(6):3179-86

Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. Bennett MK, et al. **J Biol Chem** 1995 Oct 27;270(43):25578-83

Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters. Berthelsen J, et al. **J Biol Chem** 1996 Feb 16;271(7):3822-30

Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. Bierhaus A, et al. **J Biol Chem** 1995 Nov 3;270(44):26419-32

Interaction of mtTFB and mtRNA polymerase at core promoters for transcription of Xenopus laevis mtDNA. Bogenhagen DF. **J Biol Chem** 1996 May 17; 271(20):12036-41

Repression of I-A beta gene expression by the transcription factor PU.1. Borràs FE, et al. **J Biol Chem** 1995 Oct 13; 270(41):24385-91

Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. Bosserhoff AK, et al. **J Biol Chem** 1996 Jan 5;271(1):490-5

Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. Boudreaux JM, et al. **J Biol Chem** 1996 Mar 29;271(13):7508-15

Determining the requirements for cooperative DNA binding by Swi5p and Pho2p (Grf10p/Bas2p) at the HO promoter. Brazas RM, et al. **J Biol Chem** 1995 Dec 8;270(49):29151-61

Functional analysis of the human cyclin D2 and cyclin D3 promoters. Brooks AR, et al. **J Biol Chem** 1996 Apr 12; 271(15):9090-9

The different activities of the two activation domains of the Brn-3a transcription factor are dependent on the context of the binding site. Budhram-Mahadeo V, et al. **J Biol Chem** 1996 Apr 12;271(15):9108-13

Competition for a unique response element mediates retinoic acid inhibition of vitamin D3-stimulated transcription. Cao X, et al. **J Biol Chem** 1996 Aug 23;271(34):20650-4

Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. Cervini R, et al. **J Biol Chem** 1995 Oct 20; 270(42):24654-7

Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor. Chandran UR, et al. **J Biol Chem** 1996 Aug 23;271(34):20412-20

Different regulation of the human thymidine kinase promoter in normal human diploid IMR-90 fibroblasts and HeLa cells. Chang ZF, et al. **J Biol Chem** 1995 Nov 10; 270(45):27374-9

Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain. Charron G, et al. **J Biol Chem** 1995 Dec 22;270(51):30604-10

SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. Chen H, et al. **J Biol Chem** 1996 Jun 14;271(24):13959-67

Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. Chen H, et al. **J Biol Chem** 1996 Jun 28;271(26):15743-52

An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. Chung KY, et al. **J Biol Chem** 1996 Feb 9;271(6):3272-8

The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. Claessens F, et al. **J Biol Chem** 1996 Aug 9;271(32):19013-6

Promoter sequences in the R1 beta subunit gene of cAMP-dependent protein kinase required for transgene expression in mouse brain. Clegg CH, et al. **J Biol Chem** 1996 Jan 19;271(3):1638-44

Identification of sequences which regulate the expression of Drosophila melanogaster Doc elements. Contursi C, et al. **J Biol Chem** 1995 Nov 3;270(44):26570-6

The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit. Coustry F, et al. **J Biol Chem** 1996 Jun 14;271(24):14485-91

Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter. Daniel S, et al. **J Biol Chem** 1996 Jan 19;271(3):1385-92

Characterization of the complete genomic structure of the human WNT-5A gene, functional analysis of its promoter, chromosomal mapping, and expression in early human embryogenesis. Danielson KG, et al. **J Biol Chem** 1995 Dec 29;270(52):31225-34

Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. Datto MB, et al. **J Biol Chem** 1995 Dec 1;270(48):28623-8

Redundant domains contribute to the transcriptional activity of the thyroid transcription factor 1. De Felice M, et al. **J Biol Chem** 1995 Nov 3;270(44):26649-56

Sp3 represses transcription when tethered to promoter DNA or targeted to promoter proximal RNA. De Luca P, et al. **J Biol Chem** 1996 Apr 12;271(15):8533-6

DNA binding by the coliphage 186 repressor protein CI. Dodd IB, et al. **J Biol Chem** 1996 May 10;271(19):11532-40

Identification of a TAAT-containing motif required for high level expression of the COL1A1 promoter in differentiated osteoblasts of transgenic mice. Dodig M, et al. **J Biol Chem** 1996 Jul 5;271(27):16422-9

Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor epsilon-subunit gene. Duclert A, et al. **J Biol Chem** 1996 Jul 19; 271(29):17433-8

Multiple proteins interact with the nuclear inhibitory protein repressor element in the human interleukin-3 promoter. Engeland K, et al. **J Biol Chem** 1995 Oct 13; 270(41):24572-9

Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter. Erdmann D, et al. **J Biol Chem** 1995 Sep 29;270(39):22988-96

The c-Jun delta-domain inhibits neuroendocrine promoter activity in a DNA sequence- and pituitary-specific manner. Farrow KN, et al. **J Biol Chem** 1996 Jul 19; 271(29):17139-46

The mouse bone morphogenetic protein-4 gene. Analysis of promoter utilization in fetal rat calvarial osteoblasts and regulation by COUP-TFI orphan receptor. Feng JQ, et al. **J Biol Chem** 1995 Nov 24;270(47):28364-73

Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors. Feng XH, et al. **J Biol Chem** 1995 Oct 13;270(41):24237-45

Role of a proximal NF-Y binding promoter element in S phase-specific expression of mouse ribonucleotide reductase R2 gene. Filatov D, et al. **J Biol Chem** 1995 Oct 20;270(42):25239-43

Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene. Identification of multiple transcription units. Furukawa K, et al. **J Biol Chem** 1996 Aug 23;271(34):20836-44

Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. Gächter T, et al. **J Biol Chem** 1996 Jan 5; 271(1):124-9

c-Krox binds to several sites in the promoter of both mouse type I collagen genes. Structure/function study and developmental expression analysis. Galéra P, et al. **J Biol Chem** 1996 Aug 30;271(35):21331-9

Cloning and characterization of the promoter for a potassium channel expressed in high frequency firing neurons. Gan L, et al. **J Biol Chem** 1996 Mar 8;271(10):5859-65

Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site. Gately DP, et al. **J Biol Chem** 1996 Aug 23; 271(34):20588-93

The GA-binding protein can serve as both an activator and repressor of ribosomal protein gene transcription. Genuario RR, et al. **J Biol Chem** 1996 Feb 23;271(8):4388-95

A PEBP2 alpha/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. Geoffroy V, et al. **J Biol Chem** 1995 Dec 29;270(52):30973-9

Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16. Ghosh S, et al. **J Biol Chem** 1996 Apr 26; 271(17):9911-8

Genomic structure and promoter analysis of the human obese gene. Gong DW, et al. **J Biol Chem** 1996 Feb 23; 271(8):3971-4

The Spo0A protein of Bacillus subtilis inhibits transcription of the abrB gene without preventing binding of the polymerase to the promoter. Greene EA, et al. **J Biol Chem** 1996 May 10;271(19):11455-61

Lipopolysaccharide induction of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the tissue factor promoter. Groupp ER, et al. **J Biol Chem** 1996 May 24; 271(21):12423-30

Regulation of gene expression by cGMP-dependent protein kinase. Transactivation of the c-fos promoter. Gudi T, et al. **J Biol Chem** 1996 Mar 1;271(9):4597-600

Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. Gum R, et al. **J Biol Chem** 1996 May 3;271(18):10672-80

Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. Gustafson KS, et al. **J Biol Chem** 1996 Aug 16;271(33):20035-46

Stimulation of luteinizing hormone beta gene promoter activity by the orphan nuclear receptor, steroidogenic factor-1. Halvorson LM, et al. **J Biol Chem** 1996 Mar 22; 271(12):6645-50

Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. Hashimoto Y, et al. **J Biol Chem** 1995 Oct 13; 270(41):24532-9

Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. Haugen BR, et al. **J Biol Chem** 1996 Jan 5; 271(1):385-9

The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha. He Y, et al. **J Biol Chem** 1995 Dec 1; 270(48):28887-91

Different composite regulatory elements direct expression of the human alpha subunit gene to pituitary and placenta. Heckert LL, et al. **J Biol Chem** 1995 Nov 3; 270(44):26497-504

Differential activation of lung-specific genes by two forkhead proteins, FREAC-1 and FREAC-2. Hellqvist M, et al. **J Biol Chem** 1996 Feb 23;271(8):4482-90

A conserved domain of the viviparous-1 gene product enhances the DNA binding activity of the bZIP protein EmBP-1 and other transcription factors. Hill A, et al. **J Biol Chem** 1996 Feb 16;271(7):3366-74

Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. Honkakoski P, et al. **J Biol Chem** 1996 Apr 19;271(16):9746-53

The chicken beta-globin gene promoter forms a novel "cinched" tetrahelical structure. Howell RM, et al. **J Biol Chem** 1996 Mar 1;271(9):5208-14

Human fatty-acid synthase gene. Evidence for the presence of two promoters and their functional interaction. Hsu MH, et al. **J Biol Chem** 1996 Jun 7;271(23):13584-92

Characterization of the 5'-flanking region of the gene for the alpha chain of human fibrinogen. Hu CH, et al. **J Biol Chem** 1995 Nov 24;270(47):28342-9

Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. Hu JF, et al. **J Biol Chem** 1996 Jul 26;271(30):18253-62

Multiple and tissue-specific promoter control of gonadal and non-gonadal prolactin receptor gene expression. Hu Z, et al. **J Biol Chem** 1996 Apr 26;271(17):10242-6

Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. Hughes CC, et al. **J Biol Chem** 1996 Mar 8; 271(10):5369-77

Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. Hung HL, et al. **J Biol Chem** 1996 Jan 26;271(4):2323-31

Cell cycle-dependent regulation of the cyclin B1 promoter. Hwang A, et al. **J Biol Chem** 1995 Nov 24;270(47):28419-24

Cloning and kidney cell-specific activity of the promoter of the murine renal Na-K-C1 cotransporter gene. Igarashi P, et al. **J Biol Chem** 1996 Apr 19;271(16):9666-74

A conserved downstream element defines a new class of RNA polymerase II promoters. Ince TA, et al. **J Biol Chem** 1995 Dec 22;270(51):30249-52

Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells. Isaacs RJ, et al. **J Biol Chem** 1996 Jul 12;271(28):16741-7

Genomic organization and promoter function of the human thyrotropin-releasing hormone receptor gene. Iwasaki T, et al. **J Biol Chem** 1996 Sep 6;271(36):22183-8

An NF1-like protein functions as a repressor of the von

Willebrand factor promoter. Jahroudi N, et al. J Biol Chem 1996 Aug 30;271(35):21413–21

Cloning, sequencing, and regulation of the glutathione reductase gene from the cyanobacterium Anabaena PCC 7120. Jiang F, et al. J Biol Chem 1995 Sep 29; 270(39):22882–9

Abortive initiation and first bond formation at an activated adenovirus E4 promoter. Jiang Y, et al. J Biol Chem 1995 Nov 10;270(45):27332–8

A mutant RNA polymerase reveals a kinetic mechanism for the switch between nonproductive stuttering synthesis and productive initiation during promoter clearance. Jin DJ. J Biol Chem 1996 May 17;271(20):11659–67

The TATA-less promoter of mouse ribonucleotide reductase R1 gene contains a TFII-I binding initiator element essential for cell cycle-regulated transcription. Johansson E, et al. J Biol Chem 1995 Dec 15;270(50):30162–7

Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promotor. Kang SH, et al. J Biol Chem 1996 Mar 29;271(13):7330–5

A steroidogenic factor-1 binding site is required for activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic mice. Keri RA, et al. J Biol Chem 1996 May 3;271(18):10782–5

Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. Khachigian LM, et al. J Biol Chem 1995 Nov 17;270(46):27679–86

A negative cofactor containing Dr1/p19 modulates transcription with TFIIA in a promoter-specific fashion. Kim J, et al. J Biol Chem 1996 Aug 2;271(31):18405–12

Oct-1 protein promotes functional transcription complex assembly on the mouse mammary tumor virus promoter. Kim MH, et al. J Biol Chem 1995 Nov 17;270(46):27823–8

Triple helix-forming oligonucleotide corresponding to the polypyrimidine sequence in the rat alpha 1(I) collagen promoter specifically inhibits factor binding and transcription. Kovacs A, et al. J Biol Chem 1996 Jan 19; 271(3):1805–12

Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter. Kovarik A, et al. J Biol Chem 1996 Jul 26;271(30):18140–7

Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells. Kraft HJ, et al. J Biol Chem 1996 May 31;271(22):12873–8

Identification and characterization of 1,25-dihydroxyvitamin D3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene. Kremer R, et al. J Biol Chem 1996 Jul 5;271(27):16310–6

Differential appearance of DNase I-hypersensitive sites correlates with differential transcription of Pgk genes during spermatogenesis in the mouse. Kumari M, et al. J Biol Chem 1996 Jun 14;271(24):14390–7

Promoter selectivity of Escherichia coli RNA polymerase E sigma 70 and E sigma 38 holoenzymes. Effect of DNA supercoiling. Kusano S, et al. J Biol Chem 1996 Jan 26; 271(4):1998–2004

Promoter analysis of Zfp-36, the mitogen-inducible gene encoding the zinc finger protein tristetraprolin. Lai WS, et al. J Biol Chem 1995 Oct 20;270(42):25266–72

X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter. Lee H, et al. J Biol Chem 1995 Dec 29;270(52):31405–12

Suppression of gene expression on the simian virus 40 major late promoter by human TR4 orphan receptor. A member of the steroid receptor superfamily. Lee HJ, et al. J Biol Chem 1995 Dec 15;270(50):30129–33

The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element. Lee JH, et al. J Biol Chem 1996 Feb 23;271(8):4561–8

Cellular factors binding to a novel cis-acting element mediate steroid hormone responsiveness of mouse mammary tumor virus promoter. Lee KI, et al. J Biol Chem 1995 Oct 13; 270(41):24502–8

Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. Lengyel E, et al. J Biol Chem 1995 Sep 29; 270(39):23007–12

The human medium chain acyl-CoA dehydrogenase gene promoter consists of a complex arrangement of nuclear receptor response elements and Sp1 binding sites. Leone TC, et al. J Biol Chem 1995 Oct 13;270(41):24622

A functional initiator element in the human beta-globin promoter. Lewis BA, et al. J Biol Chem 1995 Nov 24; 270(47):28139–44

Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene. Li R, et al. J Biol Chem 1996 Aug 2;271(31):18925–30

ATF3 gene. Genomic organization, promoter, and regulation. Liang G, et al. J Biol Chem 1996 Jan 19; 271(3):1695–701

Expression of a Drosophila GATA transcription factor in multiple tissues in the developing embryos. Identification of homozygous lethal mutants with P-element insertion at the promoter region. Lin WH, et al. J Biol Chem 1995 Oct 20;270(42):25150–8

Transcription of the blk gene in human B lymphocytes is controlled by two promoters. Lin YH, et al. J Biol Chem 1995 Oct 27;270(43):25968–75

The ability of the inhibitory domain of the POU family transcription factor Oct-2 to interfere with promoter activation by different classes of activation domains is dependent upon the nature of the basal promoter elements. Liu YZ, et al. J Biol Chem 1996 Aug 23;271(34):20853–60

Transcriptional modulators affect in vivo protein binding to the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase promoters. Lloyd DB, et al. J Biol Chem 1995 Oct 27; 270(43):25812–8

Tissue-specific regulation of the type X collagen gene. Analyses by in vivo footprinting and transfection with a proximal promoter region. Long F, et al. J Biol Chem 1995 Dec 29;270(52):31310–4

Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. Ludlow LB, et al. J Biol Chem 1996 Sep 6;271(36):22076–80

CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91phox promoter. Luo W, et al. J Biol Chem 1996 Jul 26;271(30):18203–10

Negative regulatory element involved in the hormonal regulation of GlcNAc-1-P transferase gene in mouse mammary gland. Ma J, et al. J Biol Chem 1996 May 10; 271(19):11197–203

Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. McCarthy TL, et al. J Biol Chem 1996 Mar 22; 271(12):6666–71

The Pem homeobox gene. Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing. Maiti S, et al. J Biol Chem 1996 Jul 19; 271(29):17536–46

p53 stimulates promoter activity of the sgk. serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. Maiyar AC, et al. J Biol Chem 1996 May 24;271(21):12414–22

TFII is required for transcription of the naturally TATA-less but initiator-containing Vbeta promoter. Manzano-Winkler B, et al. J Biol Chem 1996 May 17; 271(20):12076–81

B-Myb expression in vascular smooth muscle cells occurs in a cell cycle-dependent fashion and down-regulates promoter activity of type I collagen genes. Marhamati DJ, et al. J Biol Chem 1996 Feb 16;271(7):3359–65

Keratinocyte transglutaminase promoter analysis. Identification of a functional response element. Mariniello L, et al. J Biol Chem 1995 Dec 29;270(52):31358–63

Tissue-specific activity of the gammac chain gene promoter depends upon an Ets binding site and is regulated by GA-binding protein. Markiewicz S, et al. J Biol Chem 1996 Jun 21;271(25):14849–55

Promoter region of the rat m4 muscarinic acetylcholine receptor gene contains a cell type-specific silencer element. Mieda M, et al. J Biol Chem 1996 Mar 1;271(9):5177–82

Interference of PR-bound RNA polymerase with open complex formation at PRM is relieved by a 10-base pair deletion between the two promoters. Mita BC, et al. J Biol Chem 1995 Dec 22;270(51):30428–33

Characterization of the 5'-flanking region of the gene for the gamma chain of human fibrinogen. Mizuguchi J, et al. J Biol Chem 1995 Nov 24;270(47):28350–6

Functional characterization of the transcription silencer element located within the human Pi class glutathione S-transferase promoter. Moffat GJ, et al. J Biol Chem 1996 Aug 23;271(34):20740–7

GH3 cell-specific expression of Kv1.5 gene. Regulation by a silencer containing a dinucleotide repetitive element. Mori Y, et al. J Biol Chem 1995 Nov 17;270(46):27788–96

A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. Morishita K, et al. J Biol Chem 1995 Nov 17; 270(46):27948–53

Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. Morooka H, et al. J Biol Chem 1995 Dec 15;270(50):30084–92

An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. Morris JK, et al. J Biol Chem 1996 Jul 12;271(28):16633–43

Identification of a novel repressive element in the proximal lck promoter. Muise-Helmericks RC, et al. J Biol Chem 1995 Nov 17;270(46):27538–43

Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. Mukhopadhyay K, et al. J Biol Chem 1995 Nov 17;270(46):27711–9

Identification of a negative cis-regulatory element and trans-acting protein that inhibit transcription of the angiotensin II type 1a receptor gene. Murasawa S, et al. J Biol Chem 1995 Oct 13;270(41):24282–6

Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. Nagy L, et al. J Biol Chem 1996 Feb 23;271(8):4355–65

Cloning and characterization of a functional promoter of the rat pp120 gene, encoding a substrate of the insulin receptor tyrosine kinase. Najjar SM, et al. J Biol Chem 1996 Apr 12;271(15):8809–17

Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. Neish AS, et al. J Biol Chem 1995 Dec 1;270(48):28903–9

Potential for H-DNA in the human MUC1 mucin gene promoter. Nelson KL, et al. J Biol Chem 1996 Jul 26; 271(30):18061–7

Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene. Ng SW, et al. J Biol Chem 1995 Oct 27;270(43):25850–8

Function of the human insulin promoter in primary cultured islet cells. Odagiri H, et al. J Biol Chem 1996 Jan 26; 271(4):1909–15

Transcriptional regulation of the human GLUT4 gene promoter in diabetic transgenic mice. Olson AL, et al. J Biol Chem 1995 Oct 6;270(40):23491–5

CCAAT/enhancer-binding proteins alpha and beta interact with the silencer element in the promoter of glutathione S-transferase P gene during hepatocarcinogenesis. Osada S, et al. J Biol Chem 1995 Dec 29;270(52):31288–93

Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat hexokinase II gene. Osawa H, et al. J Biol Chem 1996 Jul 19; 271(29):17296–303

Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-kappa B/Rel family. Pan J, et al. J Biol Chem 1995 Sep 29; 270(39):23077–83

Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. Paradis P, et al. J Biol Chem 1996 May 3; 271(18):10827–33

Effects of integration host factor and DNA supercoiling on transcription from the ilvPG promoter of Escherichia coli. Parekh BS, et al. J Biol Chem 1996 Aug 23; 271(34):20258–64

The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. Parks CL, et al. J Biol Chem 1996 Feb 23;271(8):4417–30

Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. Patterson C, et al. J Biol Chem 1995 Sep 29; 270(39):23111–8

Identification of a negative glucocorticoid response element in the rat type 1 vasoactive intestinal polypeptide receptor gene. Pei L. J Biol Chem 1996 Aug 23;271(34):20879–84

The human synapsin II gene promoter. Possible role for the transcription factor zif268/egr-1, polyoma enhancer activator 3, and AP2. Petersohn D, et al. J Biol Chem 1995 Oct 13;270(41):24361–9

An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. Piedrafita FJ, et al. J Biol Chem 1996 Jun 14; 271(24):14412–20

Functional characterization of the human factor VII 5'-flanking region. Pollak ES, et al. J Biol Chem 1996 Jan 19;271(3):1738–47

Formation of a combined H-DNA/open TATA box structure in the promoter sequence of the human Na,K-ATPase alpha2 gene. Potaman VN, et al. J Biol Chem 1996 Jun 7;271(23):13441–7

The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta-protein precursor promoter. Quitschke WW, et al. J Biol Chem 1996 Sep 6;271(36):22231–9

Transcriptional regulation of murine beta1,4-galactosyltransferase in somatic cells. Analysis of a gene that serves both a housekeeping and a mammary gland-specific function. Rajput B, et al. J Biol Chem 1996 Mar 1;271(9):5131–42

Identification of an inverted CCAAT box motif in the fatty-acid synthase gene as an essential element for modification of transcriptional regulation by cAMP. Rangan VS, et al. J Biol Chem 1996 Jan 26;271(4):2307–12

The transcriptional effect of WT1 is modulated by choice of expression vector. Reddy JC, et al. J Biol Chem 1995 Dec 15;270(50):29976–82

Expression of human squamous cell differentiation marker, SPR1, in tracheobronchial epithelium depends on JUN and TRE motifs. Reddy SP, et al. J Biol Chem 1995 Nov 3; 270(44):26451–9

Protein kinase C isozymes differentially regulate promoters containing PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs. Reifel-Miller AE, et al. J Biol Chem 1996 Aug 30;271(35):21666–71

Mechanism of metallothionein gene regulation by heme-hemopexin. Roles of protein kinase C, reactive oxygen species, and cis-acting elements. Ren Y, et al. J Biol Chem 1995 Oct 13;270(41):23988–95

Localization of subunits of transcription factors IIE and IIF immediately upstream of the transcriptional initiation site of the adenovirus major late promoter. Robert F, et al. J Biol Chem 1996 Apr 12;271(15):8517–20

A GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes. Implication In the overactivity of FAS promoter in obese Zucker rats. Rolland V, et al. J Biol Chem 1996 Aug 30; 271(35):21297–302

Interactions between the repressor and the early operator region of bacteriophage Mu. Rousseau P, et al. **J Biol Chem** 1996 Apr 19;271(16):9739–45

Hormonally regulated double- and single-stranded DNA-binding complexes involved in mouse beta-casein gene transcription. Saito H, et al. **J Biol Chem** 1996 Apr 12;271(15):8911–8

Interactions of a transcriptional activator in the env gene of the mouse mammary tumor virus with activation-dependent, T cell-specific transacting factors. Sambasivarao D, et al. **J Biol Chem** 1996 Apr 12; 271(15):8942–50

Functional analyses of the human metallothionein-IG gene. In vitro and in vivo studies. Samson SL, et al. **J Biol Chem** 1995 Oct 20;270(42):25194–9

Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. Santee SM, et al. **J Biol Chem** 1996 Aug 30;271(35):21151–9

Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter. Scarpati EM, et al. **J Biol Chem** 1996 Feb 9;271(6):3025–32

CCAAT/enhancer-binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GHFT1-5 cells. Schaufele F. **J Biol Chem** 1996 Aug 30; 271(35):21484–9

Regulation of tissue-specific expression of the skeletal muscle ryanodine receptor gene. Schmoelzl S, et al. **J Biol Chem** 1996 Mar 1;271(9):4763–9

Neuron-specific gene expression of synapsin I. Major role of a negative regulatory mechanism. Schoch S, et al. **J Biol Chem** 1996 Feb 9;271(6):3317–23

Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. They also bind COUP-TF homodimers. Schräder M, et al. **J Biol Chem** 1996 Aug 16;271(33):19732–6

The human gp39 promoter. Two distinct nuclear factors of activated T cell protein-binding elements contribute independently to transcriptional activation. Schubert LA, et al. **J Biol Chem** 1995 Dec 15;270(50):29624–7

Cytochrome c oxidase subunit VIIa liver isoform. Characterization and identification of promoter elements in the bovine gene. Seelan RS, et al. **J Biol Chem** 1996 Jan 26;271(4):2112–20

Differential regulation of vitronectin in mice and humans in vitro. Seiffert D, et al. **J Biol Chem** 1996 Mar 8; 271(10):5474–80

Tissue-specific expression and dietary regulation of chimeric mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase/human growth hormone gene in transgenic mice. Serra D, et al. **J Biol Chem** 1996 Mar 29;271(13):7529–34

Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF. Sharma S, et al. **J Biol Chem** 1996 Jan 26;271(4):2294–9

Characterization of the human cyclin-dependent kinase 2 gene. Promoter analysis and gene structure. Shiffman D, et al. **J Biol Chem** 1996 May 24;271(21):12199–204

The N-terminal region of E2F-1 is required for transcriptional activation of a new class of target promoter. Shin EK, et al. **J Biol Chem** 1996 May 24;271(21):12261–8

Activation of the interleukin-5 promoter by cAMP in murine EL-4 cells requires the GATA-3 and CLE0 elements. Siegel MD, et al. **J Biol Chem** 1995 Oct 13; 270(41):24548–55

Cloning of the gene for human pemphigus vulgaris antigen (desmoglein 3), a desmosomal cadherin. Characterization of the promoter region and identification of a keratinocyte-specific cis-element. Silos SA, et al. **J Biol Chem** 1996 Jul 19;271(29):17504–11

Hormonal and nutritional control of the fatty acid synthase promoter in transgenic mice. Soncini M, et al. **J Biol Chem** 1995 Dec 22;270(51):30339–43

Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Spek CA, et al. **J Biol Chem** 1995 Oct 13;270(41):24216–21

The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-kappa B. Spink J, et al. **J Biol Chem** 1995 Dec 8;270(49):29541–7

Genomic structure and expression of the human gene encoding cytochrome b561, an integral protein of the chromaffin granule membrane. Srivastava M. **J Biol Chem** 1995 Sep 29;270(39):22714–20

SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. Streicher R, et al. **J Biol Chem** 1996 Mar 22; 271(12):7128–33

Activation of a nuclear DNA-binding protein recognized by a transcriptional element, bcn-1, from the laminin B2 chain gene promoter. Suzuki H, et al. **J Biol Chem** 1996 Aug 2;271(31):18981–8

DNA replication-related elements cooperate to enhance promoter activity of the drosophila DNA polymerase alpha 73-kDa subunit gene. Takahashi Y, et al. **J Biol Chem** 1996 Jun 14;271(24):14541–7

Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3. Taylor DS, et al. **J Biol Chem** 1996 Jun 14;271(24):14020–7

Enhanced expression of the eosinophil-derived neurotoxin ribonuclease (RNS2) gene requires interaction between the promoter and intron. Tiffany HL, et al. **J Biol Chem** 1996 May 24;271(21):12387–93

Abortive cycling and the release of polymerase for elongation at the sigma 54-dependent glnAp2 promoter. Tintut Y, et al. **J Biol Chem** 1995 Oct 13;270(41):24392–8

c-sis/PDGF-B promoter transactivation by the Yax protein of human T-cell leukemia virus type 1. Trejo SR, et al. **J Biol Chem** 1996 Jun 14;271(24):14584–90

The genomic structure of the rat corticotropin releasing factor receptor. A member of the class II G protein-coupled receptors. Tsai-Morris CH, et al. **J Biol Chem** 1996 Jun 14;271(24):14519–25

The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. Tsytsykova AV, et al. **J Biol Chem** 1996 Feb 16;271(7):3763–70

Cataractogenesis in transgenic mice containing the HIV-1 protease linked to the lens alpha A-crystallin promoter. Tumminia SJ, et al. **J Biol Chem** 1996 Jan 5;271(1):425–31

Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors. Tzameli I, et al. **J Biol Chem** 1996 Apr 5;271(14):8402–15

Characterization of cis-acting elements of the gene for macrophage-stimulating protein from the human. The involvement of positive and negative regulatory elements. Ueda A, et al. **J Biol Chem** 1996 Aug 23;271(34):20265–72

Transcriptional regulation of the human biglycan gene. Ungefroren H, et al. **J Biol Chem** 1996 Jun 28; 271(26):15787–95

Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. Varanasi U, et al. **J Biol Chem** 1996 Jan 26;271(4):2147–55

Functional characterization of mouse syndecan-1 promoter. Vihinen T, et al. **J Biol Chem** 1996 May 24; 271(21):12532–41

Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor. Vu TH, et al. **J Biol Chem** 1996 Apr 12;271(15):9014–23

Upstream stimulatory factors bind to insulin response sequence of the fatty acid synthase promoter. USF1 is regulated. Wang D, et al. **J Biol Chem** 1995 Dec 1; 270(48):28716–22

Three N-terminal variants of the AE2 Cl-/HCO3- exchanger are encoded by mRNAs transcribed from alternative promoters. Wang Z, et al. **J Biol Chem** 1996 Mar 29;271(13):7835–43

Purification and stabilization of transcriptionally active glucocorticoid receptor. Warren BS, et al. **J Biol Chem** 1996 May 10;271(19):11434–40

JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Watanabe S, et al. **J Biol Chem** 1996 May 24;271(21):12681–6

Promoter and upstream regulatory activities of the mouse cellular retinoic acid-binding protein-I gene. Wei LN, et al. **J Biol Chem** 1996 Mar 1;271(9):5073–8

Regulation of human involucrin promoter activity by POU domain proteins. Welter JF, et al. **J Biol Chem** 1996 Jun 21;271(25):14727–33

Identification of promoter elements involved in cell-specific regulation of rat smooth muscle myosin heavy chain gene transcription. White SL, et al. **J Biol Chem** 1996 Jun 21; 271(25):15008–17

Polymerization of microtubule-associated protein tau under near-physiological conditions. Wilson DM, et al. **J Biol Chem** 1995 Oct 13;270(41):24306–14

Structure of the m4 cholinergic muscarinic receptor gene and its promoter. Wood IC, et al. **J Biol Chem** 1995 Dec 29;270(52):30933–40

Neural specific expression of the m4 muscarinic acetylcholine receptor gene is mediated by a RE1/NRSE-type silencing element. Wood IC, et al. **J Biol Chem** 1996 Jun 14; 271(24):14221–5

Characterization of a polypyrimidine/polypurine tract in the promoter of the gene for chicken malic enzyme. Xu G, et al. **J Biol Chem** 1996 Jul 5;271(27):16008–19

Analysis of abrB mutations, mutant proteins, and why abrB does not utilize a perfect consensus in the -35 region of its sigma A promoter. Xu K, et al. **J Biol Chem** 1996 Feb 2;271(5):2621–6

Essential role of E2F recognition sites in regulation of the proliferating cell nuclear antigen gene promoter during Drosophila development. Yamaguchi M, et al. **J Biol Chem** 1995 Oct 20;270(42):25159–65

Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. Yang N, et al. **J Biol Chem** 1996 Mar 8; 271(10):5795–804

Regulation of Na+/H+ exchanger gene expression. Role of a novel poly(dA.dT) element in regulation of the NHE1 promoter. Yang W, et al. **J Biol Chem** 1996 Aug 23; 271(34):20444–9

Transcriptional regulation of the chicken caldesmon gene. Activation of gizzard-type caldesmon promoter requires a CArG box-like motif. Yano H, et al. **J Biol Chem** 1995 Oct 6;270(40):23661–6

Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. Ye S, et al. **J Biol Chem** 1996 May 31;271(22):13055–60

Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. Zhan S, et al. **J Biol Chem** 1995 Nov 24;270(47):27983–6

The human histidine decarboxylase promoter is regulated by gastrin and phorbol 12-myristate 13-acetate through a downstream cis-acting element. Zhang Z, et al. **J Biol Chem** 1996 Jun 14;271(24):14188–97

Transcriptional regulation of the yeast DnaJ homologue SIS1. Zhong T, et al. **J Biol Chem** 1996 Jan 19; 271(3):1349–56

Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. Zhou D, et al. **J Biol Chem** 1996 Jun 21; 271(25):15194–202

Multiple transcription factors are required for activation of human interleukin 9 gene in T cells. Zhu YX, et al. **J Biol Chem** 1996 Jun 28;271(26):15815–22

Mutually exclusive interaction of a novel matrix attachment region binding protein and the NF-muNR enhancer repressor. Implications for regulation of immunoglobulin heavy chain expression. Zong RT, et al. **J Biol Chem** 1995 Oct 13;270(41):24010–8

Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. Stein U, et al. **J Cancer Res Clin Oncol** 1996;122(5):275–82

Cis elements for transcriptional regulation of the human endothelin-A receptor gene. Yamashita J, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S26–8

Identification of an osteocalcin gene promoter sequence that binds AP1. Goldberg D, et al. **J Cell Biochem** 1996 Mar 15;60(4):447–57

G/C element contributes to the cell line-specific expression of the proximal osteocalcin promoter. Goldberg D, et al. **J Cell Biochem** 1995 Aug;58(4):499–508

Glucocorticoids coordinately regulate type I collagen pro alpha 1 promoter activity through both the glucocorticoid and transforming growth factor beta response elements: a novel mechanism of glucocorticoid regulation of eukaryotic genes. Meisler N, et al. **J Cell Biochem** 1995 Nov;59(3):376–88

Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene. Miller TL, et al. **J Cell Biochem** 1996 Mar 15;60(4):560–71

Bipartite structure of the proximal promoter of a human H4 histone gene. Wright KL, et al. **J Cell Biochem** 1995 Jul; 58(3):372–9

Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. Li L, et al. **J Cell Biol** 1996 Mar;132(5):849–59

Examination of the phosphoenolpyruvate carboxykinase gene promoter in patients with noninsulin-dependent diabetes mellitus. Ludwig DS, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):503–6

Human diabetes associated with defects in nuclear regulatory proteins for the insulin receptor gene. Brunetti A, et al. **J Clin Invest** 1996 Jan 1;97(1):258–62

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. Chen L, et al. **J Clin Invest** 1995 Dec; 96(6):2775–82

Three alternative promoters of the rat gamma-glutamyl transferase gene are active in developing lung and are differentially regulated by oxygen after birth. Joyce-Brady M, et al. **J Clin Invest** 1996 Apr 1;97(7):1774–9

Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. Kopecky J, et al. **J Clin Invest** 1995 Dec;96(6):2914–23

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia [see comments] Li WW, et al. **J Clin Invest** 1995 Dec;96(6):2601–5. Comment in: J Clin Invest 1996 Dec;96(6):2546.

Monocytic cell type-specific transcriptional induction of collagenase. Pierce RA, et al. **J Clin Invest** 1996 Apr 15; 97(8):1890–9

Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. Poitout V, et al. **J Clin Invest** 1996 Feb 15;97(4):1041–6

Rapid identification of mycobacterial species by PCR amplification of hypervariable 16S rRNA gene promoter region. Dobner P, et al. **J Clin Microbiol** 1996 Apr; 34(4):866–9

Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. Li X, et al. **J Endocrinol** 1996 Apr; 149(1):117–24

The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. Ma X, et al. **J Exp Med** 1996 Jan 1;183(1):147–57

A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. Melillo G, et al. **J Exp Med** 1995 Dec 1;182(6):1683–93

Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. Reimold AM, et al. **J Exp Med** 1996 Feb 1;183(2):393–401

Descriptive and functional characterization of variation in the Fundulus heteroclitus Ldh-B proximal promoter. Segal JA, et al. **J Exp Zool** 1996 Aug 1;275(5):355–64

B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of

the W promoter. Contreras-Brodin B, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1159-62

Role of cis-acting sequences of the ICP0 promoter of herpes simplex virus type 1 in viral pathogenesis, latency and reactivation. Davido DJ, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1853-63

Functional promoters in the genome of human papillomavirus type 6b. Karlen S, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):11-6

Baculovirus infection of Spodoptera exigua larvae: lacZ expression driven by promoters of early genes pe38 and me53 in larval tissue. Knebel-Mörsdorf D, et al. **J Gen Virol** 1996 May;77 (Pt 5):815-24

Evidence for a promoter-like activity in the short non-coding region of human papillomaviruses. Maki H, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):453-8

Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. Ponnazhagan S, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1111-22

Sp1 is critical for basal and E2-transactivated transcription from the bovine papillomavirus type 1 P89 promoter. Sandler AB, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):189-98

Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2669-78

PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2679-92

Expression of polydnavirus genes under polydnavirus promoter regulation in insect larvae infected with baculovirus recombinants. Soldevila AI, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1379-88

Pseudorabies virus early protein 0 transactivates the viral gene promoters. Watanabe S, et al. **J Gen Virol** 1995 Nov; 76 (Pt 11):2881-5

Unusual activation of the integrated preS1 promoter of woodchuck hepatitis virus in a liver tumour. Wei Y, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):177-82

The transcription factor B-cell-specific activator protein is not involved in the IL-4-induced activation of the human IgE germline promoter. Albrecht B, et al. **J Immunol** 1996 Aug 15;157(4):1538-43

Nuclear factor-IL6 activates the human IL-4 promoter in T cells. Davydov IV, et al. **J Immunol** 1995 Dec 1; 155(11):5273-9

Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. Holguin MH, et al. **J Immunol** 1996 Aug 15;157(4):1659-68

Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. Nelson PJ, et al. **J Immunol** 1996 Aug 1; 157(3):1139-48

Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells. Rigaud G, et al. **J Immunol** 1996 Jun 1;156(11):4254-8

Superantigen-induced transcriptional activation of the human TNF gene promoter in T cells. Krämer B, et al. **J Inflamm** 1995;45(3):183-92

Characterization of protein complexes formed on the repressor elements of the human tumor necrosis factor alpha gene. Fong CW, et al. **J Interferon Cytokine Res** 1995 Oct;15(10):887-95

Analysis of human interferon-alpha gene promoters by multiple sequence alignment. Houle JL, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):93-8

Abnormal IL-4 gene expression by atopic dermatitis T lymphocytes is reflected in altered nuclear protein interactions with IL-4 transcriptional regulatory element. Chan SC, et al. **J Invest Dermatol** 1996 May;106(5):1131-6

Collagenase gene expression in cutis laxa fibroblasts is upregulated by transcriptional activation of the promoter gene through a 12-0-tetradecanoyl-phorbol-13-acetate (TPA)-responsive element. Hatamochi A, et al. **J Invest Dermatol** 1996 Apr;106(4):631-6

Ten allelic apolipoprotein[a] 5' flanking fragments exhibit comparable promoter activities in HepG2 cells. Bopp S, et al. **J Lipid Res** 1995 Aug;36(8):1721-8

Hormonal regulation of the cholesterol 7 alpha-hydroxylase gene (CYP7). Crestani M, et al. **J Lipid Res** 1995 Nov; 36(11):2419-32

Functional redundancy of promoter elements ensures efficient transcription of the human 7SK gene in vivo. Boyd DC, et al. **J Mol Biol** 1995 Nov 10;253(5):677-90

Identification of an UP element within the IHF binding site at the PL1-PL2 tandem promoter of bacteriophage lambda. Giladi H, et al. **J Mol Biol** 1996 Jul 26;260(4):484-91

Characterization of pre-transcription complexes made at a bacteriophage T4 middle promoter: involvement of the T4 MotA activator and the T4 AsiA protein, a sigma 70 binding protein, in the formation of the open complex. Hinton DM, et al. **J Mol Biol** 1996 Feb 23;256(2):235-48

Adjacent upstream superhelical writhe influences an Escherichia coli promoter as measured by in vivo strength and in vitro open complex formation. Hirota Y, et al. **J Mol Biol** 1995 Dec 8;254(4):566-78

Repression of lac promoter as a function of distance, phase and quality of an auxiliary lac operator. Müller J, et al. **J Mol Biol** 1996 Mar 22;257(1):21-9

Identification of a phage-coded DNA-binding protein that regulates transcription from late promoters in bacteriophage P4. Polo S, et al. **J Mol Biol** 1996 Apr 12; 257(4):745-55

The architecture of the heat-inducible Drosophila hsp27 promoter in nuclei. Quivy JP, et al. **J Mol Biol** 1996 Feb 23;256(2):249-63

Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells. Sadot E, et al. **J Mol Biol** 1996 Mar 15;256(5):805-12

Requirement of a 3'-terminal stem-loop in in vitro transcription by an RNA-dependent RNA polymerase. Song C, et al. **J Mol Biol** 1995 Nov 17;254(1):6-14

Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome. Swaminathan S, et al. **J Mol Biol** 1996 May 24; 258(5):736-46

Molecular cloning and characterization of the yellowtail GH gene and its promoter: a consensus sequence for teleost and avian Pit-1/GHF-1 binding sites. Ohkubo T, et al. **J Mol Endocrinol** 1996 Feb;16(1):63-72

Functional analysis of the human pro-opiomelanocortin promoter in the small cell lung carcinoma cell line DMS-79. Picon A, et al. **J Mol Endocrinol** 1995 Oct; 15(2):187-94

Cloning and promoter analysis of the human B-50/GAP-43 gene. de Groen PC, et al. **J Mol Neurosci** 1995;6(2):109-19

NF-kappa B site-mediated negative regulation of the HIV-1 promoter by CCAAT/enhancer binding proteins in brain-derived cells. Mondal D, et al. **J Mol Neurosci** 1994-95;5(4):241-58

Characterization and regulation of the protein binding to a cis-acting element, RET 1, in the rat opsin promoter. Yu X, et al. **J Mol Neurosci** 1994-95;5(4):259-71

Analysis of the neuronal promoter of the rat aromatic L-amino acid decarboxylase gene. Aguanno A, et al. **J Neurochem** 1995 Nov;65(5):1944-54

Characterization of the human protease nexin-1 promoter and its regulation by Sp1 through a G/C-rich activation domain. Guttridge DC, et al. **J Neurochem** 1996 Aug; 67(2):498-507

Alternate promoters in the rat aromatic L-amino acid decarboxylase gene for neuronal and nonneuronal expression: an in situ hybridization study. Jahng JW, et al. **J Neurochem** 1996 Jan;66(1):14-9

3.6 kb of the 5' flanking DNA activates the mouse tyrosine hydroxylase gene promoter without catecholaminergic-specific expression. Morgan WW, et al. **J Neurochem** 1996 Jan;66(1):20-5

Nicotine acts directly on pituitary GH3 cells to inhibit prolactin promoter activity. Coleman DT, et al. **J Neuroendocrinol** 1995 Oct;7(10):785-9

Dissociation of 4-hydroxytamoxifen, but not estradiol or tamoxifen aziridine, from the estrogen receptor as the receptor binds estrogen response element DNA. Klinge CM, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):51-66

Chicken ovalbumin upstream promoter-transcription factors and their regulation. Qiu Y, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):81-5 (30 ref.)

Activation of the human thymidine kinase (TK) promoter by simian virus 40 large T antigen requires both the T antigen pRb family-binding domain and TK promoter sequences resembling E2F-binding sites. Anderson MM, et al. **J Virol** 1996 Sep;70(9):6304-13

The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. Baskar JF, et al. **J Virol** 1996 May;70(5):3207-14

Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. Baum C, et al. **J Virol** 1995 Dec;69(12):7541-7

Interaction between T antigen and TEA domain of the factor TEF-1 derepresses simian virus 40 late promoter in vitro: identification of T-antigen domains important for transcription control. Berger LC, et al. **J Virol** 1996 Feb; 70(2):1203-12

A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. Biswas DK, et al. **J Virol** 1995 Dec;69(12):7437-44

Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. Bondesson M, et al. **J Virol** 1996 Jun; 70(6):3844-51

Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. Borras AM, et al. **J Virol** 1996 Jun;70(6):3894-901

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. Buckwold VE, et al. **J Virol** 1996 Sep; 70(9):5845-51

The promoter and transcriptional unit of a novel herpes simplex virus 1 alpha gene are contained in, and encode a protein in frame with, the open reading frame of the alpha 22 gene. Carter KL, et al. **J Virol** 1996 Jan; 70(1):172-8

Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression. Caswell R, et al. **J Virol** 1996 Jun;70(6):4028-37

The UCUAAAC promoter motif is not required for high-frequency leader recombination in bovine coronavirus defective interfering RNA. Chang RY, et al. **J Virol** 1996 May;70(5):2720-9

Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. Chen X, et al. **J Virol** 1995 Dec;69(12):7899-908

Initiator elements and regulated expression of the herpes simplex virus thymidine kinase gene. Cook WJ, et al. **J Virol** 1995 Nov;69(11):7291-4

Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. DiLorenzo TP, et al. **J Virol** 1995 Nov; 69(11):6865-72

Molecular genetic analysis of Epstein-Barr virus Cp promoter function. Evans TJ, et al. **J Virol** 1996 Mar; 70(3):1695-705

Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. Flamand L, et al. **J Virol** 1996 Mar;70(3):1784-91

Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. Flory E, et al. **J Virol** 1996 Apr;70(4):2260-8

5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. Franken M, et al. **J Virol** 1995 Dec;69(12):8011-9

ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. Fuks F, et al. **J Virol** 1996 Mar;70(3):1331-9

Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. Grassmann K, et al. **J Virol** 1996 Apr;70(4):2339-49

Identification of Simian virus 40 promoter DNA sequences capable of conferring restriction endonuclease hypersensitivity. Hermansen R, et al. **J Virol** 1996 Jun; 70(6):3416-22

Host-dependent evolution of the Sindbis virus promoter for subgenomic mRNA synthesis. Hertz JM, et al. **J Virol** 1995 Dec;69(12):7775-81

Evolution of the Sindbis virus subgenomic mRNA promoter in cultured cells. Hertz JM, et al. **J Virol** 1995 Dec; 69(12):7768-74

The herpes simplex virus type 1 VP5 promoter contains a cis-acting element near the cap site which interacts with a cellular protein. Huang CJ, et al. **J Virol** 1996 Mar; 70(3):1898-904

Binding of cellular repressor protein or the IE2 protein to a cis-acting negative regulatory element upstream of a human cytomegalovirus early promoter. Huang L, et al. **J Virol** 1995 Dec;69(12):7612-21

The A2L intermediate gene product is required for in vitro transcription from a vaccinia virus late promoter. Hubbs AE, et al. **J Virol** 1996 Jan;70(1):327-31

Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter. Kundu M, et al. **J Virol** 1995 Nov; 69(11):6940-6

Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein. Kyöstiö SR, et al. **J Virol** 1995 Nov;69(11):6787-96

Adenovirus-mediated expression of ribozymes in mice. Lieber A, et al. **J Virol** 1996 May;70(5):3153-8

Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. Liu C, et al. **J Virol** 1996 Apr;70(4):2545-55

Efficient transactivation of the minute virus of mice P38 promoter requires upstream binding of NS1. Lorson C, et al. **J Virol** 1996 Feb;70(2):834-42

Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. Lutz P, et al. **J Virol** 1996 Mar;70(3):1396-405

Cellular or viral protein binding to a cytomegalovirus promoter transcription initiation site: effects on transcription. Macias MP, et al. **J Virol** 1996 Jun; 70(6):3628-35

Characterization of two novel YY1 binding sites in the polyomavirus late promoter. Martelli F, et al. **J Virol** 1996 Mar;70(3):1433-8

Transcription of the JC virus archetype late genome: importance of the kappa B and the 23-base-pair motifs in late promoter activity in glial cells. Mayreddy RP, et al. **J Virol** 1996 Apr;70(4):2387-93

Neurons differentially control expression of a herpes simplex virus type 1 immediate-early promoter in transgenic mice. Mitchell WJ. **J Virol** 1995 Dec;69(12):7942-50

Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. Nonkwelo C, et al. **J Virol** 1996 Jan;70(1):623-7

Transcription of a vaccinia virus late promoter template: requirement for the product of the A2L intermediate-stage gene. Passarelli AL, et al. **J Virol** 1996 Jul;70(7):4444–50

Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. Ponnazhagan S, et al. **J Virol** 1995 Dec;69(12):8096–101

oriP is essential for EBNA gene promoter activity in Epstein–Barr virus–immortalized lymphoblastoid cell lines. Puglielli MT, et al. **J Virol** 1996 Sep;70(9):5758–68

Transcriptional regulation of human polyomavirus JC: evidence for a functional interaction between RelA (p65) and the Y-box–binding protein, YB-1. Raj GV, et al. **J Virol** 1996 Sep;70(9):5944–53

Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein–Barr virus BZLF1 promoter. Ruf IK, et al. **J Virol** 1995 Dec;69(12):7648–57

Transcription of the Epstein–Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells. Schlager S, et al. **J Virol** 1996 Jun;70(6):3561–70

The promoter activity of long terminal repeats of the HERV-H family of human retrovirus–like elements is critically dependent on Sp1 family proteins interacting with a GC/GT box located immediately 3' to the TATA box. Sjøttem E, et al. **J Virol** 1996 Jan;70(1):188–98

E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. Stubenrauch F, et al. **J Virol** 1996 Jan;70(1):119–26

Transactivation of a cellular promoter by the NS1 protein of the parvovirus minute virus of mice through a putative hormone-responsive element. Vanacker JM, et al. **J Virol** 1996 Apr;70(4):2369–77

Regulation of coronavirus mRNA transcription. van Marle G, et al. **J Virol** 1995 Dec;69(12):7851–6

Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. Xu Z, et al. **J Virol** 1996 Jan;70(1):133–40

Adenovirus E1A243 disrupts the ATF/CREB–YY1 complex at the mouse c-fos promoter. Zhou Q, et al. **J Virol** 1995 Dec;69(12):7402–9

Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. Dokter WHA, et al. **Leukemia** 1996 Aug;10(8):1308–16

A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Hafner M, et al. **Matrix Biol** 1995 Dec;14(9):733–41

Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. White LA, et al. **Matrix Biol** 1995 Dec;14(9):715–25

Dual organisation of the Drosophila neuropeptide receptor NKD gene promoter. Rosay P, et al. **Mech Dev** 1995 Jun; 51(2–3):329–39

Induction of signal transduction pathways through promoter activation. Walden R, et al. **Methods Cell Biol** 1995; 49:455–69 (26 ref.)

Replication-competent and -defective retrovirus vectors for oncogenic studies. Samarut J, et al. **Methods Enzymol** 1995; 254:206–28

Electroporation of Physarum polycephalum. Burland TG, et al. **Methods Mol Biol** 1995;47:303–20

Activity of mycobacterial promoters during intracellular and extracellular growth. Dellagostin OA, et al. **Microbiology** 1995 Aug;141 (Pt 8):1785–92

A Bacillus subtilis secreted phosphodiesterase/alkaline phosphatase is the product of a Pho regulon gene, phoD. Eder S, et al. **Microbiology** 1996 Aug;142 (Pt 8):2041–7

Expression of foreign genes and selection of promoter sequences in Acholeplasma laidlawii. Jarhede TK, et al. **Microbiology** 1995 Sep;141 (Pt 9):2071–9

RNA polymerase, PurR and MetR interactions at the glyA promoter of Escherichia coli. Lorenz E, et al. **Microbiology** 1996 Jul;142 (Pt 7):1819–24

Promoters from Corynebacterium glutamicum: cloning, molecular analysis and search for a consensus motif. Pátek M, et al. **Microbiology** 1996 May;142 (Pt 5):1297–309

The bacteriophage 434 operator/repressor system in yeast. Webster CI, et al. **Microbiology** 1995 Sep;141 (Pt 9):2191–200

Analysis of the 170-kDa lectin gene promoter of Entamoeba histolytica. Buss H, et al. **Mol Biochem Parasitol** 1995 Jun; 72(1–2):1–10

The putative promoter for a metacyclic VSG gene in African trypanosomes. Nagoshi YL, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):33–45

Transient expression mediated by the Trypanosoma cruzi rRNA promoter. Tyler-Cross RE, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):23–31

Amylase gene structures in primates: retroposon insertions and promoter evolution. Samuelson LC, et al. **Mol Biol Evol** 1996 Jul;13(6):767–79

Characterization of a promoter for gamma-glutamyl transpeptidase activated in rat liver in response to aflatoxin B1 and ethoxyquin. Griffiths SA, et al. **Mol Carcinog** 1995 Dec;14(4):251–62

Interference of benzo[a]pyrene diol epoxide–deoxyguanosine adducts in a GC box with binding of the transcription factor Sp1. MacLeod MC, et al. **Mol Carcinog** 1996 May; 16(1):44–52

Promoter demethylation in MMTV/N-rasN transgenic mice required for transgene expression and tumorigenesis. Mangues R, et al. **Mol Carcinog** 1995 Oct;14(2):94–102

Influence of thyroid hormones on the human ATP synthase beta-subunit gene promoter. Martin I, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):107–11

Adenovirus type 12–induced fragility of the human RNU2 locus requires U2 small nuclear RNA transcriptional regulatory elements. Bailey AD, et al. **Mol Cell Biol** 1995 Nov;15(11):6246–55

Genetic characterization of transactivation of the human T-cell leukemia virus type I promoter: Binding of Tax to Tax-responsive element 1 is mediated by the cyclic AMP–responsive members of the CREB/ATF family of transcription factors. Bantignies F, et al. **Mol Cell Biol** 1996 May;16(5):2174–82

Distinct cis-acting elements mediate clock, light, and developmental regulation of the Neurospora crassa eas (ccg-2) gene. Bell-Pedersen D, et al. **Mol Cell Biol** 1996 Feb;16(2):513–21

The major histocompatibility complex class II Ea promoter requires TFIID binding to an initiator sequence. Bellorini M, et al. **Mol Cell Biol** 1996 Feb;16(2):503–12

Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation. Boccia LM, et al. **Mol Cell Biol** 1996 May; 16(5):1929–35

Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Botz J, et al. **Mol Cell Biol** 1996 Jul;16(7):3401–9

A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Candeliere GA, et al. **Mol Cell Biol** 1996 Feb;16(2):584–92

Functional reconstruction of trans regulation of the Ultrabithorax promoter by the products of two antagonistic genes, trithorax and Polycomb. Chang YL, et al. **Mol Cell Biol** 1995 Dec;15(12):6601–12

Constitutive repression and nuclear factor I-dependent hormone activation of the mouse mammary tumor virus promoter in Saccharomyces cerevisiae. Chávez S, et al. **Mol Cell Biol** 1995 Dec;15(12):6987–98

Helix-loop-helix transcription factors mediate activation and repression of the p75LNGFR gene. Chiaramello A, et al. **Mol Cell Biol** 1995 Nov;15(11):6036–44

Identification of a silencer module which selectively represses cyclic AMP–responsive element–dependent gene expression. Chung KC, et al. **Mol Cell Biol** 1995 Nov; 15(11):6139–49

A role for a bent DNA structure in E2F-mediated transcription activation. Cress WD, et al. **Mol Cell Biol** 1996 May;16(5):2119–27

Requirements for interleukin 2 promoter transactivation by the Tax protein of human T-cell leukemia virus type 1. Curtiss VE, et al. **Mol Cell Biol** 1996 Jul;16(7):3567–75

Transcriptional regulation of a sterol-biosynthetic enzyme by sterol levels in Saccharomyces cerevisiae. Dimster-Denk D, et al. **Mol Cell Biol** 1996 Aug; 16(8):3981–9

Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: role for nuclear receptors in cardiac and brown adipose expression. Disch DL, et al. **Mol Cell Biol** 1996 Aug;16(8):4043–51

The atrial natriuretic factor promoter is a downstream target for Nkx-2.5 in the myocardium. Durocher D, et al. **Mol Cell Biol** 1996 Sep;16(9):4648–55

Core promoter specificities of the Sp1 and VP16 transcriptional activation domains. Emami KH, et al. **Mol Cell Biol** 1995 Nov;15(11):5906–16

The activity of the highly inducible mouse phenylalanine hydroxylase gene promoter is dependent upon a tissue-specific, hormone-inducible enhancer. Faust DM, et al. **Mol Cell Biol** 1996 Jun;16(6):3125–37

The POU domain of SCIP/Tst-1/Oct-6 is sufficient for activation of any acetylcholine receptor promoter. Fyodorov D, et al. **Mol Cell Biol** 1996 Sep;16(9):5004–14

Transcriptional regulation of metacyclic variant surface glycoprotein gene expression during the life cycle of Trypanosoma brucei. Graham SV, et al. **Mol Cell Biol** 1995 Nov;15(11):5945–56

Tyrosine dephosphorylation of nuclear proteins mimics transforming growth factor beta 1 stimulation of alpha 2(I) collagen gene expression. Greenwel P, et al. **Mol Cell Biol** 1995 Dec;15(12):6813–9

The human topoisomerase I gene promoter is regulated by NF-IL6. Heiland S, et al. **Mol Cell Biol** 1995 Dec; 15(12):6623–31

Transcription factor PU.1 mediates induction of c-fms in vascular smooth muscle cells: a mechanism for phenotypic change to phagocytic cells. Inaba T, et al. **Mol Cell Biol** 1996 May;16(5):2264–73

Mechanism of differential utilization of the his3 TR and TC TATA elements. Iyer V, et al. **Mol Cell Biol** 1995 Dec; 15(12):7059–66

Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein–protein interactions. Jabrane-Ferrat N, et al. **Mol Cell Biol** 1996 Sep;16(9):4683–90

A three-step pathway of transcription initiation leading to promoter clearance at an activation RNA polymerase II promoter. Jiang Y, et al. **Mol Cell Biol** 1996 Apr; 16(4):1614–21

Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3. Jin T, et al. **Mol Cell Biol** 1996 Jan; 16(1):19–28

cis-acting sequences located downstream of the human immunodeficiency virus type 1 promoter affect its chromatin structure and transcriptional activity. el Kharroubi A, et al. **Mol Cell Biol** 1996 Jun;16(6):2958–66

A soluble transcription factor, Oct-1, is also found in the insoluble nuclear matrix and possesses silencing activity in its alanine-rich domain. Kim MK, et al. **Mol Cell Biol** 1996 Aug;16(8):4366–77

In vivo genomic footprinting of thyroid hormone–responsive genes in pituitary tumor cell lines. Kim SW, et al. **Mol Cell Biol** 1996 Aug;16(8):4465–77

A class of activation domains interacts directly with TFIIA and stimulates TFIIA–TFIID–promoter complex assembly. Kobayashi N, et al. **Mol Cell Biol** 1995 Nov;15(11):6465–73

EGT2 gene transcription is induced predominantly by Swi5 in early G1. Kovacech B, et al. **Mol Cell Biol** 1996 Jul; 16(7):3264–74

Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Kurabayashi M, et al. **Mol Cell Biol** 1995 Nov; 15(11):6386–97

Role of chromatin and Xenopus laevis heat shock transcription factor in regulation of transcription from the X. laevis hsp70 promoter in vivo. Landsberger N, et al. **Mol Cell Biol** 1995 Nov;15(11):6013–24

Flanking sequences modulate the cell specificity of M-CAT elements. Larkin SB, et al. **Mol Cell Biol** 1996 Jul; 16(7):3742–55

Developmental silencing of the embryonic zeta-globin gene: concerted action of the promoter and the 3'-flanking region combined with stage-specific silencing by the transcribed segment. Liebhaber SA, et al. **Mol Cell Biol** 1996 Jun; 16(6):2637–46

Activation of NF-kappaB/Rel by CD40 engagement induces the mouse germ line immunoglobulin Cgamma1 promoter. Lin SC, et al. **Mol Cell Biol** 1996 Sep;16(9):4591–603

Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Ludwig RL, et al. **Mol Cell Biol** 1996 Sep;16(9):4952–60

12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. McCoy C, et al. **Mol Cell Biol** 1995 Nov;15(11):6100–8

Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene. McGlynn LK, et al. **Mol Cell Biol** 1996 May; 16(5):1936–45

Distinct gene expression patterns in skeletal and cardiac muscle are dependent on common regulatory sequences in the MLC1/3 locus. McGrew MJ, et al. **Mol Cell Biol** 1996 Aug;16(8):4524–34

Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Mol PC, et al. **Mol Cell Biol** 1995 Dec;15(12):6999–7009

Involvement of an AP-1 complex in zone-specific expression of the CYP11B1 gene in the rat adrenal cortex. Mukai K, et al. **Mol Cell Biol** 1995 Nov;15(11):6003–12

Common core sequences are found in skeletal muscle slow- and fast-fiber–type-specific regulatory elements. Nakayama M, et al. **Mol Cell Biol** 1996 May;16(5):2408–17

Site-specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression. Ngô V, et al. **Mol Cell Biol** 1996 Jul;16(7):3245–54

Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Noti JD, et al. **Mol Cell Biol** 1996 Jun;16(6):2940–50

The pancreatic islet factor STF-1 binds cooperatively with Pbx to a regulatory element in the somatostatin promoter: importance of the FPWMK motif and of the homeodomain. Peers B, et al. **Mol Cell Biol** 1995 Dec;15(12):7091–7

Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Perrotti D, et al. **Mol Cell Biol** 1995 Nov;15(11):6075–87

Distinct regulatory elements control muscle-specific, fiber-type-selective, and axially graded expression of a myosin light-chain gene in transgenic mice. Rao MV, et al. **Mol Cell Biol** 1996 Jul;16(7):3909–22

Accessibility of alpha 2-repressed promoters to the activator Gal4. Redd MJ, et al. **Mol Cell Biol** 1996 Jun;16(6):2865–9

Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Rooney JW, et al. **Mol Cell Biol** 1995 Nov; 15(11):6299–310

Fast-muscle–specific DNA–protein interactions occurring in vivo at the human aldolase A M promoter are necessary for correct promoter activity in transgenic mice. Salminen M, et al. **Mol Cell Biol** 1996 Jan;16(1):76–85

Negative regulation of expression of the pituitary-specific transcription factor GHF-1/Pit-1 by thyroid hormones through interference with promoter enhancer elements. Sanchez-Pacheco A, et al. **Mol Cell Biol** 1995 Nov; 15(11):6322–30

Isolation of a novel retinoic acid–responsive gene by selection

of genomic fragments derived from CpG-island-enriched DNA. Shago M, et al. **Mol Cell Biol** 1996 Aug; 16(8):4337–48

Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Shivakumar CV, et al. **Mol Cell Biol** 1995 Dec;15(12):6785–93

Bending DNA can repress a eukaryotic basal promoter and inhibit TFIID binding. TenHarmsel A, et al. **Mol Cell Biol** 1995 Oct;15(10):5492–8

In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Tommasi S, et al. **Mol Cell Biol** 1995 Dec;15(12):6901–13

The Saccharomyces cerevisiae HSP12 gene is activated by the high-osmolarity glycerol pathway and negatively regulated by protein kinase A. Varela JC, et al. **Mol Cell Biol** 1995 Nov;15(11):6232–45

Cell-type-specific expression of the platelet-derived growth factor alpha receptor: a role for GATA-binding protein. Wang C, et al. **Mol Cell Biol** 1996 Feb;16(2):712–23

Protein-DNA interactions at the major and minor promoters of the divergently transcribed dhfr and rep3 genes during the Chinese hamster ovary cell cycle. Wells J, et al. **Mol Cell Biol** 1996 Feb;16(2):634–47

The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Ye J, et al. **Mol Cell Biol** 1996 Sep;16(9):4744–53

Characterization of the human granulocyte-macrophage colony-stimulating factor gene promoter: an AP1 complex and an Sp1-related complex transactivate the promoter activity that is suppressed by a YY1 complex. Ye J, et al. **Mol Cell Biol** 1996 Jan;16(1):157–67

Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. Zhang W, et al. **Mol Cell Biol** 1995 Nov; 15(11):6055–63

Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Zweidler-Mckay PA, et al. **Mol Cell Biol** 1996 Aug; 16(8):4024–34

The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. An MR, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):77–89

Structure of the human luteinizing hormone-choriogonadotropin receptor gene: unusual promoter and 5' non-coding regions. Atger M, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):113–23

The D2 receptor: blocked transcription in GH3 cells and cellular pathways employed by D2A to regulate prolactin promoter activity. Fischberg DJ, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):129–37

Identification of a composite steroid hormone response element on the human placental lactogen promoter. Stephanou A, et al. **Mol Cell Endocrinol** 1995 Jul; 112(1):123–9

Constitutively active Gq-alpha stimulates prolactin promoter activity via a pathway involving Raf activity. Tian J, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):249–56

Repression of somatostatin gene transcription mediated by two promoter silencer elements. Vallejo M, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):61–72

A 338-bp proximal fragment of the glucose transporter type 2 (GLUT2) promoter drives reporter gene expression in the pancreatic islets of transgenic mice. Waeber G, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):205–15

Analysis of cytochrome P-450 side-chain cleavage gene promoter activation during trophoblast cell differentiation. Yamamoto T, et al. **Mol Cell Endocrinol** 1995 Sep 22; 113(2):183–94

Mutational analysis of muscle and brain specific promoter regions of dystrophin gene in DMD/BMD Italian patients by denaturing gradient gel electrophoresis (DGGE). Tubiello G, et al. **Mol Cell Probes** 1995 Dec;9(6):441–6

Contributions of distal and proximal promoter elements to glucocorticoid regulation of osteocalcin gene transcription. Aslam F, et al. **Mol Endocrinol** 1995 Jun;9(6):679–90

In vivo functional analysis of the mouse estrogen receptor gene promoter: a transgenic mouse model to study tissue-specific and developmental regulation of estrogen receptor gene transcription. Cicatiello L, et al. **Mol Endocrinol** 1995 Aug;9(8):1077–90

Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence. Elgort MG, et al. **Mol Endocrinol** 1996 May;10(5):477–87

The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Hollenberg AN, et al. **Mol Endocrinol** 1995 May;9(5):540–50

Differential biallelic activation of three insulin-like growth factor II promoters in the mouse central nervous system. Hu JF, et al. **Mol Endocrinol** 1995 May;9(5):628–36

Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Kallio PJ, et al. **Mol Endocrinol** 1995 Aug;9(8):1017–28

Control of insulin-like growth factor-II/mannose 6-phosphate receptor gene transcription by proximal promoter elements. Liu Z, et al. **Mol Endocrinol** 1995 Nov; 9(11):1477–87

An Ets site in the whey acidic protein gene promoter mediates transcriptional activation in the mammary gland of pregnant mice but is dispensable during lactation. McKnight RA, et al. **Mol Endocrinol** 1995 Jun;9(6):717–24

Influence of hormone antagonists on chromatin remodeling and transcription factor binding to the mouse mammary tumor virus promoter in vivo. Mymryk JS, et al. **Mol Endocrinol** 1995 Dec;9(12):1825–34

Hepatocyte nuclear factor 1 alpha activates promoter 1 of the human insulin-like growth factor I gene via two distinct binding sites. Nolten LA, et al. **Mol Endocrinol** 1995 Nov; 9(11):1488–99

Developmental maturation of pineal gland function: synchronized CREM inducibility and adrenergic stimulation. Stehle JH, et al. **Mol Endocrinol** 1995 Jun; 9(6):706–16

Negative regulation of chicken GATA-1 promoter activity mediated by a hormone response element. Trainor CD, et al. **Mol Endocrinol** 1995 Sep;9(9):1135–46

Characterization of an EcR/USP heterodimer target site that mediates ecdysone responsiveness of the Drosophila Lsp-2 gene. Antoniewski C, et al. **Mol Gen Genet** 1995 Dec 15; 249(5):545–56

Identification of the DNA damage-responsive elements of the rhp51+ gene, a recA and RAD51 homolog from the fission yeast Schizosaccharomyces pombe. Jang YK, et al. **Mol Gen Genet** 1996 May 23;251(2):167–75

The promoter from the rice nuclear gene encoding chloroplast aldolase confers mesophyll-specific and light-regulated expression in transgenic tobacco. Kagaya Y, et al. **Mol Gen Genet** 1995 Oct 25;248(6):668–74

Identification of cis-acting DNA sequences involved in the transcription of the virulence regulatory gene spvR in Salmonella typhimurium. Kowarz L, et al. **Mol Gen Genet** 1996 May 23;251(2):225–35

Effects of different growth conditions on the in vivo activity of the tandem Escherichia coli ribosomal RNA promoters P1 and P2. Liebig B, et al. **Mol Gen Genet** 1995 Nov 27; 249(3):328–35

Gel mobility shift scanning of the acetate-inducible promoters from Neurospora crassa reveals a common co-inducible DNA-binding protein. Mizote T, et al. **Mol Gen Genet** 1996 Mar 7;250(4):421–7

Cis-elements important for the expression of the ADP-glucose pyrophosphorylase small-subunit are located both upstream and downstream form its structural gene. Nakata PA, et al. **Mol Gen Genet** 1996 Mar 20; 250(5):581–92

Identification of elements in the PDA1 promoter of Nectria haematococca necessary for a high level of transcription in vitro. Ruan Y, et al. **Mol Gen Genet** 1996 Jan 15; 250(1):29–38

Hordein promoter methylation and transcriptional activity in wild-type and mutant barley endosperm. Sørensen MB, et al. **Mol Gen Genet** 1996 Apr 10;250(6):750–60

Requirement for two conserved cysteine residues in the Ada protein of Escherichia coli for transactivation of the ada promoter. Taketomi A, et al. **Mol Gen Genet** 1996 Mar 20;250(5):523–32

Characterization and subcellular localization of a small GTP-binding protein (Ara-4) from Arabidopsis: conditional expression under control of the promoter of the gene for heat-shock protein HSP81-1. Ueda T, et al. **Mol Gen Genet** 1996 Mar 20;250(5):533–9

Genomic organization and sequence of the human NRAMP gene: identification and mapping of a promoter region polymorphism. Blackwell JM, et al. **Mol Med** 1995 Jan; 1(2):194–205

The dnaK operon of Streptomyces coelicolor encodes a novel heat-shock protein which binds to the promoter region of the operon. Bucca G, et al. **Mol Microbiol** 1995 Aug;17(4):663–74

Characterization of the distal promoter element of halobacteria in vivo using saturation mutagenesis and selection. Danner S, et al. **Mol Microbiol** 1996 Mar; 19(6):1265–76

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase-induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

Regulatory noise in prokaryotic promoters: how bacteria learn to respond to novel environmental signals. de Lorenzo V, et al. **Mol Microbiol** 1996 Mar;19(6):1177–84 (37 ref.)

Promoter selectivity control of Escherichia coli RNA polymerase by ionic strength: differential recognition of osmoregulated promoters by E sigma D and E sigma S holoenzymes. Ding Q, et al. **Mol Microbiol** 1995 May; 16(4):649–56

Purification of ArcA and analysis of its specific interaction with the pfl promoter-regulatory region. Drapal N, et al. **Mol Microbiol** 1995 May;16(3):597–607

Generation of Campylobacter fetus S-layer protein diversity utilizes a single promoter on an invertible DNA segment. Dworkin J, et al. **Mol Microbiol** 1996 Mar;19(6):1241–53

Antagonistic involvement of FIS and H-NS proteins in the transcriptional control of hns expression. Falconi M, et al. **Mol Microbiol** 1996 Mar;19(5):965–75

Molecular characterization of the eps gene cluster of Pseudomonas solanacearum and its transcriptional regulation at a single promoter. Huang J, et al. **Mol Microbiol** 1995 Jun;16(5):977–89

Analysis of an Escherichia coli mutant TyrR protein with impaired capacity for tyrosine-mediated repression, but still able to activate at sigma 70 promoters. Kwok T, et al. **Mol Microbiol** 1995 Aug;17(3):471–81

Activation of a temporally regulated Caulobacter promoter by upstream and downstream sequence elements. Marques MV, et al. **Mol Microbiol** 1995 Apr;16(2):279–89

Regulatory characteristics and promoter analysis of csiE, a stationary phase-inducible gene under the control of sigma S and the cAMP-CRP complex in Escherichia coli. Marschall C, et al. **Mol Microbiol** 1995 Oct;18(1):175–84

Distinct transcriptional regulation of a gene coding for a mitochondrial protein in the yeasts Saccharomyces cerevisiae and Kluyveromyces lactis despite similar promoter structures. Mulder W, et al. **Mol Microbiol** 1995 Sep;17(5):813–24

Isolation and characterization of genes that promote the expression of inositol transporter gene ITR1 in Saccharomyces cerevisiae. Nikawa J, et al. **Mol Microbiol** 1995 Apr;16(2):301–8

Gene-regulatory modules in Escherichia coli: nucleoprotein complexes formed by cAMP-CRP and CytR at the nupG promoter. Pedersen H, et al. **Mol Microbiol** 1995 Sep; 17(5):843–53

Stress-activated expression of a Streptomyces pristinaespiralis multidrug resistance gene (ptr) in various Streptomyces spp. and Escherichia coli. Salah-Bey K, et al. **Mol Microbiol** 1995 Sep;17(5):1001–12

Unusual regulatory mechanism for a Streptomyces multidrug resistance gene, ptr, involving three homologous protein-binding sites overlapping the promoter region. Salah-Bey K, et al. **Mol Microbiol** 1995 Sep;17(6):1109–19

The genetic basis of colony opacity in Streptococcus pneumoniae: evidence for the effect of box elements on the frequency of phenotypic variation. Saluja SK, et al. **Mol Microbiol** 1995 Apr;16(2):215–27

The Cryptococcus neoformans GAL7 gene and its use as an inducible promoter. Wickes BL, et al. **Mol Microbiol** 1995 Jun;16(6):1099–109

Separate promoters in the human A1 adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance. Ren H, et al. **Mol Pharmacol** 1995 Dec;48(6):975–80

Infections with various types of organisms stimulate transcription from a short promoter fragment of the potato gst1 gene. Strittmatter G, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):68–73

Different transmission rates of herpesvirus thymidine kinase reporter transgenes from founder male parents and male parents of subsequent generations. Ellison AR, et al. **Mol Reprod Dev** 1995 Aug;41(4):425–34

Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice. Ghebranious N, et al. **Mol Reprod Dev** 1995 Sep;42(1):1–6

Gotta have GATA [news; comment] Simon MC. **Nat Genet** 1995 Sep;11(1):9–11. Comment on: Nat Genet 1995 Sep;11(1):40–4.

Topology and reorganization of a human TFIID-promoter complex. Oelgeschläger T, et al. **Nature** 1996 Aug 22; 382(6593):735–8

Promoter elements conferring neuron-specific expression of the beta 2-subunit of the neuronal nicotinic acetylcholine receptor studied in vitro and in transgenic mice. Bessis A, et al. **Neuroscience** 1995 Dec;69(3):807–19

A strong ubiquitous promoter-enhancer for development and aging of Drosophila melanogaster. Ackermann R, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2452–3

Regulation of mouse thymidylate synthase gene expression in growth-stimulated cells: upstream S phase control elements are indistinguishable from the essential promoter elements. Ash J, et al. **Nucleic Acids Res** 1995 Nov 25; 23(22):4649–56

Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Baron U, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3605–6

Location of the C-terminal domain of the RNA polymerase alpha subunit in different open complexes at the Escherichia coli galactose operon regulatory region. Belyaeva TA, et al. **Nucleic Acids Res** 1996 Jun 15; 24(12):2242–51

The PARP promoter of Trypanosoma brucei is developmentally regulated in a chromosomal context. Biebinger S, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1202–11

Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1. Brown PC, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3235–41

Phosphorylation/dephosphorylation of the repressor MDBP-2-H1 selectively affects the level of transcription from a methylated promoter in vitro. Bruhat A, et al. **Nucleic Acids Res** 1996 May 15;24(10):1816–21

Positive elements in the laminin gamma 1 gene synergize to activate high level transcription during cellular differentiation. Chang HS, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1360–8

Comparative and functional analysis of the AP2 promoter indicates that conserved octamer and initiator elements are critical for activity. Creaser PC, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2597–605

Functional interaction between a RARE and an AP-2 binding site in the regulation of the human HOX A4 gene

promoter. Doerksen LF, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2849–56

Isolation and characterization of the QM promoter. Farmer AA, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2158–65

Promoter recognition in archaea is mediated by transcription factors: identification of transcription factor aTFB from Methanococcus thermolithotrophicus as archaeal TATA-binding protein. Gohl HP, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3837–41

5' upstream sequences of MyD88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites. Harroch S, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3539–46

Evidence for three major transcription activation elements in the proximal mouse proalpha2(I) collagen promoter. Hasegawa T, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3253–60

Transcriptional regulation of the Sex-lethal gene by helix-loop-helix proteins. Hoshijima K, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3441–8

Experimentally determined weight matrix definitions of the initiator and TBP binding site elements of promoters. Kraus RJ, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1531–9

Elk-1 can recruit SRF to form a ternary complex upon the serum response element. Latinkić BV, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1345–51

Identification of a very early promoter of insect Hz-1 virus using a novel dual-expression shuttle vector. Lee ST, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4683–9

Transcriptional regulation of the MHC class I HLA-A11 promoter by the zinc finger protein ZFX. L'Haridon M, et al. **Nucleic Acids Res** 1996 May 15;24(10):1928–35

Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. Makino Y, et al. **Nucleic Acids Res** 1996 May 15;24(10):1873–8

Common DNA structural features exhibited by eukaryotic ribosomal gene promoters. Marilley M, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2204–11

Binding of DNA oligonucleotides to sequences in the promoter of the human bcl-2 gene. Olivas WM, et al. **Nucleic Acids Res** 1996 May 1;24(9):1758–64

Structure of open promoter complexes with Escherichia coli RNA polymerase as revealed by the DNase I footprinting technique: compilation analysis. Ozoline ON, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4533–41

A DNA binding factor (UBF) interacts with a positive regulatory element in the promoters of genes expressed during meiosis and vegetative growth in yeast. Prinz S, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3449–56

CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA. Ronchi A, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4565–72

Promoter elements of the PHR1 gene of Saccharomyces cerevisiae and their roles in the response to DNA damage. Sancar GB, et al. **Nucleic Acids Res** 1995 Nov 11; 23(21):4320–8

Kluyveromyces lactis killer system: analysis of cytoplasmic promoters of the linear plasmids. Schickel J, et al. **Nucleic Acids Res** 1996 May 15;24(10):1879–86

Silencing of the Escherichia coli bgl promoter: effects of template supercoiling and cell extracts on promoter activity in vitro. Schnetz K, et al. **Nucleic Acids Res** 1996 Jun 15; 24(12):2422–8

Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 proto-oncogene promotor. Svinarchuk F, et al. **Nucleic Acids Res** 1996 Jan 15; 24(2):295–302

A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Taniguchi Y, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2746–52

Tissue-specific in vivo protein-DNA interactions at the promoter region of the Xenopus 63 kDa keratin gene during metamorphosis. Warshawsky D, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4502–9

Orientation of functional activating regions in the Escherichia coli CRP protein during transcription activation at class II promoters. Williams RM, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1112–8

The tandem repeat AGGGTAGGGT is, in the fission yeast, a proximal activation sequence and activates basal transcription mediated by the sequence TGTGACTG. Witt I, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4296–302

Variable pause positions of RNA polymerase II lie proximal to the c-myc promoter irrespective of transcriptional activity. Wolf DA, et al. **Nucleic Acids Res** 1995 Sep 11; 23(17):3373–9

Obligatory activator-polymerase addition order at promoters. Zhang X, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2575–7

Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter. Bräuninger A, et al. **Oncogene** 1995 Nov 2;11(9):1793–800

PU.1 (Spi-1) autoregulates its expression in myeloid cells. Chen H, et al. **Oncogene** 1995 Oct 19;11(8):1549–60

A novel mutation in the promotor region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene. Cowell JK, et al. **Oncogene** 1996 Jan 18;12(2):431–6

An E2F-dependent late-serum-response promoter in a gene that controls glycolysis. Darville MI, et al. **Oncogene** 1995 Oct 19;11(8):1509–17

Regulation of the c-fms promoter in murine tumour cell lines. Favot P, et al. **Oncogene** 1995 Oct 5;11(7):1371–81

The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Frank R, et al. **Oncogene** 1995 Dec 21;11(12):2667–74

An Inr-containing sequence flanking the TATA box of the human c-sis (PDGF-B) proto-oncogene promoter functions in cis as a co-activator for its intronic enhancer. Franklin GC, et al. **Oncogene** 1995 Nov 2;11(9):1873–84

Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP. Janknecht R, et al. **Oncogene** 1996 May 2;12(9):1961–9

Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Johnson DG. **Oncogene** 1995 Nov 2;11(9):1685–92

Lymphoid- and myeloid-specific activity of the PU.1 promoter is determined by the combinatorial action of octamer and ets transcription factors. Kistler B, et al. **Oncogene** 1995 Sep 21;11(6):1095–106

IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s). Kojima H, et al. **Oncogene** 1996 Feb 1;12(3):547–54

Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation. Malik KT, et al. **Oncogene** 1995 Oct 19;11(8):1589–95

The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Nayeri S, et al. **Oncogene** 1995 Nov 2;11(9):1853–8

Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Rochefort P, et al. **Oncogene** 1996 Jan 4;12(1):111–8

The adenovirus E1A-associated 300 kDa adaptor protein counteracts the inhibition of the collagenase promoter by E1A and represses transformation. Smits PH, et al. **Oncogene** 1996 Apr 4;12(7):1529–35

Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Stadler M, et al. **Oncogene** 1995 Dec 21; 11(12):2565–73

c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs. Tobias KE, et al. **Oncogene** 1995 Nov 2;11(9):1721–7

TATA-dependent repression of human immunodeficiency virus type-1 transcription by the adenovirus E1A 243R oncoprotein. Tsang SX, et al. **Oncogene** 1996 Feb 15; 12(4):819–26

Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Kopnin BP, et al. **Oncol Res** 1995;7(6):299–306

Direct gene quantitation by PCR reveals differential accumulation of ectopic enzyme in rat-1 cells, v-fos transformants, and revertants. Bahramian MB, et al. **PCR Methods Appl** 1994 Dec;4(3):145–53

Implication of nitric oxide synthase in carcinogenesis: analysis of the human inducible nitric oxide synthase gene. Esumi H, et al. **Pharmacogenetics** 1995;5 Spec No:S166–70

The regulator of MAT2 (ROM2) protein binds to early maturation promoters and represses PvALF-activated transcription. Chern MS, et al. **Plant Cell** 1996 Feb; 8(2):305–21

A DNA binding activity for one of two closely defined phytochrome regulatory elements in an Lhcb promoter is more abundant in etiolated than in green plants. Degenhardt J, et al. **Plant Cell** 1996 Jan;8(1):31–41

Gibberellin-regulated expression of a myb gene in barley aleurone cells: evidence for Myb transactivation of a high-pI alpha-amylase gene promoter. Gubler F, et al. **Plant Cell** 1995 Nov;7(11):1879–91

Localization and interaction of the cis-acting elements for abscisic acid, VIVIPAROUS1, and light activation of the C1 gene of maize. Kao CY, et al. **Plant Cell** 1996 Jul; 8(7):1171–9

Transcription factor veracity: is GBF3 responsible for ABA-regulated expression of Arabidopsis Adh? Lu G, et al. **Plant Cell** 1996 May;8(5):847–57

GT-2: in vivo transcriptional activation activity and definition of novel twin DNA binding domains with reciprocal target sequence selectivity. Ni M, et al. **Plant Cell** 1996 Jun;8(6):1041–59

Modular nature of abscisic acid (ABA) response complexes: composite promoter units that are necessary and sufficient for ABA induction of gene expression in barley. Shen Q, et al. **Plant Cell** 1996 Jul;8(7):1107–19

SRK, the stigma-specific S locus receptor kinase of Brassica, is targeted to the plasma membrane in transgenic tobacco. Stein JC, et al. **Plant Cell** 1996 Mar;8(3):429–45

Calmodulin isoforms differentially enhance the binding of cauliflower nuclear proteins and recombinant TGA3 to a region derived from the Arabidopsis Cam-3 promoter. Szymanski DB, et al. **Plant Cell** 1996 Jun;8(6):1069–77

Overlap of Viviparous1 (VP1) and abscisic acid response elements in the Em promoter: G-box elements are sufficient but not necessary for VP1 transactivation. Vasil V, et al. **Plant Cell** 1995 Sep;7(9):1511–8

TATA box and initiator functions in the accurate transcription of a plant minimal promoter in vitro. Zhu Q, et al. **Plant Cell** 1995 Oct;7(10):1681–9

Effects of sulfate concentrations on the expression of a soybean seed storage protein gene and its reversibility in transgenic Arabidopsis thaliana. Hirai MY, et al. **Plant Cell Physiol** 1995 Oct;36(7):1331–9

A far-upstream sequence of the wheat histone H3 promoter functions differently in rice and tobacco cultured cells. Ito T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1281–9

Potential transcription regulatory sequences in a promoter region of the wheat basic/leucine zipper protein HBP-1b(c38) gene. Mikami K, et al. **Plant Cell Physiol** 1995 Oct;36(7):1375–9

Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Mitsuhara I, et al. **Plant Cell Physiol** 1996 Jan; 37(1):49–59

A zinc-finger-type transcription factor WZF-1 that binds to a novel cis-acting element of histone gene promoters represses its own promoter. Sakamoto A, et al. **Plant Cell Physiol** 1996 Jun;37(4):557–62

Three protein fractions that bind to a narrow region of the promoter of the ribosomal RNA gene in Vicia faba. Suzuki A, et al. **Plant Cell Physiol** 1995 Sep;36(6):1051–8

cis-regulatory elements responsible for quantitative regulation of the rice seed storage protein glutelin GluA-3 gene. Yoshihara T, et al. **Plant Cell Physiol** 1996 Jan; 37(1):107–11

Interactions of the glutelin Gt3 5' flanking regulatory regions with rice nuclear proteins. Zhao Y, et al. **Plant Cell Physiol** 1995 Dec;36(8):1657–67

PvAlf, an embryo-specific acidic transcriptional activator enhances gene expression from phaseolin and phytohemagglutinin promoters. Bobb AJ, et al. **Plant J** 1995 Sep;8(3):331–43

Regulation of a carotenoid biosynthesis gene promoter during plant development. Corona V, et al. **Plant J** 1996 Apr; 9(4):505–12

Isolation of Arabidopsis mutants altered in the light-regulation of chalcone synthase gene expression using a transgenic screening approach. Jackson JA, et al. **Plant J** 1995 Sep;8(3):369–80

The use of an alternative promoter in the Arabidopsis thaliana HMG1 gene generates an mRNA that encodes a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase isoform with an extended N-terminal region. Lumbreras V, et al. **Plant J** 1995 Oct;8(4):541–9

Expression of an amino acid biosynthesis gene in tomato flowers: developmental upregulation and MeJa response are parenchyma-specific and mutually compatible. Samach A, et al. **Plant J** 1995 Sep;8(3):391–406

Alfalfa NADH-dependent glutamate synthase: structure of the gene and importance in symbiotic N2 fixation. Vance CP, et al. **Plant J** 1995 Sep;8(3):345–58

Isolation and characterization of the Adh2 5' region from Petunia hybrida. Atkinson EF, et al. **Plant Mol Biol** 1996 Jan;30(2):367–71

The PR-1a promoter contains a number of elements that bind GT-1-like nuclear factors with different affinity. Buchel AS, et al. **Plant Mol Biol** 1996 Feb;30(3):493–504

The maize caffeic acid O-methyltransferase gene promoter is active in transgenic tobacco and maize plant tissues. Capellades M, et al. **Plant Mol Biol** 1996 May;31(2):307–22

The expression pattern of alfalfa flavanone 3-hydroxylase promoter-gus fusion in Nicotiana benthamiana correlates with the presence of flavonoids detected in situ. Charrier B, et al. **Plant Mol Biol** 1996 Mar;30(6):1153–68

Identification of tissue-specific, dehydration-responsive elements in the Trg-31 promoter. Chaudhary S, et al. **Plant Mol Biol** 1996 Mar;30(6):1247–57

A promoter identified in the 3' end of the Ac transposon can be activated by cis-acting elements in transgenic Arabidopsis lines. Cocherel S, et al. **Plant Mol Biol** 1996 Feb;30(3):539–51

Promoter analysis of the auxin-regulated tobacco glutathione S-transferase genes Nt103-1 and Nt103-35. Droog F, et al. **Plant Mol Biol** 1995 Nov;29(3):413–29

Tissue-specific expression of the PAL3 promoter requires the interaction of two conserved cis sequences. Hatton D, et al. **Plant Mol Biol** 1996 May;31(2):393–7

The maize transcription factor Opaque-2 activates a wheat glutenin promoter in plant and yeast cells. Holdsworth MJ, et al. **Plant Mol Biol** 1995 Nov;29(4):711–20

Comparison of different constitutive and inducible promoters for the overexpression of transgenes in Arabidopsis thaliana. Holtorf S, et al. **Plant Mol Biol** 1995 Nov; 29(4):637–46

Cis elements and potential trans-acting factors for the developmental regulation of the Phaseolus vulgaris CHS15 promoter. Hotter GS, et al. **Plant Mol Biol** 1995 Sep; 28(6):967–81

Phytohormone control of the tobacco anionic peroxidase promoter. Klotz KL, et al. **Plant Mol Biol** 1996 Jun; 31(3):565–73

The gene promoter for a bean abscission cellulase is ethylene-induced in transgenic tomato and shows high sequence conservation with a soybean abscission cellulase. Koehler SM, et al. **Plant Mol Biol** 1996 Jun;31(3):595–606

The maize GapC4 promoter confers anaerobic reporter gene expression and shows homology to the maize anthocyanin regulatory locus C1. Köhler U, et al. **Plant Mol Biol** 1995 Dec;29(6):1293–8

Fine structure and function of the osmotin gene promoter. Liu D, et al. **Plant Mol Biol** 1995 Dec;29(5):1015–26

Sequence-specific interactions of wound-inducible nuclear factors with mannopine synthase 2' promoter wound-responsive elements. Ni M, et al. **Plant Mol Biol** 1996 Jan;30(1):77–96

Tissue-specific and light-responsive regulation of the promoter region of the Arabidopsis thaliana chloroplast omega-3 fatty acid desaturase gene (FAD7). Nishiuchi T, et al. **Plant Mol Biol** 1995 Nov;29(3):599–609

Heat shock elements are involved in heat shock promoter activation during tobacco seed maturation. Prändl R, et al. **Plant Mol Biol** 1996 Apr;31(1):157–62

Members of a new family of DNA-binding proteins bind to a conserved cis-element in the promoters of alpha-Amy2 genes. Rushton PJ, et al. **Plant Mol Biol** 1995 Nov; 29(4):691–702

The expression of an abundant transmitting tract-specific endoglucanase (Sp41) is promoter-dependent and not essential for the reproductive physiology of tobacco. Sessa G, et al. **Plant Mol Biol** 1995 Dec;29(5):969–82

Intron position affects expression from the tpi promoter in rice. Snowden KC, et al. **Plant Mol Biol** 1996 Jun; 31(3):689–92

Functional analysis of linker insertions and point mutations in the alpha-Amy2/54 GA-regulated promoter. Tregear JW, et al. **Plant Mol Biol** 1995 Nov;29(4):749–58

A 200 bp region of the pea ENOD12 promoter is sufficient for nodule-specific and nod factor induced expression. Vijn I, et al. **Plant Mol Biol** 1995 Sep;28(6):1103–10

Promoter regions of cysteine endopeptidase genes from legumes confer germination-specific expression in transgenic tobacco seeds. Yamauchi D, et al. **Plant Mol Biol** 1996 Jan;30(2):321–9

Isolation of a polyubiquitin promoter and its expression in transgenic potato plants. Garbarino JE, et al. **Plant Physiol** 1995 Dec;109(4):1371–8

Transgenic analysis of a hybrid poplar wound-inducible promoter reveals developmental patterns of expression similar to that of storage protein genes. Hollick JB, et al. **Plant Physiol** 1995 Sep;109(1):73–85

Auxin-sensitive elements from promoters of tobacco GST genes and a consensus as-1-like element differ only in relative strength. van der Zaal BJ, et al. **Plant Physiol** 1996 Jan;110(1):79–88

Stress activation of a bean hydroxyproline-rich glycoprotein promoter is superimposed on a pattern of tissue-specific developmental expression. Wycoff KL, et al. **Plant Physiol** 1995 Sep;109(1):41–52

Characterization of bacteriophage T4 early promoters in vivo with a new promoter probe vector. Wilkens K, et al. **Plasmid** 1996 Mar;35(2):108–20

A functional Rev-erb alpha responsive element located in the human Rev-erb alpha promoter mediates a repressing activity. Adelmant G, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3553–8

Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells. Aguila HL, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10192–6

Distortion in the spacer region of Pm during activation of middle transcription of phage Mu. Artsimovitch I, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9408–13

Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. Bowman BH, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12115–9

Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Busslinger M, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6129–34

The human lysozyme promoter directs reporter gene expression to activated myelomonocytic cells in transgenic mice. Clarke S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1434–8

Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum. Crabb BS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7289–94

Identification of the promoter of the mouse obese gene. de la Brousse FC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4096–101

Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. de Vera ME, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1054–9

Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene. Ericsson J, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):945–50

A mammalian arginine/lysine transporter uses multiple promoters. Finley KD, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9378–82

Transcription of the lymphocyte-specific terminal deoxynucleotidyltransferase gene requires a specific core promoter structure. Garraway IP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4336–41

Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette [see comments] Hofmann A, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5185–90. Comment in: Proc Natl Acad Sci U S A 1996 May 28;93(11):5173–6.

Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Hwang CS, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):873–7

Creation of a reversible on/off system for site-specific in vivo control of exogenous gene activity in the renal glomerulus. Kitamura M. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7387–91

Glucocorticoid and progestin receptors are differently involved in the cooperation with a structural element of the mouse mammary tumor virus promoter. Le Ricousse S, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):5072–7

Constitutively active human Notch1 binds to the transcription factor CBF1 and stimulates transcription through a promoter containing a CBF1-responsive element. Lu FM, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5663–7

Promoter regions involved in density-dependent regulation of basic fibroblast growth factor gene expression in human astrocytic cells. Moffett J, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2470–5

Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Morris GF, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):895–9

Tissue-specific response of the human platelet-activating factor receptor gene to retinoic acid and thyroid hormone by alternative promoter usage. Mutoh H, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):774–9

Transcriptional activation by protein-induced DNA bending: evidence for a DNA structural transmission model. Parekh BS, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1173–7

Krüppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements. Pengue G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1015–20

Characterization of the promoter region of the mouse Xist gene. Pillet N, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12515–9

The basic motif-leucine zipper transcription factor Nrl can positively regulate rhodopsin gene expression. Rehemtulla A, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):191–5

The chicken beta 2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: a small, G+C-rich gene with X and Y boxes in the promoter. Riegert P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1243–8

Identification of a minimal sequence of the mouse pro-alpha 1(I) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Rossert JA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1027–31

Characterization of the osmotic response element of the human aldose reductase gene promoter. Ruepp B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8624–9

Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Schaefer BC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10565–9

Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Schaefer TS, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9097–101

Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Schulze A, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11264–8

Two Arabidopsis cyclin promoters mediate distinctive transcriptional oscillation in synchronized tobacco BY-2 cells. Shaul O, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4868–72

Cytochrome P450 1A1 promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Smith JD, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11926–30

Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Somasundaram K, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3088–93

Modulation of promoter occupancy by cooperative DNA binding and activation-domain function is a major determinant of transcriptional regulation by activators in vivo. Tanaka M. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4311–5

Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Taneja R, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6197–202

Protein-protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Tang H, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1119–24

Dominant-negative mutant thyroid hormone receptors prevent transcription from Xenopus thyroid hormone receptor beta gene promoter in response to thyroid hormone in Xenopus tadpoles in vivo. Ulisse S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1205–9

The activation domain of GAL4 protein mediates cooperative promoter binding with general transcription factors in vivo. Vashee S, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10683–7

Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Wang XS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12416–20

The transcriptional transactivator of simian foamy virus 1 binds to a DNA target element in the viral internal promoter. Zou JX, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):326–30

Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213–22 (35 ref.)

A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63–96 (121 ref.)

Mouse testis Pdha-2 promoter upstream sequences confer tissue-and temporal-specific activity in transgenic mice. Iannello RC, et al. **Reprod Fertil Dev** 1994;6(5):599–604

A model for understanding gene regulation during spermatogenesis: the mouse testis Pdha-2 promoter. Iannello RC, et al. **Reprod Fertil Dev** 1995;7(4):705–12 (51 ref.)

Coactivator and promoter-selective properties of RNA polymerase I TAFs. Beckmann H, et al. **Science** 1995 Dec 1;270(5241):1506–9

Egr-1-induced endothelial gene expression: a common theme in vascular injury. Khachigian LM, et al. **Science** 1996 Mar 8;271(5254):1427–31

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [see comments] Yang NN, et al. **Science** 1996 Aug 30; 273(5279):1222–5. Comment in: Science 1996 Aug 30;273(5279):1171.

Cell cycle regulation of E2F site occupation in vivo. Zwicker J, et al. **Science** 1996 Mar 15;271(5255):1595–7

Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas-Brundage K, et al. **Semin Immunol** 1996 Jun;8(3):141–50 (68 ref.)

Molecular analysis of the human fetal-to-adult globin switching. Katsube T, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:212–20

Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Heywood DM, et al. **Thromb Haemost** 1996 Mar;75(3):401–6

DNA length polymorphism present in the antithrombin III promoter region does not influence plasma antithrombin III activity levels [letter] Niessen RW, et al. **Thromb Haemost** 1996 Feb;75(2):376–7

The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de l'Infarctus du Mycocarde. Ye S, et al. **Thromb Haemost** 1995 Sep;74(3):837–41

Deletion analysis of the porcine E-selectin promoter. Brostjan C, et al. **Transplant Proc** 1996 Apr;28(2):639–41

Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Cowan PJ, et al. **Transplantation** 1996 Jul 27; 62(2):155–60

Cell type-dependent regulation of the activity of the negative regulatory element of the hepatitis B virus core promoter. Chen M, et al. **Virology** 1995 Dec 1;214(1):198–206

Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Daniel AM, et al. **Virology** 1996 Feb 1;216(1):90–101

Interaction of host proteins with the plus-strand promoter of brome mosaic virus RNA-2. Duggal R, et al. **Virology** 1995 Dec 20;214(2):638–41

Equine herpesvirus 1 gene 12, the functional homologue of herpes simplex virus VP16, transactivates via octamer sequences in the equine herpesvirus IE gene promoter. Elliott G, et al. **Virology** 1995 Oct 20;213(1):258–62

Phenotypic determinants of adenovirus E1A gene autoregulation: variable region between conserved coding domains 2 and 3. Hamid R, et al. **Virology** 1995 Nov 10; 213(2):666–70

Deletion analysis of the promoter for the cucumber necrosis virus 0.9-kb subgenomic RNA. Johnston JC, et al. **Virology** 1995 Dec 1;214(1):100–9

Trans-activation of a cell housekeeping gene promoter by the IE1 gene product of baculoviruses. Lu M, et al. **Virology** 1996 Apr 1;218(1):103–13

The varicella-zoster virus immediate-early 62 promoter contains a negative regulatory element that binds transcriptional factor NF-Y. Moriuchi H, et al. **Virology** 1995 Dec 1;214(1):256–8

Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)

Transactivation of the two promoters of SFV-3 by different mechanisms. Renne R, et al. **Virology** 1996 Jul 15; 221(2):362–7

Conservation of DNA sequence in the predicted major late promoter regions of selected mastadenoviruses. Song B, et al. **Virology** 1996 Jun 15;220(2):390–401

Characterization of Epstein-Barr virus recombinants with deletions of the BamHI C promoter. Swaminathan S. **Virology** 1996 Mar 15;217(2):532–41

Analysis of the determinants of neurotropism and neurotoxicity of HFV in transgenic mice. Tschopp RR, et al. **Virology** 1996 Feb 15;216(2):338–46

Tissue-specific gene expression from Mo-MLV retroviral

vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Vile RG, et al. **Virology** 1995 Dec 1; 214(1):307–13

Herpes simplex virus recombination vectors designed to allow insertion of modified promoters into transcriptionally "neutral" segments of the viral genome. Singh J, et al. **Virus Genes** 1995;10(2):127–36

Characterization of 5'-upstream sequence of the latent membrane protein 1 (LMP-1) gene of an Epstein-Barr virus identified in nasopharyngeal carcinoma tissues. Chen ML, et al. **Virus Res** 1995 Jun;37(1):75–84

The effect of transcription on genetic recombination in poxvirus-infected cells. Parks RJ, et al. **Virus Res** 1996 Mar;41(1):11–23

Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Ray RB, et al. **Virus Res** 1995 Aug;37(3):209–20

[Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter] Bois-Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541–50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Serum stimulates the transcriptional activity of the enhancer of the immediate-early genes of the murine cytomegalovirus through p21 ras] Angeretti A, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec;86(1-12):55–64 (Eng. Abstr.) **(Ita)**

[Protein p53 inhibits the activity of the enhancer of the immediate-early genes of murine cytomegalovirus] Lembo D, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec; 86(1-12):43–54 (Eng. Abstr.) **(Ita)**

[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**

[Transcriptional machinery and its regulatory elements of HBV genome] Nishizono A, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:28–34 (30 ref.) **(Jpn)**

[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618–23 (13 ref.) **(Jpn)**

[Promoter and enhancer of the ornithine transcarbamylase gene] Nishiyori A, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2606–12 (26 ref.) **(Jpn)**

[Inducible regulatable promoter--ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624–30 (25 ref.) **(Jpn)**

[Effect of a specific promotor sequence on nucleosome phasing] Kraevskiĭ VA, et al. **Dokl Akad Nauk** 1996 Jan; 346(3):403–5 **(Rus)**

[The purine-pyrimidine tract activates transcription of the minimal retroviral promotor] Kraevskiĭ VA, et al. **Dokl Akad Nauk** 1996 Feb;346(4):555–7 **(Rus)**

[Transcription factors C-EBP and AP-1 modulate the promotor activity of the regulatory region of human p53 gene] Kukushkin AN, et al. **Mol Biol (Mosk)** 1996 Jan-Feb; 30(1):93–103 **(Rus)**

[Effect of sequences flanking the "-10" homology region of the spc-promotor from the starting point, on the interaction with Escherichia coli RNA polymerase] Savinkova LK, et al. **Mol Biol (Mosk)** 1996 Jan-Feb;30(1):188–91 **(Rus)**

DRUG EFFECTS

Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level. Andrew PJ, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):949–56

Staurosporine potentiates cAMP-mediated promoter activity of the vasoactive intestinal polypeptide gene in rat pheochromocytoma PC12 cells. Sasaki K, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1114–20

Regulation of the mouse inducible-type nitric oxide synthase gene promoter by interferon-gamma, bacterial lipopolysaccharide and NG-monomethyl-L-arginine. Weisz A, et al. **Biochem J** 1996 May 15;316 (Pt 1):209–15

Granulocyte-macrophage colony-stimulating factor, phorbol ester, and sodium butyrate induce the CD11c integrin gene promoter activity during myeloid cell differentiation. Rubio MA, et al. **Blood** 1995 Nov 15;86(10):3715–24

Tissue-specific factors additively increase the probability of the all-or-none formation of a hypersensitive site. Boyes J, et al. **EMBO J** 1996 May 15;15(10):2496–507

Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. Rempel A, et al. **FEBS Lett** 1996 May 6;385(3):233–7

The protein tyrosine kinase Fyn activates transcription from the HIV promoter via activation of NF kappa B-like DNA-binding proteins. Hohashi N, et al. **Int Immunol** 1995 Nov;7(11):1851–9

The potent anti-proliferative effect of 20-epi analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity. Mørk Hansen C, et al. **Int J Cancer** 1996 Sep 4;67(5):739–42

Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. Cleutjens KB, et al. **J Biol Chem** 1996 Mar 15; 271(11):6379–88

Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristate 13-acetate is mediated by activator protein 2. Johnson AC. **J Biol Chem** 1996 Feb 9;271(6):3033–8

Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. Li JM, et al. **J Biol Chem** 1995 Nov 10;270(45):26750–3

Activation of the human DNA polymerase beta promoter by a DNA-alkylating agent through induced phosphorylation of cAMP response element-binding protein-1. Narayan S, et al. **J Biol Chem** 1996 Aug 2; 271(31):18508–13

Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells. Evidence for mechanisms other than NF-kappaB. Perrella MA, et al. **J Biol Chem** 1996 Jun 7;271(23):13776–80

Identification and charaterization of the second retoinoic acid response element in the phosphoenolpyruvate carboxkinase gene promoter. Scott DK, et al. **J Biol Chem** 1996 Mar 15;271(11):6260–4

Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter. Zhang Z, et al. **J Biol Chem** 1995 Oct 13;270(41):24287–91

Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation. Kuprash DV, et al. **J Immunol** 1996 Apr 1;156(7):2465–72

Characterization of novel phorbol ester- and serum-responsive sequences of the rat ornithine decarboxylase gene promoter. Mar PK, et al. **Mol Carcinog** 1995 Dec;14(4):240–50

ETS1 transactivates the human GM-CSF promoter in Jurkat T cells stimulated with PMA and ionomycin. Thomas RS, et al. **Oncogene** 1995 Nov 16;11(10):2135–43

8-methoxypsoralen and ultraviolet a radiation activate the human elastin promoter in transgenic mice: in vivo and in vitro evidence for gene induction. Bernstein EF, et al. **Photochem Photobiol** 1996 Aug;64(2):369–74

Induction of nopaline synthase promoter activity by H2O2 has no direct correlation with salicylic acid. Dai Z, et al. **Plant Physiol** 1995 Dec;109(4):1191–7

Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Bjarnadóttir M, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):617–23

GENETICS

Erythroid-specific activation of the distal (testis) promoter of GATA1 during differentiation of purified normal murine hematopoietic stem cells. Migliaccio AR, et al. **Acta Haematol** 1996;95(3-4):229–35

Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)

Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids. Rust K, et al. **Am J Respir Cell Mol Biol** 1996 Feb;14(2):121–30

Single-strand-DNA-binding factors specifically recognize the pyrimidine element in the chick alpha2(I) collagen gene promoter. Bayarsaihan D, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):293–6

A negative regulatory element in the promoter region of the rat alpha 2A-adrenergic receptor gene overlaps an SP1 consensus binding site. Handy DE, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):541–7

Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Wick M, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):549–54

Common promoter features in human and mouse liver type phosphofructokinase gene. Levanon D, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):929–36

Mutational analysis of the adenovirus E2-early promoter in fission yeast Schizosaccharomyces pombe. Manohar CF, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):653–63

Localization of a transcription promoter within the second exon of the cytochrome P-450c27/25 gene for the expression of the major species of two-kilobase mRNA. Mullick J, et al. **Biochemistry** 1995 Oct 24;34(42):13729–42

Expression of the testis-specific histone H1t gene: evidence for involvement of multiple cis-acting promoter elements. Wolfe SA, et al. **Biochemistry** 1995 Sep 26;34(38):12461–9

Computer-aided analysis of potential transcription-factor binding sites in the rabbit beta-casein gene promoter. Malewski T, et al. **Biosystems** 1995;36(2):109–19

Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Aries A, et al. **Blood** 1996 Apr 1;87(7):2885–90

Transcriptional regulation of the human factor IX promoter by the orphan receptor superfamily factor, HNF4, ARP1 and COUP/Ear3. Naka H, et al. **Br J Haematol** 1996 Jan; 92(1):231–40

Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Lahiri DK, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):233–40

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147–59 (133 ref.)

Activity of the rat lactase gene promoter in transfected human colon cancer cells. Boukamel R, et al. **C R Acad Sci III** 1995 Nov;318(11):1133–40

The two overlapping Azospirillum brasilense upstream activator sequences have differential effects on nifH promoter activity. Passaglia LM, et al. **Can J Microbiol** 1995 Sep;41(9):849–54

Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Rishi AK, et al. **Cancer Res** 1995 Nov 1; 55(21):4999–5006

Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Tanaka T, et al. **Cancer Res** 1996 Mar 15;56(6):1341–5

Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. Zhang L, et al. **Cancer Res** 1996 Mar 15;56(6):1367–73

Contacts in context: promoter specificity and macromolecular interactions in transcription. Goodrich JA, et al. **Cell** 1996 Mar 22;84(6):825–30 (32 ref.)

A ribosomal DNA promoter replacing the promoter of a telomeric VSG gene expression site can be efficiently switched on and off in T. brucei. Rudenko G, et al. **Cell** 1995 Nov 17;83(4):547–53

Identification of regulatory elements necessary for the expression of the COL1A1 promoter in murine odontoblasts. Thomas HF, et al. **Connect Tissue Res** 1995; 33(1-3):81–5

Biological activity in the repopulating rat spermatocyte after the withdrawal of gossypol treatment. VI. Alteration in nuclear factors for interaction with histone gene promoter. Teng CS, et al. **Contraception** 1995 Aug;52(2):129–34

Characterization of a SpAN promoter sufficient to mediate correct spatial regulation along the animal-vegetal axis of the sea urchin embryo. Kozlowski DJ, et al. **Dev Biol** 1996 May 25;176(1):95–107

A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation. Albanesi C, et al. **Development** 1996 Apr;122(4):1291–302

Binding of a CTF/NF1-like protein to the mouse colony-stimulating factor-1 gene promoter. Konicek BW, et al. **DNA Cell Biol** 1995 Nov;14(11):961–9

Characterization of nuclear protein binding sites in the promoter of keratin K17 gene. Milisavljevic V, et al. **DNA Cell Biol** 1996 Jan;15(1):65–74

The CYP2B1 proximal promoter contains a functional C/EBP regulatory element. Park Y, et al. **DNA Cell Biol** 1996 Aug;15(8):693–701

Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. Rudert F, et al. **DNA Cell Biol** 1995 Nov;14(11):931–7

A tissue-specific repressor in the sea urchin embryo of Lytechinus pictus binds the distal G-string element in the LpS1-beta promoter. Seid CA, et al. **DNA Cell Biol** 1996 Jun;15(6):511–7

Characterization of the rat catechol-O-methyltransferase gene proximal promoter: identification of a nuclear protein-DNA interaction that contributes to the tissue-specific regulation. Tenhunen J. **DNA Cell Biol** 1996 Jun;15(6):461–73

The role of a positioned nucleosome at the Drosophila melanogaster hsp26 promoter. Lu Q, et al. **EMBO J** 1995 Oct 2;14(19):4738–46

Basal and vitamin D-responsive activity of the rat osteocalcin promoter in stably transfected osteosarcoma cells: requirement of upstream sequences for control by the proximal regulatory domain. Frenkel B, et al. **Endocrinology** 1996 Mar;137(3):1080–88

Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. Kristjuhan A, et al. **Eur J Biochem** 1995 Dec 15; 234(3):827–31

Structural and functional analysis of the promoter of the murine V gamma 1.1 T cell receptor gene. Ofir R, et al. **Eur J Immunol** 1995 Nov;25(11):3070–8

ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. Desdouets C, et al. **FEBS Lett** 1996 Apr 29;385(1-2):34–8

T7 DNA-dependent RNA polymerase can transcribe RNA from tick-borne encephalitis virus (TBEV) cDNA with SP6 promoter. Dobrikova EY, et al. **FEBS Lett** 1996 Mar 18;382(3):327–9

Insulin- and polyunsaturated fatty acid-responsive region(s) of rat ATP citrate lyase gene promoter. Fukuda H, et al. **FEBS Lett** 1996 Feb 12;380(1-2):204–7

In vitro characterization of the ORF1-ntrBC promoter of Rhizobium etli. Martino M, et al. **FEBS Lett** 1996 Jun 10; 388(1):53–8

Characterization of a short unique sequence in the yeast HO gene promoter that regulates HO transcription in a SIN1 dependent manner. Yona E, et al. **FEBS Lett** 1996 Mar 11;382(1-2):97–100

Analysis of the shut-off of ribosomal RNA promoters in Escherichia coli upon entering the stationary phase of growth. Aviv M, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):71–6

Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Laskus T, et al. **Gastroenterology** 1995 Nov;109(5):1618–23

Negative transcriptional regulation of PH081 expression in Saccharomyces cerevisiae. Creasy CL, et al. **Gene** 1996 Feb 2;168(1):23–9

Structure of the growth hormone-encoding gene and its promoter in mice. Das P, et al. **Gene** 1996 Mar 9; 169(2):209–13

Characteristic sequences in the promoter region of the chicken tyrosinase-encoding gene. Ferguson CA, et al.

Gene 1996 Mar 9;169(2):191–5
The upstream region of the SP–B gene: intrinsic promoter activity and glucocorticoid responsiveness related to a new DNA–binding protein. Luzi P, et al. Gene 1995 Nov 20; 165(2):285–90
The σ29x gene of symbiotic bacteria in Amoeba proteus with a novel promoter. Pak JW, et al. Gene 1996 May 24; 171(1):89–93
High–level, stage– and mammary–tissue–specific expression of a caprine kappa–casein–encoding minigene driven by a beta–casein promoter in transgenic mice. Persuy MA, et al. Gene 1995 Nov 20;165(2):291–6
Sequence of the flounder (Paralichthys olivaceus) growth hormone–encoding gene and its promoter region. Tanaka M, et al. Gene 1995 Nov 20;165(2):321–2
The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis. Waterfield NR, et al. Gene 1995 Nov 7;165(1):9–15
Retroviral vector sequences may interact with some internal promoters and influence expression. Wu X, et al. Hum Gene Ther 1996 Jan 20;7(2):159–71
Expression and regulation of the dystrophin Purkinje promoter in human skeletal muscle, heart, and brain. Holder E, et al. Hum Genet 1996 Feb;97(2):232–9
A small automaton for word recognition in DNA sequences and its application to consensus analysis of regulatory elements in DNA regions controlling gene expression. Lefèvre C, et al. Ismb 1993;1:243–50
Sites required for GltC–dependent regulation of Bacillus subtilis glutamate synthase expression. Belitsky BR, et al. J Bacteriol 1995 Oct;177(19):5686–95
Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of Bordetella pertussis. Boucher PE, et al. J Bacteriol 1995 Nov;177(22):6486–91
Five promoters integrate control of the cob/pdu regulon in Salmonella typhimurium. Chen P, et al. J Bacteriol 1995 Oct;177(19):5401–10
Binding affinity and functional significance of NIT2 and NIT4 binding sites in the promoter of the highly regulated nit–3 gene, which encodes nitrate reductase in Neurospora crassa. Chiang TY, et al. J Bacteriol 1995 Nov; 177(21):6093–9
Activation of transcription initiation from the nac promoter of Klebsiella aerogenes. Feng J, et al. J Bacteriol 1995 Oct; 177(19):5523–34
Repression of the Klebsiella aerogenes nac promoter. Feng J, et al. J Bacteriol 1995 Oct;177(19):5535–8
Characterization of the regulatory region of a cell interaction–dependent gene in Myxococcus xanthus. Fisseha M, et al. J Bacteriol 1996 May;178(9):2539–50
Conserved cis–acting promoter elements are required for density–dependent transcription of Agrobacterium tumefaciens conjugal transfer genes. Fuqua C, et al. J Bacteriol 1996 Jan;178(2):435–40
The hypBFCDE operon from Rhizobium leguminosarum biovar viciae is expressed from an Fnr–type promoter that escapes mutagenesis of the fnrN gene. Hernando Y, et al. J Bacteriol 1995 Oct;177(19):5661–9
Specific binding of the activator Mga to promoter sequences of the emm and scpA genes in the group A streptococcus. McIver KS, et al. J Bacteriol 1995 Nov;177(22):6619–24
Multiple promoters and induction by heat shock of the gene encoding the alternative sigma factor AlgU (sigma E) which controls mucoidy in cystic fibrosis isolates of Pseudomonas aeruginosa. Schurr MJ, et al. J Bacteriol 1995 Oct;177(19):5670–9
The dnaKJ operon of Agrobacterium tumefaciens: transcriptional analysis and evidence for a new heat shock promoter. Segal G, et al. J Bacteriol 1995 Oct; 177(20):5952–8
Regulation of groE expression in Bacillus subtilis: the involvement of the sigma A–like promoter and the roles of the inverted repeat sequence (CIRCE). Yuan G, et al. J Bacteriol 1995 Oct;177(19):5427–33
Isolation and characterization of the promoter region of the rat DNA topoisomerase II alpha gene. Park SH, et al. J Biochem (Tokyo) 1995 Oct;118(4):725–33
Neuron specificity of the neurofilament light promoter in transgenic mice requires the presence of DNA unwinding elements. Charron G, et al. J Biol Chem 1995 Oct 27; 270(43):25739–45
Sp1–mediated transcriptional activation of the human Pi class glutathione S–transferase promoter. Moffat GJ, et al. J Biol Chem 1996 Jan 12;271(2):1054–60
Two Sp1–binding sites mediate cAMP–induced transcription of the bovine CYP11A gene through the protein kinase A signaling pathway. Venepally P, et al. J Biol Chem 1995 Oct 27;270(43):25402–10
The mouse APLP2 gene. Chromosomal localization and promoter characterization. von Koch CS, et al. J Biol Chem 1995 Oct 27;270(43):25475–80
The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. Takahashi K, et al. J Gen Virol 1995 Dec; 76 (Pt 12):3159–64
Interaction of bovine herpesvirus 4 (BHV–4) immediate early 2 gene product with BHV–4 thymidine kinase promoter–regulatory region. Zhang L, et al. J Gen Virol 1995 Oct;76 (Pt 10):2433–45
Polymorphic nucleotides within the human IL–4 promoter that mediate overexpression of the gene. Song Z, et al. J Immunol 1996 Jan 15;156(2):424–9
Absence of mutations in the promoter of the COL1A1 gene of type I collagen in patients with osteogenesis imperfecta type I. Willing MC, et al. J Med Genet 1995 Sep; 32(9):697–700
The Bacillus subtilis response regulator Spo0A stimulates transcription of the spoIIG operon through modification of RNA polymerase promoter complexes. Bird TH, et al. J Mol Biol 1996 Mar 1;256(3):436–48
Kinetics of RNA polymerase initiation and pausing at the lambda late gene promoter in vivo. Kainz M, et al. J Mol Biol 1995 Dec 15;254(5):808–14
Myotube–specific activity of the human aldolase A M–promoter requires an overlapping binding site for NF1 and MEF2 factors in addition to a binding site (M1) for unknown proteins. Salminen M, et al. J Mol Biol 1995 Oct 13;253(1):17–31
Sequence–specific interactions between promoter DNA and the RNA polymerase sigma factor E. Tatti KM, et al. J Mol Biol 1995 Oct 13;253(1):8–16
Transcription activation parameters at ara pBAD. Zhang X, et al. J Mol Biol 1996 Apr 26;258(1):14–24
Immediate upstream promoter regions required for neurospecific expression of SNAP–25. Ryabinin AE, et al. J Mol Neurosci 1995;6(3):201–10
A tau promoter region without neuronal specificity. Andreadis A, et al. J Neurochem 1996 Jun;66(6):2257–63
Promoter region and alternatively spliced exons of the rat mu–opioid receptor gene. Mayer P, et al. J Neurochem 1996 Jun;66(6):2272–8
Identification and characterization of a 47 base pair activity–dependent enhancer of the rat nicotinic acetylcholine receptor delta–subunit promoter. Walke W, et al. J Neurosci 1996 Jun 1;16(11):3641–51
Cis–elements in the promoter region of the human myeloperoxidase (MPO) gene. Zhao WG, et al. Leukemia 1996 Jul;10(7):1089–103
In vitro transcription of class II promoters in higher plants. Cooke R, et al. Methods Mol Biol 1995;49:271–89 (19 ref.)
Depression of streptomycin production by Streptomyces griseus at elevated growth temperature: studies using gene fusions. Deeble VJ, et al. Microbiology 1995 Oct;141 (Pt 10):2511–8
Mapping of a replication origin within the promoter region of two unlinked, abundantly transcribed actin genes of Physarum polycephalum. Bénard M, et al. Mol Cell Biol 1996 Mar;16(3):968–76
An essential E box in the promoter of the gene encoding the mRNA cap–binding protein (eukaryotic initiation factor 4E) is a target for activation by c–myc. Jones RM, et al. Mol Cell Biol 1996 Sep;16(9):4754–64
An RNA polymerase II promoter in the hsp70 locus of Trypanosoma brucei. Lee MG. Mol Cell Biol 1996 Mar; 16(3):1220–30
Regulation of interleukin 12 p40 expression through an NF–kappa B half–site. Murphy TL, et al. Mol Cell Biol 1995 Oct;15(10):5258–67
G10BP, an E1A–inducible negative regulator of Sp1, represses transcription of the rat fibronectin gene. Suzuki M, et al. Mol Cell Biol 1995 Oct;15(10):5423–33
Specific binding of proteins to the noncoding strand of a crucial element of the variant surface glycoprotein, procyclin, and ribosomal promoters of trypanosoma brucei. Vanhamme L, et al. Mol Cell Biol 1995 Oct; 15(10):5598–606
A DNA methylation site in the male–specific P450 (Cyp 2d–9) promoter and binding of the heteromeric transcription factor GABP. Yokomori N, et al. Mol Cell Biol 1995 Oct;15(10):5355–62
Silkworm TFIIIB binds both constitutive and silk gland–specific tRNA Ala promoters but protects only the constitutive promoter from DNase I cleavage. Young LS, et al. Mol Cell Biol 1996 Mar;16(3):1256–66
Characterization and regulation of the mouse insulin receptor substrate gene promoter. Araki E, et al. Mol Endocrinol 1995 Oct;9(10):1367–79
A T7 promoter–specific, inducible protein expression system for Bacillus subtilis. Conrad B, et al. Mol Gen Genet 1996 Feb 5;250(2):230–6
The tef1 box, a ubiquitous cis–acting element involved in the activation of plant genes that are highly expressed in cycling cells. Regad F, et al. Mol Gen Genet 1995 Oct 25;248(6):703–11
Yeast killer plasmid pGKL2: molecular analysis of UCS5, a cytoplasmic promoter element essential for ORF5 gene function. Schaffrath R, et al. Mol Gen Genet 1996 Feb 25; 250(3):286–94
A ribosomal protein gene (rpl32) from tobacco chloroplast DNA is transcribed from alternative promoters: similarities in promoter region organization in plastid housekeeping genes. Vera A, et al. Mol Gen Genet 1996 Jul 19; 251(5):518–25
Fnr activates transcription from the P6 promoter of the pfl operon in vitro. Kaiser M, et al. Mol Microbiol 1995 Oct; 18(2):331–42
The –16 region, a vital sequence for the utilization of a promoter in Bacillus subtilis and Escherichia coli. Voskuil MI, et al. Mol Microbiol 1995 Jul;17(2):271–9
DNA binding of hypothalamic nuclear proteins on estrogen response element and preproenkephalin promoter: modification by estrogen. Zhu YS, et al. Neuroendocrinology 1995 Nov;62(5):454–66
Analysis of varicella–zoster virus promoter sequences. Kantakamalakul W, et al. Neurology 1995 Dec;45(12 Suppl 8):S28–9 (3 ref.)
Transcription activation by the bacteriophage Mu Mor protein: analysis of promoter mutations in Pm identifies a new region required for promoter function. Artsimovitch I, et al. Nucleic Acids Res 1996 Feb 1;24(3):450–7
Thyroid hormone receptors bind to the promoter of the mouse histone H10 gene and modulate its transcription. Bauer–Hofmann R, et al. Nucleic Acids Res 1995 Dec 25; 23(24):5034–40
Computer assisted identification and classification of streptomycete promoters. Bourn WR, et al. Nucleic Acids Res 1995 Sep 25;23(18):3696–703
Molecular and functional analysis of the utrophin promoter. Dennis CL, et al. Nucleic Acids Res 1996 May 1; 24(9):1646–52
A novel PRD I and TG binding activity involved in virus–induced transcription of IFN–A genes. Génin P, et al. Nucleic Acids Res 1995 Dec 25;23(24):5055–63
A promotor directing alpha–amanitin–sensitive transcription of GARP, the major surface antigen of insect stage Trypanosoma congolense. Graham SV, et al. Nucleic Acids Res 1996 Jan 15;24(2):272–81
Transcription factors interacting with herpes simplex virus alpha gene promoters in sensory neurons. Hagmann M, et al. Nucleic Acids Res 1995 Dec 25;23(24):4978–85
RNA polymerase III dependence of the human L1 promoter and possible participation of the RNA polymerase II factor YY1 in the RNA polymerase III transcription system. Kurose K, et al. Nucleic Acids Res 1995 Sep 25; 23(18):3704–9
Transcription factors RFX1/EF–C and ATF–1 associate with the adenovirus E1A–responsive element of the human proliferating cell nuclear antigen promoter. Labrie C, et al. Nucleic Acids Res 1995 Sep 25;23(18):3732–41
Construction of trypanosome artificial mini–chromosomes. Lee MG, et al. Nucleic Acids Res 1995 Dec 11; 23(23):4893–9
Identification of promoter and stringent regulation of transcription of the fabH, fabD and fabG genes encoding fatty acid biosynthetic enzymes of Escherichia coli. Podkovyrov SM, et al. Nucleic Acids Res 1996 May 1; 24(9):1747–52
CACCC and GATA–1 sequences make the constitutively expressed alpha–globin gene erythroid–responsive in mouse erythroleukemia cells. Ren S, et al. Nucleic Acids Res 1996 Jan 15;24(2):342–7
The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Schorpp M, et al. Nucleic Acids Res 1996 May 1;24(9):1787–8
Activation domains of transcription factors mediate replication dependent transcription from a minimal HIV–1 promoter. Williams RD, et al. Nucleic Acids Res 1996 Feb 15;24(4):549–57
The minimal ribosomal RNA gene promoter of Arabidopsis thaliana includes a critical element at the transcription initiation site. Doelling JH, et al. Plant J 1995 Nov; 8(5):683–92
The promoter of the Vicia faba L. VfENOD–GRP3 gene encoding a glycine–rich early nodulin mediates a predominant gene expression in the interzone II–III region of transgenic Vicia hirsuta root nodules. Küster H, et al. Plant Mol Biol 1995 Nov;29(4):759–72
Site–directed mutagenesis of the enhancer region of the 780 gene promoter of T–DNA. O'Grady K, et al. Plant Mol Biol 1995 Oct;29(1):99–108
The promoter of the human monoamine oxidase A gene. Denney RM. Prog Brain Res 1995;106:57–66
Mutations which result in constitutive expression of the Bordetella pertussis filamentous haemagglutinin gene. Goyard S, et al. Res Microbiol 1995 Jun;146(5):363–70
Studies of the anaerobically induced promoter pnirB and the improved expression of bacterial antigens. Newton SM, et al. Res Microbiol 1995 Mar–Apr;146(3):193–202
The human cystatin C gene promoter: functional analysis and identification of heterogeneous mRNA. Olafsson I. Scand J Clin Lab Invest 1995 Nov;55(7):597–607
Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. Semin Cell Biol 1995 Aug;6(4):177–83 (52 ref.)
Characterization of the promoter region of human steroid sulfatase: a gene which escapes X inactivation. Li XM, et al. Somat Cell Mol Genet 1996 Mar;22(2):105–17
Ubiquitin promoter–based vectors for high–level expression of selectable and/or screenable marker genes in monocotyledonous plants. Christensen AH, et al. Transgenic Res 1996 May;5(3):213–8
Evaluation in tobacco of the organ specificity and strength of the rolD promoter, domain A of the 35S promoter and the 35S2 promoter. Elmayan T, et al. Transgenic Res 1995 Nov;4(6):388–96
An in vivo analysis of transcriptional elements in the mouse alpha–myosin heavy chain gene promoter. Rindt H, et al. Transgenic Res 1995 Nov;4(6):397–405
Tandem placement of a coronavirus promoter results in enhanced mRNA synthesis from the downstream–most initiation site. Krishnan R, et al. Virology 1996 Apr 15; 218(2):400–5
Characterization of sequences controlling the synthesis of alfalfa mosaic virus subgenomic RNA in vivo. van der Vossen EA, et al. Virology 1995 Oct 1;212(2):663–72
Further definition of the sequence and position requirements

of the arginine control element that mediates repression and induction by arginine in Saccharomyces cerevisiae. Crabeel M, et al. **Yeast** 1995 Nov;11(14):1367–80

Structure of the human apolipoprotein C–II gene promoter. Streicher R, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:49–50

IMMUNOLOGY

Sequence elements required for function of the MHC class II A beta gene promoter in murine macrophages. Johnson SP, et al. **Cell Immunol** 1995 Dec;166(2):207–16

Signal requirements for interleukin 4 promoter activation in human T cells. Paliogianni F, et al. **Cell Immunol** 1996 Feb 25;168(1):33–8

Identification of Sp1–binding sites in the CD11c (p150,95 alpha) and CD11a (LFA–1 alpha) integrin subunit promoters and their involvement in the tissue–specific expression of CD11c. López–Rodríguez C, et al. **Eur J Immunol** 1995 Dec;25(12):3496–503

Ultrastructural allelic variation in HLA–DQB1 promoter elements. Leech N, et al. **Hum Immunol** 1995 Aug; 43(4):251–8

C–myc represses transiently transfected HLA class I promoter sequences not locus–specifically. Griffioen M, et al. **Immunobiology** 1995 Jul;193(2–4):238–47

Regulation of expression of the LFA–1 and p150,95 leukocyte integrins: involvement of the CD11a and CD11c gene promoters. López–Rodríguez C, et al. **Immunobiology** 1995 Jul;193(2–4):315–21

The inducible transcription factor NF–AT plays an important role in the activation of the murine interleukin–4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2–4):268–72 (14 ref.)

Promoter analysis of the human interleukin–8 receptor genes, IL–8RA and IL–8RB. Sprenger H, et al. **Immunobiology** 1995 Jul;193(2–4):334–40

Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249–62 (54 ref.)

Evidence for a calcium regulated, bidirectional intronic promoter in the murine TCR V alpha 1 gene. Maeda T, et al. **Int Immunol** 1995 Aug;7(8):1339–51

Transcriptional regulation of the junB promoter in mature B lymphocytes. Activation through a cyclic adenosine 3',5'–monophosphate–like binding site. Amato SF, et al. **J Immunol** 1996 Jul 1;157(1):146–55

Promoter region of the human gene coding for beta–chain of C4b binding protein. Hepatocyte nuclear factor–3 and nuclear factor–I/CTF transcription factors are required for efficient expression of C4BPB in HepG2 cells. Arenzana N, et al. **J Immunol** 1996 Jan 1;156(1):168–75

Sublethal levels of oxidative stress stimulate transcriptional activation of c–jun and suppress IL–2 promoter activation in Jurkat T cells. Beiqing L, et al. **J Immunol** 1996 Jul 1;157(1):160–9

Differential transcription efficiency of two Ig VH promoters in vitro. Buchanan KL, et al. **J Immunol** 1995 Nov 1; 155(9):4270–7

Early B cell factor interacts with a subset of kappa promoters. Sigvardsson M, et al. **J Immunol** 1996 May 15; 156(10):3788–96

Structural analysis of human natural resistance–associated macrophage protein 1 promoter. Kishi F, et al. **Mol Immunol** 1996 Feb;33(3):265–8

PHYSIOLOGY

gamma–Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Lieberman MW, et al. **Am J Pathol** 1995 Nov; 147(5):1175–85 (91 ref.)

The gene for the major protein (SVSP109) of bovine semen: structure and promoter analysis. Bräuer C, et al. **Biol Chem Hoppe Seyler** 1995 Oct;376(10):631–6

Autoregulation of human CYP1A1 gene promotor activity in HepG2 and MCF–7 cells. Jørgensen EC, et al. **Carcinogenesis** 1996 Mar;17(3):435–41

Three–dimensional structure of E. coli core RNA polymerase: promoter binding and elongation conformations of the enzyme. Polyakov A, et al. **Cell** 1995 Nov 3;83(3):365–73

The glucocorticoid receptor synergizes with Jun homodimers to activate AP–1–regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251–5 (17 ref.)

Redundant control of Ultrabithorax by zeste involves functional levels of zeste protein binding at the Ultrabithorax promoter. Laney JD, et al. **Development** 1996 Jul;122(7):2303–11

Response of Drosophila metallothionein promoters to metallic, heat shock and oxidative stresses. Bonneton F, et al. **FEBS Lett** 1996 Feb 12;380(1–2):33–8

The mechanism of CAP–lac repressor binding cooperativity at the E. coli lactose promoter. Vossen KM, et al. **J Mol Biol** 1996 Jan 12;255(1):44–54

Brain cell type specificity and gliosis–induced activation of the human cytomegalovirus immediate–early promoter in transgenic mice. Fritschy JM, et al. **J Neurosci** 1996 Apr 1;16(7):2275–82

Regulation of PNMT gene promoter constructs transfected into the TE 671 human medulloblastoma cell line. Hemmick LM, et al. **Neurosci Lett** 1995 Dec 1;201(1):77–80

In vivo footprinting of the mouse inducible nitric oxide synthase gene: inducible protein occupation of numerous sites including Oct and NF–IL6. Goldring CE, et al. **Nucleic Acids Res** 1996 May 1;24(9):1682–7

Selective activation of the proto–oncogene c–jun promoter by the transforming protein v–Rel. Fujii M, et al. **Oncogene** 1996 May 16;12(10):2193–202

p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Roemer K, et al. **Oncogene** 1996 May 16;12(10):2069–79

p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription. Zhao J, et al. **Oncogene** 1996 Jul 18;13(2):293–302

Identification of a calcium–inducible, cyclosporine sensitive element in the IFN–gamma promoter that is a potential NFAT binding site. Campbell PM, et al. **Transplantation** 1996 Mar 27;61(6):933–9

RADIATION EFFECTS

8–methoxypsoralen and ultraviolet a radiation activate the human elastin promoter in transgenic mice: in vivo and in vitro evidence for gene induction. Bernstein EF, et al. **Photochem Photobiol** 1996 Aug;64(2):369–74

PROMOTION OF HEALTH see **HEALTH PROMOTION**

PROMYELOCYTES see **GRANULOCYTES**

PROMYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PRONASE

The use of pronase–digested human leukocytes to improve specificity of the flow cytometric crossmatch. Lobo PI, et al. **Transpl Int** 1995;8(6):472–80

METABOLISM

Use of protease sensitivity to probe the conformations of newly synthesised mutant forms of mitochondrial aspartate aminotransferase. Azzariti A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):800–7

PRONATION

An axially loaded model of the ankle after pronation external rotation injury. Michelson JD, et al. **Clin Orthop** 1996 Jul; (328):285–93

Rearfoot posture in subjects with patellofemoral pain. Powers CM, et al. **J Orthop Sports Phys Ther** 1995 Oct;22(4):155–60

PHYSIOLOGY

Video assessment of rearfoot movements during walking: a reliability study. Keenan AM, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):651–5

PRONE POSITION

Prone positioning improves pulmonary function in obese patients during general anesthesia. Pelosi P, et al. **Anesth Analg** 1996 Sep;83(3):578–83

Prone position: visceral hypoperfusion and rhabdomyolysis. Ziser A, et al. **Anesth Analg** 1996 Feb;82(2):412–5

Risk factors for the infant prone sleep position. Taylor JA, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):834–7

The prone position in acute respiratory distress syndrome [editorial] Ryan DW, et al. **BMJ** 1996 Apr 6; 312(7035):860–1

Prone sleeping in healthy infants and victims of sudden infant death syndrome [editorial] Hunt CE. **J Pediatr** 1996 May; 128(5 Pt 1):594–6

Prone sleep position and the sudden infant death syndrome in King County, Washington: a case–control study. Taylor JA, et al. **J Pediatr** 1996 May;128(5 Pt 1):626–30

"Back to sleep" program [letter] Johnson CM, et al. **Pediatrics** 1996 Jul;98(1):163–5

On listening to parents: the sudden infant death syndrome over 25 years. Tonkin S. **Pediatrics** 1996 Jun;97(6 Pt 1):896–7

[Ventilation in the prone position in acute respiratory distress syndrome (ARDS)] Jolliet P, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):879–92 (77 ref.) (Eng. Abstr.) **(Fre)**

[Haines--a modified posture in first aid drainage. Time to reevaluate prone position?] Gärdelöf B, et al. **Lakartidningen** 1996 Aug 28;93(35):2957–8 **(Swe)**

PHYSIOLOGY

Colonic pseudo–obstruction: value of prone lateral view of the rectum. Low VH. **Abdom Imaging** 1995 Nov–Dec; 20(6):531–3

Skull morphology affected by different sleep positions in infancy. Huang CS, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):413–9

Sleeping position and sudden infant death syndrome: a review of the literature and the implications for infants in the United States. Bradshaw CM. **Indiana Med** 1996 Jan–Feb; 89(1):64–73 (0 ref.)

Error prone? [letter; comment] Carrillo P. **J Pediatr** 1996 Jun;128(6):865–6. Comment on: J Pediatr 1995 Oct;127(4):609–14.

Face–straight–down and face–near–straight–down positions in healthy, prone–sleeping infants. Waters KA, et al. **J Pediatr** 1996 May;128(5 Pt 1):616–25

Infant room–sharing and prone sleep position in sudden infant death syndrome. New Zealand Cot Death Study Group [see comments] Scragg RK, et al. **Lancet** 1996 Jan 6; 347(8993):7–12. Comment in: Lancet 1996 Jan 6;347(8993):2.

Decreased cardiac responses to auditory stimulation during prone sleep. Franco P, et al. **Pediatrics** 1996 Feb; 97(2):174–8

[Glaucoma in Marfan syndrome: position–dependent measurement of intraocular pressure as a diagnostic criterium] Schlote T, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):386–8 (Eng. Abstr.) **(Ger)**

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

PRONORMOBLASTS see **ERYTHROBLASTS**

PRONUCLEAR STAGE TRANSFER see **ZYGOTE INTRAFALLOPIAN TRANSFER**

PRO-OPIOCORTIN see **PRO-OPIOMELANOCORTIN**

PRO-OPIOMELANOCORTIN

AGONISTS

Cyclosporin A and FK506 are potent activators of proopiomelanocortin–derived peptide secretion without affecting corticotrope glucocorticoid receptor function. Sheppard KE. **J Neuroendocrinol** 1995 Nov;7(11):833–40

ANALOGS & DERIVATIVES

Proopiomelanocortin, its derived peptides, and the skin. Wintzen M, et al. **J Invest Dermatol** 1996 Jan;106(1):3–10 (155 ref.)

ANALYSIS

The appearance of proopiomelanocortin early in vertebrate evolution: cloning and sequencing of POMC from a Lamprey pituitary cDNA library. Heinig JA, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):137–44

Evidence for the presence of immunoreactive POMC–derived peptides and cytokines in the thymus of the goldfish (Carassius c. auratus). Ottaviani E, et al. **Histochem J** 1995 Aug;27(8):597–601

Levels of pro–opiomelanocortin and prolactin mRNA in the fetal sheep pituitary following hypoxaemia and glucocorticoid treatment in late gestation. Matthews SG, et al. **J Endocrinol** 1995 Oct;147(1):139–46

BIOSYNTHESIS

Effect of S(-)– and R(+)–salsolinol on the POMC gene expression and ACTH release of an anterior pituitary cell line. Putscher I, et al. **Alcohol** 1995 Sep–Oct;12(5):447–52

Glutamate enhances the adenylyl cyclase–cAMP system–induced beta–endorphin secretion and POMC mRNA expression in rat hypothalamic neurons in culture: NMDA receptor–mediated modulation. Yang Z, et al. **Brain Res** 1995 Sep 18;692(1–2):129–36

Differential regulation of proopiomelanocortin messenger ribonucleic acid in the pars distalis and pars intermedia of the pituitary gland after prolonged hypoxemia in fetal sheep. Braems GA, et al. **Endocrinology** 1996 Jul; 137(7):2731–8

Functional identification of genes up– and down–regulated by glucocorticoids in AtT–20 pituitary cells using an enhancer trap. Harrison RW, et al. **Endocrinology** 1996 Jul; 137(7):2758–65

Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat. Wajs E, et al. **Eur J Endocrinol** 1995 Dec;133(6):754–60

Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. Ray DW, et al. **J Clin Invest** 1996 Apr 15;97(8):1852–9

Functional analysis of the human pro–opiomelanocortin promoter in the small cell lung carcinoma cell line DMS–79. Picon A, et al. **J Mol Endocrinol** 1995 Oct; 15(2):187–94

Changes in pro–opiomelanocortin and pre–proenkephalin mRNA levels in the ovine brain during pregnancy, parturition and lactation and in response to oestrogen and progesterone. Broad KD, et al. **J Neuroendocrinol** 1993 Dec;5(6):711–9

Differential effects of estrogen and progesterone on levels of POMC mRNA levels in the arcuate nucleus: relationship to the timing of LH surge release. Petersen SL, et al. **J Neuroendocrinol** 1993 Dec;5(6):643–8

Effect of centrally administered neuropeptide Y on hypothalamic and hypophyseal proopiomelanocortin–derived peptides in the rat. Blasquez C, et al. **Neuroscience** 1995 Sep;68(1):221–7

Current topic: the placental corticotrophin–releasing hormone–adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)

PRO-OPIOMELANOCORTIN

GENETICS

Translocon-associated protein TRAP delta and a novel TRAP-like protein are coordinately expressed with pro-opiomelanocortin in Xenopus intermediate pituitary. Holthuis JC, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):205-13

DNA elements with AT-rich core sequences direct pituitary cell-specific expression of the pro-opiomelanocortin gene in transgenic mice. Liu B, et al. **Biochem J** 1995 Dec 15; 312 (Pt 3):827-32

The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. Slominski A, et al. **Biochim Biophys Acta** 1996 Mar 15;1289(2):247-51

Increased expression of proopiomelanocortin (POMC) mRNA in adrenal glands of mice undergoing graft-versus-host disease (GVHD): association with persistent elevated plasma corticosterone levels. You-Ten KE, et al. **Clin Exp Immunol** 1995 Dec;102(3):596-602

Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat. Wajs E, et al. **Eur J Endocrinol** 1995 Dec;133(6):754-60

Thy-1+ dendritic cells express truncated form of POMC mRNA. Farooqui JZ, et al. **Exp Dermatol** 1995 Oct; 4(5):297-301

Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. Slominski A, et al. **FEBS Lett** 1995 Oct 23;374(1):113-6

The appearance of proopiomelanocortin early in vertebrate evolution: cloning and sequencing of POMC from a Lamprey pituitary cDNA library. Heinig JA, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):137-44

Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Lamonerie T, et al. **Genes Dev** 1996 May 15;10(10):1284-95

The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. de Keyzer Y, et al. **J Clin Invest** 1996 Mar 1;97(5):1311-8

Ultraviolet B and melanocyte-stimulating hormone (MSH) stimulate mRNA production for alpha MSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes. Chakraborty A, et al. **J Invest Dermatol** 1995 Nov;105(5):655-9

Proopiomelanocortin gene product regulation in keratinocytes. Wintzen M, et al. **J Invest Dermatol** 1996 Apr;106(4):673-8

Functional analysis of the human pro-opiomelanocortin promoter in the small cell lung carcinoma cell line DMS-79. Picon A, et al. **J Mol Endocrinol** 1995 Oct; 15(2):187-94

The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary. Holthuis JC, et al. **J Neurochem** 1996 Jun;66(6):2248-56

Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Boutillier AL, et al. **Mol Endocrinol** 1995 Jun; 9(6):745-55

Gonadal steroid hormone regulation of proopiomelanocortin gene expression in arcuate neurons that innervate the medial preoptic area of the rat. Cheung S, et al. **Neuroendocrinology** 1995 Sep;62(3):283-92

Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Rubinstein M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3995-4000

IMMUNOLOGY

Evidence for the presence of immunoreactive POMC-derived peptides and cytokines in the thymus of the goldfish (Carassius c. auratus). Ottaviani E, et al. **Histochem J** 1995 Aug;27(8):597-601

METABOLISM

Yeast and mammalian basic residue-specific aspartic proteases in prohormone conversion. Loh YP, et al. **Adv Exp Med Biol** 1995;362:519-27

Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). Azaryan AV, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):937-44

Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Chakraborty AK, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):130-8

Ontogeny of basal and regulated proopiomelanocortin-derived peptide secretion from fetal and neonatal pituitary intermediate lobe cells: melanotrophs exhibit transient glucocorticoid responses during development. Lugo DI, et al. **Dev Biol** 1996 Jan 10; 173(1):110-8

Expression of recombinant pro-neuropeptide Y, proopiomelanocortin, and proenkephalin: relative processing by 'prohormone thiol protease' (PTP). Schiller MR, et al. **FEBS Lett** 1996 Mar 11;382(1-2):6-10

Identification of POMC processing products in single melanotrope cells by matrix-assisted laser desorption/ionization mass spectrometry. van Strien FJ, et al. **FEBS Lett** 1996 Jan 29;379(2):165-70

Dietary sodium intake modulates pituitary proopiomelanocortin mRNA abundance. Mayan H, et al. **Hypertension** 1996 Aug;28(2):244-9

Molecular probing of the secretory pathway in peptide hormone-producing cells. Holthuis JC, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3295-305

Impaired processing of proopiomelanocortin in corticotroph macroadenomas. Gibson S, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):497-502

Differential acetylation of pro-opiomelanocortin-derived peptides in the pituitary gland of Xenopus laevis in relation to background adaptation. van Strien FJ, et al. **J Endocrinol** 1995 Jul;146(1):159-67

Proopiomelanocortin, its derived peptides, and the skin. Wintzen M, et al. **J Invest Dermatol** 1996 Jan;106(1):3-10 (155 ref.)

Biosynthesis and processing of the N-terminal part of proopiomelanocortin in Xenopus laevis: characterization of gamma-MSH peptides. van Strien FJ, et al. **J Neuroendocrinol** 1995 Oct;7(10):807-15

Central diabetes insipidus in a dog with a pro-opiomelanocortin-producing pituitary tumor not causing hyperadrenocorticism. Goossens MM, et al. **J Vet Intern Med** 1995 Sep-Oct;9(5):361-5

Evidence for the paracrine action of islet-derived corticotropin-like peptides on the regulation of insulin release. Borelli MI, et al. **Metabolism** 1996 May; 45(5):565-70

Ionic milieu controls the compartment-specific activation of pro-opiomelanocortin processing in AtT-20 cells. Schmidt WK, et al. **Mol Biol Cell** 1995 Oct;6(10):1271-85

alpha-2-Adrenergic activation of proopiomelanocortin-containing neurons in the arcuate nucleus causes opioid-mediated hypotension and bradycardia. Li SJ, et al. **Neuroendocrinology** 1996 Mar; 63(3):275-83

Lesions of the afferent catecholaminergic pathways inhibit the temporal activation of the CRH and POMC gene expression and ACTH release induced by human interleukin-1beta in the male rat. Parsadaniantz SM, et al. **Neuroendocrinology** 1995 Dec;62(6):586-95

Chromogranin B (secretogranin I) promotes sorting to the regulated secretory pathway of processing intermediates derived from a peptide hormone precursor. Natori S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4431-6

PHARMACOLOGY

Stimulation of tyrosinase in human melanocytes by pro-opiomelanocortin-derived peptides. McLeod SD, et al. **J Endocrinol** 1995 Sep;146(3):439-47

Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. Bhardwaj RS, et al. **J Immunol** 1996 Apr 1;156(7):2517-21

Proopiomelanocorticotropin (POMC) peptides and lipoprotein lipase activity in vitro. Eichhorn P, et al. **Peptides** 1995;16(4):665-71

PHYSIOLOGY

Targeted ablation of pituitary pre-proopiomelanocortin cells by herpes simplex virus-1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Allen RG, et al. **Mol Endocrinol** 1995 Aug; 9(8):1005-16

RADIATION EFFECTS

Ultraviolet B and melanocyte-stimulating hormone (MSH) stimulate mRNA production for alpha MSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes. Chakraborty A, et al. **J Invest Dermatol** 1995 Nov;105(5):655-9

SECRETION

Ontogeny of basal and regulated secretion from POMC cells of the developing anterior lobe of the rat pituitary gland. Lugo DI, et al. **Dev Biol** 1996 Jan 10;173(1):95-109

Effect of histamine on gene expression and release of proopiomelanocortin-derived peptides from the anterior and intermediate pituitary lobes in conscious male rats. Knigge U, et al. **Neuroendocrinology** 1995 Oct;62(4):319-25

PROPAFENONE

ADMINISTRATION & DOSAGE

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587-91

Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. Bianconi L, et al. **J Am Coll Cardiol** 1996 Sep;28(3):700-6

[A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation] Satullo G, et al. **Minerva Cardioangiol** 1996 Mar;44(3):141-4 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Chimienti M, et al. **Eur Heart J** 1995 Dec;16(12):1943-51

Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Mörike K, et al. **J Intern Med** 1995 Nov; 238(5):469-72

ANALOGS & DERIVATIVES

Effect of diprafenone on the pharmacokinetics of digoxin. Koytchev R, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):97-100

Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers. Hinderling PH, et al. **J Clin Pharmacol** 1995 Jul;35(7):721-9

BLOOD

Quantitation of R- and S-propafenone and of the main metabolite in plasma. Böhm R, et al. **Pharmazie** 1995 Aug; 50(8):542-5

METABOLISM

Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Mörike K, et al. **J Intern Med** 1995 Nov; 238(5):469-72

PHARMACOKINETICS

Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Fromm MF, et al. **Eur J Clin Pharmacol** 1995;48(3-4):279-83

PHARMACOLOGY

Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia. Gillis AM, et al. **Am J Cardiol** 1996 Sep 1;78(5):579-81

Effects of propafenone on the median frequency of ventricular fibrillation in Langendorff perfused guinea-pig hearts. Eggenreich U, et al. **Cardiovasc Res** 1996 Jun; 31(6):926-31

Rate-dependent effects of detajmium and propafenone on ventricular conduction and refractoriness in isolated guinea pig hearts. Stark U, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):125-31

Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Chiba P, et al. **Mol Pharmacol** 1996 Jun; 49(6):1122-30

[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation] Telichowski A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):132-43 (Eng. Abstr.) **(Pol)**

[Use-dependence of propafenone. Clinical demonstration of the hypothesis of modulated receptors] Labadet CD, et al. **Medicina (B Aires)** 1995;55(1):33-8 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E, et al. **Am J Cardiol** 1996 Jan 25;77(3):66A-71A

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Chimienti M, et al. **Am J Cardiol** 1996 Jan 25;77(3):60A-75A

Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Doni F, et al. **Am J Cardiol** 1995 Dec 15;76(17):1243-6

Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Podrid PJ, et al. **Am J Cardiol** 1996 Aug 15;78(4):430-4

A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. **Circulation** 1995 Nov 1;92(9):2550-7

Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Bellandi F, et al. **Clin Cardiol** 1995 Nov;18(11):631-4

Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Fresco C, et al. **Clin Cardiol** 1996 May;19(5):409-12

Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250-62 (73 ref.)

Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. Stevens SK, et al. **J Am Coll Cardiol** 1996 Aug;28(2):418-22

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353-64 (74 ref.)

[Facilitating effect of propafenone pretreatment in the interruption of atrial flutter by transesophageal pacing] Doni F, et al. **Cardiologia** 1996 Feb;41(2):135–40 (Eng. Abstr.) **(Ita)**

[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine] Mondillo S, et al. **Clin Ter** 1995 Dec;146(12):769–74 (Eng. Abstr.) **(Ita)**

[Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study] Bellandi F, et al. **G Ital Cardiol** 1996 Apr;26(4):379–90 (Eng. Abstr.) **(Ita)**

PROPAGANDA

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)

[Lies told by the alcohol and tobacco industries and their friends (letter)] Nešpor K, et al. **Cas Lek Cesk** 1995 Sep 20;134(18):596 **(Cze)**

PROPANE

Injuries from propane gas grills. Schieber RA, et al. **JAMA** 1996 Mar 20;275(11):886

ANALOGS & DERIVATIVES

Update of the mortality experience of employees with occupational exposure to 1,2-dibromo-3-chloropropane (DBCP). Olsen GW, et al. **Am J Ind Med** 1995 Sep; 28(3):399–410

1,2 Dibromo-3-chloropropane (DBCP) and ethylene dibromide (EDB) in well water in the Fresno/Clovis metropolitan area, California. Kloos H. **Arch Environ Health** 1996 Jul-Aug;51(4):291–9

Organ-specific and transplacental DNA damage and its repair in rats treated with 1,2-dibromo-3-chloropropane. Brunborg G, et al. **Chem Biol Interact** 1996 Jun; 101(1):33–48

Catalysis of nitro-aci tautomerism of the genotoxicant 2-nitropropane by cytosol from rodent and human liver. Kohl C, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):219–26

Identification of N-acetylcysteine conjugates of 1,2-dibromo-3-chloropropane: evidence for cytochrome P450 and glutathione mediated bioactivation pathways. Weber GL, et al. **Chem Res Toxicol** 1995 Jun;8(4):560–73

Comparative toxicity of (+)-(R)- and (-)-(S)-1,2-dibromo-3-chloropropane. Kouzi SA, et al. **Chirality** 1995;7(5):359–64

Preventive effects of green tea against liver oxidative DNA damage and hepatotoxicity in rats treated with 2-nitropropane. Hasegawa R, et al. **Food Chem Toxicol** 1995 Nov;33(11):961–70

Developmental toxicity of 1,2-dichloropropane (PDC) in rats and rabbits following oral gavage. Kirk HD, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):18–26

Dibromochloropropane (DBCP): a 17-year reassessment of testicular function and reproductive performance. Potashnik G, et al. **J Occup Environ Med** 1995 Nov; 37(11):1287–92

Mechanism of sex-related differences in nephrotoxicity of 1.2-dichloropropane in rats. Odinecs A, et al. **Ren Fail** 1995 Sep;17(5):517–24

In vitro toxicity of 1,2-dibromo-3-chloropropane (DBCP) in different testicular cell types from rats. Bjørge C, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):461–73

[Alkylation of gem-dibromocyclopropanes with higher-order organocuprates] Harayama T, et al. **Yakugaku Zasshi** 1995 Oct;115(10):863–70 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Lack of cross-tolerance for hypophagia induced by DOI versus m-CPP suggests separate mediation by 5-HT2A and 5-HT2C receptors, respectively. Aulakh CS, et al. **Neuropsychopharmacology** 1995 Aug;13(1):1–8

PROPANEDIAL see **MALONDIALDEHYDE**

PROPANEDIOLS

Intracytoplasmic sperm injection and embryo development of human oocytes cryopreserved using 1,2-propanediol. Gook DA, et al. **Hum Reprod** 1995 Oct;10(10):2637–41

ADMINISTRATION & DOSAGE

Analysis of anticonvulsant and neurotoxic responses to combination therapy with carbamazepine, felbamate and phenytoin by response-surface modeling. Gennings C, et al. **Arzneimittelforschung** 1995 Jul;45(7):739–48

Effect of propylene glycol supplementation around parturition on milk yield, reproduction performance and some hormonal and metabolic characteristics in dairy cows. Formigoni A, et al. **J Dairy Res** 1996 Feb;63(1):11–24

Embolisation of a cystic lymphatic malformation of the neck. Debakker G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):267–8

A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Suzuki S, et al. **Transplantation** 1996 Jan 27;61(2):200–5

ADVERSE EFFECTS

Contact sensitization to dipropylene glycol in an eczema population. Johansen JD, et al. **Contact Dermatitis** 1995 Sep;33(3):211–2

Contact allergy to neopentyl glycol di-iso-octanoate. Nishioka K, et al. **Contact Dermatitis** 1995 Sep;33(3):208–9

Contact dermatitis from propylene glycol in Rifocine. el Sayed F, et al. **Contact Dermatitis** 1995 Aug;33(2):127–8

Felbamate-induced headache. Ettinger AB, et al. **Epilepsia** 1996 May;37(5):503–5

Psychosis associated with felbamate treatment [letter] Knable MB, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):292–3

Propylene glycol toxicity caused by prolonged infusion of etomidate. Van de Wiele B, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):259–62

Felbamate-associated fatal acute hepatic necrosis. O'Neil MG, et al. **Neurology** 1996 May;46(5):1457–9

Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Levy ML, et al. **Neurosurgery** 1995 Aug;37(2):363–9; discussion 369–71

Treatment of head injury in mice, using a fructose 1,6-diphosphate and dimethyl sulfoxide combination [letter] Parkinson D. **Neurosurgery** 1996 Jan;38(1):232

BLOOD

Felbamate levels in patients with epilepsy. Harden CL, et al. **Epilepsia** 1996 Mar;37(3):280–3

CHEMISTRY

Isolation of a novel association network in a polymer gel. Ilzhoefer JR, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):467–8

METABOLISM

Distribution of felbamate in brain. Cornford EM, et al. **Epilepsia** 1996 Jan;37(1):15–8

Glutathione is required for maximal transcription of the cobalamin biosynthetic and 1,2-propanediol utilization (cob/pdu) regulon and for the catabolism of ethanolamine, 1,2-propanediol, and propionate in Salmonella typhimurium LT2. Rondon MR, et al. **J Bacteriol** 1995 Oct;177(19):5434–9

DNA polymerase I function is required for the utilization of ethanolamine, 1,2-propanediol, and propionate by Salmonella typhimurium LT2. Rondon MR, et al. **J Bacteriol** 1995 Dec;177(24):7119–24

Taxonomic diversity of anaerobic glycerol dissimilation in the Enterobacteriaceae. Bouvet OM, et al. **Res Microbiol** 1995 May;146(4):279–90

PHARMACOKINETICS

Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Weber W, et al. **Arzneimittelforschung** 1995 Jul;45(7):781–4

Pharmacokinetic interaction studies between felbamate and vigabatrin. Reidenberg P, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):157–60

Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Hooper WD, et al. **Epilepsia** 1996 Jan;37(1):91–7

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Banfield CR, et al. **Ther Drug Monit** 1996 Feb; 18(1):19–29

PHARMACOLOGY

Electrophysiological actions of felbamate on rat striatal neurones. Pisani A, et al. **Br J Pharmacol** 1995 Oct; 116(3):2053–61

Weight loss in patients taking felbamate. Bergen DC, et al. **Clin Neuropharmacol** 1995 Feb;18(1):23–7

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Hulsman JA, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):383–9

Effects of felbamate on the pharmacokinetics of phenobarbital. Reidenberg P, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):279–87

Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Saano V, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):523–31

Felbamate neuroprotection against CA1 traumatic neuronal injury. Wallis RA, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2-3):475–82

Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hovatta O, et al. **Hum Reprod** 1996 Jun; 11(6):1268–72

Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. Imamura Y, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):177–82

Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor. Kume A, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1784–92

Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. Libri V, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1759–69

Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. Stefani A, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):121–7

Effects of felbamate, kynurenic acid derivatives and NMDA antagonists on in vitro kainate-induced epileptiform activity. Domenici MR, et al. **Life Sci** 1996 May 24; 58(26):PL391–6

The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Kosten TA, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):323–33

Effect of PGML excipient mixture in a transdermal system on the in vitro transport of estradiol across skin. Irion GD, et al. **Pharm Res** 1995 Nov;12(11):1618–22

Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720. Suzuki S, et al. **Transplant Proc** 1996 Aug;28(4):2049–50

POISONING

Felbamate overdose: a case report and discussion of a new antiepileptic drug. Nagel TR, et al. **Pediatr Emerg Care** 1995 Dec;11(6):369–71

THERAPEUTIC USE

The use of felbamate in patients with periodic lateralized epileptiform discharges (PLEDs). Hughes JR, et al. **Clin Electroencephalogr** 1995 Jul;26(3):180–3

Felbamate relieved trigeminal neuralgia. Cheshire WP. **Clin J Pain** 1995 Jun;11(2):139–42

Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. French JA. **Epilepsia** 1996;37 Suppl 2:S23–S26

Felbamate. Leppik IE. **Epilepsia** 1995;36 Suppl 2:S66–72 (55 ref.)

Felbamate monotherapy: implications for antiepileptic drug development. Theodore WH, et al. **Epilepsia** 1995 Nov; 36(11):1105–10

Taming the brain storms: felbamate updated. Brodie MJ, et al. **Lancet** 1995 Oct 7;346(8980):918–9

Felbamate and tremor [letter; comment] Edwards KR. **Neurology** 1995 Oct;45(10):1951. Comment on: Neurology 1995 Jan;45(1):185–7.

Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Thomsen MS, et al. **Pharmacol Toxicol** 1995 Jun;76(6):395–9

Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Gay PE, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1208–10

Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia. Wasterlain CG, et al. **Stroke** 1996 Jul;27(7):1236–40

FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Chiba K, et al. **Transplant Proc** 1996 Apr;28(2):1056–9

FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Hoshino Y, et al. **Transplant Proc** 1996 Apr;28(2):1060–1

FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Kawaguchi T, et al. **Transplant Proc** 1996 Apr;28(2):1062–3

Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Suzuki S, et al. **Transplant Proc** 1996 Jun;28(3):1375–6

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

[Felbamate: perspectives for new antiepileptic treatment] Pérez-Miranda J, et al. **Rev Neurol** 1995 Nov-Dec; 23(124):1220–5 (46 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Mayeno AN, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):911–6

Hematological alterations in propylene glycol-dosed female rats are minimal. Saini M, et al. **Vet Hum Toxicol** 1996 Apr;38(2):81–5

URINE

Exposure to glycols and their renal effects in motor servicing workers. Laitinen J, et al. **Occup Med (Oxf)** 1995 Oct; 45(5):259–62

PROPANIDID

[Anesthesia with propanidid in a liposomal preparation. An experimental study in swine] Klockgether-Radke A, et al. **Anaesthesist** 1995 Aug;44(8):573–80 (Eng. Abstr.) **(Ger)**

PROPANIL

TOXICITY

Changes in primary and secondary lymphoid organ T-cell subpopulations resulting from acute in vivo exposure to propanil. Zhao W, et al. **J Toxicol Environ Health** 1995 Oct;46(2):171-81

PROPANOL see **ALCOHOL, PROPYL**

PROPANOLAMINES

ADMINISTRATION & DOSAGE

Brevibloc drug errors [letter] Pearce DJ. **Can J Anaesth** 1996 Apr;43(4):419

ADVERSE EFFECTS

Contact dermatitis from levobunolol and befunolol. Zucchelli V, et al. **Contact Dermatitis** 1995 Jul;33(1):66-7

ANALYSIS

[Analysis of some neuroleptics and carazolol in pork kidneys] Arneth W. **Z Lebensm Unters Forsch** 1995 Sep;201(3):261-5 (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

[Preparation of aryloxyaminopropanol derivatives with potential effects on the cardiovascular system] Hlaváčová H, et al. **Ceska Slov Farm** 1995 Oct;44(5):261-4 (Eng. Abstr.) **(Cze)**

DIAGNOSTIC USE

Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X. Rosen SD, et al. **Am J Cardiol** 1996 Jul 1;78(1):37-42

In vivo quantification of human pulmonary beta-adrenoceptor density using PET: comparison with in vitro radioligand binding. Qing F, et al. **J Nucl Med** 1996 Aug;37(8):1275-81

METABOLISM

Determination and properties of acetyl conjugate of N-desisopropylpropranolol, AcNDP. Noda A, et al. **Biol Pharm Bull** 1995 Oct;18(10):1454-5

Effect of 3-methylcholanthrene on bunitrolol metabolism. Kinetics and immunological studies on 4-hydroxylation of bunitrolol catalyzed by two species of cytochromes P450 in rat liver microsomes. Fujita S, et al. **Drug Metab Dispos** 1996 Feb;24(2):254-9

Relationships between conformational behaviour and binding affinity towards beta 1 and beta 2 adrenoceptors of some chiral phenoxypropanolamines with bulky N-substituents. Villa L, et al. **Farmaco** 1995 Oct;50(10):643-58

Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. Gaillard P, et al. **J Med Chem** 1996 Jan 5;39(1):126-34

[The metabolism of the beta receptor blocker talinolol in humans--relationship between structure, polarity and amount excreted] Oertel R, et al. **Pharmazie** 1995 Sep; 50(9):637-8 **(Ger)**

PHARMACOKINETICS

Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Trausch B, et al. **Biopharm Drug Dispos** 1995 Jul;16(5):403-14

Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Gramatté T, et al. **Clin Pharmacol Ther** 1996 May; 59(5):541-9

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Wetterich U, et al. **Pharm Res** 1996 Apr;13(4):514-22

[The pharmacokinetics of different drug forms of nifedipine when used singly and in a course as monotherapy and in combination with Cordanum and triampur preparations in patients with arterial hypertension] Kukes VG, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):22-5 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Korpinen R, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):809-13

Effect of beta-blockade on dobutamine stress echocardiography. Weissman NJ, et al. **Am Heart J** 1996 Apr;131(4):698-703

Cardiac surgical conditions induced by beta-blockade: effect on myocardial fluid balance. Mehlhorn U, et al. **Ann Thorac Surg** 1996 Jul;62(1):143-50

The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Tham TC, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):19-23

Noradrenaline-induced relaxation of rat oesophageal muscularis mucosae: mediation solely by innervated beta 3-adrenoceptors. de Boer RE, et al. **Br J Pharmacol** 1995 Oct;116(3):1945-7

Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. De Ponti F, et al. **Br J Pharmacol** 1996 Apr;117(7):1374-6

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24-9 (24 ref.)

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8-16 (37 ref.)

Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Adachi T, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):201-4

The electrophysiologic effects of ersentilide on canine hearts. Lee JH, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):25-35

Carazolol: a potent, selective beta 3-adrenoceptor agonist. Méjean A, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):359-66

Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Yue TL, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):585-91

Effect of bupranolol on CGP 12177-induced relaxation and cAMP accumulation in the guinea pig taenia caecum. Koike K, et al. **Gen Pharmacol** 1995 Dec;26(8):1791-4

Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. Schwarz ER, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1637-45

(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. Bielawska A, et al. **J Biol Chem** 1996 May 24;271(21):12646-54

Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings [see comments] Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):530-40. Comment in: J Cardiovasc Pharmacol 1995 Oct;26(4):524-7.

Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. de Mey C, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):879-8

The ethical issue--not only healthy volunteers! [editorial; comment] Edvardsson N, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):528-9. Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):524-7.

Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. Wiesfeld AC, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):594-600

Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. Jacob S, et al. **J Hypertens** 1996 Apr;14(4):489-94

Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol. Dubois EA, et al. **J Med Chem** 1996 Aug 16; 39(17):3256-62

Vaninolol: a novel compound for the treatment of glaucoma and ischemic retinopathy. Wu BN, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):213-20

Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. Ma XL, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):128-36

Comparison of two bolus doses of esmolol for attenuation of haemodynamic response to tracheal intubation. Sharma S, et al. **Med J Malaysia** 1995 Dec;50(4):372-6

Effect of 3-amino-1-propanol, indomethacin and 4-bromophenacyl bromide on the hormone binding of insulin pretreated Tetrahymena: influence of phospholipid metabolism disturbances on hormonal imprinting. Kovács P, et al. **Microbios** 1995;84(341):255-61

Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Nisoli E, et al. **Mol Pharmacol** 1996 Jan;49(1):7-14

Characterization of the sensitivity of cardiac outwardly-rectifying K+ channels to class III antiarrhythmics: the influence of inhibitory sulfonamide derivatives. Benz I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):313-21

Electrophysiological effects of dridocainide on isolated canine, guinea-pig and human cardiac tissues. Pankucsi C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):520-8

Comparison of coronary microvascular response to nipradilol and nitroglycerin. Lamping KG, et al. **Pharmacology** 1995 Nov;51(5):315-22

Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Lopez BL, et al. **Pharmacology** 1995 Sep;51(3):165-73

Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure. Scarpace PJ, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):374-80

[Prevention of increase of blood pressure and intracranial pressure during endotracheal intubation in neurosurgery: esmolol versus lidocaine] Samaha T, et al. **Ann Fr Anesth Reanim** 1996;15(1):36-40 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Krum H, et al. **Am Heart J** 1996 Feb;131(2):337-41

Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Yoshikawa T, et al. **Am Heart J** 1996 Feb;131(2):329-36

Esmolol aids extubation in intensive care patient with ischaemic pulmonary oedema. Duane DT, et al. **Anaesthesia** 1996 May;51(5):474-7

The effect of esmolol pretreatment on the incidence of regional wall motion abnormalities during electroconvulsive therapy [see comments] O'Connor CJ, et al. **Anesth Analg** 1996 Jan;82(1):143-7. Comment in: Anesth Analg 1996 Jul;83(1):199.

Quality of life in hypertensive patients treated with either carvedilol or enalapril. Ostergren J, et al. **Blood Press** 1996 Jan;5(1):41-9

Use of esmolol in a parturient with hypertrophic obstructive cardiomyopathy. Fairley CJ, et al. **Br J Anaesth** 1995 Dec; 75(6):801-4

Effect of carvedilol on mortality and morbidity in patients with chronic heart failure [news] **Circulation** 1996 Aug 15; 94(4):592

Effects of chronic treatment with carvedilol on abnormalities of endothelium-dependent relaxation and structure of endothelium in resistance arteries of SHRSP. Sasaki F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S329-30

Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension. Haneda T, et al. **Clin Ther** 1995 Jul-Aug;17(4):667-79

The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325-42 (43 ref.)

Carvedilol for hypertension. **Drug Ther Bull** 1995 May; 33(5):39-40 (19 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38-42 (21 ref.)

Vasodilating beta-blockers in heart failure. Raftery EB. **Eur Heart J** 1995 Jul;16 Suppl F:32-7

The preventative effects of vasodilating beta-blockers in cardiovascular disease. Raftery EB. **Eur Heart J** 1996 Apr; 17 Suppl B:30-8

Carvedilol therapy in heart failure--II [letter; comment] Carbajal EV. **J Am Coll Cardiol** 1995 Nov 1; 26(5):1399-400; discussion 1400-1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225-31.

Carvedilol therapy in heart failure--I [letter; comment] Ghali JK. **J Am Coll Cardiol** 1995 Nov 1;26(5):1399; discussion 1400-1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225-31.

Carvedilol therapy in heart failure--III [letter; comment] Lee YC. **J Am Coll Cardiol** 1995 Nov 1;26(5):1400-1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225-31.

Effects of optical enantiomers CK-4000(S) and CK-4001(R) on defibrillation and enhancement of shock-induced extension of action potential duration. Beatch GN, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):716-28

Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):198-206

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. Maggi E, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):532-8

Individuals who swallow crack cocaine do not develop significant toxic reactions [letter; comment] Hollander JE. **J Emerg Med** 1995 Jul-Aug;13(4):538-9; discussion 539-43 . Comment on: J Emerg Med 1994 Jul-Aug;12(4):485-90.

Effect of beta-blockade on chronic heart failure. Bloomenthal R. **J Fam Pract** 1996 Aug;43(2):116-7

Esmolol and percutaneous cardiopulmonary bypass enhance myocardial salvage during ischemia in a dog model. Laub GW, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1085-91

Carvedilol for heart failure, with care. Cleland JG, et al. **Lancet** 1996 May 4;347(9010):1199-201

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group [see comments] Packer M, et al. **N Engl J Med** 1996 May 23;334(21):1349-55. Comment in: N Engl J Med 1996 May 23;334(21):1396-7.

Beta-adrenergic blockers and survival in heart failure [editorial; comment] Pfeffer MA, et al. **N Engl J Med** 1996 May 23;334(21):1396-7. Comment on: N Engl J Med 1996 May 23;334(21):1349-55.

Electrophysiological, rate dependent, and autonomic effects

of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):802–10

[Carvedilol in cardiac decompensation] Dib J. **Rev Med Liege** 1996 Feb;51(2):198–200 **(Fre)**

[Effect of the beta receptor blockader carazolol on the dropping and retention of the placenta in the camel (C. dromedarius)] Nasr MT, et al. **Tierarztl Prax** 1996 Jun; 24(3):319–21 (Eng. Abstr.) **(Ger)**

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

[Beta receptor blockade in heart failure: a new look at an old topic (editorial)] Klein W. **Wien Med Wochenschr** 1996; 146(5):96–7 **(Ger)**

[Balanced beta-–alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension] Perocchio M, et al. **Minerva Cardioangiol** 1996 Mar;44(3):115–21 (Eng. Abstr.) **(Ita)**

[Coronary artery bypass grafting under bradycardia induced by ultra-short acting beta blocker] Miyamoto Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):801–5 (Eng. Abstr.) **(Jpn)**

TOXICITY

Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Webster WS, et al. **Teratology** 1996 Mar;53(3):168–75

PROPANOLIDE see **PROPIOLACTONE**

PROPANTHELINE

ADVERSE EFFECTS

[Allergic contact dermatitis due to propantheline bromide (letter)] Jansen T, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):41–2 **(Ger)**

ANALOGS & DERIVATIVES

Soft drugs. 21. Design and evaluation of soft analogs of propantheline. Brouillette G, et al. **J Pharm Sci** 1996 Jun; 85(6):619–23

PHARMACOLOGY

Soft drugs. 21. Design and evaluation of soft analogs of propantheline. Brouillette G, et al. **J Pharm Sci** 1996 Jun; 85(6):619–23

PROPENE POLYMERS see **POLYPROPYLENES**

PROPENYLACRYLIC ACID see **SORBIC ACID**

PROPERDIN

CHEMISTRY

Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. Higgins JM, et al. **J Immunol** 1995 Dec 15;155(12):5777–85

DEFICIENCY

Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency. Fijen CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):290–6

Fluorescent detection of microsatellite polymorphisms: properdin deficiency linked to PFC microsatellite. Agardi D, et al. **Exp Clin Immunogenet** 1995;12(2):111–4

Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Westberg J, et al. **Genomics** 1995 Sep 1;29(1):1–8

Recurrent meningococcal septicaemia and properdin deficiency. Cunliffe NA, et al. **J Infect** 1995 Jul;31(1):67–8

[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis] Frémeaux-Bacchi V, et al. **Presse Med** 1995 Sep 30;24(28):1305–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Apropos of partial properdin deficiency disclosed by Neisseria meningitidis septicemia (letter)] Riou JY, et al. **Presse Med** 1996 Mar 23;25(10):510 **(Fre)**

GENETICS

Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Westberg J, et al. **Genomics** 1995 Sep 1;29(1):1–8

Cloning and characterization of the cDNA encoding guinea-pig properdin: a comparison of properdin from three species. Maves KK, et al. **Immunology** 1995 Nov; 86(3):475–9

Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. Higgins JM, et al. **J Immunol** 1995 Dec 15;155(12):5777–85

PROPERDIN FACTOR B

BIOSYNTHESIS

Interleukin-1 alpha, interleukin 6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro. Berge V, et al. **APMIS** 1996 Mar;104(3):213–9

Cytokine-regulated production of the major histocompatibility complex class-III-encoded complement proteins factor B and C4 by human glomerular mesangial cells. Timmerman JJ, et al. **Hum Immunol** 1995 May; 43(1):19–28

GENETICS

Complement C4, factor B and C3 polymorphism in north India. Kramer J, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):315–9

Serum concentrations of C4 isotypes and factor B in type I C2 deficiency suggest haplotype-dependent quantitative expression of MHC class III complement genes. Truedsson L, et al. **Exp Clin Immunogenet** 1995;12(2):66–73

A complement factor B-like cDNA clone from the zebrafish (Brachydanio rerio). Seeger A, et al. **Mol Immunol** 1996 Apr;33(6):511–20

[Genetic polymorphism of properdin factor B in the Han population in Chengdu, China] Chen G, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):424–6 (Eng. Abstr.) **(Chi)**

METABOLISM

Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. Lambris JD, et al. **J Immunol** 1996 Jun 15;156(12):4821–32

PROPERDIN FACTOR D

ANTAGONISTS & INHIBITORS

Factor J, an inhibitor of the classical and alternative complement pathway, does not inhibit esterolysis by factor D. González-Rubio C, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):174–8

PHYSIOLOGY

Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. Balke N, et al. **FEBS Lett** 1995 Sep 11;371(3):300–2

Complement factor D, a novel serine protease. Volanakis JE, et al. **Protein Sci** 1996 Apr;5(4):553–64 (70 ref.)

PROPERDIN PATHWAY see **COMPLEMENT PATHWAY, ALTERNATIVE**

PROPHAGE EXCISION see **VIRUS ACTIVATION**

PROPHAGE INDUCTION see **VIRUS ACTIVATION**

PROPHAGE INTEGRATION see **LYSOGENY**

PROPHASE

Meiosis in the leek (Allium porrum L.) revisited. I. Prophase I pairing. Khazanehdari KA, et al. **Chromosome Res** 1995 Nov;3(7):433–9

Serotonin-induced meiosis reinitiation from the first prophase and from the first metaphase in oocytes of the marine bivalve Hiatella flaccida: respective changes in intracellular Ca2+ and pH. Deguchi R, et al. **Dev Biol** 1995 Oct; 171(2):483–96

Maintenance of bovine oocytes in prophase of meiosis I by high [cAMP]i. Aktas H, et al. **J Reprod Fertil** 1995 Nov; 105(2):227–35

[Patterns in the condensation of bovine chromosomes in the prophase-late metaphase of mitosis] Treus VV, et al. **Tsitologiia** 1995;37(9–10):915–23 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Plant mitosis promoting factor disassembles the microtubule preprophase band and accelerates prophase progression in Tradescantia. Hush J, et al. **Cell Biol Int** 1996 Apr; 20(4):275–87

Maintenance of meiotic arrest by increasing [cAMP]i may have physiological relevance in bovine oocytes. Aktas H, et al. **J Reprod Fertil** 1995 Nov;105(2):237–45

PHYSIOLOGY

A postprophase topoisomerase II-dependent chromatid core separation step in the formation of metaphase chromosomes. Giménez-Abián JF, et al. **J Cell Biol** 1995 Oct;131(1):7–17

Centromere and telomere movements during early meiotic prophase of mouse and man are associated with the onset of chromosome pairing. Scherthan H, et al. **J Cell Biol** 1996 Sep;134(5):1109–25

PROPHENIRAMINE see **PHENIRAMINE**

PROPHENPYRIDAMINE see **PHENIRAMINE**

PROPIDIUM

Viability assessment of mammalian sperm using SYBR-14 and propidium iodide. Garner DL, et al. **Biol Reprod** 1995 Aug;53(2):276–84

Improvement of fluorescence in situ hybridization (RNA-FISH) on human paraffin sections by propidium iodide counterstaining. Wulf M, et al. **Biotechniques** 1995 Sep;19(3):368–70, 372

CHEMISTRY

Thermodynamic investigation of the association of ethidium, propidium and bis-ethidium to DNA hairpins. Rentzeperis D, et al. **Bioorg Med Chem** 1995 Jun;3(6):751–9

Intercalative interactions of ethidium dyes with triplex structures. Tuite E, et al. **Bioorg Med Chem** 1995 Jun; 3(6):701–11

Stabilization of parallel (recombinant) triplex with propidium iodide. Borisova OF, et al. **J Biomol Struct Dyn** 1995 Aug; 13(1):15–27

DIAGNOSTIC USE

Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Dengler WA, et al. **Anticancer Drugs** 1995 Aug;6(4):522–32

Use of BCECF and propidium iodide to assess membrane integrity of acutely isolated CA1 neurons from rat hippocampus. Bevensee MO, et al. **J Neurosci Methods** 1995 May;58(1–2):61–75

METABOLISM

Electropermeabilization and fluorescent tracer exchange: the role of whole-cell capacitance. Sukhorukov VL, et al. **Cytometry** 1995 Nov 1;21(3):230–40

PHARMACOLOGY

[Comparison of 2 techniques for measuring lymphocyte proliferation: tritiated methyl-thymidine incorporation and propidium iodide fluorometry] Brohee D, et al. **Rev Med Brux** 1995 Nov;16(5):368–71 (10 ref.) (Eng. Abstr.) **(Fre)**

PROPIOLACTONE

PHARMACOLOGY

Evaluation by polymerase chain reaction on the effect of beta-propiolactone and binary ethyleneimine on DNA. Groseil C, et al. **Biologicals** 1995 Sep;23(3):213–20

Inactivation of DNA by beta-propiolactone. Perrin P, et al. **Biologicals** 1995 Sep;23(3):207–11

A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Race E, et al. **Vaccine** 1995 Nov;13(16):1567–75

TOXICITY

Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow. Brault D, et al. **Mutat Res** 1996 Jun 10;360(2):83–7

PROPIONATES

ADMINISTRATION & DOSAGE

Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Berggren AM, et al. **Br J Nutr** 1996 Aug;76(2):287–94

CHEMICAL SYNTHESIS

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. Rowlands MG, et al. **J Med Chem** 1995 Oct 13; 38(21):4191–7

CHEMISTRY

Chiral alpha -hydroxy acids: racemic 2-hydroxy-2,3,3-trimethylbutanoic acid and 2-hydroxy-2-trimethylsilylpropanoic acid. Murray RW, et al. **Acta Crystallogr C** 1996 May 15;52 (Pt 5):1282–5

The reduction of propionic anhydride by aldehyde dehydrogenase-NADH mixtures AT pH 7. Motion RL, et al. **Adv Exp Med Biol** 1995;372:53–60

Asymmetric aldol condensation as a route to polypropionate derived pheromones. DiBattista JP, et al. **Bioorg Med Chem** 1996 Mar;4(3):423–8

DIAGNOSTIC USE

Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Irie T, et al. **J Nucl Med** 1996 Apr;37(4):649–55

METABOLISM

Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora. Miller TL, et al.

Appl Environ Microbiol 1996 May;62(5):1589–92

Stereo–selective affinity labelling of sheep liver sorbitol dehydrogenase by chloro–substituted analogues of 2–bromo–3–(5–imidazolyl)propionic acid. Lindstad RI, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):267–71

Verlukast (MK–0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. Nicoll–Griffith DA, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1085–93

Effects of glycine and bovine serum albumin on inhibition of propionate metabolism in ovine hepatocytes caused by reduced phenolic monomers. Cremin JD Jr, et al. **J Anim Sci** 1995 Oct;73(10):3009–21

DNA polymerase I function is required for the utilization of ethanolamine, 1,2–propanediol, and propionate by Salmonella typhimurium LT2. Rondon MR, et al. **J Bacteriol** 1995 Dec;177(24):7119–24

Metabolism of beclamide after a single oral dose in man: quantitative studies. Ahmadi M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):876–8

In vivo studies of acetylcholinesterase activity using a labeled substrate, N–[11C]methylpiperdin–4–yl propionate ([11C]PMP). Kilbourn MR, et al. **Synapse** 1996 Feb; 22(2):123–31

PHARMACOKINETICS

Short chain fatty acid absorption from the human distal colon: interactions between acetate, propionate and calcium. Wolever TM, et al. **J Am Coll Nutr** 1995 Aug; 14(4):393–8

PHARMACOLOGY

Effect of acetate and propionate on calcium absorption from the rectum and distal colon of humans. Trinidad TP, et al. **Am J Clin Nutr** 1996 Apr;63(4):574–8

Anaplerotic effects of propionate on oxidations of acetate and long–chain fatty acids. Liedtke AJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2197–203

Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Kimmelstiel CD, et al. **Cardiology** 1996 Jan–Feb; 87(1):46–53

Propionate modifies lipid biosynthesis in rat peritoneal macrophages. Rosa LF, et al. **Gen Pharmacol** 1995 Mar; 26(2):411–6

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Ando S, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1160–6

THERAPEUTIC USE

Suppression of atherosclerotic changes in cholesterol–fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Kugiyama K, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1080–7

URINE

Novel urinary metabolite of alpha–tocopherol, 2,5,7,8–tetramethyl–2(2'–carboxyethyl)–6–hydroxychroman, as an indicator of an adequate vitamin E supply? Schultz M, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1527S–1534S

PROPIONIBACTERIUM

Kinetics of nitric oxide synthase induction by Propionibacterium avidum and lipopolysaccharide. Dhouib M, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):439–45

CHEMISTRY

[Mechanism of reactivating Escherichia coli inactivated by ultraviolet light with cell extracts of propionic acid bacteria] Vorob'eva LI, et al. **Mikrobiologiia** 1995 Sep–Oct; 64(5):651–6 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin–resistant propionibacteria. Eady EA, et al. **Br J Dermatol** 1996 Jan;134(1):107–13

ENZYMOLOGY

Metal uptake of recombinant cambialistic superoxide dismutase from Propionibacterium shermanii is affected by growth conditions of host Escherichia coli cells. Gabbianelli R, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):841–7

Kinetic and spectroscopic studies on a superoxide dismutase from Propionibacterium shermanii that is active with iron or manganese: pH–dependence. Meier B, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):945–50

Initial rate and equilibrium isotope exchange studies on the ATP–dependent activity of polyphosphate Glucokinase from Propionibacterium shermanii. Kowalczyk TH, et al. **Biochemistry** 1996 May 28;35(21):6777–85

Tritium isotope effects in adenosylcobalamin–dependent methylmalonyl–CoA mutase. Meier TW, et al. **Biochemistry** 1996 Sep 10;35(36):11791–6

EXAFS investigation of the active site of iron superoxide dismutase of Escherichia coli and Propionibacterium shermanii. Scherk C, et al. **Eur Biophys J** 1996;24(4):243–50

IMMUNOLOGY

Immunostimulation by propionibacteria—effects on immune status and antineoplastic treatment. Isenberg J, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2363–8

Propionibacterium granulosum activities in rats during the muscle phase of Trichinella spiralis invasion. Moskwa B. **Wiad Parazytol** 1996;42(1):45–56

METABOLISM

[Protective and reactive effect of a cellular extract from propionic acid bacteria on Candida guilliermondii and Escherichia coli, inactivated by ultraviolet radiation] Fralkin Gla, et al. **Mikrobiologiia** 1995 Nov–Dec; 64(6):756–61 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Short–chain fatty acids modulate growth of lactobacilli in mixed culture fermentations with propionibacteria. Pérez Chaia A, et al. **Int J Food Microbiol** 1995 Aug;26(3):365–74

PROPIONIBACTERIUM ACNES

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694–5 (10 ref.)

Chronic contained rupture of an abdominal aortic aneurysm complicated by infection and femoral neuropathy. Case report. Aune S, et al. **Eur J Surg** 1995 Aug;161(8):613–4

Corynebacterium parvum versus tetracycline as pleural sclerosing agents in rabbits. Vargas FS, et al. **Eur Respir J** 1995 Dec;8(12):2174–7

[Positive corneal findings of Propioni bacterium acnes and keratitis] Morel C, et al. **J Fr Ophtalmol** 1996;19(1):4–7 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Hepatoprotective effect of SY–640, a novel acetamide derivative, on Propionibacterium acnes and lipopolysaccharide–induced liver injury in mice. Tanaka Y, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr; 329(2):319–30

Minimum bactericidal concentrations of Propionibacterium acnes isolates from cases of chronic endophthalmitis. Hall GS, et al. **Diagn Microbiol Infect Dis** 1995 Apr;21(4):187–90

Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test. Smith MA, et al. **J Clin Microbiol** 1996 Apr;34(4):1024–6

Anti–lipase activity of Kampo formulations, coptidis rhizoma and its alkaloids against Propionibacterium acnes. Higaki S, et al. **J Dermatol** 1996 May;23(5):310–4

IMMUNOLOGY

Efficacy of a Propionibacterium acnes immunostimulant for treatment of chronic Staphylococcus aureus mastitis. Dinsmore RP, et al. **J Dairy Sci** 1995 Sep;78(9):1932–6

ISOLATION & PURIFICATION

Propionibacterium acnes endocarditis. Huynh TT, et al. **Can J Cardiol** 1995 Oct;11(9):785–7

Chronic anaerobic bacterial endophthalmitis in pseudophakic rabbit eyes. Nobe JR, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):259–63

Surgical wound infections due to Propionibacterium acnes: a study of 10 cases. Esteban J, et al. **J Hosp Infect** 1995 Jul;30(3):229–32

METABOLISM

Singlet oxygen (1 delta g) generation from coproporphyrin in Propionibacterium acnes on irradiation. Arakane K, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):578–82

PATHOGENICITY

Prevention of endotoxin–induced acute lethality in Propionibacterium acnes–primed rabbits by an antibody to leukocyte integrin beta 2 with concomitant reduction of cytokine production. Ikeda N, et al. **Infect Immun** 1995 Dec;63(12):4812–7

PHYSIOLOGY

Heat–killed Corynebacterium parvum enhances endotoxin lung injury with increased TNF production in guinea pigs. Tasaka S, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1047–55

RADIATION EFFECTS

Intracellular pH changes induced in Propionibacterium acnes by UVA radiation and blue light. Futsaether CM, et al. **J Photochem Photobiol B** 1995 Dec;31(3):125–31

PROPIONIC ACIDS

Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism. Burns SP, et al. **Eur J Pediatr** 1996 Jan; 155(1):31–5

Carmine–propionic acid stain for elucidation of fine cellular structure in nematodes. Khrustalev AV, et al. **J Parasitol** 1996 Feb;82(1):176–8

ADVERSE EFFECTS

Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3–nitropropionic acid). He F, et al. **Neurology** 1995 Dec;45(12):2178–83

ANALYSIS

[Enzyme immunoassay for determination of tiaprofenic acid (Surgam)] Unterhalt B, et al. **Pharmazie** 1995 Aug; 50(8):571–2 **(Ger)**

BLOOD

Efficient removal of albumin–bound furancarboxylic acid by protein–leaking hemodialysis. Niwa T, et al. **Am J Nephrol** 1995;15(6):463–7

Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Rochat B, et al. **Chirality** 1995; 7(6):389–95

Propionic acidemia presenting as pyloric stenosis. Katzman PJ, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):613–5

Acute pancreatitis in propionic acidaemia. Burlina AB, et al. **J Inherit Metab Dis** 1995;18(2):169–72

Liver transplantation in two cases of propionic acidaemia. Schlenzig JS, et al. **J Inherit Metab Dis** 1995;18(4):448–61

On the differences between urinary metabolite excretion and odd–numbered fatty acid production in propionic and methylmalonic acidaemias. Wendel U, et al. **J Inherit Metab Dis** 1995;18(5):584–91

Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638–42

Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin–bound furan dicarboxylic acid. Costigan MG, et al. **Nephrol Dial Transplant** 1995;10(5):648–52

Retention of an albumin–bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant. Costigan MG, et al. **Nephrol Dial Transplant** 1996 May;11(5):803–7

CHEMICAL SYNTHESIS

Amide and ester derivatives of N3–trans–epoxysuccinoyl–L–2,3–diaminopropanoic acid: inhibitors of glucosamine–6–phosphate synthase. Andruszkiewicz R, et al. **J Enzym Inhib** 1995;9(2):123–33

CHEMISTRY

Comparison of official methods for 'readily oxidizable substances' in propionic acid as a food additive. Ishiwata H, et al. **Food Addit Contam** 1996 Jan;13(1):1–4

Inclusion complexation of heptakis(2,6–di–O–ethyl)–beta–cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH–dependent release and stereoselective dissolution. Vakily M, et al. **J Pharm Sci** 1995 Aug;84(8):1014–9

METABOLISM

Population dynamics of propionate–oxidizing bacteria under methanogenic and sulfidogenic conditions in anaerobic granular sludge. Harmsen HJ, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2163–8

Metabolism of [3–13C]pyruvate and [3–13C]propionate in normal and ischaemic rat heart in vivo: 1H– and 13C–NMR studies. Sumegi B, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):75–81

Characterization of binding site of uremic toxins on human serum albumin. Sakai T, et al. **Biol Pharm Bull** 1995 Dec; 18(12):1755–61

An iron dioxygenase from Alcaligenes faecalis catalyzing the oxidation of pyruvic oxime to nitrite. Ono Y, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):103–8

The management and outcome of propionic and methylmalonic acidaemia. Leonard JV. **J Inherit Metab Dis** 1995;18(4):430–4 (29 ref.)

The effect of co–administered drugs on oxaprozin binding to human serum albumin. Aubry AF, et al. **J Pharm Pharmacol** 1995 Nov;47(11):937–44

PHARMACOKINETICS

A population pharmacokinetic study of alminoprofen penetration into synovial fluid. Tod M, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):627–34

Stereospecific determination of tiaprofenic acid in plasma: problems with drug degradation. Geisslinger G, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):77–81

Inclusion complexation of heptakis(2,6–di–O–ethyl)–beta–cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH–dependent release and stereoselective dissolution. Vakily M, et al. **J Pharm Sci** 1995 Aug;84(8):1014–9

Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn

derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638–42

Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Costigan MG, et al. **Kidney Int** 1996 Mar;49(3):634–8

PHARMACOLOGY

Enzyme-to-enzyme channelling of Krebs cycle metabolic intermediates in Caco-2 cells exposed to [2-13c]propionate. Malaisse WJ, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):861–3

Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Demigné C, et al. **Br J Nutr** 1995 Aug;74(2):209–19

Differences in propionate-induced inhibition of cholesterol and triacylglycerol synthesis between human and rat hepatocytes in primary culture. Lin Y, et al. **Br J Nutr** 1995 Aug;74(2):197–207

Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Borlongan CV, et al. **Brain Res** 1995 Oct 30;697(1-2):254–7

Enhancement of NMDA-induced increases in levels of endogenous adenosine by adenosine deaminase and adenosine transport inhibition in rat striatum. Delaney SM, et al. **Brain Res** 1995 Dec 8;702(1-2):72–6

Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Brouillet E, et al. **Curr Opin Neurol** 1995 Dec;8(6):469–73 (44 ref.)

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050–75 (146 ref.)

Effect of acetate and propionate on fasting hepatic glucose production in humans. Laurent C, et al. **Eur J Clin Nutr** 1995 Jul;49(7):484–91

Potentiation of glucocorticoid-mediated gene expression by the novel benzoquinone derivative (2E)-3-[5-(2,3-dimethoxy-o-methyl-1, 4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330). Tanaka H, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):121–7

Energy and glutamate dependency of 3-Nitropropionic acid neurotoxicity in culture. Fink SL, et al. **Exp Neurol** 1996 Apr;138(2):298–304

Effect of intraruminal propionic acid infusion on metabolism of mesenteric- and portal-drained viscera in growing steers fed a forage diet: II. Ammonia, urea, amino acids, and peptides. Seal CJ, et al. **J Anim Sci** 1996 Jan;74(1):245–56

Comparative assessment of bacterial inoculation and propionic acid treatment of aerobic stability and microbial populations of ensiled high-moisture ear corn. Sebastian S, et al. **J Anim Sci** 1996 Feb;74(2):447–56

Effects of intraruminal infusion of propionate on the concentrations of ammonia and insulin in peripheral blood of cows receiving an intraruminal infusion of urea. Choung JJ, et al. **J Dairy Res** 1995 Nov;62(4):549–57

Amide and ester derivatives of N3-trans-epoxysuccinoyl-L-2,3-diaminopropanoic acid: inhibitors of glucosamine-6-phosphate synthase. Andruszkiewicz R, et al. **J Enzym Inhib** 1995;9(2):123–33

Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. Palfi S, et al. **J Neurosci** 1996 May 1;16(9):3019–25

DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. Herbert JM, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1030–8

Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. Zeevalk GD, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1124–30

Changes of contractile properties of extensor digitorum longus in response to creatine-analogue administration and/or hindlimb suspension in rats. Wakatsuki T, et al. **Jpn J Physiol** 1995;45(6):979–89

Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B. Goto M, et al. **Mol Pharmacol** 1996 May;49(5):860–73

Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle tonus. Shimano Y, et al. **Obes Res** 1995 Dec;3 Suppl 5:779S–784S

Effects of beta-guanidinopropionic acid-feeding on the patterns of myosin isoforms in rat fast-twitch muscle. Ren JM, et al. **Pflugers Arch** 1995 Jul;430(3):389–93

The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia? Andreassen OA, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):474–6

DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Hara T, et al. **Thromb Haemost** 1995 Aug;74(2):635–9

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Hara T, et al. **Thromb Res** 1995 Oct 1;80(1):99–104

POISONING

Hypothalamic neurons are resistant to the intoxication with 3-nitropropionic acid that induces lesions in the striatum and hippocampus via the damage in the blood-brain barrier. Nishino H, et al. **Neurobiology (Bp)** 1995;3(3-4):257–67

Consistent striatal damage in rats induced by 3-nitropropionic acid and cultures of arthrinium fungus. Fu Y, et al. **Neurotoxicol Teratol** 1995 Jul-Aug;17(4):413–8

THERAPEUTIC USE

Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Weaver A, et al. **Clin Ther** 1995 Jul-Aug; 17(4):735–45

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050–75 (146 ref.)

Field trials of an oral calcium propionate paste as an aid to prevent milk fever in periparturient dairy cows. Goff JP, et al. **J Dairy Sci** 1996 Mar;79(3):378–83

TOXICITY

Chloropropionic acid-induced alterations in glucose metabolic status: possible relevance to cerebellar granule cell necrosis. Lock EA, et al. **Arch Toxicol** 1995;69(9):640–3

Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum. Bowyer JF, et al. **Brain Res** 1996 Mar 18;712(2):221–9

The effects of perinatal hypoxia on the behavioral, neurochemical, and neurohistological toxicity of the metabolic inhibitor 3-nitropropionic acid. Binienda Z, et al. **Metab Brain Dis** 1995 Dec;10(4):269–82

[125I]endothelin binding in rat cerebellum is increased following L-2-chloropropionic-acid-induced granule cell necrosis. Widdowson PS, et al. **Peptides** 1995;16(5):897–902

L-2-chloropropionic acid-induced neurotoxicity is prevented by MK-801: possible role of NMDA receptors in the neuropathology. Widdowson PS, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):138–45

Changes in cerebellar amino acid neurotransmitter concentrations and receptors following administration of the neurotoxin L-2-chloropropionic acid. Widdowson PS, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):57–66

URINE

On the differences between urinary metabolite excretion and odd-numbered fatty acid production in propionic and methylmalonic acidaemias. Wendel U, et al. **J Inherit Metab Dis** 1995;18(5):584–91

PROPIOPHENONES

Methcathinone: the next illicit stimulant epidemic? Calkins RF, et al. **J Psychoactive Drugs** 1995 Jul-Sep;27(3):277–85

CHEMICAL SYNTHESIS

Synthesis and hypolipidemic evaluation of beta-alkylaminopropiophenone and beta-alkylaminopropio-2'-naphthone derivatives in rodents. Huang Y, et al. **Pharmazie** 1996 Apr;51(4):199–206

CHEMISTRY

Isolation and characterization of two major degradation products of cyclonine hydrochloride. Liang CY, et al. **J Pharm Sci** 1995 Sep;84(9):1141–3

PHARMACOLOGY

Methcathinone: an initial study of its effects on monoaminergic systems. Gygi MP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1066–72

THERAPEUTIC USE

Antineoplastic activities of alpha-, beta-, and gamma-alkylaminopropiophenone derivatives in mice and in murine and human tissue culture cells. Huang Y, et al. **Anticancer Res** 1996 Mar-Apr;16(2):597–604

PROPITOCAINE see PRILOCAINE

PROPLAST

Cine MRI in the evaluation of the Proplast-Teflon TMJ interpositional implant. Dorsay TA, et al. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):800–3

ADVERSE EFFECTS

Morphologic and immunohistochemical observation of explanted Proplast-Teflon temporomandibular joint interpositional implants. Trumpy IG, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):63–8; discussion 68–70

ANALOGS & DERIVATIVES

Use of Proplast II as a subperiosteal implant for the correction of anophthalmic enophthalmos. Shah S, et al. **Br J Ophthalmol** 1995 Sep;79(9):830–3

PROPOFOL

Propofol for conscious sedation: a case series [letter] Swanson ER, et al. **Acad Emerg Med** 1995 Jul;2(7):661–3

The use of propofol for sedation in the emergency department. Swanson ER, et al. **Acad Emerg Med** 1996 Mar;3(3):234–8

Influence of sufentanil on propofol anesthesia using a target controlled infusion system. Los GJ, et al. **Acta Anaesthesiol Belg** 1995;46(3-4):153–9

The influence of alfentanil pre-treatment on ventilatory effects of doxapram following induction of anaesthesia with propofol. O'Connor B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):156–9

The influence of anaesthetic drugs on the lower oesophageal sphincter in propofol/nitrous oxide anaesthetized dogs. Pressure profilometry in an animal model. van der Hoeven CW, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):822–6

Postural control after propofol anaesthesia in minor surgery. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:313–6

Breathing patterns under enflurane, halothane and propofol sedation in humans. Nagyova B, et al. **Adv Exp Med Biol** 1995;393:101–4

Evaluation of propofol for general anesthesia in premedicated horses. Mama KR, et al. **Am J Vet Res** 1996 Apr; 57(4):512–6

The taste of propofol [letter] Low SW. **Anaesth Intensive Care** 1995 Dec;23(6):753–4

Induction end-point and laryngeal mask placement [letter; comment] Driver IK, et al. **Anaesthesia** 1995 Oct;50(10):921 . Comment on: Anaesthesia 1995 May;50(5):464–6.

Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42

Influence of nitrous oxide on propofol dosage and recovery after intravenous anaesthesia [letter; comment] Heath KJ, et al. **Anaesthesia** 1995 Dec;50(12):1101–2. Comment on: Anaesthesia 1995 May;50(5):397–9.

Is propofol infusion better than inhalational anaesthesia for paediatric MRI? [letter] MacIntyre PA, et al. **Anaesthesia** 1996 May;51(5):517

Induction of anaesthesia with midazolam and a target-controlled propofol infusion. Tzabar Y, et al. **Anaesthesia** 1996 Jun;51(6):536–8

Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Crowther J, et al. **Anesth Analg** 1996 Mar;82(3):475–8

Sevoflurane for outpatient anesthesia: a comparison with propofol. Fredman B, et al. **Anesth Analg** 1995 Oct; 81(4):823–8

The neuromuscular effects of mivacurium chloride during propofol anesthesia in children. Shorten GD, et al. **Anesth Analg** 1996 Jun;82(6):1170–5

Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting [letter; comment] Tezcan C, et al. **Anesth Analg** 1996 Jan; 82(1):219. Comment on: Anesth Analg 1995 May;80(5):861–3.

Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. Daniel M, et al. **Anesthesiology** 1996 Jan;84(1):75–80

Prediction of movement during propofol/nitrous oxide anesthesia. Performance of concentration, electroencephalographic, pupillary, and hemodynamic indicators. Leslie K, et al. **Anesthesiology** 1996 Jan; 84(1):52–63

Comparison of propofol and methohexitone in anaesthesia for ECT: effect on seizure duration and outcome. Kirkby KC, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):299–303

Effect of i.v. lignocaine on the breathing of patients anaesthetized with propofol. Goodman NW, et al. **Br J Anaesth** 1995 Nov;75(5):573–7

Recovery after electroconvulsive therapy: comparison of propofol with methohexitone anaesthesia. Matters RM, et al. **Br J Anaesth** 1995 Sep;75(3):297–300

Recall during intermittent propofol anaesthesia. Nordström O, et al. **Br J Anaesth** 1996 May;76(5):699–701

Psychological and cardiovascular predictors of anaesthesia induction, operative and post-operative complications in minor gynaecological surgery. Abbott J, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):613–25

The choice of anaesthetic for carotid endarterectomy: does it matter? [editorial] Archer DP, et al. **Can J Anaesth** 1995 Jul;42(7):566–70 **(Eng, Fre)**

Haemodynamic instability and myocardial ischaemia during carotid endarterectomy: a comparison of propofol and isoflurane. Mutch WA, et al. **Can J Anaesth** 1995 Jul; 42(7):577–87

A comparison of the effects of the propofol versus midazolam during total intravenous anesthesia for gynecological surgery procedures. Ye T, et al. **Chin Med Sci J** 1995 Sep; 10(3):181–4

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827–47 (64 ref.)

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875–86 (38 ref.)

Rocuronium with alfentanil and propofol allows intubation within 45 seconds. Crul JF, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:111–2

Propofol versus propofol with midazolam for laryngeal mask insertion. Godsiff L, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:35–40

Time-course of action and intubating conditions with rocuronium bromide under propofol-alfentanil anaesthesia. Hofmockel R, et al. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:69–72

Propofol infusion for induction and maintenance of anesthesia

in elderly patients: recovery and hemodynamic profiles. Chan VW, et al. **J Clin Anesth** 1996 Jun;8(4):317–23

Ketorolac and propofol anesthesia in a patient taking chronic monoamine oxidase inhibitors. Fischer SP, et al. **J Clin Anesth** 1996 May;8(3):245–7

Propofol and alfentanil mixture for outpatient surgery [letter; comment] Isert P. **J Clin Anesth** 1995 Jun;7(4):357. Comment on: J Clin Anesth 1994 Mar–Apr;6(2):166–7.

Compatibility of propofol, fentanyl, and vecuronium mixtures designed for potential use in anesthesia and patient transport. Isert PR, et al. **J Clin Anesth** 1996 Jun; 8(4):329–36

Propofol-based anesthesia as compared with standard anesthetic techniques for middle ear surgery. Jellish WS, et al. **J Clin Anesth** 1995 Jun;7(4):292–6

Total intravenous anesthesia for children undergoing brief diagnostic or therapeutic procedures. McDowall RH, et al. **J Clin Anesth** 1995 Jun;7(4):273–80

Propofol permits tracheal intubation but does not affect postoperative myalgias. Mingus ML, et al. **J Clin Anesth** 1996 May;8(3):220–4

Use of analgesics during propofol sedation: a comparison of ketorolac, dezocine, and fentanyl. Ramirez-Ruiz M, et al. **J Clin Anesth** 1995 Sep;7(6):481–5

Propofol analgesia in central pain: preliminary clinical observations. Canavero S, et al. **J Neurol** 1995 Sep; 242(9):561–7

Depression of excitatory effects of propofol induction by fentanyl. Ghabash M, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):419–25

Total intravenous anesthesia for diagnostic endoscopy in myasthenia gravis child—a case report. Khan RM, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):415–8

Propofol and postoperative infections [letter; comment] Bach A, et al. **N Engl J Med** 1995 Nov 30;333(22):1505–6; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Grounds RM. **N Engl J Med** 1995 Nov 30;333(22):1506; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Kolbitsch C, et al. **N Engl J Med** 1995 Nov 30; 333(22):1506–7. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol reduces the incidence of vomiting after tonsillectomy in children. Barst SM, et al. **Paediatr Anaesth** 1995;5(4):249–52

Anaesthesia for a child with centronuclear myopathy. Price SR, et al. **Paediatr Anaesth** 1995;5(4):267–8

Effects of TRH and atropine on induction and duration of anesthesia with propofol in rats. Larsson JE, et al. **Peptides** 1996;17(2):293–7

[The lipid peroxidation level and antioxidant status of the plasma in patients operated on under propofol (Diprivan) anesthesia] Khinev S, et al. **Khirurgiia (Sofiia)** 1995; 48(5):23–5 (Eng. Abstr.) **(Bul)**

[Endotracheal intubation under propofol with or without vecuronium] Rousseau JM, et al. **Ann Fr Anesth Reanim** 1995;14(3):261–4 (Eng. Abstr.) **(Fre)**

[EEG changes during propofol–alfentanil–nitrous oxide anesthesia] Arndt VM, et al. **Anaesthesiol Reanim** 1995; 20(5):126–33 (Eng. Abstr.) **(Ger)**

[Comparison of various methods of anesthesia by plasma catecholamine determination] Hertel VG, et al. **Anaesthesiol Reanim** 1995;20(5):116–25 (Eng. Abstr.) **(Ger)**

[Total intravenous anesthesia (TIVA) in geriatric surgery. S-(+)-ketamine versus alfentanil] Adams HA, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S540–8 (Eng. Abstr.) **(Ger)**

[Neuromuscular blockade after atracurium and alcuronium with propofol and thiopental] Ginz HF, et al. **Anaesthesist** 1996 Jan;45(1):47–51 (Eng. Abstr.) **(Ger)**

[Qualitative comparison of modified neurolept-, balanced and intravenous anesthesia. 2. Results of a clinical study, 1992] Harke H, et al. **Anaesthesist** 1995 Oct;44(10):687–94 (Eng. Abstr.) **(Ger)**

[Remarks on the work of A. Klockgether-Radke et al. The effect of propofol on vomiting in children following strabismus surgery (letter)] Holas A, et al. **Anaesthesist** 1996 May;45(5):464–7 **(Ger)**

[The effect of propofol on vomiting after strabismus surgery in children] Klockgether-Radke A, et al. **Anaesthesist** 1995 Nov;44(11):755–60 (Eng. Abstr.) **(Ger)**

[A comparative study of the use of sevoflurane and propofol in ambulatory surgery] Motsch J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S57–62 (Eng. Abstr.) **(Ger)**

[Endotracheal intubation with propofol and fentanyl] Striebel HW, et al. **Anaesthesist** 1995 Dec;44(12):809–17 (Eng. Abstr.) **(Ger)**

[Etomidate versus propofol for anesthesia in ambulatory cardioversion] Kick O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):288–92 (Eng. Abstr.) **(Ger)**

[Cardiocirculatory stability and early extubation in patients undergoing thoracic surgery with propofol as the single anesthetic agent] Tommasi Rosso M, et al. **Minerva Anestesiol** 1995 May;61(5):183–9 (Eng. Abstr.) **(Ita)**

[Prospects of balanced anesthesia—combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158–61; discussion S173–6 (6 ref.) **(Jpn)**

[Isoflurane versus propofol for sedation after heart surgery] Gómez JI, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep; 42(7):261–8 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Intubating conditions and neuromuscular effects of mivacurium during propofol–alfentanil anaesthesia. Van Aken H, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:26–9

Long-term propofol infusion and airway management in a patient with Goldenhar's syndrome. Fan SZ, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):233–6

Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. Kress JP, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1012–8

Propofol and epilepsy [letter] Slater BL. **Anaesth Intensive Care** 1995 Aug;23(4):517

Metoclopramide and prochlorperazine do not decrease propofol hypnotic requirements. Ali PB, et al. **Anaesthesia** 1995 Nov;50(11):990–1

Is rectal administration of propofol effective? [letter] Ceriana R, et al. **Anaesthesia** 1996 May;51(5):504

A novel device for patient-controlled sedation: laboratory and clinical evaluation of the Baxter Intermate LV250 infusor and patient-control module. Hamid SK, et al. **Anaesthesia** 1996 Feb;51(2):145–50

Serum triglyceride levels and propofol infusion [letter] Kunst G, et al. **Anaesthesia** 1995 Dec;50(12):1101

Effect of bupivacaine-induced spinal block on the hypnotic requirement of propofol. Tverskoy M, et al. **Anaesthesia** 1996 Jul;51(7):652–3

The effects of propofol on hemodynamics and renal blood flow in healthy and in septic sheep, and combined with fentanyl in septic sheep. Booke M, et al. **Anesth Analg** 1996 Apr;82(4):738–43

Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Eriksson H, et al. **Anesth Analg** 1996 Mar;82(3):533–8

Propofol–opioid mixtures during prolonged infusions [letter] Ghouri AF, et al. **Anesth Analg** 1996 Apr;82(4):888–9

Lidocaine and no carrier fluid for the prevention of pain due to injection of propofol [letter; comment] Gozal Y. **Anesth Analg** 1996 May;82(5):1111. Comment on: Anesth Analg 1995 Nov;81(5):1087–8.

A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Hogue CW Jr, et al. **Anesth Analg** 1996 Aug;83(2):279–85

The effect of carrier intravenous fluid speed on the injection pain of propofol [see comments] Huang CL, et al. **Anesth Analg** 1995 Nov;81(5):1087–8. Comment in: Anesth Analg 1996 May;82(5):1111.

The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. Jellish WS, et al. **Anesth Analg** 1996 Mar; 82(3):479–85

Comparison of eltanolone and propofol on a pressure–volume analysis of the heart. Mulier JP, et al. **Anesth Analg** 1996 Aug;83(2):233–7

Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Vuyk J, et al. **Anesth Analg** 1995 Dec;81(6):1275–82

Spectral analysis of arterial pressure variability during induction of propofol anesthesia. Wang H, et al. **Anesth Analg** 1996 May;82(5):914–9

Dose of propofol for laryngeal mask airway insertion in children: effect of premedication with midazolam. Martlew RA, et al. **Br J Anaesth** 1996 Feb;76(2):308–9

Manual compared with target-controlled infusion of propofol. Russell D, et al. **Br J Anaesth** 1995 Nov; 75(5):562–6

Prospective evaluation of pharmacokinetic model-controlled infusion of propofol in adult patients. Short TG, et al. **Br J Anaesth** 1996 Feb;76(2):313–5

Sudden unexpected sneezing during the insertion of peribulbar block under propofol sedation. Abramson DC. **Can J Anaesth** 1995 Aug;42(8):740–3

Propofol emulsion and bacterial contamination. McHugh GJ, et al. **Can J Anaesth** 1995 Sep;42(9):801–4

Propofol for ICU sedation [letter; comment] Sherman E. **Chest** 1996 Apr;109(4):1128. Comment on: Chest 1995 Aug;108(2):539–48.

Modulating effects of propofol on metabolic and cardiopulmonary responses to stressful intensive care unit procedures. Cohen D, et al. **Crit Care Med** 1996 Apr; 24(4):612–7

A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. Reed MD, et al. **Crit Care Med** 1996 Sep; 24(9):1473–81

A comparison between total intravenous anaesthesia using a propofol/alfentanil mixture and an inhalational technique for laparoscopic gynaecological sterilization. Collins SJ, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):33–7

Serum lipid and glucose concentrations with a propofol infusion for cardiac surgery. Myles PS, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):373–8

Continuous infusions of alfentanil and propofol for coronary artery surgery. Rockaerts PM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):362–7

Comparison of the use of a propofol infusion in cardiac surgical patients with normal and low cardiac output states. Sherry KM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):368–72

The bispectral index during induction of anesthesia with midazolam and propofol. Hoffman WE, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):15–20

Propofol: an alternative general anesthetic for outpatient oral surgery. Pastuovic MN, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):943–8

Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1996 Feb;37(2):79–83

Dose of propofol required to insert the laryngeal mask airway in children. Allsop E, et al. **Paediatr Anaesth** 1995; 5(1):47–51

Role of propofol in paediatric anaesthetic practice [editorial] Meakin G. **Paediatr Anaesth** 1995;5(3):147–9

Deep sedation with propofol in preschool children undergoing radiation therapy. Scheiber G, et al. **Paediatr Anaesth** 1996;6(3):209–13

Computer-assisted continuous infusion for the delivery of target-controlled infusions of propofol during outpatient surgery. Arndt GA, et al. **Pharmacotherapy** 1995 Jul–Aug; 15(4):512–6

[Cerebrovascular reactivity to CO2 during general anesthesia maintained with either isoflurane-N2O or propofol-N2O. A comparative study by transcranial Doppler velocimetry] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(2):166–71 (Eng. Abstr.) **(Fre)**

[Anesthesia with continuous + infusion of propofol for trans-sternal thymectomy in myasthenic patients] García-Aguado R, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):283–5 (Eng. Abstr.) **(Spa)**

[Propofol in continuous perfusion as anesthetic in experimental surgery in the rabbit] Pérez-Martínez A, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):253–6 (Eng. Abstr.) **(Spa)**

[Cardiorespiratory and analgesic effects of continuous infusion of propofol in swine as experimental animals] Tendillo FJ, et al. **Rev Esp Anestesiol Reanim** 1996 Apr; 43(4):126–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Disturbance of hepatocellular integrity associated with propofol anaesthesia in surgical patients. Tiainen P, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):840–4

Infections linked to lax handling of propofol [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2061, 2066

Fatal cardiovascular collapse following propofol induction in high-risk patients [letter; comment] Mackay P. **Anaesth Intensive Care** 1996 Feb;24(1):125–6. Comment on: Anaesth Intensive Care 1995 Aug;23(4):485–7.

Fatal cardiovascular collapse following propofol induction in high-risk patients and dilemmas in the selection of a short-acting induction agent [see comments] Warden JC, et al. **Anaesth Intensive Care** 1995 Aug;23(4):485–7. Comment in: Anaesth Intensive Care 1996 Feb;24(1):125–6.

Does propofol cause deaths in children? [letter] Dearlove O, et al. **Anaesthesia** 1995 Oct;50(10):916

The effect of temperature upon pain during injection of propofol. Fletcher GC, et al. **Anaesthesia** 1996 May; 51(5):498–9

The haemodynamic effects of propofol in combination with ephedrine. Gamlin F, et al. **Anaesthesia** 1996 May; 51(5):488–91

Propofol—an interesting new side effect? [letter] Hocking G. **Anaesthesia** 1996 Jan;51(1):101

Modification of pain on injection of propofol. A comparison of pethidine and lignocaine. Lyons B, et al. **Anaesthesia** 1996 Apr;51(4):394–5

Anticholinergic treatment for choreoathetosis in a child after induction with propofol [letter] Diltoer MW, et al. **Anesth Analg** 1996 Mar;82(3):670

Reducing pain during propofol injection: the role of the solvent. Doenicke AW, et al. **Anesth Analg** 1996 Mar; 82(3):472–4

Propofol-induced myotonia in myotonic dystrophy [letter] Kinney MA, et al. **Anesth Analg** 1996 Sep;83(3):665–6

Propofol-induced dyskinesias in Parkinson's disease. Krauss JK, et al. **Anesth Analg** 1996 Aug;83(2):420–22

Reducing the pain on injection of propofol [letter] Nathanson MH, et al. **Anesth Analg** 1996 Jun;82(6):1307–8

Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71

Propofol and postoperative pancreatitis. Leisure GS, et al. **Anesthesiology** 1996 Jan;84(1):224–7

Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans [see comments] Mathru M, et al. **Anesthesiology** 1996 Feb;84(2):273–9. Comment in: Anesthesiology 1996 Feb;84(2):253–5.

Vomiting and recovery after outpatient tonsillectomy and adenoidectomy in children. Comparison of four anesthetic techniques using nitrous oxide with halothane or propofol. Ved SA, et al. **Anesthesiology** 1996 Jul;85(1):4–10

Cardiovascular responses during sedation after coronary revascularization. Incidence of myocardial ischemia and hemodynamic episodes with propofol versus midazolam. Institutions of the McSPI Research Group. Wahr JA, et al. **Anesthesiology** 1996 Jun;84(6):1350–60

Pancreatitis after propofol administration: is there a relationship? [letter] Wingfield TW. **Anesthesiology** 1996 Jan;84(1):236–7

Testing the porphyrinogenicity of propofol in a primed rat model [see comments] Böhrer H, et al. **Br J Anaesth** 1995 Sep;75(3):334–8. Comment in: Br J Anaesth 1996 Jan;76(1):171–2. Comment in: Br J Anaesth 1996 Jan;76(1):172.

Unilateral convulsion after induction of anaesthesia with propofol. Cochran D, et al. **Br J Anaesth** 1996 Apr; 76(4):570–2

Porphyria, propofol and rats [letter; comment] Gorchein A. **Br J Anaesth** 1996 Jan;76(1):172. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Porphyria, propofol and rats [letter; comment] Tidmarsh MD. **Br J Anaesth** 1996 Jan;76(1):171–2. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Anaesthesia during carotid surgery [letter] Smith M. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):54

Prophylaxis against the systemic hypotension induced by propofol during rapid–sequence intubation. el–Beheiry H, et al. **Can J Anaesth** 1995 Oct;42(10):875–8

Thiopentone pretreatment for propofol injection pain in ambulatory patients. Haugen RD, et al. **Can J Anaesth** 1995 Dec;42(12):1108–12

Prolonged myoclonus and meningism following propofol. Hughes NJ, et al. **Can J Anaesth** 1995 Aug;42(8):744–6

Propofol myoclonus [letter] Strachan AN, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):536–7

Lactic acidosis associated with propofol [letter] Marinella MA. **Chest** 1996 Jan;109(1):292

Lipid deposition during the long–term infusion of propofol. el–Ebiary M, et al. **Crit Care Med** 1995 Nov;23(11):1928–30

Propofol bashing: the time to stop is now! [letter; comment] Reed MD, et al. **Crit Care Med** 1996 Jan;24(1):175–6. Comment on: Crit Care Med 1995 Feb;23(2):405–9.

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Propofol in prehospital treatment of convulsive status epilepticus. Kuisma M, et al. **Epilepsia** 1995 Dec; 36(12):1241–3

Nausea and vomiting after laparoscopic surgery: a comparison of propofol and thiopentone/halothane anaesthesia. Klockgether–Radke A, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):3–9

Case 2—1995. Seizures associated with propofol anesthesia [clinical conference] Eimerl D, et al. **Isr J Med Sci** 1996 May;32(5):334–6

Propofol (Diprivan) [letter] Young RF. **Neurosurgery** 1995 Jul;37(1):160–1

An audit of adverse events in children sedated with chloral hydrate or propofol during imaging studies. Merola C, et al. **Paediatr Anaesth** 1995;5(6):375–8

Propofol and green urine [letter] Tirosh R, et al. **Paediatr Anaesth** 1996;6(3):244

[A case of generalized convulsion during induction with Diprivan] Karadimov D, et al. **Khirurgiia (Sofiia)** 1994; 47(5):41–2 (Eng. Abstr.) **(Bul)**

BLOOD

Propofol blood concentration and the Bispectral Index predict suppression of learning during propofol/epidural anesthesia in volunteers. Leslie K, et al. **Anesth Analg** 1995 Dec;81(6):1269–74

Propofol binding to human blood proteins. Altmayer P, et al. **Arzneimittelforschung** 1995 Oct;45(10):1053–6

Comparison of arterialized venous with arterial blood propofol concentrations during sub–anaesthetic infusions in volunteers. Johnston KR, et al. **Br J Anaesth** 1996 Mar; 76(3):401–4

Quantitation of propofol in whole blood by gas chromatography–mass spectrometry. Guitton J, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):358–65

Measurement of propofol concentration in sheep blood and plasma: effect of storage at different temperatures. Weaver BM, et al. **J Pharmacol Toxicol Methods** 1995 Dec; 34(4):199–202

ECONOMICS

Cost analysis of propofol versus thiopental induction anesthesia in outpatient laparoscopic gynecologic surgery. Wagner BK, et al. **Clin Ther** 1995 Jul–Aug;17(4):770–6

METABOLISM

Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs. Le Guellec C, et al. **Anesth Analg** 1995 Oct;81(4):855–61

PHARMACOKINETICS

Propofol concentrations—an alternative explanation [letter; comment] Eger EI 2nd. **Anesth Analg** 1996 Feb;82(2):438–9 . Comment on: Anesth Analg 1995 Jul;81(1):175–8.

Performance of computer–controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Vuyk J, et al. **Anesth Analg** 1995 Dec;81(6):1275–82

Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. Bailey JM, et al. **Anesthesiology** 1996 Jun;84(6):1288–97

Pharmacokinetics of propofol after a single dose in children aged 1–3 years with minor burns. Comparison of three data analysis approaches. Murat I, et al. **Anesthesiology** 1996 Mar;84(3):526–32

Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. Raoof AA, et al. **Eur J Clin Pharmacol** 1996;50(1–2):91–6

Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Frenkel C, et al. **Intensive Care Med** 1995 Dec;21(12):981–8

Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. Lee HS, et al. **Ther Drug Monit** 1995 Aug;17(4):336–41

[Pharmacokinetics of propofol during liver transplantation in small pigs] Mashimo T, et al. **Masui** 1996 Mar; 45(3):293–7 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Comparison of propofol and increased doses of thiopentone for laryngeal mask insertion. Brown GW, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1103–4

A cost–benefit evaluation of using propofol and alfentanil for a short gynecological procedure. Enlund M, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):416–20

The effect of edothelium on the response to propofol on bovine coronary artery rings. Gacar N, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1080–3

Propofol and isoflurane induced EEG burst suppression patterns in rabbits. Hartikainen K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):814–8

Propofol influences the electroretinogram to a lesser degree than thiopentone. Tanskanen P, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):480–5

Comparative responses to propofol anaesthesia alone and with alpha 2–adrenergic medications in a canine model. Bufalari A, et al. **Acta Vet Scand** 1996;37(2):187–201

Behavioral effects and pharmacokinetics of propofol in rats selected for differential ethanol sensitivity. Liu Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):874–8

Cerebral effects of propofol following bolus administration in sheep. Ludbrook GL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):26–31

Effect of propofol infusion on the endocrine response to cardiac surgery. NG A, et al. **Anaesth Intensive Care** 1995 Oct;23(5):543–7

Spontaneous movement after injection of propofol. Chan A, et al. **Anaesthesia** 1996 Jul;51(7):663–6

Middle latency auditory evoked potentials during repeated transitions from consciousness to unconsciousness. Davies FW, et al. **Anaesthesia** 1996 Feb;51(2):107–13

Propofol–induced bronchodilation in status asthmaticus? [letter] Parmar M, et al. **Anaesthesia** 1995 Nov; 50(11):1003–4

Propofol infusion anaesthesia and the immune response in elderly patients undergoing ophthalmic surgery. Pirttikangas CO, et al. **Anaesthesia** 1996 Apr;51(4):318–23

The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats. Bielen SJ, et al. **Anesth Analg** 1996 May;82(5):920–4

Effects of temperature and propofol on hepatic blood flow [letter; comment] Carmichael FJ. **Anesth Analg** 1996 Feb; 82(2):426. Comment on: Anesth Analg 1995 May;80(5):1007–14.

Large–dose propofol alone in adult epileptic patients: electrocorticographic results. Cheng MA, et al. **Anesth Analg** 1996 Jul;83(1):169–74

Subanesthetic concentrations of desflurane and propofol suppress recall of emotionally charged information [see comments] Chortkoff BS, et al. **Anesth Analg** 1995 Oct; 81(4):728–36. Comment in: Anesth Analg 1995 Oct;81(4):668–70.

Concentrations of desflurane and propofol that suppress response to command in humans. Chortkoff BS, et al. **Anesth Analg** 1995 Oct;81(4):737–43

Propofol and ethanol produce additive hypnotic and anesthetic effects in the mouse. Garfield JM, et al. **Anesth Analg** 1996 Jul;83(1):156–61

Propofol induces dilation and inhibits constriction in guinea pig basilar arteries. Gelb AW, et al. **Anesth Analg** 1996 Sep;83(3):472–6

Biochemical characterization of the stimulatory effects of halothane and propofol on purified brain protein kinase C. Hemmings HC Jr, et al. **Anesth Analg** 1995 Dec; 81(6):1216–22

Propofol blood concentration and the Bispectral Index predict suppression of learning during propofol/epidural anesthesia in volunteers. Leslie K, et al. **Anesth Analg** 1995 Dec;81(6):1269–74

Pink urine during propofol anesthesia [letter] Masuda A, et al. **Anesth Analg** 1996 Sep;83(3):666–7

Propofol–associated dilation of rat distal coronary arteries is mediated by multiple substances, including endothelium–derived nitric oxide. Park KW, et al. **Anesth Analg** 1995 Dec;81(6):1191–6

The effects of propofol on the 40–Hz auditory steady–state response and on the electroencephalogram in humans. Plourde G. **Anesth Analg** 1996 May;82(5):1015–22

Propofol produces differences in behavior but not chloride channel function between selected lines of mice. Simpson VJ, et al. **Anesth Analg** 1996 Feb;82(2):327–31

Inhibition of regulated neuropeptide secretion from mouse pituitary cells by propofol. YaDeau JT. **Anesth Analg** 1996 Sep;83(3):611–7

Propofol reduces neuronal transmission damage and attenuates the changes in calcium, potassium, and sodium during hyperthermic anoxia in the rat hippocampal slice. Amorim P, et al. **Anesthesiology** 1995 Dec;83(6):1254–65

Propofol modulates the effects of chemoconvulsants acting at GABAergic, glycinergic, and glutamate receptor subtypes. Bansinath M, et al. **Anesthesiology** 1995 Oct; 83(4):809–15

Volatile and intravenous anesthetics decrease glutamate release from cortical brain slices during anoxia. Bickler PE, et al. **Anesthesiology** 1995 Dec;83(6):1233–40

Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Eames WO, et al. **Anesthesiology** 1996 Jun; 84(6):1307–11

Propofol attenuates hydrogen peroxide–induced mechanical and metabolic derangements in the isolated rat heart. Kokita N, et al. **Anesthesiology** 1996 Jan;84(1):117–27

Propofol alters left ventricular afterload as evaluated by aortic input impedance in dogs. Lowe D, et al. **Anesthesiology** 1996 Feb;84(2):368–76

Reconciling differences between in vitro and in vivo effects of propofol [letter] Orser BA, et al. **Anesthesiology** 1996 Mar;84(3):749–50

Effect of propofol on affective state as assessed by place conditioning paradigm in rats. Pain L, et al. **Anesthesiology** 1996 Jul;85(1):121–8

Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. Pavlin DJ, et al. **Anesthesiology** 1996 Jan;84(1):23–37

Tolerance to propofol generally does not develop in pediatric patients undergoing radiation therapy. Setlock MA, et al. **Anesthesiology** 1996 Jul;85(1):207–9

Propofol and cellular calcium homeostasis [letter; comment] Sztark F, et al. **Anesthesiology** 1995 Dec;83(6):1386. Comment on: Anesthesiology 1994 Nov;81(5):1220–9.

Effect of propofol on spinal dorsal horn neurons. Comparison with lack of ketamine effects. Uchida H, et al. **Anesthesiology** 1995 Dec;83(6):1312–22

Pharmacodynamic interaction between propofol and alfentanil when given for induction of anesthesia. Vuyk J, et al. **Anesthesiology** 1996 Feb;84(2):288–99

Inhibitory effects of thiopental, ketamine, and propofol on voltage–dependent Ca2+ channels in porcine tracheal smooth muscle cells. Yamakage M, et al. **Anesthesiology** 1995 Dec;83(6):1274–82

Propofol inhibits cardiac L–type calcium current in guinea pig ventricular myocytes. Yang CY, et al. **Anesthesiology** 1996 Mar;84(3):626–35

Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. Cervantes M, et al. **Arch Med Res** 1995 Winter;26(4):385–95

Biochemical evaluations of the effects of loreclezole and propofol on the GABAA receptor in rat brain. Ghiani CA, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1527–34

Effects of propofol and thiopentone on potassium– and carbachol–evoked [3H]noradrenaline release and increased [Ca2+]i from SH–SY5Y human neuroblastoma cells. Lambert DG, et al. **Biochem Pharmacol** 1996 Jun 28; 51(12):1613–21

Propofol blocks voltage–gated potassium channels in human T lymphocytes. Mozrzymas JW, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):843–9

Effects of propofol and isoflurane on right ventricular function [letter; comment] Boyd O, et al. **Br J Anaesth** 1996 Apr;76(4):598. Comment on: Br J Anaesth 1995 Nov;75(5):578–82.

Difference between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450–dependent mono–oxygenases. Chen TL, et al. **Br J Anaesth** 1995 Oct;75(4):462–6

Is there implicit memory after propofol sedation? Cork RC, et al. **Br J Anaesth** 1996 Apr;76(4):492–8

Propofol–induced alterations in the microcirculation of hamster striated muscle. Holzmann A, et al. **Br J Anaesth** 1995 Oct;75(4):452–6

Effects of propofol on isolated rabbit mesenteric arteries and veins. Kamitani K, et al. **Br J Anaesth** 1995 Oct; 75(4):457–61

Comparison of the effects of propofol and isoflurane anaesthesia on right ventricular function and shunt fraction during thoracic surgery [see comments] Kellow NH, et al. **Br J Anaesth** 1995 Nov;75(5):578–82. Comment in: Br J Anaesth 1996 Apr;76(4):598.

Effect of propofol and thiopentone on free radical mediated oxidative stress of the erythrocyte. Murphy PG, et al. **Br J Anaesth** 1996 Apr;76(4):536–43

Comparison of the effects of sub–hypnotic concentrations of propofol and halothane on the acute ventilatory response to hypoxia. Nagyova B, et al. **Br J Anaesth** 1995 Dec; 75(6):713–8

Effects of graded infusion rates of propofol on cardiovascular haemodynamics, coronary circulation and myocardial metabolism in dogs. Nakaigawa Y, et al. **Br J Anaesth** 1995 Nov;75(5):616–21

A perfusion system for in vitro measurement of human cilia beat frequency. Selwyn DA, et al. **Br J Anaesth** 1996 Jan; 76(1):111–5

Activation of the electrocorticogram by propofol during

surgery for epilepsy. Smith M, et al. **Br J Anaesth** 1996 Apr;76(4):499–502

Effects of propofol on rabbit mesenteric arteries and veins [letter] Stratford N. **Br J Anaesth** 1996 Feb;76(2):333–4

EEG arousal during laryngoscopy and intubation: comparison of thiopentone or propofol supplemented with nitrous oxide. Wilder-Smith OH, et al. **Br J Anaesth** 1995 Oct;75(4):441–6

Anaesthesia during carotid surgery [letter] Andrzejowski J, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):54

Changes in intraocular pressure during low dose intravenous sedation with propofol before cataract surgery. Neel S, et al. **Br J Ophthalmol** 1995 Dec;79(12):1093–7

Potentiation, activation and blockade of GABAA receptors of clonal murine hypothalamic GT1-7 neurones by propofol. Adodra S, et al. **Br J Pharmacol** 1995 Jul; 115(6):953–60

Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Orser BA, et al. **Br J Pharmacol** 1995 Sep;116(2):1761–8

Differential effects of propofol, thiamylal and ketamine on the cricothyroid and posterior cricoarytenoid muscles of the canine larynx. Iwasaki H, et al. **Can J Anaesth** 1996 Jan;43(1):39–43

Effects of propofol and thiopentone on picrotoxin convulsive threshold in the rabbit. Hasan Z, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):714–7

Topographic electroencephalogram of propofol-induced conscious sedation. Kishimoto T, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):666–74

Induction of anaesthesia by propofol and hepatic blood flow in the rabbit. Demeure dit Latte D, et al. **Clin Physiol** 1995 Sep;15(5):515–22

Effect of propofol on human sphincter of Oddi. Goff JS. **Dig Dis Sci** 1995 Nov;40(11):2364–7

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636–57 (205 ref.)

The effects of propofol on laryngeal reactivity and the haemodynamic response to laryngeal mask insertion. Acalovschi I, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):351–6

The pulmonary vascular response to propofol in the isolated perfused rat lung. Erdemli O, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):617–23

Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Conti G, et al. **Intensive Care Med** 1995 Oct;21(10):808–12

Inhibitory effect of propofol on sympathetic neurotransmission results in changes of plasma neuropeptide Y in rats. Chang CL, et al. **J Auton Pharmacol** 1996 Feb;16(1):29–33

Onset of segmental relaxation dysfunction with decreased myocardial tissue perfusion: modulation by propofol. Vermeyen KM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):379–88

Electropharmacological actions of propofol on calcium current in guinea-pig ventricular myocytes. Luk HN, et al. **J Electrocardiol** 1995 Oct;28(4):332–3

A comparison of the electrophysiologic characteristics of EEG burst-suppression as produced by isoflurane, thiopental, etomidate, and propofol. Akrawi WP, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):40–6

Effect of propofol on in vitro lipid peroxidation induced by different free radical generating systems: a comparison with vitamin E. Hans P, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):154–8

Effects of propofol on nociceptive response and power spectra of electroencephalographic and systemic arterial pressure signals in the rat: correlation with plasma concentration. Yang CH, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1568–74

The effect of propofol on CA1 pyramidal cell excitability and GABAA-mediated inhibition in the rat hippocampal slice. Albertson TE, et al. **Life Sci** 1996 May 24; 58(26):2397–407

Effect of 2,6-diisopropylphenol on the delayed hippocampal cell loss following transient forebrain ischemia in the gerbil. Arcadi FA, et al. **Life Sci** 1996;58(12):961–70

Haemodynamic and haemoximetric aspects of experimental orthotopic liver transplantation: comparison between two different doses of propofol. Fabbri LP, et al. **Minerva Anestesiol** 1995 Nov;61(11):441–50

The effects of propofol on rat transcranial magnetic motor evoked potentials. Fishback AS, et al. **Neurosurgery** 1995 Nov;37(5):969–74

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part I. Propofol anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1995 Mar-Apr;47(2):143–52

[Combination of propofol-sufentanil on somatosensory evoked potentials in surgery of the spine] Borrissov B, et al. **Ann Fr Anesth Reanim** 1995;14(4):326–30 (Eng. Abstr.) **(Fre)**

[Incidence and quality of dreaming during anesthesia with propofol in comparison with enflurane] Käsmacher H, et al. **Anaesthesist** 1996 Feb;45(2):146–53 (Eng. Abstr.) **(Ger)**

[Effects of propofol on contractility and electrophysiological properties of canine single cardiomyocytes] Shibuya N, et al. **Masui** 1996 Apr;45(4):408–14 (Eng. Abstr.) **(Jpn)**

[Use of propofol (diprivan) for induction of anesthesia in neurosurgical patients. I. Pressor reaction to laryngoscopy and intubation of the trachea] Tseitlin AM, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):46–9 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Infusions of subhypnotic doses of propofol for the prevention of postoperative nausea and vomiting. Montgomery JE, et al. **Anaesthesia** 1996 Jun;51(6):554–7

The publication of commercially supported supplements statement [letter; comment] Cullen DJ. **Anesth Analg** 1995 Oct;81(4):886–7; discussion 888–9. Comment on: Anesth Analg 1993 Oct;77(4):651–2.

The effects of anesthetic technique on the hemodynamic response and recovery profile in coronary revascularization patients [see comments] Mora CT, et al. **Anesth Analg** 1995 Nov;81(5):900–10. Comment in: Anesth Analg 1995 Nov;81(5):895–6.

Propofol in the management of myoclonus syndrome induced by chloralose poisoning [letter] Quinio P, et al. **Anesthesiology** 1995 Oct;83(4):875

Propofol and chemotherapy-induced emesis [letter; comment] Jones P, et al. **Can J Anaesth** 1995 Jul;42(7):659 . Comment on: Can J Anaesth 1994 Nov;41(11):1117–9.

Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Chamorro C, et al. **Crit Care Med** 1996 Jun;24(6):932–9

Practice parameters for intravenous analgesia and sedation [letter; comment] Collins P, et al. **Crit Care Med** 1996 Feb; 24(2):367–9. Comment on: Crit Care Med 1995 Sep;23(9):1596–600.

Propofol vs. midazolam for sedation [letter; comment] Hansen-Flaschen J, et al. **Crit Care Med** 1996 Jan;24(1):179 . Comment on: Crit Care Med 1995 Feb;23(2):286–93.

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636–57 (205 ref.)

Propofol in prehospital treatment of convulsive status epilepticus. Kuisma M, et al. **Epilepsia** 1995 Dec; 36(12):1241–3

Recovery characteristics following anaesthesia with sevoflurane or propofol in adults undergoing out-patient surgery. Wandel C, et al. **Eur J Clin Pharmacol** 1995; 48(3–4):185–8

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S–66S (81 ref.)

Propofol in terminal care. Mercadante S, et al. **J Pain Symptom Manage** 1995 Nov;10(8):639–42

The use of propofol in palliative medicine. Moyle J. **J Pain Symptom Manage** 1995 Nov;10(8):643–6

Comparison of the effects of propofol and halothane on acute myocardial ischaemia and myocardial reperfusion injury. Coetzee A. **S Afr Med J** 1996 Apr;86 Suppl 2:C85–90

[Infusion of propofol as anesthetic and antiemetic drug] Castaño I, et al. **Rev Esp Anestesiol Reanim** 1995 Aug-Sep; 42(7):257–60 (Eng. Abstr.) **(Spa)**

TOXICITY

Inhibitory effects of propofol on catecholamine secretion and uptake in cultured bovine adrenal medullary cells. Minami K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):572–8

PROPOLIS

Antibacterial diterpenic acids from Brazilian propolis. Bankova V, et al. **Z Naturforsch [C]** 1996 May-Jun; 51(5–6):277–80

ADMINISTRATION & DOSAGE

[The use of ocular drug films of propolis in the sequelae of ophthalmic herpes] Maichuk IuF, et al. **Voen Med Zh** 1995 Dec;(12):36–9, 80 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Propolis protects against doxorubicin-induced myocardiopathy in rats. Chopra S, et al. **Exp Mol Pathol** 1995 Jun;62(3):190–8

Immunomodulatory action of propolis. V. Anticomplementary activity of a water-soluble derivative. Ivanovska ND, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):135–43

Immunomodulatory action of propolis. VI. Influence of a water soluble derivative on complement activity in vivo. Ivanovska ND, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):145–7

[Propolis: its use in technology and research] Gallo FR, et al. **Boll Chim Farm** 1995 Oct;134(9):483–91 (15 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. de Castro SL, et al. **J Ethnopharmacol** 1995 Apr;46(1):55–8

[Apitherapy in the combined treatment of patients with pulmonary tuberculosis taking into account the hypophyseal-adrenal system indices] Masterov GD. **Vrach Delo** 1995 Jan-Feb;(1–2):120–2 (Eng. Abstr.) **(Rus)**

[The indices of the antioxidant system and the status of the cerebral blood supply in patients with an ischemic stroke on apitherapy] Samoliuk VA. **Vrach Delo** 1995 Jan-Feb; (1–2):68–70 (Eng. Abstr.) **(Ukr)**

PROPORTIONAL HAZARDS MODELS

Estimability and interpretation of vaccine efficacy using frailty mixing models. Halloran ME, et al. **Am J Epidemiol** 1996 Jul 1;144(1):83–97

Collapsing ordered outcome categories: a note of concern. Strömberg U. **Am J Epidemiol** 1996 Aug 15;144(4):421–4

Outcome analysis using hazard function methodology. Blackstone EH. **Ann Thorac Surg** 1996 Feb;61(2 Suppl):S2–7; discussion S33–4

A proportional hazards model for arbitrarily censored and truncated data. Alioum A, et al. **Biometrics** 1996 Jun; 52(2):512–24

Bayesian analysis of proportional hazards models built from monotone functions. Gelfand AE, et al. **Biometrics** 1995 Sep;51(3):843–52

Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Grambsch PM, et al. **Biometrics** 1995 Dec;51(4):1469–82

Time-dependent effects of fixed covariates in Cox regression. Verweij PJ, et al. **Biometrics** 1995 Dec;51(4):1550–6

Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial. Tamura RN, et al. **J Biopharm Stat** 1996 May;6(2):127–37

Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. Concato J, et al. **J Clin Epidemiol** 1995 Dec;48(12):1495–501

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. Peduzzi P, et al. **J Clin Epidemiol** 1995 Dec;48(12):1503–10

Percentage of CD4 lymphocytes and risk of AIDS [letter; comment] Mocroft A, et al. **JAMA** 1995 Dec 20; 274(23):1836. Comment on: JAMA 1995 Aug 16;274(7):554–8.

Confidence intervals for cost-effectiveness ratios. Gardiner J, et al. **Med Decis Making** 1995 Jul-Sep;15(3):254–63

A comparison of two computer-based prognostic systems for AIDS. Ohno-Machado L, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:737–41

A joint hazard and time scaling model to compare survival curves. Klawansky S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8183–8

Models of human exposure based on environmental monitoring. Lebret E. **Sci Total Environ** 1995 Jun 16; 168(2):179–85

The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Herndon JE 2nd, et al. **Stat Med** 1995 Oct 15;14(19):2119–29

Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Hess KR. **Stat Med** 1995 Aug 15;14(15):1707–23

Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Karrison T. **Stat Med** 1996 Jan 30; 15(2):171–82

Transient effects in the Cox proportional hazards regression model. Mauger EA, et al. **Stat Med** 1995 Jul 30; 14(14):1553–65

Construction, validation and updating of a prognostic model for kidney graft survival. Van Houwelingen HC, et al. **Stat Med** 1995 Sep 30;14(18):1999–2008

Bias due to observation of different parts of a nonconstant hazard curve over time. Steineck G, et al. **Urology** 1996 Jul;48(1):105–9

[Order by hazard] Tonnelat J. **C R Seances Soc Biol Fil** 1995; 189(2):215–37 (Eng. Abstr.) **(Fre)**

["Razón relativa" and "tasa relativa" as translations of odds ratio and hazard ratio (letter)] Bautista LE. **Bol Oficina Sanit Panam** 1995 Sep;119(3):278–82 **(Spa)**

PROPOXUR see **APROCARB**

PROPOXYCAINE

Severe toxic keratopathy secondary to topical anesthetic abuse. Rocha G, et al. **Can J Ophthalmol** 1995 Jun; 30(4):198–202

ADMINISTRATION & DOSAGE

Drop, then decide approach to topical anesthesia [see comments] Dinsmore SC. **J Cataract Refract Surg** 1995 Nov;21(6):666–71. Comment in: J Cataract Refract Surg 1996 Mar;22(2):156–8.

ADVERSE EFFECTS

Misuse of nonophthalmic and ophthalmic drops due to packaging similarity [letter] Steinemann TL, et al. **Arch Ophthalmol** 1995 Dec;113(12):1578-9

PROPOXYPHENE

PHARMACOLOGY

The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. O'Neill WM, et al. **Eur J Clin Pharmacol** 1995; 48(6):447-53

Determination of analgesic interaction between acetaminophen and d-propoxyphene obtained by means of the surface of synergistic interaction. López-Muñoz FJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun; 17(5):311-20

POISONING

Propoxyphene overdose in Chinese subjects [letter] Chan TY. **J Toxicol Clin Toxicol** 1996;34(2):251-2

[Intraventricular arrhythmia after propoxyphene poisoning (letter)] Staikowsky F, et al. **Presse Med** 1995 Sep 2-9; 24(25):1179 **(Fre)**

[Poisonings with analgesics. Paracetamol and dextropropoxyphene dominate and cause the most severe symptoms in a 3-year material] Torell E, et al. **Lakartidningen** 1996 May 15;93(20):1955-60 **(Swe)**

THERAPEUTIC USE

12 years on: co-proxamol revisited. Haigh S. **Lancet** 1996 Jun 29;347(9018):1840-1

Coproxamol revisited [letter] Sykes JV, et al. **Lancet** 1996 Aug 10;348(9024):408

D-PROPOXYPHENE see **PROPOXYPHENE**

PROPOXYPROCAINE see **PROPOXYCAINE**

PROPRANOLOL

beta-blockers. Drug interactions of clinical significance. Blaufarb I, et al. **Drug Saf** 1995 Dec;13(6):359-70 (114 ref.)

ADMINISTRATION & DOSAGE

Effects of intravenous propranolol on cardiovascular hemodynamics during supraventricular tachycardia. Alboni P, et al. **Am J Cardiol** 1996 Aug 1;78(3):347-50

Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol. Vercruysse I, et al. **Eur J Clin Pharmacol** 1995;49(1-2):121-5

Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. Cox MM, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1293-8

Effects of propranolol on intestinal microcirculation of normal and portal hypertensive rats. Wu ZY, et al. **J Hepatol** 1995 Jun;22(6):677-84

Preparation and evaluation of proliposomes containing propranolol hydrochloride. Ahn BN, et al. **J Microencapsul** 1995 Jul-Aug;12(4):363-75

[The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug] Belolipetskaia VG, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):56-9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment [letter] Choi KL, et al. **Aust N Z J Med** 1995 Jun;25(3):257

Fulminant hepatitis after carbimazole and propranolol administration. Epeirier JM, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):287-8

ANALOGS & DERIVATIVES

Determination and properties of acetyl conjugate of N-desisopropylpropranolol, AcNDP. Noda A, et al. **Biol Pharm Bull** 1995 Oct;18(10):1454-5

Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Takahashi K, et al. **Biol Pharm Bull** 1995 Oct;18(10):1401-4

Characterization of a chemically reactive propranolol metabolite that binds to microsomal proteins of rat liver. Narimatsu S, et al. **Chem Res Toxicol** 1995 Jul-Aug; 8(5):721-8

ANALYSIS

Solid state NMR and extraction studies on "phenyl"-bonded stationary phases used for solid phase extraction. Brindle R, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1305-12

BLOOD

Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Power JM, et al. **Biopharm Drug Dispos** 1995 Oct;16(7):579-89

Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. Vanakoski J, et al. **Eur J Clin Pharmacol** 1995;48(2):133-7

Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol. Vercruysse I, et al. **Eur J Clin Pharmacol** 1995;49(1-2):121-5

CHEMISTRY

Experimental and theoretical study of the adsorption behavior and mass transfer kinetics of propranolol enantiomers on cellulase protein as the selector. Fornstedt T, et al. **Anal Chem** 1996 Jul 15;68(14):2370-8

Stereoselective hydrolysis and penetration of propranolol prodrugs: in vitro evaluation using hairless mouse skin. Ahmed S, et al. **J Pharm Sci** 1995 Jul;84(7):877-83

Influence of pH on the release of propranolol hydrochloride from matrices containing hydroxypropylmethylcellulose K4M and carbopol 974. Perez-Marcos B, et al. **J Pharm Sci** 1996 Mar;85(3):330-4

DIAGNOSTIC USE

Effects of propranolol inhalation on the diurnal increase in FEV1 and on propranolol airways responsiveness in atopic subjects with asthma. Oosterhoff Y, et al. **Thorax** 1995 Sep; 50(9):937-40

ISOLATION & PURIFICATION

Solid state NMR and extraction studies on "phenyl"-bonded stationary phases used for solid phase extraction. Brindle R, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1305-12

Comparison of two extraction methods for determination of propranolol and furosemide in human plasma by mixed-mode chromatography. Walshe M, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):475-81

METABOLISM

Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Takahashi K, et al. **Biol Pharm Bull** 1995 Oct;18(10):1401-4

Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Walle T, et al. **Br J Clin Pharmacol** 1996 Apr; 41(4):305-9

Influence of vitamin C on the absorption and first pass metabolism of propranolol. Gonzalez JP, et al. **Eur J Clin Pharmacol** 1995;48(3-4):295-7

The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. Glennon RA, et al. **Mol Pharmacol** 1996 Jan;49(1):198-206

PHARMACOKINETICS

Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Power JM, et al. **Biopharm Drug Dispos** 1995 Oct;16(7):579-89

Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Bode W, et al. **Chirality** 1995;7(8):626-31

Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. Laethem ME, et al. **Chirality** 1995;7(8):616-22

Sex differences in pharmacokinetics of oral propranolol in healthy Chinese volunteers. Xie HG, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):468-70

Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Lai ML, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):264-8

Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Semple HA, et al. **Drug Metab Dispos** 1995 Aug;23(8):794-8

Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. Vanakoski J, et al. **Eur J Clin Pharmacol** 1995;48(2):133-7

Influence of aging on the oxidative and conjugative metabolism of propranolol. Tateishi T, et al. **Int J Clin Pharmacol Res** 1995;15(3):95-101

The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. Panton LB, et al. **J Clin Pharmacol** 1995 Sep;35(9):885-94

Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. Salazar DE, et al. **J Clin Pharmacol** 1995 Nov; 35(11):1109-18

The secretion of propranolol enantiomers in human saliva: evidence for active transport? Höld KM, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1401-7

[The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug] Belolipetskaia VG, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):56-9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Darbar D, et al. **Am J Cardiol** 1996 Jun 15;77(15):1351-5

Effect of bethanechol, neostigmine, metoclopramide, and propranolol on myoelectric activity of the ileocecocolic area in cows. Steiner A, et al. **Am J Vet Res** 1995 Aug; 56(8):1081-6

Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Aarsland A, et al. **Ann Surg** 1996 Jun; 223(6):777-87; discussion 787-9

Propranolol suppresses reactivation of herpesvirus. Gebhardt BM, et al. **Antiviral Res** 1995 Jun;27(3):255-61

Ryanodine receptor/calcium release channel conformations as reflected in the different effects of propranolol on its ryanodine binding and channel activity. Zchut S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):377-83

Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Anderson R, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):341-9

Microwave influence on the isolated heart function: II. Combined effect of radiation and some drugs. Pakhomov AG, et al. **Bioelectromagnetics** 1995;16(4):250-4

Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis. Combis JM, et al. **Br J Clin Pharmacol** 1996 May;41(5):409-13

Beta-adrenergic control of renin in sodium-deprived conscious dogs: renal versus extrarenal location. Blair ML, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1198-202

Adrenergic, insulin, and work interactions with adenosine's effects on in situ myocardial glucose uptake. Law WR, et al. **Cardiovasc Res** 1996 May;31(5):691-8

Complementary effects of propranolol and nonoxynol-9 upon human sperm motility. White DR, et al. **Contraception** 1995 Oct;52(4):241-7

Propranolol suppression of ocular HSV-1 recurrence and associated corneal lesions following spontaneous reactivation in the rabbit. Kaufman HE, et al. **Curr Eye Res** 1996 Jun;15(6):680-4

Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Lacroix JS, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):298-303

Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. Vanakoski J, et al. **Eur J Clin Pharmacol** 1995;48(2):133-7

Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Tincani E, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):893-7

Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. Benschop RJ, et al. **FASEB J** 1996 Mar;10(4):517-24

Studies on psychomotor performance in healthy volunteers after diazepam, propranolol and alcohol given alone or in combination. Khajuria V, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):242-6

Effects of acute non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al. **Int J Sports Med** 1995 Aug;16(6):373-7

The effect of beta-adrenergic blockade on non-esterified fatty acid uptake of exercising skeletal muscle during arm cranking. Schrauwen P, et al. **Int J Sports Med** 1995 Oct; 16(7):439-44

Investigations of the inhibitory effect of propranolol, chlorpromazine, quinine, and dicyclohexylcarbodiimide on the swelling of yeast mitochondria in potassium acetate. Evidences for indirect effects mediated by the lipid phase. Roucou X, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):353-62

Alteration of ventricular fibrillation by propranolol and isoproterenol detected by epicardial mapping with 506 electrodes. Hillsley RE, et al. **J Cardiovasc Electrophysiol** 1995 Jun;6(6):471-85

Different actions between pindolol and propranolol on the ionic currents in spontaneously beating rabbit sino-atrial node cells. Satoh H. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):967-72

Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers. Hinderling PH, et al. **J Clin Pharmacol** 1995 Jul;35(7):721-9

Protective effects of propranolol on experimentally head-injured mouse brains. Liu MY. **J Formos Med Assoc** 1995 Jul;94(7):386-90

Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. Lin HC, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):281-6

Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Payen JL, et al. **J Hepatol** 1995 Dec; 23(6):689-96

Beta-blockade enhances adrenergic immunosuppression in rats via inhibition of melatonin release. Liebmann PM, et al. **J Neuroimmunol** 1996 Jul;67(2):137-42

K-7259, a novel dilazep derivative, and d-propranolol attenuate H2O2-induced cell damage. Hoque N, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):207-11

Propranolol inhibits the spontaneous closure of the ductus arteriosus in newborn rats. Arishima K, et al. **J Vet Med Sci** 1995 Oct;57(5):943-4

Plasma catecholamine and ventilatory responses to cycling after propranolol treatment. Schneider DA, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1616-20

Effects of the beta-adrenergic blockers propranolol and acebutolol on stress-induced learned helplessness behavior of rats. Danchev N, et al.
Methods Find Exp Clin Pharmacol 1995 Sep;17(7):463-7

Amygdala beta-noradrenergic influences on memory storage involve cholinergic activation. Introini-Collison IB, et al.
Neurobiol Learn Mem 1996 Jan;65(1):57-64

Betel chewing increases the skin temperature: effects of atropine and propranolol. Chu NS. **Neurosci Lett** 1995 Jul 14;194(1-2):130-2

Effect of drugs on chemoreceptor responsiveness in fetal sheep. Boekkooi PF, et al. **Pediatr Res** 1995 Dec; 38(6):938-43

The inhibitory effects of propranolol on genital reflexes in male rats. Smith ER, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):541-6

[Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats] Reichel K, et al.
Arch Tierernahr 1993;45(3):211-25 (Eng. Abstr.) **(Ger)**

[Analysis of the effect of anapriline on circulatory system function] Syrenskiĭ AV, et al. **Biull Eksp Biol Med** 1995 May;119(5):510-2 **(Rus)**

[The effect of damage to the hypothalamic suprachiasmatic nuclei in rats on the restructuring of the dynamic indices of the cardiointervalogram induced by propranolol] Arushanian EB, et al. **Eksp Klin Farmakol** 1995 Jul-Aug; 58(4):29-32 (Eng. Abstr.) **(Rus)**

[Poststress lesions of the gastric mucosa in inbred mice after the peripheral administration of cyproheptadine and propranolol] Koriakina LA.
Fiziol Zh Im I M Sechenova 1995 Feb;81(2):19-25 (Eng. Abstr.) **(Rus)**

POISONING

Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Love JN, et al.
Ann Emerg Med 1996 Jul;28(1):1-6

Reduced survival after isoprenaline/dopamine in d,l-propranolol intoxicated rats. Toet AE, et al.
Hum Exp Toxicol 1996 Feb;15(2):120-8

THERAPEUTIC USE

Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia--beneficial effect of propranolol. Dabadghao S, et al.
Acta Haematol 1996;96(2):112

Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Shankle WR, et al.
Alzheimer Dis Assoc Disord 1995 Winter;9(4):233-7

Reduction by beta-adrenoceptor blockade of hypoxia-induced right heart hypertrophy in the rat. Ostman-Smith I. **Br J Pharmacol** 1995 Nov; 116(6):2698-702

Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Ostman-Smith I. **Br J Pharmacol** 1995 Nov;116(6):2703-9

Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. Ramos-Dias JC, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):583-9

Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616-21 (65 ref.)

Protective effect of beta-blockade on dipyridamole-induced myocardial ischaemia. Role of heart rate. Ferrara N, et al. **Eur Heart J** 1995 Jul;16(7):903-8

Propranolol reduces the anxiety associated with day case surgery. Mealy K, et al. **Eur J Surg** 1996 Jan;162(1):11-4

Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study. Elsayed SS, et al. **Gut** 1996 May; 38(5):770-4

Propranolol in supraventricular tachycardia [letter; comment] Gulati SK, et al. **Indian Pediatr** 1995 Feb; 32(2):244-6. Comment on: Indian Pediatr 1994 May;31(5):588-91.

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. Shimizu W, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1299-309

Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Horwitz RI, et al.
J Clin Epidemiol 1996 Apr;49(4):395-400

Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension [see comments] Pérez-Stable EJ, et al.
J Gen Intern Med 1995 Aug;10(8):419-28. Comment in: J Gen Intern Med 1995 Aug;10(8):472-3.

Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. Mally J, et al. **J Neurol Sci** 1995 Oct;132(2):129-32

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis [see comments] Feu F, et al. **Lancet** 1995 Oct 21;346(8982):1056-9. Comment in: Lancet 1995 Oct 21;346(8982):1046-7.

Propranolol or sclerotherapy to prevent variceal rebleeding. Dwivedi M, et al. **Natl Med J India** 1995 Sep-Oct;8(5):222

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Carpentier AF, et al. **Neurology** 1996 Jun;46(6):1548-51

A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al.
Rom J Neurol Psychiatry 1995 Jul-Dec;33(3-4):203-14

[Medical treatment of aortic aneurysms using beta-blockers] Chakkour K, et al. **J Mal Vasc** 1995;20(4):288-9 (Eng. Abstr.) **(Fre)**

[Treatment of essential tremor] Marchand L.
Union Med Can 1995 Nov;124(3):32-4 **(Fre)**

[Sodium valproate versus propranolol in the prophylactic treatment of migraine] Kozubski W, et al.
Neurol Neurochir Pol 1995 Nov-Dec;29(6):937-47 (Eng. Abstr.) **(Pol)**

[Effect of essentiale on the cardioprotective action of anapriline, nitroglycerin and their combinations in acute total myocardial ischemia] Bender KI, et al.
Patol Fiziol Eksp Ter 1995 Oct-Dec;(4):12-5 (Eng. Abstr.) **(Rus)**

[The lipid peroxidation indices of hypertension patients undergoing combined therapy with anaprilin, korinfar and hypothiazide] Iarema NI, et al. **Ter Arkh** 1995;67(8):28-30 (Eng. Abstr.) **(Rus)**

[Biochemical changes in hypertensive patients during a 1-year cross-over study of treatment with hydrochlorothiazide and propranolol] Bagatin J, et al.
Lijec Vjesn 1996 Jan-Feb;118(1-2):11-6 (Eng. Abstr.) **(Scr)**

[The effect of gallopamil and propranolol in patients with ischemic cardiopathy and moderate depression of ventricular function] Simarro E, et al. **Rev Esp Cardiol** 1995 Nov;48(11):741-5 (Eng. Abstr.) **(Spa)**

[Migraine in childhood and adolescence: a retrospective review of hospital cases] Castro-Gago M, et al.
Rev Neurol 1995 Jul-Aug;23(122):769-72 (Eng. Abstr.) **(Spa)**

TOXICITY

Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Bode W, et al. **Chirality** 1995;7(8):626-31

PROPRIOCEPTION

Proprioception of knee joints with a lesion of the medial meniscus. Jerosch J, et al. **Acta Orthop Belg** 1996 Mar; 62(1):41-5

Knee joint proprioception in below-knee amputees. Liao KI, et al. **Am J Knee Surg** 1995 Summer;8(3):105-9

Prolonged reaction time in patients with chronic lateral instability of the ankle. Löfvenberg R, et al.
Am J Sports Med 1995 Jul-Aug;23(4):414-7

Role of proprioception in pathoetiology of shoulder instability. Warner JJ, et al. **Clin Orthop** 1996 Sep; (330):35-9

Body sway in diabetic neuropathy. Uccioli L, et al.
Diabetes Care 1995 Mar;18(3):339-44

A comparative ultrastructural study of primary afferents from the brachial and cervical plexuses to the external cuneate nucleus of gerbils. Lan CT, et al. **J Anat** 1995 Aug;187 (Pt 1):115-25

Soft-tissue balance and recovery of proprioception after total knee replacement. Attfield SF, et al.
J Bone Joint Surg Br 1996 Jul;78(4):540-5

The inertia tensor as a basis for the perception of limb orientation. Pagano CC, et al.
J Exp Psychol Hum Percept Perform 1995 Oct; 21(5):1070-87

Proprioceptive mechanisms in the cruciate ligaments: an electromyographic study on reflex activity in the thigh muscles. Raunest J, et al. **J Trauma** 1996 Sep;41(3):488-93

Does the glenohumeral joint capsule have proprioceptive capability? Jerosch J, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(2):80-4

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161-72 (20 ref.)

[The occlusal plane: an architectural myth or a proprioceptive myth?] Blocquel H.
Bull Group Int Rech Sci Stomatol Odontol 1996 Feb-Mar; 39(1-2):17-23 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Eye movements in normal subjects induced by vibratory activation of neck muscle proprioceptors. Han Y, et al.
Acta Ophthalmol Scand 1995 Oct;73(5):414-6

Caloric tests on platform: "paradoxical responsiveness". Hadj-Djilani AM. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:437-9

Perceptual studies in patients with vestibular neurectomy. Kanayama R, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:408-11

The perception of head rotation in Parkinson's disease. Nakamura T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:387-91

Posturography: head stabilisation compared with platform recording. Application in vestibular disorders. Norré ME. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:434-6

Proprioception in classical ballet dancers. A prospective study of the influence of an ankle sprain on proprioception in the ankle joint. Leanderson J, et al.
Am J Sports Med 1996 May-Jun;24(3):370-4

Egocentric visual target position and velocity coding: role of ocular muscle proprioception. Gauthier GM, et al.
Ann Biomed Eng 1995 Jul-Aug;23(4):423-35 (34 ref.)

Knee bracing: effects of proprioception. McNair PJ, et al.
Arch Phys Med Rehabil 1996 Mar;77(3):287-9

Special issue: Interoception and behavior. **Biol Psychol** 1996 Jan 5;42(1-2):1-244

Somatic graviception. Mittelstaedt H. **Biol Psychol** 1996 Jan 5;42(1-2):53-74

Simulated micro-gravity and cortical inhibition: a study of the hemodynamic-brain interaction. Vaitl D, et al.
Biol Psychol 1996 Jan 5;42(1-2):87-103

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1-2):1-27 (100 ref.)

Presence of neuroreceptors in normal and diseased temporo-mandibular joints. Favia G, et al.
Boll Soc Ital Biol Sper 1995 Jul-Aug;71(7-8):205-12

Proprioceptive representation of the levator veli palatini muscle in the solitary nucleus of the rat. Furusawa K, et al. **Cleft Palate Craniofac J** 1996 May;33(3):213-8

Proprioceptive regulation of locomotion. Pearson KG.
Curr Opin Neurobiol 1995 Dec;5(6):786-91 (38 ref.)

Modifications with aging in the role played by vision and proprioception for movement control. Chaput S, et al.
Exp Aging Res 1996 Jan-Mar;22(1):1-21

The interaction of visual and proprioceptive inputs in pointing to actual and remembered targets. Berkinblit MB, et al. **Exp Brain Res** 1995;107(2):326-30

Structural and functional characterization of a muscle tendon proprioceptor in lobster. Combes D, et al.
J Comp Neurol 1995 Dec 11;363(2):221-34

Proprioceptive feedback in locust kicking and jumping during maturation. Norman AP. **J Comp Physiol [A]** 1996 Aug;179(2):195-205

Postural sensitivity to visual flow in aging adults with and without balance problems. Sundermier L, et al.
J Gerontol A Biol Sci Med Sci 1996 Mar;51(2):M45-52

Parietal kinetic ataxia without proprioceptive deficit. Ghika J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):531-3

Perception of passive whole-body rotations in the absence of neck and body proprioception. Blouin J, et al.
J Neurophysiol 1995 Nov;74(5):2216-9

Vectorial coding of movement: vision, proprioception, or both? Rossetti Y, et al. **J Neurophysiol** 1995 Jul; 74(1):457-63

The effects of muscle fatigue on and the relationship of arm dominance to shoulder proprioception. Voight ML, et al.
J Orthop Sports Phys Ther 1996 Jun;23(6):348-52

Proprioceptive function of the shoulder girdle in healthy volunteers. Jerosch J, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):219-25

Pure stimulus-sensitive truncal myoclonus of propriospinal origin. Schulze-Bonhage A, et al. **Mov Disord** 1996 Jan; 11(1):87-90

Open-loop and closed-loop postural control mechanisms in Parkinson's disease: increased mediolateral activity during quiet standing. Mitchell SL, et al. **Neurosci Lett** 1995 Sep 8;197(2):133-6

The primary afferent pathway of extraocular muscle proprioception in the pigeon. Hayman MR, et al.
Neuroscience 1995 Nov;69(2):671-83

Proprioceptive hair cells on the neck of the squid Lolliguncula brevis: a sense organ in cephalopods for the control of head-to-body position. Preuss T, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Aug 29; 349(1328):153-78

Acoustic cues and postural control. Petersen H, et al.
Scand J Rehabil Med 1995 Jun;27(2):99-104

[Proprioceptive capacities of the healthy knee joint: modification by an elastic bandage] Jerosch J, et al.
Sportverletz Sportschaden 1995 Sep;9(3):72-6 (Eng. Abstr.) **(Ger)**

[Proprioceptive deficit following cruciate lesions--afferent disorder or compensatory mechanism?] Hopf T, et al.
Z Orthop Ihre Grenzgeb 1995 Jul-Aug;133(4):347-51 (Eng. Abstr.) **(Ger)**

[Effect of transcranial polarization on the state of supraspinal mechanisms of regulation of muscle tonus in patients with Parkinson's disease] Lomarev MP. **Fiziol Cheloveka** 1996 Mar-Apr;22(2):132-3 **(Rus)**

[The role of interoceptive afferentation in regulating motor activity in the early postnatal ontogeny of rats] Kulaev BS, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr; 81(4):99-102 **(Rus)**

[The central effects of interoceptive signalization] Zakharzhevskiĭ VB. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):1-12 (64 ref.) **(Rus)**

[The effect of changes in the level of interoceptive afferentation on the spontaneous periodic motor activity of rat pups] Kulaev BS, et al. **Zh Evol Biokhim Fiziol** 1994 Nov-Dec;30(6):769-75 (Eng. Abstr.) **(Rus)**

[The effect of unconscious interoceptive afferentation on the spatial organization of the electrical activity in the human cerebral cortex] Sviderskaia NE, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1995 Sep-Oct; 45(5):867-75 (Eng. Abstr.) **(Rus)**

PROPTOSIS see EXOPHTHALMOS

PROPYL GALLATE

PHARMACOLOGY

Inhibitory effects of alkyl gallate and its derivatives on fatty acid desaturation. Kawashima H, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):34–8

THERAPEUTIC USE

Attenuation of reperfusion injury by the antioxidant n–propyl gallate. Bhatnagar A. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):343–7

PROPYLADIPHENIN see PROADIFEN

N–PROPYLAJMALINE see PRAJMALINE

PROPYLAMINE TRANSFERASE

METABOLISM

Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Gilad GM, et al. **Biol Psychiatry** 1995 Aug 15;38(4):227–34

PROPYLAMINES

ADMINISTRATION & DOSAGE

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose–response study. Dapoigny M, et al. **Dig Dis Sci** 1995 Oct;40(10):2244–9

ADVERSE EFFECTS

Contact allergy to oleamidopropyl dimethylamine and related substances. Foti C, et al. **Contact Dermatitis** 1995 Aug;33(2):132–3

BLOOD

Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic–concentration relationship in vitro. Hachisu M, et al. **Drugs Exp Clin Res** 1995;21(4):145–51

CHEMICAL SYNTHESIS

Synthesis of uridine–5–propylamine derivatives and their use in affinity chromatography of N–acetylglucosaminyltransferases I and II. Reck F. **Carbohydr Res** 1995 Oct 23;276(2):321–35

[Synthesis and pharmacological study of adamantyl benzene propanamines and propenamines] Pouli N, et al. **Ann Pharm Fr** 1995;53(4):163–9 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Investigation of the inhibition of leukotriene A4 hydrolase. Ollmann IR, et al. **Bioorg Med Chem** 1995 Jul;3(7):969–95

Phenoxypropylamines: a new series of squalene synthase inhibitors. Brown GR, et al. **J Med Chem** 1995 Oct 13; 38(21):4157–60

Structural determinants of activity at the GABAB receptor. A comparison of phosphoethanolamine and related GABA analogs. Klunk WE, et al. **Mol Chem Neuropathol** 1995 Sep;26(1):15–30

METABOLISM

Interactions of intercalative and minor groove binding ligands with triplex poly(dA).[poly(dT)]2 and with duplex poly(dA).poly(dT) and poly[d(A–T)]2 studied by CD, LD, and normal absorption. Kim HK, et al. **Biochemistry** 1996 Jan 30;35(4):1187–94

Identification of the cytochrome P450 isozymes involved in the metabolism of N–nitrosodipropyl–,N–nitrosodibutyl– and N–nitroso–n–butyl–n–propylamine. Shu L, et al. **Carcinogenesis** 1996 Apr;17(4):839–48

New sigma and 5–HT1A receptor ligands: omega–(tetralin–1–yl)–n–alkylamine derivatives. Berardi F, et al. **J Med Chem** 1996 Jan 5;39(1):176–82

Autoradiographic characterization of binding sites for [3H]NE–100 in guinea pig brain. Okuyama S, et al. **Life Sci** 1995;57(21):PL333–7

PHARMACOLOGY

Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic–concentration relationship in vitro. Hachisu M, et al. **Drugs Exp Clin Res** 1995;21(4):145–51

(–)Deprenyl and (–)1–phenyl–2–propylaminopentane, [(–)PPAP], act primarily as potent stimulants of action potential–transmitter release coupling in the catecholaminergic neurons. Knoll J, et al. **Life Sci** 1996; 58(10):817–27

High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Knoll J, et al. **Life Sci** 1996;58(11):945–52

In vitro trypanocidal activities of a novel series of N, N–dimethyl–2–propen–1–amine derivative. De Conti R, et al. **Microbios** 1996;85(343):83–7

[Synthesis and pharmacological study of adamantyl benzene propanamines and propenamines] Pouli N, et al. **Ann Pharm Fr** 1995;53(4):163–9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

(–)–anipamil retards atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Hansen BF, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):485–9

PROPYLBENZILYLCHOLINE MUSTARD

PHARMACOLOGY

Muscarinic M2 receptor synthesis: study of receptor turnover with propylbenzilylcholine mustard. Haddad EB, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):201–5

PROPYLENE GLYCOLS see PROPANEDIOLS

PROPYLENE POLYMERS see POLYPROPYLENES

PROPYLTHIOURACIL

ADMINISTRATION & DOSAGE

Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Yeung SC, et al. **Thyroid** 1995 Oct;5(5):403–5

ADVERSE EFFECTS

Antineutrophil cytoplasmic antibody–positive crescentic glomerulonephritis associated with anti–thyroid drug treatment. D'Cruz D, et al. **Br J Rheumatol** 1995 Nov; 34(11):1090–1

Intermittent polyarthritis due to propylthiouracil. Tosun M, et al. **Clin Rheumatol** 1995 Sep;14(5):574–5

In utero diagnosis and treatment of fetal goitrous hypothyroidism, caused by maternal use of propylthiouracil. Van Loon AJ, et al. **Prenat Diagn** 1995 Jul;15(7):599–604

[Acute pancreatitis and propylthiouracil (letter)] Collet T, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):952 **(Fre)**

IMMUNOLOGY

T cells ignore the parent drug propylthiouracil but are sensitized to a reactive metabolite generated in vivo. von Schmiedeberg S, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):162–70

METABOLISM

T cells ignore the parent drug propylthiouracil but are sensitized to a reactive metabolite generated in vivo. von Schmiedeberg S, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):162–70

PHARMACOLOGY

Propylthiouracil tasting: determination of underlying threshold distributions using maximum likelihood. Reed DR, et al. **Chem Senses** 1995 Oct;20(5):529–33

Comparison of the effects of propylthiouracil and selenium deficiency on T3 production in the rat. Veronikis IE, et al. **Endocrinology** 1996 Jun;137(6):2580–5

Effect of hypothyroidism induced by propylthiouracil and thiourea on male and female reproductive systems of neonatal mice. Chan WY, et al. **J Exp Zool** 1995 Oct 1; 273(2):160–9

Premature rats treated with propylthiouracil show enhanced pulmonary antioxidant enzyme gene expression and improved survival during prolonged exposure to hyperoxia. Chen Y, et al. **Pediatr Res** 1995 Sep;38(3):292–7

THERAPEUTIC USE

The effect of diltiazem on the manifestations of hyperthyroidism and thyroid function tests. Keleştimur F, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):38–42

Low–dose oral propylthiouracil in the treatment of plaque psoriasis [letter] Elias AR, et al. **Int J Dermatol** 1995 Jul; 34(7):519–20

Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. Kallner G, et al. **J Intern Med** 1996 Jun;239(6):525–9

Successful treatment of recurrent non–immune hydrops secondary to fetal hyperthyroidism. Treadwell MC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):838–40

Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Tuttle RM, et al. **Thyroid** 1995 Aug;5(4):243–7

PROSCILLARIDIN

IMMUNOLOGY

Pulse pressure correlates in humans with a proscillaridin A immunoreactive compound. Sich B, et al. **Hypertension** 1996 May;27(5):1073–8

PROSCILLARIDIN A see PROSCILLARIDIN

PROSENCEPHALON

Long–term functional recovery from age–induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain. Martínez–Serrano A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6355–60

Granular cell tumour in the central nervous system of a ferret (Mustela putorius furo). Sleeman JM, et al. **Vet Rec** 1996 Jan 20;138(3):65–6

ABNORMALITIES

Triopia: craniofacial malformation with prosencephalic duplication. Stelnicki EJ, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):334–45

Ethmocephaly, encephalocele and proboscis. Lakshminarayana P, et al. **J Indian Med Assoc** 1995 Dec; 93(12):466–7

ANATOMY & HISTOLOGY

Afferent and efferent connections of the central prosencephalic nucleus in the Pacific hagfish. Amemiya F, et al. **Brain Behav Evol** 1996;47(3):149–55

A segmental morphological paradigm for understanding vertebrate forebrains. Puelles L. **Brain Behav Evol** 1995; 46(4–5):319–37 (145 ref.)

Parallel pathways and convergence onto HVc and adjacent neostriatum of adult zebra finches (Taeniopygia guttata). Fortune ES, et al. **J Comp Neurol** 1995 Sep 25; 360(3):413–41

Topographic organization of a forebrain pathway involved with vocal learning in zebra finches. Johnson F, et al. **J Comp Neurol** 1995 Jul 24;358(2):260–78

Inverse relationship between brain size and callosal connectivity. Steinmetz H, et al. **Naturwissenschaften** 1996 May;83(5):221

Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478–500 (181 ref.)

BLOOD SUPPLY

Ginseng root prevents learning disability and neuronal loss in gerbils with 5–minute forebrain ischemia. Wen TC, et al. **Acta Neuropathol (Berl)** 1996;91(1):15–22

Pericyte–endothelial gap junctions in developing rat cerebral capillaries: a fine structural study. Fujimoto K. **Anat Rec** 1995 Aug;242(4):562–5

HSP70 heat shock protein induction following global ischemia in the rat. Gaspary H, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):327–32

The influence of insulin–induced hypoglycemia on the calcium transients accompanying reversible forebrain ischemia in the rat. Li PA, et al. **Exp Brain Res** 1995; 105(3):363–9

Effect of delayed MK–801 (dizocilpine) treatment with or without immediate postischemic hypothermia on chronic neuronal survival after global forebrain ischemia in rats. Dietrich WD, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):960–8

Isovolemic hemodilution normalizes the prolonged passage of red cells and plasma through cerebral microvessels in the partially ischemic forebrain of rats. Lin SZ, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):280–9

Forebrain ischemia increases GLUT1 protein in brain microvessels and parenchyma. McCall AL, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):69–76

Carbon monoxide, a novel neural messenger, does not modulate extracellular glutamate concentration in forebrain ischemia. Takizawa S, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):1075–8

A one–dimensional (proton and phosphorus) and two–dimensional (proton) in vivo NMR spectroscopic study of reversible global cerebral ischemia. Brulatout S, et al. **J Neurochem** 1996 Jun;66(6):2491–9

Acetyl–L–carnitine attenuates neuronal damage in gerbils with transient forebrain ischemia only when given before the insult. Shuaib A, et al. **Neurochem Res** 1995 Sep; 20(9):1021–5

Hypothermic prevention of nuclear DNA fragmentation in gerbil hippocampus following transient forebrain ischemia. Hara A, et al. **Neurol Res** 1995 Dec;17(6):461–4

Clomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult. Shuaib A, et al. **Neurosci Lett** 1995 Sep 8;197(2):109–12

Apoptosis in substantia nigra following developmental hypoxic–ischemic injury. Oo TF, et al. **Neuroscience** 1995 Dec;69(3):893–901

Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Clemens JA, et al. **Stroke** 1996 Mar;27(3):527–35

Acute changes in intracranial pressure and pressure–volume index after forebrain ischemia in normoglycemic and hyperglycemic rats. Morimoto Y, et al. **Stroke** 1996 Aug; 27(8):1405–9; discussion 1410

23Na nuclear magnetic resonance spectral changes during and after forebrain ischemia in hypoglycemic, normoglycemic, and hyperglycemic rats. Tyson RL, et al. **Stroke** 1996 May;27(5):957–64

[Identification of neuronal death and DNA fragmentation in early stage after rat transient forebrain ischemia] Kazahari S, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):451–5 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Microtubule–associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease. Gai WP, et al. **Acta Neuropathol (Berl)** 1996;91(1):78–81

Calcitonin gene–related peptide (CGRP) content and CGRP receptor binding sites in discrete forebrain regions of alcohol–preferring vs. –nonpreferring rats, and high alcohol–drinking vs. low alcohol–drinking rats. Hwang BH, et al. **Brain Res** 1995 Sep 4;690(2):249–53

Migrating luteinizing hormone–releasing hormone (LHRH) neurons and processes are associated with a substrate that expresses S100. Cummings DM, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):148–57

Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Henkemeyer M, et al. **Cell** 1996 Jul 12;86(1):35–46

Neuropeptide Y in the forebrain and retina of the killifish, Fundulus heteroclitus. Subhedar N, et al. **Cell Tissue Res** 1996 Feb;283(2):313–23

Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine. Mudò G, et al. **Epilepsia** 1996 Feb;37(2):198–207

Autoradiographic localization of D1–like dopamine receptors in the forebrain of male and female Japanese quail and their relationship with immunoreactive tyrosine hydroxylase. Ball GF, et al. **J Chem Neuroanat** 1995 Aug;9(2):121–33

Development of muscarinic receptor subtypes in the forebrain of the mouse. Hohmann CF, et al. **J Comp Neurol** 1995 Jul 17;358(1):88–101

Developmental profile of GABAA–receptors in the marmoset monkey: expression of distinct subtypes in pre– and postnatal brain. Hornung JP, et al. **J Comp Neurol** 1996 Apr 8;367(3):413–30

Hu protein as an early marker of neuronal phenotypic differentiation by subependymal zone cells of the adult songbird forebrain. Barami K, et al. **J Neurobiol** 1995 Sep; 28(1):82–101

Beta–dystroglycan: subcellular localisation in rat brain and detection of a novel immunologically related, postsynaptic density–enriched protein. Mummery R, et al. **J Neurochem** 1996 Jun;66(6):2455–9

Distribution of prolactin receptors in the rat forebrain. Immunohistochemical study. Roky R, et al. **Neuroendocrinology** 1996 May;63(5):422–9

Reactive astrocytes express substance–P immunoreactivity in the adult forebrain after injury. Lin RC. **Neuroreport** 1995 Dec 29;7(1):310–2

Dissociation of galaninergic and neurotrophic plasticity in Down syndrome and Alzheimer disease. Mufson EJ, et al. **Prog Clin Biol Res** 1995;393:105–22

CYTOLOGY

Cultured basal forebrain cholinergic neurons from postnatal rats show both overlapping and non–overlapping responses to the neurotrophins. Nonomura T, et al. **Brain Res** 1995 Jun 12;683(1):129–39

Adrenergic innervation of forebrain neurons that project to the paraventricular thalamic nucleus in the rat. Otake K, et al. **Brain Res** 1995 Oct 30;697(1–2):17–26

Cytophysiology of gonadotropin–releasing–hormone neurons in chum salmon (Oncorhynchus keta) forebrain before and after upstream migration. Kudo H, et al. **Cell Tissue Res** 1996 May;284(2):261–7

The dorsomedial and dorsolateral forebrain of the zebra finch, Taeniopygia guttata: a Golgi study. Montagnese CM, et al. **Cell Tissue Res** 1996 Feb;283(2):263–82

A reexamination of ganglioside GD3–immunopositive glial cells in the forebrains of rats and mice less than 1 week of age. Cammer W, et al. **J Histochem Cytochem** 1996 Feb; 44(2):143–9

Carbonic anhydrase II in microglia in forebrains of neonatal rats. Cammer W, et al. **J Neuroimmunol** 1996 Jul; 67(2):131–6

Lineage, migration, and fate determination of postnatal subventricular zone cells in the mammalian CNS. Goldman JE. **J Neurooncol** 1995;24(1):61–4 (15 ref.)

Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. Vaucher E, et al. **J Neurosci** 1995 Nov;15(11):7427–41

192IgG–saporin immunotoxin–induced loss of cholinergic cells differentially activates microglia in rat basal forebrain nuclei. Rossner S, et al. **J Neurosci Res** 1995 Jun 15; 41(3):335–46

Population trends in the fine spatial re–organization of synaptic elements in forebrain regions of chicks 0.5 and 24 hours after passive avoidance training. Ruskov DA, et al. **Neuroscience** 1995 May;66(2):291–307

DRUG EFFECTS

Interfering with somatosensory stimulation from pups sensitizes experienced, postpartum rat mothers to oxytocin antagonist inhibition of maternal behavior. Pedersen CA, et al. **Behav Neurosci** 1995 Oct;109(5):980–90

A new cognition–enhancing agent, (R)–(–)–1–(benzo[b]thiophen–5–yl)–2–[2–(N,N–diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions. Ono S, et al. **Biol Pharm Bull** 1995 Dec;18(12):1779–83

Evidence that activation of 5–HT2 receptors in the forebrain of anaesthetized cats causes sympathoexcitation. Anderson IK, et al. **Br J Pharmacol** 1995 Sep;116(2):1751–6

Interaction between a selective 5–HT1A receptor antagonist and an SSRI in vivo: effects on 5–HT cell firing and extracellular 5–HT. Gartside SE, et al. **Br J Pharmacol** 1995 Jul;115(6):1064–70

Effects of CGS 21680 in vivo on dopamine D2 agonist binding in the rat brain. Hillefors–Berglund M, et al. **Brain Res** 1995 Aug 28;690(1):34–40

The opposing effects of interleukin –1 beta microinjected into the preoptic hypothalamus and the ventromedial hypothalamus on nociceptive behavior in rats. Oka T, et al. **Brain Res** 1995 Nov 27;700(1–2):271–8

Ascorbate potentiates amphetamine–induced conditioned place preference and forebrain dopamine release in rats. Pierce RC, et al. **Brain Res** 1995 Aug 7;688(1–2):21–6

Domoic acid–induced neuronal degeneration in the primate forebrain revealed by degeneration specific histochemistry. Schmued LC, et al. **Brain Res** 1995 Oct 9;695(1):64–70

Mineralization of the globus pallidus following excitotoxic lesions of the basal forebrain. Stewart GR, et al. **Brain Res** 1995 Oct 9;695(1):81–7

Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Wan W, et al. **Brain Res** 1995 Aug 7; 688(1–2):95–104

Neuropeptide Y injection into the fourth cerebroventricle stimulates c–Fos expression in the paraventricular nucleus and other nuclei in the forebrain: effect of food consumption. Xu B, et al. **Brain Res** 1995 Nov 6; 698(1–2):227–31

The effects of D1 or D2 dopamine receptor blockade on zif/268 and preprodynorphin gene expression in rat forebrain following a short–term cocaine binge. Daunais JB, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):237–48

Differential effects of forebrain 5–hydroxytryptamine depletions on Pavlovian aversive conditioning to discrete and contextual stimuli in the rat. Wilkinson LS, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2042–52

Morphine–induced changes in cerebral and cerebellar nitric oxide synthase activity. Leza JC, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):95–8

Subchronic morphine increases amphetamine–induced potentiation of brain stimulation reward: reversal by DNQX. Bespalov AYu, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):89–93

Influence of dexamethasone on neurotoxicity caused by oxygen and glucose deprivation in vitro. Flavin MP. **Exp Neurol** 1996 May;139(1):34–8

Role of nerve growth factor in the expression of trkA mRNA in cultured embryonic rat basal forebrain cholinergic neurons. Kojima M, et al. **J Neurosci Res** 1995 Dec 15; 42(6):775–83

Glial cell line–derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose–response comparison to nerve growth factor and brain–derived neurotrophic factor. Williams LR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1140–51

Lesions of the cholinergic nuclei in the rat basal forebrain: excitotoxins vs. an immunotoxin. Waite JJ, et al. **Life Sci** 1996;58(22):1947–53

Epidermal growth factor–mediated inhibition of neurotransmitter glutamate release from rat forebrain synaptosomes. Barrie A, et al. **Mol Pharmacol** 1996 Mar; 49(3):399–403

Technical note on omega–conotoxin GVIA disrupts memory formation in the day–old chick. Deyo RA. **Neurobiol Learn Mem** 1996 Jul;66(1):89–90; discussion 91–2

Effect of dimaprit and cimetidine on the somatostatinergic system in the rat frontoparietal cortex. Puebla L, et al. **Neuropsychopharmacology** 1996 May;14(5):367–74

Effect of chronic toluene exposure on tyrosine hydroxylase–positive nerve elements in the rat forebrain: an immunohistochemical study combined with semiquantitative morphometric analysis. Iizumi H, et al. **Neuroreport** 1995 Dec 29;7(1):81–4

The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha 1–adrenergic or 5HT2 receptor blockade to haloperidol. Fink–Jensen A, et al. **Neurosci Lett** 1995 Jul 14; 194(1–2):77–80

Immunolesioning of basal forebrain cholinergic neurons facilitates hippocampal kindling and perturbs neurotrophin messenger RNA regulation. Kokaia M, et al. **Neuroscience** 1996 Jan;70(2):313–27

Effects of prenatal cocaine exposure on postnatal growth patterns of male Wistar rats. Silva MC, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):471–7

Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain. Holley LA, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):99–108

EMBRYOLOGY

Pericyte–endothelial gap junctions in developing rat cerebral capillaries: a fine structural study. Fujimoto K. **Anat Rec** 1995 Aug;242(4):562–5

Conditioned medium from activated microglia promotes cholinergic differentiation in the basal forebrain in vitro. Jonakait GM, et al. **Dev Biol** 1996 Jul 10;177(1):85–95

Initial organization of neurons and tracts in the embryonic mouse fore– and midbrain. Mastick GS, et al. **Dev Biol** 1996 Jan 10;173(1):79–94

Rpx: a novel anterior–restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. Hermesz E, et al. **Development** 1996 Jan;122(1):41–52

Longitudinal organization of the anterior neural plate and neural tube. Shimamura K, et al. **Development** 1995 Dec; 121(12):3923–33 (66 ref.)

Pattern formation in the mammalian forebrain: striatal patch and matrix neurons intermix prior to compartment formation. Krushel LA, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1210–9

Development of acetylcholinesterase–positive thalamic and basal forebrain afferents to embryonic rat neocortex. De Carlos JA, et al. **Exp Brain Res** 1995;104(3):385–401

The T/ebp null mouse: thyroid–specific enhancer–binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Kimura S, et al. **Genes Dev** 1996 Jan 1;10(1):60–9

Null mutation of Dlx–2 results in abnormal morphogenesis of proximal first and second branchial arch derivatives and abnormal differentiation in the forebrain. Qiu M, et al. **Genes Dev** 1995 Oct 15;9(20):2523–38

Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)

Fate of the anterior neural ridge and the morphogenesis of the Xenopus forebrain. Eagleson G, et al. **J Neurobiol** 1995 Oct;28(2):146–58

Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran–Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):169–78 (77 ref.)

Expression patterns of the paired–related homeobox genes MHox/Prx1 and S8/Prx2 suggest roles in development of the heart and the forebrain. Leussink B, et al. **Mech Dev** 1995 Jul;52(1):51–64

Function of the Eph–related kinase rtk1 in patterning of the zebrafish forebrain. Xu Q, et al. **Nature** 1996 May 23; 381(6580):319–22

Regional incorporation and site–specific differentiation of striatal precursors transplanted to the embryonic forebrain ventricle. Campbell K, et al. **Neuron** 1995 Dec; 15(6):1259–73

Regionalization of the forebrain from neural plate to neural tube. Papalopulu N. **Perspect Dev Neurobiol** 1995; 3(1):39–52 (125 ref.)

ENZYMOLOGY

Changes in NADPH diaphorase activity in forebrain structures of the laminae terminalis after chronic dehydration. Ciriello J, et al. **Brain Res** 1996 Feb 5; 708(1–2):167–72

Delta–aminolevulinic acid dehydratase activity in weanling and adult rats exposed to lead acetate. Rodrigues AL, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):47–53

Effect of hypothyroidism on the subcellular distribution of Ca2+/calmodulin–stimulated protein kinase II in chicken brain during posthatch development. Wang X, et al. **J Neurochem** 1996 Apr;66(4):1625–32

Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle: effects of estrogen and progesterone. Gibbs RB. **J Neurosci** 1996 Feb 1;16(3):1049–55

Purified inositol hexakisphosphate kinase is an ATP synthase: diphosphoinositol pentakisphosphate as a high–energy phosphate donor. Voglmaier SM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4305–10

Developmental activity variations of DNA polymerase alpha, delta, epsilon in mouse forebrains and spleens. Yang R, et al. **Sci China B** 1995 Oct;38(10):1237–45

GROWTH & DEVELOPMENT

Developmental changes of NADPH–diaphorase neurons in the forebrain of neonatal and adult cat. Riche D, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):139–45

Regulation of neural precursor differentiation in the embryonic and adult forebrain. Bartlett PF, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):559–62 (21 ref.)

Exposure of postnatal rats to glucocorticoids suppresses the development of choline acetyltransferase–immunoreactive neurons: role of adrenal steroids in the development of forebrain cholinergic neurons. Hu Z, et al. **J Chem Neuroanat** 1996 Feb;10(1):1–10

Development of the catecholaminergic innervation of the song system of the male zebra finch. Soha JA, et al. **J Neurobiol** 1996 Apr;29(4):473–89

Developmental changes in glutamate receptor stimulated inositol phospholipid metabolism and 45Ca(2+)–accumulation in posthatch chicken forebrain. Kavanagh JM, et al. **Neurosci Lett** 1995 Jul 21;194(3):161–4

IMMUNOLOGY

Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. Moffett JR, et al. **J Neurocytol** 1995 Jun;24(6):409–33

Induction of HSP70 in rat brain following subarachnoid hemorrhage produced by endovascular perforation. Matz PG, et al. **J Neurosurg** 1996 Jul;85(1):138–45

INJURIES

Perseverative errors and reversal of a visual discrimination following basal forebrain lesions in the rat. Wilson WJ, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(4):295–9

METABOLISM

Age-related decrease of nerve growth factor-like immunoreactivity in the basal forebrain of senescence-accelerated mice. Ohnishi K, et al. **Acta Neuropathol (Berl)** 1995;90(1):11–6

NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Suzuki T, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):582–8

Pontine and basal forebrain transections disinhibit brown fat thermogenesis in neonatal rats. Blumberg MS, et al. **Brain Res** 1995 Nov 20;699(2):214–20

Alterations in immediate-early gene proteins in the rat forebrain induced by acute morphine injection. Garcia MM, et al. **Brain Res** 1995 Sep 18;692(1–2):23–40

Charting of Jun family member proteins in the rat forebrain and midbrain: immunocytochemical evidence for a new Jun-related antigen. Harlan RE, et al. **Brain Res** 1995 Sep 18;692(1–2):1–22

Regional and cellular expression sites of the alpha 1 subunit of GABAA receptors in the rat basal forebrain: a cytochemical study with glutamic acid decarboxylase, choline acetyltransferase, calcium-binding proteins and nitric oxide synthase as second markers. Härtig W, et al. **Brain Res** 1995 Sep 18;692(1–2):215–26

Discrimination training in a GO/NOGO-procedure alters the 2-deoxyglucose pattern in the Starling's forebrain. Scharmann MG, et al. **Brain Res** 1995 Jun 5;682(1–2):83–92

Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Tassorelli C, et al. **Brain Res** 1995 Jun 5;682(1–2):167–81

Effect of hypothyroidism on vasoactive intestinal polypeptide-immunoreactive neurons in forebrain-neurohypophysial nuclei of the rat brain. Toni R, et al. **Brain Res** 1995 Jun 5;682(1–2):101–15

The effects of D1 or D2 dopamine receptor blockade on zif/268 and preprodynorphin gene expression in rat forebrain following a short-term cocaine binge. Daunais JB, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):237–48

Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201–8

An alteration in the gamma-aminobutyric acid receptor system in experimentally induced septic shock in rats. Kadoi Y, et al. **Crit Care Med** 1996 Feb;24(2):298–305

Rpx: a novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. Hermesz E, et al. **Development** 1996 Jan;122(1):41–52

Sodium channel mRNA in the B104 neuroblastoma cell line. Dib-Hajj SD, et al. **FEBS Lett** 1996 Apr 8;384(1):78–82

Pharmacological induction of heat shock protein 68 synthesis in cultured rat astrocytes. Nishimura RN, et al. **J Biol Chem** 1995 Dec 15;270(50):29967–70

Fos expression in forebrain afferents to the hypothalamic paraventricular nucleus following swim stress. Cullinan WE, et al. **J Comp Neurol** 1996 Apr 22;368(1):88–99

NGF mRNA is expressed by GABAergic but not cholinergic neurons in rat basal forebrain. Lauterborn JC, et al. **J Comp Neurol** 1995 Sep 25;360(3):454–62

N-substituted analogs of 2 beta-carbomethoxy-3 beta-(4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. Neumeyer JL, et al. **J Med Chem** 1996 Jan 19;39(2):543–8

Differential effects of nerve growth factor on expression of choline acetyltransferase and sodium-coupled choline transport in basal forebrain cholinergic neurons in culture. Pongrac JL, et al. **J Neurochem** 1996 Feb;66(2):804–10

Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain. Wang JQ, et al. **J Neurochem** 1995 Dec;65(6):2706–15

Mating-induced FOS-like immunoreactivity in the rat forebrain: a sex comparison and a dimorphic effect of pelvic nerve transection. Wersinger SR, et al. **J Neuroendocrinol** 1993 Oct;5(5):557–68

PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. Hunt CA, et al. **J Neurosci** 1996 Feb 15;16(4):1380–8

Early patterns of migration, morphogenesis, and intermediate filament expression of subventricular zone cells in the postnatal rat forebrain. Zerlin M, et al. **J Neurosci** 1995 Nov;15(11):7238–49

Galanin receptors in human basal forebrain differ from receptors in the hypothalamus: characterization using [125I]galanin (porcine) and [125I]galantide. Deecher DC, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):720–7

A single homeodomain binding site restricts spatial expression of Wnt-1 in the developing brain. Iler N, et al. **Mech Dev** 1995 Sep;53(1):87–96

Wnt4 affects morphogenesis when misexpressed in the zebrafish embryo. Ungar AR, et al. **Mech Dev** 1995 Aug; 52(2–3):153–64

Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Clark WM, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):213–30

Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration. Venero JL, et al. **Mol Pharmacol** 1996 Feb;49(2):303–10

Oestrogen and mental state [letter] Fink G, et al. **Nature** 1996 Sep 26;383(6598):306

Analysis of glutamate receptors in primary cultured neurons from fetal rat forebrain. Oillet J, et al. **Neurochem Res** 1995 Jun;20(6):761–8

Affinity purification of rat cortical and chicken forebrain synaptosomes using a biotinylated derivative of omega-CgTx GVIA. Bowman D, et al. **Neuropharmacology** 1995 Jul;34(7):743–52

Loss of p75 nerve growth factor receptor mRNA containing neurons in rat forebrain after intraventricular IgG 192-saporin administration. Singh V, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):117–20

Burst stimulation of the medial forebrain bundle selectively increase Fos-like immunoreactivity in the limbic forebrain of the rat. Chergui K, et al. **Neuroscience** 1996 May; 72(1):141–56

The association of thirst, sodium appetite and vasopressin release with c-fos expression in the forebrain of the rat after intracerebroventricular injection of angiotensin II, angiotensin-(1–7) or carbachol. Mahon JM, et al. **Neuroscience** 1995 Nov;69(1):199–208

Induction of c-fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine levels. Moorman JM, et al. **Neuroscience** 1995 Oct;68(4):1089–96

Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Tao R, et al. **Neuroscience** 1995 Sep; 68(2):553–61

Behavioural, autonomic and endocrine responses associated with C-fos expression in the forebrain and brainstem after intracerebroventricular infusions of endothelins. Zhu B, et al. **Neuroscience** 1996 Apr;71(4):1049–62

Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. Satoh S, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5980–4

23Na nuclear magnetic resonance spectral changes during and after forebrain ischemia in hypoglycemic, normoglycemic, and hyperglycemic rats. Tyson RL, et al. **Stroke** 1996 May;27(5):957–64

Distribution of GABAA receptor alpha 1 subunit-like immunoreactivity in comparison with that of enkephalin and substance P in the rat forebrain. Marksteiner J, et al. **Synapse** 1995 Jun;20(2):165–74

PATHOLOGY

Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Clark WM, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):213–30

Protective effect of dichloroacetate in a rat model of forebrain ischemia. Peeling J, et al. **Neurosci Lett** 1996 Apr 12;208(1):21–4

PHYSIOLOGY

Influence of forebrain lesions and isoflurane anaesthesia, respectively, on responses to the intracarotid infusion of angiotensin II in sheep. Eriksson S, et al. **Acta Physiol Scand** 1995 Dec;155(4):427–34

Spatial learning impairment in aged rats: comparing between aged basal forebrain lesioned and normal aged rats. Nakamura S, et al. **Behav Brain Res** 1995 Sep;70(1):69–76

beta-Amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. Sigurdsson EM, et al. **Behav Brain Res** 1995 Dec 14; 72(1–2):141–56

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1–2):13–25 (123 ref.)

Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. McGaughy J, et al. **Behav Neurosci** 1996 Apr; 110(2):247–65

Excitotoxic lesions of the parabrachial nuclei prevent conditioned taste aversions and sodium appetite in rats. Scalera G, et al. **Behav Neurosci** 1995 Oct;109(5):997–1008

Gustatory detection thresholds after parabrachial nuclei lesions in rats. Spector AC, et al. **Behav Neurosci** 1995 Oct; 109(5):939–54

Maze learning and morphology of frontal cortex in adult and aged basal forebrain-lesioned rats. Wellman CL, et al. **Behav Neurosci** 1995 Oct;109(5):837–50

Beneficial effects of biota, a traditional Chinese herbal medicine on learning impairment induced by basal forebrain-lesion in mice. Nishiyama N, et al. **Biol Pharm Bull** 1995 Nov;18(11):1513–7

Comparative aspects of forebrain organization in the ray-finned fishes: touchstones or not? Braford MR Jr. **Brain Behav Evol** 1995;46(4–5):259–74 (96 ref.)

The forebrain of gnathostomes: in search of a morphotype. Northcutt RG. **Brain Behav Evol** 1995;46(4–5):275–318 (256 ref.)

Age and the effects of 2-D,L-amino-5-phosphonovalerate in an area of the chick forebrain which is essential for early learning. Bradley PM, et al. **Brain Res** 1995 Nov 13; 699(1):103–8

A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Pascual T, et al. **Brain Res** 1995 Oct 16; 695(2):289–92

192IgG-saporin-induced immunotoxic lesions of cholinergic basal forebrain system differentially affect glutamatergic and GABAergic markers in cortical rat brain regions. Rossner S, et al. **Brain Res** 1995 Oct 23;696(1–2):165–76

Discrimination training in a GO/NOGO-procedure alters the 2-deoxyglucose pattern in the Starling's forebrain. Scharmann MG, et al. **Brain Res** 1995 Jun 5;682(1–2):83–92

Antisense oligonucleotide to NOR-1, a novel orphan nuclear receptor, induces migration and neurite extension of cultured forebrain cells. Ohkura N, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):309–13

Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. Coffey LL, et al. **Epilepsia** 1996 Feb;37(2):188–97

Pattern formation in the mammalian forebrain: striatal patch and matrix neurons intermix prior to compartment formation. Krushel LA, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1210–9

Expression of the lacZ reporter gene in the rat basal forebrain, hippocampus, and nigrostriatal pathway using a nonreplicating herpes simplex vector. Maidment NT, et al. **Exp Neurol** 1996 May;139(1):107–14

Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):190–9 (21 ref.)

Low-voltage activated calcium currents increase in basal forebrain neurons from aged rats. Murchison D, et al. **J Neurophysiol** 1995 Aug;74(2):876–87

Basal forebrain cholinergic lesions disrupt increments but not decrements in conditioned stimulus processing. Chiba AA, et al. **J Neurosci** 1995 Nov;15(11):7315–22

Forebrain contribution to the induction of a cellular correlate of conditioned taste aversion in the nucleus of the solitary tract. Schafe GE, et al. **J Neurosci** 1995 Oct;15(10):6789–96

The involvement of Ca2+/calmodulin-dependent protein kinase in memory formation in day-old chicks. Zhao WQ, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):24–35

Role of forebrain glucose-monitoring neurons in the central control of feeding: II. Complex functional attributes. Karádi Z, et al. **Neurobiology (Bp)** 1995;3(3–4):241–56

Role of forebrain glucose-monitoring neurons in the central control of feeding: I. Behavioral properties and neurotransmitter sensitivities. Lénárd L, et al. **Neurobiology (Bp)** 1995;3(3–4):223–39

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1–4 (16 ref.)

Noradrenaline and potentiation in the chick brain slice. Bradley PM, et al. **Neuroreport** 1995 Jul 31;6(11):1501–4

Prostaglandin D2 modulates sleep-related and noradrenaline-induced activity of preoptic and basal forebrain neurons in the rat. Osaka T, et al. **Neurosci Res** 1995 Oct;23(3):257–68

GABAergic axons in the ventral forebrain of the rat: an electron microscopic study. Chang HT, et al. **Neuroscience** 1995 Sep;68(1):207–20

The mediodorsal nucleus of the thalamus in rats--I. forebrain gabaergic innervation. Churchill L, et al. **Neuroscience** 1996 Jan;70(1):93–102

Projection neurons in fetal striatal transplants are predominantly derived from the lateral ganglionic eminence. Olsson M, et al. **Neuroscience** 1995 Dec; 69(4):1169–82

Differential effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate receptor antagonists applied to the basal forebrain on cortical acetylcholine release and electroencephalogram desynchronization. Rasmusson DD, et al. **Neuroscience** 1996 May;72(2):419–27

Effects of excitotoxic lesions of the basal forebrain on MFB self-stimulation. Arvanitogiannis A, et al. **Physiol Behav** 1996 Apr-May;59(4–5):795–806

Frontal forebrain lesions: effects on the foraging and apomorphine pecking of pigeons. Wynne B, et al. **Physiol Behav** 1996 Apr-May;59(4–5):757–62

How the songbird makes his song [news; comment] Pennisi E. **Science** 1996 Sep 27;273(5283):1801–2. Comment on: Science 1996 Sep 27;273(5283):1871–5.

Temporal hierarchical control of singing in birds [see comments] Yu AC, et al. **Science** 1996 Sep 27; 273(5283):1871–5. Comment in: Science 1996 Sep 27;273(5283):1801–2.

Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478–500 (181 ref.)

PHYSIOPATHOLOGY

Calcium deposit formation and glial reaction in rat brain after

ibotenic acid-induced basal forebrain lesion. Saura J, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1569–78

Forebrain involvement in fatal cardiac arrhythmia. Wolf S. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):215–25

Role of nitric oxide and acetylcholine in neocortical hyperemia elicited by basal forebrain stimulation: evidence for an involvement of endothelial nitric oxide. Zhang F, et al. **Neuroscience** 1995 Dec;69(4):1195–204

RADIATION EFFECTS

Gamma-radiation-induced cell death in the fetal rat brain possesses molecular characteristics of apoptosis and is associated with specific messenger RNA elevations. Borovitskaya AE, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):19–30

SECRETION

Epidermal growth factor-mediated inhibition of neurotransmitter glutamate release from rat forebrain synaptosomes. Barrie A, et al. **Mol Pharmacol** 1996 Mar; 49(3):399–403

TRANSPLANTATION

Transplantation of basal forebrain cells of foetal rats into the subarachnoid space: improvement of disturbance of passive avoidance memory due to injury of nucleus basalis magnocellularis. Kyoshima K, et al.
Acta Neurochir (Wien) 1995;133(1–2):68–72

Development of an intact blood-brain barrier in brain tissue transplants is dependent on the site of transplantation. Granholm AC, et al. **Cell Transplant** 1996 Mar–Apr; 5(2):305–14

ULTRASTRUCTURE

Long-term increases in synaptic density in chick CNS after passive avoidance training are blocked by an inhibitor of protein synthesis. Sojka M, et al. **Brain Res** 1995 Jul 3; 684(2):209–14

GABAergic axons in the ventral forebrain of the rat: an electron microscopic study. Chang HT, et al.
Neuroscience 1995 Sep;68(1):207–20

[The ultrastructure of the capillaries and pericapillary area in the formations of the rat forebrain in hypokinesia] Zhvaniia MG, et al. **Morfologiia** 1994 Jul–Dec; 107(7–12):47–53 (Eng. Abstr.) **(Rus)**

PROSIMII see **STREPSIRHINI**

PROSPECTIVE PAYMENT SYSTEM

The relationship between hospital per diem billing and DRG reimbursement for urban trauma patients. Sloan EP, et al. **J Med Syst** 1995 Oct;19(5):375–9

The relationship between resource constraints and physician problem solving. Implications for improving the process of care. Lescoe-Long MA, et al. **Med Care** 1996 Sep; 34(9):931–53

ECONOMICS

The etiology and determinants of hospital closure. Longo DR, et al. **J Health Care Finance** 1996 Spring;22(3):34–48

Futile care in the pediatric intensive care unit: ethical and economic considerations [editorial; comment] Tilford JM, et al. **J Pediatr** 1996 Jun;128(6):725–7. Comment on: J Pediatr 1996 Jun;128(6):742–7.

Effects of Medicare's prospective payment system on service use by depressed elderly inpatients. Davis LM, et al.
Psychiatr Serv 1995 Nov;46(11):1178–84

ORGANIZATION & ADMINISTRATION

Function-based payment model for inpatient medical rehabilitation: an evaluation. Sutton JP, et al.
Arch Phys Med Rehabil 1996 Jul;77(7):693–701

PROSPECTIVE PRICING see **PROSPECTIVE PAYMENT SYSTEM**

PROSPECTIVE REIMBURSEMENT see **PROSPECTIVE PAYMENT SYSTEM**

PROSPECTIVE STUDIES

A tree-based method of analysis for prospective studies. Zhang H, et al. **Stat Med** 1996 Jan 15;15(1):37–49

[Alternatives and access routes in hysterectomies. Are randomizations dangerous?] Cosson M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(3):257–63 (15 ref.) (Eng. Abstr.) **(Fre)**

[Informed consent and the approval of evaluation committees in Mexican medical research] López-de-la-Peña XA.
Rev Invest Clin 1995 Sep–Oct;47(5):399–404 (Eng. Abstr.) **(Spa)**

PROST see **ZYGOTE INTRAFALLOPIAN TRANSFER**

PROSTACYCLIN see **EPOPROSTENOL**

PROSTAGLANDIN ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PROSTAGLANDIN ANTAGONISTS

see related
CYCLOOXYGENASE INHIBITORS

ADMINISTRATION & DOSAGE

Peri-operative administration of rectal diclofenac sodium. The effect on renal function in patients undergoing minor orthopaedic surgery. Irwin MG, et al.
Eur J Anaesthesiol 1995 Jul;12(4):403–6

ISOLATION & PURIFICATION

Anti-inflammatory compounds isolated from Menyanthes trifoliata L. Huang C, et al. **Yao Hsueh Hsueh Pao** 1995; 30(8):621–6

METABOLISM

In vitro studies to elucidate the metabolic pathway of (+)-S-145, a thromboxane A2 receptor antagonist, in rats. Evidence for two independent pathways in peroxisomal beta-oxidation. Yamaguchi Y, et al. **Drug Metab Dispos** 1995 Nov;23(11):1195–201

PHARMACOKINETICS

Pharmacokinetics of a new thromboxane A2 receptor antagonist, S-1452, and its effect on platelet aggregation in healthy volunteers. Fujimura A, et al.
J Clin Pharmacol 1996 May;36(5):409–13

PHARMACOLOGY

Influence of indomethacin on bone turnover related to orthodontic tooth movement in miniature pigs. Giunta D, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct; 108(4):361–6

6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Woodward DF, et al.
Biochem Pharmacol 1995 Nov 9;50(10):1731–3

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al.
Drugs Exp Clin Res 1995;21(3):85–8

Prostanoid-induced contractions are blocked by sulfonylureas. Delaey C, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):179–84

Effect of thromboxane A2 antagonist GR32191B on prostanoid and nonprostanoid receptors in the human internal mammary artery. He GW, et al.
J Cardiovasc Pharmacol 1995 Jul;26(1):13–9

Pharmacokinetics of a new thromboxane A2 receptor antagonist, S-1452, and its effect on platelet aggregation in healthy volunteers. Fujimura A, et al.
J Clin Pharmacol 1996 May;36(5):409–13

Screening of Zulu medicinal plants for prostaglandin-synthesis inhibitors. Jäger AK, et al.
J Ethnopharmacol 1996 Jun;52(2):95–100

Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. Tunón H, et al.
J Ethnopharmacol 1995 Oct;48(2):61–76

Possible evidence that the herbal medicine shakuyaku-kanzo-to decreases prostaglandin levels through suppressing arachidonate turnover in endometrium. Imai A, et al. **J Med** 1995;26(3–4):163–74

Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. Hallinan EA, et al.
J Med Chem 1996 Jan 19;39(2):609–13

Prostaglandins, their inhibitors and cancer. Lupulescu A.
Prostaglandins Leukot Essent Fatty Acids 1996 Feb; 54(2):83–94 (109 ref.)

PHYSIOLOGY

Signal transduction mechanisms in substance P-mediated ciliostimulation. Schlosser RJ, et al.
Otolaryngol Head Neck Surg 1995 Nov;113(5):582–8

THERAPEUTIC USE

Effects of prostaglandin antagonist phloretin derivatives on mouse ear edema induced with different skin irritants. Blazsó G, et al. **Prostaglandins** 1995 Sep;50(3):161–8

TOXICITY

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al.
Drugs Exp Clin Res 1995;21(3):85–8

PROSTAGLANDIN D2

ANALOGS & DERIVATIVES

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Forman BM, et al. **Cell** 1995 Dec 1;83(5):803–12

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Kliewer SA, et al. **Cell** 1995 Dec 1;83(5):813–9

Involvement of protein kinase in delta 12-prostaglandin J2-induced expression of rat heme oxygenase-1 gene. Negishi M, et al. **FEBS Lett** 1995 Sep 25;372(2–3):279–82

Regulation of BiP gene expression by cyclopentenone prostaglandins through unfolded protein response element. Odani N, et al. **J Biol Chem** 1996 Jul 12;271(28):16609–13

Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. Rozera C, et al.
J Clin Invest 1996 Apr 15;97(8):1795–803

Biological actions of delta 12-prostaglandin J2. Negishi M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):443–8 (23 ref.)

ANALYSIS

Decreased hypothalamic prostaglandin D2 and prostaglandin E2 contents during isoflurane anaesthesia in rats. Sato T, et al. **Can J Anaesth** 1995 Nov;42(11):1031–4

BIOSYNTHESIS

Down-regulation of canine airway mast cell function following exposure to ozone in vivo. Spannhake EW.
Exp Lung Res 1996 Mar–Apr;22(2):163–78

Feedback-inhibition of glucagon-stimulated glycogenolysis in hepatocyte/Kupffer cell cocultures by glucagon-elicited prostaglandin production in Kupffer cells. Hespeling U, et al. **Hepatology** 1995 Nov;22(5):1577–83

IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2. Murakami M, et al. **J Immunol** 1995 Nov 1;155(9):4445–53

Biosynthesis of prostaglandin D2 by motoneurons and dorsal horn microneurons: a biochemical and high resolution immunocytochemical study in chick spinal cord. Vesin MF, et al. **Neuroscience** 1995 Dec;69(3):967–75

CEREBROSPINAL FLUID

Concentration of prostaglandin D2 in cerebrospinal fluid exhibits a circadian alteration in conscious rats. Pandey HP, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):431–7

METABOLISM

Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. O'Sullivan S, et al.
J Allergy Clin Immunol 1996 Aug;98(2):421–32

Profile of prostaglandin levels in the rat hippocampus in pilocarpine model of epilepsy. Naffah-Mazzacoratti MG, et al. **Neurochem Int** 1995 Dec;27(6):461–6

Brain PGD2 and PGE2 changes during posthaemorrhagic hypovolemia in rats. Cernak I, et al. **Vojnosanit Pregl** 1994 Sep–Oct;51(5):363–75 **(Eng, Scr)**

[Production and metabolism of prostaglandin D2 by cultured chick retinal pigment epithelial cells] Shiroma T, et al.
Nippon Ganka Gakkai Zasshi 1996 Jul;100(7):501–6 (Eng. Abstr.) **(Jpn)**

[Content of prostaglandins E2 and F1alpha in small intestine epithelium in cattle as a function of age and pathology in non-infectious diarrhea] Usatiuk PV, et al.
Ukr Biokhim Zh 1995 Mar–Apr;67(2):106–8 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Induction of protein disulfide isomerase mRNA by delta 12-prostaglandin J2. Odani N, et al.
Biochem Biophys Res Commun 1996 Mar 18;220(2):264–8

delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation. McClay EF, et al. **Cancer Res** 1996 Sep 1;56(17):3866–9

Roles of prostaglandins D2 and E2 in interleukin-1-induced activation of norepinephrine turnover in the brain and peripheral organs of rats. Terao A, et al. **J Neurochem** 1995 Dec;65(6):2742–7

Prostaglandin D2 modulates sleep-related and noradrenaline-induced activity of preoptic and basal forebrain neurons in the rat. Osaka T, et al.
Neurosci Res 1995 Oct;23(3):257–68

Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Hardy E, et al.
Thromb Haemost 1995 Oct;74(4):1132–7

[The effect of the mast-cell mediators histamine and prostaglandins on the afferent nerve fibers of the small intestine in the cat] Akoev GN, et al.
Fiziol Zh Im I M Sechenova 1996 Feb;82(2):79–84 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor? Rangachari PK, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):611–7

Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. Satoh S, et al.
Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5980–4

SECRETION

IgE-anti-IgE-induced prostaglandin D2 release from cultured human mast cells. Obata T, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1015-20

Effect of CC chemokines on mediator release from human skin mast cells and basophils. Hartmann K, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):224-30

Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. Patella V, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):23-9

PROSTAGLANDIN E ANALOGS see PROSTAGLANDINS E, SYNTHETIC

PROSTAGLANDIN E RECEPTORS see RECEPTORS, PROSTAGLANDIN E

PROSTAGLANDIN E1 see ALPROSTADIL

PROSTAGLANDIN E2 see DINOPROSTONE

PROSTAGLANDIN E2ALPHA see DINOPROSTONE

PROSTAGLANDIN ENDOPEROXIDE ANALOGS see PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC

PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE

ANALYSIS

Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane. Ren Y, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):205-14

Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gustafson-Svärd C, et al. **Gut** 1996 Jan;38(1):79-84

ANTAGONISTS & INHIBITORS see CYCLOOXYGENASE INHIBITORS

BIOSYNTHESIS

Interleukin-1 beta induces cyclooxygenase-2 in cultured human decidual cells. Kennard EA, et al. **Am J Reprod Immunol** 1995 Aug;34(2):65-71

Activity of nimesulide on constitutive and inducible cyclooxygenases. Tavares IA, et al. **Arzneimittelforschung** 1995 Oct;45(10):1093-5

The induction of cyclo-oxygenase-2 in human pulmonary epithelial cell culture (A549) activated by IL-1beta is inhibited by tyrosine kinase inhibitors. Akarasereenont P, et al. **Biochem Biophys Res Commun** 1996 Mar 7; 220(1):181-5

The concerted regulation of cPLA2, COX2, and lipocortin 1 expression by IL-1beta in A549 cells. Croxtal JD, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):491-5

Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2. Hayakawa M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):681-6

Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Blanco A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):419-23

Hyperosmolarity stimulates prostaglandin synthesis and cyclooxygenase-2 expression in activated rat liver macrophages. Zhang F, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):135-43

Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production. Glaser KB, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):913-22

Prostaglandin synthase 2. Herschman HR. **Biochim Biophys Acta** 1996 Jan 5;1299(1):125-40 (136 ref.)

Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Matijevic-Aleksic N, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):167-75

Possible involvement of prostaglandin H synthase-1 induction in the differentiation of U-937 cells. Bartolini G, et al. **Biofactors** 1995 May;5(1):11-8

Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Cao C, et al. **Brain Res** 1995 Oct 30;697(1-2):187-96

Induction of PGH synthase and c-fos mRNA during early reperfusion of ischemic rat brain. Holtz ML, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):339-43

G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, et al. **Cancer Res** 1996 Feb 15; 56(4):733-7

Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Katiyar SK, et al. **Cancer Res** 1996 Mar 1;56(5):1023-30

Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin in mucosal cells from human fallopian tubes. Han SW, et al. **Endocrinology** 1996 Jul; 137(7):2929-37

Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. Peri KG, et al. **J Biol Chem** 1995 Oct 13;270(41):24615-20

Interleukin-1beta activates protein kinase C zeta in renal mesangial cells. Potential role in prostaglandin E2 up-regulation. Rzymkiewicz DM, et al. **J Biol Chem** 1996 Jul 19;271(29):17241-6

v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. Xie W, et al. **J Biol Chem** 1995 Nov 17;270(46):27622-8

Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. Yamamoto K, et al. **J Biol Chem** 1995 Dec 29;270(52):31315-20

Interleukin-4 inhibits lipopolysaccharide-induced expression of prostaglandin H synthase-2 in human alveolar macrophages. Yano T, et al. **J Cell Physiol** 1995 Oct; 165(1):77-82

Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. Anderson GD, et al. **J Clin Invest** 1996 Jun 1;97(11):2672-9

Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. Tetsuka T, et al. **J Clin Invest** 1996 May 1;97(9):2051-6

LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-gamma. Endo T, et al. **J Immunol** 1996 Mar 15; 156(6):2240-6

IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2. Murakami M, et al. **J Immunol** 1995 Nov 1;155(9):4445-53

Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. Adams J, et al. **J Neurochem** 1996 Jan;66(1):6-13

Mediation of inflammation by encephalitogenic cells: interferon gamma induction of nitric oxide synthase and cyclooxygenase 2. Misko TP, et al. **J Neuroimmunol** 1995 Sep;61(2):195-204

Human immunodeficiency virus type 1 envelope protein does not stimulate either prostaglandin formation or the expression of prostaglandin H synthase in THP-1 human monocytes/macrophages. Hui R, et al. **J Virol** 1995 Dec; 69(12):8020-6

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Griswold DE, et al. **Med Res Rev** 1996 Mar;16(2):181-206 (143 ref.)

Acidic fibroblast factor induction of cyclooxygenase II in rabbit cardiac muscle microvessel endothelial cells: mediation by protein kinase C. Moatter T, et al. **Microcirculation** 1994 Apr;1(1):79-88

Discordance between macrophage arachidonate metabolic phenotype and the expression of cytosolic phospholipase A2 and cyclooxygenase. Dolecki GJ, et al. **Prostaglandins** 1995 Jun;49(6):397-414

Regulation of two isozymes of prostaglandin endoperoxide synthase and thromboxane synthase in human monoblastoid cell line U937. Nanayama T, et al. **Prostaglandins** 1995 Jun; 49(6):371-82

The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4. Spaziani EP, et al. **Prostaglandins** 1996 Mar;51(3):215-23

Induction of both cytosolic phospholipase A2 and prostaglandin H synthase-2 by interleukin-1 beta in WISH cells in inhibited by dexamethasone. Xue S, et al. **Prostaglandins** 1996 Feb;51(2):107-24

EGF and TPA stimulate de novo synthesis of PGHS-1 and PGHS-2 through different signal transduction pathways. Hamasaki Y, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):225-9

Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Habib A, et al. **Thromb Haemost** 1995 Aug;74(2):770-7

Targeted in vivo gene transfection modulated hyperacute rejection of pig lungs perfused with human blood. Pierson RN 3rd, et al. **Transplant Proc** 1996 Apr;28(2):763

BLOOD

Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Panara MR, et al. **Br J Pharmacol** 1995 Nov;116(5):2429-34

CHEMISTRY

Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. Houtzager V, et al. **Biochemistry** 1996 Aug 20;35(33):10974-84

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Loll PJ, et al. **Biochemistry** 1996 Jun 11;35(23):7330-40

Study of the coordination chemistry of prostaglandin G/H synthase by resonance Raman spectroscopy. Gaspard S, et al. **Eur J Biochem** 1996 Jun 1;238(2):529-37

Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. Bhattacharyya DK, et al. **J Biol Chem** 1996 Jan 26;271(4):2179-84

A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. Gierse JK, et al. **J Biol Chem** 1996 Jun 28;271(26):15810-4

Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. Mancini JA, et al. **J Biol Chem** 1995 Dec 8;270(49):29372-7

Photolabeling of prostaglandin endoperoxide H synthase-1 with 3-trifluoro-3-(m-[125I]iodophenyl)diazirine as a probe of membrane association and the cyclooxygenase active site. Otto JC, et al. **J Biol Chem** 1996 Apr 26; 271(17):9906-10

Prostaglandin endoperoxide synthases-1 and -2. Otto JC, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):139-56 (85 ref.)

Aspirin and inflammation [editorial; comment] **Nat Struct Biol** 1995 Aug;2(8):605-6. Comment on: Nat Struct Biol 1995 Aug;2(8):637-47.

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. **Nat Struct Biol** 1995 Aug; 2(8):637-43. Comment in: Nat Struct Biol 1995 Aug;2(8):605-6.

Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Ballif BA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5544-9

DEFICIENCY

Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency. Matijevic-Aleksic N, et al. **Br J Haematol** 1996 Jan;92(1):212-7

Vascular thromboxane formation in hemostasis mechanism: correlation between bleeding time and vascular TXB2 in a patient with congenital platelet cyclo-oxygenase deficiency. Fuse I, et al. **Int J Hematol** 1996 Jun; 63(4):317-24

DRUG EFFECTS

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Glaser K, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):107-11

Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. Guo Q, et al. **J Biol Chem** 1996 Aug 9;271(32):19134-9

Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. Li JJ, et al. **J Med Chem** 1996 Apr 26;39(9):1846-56

Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. Thompson HJ, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1259-60

Aspirin--now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882-3 (13 ref.)

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Dinchuk JE, et al. **Nature** 1995 Nov 23;378(6555):406-9

GENETICS

In vivo and in vitro osmotic regulation of HSP-70 and prostaglandin synthase gene expression in kidney cells. Cowley BD Jr, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F854-62

Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid. Chulada PC, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):301-13

Regulation of prostaglandin endoperoxide H synthase-2 expression by 2,3,7,8,-tetrachlorodibenzo-p-dioxin. Kraemer SA, et al. **Arch Biochem Biophys** 1996 Jun 15; 330(2):319-28

Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Barrios-Rodiles M, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):896-900

Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Ristimäki A, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):325-31

The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. Yoshimi N, et al. **Cancer Lett** 1995 Oct 20;97(1):75-82

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Langenbach R, et al. **Cell** 1995 Nov 3;83(3):483-92

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Morham SG, et al. **Cell** 1995 Nov 3;83(3):473-82

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Tsujii M, et al. **Cell** 1995 Nov 3;83(3):493-501

Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Zoldhelyi P, et al. **Circulation** 1996 Jan 1;93(1):10-7

Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Liu SF, et al. **Clin Sci (Colch)** 1996 Apr;90(4):301-6

Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Han SW, et al. **Endocrinology** 1996 May;137(5):1791-7

Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells. Vadas P, et al. **Eur J Biochem** 1996 Feb 1; 235(3):557-63

Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. Beiche F, et al. **FEBS Lett** 1996 Jul 22;390(2):165-9

Interleukin-1 beta induces expression of cyclooxygenase-2 mRNA in human gingival fibroblasts. Yucel-Lindberg T, et al. **Inflammation** 1995 Oct;19(5):549-60

Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. Inoue H, et al. **J Biol Chem** 1995 Oct 20;270(42):24965-71

An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. Morris JK, et al. **J Biol Chem** 1996 Jul 12;271(28):16633-43

Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation. Tetsuka T, et al. **J Biol Chem** 1996 May 17;271(20):11689-93

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Kutchera W, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4816-20

Effects of protein kinase C activation on prostaglandin production and cyclooxygenase mRNA levels in ovine astroglia. Nam MJ, et al. **Prostaglasndins** 1996 Mar; 51(3):203-13

Prostaglandin H synthase-2 expression increases in human gestational tissues with spontaneous labour onset. Hirst JJ, et al. **Reprod Fertil Dev** 1995;7(3):633-7

Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517-20 (12 ref.)

ISOLATION & PURIFICATION

Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Johnson JL, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):26-34

Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Leong J, et al. **Exp Cell Res** 1996 Apr 10;224(1):79-87

METABOLISM

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301-6 (66 ref.)

Inducible cyclooxygenase and nitric oxide synthase. Wu KK. **Adv Pharmacol** 1995;33:179-207 (148 ref.)

Ozone exposure of human tracheal epithelial cells inactivates cyclooxygenase and increases 15-HETE production. Alpert SE, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L734-43

Prostaglandin endoperoxide synthase: why two isoforms? Williams CS, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G393-400 (75 ref.)

Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition. Frölich JC. **Ann Rheum Dis** 1995 Dec;54(12):942-3

Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid. Chulada PC, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):301-13

Prostaglandin synthase 2 expression in epidermal growth factor-dependent proliferation of mouse keratinocytes. Loftin CD, et al. **Arch Biochem Biophys** 1996 Jun 15; 330(2):419-29

Expression of prostaglandin H synthase-2 in endotoxic shock induced in rats. Takahashi S, et al. **Arch Int Pharmacodyn Ther** 1995 Jul-Aug;330(1):102-15

Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Vago T, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1096-8

Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Barrios-Rodiles M, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):896-900

Activation of 2-aminofluorene by prostaglandin endoperoxide H synthase-2. Liu Y, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):346-54

Cyclooxygenase-2: regulation and relevance in inflammation. Mitchell JA, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1535-42 (92 ref.)

Oxidized low-density lipoprotein stimulates protein kinase C (PKC) and induces expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 macrophage-like cells. Claus R, et al. **Biochemistry** 1996 Apr 16; 35(15):4911-22

Kinetics of the interaction of nonsteroidal antiinflammatory drugs with prostaglandin endoperoxide synthase-1 studied by limited proteolysis. Kalgutkar AS, et al. **Biochemistry** 1996 Jul 16;35(28):9076-82

Mechanism of hydroperoxide reduction by mangano-prostaglandin endoperoxide synthase. Landino LM, et al. **Biochemistry** 1996 Feb 27;35(8):2637-43

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Loll PJ, et al. **Biochemistry** 1996 Jun 11;35(23):7330-40

Peroxidative oxidation of leuco-dichlorofluorescein by prostaglandin H synthase in prostaglandin biosynthesis from polyunsaturated fatty acids. Larsen LN, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):47-53

Regulation of prostaglandin synthesis in Madin Darby canine kidney cells: role of prostaglandin G/H synthase and secreted phospholipase A2. Schaefers HJ, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):197-202

Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Akarasereenont P, et al. **Br J Pharmacol** 1995 Jun;115(3):401-8

Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Kang RY, et al. **Br J Rheumatol** 1996 Aug;35(8):711-8

Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Boolbol SK, et al. **Cancer Res** 1996 Jun 1;56(11):2556-60

Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Rao CV, et al. **Cancer Res** 1996 Feb 1;56(3):532-7

Prostaglandin H synthase-catalyzed ring oxygenation of 2-naphthylamine: evidence for two distinct oxidation pathways. Curtis JF, et al. **Chem Res Toxicol** 1995 Sep; 8(6):875-83

Free radical oxidation of (E)-retinoic acid by prostaglandin H synthase. Samokyszyn VM, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):807-15

Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Smith CJ, et al. **Circ Res** 1996 Jan;78(1):58-64

Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Hurst JS, et al. **Curr Eye Res** 1995 Sep;14(9):769-75

Regulation of hen granulosa cell prostaglandin production by transforming growth factors during follicular development: involvement of cyclooxygenase II. Li J, et al. **Endocrinology** 1996 Jun;137(6):2522-9

Modulation of prostaglandin G/H synthase expression in mesangial cells transfected by pp60c-src proto-oncogene. Reiser CO, et al. **Exp Cell Res** 1996 Feb 1;222(2):304-11

Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. Wennogle LP, et al. **FEBS Lett** 1995 Sep 11;371(3):315-20

Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. DuBois RN, et al. **Gastroenterology** 1996 Apr;110(4):1259-62

Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Fernández M, et al. **Gastroenterology** 1996 May;110(5):1529-35

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Kargman S, et al. **Gastroenterology** 1996 Aug;111(2):445-54

Evidence for cyclooxygenase activation by nitric oxide in astrocytes. Molina-Holgado F, et al. **Glia** 1995 Oct; 15(2):167-72

A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2). Huff R, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S145-6

Prostaglandin biosynthesis and subcellular localization of prostaglandin H synthase activity in the lone star tick, Amblyomma americanum. Pedibhotla VK, et al. **Insect Biochem Mol Biol** 1995 Oct;25(9):1027-39

The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. Callan OH, et al. **J Biol Chem** 1996 Feb 16;271(7):3548-54

Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. Kulmacz RJ, et al. **J Biol Chem** 1995 Oct 13; 270(41):24019-23

Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. Praticó D, et al. **J Biol Chem** 1996 Apr 12;271(15):8919-24

Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. Reddy ST, et al. **J Biol Chem** 1996 Jan 5;271(1):186-91

Phospholipase D-derived products in the regulation of 12-O-tetradecanoylphorbol-13-acetate-stimulated prostaglandin synthesis in madin-darby canine kidney cells. Sciorra VA, et al. **J Biol Chem** 1996 Jun 14; 271(24):14226-32

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. Takahashi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):219-22

Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. Kähler CM, et al. **J Cell Physiol** 1996 Mar;166(3):601-8

Role of cyclo-oxygenase pathways in the stimulatory influence of immune challenge on the transcription of a specific CRF receptor subtype in the rat brain. Lacroix S, et al. **J Chem Neuroanat** 1996 Feb;10(1):53-71

Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. Kahn RM, et al. **J Clin Invest** 1996 Jul 15;98(2):299-307

Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. Salvemini D, et al. **J Clin Invest** 1996 Jun 1;97(11):2562-8

Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites. Petitclerc E, et al. **J Immunol** 1996 May 1;156(9):3426-34

Prostaglandin endoperoxide synthases-1 and -2. Otto JC, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):139-56 (85 ref.)

Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. O'Banion MK, et al. **J Neurochem** 1996 Jun;66(6):2532-40

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329-37 (39 ref.)

Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. Appleton I, et al. **J Pathol** 1995 Aug;176(4):413-20

U46619 (a thromboxane A2 mimetic) induces airflow obstruction and airway plasma extravasation in the guinea pig: the role of histamine, cyclooxygenase metabolites, leukotrienes and PAF. Kawikova I, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):268-76

Induction of cyclooxygenase type-2 (COX-2) in rat endometrium at the peak of serum estradiol during the estrus cycle. Shoda T, et al. **Jpn J Pharmacol** 1995 Nov; 69(3):289-91

Aspirin and inflammation [editorial; comment] **Nat Struct Biol** 1995 Aug;2(8):605-6. Comment on: Nat Struct Biol 1995 Aug;2(8):637-47.

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. **Nat Struct Biol** 1995 Aug; 2(8):637-43. Comment in: Nat Struct Biol 1995 Aug;2(8):605-6.

Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Ballif BA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5544-9

Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Hinson RM, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4885-90

COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Kaufmann WE, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2317-21

Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407). Gustafson-Svärd C, et al. **Scand J Gastroenterol** 1995 Oct;30(10):1000-7

Closing in on a stomach-sparing aspirin substitute [news] Service RF. **Science** 1996 Sep 20;273(5282):1660

[Regulation of cyclooxygenase activity in airway epithelium by endogenous nitric oxide] Takemura H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):632-8 (Eng. Abstr.) **(Jpn)**

[The role of arachidonic acid cycle enzymes in platelet activation by low density lipoproteins] Vlasova II, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):376-9 **(Rus)**

PHARMACOLOGY

Possible contribution of platelet cyclooxygenase to the renal vascular action of 5,6-epoxyeicosatrienoic acid. Fulton D, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1195-9

PHYSIOLOGY

Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Herschman HR, et al. **Bioessays** 1995 Dec;17(12):1031-7 (65 ref.)

Effects of the cyclooxygenase inhibitor ibuprofen on retinal and choroidal blood flow during hyperoxia in newborn piglets. Stiris TA, et al. **Biol Neonate** 1996;69(2):101-8

Nitric oxide synthase-cyclo-oxygenase pathways in organum vasculosum laminae terminalis: possible role in pyrogenic fever in rabbits. Lin JH, et al. **Br J Pharmacol** 1996 May; 118(1):179-85

Introduction: mechanism of action of NSAIDs. Vane JR. **Br J Rheumatol** 1996 Apr;35 Suppl 1:1-3

Cyclo-oxygenase mediation of endotoxin-induced fever, anterior and posterior pituitary hormone release, and

hypothalamic c-Fos expression in the prepubertal pig. Parrott RF, et al. **Exp Physiol** 1995 Jul;80(4):663-74

Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. Karim S, et al. **J Biol Chem** 1996 May 17;271(20):12042-8

IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. Onoe Y, et al. **J Immunol** 1996 Jan 15; 156(2):758-64

Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites. Petitclerc E, et al. **J Immunol** 1996 May 1;156(9):3426-34

Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. Wu KK. **J Lab Clin Med** 1996 Sep; 128(3):242-5 (28 ref.)

Clinical implications of selective cyclooxygenase-2 inhibition. Emery P. **Scand J Rheumatol Suppl** 1996; 102:23-8

[Role of cyclooxygenase metabolites in the increase in pulmonary vascular permeability caused by mechanically activated white blood cells] Tatsuo T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1093-8 (Eng. Abstr.) **(Jpn)**

PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN ENDOPEROXIDE SYNTHETASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN ENDOPEROXIDES

ANALOGS & DERIVATIVES see **PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC**

BIOSYNTHESIS

Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. Praticó D, et al. **J Biol Chem** 1996 Apr 12;271(15):8919-24

PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC

PHARMACOLOGY

Prostacyclin aerosol and inhaled nitric oxide fail to reverse pulmonary vasoconstriction induced by thromboxane analogue in dogs. Welte M, et al. **Acta Physiol Scand** 1995 Jul;154(3):395-405

Meconium inhibits the contraction of umbilical vessels induced by the thromboxane A2 analog U46619. Montgomery LD, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1075-8

Pregnancy enhances the pressor response to thromboxane analogues in rabbits. Losonczy G, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R720-5

The thromboxane mimetic, U-46619, induces the aggregation of fish thrombocytes. Hill DJ, et al. **Br J Haematol** 1996 Jan;92(1):200-11

Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro. Kemp BK, et al. **Br J Pharmacol** 1995 Oct; 116(4):2183-90

Characterization of the thromboxane (TP-) receptor subtype involved in proliferation in cultured vascular smooth muscle cells of rat. Ko FN, et al. **Br J Pharmacol** 1995 Sep;116(2):1801-8

Thromboxane/prostaglandin endoperoxide-induced hypertrophy of rat vascular smooth muscle cells is signaled by protein kinase C-dependent increases in transforming growth factor-beta. Craven PA, et al. **Hypertension** 1996 Aug;28(2):169-76

Thromboxane A2 and vascular smooth muscle cell proliferation. Sachinidis A, et al. **Hypertension** 1995 Nov; 26(5):771-80

Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. Saklatvala J, et al. **J Biol Chem** 1996 Mar 22;271(12):6586-9

U46619 (a thromboxane A2 mimetic) induces airflow obstruction and airway plasma extravasation in the guinea pig: the role of histamine, cyclooxygenase metabolites, leukotrienes and PAF. Kawikova I, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):268-76

Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1497-505

The effect of C5a and U46619 on the isolated, perfused human placental lobule: development of a method for the online estimation of tissue fluid accumulation. Finch AM, et al. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):133-41

Thromboxane A2 mimetic (U-46619) induces hyperresponsiveness of smooth muscle in the canine bronchiole, but not in the trachea. Takata S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):129-34

PROSTAGLANDIN F ANALOGS see **PROSTAGLANDINS F, SYNTHETIC**

PROSTAGLANDIN F2 see **DINOPROST**

PROSTAGLANDIN F2ALPHA see **DINOPROST**

PROSTAGLANDIN H SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN I2 see **EPOPROSTENOL**

PROSTAGLANDIN INHIBITORS see **PROSTAGLANDIN ANTAGONISTS**

PROSTAGLANDIN RECEPTORS see **RECEPTORS, PROSTAGLANDIN**

PROSTAGLANDIN SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN SYNTHESIS ANTAGONISTS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN X see **EPOPROSTENOL**

PROSTAGLANDINS

see related
PROSTAGLANDIN ANTAGONISTS
RECEPTORS, PROSTAGLANDIN

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115-9 (42 ref.)

Monthly prostaglandin bibliography prepared by the University of Sheffield Biomedical Information Service. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):B11-7

Monthly prostaglandin bibliography prepared by the University of Sheffield Biomedical Information Service. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):B18-29

Monthly prostaglandin bibliography prepared by the University of Sheffield Biomedical Information Service. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):B30-8

Monthly prostaglandin bibliography prepared by the University of Sheffield Biomedical Information Service. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):B39-46

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13-27 (42 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Prostaglandin injection therapy for men with a reasonable level of sexual activity. Heeg MM. **N J Med** 1995 Dec; 92(12):785-8

ADVERSE EFFECTS

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592-8 (43 ref.) (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES see **PROSTAGLANDINS, SYNTHETIC**

ANALYSIS

Laser high performance liquid chromatography determination of prostaglandins in pleural effusions. Ikuta N, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):521-7

Polyunsaturated fatty acid composition of the salmon (Salmo salar L.) pineal organ: modification by diet and effect on prostaglandin production. Henderson RJ, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):289-98

ANTAGONISTS & INHIBITORS see **PROSTAGLANDIN ANTAGONISTS**

BIOSYNTHESIS

Inducible cyclooxygenase and nitric oxide synthase. Wu KK. **Adv Pharmacol** 1995;33:179-207 (148 ref.)

Intrauterine infection and the effects of inflammatory mediators on prostaglandin production by myometrial cells from pregnant women. Pollard JK, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):682-6

Pulsating fluid flow increases prostaglandin production by cultured chicken osteocytes--a cytoskeleton-dependent process. Ajubi NE, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):62-8

Effect of cyclic AMP and prostaglandin E2 on the induction of nitric oxide- and prostanoid-forming pathways in cultured rat mesangial cells. Nüsing RM, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):617-23

Hyperosmolarity stimulates prostaglandin synthesis and cyclooxygenase-2 expression in activated rat liver macrophages. Zhang F, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):135-43

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Hanif R, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):237-45

Prostaglandin synthase 2. Herschman HR. **Biochim Biophys Acta** 1996 Jan 5;1299(1):125-40 (136 ref.)

Peroxidative oxidation of leuco-dichlorofluorescein by prostaglandin H synthase in prostaglandin biosynthesis from polyunsaturated fatty acids. Larsen LN, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):47-53

Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts. Sundqvist G, et al. **Cytokine** 1996 Feb;8(2):168-77

Regulation of hen granulosa cell prostaglandin production by transforming growth factors during follicular development: involvement of cyclooxygenase II. Li J, et al. **Endocrinology** 1996 Jun;137(6):2522-9

Changes in prostaglandin synthesis and metabolism associated with labour, and the influence of dexamethasone, RU 486 and progesterone. Brennand JE, et al. **Eur J Endocrinol** 1995 Nov;133(5):527-33

Oesophagostomum dentatum: population dynamics and synthesis of prostanoids by histotropic stages cultured in vitro. Daugschies A. **Exp Parasitol** 1995 Dec;81(4):574-83

Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Zanagnolo V, et al. **Fertil Steril** 1996 May;65(5):1036-43

Prostaglandin biosynthesis and subcellular localization of prostaglandin H synthase activity in the lone star tick, Amblyomma americanum. Pedibhotla VK, et al. **Insect Biochem Mol Biol** 1995 Oct;25(9):1027-39

Phospholipase D-derived products in the regulation of 12-O-tetradecanoylphorbol-13-acetate-stimulated prostaglandin synthesis in madin-darby canine kidney cells. Sciorra VA, et al. **J Biol Chem** 1996 Jun 14; 271(24):14226-32

Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa. Fukuda T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S5-7

Screening of Zulu medicinal plants for prostaglandin-synthesis inhibitors. Jäger AK, et al. **J Ethnopharmacol** 1996 Jun;52(2):95-100

Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. Tunón H, et al. **J Ethnopharmacol** 1995 Oct;48(2):61-76

Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. Minghetti L, et al. **J Neurochem** 1995 Dec; 65(6):2690-8

Inhibition of prostaglandin synthesis in newborn pigs increases cerebral microvessel prostaglandin F2 alpha and prostaglandin E2 receptors, their second messengers and vasoconstrictor response to adult levels. Li DY, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):370-7

Prostanoid production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. Daley JT, et al. **J Urol** 1996 Sep;156(3):1169-73

Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. Daley JT, et al. **J Urol** 1996 Apr;155(4):1482-7

The relationship between plasma insulin level, prostaglandin production by adipose tissue, and blood pressure in normal rats and rats with diabetes mellitus and diabetic ketoacidosis. Chatzipanteli K, et al. **Metabolism** 1996 Jun; 45(6):691-8

Effect of diltiazem and methyldopa on gestation-related renal complications in rats with adriamycin nephrosis. Relationship to glomerular prostanoid synthesis. Podjarny E, et al. **Nephrol Dial Transplant** 1995;10(9):1598-602

Beta-endorphin inhibits prostaglandin synthesis in rat ovaries and blocks induced ovulation. Faletti A, et al. **Prostaglandins** 1995 Feb;49(2):93-103

Lateral hypothalamic lesion induces sympathetic stimulation and hyperthermia by activating synthesis of cerebral prostaglandins. Monda M, et al. **Prostaglandins** 1996 Mar; 51(3):169-78

Effects of protein kinase C activation on prostaglandin production and cyclooxygenase mRNA levels in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1996 Mar; 51(3):203-13

Protein kinases and prostaglandin production in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1995 Jul; 50(1):33-45

A nitric oxide synthesis inhibitor decreased prostaglandin production in rat mesenteric vasculature. Soma M, et al. **Prostaglandins** 1996 Mar;51(3):225-32

Prostaglandin synthesis in human cancer cells: influence of fatty acids and butyrate. Awad AB, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):87-93

Requirement for prostaglandin synthesis in secretion of atrial natriuretic factor from isolated rat heart. Melo LG, et al. **Regul Pept** 1995 Dec 7;60(1):79-87

[The effect of Shakuyaku-kanzo-to on prostaglandin production in human uterine myometrium] Shibata T, et

al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May; 48(5):321–7 (Eng. Abstr.) **(Jpn)**

[Effects of age and length of service on the state of the renin–angiotensin–aldosterone system and prostaglandin synthesis in coal miners] Plotkin VIa, et al. **Med Tr Prom Ekol** 1995;(6):15–7 (Eng. Abstr.) **(Rus)**

BLOOD

Effects of continuous infusion fentanyl citrate on cerebrovascular and systemic prostanoids in postsurgical newborn piglets. Modanlou HD, et al. **J Investig Med** 1996 Aug;44(6):362–9

Ingestion of n–3 polyunsaturated fatty acids and ovulation in rats. Trujillo EP, et al. **J Reprod Fertil** 1995 Nov; 105(2):197–203

Acute burn down regulates rabbit splanchnic and renal prostanoid release. Myers SI, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):219–24

Analysis of prostanoid release from the liver graft following transplantation in pigs. Kim YI, et al. **Transplant Proc** 1996 Jun;28(3):1773–4

[Dynamics of prostaglandin contents and several indicators of lipid metabolism in man exposed to prolonged hypokinesis] Naĭdina VP, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):33–6 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Clavulones and related tert–hydroxycyclopentenone fatty acids: occurrence, physiological activity and problem of biogenetic origin. Grechkin AN. **J Lipid Mediat Cell Signal** 1995 May;11(3):205–18 (68 ref.)

METABOLISM

Effects of indomethacin on brain blood flow, cerebral metabolism, and sagittal sinus prostanoids after hypoxia. Coyle MG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1450–9

Involvement of (n–6) essential fatty acids and prostaglandins in liver lipid accumulation in Japanese quail. Murai A, et al. **Am J Vet Res** 1996 Mar;57(3):342–5

Effects of furosemide, captopril and indometacin on the renin–angiotensin system and the renal prostaglandins in anesthetized neonatal piglets. Joppich R, et al. **Arzneimittelforschung** 1995 Jul;45(7):822–5

Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts—correlation with prostaglandin upregulation. Klein–Nulend J, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):640–8

Secretion of prostaglandins elicited by lipopolysaccharide and ethanol in cultured rat Kupffer cells. Victorov AV, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):691–7

Effects of dietary fiber on prostanoid concentrations in cecal mucosa of rats. Goto H, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):437–43

Mucosa–dependent muscarinic liberation of prostaglandins from rat isolated trachea. Brunn G, et al. **Br J Pharmacol** 1995 Oct;116(3):1991–8

Effects of dietary fibre on dimethylhydrazine–induced changes in prostanoid concentrations in rat colonic mucosa. Kanamori S, et al. **Clin Exp Pharmacol Physiol** 1995 Oct; 22(10):739–42

Prostaglandin–metabolizing enzymes during pregnancy: characterization of NAD(+)–dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450–dependent prostaglandin omega–hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)

Changes in prostaglandin synthesis and metabolism associated with labour, and the influence of dexamethasone, RU 486 and progesterone. Brennand JE, et al. **Eur J Endocrinol** 1995 Nov;133(5):527–33

Stimulation of glycogen phosphorylase in rat hepatocytes via prostanoid release from Kupffer cells by recombinant rat anaphylatoxin C5a but not by native human C5a in hepatocyte/Kupffer cell co–cultures. Hespeling U, et al. **FEBS Lett** 1995 Sep 18;372(1):108–12

The controversial role of cAMP on amnionic prostaglandin release: effect of adenylate cyclase inhibition. Vesce F, et al. **Gynecol Obstet Invest** 1995;40(2):73–9

Importance of nitric oxide and prostaglandins in the control of rat renal papillary blood flow. Ortiz MC, et al. **Hypertension** 1996 Mar;27(3 Pt 1):377–81

Prostaglandins mediate the stimulatory effects of endothelin–1 on cyclic adenosine monophosphate accumulation in ciliary smooth muscle isolated from bovine, cat, and other mammalian species. Abdel–Latif AA, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):328–38

Effect of pregnancy–specific protein B on luteal cell progesterone, prostaglandin, and oxytocin production during two stages of the bovine estrous cycle. Del Vecchio RP, et al. **J Anim Sci** 1995 Sep;73(9):2662–8

Prostaglandin G/H synthase–2 is a major contributor of brain prostaglandins in the newborn. Peri KG, et al. **J Biol Chem** 1995 Oct 13;270(41):24615–20

Tissue concentrations and correlations of prostaglandins in healthy and inflamed human esophageal and jejunal mucosa. Tihanyi K, et al. **J Gastroenterol** 1996 Apr; 31(2):149–52

Effects of gestational age on prostaglandin production and its regulation in human myometrial cells. Pollard JK, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):93–8

Possible evidence that the herbal medicine shakuyaku–kanzo–to decreases prostaglandin levels through suppressing arachidonate turnover in endometrium. Imai A, et al. **J Med** 1995;26(3–4):163–74

Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase–catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. Arlen RR, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1649–58

Modulation of renal medullary ionic hypertonicity by prostaglandins: data from tissue admittance studies in the rat. Dobrowolski L, et al. **J Physiol (Lond)** 1995 Jun 15; 485 (Pt 3):827–34

Simultaneous manipulation of the nitric oxide and prostanoid pathways reduces myocardial reperfusion injury. Wanna FS, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1054–62

Human immunodeficiency virus type 1 envelope protein does not stimulate either prostaglandin formation or the expression of prostaglandin H synthase in THP–1 human monocytes/macrophages. Hui R, et al. **J Virol** 1995 Dec; 69(12):8020–6

Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP–1904. Yoshida T, et al. **Lupus** 1996 Apr;5(2):129–38

Changes in the hypothalamic interaction between norepinephrine and prostaglandin E2 during sexual maturation in female rats. Franchi A, et al. **Neuroendocrinology** 1995 Sep;62(3):226–30

Calcium channel blockers in experimental acute pancreatitis: effect on tissue prostanoids and oxygen free radicals. Closa D, et al. **Pancreas** 1996 Mar;12(2):178–82

Placental prostanoid release in severe intrauterine growth retardation. Sorem KA, et al. **Placenta** 1995 Sep; 16(6):503–15

Relationship between prostaglandin in peritoneal fluid and pelvic venous congestion after sterilization. Ruifang W, et al. **Prostaglandins** 1996 Feb;51(2):161–7

Effect of high potassium diets on the vascular and renal prostaglandin system in stroke–prone spontaneously hypertensive rats. Ishimitsu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):255–60

Effect of in vitro incorporation of prostanoid precursors, superoxide radical and hydrogen peroxide on platelet function. Akinshola BE, et al. **Thromb Res** 1995 Aug 15; 79(4):343–51

[Effects of medical vagotomy and sympathectomy on gastric mucosal prostaglandins in water immersion restrain rats] Tanaka M. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug; 92(8):1133–42 (Eng. Abstr.) **(Jpn)**

[Antithrombotic effect of piavit—a substance from the medicinal leech (Hirudo medicinalis), containing prostanoid and destabilase fractions] Baskova IP, et al. **Biokhimiia** 1995 Nov;60(11):1775–83 (Eng. Abstr.) **(Rus)**

[Change in prostaglandin levels and ATPase activity of cardiac membrane fractions during the formation of cerebral hematomas in animals with a hereditary predisposition to stroke] Vasil'eva EM, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):16–9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

cGMP and cAMP in prostaglandin–induced pial artery dilation and increased CSF opioid concentration. Armstead WM. **Am J Physiol** 1996 Jul;271(1 Pt 2):H166–72

Prostaglandins increase HDL binding to human cells in culture. Middleton A, et al. **Biochem Soc Trans** 1995 Aug; 23(3):448S

A comparison of the effects of exogenous and endogenous prostaglandins on fast and slow contractions of field–stimulated guinea–pig vas deferens. McKay AM, et al. **Br J Pharmacol** 1995 Nov;116(6):2679–84

Role of nitric oxide and prostaglandins in the regulation of blood pressure in conscious rats. Inglés AC, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):693–8

Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Lowe GN, et al. **Endocrinology** 1996 Jun;137(6):2208–16

Prostanoid–induced contractions are blocked by sulfonylureas. Delaey C, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):179–84

Nitric oxide and prostaglandin systems inhibition on the isolated perfused human placenta from normal and preeclamptic pregnancies. González C, et al. **Gynecol Obstet Invest** 1995;40(4):244–8

Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. Radziszewski W, et al. **Int J Cardiol** 1995 Oct;51(3):211–20

Differential activation of peroxisome proliferator–activated receptors by eicosanoids. Yu K, et al. **J Biol Chem** 1995 Oct 13;270(41):23975–83

The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. Woodward DF, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):339–47

Response of human gingival fibroblasts to prostaglandins. Arai H, et al. **J Periodontal Res** 1995 Sep;30(5):303–11

Effects of prostaglandins and oestradiol–17 beta on oxytocin binding in cultured bovine luteal cells. Okuda K, et al. **Reprod Fertil Dev** 1995;7(5):1045–51

[Further evidence of the role of prostaglandin on the effects of hormones on blood circulation in bones] Kapitola J, et al. **Sb Lek** 1996;97(1):151–9 (Eng. Abstr.) **(Cze)**

[The therapeutic contribution of prostaglandins in obstetrics] Lambotte R. **Rev Med Liege** 1996 Jan;51(1):139–41 **(Fre)**

PHYSIOLOGY

Prostaglandins and sleep. Hayaishi O, et al. **Adv Neuroimmunol** 1995;5(2):211–6 (9 ref.)

Prostaglandins, NSAIDS, and GI mucosal integrity: can we identify patients at risk of NSAID–induced gastric injury? [editorial; comment] Dajani EZ. **Am J Gastroenterol** 1996 May;91(5):835–6. Comment on: Am J Gastroenterol 1996 May;91(5):873–8.

Nitric oxide and prostaglandins are involved in the macula densa control of the renin system. Schricker K, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F825–30

Role of prostaglandins and enteric nerves in Escherichia coli heat–stable enterotoxin (STa)–induced intestinal secretion in pigs. Hayden UL, et al. **Am J Vet Res** 1996 Feb; 57(2):211–5

Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor? Miura T, et al. **Basic Res Cardiol** 1995 May–Jun;90(3):240–6

Prostaglandins inhibit pancreatic beta–cell replication and long–term insulin secretion by pertussis toxin–insensitive mechanisms but do not mediate the actions of interleukin–1 beta. Sjöholm A. **Biochim Biophys Acta** 1996 Aug 28; 1313(2):106–10

Mediation by prostaglandins of the nitric oxide–induced neurogenic vasodilatation in rat skin. Holzer P, et al. **Br J Pharmacol** 1995 Nov;116(5):2365–70

A comparison of the effects of exogenous and endogenous prostaglandins on fast and slow contractions of field–stimulated guinea–pig vas deferens. McKay AM, et al. **Br J Pharmacol** 1995 Nov;116(6):2679–84

Insulin and prostaglandins as signals between tumor and the host immune system. Curi R, et al. **Braz J Med Biol Res** 1995 Jul;28(7):773–9 (46 ref.)

Angiotensin II–induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Sigusch HH, et al. **Cardiovasc Res** 1996 Apr;31(4):546–54

Yes, but do they still get headaches? DeWitt D, et al. **Cell** 1995 Nov 3;83(3):345–8 (16 ref.)

Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Bhagat K, et al. **Circulation** 1995 Oct 15;92(8):2113–8

Prostaglandins and sodium handling in Lyon hypertensive rats. Sassard J, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S423–5 (18 ref.)

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173–85 (169 ref.)

Isoproterenol–induced gastric mucosal protection from bile acid. Role of endogenous prostaglandins. Mercer DW, et al. **Dig Dis Sci** 1995 Oct;40(10):2227–35

Healing of chronic gastric ulcerations by L–arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Brzozowski T, et al. **Digestion** 1995;56(6):463–71

Intravenous interleukin–1–beta–induced inhibition of gastric emptying: involvement of central corticotrophin–releasing factor and prostaglandin pathways in rats. Sütö G, et al. **Digestion** 1996;57(2):135–40

Mucosal ulceration in isolated amphibian stomachs in vitro. Roles of nutrient HC03– and endogenous prostaglandins. Takeuchi K, et al. **Digestion** 1995;56(5):357–63

Corticotropin–releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic–pituitary–adrenal response to acute local inflammation in the rat. Turnbull AV, et al. **Endocrinology** 1996 Feb;137(2):455–63

Mycoplasma fermentans–derived lipid inhibits class II major histocompatibility complex expression without mediation by interleukin–6, interleukin–10, tumor necrosis factor, transforming growth factor–beta, type I interferon, prostaglandins or nitric oxide. Frisch M, et al. **Eur J Immunol** 1996 May;26(5):1050–7

Role of nitric oxide and prostaglandins in lipopolysaccharide–induced increase in vascular permeability in mouse skin. Fujii E, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):257–63

Nicotine effects on prostaglandin–dependent gastric slow wave rhythmicity and antral motility in nonsmokers and smokers. Kohagen KR, et al. **Gastroenterology** 1996 Jan; 110(1):3–11

Prostaglandins modulate the responsiveness of the gastric microcirculation of sodium nitroprusside in cirrhotic rats. Geraldo J, et al. **Hepatology** 1996 Jan;23(1):123–9

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)

Role of prostaglandins in acetylcholine–induced contraction of aorta from spontaneously hypertensive and Wistar–Kyoto rats. Rapoport RM, et al. **Hypertension** 1996 Jul;28(1):64–75

Involvement of central histaminergic mechanisms and

prostaglandins in carbachol-induced corticosterone secretion. Borycz J, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S60-1

Effect of prostaglandins and nitric oxide on basal blood flow and acetylcholine-induced vasodilation in rat diaphragmatic microcirculation. Chang HY, et al. **J Formos Med Assoc** 1995 Jun;94(6):332-40

Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium. Kinoshita M, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):494-501

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205-13 (106 ref.)

Prostaglandin-dependent c-Fos expression in the median preoptic nucleus of pigs subjected to restraint: correlation with hyperthermia. Vellucci SV, et al. **Neurosci Lett** 1995 Sep 22;198(1):49-51

Hematoma-induced enhanced cerebral vasoconstrictions to leukotriene C4 and endothelin-1 in piglets: role of prostanoids. Yakubu MA, et al. **Pediatr Res** 1995 Jul; 38(1):119-23

Behaviorally conditioned anorexia: role of gastric emptying and prostaglandins. Exton MS, et al. **Physiol Behav** 1995 Sep;58(3):471-6

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367-80 (80 ref.)

Obituary for Professor Priscilla Piper. Costello J. **Prostaglandins** 1995 Jun;49(6):319-22

Prostaglandins, their inhibitors and cancer. Lupulescu A. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):83-94 (109 ref.)

Prostaglandins and parturition. Mitchell MD, et al. **Reprod Fertil Dev** 1995;7(3):623-32 (79 ref.)

The role of prostaglandins in gastric mucosal protection. Wilson DE. **Trans Am Clin Climatol Assoc** 1995;107:99-113; discussion 113-4 (78 ref.)

[Lipid mediators and liver injury] Liu Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):363-6 (10 ref.) **(Chi)**

[Secretion of inflammatory cytokines and prostaglandins by fetal trophoblast cells induces uterine contraction and labor onset] Steinbron A, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:83-7 (Eng. Abstr.) **(Ger)**

[The prostanoid system in patients with disordered heart rhythm] Bobrov VA, et al. **Ter Arkh** 1995;67(8):68-71 (69 ref.) **(Rus)**

[Prostaglandins in chronic liver diseases] Loginov AS, et al. **Vestn Ross Akad Med Nauk** 1995;(12):32-8 (83 ref.) (Eng. Abstr.) **(Rus)**

[The prostaglandin system in the kidney] Stošić Z. **Med Pregl** 1996;49(1-2):32-6 (38 ref.) (Eng. Abstr.) **(Scr)**

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317-27 (47 ref.) (Eng. Abstr.) **(Spa)**

[The interrelationships of the hypothalamo-neurohypophyseal, renin-angiotensin-aldosterone and prostanoid systems i regulating central hemodynamics in the acute period of traumatic disease] Barinov EF, et al. **Fiziol Zh** 1995 Jan-Apr;41(1-2):86-91 (Eng. Abstr.) **(Ukr)**

SECRETION

Taenia multiceps (Cestoda): Ia antigen expression and prostaglandin secretion by parasite-modified, murine peritoneal macrophages. Rakha NK, et al. **Parasite** 1996 Jun;3(2):135-41

Prostaglandin release from human cervical tissue in the first trimester of pregnancy after preoperative dilatation with hygroscopic tents. Bokström H, et al. **Prostaglandins** 1995 Oct;50(4):179-88

DNA synthesis and prostaglandin secretion by bovine endometrial cells as regulated by interleukin-1. Davidson JA, et al. **Reprod Fertil Dev** 1995;7(5):1037-43

THERAPEUTIC USE

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973-84 (40 ref.)

Protecting against stomatitis [news] **Oncology (Huntingt)** 1995 Oct;9(10):932

[Current views on the use of vasodilators in pulmonary hypertension] Ceriana P, et al. **Minerva Cardioangiol** 1995 Jun;43(6):273-9 (Eng. Abstr.) **(Ita)**

[The modification of a radiation lesion with 9a-homo-13-thiaprostanoids] Kuz'mitskiĭ BB, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):344-8 (Eng. Abstr.) **(Rus)**

URINE

Prostaglandins and diabetic nephropathy. Umeda F, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):334-6

PROSTAGLANDINS A

ANALOGS & DERIVATIVES see PROSTAGLANDINS A, SYNTHETIC

CHEMISTRY

Clavulones and related tert-hydroxycyclopentenone fatty acids: occurrence, physiological activity and problem of biogenetic origin. Grechkin AN. **J Lipid Mediat Cell Signal** 1995 May;11(3):205-18 (68 ref.)

PHARMACOLOGY

Prostaglandin A1 inhibits replication of Mayaro virus in Aedes albopictus cells. Barbosa JA, et al. **Braz J Med Biol Res** 1995 Jan;28(1):27-30

Modulation of prostaglandin A1-induced thermotolerance by quercetin in human leukemic cells: role of heat shock protein 70. Elia G, et al. **Cancer Res** 1996 Jan 1;56(1):210-7

Role of p21 in prostaglandin A2-mediated cellular arrest and death. Gorospe M, et al. **Cancer Res** 1996 Feb 1;56(3):475-9

Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Toris CB, et al. **Exp Eye Res** 1995 Dec;61(6):649-57

Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation. Hitomi M, et al. **J Biol Chem** 1996 Apr 19;271(16):9376-83

Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. Rozera C, et al. **J Clin Invest** 1996 Apr 15;97(8):1795-803

Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Gorospe M, et al. **Mol Cell Biol** 1996 Mar;16(3):762-70

THERAPEUTIC USE

TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats. Ohta T, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):450-5

PROSTAGLANDINS D

PHARMACOLOGY

Novel prostanoid thromboxane A2 agonists. Joachim KD, et al. **Prostaglandins** 1995 Aug;50(2):57-63

PROSTAGLANDINS E

ANALOGS & DERIVATIVES see PROSTAGLANDINS E, SYNTHETIC

ANALYSIS

[Prostaglandins of series E in morphologic variants of osteogenic sarcoma and evaluation of the degree of therapeutic pathomorphism of the tumor] Kushlinskiĭ NE, et al. **Arkh Patol** 1995 Sep-Oct;57(5):25-30 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Effects of eicosapentaenoic and docosahexaenoic acid on cell growth and prostaglandin E and leukotriene B production by a human breast cancer cell line (MDA-MB-231). Noguchi M, et al. **Oncology** 1995 Nov-Dec;52(6):458-64

Diets rich in eicosapentaenoic acid and gamma-linolenic acid affect phospholipid fatty acid composition and production of prostaglandins E1, E2 and E3 in turbot (Scophthalmus maximus), a species deficient in delta 5 fatty acid desaturase. Bell JG, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct;53(4):279-86

BLOOD

Effect of ethanol on prostacyclin, thromboxane, and prostaglandin E production in human umbilical veins. Randall CL, et al. **Alcohol Clin Exp Res** 1995 Jun; 19(3):741-6

Pre-pubertal growth in the hyperprostaglandin E syndrome. Seidel C, et al. **Pediatr Nephrol** 1995 Dec;9(6):723-8

CHEMISTRY

FTIR spectral study of intramolecular hydrogen bonding in E-type of 15-keto-prostaglandins in dilute CCl4 solution: structure-activity relationships. Takasuka M, et al. **Bioorg Med Chem** 1995 Apr;3(4):459-69

METABOLISM

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Hancock WW, et al. **Am J Pathol** 1995 Nov;147(5):1193-9

Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Calcutt NA, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):189-97

Interleukin-1-mediated stimulation of prostaglandin E production is without effect on plasminogen activator activity in human granulosa lutein cell cultures. Hurwitz A, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3018-24

Influence of progesterone levels on prostaglandin concentrations in isolated uterine tissue and incubation medium from pseudopregnant rats. Motta A, et al. **Prostaglandins** 1995 Oct;50(4):213-23

[Lipid peroxidation, production of PGE2 and cellular mortality induced by UV in cultured human skin fibroblasts] Filipe PM, et al. **C R Seances Soc Biol Fil** 1995; 189(3):443-51 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. Ben-Av P, et al. **FEBS Lett** 1995 Sep 18;372(1):83-7

[Simultaneous study of duodenal and biliopancreatic bicarbonates in rats] Lesur G, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):613-8 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179-83 (35 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen:antibody ratio. Berger S, et al. **Eur J Immunol** 1996 Jun;26(6):1297-301

Opposite effects of interleukin-13 and interleukin-12 on the release of inflammatory cytokines, cytokine inhibitors and prostaglandin E from synovial fibroblasts and blood mononuclear cells. Seitz M, et al. **Eur J Immunol** 1996 Sep;26(9):2198-2202

THERAPEUTIC USE

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Szczeklik A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):567-71

PROSTAGLANDINS E, SYNTHETIC

ADVERSE EFFECTS

[Misoprostol: prevention of ulcers caused by NSAID] Matzen P, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4782-5 **(Dan)**

PROSTAGLANDINS F

ANALOGS & DERIVATIVES see PROSTAGLANDINS F, SYNTHETIC

BLOOD

Prostaglandin F1a and prostaglandin E2 plasma levels after transvaginal cervical cerclage. Vitoratos N, et al. **Clin Exp Obstet Gynecol** 1996;23(1):21-5

Influence of different flow modi during extracorporeal circulation on endothelial-derived vasoactive substances. Knothe CH, et al. **Perfusion** 1995 Jul;10(4):229-36

METABOLISM

[Content of prostaglandins E2 and F1alpha in small intestine epithelium in cattle as a function of age and pathology in non-infectious diarrhea] Usatiuk PV, et al. **Ukr Biokhim Zh** 1995 Mar-Apr;67(2):106-8 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179-83 (35 ref.) (Eng. Abstr.) **(Pol)**

PROSTAGLANDINS F, SYNTHETIC

ADMINISTRATION & DOSAGE

Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Mishima HK, et al. **Am J Ophthalmol** 1996 Mar;121(3):319-21

PHARMACOLOGY

The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Kjellgren D, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):233-6

Calving rates in a tropical beef herd after treatment with a synthetic progestagen, norgestomet, or a prostaglandin analogue, cloprostenol. Frisch JE, et al. **Aust Vet J** 1996 Mar;73(3):98-102

Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Chen J, et al. **Br J Pharmacol** 1995 Dec;116(7):3035-41

Effects of fenprostalene and estradiol-17 beta benzoate on parturition and retained placenta in dairy cows and heifers. Rasmussen FE, et al. **J Dairy Sci** 1996 Feb;79(2):227-34

THERAPEUTIC USE

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle

glaucoma or ocular hypertension. Fristrom B.
Acta Ophthalmol Scand 1996 Apr;74(2):140–4
Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? [editorial; comment] Higginbotham EJ. **Arch Ophthalmol** 1996 Aug;114(8):998–9 (16 ref.). Comment on: Arch Ophthalmol 1996 Aug;114(8):929–32.
A comparison of latanoprost and timolol in primary open–angle glaucoma and ocular hypertension. A 12–week study [see comments] Mishima HK, et al.
Arch Ophthalmol 1996 Aug;114(8):929–32. Comment in: Arch Ophthalmol 1996 Aug;114(8):998–9.
Around–the–clock intraocular pressure reduction with once–daily application of latanoprost by itself or in combination with timolol. Rácz P, et al.
Arch Ophthalmol 1996 Mar;114(3):268–73
Evaluation of the use of intrauterine infusions of oxytetracycline, subcutaneous injections of fenprostalene, or a combination of both, for the treatment of retained fetal membranes in dairy cows. Stevens RD, et al.
J Am Vet Med Assoc 1995 Dec 15;207(12):1612–5
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six–month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Camras CB. **Ophthalmology** 1996 Jan;103(1):138–47
Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal–pressure glaucoma. Rulo AH, et al. **Ophthalmology** 1996 Aug; 103(8):1276–82
A six–month, randomized, double–masked study comparing latanoprost with timolol in open–angle glaucoma and ocular hypertension. The Latanoprost Study Group. Watson P, et al. **Ophthalmology** 1996 Jan;103(1):126–37

URINE

Evidence of free radical–mediated injury (isoprostane overproduction) in scleroderma. Stein CM, et al.
Arthritis Rheum 1996 Jul;39(7):1146–50

PROSTAGLANDINS H

METABOLISM

Lipopolysaccharide induces time–dependent increases in prostaglandin H synthase–2 and cytosolic phospholipase A2 mRNA in cultured human microvessel–derived endothelial cells. Flynn JT, et al. **Shock** 1995 Dec; 4(6):433–40

PROSTAGLANDINS, SYNTHETIC

The role of synthetic prostaglandines in the induction of therapeutical miscarriage. Rolfini G, et al.
Clin Exp Obstet Gynecol 1995;22(4):345–9
Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

CHEMISTRY

Formation of F2–isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol. Salami M, et al. **Pharmacol Res** 1995 May;31(5):275–9

PHARMACOLOGY

Prostacyclin analogues [letter; comment] Izzat MB, et al.
Eur J Vasc Endovasc Surg 1996 Feb;11(2):248–9. Comment on: Eur J Vasc Surg 1993 Nov;7(6):621–7. Comment on: Eur J Vasc Surg 1994 May;8(3):335–41.
The effect of misoprostol on indomethacin–induced renal dysfunction in well–compensated cirrhosis. Wong F, et al.
J Hepatol 1995 Jul;23(1):1–7
Protective effect of a prostaglandin I2 analogue on grafted livers subjected to in situ warm ischemia in porcine orthotopic liver transplantation: immunohistochemical analysis of thrombomodulin. Ejiri S, et al.
Transplant Proc 1996 Apr;28(2):1086–8
[The effect of new synthetic prostanoids on the aggregation activity of human thrombocytes] Petrukhina GN, et al.
Eksp Klin Farmakol 1995 Nov–Dec;58(6):45–8 (Eng. Abstr.) **(Rus)**
[The effect of new synthetic prostanoids on the indices of the blood coagulation system] Petrukhina GN, et al.
Eksp Klin Farmakol 1995 Sep–Oct;58(5):37–40 (Eng. Abstr.) **(Rus)**

PROSTANOIC ACIDS

PHARMACOLOGY

Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor. Woodward DF, et al.
J Ocul Pharmacol Ther 1995 Fall;11(3):447–54

PROSTATE

see related
PROSTATECTOMY
Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy. Anscher MS. **Am J Clin Oncol** 1995 Dec; 18(6):481–3
Prostatic tissue in benign cystic ovarian teratomas. Vadmal M, et al. **Hum Pathol** 1996 Apr;27(4):428–9
Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localized prostate cancer. Rudat V, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1027–34
Benign ectopic prostatic tissue involving the seminal vesicle in a patient with prostate cancer: recognition and implications for staging. Salem CE, et al. **Urology** 1996 Sep;48(3):490–3
Ectopic prostatic tissue in the spleen. Vogel U, et al.
Virchows Arch 1996 Feb;427(5):543–5

ANATOMY & HISTOLOGY

Effect of castration on metalloprotease activities in the lateral, dorsal, and anterior lobes of the rat prostate. Wilson MJ, et al. **Arch Androl** 1995 Sep–Oct;35(2):119–25
The ratio of free to total prostate–specific antigen in serum is correlated to the prostate volume [letter] Stephan C, et al. **Int J Cancer** 1996 Jul 29;67(3):461–2
Variation in prostate position relative to adjacent bony anatomy. Althof VG, et al.
Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):709–15
Prostate gland: structure, functions and regulation. Kumar VL, et al. **Int Urol Nephrol** 1995;27(3):231–43 (104 ref.)
Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. Masumori N, et al. **J Urol** 1996 Apr;155(4):1324–7
Effect of chlormadinone acetate–pellet implantation on the volume of prostate, peripheral blood levels of sex hormones and semen quality in the dog. Shimizu M, et al.
J Vet Med Sci 1995 Jun;57(3):395–9
Prostate specific antigen in a community–based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Bosch JL, et al. **Prostate** 1995 Nov;27(5):241–9
Prostatic ductal system in rats: regional variation in stromal organization. Nemeth JA, et al. **Prostate** 1996 Feb; 28(2):124–8
Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone–releasing hormone analog), Finasteride (a 5 alpha–reductase inhibitor), and castration on the lobar subdivisions of the rat prostate. Yamashita A, et al.
Prostate 1996 Jul;29(1):1–14
Prostate zones in three–dimensional transrectal ultrasound. Strasser H, et al. **Urology** 1996 Apr;47(4):485–90
[Morphometry of the prostate in Black Africans. Apropos of 300 cases] N'Dri K, et al. **J Urol (Paris)** 1995;101(2):93–5 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Microvascular invasion in prostate cancer correlates with pathologic stage. Salomao DR, et al.
Arch Pathol Lab Med 1995 Nov;119(11):1050–4
Transient arteriovenous fistulae after transrectal prostate biopsy: diagnosis with color Doppler ultrasonography. Wachsberg RH, et al. **J Ultrasound Med** 1996 Jan; 15(1):57–61
Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation [see comments] Smith RC, et al. **J Urol** 1996 Aug;156(2 Pt 1):454–7; discussion 457–8. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.
Increased prostatic blood flow in response to microwave thermal treatment: preliminary findings in two patients with benign prostatic hyperplasia. Larson TR, et al. **Urology** 1995 Oct;46(4):584–90

CHEMISTRY

Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies. Castellucci E, et al.
Ann N Y Acad Sci 1996 Apr 30;784:496–508
A new selenoprotein found in the glandular epithelial cells of the rat prostate. Kalcklösch M, et al.
Biochem Biophys Res Commun 1995 Dec 5;217(1):162–70
The alpha 1C–adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Tseng–Crank J, et al. **Br J Pharmacol** 1995 Aug; 115(8):1475–85
Evaluation of mucinous metaplasia of the prostate gland by mucin histochemistry. Gal R, et al. **Br J Urol** 1996 Jan; 77(1):113–7
Tissue fibronectin levels of human prostatic cancer, as a tumor marker. Sönmez H, et al.
Cancer Biochem Biophys 1995 Nov;15(2):107–10
Tissue sialic acid and fibronectin levels in human prostatic cancer. Süer S, et al. **Cancer Lett** 1996 Feb 6;99(2):135–7
Functional melatonin receptors in human prostate epithelial cells. Gilad E, et al. **Endocrinology** 1996 Apr;137(4):1412–7
The TRH–like peptides in rabbit testis are different from the TRH–like peptide in the prostate. Linden H, et al.
FEBS Lett 1996 Jan 22;379(1):11–4
Forensic application of organ–specific antigens. Takahama K. **Forensic Sci Int** 1996 Jun 28;80(1–2):63–9
D–aspartate in the male and female reproductive system of Octopus vulgaris lam. D'Aniello A, et al.
Gen Comp Endocrinol 1995 Oct;100(1):69–72
Production of monoclonal antibody against the C1 component of rat estramustine–binding protein: immunohistochemical study of rat prostate. Tamura Y, et al. **Histochem Cell Biol** 1995 Dec;104(6):429–33
Norepinephrine contents of human prostatic hyperplasia: differences between pathological subtypes. Ishigooka M, et al. **Int Urol Nephrol** 1996;28(1):61–6
Cloning and partial sequence of the rabbit androgen receptor: expression in fetal urogenital tissues. Krongrad A, et al. **J Androl** 1995 May–Jun;16(3):209–12
Localization of androgen receptor and cell–specific cytokeratins in basal cells of rat ventral prostate. Soeffing WJ, et al. **J Androl** 1995 May–Jun;16(3):197–208
Insulin–like growth factor–binding protein–2 and –3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. Tennant MK, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):411–20
Inhibin–related proteins in rat prostate. Risbridger GP, et al. **J Endocrinol** 1996 Apr;149(1):93–9
Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. Kim ED, et al. **J Urol** 1995 Nov;154(5):1802–5
Localization of the alpha 1A–adrenoceptor in the human prostate. Lepor H, et al. **J Urol** 1995 Dec;154(6):2096–9
Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. Persson BE, et al. **J Urol** 1996 Mar; 155(3):958–60
High levels of soluble p55–TNF receptors in seminal and prostatic fluids of normal and infertile men. Tur–Kaspa I, et al. **J Urol** 1996 Apr;155(4):1436–8
Expression of estrogen receptor in diseased human prostate assessed by non–radioactive in situ hybridization and immunohistochemistry. Ehara H, et al. **Prostate** 1995 Dec; 27(6):304–13
Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. Ghatak S, et al. **Prostate** 1996 Aug; 29(2):91–100
Demonstration of fibroblast growth factor receptor–I in human prostate by polymerase chain reaction and immunohistochemistry. Hamaguchi A, et al. **Prostate** 1995 Sep;27(3):141–7
Concentration of the endogenous antiandrogen epitestosterone and androgenic C19–steroids in hyperplastic prostatic tissue. Hill M, et al. **Prostate** 1996 Jun;28(6):347–51
Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Ishigooka M, et al. **Prostate** 1996 Jun;28(6):385–91
Identification of endothelin receptors in normal and hyperplasic human prostate tissues. Le Brun G, et al.
Prostate 1996 Jun;28(6):379–84
Expression and processing of peptidylglycine alpha–amidating monooxygenase messenger RNA in rat prostate. Samos LF, et al. **Prostate** 1996 Aug;29(2):101–6
Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Wilson MJ, et al. **Prostate** 1996 Apr;28(4):239–50
Prostate cancer: metabolic response to cryosurgery as detected with 3D H–1 MR spectroscopic imaging. Kurhanewicz J, et al. **Radiology** 1996 Aug;200(2):489–96
Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue. Sciarra F, et al. **Urol Res** 1995; 23(6):387–90
Effect of irrigating fluids and prostate tissue extracts on isolated cardiomyocytes. Zhang W, et al. **Urology** 1995 Dec;46(6):821–4

CYTOLOGY

Immunohistochemical localization of the epidermal growth factor–receptor in rhesus–monkey prostate. Wakui S, et al.
Anat Histol Embryol 1996 Jun;25(2):109–11
Androgen–regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS–1). Gerdes MJ, et al. **Endocrinology** 1996 Mar;137(3):864–72
Induction of transforming growth factor–beta autocrine activity by all–trans–retinoic acid and 1 alpha,25–dihydroxyvitamin D3 in NRP–152 rat prostatic epithelial cells. Danielpour D. **J Cell Physiol** 1996 Jan; 166(1):231–9
Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. Landry F, et al.
J Urol 1996 Jan;155(1):386–90
Gap–junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mehta PP, et al. **Mol Carcinog** 1996 Jan;15(1):18–32
Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)
Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Kinbara H, et al. **Prostate** 1996 Aug;29(2):107–16
[Effect of bombesin on cultured prostatic cells] Larrán López J, et al. **Actas Urol Esp** 1995 Oct;19(9):733–9 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Chen M, et al. **AJR Am J Roentgenol** 1996 May;166(5):1157–63

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Vaillancourt L, et al. **Am J Surg Pathol** 1996 Jan;20(1):86–93

Alteration of collagen biosynthesis and analysis of type I and type III collagens of prostate in young rats following sex hormone treatments. Suzuki H, et al. **Arch Androl** 1996 May–Jun;36(3):205–16

A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Mathé G, et al. **Biomed Pharmacother** 1995;49(7–8):341–3

Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Marshall I, et al. **Br J Pharmacol** 1995 Jul;115(5):781–6

Antiandrogenic activity and endocrinological profile of a novel antiandrogen, TZP-4238, in the rat. Mieda M, et al. **Endocr J** 1994 Aug;41(4):445–52

Inhibition of 5 alpha-reductase activity impairs the testosterone-dependent restoration of spermiogenesis in adult rats. O'Donnell L, et al. **Endocrinology** 1996 Jul; 137(7):2703–10

Effect of bunazosin, alpha 1-adrenoceptor blocker, on multidirectional contractile response and localization of bunazosin binding sites in human hypertrophied prostate. Moriyama N, et al. **Gen Pharmacol** 1995 Sep;26(5):1033–7

KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. Peehl DM, et al. **Growth Regul** 1996 Mar;6(1):22–31

Effects of melatonin, testosterone and the two hormones administered in parallel on ventral prostate of the rat treated with stilbestrol in the first day of life. Limanowski A, et al. **Histol Histopathol** 1995 Oct;10(4):869–74

Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Chang SC, et al. **Int J Cancer** 1996 Aug 7; 67(4):555–62

Effect of s-triazine compounds on testosterone metabolism in the rat prostate. Kniewald J, et al. **J Appl Toxicol** 1995 May–Jun;15(3):215–8

Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. Hiraoka Y, et al. **J Auton Pharmacol** 1995 Aug; 15(4):271–8

Evidence for atrophy and apoptosis in the prostates of men given finasteride. Rittmaster RS, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):814–9

Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. Montironi R, et al. **J Clin Pathol** 1996 Apr;49(4):324–8

Anti-idiotypic antibody as an oestrogen mimetic in vivo: stimulation of creatine kinase specific activity in rat animal models. Sömjen D, et al. **J Endocrinol** 1996 May; 149(2):305–12

Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. Deplanne V, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):527–34

Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. Palea S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):700–5

Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. Testa R, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1237–46

Phenylacetate is an inhibitor of prostatic growth and development in organ culture. Lipschutz JH, et al. **J Urol** 1996 May;155(5):1762–70

Pharmacological characterization of the isolated canine prostate. Normandin DE, et al. **J Urol** 1996 May; 155(5):1758–61

Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins. Chen C, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):1–13

Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells. Costello LC, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):45–51

Androgen-independent effects of prolactin on the different lobes of the immature rat prostate. Reiter E, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):113–22

Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Laroque PA, et al. **Prostate** 1995 Sep;27(3):121–8

Effect of prostatic growth factor, basic fibroblast growth factor, epidermal growth factor, and steroids on the proliferation of human fetal prostatic fibroblasts. Luo D, et al. **Prostate** 1996 Jun;28(6):352–8

Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328–37

Growth factors as mediators of androgen action during male urogenital development. Cunha GR. **Prostate Suppl** 1996; 6:22–5 (33 ref.)

Role of androgen in prostate growth and regression: stromal–epithelial interaction. Lee C. **Prostate Suppl** 1996; 6:52–6 (26 ref.)

In utero and lactational exposure of the male rat to 2,3,7,8-tetrachlorodibenzo-p-dioxin: impaired prostate growth and development without inhibited androgen production. Roman BL, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):241–50

Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Winter ML, et al. **Toxicol Appl Pharmacol** 1996 Feb; 136(2):211–9

[Azithromycin: tissue pharmacology] Bergogne-Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

[Effect of bombesin on cultured prostatic cells] Larrán López J, et al. **Actas Urol Esp** 1995 Oct;19(9):733–9 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia in the developing human prostate. II. Persistent changes after removal of diethylstilbestrol. Yonemura CY, et al. **Acta Anat (Basel)** 1995;153(1):1–11

Development of peptide-containing nerves in the human fetal prostate gland. Jen PY, et al. **J Anat** 1995 Aug;187 (Pt 1):169–79

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

[Epidermal growth factor (EGF) can induce prostatic buds in the absence of androgens] Saito M, et al. **C R Seances Soc Biol Fil** 1995;189(4):637–41 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Inhibition of steroid 5 alpha-reductase activity by aliphatic fatty acids. Candidates for chemoprevention of prostate cancer. Niederprüm HJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:227–30

Immunohistochemical analysis of steroid 5 alpha-reductase type 1 in human scalp and prostate. Patel S, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:27–39

Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Montironi R, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2057–62

Effect of castration on metalloprotease activities in the lateral, dorsal, and anterior lobes of the rat prostate. Wilson MJ, et al. **Arch Androl** 1995 Sep–Oct;35(2):119–25

Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Dubbink HJ, et al. **Biochem J** 1996 May 1;315 (Pt 3):901–8

Protein kinase C isozymes in prostatic epithelial cells from normal, diabetic and insulin-treated diabetic rats. Garcia-Paramio PL, et al. **Gen Pharmacol** 1995 Dec; 26(8):1673–8

The folding intermediate of reversibly denatured human prostatic acid phosphatase. Kuciel R, et al. **Int J Biol Macromol** 1996 Apr;18(3):167–75

Single-step purification of prostatic acid phosphatase: immunoaffinity chromatography with a monoclonal antibody. Yoshiki T, et al. **Int J Urol** 1995 Sep;2(4):261–6

Prostatic acid phosphatase and prostate specific antigen in liver disease. Kadayifci A, et al. **Int Urol Nephrol** 1996; 28(1):67–71

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Sasagawa I, et al. **Int Urol Nephrol** 1995;27(6):769–74

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. Dubé JY, et al. **J Androl** 1995 Jul–Aug;16(4):304–11

Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. Levine AC, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):384–9

Proteolysis of insulin-like growth factor-binding protein-3 in the male reproductive tract. Plymate SR, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):618–24

Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. Evans BA, et al. **J Endocrinol** 1995 Nov;147(2):295–302

An enzyme linked immunosorbent assay (ELISA) for detection of seminal fluid using a monoclonal antibody to prostatic acid phosphatase. Allen SM. **J Immunoassay** 1995 Aug;16(3):297–308

Apoptosis of epithelial cells in vivo involves tissue transglutaminase upregulation. Cummings M. **J Pathol** 1996 Jul;179(3):288–93

Characterization and solubilization of testosterone 17 beta-hydroxysteroid dehydrogenase in human hyperplastic prostate. Carre JL, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):265–7

Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form. Iehlé C, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):177–82

Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. Iehlé C, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5–6):273–9

Kinetic analysis of rat steroid 5alpha-reductase activity in prostate and epididymis homogenates at neutral pH: evidence for type I activity in epididymis. Span PN, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1–2):95–101

Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues. Li SS. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):441–7

Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. Liu Y, et al. **Metabolism** 1996 Apr;45(4):442–9

Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells. Costello LC, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):45–51

Expression of galactosyltransferase in prostatic tumors. Amselgruber WM, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):638–42

Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. Brawn PN, et al. **Prostate** 1996 May;28(5):295–9

Protein kinase C regulation of the adenylyl cyclase system in rat prostatic epithelium. Carmena MJ, et al. **Prostate** 1995 Oct;27(4):204–11

There are multiple forms of glyceraldehyde-3-phosphate dehydrogenase in prostate cancer cells and normal prostate tissue. Epner DE, et al. **Prostate** 1996 Jun;28(6):372–8

[Various immunohistochemical markers of precancer and variants of prostate cancer] Romanenko AM, et al. **Arkh Patol** 1995 Jul–Aug;57(4):38–41 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Normal development and carcinogenesis of the prostate. A unifying hypothesis. Hayward SW, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:50–62 (41 ref.)

Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)

Expression of the homeotic gene Hox-d13 in the developing and adult mouse prostate. Oefelein M, et al. **J Urol** 1996 Jan;155(1):342–6

Influence of hormone treatment on prostate growth and micturition characteristics of the rat. Constantinou CE. **Prostate** 1996 Jul;29(1):30–5

Regulation of prostatic growth and function by peptide growth factors. Culig Z, et al. **Prostate** 1996 Jun; 28(6):392–405 (142 ref.)

Regulation of prostate growth by fibroblast growth factors. Story MT. **World J Urol** 1995;13(5):297–305 (96 ref.)

IMMUNOLOGY

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Pang S, et al. **Hum Gene Ther** 1995 Nov;6(11):1417–26

Nonprostatic prostate-specific antigen [editorial] Talib VH, et al. **Indian J Pathol Microbiol** 1996 Jan;39(1):1–3

INJURIES

Transperineal photodynamic ablation of the canine prostate. Selman SH, et al. **J Urol** 1996 Jul;156(1):258–60

Healing response of the canine prostate to Nd:YAG laser radiation. Pow-Sang M, et al. **Prostate** 1996 May; 28(5):287–94

Factors affecting size and configuration of electrovaporization lesions in the prostate. Narayan P, et al. **Urology** 1996 May;47(5):679–88

INNERVATION

Immunohistochemical properties and spinal connections of pelvic autonomic neurons that innervate the rat prostate gland. Kepper M, et al. **Cell Tissue Res** 1995 Sep; 281(3):533–42

Development of peptide-containing nerves in the human fetal prostate gland. Jen PY, et al. **J Anat** 1995 Aug;187 (Pt 1):169–79

Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation [see comments] Smith RC, et al. **J Urol** 1996 Aug;156(2 Pt 1):454–7; discussion 457–8. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Neurogenic erectile dysfunction: the course of nicotinamide adenine dinucleotide phosphate diaphorase-positive nerve fibers on the surface of the prostate. Zvara P, et al. **Urology** 1996 Jan;47(1):146–51

METABOLISM

Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats. Ghatak S, et al.

Biochem Biophys Res Commun 1996 May 15;222(2):362–7
Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Canada AT, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):87–90
Expression of I2-imidazoline sites in rat prostate. Effect of castration and aging. Regunathan S, et al.
Biochem Pharmacol 1996 Feb 23;51(4):455–9
Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Deperthes D, et al.
Biochim Biophys Acta 1995 Dec 14;1245(3):311–6
Autologous regulation of androgen receptor messenger ribonucleic acid in the separate lobes of the rat prostate gland. Prins GS, et al. **Biol Reprod** 1995 Sep;53(3):609–19
Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens. Palea S, et al.
Br J Pharmacol 1995 Nov;116(5):2401–6
Two differentially expressed genes in normal human prostate tissue and in carcinoma. Wang FL, et al. **Cancer Res** 1996 Aug 15;56(16):3634–7
Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Webber MM, et al.
Carcinogenesis 1996 Aug;17(8):1641–6
Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Wilson MJ, et al. **Cell Mol Biol Res** 1995;41(6):603–12
Keratin 19 in the adult human prostate: tissue and cell culture studies. Peehl DM, et al. **Cell Tissue Res** 1996 Jul; 285(1):171–6
Regulation of immunoreactive androgen receptor in the adrenal gland of the adult rat. Bentvelsen FM, et al.
Endocrinology 1996 Jul;137(7):2659–63
Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Nevalainen MT, et al.
Endocrinology 1996 Jul;137(7):3078–88
Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Solano RM, et al.
Endocrinology 1996 Jul;137(7):2815–22
Differential subcellular distribution of rat prostatic steroid 5alpha-reductase isozyme activities. Span PN, et al.
Eur J Endocrinol 1996 Mar;134(3):386–92
Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. Michel MC, et al.
J Auton Pharmacol 1996 Feb;16(1):21–8
Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. Danielpour D. **J Cell Physiol** 1996 Jan; 166(1):231–9
Putative melatonin receptors in benign human prostate tissue. Laudon M, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1336–42
Fertilization-promoting peptide: a novel peptide, structurally similar to TRH, with potent physiological activity. Cockle SM. **J Endocrinol** 1995 Jul;146(1):3–8
Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. Bonasera TA, et al.
J Nucl Med 1996 Jun;37(6):1009–15
Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. Schmitt JF, et al.
J Steroid Biochem Mol Biol 1996 Feb;57(3–4):173–8
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. Kramer G, et al. **J Urol** 1995 Nov;154(5):1636–41
Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. Morton RA Jr, et al. **J Urol** 1996 Aug;156(2 Pt 1):512–6
Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Sánchez-Visconti G, et al.
Mech Ageing Dev 1995 Jul 28;82(1):19–29
Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. Liu Y, et al.
Metabolism 1996 Apr;45(4):442–9
Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Tatoud R, et al.
Mol Cell Endocrinol 1995 Sep 22;113(2):195–204
Expression of prostatic secretory protein (PSP)-like protein in porcine corpus luteum: isolation and characterization of a new gene encoding PSP94-like protein. Tanaka T, et al. **Mol Reprod Dev** 1995 Oct;42(2):149–56
Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Smith RC, et al. **Nat Med** 1995 Oct;1(10):1040–5
Localization of beta-2-microglobulin in prostatic corpora amylacea of prostatic hypertrophy patients [letter] Horita S, et al. **Nephron** 1996;72(4):730–1
Alternative splicing of PSP94 (prostatic secretory protein of 94 amino acids) mRNA in prostate tissue. Xuan JW, et al. **Oncogene** 1995 Sep 21;11(6):1041–7
Cloning of a novel receptor expressed in rat prostate and ovary. Kuiper GG, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5925–30
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Yeh S, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5517–21
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? [letter; comment] Jung K, et al. **Prostate** 1996 Jul;29(1):65–6 . Comment on: Prostate 1995 Sep;27(3):166–75. Comment on: Prostate 1996 Oct;27(4):212–9.
Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells. Story MT, et al. **Prostate** 1996 Apr; 28(4):219–26
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH, et al.
Prostate 1996 Apr;28(4):227–31
Binding of 17-alpha-methyltestosterone in vitro to human sex hormone binding globulin and rat ventral prostate androgen receptors. Wiita B, et al. **Ther Drug Monit** 1995 Aug;17(4):377–80
Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Maines MD, et al. **Urology** 1996 May;47(5):727–33
Calcitonin receptor mRNA expression in the human prostate. Wu G, et al. **Urology** 1996 Mar;47(3):376–81

PATHOLOGY

Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia in the developing human prostate. II. Persistent changes after removal of diethylstilbestrol. Yonemura CY, et al. **Acta Anat (Basel)** 1995;153(1):1–11
Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Ljung G, et al. **Acta Oncol** 1995;34(7):945–52
Contribution to the clarification of heterogeneous foci within the prostate. Zát'ura F, et al.
Acta Univ Palacki Olomuc Fac Med 1994;138:65–7
Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Chen M, et al.
AJR Am J Roentgenol 1996 May;166(5):1157–63
Prostatic biopsy after proctocolectomy: a transgluteal, CT-guided approach. Papanicolaou N, et al.
AJR Am J Roentgenol 1996 Jun;166(6):1332–4
Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma [see comments] Gaudin PB, et al.
Am J Clin Pathol 1995 Dec;104(6):620–6. Comment in: Am J Clin Pathol 1995 Dec;104(6):607–10.
Tumor-like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.). Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.
Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Epstein JI, et al. **Am J Surg Pathol** 1996 Jul;20(7):851–7
Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. McNeal JE, et al.
Am J Surg Pathol 1996 Jul;20(7):802–14
A hybrid neural and statistical classifier system for histopathologic grading of prostatic lesions. Stotzka R, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):204–18
Image segmentation of cribriform gland tissue. Thompson D, et al. **Anal Quant Cytol Histol** 1995 Oct;17(5):314–22
Morphological features and kinetics of primary cultures of BPH tissue supported by TV1 medium. De Angeli S, et al. **Anat Anz** 1996 Jan;178(1):41–8
Changes in the prostate after the cryoapplication in dogs. Galanty M, et al. **Arch Vet Pol** 1994;34(1–2):45–54
A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Tamimi Y, et al. **Br J Cancer** 1996 Aug;74(4):573–8
Reproducibility of prostate volume measurements from transrectal ultrasonography by an automated and a manual technique. Aarnink RG, et al. **Br J Urol** 1996 Aug; 78(2):219–23
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Brewster SF, et al. **Br J Urol** 1995 Sep;76(3):351–4
A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Ravery V, et al.
Br J Urol 1996 May;77(5):724–8
Digitally-guided prostatic biopsies—the Sheffield biopsy guide. Woo HH, et al. **Br J Urol** 1996 Jan;77(1):152
Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, et al.
Cancer 1996 Jun 1;77(11):2386–92
Radiation-induced neoplastic transformation of human prostate epithelial cells. Kuettel MR, et al. **Cancer Res** 1996 Jan 1;56(1):5–10
Determinants of complications after multiple transrectal core biopsies of the prostate. Norberg M, et al. **Eur Radiol** 1996; 6(4):457–61
Stromal nodules in benign prostatic hyperplasia. Bierhoff E, et al. **Eur Urol** 1996;29(3):345–54
Benign prostatic hyperplasia in the nonhuman primate Leontopithecus. Ferreira BR, et al.
Folia Primatol (Basel) 1995;65(1):48–53
Hair granuloma of the prostate. Day DS, et al.
Hum Pathol 1996 Feb;27(2):196–7
Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Chang SC, et al. **Int J Cancer** 1996 Aug 7; 67(4):555–62
Localization of the prostatic apex for radiation treatment planning [see comments] Algan O, et al.
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):925–30. Comment in: Int J Radiat Oncol Biol Phys 1996 Apr 1;35(1):197–8.
Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):273–9
Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Roach M 3rd, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1011–8
Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times [editorial; comment] Stamey TA. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):967–8; discussion 972. Comment on: Int J Radiat Oncol Biol Phys 1995 May 15;32(2):287–92.
Phyllodes type of atypical prostatic hyperplasia. Fujita K, et al. **Int J Urol** 1996 Mar;3(2):158–60
Usefulness of digital rectal examination, serum prostate-specific antigen, transrectal ultrasonography and systematic prostate biopsy for the detection of organ-confined prostate cancer. Gohji K, et al.
Int J Urol 1995 May;2(2):116–20
ACP Broadsheet No 146: August 1995. Macroscopic examination of prostatic specimens [see comments] Harnden P, et al. **J Clin Pathol** 1995 Aug;48(8):693–700 (48 ref.). Comment in: J Clin Pathol 1996 Feb;49(2):187–8.
Comparison of transrectal ultrasound prostatic volume estimation with magnetic resonance imaging volume estimation and surgical specimen weight in patients with benign prostatic hyperplasia. Tewari A, et al.
J Clin Ultrasound 1996 May;24(4):169–74
Balloon dilation of the prostate: correlation with magnetic resonance imaging and transrectal ultrasound findings. Renfer L, et al. **J Endourol** 1995 Jun;9(3):283–6
Transient arteriovenous fistulae after transrectal prostate biopsy: diagnosis with color Doppler ultrasonography. Wachsberg RH, et al. **J Ultrasound Med** 1996 Jan; 15(1):57–61
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. Bostwick DG, et al. **J Urol** 1996 Apr;155(4):1361–7
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213–9. Comment in: J Urol 1996 Jan;155(1):226–7.
Clinical and pathological features of hereditary prostate cancer. Keetch DW, et al. **J Urol** 1996 Jun;155(6):1841–3
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. Keetch DW, et al. **J Urol** 1995 Nov;154(5):1795–7
Re: Automated prostate volume determination with ultrasonographic imaging [letter; comment] Kimura A.
J Urol 1996 Mar;155(3):1039–40. Comment on: J Urol 1995 May;153(5):1549–54.
Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [editorial] Klein EA. **J Urol** 1996 Aug;156(2 Pt 1):443–4
Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy [see comments] Langer JE, et al. **J Urol** 1996 Jan; 155(1):228–31. Comment in: J Urol 1996 Jan;155(1):243.
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients [see comments] Noldus J, et al.
J Urol 1996 Jan;155(1):232–7. Comment in: J Urol 1996 Jan;155(1):243.
Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al.
J Urol 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.
Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. Pagano F, et al. **J Urol** 1996 Jan;155(1):244–7
Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence [see comments] Ravery V, et al. **J Urol** 1996 Jun;155(6):1981–2. Comment in: J Urol 1996 Jun;155(6):1987–8.
Diagnosis of prostatic intraepithelial neoplasia in whole mount sections of prostates. Chan LP.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 May; 12(5):290–4
Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Timme TL, et al.
Lab Invest 1996 Apr;74(4):747–60
Haematogenous dissemination of prostate epithelial cells during surgery [letter; comment] Oefelein MG, et al.
Lancet 1996 Feb 3;347(8997):324–5. Comment on: Lancet 1995 Dec 9;346(8989):1528–30.
Creation of a volume lesion in the dog prostate using neodymium:YAG laser coagulation: concepts for clinical

treatment. Perlmutter AP, et al. **Lasers Surg Med** 1995; 17(1):59–63

Contrast–enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

Hazards of transrectal biopsy of prostate [letter] [see comments] Hughes PD, et al. **Med J Aust** 1995 Sep 4; 163(5):276–7. Comment in: Med J Aust 1995 Nov 6;163(9):503–4. Comment in: Med J Aust 1995 Nov 6;163(9):504.

Hazards of transrectal biopsy of prostate [letter; comment] Kaye KW. **Med J Aust** 1995 Nov 6;163(9):504. Comment on: Med J Aust 1995 Sep 4;163(5):276–7.

Hazards of transrectal biopsy of prostate [letter; comment] Korbel EI, et al. **Med J Aust** 1995 Nov 6;163(9):503–4. Comment on: Med J Aust 1995 Sep 4;163(5):276–7.

Histopathologic effects of laser radiation on the human prostate. Cowan DF, et al. **Mod Pathol** 1995 Sep; 8(7):716–21

Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Van de Voorde WM, et al. **Mod Pathol** 1995 Aug;8(6):591–8

Localization of beta–2–microglobulin in prostatic corpora amylacea of prostatic hypertrophy patients [letter] Horita S, et al. **Nephron** 1996;72(4):730–1

Down regulation of Bcl–2 is the first step on Fas–mediated apoptosis of male reproductive tract. Suzuki A, et al. **Oncogene** 1996 Jul 4;13(1):31–7

Transurethral microwave thermotherapy for benign prostatic hyperplasia: relation between clinical response and prostate histology. Arai Y, et al. **Prostate** 1996 Feb;28(2):84–8

Expression of estrogen receptor in diseased human prostate assessed by non–radioactive in situ hybridization and immunohistochemistry. Ehara H, et al. **Prostate** 1995 Dec; 27(6):304–13

Relationship of ultrasonic and histologic findings in benign prostatic hyperplasia. Hasegawa Y, et al. **Prostate** 1996 Feb; 28(2):111–6

Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings. Ishigooka M, et al. **Prostate** 1996 Aug;29(2):77–82

Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Ishigooka M, et al. **Prostate** 1996 Jun;28(6):385–91

Stromal cells of the human prostate: initial isolation and characterization. Kassen A, et al. **Prostate** 1996 Feb; 28(2):89–97

Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. McNeal JE, et al. **Prostate** 1995 Nov;27(5):258–68

Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? Matzkin H, et al. **Prostate** 1996 Jul;29(1):42–5

Effect of aromatase inhibitor, TZA–2209, on the prostate of androstenedione–treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328–37

Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. Harris RD, et al. **Radiographics** 1995 Jul;15(4):813–29; discussion 829–32

Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Lee WR, et al. **Radiology** 1996 Feb;198(2):439–42

Clinical evaluation of prostate biopsy parameters: gland volume and elevated prostate–specific antigen level. Rubens DJ, et al. **Radiology** 1996 Apr;199(1):159–63

Prostate motion during standard radiotherapy as assessed by fiducial markers. Crook JM, et al. **Radiother Oncol** 1995 Oct;37(1):35–42

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta–analysis of randomized clinical trials. Boyle P, et al. **Urology** 1996 Sep; 48(3):398–405

Cryosurgical ablation of the prostate: two–year prostate–specific antigen and biopsy results. Cohen JK, et al. **Urology** 1996 Mar;47(3):395–401

Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Gleason DF. **Urology** 1996 Mar;47(3):289–91 (6 ref.)

Temperature–correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Larson TR, et al. **Urology** 1996 Apr;47(4):463–9

Diagnostic yield of repeated transrectal ultrasound–guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Roehrborn CG, et al. **Urology** 1996 Mar;47(3):347–52

Transperineal prostate needle biopsy guided by transurethral ultrasound in patients without a rectum. Seaman EK, et al. **Urology** 1996 Mar;47(3):353–5

The influence of prostate size on cancer detection. Uzzo RG, et al. **Urology** 1995 Dec;46(6):831–6

Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study. Zlota Ar, et al. **Urology** 1996 Mar;47(3):329–34

[Prostatic biopsy: technic, value and complications] Gasman D, et al. **Ann Urol (Paris)** 1995;29(5):229–301 **(Fre)**

[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases] Chefchaouni MC, et al. **J Urol (Paris)** 1996;102(2):51–5 (18 ref.) (Eng. Abstr.) **(Fre)**

[Pathologic–anatomic examination of prostatovesiculectomy samples in prostate carcinoma] Hailemariam S, et al. **Pathologe** 1996 May;17(3):227–30 (Eng. Abstr.) **(Ger)**

[Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy] Miyamoto S, et al. **Hinyokika Kiyo** 1995 Oct;41(10):767–70 (Eng. Abstr.) **(Jpn)**

[Comparisons of histological grading between biopsy and radical prostatectomy specimens in prostatic adenocarcinoma] Fujinami K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1460–5 (Eng. Abstr.) **(Jpn)**

[Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy] Saikawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1673–80 (Eng. Abstr.) **(Jpn)**

[Clinical significance of PSA–density in differential diagnosis between BPH and early stages prostate cancer] Uno H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1776–83 (Eng. Abstr.) **(Jpn)**

[The relationship between serum PSA value and the weight of the inner gland of the prostate in the cases of benign prostatic hyperplasia] Wu B, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1525–9 (Eng. Abstr.) **(Jpn)**

[Metastases to the temporal bone. A report of two cases] Grijalba Uche M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):441–3 (Eng. Abstr.) **(Spa)**

[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] Sánchez Sánchez E, et al. **Actas Urol Esp** 1995 Mar;19(3):181–6 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Oxytocin and prostatic function. Nicholson HD, et al. **Adv Exp Med Biol** 1995;395:529–38 (42 ref.)

Experimental research on the morphofunctional differentiation of the rat ventral prostate: roles of the gonads at birth. Corbier P, et al. **Arch Physiol Biochem** 1995 Dec;103(6):699–714

Use of a DNA microfluorometric assay to measure proliferative response of mink lung cells to purified TGF beta and to TGF beta activity found in prostate cell conditioned medium. Mitchen J, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):692–7

Effect of tobacco consumption on the function of male accessory sex glands. Pakrashi A, et al. **Int J Androl** 1995 Oct;18(5):232–6

Prostate gland: structure, functions and regulation. Kumar VL, et al. **Int Urol Nephrol** 1995;27(3):231–43 (104 ref.)

Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. Lin AT, et al. **J Urol** 1995 Nov; 154(5):1930–3

RS–17053 (N–[2–(2–cyclopropylmethoxyphenoxy)ethyl]–5–chloro–alpha, alpha–dimethyl–1H–indole–3–ethanamine hydrochloride), a selective alpha 1A–adrenoceptor antagonist, displays low affinity for functional alpha 1–adrenoceptors in human prostate: implications for adrenoceptor classification. Ford AP, et al. **Mol Pharmacol** 1996 Feb;49(2):209–15

Regulation of prostatic growth and function by peptide growth factors. Culig Z, et al. **Prostate** 1996 Jun; 28(6):392–405 (142 ref.)

Roles of estrogen and SHBG in prostate physiology. Farnsworth WE. **Prostate** 1996 Jan;28(1):17–23 (49 ref.)

Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. Ghatak S, et al. **Prostate** 1996 Aug; 29(2):91–100

Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Kinbara H, et al. **Prostate** 1996 Aug;29(2):107–16

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

The insulin–like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

Keratinocyte growth factor: an androgen–regulated mediator of stromal–epithelial interactions in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):312–7 (43 ref.)

Epidermal growth factor–related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)

PHYSIOPATHOLOGY

Analysis of prostate and seminal vesicle motion: implications for treatment planning. Beard CJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):451–8

Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat. Constantinou CE, et al. **Neurourol Urodyn** 1996;15(1):85–101

[Evaluation of reliability of IPSS by 24–hour uroflowmetry] Kimura A, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1728–34 (Eng. Abstr.) **(Jpn)**

[Quantitative analysis of mechanical characteristics of pathologically altered soft biological tissues] Skovorda AR, et al. **Biofizika** 1995 Nov–Dec;40(6):1335–40 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Histopathologic effects of laser radiation on the human prostate. Cowan DF, et al. **Mod Pathol** 1995 Sep; 8(7):716–21

In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Lee LK, et al. **Photochem Photobiol** 1995 Nov;62(5):882–6

Radiation inactivation of human prostate cancer cells: the role of apoptosis. Algan O, et al. **Radiat Res** 1996 Sep; 146(3):267–75

Prostate motion during standard radiotherapy as assessed by fiducial markers. Crook JM, et al. **Radiother Oncol** 1995 Oct;37(1):35–42

RADIOGRAPHY

Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility. Balter JM, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1281–6

The effects of out–of–plane rotations on two dimensional portal image registration in conformal radiotherapy of the prostate. Hanley J, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1331–43

Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Roeske JC, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1321–9

[A comparative assessment between transrectal echography, venous urography, CAT and morphology in patients with prostatic carcinoma] Mladenov D, et al. **Khirurgiia (Sofiia)** 1994;47(5):20–1 (Eng. Abstr.) **(Bul)**

RADIONUCLIDE IMAGING

A putative mechanism for the non–specific uptake of intact radiolabelled monoclonal antibodies in the testes and prostate. Ahlström KE, et al. **Acta Oncol** 1996;35(3):303–7

SECRETION

Electrophoretic modification of sperm plasma membrane by ventral prostate secretion in golden hamsters. Cheng LY, et al. **Arch Androl** 1995 Jul–Aug;35(1):13–20

Physical activity releases prostate–specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Oremek GM, et al. **Clin Chem** 1996 May;42(5):691–5

Secretion of insulin–like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. Boudon C, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):612–7

Success with intravaginal insemination of frozen–thawed dog semen—a retrospective study. Nöthling JO, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):49–55

Parathyroid hormone—related protein (PTHrP) is an epidermal growth factor–regulated secretory product of human prostatic epithelial cells. Cramer SD, et al. **Prostate** 1996 Jul;29(1):20–9

Ductal heterogeneity in rat dorsal–lateral prostate. Kinbara H, et al. **Prostate** 1996 Jan;28(1):58–64

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Cryodestruction technique in the prostatic gland in dogs. Galanty M, et al. **Arch Vet Pol** 1994;34(1–2):37–44

Changes in the prostate after the cryoapplication in dogs. Galanty M, et al. **Arch Vet Pol** 1994;34(1–2):45–54

Organism reaction to cryodestruction of the prostatic gland in dogs. Galanty M. **Arch Vet Pol** 1994;34(1–2):55–62

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):359–66 (59 ref.)

Transurethral balloon laser thermotherapy: effects of a directionally shielded balloon in canine prostates. Suzuki T, et al. **Int J Urol** 1996 Jan;3(1):35–8

Laparoscopic pelvic lymphadenectomy during epidural anesthesia. Kelly D, et al. **J Clin Anesth** 1995 Dec; 7(8):648–51

Laser photocoagulation of prostate: influence of dosimetry. Motamedi M, et al. **Lasers Surg Med** 1995;17(1):49–58

Creation of a volume lesion in the dog prostate using neodymium:YAG laser coagulation: concepts for clinical treatment. Perlmutter AP, et al. **Lasers Surg Med** 1995; 17(1):59–63

Histological and immunohistochemical changes after transurethral balloon laser hyperthermia in the canine prostate. Suzuki T, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):39–48

Cryoablation of the prostate [letter; comment] Badalament RA, et al. **Urology** 1995 Dec;46(6):901–2; discussion 903. Comment on: Urology 1995 Jun;45(6):932–5. Comment on: Urology 1995 Jun;45(6):936–41.

Cryoablation of the prostate [letter; comment] Cohen JK. **Urology** 1995 Dec;46(6):902–3. Comment on: Urology 1995 Jun;45(6):932–5.

Cryosurgical ablation of the prostate: two–year prostate–specific antigen and biopsy results. Cohen JK, et al. **Urology** 1996 Mar;47(3):395–401

Electrosurgical vaporization of the prostate in the canine model. Perlmutter AP, et al. **Urology** 1995 Oct;46(4):518–23

TRANSPLANTATION

Maintenance of human hyperplastic prostate implants at different sites in athymic mice. Soós G, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2007–11

ULTRASONOGRAPHY

Transrectal ultrasonically–guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Ljung G, et al. **Acta Oncol** 1995;34(7):945–52

Contribution to the clarification of heterogeneous foci within the prostate. Zát'ura F, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:65–7

Transrectal ultrasonography of the prostate. el Din KE, et al. **Br J Urol** 1996 Jul;78(1):2–9 (64 ref.)

Comparison of prostatic volume and dimensions by transrectal and transurethral ultrasonography. Nathan MS, et al. **Br J Urol** 1996 Jul;78(1):84–9

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515–23

Determination of prostate gland volume by transrectal ultrasound: correlation with radical prostatectomy specimens. Wolff JM, et al. **Eur Urol** 1995;28(1):10–2

Reliability of volume or age–adjusted prostate specific antigen to improve diagnostic accuracy. Ciatto S, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):226–8

Accuracy of prostatic volume calculation in transrectal ultrasonography. Kimura A, et al. **Int J Urol** 1995 Sep; 2(4):252–6

Transrectal ultrasound of the prostate bed after collagen injection. Salomon CG, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):279–82

Intraluminal ultrasound–guided biopsy of the prostate: case report. Kirby KA, et al. **J Endourol** 1995 Aug;9(4):323–4

Balloon dilation of the prostate: correlation with magnetic resonance imaging and transrectal ultrasound findings. Renfer L, et al. **J Endourol** 1995 Jun;9(3):283–6

Relationship between serum prostate specific antigen concentration and prostate volume. Yu HJ, et al. **J Formos Med Assoc** 1995 Nov;94(11):666–70

Re: Automated prostate volume determination with ultrasonographic imaging [letter; comment] Bangma CH, et al. **J Urol** 1996 Jan;155(1):292–3. Comment on: J Urol 1995 May;153(5):1549–54.

Determination of prostatic volume with transrectal ultrasound: A study of intra–observer and interobserver variation. Bates TS, et al. **J Urol** 1996 Apr;155(4):1299–300

Re: Automated prostate volume determination with ultrasonographic imaging [letter; comment] Kimura A. **J Urol** 1996 Mar;155(3):1039–40. Comment on: J Urol 1995 May;153(5):1549–54.

Construction and application of hierarchical decision tree for classification of ultrasonographic prostate images. Giesen RJ, et al. **Med Biol Eng Comput** 1996 Mar;34(2):105–9

Planimetric volumetry of the prostate: how accurate is it? Aarnink RG, et al. **Physiol Meas** 1995 Aug;16(3):141–50

Transrectal ultrasonic volumetry of the prostate: in vivo comparison of different methods. Bangma CH, et al. **Prostate** 1996 Feb;28(2):107–10

Relationship of ultrasonic and histologic findings in benign prostatic hyperplasia. Hasegawa Y, et al. **Prostate** 1996 Feb; 28(2):111–6

Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population: regarding Bangma et al. UMB 21 (1):11–16; 1995 [letter; comment] Aarnink RG, et al. **Ultrasound Med Biol** 1995;21(8):1083–4. Comment on: Ultrasound Med Biol 1995;21(1):11–6.

Correlation of transrectal ultrasonographic findings of the prostate with the occurrence of detrusor instability in patients with benign prostatic hyperplasia. Tong YC, et al. **Urol Int** 1995;55(3):154–7

Prostate zones in three–dimensional transrectal ultrasound. Strasser H, et al. **Urology** 1996 Apr;47(4):485–90

[The diagnosis, biopsy and treatment follow–up by ultrasound in patients with prostatic carcinoma] Mladenov D, et al. **Khirurgiia (Sofiia)** 1994;47(5):15–7 (Eng. Abstr.) **(Bul)**

[A comparative assessment between transrectal echography, venous urography, CAT and morphology in patients with prostatic carcinoma] Mladenov D, et al. **Khirurgiia (Sofiia)** 1994;47(5):20–1 (Eng. Abstr.) **(Bul)**

[Transrectal prostatic echography in the study of hemospermia. An assessment of an 85–patient case load] Gattoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):424–8 (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

A monoclonal antibody identifies vimentin filaments in Sertoli cells and in a subset of epithelial cells in the rat epididymis, urinary bladder, and prostate. Danahey DG, et al. **J Urol** 1995 Dec;154(6):2190–6

VIROLOGY

Kaposi's sarcoma–associated herpesvirus DNA sequences in prostate tissue and human semen. Monini P, et al. **N Engl J Med** 1996 May 2;334(18):1168–72

PROSTATE–SPECIFIC ANTIGEN

Impact of prostate–specific antigen screening on prostate cancer [letter] Zincke H. **Urology** 1996 May;47(5):783

ANALYSIS

The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988–1992. Schneider SB, et al. **Am J Clin Oncol** 1996 Feb;19(1):65–72

Cancer (prostate–specific antigen). Castellani WJ. **Anal Chem** 1995 Jun 15;67(12):399R–403R (67 ref.)

Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer—a local experience. Tan HH, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):550–6

Measurement of prostate specific antigen as screening test for prostate cancer. Measurement presents technical difficulties [letter; comment] Bartlett WA, et al. **BMJ** 1996 Mar 16;312(7032):709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view [letter; comment] Neal DE, et al. **BMJ** 1996 Mar 16;312(7032):709; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening [letter; comment] Sandhu S, et al. **BMJ** 1996 Mar 16;312(7032):709; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. False positive results cast doubt on conclusion [letter; comment] Warren P. **BMJ** 1996 Mar 16;312(7032):708–9; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Detection of circulating prostate–specific antigen–positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Fadlon EJ, et al. **Br J Cancer** 1996 Aug;74(3):400–5

Prostatic adenocarcinoma labelled with a monoclonal antibody and polyclonal serum: a quantitative assessment. Gray E, et al. **Br J Urol** 1996 Jul;78(1):104–8

Early detection of prostate cancer. Results of a prostate specific antigen–based detection program in Japan. Egawa S, et al. **Cancer** 1995 Aug 1;76(3):463–72

Evaluation and comparison of two new prostate carcinoma markers. Free–prostate specific antigen and prostate specific membrane antigen. Murphy GP, et al. **Cancer** 1996 Aug 15;78(4):809–18

The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Smitt MC, et al. **Cancer** 1996 Mar 1;77(5):928–33

The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence—data from the Utah Cancer Registry. Stephenson RA, et al. **Cancer** 1996 Apr 1;77(7):1342–8

Quantitative immunoassay for complexes of prostate–specific antigen with alpha2–macroglobulin. España F, et al. **Clin Chem** 1996 Apr;42(4):545–50

Ultrasensitive detection of prostate–specific antigen by a time–resolved immunofluorometric assay and the Immulite immunochemiluminescent third–generation assay: potential applications in prostate and breast cancers. Ferguson RA, et al. **Clin Chem** 1996 May;42(5):675–84

Immunoreactivity of prostate–specific antigen in plasma and saliva of healthy women. Mannello F, et al. **Clin Chem** 1996 Jul;42(7):1110–1

Monoclonal antibody–based dual–label time–resolved fluorometric assays in a simplified one–step format. Meriö L, et al. **Clin Chem** 1996 Sep;42(9):1513–7

Detection of prostate–specific antigen mRNA and protein in breast tumors. Zarghami N, et al. **Clin Chem** 1996 Mar; 42(3):361–6

Nonprostatic prostate–specific antigen [editorial] Talib VH, et al. **Indian J Pathol Microbiol** 1996 Jan;39(1):1–3

Determination of free PSA in breast cancer cytosols by IRMA [letter] Abbate I, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):53–4

Prostate specific antigen in non–serum samples from women [letter] Filella X, et al. **Int J Biol Markers** 1995 Oct–Dec; 10(4):238–9

Characterization of a prostate carcinoma mucin–like antigen (PMA). Beckett ML, et al. **Int J Cancer** 1995 Sep 15; 62(6):703–10

Prostate–specific antigen in breast cyst fluid: possible role of prostate–specific antigen in hormone–dependent breast cancer. Lai LC, et al. **Int J Cancer** 1996 Jun 11;66(6):743–6

PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum. Wu JT, et al. **J Clin Lab Anal** 1995;9(4):243–51

Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate–specific antigen failure in patients with clinically organ–confined prostate cancer. D'Amico AV, et al. **J Clin Oncol** 1996 Jun;14(6):1770–7

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Diamandis EP, et al. **J Urol** 1996 Jan;155(1):294; discussion 295. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. Elgamal AA, et al. **J Urol** 1996 Aug;156(2 Pt 1):464–8

Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. Kim ED, et al. **J Urol** 1995 Nov;154(5):1802–5

Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA, et al. **J Urol** 1996 Apr; 155(4):1348–51

Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Visvanathan K. **J Urol** 1996 Jan; 155(1):294; discussion 295. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Prostate–specific antigen in nipple aspirate [letter] Foretova L, et al. **Lancet** 1996 Jun 8;347(9015):1631

Trust me, I'm a scientist: will urologists set a lead for geneticists to follow? [see comments] Raffle AE. **Lancet** 1996 Mar 30;347(9005):883–4. Comment in: Lancet 1996 Jun 8;347(9015):1629.

Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate [see comments] Huber PR, et al. **Prostate** 1995 Oct;27(4):212–9. Comment in: Prostate 1996 Jul;29(1):65–6.

[Early diagnosis and screening of cancer of the prostate] Fendler JP, et al. **Presse Med** 1995 Oct 28;24(32):1461–3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Bone and bone marrow metastases of prostatic adenocarcinoma: the serum level of prostate–specific antigen may be normal (letter)] Marlier S, et al. **Presse Med** 1996 May 4–11;25(16):777 **(Fre)**

[Effects of digital rectal examination on serum prostate specific antigen] Nord MP, et al. **Presse Med** 1996 Apr 6;25(12):577–80 (Eng. Abstr.) **(Fre)**

[Prostate–specific membrane antigen (letter)] Hovig E, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):411–2 **(Nor)**

[Increased incidence of prostatic cancer. The significance of prostate–specific antigen] Otnes B, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1795–9 (Eng. Abstr.) **(Nor)**

[Various immunohistochemical markers of precancer and variants of prostate cancer] Romanenko AM, et al. **Arkh Patol** 1995 Jul–Aug;57(4):38–41 (Eng. Abstr.) **(Rus)**

[PSA and PSAD study in patients with renal dysfunction] Sánchez de la Muela P, et al. **Actas Urol Esp** 1996 Mar; 20(3):255–60 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25–dihydroxyvitamin D3 in the androgen–dependent LNCaP cells. Hsieh TY, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):141–6

Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Webber MM, et al. **Carcinogenesis** 1996 Aug;17(8):1641–6

Expression and androgenic regulation of human prostate–specific kallikreins. Young CY, et al. **J Androl** 1995 Mar–Apr;16(2):97–9 (16 ref.)

Generation, purification, and characterization of a recombinant source of human prostate–specific antigen. Bei R, et al. **J Clin Lab Anal** 1995;9(4):261–8

Biochemical characteristics and recent biological knowledge on prostate–specific antigen. Seregni E, et al. **Tumori** 1996 Jan–Feb;82(1):72–7 (70 ref.)

Upregulation of prostate–specific membrane antigen after androgen–deprivation therapy. Wright GL Jr, et al. **Urology** 1996 Aug;48(2):326–34

BLOOD

Serum prostate–specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Huncharek M, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):364–7

Management of BPH: educating patients about PSA [letter; comment] Malvea BP. **Am Fam Physician** 1996 Mar; 53(4):1080, 1082. Comment on: Am Fam Physician 1995 Jul;52(1):135–42, 145–6.

PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. Miller LS, et al. **Am J Clin Oncol** 1996 Jun;19(3):217–22

Salivary duct carcinoma secreting prostate–specific antigen. James GK, et al. **Am J Clin Pathol** 1996 Aug;106(2):242–7

Prostate cancer: emerging concepts. Part I. Garnick MB, et al. **Ann Intern Med** 1996 Jul 15;125(2):118–25 (50 ref.)

Tumour serum markers: clinical and economical aspects. Kardamakis D. **Anticancer Res** 1996 Jul–Aug; 16(4B):2285–8 (17 ref.)

Assessment of response to carboplatin in patients with hormone–refractory prostate cancer: a critical analysis of

drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2825–8

DRE-PSA data revisited: PSA sampling should precede DREs [letter] Douville P, et al. **Arch Intern Med** 1996 Jun 24;156(12):1352–3

The impact of informed consent on patient interest in prostate-specific antigen screening [see comments] Wolf AM, et al. **Arch Intern Med** 1996 Jun 24;156(12):1333–6. Comment in: Arch Intern Med 1996 Jun 24;156(12):1262–3.

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer [see comments] Parkes C, et al. **BMJ** 1995 Nov 18; 311(7016):1340–3. Comment in: BMJ 1996 Mar 16;312(7032):708–9; discussion 709–10. Comment in: BMJ 1996 Mar 16;312(7032):709; discussion 709–10. Comment in: BMJ 1996 Mar 16;312(7032):709–10.

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Auvinen A, et al. **Br J Cancer** 1996 Aug; 74(4):568–72

Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site. Harper CL, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):367–8

Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy. Bangma CH, et al. **Br J Urol** 1995 Nov;76(5):595–9

Derivation and application of upper limits for prostate specific antigen in men aged 50–74 years with no clinical evidence of prostatic carcinoma. Dalkin BL, et al. **Br J Urol** 1995 Sep;76(3):346–50

Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Gustafsson O, et al. **Br J Urol** 1996 Mar;77(3):433–40

Prostate-specific antigen levels in patients receiving long-term dialysis. Harper L, et al. **Br J Urol** 1995 Oct; 76(4):482–3

The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Olsson CA, et al. **Br J Urol** 1996 Mar;77(3):411–7

Serum prostate specific antigen levels in non-specific granulomatous prostatitis. Speights VO Jr, et al. **Br J Urol** 1996 Mar;77(3):408–10

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy. van Iersel MP, et al. **Br J Urol** 1996 Mar; 77(3):418–22

Early detection of prostate cancer. Role of prostate-specific antigen. Prabhakaran VM. **Can Fam Physician** 1996 Apr; 42:709–12 (20 ref.)

The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. Demura T, et al. **Cancer** 1996 Mar 15;77(6):1137–43

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Leibman BD, et al. **Cancer** 1995 Dec 15;76(12):2530–4

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515–23

Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? Raviv G, et al. **Cancer** 1996 May 15;77(10):2103–8

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, et al. **Cancer** 1996 Jun 1;77(11):2386–92

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Storlie JA, et al. **Cancer** 1995 Jul 1; 76(1):96–100

A guide to the interpretation of serum prostate specific antigen levels. Bunting PS. **Clin Biochem** 1995 Jun; 28(3):221–41 (174 ref.)

An ultrasensitive immunoassay for prostate-specific antigen based on conventional colorimetric detection. Khosravi MJ, et al. **Clin Biochem** 1995 Aug;28(4):407–14

Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Cuny C, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1243–9

Ultrasensitive prostate-specific antigen assays and their clinical application [comment] Diamandis EP, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):853–7. Comment on: Clin Chem 1996 Jun;42(6 Pt 1):849–52.

Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells [letter] Henke W, et al. **Clin Chem** 1996 Sep;42(9):1499–500

Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Hoffman BR, et al. **Clin Chem** 1996 Apr;42(4):536–44

Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Jung K, et al. **Clin Chem** 1996 Jul;42(7):1026–33

Rapid screening of PSA: evaluation of an immunochemical membrane strip test [letter] Lein M, et al. **Clin Chem** 1995 Oct;41(10):1545–7

Singleton vs duplicate prostate-specific antigen measurements. Lo SF, et al. **Clin Chem** 1995 Oct; 41(10):1535–7

Immunoreactivity of prostate-specific antigen in plasma and saliva of healthy women. Mannello F, et al. **Clin Chem** 1996 Jul;42(7):1110–1

Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Oremek GM, et al. **Clin Chem** 1996 May;42(5):691–5

Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex [see comments] Pettersson K, et al. **Clin Chem** 1995 Oct;41(10):1480–8. Comment in: Clin Chem 1996 Aug;42(8 Pt 1):1297–8.

Serum prostate-specific antigen measured in children from birth to age 18 years. Randell EW, et al. **Clin Chem** 1996 Mar;42(3):420–3

Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians [see comments] Stamey TA. **Clin Chem** 1996 Jun;42(6 Pt 1):849–52. Comment in: Clin Chem 1996 Jun;42(6 Pt 1):853–7.

Role of free PSA in discordance across commercial PSA assays. Strobel S, et al. **Clin Chem** 1996 Apr;42(4):645–7

Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient. Van Duijnhoven HL, et al. **Clin Chem** 1996 Apr;42(4):637–41

Variation in measurement of prostate-specific antigen: importance of method and lot variability. Wener MH, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1730–7

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study [see comments] Filella X, et al. **Eur J Cancer** 1996 Jun;32A(7):1125–8. Comment in: Eur J Cancer 1996 Jun;32A(7):1097–9.

PSA and prostate cancer diagnosis [editorial; comment] Savage P, et al. **Eur J Cancer** 1996 Jun;32A(7):1097–9. Comment on: Eur J Cancer 1996 Jun;32A(7):1125–8.

Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen. Blijenberg BG, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec; 33(12):965–73

The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen. Blijenberg BG, et al. **Eur J Clin Chem Clin Biochem** 1995 Jun;33(6):383–92

Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)—multi-centre study results. The PSA Study Group. Schambeck CM. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):541–7

The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Akdas A, et al. **Eur Urol** 1996; 29(2):189–92

Longitudinal evaluation of prostate-specific antigen levels in a case-control study. De Biasi F, et al. **Eur Urol** 1996; 29(2):184–8

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

The prostate specific antigen. Its use as a tumor marker for prostate cancer. Kantoff PW, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):555–72 (66 ref.)

PSA: to screen or not to screen. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):145–6

Reliability of prostate-specific antigen evaluation according to age-specific range [letter] Ciatto S, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):182

Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy. Ciatto S, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):226–8

Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Correale M, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):24–8

Is serum PSA measurement a good test for early diagnosis of prostate cancer? Results of a pilot study and cost analysis. De Biasi F, et al. **Int J Biol Markers** 1996 Jan-Mar; 11(1):18–23

Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. Devine PL, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):221–5

Usefulness of PSA density and PSA excess in the differential diagnosis between prostate cancer and benign prostatic hypertrophy. Diaz F, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):12–7

Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays. Filella X, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):40–5

Third-generation PSA: ultrasensitive or ultraprecise assay? Mione R, et al. **Int J Biol Markers** 1995 Oct-Dec; 10(4):229–33

Impact of kidney and liver metabolism on serum prostate specific antigen levels [letter] Morote J, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):236–7

Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Filella X, et al. **Int J Cancer** 1995 Dec 11;63(6):780–4

The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume [letter] Stephan C, et al. **Int J Cancer** 1996 Jul 29;67(3):461–2

Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution? [editorial] Anscher MS. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):745–7

Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):273–9

Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):549–53

Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML [see comments] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):861–8 . Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1115.

PSA following irradiation for prostate cancer: the upcoming ASTRO symposium [editorial; comment] Shipley WU. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):1115. Comment on: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):861–8.

Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times [editorial; comment] Stamey TA. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):967–8; discussion 972. Comment on: Int J Radiat Oncol Biol Phys 1995 May 15;32(2):287–92.

Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey. Teshima T, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):809–14

Usefulness of digital rectal examination, serum prostate-specific antigen, transrectal ultrasonography and systematic prostate biopsy for the detection of organ-confined prostate cancer. Gohji K, et al. **Int J Urol** 1995 May;2(2):116–20

Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. Masai M, et al. **Int J Urol** 1996 Mar;3(2):118–23

Prostate-specific antigen in mass screening for carcinoma of the prostate. Shimizu TS, et al. **Int J Urol** 1995 Sep; 2(4):257–60

Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). Dutkiewicz S, et al. **Int Urol Nephrol** 1995;27(6):763–8

Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. Işikay L, et al. **Int Urol Nephrol** 1995; 27(6):757–61

Prostatic acid phosphatase and prostate specific antigen in liver disease. Kadayifci A, et al. **Int Urol Nephrol** 1996; 28(1):67–71

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Sasagawa I, et al. **Int Urol Nephrol** 1995;27(6):769–74

Screening for prostate cancer [letter; comment] Benbassat J. **Isr J Med Sci** 1995 Sep;31(9):579–80. Comment on: Isr J Med Sci 1995 Feb-Mar;31(2-3):125–8.

Screening by the prostate-specific antigen test: what do the patients know? Diefenbach PN, et al. **J Cancer Educ** 1996 Spring;11(1):39–44

Development of a microplate ELISA for free PSA and PSA-ACT complex in serum. Wu JT, et al. **J Clin Lab Anal** 1995;9(4):252–60

Technicon Immuno 1 PSA assay measures both free and alpha-1-antichymotrypsin-complexed prostate-specific antigen on an equimolar basis. Zhou Z, et al. **J Clin Lab Anal** 1996;10(3):155–9

Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. Hanks GE, et al. **J Clin Oncol** 1996 Apr;14(4):1093–7

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. Sridhara R, et al. **J Clin Oncol** 1995 Dec; 13(12):2944–53

Relationship between serum prostate specific antigen concentration and prostate volume. Yu HJ, et al. **J Formos Med Assoc** 1995 Nov;94(11):666–70

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! [editorial; comment] Eisenberger MA, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):779–81. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):794–801.

PSA levels after radiotherapy: how low must they go? [news] McNeil C. **J Natl Cancer Inst** 1996 Jun 19;88(12):791–2

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [see comments] Thalmann GN, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):794–801

. Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):779–81.

Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. Babaian RJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):432–7

Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. Babaian RJ, et al. **J Urol** 1995 Nov;154(5):1808–12

The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. Cooper CS, et al. **J Urol** 1996 Aug;156(2 Pt 1):438–41; discussion 441–2

The effect of bicycle riding on serum prostate specific antigen levels [see comments] Crawford ED 3rd, et al. **J Urol** 1996 Jul;156(1):103–5. Comment in: J Urol 1996 Jul;156(1):114.

Free–to–total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. Elgamal AA, et al. **J Urol** 1996 Sep;156(3):1042–7; discussion 1047–9

Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml. [see comments] Geary ES, et al. **J Urol** 1996 Sep;156(3):1056–8. Comment in: J Urol 1996 Sep;156(3):1069–70.

Prostate specific antigen detected prostate cancer [editorial; comment] Gibbons RP. **J Urol** 1996 Mar;155(3):827. Comment on: J Urol 1996 Mar;155(3):816–20. Comment on: J Urol 1996 Mar;155(3):821–6.

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213–9. Comment in: J Urol 1996 Jan;155(1):226–7.

Characterization of patients with androgen–independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J, et al. **J Urol** 1996 Feb;155(2):620–3

Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. Huland H, et al. **J Urol** 1996 Apr;155(4):1344–7

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening [see comments] Humphrey PA, et al. **J Urol** 1996 Mar;155(3):816–20 (34 ref.). Comment in: J Urol 1996 Mar;155(3):827.

Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves [letter; comment] Jacobsen SJ, et al. **J Urol** 1996 Apr;155(4):1395–6. Comment on: J Urol 1994 Dec;152(6 Pt 1):2037–42.

Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia [editorial; comment] Jonas U, et al. **J Urol** 1996 Sep;156(3):1040–1 . Comment on: J Urol 1996 Sep;156(3):1020–5. Comment on: J Urol 1996 Sep;156(3):1026–34. Comment on: J Urol 1996 Sep;156(3):1035–9.

Pitfalls in interpreting prostate specific antigen velocity [see comments] Kadmon D, et al. **J Urol** 1996 May; 155(5):1655–7. Comment in: J Urol 1996 May;155(5):1661–2.

Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. Keetch DW, et al. **J Urol** 1995 Nov;154(5):1795–7

Clinical and pathological features of hereditary prostate cancer. Keetch DW, et al. **J Urol** 1996 Jun;155(6):1841–3

Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. Keetch DW, et al. **J Urol** 1996 Aug;156(2 Pt 1):428–31

Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [editorial] Klein EA. **J Urol** 1996 Aug;156(2 Pt 1):443–4

Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer [letter; comment] Lawrence G. **J Urol** 1996 Aug;156(2 Pt 1):484 . Comment on: J Urol 1995 Oct;154(4):1418–9.

Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease–free survival [see comments] Lee WR, et al. **J Urol** 1996 Aug; 156(2 Pt 1):450–3. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis [see comments] Lerner SE, et al. **J Urol** 1996 Mar;155(3):821–6. Comment in: J Urol 1996 Mar;155(3):827.

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia [see comments] Marks LS, et al. **J Urol** 1996 Sep;156(3):1035–9. Comment in: J Urol 1996 Sep;156(3):1040–1.

The effects of ejaculation on serum prostate specific antigen. Netto NR Jr, et al. **J Urol** 1996 Apr;155(4):1329–31

Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients [see comments] Noldus J, et al. **J Urol** 1996 Jan;155(1):232–7. Comment in: J Urol 1996 Jan;155(1):243.

Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less [see comments] Noldus J, et al. **J Urol** 1996 Feb;155(2):441–3. Comment in: J Urol 1996 Feb;155(2):610–1.

The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. Oefelein MG, et al. **J Urol** 1995 Dec;154(6):2128–31

The periurethral glands do not significantly influence the serum prostate specific antigen concentration [see comments] Oesterling JE, et al. **J Urol** 1996 May; 155(5):1658–60. Comment in: J Urol 1996 May;155(5):1661–2.

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy [see comments] Olsson CA, et al. **J Urol** 1996 May;155(5):1557–62. Comment in: J Urol 1996 May;155(5):1661–2.

Standard versus age–specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. Partin AW, et al. **J Urol** 1996 Apr;155(4):1336–9

Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers [see comments] Prestigiacomo AF, et al. **J Urol** 1996 Jun; 155(6):1977–80. Comment in: J Urol 1996 Jun;155(6):1987–8.

A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Prestigiacomo AF, et al. **J Urol** 1996 Aug;156(2 Pt 1):350–4

Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence [see comments] Ravery V, et al. **J Urol** 1996 Jun;155(6):1981–2. Comment in: J Urol 1996 Jun;155(6):1987–8.

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Schmid HP. **J Urol** 1996 Jan; 155(1):294–5. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Re: Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass [letter; comment] Semjonow A, et al. **J Urol** 1996 Jan;155(1):295–6. Comment on: J Urol 1994 Dec;152(6 Pt 1):2043–5.

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Small EJ. **J Urol** 1996 May;155(5):1704–5. Comment on: J Urol 1995 Aug;154(2 Pt 1):448–53.

Prostate cancer—our patients' questions [editorial; comment] Theodorescu D. **J Urol** 1996 May;155(5):1661–2. Comment on: J Urol 1996 May;155(5):1557–62. Comment on: J Urol 1996 May;155(5):1655–7. Comment on: J Urol 1996 May;155(5):1658–60.

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Walsh PC. **J Urol** 1996 May;155(5):1705. Comment on: J Urol 1995 Aug;154(2 Pt 1):448–53.

Free serum prostate–specific antigen and screening for prostate cancer [letter; comment] Bangma CH, et al. **JAMA** 1996 Mar 20;275(11):837–8. Comment on: JAMA 1995 Oct 18;274(15):1214–20.

PSA screening and prostate cancer incidence [letter; comment] Berman JJ, et al. **JAMA** 1996 Apr 17; 275(15):1155–6. Comment on: JAMA 1995 Nov 8;274(18):1445–9.

Evaluation of percentage of free serum prostate–specific antigen to improve specificity of prostate cancer screening [see comments] Catalona WJ, et al. **JAMA** 1995 Oct 18; 274(15):1214–20. Comment in: JAMA 1996 Mar 20;275(11):837–8.

Prostate–specific antigen values at the time of prostate cancer diagnosis in African–American men. Moul JW, et al. **JAMA** 1995 Oct 25;274(16):1277–81

PSA screening and prostate cancer incidence [letter; comment] Rhoads GG, et al. **JAMA** 1996 Apr 17; 275(15):1155–6. Comment on: JAMA 1995 Nov 8;274(18):1445–9.

Screening for early detection of prostate cancer [letter; comment] Catalona WJ. **Lancet** 1996 Jun 8;347(9015):1629 . Comment on: Lancet 1996 Mar 30;347(9005):883–4.

Prostate–specific antigen in black men [letter] Sawyer R, et al. **Lancet** 1996 May 11;347(9011):1329

Evaluation of serum prostate–specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer. Buskirk SJ, et al. **Mayo Clin Proc** 1996 Mar;71(3):242–8

Serum prostate–specific antigen concentration before and after vasectomy. Lassen PM, et al. **Mil Med** 1996 Jun; 161(6):356–7

Microparticle immunoenzymatic assay for detection of prostate specific antigen: characterization of the technique and comparative analysis with a monoclonal immunoradiometric assay. Sánchez de la Muela P, et al. **Mil Med** 1995 Aug;160(8):416–9

How valuable is prostate–specific antigen screening? [letter; comment] Handler S. **Minn Med** 1996 Jun;79(6):2. Comment on: Minn Med 1996 Apr;79(4):46–9. Comment on: Minn Med 1996 Apr;79(4):50–1.

Early detection of prostate cancer. Decreasing the mortality rate [see comments] Oesterling JE. **Minn Med** 1996 Apr; 79(4):46–9. Comment in: Minn Med 1996 Jun;79(6):2.

Does screening with prostate/specific antigen improve outcomes? [see comments] Ohrt D. **Minn Med** 1996 Apr; 79(4):50–1. Comment in: Minn Med 1996 Jun;79(6):2.

Screening for prostate cancer [letter; comment] Budenholzer B. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.

Screening for prostate cancer [letter; comment] Catalona WJ. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.

Screening for prostate cancer [letter; comment] Hensel WA. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.

Age–specific reference ranges for prostate–specific antigen in black men [see comments] Morgan TO, et al. **N Engl J Med** 1996 Aug 1;335(5):304–10. Comment in: N Engl J Med 1996 Aug 1;335(5):345–6.

Age–specific reference ranges for serum PSA [editorial; comment] Oesterling JE. **N Engl J Med** 1996 Aug 1; 335(5):345–6. Comment on: N Engl J Med 1996 Aug 1;335(5):304–10.

Screening for prostate cancer [letter; comment] Stevens R. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.

Screening for prostate cancer with prostate–specific antigen. An examination of the evidence [see comments] Woolf SH. **N Engl J Med** 1995 Nov 23;333(21):1401–5 (62 ref.). Comment in: N Engl J Med 1996 Mar 7;344(10):666–7; discussion 667–8. Comment in: N Engl J Med 1996 Mar 7;344(10):667; discussion 667–8.

New 'calibrator' should improve prostate cancer testing [news] **Oncology (Huntingt)** 1995 Nov;9(11):1222

Prostate–specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al. **Postgrad Med** 1996 Feb;99(2):227–8, 231–4 (14 ref.)

Elevated serum prostate–specific antigen and pancreatic carcinoma. Ranganath LR, et al. **Postgrad Med J** 1996 Jun; 72(848):363–4

Prostate specific antigen in a community–based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Bosch JL, et al. **Prostate** 1995 Nov;27(5):241–9

Isoforms of prostate–specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? [letter; comment] Jung K, et al. **Prostate** 1996 Jul;29(1):65–6 . Comment on: Prostate 1995 Sep;27(3):166–75. Comment on: Prostate 1996 Oct;27(4):212–9.

Measurement of prostate–specific membrane antigen in the serum with a new antibody. Murphy GP, et al. **Prostate** 1996 Apr;28(4):266–71

Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF, et al. **Prostate** 1996 Jul;29(1):46–50

Quantitating regrowth delay of prostate cancers after failure of radiation therapy. Hood–Hanks S, et al. **Radiology** 1996 Aug;200(2):505–8

Clinical evaluation of prostate biopsy parameters: gland volume and elevated prostate–specific antigen level. Rubens DJ, et al. **Radiology** 1996 Apr;199(1):159–63

Serum concentrations of prostate–specific antigen after diagnostic procedures and transurethral microwave thermotherapy of benign prostatic hyperplasia. Daehlin L, et al. **Scand J Clin Lab Invest** 1996 May;56(3):269–73

T1c cancer: what is it? Flanigan RC, et al. **Semin Urol Oncol** 1995 Aug;13(3):173–5 (18 ref.)

Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate–specific antigen. Ciatto S, et al. **Tumori** 1995 Jul–Aug;81(4):225–9

Usefulness of prostate–specific antigen density as a diagnostic test of prostate cancer. Filella X, et al. **Tumour Biol** 1996; 17(1):20–6

Prostatic intraepithelial neoplasia does not appear to raise serum prostate–specific antigen concentration. Alexander EE, et al. **Urology** 1996 May;47(5):693–8

Reference range of prostate–specific antigen after transurethral resection of the prostate. Aus G, et al. **Urology** 1996 Apr;47(4):529–31

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate–specific analysis ratio, age–specific reference ranges, and PSA density. Bangma CH, et al. **Urology** 1995 Dec;46(6):779–84

Should Medicare provide reimbursement for prostate–specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Barry MJ, et al. **Urology** 1995 Oct;46(4):445–61

Using proportions of free to total prostate–specific antigen, age, and total prostate–specific antigen to predict the probability of prostate cancer. Chen YT, et al. **Urology** 1996 Apr;47(4):518–24

Postoperative prostate–specific antigen as a prognostic indicator in patients with margin–positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Coetzee LJ, et al. **Urology** 1996 Feb; 47(2):232–5

Cryosurgical ablation of the prostate: two–year prostate–specific antigen and biopsy results. Cohen JK, et al. **Urology** 1996 Mar;47(3):395–401

Local recurrence after radical prostatectomy: characteristics

in size, location, and relationship to prostate-specific antigen and surgical margins. Connolly JA, et al. **Urology** 1996 Feb;47(2):225–31

Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Crawford ED, et al. **Urology** 1996 Jun; 47(6):863–9

An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. D'Amico AV, et al. **Urology** 1996 Apr; 47(4):538–47

Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. DeAntoni EP, et al. **Urology** 1996 Aug;48(2):234–9

Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Froschermaier SE, et al. **Urology** 1996 Apr; 47(4):525–8

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Gleave ME, et al. **Urology** 1996 May; 47(5):708–12

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870–7

Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Komatsu K, et al. **Urology** 1996 Mar; 47(3):343–6

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P, et al. **Urology** 1996 Aug;48(2):249–60

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Labrie F, et al. **Urology** 1996 Feb;47(2):212–7

Effect of elective prolonged urethral catheterization on serum prostate-specific antigen concentration. Matzkin H, et al. **Urology** 1996 Jul;48(1):63–6

An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. Oesterling JE, et al. **Urology** 1995 Oct; 46(4):524–32

Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Ohori M, et al. **Urology** 1995 Nov;46(5):666–71

p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Papadopoulos I, et al. **Urology** 1996 Aug; 48(2):261–8

Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Reissigl A, et al. **Urology** 1995 Nov; 46(5):662–5

Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Roehrborn CG, et al. **Urology** 1996 Mar;47(3):347–52

Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Roehrborn CG, et al. **Urology** 1996 Jan; 47(1):59–66

Impact of prostate-specific antigen screening on the natural history of prostate cancer. Rosen MA. **Urology** 1995 Dec; 46(6):757–68 (95 ref.)

Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Schild SE, et al. **Urology** 1996 Jun;47(6):878–81

Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels. Schmid HP, et al. **Urology** 1996 May;47(5):699–703

Ejaculation increases the serum prostate-specific antigen concentration. Tchetgen MB, et al. **Urology** 1996 Apr; 47(4):511–6

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Zietman AL, et al. **Urology** 1996 Feb;47(2):236–9

Serologic markers in prostate cancer. Harris D, et al. **West J Med** 1996 Apr;164(4):344–5

[Detection of prostatic cancer in symptomatic patients with serum levels of prostate-specific antigen between 4 and 10 ng/ml] Ravery V, et al. **Presse Med** 1996 Feb 24; 25(7):272–6 (Eng. Abstr.) **(Fre)**

[Prostate-specific antigen] Huland H. **Dtsch Med Wochenschr** 1996 May 24;121(21):710 **(Ger)**

[Is radical prostatectomy a suitable model for determination of PSA half-life?] Brändle E, et al. **Urologe A** 1995 Sep; 34(5):419–23 (Eng. Abstr.) **(Ger)**

[PSA and prostatic adenocarcinoma. Experience with 805 patients] Grasso-Leanza F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):161–5 (Eng. Abstr.) **(Ita)**

[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer] Kageyama Y, et al. **Hinyokika Kiyo** 1996 Mar;42(3):197–9 (Eng. Abstr.) **(Jpn)**

[Prostate cancer screening in total health care check--using serum PSA and AUA score] Komeda Y, et al. **Hinyokika Kiyo** 1996 Apr;42(4):275–8 (Eng. Abstr.) **(Jpn)**

[Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy] Miyamoto S, et al. **Hinyokika Kiyo** 1995 Oct;41(10):767–70 (Eng. Abstr.) **(Jpn)**

[Determination of free type and complex type prostate-specific antigen (PSA): differences in immunorecognition by Delfia PSA, ACS-PSA and Eiken PA kits] Sumi S, et al. **Hinyokika Kiyo** 1996 Apr; 42(4):279–84 (Eng. Abstr.) **(Jpn)**

[Early detection of prostate cancer--results of a prostate specific antigen-based detection program at a "multiphasic screening] Egawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1711–9 (Eng. Abstr.) **(Jpn)**

[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention] Nishitani M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1368–74 (Eng. Abstr.) **(Jpn)**

[Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer] Uno H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1776–83 (Eng. Abstr.) **(Jpn)**

[The relationship between serum PSA value and the weight of the inner gland of the prostate in the cases of benign prostatic hyperplasia] Wu B, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1525–9 (Eng. Abstr.) **(Jpn)**

[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age] Yamazaki H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):702–9 (Eng. Abstr.) **(Jpn)**

[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method] Arai K, et al. **Rinsho Byori** 1996 Apr; 44(4):345–50 (Eng. Abstr.) **(Jpn)**

[Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay] Chichibu K, et al. **Rinsho Byori** 1995 Nov;43(11):1153–8 (Eng. Abstr.) **(Jpn)**

[The diagnostic utility of PSA density] Alcover J, et al. **Actas Urol Esp** 1995 Mar;19(3):192–5 (Eng. Abstr.) **(Spa)**

[The index of PSA age vs PSA density. 2 new instruments in the detection of prostatic carcinoma] Fernández Arjona M, et al. **Actas Urol Esp** 1995 Mar;19(3):187–91 (Eng. Abstr.) **(Spa)**

[Effect of cell differentiation in prostatic cancer on basal PSA] Llorente Abarca C, et al. **Actas Urol Esp** 1995 Nov-Dec;19(10):755–8 (Eng. Abstr.) **(Spa)**

[Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer (editorial)] Morote Robles J. **Actas Urol Esp** 1996 Jan;20(1):1–12 (71 ref.) **(Spa)**

[PSA and hormone-refractory period in prostatic cancer] Ojea Calvo A, et al. **Actas Urol Esp** 1996 Feb;20(2):168–71 (Eng. Abstr.) **(Spa)**

[PSA levels and its relationship with digital examination, age, and score of prostatic symptoms] Pereiro M, et al. **Actas Urol Esp** 1996 Feb;20(2):149–54 (Eng. Abstr.) **(Spa)**

[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade] Regueiro López JC, et al. **Actas Urol Esp** 1995 May;19(5):357–62 (Eng. Abstr.) **(Spa)**

[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] Sánchez Sánchez E, et al. **Actas Urol Esp** 1995 Mar;19(3):181–6 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera. Heeb MJ, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):917–23

Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Bélanger A, et al. **Prostate** 1995 Oct; 27(4):187–97

DIAGNOSTIC USE

Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site. Harper CL, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):367–8

DRUG EFFECTS

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

GENETICS

Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Lee CH, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1805–11

Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry. Galvan B, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1705–9

Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen [editorial; comment] Heston WD. **Clin Chem** 1995 Dec;41(12 Pt 1):1687–8. Comment on: Clin Chem 1995 Dec;41(12 Pt 1):1698–704.

Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen [see comments] Loric S, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1698–704. Comment in: Clin Chem 1995 Dec;41(12 Pt 1):1687–8.

Detection of prostate-specific antigen mRNA and protein in breast tumors. Zarghami N, et al. **Clin Chem** 1996 Mar; 42(3):361–6

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Pang S, et al. **Hum Gene Ther** 1995 Nov;6(11):1417–26

Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. Cleutjens KB, et al. **J Biol Chem** 1996 Mar 15; 271(11):6379–88

Prostate-specific antigen expression is regulated by an upstream enhancer. Schuur ER, et al. **J Biol Chem** 1996 Mar 22;271(12):7043–51

Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues. Li SS. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):441–7

A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostate tissue. Baffa R, et al. **Urology** 1996 Jun;47(6):795–800

IMMUNOLOGY

A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Hodge JW, et al. **Int J Cancer** 1995 Oct 9;63(2):231–7

Dual monoclonal antibody immunoassay for free prostate-specific antigen. Wang TJ, et al. **Prostate** 1996 Jan;28(1):10–6

[Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate] Saad F, et al. **Ann Chir** 1995;49(8):680–4 (Eng. Abstr.) **(Fre)**

[Prostate-specific antigen or PSA. Facts and probabilities] Boccon-Gibod L. **Presse Med** 1995 Oct 28;24(32):1471–2 (Eng. Abstr.) **(Fre)**

[Prostate specific antigen. Clinical applications of ultrasensitive assay] Haab F, et al. **Presse Med** 1995 Nov 25;24(36):1697–702 (43 ref.) (Eng. Abstr.) **(Fre)**

[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer] Kippersund JT, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3612–5 (Eng. Abstr.) **(Nor)**

ISOLATION & PURIFICATION

Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Zhang WM, et al. **Clin Chem** 1995 Nov;41(11):1567–73

Biological activity of prostate-specific antigen isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroelution. Tessmer U, et al. **Electrophoresis** 1995 May;16(5):793–9

Identity of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Stamey TA, et al. **Prostate** 1995 Oct; 27(4):198–203

METABOLISM

Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy. Anscher MS. **Am J Clin Oncol** 1995 Dec; 18(6):481–3

Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer. Igawa M, et al. **Br J Urol** 1996 Jan;77(1):107–12

Lyophilized PSA-ACT complex is stable [letter; comment] Chen Z, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1297–8. Comment on: Clin Chem 1995 Oct;41(10):1480–8.

Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor. Kise H, et al. **Eur J Biochem** 1996 May 15; 238(1):88–96

Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Yoshida E, et al. **Int J Cancer** 1995 Dec 11;63(6):863–5

The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy. Romics I, et al. **Int Urol Nephrol** 1995;27(3):319–24

Immunoreactive prostate-specific antigen in lung tumors. Levesque M, et al. **J Clin Lab Anal** 1995;9(6):375–9

Prostate specific antigen is metabolized in the liver. Agha AH, et al. **J Urol** 1996 Apr;155(4):1332–5

Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. Cramer SD, et al. **J Urol** 1996 Aug;156(2

Pt 1):526–31
Prostate specific antigen releases a kinin-like substance on proteolysis of seminal vesicle fluid that stimulates smooth muscle contraction. Fichtner J, et al. **J Urol** 1996 Feb; 155(2):738–42
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin [see comments] Huber PR, et al. **Prostate** 1995 Sep;27(3):166–75. Comment in: Prostate 1996 Jul;29(1):65–6.
Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Iwamura M, et al. **Urology** 1996 Aug;48(2):317–25
Prostate-specific antigen density—a reliable parameter for the detection of prostate cancer? Thon WF, et al. **World J Urol** 1996;14(1):53–8

PHYSIOLOGY

Complex formation between PSA isoenzymes and protease inhibitors. Leinonen J, et al. **J Urol** 1996 Mar; 155(3):1099–103

SECRETION

Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Oremek GM, et al. **Clin Chem** 1996 May;42(5):691–5
... and secreted tumour suppressors [letter; comment] Diamandis EP. **Nat Genet** 1996 Jul;13(3):268; discussion 269–72. Comment on: Nat Genet 1996 Mar;12(3):303–8.

STANDARDS

Production, analysis, and characterization of reference materials for prostate-specific antigen. Garg UC, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1104–8

PROSTATECTOMY

Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy. Anscher MS. **Am J Clin Oncol** 1995 Dec; 18(6):481–3
Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Epstein JI, et al. **Am J Surg Pathol** 1996 Jul;20(7):851–7
Anaesthesia and adverse effects after intrathecal pethidine hydrochloride for urological surgery. Grace D, et al. **Anaesthesia** 1995 Dec;50(12):1036–40
Silent myocardial ischaemia in patients undergoing transurethral prostatectomy. A study to evaluate risk scoring and anaesthetic technique with outcome. Windsor A, et al. **Anaesthesia** 1996 Aug;51(8):728–32
Anesthesia, blood loss, and coagulopathy during transurethral resection of the prostate [letter; comment] Hahn RG. **Anesth Analg** 1996 Jul;83(1):195. Comment on: Anesth Analg 1995 Oct;81(4):680–5.
Coagulopathies in patients after transurethral resection of the prostate: spinal versus general anesthesia [see comments] Smyth R, et al. **Anesth Analg** 1995 Oct;81(4):680–5. Comment in: Anesth Analg 1996 Jul;83(1):195.
Radical prostatectomy for prostate cancer—an experience of fifteen cases in Singapore. Cheng C, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):557–61
Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131–8 (38 ref.)
Garlic and the risk of TURP bleeding. German K, et al. **Br J Urol** 1995 Oct;76(4):518
Prostate cancer: anatomical and surgical considerations. Gil-Vernet JM. **Br J Urol** 1996 Aug;78(2):161–8 (28 ref.)
Effect of age, comorbidity and type of surgery on perioperative complications and mortality of prostatectomy. Ibrahim AI, et al. **Br J Urol** 1995 Sep; 76(3):341–5
Orgasm after radical prostatectomy. Koeman M, et al. **Br J Urol** 1996 Jun;77(6):861–4
Nottingham health profile measurement in the assessment of clinical outcome after prostatectomy. Northern Regional Prostate Audit Group. Thorpe AC, et al. **Br J Urol** 1995 Oct;76(4):446–50
Ketorolac does not decrease postoperative pain in elderly men after transvesical prostatectomy. Fredman B, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):438–41
Surgical management of prostate cancer [letter] Aref I. **Cancer** 1995 Nov 1;76(9):1682–4
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Leibman BD, et al. **Cancer** 1995 Dec 15;76(12):2530–4
Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [see comments] Oefelein MG, et al. **Cancer** 1995 Dec 15; 76(12):2535–42. Comment in: Cancer 1996 Jul 1;78(1):181–2.
Staging and reporting of prostate cancer—sampling of the radical prostatectomy specimen. Sakr WA, et al. **Cancer** 1996 Jul 15;78(2):366–8
The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Smitt MC, et al. **Cancer** 1996 Mar 1;77(5):928–33
Hospital acquired pre-prostatectomy bacteriuria: risk factors and implications. Ibrahim AI. **East Afr Med J** 1996 Feb; 73(2):107–10
Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Bartolozzi C, et al. **Eur Radiol** 1996;6(3):339–45
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Abrahamsson PA. **Eur Urol** 1996;29 Suppl 2:27–30 (12 ref.)
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Huland H. **Eur Urol** 1996;29 Suppl 2:31–3 (16 ref.)
The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Voges GE, et al. **Eur Urol** 1995; 28(3):209–14
The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Schild SE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):535–41
En bloc radical cystoprostatourethrectomy with preservation of sexual function. Arai Y, et al. **Int J Urol** 1995 Sep; 2(4):249–51
A non-randomized comparative study of visual laser ablation and transurethral resection of the prostate in benign prostatic hyperplasia. Uchida T, et al. **Int J Urol** 1996 Mar; 3(2):108–12
The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy. Romics I, et al. **Int Urol Nephrol** 1995;27(3):319–24
Prostate cancer treatment article incomplete [letter; comment] Foens C. **Iowa Med** 1996 Apr;86(4):155. Comment on: Iowa Med 1995 Dec;85(12):489–90.
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. Bubendorf L, et al. **J Pathol** 1996 Apr;178(4):437–41
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy [see comments] Bettencourt MC, et al. **J Urol** 1996 Sep;156(3):1064–8. Comment in: J Urol 1996 Sep;156(3):1069–70.
Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. Dalkin BL, et al. **J Urol** 1996 Apr;155(4):1357–60
Benign prostatic hyperplasia: practice makes perfect [editorial; comment] Dowd JB. **J Urol** 1996 Jan;155(1):190 . Comment on: J Urol 1996 Jan;155(1):176–80. Comment on: J Urol 1996 Jan;155(1):181–5. Comment on: J Urol 1996 Jan;155(1):186–9.
The artificial urinary sphincter for post-radical prostatectomy incontinence: impact on urinary symptoms and quality of life. Fleshner N, et al. **J Urol** 1996 Apr; 155(4):1260–4
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213–9. Comment in: J Urol 1996 Jan;155(1):226–7.
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. Goldenberg SL, et al. **J Urol** 1996 Sep;156(3):873–7
Quantification of voiding dysfunction in patients awaiting transurethral prostatectomy. Javlé P, et al. **J Urol** 1996 Sep;156(3):1014–8; discussion 1018–9
Blood loss during radical retropubic prostatectomy: is preoperative autologous blood donation indicated? Koch MO, et al. **J Urol** 1996 Sep;156(3):1077–9; discussion 1079–80
Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. Leach GE, et al. **J Urol** 1996 Apr; 155(4):1256–9
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis [see comments] Lerner SE, et al. **J Urol** 1996 Mar;155(3):821–6. Comment in: J Urol 1996 Mar;155(3):827.
Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia [see comments] Marks LS, et al. **J Urol** 1996 Sep;156(3):1035–9. Comment in: J Urol 1996 Sep;156(3):1040–1.
Prostate cancer and aspects of radical prostatectomy [editorial] Middleton RG. **J Urol** 1996 Sep;156(3):1092–3
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting [see comments] Moul JW, et al. **J Urol** 1996 May;155(5):1667–73. Comment in: J Urol 1996 May;155(5):1678–80.
Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. Moul JW, et al. **J Urol** 1996 Mar; 155(3):982–5
Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.
Prognostic significance of positive surgical margins in radical prostatectomy specimens. Ohori M, et al. **J Urol** 1995 Nov; 154(5):1818–24
Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy [see comments] Olsson CA, et al. **J Urol** 1996 May;155(5):1557–62. Comment in: J Urol 1996 May;155(5):1661–2.
Fine-tuning the indication for prostatectomy [editorial; comment] Roehrborn CG. **J Urol** 1996 Jan;155(1):203–5. Comment on: J Urol 1996 Jan;155(1):191–6. Comment on: J Urol 1996 Jan;155(1):197–9. Comment on: J Urol 1996 Jan;155(1):200–2.
Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup [see comments] Schoenberg MP, et al. **J Urol** 1996 Feb;155(2):490–4. Comment in: J Urol 1996 Feb;155(2):504–5.
Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. Walsh PC. **J Urol** 1996 Jul;156(1):301–2
Results of radical prostatectomy in men with clinically localized prostate cancer. Gerber GS, et al. **JAMA** 1996 Aug 28;276(8):615–9
Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy [see comments] Eschwège P, et al. **Lancet** 1995 Dec 9;346(8989):1528–30. Comment in: Lancet 1995 Dec 9;346(8989):1506–7. Comment in: Lancet 1996 Feb 3;347(8997):324–5. Comment in: Lancet 1996 Feb 3;347(8997):325. Comment in: Lancet 1996 Feb 3;347(8997):325–6. Comment in: Lancet 1996 Mar 30;347(9005):913.
Transurethral Nd:YAG laser prostatectomy with a laterally firing fiber: local effects on tissue associated with erectile dysfunction. Breza J, et al. **Lasers Surg Med** 1995; 17(4):364–9
Transurethral balloon laser prostatectomy in the canine: medium-term, follow-up results. Suzuki T, et al. **Lasers Surg Med** 1995;17(4):358–63
Is there always a role for radical prostatectomy in the treatment of localized prostate cancer? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):117–24 (26 ref.)
Outcome variations for BPH-TURP patients. Hardy D, et al. **Mo Med** 1995 Oct;92(10):640–3
Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. Moon TD, et al. **Monogr Natl Cancer Inst** 1995;(19):69–71
Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Lerner SE, et al. **Oncology (Huntingt)** 1995 May;9(5):379–82; discussion 382, 385–6, 389
Suramin as adjuvant therapy with radical prostatectomy. Saffrin R, et al. **Prostate** 1996 May;28(5):325–7
Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF, et al. **Prostate** 1996 Jul;29(1):46–50
The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy. Hunter DJ, et al. **Qual Life Res** 1995 Aug;4(4):335–41
Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Arcangeli G, et al. **Radiother Oncol** 1995 May;35(2):123–8
The symptomatic outcome of transurethral prostatectomy evaluated with the DAN-PSS-1 score system. Flyger HL, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):45–9
Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Lukkarinen O, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):33–6
Orthotopic bladder substitutes: histopathologic risk factors. Nabeeh A, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):463–7
Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)
Cost-efficient radical prostatectomy. Koch MO. **Semin Urol Oncol** 1995 Aug;13(3):197–203
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)
Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)
Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)
Reference range of prostate-specific antigen after transurethral resection of the prostate. Aus G, et al. **Urology** 1996 Apr;47(4):529–31
Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Coetzee LJ, et al. **Urology** 1996 Feb; 47(2):232–5
Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Connolly JA, et al. **Urology** 1996 Feb;47(2):225–31

Patient selection for experimental adjuvant therapy after radical prostatectomy [letter; comment] Douglas TH, et al. **Urology** 1996 Feb;47(2):284–5. Comment on: Urology 1995 May;45(5):831–8.

Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Flanigan RC, et al. **Urology** 1996 Sep;48(3):428–32

Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation. Forman JD, et al. **Urology** 1996 Mar;47(3):382–6

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870–7

Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Hall JC, et al. **Urology** 1996 Jun; 47(6):852–6

Conservative management of rectocutaneous fistula following radical perineal prostatectomy. Lassen PM, et al. **Urology** 1996 Apr;47(4):592–4; discussion 594–5

Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain. Niesel T, et al. **Urology** 1996 Jul; 48(1):91–4

Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Schild SE, et al. **Urology** 1996 Jun;47(6):878–81

Combination of laser irradiation and transurethral resection of the prostate [letter] Vanwaeyenbergh J, et al. **Urology** 1995 Oct;46(4):603

Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Watson RB, et al. **Urology** 1996 Jul;48(1):80–90

[Urethral strictures following transurethral resection of the prostate] Nelkov K, et al. **Khirurgiia (Sofiia)** 1994; 47(3):19–21 (Eng. Abstr.) **(Bul)**

[Results of surgical treatment of benign prostatic hyperplasia] Kawaciuk I, et al. **Rozhl Chir** 1995 Nov;74(7):339–47 (Eng. Abstr.) **(Cze)**

[Subjective symptoms before and after prostate surgery. The International Symptom Scoring System, I-PSS] Kawaciuk I, et al. **Rozhl Chir** 1995 Nov;74(7):334–8 (Eng. Abstr.) **(Cze)**

[Detubularized U-shaped enterocystoplasty after cystoprostatectomy] el Mrini M, et al. **Ann Urol (Paris)** 1996;30(2):85–8 (Eng. Abstr.) **(Fre)**

[Peroperative biopsy of the sub-apical urethra during prostatectomy for cancer] Ponthieu A, et al. **Prog Urol** 1996 Apr;6(2):250–5; discussion 255–6 (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Patient-controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134–8 (Eng. Abstr.) **(Ger)**

[Transurethral prostatic resection or observation of the course of benign prostatic hyperplasia?] Kleinschmidt K. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1491–2 **(Ger)**

[Pathologic-anatomic examination of prostatovesiculectomy samples in prostate carcinoma] Hailemariam S, et al. **Pathologe** 1996 May;17(3):227–30 (Eng. Abstr.) **(Ger)**

[Survival after radical retropubic prostatectomy in patients with poorly differentiated prostatic carcinoma] Weigel C. **Strahlenther Onkol** 1996 Jul;172(7):404–5 **(Ger)**

[Is radical prostatectomy a suitable model for determination of PSA half-life?] Brändle E, et al. **Urologe A** 1995 Sep; 34(5):419–23 (Eng. Abstr.) **(Ger)**

[Visual laser ablation of the prostate--a prospective study] Jung P, et al. **Urologe A** 1995 Nov;34(6):461–5 (Eng. Abstr.) **(Ger)**

[Radiologic evaluation of parietal infiltration of bladder cancer (integrated imaging: US, TC, RM) and comparison with transurethral resection (TUR)] Gauldi GF, et al. **Clin Ter** 1995 Nov;146(11):691–711 (Eng. Abstr.) **(Ita)**

[Surgical treatment of benign prostatic hypertrophy and Kelami syndrome] Bodo G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):81–3 (Eng. Abstr.) **(Ita)**

[Comments on radical prostatectomy three month after hormone therapy] Selvaggi FP, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):215–7 **(Ita)**

[Clinical outcome of radical prostatectomy and pelvic lymph node dissection] Mizutani K, et al. **Hinyokika Kiyo** 1995 Nov;41(11):867–71 (Eng. Abstr.) **(Jpn)**

[Blood coagulation-fibrinolysis system during transurethral resection evaluated by thrombelastography] Tomiyama Y, et al. **Masui** 1996 May;45(5):565–70 (Eng. Abstr.) **(Jpn)**

[Comparisons of histological grading between biopsy and radical prostatectomy specimens in prostatic adenocarcinoma] Fujinami K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1460–5 (Eng. Abstr.) **(Jpn)**

[A clinical study of radial prostatectomy] Hotta H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):760–5 (Eng. Abstr.) **(Jpn)**

[Preoperative use of erythropoietin (rH-EPO) and determination of optimal doses in patients with benign prostatic hypertrophy for future autologous blood transfusion] Inatsuchi H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1720–7 (Eng. Abstr.) **(Jpn)**

[Radical prostatectomy in a patient with hemophilia B] Irie A, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep; 86(9):1501–3 (Eng. Abstr.) **(Jpn)**

[A clinical and pathological study of radical prostatectomy for prostate cancer] Taguchi I, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):772–9 (Eng. Abstr.) **(Jpn)**

[Therapeutic tactics and results of prostatic adenomectomy in the presence of aggravating factors] Dovlatian AA. **Klin Med (Mosk)** 1995;73(4):68–72 (Eng. Abstr.) **(Rus)**

[Phytoperfusion of the bladder after adenomectomy] Davidov MI, et al. **Urol Nefrol (Mosk)** 1995 Sep-Oct; (5):19–20 (Eng. Abstr.) **(Rus)**

[Laser technology in prostatic surgery] Kornev AI, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):49–52 (39 ref.) **(Rus)**

[Non-palpable prostatic cancer. Cure with adenomectomy?] Cambronero Santos J, et al. **Actas Urol Esp** 1996 Apr; 20(4):346–50 (Eng. Abstr.) **(Spa)**

[Radical surgery of locally advanced prostatic cancer] Pesqueira D, et al. **Actas Urol Esp** 1995 Jul-Aug; 19(7):549–54 (Eng. Abstr.) **(Spa)**

[Transurethral resection of prostate cancer: efficacy and morbidity] Mora Durban M, et al. **Arch Esp Urol** 1995 Oct;48(8):829–35 (Eng. Abstr.) **(Spa)**

[The use of autologous blood in treating urinary incontinence after performing a transurethral operation] Ukhal' MI, et al. **Klin Khir** 1995;(6):52 **(Ukr)**

ADVERSE EFFECTS

Hyponatraemia in the transurethral resection of prostate syndrome. Dixon B, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):102–3

Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Bogden AE, et al. **Br J Cancer** 1996 Jan;73(1):73–8

Obturator herniation following radical cystoprostatectomy. Austin RC, et al. **Br J Urol** 1995 Dec;76(6):800

Intraprostatic vasopressin before TURP. Sharma DP. **Br J Urol** 1995 Sep;76(3):393

Artificial urinary sphincter for post-prostatectomy incontinence. Singh G, et al. **Br J Urol** 1996 Feb; 77(2):248–51

Operative factors and the long-term incidence of acute myocardial infarction after transurethral resection of the prostate. Hahn RG, et al. **Epidemiology** 1996 Jan;7(1):93–5

Life-threatening transurethral resection syndrome despite monitoring of fluid absorption with ethanol. Hahn RG. **Eur J Anaesthesiol** 1995 Jul;12(4):431–3

Bladder neck preservation following radical prostatectomy: continence and margins. Braslis KG, et al. **Eur Urol** 1995; 28(3):202–8

Rectal perforation after retropubic radical prostatectomy: occurrence and management. Häggman M, et al. **Eur Urol** 1996;29(3):337–40

How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. Mazur DJ, et al. **J Am Geriatr Soc** 1996 Aug;44(8):934–7

Antegrade collagen injection for stress incontinence after radical prostatectomy: technique and early results. Klutke CG, et al. **J Endourol** 1996 Jun;10(3):279–82

Surgeon's workshop: antegrade collagen injection: new technique for postprostatectomy stress incontinence. Klutke CG, et al. **J Endourol** 1995 Dec;9(6):513–5

Endoscopic management of the obliterated anastomosis following radical prostatectomy. Carr LK, et al. **J Urol** 1996 Jul;156(1):70–2

Endoscopic evaluation and treatment of anastomotic strictures after radical retropubic prostatectomy [see comments] Dalkin BL. **J Urol** 1996 Jan;155(1):206–8. Comment in: J Urol 1996 Jan;155(1):226–7.

Urodynamic assessment of urethral sphincter function in post-prostatectomy incontinence. Gudziak MR, et al. **J Urol** 1996 Sep;156(3):1131–4; discussion 1134–5

Re: Synchronous management of anastomotic contracture and stress urinary incontinence following radical prostatectomy [letter] Morey AF, et al. **J Urol** 1995 Nov; 154(5):1871

Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy [see comments] Talja M, et al. **J Urol** 1995 Dec;154(6):2089–92 . Comment in: J Urol 1995 Dec;154(6):2093–5.

Acute myocardial infarction after prostatectomy [letter; comment] Hahn RG, et al. **Lancet** 1996 Feb 3;347(8997):335 . Comment on: Lancet 1995 Dec 9;346(8989):1521–4.

Haematogenous dissemination of prostate epithelial cells during surgery [letter; comment] Oefelein MG, et al. **Lancet** 1996 Feb 3;347(8997):324–5. Comment on: Lancet 1995 Dec 9;346(8989):1528–30.

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125–9, 133–4, 136 (18 ref.)

Management of erectile dysfunction after radical prostatectomy. Hall MC. **Semin Urol Oncol** 1995 Aug; 13(3):215–23 (46 ref.)

Prevention and treatment of incontinence after radical prostatectomy. Milam DF, et al. **Semin Urol Oncol** 1995 Aug;13(3):224–37 (50 ref.)

Postprostatectomy incontinence. Haab F, et al. **Urol Clin North Am** 1996 Aug;23(3):447–57 (70 ref.)

Management of rectal injury during perineal prostatectomy. Boeckmann W, et al. **Urol Int** 1995;55(3):147–9

Rhabdomyolysis and acute renal failure following radical perineal prostatectomy. Bruce RG, et al. **Urology** 1996 Mar; 47(3):427–30 (14 ref.)

Treatment of recurrent vesicourethral anastomotic stricture after radical prostatectomy with endourethroplasty. Chiou RK, et al. **Urology** 1996 Mar;47(3):422–5

A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Jønler M, et al. **Urology** 1996 Sep; 48(3):433–40

Incidence of inguinal hernias following radical retropubic prostatectomy. Regan TC, et al. **Urology** 1996 Apr; 47(4):536–7

[The TUR syndrome] Glogov S. **Khirurgiia (Sofiia)** 1995; 48(5):66–70 (32 ref.) (Eng. Abstr.) **(Bul)**

[Vena iliaca externa thrombosis after open operation of the bladder and prostate] Wu H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):502–4 (Eng. Abstr.) **(Chi)**

[Thromboembolic complications in urology] Krška Z, et al. **Sb Lek** 1995;96(2):121–30 (Eng. Abstr.) **(Cze)**

[Spontaneous resolution of urodynamically proven sphincter lesion following surgery for prostatic hyperplasia] Fuglsig S, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2126–8 (Eng. Abstr.) **(Dan)**

[Closure of a hypogastric urinary fistula after replacement enterocystoplasty with a flap of the rectus abdominis muscle] Gout A, et al. **J Urol (Paris)** 1995;101(2):89–92 (Eng. Abstr.) **(Fre)**

[Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto-prostatectomy] Llopis J, et al. **J Urol (Paris)** 1995;101(2):104–6 (Eng. Abstr.) **(Fre)**

[Rectal injuries in radical prostatectomies for cancer. Survey of the ANFUC (Association National de Formation Urologique Continue) 1994] Viville C. **J Urol (Paris)** 1995; 101(2):65–8 (Eng. Abstr.) **(Fre)**

[Results of treatment and quality of life after radical prostatectomy] Hinkelbein W, et al. **Strahlenther Onkol** 1995 Dec;171(12):717–8 **(Ger)**

[Iatrogenic injuries of the rectum] Ilijevski N, et al. **Vojnosanit Pregl** 1995 Jul-Aug;52(4):407–10 **(Scr)**

[Clinical and neuro-urodynamic assessment of radical prostatectomy] González-Chamorro F, et al. **Arch Esp Urol** 1996 Mar;49(2):125–31 (Eng. Abstr.) **(Spa)**

[Sand-clock lithiasis on prostatic transurethral resection bed] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Sep;48(7):743–6 (Eng. Abstr.) **(Spa)**

ECONOMICS

The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy. Keoghane SR, et al. **Br J Urol** 1996 Mar;77(3):386–90

Cost-effectiveness of laser ablation of the prostate. Premature evaluation. Jackson T, et al. **Int J Technol Assess Health Care** 1995 Summer; 11(3):595–610

An analysis of the costs of alternative treatments for benign prostatic hypertrophy. Vale JA, et al. **J R Soc Med** 1995 Nov;88(11):644P–648P

Cost-efficient radical prostatectomy with a clinical care path [see comments] Litwin MS, et al. **J Urol** 1996 Mar; 155(3):989–93. Comment in: J Urol 1996 Mar;155(3):1004.

Cell saver and radical retropubic prostatectomy: analysis of cost-effectiveness. Gilbert JB, et al. **Urology** 1995 Oct; 46(4):542–4

Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Klein EA, et al. **Urology** 1996 Aug;48(2):269–76

Same day surgery for radical retropubic prostatectomy: is it an attainable goal? Palmer JS, et al. **Urology** 1996 Jan; 47(1):23–8

INSTRUMENTATION

Multiple use of fibres in the visual laser ablation of the prostate. Gilbert HW, et al. **Br J Urol** 1996 Jun; 77(6):839–42

Transurethral Needle Ablation of the prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. Harewood LM, et al. **J Endourol** 1995 Oct;9(5):407–12

Electrovaporization of the prostate: new technique for treatment of symptomatic benign hyperplasia. Stewart SC, et al. **J Endourol** 1995 Oct;9(5):413–6

Holmium: YAG laser prostatectomy canine feasibility study. Kabalin JN. **Lasers Surg Med** 1996;18(3):221–4

Laparoscopic monitoring of cryosurgical ablation of the prostate. Sklar GN, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):376–81

An original balloon-expanding urethral suture guide for radical prostatectomy. Da Pozzo LF, et al. **Urology** 1995 Oct;46(4):562–4

Variation in output power of laser prostatectomy fibers: a

need for power measurements. Van Swol CF, et al. **Urology** 1996 May;47(5):672–7; discussion 677–8

[Mechanical autotransfusion also in transurethral resection of prostatic adenoma? Studies of preserved washed erythrocyte concentrates before possible retransfusion] Tumbass VE, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Mar; 31(2):77–84 (Eng. Abstr.) **(Ger)**

[The Urovac bladder evacuator: comparison with traditionally used devices] Fiore AA, et al.
Minerva Urol Nefrol 1995 Jun;47(2):97–8 (Eng. Abstr.) **(Ita)**

METHODS

A randomised single institution study comparing laser prostatectomy and transurethral resection of the prostate. Costello AJ, et al. **Ann Acad Med Singapore** 1995 Sep; 24(5):700–4

Prostate procedures [letter; comment] Moody J. **AORN J** 1995 Sep;62(3):334. Comment on: AORN J 1995 May;61(5):807–13; quiz 816–7, 819–20.

Treatment of priapism during transurethral resection of the prostate. Quinney N, et al. **Br J Hosp Med** 1995 Oct 18–31; 54(8):393–4

Induction androgen deprivation therapy before radical prostatectomy for prostate cancer—initial results. Abbas F, et al. **Br J Urol** 1996 Mar;77(3):423–8

Comparison of three different irrigation fluids used in transurethral prostatectomy based on plasma volume expansion and metabolic effects. Akan H, et al.
Br J Urol 1996 Aug;78(2):224–7

Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy. Bangma CH, et al. **Br J Urol** 1995 Nov;76(5):595–9

Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Dahlstrand C, et al. **Br J Urol** 1995 Nov;76(5):614–8

How complete is a transurethral resection of the prostate? Green JS, et al. **Br J Urol** 1996 Mar;77(3):398–400

Computer-controlled monitoring of bladder pressure in the prevention of 'TUR syndrome': a randomized study of 53 cases. Hubert J, et al. **Br J Urol** 1996 Aug;78(2):228–33

Is day-case prostatectomy feasible? Keoghane SR, et al.
Br J Urol 1995 Nov;76(5):600–3

The Oxford Laser Prostate Trial: a double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results. Keoghane SR, et al. **Br J Urol** 1996 Mar;77(3):382–5

Contact laser prostatectomy in anti-coagulated patients: mixed results. Keoghane SR, et al. **Br J Urol** 1996 Apr; 77(4):613–4

Fluid balance during transurethral resection of the prostate [letter] Lyon RP. **Br J Urol** 1996 Apr;77(4):617

Endoscopic rollerball electrovaporization of the prostate—the sandwich technique: evaluation of the initial efficacy and morbidity in the treatment of benign prostatic obstruction. Meade WM, et al. **Br J Urol** 1996 May; 77(5):696–700

Video-resection does not stop corneal contamination during transurethral resection of the prostate. Muir GH, et al.
Br J Urol 1996 Jun;77(6):836–8

The impact of pre-donated autologous blood and intra-operative isovolaemic haemodilution on the outcome of transfusion in patients undergoing radical retropubic prostatectomy. Nash PA, et al. **Br J Urol** 1996 Jun; 77(6):856–60

Femoral vein blood flow during transurethral resection of the prostate. Nilsson A, et al. **Br J Urol** 1996 Feb; 77(2):207–11

Isothermic irrigation during transurethral resection of the prostate: effects on peri-operative hypothermia, blood loss, resection time and patient satisfaction. Pit MJ, et al.
Br J Urol 1996 Jul;78(1):99–103

Impalpable prostate cancer: clinicopathological features. Rogers E, et al. **Br J Urol** 1996 Mar;77(3):429–32

The role of cystoscopy before radical prostatectomy. Schwartz BF, et al. **Br J Urol** 1996 Jan;77(1):93–5

A step towards day case prostatectomy. Suvakovic N, et al. **Br J Urol** 1996 Feb;77(2):212–4

Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? te Slaa E, et al.
Br J Urol 1996 Feb;77(2):228–32

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy. van Iersel MP, et al. **Br J Urol** 1996 Mar; 77(3):418–22

Blood loss during transurethral prostatic resection with continuous bladder irrigation. Lukojć K, et al.
Int Urol Nephrol 1995;27(6):753–5

Cryoprostatectomy consistently elevates serum creatine kinase-MB isoenzyme. Bokesch PM, et al.
J Clin Anesth 1996 May;8(3):175–9

Video-assisted percutaneous cystoscopy of the bladder and prostatic urethra in the dog: new approach for visual laser ablation of the prostate. Van Lue SJ, et al. **J Endourol** 1995 Dec;9(6):503–7

Comparing comorbid-illness indices assessing outcome variation: the case of prostatectomy. Krousel-Wood MA, et al. **J Gen Intern Med** 1996 Jan;11(1):32–8

Evaluation of fluid absorption during laser prostatectomy by breath ethanol techniques [see comments] Cummings JM, et al. **J Urol** 1995 Dec;154(6):2080–2. Comment in: J Urol 1995 Dec;154(6):2093–5.

Benign prostatic hyperplasia: practice makes perfect [editorial; comment] Dowd JB. **J Urol** 1996 Jan;155(1):190 . Comment on: J Urol 1996 Jan;155(1):176–80. Comment on: J Urol 1996 Jan;155(1):181–5. Comment on: J Urol 1996 Jan;155(1):186–9.

Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. Formenti SC, et al. **J Urol** 1996 Feb;155(2):616–9

Radical prostatectomy with preservation of urinary continence [see comments] Gaker DL, et al. **J Urol** 1996 Aug;156(2 Pt 1):445–9. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Radical retropubic prostatectomy: limited benefit of autologous blood donation. Goad JR, et al. **J Urol** 1995 Dec;154(6):2103–9

Applied stapling technique in radical retropubic prostatectomy: efficient, effective and efficacious. Gould DL, et al. **J Urol** 1996 Mar;155(3):1008–10

Transurethral needle ablation of the prostate: report of initial United States clinical trial [see comments] Issa MM.
J Urol 1996 Aug;156(2 Pt 1):413–9. Comment in: J Urol 1996 Aug;156(2 Pt 1):426–7.

Laser prostatectomy—what we have accomplished and future directions [editorial; comment] Kabalin JN.
J Urol 1995 Dec;154(6):2093–5. Comment on: J Urol 1995 Dec;154(6):2080–2. Comment on: J Urol 1995 Dec;154(6):2083–8. Comment on: J Urol 1995 Dec;154(6):2089–92.

Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients [see comments] Kabalin JN, et al. **J Urol** 1996 Jan;155(1):181–5. Comment in: J Urol 1996 Jan;155(1):190.

Radical prostatectomy: is complete resection of the seminal vesicles really necessary? Korman HJ, et al. **J Urol** 1996 Sep;156(3):1081–3

Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: the impact of surgical techniques [see comments] Mozes B, et al. **J Urol** 1996 Jan;155(1):191–6. Comment in: J Urol 1996 Jan;155(1):203–5.

A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia [see comments] Narayan P, et al. **J Urol** 1995 Dec;154(6):2083–8. Comment in: J Urol 1995 Dec;154(6):2093–5.

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. Parra RO, et al. **J Urol** 1996 Feb;155(2):612–5

New use of Foley catheter for precise vesicourethral anastomosis during radical retropubic prostatectomy. Petroski RA, et al. **J Urol** 1996 Apr;155(4):1376–7

Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation [see comments] Smith RC, et al. **J Urol** 1996 Aug;156(2 Pt 1):454–7; discussion 457–8. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy [see comments] Talja M, et al. **J Urol** 1995 Dec;154(6):2089–92 . Comment in: J Urol 1995 Dec;154(6):2093–5.

Re: Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach [letter; comment] Walsh PC. **J Urol** 1996 Jan;155(1):294. Comment on: J Urol 1995 Jun;153(6):1875–7.

Acute myocardial infarction after prostatectomy [letter; comment] Hahn RG, et al. **Lancet** 1996 Feb 3;347(8997):335 . Comment on: Lancet 1995 Dec 9;346(8989):1521–4.

Early clinical experience with percutaneous cryosurgical ablation of the prostate. Hawatmeh AS, et al. **Mo Med** 1995 Nov;92(11):705–9

Preventive wire ligature of venae dorsales penis in radical retropubic surgery. Simon V, et al. **Sb Lek** 1995;96(1):23–6

Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS.
Semin Urol Oncol 1995 Aug;13(3):204–14 (47 ref.)

Cryosurgery of the prostate: techniques and pitfalls. Zippe CD. **Urol Clin North Am** 1996 Feb;23(1):147–63 (11 ref.)

Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Gilling PJ, et al. **Urology** 1996 Jan;47(1):48–51

Transurethral enzymatic ablation of the prostate: canine model. Harmon WJ, et al. **Urology** 1996 Aug;48(2):229–33

The Oxford Laser Prostate Trial: sensitivity to change of three measures of outcome. Keoghane SR, et al.
Urology 1996 Jan;47(1):43–7

Laser prostatectomy: two and a half years' experience with aggressive multifocal therapy. Kollmorgen TA, et al.
Urology 1996 Aug;48(2):217–22

Radical prostatectomy: the retropubic approach [editorial] Oesterling JE. **Urology** 1996 Apr;47(4):460–2

Laser-tissue interactions during laser prostatectomy. Razvi H, et al. **Urology** 1996 Jul;48(1):133–4

Radical prostatectomy: the perineal approach [editorial] Resnick MI. **Urology** 1996 Apr;47(4):457–9

Improved continence with tubularized bladder neck reconstruction following radical retropubic prostatectomy. Seaman EK, et al. **Urology** 1996 Apr;47(4):532–5

[Blood loss during transurethral resection of the prostate] Miskowiak J, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3924–7 (Eng. Abstr.) **(Dan)**

[Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results] Hermans BP, et al.
Acta Urol Belg 1996 Mar;64(1):27–31 **(Fre)**

[Simplified vesico-urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**

[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Sexual function after transurethral prostate resection] Lunglmayr G. **Wien Med Wochenschr** 1996;146(8):175–7 (Eng. Abstr.) **(Ger)**

[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

[The role of laparoscopy in the management of prostatic cancer] Haas GP, et al. **Orv Hetil** 1995 Sep 10; 136(37):2005–7 (Eng. Abstr.) **(Hun)**

[Results of transurethral resection of prostate plus incision (TUR-P+I) for benign prostatic hypertrophy] Ishizaka K, et al. **Hinyokika Kiyo** 1996 Mar;42(3):207–11 (Eng. Abstr.) **(Jpn)**

[A basic study of the interstitial laser prostatectomy using pulsed holmium: yttrium-aluminum-garnet (Ho:YAG) laser] Daidoh Y. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):650–9 (Eng. Abstr.) **(Jpn)**

[Transurethral endoscopic dissection of the bladder neck and prostate] Martov AG, et al. **Urol Nefrol (Mosk)** 1995 Jul-Aug;(4):29–31 (Eng. Abstr.) **(Rus)**

[Trigono-cervico-prostatotomy (TCP) versus transurethral resection of the prostate (TURP). Our experience] Arceo Santiago R, et al. **Arch Esp Urol** 1995 Oct;48(8):823–6; discussion 827 (Eng. Abstr.) **(Spa)**

[Rebirth of perineal prostatectomy in the era of laparoscopic lymphadenectomy] Ruiz Quijano RA, et al.
Bol Asoc Med P R 1995 Jul-Sep;87(7–9):130–4 (Eng. Abstr.) **(Spa)**

[TUV-p is a logical name for the new treatment of prostatic hypertrophy (letter)] Nilsson S. **Lakartidningen** 1995 Nov 22;92(47):4405 **(Swe)**

MORTALITY

Mortality after transurethral and open prostatectomy in Scotland. Hargreave TB, et al. **Br J Urol** 1996 Apr; 77(4):547–53

Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [letter; comment] Thompson IM. **Cancer** 1996 Jul 1; 78(1):181–2. Comment on: Cancer 1995 Dec 15;76(12):2535–42.

Mortality after prostatectomy: selection and surgical approach [see comments] Seagroatt V. **Lancet** 1995 Dec 9;346(8989):1521–4. Comment in: Lancet 1996 Feb 3;347(8997):335.

Transurethral prostatectomy: mortality and morbidity. Horninger W, et al. **Prostate** 1996 Mar;28(3):195–200

[Recent improvements and results of radical prostatectomy] Usami M. **Gan To Kagaku Ryoho** 1996 Mar;23(4):407–12 (20 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Additional therapy after prostatectomy: implications for patient counseling [editorial] Chodak GW.
J Natl Cancer Inst 1996 Feb 21;88(3–4):139–40

REHABILITATION

The effect of prostatectomy on symptom severity and quality of life. Emberton M, et al. **Br J Urol** 1996 Feb;77(2):233–47

STANDARDS

Two-dimensional outcome analysis as a guide for quality assurance of prostatectomy. Cohen YC, et al.
Int J Qual Health Care 1996 Feb;8(1):67–73

Influence of patient age and co-morbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. Koch MO, et al. **J Urol** 1996 May; 155(5):1681–4

Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Klein EA, et al. **Urology** 1996 Aug;48(2):269–76

[Indications for radical prostatectomy in the US] Sack H.
Strahlenther Onkol 1995 Dec;171(12):715 **(Ger)**

STATISTICS & NUMERICAL DATA

Radical prostatectomy: prospective assessment of mortality and morbidity. Davidson PJ, et al. **Eur Urol** 1996; 29(2):168–73

[The frequency of surgery of benign prostatic hypertrophy] Janin P, et al. **Prog Urol** 1995 Sep;5(4):515–21 (Eng. Abstr.) **(Fre)**

TRENDS

[New horizons of radical prostatectomy in the treatment of localized prostatic cancer (editorial)] Solsona Narbón E.
Actas Urol Esp 1995 Mar;19(3):175–9 **(Spa)**

UTILIZATION

International variation in intervention rates. What are the implications for patient selection? Black N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):719–32

VETERINARY

Inadvertent prostatectomy as a complication of cryptorchidectomy in four dogs. Schulz KS, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):211–4

PROSTATECTOMY, TRANSURETHRAL see **PROSTATECTOMY**

PROSTATIC ADENOMA see **PROSTATIC HYPERPLASIA**

PROSTATIC DISEASES

Tumors of the bladder and prostatic diseases. Papers dedicated to Hans Wolf on the occasion of his 60th birthday. **Scand J Urol Nephrol Suppl** 1995;172:1–115

[Prostatic abscess: diagnosis and treatment] Franco A, et al. **Actas Urol Esp** 1996 Feb;20(2):189–92 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Acute retention of urine due to prostatic a abscess. Kundu AK, et al. **Trop Doct** 1995 Oct;25(4):186

Staphylococcus periprostatic abscess: an unusual cause of acute urinary retention. Savariraiyan S, et al. **Urology** 1995 Oct;46(4):573–4

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Prostatic cyst. An unusual but important finding in male urogenital dysfunction. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):345–9 (30 ref.)

DIAGNOSIS

Concerning the article by Terasaki T, Watanabe H, et al. Eur Urol 1995;27:280–285. Magnetic resonance angiography in prostatodynia [letter; comment] Barbalias GA. **Eur Urol** 1995;28(4):348. Comment on: Eur Urol 1995;27(4):280–5.

Reliability of volume or age–adjusted prostate specific antigen to improve diagnostic accuracy. Ciatto S, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):226–8

Prostate disease potpourri—measurement reliability, therapeutic effectiveness and pathophysiological diagnosis [editorial] Barry MJ. **J Urol** 1996 Apr;155(4):1309–10

Contrast–enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

Tuberculosis of the prostate: MR imaging. Tajima H, et al. **Radiat Med** 1995 Jul–Aug;13(4):171–3

GENETICS

Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. McGarvey TW, et al. **Exp Mol Pathol** 1995 Aug;63(1):52–62

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Wertz IE, et al. **Hum Pathol** 1996 Jun;27(6):573–80

METABOLISM

A guide to the interpretation of serum prostate specific antigen levels. Bunting PS. **Clin Biochem** 1995 Jun; 28(3):221–41 (174 ref.)

Expression of estrogen receptor in diseased human prostate assessed by non–radioactive in situ hybridization and immunohistochemistry. Ehara H, et al. **Prostate** 1995 Dec; 27(6):304–13

MICROBIOLOGY

Tuberculous abscess of the prostate in AIDS [letter] Wolf LE. **Ann Intern Med** 1996 Jul 15;125(2):156

PATHOLOGY

Reproducibility of prostate volume measurements from transrectal ultrasonography by an automated and a manual technique. Aarnink RG, et al. **Br J Urol** 1996 Aug; 78(2):219–23

Antimicrobial prophylaxis for transrectal prostatic biopsy [letter] Anjum MI, et al. **Br J Urol** 1996 Apr;77(4):618–9

Infection after transrectal core biopsies of the prostate—risk factors and antibiotic prophylaxis. Aus G, et al. **Br J Urol** 1996 Jun;77(6):851–5

Digitally–guided prostatic biopsies—the Sheffield biopsy guide. Woo HH, et al. **Br J Urol** 1996 Jan;77(1):152

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Wertz IE, et al. **Hum Pathol** 1996 Jun;27(6):573–80

Cytohistomorphology of prostatic lesions—by FNAC & scrape methods. Iyer M, et al. **Indian J Cancer** 1994 Sep; 31(3):185–91

[Malacoplakia of the prostate: report of a case] Iwaki H, et al. **Hinyokika Kiyo** 1995 Nov;41(11):895–7 (Eng. Abstr.) **(Jpn)**

[Malacoplakia of the prostate and seminal vesicle. Ultrastructural study and review of the literature] Sánchez Chapado M, et al. **Arch Esp Urol** 1995 Oct;48(8):775–8 (34 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Prostatic calcifications detected on Tc–99m MDP bone scan mimicking bone metastasis. Campeau NG, et al. **Clin Nucl Med** 1996 Jan;21(1):24–6

SURGERY

Life threatening secondary haemorrhage following endoscopic laser ablation of the prostate in an anti–coagulated patient. Bellringer JF, et al. **Br J Urol** 1996 Mar;77(3):463–4

Expired breath ethanol measurement to calculate irrigating fluid absorption during transurethral resection of the prostate: experience in a district general hospital. Checketts MR, et al. **Br J Urol** 1996 Feb;77(2):198–202

Long–term predictive role of urodynamics: an 8–year follow–up of prostatic surgery for lower urinary tract symptoms. Jensen KM, et al. **Br J Urol** 1996 Aug; 78(2):213–8

Is day–case prostatectomy feasible? Keoghane SR, et al. **Br J Urol** 1995 Nov;76(5):600–3

Urodynamic study of laser ablation of the prostate [letter; comment] Keoghane SR, et al. **Br J Urol** 1996 Jan; 77(1):169–70. Comment on: Br J Urol 1995 Aug;76(2):179–83.

The posterior sagittal approach for the excision of a prostatic utricle cyst. Keramidas DC, et al. **Br J Urol** 1995 Sep; 76(3):397–8

Cost–effectiveness of laser ablation of the prostate. Premature evaluation. Jackson T, et al. **Int J Technol Assess Health Care** 1995 Summer; 11(3):595–610

Transurethral marsupialization of a medial prostatic cyst in patients with prostatitis–like symptoms. Dik P, et al. **J Urol** 1996 Apr;155(4):1301–4

[Posterior trans–anal–sphincter approach in the management of urethro–prostate–rectal fistula] Fournier R, et al. **J Urol (Paris)** 1996;102(2):75–8 (Eng. Abstr.) **(Fre)**

THERAPY

The benefits of a shared–care prostate clinic. Booth CM, et al. **Br J Urol** 1996 Jun;77(6):830–5

Minimal invasive therapy of prostatic abscess by transrectal ultrasound–guided perineal drainage. Bachor R, et al. **Eur Urol** 1995;28(4):320–4

[Transrectal ultrasound–controlled needle aspiration of a prostatic cyst] Pinthus JH, et al. **Harefuah** 1996 Mar 1; 130(5):310–3, 359 (Eng. Abstr.) **(Heb)**

ULTRASONOGRAPHY

Transrectal ultrasonography of the prostate. el Din KE, et al. **Br J Urol** 1996 Jul;78(1):2–9 (64 ref.)

The use of transrectal ultrasonography in the diagnosis of urethroprostatic reflux. Turner PJ, et al. **Br J Urol** 1996 Feb;77(2):314–5

[Transrectal ultrasound–controlled needle aspiration of a prostatic cyst] Pinthus JH, et al. **Harefuah** 1996 Mar 1; 130(5):310–3, 359 (Eng. Abstr.) **(Heb)**

VETERINARY

Mineralized paraprostatic cyst in a dog. Girard C, et al. **Can Vet J** 1995 Sep;36(9):573–4

Intracapsular prostatic omentalization: a new technique for management of prostatic abscesses in dogs. White RA, et al. **Vet Surg** 1995 Sep–Oct;24(5):390–5

PROSTATIC HYPERPLASIA

Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Harper ME, et al. **Eur J Cancer** 1995;31A(9):1492–7

Benign prostatic hyperplasia [editorial] Bueschen AJ. **J Urol** 1996 Apr;155(4):1328

Benign prostatic hyperplasia: practice makes perfect [editorial; comment] Dowd JB. **J Urol** 1996 Jan;155(1):190 . Comment on: J Urol 1996 Jan;155(1):176–80. Comment on: J Urol 1996 Jan;155(1):181–5. Comment on: J Urol 1996 Jan;155(1):186–9.

Complications of invasive, urodynamic examinations and prostate biopsies in patients with benign prostatic hyperplasia. Berge V, et al. **Scand J Urol Nephrol Suppl** 1995;172:95–8

Controversies about the clinical assessment of benign prostatic hyperplasia. Riehmann M, et al. **Scand J Urol Nephrol Suppl** 1995;172:81–94 (155 ref.)

[Basic study in the natural history of benign prostatic hyperplasia: biology of prostatic growth] Sugimura Y. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):721–39 (157 ref.) **(Jpn)**

BLOOD

Prostate–specific antigen levels in patients receiving long–term dialysis. Harper L, et al. **Br J Urol** 1995 Oct; 76(4):482–3

Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Correale M, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):24–8

Prostate–specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ–confined prostate carcinoma and advanced prostate carcinoma. Işikay L, et al. **Int Urol Nephrol** 1995; 27(6):757–61

Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. Cussenot O, et al. **J Urol** 1996 Apr;155(4):1340–3

A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Prestigiacomo AF, et al. **J Urol** 1996 Aug;156(2 Pt 1):350–4

Evaluation of percentage of free serum prostate–specific antigen to improve specificity of prostate cancer screening [see comments] Catalona WJ, et al. **JAMA** 1995 Oct 18; 274(15):1214–20. Comment in: JAMA 1996 Mar 20;275(11):837–8.

Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. Dutkiewicz S. **Mater Med Pol** 1995 Jan–Mar; 27(1):15–7

Prostate specific antigen in a community–based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Bosch JL, et al. **Prostate** 1995 Nov;27(5):241–9

Serum concentrations of prostate–specific antigen after diagnostic procedures and transurethral microwave thermotherapy of benign prostatic hyperplasia. Daehlin L, et al. **Scand J Clin Lab Invest** 1996 May;56(3):269–73

Reference range of prostate–specific antigen after transurethral resection of the prostate. Aus G, et al. **Urology** 1996 Apr;47(4):529–31

Early detection of prostate cancer in men with prostatism and intermediate prostate–specific antigen levels. Schmid HP, et al. **Urology** 1996 May;47(5):699–703

[Activity of protein C in blood of patients with prostatic carcinoma] Iwan–Ziętek I, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):94–5 (Eng. Abstr.) **(Pol)**

[Activity of alpha 1–antitrypsin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):89–90 (Eng. Abstr.) **(Pol)**

[Antithrombin III and alpha 2–antiplasmin in blood of patients operated on for benign prostatic hyperplasia] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):75–6 (Eng. Abstr.) **(Pol)**

[Activity of alpha 1–antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):77–8 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Induction of atypical hyperplasia, apoptosis, and type II estrogen–binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol–17 beta. Ho SM, et al. **Lab Invest** 1995 Sep; 73(3):356–65

Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Winter ML, et al. **Toxicol Appl Pharmacol** 1996 Feb; 136(2):211–9

COMPLICATIONS

Association between family history of benign prostatic hyperplasia and urinary symptoms: results of a population–based study. Roberts RO, et al. **Am J Epidemiol** 1995 Nov 1;142(9):965–73

The ICS–'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Donovan JL, et al. **Br J Urol** 1996 Apr;77(4):554–62

A new technique for detrusor biopsy and its applicability in the ultrastructural study and diagnosis of voiding dysfunction. Holm NR, et al. **Br J Urol** 1996 Jun; 77(6):785–91

The significance of terminal dribbling in men with lower urinary tract symptoms. Reynard JM, et al. **Br J Urol** 1996 May;77(5):705–10

Evaluation of a tubular mesh and a spiral stent woven from titanium nickel alloy for prostatic obstruction in patients at high risk for surgery. Report of 62 cases. Sun Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):769–73

Epidemiological and clinical aspects of incidental carcinoma of the prostate in Africans: experience at the Lagos University Teaching Hospital, Lagos and the Kenyatta National Hospital, Nairobi. Magoha GA. **East Afr Med J** 1995 May;72(5):283–7

Assessment of sextant biopsy of the prostate for detecting cancer prior to therapy in patients clinically diagnosed as benign prostatic hyperplasia. Egawa S, et al. **Int J Urol** 1995 May;2(2):110–5

The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score [see comments] el Din KE, et al. **J Urol** 1996 Sep;156(3):1020–5. Comment in: J Urol 1996 Sep;156(3):1040–1.

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. Jacobsen SJ, et al. **J Urol** 1996 Feb;155(2):595–600

Do reported micturition symptoms on the American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings? [see comments] Matzkin H, et al. **J Urol** 1996 Jan;155(1):197–9. Comment in: J Urol 1996 Jan;155(1):203–5.

The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report [see comments] Puchner PJ, et al. **J Urol** 1995 Nov;154(5):1779–82. Comment in: J Urol 1995 Nov;154(5):1783–4.

Re: Editorial: benign prostatic hyperplasia [letter; comment] Schäfer W. **J Urol** 1996 Jan;155(1):293. Comment on: J Urol 1995 May;153(5):1540–2.

The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. van Venrooij GE, et al. **J Urol** 1996 Jun;155(6):2014–8

Some observations on a condition of relatively lower detrusor contractility in stable versus unstable unobstructed bladders. Cucchi A. **Neurourol Urodyn** 1995;14(4):317–24

Comparison of passive urethral resistance relation and urethral resistance factor in analysis of bladder outlet obstruction in patients with benign prostatic enlargement. Rosier PF, et al. **Neurourol Urodyn** 1996;15(1):1–10; discussion 10–5

A unifying hypothesis that links benign prostatic hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Invited comments. Harvey H. **Pathol Res Pract** 1995 Sep; 191(9):924–34

Night-time polyuria and nocturia. Matthiesen TB, et al. **Scand J Urol Nephrol Suppl** 1995;173:81–2

Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Dahm TL, et al. **Urol Int** 1995;55(4):205–8

Correlation of transrectal ultrasonographic findings of the prostate with the occurrence of detrusor instability in patients with benign prostatic hyperplasia. Tong YC, et al. **Urol Int** 1995;55(3):154–7

Laser prostatectomy: two and a half years' experience with aggressive multifocal therapy. Kollmorgen TA, et al. **Urology** 1996 Aug;48(2):217–22

[Sexual consequences of benign prostatic hyperplasia] Kawaciuk I, et al. **Rozhl Chir** 1995 Nov;74(7):348–56 (Eng. Abstr.) **(Cze)**

[Problems with urination? (letter)] Hansen BJ. **Ugeskr Laeger** 1996 May 20;158(21):2999–3000 **(Dan)**

[Urination disorders in HIV infected patients] Hermieu JF, et al. **Presse Med** 1995 Sep 30;24(28):1287–90 (Eng. Abstr.) **(Fre)**

[General practitioners' approach to urination disorders in men over the age of 50. A survey of 250 physicians in Brittany] Coeurdacier P, et al. **Prog Urol** 1996 Feb; 6(1):52–9 (Eng. Abstr.) **(Fre)**

[The importance and significance of post-micturitional bladder residue in the evaluation of prostatism] Leblanc G, et al. **Prog Urol** 1995 Sep;5(4):511–4 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Management of BPH: educating patients about PSA [letter; comment] Malvea BP. **Am Fam Physician** 1996 Mar; 53(4):1080, 1082. Comment on: Am Fam Physician 1995 Jul;52(1):135–42, 145–6.

Interstitial cystitis misdiagnosed as benign prostatic hyperplasia [letter; comment] Reynolds FP. **Am Fam Physician** 1995 Nov 1;52(6):1684. Comment on: Am Fam Physician 1995 Jul;52(1):135–42, 145–6.

Current assessment and proposed staging of patients with benign prostatic hyperplasia. Foo KT. **Ann Acad Med Singapore** 1995 Jul;24(4):648–51

Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Hansen BJ, et al. **Br J Urol** 1995 Oct;76(4):451–8

Measurement properties of the AUA symptom score: a methodological clarification. Lawrence K. **Br J Urol** 1996 Feb;77(2):175–80 (25 ref.)

The symptom questionnaire for benign prostatic hyperplasia: an ambiguous indicator for an ambiguous disease. Stoevelaar HJ, et al. **Br J Urol** 1996 Feb;77(2):181–5

Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Thomas SA, et al. **Br J Urol** 1996 Mar;77(3):367–72

Benign prostatic hyperplasia: an approach for the internist. Zippe CD. **Cleve Clin J Med** 1996 Jul-Aug;63(4):226–36 (23 ref.)

The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Akdas A, et al. **Eur Urol** 1996; 29(2):189–92

Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. Devine PL, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):221–5

Usefulness of PSA density and PSA excess in the differential diagnosis between prostate cancer and benign prostatic hypertrophy. Diaz F, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):12–7

Phyllodes type of atypical prostatic hyperplasia. Fujita K, et al. **Int J Urol** 1996 Mar;3(2):158–60

Vimentin and cytokeratin expression in nodular hyperplasia and carcinoma of the prostate. Heatley M, et al. **J Clin Pathol** 1995 Nov;48(11):1031–4

Comparison of transrectal ultrasound prostatic volume estimation with magnetic resonance imaging volume estimation and surgical specimen weight in patients with benign prostatic hyperplasia. Tewari A, et al. **J Clin Ultrasound** 1996 May;24(4):169–74

Balloon dilation of the prostate: correlation with magnetic resonance imaging and transrectal ultrasound findings. Renfer L, et al. **J Endourol** 1995 Jun;9(3):283–6

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?[see comments] Barry MJ, et al. **J Urol** 1995 Nov; 154(5):1770–4. Comment in: J Urol 1995 Nov;154(5):1783–4.

Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia [see comments] el Din KE, et al. **J Urol** 1996 Jun;155(6):1959–64 . Comment in: J Urol 1996 Jun;155(6):1975–6.

Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia [editorial; comment] Jonas U, et al. **J Urol** 1996 Sep;156(3):1040–1 . Comment on: J Urol 1996 Sep;156(3):1020–5. Comment on: J Urol 1996 Sep;156(3):1026–34. Comment on: J Urol 1996 Sep;156(3):1035–9.

The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? [see comments] Kaplan SA, et al. **J Urol** 1996 Jun;155(6):1971–4. Comment in: J Urol 1996 Jun;155(6):1975–6.

Correlation between the International Prostatic Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia [see comments] Netto Júnior NR, et al. **J Urol** 1996 Jan;155(1):200–2. Comment in: J Urol 1996 Jan;155(1):203–5.

Fine-tuning the indication for prostatectomy [editorial; comment] Roehrborn CG. **J Urol** 1996 Jan;155(1):203–5. Comment on: J Urol 1996 Jan;155(1):191–6. Comment on: J Urol 1996 Jan;155(1):197–9. Comment on: J Urol 1996 Jan;155(1):200–2.

The American Urological Association symptom index—concerns and confirmation [editorial; comment] Roehrborn CG. **J Urol** 1996 Jun;155(6):1975–6. Comment on: J Urol 1996 Jun;155(6):1959–64. Comment on: J Urol 1996 Jun;155(6):1965–70. Comment on: J Urol 1996 Jun;155(6):1971–4.

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Schmid HP. **J Urol** 1996 Jan; 155(1):294–5. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Venous obstruction due to a distended urinary bladder. Evans JM, et al. **Mayo Clin Proc** 1995 Nov;70(11):1077–9 (17 ref.)

Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Kurhanewicz J, et al. **Radiology** 1996 Mar; 198(3):795–805

Does anamnestic symptom evaluation or clinical examination give enough information to evaluate the severity of obstruction in benign prostatic hyperplasia? Waldén M, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):469–76

The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Plante M, et al. **Urology** 1996 Mar; 47(3):326–8

Prostate-specific antigen density—a reliable parameter for the detection of prostate cancer? Thon WF, et al. **World J Urol** 1996;14(1):53–8

[Subjective symptoms before and after prostate surgery. The International Symptom Scoring System, I-PSS] Kawaciuk I, et al. **Rozhl Chir** 1995 Nov;74(7):334–8 (Eng. Abstr.) **(Cze)**

[Diagnosis and treatment of benign prostatic hyperplasia in the North Bohemia Region in 1994] Mečl J. **Rozhl Chir** 1995 Nov;74(7):373–5 (Eng. Abstr.) **(Cze)**

[Evaluation of symptoms in patients with benign prostatic hyperplasia] Riehmann M, et al. **Ugeskr Laeger** 1996 May 13;158(20):2853–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Variation in the diagnosis and treatment of benign prostatic hyperplasia in urological practice] Stoevelaar HJ, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):837–42 (Eng. Abstr.) **(Dut)**

[Validation of a French adaptation of the international prostatic symptom score] Grégoire JP, et al. **Prog Urol** 1996 Apr;6(2):240–9 (Eng. Abstr.) **(Fre)**

[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan–Feb; 147(1-2):51–66 (29 ref.) (Eng. Abstr.) **(Ita)**

[A study on international prostate symptom score in the assessment of therapeutic effects and severity of symptoms due to benign prostatic hyperplasia] Okajima E, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1466–74 (Eng. Abstr.) **(Jpn)**

[Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer] Uno H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1776–83 (Eng. Abstr.) **(Jpn)**

[The international system of overall scoring assessment of the symptoms and quality of life of patients with benign prostatic hyperplasia] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):2–4 (Eng. Abstr.) **(Rus)**

[PSA levels and its relationship with digital examination, age, and score of prostatic symptoms] Pereiro M, et al. **Actas Urol Esp** 1996 Feb;20(2):149–54 (Eng. Abstr.) **(Spa)**

[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] Sánchez Sánchez E, et al. **Actas Urol Esp** 1995 Mar;19(3):181–6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Finasteride in the treatment of benign prostatic hyperplasia. Ekman P, et al. **Acta Urol Belg** 1996 Mar;64(1):IX–XII

Pharmacotherapy in benign prostatic hyperplasia. Tan EC. **Ann Acad Med Singapore** 1995 Jul;24(4):615–8 (35 ref.)

Current treatment of BPH. Roylance P, et al. **Biomed Pharmacother** 1995;49(7–8):332–8 (68 ref.)

Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr–May;50(3):154–63 (70 ref.)

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Abrams P, et al. **Br J Urol** 1995 Sep;76(3):325–36

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Byrnes CA, et al. **Clin Ther** 1995 Sep–Oct;17(5):956–69

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455–9 (23 ref.)

Finasteride and benign prostatic hyperplasia. **Drug Ther Bull** 1995 Mar;33(3):19–21 (24 ref.)

Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374–84 (52 ref.)

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Chapple CR, et al. **Eur Urol** 1996;29(2):155–67

Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Chapple CR. **Eur Urol** 1996;29(2):129–44 (67 ref.)

Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Kaplan SA, et al. **Eur Urol** 1995;28(3):223–8

Proscar: five-year experience. Moore E, et al. **Eur Urol** 1995; 28(4):304–9

Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Onu PE. **Eur Urol** 1995;28(3):229–35

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Schulman CC, et al. **Eur Urol** 1996; 29(2):145–54

Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia. Yoshida O, et al. **Hinyokika Kiyo** 1996 Apr;42(4):323–31

Doxazosin—an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two). Dutkiewicz S, et al. **Int Urol Nephrol** 1995;27(4):413–7

Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Dutkiewicz S. **Int Urol Nephrol** 1996; 28(1):49–53

Doxazosin—an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). Dutkiewicz S, et al. **Int Urol Nephrol** 1995; 27(3):311–8

Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy [editorial] Bredin HC. **Ir Med J** 1996 May–Jun;89(3):86, 88

Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. Montironi R, et al. **J Clin Pathol** 1996 Apr;49(4):324–8

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia [letter; comment] Hansen BJ. **J Urol** 1996 Jul;156(1):184–5. Comment on: J Urol 1995 Sep;154(3):923–34.

The effect of low dose finasteride therapy in a man with prostatism. Sullivan MJ, et al. **J Urol** 1996 Feb;155(2):652

Urodynamic and clinical effects of terazosin therapy in

patients with symptomatic benign prostatic hyperplasia. Witjes WP, et al. **J Urol** 1996 Apr;155(4):1117–23

Treatment of benign prostatic hyperplasia. The Scandinavian BPH Study Group [letter] Andersen JT. **Lancet** 1996 May 4;347(9010):1270

Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. Dutkiewicz S. **Mater Med Pol** 1995 Jan–Mar; 27(1):15–7

Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential. Dutkiewicz S. **Mater Med Pol** 1995 Jan–Mar;27(1):3–6 (41 ref.)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments] Lepor H, et al. N **Engl J Med** 1996 Aug 22;335(8):533–9 . Comment in: N Engl J Med 1996 Aug 22;335(8):586–7.

Treatment of benign prostatic hyperplasia [editorial; comment] Walsh PC. N **Engl J Med** 1996 Aug 22; 335(8):586–7. Comment on: N Engl J Med 1996 Aug 22;335(8):533–9.

Analyzing finasteride data. Frankel S. **Neurourol Urodyn** 1995;14(6):619–24

Effects of finasteride on health–related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. Girman CJ, et al. **Prostate** 1996 Aug; 29(2):83–90

Effect of aromatase inhibitor, TZA–2209, on the prostate of androstenedione–treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328–37

Effects of a new steroidal antiandrogen, TZP–4238 (17 alpha–acetoxy–6–chloro–2–oxa–4, 6–pregnadiene–3, 20–dione), on spontaneously developed canine benign prostatic hyperplasia. Takezawa Y, et al. **Prostate** 1995 Dec;27(6):321–8

5alpha–reductase inhibitors/finasteride. Stoner E. **Prostate Suppl** 1996;6:82–7 (28 ref.)

1st Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, 27–30 September 1995, and Synthelabo Symposium Alpha 1–blockers in BPH Uroselectivity and Quality of Life. Abstracts. **Therapie** 1995;Suppl:S1–191

Can finasteride reverse the progress of benign prostatic hyperplasia? A two–year placebo–controlled study. The Scandinavian BPH Study Group. Andersen JT, et al. **Urology** 1995 Nov;46(5):631–7

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta–analysis of randomized clinical trials. Boyle P, et al. **Urology** 1996 Sep; 48(3):398–405

A multicenter, randomized, double–blind, placebo–controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Elhilali MM, et al. **Urology** 1996 Mar;47(3):335–42

Transurethral enzymatic ablation of the prostate: canine model. Harmon WJ, et al. **Urology** 1996 Aug;48(2):229–33

A dose–response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Narayan P, et al. **Urology** 1996 Apr;47(4):497–504

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double–blind, placebo–controlled studies. Roehrborn CG, et al. **Urology** 1996 Sep;48(3):406–15

The Hytrin Community Assessment Trial study: a one–year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Roehrborn CG, et al. **Urology** 1996 Feb;47(2):159–68

[The current principles of the conservative treatment of patients with benign prostatic hypertrophy] Ianev V, et al. **Khirurgiia (Sofiia)** 1994;47(3):36–8 (19 ref.) (Eng. Abstr.) **(Bul)**

[Indications of antiandrogens in benign hyperplasia of the prostate (letter)] Benassayag E. **J Urol (Paris)** 1995; 101(2):109–10 **(Fre)**

[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Pharma–clinics. Drug of the month. Terazosine (Hytrin)] Scheen AJ. **Rev Med Liege** 1995 Dec;50(12):540–1 **(Fre)**

[Drug treatment of benign prostatic hyperplasia (editorial)] Schmid HP. **Schweiz Rundsch Med Prax** 1995 Sep 26; 84(39):1061–2 **(Ger)**

[The effect of 5–alpha–reductase inhibitors on benign prostatic hyperplasia] Djavan B, et al. **Wien Med Wochenschr** 1996;146(8):165–8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161–4 (12 ref.) (Eng. Abstr.) **(Ger)**

[Multicenter clinical study of the effects of once daily administration of mepartricin 150.000 U. in benign prostatic hypertrophy] Pisani E. **Arch Ital Urol Androl** 1995 Sep; 67(4):223–30 (Eng. Abstr.) **(Ita)**

[Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial] Mirone V, et al. **Minerva Med** 1996 Apr;87(4):147–54 (Eng. Abstr.) **(Ita)**

[Mepartricin in BPH. A new dosage approach] Prezioso D, et al. **Minerva Urol Nefrol** 1996 Jun;48(2):117–20 (Eng. Abstr.) **(Ita)**

[Permixon in the treatment of benign prostatic hyperplasia] Gorilovskil LM. **Ter Arkh** 1995;67(8):62–4 **(Rus)**

[The long–term treatment of patients with benign prostatic hyperplasia using Proscar] Lopatkin NA, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):2–4 (Eng. Abstr.) **(Rus)**

[A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia] Pushkar' DIu, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):32–5 (Eng. Abstr.) **(Rus)**

[The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)] Stepanov VN, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):28–30 (Eng. Abstr.) **(Rus)**

ECONOMICS

An analysis of the costs of alternative treatments for benign prostatic hypertrophy. Vale JA, et al. **J R Soc Med** 1995 Nov;88(11):644P–648P

Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. Chirikos TN, et al. **J Urol** 1996 Apr;155(4):1311–6

Is medical therapy an expensive way for delaying surgery in BPH patients? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):177–84 (20 ref.)

An estimate of the life–time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Ahlstrand C, et al. **Scand J Urol Nephrol** 1996 Feb; 30(1):37–43

Economic modeling to assess the costs of treatment for benign prostatic hyperplasia [letter; comment] Ansong KS. **Urology** 1996 Jan;47(1):152. Comment on: Urology 1995 Oct;46(4):477–83.

The cost–effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Hillman AL, et al. **Urology** 1996 Feb; 47(2):169–78

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia [see comments] Lowe FC, et al. **Urology** 1995 Oct;46(4):477–83. Comment in: Urology 1996 Jan;47(1):152.

ENZYMOLOGY

Characterization of 17beta–hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Elo JP, et al. **Int J Cancer** 1996 Mar 28;66(1):37–41

5 alpha–reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. Smith CM, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1361–6

Characterization and solubilization of testosterone 17 beta–hydroxysteroid dehydrogenase in human hyperplastic prostate. Carre JL, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):265–7

Kinetic analysis of steroid 5alpha–reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. Span PN, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):103–8

Expression of transcripts encoding steroid UDP–glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Bélanger G, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):165–73

Plasminogen activator activities in short–term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Festuccia C, et al. **Oncol Res** 1995;7(3–4):131–8

Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate [see comments] Huber PR, et al. **Prostate** 1995 Oct;27(4):212–9. Comment in: Prostate 1996 Jul;29(1):65–6.

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha–reductase activity in human benign prostatic hyperplasia. Weisser H, et al. **Prostate** 1996 May; 28(5):300–6

EPIDEMIOLOGY

Prostate screening—the Singapore experience. Tay KP, et al. **Int J Urol** 1996 Mar;3(2):102–7

Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older [see comments] Hunter DJ, et al. **J Urol** 1996 Jun; 155(6):1965–70. Comment in: J Urol 1996 Jun;155(6):1975–6.

Prostates and profits: the social construction of benign prostatic hyperplasia in American men. McDade T. **Med Anthropol** 1996 May;17(1):1–22

Benign prostatic hyperplasia morbidity and mortality among immigrants in Australia and Canada. Kliewer EV. **Prostate** 1996 Apr;28(4):211–8

Age– and race–specific reference ranges for prostate–specific antigen from a large community–based study. DeAntoni EP, et al. **Urology** 1996 Aug;48(2):234–9

Analysis of the prevalence of voiding symptoms in Maori, Pacific Island, and Caucasian New Zealand men. Nacey JN, et al. **Urology** 1995 Oct;46(4):506–11

ETIOLOGY

Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Soygür T, et al. **Int Urol Nephrol** 1996; 28(1):55–9

Benign prostatic hyperplasia: a review of its histogenesis and natural history. Oesterling JE. **Prostate Suppl** 1996;6:67–73 (36 ref.)

GENETICS

Association between family history of benign prostatic hyperplasia and urinary symptoms: results of a population–based study. Roberts RO, et al. **Am J Epidemiol** 1995 Nov 1;142(9):965–73

Monocyte chemoattractant protein–1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Mazzucchelli L, et al. **Am J Pathol** 1996 Aug;149(2):501–9

Flow cytometric DNA analysis of fine–needle aspirates of prostatic benign lesions. Paz–Bouza JI, et al. **Anal Cell Pathol** 1995 Apr;8(3):259–64

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Glynne–Jones E, et al. **Hum Pathol** 1996 Jul;27(7):688–94

NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. Borchers H, et al. **J Urol** 1996 Jun;155(6):2080–4

A comparative analysis of prostate–specific antigen gene sequence in benign and malignant prostate tissue. Baffa R, et al. **Urology** 1996 Jun;47(6):795–800

Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Qian J, et al. **Urology** 1995 Dec;46(6):837–42

IMMUNOLOGY

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Jung K, et al. **Eur J Cancer** 1996 Apr;32A(4):627–30

Dual monoclonal antibody immunoassay for free prostate–specific antigen. Wang TJ, et al. **Prostate** 1996 Jan;28(1):10–6

[The relationship between serum PSA value and the weight of the inner gland of the prostate in the cases of benign prostatic hyperplasia] Wu B, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1525–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies. Castellucci E, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:496–508

Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Zhang XH, et al. **Br J Urol** 1996 Mar;77(3):441–4

Tissue fibronectin levels of human prostatic cancer, as a tumor marker. Sönmez H, et al. **Cancer Biochem Biophys** 1995 Nov;15(2):107–10

Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase–activating peptide receptors in human benign hyperplastic prostate. Solano RM, et al. **Endocrinology** 1996 Jul;137(7):2815–22

Effect of bunazosin, alpha 1–adrenoceptor blocker, on multidirectional contractile response and localization of bunazosin binding sites in human hypertrophied prostate. Moriyama N, et al. **Gen Pharmacol** 1995 Sep;26(5):1033–7

Quantitative autoradiography of alpha 1 adrenoceptors with [3H]tamsulosin in human hypertrophied prostate using computerized image analysis. Kurimoto S, et al. **Histochem J** 1995 Dec;27(12):1007–13

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Glynne–Jones E, et al. **Hum Pathol** 1996 Jul;27(7):688–94

Norepinephrine contents of human prostatic hyperplasia: differences between pathological subtypes. Ishigooka M, et al. **Int Urol Nephrol** 1996;28(1):61–6

Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1–adrenoceptor subtypes and in human prostate. Michel MC, et al. **J Auton Pharmacol** 1996 Feb;16(1):21–8

Putative melatonin receptors in benign human prostate tissue. Laudon M, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1336–42

Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. Kim ED, et al. **J Urol** 1995 Nov;154(5):1802–5

High expression of a CD38–like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. Kramer G, et al. **J Urol** 1995 Nov;154(5):1636–41

Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. Morton RA Jr, et al. **J Urol** 1996 Aug;156(2 Pt 1):512–6

Ageing and prostate: age–related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Sánchez–Visconti G, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):19–29

Localization of beta–2–microglobulin in prostatic corpora amylacea of prostatic hypertrophy patients [letter] Horita S, et al. **Nephron** 1996;72(4):730–1

Expression of estrogen receptor in diseased human prostate assessed by non–radioactive in situ hybridization and

immunohistochemistry. Ehara H, et al. **Prostate** 1995 Dec; 27(6):304–13

Demonstration of fibroblast growth factor receptor–I in human prostate by polymerase chain reaction and immunohistochemistry. Hamaguchi A, et al. **Prostate** 1995 Sep;27(3):141–7

Concentration of the endogenous antiandrogen epitestosterone and androgenic C19–steroids in hyperplastic prostatic tissue. Hill M, et al. **Prostate** 1996 Jun;28(6):347–51

Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Ishigooka M, et al. **Prostate** 1996 Jun;28(6):385–91

Isoforms of prostate–specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? [letter; comment] Jung K, et al. **Prostate** 1996 Jul;29(1):65–6 . Comment on: Prostate 1995 Sep;27(3):166–75. Comment on: Prostate 1996 Oct;27(4):212–9.

Identification of endothelin receptors in normal and hyperplasic human prostate tissues. Le Brun G, et al. **Prostate** 1996 Jun;28(6):379–84

In situ hybridization studies of alpha 2–macroglobulin receptor and receptor–associated protein in human prostate carcinoma. McGarvey T, et al. **Prostate** 1996 May; 28(5):311–7

Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells. Story MT, et al. **Prostate** 1996 Apr; 28(4):219–26

Expression of heme oxygenase–1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Maines MD, et al. **Urology** 1996 May;47(5):727–33

[PSA and PSAD study in patients with renal dysfunction] Sánchez de la Muela P, et al. **Actas Urol Esp** 1996 Mar; 20(3):255–60 (Eng. Abstr.) **(Spa)**

MORTALITY

Mortality after transurethral and open prostatectomy in Scotland. Hargreave TB, et al. **Br J Urol** 1996 Apr; 77(4):547–53

Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph [see comments] Boyle P, et al. **J Urol** 1996 Jan;155(1):176–80. Comment in: J Urol 1996 Jan;155(1):190.

Benign prostatic hyperplasia morbidity and mortality among immigrants in Australia and Canada. Kliewer EV. **Prostate** 1996 Apr;28(4):211–8

PATHOLOGY

Tumor–like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.). Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.

Morphological features and kinetics of primary cultures of BPH tissue supported by TV1 medium. De Angeli S, et al. **Anat Anz** 1996 Jan;178(1):41–8

Maintenance of human hyperplastic prostate implants at different sites in athymic mice. Soós G, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2007–11

A Pygeum africanum extract with so–called phyto–estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Mathé G, et al. **Biomed Pharmacother** 1995;49(7–8):341–3

Transrectal ultrasonography: why are estimates of prostate volume and dimension so inaccurate? Nathan MS, et al. **Br J Urol** 1996 Mar;77(3):401–7

Benign prostatic hyperplasia in an unselected community–based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Simpson RJ, et al. **Br J Urol** 1996 Feb;77(2):186–91

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)

Overexpression of her–2/neu in human prostate cancer and benign hyperplastic. Gu K, et al. **Cancer Lett** 1996 Feb 6; 99(2):185–9

Stromal nodules in benign prostatic hyperplasia. Bierhoff E, et al. **Eur Urol** 1996;29(3):345–54

Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Kyprianou N, et al. **Hum Pathol** 1996 Jul;27(7):668–75

Atypical adenomatous hyperplasia (adenosis) of the prostate: development of a Bayesian belief network for its distinction from well–differentiated adenocarcinoma. Montironi R, et al. **Hum Pathol** 1996 Apr;27(4):396–407

Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. Landry F, et al. **J Urol** 1996 Jan;155(1):386–90

Induction of atypical hyperplasia, apoptosis, and type II estrogen–binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol–17 beta. Ho SM, et al. **Lab Invest** 1995 Sep; 73(3):356–65

Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Vartanian RK, et al. **Lab Invest** 1995 Dec;73(6):844–50

Localization of beta–2–microglobulin in prostatic corpora amylacea of prostatic hypertrophy patients [letter] Horita S, et al. **Nephron** 1996;72(4):730–1

Prostatic Intraepithelial Neoplasia and the Origins of Prostatic Carcinoma. Proceedings of the first international consultation meeting. Ancona, Italy, September 11–12, 1994. **Pathol Res Pract** 1995 Sep;191(9):828–959

Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Algaba F, et al. **Pathol Res Pract** 1995 Sep;191(9):836–7

Boundary in the pathologic evaluation of premalignant prostatic lesions. Algaba F. **Pathol Res Pract** 1995 Sep; 191(9):856–9

Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)

Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):828–32

Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Helpap B. **Pathol Res Pract** 1995 Sep;191(9):904–7

Nucleolar and AgNOR–analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. Helpap B, et al. **Pathol Res Pract** 1995 Jun;191(5):381–90

The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Qian J, et al. **Pathol Res Pract** 1995 Sep; 191(9):860–7

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

Relationship of ultrasonic and histologic findings in benign prostatic hyperplasia. Hasegawa Y, et al. **Prostate** 1996 Feb; 28(2):111–6

Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings. Ishigooka M, et al. **Prostate** 1996 Aug;29(2):77–82

Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Ishigooka M, et al. **Prostate** 1996 Jun;28(6):385–91

Stromal cells of the human prostate: initial isolation and characterization. Kassen A, et al. **Prostate** 1996 Feb; 28(2):89–97

Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5–alpha reductase inhibitors. Laroque PA, et al. **Prostate** 1995 Sep;27(3):121–8

Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? Matzkin H, et al. **Prostate** 1996 Jul;29(1):42–5

Effect of aromatase inhibitor, TZA–2209, on the prostate of androstenedione–treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328–37

Estrogen receptors in the human male bladder, prostatic urethra, and prostate. An immunohistochemical and biochemical study. Bødker A, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):161–5

Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue. Sciarra F, et al. **Urol Res** 1995; 23(6):387–90

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta–analysis of randomized clinical trials. Boyle P, et al. **Urology** 1996 Sep; 48(3):398–405

Prostate size and transurethral laser evaporation of the prostate [letter; comment] Keoghane SR, et al. **Urology** 1995 Oct;46(4):605–6. Comment on: Urology 1995 May;45(5):776–82.

Temperature–correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Larson TR, et al. **Urology** 1996 Apr;47(4):463–9

Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian–American men. Lepor H, et al. **Urology** 1996 Jan;47(1):38–42

Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study. Zlota Ar, et al. **Urology** 1996 Mar;47(3):329–34

[Sclerosing adenosis of the prostate. Carcinoma simulation] Meister P. **Pathologe** 1996 Mar;17(2):157–62 (Eng. Abstr.) **(Ger)**

[Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy] Saikawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1673–80 (Eng. Abstr.) **(Jpn)**

[Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia] Sakai S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):695–701 (Eng. Abstr.) **(Jpn)**

[Assessment of the effect of a 5–alpha–reductase inhibitor on cultured explants of human prostate] López Muñoz A, et al. **Actas Urol Esp** 1996 Apr;20(4):316–22; discussion 323 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Hormones and/or growth factors in prostate hypertrophy, pathophysiology and treatment [editorial] Mathé G. **Biomed Pharmacother** 1995;49(7–8):317–8

The day–to–day variation (test–retest reliability) of residual urine measurement. Dunsmuir WD, et al. **Br J Urol** 1996 Feb;77(2):192–3

Regression to the mean occurs in measuring peak urinary flow. Prescott RJ, et al. **Br J Urol** 1995 Nov;76(5):611–3

The value of multiple free–flow studies in men with lower urinary tract symptoms. Reynard JM, et al. **Br J Urol** 1996 Jun;77(6):813–8

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455–9 (23 ref.)

Maximum flow rate—the single uroflowmetric parameter in clinical trials for benign prostatic hyperplasia? Homma Y, et al. **Int J Urol** 1995 Nov;2(5):322–5

Relationship between prostate–specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). Dutkiewicz S, et al. **Int Urol Nephrol** 1995;27(6):763–8

Secretion of insulin–like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. Boudon C, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):612–7

Quantification of voiding dysfunction in patients awaiting transurethral prostatectomy. Javlé P, et al. **J Urol** 1996 Sep;156(3):1014–8; discussion 1018–9

Differential diagnosis of prostatism: A 12–year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. Kaplan SA, et al. **J Urol** 1996 Apr;155(4):1305–8

Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms: development and urodynamic validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. Rosier PF, et al. **J Urol** 1996 May; 155(5):1649–54

Evaluation of detrusor activity during micturition in patients with benign prostatic enlargement with a clinical nomogram. Rosier PF, et al. **J Urol** 1996 Aug;156(2 Pt 1):473–8; discussion 478–9

Analysis of maximum detrusor contraction power in relation to bladder emptying in patients with lower urinary tract symptoms and benign prostatic enlargement. Rosier PF, et al. **J Urol** 1995 Dec;154(6):2137–42

Continuous occlusion test to determine detrusor contractile performance. Sullivan MP, et al. **J Urol** 1995 Nov; 154(5):1834–40

Variability of clinical and pressure–flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement [see comments] Witjes WP, et al. **J Urol** 1996 Sep; 156(3):1026–34. Comment in: J Urol 1996 Sep;156(3):1040–1.

Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. Witjes WP, et al. **J Urol** 1996 Apr;155(4):1117–23

Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat. Constantinou CE, et al. **Neurourol Urodyn** 1996;15(1):85–101

Is detrusor instability in elderly males related to the grade of obstruction? Rosier PF, et al. **Neurourol Urodyn** 1995; 14(6):625–33

Effects of finasteride on health–related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. Girman CJ, et al. **Prostate** 1996 Aug; 29(2):83–90

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Ezz el Din K, et al. **Urology** 1996 Sep;48(3):393–7

Reproducibility of uroflow measurement: experience during a double–blind, placebo–controlled study of doxazosin in benign prostatic hyperplasia. Feneley MR, et al. **Urology** 1996 May;47(5):658–63

Effects of androgen deprivation on prostate alpha 1–adrenergic receptors. Lacey JP, et al. **Urology** 1996 Aug; 48(2):335–41

Reproducibility of pressure–flow variables in patients with symptomatic benign prostatic hyperplasia. Madsen FA, et al. **Urology** 1995 Dec;46(6):816–20

Significance of intermittency in men with lower urinary tract symptoms. Reynard J, et al. **Urology** 1996 Apr;47(4):491–6

The insulin–like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

[Pathophysiology of benign prostatic hyperplasia] Frick J. **Wien Med Wochenschr** 1996;146(8):158–60 (29 ref.) (Eng. Abstr.) **(Ger)**

[Obstruction of the lower urinary tract: contractile capacity of the detrusor and obstruction degree. Analysis of pressure/flow curves] Prieto Chaparro L, et al. **Arch Esp Urol** 1995 Sep;48(7):720–8 (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Histopathologic effects of laser radiation on the human prostate. Cowan DF, et al. **Mod Pathol** 1995 Sep; 8(7):716–21

[The treatment of prostatic adenoma by transurethral microwave therapy] Vozianov AF, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):142–6 (Eng. Abstr.) **(Rus)**

SURGERY

Visual laser ablation of the prostate (VLAP): an effective alternative treatment of benign prostatic hyperplasia. Mattelaer P, et al. **Acta Urol Belg** 1995 Sep;63(3):45–9

Urodynamic effects of Prolase 2 laser prostatectomy in benign prostatic hyperplasia. Van Erps P, et al. **Acta Urol Belg** 1995 Sep;63(3):39–43

Minimally invasive surgery for benign prostatic hyperplasia—a review. Kour NW. **Ann Acad Med Singapore** 1995 Jul;24(4):619–26 (77 ref.)

Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131–8 (38 ref.)

Case report: uneventful treatment of a giant prostate. La Marca F, et al. **Arch Esp Urol** 1995 Dec;48(10):1060–1 (7 ref.)

Factors influencing electrovaporization in the treatment of benign prostatic hyperplasia. Lim LM, et al. **Biomed Sci Instrum** 1996;32:197–204

Transurethral interstitial laser coagulation for benign prostatic hyperplasia: treatment outcome and quality of life. Arai Y, et al. **Br J Urol** 1996 Jul;78(1):93–8

Visual laser ablation of the prostate for patients with acute urinary retention. Farsi HM. **Br J Urol** 1996 Jul;78(1):90–2

Multiple use of fibres in the visual laser ablation of the prostate. Gilbert HW, et al. **Br J Urol** 1996 Jun; 77(6):839–42

How complete is a transurethral resection of the prostate? Green JS, et al. **Br J Urol** 1996 Mar;77(3):398–400

Effect of age, comorbidity and type of surgery on perioperative complications and mortality of prostatectomy. Ibrahim AI, et al. **Br J Urol** 1995 Sep; 76(3):341–5

The Oxford Laser Prostate Trial: a double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results. Keoghane SR, et al. **Br J Urol** 1996 Mar;77(3):382–5

The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy. Keoghane SR, et al. **Br J Urol** 1996 Mar;77(3):386–90

Endoscopic rollerball electrovaporization of the prostate—the sandwich technique: evaluation of the initial efficacy and morbidity in the treatment of benign prostatic obstruction. Meade WM, et al. **Br J Urol** 1996 May; 77(5):696–700

Femoral vein blood flow during transurethral resection of the prostate. Nilsson A, et al. **Br J Urol** 1996 Feb; 77(2):207–11

A step towards day case prostatectomy. Suvakovic N, et al. **Br J Urol** 1996 Feb;77(2):212–4

Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? te Slaa E, et al. **Br J Urol** 1996 Feb;77(2):228–32

Urodynamic assessment in the laser treatment of benign prostatic enlargement. Te Slaa E, et al. **Br J Urol** 1995 Nov;76(5):604–10

Transurethral needle ablation of the prostate: clinical experience in patients in urinary acute retention. Zlotta AR, et al. **Br J Urol** 1996 Mar;77(3):391–7

Use of an intraurethral catheter instead of a Foley catheter after laser treatment of benign prostatic hyperplasia. Nissenkorn I, et al. **Eur Urol** 1996;29(3):341–4

Transurethral laser surgery with a conventional modified resectoscope. Tasca A, et al. **Eur Urol** 1995;28(2):171–4

Two-dimensional outcome analysis as a guide for quality assurance of prostatectomy. Cohen YC, et al. **Int J Qual Health Care** 1996 Feb;8(1):67–73

International variation in intervention rates. What are the implications for patient selection? Black N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):719–32

Interstitial laser coagulation for benign prostatic hyperplasia: preliminary clinical results. Arai Y, et al. **Int J Urol** 1995 May;2(2):104–9

A non-randomized comparative study of visual laser ablation and transurethral resection of the prostate in benign prostatic hyperplasia. Uchida T, et al. **Int J Urol** 1996 Mar; 3(2):108–12

Blood loss during transurethral prostatic resection with continuous bladder irrigation. Lukojć K, et al. **Int Urol Nephrol** 1995;27(6):753–5

Postoperative MRI in patients undergoing interstitial laser coagulation thermotherapy of benign prostatic hyperplasia. Mueller-Lisse UG, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):273–8

Transurethral Needle Ablation of the prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. Harewood LM, et al. **J Endourol** 1995 Oct;9(5):407–12

Heat-expansible permanent intraurethral stents for benign prostatic hyperplasia and urethral strictures. Ricciotti G, et al. **J Endourol** 1995 Oct;9(5):417–22

Electrovaporization of the prostate: new technique for treatment of symptomatic benign hyperplasia. Stewart SC, et al. **J Endourol** 1995 Oct;9(5):413–6

Comparing comorbid–illness indices assessing outcome variation: the case of prostatectomy. Krousel-Wood MA, et al. **J Gen Intern Med** 1996 Jan;11(1):32–8

Transurethral needle ablation of the prostate: report of initial United States clinical trial [see comments] Issa MM. **J Urol** 1996 Aug;156(2 Pt 1):413–9. Comment in: J Urol 1996 Aug;156(2 Pt 1):426–7.

Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients [see comments] Kabalin JN, et al. **J Urol** 1996 Jan;155(1):181–5. Comment in: J Urol 1996 Jan;155(1):190.

Benign prostatic hyperplasia—are we too "hot" on new therapies? [editorial; comment] Kaplan SA. **J Urol** 1996 Aug;156(2 Pt 1):426–7. Comment on: J Urol 1996 Aug;156(2 Pt 1):413–9. Comment on: J Urol 1996 Aug;156(2 Pt 1):420–4; discussion 425.

A comparative study of transurethral resection of the prostate using a modified electro-vaporizing loop and transurethral laser vaporization of the prostate. Kaplan SA, et al. **J Urol** 1995 Nov;154(5):1785–90

Comparison of robotic versus human laparoscopic camera control. Kavoussi LR, et al. **J Urol** 1995 Dec;154(6):2134–6

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia [see comments] Marks LS, et al. **J Urol** 1996 Sep;156(3):1035–9. Comment in: J Urol 1996 Sep;156(3):1040–1.

Interstitial radiofrequency therapy of the prostate: results of a pilot study. Mostafid AH, et al. **J Urol** 1996 Jun; 155(6):1946–8; discussion 1948–9

Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: the impact of surgical techniques [see comments] Mozes B, et al. **J Urol** 1996 Jan;155(1):191–6. Comment in: J Urol 1996 Jan;155(1):203–5.

Fine-tuning the indication for prostatectomy [editorial; comment] Roehrborn CG. **J Urol** 1996 Jan;155(1):203–5. Comment on: J Urol 1996 Jan;155(1):191–6. Comment on: J Urol 1996 Jan;155(1):197–9. Comment on: J Urol 1996 Jan;155(1):200–2.

Laser treatment of the prostate using the Urolase fiber: the Dutch experience [see comments] te Slaa E, et al. **J Urol** 1996 Aug;156(2 Pt 1):420–4; discussion 425. Comment in: J Urol 1996 Aug;156(2 Pt 1):426–7.

Outcome variations for BPH–TURP patients. Hardy D, et al. **Mo Med** 1995 Oct;92(10):640–3

New method to quantify the urodynamic improvement when treating bladder outlet obstruction: the efficacy of transurethral resection in benign prostatic hypertrophy. Spångberg A, et al. **Neurourol Urodyn** 1995;14(4):325–35

An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Ahlstrand C, et al. **Scand J Urol Nephrol** 1996 Feb; 30(1):37–43

Reference range of prostate-specific antigen after transurethral resection of the prostate. Aus G, et al. **Urology** 1996 Apr;47(4):529–31

Complications during transurethral vaporization of the prostate. Ekengren J, et al. **Urology** 1996 Sep;48(3):424–7

Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Gilling PJ, et al. **Urology** 1996 Jan;47(1):48–51

Transurethral fulguration of the prostate with the roller ball. Juma S. **Urology** 1996 Jan;47(1):53–8

Detailed prostatic interstitial thermal mapping during transurethral grooved rollerball electrovaporization and loop electrosurgery for benign prostatic hyperplasia. Larson TR, et al. **Urology** 1996 Sep;48(3):501–7

Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. Muschter R, et al. **Urology** 1996 Aug;48(2):223–8

Transurethral vaportrode electrovaporization of the prostate: physical principles, technique, and results. Narayan P, et al. **Urology** 1996 Apr;47(4):505–10

[Results of surgical treatment of benign prostatic hyperplasia] Kawaciuk I, et al. **Rozhl Chir** 1995 Nov;74(7):339–47 (Eng. Abstr.) **(Cze)**

[Diagnosis and treatment of benign prostatic hyperplasia in the North Bohemia Region in 1994] Mečl J. **Rozhl Chir** 1995 Nov;74(7):373–5 (Eng. Abstr.) **(Cze)**

[Spontaneous resolution of urodynamically proven sphincter lesion following surgery for prostatic hyperplasia] Fuglsig S, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2126–8 (Eng. Abstr.) **(Dan)**

[Transurethral vaporization of the prostate for benign hypertrophy: preliminary clinical and histological study] Zerbib M, et al. **J Urol (Paris)** 1996;102(2):79–80 (Eng. Abstr.) **(Fre)**

[Surgical treatment of benign hypertrophy of the prostate] Lanson Y. **Presse Med** 1995 Oct 28;24(32):1481–4 (6 ref.) (Eng. Abstr.) **(Fre)**

[Electrovaporization of the prostate (EVP) for the treatment of prostatic adenoma] Colombel M, et al. **Prog Urol** 1996 Apr;6(2):236–9 (Eng. Abstr.) **(Fre)**

[Comparative study of the treatment of prostatic adenoma: laser photocoagulation versus endoscopic resection] Colombel M, et al. **Prog Urol** 1995 Dec;5(6):974–9 (Eng. Abstr.) **(Fre)**

[The frequency of surgery of benign prostatic hypertrophy] Janin P, et al. **Prog Urol** 1995 Sep;5(4):515–21 (Eng. Abstr.) **(Fre)**

[Mechanical autotransfusion also in transurethral resection of prostatic adenoma? Studies of preserved washed erythrocyte concentrates before possible retransfusion] Tumbass VE, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):77–84 (Eng. Abstr.) **(Ger)**

[Visual laser ablation of the prostate—a prospective study] Jung P, et al. **Urologe A** 1995 Nov;34(6):461–5 (Eng. Abstr.) **(Ger)**

[Sexual function after transurethral prostate resection] Lunglmayr G. **Wien Med Wochenschr** 1996;146(8):175–7 (Eng. Abstr.) **(Ger)**

[Surgical treatment of benign prostatic hypertrophy and Kelami syndrome] Bodo G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):81–3 (Eng. Abstr.) **(Ita)**

[A new method for treating benign prostatic hypertrophy: transurethral prostatic vaporization] Tizzani A, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):53–4 **(Ita)**

[Results of transurethral resection of prostate plus incision (TUR-P+I) for benign prostatic hypertrophy] Ishizaka K, et al. **Hinyokika Kiyo** 1996 Mar;42(3):207–11 (Eng. Abstr.) **(Jpn)**

[A basic study of the interstitial laser prostatectomy using pulsed holmium: yttrium-aluminum-garnet (Ho:YAG) laser] Daidoh Y. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):650–9 (Eng. Abstr.) **(Jpn)**

[Visual laser coagulation for benign prostatic hyperplasia. Preliminary experiences] Wold T, et al. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1223–5 (Eng. Abstr.) **(Nor)**

[Therapeutic tactics and results of prostatic adenomectomy in the presence of aggravating factors] Dovlatian AA. **Klin Med (Mosk)** 1995;73(4):68–72 (Eng. Abstr.) **(Rus)**

[Our experience with the pre- and postoperative management of middle-aged and elderly patients undergoing a urological surgical intervention] Gorilovskiĭ LM. **Ter Arkh** 1995;67(10):51–3 **(Rus)**

[The use of the IPSS questionnaire in surgical patients. International Prostatic Symptom Score] Batista-Miranda JE, et al. **Actas Urol Esp** 1995 Mar;19(3):227–33 (Eng. Abstr.) **(Spa)**

[Nosocomial infection in BPH: economic costs and increase in hospital stay] Fernández Arjona M, et al. **Actas Urol Esp** 1996 Mar;20(3):269–73 (Eng. Abstr.) **(Spa)**

[Treatment of prostatic benign hyperplasia with endoscopically controlled laser fiber] Martínez Sarmiento M, et al. **Actas Urol Esp** 1995 Apr;19(4):307–12 (Eng. Abstr.) **(Spa)**

[Role of autotransfusion of pre-stored blood in benign prostate hyperplasia. Our experience] Mínguez Martínez R, et al. **Actas Urol Esp** 1995 Oct;19(9):686–91 (Eng. Abstr.) **(Spa)**

[Trigono-cervico-prostatotomy (TCP) versus transurethral resection of the prostate (TURP). Our experience] Arceo Santiago R, et al. **Arch Esp Urol** 1995 Oct;48(8):823–6; discussion 827 (Eng. Abstr.) **(Spa)**

[TUV-p is a logical name for the new treatment of prostatic hypertrophy (letter)] Nilsson S. **Lakartidningen** 1995 Nov 22;92(47):4405 **(Swe)**

THERAPY

Transurethral microwave thermotherapy. A comparison between clinical outcome and morphologic effects assessed by urethrography. Nordenstam G, et al. **Acta Radiol** 1996 Jul;37(4):524–8

Transrectal and transurethral hyperthermia versus sham treatment in benign prostatic hyperplasia: a double-blind randomized multicentre clinical trial. The French BPH Hyperthermia. Abbou CC, et al. **Br J Urol** 1995 Nov; 76(5):619–24

Shared care for benign prostatic hyperplasia: a feasibility study [letter] Booth CM, et al. **Br J Urol** 1996 Jun;77(6):932

Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Dahlstrand C, et al. **Br J Urol** 1995 Nov;76(5):614–8

Transurethral microwave thermotherapy: an evolving technology in the treatment of benign prostatic enlargement [see comments] de Wildt MJ, et al. **Br J Urol** 1995 Nov;76(5):531–8 (47 ref.). Comment in: Br J Urol 1996 May;77(5):764.

A 12-month study of the placebo effect in transurethral microwave thermotherapy. De Wildt MJ, et al. **Br J Urol** 1996 Feb;77(2):221–7

Benign prostatic hyperplasia: an approach for the internist. Zippe CD. **Cleve Clin J Med** 1996 Jul–Aug;63(4):226–36 (23 ref.)

Newly developed transurethral radiofrequency thermotherapy device for benign prostatic hyperplasia: a pilot study in canine prostate. Terai A, et al. **Int J Hyperthermia** 1995 Sep–Oct;11(5):627–35

Treatment of benign prostatic hyperplasia with high intensity focused ultrasound: an initial clinical trial in Japan with magnetic resonance imaging of the treated area. Nakamura K, et al. **Int J Urol** 1995 Jul;2(3):176–80

Increasing the thermal dose in transurethral microwave thermotherapy produces no improvement in therapeutic efficacy. Terai A, et al. **Int J Urol** 1995 Jul;2(3):186–90

High intensity focused ultrasound for benign prostatic hyperplasia. Uchida T, et al. **Int J Urol** 1995 Jul;2(3):181–5

An accurate technique for detailed prostatic interstitial temperature-mapping in patients receiving microwave thermal treatment. Larson TR, et al. **J Endourol** 1995 Aug; 9(4):339–47

Is there a role for transrectal microwave hyperthermia in the treatment of benign prostatic hyperplasia? A critical review of a six-year experience. Montorsi F, et al. **J Endourol** 1995 Aug;9(4):333–7

Balloon dilation of the prostate: correlation with magnetic resonance imaging and transrectal ultrasound findings. Renfer L, et al. **J Endourol** 1995 Jun;9(3):283–6

Three-dimensional sonographic guidance for interstitial laser therapy in benign prostatic hyperplasia. Strasser H, et al. **J Endourol** 1995 Dec;9(6):497–501

Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. Chirikos TN, et al. **J Urol** 1996 Apr;155(4):1311–6

High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group. de la Rosette JJ, et al. **J Urol** 1996 Jul;156(1):97–101; discussion 101–2

Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis [see comments] de Wildt MJ, et al. **J Urol** 1995 Nov; 154(5):1775–8. Comment in: J Urol 1995 Nov;154(5):1783–4.

Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. Kaplan SA, et al. **J Urol** 1996 Apr;155(4):1305–8

A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia [see comments] Narayan P, et al. **J Urol** 1995 Dec;154(6):2083–8. Comment in: J Urol 1995 Dec;154(6):2093–5.

Benign prostatic hypertrophy—measurement of clinical outcomes [editorial; comment] Slawin KM. **J Urol** 1995 Nov;154(5):1783–4. Comment on: J Urol 1995 Nov;154(5):1770–4. Comment on: J Urol 1995 Nov;154(5):1775–8. Comment on: J Urol 1995 Nov;154(5):1779–82.

High-intensity focused ultrasound (HIFU) in the treatment of benign prostatic hyperplasia (BPH). Ebert T, et al. **Keio J Med** 1995 Dec;44(4):146–9

The prostatron: microwaves for benign prostatic hyperplasia. **Med Lett Drugs Ther** 1996 Jun 7;38(976):53–4

Is medical therapy an expensive way for delaying surgery in BPH patients? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):177–84 (20 ref.)

Theoretical analysis of transurethral laser-induced thermo-therapy for treatment of benign prostatic hyperplasia. Evaluation of a water-cooled applicator. Sturesson C, et al. **Phys Med Biol** 1996 Mar;41(3):445–63

Transurethral microwave thermotherapy for benign prostatic hyperplasia: relation between clinical response and prostate histology. Arai Y, et al. **Prostate** 1996 Feb;28(2):84–8

Responders and non-responders to treatment of benign prostatic hyperplasia with transurethral microwave thermotherapy. Eliasson TU, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):183–91

Pre treatment decision making in prostatism—a stochastic analysis based on the most used diagnostic tests. Zdanowski A, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):173–81

Prostatism: benign prostatic hyperplasia. Hollander JB, et al. **Urol Clin North Am** 1996 Feb;23(1):75–86 (96 ref.)

Economic modeling to assess the costs of treatment for benign prostatic hyperplasia [letter; comment] Ansong KS. **Urology** 1996 Jan;47(1):152. Comment on: Urology 1995 Oct;46(4):477–83.

Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: durability of response. Baba S, et al. **Urology** 1996 May;47(5):664–71

High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. de Wildt MJ, et al. **Urology** 1996 Sep;48(3):416–23

Increased prostatic blood flow in response to microwave thermal treatment: preliminary findings in two patients with benign prostatic hyperplasia. Larson TR, et al. **Urology** 1995 Oct;46(4):584–90

Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Larson TR, et al. **Urology** 1996 Apr;47(4):463–9

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Lowe FC, et al. **Urology** 1996 Jul; 48(1):12–20 (55 ref.)

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia [see comments] Lowe FC, et al. **Urology** 1995 Oct;46(4):477–83. Comment in: Urology 1996 Jan;47(1):152.

[Variation in the diagnosis and treatment of benign prostatic hyperplasia in urological practice] Stoevelaar HJ, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):837–42 (Eng. Abstr.) **(Dut)**

[Localized transrectal hyperthermia. Transurethral hyperthermia and thermotherapy in the treatment of benign hyperplasia of the prostate] Mazo E, et al. **J Urol (Paris)** 1996;102(1):23–5 (Eng. Abstr.) **(Fre)**

[Non-surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477–80 (9 ref.) (Eng. Abstr.) **(Fre)**

[Transurethral prostatic resection or observation of the course of benign prostatic hyperplasia?] Kleinschmidt K. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1491–2 **(Ger)**

[Bloodless prostate treatment using high-intensity focused ultrasound (HIFU)] Eberle J, et al. **Schweiz Med Wochenschr** 1996 Aug 17;126(33):1385–92 (Eng. Abstr.) **(Ger)**

[High energy focused ultrasound in treatment of benign prostatic hyperplasia] Ebert T, et al. **Urologe A** 1995 Sep; 34(5):404–8 (Eng. Abstr.) **(Ger)**

[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

[Preoperative use of erythropoietin (rH-EPO) and determination of optimal doses in patients with benign prostatic hypertrophy for future autologous blood transfusion] Inatsuchi H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1720–7 (Eng. Abstr.) **(Jpn)**

[A single session of transurethral balloon laser thermotherapy for benign prostatic hyperplasia] Kubota S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1610–5 (Eng. Abstr.) **(Jpn)**

[How does thermotherapy effectively work on benign prostatic hyperplasia—an experimental study] Park YC, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1360–7 (Eng. Abstr.) **(Jpn)**

[Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia] Sakai S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):695–701 (Eng. Abstr.) **(Jpn)**

[The treatment of prostatic adenoma by means of local hyperthermia and thermotherapy] Krivoborodov GG, et al. **Ter Arkh** 1995;67(10):48–50 (Eng. Abstr.) **(Rus)**

[Transurethral radiofrequency thermotherapy using the Thermex unit in benign prostatic hyperplasia] Dolgopiatov DG, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec;(6):48–50 (38 ref.) **(Rus)**

[Late results of local transrectal hyperthermia in patients with benign prostatic hyperplasia and its complications] Krivoborodov GG, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec;(6):47–8 (Eng. Abstr.) **(Rus)**

[The transurethral microwave thermotherapy of benign prostatic hyperplasia] Neimark AI, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):30-2 (Eng. Abstr.) **(Rus)**

[Transurethral thermotherapy with microwaves in symptomatic prostatic benign hypertrophy: comparison between the high-energy (2.5) protocol and the standard protocol (2.0)] Mompo Sanchis JA, et al. **Arch Esp Urol** 1996 Mar;49(2):99–109 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Suprapubic versus transrectal ultrasonography in assessing the volume of the prostate and the transition zone in patients with benign prostatic hyperplasia. Prassopoulos P, et al. **Abdom Imaging** 1996 Jan-Feb;21(1):75–7

Contribution to the clarification of heterogeneous foci within the prostate. Zátura F, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:65–7

Comparison of prostatic volume and dimensions by transrectal and transurethral ultrasonography. Nathan MS, et al. **Br J Urol** 1996 Jul;78(1):84–9

Ultrasonographic and pathologic changes in the prostate of patients with benign prostatic hyperplasia after transurethral balloon laser therapy. Furuya S, et al. **J Endourol** 1995 Aug;9(4):325–31

Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. Kaplan SA, et al. **J Urol** 1995 Nov;154(5):1764–9

The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia [see comments] Koch WF, et al. **J Urol** 1996 Jan;155(1):186–9 . Comment in: J Urol 1996 Jan;155(1):190.

Relationship of ultrasonic and histologic findings in benign prostatic hyperplasia. Hasegawa Y, et al. **Prostate** 1996 Feb; 28(2):111–6

Correlation of transrectal ultrasonographic findings of the prostate with the occurrence of detrusor instability in patients with benign prostatic hyperplasia. Tong YC, et al. **Urol Int** 1995;55(3):154–7

Prostate zones in three-dimensional transrectal ultrasound. Strasser H, et al. **Urology** 1996 Apr;47(4):485–90

URINE

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Ikeda I, et al. **Br J Urol** 1996 Jan;77(1):102–6

Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. O'Brien TS, et al. **Br J Urol** 1995 Sep;76(3):311–4

[The importance and significance of post-micturitional bladder residue in the evaluation of prostatism] Leblanc G, et al. **Prog Urol** 1995 Sep;5(4):511–4 (Eng. Abstr.) **(Fre)**

VETERINARY

Benign prostatic hyperplasia in the nonhuman primate Leontopithecus. Ferreira BR, et al. **Folia Primatol (Basel)** 1995;65(1):48–53

Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog. Kawakami E, et al. **Int J Androl** 1995 Oct;18(5):248–55

Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: comparative pathology in human and nonhuman primates. McEntee MF, et al. **Prostate** 1996 Jul;29(1):31–9

VIROLOGY

Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. Stapleton AMF, et al. **J Urol** 1996 Aug;156(2 Pt 1):542–5

Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Wideroff L, et al. **Prostate** 1996 Feb;28(2):117–23

PROSTATIC HYPERTROPHY see **PROSTATIC HYPERPLASIA**

PROSTATIC HYPERTROPHY, BENIGN see **PROSTATIC HYPERPLASIA**

PROSTATIC INTRAEPITHELIAL NEOPLASIA

BLOOD

Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. Işikay L, et al. **Int Urol Nephrol** 1995; 27(6):757–61

Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Alexander EE, et al. **Urology** 1996 May;47(5):693–8

CHEMISTRY

Immunolocalization of glycoprotein A-80 in prostatic carcinoma and prostatic intraepithelial neoplasia. Gould VE, et al. **Hum Pathol** 1996 Jun;27(6):547–52

Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. Tennant MK, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):411–20

Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. Humphrey PA, et al. **Pathol Res Pract** 1995 Sep;191(9):881–7

DIAGNOSIS

Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? Raviv G, et al. **Cancer** 1996 May 15;77(10):2103–8

Prostatic intraepithelial neoplasia: will it help doctors pinpoint early prostate cancer? [news] Stone E. **J Natl Cancer Inst** 1996 Aug 7;88(15):1023–4

Prostatic intraepithelial neoplasia (PIN). Performance of Bayesian belief network for diagnosis and grading. Montironi R, et al. **J Pathol** 1995 Oct;177(2):153–62

EPIDEMIOLOGY

The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. Bostwick DG, et al. **J Urol** 1995 Nov; 154(5):1791–4

Epidemiology of high grade prostatic intraepithelial neoplasia. Sakr WA, et al. **Pathol Res Pract** 1995 Sep; 191(9):838–41

Neoplastic and borderline lesions of the prostate: autopsy study and epidemiological data. Silvestri F, et al. **Pathol Res Pract** 1995 Sep;191(9):908–16

ETIOLOGY

A unifying hypothesis that links benign prostatic hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Invited comments. Harvey H. **Pathol Res Pract** 1995 Sep; 191(9):924–34

GENETICS

Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Qian J, et al. **Cancer Res** 1995 Nov 15; 55(22):5408–14

PATHOLOGY

Knowledge-guided histometry of the basal cell layer in prostatic intraepithelial neoplasia. Thompson D, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):177–84

International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Rochester, Minnesota, November 3–4, 1995. **Cancer** 1996 Jul 15;78(2):320–81

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)

The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. Bostwick DG, et al. **J Urol** 1995 Nov; 154(5):1791–4

Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy [see comments] Langer JE, et al. **J Urol** 1996 Jan; 155(1):228–31. Comment in: J Urol 1996 Jan;155(1):243.

Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. Raviv

G, et al. **J Urol** 1996 Sep;156(3):1050–4; discussion 1054–5

Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. Shepherd D, et al. **J Urol** 1996 Aug;156(2 Pt 1):460–2; discussion 462–3

Diagnosis of prostatic intraepithelial neoplasia in whole mount sections of prostates. Chan LP.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 May; 12(5):290–4

Prostatic Intraepithelial Neoplasia and the Origins of Prostatic Carcinoma. Proceedings of the first international consultation meeting. Ancona, Italy, September 11–12, 1994. **Pathol Res Pract** 1995 Sep;191(9):828–959

Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Algaba F, et al.
Pathol Res Pract 1995 Sep;191(9):836–7

Boundary in the pathologic evaluation of premalignant prostatic lesions. Algaba F. **Pathol Res Pract** 1995 Sep; 191(9):856–9

High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. Arakawa A, et al.
Pathol Res Pract 1995 Sep;191(9):868–72

Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):850–5

Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):828–32

Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Helpap B. **Pathol Res Pract** 1995 Sep;191(9):904–7

Nucleolar and AgNOR–analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. Helpap B, et al.
Pathol Res Pract 1995 Jun;191(5):381–90

Prostatic intraepithelial neoplasia. Quantitation of the basal cell layer with machine vision system. Montironi R, et al. **Pathol Res Pract** 1995 Sep;191(9):917–23

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Montironi R, et al. **Pathol Res Pract** 1995 Sep; 191(9):873–80

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al.
Pathol Res Pract 1995 Sep;191(9):842–9 (49 ref.)

The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Qian J, et al. **Pathol Res Pract** 1995 Sep; 191(9):860–7

Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)

ULTRASONOGRAPHY

[High–grade intraepithelial prostatic neoplasms: diagnosis and association with prostate cancer] Raviv G, et al.
Acta Urol Belg 1996 Mar;64(1):11–5 (Eng. Abstr.) **(Fre)**

PROSTATIC NEOPLASMS

Prostate cancer: emerging concepts. Part I. Garnick MB, et al. **Ann Intern Med** 1996 Jul 15;125(2):118–25 (50 ref.)

ABC of urology. Urological malignancy—1: Prostate cancer. Dawson C, et al. **BMJ** 1996 Apr 20;312(7037):1032–4 (0 ref.)

Pain relief and quality–of–life assessment following intravenous and oral clodronate in hormone–escaped metastatic prostate cancer. Cresswell SM, et al.
Br J Urol 1995 Sep;76(3):360–5

Prostate cancer: anatomical and surgical considerations. Gil–Vernet JM. **Br J Urol** 1996 Aug;78(2):161–8 (28 ref.)

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate—an Australian multicentre trial. Zalcberg JR, et al. **Br J Urol** 1996 Jun;77(6):865–9

The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Mettlin CJ, et al. **Cancer** 1995 Sep 15;76(6):1104–12

The accuracy of prostate cancer staging in a population–based tumor registry and its impact on the black–white stage difference (Connecticut, United States). Liu WL, et al. **Cancer Causes Control** 1995 Sep;6(5):425–30

Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA–III) in L–W rats. Pollard M. **Cancer Lett** 1996 Mar 19;101(1):21–4

An update on prostate cancer. Klein EA.
Cleve Clin J Med 1995 Sep–Oct;62(5):325–38 (81 ref.)

Epidemiological and clinical aspects of incidental carcinoma of the prostate in Africans: experience at the Lagos University Teaching Hospital, Lagos and the Kenyatta National Hospital, Nairobi. Magoha GA.
East Afr Med J 1995 May;72(5):283–7

Prostate Cancer: Current Issues, New Approaches. Proceedings of an international congress. London, England, October 19–21, 1995. **Eur Urol** 1996;29 Suppl 2:1–135

Quality of life in prostate cancer: what are the issues and how are they measured? Fossâ SD. **Eur Urol** 1996;29 Suppl 2:121–3 (15 ref.)

Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Helweg–Larsen S, et al.
Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):595–8

Insulin–like growth factor (IGF) system components in human prostatic cancer cell–lines: LNCaP, DU145, and PC–3 cells. Kimura G, et al. **Int J Urol** 1996 Jan;3(1):39–46

What to expect from prostate cancer [editorial] [see comments] Chodak GW. **J Urol** 1995 Dec;154(6):2132–3. Comment in: J Urol 1996 Sep;156(3):1138; discussion 1139. Comment in: J Urol 1996 Sep;156(3):1138–9.

Prostate cancer [editorial; comment] deKernion JB.
J Urol 1996 Jan;155(1):226–7. Comment on: J Urol 1996 Jan;155(1):206–8. Comment on: J Urol 1996 Jan;155(1):209–12. Comment on: J Urol 1996 Jan;155(1):213–9. Comment on: J Urol 1996 Jan;155(1):220–5.

Some aspects of prostate cancer [editorial; comment] McLeod DG. **J Urol** 1996 Jun;155(6):1987–8. Comment on: J Urol 1996 Jun;155(6):1977–80. Comment on: J Urol 1996 Jun;155(6):1981–2. Comment on: J Urol 1996 Jun;155(6):1983–6.

Prostate cancer—educating ourselves and our nonurological colleagues [editorial; comment] Partin AW. **J Urol** 1996 Feb;155(2):610–1. Comment on: J Urol 1996 Feb;155(2):441–3. Comment on: J Urol 1996 Feb;155(2):601–4. Comment on: J Urol 1996 Feb;155(2):605–9.

Prostate cancer—adjusting the tiller [editorial; comment] Pisters LL. **J Urol** 1996 May;155(5):1678–80. Comment on: J Urol 1996 May;155(5):1663–6. Comment on: J Urol 1996 May;155(5):1667–73. Comment on: J Urol 1996 May;155(5):1674–7.

Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer [see comments] Plawker MW, et al. **J Urol** 1996 Feb;155(2):601–4. Comment in: J Urol 1996 Feb;155(2):610–1.

PSA screening and prostate cancer incidence [letter; comment] Berman JJ, et al. **JAMA** 1996 Apr 17; 275(15):1155–6. Comment on: JAMA 1995 Nov 8;274(18):1445–9.

PSA screening and prostate cancer incidence [letter; comment] Rhoads GG, et al. **JAMA** 1996 Apr 17; 275(15):1155–6. Comment on: JAMA 1995 Nov 8;274(18):1445–9.

Small cell carcinoma of the bladder and prostate. Abbas F, et al. **Urology** 1995 Nov;46(5):617–30 (114 ref.)

Reflections of a prostate cancer patient. DeHart E.
Urology 1996 Aug;48(2):171–6; discussion 176–7

Performance measurement in prostate cancer care: beyond report cards. Ullman M, et al. **Urology** 1996 Mar; 47(3):356–65 (80 ref.)

Impact of prostate–specific antigen screening on prostate cancer [letter] Zincke H. **Urology** 1996 May;47(5):783

[Natural history of prostatic adenocarcinoma. Recent advances in prognostic parameters and biological behavior] Mirone V, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):171–5 (11 ref.) (Eng. Abstr.) **(Ita)**

[Why is prostate cancer important in clinical field, now?] Akaza H. **Gan To Kagaku Ryoho** 1996 Mar;23(4):401–2 **(Jpn)**

[Primary mucinous adenocarcinoma of the prostate] Gomiz Léon JJ, et al. **Actas Urol Esp** 1995 Jun;19(6):473–5 (16 ref.) (Eng. Abstr.) **(Spa)**

[Intraprostatic blue nevus] Vesga Molina F, et al.
Arch Esp Urol 1995 Dec;48(10):985–6 (Eng. Abstr.) **(Spa)**

[Statistical scientific scrutiny has not been done (letter)] Taube A. **Lakartidningen** 1996 May 8;93(19):1814 **(Swe)**

BLOOD

Prostate specific antigen–alpha 2–macroglobulin complexes in prostate cancer patient sera. Heeb MJ, et al.
Biochem Mol Biol Int 1995 Nov;37(5):917–23

Detection of circulating prostate–specific antigen–positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Fadlon EJ, et al. **Br J Cancer** 1996 Aug;74(3):400–5

Eliminating the need for per–operative frozen section analysis of pelvic lymph nodes during radical prostatectomy. Bangma CH, et al. **Br J Urol** 1995 Nov;76(5):595–9

Prostate–specific antigen levels in patients receiving long–term dialysis. Harper L, et al. **Br J Urol** 1995 Oct; 76(4):482–3

Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma. Cipolla BG, et al. **Cancer** 1996 Sep 1; 78(5):1055–65

Serum basic fibroblast growth factor in men with and without prostate carcinoma. Meyer GE, et al. **Cancer** 1995 Dec 1;76(11):2304–11

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515–23

Serum androgens and sex hormone–binding globulins in relation to lifestyle factors in older African–American, white, and Asian men in the United States and Canada. Wu AH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov;4(7):735–41

Tumor necrosis factor and coagulopathy in patients with prostate cancer. Nakashima J, et al. **Cancer Res** 1995 Nov 1;55(21):4881–5

Effects of androgen suppression by gonadotropin–releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Denti L, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1176–81

Ultrasensitive prostate–specific antigen assays and their clinical application [comment] Diamandis EP, et al.
Clin Chem 1996 Jun;42(6 Pt 1):853–7. Comment on: Clin Chem 1996 Jun;42(6 Pt 1):849–52.

Ultrasensitive detection of prostate–specific antigen by a time–resolved immunofluorometric assay and the Immulite immunochemiluminescent third–generation assay: potential applications in prostate and breast cancers. Ferguson RA, et al. **Clin Chem** 1996 May;42(5):675–84

Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate–specific antigen assays mislead clinicians [see comments] Stamey TA.
Clin Chem 1996 Jun;42(6 Pt 1):849–52. Comment in: Clin Chem 1996 Jun;42(6 Pt 1):853–7.

Large discrepancy between prostate–specific antigen results from different assays during longitudinal follow–up of a prostate cancer patient. Van Duijnhoven HL, et al.
Clin Chem 1996 Apr;42(4):637–41

Red blood cell polyamines, anaemia and tumour growth in the rat. Quemener V, et al. **Eur J Cancer** 1996 Feb; 32A(2):316–21

Longitudinal evaluation of prostate–specific antigen levels in a case–control study. De Biasi F, et al. **Eur Urol** 1996; 29(2):184–8

Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Correale M, et al.
Int J Biol Markers 1996 Jan–Mar;11(1):24–8

Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution? [editorial] Anscher MS.
Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):745–7

Prostate cancer volume adds significantly to prostate–specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):273–9

Pretreatment prostate–specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):549–53

Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate–specific antigen > or = 10 NG/ML [see comments] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):861–8 . Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1115.

PSA following irradiation for prostate cancer: the upcoming ASTRO symposium [editorial; comment] Shipley WU.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1115. Comment on: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):861–8.

Pretreatment prostate–specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey. Teshima T, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):809–14

Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. Masai M, et al. **Int J Urol** 1996 Mar;3(2):118–23

Prostate–specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ–confined prostate carcinoma and advanced prostate carcinoma. Işikay L, et al. **Int Urol Nephrol** 1995; 27(6):757–61

Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice. Stearns ME.
Invasion Metastasis 1995;15(5–6):232–41

Treatment of prostate cancer with gonadotropin–releasing hormone analogue: effect on lipoprotein[a]. Arrer E, et al.
J Clin Endocrinol Metab 1996 Jul;81(7):2508–11

Development of a microplate ELISA for free PSA and PSA–ACT complex in serum. Wu JT, et al.
J Clin Lab Anal 1995;9(4):252–60

Evaluation of prostate–specific antigen as a surrogate marker for response of hormone–refractory prostate cancer to suramin therapy. Sridhara R, et al. **J Clin Oncol** 1995 Dec; 13(12):2944–53

Prospective study of sex hormone levels and risk of prostate cancer [see comments] Gann PH, et al.
J Natl Cancer Inst 1996 Aug 21;88(16):1118–26. Comment in: J Natl Cancer Inst 1996 Aug 21;88(16):1093–5.

Hormones and prostate cancer: where do we go from here? [editorial; comment] Hsing AW. **J Natl Cancer Inst** 1996 Aug 21;88(16):1093–5. Comment on: J Natl Cancer Inst 1996 Aug 21;88(16):1118–26.

A multivariate approach to the description of patient populations. An example of the analysis of the hormone profiles of patients with advanced prostate cancer. Ojasoo T, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):183–93

Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. Babaian RJ, et al. **J Urol** 1995 Nov;154(5):1808–12

Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. Cussenot O, et al. **J Urol** 1996 Apr;155(4):1340–3

Free–to–total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. Elgamal AA, et al. **J Urol** 1996 Sep;156(3):1042–7;

discussion 1047–9

Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml. [see comments] Geary ES, et al. **J Urol** 1996 Sep;156(3):1056–8. Comment in: J Urol 1996 Sep;156(3):1069–70.

Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival [see comments] Lee WR, et al. **J Urol** 1996 Aug; 156(2 Pt 1):450–3. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less [see comments] Noldus J, et al. **J Urol** 1996 Feb;155(2):441–3. Comment in: J Urol 1996 Feb;155(2):610–1.

The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. Oefelein MG, et al. **J Urol** 1995 Dec;154(6):2128–31

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy [see comments] Olsson CA, et al. **J Urol** 1996 May;155(5):1557–62. Comment in: J Urol 1996 May;155(5):1661–2.

Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. Partin AW, et al. **J Urol** 1996 Apr;155(4):1336–9

The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. Pelger RC, et al. **J Urol** 1996 Jul;156(1):122–6

A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Prestigiacomo AF, et al. **J Urol** 1996 Aug;156(2 Pt 1):350–4

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Small EJ. **J Urol** 1996 May;155(5):1704–5. Comment on: J Urol 1995 Aug;154(2 Pt 1):448–53.

Free serum prostate-specific antigen and screening for prostate cancer [letter; comment] Bangma CH, et al. **JAMA** 1996 Mar 20;275(11):837–8. Comment on: JAMA 1995 Oct 18;274(15):1214–20.

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening [see comments] Catalona WJ, et al. **JAMA** 1995 Oct 18; 274(15):1214–20. Comment in: JAMA 1996 Mar 20;275(11):837–8.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. Moul JW, et al. **JAMA** 1995 Oct 25;274(16):1277–81

Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):157–63

Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer. Buskirk SJ, et al. **Mayo Clin Proc** 1996 Mar;71(3):242–8

Serum prostate-specific antigen concentration before and after vasectomy. Lassen PM, et al. **Mil Med** 1996 Jun; 161(6):356–7

Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer [letter] Ivanovic V, et al. **Nat Med** 1995 Apr;1(4):282–4

Prostate-specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al. **Postgrad Med** 1996 Feb;99(2):227–8, 231–4 (14 ref.)

Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients. Stege R, et al. **Prostate** 1996 May; 28(5):307–10

Collagen derived serum markers in carcinoma of the prostate. Rudnicki M, et al. **Scand J Urol Nephrol** 1995 Sep; 29(3):317–21

Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer. Filella X, et al. **Tumour Biol** 1996; 17(1):20–6

Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Alexander EE, et al. **Urology** 1996 May;47(5):693–8

Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Chen YT, et al. **Urology** 1996 Apr;47(4):518–24

An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. D'Amico AV, et al. **Urology** 1996 Apr; 47(4):538–47

Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Froschermaier SE, et al. **Urology** 1996 Apr; 47(4):525–8

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Gleave ME, et al. **Urology** 1996 May; 47(5):708–12

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P, et al. **Urology** 1996 Aug;48(2):249–60

Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Lerner SE, et al. **Urology** 1996 Aug;48(2):240–8

Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Reissigl A, et al. **Urology** 1995 Nov; 46(5):662–5

Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Schild SE, et al. **Urology** 1996 Jun;47(6):878–81

Acid phosphatase: defining a role in androgen-independent prostate cancer. Steineck G, et al. **Urology** 1996 May; 47(5):719–26

[Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate] Saad F, et al. **Ann Chir** 1995;49(8):680–4 (Eng. Abstr.) **(Fre)**

[Detection of prostatic cancer in symptomatic patients with serum levels of prostate-specific antigen between 4 and 10 ng/ml] Ravery V, et al. **Presse Med** 1996 Feb 24; 25(7):272–6 (Eng. Abstr.) **(Fre)**

[Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):9–12 (Eng. Abstr.) **(Ita)**

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma] Iwan-Ziętek I, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):91–3 (Eng. Abstr.) **(Pol)**

[Activity of protein C in blood of patients with prostatic carcinoma] Iwan-Ziętek I, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):94–5 (Eng. Abstr.) **(Pol)**

[Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):77–8 (Eng. Abstr.) **(Pol)**

[Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):89–90 (Eng. Abstr.) **(Pol)**

[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):86–8 (Eng. Abstr.) **(Pol)**

[Effect of cell differentiation in prostatic cancer on basal PSA] Llorente Abarca C, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):755–8 (Eng. Abstr.) **(Spa)**

[PSA and hormone-refractory period in prostatic cancer] Ojea Calvo A, et al. **Actas Urol Esp** 1996 Feb;20(2):168–71 (Eng. Abstr.) **(Spa)**

[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade] Regueiro López JC, et al. **Actas Urol Esp** 1995 May;19(5):357–62 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Brawer MK. **Cancer** 1996 Jul 15;78(2):345–9 (25 ref.)

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Joseph IB, et al. **Cancer Res** 1996 Aug 1; 56(15):3404–8

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Bostwick DG, et al. **Urology** 1996 Jul;48(1):47–57

CHEMICALLY INDUCED

Phenobarbital promotes the development of adenocarcinomas in the accessory sex glands of MNU-inoculated L-W rats. Pollard M, et al. **Carcinogenesis** 1995 Oct;16(10):2419–21

Direct effects of testosterone, dihydrotestosterone and estrogen on 3,2'-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in castrated F344 rats. Mori T, et al. **Jpn J Cancer Res** 1996 Jun;87(6):570–4

Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2'-dimethyl-4-aminobiphenyl: dose-dependent induction of invasive carcinomas. Shirai T, et al. **Jpn J Cancer Res** 1995 Jul;86(7):645–8

Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats. Schleicher RL, et al. **Prostate** 1996 Jan;28(1):32–43

CHEMISTRY

Prognostic significance of Bcl-2 in clinically localized prostate cancer. Bubendorf L, et al. **Am J Pathol** 1996 May; 148(5):1557–65

Expression of E-cadherin in primary and metastatic prostate cancer. Cheng L, et al. **Am J Pathol** 1996 May; 148(5):1375–80

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Krajewska M, et al. **Am J Pathol** 1996 May;148(5):1567–76

Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies. Castellucci E, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:496–508

Evaluation of mucinous metaplasia of the prostate gland by mucin histochemistry. Gal R, et al. **Br J Urol** 1996 Jan; 77(1):113–7

Prostatic adenocarcinoma labelled with a monoclonal antibody and polyclonal serum: a quantitative assessment. Gray E, et al. **Br J Urol** 1996 Jul;78(1):104–8

Estramustine-binding protein to dihydrotestosterone ratio in human prostatic carcinoma: a new marker for predicting disease progression. Shiina H, et al. **Br J Urol** 1996 Jan; 77(1):96–101

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Murphy GP, et al. **Cancer** 1996 Aug 15;78(4):809–18

Tissue fibronectin levels of human prostatic cancer, as a tumor marker. Sönmez H, et al. **Cancer Biochem Biophys** 1995 Nov;15(2):107–10

Tissue sialic acid and fibronectin levels in human prostatic cancer. Süer S, et al. **Cancer Lett** 1996 Feb 6;99(2):135–7

Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Perry JE, et al. **Cancer Res** 1996 Apr 1;56(7):1539–44

Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Harper ME, et al. **Eur J Cancer** 1995;31A(9):1492–7

Immunolocalization of glycoprotein A-80 in prostatic carcinoma and prostatic intraepithelial neoplasia. Gould VE, et al. **Hum Pathol** 1996 Jun;27(6):547–52

Distribution of lipochrome pigment in the prostate gland: biological and diagnostic implications. Leung CS, et al. **Hum Pathol** 1995 Dec;26(12):1302–7

Characterization of a prostate carcinoma mucin-like antigen (PMA). Beckett ML, et al. **Int J Cancer** 1995 Sep 15; 62(6):703–10

Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Stattin P, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):885–9

Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. Tennant MK, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):411–20

PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum. Wu JT, et al. **J Clin Lab Anal** 1995;9(4):243–51

beta hCG as a prognostic marker in adenocarcinoma of the prostate. Sheaff MT, et al. **J Clin Pathol** 1996 Apr; 49(4):329–32

Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. Kim ED, et al. **J Urol** 1995 Nov;154(5):1802–5

Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. Moul JW, et al. **J Urol** 1996 Mar; 155(3):982–5

Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations [see comments] Thrasher JB, et al. **J Urol** 1996 Mar;155(3):999–1003. Comment in: J Urol 1996 Mar;155(3):1004.

Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Eastham JA, et al. **Lab Invest** 1995 Nov;73(5):628–35

Role of basic fibroblast growth factor in prostatic tumors. Sinowatz F, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):619–21

Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. Humphrey PA, et al. **Pathol Res Pract** 1995 Sep;191(9):881–7

In situ hybridization studies of alpha 2-macroglobulin receptor and receptor-associated protein in human prostate carcinoma. McGarvey T, et al. **Prostate** 1996 May; 28(5):311–7

Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. Noordzij MA, et al. **Prostate** 1995 Sep;27(3):154–9

Expression of CD44 isoforms in human prostate tumor cell lines. Stevens JW, et al. **Prostate** 1996 Mar;28(3):153–61

DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis. Warzynski MJ, et al. **Prostate** 1995 Dec; 27(6):329–35

Clinical implication of neuroendocrine differentiation in prostatic adenocarcinomas. Constantinides C, et al. **Urol Int** 1995;55(3):134–6

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Stricker HJ, et al. **Urology** 1996 Mar;47(3):366–9

[Various immunohistochemical markers of precancer and variants of prostate cancer] Romanenko AM, et al. **Arkh Patol** 1995 Jul–Aug;57(4):38–41 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

The TNM classification of prostate cancer: a discussion of the 1992 classification. The British Association of Urological Surgeons TNM Subcommittee. **Br J Urol** 1995

Sep;76(3):279–85 (22 ref.)

COMPLICATIONS

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428–33

Paget's disease of the scrotum: report of a case with underlying carcinoma of the prostate. Koh KB, et al. **Br J Dermatol** 1995 Aug;133(2):306–7

A case of Cowden's disease accompanied by prostatic cancer. Inagaki T, et al. **Br J Urol** 1996 Jun;77(6):918–9

Evaluation of a tubular mesh and a spiral stent woven from titanium nickel alloy for prostatic obstruction in patients at high risk for surgery. Report of 62 cases. Sun Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):769–73

Spinal cord compression due to anaerobic vertebral osteomyelitis in a patient with metastatic prostate cancer [letter] Bilgrami S, et al. **Clin Infect Dis** 1995 Aug; 21(2):457–8

Acute renal failure in a patient with chronic glomerulonephritis after the administration of luteinizing hormone-releasing hormone analogue given for rectal obstruction due to prostate cancer. Takezawa Y, et al. **Int J Urol** 1996 Jan;3(1):67–9

Vivre ou laisser mourir [letter] Rutschmann OT, et al. **J Am Geriatr Soc** 1996 Jan;44(1):104

Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma [letter] Schuval BJ, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):864

The use of a removable stent in patients with prostate cancer and obstruction. Yachia D, et al. **J Urol** 1996 Jun; 155(6):1956–8

A 72-year-old man with localized prostate cancer, 1 year later [comment] Delbanco TL, et al. **JAMA** 1996 Feb 14; 275(6):485. Comment on: JAMA 1995 Jul 5;274(1):69–74.

Case report: confusion responding to dexamethasone in a patient with cancer of the prostate. Wilcock A, et al. **Palliat Med** 1995 Oct;9(4):337–8

Schistosomiasis and prostate cancer. Cohen RJ, et al. **Pathology** 1995 Apr;27(2):115–6

The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy. Hunter DJ, et al. **Qual Life Res** 1995 Aug;4(4):335–41

Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Agarawal SK, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):351–3 (8 ref.)

Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Nakahama H, et al. **Urol Int** 1995;55(1):38–40

Gammopathy associated with advanced prostate carcinoma. Abdul M, et al. **Urol Res** 1995;23(3):185–8

A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Jønler M, et al. **Urology** 1996 Sep; 48(3):433–40

Utility of chest radiography and cystoscopy in the evaluation of patients with localized prostate cancer. Ranparia DJ, et al. **Urology** 1996 Jul;48(1):72–4

[Internal urinary diversion in pelvic cancers and quality of life. Value of double "J" endoprosthesis] Giannakopoulos X, et al. **J Urol (Paris)** 1995;101(5–6):221–7 (Eng. Abstr.) **(Fre)**

[Prostatic tuberculous abscess in AIDS. 2 cases (letter)] Greder-Belan A, et al. **Presse Med** 1995 Sep 30;24(28):1315 **(Fre)**

[Disseminated intravascular coagulation syndrome with secondary fibrinolysis activation in prostatic carcinoma] Iwan-Ziętek I, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):100–1 (Eng. Abstr.) **(Pol)**

[Inappropriate antidiuretic hormone secretion syndrome: a rare manifestation of prostatic adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Dec;48(10):1042–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Imaging of prostate cancer. Choyke PL. **Abdom Imaging** 1995 Nov-Dec;20(6):505–15 (40 ref.)

Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. Jager GJ, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):845–52

Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. Presti JC Jr, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):103–8

Management of BPH: educating patients about PSA [letter; comment] Malvea BP. **Am Fam Physician** 1996 Mar; 53(4):1080, 1082. Comment on: Am Fam Physician 1995 Jul;52(1):135–42, 145–6.

Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy. Anscher MS. **Am J Clin Oncol** 1995 Dec; 18(6):481–3

PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. Miller LS, et al. **Am J Clin Oncol** 1996 Jun;19(3):217–22

Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer--a local experience. Tan HH, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):550–6

Changes in early detection of prostate cancer in the United States. Mettlin C. **Ann N Y Acad Sci** 1995 Sep 30;768:68–72 (14 ref.)

Tumour serum markers: clinical and economical aspects. Kardamakis D. **Anticancer Res** 1996 Jul–Aug; 16(4B):2285–8 (17 ref.)

DRE-PSA data revisited: PSA sampling should precede DREs [letter] Douville P, et al. **Arch Intern Med** 1996 Jun 24;156(12):1352–3

The impact of informed consent on patient interest in prostate-specific antigen screening [see comments] Wolf AM, et al. **Arch Intern Med** 1996 Jun 24;156(12):1333–6. Comment in: Arch Intern Med 1996 Jun 24;156(12):1262–3.

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Grignon DJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1122–6 (79 ref.)

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer [see comments] Parkes C, et al. **BMJ** 1995 Nov 18; 311(7016):1340–3. Comment in: BMJ 1996 Mar 16;312(7032):708–9; discussion 709–10. Comment in: BMJ 1996 Mar 16;312(7032):709; discussion 709–10. Comment in: BMJ 1996 Mar 16;312(7032):709–10.

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Auvinen A, et al. **Br J Cancer** 1996 Aug; 74(4):568–72

Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site. Harper CL, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):367–8

Comment: dilemmas of diagnosis and treatment of prostate cancer [see comments] Sandu DP. **Br J Hosp Med** 1996 Mar 6–19;55(5):233–4. Comment in: Br J Hosp Med 1996 Mar 6–19;55(5):232–3.

Short communication: the use of sodium ironedetate (Sytron) as an MRI rectal contrast agent. Buxton PJ. **Br J Radiol** 1996 Mar;69(819):266–8

Derivation and application of upper limits for prostate specific antigen in men aged 50–74 years with no clinical evidence of prostatic carcinoma. Dalkin BL, et al. **Br J Urol** 1995 Sep;76(3):346–50

Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Gustafsson O, et al. **Br J Urol** 1996 Mar;77(3):433–40

Primary non-Hodgkin's lymphoma of the prostate mimicking acute prostatitis. Parks RW, et al. **Br J Urol** 1995 Sep; 76(3):409

Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Thomas SA, et al. **Br J Urol** 1996 Mar;77(3):367–72

Detection of residual prostate cancer after external radiotherapy [letter; comment] Anand A, et al. **Cancer** 1995 Nov 1;76(9):1682. Comment on: Cancer 1995 Apr 15;75(8):2153–8.

The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. Demura T, et al. **Cancer** 1996 Mar 15;77(6):1137–43

Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Egawa S, et al. **Cancer** 1995 Aug 1;76(3):463–72

The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Mettlin C, et al. **Cancer** 1996 Jan 1;77(1):150–9

Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia. Myers RE, et al. **Cancer** 1996 Aug 1; 78(3):471–9

Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? Raviv G, et al. **Cancer** 1996 May 15;77(10):2103–8

The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry. Stephenson RA, et al. **Cancer** 1996 Apr 1;77(7):1342–8

Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells [letter] Henke W, et al. **Clin Chem** 1996 Sep;42(9):1499–500

Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen [editorial; comment] Heston WD. **Clin Chem** 1995 Dec;41(12 Pt 1):1687–8. Comment on: Clin Chem 1995 Dec;41(12 Pt 1):1698–704.

Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen [see comments] Loric S, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1698–704. Comment in: Clin Chem 1995 Dec;41(12 Pt 1):1687–8.

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study [see comments] Filella X, et al. **Eur J Cancer** 1996 Jun;32A(7):1125–8. Comment in: Eur J Cancer 1996 Jun;32A(7):1097–9.

PSA and prostate cancer diagnosis [editorial; comment] Savage P, et al. **Eur J Cancer** 1996 Jun;32A(7):1097–9. Comment on: Eur J Cancer 1996 Jun;32A(7):1125–8.

Update on urology--prostate cancer. Screening for prostate cancer: an European view. de Silva FC. **Eur J Surg Oncol** 1996 Apr;22(2):189–91, 196 (9 ref.)

The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Akdas A, et al. **Eur Urol** 1996; 29(2):189–92

Attitudes of European urologists to early prostatic carcinoma. I. Diagnostic work-up on suspected prostatic cancer cases. Hansen MV, et al. **Eur Urol** 1995;28(3):189–95

Advances in the assessment of clinically localized prostate cancer. Ravery V, et al. **Eur Urol** 1996;29(3):257–65 (34 ref.)

The prostate specific antigen. Its use as a tumor marker for prostate cancer. Kantoff PW, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):555–72 (66 ref.)

Management dilemmas in prostate cancer. Bruskewitz R, et al. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):79–86

PSA: to screen or not to screen. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):145–6

Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy. Ciatto S, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):226–8

Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Correale M, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):24–8

Is serum PSA measurement a good test for early diagnosis of prostate cancer? Results of a pilot study and cost analysis. De Biasi F, et al. **Int J Biol Markers** 1996 Jan–Mar; 11(1):18–23

Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. Devine PL, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):221–5

Usefulness of PSA density and PSA excess in the differential diagnosis between prostate cancer and benign prostatic hypertrophy. Diaz F, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):12–7

Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays. Filella X, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):40–5

Third-generation PSA: ultrasensitive or ultraprecise assay? Mione R, et al. **Int J Biol Markers** 1995 Oct–Dec; 10(4):229–33

Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Filella X, et al. **Int J Cancer** 1995 Dec 11;63(6):780–4

Assessment of sextant biopsy of the prostate for detecting cancer prior to therapy in patients clinically diagnosed as benign prostatic hyperplasia. Egawa S, et al. **Int J Urol** 1995 May;2(2):110–5

Usefulness of digital rectal examination, serum prostate-specific antigen, transrectal ultrasonography and systematic prostate biopsy for the detection of organ-confined prostate cancer. Gohji K, et al. **Int J Urol** 1995 May;2(2):116–20

Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. Takahashi S, et al. **Int J Urol** 1995 Sep;2(4):215–23 (49 ref.)

Transrectal needle aspiration versus transperineal needle biopsy in diagnosis of prostatic carcinoma. Deliveliotis C, et al. **Int Urol Nephrol** 1995;27(2):173–7

Screening for prostate cancer [letter; comment] Benbassat J. **Isr J Med Sci** 1995 Sep;31(9):579–80. Comment on: Isr J Med Sci 1995 Feb–Mar;31(2–3):125–8.

Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. D'Amico AV, et al. **J Clin Oncol** 1996 Jun;14(6):1770–7

Vimentin and cytokeratin expression in nodular hyperplasia and carcinoma of the prostate. Heatley M, et al. **J Clin Pathol** 1995 Nov;48(11):1031–4

Prostate cancer screening [letter; comment] Lawrence G. **J Fam Pract** 1995 Dec;41(6):536–7. Comment on: J Fam Pract 1995 Jul;41(1):33–41.

Defining clinically significant prostate cancer: pathologic criteria versus outcomes data [editorial; comment] Albertsen PC. **J Natl Cancer Inst** 1996 Sep 4;88(17):1177–8 . Comment on: J Natl Cancer Inst 1996 Sep 4;88(17):1216–21.

Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors [see comments] Helgesen F, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1216–21. Comment in: J Natl Cancer Inst 1996 Sep 4;88(17):1177–8.

Prostatic intraepithelial neoplasia: will it help doctors pinpoint early prostate cancer? [news] Stone E. **J Natl Cancer Inst** 1996 Aug 7;88(15):1023–4

Prostatic intraepithelial neoplasia (PIN). Performance of Bayesian belief network for diagnosis and grading. Montironi R, et al. **J Pathol** 1995 Oct;177(2):153–62

Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. Babaian RJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):432–7

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Diamandis EP, et al. **J Urol** 1996 Jan;155(1):294; discussion 295. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. Elgamal AA, et al. **J Urol** 1996 Aug;156(2

Pt 1):464–8
Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. Elgamal AA, et al. **J Urol** 1996 Sep;156(3):1042–7; discussion 1047–9
Prostate specific antigen detected prostate cancer [editorial; comment] Gibbons RP. **J Urol** 1996 Mar;155(3):827. Comment on: J Urol 1996 Mar;155(3):816–20. Comment on: J Urol 1996 Mar;155(3):821–6.
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. Huland H, et al. **J Urol** 1996 Apr;155(4):1344–7
Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves [letter; comment] Jacobsen SJ, et al. **J Urol** 1996 Apr;155(4):1395–6. Comment on: J Urol 1994 Dec;152(6 Pt 1):2037–42.
Pitfalls in interpreting prostate specific antigen velocity [see comments] Kadmon D, et al. **J Urol** 1996 May; 155(5):1655–7. Comment in: J Urol 1996 May;155(5):1661–2.
Clinical and pathological features of hereditary prostate cancer. Keetch DW, et al. **J Urol** 1996 Jun;155(6):1841–3
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. Keetch DW, et al. **J Urol** 1996 Aug;156(2 Pt 1):428–31
Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer [letter; comment] Lawrence G. **J Urol** 1996 Aug;156(2 Pt 1):484 . Comment on: J Urol 1995 Oct;154(4):1418–9.
Prostate cancer—staging and prognosis [editorial] Miles BJ. **J Urol** 1996 Apr;155(4):1355–6
Cathepain D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. Moul JW, et al. **J Urol** 1996 Mar; 155(3):982–5
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients [see comments] Noldus J, et al. **J Urol** 1996 Jan;155(1):232–7. Comment in: J Urol 1996 Jan;155(1):243.
Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Schmid HP. **J Urol** 1996 Jan; 155(1):294–5. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.
Prostate cancer—improvements in detection and diagnosis [editorial; comment] Schmidt JD. **J Urol** 1996 Jan; 155(1):243. Comment on: J Urol 1996 Jan;155(1):228–31. Comment on: J Urol 1996 Jan;155(1):232–7. Comment on: J Urol 1996 Jan;155(1):238–42.
Prostate cancer [editorial] Sheinfeld J, et al. **J Urol** 1995 Nov; 154(5):1806–7
Prostate cancer—our patients' questions [editorial; comment] Theodorescu D. **J Urol** 1996 May;155(5):1661–2. Comment on: J Urol 1996 May;155(5):1557–62. Comment on: J Urol 1996 May;155(5):1655–7. Comment on: J Urol 1996 May;155(5):1658–60.
The definition and preoperative prediction of clinically insignificant prostate cancer. Walsh PC. **J Urol** 1996 Jul; 156(1):300–1
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing [see comments] Jacobsen SJ, et al. **JAMA** 1995 Nov 8;274(18):1445–9. Comment in: JAMA 1996 Apr 17;275(15):1155–6.
Trust me, I'm a scientist: will urologists set a lead for geneticists to follow? [see comments] Raffle AE. **Lancet** 1996 Mar 30;347(9005):883–4. Comment in: Lancet 1996 Jun 8;347(9015):1629.
Is prostate cancer worth diagnosing? Waxman J, et al. **Lancet** 1995 Nov 4;346(8984):1177–8
Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)
Hazards of transrectal biopsy of the prostate [letter] Glancy JJ, et al. **Med J Aust** 1996 Mar 4;164(5):320
Screening for prostate cancer: the case against. Hirst GH, et al. **Med J Aust** 1996 Mar 4;164(5):285–8
Screening for prostate cancer [letter; comment] Budenholzer B. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.
Screening for prostate cancer [letter; comment] Catalona WJ. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.
Screening for prostate cancer [letter; comment] Hensel WA. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.
Age-specific reference ranges for prostate-specific antigen in black men [see comments] Morgan TO, et al. **N Engl J Med** 1996 Aug 1;335(5):304–10. Comment in: N Engl J Med 1996 Aug 1;335(5):345–6.
Age-specific reference ranges for serum PSA [editorial; comment] Oesterling JE. **N Engl J Med** 1996 Aug 1; 335(5):345–6. Comment on: N Engl J Med 1996 Aug 1;335(5):304–10.
Screening for prostate cancer [letter; comment] Stevens R. **N Engl J Med** 1996 Mar 7;334(10):667; discussion 667–8 . Comment on: N Engl J Med 1995 Nov 23;333(21):1401–5.
Screening for prostate cancer with prostate-specific antigen. An examination of the evidence [see comments] Woolf SH. **N Engl J Med** 1995 Nov 23;333(21):1401–5 (62 ref.). Comment in: N Engl J Med 1996 Mar 7;344(10):666–7; discussion 667–8. Comment in: N Engl J Med 1996 Mar 7;344(10):667; discussion 667–8.
The impact of family history on early detection of prostate cancer [letter] Narod SA, et al. **Nat Med** 1995 Feb; 1(2):99–101
New 'calibrator' should improve prostate cancer testing [news] **Oncology (Huntingt)** 1995 Nov;9(11):1222
Diagnostic decision support for prostate lesions. Bartels PH, et al. **Pathol Res Pract** 1995 Sep;191(9):945–57
Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)
Screening for prostate cancer. Is it a service or a disservice? Luttge S, et al. **Postgrad Med** 1996 Sep;100(3):90–2, 95–6, 101–2 (5 ref.)
Prostate-specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al. **Postgrad Med** 1996 Feb;99(2):227–8, 231–4 (14 ref.)
Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. Brawn PN, et al. **Prostate** 1996 May;28(5):295–9
Small cell carcinoma of the prostate: CT and MRI findings. Munechika H, et al. **Radiat Med** 1995 May–Jun; 13(3):137–42
Quantitating regrowth delay of prostate cancers after failure of radiation therapy. Hood–Hanks S, et al. **Radiology** 1996 Aug;200(2):505–8
Prostate carcinoma: MR imaging findings after cryosurgery. Kalbhen CL, et al. **Radiology** 1996 Mar;198(3):807–11
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Kurhanewicz J, et al. **Radiology** 1996 Mar; 198(3):795–805
Clinical evaluation of prostate biopsy parameters: gland volume and elevated prostate-specific antigen level. Rubens DJ, et al. **Radiology** 1996 Apr;199(1):159–63
Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):139–44 (51 ref.)
Preoperative estimate of extent of disease in T1c: how well can we predict? Austenfeld MS. **Semin Urol Oncol** 1995 Aug;13(3):176–80 (42 ref.)
Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Barry MJ, et al. **Urology** 1995 Oct;46(4):445–61
Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Benoit RM, et al. **Urology** 1995 Oct;46(4):533–6; discussion 536–7 (43 ref.)
Neurofibromatosis with involvement of the prostate gland. Chung AK, et al. **Urology** 1996 Mar;47(3):448–51 (34 ref.)
Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Coetzee LJ, et al. **Urology** 1996 Feb; 47(2):232–5
Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Connolly JA, et al. **Urology** 1996 Feb;47(2):225–31
Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Crawford ED, et al. **Urology** 1996 Jun; 47(6):863–9
Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Deftos LJ, et al. **Urology** 1996 Jul; 48(1):58–62
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Labrie F, et al. **Urology** 1996 Feb;47(2):212–7
Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Ohori M, et al. **Urology** 1995 Nov;46(5):666–71
Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Reissigl A, et al. **Urology** 1995 Nov; 46(5):662–5
Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Roehrborn CG, et al. **Urology** 1996 Mar;47(3):347–52
Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels. Schmid HP, et al. **Urology** 1996 May;47(5):699–703
The influence of prostate size on cancer detection. Uzzo RG, et al. **Urology** 1995 Dec;46(6):831–6
More on the prostate cancer screening controversy [letter; comment] Ganiats TG. **West J Med** 1995 Aug;163(2):183 . Comment on: West J Med 1995 Mar;162(3):235–42.
Serologic markers in prostate cancer. Harris D, et al. **West J Med** 1996 Apr;164(4):344–5
Prostate-specific antigen density—a reliable parameter for the detection of prostate cancer? Thon WF, et al. **World J Urol** 1996;14(1):53–8
[A comparative assessment between transrectal echography, venous urography, CAT and morphology in patients with prostatic carcinoma] Mladenov D, et al. **Khirurgiia (Sofiia)** 1994;47(5):20–1 (Eng. Abstr.) **(Bul)**
[Prostate-specific antigen or PSA. Facts and probabilities] Boccon-Gibod L. **Presse Med** 1995 Oct 28;24(32):1471–2 (Eng. Abstr.) **(Fre)**
[Early diagnosis and screening of cancer of the prostate] Fendler JP, et al. **Presse Med** 1995 Oct 28;24(32):1461–3 (10 ref.) (Eng. Abstr.) **(Fre)**
[Prostate specific antigen. Clinical applications of ultrasensitive assay] Haab F, et al. **Presse Med** 1995 Nov 25;24(36):1697–702 (43 ref.) (Eng. Abstr.) **(Fre)**
[Advances in the diagnosis and therapy of prostate cancer. International symposium, 13 March 1993, Vienna] **Urologe A** 1993 Jul;32(4 Suppl):1–8 **(Ger)**
[Screening for prostatic cancer] Laufer M, et al. **Harefuah** 1995 Jul;129(1–2):39–43 (28 ref.) **(Heb)**
[Radiologic evaluation of parietal infiltration of bladder cancer (integrated imaging: US, TC, RM) and comparison with transurethral resection (TUR)] Gauldi GF, et al. **Clin Ter** 1995 Nov;146(11):691–711 (Eng. Abstr.) **(Ita)**
[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan–Feb; 147(1–2):51–66 (29 ref.) (Eng. Abstr.) **(Ita)**
[Prognostic factors of prostatic cancer] Okada Y, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1999–2005 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Determination of free type and complex type prostate-specific antigen (PSA): differences in immunorecognition by Delfia PSA, ACS-PSA and Eiken PA kits] Sumi S, et al. **Hinyokika Kiyo** 1996 Apr; 42(4):279–84 (Eng. Abstr.) **(Jpn)**
[Early detection of prostate cancer–results of a prostate specific antigen-based detection program at a "multiphasic screening] Egawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1711–9 (Eng. Abstr.) **(Jpn)**
[Transrectal ultrasound guided biopsies in 266 patients] Kurita Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov; 86(11):1631–5 (Eng. Abstr.) **(Jpn)**
[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention] Nishitani M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1368–74 (Eng. Abstr.) **(Jpn)**
[Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer] Uno H. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1776–83 (Eng. Abstr.) **(Jpn)**
[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma—the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method] Arai K, et al. **Rinsho Byori** 1996 Apr; 44(4):345–50 (Eng. Abstr.) **(Jpn)**
[Approaches in the prognostication of prostatic neoplasms] Teploukhova IM, et al. **Vopr Onkol** 1996;42(2):12–6 (42 ref.) **(Rus)**
[The diagnostic utility of PSA density] Alcover J, et al. **Actas Urol Esp** 1995 Mar;19(3):192–5 (Eng. Abstr.) **(Spa)**
[The index of PSA age vs PSA density. 2 new instruments in the detection of prostatic carcinoma] Fernández Arjona M, et al. **Actas Urol Esp** 1995 Mar;19(3):187–91 (Eng. Abstr.) **(Spa)**
[Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer (editorial)] Morote Robles J. **Actas Urol Esp** 1996 Jan;20(1):1–12 (71 ref.) **(Spa)**

DIET THERAPY

Re: Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet [letter] Pollard M. **J Natl Cancer Inst** 1996 Jan 3;88(1):56–7

DRUG THERAPY

Intermittent androgen therapy. Abi Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):91–2
Complete hormonal blockage—antiandrogens. Bierkens AF, et al. **Acta Urol Belg** 1996 May;64(2):77–9
Quality of life and intermittent hormonal therapy. da Silva FC. **Acta Urol Belg** 1996 May;64(2):93
Controversies surrounding hormonal deprivation. Denis LJ. **Acta Urol Belg** 1996 May;64(2):81–4
New molecules and treatment modulation in advanced prostatic cancer. Mahler C, et al. **Acta Urol Belg** 1996 May; 64(2):95–8
Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy. Scalliet P. **Acta Urol Belg** 1996 May;64(2):63–4
Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Chen M, et al. **AJR Am J Roentgenol** 1996 May;166(5):1157–63
Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Atkins JN, et al. **Am J Clin Oncol** 1996 Feb; 19(1):23–5
Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A

Southwest Oncology Group Study. Marshall ME, et al. **Am J Clin Oncol** 1995 Oct;18(5):400–2

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1996 Aug; 19(4):368–70

Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. Tisdale JF, et al. **Am J Hematol** 1996 Feb;51(2):152–7

Therapeutic options in patients with hormone–refractory prostate cancer [letter; comment] Anand A. **Am J Med** 1996 Feb;100(2):243–4. Comment on: Am J Med 1995 Apr;98(4):412–4.

Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Hemady RK, et al. **Am J Ophthalmol** 1996 Mar;121(3):291–6

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Vaillancourt L, et al. **Am J Surg Pathol** 1996 Jan;20(1):86–93

Phase I/II dose–escalation study of liarozole in patients with stage D, hormone–refractory carcinoma of the prostate. Seidmon EJ, et al. **Ann Surg Oncol** 1995 Nov;2(6):550–6

Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Lunglmayr G. **Anticancer Drugs** 1995 Aug; 6(4):508–13

Assessment of response to carboplatin in patients with hormone–refractory prostate cancer: a critical analysis of drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2825–8

Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. Schned AR, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):96–100

The synthetic retinoid N–(4–hydroxyphenyl) retinamide (4–HPR) exerts antiproliferative and apoptosis–inducing effects in the androgen–independent human prostatic JCA–1 cells. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):499–506

Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA–1 cells treated with modified citrus pectin. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):833–41

Gn–RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7–8):325–31 (60 ref.)

Maximal androgen blockade (MAB) for the treatment of prostate cancer [letter] Kirby RS. **Br J Clin Pract** 1996 Jul–Aug;50(5):287

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):359–66 (59 ref.)

Anti–androgens in the treatment of prostate cancer. Newling DW. **Br J Urol** 1996 Jun;77(6):776–84 (51 ref.)

Cost–effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL, et al. **Cancer** 1996 May 1;77(9):1854–61

Antitumor activity of suramin in hormone–refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Dawson NA, et al. **Cancer** 1995 Aug 1; 76(3):453–62

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone–refractory prostate carcinoma patients. Maulard–Durdux C, et al. **Cancer** 1996 Mar 15;77(6):1144–8

Brachytherapy and continuous infusion 5–fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. See WA, et al. **Cancer** 1996 Mar 1;77(5):924–7

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Small EJ, et al. **Cancer** 1995 Oct 15;76(8):1428–34

In vitro modulation of tumor progression–associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH, et al. **Cancer** 1996 May 1;77(9):1862–72

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone–refractory metastatic prostate carcinoma. Storlie JA, et al. **Cancer** 1995 Jul 1; 76(1):96–100

Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen–independent prostate cancer. Sella A, et al. **Cancer Biother** 1995 Fall;10(3):225–35

Effect of gonadotropin–releasing hormone analogs and their conjugates on gonadotropin–releasing hormone receptor—positive human cancer cell lines. Pályi I, et al. **Cancer Detect Prev** 1996;20(2):146–52

Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Liao S, et al. **Cancer Lett** 1995 Sep 25;96(2):239–43

Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors. Rokhlin OW, et al. **Cancer Lett** 1995 Nov 27;98(1):103–10

Endogenous interleukin 6 is a resistance factor for cis–diamminedichloroplatinum and etoposide–mediated cytotoxicity of human prostate carcinoma cell lines. Borsellino N, et al. **Cancer Res** 1995 Oct 15;55(20):4633–9

Estramustine revisited. Kreis W. **Cancer Treat Res** 1995; 78:163–84 (90 ref.)

Estimating the cost–effectiveness of flutamide in metastatic cancer. Hillner BE. **Cancer Treat Rev** 1996 Jan;22 Suppl A:103–8

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105–18 (61 ref.)

Effects of androgen suppression by gonadotropin–releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Denti L, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1176–81

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Morsi A, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):121–4

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Perry CM, et al. **Drugs Aging** 1995 Jul;7(1):49–74 (124 ref.)

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group [see comments] Brausi M, et al. **Eur J Cancer** 1995 Sep;31A(10):1622–6. Comment in: Eur J Cancer 1995 Sep;31A(10):1565–6.

Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients [letter] Santarossa S, et al. **Eur J Cancer** 1995 Sep;31A(10):1718

Update on urology—prostate cancer. 3—Systemic and palliative treatment of prostate cancer. Ekman P. **Eur J Surg Oncol** 1995 Oct;21(5):555–7; quiz 557, 567 (12 ref.)

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54–61 (28 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Debruyne FM. **Eur Urol** 1996;29 Suppl 2:34–6 (8 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Fitzpatrick JM. **Eur Urol** 1996;29 Suppl 2:37–9 (7 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78–82 (30 ref.)

The management of hormone refractory prostate cancer. Newling DW. **Eur Urol** 1996;29 Suppl 2:69–74 (24 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone–releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:105–9

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124–31 (62 ref.)

Flutamide–induced liver toxicity including fatal hepatic necrosis. Crownover RL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):911–5

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Yang FE, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1009–17

Etoposide, epirubicin and carboplatin in hormone–refractory prostate cancer. Fuse H, et al. **Int Urol Nephrol** 1996; 28(1):79–85

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone–releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Sasagawa I, et al. **Int Urol Nephrol** 1995;27(6):769–74

Phase II study of topotecan in metastatic hormone–refractory prostate cancer. Hudes GR, et al. **Invest New Drugs** 1995; 13(3):235–40

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995; 13(2):167–70

Depression during hormonal treatment of prostate cancer. Rosenblatt DE, et al. **J Am Board Fam Pract** 1995 Jul–Aug; 8(4):317–20

Treatment of prostate cancer with gonadotropin–releasing hormone analogue: effect on lipoprotein[a]. Arrer E, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2508–11

Lack of effect of a gonadotropin–releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma [letter] Schuval BJ, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):864

Double–blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Chang A, et al. **J Clin Oncol** 1996 Aug; 14(8):2250–7

Suramin in hormone–refractory metastatic prostate cancer: a drug with limited efficacy. Rosen PJ, et al. **J Clin Oncol** 1996 May;14(5):1626–36

Doxorubicin and dose–escalated cyclophosphamide with granulocyte colony–stimulating factor for the treatment of hormone–resistant prostate cancer. Small EJ, et al. **J Clin Oncol** 1996 May;14(5):1617–25

Evaluation of prostate–specific antigen as a surrogate marker for response of hormone–refractory prostate cancer to suramin therapy. Sridhara R, et al. **J Clin Oncol** 1995 Dec; 13(12):2944–53

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone–resistant prostate cancer: a Canadian randomized trial with palliative end points [see comments] Tannock IF, et al. **J Clin Oncol** 1996 Jun;14(6):1756–64. Comment in: J Clin Oncol 1996 Jun;14(6):1753–5.

One hundred thirteen men with hormone–refractory prostate cancer died today [editorial; comment] Vogelzang NJ. **J Clin Oncol** 1996 Jun;14(6):1753–5. Comment on: J Clin Oncol 1996 Jun;14(6):1756–64.

Conservative treatment of prostate cancer. Barry HC. **J Fam Pract** 1996 Mar;42(3):224, 226

3– and 4–pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha–hydroxylase/C17,20–lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. Chan FC, et al. **J Med Chem** 1996 Aug 16;39(17):3319–23

How much can we rely on the level of prostate–specific antigen as an end point for evaluation of clinical trials? A word of caution! [editorial; comment] Eisenberger MA, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):779–81. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):794–801.

Survey shows M.D.s' ambivalence about maximum androgen blockade [news] Randal J. **J Natl Cancer Inst** 1995 Dec 20;87(24):1827–9

Induction of apoptosis by diethylstilbestrol in hormone–insensitive prostate cancer cells. Robertson CN, et al. **J Natl Cancer Inst** 1996 Jul 3;88(13):908–17

Suramin–induced decrease in prostate–specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [see comments] Thalmann GN, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):794–801 . Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):779–81.

P450–dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)

Antisense oligonucleotide intralesional therapy for human PC–3 prostate tumors carried in athymic nude mice. Rubenstein M, et al. **J Surg Oncol** 1996 Jul;62(3):194–200

Estrogens in the treatment of prostate cancer. Cox RL, et al. **J Urol** 1995 Dec;154(6):1991–8 (96 ref.)

The mitotoxin, basic fibroblast growth factor–saporin, effectively targets human prostatic carcinoma in an animal model. Davol P, et al. **J Urol** 1996 Sep;156(3):1174–9

A new long acting formulation of the luteinizing hormone–releasing hormone analogue goserelin: results of studies in prostate cancer. Debruyne FM, et al. **J Urol** 1996 Apr;155(4):1352–4

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. Fleshner NE, et al. **J Urol** 1995 Nov; 154(5):1642–5; discussion 1645–6

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

Characterization of patients with androgen–independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J, et al. **J Urol** 1996 Feb;155(2):620–3

Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. Kruithof–Dekker IG, et al. **J Urol** 1996 Sep;156(3):1194–7

In vivo antitumor activity of bropirimine against PAIII and Dunning MAT–LyLu rodent prostate cancers. Sarosdy MF, et al. **J Urol** 1996 Jun;155(6):2085–9

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Small EJ. **J Urol** 1996 May;155(5):1704–5. Comment on: J Urol 1995 Aug;154(2 Pt 1):448–53.

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long–term endocrine effects of monotherapy. Soloway MS, et al. **J Urol** 1995 Dec; 154(6):2110–4

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Walsh PC. **J Urol** 1996 May;155(5):1705. Comment on: J Urol 1995 Aug;154(2 Pt 1):448–53.

Flutamide hepatotoxicity [see comments] Wysowski DK, et al. **J Urol** 1996 Jan;155(1):209–12. Comment in: J Urol 1996 Jan;155(1):226–7.

Estrogen therapy for prostate carcinoma. Presti JC Jr. **JAMA** 1996 Apr 17;275(15):1153

Haematogenous dissemination of prostate epithelial cells during surgery [letter; comment] Hamdy FC, et al. **Lancet** 1996 Feb 3;347(8997):325. Comment on: Lancet 1995 Dec 9;346(8989):1528–30.

Anti-androgens in treatment of prostate cancer [letter; comment] Waxman J, et al. **Lancet** 1995 Oct 14; 346(8981):1030. Comment on: Lancet 1995 Jul 29;346(8970):265–9.

Bicalutamide for prostate cancer. **Med Lett Drugs Ther** 1996 Jun 21;38(977):56–7

Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Kondapaka BS, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):53–8

IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. Stearns ME, et al. **Oncol Res** 1995;7(3–4):157–63

Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Viljoen TC, et al. **Oncology** 1995 Nov–Dec;52(6):465–9

The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Middleman MN, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):376–81

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Cronauer MV, et al. **Prostate** 1996 Mar;28(3):172–81

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233–40 (43 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR., et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Suramin as adjuvant therapy with radical prostatectomy. Saffrin R, et al. **Prostate** 1996 May;28(5):325–7

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297–303 (69 ref.)

Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)

Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Sutkowski DM, et al. **Prostate Suppl** 1996;6:62–6

Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues. Sundkvist GM, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):29–32

Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C – vitamin K3 combinations against human prostatic carcinoma cells. Gilloteaux J, et al. **Scanning Microsc** 1995 Mar;9(1):159–73

Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Hudes GR, et al. **Semin Oncol** 1995 Oct; 22(5 Suppl 12):41–5

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. Locatelli MC, et al. **Support Care Cancer** 1996 May;4(3):218–9

Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6–9, 1995. **Urology** 1996 Jan;47(1A Suppl):1–96

High-dose bicalutamide monotherapy for the treatment of prostate cancer. Blackledge GR. **Urology** 1996 Jan;47(1A Suppl):44–7; discussion 48–53

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G, et al. **Urology** 1995 Dec; 46(6):849–55

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer [letter; comment] Crawford ED. **Urology** 1995 Dec; 46(6):899–901. Comment on: Urology 1995 May;45(5):745–52.

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. Goldenberg SL, et al. **Urology** 1996 Jun; 47(6):882–4

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870–7

Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70–9; discussion 80–4 (29 ref.)

Defining the role of antiandrogens in the treatment of prostate cancer. McLeod DG, et al. **Urology** 1996 Jan; 47(1A Suppl):85–9; discussion 90–6 (40 ref.)

Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Naik H, et al. **Urology** 1996 Sep;48(3):508–11

Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Noldus J, et al. **Urology** 1996 May;47(5):713–8

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Schellhammer P, et al. **Urology** 1996 Jan;47(1A Suppl):54–60; discussion 80–4

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Scher HI, et al. **Urology** 1996 Jan;47(1A Suppl):61–9 (50 ref.)

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Soloway MS, et al. **Urology** 1996 Jan;47(1A Suppl):33–7; discussion 48–53

[Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results] Hermans BP, et al. **Acta Urol Belg** 1996 Mar;64(1):27–31 **(Fre)**

[Fulminant hepatitis caused by flutamide (letter)] Andréjak M, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):121–2 **(Fre)**

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape] Barthélémy Y, et al. **Prog Urol** 1996 Feb;6(1):93–7 (Eng. Abstr.) **(Fre)**

[Hot flashes and hormonal treatment of prostate cancer] Lanfrey P, et al. **Prog Urol** 1996 Feb;6(1):17–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study] Otto T, et al. **Urologe A** 1996 Mar;35(2):142–5 (Eng. Abstr.) **(Ger)**

[Medical therapy of locally advanced prostatic neoplasms] Boccardo F, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):203–8 **(Ita)**

[What is the role of neoadjuvant therapy in prostate cancer?] Witjes WP, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):209–14 (53 ref.) **(Ita)**

[An overview of clinical trials in endocrine therapy for cancer] Hinotsu S, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):689–94 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment for hormone-refractory or relapsing prostatic cancer] Hirao Y, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):418–26 (17 ref.) (Eng. Abstr.) **(Jpn)**

[QOL assessment in the treatment of prostate cancer] Isaka S. **Gan To Kagaku Ryoho** 1996 Mar;23(4):427–31 (Eng. Abstr.) **(Jpn)**

[Progress of endocrine therapy for prostate cancer and results] Kanetake H. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):413–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of prostate cancer resistant to endocrine therapy successfully treated with intra-arterial chemotherapy] Mima H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1694–6 (Eng. Abstr.) **(Jpn)**

[New development of endocrine therapy in prostate cancer] Naito S. **Gan To Kagaku Ryoho** 1996 May;23(6):684–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)] Kondo I, et al. **Hinyokika Kiyo** 1996 Mar;42(3):201–6 (Eng. Abstr.) **(Jpn)**

[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):143–53 (Eng. Abstr.) **(Jpn)**

[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):157–68 (Eng. Abstr.) **(Jpn)**

[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer] Komatus H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):789–96 (Eng. Abstr.) **(Jpn)**

[Intermittent intra-arterial chemotherapy for the treatment of patients with bladder cancer or prostate cancer using implantable injection pump] Sumiyoshi Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):682–7 (Eng. Abstr.) **(Jpn)**

[Experimental study and clinical application of a new combination chemotherapy with cis-platinum, adriamycin and carboquone in patients with advanced prostate cancer] Ito H. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):456–68 (Eng. Abstr.) **(Jpn)**

[Pharmacologic treatment of mild proliferation of prostatic cancer (editorial)] Dutkiewicz S. **Pol Tyg Lek** 1996 Feb; 51(6–9):67–72 (Eng. Abstr.) **(Pol)**

[An experimental study of the antitumor activity of preparations in a model of prostatic cancer] Burenin IS, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):33–5 (Eng. Abstr.) **(Rus)**

[Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer] Stepanov VN, et al. **Urol Nefrol (Mosk)** 1995 Nov–Dec;(6):33–6 (Eng. Abstr.) **(Rus)**

ECONOMICS

Cost conscious evaluation and treatment of prostate cancer [editorial; comment] Presti J Jr. **J Urol** 1996 Mar; 155(3):1004. Comment on: J Urol 1996 Mar;155(3):989–93. Comment on: J Urol 1996 Mar;155(3):994–8. Comment on: J Urol 1996 Mar;155(3):999–1003.

EMBRYOLOGY

Hypothesis: the prenatal origins of prostate cancer [editorial] Gardner WA. **Hum Pathol** 1995 Dec;26(12):1291–2

ENZYMOLOGY

Urokinase-type plasminogen activator expression in human prostate carcinomas. Van Veldhuizen PJ, et al. **Am J Med Sci** 1996 Jul;312(1):8–11

Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Montironi R, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2057–62

Tyrosine phosphorylation of a 185 kDa phosphoprotein (pp185) inversely correlates with the cellular activity of human prostatic acid phosphatase. Lin MF, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):206–13

Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Block JL, et al. **Cancer Lett** 1996 Apr 19;102(1–2):167–72

Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line. Block JL, et al. **Cancer Lett** 1996 Mar 29;101(2):143–8

Glyoxalase activities in tumor and non-tumor human urogenital tissues. Di Ilio C, et al. **Cancer Lett** 1995 Sep 25;96(2):189–93

Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors. Rokhlin OW, et al. **Cancer Lett** 1995 Nov 27;98(1):103–10

Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Lokeshwar VB, et al. **Cancer Res** 1996 Feb 1;56(3):651–7

Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Powell CT, et al. **Cancer Res** 1996 Sep 15;56(18):4137–41

Telomerase activity: a prevalent marker of malignant human prostate tissue. Sommerfeld HJ, et al. **Cancer Res** 1996 Jan 1;56(1):218–22

Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Zarghami N, et al. **Clin Biochem** 1995 Jun;28(3):243–53

Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Elo JP, et al. **Int J Cancer** 1996 Mar 28;66(1):37–41

Correlation of survival with quantitative tissue staining of prostate specific acid phosphatase in patients with prostate carcinoma by using microscopic image analysis: a preliminary report of correlative studies on RTOG protocols 75-06, 77-06, and 83-07. Zhou R, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):823–9

5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. Smith CM, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1361–6

The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. Murray GI, et al. **J Pathol** 1995 Oct;177(2):147–52

Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. Guillemette C, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):355–62

Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma. Duncan MD, et al. **J Surg Res** 1996 Jun;63(1):359–63

Matrilysin expression in human prostate carcinoma. Knox JD, et al. **Mol Carcinog** 1996 Jan;15(1):57–63

Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Bélanger G, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):165–73

Expression of galactosyltransferase in prostatic tumors. Amselgruber WM, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):638–42

Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Festuccia C, et al. **Oncol Res** 1995;7(3–4):131–8

A tyrosine kinase profile of prostate carcinoma. Robinson D, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):5958–62

There are multiple forms of glyceraldehyde-3-phosphate dehydrogenase in prostate cancer cells and normal prostate tissue. Epner DE, et al. **Prostate** 1996 Jun;28(6):372–8

Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate [see comments] Huber PR, et al. **Prostate** 1995 Oct;27(4):212–9. Comment in: Prostate 1996 Jul;29(1):65–6.

Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors. Krekels MD, et al. **Prostate** 1996 Jul;29(1):36–41

Deoxythymidine kinase in the staging of prostatic adenocarcinoma. Letocha H, et al. **Prostate** 1996 Jul; 29(1):15–9

Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Liu DF, et al. **Prostate** 1995 Nov;27(5):269–76

Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Lyon PB, et al. **Prostate** 1995 Oct;27(4):179–86

EPIDEMIOLOGY

Alcohol use and prostate cancer risk in US blacks and whites. Hayes RB, et al. **Am J Epidemiol** 1996 Apr 1;143(7):692–7

A case-control study of cancer of the prostate in Somerset and east Devon. Ewings P, et al. **Br J Cancer** 1996 Aug; 74(4):661–6

The impending Canadian prostate cancer epidemic. Morrison HI, et al. **Can J Public Health** 1995 Jul–Aug;86(4):274–8

Familial prostate cancer in Sweden. A nationwide register cohort study. Grönberg H, et al. **Cancer** 1996 Jan 1; 77(1):138–43 (20 ref.)

The National Cancer Data Base report on longitudinal observations on prostate cancer. Mettlin CJ, et al. **Cancer** 1996 May 15;77(10):2162–6

European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Schröder FH, et al. **Cancer** 1995 Jul 1;76(1):129–34

The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence—data from the Utah Cancer Registry. Stephenson RA, et al. **Cancer** 1996 Apr 1;77(7):1342–8

Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972–91 [see comments] McCredie M, et al. **Cancer Causes Control** 1996 May;7(3):337–44. Comment in: Cancer Causes Control 1996 May;7(3):299–301.

Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989–1993. Gilliland FD, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):797–800

The practice of causal inference in cancer epidemiology. Weed DL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):303–11 (175 ref.)

Association of prostate cancer with vitamin D receptor gene polymorphism. Taylor JA, et al. **Cancer Res** 1996 Sep 15; 56(18):4108–10

Prostate cancer in Czech Republic 1959–1992. Descriptive survey. Celko AM. **Cent Eur J Public Health** 1995 Aug; 3(3):119–23

Assault on the male. Twombly R. **Environ Health Perspect** 1995 Sep;103(9):802–5

Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165–70 (58 ref.)

High birthweight as a predictor of prostate cancer risk [see comments] Tibblin G, et al. **Epidemiology** 1995 Jul; 6(4):423–4. Comment in: Epidemiology 1995 Jul;6(4):347–9.

Quality of prostate cancer data in the cancer registry of Norway. Harvei S, et al. **Eur J Cancer** 1996 Jan; 32A(1):104–10

Cancer of the prostate in Norway 1957–1991—a descriptive study. Harvei S, et al. **Eur J Cancer** 1996 Jan;32A(1):111–7

Incidence of prostate cancer will double by the year 2030: the argument for. Boyle P, et al. **Eur Urol** 1996;29 Suppl 2:3–9 (31 ref.)

Incidence of prostate cancer will double by the year 2030: the argument against. George NJ. **Eur Urol** 1996;29 Suppl 2:10–2 (7 ref.)

Prospects for prostatic cancer incidence and treatment by the year 2000. Forti G, et al. **Int J Androl** 1996 Feb; 19(1):1–10 (81 ref.)

Analysis of cancer rates using excess risk age–period–cohort models. Lee WC, et al. **Int J Epidemiol** 1995 Aug; 24(4):671–7

Epidemiological characteristics of prostate cancer in Gunma Prefecture, Japan. Gunma University Urological Oncology Study Group. Nakata S, et al. **Int J Urol** 1995 Jul;2(3):191–7

Prostate cancer—look to Denmark? [letter] Tretli S, et al. **J Natl Cancer Inst** 1996 Jan 17;88(2):128

The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. Bostwick DG, et al. **J Urol** 1995 Nov; 154(5):1791–4

Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. Grönberg H, et al. **J Urol** 1996 Mar;155(3):969–74

Influence of patient age and co-morbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. Koch MO, et al. **J Urol** 1996 May; 155(5):1681–4

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing [see comments] Jacobsen SJ, et al. **JAMA** 1995 Nov 8;274(18):1445–9. Comment in: JAMA 1996 Apr 17;275(15):1155–6.

Prostate cancer incidence in Missouri: an updated analysis. Chang JC, et al. **Mo Med** 1995 Nov;92(11):693–5

The impact of family history on early detection of prostate cancer [letter] Narod SA, et al. **Nat Med** 1995 Feb; 1(2):99–101

Epidemiology of high grade prostatic intraepithelial neoplasia. Sakr WA, et al. **Pathol Res Pract** 1995 Sep; 191(9):838–41

Neoplastic and borderline lesions of the prostate: autopsy study and epidemiological data. Silvestri F, et al. **Pathol Res Pract** 1995 Sep;191(9):908–16

Work environment and prostate cancer risk. van der Gulden JW, et al. **Prostate** 1995 Nov;27(5):250–7

Prostate cancer in Rhode Island. Fulton JP. **R I Med** 1995 Nov;78(11):328–9

Prostatic tumours in Benin City, Nigeria. Akang EE, et al. **West Afr J Med** 1996 Jan–Mar;15(1):56–60

[Prostatic cancer in Oslo—a real decline?] Harvei S, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):750–4 (Eng. Abstr.) **(Nor)**

[Increased incidence of prostatic cancer. The significance of prostate-specific antigen] Otnes B, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1795–9 (Eng. Abstr.) **(Nor)**

[Epidemiology of prostate cancer] Ilić M, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):585–9 **(Scr)**

ETHNOLOGY

Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Corder EH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):655–9

Ethnic variation in prostate cancer survival in New Mexico. Gilliland FD, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):247–51

Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Wu AH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov;4(7):735–41

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. Moul JW, et al. **JAMA** 1995 Oct 25;274(16):1277–81

Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Schapira MM, et al. **Med Care** 1995 Nov;33(11):1079–88

Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Powell IJ, et al. **Urology** 1995 Dec;46(6):825–30

ETIOLOGY

Occupational risk factors for prostate cancer: results from a case-control study in Montréal, Québec, Canada. Aronson KJ, et al. **Am J Epidemiol** 1996 Feb 15; 143(4):363–73

Normal development and carcinogenesis of the prostate. A unifying hypothesis. Hayward SW, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:50–62 (41 ref.)

Farmers at risk for prostate cancer. Van Der Gulden JW, et al. **Br J Urol** 1996 Jan;77(1):6–14 (98 ref.)

Origins of prostate cancer. Montironi R, et al. **Cancer** 1996 Jul 15;78(2):362–5

A change in practice: current urologic practice in response to reports concerning vasectomy and prostate cancer. Sandlow JI, et al. **Fertil Steril** 1996 Aug;66(2):281–4

Hypothesis: the prenatal origins of prostate cancer [editorial] Gardner WA. **Hum Pathol** 1995 Dec;26(12):1291–2

Intake of carotenoids and retinol in relation to risk of prostate cancer. Giovannucci E, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1767–76

A unifying hypothesis that links benign prostatic hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Invited comments. Harvey H. **Pathol Res Pract** 1995 Sep; 191(9):924–34

Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Bosland MC. **Prog Clin Biol Res** 1996;394:309–52 (225 ref.)

Work environment and prostate cancer risk. van der Gulden JW, et al. **Prostate** 1995 Nov;27(5):250–7

Cellular biology of prostatic growth factors. Peehl DM. **Prostate Suppl** 1996;6:74–8 (55 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79–81 (22 ref.)

Tobacco, alcohol, diet and risk of prostate cancer. De Stefani E, et al. **Tumori** 1995 Sep–Oct;81(5):315–20

[Risk factors in carcinoma of the prostate] Kohout J, et al. **Cas Lek Cesk** 1995 Nov 1;134(21):679–80 (31 ref.) (Eng. Abstr.) **(Cze)**

[Etiology of prostate cancer and significance of screening for early prostate cancer] Imai K, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):403–6 (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic basis and clonal evolution of human prostate cancer. Kallioniemi OP, et al. **Adv Cancer Res** 1996;68:225–55 (118 ref.)

Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromosome 13 [letter] Doll JA, et al. **Am J Hum Genet** 1996 Feb;58(2):425–8

Germ-line BRCA1 mutations in selected men with prostate cancer [letter] Langston AA, et al. **Am J Hum Genet** 1996 Apr;58(4):881–4

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Koivisto P, et al. **Am J Pathol** 1995 Dec;147(6):1608–14

Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Konishi N, et al. **Am J Pathol** 1995 Oct; 147(4):1112–22

Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Mazzucchelli L, et al. **Am J Pathol** 1996 Aug;149(2):501–9

Direct molecular analysis of archival tumor tissue for loss of heterozygosity. Johnson DR, et al. **Biotechniques** 1995 Aug;19(2):190–2

A microdissection approach to detect molecular markers during progression of prostate cancer. Berthon P, et al. **Br J Cancer** 1995 Oct;72(4):946–51

P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Dahiya R, et al. **Br J Cancer** 1996 Jul;74(2):264–8

p16 mutations/deletions are not frequent events in prostate cancer. Tamimi Y, et al. **Br J Cancer** 1996 Jul;74(1):120–2

Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer. Taniguchi J, et al. **Br J Urol** 1996 May;77(5):719–23

Hereditary prostate cancer [letter; comment] Levy I, et al. **Can Med Assoc J** 1996 Feb 1;154(3):300–1. Comment on: Can Med Assoc J 1995 Oct 1;153(7):895–900.

Hereditary aspects of prostate cancer [see comments] McLellan DL, et al. **Can Med Assoc J** 1995 Oct 1; 153(7):895–900 (26 ref.). Comment in: Can Med Assoc J 1995 Oct 1;153(7):935–8. Comment in: Can Med Assoc J 1996 Feb 1;154(3):300–1.

The dilemma of hereditary prostate cancer [editorial; comment] Nickel JC. **Can Med Assoc J** 1995 Oct 1; 153(7):935–8. Comment on: Can Med Assoc J 1995 Oct 1;153(7):895–900.

Familial prostate cancer in Sweden. A nationwide register cohort study. Grönberg H, et al. **Cancer** 1996 Jan 1; 77(1):138–43 (20 ref.)

Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Kunimi K, et al. **Cancer Detect Prev** 1996;20(3):218–22

Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)

Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. Jackson-Cook C, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):14–23

Cytogenetic support for primary prostatic cancer in a patient presenting with a soft tissue mass in the leg. Molenaar WM, et al. **Cancer Genet Cytogenet** 1996 Feb;86(2):147–9

del(1)(q12) in adenocarcinomas of the prostate. Qi H, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):79–81

Cytogenetic abnormalities are frequent in uncultured prostate cancer cells. Webb HD, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):126–32

Homologous centromere association of chromosomes 9 and 17 in prostate cancer. Williams BJ, et al. **Cancer Genet Cytogenet** 1995 Dec;85(2):143–51

Combined cytogenetic and molecular genetic analyses of fifty-nine untreated human prostate carcinomas. Zitzelsberger H, et al. **Cancer Genet Cytogenet** 1996 Aug; 90(1):37–44

Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system. Blount LV, et al. **Cancer Lett** 1996 Jan 2;98(2):213–8

An uncertain role for p53 gene alterations in human prostate cancers. Brooks JD, et al. **Cancer Res** 1996 Aug 15; 56(16):3814–22

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cher ML, et al. **Cancer Res** 1996 Jul 1;56(13):3091–102

Distinct regions of allelic loss on 13q in prostate cancer. Cooney KA, et al. **Cancer Res** 1996 Mar 1;56(5):1142–5

Identification and characterization of proximal 6q deletions in prostate cancer. Cooney KA, et al. **Cancer Res** 1996 Sep 15;56(18):4150–3

Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Ewing CM, et al. **Cancer Res** 1995 Nov 1;55(21):4813–7

E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Graff JR, et al. **Cancer Res** 1995 Nov 15;55(22):5195–9

Loss of the chromosomal region 10q23–25 in prostate cancer. Gray IC, et al. **Cancer Res** 1995 Nov 1;55(21):4800–3

Allelic loss on chromosome 10 in prostate adenocarcinoma. Ittmann M. **Cancer Res** 1996 May 1;56(9):2143–7

Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Macoska JA, et al. **Cancer Res** 1995 Nov 15;55(22):5390–5

Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Murakami YS, et al. **Cancer Res** 1996 May 1;56(9):2157–60

Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Qian J, et al. **Cancer Res** 1995 Nov 15; 55(22):5408–14

Association of prostate cancer with vitamin D receptor gene polymorphism. Taylor JA, et al. **Cancer Res** 1996 Sep 15; 56(18):4108–10

The t(6;16)(p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene. Veronese ML, et al. **Cancer Res** 1996 Feb 15;56(4):728–32

Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12–21. Vocke CD, et al. **Cancer Res** 1996 May 15;56(10):2411–6

Two differentially expressed genes in normal human prostate tissue and in carcinoma. Wang FL, et al. **Cancer Res** 1996 Aug 15;56(16):3634–7

Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)

Genetic alterations in prostate cancer. Isaacs WB, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:653–9 (67 ref.)

Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancer. Alers JC, et al. **Cytometry** 1995 Sep 1;21(1):84–94

DNA ploidy and proliferation heterogeneity in human

prostate cancers. Shankey TV, et al. **Cytometry** 1995 Sep 1;21(1):30–9

A human gene encoding diazepam–binding inhibitor/acyl–CoA–binding protein: transcription and hormonal regulation in the androgen–sensitive human prostatic adenocarcinoma cell line LNCaP. Swinnen JV, et al. **DNA Cell Biol** 1996 Mar;15(3):197–208

Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA–1: evidence that the antiproliferative effects of 1 alpha, 25–dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Hedlund TE, et al. **Endocrinology** 1996 May;137(5):1554–61

Prostate gene isolated [news] **Environ Health Perspect** 1995 Jul–Aug;103(7–8):652

Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. McGarvey TW, et al. **Exp Mol Pathol** 1995 Aug;63(1):52–62

Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Brothman AR, et al. **Genes Chromosomes Cancer** 1995 Aug; 13(4):278–84

Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Joos S, et al. **Genes Chromosomes Cancer** 1995 Dec;14(4):267–76

Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Nihei N, et al. **Genes Chromosomes Cancer** 1995 Oct;14(2):112–9

Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Bova GS, et al. **Genomics** 1996 Jul 1;35(1):46–54

Structure and methylation–associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. MacGrogan D, et al. **Genomics** 1996 Jul 1;35(1):55–65

Interphase in situ hybridization to disaggregated and intact tissue specimens of prostatic adenocarcinomas. Alers JC, et al. **Histochem Cell Biol** 1995 Dec;104(6):479–86

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Glynne–Jones E, et al. **Hum Pathol** 1996 Jul;27(7):688–94

Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Ittmann MM, et al. **Hum Pathol** 1996 Jan;27(1):28–34

Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. König JJ, et al. **Hum Pathol** 1996 Jul; 27(7):720–7

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Wertz IE, et al. **Hum Pathol** 1996 Jun;27(6):573–80

Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Crundwell MC, et al. **Int J Cancer** 1996 Aug 22;69(4):295–300

Recurrent cytogenetic alterations of prostate carcinoma and amplification of c–myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Degeorges A, et al. **Int J Cancer** 1995 Sep 15;62(6):724–31

Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Lacombe L, et al. **Int J Cancer** 1996 Apr 22;69(2):110–3

The BRCA2 gene is not relevant to sporadic prostate tumours [letter] Latil A, et al. **Int J Cancer** 1996 Apr 10;66(2):282–3

Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. Elo JP, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3494–500

Clues to prostate cancer gene are few, but possibilities emerge [news] Bankhead C. **J Natl Cancer Inst** 1996 Jan 3; 88(1):11–2

Search for prostate cancer gene sites may succeed in 1996 [news] Eastman P. **J Natl Cancer Inst** 1996 Jul 17; 88(14):952–3

NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. Borchers H, et al. **J Urol** 1996 Jun;155(6):2080–4

Commentary on tumor suppressor gene, distal to BRCA–1, in prostate cancer [comment] Chung LW. **J Urol** 1996 Feb; 155(2):430–1. Comment on: J Urol 1996 Feb;155(2):720–5.

Familial aspects of prostate cancer: a case control study. Keetch DW, et al. **J Urol** 1995 Dec;154(6):2100–2

Clinical and pathological features of hereditary prostate cancer. Keetch DW, et al. **J Urol** 1996 Jun;155(6):1841–3

p53 immunohistochemical and genetic alterations are associated at high incidence with post–irradiated locally persistent prostate carcinoma. Prendergast NJ, et al. **J Urol** 1996 May;155(5):1685–92

Increased expression of early growth response–1 messenger ribonucleic acid in prostatic adenocarcinoma. Thigpen AE, et al. **J Urol** 1996 Mar;155(3):975–81

Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer [see comments] Williams BJ, et al. **J Urol** 1996 Feb;155(2):720–5. Comment in: J Urol 1996 Feb;155(2):430–1.

Prostate cancer gene hunters track their quarry [news] Stephenson J. **JAMA** 1996 Sep 18;276(11):861–3

Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Komiya A, et al. **Jpn J Cancer Res** 1995 Jul;86(7):622–5

Microsatellite instability and other molecular abnormalities in human prostate cancer. Suzuki H, et al. **Jpn J Cancer Res** 1995 Oct;86(10):956–61

APC gene mutations in human prostate cancer. Watanabe M, et al. **Jpn J Clin Oncol** 1996 Apr;26(2):77–81

Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues. Li SS. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):441–7

Evidence of an X–linked or recessive genetic component to prostate cancer risk [see comments] Monroe KR, et al. **Nat Med** 1995 Aug;1(8):827–9. Comment in: Nat Med 1995 Sep;1(9):848–9.

Metastases suppressors and prostate cancer. Petrylak DP. **Nat Med** 1995 Aug;1(8):739–40

Androgen receptor and familial prostate cancer [letter; comment] Sun S, et al. **Nat Med** 1995 Sep;1(9):848–9. Comment on: Nat Med 1995 Aug;1(8):827–9.

Neu differentiation factor (Heregulin) activates a p53–dependent pathway in cancer cells. Bacus SS, et al. **Oncogene** 1996 Jun 20;12(12):2535–47

Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Gao X, et al. **Oncogene** 1995 Oct 5; 11(7):1395–8

Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. Gao X, et al. **Oncogene** 1995 Oct 5;11(7):1241–7

Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Kagan J, et al. **Oncogene** 1995 Nov 16; 11(10):2121–6

Over–expression of fibroblast growth factor–8 in human prostate cancer. Leung HY, et al. **Oncogene** 1996 Apr 18; 12(8):1833–5

Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Cohen RJ, et al. **Pathology** 1995 Jul; 27(3):229–32

Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter–q11. Sanchez Y, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2551–6

Point mutations in the Ki–ras2 gene of codon 12 in the Dunning R–3327 Prostatic Adenocarcinoma system. Blount LV, et al. **Prostate** 1996 Jan;28(1):44–50

Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Evans BA, et al. **Prostate** 1996 Mar; 28(3):162–71

Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Ittmann MM. **Prostate** 1996 May;28(5):275–81

Selection toward diploid cells in prostatic carcinoma derived cell cultures. Ketter R, et al. **Prostate** 1996 Jun;28(6):364–71

Retinoblastoma gene mutations in primary human prostate cancer. Kubota Y, et al. **Prostate** 1995 Dec;27(6):314–20

Development of a high–efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta–galactosidase. Rinker–Schaeffer CW, et al. **Prostate** 1996 Jul;29(1):60–4

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H, et al. **Prostate** 1996 May;28(5):318–24

Provocative aspects of androgen genetics. Brown TR. **Prostate Suppl** 1996;6:9–12 (14 ref.)

Metastasis suppressor genes for prostate cancer. Ichikawa T, et al. **Prostate Suppl** 1996;6:31–5

DNA methylation, molecular genetic, and linkage studies in prostate cancer. Jarrard DF, et al. **Prostate Suppl** 1996; 6:36–44 (88 ref.)

A comparative analysis of prostate–specific antigen gene sequence in benign and malignant prostate tissue. Baffa R, et al. **Urology** 1996 Jun;47(6):795–800

Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Blades RA, et al. **Urology** 1995 Nov;46(5):681–6; discussion 686–7

Metaphase cytogenetics and DNA flow cytometry with analysis of S–phase fraction in prostate cancer: influence on prognosis. Bratt O, et al. **Urology** 1996 Feb;47(2):218–24

Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Meyer–Siegler K, et al. **Urology** 1996 Sep;48(3):448–52

Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Qian J, et al. **Urology** 1995 Dec;46(6):837–42

[Hereditary prostate carcinoma. National Work Group Hereditary Urological tumors. Foundation Tracing Hereditary Tumors] Kiemeney LA, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1068–72 (29 ref.) **(Dut)**

[Genetic alterations in localized cancers of the prostate: identification of a common region of deletion on the chromosome 18q] Latil A, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):589–97 (Eng. Abstr.) **(Fre)**

[The PROGENE study, the French project of genetic analysis of familial prostatic cancer: recruitment and analysis] Valeri A, et al. **Prog Urol** 1996 Apr;6(2):226–35 (Eng. Abstr.) **(Fre)**

[Familial aspects of prostatic carcinoma. Personal experience and review of the literature] Magno C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):113–5 (Eng. Abstr.) **(Ita)**

[An analysis of familial prostate cancer] Nakata S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1483–7 (Eng. Abstr.) **(Jpn)**

[Chromosome changes in prostatic cancer. Historic evolution and future perspective (editorial)] Alcaraz A, et al. **Actas Urol Esp** 1995 Jul–Aug;19(7):539–43 **(Spa)**

[Significance of ploidy in prostatic cancer, quantified by a prospectively applicable procedure] Valle Gerhold J, et al. **Arch Esp Urol** 1996 Mar;49(2):139–45 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988–1992. Schneider SB, et al. **Am J Clin Oncol** 1996 Feb;19(1):65–72

DRE–PSA data revisited: PSA sampling should precede DREs [letter] Douville P, et al. **Arch Intern Med** 1996 Jun 24;156(12):1352–3

Early detection of prostate cancer. Role of prostate–specific antigen. Prabhakaran VM. **Can Fam Physician** 1996 Apr; 42:709–12 (20 ref.)

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Leibman BD, et al. **Cancer** 1995 Dec 15;76(12):2530–4

Immunohistochemical study of HNK–1 (Leu–7) antigen in prostate cancer and its clinical significance. Liu X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):516–21

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Jung K, et al. **Eur J Cancer** 1996 Apr;32A(4):627–30

Prostate tissue specificity of the prostate–specific antigen promoter isolated from a patient with prostate cancer. Pang S, et al. **Hum Gene Ther** 1995 Nov;6(11):1417–26

Characterization of a prostate carcinoma mucin–like antigen (PMA). Beckett ML, et al. **Int J Cancer** 1995 Sep 15; 62(6):703–10

Patterns–of–failure analysis of patients with high pretreatment prostate–specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. Hanks GE, et al. **J Clin Oncol** 1996 Apr;14(4):1093–7

How much can we rely on the level of prostate–specific antigen as an end point for evaluation of clinical trials? A word of caution! [editorial; comment] Eisenberger MA, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):779–81. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):794–801.

PSA levels after radiotherapy: how low must they go? [news] McNeil C. **J Natl Cancer Inst** 1996 Jun 19;88(12):791–2

Suramin–induced decrease in prostate–specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [see comments] Thalmann GN, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):794–801 . Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):779–81.

Haematogenous dissemination of prostate epithelial cells during surgery [letter; comment] Oefelein MG, et al. **Lancet** 1996 Feb 3;347(8997):324–5. Comment on: Lancet 1995 Dec 9;346(8989):1528–30.

Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL–2) and alpha–interferon (A–IFN) for stage D3 prostate carcinoma failing second–line hormonal treatment. Maffezzini M, et al. **Prostate** 1996 May; 28(5):282–6

Presentation of prostate tumor antigens by dendritic cells stimulates T–cell proliferation and cytotoxicity. Tjoa B, et al. **Prostate** 1996 Jan;28(1):65–9

Dual monoclonal antibody immunoassay for free prostate–specific antigen. Wang TJ, et al. **Prostate** 1996 Jan;28(1):10–6

[PSA and prostatic adenocarcinoma. Experience with 805 patients] Grasso–Leanza F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):161–5 (Eng. Abstr.) **(Ita)**

[The role of TPS in the diagnosis of prostatic carcinoma] Panella P, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):167–70 (Eng. Abstr.) **(Ita)**

[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer] Kageyama Y, et al. **Hinyokika Kiyo** 1996 Mar;42(3):197–9 (Eng. Abstr.) **(Jpn)**

[Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy] Miyamoto S, et al. **Hinyokika Kiyo** 1995 Oct;41(10):767–70 (Eng. Abstr.) **(Jpn)**

[Effect of the spread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer] Ivshina AV, et al. **Urol Nefrol (Mosk)** 1995 Nov–Dec;(6):36–8 (Eng. Abstr.) **(Rus)**

[The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action] Panteleeva ES, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):28–31 (Eng. Abstr.) **(Rus)**

METABOLISM

Cancer (prostate–specific antigen). Castellani WJ. **Anal Chem** 1995 Jun 15;67(12):399R–403R (67 ref.)

Human prostate carcinoma cell lines secrete GM–CSF and express GM–CSF–receptor on their cell surface. Rokhlin OW, et al. **Anticancer Res** 1996 Mar–Apr;16(2):557–63

Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Canada AT, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):87-90

Different biodistribution of 99mTc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human. Oriuchi N, et al. **Br J Cancer** 1996 Jun; 73(12):1466-72

Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer. Igawa M, et al. **Br J Urol** 1996 Jan;77(1):107-12

Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Zhang XH, et al. **Br J Urol** 1996 Mar;77(3):441-4

Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Corder EH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):655-9

Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system. Blount LV, et al. **Cancer Lett** 1996 Jan 2;98(2):213-8

Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma. Vollmer G, et al. **Cancer Lett** 1996 Mar 29; 101(2):185-92

The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219-28 (67 ref.)

Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Grove KL, et al. **Cancer Res** 1996 Sep 15;56(18):4187-91

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253-5

Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Kim IY, et al. **Cancer Res** 1996 Jan 1;56(1):44-8

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Nelson JB, et al. **Cancer Res** 1996 Feb 15;56(4):663-8

Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Ranganathan S, et al. **Cancer Res** 1996 Jun 1; 56(11):2584-9

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Kostenuik PJ, et al. **Clin Exp Metastasis** 1996 Jan;14(1):19-26

Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Rusnak JM, et al. **Exp Cell Res** 1996 Apr 10;224(1):189-99

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Glynne-Jones E, et al. **Hum Pathol** 1996 Jul;27(7):688-94

Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Peterziel H, et al. **Int J Cancer** 1995 Nov 15;63(4):544-50

bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Matsushima H, et al. **Int J Urol** 1996 Mar;3(2):113-7

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. Soff GA, et al. **J Clin Invest** 1995 Dec;96(6):2593-600

Insulin-like growth factor-binding protein-6 produced by human PC-3 prostate cancer cells: isolation, characterization and its biological action. Srinivasan N, et al. **J Endocrinol** 1996 May;149(2):297-303

Antiproliferative effect of a prostatic cell-derived activity on the human androgen-dependent prostatic carcinoma cell line LNCaP. Abolhassani M, et al. **J Interferon Cytokine Res** 1995 Feb;15(2):179-85

Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. Délos S, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3-4):375-83

Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. Guillemette C, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3-4):355-62

Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. Guillemette C, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3-4):225-31

Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. Schmitt JF, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3-4):173-8

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy [see comments] Bettencourt MC, et al. **J Urol** 1996 Sep;156(3):1064-8. Comment in: J Urol 1996 Sep;156(3):1069-70.

Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. Faas FH, et al. **J Urol** 1996 Jul;156(1):243-8

High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. Kramer G, et al. **J Urol** 1995 Nov;154(5):1636-41

Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. Kruithof-Dekker IG, et al. **J Urol** 1996 Sep;156(3):1194-7

Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. Morton RA Jr, et al. **J Urol** 1996 Aug;156(2 Pt 1):512-6

Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Sánchez-Visconti G, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):19-29

Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Smith RC, et al. **Nat Med** 1995 Oct;1(10):1040-5

Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. Stearns M, et al. **Oncol Res** 1995;7(3-4):173-81

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Carter RE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):749-53

Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Su ZZ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7252-7

Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry. Ehara H, et al. **Prostate** 1995 Dec; 27(6):304-13

Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? [letter; comment] Jung K, et al. **Prostate** 1996 Jul;29(1):65-6 . Comment on: Prostate 1995 Sep;27(3):166-75. Comment on: Prostate 1996 Oct;27(4):212-9.

Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Smets G, et al. **Prostate** 1995 Sep;27(3):129-40

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH, et al. **Prostate** 1996 Apr;28(4):227-31

Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid. Viljoen TC, et al. **Prostate** 1995 Sep;27(3):160-5

Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Kurhanewicz J, et al. **Radiology** 1996 Aug;200(2):489-96

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Moul JW, et al. **Surgery** 1996 Aug;120(2):159-66; discussion 166-7

Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Maines MD, et al. **Urology** 1996 May;47(5):727-33

p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Papadopoulos I, et al. **Urology** 1996 Aug; 48(2):261-8

MORTALITY

Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Coughlin SS, et al. **Am J Epidemiol** 1996 May 15;143(10):1002-6

Perinatal characteristics in relation to incidence of and mortality from prostate cancer. Ekbom A, et al. **BMJ** 1996 Aug 10;313(7053):337-41

Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [see comments] Oefelein MG, et al. **Cancer** 1995 Dec 15; 76(12):2535-42. Comment in: Cancer 1996 Jul 1;78(1):181-2.

Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [letter; comment] Thompson IM. **Cancer** 1996 Jul 1; 78(1):181-2. Comment on: Cancer 1995 Dec 15;76(12):2535-42.

Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States). Danley KL, et al. **Cancer Causes Control** 1995 Nov;6(6):492-8

Heart rate and prostate cancer mortality: results of a prospective analysis. Gann PH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):611-6

Ethnic variation in prostate cancer survival in New Mexico. Gilliland FD, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):247-51

Impact of nitrates in drinking water on cancer mortality in Valencia, Spain. Morales-Suárez-Varela MM, et al. **Eur J Epidemiol** 1995 Feb;11(1):15-21

Conservative treatment of prostate cancer. Barry HC. **J Fam Pract** 1996 Mar;42(3):224, 226

Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors [see comments] Helgesen F, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1216-21. Comment in: J Natl Cancer Inst 1996 Sep 4;88(17):1177-8.

Re: Long-term survival and mortality in prostate cancer treated with noncurative intent [letter; comment] Abrahamsson A, et al. **J Urol** 1996 Jan;155(1):296-8. Comment on: J Urol 1995 Aug;154(2 Pt 1):460-5.

The impact of co-morbidity on life expectancy among men with localized prostate cancer [see comments] Albertsen PC, et al. **J Urol** 1996 Jul;156(1):127-32. Comment in: J Urol 1996 Jul;156(1):144-5.

Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer [see comments] Cher ML, et al. **J Urol** 1996 May; 155(5):1674-7. Comment in: J Urol 1996 May;155(5):1678-80.

Re: Long-term survival and mortality in prostate cancer treated with noncurative intent [letter; comment] Chodak GW, et al. **J Urol** 1996 Jun;155(6):2039; discussion 2039-41 . Comment on: J Urol 1995 Aug;154(2 Pt 1):460-5.

Re: Long-term survival and mortality in prostate cancer treated with noncurative intent [letter; comment] Chun TY. **J Urol** 1996 Jun;155(6):2039; discussion 2039-41. Comment on: J Urol 1995 Aug;154(2 Pt 1):460-5.

A better prognosis for obese men with prostate cancer [see comments] Daniell HW. **J Urol** 1996 Jan;155(1):220-5. Comment in: J Urol 1996 Jan;155(1):226-7.

Re: Editorial: what to expect from prostate cancer [letter; comment] Fournier GR Jr. **J Urol** 1996 Sep;156(3):1138-9 . Comment on: J Urol 1995 Dec;154(6):2132-3.

Survival in blacks and whites after treatment for localized prostate cancer [see comments] Fowler JE Jr, et al. **J Urol** 1996 Jul;156(1):133-6. Comment in: J Urol 1996 Jul;156(1):144-5.

Prostate cancer mortality in patients surviving more than 10 years after diagnosis. Hugosson J, et al. **J Urol** 1995 Dec;154(6):2115-7

Re: Editorial: what to expect from prostate cancer [letter; comment] Hugosson J, et al. **J Urol** 1996 Sep;156(3):1138; discussion 1139. Comment on: J Urol 1995 Dec;154(6):2132-3.

Mortality in prostate cancer. Krongrad A, et al. **J Urol** 1996 Sep;156(3):1084-91

Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy [see comments] Lerner SE, et al. **J Urol** 1996 Jul;156(1):137-43. Comment in: J Urol 1996 Jul;156(1):144-5.

Prostate cancer--the added factors [editorial; comment] Lynch JH. **J Urol** 1996 Jul;156(1):144-5. Comment on: J Urol 1996 Jul;156(1):127-32. Comment on: J Urol 1996 Jul;156(1):133-6. Comment on: J Urol 1996 Jul;156(1):137-43.

Survival and conservative treatment for localized prostate cancer [letter; comment] Cowen ME, et al. **JAMA** 1996 Jan 3;275(1):31-2. Comment on: JAMA 1995 Aug 23-30;274(8):626-31.

Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. Optenberg SA, et al. **JAMA** 1995 Nov 22-29;274(20):1599-605

Survival and conservative treatment for localized prostate cancer [letter; comment] Swanson G. **JAMA** 1996 Jan 3; 275(1):31; discussion 32. Comment on: JAMA 1995 Aug 23-30;274(8):626-31.

Analysis of mortality rate from carcinoma of prostate. Clive JM, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):31-41

In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Cipolla B, et al. **Urol Res** 1996;24(2):93-8; discussion 99

Impact of competing mortality on the cancer-related mortality in localized prostate cancer. Aus G, et al. **Urology** 1995 Nov;46(5):672-5

Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen ERA. Gilliland FD, et al. **Urology** 1996 Jul;48(1):67-71

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Zietman AL, et al. **Urology** 1996 Feb;47(2):236-9

[Survival after radical retropubic prostatectomy in patients with poorly differentiated prostatic carcinoma] Weigel C. **Strahlenther Onkol** 1996 Jul;172(7):404-5 **(Ger)**

[The late results of the combined hormonal chemoradiation treatment of prostatic cancer] Sviridova TV, et al. **Urol Nefrol (Mosk)** 1996 Jan-Feb;(1):31-4 (Eng. Abstr.) **(Rus)**

[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336-45 (46 ref.) (Eng. Abstr.) **(Spa)**

[Prognostic value of cytology in terms of survival in prostatic cancer] Valle Gerhold J, et al. **Actas Urol Esp** 1996 Apr; 20(4):330-5 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Metastatic pleural effusion as presenting sign of prostatic carcinoma. Druwé PM, et al. **Acta Clin Belg** 1995; 50(4):227-30

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87-90 (13 ref.)

Genetic basis and clonal evolution of human prostate cancer. Kallioniemi OP, et al. **Adv Cancer Res** 1996;68:225-55 (118 ref.)

Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Chen M, et al. **AJR Am J Roentgenol** 1996 May;166(5):1157-63

Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Amin MB, et al. **Am J Clin Pathol**

1996 Jun;105(6):667–70

Tumor–like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.). Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.

Prostatic carcinoma simulating a rectal leiomyoma. Cantor DS. **Am J Gastroenterol** 1996 May;91(5):1041–3

Neuroendocrine differentiation in human prostatic tumor models. Noordzij MA, et al. **Am J Pathol** 1996 Sep; 149(3):859–71

Development of seven new human prostate tumor xenograft models and their histopathological characterization. van Weerden WM, et al. **Am J Pathol** 1996 Sep;149(3):1055–62

Clinical and cost impact of second–opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Epstein JI, et al. **Am J Surg Pathol** 1996 Jul;20(7):851–7

Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. McNeal JE, et al. **Am J Surg Pathol** 1996 Jul;20(7):802–14

Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Nelson RS, et al. **Am J Surg Pathol** 1996 Apr;20(4):419–26

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Vailancourt L, et al. **Am J Surg Pathol** 1996 Jan;20(1):86–93

Chromatin texture analysis in three–dimensional images from confocal scanning laser microscopy. Beil M, et al. **Anal Quant Cytol Histol** 1995 Oct;17(5):323–31

Flow and image cytometric DNA measurements in fine needle aspiration samples of prostatic neoplasms. Piaton E, et al. **Anal Quant Cytol Histol** 1995 Oct;17(5):351–60

A hybrid neural and statistical classifier system for histopathologic grading of prostatic lesions. Stotzka R, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):204–18

Knowledge–guided histometry of the basal cell layer in prostatic intraepithelial neoplasia. Thompson D, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):177–84

Multiple estrogen function in human prostate cancer cells. Carruba G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:70–84

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)

Prostate cancer metastatic to the orbit [see comments] Maschka DA, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):70–1. Comment in: Ann Otol Rhinol Laryngol 1996 Jul;105(7):584.

A case of prostatic cancer metastatic to the orbit and ethmoid sinus [letter; comment] Saleh HA. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):584. Comment on: Ann Otol Rhinol Laryngol 1996 Jan;105(1):70–1.

A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. Lipponen P, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2095–100

Immunohistochemical evaluation of type IV collagenase (72–kd metalloproteinase) in prostatic intraepithelial neoplasia. Montironi R, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2057–62

The effects of omega–3 and omega–6 fatty acids on in vitro prostate cancer growth. Pandalai PK, et al. **Anticancer Res** 1996 Mar–Apr;16(2):815–20

Microvascular invasion in prostate cancer correlates with pathologic stage. Salomao DR, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1050–4

Transfecting well–differentiated prostatic cancer cell line LNCaP. Ruokonen M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):794–6

Reversion of malignant phenotype by 5–iodo–6–amino–1,2–benzopyrone a non–covalently binding ligand of poly(ADP–ribose) polymerase. Bauer PI, et al. **Biochimie** 1995;77(5):374–7

ABC of urology. Article on prostate cancer should have adhered to agreed staging terminology [letter] Hehir M, et al. **BMJ** 1996 Aug 24;313(7055):492; discussion 493

Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Bogden AE, et al. **Br J Cancer** 1996 Jan;73(1):73–8

P53 tumour–suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Dahiya R, et al. **Br J Cancer** 1996 Jul;74(2):264–8

A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Tamimi Y, et al. **Br J Cancer** 1996 Aug;74(4):573–8

The significance of prostatic intra–epithelial neoplasia. Aboseif S, et al. **Br J Urol** 1995 Sep;76(3):355–9

Eliminating the need for per–operative frozen section analysis of pelvic lymph nodes during radical prostatectomy. Bangma CH, et al. **Br J Urol** 1995 Nov;76(5):595–9

Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Boyle M, et al. **Br J Urol** 1996 Mar;77(3):445–8 (16 ref.)

Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Brewster SF, et al. **Br J Urol** 1995 Sep;76(3):351–4

Local staging of prostate cancer by endorectal MRI using fast spin–echo sequences: prospective correlation with pathological findings after radical prostatectomy. Cornud F, et al. **Br J Urol** 1996 Jun;77(6):843–50

Clinico–pathological findings simulating prostatic malignancy following sclerotherapy: a diagnostic pitfall. Feneley M, et al. **Br J Urol** 1996 Jan;77(1):157–8

Mucinous (colloid) adenocarcinoma of the prostate. López JI, et al. **Br J Urol** 1995 Dec;76(6):805–6

The use of RT–PCR for prostate–specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Olsson CA, et al. **Br J Urol** 1996 Mar;77(3):411–7

A single positive prostate biopsy in six does not predict a low–volume prostate tumour. Ravery V, et al. **Br J Urol** 1996 May;77(5):724–8

Impalpable prostate cancer: clinicopathological features. Rogers E, et al. **Br J Urol** 1996 Mar;77(3):429–32

Sternal dehiscence secondary to prostatic carcinoma. Sandhu SS, et al. **Br J Urol** 1995 Nov;76(5):660–1

Staging incidental carcinoma of the prostate [letter; comment] Schmid HP. **Br J Urol** 1995 Oct;76(4):526–7. Comment on: Br J Urol 1995 Jan;75(1):14–20.

International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Rochester, Minnesota, November 3–4, 1995. **Cancer** 1996 Jul 15;78(2):320–81

Assessment of prostate carcinoma in core needle biopsy—definition of minimal criteria for the diagnosis of cancer in biopsy material. Algaba F, et al. **Cancer** 1996 Jul 15;78(2):376–81

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)

Leiomyosarcoma of the prostate. Report of 23 cases. Cheville JC, et al. **Cancer** 1995 Oct 15;76(8):1422–7

Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma. Davis GL. **Cancer** 1995 Aug 15;76(4):661–8

Neuroendocrine differentiation in prostatic malignancy. di Sant'Agnese PA, et al. **Cancer** 1996 Jul 15;78(2):357–61 (32 ref.)

Carcinosarcoma of the prostate. Report of 21 cases. Dundore PA, et al. **Cancer** 1995 Sep 15;76(6):1035–42

The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Epstein JI. **Cancer** 1996 Jul 15;78(2):350–6 (39 ref.)

Prognostic criteria in patients with stage D2 prostate cancer. Correlation with mean nuclear volume. Fujikawa K, et al. **Cancer** 1995 Jul 1;76(1):91–5

Pathologic staging of prostate carcinoma. What are the issues? Grignon DJ, et al. **Cancer** 1996 Jul 15;78(2):337–40 (29 ref.)

Current prognostic factors and their relevance to staging. Hutter RV, et al. **Cancer** 1996 Jul 15;78(2):369–71

Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma [letter] Jager GJ. **Cancer** 1996 Mar 1;77(5):1003–5

In vitro characterization of prolactin–induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Janssen T, et al. **Cancer** 1996 Jan 1;77(1):144–9

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Leibman BD, et al. **Cancer** 1995 Dec 15;76(12):2530–4

Current prognostic factors for prostate carcinoma. Montie JE. **Cancer** 1996 Jul 15;78(2):341–4 (24 ref.)

Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [see comments] Oefelein MG, et al. **Cancer** 1995 Dec 15; 76(12):2535–42. Comment in: Cancer 1996 Jul 1;78(1):181–2.

Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome–based analysis. Pinover WH, et al. **Cancer** 1996 Apr 1;77(7):1334–41

Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1–T2 prostate carcinoma? Ravery V, et al. **Cancer** 1996 Sep 1;78(5):1079–84

Staging and reporting of prostate cancer—sampling of the radical prostatectomy specimen. Sakr WA, et al. **Cancer** 1996 Jul 15;78(2):366–8

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone–refractory metastatic prostate carcinoma. Storlie JA, et al. **Cancer** 1995 Jul 1; 76(1):96–100

Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. von Eschenbach AC, et al. **Cancer** 1996 Jul 15;78(2):372–5

The biologic dilemma of early carcinoma of the prostate. von Eschenbach AC. **Cancer** 1996 Jul 15;78(2):326–9

Overexpression of her–2/neu in human prostate cancer and benign hyperplasia. Gu K, et al. **Cancer Lett** 1996 Feb 6; 99(2):185–9

Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Miniati DN, et al. **Cancer Lett** 1996 Jul 12;104(2):137–44

The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)

Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re–expression of alpha–catenin and restoration of E–cadherin function. Ewing CM, et al. **Cancer Res** 1995 Nov 1;55(21):4813–7

Metastatic prostate cancer in a transgenic mouse. Gingrich JR, et al. **Cancer Res** 1996 Sep 15;56(18):4096–102

Taxol induces bcl–2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253–5

Association of elevated levels of hyaluronidase, a matrix–degrading enzyme, with prostate cancer progression. Lokeshwar VB, et al. **Cancer Res** 1996 Feb 1;56(3):651–7

Expression of cell cycle–regulated proteins in prostate cancer. Mashal RD, et al. **Cancer Res** 1996 Sep 15; 56(18):4159–63

CWR22: the first human prostate cancer xenograft with strongly androgen–dependent and relapsed strains both in vivo and in soft agar. Nagabhushan M, et al. **Cancer Res** 1996 Jul 1;56(13):3042–6

Anti–epidermal growth factor receptor monoclonal antibody 225 up–regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Peng D, et al. **Cancer Res** 1996 Aug 15;56(16):3666–9

Chaotic oscillations in cultured cells: rat prostate cancer. Posadas EM, et al. **Cancer Res** 1996 Aug 15;56(16):3682–8

Overexpression of protein kinase C–zeta (PKC–zeta) inhibits invasive and metastatic abilities of Dunning R–3327 MAT–LyLu rat prostate cancer cells. Powell CT, et al. **Cancer Res** 1996 Sep 15;56(18):4137–41

Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer–derived cell lines in vitro. Sehgal I, et al. **Cancer Res** 1996 Jul 15;56(14):3359–65

Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Trybus TM, et al. **Cancer Res** 1996 May 15;56(10):2263–7

Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model. Mohler JL, et al. **Clin Exp Metastasis** 1995 Nov;13(6):474–80

Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Rabinovitz I, et al. **Clin Exp Metastasis** 1995 Nov;13(6):481–91

In vitro invasiveness of DU–145 human prostate carcinoma cells is modulated by EGF receptor–mediated signals. Xie H, et al. **Clin Exp Metastasis** 1995 Nov;13(6):407–19

Primary non–Hodgkin's lymphoma of the prostate gland: case report and review of the literature. Bell CR, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):409–10 (11 ref.)

Endorectal MRI using a 0.5 T mid–field system in the staging of localized prostate cancer. Bates TS, et al. **Clin Radiol** 1996 Aug;51(8):550–3

The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Brown G, et al. **Clin Radiol** 1995 Sep;50(9):601–6

Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Huch Böni RA, et al. **Clin Radiol** 1995 Sep;50(9):593–600

Autocrine regulation of cell proliferation by the insulin–like growth factor (IGF) and IGF binding protein–3 protease system in a human prostate carcinoma cell line (PC–3). Angelloz–Nicoud P, et al. **Endocrinology** 1995 Dec; 136(12):5485–92

Transforming growth factor–beta1 is a mediator of androgen–regulated growth arrest in an androgen–responsive prostatic cancer cell line, LNCaP. Kim IY, et al. **Endocrinology** 1996 Mar;137(3):991–9

Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Pantel K, et al. **Eur J Cancer** 1995 Sep; 31A(10):1627–32

Characterisation of platelet aggregation induced by PC–3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. Swaim MW, et al. **Eur J Cancer** 1996 Apr;32A(4):715–21

5—Surgical pathology of prostate cancer. Algaba F. **Eur J Surg Oncol** 1996 Feb;22(1):102–7 (18 ref.)

Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole–mount radical prostatectomy specimens. Bartolozzi C, et al. **Eur Radiol** 1996;6(3):339–45

Primary staging of prostate cancer. Jager GJ, et al. **Eur Radiol** 1996;6(2):134–9 (47 ref.)

A heterogeneous pattern of progression in endocrine–treated patients with prostate cancer. Arai Y, et al. **Eur Urol** 1996; 29(3):331–6

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Kaisary AV, et al. **Eur Urol** 1995;28(3):215–22

Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer? Perachino M, et al. **Eur Urol** 1996;29(3):366–9

The final analysis of the EORTC Genito–Urinary Tract Cancer Co–Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR, et al. **Eur Urol** 1995;28(4):273–83

Modulation of sensitivity to transforming growth factor–beta 1 (TGF–beta 1) and the level of type II TGF–beta receptor in LNCaP cells by dihydrotestosterone. Kim IY, et al. **Exp Cell Res** 1996 Jan 10;222(1):103–10

A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM–2 mRNA levels in human prostate tumor xenografts. Wright PS, et al. **Exp Cell Res** 1996 Jan 10;222(1):54–60

Neoplastic endocrine cells in prostatic carcinoma: a case report with immunocytochemical and electron microscopic findings. Watanabe K, et al. **Fukushima J Med Sci** 1995 Jun;41(1):51–60

Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Nihei N, et al. **Genes Chromosomes Cancer** 1995 Oct;14(2):112–9

KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. Peehl DM, et al. **Growth Regul** 1996 Mar;6(1):22–31

Histologic variant of the epithelial–myoepithelial carcinoma of the salivary gland: a case report. Cheung FM, et al. **Head Neck** 1995 Sep–Oct;17(5):437–44

Pre-neoplastic lesions of the prostate. Parkinson MC. **Histopathology** 1995 Oct;27(4):301–11 (103 ref.)

Case in point. Metastatic carcinoma of the prostate. Fred HL, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):76

Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomical and Surgical Pathology. **Hum Pathol** 1996 Apr;27(4):321–3

Neuroendocrine cells in prostatic carcinoma [letter; comment] Angelsen A, et al. **Hum Pathol** 1995 Dec; 26(12):1389–90. Comment on: Hum Pathol 1995 Feb;26(2):167–70.

Distribution of lipochrome pigment in the prostate gland: biological and diagnostic implications. Leung CS, et al. **Hum Pathol** 1995 Dec;26(12):1302–7

Atypical adenomatous hyperplasia (adenosis) of the prostate: development of a Bayesian belief network for its distinction from well–differentiated adenocarcinoma. Montironi R, et al. **Hum Pathol** 1996 Apr;27(4):396–407

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Weinstein MH, et al. **Hum Pathol** 1996 Jul;27(7):683–7

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Wertz IE, et al. **Hum Pathol** 1996 Jun;27(6):573–80

Primary non–Hodgkin's lymphoma of the prostate gland—a case report. Masih K, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S56–7

Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer. Warren GP, et al. **Indiana Med** 1996 May–Jun; 89(3):274–7

Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic–cancer cell lines. Desruisseau S, et al. **Int J Cancer** 1996 Jun 11;66(6):796–801

Leukemia–inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Kellokumpu–Lehtinen P, et al. **Int J Cancer** 1996 May 16;66(4):515–9

Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF–beta 1 and its type–I and type–II receptors. Landström M, et al. **Int J Cancer** 1996 Aug 7;67(4):573–9

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Liu AY, et al. **Int J Cancer** 1996 Jan 3;65(1):85–9

Prevention of prostate–cancer metastasis in vivo by a novel synthetic inhibitor of urokinase–type plasminogen activator (uPA). Rabbani SA, et al. **Int J Cancer** 1995 Dec 11; 63(6):840–5

Loss of cell–contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Silletti S, et al. **Int J Cancer** 1995 Sep 27;63(1):100–5

Heterotopic growth of human prostate carcinoma in the femurs of nude mice: an osseous metastatic model [letter] Soos G, et al. **Int J Cancer** 1996 Apr 10;66(2):280–1

Modulation of growth and apoptosis response in PC–3 and LNCAP prostate–cancer cell lines by Fas. Takeuchi T, et al. **Int J Cancer** 1996 Sep 4;67(5):709–14

Localization of the prostatic apex for radiation treatment planning [see comments] Algan O, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):925–30. Comment in: Int J Radiat Oncol Biol Phys 1996 Apr 1;35(1):197–8.

Prostate cancer volume adds significantly to prostate–specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):273–9

You say either, I say either, but let's not call the whole thing off: models for predicting the risk of lymph node involvement in patients with prostate cancer [editorial; comment] Roach M 3rd. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):749–51. Comment on: Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):543–7.

Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models [see comments] Spevack L, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):543–7. Comment in: Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):749–51.

Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times [editorial; comment] Stamey TA. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):967–8; discussion 972. Comment on: Int J Radiat Oncol Biol Phys 1995 May 15;32(2):287–92.

Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Stock RG, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1; 33(4):815–21

A case of prostate carcinoma metastasizing to renal cell carcinoma. Inatomi H, et al. **Int J Urol** 1996 Mar;3(2):155–7

Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. Masai M, et al. **Int J Urol** 1996 Mar;3(2):118–23

Diffuse spinal leptomeningeal metastases from prostatic cancer. A case report. Matsui H, et al. **Int Orthop** 1995; 19(5):315–8 (18 ref.)

Collision metastasis of bladder and prostate carcinoma to a single pelvic lymph node. Ergen A, et al. **Int Urol Nephrol** 1995;27(6):743–5

Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas. Ozdamar SO, et al. **Int Urol Nephrol** 1996;28(1):73–7

Carcinoma of the prostate—state at initial presentation. Srinivas V, et al. **Int Urol Nephrol** 1995;27(4):419–22

Perineal prostatic cancer seeding following Urocut needle biopsy. Szentgyörgyi E. **Int Urol Nephrol** 1996;28(1):87–90

Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice. Stearns ME. **Invasion Metastasis** 1995;15(5–6):232–41

Proliferation of cultured human prostate cancer cells is inhibited by insulin–like growth factor (IGF) binding protein–1: evidence for an IGF–II autocrine growth loop. Figueroa JA, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3476–82

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor–associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. Soff GA, et al. **J Clin Invest** 1995 Dec;96(6):2593–600

Macroscopic examination of prostatic specimens [letter] Fuller CE. **J Clin Pathol** 1996 Jul;49(7):614

Macroscopic examination of prostatic specimens [letter; comment] Furness P. **J Clin Pathol** 1996 Feb;49(2):187–8. Comment on: J Clin Pathol 1995 Aug;48(8):693–700.

Centred contact density functions for the statistical analysis of random sets. A stereological study on benign and malignant glandular tissue using image analysis. Mattfeldt T, et al. **J Microsc** 1996 Aug;183 (Pt 2):158–69

Bone metastasis with superimposed osteomyelitis in prostate cancer. Pruckmayer M, et al. **J Nucl Med** 1996 Jun; 37(6):999–1001

Disseminated intravascular coagulation in metastatic prostate cancer [letter; comment] Riddell AJ. **J Nucl Med** 1996 Feb; 37(2):401. Comment on: J Nucl Med 1994 Oct;35(10):1662–4.

Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. Bubendorf L, et al. **J Pathol** 1996 Apr;178(4):437–41

Prostate biopsies: optimized cancer detection and staging. Shaw EB, et al. **J S C Med Assoc** 1996 Jun;92(6):261–6

Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. Joly–Pharaboz MO, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):67–76

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

Cutaneous metastases from prostatic carcinoma. Piqué Duran E, et al. **J Surg Oncol** 1996 Jun;62(2):144–7

Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. Babaian RJ, et al. **J Urol** 1995 Nov;154(5):1808–12

Value of systematic transition zone biopsies in the early detection of prostate cancer [see comments] Bazinet M, et al. **J Urol** 1996 Feb;155(2):605–6. Comment in: J Urol 1996 Feb;155(2):610–1.

Significant versus insignificant prostate cancer—can we identify the tigers from the pussy cats? [editorial; comment] Boccon–Gibod L. **J Urol** 1996 Sep;156(3):1069–70. Comment on: J Urol 1996 Sep;156(3):1056–8. Comment on: J Urol 1996 Sep;156(3):1059–63. Comment on: J Urol 1996 Sep;156(3):1064–8.

The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. Bostwick DG, et al. **J Urol** 1995 Nov; 154(5):1791–4

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. Bostwick DG, et al. **J Urol** 1996 Apr;155(4):1361–7

Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer [see comments] Cher ML, et al. **J Urol** 1996 May; 155(5):1674–7. Comment in: J Urol 1996 May;155(5):1678–80.

Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. Davidson PJ, et al. **J Urol** 1995 Dec;154(6):2118–22

Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion [see comments] Esrig D, et al. **J Urol** 1996 Sep;156(3):1071–6. Comment in: J Urol 1996 Sep;156(3):972–4.

Prognostic criteria in patients with prostate cancer: correlation with volume weighted mean nuclear volume. Fujikawa K, et al. **J Urol** 1995 Dec;154(6):2123–7

Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml. [see comments] Geary ES, et al. **J Urol** 1996 Sep;156(3):1056–8. Comment in: J Urol 1996 Sep;156(3):1069–70.

Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies [see comments] Goto Y, et al. **J Urol** 1996 Sep; 156(3):1059–63. Comment in: J Urol 1996 Sep;156(3):1069–70.

Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy. Griffin JH, et al. **J Urol** 1996 May;155(5):1701–2

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening [see comments] Humphrey PA, et al. **J Urol** 1996 Mar;155(3):816–20 (34 ref.). Comment in: J Urol 1996 Mar;155(3):827.

Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. Keetch DW, et al. **J Urol** 1995 Nov;154(5):1795–7

Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [editorial] Klein EA. **J Urol** 1996 Aug;156(2 Pt 1):443–4

Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy [see comments] Langer JE, et al. **J Urol** 1996 Jan; 155(1):228–31. Comment in: J Urol 1996 Jan;155(1):243.

Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA, et al. **J Urol** 1996 Apr; 155(4):1348–51

Preoperative diagnosis and staging of prostate cancer [editorial; comment] Lowe FC. **J Urol** 1996 Jul;156(1):114. Comment on: J Urol 1996 Jul;156(1):103–5. Comment on: J Urol 1996 Jul;156(1):106–9. Comment on: J Urol 1996 Jul;156(1):110–3.

Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. Nash PA, et al. **J Urol** 1996 Feb;155(2):607–9

Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less [see comments] Noldus J, et al. **J Urol** 1996 Feb;155(2):441–3. Comment in: J Urol 1996 Feb;155(2):610–1.

Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.

Prognostic significance of positive surgical margins in radical prostatectomy specimens. Ohori M, et al. **J Urol** 1995 Nov; 154(5):1818–24

Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. Pagano F, et al. **J Urol** 1996 Jan;155(1):244–7

Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer. Pandey P, et al. **J Urol** 1995 Nov;154(5):1798–801

Endo–rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? [see comments] Perrotti M, et al. **J Urol** 1996 Jul;156(1):106–9. Comment in: J Urol 1996 Jul;156(1):114.

Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence [see comments] Ravery V, et al. **J Urol** 1996 Jun;155(6):1981–2. Comment in: J Urol 1996 Jun;155(6):1987–8.

Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. Raviv G, et al. **J Urol** 1996 Sep;156(3):1050–4; discussion 1054–5

Inverted papilloma: an unusual recurrent, multiple and multifocal lesion. Rozanski TA. **J Urol** 1996 Apr; 155(4):1391

Spontaneous remission of a bony metastasis in prostatic adenocarcinoma. Schurmans JR, et al. **J Urol** 1996 Feb; 155(2):653

Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. Shepherd D, et al. **J Urol** 1996 Aug;156(2 Pt 1):460–2; discussion 462–3

Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer [see comments] Thickman D, et al. **J Urol** 1996 Jul;156(1):110–3. Comment in: J Urol 1996 Jul;156(1):114.

Primary malignant melanoma of the prostate. Wang CJ, et al. **J Urol** 1995 Nov;154(5):1865

The definition and preoperative prediction of clinically insignificant prostate cancer [see comments] Dugan JA, et al. **JAMA** 1996 Jan 24–31;275(4):288–94. Comment in: JAMA 1996 Jul 3;276(1):28–9.

Defining clinically insignificant prostate cancer [letter; comment] Woolf SH. **JAMA** 1996 Jul 3;276(1):28–9. Comment on: JAMA 1996 Jan 24–31;275(4):288–94.

Site–specific effects of testosterone propionate on the prostate of rat pretreated with 3,2'–dimethyl–4–aminobiphenyl: dose–dependent induction of invasive carcinomas. Shirai T, et al. **Jpn J Cancer Res** 1995 Jul;86(7):645–8

Changes in histologic grade and argyrophilic nucleolar organizer regions during progression of prostate cancer. Ohki T, et al. **Jpn J Clin Oncol** 1996 Apr;26(2):82–7

Diagnosis of prostatic intraepithelial neoplasia in whole

mount sections of prostates. Chan LP. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):290–4

Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Vartanian RK, et al. **Lab Invest** 1995 Dec;73(6):844–50

Factors that determine the treatment for local and regional prostate cancer. Desch CE, et al. **Med Care** 1996 Feb; 34(2):152–62

Cell proliferation and apoptosis in prostate cancer—correlation with pathologic stage? Brown C, et al. **Mod Pathol** 1996 Mar;9(3):205–9

Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Van de Voorde WM, et al. **Mod Pathol** 1995 Aug;8(6):591–8

Gap–junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mehta PP, et al. **Mol Carcinog** 1996 Jan;15(1):18–32

Phenylacetate inhibits protein isoprenylation and growth of the androgen–independent LNCaP prostate cancer cells transfected with the T24 Ha–ras oncogene. Danesi R, et al. **Mol Pharmacol** 1996 Jun;49(6):972–9

RRR–alpha–tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Israel K, et al. **Nutr Cancer** 1995;24(2):161–9

IL–10 blocks collagen IV invasion by "invasion stimulating factor" activated PC–3 ML cells: upregulation of TIMP–1 expression. Stearns ME, et al. **Oncol Res** 1995;7(3–4):157–63

Pathologic evaluation of prostatic carcinoma: critical information for the oncologist. Epstein JI. **Oncology (Huntingt)** 1996 Apr;10(4):527–34; discussion 539, 541–3 (50 ref.)

Disseminated intravascular coagulopathy (DIC) complicating intramedullary fixation of impending femur fracture from metastatic prostate cancer. Ward WG, et al. **Orthopedics** 1995 Nov;18(11):1115–8; discussion 1118–9

Prostatic Intraepithelial Neoplasia and the Origins of Prostatic Carcinoma. Proceedings of the first international consultation meeting. Ancona, Italy, September 11–12, 1994. **Pathol Res Pract** 1995 Sep;191(9):828–959

Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Algaba F, et al. **Pathol Res Pract** 1995 Sep;191(9):836–7

Boundary in the pathologic evaluation of premalignant prostatic lesions. Algaba F. **Pathol Res Pract** 1995 Sep; 191(9):856–9

Machine vision–based histometry of premalignant and malignant prostatic lesions. Bartels PH, et al. **Pathol Res Pract** 1995 Sep;191(9):935–44

Improved tissue culture method for the study of prostatic carcinoma: a significant diagnostic tool. Bologna M, et al. **Pathol Res Pract** 1995 Sep;191(9):899–903

Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)

Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):850–5

Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):828–32

Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Helpap B. **Pathol Res Pract** 1995 Sep;191(9):904–7

Nucleolar and AgNOR–analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. Helpap B, et al. **Pathol Res Pract** 1995 Jun;191(5):381–90

Prostatic intraepithelial neoplasia. Quantitation of the basal cell layer with machine vision system. Montironi R, et al. **Pathol Res Pract** 1995 Sep;191(9):917–23

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Montironi R, et al. **Pathol Res Pract** 1995 Sep; 191(9):873–80

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)

The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Qian J, et al. **Pathol Res Pract** 1995 Sep; 191(9):860–7

Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Cohen RJ, et al. **Pathology** 1995 Jul; 27(3):229–32

Antisense RNA to the type I insulin–like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Burfeind P, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7263–8

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25–dihydroxycholecalciferol, all–trans retinoic acid, 9–cis retinoic acid, and phenylacetate. Esquenet M, et al. **Prostate** 1996 Mar;28(3):182–94

Microvascular invasion of the seminal vesicles in adenocarcinoma of the prostate. Graham SD Jr, et al. **Prostate** 1996 Jun;28(6):359–63

Androgen receptor status of lymph node metastases from prostate cancer. Hobisch A, et al. **Prostate** 1996 Feb; 28(2):129–35

Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DU145, and LNCaP prostatic cancer cell lines: relationship with DNA ploidy level. Janssen T, et al. **Prostate** 1995 Nov;27(5):277–86

Adenocarcinoma of the prostate metastatic to the choroid of the eye. Keizur JJ, et al. **Prostate** 1995 Dec;27(6):336–9

Stimulation of human prostate cancer cell lines by factors present in human osteoblast–like cells but not in bone marrow. Lang SH, et al. **Prostate** 1995 Nov;27(5):287–93

Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC–3. Liu DF, et al. **Prostate** 1995 Nov;27(5):269–76

Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Lyon PB, et al. **Prostate** 1995 Oct;27(4):179–86

Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. McNeal JE, et al. **Prostate** 1995 Nov;27(5):258–68

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Neubauer BL, et al. **Prostate** 1995 Oct;27(4):220–9

Determination of Ki–67 defined growth fraction by monoclonal antibody MIB–1 in formalin–fixed, paraffin–embedded prostatic cancer tissues. Noordzij MA, et al. **Prostate** 1995 Sep;27(3):154–9

Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Rajan R, et al. **Prostate** 1996 Jan;28(1):1–9

Orthotopic placement of the Dunning R3327 AT–3 prostate tumor in the Copenhagen X Fischer rat. Rubenstein M, et al. **Prostate** 1995 Sep;27(3):148–53

DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma—necessitating multiple site analysis. Warzynski MJ, et al. **Prostate** 1995 Dec; 27(6):329–35

Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Zhang H, et al. **Prostate** 1996 Aug;29(2):69–76

Transfected neu oncogene induces human prostate cancer metastasis. Zhau HY, et al. **Prostate** 1996 Feb;28(2):73–83

Inhibition of chemomigration of a human prostatic carcinoma cell (TSU–pr1) line by inhibition of epidermal growth factor receptor function. Zolfaghari A, et al. **Prostate** 1996 Apr;28(4):232–8

Neuroendocrine differentiation and hormone–refractory prostate cancer. Abrahamsson PA. **Prostate Suppl** 1996; 6:3–8 (26 ref.)

Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)

Radiation inactivation of human prostate cancer cells: the role of apoptosis. Algan O, et al. **Radiat Res** 1996 Sep; 146(3):267–75

Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. Harris RD, et al. **Radiographics** 1995 Jul;15(4):813–29; discussion 829–32

Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Lee WR, et al. **Radiology** 1996 Feb;198(2):439–42

Pathology and histochemistry of small cell carcinoma of the prostate. Raica M. **Rom J Morphol Embryol** 1995 Jul–Dec; 41(3–4):107–10

Estrogen receptors in the human male bladder, prostatic urethra, and prostate. An immunohistochemical and biochemical study. Bødker A, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):161–5

Open versus laparoscopic diagnostic pelvic lymphadenectomy. Mommsen S. **Scand J Urol Nephrol Suppl** 1995;172:23–5

The effect of castration on tumor growth rate and cell kinetics in hormone sensitive and hormone insensitive rat prostatic adenocarcinomas. Salling LN, et al. **Scand J Urol Nephrol Suppl** 1995;172:73–9

Laparoscopic pelvic lymphadenectomy: transperitoneal approach. Gill IS. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):126–33 (39 ref.)

Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Belville WD. **Semin Urol Oncol** 1995 Aug;13(3):181–6 (22 ref.)

T1c cancer: what is it? Flanigan RC, et al. **Semin Urol Oncol** 1995 Aug;13(3):173–5 (18 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Appendicular metastatic prostate cancer simulating osteosarcoma, Paget's disease, and Paget's sarcoma. Igou D, et al. **Skeletal Radiol** 1995 Aug;24(6):447–9

Recent advances in prostate cancer metastasis. Waltregny D, et al. **Tumori** 1996 May–Jun;82(3):193–204 (120 ref.)

Investigations on bone metabolism of urological tumors forming metastases. Bichler KH, et al. **Urol Int** 1996; 56(2):61–8

Laparoscopic pelvic lymphadenectomy in prostatic cancer: an analysis of seventy consecutive cases. Klän R, et al. **Urol Int** 1995;55(2):78–83

Biomodulation of 5–Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer. Breul J, et al. **Urol Res** 1995;23(3):163–7

Effect of tumor necrosis factor–alpha and interferon–gamma on the growth of human prostate cancer cell lines. Nakajima Y, et al. **Urol Res** 1995;23(4):205–10

Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. Bazinet M, et al. **Urology** 1996 Jun;47(6):857–62

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Bostwick DG, et al. **Urology** 1996 Jul;48(1):47–57

A new minimally invasive open pelvic lymphadenectomy surgical technique for the staging of prostate cancer. Brant LA, et al. **Urology** 1996 Mar;47(3):416–21

Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Bruce RG, et al. **Urology** 1996 Jul;48(1):75–9

Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Edelstein RA, et al. **Urology** 1996 Mar;47(3):370–5

Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer. Egawa S, et al. **Urology** 1996 Apr;47(4):548–52

Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Flanigan RC, et al. **Urology** 1996 Sep;48(3):428–32

Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Gleason DF. **Urology** 1996 Mar;47(3):289–91 (6 ref.)

Prostate cancer staging after radiation utilizing laparoscopic pelvic lymphadenectomy. Jarrard DF, et al. **Urology** 1995 Oct;46(4):538–41

Prostate needle biopsy following radiotherapy for prostate cancer [letter; comment] Kabalin JN. **Urology** 1995 Oct; 46(4):603–5. Comment on: Urology 1995 Apr;45(4):624–31; discussion 631–2.

Giant multilocular cystadenoma of the prostate. Kirsch AJ, et al. **Urology** 1996 Aug;48(2):303–5

Correlation of clinical and pathologic factors with rising prostate–specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P, et al. **Urology** 1996 Aug;48(2):249–60

Free, complexed, and total serum prostate–specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Lerner SE, et al. **Urology** 1996 Aug;48(2):240–8

Mucinous adenocarcinoma of the prostate: a report of a case of long–term survival. Olivas TP, et al. **Urology** 1996 Feb; 47(2):256–8 (7 ref.)

p53 expression, proliferation marker Ki–S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Papadopoulos I, et al. **Urology** 1996 Aug; 48(2):261–8

Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Pienta KJ, et al. **Urology** 1996 Jul;48(1):164–70

Benign ectopic prostatic tissue involving the seminal vesicle in a patient with prostate cancer: recognition and implications for staging. Salem CE, et al. **Urology** 1996 Sep;48(3):490–3

Transperineal prostate needle biopsy guided by transurethral ultrasound in patients without a rectum. Seaman EK, et al. **Urology** 1996 Mar;47(3):353–5

Recombinant adenovirus vector expressing wild–type p53 is a potent inhibitor of prostate cancer cell proliferation. Srivastava S, et al. **Urology** 1995 Dec;46(6):843–8

Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Tatsutani K, et al. **Urology** 1996 Sep;48(3):441–7

Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Watson RB, et al. **Urology** 1996 Jul;48(1):80–90

Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)

Metastatic carcinoma of the penis. Char G, et al. **West Indian Med J** 1996 Mar;45(1):37–8

Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. Szentirmai M, et al. **West J Med** 1995 Dec;163(6):577–8

Nucleolar organizer regions in low– and high–grade carcinomas of the prostate. Helpap B, et al. **World J Urol** 1995;13(3):195–9

[Assessment of cells from solid tumors in peripheral blood] Thøgersen VB, et al. **Ugeskr Laeger** 1996 Jul 29; 158(31):4418 **(Dan)**

[Rare tumors of the prostate or seminal vesicles. Report of a case of leiomyosarcoma] Cordonnier C, et al. **Ann Pathol** 1996;16(1):37–40 (Eng. Abstr.) **(Fre)**

[Prostatic biopsy: technic, value and complications] Gasman D, et al. **Ann Urol (Paris)** 1995;29(5):229–301 **(Fre)**

[Reliability of the anatomopathological diagnosis by static image transfer] Viellefond A, et al. **Arch Anat Cytol Pathol** 1995;43(4):246–50 (Eng. Abstr.) **(Fre)**

[Modulation of the tumoral progression by anti-idiotypic antibodies of angiogenesis factors] Ortéga N, et al. **C R Acad Sci III** 1996 May;319(5):411–5 (Eng. Abstr.) **(Fre)**

[Multiple isolated hepatic metastases of cystic aspect of prostatic adenocarcinoma (letter)] Demarquay JF, et al. **Gastroenterol Clin Biol** 1996;20(5):511–2 **(Fre)**

[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561–72 (61 ref.) (Eng. Abstr.) **(Fre)**

[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases] Chefchaouni MC, et al. **J Urol (Paris)** 1996;102(2):51–5 (18 ref.) (Eng. Abstr.) **(Fre)**

[Macrophage activation syndrome following bone metastases of prostatic cancer (letter)] Berthelot JM, et al. **Presse Med** 1996 Apr 27;25(15):733 **(Fre)**

[Bone and bone marrow metastases of prostatic adenocarcinoma: the serum level of prostate-specific antigen may be normal (letter)] Marlier S, et al. **Presse Med** 1996 May 4–11;25(16):777 **(Fre)**

[A single positive prostatic biopsy out of six systematic biopsies is not correlated with the intracapsular nature of the tumor on an individual level] Ravery V, et al. **Prog Urol** 1996 Feb;6(1):70–5 (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Pathologic-anatomic examination of prostatovesiculectomy samples in prostate carcinoma] Hailemariam S, et al. **Pathologe** 1996 May;17(3):227–30 (Eng. Abstr.) **(Ger)**

[Sclerosing adenosis of the prostate. Carcinoma simulation] Meister P. **Pathologe** 1996 Mar;17(2):157–62 (Eng. Abstr.) **(Ger)**

[Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma] Hammerer P, et al. **Urologe A** 1995 Sep;34(5):413–8 (Eng. Abstr.) **(Ger)**

[Non-Hodgkin's lymphoma with primary localization in the bladder and prostate region. Description of a case] Mahlknecht A, et al. **Minerva Urol Nefrol** 1995 Mar; 47(1):39–41 (Eng. Abstr.) **(Ita)**

[Carcinoma of the prostate, stage C] Zattoni F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):197–201 (32 ref.) **(Ita)**

[A case of huge prostate cancer] Miyajima A, et al. **Hinyokika Kiyo** 1995 Sep;41(9):683–5 (Eng. Abstr.) **(Jpn)**

[Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report] Nishimura K, et al. **Hinyokika Kiyo** 1995 Oct;41(10):805–7 (Eng. Abstr.) **(Jpn)**

[Primary squamous cell carcinoma of the prostate: a case report] Okamoto T, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):67–70 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of prostate cancer with Paneth cell-like change] Soga N, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):891–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Prognostic factor in patients with prostate cancer] Fujikawa K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1745–50 (Eng. Abstr.) **(Jpn)**

[Comparisons of histological grading between biopsy and radical prostatectomy specimens in prostatic adenocarcinoma] Fujinami K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1460–5 (Eng. Abstr.) **(Jpn)**

[A case of mucinous adenocarcinoma of the prostate] Hayakawa K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):78–81 (Eng. Abstr.) **(Jpn)**

[Primary seminoma of the prostate and embryonal cell carcinoma of the left testis in one patient: a case report] Kimura F, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1497–500 (Eng. Abstr.) **(Jpn)**

[Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy] Saikawa S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1673–80 (Eng. Abstr.) **(Jpn)**

[Tumor cells in peripheral blood and bone marrow in patients with prostatic cancer. Many unanswered questions] Fosså SD. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3599–600 **(Nor)**

[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer] Kippersund JT, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3612–5 (Eng. Abstr.) **(Nor)**

[Apudoma of the prostate] Serezhin BS. **Arkh Patol** 1995 Sep–Oct;57(5):57–63 (Eng. Abstr.) **(Rus)**

[Morphological factors in the prognosis of the treatment results in prostatic cancer] Murzaliev AD, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):22–5 (Eng. Abstr.) **(Rus)**

[Metastases to the temporal bone. A report of two cases] Grijalba Uche M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):441–3 (Eng. Abstr.) **(Spa)**

[Complications of ultrasound-guided transperineal puncture biopsy of the prostate] Castiñeiras J, et al. **Actas Urol Esp** 1995 Jul–Aug;19(7):544–8 (12 ref.) (Eng. Abstr.) **(Spa)**

[Effect of cell differentiation in prostatic cancer on basal PSA] Llorente Abarca C, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):755–8 (Eng. Abstr.) **(Spa)**

[Prognostic value of cytology in terms of survival in prostatic cancer] Valle Gerhold J, et al. **Actas Urol Esp** 1996 Apr; 20(4):330–5 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Fornaro M, et al. **Am J Pathol** 1996 Sep;149(3):765–73

Waning sexual function—the most important disease-specific distress for patients with prostate cancer. Helgason AR, et al. **Br J Cancer** 1996 Jun;73(11):1417–21

Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture. Santibáñez JF, et al. **Br J Cancer** 1996 Aug;74(3):418–22

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Eriksson S, et al. **Calcif Tissue Int** 1995 Aug;57(2):97–9

Protein kinase C-dependent and -independent pathways of signal transduction in prostate cancer cells: fibroblast growth factor utilization of a protein kinase C-independent pathway. Hrženjak M, et al. **Cell Growth Differ** 1995 Sep; 6(9):1129–42

Human prostate cancer: a direct role for oestrogens. Castagnetta LA, et al. **Ciba Found Symp** 1995;191:269–86; discussion 286–9 (55 ref.)

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nelson JB, et al. **Nat Med** 1995 Sep;1(9):944–9

The insulin-like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)

[Fibrinolysis process in prostatic carcinoma] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):107–8 (26 ref.) **(Pol)**

[Quantitative analysis of mechanical characteristics of pathologically altered soft biological tissues] Skovorda AR, et al. **Biofizika** 1995 Nov–Dec;40(6):1335–40 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

The potential application of finasteride for chemoprevention of prostate cancer. Gormley GJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:163–9 (22 ref.)

Changes in early detection of prostate cancer in the United States. Mettlin C. **Ann N Y Acad Sci** 1995 Sep 30;768:68–72 (14 ref.)

Inhibition of steroid 5 alpha-reductase activity by aliphatic fatty acids. Candidates for chemoprevention of prostate cancer. Niederprüm HJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:227–30

Measurement of prostate specific antigen as screening test for prostate cancer. Measurement presents technical difficulties [letter; comment] Bartlett WA, et al. **BMJ** 1996 Mar 16;312(7032):709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view [letter; comment] Neal DE, et al. **BMJ** 1996 Mar 16;312(7032):709; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening [letter; comment] Sandhu S, et al. **BMJ** 1996 Mar 16;312(7032):709; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Measurement of prostate specific antigen as screening test for prostate cancer. False positive results cast doubt on conclusion [letter; comment] Warren P. **BMJ** 1996 Mar 16;312(7032):708–9; discussion 709–10. Comment on: BMJ 1995 Nov 18;311(7016):1340–3.

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Auvinen A, et al. **Br J Cancer** 1996 Aug; 74(4):568–72

The preventive role of diet in prostatic disease. Morton MS, et al. **Br J Urol** 1996 Apr;77(4):481–93 (149 ref.)

Ethical issues in urology: the patient's perspective. Wilkie P. **Br J Urol** 1995 Nov;76 Suppl 2:5–7 (6 ref.)

The dilemma of hereditary prostate cancer [editorial; comment] Nickel JC. **Can Med Assoc J** 1995 Oct 1; 153(7):935–8. Comment on: Can Med Assoc J 1995 Oct 1;153(7):895–900.

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Joseph IB, et al. **Cancer Res** 1996 Aug 1; 56(15):3404–8

Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Lucia MS, et al. **Cancer Res** 1995 Dec 1;55(23):5621–7

Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Hoffman BR, et al. **Clin Chem** 1996 Apr;42(4):536–44

Update on urology—prostate cancer. Screening for prostate cancer: an European view. de Silva FC. **Eur J Surg Oncol** 1996 Apr;22(2):189–91, 196 (9 ref.)

Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. Brawer MK. **Eur Urol** 1996;29 Suppl 2:19–23 (43 ref.)

Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)

Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Hall RR. **Eur Urol** 1996;29 Suppl 2:24–6 (5 ref.)

Epidemiology, prevention and screening for prostate cancer. Pavone-Macaluso M. **Eur Urol** 1996;29 Suppl 2:49–53 (21 ref.)

Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)

European randomized study of screening for prostate cancer—the Rotterdam pilot studies. Schröder FH, et al. **Int J Cancer** 1996 Jan 17;65(2):145–51

Prostate-specific antigen in mass screening for carcinoma of the prostate. Shimizu TS, et al. **Int J Urol** 1995 Sep; 2(4):257–60

Prostate screening—the Singapore experience. Tay KP, et al. **Int J Urol** 1996 Mar;3(2):102–7

Screening by the prostate-specific antigen test: what do the patients know? Diefenbach PN, et al. **J Cancer Educ** 1996 Spring;11(1):39–44

Prostate cancer in African American men: increasing knowledge and self-efficacy. Boehm S, et al. **J Community Health Nurs** 1995;12(3):161–9

Prostate cancer meeting confronts controversies [news] Fintor L, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1743–4

Attitudes of African Americans regarding screening for prostate cancer. Robinson SB, et al. **J Natl Med Assoc** 1996 Apr;88(4):241–6

Prostate cancer screening in a large corporation population. Kantrowitz W, et al. **J Occup Environ Med** 1995 Oct; 37(10):1193–8

Re: The clinical usefulness of prostate specific antigen: update 1994 [letter; comment] Visvanathan K. **J Urol** 1996 Jan; 155(1):294; discussion 295. Comment on: J Urol 1994 Nov;152(5 Pt 1):1358–68.

Conference seeks to provide basis for prostate cancer guidance message [news] Gunby P. **JAMA** 1995 Oct 11; 274(14):1103, 1105–6

Improved screening for prostate cancer offers challenging new data to cope with high incidence [news] Gunby P. **JAMA** 1996 Aug 21;276(7):515–6

Screening for early detection of prostate cancer [letter; comment] Catalona WJ. **Lancet** 1996 Jun 8;347(9015):1629 . Comment on: Lancet 1996 Mar 30;347(9005):883–4.

Trust me, I'm a scientist: will urologists set a lead for geneticists to follow? [see comments] Raffle AE. **Lancet** 1996 Mar 30;347(9005):883–4. Comment in: Lancet 1996 Jun 8;347(9015):1629.

Prostate cancer screening. Hostetler RM, et al. **Med Clin North Am** 1996 Jan;80(1):83–98 (70 ref.)

Screening for prostate cancer: the case against. Hirst GH, et al. **Med J Aust** 1996 Mar 4;164(5):285–8

Prostate cancer: enthusiasm for screening [letter] Kaye KW. **Med J Aust** 1996 Mar 4;164(5):319

Prostate cancer: enthusiasm for screening [letter; comment] Sladden MJ, et al. **Med J Aust** 1995 Oct 2;163(7):389–90 . Comment on: Med J Aust 1995 May 15;162(10):540–1.

Prostate cancer: don't be too casual [letter] Stricker PD. **Med J Aust** 1996 Mar 4;164(5):319–20

How valuable is prostate-specific antigen screening? [letter; comment] Handler S. **Minn Med** 1996 Jun;79(6):2. Comment on: Minn Med 1996 Apr;79(4):46–9. Comment on: Minn Med 1996 Apr;79(4):50–1.

Early detection of prostate cancer. Decreasing the mortality rate [see comments] Oesterling JE. **Minn Med** 1996 Apr; 79(4):46–9. Comment in: Minn Med 1996 Jun;79(6):2.

Does screening with prostate/specific antigen improve outcomes? [see comments] Ohrt D. **Minn Med** 1996 Apr; 79(4):50–1. Comment in: Minn Med 1996 Jun;79(6):2.

Screening in the new environment of medicine: questions and answers. **Mt Sinai J Med** 1995 Sep;62(4):262–3

Screening in the new environment of medicine: colon and prostate cancer. Introduction. Gilbert PL. **Mt Sinai J Med** 1995 Sep;62(4):251

Screening in the new environment of medicine: prostate cancer. Kirschenbaum A. **Mt Sinai J Med** 1995 Sep; 62(4):257–61

Prostate cancer screening practices: differences between clinic and private patients. Perez N, et al. **Mt Sinai J Med** 1995 Sep;62(4):316–21

Prostate cancer screening is experimental. Cox B. **N Z Med J** 1996 Mar 8;109(1017):63–4

Digital rectal examinations and prostate cancer screening: attitudes of African American men. Gelfand DE, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1253–5

Using brochures to educate the public about the early detection of prostate and colorectal cancer. Mahon SM. **Oncol Nurs Forum** 1995 Oct;22(9):1413–20

AUA's response to the OTA study on prostate cancer screening for elderly men [news] **Oncology (Huntingt)** 1995 Nov;9(11):1123

An overview cost-utility analysis of prostate cancer screening. Thompson IM, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):141-5 (24 ref.)

Update: prostate cancer screening. Fulton JP, et al. **R I Med** 1995 Nov;78(11):330-1

Does screening for prostate cancer make sense? Hanks GE, et al. **Sci Am** 1996 Sep;275(3):114-5

Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Belville WD. **Semin Urol Oncol** 1995 Aug;13(3):181-6 (22 ref.)

Screening for prostate cancer: opportunities for prevention. Thompson IM, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):4-10; discussion 10-1 (28 ref.)

Screening for prostate cancer: a comparison of urologists and primary care physicians. McKnight JT, et al. **South Med J** 1996 Sep;89(9):885-8

Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen. Ciatto S, et al. **Tumori** 1995 Jul-Aug;81(4):225-9

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Bangma CH, et al. **Urology** 1995 Dec;46(6):779-84

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Bangma CH, et al. **Urology** 1995 Dec;46(6):773-8

Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Komatsu K, et al. **Urology** 1996 Mar; 47(3):343-6

Impact of prostate-specific antigen screening on the natural history of prostate cancer. Rosen MA. **Urology** 1995 Dec; 46(6):757-68 (95 ref.)

[A fair trial? The European randomized prostate cancer study (letter; comment)] Schröder FH. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1903-4. Comment on: Ned Tijdschr Geneeskd 1995 Jun 24;139(25):1271-5. Comment on: Ned Tijdschr Geneeskd 1995 Jun 24;139(25):1302-3. **(Dut)**

[Chemoprevention of cancer of the prostate] Droz JP. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:178s-180s (Eng. Abstr.) **(Fre)**

[Prostate cancer screening in total health care check---using serum PSA and AUA score] Komeda Y, et al. **Hinyokika Kiyo** 1996 Apr;42(4):275-8 (Eng. Abstr.) **(Jpn)**

[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age] Yamazaki H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):702-9 (Eng. Abstr.) **(Jpn)**

[Prostate cancer screening in the primary care consultation (editorial)] Subias Loren PJ, et al. **Aten Primaria** 1996 May 31;17(9):545-6 **(Spa)**

[Experiences from six years' examinations of prostatic cancer. Mass screening is not of immediate interest!] Varenhorst E, et al. **Lakartidningen** 1996 Aug 28;93(35):2940-6 **(Swe)**

PSYCHOLOGY

Quality of life and intermittent hormonal therapy. da Silva FC. **Acta Urol Belg** 1996 May;64(2):93

Waning sexual function---the most important disease-specific distress for patients with prostate cancer. Helgason AR, et al. **Br J Cancer** 1996 Jun;73(11):1417-21

Attitude of African-Americans regarding prostate cancer clinical trials. Robinson SB, et al. **J Community Health** 1996 Apr;21(2):77-87

Information and decision-making preferences of men with prostate cancer. Davison BJ, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1401-8

Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Lucas MD, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):497-500

RADIOGRAPHY

Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Huncharek M, et al. **Abdom Imaging** 1996 Jul-Aug;21(4):364-7

CT findings after laparoscopic pelvic lymph node dissection and transperineal radioactive seed implantation for prostatic carcinoma. Glajchen N, et al. **AJR Am J Roentgenol** 1996 May;166(5):1165-8

Embryonal rhabdomyosarcoma of the prostate. Lazar EB, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):72

The effects of out-of-plane rotations on two dimensional portal image registration in conformal radiotherapy of the prostate. Hanley J, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1331-43

Ultrasound image fusion for external beam radiotherapy for prostate cancer. Holupka EJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):975-84

Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registration. van Herk M, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1311-20

Giant Müllerian duct cyst mimicking prostatic malignancy. Sanchez-Chapado M, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):229-31

Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Flanigan RC, et al. **Urology** 1996 Sep;48(3):428-32

[Value of iliac direct-view retroperitoneoscopy (or "extraperitoneal pelvioscopy") in the assessment of lymph node invasion by pelvic cancer] Wurtz A, et al. **Ann Chir** 1995;49(5):383-9 (Eng. Abstr.) **(Fre)**

[Prostatic leiomyoma] Coulier B, et al. **J Belge Radiol** 1995 Jun;78(3):182-3 (Eng. Abstr.) **(Fre)**

[X-ray intravascular surgery in oncologic urology] Granov AM, et al. **Vestn Rentgenol Radiol** 1996 Jan-Feb;(1):35-7 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351. Feneley MR, et al. **Br J Urol** 1996 Mar;77(3):373-81

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Nilsson S, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5805s-5810s

Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer. Nielsen JT, et al. **Clin Physiol** 1995 Sep;15(5):467-81

Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Jørgensen T, et al. **Eur Urol** 1995;28(1):40-6

Monoclonal antibody scan holds promise for prostate cancer staging [news] Kotz D. **J Nucl Med** 1996 Apr; 37(4):11N-12N, 15N

Radiation absorbed dose from indium-111-CYT-356. Mardirossian G, et al. **J Nucl Med** 1996 Sep;37(9):1583-8

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose [see comments] Effert PJ, et al. **J Urol** 1996 Mar;155(3):994-8. Comment in: J Urol 1996 Mar;155(3):1004.

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Shreve PD, et al. **Radiology** 1996 Jun;199(3):751-6

Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues. Sundkvist GM, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):29-32

[Clear skeletal visualization on whole body 201Tl-chloride scintigraphy: a case of prostatic cancer with diffuse bone metastases] Tsubuku M, et al. **Kaku Igaku** 1995 Nov; 32(11):1249-53 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

External beam radiotherapy of localized prostatic adenocarcinoma. Evaluation of conformal therapy, field number and target margins. Lennernäs B, et al. **Acta Oncol** 1995;34(7):953-8

Field displacement during external radiotherapy in prostatic adenocarcinoma treated with radioactive 198Au implants and external irradiation. Lennernäs B, et al. **Acta Oncol** 1995;34(7):959-64

Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Ljung G, et al. **Acta Oncol** 1995;34(7):945-52

Adverse effects after radical external beam radiotherapy of localized prostatic adenocarcinoma using two-dimensional dose-planning and a limited field technique. Ljung G, et al. **Acta Oncol** 1996;35(4):445-50

Adjuvant radiation therapy for pT3 prostate cancer. Boccon-Gibod L. **Acta Urol Belg** 1996 May;64(2):65-6

Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy. Scalliet P. **Acta Urol Belg** 1996 May;64(2):63-4

The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992. Schneider SB, et al. **Am J Clin Oncol** 1996 Feb;19(1):65-72

Percutaneous iodine-125 seed implantation for carcinoma of the prostate. Kaye KW, et al. **Aust N Z J Surg** 1995 Sep; 65(9):658-63

Acute morbidity of radiation therapy for prostate carcinoma. Franklin CI. **Australas Radiol** 1996 May;40(2):140-5

The optimization and inherent limitations of 3D conformal radiotherapy treatment plans of the prostate. Oldham M, et al. **Br J Radiol** 1995 Aug;68(812):882-93

Changes in sexual function after radiotherapy treatment of prostate cancer. Beckendorf V, et al. **Br J Urol** 1996 Jan; 77(1):118-23

Treatment of prostate cancer using external beam radiotherapy after laparoscopic pelvic lymph node dissection. Gerber GS, et al. **Br J Urol** 1996 Jun;77(6):870-5

Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Fransson P, et al. **Cancer** 1996 Sep 1; 78(5):1066-78

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Miller RJ Jr, et al. **Cancer** 1996 Apr 15; 77(8):1510-4

Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Pinover WH, et al. **Cancer** 1996 Apr 1;77(7):1334-41

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515-23

Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. See WA, et al. **Cancer** 1996 Mar 1;77(5):924-7

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, et al. **Cancer** 1996 Jun 1;77(11):2386-92

A case of therapy-related extramedullary acute promyelocytic leukemia. Chen Z, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):29-30

Radiosensitizing effect of cisplatin in prostate cancer cell lines. Geldof AA, et al. **Cancer Lett** 1996 Mar 29; 101(2):233-9

Radiotherapy for prostate cancer: the changing scene [editorial] Dearnaley DP. **Clin Oncol (R Coll Radiol)** 1995; 7(3):147-50 (35 ref.)

3-D conformal radiotherapy for carcinoma of the prostate. Clinical experience at the Memorial Sloan-Kettering Cancer Center. Leibel SA, et al. **Front Radiat Ther Oncol** 1996;29:229-37

Multi-institutional clinical trials: 3-D conformal radiotherapy quality assurance. Guidelines in an NCI/RTOG study evaluating dose escalation in prostate cancer radiotherapy. Purdy JA, et al. **Front Radiat Ther Oncol** 1996;29:255-63

3-D conformal radiotherapy for prostate cancer. The University of Michigan experience. Sandler HM. **Front Radiat Ther Oncol** 1996;29:238-43

Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Essand M, et al. **Int J Cancer** 1995 Nov 3;63(3):387-94

Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Zamora PO, et al. **Int J Cancer** 1996 Jan 17;65(2):214-20

Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility. Balter JM, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1281-6

Analysis of prostate and seminal vesicle motion: implications for treatment planning. Beard CJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):451-8

High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging [see comments] Bel A, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):321-32 . Comment in: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):415-6.

Regarding Algan et al., IJROBP 33(4):925-930; 1995 [letter; comment] Ben-Josef E, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):197-8. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):925-30.

Three dimensional conformal treatment planning with multileaf collimators. Brewster L, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1081-9

Hip stiffness following mixed conformal neutron and photon radiotherapy: a dose-volume relationship. Chuba PJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):693-9

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Dattoli M, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15; 35(5):875-9

Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Edmundson GK, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1; 33(5):1257-63

Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Forman JD, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):259-66

Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study. Forman JD, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):655-62

Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation [see comments] Freedman GM, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):243-50. Comment in: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):407-9.

Patterns of care survey results: treatment planning for carcinoma of the prostate. Gerber RL, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):803-8

Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML [see comments] Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):861-8 . Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1115.

Pretreatment prostate-specific antigen doubling times:

clinical utility of this predictor of prostate cancer behavior. Hanks GE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):549–53

Neutron–photon treatment: modern day Pyrrhic victory? Regarding Haraf et al. IJROBP 33(1): 3–14; 1995 [letter; comment] Hanks GE, et al.
Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):757. Comment on: Int J Radiat Oncol Biol Phys 1995 Aug 30;33(1):3–14.

The effects of out–of–plane rotations on two dimensional portal image registration in conformal radiotherapy of the prostate. Hanley J, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1331–43

Potency following conformal neutron/photon irradiation for localized prostate cancer. Hart KB, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):881–4

New wine in an old bottle? Dose escalation under dose–volume constraints: a model of conformal therapy of the prostate [editorial; comment] Kutcher GJ, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):415–6. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):251–7. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):321–32. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):333–42.

Radiotherapy for regionally localized hormone refractory prostate cancer. Lankford SP, et al.
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):907–12

Prostate cancer—evaluating cancer–free survival: regarding Hahn et al. IJROBP 34(1):41–47; 1996 [letter] Lawrence G, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):855–6

Variation in volumes, dose–volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Lebesque JV, et al.
Int J Radiat Oncol Biol Phys 1995 Dec 1;33(5):1109–19

Lateral rectal shielding reduces late rectal morbidity following high dose three–dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect [see comments] Lee WR, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1; 35(2):251–7. Comment in: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):415–6.

Conformal radiation treatment of prostate cancer using inversely–planned intensity–modulated photon beams produced with dynamic multileaf collimation [see comments] Ling CC, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):721–30. Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):845–6.

A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. Lu Y, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1; 33(5):1121–5

A method of incorporating organ motion uncertainties into three–dimensional conformal treatment plans [see comments] Mageras GS, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):333–42. Comment in: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):415–6.

Conformal prostate brachytherapy: initial experience of a phase I/II dose–escalating trial. Martinez A, et al.
Int J Radiat Oncol Biol Phys 1995 Dec 1;33(5):1019–27

Radiotherapy vs. surgery for prostate cancer: an age old question [editorial; comment] Pollack A, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):407–9. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):243–50.

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Pollack A, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1; 34(3):555–64

Intensity–modulated radiation therapy [editorial; comment] Purdy JA. **Int J Radiat Oncol Biol Phys** 1996 Jul 1; 35(4):845–6. Comment on: Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):721–30.

A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Roach M 3rd, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):869–74

The "critical volume tolerance method" for estimating the limits of dose escalation during three–dimensional conformal radiotherapy for prostate cancer. Roach M 3rd, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15; 35(5):1019–25

Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Roeske JC, et al.
Int J Radiat Oncol Biol Phys 1995 Dec 1;33(5):1321–9

Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localized prostate cancer. Rudat V, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1027–34

Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Sandler HM, et al.
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):797–801

PSA following irradiation for prostate cancer: the upcoming ASTRO symposium [editorial; comment] Shipley WU.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):1115. Comment on: Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):861–8.

Orchidectomy prior to definitive radiotherapy for localized prostatic cancer. Spry NA, et al.
Int J Radiat Oncol Biol Phys 1996 Mar 15;34(5):1045–53

Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times [editorial; comment] Stamey TA. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):967–8; discussion 972. Comment on: Int J Radiat Oncol Biol Phys 1995 May 15;32(2):287–92.

Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Stattin P, et al.
Int J Radiat Oncol Biol Phys 1996 Jul 15;35(5):885–9

Sexual potency following interactive ultrasound–guided brachytherapy for prostate cancer. Stock RG, et al.
Int J Radiat Oncol Biol Phys 1996 May 1;35(2):267–72

RTOG's first quality of life study—RTOG 90–20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer [see comments] Watkins–Bruner D, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):901–6. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):965–6.

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Yang FE, et al.
Int J Radiat Oncol Biol Phys 1995 Dec 1;33(5):1009–17

Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. Yu Y, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1; 34(3):717–25

Prostate brachytherapy: importance of technique [letter; comment] Blasko JC, et al. **J Clin Oncol** 1996 Jun; 14(6):1965–7. Comment on: J Clin Oncol 1996 Jan;14(1):304–15.

Prostate interstitial implantation: half the solution [letter; comment] Critz FA. **J Clin Oncol** 1996 Jun;14(6):1965. Comment on: J Clin Oncol 1996 Jan;14(1):304–15.

Role of interstitial radiotherapy in the management of clinically organ–confined prostate cancer: the jury is still out [see comments] D'Amico AV, et al. **J Clin Oncol** 1996 Jan;14(1):304–15 (35 ref.). Comment in: J Clin Oncol 1996 Jun;14(6):1965. Comment in: J Clin Oncol 1996 Jun;14(6):1965–7.

Outcomes of external–beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. Fowler FJ Jr, et al. **J Clin Oncol** 1996 Aug;14(8):2258–65

Patterns–of–failure analysis of patients with high pretreatment prostate–specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. Hanks GE, et al. **J Clin Oncol** 1996 Apr;14(4):1093–7

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. Wallner K, et al. **J Clin Oncol** 1996 Feb;14(2):449–53

PSA levels after radiotherapy: how low must they go? [news] McNeil C. **J Natl Cancer Inst** 1996 Jun 19;88(12):791–2

Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. Formenti SC, et al. **J Urol** 1996 Feb;155(2):616–9

Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease–free survival [see comments] Lee WR, et al. **J Urol** 1996 Aug; 156(2 Pt 1):450–3. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

p53 immunohistochemical and genetic alterations are associated at high incidence with post–irradiated locally persistent prostate carcinoma. Prendergast NJ, et al.
J Urol 1996 May;155(5):1685–92

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control [see comments] Syndikus I, et al. **J Urol** 1996 Jun;155(6):1983–6. Comment in: J Urol 1996 Jun;155(6):1987–8.

Evaluation of serum prostate–specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer. Buskirk SJ, et al. **Mayo Clin Proc** 1996 Mar;71(3):242–8

Spatial information on dose distribution using multisectional dose–volume histograms. Datta NR, et al. **Med Dosim** 1996 Spring;21(1):19–22

125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer. D'Addessi A, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):105–11 (33 ref.)

Radiation therapy in the treatment of localized prostate cancer: an alternative to an emerging consensus. Perez CA, et al. **Mo Med** 1995 Nov;92(11):696–704

Strontium–89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)

Fox Chase/Stanford study: radiation therapy effective in treating younger men with early–stage prostate cancer [news] **Oncology (Huntingt)** 1996 Apr;10(4):522, 525

High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. Arakawa A, et al.
Pathol Res Pract 1995 Sep;191(9):868–72

Injury–specific cytotoxic response of tumor cells and endothelial cells. Ts'ao C, et al. **Pathol Res Pract** 1996 Jan; 192(1):1–9

Quantitating regrowth delay of prostate cancers after failure of radiation therapy. Hood–Hanks S, et al. **Radiology** 1996 Aug;200(2):505–8

Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Lee WR, et al. **Radiology** 1996 Feb;198(2):439–42

Optimal placement of radioisotopes for permanent prostate implants. Narayana V, et al. **Radiology** 1996 May; 199(2):457–60

Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Arcangeli G, et al. **Radiother Oncol** 1995 May;35(2):123–8

Reproducibility of conformal radiation therapy in localized carcinoma of the prostate without rigid immobilization. Bieri S, et al. **Radiother Oncol** 1996 Mar;38(3):223–30

Prostate motion during standard radiotherapy as assessed by fiducial markers. Crook JM, et al. **Radiother Oncol** 1995 Oct;37(1):35–42

Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Dusserre A, et al. **Radiother Oncol** 1995 Sep;36(3):229–34

Comparison of treatment techniques for conformal radiotherapy of the prostate using dose–volume histograms and normal tissue complication probabilities. Neal AJ, et al. **Radiother Oncol** 1995 Oct;37(1):29–34

A comparison of conventional 'forward planning' with inverse planning for 3D conformal radiotherapy of the prostate. Oldham M, et al. **Radiother Oncol** 1995 Jun; 35(3):248–62

The optimisation of wedge filters in radiotherapy of the prostate. Oldham M, et al. **Radiother Oncol** 1995 Dec; 37(3):209–20

Urethrography and ischial intertuberosity line in radiation therapy planning for prostate carcinoma. Sadeghi A, et al. **Radiother Oncol** 1996 Mar;38(3):215–22

Optimization of intensity–modulated 3D conformal treatment plans based on biological indices. Wang XH, et al.
Radiother Oncol 1995 Nov;37(2):140–52

Radiotherapy of T1c prostate cancer. Ben–Josef E, et al. **Semin Urol Oncol** 1995 Aug;13(3):191–6 (52 ref.)

Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Crook J, et al. **Urology** 1996 Mar;47(3):387–94

An analysis of the time course of postoperative prostate–specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. D'Amico AV, et al. **Urology** 1996 Apr; 47(4):538–47

Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation. Forman JD, et al. **Urology** 1996 Mar;47(3):382–6

Should we treat localized prostate cancer? An opinion [letter; comment] Hanks GE. **Urology** 1996 Apr;47(4):615–6. Comment on: Urology 1995 Nov;46(5):607–16.

Urinary incontinence following external–beam radiotherapy for clinically localized prostate cancer. Lee WR, et al.
Urology 1996 Jul;48(1):95–9

Do the results of systematic biopsies predict outcome in patients with T1–T2 prostate cancer treated with radiation therapy alone? Lee WR, et al. **Urology** 1996 May; 47(5):704–7

[Low–dose radiotherapy of localized prostate neoplasms: How low is high enough?] Huguenin P, et al.
Strahlenther Onkol 1995 Dec;171(12):679–84 (Eng. Abstr.) **(Ger)**

[Improvement of interstitial brachytherapy for localized prostate neoplasms with a new implantation technique] Kovács G, et al. **Strahlenther Onkol** 1995 Dec; 171(12):685–8 (Eng. Abstr.) **(Ger)**

[Treatment sequelae following definitive percutaneous radiotherapy of prostatic neoplasms] Sack H.
Strahlenther Onkol 1995 Dec;171(12):716 **(Ger)**

[Leiomyosarcoma of the prostate: a case report of remission for 9 years by radiotherapy] Sakano Y, et al.
Hinyokika Kiyo 1995 Aug;41(8):629–32 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The comparative efficacy of radiation and thermoradiation treatments in prostatic cancer] Tkachev SI, et al.
Urol Nefrol (Mosk) 1996 Jan–Feb;(1):25–8 (Eng. Abstr.) **(Rus)**

[Brachytherapy in the treatment of prostatic carcinoma] Casas F, et al. **Actas Urol Esp** 1995 Sep;19(8):662–9 (34 ref.) (Eng. Abstr.) **(Spa)**

[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336–45 (46 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

A new staging system for transitional cell carcinoma involvement of the prostate and reconfirmation studies of intravesical therapy for superficial bladder cancer [editorial; comment] Hudson MR. **J Urol** 1996 Sep; 156(3):972–4. Comment on: J Urol 1996 Sep;156(3):962–6. Comment on: J Urol 1996 Sep;156(3):967–71. Comment on: J Urol 1996 Sep;156(3):1071–6.

The prostate involvement as prognostic factor in patients with superficial bladder tumors. Solsona E, et al.
J Urol 1995 Nov;154(5):1710–3

Renal cell carcinoma metastatic to the gallbladder or prostate: two case reports. King DH, et al. **Urology** 1995 Nov;46(5):722–5

SECRETION

Prostate-derived soluble factors block osteoblast differentiation in culture. Martínez J, et al. **J Cell Biochem** 1996 Apr;61(1):18–25

SURGERY

Total androgenic blockade: a review. Bianchi G, et al. **Acta Urol Belg** 1995 Sep;63(3):11–9 (54 ref.)

Radical prostatectomy for prostate cancer—an experience of fifteen cases in Singapore. Cheng C, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):557–61

Radical surgery for clinically confined prostate cancer. Pagano F, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:85–92

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428–33

A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. Lipponen P, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2095–100

Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Bogden AE, et al. **Br J Cancer** 1996 Jan;73(1):73–8

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):359–66 (59 ref.)

Critical temperature for in vivo cryoablation of human prostate cancer in a xenograft model. Cozzi PJ, et al. **Br J Urol** 1996 Jan;77(1):89–92

Orgasm after radical prostatectomy. Koeman M, et al. **Br J Urol** 1996 Jun;77(6):861–4

The role of cystoscopy before radical prostatectomy. Schwartz BF, et al. **Br J Urol** 1996 Jan;77(1):93–5

Surgical management of prostate cancer [letter] Aref I. **Cancer** 1995 Nov 1;76(9):1682–4

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Miller RJ Jr, et al. **Cancer** 1996 Apr 15; 77(8):1510–4

Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. Petrovich Z, et al. **Cancer** 1995 Nov 1;76(9):1621–8

The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Smitt MC, et al. **Cancer** 1996 Mar 1;77(5):928–33

5—Surgical pathology of prostate cancer. Algaba F. **Eur J Surg Oncol** 1996 Feb;22(1):102–7 (18 ref.)

The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Abrahamsson PA. **Eur Urol** 1996;29 Suppl 2:27–30 (12 ref.)

Bladder neck preservation following radical prostatectomy: continence and margins. Braslis KG, et al. **Eur Urol** 1995; 28(3):202–8

Radical prostatectomy: prospective assessment of mortality and morbidity. Davidson PJ, et al. **Eur Urol** 1996; 29(2):168–73

The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Huland H. **Eur Urol** 1996;29 Suppl 2:31–3 (16 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Weinstein MH, et al. **Hum Pathol** 1996 Jul;27(7):683–7

Radiotherapy vs. surgery for prostate cancer: an age old question [editorial; comment] Pollack A, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):407–9. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):243–50.

Mini-laparotomy staging pelvic lymph node dissection for localized prostate cancer. Arai Y, et al. **Int J Urol** 1995 May;2(2):121–3

The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy. Romics I, et al. **Int Urol Nephrol** 1995;27(3):319–24

Prostate cancer management in older patients [see comments] See W. **Iowa Med** 1995 Dec;85(12):489–90. Comment in: Iowa Med 1996 Apr;86(4):155.

Epididymo-orchitis after cryoablation of prostate for prostate cancer. Fournier G, et al. **J Endourol** 1995 Aug;9(4):349–51

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. Lu-Yao GL, et al. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):166–73

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy [see comments] Bettencourt MC, et al. **J Urol** 1996 Sep;156(3):1064–8. Comment in: J Urol 1996 Sep;156(3):1069–70.

Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. Coogan CL, et al. **J Urol** 1995 Nov; 154(5):1813–7

Re: Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma [letter; comment] Dorrance HR, et al. **J Urol** 1996 Aug;156(2 Pt 1):484–5. Comment on: J Urol 1995 May;153(5):1635–6.

Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. Formenti SC, et al. **J Urol** 1996 Feb;155(2):616–9

Radical prostatectomy with preservation of urinary continence [see comments] Gaker DL, et al. **J Urol** 1996 Aug;156(2 Pt 1):445–9. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Radical retropubic prostatectomy: limited benefit of autologous blood donation. Goad JR, et al. **J Urol** 1995 Dec;154(6):2103–9

Applied stapling technique in radical retropubic prostatectomy: efficient, effective and efficacious. Gould DL, et al. **J Urol** 1996 Mar;155(3):1008–10

Re: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer [letter; comment] Höltl W, et al. **J Urol** 1996 Jan;155(1):296 . Comment on: J Urol 1994 May;151(5):1315–20.

Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients [see comments] Kabalin JN, et al. **J Urol** 1996 Jan;155(1):181–5. Comment in: J Urol 1996 Jan;155(1):190.

Influence of patient age and co-morbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. Koch MO, et al. **J Urol** 1996 May; 155(5):1681–4

Radical prostatectomy: is complete resection of the seminal vesicles really necessary? Korman HJ, et al. **J Urol** 1996 Sep;156(3):1081–3

Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis [see comments] Lerner SE, et al. **J Urol** 1996 Mar;155(3):821–6. Comment in: J Urol 1996 Mar;155(3):827.

Prostate cancer and aspects of radical prostatectomy [editorial] Middleton RG. **J Urol** 1996 Sep;156(3):1092–3

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting [see comments] Moul JW, et al. **J Urol** 1996 May;155(5):1667–73. Comment in: J Urol 1996 May;155(5):1678–80.

Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy [see comments] Olsson CA, et al. **J Urol** 1996 May;155(5):1557–62. Comment in: J Urol 1996 May;155(5):1661–2.

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. Parra RO, et al. **J Urol** 1996 Feb;155(2):612–5

Mini-laparotomy pelvic lymph node dissection minimizes morbidity, hospitalization and cost of pelvic lymph node dissection. Perrotti M, et al. **J Urol** 1996 Mar;155(3):986–8

Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. Shinohara K, et al. **J Urol** 1996 Jul;156(1):115–20; discussion 120–1

Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation [see comments] Smith RC, et al. **J Urol** 1996 Aug;156(2 Pt 1):454–7; discussion 457–8. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Cryosurgical ablation of the prostate for localized adenocarcinoma: a preliminary experience [see comments] Wake RW, et al. **J Urol** 1996 May;155(5):1663–6. Comment in: J Urol 1996 May;155(5):1678–80.

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. Walsh PC. **J Urol** 1996 Jul;156(1):301–2

Re: Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach [letter; comment] Walsh PC. **J Urol** 1996 Jan;155(1):294. Comment on: J Urol 1995 Jun;153(6):1875–7.

The definition and preoperative prediction of clinically insignificant prostate cancer [see comments] Dugan JA, et al. **JAMA** 1996 Jan 24–31;275(4):288–94. Comment in: JAMA 1996 Jul 3;276(1):28–9.

Results of radical prostatectomy in men with clinically localized prostate cancer. Gerber GS, et al. **JAMA** 1996 Aug 28;276(8):615–9

Is there always a role for radical prostatectomy in the treatment of localized prostate cancer? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):117–24 (26 ref.)

Early clinical experience with percutaneous cryosurgical ablation of the prostate. Hawatmeh AS, et al. **Mo Med** 1995 Nov;92(11):705–9

Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Lerner SE, et al. **Oncology (Huntingt)** 1995 May;9(5):379–82; discussion 382, 385–6, 389

Suramin as adjuvant therapy with radical prostatectomy. Saffrin R, et al. **Prostate** 1996 May;28(5):325–7

Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF, et al. **Prostate** 1996 Jul;29(1):46–50

The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy. Hunter DJ, et al. **Qual Life Res** 1995 Aug;4(4):335–41

Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Kurhanewicz J, et al. **Radiology** 1996 Aug;200(2):489–96

Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Arcangeli G, et al. **Radiother Oncol** 1995 May;35(2):123–8

Orthotopic bladder substitutes: histopathologic risk factors. Nabeeh A, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):463–7

Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Iversen P, et al. **Scand J Urol Nephrol Suppl** 1995;172:65–72

Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar–Apr 12(2):139–44 (51 ref.)

Histopathological effects of androgen deprivation in prostatic cancer. Civantos F, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):22–31

Stage T1c prostate cancer: perspectives on clinical management. Smith JA Jr. **Semin Urol Oncol** 1995 Aug; 13(3):238–44 (27 ref.)

Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS. **Semin Urol Oncol** 1995 Aug;13(3):204–14 (47 ref.)

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

Laparoscopic monitoring of cryosurgical ablation of the prostate. Sklar GN, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):376–81

Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Vamvakas EC. **Transfusion** 1995 Sep;35(9):760–8

Management of prostate and bladder cancer in the elderly. Dreicer R, et al. **Urol Clin North Am** 1996 Feb;23(1):87–97 (85 ref.)

Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Bales GT, et al. **Urology** 1995 Nov;46(5):676–80

Erectile dysfunction following minimally invasive treatments for prostate cancer. Chaikin DC, et al. **Urology** 1996 Jul; 48(1):100–4

Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Cohen JK, et al. **Urology** 1996 Mar;47(3):395–401

Cryosurgical ablation of the prostate: pro [editorial] Cohen JK. **Urology** 1996 Aug;48(2):178–80

Cryosurgical ablation of the prostate: the con side in 1996 [editorial] Cox RL, et al. **Urology** 1996 Aug;48(2):181–3

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870–7

Should we treat localized prostate cancer? An opinion [letter; comment] Hanks GE. **Urology** 1996 Apr;47(4):615–6. Comment on: Urology 1995 Nov;46(5):607–16.

A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Jønler M, et al. **Urology** 1996 Sep; 48(3):433–40

A comparison of the W-stapled ileal reservoir with hand-sewn reservoirs for orthotopic bladder replacement. Montie JE, et al. **Urology** 1996 Apr;47(4):476–81

Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Noldus J, et al. **Urology** 1996 May;47(5):713–8

Radical prostatectomy: the perineal approach [editorial] Resnick MI. **Urology** 1996 Apr;47(4):457–9

Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Schild SE, et al. **Urology** 1996 Jun;47(6):878–81

Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer. Zhang XZ, et al. **Urology** 1996 Mar;47(3):402–4

Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)

Surgery in rhabdomyosarcoma of the bladder, prostate and vagina. Fisch M, et al. **World J Urol** 1995;13(4):213–8

[Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results] Hermans BP, et al. **Acta Urol Belg** 1996 Mar;64(1):27–31 **(Fre)**

[Simplified vesico-urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**

[Pelvic lymphadenectomy: celioscopy or laparotomy?] Péloquin F, et al. **J Urol (Paris)** 1996;102(1):28–9 (Eng. Abstr.) **(Fre)**

[Rectal injuries in radical prostatectomies for cancer. Survey of the ANFUC (Association National de Formation Urologique Continue) 1994] Viville C. **J Urol (Paris)** 1995; 101(2):65–8 (Eng. Abstr.) **(Fre)**

[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Peroperative biopsy of the sub-apical urethra during prostatectomy for cancer] Ponthieu A, et al. **Prog Urol** 1996 Apr;6(2):250–5; discussion 255–6 (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression

and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Patient-controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134–8 (Eng. Abstr.) **(Ger)**

[Results of treatment and quality of life after radical prostatectomy] Hinkelbein W, et al. **Strahlenther Onkol** 1995 Dec;171(12):717–8 **(Ger)**

[Indications for radical prostatectomy in the US] Sack H. **Strahlenther Onkol** 1995 Dec;171(12):715 **(Ger)**

[Is radical prostatectomy a suitable model for determination of PSA half-life?] Brändle E, et al. **Urologe A** 1995 Sep; 34(5):419–23 (Eng. Abstr.) **(Ger)**

[The role of laparoscopy in the management of prostatic cancer] Haas GP, et al. **Orv Hetil** 1995 Sep 10; 136(37):2005–7 (Eng. Abstr.) **(Hun)**

[A new method for treating benign prostatic hypertrophy: transurethral prostatic vaporization] Tizzani A, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):53–4 **(Ita)**

[Recent improvements and results of radical prostatectomy] Usami M. **Gan To Kagaku Ryoho** 1996 Mar;23(4):407–12 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical outcome of radical prostatectomy and pelvic lymph node dissection] Mizutani K, et al. **Hinyokika Kiyo** 1995 Nov;41(11):867–71 (Eng. Abstr.) **(Jpn)**

[Retroperitoneal laparoscopic pelvic lymphadenectomy for patients with prostate cancer] Ushiyama T, et al. **Hinyokika Kiyo** 1996 Jan;42(1):23–6 (Eng. Abstr.) **(Jpn)**

[A clinical study of radial prostatectomy] Hotta H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):760–5 (Eng. Abstr.) **(Jpn)**

[A clinical and pathological study of radical prostatectomy for prostate cancer] Taguchi I, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):772–9 (Eng. Abstr.) **(Jpn)**

[Prognosis after radical surgery in prostatic cancer patients with lymph nodes metastases] Tomita K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1322–7 (Eng. Abstr.) **(Jpn)**

[X-ray intravascular surgery in oncologic urology] Granov AM, et al. **Vestn Rentgenol Radiol** 1996 Jan–Feb;(1):35–7 (Eng. Abstr.) **(Rus)**

[Non-palpable prostatic cancer. Cure with adenomectomy?] Cambronero Santos J, et al. **Actas Urol Esp** 1996 Apr; 20(4):346–50 (Eng. Abstr.) **(Spa)**

[Radical surgery of locally advanced prostatic cancer] Pesqueira D, et al. **Actas Urol Esp** 1995 Jul–Aug; 19(7):549–54 (Eng. Abstr.) **(Spa)**

[New horizons of radical prostatectomy in the treatment of localized prostatic cancer (editorial)] Solsona Narbón E. **Actas Urol Esp** 1995 Mar;19(3):175–9 **(Spa)**

[Transurethral resection of prostate cancer: efficacy and morbidity] Mora Durban M, et al. **Arch Esp Urol** 1995 Oct;48(8):829–35 (Eng. Abstr.) **(Spa)**

[Rebirth of perineal prostatectomy in the era of laparoscopic lymphadenectomy] Ruiz Quijano RA, et al. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):130–4 (Eng. Abstr.) **(Spa)**

THERAPY

Prostate cancer—treatment of disseminated disease. Abi-Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):67–76 (78 ref.)

Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients. Oosterlinck W, et al. **Acta Urol Belg** 1995 Sep;63(3):1–9

Canary-pox (ALVAC) virus-mediated cytokine gene therapy induces tumor specific and non-specific immunity against mouse prostate tumor. Ratliff TL, et al. **Acta Urol Belg** 1996 May;64(2):85

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al. **Acta Urol Belg** 1996 May;64(2):57–61 (32 ref.)

CT findings after laparoscopic pelvic lymph node dissection and transperineal radioactive seed implantation for prostatic carcinoma. Glajchen N, et al. **AJR Am J Roentgenol** 1996 May;166(5):1165–8

American Urological Association releases guidelines for the management of localized prostate cancer. **Am Fam Physician** 1996 Jun;53(8):2751–2

Patient counseling regarding treatment of T1/2 (A/B) prostate cancer. A personal view. Schellhammer PF. **Am J Clin Oncol** 1995 Dec;18(6):532–7

Prostate cancer: current and evolving strategies. Cersosimo RJ, et al. **Am J Health Syst Pharm** 1996 Feb 15; 53(4):381–96; quiz 446–8 (153 ref.)

Active immunization against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma. Ladd A, et al. **Am J Reprod Immunol** 1995 Sep;34(3):200–6

Prostate cancer: emerging concepts. Part II. Garnick MB, et al. **Ann Intern Med** 1996 Aug 1;125(3):205–12 (60 ref.)

The management of localized prostate cancer [editorial] [see comments] Clarke NW. **Br J Hosp Med** 1996 Mar 6–19; 55(5):232–3. Comment in: Br J Hosp Med 1996 Mar 6–19;55(5):233–4.

Induction androgen deprivation therapy before radical prostatectomy for prostate cancer—initial results. Abbas F, et al. **Br J Urol** 1996 Mar;77(3):423–8

The burden of prostate cancer from diagnosis until death. Otnes B, et al. **Br J Urol** 1995 Nov;76(5):587–94

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate—an Australian multicentre trial. Zalcberg JR, et al. **Br J Urol** 1996 Jun;77(6):865–9

The management of clinically localized prostate cancer: guidelines from the American Urological Association. Middleton RG. **CA Cancer J Clin** 1996 Jul–Aug; 46(4):249–53

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Eriksson S, et al. **Calcif Tissue Int** 1995 Aug;57(2):97–9

in vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Eastham JA, et al. **Cancer Res** 1995 Nov 15; 55(22):5151–5

Management of localized prostate cancer: an epidemiological perspective. Harwood RH. **Clin Oncol (R Coll Radiol)** 1995; 7(3):151–9 (43 ref.)

The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. da Silva FC, et al. **Eur J Cancer** 1996 Jan; 32A(1):72–7

Prostate cancer—what should be studied? [editorial; comment] James ND, et al. **Eur J Cancer** 1995 Sep; 31A(10):1565–6 (15 ref.). Comment on: Eur J Cancer 1995 Sep;31A(10):1622–6.

Intermittent hormone therapy in prostate and breast cancers [letter; comment] Stoll BA. **Eur J Cancer** 1995 Dec; 31A(13–14):2415–6. Comment on: Eur J Cancer 1995 Jun;31A(6):859–60.

Update on urology—prostate cancer. 4—Treatment of local disease. Bowsher WG. **Eur J Surg Oncol** 1995 Dec; 21(6):679–82

The management of localised cancer of the prostate. Boccon-Gibod L. **Eur Urol** 1996;29 Suppl 2:62–8 (51 ref.)

Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, et al. **Eur Urol** 1995; 28(3):177–88 (98 ref.)

Current controversies in the management of localized prostate cancer. Dillioglugil O, et al. **Eur Urol** 1995; 28(2):85–101 (120 ref.)

Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Gelet A, et al. **Eur Urol** 1996;29(2):174–83

Attitudes of European urologists to early prostatic carcinoma, II. Attitude to therapy and to screening examinations. Hansen MV, et al. **Eur Urol** 1995; 28(3):196–201

Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Jørgensen T, et al. **Eur Urol** 1995;28(1):40–6

The future management of prostate cancer? Kirby RS. **Eur Urol** 1996;29 Suppl 2:132–3 (6 ref.)

Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies. Maier U, et al. **Eur Urol** 1996;29(2):221–3

Appraisal of current therapies for prostate cancer. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:110–3 (18 ref.)

Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Voges GE, et al. **Eur Urol** 1995; 28(3):209–14

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Eastham JA, et al. **Hum Gene Ther** 1996 Mar 1;7(4):515–23

Prospects for prostatic cancer incidence and treatment by the year 2000. Forti G, et al. **Int J Androl** 1996 Feb; 19(1):1–10 (81 ref.)

Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution? [editorial] Anscher MS. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):745–7

The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Schild SE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):535–41

Prostate cancer treatment article incomplete [letter; comment] Foens C. **Iowa Med** 1996 Apr;86(4):155. Comment on: Iowa Med 1995 Dec;85(12):489–90.

Hormonal treatment of prostate cancer [editorial] Smith S. **Ir Med J** 1996 Mar–Apr;89(2):50

How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. Mazur DJ, et al. **J Am Geriatr Soc** 1996 Aug;44(8):934–7

Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. Sagaster P, et al. **J Cancer Res Clin Oncol** 1996; 122(3):171–76

Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. Berglund L, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2633–7

Defining clinically significant prostate cancer: pathologic criteria versus outcomes data [editorial; comment] Albertsen PC. **J Natl Cancer Inst** 1996 Sep 4;88(17):1177–8 . Comment on: J Natl Cancer Inst 1996 Sep 4;88(17):1216–21.

CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. Cheng L, et al. **J Natl Cancer Inst** 1996 May 1;88(9):607–11

Additional therapy after prostatectomy: implications for patient counseling [editorial] Chodak GW. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):139–40

The Hospice Supportive Care Program: a new "transitionless" model of palliative care for patients with incurable prostate cancer [letter] Pienta KJ, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):55–6

Re: Long-term survival and mortality in prostate cancer treated with noncurative intent [letter; comment] Abrahamsson A, et al. **J Urol** 1996 Jan;155(1):296–8. Comment on: J Urol 1995 Aug;154(2 Pt 1):460–5.

Prostate cancer [editorial; comment] Brendler CB. **J Urol** 1996 Aug;156(2 Pt 1):459. Comment on: J Urol 1996 Aug;156(2 Pt 1):445–9. Comment on: J Urol 1996 Aug;156(2 Pt 1):450–3. Comment on: J Urol 1996 Aug;156(2 Pt 1):454–7; discussion 457–8.

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. Dalkin BL, et al. **J Urol** 1996 Apr;155(4):1357–60

5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. Glazier DB, et al. **J Urol** 1996 Feb;155(2):624–7

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213–9. Comment in: J Urol 1996 Jan;155(1):226–7.

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. Goldenberg SL, et al. **J Urol** 1996 Sep;156(3):873–7

Strategies to manage prostate cancer [editorial] Haas GP. **J Urol** 1996 Feb;155(2):628–9

Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer [letter; comment] Horan AH. **J Urol** 1996 Apr;155(4):1395. Comment on: J Urol 1995 Aug;154(2 Pt 1):535–6.

Mortality in prostate cancer. Krongrad A, et al. **J Urol** 1996 Sep;156(3):1084–91

Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. Middleton RG, et al. **J Urol** 1995 Dec;154(6):2144–8

Re: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer [letter; comment] Walsh PC. **J Urol** 1996 Jun;155(6):2038–9. Comment on: J Urol 1995 Oct;154(4):1420–5.

A 72-year-old man with localized prostate cancer, 1 year later [comment] Delbanco TL, et al. **JAMA** 1996 Feb 14; 275(6):485. Comment on: JAMA 1995 Jul 5;274(1):69–74.

A 72-year-old man with localized prostate cancer [letter; comment] Miles BJ, et al. **JAMA** 1995 Nov 8; 274(18):1426–7. Comment on: JAMA 1995 Jul 5;274(1):69–74.

Severe thrombocytopenia in a man with prostatic cancer. Hamid S, et al. **JPMA J Pak Med Assoc** 1995 Sep; 45(9):252–4

Anti-androgens in treatment of prostate cancer [letter; comment] Labrie F, et al. **Lancet** 1995 Oct 14; 346(8981):1030–1. Comment on: Lancet 1995 Jul 29;346(8970):265–9.

Anti-androgens in treatment of prostate cancer [letter; comment] Quartey P. **Lancet** 1995 Oct 14;346(8981):1031 . Comment on: Lancet 1995 Jul 29;346(8970):265–9.

Factors that determine the treatment for local and regional prostate cancer. Desch CE, et al. **Med Care** 1996 Feb; 34(2):152–62

Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Schapira MM, et al. **Med Care** 1995 Nov;33(11):1079–88

Design and optimization of an aperiodic ultrasound phased array for intracavitary prostate thermal therapies. Hutchinson EB, et al. **Med Phys** 1996 May;23(5):767–76

Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. Moon TD, et al. **Monogr Natl Cancer Inst** 1995;(19):69–71

Prostate Cancer Intervention Versus Observation Trial: economic analysis in study design and conditions of uncertainty. Schwartz JS. **Monogr Natl Cancer Inst** 1995; (19):73–5

Information and decision-making preferences of men with prostate cancer. Davison BJ, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1401–8

Locoregional therapies for early-stage prostate cancer. Stock RG. **Oncology (Huntingt)** 1995 Sep;9(9):803–11; discussion 815–6 (82 ref.)

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125–9, 133–4, 136 (18 ref.)

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

Treatment of localized prostate cancer. Choosing the best alternative. Williams TR, et al. **Postgrad Med** 1996 Sep; 100(3):105–7, 111–2, 118–20 (25 ref.)

Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL–2) and alpha–interferon (A–IFN) for stage D3 prostate carcinoma failing second–line hormonal treatment. Maffezzini M, et al. **Prostate** 1996 May; 28(5):282–6

The case for early endocrine treatment of advanced or metastatic prostate cancer. Schmidt JD. **Prostate** 1996 Mar; 28(3):201–4

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node–positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Schmidt JD, et al. **Prostate** 1996 Jan;28(1):51–7

Carcinoma of prostate: case against immediate hormonal therapy. Smith PH. **Prostate** 1996 Mar;28(3):205–8

Future directions in prostate cancer treatment: an oncologist's perspective. Hussain M. **Prostate Suppl** 1996; 6:26–30 (40 ref.)

A glimpse at the future of some endocrine aspects of prostate cancer. Montie JE. **Prostate Suppl** 1996;6:57–61 (27 ref.)

Flutamide–associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Rosenthal SA, et al. **Radiology** 1996 May; 199(2):451–5

Adjuvant systemic therapy of prostate cancer. Raghavan D. **Semin Oncol** 1995 Dec;22(6):633–40 (72 ref.)

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Counseling patients about therapy for localized prostate cancer. Middleton RG. **Semin Urol Oncol** 1995 Aug; 13(3):187–90 (8 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)

In vivo, synergestic inhibition of MAT–LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low–dose cyclophosphamide. Cipolla B, et al. **Urol Res** 1996;24(2):93–8; discussion 99

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Bales GT, et al. **Urology** 1996 Jan;47(1A Suppl):38–43; discussion 48–53

Hormone therapy for prostate cancer: a topical perspective. Klein EA. **Urology** 1996 Jan;47(1A Suppl):3–12; discussion 29–32 (33 ref.)

Should we treat localized prostate cancer? An opinion [see comments] Menon M, et al. **Urology** 1995 Nov;46(5):607–16 . Comment in: Urology 1996 Apr;47(4):615–6.

Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF. **Urology** 1996 May;47(5):622–8 (46 ref.)

Upregulation of prostate–specific membrane antigen after androgen–deprivation therapy. Wright GL Jr, et al. **Urology** 1996 Aug;48(2):326–34

Should we and can we cure prostate cancer? Weldon VE. **West J Med** 1996 Apr;164(4):341–2

[Localized transrectal hyperthermia. Transurethral hyperthermia and thermotherapy in the treatment of benign hyperplasia of the prostate] Mazo E, et al. **J Urol (Paris)** 1996;102(1):23–5 (Eng. Abstr.) **(Fre)**

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465–70 (10 ref.) (Eng. Abstr.) **(Fre)**

[How to treat locally advanced and metastatic untreated cancer of the prostate?] Khoury S. **Prog Urol** 1996 Apr; 6(2 Suppl 1):42–5 **(Fre)**

[How to treat hormone–resistant prostatic cancer?] Khoury S. **Prog Urol** 1996 Apr;6(2 Suppl 1):46–56 **(Fre)**

[Bloodless prostate treatment using high–intensity focused ultrasound (HIFU)] Eberle J, et al. **Schweiz Med Wochenschr** 1996 Aug 17;126(33):1385–92 (Eng. Abstr.) **(Ger)**

[Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma] Strnad V, et al. **Strahlenther Onkol** 1996 Apr;172(4):225–8 (Eng. Abstr.) **(Ger)**

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma] Bruchovsky N, et al. **Urologe A** 1995 Sep;34(5):389–92 (8 ref.) (Eng. Abstr.) **(Ger)**

[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma] DeAntoni E, et al. **Urologe A** 1995 Sep;34(5):382–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations] Newling DW. **Urologe A** 1995 Sep;34(5):374–81 (32 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393–7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**

[Advanced prostatic carcinoma—which hormone therapy when?] Studer UE. **Urologe A** 1995 Sep;34(5):361–6 (34 ref.) **(Ger)**

[Comments on radical prostatectomy three month after hormone therapy] Selvaggi FP, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):215–7 **(Ita)**

[Prognostic factors in stage D2 prostate cancer: results of univariate and multivariate analyses] Masukagami T, et al. **Hinyokika Kiyo** 1996 Apr;42(4):269–74 (Eng. Abstr.) **(Jpn)**

[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1530–7 (Eng. Abstr.) **(Jpn)**

[Prognostic factors in patients with advanced prostatic cancer (stage D2) initially treated with endocrine therapy] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):688–94 (Eng. Abstr.) **(Jpn)**

[5–Fluorouracil and alpha–2a interferon in patients with hormone–refractory prostate cancer] Shinohara N, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1557–62 (Eng. Abstr.) **(Jpn)**

[Treatment of prostatic carcinoma—controversies] Peeling WS. **Pol Tyg Lek** 1996 Feb;51(6–9):116–20 **(Pol)**

[The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action] Panteleeva ES, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):28–31 (Eng. Abstr.) **(Rus)**

[The late results of the combined hormonal chemoradiation treatment of prostatic cancer] Sviridova TV, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb;(1):31–4 (Eng. Abstr.) **(Rus)**

[Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications] Morote J, et al. **Actas Urol Esp** 1995 Sep; 19(8):604–10 (Eng. Abstr.) **(Spa)**

[Symptomatic prostatic cancer must be treated! (letter)] Bratt O, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2494 **(Swe)**

ULTRASONOGRAPHY

Contribution to the clarification of heterogeneous foci within the prostate. Zát'ura F, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:65–7

Multiple transrectal ultrasound–guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion. Norberg M, et al. **Eur Radiol** 1996;6(1):56–61

Color Doppler ultrasonographic scanning in prostatitis: clinical correlation. Veneziano S, et al. **Eur Urol** 1995; 28(1):6–9

Determination of prostate gland volume by transrectal ultrasound: correlation with radical prostatectomy specimens. Wolff JM, et al. **Eur Urol** 1995;28(1):10–2

Ultrasound image fusion for external beam radiotherapy for prostate cancer. Holupka EJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):975–84

The impact of transrectal ultrasound on stage migration in a predominantly African–American population. Saffrin R, et al. **J Natl Med Assoc** 1995 Oct;87(10):759–61

Cystic carcinoma of the prostate. Agha AH, et al. **J Ultrasound Med** 1996 Jan;15(1):75–7

Construction and application of hierarchical decision tree for classification of ultrasonographic prostate images. Giesen RJ, et al. **Med Biol Eng Comput** 1996 Mar;34(2):105–9

Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. Bazinet M, et al. **Urology** 1996 Jun;47(6):857–62

[The diagnosis, biopsy and treatment follow–up by ultrasound in patients with prostatic carcinoma] Mladenov D, et al. **Khirurgiia (Sofiia)** 1994;47(5):15–7 (Eng. Abstr.) **(Bul)**

[The significance of focal hypoechoic lesions in the peripheral zone of the prostate] Oyen R, et al. **J Belge Radiol** 1995 Dec;78(6):356–8 (Eng. Abstr.) **(Dut)**

[High–grade intraepithelial prostatic neoplasms: diagnosis and association with prostate cancer] Raviv G, et al. **Acta Urol Belg** 1996 Mar;64(1):11–5 (Eng. Abstr.) **(Fre)**

[Prostatic leiomyoma] Coulier B, et al. **J Belge Radiol** 1995 Jun;78(3):182–3 (Eng. Abstr.) **(Fre)**

[Ultrasonography and prostatic adenocarcinoma] Grasso–Leanza F, et al. **Arch Ital Urol Androl** 1995 Sep; 67(4):237–41 (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Takeda H, et al. **Cancer** 1996 Mar 1;77(5):934–40

URINE

Pyridinium cross–links as urinary markers of bone metastases in patients with prostate cancer. Ikeda I, et al. **Br J Urol** 1996 Jan;77(1):102–6

VETERINARY

Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: comparative pathology in human and nonhuman primates. McEntee MF, et al. **Prostate** 1996 Jul;29(1):51–9

VIROLOGY

Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and –18 DNA. Naghashfar Z, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):47–54

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H, et al. **Prostate** 1996 May;28(5):318–24

Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Wideroff L, et al. **Prostate** 1996 Feb;28(2):117–23

PROSTATITIS

[Chronic prostatitis: diagnostic and therapeutic considerations] Jara J, et al. **Actas Urol Esp** 1996 Mar; 20(3):261–8 (Eng. Abstr.) **(Spa)**

BLOOD

Serum prostate specific antigen levels in non–specific granulomatous prostatitis. Speights VO Jr, et al. **Br J Urol** 1996 Mar;77(3):408–10

COMPLICATIONS

[Subvesical obstruction following chronic bacterial prostatitis] Neĭkov K, et al. **Khirurgiia (Sofiia)** 1994; 47(5):17–9 (Eng. Abstr.) **(Bul)**

DIAGNOSIS

Primary non–Hodgkin's lymphoma of the prostate mimicking acute prostatitis. Parks RW, et al. **Br J Urol** 1995 Sep; 76(3):409

Prostate–specific antigen (PSA) and cancer–associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. Devine PL, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):221–5

Prostatic abscess in a child. Shokeir AA, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):525–6

[Granulomatous prostatitis] Mottola A, et al. **Minerva Urol Nefrol** 1996 Jun;48(2):89–92 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Ten years experience with chronic prostatitis in Africans. Magoha GA. **East Afr Med J** 1996 Mar;73(3):176–8

62 cases of chronic prostatitis treated by rectal ionintroduction of TCM suppository. Chen Z. **J Tradit Chin Med** 1996 Mar;16(1):15–7

Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double–blind controlled study. Persson BE, et al. **J Urol** 1996 Mar;155(3):961–4

Allopurinol for prostatitis: where is the evidence? Nickel JC, et al. **Lancet** 1996 Jun 22;347(9017):1711–2

Non–bacterial prostatitis [letter] Persson BE, et al. **Lancet** 1996 Sep 14;348(9029):761

Cryptococcal prostatitis in a patient with Behçet's disease treated with fluconazole. Fuse H, et al. **Mycopathologia** 1995 Jun;130(3):147–50

[Ciprofloxacin–associated bilateral acute achilles tendinitis] Mirovsky Y, et al. **Harefuah** 1995 Dec 1;129(11):470–2, 535 (Eng. Abstr.) **(Heb)**

[A possible therapeutic improvement of the antibacterial effect by monitoring the production of leukocyte free oxygen radicals during antibiotic treatment of infertile patients with chronic bacterial prostatitis] Vicari E, et al. **Arch Ital Urol Androl** 1996 Apr;68(2):91–7 (Eng. Abstr.) **(Ita)**

[Ciprofloxacin in the treatment of chronic bacterial prostatitis] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):20–3 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Clinico–pathological findings simulating prostatic malignancy following sclerotherapy: a diagnostic pitfall. Feneley M, et al. **Br J Urol** 1996 Jan;77(1):157–8

Ten years experience with chronic prostatitis in Africans. Magoha GA. **East Afr Med J** 1996 Mar;73(3):176–8

Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. Persson BE, et al. **J Urol** 1996 Mar; 155(3):958–60

GENETICS

Flow cytometric DNA analysis of fine–needle aspirates of prostatic benign lesions. Paz–Bouza JI, et al. **Anal Cell Pathol** 1995 Apr;8(3):259–64

IMMUNOLOGY

[Seminal plasma cytokines in nonbacterial prostatitis: changes following sparfloxacin treatment] Yasumoto R, et al. **Hinyokika Kiyo** 1995 Oct;41(10):771–4 (Eng. Abstr.) **(Jpn)**

METABOLISM

Production of reactive nitrogen intermediates (RNI) by peritoneal macrophages from rats with experimental autoimmune prostatitis (EAP). Orsilles MA, et al. **Inflammation** 1995 Aug;19(4):415–22

Seminal plasma zinc analysis and bacteriological cultures in chronic staphylococcal prostatitis. Evliyaoğlu Y, et al. **Int Urol Nephrol** 1995;27(3):341–5

Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Itoh M, et al. **Urol Int** 1995;55(2):101–4

MICROBIOLOGY

Histoplasma prostatic abscess: rare cause in an immunocompromised patient [letter] Shah RD, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):471

Corynebacterium seminale sp. nov., a new species associated with genital infections in male patients. Riegel P, et al. **J Clin Microbiol** 1995 Sep;33(9):2244–9

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

[Abscessed brucellar prostatitis. An infrequent location] Guinda Sevillano C, et al. **Actas Urol Esp** 1995 Sep; 19(8):647–50 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Sickness impact of chronic nonbacterial prostatitis and its correlates. Wenninger K, et al. **J Urol** 1996 Mar; 155(3):965–8

RADIOTHERAPY

Transurethral microwave thermotherapy in the treatment of chronic abacterial prostatitis: a 2 years follow-up. Michielsen D, et al. **Acta Urol Belg** 1995 Dec;63(4):1–4

THERAPY

Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. Nickel JC, et al. **J Urol** 1996 Jun; 155(6):1950–4; discussion 1954–5

[The treatment of chronic prostatitis complicated by sexual disorders with vibrotherapy] Havryliuk IP, et al. **Lik Sprava** 1995 May–Jun;(5–6):169–72 (Eng. Abstr.) **(Ukr)**

[A new method for treating patients with chronic prostatitis] Bolko MI. **Vrach Delo** 1995 Jan–Feb;(1–2):65–7 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Color Doppler ultrasonographic scanning in prostatitis: clinical correlation. Veneziano S, et al. **Eur Urol** 1995; 28(1):6–9

URINE

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Benign prostatic hyperplasia in the nonhuman primate Leontopithecus. Ferreira BR, et al. **Folia Primatol (Basel)** 1995;65(1):48–53

PROSTHESIS

see related

PROSTHODONTICS

Experimental study of the acoustic properties of incus replacement prostheses in a human temporal bone model. Nishihara S, et al. **Am J Otol** 1994 Jul;15(4):485–94

Placement of an endotracheal device via the laryngeal mask airway in a patient with tracheal stenosis [letter] Catalá JC, et al. **Anesthesiology** 1996 Jan;84(1):239–40

Extensive use of artificial chordae for repairing diffuse mitral valve prolapse. Morita S, et al. **Ann Thorac Surg** 1996 Sep; 62(3):878–80

Gait analysis of transfemoral amputee patients using prostheses with two different knee joints. Boonstra AM, et al. **Arch Phys Med Rehabil** 1996 May;77(5):515–20

Experimental reconstruction of the intrathoracic trachea using a new prosthesis made from collagen grafted mesh. Okumura N, et al. **ASAIO J** 1994 Jul–Sep;40(3):M834–9

Replacement of long segments of the esophagus with a collagen–silicone composite tube. Takimoto Y, et al. **ASAIO J** 1995 Jul–Sep;41(3):M605–8

A new porous tracheal prosthesis sealed with collagen sponge. Teramachi M, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M306–10

Comparative animal study of three ligament prostheses for the replacement of the anterior cruciate and medial collateral ligament. Dürselen L, et al. **Biomaterials** 1996 May;17(10):977–82

Mechanical behaviour of composite artificial tendons and ligaments. Iannace S, et al. **Biomaterials** 1995 Jun; 16(9):675–80

Shielding of augmented tendon—tendon repair. Rogers GJ, et al. **Biomaterials** 1995 Jul;16(10):803–7

Atkinson tube placement. Reed CE. **Chest Surg Clin N Am** 1995 Aug;5(3):481–8

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul–Aug; 80(3):323–8 (30 ref.)

Biological response to Bard Clamshell Septal Occluders in the canine heart. Kuhn MA, et al. **Circulation** 1996 Apr 1;93(7):1459–63

Do palatal lift prostheses stimulate velopharyngeal neuromuscular activity? Witt PD, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):469–75

Influence of glenohumeral prosthesis geometry and placement on shoulder muscle forces. de Leest O, et al. **Clin Orthop** 1996 Sep;(330):222–33

Long term bone remodeling around the Charnley femoral prostheses. Kobayashi S, et al. **Clin Orthop** 1996 May; (326):162–73

Endoscopic removal of an Angelchik prosthesis after migration through the gastro–oesophageal junction. Souka H, et al. **Endoscopy** 1995 Aug;27(6):464

Mediastinal stabilization by an expansion prosthesis in postoperative congenital diaphragmatic hernia with severe pulmonary hypoplasia. Becmeur F, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):295–8

Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. De Palma GD, et al. **Gastrointest Endosc** 1996 May;43(5):478–82

A PC–based ultrasonic data acquisition system for computer–aided prosthetic socket design. He P, et al. **IEEE Trans Rehabil Eng** 1996 Jun;4(2):114–9

Automated hexahedral mesh generation from biomedical image data: applications in limb prosthetics. Zachariah SG, et al. **IEEE Trans Rehabil Eng** 1996 Jun;4(2):91–102

Bone–anchored craniofacial prosthesis study. Tolman DE, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):159–68

Remarks on the complications following ACL reconstruction using synthetic ligaments. Savarese A, et al. **Ital J Orthop Traumatol** 1993;19(1):79–86

Longitudinal deficiency of the fibula. Operative treatment. Fulp T, et al. **J Bone Joint Surg Am** 1996 May;78(5):674–82

Osseointegrated thumb prostheses: a concept for fixation of digit prosthetic devices. Lundborg G, et al. **J Hand Surg [Am]** 1996 Mar;21(2):216–21

Benefits and use of digital prostheses. Pereira BP, et al. **J Hand Surg [Am]** 1996 Mar;21(2):222–8

Artificial chordae. Zussa C. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S249–54; discussion S254–6

A synthetic dural prosthesis constructed from hydroxyethylmethacrylate hydrogels. Bhatia S, et al. **J Neurosurg** 1995 Nov;83(5):897–902

Technique for fabricating a mirror–image prosthetic ear. Lemon JC, et al. **J Prosthet Dent** 1996 Mar;75(3):292–3

Use of a modified ear face–bow for surgical stent location during ear implant placement: a clinical report. Tan KB, et al. **J Prosthet Dent** 1996 Feb;75(2):117–21

Volumetric determinations with CAD/CAM in prosthetics and orthotics: errors of measurement. Lilja M, et al. **J Rehabil Res Dev** 1995 May;32(2):141–8

Energy expenditure during ambulation in dysvascular and traumatic below–knee amputees: a comparison of five prosthetic feet. Torburn L, et al. **J Rehabil Res Dev** 1995 May;32(2):111–9

Esmarch closure of laparotomy incisions in unstable trauma patients. Cohn SM, et al. **J Trauma** 1995 Nov;39(5):978–9

Aspects of silicone rubber as encapsulant for neurological prostheses. Part 3: Adhesion to mixed oxides. Donaldson PE. **Med Biol Eng Comput** 1995 Sep;33(5):725–7

Aspects of silicone rubber as encapsulant for neurological prostheses. Part 2: Adhesion to binary oxides. Donaldson PE, et al. **Med Biol Eng Comput** 1995 May;33(3):289–92

Adhesion of urogenital organisms to polymers and prosthetic devices. Reid G. **Methods Enzymol** 1995;253:514–9

Prevention and treatment of complications after endoscopic prostheses placement in tumors of the upper gastrointestinal tract. Spinelli P, et al. **Minerva Chir** 1995 Oct;50(10):843–8

Peripheral nerve regeneration in a silicone tube: effect of collagen sponge prosthesis, laminin, and pyrimidine compound administration. Ohbayashi K, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):428–33

Keratoprosthesis as an aid to learning surgical techniques on cadaver eyes. Eckardt U, et al. **Ophthalmic Surg** 1995 Jul–Aug;26(4):358–9

Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Ward WG, et al. **Orthop Clin North Am** 1996 Jul;27(3):493–502 (43 ref.)

Prosthetic management of velopharyngeal insufficiency induced by uvulopalatopharyngoplasty. Finkelstein Y, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):611–6

Utilizing the osseointegration principle for fixation of nail prostheses. Baruchin AM, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1665–71

Autogenous soft–tissue procedures and osseointegrated alloplastic reconstruction: their role in the treatment of complex craniofacial defects. Harris L, et al. **Plast Reconstr Surg** 1996 Sep;98(3):387–92

Thin Silastic sheet for orbital floor repair [letter] Tercan M. **Plast Reconstr Surg** 1995 Oct;96(5):1238–9

Papers from the consensus conference on appropriate prosthetic technology for developing countries held in Phnom Penh, Kingdom of Cambodia, 5–10 June 1995. **Prosthet Orthot Int** 1996 Apr;20(1):12–64 (0 ref.)

Prosthetics in the developing world: a review of the literature. Cummings D. **Prosthet Orthot Int** 1996 Apr; 20(1):51–60 (63 ref.)

A review of the consensus conference on appropriate prosthetic technology in developing countries. Day HJ. **Prosthet Orthot Int** 1996 Apr;20(1):15–23 (0 ref.)

Report on ICRC technical orthopaedic programme for war disabled. Garachon A. **Prosthet Orthot Int** 1996 Apr; 20(1):31–8

The work of GTZ (Deutsche Gesellschaft für Technische Zusammenarbeit GmbH). Heim S. **Prosthet Orthot Int** 1996 Apr;20(1):39–41

Carbon fibre and fibre lamination in prosthetics and orthotics: some basic theory and practical advice for the practitioner. Klasson BL. **Prosthet Orthot Int** 1995 Aug;19(2):74–91

A technique for correct placement of the Wilson Cook oesophageal prosthesis in malignant tracheo–oesphageal fistula. McBirnie JM, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):79–81

Vertebral body replacement with a ceramic prosthesis for metastatic spinal tumors. Hosono N, et al. **Spine** 1995 Nov 15;20(22):2454–62

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

Bone graft substitutes. Lane JM. **West J Med** 1995 Dec; 163(6):565–6

[Using temporal bone artificial implantation for the fixation of external ear prosthesis] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):379–81 (15 ref.) **(Chi)**

[Preliminary evaluation of composite materials for the repair of incisional hernias] Amid K, et al. **Ann Chir** 1995; 49(6):539–42; discussion 542–3 (Eng. Abstr.) **(Fre)**

[Dilatation enteroplasty for obstructive Crohn disease. Experience of the University of Montreal] Montreuil B, et al. **Ann Chir** 1995;49(8):664–8 (Eng. Abstr.) **(Fre)**

[Ear prosthesis anchored on osseointegrated implants. Experience with 9 cases] Charles X, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):145–9 (Eng. Abstr.) **(Fre)**

[Artificial cornea] Renard G. **Bull Acad Natl Med** 1996 Mar; 180(3):659–65; discussion 665–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Is there a reasonable role for prosthetic materials in the emergency treatment of hernias?] Henry X, et al. **Chirurgie** 1994–95;120(12):123–8 (Eng. Abstr.) **(Fre)**

[Use of prostheses in emergency surgery. Retrospective study of 204 strangulated inguinal hernias] Palot JP, et al. **Chirurgie** 1996;121(1):48–50 (16 ref.) **(Fre)**

[Closure of a large esophagotracheal fistula in esophageal cancer, using two endoprostheses: one tracheobronchial silicone–covered prosthesis and another: expandable silicone–covered metal esophageal prosthesis (letter)] Baldeyrou P, et al. **Gastroenterol Clin Biol** 1996;20(3):317–9 **(Fre)**

[An odd hunting accident: acute obstruction of a biliary prosthesis caused by a buck shot (letter)] Maroy B. **Gastroenterol Clin Biol** 1996 Feb;20(1):123 **(Fre)**

[Posterior urethral valves in children. Apropos of 22 cases] Angwafo F, et al. **J Urol (Paris)** 1995;101(3):132–7 (Eng. Abstr.) **(Fre)**

[Surgery for severe traumas of the kidney. Value of initial computed tomography, problem of surgical indication and use of a perirenal resorbable prosthesis of polyglactin 910] Bittard H, et al. **J Urol (Paris)** 1995;101(5–6):209–14 (Eng. Abstr.) **(Fre)**

[Non–surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477–80 (9 ref.) (Eng. Abstr.) **(Fre)**

[Large eventrations: deep extensive cleavage of the abdominal wall and prosthetic repair] Micheau P, et al. **Presse Med** 1995 Oct 21;24(31):1433–7 (Eng. Abstr.) **(Fre)**

[Humeral retroversion and shoulder prosthesis] Hernigou P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(5):419–27 (Eng. Abstr.) **(Fre)**

[Preperitoneal prosthesis implantation in surgical management of recurrent inguinal hernia. Retrospective evaluation of our results 1989–1994] Langer I, et al. **Chirurg** 1996 Apr;67(4):394–402 (Eng. Abstr.) **(Ger)**

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

[Proximal reinsertion in alloplastic replacement of the anterior cruciate ligament. Experimental studies of a modified over the top technique] Paar O, et al. **Chirurg** 1995 Nov;66(11):1115–9 (Eng. Abstr.) **(Ger)**

[Vertebral replacement in palliative tumor therapy. Possible surgical procedures—significant improvement in quality of life] Plötz W, et al. **Fortschr Med** 1995 Nov 10; 113(31):437–40 (Eng. Abstr.) **(Ger)**

[Palliative treatment of large bile duct stones by endoscopic implantation of endoprosthesis in high risk patients] Döbrönte Z, et al. **Orv Hetil** 1996 Mar 3;137(9):461–4 (Eng. Abstr.) **(Hun)**

[Use of prostheses in the treatment of large laparoceles] Lucantoni R, et al. **G Chir** 1996 Mar;17(3):125–7 (Eng. Abstr.) **(Ita)**

PROSTHESIS

[Reconstruction after wide resection of the chest wall: application of plates as rigid prosthetic materials] Handa M, et al. **Kyobu Geka** 1996 Jan;49(1):48–52 (Eng. Abstr.) **(Jpn)**

[Roll repair of nonconfluent pulmonary artery] Komiya T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1828–35 (Eng. Abstr.) **(Jpn)**

[The efficacy of a microtrabecular prosthesis in the surgery of refractory glaucomas] Chiselită D, et al. **Oftalmologia** 1995 Oct–Dec;39(4):322–32 (Eng. Abstr.) **(Rum)**

[Reconstruction of the ossicle–tympanic system with a variable configuration prosthesis] Ostrovskiĭ AI. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):37–9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Microbiology of tracheal granulation tissue associated with silicone airway prostheses. Brown MT, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):624–7

An unusual solution in a case of dislodgement of a cuffed esophageal prosthesis. Figueiredo P, et al. **Endoscopy** 1995 May;27(4):346

Potential of exocellular carbohydrate antigens of Staphylococcus epidermidis in the serodiagnosis of orthopaedic prosthetic infection. Lambert PA, et al. **J Med Microbiol** 1996 May;44(5):355–61

Analysis of immunological alterations associated with testicular prostheses. Henderson J, et al. **J Urol** 1995 Nov; 154(5):1748–51

[Complication of keratoprosthesis of posterior fixation: retroprosthetic membranes. Apropos of 4 cases] Mortemousque B, et al. **J Fr Ophtalmol** 1995;18(10):608–13 (23 ref.) (Eng. Abstr.) **(Fre)**

[Obstruction of the urethral conduct following implantation of the endoprosthesis Urolume: therapeutic management] Pereira Arias JG, et al. **Actas Urol Esp** 1995 May; 19(5):401–6 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Breast forms after mastectomy—patient's issues. Münstedt K, et al. **Support Care Cancer** 1995 Nov;3(6):428–31

STANDARDS

Breast forms after mastectomy—patient's issues. Münstedt K, et al. **Support Care Cancer** 1995 Nov;3(6):428–31

[European regulations concerning medical devices] Savarino L, et al. **Minerva Med** 1995 Nov;86(11):481–93 (26 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Amputation and prosthesis. St. Jean G. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):249–61 (13 ref.)

PROSTHESIS COLORING

METHODS

Controlling coloration for titanium restorations. Wang RR. **J Prosthet Dent** 1995 Aug;74(2):206–8

STANDARDS

Effects of chlorine-containing disinfecting compounds on shade guides made of acrylic resin. Cernavin I. **J Prosthet Dent** 1996 May;75(5):574

Color stability of facial prostheses. Lemon JC, et al. **J Prosthet Dent** 1995 Dec;74(6):613–8

PROSTHESIS, DENTAL see **DENTAL PROSTHESIS**

PROSTHESIS DESIGN

see related
DENTURE DESIGN

Autologous tissue cardiac valve for aortic valve replacement: technical aspects and early results. Gross C, et al. **Ann Thorac Surg** 1996 Jun;61(6):1759–63

Omniscience valve evolution and literature [letter; comment] Mikhail AA. **Ann Thorac Surg** 1996 Aug;62(2):624–6. Comment on: Ann Thorac Surg 1995 Dec;60(6):1836–44.

A combined obturator and expansion appliance for use in patients with patent oral–nasal fistula. Hobson RS, et al. **Br J Orthod** 1995 Nov;22(4):357–9

Comparison of alloys and designs in a hip simulator study of metal on metal implants. Medley JB, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S148–59

Clinical experience with two-component first metatarsal phalangeal joint implants. Gerbert J, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):403–13

A special photo-epithesis. Case report. de Keizer RJ, et al. **Doc Ophthalmol** 1995;90(1):81–5

Engineered bar design for a midface defect: a case report. Anderson JD, et al. **Int J Oral Maxillofac Implants** 1996 May–Jun;11(3):400–4

Bone-anchored craniofacial prosthesis study. Tolman DE, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):159–68

Instrumented implant for measuring tibiofemoral forces. Kaufman KR, et al. **J Biomech** 1996 May;29(5):667–71

RSA in the assessment of aseptic loosening [letter] Loudon JR. **J Bone Joint Surg Br** 1996 Jul;78(4):682

Prosthetic heart valves—the integration of analysis with design. Hose R, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S50–4

Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass: implications for the surgical management of aortic stenosis. González-Juanatey JR, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):273–80

The Christensen prosthesis. A retrospective clinical study [see comments] Chase DC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):273–8. Comment in: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Feb;81(2):134–5.

The Christensen prosthesis [letter; comment] Mercuri LG. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):134–5. Comment on: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Sep;80(3):273–8.

Finite element analysis in the design and characterization of an absorbable cement restrictor. Wilson SF, et al. **Proc Inst Mech Eng [H]** 1995;209(3):163–7

PROSTHESIS FAILURE

Stem loosening more common with ITH than Lubinus prosthesis. A 5-year clinical and radiographic follow-up of 142 patients. Jacobsson SA, et al. **Acta Orthop Scand** 1995 Oct;66(5):425–31

Salvaging the exposed mammary prosthesis. Planas J, et al. **Aesthetic Plast Surg** 1995 Nov–Dec;19(6):535–40

Successful revision of failed cochlear implants in severe labyrinthitis ossificans. Telian SA, et al. **Am J Otol** 1996 Jan;17(1):53–60

Silicone breast implant bleed and rupture: clinical diagnosis and predictive value of mammography and ultrasound. Beekman WH, et al. **Ann Plast Surg** 1996 Apr;36(4):345–7

Kikuchi's histiocytic necrotizing lymphadenitis associated with ruptured silicone breast implant. Sever CE, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):380–5

Loosening of a revision total hip replacement in a 60-year-old woman with longstanding rheumatoid arthritis [clinical conference] Gravallese EM, et al. **Arthritis Rheum** 1995 Sep;38(9):1315–24

Results from pouch salvage. Korsgen S, et al. **Br J Surg** 1996 Mar;83(3):372–4

Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Horowitz SM, et al. **Calcif Tissue Int** 1995 Oct;57(4):301–5

Aseptic loosening in uncemented total hip arthroplasty in a canine model. Dowd JE, et al. **Clin Orthop** 1995 Oct; (319):106–21

In vitro studies on the role of titanium in aseptic loosening. Gonzales JB, et al. **Clin Orthop** 1996 Sep;(330):244–50

Microbial colonization of the Groningen speaking valve and its relationship to valve failure. Ell SR, et al. **Clin Otolaryngol** 1995 Dec;20(6):555–6

Fracture of the metal tibial tray after Kinematic total knee replacement. A common cause of early aseptic failure. Abernethy PJ, et al. **J Bone Joint Surg Br** 1996 Mar; 78(2):220–5

RSA in the assessment of aseptic loosening [letter] Loudon JR. **J Bone Joint Surg Br** 1996 Jul;78(4):682

Partial deflation of a saline breast implant [letter] Cederna JP. **Plast Reconstr Surg** 1996 Mar;97(3):684

Ruptured silicone breast implant: a misleading chest X-ray. Dick AC, et al. **Ulster Med J** 1994 Oct;63(2):238–40

[Systematic transesophageal echocardiography during the postoperative first 24 hours after mitral valve replacement] Bonnefoy E, et al. **Arch Mal Coeur Vaiss** 1995 Mar; 88(3):315–9 (Eng. Abstr.) **(Fre)**

[Femoral loosening of total hip prosthesis caused by pseudarthrosis resulting from trochanterotomy] Langlais F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(2):95–105 (Eng. Abstr.) **(Fre)**

PROSTHESIS FITTING

Computer-stimulated test fitting of an implantable hearing aid using implantable hearing aid using three-dimensional CT scans of the temporal bone: preliminary study. Esselman GH, et al. **Am J Otol** 1994 Nov;15(6):702–9

Fitting hearing aids to individual loudness-perception measures. Ricketts TA. **Ear Hear** 1996 Apr;17(2):124–32

The time course of effects on intensity discrimination following monaural fitting of hearing aids [letter] Robinson K, et al. **J Acoust Soc Am** 1996 Feb;99(2):1255–8

Target-matched insertion gain derived from three different hearing aid selection procedures. Punch JL, et al. **J Am Acad Audiol** 1995 Nov;6(6):425–32

INSTRUMENTATION

Precision of surface measurements for below-knee residua. Commean PK, et al. **Arch Phys Med Rehabil** 1996 May; 77(5):477–86

METHODS

A special photo-epithesis. Case report. de Keizer RJ, et al. **Doc Ophthalmol** 1995;90(1):81–5

PROSTHESIS LOOSENING see **PROSTHESIS FAILURE**

PROSTHESIS-RELATED INFECTIONS

see related
BIOFILMS

Loosening of a revision total hip replacement in a 60-year-old woman with longstanding rheumatoid arthritis [clinical conference] Gravallese EM, et al. **Arthritis Rheum** 1995 Sep;38(9):1315–24

Tuberculous and foreign-body granulomatous reactions involving a total knee prosthesis. Lusk RH, et al. **Arthritis Rheum** 1995 Sep;38(9):1325–7

Differences in early versus late extracavitary arterial graft infections. Calligaro KD, et al. **J Vasc Surg** 1995 Dec; 22(6):680–5; discussion 685–8

Localized atypical mycobacteria [letter] Wilkinson TS. **Plast Reconstr Surg** 1995 Dec;96(7):1747–8

[Comparative outcome of aortic valve endocarditis with or without annular abscess] Stchepinsky O, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):993–8 (Eng. Abstr.) **(Fre)**

[Infection of aorto-bifemoral vascular prosthesis complicated by multiple visceral fistulas. A case report] Floriani M, et al. **Ann Ital Chir** 1995 Jul–Aug;66(4):513–6 (Eng. Abstr.) **(Ita)**

BLOOD

Inflammatory reactions after vascular prosthesis implantation: a comparison of gelatin-sealed and unsealed Dacron prostheses. Utoh J, et al. **Surg Today** 1996;26(4):258–61

COMPLICATIONS

Infected arteriovenous hemodialysis graft presenting as left and right infective endocarditis. Mohamed M, et al. **Am J Nephrol** 1995;15(6):521–3

CT-guided aspiration in potentially infected total hip replacements complicated by heterotopic bone. Chew FS, et al. **Eur J Radiol** 1995 May;20(1):72–4

Vascular-enteric fistula: diagnosis by colonoscopy. Hamdani R, et al. **Gastrointest Endosc** 1995 Jul;42(1):80–1

Failure of transesophageal echocardiography to visualize a large mitral prosthesis vegetation detected solely by transthoracic echocardiography. Tenenbaum A, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):944–6

Streptococcus bovis-infected total hip arthroplasty. Emerton ME, et al. **J Arthroplasty** 1995 Aug;10(4):554–5

Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. Eishi K, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1745–55

[Comparative outcome of aortic valve endocarditis with or without annular abscess] Stchepinsky O, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):993–8 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Cardiobacterium hominis prosthetic valve endocarditis diagnosed in Portugal [letter] Marques MT, et al. **Ann Biol Clin (Paris)** 1995;53(5):299–300

Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

Diagnosing infection of extracardiac conduit in children. Kawamura S, et al. **Heart Vessels** 1995;10(4):214–7

Aspiration arthrography of the hip joint. Its uses and limitations in revision hip surgery. Mulcahy DM, et al. **J Arthroplasty** 1996 Jan;11(1):64–8

Aspiration of the hip joint before revision total hip arthroplasty. Clinical and laboratory factors influencing attainment of a positive culture. Lachiewicz PF, et al. **J Bone Joint Surg Am** 1996 May;78(5):749–54

Endovascular stent infection. Deiparine MK, et al. **J Vasc Surg** 1996 Mar;23(3):529–33

Diagnosis and management of the infected hip prosthesis. Fitzgerald RH Jr. **Orthopedics** 1995 Sep;18(9):833–5 (18 ref.)

["Circumscribed defibrillator erythema": a differential diagnostic and therapeutic problem in differential occult defibrillator infection diagnosis] Cierpka R, et al. **Z Kardiol** 1996 May;85(5):312–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Brouqui P, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2423–5

Use of itraconazole for treatment of sporotrichosis involving a knee prosthesis [letter] DeHart DJ. **Clin Infect Dis** 1995 Aug;21(2):450

The role of antibiotic-loaded cement in the treatment of an infection after a hip replacement [letter] Waertel G. **J Bone Joint Surg Am** 1996 Mar;78(3):472–3

Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model. Owusu-Ababio G, et al. **J Med Microbiol** 1995 Nov;43(5):368–76

[Local antisepsis in infected total hip endoprosthesis] Wagner M. **Orthopade** 1995 Aug;24(4):319–25 (Eng. Abstr.) **(Ger)**

[Role of antibiotics in the treatment of infected joint prosthesis] Zimmerli W. **Orthopade** 1995 Aug;24(4):308–13

(22 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

The economic impact of infected joint arthroplasty. Sculco TP. **Orthopedics** 1995 Sep;18(9):871-3

EPIDEMIOLOGY

The prevalence of infective endocarditis after aortic valve replacement. Agnihotri AK, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1708-20; discussion 1720-4

Risk factors for penile prosthetic infection. Jarow JP. **J Urol** 1996 Aug;156(2 Pt 1):402-4

Cerebrospinal fluid shunt infections in children. Ronan A, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):782-6

[Risk of development of false aneurysm and graft infection after aorta-femoral bypass graft. Retrospective study. Report of 211 cases] Aguiar ET, et al. **J Mal Vasc** 1996; 21(1):36-9 (Eng. Abstr.) **(Fre)**

ETIOLOGY

The thrombosed prosthetic graft is a risk for infection of an adjacent graft. Marsan BU, et al. **Am J Surg** 1996 Aug; 172(2):175-7

Immunosuppression augments growth of graft-adherent Staphylococcus epidermidis. Bergamini TM, et al. **Arch Surg** 1995 Dec;130(12):1345-50

Localized chronic suppurative bone infection as a sequel of peri-implantitis in a hydroxyapatite-coated dental implant. Piattelli A, et al. **Biomaterials** 1995 Aug;16(12):917-20

Prosthetic graft infection in the descending thoracic aorta treated by extra-anatomic rerouting. Barnard SP, et al. **Cardiovasc Surg** 1995 Dec;3(6):703-5

Total hip arthroplasty complicated by tuberculous infection. Kreder HJ, et al. **J Arthroplasty** 1996 Jan;11(1):111-4

Infection after total hip arthroplasty. Past, present, and future. Garvin KL, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1576-88 (139 ref.)

RE: Combined use of bowel and the artificial urinary sphincter in reconstruction of the lower urinary tract: infectious complications [letter; comment] Singh G, et al. **J Urol** 1996 May;155(5):1704. Comment on: J Urol 1995 Feb;153(2):331-3.

Fatal fungal infection of an ascending aortic graft. Wandschneider W, et al. **Thorac Cardiovasc Surg** 1995 Aug; 43(4):217-9

[Coxiella burnetti endocarditis on bioprosthesis. Apropos of a case] Maillet JM, et al. **Arch Mal Coeur Vaiss** 1996 Jan; 89(1):95-7 (Eng. Abstr.) **(Fre)**

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671-7 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. Ragni MV, et al. **J Arthroplasty** 1995 Dec;10(6):716-21

MICROBIOLOGY

Prosthetic valve endocarditis caused by Staphylococcus capitis [letter] Terada Y, et al. **Ann Thorac Surg** 1996 Jul; 62(1):324

Seven surgical silicones retain Staphylococcus aureus differently in vitro. Arciola CR, et al. **Biomaterials** 1995 Jun;16(9):681-4

Corrosion of intra-oral magnets in the presence and absence of biofilms of Streptococcus sanguis. Wilson M, et al. **Biomaterials** 1995 Jun;16(9):721-5

Propionibacterium acnes endocarditis. Huynh TT, et al. **Can J Cardiol** 1995 Oct;11(9):785-7

Prosthetic valve endocarditis due to Staphylococcus saccharolyticus. Krishnan S, et al. **Clin Infect Dis** 1996 Apr; 22(4):722-3

Microflora associated with percutaneous craniofacial implants used for the retention of facial prostheses: a pilot study. Toljanic JA, et al. **Int J Oral Maxillofac Implants** 1995 Sep-Oct;10(5):578-82

Mycobacterium chelonae infection following a total knee arthroplasty. Pring M, et al. **J Arthroplasty** 1996 Jan; 11(1):115-6

An improved model for bacterial encrustation studies. Sarangapani S, et al. **J Biomed Mater Res** 1995 Oct; 29(10):1185-91

The role of intraoperative frozen sections in revision total joint arthroplasty. Feldman DS, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1807-13

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840-2 (5 ref.)

Intramural migration of implantable cardioverter-defibrillator patch [letter; comment] Wolfhard U, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):681. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):258-64.

Clostridium septicum bacteremia associated with aortic graft infection. Upchurch GR Jr, et al. **J Vasc Surg** 1995 Oct; 22(4):493-5

Bacteroides fragilis infection of a knee prosthesis after haemorrhoidectomy [letter] Pattison RM, et al. **Lancet** 1995 Oct 21;346(8982):1097

Salmonella infection following breast reconstruction [letter] Asaadi M, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1749-50

Paecilomyces variotii contamination in the lumen of a saline-filled breast implant. Young VL, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1430-4

Total knee arthroplasty complicated by Corynebacterium jeikeium infection. Yildiz S, et al. **Scand J Infect Dis** 1995; 27(6):635-6

[Subacute infectious endocarditis caused by Cardiobacterium hominis. Presentation of a case (letter)] Carasusán MJ, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):496 **(Spa)**

MORTALITY

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671-7 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

A bacteriologic and scanning electron microscope study after implantation of foreign bodies in the biliary tract in rats. Yu JL, et al. **Scand J Gastroenterol** 1996 Feb;31(2):175-81

[Abscess development caused by ingrown nitinol spiral as a fatal complication of a partially deteriorated MEMOSOND-PEG] Gossner L, et al. **Z Gastroenterol** 1996 Jun;34(6):378-81 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Use of fibrinolytic agents to coat wire implants to decrease infection. An animal model. Nakamoto DA, et al. **Invest Radiol** 1995 Jun;30(6):341-4

Case against antibiotic prophylaxis for endocarditis and prosthesis infection in dermatologic procedures involving uninfected skin [letter; comment] George PM. **J Am Acad Dermatol** 1996 Jan;34(1):153-4. Comment on: J Am Acad Dermatol 1995 Feb;32(2 Pt 1):155-76; quiz 177-80.

Bacterial growth on antibiotic-loaded acrylic cement. A prospective in vivo retrieval study. Kendall RW, et al. **J Arthroplasty** 1995 Dec;10(6):817-22

Monofilament polypropylene sutures in aortic valve replacement [letter; comment] Kärkölä P, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):286-7. Comment on: J Thorac Cardiovasc Surg 1995 Mar;109(3):536-44; discussion 544-5.

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991-4

Prevention of vascular graft infection by sisomicin incorporated into fibrin glue. Yamamura K, et al. **Microbiol Immunol** 1995;39(11):895-96

[Antibiotic bonding on arterial prostheses: a necessity] Goeau-Brissonniere O. **J Mal Vasc** 1996;21 Suppl A:146-51 (42 ref.) (Eng. Abstr.) **(Fre)**

[Antibiotic-impregnated prostheses: eclectic indications] Melliere D, et al. **J Mal Vasc** 1996;21 Suppl A:139-45 (Eng. Abstr.) **(Fre)**

[Prevention and therapy of prosthesis infections in the thoracic area] Haverich A, et al. **Zentralbl Chir** 1995; 120(8):630-4 (21 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Periprosthetic mycobacterial infection. CT and mammographic findings. Walsh R, et al. **Clin Imaging** 1995 Jul-Sep;19(3):193-6

[Infection following shoulder and elbow arthroplasty. Diagnosis and therapy] Schwyzer HK, et al. **Orthopade** 1995 Aug;24(4):367-75 (44 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Avidin and 111In-labelled biotin scan: a new radioisotopic method for localising vascular graft infection. Chiesa R, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):405-14

Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. Samuel A, et al. **J Nucl Med** 1996 Jan;37(1):55-61

The role of biphasic scintigraphy with 99mTc-HMPAO leukocytes in detection of synthetic vascular graft infections--preliminary results. Davidović B, et al. **Med Pregl** 1993;46 Suppl 1:23-5

SURGERY

Two-stage cementless revision THR after infection. 5 recurrences in 40 cases followed 2.5-7 years. Lai KA, et al. **Acta Orthop Scand** 1996 Aug;67(4):325-8

An overview of the treatment of infected prosthetic vascular grafts. Calligaro KD, et al. **Adv Surg** 1996;29:3-16 (52 ref.)

The case for conservative management of infected prosthetic grafts. Perler BA. **Adv Surg** 1996;29:17-32 (85 ref.)

The case against the conservative nonresectional management of infected prosthetic grafts. Yeager RA, et al. **Adv Surg** 1996;29:33-9 (35 ref.)

Arthrodesis after infected knee arthroplasty using long arthrodesis nail. A report of five cases. Jørgensen PS, et al. **Am J Knee Surg** 1995 Summer;8(3):110-3

Management and outcome of infrapopliteal arterial graft infections with distal graft involvement. Calligaro KD, et al. **Am J Surg** 1996 Aug;172(2):178-80

Long-term results of operation for paravalvular abscess. d'Udekem Y, et al. **Ann Thorac Surg** 1996 Jul;62(1):48-53

Eradication of aortic infections with the use of cryopreserved arterial homografts. Vogt PR, et al. **Ann Thorac Surg** 1996 Sep;62(3):640-5

Infected lower extremity extra-anatomic bypass grafts: management of a serious complication in high-risk patients. de Virgilio C, et al. **Ann Vasc Surg** 1995 Sep;9(5):459-66

Surgical management of infected PTFE hemodialysis grafts: analysis of a 15-year experience. Tabbara MR, et al. **Ann Vasc Surg** 1995 Jul;9(4):378-84

Outcomes in the management of vascular prosthetic graft infections confined to the groin: a reappraisal. Taylor SM, et al. **Ann Vasc Surg** 1996 Mar;10(2):117-22

Aortic prosthetic infection: 50 patients treated by radical or local surgery. Hannon RJ, et al. **Br J Surg** 1996 May; 83(5):654-8

Technique for removal of femoral components with intercondylar articulation in total knee arthroplasty. Alpert SW, et al. **Bull Hosp Jt Dis** 1993-95;53(4):48-9

Prosthetic graft infection in the descending thoracic aorta treated by extra-anatomic rerouting. Barnard SP, et al. **Cardiovasc Surg** 1995 Dec;3(6):703-5

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441-4

Patient outcome with reinfection following reimplantation for the infected total knee arthroplasty. Hanssen AD, et al. **Clin Orthop** 1995 Dec;(321):55-67

Treatment of infected total knee arthroplasty using an articulating spacer. Hofmann AA, et al. **Clin Orthop** 1995 Dec;(321):45-54

One-stage revision of total hip arthroplasty for deep infection. Long-term followup. Raut VV, et al. **Clin Orthop** 1995 Dec;(321):202-7

Knee arthrodesis in the treatment of failed total knee replacement. Vlasak R, et al. **Clin Orthop** 1995 Dec; (321):138-44

Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Vogt PR, et al. **Eur J Cardiothorac Surg** 1995;9(9):502-6

Long-term results of aortic valve translocation for mycotic periannular abscess: comparative study of Danielson's original method and our threadless method. Endo M, et al. **Heart Vessels** 1995;10(6):318-22

Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. Spinner RJ, et al. **J Arthroplasty** 1996 Feb;11(2):217-22 (46 ref.)

Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. Eishi K, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1745-55

Surgical treatment of prosthetic valve endocarditis. Lytle BW, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):198-207; discussion 207-10

The prosthesis salvage operation: immediate replacement of the infected penile prosthesis [see comments] Brant MD, et al. **J Urol** 1996 Jan;155(1):155-7. Comment in: J Urol 1996 Jan;155(1):158.

Erections--broken, leaking and salvaged [editorial; comment] Montague DK. **J Urol** 1996 Jan;155(1):158. Comment on: J Urol 1996 Jan;155(1):148-9. Comment on: J Urol 1996 Jan;155(1):148-9. Comment on: J Urol 1996 Jan;155(1):150-4. Comment on: J Urol 1996 Jan;155(1):155-7.

Regarding "Surgical management of infrainguinal arterial prosthetic graft infections" [letter] Calligaro KD. **J Vasc Surg** 1996 Feb;23(2):376

Redo aortic grafting after treatment of aortic graft infection. DiMuzio PJ, et al. **J Vasc Surg** 1996 Sep;24(3):328-35; discussion 336-7

Durability of cross-femoral grafts after aortic graft infection: the fate of autogenous conduits. Jicha DL, et al. **J Vasc Surg** 1995 Oct;22(4):393-405; discussion 406-7

Operative management of the infected knee. Petty W. **Orthopedics** 1995 Sep;18(9):927-9

Stentless fresh pulmonary homograft in mitral position. Renzulli A, et al. **Tex Heart Inst J** 1995;22(4):301-3

[Surgery of infectious complications in prostheses in the abdominal aorta] Miler I, et al. **Rozhl Chir** 1995 Aug; 74(5):203-5 (Eng. Abstr.) **(Cze)**

[Replacement of infected total hip prosthesis in two stages] Lenoble E, et al. **Int Orthop** 1995;19(3):151-6 (Eng. Abstr.) **(Fre)**

[Treatment of prostheto-digestive using arterial allograft] Bahnini A, et al. **J Mal Vasc** 1996;21 Suppl A:167-70 (Eng. Abstr.) **(Fre)**

[Treatment of prostheto-digestive fistulas using in situ prosthetic bypass] Fiorani P, et al. **J Mal Vasc** 1996;21 Suppl A:162-6 (Eng. Abstr.) **(Fre)**

[Treatment of an exposed femorol-popliteal bypass: ex-situ replacement] Gouny P, et al. **J Mal Vasc** 1996;21 Suppl A:152-7 (Eng. Abstr.) **(Fre)**

[Exposed infra-inguinal bypass: conservative treatment or in situ replacement] Siat J, et al. **J Mal Vasc** 1996;21 Suppl A:158-61 (Eng. Abstr.) **(Fre)**

PROSTHESIS-RELATED INFECTIONS

[2-stage exchange in the treatment of infected knee prosthesis] Drobny TK, et al. **Orthopade** 1995 Aug; 24(4):360–6 (Eng. Abstr.) **(Ger)**

[Total hip endoprosthesis following resection arthroplasty] Engelbrecht E, et al. **Orthopade** 1995 Aug;24(4):344–52 (Eng. Abstr.) **(Ger)**

[Salvage surgery in chronic infection following total hip prosthesis] Ochsner PE, et al. **Orthopade** 1995 Aug; 24(4):353–9 (Eng. Abstr.) **(Ger)**

[Treatment of periprosthetic infection of the hip using one-stage exchange surgery] Steinbrink K, et al. **Orthopade** 1995 Aug;24(4):335–43 (30 ref.) (Eng. Abstr.) **(Ger)**

[Infected hip joint prosthesis. Viewpoints for 1-stage and 2-stage prosthesis exchange] Wagner H, et al. **Orthopade** 1995 Aug;24(4):314–8 (Eng. Abstr.) **(Ger)**

[A case report of active prosthetic valve endocarditis caused by MRSA] Kurimoto Y, et al. **Kyobu Geka** 1995 Dec; 48(13):1082–4 (Eng. Abstr.) **(Jpn)**

[Supra-annular mitral valve replacement for a patient with prosthetic valve endocarditis] Sadahiro M, et al. **Kyobu Geka** 1995 Sep;48(10):820–3 (Eng. Abstr.) **(Jpn)**

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Re-replacement of Starr-Edwards mitral valve (model 6320) for prosthetic valve endocarditis 22 years after replacement] Ko T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1187–90 (Eng. Abstr.) **(Jpn)**

THERAPY

CT-guided aspiration in potentially infected total hip replacements complicated by heterotopic bone. Chew FS, et al. **Eur J Radiol** 1995 May;20(1):72–4

Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. Tsukayama DT, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):512–23

Use of the rotating hinge for salvage of the infected total knee arthroplasty. Berman AT, et al. **Orthopedics** 1996 Jan; 19(1):73–6

[Valve ring abscesses: apropos of 59 cases. A multicenter study] Lesbre JP, et al. **Arch Mal Coeur Vaiss** 1995 Mar; 88(3):321–8 (Eng. Abstr.) **(Fre)**

[Treatment of infected total prosthesis arthroplasty of the hip joint] Herzog R, et al. **Orthopade** 1995 Aug; 24(4):326–34 (75 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616–8 (8 ref.)

Chordae tendineae mimicking vegetation after mitral valve replacement [letter] Malaterre HR, et al. **Ann Thorac Surg** 1996 Sep;62(3):944–5

Clinical outcome and echocardiographic findings of native and prosthetic valve endocarditis in the 1990's. Schulz R, et al. **Eur Heart J** 1996 Feb;17(2):281–8

PROSTHODONTICS

see related

SURGERY, ORAL, PREPROSTHETIC

Removable prosthodontics: a survey of practices and attitudes among South Australian dentists. Coates AJ, et al. **Aust Dent J** 1996 Jun;41(3):151–8

Occlusal vertical dimension in prosthodontics. Chou TM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):260–6 (34 ref.)

[Denturology (letter; comment)] Soucy B. **J Can Dent Assoc** 1996 Jun;62(6):470. Comment on: J Can Dent Assoc 1996 May;62(5):378. **(Fre)**

[Geriatric dentistry—an interdisciplinary challenge. A report on the preliminary course and annual meeting of the Swiss Society for the Dental Care of the Handicapped and Aged (SGZBB) and of the Dental Prosthetics Society of Switzerland (ZPGS) of 7 to 9 September 1995 in Zurich] Geissberger R. **Schweiz Monatsschr Zahnmed** 1995; 105(11):1474–6 **(Ger)**

ECONOMICS

Use of the Internet for educational applications in prosthodontics. van Putten MC Jr. **J Prosthet Dent** 1996 Aug;76(2):200–8

EDUCATION

The study club as a continuing education format for training in implant dentistry. Rubenstein JE, et al. **J Dent Educ** 1996 Mar;60(3):297–301

A graduate student's, graduate program director's, and chairman's perspective of the Dentist Scientist Award program. Felton DA. **J Prosthet Dent** 1996 Jun;75(6):671–4

Clinical evaluation in prosthodontics: practical methods to improve validity and reliability at the undergraduate level. Gerrow JD, et al. **J Prosthet Dent** 1996 Jun;75(6):675–80

The Dentist Scientist Award program and prosthodontics. Lipton JA. **J Prosthet Dent** 1996 Jun;75(6):666–70

INSTRUMENTATION

Custom-made mouth prop. Walker RS. **J Prosthet Dent** 1996 Apr;75(4):472

TRENDS

[The determination of the status of prosthodontics at Basel 1995] Besimo C. **Schweiz Monatsschr Zahnmed** 1995; 105(9):1200–2 **(Ger)**

PROSTITUTION

AIDS knowledge, risk behaviors, and factors related to condom use among male commercial sex workers and male tourist clients in Bali, Indonesia. Ford K, et al. **AIDS** 1995 Jul;9(7):751–9

Dual seroreactivity to HIV-1 and HIV-2 in female sex workers in Abidjan, Côte d'Ivoire. Ghys PD, et al. **AIDS** 1995 Aug;9(8):955–8

Factors related to inconsistent condom use with commercial sex workers in northern Thailand [letter] Kuntolbutra S, et al. **AIDS** 1996 May;10(5):556–8

Socio-economic and demographic characteristics and HIV-1 infection among female commercial sex workers in Thailand. van Griensven GJ, et al. **AIDS Care** 1995; 7(5):557–65

Re: "Sexual transmission of human T-lymphotropic virus type I among female prostitutes and among patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan" [letter; comment] Stuver SO, et al. **Am J Epidemiol** 1995 Dec 1;142(11):1247–8. Comment on: Am J Epidemiol 1995 Feb 15;141(4):305–11.

Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. Thomas DB, et al. **Am J Epidemiol** 1996 Apr 15;143(8):779–86

Condom use among female commercial sex workers in Nevada's legal brothels [see comments] Albert AE, et al. **Am J Public Health** 1995 Nov;85(11):1514–20 (50 ref.). Comment in: Am J Public Health 1995 Nov;85(11):1485–8.

Reducing the risk of HIV infection among South African sex workers: socioeconomic and gender barriers [see comments] Karim QA, et al. **Am J Public Health** 1995 Nov; 85(11):1521–5. Comment in: Am J Public Health 1995 Nov;85(11):1485–8.

A comparative study of the Abbott and Murex enzyme immunoassay, and cell culture in the detection of cervical chlamydial infection in female sex workers in Singapore. Chan RK, et al. **Ann Acad Med Singapore** 1995 Jul; 24(4):523–7

Human immunodeficiency virus (HIV) antigen testing to detect HIV infection in female sex workers in Singapore. Chan RK, et al. **Ann Acad Med Singapore** 1995 Jul; 24(4):534–6

Prevalence of sexually transmitted diseases among commercial sex workers in Singapore from 1977 to 1993: the effects of screening measures. Goh CL, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):500–4

Professional HIV risk taking, levels of victimization, and well-being in female prostitutes in The Netherlands. Vanwesenbeeck I, et al. **Arch Sex Behav** 1995 Oct; 24(5):503–15

Prevention of AIDS in Sri Lanka, the debate continues [letter; comment] Vitarana T. **Ceylon Med J** 1995 Dec; 40(4):160–1. Comment on: Ceylon Med J 1995 Sep;40(3):127–8.

Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. Pineda JA, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):460–4

Sexual health and use of condoms among local and international sex workers in Sydney. O'Connor CC, et al. **Genitourin Med** 1996 Feb;72(1):47–51

Beyond medical model of STD intervention--lessons from Sonagachi. Jana S, et al. **Indian J Public Health** 1995 Jul-Sep;39(3):125–31

Validity of self-reported sexually transmitted diseases in a cohort of drug-using prostitutes in Amsterdam: trends from 1986 to 1992. Fennema JS, et al. **Int J Epidemiol** 1995 Oct; 24(5):1034–41

Chlamydia trachomatis prevalence in high risk women, Tijuana, Mexico, 1993—a pilot study [letter] Gunn RA, et al. **Int J STD AIDS** 1995 Nov-Dec;6(6):456–8

Epidemic spread of plasmid-mediated tetracycline resistant Neisseria gonorrhoeae in Zaire. Van Dyck E, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):345–7

Comparison of the declines in CD4 counts in HIV-1-seropositive female sex workers and women from the general population in Nairobi, Kenya. Bwayo JJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):457–61

AIDS knowledge, risk behaviors, and condom use among four groups of female sex workers in Bali, Indonesia. Ford K, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):569–76

High rates of sexual contact with female sex workers, sexually transmitted diseases, and condom neglect among HIV-infected and uninfected men with tuberculosis in Abidjan, Côte d'Ivoire. Sassan-Morokro M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):183–7

HIV seroprevalence study among 729 female prostitutes in Italy [letter] Tirelli U, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):208–9

Determinants of HIV infection among female commercial sex workers in northeastern Thailand: results from a longitudinal study. Ungchusak K, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):500–7

Genital ulcers associated with human immunodeficiency virus-related immunosuppression in female sex workers in Abidjan, Ivory Coast [see comments] Ghys PD, et al. **J Infect Dis** 1995 Nov;172(5):1371–4. Comment in: J Infect Dis 1996 Aug;174(2):445–7.

Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. Kimani J, et al. **J Infect Dis** 1996 Jun;173(6):1437–44

The ethics of surrogacy: women's reproductive labour. van Niekerk A, et al. **J Med Ethics** 1995 Dec;21(6):345–9

High syphilis and low but rising HIV seroprevalence rates in Madagascar [letter] Behets FM, et al. **Lancet** 1996 Mar 23;347(9004):831

Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya [see comments] Gilks CF, et al. **Lancet** 1996 Mar 16; 347(9003):718–23. Comment in: Lancet 1996 May 18;347(9012):1414.

HIV and the social world of female commercial sex workers. Waddell C. **Med Anthropol Q** 1996 Mar;10(1):75–82

HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)

Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D. **NIDA Res Monogr** 1994;143:114–31 (18 ref.)

The development of healthcare services for drug misusers and prostitutes. Morrison CL, et al. **Postgrad Med J** 1995 Oct;71(840):593–7

Prevalence of genital Chlamydia trachomatis infection in selected populations in China. Bai H, et al. **Sex Transm Dis** 1995 Nov-Dec;22(6):383–4

AIDS knowledge and risk behaviors among domestic clients of female sex workers in Bali, Indonesia. Fajans P, et al. **Soc Sci Med** 1995 Aug;41(3):409–17

Origins and working conditions of female sex workers in urban Thailand: consequences of social context for HIV transmission. Wawer MJ, et al. **Soc Sci Med** 1996 Feb; 42(3):453–62

Understanding the social needs of streetwalking prostitutes. Weiner A. **Soc Work** 1996 Jan;41(1):97–105 (12 ref.)

[Seroepidemiological study of HBV and HCV infection in sexually promiscuous groups] Zhang GQ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug; 16(4):213–6 (Eng. Abstr.) **(Chi)**

[Trends and analysis of HIV and sexually transmitted disease infection in foreign commercial sex workers in Japan] Uchino H. **Nippon Koshu Eisei Zasshi** 1995 Sep; 42(9):808–14 **(Jpn)**

[Characteristics related to STD/HIV in men working in Mexico City bars where female prostitution takes place] Uribe-Salas F, et al. **Salud Publica Mex** 1995 Sep-Oct; 37(5):385–93 (Eng. Abstr.) **(Spa)**

[Prostitution and AIDS in the city of Mexico] Uribe-Zúñiga P, et al. **Salud Publica Mex** 1995 Nov-Dec;37(6):592–601 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Buying sex, safely [editorial] **Lancet** 1996 Aug 10; 348(9024):347

PSYCHOLOGY

Risk practices for HIV infection and other STDs amongst female prostitutes working in legalized brothels. Pyett PM, et al. **AIDS Care** 1996 Feb;8(1):85–94

The social meanings behind male sex work: implications for sexual interactions. Browne J, et al. **Br J Sociol** 1995 Dec; 46(4):598–622

STATISTICS & NUMERICAL DATA

Teenage prostitution—child abuse: a survey of the Ilorin situation. Adedoyin M, et al. **Afr J Med Med Sci** 1995 Mar;24(1):27–31

Impact of an intervention on HIV, sexually transmitted diseases, and condom use among sex workers in Bombay, India. Bhave G, et al. **AIDS** 1995 Jul;9 Suppl 1:S21–30

Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. Cohen CR, et al. **AIDS** 1995 Sep;9(9):1093–7

HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. Fennema JS, et al. **AIDS** 1995 Sep;9(9):1071–8

Socioeconomic status and risk of HIV-1, syphilis and hepatitis B infection among sex workers in São Paulo State, Brazil. Instituto Adolfo Lutz Study Group. Lurie P, et al. **AIDS** 1995 Jul;9 Suppl 1:S31–7

'Superstar' and 'model brothel': developing and evaluating a condom promotion program for sex establishments in Chiang Mai, Thailand. Visrutaratna S, et al. **AIDS** 1995 Jul;9 Suppl 1:S69–75

Female prostitutes in south London: use of heroin, cocaine and alcohol, and their relationship to health risk behaviours. Gossop M, et al. **AIDS Care** 1995;7(3):253–60

HTLV infection in a group of prostitutes and their male sexual clients in Brazil: seroprevalence and risk factors. Bellei NC, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr; 90(2):122–5

A survey of the use of prostitutes (commercial sex workers) by new male attenders at a genito urinary medicine clinic. Lim CC, et al. **Ulster Med J** 1995 Apr;64(1):34–8

PROTAMINE KINASE

METABOLISM

Activation of cyclin E–dependent kinase by DNA–damage signals during apoptosis. Dou QP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):771–80

Leishmania mexicana p12cks1, a homologue of fission yeast p13suc1, associates with a stage–regulated histone H1 kinase. Mottram JC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):833–9

In vitro activation of a 60–70 kDa histone H4 protein kinase from neutrophils by limited proteolysis. Liu R, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):89–95

Uncoupling of M–phase kinase activation from the completion of S–phase by heat shock. Mackey MA, et al. **Cancer Res** 1996 Apr 15;56(8):1770–4

Resolution of kinase activities during the HeLa cell cycle: identification of kinases with cyclic activities. Monteiro MJ, et al. **Exp Cell Res** 1996 Mar 15;223(2):443–51

Insulin activates a p21–activated kinase in muscle cells via phosphatidylinositol 3–kinase. Tsakiridis T, et al. **J Biol Chem** 1996 Aug 16;271(33):19664–7

PROTAMINE SULFATE see PROTAMINES

PROTAMINES

A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction. Byun Y, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M301–5

Bladder injury model induced in rats by exposure to protamine sulfate followed by bacterial endotoxin. Stein PC, et al. **J Urol** 1996 Mar;155(3):1133–8

ADMINISTRATION & DOSAGE

Single doses of intravenous protamine result in the formation of protamine–specific IgE and IgG antibodies. Nyhan DP, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):991–7

ADVERSE EFFECTS

Neither skin tests nor serum enzyme–linked immunosorbent assay tests provide specificity for protamine allergy. Horrow JC, et al. **Anesth Analg** 1996 Feb;82(2):386–9

Protamine and acute depletion of magnesium limit bone response to parathyroid hormone. Ragosta KG, et al. **Anesth Analg** 1996 Jan;82(1):29–32

Anaphylactoid reaction to protamine confirmed by plasma tryptase in a diabetic patient during open heart surgery. Takenoshita M, et al. **Anesthesiology** 1996 Jan;84(1):233–5

Hydrocortisone pretreatment for attenuation of protamine–induced adverse hemodynamic reactions [letter] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):481–2

Protamine–induced hypotension in heart operations: application of the concept of ventricular–arterial coupling. Oe M, et al. **J Thorac Cardiovasc Surg** 1996 Aug; 112(2):462–71

[Anaphylactic reaction to protamine in cardiovascular surgery] Hrubý M, et al. **Rozhl Chir** 1995 Sep;74(6):282–3 (Eng. Abstr.) **(Cze)**

ANALYSIS

Chromomycin A3–staining as an indicator of protamine deficiency and fertilization. Lolis D, et al. **Int J Androl** 1996 Feb;19(1):23–7

Ultrastructural immunolocalisation of histones (H2B, H3, H4), transition protein (TP1) and protamine in rabbit spermatids and spermatozoa nuclei. Relation to condensation of the chromatin. Courtens JL, et al. **Reprod Nutr Dev** 1995;35(5):569–82

CHEMISTRY

Development of protamine–bonded phase for separation of saccharides in liquid chromatography. Yamauchi S, et al. **J Chromatogr A** 1996 Jun 21;737(2):149–56

GENETICS

The rat Prm3 gene is an intronless member of the protamine gene cluster and is expressed in haploid male germ cells. Schlüter G, et al. **Cytogenet Cell Genet** 1995;71(4):352–5

Computer assisted promoter analysis of a human sperm specific nucleoprotein gene cluster. Nelson JE, et al. **DNA Seq** 1995;5(6):329–37

Nuclear matrix interactions within the sperm genome. Kramer JA, et al. **J Biol Chem** 1996 May 17; 271(20):11619–22

The evolution of protamine P1 genes in dasyurid marsupials. Retief JD, et al. **J Mol Evol** 1995 Nov;41(5):549–55

A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low–molecular–weight heparin anticoagulation. Wakefield TW, et al. **J Surg Res** 1996 Jun;63(1):280–6

IMMUNOLOGY

Single doses of intravenous protamine result in the formation of protamine–specific IgE and IgG antibodies. Nyhan DP, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):991–7

ISOLATION & PURIFICATION

Precipitation of insulinotropin in the presence of protamine: effect of phenol and zinc on the isophane ratio and the insulinotropin concentration in the supernatant. Kim Y, et al. **Pharm Res** 1995 Sep;12(9):1284–8

METABOLISM

A precursor–product relationship in molluscan sperm proteins from Ensis minor. Bandiera A, et al. **Eur J Biochem** 1995 Nov 1;233(3):744–9

Premature translation of protamine 1 mRNA causes precocious nuclear condensation and arrests spermatid differentiation in mice. Lee K, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12451–5

PHARMACOLOGY

Effects of heparin on the inhibitory action of protamine on endothelium–mediated vasorelaxation. Akata T, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):698–704

Paracellular transport of water and carbohydrates during intestinal perfusion of protamine in the rat. Shi X, et al. **Am J Med Sci** 1996 Mar;311(3):107–12

Direct and interactive effects of cardioplegic arrest and protamine on myocyte contractility. O SJ, et al. **Ann Thorac Surg** 1996 Aug;62(2):489–94

Effects of ciprofloxacin and protamine sulfate combinations against catheter–associated Pseudomonas aeruginosa biofilms. Soboh F, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1281–6

Effect of protamine on the solubilization of collagen–tailed acetylcholinesterase: potential heparin–binding consensus sequences in the tail of the enzyme. Deprez PN, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):53–8

Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2. Emadi S, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):226–32

Effect of inspired oxygen on the cardiovascular effects of protamine after cardiopulmonary bypass. Lomax D, et al. **Br J Anaesth** 1995 Oct;75(4):413–6

Direct effects of protamine sulfate on myocyte contractile processes. Cellular and molecular mechanisms. Hird RB, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II433–46

Modification of malondialdehyde concentration by administration of protamine sulfate [letter] Bartels C, et al. **Clin Chem** 1995 Oct;41(10):1544

Modulation of coronary collateral angiogenesis: a canine model of neovascularization induced by chronic ischemia. Kersten JR, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):354–7

A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low–molecular–weight heparin anticoagulation. Wakefield TW, et al. **J Surg Res** 1996 Jun;63(1):280–6

Nitric oxide inhibition attenuates systemic hypotension produced by protamine. Raikar GV, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1240–6; discussion 1246–7

Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers. Hoppensteadt DA, et al. **Thromb Res** 1995 Aug 1;79(3):325–30

STANDARDS

[Protamine sulfate reference standard (Control 941) of the National Institute of Health Sciences] Tanimoto T, et al. **Eisei Shikenjo Hokoku** 1995;(113):133–4 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Effects of differing rates of protamine reversal of heparin anticoagulation. Wakefield TW, et al. **Surgery** 1996 Feb; 119(2):123–8

TOXICITY

Heparin–protamine complexes cause pulmonary hypertension in goats. Horiguchi T, et al. **Anesthesiology** 1995 Oct; 83(4):786–91

PROTEASE ANTAGONISTS see PROTEASE INHIBITORS

PROTEASE INHIBITORS

Inhibitors of farnesyltransferase and Ras processing peptidase. Hall CC, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):728–32

Structure of the human TIMP–3 gene and its cell cycle–regulated promoter. Wick M, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):549–54

Clinical validation of renin monoclonal antibody–based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity [see comments] Derkx FH, et al. **Clin Chem** 1996 Jul; 42(7):1051–63. Comment in: Clin Chem 1996 Jul;42(7):993–4.

Spectroscopic characterization by photodiode array detection of human urinary and amniotic protein HC subpopulations fractionated by anion–exchange and size–exclusion high–performance liquid chromatography. Calero M, et al. **J Chromatogr A** 1996 Jan 5;719(1):149–57

Transfection of an invasive human astrocytoma cell line with a TIMP–1 cDNA: modulation of astrocytoma invasive potential. Matsuzawa K, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):88–96

Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Kanauchi M, et al. **Nippon Jinzo Gakkai Shi** 1996 Mar;38(3):124–8

Sorsby's fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases–3 gene on chromosome 22. Peters AL, et al. **Retina** 1995;15(6):480–5

[Non–nucleoside antiretroviral agents] Sereni D, et al. **Presse Med** 1996 Mar 2–9;25(8):361–4, 366–9 (29 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Takeda K, et al. **Am J Surg** 1996 Apr;171(4):394–8

Preoperative disseminated intravascular coagulation (DIC) associated with aortic aneurysm—does it need to be corrected before surgery? Oba J, et al. **Surg Today** 1995; 25(12):1011–4

Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). Angus RM, et al. **Thorax** 1996 Jan; 51(1):71–4

ADVERSE EFFECTS

Soybean protease inhibitors and pancreatic carcinogenesis [letter; comment] Liener IE. **J Nutr** 1996 Feb;126(2):582–5 . Comment on: J Nutr 1995 Mar;125(3 Suppl):733S–743S.

ANALYSIS

High levels of tissue inhibitor of metalloproteinase–2 (TIMP–2) expression are associated with poor outcome in invasive bladder cancer. Grignon DJ, et al. **Cancer Res** 1996 Apr 1;56(7):1654–9

Differential effects of transforming growth factor–beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Edwards DR, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):207–23

Expression of the tissue metalloproteinase inhibitors TIMP–1 and TIMP–2 in malignant fibrous histiocytomas and dermatofibromas as studied by in situ hybridization and immunohistochemistry. Hurskainen T, et al. **Hum Pathol** 1996 Jan;27(1):42–9

Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. Goldberg MJ, et al. **J Anim Sci** 1996 Apr;74(4):849–57

Gingival crevicular stromelysin, collagenase and tissue inhibitor of metalloproteinases levels in healthy and diseased sites. Haerian A, et al. **J Clin Periodontol** 1995 Jul;22(7):505–9

Determination of tissue inhibitor of metalloproteinases–2 (TIMP–2) in experimental animals using monoclonal antibodies against TIMP–2–specific oligopeptides. Fujimoto N, et al. **J Immunol Methods** 1995 Nov 16; 187(1):33–9

Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1–proteinase inhibitor, and alpha2–macroglobulin. Grinnell F, et al. **J Invest Dermatol** 1996 Feb;106(2):335–41

Soybean protease inhibitors and pancreatic carcinogenesis [letter; comment] Liener IE. **J Nutr** 1996 Feb;126(2):582–5 . Comment on: J Nutr 1995 Mar;125(3 Suppl):733S–743S.

Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Sternlicht MD, et al. **Lab Invest** 1996 Apr;74(4):781–96

Cell cycle–dependent localization of tissue inhibitor of metalloproteinases–1 immunoreactivity in cultured human gingival fibroblasts. Li H, et al. **Nagoya J Med Sci** 1995 Dec;58(3–4):133–42

Assessment of serum levels of alpha–1–microglobulin, beta–2–microglobulin, and retinol binding protein in the fetal blood. A method for prenatal evaluation of renal function. Cobet G, et al. **Prenat Diagn** 1996 Apr; 16(4):299–305

BLOOD

Identification and purification of a 90–kDa membrane–bound endogenous inhibitor of multicatalytic proteinase from human erythrocytes. Khan MT, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):957–62

Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. Kikuchi K, et al. **J Am Acad Dermatol** 1995 Dec;33(6):973–8

Quantification of a dual angiotensin I–converting enzyme–neutral endopeptidase inhibitor and the active thiol metabolite in dog plasma by high–performance liquid chromatography with ultraviolet absorbance detection.

Heath TG, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):91–101

Development of an enzyme-linked immunosorbent assay for human plasma inter-alpha-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. Mizon C, et al. **J Immunol Methods** 1996 Mar 28; 190(1):61–70

Actions of Vibrio vulnificus metalloprotease on human plasma proteinase-proteinase inhibitor systems: a comparative study of native protease with its derivative modified by polyethylene glycol. Miyoshi S, et al. **Microbiol Immunol** 1995;39(12):959–66

Study on proteinase-inhibiting capacity of plasma alpha 2-macroglobulin in idiopathic nephrotic syndrome. Asami T, et al. **Nephron** 1996;72(4):512–7

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15–21 (49 ref.) (Eng. Abstr.) **(Hun)**

[Plasma proteinase inhibitors and their clinical significance] Prandota J, et al. **Pediatr Pol** 1995 Aug;70(8):667–72 (31 ref.) (Eng. Abstr.) **(Pol)**

[Clinical significance of alpha-1 acid glycoprotein and antiprotease blood proteins in salmonellosis and food poisoning] Mironova OG, et al. **Klin Med (Mosk)** 1995; 73(4):78–80 **(Rus)**

[Reactions between protease inhibitors in blood plasma and collagen] Zorin NA, et al. **Vopr Med Khim** 1995 Nov–Dec; 41(6):53–5 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Tamaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1883–93

Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. Jirácek J, et al. **J Biol Chem** 1996 Aug 9; 271(32):19606–11

Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors. Coric P, et al. **J Med Chem** 1996 Mar 15; 39(6):1210–9

Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. Fournie-Zaluski MC, et al. **J Med Chem** 1996 Jun 21;39(13):2594–608

Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. McBride JD, et al. **J Mol Biol** 1996 Jun 21; 259(4):819–27

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May-Jun;51(3):161–4 (44 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Formation and microscopical application of a fluorescent 1,10-phenanthroline derivative of ruthenium red. Bertolesi GE, et al. **Acta Histochem** 1995 Oct;97(4):401–8

Purification and characterization of a tetrameric alpha-macroglobulin proteinase inhibitor from the gastropod mollusc Biomphalaria glabrata. Bender RC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):893–900

Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):191–5

Active site structure of a hemagglutinating protease from Porphyromonas gingivalis: similarity to clostripain. Nishikata M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):547–53

New subtilisin-trypsin inhibitors produced by Streptomyces: primary structures and their relationship to other proteinase inhibitors from Streptomyces. Terabe M, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):233–40

Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro. Masuda K, et al. **Br J Pharmacol** 1995 Jul;115(6):883–8

Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Tamaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1883–93

Purification and characterization of a 58,000-Da proteinase inhibitor from the hemolymph of a solitary ascidian, Halocynthia roretzi. Shishikura F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):1–9

Taxonomic characterization of closely related Streptomyces spp. based on the amino acid sequence analysis of protease inhibitor proteins. Taguchi S, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):169–73

Belactins A and B, new serine carboxypeptidase inhibitors produced by Actinomycete. II. Physico-chemical properties, structure determinations and enzymatic inhibitory activities compared with other beta-lactone containing inhibitors. Murakami S, et al. **J Enzym Inhib** 1995;9(4):277–84

Influence of pH on the release of propranolol hydrochloride from matrices containing hydroxypropylmethylcellulose K4M and carbopol 974. Perez-Marcos B, et al. **J Pharm Sci** 1996 Mar;85(3):330–4

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects. Ascenzi P, et al. **Mol Aspects Med** 1995; 16(3):215–313 (319 ref.)

Structure of astacin with a transition-state analogue inhibitor [letter] Grams F, et al. **Nat Struct Biol** 1996 Aug;3(8):671–5

Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Botos I, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2749–54

Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Abad-Zapatero C, et al. **Protein Sci** 1996 Apr;5(4):640–52

Atomic solvation parameters in the analysis of protein-protein docking results. Cummings MD, et al. **Protein Sci** 1995 Oct;4(10):2087–99

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. **Protein Sci** 1996 Feb;5(2):357–62

ECONOMICS

[Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study] Rodloff AC, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):172–80 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Fujimoto N, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):827–33

ISOLATION & PURIFICATION

Purification and characterization of a tetrameric alpha-macroglobulin proteinase inhibitor from the gastropod mollusc Biomphalaria glabrata. Bender RC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):893–900

A proteinase inhibitor from egg yolk of hen is an ovoinhibitor analog. Sugimoto Y, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):96–102

Expression of a biologically active murine tissue inhibitor of metalloproteinases-1 (TIMP-1) in baculovirus-infected insect cells. Purification and tissue distribution in the rat. Kurschat P, et al. **Eur J Biochem** 1995 Dec 1;234(2):485–91

Matrix metalloproteinases and their inhibitors in aqueous humor. Huang SH, et al. **Exp Eye Res** 1996 May; 62(5):481–90

Novel triterpene sulfates from Fusarium compactum using a rhinovirus 3C protease inhibitor screen. Brill GM, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):541–6

Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor. Normant E, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12225–9

Peptides inhibitory to endopeptidase and aminopeptidase from Lactococcus lactis ssp. lactis MG1363, released from bovine beta-casein by chymosin, trypsin or chymotrypsin. Stepaniak L, et al. **Z Lebensm Unters Forsch** 1996 Apr; 202(4):329–33

METABOLISM

The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with a renin inhibitor CP-80794. Pitts JE, et al. **Adv Exp Med Biol** 1995;362:543–7

Molecular cloning and immunocytochemical localization of jasmonic acid inducible cathepsin D inhibitors from potato. Strukelj B, et al. **Adv Exp Med Biol** 1995;362:293–8

Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Ricou B, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):346–52

Identification of matrix metalloproteinases and their inhibitor in the articular disc of the craniomandibular joint of the rabbit. Breckon JJ, et al. **Arch Oral Biol** 1996 Apr; 41(4):315–22

Expression of mRNA for matrix metalloproteinases and tissue inhibitors of metalloproteinases in periodontitis-affected human gingival tissue. Kubota T, et al. **Arch Oral Biol** 1996 Mar;41(3):253–62

Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Nemoto O, et al. **Arthritis Rheum** 1996 Apr;39(4):560–6

Absence of a calmitine-specific protease inhibitor in skeletal muscle mitochondria of patients with Duchenne's muscular dystrophy. Lucas-Heron B. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):701–4

Simian virus 40 transformation alters the actin cytoskeleton, expression of matrix metalloproteinases and inhibitors of metalloproteinases, and invasive behavior of normal and ataxia-telangiectasia human skin fibroblasts. Hansell EJ, et al. **Biochem Cell Biol** 1995 Jul-Aug;73(7-8):373–89

Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2' residue of substrates and inhibitors. Dion N, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):623–7

Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Fujimoto N, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):827–33

Complexation of the tissue plasminogen activator protease with benzamidine-type inhibitors: interference by the kringle 2 module. Hu CK, et al. **Biochemistry** 1996 Mar 12;35(10):3270–6

Synthesis and structure determination by NMR of a putative vacuolar targeting peptide and model of a proteinase inhibitor from Nicotiana alata. Nielsen KJ, et al. **Biochemistry** 1996 Jan 16;35(2):369–78

Two-metal ion mechanism of bovine lens leucine aminopeptidase: active site solvent structure and binding mode of L-leucinal, a gem-diolate transition state analogue, by X-ray crystallography. Sträter N, et al. **Biochemistry** 1995 Nov 14;34(45):14792–800

Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Chua CC, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):175–80

New subtilisin-trypsin inhibitors produced by Streptomyces: primary structures and their relationship to other proteinase inhibitors from Streptomyces. Terabe M, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):233–40

Expression and activity of ovarian tissue inhibitors of metalloproteinases during pseudopregnancy in the rat. Nothnick WB, et al. **Biol Reprod** 1995 Sep;53(3):684–91

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385–401 (65 ref.)

Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Tamakoshi K, et al. **Cancer** 1995 Dec 15;76(12):2565–71

Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97–111 (109 ref.)

Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Parshley DE, et al. **Curr Eye Res** 1995 Jul;14(7):537–44

Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Baricos WH. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):365–8 (24 ref.)

Proteolysis and antiproteolysis--a delicate balance [editorial; comment] Matthews AG. **Equine Vet J** 1994 Mar; 26(2):89–90. Comment on: Equine Vet J 1994 Mar;26(2):122–4.

Both action potentials and variation potentials induce proteinase inhibitor gene expression in tomato. Stanković B, et al. **FEBS Lett** 1996 Jul 29;390(3):275–9

The location and deletion of the genes which code for SSI-like protease inhibitors in Streptomyces species. Kuramoto A, et al. **FEMS Microbiol Lett** 1996 May 15; 139(1):37–42

Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Benyon RC, et al. **Gastroenterology** 1996 Mar;110(3):821–31

Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Terada T, et al. **Hepatology** 1996 Jun;23(6):1341–4

Fibroblast growth factor stimulates the gene expression and production of tissue inhibitor of metalloproteinase-1 in bovine granulosa cells. Hoshi H, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul-Aug;31(7):559–63

Intra-articular injection of stromelysin into rabbit knees as a model to evaluate matrix metalloproteinase inhibitors. Goldberg RL, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S115–6

A simple immunoassay to detect protease inhibitors in microbial fermentation broths. Carrano L, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1511–4

Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. Tyagi SC, et al. **J Cell Biochem** 1995 Jul;58(3):360–71

Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes. Zafarullah M, et al. **J Cell Biochem** 1996 Feb;60(2):211–7

Vascular co-localization of proteolytic enzymes and proteinase inhibitors in advanced periodontitis. Pinchback JS, et al. **J Pathol** 1996 Jul;179(3):326–32

Growth factor effects on the expression of collagenase and TIMP-1 in periodontal ligament cells. Alvares O, et al. **J Periodontol** 1995 Jul;66(7):552–8

Mechanism of the activation of proteinase inhibitor synthesis by systemin involves beta-sheet structure, a specific DNA-binding protein domain. Slósarek G, et al. **J Struct Biol** 1995 Jul-Aug;115(1):30–6

Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Iwata H, et al. **Jpn J Cancer Res** 1996 Jun;87(6):602–11

Expression of type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in newly established human oral malignant tumor lines. Nii M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):117–23

Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. Stearns M, et al. **Oncol Res** 1995;7(3-4):173–81

Induction of wound response genes in tomato leaves by bestatin, an inhibitor of aminopeptidases. Schaller A, et al. **Plant Cell** 1995 Nov;7(11):1893–8

The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Gallegos NC, et al. **Surg Oncol** 1995;4(2):111–9

Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin. Jauch R, et al. **Xenobiotica** 1996

Mar;26(3):285–95
[The effect of smoking on the status of immunity and on antiprotease protection] Golub NI. **Ter Arkh** 1996; 68(1):64–7 (43 ref.) **(Rus)**
[The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells] Zhabin SG, et al. **Vopr Med Khim** 1995 May–Jun;41(3):34–7 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Discovery of inhibitors of human renin with high oral bioavailability. Hoover DJ, et al. **Adv Exp Med Biol** 1995; 362:167–80
Lead development: validation and application of high throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors. Singh J, et al. **Bioorg Med Chem** 1996 May;4(5):639–43
Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6–14 (71 ref.)
Pharmacokinetic–pharmacodynamic (PK–PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Fettner SH, et al. **Eur J Clin Pharmacol** 1995;48(5):351–9
Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor 4–dedimethylaminotetracycline in inflamed joints of adjuvant arthritic rats. Leung MK, et al. **J Rheumatol** 1995 Sep;22(9):1726–31
Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. Coassolo P, et al. **Xenobiotica** 1996 Mar;26(3):333–45
Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Richter WF, et al. **Xenobiotica** 1996 Mar;26(3):243–54

PHARMACOLOGY

Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Brown PD. **Adv Enzyme Regul** 1995; 35:293–301
Inhibition of coronavirus MHV–A59 replication by proteinase inhibitors. Denison MR, et al. **Adv Exp Med Biol** 1995;380:391–7
Discovery of inhibitors of human renin with high oral bioavailability. Hoover DJ, et al. **Adv Exp Med Biol** 1995; 362:167–80
A novel intracellular acid proteinase from the plasmodia of a true slime mold, Physarum polycephalum. Murakami-Murofushi K, et al. **Adv Exp Med Biol** 1995; 362:565–8
Pepstatin–insensitive carboxyl proteinases. Oda K, et al. **Adv Exp Med Biol** 1995;362:529–42
Hemodynamic effects of renin inhibitors. Kleinert HD. **Am J Nephrol** 1996;16(3):252–60 (58 ref.)
Inhibition of the protease activity in tracheobronchial aspirates of horses with chronic obstructive pulmonary disease. Koivunen AL, et al. **Am J Vet Res** 1996 May; 57(5):603–7
Different organization of von Willebrand factor oligomers in type–2A and –2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors. Casonato A, et al. **Ann Hematol** 1995 Oct;71(4):189–94
Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Kawabata K, et al. **Ann Rheum Dis** 1996 Apr;55(4):248–52
In vivo effects of stromelysin on the composition and physical properties of rabbit articular cartilage in the presence and absence of a synthetic inhibitor. Bonassar LJ, et al. **Arthritis Rheum** 1995 Nov;38(11):1678–86
Endothelin–converting enzyme: substrate specificity and inhibition by novel analogs of phosphoramidon. Keller PM, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):372–8
Proadrenomedullin N–terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Nagatomo Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):539–43
Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol–linked protein in a pre–Golgi compartment. Oda K, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):800–5
Promotion of heat–induced apoptosis in FM3A cells by protease inhibitors. Zhu WG, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):924–31
Benzyloxycarbonyl–Val–Ala–Asp (OMe) fluoromethylketone (Z–VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Slee EA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):21–4
Coordinate activation of lysosomal, Ca 2+–activated and ATP–ubiquitin–dependent proteinases in the unweighted rat soleus muscle. Taillandier D, et al. **Biochem J** 1996 May 15;316 (Pt 1):65–72
Effects of metalloproteinase inhibitors on leukotriene A4 hydrolase in human airway epithelial cells. Baker JR, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):905–12
A study of the pH dependence of the reaction of benzyloxycarbonyltryptophanylchloromethane with chymotrypsin. Mahon MM, et al. **Biochem Soc Trans** 1996 Feb;24(1):131S
Penems as research tools to investigate the activity of E.coli leader peptidase. Perry CR, et al. **Biochem Soc Trans** 1995 Nov;23(4):548S
Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5838–46
Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Baum EZ, et al. **Biochemistry** 1996 May 7;35(18):5847–55
Site of action of proteinases in the activation of steroidogenesis in rat adrenal gland. Mele PG, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):260–8
Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Kos J, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):401–5
Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Fukuda Y, et al. **Biol Pharm Bull** 1995 Jun; 18(6):891–4
Enkephalinase–blocking agent thiorphan affects cell growth and differentiation in long term culture of mouse bone marrow. Krizanac–Bengez L, et al. **Biomed Pharmacother** 1995;49(7–8):375–80
Pharmacological activity of the C–terminal and N–terminal domains of secretory leukoprotease inhibitor in vitro. Masuda K, et al. **Br J Pharmacol** 1995 Jul;115(6):883–8
Effect of endopeptidase–24.11 inhibitors and C–ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Peyroux J, et al. **Br J Pharmacol** 1995 Dec;116(8):3117–24
Phosphoramidon inhibition of the in vivo conversion of big endothelin–1 to endothelin–1 in the human forearm. Plumpton C, et al. **Br J Pharmacol** 1995 Sep;116(2):1821–8
Inhibition of neuronal surface proteases decreases the requirement for GAP–43 in neurite outgrowth. Shea TB. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):87–90
Lethal interaction between hydrogen peroxide and o–phenanthroline in Escherichia coli. Asad NR, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2551–5
The field bean protease inhibitor can effectively suppress 7,12–dimethylbenz[a]anthracene–induced skin tumorigenesis in mice. Fernandes AO, et al. **Cancer Lett** 1996 Jul 12;104(2):219–24
Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells. Lumelsky NL, et al. **Cancer Res** 1996 Sep 1;56(17):3909–14
Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Kimmelstiel CD, et al. **Cardiology** 1996 Jan–Feb; 87(1):46–53
Degradation of CFTR by the ubiquitin–proteasome pathway. Ward CL, et al. **Cell** 1995 Oct 6;83(1):121–7
Inhibition of secretion from isolated rat alveolar epithelial type II cells by the cell permeant calpain inhibitor II (N–acetyl–leucyl–leucyl–methioninal). Zimmerman UJ, et al. **Cell Calcium** 1995 Jul;18(1):1–8
Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Bendeck MP, et al. **Circ Res** 1996 Jan; 78(1):38–43
Interaction of human pregnancy–associated plasma protein–A with serine proteinases. Zorin NA, et al. **Clin Chim Acta** 1995 Jul 31;239(1):47–55
The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats. Nomura N, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1219–31
The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats. Ura N, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1183–96
Interaction of a neutral endopeptidase inhibitor with an ANP–C receptor ligand in anesthetized dogs. Wegner M, et al. **Clin Exp Hypertens** 1995 Aug;17(6):861–76
Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Conway JG, et al. **Clin Exp Metastasis** 1996 Mar;14(2):115–24
Nafamostat enhances IBMX and secretin–stimulated water and bicarbonate secretion in the isolated, blood–perfused dog pancreas. Horiuchi A, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):987–9
Autoradiographic localization of active renin in the juxtaglomerular apparatus of the dog kidney: effects of sodium intake. Zhuo J, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):291–8
Cytokine–processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)
7S nerve growth factor is an insulin–like growth factor–binding protein protease. Rajah R, et al. **Endocrinology** 1996 Jul;137(7):2676–82
Carboxypeptidase A hydrolyses benzoylglycyl–histidyl–leucine but not furylacryloyl–phenylalanyl–glycyl–glycine, two usual substrates for angiotensin I–converting enzyme. Baudin B, et al. **Enzyme Protein** 1994–95;48(2):81–9
Protease inhibitor studies and cloning of a serine carboxypeptidase cDNA from germinating seeds of pea (Pisum sativum L.). Jones CG, et al. **Eur J Biochem** 1996 Feb 1;235(3):574–8
Insulin–induced proteolysis of the insulin receptor alpha–subunit from rat liver does not occur in vivo but is prevented in vitro by blood serum proteinase inhibitors. Sánchez–Casas P, et al. **Eur J Biochem** 1995 Sep 15; 232(3):747–54
Neutral endopeptidase inhibition, a new approach in the exploration of diabetic vasculopathy in rats. Chakir M, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):11–8
TIMP–2 growth–stimulatory activity: a concentration– and cell type–specific response in the presence of insulin. Nemeth JA, et al. **Exp Cell Res** 1996 Apr 10;224(1):110–5
Protease inhibitors block apoptosis at intermediate stages: a compared analysis of DNA fragmentation and apoptotic nuclear morphology. Ghibelli L, et al. **FEBS Lett** 1995 Dec 11;377(1):9–14
Nuclear scaffold–associated protease: in situ nuclear localization and effects of a protease inhibitor on growth and morphology of a ras–transformed hepatocyte cell line. Clawson GA, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1230–5
An aminopeptidase inhibitor, bestatin, enhances progesterone and oestradiol secretion by porcine granulosa cells stimulated with follicle stimulating hormone in vitro. Tachibana T, et al. **Hum Reprod** 1996 Mar;11(3):497–502
Enzymatic activity of DPIV/CD26 is involved in PMA–induced hyperphosphorylation of p56lck. Kähne T, et al. **Immunol Lett** 1995 May;46(1–2):189–93
Protease inhibitors diminish lymphocyte stimulation in vitro. Tchórzewski H, et al. **Immunol Lett** 1995 Jun;46(3):237–40
Biological evaluation of matrix metalloproteinase inhibitors, 18 May 1995, New York. Pratta MA. **Inflamm Res** 1995 Nov;44(11):458–60
Metalloprotease inhibitors halt collagen breakdown in IL–1 induced bovine nasal cartilage cultures. Spirito S, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S131–2
Secretion of human monocyte mature IL–1 beta: optimization of culture conditions and inhibition by ICE inhibitors. Uhl J, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S211–2
Inhibition of neutrophil chemotaxis by protease inhibitors. Differential effect of inhibitors of serine and thiol proteases. Barna JB, et al. **Inflammation** 1995 Oct;19(5):561–74
Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Barletta JP, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):20–8
Specific inhibition of mature fungal serine proteinases and metalloproteinases by their propeptides. Markaryan A, et al. **J Bacteriol** 1996 Apr;178(8):2211–5
The primary structure of pepstatin–insensitive carboxyl proteinase produced by Pseudomonas sp. No. 101. Hayashi K, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):738–44
Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. Arribas J, et al. **J Biol Chem** 1996 May 10;271(19):11376–82
Shedding of the lymphocyte L–selectin adhesion molecule is inhibited by a hydroxamic acid–based protease inhibitor. Identification with an L–selectin–alkaline phosphatase reporter. Feehan C, et al. **J Biol Chem** 1996 Mar 22; 271(12):7019–24
The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Regan LM, et al. **J Biol Chem** 1996 Jul 19;271(29):17499–503
[Phe22]–big endothelin–1[19–37]: a new and potent inhibitor of the endothelin–converting enzyme. Claing A, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S72–4
S 17162 is a novel selective inhibitor of big ET–1 responses in the rat. Descombes JJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S61–4
Differential structure–activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin–converting enzyme, neutral endopeptidase, and angiotensin–converting enzyme. Kukkola PJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S65–8
Dexamethasone and phosphoramidon inhibit endothelin release by cultured nonciliated bronchiolar epithelial (Clara) cells. Laporte J, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S53–5
Inhibition of big ET–1–induced pressor response by an orally active dual inhibitor of endothelin–converting enzyme and neutral endopeptidase 24.11. Trapani AJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S69–71
Suppression of UV– and interferon–alpha–refractoriness by antipain in human IFr cells established from RSa cells sensitive to both stimuli. Suzuki N. **J Cell Physiol** 1996 Apr;167(1):47–51
Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. Williams LM, et al. **J Clin Invest** 1996 Jun 15; 97(12):2833–41
Eclosion hormone–stimulated cGMP levels in the central nervous system of Manduca sexta: inhibition by lipid metabolism blockers, increase in inositol(1,4,5)trisphosphate and further evidence against the involvement of nitric oxide. Morton DB, et al. **J Comp Physiol [B]** 1995; 165(6):417–27
Belactins A and B, new serine carboxypeptidase inhibitors produced by Actinomycete. I. Taxonomy, production, isolation and biological activities. Murakami S, et al. **J Enzym Inhib** 1995;9(4):263–75
Hydroxamate–based metalloprotease inhibitor blocks shedding of L–selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. Bennett TA, et al. **J Immunol** 1996 May 1;156(9):3093–7
A metalloprotease inhibitor blocks shedding of the IL–6

receptor and the p60 TNF receptor. Müllberg J, et al. **J Immunol** 1995 Dec 1;155(11):5198–205

Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1-38) and diaspirin cross-linked hemoglobin in rats. Gulati A, et al. **J Lab Clin Med** 1995 Dec;126(6):559–70

Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors. Pyle LE, et al. **J Lipid Res** 1995 Nov;36(11):2355–61

Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles. Edwards PD, et al. **J Med Chem** 1995 Sep 29;38(20):3972–82

Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Fink CA, et al. **J Med Chem** 1996 Aug 2;39(16):3158–68

New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. Fink CA, et al. **J Med Chem** 1995 Dec 22;38(26):5023–30

alpha-Hydroxy phosphinyl-based inhibitors of human renin. Patel DV, et al. **J Med Chem** 1995 Oct 27;38(22):4557–69

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Robl JA, et al. **J Med Chem** 1996 Jan 19;39(2):494–502

Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Gómez J, et al. **J Mol Biol** 1995 Sep 22;252(3):337–50

Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. Bai JP, et al. **J Pharm Sci** 1995 Nov;84(11):1291–4

Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. Marie C, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1324–31

Collagen degradation within subcutaneous air pouches in vivo: the effects of proteinase inhibitors. Karran EH, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):97–102

Peripheral excitatory effects of two enkephalinase inhibitors, acetorphan and thiorphan, and an enkephalin analogue, [D-Ala2-Met5]-enkephalinamide, on uterine motility in periparturient rats in vivo and in vitro. Adjroud O. **J Reprod Fertil** 1995 Jul;104(2):181–6

Pancreatic injuries in rats with fecal peritonitis: protective effect of a new synthetic protease inhibitor, sepinostat mesilate (FUT-187). Hirano T. **J Surg Res** 1996 Mar; 61(2):301–6

Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics. LaFemina RL, et al. **J Virol** 1996 Jul;70(7):4819–24

Vitamin A incorporation into lipofuscin-like inclusions in the retinal pigment epithelium. Katz ML, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):29–38

Nordihydroguaiaretic acid and RHC 80267 potentiate astroglial injury during combined glucose-oxygen deprivation. Haun SE, et al. **Mol Chem Neuropathol** 1995 May;25(1):35–49

Inhibition of proteolysis enhances aluminum-induced perikaryal neurofilament accumulation but does not enhance tau accumulation. Shea TB, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):195–212

Field bean protease inhibitor mitigates the sister-chromatid exchanges induced by bromoform and depresses the spontaneous sister-chromatid exchange frequency of human lymphocytes in vitro. Banerji AP, et al. **Mutat Res** 1996 May 17;360(1):29–35

Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors. Marin C, et al. **Neuropharmacology** 1995 Jun;34(6):677–82

Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Shimizu S, et al. **Oncogene** 1996 May 16; 12(10):2045–50

Induction of wound response genes in tomato leaves by bestatin, an inhibitor of aminopeptidases. Schaller A, et al. **Plant Cell** 1995 Nov;7(11):1893–8

Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Griscavage JM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16; 93(8):3308–12

Phosphinate analogs of D-, D-dipeptides: slow-binding inhibition and proteolysis protection of VanX, a D-, D-dipeptidase required for vancomycin resistance in Enterococcus faecium. Wu Z, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11603–7

Amplification of arachidonic acid metabolism in rat liver cells (the C-9 cell-line) by tosyl-L-phenylalanine chloromethyl ketone and phenylmethyl-sulfonyl fluoride. Levine L. **Prostaglandins** 1995 Aug;50(2):89–101

Peptidase inhibitors potentiate lysylbradykinin-induced bronchoconstriction in the rat. Schilero GJ, et al. **Regul Pept** 1996 Apr 9;62(1):41–5

Nafamostat mesilate prevents warm ischemia-reperfusion injury in canine pancreas autotransplantation. Shimizu Y, et al. **Transplant Proc** 1995 Dec;27(6):3191–2

Prevention of reperfusion injury after rat pancreas preservation using rinse solution containing nafamostat mesilate. Urushihara T, et al. **Transplant Proc** 1996 Jun; 28(3):1874–5

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May-Jun;51(3):161–4 (44 ref.) (Eng. Abstr.) **(Fre)**

[Partial characteristics of the basic phenylmethylsulfonylfluoride-inhibited carboxypeptidase from cat brain] Vernigora AN, et al. **Biokhimiia** 1995 Nov; 60(11):1860–6 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[The function of the kallikrein-kinin system and the activity of proteinase inhibitors during physical loading and infrared laser irradiation] Zubkova SM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov-Dec; (6):9–11 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Protease inhibitors for HIV infection [editorial; comment] Bartlett JG. **Ann Intern Med** 1996 Jun 15;124(12):1086–8 . Comment on: Ann Intern Med 1996 Jun 15;124(12):1039–50.

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967–74 (48 ref.)

Pneumothorax and wound dehiscence related to collagenase deregulation: treatment with diphenylhydantoin. O'Toole MJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1646–50

Antitumor activity of bestatin and thiorphan in mice. Kowalski J, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5-6):265–71

Effect of the oral administration of sepimostat mesilate on cerulein induced acute pancreatitis in rats. Wang ZH, et al. **Arzneimittelforschung** 1995 Oct;45(10):1082–6

A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Cox CE, et al. **Clin Infect Dis** 1995 Jul;21(1):86–92

Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Fettner SH, et al. **Eur J Clin Pharmacol** 1995;48(5):351–9

Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Hewson AK, et al. **Inflamm Res** 1995 Aug; 44(8):345–9

Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Norga K, et al. **Inflamm Res** 1995 Dec;44(12):529–34

Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. O'Byrne EM, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S117–8

Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Raychaudhuri A, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S141–2

Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. French JF, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):107–13

Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188–94 (22 ref.)

Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. Favrat B, et al. **J Hypertens** 1995 Jul;13(7):797–804

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. Trippodo NC, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):745–52

Neuromuscular recovery after peripheral nerve repair: effects of an orally-administered peptide in a primate model. Badalamente MA, et al. **J Reconstr Microsurg** 1995 Nov; 11(6):429–37

Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. Binns OA, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):607–13

Fighting obesity the Franco-British way [news] Jack DB. **Lancet** 1996 Jun 22;347(9017):1756

Calpain as a novel target for treating acute neurodegenerative disorders. Bartus RT, et al. **Neurol Res** 1995 Aug; 17(4):249–58 (40 ref.)

Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics. Araida T, et al. **Pancreas** 1995 Aug;11(2):132–40

[HIV: highly promising results with the new protease inhibitor (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Aug 23;121(34-35):A35 **(Ger)**

TOXICITY

Ortho-phenanthroline modulates enzymes of cellular energy metabolism. Gerber E, et al. **Toxicology** 1996 Jun 17; 110(1-3):85–93

URINE

Amino acid sequences for human urinary bikunin (trypsin inhibitor) isomers. Yuki Y, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1599–601

Is nephrocalcin related to the urinary derivative (bikunin) of inter-alpha-trypsin inhibitor? Tang Y, et al. **Br J Urol** 1995 Oct;76(4):425–30

A mathematical equation to differentiate overload proteinuria from tubulo-interstitial involvement in glomerular diseases. Hofmann W, et al. **Clin Nephrol** 1995 Jul;44(1):28–31

Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria. Honkanen E, et al. **Clin Nephrol** 1995 Jul; 44(1):22–7

Microalbuminuria or micro-alpha-1-microglobulinuria: which one is better predictor of the development of the secondary nephropathy? [letter] Marczewski KT, et al. **Clin Nephrol** 1996 Feb;45(2):136–7

Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor. Atmani F, et al. **Eur J Biochem** 1996 Mar 15;236(3):984–90

The determination of alpha 1-microglobulin by means of an automated latex immunoassay. Straub JP, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):425–31

Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Carraro M, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):444–8

Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin. Jauch R, et al. **Xenobiotica** 1996 Mar;26(3):285–95

PROTECTIVE CLOTHING

In-line skating: play it safe [editorial] Hensinger RN. **Am Fam Physician** 1996 Jun;53(8):2430

A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Slaughter S, et al. **Ann Intern Med** 1996 Sep 15;125(6):448–56

A comparison of two skin preps used in cardiac surgical procedures. Hagen KS, et al. **AORN J** 1995 Sep; 62(3):393–402

Control of liquid cooling garments: subjective versus technical control of thermal comfort. Hexamer M, et al. **Appl Human Sci** 1995 Nov;14(6):271–8

Assessment of human exposure to pesticides in greenhouses and effectiveness of personal protective devices. Iorizzo L, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):25–33

Continuous and intermittent personal microclimate cooling strategies. Bomalaski SH, et al. **Aviat Space Environ Med** 1995 Aug;66(8):745–50

MRI update: the effect of dentist attire on patient perceptions of skill, caring and professionalism. Waddington TJ. **Br Dent J** 1996 Feb 10;180(3):86–7

Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Soto J, et al. **Clin Infect Dis** 1995 Sep; 21(3):599–602

Effects of 6 versus 12 days of heat acclimation on heat tolerance in lightly exercising men wearing protective clothing. Aoyagi Y, et al. **Eur J Appl Physiol** 1995; 71(2-3):187–96

Maximal physical work performance with European standard based fire-protective clothing system and equipment in relation to individual characteristics. Louhevaara V, et al. **Eur J Appl Physiol** 1995;71(2-3):223–9

Gown-glove interface: a possible solution to the danger zone. Meyer KK, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):488–90

What should doctors wear in the accident and emergency department? Patients' perception [letter; comment] Stell M. **J Accid Emerg Med** 1995 Jun;12(2):161–2. Comment on: J Accid Emerg Med 1994 Sep;11(3):175–7.

Energy-shunting hip padding system attenuates femoral impact force in a simulated fall. Robinovitch SN, et al. **J Biomech Eng** 1995 Nov;117(4):409–13

Guidelines for the use of protective barriers in clinical practices. The Hospital Infection Control Group of Thailand. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S129–30

Thermal responses to swimming in three water temperatures: influence of a wet suit. Trappe TA, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1014–21

Exposure to polycyclic aromatic hydrocarbons in coal liquefaction workers: impact of a workwear policy on excretion of urinary 1-hydroxypyrene. Quinlan R, et al. **Occup Environ Med** 1995 Sep;52(9):600–5

Selecting personal protective apparel. Johnson LF. **Occup Health Saf** 1996 May;65(5):67, 70, 76

Practical considerations in purchasing new products. Fecteau DL. **Surg Clin North Am** 1995 Dec;75(6):1167–73

Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141–57 (27 ref.)

[Professional protective work clothing] **Gesundheitswesen** 1992 Nov;54(11 Suppl):1–8 **(Ger)**

[Substantiation of physiologic and hygienic requirements of heat-proof properties of winter headgear] Afanas'eva RF, et al. **Med Tr Prom Ekol** 1995;(7):4–8 (Eng. Abstr.) **(Rus)**

[Antimicrobial means for individual protection used by medical personnel in emergency situations] Selov AV, et

al. **Med Tr Prom Ekol** 1995;(10):35–7 (Eng. Abstr.) **(Rus)**

[The determination of the maximum permissible time of human tolerance for low environmental temperatures in different flight clothing outfits] Rusaliev KIa, et al. **Voen Med Zh** 1995 Feb;(2):58–60, 80 (Eng. Abstr.) **(Rus)**

[A headband—dry and wet (letter)] Hagström B. **Lakartidningen** 1996 May 8;93(19):1816 **(Swe)**

ADVERSE EFFECTS

Heat strain in protective clothing following hot–wet or hot–dry heat acclimation. McLellan TM, et al. **Can J Appl Physiol** 1996 Apr;21(2):90–108

CLASSIFICATION

Sun protection: SPF versus UPF [letter] Stanford DG, et al. **Med J Aust** 1996 Feb 19;164(4):253–4

ECONOMICS

Cost v cost–effective. Belkin NL. **AORN J** 1996 Mar; 63(3):632–3

STANDARDS

Determination of surgeon–generated gown pressures during various surgical procedures in the operating room. Smith JW, et al. **Am J Infect Control** 1995 Aug;23(4):237–46

Proposed recommended practices for use and selection of barrier materials for surgical gowns and drapes. **AORN J** 1995 Sep;62(3):449–53

Recommended practices for use and selection of barrier materials for surgical gowns and drapes. Association of Operating Room Nurses. **AORN J** 1996 Mar;63(3):650, 653–4

Cold water immersion simulations using the Wissler Texas Thermal Model: validation and sensitivity analysis. Shender BS, et al. **Aviat Space Environ Med** 1995 Jul;66(7):678–86

Effect of abrasion on protective properties of polyester and cotton/polyester blend fabrics. Shaw A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):935–41

Dry particulate protection: new technologies mean more choices. Mann P. **Occup Health Saf** 1995 Dec;64(12):25–6

Selecting chemical protective clothing. Stull JO. **Occup Health Saf** 1995 Dec;64(12):20–1, 24

SUPPLY & DISTRIBUTION

Sun protection: SPF versus UPF [letter] Stanford DG, et al. **Med J Aust** 1996 Feb 19;164(4):253–4

UTILIZATION

A community survey of sun exposure, sunburn and sun protection. McGee R, et al. **N Z Med J** 1995 Dec 8; 108(1013):508–10

PROTECTIVE DEVICES

The safety value of guardrails and crash cushions: a meta–analysis of evidence from evaluation studies. Elvik R. **Accid Anal Prev** 1995 Aug;27(4):523–49

Effectiveness estimates for center high mounted stop lamps: a six–year study. Farmer CM. **Accid Anal Prev** 1996 Mar; 28(2):201–8

The influence of seat–back and head–restraint properties on the head–neck motion during rear–impact. Svensson MY, et al. **Accid Anal Prev** 1996 Mar;28(2):221–7

An HIV–infected RN finds a cause: universal use of safer needles [news] **Am J Nurs** 1996 Apr;96(4):69–70

Bite block for the laryngeal mask airway [letter] Townend M, et al. **Anaesthesia** 1995 Oct;50(10):918

An effective shield for free: pulsed lavage in total knee replacement. Witte KK, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):383

A safety scalpel. Arnold DD. **Br J Urol** 1996 Jul;78(1):125–7

Electrosurgical active electrode shielding systems. **Health Devices** 1995 Dec;24(12):492–4

Energy–shunting external hip protector attenuates the peak femoral impact force below the theoretical fracture threshold: an in vitro biomechanical study under falling conditions of the elderly. Parkkari J, et al. **J Bone Miner Res** 1995 Oct;10(10):1437–42

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct–Dec;8(4):252–7 (43 ref.)

Analysis of wounds incurred by U.S. Army Seventh Corps personnel treated in Corps hospitals during Operation Desert Storm, February 20 to March 10, 1991. Carey ME. **J Trauma** 1996 Mar;40(3 Suppl):S165–9

Protection of the lung from blast overpressure by thoracic stress wave decouplers. Cooper GJ. **J Trauma** 1996 Mar; 40(3 Suppl):S105–10

The influence of personal blast protection on the distribution and severity of primary blast gut injury. Cripps NP, et al. **J Trauma** 1996 Mar;40(3 Suppl):S206–11

Sudden death during sports activities [letter; comment] Sinclair JB. **N Engl J Med** 1995 Dec 28;333(26):1785. Comment on: N Engl J Med 1995 Aug 10;333(6):380–1.

Safe transportation of premature and low birth weight infants. American Academy of Pediatrics. Committee on Injury and Poison Prevention and Committee on Fetus and Newborn. **Pediatrics** 1996 May;97(5):758–60

Selecting and using the most appropriate car safety seats for growing children: guidelines for counseling parents. American Academy of Pediatrics. Committee on Injury and Poison Prevention. **Pediatrics** 1996 May;97(5):761–3

The effect of lumbar belts on isolated lumbar muscle [letter; comment] Mauz JJ. **Spine** 1995 Aug 15;20(16):1847. Comment on: Spine 1995 Jan 1;20(1):68–73.

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281–301 (49 ref.)

Effectiveness of prophylactic ankle stabilisers for prevention of ankle injuries. Sitler MR, et al. **Sports Med** 1995 Jul; 20(1):53–7 (24 ref.)

Practical considerations in purchasing new products. Fecteau DL. **Surg Clin North Am** 1995 Dec;75(6):1167–73

Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141–57 (27 ref.)

How to select and evaluate new products on the market. Quebbeman EJ, et al. **Surg Clin North Am** 1995 Dec; 75(6):1159–65

[New airbag–associated injuries in traffic accidents] Rebel A, et al. **Anaesthesist** 1996 Apr;45(4):359–62 (Eng. Abstr.) **(Ger)**

[Effect of radiation emitted from personal computer terminal on urethan–induced lung tumors in mice] Anisimov VN, et al. **Vopr Onkol** 1996;42(1):77–81 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

"Splint–top" fracture of the forearm: a description of an in–line skating injury associated with the use of protective wrist splints. Cheng SL, et al. **J Trauma** 1995 Dec; 39(6):1194–7

Personal aerosol protection devices: caring for victims of exposure. Claman FL, et al. **Nurse Pract** 1995 Nov;20(11 Pt 1):52, 54–6, 58

[Femoral neck fractures in bicyclists due to clipless pedals (letter; comment)] Leeuwenberg A. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1663. Comment on: Ned Tijdschr Geneeskd 1995 Jun 3;139(22):1141–3. **(Dut)**

[Femoral neck fractures in bicyclists due to clipless pedals (letter; comment)] Verheij TC. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1662–3. Comment on: Ned Tijdschr Geneeskd 1995 Jun 3;139(22):1141–3. **(Dut)**

STANDARDS

Avoid injury in confined spaces. Bove K, et al. **Occup Health Saf** 1995 Sep;64(9):42–6

STATISTICS & NUMERICAL DATA

Finding homes without smoke detectors: one step in planning burn prevention programs. McKnight RH, et al. **J Burn Care Rehabil** 1995 Sep–Oct;16(5):548–56

PROTECTIVE GLOVES see **GLOVES, PROTECTIVE**

PROTEIN A see **STAPHYLOCOCCAL PROTEIN A**

PROTEIN AA see **AMYLOID PROTEIN AA**

PROTEIN ARGININE METHYLTRANSFERASE

METABOLISM

The predominant protein–arginine methyltransferase from Saccharomyces cerevisiae. Gary JD, et al. **J Biol Chem** 1996 May 24;271(21):12585–94

PROTEIN BINDING

see related
BINDING SITES
CARRIER PROTEINS
METALLOPROTEINS
RADIOLIGAND ASSAY
THYROXINE–BINDING PROTEINS

Capillary electrophoresis/frontal analysis for microanalysis of enantioselective protein binding of a basic drug. Ohara T, et al. **Anal Chem** 1995 Oct 1;67(19):3520–5

Specificity of minor–groove and major–groove interactions in a homeodomain–DNA complex. Ades SE, et al. **Biochemistry** 1995 Nov 7;34(44):14601–8

Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Farrell N, et al. **Biochemistry** 1995 Nov 28;34(47):145480–6

Protein–protein interfaces: architectures and interactions in protein–protein interfaces and in protein cores. Their similarities and differences. Tsai CJ, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):127–52 (50 ref.)

Conformational and receptor–binding properties of the insect neuropeptide proctolin and its analogues. Odell B, et al. **J Comput Aided Mol Des** 1996 Apr;10(2):89–99

Computational methods to predict binding free energy in ligand–receptor complexes. Murcko A, et al. **J Med Chem** 1995 Dec 22;38(26):4953–67 (90 ref.)

Determination of protein binding by in vitro charcoal adsorption. Yuan J, et al. **J Pharmacokinet Biopharm** 1995 Feb;23(1):41–55

A mathematical model for biopanning (affinity selection) using peptide libraries on filamentous phage. Mandecki W, et al. **J Theor Biol** 1995 Oct 21;176(4):523–30

Calorimetric methods for interpreting protein–ligand interactions. Fisher HF, et al. **Methods Enzymol** 1995; 259:194–221

Two–hybrid system as a model to study the interaction of beta–amyloid peptide monomers. Hughes ST, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2065–70

Principles of protein–protein interactions. Jones S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):13–20 (47 ref.)

A mean field model of ligand–protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor–specific binding. Verkhivker GM, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):60–4

Comparison of atomic solvation parametric sets: applicability and limitations in protein folding and binding. Juffer AH, et al. **Protein Sci** 1995 Dec;4(12):2499–509

Computational method for relative binding energies of enzyme–substrate complexes. Zhang T, et al. **Protein Sci** 1996 Feb;5(2):348–56

A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Jedrzejas MJ, et al. **Proteins** 1995 Oct;23(2):264–77

DRUG EFFECTS

Mechanism of acetaminophen–induced hepatotoxicity: covalent binding versus oxidative stress. Gibson JD, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):580–5

GENETICS

The two–hybrid: an in vivo protein–protein interaction assay. Transy C, et al. **Mol Biol Rep** 1995;21(2):119–27

IMMUNOLOGY

New methods to predict MHC–binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263–9 (60 ref.)

Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Stryhn A, et al. **Eur J Immunol** 1996 Aug;26(8):1911–8

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide–binding motifs. D'Amaro J, et al. **Hum Immunol** 1995 May; 43(1):13–8

Detailed motifs for peptide binding to HLA–A*0201 derived from large random sets of peptides using a cellular binding assay. Drijfhout JW, et al. **Hum Immunol** 1995 May; 43(1):1–12

Passive adsorption of immunologically active and inactive synthetic peptides to polystyrene is influenced by the proportion of non–polar residues in the peptide. Sällberg M, et al. **Immunol Lett** 1995 May;46(1–2):25–30

Tissue–specific, peptide–binding transplantation antigens: lessons from the Qa–2 system. Stroynowski I. **Immunol Rev** 1995 Oct;147:91–108 (85 ref.)

PHYSIOLOGY

Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Aguirre C, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):53–72

PROTEIN-BINDING RADIOASSAY see **RADIOLIGAND ASSAY**

PROTEIN-BOUND IODINE TEST see **THYROID FUNCTION TESTS**

PROTEIN C

Activated protein C resistance and pregnancy complications [letter] Grisaru D, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):801–2

Diagnosis of APC Resistance during pregnancy [letter] Cumming AM, et al. **Br J Haematol** 1996 Mar;92(4):1026–9

Prothrombin fragment 1+2 and thrombin–antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Simioni P, et al. **Br J Haematol** 1996 Feb;92(2):435–41

Activated protein C and retinal vein occlusion [editorial;comment] Hunt BJ. **Br J Ophthalmol** 1996 Mar; 80(3):194. Comment on: Br J Ophthalmol 1996 Mar;80(3):200–2. Comment on: Br J Ophthalmol 1996 Mar;80(3):203–8.

Factor V: Q506 and a negative APC–resistance test [letter; comment] Keeling DM. **Thromb Haemost** 1995 Nov; 74(5):1380–1. Comment on: Thromb Haemost 1995 May;73(5):739–42.

[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506—>Gln mutation of the gene of factor V] Levoir D, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):729–31 (Eng. Abstr.) **(Fre)**

PROTEIN C

ANALYSIS

Anticoagulant protein C activity in non-insulin-dependent diabetic patients with normoalbuminuria and microalbuminuria. Veglio M, et al. **Acta Diabetol** 1995 Jun; 32(2):106–9

Influence of protein C resistance (APC-R) on the determination of proteins C and S by functional clotting assays [letter] Ortega IS, et al.
Blood Coagul Fibrinolysis 1995 Oct;6(7):683

Activated protein C resistance in a neonate with venous thrombosis. Kodish E, et al. **J Pediatr** 1995 Oct; 127(4):645–8

Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. Petäjä J, et al.
J Thorac Cardiovasc Surg 1996 Sep;112(3):665–71

Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Henkens CM, et al.
Thromb Haemost 1995 Nov;74(5):1271–5

False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract [letter; comment] Martorell JR, et al. **Thromb Haemost** 1995 Aug;74(2):796–7. Comment on: Thromb Haemost 1994 Oct;72(4):645–6.

Parameters of haemostasis during acute venous thrombosis. Reiter W, et al. **Thromb Haemost** 1995 Aug;74(2):596–601

False-positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets [letter] Shizuka R, et al. **Thromb Res** 1995 Apr 15;78(2):189–90

[May (must?) in a for recurrent thrombophlebitis [with normal AT III/ protein C+S] fully "marcumarized" patient (with [otherwise?] negative contraindications) with acute posterior wall infarct (15 min "old") a brief lysis therapy be instituted?] Seitz R. **Internist (Berl)** 1995 Dec;36(12):1202 **(Ger)**

[Protein C] Hayashi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:112–6 (17 ref.) **(Jpn)**

[Activated protein C-protein C inhibitor complex (APC-PCI complex)] Nishioka J, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:125–9 (14 ref.) **(Jpn)**

[Clinical significance of the determination of protein C dependent disorders of hemostasis in surgical patients] Karelin AA, et al. **Klin Med (Mosk)** 1995;73(5):57–9 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Hamamoto T, et al. **Thromb Res** 1995 Nov 15;80(4):291–7

BIOSYNTHESIS

Rate limitations in posttranslational processing by the mammary gland of transgenic animals. Subramanian A, et al. **Ann N Y Acad Sci** 1996 May 15;782:87–96

CEREBROSPINAL FLUID

[C-reactive protein (CRP) and its significance in purulent meningitis] Przyjalkowski W, et al.
Neurol Neurochir Pol 1995 Sep–Oct;29(5):687–93 (Eng. Abstr.) **(Pol)**

CHEMISTRY

The hydrophobic nature of residue-5 of human protein C is a major determinant of its functional interactions with acidic phospholipid vesicles. Jalbert LR, et al.
Biochemistry 1996 Jun 4;35(22):7093–9

DEFICIENCY

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135–75 (114 ref.)

The incidence of protein C deficiency in thrombosis-related portal hypertension. Majluf-Cruz A, et al.
Am J Gastroenterol 1996 May;91(5):976–80

Budd–Chiari syndrome attributed to protein C deficiency. Sugano S, et al. **Am J Gastroenterol** 1996 Apr;91(4):777–9

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Bucalossi A, et al. **Am J Hematol** 1996 May;52(1):14–20

Thrombotic risk in hereditary antithrombin -III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Pabinger I, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):742–8

Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. Simioni P, et al. **Blood** 1996 Sep 15;88(6):2101–8

Survival in families with hereditary protein C deficiency, 1820 to 1993. Allaart CF, et al. **BMJ** 1995 Oct 7; 311(7010):910–3

Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Gordon B, et al.
Bone Marrow Transplant 1996 Mar;17(3):415–9

Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Minford AM, et al. **Br J Haematol** 1996 Apr;93(1):215–6

Resistance to activated protein C in healthy women taking oral contraceptives. Olivieri O, et al. **Br J Haematol** 1995 Oct;91(2):465–70

Hereditary deficiency of protein C, protein S and antithrombin III. Vittore CP, et al. **Can Assoc Radiol J** 1996 Aug;47(4):251–6

Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency. Fijen CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):290–6

Homozygous protein C deficiency—management with protein C concentrate. Baliga V, et al. **Eur J Pediatr** 1995 Jul;154(7):534–8

Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Müller FM, et al. **Eur J Pediatr** 1996 Jan;155(1):20–5

Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Bertram B, et al. **Ger J Ophthalmol** 1995 Nov;4(6):332–5

Successful management of congenital protein C deficiency with recurrent pregnancy loss. Ogasawara M, et al.
Int J Gynaecol Obstet 1995 Aug;50(2):185–7

Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Spek CA, et al.
J Biol Chem 1995 Oct 13;270(41):24216–21

Eosinophilic gastro-enteritis associated with protein-losing enteropathy and protein C deficiency. Wing-Harkins DL, et al. **J Int Med Res** 1996 Jan–Feb;24(1):155–63 (44 ref.)

Protein C deficiency in Kuwait. Mohanty D, et al.
J Lab Clin Med 1995 Oct;126(4):373–6

Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. Hallam PJ, et al. **J Med Genet** 1995 Jul;32(7):543–5

Case records of the Massachusetts General Hospital. Weekly Clinicopathological Exercises. Case 12–1996. An 18-year old woman with hepatomegaly and ascites [clinical conference] **N Engl J Med** 1996 Apr 18;334(16):1045–51

Protein C deficiency: summary of the 1995 database update. Reitsma PH. **Nucleic Acids Res** 1996 Jan 1;24(1):157–9

Case 04–1995: a neonate with seizures [clinical conference] Walsh IR, et al. **Pediatr Emerg Care** 1995 Oct;11(5):307–12

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al.
Semin Thromb Hemost 1995;21(4):371–81 (26 ref.)

Apparent heterozygous type II protein C deficiency caused by the factor V 506 Arg to Gln mutation [letter] Ireland H, et al. **Thromb Haemost** 1995 Apr;73(4):731–2

Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Reitsma PH, et al. **Thromb Haemost** 1995 May;73(5):876–89 (112 ref.)

The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Sanson BJ, et al.
Thromb Haemost 1996 Mar;75(3):387–8

Heterozygous protein C deficiency and dysfibrinogenemia acquired by liver transplantation. Cransac M, et al.
Transpl Int 1995;8(4):307–11

[General anticoagulant factor deficiency related to venous thrombosis has been identified (editorial)] Syrjälä M.
Duodecim 1994;110(14):1307–9 **(Fin)**

[Pseudothromboangiitis obliterans and qualitative protein C deficiency: report of a case] Cailleux N, et al.
J Mal Vasc 1996;21(1):47–9 (Eng. Abstr.) **(Fre)**

[Post-partum cerebral thrombophlebitis disclosing congenital protein C deficiency (letter)] Mabire D, et al.
Rev Med Interne 1996;17(1):92–3 **(Fre)**

DRUG EFFECTS

Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation. McBane RD, et al. **Thromb Haemost** 1995 Sep;74(3):879–85

GENETICS

Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Zehnder JL, et al. **Am J Clin Pathol** 1996 Jul;106(1):107–11

Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Kalafatis M, et al.
Arterioscler Thromb Vasc Biol 1995 Dec;15(12):2181–7

Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation? [letter] Eikelboom J, et al. **Aust N Z J Med** 1996 Apr; 26(2):243–4

Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Brenner B, et al.
Blood 1996 Aug 1;88(3):877–80

Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. Formstone CJ, et al. **Blood** 1996 May 1;87(9):3731–7

Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Katsumi A, et al. **Blood** 1996 May 15;87(10):4164–75

Polymorphic variation in the human protein C (PROC) gene promoter can influence transcriptional efficiency in vitro. Scopes D, et al. **Blood Coagul Fibrinolysis** 1995 Jun; 6(4):317–21

Homozygosity for R87H missense mutation and for a rare intron 7 DNA variant (7054G —> A) in the PROC genes of three siblings initially classified as heterozygotes for protein C deficiency. Soria JM, et al.
Blood Coagul Fibrinolysis 1996 Jan;7(1):15–23

Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Roelse JC, et al. **Br J Haematol** 1996 Mar;92(3):740–3

Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Liu XY, et al. **Diagn Mol Pathol** 1995 Sep;4(3):191–7

Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. Ireland HA, et al.
Hum Mutat 1996;7(2):176–9

Proteolytic processing of human protein C in swine mammary gland. Lee TK, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):81–7

Transcriptional regulation of the gene coding for human protein C. Miao CH, et al. **J Biol Chem** 1996 Apr 19; 271(16):9587–94

Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Spek CA, et al.
J Biol Chem 1995 Oct 13;270(41):24216–21

Strikes in French public transport and resistance to activated protein C [letter] Eschwège V, et al. **Lancet** 1996 Jan 20; 347(8995):206

Activated protein C resistance in childhood stroke [letter] Ganesan V, et al. **Lancet** 1996 Jan 27;347(8996):260

Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Födinger M, et al.
Nephrol Dial Transplant 1996 Apr;11(4):668–72

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al.
Thromb Haemost 1995 Jul;74(1):81–9 (120 ref.)

Purpura fulminans in a patient homozygous for a mutation in the protein C gene—prenatal diagnosis in a subsequent pregnancy [letter] Alessi MC, et al. **Thromb Haemost** 1996 Mar;75(3):525–6

Protein C Osaka 10 with aberrant propeptide processing: loss of anticoagulant activity due to an amino acid substitution in the protein C precursor. Miyata T, et al.
Thromb Haemost 1995 Oct;74(4):1003–8

Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Reitsma PH, et al. **Thromb Haemost** 1995 May;73(5):876–89 (112 ref.)

Severe type I protein C deficiency in a compound heterozygote for Y124C and Q132X mutations in exon 6 of the PROC gene. Soria JM, et al. **Thromb Haemost** 1995 Nov;74(5):1215–20

[Activated protein C resistance and mutation of coagulation factor V (editorial)] Samama MM.
Arch Mal Coeur Vaiss 1996 Jun;89(6):669–70 **(Fre)**

[Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users] Szucs T, et al. **Med Klin** 1996 May 15;91(5):317–9 (Eng. Abstr.) **(Ger)**

[Point mutation G—>A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464–70 (11 ref.) (Eng. Abstr.) **(Pol)**

[Thrombophilia in a family with resistance to activated protein C and protein S deficiency] Lewandowski K, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):518–24 (Eng. Abstr.) **(Pol)**

[A test for APC resistance prior to prescription of oral contraceptives? Discussion about screening should be based on facts] Dahlbäck B. **Lakartidningen** 1995 Nov 29; 92(48):4558, 4561 **(Swe)**

IMMUNOLOGY

Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Tsakiris DA, et al.
Ann Hematol 1995 Oct;71(4):195–8

High prevalence of activated protein C resistance in patients with systemic sclerosis [letter] De Lucia D, et al.
Int J Clin Lab Res 1995;25(4):226–7

[Resistance to activated protein C. A common genetic risk factor in venous thrombosis] Berntorp E, et al.
Lakartidningen 1995 Sep 27;92(39):3587–90 (27 ref.) **(Swe)**

ISOLATION & PURIFICATION

Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate. Orthner CL, et al. **Vox Sang** 1995;69(4):309–18

METABOLISM

Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Aparicio C, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):467–72

The hydrophobic nature of residue-5 of human protein C

is a major determinant of its functional interactions with acidic phospholipid vesicles. Jalbert LR, et al. **Biochemistry** 1996 Jun 4;35(22):7093–9

Kinetics of the interaction between the human factor VIIIa subunits: effects of pH, ionic strength, Ca2+ concentration, heparin, and activated protein C–catalyzed proteolysis. Persson E, et al. **Biochemistry** 1995 Oct 3;34(39):12775–81

Tryptophans 231 and 234 in protein C report the Ca(2+)-dependent conformational change required for activation by the thrombin–thrombomodulin complex. Rezaie AR, et al. **Biochemistry** 1995 Sep 26;34(38):12221–6

Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)–resistant individuals during clotting: an insight into the APC–resistance assay. Kalafatis M, et al. **Blood** 1996 Jun 1;87(11):4695–707

Comparison of activated protein C/protein S–mediated inactivation of human factor VIII and factor V. Lu D, et al. **Blood** 1996 Jun 1;87(11):4708–17

Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Legnani C, et al. **Br J Haematol** 1996 Jun 1;93(3):694–9

Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening. Luddington R, et al. **Br J Haematol** 1996 Mar;92(3):744–6

Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Nowak–Göttl U, et al. **Br J Haematol** 1996 Mar;92(4):992–8

Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Rai RS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):842–4

Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. De Stefano V, et al. **Haematologica** 1995 Jul–Aug;80(4):344–56 (99 ref.)

Protein C levels in ischaemic heart disease. Ganapathyraman L, et al. **Indian Heart J** 1996 Mar–Apr;48(2):125–7

Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression. Peus D, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):306–9

The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. Fukudome K, et al. **J Biol Chem** 1996 Jul 19; 271(29):17491–8

The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Regan LM, et al. **J Biol Chem** 1996 Jul 19;271(29):17499–503

Activated protein C–catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase. Regan LM, et al. **J Biol Chem** 1996 Feb 23;271(8):3982–7

Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. Rosing J, et al. **J Biol Chem** 1995 Nov 17;270(46):27852–8

Anticoagulant response to activated protein C: method validation and assay comparison. Calkins T, et al. **J Clin Lab Anal** 1995;9(6):418–23

Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. Tabbara IA, et al. **J Hematother** 1996 Feb;5(1):79–84

A physiologic anti–inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. Grey ST, et al. **J Immunol** 1996 Mar 15;156(6):2256–63

Effect of sodium on the energetics of thrombin–thrombomodulin interaction and its relevance for protein C hydrolysis. De Cristofaro R, et al. **J Mol Biol** 1996 Apr 26;258(1):190–200

Evidence against heterozygous coagulation factor V 1691 G—>A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. Prohaska W, et al. **J Mol Med** 1995 Oct;73(10):521–4

Cultured human endothelial cells seeded on expanded polytetrafluoroethylene support thrombin–mediated activation of protein C. Gillis–Haegerstrand C, et al. **J Vasc Surg** 1996 Aug;24(2):226–34

Activated protein C resistance: prevalence and implications in peripheral vascular disease. Ouriel K, et al. **J Vasc Surg** 1996 Jan;23(1):46–51, Discussion 51–2

Multiple organ dysfunction syndrome in bone marrow transplantation. Haire WD, et al. **JAMA** 1995 Oct 25; 274(16):1289–95

Activated protein C and pulmonary embolism [letter] Amoura Z, et al. **Lancet** 1996 Jun 29;347(9018):1841

Activated protein C and pulmonary embolism [letter] Bazzan M, et al. **Lancet** 1996 Jun 29;347(9018):1842

Are we ready for factor V Leiden screening? [see comments] Dahlbäck B. **Lancet** 1996 May 18;347(9012):1346–7. Comment in: Lancet 1996 May 18;347(9012):1374–5.

Resistance to activated protein C in an unselected population of patients with pulmonary embolism [see comments] Desmarais S, et al. **Lancet** 1996 May 18;347(9012):1374–5 . Comment in: Lancet 1996 May 18;347(9012):1346–7.

Activated protein C and pulmonary embolism [letter] Roberts I. **Lancet** 1996 Jun 29;347(9018):1841

Thrombophilia, homocystinuria, and mutation of the factor V gene [letter; comment] D'Angelo A, et al. **N Engl J Med** 1996 Jul 25;335(4):289; discussion 290. Comment on: N Engl J Med 1996 Mar 21;334(12):763–8.

Homodimerization of the human U1 snRNP–specific protein C. Gunnewiek JM, et al. **Nucleic Acids Res** 1995 Dec 11; 23(23):4864–71

Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. Drews R, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10462–6

Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Berg DT, et al. **Science** 1996 Sep 6;273(5280):1389–91

Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Press RD, et al. **Stroke** 1996 Jan;27(1):44–8

Isolated cortical vein thrombosis and activated protein C resistance [letter] Vuillier F, et al. **Stroke** 1996 Aug; 27(8):1440–1

Resistance to activated protein C—diagnostic strategy in a laboratory of haemostasis [letter] Aillaud MF, et al. **Thromb Haemost** 1995 Oct;74(4):1197–8

Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Bertina RM, et al. **Thromb Haemost** 1995 Jul;74(1):449–53 (53 ref.)

Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants [letter] Cadroy Y, et al. **Thromb Haemost** 1995 Apr;73(4):734–5

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.). Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139–48 (112 ref.)

Activated protein C resistance: molecular mechanisms. Griffin JH, et al. **Thromb Haemost** 1995 Jul;74(1):444–8 (35 ref.)

Lowered APC–sensitivity ratio related to increased factor VIII–clotting activity [letter] Henkens CM, et al. **Thromb Haemost** 1995 Oct;74(4):1198–9

The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va. Nishioka J, et al. **Thromb Haemost** 1996 Feb;75(2):275–82

Diagnosis of APC resistance in patients on oral anticoagulant therapy [letter] Tosetto A, et al. **Thromb Haemost** 1995 Apr;73(4):732–3

Recombinant human soluble thrombomodulin reduces endotoxin–induced pulmonary vascular injury via protein C activation in rats. Uchiba M, et al. **Thromb Haemost** 1995 Nov;74(5):1265–70

Homozygous APC–resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Zöller B, et al. **Thromb Haemost** 1995 May;73(5):743–5

Activation of the protein C pathway in acute sepsis. Alcaraz A, et al. **Thromb Res** 1995 Jul 1;79(1):83–93

Effects of hemodialysis and long–term erythropoietin treatment on protein C, and on free and total protein S. Clyne N, et al. **Thromb Res** 1995 Oct 15;80(2):161–8

Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506–factor V. Greengard JS, et al. **Thromb Res** 1995 Dec 1;80(5):441–3

Cofactors V and VIII after endotoxin administration to human volunteers. Wyshock EG, et al. **Thromb Res** 1995 Dec 1;80(5):377–89

Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte–dependent proliferative responses. Hancock WW, et al. **Transplantation** 1995 Dec 27;60(12):1525–32

[Resistance to activated protein C] Yang L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):776–8 (19 ref.) (Eng. Abstr.) **(Chi)**

[Relationship between anti–coagulation system changes of coronary heart disease patients and different syndrome–type in TCM] Liang TJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):599–600 (Eng. Abstr.) **(Chi)**

[A new cause of hereditary venous thrombosis: activated protein C resistance] Trossaërt M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):438–42 (7 ref.) **(Fre)**

[Resistance to activated protein C: a new cause of hypercoagulability] Fouéré S, et al. **Ann Dermatol Venereol** 1996;123(1):37–9 **(Fre)**

[Resistance to activated protein C disclosed by postphlebitic disease. Two cases] Foueré S, et al. **Ann Dermatol Venereol** 1996;123(1):24–5 (Eng. Abstr.) **(Fre)**

[Activity of protein C in blood of patients with prostatic carcinoma] Iwan–Ziętek I, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):94–5 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Heparin–induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance. Gardyn J, et al. **Am J Hematol** 1995 Dec;50(4):292–5

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)

Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Bokarewa MI, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):417–22

No association of APC resistance with myocardial infarction. Demarmels Biasiutti F, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):456–9

Phenotypic correction of activated protein C resistance following orthotopic liver transplantation. Foster PA, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):65–8

Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury. Hahn RA, et al. **J Pharmacol Exp Ther** 1996 Mar; 276(3):1104–10

Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke [letter] Albucher JF, et al. **Stroke** 1996 Apr;27(4):766–7

Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors—correlation with absence of Arg506–Gln mutation of factor V gene [letter] Chan LC, et al. **Thromb Haemost** 1996 Mar;75(3):522–3

The modified APC resistance test [letter] Denson KW, et al. **Thromb Haemost** 1995 Sep;74(3):995

Technical and biological conditions influencing the functional APC resistance test. Freyburger G, et al. **Thromb Haemost** 1996 Mar;75(3):460–5

Warfarin induced skin necrosis associated with activated protein C resistance [letter] Makris M, et al. **Thromb Haemost** 1996 Mar;75(3):523–4

Influence of plasma platelets on activated protein C resistance assay [letter] Sidelmann J, et al. **Thromb Haemost** 1995 Sep; 74(3):993–4

"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Simioni P, et al. **Thromb Haemost** 1996 Mar;75(3):422–6

APC–resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population [letter] Takamiya O, et al. **Thromb Haemost** 1995 Sep;74(3):996

The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant [letter] Trossaërt M, et al. **Thromb Haemost** 1996 Mar;75(3):521–2

Influence of factor V and factor Va on APC–induced cleavage of human factor VIII [letter] Váradi K, et al. **Thromb Haemost** 1995 Apr;73(4):730–1

Laboratory diagnosis of APC–resistance in patients with lupus anticoagulant [letter] Villa P, et al. **Thromb Haemost** 1995 Dec;74(6):1606–7

Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C. Kraus M, et al. **Thromb Res** 1995 Nov 1;80(3):255–64

[Activated protein C resistance: role in venous and arterial thrombosis] Emmerich J, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):741–5 (31 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Physiological anticoagulants and activated protein C resistance in childhood stroke. Riikonen RS, et al. **Acta Paediatr** 1996 Feb;85(2):242–4

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135–75 (114 ref.)

Utilization of testing for activated protein C resistance in a reference laboratory [see comments] Florell SR, et al. **Am J Clin Pathol** 1996 Aug;106(2):248–52. Comment in: Am J Clin Pathol 1996 Aug;106(2):161–2.

Testing for heredity hypercoagulability Activated protein C resistance [editorial; comment] Koepke JA. **Am J Clin Pathol** 1996 Aug;106(2):161–2. Comment on: Am J Clin Pathol 1996 Aug;106(2):248–52.

Prevalence and patient profile in activated protein C resistance. Samaha M, et al. **Am J Clin Pathol** 1995 Oct; 104(4):450–4

Factor V R506Q gene mutation analysis by PCR–RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Voelkerding KV, et al. **Am J Clin Pathol** 1996 Jul;106(1):100–6

Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. van der Bom JG, et al. **Ann Intern Med** 1996 Aug 15;125(4):265–9

Activated protein C resistance caused by factor V Arg 506—>Gln mutation has no role in thrombotic manifestations of Behçet's disease [letter] Lesprit P, et al. **Ann Rheum Dis** 1995 Oct;54(10):860

Resistance to activated protein C: a common inherited cause of venous thrombosis. Gillespie DL, et al. **Ann Vasc Surg** 1996 Mar;10(2):174–7

The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI–dependent. Bajzar L, et al. **Blood** 1996 Sep 15;88(6):2093–100

Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Koppelman SJ, et al. **Blood** 1996 Mar 15;87(6):2292–300

Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration. Munkvad S, et al. **Br J Dermatol** 1996 Feb;134(2):296–8

Activated protein C sensitivity ratio in pregnant women at

delivery. Mathonnet F, et al. **Br J Haematol** 1996 Jan; 92(1):244–6

Activated protein C resistance in young adults with central retinal vein occlusion [see comments] Larsson J, et al. **Br J Ophthalmol** 1996 Mar;80(3):200–2. Comment in: Br J Ophthalmol 1996 Mar;80(3):194.

Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study [see comments] Williamson TH, et al. **Br J Ophthalmol** 1996 Mar;80(3):203–8. Comment in: Br J Ophthalmol 1996 Mar;80(3):194.

Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Braun A, et al. **Hum Genet** 1996 Feb;97(2):263–4

Thrombophilia: some recent advances in understanding. James CM. **J R Nav Med Serv** 1995 Winter;81(3):203–6 (15 ref.)

Ischemic stroke and activated protein C resistance [letter] Bachmeyer C, et al. **JAMA** 1995 Oct 25;274(16):1266

Activated protein C resistance and thrombosis. Nichols WL, et al. **Mayo Clin Proc** 1996 Sep;71(9):897–8 (6 ref.)

Cellular regulation of the protein C pathway. Esmon CT, et al. **Semin Cell Biol** 1995 Oct;6(5):259–68 (73 ref.)

Thrombotic risk during pregnancy and puerperium in women with APC-resistance—effective subcutaneous heparin prophylaxis in a pregnant patient [letter] De Stefano V, et al. **Thromb Haemost** 1995 Aug;74(2):793–4

Acquired activated protein C–resistance in patients with lupus anticoagulants [letter] Ehrenforth S, et al. **Thromb Haemost** 1995 Aug;74(2):797–8

Diagnosis of APC resistance in patients on standard or low molecular weight heparin [letter] Gilmore G, et al. **Thromb Haemost** 1996 Feb;75(2):372–3

The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance [see comments] Kirschbaum NE, et al. **Thromb Haemost** 1995 Sep;74(3):874–8. Comment in: Thromb Haemost 1996 Mar;75(3):520.

The suppression of the coagulation of nonanticoagulated whole blood in vitro by human umbilical endothelial cells cultivated on microcarriers is not dependent on protein C activation. Kohler HP, et al. **Thromb Haemost** 1995 Apr; 73(4):719–24

Inherited homozygous resistance to activated protein C [letter] Villa P, et al. **Thromb Haemost** 1995 Aug; 74(2):794–5

A more discriminating test for APC resistance and a possible screening test to include protein C and protein S. Denson KW, et al. **Thromb Res** 1996 Jan 1;81(1):151–6

[Retinal vein occlusion and resistance to activated protein C] Scat Y, et al. **J Fr Ophtalmol** 1995;18(12):758–62 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Murakami K, et al. **Blood** 1996 Jan 15; 87(2):642–7

Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Müller FM, et al. **Eur J Pediatr** 1996 Jan;155(1):20–5

Protein C in the treatment of coagulopathy in meningococcal disease. Rintala E, et al. **Lancet** 1996 Jun 22;347(9017):1767

Association of membranous nephropathy with familial resistance to activated protein C. Montinaro V, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2133–6

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al. **Semin Thromb Hemost** 1995;21(4):371–81 (26 ref.)

Single point mutation at Arg506 of factor V associated with APC resistance and venous thromboembolism: improved detection by PCR-mediated site-directed mutagenesis [letter] Rabes JP, et al. **Thromb Haemost** 1995 Nov; 74(5):1379–80

[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308–12, 324 (49 ref.) **(Ger)**

PROTEIN C INHIBITOR

ANALYSIS

[Activated protein C–protein C inhibitor complex (APC-PCI complex)] Nishioka J, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:125–9 (14 ref.) **(Jpn)**

CHEMISTRY

Intermolecular interactions between protein C inhibitor and coagulation proteases. Cooper ST, et al. **Biochemistry** 1995 Oct 10;34(40):12991–7

Glycosaminoglycan specificity of a heparin-binding peptide. Taylor GJ, et al. **Pept Res** 1995 Sep–Oct;8(5):286–93

GENETICS

Characterization of a cDNA for rhesus monkey protein C inhibitor—evidence for N-terminal involvement in heparin stimulation. Radtke KP, et al. **Thromb Haemost** 1995 Oct; 74(4):1079–87

METABOLISM

Complexes of tissue kallikrein with protein C inhibitor in human semen and urine. España F, et al. **Eur J Biochem** 1995 Dec 1;234(2):641–9

Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor. Kise H, et al. **Eur J Biochem** 1996 May 15; 238(1):88–96

Glycosaminoglycan specificity of a heparin-binding peptide. Taylor GJ, et al. **Pept Res** 1995 Sep–Oct;8(5):286–93

PHARMACOLOGY

Protein C inhibitor is a potent inhibitor of the thrombin–thrombomodulin complex. Rezaie AR, et al. **J Biol Chem** 1995 Oct 27;270(43):25336–9

URINE

Urinary protein C inhibitor binding region in the A alpha-chain of human fibrinogen. Hayashi S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):382–7

PROTEIN-CALORIE MALNUTRITION see **PROTEIN-ENERGY MALNUTRITION**

PROTEIN CONFORMATION

A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region. Andreeva NS, et al. **Adv Exp Med Biol** 1995;362:19–32

Intra- and inter-chain disulfide bridges of J chain in human S-IgA. Bastian A, et al. **Adv Exp Med Biol** 1995; 371A:581–3

Structure of IgA: facts and gaps in our data on disulfide bonds. Biewenga J. **Adv Exp Med Biol** 1995;371A:575–9 (18 ref.)

Computer simulation and analysis of the reaction pathway for the decomposition of the hydrated peptide bond in aspartic proteases. Cachau RE, et al. **Adv Exp Med Biol** 1995;362:461–5

Mechanism of autoprocessing of a mini-precursor of the aspartic protease of human immunodeficiency virus type 1. Co E, et al. **Adv Exp Med Biol** 1995;362:379–86

Comparison of the active site specificity of the aspartic proteinases based on a systematic series of peptide substrates. Dunn BM, et al. **Adv Exp Med Biol** 1995;362:1–9

The covalent linkage of the secretory component to IgA. Fallgren-Gebauer E, et al. **Adv Exp Med Biol** 1995; 371A:625–8

Molecular modeling of the structure of FIV protease. Gustchina A. **Adv Exp Med Biol** 1995;362:479–84

The molecular structure of human progastricsin and its comparison with that of porcine pepsinogen. James M, et al. **Adv Exp Med Biol** 1995;362:11–8

Human procathepsin D: three-dimensional model and isolation. Koelsch G, et al. **Adv Exp Med Biol** 1995; 362:273–8

Conformation analysis of non-pepsin-type acid proteinase A from the fungus Aspergillus niger by NMR. Kojima M, et al. **Adv Exp Med Biol** 1995;362:611–5

Rearranging pepsinogen and pepsin by protein engineering. Lin X, et al. **Adv Exp Med Biol** 1995;362:33–40

Influence of casein peptide conformations on textural properties of cheese. Malin EL, et al. **Adv Exp Med Biol** 1995;367:303–10

The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with a renin inhibitor CP-80794. Pitts JE, et al. **Adv Exp Med Biol** 1995;362:543–7

X-ray crystallographic study of a non-pepsin-type acid proteinase, Aspergillus niger proteinase A. Sasaki H, et al. **Adv Exp Med Biol** 1995;362:605–9

A comparative study on amino acid sequences of three major isoforms of human pepsin A. Tarasova N, et al. **Adv Exp Med Biol** 1995;362:77–81

Enthalpic contribution to protein stability: insights from atom-based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231–306 (129 ref.)

Energetics of protein structure. Makhatadze GI, et al. **Adv Protein Chem** 1995;47:307–425 (338 ref.)

Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83–229 (423 ref.)

Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope. Lee CN, et al. **AIDS Res Hum Retroviruses** 1995 Jul; 11(7):777–81

Structure and thermodynamics of antigen recognition by antibodies. Braden BC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:315–27

Stabilization of recombinantly expressed proteins. Matthiesen F, et al. **Ann N Y Acad Sci** 1996 May 15;782:413–21

Molecular dissection of the growth hormone receptor. Identification of distinct cytoplasmic domains corresponding to different signaling pathways. Nielsen JH, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:481–3

Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4. Szklarz GD, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):308–18

Use of protease sensitivity to probe the conformations of newly synthesised mutant forms of mitochondrial aspartate aminotransferase. Azzariti A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):800–7

A model molecule of the hydrogen-bonded chain in the active site of bacteriorhodopsin. Brzezinski B, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):273–6

Conformational study of two linear hexapeptides by two-dimensional NMR and computer-simulated modeling: implication for peptide cyclization in solution. Chiou AJ, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):572–9

Conversion of acetylcholinesterase hydrophilic tetramers into amphiphilic dimers and monomers. Flores-Flores C, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):53–8

Study of the new stability properties induced by amino acid replacement of tyrosine 64 in cytochrome C553 from Desulfovibrio vulgaris Hildenborough using electrospray ionization mass spectrometry. Guy P, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):97–103

Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Hornshaw MP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):993–9

Amino acids in highly conserved regions near the C-terminus of rat prolactin (PRL) play critical roles similar to those in binding of human GH to the PRL receptor. Kato Y, et al. **Biochem Biophys Res Commun** 1996 May 15; 222(2):547–52

Structural analysis of invasion plasmid antigen D (IpaD) from Shigella flexneri. Marquart ME, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):963–70

Effect of serine O-glycosylation on cis-trans proline isomerization. Pao YL, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):157–62

Replacement of the sole histidinyl residue in OmpF porin from E. coli by threonine (H21T) does not affect channel structure and function. Saint N, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):118–22

Long time-scale probing of the protein globular core using hydrogen-exchange and room temperature phosphorescence. Schlyer BD, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):670–4

Ability of a beta-casein phosphopeptide to modulate the precipitation of calcium phosphate by forming amorphous dicalcium phosphate nanoclusters. Holt C, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1035–9

Demonstration that 1-trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) is one of the most effective low Mr inhibitors of trypsin-catalysed hydrolysis. Characterization by kinetic analysis and by energy minimization and molecular dynamics simulation of the E-64-beta-trypsin complex. Sreedharan SK, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):777–86

Metal content and conformation of the metalloprotease from the marine sponge Spheciospongia vesparia. Arreguín R, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):827–33

Hydrophobic interaction and folding propensity of chicken heart apocytochrome c. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1177–86

1H NMR studies of peptide fragments from the N-terminus of chicken and human transthyretin. Wilce JA, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1153–9

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111–6 (19 ref.)

ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Peitsch MC. **Biochem Soc Trans** 1996 Feb;24(1):274–9

NMR studies of flavoproteins. Rüterjans H, et al. **Biochem Soc Trans** 1996 Feb;24(1):116–21

Crystal structures of a ferredoxin: NADP+ reductase and of a complex with NADP+. Serre L, et al. **Biochem Soc Trans** 1996 Feb;24(1):10S

The simulation of substantial conformational transitions of proteins: progress in the application of path energy minimization in internal coordinate space. Smart OS. **Biochem Soc Trans** 1996 Feb;24(1):125S

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268–74 (43 ref.)

Molecular recognition by proteins: protein-ligand interactions from a structural perspective. Wallace AC, et al. **Biochem Soc Trans** 1996 Feb;24(1):280–4

Conformation of xanthene dyes in the sulfhydryl 1 binding site of myosin. 2. Ajtai K, et al. **Biochemistry** 1995 Dec 12;34(49):15943–52

Direct binding of ethanol to bovine serum albumin: a fluorescent and 13C NMR multiplet relaxation study. Avdulov NA, et al. **Biochemistry** 1996 Jan 9;35(1):340–7

Structure of the Escherichia coli response regulator NarL. Baikalov I, et al. **Biochemistry** 1996 Aug 27;35(34):11053–61

Designing subtilisin BPN' to cleave substrates containing dibasic residues. Ballinger MD, et al. **Biochemistry** 1995 Oct 17;34(41):13312–9

Structural requirements for the association of native and

partially folded conformations of alpha-lactalbumin with model membranes. Bañuelos S, et al. **Biochemistry** 1996 Apr 2;35(13):3892–8

Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Barak D, et al. **Biochemistry** 1995 Nov 28;34(47):15444–52

Binding of phenylphosphocholine-carrier conjugates to the combining site of antibodies maintains a conformation of the hapten. Barbar E, et al. **Biochemistry** 1996 Mar 5; 35(9):2958–67

Unusual effects of an engineered disulfide on global and local protein stability. Betz SF, et al. **Biochemistry** 1996 Jun 11; 35(23):7422–8

Characterization of the different spectral forms of glutamate 1-semialdehyde aminotransferase by mass spectrometry. Brody S, et al. **Biochemistry** 1995 Dec 12;34(49):15918–24

Contribution to activity of histidine-aromatic, amide-aromatic, and aromatic-aromatic interactions in the extended catalytic site of cysteine proteinases. Brömme D, et al. **Biochemistry** 1996 Apr 2;35(13):3970–9

Analysis of the structure of ribonuclease A in native and partially denatured states by time-resolved noradiative dynamic excitation energy transfer between site-specific extrinsic probes. Buckler DR, et al. **Biochemistry** 1995 Dec 12;34(49):15965–78

The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz-type inhibitor structurally homologous to BPTI. Chang JY. **Biochemistry** 1996 Sep 10; 35(36):11702–9

Rabbit muscle creatine kinase: consequences of the mutagenesis of conserved histidine residues. Chen LH, et al. **Biochemistry** 1996 Jun 18;35(24):7895–902

Conformational change and inactivation of membrane phospholipid-related activity of cardiotoxin V from Taiwan cobra venom at acidic pH. Chiang CM, et al. **Biochemistry** 1996 Jul 16;35(28):9167–76

The role of acidic amino acid residues in the structural stability of snake cardiotoxins. Chiang CM, et al. **Biochemistry** 1996 Jul 16;35(28):9177–86

Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2'-deoxyuridine 5'-monophosphate. Costi PM, et al. **Biochemistry** 1996 Apr 2;35(13):3944–9

Kinetic analysis of cAMP-dependent protein kinase: mutations at histidine 87 affect peptide binding and pH dependence. Cox S, et al. **Biochemistry** 1995 Dec 12; 34(49):16203–9

Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. Craescu CT, et al. **Biochemistry** 1996 Aug 27;35(34):11045–52

A mutational analysis of the binding of two different proteins to the same antibody. Dall'Acqua W, et al. **Biochemistry** 1996 Jul 30;35(30):9667–76

Three-dimensional structure of the second cysteine-rich repeat from the human low-density lipoprotein receptor. Daly NL, et al. **Biochemistry** 1995 Nov 7;34(44):14474–81

Modulation of protein function by exogenous ligands in protein cavities: CO binding to a myoglobin cavity mutant containing unnatural proximal ligands. Decatur SM, et al. **Biochemistry** 1996 Apr 2;35(13):3925–32

Acid-induced molten globule state of a fully active mutant of human interleukin-6. De Filippis V, et al. **Biochemistry** 1996 Sep 3;35(35):11503–11

Ubiquinone pair in the Qo site central to the primary energy conversion reactions of cytochrome bc1 complex. Ding H, et al. **Biochemistry** 1995 Dec 12;34(49):15979–96

Changing the transition state for protein (Un) folding. Doyle DF, et al. **Biochemistry** 1996 Jun 11;35(23):7403–11

Tuning the equilibrium ion affinity and selectivity of the EF-hand calcium binding motif: substitutions at the gateway position. Drake SK, et al. **Biochemistry** 1996 May 28;35(21):6697–705

Solution structure of rat apo-S100B(beta beta) as determined by NMR spectroscopy. Drohat AC, et al. **Biochemistry** 1996 Sep 10;35(36):11577–88

Solution structure of the IIB domain of the glucose transporter of Escherichia coli. Eberstadt M, et al. **Biochemistry** 1996 Sep 3;35(35):11286–92

Thermodynamics of the unfolding and spectroscopic properties of the V66W mutant of Staphylococcal nuclease and its 1–136 fragment. Eftink MR, et al. **Biochemistry** 1996 Jun 18;35(24):8084–94

Competition between DsbA-mediated oxidation and conformational folding of RTEM1 beta-lactamase. Frech C, et al. **Biochemistry** 1996 Sep 3;35(35):11386–95

Probing the conformation of the lactose permease of Escherichia coli by in situ site-directed sulfhydryl modification. Frillingos S, et al. **Biochemistry** 1996 Apr 2;35(13):3950–6

Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A, et al. **Biochemistry** 1996 Jun 11;35(23):7474–81

Three-dimensional structure of the alpha-conotoxin GI at 1.2 A resolution. Guddat LW, et al. **Biochemistry** 1996 Sep 3;35(35):11329–35

Active site structure of Rieske-type proteins: electron nuclear double resonance studies of isotopically labeled phthalate dioxygenase from Pseudomonas cepacia and Rieske protein from Rhodobacter capsulatus and molecular modeling studies of a Rieske center. Gurbiel RJ, et al. **Biochemistry** 1996 Jun 18;35(24):7834–45

Analysis of the substrate-recognition mode of aromatic amino acid aminotransferase by combined use of quasisubstrates and site-directed mutagenesis: systematic hydroxy-group addition/deletion studies to probe the enzyme-substrate interactions. Hayashi H, et al. **Biochemistry** 1996 May 28; 35(21):6754–61

Protein stabilization by removal of unsatisfied polar groups: computational approaches and experimental tests. Hendsch ZS, et al. **Biochemistry** 1996 Jun 18;35(24):7621–5

Structure of a hydrophobically collapsed intermediate on the conformational folding pathway of ribonuclease A probed by hydrogen-deuterium exchange. Houry WA, et al. **Biochemistry** 1996 Sep 10;35(36):11734–46

Circular dichroism evidence for the presence of burst-phase intermediates on the conformational folding pathway of ribonuclease A. Houry WA, et al. **Biochemistry** 1996 Aug 6;35(31):10125–33

Direct measurement of the aspartic acid 26 pKa for reduced Escherichia coli thioredoxin by 13C NMR. Jeng MF, et al. **Biochemistry** 1996 Jan 9;35(1):1–6

The polypeptide chain of eukaryotic initiation factor 5A occurs in two distinct conformations in the absence of the hypusine modification. João HC, et al. **Biochemistry** 1995 Nov 14;34(45):14703–11

Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence. Katz BA. **Biochemistry** 1995 Nov 28; 34(47):15421–9

Structure determination of the N-terminal thioredoxin-like domain of protein disulfide isomerase using multidimensional heteronuclear 13C/15N NMR spectroscopy. Kemmink J, et al. **Biochemistry** 1996 Jun 18; 35(24):7684–91

Individual subunits of heterodimers comprised of retinoic acid and retinoid X receptors interact with their ligands independently. Kersten S, et al. **Biochemistry** 1996 Mar 26; 35(12):3816–24

Cardiac troponin I induced conformational changes in cardiac troponin C as monitored by NMR using site-directed spin and isotope labeling. Kleerekoper Q, et al. **Biochemistry** 1995 Oct 17;34(41):13343–52

The structural basis for pseudoreversion of the E165D lesion by the secondary S96P mutation in triosephosphate isomerase depends on the positions of active site water molecules. Komives EA, et al. **Biochemistry** 1995 Oct 17; 34(41):13612–21

Catalytic strategy of citrate synthase: subunit interactions revealed as a consequence of a single amino acid change in the oxaloacetate binding site. Kurz LC, et al. **Biochemistry** 1995 Oct 17;34(41):13278–88

Conformational changes and calcium binding by calretinin and its recombinant fragments containing different sets of EF hand motifs. Kuźnicki J, et al. **Biochemistry** 1995 Nov 28;34(47):15389–94

A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Novel mixed mode Monte Carlo/stochastic dynamics simulations of the complex between TRH and TRH receptor. Laakkonen LJ, et al. **Biochemistry** 1996 Jun 18;35(24):7651–63

Protein kinase A-catalyzed phosphorylation and its effect on conformation in phytochrome A. Lapko VN, et al. **Biochemistry** 1996 May 28;35(21):6585–94

Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A2. Lee BI, et al. **Biochemistry** 1996 Apr 2;35(13):4231–40

Trimeric assembly and three-dimensional structure model of the FACIT collagen COL1-NC1 junction from CD and NMR analysis. Lesage A, et al. **Biochemistry** 1996 Jul 30; 35(30):9647–60

Comparison of the "Rieske" [2Fe-2S] center in the bc1 complex and in bacterial dioxygenases by circular dichroism spectroscopy and cyclic voltammetry. Link TA, et al. **Biochemistry** 1996 Jun 11;35(23):7546–52

UDP-galactose 4-epimerase: NAD+ content and a charge-transfer band associated with the substrate-induced conformational transition. Liu Y, et al. **Biochemistry** 1996 Jun 11;35(23):7615–20

Motion of spin-labeled side chains in T4 lysozyme. Correlation with protein structure and dynamics. Mchaourab HS, et al. **Biochemistry** 1996 Jun 18; 35(24):7692–704

Structure of the R65Q mutant of yeast 3-phosphoglycerate kinase complexed with Mg-AMP-PNP and 3-phospho-D-glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

Functional site in alpha-lactalbumin encompasses a region corresponding to a subsite in lysozyme and parts of two adjacent flexible substructures. Malinovskii VA, et al. **Biochemistry** 1996 Jul 30;35(30):9710–5

Folding, unfolding, and refolding of the vesicular stomatitis virus glycoprotein. Mathieu ME, et al. **Biochemistry** 1996 Apr 2;35(13):4084–93

Binding studies of a triple-helical peptide model of macrophage scavenger receptor to tetraplex nucleic acids. Mielewczyk SS, et al. **Biochemistry** 1996 Sep 3; 35(35):11396–402

Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states. Mitchell EP, et al. **Biochemistry** 1996 Jun 11;35(23):7341–55

Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase. Murthy BS, et al. **Biochemistry** 1996 Apr 2;35(13):3880–5

A designed heterotrimeric coiled coil. Nautiyal S, et al. **Biochemistry** 1995 Sep 19;34(37):11645–51

Conformational stability of the Escherichia coli HPr protein: test of the linear extrapolation method and a thermodynamic characterization of cold denaturation. Nicholson EM, et al. **Biochemistry** 1996 Sep 3; 35(35):11369–78

Mechanism of laminin chain assembly into a triple-stranded coiled-coil structure. Nomizu M, et al. **Biochemistry** 1996 Mar 5;35(9):2885–93

New approach to the study of transient protein conformations: the formation of a semiburied salt link in the folding pathway of barnase. Oliveberg M, et al. **Biochemistry** 1996 May 28;35(21):6795–805

Three-dimensional structure analysis of mu-agatoxins: further evidence for common motifs among neurotoxins with diverse ion channel specificities. Omecinsky DO, et al. **Biochemistry** 1996 Mar 5;35(9):2836–44

A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Perlman JH, et al. **Biochemistry** 1996 Jun 18;35(24):7643–50

Domain organization and DNA-induced conformational changes of an archaeal family B DNA polymerase. Pisani FM, et al. **Biochemistry** 1996 Jul 16;35(28):9158–66

Reexamination of induced fit as a determinant of substrate specificity in enzymatic reactions. Post CB, et al. **Biochemistry** 1995 Dec 12;34(49):15881–5

Ionization equilibria for side-chain carboxyl groups in oxidized and reduced human thioredoxin and in the complex with its target peptide from the transcription factor NF kappa B. Qin J, et al. **Biochemistry** 1996 Jan 9;35(1):7–13

Limited proteolysis of Salmonella typhimurium nicotinic acid phosphoribosyltransferase reveals ATP-linked conformational change. Rajavel M, et al. **Biochemistry** 1996 Apr 2;35(13):3909–16

Exchange of K+ or Cs+ for Na+ induces local and long-range changes in the three-dimensional structure of the tryptophan synthase alpha2beta2 complex. Rhee S, et al. **Biochemistry** 1996 Apr 2;35(13):4211–21

A linkage of the pKa's of asp-85 and glu-204 forms part of the reprotonation switch of bacteriorhodopsin. Richter HT, et al. **Biochemistry** 1996 Apr 2;35(13):4054–62

Deterministic pressure dissociation and unfolding of triose phosphate isomerase: persistent heterogeneity of a protein dimer. Rietveld AW, et al. **Biochemistry** 1996 Jun 18; 35(24):7743–51

Follitropin conformational stability mediated by loop 2 beta effects follitropin-receptor interaction. Roth KE, et al. **Biochemistry** 1996 Jun 18;35(24):7928–35

Electron paramagnetic resonance spectroscopy of the heme domain of inducible nitric oxide synthase: binding of ligands at the arginine site induces changes in the heme ligation geometry. Salerno JC, et al. **Biochemistry** 1996 Jun 18; 35(24):7626–30

NMR analysis of site-specific ligand binding in oligomeric proteins. Dynamic studies on the interaction of riboflavin synthase with trifluoromethyl-substituted intermediates. Scheuring J, et al. **Biochemistry** 1996 Jul 30;35(30):9637–46

Reversible oligomerization and denaturation of the chaperonin GroES. Seale JW, et al. **Biochemistry** 1996 Apr 2;35(13):4079–83

Reversible thermal unfolding of ribonuclease T1 in reverse micelles. Shastry MC, et al. **Biochemistry** 1996 Apr 2; 35(13):4094–101

NMR solution structure of a synthetic troponin C heterodimeric domain. Shaw GS, et al. **Biochemistry** 1996 Jun 11;35(23):7429–38

Calcium-induced interactions of calmodulin domains revealed by quantitative thrombin footprinting of Arg37 and Arg106. Shea MA, et al. **Biochemistry** 1996 Mar 5; 35(9):2943–57

Probing intradomain and interdomain conformational changes during equilibrium unfolding of phosphoglycerate kinase: fluorescence and circular dichroism study of tryptophan mutants. Sherman MA, et al. **Biochemistry** 1995 Oct 24;34(42):13934–42

NMR solution structure of calcium-saturated skeletal muscle troponin C. Slupsky CM, et al. **Biochemistry** 1995 Dec 12; 34(49):15953–64

Structural consequences of heme removal: molecular dynamics simulations of rat and bovine apocytochrome b5. Storch EM, et al. **Biochemistry** 1996 Sep 10; 35(36):11596–604

Temperature and pH dependences of hydrogen exchange and global stability for ovomucoid third domain. Swint-Kruse L, et al. **Biochemistry** 1996 Jan 9;35(1):171–80

Crystal structures of the binary and ternary complexes of 7 alpha-hydroxysteroid dehydrogenase from Escherichia coli. Tanaka N, et al. **Biochemistry** 1996 Jun 18; 35(24):7715–30

Nuclear magnetic resonance solution structure of the growth factor receptor-bound protein 2 Src homology 2 domain. Thornton KH, et al. **Biochemistry** 1996 Sep 10; 35(36):11852–64

The single-ring Thermoanaerobacter brockii chaperonin 60 (Tbr-EL7) dimerizes to Tbr-EL14.Tbr-ES7 under protein folding conditions. Todd MJ, et al. **Biochemistry** 1995 Nov

14;34(45):14932–41

Solution conformation of the extracellular domain of the human tumor necrosis factor receptor probed by Raman and UV–resonance Raman spectroscopy: structural effects of an engineered PEG linker. Tuma R, et al. **Biochemistry** 1995 Nov 21;34(46):15150–6

Conformation and dynamics of [3–13C]Ala– labeled bacteriorhodopsin and bacterioopsin, induced by interaction with retinal and its analogs, as studied by 13C nuclear magnetic resonance. Tuzi S, et al. **Biochemistry** 1996 Jun 11;35(23):7520–7

Kinetically trapped structure in the renaturation of reduced oxindolealanine 62 lysozyme. Ueda T, et al. **Biochemistry** 1995 Dec 12;34(49):16178–85

Conformational heterogeneity of stability of apomyoglobin studied by hydrogen/deuterium exchange and electrospray ionization mass spectrometry. Wang F, et al. **Biochemistry** 1996 Apr 2;35(13):4069–78

Molecular model of the solution structure for the paramagnetic four–iron ferredoxin from the hyperthermophilic archaeon Thermococcus litoralis. Wang PL, et al. **Biochemistry** 1996 Sep 3;35(35):11319–28

DNA polymerase beta: pre–steady–state kinetic analysis and roles of arginine–283 in catalysis and fidelity. Werneburg BG, et al. **Biochemistry** 1996 Jun 4;35(22):7041–50

Hydrogen bonds of water and C= =O groups coordinate long–range structural changes in the L photointermediate of bacteriorhodopsin. Yamazaki Y, et al. **Biochemistry** 1996 Apr 2;35(13):4063–8

Variable conformation and dynamics of calmodulin complexed with peptides derived from the autoinhibitory domains of target proteins. Yao Y, et al. **Biochemistry** 1996 May 28;35(21):6815–27

A binding site for chlorambucil on metallothionein. Zaia J, et al. **Biochemistry** 1996 Mar 5;35(9):2830–5

Kinetics and mechanisms of activation and inhibition of porcine liver fructose–1,6–bisphosphatase by monovalent cations. Zhang R, et al. **Biochemistry** 1996 Mar 5; 35(9):3038–43

Mechanistic implication of crystal structures of the cyclophilin–dipeptide complexes. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7362–8

Interactions of Escherichia coli tryptophanase with quasisubstrates and monovalent cations studied by the circular dichroism and fluorescence methods. Ben–Kasus T, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):147–52

Conformation of the propeptide domain of factor IX. Cheng JW, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):227–31

Alteration in the conformational stability of collagen caused by the incorporation of the lysine analogue S–2–aminoethylcysteine. Christner P, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):37–47

Conformation of Vespa basalis mastoparan–B in trifluoroethanol–containing aqueous solution. Chuang CC, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):1–8

Hydrostatic pressure induces conformational and catalytic changes on two alcohol dehydrogenases but no oligomeric dissociation. Dallet S, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):15–24

Thermal unfolding of the cytotoxin alpha–sarcin: phospholipid binding induces destabilization of the protein structure. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):126–34

Conformational analysis of pentapeptide sequences matching a proposed recognition motif for lysosomal degradation. Gorinsky B, et al. **Biochim Biophys Acta** 1996 Apr 16; 1293(2):243–53

Inactivation and conformation changes of the glycated and non–glycated D–glyceraldehyde–3–phosphate dehydrogenase during guanidine–HCl denaturation. He RQ, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):47–56

Effect of chaotropic denaturant on the binding of 1–anilino–8–naphthalene sulfonic acid to proteins. Kumar TK, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):103–5

Conformation of polymyxin B analogs in DMSO from NMR spectra and molecular modeling. Liao SY, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):312–20

Spin–labeling probe on conformational change at the active sites of creatine kinase during denaturation by guanidine hydrochloride. Liu ZJ, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):63–8

Fluorescence studies of the effect of pH, guanidine hydrochloride and urea on equinatoxin II conformation. Malavalič M, et al. **Biochim Biophys Acta** 1996 Apr 3; 1280(1):65–72

Functional comparison of the myoglobins reconstituted with symmetric deuterohemes. Neya S, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):245–9

Spectroscopic studies of myo–inositol monophosphatase with a novel fluorescent substrate. Pineda T, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):259–64

The detection of kinetic intermediates during the unfolding of lipoxygenase–1 by urea or guanidine hydrochloride. Srinivasulu S, et al. **Biochim Biophys Acta** 1996 May 23; 1294(2):115–20

Determination of the structural role of the N–terminal domain of human extracellular superoxide dismutase by use of protein fusions. Tibell LA, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):47–52

Inactivation precedes overall molecular conformation changes during enzyme denaturation. Tsou CL. **Biochim Biophys Acta** 1995 Dec 6;1253(2):151–62 (107 ref.)

Conformation of human serum apolipoprotein A–I(166–185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H–NMR and CD. Evidence for specific peptide–SDS interactions. Wang G, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):174–84

Conformational changes at the active site of bovine pancreatic RNase A at low concentrations of guanidine hydrochloride probed by pyridoxal 5'–phosphate. Xiao GS, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):1–7

Crystallographic structure of a peptidyl keto acid inhibitor and human alpha–thrombin. Håkansson K, et al. **Bioorg Med Chem** 1995 Aug;3(8):1009–17

Peptide–derived transition state analogue inhibitors of thrombin; synthesis, activity and selectivity. Jetten M, et al. **Bioorg Med Chem** 1995 Aug;3(8):1099–114

Computational screening of combinatorial libraries. Zheng Q, et al. **Bioorg Med Chem** 1996 May;4(5):631–8

The enthalpy of transfer of unfolded proteins into solutions of urea and guanidinium chloride. Schellman JA, et al. **Biophys Chem** 1996 Apr 16;59(3):259–75

Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329–39 (102 ref.)

Investigation of electrostatic interactions in two–stranded coiled–coils through residue shuffling. Yu Y, et al. **Biophys Chem** 1996 Apr 16;59(3):299–314

Computation of the dipole moments of proteins. Antosiewicz J. **Biophys J** 1995 Oct;69(4):1344–54

Modeling of polypeptide chains as C alpha chains, C alpha chains with C beta, and C alpha chains with ellipsoidal lateral chains. Fogolari F, et al. **Biophys J** 1996 Mar; 70(3):1183–97

The shapes of the motor domains of two oppositely directed microtubule motors, ncd and kinesin: a neutron scattering study. Fujiwara S, et al. **Biophys J** 1995 Oct;69(4):1563–8

Fourier transform infrared spectroscopy indicates a major conformational rearrangement in the activation of rhodopsin. Garcia–Quintana D, et al. **Biophys J** 1995 Sep; 69(3):1077–82

Thermodynamics of water mediating protein–ligand interactions in cytochrome P450cam: a molecular dynamics study. Helms V, et al. **Biophys J** 1995 Sep;69(3):810–24

Characterization of Langmuir–Blodgett films of rhodopsin: thermal stability studies. Maxia L, et al. **Biophys J** 1995 Oct;69(4):1440–6

New tubular single–stranded helix of poly–L–amino acids suggested by molecular mechanics calculations: I. Homopolypeptides in isolated environments. Monoi H. **Biophys J** 1995 Sep;69(3):1130–41

Cooperative subunit interactions in C–type inactivation of K channels. Ogielska EM, et al. **Biophys J** 1995 Dec; 69(6):2449–57

The folding and stability of titin immunoglobulin–like modules, with implications for the mechanism of elasticity. Politou AS, et al. **Biophys J** 1995 Dec;69(6):2601–10

Estimating friction coefficients of mixed globular/chain molecules, such as protein/DNA complexes. Robert CH. **Biophys J** 1995 Sep;69(3):840–8

Characterizing the secondary hydration shell on hydrated myoglobin, hemoglobin, and lysozyme powders by its vitrification behavior on cooling and its calorimetric glass–>liquid transition and crystallization behavior on reheating. Sartor G, et al. **Biophys J** 1995 Dec; 69(6):2679–94

High–pressure near–infrared Raman spectroscopy of bacteriorhodopsin light to dark adaptation. Schulte A, et al. **Biophys J** 1995 Oct;69(4):1554–62

Interaction of substrate uridyl 3',5'–adenosine with ribonuclease A: a molecular dynamics study. Seshadri K, et al. **Biophys J** 1995 Dec;69(6):2185–94

A random flight chain model for the tether of the Shaker K+ channel inactivation domain. Timpe LC, et al. **Biophys J** 1995 Dec;69(6):2415–8

Structural predictions of the binding site architecture for monoclonal antibody NC6.8 using computer–aided molecular modeling, ligand binding, and spectroscopy. Viswanathan M, et al. **Biophys J** 1995 Sep;69(3):741–53

Molecular dynamics study of the M412 intermediate of bacteriorhodopsin. Xu D, et al. **Biophys J** 1995 Dec; 69(6):2745–60

Calculation of translational friction and intrinsic viscosity. II. Application to globular proteins. Zhou XZ. **Biophys J** 1995 Dec;69(6):2298–303

Proceedings of the 4th Naples Workshop on Bioactive Peptides. Capri, Italy, May 22–25, 1994. **Biopolymers** 1995 Oct;36(4):399–558

Conformational analysis of dolastatin 10: an NMR and theoretical approach. Benedetti E, et al. **Biopolymers** 1995 Oct;36(4):525–38

Conformational studies of retro–inverso peptides: the crystal and molecular structure of the hydantoin from H–Ala–g–Ala–mGly–OBzl. Benedetti E, et al. **Biopolymers** 1995 Nov;36(5):659–67

Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate. Beusen DD, et al. **Biopolymers** 1995 Aug;36(2):181–200

Design and characterization of a model alpha beta peptide. Butcher DJ, et al. **Biopolymers** 1995 Aug;36(2):109–20

Conformation and interactions of bombolitin I analogues with SDS micelles and phospholipid vesicles: CD, fluorescence, two–dimensional NMR and computer simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):473–84

Conformation of parathyroid hormone antagonists by CD, NMR, and molecular dynamics simulations. Chorev M, et al. **Biopolymers** 1995 Oct;36(4):485–95

Conformational studies of heterochiral peptides with diastereoisomeric residues: crystal and molecular structures of linear dipeptides derived from leucine, isoleucine, and allo–isoleucine. Di Blasio B, et al. **Biopolymers** 1995 Oct; 36(4):401–8

Conformational study of linear alternating and mixed D– and L–proline oligomers using electronic and vibrational CD and Fourier transform IR. Mästle W, et al. **Biopolymers** 1995 Nov;36(5):623–31

Conformationally readdressed CCK–B/delta–opioid peptide ligands. Nikiforovich GV, et al. **Biopolymers** 1995 Oct; 36(4):439–52

Conformation of cyclobradykinin by NMR and distance geometry calculations. Pellegrini M, et al. **Biopolymers** 1995 Oct;36(4):461–72

Intramolecular electronic energy transfer in peptides carrying naphthalene and protoporphyrin molecules: a spectroscopic and conformational statistics investigation. Pispisa B, et al. **Biopolymers** 1995 Oct;36(4):497–510

Bioactive peptides: conformational studies of [Tyr4] cyclolinopeptide A. Saviano M, et al. **Biopolymers** 1995 Oct;36(4):453–60

Exploration of compact protein conformations using the guided replication Monte Carlo method. Solomon JE, et al. **Biopolymers** 1995 Nov;36(5):579–97

Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side–chain topology. Tourwé D, et al. **Biopolymers** 1996 Jan;38(1):1–12

Transforming growth factors beta: conformational stability and features of the denaturation of recombinant human transforming growth factors beta 2 and beta 3. Runser S, et al. **Biotechnol Appl Biochem** 1995 Aug;22 (Pt 1):39–53

Glanzmann thrombasthenia due to a two amino acid deletion in the fourth calcium–binding domain of alpha IIb: demonstration of the importance of calcium–binding domains in the conformation of alpha IIb beta 3. Basani RB, et al. **Blood** 1996 Jul 1;88(1):167–73

Molecular analysis in three cases of X91– variant chronic granulomatous disease. Bu–Ghanim HN, et al. **Blood** 1995 Nov 1;86(9):3575–82

Immobilized anti–KIT monoclonal antibody induces ligand–independent dimerization and activation of Steel factor receptor: biologic similarity with membrane–bound form of Steel factor rather than its soluble form. Kurosawa K, et al. **Blood** 1996 Mar 15;87(6):2235–43

T–lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient. Morelon E, et al. **Blood** 1996 Sep 1; 88(5):1708–17

Use of thermal fluctuations to study the length and flexibility of ligand–receptor bonds. Pierres A, et al. **C R Acad Sci III** 1995 Dec;318(12):1191–6

Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Chen P, et al. **Cell** 1996 Sep 6;86(5):835–43

Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Ferguson KM, et al. **Cell** 1995 Dec 15; 83(6):1037–46

G protein heterodimers: new structures propel new questions. Neer EJ, et al. **Cell** 1996 Jan 26;84(2):175–8 (15 ref.)

Mechanism of corepressor–mediated specific DNA binding by the purine repressor. Schumacher MA, et al. **Cell** 1995 Oct 6;83(1):147–55

Atomic model of a pyrimidine dimer excision repair enzyme complexed with a DNA substrate: structural basis for damaged DNA recognition. Vassylyev DG, et al. **Cell** 1995 Dec 1;83(5):773–82

The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. Wall MA, et al. **Cell** 1995 Dec 15;83(6):1047–58

The solution structure of the human ETS1–DNA complex reveals a novel mode of binding and true side chain intercalation. Werner MH, et al. **Cell** 1995 Dec 1; 83(5):761–71

Characterization of the molecular and structural properties of the transformed and nuclear aryl hydrocarbon (Ah) receptor complexes by proteolytic digestion. Santostefano M, et al. **Chem Biol Interact** 1996 May 6;100(3):221–40

Computation of low–frequency normal modes in macromolecules: improvements to the method of diagonalization in a mixed basis and application to hemoglobin. Perahia D, et al. **Comput Chem** 1995 Sep; 19(3):241–6

Protein structure prediction: recognition of primary, secondary, and tertiary structural features from amino acid sequence. Eisenhaber F, et al. **Crit Rev Biochem Mol Biol** 1995;30(1):1–94 (487 ref.)

New strategies in protein design. Desjarlais JR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):460–6 (52 ref.)

Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375–81 (75 ref.)

Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437–51 (222 ref.)

Theory and simulation. **Curr Opin Struct Biol** 1996 Apr; 6(2):267–75

Circular assemblies. Antson AA, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):142–50 (41 ref.)

The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69–75 (38 ref.)

The Rel family of eukaryotic transcription factors. Chytil M, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):91–100

Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3–10 (104 ref.)

Novel methods for molecular dynamics simulations. Elber R. **Curr Opin Struct Biol** 1996 Apr;6(2):232–5 (29 ref.)

Structure–derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195–209 (92 ref.)

Alternative conformations of amyloidogenic proteins govern their behavior. Kelly JW. **Curr Opin Struct Biol** 1996 Feb; 6(1):11–7 (44 ref.)

Mean–field minimization methods for biological macromolecules. Koehl P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):222–6 (36 ref.)

Seeking significance in three–dimensional protein structure comparisons. Mizuguchi K, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):377–82 (43 ref.)

RNA–protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53–61 (60 ref.)

Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227–31 (40 ref.)

Retroviral integrases and their cousins. Rice P, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):76–83 (65 ref.)

Structural analysis of non–native states of proteins by NMR methods. Shortle DR. **Curr Opin Struct Biol** 1996 Feb; 6(1):24–30 (58 ref.)

Modeling side–chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)

Homeodomain interactions. Wolberger C. **Curr Opin Struct Biol** 1996 Feb;6(1):62–8 (39 ref.)

An extradenticle–induced conformational change in a HOX protein overcomes an inhibitory function of the conserved hexapeptide motif. Chan SK, et al. **EMBO J** 1996 May 15;15(10):2476–87

Solution structure of the single–stranded DNA binding protein of the filamentous Pseudomonas phage Pf3: similarity to other proteins binding to single–stranded nucleic acids. Folmer RH, et al. **EMBO J** 1995 Sep 1; 14(17):4132–42

Extending dimerization interfaces: the bZIP basic region can form a coiled coil. Krylov D, et al. **EMBO J** 1995 Nov 1;14(21):5329–37

A specific targeting domain in mature exotoxin A is required for its extracellular secretion from Pseudomonas aeruginosa. Lu HM, et al. **EMBO J** 1996 Jan 15; 15(2):429–36

Solution structure of porcine pancreatic phospholipase A2. van den Berg B, et al. **EMBO J** 1995 Sep 1;14(17):4123–31

Epitope peptides from interleukin–6 receptor which inhibit the growth of human myeloma cells. Halimi H, et al. **Eur Cytokine Netw** 1995 May–Jun;6(3):135–43

Solution conformation of the Pseudomonas syringae pv. syringae phytotoxic lipodepsipeptide syringopeptin 25–A. Two–dimensional NMR, distance geometry and molecular dynamics. Ballio A, et al. **Eur J Biochem** 1995 Dec 15; 234(3):747–58

Conformational dynamics of a mobile loop in the NAD(H)–binding subunit of proton–translocating transhydrogenases from Rhodospirillum rubrum and Escherichia coli. Diggle C, et al. **Eur J Biochem** 1995 Aug 15;232(1):315–26

The emerging three–dimensional structure of a receptor. The nicotinic acetylcholine receptor. Hucho F, et al. **Eur J Biochem** 1996 Aug 1;239(3):539–57 (180 ref.)

NMR investigation of the solution conformation of oxidized flavodoxin from Desulfovibrio vulgaris. Determination of the tertiary structure and detection of protein–bound water molecules. Knauf MA, et al. **Eur J Biochem** 1996 Jun 1; 238(2):423–34

Crystal structures and solution studies of oxime adducts of mitochondrial aspartate aminotransferase. Marković–Housley Z, et al. **Eur J Biochem** 1996 Mar 15; 236(3):1025–32

In vivo assembly kinetics of fluorescently labeled Xenopus lamin A mutants. Schmidt M, et al. **Eur J Cell Biol** 1995 Dec;68(4):345–54

The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306–318 and human myelin basic protein peptide 152–165 binding to several DR molecules: definition of a common extended DR binding motif. Posch PE, et al. **Eur J Immunol** 1996 Aug;26(8):1884–91

Computer–generated model of the quaternary structure of alpha crystallin in the lens [letter] Groth–Vasselli B, et al. **Exp Eye Res** 1995 Aug;61(2):249–53

Possible tetramer–based quaternary structure for alpha–crystallins and small heat shock proteins [letter]. Wistow G. **Exp Eye Res** 1993 Jun;56(6):729–32

IR circular dichroism of turns in small peptides. Xie P, et al. **Faraday Discuss** 1994;(99):233–43

Protein motifs. 8. The triple–helix motif in proteins. Brodsky B, et al. **FASEB J** 1995 Dec;9(15):1537–46 (65 ref.)

Assigning amino acid sequences to 3–dimensional protein folds. Fischer D, et al. **FASEB J** 1996 Jan;10(1):126–36 (54 ref.)

NMR identification of calcineurin B residues affected by binding of a calcineurin A peptide. Anglister J, et al. **FEBS Lett** 1995 Nov 13;375(1–2):108–12

Self–association of CPV3, an avian thymic parvalbumin. Henzl MT, et al. **FEBS Lett** 1995 Nov 13;375(1–2):137–42

The three–dimensional structure of capsule–specific CMP: 2–keto–3–deoxy–manno–octonic acid synthetase from Escherichia coli. Jelakovic S, et al. **FEBS Lett** 1996 Aug 5;391(1–2):157–61

Influence of ADP, AMP–PNP and of depletion of nucleotides on the structural properties of F1ATPase: a Fourier transform infrared spectroscopic study. Lippe G, et al. **FEBS Lett** 1995 Oct 9;373(2):141–5

Chemical cross–linking leads to two high molecular mass aggregates of rat alpha 1 beta 1 integrin differing in their conformation but not in their composition. Löster K, et al. **FEBS Lett** 1995 Oct 16;373(3):234–8

Structural and functional characterization of cytochrome c3 from D. desulfuricans ATCC 27774 by 1H–NMR. Louro RO, et al. **FEBS Lett** 1996 Jul 15;390(1):59–62

Reduced–denatured ribonuclease A is not in a compact state. Nöppert A, et al. **FEBS Lett** 1996 Feb 12;380(1–2):179–82

Stable monomeric form of an originally dimeric serine proteinase inhibitor, ecotin, was constructed via site directed mutagenesis. Pál G, et al. **FEBS Lett** 1996 May 6;385(3):165–70

Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions. Papandreou MJ, et al. **FEBS Lett** 1996 Jan 29;379(2):171–6

Cloning and sequencing of winged bean (Psophocarpus tetragonolobus) basic agglutinin (WBA I): presence of second glycosylation site and its implications in quaternary structure. Sharma V, et al. **FEBS Lett** 1996 Jul 8; 389(3):289–92

alpha–Crystallin quaternary structure: molecular basis for its chaperone activity. Singh K, et al. **FEBS Lett** 1995 Sep 25;372(2–3):283–7

Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. Stubbs MT, et al. **FEBS Lett** 1995 Nov 13;375(1–2):103–7

Attempts to convert chymotrypsin to trypsin. Venekei I, et al. **FEBS Lett** 1996 Jan 29;379(2):143–7

Novel disulfide–constrained pentapeptides as models for beta–VIa turns in proteins. Weisshoff H, et al. **FEBS Lett** 1995 Sep 25;372(2–3):203–9

Redox–linked conformational changes in cytochrome c oxidase. Wittung P, et al. **FEBS Lett** 1996 Jun 10; 388(1):47–9

Structural and functional homology between periplasmic bacterial molecular chaperones and small heat shock proteins. Zav'yalov VP, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):265–72

Nucleotide sequence analysis of HLA–B*1523 and B*8101. Dominant alpha–helical motifs produce complex serologic recognition patterns for the HLA–B*DT* and HLA–B*NM5* antigens. Ellexson ME, et al. **Hum Immunol** 1995 Oct;44(2):103–10

Homotypic cell aggregation via conformational change of CD44 molecule induced by anti–CD44 monoclonal antibodies. Cao L, et al. **Immunobiology** 1995 Jun; 193(1):1–14

The 3rd International Satellite Symposium on the Conformational Analysis of Carbohydrates and Protein/Carbohydrate Interactions. Val Morin, Quebec, Canada, 24–28 July 1994. Proceedings. **Int J Biol Macromol** 1995 Jun;17(3–4):115–235

The folding intermediate of reversibly denatured human prostatic acid phosphatase. Kuciel R, et al. **Int J Biol Macromol** 1996 Apr;18(3):167–75

Modelling of the interaction of verotoxin–1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3). Nyholm PG, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):199–204

Electrostatic parameters of the theoretical quaternary structure of bovine alpha–crystallin. Singh K, et al. **Int J Biol Macromol** 1996 Apr;18(3):205–9

Nitrosyl hemoglobins: EPR above 80 K. Wajnberg E, et al. **Int J Biol Macromol** 1996 Apr;18(3):231–5

Stereochemical analysis of the antigenic tip of the V3 loop peptide of HIV–1 gp120. Gunasekaran K, et al. **Int J Pept Protein Res** 1995 Nov;46(5):359–65

Polymethylene spacer linked bis(Ala) peptides form modified beta–sheet structures. Crystal structure and self–assembly pattern of adipoyl and suberoyl analogues. Karle IL, et al. **Int J Pept Protein Res** 1995 Jul;46(1):24–9

Conformation and activity of +H2–Pro–Leu–Gly–NH2 and its analogues modified at the leucyl residue. Kim YJ, et al. **Int J Pept Protein Res** 1995 Nov;46(5):381–90

Synthesis, crystal structure and conformation in solution of four stereoisomeric cyclo–lanthionine derivatives. Osapay G, et al. **Int J Pept Protein Res** 1995 Sep–Oct; 46(3–4):290–301

Solution conformation of mu–selective dermorphin and delta–selective deltorphin–I in phospholipid micelles, studied by NMR spectroscopy and molecular dynamics simulations. Segawa M, et al. **Int J Pept Protein Res** 1995 Jul;46(1):37–46

Simulations of conformers of tuftsin and a cyclic tuftsin analog. Valdeavella CV, et al. **Int J Pept Protein Res** 1995 Nov;46(5):372–80

Protein docking combining symbolic descriptions of molecular surfaces and grid–based scoring functions. Ackermann F, et al. **Ismb** 1995;3:3–11

Characterizing oriented protein structural sites using biochemical properties. Bagley SC, et al. **Ismb** 1995;3:12–20

Predicting free energy contributions to the conformational stability of folded proteins from the residue sequence with radial basis function networks. Casadio R, et al. **Ismb** 1995; 3:81–8

Neural net representations of empirical protein potentials. Grossman T, et al. **Ismb** 1995;3:154–61

3–D lookup: fast protein structure database searches at 90% reliability. Holm L, et al. **Ismb** 1995;3:179–87

Segmentation and interpretation of 3D protein images. Leherte L, et al. **Ismb** 1994;2:261–8

A constraint–based assignment system for automating long side chain assignments in protein 2D NMR spectra. Leishman S, et al. **Ismb** 1995;3:231–9

Relation between protein structure, sequence homology and composition of amino acids. Mayoraz E, et al. **Ismb** 1995; 3:240–8

A multi–level description scheme of protein conformation. Onizuka K, et al. **Ismb** 1993;1:301–9

Geometric problems in molecular biology and robotics. Parsons D, et al. **Ismb** 1994;2:322–30

TOPITS: threading one–dimensional predictions into three–dimensional structures. Rost B. **Ismb** 1995;3:314–21

Solvent accessible surface representation in a database system for protein docking. Seidl T, et al. **Ismb** 1995;3:350–8

Recursive dynamic programming for adaptive sequence and structure alignment. Thiele R, et al. **Ismb** 1995;3:384–92

A constraint reasoning system for automating sequence–specific resonance assignments from multidimensional protein NMR spectra. Zimmerman DE, et al. **Ismb** 1993;1:447–55

The ToxR protein of Vibrio cholerae forms homodimers and heterodimers. Ottemann KM, et al. **J Bacteriol** 1996 Jan; 178(1):156–62

Analysis of a conformation–independent epitope and a conformational epitope in a protein: a study on cobrotoxin from Taiwan cobra venom. Chang LS, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):863–8

Correlation between the differences in the free energy change and conformational energy in the folded state of hen lysozymes with Gly–Pro and Pro–Gly sequences introduced to the same site. Motoshima H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1138–44

Structure–function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)

The structure of copper–nitrite reductase from Achromobacter cycloclastes at five pH values, with NO2– bound and with type II copper depleted. Adman ET, et al. **J Biol Chem** 1995 Nov 17;270(46):27458–74

Kinetic characterization of channel impaired mutants of tryptophan synthase. Anderson KS, et al. **J Biol Chem** 1995 Dec 15;270(50):29936–44

Spectral analysis of lactoperoxidase. Evidence for a common heme in mammalian peroxidases. Andersson LA, et al. **J Biol Chem** 1996 Feb 16;271(7):3406–12

A binding site for thrombin in the apple 1 domain of factor XI. Baglia FA, et al. **J Biol Chem** 1996 Feb 16; 271(7):3652–8

Binding of molten globule–like conformations to lipid bilayers. Structure of native and partially folded alpha–lactalbumin bound to model membranes. Bañuelos S, et al. **J Biol Chem** 1995 Dec 15;270(50):29910–5

Apolipoprotein A–I conformation in reconstituted discoidal lipoproteins varying in phospholipid and cholesterol content. Bergeron J, et al. **J Biol Chem** 1995 Nov 17; 270(46):27429–38

Structural studies of a peptide activator of human lecithin–cholesterol acyltransferase. Buchko GW, et al. **J Biol Chem** 1996 Feb 9;271(6):3039–45

Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein. Candi E, et al. **J Biol Chem** 1995 Nov 3;270(44):26382–90

Unfolding pathway in red kidney bean acid phosphatase is dependent on ligand binding. Cashikar AG, et al. **J Biol Chem** 1996 Mar 1;271(9):4741–6

Active human cytomegalovirus protease is a dimer. Darke PL, et al. **J Biol Chem** 1996 Mar 29;271(13):7445–9

X–ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. Davis GJ, et al. **J Biol Chem** 1996 Jul 19;271(29):17057–61

Low pH activates the vacuolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant. de Bernard M, et al. **J Biol Chem** 1995 Oct 13;270(41):23937–40

Identification of the phospholipid binding site in the vitamin K–dependent blood coagulation protein factor IX. Freedman SJ, et al. **J Biol Chem** 1996 Jul 5; 271(27):16227–36

Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand–specific conformational changes. Gether U, et al. **J Biol Chem** 1995 Nov 24;270(47):28268–75

Tetramethylrhodamine dimer formation as a spectroscopic probe of the conformation of Escherichia coli ribosomal protein L7/L12 dimers. Hamman BD, et al. **J Biol Chem** 1996 Mar 29;271(13):7568–73

Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. Hansen S, et al. **J Biol Chem** 1996 Feb 16;271(7):3917–24

Identification of the high affinity receptor binding region in human immunoglobulin E. Helm BA, et al.

J Biol Chem 1996 Mar 29;271(13):7494–500

Conformational changes in the fibronectin binding MSCRAMMs are induced by ligand binding. House-Pompeo K, et al. J Biol Chem 1996 Jan 19; 271(3):1379–84

The common I172N mutation causes conformational change of cytochrome P450c21 revealed by systematic mutation, kinetic, and structural studies. Hsu LC, et al. J Biol Chem 1996 Feb 9;271(6):3306–10

Further evidence for the structure of the subtilisin propeptide and for its interactions with mature subtilisin. Hu Z, et al. J Biol Chem 1996 Feb 16;271(7):3375–84

Global conformational transitions in Escherichia coli primary replicative helicase DnaB protein induced by ATP, ADP, and single-stranded DNA binding. Multiple conformational states of the helicase hexamer. Jezewska MJ, et al. J Biol Chem 1996 Feb 23;271(8):4261–5

Analysis of three DnaK mutant proteins suggests that progression through the ATPase cycle requires conformational changes. Kamath-Loeb AS, et al. J Biol Chem 1995 Dec 15;270(50):30051–9

Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in Escherichia coli. Comparison of resting and activated states. Kappock TJ, et al. J Biol Chem 1995 Dec 22;270(51):30532–44

Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. Kast C, et al. J Biol Chem 1996 Apr 19;271(16):9240–8

An isoleucine to valine substitution in Escherichia coli acyl carrier protein results in a functional protein of decreased molecular radius at elevated pH. Keating DH, et al. J Biol Chem 1996 Jul 5;271(27):15905–10

Altered structural and mechanistic properties of mutant dihydropteridine reductases. Kiefer PM, et al. J Biol Chem 1996 Feb 16;271(7):3437–44

Crystal structure of a complement factor D mutant expressing enhanced catalytic activity. Kim S, et al. J Biol Chem 1995 Oct 13;270(41):24399–405

Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. Klatt P, et al. J Biol Chem 1996 Mar 29;271(13):7336–42

Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. Kuil CW, et al. J Biol Chem 1995 Nov 17;270(46):27569–76

Controlling substrate preference and transglycosylation activity of neopullulanase by manipulating steric constraint and hydrophobicity in active center. Kuriki T, et al. J Biol Chem 1996 Jul 19;271(29):17321–9

Functional studies and polymerization of recombinant hemoglobin Glu-alpha2beta26(A3) --> Val/Glu-7(A4) --> Ala. Lesecq S, et al. J Biol Chem 1996 Jul 19; 271(29):17211–4

A bacterial thioredoxin-like protein that is exposed to the periplasm has redox properties comparable with those of cytoplasmic thioredoxins. Loferer H, et al. J Biol Chem 1995 Nov 3;270(44):26178–83

Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355–425) of the common beta 1 chain. Luque A, et al. J Biol Chem 1996 May 10; 271(19):11067–75

Studies on the dissociation of cryptomonad biliproteins. MacColl R, et al. J Biol Chem 1995 Nov 17; 270(46):27555–61

Identification of the structural and functional domains of MutY, an Escherichia coli DNA mismatch repair enzyme. Manuel RC, et al. J Biol Chem 1996 Jul 5;271(27):16218–26

Bovine hemoglobin cross-linked through the beta chains: functional and structural aspects. Marta M, et al. J Biol Chem 1996 Mar 29;271(13):7473–8

Ligand-induced conformational changes of GroEL are dependent on the bound substrate polypeptide. Mendoza JA, et al. J Biol Chem 1996 Jul 5;271(27):16344–9

The role of Phe-92 in the Ca(2+)-induced conformational transition in the C-terminal domain of calmodulin. Meyer DF, et al. J Biol Chem 1996 May 10;271(19):11284–90

A single mutation of the neurokinin-2 (NK2) receptor prevents agonist-induced desensitization. Divergent conformational requirements for NK2 receptor signaling and agonist-induced desensitization in Xenopus oocytes. Nemeth K, et al. J Biol Chem 1995 Nov 17;270(46):27601–5

Protein conformational changes during the bacteriorhodopsin photocycle. A Fourier transform infrared/resonance Raman study of the alkaline form of the mutant Asp-85-->Asn. Nilsson A, et al. J Biol Chem 1995 Dec 15;270(50):29746–51

Lysine 71 of the chaperone protein Hsc70 Is essential for ATP hydrolysis. O'Brien MC, et al. J Biol Chem 1996 Jul 5;271(27):15874–8

Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids. Oldenburg KR, et al. J Biol Chem 1996 Jul 19;271(29):17582–91

Activation of the integrin alpha v beta 3 involves a discrete cation-binding site that regulates conformation. Pelletier AJ, et al. J Biol Chem 1996 Jan 19;271(3):1364–70

Functionalized protein-like structures from conformationally defined synthetic combinatorial libraries. Pérez-Payá E, et al. J Biol Chem 1996 Feb 23;271(8):4120–6

Structural analysis of bovine somatotropin using monoclonal antibodies and the conformation-sensitive immunoassay. Pfund WP, et al. J Biol Chem 1996 Jun 14;271(24):14055–61

Spectroscopic and kinetic characterization of the recombinant wild-type and C242S mutant of the cytochrome b reductase fragment of nitrate reductase. Ratnam K, et al. J Biol Chem 1995 Oct 13;270(41):24067–72

Partial G protein activation by fluorescent guanine nucleotide analogs. Evidence for a triphosphate-bound but inactive state. Remmers AE, et al. J Biol Chem 1996 Mar 1; 271(9):4791–7

Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin CR3 mediate its binding to the neutrophil inhibitory factor. Rieu P, et al. J Biol Chem 1996 Jul 5;271(27):15858–61

Conformation of human leukocyte antigen class II molecules. Evidence for superdimers and empty molecules on human antigen presenting cells. Roucard C, et al. J Biol Chem 1996 Jun 14;271(24):13993–4000

Localization of the site on the complement component C1q required for the stimulation of neutrophil superoxide production. Ruiz S, et al. J Biol Chem 1995 Dec 22; 270(51):30627–34

Circular dichroism and x-ray spectroscopies of Azotobacter vinelandii nitrogenase iron protein. MgATP and MgADP induced protein conformational changes affecting the [4Fe-4S] cluster and characterization of a [2Fe-2S] form. Ryle MJ, et al. J Biol Chem 1996 Jan 19;271(3):1551–7

Recombinant core streptavidins. A minimum-sized core streptavidin has enhanced structural stability and higher accessibility to biotinylated macromolecules. Sano T, et al. J Biol Chem 1995 Nov 24;270(47):28204–9

Transcriptional activation domain of the herpesvirus protein VP16 becomes conformationally constrained upon interaction with basal transcription factors. Shen F, et al. J Biol Chem 1996 Mar 1;271(9):4827–37

Site-directed mutagenesis of residues at subunit interfaces of porcine fructose-1,6-bisphosphatase. Shyur LF, et al. J Biol Chem 1996 Feb 9;271(6):3005–10

Intermediates in the catalytic cycle of copper-quinoprotein amine oxidase from Escherichia coli. Steinebach V, et al. J Biol Chem 1996 Mar 8;271(10):5580–8

Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. Szeltner Z, et al. J Biol Chem 1996 Mar 8;271(10):5458–63

The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain. Tamm A, et al. J Biol Chem 1996 Feb 16; 271(7):3659–66

Blocking the Ca2+-induced conformational transitions in calmodulin with disulfide bonds. Tan RY, et al. J Biol Chem 1996 Mar 29;271(13):7479–83

Immunochemical analysis of the structure of diphtheria toxin shows all three domains undergo structural changes at low pH. Tortorella D, et al. J Biol Chem 1995 Nov 17; 270(46):27439–45

Tolerance to amino acid variations in peptides binding to the major histocompatibility complex class I protein H-2Kb. Udaka K, et al. J Biol Chem 1995 Oct 13; 270(41):24130–4

The role of threonine 54 in adrenodoxin for the properties of its iron-sulfur cluster and its electron transfer function. Uhlmann H, et al. J Biol Chem 1995 Dec 15; 270(50):29959–66

pH-dependent conformational properties of saposins and their interactions with phospholipid membranes. Vaccaro AM, et al. J Biol Chem 1995 Dec 22;270(51):30576–80

In vitro dissociation of BiP-peptide complexes requires a conformational change in BiP after ATP binding but does not require ATP hydrolysis. Wei J, et al. J Biol Chem 1995 Nov 3;270(44):26677–82

Probing the indirect readout of the restriction enzyme EcoRV. Mutational analysis of contacts to the DNA backbone. Wenz C, et al. J Biol Chem 1996 Mar 8; 271(10):5565–73

Probing the roles of active site residues in D-xylose isomerase. Whitaker RD, et al. J Biol Chem 1995 Sep 29; 270(39):22895–906

Nucleotide and DNA-induced conformational changes in the bacteriophage T7 gene 4 protein. Yong Y, et al. J Biol Chem 1995 Oct 13;270(41):24509–17

Effects of assembly and mutations outside the active site on the functional pH dependence of Escherichia coli aspartate transcarbamylase. Yuan X, et al. J Biol Chem 1996 Jan 19;271(3):1285–94

Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. Zhuang P, et al. J Biol Chem 1996 Jun 14;271(24):14323–32

Do NOE distances contain enough information to assess the relative populations of multi-conformer structures? Bonvin AM, et al. J Biomol NMR 1996 Jan;7(1):72–6

Solution conformations of proline rings in proteins studied by NMR spectroscopy. Cai M, et al. J Biomol NMR 1995 Sep;6(2):123–8

Assignment of aliphatic side-chain 1HN/15N resonances in perdeuterated proteins. Farmer BT 2nd, et al. J Biomol NMR 1996 Jan;7(1):59–71

Validation of the use of intermolecular NOE constraints for obtaining docked structures of protein-ligand complexes. Gradwell MJ, et al. J Biomol NMR 1996 Jan;7(1):48–58

Separation of intramolecular NOE and exchange peaks in water exchange spectroscopy using spin-echo filters. Mori S, et al. J Biomol NMR 1996 Jan;7(1):77–82

Characterization of an artificial dimer of ribonuclease H using 1H NMR spectroscopy. Yang D, et al. J Biomol NMR 1996 Jan;7(1):29–34

Flexible loop in the structure of S-adenosylmethionine synthetase crystallized in the tetragonal modification. Fu Z, et al. J Biomol Struct Dyn 1996 Apr;13(5):727–39

Chromatin conformation and salt-induced compaction: three-dimensional structural information from cryoelectron microscopy. Bednar J, et al. J Cell Biol 1995 Dec;131(6 Pt 1):1365–76

Import of a DHFR hybrid protein into glycosomes in vivo is not inhibited by the folate-analogue aminopterin. Häusler T, et al. J Cell Biol 1996 Feb;132(3):311–24

Sequence and submolecular localization of the 115-kD accessory subunit of the heterotrimeric kinesin-II (KRP85/95) complex. Wedaman KP, et al. J Cell Biol 1996 Feb;132(3):371–80

Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy. Marcello A, et al. J Chemother 1995 Oct;7(5):403–5

Molecular structure of staphylococcus and streptococcus superantigens. Schlievert PM, et al. J Clin Immunol 1995 Nov;15(6 Suppl):4S–10S

The atom assignment problem in automated de novo drug design. 5. Tests for envelope-directed fragment placement based on molecular similarity. Barakat MT, et al. J Comput Aided Mol Des 1995 Oct;9(5):457–62

A new procedure for improving the predictiveness of CoMFA models and its application to a set of dihydrofolate reductase inhibitors. Kroemer RT, et al. J Comput Aided Mol Des 1995 Oct;9(5):396–406

Conformational and receptor-binding properties of the insect neuropeptide proctolin and its analogues. Odell B, et al. J Comput Aided Mol Des 1996 Apr;10(2):89–99

The coordination of the catalytic zinc in alcohol dehydrogenase studied by combined quantum-chemical and molecular mechanics calculations. Ryde U. J Comput Aided Mol Des 1996 Apr;10(2):153–64

Algorithms for protein structural motif recognition. Berger B. J Comput Biol 1995 Spring;2(1):125–38

Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function associated-1. Miller J, et al. J Exp Med 1995 Nov 1;182(5):1231–41

Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the alpha 2 and alpha 3 domains of MHC class I. Sun J, et al. J Exp Med 1995 Nov 1; 182(5):1275–80

Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. Zerva L, et al. J Exp Med 1996 Mar 1; 183(3):829–36

Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. Langedijk JP, et al. J Gen Virol 1996 Jun;77 (Pt 6):1249–57

Conformational changes between human immunodeficiency virus type 1 nucleocapsid protein NCp7 and its precursor NCp15 as detected by anti-NCp7 monoclonal antibodies. Tanchou V, et al. J Gen Virol 1995 Oct;76 (Pt 10):2457–66

Structural requirements for mucosal vascular addressin binding to its lymphocyte receptor alpha 4 beta 7. Common themes among integrin-Ig family interactions. Briskin MJ, et al. J Immunol 1996 Jan 15;156(2):719–26

The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. Tamm A, et al. J Immunol 1996 Aug 15;157(4):1576–81

Modification of monoclonal and polyclonal IgG with palladium (II) coproporphyrin I: stimulatory and inhibitory functional effects induced by two different methods. Martsev SP, et al. J Immunol Methods 1995 Oct 26; 186(2):293–304

Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. Chatterton JE, et al. J Lipid Res 1995 Sep;36(9):2027–37

Modeling study on a hydrolytic mechanism of class A beta-lactamases. Ishiguro M, et al. J Med Chem 1996 May 24;39(11):2207–18

Molecular structure, conformational analysis, and structure-activity studies of Dendrotoxin and its homologues using molecular mechanics and molecular dynamics techniques. Swaminathan P, et al. J Med Chem 1996 May 24;39(11):2141–55

The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations. Tuchman M, et al. J Med Genet 1995 Sep;32(9):680–8

The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. Aboul-ela F, et al. J Mol Biol 1995 Oct 20; 253(2):313–32

Inter-ring communication is disrupted in the GroEL mutant Arg13 --> Gly; Ala126 --> Val with known crystal structure. Aharoni A, et al. J Mol Biol 1996 May 24; 258(5):732–5

Thermodynamic investigation of hirudin binding to the slow and fast forms of thrombin: evidence for folding transitions in the inhibitor and protease coupled to binding. Ayala YM, et al. J Mol Biol 1995 Nov 10;253(5):787–98

The structure of recombinant human annexin VI in crystals and membrane-bound. Benz J, et al. **J Mol Biol** 1996 Aug 2;260(5):638–43

Acid and thermal denaturation of barnase investigated by molecular dynamics simulations. Caflisch A, et al. **J Mol Biol** 1995 Oct 6;252(5):672–708

Stoichiometry and domainal organization of the long tail-fiber of bacteriophage T4: a hinged viral adhesin. Cerritelli ME, et al. **J Mol Biol** 1996 Aug 2;260(5):767–80

Conformational pathway of the polypeptide chain of chymotrypsin inhibitor-2 growing from its N terminus in vitro. Parallels with the protein folding pathway. de Prat Gay G, et al. **J Mol Biol** 1995 Dec 15;254(5):968–79

A surface of minimum area metric for the structural comparison of proteins. Falicov A, et al. **J Mol Biol** 1996 May 24;258(5):871–92

Reversible association of the equilibrium unfolding intermediate of lambda Cro repressor. Filimonov VV, et al. **J Mol Biol** 1996 Feb 9;255(5):767–77

The motile major sperm protein (MSP) from Ascaris suum is a symmetric dimer in solution. Haaf A, et al. **J Mol Biol** 1996 Jul 12;260(2):251–60

Structural studies on human rhinovirus 14 drug-resistant compensation mutants. Hadfield AT, et al. **J Mol Biol** 1995 Oct 13;253(1):61–73

High helical propensity of the peptide fragments derived from beta-lactoglobulin, a predominantly beta-sheet protein. Hamada D, et al. **J Mol Biol** 1995 Dec 8; 254(4):737–46

X-ray crystal structure of the two site-specific mutants Ile7Ser and Phe110Ser of azurin from Pseudomonas aeruginosa. Hammann C, et al. **J Mol Biol** 1996 Jan 26; 255(3):362–6

Crystal structure of concanavalin B at 1.65 A resolution. An "inactivated" chitinase from seeds of Canavalia ensiformis. Hennig M, et al. **J Mol Biol** 1995 Nov 24;254(2):237–46

From structure to sequence and back again. Hinds DA, et al. **J Mol Biol** 1996 Apr 26;258(1):201–9

Effects of experimentally achievable improvements in the quality of NMR distance constraints on the accuracy of calculated protein structures. Hoogstraten CG, et al. **J Mol Biol** 1996 May 3;258(2):334–48

Structure and dynamics of a protein assembly. 1H-NMR studies of the 36 kDa R6 insulin hexamer. Jacoby E, et al. **J Mol Biol** 1996 Apr 26;258(1):136–57

The refined crystallographic structure of a DD-peptidase penicillin-target enzyme at 1.6 A resolution. Kelly JA, et al. **J Mol Biol** 1995 Nov 24;254(2):223–36

Ionisation of cysteine residues at the termini of model alpha-helical peptides. Relevance to unusual thiol pKa values in proteins of the thioredoxin family. Kortemme T, et al. **J Mol Biol** 1995 Nov 10;253(5):799–812

The crystal structure of ribonuclease Rh from Rhizopus niveus at 2.0 A resolution. Kurihara H, et al. **J Mol Biol** 1996 Jan 19;255(2):310–20

Crystal structure of diferric hen ovotransferrin at 2.4 A resolution. Kurokawa H, et al. **J Mol Biol** 1995 Nov 24; 254(2):196–207

Genetic dissection of intersubunit contacts within human protein kinase CK2. Kusk M, et al. **J Mol Biol** 1995 Nov 10;253(5):703–11

A global taxonomy of loops in globular proteins. Kwasigroch JM, et al. **J Mol Biol** 1996 Jun 21;259(4):855–72

Three hTIM mutants that provide new insights on why TIM is a dimer. Mainfroid V, et al. **J Mol Biol** 1996 Mar 29; 257(2):441–56

Mass spectrometric composition and molecular mass of Lumbricus terrestris hemoglobin: a refined model of its quaternary structure. Martin PD, et al. **J Mol Biol** 1996 Jan 12;255(1):154–69

Molecular symmetry of the dodecamer subunit of Lumbricus terrestris hemoglobin. Martin PD, et al. **J Mol Biol** 1996 Jan 12;255(1):170–5

The C-terminal domain revealed in the structure of RNA polymerase II. Meredith GD, et al. **J Mol Biol** 1996 May 10;258(3):413–9

Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data. Mikol V, et al. **J Mol Biol** 1995 Nov 17; 254(1):86–95

Motions in hemoglobin studied by normal mode analysis and energy minimization: evidence for the existence of tertiary T-like, quaternary R-like intermediate structures. Mouawad L, et al. **J Mol Biol** 1996 May 3;258(2):393–410

Three-dimensional solution structure of bombyxin-II an insulin-like peptide of the silkmoth Bombyx mori: structural comparison with insulin and relaxin. Nagata K, et al. **J Mol Biol** 1995 Nov 10;253(5):749–58

Identification of the receptor-recognition surface of bombyxin-II, an insulin-like peptide of the silkmoth Bombyx mori: critical importance of the B-chain central part. Nagata K, et al. **J Mol Biol** 1995 Nov 10;253(5):759–70

High-resolution crystal structure of magnesium (MgII)-iron (FeII) hybrid hemoglobin with liganded beta subunits. Park SY, et al. **J Mol Biol** 1996 Feb 9;255(5):726–34

Structure of the CAP-DNA complex at 2.5 angstroms resolution: a complete picture of the protein-DNA interface. Parkinson G, et al. **J Mol Biol** 1996 Jul 19; 260(3):395–408

Hyperthermostable surface layer protein tetrabrachion from the archaebacterium Staphylothermus marinus: evidence for the presence of a right-handed coiled coil derived from the primary structure. Peters J, et al. **J Mol Biol** 1996 Apr 19;257(5):1031–41

Correlation between conformational and binding properties of nebulin repeats. Pfuhl M, et al. **J Mol Biol** 1996 Mar 29;257(2):367–84

Nuclear magnetic resonance solution structure of the human Hsp40 (HDJ-1) J-domain. Qian YQ, et al. **J Mol Biol** 1996 Jul 12;260(2):224–35

Three-dimensional structure of glutathione S-transferase from Arabidopsis thaliana at 2.2 A resolution: structural characterization of herbicide-conjugating plant glutathione S-transferases and a novel active site architecture. Reinemer P, et al. **J Mol Biol** 1996 Jan 19;255(2):289–309

Studies on the lumazine synthase/riboflavin synthase complex of Bacillus subtilis: crystal structure analysis of reconstituted, icosahedral beta-subunit capsids with bound substrate analogue inhibitor at 2.4 A resolution. Ritsert K, et al. **J Mol Biol** 1995 Oct 13;253(1):151–67

The 2.0 A crystal structure of Scapharca tetrameric hemoglobin: cooperative dimers within an allosteric tetramer. Royer WE Jr, et al. **J Mol Biol** 1995 Oct 13; 253(1):168–86

Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. Schmidt TG, et al. **J Mol Biol** 1996 Feb 9;255(5):753–66

Different subdomains are most protected from hydrogen exchange in the molten globule and native states of human alpha-lactalbumin. Schulman BA, et al. **J Mol Biol** 1995 Nov 10;253(5):651–7

Refined crystal structure of recombinant murine interferon-beta at 2.15 A resolution. Senda T, et al. **J Mol Biol** 1995 Oct 13;253(1):187–207

Comparison between the phi distribution of the amino acids in the protein database and NMR data indicates that amino acids have various phi propensities in the random coil conformation. Serrano L. **J Mol Biol** 1995 Nov 24; 254(2):322–33

Analysis of main chain torsion angles in proteins: prediction of NMR coupling constants for native and random coil conformations. Smith LJ, et al. **J Mol Biol** 1996 Jan 26; 255(3):494–506

Crystal structure of cellular retinoic acid binding protein I shows increased access to the binding cavity due to formation of an intermolecular beta-sheet. Thompson JR, et al. **J Mol Biol** 1995 Sep 29;252(4):433–46

1H, 15N resonance assignment and three-dimensional structure of CYP1 (HAP1) DNA-binding domain. Timmerman J, et al. **J Mol Biol** 1996 Jun 21;259(4):792–804

Separation of scrapie prion infectivity from PrP amyloid polymers. Wille H, et al. **J Mol Biol** 1996 Jun 21; 259(4):608–21

Cold denaturation of barstar: 1H, 15N and 13C NMR assignment and characterisation of residual structure. Wong KB, et al. **J Mol Biol** 1996 Jun 21;259(4):805–18

Crystal structures of CO-, deoxy- and met-myoglobins at various pH values. Yang F, et al. **J Mol Biol** 1996 Mar 8;256(4):762–74

Conformational properties of four peptides spanning the sequence of hen lysozyme. Yang JJ, et al. **J Mol Biol** 1995 Sep 29;252(4):483–91

A microscopic view of helix propagation: N and C-terminal helix growth in alanine helices. Young WS, et al. **J Mol Biol** 1996 Jun 14;259(3):560–72

Conformational states bound by the molecular chaperones GroEL and secB: a hidden unfolding (annealing) activity. Zahn R, et al. **J Mol Biol** 1996 Aug 9;261(1):43–61

Annotating PDB files with scene information. Couch GS, et al. **J Mol Graph** 1995 Jun;13(3):153–8, 193

SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. Laskowski RA. **J Mol Graph** 1995 Oct;13(5):323–30, 307–8

Systematic representation of protein folding patterns. Lesk AM. **J Mol Graph** 1995 Jun;13(3):159–64

PReDS: a graphics program to aid in the solution of difficult structures. Stock MD, et al. **J Mol Graph** 1995 Oct; 13(5):309–11, 303–4

Transmembrane topology of the glutamate receptors. A tale of novel twists and turns. Hughes TE. **J Mol Neurosci** 1994–95;5(4):211–7 (36 ref.)

Conservation of water molecules in an antibody-antigen interaction. Braden BC, et al. **J Mol Recognit** 1995 Sep–Oct;8(5):317–25

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. Neurath AR, et al. **J Mol Recognit** 1995 Sep–Oct;8(5):304–16

Glycine and GABA receptors: molecular mechanisms controlling chloride ion flux. Aprison MH, et al. **J Neurosci Res** 1996 Feb 1;43(3):372–81

Differential expression of exons 10 and 11 in normal tau and tau associated with paired helical filaments. Ksiezak-Reding H, et al. **J Neurosci Res** 1995 Aug 1; 41(5):583–93

Extensive modifications for methionine enhancement in the beta-barrels do not alter the structural stability of the bean seed storage protein phaseolin. Dyer JM, et al. **J Protein Chem** 1995 Nov;14(8):665–78

Chaperone SecB: conformational changes demonstrated by circular dichroism. Fasman GD, et al. **J Protein Chem** 1995 Oct;14(7):595–600

Structure-function studies of mEGF: probing the type I beta-turn between residues 25 and 26. Lester CC, et al. **J Protein Chem** 1995 Nov;14(8):753–62

Structural effects of the binding of GTP to the wild-type and oncogenic forms of the ras-gene-encoded p21 proteins. Monaco R, et al. **J Protein Chem** 1995 Nov;14(8):721–9

Conformational changes of alpha-lactalbumin induced by the stepwise reduction of its disulfide bridges: the effect of the disulfide bridges on the structural stability of the protein in sodium dodecyl sulfate solution. Takeda K, et al. **J Protein Chem** 1995 Nov;14(8):679–84

Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. Bruss V, et al. **J Virol** 1995 Nov;69(11):6652–7

Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein. Gilbert JM, et al. **J Virol** 1995 Dec;69(12):7410–5

Association of reovirus outer capsid proteins sigma 3 and mu 1 causes a conformational change that renders sigma 3 protease sensitive. Shepard DA, et al. **J Virol** 1995 Dec; 69(12):8180–4

Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. Shugars DC, et al. **J Virol** 1996 May;70(5):2982–91

Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453–84 (92 ref.)

Synthetic metallopeptides as probes of protein-DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)

Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)

Ternary metal ion–nucleic acid base–protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)

Purification and domain-mapping of mammalian DNA polymerase beta. Beard WA, et al. **Methods Enzymol** 1995; 262:98–107

Simple force field for study of peptide and protein conformational properties. Creamer TP, et al. **Methods Enzymol** 1995;259:576–89

Alignment of three-dimensional protein structures: network server for database searching. Holm L, et al. **Methods Enzymol** 1996;266:653–62

X-ray studies of quinoproteins. Mathews FS. **Methods Enzymol** 1995;258:191–216

Solution structure of DNA polymerases and DNA polymerase-substrate complexes. Mullen GP. **Methods Enzymol** 1995;262:147–71

Converting sequence block alignments into structural insights. Poch O, et al. **Methods Enzymol** 1996;266:662–80

Hydrostatic and osmotic pressure as tools to study macromolecular recognition. Robinson CR, et al. **Methods Enzymol** 1995;259:395–427

Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)

Spectroscopic studies of galactose oxidase. Whittaker JW. **Methods Enzymol** 1995;258:262–77

Fourier transform infrared analysis of carbonyl and nitrosyl complexes of cytochrome-c oxidase from Saccharomyces cerevisiae. Zhao XJ, et al. **Methods Enzymol** 1995; 260:399–406

Structure determination using isomorphous replacement. Abdel-Meguid SS. **Methods Mol Biol** 1996;56:153–71

Preliminary characterization of crystals. Abdel-Meguid SS, et al. **Methods Mol Biol** 1996;56:55–86

Recent developments for crystallographic refinement of macromolecules. Brünger AT. **Methods Mol Biol** 1996; 56:245–66 (81 ref.)

Density modification in x-ray crystallography. Podjarny AD, et al. **Methods Mol Biol** 1996;56:205–26 (88 ref.)

Crystallographic and chromatographic methods for study of antibody light chains and other proteins. Schiffer M, et al. **Methods Mol Biol** 1995;51:83–98

Structure and properties of human immunoglobulin light-chain dimers. Stevens FJ, et al. **Methods Mol Biol** 1995;51:51–81

Molecular replacement using known structural information. Tickle IJ, et al. **Methods Mol Biol** 1996;56:173–203 (92 ref.)

Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)

Direct structure determination by electron crystallography: protein data sets. Dorset DL. **Micron** 1995;26(6):511–20

Agonist-specific conformational changes in the yeast alpha-factor pheromone receptor. Büküşoğlu G, et al. **Mol Cell Biol** 1996 Sep;16(9):4818–23

Cyclin-binding motifs are essential for the function of p21CIP1. Chen J, et al. **Mol Cell Biol** 1996 Sep; 16(9):4673–82

Protein-protein and protein-DNA interaction regions within the DNA end-binding protein Ku70-Ku86. Wu X, et al. **Mol Cell Biol** 1996 Sep;16(9):5186–93

Vibrio spp. secrete proaerolysin as a folded dimer without the need for disulphide bond formation. Hardie KR, et al. **Mol Microbiol** 1995 Sep;17(6):1035–44

Genetic origins of protein shape and interaction rules [comment] [see comments] Blalock JE. **Nat Med** 1995 Sep; 1(9):876–8 (20 ref.). Comment on: Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.

Challenging the predictors II [editorial; comment]

Nat Struct Biol 1996 Mar;3(3):209–10. Comment on: Nat Struct Biol 1996 Mar;3(3):233–9. Comment on: Nat Struct Biol 1996 Mar;3(3):290–7.

Quantitative structure–activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Block C, et al. Nat Struct Biol 1996 Mar;3(3):244–51

A ligand–gated, hinged loop rearrangement opens a channel to a buried artificial protein cavity. Fitzgerald MM, et al. Nat Struct Biol 1996 Jul;3(7):626–31

One–step evolution of a dimer from a monomeric protein. Green SM, et al. Nat Struct Biol 1995 Sep;2(9):746–51

C2 domain conformational changes in phospholipase C–delta 1. Grobler JA, et al. Nat Struct Biol 1996 Sep;3(9):788–95

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. Nat Struct Biol 1995 Aug; 2(8):637–43. Comment in: Nat Struct Biol 1995 Aug;2(8):605–6.

Crystal structure of dimeric HIV–1 capsid protein. Momany C, et al. Nat Struct Biol 1996 Sep;3(9):763–70

Comparison of two different DNA–binding modes of the NF–kappa B p50 homodimer [letter] Müller CW, et al. Nat Struct Biol 1996 Mar;3(3):224–7

Characterization of non–inducible Tet repressor mutants suggests conformational changes necessary for induction. Müller G, et al. Nat Struct Biol 1995 Aug;2(8):693–703

X–ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme [see comments] Pares S, et al. Nat Struct Biol 1996 Mar;3(3):284–9. Comment in: Nat Struct Biol 1996 Mar;3(3):218–9.

Not just your average structures [news] Petsko GA. Nat Struct Biol 1996 Jul;3(7):565–6

Stabilization of the T1 fragment of glycophorin A(N) through interactions with N–and O–linked glycans [letter] Pieper J, et al. Nat Struct Biol 1996 Mar;3(3):228–32

Structural basis for specificity of Grb2–SH2 revealed by a novel ligand binding mode [letter] Rahuel J, et al. Nat Struct Biol 1996 Jul;3(7):586–9

Three dimensional structure of human C–reactive protein. Shrive AK, et al. Nat Struct Biol 1996 Apr;3(4):346–54

Molecular docking programs successfully predict the binding of a beta–lactamase inhibitory protein to TEM–1 beta–lactamase [see comments] Strynadka NC, et al. Nat Struct Biol 1996 Mar;3(3):233–9. Comment in: Nat Struct Biol 1996 Mar;3(3):209–10.

A potent new mode of beta–lactamase inhibition revealed by the 1.7 A X–ray crystallographic structure of the TEM–1–BLIP complex [see comments] Strynadka NC, et al. Nat Struct Biol 1996 Mar;3(3):290–7. Comment in: Nat Struct Biol 1996 Mar;3(3):209–10.

Reading the minor groove [news] Travers AA. Nat Struct Biol 1995 Aug;2(8):615–8

A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold. Zhao B, et al. Nat Struct Biol 1995 Dec;2(12):1131–7

Errors in protein structures [letter] Hooft RW, et al. Nature 1996 May 23;381(6580):272

Storing diffraction data [letter] Jones TA, et al. Nature 1996 Sep 5;383(6595):18–9

A strongly interacting pair of residues on the contact surface of charybdotoxin and a Shaker K+ channel. Naranjo D, et al. Neuron 1996 Jan;16(1):123–30

Spatial localization of the K+ channel selectivity filter by mutant cycle–based structure analysis. Ranganathan R, et al. Neuron 1996 Jan;16(1):131–9

Exposure of residues in the cyclic nucleotide–gated channel pore: P region structure and function in gating. Sun ZP, et al. Neuron 1996 Jan;16(1):141–9

Molecular basis of charge movement in voltage–gated sodium channels. Yang N, et al. Neuron 1996 Jan;16(1):113–22

Cloning and sequencing of V genes from anti–osteosarcoma monoclonal antibodies TP–1 and TP–3: location of lysine residues and implications for radiolabeling. Olafsen T, et al. Nucl Med Biol 1995 Aug;22(6):765–71

Identification of an elicitor active site within the three–dimensional structure of the tobacco mosaic tobamovirus coat protein. Taraporewala ZF, et al. Plant Cell 1996 Feb;8(2):169–78

Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation. Baldwin RL, et al. Proc Natl Acad Sci U S A 1996 Feb 6; 93(3):1021–6

Interaction of cyclooxygenases with an apoptosis– and autoimmunity–associated protein. Ballif BA, et al. Proc Natl Acad Sci U S A 1996 May 28;93(11):5544–9

Disruption of the aldolase A tetramer into catalytically active monomers. Beernink PT, et al. Proc Natl Acad Sci U S A 1996 May 28;93(11):5374–9

In vivo and in vitro characterization of the B1 and B2 zinc–binding domains from the acute promyelocytic leukemia protooncoprotein PML. Borden KL, et al. Proc Natl Acad Sci U S A 1996 Feb 20;93(4):1601–6

Crystal structure of the cell cycle–regulatory protein suc1 reveals a beta–hinge conformational switch. Bourne Y, et al. Proc Natl Acad Sci U S A 1995 Oct 24;92(22):10232–6

How are close residues of protein structures distributed in primary sequence? Brocchieri L, et al. Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12136–40

Role of hydrophobic interactions and desolvation in determining the structural properties of a model alpha beta peptide. Butcher DJ, et al. Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1135–40

Compressibility as a means to detect and characterize globular protein states. Chalikian TV, et al. Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1012–4

A soluble domain of the membrane–anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low–pH–induced conformation. Chen J, et al. Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12205–9

Toward a mechanism for GroEL.GroES chaperone activity: an ATPase–gated and –pulsed folding and annealing cage. Corrales FJ, et al. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4509–12

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. Proc Natl Acad Sci U S A 1996 Apr 2; 93(7):2735–40

Direct structure analysis in protein electron crystallography: crystallographic phases for halorhodopsin to 6–A resolution. Dorset DL. Proc Natl Acad Sci U S A 1995 Oct 24;92(22):10074–8

Molecular basis for dysfunction of some mutant forms of methylmalonyl–CoA mutase: deductions from the structure of methionine synthase. Drennan CL, et al. Proc Natl Acad Sci U S A 1996 May 28;93(11):5550–5

Specific interactions outside the proline–rich core of two classes of Src homology 3 ligands. Feng S, et al. Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12408–15

Probing the oligomeric structure of an enzyme by electrospray ionization time–of–flight mass spectrometry. Fitzgerald MC, et al. Proc Natl Acad Sci U S A 1996 Jul 9;93(14):6851–6

Conformations and folding of lysozyme ions in vacuo. Gross DS, et al. Proc Natl Acad Sci U S A 1996 Apr 2; 93(7):3143–8

Stopped–flow NMR spectroscopy: real–time unfolding studies of 6–19F–tryptophan–labeled Escherichia coli dihydrofolate reductase. Hoeltzli SD, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9318–22

Three quaternary structures for a single protein. Huang DB, et al. Proc Natl Acad Sci U S A 1996 Jul 9;93(14):7017–21

Receptor–G protein coupling is established by a potential conformational switch in the beta gamma complex. Kisselev O, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9102–6

Crystal structure of the large fragment of Thermus aquaticus DNA polymerase I at 2.5–A resolution: structural basis for thermostability. Korolev S, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9264–8

The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin. Li M, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9308–12

Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Li M, et al. Proc Natl Acad Sci U S A 1996 Jul 9;93(14):6902–6

On the nucleation and growth of amyloid beta–protein fibrils: detection of nuclei and quantitation of rate constants. Lomakin A, et al. Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1125–9

The putative actin–binding role of hydrophobic residues Trp546 and Phe547 in chicken gizzard heavy meromyosin. Onishi H, et al. Proc Natl Acad Sci U S A 1995 Dec 19; 92(26):11965–9

Mutational analysis of NM23–H2/NDP kinase identifies the structural domains critical to recognition of a c–myc regulatory element. Postel EH, et al. Proc Natl Acad Sci U S A 1996 Jul 9;93(14):6892–7

Similar antigenic surfaces, rather than sequence homology, dictate T–cell epitope molecular mimicry. Quaratino S, et al. Proc Natl Acad Sci U S A 1995 Oct 24;92(22):10398–402

Site–directed mutagenesis of Azotobacter vinelandii ferredoxin I: cysteine ligation of the [4Fe–4S] cluster with protein rearrangement is preferred over serine ligation. Shen B, et al. Proc Natl Acad Sci U S A 1995 Oct 24; 92(22):10064–8

Protein–protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Tang H, et al. Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1119–24

Chaperonin–facilitated protein folding: optimization of rate and yield by an iterative annealing mechanism. Todd MJ, et al. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4030–5

Direct measurement of salt–bridge solvation energies using a peptide model system: implications for protein stability. Wimley WC, et al. Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2985–90

Clusters of charged residues in protein three–dimensional structures. Zhu ZY, et al. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8350–5

Optimal protein structure alignments by multiple linkage clustering: application to distantly related proteins. Boutonnet NS, et al. Protein Eng 1995 Jul;8(7):647–62

Comparative molecular dynamics simulation studies of salmon and bovine trypsins in aqueous solution. Heimstad ES, et al. Protein Eng 1995 Apr;8(4):379–88

Finding the global minimum: a fuzzy end elimination implementation. Keller DA, et al. Protein Eng 1995 Sep; 8(9):893–904

Enhanced dead–end elimination in the search for the global minimum energy conformation of a collection of protein side chains. Lasters I, et al. Protein Eng 1995 Aug; 8(8):815–22

The application of hydrogen bonding analysis in X–ray crystallography to help orientate asparagine, glutamine and histidine side chains. McDonald IK, et al. Protein Eng 1995 Mar;8(3):217–24

Enzyme–catalyzed dehalogenation of pentachloroethane: why F87W–cytochrome P450cam is faster than wild type. Manchester JI, et al. Protein Eng 1995 Aug;8(8):801–7

Improved genetic algorithm–based protein structure comparisons: pairwise and multiple superpositions. May AC, et al. Protein Eng 1995 Sep;8(9):873–82

Neural network system for the evaluation of side–chain packing in protein structures. Milik M, et al. Protein Eng 1995 Mar;8(3):225–36

Are database–derived potentials valid for scoring both forward and inverted protein folding? Rooman MJ, et al. Protein Eng 1995 Sep;8(9):849–58 (82 ref.)

A simple protein folding algorithm using a binary code and secondary structure constraints. Sun S, et al. Protein Eng 1995 Aug;8(8):769–78

Structural basis for the extreme thermostability of D–glyceraldehyde–3–phosphate dehydrogenase from Thermotoga maritima: analysis based on homology modelling. Szilágyi A, et al. Protein Eng 1995 Aug; 8(8):779–89

Protein docking for low–resolution structures. Vakser IA. Protein Eng 1995 Apr;8(4):371–7

1.85 A structure of anti–fluorescein 4–4–20 Fab. Whitlow M, et al. Protein Eng 1995 Aug;8(8):749–61

Predicting protein structural classes from amino acid composition: application of fuzzy clustering. Zhang CT, et al. Protein Eng 1995 May;8(5):425–35

Domains in folding of model proteins. Abkevich VI, et al. Protein Sci 1995 Jun;4(6):1167–77

Covalent tethering of the dimer interface annuls aggregation in thymidylate synthase. Agarwalla S, et al. Protein Sci 1996 Feb;5(2):270–7

Structure–based modeling of the ligand binding domain of the human cell surface receptor CD23 and comparison of two independently derived molecular models. Bajorath J, et al. Protein Sci 1996 Feb;5(2):240–7

Second–site suppression of regulatory phosphorylation in Escherichia coli isocitrate dehydrogenase. Chen R, et al. Protein Sci 1996 Feb;5(2):287–95

Exhaustive enumeration of protein conformations using experimental restraints. DeWitte RS, et al. Protein Sci 1995 Sep;4(9):1780–91

Side–chain conformational entropy in protein folding. Doig AJ, et al. Protein Sci 1995 Nov;4(11):2247–51 (31 ref.)

De novo prediction of polypeptide conformations using dihedral probability grid Monte Carlo methodology. Evans JS, et al. Protein Sci 1995 Jun;4(6):1203–16

Prediction of polyelectrolyte polypeptide structures using Monte Carlo conformational search methods with implicit solvation modeling. Evans JS, et al. Protein Sci 1995 Oct; 4(10):2019–31

Characterization of a new four–chain coiled–coil: influence of chain length on stability. Fairman R, et al. Protein Sci 1995 Aug;4(8):1457–69

C alpha–based torsion angles: a simple tool to analyze protein conformational changes. Flocco MM, et al. Protein Sci 1995 Oct;4(10):2118–22

Are turns required for the folding of ribonuclease T1? Garrett JB, et al. Protein Sci 1996 Feb;5(2):204–11

Are proteins ideal mixtures of amino acids? Analysis of energy parameter sets. Godzik A, et al. Protein Sci 1995 Oct;4(10):2107–17

Structural resiliency of an EGF–like subdomain bound to its target protein, thrombin. Hrabal R, et al. Protein Sci 1996 Feb;5(2):195–203

Water molecules participate in proteinase–inhibitor interactions: crystal structures of Leu18, Ala18, and Gly18 variants of turkey ovomucoid inhibitor third domain complexed with Streptomyces griseus proteinase B. Huang K, et al. Protein Sci 1995 Oct;4(10):1985–97

Molecular modeling studies of HIV–1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Kroeger Smith MB, et al. Protein Sci 1995 Oct;4(10):2203–22

Homology modeling of an immunoglobulin–like domain in the Saccharomyces cerevisiae adhesion protein alpha–agglutinin. Lipke PN, et al. Protein Sci 1995 Oct; 4(10):2168–78

Building proteins from C alpha coordinates using the dihedral probability grid Monte Carlo method. Mathiowetz AM, et al. Protein Sci 1995 Jun;4(6):1217–32

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. Protein Sci 1996 Feb;5(2):357–62

A statistical mechanical model for hydrogen exchange in globular proteins. Miller DW, et al. Protein Sci 1995 Sep; 4(9):1860–73

Equilibrium dissociation and unfolding of the dimeric human papillomavirus strain–16 E2 DNA–binding domain. Mok YK, et al. Protein Sci 1996 Feb;5(2):310–9

Urease activity in the crystalline state. Moncrief MB, et al. Protein Sci 1995 Oct;4(10):2234–6

Modeling conformational changes in cyclosporin A. O'Donohue MF, et al. Protein Sci 1995 Oct;4(10):2191–202

Structural similarity between the pleckstrin homology domain and verotoxin: the problem of measuring and evaluating structural similarity. Orengo CA, et al. Protein Sci 1995 Oct;4(10):1977–83

Topology prediction of membrane proteins. Persson B, et al. **Protein Sci** 1996 Feb;5(2):363–71

Active site properties of monomeric triosephosphate isomerase (monoTIM) as deduced from mutational and structural studies. Schliebs W, et al. **Protein Sci** 1996 Feb; 5(2):229–39

A ligand–induced conformational change in the Yersinia protein tyrosine phosphatase. Schubert HL, et al. **Protein Sci** 1995 Sep;4(9):1904–13

Structural coupling of the inhibitory regions flanking the ETS domain of murine Ets–1. Skalicky JJ, et al. **Protein Sci** 1996 Feb;5(2):296–309

Predicting oligomerization states of coiled coils. Woolfson DN, et al. **Protein Sci** 1995 Aug;4(8):1596–607

Folding proteins with a simple energy function and extensive conformational searching. Yue K, et al. **Protein Sci** 1996 Feb;5(2):254–61

Identification of a pattern in protein structure based on energetic and statistical considerations. Amadei A, et al. **Proteins** 1996 Jan;24(1):35–50

Determination of the conformation of folding initiation sites in proteins by computer simulation. Avbelj F, et al. **Proteins** 1995 Oct;23(2):129–41

Conformational sampling by NMR solution structures calculated with the program DIANA evaluated by comparison with long–time molecular dynamics calculations in explicit water. Berndt KD, et al. **Proteins** 1996 Mar;24(3):304–13

Crystallographic structure of metal–free concanavalin A at 2.5 A resolution. Bouckaert J, et al. **Proteins** 1995 Dec; 23(4):510–24

Homology modeling by the ICM method. Cardozo T, et al. **Proteins** 1995 Nov;23(3):403–14

The use of position–specific rotamers in model building by homology. Chinea G, et al. **Proteins** 1995 Nov;23(3):415–21

Evaluation of current techniques for ab initio protein structure prediction. Defay T, et al. **Proteins** 1995 Nov; 23(3):431–45

Structural superposition of proteins with unknown alignment and detection of topological similarity using a six–dimensional search algorithm. Diederichs K. **Proteins** 1995 Oct;23(2):187–95

Molecular modeling indicates that homodimers form the basis for intermediate filament assembly from human and mouse epidermal keratins. Downing DT. **Proteins** 1995 Oct; 23(2):204–17

Perfect temperature for protein structure prediction and folding. Finkelstein AV, et al. **Proteins** 1995 Oct; 23(2):151–62

Why do protein architectures have Boltzmann–like statistics? Finkelstein AV, et al. **Proteins** 1995 Oct;23(2):142–50

Secondary structure prediction and unrefined tertiary structure prediction for cyclin A, B, and D. Gerloff DL, et al. **Proteins** 1996 Jan;24(1):18–34

Purification, crystallization, and preliminary X–ray analysis of Bacillus subtilis ferrochelatase. Hansson M, et al. **Proteins** 1995 Dec;23(4):607–9

Analysis of six protein structures predicted by comparative modeling techniques. Harrison RW, et al. **Proteins** 1995 Dec;23(4):463–71

Fold recognition and ab initio structure predictions using hidden Markov models and beta–strand pair potentials. Hubbard TJ, et al. **Proteins** 1995 Nov;23(3):398–402

Protein–protein interaction at crystal contacts. Janin J, et al. **Proteins** 1995 Dec;23(4):580–7

A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Jedrzejas MJ, et al. **Proteins** 1995 Oct;23(2):264–77

Kinetic folding and unfolding of staphylococcal nuclease and its six mutants studied by stopped–flow circular dichroism. Kalnin NN, et al. **Proteins** 1995 Oct;23(2):163–76

Crystallization and preliminary crystallographic analysis of an amylopullulanase from the hyperthermophilic archaeon Pyrococcus woesei. Knapp S, et al. **Proteins** 1995 Dec; 23(4):595–7

Crystallization and preliminary X–ray crystallographic analysis of ImmE7 protein of colicin E7. Ku WY, et al. **Proteins** 1995 Dec;23(4):588–90

Protein structure prediction by threading methods: evaluation of current techniques. Lemer CM, et al. **Proteins** 1995 Nov; 23(3):337–55

Threading a database of protein cores. Madej T, et al. **Proteins** 1995 Nov;23(3):356–69

Size–independent comparison of protein three–dimensional structures. Maiorov VN, et al. **Proteins** 1995 Jul; 22(3):273–83

Hinge–bending motion in citrate synthase arising from normal mode calculations. Marques O, et al. **Proteins** 1995 Dec;23(4):557–60

An automated method for dynamic ligand design. Miranker A, et al. **Proteins** 1995 Dec;23(4):472–90

A large–scale experiment to assess protein structure prediction methods. Moult J, et al. **Proteins** 1995 Nov; 23(3):ii–v

High pressure effects on protein structure and function. Mozhaev VV, et al. **Proteins** 1996 Jan;24(1):81–91 (56 ref.)

Ab initio structure prediction for small polypeptides and protein fragments using genetic algorithms. Pedersen JT, et al. **Proteins** 1995 Nov;23(3):454–60

Crystallization and preliminary crystallographic study of human lithostathine. Pignol D, et al. **Proteins** 1995 Dec; 23(4):604–6

Evaluation of comparative protein modeling by MODELLER. Sali A, et al. **Proteins** 1995 Nov; 23(3):318–26

Confronting the problem of interconnected structural changes in the comparative modeling of proteins. Samudrala R, et al. **Proteins** 1995 Nov;23(3):327–36

Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Schiweck W, et al. **Proteins** 1995 Dec;23(4):561–5

Crystallization and X–ray analysis of a single fab binding domain from protein L of Peptostreptococcus magnus. Sohi MK, et al. **Proteins** 1995 Dec;23(4):610–2

Empirical evaluation of the influence of side chains on the conformational entropy of the polypeptide backbone. Stites WE, et al. **Proteins** 1995 Jun;22(2):132–40

Control of crystal forms of apoferritin by site–directed mutagenesis. Takeda S, et al. **Proteins** 1995 Dec; 23(4):548–56

Prediction of the structure of GroES and its interaction with GroEL. Valencia A, et al. **Proteins** 1995 Jul;22(3):199–209

Toward understanding the structure and interactions of microtubules and motor proteins. Wade RH, et al. **Proteins** 1995 Dec;23(4):502–9

Preliminary X–ray crystallographic analysis of Tritrichomonas foetus inosine–5'–monophosphate dehydrogenase. Whitby FG, et al. **Proteins** 1995 Dec; 23(4):598–603

Parametric sensitivity analysis of avian pancreatic polypeptide (APP). Zhang H, et al. **Proteins** 1995 Oct; 23(2):218–32

Protein design: a hierarchic approach. Bryson JW, et al. **Science** 1995 Nov 10;270(5238):935–41 (107 ref.)

Direct observation of protein solvation and discrete disorder with experimental crystallographic phases. Burling FT, et al. **Science** 1996 Jan 5;271(5245):72–7

Structure of the FKBP12–rapamycin complex interacting with the binding domain of human FRAP [see comments] Choi J, et al. **Science** 1996 Jul 12;273(5272):239–42. Comment in: Science 1996 Jul 12;273(5272):183.

CD2: an exception to the immunoglobulin superfamily concept? [letter] Davis SJ, et al. **Science** 1996 Aug 30; 273(5279):1241–2

The radius of gyration of an apomyoglobin folding intermediate. Eliezer D, et al. **Science** 1995 Oct 20; 270(5235):487–8

Structure of gene–tag protein solved [news; comment] Gura T. **Science** 1996 Sep 6;273(5280):1336. Comment on: Science 1996 Sep 6;273(5280):1392–5.

Crystal structure of the biphenyl–cleaving extradiol dioxygenase from a PCB–degrading pseudomonad. Han S, et al. **Science** 1995 Nov 10;270(5238):976–80

Structural basis of light harvesting by carotenoids: peridinin–chlorophyll–protein from Amphidinium carterae [see comments] Hofmann E, et al. **Science** 1996 Jun 21; 272(5269):1788–91. Comment in: Science 1996 Jun 21;272(5269):1743–4.

Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)

Which came first, protein sequence or structure? [comment] Karkar M. **Science** 1996 Aug 2;273(5275):610. Comment on: Science 1996 Aug 2;273(5275):666–9.

Emergence of preferred structures in a simple model of protein folding [see comments] Li H, et al. **Science** 1996 Aug 2;273(5275):666–9. Comment in: Science 1996 Aug 2;273(5275):610.

A protein phosphorylation switch at the conserved allosteric site in GP. Lin K, et al. **Science** 1996 Sep 13; 273(5281):1539–42

Structure of the heat shock protein chaperonin–10 of Mycobacterium leprae [see comments] [published erratum appears in Science 1996 Mar 22;271(5256):1655] Mande SC, et al. **Science** 1996 Jan 12;271(5246):203–7. Comment in: Science 1996 Jan 12;271(5246):161–2.

Direct physical measure of conformational rearrangement underlying potassium channel gating. Mannuzzu LM, et al. **Science** 1996 Jan 12;271(5246):213–6

Lord of the rings: GroES structure [comment] Mayhew M, et al. **Science** 1996 Jan 12;271(5246):161–2. Comment on: Science 1996 Jan 12;271(5246):203–7.

Tertiary and quaternary structural changes in Gi alpha 1 induced by GTP hydrolysis [see comments] Mixon MB, et al. **Science** 1995 Nov 10;270(5238):954–60. Comment in: Science 1995 Nov 10;270(5238):933–4.

Form follows function when plants harvest light [news; comment] Moffat AS. **Science** 1996 Jun 21; 272(5269):1743–4. Comment on: Science 1996 Jun 21;272(5269):1788–91.

Crystal structure of the Aequorea victoria green fluorescent protein [see comments] Ormö M, et al. **Science** 1996 Sep 6;273(5280):1392–5. Comment in: Science 1996 Sep 6;273(5280):1336.

Support for the prion hypothesis for inheritance of a phenotypic trait in yeast [see comments] Patino MM, et al. **Science** 1996 Aug 2;273(5275):622–6. Comment in: Science 1996 Aug 2;273(5275):580.

Teams tackle protein prediction [news] Pennisi E. **Science** 1996 Jul 26;273(5274):426–8

Flexing muscle with just one amino acid [news] [see comments] Service RF. **Science** 1996 Jan 5;271(5245):31. Comment in: Science 1996 Mar 29;271(5257):1792–3.

Computational molecular biology. Software matchmakers help make sense of sequences [news] Taubes G. **Science** 1996 Aug 2;273(5275):588–90

The whole structure of the 13–subunit oxidized cytochrome c oxidase at 2.8 A [see comments] Tsukihara T, et al. **Science** 1996 May 24;272(5265):1136–44. Comment in: Science 1996 May 24;272(5265):1125.

Yeast prions: DNA–free genetics [news; comment] Vogel G. **Science** 1996 Aug 2;273(5275):580. Comment on: Science 1996 Aug 2;273(5275):622–6.

Crystal structure of the dual specificity protein phosphatase VHR. Yuvaniyama J, et al. **Science** 1996 May 31; 272(5266):1328–31

Substrate binding and carboxylation by dethiobiotin synthetase—a kinetic and X–ray study. Alexeev D, et al. **Structure** 1995 Nov 15;3(11):1207–15

A role for quaternary structure in the substrate specificity of leucine dehydrogenase. Baker PJ, et al. **Structure** 1995 Jul 15;3(7):693–705

The crystal structure of cyclin A [see comments] Brown NR, et al. **Structure** 1995 Nov 15;3(11):1235–47. Comment in: Structure 1995 Nov 15;3(11):1131–4.

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Cutfield SM, et al. **Structure** 1995 Nov 15;3(11):1261–71

Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127–9 (22 ref.). Comment on: Structure 1995 Nov 15;3(11):1171–84.

Ab initio determination of the crystal structure of cytochrome c6 and comparison with plastocyanin. Frazão C, et al. **Structure** 1995 Nov 15;3(11):1159–69

Crystal structure of the di–haem cytochrome c peroxidase from Pseudomonas aeruginosa. Fülöp V, et al. **Structure** 1995 Nov 15;3(11):1225–33

How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.). Comment on: Structure 1995 Dec 15;3(12):1295–306.

Crystal structure of an acetylcholinesterase–fasciculin complex: interaction of a three–fingered toxin from snake venom with its target. Harel M, et al. **Structure** 1995 Dec 15;3(12):1355–66

The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)

Crystal structure of human Charcot–Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate–binding family of galectins. Leonidas DD, et al. **Structure** 1995 Dec 15;3(12):1379–93

Structuring cell–cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131–4 (52 ref.). Comment on: Structure 1995 Nov 15;3(11):1235–47.

A 26 kDa yeast DNA topoisomerase I fragment: crystallographic structure and mechanistic implications. Lue N, et al. **Structure** 1995 Dec 15;3(12):1315–22

14–3–3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)

Crystal structure of Escherichia coli pyruvate kinase type I: molecular basis of the allosteric transition. Mattevi A, et al. **Structure** 1995 Jul 15;3(7):729–41

Solution structure of the cardiostimulant polypeptide anthopleurin–B and comparison with anthopleurin–A [published erratum appears in Structure 1995 Oct 15;3(10):1126] Monks SA, et al. **Structure** 1995 Aug 15; 3(8):791–803

X–ray structure of human nucleoside diphosphate kinase B complexed with GDP at 2 A resolution. Moréra S, et al. **Structure** 1995 Dec 15;3(12):1307–14

A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649–52 (18 ref.)

Structural comparison of the free and DNA–bound forms of the purine repressor DNA–binding domain. Nagadoi A, et al. **Structure** 1995 Nov 15;3(11):1217–24

Structure and catalytic mechanism of glucosamine 6–phosphate deaminase from Escherichia coli at 2.1 A resolution. Oliva G, et al. **Structure** 1995 Dec 15; 3(12):1323–32

Crystal structure of a quinoenzyme: copper amine oxidase of Escherichia coli at 2 A resolution [see comments] Parsons MR, et al. **Structure** 1995 Nov 15;3(11):1171–84. Comment in: Structure 1995 Nov 15;3(11):1127–9.

Bound to activate: conformational consequences of cyclin binding to CDK2. Radzio–Andzelm E, et al. **Structure** 1995 Nov 15;3(11):1135–41

Three–dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Rudenko G, et al. **Structure** 1995 Nov 15;3(11):1249–59

The low ionic strength crystal structure of horse cytochrome c at 2.1 A resolution and comparison with its high ionic strength counterpart. Sanishvili R, et al. **Structure** 1995 Jul 15;3(7):707–16

The crystal structure of the catalytic domain of human urokinase–type plasminogen activator. Spraggon G, et al. **Structure** 1995 Jul 15;3(7):681–91

Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)

Homeodomains: together again for the first time. Tullius T. **Structure** 1995 Nov 15;3(11):1143–5 (15 ref.)

The structure of Pyrococcus furiosus glutamate dehydrogenase reveals a key role for ion–pair networks

in maintaining enzyme stability at extreme temperatures. Yip KS, et al. **Structure** 1995 Nov 15;3(11):1147–58

Solution structure of the pleckstrin homology domain of Drosophila beta-spectrin. Zhang P, et al. **Structure** 1995 Nov 15;3(11):1185–95

Structure–function relationship of the A1 domain of von Willebrand factor. Girma JP, et al. **Thromb Haemost** 1995 Jul;74(1):156–60

Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t–PA–catalysed plasminogen activation. Haddeland U, et al. **Thromb Haemost** 1996 Feb; 75(2):326–31

Platelet–associated anti–glycoprotein (GP) IIb–IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation–dependent conformations: comparison with the epitopes of serum autoantibodies. Kosugi S, et al. **Thromb Haemost** 1996 Feb;75(2):339–45

Dali: a network tool for protein structure comparison. Holm L, et al. **Trends Biochem Sci** 1995 Nov;20(11):478–80

The influenza virus NS1 protein forms multimers in vitro and in vivo. Nemeroff ME, et al. **Virology** 1995 Oct 1; 212(2):422–8

Conformational changes involved in the switch from ovalbumin to S–ovalbumin. Castellano AC, et al. **Z Naturforsch [C]** 1996 May–Jun;51(5–6):379–85

Rubisco, an old challenge with new perspectives. Wildner GF, et al. **Z Naturforsch [C]** 1996 May–Jun;51(5–6):273–86 (63 ref.)

[Amyloidosis, protein conformation dynamics and neurologic diseases] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):153–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Thermodynamic basis for the water–bridge structure of collagen] Burdzhanadze TV. **Biofizika** 1992 Mar–Apr; 37(2):231–7 (Eng. Abstr.) **(Rus)**

[Statistical criteria for evaluating the spatial structure, used in the reverse case of forming protein globules] Siuniaev ShR, et al. **Biofizika** 1995 Nov–Dec;40(6):1165–70 (Eng. Abstr.) **(Rus)**

[Conformational changes of the platelet membrane glycoprotein IIb–IIIa complex stimulated by a monoclonal antibody to the N–terminal segment of glycoprotein IIIa] Khaspekova SG, et al. **Biokhimiia** 1996 Mar;61(3):412–28 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Eye CNG channel is modulated by nicotine. McGeoch JE, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):879–87

Effects of the type of divalent cation, Ca2+ or Mg2+, bound at the high–affinity site and of the ionic composition of the solution on the structure of F–actin. Strzelecka–Golaszewska H, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):713–21

Calcium–induced conformational change in cardiac troponin C studied by fluorescence probes attached to Cys–84. Dong WJ, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):139–46

(RP)–cAMPS inhibits the cAMP–dependent protein kinase by blocking the cAMP–induced conformational transition. Dostmann WR. **FEBS Lett** 1995 Nov 20;375(3):231–4

Conformational aberrance of the sendai virus F0 protein in thapsigargin–treated cells allowing exit from the endoplasmic reticulum but causing arrest at the Golgi complex. Ono A, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1248–54

How do volatile anesthetics inhibit Ca(2+)–ATPases? Lopez MM, et al. **J Biol Chem** 1995 Nov 24;270(47):28239–45

Changes in an HER–2 peptide upregulating HLA–A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor–specific CTL induction. Fisk B, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):197–209

Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. McDonnell DP, et al. **Mol Endocrinol** 1995 Jun;9(6):659–69

Chemical crosslinking of the subunits of HIV–1 reverse transcriptase. Debyser Z, et al. **Protein Sci** 1996 Feb; 5(2):278–86

Trehalose protects yeast pyrophosphatase against structural and functional damage induced by guanidinium chloride. Sola–Penna M, et al. **Z Naturforsch [C]** 1996 Mar–Apr; 51(3–4):160–4

RADIATION EFFECTS

Structure of the N intermediate of bacteriorhodopsin revealed by x–ray diffraction. Kamikubo H, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1386–90

PROTEIN CONFORMATION, ALPHA–HELICAL see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN CONFORMATION, BETA–SHEET see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN DEFICIENCY

Impact of early growth retardation on glucoregulatory control and insulin action in mature rats. Holness MJ. **Am J Physiol** 1996 Jun;270(6 Pt 1):E946–54

Effect of dietary protein restriction on liver transcription factors. Marten NW, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):361–70

Long–term effects of gestational protein malnutrition on postnatal growth, insulin–like growth factor (IGF)–I, and IGF–binding proteins in rat progeny. Muaku SM, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):649–55

BLOOD

The effects of protein malnutrition and experimental infection with Trypanosoma brucei on gossypol treatment in the rat: haematological and serum biochemical changes. Akingbemi BT, et al. **J Comp Pathol** 1995 May;112(4):361–71

Time course of changes in rat serum lecithin–cholesterol acyl–transferase activity and high–density–lipoprotein composition during the consumption of two different low–protein diets followed by a balanced diet. Lamri MY, et al. **Nutrition** 1995 Sep–Oct;11(5):444–9

COMPLICATIONS

Two unusual cases of kwashiorkor: can protein deficiency explain the mystery? Oyelami OA, et al. **Ann Trop Paediatr** 1995 Sep;15(3):217–9

Evaluation of nutritional status in patients with endemic pemphigus foliaceus. Barraviera SR, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):51–8

CONGENITAL

Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Müller FM, et al. **Eur J Pediatr** 1996 Jan;155(1):20–5

DIET THERAPY

Comparative effects of dietary nucleoside–nucleotide mixture and its components on endotoxin induced bacterial translocation and small intestinal injury in protein deficient mice. Adjei AA, et al. **Gut** 1996 Apr;38(4):531–7

ENZYMOLOGY

Very low protein diets induce a rapid decrease in hepatic cAMP–dependent protein kinase followed by a lower increase in adenylyl cyclase activity in rats. Stephen LL, et al. **J Nutr** 1996 Jul;126(7):1799–807

ETIOLOGY

Caloric rather than protein deficiency predominates in stable chronic haemodialysis patients. Lorenzo V, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1885–9

IMMUNOLOGY

Influence of dietary protein on DDT–induced immune responsiveness in rats. Banerjee BD, et al. **Indian J Exp Biol** 1995 Oct;33(10):739–44

METABOLISM

Chronic protein deficiency differentially affects the kinetics of plasma proteins in young pigs. Jahoor F, et al. **J Nutr** 1996 May;126(5):1489–95

Protein and lipid refeeding changes protein metabolism and colonic but not small intestinal morphology in protein–depleted rats. Qu Z, et al. **J Nutr** 1996 Apr; 126(4):906–12

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485–92

PHYSIOPATHOLOGY

Anastomotic healing of small bowel with or without chronic radiation damage in protein–deficient malnourished rats. Jahnson S, et al. **Eur J Surg** 1996 Jan;162(1):47–53

Effects of protein deficiency and diet consistency on the parotid gland and parotid saliva of rats. Johnson DA, et al. **J Dent Res** 1995 Aug;74(8):1444–52

Severe protein deficiency and repletion alter body and brain composition and organ weights in infant pigs. Pond WG, et al. **J Nutr** 1996 Jan;126(1):290–302

Prenatal cocaine but not prenatal malnutrition affects foster mother–pup interactions in rats. Tonkiss J, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):601–8

The effects of cocaine exposure prior to and during pregnancy in rats fed low or adequate protein diets. Tonkiss J, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):593–600

VETERINARY

Beta–adrenergic receptors in porcine adipocyte membranes: modification by animal age, depot site, and dietary protein deficiency. Akanbi KA, et al. **J Anim Sci** 1996 Mar; 74(3):551–61

Comparison between 3–methylhistidine production and proteinase activity as measures of skeletal muscle breakdown in protein–deficient growing barrows. van den Hemel–Grooten HN, et al. **J Anim Sci** 1995 Aug; 73(8):2272–81

PROTEIN DENATURATION

Changing the transition state for protein (Un) folding. Doyle DF, et al. **Biochemistry** 1996 Jun 11;35(23):7403–11

Ribonuclease A revisited: infrared spectroscopic evidence for lack of native–like secondary structures in the thermally denatured state. Fabian H, et al. **Biochemistry** 1995 Oct 17;34(41):13651–5

Covalent reinforcement of a fragile region in the dimeric enzyme thymidylate synthase stabilizes the protein against chaotrope–induced unfolding. Gokhale RS, et al. **Biochemistry** 1996 Jun 4;35(22):7150–8

Residual structure in urea–denatured chaperonin GroEL. Gorovits BM, et al. **Biochemistry** 1995 Oct 24; 34(42):13928–33

Protein stability: urea–induced versus guanidine–induced unfolding of metmyoglobin. Gupta R, et al. **Biochemistry** 1996 Sep 10;35(36):11925–30

The observed change in heat capacity accompanying the thermal unfolding of proteins depends on the composition of the solution and on the method employed to change the temperature of unfolding. Liu Y, et al. **Biochemistry** 1996 Mar 5;35(9):3059–62

Folding, unfolding, and refolding of the vesicular stomatitis virus glycoprotein. Mathieu ME, et al. **Biochemistry** 1996 Apr 2;35(13):4084–93

Induction of alpha–helix in the beta–sheet protein tumor necrosis factor–alpha: thermal– and trifluoroethanol–induced denaturation at neutral pH. Narhi LO, et al. **Biochemistry** 1996 Sep 3;35(35):11447–53

Induction of alpha–helix in the beta–sheet protein tumor necrosis factor–alpha: acid–induced denaturation. Narhi LO, et al. **Biochemistry** 1996 Sep 3;35(35):11454–60

Conformational stability of the Escherichia coli HPr protein: test of the linear extrapolation method and a thermodynamic characterization of cold denaturation. Nicholson EM, et al. **Biochemistry** 1996 Sep 3; 35(35):11369–78

Exploring the role of the solvent in the denaturation of a protein: a molecular dynamics study of the DNA binding domain of the 434 repressor. Schiffer CA, et al. **Biochemistry** 1995 Nov 21;34(46):15057–67

Guanidine hydrochloride unfolding of peptide helices: separation of denaturant and salt effects. Smith JS, et al. **Biochemistry** 1996 Jun 4;35(22):7292–7

Motional dynamics of a buried tryptophan reveals the presence of partially structured forms during denaturation of barstar. Swaminathan R, et al. **Biochemistry** 1996 Jul 16;35(28):9150–7

Unfolding and refolding of Coprinus cinereus peroxidase at high pH, in urea, and at high temperature. Effect of organic and ionic additives on these processes. Tams JW, et al. **Biochemistry** 1996 Jun 11;35(23):7573–9

High–pressure denaturation of staphylococcal nuclease proline–to–glycine substitution mutants. Vidugiris GJ, et al. **Biochemistry** 1996 Mar 26;35(12):3857–64

Inactivation and conformation changes of the glycated and non–glycated D–glyceraldehyde–3–phosphate dehydrogenase during guanidine–HCl denaturation. He RQ, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):47–56

Spin–labeling probe on conformational change at the active sites of creatine kinase during denaturation by guanidine hydrochloride. Liu ZJ, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):63–8

Prediction of denaturing tendency of organic solvents in mixtures with water by measurement of naphthalene solubility. Rosell CM, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):158–64

Inactivation precedes overall molecular conformation changes during enzyme denaturation. Tsou CL. **Biochim Biophys Acta** 1995 Dec 6;1253(2):151–62 (107 ref.)

Sequential unfolding of adenylate kinase during denaturation by guanidine hydrochloride. Zhang YL, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):239–44

In vivo reactivation of heat–denatured protein in the endoplasmic reticulum of yeast. Jämsä E, et al. **EMBO J** 1995 Dec 1;14(23):6028–33

A zinc finger–like domain of the molecular chaperone DnaJ is involved in binding to denatured protein substrates. Szabo A, et al. **EMBO J** 1996 Jan 15;15(2):408–17

Reversible super–reduction of the cubane [4Fe–4S](3+;2+;1+) in the high–potential iron–sulfur protein under non–denaturing conditions. EPR spectroscopic and electrochemical studies. Heering HA, et al. **Eur J Biochem** 1995 Sep 15;232(3):811–7

Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)

The denatured state (the other half of the folding equation) and its role in protein stability. Shortle D. **FASEB J** 1996 Jan;10(1):27–34 (39 ref.)

Variability in heat–induced fragmentation of a protein in the presence of dodecyl sulfate: the role of an intramolecular sulfhydryl/disulfide exchange. Kubo K. **J Biochem (Tokyo)** 1995 Dec;118(6):1112–7

Pressure–induced dissociation and denaturation of allophycocyanin at subzero temperatures. Foguel D, et al. **J Biol Chem** 1995 Dec 1;270(48):28759–66

Refolding of denatured and denatured/reduced lysozyme at high concentrations. Raman B, et al. **J Biol Chem** 1996 Jul 19;271(29):17067–72

Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. Hollander AP, et al. **J Clin Invest** 1995 Dec; 96(6):2859–69

Scanning tunnelling microscopy and dynamic contact angle studies of the effects of partial denaturation on

immunoassay solid phase antibody. Davies J, et al. **J Immunol Methods** 1995 Oct 12;186(1):111–23

pH-dependent denaturation of extracellular aspartic proteinases from Candida species. Wagner T, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):275–8

A comparison of the pH, urea, and temperature-denatured states of barnase by heteronuclear NMR: implications for the initiation of protein folding. Arcus VL, et al. **J Mol Biol** 1995 Nov 24;254(2):305–21

Acid and thermal denaturation of barnase investigated by molecular dynamics simulations. Caflisch A, et al. **J Mol Biol** 1995 Oct 6;252(5):672–708

Perturbed pKA-values in the denatured states of proteins. Tan YJ, et al. **J Mol Biol** 1995 Dec 15;254(5):980–92

Cold denaturation of barstar: 1H, 15N and 13C NMR assignment and characterisation of residual structure. Wong KB, et al. **J Mol Biol** 1996 Jun 21;259(4):805–18

Use of multiple spectroscopic methods to monitor equilibrium unfolding of proteins. Eftink MR. **Methods Enzymol** 1995; 259:487–512

Thermal denaturation methods in the study of protein folding. Freire E. **Methods Enzymol** 1995;259:144–68

Detection of rare partially folded molecules in equilibrium with the native conformation of RNaseH. Chamberlain AK, et al. **Nat Struct Biol** 1996 Sep;3(9):782–7

Reactivation of denatured proteins by 23S ribosomal RNA: role of domain V. Chattopadhyay S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8284–7

Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Gursky O, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2991–5

Chemically crosslinked protein dimers: stability and denaturation effects. Byrne MP, et al. **Protein Sci** 1995 Dec; 4(12):2545–58

Structural and dynamic characterization of the urea denatured state of the immunoglobulin binding domain of streptococcal protein G by multidimensional heteronuclear NMR spectroscopy. Frank MK, et al. **Protein Sci** 1995 Dec;4(12):2605–15

Irreversible thermal denaturation of Torpedo californica acetylcholinesterase. Kreimer DI, et al. **Protein Sci** 1995 Nov;4(11):2349–57

Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Myers JK, et al. **Protein Sci** 1995 Oct;4(10):2138–48

How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.). Comment on: Structure 1995 Dec 15;3(12):1295–306.

DRUG EFFECTS

Sucrose reduces the efficiency of protein denaturation by a chaotropic agent. Taylor LS, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):39–46

Effect of antidenaturant drugs on lysozyme deposit formation on soft contact lenses by liquid chromatography--electrochemical detection. Guerrieri A, et al. **Biomaterials** 1995 Sep;16(13):1025–30

GENETICS

Glycine-15 in the bend between two alpha-helices can explain the thermostability of DNA binding protein HU from Bacillus stearothermophilus. Kawamura S, et al. **Biochemistry** 1996 Jan 30;35(4):1195–200

IMMUNOLOGY

A comparison of the immunogenicity of the native and denatured forms of a protein. Koch C, et al. **APMIS** 1996 Feb;104(2):115–25

PHYSIOLOGY

Analysis of thermal injury process based on enzyme deactivation mechanisms. Xu Y, et al. **J Biomech Eng** 1995 Nov;117(4):462–5

[The formation and development of the denaturation theory of injuries and irritation] Aleksandrov VIa. **Tsitologiia** 1995; 37(12):1101–22 (124 ref.) (Eng. Abstr.) **(Rus)**

[The functional state of denatured proteins: the principles of modelling and the first results] Bychkova VE, et al. **Tsitologiia** 1995;37(12):1238–50 (48 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

The molecular chaperone alpha-crystallin inhibits UV-induced protein aggregation. Borkman RF, et al. **Exp Eye Res** 1996 Feb;62(2):141–8

Comments on "A critical analysis of the use of radiation inactivation to measure the mass of protein" by Lidzey et al. (Radiat. Res. 143, 181–186, 1995) [letter; comment] Kempner ES. **Radiat Res** 1996 May;145(5):649–51. Comment on: Radiat Res 1995 Aug;143(2):181–6.

PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE)

DRUG EFFECTS

Age-dependent effects of t-BuOOH on glutathione disulfide reductase, glutathione peroxidase, and malondialdehyde in the brain. Chang ML, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):95–106

PROTEIN-ENERGY MALNUTRITION

Undernutrition and elderly hospital patients: a review. Tierney AJ. **J Adv Nurs** 1996 Feb;23(2):228–36 (66 ref.)

[Malnutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):297–300 (9 ref.) **(Jpn)**

BLOOD

Long-chain polyunsaturated fatty acids in children with severe protein-energy malnutrition with and without human immunodeficiency virus-1 infection. Decsi T, et al. **Am J Clin Nutr** 1995 Dec;62(6):1283–8

Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen. Seifart HI, et al. **Ann Trop Paediatr** 1995 Sep;15(3):249–54

The blood constituents of gossypol-treated, protein-malnourished Wistar rats. Nwoha PU. **Contraception** 1995 Oct;52(4):249–54

The effects of gossypol and chloroquine interaction on serum electrolytes of protein-malnourished rats. Nwoha PU, et al. **Contraception** 1995 Oct;52(4):255–9

Haematogram and serum iron status of malnourished Nigerian children. Alemnji GA, et al. **East Afr Med J** 1995 Sep;72(9):605–8

Serum iron, zinc, copper and bromine in malnourished children in Dar es Salaam, Tanzania. Chuwa LM, et al. **East Afr Med J** 1996 May;73(5 Suppl):S21–3

Prison deprivation and protein nutritional status of inmates of a developing community prison. Olubodun JO, et al. **Eur J Clin Nutr** 1996 Jan;50(1):58–60

Serum amino acids and genesis of protein energy malnutrition. Phadke MA, et al. **Indian Pediatr** 1995 Mar; 32(3):301–6

Effects of protein energy malnutrition on circulating thyroid hormones. Turkay S, et al. **Indian Pediatr** 1995 Feb; 32(2):193–7

Thyroid homeostasis and retinol circulating complex relationships in a severe iodine-deficient area of Senegal. Centanni M, et al. **J Endocrinol Invest** 1995 Sep; 18(8):608–12

Significance of very low retinol levels during severe protein-energy malnutrition. Goetghebuer T, et al. **J Trop Pediatr** 1996 Jun;42(3):158–61

[Limits of PINI (prognostic nutritional anf inflammatory index) in the evaluation of nutritional status in children] Rault JP, et al. **Med Trop (Mars)** 1995;55(4):343–6 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

A proposed revision of current ICD-9-CM malnutrition code definitions. Swails WS, et al. **J Am Diet Assoc** 1996 Apr; 96(4):370–3

COMPLICATIONS

Malnutrition in hospitalized pediatric patients. Current prevalence. Hendricks KM, et al. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1118–22

The role of nutrition in increased morbidity and mortality. Sullivan DH. **Clin Geriatr Med** 1995 Nov;11(4):661–74 (49 ref.)

Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF). Sezi CL. **East Afr Med J** 1996 May;73(5 Suppl):S24–8

Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man. Sezi CL. **East Afr Med J** 1996 May;73(5 Suppl):S11–6

Reversible brain atrophy and reversible developmental retardation in a malnourished infant. Kessel A, et al. **Isr J Med Sci** 1996 May;32(5):306–8

The malarial impact on the nutritional status of Amazonian adult subjects. Pereira PC, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):19–24

DIAGNOSIS

Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Mendenhall C, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):635–41

Lean body mass estimation by creatinine kinetics, bioimpedance, and dual energy x-ray absorptiometry in patients on continuous ambulatory peritoneal dialysis. Bhatla B, et al. **ASAIO J** 1995 Jul–Sep;41(3):M442–6

Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. Mendenhall CL, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):258–65

Nutritional status in continuous ambulatory peritoneal dialysis patients. Sheil K, et al. **Perit Dial Int** 1996;16 Suppl 1:S461–3

Nutrition-related hair signs in Zairian preschool children and associations with anthropometry. van den Biggelaar I, et al. **Trop Geogr Med** 1995;47(6):248–51

[Diagnosis and therapy of "malnutrition" risk factors (editorial)] Müller JM. **Zentralbl Chir** 1995;120(9):667–9 **(Ger)**

[Preoperative status of serum proteins in lung surgery patients] Schulz T, et al. **Zentralbl Chir** 1995;120(9):677–81 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Antimicrobial effects of granulocyte-macrophage colony-stimulating factor in protein-energy malnutrition. Hill AD, et al. **Arch Surg** 1995 Dec;130(12):1273–7; discussion 1277–8

High doses of dietary arginine during repletion impair weight gain and increase infectious mortality in protein-malnourished mice. Peck MD, et al. **Br J Nutr** 1995 Dec;74(6):787–95

The blood constituents of gossypol-treated, protein-malnourished Wistar rats. Nwoha PU. **Contraception** 1995 Oct;52(4):249–54

EMBRYOLOGY

[The morphological state of the adenohypophyseal somatotrophs during body development under conditions of protein-energy insufficiency] Medvedev DI, et al. **Aviakosm Ekolog Med** 1995;29(3):28–31 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

The role of nutrition in increased morbidity and mortality. Sullivan DH. **Clin Geriatr Med** 1995 Nov;11(4):661–74 (49 ref.)

Nutrient intake amongst adolescent girls belonging to poor socioeconomic group of rural area of Rajasthan. Chaturvedi S, et al. **Indian Pediatr** 1996 Mar;33(3):197–201

Nutritional adequacy of boys in orphanages. Khan S, et al. **Indian Pediatr** 1996 Mar;33(3):226–8

Nutritional status of children: validity of mid-upper arm circumference for screening undernutrition. Kumar R, et al. **Indian Pediatr** 1996 Mar;33(3):189–96

Validity of single-weight measurements to predict current malnutrition and mortality in children. Van den Broeck J, et al. **J Nutr** 1996 Jan;126(1):113–20

Protein energy malnutrition in the Bloemfontein area [letter] Pelser HH, et al. **S Afr Med J** 1995 Aug;85(8):790

Profile of protein energy malnutrition amongst children under four years in urban areas of Rivers State. Akaninwor JO, et al. **West Afr J Med** 1996 Jan–Mar;15(1):50–5

ETIOLOGY

Malnutrition in alcoholic and virus-related cirrhosis. Caregaro L, et al. **Am J Clin Nutr** 1996 Apr;63(4):602–9

Lean body mass estimation by creatinine kinetics, bioimpedance, and dual energy x-ray absorptiometry in patients on continuous ambulatory peritoneal dialysis. Bhatla B, et al. **ASAIO J** 1995 Jul–Sep;41(3):M442–6

Seasonal variations in energy balance among agriculturalists in central Mali: compromise or adaptation? Adams AM. **Eur J Clin Nutr** 1995 Nov;49(11):809–23

Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)

Nutritional Markers as predictors of survival in patients on CAPD. Dombros NV, et al. **Perit Dial Int** 1995;15(5 Suppl):S10–9 (66 ref.)

Nutritional status of CAPD patients at three years. Palop L, et al. **Perit Dial Int** 1996;16 Suppl 1:S195–202

GENETICS

Costello syndrome: report of an 8-month-old marasmic boy. Popa M, et al. **Genet Couns** 1996;7(1):27–30

IMMUNOLOGY

Expansion of the humoral effector cell compartment of both systemic and mucosal immune systems in a weanling murine model which duplicates critical features of human protein-energy malnutrition. Ha CL, et al. **Br J Nutr** 1996 Mar;75(3):445–60

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)

The CD4/CD8 ratio in the blood does not reflect the response of this index in secondary lymphoid organs of weanling mice in models of protein-energy malnutrition known to depress thymus-dependent immunity. Lee WH, et al. **J Nutr** 1996 Apr;126(4):849–59

The CD45RA+ (quiescent) cellular phenotype is overabundant relative to the CD45RA- phenotype within the involuted splenic T cell population of weanling mice subjected to wasting protein-energy malnutrition. Woodward BD, et al. **J Nutr** 1995 Oct;125(10):2471–82

Response of Egyptian infants with protein calorie malnutrition to hepatitis B vaccination. el-Gamal Y, et al. **J Trop Pediatr** 1996 Jun;42(3):144–5

Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)

Astounding influence of 'substance abuse', malnutrition and immune suppression on immune response to hepatitis B vaccine [letter] Arya SC. **Vaccine** 1995 Jun;13(9):879

METABOLISM

Changes in protein distribution in normal and protein-deficient rats during an acute-phase 'injury'

response. Jennings G, et al. **Br J Nutr** 1996 Jul;76(1):123–32
Impaired pancreatic bicarbonate secretion in chronic malnutrition. Keni S, et al. **Indian Pediatr** 1995 Mar; 32(3):323–9
Nutritional regulation of gene expression of insulin-like growth factor-binding proteins and the acid-labile subunit in various tissues of rats. Takenaka A, et al. **J Endocrinol** 1996 Jul;150(1):33–41
Chronic low protein intake reduces tissue protein synthesis in a pig model of protein malnutrition. Wykes LJ, et al. **J Nutr** 1996 May;126(5):1481–8
Effect of prenatal malnutrition on release of monoamines from hippocampal slices. Chen JC, et al. **Life Sci** 1995; 57(16):1467–75

MORTALITY

Why have mortality rates for severe malnutrition remained so high? Schofield C, et al. **Bull World Health Organ** 1996; 74(2):223–9 (71 ref.)
Malnutrition and mortality [editorial] Van den Broeck J. **J R Soc Med** 1995 Sep;88(9):487–90
Assumptions and contradictions in measles and measles immunization research: is measles good for something? Aaby P. **Soc Sci Med** 1995 Sep;41(5):673–86
Trends in admission and case fatality for acute malnutrition (Kingston 1982–1991). Cooper ES, et al. **West Indian Med J** 1996 Mar;45(1):22–4

PHYSIOPATHOLOGY

Anaphylactic intestinal response to milk proteins during malnutrition in guinea pigs. Darmon N, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G442–8
Effects of an every other day rapid kindling procedure in prenatally protein malnourished rats. Shultz PL, et al. **Brain Res** 1995 Jun 5;682(1–2):35–40
Embryotoxicity of methanol in well-nourished and malnourished rats. De-Carvalho RR, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2915–23
Effects of protein malnutrition on glucose tolerance in rats with alloxan-induced diabetes. de-Mello MA, et al. **Braz J Med Biol Res** 1995 Apr;28(4):467–70
Tensile strength and histological changes of abdominal aorta of malnourished rats. Yoshida WB, et al. **Cardiovasc Surg** 1995 Aug;3(4):437–9
Nutrition and the gut mucosal barrier. Deitch EA. **Curr Opin Gen Surg** 1993;:85–91 (34 ref.)
Suboptimal protein nutrition in early life later influences insulin action in pregnant rats. Holness MJ, et al. **Diabetologia** 1996 Jan;39(1):12–21
Growth hormone effects on wound healing in malnourished animals: a histological study. Zaizen Y, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):226–30
The long-term effect of low protein diet on the somatostatin hypothalamic neuronal system and the pituitary growth hormone cells in growing ewe. Polkowska J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):59–66
Lung functions in malnourished children aged five to eleven years. Faridi MM, et al. **Indian Pediatr** 1995 Jan;32(1):35–42
Mild-to-moderate malnutrition and small intestine of young rhesus monkeys. Rana S, et al. **Nutrition** 1995 May-Jun; 11(3):292–5
Body composition of children on CAPD. Stefanidis C, et al. **Perit Dial Int** 1996;16 Suppl 1:S561–6
Normalization of protein equivalent of nitrogen appearance and dialytic adequacy in CAPD. Virga G, et al. **Perit Dial Int** 1996;16 Suppl 1:S185–9
[Reduced nutritional status enhances ototoxicity] Lautermann J, et al. **Laryngorhinootologie** 1995 Dec;74(12):724–7 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Glutamine--a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897–900 (40 ref.)
Improving the nutrition of refugees and displaced people in Africa: workshop in Machakos, Kenya, 5–7 December 1994. Wallace J, et al. **Disasters** 1996 Jun;20(2):157–8
Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)

PSYCHOLOGY

Impact of chronic undernutrition on higher mental functions in Indian boys aged 10–12 years. Agarwal KN, et al. **Acta Paediatr** 1995 Dec;84(12):1357–61
Activity and behavioral development in stunted and nonstunted children and response to nutritional supplementation. Meeks Gardner J, et al. **Child Dev** 1995 Dec;66(6):1785–97
Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)
Nutrition, maternal responsiveness and mental development of Ethiopian children. Aboud FE, et al. **Soc Sci Med** 1995 Sep;41(5):725–32

RADIOGRAPHY

The computed axial tomography of the brain in protein energy malnutrition. Akinyinka OO, et al. **Ann Trop Paediatr** 1995 Dec;15(4):329–33

THERAPY

Nutrition support following liver transplantation: comparison of jejunal versus parenteral routes. Mehta PL, et al. **Clin Transplant** 1995 Oct;9(5):364–9
Nutritional support during liver failure. Gecelter GR, et al. **Crit Care Clin** 1995 Jul;11(3):675–83 (52 ref.)
Nutritional support during pulmonary failure. Pinard B, et al. **Crit Care Clin** 1995 Jul;11(3):705–15 (33 ref.)
Nutritional support in liver disease. Cabré E, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):528–32 (42 ref.)
Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. Mendenhall CL, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul-Aug;19(4):258–65
Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Balfe JW. **Perit Dial Int** 1996;16 Suppl 1:S515–6
Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)
Tube feeding in infants on peritoneal dialysis. Geary DF, et al. **Perit Dial Int** 1996;16 Suppl 1:S517–20
Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67–74 (68 ref.)
Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)
[Comparative study of arginine and glutamine supplements in malnourished surgical patients] Morais AA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep-Oct; 50(5):276–9 (Eng. Abstr.) **(Por)**

VIROLOGY

[AIDS and malnutrition in a pediatric semi-rural milieu of Ivory Coast] Mutombo T, et al. **Med Trop (Mars)** 1995; 55(4):357–9 (Eng. Abstr.) **(Fre)**

PROTEIN ENGINEERING

Molecular engineering of cholera toxin. Burnette WN, et al. **Adv Exp Med Biol** 1995;371B:1513–8 (43 ref.)
Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):191–5
Identifying the physiological electron transfer site of cytochrome c peroxidase by structure-based engineering. Miller MA, et al. **Biochemistry** 1996 Jan 23;35(3):667–73
Engineering specificity for folate into dihydrofolate reductase from Escherichia coli. Posner BA, et al. **Biochemistry** 1996 Feb 6;35(5):1653–63
Interaction of an engineered [3Fe-4S] cluster with a menaquinol binding site of Escherichia coli DMSO reductase. Rothery RA, et al. **Biochemistry** 1996 Mar 12; 35(10):3247–57
Elucidation of a MgATP signal transduction pathway in the nitrogenase iron protein: formation of a conformation resembling the MgATP-bound state by protein engineering. Ryle MJ, et al. **Biochemistry** 1996 Apr 16; 35(15):4766–75
Phospholipase A2 engineering. The roles of disulfide bonds in structure, conformational stability, and catalytic function. Zhu H, et al. **Biochemistry** 1995 Nov 21; 34(46):15307–14
Engineering the C-terminus of firefly luciferase as an indicator of covalent modification of proteins. Waud JP, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):89–98
Protein engineering. Protein biosynthesis and chemical synthesis. **Curr Opin Biotechnol** 1996 Aug;7(4):463–85
Protein engineering. **Curr Opin Biotechnol** 1995 Aug; 6(4):473–90
Web alert. Protein engineering. Baxevanis AD, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):462
Are engineered proteins getting competition from RNA? Breaker RR. **Curr Opin Biotechnol** 1996 Aug;7(4):442–8 (54 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
Engineering membrane proteins. Popot JL, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):394–402 (90 ref.)
Protein engineering as a tool for crystallography. Price SR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):425–30 (40 ref.)
Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)
Engineering and design. **Curr Opin Struct Biol** 1996 Aug; 6(4):572–81
Engineering and design. **Curr Opin Struct Biol** 1995 Aug; 5(4):557–68
Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3–10 (104 ref.)
Antibody engineering. Nilsson B. **Curr Opin Struct Biol** 1995 Aug;5(4):450–6 (77 ref.)
Phage display: protein engineering by directed evolution. O'Neil KT, et al. **Curr Opin Struct Biol** 1995 Aug; 5(4):443–9 (54 ref.)
Engineering and design of blood substitutes. Sanders KE, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):534–40 (60 ref.)
Engineering new functions and altering existing functions. Shao Z, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):513–8 (52 ref.)
Engineering of lysozyme. Imoto T. **EXS** 1996;75:163–81 (80 ref.)
Cell-surface engineering with GPI-anchored proteins. Medof ME, et al. **FASEB J** 1996 Apr;10(5):574–86 (82 ref.)
Effect of engineering Hsp70 copy number on Hsp70 expression and tolerance of ecologically relevant heat shock in larvae and pupae of Drosophila melanogaster. Feder ME, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1837–44
The structure of the transition state for folding of chymotrypsin inhibitor 2 analysed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):260–88
Extensive modifications for methionine enhancement in the beta-barrels do not alter the structural stability of the bean seed storage protein phaseolin. Dyer JM, et al. **J Protein Chem** 1995 Nov;14(8):665–78
Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)
Structure-based design of a lysozyme with altered catalytic activity [see comments] Kuroki R, et al. **Nat Struct Biol** 1995 Nov;2(11):1007–11. Comment in: Nat Struct Biol 1995 Nov;2(11):923–5.
Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro. Melekhovets YF, et al. **Nucleic Acids Res** 1996 May 15;24(10):1908–12
Modification of the substrate specificity of an acyl-acyl carrier protein thioesterase by protein engineering. Yuan L, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10639–43
The 7th annual meeting of the Protein Engineering Society of Japan. Tokyo, May 1–2, 1995. Abstracts. **Protein Eng** 1995 Sep;8(9):947–73
In search of the ideal protein sequence. Godzik A. **Protein Eng** 1995 May;8(5):409–16
In vivo system for the detection of low level activity barnase mutants. Jucovic M, et al. **Protein Eng** 1995 May;8(5):497–9
Biosynthetic incorporation of 7-azatryptophan into the phage lambda lysozyme: estimation of tryptophan accessibility, effect on enzymatic activity and protein stability. Soumillion P, et al. **Protein Eng** 1995 May;8(5):451–6
Restoration of pore-forming activity in staphylococcal alpha-hemolysin by targeted covalent modification. Walker B, et al. **Protein Eng** 1995 May;8(5):491–5
Engineering yeast alcohol dehydrogenase. Replacing Trp54 by Leu broadens substrate specificity. Weinhold EG, et al. **Protein Eng** 1995 May;8(5):457–61
Protein design: a hierarchic approach. Bryson JW, et al. **Science** 1995 Nov 10;270(5238):935–41 (107 ref.)
Minimization of a polypeptide hormone. Li B, et al. **Science** 1995 Dec 8;270(5242):1657–60
Guidelines for protein design: the energetics of beta sheet side chain interactions. Smith CK, et al. **Science** 1995 Nov 10;270(5238):980–2
Design of a monomeric 23-residue polypeptide with defined tertiary structure. Struthers MD, et al. **Science** 1996 Jan 19;271(5247):342–5
Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)
[Transfer of functional properties from bovine hemoglobin to human hemoglobin] Baudin V, et al. **Transfus Clin Biol** 1995;2(6):469–71 (Eng. Abstr.) **(Fre)**
[Nucleic acid chemistry and protein engineering] Ikehara M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1660–2 (0 ref.) **(Jpn)**
[South-Hyougo earthquake and Institute for Protein Research] Nakamura M. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1871–5 **(Jpn)**
[Study of the role of histidine residues in the function of uridine phosphorylase from Escherichia coli K-12 by protein engineering] Velko VP, et al. **Bioorg Khim** 1995 Nov;21(11):834–7 (Eng. Abstr.) **(Rus)**

METHODS

Breaking the shackles of the genetic code: engineering retroviral proteases through total chemical synthesis. Kent SB, et al. **Adv Exp Med Biol** 1995;362:425–38
Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143–58 (81 ref.)
Depletion and replacement of protein metal ligands. Barrick D. **Curr Opin Biotechnol** 1995 Aug;6(4):411–8 (59 ref.)
Designing DNA-binding proteins on the surface of filamentous phage. Choo Y, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):431–6 (23 ref.)
Sequence 'minimization': exploring the sequence landscape with simplified sequences. Clarke ND. **Curr Opin Biotechnol** 1995 Aug;6(4):467–72 (19 ref.)

New strategies in protein design. Desjarlais JR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):460–6 (52 ref.)
Metalloprotein design. Hellinga HW. **Curr Opin Biotechnol** 1996 Aug;7(4):437–41 (56 ref.)
Enhancing expression of recombinant proteins in mammalian cells using the herpesvirus VP16 transactivator. Hippenmeyer PJ, et al. **Curr Opin Biotechnol** 1995 Oct; 6(5):548–52 (15 ref.)
Interfacial metal–binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)
Protein engineering and design for drug delivery. Murphy JR. **Curr Opin Struct Biol** 1996 Aug;6(4):541–5 (25 ref.)
Engineering enzymes for stability. Shaw A, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):546–50 (45 ref.)
Lactococcal expression systems for protein engineering of nisin. Kuipers OP, et al. **Dev Biol Stand** 1995;85:605–13
A cassette vector for protein engineering the lantibiotic nisin. Dodd HM, et al. **Gene** 1995 Aug 30;162(1):163–4
Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed beta–protein IL–6 antagonist. Martin F, et al. **J Mol Biol** 1996 Jan 12;255(1):86–97
A gene replacement strategy for engineering nisin. Dodd HM, et al. **Microbiology** 1996 Jan;142 (Pt 1):47–55
A review of protein engineering for the food industry. Goodenough PW. **Mol Biotechnol** 1995 Oct;4(2):151–66 (55 ref.)
Evaluation of mass spectrometric techniques for characterization of engineered proteins. Roepstorff P, et al. **Mol Biotechnol** 1995 Aug;4(1):1–12
Synthetic human antibodies. Barbas CF 3rd. **Nat Med** 1995 Aug;1(8):837–9 (32 ref.)
De novo design and structural analysis of a model beta–hairpin peptide system. Ramírez–Alvarado M, et al. **Nat Struct Biol** 1996 Jul;3(7):604–12
Applying genetic engineering to the structural analysis of proteins. Hamilton PT. **Pharm Biotechnol** 1995;7:329–50 (102 ref.)
A highly active decarboxylating dehydrogenase with rationally inverted coenzyme specificity. Chen R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11666–70
Engineering ribonuclease A: production, purification and characterization of wild–type enzyme and mutants at Gln11. delCardayré SB, et al. **Protein Eng** 1995 Mar; 8(3):261–73
Second–generation octarellins: two new de novo (beta/alpha)8 polypeptides designed for investigating the influence of beta–residue packing on the alpha/beta–barrel structure stability. Houbrechts A, et al. **Protein Eng** 1995 Mar;8(3):249–59
Engineering disulfide–linked single–chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti–digoxin 26–10 (sFv')2 and anti–c–erbB–2 741F8 (sFv')2 made by protein folding and bonded through C–terminal cysteinyl peptides. McCartney JE, et al. **Protein Eng** 1995 Mar;8(3):301–14

PROTEIN FOLDING

see related
PROTEIN CONFORMATION

Enthalpic contribution to protein stability: insights from atom–based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231–306 (129 ref.)
Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83–229 (423 ref.)
Effect of the concentration of 8–anilinonaphthalenesulfonic acid on the detection of folding intermediates in alpha–urease. Beauregard M. **Anal Biochem** 1996 Feb 15; 234(2):233–4
A sparse matrix screen to establish initial conditions for protein renaturation. Hofmann A, et al. **Anal Biochem** 1995 Sep 1;230(1):8–15
Production of soluble tumor necrosis factor receptor type I in Escherichia coli: optimization of the refolding yields by a microtiter dilution assay. Merli S, et al. **Anal Biochem** 1995 Sep 1;230(1):85–91
Improving protein refolding yields by minimizing aggregation. Chaudhuri JB, et al. **Ann N Y Acad Sci** 1996 May 15;782:495–505
Chaperone–like effect during in vitro refolding of insulin–like growth factor I using a solubilizing fusion partner. Samuelsson E, et al. **Ann N Y Acad Sci** 1996 May 15; 782:486–94
Stability and folding of precursor and mature tryptophan–substituted ribose binding protein of Escherichia coli. Lee H, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):78–84
Reversible unfolding of Escherichia coli alkaline phosphatase: active site can be reconstituted by a number of pathways. Sarkar SN, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):174–80
Effect of nonenzymatic histone acetylation on chromatin high–order folding. Krajewski WA. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):295–9
Ascertaining the number of essential thiol groups for the folding of creatine kinase. Wang HR, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):174–80
Expression of fungal Mn peroxidase in E. coli and refolding to yield active enzyme. Whitwam RE, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1013–7
Type–III procollagen assembly in semi–intact cells: chain association, nucleation and triple–helix folding do not require formation of inter–chain disulphide bonds but triple–helix nucleation does require hydroxylation. Bulleid NJ, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):195–202
Expression of lignin peroxidase H8 in Escherichia coli: folding and activation of the recombinant enzyme with Ca2+ and haem. Doyle WA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):15–9
Modulation of the higher–order folding of chromatin by deletion of histone H3 and H4 terminal domains. Krajewski WA, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):395–400
The refolding of hen egg white riboflavin–binding protein: effect of protein disulphide isomerase on the reoxidation of the reduced protein. McClelland DA, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):133–7
Heparin binding to platelet factor–4. An NMR and site–directed mutagenesis study: arginine residues are crucial for binding. Mayo KH, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):357–65
A rapid single–step purification method for human interferon–gamma from isolated Escherichia coli inclusion bodies. Haelewyn J, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1163–71
Thermodynamic aspects of the thermal stability of human serum albumin. Picó G. **Biochem Mol Biol Int** 1995 Aug; 36(5):1017–23
Hydrophobic interaction and folding propensity of chicken heart apocytochrome c. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1177–86
Lattice models of protein folding. Brass A, et al. **Biochem Soc Trans** 1995 Nov;23(4):715–9
Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)
Probing protein structure with proteases: studies of an equilibrium intermediate in protein unfolding. Webb T, et al. **Biochem Soc Trans** 1995 Aug;23(3):477S
Folding and stability of endoglucanase III, a single–domain cellulase from Trichoderma reesei. Arunachalam U, et al. **Biochemistry** 1996 Sep 3;35(35):11379–85
Proton–translocating carboxyl of subunit c of F1Fo H(+)–ATP synthase: the unique environment suggested by the pKa determined by 1H NMR. Assadi–Porter FM, et al. **Biochemistry** 1995 Dec 12;34(49):16186–93
Structural requirements for the association of native and partially folded conformations of alpha–lactalbumin with model membranes. Bañuelos S, et al. **Biochemistry** 1996 Apr 2;35(13):3892–8
Sequential domain unfolding in phosphoglycerate kinase: fluorescence intensity and anisotropy stopped–flow kinetics of several tryptophan mutants. Beechem JM, et al. **Biochemistry** 1995 Oct 24;34(42):13943–8
Assembly of light–harvesting chlorophyll a/b complex in vitro. Time–resolved fluorescence measurements. Booth PJ, et al. **Biochemistry** 1996 Apr 23;35(16):5103–8
The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz–type inhibitor structurally homologous to BPTI. Chang JY. **Biochemistry** 1996 Sep 10; 35(36):11702–9
Folding properties of an annexin I domain: a 1H–15N NMR and CD study. Cordier–Ochsenbein F, et al. **Biochemistry** 1996 Aug 13;35(32):10347–57
Modeling unfolded states of peptides and proteins. Creamer TP, et al. **Biochemistry** 1995 Dec 19;34(50):16245–50
Thermodynamic role of the pro region of the neurophysin precursor in neurophysin folding: evidence from the effects of ligand peptides on folding. Deeb R, et al. **Biochemistry** 1996 Jan 23;35(3):864–73
Folding and unfolding kinetics of the proline–to–alanine mutants of bovine pancreatic ribonuclease A. Dodge RW, et al. **Biochemistry** 1996 Feb 6;35(5):1548–59
Changing the transition state for protein (Un) folding. Doyle DF, et al. **Biochemistry** 1996 Jun 11;35(23):7403–11
Ribonuclease A revisited: infrared spectroscopic evidence for lack of native–like secondary structures in the thermally denatured state. Fabian H, et al. **Biochemistry** 1995 Oct 17;34(41):13651–5
Crucial role of an idiosyncratic insertion in the Rossman fold of class 1 aminoacyl–tRNA synthetases: the case of methionyl–tRNA synthetase. Fourmy D, et al. **Biochemistry** 1995 Dec 5;34(48):15681–8
Folding nuclei of the scFv fragment of an antibody. Freund C, et al. **Biochemistry** 1996 Jun 25;35(25):8457–64
Testing the correlation between delta A and delta V of protein unfolding using m value mutants of staphylococcal nuclease. Frye KJ, et al. **Biochemistry** 1996 Aug 6; 35(31):10234–9
Covalent reinforcement of a fragile region in the dimeric enzyme thymidylate synthase stabilizes the protein against chaotrope–induced unfolding. Gokhale RS, et al. **Biochemistry** 1996 Jun 4;35(22):7150–8
Protein stability: urea–induced versus guanidine–induced unfolding of metmyoglobin. Gupta R, et al. **Biochemistry** 1996 Sep 10;35(36):11925–30
Structure of a hydrophobically collapsed intermediate on the conformational folding pathway of ribonuclease A probed by hydrogen–deuterium exchange. Houry WA, et al. **Biochemistry** 1996 Sep 10;35(36):11734–46
Nature of the unfolded state of ribonuclease A: effect of cis–trans X–Pro peptide bond isomerization. Houry WA, et al. **Biochemistry** 1996 Sep 10;35(36):11719–33
Circular dichroism evidence for the presence of burst–phase intermediates on the conformational folding pathway of ribonuclease A. Houry WA, et al. **Biochemistry** 1996 Aug 6;35(31):10125–33
Nature and consequences of GroEL–protein interactions. Itzhaki LS, et al. **Biochemistry** 1995 Nov 7;34(44):14581–7
Influence of primary sequence transpositions on the folding pathways of ribonuclease T1. Johnson JL, et al. **Biochemistry** 1996 Aug 6;35(31):10223–33
Nonlinear free energy relationships in Arc repressor unfolding imply the existence of unstable, native–like folding intermediates. Jonsson T, et al. **Biochemistry** 1996 Apr 16;35(15):4795–802
Intestinal fatty acid–binding protein: the structure and stability of a helix–less variant. Kim K, et al. **Biochemistry** 1996 Jun 11;35(23):7553–8
Denaturant unfolding of the ferric enterobactin receptor and ligand–induced stabilization studied by site–directed spin labeling. Klug CS, et al. **Biochemistry** 1995 Oct 31; 34(43):14230–6
The observed change in heat capacity accompanying the thermal unfolding of proteins depends on the composition of the solution and on the method employed to change the temperature of unfolding. Liu Y, et al. **Biochemistry** 1996 Mar 5;35(9):3059–62
Characterization of the slow folding reactions of trp aporepressor from Escherichia coli by mutational analysis of prolines and catalysis by a peptidyl–prolyl isomerase. Mann CJ, et al. **Biochemistry** 1995 Nov 7;34(44):14573–80
Folding, unfolding, and refolding of the vesicular stomatitis virus glycoprotein. Mathieu ME, et al. **Biochemistry** 1996 Apr 2;35(13):4084–93
Movement of the position of the transition state in protein folding. Matouschek A, et al. **Biochemistry** 1995 Oct 17; 34(41):13656–62
Induction of alpha–helix in the beta–sheet protein tumor necrosis factor–alpha: thermal– and trifluoroethanol–induced denaturation at neutral pH. Narhi LO, et al. **Biochemistry** 1996 Sep 3;35(35):11447–53
Folding topologies of human interleukin–6 and its mutants as studied by NMR spectroscopy. Nishimura C, et al. **Biochemistry** 1996 Jan 9;35(1):273–81
Nonnative capping structure initiates helix folding in an annexin I fragment. A 1H NMR conformational study. Odaert B, et al. **Biochemistry** 1995 Oct 3;34(39):12820–9
Formation of electrostatic interactions on the protein–folding pathway. Oliveberg M, et al. **Biochemistry** 1996 Feb 27; 35(8):2726–37
New approach to the study of transient protein conformations: the formation of a semiburied salt link in the folding pathway of barnase. Oliveberg M, et al. **Biochemistry** 1996 May 28;35(21):6795–805
Extensive nonrandom structure in reduced and unfolded bovine pancreatic trypsin inhibitor. Pan H, et al. **Biochemistry** 1995 Oct 31;34(43):13974–81
Role of the prodomain in folding and secretion of rat pancreatic carboxypeptidase A1. Phillips MA, et al. **Biochemistry** 1996 May 28;35(21):6771–6
Is the continuity of the domains required for the correct folding of a two–domain protein? Ritco–Vonsovici M, et al. **Biochemistry** 1995 Dec 26;34(51):16543–51
Reversible oligomerization and denaturation of the chaperonin GroES. Seale JW, et al. **Biochemistry** 1996 Apr 2;35(13):4079–83
Simulations of chaperone–assisted folding. Sfatos CD, et al. **Biochemistry** 1996 Jan 9;35(1):334–9
Reversible thermal unfolding of ribonuclease T1 in reverse micelles. Shastry MC, et al. **Biochemistry** 1996 Apr 2; 35(13):4094–101
Probing intradomain and interdomain conformational changes during equilibrium unfolding of phosphoglycerate kinase: fluorescence and circular dichroism study of tryptophan mutants. Sherman MA, et al. **Biochemistry** 1995 Oct 24;34(42):13934–42
Guanidine hydrochloride unfolding of peptide helices: separation of denaturant and salt effects. Smith JS, et al. **Biochemistry** 1996 Jun 4;35(22):7292–7
Motional dynamics of a buried tryptophan reveals the presence of partially structured forms during denaturation of barstar. Swaminathan R, et al. **Biochemistry** 1996 Jul 16;35(28):9150–7
Unfolding and refolding of Coprinus cinereus peroxidase at high pH, in urea, and at high temperature. Effect of organic and ionic additives on these processes. Tams JW, et al. **Biochemistry** 1996 Jun 11;35(23):7573–9
Importance of two buried salt bridges in the stability and folding pathway of barnase. Tissot AC, et al. **Biochemistry** 1996 May 28;35(21):6786–94
The single–ring Thermoanaerobacter brockii chaperonin 60 (Tbr–EL7) dimerizes to Tbr–EL14.Tbr–ES7 under protein folding conditions. Todd MJ, et al. **Biochemistry** 1995 Nov 14;34(45):14932–41
V92A mutation altered the folding propensity of chicken apocytochrome c and its interaction with phospholipids. Tong JC, et al. **Biochemistry** 1996 Jul 23;35(29):9460–8
Kinetically trapped structure in the renaturation of reduced oxindolealanine 62 lysozyme. Ueda T, et al. **Biochemistry** 1995 Dec 12;34(49):16178–85
Prolyl isomerase as a probe of stability of slow–folding intermediates. Veeraraghavan S, et al. **Biochemistry** 1995

Oct 3;34(39):12892–902
Autocatalyzed protein folding. Veeraraghavan S, et al. **Biochemistry** 1996 Aug 20;35(33):10601–7
Evidence for a two-state transition in the folding process of the activation domain of human procarboxypeptidase A2. Villegas V, et al. **Biochemistry** 1995 Nov 21; 34(46):15105–10
Prodomain mutations at the subtilisin interface: correlation of binding energy and the rate of catalyzed folding. Wang L, et al. **Biochemistry** 1995 Nov 28;34(47):15415–20
The equilibrium folding pathway of staphylococcal nuclease: identification of the most stable chain–chain interactions by NMR and CD spectroscopy. Wang Y, et al. **Biochemistry** 1995 Dec 12;34(49):15895–905
Roles of the propeptide and metal ions in the folding and stability of the catalytic domain of stromelysin (matrix metalloproteinase 3). Wetmore DR, et al. **Biochemistry** 1996 May 28;35(21):6549–58
Fast events in protein folding: helix melting and formation in a small peptide. Williams S, et al. **Biochemistry** 1996 Jan 23;35(3):691–7
Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism. Zhang M, et al. **Biochemistry** 1996 Jul 30;35(30):9728–36
Solution structure of bovine neutrophil beta-defensin-12: the peptide fold of the beta-defensins is identical to that of the classical defensins. Zimmermann GR, et al. **Biochemistry** 1995 Oct 17;34(41):13663–71
Probing the folding mechanism of a leucine zipper peptide by stopped-flow circular dichroism spectroscopy. Zitzewitz JA, et al. **Biochemistry** 1995 Oct 3;34(39):12812–9
High-pressure-assisted reconstitution of recombinant chloroperoxidase. Zong Q, et al. **Biochemistry** 1995 Sep 26;34(38):12420–5
Plant glyoxysomal but not mitochondrial malate dehydrogenase can fold without chaperone assistance. Gietl C, et al. **Biochim Biophys Acta** 1996 May 20; 1274(1–2):48–58
The detection of kinetic intermediates during the unfolding of lipoxygenase-1 by urea or guanidine hydrochloride. Srinivasulu S, et al. **Biochim Biophys Acta** 1996 May 23; 1294(2):115–20
Refolding of riboflavin carrier protein as probed by biochemical and immunological parameters. Velu NK, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):231–7
Expression of full-length human procathepsin L cDNA in Escherichia coli and refolding of the expression product. Dolinar M, et al. **Biol Chem Hoppe Seyler** 1995 Jun; 376(6):385–8
The enthalpy of transfer of unfolded proteins into solutions of urea and guanidinium chloride. Schellman JA, et al. **Biophys Chem** 1996 Apr 16;59(3):259–75
Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329–39 (102 ref.)
Use of fluorescence decay times of 8-ANS-protein complexes to study the conformational transitions in proteins which unfold through the molten globule state. Uversky VN, et al. **Biophys Chem** 1996 Jun 11;60(3):79–88
Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365–71 (45 ref.)
The folding and stability of titin immunoglobulin-like modules, with implications for the mechanism of elasticity. Politou AS, et al. **Biophys J** 1995 Dec;69(6):2601–10
Oxidative folding of omega-conotoxin MVIIC: effects of temperature and salt. Kubo S, et al. **Biopolymers** 1996 Jun; 38(6):733–44
Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)
Characterization of the active intermediate of a GroEL–GroES-mediated protein folding reaction. Weissman JS, et al. **Cell** 1996 Feb 9;84(3):481–90
For protein misassembly, it's the "I" decade. Wetzel R. **Cell** 1996 Sep 6;86(5):699–702 (20 ref.)
Preparation of characteristic diagram for refolding of lysozyme. Tano K, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):2027–9
Protein folds and functional similarity; the Greek key/immunoglobulin fold. Crabbe MJ, et al. **Comput Chem** 1995 Dec;19(4):343–9
Protein folding. Prolyl isomerases join the fold. Schmid FX. **Curr Biol** 1995 Sep 1;5(9):993–4 (12 ref.)
Expression of correctly folded proteins in Escherichia coli. Georgiou G, et al. **Curr Opin Biotechnol** 1996 Apr; 7(2):190–7 (40 ref.)
Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375–81 (75 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
The role of protein–solvent interactions in protein unfolding. Schiffer CA, et al. **Curr Opin Biotechnol** 1996 Aug; 7(4):428–32 (58 ref.)
Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Wall JG, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):507–16 (77 ref.)
Folding and binding. **Curr Opin Struct Biol** 1996 Feb; 6(1):101–27
Folding of beta-sheet proteins. Carlsson U, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):482–7 (51 ref.)
Molecular chaperones in protein folding and translocation. Clarke AR. **Curr Opin Struct Biol** 1996 Feb;6(1):43–50 (73 ref.)
Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3–10 (104 ref.)
Potential energy functions for threading. Jones DT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):210–6 (40 ref.)
Collapse and cooperativity in protein folding. Miranker AD, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):31–42 (80 ref.)
Protein folds in channel structure. Montal M. **Curr Opin Struct Biol** 1996 Aug;6(4):499–510 (111 ref.)
Protein folding and association: in vitro studies for self-organization and targeting in the cell. Jaenicke R. **Curr Top Cell Regul** 1996;34:209–314 (520 ref.)
Preferential binding of an unfolded protein to DsbA. Frech C, et al. **EMBO J** 1996 Jan 15;15(2):392–98
The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. Freeman BC, et al. **EMBO J** 1996 Jun 17;15(12):2969–79
Competition between folding and glycosylation in the endoplasmic reticulum. Holst B, et al. **EMBO J** 1996 Jul 15;15(14):3538–46
Trigger factor is involved in GroEL-dependent protein degradation in Escherichia coli and promotes binding of GroEL to unfolded proteins. Kandror O, et al. **EMBO J** 1995 Dec 1;14(23):6021–7
The molecular basis for the recognition of misfolded glycoproteins by the UDP-Glc:glycoprotein glucosyltransferase. Sousa M, et al. **EMBO J** 1995 Sep 1; 14(17):4196–203
A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. Stoller G, et al. **EMBO J** 1995 Oct 16;14(20):4939–48
Refolding pathway and association intermediates of glutamate dehydrogenase from the hyperthermophile Pyrococcus furiosus. Consalvi V, et al. **Eur J Biochem** 1996 Aug 1;239(3):679–85
In vitro folding of Escherichia coli outer-membrane phospholipase A. Dekker N, et al. **Eur J Biochem** 1995 Aug 15;232(1):214–9
Template-directed protein folding into a metastable state of increased activity. Flecker P. **Eur J Biochem** 1995 Sep 1; 232(2):528–35
Folding and activation of human procathepsin S from inclusion bodies produced in Escherichia coli. Kopitar G, et al. **Eur J Biochem** 1996 Mar 1;236(2):558–62
The effect of pH on the folding and stability of the myosin rod. Ozog A, et al. **Eur J Biochem** 1995 Dec 1;234(2):501–5
Effect of cross-linking on the chaperone-like function of alpha crystallin. Sharma KK, et al. **Exp Eye Res** 1995 Oct; 61(4):413–21
Folding of lysozyme. Fischer B. **EXS** 1996;75:143–61 (59 ref.)
Second-site reversion of a structural defect in bacteriophage T4 lysozyme. Bouvier SE, et al. **FASEB J** 1996 Jan; 10(1):159–63
Supervising the fold: functional principles of molecular chaperones. Buchner J. **FASEB J** 1996 Jan;10(1):10–9 (73 ref.)
Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)
The roles of partly folded intermediates in protein folding. Creighton TE, et al. **FASEB J** 1996 Jan;10(1):110–8 (55 ref.)
Protein folding in the cell: competing models of chaperonin function. Ellis RJ, et al. **FASEB J** 1996 Jan;10(1):20–6 (43 ref.)
Assigning amino acid sequences to 3-dimensional protein folds. Fischer D, et al. **FASEB J** 1996 Jan;10(1):126–36 (54 ref.)
Unproductive folding of the human G6PD-deficient variant A-. Gómez-Gallego F, et al. **FASEB J** 1996 Jan; 10(1):153–8
The role of molecular chaperones in protein folding. Hendrick JP, et al. **FASEB J** 1995 Dec;9(15):1559–69 (76 ref.)
Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles. Jaenicke R. **FASEB J** 1996 Jan;10(1):84–92 (50 ref.)
Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. **FASEB J** 1996 Jan;10(1):57–66 (63 ref.)
The molten globule state of alpha-lactalbumin. Kuwajima K. **FASEB J** 1996 Jan;10(1):102–9 (103 ref.)
Protein folding by a biased Monte Carlo procedure in the dihedral angle space. Lee B, et al. **FASEB J** 1996 Jan; 10(1):119–25 (43 ref.)
A quantitative assessment of the role of the chaperonin proteins in protein folding in vivo. Lorimer GH. **FASEB J** 1996 Jan;10(1):5–9 (43 ref.)
Structural and genetic analysis of the folding and function of T4 lysozyme. Matthews BW. **FASEB J** 1996 Jan; 10(1):35–41 (29 ref.)
Protein fold recognition by sequence threading: tools and assessment techniques. Miller RT, et al. **FASEB J** 1996 Jan;10(1):171–8
Investigation of protein folding by mass spectrometry. Miranker A, et al. **FASEB J** 1996 Jan;10(1):93–101 (47 ref.)
From protein coagulation and reversible denaturation to the protein folding problem: Chris Anfinsen defining the transition. Moudrianakis EN. **FASEB J** 1996 Jan; 10(1):179–83
Forces contributing to the conformational stability of proteins. Pace CN, et al. **FASEB J** 1996 Jan;10(1):75–83 (52 ref.)
A determinable but unresolved problem. Ptitsyn OB. **FASEB J** 1996 Jan;10(1):3–4 (34 ref.)
In vitro folding of inclusion body proteins. Rudolph R, et al. **FASEB J** 1996 Jan;10(1):49–56 (80 ref.)
Sequence determinants of folding and stability for the P22 Arc repressor dimer. Sauer RT, et al. **FASEB J** 1996 Jan; 10(1):42–8 (21 ref.)
The denatured state (the other half of the folding equation) and its role in protein stability. Shortle D. **FASEB J** 1996 Jan;10(1):27–34 (39 ref.)
In vivo protein folding: suppressor analysis of mutations in the groES cochaperone gene of Escherichia coli. Zeilstra-Ryalls J, et al. **FASEB J** 1996 Jan;10(1):148–52
Detection of alpha/beta-hydrolase fold in the cell surface esterases of Acinetobacter species using an analysis of 3D profiles. Alon RN, et al. **FEBS Lett** 1995 Sep 11; 371(3):231–5
The protein fold of the hyaluronate-binding proteoglycan tandem repeat domain of link protein, aggrecan and CD44 is similar to that of the C-type lectin superfamily. Brissett NC, et al. **FEBS Lett** 1996 Jun 17;388(2–3):211–6
Expression and folding of an interleukin-2–proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence. Castellanos-Serra LR, et al. **FEBS Lett** 1996 Jan 8;378(2):171–6
Salt-stabilized globular protein structure in 7 M aqueous urea solution. Dötsch V, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):288–90
Linguistic analysis of protein folding. Gross M. **FEBS Lett** 1996 Jul 29;390(3):249–52
Protein disulfide isomerase mutant lacking its isomerase activity accelerates protein folding in the cell. Hayano T, et al. **FEBS Lett** 1995 Dec 27;377(3):505–11
Mechanical unfolding of alpha2-macroglobulin molecules with atomic force microscope. Mitsui K, et al. **FEBS Lett** 1996 Apr 29;385(1–2):29–33
Partially folded structure of monomeric bovine beta-lactoglobulin. Molinari H, et al. **FEBS Lett** 1996 Mar 4;381(3):237–43
Modification of a specific tyrosine enables tracing of the end-to-end distance during apomyoglobin folding. Rischel C, et al. **FEBS Lett** 1995 Oct 23;374(1):105–9
Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. Stubbs MT, et al. **FEBS Lett** 1995 Nov 13;375(1–2):103–7
Classification of multi-helical DNA-binding domains and application to predict the DBD structures of sigma factor, LysR, OmpR/PhoB, CENP-B, RapI, and Xy1S/Ada/AraC. Suzuki M, et al. **FEBS Lett** 1995 Sep 25;372(2–3):215–21
Differential effects of molecular chaperones on refolding of homologous proteins. Widmann M, et al. **FEBS Lett** 1995 Dec 27;377(3):481–4
Protein folding: from basic science to biotechnology. Miller WT, et al. **Genet Anal** 1996 Mar;12(5–6):169–72
Calnexin leads glycoproteins into the fold [letter] Williams DB. **Glycoconj J** 1995 Jun;12(3):iii–iv
Mutation in the carboxy-terminal propeptide of the Pro alpha 1(I) chain of type I collagen in a child with severe osteogenesis imperfecta (OI type III): possible implications for protein folding. Oliver JE, et al. **Hum Mutat** 1996; 7(4):318–26
The liquid amide transfer model and the unfolding thermodynamics of small globular proteins. Barone G, et al. **Int J Biol Macromol** 1995 Oct;17(5):251–7
An intelligent system for comparing protein structures. Benatan E. **Ismb** 1994;2:37–43
Predicting free energy contributions to the conformational stability of folded proteins from the residue sequence with radial basis function networks. Casadio R, et al. **Ismb** 1995; 3:81–8
Protein topology prediction through parallel constraint logic programming. Clark DA, et al. **Ismb** 1993;1:83–91
Predicting protein folding classes without overly relying on homology. Craven MW, et al. **Ismb** 1995;3:98–106
Comparison of two variations of neural network approach to the prediction of protein folding pattern. Dubchak I, et al. **Ismb** 1993;1:118–26
Inductive logic programming used to discover topological constraints in protein structures. King RD, et al. **Ismb** 1994; 2:219–26
Relation between protein structure, sequence homology and composition of amino acids. Mayoraz E, et al. **Ismb** 1995; 3:240–8
The Multi-Scale 3D–1D compatibility scoring for inverse protein folding problem. Onizuka K, et al. **Ismb** 1994; 2:314–21
Towards an intelligent system for the automatic assignment of domains in globular proteins. Sternberg MJ, et al. **Ismb** 1995;3:376–83
SurA assists the folding of Escherichia coli outer membrane proteins. Lazar SW, et al. **J Bacteriol** 1996 Mar; 178(6):1770–3

Importance of the E-46-D-160 polypeptide segment of the non-penicillin-binding module for the folding of the low-affinity, multimodular class B penicillin-binding protein 5 of Enterococus hirae. Mollerach ME, et al. **J Bacteriol** 1996 Mar;178(6):1774–5

Osmotic pressure method to measure salt induced folding/unfolding of bovine serum albumin. Zimmerman RJ, et al. **J Biochem Biophys Methods** 1995 Jun; 30(2–3):113–31

Malfolded cytochrome P-450(M1) localized in unusual membrane structures of the endoplasmic reticulum in cultured animal cells. Ishihara N, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):397–404

Purification and refolding of recombinant human proMMP-7 (pro-matrilysin) expressed in Escherichia coli and its characterization. Itoh M, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):667–73

Acid-induced folding of yeast alcohol dehydrogenase under low pH conditions. Le WP, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):674–9

Correlation between the differences in the free energy change and conformational energy in the folded state of hen lysozymes with Gly-Pro and Pro-Gly sequences introduced to the same site. Motoshima H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1138–44

Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence. Boffa LC, et al. **J Biol Chem** 1996 May 31;271(22):13228–33

Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein. Bu G, et al. **J Biol Chem** 1996 Sep 6;271(36):22218–24

Structural studies on folding intermediates of serine hydroxymethyltransferase using single tryptophan mutants. Cai K, et al. **J Biol Chem** 1996 Feb 9;271(6):2987–94

The properties of scrambled hirudins. Chang JY. **J Biol Chem** 1995 Oct 27;270(43):25661–6

A novel function of Escherichia coli chaperone DnaJ. Protein-disulfide isomerase. de Crouy-Chanel A, et al. **J Biol Chem** 1995 Sep 29;270(39):22669–72

Increased efficiency of GroE-assisted protein folding by manganese ions. Diamant S, et al. **J Biol Chem** 1995 Nov 24;270(47):28387–91

Folding-related dimerization of human cystatin C. Ekiel I, et al. **J Biol Chem** 1996 Jan 19;271(3):1314–21

Core histone tail domains mediate oligonucleosome folding and nucleosomal DNA organization through distinct molecular mechanisms. Fletcher TM, et al. **J Biol Chem** 1995 Oct 27;270(43):25359–62

Arrest of subunit folding and assembly of nicotinic acetylcholine receptors in cultured muscle cells by dithiothreitol. Gelman MS, et al. **J Biol Chem** 1996 May 3;271(18):10709–14

Refolding and oxidation of recombinant human stem cell factor produced in Escherichia coli. Jones MD, et al. **J Biol Chem** 1996 May 10;271(19):11301–8

Functional analysis of the propeptide of subtilisin E as an intramolecular chaperone for protein folding. Refolding and inhibitory abilities of propeptide mutants. Li Y, et al. **J Biol Chem** 1995 Oct 20;270(42):25127–32

Requirement for the carboxyl-terminal domain of Saccharomyces cerevisiae carbamoyl-phosphate synthetase. Lim AL, et al. **J Biol Chem** 1996 May 10; 271(19):11400–9

Biochemical characterization of symmetric GroEL-GroES complexes. Evidence for a role in protein folding. Llorca O, et al. **J Biol Chem** 1996 Jan 5;271(1):68–76

Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. Loo TW, et al. **J Biol Chem** 1995 Sep 29;270(39):22957–61

The histone folds in transcription factor TFIID. Nakatani Y, et al. **J Biol Chem** 1996 Mar 22;271(12):6575–8

Occurrence of transient multimeric species during the refolding of a monomeric protein. Pecorari F, et al. **J Biol Chem** 1996 Mar 1;271(9):5270–6

Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. Qu BH, et al. **J Biol Chem** 1996 Mar 29;271(13):7261–4

Refolding of denatured and denatured/reduced lysozyme at high concentrations. Raman B, et al. **J Biol Chem** 1996 Jul 19;271(29):17067–72

GroEL binds to and unfolds rhodanese posttranslationally. Reid BG, et al. **J Biol Chem** 1996 Mar 22;271(12):7212–7

Examining rhodopsin folding and assembly through expression of polypeptide fragments. Ridge KD, et al. **J Biol Chem** 1996 Mar 29;271(13):7860–7

Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization. Riikonen A, et al. **J Biol Chem** 1996 Aug 30; 271(35):21340–4

Artificial chaperone-assisted refolding of carbonic anhydrase B. Rozema D, et al. **J Biol Chem** 1996 Feb 16; 271(7):3478–87

Biogenesis of mitochondrial heme lyases in yeast. Import and folding in the intermembrane space. Steiner H, et al. **J Biol Chem** 1995 Sep 29;270(39):22842–9

Kinetics of folding and membrane insertion of a beta-barrel membrane protein. Surrey T, et al. **J Biol Chem** 1995 Nov 24;270(47):28199–203

Protein misfolding and inclusion body formation in recombinant Escherichia coli cells overexpressing Heat-shock proteins. Thomas JG, et al. **J Biol Chem** 1996 May 10;271(19):11141–7

Quasi-native chaperonin-bound intermediates in facilitated protein folding. Tian G, et al. **J Biol Chem** 1995 Oct 13; 270(41):23910–3

Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes. Walker D, et al. **J Biol Chem** 1996 Feb 23;271(8):4082–5

Posttranslational folding of alpha 1-inhibitor 3. Evidence for a compaction process. Wassler M, et al. **J Biol Chem** 1995 Oct 13;270(41):24598–603

The unfolded protein response pathway in Saccharomyces cerevisiae. Oligomerization and trans-phosphorylation of Ire1p (Ern1p) are required for kinase activation. Welihinda AA, et al. **J Biol Chem** 1996 Jul 26;271(30):18181–7

Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. Zhuang P, et al. **J Biol Chem** 1996 Jun 14;271(24):14323–32

Characterization of the denaturation and renaturation of human plasma vitronectin. II. Investigation into the mechanism of formation of multimers. Zhuang P, et al. **J Biol Chem** 1996 Jun 14;271(24):14333–43

Expression of lysyl oxidase from cDNA constructs in mammalian cells: the propeptide region is not essential to the folding and secretion of the functional enzyme. Kagan HM, et al. **J Cell Biochem** 1995 Nov;59(3):329–38

Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1–2):1–4 (32 ref.)

Fast protein folding in the hydrophobic-hydrophilic model within three-eighths of optimal. Hart WE, et al. **J Comput Biol** 1996 Spring;3(1):53–96

Co-expression of the Epstein-Barr virus BXLF2 and BKRF2 genes with a recombinant baculovirus produces gp85 on the cell surface with antigenic similarity to the native protein. Pulford DJ, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3145–52

Impact of local and non-local interactions on thermodynamics and kinetics of protein folding. Abkevich VI, et al. **J Mol Biol** 1995 Sep 29;252(4):460–71

A comparison of the pH, urea, and temperature-denatured states of barnase by heteronuclear NMR: implications for the initiation of protein folding. Arcus VL, et al. **J Mol Biol** 1995 Nov 24;254(2):305–21

Insight into a random coil conformation and an isolated helix: structural and dynamical characterisation of the C-helix peptide from hen lysozyme. Bolin KA, et al. **J Mol Biol** 1996 Aug 23;261(3):443–53

Substrate shuttling between the DnaK and GroEL systems indicates a chaperone network promoting protein folding. Buchberger A, et al. **J Mol Biol** 1996 Aug 23;261(3):328–33

High-resolution structure of the catalytic domain of avian sarcoma virus integrase. Bujacz G, et al. **J Mol Biol** 1995 Oct 20;253(2):333–46

Implications of N and C-terminal proximity for protein folding. Christopher JA, et al. **J Mol Biol** 1996 Mar 22; 257(1):175–87

Easily searched protein folding potentials. Crippen GM. **J Mol Biol** 1996 Jul 19;260(3):467–75

Structure of the transition state for folding of a protein derived from experiment and simulation. Daggett V, et al. **J Mol Biol** 1996 Mar 29;257(2):430–40

Identifying the tertiary fold of small proteins with different topologies from sequence and secondary structure using the genetic algorithm and extended criteria specific for strand regions. Dandekar T, et al. **J Mol Biol** 1996 Mar 1;256(3):645–60

Conformational pathway of the polypeptide chain of chymotrypsin inhibitor-2 growing from its N terminus in vitro. Parallels with the protein folding pathway. de Prat Gay G, et al. **J Mol Biol** 1995 Dec 15;254(5):968–79

Partially folded states of proteins: characterization by X-ray scattering. Doniach S, et al. **J Mol Biol** 1995 Dec 15; 254(5):960–7

Assessment of protein fold predictions from sequence information: the predicted alpha/beta doubly wound fold of the von Willebrand factor type A domain is similar to its crystal structure. Edwards YJ, et al. **J Mol Biol** 1996 Jul 12;260(2):277–85

Reversible association of the equilibrium unfolding intermediate of lambda Cro repressor. Filimonov VV, et al. **J Mol Biol** 1996 Feb 9;255(5):767–77

Stability changes upon mutation of solvent-accessible residues in proteins evaluated by database-derived potentials. Gilis D, et al. **J Mol Biol** 1996 Apr 19; 257(5):1112–26

Disordered C-terminal domain of tyrosyl transfer-RNA synthetase: evidence for a folded state. Guez-Ivanier V, et al. **J Mol Biol** 1996 Jan 12;255(1):110–20

Native and non-native structure in a protein-folding intermediate: spectroscopic studies of partially reduced IGF-I and an engineered alanine model. Hua QX, et al. **J Mol Biol** 1996 Jun 7;259(2):297–313

Recognizing native folds by the arrangement of hydrophobic and polar residues. Huang ES, et al. **J Mol Biol** 1995 Oct 6;252(5):709–20

The structure of the transition state for folding of chymotrypsin inhibitor 2 analysed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):260–88

Search for nucleation sites in smaller fragments of chymotrypsin inhibitor 2. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):289–304

Calcium binding properties of an epidermal growth factor-like domain pair from human fibrillin-1. Knott V, et al. **J Mol Biol** 1996 Jan 12;255(1):22–7

Comparison of the (30–51, 14–38) two-disulphide folding intermediates of the homologous proteins dendrotoxin K and bovine pancreatic trypsin inhibitor by two-dimensional 1H nuclear magnetic resonance. Kortemme T, et al. **J Mol Biol** 1996 Mar 22;257(1):188–98

The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. Maurer P, et al. **J Mol Biol** 1995 Oct 20;253(2):347–57

Residue-residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. Miyazawa S, et al. **J Mol Biol** 1996 Mar 1;256(3):623–44

Energy functions that discriminate X-ray and near native folds from well-constructed decoys. Park B, et al. **J Mol Biol** 1996 May 3;258(2):367–92

An integrated kinetic analysis of intermediates and transition states in protein folding reactions. Parker MJ, et al. **J Mol Biol** 1995 Nov 10;253(5):771–86

Intermediate states in protein folding. Privalov PL. **J Mol Biol** 1996 May 24;258(5):707–25 (122 ref.)

Evidence for coupling of folding and function in trp repressor: physical characterization of the superrepressor mutant AV77. Reedstrom RJ, et al. **J Mol Biol** 1995 Oct 20;253(2):266–76

Time-resolved fluorescence studies of the molten globule state of apomyoglobin. Rischel C, et al. **J Mol Biol** 1996 Apr 12;257(4):877–85

Protein fold recognition by mapping predicted secondary structures. Russell RB, et al. **J Mol Biol** 1996 Jun 14; 259(3):349–65

Proline in a transmembrane helix compensates for cavities in the photosynthetic reaction center. Schiffer M, et al. **J Mol Biol** 1995 Sep 29;252(4):472–82

Three-dimensional structures of free form and two substrate complexes of an extradiol ring-cleavage type dioxygenase, the BphC enzyme from Pseudomonas sp. strain KKS102. Senda T, et al. **J Mol Biol** 1996 Feb 9;255(5):735–52

Effect of folding on the export of ribose-binding protein studied with the genetically isolated suppressors for the signal sequence mutation. Song T, et al. **J Mol Biol** 1995 Oct 20;253(2):304–12

Dynamics of the GroEL-protein complex: effects of nucleotides and folding mutants. Sparrer H, et al. **J Mol Biol** 1996 Apr 26;258(1):74–87

Local interactions dominate folding in a simple protein model. Unger R, et al. **J Mol Biol** 1996 Jun 28; 259(5):988–94

Further evidence on the equilibrium "pre-molten globule state": four-state guanidinium chloride-induced unfolding of carbonic anhydrase B at low temperature. Uversky VN, et al. **J Mol Biol** 1996 Jan 12;255(1):215–28

Vibrational Raman optical activity of alpha-lactalbumin: comparison with lysozyme, and evidence for native tertiary folds in molten globule states. Wilson G, et al. **J Mol Biol** 1995 Dec 8;254(4):747–60

The native-like tertiary fold in molten globule alpha-lactalbumin appears to be controlled by a continuous phase transition. Wilson G, et al. **J Mol Biol** 1996 Aug 23;261(3):341–7

Cold denaturation of barstar: 1H, 15N and 13C NMR assignment and characterisation of residual structure. Wong KB, et al. **J Mol Biol** 1996 Jun 21;259(4):805–18

Radial mass analysis of the flagellar filament of Salmonella: implications for the subunit folding. Yamashita I, et al. **J Mol Biol** 1995 Nov 3;253(4):547–58

Free energy determinants of secondary structure formation: III. beta-turns and their role in protein folding. Yang AS, et al. **J Mol Biol** 1996 Jun 21;259(4):873–82

Simulating the folding of small proteins by use of the local minimum energy and the free solvation energy yields native-like structures. Brasseur R. **J Mol Graph** 1995 Oct; 13(5):312–22

Systematic representation of protein folding patterns. Lesk AM. **J Mol Graph** 1995 Jun;13(3):159–64

Refolding of trypsin-subtilisin inhibitor from marine turtle eggwhite. Chaudhuri TK, et al. **J Protein Chem** 1996 Apr; 15(3):315–20

Inactivation and unfolding of aminoacylase during denaturation in sodium dodecyl sulfate solutions. He B, et al. **J Protein Chem** 1995 Jul;14(5):349–57

An eigenvalue-eigenvector approach to predicting protein folding types. Zhang CT, et al. **J Protein Chem** 1995 Jul; 14(5):309–26

An analysis of protein folding type prediction by seed-propagated sampling and jackknife test. Zhang CT, et al. **J Protein Chem** 1995 Oct;14(7):583–93

Modelling the optimal simulation path in the peptide chain folding—studies based on geometry of alanine heptapeptide. Roterman I. **J Theor Biol** 1995 Dec 7; 177(3):283–8

Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding. Billstrom MA, et al.

J Virol 1995 Nov;69(11):7015–22
Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. Dubuisson J, et al. J Virol 1996 Feb;70(2):778–86
Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. Otteken A, et al. J Virol 1996 Jun;70(6):3407–15
Calnexin acts as a molecular chaperone during the folding of glycoprotein B of human cytomegalovirus. Yamashita Y, et al. J Virol 1996 Apr;70(4):2237–46
Understanding protein structure: using scop for fold interpretation. Brenner SE, et al. Methods Enzymol 1996; 266:635–43
Use of multiple spectroscopic methods to monitor equilibrium unfolding of proteins. Eftink MR. Methods Enzymol 1995; 259:487–512
Thermal denaturation methods in the study of protein folding. Freire E. Methods Enzymol 1995;259:144–68
Alignment of three-dimensional protein structures: network server for database searching. Holm L, et al. Methods Enzymol 1996;266:653–62
Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Johnson MS, et al. Methods Enzymol 1996;266:575–98
Evaluating contribution of hydrogen bonding and hydrophobic bonding to protein folding. Pace CN. Methods Enzymol 1995;259:538–54
Iterative template refinement: protein–fold prediction using iterative search and hybrid sequence/structure templates. Yi TM, et al. Methods Enzymol 1996;266:322–39
Transient, lectin–like association of calreticulin with folding intermediates of cellular and viral glycoproteins. Peterson JR, et al. Mol Biol Cell 1995 Sep;6(9):1173–84
Correct disulfide pairing and efficient refolding of detergent–solubilized single–chain Fv proteins from bacterial inclusion bodies. Kurucz I, et al. Mol Immunol 1995 Dec;32(17–18):1443–52
Pro–sequence–assisted protein folding. Eder J, et al. Mol Microbiol 1995 May;16(4):609–14 (59 ref.)
Characterization of an Escherichia coli rotA mutant, affected in periplasmic peptidyl–prolyl cis/trans isomerase. Kleerebezem M, et al. Mol Microbiol 1995 Oct;18(2):313–20
The antisense homology box: a new motif within proteins that encodes biologically active peptides [see comments] Baranyi L, et al. Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Sep;1(9):876–8. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
Genetic origins of protein shape and interaction rules [comment] [see comments] Blalock JE. Nat Med 1995 Sep; 1(9):876–8 (20 ref.). Comment on: Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
...but not to protein folding? [letter; comment] Kierzek A, et al. Nat Med 1995 Dec;1(12):1222–3. Comment on: Nat Med 1995 Sep;1(9):876–8. Comment on: Nat Med 1995 Sep;1(9):894–901.
Picture story. Bundled up against the heat. Nat Struct Biol 1996 Mar;3(3):221
Mapping the lipid–exposed surfaces of membrane proteins. Arkin IT, et al. Nat Struct Biol 1996 Mar;3(3):240–3
Following protein folding in real time using NMR spectroscopy [see comments] Balbach J, et al. Nat Struct Biol 1995 Oct;2(10):865–70. Comment in: Nat Struct Biol 1995 Oct;2(10):817–20.
Detection of rare partially folded molecules in equilibrium with the native conformation of RNaseH. Chamberlain AK, et al. Nat Struct Biol 1996 Sep;3(9):782–7
A third native one–disulphide intermediate in the folding of bovine pancreatic trypsin inhibitor. Dadlez M, et al. Nat Struct Biol 1995 Aug;2(8):674–9
Cooperatively folded proteins in random sequence libraries. Davidson AR, et al. Nat Struct Biol 1995 Oct;2(10):856–64
Closure of a tyrosine/tryptophan aromatic gate leads to a compact fold in apo flavodoxin [letter] Genzor CG, et al. Nat Struct Biol 1996 Apr;3(4):329–32
Gathering them in to the fold. Hubbard TJ, et al. Nat Struct Biol 1996 Apr;3(4):313
Refolding and unfolding kinetics of the equilibrium folding intermediate of apomyoglobin. Jamin M, et al. Nat Struct Biol 1996 Jul;3(7):613–8
Breathing life into the folding pathway of cytochrome c [news] Kallenbach NR. Nat Struct Biol 1995 Oct; 2(10):813–6
Packing interactions in the apomyoglobin folding intermediate. Kay MS, et al. Nat Struct Biol 1996 May;3(5):439–45
Evidence for a three–state model of protein folding from kinetic analysis of ubiquitin variants with altered core residues. Khorasanizadeh S, et al. Nat Struct Biol 1996 Feb; 3(2):193–205
The dimeric DNA binding domain of the human papillomavirus E2 protein folds through a monomeric intermediate which cannot be native–like. Mok YK, et al. Nat Struct Biol 1996 Aug;3(8):711–7
How molten is the molten globule?[news] Ptitsyn O. Nat Struct Biol 1996 Jun;3(6):488–90
Watching protein folding unfold [news; comment] Roder H. Nat Struct Biol 1995 Oct;2(10):817–20. Comment on: Nat Struct Biol 1995 Oct;2(10):865–70.
A novel mode of carbohydrate recognition in jacalin, a Moraceae plant lectin with a beta–prism fold. Sankaranarayanan R, et al. Nat Struct Biol 1996 Jul; 3(7):596–603
Extremely rapid protein folding in the absence of intermediates. Schindler T, et al. Nat Struct Biol 1995 Aug; 2(8):663–73
Proline scanning mutagenesis of a molten globule reveals non–cooperative formation of a protein's overall topology. Schulman BA, et al. Nat Struct Biol 1996 Aug;3(8):682–7
A short linear peptide derived from the N–terminal sequence of ubiquitin folds into a water–stable non–native beta–hairpin. Searle MS, et al. Nat Struct Biol 1995 Nov; 2(11):999–1006
Initial hydrophobic collapse in the folding of barstar. Agashe VR, et al. Nature 1995 Oct 26;377(6551):754–7
Release of both native and non–native proteins from a cis–only GroEL ternary complex. Burston SG, et al. Nature 1996 Sep 5;383(6595):96–9
Molecular chaperones in cellular protein folding. Hartl FU. Nature 1996 Jun 13;381(6583):571–9 (154 ref.)
Protein folding in the central cavity of the GroEL–GroES chaperonin complex. Mayhew M, et al. Nature 1996 Feb 1;379(6564):420–6
Unique fold and active site in cytomegalovirus protease. Qiu X, et al. Nature 1996 Sep 19;383(6597):275–9
Conserved residues and the mechanism of protein folding. Shakhnovich E, et al. Nature 1996 Jan 4;379(6560):96–8
A new serine–protease fold revealed by the crystal structure of human cytomegalovirus protease. Tong L, et al. Nature 1996 Sep 19;383(6597):272–5
The FSSP database: fold classification based on structure–structure alignment of proteins. Holm L, et al. Nucleic Acids Res 1996 Jan 1;24(1):206–9
(S)–C alpha–ethyl, C alpha–benzylglycine [(S)–(alpha Et)Phe] peptides fold in left–handed helical structures. Doi M, et al. Pept Res 1995 Sep–Oct;8(5):294–7
How the first biopolymers could have evolved. Abkevich VI, et al. Proc Natl Acad Sci U S A 1996 Jan 23; 93(2):839–44
The protein–folding activity of chaperonins correlates with the symmetric GroEL14(GroES7)2 heterooligomer. Azem A, et al. Proc Natl Acad Sci U S A 1995 Dec 19; 92(26):12021–5
Why is protein folding so fast? [comment] Baldwin RL. Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2627–8. Comment on: Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2629–34.
Direct observation of fast protein folding: the initial collapse of apomyoglobin. Ballew RM, et al. Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5759–64
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Blagosklonny MV, et al. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8379–83
Reactivation of denatured proteins by 23S ribosomal RNA: role of domain V. Chattopadhyay S, et al. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8284–7
A soluble domain of the membrane–anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low–pH–induced conformation. Chen J, et al. Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12205–9
Toward a mechanism for GroEL.GroES chaperone activity: an ATPase–gated and –pulsed folding and annealing cage. Corrales FJ, et al. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4509–12
The folding mechanism of larger model proteins: role of native structure. Dinner AR, et al. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8356–61
Prediction of protein folding class using global description of amino acid sequence. Dubchak I, et al. Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8700–4
On constructing folding heteropolymers. Ebeling M, et al. Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8798–802
Optimization of rates of protein folding: the nucleation–condensation mechanism and its implications. Fersht AR. Proc Natl Acad Sci U S A 1995 Nov 21; 92(24):10869–73
Conformations and folding of lysozyme ions in vacuo. Gross DS, et al. Proc Natl Acad Sci U S A 1996 Apr 2; 93(7):3143–8
How optimization of potential functions affects protein folding. Hao MH, et al. Proc Natl Acad Sci U S A 1996 May 14;93(10):4984–9
Inhibition of immunoglobulin folding and secretion by dominant negative BiP ATPase mutants. Hendershot L, et al. Proc Natl Acad Sci U S A 1996 May 28;93(11):5269–74
Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases. Henrissat B, et al. Proc Natl Acad Sci U S A 1996 May 28;93(11):5674
Swiveling–domain mechanism for enzymatic phosphotransfer between remote reaction sites. Herzberg O, et al. Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2652–7
Stopped–flow NMR spectroscopy: real–time unfolding studies of 6–19F–tryptophan–labeled Escherichia coli dihydrofolate reductase. Hoeltzli SD, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9318–22
Kinetic traps in lysozyme folding. Kiefhaber T. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9029–33
Crystal structure of the large fragment of Thermus aquaticus DNA polymerase I at 2.5–A resolution: structural basis for thermostability. Korolev S, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9264–8
Effects of inefficient cleavage of the signal sequence of HIV–1 gp 120 on its association with calnexin, folding, and intracellular transport. Li Y, et al. Proc Natl Acad Sci U S A 1996 Sep 3;93(18):9606–11
Submillisecond events in protein folding. Nölting B, et al. Proc Natl Acad Sci U S A 1995 Nov 7;92(23):10668–72
Negative activation enthalpies in the kinetics of protein folding. Oliveberg M, et al. Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8926–9
Foldons, protein structural modules, and exons. Panchenko AR, et al. Proc Natl Acad Sci U S A 1996 Mar 5; 93(5):2008–13
Lattice model for rapidly folding protein–like heteropolymers. Shrivastava I, et al. Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9206–9
Least activation path for protein folding: investigation of staphylococcal nuclease folding by stopped–flow circular dichroism. Su ZD, et al. Proc Natl Acad Sci U S A 1996 Mar 19;93(6):2539–44
Chaperonin–facilitated protein folding: optimization of rate and yield by an iterative annealing mechanism. Todd MJ, et al. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4030–5
Barriers to protein folding: formation of buried polar interactions is a slow step in acquisition of structure [see comments] Waldburger CD, et al. Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2629–34. Comment in: Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2627–8.
A thermodynamic coupling mechanism for GroEL–mediated unfolding. Walter S, et al. Proc Natl Acad Sci U S A 1996 Sep 3;93(18):9425–30
Simple model of protein folding kinetics. Zwanzig R. Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9801–4
Folding of chains with random and edited sequences: similarities and differences. Galzitskaya OV, et al. Protein Eng 1995 Sep;8(9):883–92
In search of the ideal protein sequence. Godzik A. Protein Eng 1995 May;8(5):409–16
Hydrophobic potential by pairwise surface area sum. Kurochkina N, et al. Protein Eng 1995 May;8(5):437–42
Are database–derived potentials valid for scoring both forward and inverted protein folding? Rooman MJ, et al. Protein Eng 1995 Sep;8(9):849–58 (82 ref.)
Contact pattern–induced pair potentials for protein fold recognition. Selbig J. Protein Eng 1995 Apr;8(4):339–51
A simple protein folding algorithm using a binary code and secondary structure constraints. Sun S, et al. Protein Eng 1995 Aug;8(8):769–78
Inverse protein folding by the residue pair preference profile method: estimating the correctness of alignments of structurally compatible sequences. Wilmanns M, et al. Protein Eng 1995 Jul;8(7):627–39
Domains in folding of model proteins. Abkevich VI, et al. Protein Sci 1995 Jun;4(6):1167–77
Xylanase homology modeling using the inverse protein folding approach. Chen X, et al. Protein Sci 1996 Apr; 5(4):705–8
Interaction of SecB with intermediates along the folding pathway of maltose–binding protein. Diamond DL, et al. Protein Sci 1995 Jun;4(6):1118–23
Side–chain conformational entropy in protein folding. Doig AJ, et al. Protein Sci 1995 Nov;4(11):2247–51 (31 ref.)
Kinetics of interaction of partially folded proteins with a hydrophobic dye: evidence that molten globule character is maximal in early folding intermediates. Engelhard M, et al. Protein Sci 1995 Aug;4(8):1553–62
Are turns required for the folding of ribonuclease T1? Garrett JB, et al. Protein Sci 1996 Feb;5(2):204–11
A phage display system for studying the sequence determinants of protein folding. Gu H, et al. Protein Sci 1995 Jun;4(6):1108–17
Thrombin–binding affinities of different disulfide–bonded isomers of the fifth EGF–like domain of thrombomodulin. Hunter MJ, et al. Protein Sci 1995 Oct;4(10):2129–37
Solvent isotope effects on the refolding kinetics of hen egg–white lysozyme. Itzhaki LS, et al. Protein Sci 1996 Jan;5(1):140–6
Comparison of atomic solvation parametric sets: applicability and limitations in protein folding and binding. Juffer AH, et al. Protein Sci 1995 Dec;4(12):2499–509
Alignment of 700 globin sequences: extent of amino acid substitution and its correlation with variation in volume. Kapp OH, et al. Protein Sci 1995 Oct;4(10):2179–90
Crystal structure of thioltransferase at 2.2 A resolution. Katti SK, et al. Protein Sci 1995 Oct;4(10):1998–2005
Equilibrium dissociation and unfolding of the dimeric human papillomavirus strain–16 E2 DNA–binding domain. Mok YK, et al. Protein Sci 1996 Feb;5(2):310–9
Contact interactions method: a new algorithm for protein folding simulations. Toma L, et al. Protein Sci 1996 Jan; 5(1):147–53
Control of aggregation in protein refolding: a variety of surfactants promote renaturation of carbonic anhydrase II. Wetlaufer DB, et al. Protein Sci 1995 Aug;4(8):1535–43
Folding proteins with a simple energy function and extensive conformational searching. Yue K, et al. Protein Sci 1996 Feb;5(2):254–61
Automatic recognition of hydrophobic clusters and their correlation with protein folding units. Zehfus MH. Protein Sci 1995 Jun;4(6):1188–202
Urea–induced dissociation and unfolding of dodecameric

glutamine synthetase from Escherichia coli: calorimetric and spectral studies. Zolkiewski M, et al. **Protein Sci** 1995 Aug;4(8):1544–52

Determination of the conformation of folding initiation sites in proteins by computer simulation. Avbelj F, et al. **Proteins** 1995 Oct;23(2):129–41

Helical fold prediction for the cyclin box. Bazan JF. **Proteins** 1996 Jan;24(1):1–17

Comparing folding codes for proteins and polymers. Chan HS, et al. **Proteins** 1996 Mar;24(3):335–44

A simple model of chaperonin-mediated protein folding. Chan HS, et al. **Proteins** 1996 Mar;24(3):345–51

Local moves: an efficient algorithm for simulation of protein folding. Elofsson A, et al. **Proteins** 1995 Sep;23(1):73–82

Why do protein architectures have Boltzmann-like statistics? Finkelstein AV, et al. **Proteins** 1995 Oct;23(2):142–50

Perfect temperature for protein structure prediction and folding. Finkelstein AV, et al. **Proteins** 1995 Oct; 23(2):151–62

Progress in fold recognition. Flöckner H, et al. **Proteins** 1995 Nov;23(3):376–86

Optimal local propensities for model proteins. Govindarajan S, et al. **Proteins** 1995 Aug;22(4):413–8

Solvent polarity-dependent structural refolding: a CD and NMR study of a 15 residue peptide. Graf von Stosch A, et al. **Proteins** 1995 Oct;23(2):196–203

Fold recognition and ab initio structure predictions using hidden Markov models and beta-strand pair potentials. Hubbard TJ, et al. **Proteins** 1995 Nov;23(3):398–402

Successful protein fold recognition by optimal sequence threading validated by rigorous blind testing. Jones DT, et al. **Proteins** 1995 Nov;23(3):387–97

Atomic and residue hydrophilicity in the context of folded protein structures. Kuhn LA, et al. **Proteins** 1995 Dec; 23(4):536–47

Assessment of a protein fold recognition method that takes into account four physicochemical properties: side-chain packing, solvation, hydrogen-bonding, and local conformation. Matsuo Y, et al. **Proteins** 1995 Nov; 23(3):370–5

Accurate general method for lattice approximation of three-dimensional structure of a chain molecule. Rykunov DS, et al. **Proteins** 1995 Jun;22(2):100–9

LINUS: a hierarchic procedure to predict the fold of a protein. Srinivasan R, et al. **Proteins** 1995 Jun;22(2):81–99

Effects of cavity-creating mutations on conformational stability and structure of the dimeric 4-alpha-helical protein ROP: thermal unfolding studies. Steif C, et al. **Proteins** 1995 Sep;23(1):83–96

The radius of gyration of an apomyoglobin folding intermediate. Eliezer D, et al. **Science** 1995 Oct 20; 270(5235):487–8

The "bio" in biochemistry: protein folding inside and outside the cell [comment] Ellis RJ. **Science** 1996 Jun 7; 272(5267):1448–9 (10 ref.). Comment on: Science 1996 Jun 7;272(5267):1497–502.

Principles of chaperone-assisted protein folding: differences between in vitro and in vivo mechanisms [see comments] Frydman J, et al. **Science** 1996 Jun 7;272(5267):1497–502 . Comment in: Science 1996 Jun 7;272(5267):1448–9.

Which came first, protein sequence or structure? [comment] Karkar M. **Science** 1996 Aug 2;273(5275):610. Comment on: Science 1996 Aug 2;273(5275):666–9.

Emergence of preferred structures in a simple model of protein folding [see comments] Li H, et al. **Science** 1996 Aug 2;273(5275):666–9. Comment in: Science 1996 Aug 2;273(5275):610.

Lord of the rings: GroES structure [comment] Mayhew M, et al. **Science** 1996 Jan 12;271(5246):161–2. Comment on: Science 1996 Jan 12;271(5246):203–7.

Protein folding triggered by electron transfer. Pascher T, et al. **Science** 1996 Mar 15;271(5255):1558–60

Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix. Petersen JM, et al. **Science** 1995 Sep 29;269(5232):1866–9

Between the sheets: why do proteins strands line up? [news] Service RF. **Science** 1996 Oct 4;274(5284):34–5

Folding proteins caught in the act [news] Service RF. **Science** 1996 Jul 5;273(5271):29–30

Misfolding the way to disease [news] Taubes G. **Science** 1996 Mar 15;271(5255):1493–5

Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB. Zahn R, et al. **Science** 1996 Feb 2;271(5249):642–5

The prosegment-subtilisin BPN' complex: crystal structure of a specific 'foldase'. Gallagher T, et al. **Structure** 1995 Sep 15;3(9):907–14

Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Li J, et al. **Structure** 1995 Jun 15;3(6):541–9

Weighing the evidence for structure: electrospray ionization mass spectrometry of proteins. Robinson CV, et al. **Structure** 1995 Sep 15;3(9):861–5 (19 ref.)

Interventional thermal injury of the arterial wall: unfolding of von Willebrand factor and its increased binding to collagen after 55 degrees C heating. Post MJ, et al. **Thromb Haemost** 1996 Mar;75(3):515–9

How the molten globule became. Ptitsyn OB. **Trends Biochem Sci** 1995 Sep;20(9):376–9 (43 ref.)

Defective protein folding as a basis of human disease. Thomas PJ, et al. **Trends Biochem Sci** 1995 Nov;20(11):456–9 (43 ref.)

[Statistical criteria for evaluating the spatial structure, used in the reverse case of forming protein globules] Siuniaev ShR, et al. **Biofizika** 1995 Nov-Dec;40(6):1165–70 (Eng. Abstr.) **(Rus)**

PROTEIN FOLDING, GLOBULAR see **PROTEIN FOLDING**

PROTEIN-FREE MEDIA see **CULTURE MEDIA, SERUM-FREE**

PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE

ANALYSIS

Liver transglutaminases and vitamin-A deficiency in hairless mice. Savouré N, et al. **Ann Nutr Metab** 1996;40(1):52–60

Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides. Smethurst PA, et al. **Biochem J** 1996 Feb 1; 313 (Pt 3):803–8

Transglutaminase activity in rat liver after acute ethanol administration. Sessa A, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):371–5

Transglutaminases in Crohn's disease. D'Argenio G, et al. **Gut** 1995 Nov;37(5):690–5

Tissue-type transglutaminase is not a tumor-related marker. Takaku K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1268–70

Localization of transglutaminase in human lenses. Hidasi V, et al. **J Histochem Cytochem** 1995 Nov;43(11):1173–7

Specificity of B.C1 for TGK after renaturation prior to transfer of proteins [letter; comment] Hohl D, et al. **J Invest Dermatol** 1996 Apr;106(4):801–3. Comment on: J Invest Dermatol 1995 Feb;104(2):211–7.

Immunohistochemical detection of coagulation factor XIIIa in postmortem human brain tissue. Akiyama H, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):29–32

[Changes of factor XIII a and b subunit in patients with disseminated intravascular coagulation syndrome] Sugimura D, et al. **Rinsho Byori** 1996 Apr;44(4):355–61 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Analysis of up-regulated genes during chondrocyte hypertrophy. Nurminskaya M, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:309–10

Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. Benedetti L, et al. **Blood** 1996 Mar 1;87(5):1939–50

Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina. Zhang SR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1793–9

Tissue-type transglutaminase is not a tumor-related marker. Takaku K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1268–70

The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element. Lee JH, et al. **J Biol Chem** 1996 Feb 23;271(8):4561–8

The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene. Ueda E, et al. **J Biol Chem** 1996 Apr 19;271(16):9790–4

Expression of transglutaminase C during the prenatal development of human submandibular glands. Lee SK, et al. **J Dent Res** 1995 Nov;74(11):1812–6

Isolation of neonatal cardiomyocytes reduces the expression of the GTP-binding protein, Gh. Vincan E, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2393–6

Differentiation of U937 myelomonocytic cell line by all-trans retinoic acid and 1,25-dihydroxyvitamin D3: synergistic effects on tissue transglutaminase. Defacque H, et al. **Leukemia** 1995 Oct;9(10):1762–7

Reduction in Gh protein expression is associated with cytodifferentiation of vascular smooth muscle cells. Vincan E, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):107–10

CHEMISTRY

Identification of factor-XIIIa-reactive glutaminyl residues in the propolypeptide of bovine von Willebrand factor. Takagi J, et al. **Eur J Biochem** 1995 Sep 15;232(3):773–7

Identification of the alpha chain lysine donor sites involved in factor XIIIa fibrin cross-linking. Sobel JH, et al. **J Biol Chem** 1996 Aug 9;271(32):19288–97

GENETICS

A third human tissue transglutaminase homologue as a result of alternative gene transcripts. Fraij BM, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):63–74

Tissue-type transglutaminase from red sea bream (Pagrus major). Sequence analysis of the cDNA and functional expression in Escherichia coli. Yasueda H, et al. **Eur J Biochem** 1995 Sep 1;232(2):411–9

Subtyping of coagulation factor XIIIA. Arnold G, et al. **Hum Hered** 1995 Nov-Dec;45(6):319–22

Autosomal recessive lamellar ichthyosis: identification of a new mutation in transglutaminase 1 and evidence for genetic heterogeneity. Parmentier L, et al. **Hum Mol Genet** 1995 Aug;4(8):1391–5

Increased factor XIIIa transglutaminase expression in dermal dendrocytes after treatment with alpha-hydroxy acids: potential physiologic significance. Griffin TD, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):196–203

The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element. Lee JH, et al. **J Biol Chem** 1996 Feb 23;271(8):4561–8

Keratinocyte transglutaminase promoter analysis. Identification of a functional response element. Mariniello L, et al. **J Biol Chem** 1995 Dec 29;270(52):31358–63

Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. Nagy L, et al. **J Biol Chem** 1996 Feb 23;271(8):4355–65

The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene. Ueda E, et al. **J Biol Chem** 1996 Apr 19;271(16):9790–4

Evidence for separate control mechanisms at the message, protein, and enzyme activation levels for transglutaminase during calcium-induced differentiation of normal and transformed human keratinocytes. Gibson DF, et al. **J Invest Dermatol** 1996 Jan;106(1):154–61

A point mutation in an invariant splice acceptor site results in a decreased mRNA level in a patient with severe coagulation factor XIII subunit A deficiency. Vreken P, et al. **Thromb Haemost** 1995 Aug;74(2):584–9

ISOLATION & PURIFICATION

Purification and properties of transglutaminase from soybean (Glycine max) leaves. Kang H, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):288–92

Identification and biochemical characterization of an 80 kilodalton GTP-binding/transglutaminase from rabbit liver nuclei. Singh US, et al. **Biochemistry** 1995 Dec 5; 34(48):15863–71

Purification and partial characterization of a transglutaminase from dog filarial parasite, Dirofilaria immitis. Singh RN, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1285–91

Purification and characterization of rat brain transglutaminase. Ohashi H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1271–8

Association of a transglutaminase-related antigen with intermediate filaments. Trejo-Skalli AV, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8940–4

METABOLISM

Detection of the amine acceptor protein substrates of transglutaminase with 5-(biotinamido) pentylamine. Singh RN, et al. **Anal Biochem** 1995 Oct 10;231(1):261–3

Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae. Lustigman S, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1913–9

GTP hydrolysis by human tissue transglutaminase homologue. Fraij BM. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):45–9

Purification and properties of transglutaminase from soybean (Glycine max) leaves. Kang H, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):288–92

Transglutaminase forms midkine homodimers in cerebellar neurons and modulates the neurite-outgrowth response. Mahoney SA, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):147–52

Inactive zymogen and highly active proteolytically processed membrane-bound forms of the transglutaminase 1 enzyme in human epidermal keratinocytes. Steinert PM, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):101–6

Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Dubbink HJ, et al. **Biochem J** 1996 May 1;315 (Pt 3):901–8

Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides. Smethurst PA, et al. **Biochem J** 1996 Feb 1; 313 (Pt 3):803–8

A 50 KDa protein modulates guanine nucleotide binding of transglutaminase II. Baek KJ, et al. **Biochemistry** 1996 Feb 27;35(8):2651–7

Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Kleman JP, et al. **Biochemistry** 1995 Oct 24;34(42):13768–75

Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Matsuka YV, et al. **Biochemistry** 1996 May 7;35(18):5810–6

Type II transglutaminase expression in rabbit articular chondrocytes in culture: relation with cell differentiation, cell growth, cell adhesion and cell apoptosis. Borge L, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):117–24

Enhanced susceptibility to transglutaminase reaction of alpha-lactalbumin in the molten globule state. Matsumura Y, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):69–76

Properties of particulate transglutaminase from Yoshida tumor cells. Signorini M, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):167–73

Monoclonal antibody directed to a fibrinogen A alpha #529–539 epitope inhibits alpha-chain crosslinking by transglutaminases. Mitkevich OV, et al.

Blood Coagul Fibrinolysis 1996 Jan;7(1):85–92
Transglutaminase-positive cells in psoriatic epidermis during treatment with calcitriol (1alpha,25 dihydroxy vitamin D3) and tacalcitol (1alpha,24 dihydroxy vitamin D3) [letter] Gerritsen MJ, et al. **Br J Dermatol** 1995 Oct;133(4):656–9
Rat seminal vesicle protein SV-IV and its transglutaminase-synthesized polyaminated derivative SPD2-SV-IV induce cytokine release from human resting lymphocytes and monocytes in vitro. Tufano MA, et al. **Cell Immunol** 1996 Mar 15;168(2):148–57
Alpha 1-adrenergic receptor coupling with Gh in the failing human heart [see comments] Hwang KC, et al. **Circulation** 1996 Aug 15;94(4):718–26. Comment in: Circulation 1996 Aug 15;94(4):602–3.
Requirement for transglutaminase in progesterone-induced decidualization of human endometrial stromal cells. Fujimoto M, et al. **Endocrinology** 1996 Mar;137(3):1096–101
Suppression of cornified envelope formation and type 1 transglutaminase by epidermal growth factor in neoplastic keratinocytes. Monzon RI, et al. **Endocrinology** 1996 May; 137(5):1727–34
Association of transglutaminase with the reconstituted keratin filaments isolated from rat vaginal epithelial cells. Vijayalakshmi V, et al. **Epithelial Cell Biol** 1994;3(4):168–74
Hepatocyte growth factor induces transglutaminase activity that negatively regulates the growth signal in primary cultured hepatocytes. Katoh S, et al. **Exp Cell Res** 1996 Feb 1;222(2):255–61
Characterization of cells containing factor XIII subunit a in benign and malignant buccal lesions. Toida M, et al. **Histochem J** 1995 Jun;27(6):449–56
Purification and characterization of rat brain transglutaminase. Ohashi H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1271–8
Core histones are glutaminyl substrates for tissue transglutaminase. Ballestar E, et al. **J Biol Chem** 1996 Aug 2;271(31):18817–24
Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein. Candi E, et al. **J Biol Chem** 1995 Nov 3;270(44):26382–90
Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling. Feng JF, et al. **J Biol Chem** 1996 Jul 12;271(28):16451–4
Substrate requirements for transglutaminases. Influence of the amino acid residue preceding the amine donor lysine in a native protein. Grootjans JJ, et al. **J Biol Chem** 1995 Sep 29;270(39):22855–8
Exons lost and found. Unusual evolution of a seminal vesicle transglutaminase substrate. Hagstrom JE, et al. **J Biol Chem** 1996 Aug 30;271(35):21114–9
Two adjacent N-terminal glutamines of BM-40 (osteonectin, SPARC) act as amine acceptor sites in transglutaminaseC-catalyzed modification. Hohenadl C, et al. **J Biol Chem** 1995 Oct 6;270(40):23415–20
Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C. Hwang KC, et al. **J Biol Chem** 1995 Nov 10;270(45):27058–62
Evidence for separate control mechanisms at the message, protein, and enzyme activation levels for transglutaminase during calcium-induced differentiation of normal and transformed human keratinocytes. Gibson DF, et al. **J Invest Dermatol** 1996 Jan;106(1):154–61
Lamellar ichthyosis is genetically heterogeneous—cases with normal keratinocyte transglutaminase. Huber M, et al. **J Invest Dermatol** 1995 Nov;105(5):653–4
The covalent structure of factor XIIIa crosslinked fibrinogen fibrils. Mosesson MW, et al. **J Struct Biol** 1995 Jul-Aug; 115(1):88–101
Retinoid-regulated expression of BCL-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells. Nagy L, et al. **Leuk Res** 1996 Jun;20(6):499–505
High-resolution structural studies of the factor XIIIa crosslinking site and the first type 1 module of fibronectin [letter] Potts JR, et al. **Nat Struct Biol** 1995 Nov; 2(11):946–50
Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Muszbek L, et al. **Thromb Haemost** 1995 Apr;73(4):702–5
Orientation of the carboxy-terminal regions of fibrin gamma chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa. Siebenlist KR, et al. **Thromb Haemost** 1995 Oct; 74(4):1113–9

PHARMACOLOGY

Effects of exogenous transglutaminase on spreading of human colorectal carcinoma cells. Zirvi KA, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):283–94
Serum-induced collagen gel contraction. Akiba J, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):430–4
Transglutaminase cross-linking of the tau protein. Miller ML, et al. **J Neurochem** 1995 Oct;65(4):1760–70

PHYSIOLOGY

The role of factor XIIIa in the mesenchymatogenesis of the human placenta: an immunohistochemical analysis. Agapitos E, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):83–6
Transglutaminase induced by epidermal growth factor negatively regulates the growth signal in primary cultured hepatocytes. Katoh S, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):305–9
Apoptosis of epithelial cells in vivo involves tissue transglutaminase upregulation. Cummings M. **J Pathol** 1996 Jul;179(3):288–93

PROTEIN HYBRIDIZATION

Analyzing protein-protein interactions using two-hybrid system. Bartel PL, et al. **Methods Enzymol** 1995;254:241–63
Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Kim YG, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1156–60

PROTEIN HYDROLYSATES

Dietary protection against diabetes in NOD mice: lack of a major change in the immune system. Hermitte L, et al. **Diabete Metab** 1995 Oct;21(4):261–8
[The use of an enzymatic hydrolyzate of Chlorella biomass in media for growing eukaryotic cells] Blinkova LP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):6 **(Rus)**

ADMINISTRATION & DOSAGE

Serum amino acid concentrations in growing rats fed intact protein versus enzymatic protein hydrolysate-based diets. Baró L, et al. **Biol Neonate** 1995;68(1):55–61
Effects of abomasal infusions of sodium caseinate and of casein hydrolysates varying in the relative proportions of peptides and free amino acids on milk production in dairy cows. Choung JJ, et al. **J Dairy Res** 1995 Aug;62(3):423–9
Influence of casein and casein hydrolysate diets on nutritional recovery of starved rats. Boza J, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun;19(3):216–21

ANALYSIS

Nutritional evaluation of protein hydrolysate formulas. Rigo J, et al. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S26–38
A modified procedure for caseinophosphopeptide analysis. Lin JH, et al. **J Chromatogr Sci** 1996 Aug;34(8):358–61
Detection of undegraded beta-lactoglobulins and evaluation of the molecular weight of peptides in hydrolysate cow's milk formulae. Chiancone E, et al. **J Investig Allergol Clin Immunol** 1995 Jul-Aug;5(4):228–31

IMMUNOLOGY

Raising the pH of the pepsin-catalysed hydrolysis of bovine whey proteins increases the antigenicity of the hydrolysates. Schmidt DG, et al. **Clin Exp Allergy** 1995 Oct;25(10):1007–17

METABOLISM

Proferrioxamine synthesis in Erwinia amylovora in response to precursor or hydroxylysine feeding: metabolic profiling with liquid chromatography-electrospray mass spectrometry. Feistner GJ. **Biometals** 1995 Oct;8(4):318–27

PHARMACOLOGY

The protein hydrolysate, Primatone RL, is a cost-effective multiple growth promoter of mammalian cell culture in serum-containing and serum-free media and displays anti-apoptosis properties. Schlaeger EJ. **J Immunol Methods** 1996 Aug 14;194(2):191–9
[The action of radioprotectors of natural origin (MIGI-K and carnosine) on the catecholamine level in irradiated rats] Goncharenko EN, et al. **Radiats Biol Radioecol** 1995 Nov-Dec;35(6):880–3 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The effect of hypo-allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)
Hydrolysed protein formulas: thoughts from the Isle of Wight meeting. Hide D, et al. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S100–6
The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)
Symptomatology and growth in infants with cow's milk protein intolerance using two different whey-protein hydrolysate based formulas in a Primary Health Care setting. Verwimp JJ, et al. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S39–48

PROTEIN I see **SYNAPSINS**

PROTEIN III see **SYNAPSINS**

PROTEIN ISOPRENYLATION

Inhibition of protein prenylation down-regulates signalling by inflammatory mediators in human keratinocytes. Alaei P, et al. **Biochem Biophys Res Commun** 1996 May 6; 222(1):133–8
Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Chen Y, et al. **Biochemistry** 1996 Mar 12;35(10):3227–37
Characterization of prenyl protein transferase enzymes in a human keratinocyte cell line. MacNulty EE, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):41–50
Changes in protein prenylation and prenyltransferase activity in the rat seminiferous epithelium during early stages of spermatogenesis. Dugan JM, et al. **Biol Reprod** 1995 Oct; 53(4):958–73
Identification of spinach farnesyl protein transferase. Dithiothreitol as an acceptor in vitro. Parmryd I, et al. **Eur J Biochem** 1995 Dec 15;234(3):723–31
Entamoeba histolytica: isoprenylation of p21ras and p21rap in vitro. Shen PS, et al. **Exp Parasitol** 1996 Jan;82(1):65–8
Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. Miyake M, et al. **FEBS Lett** 1996 Jan 2;378(1):15–8
Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation. De Smedt F, et al. **J Biol Chem** 1996 Apr 26;271(17):10419–24
Efficient interaction with a receptor requires a specific type of prenyl group on the G protein gamma subunit. Kisselev O, et al. **J Biol Chem** 1995 Oct 27;270(43):25356–8
The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. Otto JC, et al. **J Biol Chem** 1996 Mar 1;271(9):4569–72
Nucleotide dependence of Rab geranylgeranylation. Rab escort protein interacts preferentially with GDP-bound Rab. Seabra MC. **J Biol Chem** 1996 Jun 14; 271(24):14398–404
Induction of a prenylated 65-kd protein in macrophages by interferon or lipopolysaccharide. Vestal DJ, et al. **J Leukoc Biol** 1995 Nov;58(5):607–15
Determination of protein isoprenylation in vitro and in vivo. Zhu JK, et al. **Methods Cell Biol** 1995;50:31–9
Prenylation and palmitoylation analysis. Hancock JF. **Methods Enzymol** 1995;255:237–45
Prenylcysteine-directed carboxyl methyltransferase activity in human neutrophil membranes. Philips MR, et al. **Methods Enzymol** 1995;256:49–63
Isoprenylation of proteins in the protozoan Giardia lamblia. Luján HD, et al. **Mol Biochem Parasitol** 1995 Jun; 72(1-2):121–7

DRUG EFFECTS

Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Hudgins WR, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1273–9
Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Shack S, et al. **Int J Cancer** 1995 Sep 27;63(1):124–9
Effects of lovastatin on trafficking of cystic fibrosis transmembrane conductance regulator in human tracheal epithelium. Shen BQ, et al. **J Biol Chem** 1995 Oct 20; 270(42):25102–6
Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Kohl NE, et al. **J Cell Biochem Suppl** 1995;22:145–50 (29 ref.)
Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. Macchia M, et al. **J Med Chem** 1996 Mar 29;39(7):1352–6
Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Danesi R, et al. **Mol Pharmacol** 1996 Jun;49(6):972–9

GENETICS

Nucleotide induced conformation determines posttranslational isoprenylation of the ras related rab6 protein in insect cells. Schiedel AC, et al. **FEBS Lett** 1995 Nov 27;376(1-2):113–9

PHYSIOLOGY

2',3'-Cyclic nucleotide 3'-phosphodiesterase binds to actin-based cytoskeletal elements in an isoprenylation-independent manner. De Angelis DA, et al. **J Neurochem** 1996 Sep;67(3):943–51
Isoprenoids and Ras: potential role in chronic rejection. O'Donnell MP, et al. **Kidney Int Suppl** 1995 Dec;52:S29–33 (49 ref.)
Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)

PROTEIN KINASE A see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

PROTEIN KINASE C

AGONISTS

Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Sabatini M, et al. **Bone** 1996 Jan;18(1):59–65
Phorbol myristate acetate ex vivo model of enhanced colonic epithelial permeability. Reactive oxygen metabolite and protease independence. Berin MC, et al. **Dig Dis Sci** 1995 Oct;40(10):2268–79
GABA rho1 receptor: inhibition by protein kinase C activators. Kusama T, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):431–4

Ergocalciferol and cycloheximide in vivo stimulate protein kinase C of intestinal crypt cells. Usta J, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):91–5

Interferon–gamma affects protein kinase C activity in human neutrophils. Aas V, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):777–84

Polyunsaturation in cell membranes and lipid bilayers and its effects on membrane proteins. Slater SJ, et al. **Lipids** 1996 Mar;31 Suppl:S189–92

Gangliosides inhibit PDGF–induced signal transduction events in U–1242 MG human glioma cells. Saqr HE, et al. **Neurochem Res** 1995 Nov;20(11):1389–95

Effects of protein kinase C activation on prostaglandin production and cyclooxygenase mRNA levels in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1996 Mar; 51(3):203–13

Effect of protein kinase C modulation on gonadotrophin–induced granulosa cell steroidogenesis. He H, et al. **Reprod Fertil Dev** 1995;7(1):83–95

ANALYSIS

Immunoreactivity of PKC gammalambda and RACK1 in baker's yeast, lobster and wheat germ. Kuo WN, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):957–63

Localization of protein kinase C isozymes in rat colon. Jiang YH, et al. **Cell Growth Differ** 1995 Nov;6(11):1381–6

Imaging protein kinase C activation in living sea urchin eggs after fertilization. Olds JL, et al. **Dev Biol** 1995 Dec; 172(2):675–82

Elucidation of the protein kinase C–dependent apoptosis pathway in distinct subsets of T lymphocytes in MRL–lpr/lpr mice. Ohkusu K, et al. **Eur J Immunol** 1995 Nov;25(11):3180–6

Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. Borgatti P, et al. **Exp Cell Res** 1996 Apr 10;224(1):72–8

Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival. Martínez–Gimeno C, et al. **Head Neck** 1995 Nov–Dec;17(6):516–25

The role of the calpain–calpastatin system in thyrotropin–releasing hormone–induced selective down–regulation of a protein kinase C isozyme, nPKC epsilon, in rat pituitary GH4C1 cells. Eto A, et al. **J Biol Chem** 1995 Oct 20;270(42):25115–20

Phorbol esters induce death in MCF–7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53–independent induction of gadd–45 in initiating death. de Vente JE, et al. **J Clin Invest** 1995 Oct; 96(4):1874–86

Stimulus–dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor–beta 1 in cardiac myocytes. Disatnik MH, et al. **J Mol Cell Cardiol** 1995 Nov;27(11):2473–81

Glutathione and protein kinase C in peripheral nervous tissue. Romero FJ, et al. **Methods Enzymol** 1995;252:146–53

Identification of protein kinase C zeta isozyme in hamster pancreas and pancreatic carcinoma cell lines. Nair SC, et al. **Mol Carcinog** 1995 Nov;14(3):205–13

Hypophosphorylation of topoisomerase II in etoposide (VP–16)–resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Ritke MK, et al. **Mol Pharmacol** 1995 Nov;48(5):798–805

ANTAGONISTS & INHIBITORS

In vitro vasorelaxant effects of indolocarbazole and bis–indole protein kinase C inhibitors on rabbit renal arteries. Fabre S, et al. **Arch Int Pharmacodyn Ther** 1995 May–Jun;329(3):397–404

Phenylamino–pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Zimmermann J, et al. **Arch Pharm (Weinheim)** 1996 Jul; 329(7):371–6

Protein kinase C inhibitors enhance the synergistic mitogenic effects of ethanolamine analogues and insulin in NIH 3T3 fibroblasts. Kiss Z, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):125–30

Inhibition of demecolcin–induced DNA synthesis by inhibitors of phospholipase C and protein kinase C. Suzuki K, et al. **Biochem Biophys Res Commun** 1996 Feb 6; 219(1):163–7

Inhibition of protein kinase C by snake venom toxins: comparison of enzyme inhibition, lethality and hemolysis among different cardiotoxin isoforms. Chiou SH, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1103–12

Protein kinase C inhibitor, chelerythrine, potentiates the adrenaline–mediated aggregation of human platelets through calcium influx. Shah BH, et al. **Biochem Mol Biol Int** 1996 May;38(6):1135–41

Virtual kinetics: using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. Bronson DD, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):823–31

Generation of a free radical from calphostin C by microsomal cytochrome P450 reductase in rat and human liver. Patterson LH, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):599–603

Regulation of bradykinin responses by PKC epsilon and histamine responses by PKC alpha in adrenal chromaffin cells. Boarder MR, et al. **Biochem Soc Trans** 1995 Aug; 23(3):424S

Protein kinase C inhibitor potentiates the agonist–induced GTPase activity in COS cell membranes expressing delta–opioid receptor. Hayashi C, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):347–50

Interphase and M–phase oral KB carcinoma cells are targetted in staurosporine–induced apoptosis. Swe M, et al. **Cancer Lett** 1996 Jul 12;104(2):145–52

Growth inhibition and apoptosis in human neuroblastoma SK–N–SH cells induced by hypericin, a potent inhibitor of protein kinase C. Zhang W, et al. **Cancer Lett** 1995 Sep 4;96(1):31–5

Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Chmura SJ, et al. **Cancer Res** 1996 Jun 15;56(12):2711–4

Inhibition of Growth of Human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C–alpha expression. Dean N, et al. **Cancer Res** 1996 Aug 1;56(15):3499–507

Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)

Both activators and inhibitors of protein kinase C promote the inhibition of phenylephrine–induced [Ca2+]i oscillations in single intact rat hepatocytes. Berrie CP, et al. **Cell Calcium** 1995 Sep;18(3):232–44

Apoptosis induced by protein kinase C inhibition in a neuroblastoma cell line. Behrens MM, et al. **Cell Growth Differ** 1995 Nov;6(11):1375–80

Apoptosis in 7–hydroxystaurosporine–treated T lymphoblasts correlates with activation of cyclin–dependent kinases 1 and 2. Wang Q, et al. **Cell Growth Differ** 1995 Aug; 6(8):927–36

Effects of ethanol metabolism on PKC activity in isolated rat hepatocytes. Domenicotti C, et al. **Chem Biol Interact** 1996 Mar 25;100(2):155–63

No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Vahlhaus C, et al. **Circ Res** 1996 Sep;79(3):407–14

Production of an endogenous inhibitor of protein kinase C by embryonic myoblasts undergoing differentiation. Eyster KM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov;112(3):549–55

Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C. Harris MS, et al. **Curr Eye Res** 1996 Mar; 15(3):255–62

Augmentation of TNF cytotoxicity by protein kinase C inhibitors: role of arachidonic acid and manganese superoxide dismutase. Prezioso JA, et al. **Cytokine** 1995 Aug;7(6):517–25

Effect of inhibitors of protein kinase C on enhanced superoxide production of human leucocytes by ofloxacin and fleroxacin. Matsumoto T, et al. **Drugs** 1995;49 Suppl 2:286–8

Control of 1,25–dihydroxyvitamin D3 receptor–mediated enhancement of osteocalcin gene transcription: effects of perturbing phosphorylation pathways by okadaic acid and staurosporine. Desai RK, et al. **Endocrinology** 1995 Dec; 136(12):5685–93

Forskolin inhibits protein kinase C–induced mitogen activated protein kinase activity in MC3T3–E1 osteoblasts. Siddhanti SR, et al. **Endocrinology** 1995 Nov; 136(11):4834–41

Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Rothhut B, et al. **Eur J Biochem** 1995 Sep 15;232(3):865–72

Inhibitions of protein kinase C and proto–oncogene expressions in NIH 3T3 cells by apigenin. Huang YT, et al. **Eur J Cancer** 1996 Jan;32A(1):146–51

Selectivity of action of staurosporine on Ca2+ movements and contractions in vascular smooth muscles. Asano M, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):693–701

Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu–opioid receptor agonist in the mouse. Narita M, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R1–3

Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H–7 and H–8. Tokuyama S, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):101–7

Pharmacological studies on mechanisms involved in Ca2+ oscillations in rat megakaryocytes. Uneyama C, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):381–6

Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. Gschwendt M, et al. **FEBS Lett** 1996 Aug 26;392(2):77–80

Protein kinase C inhibitors enhance G–protein induced phospholipase A2 activation in intact human platelets. Iorio P, et al. **FEBS Lett** 1996 Mar 4;381(3):244–8

H–7, a protein kinase C inhibitor, inhibits spontaneous tone and spasmogenic responses in normal and sensitized guinea pig trachea. de Diego A, et al. **Gen Pharmacol** 1995 Dec; 26(8):1747–55

Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant–induced arthritis (AA) in rats. DiMartino M, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S123–4

The effect of spermine on calcium requirement for protein kinase C association with phospholipid vesicles. Moruzzi MS, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):783–8

Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. Fredenhagen A, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1355–8

Syntheses and antimicrobial activities of five–membered ring heterocycles coupled to indole moieties. Pereira ER, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):380–5

Antimicrobial activities of indolocarbazole and bis–indole protein kinase C inhibitors. II. Substitution on maleimide nitrogen with functional groups bearing a labile hydrogen. Pereira ER, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):863–8

Modulation of elastin expression by heparin is dependent on the growth condition of vascular smooth muscle cells: up–regulation of elastin expression by heparin in the proliferating cells is mediated by the inhibition of protein kinase C activity. Wachi H, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):582–6

Partial reversal of multidrug resistance in human breast cancer cells by an N–myristoylated protein kinase C–alpha pseudosubstrate peptide. Gupta KP, et al. **J Biol Chem** 1996 Jan 26;271(4):2102–11

Ceramide inactivates cellular protein kinase Calpha. Lee JY, et al. **J Biol Chem** 1996 May 31;271(22):13169–74

C2 region–derived peptides inhibit translocation and function of beta protein kinase C in vivo. Ron D, et al. **J Biol Chem** 1995 Oct 13;270(41):24180–7

Protein kinase C deficiency blocks recovery from agonist–induced desensitization. Shih M, et al. **J Biol Chem** 1996 Aug 30;271(35):21478–83

Staurosporine inhibits interferon alpha–induced gene expression in Friend erythroleukemia cells through a PKC independent pathway. Percario ZA, et al. **J Biol Regul Homeost Agents** 1995 Jan–Mar;9(1):7–14

Dexniguldipine hydrochloride, a protein–kinase–C–specific inhibitor, affects the cell cycle, differentiation, P–glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells. Patterson KK, et al. **J Cancer Res Clin Oncol** 1996;122(8):465–75

Pre–clamp cardioprotection by protein kinase C (PKC) inhibitor improves left ventricular function following canine normothermic arrest. Anagnostopoulos CE, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):141–3

Endogenously inhibited protein kinase C in transgenic Drosophila embryonic neuroblasts down regulates the outgrowth of type I and II processes of cultured mature neurons. Broughton SJ, et al. **J Cell Biochem** 1996 Mar 15;60(4):584–99

Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP–dependent protein kinase and protein kinase C. McClintock TS, et al. **J Cell Physiol** 1996 Apr;167(1):1–7

Regulatory domain of human protein kinase C alpha dominantly inhibits protein kinase C beta–I–regulated growth and morphology in Saccharomyces cerevisiae. Parissenti AM, et al. **J Cell Physiol** 1996 Mar;166(3):609–17

Development of a high–performance liquid chromatographic method for the analysis of staurosporine. Gurley LR, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):125–38

Staurosporine induces a sequential program of mouse keratinocyte terminal differentiation through activation of PKC isozymes. Stanwell C, et al. **J Invest Dermatol** 1996 Mar;106(3):482–9

(S)–13–[(dimethylamino)methyl]–10,11,14,15–tetrahydro–4,9:16, 21–dimetheno–1H, 13H–dibenzo[e,k]pyrrolo[3,4–h][1,4,13]oxadiazacyclohexadecene–1,3(2H)–d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. Jirousek MR, et al. **J Med Chem** 1996 Jul 5;39(14):2664–71

Evidence that the modulation of membrane–associated protein kinase C activity by an endogenous inhibitor plays a role in N1E–115 murine neuroblastoma cell differentiation. Chakravarthy BR, et al. **J Neurochem** 1995 Oct;65(4):1569–79

Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor–differentiated PC12 cells. Li X, et al. **J Neurochem** 1995 Dec;65(6):2500–8

Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse. Théodore L, et al. **J Neurosci** 1995 Nov;15(11):7158–67

Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. Ikemoto H, et al. **J Neurosurg** 1995 Dec;83(6):1008–16

Effects of calmodulin and protein kinase C antagonists on muscle in the filariid, Acanthocheilonema viteae. Minardi AJ Jr, et al. **J Parasitol** 1995 Dec;81(6):989–96

Effects of naloxone and D–Phe–Cys–Tyr–D–Trp–Arg–Thr–Pen–Thr–NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):484–90

Anti–inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C. Jacobson PB, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):995–1002

Protective action of isoquinolinesulfonamides in in vitro models of neuronal apoptosis. Cagnoli CM, et al. **Life Sci** 1996;58(19):PL295–301

Tannin inhibition of protein kinase C in airway epithelium. Cloutier MM, et al. **Lung** 1995;173(5):307–19

Post–translationally modified 14–3–3 isoforms and inhibition of protein kinase C. Aitken A, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:41–9

Induction of early growth response–1 gene by interleukin–1 beta and tumor necrosis factor–alpha in normal human bone

marrow stromal an osteoblastic cells: regulation by a protein kinase C inhibitor. Chaudhary LR, et al. **Mol Cell Biochem** 1996 Mar 9;156(1):69–77

Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Freemerman AJ, et al. **Mol Pharmacol** 1996 May; 49(5):788–95

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Yazaki T, et al. **Mol Pharmacol** 1996 Aug;50(2):236–42

Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity. Hunáková L, et al. **Neoplasma** 1995;42(5):249–53

Chronic sodium azide treatment decreases membrane-bound protein kinase C activity in the rat hippocampus. Bennett MC, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):187–90

Protein kinase C inhibitors affect induction of long-lasting potentiation in the somatosensory cortex. Kawakami Y, et al. **Neurochem Res** 1995 Sep;20(9):1027–32

Phospholipids inhibit proteolysis of protein kinase C alpha by mM calcium-requiring calpain. Lang D, et al. **Neurochem Res** 1995 Nov;20(11):1361–4

Alpha-melanocyte-stimulating hormone inhibits corticotropin-releasing factor release by blocking protein kinase C. Lyson K, et al. **Neuroimmunomodulation** 1994 May-Jun;1(3):153–8

Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications. McKay RA, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):411–7

Effects of calphostin C, specific PKC inhibitor on TPA-induced normal human melanocyte growth, morphology and adhesion. Nakazawa K, et al. **Pigment Cell Res** 1996 Feb;9(1):28–34

Maytenine and 6-benzoyl-6-deacetylmayteine from Maytenus krukovii. Sekar KV, et al. **Planta Med** 1995 Aug;61(4):390

The fungal teratogen secalonic acid D is an inhibitor of protein kinase C and of cyclic AMP-dependent protein kinase. Wang BH, et al. **Planta Med** 1996 Apr;62(2):111–4

d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Tasinato A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12190–4

Effect of protein kinase C modulation on gonadotrophin-induced granulosa cell steroidogenesis. He H, et al. **Reprod Fertil Dev** 1995;7(1):83–95

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor [see comments] Ishii H, et al. **Science** 1996 May 3;272(5262):728–31. Comment in: Science 1996 May 3;272(5262):699–700.

Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699–700 (12 ref.). Comment in: Science 1996 May 3;272(5262):728–31.

Protein kinase C inhibitors enhance the 5-HT2A receptor-mediated excitatory effects of serotonin on interneurons in rat piriform cortex. Marek GJ, et al. **Synapse** 1995 Oct;21(2):123–30

Sex differences in rat hepatic cytolethality of the protein kinase C inhibitor safingol: role of biotransformation. Carfagna MA, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):173–81

Modulation of protein kinase C by heavy metals. Rajanna B, et al. **Toxicol Lett** 1995 Nov 15;81(2-3):197–203

RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Geiselhart L, et al. **Transplantation** 1996 Jun 15;61(11):1637–42

BIOSYNTHESIS

A nonradioactive assay for the insulin receptor tyrosine kinase: use in monitoring receptor kinase activity after activation of overexpressed protein kinase C alpha and high glucose treatment. Boge A, et al. **Anal Biochem** 1995 Nov 1;231(2):323–32

Identification of a brain-specific protein kinase C zeta pseudogene (psi PKC zeta) transcript. Andrea JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):835–43

Protein kinase C isoforms epsilon, eta, delta and zeta in murine adipocytes: expression, subcellular localization and tissue-specific regulation in insulin-resistant states. Frevert EU, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):865–71

Antisense oligodeoxynucleotide inhibition of delta protein kinase C expression accelerates induced differentiation of murine erythroleukaemia cells. Pessino A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):549–54

Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Spence S, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):975–82

Five isoenzymes of protein kinase C are expressed in normal and STZ-diabetic rat hepatocytes: effect of phorbol 12-myristate 13-acetate. Croquet F, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):163–8

Translocation of protein kinase C isoenzymes by elevated extracellular Ca2+ concentration in cells from a human giant cell tumor of bone. Teti A, et al. **Bone** 1995 Aug; 17(2):175–83

Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Powell CT, et al. **Cancer Res** 1996 Sep 15;56(18):4137–41

Altered expression of cyclins and c-fos in R6 cells that overproduce PKC epsilon. Han EK, et al. **Carcinogenesis** 1995 Oct;16(10):2423–8

Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids. Hirano F, et al. **Carcinogenesis** 1996 Mar;17(3):427–33

Gender-specific and developmental differences in protein kinase C isozyme expression in rat liver. Zangar RC, et al. **Carcinogenesis** 1995 Oct;16(10):2593–7

Monoclonal antibody binding to a receptor on nonspecific cytotoxic cells (NCC) increases the expression of proto-oncogene kinases and protein kinase C. Jaso-Friedmann L, et al. **Cell Signal** 1995 Jul;7(5):463–70

Expression of protein kinase C gene in the brain and heart of spontaneously hypertensive rats. Gao PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S204–6

Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Cloud-Heflin BA, et al. **Eur J Biochem** 1996 Aug 1;239(3):796–804

Retinoic acid specifically increases nuclear PKC alpha and stimulates AP-1 transcriptional activity in B16 mouse melanoma cells. Gruber JR, et al. **Exp Cell Res** 1995 Dec; 221(2):377–84

The relationship between susceptibility to retinoic acid treatment and protein kinase C alpha expression in murine melanoma cell lines. Niles RM, et al. **Exp Cell Res** 1996 Feb 25;223(1):20–8

Protein expression of the alpha, gamma, delta and epsilon subspecies of protein kinase C changes as C6 glioma cells become contact inhibited and quiescent in the presence of serum. Moreton K, et al. **FEBS Lett** 1995 Sep 18; 372(1):33–8

Promoting phorbol ester-TPA enhances migration of C3H 10T1/2 cells. The role of protein kinase C and its relation to carcinogenesis. Janik P, et al. **Folia Biol (Krakow)** 1995; 43(3-4):83–7

Co-localization of c-fos protein and protein kinase C gamma in the rat brain following anodal polarization. Islam N, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):209–15

1,25-Dihydroxyvitamin D3 stimulates expression and translocation of protein kinase Calpha and Cdelta via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. Berry DM, et al. **J Biol Chem** 1996 Jul 5;271(27):16090–6

Overexpression of epsilon-protein kinase C enhances nerve growth factor-induced phosphorylation of mitogen-activated protein kinases and neurite outgrowth. Hundle B, et al. **J Biol Chem** 1995 Dec 15;270(50):30134–40

Increased expression of protein kinase C beta activates ERK3. Sauma S, et al. **J Biol Chem** 1996 May 10; 271(19):11422–6

Protein kinase C-delta mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate. Shih NY, et al. **J Biol Chem** 1996 Jul 5;271(27):16040–6

Protein kinase C isoform expression during the differentiation of 3T3-L1 preadipocytes: loss of protein kinase C-alpha isoform correlates with loss of phorbol 12-myristate 13-acetate activation of nuclear factor kappaB and acquisition of the adipocyte phenotype. McGowan K, et al. **J Cell Physiol** 1996 Apr;167(1):113–20

Differential down-regulation of protein kinase C subspecies in normal human melanocytes: possible involvement of the zeta subspecies in growth regulation. Oka M, et al. **J Invest Dermatol** 1995 Oct;105(4):567–71

Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. Baltuch GH, et al. **J Neurooncol** 1995;24(3):241–50

Antisense suppresssion of protein kinase C-alpha and -delta in vascular smooth muscle. Busuttil SJ, et al. **J Surg Res** 1996 Jun;63(1):137–42

Expression of protein kinase C gamma regulatory domain elements containing cysteine-rich zinc-coordinating regions as glutathione S-transferase fusion proteins. Quest AF, et al. **Methods Enzymol** 1995;252:153–67

Differential expression of protein kinase C isoforms in glial and neuronal cells. Translocation and down-regulation of PKC isoforms in C6 glioma and NG 108-15 hybrid cells: effects of extracellular Ca(2+)-depletion. Chen CC, et al. **Neurochem Int** 1995 May;26(5):455–64

Down-regulation of protein kinase C activity preferentially attenuates high K(+)-stimulated tyrosine hydroxylase activity in adrenal chromaffin cells cultured with insulin-like growth factor-I. Dahmer MK. **Neurosci Lett** 1995 Dec 8;201(2):99–102

Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Perletti GP, et al. **Oncogene** 1996 Feb 15;12(4):847–54

Characterization of protein kinase C expression in human kidney. Fukuzaki A, et al. **Tohoku J Exp Med** 1996 Mar; 178(3):263–9

[Changes in distribution and isoenzymatic expression of protein kinase C in B lymphocytes induced by alloantigenic stimulation] Genaro AM, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):124–34 (Eng. Abstr.) **(Spa)**

BLOOD

GTPgammaS-stimulated phospholipase D activation in human neutrophils occurs by protein kinase C-dependent and -independent pathways but not tyrosine kinases. Lowe GM, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):484–90

Stimulatory antibody-induced activation and selective translocation of protein kinase C isoenzymes in human platelets. Wang F, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):401–6

Identification of 14-3-3 proteins in human platelets: effects of synthetic peptides on protein kinase C activation. Wheeler-Jones CP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):41–7

Investigation of the role of protein kinase C and tyrosine kinases during the rapid and sustained release of superoxide from adherent human neutrophils. Lindsay MA, et al. **Biochem Soc Trans** 1996 Feb;24(1):67S

Specific loss of protein kinase activities in senescent erythrocytes. Jindal HK, et al. **Blood** 1996 Aug 15; 88(4):1479–87

Anti-CD3-induced changes in protein kinase C isozymes expression in human CD4+ and CD8+ T lymphocytes. Harris W, et al. **J Clin Immunol** 1995 Sep;15(5):232–41

CHEMISTRY

Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Konishi H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):526–34

Membrane structure of protein kinase C and calmodulin binding domain of myristoylated alanine rich C kinase substrate determined by site-directed spin labeling. Qin Z, et al. **Biochemistry** 1996 Mar 5;35(9):2917–25

Solution and membrane bound structure of a peptide derived from the protein kinase C substrate domain of neuromodulin. Wertz SL, et al. **Biochemistry** 1996 Aug 27; 35(34):11104–12

The protein kinase C and protein kinase C related gene families. Dekker LV, et al. **Curr Opin Struct Biol** 1995 Jun; 5(3):396–402 (35 ref.)

Protein kinase C: structure, function, and regulation. Newton AC. **J Biol Chem** 1995 Dec 1;270(48):28495–8 (78 ref.)

Protein kinase Calpha contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities. Slater SJ, et al. **J Biol Chem** 1996 Mar 1; 271(9):4627–31

Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells. Szallasi Z, et al. **J Biol Chem** 1996 Aug 2;271(31):18299–301

Determination of in vivo phosphorylation sites in protein kinase C. Tsutakawa SE, et al. **J Biol Chem** 1995 Nov 10; 270(45):26807–12

Characterization and purification of a protein kinase C substrate in human B cells. Identification as lymphocyte-specific protein 1 (LSP1). Carballo E, et al. **J Immunol** 1996 Mar 1;156(5):1709–13

Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C. Wang S, et al. **J Med Chem** 1996 Jun 21;39(13):2541–53

Characterization of the cysteine-rich zinc-binding domains of protein kinase C by X-ray absorption spectroscopy. Hubbard SR. **Methods Enzymol** 1995;252:123–32

Three-dimensional structure of human protein kinase C interacting protein 1, a member of the HIT family of proteins. Lima CD, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5357–62

Extending the C2 domain family: C2s in PKCs delta, epsilon, eta, theta, phospholipases, GAPs, and perforin. Ponting CP, et al. **Protein Sci** 1996 Jan;5(1):162–6

[Structural studies of phorbol ester-binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

DRUG EFFECTS

Biochemical characterization of the stimulatory effects of halothane and propofol on purified brain protein kinase C. Hemmings HC Jr, et al. **Anesth Analg** 1995 Dec; 81(6):1216–22

Activation of endogenous protein kinase C by halothane in synaptosomes. Hemmings HC Jr, et al. **Anesthesiology** 1996 Mar;84(3):652–62

Effect of bolesatine on phospholipid/calcium dependent protein kinase in Vero cells and in rat thymus. Ennamany R, et al. **Arch Toxicol** 1995;69(9):624–30

Acyl chain dependence of diacylglycerol activation of protein kinase C activity in vitro. Marignani PA, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):469–73

Activation of protein kinase C by lysophosphatidic acid: dependence on composition of phospholipid vesicles. Sando JJ, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):583–8

Differential modulation of protein kinase C isozymes in rat parotid acinar cells. Relation to amylase secretion. Terzian AR, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):569–77

Bryostatin 1, a novel antineoplastic agent and protein kinase

C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Hickman PF, et al. **Br J Cancer** 1995 Oct;72(4):998–1003

Enhancing effect of staurosporine on NO production in rat peritoneal macrophages via a protein kinase C–independent mechanism. Sowa G, et al. **Br J Pharmacol** 1995 Sep; 116(2):1711–2

Dexamethasone and activators of the protein kinase A and C signal transduction pathways regulate neuronal calcitonin gene–related peptide expression and release. Supowit SC, et al. **Brain Res** 1995 Jul 17;686(1):77–86

Tamoxifen antagonizes proliferation and invasion of estrogen receptor–negative metastatic follicular thyroid cancer cells via protein kinase C. Hoelting T, et al. **Cancer Lett** 1996 Feb 27;100(1–2):89–93

Differential regulation of human T lymphocyte protein kinase C activity by unsaturated fatty acids. Rossetti RG, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):220–4

Effects of wortmannin on glucose uptake and protein kinase C activity in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):143–52

Association of phosphatidylinositol 3 kinase to protein kinase C zeta during interleukin-2 stimulation. Gómez J, et al. **Eur J Immunol** 1996 Aug;26(8):1781–7

NO2-induced expression of specific protein kinase C isoforms and generation of phosphatidylcholine–derived diacylglycerol in cultured pulmonary artery endothelial cells. Li YD, et al. **FEBS Lett** 1996 Jul 1;389(2):131–5

Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. Chen CC, et al. **J Immunol** 1995 Oct 1; 155(7):3538–45

Involvement of a phorbol ester–insensitive protein kinase C in the alpha2-adrenergic inhibition of voltage-gated calcium current in chick sympathetic neurons. Boehm S, et al. **J Neurosci** 1996 Aug 1;16(15):4596–603

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. Pollack IF, et al. **J Neurosurg** 1996 Jun;84(6):1024–32

Calcium dependence of indolactam–mediated contractions in resistance vessels. Hill MA, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):867–74

Angiotensin II–mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis–independent activation of protein kinase C in rat portal vein myocytes. Macrez-Leprêtre N, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):468–75

Modifications of cysteine-rich regions in protein kinase C induced by oxidant tumor promoters and enzyme–specific inhibitors. Gopalakrishna R, et al. **Methods Enzymol** 1995; 252:132–46

Phorbol ester alters the electrophysiological responses to hypoxia and ischemic-like conditions in the rat hippocampal slice. Fowler JC. **Mol Chem Neuropathol** 1995 Sep;26(1):31–42

Phosphatidic acid activation of protein kinase C in LA–N-1 neuroblastoma cells. Lang D, et al. **Neurosci Lett** 1995 Dec 15;201(3):199–202

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425–38 (72 ref.)

The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

Down-regulation of PKC alpha by lithium in vitro. Bitran JA, et al. **Psychopharmacol Bull** 1995;31(2):449–52

GENETICS

Identification of a brain-specific protein kinase C zeta pseudogene (psi PKC zeta) transcript. Andrea JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):835–43

Isozyme specific changes in the expression of protein kinase C isozyme (alpha-zeta) genes in the hippocampus of rats induced by kindling epileptogenesis. Kamphuis W, et al. **Brain Res** 1995 Dec 8;702(1–2):94–100

Protein F1/GAP-43 and PKC gene expression patterns in hippocampus are altered 1–2 h after LTP. Meberg PJ, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):343–6

Impaired motor coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice. Chen C, et al. **Cell** 1995 Dec 29;83(7):1233–42

Impaired synapse elimination during cerebellar development in PKC gamma mutant mice. Kano M, et al. **Cell** 1995 Dec 29;83(7):1223–31

In situ effects of interferon on human glioma protein kinase C–alpha and –beta ultrastructural localization. Acevedo-Duncan M, et al. **Cell Growth Differ** 1995 Nov; 6(11):1353–65

Localization of protein kinase C isozymes in rat colon. Jiang YH, et al. **Cell Growth Differ** 1995 Nov;6(11):1381–6

PKC2 gene enquiry [letter; comment] Edwards KJ. **Curr Biol** 1995 Aug 1;5(8):956. Comment on: Curr Biol 1994 Nov 1;4(11):990–5.

Nuclear translocation of beta II PKC isoenzyme in phorbol ester–stimulated KM-3 pre–B human leukemic cells. Trubiani O, et al. **Exp Cell Res** 1995 Nov;221(1):172–8

Functional expression and characterization of the mouse epitope tag–protein kinase C isoforms, alpha, beta I, beta II, gamma, delta and epsilon. Tseng CP, et al. **Gene** 1996 Mar 9;169(2):287–8

Suppressors of a Saccharomyces cerevisiae pkc1 mutation identify alleles of the phosphatase gene PTC1 and of a novel gene encoding a putative basic leucine zipper protein. Huang KN, et al. **Genetics** 1995 Dec;141(4):1275–85

Genetic mapping of a gene encoding an atypical protein kinase C, protein kinase C lambda, to the proximal region of mouse chromosome 3. Quaderi NA, et al. **Genomics** 1995 Oct 10;29(3):815–6

Non–equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester–induced translocation in NIH 3T3 cells. Szallasi Z, et al. **J Biol Chem** 1996 Aug 2;271(31):18299–301

Isolation and characterization of cell lines with genetically distinct mutations downstream of protein kinase C that result in defective activation–dependent regulation of T cell integrin function. Mobley JL, et al. **J Immunol** 1996 Feb 1;156(3):948–56

Expression and characterization of Aplysia protein kinase C: a negative regulatory role for the E region. Sossin WS, et al. **J Neurosci** 1996 Jan;16(1):10–8

Protein kinase C–alpha and –epsilon are enriched in growth cones of differentiating SH-SY5Y human neuroblastoma cells. Parrow V, et al. **J Neurosci Res** 1995 Aug 15; 41(6):782–91

Expression of PKC isozyme and MDR–associated genes in primary and relapsed state AML. Beck J, et al. **Leukemia** 1996 Mar;10(3):426–33

Cloning and characterisation of genes (pkc1 and pkcA) encoding protein kinase C homologues from Trichoderma reesei and Aspergillus niger. Morawetz R, et al. **Mol Gen Genet** 1996 Jan 15;250(1):17–28

Phorbol ester stimulation of phosphatidylcholine synthesis in four cultured neural cell lines: correlations with expression of protein kinase C isoforms. Sproull SA, et al. **Neurochem Res** 1995 Dec;20(12):1397–407

IMMUNOLOGY

Antibodies specific for proteolyzed forms of protein kinase C alpha. Kikuchi H, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):253–9

Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Mao J, et al. **Brain Res** 1995 Apr 24;677(2):257–67

Involvement of LFA–1/ICAM–2 adhesive interactions and PKC in activation–induced cell death following SEB rechallenge. Tchilian EZ, et al. **Immunology** 1996 Apr; 87(4):566–72

Protein kinase C alpha, beta immunoreactivity in baker's yeast, lobster and wheat germ. Kuo WN, et al. **Microbios** 1996;85(344):139–44

ISOLATION & PURIFICATION

Separation of H7–resistant protein kinase C isoforms from gonadotroph–derived alpha T3–1 cells. Simpson J, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):720–5

METABOLISM

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)

Expression of protein kinase C isoforms during cardiac ventricular development. Clerk A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1087–97

PDGF and IL–1 induce and activate specific protein kinase C isoforms in mesangial cells. Ganz MB, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F108–13

PGE2 reverses AVP inhibition of HCO3– absorption in rat MTAL by activation of protein kinase C. Good DW. **Am J Physiol** 1996 Jun;270(6 Pt 2):F978–85

Role of endogenous renin–angiotensin system in c–fos activation and PKC–epsilon translocation in adult rat hearts. Kang PM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2177–83

Adenosine A1 receptor–induced upregulation of protein kinase C: role of pertussis toxin–sensitive G protein(s). Marala RB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1619–24

Acute effects of glucose on reactivity of cerebral microcirculation: role of activation of protein kinase C. Mayhan WG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1297–302

Protein kinase C modulates natriuretic peptide receptors in astroglial cultures from rat brain. Paulding WR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C740–7

Protein kinase C in cyclic stretch–induced nerve growth factor production by urinary tract smooth muscle cells. Persson K, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1018–24

TNF–alpha induces peroxynitrite–mediated depletion of lung endothelial glutathione via protein kinase C. Phelps DT, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L551–9

Protein kinase C, interleukin–1 beta, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Levine SJ, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):254–61

Spinal anesthesia by local anesthetics stimulates the enzyme protein kinase C and induces the expression of an immediate early oncogene, c–Fos. Nivarthi RN, et al. **Anesth Analg** 1996 Sep;83(3):542–7

Fc receptor stimulation of PI 3–kinase in NK cells is associated with protein kinase C–independent granule release and cell–mediated cytotoxicity. Bonnema JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:209–13

Defective protein kinase C alpha leads to impaired secretion of soluble beta–amyloid precursor protein from Alzheimer's disease fibroblasts. Govoni S, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:332–7

Modulation of prohormone convertase mRNA by second messenger activators and drugs. Mania–Farnell B, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:134–44

Protein kinase C mediates short– and long–term effects on receptor tyrosine kinases. Regulation of tyrosine phosphorylation and degradation. Seedorf K, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:459–62

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione–S–transferase, topoisomerase II and MRP in multidrug resistant cell lines. Utz I, et al. **Anticancer Res** 1996 Jan–Feb;16(1):289–96

Substrate–induced translocation of PKC–alpha to the membrane. Bruins RH, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):216–22

Binding of myristoylated alanine–rich protein kinase C substrate to phosphoinositides attenuates the phosphorylation by protein kinase C. Seki K, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):193–201

Modulation of protein kinase C–related signal transduction by 2,3,7,8–tetrachlorodibenzo–p–dioxin exhibits cell cycle dependence. Weber TJ, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):227–32

Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium–derived nitric oxide and endothelium–derived hyperpolarizing factor independent of protein kinase C activation. Cowan CL, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2290–7

Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Minamino T, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2298–304

Inhibition of nitric oxide biosynthesis promotes P–selectin expression in platelets. Role of protein kinase C. Murohara T, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):2068–75

Role of protein kinase C in ischemic preconditioning: in search of the "pure and simple truth". Przyklenk K, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):41–3 (11 ref.)

Differential activation of PKC isozymes by 14–3–3 zeta protein. Acs P, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):103–9

Expression of protein kinase C isozymes that are required for chondrogenesis of chick limb bud mesenchymal cells. Choi B, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1034–40

Differential expression of five protein kinase C isoenzymes in FAO and HepG2 hepatoma cell lines compared with normal rat hepatocytes. Ducher L, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):546–53

The polyether bistratene A activates protein kinase C–delta and induces growth arrest in HL60 cells. Griffiths G, et al. **Biochem Biophys Res Commun** 1996 May 24; 222(3):802–8

Protein kinase C increases force and slows relaxation in smooth muscle: evidence for regulation of the myosin light chain phosphatase. Ikebe M, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):370–6

Arachidonic acid potentiates ACh receptor currents by protein kinase C activation but not by receptor phosphorylation. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):716–21

Zeta PKC in rat preadipocytes: modulation by insulin and serum mitogenic factors and possible role in adipogenesis. Lacasa D, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):123–30

Stimulation of protein kinase C activity by compactin in vascular smooth muscle cells. Latruffe N, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):459–65

Influence of various domains of protein kinase C epsilon on its PMA–induced translocation from the Golgi to the plasma membrane. Lehel C, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):98–103

Differential effects of overexpression of PKC alpha and PKC delta/epsilon on cellular E2F activity in late G1 phase. Nakaigawa N, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):95–100

Correlation between levels of delta protein kinase C and resistance to differentiation in murine erythroleukemia cells. Patrone M, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):26–30

Epsilon PKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture. Perletti G, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):688–91

Involvement of protein kinase C in hypoxia–induced desensitization of the beta–adrenergic system in human endothelial cells. Resink T, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):753–8

The protein kinase C activator Bryostatin–1 induces the rapid release of TNF alpha from MONO–MAC–6 cells. Steube KG, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1197–203

Development of a rapid approach to identification of tyrosine phosphorylation sites: application to PKC delta phosphorylated upon activation of the high affinity receptor for IgE in rat basophilic leukemia cells. Szallasi Z, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):888–94

Activation of protein kinase C by oxidized diacylglycerols. Takekoshi S, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):654–60

Phosphorylation of myosin-I from rat liver by protein kinase C reduces calmodulin binding. Williams R, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):90–102

The involvement of PKC in N-cadherin-mediated adherens junction assembly in cultured cardiomyocytes. Wu JC, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):733–9

Signal transduction in isolated islets from the ob/ob mouse: enhanced sensitivity of protein kinase C to stimulation. Zawalich WS, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):618–23

Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity. Zong Z, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):480–5

Human papillomavirus type 6 E7 protein is a substrate in vitro of protein kinase C. Armstrong DJ, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):667–70

Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Blanco A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):419–23

Bile acid stimulation of early growth response gene and mitogen-activated protein kinase is protein kinase C-dependent. Brady LM, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):765–9

Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. Clerk A, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):109–18

Phosphorylation of human pleckstrin on Ser-113 and Ser-117 by protein kinase C. Craig KL, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):937–42

Dual bradykinin B2 receptor signalling in A431 human epidermoid carcinoma cells: activation of protein kinase C is counteracted by a GS-mediated stimulation of the cyclic AMP pathway. Liebmann C, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):109–18

Chemical cross-linking of pleckstrin in human platelets: evidence for oligomerization of the protein and its dissociation by protein kinase C. McDermott AM, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):119–24

The role of protein kinase C in carbachol-induced and of cAMP-dependent protein kinase in isoproterenol-induced secretion in primary cultured guinea pig parotid acinar cells. Möller K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):181–7

Streptozotocin-induced diabetes elicits the phosphorylation of hepatocyte Gi2 alpha at the protein kinase C site but not at the protein kinase A-controlled site. Morris NJ, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):417–20

Phosphorylation of GAP-43 (growth-associated protein of 43 kDa) by conventional, novel and atypical isotypes of the protein kinase C gene family: differences between oligopeptide and polypeptide phosphorylation. Oehrlein SA, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):219–24

Early signalling events implicated in leukotriene B4-induced activation of the NADPH oxidase in eosinophils: role of Ca2+, protein kinase C and phospholipases C and D. Perkins RS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):795–806

Arachidonic acid and lipoxygenase products stimulate protein kinase C beta mRNA levels in pituitary alpha T3-1 cell line: role in gonadotropin-releasing hormone action. Shraga-Levine Z, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):667–70

The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Si-Tahar M, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):401–8

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039–46

Molecular evidence for the direct involvement of a protein kinase C in developmental and behavioural susceptibility to tumour-promoting phorbol esters in Caenorhabditis elegans. Tabuse Y, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):69–74

Protein kinase C in rod outer segments: effects of phosphorylation of the phosphodiesterase inhibitory subunit. Udovichenko IP, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):291–5

Acidic phospholipids inhibit the intramolecular association between the N- and C-terminal regions of vinculin, exposing actin-binding and protein kinase C phosphorylation sites. Weekes J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):827–32

Contrasting effects of phorbol ester and agonist-mediated activation of protein kinase C on phosphoinositide and Ca2+ signalling in a human neuroblastoma. Willars GB, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):905–13

Insulin and vasopressin elicit inhibition of cholera-toxin-stimulated adenylate cyclase activity in both hepatocytes and the P9 immortalized hepatocyte cell line through an action involving protein kinase C. Zeng L, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):769–74

Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. De Petrocellis L, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1127–33

Protein kinase C phosphorylates two of the four known syndecan cytoplasmic domains in vitro. Prasthofer T, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):793–802

Interaction of purified protein kinase C with key proteins of energy metabolism and cellular motility. Reiss N, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):711–9

The myristoylated alanine-rich C-kinase substrate (MARCKS) is not required for mitogenic signalling via protein kinase C in cultured rat intestinal epithelial (RIE-1) cells. Smith RD. **Biochem Mol Biol Int** 1995 Apr; 35(5):1029–35

Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Ahn CH, et al. **Biochem Pharmacol** 1996 Aug 9; 52(3):393–9

The inhibitory effects of boldine, glaucine, and probucol on TPA-induced down regulation of gap junction function. Relationships to intracellular peroxides, protein kinase C translocation, and connexin 43 phosphorylation. Hu J, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1635–43

Dual effect of 1 alpha,25-dihydroxyvitamin D3 on hsp28 and PKC beta gene expression in phorbol ester-resistant human myeloid HL-525 leukemic cells. Lee YJ, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):311–9

Ca2+ entry induced by calcium influx factor and its regulation by protein kinase C in rabbit neutrophils. Shibata K, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):167–71

The MARCKS family of protein kinase-C substrates. Aderem A. **Biochem Soc Trans** 1995 Aug;23(3):587–91 (31 ref.)

Protein kinase C isoform expression and ATP response change with smooth muscle cell differentiation. Assender JW, et al. **Biochem Soc Trans** 1995 Aug;23(3):453S

Stimulation of prostacyclin release by endothelial ATP receptors requires activation of protein kinase C and tyrosine kinases. Brown CA, et al. **Biochem Soc Trans** 1996 Feb;24(1):55S

A role for protein kinase C in the multidrug resistance phenotype of human carcinoma KB cell lines. Drew L, et al. **Biochem Soc Trans** 1995 Aug;23(3):447S

The relationship between protein kinase C subspecies and multidrug resistance in vincristine resistant Chinese hamster ovary cells. Fenton JA, et al. **Biochem Soc Trans** 1995 Aug; 23(3):450S

Ca(2+)-dependent and Ca(2+)-independent protein kinase C activity in human breast biopsies. Gordge PC, et al. **Biochem Soc Trans** 1995 Aug;23(3):449S

Intracellular targeting of protein kinase C isoenzymes: functional implications. Kiley SC, et al. **Biochem Soc Trans** 1995 Aug;23(3):601–5 (34 ref.)

Investigation into the role of protein kinase C in IL1 and PMA signalling in EL4.NOB-1 thymoma cells. Mahon TM, et al. **Biochem Soc Trans** 1996 Feb;24(1):81S

Demyristoylation of myristoylated alanine-rich C kinase substrate. Manenti S, et al. **Biochem Soc Trans** 1995 Aug; 23(3):561–4

Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596–600 (32 ref.)

Changes in PKC subspecies protein expression as C6 cells reach G(0) by contact inhibition in the presence of serum. Moreton K, et al. **Biochem Soc Trans** 1995 Aug;23(3):446S

Protein kinase C isoforms in endothelial cells: role in agonist stimulated prostacyclin release. Patel V, et al. **Biochem Soc Trans** 1996 Feb;24(1):56S

Protein kinase C modulation of phosphoinositidase C in 1321N1 human astrocytoma cells. Purkiss JR. **Biochem Soc Trans** 1996 Feb;24(1):54S

Activation of phospholipase D in SH-SY5Y neuroblastoma cells: dependence on Ca2+ and protein kinase C. Purkiss JR. **Biochem Soc Trans** 1995 Aug;23(3):427S

Diabetic complications and the mechanism of the hyperglycaemia-induced damage to the mt DNA of cultured vascular endothelial cells: (II) The involvement of protein kinase C. Swoboda BE, et al. **Biochem Soc Trans** 1995 Nov;23(4):519S

Oxidized low-density lipoprotein stimulates protein kinase C (PKC) and induces expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 macrophage-like cells. Claus R, et al. **Biochemistry** 1996 Apr 16; 35(15):4911–22

Calcium-independent binding to interfacial phorbol esters causes protein kinase C to associate with membranes in the absence of acidic lipids. Mosior M, et al. **Biochemistry** 1996 Feb 6;35(5):1612–23

Phospholipid binding, phosphorylation by protein kinase C, and filament assembly of the COOH terminal heavy chain fragments of nonmuscle myosin II isoforms MIIA and MIIB. Murakami N, et al. **Biochemistry** 1995 Dec 12; 34(49):16046–55

Membrane structure of protein kinase C and calmodulin binding domain of myristoylated alanine rich C kinase substrate determined by site-directed spin labeling. Qin Z, et al. **Biochemistry** 1996 Mar 5;35(9):2917–25

Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle. Romanova LY, et al. **Biochemistry** 1996 Jul 30;35(30):9900–6

Cellular distribution of isoforms of protein kinase C (PKC) in pancreatic acini. Bastani B, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):307–15

Biological activity of 26-succinylbryostatin 1. Bignami GS, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):197–206

The selective uptake of the cholesteryl esters of low density lipoproteins parallels the activity of protein kinase C. Brissette L, et al. **Biochim Biophys Acta** 1996 May 31; 1301(1-2):133–40

Protein kinase C-alpha is multiply phosphorylated in response to phorbol ester stimulation of PC12 cells. Gatti A, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):111–8

Isoform-specific redistribution of protein kinase C in living cells. Godson C, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):63–71

Antigen-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells: possible involvement of calcium/calmodulin. Kumada T, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):107–14

Modulation of queuine uptake and incorporation into tRNA by protein kinase C and protein phosphatase. Morris RC, et al. **Biochim Biophys Acta** 1996 Apr 24;1311(2):124–32

Induction of apoptosis in thymocytes: new evidence for an interaction of PKC and PKA pathways. Ojeda F, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):389–93

Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Emoto Y, et al. **Blood** 1996 Mar 1;87(5):1990–6

Protein kinase C inhibits human hair follicle growth and hair fibre production in organ culture. Harmon CS, et al. **Br J Dermatol** 1995 Nov;133(5):686–93

Down-regulation of Langerhans cell protein kinase C-beta isoenzyme expression in inflammatory and hyperplastic dermatoses. Reynolds NJ, et al. **Br J Dermatol** 1995 Aug; 133(2):157–67

Protein kinase C isozymes in human megakaryoblastic leukemia cell line, MEG-01: possible involvement of the isozymes in the differentiation process of MEG-01 cells. Nagata KI, et al. **Br J Haematol** 1996 Jun 2;93(4):762–71

PMA-induced megakaryocytic differentiation of HEL cells is accompanied by striking modifications of protein kinase C catalytic activity and isoform composition at the nuclear level. Zauli G, et al. **Br J Haematol** 1996 Mar;92(3):530–6

Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. Zauli G, et al. **Br J Haematol** 1996 Jun 1;93(3):542–50

Role of protein kinase C in mesenteric pressor responses of rats with portal hypertension. Atucha NM, et al. **Br J Pharmacol** 1996 May;118(2):277–82

Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Mann CD, et al. **Br J Pharmacol** 1995 Jun;115(4):595–600

Phorbol ester activation of chloride current in guinea-pig ventricular myocytes. Shuba LM, et al. **Br J Pharmacol** 1996 Apr;117(7):1395–404

Relationship between opioids and activation of phospholipase C and protein kinase C in brain injury induced pial artery vasoconstriction. Armstead WM. **Brain Res** 1995 Aug 21; 689(2):183–8

Sympathetic sprouting reverses decreases in membrane-associated activity of protein kinase C following septohippocampal denervation of the rat hippocampus. Ayyagari PV, et al. **Brain Res** 1996 Feb 5;708(1-2):205–8

Learning-specific, time-dependent increase in [3H]phorbol dibutyrate binding to protein kinase C in selected regions of the rat brain. Bernabeu R, et al. **Brain Res** 1995 Jul 10;685(1-2):163–8

Activation of protein kinase C does not participate in disruption of the blood-brain barrier to albumin during acute hypertension. Mayhan WG, et al. **Brain Res** 1995 Oct 23;696(1-2):106–12

Activation of endogenous protein kinase C enhances currents through alpha 1 and alpha 2 glycine receptor channels. Nishizaki T, et al. **Brain Res** 1995 Jul 31;687(1-2):214–6

PKC-dependent reduction of the acetylcholine-evoked inward Na current in Aplysia D-neurons: effect of injected PKC and PKC activators. Papp A, et al. **Brain Res** 1996 Feb 5;708(1-2):123–7

Hippocampal long-term potentiation: transient increase but no persistent translocation of protein kinase C isoenzymes alpha and beta. Staak S, et al. **Brain Res** 1995 Jun 5; 682(1-2):55–62

Effect of diacylglycerols on osteoclastic bone resorption. Moonga BS, et al. **Calcif Tissue Int** 1996 Aug;59(2):105–8

Protein kinase C and growth regulation of malignant gliomas. Baltuch GH, et al. **Can J Neurol Sci** 1995 Nov;22(4):264–71 (98 ref.)

The altered activity of membrane-bound protein kinase C in human liver cancer. Chang KJ, et al. **Cancer Lett** 1996 Aug 2;105(2):211–5

Down-regulation of protein kinase C in murine splenocytes: a potential mechanism for 2-acetylaminofluorene-mediated

immunosuppression. Lee M, et al. **Cancer Lett** 1996 Mar 19;101(1):53–7

Cholesterol sulfate, a second messenger for the eta isoform of protein kinase C, inhibits promotional phase in mouse skin carcinogenesis. Chida K, et al. **Cancer Res** 1995 Nov 1;55(21):4865–9

Regulation of the adhesion of a human breast carcinoma cell line to type IV collagen and vitronectin: roles for lipoxygenase and protein kinase C. Palmantier R, et al. **Cancer Res** 1996 May 1;56(9):2206–12

Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Reddy BS, et al. **Cancer Res** 1996 May 15;56(10):2314–20

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C–independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi Z, et al. **Cancer Res** 1996 May 1;56(9):2105–11

Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Yang JM, et al. **Cancer Res** 1996 Aug 1;56(15):3490–4

Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Zhang X, et al. **Cancer Res** 1996 Feb 15;56(4):802–8

Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C. Stanwell C, et al. **Carcinogenesis** 1996 Jun;17(6):1259–65

Spectroscopic characterization of specific phorbol ester binding to PKC-receptor sites in membranes in situ. Svetek J, et al. **Carcinogenesis** 1995 Oct;16(10):2589–92

The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Díaz-Meco MT, et al. **Cell** 1996 Sep 6; 86(5):777–86

Protein kinase C modulates cytosolic free calcium by stimulating calcium pump activity in Jurkat T cells. Balasubramanyam M, et al. **Cell Calcium** 1995 Dec; 18(6):526–41

Both activators and inhibitors of protein kinase C promote the inhibition of phenylephrine-induced [Ca2+]i oscillations in single intact rat hepatocytes. Berrie CP, et al. **Cell Calcium** 1995 Sep;18(3):232–44

24,25(OH)2 vitamin D3 modulates the L-type Ca2+ channel current in UMR 106 cells: involvement of protein kinase A and protein kinase C. Li B, et al. **Cell Calcium** 1996 Mar;19(3):193–200

Selective activation of protein kinase C isoforms by v-Src. Zang Q, et al. **Cell Growth Differ** 1995 Nov;6(11):1367–73

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

Phosphatidylcholine could be the source of 1,2-DAG which activates protein kinase C in EGF-stimulated colon carcinoma cells (HT29). Balogh A, et al. **Cell Signal** 1995 Nov;7(8):793–801

Involvement of protein kinase C and of protein phosphatases 1 and/or 2A in p47 phox phosphorylation in formylmet-Leu-Phe stimulated neutrophils: studies with selective inhibitors RO 31-8220 and calyculin A. Bengis-Garber C, et al. **Cell Signal** 1995 Sep;7(7):721–32

Down-regulation and differential restoration of cAMP responses upon transient phorbol ester treatment of primary osteoblastic cells. Bos MP, et al. **Cell Signal** 1995 Aug; 7(6):617–26

Signal transduction pathways leading to arachidonic acid release from neutrophilic HL-60 cells. The involvement of G protein, protein kinase C and phospholipase A2. Buhl WJ, et al. **Cell Signal** 1995 May;7(4):351–64

Differential regulation of phospholipase D and phospholipase C by protein kinase C-beta and -delta in liver macrophages. Dieter P, et al. **Cell Signal** 1995 Sep;7(7):687–94

Is the glycogen synthase analogue C1-peptide a suitable fluorescent substrate for routine measurements of protein kinase C? Erdbrügger W, et al. **Cell Signal** 1995 Aug; 7(6):635–42

The heat-stable protein kinase C (PKC) stimulatory factor in the rat ovary may allow PKC to be active independent of cell membrane lipids. Eyster KM. **Cell Signal** 1995 Jul; 7(5):457–61

Phosphorylation of MARCKS, neuromodulin, and neurogranin by protein kinase C exhibits differential responses to diacylglycerols. Mahoney CW, et al. **Cell Signal** 1995 Sep;7(7):679–85

The presence of phorbol ester responsive and non-responsive forms of the zeta isozyme of protein kinase C in mouse epidermal cells. Nishikawa K, et al. **Cell Signal** 1995 Jul; 7(5):491–504

Signal transduction mechanism in response to aflatoxin B1 exposure: protein kinase C activity. Mistry KJ, et al. **Chem Biol Interact** 1996 Mar 25;100(2):177–85

Adenosine A1 stimulation activates delta-protein kinase C in rat ventricular myocytes. Henry P, et al. **Circ Res** 1996 Jan;78(1):161–5

Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Hu K, et al. **Circ Res** 1996 Mar;78(3):492–8

Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Liu Y, et al. **Circ Res** 1996 Mar; 78(3):443–54

Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Murohara T, et al. **Circ Res** 1996 May;78(5):780–9

Identification of protein kinase C isoforms in rat mesenteric small arteries and their possible role in agonist-induced contraction. Ohanian V, et al. **Circ Res** 1996 May; 78(5):806–12

Thyroid hormone represses protein kinase C isoform expression and activity in rat cardiac myocytes. Rybin V, et al. **Circ Res** 1996 Sep;79(3):388–98

Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Speechly-Dick ME, et al. **Circ Res** 1995 Nov;77(5):1030–5

Coronary artery spasm does not depend on the intracellular calcium store but is substantially mediated by the protein kinase C–mediated pathway in a swine model with interleukin-1 beta in vivo. Kadokami T, et al. **Circulation** 1996 Jul 15;94(2):190–6

Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Kitakaze M, et al. **Circulation** 1996 Feb 15;93(4):781–91

Differential regulation of human T lymphocyte protein kinase C activity by unsaturated fatty acids. Rossetti RG, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):220–4

Increased membrane-bound protein kinase C in porcine thyroid cells following TSH exposure. Matowe WC, et al. **Clin Invest Med** 1995 Jun;18(3):186–92

The zeta protein kinase C isoform from the testis of the grey mullet Mugil cephalus with a specific reaction protein of M(r) 48,000 on oolemma. Huang CF, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):429–33

Protein kinase C. Seeing two domains. Newton AC. **Curr Biol** 1995 Sep 1;5(9):973–6 (20 ref.)

Protein kinase C isoforms in iris sphincter smooth muscle: differential effects of phorbol ester on contraction and cAMP accumulation are species specific. Husain S, et al. **Curr Eye Res** 1996 Mar;15(3):329–34

Protein kinase C isozymes and substrates. Jaken S. **Curr Opin Cell Biol** 1996 Apr;8(2):168–73 (58 ref.)

Protein kinase C-delta, an important signaling molecule in the platelet-derived growth factor beta receptor pathway. Li W, et al. **Curr Top Microbiol Immunol** 1996;211:55–65 (23 ref.)

LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. Birch KA, et al. **Diabetes** 1996 May;45(5):642–50

Vitamin E normalizes diacylglycerol-protein kinase C activation induced by hyperglycemia in rat vascular tissues. Kunisaki M, et al. **Diabetes** 1996 Jul;45 Suppl 3:S117–9

EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3-kinase. Akimoto K, et al. **EMBO J** 1996 Feb 15;15(4):788–98

Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. Berra E, et al. **EMBO J** 1995 Dec 15;14(24):6157–63

Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. Emoto Y, et al. **EMBO J** 1995 Dec 15;14(24):6148–56

A pathway in the yeast cell division cycle linking protein kinase C (Pkc1) to activation of Cdc28 at START. Marini NJ, et al. **EMBO J** 1996 Jun 17;15(12):3040–52

A downstream target of RHO1 small GTP-binding protein is PKC1, a homolog of protein kinase C, which leads to activation of the MAP kinase cascade in Saccharomyces cerevisiae. Nonaka H, et al. **EMBO J** 1995 Dec 1; 14(23):5931–8

Lineage commitment of transformed haematopoietic progenitors is determined by the level of PKC activity. Rossi F, et al. **EMBO J** 1996 Apr 15;15(8):1894–901

Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649–81 (268 ref.)

Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Ignar-Trowbridge DM, et al. **Endocrinology** 1996 May;137(5):1735–44

Relationship among cellular diacylglycerol, sphingosine formation, protein kinase C activity, and parathyroid hormone secretion from dispersed bovine parathyroid cells. McKay C, et al. **Endocrinology** 1996 Jun;137(6):2473–9

Insulin stimulates phospholipase D-dependent phosphatidylcholine hydrolysis, Rho translocation, de novo phospholipid synthesis, and diacylglycerol/protein kinase C signaling in L6 myotubes. Standaert ML, et al. **Endocrinology** 1996 Jul;137(7):3014–20

Activators of protein kinase C but not of phospholipase C modulate adenylate cyclase-responses of normal pig epidermis. Iizuka H, et al. **Epithelial Cell Biol** 1995; 4(1):35–41

Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Rothhut B, et al. **Eur J Biochem** 1995 Sep 15;232(3):865–72

Physical association and functional relationship between protein kinase C zeta and the actin cytoskeleton. Gómez J, et al. **Eur J Immunol** 1995 Sep;25(9):2673–8

Association of phosphatidylinositol 3 kinase to protein kinase C zeta during interleukin-2 stimulation. Gómez J, et al. **Eur J Immunol** 1996 Aug;26(8):1781–7

Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta. Bazan E, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):253–7

Feedforward control of agonist-induced Ca2+ signalling by protein kinase C in airway smooth muscle cells. Hoiting BH, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):R5–7

Ca2+ channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats. Tokuyama S, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):93–8

1,25-dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Bhatia M, et al. **Exp Cell Res** 1996 Jan 10;222(1):61–9

Fertilization in Dictyostelium: pharmacological analyses and the presence of a substrate protein suggest protein kinase C is essential for gamete fusion. Gunther KE, et al. **Exp Cell Res** 1995 Oct;220(2):325–331

Chronic exposure of LLC-PK1 epithelia to the phorbol ester TPA produces polyp-like foci with leaky tight junctions and altered protein kinase C-alpha expression and localization. Mullin JM, et al. **Exp Cell Res** 1996 Aug 25; 227(1):12–22

Protein kinase C-delta associates with vimentin intermediate filaments in differentiated HL60 cells. Owen PJ, et al. **Exp Cell Res** 1996 Jun 15;225(2):366–73

Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Park HY, et al. **Exp Cell Res** 1996 Aug 25;227(1):70–9

Inhibition by Interleukin-4 of stromelysin expression in human skin fibroblasts: role of PKC. Prontera C, et al. **Exp Cell Res** 1996 Apr 10;224(1):183–8

Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Rusnak JM, et al. **Exp Cell Res** 1996 Apr 10;224(1):189–99

Insulin leads to a parallel translocation of PI-3-kinase and protein kinase C zeta [see comments] Mosthaf L, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):19–24. Comment in: Exp Clin Endocrinol Diabetes 1996;104(1):17–8.

Diabetes: many leads to PKC (protein kinase C) [comment] Pfeiffer A. **Exp Clin Endocrinol Diabetes** 1996;104(1):17–8 . Comment on: Exp Clin Endocrinol Diabetes 1996;104(1):19–24.

Protein kinase C substrates in corneal epithelium during wound healing: the phosphorylation of growth associated protein-43 (GAP-43). Lin N, et al. **Exp Eye Res** 1995 Oct; 61(4):451–9

Upregulation of PKC delta- and downregulation of PKC alpha-mRNA and protein by phorbol ester in human T84 cells. Assert R, et al. **FEBS Lett** 1996 Jun 17;388(2-3):195–9

PKC alpha regulates thrombin-induced PDGF-B chain gene expression in mesangial cells. Biswas P, et al. **FEBS Lett** 1995 Oct 9;373(2):146–50

The beta 1-subunit is essential for modulation by protein kinase C of an human and a non-human L-type Ca2+ channel. Bouron A, et al. **FEBS Lett** 1995 Dec 18; 377(2):159–62

In vitro activation and substrates of recombinant, baculovirus expressed human protein kinase C mu. Dieterich S, et al. **FEBS Lett** 1996 Mar 4;381(3):183–7

Down-regulation of the protein kinase A pathway by activators of protein kinase C and intracellular Ca2+ in fibroblast cells. Döbbeling U, et al. **FEBS Lett** 1996 Aug 5;391(1-2):131–3

Cellular distribution of protein kinase C isozymes in CD3-mediated stimulation of human T lymphocytes with aging. Fulop T Jr, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):69–74

Regulation of type V adenylyl cyclase by PMA-sensitive and -insensitive protein kinase C isoenzymes in intact cells. Kawabe Ji, et al. **FEBS Lett** 1996 Apr 22;384(3):273–6

Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes. Kieser A, et al. **FEBS Lett** 1995 Sep 25;372(2-3):189–93

NO2-induced expression of specific protein kinase C isoforms and generation of phosphatidylcholine-derived diacylglycerol in cultured pulmonary artery endothelial cells. Li YD, et al. **FEBS Lett** 1996 Jul 1;389(2):131–5

Regulation of the mouse retinal taurine transporter (TAUT) by protein kinases in Xenopus oocytes. Loo DD, et al. **FEBS Lett** 1996 Sep 2;392(3):250–4

Possible role of protein kinase C in the regulation of intracellular stability of focal adhesion kinase in mouse 3T3 cells. Mogi A, et al. **FEBS Lett** 1995 Oct 9;373(2):135–40

Adenosine evokes potassium currents by protein kinase C activated via a novel signaling pathway in superior colliculus neurons. Nishizaki T, et al. **FEBS Lett** 1996 Jan 2;378(1):1–6

PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and serine 163. Palmer RH, et al. **FEBS Lett** 1996 Jan 15;378(3):281–5

Modulation by protein kinase C activation of rat brain delayed-rectifier K+ channel expressed in Xenopus oocytes. Peretz T, et al. **FEBS Lett** 1996 Feb 26; 381(1-2):71–6

The recombinant GABA transporter GAT1 is downregulated upon activation of protein kinase C. Sato K, et al. **FEBS Lett** 1995 Nov 13;375(1–2):99–102

Intramolecular interactions regulate serine/threonine phosphorylation of vinculin. Schwienbacher C, et al. **FEBS Lett** 1996 Apr 8;384(1):71–4

The protein kinase C activator TPA modulates cellular levels and distribution of E–cadherin in HT–29 human intestinal epithelial cells. Skoudy A, et al. **FEBS Lett** 1995 Nov 6; 374(3):415–8

Terminal deoxynucleotidil transferase is a nuclear PKC substrate. Trubiani O, et al. **FEBS Lett** 1995 Nov 6; 374(3):367–70

The significance of Ser1029 of the heat–stable enterotoxin receptor (STaR): relation of STa–mediated guanylyl cyclase activation and signaling by phorbol myristate acetate. Wada A, et al. **FEBS Lett** 1996 Apr 8;384(1):75–7

Activation of mitogen–activated protein kinase by protein kinase C isotypes alpha, beta I and gamma, but not epsilon. Young SW, et al. **FEBS Lett** 1996 Apr 15;384(2):181–4

Protein kinase C and F–actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G–proteins and amyloid beta protein. Zhang C, et al. **FEBS Lett** 1996 May 20;386(2–3):185–8

Lateral mobility of Fc gamma RIIa is reduced by protein kinase C activation. Zhang F, et al. **FEBS Lett** 1995 Nov 27;376(1–2):77–80

Effects of glucose, tetrapyrroles and protein kinase C activators on cell proliferation in cultures of Saccharomyces cerevisiae. Overgaard AK, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):159–63

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Beuers U, et al. **Gastroenterology** 1996 May;110(5):1553–63

Protein kinase C isoforms in the chemopreventive effects of a novel vitamin D3 analogue in rat colonic tumorigenesis. Wali RK, et al. **Gastroenterology** 1996 Jul;111(1):118–26

Epidermal growth factor inhibits carbachol–stimulated canine parietal cell function via protein kinase C. Wang L, et al. **Gastroenterology** 1996 Feb;110(2):469–77

Interactions between signaling pathways in mediating GnRH–stimulated GTH release from goldfish pituitary cells: protein kinase C, but not cyclic AMP is an important mediator of GnRH–stimulated gonadotropin secretion in goldfish. Jobin RM, et al. **Gen Comp Endocrinol** 1996 Jun; 102(3):327–41

Protein kinase C isozymes in prostatic epithelial cells from normal, diabetic and insulin–treated diabetic rats. Garcia–Paramio PL, et al. **Gen Pharmacol** 1995 Dec; 26(8):1673–8

Estrogen induces expression of c–fos and c–jun via activation of protein kinase C in an endometrial cancer cell line and fibroblasts derived from human uterine endometrium. Fujimoto J, et al. **Gynecol Endocrinol** 1996 Apr; 10(2):109–18

The effect of protein kinase C stimulator and inhibitor on cochlear potentials in the guinea pig. Kitano I, et al. **Hear Res** 1995 May;85(1–2):11–7

Mitogen–activated protein kinase activation in hepatocyte growth factor–stimulated rat hepatocytes: involvement of protein tyrosine kinase and protein kinase C. Adachi T, et al. **Hepatology** 1996 May;23(5):1244–53

Alterations in the immunoreactivity for muscarinic acetylcholine receptors and colocalized PKC gamma in mouse hippocampus induced by spatial discrimination learning. Van der Zee EA, et al. **Hippocampus** 1995; 5(4):349–62

Immunocytochemical evaluation of protein kinase C translocation to the inner nuclear matrix in 3T3 mouse fibroblasts after IGF–I treatment. Zini N, et al. **Histochem Cell Biol** 1995 Jun;103(6):447–57

Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C–independent mechanism. Davda RK, et al. **Hypertension** 1995 Nov;26(5):764–70

Regulation of angiotensin II type 2 receptor gene by the protein kinase C–calcium pathway. Kijima K, et al. **Hypertension** 1996 Mar;27(3 Pt 2):529–34

Prostacyclin synthesis elicited by endothelin–1 in rat aorta is mediated by an ETA receptor via influx of calcium and is independent of protein kinase C. Wright HM, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1035–40

Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentration. Yasunari K, et al. **Hypertension** 1996 Aug; 28(2):159–68

Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization. Zhang M, et al. **Hypertension** 1996 Feb;27(2):269–75

Entamoeba histolytica stimulates the unstable transcription of c–fos and tumour necrosis factor–alpha mRNA by protein kinase C signal transduction in macrophages. Seguin R, et al. **Immunology** 1995 Sep;86(1):49–57

Role of protein kinase C in growth stimulation of primary mouse colonic epithelial cells. Branting C, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov;31(10):790–5

Increased desensitization by picomolar phorbol ester of the endothelium–mediated effect of histamine in the perfused rat mesenteric bed. Ignesti G, et al. **Inflamm Res** 1996 Apr; 45(4):171–5

Differential involvement of protein kinase C in activating cytosolic phospholipase A2 in alveolar macrophages and monocyte differentiated U937 cells. Withnall MT, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S139–40

Induction of intercellular adhesion molecule–1 by tumor necrosis factor–alpha through the 55–kDa receptor is dependent on protein kinase C in human retinal pigment epithelial cells. Sippy BD, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):597–606

A novel protein phosphatase–1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. Eto M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1104–7

Purification and phosphorylation of a M(r) 25,000 protein, an effective phosphate acceptor for casein kinase II and protein kinase C, detected in the cytosolic fraction of Xenopus laevis oocytes. Hashimoto E, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):453–60

Phosphorylated sites of M(r) 25,000 protein, a putative protein phosphatase 2A modulator, and phosphorylation of the synthetic peptide containing these sites by protein kinase C. Hashimoto E, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):626–32

Effects of protein kinase C and A activation on ATP–stimulated release of [3H]noradrenaline from PC12 cells. Oda H, et al. **J Biochem (Tokyo)** 1995 Aug; 118(2):325–31

Protein kinase C regulates pleckstrin by phosphorylation of sites adjacent to the N–terminal pleckstrin homology domain. Abrams CS, et al. **J Biol Chem** 1995 Oct 6; 270(40):23317–21

Nuclear phospholipase D in Madin–Darby canine kidney cells. Guanosine 5'–O–(thiotriphosphate)–stimulated activation is mediated by RhoA and is downstream of protein kinase C. Balboa MA, et al. **J Biol Chem** 1995 Dec 15;270(50):29843–7

Protein kinase C betaII specifically binds to and is activated by F–actin. Blobe GC, et al. **J Biol Chem** 1996 Jun 28; 271(26):15823–30

Ca2+ x calmodulin prevents myristoylated alanine–rich kinase C substrate protein phosphorylation by protein kinase Cs in C6 rat glioma cells. Chakravarthy BR, et al. **J Biol Chem** 1995 Oct 20;270(42):24911–6

Stimulus–dependent phosphorylation of MacMARCKS, a protein kinase C substrate, in nerve termini and PC12 cells. Chang S, et al. **J Biol Chem** 1996 Jan 12;271(2):1174–8

Identification of the major protein kinase C–binding protein and substrate in rat embryo fibroblasts. Decreased expression in transformed cells. Chapline C, et al. **J Biol Chem** 1996 Mar 15;271(11):6417–22

Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. Chun JS, et al. **J Biol Chem** 1996 May 31;271(22):13008–12

A second osmosensing signal transduction pathway in yeast. Hypotonic shock activates the PKC1 protein kinase–regulated cell integrity pathway. Davenport KR, et al. **J Biol Chem** 1995 Dec 15;270(50):30157–61

Reversible Ca2+–dependent translocation of protein kinase C and glucose–induced insulin release. Deeney JT, et al. **J Biol Chem** 1996 Jul 26;271(30):18154–60

Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta. Denning MF, et al. **J Biol Chem** 1996 Mar 8;271(10):5325–31

Molecular characterization of the di–leucine–based internalization motif of the T cell receptor. Dietrich J, et al. **J Biol Chem** 1996 May 10;271(19):11441–8

Modulation of cytosolic protein kinase C and calcium ion activity by steroid hormones in rat distal colon. Doolan CM, et al. **J Biol Chem** 1996 Apr 12;271(15):8763–7

Differential regulation of fibroblast growth factor (FGF) receptor–1 mRNA and protein by two molecular forms of basic FGF. Modulation of FGFR–1 mRNA stability. Estival A, et al. **J Biol Chem** 1996 Mar 8;271(10):5663–70

Protein kinase C delta specifically associates with phosphatidylinositol 3–kinase following cytokine stimulation. Ettinger SL, et al. **J Biol Chem** 1996 Jun 14; 271(24):14514–8

Phosphorylation of Gz alpha by protein kinase C blocks interaction with the beta gamma complex. Fields TA, et al. **J Biol Chem** 1995 Sep 29;270(39):23119–25

Phosphorylation of Munc–18/n–Sec1/rbSec1 by protein kinase C: its implication in regulating the interaction of Munc–18/n–Sec1/rbSec1 with syntaxin. Fujita Y, et al. **J Biol Chem** 1996 Mar 29;271(13):7265–8

Cloning of a fibroblast growth factor receptor 1 splice variant from Xenopus embryos that lacks a protein kinase C site important for the regulation of receptor activity. Gillespie LL, et al. **J Biol Chem** 1995 Sep 29;270(39):22758–63

Protein kinase C–mediated phosphorylation does not regulate drug transport by the human multidrug resistance P–glycoprotein. Goodfellow HR, et al. **J Biol Chem** 1996 Jun 7;271(23):13668–74

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor–negative breast cancer cells. Gundimeda U, et al. **J Biol Chem** 1996 Jun 7; 271(23):13504–14

Phosphorylation of human m1 muscarinic acetylcholine receptors by G protein–coupled receptor kinase 2 and protein kinase C. Haga K, et al. **J Biol Chem** 1996 Feb 2;271(5):2776–82

Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. Hirsch JR, et al. **J Biol Chem** 1996 Jun 21;271(25):14740–6

Differential phosphorylation of the T lymphocyte costimulatory receptor CD28. Activation–dependent changes and regulation by protein kinase C. Hutchcroft JE, et al. **J Biol Chem** 1996 Jun 7;271(23):13362–70

A novel phosphatidylserine–binding peptide motif defined by an anti–idiotypic monoclonal antibody. Localization of phosphatidylserine–specific binding sites on protein kinase C and phosphatidylserine decarboxylase. Igarashi K, et al. **J Biol Chem** 1995 Dec 8;270(49):29075–8

Phosphorylation–dependent regulation of cardiac Na+/Ca2+ exchanger via protein kinase C. Iwamoto T, et al. **J Biol Chem** 1996 Jun 7;271(23):13609–15

Characterization of IkappaB kinases. IkappaB–alpha is not phosphorylated by Raf–1 or protein kinase C isozymes, but is a casein kinase II substrate. Janosch P, et al. **J Biol Chem** 1996 Jun 7;271(23):13868–74

Activation of yeast protein kinase C by Rho1 GTPase. Kamada Y, et al. **J Biol Chem** 1996 Apr 19;271(16):9193–6

Protein kinase C phosphorylates G12 alpha and inhibits its interaction with G beta gamma. Kozasa T, et al. **J Biol Chem** 1996 May 24;271(21):12562–7

Ubiquitination of protein kinase C–alpha and degradation by the proteasome. Lee HW, et al. **J Biol Chem** 1996 Aug 30;271(35):20973–6

Aggregation of the Fc epsilon RI in mast cells induces the synthesis of Fos–interacting protein and increases its DNA binding–activity: the dependence on protein kinase C–beta. Lewin I, et al. **J Biol Chem** 1996 Jan 19;271(3):1514–9

Role of mitogen–activated protein kinase kinase in regulation of the epidermal growth factor receptor by protein kinase C. Morrison P, et al. **J Biol Chem** 1996 May 31; 271(22):12891–6

Mechanism of interaction of protein kinase C with phorbol esters. Reversibility and nature of membrane association. Mosior M, et al. **J Biol Chem** 1995 Oct 27;270(43):25526–33

Protein kinase C: structure, function, and regulation. Newton AC. **J Biol Chem** 1995 Dec 1;270(48):28495–8 (78 ref.)

Regulation of membrane–bound phospholipase D by protein kinase C in HL60 cells. Synergistic action of small GTP–binding protein RhoA. Ohguchi K, et al. **J Biol Chem** 1996 Feb 23;271(8):4366–72

Phosphorylation of the type 1A angiotensin II receptor by G protein–coupled receptor kinases and protein kinase C. Oppermann M, et al. **J Biol Chem** 1996 May 31; 271(22):13266–72

Human cancer cells exhibit protein kinase C–dependent c–erbB–2 transmodulation that correlates with phosphatase sensitivity and kinase activity. Ouyang X, et al. **J Biol Chem** 1996 Sep 6;271(36):21786–92

"In vitro" phosphorylation of annexin 2 heterotetramer by protein kinase C. Comparative properties of the unphosphorylated and phosphorylated annexin 2 on the aggregation and fusion of chromaffin granule membranes. Regnouf F, et al. **J Biol Chem** 1995 Nov 10; 270(45):27143–50

Protein kinase C isozymes differentially regulate promoters containing PEA–3/12–O–tetradecanoylphorbol–13–acetate response element motifs. Reifel–Miller AE, et al. **J Biol Chem** 1996 Aug 30;271(35):21666–71

Mechanism of metallothionein gene regulation by heme–hemopexin. Roles of protein kinase C, reactive oxygen species, and cis–acting elements. Ren Y, et al. **J Biol Chem** 1995 Oct 13;270(41):23988–95

Differential effects of protein kinase C activation on calcium storage and capacitative calcium entry in NIH 3T3 cells. Ribeiro CMP, et al. **J Biol Chem** 1996 Aug 30; 271(35):21522–8

Interleukin–1beta activates protein kinase C zeta in renal mesangial cells. Potential role in prostaglandin E2 up–regulation. Rzymkiewicz DM, et al. **J Biol Chem** 1996 Jul 19;271(29):17241–6

Partial inhibition of multidrug resistance by safingol is independent of modulation of P–glycoprotein substrate activities and correlated with inhibition of protein kinase C. Sachs CW, et al. **J Biol Chem** 1995 Nov 3; 270(44):26639–48

Enhancement of protein kinase C–dependent O2 production in Epstein–Barr virus–transformed B lymphocytes by p120Ras–GAP antisense oligonucleotide. Schmid E, et al. **J Biol Chem** 1996 Apr 19;271(16):9320–5

Sphingosylphosphorylcholine activation of mitogen–activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin–sensitive G protein. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24334–42

Phosphorylation of 25–kDa synaptosome–associated protein. Possible involvement in protein kinase C–mediated regulation of neurotransmitter release. Shimazaki Y, et al. **J Biol Chem** 1996 Jun 14;271(24):14548–53

The in vitro generation of post–Golgi vesicles carrying viral envelope glycoproteins requires an ARF–like GTP–binding protein and a protein kinase C associated with the Golgi apparatus. Simon JP, et al. **J Biol Chem** 1996 Jul 12;271(28):16952–61

Regulation of phospholipase D by protein kinase C is synergistic with ADP–ribosylation factor and independent of protein kinase activity. Singer WD, et al. **J Biol Chem** 1996 Feb 23;271(8):4504–10

Protein kinase Calpha contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities. Slater SJ, et al. **J Biol Chem** 1996 Mar 1; 271(9):4627–31

The HIV nef protein associates with protein kinase C theta.

Smith BL, et al. **J Biol Chem** 1996 Jul 12;271(28):16753–7
Protein kinase C–mediated phosphorylation of the myristoylated alanine–rich C–kinase substrate protects it from specific proteolytic cleavage. Spizz G, et al. **J Biol Chem** 1996 Jan 5;271(1):553–62
The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene. Ueda E, et al. **J Biol Chem** 1996 Apr 19;271(16):9790–4
G(o)–protein alpha–subunits activate mitogen–activated protein kinase via a novel protein kinase C–dependent mechanism. van Biesen T, et al. **J Biol Chem** 1996 Jan 19;271(3):1266–9
Selective cleavage of the heregulin receptor ErbB–4 by protein kinase C activation. Vecchi M, et al. **J Biol Chem** 1996 Aug 2;271(31):18989–95
Phorbol ester regulation of opioid peptide gene expression in myocardial cells. Role of nuclear protein kinase. Ventura C, et al. **J Biol Chem** 1995 Dec 15;270(50):30115–20
Metabolic stress opens K+ channels in hepatoma cells through a Ca2+– and protein kinase calpha–dependent mechanism. Wang Y, et al. **J Biol Chem** 1996 Jul 26; 271(30):18107–13
Cell cycle phase–specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. Wells NJ, et al. **J Biol Chem** 1995 Nov 24; 270(47):28357–63
Heterologous desensitization of the glucagon–like peptide–1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. Widmann C, et al. **J Biol Chem** 1996 Aug 16;271(33):19957–63
Differential effects of the protein kinase C activator phorbol 12–myristate 13–acetate on calcium responses and secretion in adherent and suspended RBL–2H3 mucosal mast cells. Wolfe PC, et al. **J Biol Chem** 1996 Mar 22;271(12):6658–65
Selective inhibition of thrombin receptor–mediated Ca2+ entry by protein kinase C beta. Xu Y, et al. **J Biol Chem** 1995 Oct 13;270(41):23887–90
Regulation of yeast CTP synthetase activity by protein kinase C. Yang WL, et al. **J Biol Chem** 1996 May 10; 271(19):11113–9
Possible role for protein kinase C in the pathogenesis of inborn errors of metabolism. Boneh A. **J Cell Biochem** 1995 Sep;59(1):27–32 (38 ref.)
Protein kinase C regulates alpha v beta 5–dependent cytoskeletal associations and focal adhesion kinase phosphorylation. Lewis JM, et al. **J Cell Biol** 1996 Sep; 134(5):1323–32
Differential targeting of protein kinase C and CaM kinase II signalings to vimentin. Ogawara M, et al. **J Cell Biol** 1995 Nov;131(4):1055–66
Identification and localization of an actin–binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. Prekeris R, et al. **J Cell Biol** 1996 Jan;132(1–2):77–90
Mitosis–specific phosphorylation of vimentin by protein kinase C coupled with reorganization of intracellular membranes. Takai Y, et al. **J Cell Biol** 1996 Apr; 133(1):141–9
PDGF induction of alpha 2 integrin gene expression is mediated by protein kinase C–zeta. Xu J, et al. **J Cell Biol** 1996 Sep;134(5):1301–11
Protein kinase C mediates up–regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro. Ando Y, et al. **J Cell Physiol** 1996 Jun;167(3):500–11
Pregnancy–stimulated growth of vascular smooth muscle cells: importance of protein kinase C–dependent synergy between estrogen and platelet–derived growth factor. Keyes LE, et al. **J Cell Physiol** 1996 Jan;166(1):22–32
Interaction of insulin, glucocorticoids, and protein kinase C in the regulation of insulin–like growth factor–binding protein–1 production by H4IIE rat hepatoma cells. Lewitt MS, et al. **J Cell Physiol** 1996 Jan;166(1):121–9
Regulation of melanogenesis in B16 mouse melanoma cells by protein kinase C. Mahalingam H, et al. **J Cell Physiol** 1996 Sep;168(3):549–58
Protein kinase C beta 1 overexpression augments phorbol ester–induced increase in endothelial permeability. Nagpala PG, et al. **J Cell Physiol** 1996 Feb;166(2):249–55
Deletion of specific protein kinase C subspecies in human melanoma cells. Oka M, et al. **J Cell Physiol** 1996 Jun; 167(3):406–12
Regulatory domain of human protein kinase C alpha dominantly inhibits protein kinase C beta–I–regulated growth and morphology in Saccharomyces cerevisiae. Parissenti AM, et al. **J Cell Physiol** 1996 Mar;166(3):609–17
Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte–like HL–60 cells is linked to protein kinase C activation. Sultana C, et al. **J Cell Physiol** 1996 Jun;167(3):477–87
Nongenomic regulation of protein kinase C isoforms by the vitamin D metabolites 1 alpha,25–(OH)2D3 and 24R,25–(OH)2D3. Sylvia VL, et al. **J Cell Physiol** 1996 Jun;167(3):380–93
C–terminal fragment of parathyroid hormone–related protein, PTHrP–(107–111), stimulates membrane–associated protein kinase C activity and modulates the proliferation of human and murine skin keratinocytes. Whitfield JF, et al. **J Cell Physiol** 1996 Jan; 166(1):1–11
Stratifin, a keratinocyte specific 14–3–3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. Dellambra E, et al. **J Cell Sci** 1995 Nov; 108 (Pt 11):3569–79
Suppression of apoptosis by v–ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin–3–dependent haemopoietic cell line. Evans CA, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2591–8
Transcriptional activation of endothelial cell integrin alpha v by protein kinase C activator 12(S)–HETE. Tang DG, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2629–44
Urea signaling in cultured murine inner medullary collecting duct (mIMCD3) cells involves protein kinase C, inositol 1,4,5–trisphosphate (IP3), and a putative receptor tyrosine kinase. Cohen DM, et al. **J Clin Invest** 1996 Apr 15; 97(8):1884–9
Vascular incorporation of alpha–tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. Keaney JF Jr, et al. **J Clin Invest** 1996 Jul 15;98(2):386–94
Protein kinase C in diabetic nephropathy. Craven PA, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):241–5
Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. Haneda M, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):246–8
Role of protein kinase C and cyclic AMP/protein kinase A in high glucose–stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)
Association of protein kinase–C–alpha with cytoplasmic vesicles in melanoma cells. Timar J, et al. **J Histochem Cytochem** 1996 Feb;44(2):177–82
Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross–linking on mast cells. Kawakami Y, et al. **J Immunol** 1995 Oct 1;155(7):3556–62
CD40 ligation results in protein kinase C–independent activation of ERK and JNK in resting murine splenic B cells. Li YY, et al. **J Immunol** 1996 Aug 15;157(4):1440–7
Regulation of IkB alpha phosphorylation by PKC– and Ca(2+)–dependent signal transduction pathways. Steffan NM, et al. **J Immunol** 1995 Nov 15;155(10):4685–91
CD28–mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3–kinase, and protein kinase C. Teng JM, et al. **J Immunol** 1996 May 1;156(9):3222–32
pim–1 proto–oncogene expression in anti–CD3–mediated T cell activation is associated with protein kinase C activation and is independent of Raf–1. Wingett D, et al. **J Immunol** 1996 Jan 15;156(2):549–57
Absence of down–regulation and translocation of the eta isoform of protein kinase C in normal human keratinocytes. Murakami A, et al. **J Invest Dermatol** 1996 Apr; 106(4):790–4
Staurosporine induces a sequential program of mouse keratinocyte terminal differentiation through activation of PKC isozymes. Stanwell C, et al. **J Invest Dermatol** 1996 Mar;106(3):482–9
Protein kinase C activator inhibits progression of osteoarthritis induced in rabbit knee joints [see comments] Hamanishi C, et al. **J Lab Clin Med** 1996 Jun;127(6):540–4 . Comment in: J Lab Clin Med 1996 Jun;127(6):520–1.
A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. Labadia ME, et al. **J Leukoc Biol** 1996 Jan; 59(1):116–24
Signal transduction pathway of acylation stimulating protein: involvement of protein kinase C. Baldo A, et al. **J Lipid Res** 1995 Jul;36(7):1415–26
Conformationally constrained analogues of diacylglycerol. 12. Ultrapotent protein kinase C ligands based on a chiral 4,4–disubstituted heptono–1,4–lactone template. Lee J, et al. **J Med Chem** 1996 Jan 5;39(1):36–45
Conformationally constrained analogues of diacylglycerol. 11. Ultrapotent protein kinase C ligands based on a chiral 5–disubstituted tetrahydro–2–furanone template. Lee J, et al. **J Med Chem** 1996 Jan 5;39(1):29–35
Conformationally constrained analogues of diacylglycerol. 10. Ultrapotent protein kinase C ligands based on a racemic 5–disubstituted tetrahydro–2–furanone template. Sharma R, et al. **J Med Chem** 1996 Jan 5;39(1):19–28
Regulation of epithelial Na+ permeability by protein kinase C is tissue specific. Chalfant ML, et al. **J Membr Biol** 1996 Aug;152(3):207–15
Identification of isoforms of G proteins and PKC that colocalize with tight junctions. Dodane V, et al. **J Membr Biol** 1996 Feb;149(3):199–209
Regulation of Na–K–ATPase activity in the proximal tubule: role of the protein kinase C pathway and of eicosanoids. Ominato M, et al. **J Membr Biol** 1996 Aug;152(3):235–43
Dioctanoyl–glycerol inhibits L–type calcium current in embryonic chick cardiomyocytes independent of protein kinase C activation. Conforti L, et al. **J Mol Cell Cardiol** 1995 May;27(5):1219–24
Role of protein kinase C in mediating effects of hydrogen peroxide in guinea–pig ventricular myocytes. Ward CA, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1089–97
Fibrinogen promotes monocyte adhesion via a protein kinase C dependent mechanism. Kreuzer J, et al. **J Mol Med** 1996 Mar;74(3):161–5
Activation of protein kinase C augments peptide release from rat sensory neurons. Barber LA, et al. **J Neurochem** 1996 Jul;67(1):72–80
Evidence that the modulation of membrane–associated protein kinase C activity by an endogenous inhibitor plays a role in N1E–115 murine neuroblastoma cell differentiation. Chakravarthy BR, et al. **J Neurochem** 1995 Oct;65(4):1569–79
Surface phosphorylation by ecto–protein kinase C in brain neurons: a target for Alzheimer's beta–amyloid peptides. Hogan MV, et al. **J Neurochem** 1995 Nov;65(5):2022–30
Involvement of protein kinase C in gamma–aminobutyric acid release from Xenopus oocytes injected with rat brain mRNA. Kan S, et al. **J Neurochem** 1996 Aug;67(2):868–71
Staurosporine induces astrocytic phenotypes and differential expression of specific PKC isoforms in C6 glial cells. Kronfeld I, et al. **J Neurochem** 1995 Oct;65(4):1505–14
Ca2+–dependent and Ca2+–independent protein kinase C changes in the brain of patients with Alzheimer's disease. Matsushima H, et al. **J Neurochem** 1996 Jul;67(1):317–23
Phosphorylation of the conditioning–associated GTP–binding protein cp20 by protein kinase C. Nelson TJ, et al. **J Neurochem** 1995 Nov;65(5):2350–7
Activation of protein kinase C by trimethyltin: relevance to neurotoxicity. Pavlaković G, et al. **J Neurochem** 1995 Nov; 65(5):2338–43
Modulation of a recombinant glycine transporter (GLYT1b) by activation of protein kinase C. Sato K, et al. **J Neurochem** 1995 Nov;65(5):1967–73
Calcium influx into human neuroblastoma cells induces ALZ–50 immunoreactivity: involvement of calpain–mediated hydrolysis of protein kinase C. Shea TB, et al. **J Neurochem** 1996 Apr;66(4):1539–49
Stimulation of an insulin receptor activates and down–regulates the Ca2+–independent protein kinase C, Apl II, through a Wortmannin–sensitive signaling pathway in Aplysia. Sossin WS, et al. **J Neurochem** 1996 Jul; 67(1):220–8
Phorbol ester–enhanced noradrenaline secretion correlates with the presence and activity of protein kinase C–alpha in human SH–SY5Y neuroblastoma cells. Turner NA, et al. **J Neurochem** 1996 Jun;66(6):2381–9
Modulation of zeta–protein kinase C by cyclic AMP in PC12 cells occurs through phosphorylation by protein kinase A. Wooten MW, et al. **J Neurochem** 1996 Sep;67(3):1023–31
Ischemia–triggered translocation and inactivation of protein kinase C isoforms in the fetal brain. Yavin E, et al. **J Neurochem** 1995 Dec;65(6):2594–602
Dopamine receptor stimulation decreases cytosolic gamma protein kinase C immunoreactivity in rat hippocampal slices: evidence for increased Ca(2+)–dependent proteolysis. Yurko–Mauro KA, et al. **J Neurochem** 1995 Oct;65(4):1622–30
Activation of protein kinase C induces neurofilament fragmentation, hyperphosphorylation of perikaryal neurofilaments and proximal dendritic swellings in cultured motor neurons. Doroudchi MM, et al. **J Neuropathol Exp Neurol** 1996 Feb;55(2):246–56
Hyperphosphorylation of Tau and filopodial retraction following microinjection of protein kinase C catalytic subunits. Cressman CM, et al. **J Neurosci Res** 1995 Dec; 42(5):648–56
Lipopolysaccharide stimulates differential expression of myristoylated protein kinase C substrates in murine microglia. Rosé SD, et al. **J Neurosci Res** 1996 May 1; 44(3):235–42
New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation. Lang F, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):171–6
Translocation of protein kinase C isozymes in rat pituitary lactotroph–enriched cell cultures by substance P: effects of sex and age. Mau SE, et al. **J Recept Signal Transduct Res** 1995 Jul;15(6):801–9
Alpha–adrenergic preservation of myocardial pH during ischemia is PKC isoform dependent. Rehring TF, et al. **J Surg Res** 1996 Jun;63(1):324–7
Role of protein kinase C in attachment, spreading, and migration of human endothelial cells. Yamamura S, et al. **J Surg Res** 1996 Jun;63(1):349–54
Protein kinase C mechanism enhances vascular muscle relaxation by the Ca2+ antagonist, Ro 40–5967. Hermsmeyer K, et al. **J Vasc Res** 1996 Jan–Feb;33(1):71–7
Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF–kappa B binding and protein kinase C activity in primary human astrocytes. Conant K, et al. **J Virol** 1996 Mar;70(3):1384–9
Protein kinase C–zeta mediates NF–kappa B activation in human immunodeficiency virus–infected monocytes. Folgueira L, et al. **J Virol** 1996 Jan;70(1):223–31
Human T–cell lymphotropic virus type 1 Tax1 activation of NF–kappa B: involvement of the protein kinase C pathway. Lindholm PF, et al. **J Virol** 1996 Apr; 70(4):2525–32
Casein kinase II and protein kinase C modulate hepatitis delta virus RNA replication but not empty viral particle assembly. Yeh TS, et al. **J Virol** 1996 Sep;70(9):6190–8
Activation of protein kinase C by mycobacterial cord factor, trehalose 6–monomycolate, resulting in tumor necrosis factor–alpha release in mouse lung tissues. Sueoka E, et al. **Jpn J Cancer Res** 1995 Aug;86(8):749–55
Regulation of the renal Na–HCO3 cotransporter: VI.

Mechanism of the stimulatory effect of protein kinase C. Ruiz OS, et al. **Kidney Int** 1996 Mar;49(3):696–704

Effects of high glucose concentration on c-fos: role of protein kinase C. Cosio FG, et al. **Kidney Int Suppl** 1995 Sep; 51:S12–7

High glucose activates protein kinase C and stimulates fibronectin gene expression by enhancing a cAMP response element. Kreisberg JI, et al. **Kidney Int Suppl** 1995 Sep; 51:S3–11

Doppa induces cell death but not differentiation of U937 cells: evidence for the involvement of PKC-beta 1 in the regulation of apoptosis. Pongracz J, et al. **Leuk Res** 1996 Apr;20(4):319–26

Distribution and translocation of isoforms of protein kinase C in rat submandibular acinar cells. Fleming N, et al. **Life Sci** 1995;57(22):2003–10

A non-radioactive fluorescent method for measuring protein kinase C activity. Isbell JC, et al. **Life Sci** 1995; 57(18):1701–7

A phorbol ester that activates protein kinase C mimics the action of estradiol or epidermal growth factor for initiating embryo implantation in the delayed implanting hypophysectomized rat. Johnson DC. **Life Sci** 1996; 58(10):861–7

Protein kinase C-alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Leszczynski D, et al. **Life Sci** 1996;58(7):599–606

Ca(+2)-phosphatidylserine-dependent protein kinase C activity in fetal, neonatal and adult rabbit lung and isolated lamellar bodies. Samuels ER, et al. **Life Sci** 1995; 57(17):1557–68

Ethanol enhances the in situ phosphorylation of MARCKS and protein kinase C activity in primary cultures of astrocytes. Smith TL, et al. **Life Sci** 1996;58(10):855–60

Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Ishizuka T, et al. **Metabolism** 1996 Feb; 45(2):206–10

Acidic fibroblast factor induction of cyclooxygenase II in rabbit cardiac muscle microvessel endothelial cells: mediation by protein kinase C. Moatter T, et al. **Microcirculation** 1994 Apr;1(1):79–88

Desensitization of 5HT2 receptors by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture. Weng W, et al. **Microcirculation** 1994 Jul; 1(2):129–35

Protein kinase C regulates the recruitment of syndecan-4 into focal contacts. Baciu PC, et al. **Mol Biol Cell** 1995 Nov; 6(11):1503–13

Differential regulation of distinct types of gap junction channels by similar phosphorylating conditions. Kwak BR, et al. **Mol Biol Cell** 1995 Dec;6(12):1707–19

High-fat diet blocks the inhibition of skin carcinogenesis and reductions in protein kinase C by moderate energy restriction. Birt DF, et al. **Mol Carcinog** 1996 Jun; 16(2):115–20

Dietary energy restriction-induced modulation of protein kinase C zeta isozyme in the hamster pancreas. Nair SC, et al. **Mol Carcinog** 1995 Sep;14(1):10–5

Enhanced expression of GTP-binding proteins in differentiated U937 monocytic cells: possible involvement of tyrosine kinase and protein kinase C. Ali N, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):113–20

Phorbol ester and diacylglycerol activation of native protein kinase C species from various tissues. Johnson MS, et al. **Mol Cell Biochem** 1995 May 24;146(2):127–37

Protein kinase C beta from Friend erythroleukemia cells is associated with chromatin and DNA. Mallia CM, et al. **Mol Cell Biochem** 1995 Oct 18;151(2):107–11

Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):65–72 (72 ref.)

Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Baier-Bitterlich G, et al. **Mol Cell Biol** 1996 Apr; 16(4):1842–50

Lambda-interacting protein, a novel protein that specifically interacts with the zinc finger domain of the atypical protein kinase C isotype lambda/iota and stimulates its kinase activity in vitro and in vivo. Diaz-Meco MT, et al. **Mol Cell Biol** 1996 Jan;16(1):105–14

BRO1, a novel gene that interacts with components of the Pkc1p-mitogen-activated protein kinase pathway in Saccharomyces cerevisiae. Nickas ME, et al. **Mol Cell Biol** 1996 Jun;16(6):2585–93

Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Eizirik DL, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):159–65

Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin-sensitive G protein. Sim PJ, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):257–63

Regulation of protein kinase C activity in cerebral microvessels. Moore P, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):259–68

Protein kinase C-dependent growth hormone releasing peptides stimulate cyclic adenosine 3',5'-monophosphate production by human pituitary somatotropinomas expressing gsp oncogenes: evidence for crosstalk between transduction pathways. Adams EF, et al. **Mol Endocrinol** 1996 Apr;10(4):432–8

Regulation of gonadotropin-releasing hormone transcription by protein kinase C is mediated by evolutionarily conserved promoter-proximal elements. Eraly SA, et al. **Mol Endocrinol** 1995 Jul;9(7):848–59

Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Rochette-Egly C, et al. **Mol Endocrinol** 1995 Jul;9(7):860–71

Protein-protein interactions in the yeast PKC1 pathway: Pkc1p interacts with a component of the MAP kinase cascade. Paravicini G, et al. **Mol Gen Genet** 1996 Jul 26; 251(6):682–91

Protein kinase C isozyme-specific modulation of cyclic AMP-dependent phosphodiesterase in hypertrophic cardiomyopathic hamster hearts. Cai JJ, et al. **Mol Pharmacol** 1996 Jan;49(1):81–8

Enhancement of recombinant alpha 1 beta 1 gamma 2L gamma-aminobutyric acidA receptor whole-cell currents by protein kinase C is mediated through phosphorylation of both beta 1 and gamma 2L subunits. Lin YF, et al. **Mol Pharmacol** 1996 Jul;50(1):185–95

Inhibition of the phosphorylation of a myristoylated alanine-rich C kinase substrate by methyl methanesulfonate in cultured NIH 3T3 cells. Shin I, et al. **Mutat Res** 1996 Apr 13;351(2):163–71

Cerebral microvessels in Alzheimer's have reduced protein kinase C activity. Grammas P, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):563–9

Protein phosphorylation in the blood-brain barrier. Possible presence of MARCKS in brain microvessels. Edgardo Catalán R, et al. **Neurochem Int** 1996 Jan;28(1):59–65

The effect of kainate on protein kinase C, GABA, and the uptake of serotonin in the rabbit retina in vivo. Osborne NN, et al. **Neurochem Res** 1995 Jun;20(6):635–41

Modulation of regulatory and catalytic subunit levels of cAMP-dependent protein kinase A in anterior pituitary cells in response to direct activation of protein kinases A and C or after GnRH stimulation. Garrel G, et al. **Neuroendocrinology** 1995 Nov;62(5):514–22

Interrelation between protein kinase C and nitric oxide in the development of vasospasm after subarachnoid hemorrhage. Nishizawa S, et al. **Neurol Res** 1996 Feb; 18(1):89–95

Synergistic regulation of a neuronal chloride current by intracellular calcium and muscarinic receptor activation: a role for protein kinase C. Marsh SJ, et al. **Neuron** 1995 Sep;15(3):729–37

Determinants of PKC-dependent modulation of a family of neuronal calcium channels. Stea A, et al. **Neuron** 1995 Oct; 15(4):929–40

The influence of experimental ischaemia on protein kinase C and the GABAergic system in the rabbit retina. Osborne NN, et al. **Neuropharmacology** 1995 Oct;34(10):1279–88

Characterization of taurine transport in human glioma GL15 cell line: regulation by protein kinase C. Tchoumkeu-Nzouessa GC, et al. **Neuropharmacology** 1996 Jan;35(1):37–44

[3H]phorbol 12,13-dibutyrate/PKC binding in thoracic spinal cord: no change in amyotrophic lateral sclerosis. Krieger C, et al. **Neuroreport** 1995 Jul 10;6(10):1381–4

Potentiation of 5-HT3 receptor-mediated responses by protein kinase C activation. Zhang L, et al. **Neuroreport** 1995 Jul 10;6(10):1464–8

Increases in protein kinase C gamma immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy. Mao J, et al. **Neurosci Lett** 1995 Sep 29; 198(2):75–8

Activation of protein kinase C down-regulates glial but not neuronal taurine uptake. Tchoumkeu-Nzouessa GC, et al. **Neurosci Lett** 1996 Mar 8;206(1):61–4

Involvement of protein kinase C and nitric oxide in the modulation by insulin-like growth factor-I of glutamate-induced GABA release in the cerebellum. Castro-Alamancos MA, et al. **Neuroscience** 1996 Feb; 70(4):843–7

Synergistic activation by cis-fatty acid and diacylglycerol of protein kinase C and protein phosphorylation in hippocampal slices. Chen SG, et al. **Neuroscience** 1995 Oct; 68(4):1017–26

Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Greenwood AF, et al. **Neuroscience** 1995 Nov;69(1):125–38

Induction of c-fos and zif/268 gene expression in rat striatal neurons, following stimulation of D1-like dopamine receptors, involves protein kinase A and protein kinase C. Simpson CS, et al. **Neuroscience** 1995 Sep;68(1):97–106

Protein kinase C activation is necessary but not sufficient for induction of long-term potentiation at the synapse of mossy fiber-CA3 in the rat hippocampus. Son H, et al. **Neuroscience** 1996 May;72(1):1–13

The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)

Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells. Li W, et al. **Oncogene** 1996 Aug 15;13(4):731–7

Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. Milne DM, et al. **Oncogene** 1996 Jul 4;13(1):205–11

The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Mayer DJ, et al. **Pain** 1995 Jun;61(3):365–74

PKC activators stimulate H+ conductance in chicken enterocytes. Calonge ML, et al. **Pflugers Arch** 1996 Feb; 431(4):594–8

Protein kinase C consensus sites and the regulation of renal Na/Pi-cotransport (NaPi-2) expressed in XENOPUS laevis oocytes. Hayes G, et al. **Pflugers Arch** 1995 Sep; 430(5):819–24

Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Ahn KS, et al. **Planta Med** 1996 Feb;62(1):7–9

Microspectroscopic imaging tracks the intracellular processing of a signal transduction protein: fluorescent-labeled protein kinase C beta I. Bastiaens PI, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8407–12

Serine-1321-independent regulation of the mu 1 adult skeletal muscle Na+ channel by protein kinase C. Bendahhou S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12003–7

Role of phospholipids containing docosahexaenoyl chains in modulating the activity of protein kinase C. Giorgione J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9767–70

Tyrosine phosphorylation of protein kinase C-delta in response to the activation of the high-affinity receptor for immunoglobulin E modifies its substrate recognition. Haleem-Smith H, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9112–6

12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids [published erratum appears in Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11322] Liu B, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9323–7

Protein kinase C chimeras: catalytic domains of alpha and beta II protein kinase C contain determinants for isotype-specific function. Walker SD, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9156–60

Prostaglandin E2 induces Egr-1 mRNA in MC3T3-E1 osteoblastic cells by a protein kinase C-dependent pathway. Fang MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):109–14

Induction and phosphorylation of protein kinase C-alpha and mitogen-activated protein kinase by hypoxia and by radiation in Chinese hamster V79 cells. Hasan NM, et al. **Radiat Res** 1996 Feb;145(2):128–33

Protein kinase C is not necessary for beta-casein gene induction by prolactin in HC11 mouse mammary cells. Mitev V, et al. **Reprod Nutr Dev** 1995;35(4):437–42

Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Amano M, et al. **Science** 1996 Feb 2;271(5249):648–50

PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Eliasson L, et al. **Science** 1996 Feb 9;271(5250):813–5

Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Klauck TM, et al. **Science** 1996 Mar 15;271(5255):1589–92

Bipartite Ca2+-binding motif in C2 domains of synaptotagmin and protein kinase C. Shao X, et al. **Science** 1996 Jul 12;273(5272):248–51

Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. Watanabe G, et al. **Science** 1996 Feb 2;271(5249):645–8

Chronological changes of arterial diameter, cGMP, and protein kinase C in the development of vasospasm [see comments] Nishizawa S, et al. **Stroke** 1995 Oct; 26(10):1916–20; discussion 1920–1. Comment in: Stroke 1996 Feb;27(2):342–3.

Protein kinase C activation during cerebral vasospasm [letter; comment] Peterson JW. **Stroke** 1996 Feb;27(2):342–3. Comment on: Stroke 1995 Oct;26(10):1916–20; discussion 1920–1.

Regulation of protein kinase C isoforms in FRTL-5 thyroid cells by TSH and phorbol ester. Matowe WC, et al. **Thyroid** 1996 Feb;6(1):53–8

[Modulation by some fatty acids of protein kinase C-dependent NADPH oxidase in human adherent monocyte: mechanism of action, possible implication in atherogenesis] Léger CL, et al. **C R Seances Soc Biol Fil** 1995;189(5):765–79 (Eng. Abstr.) **(Fre)**

[Phosphorylation of adrenal cortex proteins by protein kinase C induced by prolactin] Sautin IuIu, et al. **Biokhimiia** 1996 Jan;61(1):34–41 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Protein kinase C inhibits delayed rectifier K+ current in rabbit vascular smooth muscle cells. Aiello EA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H109–19

Protein kinase C-induced contraction is inhibited by halothane but enhanced by isoflurane in rat coronary arteries. Park KW, et al. **Anesth Analg** 1996 Aug; 83(2):286–90

Signaling pathways regulating ornithine decarboxylase activity in the embryonic chicken. Shibley IA Jr, et al. **Biol Neonate** 1995;67(6):441–9

Cell-free activation of the respiratory burst oxidase by protein kinase C. el-Benna J, et al. **Blood Cells Mol Dis** 1995;21(3):201–6

PKC-dependent reduction of the acetylcholine-evoked inward Na current in Aplysia D-neurons: effect of injected PKC and PKC activators. Papp A, et al. **Brain Res** 1996 Feb 5;708(1-2):123-7

Phorbol esters and PKC signaling regulate proliferation, vimentin cytoskeleton assembly and glutamine synthetase activity of chick embryo cerebrum astrocytes in culture. Mangoura D, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):1-11

Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels. A possible mechanistic link to ischemic preconditioning. Light PE, et al. **Circ Res** 1996 Sep;79(3):399-406

Production of recombinant human brain type I inositol-1,4,5-trisphosphate 5-phosphatase in Escherichia coli. Lack of phosphorylation by protein kinase C. Erneux C, et al. **Eur J Biochem** 1995 Dec 1;234(2):598-602

Phosphorylation of elongation factor 1 (EF-1) by protein kinase C stimulates GDP/GTP-exchange activity. Peters HI, et al. **Eur J Biochem** 1995 Dec 1;234(2):550-6

Lateral mobility of Fc gamma RIIa is reduced by protein kinase C activation. Zhang F, et al. **FEBS Lett** 1995 Nov 27;376(1-2):77-80

Interleukin 1-beta- and tumor necrosis factor-alpha-mediated regulation of ICAM-1 gene expression in astrocytes requires protein kinase C activity. Ballestas ME, et al. **Glia** 1995 Aug;14(4):267-78

Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis. Karimi K, et al. **J Immunol** 1995 Dec 15;155(12):5786-94

Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse. Théodore L, et al. **J Neurosci** 1995 Nov;15(11):7158-67

Protein kinase C modulates exogenous acetylcholine current in Xenopus oocytes. Mileo AM, et al. **J Neurosci Res** 1995 Jul 1;41(4):443-51

Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. Copeland BJ, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1527-32

Endothelin-1 stimulates myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation in rat cerebellar slices. Catalán RE, et al. **Neurosci Lett** 1995 Jul 14; 194(1-2):53-6

Interleukin-1 beta-stimulated prostaglandin synthesis by human decidual cells is independent of protein kinase C. Cole OF, et al. **Prostaglandins** 1995 Feb;49(2):69-77

PHYSIOLOGY

Possible mechanism to induce protein kinase C-dependent arterial smooth muscle contraction after subarachnoid haemorrhage. Ohta S, et al. **Acta Neurochir (Wien)** 1995; 137(3-4):217-25

NO modulates the apicolateral cytoskeleton of isolated hepatocytes by a PKC-dependent, cGMP-independent mechanism. Burgstahler AD, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 1):G789-99

Enhanced growth of fetal and neonatal pulmonary artery adventitial fibroblasts is dependent on protein kinase C. Das M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L660-7

PKC mediates LPS- and phorbol-induced cardiac cell nitric oxide synthase activity and hypocontractility. McKenna TM, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1891-8

Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. Ruan X, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F945-52

Thromboxane A2-stimulated phospholipase D in osteoblast-like cells: possible involvement of PKC. Shinoda J, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E524-9

Protein kinase C activation in the heart: effects on calcium and contractile proteins. Buenaventura P, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S505-8

Expression of asparagine synthetase mRNA through asparagine independent signal transduction pathway that might involve protein kinase C in BALB3T3 cells. Chiyo T, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1929-35

Protein kinase C-dependent modulation of stimulatory guanine nucleotide binding protein of fetal rat skin keratinocytes. Tamura T, et al. **Arch Dermatol Res** 1996; 288(1):24-30

Furosemide-sensitive K+ transport in transformed and nontransformed rat liver epithelial cells: regulation by protein kinase C and involvement in cell growth. Anger JP, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr; 329(2):307-18

Investigations on the role of hippocampal protein kinase C on memory processes: pharmacological approach. Nogués X, et al. **Behav Brain Res** 1996 Feb;75(1-2):139-46

Lysophosphatidylcholine inhibits NMDA-induced currents by a mechanism independent of phospholipase A2-mediated protein kinase C activation in hippocampal glial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):811-6

Diversity of roles of protein kinase C alpha in the proliferation of Swiss 3T3 cells. Florin-Christensen J, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):513-6

Evidence for a role of conventional protein kinase-C alpha in the control of homotypic contacts and cell scattering of HT-29 human intestinal cells. Llosas MD, et al. **Biochem J** 1996 May 1;315 (Pt 3):1049-54

Bradykinin-stimulated phosphatidylcholine hydrolysis in airway smooth muscle: the role of Ca2+ and protein kinase C. Pyne S, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):637-42

The important role of PKC in controlling polyploidy formation in cultured fibrosarcoma cell line. Zong ZP, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1009-15

Physiological inhibitors of protein kinase C. Melner MH. **Biochem Pharmacol** 1996 Apr 12;51(7):869-77 (79 ref.)

Effects of protein kinase C and phosphoprotein phosphatase modulators on Ehrlich cell plasma membrane redox system activity. del Castillo-Olivares A, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):157-60

Hydrogen peroxide-and fetal bovine serum-induced DNA synthesis in vascular smooth muscle cells: positive and negative regulation by protein kinase C isoforms. Fiorani M, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):98-104

Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Kamanna VS, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):161-72

Protein kinase C-dependent regulation of L-arginine transport activity in Caco-2 intestinal cells. Pan M, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):27-32

Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Haimovich B, et al. **Blood** 1996 Jan 1;87(1):152-61

Inhibition of protein kinase C suppresses megakaryocytic differentiation and stimulates erythroid differentiation in HEL cells. Hong Y, et al. **Blood** 1996 Jan 1;87(1):123-31

Protein kinase C isoforms in bovine aortic endothelial cells: role in regulation of P2Y- and P2U-purinoceptor-stimulated prostacyclin release. Patel V, et al. **Br J Pharmacol** 1996 May;118(1):123-30

Protein kinase C involvement in maintenance and modulation of noradrenaline release in the mouse brain cortex. Schroeder GE, et al. **Br J Pharmacol** 1995 Nov; 116(6):2757-63

Desensitization of the mu-opioid activation of phospholipase C in SH-SY5Y cells: the role of protein kinases C and A and Ca(2+)-activated K+ currents. Smart D, et al. **Br J Pharmacol** 1995 Nov;116(6):2655-60

Alterations in the action potential of Aplysia neurons evoked by a phorbolester are mediated by protein kinase C. Papp A, et al. **Brain Res** 1995 Jun 26;684(1):107-11

Developmental changes in the expression of alpha-, beta- and gamma-subspecies of protein kinase C at synapses in the ventral horn of the embryonic and postnatal rat spinal cord. Miki A. **Brain Res Dev Brain Res** 1995 Jun 27; 87(1):46-54

An activated mutant of the alpha subunit of G(o) increases neurite outgrowth via protein kinase C. Xie R, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):77-86

Specific sequences of fibronectin activate the protein kinase C signal transduction pathway in invasive bladder cancer. Margolis EJ, et al. **Cancer Lett** 1996 Feb 27;100(1-2):163-8

Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Wali RK, et al. **Cancer Res** 1995 Nov 15; 55(22):5257-64

Protein kinase C activation inhibits receptor-evoked inositol trisphosphate formation and induction of cytosolic calcium oscillations by decreasing the affinity-state of the cholecystokinin receptor in pancreatic acinar cells. Willems PH, et al. **Cell Calcium** 1995 Dec;18(6):471-83

Rapid activation and down-regulation of protein kinase C alpha in 12-O-Tetradecanoylphorbol-13-acetate-induced differentiation of human rhabdomyosarcoma cells. Bouché M, et al. **Cell Growth Differ** 1995 Jul;6(7):845-52

Protein kinase C-dependent and -independent pathways of signal transduction in prostate cancer cells: fibroblast growth factor utilization of a protein kinase C-independent pathway. Hrženjak M, et al. **Cell Growth Differ** 1995 Sep; 6(9):1129-42

IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Parada NA, et al. **Cell Immunol** 1996 Feb 25;168(1):100-6

The role of protein kinase C in activation and termination of mitogen-activated protein kinase activity in angiotensin II-stimulated rat aortic smooth-muscle cells. Malarkey K, et al. **Cell Signal** 1996 Feb;8(2):123-9

Regulation of phospholipase D by protein kinase C. Kiss Z. **Chem Phys Lipids** 1996 May 24;80(1-2):81-102 (243 ref.)

Role of protein kinase C in ischemic preconditioning: player or spectator? [editorial] Brooks G, et al. **Circ Res** 1996 Sep;79(3):627-30 (32 ref.)

Endothelin-dependent actions in cultured AT-1 cardiac myocytes. The role of the epsilon isoform of protein kinase C. Jiang T, et al. **Circ Res** 1996 Apr;78(4):724-36

Oleic acid-induced mitogenic signaling in vascular smooth muscle cells. A role for protein kinase C. Lu G, et al. **Circ Res** 1996 Sep;79(3):611-8

Preconditioning of bovine endothelial cells. The protective effect is mediated by an adenosine A2 receptor through a protein kinase C signaling pathway. Zhou X, et al. **Circ Res** 1996 Jan;78(1):73-81

Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Hu K, et al. **Circulation** 1995 Oct 15;92(8):2259-65

Lipid mediators and protein kinase C for intracellular signalling. Nishizuka Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S202-3

Activation of p42erk2 MAPK and p90rsk by IL-2 occurs independently of protein kinase C. Franklin RA, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):116-22

Role of cytokines, tyrosine kinase, and protein kinase C on production of superoxide and induction of scavenging enzymes in human leukocytes. Niwa Y, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):303-13

Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Feener EP, et al. **Contrib Nephrol** 1996;118:180-7

Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277-320 (95 ref.)

Protein kinase A and protein kinase C modulators have reciprocal effects on mesenchymal condensation during skin appendage morphogenesis. Noveen A, et al. **Dev Biol** 1995 Oct;171(2):677-93

Transcriptional regulation of the insulin-like growth factor-I receptor gene: evidence for protein kinase C-dependent and -independent pathways. Du J, et al. **Endocrinology** 1996 Apr;137(4):1378-84

Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. Friedman PA, et al. **Endocrinology** 1996 Jan;137(1):13-20

Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C. Sundaresan S, et al. **Endocrinology** 1996 Jan;137(1):304-11

The myristoylated alanine-rich C-kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C. Herget T, et al. **Eur J Biochem** 1995 Oct 15; 233(2):448-57

Role of protein kinase C in modulating epidermal growth factor- and phorbol ester-induced mammary epithelial cell growth in vitro. Birkenfeld HP, et al. **Exp Cell Res** 1996 Feb 25;223(1):183-91

A protein kinase C with divalent cations contributes to thromboxane A2-induced contraction in rabbit vascular smooth muscle. Yamamoto K, et al. **Fukushima J Med Sci** 1995 Jun;41(1):29-41

Protein kinase-C mediates chicken vasoactive intestinal peptide stimulated prolactin secretion and gene expression in turkey primary pituitary cells. Sun S, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):289-97

Protein kinase C involvement in apoptosis. Lucas M, et al. **Gen Pharmacol** 1995 Sep;26(5):881-7 (70 ref.)

Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. Kieser A, et al. **Genes Dev** 1996 Jun 15; 10(12):1455-66

The role of intracellular calcium and protein kinase C in endothelin-stimulated proliferation of rat type I astrocytes. Stanimirovic DB, et al. **Glia** 1995 Oct;15(2):119-30

Thromboxane/prostaglandin endoperoxide-induced hypertrophy of rat vascular smooth muscle cells is signaled by protein kinase C-dependent increases in transforming growth factor-beta. Craven PA, et al. **Hypertension** 1996 Aug;28(2):169-76

Bradykinin and protein kinase C activation fail to stimulate renal sensory neurons in hypertensive rats. Kopp UC, et al. **Hypertension** 1996 Mar;27(3 Pt 2):607-12

Protein kinase C isotype expression and regulation of lymphoid cell motility. Thorp KM, et al. **Immunology** 1996 Mar;87(3):434-8

Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii. Grunvald E, et al. **Infect Immun** 1996 Jun;64(6):2010-8

Inhibition of protein kinase C-dependent protein phosphorylation correlates with increased polarity and locomotion in Walker 256 carcinosarcoma cells. Niggli V, et al. **Int J Cancer** 1996 Feb 8;65(4):473-8

Dictyostelium myosin II is regulated during chemotaxis by a novel protein kinase C. Abu-Elneel K, et al. **J Biol Chem** 1996 Jan 12;271(2):977-84

Novel role for Sp1 in phorbol ester enhancement of human platelet thromboxane receptor gene expression. D'Angelo DD, et al. **J Biol Chem** 1996 Aug 16;271(33):19696-704

Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. Jarvis WD, et al. **J Biol Chem** 1996 Apr 5; 271(14):8275-84

Plasma membrane Na+/H+ exchanger isoforms (NHE-1, -2, and -3) are differentially responsive to second messenger agonists of the protein kinase A and C pathways. Kandasamy RA, et al. **J Biol Chem** 1995 Dec 8; 270(49):29209-16

Primary structure of a gamma subunit of G protein, gamma 12, and its phosphorylation by protein kinase C. Morishita R, et al. **J Biol Chem** 1995 Dec 8;270(49):29469-75

Phorbol ester inhibits the phosphorylation of the retinoblastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells. Sasaguri T, et al. **J Biol Chem** 1996 Apr 5;271(14):8345-51

Interactions of protein kinase C with insulin signaling. Influence on GAP and Sos activities. Schubert C, et al. **J Biol Chem** 1996 Jun 28;271(26):15311-4

Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins. Whalen SG, et al. **J Biol Chem** 1996 May 17;

271(20):11831-7
Staurosporine inhibits interferon alpha-induced gene expression in Friend erythroleukemia cells through a PKC independent pathway. Percario ZA, et al. **J Biol Regul Homeost Agents** 1995 Jan-Mar;9(1):7-14
Endothelin-1-induced phospholipase C-beta and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. Lamers JM, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S100-3
Activation of protein kinase C as a modulator of potentiated UK-14304-induced contractions in dog mesenteric artery and vein. Shimamoto H, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):923-31
Pre-clamp cardioprotection by protein kinase C (PKC) inhibitor improves left ventricular function following canine normothermic arrest. Anagnostopoulos CE, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):141-3
Involvement of protein phosphatase 2A in PKC-independent pathway of neutrophil superoxide generation by fMLP. Okuyama M, et al. **J Cell Biochem** 1996 Feb;60(2):279-88
Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Schmitz JP, et al. **J Cell Physiol** 1996 Sep;168(3):570-9
Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). Tang DG, et al. **J Cell Physiol** 1995 Nov; 165(2):291-306
Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by alpha 1-adrenergic receptors in Madin-Darby canine kidney cells. Xing M, et al. **J Clin Invest** 1996 Mar 1; 97(5):1302-10
Phorbol ester-stimulated 6-keto-prostaglandin F1 alpha in aortas from control and aldosterone-salt rats. Jones SB, et al. **J Hypertens** 1995 Jul;13(7):723-9
Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. Williams B. **J Hypertens** 1995 May;13(5):477-86 (96 ref.)
HIV glycoprotein 120 enhances intercellular adhesion molecule-1 gene expression in glial cells. Involvement of Janus kinase/signal transducer and activator of transcription and protein kinase C signaling pathways. Shrikant P, et al. **J Immunol** 1996 Feb 1;156(3):1307-14
Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway. Tachado SD, et al. **J Immunol** 1996 Mar 1; 156(5):1897-1907
Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. Tamir A, et al. **J Immunol** 1996 Aug 15;157(4):1514-22
Role of tyrosine kinases, protein kinase C, and protein kinase A in the regulation of interferon-alpha production induced by herpes simplex virus type 1. Li Q, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):109-18
Potentiation by thyroxine of interferon-gamma-induced HLA-DR expression is protein kinase A- and C-dependent. Lin HY, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):17-24
Enhanced expression of protein kinase C subspecies in melanogenic compartments in B16 melanoma cells by UVB or MSH [letter] Oka M, et al. **J Invest Dermatol** 1996 Feb; 106(2):377-8
Interferon-gamma-dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: modulation of the apoptotic process by protein kinase C. Takahashi H, et al. **J Invest Dermatol** 1995 Dec;105(6):810-5
Increases in HSF1 translocation and synthesis in human epidermoid A-431 cells: role of protein kinase C and [Ca2+]i. Ding XZ, et al. **J Investig Med** 1996 Apr; 44(4):144-53
Protein kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells. Terry CM, et al. **J Lab Clin Med** 1996 Jan;127(1):81-93
Protein kinase C and intracellular pH regulate zymosan-induced lysosomal enzyme secretion in macrophages. Tapper H, et al. **J Leukoc Biol** 1995 Oct; 58(4):485-94
Regulation of Bcl-2 protein expression in human neuroblastoma SH-SY5Y cells: positive and negative effects of protein kinases C and A, respectively. Itano Y, et al. **J Neurochem** 1996 Jul;67(1):131-7
Endothelin 1 stimulates Na+,K(+)-ATPase and Na(+)-K(+)-Cl- cotransport through ETA receptors and protein kinase C-dependent pathway in cerebral capillary endothelium. Kawai N, et al. **J Neurochem** 1995 Oct; 65(4):1588-96
Overexpression of MARCKS, but not protein kinase C-alpha, increases phorbol ester-stimulated synthesis of phosphatidylcholine in human SK-N-MC neuroblastoma cells. Rose SD, et al. **J Neurochem** 1996 Apr;66(4):1766-9
Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival. Zirrgiebel U, et al. **J Neurochem** 1995 Nov;65(5):2241-50
Possible role of protein kinase C in the sensitization of primate spinothalamic tract neurons. Lin Q, et al. **J Neurosci** 1996 May 1;16(9):3026-34
Protein kinase C involvement in homologous desensitization of delta-opioid receptor coupled to Gi1-phospholipase C activation in Xenopus oocytes. Ueda H, et al. **J Neurosci** 1995 Nov;15(11):7485-99
Modulation of calcium efflux from cultured rat dorsal root ganglion neurons. Werth JL, et al. **J Neurosci** 1996 Feb 1;16(3):1008-15
Nutritional modulation of guinea pig skin hyperproliferation by essential fatty acid deficiency is associated with selective down regulation of protein kinase C-beta. Cho Y, et al. **J Nutr** 1995 Nov;125(11):2741-50
Protein kinase C mediates spontaneous tone in the cat lower esophageal sphincter. Hillemeier C, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):144-9
The actions of prostaglandin E2 on potassium currents in rat tail artery vascular smooth muscle cells: regulation by protein kinase A and protein kinase C. Ren J, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):394-402
Activation of the plasma membrane chloride channel by protein kinase C in isolated guinea-pig hepatocytes. Koumi S, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):379-94
Tumor necrosis factor mediates apoptosis via Ca++/Mg++ dependent endonuclease with protein kinase C as a possible mechanism for cytokine resistance in human renal carcinoma cells. Woo KR, et al. **J Urol** 1996 May;155(5):1779-83
Adenine nucleotide and protein kinase C regulation of renal tubular epithelial cell wound healing. Sponsel HT, et al. **Kidney Int** 1995 Jul;48(1):85-92
Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Studer RK, et al. **Kidney Int** 1995 Aug; 48(2):422-30
TGF-beta and phorbol esters inhibit mitogenesis utilizing parallel protein kinase C-dependent pathways. Weiss RH, et al. **Kidney Int** 1995 Sep;48(3):738-44
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191-221 (402 ref.)
Regulation of c-fos mRNA expression in Sertoli cells by cyclic AMP, calcium, and protein kinase C mediated pathways. Jia MC, et al. **Mol Cell Biochem** 1996 Mar 9; 156(1):43-9
Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:51-8 (56 ref.)
Lactate dehydrogenase A subunit messenger RNA stability is synergistically regulated via the protein kinase A and C signal transduction pathways. Huang D, et al. **Mol Endocrinol** 1995 Aug;9(8):994-1004
Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287-96
Protein kinase C isoform delta is involved in the stimulation of the Na(+)-H+ exchanger in C6 glioma cells. Chen CC, et al. **Mol Pharmacol** 1995 Dec;48(6):995-1003
Multiple phosphorylation sites are required for pathway-selective uncoupling of the 5-hydroxytryptamine1A receptor by protein kinase C. Lembo PM, et al. **Mol Pharmacol** 1995 Dec;48(6):1024-9
Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C. Pizzi M, et al. **Mol Pharmacol** 1996 Apr;49(4):586-94
Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C. Rousell J, et al. **Mol Pharmacol** 1996 Apr; 49(4):629-35
Protein kinase C and skin tumor promotion. Marks F, et al. **Mutat Res** 1995 Dec;333(1-2):161-72 (100 ref.)
Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity. Hunáková L, et al. **Neoplasma** 1995;42(5):249-53
Muscarinic modulation of sodium current by activation of protein kinase C in rat hippocampal neurons. Cantrell AR, et al. **Neuron** 1996 May;16(5):1019-26
Protein kinase C enhances exocytosis from chromaffin cells by increasing the size of the readily releasable pool of secretory granules. Gillis KD, et al. **Neuron** 1996 Jun; 16(6):1209-20
Regulation of synaptic strength at mixed synapses: effects of dopamine receptor blockade and protein kinase C activation. Silva A, et al. **Neuropharmacology** 1995 Nov; 34(11):1559-65
Effect of protein kinase-C activation on the Mg(2+)-sensitivity of cloned NMDA receptors. Wagner DA, et al. **Neuropharmacology** 1996 Jan;35(1):29-36
Evidence for the role of protein kinase C in astrocyte-induced proliferation of rat cerebromicrovascular endothelial cells. Stanimirovic DB, et al. **Neurosci Lett** 1995 Sep 15;197(3):219-22
Evidence for different signalling pathways of PKC zeta and ras-p21 in Xenopus oocytes. Carnero A, et al. **Oncogene** 1995 Oct 19;11(8):1541-7
Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Chen CY, et al. **Oncogene** 1995 Oct 19;11(8):1487-98
Linking protein kinase C to the cell cycle: ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis. Livneh E, et al. **Oncogene** 1996 Apr 4;12(7):1545-55
Characterization of the signal transduction pathway mediating gamma ray-induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53. Mirzayans R, et al. **Oncogene** 1995 Oct 19;11(8):1597-605
Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins. Rutberg SE, et al. **Oncogene** 1996 Jul 4;13(1):167-76
Slow cluster formation of purified human or rhesus T cells requires protein kinase C and LFA-1. Eylar EH, et al. **P R Health Sci J** 1996 Mar;15(1):13-9
Effects of cyclic adenosine monophosphate-dependent protein kinase and calcium-dependent protein kinase modulators on stimulated gastric acid secretion in the perfused rat stomach. Rotker JD, et al. **Pharmacology** 1995 Oct;51(4):263-72
Platelet-derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3-kinase. Moriya S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):151-5
Chemical specificity and physical properties of the lipid bilayer in the regulation of protein kinase C by anionic phospholipids: evidence for the lack of a specific binding site for phosphatidylserine. Mosior M, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1907-12
Protein kinase cross-talk: membrane targeting of the beta-adrenergic receptor kinase by protein kinase C. Winstel R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):2105-9
The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55-63 (27 ref.)
Protein kinase C regulation of the adenylyl cyclase system in rat prostatic epithelium. Carmena MJ, et al. **Prostate** 1995 Oct;27(4):204-11
Persistent CD3-crosslinking down-regulates interleukin-2 responsiveness in interleukin-2-competent cloned T cells: the possible involvement of protein kinase C. Landewé RB, et al. **Scand J Immunol** 1996 Jul;44(1):45-53
Immunodeficiency in protein kinase cbeta-deficient mice. Leitges M, et al. **Science** 1996 Aug 9;273(5276):788-91
The obligate role of protein kinase C in mediating clinically accessible cardiac preconditioning. Cleveland JC Jr, et al. **Surgery** 1996 Aug;120(2):345-52; discussion 352-3
[Bovine protein kinase C isotypes transduced into Molt-4/HIV-1 cells augment the expression of HIV-1 genome] Izumi T. **Hokkaido Igaku Zasshi** 1995 Nov; 70(6):861-83 (Eng. Abstr.) **(Jpn)**
[The role of protein kinase C and muscarinic cholinoreceptors in vasopressin-stimulated water transport] Bagrov IaIu, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):33-5 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Long-wave ultraviolet radiation causes increase of membrane-bound fraction of protein kinase C in rat myeloid leukemia cells. Leszczynski D, et al. **Photodermatol Photoimmunol Photomed** 1995 Jun; 11(3):124-30

ULTRASTRUCTURE

Expression and characterization of Aplysia protein kinase C: a negative regulatory role for the E region. Sossin WS, et al. **J Neurosci** 1996 Jan;16(1):10-8

PROTEIN KINASES

ANALYSIS

Detection of protein kinase activities toward oligopeptides in sodium dodecyl sulfate-polyacrylamide gel. Kameshita I, et al. **Anal Biochem** 1996 Jun 1;237(2):198-203
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting comparisons of purified myofibrils and whole muscle preparations for evaluating titin and nebulin in postmortem bovine muscle. Huff-Lonergan E, et al. **J Anim Sci** 1996 Apr;74(4):779-85
Molecular changes of titin in left ventricular dysfunction as a result of chronic hibernation. Ausma J, et al. **J Mol Cell Cardiol** 1995 May;27(5):1203-12
Expression and assay of autophosphorylation of recombinant protein kinases. Horn MA, et al. **Methods Cell Biol** 1995; 49:531-41 (12 ref.)
Detection of flagellar protein kinases on polyvinylidene difluoride membranes following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. San Agustin JT, et al. **Methods Cell Biol** 1995;47:135-40
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Alessi DR, et al. **Methods Enzymol** 1995;255:279-90

ANTAGONISTS & INHIBITORS

Phenobarbital-induced activation of CYP2H1 and 5-aminolevulinate synthase genes in chick embryo hepatocytes is blocked by an inhibitor of protein phosphorylation. Dogra SC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):271–8

Inhibition of mitogen-activated protein kinase kinase blocks activation and redistribution of 5-lipoxygenase in HL-60 cells. Lepley RA, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):141–4

A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Agostinis P, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):613–7

Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Wang GL, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):669–75

Effect of cystathionine ketimine on the stimulus coupled responses of neutrophils and their modulation by various protein kinase inhibitors. Zhang J, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):371–6

Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Börsch-Haubold AG, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):207–12

Decreased accumulation and dephosphorylation of the mitosis-specific form of nucleophosmin/B23 in staurosporine-induced chromosome decondensation. Lu YY, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):321–7

Studies on the antiviral activity of protein kinase inhibitors against the replication of vesicular stomatitis virus. Kim YS, et al. **Biol Pharm Bull** 1995 Jun;18(6):895–9

Parthenogenic activation of pig oocytes by protein kinase inhibition. Mayes MA, et al. **Biol Reprod** 1995 Aug; 53(2):270–5

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Berns EM, et al. **Br J Cancer** 1995 Oct;72(4):964–7

Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Wang YL, et al. **Br J Dermatol** 1996 Feb;134(2):269–75

Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Guidal-Giroux C, et al. **Br J Haematol** 1996 Feb;92(2):410–9

Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Nakamaki T, et al. **Br J Haematol** 1995 Sep;91(1):139–49

CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. Schröder M, et al. **Br J Haematol** 1995 Dec;91(4):865–70

K252a, a potent inhibitor of protein kinases, inhibits the migration of cerebellar granule cells in vitro. Kobayashi S, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1-2):122–8

The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Diccianni MB, et al. **Cancer Lett** 1996 Jul 12;104(2):183–92

In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Eastham JA, et al. **Cancer Res** 1995 Nov 15; 55(22):5151–5

Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Linardopoulos S, et al. **Cancer Res** 1995 Nov 15;55(22):5168–72

Regulation of cyclin E and p27kip during mitosis in BALB/c 3T3 cells. Agrawal D, et al. **Cell Growth Differ** 1995 Oct; 6(10):1199–205

A cyclic adenosine monophosphate agonist elevates the b- and c-waves of the rabbit direct-current electroretinogram. Bragadóttir R, et al. **Doc Ophthalmol** 1995;90(3):291–303

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Meggio F, et al. **Eur J Biochem** 1995 Nov 15;234(1):317–22

Cyclin kinase inhibitors add a new dimension to cell cycle control. Yeudall WA, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):291–8 (102 ref.)

Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Tokuyama S, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):101–7

Inhibition of invasion and intraerythrocytic development of Plasmodium falciparum by kinase inhibitors. Dluzewski AR, et al. **Experientia** 1996 Jun 15;52(6):621–3

N-myristoylation of recoverin enhances its efficiency as an inhibitor of rhodopsin kinase. Senin II, et al. **FEBS Lett** 1995 Nov 27;376(1-2):87–90

Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Lilischkis R, et al. **Int J Cancer** 1996 Apr 10;66(2):249–54

Rhodopsin kinase inhibition by recoverin. Function of recoverin myristoylation. Calvert PD, et al. **J Biol Chem** 1995 Oct 13;270(41):24127–9

Regulation of interleukin-8 gene expression by interleukin-1beta, osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells. Chaudhary LR, et al. **J Biol Chem** 1996 Jul 12; 271(28):16591–6

Expression of vaccinia virus K3L protein in yeast inhibits eukaryotic initiation factor-2 kinase GCN2 and the general amino acid control pathway. Qian W, et al. **J Biol Chem** 1996 May 31;271(22):13202–7

Phosphorylation of the tight junction protein cingulin and the effects of protein kinase inhibitors and activators in MDCK epithelial cells. Citi S, et al. **J Cell Sci** 1995 Aug; 108 (Pt 8):2917–26

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. Furet P, et al. **J Comput Aided Mol Des** 1995 Dec; 9(6):465–72

p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. Doglioni C, et al. **J Pathol** 1996 Jul;179(3):248–53

Traditional Chinese medicine yields a kinase inhibitor for use in cancer and HIV [news] Jack DB. **Mol Med Today** 1996 Apr;2(4):137

Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Sil'kis IG. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):88–97 (41 ref.)

Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Kearsey JM, et al. **Oncogene** 1995 Nov 2;11(9):1675–83

CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Otterson GA, et al. **Oncogene** 1995 Sep 21;11(6):1211–6

p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Reymond A, et al. **Oncogene** 1995 Sep 21;11(6):1173–8

Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Zariwala M, et al. **Oncogene** 1996 Jan 18;12(2):451–5

Protein kinase inhibitors disrupt memory formation in two chick brain regions. Serrano PA, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):547–54

The effect of purified extract of Fagopyrum esculentum (buckwheat) on protein kinases involved in signal transduction pathways. Samel D, et al. **Planta Med** 1996 Apr;62(2):106–10

The fungal teratogen secalonic acid D is an inhibitor of protein kinase C and of cyclic AMP-dependent protein kinase. Wang BH, et al. **Planta Med** 1996 Apr;62(2):111–4

Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. Fridell RA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4421–4

Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors. Xu RM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6308–13

Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Zhang H, et al. **Prostate** 1996 Aug;29(2):69–76

Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the eIF-2 translation initiation factor. Lu Y, et al. **Virology** 1995 Dec 1;214(1):222–8

[The effect of spermine on protein kinase activity and number of cytosolic estradiol receptors] Gevorkian ES, et al. **Vopr Med Khim** 1995 May-Jun;41(3):41–2 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Marx A, et al. **Am J Pathol** 1996 Jun; 148(6):1839–50

Different expression of the myotonin protein kinase gene in discrete areas of human brain. Gennarelli M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):489–94

A 11.5-kb 5'-terminal cDNA sequence of chicken breast muscle connectin/titin reveals its Z line binding region. Yajima H, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):160–4

Alteration in gene expression of branched-chain keto acid dehydrogenase kinase but not in gene expression of its substrate in the liver of clofibrate-treated rats. Paul HS, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):411–7

Differential induction of the mitogen-activated protein kinase pathway by bacterial lipopolysaccharide in cultured monocytes and astrocytes. Willis SA, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):519–24

Progressive spatial restriction of Sek-1 and Krox-20 gene expression during hindbrain segmentation. Irving C, et al. **Dev Biol** 1996 Jan 10;173(1):26–38

JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Wilson DJ, et al. **Eur J Immunol** 1996 May;26(5):989–94

c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. Kharbanda S, et al. **J Biol Chem** 1995 Dec 22; 270(51):30278–81

Murine polo like kinase 1 gene is expressed in meiotic testicular germ cells and oocytes. Matsubara N, et al. **Mol Reprod Dev** 1995 Aug;41(4):407–15

Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease. Arendt T, et al. **Neuroscience** 1995 Sep;68(1):5–18

SRK, the stigma-specific S locus receptor kinase of Brassica, is targeted to the plasma membrane in transgenic tobacco. Stein JC, et al. **Plant Cell** 1996 Mar;8(3):429–45

The S locus receptor kinase gene encodes a soluble glycoprotein corresponding to the SKR extracellular domain in Brassica oleracea. Giranton JL, et al. **Plant J** 1995 Dec;8(6):827–34

Differential accumulation of the transcripts of 22 novel protein kinase genes in Arabidopsis thaliana. Thümmler F, et al. **Plant Mol Biol** 1995 Nov;29(3):551–65

[Regulation of biosynthesis of intracellular enzymes in Bacillus intermedius 3S-19] Znamenskaia LV, et al. **Prikl Biokhim Mikrobiol** 1995 Jul-Aug;31(4):412–6 (Eng. Abstr.) **(Rus)**

[Obtaining and properties of recombinant protein G] Gupalova TV, et al. **Vestn Ross Akad Med Nauk** 1996; (3):44–50 (Eng. Abstr.) **(Rus)**

BLOOD

A membrane-bound protein kinase from rabbit reticulocytes is an active form of multipotential S6 kinase. Bensen ES, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):249–58

CHEMISTRY

A new family of protein kinases--the mitochondrial protein kinases. Harris RA, et al. **Adv Enzyme Regul** 1995;35:147–62

Conserved C-terminus of the phosphatase CheZ is a binding domain for the chemotactic response regulator CheY. Blat Y, et al. **Biochemistry** 1996 May 7;35(18):5679–83

Structure and dynamics of a CheY-binding domain of the chemotaxis kinase CheA determined by nuclear magnetic resonance spectroscopy. McEvoy MM, et al. **Biochemistry** 1996 May 7;35(18):5633–40

Nuclear magnetic resonance assignments and global fold of a CheY-binding domain in CheA, the chemotaxis-specific kinase of Escherichia coli. McEvoy MM, et al. **Biochemistry** 1995 Oct 24;34(42):13871–80

NMR studies of the phosphotransfer domain of the histidine kinase CheA from Escherichia coli: assignments, secondary structure, general fold, and backbone dynamics. Zhou H, et al. **Biochemistry** 1995 Oct 24;34(42):13858–70

Phosphotransfer and CheY-binding domains of the histidine autokinase CheA are joined by a flexible linker. Zhou H, et al. **Biochemistry** 1996 Jan 16;35(2):433–43

The protein kinase from mitotic human cells that phosphorylates Ser-209 on the casein kinase II beta-subunit is p34cdc2. Litchfield DW, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):69–78

Sequence-specific DNA binding by covalently constrained peptide dimers of the basic leucine zipper protein GCN4. Okagami M, et al. **Bioorg Med Chem** 1995 Jun;3(6):777–84

The folding and stability of titin immunoglobulin-like modules, with implications for the mechanism of elasticity. Politou AS, et al. **Biophys J** 1995 Dec;69(6):2601–10

Factors influencing accuracy of computer-built models: a study based on leucine zipper GCN4 structure. Shen L, et al. **Biophys J** 1996 Mar;70(3):1096–104

Characterisation of protein structure/function relationship by sequence analysis without previous alignment: distinction between sub-groups of protein kinases. Guerrucci MA, et al. **Biosci Rep** 1995 Jun;15(3):161–71

When is a lipid kinase not a lipid kinase? When it is a protein kinase. Hunter T. **Cell** 1995 Oct 6;83(1):1–4 (19 ref.)

Active and inactive protein kinases: structural basis for regulation. Johnson LN, et al. **Cell** 1996 Apr 19; 85(2):149–58 (37 ref.)

The mechanically active domain of titin in cardiac muscle. Trombitás K, et al. **Circ Res** 1995 Oct;77(4):856–61

Immunological evidence that HMG-CoA reductase kinase-A is the cauliflower homologue of the RKIN1 subfamily of plant protein kinases. Ball KL, et al. **FEBS Lett** 1995 Dec 18;377(2):189–92

A molecular map of titin/connectin elasticity reveals two different mechanisms acting in series. Gautel M, et al. **FEBS Lett** 1996 Apr 29;385(1-2):11–4

Modular structure of the Rhizobium meliloti DctB protein. Giblin L, et al. **FEMS Microbiol Lett** 1996 May 15; 139(1):19–25

Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. Kentrup H, et al. **J Biol Chem** 1996 Feb 16;271(7):3488–95

Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. Woods A, et al. **J Biol Chem** 1996 Apr 26; 271(17):10282–90

Membrane topology analysis of the sensor kinase KdpD of Escherichia coli. Zimmann P, et al. **J Biol Chem** 1995 Nov 24;270(47):28282–8

Towards a molecular understanding of the elasticity of titin. Linke WA, et al. **J Mol Biol** 1996 Aug 9;261(1):62–71

The elastic I-band region of titin is assembled in a "modular" fashion by weakly interacting Ig-like domains. Politou AS, et al. **J Mol Biol** 1996 Feb 2;255(4):604–16

A Plasmodium falciparum protein kinase with two unusually large kinase inserts. Kappes B, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):163–78

An engineered allosteric switch in leucine-zipper oligomerization. Gonzalez L Jr, et al. **Nat Struct Biol** 1996 Jun;3(6):510–5

A self-replicating peptide. Lee DH, et al. **Nature** 1996 Aug

8;382(6591):525–8
Giant proteins with flour power [news] Wrigley CW. **Nature** 1996 Jun 27;381(6585):738–9
Multiple isoforms of Arabidopsis casein kinase I combine conserved catalytic domains with variable carboxyl–terminal extensions. Klimczak LJ, et al. **Plant Physiol** 1995 Oct;109(2):687–96
Specific interactions outside the proline–rich core of two classes of Src homology 3 ligands. Feng S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12408–15
Observation via one–dimensional 13Calpha NMR of local conformational substates in thermal unfolding equilibria of a synthetic analog of the GCN4 leucine zipper. Lovett EG, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1781–5
A calorimetric characterization of the salt dependence of the stability of the GCN4 leucine zipper. Kenar KT, et al. **Protein Sci** 1995 Sep;4(9):1934–8
Titanic protein gives muscles structure and bounce [news; comment] Barinaga M. **Science** 1995 Oct 13;270(5234):236 . Comment on: Science 1995 Oct 13;270(5234):293–6.
Titins: giant proteins in charge of muscle ultrastructure and elasticity [see comments] Labeit S, et al. **Science** 1995 Oct 13;270(5234):293–6. Comment in: Science 1995 Oct 13;270(5234):236.
Interhelical salt bridges, coiled–coil stability, and specificity of dimerization [letter; comment] Lavigne P, et al. **Science** 1996 Feb 23;271(5252):1136–8. Comment on: Science 1995 Apr 21;268(5209):436–9.
The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors [letter] Hofmann K, et al. **Trends Biochem Sci** 1995 Sep;20(9):347–9

CLASSIFICATION

Isozyme specific changes in the expression of protein kinase C isozyme (alpha–zeta) genes in the hippocampus of rats induced by kindling epileptogenesis. Kamphuis W, et al. **Brain Res** 1995 Dec 8;702(1–2):94–100

DEFICIENCY

Inactivation of activin–dependent transcription by kinase–deficient activin receptors. Tsuchida K, et al. **Endocrinology** 1995 Dec;136(12):5493–503

DRUG EFFECTS

Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. Correia I, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):413–24
Effects of protein phosphatase and kinase inhibitors on the cardiac L–type Ca current suggest two sites are phosphorylated by protein kinase A and another protein kinase. Hartzell HC, et al. **J Gen Physiol** 1995 Sep; 106(3):393–414
Nitric oxide and carbon monoxide activate locus coeruleus neurons through a cGMP–dependent protein kinase: involvement of a nonselective cationic channel. Pineda J, et al. **J Neurosci** 1996 Feb 15;16(4):1389–99
Involvement of glutamate receptors, protein kinases, and protein synthesis in memory for visual discrimination in the young chick. Tiunova A, et al. **Neurobiol Learn Mem** 1996 May;65(3):233–4
Ca/calmodulin–dependent kinase II inhibitor KN62 attenuates glutamate release by inhibiting voltage–dependent Ca(2+)–channels. Sihra TS, et al. **Neuropharmacology** 1995 Jul;34(7):731–41
Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen–activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

GENETICS

Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. Shindoh N, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):92–9
Structural organization of the rat branched–chain 2–oxo–acid dehydrogenase kinase gene and partial characterization of the promoter–regulatory region. Huang Y, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):603–9
Conserved C–terminus of the phosphatase CheZ is a binding domain for the chemotactic response regulator CheY. Blat Y, et al. **Biochemistry** 1996 May 7;35(18):5679–83
Effect of artificial (CTG) repeat expansion on the expression of myotonin protein kinase (MtPK) in COS–1 cells. Sasagawa N, et al. **Biochim Biophys Acta** 1996 Mar 1; 1315(2):112–6
Decreased expression of the alpha subunit of Ca2+/ calmodulin–dependent protein kinase type II mRNA in the adult rat CNS following recurrent limbic seizures. Murray KD, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):221–32
In situ hybridization of mRNA expression for IP3 receptor and IP3–3–kinase in rat brain after transient focal cerebral ischemia. Zhang SX, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):252–60
hemipterous encodes a novel Drosophila MAP kinase kinase, required for epithelial cell sheet movement. Glise B, et al. **Cell** 1995 Nov 3;83(3):451–61
Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859–69 (71 ref.)
The ksr–1 gene encodes a novel protein kinase involved in Ras–mediated signaling in C. elegans [see comments] Kornfeld K, et al. **Cell** 1995 Dec 15;83(6):903–13. Comment in: Cell 1995 Dec 15;83(6):831–4.
KSR, a novel protein kinase required for RAS signal transduction [see comments] Therrien M, et al. **Cell** 1995 Dec 15;83(6):879–88. Comment in: Cell 1995 Dec 15;83(6):831–4.
Isolation and characterization of a human cDNA clone (GCN5L1) homologous to GCN5, a yeast transcription activator. Inoue M, et al. **Cytogenet Cell Genet** 1996; 73(1–2):134–6
Nucleotide sequence of a putative sensory kinase gene from the cyanobacterium, Anacystis nidulans 6301. Fukuta M, et al. **DNA Res** 1994;1(2):97–8
Utilizing the GCN4 leader region to investigate the role of the sequence determinants in nonsense–mediated mRNA decay. Ruiz–Echevarria MJ, et al. **EMBO J** 1996 Jun 3; 15(11):2810–9
A two–component histidine kinase gene that functions in Dictyostelium development. Wang N, et al. **EMBO J** 1996 Aug 1;15(15):3890–8
Molecular cloning and characterization of a novel mammalian protein kinase harboring a homology domain that defines a subfamily of serine/threonine kinases. Becker W, et al. **Eur J Biochem** 1996 Feb 1;235(3):736–43
Complete nucleotide sequence, expression, and chromosomal localisation of human mixed–lineage kinase 2. Dorow DS, et al. **Eur J Biochem** 1995 Dec 1;234(2):492–500
A molecular map of the interactions between titin and myosin–binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Freiburg A, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):317–23
Leishmania chagasi: a gene encoding a protein kinase with a catalytic domain structurally related to MAP kinase kinase. Li S, et al. **Exp Parasitol** 1996 Mar;82(2):87–96
An additional PII in Escherichia coli: a new regulatory protein in the glutamine synthetase cascade. van Heeswijk WC, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):153–7
Cloning and characterization of the Bacillus subtilis prkA gene encoding a novel serine protein kinase. Fischer C, et al. **Gene** 1996 Feb 2;168(1):55–60
sck1, a high copy number suppressor of defects in the cAMP–dependent protein kinase pathway in fission yeast, encodes a protein homologous to the Saccharomyces cerevisiae SCH9 kinase. Jin M, et al. **Genetics** 1995 Jun; 140(2):457–67
Sequence analysis of the cDNA for the human casein kinase I delta (CSNK1D) gene and its chromosomal localization. Kusuda J, et al. **Genomics** 1996 Feb 15;32(1):140–3
The gene encoding protein kinase SEK1 maps to mouse chromosome 11 and human chromosome 17. White RA, et al. **Genomics** 1996 Jun 15;34(3):430–2
Association of CTG repeats and the 1–kb Alu insertion/deletion polymorphism at the myotonin protein kinase gene in the Japanese population suggests a common Eurasian origin of the myotonic dystrophy mutation. Yamagata H, et al. **Hum Genet** 1996 Feb;97(2):145–7
Expression of kinA and accumulation of sigma H at the onset of sporulation in Bacillus subtilis. Asai K, et al. **J Bacteriol** 1995 Nov;177(22):6679–83
Regulation of VanB–type vancomycin resistance gene expression by the VanS(B)–VanR (B) two–component regulatory system in Enterococcus faecalis V583. Evers S, et al. **J Bacteriol** 1996 Mar;178(5):1302–9
Suppression of a sensor kinase–dependent phenotype in Pseudomonas syringae by ribosomal proteins L35 and L20. Kitten T, et al. **J Bacteriol** 1996 Mar;178(6):1548–55
Non–catalytic beta– and gamma–subunit isoforms of the 5'–AMP–activated protein kinase. Gao G, et al. **J Biol Chem** 1996 Apr 12;271(15):8675–81
Diversity of the pyruvate dehydrogenase kinase gene family in humans. Gudi R, et al. **J Biol Chem** 1995 Dec 1; 270(48):28989–94
A cell wall–associated, receptor–like protein kinase. He ZH, et al. **J Biol Chem** 1996 Aug 16;271(33):19789–93
Molecular cloning and sequencing of the cytostatic G protein–activated protein kinase PAK I. Jakobi R, et al. **J Biol Chem** 1996 Mar 15;271(11):6206–11
Nuclear accumulation of multiple protein kinases during prolactin–induced proliferation of Nb2 rat lymphoma cells. Ganguli S, et al. **J Cell Physiol** 1996 May;167(2):251–60
Characterization of a 5.4 kb cDNA fragment from the Z–line region of rabbit cardiac titin reveals phosphorylation sites for proline–directed kinases. Sebestyén MG, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3029–37
Role of kinases in HTLV–I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113–23 (169 ref.)
Genomic organization of M line titin and its tissue–specific expression in two distinct isoforms. Kolmerer B, et al. **J Mol Biol** 1996 Mar 1;256(3):556–63
The murine LIM–kinase gene (limk) encodes a novel serine threonine kinase expressed predominantly in trophoblast giant cells and the developing nervous system. Cheng AK, et al. **Mech Dev** 1995 Aug;52(2–3):187–97
The dspA gene product of the cyanobacterium Synechocystis sp. strain PCC 6803 influences sensitivity to chemically different growth inhibitors and has amino acid similarity to histidine protein kinases. Bartsevich VV, et al. **Microbiology** 1995 Nov;141 (Pt 11):2915–20
Modulation of tRNA(iMet), eIF–2, and eIF–2B expression shows that GCN4 translation is inversely coupled to the level of eIF–2.GTP.Met–tRNA(iMet) ternary complexes. Dever TE, et al. **Mol Cell Biol** 1995 Nov;15(11):6351–63
The yeast carboxyl–terminal repeat domain kinase CTDK–I is a divergent cyclin–cyclin–dependent kinase complex. Sterner DE, et al. **Mol Cell Biol** 1995 Oct;15(10):5716–24
Mode of action of the qcr9 and cat3 mutations in restoring the ability of Saccharomyces cerevisiae tps1 mutants to grow on glucose. Blázquez MA, et al. **Mol Gen Genet** 1995 Dec 20;249(6):655–64
Dominant mutant alleles of yeast protein kinase gene CDC15 suppress the lte1 defect in termination of M phase and genetically interact with CDC14. Shirayama M, et al. **Mol Gen Genet** 1996 May 23;251(2):176–85
Genetic evidence for functional specificity of the yeast GCN2 kinase. Tavernarakis N, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):613–8
LIM–kinase deleted in Williams syndrome [letter] Tassabehji M, et al. **Nat Genet** 1996 Jul;13(3):272–3
Sequences 5' of the first upstream open reading frame in GCN4 mRNA are required for efficient translational reinitiation. Grant CM, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3980–8
Molecular cloning of members of the S–multigene family in self–incompatible Brassica campestris L. Suzuki G, et al. **Plant Cell Physiol** 1995 Oct;36(7):1273–80
The S locus receptor kinase gene encodes a soluble glycoprotein corresponding to the SKR extracellular domain in Brassica oleracea. Giranton JL, et al. **Plant J** 1995 Dec;8(6):827–34
Calcium–dependent protein kinase gene expression in response to physical and chemical stimuli in mungbean (Vigna radiata). Botella JR, et al. **Plant Mol Biol** 1996 Mar; 30(6):1129–37
Expression of three members of the calcium–dependent protein kinase gene family in Arabidopsis thaliana. Hong Y, et al. **Plant Mol Biol** 1996 Mar;30(6):1259–75
Multiple isoforms of Arabidopsis casein kinase I combine conserved catalytic domains with variable carboxyl–terminal extensions. Klimczak LJ, et al. **Plant Physiol** 1995 Oct;109(2):687–96
cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Cimprich KA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2850–5
Molecular cloning of a protein kinase whose phosphorylation is regulated by genetic adhesion during Chlamydomonas fertilization. Kurvari V, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):39–43
Molecular analysis of the CTG trinucleotide repeat in South African myotonic dystrophy families––implications for diagnosis and counselling. Goldman A, et al. **S Afr Med J** 1995 Nov;85(11):1161–4
Regulation of RAD53 by the ATM–like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways [see comments] Sanchez Y, et al. **Science** 1996 Jan 19; 271(5247):357–60. Comment in: Science 1996 Jan 19;271(5247):314–5.
[DNA diagnosis in myotonic dystrophy] Tachi N. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):3–8 (38 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Skeie GO, et al. **Autoimmunity** 1995; 20(2):99–104
ERK2–type mitogen–activated protein kinase (MAPK) and its substrates in postsynaptic density fractions from the rat brain. Suzuki T, et al. **Neurosci Res** 1995 Jun;22(3):277–85

ISOLATION & PURIFICATION

Characterization of protein kinases involved in dentinogenesis. Zeichner–David M, et al. **Connect Tissue Res** 1995;33(1–3):87–95
Isolation and characterization of protein kinases from Paramecium cilia. Carlson GL, et al. **Methods Cell Biol** 1995;47:473–80
Purification and assay of kinases that interact with Rac/Cdc42. Manser E, et al. **Methods Enzymol** 1995; 256:215–27

METABOLISM

Cell cycle–related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)
Differential activation of the extracellular signal–regulated kinase, Jun kinase and Janus kinase–Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS–derived Kaposi's sarcoma cells. Faris M, et al. **AIDS** 1996 Apr;10(4):369–78
Activation of multiple protein kinases by interleukin–1. Dunford JE, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:285–7
Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320–43 (151 ref.)
The stress–activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)
Regulation of expression of sodium–calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258–71 (36 ref.)

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1-33 (146 ref.)

MAPK activity is down-regulated in human colon adenocarcinoma: correlation with PKC activity. Attar BM, et al. **Anticancer Res** 1996 Jan-Feb;16(1):395-9

Growth control of human prostatic cancer cells by the phorbol ester TPA: possible involvement of protein kinases. Konno S, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1843-9

Differential phosphorylation of human tau isoforms containing three repeats by several protein kinases. Singh TJ, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):43-50

Dephosphorylation of a 30-kDa protein of fowl spermatozoa by the addition of myosin light chain kinase substrate peptide inhibits the flagellar motility. Ashizawa K, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):706-12

Regulation of rhodopsin phosphorylation by a family of neuronal calcium sensors. De Castro E, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):133-40

A novel function for nucleoside diphosphate kinase in Drosophila. Inoue H, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):887-92

Elastic properties of single titin molecules made visible through fluorescent F-actin binding. Kellermayer MS, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):491-7

Phosphorylation by MAPKAP kinase 2 activates Mg(2+)-ATPase activity of myosin II. Komatsu S, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):741-5

The signal modulator protein 14-3-3 is a target of sphingosine- or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells. Megidish T, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):739-47

alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):277-82

Specific processing of native and phosphorylated tau protein by proteases. Wang X, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):591-7

Involvement of several protein kinases in the phosphorylation of p47-phox. Yamaguchi M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):891-5

Transforming growth factor-beta type-II receptor signalling: intrinsic/associated casein kinase activity, receptor interactions and functional effects of blocking antibodies. Hall FL, et al. **Biochem J** 1996 May 15;316 (Pt 1):303-10

Protein phosphatase and kinase activities possibly involved in exocytosis regulation in Paramecium tetraurelia. Kissmehl R, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):65-76

The mitogen-activated protein kinase pathway in rat islets of Langerhans: studies on the regulation of insulin secretion. Persaud SJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):119-24

Association of cytoskeletal proteins with estrogen receptor in rat uterine cytosol: possible role in receptor movement into the nucleus. Zafar A, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1197-206

Interleukin I receptors and signal transduction. O'Neill LA. **Biochem Soc Trans** 1996 Feb;24(1):207-11 (44 ref.)

The functional relationship of plant lipid-derived second messengers and plant lipid-activated protein kinase. Scherer GF. **Biochem Soc Trans** 1995 Nov;23(4):871-5 (48 ref.)

Novel mechanism for the activation of rhodopsin kinase: implications for other G protein-coupled receptor kinases (GRK's). Dean KR, et al. **Biochemistry** 1996 May 14; 35(19):6164-72

Kinetic comparison of the specificity of the vancomycin resistance VanSfor two response regulators, VanR and PhoB. Fisher SL, et al. **Biochemistry** 1996 Apr 16; 35(15):4732-40

Identification of myosin III as a protein kinase. Ng KP, et al. **Biochemistry** 1996 Jul 23;35(29):9392-9

Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin. Rim J, et al. **Biochemistry** 1995 Sep 19;34(37):11938-45

Structural basis for ligand discrimination and response initiation in the heme-based oxygen sensor FixL. Rodgers KR, et al. **Biochemistry** 1996 Jul 23;35(29):9539-48

Modulation of rabbit reticulocyte guanine nucleotide exchange factor activity by casein kinases 1 and 2 and glycogen synthase kinase 3. Singh LP, et al. **Biochemistry** 1996 Mar 12;35(10):3206-12

Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187-99 (309 ref.)

Stimulation of rat liver AMP-activated protein kinase by AMP analogues. Henin N, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):197-203

Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells. Medina M, et al. **Biochim Biophys Acta** 1996 May 24;1316(1):43-50

Purification and sequencing of multiple forms of Brassica napus seed napin small chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):23-33

Purification and sequencing of multiple forms of Brassica napus seed napin large chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase. Neumann GM, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):34-43

Regulation of hepatic pyruvate dehydrogenase kinase by insulin and dietary manipulation in vivo. Studies with the euglycaemic-hyperinsulinaemic clamp. Sugden MC, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):114-20

RAP kinase, a new enzyme phosphorylating the acidic P proteins from Saccharomyces cerevisiae. Szyszka R, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):213-21

Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501-8 (98 ref.)

In isolated human centrosomes, the associated kinases phosphorylate a specific subset of centrosomal proteins. Keryer G, et al. **Biol Cell** 1995;84(3):155-65

The folding and stability of titin immunoglobulin-like modules, with implications for the mechanism of elasticity. Politou AS, et al. **Biophys J** 1995 Dec;69(6):2601-10

Isolation and characterisation of Kasumi-1 human myeloid leukaemia cell line resistant to tumour necrosis factor alpha-induced apoptosis. Ido M, et al. **Br J Cancer** 1996 Feb;73(3):360-5

Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629-36 (61 ref.)

Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Chen ZJ, et al. **Cell** 1996 Mar 22;84(6):853-62

TAFII250 is a bipartite protein kinase that phosphorylates the base transcription factor RAP74. Dikstein R, et al. **Cell** 1996 Mar 8;84(5):781-90

Molecular glue: kinase anchoring and scaffold proteins. Faux MC, et al. **Cell** 1996 Apr 5;85(1):9-12 (19 ref.)

Phosphorylation with protein kinases modulates calcium loading of terminal cisternae of sarcoplasmic reticulum from skeletal muscle. Mayrleitner M, et al. **Cell Calcium** 1995 Sep;18(3):197-206

Ectoprotein kinase activities on non-differentiated and differentiated U-937 cells. Geberhiwot T, et al. **Cell Signal** 1995 May;7(4):423-9

Hypoxia and hypoxia/reoxygenation activate Raf-1, mitogen-activated protein kinase kinase, mitogen-activated protein kinases, and S6 kinase in cultured rat cardiac myocytes. Seko Y, et al. **Circ Res** 1996 Jan;78(1):82-90

Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Hupp TR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:195-206

Cell polarity. The importance of being polar. Glotzer M, et al. **Curr Biol** 1995 Oct 1;5(10):1102-5 (21 ref.)

Involvement of MAP kinase in insulin signalling revealed by non-invasive imaging of luciferase gene expression in single living cells. Rutter GA, et al. **Curr Biol** 1995 Aug 1;5(8):890-9

Protein phosphorylation in neuronal plasticity and gene expression. Schulman H. **Curr Opin Neurobiol** 1995 Jun; 5(3):375-81 (47 ref.)

Regulation of nuclear envelope assembly/disassembly by MAP kinase. Moos J, et al. **Dev Biol** 1996 May 1; 175(2):358-61

BMP-4 regulates the dorsal-ventral differences in FGF/MAPKK-mediated mesoderm induction in Xenopus. Northrop J, et al. **Dev Biol** 1995 Nov;172(1):242-52

Truncated, desensitization-defective neurokinin receptors mediate sustained MAP kinase activation, cell growth and transformation by a Ras-independent mechanism. Alblas J, et al. **EMBO J** 1996 Jul 1;15(13):3351-60

Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. Berra E, et al. **EMBO J** 1995 Dec 15;14(24):6157-63

Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Bunone G, et al. **EMBO J** 1996 May 1; 15(9):2174-83

p75(NGFR) and TrkA receptors collaborate to rapidly activate a p75(NGFR)-associated protein kinase. Canossa M, et al. **EMBO J** 1996 Jul 1;15(13):3369-76

Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. Cavigelli M, et al. **EMBO J** 1995 Dec 1;14(23):5957-64

Selective interaction of JNK protein kinase isoforms with transcription factors. Gupta S, et al. **EMBO J** 1996 Jun 3;15(11):2760-70

Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. Salmeron A, et al. **EMBO J** 1996 Feb 15;15(4):817-26

The hybrid histidine kinase DokA is part of the osmotic response system of Dictyostelium. Schuster SS, et al. **EMBO J** 1996 Aug 1;15(15):3880-9

Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. Shamu CE, et al. **EMBO J** 1996 Jun 17;15(12):3028-39

Reduced phosphorylation of mitogen-activated protein kinase kinase in response to insulin in cells with truncated C-terminal domain of insulin receptor. Carel K, et al. **Endocrinology** 1996 Jun;137(6):2362-6

Insulin signaling network — waiting for Copernicus [editorial; comment] Draznin B. **Endocrinology** 1996 Jul; 137(7):2647-8 (20 ref.). Comment on: Endocrinology 1996 Jul;137(7):2649-58.

Protein kinase cascade activated by mechanical stress in cardiocytes: possible involvement of angiotensin II. Komuro I, et al. **Eur Heart J** 1995 May;16 Suppl C:8-11

Phosphorylation of calmodulin by plasma-membrane-associated protein kinase(s). Benguría A, et al. **Eur J Biochem** 1995 Nov 15;234(1):50-8

Analysis of the specificity of the AMP-activated protein kinase by site-directed mutagenesis of bacterially expressed 3-hydroxy 3-methylglutaryl-CoA reductase, using a single primer variant of the unique-site-elimination method. Ching YP, et al. **Eur J Biochem** 1996 May 1;237(3):800-8

A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Freiburg A, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):317-23

Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells. Meier R, et al. **Eur J Biochem** 1996 Mar 15;236(3):796-805

Activation of two isoforms of mitogen-activated protein kinase kinase in response to epidermal growth factor and nerve growth factor. Moriguchi T, et al. **Eur J Biochem** 1995 Nov 15;234(1):32-8

Purification and biochemical characterization of myomesin, a myosin-binding and titin-binding protein, from bovine skeletal muscle. Obermann WM, et al. **Eur J Biochem** 1995 Oct 1;233(1):110-5

Activation of the double-stranded-RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly (I).poly (C) in endothelial cells. Offermann MK, et al. **Eur J Biochem** 1995 Aug 15;232(1):28-36

Sphingomyelin-derived lipids differentially regulate the extracellular signal-regulated kinase 2 (ERK-2) and c-Jun N-terminal kinase (JNK) signal cascades in airway smooth muscle. Pyne S, et al. **Eur J Biochem** 1996 May 1; 237(3):819-26

Phosphorylation state of the RNA polymerase II C-terminal domain (CTD) in heat-shocked cells. Possible involvement of the stress-activated mitogen-activated protein (MAP) kinases. Venetianer A, et al. **Eur J Biochem** 1995 Oct 1; 233(1):83-92

Integration of titin into the sarcomeres of cultured differentiating human skeletal muscle cells. van der Loop FT, et al. **Eur J Cell Biol** 1996 Apr;69(4):301-7

HIV induces activation of phosphatidylinositol 4-kinase and mitogen-activated protein kinase by interacting with T cell CD4 surface molecules. Schmid-Antomarchi H, et al. **Eur J Immunol** 1996 Mar;26(3):717-20

Cytosolic and nuclear mitogen-activated protein kinases are regulated by distinct mechanisms. Wang Y, et al. **Exp Cell Res** 1996 Jun 15;225(2):382-8

Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes. Komuro I, et al. **FASEB J** 1996 Apr;10(5):631-6

The osmo-inducible gpd1+ gene is a target of the signaling pathway involving Wis1 MAP-kinase kinase in fission yeast. Aiba H, et al. **FEBS Lett** 1995 Dec 4;376(3):199-201

The cardiac sarcoplasmic reticulum phospholamban kinase is a distinct delta-CaM kinase isozyme. Baltas LG, et al. **FEBS Lett** 1995 Oct 2;373(1):71-5

5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. Davies SP, et al. **FEBS Lett** 1995 Dec 27;377(3):421-5

Calcium-dependent inhibition of in vitro thin-filament motility by native titin. Kellermayer MS, et al. **FEBS Lett** 1996 Feb 19;380(3):281-6

Partial purification and characterization of a protein kinase that is activated by nuclear localization signal peptides. Kurihara T, et al. **FEBS Lett** 1996 Feb 19;380(3):241-5

Golgi apparatus mammary gland casein kinase: monitoring by a specific peptide substrate and definition of specificity determinants. Lasa-Benito M, et al. **FEBS Lett** 1996 Mar 11;382(1-2):149-52

Involvement of protein kinase in delta 12-prostaglandin J2-induced expression of rat heme oxygenase-1 gene. Negishi M, et al. **FEBS Lett** 1995 Sep 25;372(2-3):279-82

Up-regulation of L- and non-L, non-N-type Ca2+ channels by basal and stimulated protein kinase C activation in insulin-secreting RINm5F cells. Platano D, et al. **FEBS Lett** 1996 Aug 5;391(1-2):189-94

Calcium-bound recoverin targets rhodopsin kinase to membranes to inhibit rhodopsin phosphorylation. Sanada K, et al. **FEBS Lett** 1996 Apr 22;384(3):227-30

Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR--an activator of AMP-activated protein kinase. Young ME, et al. **FEBS Lett** 1996 Mar 11;382(1-2):43-7

GCN4 eukaryotic transcription factor/FokI endonuclease-mediated 'Achilles' heel cleavage': quantitative study of protein-DNA interaction. Skowron PM, et al. **Gene** 1996 Apr 17;170(1):1-8

Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways. Sun Z, et al. **Genes Dev** 1996 Feb 15;10(4):395-406

Association of leukocyte surface receptors with protein kinases. Hořejší V. **Int Arch Allergy Immunol** 1996 May; 110(1):1-6 (27 ref.)

The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the

MAPK/RSK cascade. Porras A, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S43–51 (47 ref.)

Identification of a membrane protein involved in activation of the KinB pathway to sporulation in Bacillus subtilis. Dartois V, et al. **J Bacteriol** 1996 Feb;178(4):1178–86

Phosphorylation of the PII protein (glnB gene product) in the cyanobacterium Synechococcus sp. strain PCC 7942: analysis of in vitro kinase activity. Forchhammer K, et al. **J Bacteriol** 1995 Oct;177(20):5812–7

Two-component regulatory proteins ResD-ResE are required for transcriptional activation of fnr upon oxygen limitation in Bacillus subtilis. Nakano MM, et al. **J Bacteriol** 1996 Jul;178(13):3796–802

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Alessi DR, et al. **J Biol Chem** 1995 Nov 17; 270(46):27489–94

A potential SH3 domain-binding site in the Crk SH2 domain. Anafi M, et al. **J Biol Chem** 1996 Aug 30;271(35):21365–74

Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. Beyaert R, et al. **J Biol Chem** 1995 Oct 6;270(40):23293–9

Lactosylceramide stimulates Ras-GTP loading, kinases (MEK, Raf), p44 mitogen-activated protein kinase, and c-fos expression in human aortic smooth muscle cells. Bhunia AK, et al. **J Biol Chem** 1996 May 3;271(18):10660–6

Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. Bogoyevitch MA, et al. **J Biol Chem** 1995 Nov 3; 270(44):26303–10

Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. Bokemeyer D, et al. **J Biol Chem** 1996 Jan 12; 271(2):639–42

Structural and functional analysis of yeast putative adaptors. Evidence for an adaptor complex in vivo. Candau R, et al. **J Biol Chem** 1996 Mar 1;271(9):5237–45

Insulin stimulation of mitogen-activated protein kinase, p90rsk, and p70 S6 kinase in skeletal muscle of normal and insulin-resistant mice. Implications for the regulation of glycogen synthase. Chang PY, et al. **J Biol Chem** 1995 Dec 15;270(50):29928–35

Participation of reactive oxygen species in the lysophosphatidic acid-stimulated mitogen-activated protein kinase kinase activation pathway. Chen Q, et al. **J Biol Chem** 1995 Dec 1;270(48):28499–502

Characterization of a protein kinase that phosphorylates serine 189 of the mitogen-activated protein kinase homolog ERK3. Cheng M, et al. **J Biol Chem** 1996 May 17; 271(20):12057–62

Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. Dyck JRB, et al. **J Biol Chem** 1996 Jul 26;271(30):17798–803

Cross-talk between the histidine protein kinase VanS and the response regulator PhoB. Characterization and identification of a VanS domain that inhibits activation of PhoB. Fisher SL, et al. **J Biol Chem** 1995 Sep 29; 270(39):23143–9

The phosphodiesterase inhibitor SQ 20006 selectively blocks mitogen activation of p70S6k and transition to S phase of the cell division cycle without affecting the steady state phosphorylation of eIF-4E. Frost V, et al. **J Biol Chem** 1995 Nov 3;270(44):26698–706

Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. Fukuda M, et al. **J Biol Chem** 1996 Aug 16;271(33):20024–8

Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. Gum R, et al. **J Biol Chem** 1996 May 3;271(18):10672–80

Characterization of the structure and function of a novel MAP kinase kinase (MKK6). Han J, et al. **J Biol Chem** 1996 Feb 9;271(6):2886–91

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. Hanke JH, et al. **J Biol Chem** 1996 Jan 12;271(2):695–701

Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. Hawes BE, et al. **J Biol Chem** 1996 May 24;271(21):12133–6

Roles of amino acid residues surrounding phosphorylation site 1 of branched-chain alpha-ketoacid dehydrogenase (BCKDH) in catalysis and phosphorylation site recognition by BCKDH kinase. Hawes JW, et al. **J Biol Chem** 1995 Dec 29;270(52):31071–6

5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. Hawley SA, et al. **J Biol Chem** 1995 Nov 10; 270(45):27186–91

Aggregation of the FcepsilonRI on mast cells stimulates c-Jun amino-terminal kinase activity. A response inhibited by wortmannin. Ishizuka T, et al. **J Biol Chem** 1996 May 31;271(22):12762–6

Molecular cloning and sequencing of the cytostatic G protein-activated protein kinase PAK I. Jakobi R, et al. **J Biol Chem** 1996 Mar 15;271(11):6206–11

Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. Kentrup H, et al. **J Biol Chem** 1996 Feb 16;271(7):3488–95

Role of the Raf/mitogen-activated protein kinase pathway in p21ras desensitization. Klarlund JK, et al. **J Biol Chem** 1996 Jul 12;271(28):16674–7

Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. Knall C, et al. **J Biol Chem** 1996 Feb 2;271(5):2832–8

Other kinases can substitute for Jak2 in signal transduction by interferon-gamma. Kotenko SV, et al. **J Biol Chem** 1996 Jul 19;271(29):17174–82

Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter. Kovarik A, et al. **J Biol Chem** 1996 Jul 26;271(30):18140–7

Protein kinase signaling pathway triggered by cell swelling and involved in the activation of glycogen synthase and acetyl-CoA carboxylase in isolated rat hepatocytes. Krause U, et al. **J Biol Chem** 1996 Jul 12;271(28):16668–73

Identification of an I kappa B alpha-associated protein kinase in a human monocytic cell line and determination of its phosphorylation sites on I kappa B alpha. Kuno K, et al. **J Biol Chem** 1995 Nov 17;270(46):27914–9

Precision substrate targeting of protein kinases v-Abl and c-Src. Lee TR, et al. **J Biol Chem** 1995 Nov 10; 270(45):27022–6

Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. Lenormand P, et al. **J Biol Chem** 1996 Jun 28; 271(26):15762–8

Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. Lo YYC, et al. **J Biol Chem** 1996 Jun 28;271(26):15703–7

Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. Luttrell LM, et al. **J Biol Chem** 1996 Aug 9;271(32):19443–50

Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. Modur V, et al. **J Biol Chem** 1996 May 31;271(22):13094–102

Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. Montgomery RB, et al. **J Biol Chem** 1995 Dec 22;270(51):30562–6

Role of mitogen-activated protein kinase kinase in regulation of the epidermal growth factor receptor by protein kinase C. Morrison P, et al. **J Biol Chem** 1996 May 31; 271(22):12891–6

Structural and enzymatic aspects of rhodopsin phosphorylation. Ohguro H, et al. **J Biol Chem** 1996 Mar 1;271(9):5215–24

Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. Okano I, et al. **J Biol Chem** 1995 Dec 29; 270(52):31321–30

Adhesion through the interaction of lymphocyte function-associated antigen-1 with intracellular adhesion molecule-1 induces tyrosine phosphorylation of p130cas and its association with c-CrkII. Petruzzelli L, et al. **J Biol Chem** 1996 Mar 29;271(13):7796–801

Lipoyl domain-based mechanism for the integrated feedback control of the pyruvate dehydrogenase complex by enhancement of pyruvate dehydrogenase kinase activity. Ravindran S, et al. **J Biol Chem** 1996 Jan 12;271(2):653–62

Cleavage arrest of early frog embryos by the G protein-activated protein kinase PAK I. Rooney RD, et al. **J Biol Chem** 1996 Aug 30;271(35):21498–504

Phosphorylation of purified bovine bone sialoprotein and osteopontin by protein kinases. Salih E, et al. **J Biol Chem** 1996 Jul 12;271(28):16897–905

Purification of a 12,020-dalton protein that enhances the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. Scott A, et al. **J Biol Chem** 1995 Oct 13;270(41):24540–7

Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. Smith CD, et al. **J Biol Chem** 1995 Nov 24;270(47):28145–52

Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. Sorimachi H, et al. **J Biol Chem** 1995 Dec 29;270(52):31158–62

Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. Stein B, et al. **J Biol Chem** 1996 May 10;271(19):11427–33

Activation of the mitogen-activated protein kinase pathway by fMet-leu-Phe in the absence of Lyn and tyrosine phosphorylation of SHC in transfected cells. Torres M, et al. **J Biol Chem** 1996 May 31;271(22):13244–9

The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. Trejo J, et al. **J Biol Chem** 1996 Aug 30;271(35):21536–41

The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. Van Seuningen I, et al. **J Biol Chem** 1995 Nov 10;270(45):26976–85

Galpha12 and Galpha13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells. Voyno-Yasenetskaya TA, et al. **J Biol Chem** 1996 Aug 30;271(35):21081–7

Induced release of cell surface protein kinase yields CK1- and CK2-like enzymes in tandem. Walter J, et al. **J Biol Chem** 1996 Jan 5;271(1):111–9

Is protein kinase substrate efficacy a reliable barometer for successful inhibitor design? Werner DS, et al. **J Biol Chem** 1996 Jan 5;271(1):180–5

Phosphorylation of chromogranin A and catecholamine secretion stimulated by elevation of intracellular Ca2+ in cultured bovine adrenal medullary cells. Yanagihara N, et al. **J Biol Chem** 1996 Jul 19;271(29):17463–8

Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases. Deckert M, et al. **J Cell Biol** 1996 May;133(4):791–9

Studies of the interaction between titin and myosin. Houmeida A, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1471–81

Detection of protein kinase activity specifically activated at metaphase-anaphase transition. Sekimata M, et al. **J Cell Biol** 1996 Feb;132(4):635–41

Nuclear accumulation of multiple protein kinases during prolactin-induced proliferation of Nb2 rat lymphoma cells. Ganguli S, et al. **J Cell Physiol** 1996 May;167(2):251–60

Induction of down-regulation of the kinase activities of Mek, p42Erk, p90RSK, and p63SAMK in chicken embryo fibroblast at the late stage of src-induced cellular transformation. Wang HC. **J Cell Physiol** 1996 Jul; 168(1):87–96

Neither ERK nor JNK/SAPK MAP kinase subtypes are essential for histone H3/HMG-14 phosphorylation or c-fos and c-jun induction. Cano E, et al. **J Cell Sci** 1995 Nov; 108 (Pt 11):3599–609

Proteolysis of a 34 kDa phosphoprotein coincident with a decrease in protein kinase activity during the erythrocytic schizont stage of the malaria parasite. Wiser MF. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):659–64

TNF-alpha stimulates monocyte adhesion to glomerular mesangial cells. The role of intercellular adhesion molecule-1 gene expression and protein kinases. Pai R, et al. **J Immunol** 1996 Apr 1;156(7):2571–9

Role of rat liver plasma membrane phospholipids in regulation of protein kinase activities. Gavrilova NJ, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):241–52

Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. Longenecker KL, et al. **J Mol Biol** 1996 Apr 5;257(3):618–31

Surface phosphorylation by ecto-protein kinase C in brain neurons: a target for Alzheimer's beta-amyloid peptides. Hogan MV, et al. **J Neurochem** 1995 Nov;65(5):2022–30

Localization of sites in the tail domain of the middle molecular mass neurofilament subunit phosphorylated by a neurofilament-associated kinase and by casein kinase I. Hollander BA, et al. **J Neurochem** 1996 Jan;66(1):412–20

hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase. Martell KJ, et al. **J Neurochem** 1995 Oct;65(4):1823–33

Phosphorylation of VAMP/synaptobrevin in synaptic vesicles by endogenous protein kinases. Nielander HB, et al. **J Neurochem** 1995 Oct;65(4):1712–20

CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent protein kinase domain identified by interaction with neurexins. Hata Y, et al. **J Neurosci** 1996 Apr 15;16(8):2488–94

Protein synthesis-dependent formation of protein kinase Mzeta in long-term potentiation. Osten P, et al. **J Neurosci** 1996 Apr 15;16(8):2444–51

cGMP-dependent protein kinase in dorsal root ganglion: relationship with nitric oxide synthase and nociceptive neurons. Qian Y, et al. **J Neurosci** 1996 May 15; 16(10):3130–8

Neurofilament phosphorylation is modulated by myelination. Starr R, et al. **J Neurosci Res** 1996 May 15;44(4):328–37

Effect of Mg2+ concentrations on phosphorylation/activation of phosphorylase b kinase by cAMP/Ca(2+)-independent, autophosphorylation-dependent protein kinase. Yu JS, et al. **J Protein Chem** 1995 Nov;14(8):747–52

The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. Heineman TC, et al. **J Virol** 1995 Nov;69(11):7367–70

Ca(+2)-phosphatidylserine-dependent protein kinase C activity in fetal, neonatal and adult rabbit lung and isolated lamellar bodies. Samuels ER, et al. **Life Sci** 1995; 57(17):1557–68

Phosphorylation of Chlamydomonas flagellar proteins. Bloodgood RA, et al. **Methods Cell Biol** 1995;47:121–7

Purification and assay of kinases that interact with Rac/Cdc42. Manser E, et al. **Methods Enzymol** 1995; 256:215–27

Protein kinases and phosphatases during the developmental cycle of myxobacteria. Muñoz Dorado J, et al. **Microbiologia** 1995 Sep;11(3):376–8

Isolation of regulatory mutants in photosynthesis gene expression in Rhodobacter sphaeroides 2.4.1 and partial complementation of a PrrB mutant by the HupT

histidine-kinase. Gomelsky M, et al. **Microbiology** 1995 Aug;141 (Pt 8):1805-19
Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase. Thorburn J, et al. **Mol Biol Cell** 1995 Nov;6(11):1479-90
Cell adhesion-dependent inactivation of a soluble protein kinase during fertilization in Chlamydomonas. Zhang Y, et al. **Mol Biol Cell** 1996 Apr;7(4):515-27
Protein kinase C isotypes required for phorbol-ester induction of stromelysin-1 in rat fibroblasts. Gaire M, et al. **Mol Carcinog** 1996 Feb;15(2):124-33
Phosphorylation of cardiac junctional and free sarcoplasmic reticulum by PKC alpha, PKC beta, PKA and the Ca2+/calmodulin-dependent protein kinase. Allen BG, et al. **Mol Cell Biochem** 1996 Feb 23;155(2):91-103
Effects of pyruvate on pyruvate dehydrogenase kinase of rat heart. Carter TC, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:71-5
Regulation of cardiac gap junction channel permeability and conductance by several phosphorylating conditions. Kwak BR, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):93-9
Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain. Singh TJ, et al. **Mol Cell Biochem** 1996 Jan 26; 154(2):143-51
Signaling in the yeast pheromone response pathway: specific and high-affinity interaction of the mitogen-activated protein (MAP) kinases Kss1 and Fus3 with the upstream MAP kinase kinase Ste7. Bardwell L, et al. **Mol Cell Biol** 1996 Jul;16(7):3637-50
Stimulation of nuclear import by simian virus 40-transformed cell extracts is dependent on protein kinase activity. Feldherr C, et al. **Mol Cell Biol** 1995 Dec;15(12):7043-9
Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Khosravi-Far R, et al. **Mol Cell Biol** 1996 Jul;16(7):3923-33
Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Lee KS, et al. **Mol Cell Biol** 1995 Dec;15(12):7143-51
Epidermal growth factor and Ras regulate gene expression in GH4 pituitary cells by separate, antagonistic signal transduction pathways. Pickett CA, et al. **Mol Cell Biol** 1995 Dec;15(12):6777-84
MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Raingeaud J, et al. **Mol Cell Biol** 1996 Mar;16(3):1247-55
Constitutive activation of the Saccharomyces cerevisiae mating response pathway by a MAP kinase kinase from Candida albicans. Clark KL, et al. **Mol Gen Genet** 1995 Dec 20;249(6):609-21
Genetic evidence for functional specificity of the yeast GCN2 kinase. Tavernarakis N, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):613-8
Ca2+/S100 regulation of giant protein kinases [see comments] Heierhorst J, et al. **Nature** 1996 Apr 18; 380(6575):636-9. Comment in: Nature 1996 May 18;380(6575):585-7.
Protein kinases. Twitching worms catch S100 [news; comment] Johnson KA, et al. **Nature** 1996 Apr 18; 380(6575):585-7. Comment on: Nature 1996 May 18;380(6575):636-9.
Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Kuo MH, et al. **Nature** 1996 Sep 19;383(6597):269-72
Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Pombo CM, et al. **Nature** 1995 Oct 26;377(6551):750-4
Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Rossi F, et al. **Nature** 1996 May 2; 381(6577):80-2
Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Shibasaki F, et al. **Nature** 1996 Jul 25;382(6589):370-3
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Verheij M, et al. **Nature** 1996 Mar 7;380(6569):75-9
Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors. Wan Y, et al. **Nature** 1996 Apr 11;380(6574):541-4
Expression of constitutively active CaMKII in target tissue modifies presynaptic axon arbor growth. Zou DJ, et al. **Neuron** 1996 Mar;16(3):529-39
Calcium influx recruits an additional class of kinases to hyperphosphorylate tau. Shea TB, et al. **Neuroreport** 1995 Jul 10;6(10):1437-40
Increased levels of mitogen activated protein kinase (MAP-K) detected in the injured adult mouse sciatic nerve. Svensson B, et al. **Neurosci Lett** 1995 Nov 10;200(1):33-6
Stress activated protein kinases, a novel family of mitogen-activated protein kinases, are heterogeneously expressed in the adult rat brain and differentially distributed from extracellular-signal-regulated protein kinases. Carletti R, et al. **Neuroscience** 1995 Dec;69(4):1103-10
Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. Herrmann CH, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):501-8
A comparison of the different DNA binding specificities of the bZip proteins C/EBP and GCN4. Koldin B, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4162-9
In vivo association of ATFa with JNK/SAP kinase activities. Bocco JL, et al. **Oncogene** 1996 May 2;12(9):1971-80
Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Franklin CC, et al. **Oncogene** 1995 Dec 7;11(11):2365-74
Activation of the JNK pathway by distantly related protein kinases, MEKK and MUK. Hirai S, et al. **Oncogene** 1996 Feb 1;12(3):641-50
Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. Rao GN. **Oncogene** 1996 Aug 15;13(4):713-9
Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Xu X, et al. **Oncogene** 1996 Jul 4;13(1):135-42
A calcium and free fatty acid-modulated protein kinase as putative effector of the fusicoccin 14-3-3 receptor. van der Hoeven PC, et al. **Plant Physiol** 1996 Jul;111(3):857-65
Hyphal development in Neurospora crassa: involvement of a two-component histidine kinase. Alex LA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3416-21
Two redundant systems maintain levels of resident proteins within the yeast endoplasmic reticulum. Beh CT, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9820-3
Surface protein phosphorylation by ecto-protein kinase is required for the maintenance of hippocampal long-term potentiation. Chen W, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8688-93
Mos/mitogen-activated protein kinase can induce early meiotic phenotypes in the absence of maturation-promoting factor: a novel system for analyzing spindle formation during meiosis I. Choi T, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4730-5
Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands. Feng S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12408-15
Glucose stimulation of insulin release in the absence of extracellular Ca2+ and in the absence of any increase in intracellular Ca2+ in rat pancreatic islets. Komatsu M, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10728-32
In its active form, the GTP-binding protein rab8 interacts with a stress-activated protein kinase. Ren M, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5151-5
G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Schnier JB, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5941-6
Rfc5, a small subunit of replication factor C complex, couples DNA replication and mitosis in budding yeast. Sugimoto K, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7048-52
Chimeric Na+/H+ exchangers: an epithelial membrane-bound N-terminal domain requires an epithelial cytoplasmic C-terminal domain for regulation by protein kinases. Yun CH, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10723-7
IRAK: a kinase associated with the interleukin-1 receptor. Cao Z, et al. **Science** 1996 Feb 23;271(5252):1128-31
Checkpoints take the next step [comment] Carr AM. **Science** 1996 Jan 19;271(5247):314-5. Comment on: Science 1996 Jan 19;271(5247):353-6. Comment on: Science 1996 Jan 19;271(5247):357-60.
Extracellular protein kinases [letter; comment] Ehrlich YH. **Science** 1996 Jan 19;271(5247):278-9. Comment on: Science 1995 Jan 13;267(5195):177-8.
rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint [see comments] Walworth NC, et al. **Science** 1996 Jan 19;271(5247):353-6. Comment in: Science 1996 Jan 19;271(5247):314-5.
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Xia Z, et al. **Science** 1995 Nov 24; 270(5240):1326-31
The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Peng T, et al. **Virology** 1996 Feb 1;216(1):184-96
Characterization of DNA-binding proteins and protein kinase activities in Chlorella virus CVK2. Yamada T, et al. **Virology** 1996 May 15;219(2):395-406
The role of microtubules and inositol triphosphate induced Ca2+ release in the tyrosine phosphorylation of mitogen-activated protein kinase in extracts of Xenopus laevis oocytes. Duesbery NS, et al. **Zygote** 1996 Feb; 4(1):21-30
[Do catalytically active antibodies exist in healthy people? (Protein kinase activity of sIgA antibodies from human milk)] Kit IuIa, et al. **Mol Biol (Mosk)** 1995 Jul-Aug; 29(4):893-906 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

The effect of genetically expressed cardiac titin fragments on in vitro actin motility. Li Q, et al. **Biophys J** 1995 Oct; 69(4):1508-18
The acidic ribosomal proteins of different yeast species. Phosphorylation by ribosome-associated protein kinases. Cytryńska M, et al. **J Basic Microbiol** 1995;35(6):367-73
Protein kinase and G-protein regulation of Ca2+ currents in Hermissenda photoreceptors by 5-HT and GABA. Yamoah EN, et al. **J Neurosci** 1996 Aug 1;16(15):4799-809
G protein-coupled receptor kinase mediates desensitization of norepinephrine-induced Ca2+ channel inhibition. Diverse-Pierluissi M, et al. **Neuron** 1996 Mar;16(3):579-85
Expression of constitutively active CaMKII in target tissue modifies presynaptic axon arbor growth. Zou DJ, et al. **Neuron** 1996 Mar;16(3):529-39
Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323-50 (154 ref.)

PHYSIOLOGY

Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Kudo N, et al. **Biochim Biophys Acta** 1996 May 31; 1301(1-2):67-75
Nonuniform elasticity of titin in cardiac myocytes: a study using immunoelectron microscopy and cellular mechanics. Granzier H, et al. **Biophys J** 1996 Jan;70(1):430-42
Characterisation of protein structure/function relationship by sequence analysis without previous alignment: distinction between sub-groups of protein kinases. Guerrucci MA, et al. **Biosci Rep** 1995 Jun;15(3):161-71
The role of MAP kinase kinase in interleukin-3 stimulation of proliferation. Perkins GR, et al. **Blood** 1996 May 1; 87(9):3669-75
Angiotensin II-mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55-60 (68 ref.)
Spatial learning alters hippocampal calcium/calmodulin-dependent protein kinase II activity in rats. Tan SE, et al. **Brain Res** 1996 Mar 4;711(1-2):234-40
Intracellular signalling through protein kinases in the heart. Sugden PH, et al. **Cardiovasc Res** 1995 Oct;30(4):478-92 (206 ref.)
The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte. Crompton T, et al. **Cell** 1996 Jul 26;86(2):243-51
KSR: a novel player in the RAS pathway [comment] Downward J. **Cell** 1995 Dec 15;83(6):831-4 (17 ref.). Comment on: Cell 1995 Dec 15;83(6):879-88. Comment on: Cell 1995 Dec 15;83(6):889-901. Comment on: Cell 1995 Dec 15;83(6):903-13.
Stress-activated protein kinases in cardiovascular disease. Force T, et al. **Circ Res** 1996 Jun;78(6):947-53 (39 ref.)
Titin develops restoring force in rat cardiac myocytes. Helmes M, et al. **Circ Res** 1996 Sep;79(3):619-26
The chk1 pathway is required to prevent mitosis following cell-cycle arrest at 'start'. Carr AM, et al. **Curr Biol** 1995 Oct 1;5(10):1179-90
Bacterial expression of the catalytic domain of 3-hydroxy-3-methylglutaryl-CoA reductase (isoform HMGR1) from Arabidopsis thaliana, and its inactivation by phosphorylation at Ser577 by Brassica oleracea 3-hydroxy-3-methylglutaryl-CoA reductase kinase. Dale S, et al. **Eur J Biochem** 1995 Oct 15;233(2):506-13
Phosphorylation of myosin regulatory light chains by the molluscan twitchin kinase. Heierhorst J, et al. **Eur J Biochem** 1995 Oct 15;233(2):426-31
Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Tokuyama S, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):101-7
The role of protein kinases in adaptational growth of the heart. Bogoyevitch MA, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):1-12 (101 ref.)
Protein kinases as mediators of fluid shear stress stimulated signal transduction in endothelial cells: a hypothesis for calcium-dependent and calcium-independent events activated by flow. Berk BC, et al. **J Biomech** 1995 Dec; 28(12):1439-50
Deoxyadenosine blockade of G0 to G1 transition in lymphocytes: possible involvement of protein kinases. Sato T, et al. **J Cell Physiol** 1996 Feb;166(2):288-95
Calcium signals and protein tyrosine kinases are required for the induction of c-jun in Jurkat cells stimulated by the T cell-receptor complex and oxidative signals. Liu B, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):77-90
Titin domain patterns correlate with the axial disposition of myosin at the end of the thick filament. Bennett PM, et al. **J Mol Biol** 1996 Jun 28;259(5):896-903
The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules. Fürst DO, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):951-9 (76 ref.)
Mechanism of catecholamine synthesis inhibition by neuropeptide Y: role of Ca2+ channels and protein kinases. McCullough LA, et al. **J Neurochem** 1996 Sep;67(3):1090-9
Hierarchical analysis of the nerve growth factor-dependent and nerve growth factor-independent differentiation signaling pathways in PC12 cells with protein kinase inhibitors. Campbell XZ, et al. **J Neurosci Res** 1995 Oct 1;42(2):207-19
Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. Martinez-Lacaci I, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1-2):1-11 (145 ref.)
Role of protein kinase in the substance P-induced inhibition of the GABA response in neurons of the bullfrog dorsal root ganglia. Yamada K, et al. **Kurume Med J** 1996;

43(2):171–5
Drosophila MAP kinase kinase suppresses the vulvaless phenotype of lin–3, let–23 and lin–45 mutations in Caenorhabditis elegans. Koga M, et al. **Mech Dev** 1995 Sep;53(1):15–22
Regulation of phospholamban and troponin–I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)
Doxorubicin–induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Kurabayashi M, et al. **Mol Cell Biol** 1995 Nov; 15(11):6386–97
Stimulation of later functions of the yeast meiotic protein kinase Ime2p by the IDS2 gene product. Sia RA, et al. **Mol Cell Biol** 1995 Oct;15(10):5279–87
Regulation of chromosome segregation by Glc8p, a structural homolog of mammalian inhibitor 2 that functions as both an activator and an inhibitor of yeast protein phosphatase 1. Tung HY, et al. **Mol Cell Biol** 1995 Nov;15(11):6064–74
Genetic evidence for the functional redundancy of the calcineurin– and Mpk1–mediated pathways in the regulation of cellular events important for growth in Saccharomyces cerevisiae. Nakamura T, et al. **Mol Gen Genet** 1996 May 23;251(2):211–9
Effects of different kinases and phosphatases on nuclear and cytoplasmic maturation of bovine oocytes. Lévesque JT, et al. **Mol Reprod Dev** 1995 Sep;42(1):114–21
Long–term potentiation in mice lacking synapsins. Spillane DM, et al. **Neuropharmacology** 1995 Nov;34(11):1573–9
Characterization of protein kinase and phosphatase systems in chick ciliary ganglion. Lengyel I, et al. **Neuroscience** 1996 Jan;70(2):577–88
Protein kinases and prostaglandin production in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1995 Jul; 50(1):33–45
CRINKLY4: A TNFR–like receptor kinase involved in maize epidermal differentiation [see comments] Becraft PW, et al. **Science** 1996 Sep 6;273(5280):1406–9. Comment in: Science 1996 Sep 6;273(5280):1338–9.
Plants, like animals, may make use of peptide signals [news; comment] Marx J. **Science** 1996 Sep 6;273(5280):1338–9. Comment on: Science 1996 Sep 6;273(5280):1406–9.
Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)
Protein phosphorylation and signal transduction. Barik S. **Subcell Biochem** 1996;26:115–64 (182 ref.)

RADIATION EFFECTS

Both ATF–2 and c–Jun are phosphorylated by stress–activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

ULTRASTRUCTURE

Nonuniform elasticity of titin in cardiac myocytes: a study using immunoelectron microscopy and cellular mechanics. Granzier H, et al. **Biophys J** 1996 Jan;70(1):430–42

PROTEIN–LOSING ENTEROPATHIES

COMPLICATIONS

Eosinophilic gastro–enteritis associated with protein–losing enteropathy and protein C deficiency. Wing–Harkins DL, et al. **J Int Med Res** 1996 Jan–Feb;24(1):155–63 (44 ref.)
[Isolated and spontaneously regressive colonic neurofibromatosis] Becheur H, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):718–20 (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Murch SH, et al. **Lancet** 1996 May 11;347(9011):1299–301

DIAGNOSIS

Protein–losing enteropathy in an unusual form of sarcoidosis. Lindgren A, et al. **Eur J Gastroenterol Hepatol** 1995 Oct; 7(10):1005–7

ETIOLOGY

Protein–losing enteropathy after Fontan operation: resolution after baffle fenestration. Jacobs ML, et al. **Ann Thorac Surg** 1996 Jan;61(1):206–8
Protein–losing enteropathy after the Fontan operation. Feldt RH, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):672–80
Protein–losing enteropathy from cap polyposis [letter] Oshitani N, et al. **Lancet** 1995 Dec 9;346(8989):1567
Management of disseminated intra–abdominal lymphangiomatosis with protein–losing enteropathy and intestinal bleeding. Takami A, et al. **South Med J** 1995 Nov; 88(11):1156–8
[Growth in children with the exudative enteropathy syndrome due to a congenital heart defect—cor triatriatum dextrum] Koloušková S, et al. **Cas Lek Cesk** 1996 Jan 17; 135(2):59–61 (Eng. Abstr.) **(Cze)**
[Major hypoproteinemia revealing enteritis caused by Yersinia enterolytica and cytomegalovirus at the onset of chronic lymphocytic leukemia] Disdier P, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):633–6 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Enteropathy and IgG subclass deficiency [letter; comment] Garty BZ. **J Pediatr** 1996 May;128(5 Pt 1):722–3. Comment on: J Pediatr 1994 Oct;125(4):541–8.

PHYSIOPATHOLOGY

Gastro–intestinal protein loss in elderly patients with cardiac cachexia. King D, et al. **Age Ageing** 1996 May;25(3):221–3

RADIONUCLIDE IMAGING

Visualization of protein losing enteropathy in infantile systemic hyalinosis with Tc–99m HSA after albumin challenge. Shields E, et al. **Clin Nucl Med** 1996 May; 21(5):415–6
Technetium–99m dextran: a promising new protein–losing enteropathy imaging agent. Bhatnagar A, et al. **Eur J Nucl Med** 1996 May;23(5):575–8
Detection and quantification of protein–losing enteropathy with indium–111 transferrin. de Kaski MC, et al. **Eur J Nucl Med** 1996 May;23(5):530–3

SURGERY

Effect of percutaneous fenestration of the atrial septum on protein–losing enteropathy after the Fontan operation [letter] Satomi G, et al. **Heart** 1996 Jul;76(1):90–1
Protein–losing enteropathy after the Fontan operation: successful treatment by percutaneous fenestration of the atrial septum. Warnes CA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):378–9

THERAPY

Absorption of a new oral formulation of cyclosporin A in a child on parenteral nutrition. Jewkes FE, et al. **Pediatr Nephrol** 1995 Oct;9(5):617–8

PROTEIN LYSINE METHYLTRANSFERASE see **HISTONE–LYSINE METHYLTRANSFERASE**

PROTEIN–LYSINE 6–OXIDASE

ANTAGONISTS & INHIBITORS

Inhibition of lysyl oxidase by isoniazid and its effect on wound healing. Udupa SL. **Indian J Exp Biol** 1995 Apr; 33(4):278–80
Mechanism of antifibrotic effect of taurine and niacin in the multidose bleomycin–hamster model of lung fibrosis: inhibition of lysyl oxidase and collagenase. Blaisdell RJ, et al. **J Biochem Toxicol** 1995 Aug;10(4):203–10

BIOSYNTHESIS

Downregulation of lysyl oxidase in cadmium–resistant fibroblasts. Li W, et al. **Am J Respir Cell Mol Biol** 1995 Oct;13(4):418–25
Pre– and post–translational regulation of lysyl oxidase by transforming growth factor–beta 1 in osteoblastic MC3T3–E1 cells. Feres–Filho EJ, et al. **J Biol Chem** 1995 Dec 22;270(51):30797–803

CHEMISTRY

Catalytic properties and structural components of lysyl oxidase. Kagan HM, et al. **Ciba Found Symp** 1995; 192:100–15; discussion 115–21
Expression of lysyl oxidase from cDNA constructs in mammalian cells: the propeptide region is not essential to the folding and secretion of the functional enzyme. Kagan HM, et al. **J Cell Biochem** 1995 Nov;59(3):329–38
Isolation of active site peptides of lysyl oxidase. Kagan HM, et al. **Methods Enzymol** 1995;258:122–32
A crosslinked cofactor in lysyl oxidase: redox function for amino acid side chains. Wang SX, et al. **Science** 1996 Aug 23;273(5278):1078–84

DEFICIENCY

Expression of mRNAs for lysyl oxidase and type III procollagen in cultured fibroblasts from patients with the Menkes and occipital horn syndromes as determined by quantitative polymerase chain reaction. Kemppainen R, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):101–6

GENETICS

Detection of lysyl oxidase gene expression in rat skin during wound healing. Fushida–Takemura H, et al. **Arch Dermatol Res** 1996;288(1):7–10
Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF–1, and its possible role in tumor suppression. Tan RS, et al. **Cancer Res** 1996 May 15;56(10):2417–21
Regulation of lysyl oxidase by basic fibroblast growth factor in osteoblastic MC3T3–E1 cells. Feres–Filho EJ, et al. **J Biol Chem** 1996 Mar 15;271(11):6411–6
Expression of lysyl oxidase from cDNA constructs in mammalian cells: the propeptide region is not essential to the folding and secretion of the functional enzyme. Kagan HM, et al. **J Cell Biochem** 1995 Nov;59(3):329–38
Isolation and characterization of a 1 Mb region of 5q23.3–q31.2 surrounding the human lysyl oxidase gene. McAlinden TP, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2409–13
Identification of lysyl oxidase and other platelet–derived growth factor–inducible genes in vascular smooth muscle cells by differential screening. Green RS, et al. **Lab Invest** 1995 Oct;73(4):476–82
The size heterogeneity of human lysyl oxidase mRNA is due to alternate polyadenylation site and not alternate exon usage. Boyd CD, et al. **Mol Biol Rep** 1995;21(2):95–103
The notion of the Cambrian pananimalia genome. Ohno S. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8475–8

ISOLATION & PURIFICATION

Isolation of active site peptides of lysyl oxidase. Kagan HM, et al. **Methods Enzymol** 1995;258:122–32

METABOLISM

Increased expression of lysyl oxidase in skin with scleroderma. Chanoki M, et al. **Br J Dermatol** 1995 Nov; 133(5):710–5
Catalytic properties and structural components of lysyl oxidase. Kagan HM, et al. **Ciba Found Symp** 1995; 192:100–15; discussion 115–21
Regulation of lysyl oxidase by basic fibroblast growth factor in osteoblastic MC3T3–E1 cells. Feres–Filho EJ, et al. **J Biol Chem** 1996 Mar 15;271(11):6411–6
Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C–proteinase. Panchenko MV, et al. **J Biol Chem** 1996 Mar 22;271(12):7113–9
Modulation of lysyl oxidase by dietary copper in rats. Rucker RB, et al. **J Nutr** 1996 Jan;126(1):51–60
Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. Ma RH, et al. **J Oral Pathol Med** 1995 Oct; 24(9):407–12

PHARMACOLOGY

Induction of human monocyte motility by lysyl oxidase. Lazarus HM, et al. **Matrix Biol** 1995 Dec;14(9):727–31

PROTEIN METHYLASE I see **PROTEIN ARGININE METHYLTRANSFERASE**

PROTEIN METHYLASE III see **HISTONE–LYSINE METHYLTRANSFERASE**

PROTEIN METHYLASES see **PROTEIN METHYLTRANSFERASES**

PROTEIN METHYLTRANSFERASE I see **PROTEIN ARGININE METHYLTRANSFERASE**

PROTEIN METHYLTRANSFERASE III see **HISTONE–LYSINE METHYLTRANSFERASE**

PROTEIN METHYLTRANSFERASES

ANTAGONISTS & INHIBITORS

Inhibitors of farnesyl and geranylgeranyl methyltransferases prevent beta 2 integrin–induced actin polymerization without affecting beta 2 integrin–induced Ca2+ signaling in neutrophils. Molony L, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):612–7
Prenylcysteine analogs mimicking the C–terminus of GTP–binding proteins stimulate exocytosis from permeabilized HIT–T15 cells: comparison with the effect of Rab3AL peptide. Regazzi R, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):269–78

BLOOD

Prenylcysteine–directed carboxyl methyltransferase activity in human neutrophil membranes. Philips MR, et al. **Methods Enzymol** 1995;256:49–63

GENETICS

Hampered expression of isoaspartyl protein carboxyl methyltransferase gene in the human cataractous lens. Kodama T, et al. **Biochim Biophys Acta** 1995 Oct 19; 1245(2):269–72
Rapid mapping of genomic P1 clones: the mouse L–isoaspartyl/D–aspartyl methyltransferase gene. MacLaren DC, et al. **Genomics** 1996 Jul 15;35(2):299–307
Characterization of three cDNAs encoding two isozymes of an isoaspartyl protein carboxyl methyltransferase from human erythroid leukemia cells. Takeda R, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):683–5
A distinctly regulated protein repair L–isoaspartylmethyltransferase from Arabidopsis thaliana. Mudgett MB, et al. **Plant Mol Biol** 1996 Feb;30(4):723–37

ISOLATION & PURIFICATION

Prenylcysteine–directed carboxyl methyltransferase activity

in human neutrophil membranes. Philips MR, et al. **Methods Enzymol** 1995;256:49–63

METABOLISM

Characterization of prenylcysteine methyltransferase in insulin-secreting cells. Li G, et al. **Biochem J** 1996 May 15;316 (Pt 1):345–51

Glucose- and GTP-dependent stimulation of the carboxyl methylation of CDC42 in rodent and human pancreatic islets and pure beta cells. Evidence for an essential role of GTP-binding proteins in nutrient-induced insulin secretion. Kowluru A, et al. **J Clin Invest** 1996 Jul 15; 98(2):540–55

PROTEIN P34CDC2

ANALYSIS

The protein kinase from mitotic human cells that phosphorylates Ser-209 on the casein kinase II beta-subunit is p34cdc2. Litchfield DW, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):69–78

Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2. Kharbanda S, et al. **Cancer Res** 1996 Aug 15;56(16):3617–21

The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity. Goodger NM, et al. **J Pathol** 1996 Apr; 178(4):422–8

Association between p34cdc2 levels and meiotic arrest in pig oocytes during early growth. Hirao Y, et al. **Zygote** 1995 Nov;3(4):325–32

ANTAGONISTS & INHIBITORS

p25rum1 orders S phase and mitosis by acting as an inhibitor of the p34cdc2 mitotic kinase. Correa-Bordes J, et al. **Cell** 1995 Dec 15;83(6):1001–9

Rum1 and Cdc18 link inhibition of cyclin-dependent kinase to the initiation of DNA replication in Schizosaccharomyces pombe. Jallepalli PV, et al. **Genes Dev** 1996 Mar 1;10(5):541–52

Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Nishio K, et al. **Int J Cancer** 1995 Nov 27;63(5):688–93

Demonstration of cyclin-dependent kinase inhibitory serine/threonine kinase in bovine thymus. Matsuura I, et al. **J Biol Chem** 1996 Mar 8;271(10):5443–50

Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells. Van Dolah FM, et al. **J Cell Physiol** 1996 Jan;166(1):49–56

Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. Ongkeko W, et al. **J Cell Sci** 1995 Aug; 108 (Pt 8):2897–904

Cross-linking of ICAM-1 on T cells induces transient tyrosine phosphorylation and inactivation of cdc2 kinase. Chirathaworn C, et al. **J Immunol** 1995 Dec 15; 155(12):5479–82

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. He J, et al. **J Virol** 1995 Nov; 69(11):6705–11

Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. Re F, et al. **J Virol** 1995 Nov;69(11):6859–64

Drosophila Wee1 kinase rescues fission yeast from mitotic catastrophe and phosphorylates Drosophila Cdc2 in vitro. Campbell SD, et al. **Mol Biol Cell** 1995 Oct;6(10):1333–47

BIOSYNTHESIS

Cyclin B and Cdc2 expression and Cd2 kinase activity during Dictyostelium differentiation. Luo Q, et al. **DNA Cell Biol** 1995 Nov;14(11):901–8

SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. Chen H, et al. **J Biol Chem** 1996 Jun 14;271(24):13959–67

SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts. Chang TH, et al. **J Cell Biochem** 1996 Feb;60(2):161–72

Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. Mohapatra S, et al. **J Exp Med** 1996 Apr 1;183(4):1663–8

In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Tommasi S, et al. **Mol Cell Biol** 1995 Dec;15(12):6901–13

CHEMISTRY

Leishmania mexicana p12cks1, a homologue of fission yeast p13suc1, associates with a stage-regulated histone H1 kinase. Mottram JC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):833–9

Characterisation of human cdc2 lysine 33 mutations expressed in the fission yeast Schizosaccharomyces pombe. Leroy D, et al. **FEBS Lett** 1996 Feb 5;379(3):217–21

DRUG EFFECTS

Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):833–41

Comparison of acute hepatocellular proliferating cell nuclear antigen labeling indices and growth fractions, p34cdc2 kinases, and serum enzymes in carbon tetrachloride-treated rats. Monticello TM, et al. **Toxicol Pathol** 1995 Jul-Aug; 23(4):439–46

GENETICS

The yeast CDC16 and CDC27 genes restrict DNA replication to once per cell cycle. Heichman KA, et al. **Cell** 1996 Apr 5;85(1):39–48

The role of cdc2, cdc25 and cyclin A genes in the maintenance of immortalization and growth arrest in a rat embryonic fibroblast conditional cell line. Gonos ES, et al. **Cell Biol Int** 1996 Mar;20(3):159–67

Effects of the CDC2 gene on adaptive mutation in the yeast Saccharomyces cerevisiae. Baranowska H, et al. **Curr Genet** 1995 Nov;28(6):521–5

A family of trypanosome cdc2-related protein kinases. Mottram JC, et al. **Gene** 1995 Aug 30;162(1):147–52

The role of cdc2 and other genes in meiosis in Schizosaccharomyces pombe. Iino Y, et al. **Genetics** 1995 Aug;140(4):1235–45

SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. Chen H, et al. **J Biol Chem** 1996 Jun 14;271(24):13959–67

Positive regulation of cdc2 gene activity by protein phosphates type 2A. Jaramillo-Babb VL, et al. **J Biol Chem** 1996 Mar 15;271(11):5988–92

In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Tommasi S, et al. **Mol Cell Biol** 1995 Dec;15(12):6901–13

Functional analysis of the Drosophila CDC2 Dm gene in fission yeast. Bejarano ER, et al. **Mol Gen Genet** 1995 Sep 20;248(5):621–8

Novel alleles of cdc13 and cdc2 isolated as suppressors of mitotic catastrophe in Schizosaccharomyces pombe. Berry LD, et al. **Mol Gen Genet** 1996 Jul 26;251(6):635–46

Molecular cloning and characterization of a cDNA clone that encodes a Cdc2 homolog from Nicotiana tabacum. Setiady YY, et al. **Plant Cell Physiol** 1996 Apr;37(3):369–76

METABOLISM

Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Dipietrantonio A, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):837–42

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)

Is the function of the cdc2 kinase subunit proteins tuned by their propensities to oligomerize? Conformational states in solution of the cdc2 kinase partners p13suc1 and p9cksphy. Birck C, et al. **Biochemistry** 1996 Apr 30;35(17):5577–85

Characterization of microtubule-associated protein phosphoisoforms present in isolated growth cones. García Rocha M, et al. **Brain Res Dev Brain Res** 1995 Oct 27; 89(1):47–55

Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Blangy A, et al. **Cell** 1995 Dec 29;83(7):1159–69

Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Guadagno TM, et al. **Cell** 1996 Jan 12;84(1):73–82

Porcine brain neurofilament-H tail domain kinase: its identification as cdk5/p26 complex and comparison with cdc2/cyclin B kinase. Hisanaga S, et al. **Cell Motil Cytoskeleton** 1995;31(4):283–97

Genesis and evolution of high-ploidy tumour cells evaluated by means of the proliferation markers p34(cdc2), cyclin B1, PCNA and 3[H]-thymidine. Baroja A, et al. **Cell Prolif** 1996 Feb;29(2):89–100

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122–5 (16 ref.)

An accumulation of p34cdc2 at the end of mouse oocyte growth correlates with the acquisition of meiotic competence. de Vant'ery C, et al. **Dev Biol** 1996 Mar 15; 174(2):335–44

In vivo regulation of the early embryonic cell cycle in Xenopus. Hartley RS, et al. **Dev Biol** 1996 Feb 1; 173(2):408–19

Regulation of nuclear envelope assembly/disassembly by MAP kinase. Moos J, et al. **Dev Biol** 1996 May 1; 175(2):358–61

Cyclin B and Cdc2 expression and Cd2 kinase activity during Dictyostelium differentiation. Luo Q, et al. **DNA Cell Biol** 1995 Nov;14(11):901–8

Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system. Huang CY, et al. **EMBO J** 1996 May 1;15(9):2169–73

Newly synthesized protein(s) must associate with p34cdc2 to activate MAP kinase and MPF during progesterone-induced maturation of Xenopus oocytes. Nebreda AR, et al. **EMBO J** 1995 Nov 15;14(22):5597–607

Two S-phase checkpoint systems, one involving the function of both BIME and Tyr15 phosphorylation of p34cdc2, inhibit NIMA and prevent premature mitosis. Ye XS, et al. **EMBO J** 1996 Jul 15;15(14):3599–610

Inhibition of glycosphingolipid synthesis induces p34cdc2 activation in Xenopus oocyte. De Smedt V, et al. **FEBS Lett** 1995 Nov 20;375(3):249–53

Chemical synthesis of phosphopeptides using the arylthio group for protection of phosphate: application to identification of cdc2 kinase phosphorylation sites. Ueno Y, et al. **Int J Pept Protein Res** 1995 Aug;46(2):106–12

Phosphorylation of casein kinase II by p34cdc2. Identification of phosphorylation sites using phosphorylation site mutants in vitro. Bosc DG, et al. **J Biol Chem** 1995 Oct 27; 270(43):25872–8

Characterization of the mitotic specific phosphorylation site of histone H1. Absence of a consensus sequence for the p34cdc2/cyclin B kinase. Gurley LR, et al. **J Biol Chem** 1995 Nov 17;270(46):27653–60

Identification of plectin as a substrate of p34cdc2 kinase and mapping of a single phosphorylation site. Malecz N, et al. **J Biol Chem** 1996 Apr 5;271(14):8203–8

Physical and functional interactions between Lyn and p34cdc2 kinases in irradiated human B-cell precursors. Uckun FM, et al. **J Biol Chem** 1996 Mar 15;271(11):6389–97

The cell cycle in polyploid megakaryocytes is associated with reduced activity of cyclin B1-dependent cdc2 kinase. Zhang Y, et al. **J Biol Chem** 1996 Feb 23;271(8):4266–72

Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. Jin P, et al. **J Cell Biol** 1996 Aug;134(4):963–70

Expression and subcellular localization of CDK2 and cdc2 kinases and their common partner cyclin A in thyroid epithelial cells: comparison of cyclic AMP-dependent and -independent cell cycles. Baptist M, et al. **J Cell Physiol** 1996 Feb;166(2):256–73

Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes. Lucas JJ, et al. **J Cell Physiol** 1995 Nov;165(2):406–16

Active cyclin B-cdc2 kinase does not inhibit DNA replication and cannot drive prematurely fertilized sea urchin eggs into mitosis. Geneviève-Garrigues AM, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2693–703

Interaction of cdc2 and rum1 regulates Start and S-phase in fission yeast. Labib K, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3285–94

Calcium requirements during mitotic cdc2 kinase activation and cyclin degradation in Xenopus egg extracts. Lindsay HD, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3557–68

The distribution and biochemical properties of a Cdc2-related kinase, KKIALRE, in normal and Alzheimer brains. Yen SH, et al. **J Neurochem** 1995 Dec;65(6):2577–84

Novel alterations in CDK1/cyclin B1 kinase complex formation occur during the acquisition of a polyploid DNA content. Datta NS, et al. **Mol Biol Cell** 1996 Feb; 7(2):209–23

M-phase-specific phosphorylation and structural rearrangement of the cytoplasmic cross-linking protein plectin involve p34cdc2 kinase. Foisner R, et al. **Mol Biol Cell** 1996 Feb;7(2):273–88

The Ras-GTPase-activating protein SH3 domain is required for Cdc2 activation and mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen-activated protein kinase activation. Pomerance M, et al. **Mol Cell Biol** 1996 Jun;16(6):3179–86

Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Ling YH, et al. **Mol Pharmacol** 1996 May;49(5):832–41

Interaction of Cdc2 and Cdc18 with a fission yeast ORC2-like protein. Leatherwood J, et al. **Nature** 1996 Jan 25;379(6563):360–3

Structure, function, and regulation of neuronal Cdc2-like protein kinase. Lew J, et al. **Neurobiol Aging** 1995 May-Jun; 16(3):263–8; discussion 268–70

p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe. Knudsen KE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8278–83

Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc2(6–20)NH2 peptide. Kong SK, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3377–82

Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Mueller PR, et al. **Science** 1995 Oct 6; 270(5233):86–90

[Control of cell proliferation: towards new strategies suggested by modelling the mitotic oscillator] Goldbeter A, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):172–8 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Differential regulation of p34cdc2 and p33cdk2 by transforming growth factor-beta 1 in murine mammary epithelial cells. Fautsch MP, et al. **J Cell Biochem** 1995

Aug;58(4):517–26

PHYSIOLOGY

A Cdc2 dependent checkpoint maintains diploidy in Drosophila. Hayashi S. **Development** 1996 Apr; 122(4):1051–8

A single fission yeast mitotic cyclin B p34cdc2 kinase promotes both S–phase and mitosis in the absence of G1 cyclins. Fisher DL, et al. **EMBO J** 1996 Feb 15; 15(4):850–60

Newly assembled cyclin B–cdc2 kinase is required to suppress DNA replication between meiosis I and meiosis II in starfish oocytes. Picard A, et al. **EMBO J** 1996 Jul 15; 15(14):3590–8

Arresting the mitotic oscillator and the control of cell proliferation: insights from a cascade model for cdc2 kinase activation. Goldbeter A, et al. **Experientia** 1996 Mar 15; 52(3):212–6

RADIATION EFFECTS

Ultraviolet B irradiation–induced G2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Herzinger T, et al. **Oncogene** 1995 Nov 16;11(10):2151–6

PROTEIN P53

The two faces of tumor suppressor p53. Smith ML, et al. **Am J Pathol** 1996 Apr;148(4):1019–22 (39 ref.)

Correlation of tumor markers p53, bcl–2, CD34, CD44H, CD44v6, and Ki–67 with survival and metastasis in laryngeal squamous cell carcinoma. Spafford MF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):627–32

Variation in the expression of p53, c–myc, and bcl–2 oncoproteins in individual patient cultures of normal urothelium exposed to cobalt 60 gamma–rays and N–nitrosodiethanolamine. Harney JV, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):617–25

p53 stimulates promoter activity of the sgk. serum/glucocorticoid–inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. Maiyar AC, et al. **J Biol Chem** 1996 May 24;271(21):12414–22

ANALYSIS

Expression of p53 protein and Ki–67 reactivity in ovarian neoplasms. Correlation with histopathology. Harlozińska A, et al. **Am J Clin Pathol** 1996 Mar;105(3):334–40

Immunohistochemical detection of p53, bcl–2, and retinoblastoma proteins in follicular lymphoma. Nguyen PL, et al. **Am J Clin Pathol** 1996 May;105(5):538–43

Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. Prayson RA. **Am J Clin Pathol** 1996 Jun;105(6):719–26

p53 protein in benign and malignant sweat gland tumors [letter; comment] Akosa AB. **Am J Dermatopathol** 1995 Aug;17(4):425–6. Comment on: Am J Dermatopathol 1994 Apr;16(2):126–9.

Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Bergman R, et al. **Am J Dermatopathol** 1995 Dec; 17(6):547–50

Quantitative image analysis of p53 protein accumulation in keratoacanthomas [see comments] Borkowski A, et al. **Am J Dermatopathol** 1995 Aug;17(4):335–8. Comment in: Am J Dermatopathol 1995 Aug;17(4):319–20.

p53 protein and proliferating cell nuclear antigen in eccrine poroma and porocarcinoma. an immunohistochemical study. Tateyama H, et al. **Am J Dermatopathol** 1995 Oct; 17(5):457–64

The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Goldman SC, et al. **Am J Pathol** 1996 May;148(5):1381–5

Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Guinee D Jr, et al. **Am J Pathol** 1996 Aug;149(2):531–8

DNA aberrations in the epithelial cell component of adamantinoma of long bones. Hazelbag HM, et al. **Am J Pathol** 1995 Dec;147(6):1770–9

Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Lahoti C, et al. **Am J Pathol** 1996 May;148(5):1577–89

Analysis of p53, K–ras–2, and C–raf–1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM, et al. **Am J Pathol** 1996 May;148(5):1531–41

P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Boers JE, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):411–6

Expression of c–erbB–2 and p53 in colorectal adenocarcinoma. Sun XF, et al. **Anal Cell Pathol** 1995 Apr; 8(3):203–11

p53 nuclear immunostaining and gene mutations in non–small–cell lung cancer and their effects on patient survival. Mitsudomi T, et al. **Ann Oncol** 1995;6 Suppl 3:S9–13

Node–negative breast cancers with p53(–)/HER2–neu(–) status may identify women with very good prognosis. Albanell J, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):1027–32

Analysis of p53 abnormalities in endoscopic gastric biopsies. Imatani A, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2049–56

Hepatocellular carcinoma in young patients: histology, cellular differentiation, HBV infection and oncoprotein p53. Jaskiewicz K, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2723–5

p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Katoh A, et al. **Anticancer Res** 1996 May–Jun;16(3A):1301–4

Heterogeneity in proliferation markers in colorectal cancer. Kressner U, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2755–61

Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Kressner U, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):951–7

p53 immunostaining in combined type small cell lung cancer. Brief report. Higashiyama M, et al. **APMIS** 1995 Jun; 103(6):477–80

P53 protein in 204 patients with primary breast carcinoma––immunohistochemical detection and clinical value as a prognostic factor. Göhring UJ, et al. **Arch Gynecol Obstet** 1995;256(3):139–46

Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma. Subramaniam P, et al. **Aust N Z J Surg** 1995 Oct;65(10):740–2

p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Lee CS, et al. **Australas J Dermatol** 1995 Nov;36(4):192–5

Inter–observer variation of p53 immunohistochemistry––an assessment of a practical problem and comparison with other studies. Kay EW, et al. **Br J Biomed Sci** 1996 Jun; 53(2):101–7

Comparative alterations in p53 expression and apoptosis in the irradiated rat small and large intestine. Arai T, et al. **Br J Cancer** 1996 Aug;74(3):406–12

p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse–free survival. Barbareschi M, et al. **Br J Cancer** 1996 Jul;74(2):208–15

The relationship between smoking exposure and p53 overexpression in colorectal cancer. Freedman AN, et al. **Br J Cancer** 1996 Apr;73(8):902–8

TP53 mutation analyses on breast carcinomas: a study of paraffin–embedded archival material. Gretarsdottir S, et al. **Br J Cancer** 1996 Aug;74(4):555–61

p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Horne GM, et al. **Br J Cancer** 1996 Jan;73(1):29–35

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Michalides R, et al. **Br J Cancer** 1996 Mar; 73(6):728–34

Relationship between p53 status and radiosensitivity in human tumour cell lines. Siles E, et al. **Br J Cancer** 1996 Mar; 73(5):581–8

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Smith DR, et al. **Br J Cancer** 1996 Jul;74(2):216–23

Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Soong R, et al. **Br J Cancer** 1996 Aug;74(4):562–7

Evidence of reciprocity of bcl–2 and p53 expression in human colorectal adenomas and carcinomas. Watson AJ, et al. **Br J Cancer** 1996 Apr;73(8):889–95

p53 protein expression in viral warts from renal allograft recipients [letter] Ferrándiz C, et al. **Br J Dermatol** 1996 Apr;134(4):810–1

P53 expression and human papillomavirus infection in transplant recipients and in patients with epidermodysplasia verruciformis [letter] McGregor JM, et al. **Br J Dermatol** 1996 Feb;134(2):374

Large–cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Zoldan MC, et al. **Br J Haematol** 1996 May; 93(2):475–86

Biological characteristics of inverted papilloma of the urinary bladder. Urakami S, et al. **Br J Urol** 1996 Jan;77(1):55–60

Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. MacGrogan G, et al. **Breast Cancer Res Treat** 1995;36(1):71–81

Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Fujino M, et al. **Cancer** 1995 Dec 15;76(12):2457–63

Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Ishimaru S, et al. **Cancer** 1996 Jun 1; 77(11):2233–9

Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: immunohistochemical analysis of Ki–67 and p53 antigen in relation to histopathologic findings. Kawamura T, et al. **Cancer** 1996 Mar 1;77(5):843–9

p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Klemi PJ, et al. **Cancer** 1995 Oct 1;76(7):1201–8

Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Kohlberger P, et al. **Cancer** 1995 Nov 15;76(10):1786–9

The clinical significance of p53 accumulation in gastric carcinoma. Starzynska T, et al. **Cancer** 1996 May 15; 77(10):2005–12

p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):146–50

Analysis of nm23–H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. Dueñas–González A, et al. **Cancer Lett** 1996 Mar 29; 101(2):137–42

Expression of programmed cell death regulatory p53 and bcl–2 proteins in oral lesions. Ravi D, et al. **Cancer Lett** 1996 Aug 2;105(2):139–46

Immunohistochemical quantitation of 4–aminobiphenyl–DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Curigliano G, et al. **Carcinogenesis** 1996 May; 17(5):911–6

TPA decreases the p53 response to benzo[a]pyrene–DNA adducts in vivo in mouse skin. Tapiainen T, et al. **Carcinogenesis** 1996 Jun;17(6):1377–80

Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood. Schiffer D, et al. **Childs Nerv Syst** 1995 Sep;11(9):517–22

Time–resolved immunofluorometric assay of p53 protein. Levesque MA, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1720–9

Quantitative measurement of c–erbB–2 p185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay. Mabrouk GM, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):981–2

Antigen retrieval: p53 staining in benign, pre–malignant and malignant tissues of the larynx. Tan LK, et al. **Clin Otolaryngol** 1996 Apr;21(2):147–50

p53 immunocytochemical staining in diagnostic cytopathology: the relevance of the proportion of positive cells [letter] Dowell SP. **Cytopathology** 1995 Oct;6(5):361–2

Expression of cyclin D1 and p53 protein in various malignant skin tumors. Inohara S, et al. **Dermatology** 1996;192(2):94–8

p53 protein expression in fine–needle aspirates of breast cancer: an immunocytochemical assay for identifying high–grade ductal carcinomas. Colecchia M, et al. **Diagn Cytopathol** 1995 Aug;13(2):128–32; discussion 132–3

p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Grewal H, et al. **Dis Colon Rectum** 1995 Nov;38(11):1176–81

p53 immunoreactive stain and early colorectal adenocarcinomas. Hirota S, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2220–2

p53 overexpression as a prognostic factor for advanced stage bladder cancer. Kuczyk MA, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2243–7

p53 in malignant and benign liver lesions. Schaff Z, et al. **Eur J Cancer** 1995 Oct;31A(11):1847–50

Mutant p53 protein as a predictor of survival in endometrial carcinoma. Strang P, et al. **Eur J Cancer** 1996 Apr; 32A(4):598–602

TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Thorlacius S, et al. **Eur J Cancer** 1995 Oct;31A(11):1856–61

p53–HSP70 complexes in oral dysplasia and cancer: potential prognostic implications. Kaur J, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):45–9

Expression of p53 in benign breast diseases. Cardillo MR. **Eur J Gynaecol Oncol** 1995;16(6):506–8

Expression of p53 and coexistence of HPV in premalignant lesions and in cervical cancer. Markowska J, et al. **Eur J Gynaecol Oncol** 1995;16(5):368–72

p53 protein overexpression and response to biomodulated 5–fluorouracil chemotherapy in patients with advanced colorectal cancer. Brett MC, et al. **Eur J Surg Oncol** 1996 Apr;22(2):182–5

p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Jahnson S, et al. **Eur Urol** 1995;28(2):135–42

Simultaneously detected aberrant p53 tumor suppressor protein and HPV–DNA localize mostly in separate keratinocytes in anogenital and common warts. Lassus J, et al. **Exp Dermatol** 1996 Apr;5(2):72–8

Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis. Gerasimov G, et al. **Exp Mol Pathol** 1995 Feb; 62(1):52–62

Ki–ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Ohashi K, et al. **Gastroenterology** 1995 Nov;109(5):1612–7

Proliferative activity and p53 over–expression of ovarian epithelial tumors. Kuwata T, et al. **Gen Diagn Pathol** 1995 Oct;141(2):131–9

p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Bartz C, et al. **Gut** 1996 Mar; 38(3):403–9

p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Hutson R, et al. **Histopathology** 1995 Oct;27(4):367–71

Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB–1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. Costa MJ, et al. **Hum Pathol** 1996 Mar;27(3):274–81

p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Pacinda SJ, et al. **Hum Pathol** 1996 Jun;27(6):542–6

p53 in endometrial cancer and its putative precursors:

evidence for diverse pathways of tumorigenesis. Sherman ME, et al. **Hum Pathol** 1995 Nov;26(11):1268–74

Prognostic value of DNA index, S–phase fraction and p53 protein accumulation after surgical resection of esophageal squamous–cell carcinomas in Thailand. Chanvitan A, et al. **Int J Cancer** 1995 Nov 3;63(3):381–6

p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Furihata M, et al. **Int J Cancer** 1995 Oct 20;64(5):298–303

Radiation–induced apoptosis in normal and pre–neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Meyn RE, et al. **Int J Cancer** 1996 Feb 8;65(4):466–72

p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo–alveolar carcinoma correlate with poor prognosis. Nuorva K, et al. **Int J Cancer** 1995 Dec 20;64(6):424–9

Two distinct p53 immunohistochemical patterns in human squamous–cell skin cancer, precursors and normal epidermis. Ren ZP, et al. **Int J Cancer** 1996 Jun 21; 69(3):174–9

Proliferating cell nuclear antigen (PCNA) in relation to ras, c–erbB–2,p53, clinico–pathological variables and prognosis in colorectal adenocarcinoma. Sun XF, et al. **Int J Cancer** 1996 Feb 20;69(1):5–8

Frequent expression of Bcl–2 in renal–cell carcinomas carrying wild–type p53. Tomita Y, et al. **Int J Cancer** 1996 May 3;66(3):322–5

Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB–1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Amada S, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):134–42

The significance of PCNA and p53 protein in some oral tumors. Tsuji T, et al. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):221–5

P53 overexpression in head and neck carcinoma and radiotherapy results [see comments] Awwad S, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):323–32. Comment in: Int J Radiat Oncol Biol Phys 1996 Jan 15;34(2):509–10.

Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Stattin P, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):885–9

Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Ogura K, et al. **Int J Urol** 1995 Nov;2(5):302–8

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. Reles A, et al. **J Cancer Res Clin Oncol** 1996; 122(8):489–94

Clinical significance of bcl2 and p53 protein expression in diffuse large B–cell lymphoma: a population–based study. Kramer MH, et al. **J Clin Oncol** 1996 Jul;14(7):2131–8

p53 and bcl–2 proteins as prognostic markers in human papillomavirus–associated cervical lesions. Kurvinen K, et al. **J Clin Oncol** 1996 Jul;14(7):2120–30

Prognostic significance of abnormal p53 accumulation in primary, resected non–small–cell lung cancers. Nishio M, et al. **J Clin Oncol** 1996 Feb;14(2):497–502

Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. Seregard S. **J Clin Pathol** 1996 Apr;49(4):338–42

Apocrine adenosis: a precursor of aggressive breast cancer? Wells CA, et al. **J Clin Pathol** 1995 Aug;48(8):737–42

Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate. Díaz–Cascajo C, et al. **J Cutan Pathol** 1995 Aug;22(4):304–9

Abnormal location of p16 protein and overexpression of p53 protein in human radiation–induced skin cancer. Zhao P, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):25–8

Detection of P53 expression and S–phase cell fraction in paraffin–embedded tissue by a double–labeling technique. Benini E, et al. **J Histochem Cytochem** 1995 Oct; 43(10):999–1003

An immunohistochemical study of the expression of p53 protein in colon cancer. Kim YW, et al. **J Korean Med Sci** 1995 Jun;10(3):176–82

Expression of p53 protein, PCNA, and Ki–67 in osteosarcomas of bone. Park HR, et al. **J Korean Med Sci** 1995 Oct;10(5):360–7

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. Elledge RM, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1254–6

Loss of p53–immunostaining intensity in breast cancer [editorial; comment] Henson DE. **J Natl Cancer Inst** 1996 Aug 7;88(15):1015–6. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1054–9.

Loss of tumor marker–immunostaining intensity on stored paraffin slides of breast cancer [see comments] Jacobs TW, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1054–9. Comment in: J Natl Cancer Inst 1996 Aug 7;88(15):1015–6.

p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. Shin DM, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):519–29

Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki–67 and p53 antibodies. Ellison DW, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):413–9

Immunohistochemical evaluation of erbB–2 and p53 protein expression in benign and atypical human meningiomas. Chozick BS, et al. **J Neurooncol** 1996 Feb;27(2):117–26

Accumulation of wild–type p53 protein in progressive multifocal leukoencephalopathy: a flow of cytometry and DNA sequencing study. Ariza A, et al. **J Neuropathol Exp Neurol** 1996 Feb;55(2):144–9

Immunohistochemical detection of p53 overexpression in formalin–fixed, paraffin–embedded sections of endometrial carcinoma. Iwai K, et al. **J Obstet Gynaecol** 1995 Dec; 21(6):593–600

p53 protein and Ki–67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. Slootweg PJ. **J Oral Pathol Med** 1995 Oct;24(9):393–7

Detection of p53 in Hodgkin's disease using the monoclonal antibody PAb248. Doussis–Anagnostopoulou I, et al. **J Pathol** 1996 Feb;178(2):170–2

Prognostic influence of p53 expression in gastric cancer. Müller W, et al. **J Pathol** 1996 Mar;178(3):255–8

P53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis. Aizawa S, et al. **J Surg Oncol** 1996 Aug;62(4):279–83

Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. Okusa Y, et al. **J Surg Oncol** 1996 Aug; 62(4):253–7

Immunocytochemical detection of p53 in cultures of exfoliated cells from urine of patients with urothelial cancers. Okuno H, et al. **Jpn J Cancer Res** 1996 Jul; 87(7):718–23

Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Tsuda H, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1049–53

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Vet JA, et al. **Lab Invest** 1995 Dec;73(6):837–43

p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Ambros RA, et al. **Mod Pathol** 1995 May;8(4):441–5

Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S–phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c–erb–B–2. Dabbs DJ. **Mod Pathol** 1995 Aug;8(6):637–42

Expression of p53 antigen in inflamed and regenerated mucosa in ulcerative colitis and Crohn's disease. Krishna M, et al. **Mod Pathol** 1995 Aug;8(6):654–7

p53 accumulates in micronuclei after treatment with a DNA breaking chemical, methylnitrosourea, and with the spindle poison, vinblastine. Granetto C, et al. **Mutat Res** 1996 Jun 10;352(1–2):61–4

More on p53 antigen loss in stored paraffin slides [letter; comment] Kato J, et al. **N Engl J Med** 1995 Nov 30; 333(22):1507–8. Comment on: N Engl J Med 1995 Jun 1;332(22):1521–2.

p53 expression in breast cancer related to prognostic factors. Ciesielski D, et al. **Neoplasma** 1995;42(5):235–7

p53 protein overexpression associates with growth patterns rather than with metastasizing in operable breast cancer. Vojtěšek B, et al. **Neoplasma** 1995;42(6):331–6

p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Thapar K, et al. **Neurosurgery** 1996 Apr;38(4):763–70; discussion 770–1

Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Lundin J, et al. **Oncology** 1996 Mar–Apr;53(2):104–11

Immunohistochemistry of p53 protein in transitional–cell carcinoma of the bladder using an image analyzer. Shiina H, et al. **Oncology** 1996 May–Jun;53(3):233–40

Immunoreactive p53 protein in high–grade prostatic intraepithelial neoplasia. Humphrey PA, et al. **Pathol Res Pract** 1995 Sep;191(9):881–7

Estrogen and progesterone receptors, c–erbB–2, p53, and Bcl–2 in thirty–three invasive micropapillary breast carcinomas. Luna–Moré S, et al. **Pathol Res Pract** 1996 Jan;192(1):27–32

Immunohistochemical detection of p53 protein expression in mammary carcinoma: a study of 80 cases. Fernando SS, et al. **Pathology** 1995 Oct;27(4):365–9

p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Lee CS, et al. **Pathology** 1995 Apr;27(2):117–20

PCNA and protein P53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression. Kałuża J, et al. **Pol J Pathol** 1995; 46(3):155–61

The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Vatne V, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):491–5

The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia–carcinoma sequence. Polkowski W, et al. **Surg Oncol** 1995 Jun;4(3):163–71

Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Ieda S, et al. **Surg Today** 1996;26(4):230–5

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Stricker HJ, et al. **Urology** 1996 Mar;47(3):366–9

Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Kindblom LG, et al. **Virchows Arch** 1995;427(1):19–26

Differential p53 protein expression in stomach adenomas of gastric and intestinal phenotypes: possible sequences of p53 alteration in stomach carcinogenesis. Kushima R, et al. **Virchows Arch** 1996 Jul;428(4–5):223–7

Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature–gradient gel electrophoresis. Riethdorf L, et al. **Virchows Arch** 1996 Apr;428(1):47–51

Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Segers K, et al. **Virchows Arch** 1995;427(4):431–6

p53 protein expression in extrahepatic bile duct cancer. Lee YC, et al. **Yonsei Med J** 1996 Apr;37(2):112–7

[Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer] Muzeau F, et al. **Gastroenterol Clin Biol** 1996;20(5):430–7 (Eng. Abstr.) **(Fre)**

[C–erbB–2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer] Schönborn I, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):566–71 (Eng. Abstr.) **(Ger)**

[Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course] Reles A, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:93–7 (Eng. Abstr.) **(Ger)**

[Is protein p53 an independent prognostic factor in bladder carcinoma?] Keilholz L. **Strahlenther Onkol** 1995 Sep; 171(9):543–4 **(Ger)**

[Clinical implication of p53 analysis on DNA–damaging therapies of human gastric and rectal cancers] Fujiwara T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1081–3 **(Jpn)**

[Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer] Nakata B, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:151–3 (Eng. Abstr.) **(Jpn)**

[The results of p53 immunostaining in colorectal adenomas, early cancers, advanced cancers and their hepatic metastasis] Saigusa N, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:159–63 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

E6–AP directs the HPV E6–dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Huibregtse JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:237–45

mdm–2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Chen J, et al. **Mol Cell Biol** 1996 May;16(5):2445–52

A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Lutzker SG, et al. **Nat Med** 1996 Jul; 2(7):804–10

BIOSYNTHESIS

Expression of p53 protein in tissues and organs of human and mouse embryo. Lichnovský V, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:25–7

bcl–2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Diebold J, et al. **Am J Clin Pathol** 1996 Mar; 105(3):341–9

p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short–term survival. Lanza G Jr, et al. **Am J Clin Pathol** 1996 May;105(5):604–12

p53 protein expression and p53 mutation in thymic epithelial tumors [letter] Puglisi F. **Am J Clin Pathol** 1996 May; 105(5):657–8

Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Kitamura H, et al. **Am J Surg Pathol** 1996 May;20(5):553–62

p53 overexpression in the multistep process of esophageal carcinogenesis. Parenti AR, et al. **Am J Surg Pathol** 1995 Dec;19(12):1418–22

Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras–p21 and p53 by sulindac during azoxymethane–induced colon carcinogenesis. Singh J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:205–9

A case–series study of p53 nuclear overexpression in early–stage stomach cancer. Zhang ZF, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:269–71

Terminal differentiation in a non–small–cell bronchopulmonary carcinoma correlates with increased expression of p53. Liscia E, et al. **Anticancer Res** 1996 May–Jun;16(3A):1209–12

Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and downregulates cytokeratin synthesis. Mukhopadhyay T, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1683–9

Overexpression of p53 protein in benign and malignant laryngeal epithelial lesions. Poljak M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1947–51

p53 accumulation in various organs of rats after whole–body exposure to low–dose X–ray irradiation. Wang X, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1671–4

Human p53 expressed in baculovirus–infected Sf9 cells displays a two–dimensional isoform pattern identical to wild–type p53 from human cells. Patterson RM, et al.

Arch Biochem Biophys 1996 Jun 1;330(1):71–9
Expression of p53 protein in colorectal carcinoids. Cheng JY, et al. **Arch Surg** 1996 Jan;131(1):67–70
Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Katayose D, et al.
Biochem Biophys Res Commun 1995 Oct 13;215(2):446–51
Phorbol esters attenuate the expression of p53 in cells treated with doxorubicin and protect TS-P53/K562 from apoptosis. Magnelli L, et al.
Biochem Biophys Res Commun 1995 Oct 13;215(2):641–5
Regulation of p53 expression in HeLa cells. Chen ZP, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):607–16
Increased p53 mRNA expression in liver and kidney apoptosis. Cummings MC. **Biochim Biophys Acta** 1996 Mar 1;1315(2):100–4
Cell-cycle dependent biosynthesis and localization of p53 protein in untransformed human cells. Katsumoto T, et al. **Biol Cell** 1995;84(3):167–73
Cell-mediated cytotoxicity can be regulated by p53 tumor suppressor gene activity in vitro. Mahdi T, et al. **Biol Cell** 1995;84(3):175–85
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Hernandez L, et al. **Blood** 1996 Apr 15;87(8):3351–9
p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Louie DC, et al. **Blood** 1995 Oct 15;86(8):2892–9
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Archer SG, et al. **Br J Cancer** 1995 Nov;72(5):1259–66
Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. Birrell GW, et al. **Br J Cancer** 1995 Nov;72(5):1096–101
P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Costa A, et al. **Br J Cancer** 1996 Apr;73(7):914–9
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice. Mehta RR, et al. **Br J Cancer** 1995 Nov;72(5):1160–4
bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Pollina L, et al. **Br J Cancer** 1996 Jan; 73(2):139–43
Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Soong R, et al. **Br J Cancer** 1996 Aug;74(4):562–7
Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. McIlwrath AJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):423–8
Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Harris MP, et al. **Cancer Gene Ther** 1996 Mar-Apr;3(2):121–30
Wild type p53 reduces the size of tumors caused by bovine leukemia virus-infected cells. Dees C, et al. **Cancer Lett** 1996 Mar 19;101(1):115–22
p53 gene mutation in thyroid carcinoma. Ho YS, et al. **Cancer Lett** 1996 May 15;103(1):57–63
Effects of sodium saccharin and linoleic acid on mRNA levels of Her2/neu and p53 in a human breast epithelial cell line. Ogretmen B, et al. **Cancer Lett** 1996 Apr 19;102(1–2):91–9
Taxol induction of p21WAF1 and p53 requires c-raf-1. Blagosklonny MV, et al. **Cancer Res** 1995 Oct 15; 55(20):4623–6
Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Fagin JA, et al. **Cancer Res** 1996 Feb 15;56(4):765–71
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Gomez-Manzano C, et al. **Cancer Res** 1996 Feb 15; 56(4):694–9
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Herod JJ, et al. **Cancer Res** 1996 May 1;56(9):2178–84
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Righetti SC, et al. **Cancer Res** 1996 Feb 15;56(4):689–93
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Gudas JM, et al. **Carcinogenesis** 1996 Jul;17(7):1417–27
p53 expression in normal versus transformed mammalian cells. Moro F, et al. **Carcinogenesis** 1995 Oct;16(10):2435–40
p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Rämet M, et al. **Carcinogenesis** 1995 Sep;16(9):2117–24
Induction of p53 in mouse cells decreases mutagenesis by UV radiation. Yuan J, et al. **Carcinogenesis** 1995 Oct; 16(10):2295–300
Quantitation of P53 protein expression in gastrointestinal smooth muscle tumors. Clinicopathological correlation and prognostic significance. Cai J, et al. **Chin Med J (Engl)** 1995 Sep;108(9):669–73
Mutation of p53 tumor suppressor gene in flat neoplastic lesions of the colorectal mucosa. Rubio CA, et al. **Dis Colon Rectum** 1996 Feb;39(2):143–7
Overexpression of p53 in laryngeal carcinoma: clinicopathological implications. Dursun G, et al. **Ear Nose Throat J** 1995 Sep;74(9):645–8
Negative feedback regulation of wild-type p53 biosynthesis. Mosner J, et al. **EMBO J** 1995 Sep 15;14(18):4442–9
High prevalence of expression of p53 oncoprotein in oral carcinomas from India associated with betel and tobacco chewing. Kuttan NA, et al.
Eur J Cancer B Oral Oncol 1995 May;31B(3):169–73
Overexpression of p53 and MDM2 proteins in cervical neoplasia. Lukáš Z, et al. **Folia Biol (Praha)** 1995; 41(3–4):197–9
Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Oda Y, et al.
Gen Diagn Pathol 1995 Oct;141(2):97–103
Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Godley LA, et al. **Genes Dev** 1996 Apr 1;10(7):836–50
Genetic determinants of p53-induced apoptosis and growth arrest. Polyak K, et al. **Genes Dev** 1996 Aug 1; 10(15):1945–52
Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Hamel NW, et al. **Gynecol Oncol** 1996 Aug;62(2):192–8
p53 protein overexpression in early stage endometrial cancer. Kohlberger P, et al. **Gynecol Oncol** 1996 Aug;62(2):213–7
P53 expression in adenomyosis in endometrial carcinoma patients. Taskin M, et al. **Gynecol Oncol** 1996 Aug; 62(2):241–6
Immunohistochemical study of p53 expression in cancer tissues from patients undergoing radiation therapy. Hamada N, et al. **Histol Histopathol** 1995 Jul;10(3):611–7
The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients. Baas IO, et al. **Hum Pathol** 1996 Apr;27(4):324–9
Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Gulley ML, et al. **Hum Pathol** 1996 Jan; 27(1):20–7
Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Nakamura S, et al. **Hum Pathol** 1996 Mar;27(3):225–33
The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Papadaki H, et al. **Hum Pathol** 1996 Jun;27(6):567–72
p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Wistuba II, et al. **Hum Pathol** 1996 Apr;27(4):360–5
Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Cirielli C, et al. **Int J Cancer** 1995 Nov 27;63(5):673–9
p53 expression and proliferative activity predict survival in non-invasive thymomas. Pich A, et al. **Int J Cancer** 1996 Jun 21;69(3):180–3
p53 expression in gestational trophoblastic disease. Lee YS. **Int J Gynecol Pathol** 1995 Apr;14(2):119–24
p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells. Ohnishi T, et al.
J Biol Chem 1996 Jun 14;271(24):14510–3
Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. Takano Y, et al. **J Cancer Res Clin Oncol** 1996;122(3):166–70
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. Strömblad S, et al. **J Clin Invest** 1996 Jul 15;98(2):426–33
Detection of P53 expression and S-phase cell fraction in paraffin-embedded tissue by a double-labeling technique. Benini E, et al. **J Histochem Cytochem** 1995 Oct; 43(10):999–1003
Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer [letter] Bilim V, et al.
J Natl Cancer Inst 1996 May 15;88(10):686–8
p53 protein and epidermal growth factor receptor expression in human astrocytomas. Kordek R, et al. **J Neurooncol** 1995 Oct;26(1):11–6
Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Washington K, et al. **Liver** 1996 Apr; 16(2):99–104
Prognostic significance of p53 over-expression in thin melanomas. Sparrow LE, et al. **Melanoma Res** 1995 Dec; 5(6):387–92
p53 oncoprotein overexpression in choroidal melanoma. Janssen K, et al. **Mod Pathol** 1996 Mar;9(3):267–72
E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Hiebert SW, et al. **Mol Cell Biol** 1995 Dec;15(12):6864–74
The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. Zhang WW, et al.
Nucleic Acids Res 1995 Oct 25;23(20):4073–80
The human tumour suppressor gene p53 is alternatively spliced in normal cells. Flaman JM, et al. **Oncogene** 1996 Feb 15;12(4):813–8
Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Gollahon LS, et al. **Oncogene** 1996 Feb 15;12(4):715–25
UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. Gu J, et al. **Oncogene** 1995 Nov 16; 11(10):2175–8
Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Jiang MC, et al. **Oncogene** 1996 Aug 1;13(3):609–16
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Marchetti A, et al. **Oncogene** 1996 Mar 21;12(6):1319–24
Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Pocard M, et al. **Oncogene** 1996 Feb 15;12(4):875–82
Expression of p53 in normal and gamma-irradiated rat testis suggests a role for p53 in meiotic recombination and repair. Sjöblom T, et al. **Oncogene** 1996 Jun 20;12(12):2499–505
Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells. Zhang N, et al. **Oncogene** 1996 Aug 1;13(3):655–9
p53 and MDM2 expression in oral squamous cell carcinoma. Matsumura T, et al. **Oncology** 1996 Jul-Aug;53(4):308–12
K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362–8
Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Brachmann RK, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4091–5
Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Baretton GB, et al. **Scand J Gastroenterol** 1996 May;31(5):481–9
Expression of p53 protein related to human papillomavirus and DNA ploidy in superficial esophageal carcinoma. Nakamura T, et al. **Surg Today** 1995;25(7):591–7
Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Moul JW, et al. **Surgery** 1996 Aug;120(2):159–66; discussion 166–7
Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Zedenius J, et al. **Thyroid** 1996 Feb;6(1):1–9
p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Papadopoulos I, et al. **Urology** 1996 Aug; 48(2):261–8
Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Kobayashi M, et al. **Virchows Arch** 1995;427(1):27–32
[Correlation between p53 nuclear protein accumulation and mutations of the p53 gene in human esophageal cancer from linxian] Liang Y, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):412–4 (Eng. Abstr.) **(Chi)**

BLOOD

P53 levels in the evaluation of malignant/benign pancreaticobiliary disease: hope or hype? Gessner CE, et al. **Am J Gastroenterol** 1996 Feb;91(2):401–2
Serum p53 accumulation and altered antibody responses to Epstein-Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Lehtinen T, et al. **Br J Haematol** 1996 Apr;93(1):104–10
The molecular epidemiology of oncoproteins. Serum p53 protein in patients with asbestosis. Hemminki K, et al. **Chest** 1996 Mar;109(3 Suppl):22S–26S
Elevated levels of p53 protein in the neutrophils and monocytes of a patient with chronic idiopathic thrombocytopenic purpura or possible early myelodysplasia? Guinn BA, et al. **Leuk Res** 1995 Oct; 19(10):727–31

CHEMISTRY

Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Appleman LJ, et al. **Int J Cancer** 1995 Nov 15;63(4):576–83
Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. Hansen S, et al. **J Biol Chem** 1996 Feb 16;271(7):3917–24
Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor. Kernohan NM, et al. **J Biol Chem** 1996 Mar 1;271(9):4954–60
Identification of a region of p53 that confers lability. Li X, et al. **J Biol Chem** 1996 Feb 23;271(8):4447–51
Structural aspects of the p53 protein in relation to gene evolution: a second look. Soussi T, et al. **J Mol Biol** 1996 Aug 2;260(5):623–37 (143 ref.)
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Blagosklonny MV, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8379–83

DEFICIENCY

p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Bogue MA, et al. **Genes Dev** 1996 Mar 1;10(5):553–65
V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Guidos CJ, et al. **Genes Dev** 1996 Aug 15;10(16):2038–54
Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice. Cano A, et al. **Int J Cancer** 1996 Jan 17;65(2):254–62
Effects of genetic background on tumorigenesis in p53-deficient mice. Donehower LA, et al.
Mol Carcinog 1995 Sep;14(1):16–22
Cellular proofreading [comment] Brash DE. **Nat Med** 1996 May;2(5):525–6. Comment on: Nat Med 1996 May;2(5):577–80.
p53-dependent apoptosis suppresses radiation-induced

teratogenesis [see comments] Norimura T, et al. **Nat Med** 1996 May;2(5):577–80. Comment in: Nat Med 1996 May;2(5):525–6.

Gamma-ray-induced cell killing and chromosome abnormalities in the bone marrow of p53-deficient mice. Wang L, et al. **Radiat Res** 1996 Sep;146(3):259–66

DRUG EFFECTS

Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells. Shin KH, et al. **Oncogene** 1996 Mar 7;12(5):1089–96

GENETICS

Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis. Tominaga T, et al. **Acta Neurochir (Wien)** 1995;135(3–4):163–70

In situ polymerase chain reaction detection of HTLV-I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T cell leukemia. Higuchi I, et al. **Acta Neuropathol (Berl)** 1995;90(3):323–7

p53 expression and the result of adjuvant therapy of breast cancer. Stål O, et al. **Acta Oncol** 1995;34(6):767–70

Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors [see comments] Cain CT, et al. **Am J Dermatopathol** 1995 Aug;17(4):324–31. Comment in: Am J Dermatopathol 1995 Aug;17(4):319–20.

p53 mutation in hepatocellular carcinoma and chronic liver disease [letter] Ceyhan K, et al. **Am J Gastroenterol** 1996 Jul;91(7):1476–7

The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Keleti J, et al. **Am J Pathol** 1996 Jul;149(1):143–51

Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. Kitagawa Y, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):45–54

Inactivation of tumor suppressor proteins in lung cancer. Weintraub SJ. **Am J Respir Cell Mol Biol** 1996 Aug; 15(2):150–5 (39 ref.)

P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Kuwano K, et al. **Am J Respir Crit Care Med** 1996 Aug; 154(2 Pt 1):477–83

Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. Koness RJ, et al. **Ann Surg Oncol** 1996 Mar;3(2):136–43

Clinical implications of the p53 gene. Sidransky D, et al. **Annu Rev Med** 1996;47:285–301 (89 ref.)

Dbl expression driven by the neuron specific enolase promoter induces tumor formation in transgenic mice with a p53(+/-) genetic background. Colucci-D'Amato GL, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):762–70

The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Strauss BE, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):333–40

DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Take Y, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):207–12

Semiautomated quantitative detection of loss of heterozygosity in the tumor suppressor gene p53. Hahn M, et al. **Biotechniques** 1995 Jun;18(6):1040–7

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Foulkes WD, et al. **Br J Cancer** 1995 Oct;72(4):883–8

The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Harris CC. **Br J Cancer** 1996 Feb;73(3):261–9 (89 ref.)

A case of refractory anaemia with p53 point mutation at codon 249 (AGG to ATG). Kikukawa M, et al. **Br J Haematol** 1996 Mar;92(4):831–3

P53 and ploidy assessed by flow cytometry in bladder washings. Griffiths TR, et al. **Br J Urol** 1995 Nov; 76(5):575–9

Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. Taubert H, et al. **Cancer** 1995 Oct 1; 76(7):1187–96

p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China. Lung ML, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):277–84

Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. Aguiar RC, et al. **Cancer Genet Cytogenet** 1995 Oct 15; 84(2):105–12

Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Greenblatt MS, et al. **Cancer Res** 1996 May 1;56(9):2130–6

Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Kawajiri K, et al. **Cancer Res** 1996 Jan 1;56(1):72–6

Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Tishler RB, et al. **Cancer Res** 1995 Dec 15;55(24):6021–5

Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Tsai CM, et al. **Cancer Res** 1996 Jan 1;56(1):206–9

An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Waterman MJ, et al. **Cancer Res** 1996 Jan 1;56(1):158–63

Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)

Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Banerjee D, et al. **Cell Growth Differ** 1995 Nov;6(11):1405–13

Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Wosikowski K, et al. **Cell Growth Differ** 1995 Nov;6(11):1395–403

Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Hupp TR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:195–206

DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. Allday MJ, et al. **EMBO J** 1995 Oct 16;14(20):4994–5005

Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. Léveillard T, et al. **EMBO J** 1996 Apr 1;15(7):1615–24

Loss of p53 function through PAX-mediated transcriptional repression. Stuart ET, et al. **EMBO J** 1995 Nov 15; 14(22):5638–45

p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. Stürzbecher HW, et al. **EMBO J** 1996 Apr 15;15(8):1992–2002

A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. Magnusson KP, et al. **Gene** 1995 Sep 11;162(2):231–4

p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites. Jackson P, et al. **Gene Expr** 1995;5(1):19–33

Tissue-specific inactivation of p53 tumor suppression in the mouse. Bowman T, et al. **Genes Dev** 1996 Apr 1; 10(7):826–35

Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Huyghe BG, et al. **Hum Gene Ther** 1995 Nov;6(11):1403–16

p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Moll UM, et al. **Hum Pathol** 1995 Dec; 26(12):1293–301

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Wertz IE, et al. **Hum Pathol** 1996 Jun;27(6):573–80

Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Ciernik IF, et al. **Hybridoma** 1995 Apr;14(2):139–42

Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Agular-Santelises M, et al. **Int J Cancer** 1996 Apr 22;69(2):114–9

Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Appleman LJ, et al. **Int J Cancer** 1995 Nov 15;63(4):576–83

Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens. Kuczyk MA, et al. **Int J Cancer** 1995 Dec 20;64(6):399–406

Incidence of germ-line p53 mutations in patients with gliomas. Li YJ, et al. **Int J Cancer** 1995 Dec 20;64(6):383–7

Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Tanaka H, et al. **Int J Cancer** 1996 Jan 26;65(3):372–6

Accumulation of mutant p53 and hsp72 by heat treatment, and their association in a human glioblastoma cell line. Ohnishi T, et al. **Int J Hyperthermia** 1995 Sep-Oct; 11(5):663–71

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

A movable and regulable inactivation function within the central region of a temperature-sensitive p53 mutant. Chuang JY, et al. **J Biol Chem** 1995 Oct 13; 270(41):23899–902

Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. Hurd C, et al. **J Biol Chem** 1995 Dec 1;270(48):28507–10

Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice. Motokura T, et al. **J Biol Chem** 1995 Dec 29;270(52):30857–61

gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. Fujihashi K, et al. **J Exp Med** 1996 Apr 1;183(4):1929–35

Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study. Ajioka Y, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:33–5

The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. Gartenhaus RB, et al. **J Mol Med** 1996 Mar;74(3):143–7

No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas [letter] Ménard S, et al. **J Natl Cancer Inst** 1996 Jul 17; 88(14):1002–3

The use of antigen retrieval for immunohistochemical detection of p53 over-expression in malignant and benign oral mucosa: a cautionary note. Dowell SP, et al. **J Oral Pathol Med** 1996 Feb;25(2):60–4

Expression of p53 protein in oral squamous cell carcinomas and adjacent non-tumorous mucosa of the floor of the mouth: an archival immunohistochemical study using wet autoclave pretreatment for antigen retrieval. Piffkó J, et al. **J Oral Pathol Med** 1995 Sep;24(8):337–42

Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: an immunohistochemical and clinicopathological study. Yan JJ, et al. **J Oral Pathol Med** 1996 Feb;25(2):55–9

Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. Werthman PE, et al. **J Urol** 1996 Feb;155(2):753–6

Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. Chen W, et al. **J Virol** 1996 Jul; 70(7):4849–53

Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Vermeulen PB, et al. **Microvasc Res** 1996 Mar;51(2):164–74

Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Kitada H, et al. **Mol Carcinog** 1996 Apr;15(4):276–83

Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Li B, et al. **Mol Carcinog** 1995 Oct;14(2):75–83

Frameshift mutation in codon 176 of the p53 gene in rat esophageal epithelial cells transformed by benzo[a]pyrene dihydrodiol. Wang D, et al. **Mol Carcinog** 1995 Oct; 14(2):84–93

p53 activity and chemotherapy [letter; comment] Delia D, et al. **Nat Med** 1996 Jul;2(7):724–5. Comment on: Nat Med 1996 Jan;2(1):72–9.

Translational research comes of age [comment] Minna JD, et al. **Nat Med** 1996 Sep;2(9):974–5. Comment on: Nat Med 1996 Sep;2(9):985–91.

Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Danks RA, et al. **Neurosurgery** 1995 Aug;37(2):246–54

Tumor necrosis factor-alpha induces p53-dependent apoptosis in rat glioma cells. Yin D, et al. **Neurosurgery** 1995 Oct;37(4):758–62; discussion 762–3

Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Will K, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4023–8

Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53. Lieter LM, et al. **Oncogene** 1996 Jun 20;12(12):2661–8

Specific binding of MAR/SAR DNA-elements by mutant p53. Müller BF, et al. **Oncogene** 1996 May 2;12(9):1941–52

Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Bradford CR, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):408–12

Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Ramel S, et al. **Pancreas** 1995 Oct;11(3):213–22

Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Ford JM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8876–80

A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Lotem J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9672–6

Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Nishida T, et al. **Surgery** 1996 May;119(5):568–75

Spontaneous mutation of cell oncogenes plays a minor role in neoplastic transformation of virus-induced murine T-cell lymphomas. Gasparotto D, et al. **Tumori** 1995 Jul-Aug; 81(4):268–72

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Srivastava S, et al. **Urology** 1995 Dec;46(6):843–8

The clinical significance of p53 aberrations in human tumours. Bosari S, et al. **Virchows Arch** 1995;427(3):229–41 (158 ref.)

Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Grand RJ, et al. **Virology** 1996 Apr 1;218(1):23–34

[Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis] Fléjou JF, et al. **Gastroenterol Clin Biol** 1995 May; 19(5):475–81 (Eng. Abstr.) **(Fre)**

[P53 protein: a new tool for the clinician? (editorial)] Laurent-Puig P. **Gastroenterol Clin Biol** 1995 May; 19(5):463–4 (8 ref.) **(Fre)**

[Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53] Seitz JF, et al. **Gastroenterol Clin Biol** 1995 May;19(5):465–74 (Eng. Abstr.) **(Fre)**

[p53—a key gene for cancer development. Its central significance discloses itself to researchers step by step] Janssen K. **Fortschr Med** 1995 Dec 10;113(34):48–50 **(Ger)**

[Overexpression of p53 as prognosis factor in vulvar carcinoma] Kohlberger P, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):40–1 (Eng. Abstr.) **(Ger)**

[Tumor suppressor gene p53. Theoretical principles and their significance for pathology] Poremba C, et al. **Pathologe** 1996 May;17(3):181–8 (62 ref.) (Eng. Abstr.) **(Ger)**

[Endocrine tumors in transgenic mice] Fehmann HC, et al. **Z Gastroenterol** 1996 Feb;34(2):154–5 **(Ger)**

[The human adenosine deaminase gene contains a p53–responsive element] Kondratov RV, et al. **Dokl Akad Nauk** 1996 Jan;346(2):260–2 **(Rus)**

[Functional heterogeneity of p53–responsive elements] Kondratov RV, et al. **Mol Biol (Mosk)** 1996 May–Jun; 30(3):613–20 **(Rus)**

[A comparative study on the prognostic value of the nuclear expression of protein p53 vis–à–vis histopathology in colorectal cancer] Díez M, et al. **An Med Interna** 1996 May;13(5):222–6 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Lavieille JP, et al. **Anticancer Res** 1996 Jul–Aug;16(4C):2385–8

The significance of p53 autoantibodies in the serum of patients with breast cancer. Willsher PC, et al. **Anticancer Res** 1996 Mar–Apr;16(2):927–30

Autoantibodies against p53 are not increased in human ascites and pleural effusions. Munker R, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):200–1

Induction of tetraploid DNA content by mutant simian virus 40 T antigen that has reduced complex formation with p53. Lehman JM, et al. **Cytometry** 1996 Feb 1;23(2):126–30

Alpha–fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Raedle J, et al. **Dig Dis Sci** 1995 Dec; 40(12):2587–94

Detection of p53 auto–antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Regidor PA, et al. **Eur J Gynaecol Oncol** 1996;17(3):192–9

Binding of mutated Ras– and p53–derived peptides to HLA–DR molecules. Murakami S, et al. **Immunol Lett** 1996 Mar;49(3):149–53

Prognostic significance of Ki67 (MIB1) proliferation index and p53 over–expression in chondrosarcomas. Nawa G, et al. **Int J Cancer** 1996 Apr 22;69(2):86–91

Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. Ryder SD, et al. **J Clin Pathol** 1996 Apr; 49(4):295–9

TCR–mediated death of mature T lymphocytes occurs in the absence of p53. Boehme SA, et al. **J Immunol** 1996 Jun 1;156(11):4075–8

Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. Bourhis J, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1228–33

Potential false–positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. Baas IO, et al. **J Pathol** 1996 Mar; 178(3):264–7

Correlation of p53 immunoreactivity and sequencing in patients with glioma. Kyritsis AP, et al. **Mol Carcinog** 1996 Jan;15(1):1–4

Serum p53 antibodies as early markers of lung cancer. Lubin R, et al. **Nat Med** 1995 Jul;1(7):701–2

Epitope analysis of the murine p53 tumour suppressor protein. Lane DP, et al. **Oncogene** 1996 Jun 6;12(11):2461–6

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Roth J, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4781–6

Targeting p53 as a general tumor antigen. Theobald M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11993–7

METABOLISM

p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Tateyama H, et al. **Am J Clin Pathol** 1995 Oct;104(4):375–81

p53 Protein overexpression in colorectal tumors from patients with familial adenomatous polyposis: is it an early or late event? [see comments] Levi E, et al. **Am J Gastroenterol** 1996 Jan;91(1):11–4. Comment in: Am J Gastroenterol 1996 Jan;91(1):3–6.

Suppression of cellular proliferation using p53 DNA recognition site–related oligonucleotides. Ré RN, et al. **Am J Med Sci** 1996 Feb;311(2):65–72

Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Yaziji H, et al. **Am J Surg Pathol** 1996 Sep;20(9):1086–90

Correlation between ploidy status, Erb–B2 and p53 immunohistochemical expression in primary breast carcinoma. Midulla C, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):157–62

Relationships between proliferative activity and oncogene expression in human breast cancer. Geuna M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:555–63

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione–S–transferase, topoisomerase II and MRP in multidrug resistant cell lines. Utz I, et al. **Anticancer Res** 1996 Jan–Feb;16(1):289–96

Nitric oxide (NO) in apoptotic versus necrotic RAW 264.7 macrophage cell death: the role of NO–donor exposure, NAD+ content, and p53 accumulation. Messmer UK, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):1–10

Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Caminero MJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):769–72

Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Scherer SJ, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):722–8

The MDR1 downstream promoter contains sequence–specific binding sites for wild–type p53. Strauss BE, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):825–31

ADP–ribosylation of wild–type p53 in vitro: binding of p53 protein to specific p53 consensus sequence prevents its modification. Węsierska–Gądek J, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):96–102

Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. Filhol O, et al. **Biochem J** 1996 May 15;316 (Pt 1):331–5

Modulation of DNA topoisomerase I activity by p53. Gobert C, et al. **Biochemistry** 1996 May 7;35(18):5778–86

Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501–8 (98 ref.)

Lack of mutation in tumour–suppressor gene p53 in gestational trophoblastic tumours. Shi YF, et al. **Br J Cancer** 1996 May;73(10):1216–9

Linear porokeratosis with multiple squamous cell carcinomas: study of p53 expression in porokeratosis and squamous cell carcinoma [letter] Sasaki S, et al. **Br J Dermatol** 1996 Jun; 134(6):1151–3

Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Kashiwagi H, et al. **Br J Surg** 1996 Feb;83(2):225–8

Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Underwood MA, et al. **Br J Urol** 1996 May;77(5):659–66

Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Zhang XH, et al. **Br J Urol** 1996 Mar;77(3):441–4

p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Gimenez–Conti IB, et al. **Cancer** 1996 Jul 1; 78(1):17–23

Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Li SF, et al. **Cancer** 1996 Jan 15;77(2):321–9

Overexpression or mutation of the p53 tumor suppressor gene does not occur in malignant ovarian germ cell tumors [see comments] Liu FS, et al. **Cancer** 1995 Jul 15;76(2):291–5 . Comment in: Cancer 1996 Jul 1;78(1):179–81.

Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Shindoh M, et al. **Cancer** 1995 Nov 1;76(9):1513–21

p53 expression in dedifferentiated chondrosarcoma. Simms WW, et al. **Cancer** 1995 Jul 15;76(2):223–7

p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Wang LD, et al. **Cancer** 1996 Apr 1; 77(7):1244–9

Prognostic implication of the p53 protein and Ki–67 antigen immunohistochemistry in malignant fibrous histiocytoma. Yang P, et al. **Cancer** 1995 Aug 15;76(4):618–25

p53 protein accumulation in tumors of the ampulla of Vater. Younes M, et al. **Cancer** 1995 Oct 1;76(7):1150–4

Increased p53 site–specific DNA binding in cells producing mutant p53. Dees C, et al. **Cancer Lett** 1995 Sep 25; 96(2):225–31

Low frequency of p53 gene mutation and protein expression in mucinous colorectal carcinomas. Hanski C, et al. **Cancer Lett** 1996 Jun 5;103(2):163–70

p53 accumulation in the organs of low–dose X–ray–irradiated mice. Wang X, et al. **Cancer Lett** 1996 Jun 24;104(1):79–84

Microsatellite instability, apoptosis, and loss of p53 function in drug–resistant tumor cells. Anthoney DA, et al. **Cancer Res** 1996 Mar 15;56(6):1374–81

Hypersensitivity of human testicular tumors to etoposide–induced apoptosis is associated with functional p53 and a high Bax:Bcl–2 ratio. Chresta CM, et al. **Cancer Res** 1996 Apr 15;56(8):1834–41

Modulation of p53 expression by human recombinant interferon–alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Davol PA, et al. **Cancer Res** 1996 Jun 1;56(11):2522–6

Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus–related human hepatocellular carcinoma. Henkler F, et al. **Cancer Res** 1995 Dec 15; 55(24):6084–91

Interleukin–1 beta–converting enzyme mediates cisplatin–induced apoptosis in malignant glioma cells. Kondo S, et al. **Cancer Res** 1995 Dec 15;55(24):6166–71

In vivo ubiquitination and proteasome–mediated degradation of p53(1). Maki CG, et al. **Cancer Res** 1996 Jun 1; 56(11):2649–54

Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy. Nakano T, et al. **Cancer Res** 1996 Jun 15;56(12):2771–5

Cooperation between p53–dependent and p53–independent apoptotic pathways in myeloid cells. Peled A, et al. **Cancer Res** 1996 May 1;56(9):2148–56

Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Webster NJ, et al. **Cancer Res** 1996 Jun 15;56(12):2781–8

Phosphorylation of T antigen and p53 in carcinogen–treated SV40–transformed Chinese hamster cells. Paley EL. **Carcinogenesis** 1996 May;17(5):939–45

Inhibition of poly(ADP–ribose) polymerase increases (+/–)–anti–benzo [a]pyrene diolepoxide–induced micronuclei formation and p53 accumulation in isolated human peripheral blood lymphocytes. Steirum RH, et al. **Carcinogenesis** 1995 Nov;16(11):2765–71

Small peptides activate the latent sequence–specific DNA binding function of p53. Hupp TR, et al. **Cell** 1995 Oct 20;83(2):237–45

p53 Protein exhibits 3'–to–5' exonuclease activity. Mummenbrauer T, et al. **Cell** 1996 Jun 28;85(7):1089–99

Targets for transcriptional activation by wild–type p53: endogenous retroviral LTR, immunoglobulin–like promoter, and an internal promoter of the mdm2 gene. Barak Y, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:225–35

Regulation of the cryptic sequence–specific DNA–binding function of p53 by protein kinases. Hupp TR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:195–206

DNA–binding properties of the p53 tumor suppressor protein. Prives C, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:207–13

The significance of alterations in p53 expression in gynaecological neoplasms. Manek S, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):52–5 (33 ref.)

Overexpression of p53 protein and histologic grades of dysplasia in colorectal adenomas. Sameshima S, et al. **Dis Colon Rectum** 1996 May;39(5):562–7

Functional interactions between p53 and the TFIIH complex are affected by tumour–associated mutations. Léveillard T, et al. **EMBO J** 1996 Apr 1;15(7):1615–24

p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. Stürzbecher HW, et al. **EMBO J** 1996 Apr 15;15(8):1992–2002

Protein p53 modulates transcription from a promoter containing its binding site in a concentration–dependent manner. Kristjuhan A, et al. **Eur J Biochem** 1995 Dec 15; 234(3):827–31

Expression of p53 protein as a prognostic factor in patients with gastric cancer. Victorzon M, et al. **Eur J Cancer** 1996 Feb;32A(2):215–20

Value of p53 expression in oral cancer and adjacent normal mucosa in relation to the occurrence of multiple primary carcinomas. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):392–5

PCNA and p53 [letter] Migheli A. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):403–4

p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Raybaud–Diogène H, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):143–9 (66 ref.)

Differential c–myc, c–jun, c–raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Riva C, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):384–91

Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. Helps NR, et al. **FEBS Lett** 1995 Dec 27;377(3):295–300

Precise mapping of the tms1 binding site on p53. Wagner P, et al. **FEBS Lett** 1995 Dec 18;377(2):155–8

The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53–inducible and death–promoting Bax protein. Han J, et al. **Genes Dev** 1996 Feb 15;10(4):461–77

The XPB and XPD DNA helicases are components of the p53–mediated apoptosis pathway. Wang XW, et al. **Genes Dev** 1996 May 15;10(10):1219–32

p53 expression in ulcerative colitis: a longitudinal study. Ilyas M, et al. **Gut** 1995 Dec;37(6):802–4

p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Rizzi PM, et al. **Gut** 1996 Feb;38(2):265–8

p53 as a prognostic indicator in endometrial cancer. Geisler JP, et al. **Gynecol Oncol** 1996 May;61(2):245–8

Mitotic count, nuclear atypia, and immunohistochemical determination of Ki–67, c–myc, p21–ras, c–erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki–67 are indicators of poor prognosis. King LA, et al. **Gynecol Oncol** 1996 May;61(2):227–32

Overexpression of p53 is not a feature of ovarian granulosa cell tumors. Liu FS, et al. **Gynecol Oncol** 1996 Apr; 61(1):50–3

Subcellular localization of accumulated p53 in ovarian cancer

cells. Runnebaum IB, et al. **Gynecol Oncol** 1996 May; 61(2):266–71

Small cell carcinoma of the ovary of the hypercalcemic type: p53 protein accumulation and clinicopathologic features. Seidman JD. **Gynecol Oncol** 1995 Nov;59(2):283–7

p53 overexpression and bcl–2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes [see comments] Zheng W, et al. **Gynecol Oncol** 1996 May;61(2):167–74. Comment in: Gynecol Oncol 1996 May;61(2):163–5.

Prognostic significance of p53 and c–erbB–2 immunohistochemical evaluation in colorectal adenocarcinoma. Lazaris AC, et al. **Histol Histopathol** 1995 Jul;10(3):661–8

p53 in breast cancer. Its relation to histological grade, lymph–node status, hormone receptors, cell–proliferation fraction (ki–67) and c–erbB–2. Immunohistochemical study of 153 cases. Sirvent JJ, et al. **Histol Histopathol** 1995 Jul; 10(3):531–9

DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Pich A, et al. **Hum Pathol** 1996 Jul;27(7):676–82

Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. de Witte HH, et al. **Int J Cancer** 1996 Apr 22;69(2):125–30

p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Lim BH, et al. **Int J Cancer** 1996 Jun 21;69(3):200–4

p53 mutations in the non–neoplastic mucosa of the human stomach showing intestinal metaplasia. Ochiai A, et al. **Int J Cancer** 1996 Feb 20;69(1):28–33

p53 PCNA, and Ki–67 in hydropic molar and nonmolar placentas: an immunohistochemical study. Schammel DP, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):158–66

Accumulation of mutant p53 and hsp72 by heat treatment, and their association in a human glioblastoma cell line. Ohnishi T, et al. **Int J Hyperthermia** 1995 Sep–Oct; 11(5):663–71

No association between p53 status and alpha–particle–induced chromosomal instability in human lymphoblastoid cells. Kadhim MA, et al. **Int J Radiat Biol** 1996 Feb;69(2):167–74

p53 protein expression or protein function? [letter] Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15; 35(5):1123–5

Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA–binding protein. Chang J, et al. **J Biol Chem** 1995 Oct 20;270(42):25014–9

Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. Hansen S, et al. **J Biol Chem** 1996 Feb 16;271(7):3917–24

Modification of an N–terminal regulatory domain of T antigen restores p53–T antigen complex formation in the absence of an essential metal ion cofactor. Kernohan NM, et al. **J Biol Chem** 1996 Mar 1;271(9):4954–60

Identification of a region of p53 that confers lability. Li X, et al. **J Biol Chem** 1996 Feb 23;271(8):4447–51

p53 is a mediator for radiation–repressed human TR2 orphan receptor expression in MCF–7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. Lin DL, et al. **J Biol Chem** 1996 Jun 21; 271(25):14649–52

Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. Sepehrnia B, et al. **J Biol Chem** 1996 Jun 21; 271(25):15084–90

Human cytomegalovirus immediate–early protein IE2 tethers a transcriptional repression domain to p53. Tsai HL, et al. **J Biol Chem** 1996 Feb 16;271(7):3534–40

Modulation of interleukin–6–induced plasma protein secretion in hepatoma cells by p53 species. Wang L, et al. **J Biol Chem** 1995 Sep 29;270(39):23159–65

Characterization and cloning of a 58/53–kDa substrate of the insulin receptor tyrosine kinase. Yeh TC, et al. **J Biol Chem** 1996 Feb 9;271(6):2921–8

Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. Didenko VV, et al. **J Clin Invest** 1996 Apr 1;97(7):1723–31

Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. Jackson PA, et al. **J Clin Pathol** 1995 Dec; 48(12):1098–101

Expression of p53 and bcl–2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. Puglisi F, et al. **J Clin Pathol** 1996 Jun;49(6):456–9

Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression. Bito T, et al. **J Cutan Pathol** 1995 Oct;22(5):427–34

Infrequent expression of protein p53 in epidermotropic variants of cutaneous T–cell lymphoma. de Misa RF, et al. **J Dermatol** 1995 Jul;22(7):524–6

Immunohistochemical detection of p53 tumor suppressor protein in porokeratosis. Urano Y, et al. **J Dermatol** 1996 May;23(5):365–8

p53–Dependent and –independent transactivation by the E6 protein of human papillomavirus type 16. Akutsu N, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):459–63

Epstein–Barr virus EBNA–LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. Inman GJ, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2141–9

The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. Sjögren S, et al. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):173–82

p53–positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)

Nuclear p53 overexpression is an independent prognostic parameter in node–negative non–small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53–8 (41 ref.)

Detection of p53 and bcl–2 protein in carcinoma of the renal pelvis and ureter including dysplasia. Furihata M, et al. **J Pathol** 1996 Feb;178(2):133–9

In situ analysis of tissue dynamics and p53 expression in human gastric mucosa. Imatani A, et al. **J Pathol** 1996 May; 179(1):39–42

p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. Jeffers MD, et al. **J Pathol** 1995 Sep;177(1):65–70

p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. Kusama K, et al. **J Pathol** 1996 Apr;178(4):415–21

MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. Martinez JC, et al. **J Pathol** 1995 Sep; 177(1):27–34

Prognostic significance of the co–expression of p53 and c–erbB–2 proteins in breast cancer. Nakopoulou LL, et al. **J Pathol** 1996 May;179(1):31–8

Expression of p53 protein has no independent prognostic value in breast cancer. Pietiläinen T, et al. **J Pathol** 1995 Nov;177(3):225–32

p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. Tenti P, et al. **J Pathol** 1996 Jan;178(1):65–70

Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. Patel DD, et al. **J Surg Oncol** 1996 Jun; 62(2):86–92

Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. Dalal S, et al. **J Virol** 1996 Feb;70(2):683–8

BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. Harris KF, et al. **J Virol** 1996 Apr;70(4):2378–86

Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. Jault FM, et al. **J Virol** 1995 Nov;69(11):6697–704

High–risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. Li X, et al. **J Virol** 1996 Jul;70(7):4509–16

p53 accumulation in colorectal cancer with hepatic metastasis. Maruyama K, et al. **Jpn J Cancer Res** 1996 Apr; 87(4):368–76

Inhibition of p53 protein phosphorylation by 9–hydroxyellipticine: a possible anticancer mechanism. Ohashi M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):819–27

Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Muro K, et al. **Jpn J Clin Oncol** 1996 Apr;26(2):65–9

Expression of P53 protein and it's prognostic significance in breast cancer patients. Hou MF, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):471–8

Immunohistochemical pattern of P53 protein in human astrocytic tumors. Howng SL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):279–84

Expressions of c–jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. Shinoda H, et al. **Laryngoscope** 1995 Nov;105(11):1232–7

Functional inactivation of wild–type p53 protein correlates with loss of IL–2 dependence in HTLV–I transformed human T lymphocytes. Gartenhaus RB, et al. **Leukemia** 1995 Dec;9(12):2082–6

Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Ho YS, et al. **Mol Carcinog** 1996 May;16(1):20–31

Regulation of p53–mediated apoptosis and cell cycle arrest by Steel factor. Abrahamson JL, et al. **Mol Cell Biol** 1995 Dec;15(12):6953–60

Gas1–induced growth suppression requires a transactivation–independent p53 function. Del Sal G, et al. **Mol Cell Biol** 1995 Dec;15(12):7152–60

Functional interaction between p53, the TATA–binding protein (TBP), andTBP–associated factors in vivo. Farmer G, et al. **Mol Cell Biol** 1996 Aug;16(8):4295–304

Reversal of in vitro p53 squelching by both TFIIB and TFIID. Liu X, et al. **Mol Cell Biol** 1995 Nov;15(11):6474–8

p53 inhibits DNA replication in vitro in a DNA–binding–dependent manner. Miller SD, et al. **Mol Cell Biol** 1995 Dec;15(12):6554–60

Cytoplasmic sequestration of wild–type p53 protein impairs the G1 checkpoint after DNA damage. Moll UM, et al. **Mol Cell Biol** 1996 Mar;16(3):1126–37

The p53–binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Naumovski L, et al. **Mol Cell Biol** 1996 Jul;16(7):3884–92

Wild–type human p53 transactivates the human proliferating cell nuclear antigen promoter. Shivakumar CV, et al. **Mol Cell Biol** 1995 Dec;15(12):6785–93

Wild–type p53 induces diverse effects in 32D cells expressing different oncogenes. Soddu S, et al. **Mol Cell Biol** 1996 Feb;16(2):487–95

Adenovirus E1A proteins inhibit activation of transcription by p53. Steegenga WT, et al. **Mol Cell Biol** 1996 May; 16(5):2101–9

Regulation of transcription functions of the p53 tumor suppressor by the mdm–2 oncogene. Chen J, et al. **Mol Med** 1995 Jan;1(2):142–52

Characterization of the GADD45 response to ionizing radiation in WI–L2–NS cells, a p53 mutant cell line. Carrier F, et al. **Mutat Res** 1996 Jun 10;352(1–2):79–86

Oddball p53 in testicular tumors. Chresta CM, et al. **Nat Med** 1996 Jul;2(7):745–6

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Sigalas I, et al. **Nat Med** 1996 Aug;2(8):912–7

Phosphorylation of p53 at the casein kinase II site selectively regulates p53–dependent transcriptional repression but not transactivation. Hall SR, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1119–26

Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T–antigen. Hendricks–Taylor LR, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4726–33

Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Kunz C, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3710–7

Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory beta–subunit of protein kinase CK2. Appel K, et al. **Oncogene** 1995 Nov 16; 11(10):1971–8

New insights into p53 function from structural studies. Arrowsmith CH, et al. **Oncogene** 1996 Apr 4;12(7):1379–85 (59 ref.)

Neu differentiation factor (Heregulin) activates a p53–dependent pathway in cancer cells. Bacus SS, et al. **Oncogene** 1996 Jun 20;12(12):2535–47

Complex regulation of the DNA–binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Hecker D, et al. **Oncogene** 1996 Mar 7; 12(5):953–61

Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53. Lieter LM, et al. **Oncogene** 1996 Jun 20;12(12):2661–8

Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Lu X, et al. **Oncogene** 1996 Jul 18;13(2):413–8

Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vivo, even after stimulation with the phorbol ester o–tetradecanoylphorbol 13–acetate. Milne DM, et al. **Oncogene** 1996 Jul 4;13(1):205–11

Analysis of the proportion of p53 bound to mdm–2 in cells with defined growth characteristics. Momand J, et al. **Oncogene** 1996 Jun 6;12(11):2279–89

Regulation of specific DNA binding by p53: evidence for a role for O–glycosylation and charged residues at the carboxy–terminus. Shaw P, et al. **Oncogene** 1996 Feb 15; 12(4):921–30

A cellular protein activates the sequence–specific DNA–binding of p53 by interacting with the central conserved region. Srinivasan R, et al. **Oncogene** 1996 Jan 4;12(1):193–200

HPV–18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Thomas M, et al. **Oncogene** 1996 Aug 1; 13(3):471–80

S phase cell–cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway. Wyllie FS, et al. **Oncogene** 1996 Mar 7;12(5):1077–82

p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription. Zhao J, et al. **Oncogene** 1996 Jul 18;13(2):293–302

Immunohistochemical detection of Bcl–2 protein in small cell carcinomas. Yan JJ, et al. **Oncology** 1996 Jan–Feb; 53(1):6–11

Four p53 DNA–binding domain peptides bind natural p53–response elements and bend the DNA. Balagurumoorthy P, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8591–5

Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53–independent G1 arrest and apoptosis. Dou QP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9019–23

Transcriptional activation of the human proliferating–cell nuclear antigen promoter by p53. Morris GF, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):895–9

The C–terminal domain of p53 recognizes DNA damaged by ionizing radiation. Reed M, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9455–9

The ability to associate with activation domains in vitro is not required for the TATA box-binding protein to support activated transcription in vivo. Tansey WP, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10550-4

Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Yap N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4273-7

p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia. Tierney LA, et al. **Radiat Res** 1996 Feb; 145(2):181-7

The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Langendijk JA, et al. **Radiother Oncol** 1995 Sep;36(3):218-24

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Dobner T, et al. **Science** 1996 Jun 7;272(5267):1470-3

Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Nishida T, et al. **Surgery** 1996 May;119(5):568-75

Brief communication, P53 accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors. Crist KA, et al. **Toxicol Pathol** 1996 May-Jun;24(3):370-5

Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Wu CS, et al. **Urology** 1996 Mar;47(3):305-10

p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Sagartz JE, et al. **Vet Pathol** 1996 Mar; 33(2):213-21

The relationship between aneuploidy and p53 overexpression during genesis of colorectal adenocarcinoma [letter; comment] Biesterfeld S, et al. **Virchows Arch** 1995; 427(4):459. Comment on: Virchows Arch 1994;424(4):343-7.

Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Crook T, et al. **Virology** 1996 Mar 1;217(1):285-92

Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Nakagawa S, et al. **Virology** 1995 Oct 1;212(2):535-42

Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Takada S, et al. **Virology** 1996 Feb 1;216(1):80-9

p53 protein overexpression in astrocytic neoplasms. Cho MY, et al. **Yonsei Med J** 1995 Dec;36(6):521-6

[Gastric cancer with P53 overexpression and nm23 low-expression has high potential for lymph node metastasis] Zhang S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):418-21 (Eng. Abstr.) **(Chi)**

[A study of P53 protein expression in fibrous neoplasms] Li J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Feb; 25(1):7-9 (Eng. Abstr.) **(Chi)**

[Protein p53 inhibits the activity of the enhancer of the immediate-early genes of murine cytomegalovirus] Lembo D, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec; 86(1-12):43-54 (Eng. Abstr.) **(Ita)**

[Overexpressed p53 protein and cell-proliferative activity disappear or remarkably decrease in neoplastic CGA-positive endocrine and Paneth cells in cancer or dysplasia of ulcerative colitis] Matsuda K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1922-8 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Insulin-like growth factor binding protein 3 (IGFBP-3): a novel target of the tumor suppressor p53 inhibiting cell growth. Bertherat J. **Eur J Endocrinol** 1996 Apr; 134(4):426-7

Induction of p53-independent apoptosis by hygromycin B: suppression by Bcl-2 and adenovirus E1B 19-kDa protein. Chen G, et al. **Exp Cell Res** 1995 Nov;221(1):55-9

PHYSIOLOGY

p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. DiGiuseppe JA, et al. **Am J Pathol** 1995 Oct;147(4):884-8

The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Goldman SC, et al. **Am J Pathol** 1996 May;148(5):1381-5

DNA lesion-recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan-Feb;16(1):225-42 (187 ref.)

DNA ploidy, P53 expression, and cellular proliferation in normal epithelium and squamous dysplasia of non-cancerous and cancerous human oesophagi. Itakura Y, et al. **Anticancer Res** 1996 Jan-Feb;16(1):201-8

p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines. Mukhopadhyay T, et al. **Anticancer Res** 1996 Jan-Feb;16(1):105-12

GM1492 human diploid skin fibroblasts lack the p53-dependent G1 cell-cycle checkpoint. van Laar T, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):769-76

P53 and angiogenesis. Bouck N. **Biochim Biophys Acta** 1996 May 16;1287(1):63-6

p53 and translational control. Ewen ME, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):181-4 (48 ref.)

p53 in growth control and neoplasia. Gottlieb TM, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2-3):77-102 (357 ref.)

Signalling to p53: where does it all start? Kastan MB. **Bioessays** 1996 Aug;18(8):617-9 (28 ref.)

p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Cereseto A, et al. **Blood** 1996 Sep 1;88(5):1551-60

Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. Ehinger M, et al. **Blood** 1996 Feb 1;87(3):1064-74

Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis pathway in lymphoblastoid cell lines. Kruyt FA, et al. **Blood** 1996 Feb 1;87(3):938-48

p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Linn SC, et al. **Br J Cancer** 1996 Jul;74(1):63-8

p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Rand A, et al. **Cancer Lett** 1996 Jan 2;98(2):183-91

bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. D'Sa-Eipper C, et al. **Cancer Res** 1996 Sep 1; 56(17):3879-82

Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53. Foley J, et al. **Cancer Res** 1996 Sep 1; 56(17):4056-62

p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Huang LC, et al. **Cancer Res** 1996 Jul 1;56(13):2940-4

Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Iwamoto KS, et al. **Cancer Res** 1996 Sep 1;56(17):3862-5

Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Mukhopadhyay D, et al. **Cancer Res** 1995 Dec 15; 55(24):6161-5

Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absent of a p53-dependent cell cycle arrest. Nutt CL, et al. **Cancer Res** 1996 Jun 15;56(12):2748-51

Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Rusch V, et al. **Cancer Res** 1995 Nov 1;55(21):5038-42

p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Shibata MA, et al. **Cancer Res** 1996 Jul 1;56(13):2998-3003

Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Wang XW, et al. **Cancer Res** 1995 Dec 15; 55(24):6012-6

Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Yount GL, et al. **Cancer Res** 1996 Feb 1;56(3):500-6

The relationship between p53 status, DNA repair and chromatid aberration induction in G2 mouse embryo fibroblast cells treated with bleomycin. Donner EM, et al. **Carcinogenesis** 1996 May;17(5):1161-5

Biological and clinical importance of the p53 tumor suppressor gene. Velculescu VE, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):858-68 (169 ref.)

Functions of the p53 protein in growth regulation and tumor suppression. Lin J, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:215-23

Control of p53-dependent apoptosis by E1B, Bcl-2, and Ha-ras proteins. White E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:395-402

Regulation of p53-dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34-58 (103 ref.)

Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. Attardi LD, et al. **EMBO J** 1996 Jul 15;15(14):3693-701

Cell type-specific inhibition of p53-mediated apoptosis by mdm2. Haupt Y, et al. **EMBO J** 1996 Apr 1;15(7):1596-606

Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. Rowan, S, et al. **EMBO J** 1996 Feb 15;15(4):827-38

The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. Wen ST, et al. **EMBO J** 1996 Apr 1;15(7):1583-95

Antisense p53 provokes changes in HeLa cell growth and morphology. Iotsova V, et al. **Eur J Cell Biol** 1995 Oct; 68(2):122-32

From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Vaziri H, et al. **Exp Gerontol** 1996 Jan-Apr;31(1-2):295-301 (42 ref.)

Role of p53 and RB on in vitro growth of normal umbilical cord blood cells. Mahdi T, et al. **Exp Hematol** 1996 May; 24(6):702-12

ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. Desdouets C, et al. **FEBS Lett** 1996 Apr 29;385(1-2):34-8

p53: puzzle and paradigm. Ko LJ, et al. **Genes Dev** 1996 May 1;10(9):1054-72 (245 ref.)

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Linke SP, et al. **Genes Dev** 1996 Apr 15; 10(8):934-47

Mutations in the p53 and SCID genes cooperate in tumorigenesis. Nacht M, et al. **Genes Dev** 1996 Aug 15; 10(16):2055-66

In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Blagosklonny MV, et al. **Int J Cancer** 1996 Jul 29;67(3):386-92

Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma. Sangfelt O, et al. **Int J Cancer** 1996 Jul 3;67(1):106-12

The search for prognostic genetic indicators of cancer recurrence [editorial; comment] Skuse GR. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):509-10. Comment on: Int J Radiat Oncol Biol Phys 1996 Jan 15;34(2):323-32.

X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter. Lee H, et al. **J Biol Chem** 1995 Dec 29;270(52):31405-12

p53 stimulates promoter activity of the sgk. serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. Maiyar AC, et al. **J Biol Chem** 1996 May 24;271(21):12414-22

A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. Russo T, et al. **J Biol Chem** 1995 Dec 8;270(49):29386-91

Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. Takada S, et al. **J Cancer Res Clin Oncol** 1995; 121(9-10):593-601

Retrovirally mediated wild-type p53 restores S-phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53. Runnebaum IB, et al. **J Cell Biochem** 1995 Dec;59(4):537-44

Interference with p53 protein inhibits hematopoietic and muscle differentiation. Soddu S, et al. **J Cell Biol** 1996 Jul; 134(1):193-204

Tumor necrosis factor alpha: posttranscriptional stabilization of WAF1 mRNA in p53-deficient human leukemic cells. Shiohara M, et al. **J Cell Physiol** 1996 Mar;166(3):568-76

Mdm-2 is not induced by p53 in human keratinocytes in vivo. Burden AD, et al. **J Cutan Pathol** 1996 Feb;23(1):25-9

Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? Baxter EW, et al. **J Virol** 1996 Apr; 70(4):2095-100

Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. Marcellus RC, et al. **J Virol** 1996 Sep;70(9):6207-15

In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes. Wiesmüller L, et al. **J Virol** 1996 Feb;70(2):737-44

Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Akagi M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):377-84

p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines. Hirota Y, et al. **Jpn J Cancer Res** 1996 Jul;87(7):735-42

p53 transactivation through various p53-responsive elements. Park DJ, et al. **Mol Carcinog** 1996 Jun;16(2):101-8

p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Eizenberg O, et al. **Mol Cell Biol** 1996 Sep;16(9):5178-85

Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Han Z, et al. **Mol Cell Biol** 1995 Nov;15(11):5849-57

Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Latham KM, et al. **Mol Cell Biol** 1996 Aug;16(8):4445-55

Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Lin Y, et al. **Mol Cell Biol** 1995 Nov;15(11):6045-54

Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Ludwig RL, et al. **Mol Cell Biol** 1996 Sep;16(9):4952-60

Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Woods CM, et al. **Mol Med** 1995 Jul;1(5):506-26

DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879-80 (8 ref.)

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [see comments] Wahl AF, et al. **Nat Med** 1996 Jan;2(1):72-9. Comment in: Nat Med 1996 Jul;2(7):724-5.

p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Wales MM, et al. **Nat Med** 1995 Jun;1(6):570-7

Induction of the growth inhibitor IGF-binding protein 3 by p53. Buckbinder L, et al. **Nature** 1995 Oct 19; 377(6550):646-9

Cell-cycle control and its watchman [news; comment] Jacks T, et al. **Nature** 1996 Jun 20;381(6584):643-4. Comment on: Nature 1996 Jun 20;381(6584):713-6.

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Jones SN, et al. **Nature** 1995 Nov 9; 378(6553):206-8

Rescue of early embryonic lethality in mdm2-deficient mice

by deletion of p53. Montes de Oca Luna R, et al. **Nature** 1995 Nov 9;378(6553):203–6

The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)– and GADD45–mediated response to DNA damage produced by ionising radiation. Artuso M, et al. **Oncogene** 1995 Oct 19;11(8):1427–35

Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Del Sal G, et al. **Oncogene** 1996 Jan 4; 12(1):177–85

Distinct p53–mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA–damaging agents. Huang TS, et al. **Oncogene** 1996 Aug 1;13(3):625–32

Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Hwang ES, et al. **Oncogene** 1996 Feb 15;12(4):795–803

Characterization of the signal transduction pathway mediating gamma ray–induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53. Mirzayans R, et al. **Oncogene** 1995 Oct 19;11(8):1597–605

p53 represses SV40 transcription by preventing formation of transcription complexes. Perrem K, et al. **Oncogene** 1995 Oct 5;11(7):1299–307

p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Roemer K, et al. **Oncogene** 1996 May 16;12(10):2069–79

Interaction of human polyomavirus BK with the tumor–suppressor protein p53. Shivakumar CV, et al. **Oncogene** 1996 Jul 18;13(2):323–32

Induction of Fas–mediated apoptosis in p53–transfected human colon carcinoma cells. Tamura T, et al. **Oncogene** 1995 Nov 16;11(10):1939–46

Selective loss of endogenous p21waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins. Tarunina M, et al. **Oncogene** 1996 Aug 1; 13(3):589–98

Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV–18 E6 through ubiquitin mediated degradation. Thomas M, et al. **Oncogene** 1996 Jul 18;13(2):265–73

Anal carcinoma: a clinical approach to p53 and RB gene proteins. Tanum G, et al. **Oncology** 1996 Sep–Oct; 53(5):369–73

Nitric oxide–induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild–type p53. Forrester K, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2442–7

Mammalian cells resistant to tumor suppressor genes. Pietenpol JA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8390–4

Wild–type and mutant p53 differentially regulate transcription of the insulin–like growth factor I receptor gene. Werner H, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8318–23

p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)

Interaction of human cytomegalovirus with p53: possible role in coronary restenosis. Speir E, et al. **Scand J Infect Dis Suppl** 1995;99:78–81

Abnormal centrosome amplification in the absence of p53. Fukasawa K, et al. **Science** 1996 Mar 22;271(5256):1744–7

p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T–antigen. Staib C, et al. **Virology** 1996 May 1;219(1):237–46

Distinct modulation of p53 activity in transcription and cell–cycle regulation by the large (54 kDa) and small (21 kDa) adenovirus E1B proteins. Steegenga WT, et al. **Virology** 1995 Oct 1;212(2):543–54

[Opposite effect of p53 on nucleotide metabolizing enzyme activity in Rat1 cells and their sublines, transformed by N–RAS or v–mos oncogenes] Khramtsova SN, et al. **Biokhimiia** 1995 Nov;60(11):1881–8 (Eng. Abstr.) **(Rus)**

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

p53 accumulation in the organs of low–dose X–ray–irradiated mice. Wang X, et al. **Cancer Lett** 1996 Jun 24;104(1):79–84

Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Lu X, et al. **Oncogene** 1996 Jul 18;13(2):413–8

Radiation induced G1–block and p53 status in six human cell lines. Zölzer F, et al. **Radiother Oncol** 1995 Oct; 37(1):20–8

THERAPEUTIC USE

Preliminary report: the short–term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Habib NA, et al. **Cancer Detect Prev** 1996;20(2):103–7

Therapy of murine tumors with p53 wild–type and mutant sequence peptide–based vaccines. Mayordomo JI, et al. **J Exp Med** 1996 Apr 1;183(4):1357–65

PROTEIN PHOSPHATASES see **PHOSPHOPROTEIN PHOSPHATASE**

PROTEIN PRECURSORS

see related

ENZYME PRECURSORS

Dominance of conserved B–cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood–stage infections of naive Aotus monkeys. Hui GS, et al. **Infect Immun** 1996 May;64(5):1502–9

ADMINISTRATION & DOSAGE

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Burghaus PA, et al. **Infect Immun** 1996 Sep;64(9):3614–9

Role of intraduodenally administered enterostatin in rats: inhibition of food. Mei J, et al. **Obes Res** 1996 Mar; 4(2):161–5

ANALYSIS

Immunohistochemical localization of keratins and involucrin in solar keratosis and Bowen's disease. Ichikawa E, et al. **Am J Dermatopathol** 1995 Apr;17(2):151–7

Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Masliah E, et al. **Am J Pathol** 1996 Jan;148(1):201–10

Localization of prothymosin alpha in the nucleus. Castro JM, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):140–6

Biology of enterostatin. II. Development of enzyme–linked immunosorbentassay (ELISA) for enterostatin (Val–Pro–Asp–Pro–Arg), the procolipase activation peptide. Mizuma H, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):227–34

Procolipase is produced in the rat stomach--a novel source of enterostatin. Sörhede M, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):207–12

Clinical significance of simultaneous determinations of alpha–fetoprotein and des–gamma–carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Aoyagi Y, et al. **Cancer** 1996 May 1; 77(9):1781–6

Post–meal coagulation activation in diabetes mellitus: the effect of acarbose. Ceriello A, et al. **Diabetologia** 1996 Apr; 39(4):469–73

Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des–gamma–carboxy prothrombin and alpha–fetoprotein: a prospective study. Izuno K, et al. **Hepatogastroenterology** 1995 Jul–Aug; 42(4):387–93

p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Sherman ME, et al. **Hum Pathol** 1995 Nov;26(11):1268–74

Effect of oral water soluble vitamin K on PIVKA–II levels in newborns. Sharma RK, et al. **Indian Pediatr** 1995 Aug; 32(8):863–7

Trichohyalin expression in skin tumors: retrieval of trichohyalin antigenicity in tissues by microwave irradiation. Manabe M, et al. **Int J Dermatol** 1996 May; 35(5):325–9

Proenkephalin is a nuclear protein responsive to growth arrest and differentiation signals. Böttger A, et al. **J Cell Biol** 1995 Sep;130(6):1251–62

Liver cell adenoma in a young man with elevated serum PIVKA–II level. Uto H, et al. **J Gastroenterol** 1996 Jun; 31(3):441–5

Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. Grosley BM, et al. **J Lab Clin Med** 1996 Jun;127(6):553–64

Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Stapleton AM, et al. **Kidney Int** 1996 Mar;49(3):880–8

Normotest and abnormal prothrombin in liver transplantation. Nakao A, et al. **Liver** 1995 Oct;15(5):260–4

Identification of a Brazil–nut allergen in transgenic soybeans [see comments] Nordlee JA, et al. **N Engl J Med** 1996 Mar 14;334(11):688–92. Comment in: N Engl J Med 1996 Mar 14;334(11):726–8.

Identification of specific binding sites for glucagon–like peptide–1 on the posterior lobe of the rat pituitary. Göke R, et al. **Neuroendocrinology** 1995 Aug;62(2):130–4

Immunological identification of a putative precursor of the insoluble glycoprotein framework of the Chlamydomonas cell wall. Voigt J, et al. **Plant Cell Physiol** 1996 Jan; 37(1):91–101

Distribution of thymic hormones in thymic tumors and myasthenic thymus. Wu MH, et al. **Proc Natl Sci Counc Repub China B** 1996 Jan;20(1):1–5

PreproPACAP–derived peptides occur in VIP–producing tumours and co–exist with VIP. Fahrenkrug J, et al. **Regul Pept** 1995 Aug 22;58(3):89–98

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA–II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003–7 (5 ref.) **(Jpn)**

[Clinical significance of the pre–S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265–74 (26 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

S 17162 is a novel selective inhibitor of big ET–1 responses in the rat. Descombes JJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S61–4

Inhibition of big ET–1–induced pressor response by an orally active dual inhibitor of endothelin–converting enzyme and neutral endopeptidase 24.11. Trapani AJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S69–71

BIOSYNTHESIS

Production of hybrid oxytocin/vasopressin precursors and accumulation of oxytocin precursors in the rough endoplasmic reticulum of rat magnocellular neurons. Morris JF, et al. **Adv Exp Med Biol** 1995;395:49–58

Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Fan X, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):457–62

Characterization of human prodynorphin gene transcripts. Geijer T, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):881–8

Cloning and characterization of a cDNA encoding a precursor for human uroguanylin. Miyazato M, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):644–8

Expression of HIV–1 envelope glycoprotein alters cellular calmodulin. Radding W, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):192–7

Specific co–ordinated regulation of PC3 and PC2 gene expression with that of preproinsulin in insulin–producing beta TC3 cells. Schuppin GT, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):259–68

Synthesis and structure determination by NMR of a putative vacuolar targeting peptide and model of a proteinase inhibitor from Nicotiana alata. Nielsen KJ, et al. **Biochemistry** 1996 Jan 16;35(2):369–78

Ubiquitin fusion proteins are overexpressed in colon cancer but not in gastric cancer. Barnard GF, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):147–53

Effects of phosphoramidon on endothelin–1 and big endothelin–1 production in human aortic endothelial cells. Matsumura Y, et al. **Biol Pharm Bull** 1995 Mar;18(3):401–6

Size variations in the mucin–type domain of hamster oviductin: identification of the polypeptide precursors and characterization of their biosynthetic maturation. Malette B, et al. **Biol Reprod** 1995 Dec;53(6):1311–23

The effects of D1 or D2 dopamine receptor blockade on zif/268 and preprodynorphin gene expression in rat forebrain following a short–term cocaine binge. Daunais JB, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):237–48

Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. Harrington KA, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):333–42

Expression of the proenkephalin A gene in organotypic cultures of neocortex from newborn rats. Just L, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):157–63

Effect of adrenal steroids on preproneurokinin–A gene expression in discrete regions of the rat brain. Pompei P, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):209–16

Anesthesia during hormone administration abolishes the estrogen induction of preproenkephalin mRNA in ventromedial hypothalamus of female rats. Quiñones–Jenab V, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):297–303

Dopaminergic regulation of striatonigral tachykinin and dynorphin gene expression: a study with the dopamine uptake inhibitor GBR–12909. Sivam SP. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):197–210

Prenatal morphine exposure differentially alters expression of opioid peptides in striatum of newborns. Tempel A, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):227–32

Cells expressing preproenkephalin mRNA in the rat pineal gland are not serotonin–producing pinealocytes: evidence using in situ hybridization combined with immunocytochemistry for serotonin. Wang XT, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):73–84

Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Hoyt EC, et al. **Diabetes** 1996 Apr;45(4):434–9

Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Ulshen MH, et al. **Dig Dis Sci** 1996 Apr;41(4):677–83

The expression and characterization of human recombinant proinsulin–like growth factor II and a mutant that is defective in the O–glycosylation of its E domain. Yang CQ, et al. **Endocrinology** 1996 Jul;137(7):2766–73

Regulation of prothymosin alpha during the cell cycle. Vareli K, et al. **Eur J Biochem** 1996 Jun 15;238(3):799–806

Human colon produces fully processed glucagon–like peptide–1 (7–36) amide. Deacon CF, et al. **FEBS Lett** 1995 Sep 25;372(2–3):269–72

Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin–like proprotein convertases. Rouillé Y, et al. **Front Neuroendocrinol** 1995 Oct;16(4):322–61 (202 ref.)

Molecular cloning of three distinct cDNAs, each encoding a different adipokinetic hormone precursor, of the migratory locust, Locusta migratoria. Differential expression of the distinct adipokinetic hormone precursor genes during flight activity. Bogerd J, et al.

J Biol Chem 1995 Sep 29;270(39):23038–43

DNA structure determines protein binding and transcriptional efficiency of the proenkephalin cAMP-responsive enhancer. Spiro C, et al. **J Biol Chem** 1995 Nov 17;270(46):27702–10

Phorbol ester regulation of opioid peptide gene expression in myocardial cells. Role of nuclear protein kinase. Ventura C, et al. **J Biol Chem** 1995 Dec 15;270(50):30115–20

Regulation of human involucrin promoter activity by POU domain proteins. Welter JF, et al. **J Biol Chem** 1996 Jun 21;271(25):14727–33

Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. Rauly I, et al. **J Clin Invest** 1996 Apr 15;97(8):1874–83

The expression of proenkephalin and prodynorphin genes and the induction of c-fos gene by dopaminergic drugs are not altered in the straitum of MPTP-treated mice. Ziolkowska B, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):151–64

Biosynthetic processing of preprovasoactive intestinal polypeptide in parasympathetic neurons of the sphenopalatine ganglion. Nilsson C, et al. **J Neurochem** 1995 Dec;65(6):2663–70

Changes in pro-opiomelanocortin and pre-proenkephalin mRNA levels in the ovine brain during pregnancy, parturition and lactation and in response to oestrogen and progesterone. Broad KD, et al. **J Neuroendocrinol** 1993 Dec;5(6):711–9

Molecular cloning of cDNA for equine ovarian inhibin/activin beta A subunit. Yoshida S, et al. **J Vet Med Sci** 1995 Jun;57(3):469–73

Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1. Duensing TD, et al. **J Virol** 1995 Nov;69(11):7122–31

Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Mol PC, et al. **Mol Cell Biol** 1995 Dec;15(12):6999–7009

Rapid but transient increases in cholecystokinin mRNA levels in cerebral cortex following amygdaloid-kindled seizures in the rat. Burazin TC, et al. **Neurosci Lett** 1996 May 3; 209(1):65–8

Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Herrero MT, et al. **Neuroscience** 1995 Oct;68(4):1189–98

A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Wang JQ, et al. **Neuroscience** 1995 Sep; 68(1):83–95

Inhibition of p105 processing by NF-kappaB proteins in transiently transfected cells. Harhaj EW, et al. **Oncogene** 1996 Jun 6;12(11):2385–92

An abundantly expressed mucin-like protein from Toxocara canis infective larvae: the precursor of the larval surface coat glycoproteins. Gems D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1665–70

293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein. Langer SJ, et al. **Virology** 1996 Jul 1;221(1):172–9

BLOOD

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Fukase N, et al. **Acta Diabetol** 1995 Oct;32(3):165–9

Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Davidson NC, et al. **Am J Cardiol** 1996 Apr 15;77(10):828–31

Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Dickstein K, et al. **Am J Cardiol** 1995 Oct 1;76(10):679–83

Congestive heart failure and atrial natriuretic factor: a room for endothelins? [letter] Tuzcu V, et al. **Am J Cardiol** 1996 Jul 1;78(1):128–9

Pneumonitis-associated hyperprocalcitoninemia. Nylén ES, et al. **Am J Med Sci** 1996 Jul;312(1):12–8

Simple, sensitive microplate IRMAs for intact and des-31,32-proinsulin compared with HPLC and cellulose IRMAs. Mohamed-Ali V, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):977–9

Quantitation of procholecystokinin and its products in plasma by processing-independent analysis. Paloheimo LI, et al. **Clin Chim Acta** 1995 Jun 30;238(1):21–33.

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Toft-Nielson M, et al. **Diabetes** 1996 May;45(5):552–6

Hyperinsulinemia in nondiabetic Asian subjects using specific assays for insulin, intact proinsulin, and des-31, 32-proinsulin. Nagi DK, et al. **Diabetes Care** 1996 Jan; 19(1):39–42

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Göke B, et al. **Digestion** 1995;56(6):493–501

Evidence for the presence of an inactive precursor of human hepatocyte growth factor in plasma and sera of patients with liver diseases. Arakaki N, et al. **Hepatology** 1995 Dec; 22(6):1728–34

High serum procalcitonin level in a 4-year-old liver transplant recipient with a disseminated candidiasis [letter] Gérard Y, et al. **Infection** 1995 Sep-Oct;23(5):310–1

Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. Hall C, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1452–6

Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. Pacher R, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):633–41

Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans. Plumpton C, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S34–6

Quantification of inhibin pro-alpha C-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. Groome NP, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2926–32

Extragonadal alpha-inhibin precursor proteins circulate in human male serum. Lambert-Messerlian GM, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3043–9

Atrial natriuretic factor and digoxin-like immunoreactive factor in diabetic patients: their interrelation and the influence of the autonomic nervous system. Straub RH, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3385–9

Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. Azizi C, et al. **J Endocrinol** 1996 Jan; 148(1):51–7

Big endothelin in patients with complicated Plasmodium falciparum malaria. Wenisch C, et al. **J Infect Dis** 1996 May;173(5):1281–4

Procalcitonin as a marker for the early diagnosis of neonatal infection. Gendrel D, et al. **J Pediatr** 1996 Apr;128(4):570–3

Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype. Båvenholm P, et al. **Metabolism** 1995 Nov;44(11):1481–8

Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Kamata K, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1267–70

Proatrial natriuretic polypeptide (31–67) in healthy individuals: day-to-day variation and influence of sex and age. Hansen JB, et al. **Scand J Clin Lab Invest** 1995 Aug; 55(5):447–52

[Mechanism of hyperinsulinemia in gastrectomized patients with oxyhyperglycemia: preliminary report] Yoshikawa T, et al. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):587 **(Jpn)**

CHEMICAL SYNTHESIS

New cyclic bradykinin antagonists containing disulfide and lactam bridges at the N-terminal sequence. Seyfarth L, et al. **Int J Pept Protein Res** 1995 Aug;46(2):155–65

CHEMISTRY

The protoxin composition of Bacillus thuringiensis insecticidal inclusions affects solubility and toxicity. Aronson A. **Appl Environ Microbiol** 1995 Nov; 61(11):4057–60

Thermodynamic role of the pro region of the neurophysin precursor in neurophysin folding: evidence from the effects of ligand peptides on folding. Deeb R, et al. **Biochemistry** 1996 Jan 23;35(3):864–73

Prothymosin alpha: a biologically active protein with random coil conformation. Gast K, et al. **Biochemistry** 1995 Oct 10;34(40):13211–8

Functional characterization of the precursor and spliced forms of RecA protein of Mycobacterium tuberculosis. Kumar RA, et al. **Biochemistry** 1996 Feb 13;35(6):1793–802

Human pro-tumor necrosis factor is a homotrimer. Tang P, et al. **Biochemistry** 1996 Jun 25;35(25):8216–25

Conformation of the propeptide domain of factor IX. Cheng JW, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):227–31

Molecular biology of neurohormone precursors in the eyestalk of Crustacea. De Kleijn DP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):573–9 (32 ref.)

Comparison of the allatostatin neuropeptide precursors in the distantly related cockroaches Periplaneta americana and Diploptera punctata. Ding Q, et al. **Eur J Biochem** 1995 Dec 15;234(3):737–46

Solid-state 13C-NMR of [(3–13C)Pro]bacteriorhodopsin and [(4–13C)Pro]bacteriorhodopsin: evidence for a flexible segment of the C-terminal tail. Engelhard M, et al. **Eur J Biochem** 1996 Feb 1;235(3):526–33

Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor. Kise H, et al. **Eur J Biochem** 1996 May 15; 238(1):88–96

Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Malm J, et al. **Eur J Biochem** 1996 May 15;238(1):48–53

Purification and structural characterization of bovine cathelicidins, precursors of antimicrobial peptides. Storici P, et al. **Eur J Biochem** 1996 Jun 15;238(3):769–76

Modification of the targeting presequence of the bovine cytochrome P-450scc precursor lifting tissue-specific restrictions on its mitochondrial import. Novikova LA, et al. **FEBS Lett** 1996 Jan 8;378(2):182–4

Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions. Papandreou MJ, et al. **FEBS Lett** 1996 Jan 29;379(2):171–6

Isolation and structural characterization of proglucagon-derived peptides, pancreatic polypeptide, and somatostatin from the urodele Amphiuma tridactylum. Cavanaugh ES, et al. **Gen Comp Endocrinol** 1996 Jan; 101(1):12–20

Receptor-binding properties of the peptides corresponding to the ACTH-like sequence of human pro-interleukin-1 alpha. Zav'yalov VP, et al. **Immunol Lett** 1995 May; 46(1–2):125–8

Yeast proteins related to the p40/laminin receptor precursor are essential components of the 40 S ribosomal subunit. Demianova M, et al. **J Biol Chem** 1996 May 10; 271(19):11383–91

The human urinary epidermal growth factor (EGF) precursor. Isolation of a biologically active 160-kilodalton heparin-binding pro-EGF with a truncated carboxyl terminus. Parries G, et al. **J Biol Chem** 1995 Nov 17; 270(46):27954–60

Purification, sequence analysis, and cellular localization of a prodynorphin-derived peptide related to the alpha-neo-endorphin in the rhynchobdellid leech Theromyzon tessulatum. Salzet M, et al. **J Biol Chem** 1996 May 31;271(22):13191–6

Expression of lysyl oxidase from cDNA constructs in mammalian cells: the propeptide region is not essential to the folding and secretion of the functional enzyme. Kagan HM, et al. **J Cell Biochem** 1995 Nov;59(3):329–38

The specificity of glycolipid-preferredoxin interaction: requirements for membrane binding. Demel RA, et al. **Mol Membr Biol** 1995 Jul-Sep;12(3):255–61

Identification of a gene, pilV, required for type 4 fimbrial biogenesis in Pseudomonas aeruginosa, whose product possesses a pre-pilin-like leader sequence. Alm RA, et al. **Mol Microbiol** 1995 May;16(3):485–96

Pro-sequence-assisted protein folding. Eder J, et al. **Mol Microbiol** 1995 May;16(4):609–14 (59 ref.)

Identification by in vitro complementation of regions required for cell-invasive activity of Bordetella pertussis adenylate cyclase toxin. Iwaki M, et al. **Mol Microbiol** 1995 Sep;17(6):1015–24

Efficient transfection of DNA by mixing cells in suspension with calcium phosphate. Song W, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3609–11

Fluorescence polarization assay for endothelin-converting enzymes. Hazan S, et al. **Peptides** 1995;16(5):833–6

Two alternative processing pathways for a preprohormone: a bioactive form of secretin. Bonetto V, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11985–9

Homology modeling and molecular dynamics simulation of human prothrombin fragment 1. Li L, et al. **Protein Sci** 1995 Nov;4(11):2341–8

Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Rudenko G, et al. **Structure** 1995 Nov 15;3(11):1249–59

Do we know the complete sequence of metalloproteinase and nonenzymatic platelet aggregation inhibitor (disintegrin) precursor proteins? Kini RM. **Toxicon** 1995 Sep;33(9):1151–60

[Structural similarity of regions of activation cleavage of protein-precursors by reactive centers of serpins] Verevka SV. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):24–8 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. Wataya-Kaneda M, et al. **J Dermatol Sci** 1996 Mar;11(3):183–8

DEFICIENCY

Characterization of ES cells deficient for the p105 precursor (NF-kappa B1): role of p50 NLS. Ishikawa H, et al. **Oncogene** 1996 Jul 18;13(2):255–63

DIAGNOSTIC USE

Overproduction, purification, and diagnostic use of the recombinant HIV-1 Gag proteins, the precursor protein p55 and the processed products p17, p24, and p15. Saito A, et al. **Microbiol Immunol** 1995;39(7):473–83

DRUG EFFECTS

Effects of ethanol on hepatitis B virus Pre-S/S gene expression in the human hepatocellular carcinoma derived HEP G2 hepatitis B DNA positive cell line. Ganne-Carrié N, et al. **J Hepatol** 1995 Aug;23(2):153–9

Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1–38) and diaspirin cross-linked hemoglobin in rats. Gulati A, et al. **J Lab Clin Med** 1995 Dec;126(6):559–70

[The molecular mechanisms of the action of the radioprotector indometafen. The biosynthetic and bioenergetic aspects] Chernov GA, et al. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):282–91 (Eng. Abstr.) **(Rus)**

GENETICS

Safety and immunogenicity of a recombinant HIV type 1

glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. Salmon-Céron D, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1479-86

An amino acid substitution in the pyruvate dehydrogenase E1 alpha gene, affecting mitochondrial import of the precursor protein. Takakubo F, et al. **Am J Hum Genet** 1995 Oct;57(4):772-80

The involucrin gene and hominoid relationships. Green H, et al. **Am J Phys Anthropol** 1995 Oct;98(2):213-6; discussion 228-32

Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393-408 (203 ref.)

Hypothalamic NPY and prepro-NPY mRNA in Djungarian hamsters: effects of food deprivation and photoperiod. Mercer JG, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1099-106

Substance P content and preprotachykinin gene-I mRNA expression in a rat model of chronic bronchitis. Killingsworth CR, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):334-40

Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients [see comments] Richfield EK, et al. **Ann Neurol** 1995 Dec; 38(6):852-61. Comment in: Ann Neurol 1995 Dec;38(6):835-6.

Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Xia Y, et al. **Ann Neurol** 1996 Aug;40(2):207-15

Repression of involucrin gene expression by transcriptional enhancer factor 1 (TEF-1). Takahashi H, et al. **Arch Dermatol Res** 1995;287(8):740-6

Expression and characterization of the multiplied, recombinant preS1 antigen of hepatitis B virus. Sidorkiewicz M, et al. **Arch Virol** 1995;140(11):1935-44

Characterization of human prodynorphin gene transcripts. Geijer T, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):881-8

Molecular cloning and expression of mouse procalcitonin. Rehli M, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):420-5

Functional analysis of the preproendothelin-1 gene promoter in pulmonary epithelial cells and monocytes. Sun G, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):647-52

Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types. Howard L, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):45-50

Cloning and expression of a cDNA encoding a mouse brain orphanin FQ/nociceptin precursor. Pan YX, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):11-3

Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis. Porter CD, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):571-5

The cDNA for the ubiquitin-52-amino-acid fusion protein from rat encodes a previously unidentified 60 S ribosomal subunit protein. Redman KL, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):315-21

A new human guanylate cyclase-activating peptide (GCAP-II, uroguanylin): precursor cDNA and colonic expression. Hill O, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):146-9

Cloning of cDNA for rat eosinophil major basic protein. Nittoh T, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):261-4

Molecular cloning of cDNAs encoding precursors of frog skin antimicrobial peptides from Rana rugosa. Park JM, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):23-5

Isolation of a murine glucose-dependent insulinotropic polypeptide (GIP) cDNA from a tumor cell line (STC6-14) and quantification of glucose-induced increases in GIP mRNA. Schieldrop PJ, et al. **Biochim Biophys Acta** 1996 Aug 14;1308(2):111-3

Expression of SQ10 (a preprorelaxin-like gene) in the pregnant rabbit placenta and uterus. Fields P, et al. **Biol Reprod** 1995 Nov;53(5):1139-45

Determination of the prorelaxin nucleotide sequence and expression of prorelaxin messenger ribonucleic acid in the golden hamster. McCaslin RB, et al. **Biol Reprod** 1995 Aug; 53(2):454-61

The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatin mRNA in dorsal root ganglion cells--a study using non-radioactive in situ hybridization. Hanesch U, et al. **Brain Res** 1995 Nov 27;700(1-2):279-84

Evidence for the involvement of 5-lipoxygenase products in the regulation of the expression of the proenkephalin gene in cultured astroglial cells. Mamot C, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):79-86

Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Zagon IS, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):111-20

Fos is not involved in the regulation of the proenkephalin gene by haloperidol in the mouse striatum. Ziółkowska B, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):351-4

Transcriptional control of neuropeptide gene expression in sensory neurons, using the preprotachykinin-A gene as a model. Quinn JP, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):957-62 (59 ref.)

Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Wingren AG, et al. **Cell Immunol** 1996 May 1;169(2):226-37

In vitro characterization of an estrogen-regulated mRNA stabilizing activity in the avian liver. Ratnasabapathy R. **Cell Mol Biol Res** 1995;41(6):583-94

High expression of HBV S gene in Bombyx mori cell culture and in silkworms. Zhou N, et al. **Chin J Biotechnol** 1995; 11(3):149-56

Expressions of preproenkephalin mRNA during electroacupuncture analgesia enhanced by fenfluramine. Li XY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):431-4

Assignment of the human prosaposin gene (PSAP) to 10q22.1 by fluorescence in situ hybridization. Giraffidae, okapi (Okapiajohnstoni), and giraffe (Giraffa camelopardalis): evidence for ancestral telomeres at the okapi polymorphic rob (4;26) fusion site. Bar-Am I, et al. **Cytogenet Cell Genet** 1996;72(4):316-8

Localization of IGF1R and EDN genes to pig chromosomes 1 and 7 by in situ hybridization. Lahbib-Mansais Y, et al. **Cytogenet Cell Genet** 1995;71(3):225-7

Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development. Quantin B, et al. **Dev Dyn** 1995 Dec; 204(4):383-90

Differential coexpression of genes encoding prothyrotropin-releasing hormone (pro-TRH) and prohormone convertases (PC1 and PC2) in rat brain neurons: implications for differential processing of pro-TRH. Pu LP, et al. **Endocrinology** 1996 Apr; 137(4):1233-41

Glucocorticoid stimulation of pro-ANF mRNA expression of adult rat hypothalamic neurons in culture: a cAMP-dependent effect. Wang G, et al. **Endocrinology** 1996 Jan;137(1):379-82

Mouse preproendothelin-1 gene. cDNA cloning, sequence analysis and determination of sites of expression during embryonic development. Chan TS, et al. **Eur J Biochem** 1995 Dec 15;234(3):819-26

Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP. Haaning J, et al. **Eur J Biochem** 1996 Apr 1;237(1):159-63

Transient expression of a mitochondrial precursor protein. A new approach to study mitochondrial protein import in cells of higher eukaryotes. Huckriede A, et al. **Eur J Biochem** 1996 Apr 1;237(1):288-94

Expression of endothelin precursor genes in human trophoblast in culture. Robert B, et al. **Eur J Endocrinol** 1996 Apr;134(4):490-6

Plasmodium vivax: favored gene frequencies of the merozoite surface protein-1 and the multiplicity of infection in a malaria endemic region. Kolakovich KA, et al. **Exp Parasitol** 1996 Jun;83(1):11-9

Prothymosin alpha mRNA levels vary with c-myc expression during tissue proliferation, viral infection and heat shock. Vareli K, et al. **FEBS Lett** 1995 Sep 11;371(3):337-40

Legumin encoding sequences from the redwood family (Taxodiaceae) reveal precursors lacking the conserved Asn-Gly processing site. Wind C, et al. **FEBS Lett** 1996 Mar 25;383(1-2):46-50

Cloning and sequence of the Bordetella bronchiseptica adenylate cyclase-hemolysin-encoding gene: comparison with the Bordetella pertussis gene. Betsou F, et al. **Gene** 1995 Aug 30;162(1):165-6

Various transcripts are generated from the VCSA1 gene by alternative splicing and poly(A) processing in the rat submandibular gland. Courty Y, et al. **Gene** 1995 Sep 11; 162(2):291-6

Neuropeptide gene transfer into neuronal and glial cell lines. Castro MG, et al. **Gene Ther** 1994;1 Suppl 1:S15-8

Corticotrophin-releasing hormone, proenkephalin A and oxytocin mRNA's in the paraventricular nucleus during pregnancy and parturition in the rat. Douglas AJ, et al. **Gene Ther** 1994;1 Suppl 1:S85

Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human amyloid precursor protein gene. Duff K, et al. **Gene Ther** 1994 Jan;1(1):70-5

Investigation of neuropeptide gene transcription in sensory neurons transfected by microinjection of reporter plasmids. Mulderry PK, et al. **Gene Ther** 1994;1 Suppl 1:S22-3

Expression of human amyloid precursor proteins in cultured neuronal cells through the use of HSV-1 defective vectors. Wyborski RJ, et al. **Gene Ther** 1994;1 Suppl 1:S83

Expression of genes encoding the pre-TCR and CD3 complex during thymus development. Wilson A, et al. **Int Immunol** 1995 Oct;7(10):1659-64

Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. Grilli M, et al. **J Biol Chem** 1995 Nov 10; 270(45):26774-7

Transcriptional analysis of the 5'-noncoding region of the human involucrin gene. Lopez-Bayghen E, et al. **J Biol Chem** 1996 Jan 5;271(1):512-20

Extensive alternative splicing within the amino-propeptide coding domain of alpha2(XI) procollagen mRNAs. Expression of transcripts encoding truncated pro-alpha chains. Lui VCH, et al. **J Biol Chem** 1996 Jul 12; 271(28):16945-51

Estrogen induces the assembly of a multiprotein messenger ribonucleoprotein complex on the 3'-untranslated region of chicken apolipoprotein II mRNA. Margot JB, et al. **J Biol Chem** 1996 Feb 23;271(8):4452-60

DNA structure determines protein binding and transcriptional efficiency of the proenkephalin cAMP-responsive enhancer. Spiro C, et al. **J Biol Chem** 1995 Nov 17;270(46):27702-10

Blood pressure-independent inhibition by lacidipine of endothelin-1-related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats. Feron O, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S459-61

Autocrine regulation of the endothelin-1 gene in rat endothelial cells. Saito S, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S84-7

Envoplakin, a novel precursor of the cornified envelope that has homology to desmoplakin. Ruhrberg C, et al. **J Cell Biol** 1996 Aug;134(3):715-29

A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. Rutishauser J, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):192-8

Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes. Prange R, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2131-40

Unusual activation of the integrated preS1 promoter of woodchuck hepatitis virus in a liver tumour. Wei Y, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):177-82

Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. Craig AA, et al. **J Infect Dis** 1996 Aug;174(2):373-9

Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. Mischke D, et al. **J Invest Dermatol** 1996 May;106(5):989-92

Two differing precursor genes for the salmon-type gonadotropin-releasing hormone exist in salmonids. Ashihara M, et al. **J Mol Endocrinol** 1995 Aug;15(1):1-9

Induction of proenkephalin gene expression in cultured bovine chromaffin cells is dependent on protein synthesis of AP-1 proteins. Bacher B, et al. **J Neurochem** 1996 Jun; 66(6):2264-71

Differential melanin-concentrating hormone gene expression in two hypothalamic nuclei of the teleost tilapia in response to environmental changes. Gröneveld D, et al. **J Neuroendocrinol** 1995 Jul;7(7):527-33

Effect of lactation on hypothalamic preproenkephalin gene expression. Ottinger MA, et al. **J Neuroendocrinol** 1995 May;7(5):341-6

Inducible preprotachykinin mRNA expression in mucosal lymphoid organs following oral immunization with Salmonella. Bost KL. **J Neuroimmunol** 1995 Oct; 62(1):59-67

Molecular characterization of immune derived proenkephalin mRNA and the involvement of the adrenergic system in its expression in rat lymphoid cells. Ovadia H, et al. **J Neuroimmunol** 1996 Aug;68(1-2):77-83

Long-term stimulation of nicotinic receptors is required to increase proenkephalin A mRNA levels and the delayed secretion of [Met5]-enkephalin in bovine adrenal medullary chromaffin cells. Suh HW, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1663-70

NisP is related to nisin precursor processing and possibly to immunity in Lactococcus lactis. Ye SY, et al. **J Tongji Med Univ** 1995;15(4):193-7

Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. Porter DC, et al. **J Virol** 1996 Apr;70(4):2643-9

The 5' noncoding region of the mouse involucrin gene: comparison with the human gene and genes encoding other cornified envelope precursors. Gandarillas A, et al. **Mamm Genome** 1995 Sep;6(9):680-2

Characterization of nontoxic-nonhemagglutinin component of the two types of progenitor toxin (M and L) produced by Clostridium botulinum type D CB-16. Ohyama T, et al. **Microbiol Immunol** 1995;39(7):457-65

Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Kang Y, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):103-10

The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species. Longacre S. **Mol Biochem Parasitol** 1995 Oct;74(1):105-11

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):241-4

Episodic evolution and rapid divergence of members of the rat multigene family encoding the salivary prohormone-like protein SMR1. Courty Y, et al. **Mol Biol Evol** 1996 Jul;13(6):758-66

Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3. Jin T, et al. **Mol Cell Biol** 1996 Jan; 16(1):19-28

Do products of the myc proto-oncogene play a role in

transcriptional regulation of the prothymosin alpha gene? Mol PC, et al. **Mol Cell Biol** 1995 Dec;15(12):6999–7009

The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. Jin T, et al. **Mol Endocrinol** 1995 Oct;9(10):1306–20

Developmental regulation of proenkephalin gene expression in osteoblasts. Rosen H, et al. **Mol Endocrinol** 1995 Nov; 9(11):1621–31

Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery. Zeng BY, et al. **Mov Disord** 1996 Jan; 11(1):43–52

A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease. Chen HH, et al. **Nat Med** 1995 Sep;1(9):927–31

Diminution of preprosomatostatin-mRNA in cerebral cortex of the aged rat. Nilsson L, et al. **Neurochem Int** 1995 Dec; 27(6):481–7

DNA binding of hypothalamic nuclear proteins on estrogen response element and preproenkephalin promoter: modification by estrogen. Zhu YS, et al. **Neuroendocrinology** 1995 Nov;62(5):454–66

Rat meningeal fibroblasts in primary culture express the proenkephalin gene. Hildebrand B, et al. **Neuropeptides** 1995 Aug;29(2):89–95

Mutant vasopressin precursors in the human hypothalamus: evidence for neuronal somatic mutations in man. Evans DA, et al. **Neuroscience** 1996 Apr;71(4):1025–30

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Nisbet AP, et al. **Neuroscience** 1995 May;66(2):361–76

Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37LRP/p40 at chromosome 3p21.3. Jackers P, et al. **Oncogene** 1996 Aug 1;13(3):495–503

Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro. Luber B, et al. **Oncogene** 1996 Apr 18;12(8):1597–608

Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Lutz W, et al. **Oncogene** 1996 Aug 15;13(4):803–12

Functional analysis of a recently originating, atypical presequence: mitochondrial import and processing of GUS fusion proteins in transgenic tobacco and yeast. Huang J, et al. **Plant Mol Biol** 1995 Nov;29(3):519–33

Carboxyl-terminal processing protease for the D1 precursor protein: cloning and sequencing of the spinach cDNA. Inagaki N, et al. **Plant Mol Biol** 1996 Jan;30(1):39–50

Molecular characterization of an adenylate cyclase gene of the cyanobacterium Spirulina platensis. Yashiro K, et al. **Plant Mol Biol** 1996 Apr;31(1):175–81

[Leu5]enkephalin-encoding sequences are targets for a specific DNA-binding factor. Bakalkin G, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9024–8

Molecular cloning of a preprohormone from sea anemones containing numerous copies of a metamorphosis-inducing neuropeptide: a likely role for dipeptidyl aminopeptidase in neuropeptide precursor processing. Leviev I, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11647–51

Molecular characterization of PsbW, a nuclear-encoded component of the photosystem II reaction center complex in spinach. Lorković ZJ, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8930–4

Cationic lipid-mediated delivery and expression of prepro-neuropeptide Y cDNA after intraventricular administration in rat: feasibility and limitations. Thorsell A, et al. **Regul Pept** 1996 Mar 22;61(3):205–11

Wallaby serum amyloid A protein: cDNA cloning, sequence and evolutionary analysis. Uhlar CM, et al. **Scand J Immunol** 1996 Mar;43(3):271–6

Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Shi CH, et al. **Vaccine** 1995 Jul;13(10):933–7

A C-terminal PreS1 sequence is sufficient to retain hepatitis B virus L protein in 293 cells. Gallina A, et al. **Virology** 1995 Oct 20;213(1):57–69

[Enhancing immunogenicity of pres antigen of hepatitis B virus by fusing genetically it with interleukin-2] Chen Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):34–7 (Eng. Abstr.) **(Chi)**

[Expression and localization of immediate early genes and preproenkephalin gene in central nervous system following electroacupuncture stimulation] Cui X. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):230–2 (Eng. Abstr.) **(Chi)**

[Association of precore mutant HBV with HBe-seroconversion] Daikoku M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:201–4 **(Jpn)**

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

[Analysis of the pre-core/core status of healthy subject with eAb-positive HBV infection] Gotoh K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:406–10 **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

[Nucleotide mutations in the precore and core region of hepatitis B virus] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:52–7 (20 ref.) **(Jpn)**

[Genotypic changes in the precore region of HBV-DNA in chronic hepatitis B patients who seroconverted from HBe Ag to anti-HBe after interferon treatment] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:195–200 **(Jpn)**

[Mutation of the hepatitis B virus pre C region in hepatocellular carcinoma and nontumoral liver tissues] Matsushima S, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:723–9 **(Jpn)**

[Detection of HBV precore mutation by PCR-RFLP] Niitsuma H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:316–20 (7 ref.) **(Jpn)**

[Mutant of the pre-S and S region of HBV] Nishikawa M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:47–51 (15 ref.) **(Jpn)**

[Disorders of sphingolipid activator proteins] Suzuki Y. **Nippon Rinsho** 1995 Dec;53(12):3025–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**

[Clinical significance of hepatitis B virus precore/core mutants in HBe-antigen-positive and anti-HBe-positive chronic hepatitis B] Tsubota A. **Nippon Rinsho** 1995 Oct; 53 Suppl:560–4 **(Jpn)**

[Possible roles of pre-S2 peptide in generation of chronic hepatitis B] Yamauchi K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:144–7 (11 ref.) **(Jpn)**

[New intronless members of human prothymosin alpha genes] Rubtsov IuP, et al. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1320–5 **(Rus)**

IMMUNOLOGY

Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. Rovinski B, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1187–95

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. Salmon-Céron D, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1479–86

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. al-Yaman F, et al. **Am J Trop Med Hyg** 1996 May;54(5):443–8

Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Shiver JW, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:198–208

DNA inoculation induces cross clade anti-HIV-1 responses. Wang B, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:186–97

HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual. Achour A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):395–400

Production in rabbits of high levels of anti-HIV-1 gp160 antibodies. Relyveld E, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):389–93

Prohevein from the rubber tree (Hevea brasiliensis) is a major latex allergen. Alenius H, et al. **Clin Exp Allergy** 1995 Jul; 25(7):659–65

The HIV glycoprotein gp 160 has superantigen-like properties. Akolkar PN, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):255–65

Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. Bckström M, et al. **Gene** 1995 Nov 20;165(2):163–71

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Daly TM, et al. **Infect Immun** 1996 Jul;64(7):2602–8

Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. De Souza JB, et al. **Infect Immun** 1996 Sep;64(9):3532–6

Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Shi YP, et al. **Infect Immun** 1996 Jul; 64(7):2716–23

Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. Su S, et al. **Infect Immun** 1996 Jan;64(1):326–31

Fine mapping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus. Meisel H, et al. **Intervirology** 1994; 37(6):330–9

Influence of N-linked glycans in V4–V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. Bolmstedt A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):213–20

High levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid as compared to serum from patients with AIDS dementia complex. Trujillo JR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):19–25

Hepatitis B virus vaccination for older adults. Bennett RG, et al. **J Am Geriatr Soc** 1996 Jun;44(6):699–703

The main IgE-binding epitope of a major latex allergen, prohevein, is present in its N-terminal 43-amino acid fragment, hevein. Alenius H, et al. **J Immunol** 1996 Feb 15;156(4):1618–25

Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. Tian JH, et al. **J Immunol** 1996 Aug 1; 157(3):1176–83

Specific detection of the precursor of ras p21 with a mouse monoclonal anti-C-terminal peptide antibody, SARA-K1. Ishihara H, et al. **J Immunol Methods** 1995 Sep 25; 185(2):217–23

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765–9

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Mascola JR, et al. **J Infect Dis** 1996 Feb;173(2):340–8

Antibodies against the amino-terminal portion of pro-enkephalin inhibit DNA synthesis in human peripheral mononuclear cells. Padrós MR, et al. **J Neuroimmunol** 1995 Aug;61(1):79–83

Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults. Katkov WN, et al. **J Viral Hepat** 1994; 1(1):79–83

Trial results thwart HIV-vaccine hopes [news] McCarthy M. **Lancet** 1996 Apr 27;347(9009):1173

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Terrientes ZI, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:55–61

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):241–4

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Kumar S, et al. **Mol Med** 1995 Mar; 1(3):325–32

Allergies to transgenic foods—questions of policy [editorial; comment] Nestle M. **N Engl J Med** 1996 Mar 14; 334(11):726–8. Comment on: N Engl J Med 1996 Mar 14;334(11):688–92.

Generation and characterization of an antiserum reactive with a proteolytic processing site within rat procorticotrophin-releasing hormone. Castro MG, et al. **Neuropeptides** 1995 Oct;29(4):183–92

The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite. Ling IT, et al. **Parasite Immunol** 1995 Aug;17(8):425–33

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network. Gorse GJ, et al. **Vaccine** 1995 Sep; 13(13):1170–9

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Schirmbeck R, et al. **Vaccine** 1995 Jun;13(9):857–65

N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Sjölander S, et al. **Virology** 1996 Jan 15;215(2):124–33

Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Yim TJ, et al. **Virology** 1996 Apr 1;218(1):61–70

Characterization of a murine-human chimeric antibody with specificity for the pre-S2 surface antigen of hepatitis B virus expressed in baculovirus-infected insect cells. Jin BR, et al. **Virus Res** 1995 Oct;38(2–3):269–77

[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Evidence for a proprotein intermediate during maturation

of type II antifreeze protein in sea raven, Hemitripterus americanus. Duncker BP, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):312–6

Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. Hamra FK, et al. **Endocrinology** 1996 Jan;137(1):257–65

The human urinary epidermal growth factor (EGF) precursor. Isolation of a biologically active 160-kilodalton heparin-binding pro-EGF with a truncated carboxyl terminus. Parries G, et al. **J Biol Chem** 1995 Nov 17; 270(46):27954–60

Purification, sequence analysis, and cellular localization of a prodynorphin-derived peptide related to the alpha-neo-endorphin in the rhynchobdellid leech Theromyzon tessulatum. Salzet M, et al. **J Biol Chem** 1996 May 31;271(22):13191–6

Interaction of HSP 60 with proteins imported into the mitochondrial matrix. Rospert S, et al. **Methods Enzymol** 1995;260:287–92

All prepro-VIP-derived peptides, except PHI/PHV, are expressed in the female rat anterior pituitary and increased by estrogen. Skakkebaek ML, et al. **Peptides** 1995; 16(7):1287–94

METABOLISM

Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody. Krugner-Higby L, et al. **AIDS Res Hum Retroviruses** 1995 Jun;11(6):705–12

Endothelin-1 and big endothelin-1 increase in human endometrium during menstruation. Ohbuchi H, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1483–90

Precursor pool for hepatic protein synthesis in humans: effects of tracer route infusion and dietary proteins. Cayol M, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E980–7

Metabolism and influence of gastrin-52 on gastric acid secretion in humans. Hansen CP, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G600–5

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)

The processing proteases prohormone thiol protease, PC1/3 and PC2, and 70-kDa aspartic proteinase show preferences among proenkephalin, proneuropeptide Y, and proopiomelanocortin substrates. Hook VY, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):107–14

Stability and folding of precursor and mature tryptophan-substituted ribose binding protein of Escherichia coli. Lee H, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):78–84

Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1–8 (73 ref.)

Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Fan X, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):457–62

Structure and regional distribution of nociceptin/orphanin FQ precursor. Houtani T, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):714–9

Atrial natriuretic factor (ANF) prohormone accumulates in the IgG fraction of anti-ANF hybridoma-bearing mice. Milne RW, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):665–9

Degradation of aggrecan precursors within a specialized subcompartment of the chicken chondrocyte endoplasmic reticulum. Alonso M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):487–95

Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule. Galanopoulou AS, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):111–8

Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis. Porter CD, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):571–5

Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Seidah NG, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):951–60

Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Vollenweider F, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):521–32

The conformation of human big endothelin-1 favours endopeptidase hydrolysis of the TRP21-VAL22 bond. Corder R. **Biochem Pharmacol** 1996 Feb 9;51(3):259–66

SecA, a novel ATPase that converts chemical energy into a mechanical force to drive precursor protein translocation. Driessen AJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):981–5 (32 ref.)

Partitioning of HIV-1 Gag and Gag-related proteins to membranes. Ehrlich LS, et al. **Biochemistry** 1996 Apr 2; 35(13):3933–43

Functional characterization of the precursor and spliced forms of RecA protein of Mycobacterium tuberculosis. Kumar RA, et al. **Biochemistry** 1996 Feb 13;35(6):1793–802

Thermodynamics of the membrane insertion process of the M13 procoat protein, a lipid bilayer traversing protein containing a leader sequence. Soekarjo M, et al. **Biochemistry** 1996 Jan 30;35(4):1232–41

Length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. Tang P, et al. **Biochemistry** 1996 Jun 25;35(25):8226–33

Prothymosin alpha binds histones in vitro and shows activity in nucleosome assembly assay. Diaz-Jullien C, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):219–27

Evidence for a proprotein intermediate during maturation of type II antifreeze protein in sea raven, Hemitripterus americanus. Duncker BP, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):312–6

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)

Is Ca(II) ion binding to prothrombin fragment 1 intrinsically cooperative, or is the cooperative binding accounted for by self-association? Cabaniss S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):464–73

L-2-Oxothiazolidine-4-carboxylate and N-acetylcysteine as precursors of intracellular glutathione in human peritoneal mesothelial cells. Breborowicz A, et al. **Blood Purif** 1996; 14(1):1–7

Decreased beta 2-adrenergic receptor-mRNA and loricrin-mRNA, and increased involucrin-mRNA transcripts in psoriatic epidermis: analysis by reverse transcription-polymerase chain reaction. Takahashi H, et al. **Br J Dermatol** 1996 Jun;134(6):1065–9

Effects of streptozotocin-induced diabetes on prodynorphin-derived peptides in rat brain regions. Berman Y, et al. **Brain Res** 1995 Jul 10;685(1-2):129–34

Prohevein is poorly processed but shows enhanced resistance to a chitin-binding fungus in transgenic tomato plants. Lee HI, et al. **Braz J Med Biol Res** 1995 Jul;28(7):743–50

Cytokeratin subtypes and involucrin in squamous cell carcinoma of the vulva. An immunohistochemical study of 41 cases. Ansink A, et al. **Cancer** 1995 Aug 15; 76(4):638–43

HIV-1 gp120/160 expressing cells upregulate HIV-1 LTR directed gene expression in a cell line transfected with HIV-1 LTR-reporter gene constructs. Merzouki A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):445–52

Inhibition of the conversion of pre-interleukins-1 alpha and 1 beta to mature cytokines by p-benzoquinone, a metabolite of benzene. Niculescu R, et al. **Chem Biol Interact** 1995 Dec 22;98(3):211–22

Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Patel YC, et al. **Ciba Found Symp** 1995; 190:26–40; discussion 40–50 (50 ref.)

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)

Male and female cooperate in the prohormone-like processing of a Drosophila melanogaster seminal fluid protein. Park M, et al. **Dev Biol** 1995 Oct;171(2):694–702

Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Moens K, et al. **Diabetes** 1996 Feb;45(2):257–61

An efficient cellular system for mutational analysis of prohormone processing. Bundgaard JR, et al. **DNA Cell Biol** 1996 Feb;15(2):147–57

Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases. Mohamedein A, et al. **East Afr Med J** 1995 Sep;72(9):584–7

Acidic receptor domains on both sides of the outer membrane mediate translocation of precursor proteins into yeast mitochondria. Bolliger L, et al. **EMBO J** 1995 Dec 15; 14(24):6318–26

Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8

Co-translational trimerization of the reovirus cell attachment protein. Gilmore R, et al. **EMBO J** 1996 Jun 3; 15(11):2651–8

Cytoplasmic chaperones determine the targeting pathway of precursor proteins to mitochondria. Komiya T, et al. **EMBO J** 1996 Jan 15;15(2):399–407

Differential requirement for the mitochondrial Hsp70-Tim44 complex in unfolding and translocation of preproteins. Voos W, et al. **EMBO J** 1996 Jun 3;15(11):2668–77

Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. Hamra FK, et al. **Endocrinology** 1996 Jan;137(1):257–65

Expression and function of proenkephalin A messenger ribonucleic acid in murine fetal thymocytes. Linner KM, et al. **Endocrinology** 1996 Mar;137(3):857–63

Impaired processing of brain proneurotensin and promelanin-concentrating hormone in obese fat/fat mice. Rovere C, et al. **Endocrinology** 1996 Jul;137(7):2954–8

Basic fibroblast growth factor regulates the conversion of pro-luteinizing hormone-releasing hormone (Pro-LHRH) to LHRH in immortalized hypothalamic neurons. Wetsel WC, et al. **Endocrinology** 1996 Jun;137(6):2606–16

Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor. Kise H, et al. **Eur J Biochem** 1996 May 15; 238(1):88–96

Protein disulphide isomerase and a lumenal cyclophilin-type peptidyl prolyl cis-trans isomerase are in transient contact with secretory proteins during late stages of translocation. Klappa P, et al. **Eur J Biochem** 1995 Sep 15;232(3):755–64

Cyclosporin A inhibits the degradation of signal sequences after processing of presecretory proteins by signal peptidase. Klappa P, et al. **Eur J Biochem** 1996 Jul 15; 239(2):509–18

Determinants in the presequence of cytochrome b2 for import into mitochondria and for proteolytic processing. Klaus C, et al. **Eur J Biochem** 1996 Mar 15;236(3):856–61

Binding of human prothymosin alpha to the leucine-motif/activation domains of HTLV-I Rex and HIV-1 Rev. Kubota S, et al. **Eur J Biochem** 1995 Oct 1; 233(1):48–54

Purification of Escherichia coli pro-haemolysin, and a comparison with the properties of mature alpha-haemolysin. Soloaga A, et al. **Eur J Biochem** 1996 Jun 1;238(2):418–22

Influence of the signal sequence and chaperone SecB on the interaction between precursor protein prePhoE and phospholipids. Van Raalte AL, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):207–14

Processing of pro-tumor necrosis factor-alpha by venom metalloproteinases: a hypothesis explaining local tissue damage following snake bite. Moura-da-Silva AM, et al. **Eur J Immunol** 1996 Sep;26(9):2000–5

Early changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures in the rat. Romualdi P, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1850–6

Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein-1. Blackman MJ, et al. **Exp Parasitol** 1996 Jul;83(2):229–39

Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. Badman MK, et al. **FEBS Lett** 1996 Jan 15;378(3):227–31

Binding of endothelin to plasma proteins and tissue receptors: effects on endothelin determination, vasoactivity, and tissue kinetics. Brunner F, et al. **FEBS Lett** 1995 Oct 2; 373(1):97–101

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113–6 (46 ref.)

SecG plays a critical role in protein translocation in the absence of the proton motive force as well as at low temperature. Hanada M, et al. **FEBS Lett** 1996 Feb 26; 381(1-2):25–8

Uncleaved env gp160 of human immunodeficiency virus type 1 is degraded within the Golgi apparatus but not lysosomes in COS-1 cells. Kimura T, et al. **FEBS Lett** 1996 Jul 15; 390(1):15–20

Modification of the targeting presequence of the bovine cytochrome P-450scc precursor lifting tissue-specific restrictions on its mitochondrial import. Novikova LA, et al. **FEBS Lett** 1996 Jan 8;378(2):182–4

Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions. Papandreou MJ, et al. **FEBS Lett** 1996 Jan 29;379(2):171–6

Expression of recombinant pro-neuropeptide Y, proopiomelanocortin, and proenkephalin: relative processing by 'prohormone thiol protease' (PTP). Schiller MR, et al. **FEBS Lett** 1996 Mar 11;382(1-2):6–10

A role for phosphorylation in the proteolytic processing of the human NF-kappa B1 precursor. Fujimoto K, et al. **Gene** 1995 Nov 20;165(2):183–9

Nuclear and cytoplasmic localisation of procorticotrophin releasing hormone in transfected CHO-K1 cells. Morrison E, et al. **Gene Ther** 1994;1 Suppl 1:S62

Use of gene transfer to study post-translational modifications of neuropeptides in cell lines. Tomasec P, et al. **Gene Ther** 1994;1 Suppl 1:S64

Molecular role of sulfated glycoprotein-1 (SGP-1/prosaposin) in Sertoli cells. Morales CR, et al. **Histol Histopathol** 1995 Oct;10(4):1023–34 (11 ref.)

Exchange of precursor-specific elements between Pro-sigma E and Pro-sigma K of Bacillus subtilis. Carlson HC, et al. **J Bacteriol** 1996 Jan;178(2):546–9

Serine protease EpiP from Staphylococcus epidermidis catalyzes the processing of the epidermin precursor peptide. Geissler S, et al. **J Bacteriol** 1996 Jan;178(1):284–8

Role of the propilin leader peptide in the maturation of F pilin. Majdalani N, et al. **J Bacteriol** 1996 Jul; 178(13):3748–54

Structure-function relationship of bacterial prolipoprotein diacylglyceryl transferase: functionally significant conserved regions. Qi HY, et al. **J Bacteriol** 1995 Dec; 177(23):6820–4

Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. Renauld-Mongénie G, et al. **J Bacteriol** 1996 Feb;178(4):1053–60

Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase. Kamoshita K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1244–53

Conformational aberrance of the sendai virus F0 protein in thapsigargin-treated cells allowing exit from the endoplasmic reticulum but causing arrest at the Golgi complex. Ono A, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1248–54

Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. Arribas J, et al. **J Biol Chem** 1996 May 10;271(19):11376–82

Prosomatostatin processing in permeabilized cells. Calcium is required for prohormone cleavage but not formation of

nascent secretory vesicles. Austin CD, et al. **J Biol Chem** 1996 Jan 12;271(2):1194–9

Autocrine regulation of membrane transforming growth factor–alpha cleavage. Baselga J, et al. **J Biol Chem** 1996 Feb 9;271(6):3279–84

Prediction and identification of new natural substrates of the yeast mitochondrial intermediate peptidase. Branda SS, et al. **J Biol Chem** 1995 Nov 10;270(45):27366–73

Assembled pre–B cell receptor complexes are retained in the endoplasmic reticulum by a mechanism that is not selective for the pseudo–light chain. Brouns GS, et al. **J Biol Chem** 1996 Aug 9;271(32):19272–8

Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. Henseler M, et al. **J Biol Chem** 1996 Apr 5;271(14):8416–23

Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. Holthuis JCM, et al. **J Biol Chem** 1996 Jul 26;271(30):17755–60

Differential sensitivity of interleukin–1 alpha and –beta precursor proteins to cleavage by calpain, a calcium–dependent protease. Kavita U, et al. **J Biol Chem** 1995 Nov 17;270(46):27758–65

Protein import into mammalian mitochondria. Characterization of the intermediates along the import pathway of the precursor into the matrix. Komiya T, et al. **J Biol Chem** 1996 Sep 6;271(36):22105–10

Maturation of pre–apocytochrome f in vivo. A site–directed mutagenesis study in Chlamydomonas reinhardtii. Kuras R, et al. **J Biol Chem** 1995 Nov 17;270(46):27797–803

Phosphorylation of p105 PEST sequence via a redox–insensitive pathway up–regulates processing of p50 NF–KappaB. MacKichan ML, et al. **J Biol Chem** 1996 Mar 15;271(11):6084–91

Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin. Otteken A, et al. **J Biol Chem** 1996 Jan 5;271(1):97–103

Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C–proteinase. Panchenko MV, et al. **J Biol Chem** 1996 Mar 22;271(12):7113–9

Characterization of profilaggrin endoproteinase 1. A regulated cytoplasmic endoproteinase of epidermis. Resing KA, et al. **J Biol Chem** 1995 Nov 24;270(47):28193–8

Differential processing of proglucagon by the subtilisin–like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon–like peptide. Rouillé Y, et al. **J Biol Chem** 1995 Nov 3;270(44):26488–96

Evidence that PC2 is the endogenous pro–neurotensin convertase in rMTC 6–23 cells and that PC1– and PC2–transfected PC12 cells differentially process pro–neurotensin. Rovère C, et al. **J Biol Chem** 1996 May 10;271(19):11368–75

Biosynthesis of lantibiotic nisin. Posttranslational modification of its prepeptide occurs at a multimeric membrane–associated lanthionine synthetase complex. Siegers K, et al. **J Biol Chem** 1996 May 24; 271(21):12294–301

Profactor IX propeptide and glutamate substrate binding sites on the vitamin K–dependent carboxylase identified by site–directed mutagenesis. Sugiura I, et al. **J Biol Chem** 1996 Jul 26;271(30):17837–44

Stepwise movement of preproteins in the process of translocation across the cytoplasmic membrane of Escherichia coli. Uchida K, et al. **J Biol Chem** 1995 Dec 29;270(52):30862–8

Phosphorylation of the transit sequence of chloroplast precursor proteins. Waegemann K, et al. **J Biol Chem** 1996 Mar 15;271(11):6545–54

Influence of the mature portion of a precursor protein on the mitochondrial signal sequence. Waltner M, et al. **J Biol Chem** 1996 Aug 30;271(35):21226–30

Pro–OmpA derivatives with a His6 tag in their N–terminal "translocation initiation domains" are arrested by Ni2+ at an early post–targeting stage of translocation. Yoshihisa T, et al. **J Biol Chem** 1996 Apr 19;271(16):9429–36

Inhibition of convertase–related processing of proendothelin–1. Denault JB, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S47–50

Two components of the chloroplast protein import apparatus, IAP86 and IAP75, interact with the transit sequence during the recognition and translocation of precursor proteins at the outer envelope. Ma Y, et al. **J Cell Biol** 1996 Jul; 134(2):315–27

A new chloroplast protein import intermediate reveals distinct translocation machineries in the two envelope membranes: energetics and mechanistic implications. Scott SV, et al. **J Cell Biol** 1996 Jan;132(1–2):63–75

Proteolytic cleavage and activation of pro–macrophage–stimulating protein by resident peritoneal macrophage membrane proteases. Wang MH, et al. **J Clin Invest** 1996 Feb 1;97(3):720–7

Effects of graded amounts of duodenal infusions of methionine on the mammary uptake of major milk precursors in dairy cows. Guinard J, et al. **J Dairy Sci** 1995 Oct;78(10):2196–207

Differential localization of TGF–beta–precursor isotypes in psoriatic human skin. Wataya–Kaneda M, et al. **J Dermatol Sci** 1996 Mar;11(3):183–8

The effect of castration on steady state levels of luteinizing hormone–releasing hormone (LHRH) mRNA and proLHRH processing: time course study utilizing semi–quantitative reverse transcription/polymerase chain reaction. Emanuele NV, et al. **J Endocrinol** 1996 Mar; 148(3):509–15

Streptococcal cysteine proteinase releases kinins: a virulence mechanism. Herwald H, et al. **J Exp Med** 1996 Aug 1; 184(2):665–73

Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus–infected cells. Marshall GS, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1549–57

A region of the coronavirus infectious bronchitis virus 1a polyprotein encoding the 3C–like protease domain is subject to rapid turnover when expressed in rabbit reticulocyte lysate. Tibbles KW, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3059–70

Gag–Gag interactions in the C–terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly. Zhang WH, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):743–51

IL–1 beta activation in human epidermis. Nylander–Lundqvist E, et al. **J Immunol** 1996 Aug 15; 157(4):1699–704

Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. Pócsik E, et al. **J Inflamm** 1995;45(3):152–60

Characteristics of the chromaffin granule aspartic proteinase involved in proenkephalin processing. Azaryan AV, et al. **J Neurochem** 1995 Oct;65(4):1771–9

Pro–thyrotropin–releasing hormone processing by recombinant PC1. Nillni EA, et al. **J Neurochem** 1995 Dec; 65(6):2462–72

Proneuropeptide Y processing in large dense–core vesicles: manipulation of prohormone convertase expression in sympathetic neurons using adenoviruses. Paquet L, et al. **J Neurosci** 1996 Feb 1;16(3):964–73

Preparations of psi–peptide bond and peptide–aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro–atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431–40

Tyrosine kinase–dependent release of an adenovirus preterminal protein complex from the nuclear matrix. Angeletti PC, et al. **J Virol** 1996 May;70(5):3060–7

Complex formation between the NS3 serine–type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. Bartenschlager R, et al. **J Virol** 1995 Dec;69(12):7519–28

The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin–binding drug SDZ NIM 811. Dorfman T, et al. **J Virol** 1996 Sep;70(9):5751–7

Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. Sakalian M, et al. **J Virol** 1996 Jun;70(6):3706–15

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. Turpin JA, et al. **J Virol** 1996 Sep;70(9):6180–9

Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. Xu Z, et al. **J Virol** 1996 Jan;70(1):133–40

Binding of 125I–prothymosin alpha to lymphoblasts through the non–thymosin alpha 1 sequence. Cordero OJ, et al. **Life Sci** 1996;58(20):1757–70

Mitochondrial receptor complex from Neurospora crassa and Saccharomyces cerevisiae. Alconada A, et al. **Methods Enzymol** 1995;260:263–86

Analysis of mitochondrial protein import pathway in Saccharomyces cerevisiae with translocation intermediates. Cyr DM, et al. **Methods Enzymol** 1995;260:241–52

Pathways and energetics of mitochondrial protein import in Saccharomyces cerevisiae. Glick BS. **Methods Enzymol** 1995;260:224–31

Isolation of protein import components from Saccharomyces cerevisiae mitochondria. Horst M, et al. **Methods Enzymol** 1995;260:232–41

Purified and protein–loaded mitochondrial outer membrane vesicles for functional analysis of preprotein transport. Mayer A, et al. **Methods Enzymol** 1995;260:252–63

Protein import into mammalian mitochondria. Mihara K, et al. **Methods Enzymol** 1995;260:302–10

Interaction of HSP 60 with proteins imported into the mitochondrial matrix. Rospert S, et al. **Methods Enzymol** 1995;260:287–92

Protein import into plant mitochondria. Winning BM, et al. **Methods Enzymol** 1995;260:293–302

Processing of the Plasmodium chabaudi chabaudi AS merozoite surface protein 1 in vivo and in vitro. O'Dea KP, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):111–9

Phorbol ester induces the rapid processing of cell surface heparin–binding EGF–like growth factor: conversion from juxtacrine to paracrine growth factor activity. Goishi K, et al. **Mol Biol Cell** 1995 Aug;6(8):967–80

Functional interaction of cytosolic hsp70 and a DnaJ–related protein, Ydj1p, in protein translocation in vivo. Becker J, et al. **Mol Cell Biol** 1996 Aug;16(8):4378–86

Role of the intermembrane–space domain of the preprotein receptor Tom22 in protein import into mitochondria. Court DA, et al. **Mol Cell Biol** 1996 Aug;16(8):4035–42

Mitochondrial GrpE modulates the function of matrix Hsp70 in translocation and maturation of preproteins. Laloraya S, et al. **Mol Cell Biol** 1995 Dec;15(12):7098–105

Human pro–tumor necrosis factor: molecular determinants of membrane translocation, sorting, and maturation. Utsumi T, et al. **Mol Cell Biol** 1995 Nov;15(11):6398–405

Role of prohormone convertases in the tissue–specific processing of proglucagon. Dhanvantari S, et al. **Mol Endocrinol** 1996 Apr;10(4):342–55

Evidence for redundancy in propeptide/prohormone convertase activities in processing proglucagon: an antisense study. Rothenberg ME, et al. **Mol Endocrinol** 1996 Apr;10(4):331–41

Activation of the apoptotic protease CPP32 by cytotoxic T–cell–derived granzyme B. Darmon AJ, et al. **Nature** 1995 Oct 5;377(6548):446–8

Effects on NF–kappa B1/p105 processing of the interaction between the HTLV–1 transactivator Tax and the proteasome. Rousset R, et al. **Nature** 1996 May 23; 381(6580):328–31

Expression of candidate pro–GnRH processing enzymes in rat hypothalamus and an immortalized hypothalamic neuronal cell line. Wetsel WC, et al. **Neuroendocrinology** 1995 Aug;62(2):166–77

Coexpression of preprotachykinin–A, alpha–calcitonin gene–related peptide, somatostatin, and neurotrophin receptor family messenger RNAs in rat dorsal root ganglion neurons. Kashiba H, et al. **Neuroscience** 1996 Jan; 70(1):179–89

Fluorescence polarization assay for endothelin–converting enzymes. Hazan S, et al. **Peptides** 1995;16(5):833–6

A soluble protein is imported into Euglena chloroplasts as a membrane–bound precursor. Sulli C, et al. **Plant Cell** 1996 Jan;8(1):43–53

O–glycosylation of a precursor to a sweet potato vacuolar protein, sporamin, expressed in tobacco cells. Matsuoka K, et al. **Plant J** 1995 Dec;8(6):877–89

Two alternative processing pathways for a preprohormone: a bioactive form of secretin. Bonetto V, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11985–9

Secretory granule targeting of atrial natriuretic peptide correlates with its calcium–mediated aggregation. Canaff L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9483–7

Subunit cleavage of mosquito pro–vitellogenin by a subtilisin–like convertase. Chen JS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6186–90

The precursor of PsaD assembles into the photosystem I complex in two steps. Minai L, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6338–42

prlA suppressors in Escherichia coli relieve the proton electrochemical gradient dependency of translocation of wild–type precursors. Nouwen N, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5953–7

NACP, the precursor protein of the non–amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Yoshimoto M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9141–5

PreproPACAP–derived peptides occur in VIP–producing tumours and co–exist with VIP. Fahrenkrug J, et al. **Regul Pept** 1995 Aug 22;58(3):89–98

Proglucagon processing in islet and intestinal cell lines. Tucker JD, et al. **Regul Pept** 1996 Apr 9;62(1):29–35

Degradation of serum amyloid A in amyloid–susceptible and amyloid–resistant mouse strains. Elliott–Bryant R, et al. **Scand J Immunol** 1996 Sep;44(3):223–8

Role of yeast insulin–degrading enzyme homologs in propheromone processing and bud site selection. Adames N, et al. **Science** 1995 Oct 20;270(5235):464–7

D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Wang JQ, et al. **Synapse** 1996 Feb;22(2):114–22

Prepilin–like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409–10; discussion 411–3 (49 ref.)

Mutational analysis of interactions between the Gag precursor proteins of murine leukemia viruses. Alin K, et al. **Virology** 1996 Feb 15;216(2):418–24

Biological properties of recombinant HIV envelope synthesized in CHO glycosylation–mutant cell lines. Fenouillet E, et al. **Virology** 1996 Apr 1;218(1):224–31

In vivo processing of Pr160gag–pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T–lymphocytes. Lindhofer H, et al. **Virology** 1995 Dec 20;214(2):624–7

Identification and site–directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts. Martin A, et al. **Virology** 1995 Oct 20; 213(1):213–22

Mutational analysis of HIV–1 gp160–mediated receptor interference: intracellular complex formation. Martin RA, et al. **Virology** 1996 Jun 15;220(2):461–72

Membrane anchorage of gp160 is necessary and sufficient to prevent CD4 transport to the cell surface. Martin RA, et al. **Virology** 1996 Jun 15;220(2):473–9

Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Quillent C, et al. **Virology** 1996 May 1;219(1):29–36

Glycoprotein incorporation and HIV–1 infectivity despite exchange of the gp160 membrane–spanning domain. Wilk T, et al. **Virology** 1996 Apr 1;218(1):269–74

[Determination of PIVKA–II levels in patients with small hepatocellular carcinoma—comparison of new sensitive

methods] Ishijima M, et al. **Rinsho Byori** 1996 Jul; 44(7):635–9 (Eng. Abstr.) **(Jpn)**
[A family of Kex2–like endoproteases involved in processing of precursors for biologically active peptides and proteins] Nakayama K. **Seikagaku** 1995 Aug;67(8):995–1009 (95 ref.) **(Jpn)**

PHARMACOLOGY

Interaction of glucagon–like peptide–I (GLP–I) and galanin in insulin (beta TC–1)– and somatostatin (RIN T3)–secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)–secreting cells. Fehmann HC, et al. **Acta Diabetol** 1995 Oct;32(3):176–81

Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Gratton JP, et al. **Am J Hypertens** 1995 Nov; 8(11):1121–7

HIV–1 gp160 protein–macrophage interactions modulate mesangial cell proliferation and matrix synthesis. Singhal PC, et al. **Am J Pathol** 1995 Dec;147(6):1780–9

Effect of proANF–(31—67) on sodium excretion in conscious monkeys. Benjamin BA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1351–5

Point mutations in the first and third intracellular loops of the glucagon–like peptide–1 receptor alter intracellular signaling. Heller RS, et al.
Biochem Biophys Res Commun 1996 Jun 25;223(3):624–32

An investigation into the direct and indirect venoconstrictor effects of endothelin–1 and big endothelin–1 in man. Haynes WG, et al. **Br J Clin Pharmacol** 1995 Oct; 40(4):307–11

Differential effects of enterostatin, galanin and opioids on high–fat diet consumption. Barton C, et al. **Brain Res** 1995 Dec 8;702(1–2):55–60

B–lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti–idiotypic antibody to induce extracellular acidification. Renschler MF, et al. **Cancer Res** 1995 Dec 1;55(23):5642–7

HIV–1 gp160 induces transforming growth factor–beta production in human PBMC. Hu R, et al.
Clin Immunol Immunopathol 1996 Sep;80(3 Pt 1):283–9

T cell differentiation: control by the pre–TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145–50 (47 ref.)

The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Ryall RL, et al.
Clin Sci (Colch) 1995 Nov;89(5):533–41

Effect of enterostatin on insulin, glucagon, and somatostatin secretion in the perfused rat pancreas. Silvestre RA, et al. **Diabetes** 1996 Sep;45(9):1157–60

The effect of glucagon–like peptide I (GLP–I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Toft–Nielson M, et al.
Diabetes 1996 May;45(5):552–6

Effects of GLP–1 and 2,5–anhydro–D–mannitol on insulin secretion and plasma glucose in mice. Ahrén B, et al.
Endocr Res 1995 Aug;21(3):583–94

Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Chen C, et al. **Endocrinology** 1996 May;137(5):1752–7

Preprothyrotropin–releasing hormone–(178–199) does not inhibit corticotropin release. Nicholson WE, et al.
Endocrinology 1996 May;137(5):2171–4

Glucagon–like peptide–1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046–38 cells. Wang Y, et al. **Endocrinology** 1995 Nov;136(11):4910–7

Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase–hemolysin. Khelef N, et al.
FEMS Microbiol Lett 1995 Dec 1;134(1):27–32

Effect of pre–S1 antigen on human lymphocyte proliferative responses. Sulowska Z, et al. **Immunol Lett** 1995 Dec; 48(2):133–8

Prothymosin alpha 1 modulates lymphokine–activated killer cell activity and IL–2 production by peripheral blood lymphocytes from melanoma patients in vitro. Eckert K, et al. **Int J Immunopharmacol** 1995 Jul;17(7):555–61

Characterization of big endothelin–1–induced contraction in rabbit saphenous artery. Ferlenga P, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 3:S78–80

Renal effects of big endothelin–1 in experimental congestive heart failure. Gurbanov K, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 3:S473–5

Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta–cells with glucagon–like peptide 1. Otonkoski T, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3779–83

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon–like peptide–1 (GLP–1)–(7–36) amide in type 2 (noninsulin–dependent) diabetic patients. Willms B, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):327–32

Stimulation of tyrosinase in human melanocytes by pro–opiomelanocortin–derived peptides. McLeod SD, et al. **J Endocrinol** 1995 Sep;146(3):439–47

Inactivation of human immunodeficiency virus (HIV)–1 envelope–specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self–veto mechanism? Takahashi H, et al. **J Exp Med** 1996 Mar 1;183(3):879–89

Molecular characterization of fusion regulatory protein–1 (FRP–1) that induces multinucleated giant cell formation of monocytes and HIV gp160–mediated cell fusion. FRP–1 and 4F2/CD98 are identical molecules. Ohgimoto S, et al. **J Immunol** 1995 Oct 1;155(7):3585–92

Comparison of bronchodilator responses to adrenomedullin and proadrenomedullin N–terminal 20 peptide. Kanazawa H, et al. **Life Sci** 1995;57(16):PL241–5

Potentiation of glucagon–like peptide 1 insulinotropic action by succinic acid dimethyl ester. Leclercq–Meyer V, et al. **Life Sci** 1996;58(14):1195–9

Glucagon–like peptide–1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. Zawalich WS, et al. **Metabolism** 1996 Feb; 45(2):273–8

Role of intraduodenally administered enterostatin in rats: inhibition of food. Mei J, et al. **Obes Res** 1996 Mar; 4(2):161–5

The effects of glucagon–like peptide–I (GLP–I) on hormone secretion from isolated human pancreatic islets. Fehmann HC, et al. **Pancreas** 1995 Aug;11(2):196–200

Modulation of murine peritoneal macrophage functions by gastrin. de la Fuente M, et al. **Peptides** 1996;17(2):219–24

Effects of cholecystokinin and glucagon–like peptide 1 on the secretion of pancreatic polypeptide in mice. Ahrén B, et al. **Regul Pept** 1995 Nov 10;59(3):297–302

Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon–like peptide–1 during perifusion of short–term cultured canine isolated islets. van der Burg MP, et al. **Regul Pept** 1995 Dec 7;60(1):61–7

PHYSIOLOGY

Cryptdins: endogenous antibiotic peptides of small intestinal Paneth cells. Harwig SS, et al. **Adv Exp Med Biol** 1995; 371A:251–5

PYY and GLP–1 contribute to feedback inhibition from the canine ileum and colon. Wen J, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G945–52

Transgenic mice: preproenkephalin and the mu opiate receptor. Donovan DM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:19–28 (28 ref.)

Glucagon–like peptide–1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311–8 (83 ref.)

Enteral enhancement of glucose disposition by both insulin–dependent and insulin–independent processes. A physiological role of glucagon–like peptide I. D'Alessio DA, et al. **Diabetes** 1995 Dec;44(12):1433–7

Secretion of biologically active human proapolipoprotein A–I in a baculovirus–insect cell system: protection from degradation by protease inhibitors. Pyle LE, et al.
J Lipid Res 1995 Nov;36(11):2355–61

trans–acting proteins involved in RNA encapsidation and viral assembly in human immunodeficiency virus type 1. Kaye JF, et al. **J Virol** 1996 Feb;70(2):880–6

Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. Otteken A, et al. **J Virol** 1996 Jun;70(6):3407–15

Prothymosin alpha: in search of a function. Smith MR.
Leuk Lymphoma 1995 Jul;18(3–4):209–14 (41 ref.)

SECRETION

Development of adrenocorticotropin–(1–39) and precursor peptide secretory responses in the fetal sheep during the last third of gestation. Carr GA, et al. **Endocrinology** 1995 Nov;136(11):5020–7

Gastrin–releasing peptide is a novel mediator of proximal nutrient–induced proglucagon–derived peptide secretion from the distal gut. Roberge JN, et al. **Endocrinology** 1996 Jun;137(6):2383–8

Stereospecific effects of fatty acids on proglucagon–derived peptide secretion in fetal rat intestinal cultures. Rocca AS, et al. **Endocrinology** 1995 Dec;136(12):5593–9

Regulation of glucagon–like peptide–1 secretion from rat ileum by neurotransmitters and peptides. Herrmann–Rinke C, et al. **J Endocrinol** 1995 Oct;147(1):25–31

Role of glutamate in regulating hypothalamic proglucagon–derived peptide secretion in vitro.
Stobie–Hayes KM, et al. **Life Sci** 1995 Mar 10; 56(16):1325–31

Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. da Cruz e Silva EF, et al. **Mol Med** 1995 Jul;1(5):535–41

Vibrio spp. secrete proaerolysin as a folded dimer without the need for disulphide bond formation. Hardie KR, et al.
Mol Microbiol 1995 Sep;17(6):1035–44

Glucagon–like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha–glucosidase inhibition (acarbose). Qualmann C, et al. **Scand J Gastroenterol** 1995 Sep;30(9):892–6

THERAPEUTIC USE

A recombinant baculovirus 42–kilodalton C–terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Chang SP, et al. **Infect Immun** 1996 Jan;64(1):253–61

URINE

The human urinary epidermal growth factor (EGF) precursor. Isolation of a biologically active 160–kilodalton heparin–binding pro–EGF with a truncated carboxyl terminus. Parries G, et al. **J Biol Chem** 1995 Nov 17; 270(46):27954–60

PROTEIN PRENYLATION see **PROTEIN ISOPRENYLATION**

PROTEIN PROCESSING, POST-TRANSLATIONAL

Mechanism of autoprocessing of a mini–precursor of the aspartic protease of human immunodeficiency virus type 1. Co E, et al. **Adv Exp Med Biol** 1995;362:379–86

Proteolytic processing of the MHV polymerase polyprotein. Identification of the P28 cleavage site and the adjacent protein, P65. Dong S, et al. **Adv Exp Med Biol** 1995; 380:431–5

Aggregation of Thy–1 glycoprotein induces tyrosine phosphorylation of different proteins in isolated rat mast cells and rat basophilic leukemia cells. Dráberová L, et al. **Adv Exp Med Biol** 1995;371A:297–301

Bovine coronavirus nucleocapsid protein processing and assembly. Hogue BG. **Adv Exp Med Biol** 1995;380:259–63

Band 3 and its peptides during aging, radiation exposure, and Alzheimer's disease: alterations and self–recognition. Kay MM, et al. **Adv Exp Med Biol** 1995;383:167–93

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

Characterization of IgA1, IgA2 and secretory IgA carbohydrate chains using plant lectins. Wold AE, et al.
Adv Exp Med Biol 1995;371A:585–9

Induction of HIV type 1 neutralizing and env–CD4 blocking antibodies by immunization with genetically engineered HIV type 1–like particles containing unprocessed gp160 glycoproteins. Rovinski B, et al.
AIDS Res Hum Retroviruses 1995 Oct;11(10):1187–95

Synthesis and processing of hydrophobic surfactant protein C by isolated rat type II cells. Beers MF, et al.
Am J Physiol 1995 Dec;269(6 Pt 1):L744–53

Transcriptional and posttranscriptional mechanisms regulate human renin gene expression in Calu–6 cells. Lang JA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F94–100

Posttranslational processing of surfactant protein C in rat type II cells. Vorbroker DK, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L727–33

Concanavalin A– and wheat germ agglutinin–conjugated lectins as a tool for the identification of multiple N–glycosylation sites in heterologous protein expressed in yeast. García R, et al. **Anal Biochem** 1995 Nov 1; 231(2):342–8

Regulation of APP processing by intra– and intercellular signals. Buxbaum JD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:327–31 (17 ref.)

Proenkephalin–processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al.
Ann N Y Acad Sci 1996 Mar 22;780:121–33 (22 ref.)

Mechanisms of enhanced nuclear translocation of the transcription factors c–Rel and NF–kappa B by CD28 costimulation in human T lymphocytes. Lai JH, et al.
Ann N Y Acad Sci 1995 Sep 7;766:220–3

Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Lee RK, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:338–43

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al.
Ann N Y Acad Sci 1996 Jan 17;777:175–82 (28 ref.)

The role of APP processing and trafficking pathways in the formation of amyloid beta–protein. Selkoe DJ, et al.
Ann N Y Acad Sci 1996 Jan 17;777:57–64 (19 ref.)

Rate limitations in posttranslational processing by the mammary gland of transgenic animals. Subramanian A, et al. **Ann N Y Acad Sci** 1996 May 15;782:87–96

The processing proteases prohormone thiol protease, PC1/3 and PC2, and 70–kDa aspartic proteinase show preferences among proenkephalin, proneuropeptide Y, and proopiomelanocortin substrates. Hook VY, et al.
Arch Biochem Biophys 1996 Apr 1;328(1):107–14

Glycosylation and phosphorylation of lysosomal glycosylasparaginase. Park H, et al.
Arch Biochem Biophys 1996 Apr 1;328(1):73–7

A block in glycoprotein processing correlates with small plaque morphology and virion targetting to cell–cell junctions for an oral and an anal strain of herpes simplex virus type–1. Dick JW, et al. **Arch Virol** 1995; 140(12):2163–81

Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). Azaryan AV, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):937–44

Intracellular generation of amyloid beta–protein from amyloid beta–protein precursor fragment by direct cleavage with beta– and gamma–secretase. Iizuka T, et al.
Biochem Biophys Res Commun 1996 Jan 5;218(1):238–42

Folding–dependent in vitro protein splicing of the Saccharomyces cerevisiae VMA1 protozyme. Kawasaki M, et al. **Biochem Biophys Res Commun** 1996 May 24; 222(3):827–32

Cytochrome f encoded by the chloroplast genome is imported into thylakoids via the SecA–dependent pathway. Nohara T, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):474–8

Biochemical characterization and posttranslational modification of AlgU, a regulator of stress response in Pseudomonas aeruginosa. Schurr MJ, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):874–80

Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Singh SV, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):660–5

Specific processing of native and phosphorylated tau protein by proteases. Wang X, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):591–7

Extended substrate specificity of serum amine oxidase: possible involvement in protein posttranslational modification. Wang X, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):91–7

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):687–94 (36 ref.)

Production and utilization of detyrosinated tubulin in developing Artemia larvae: evidence for a tubulin-reactive carboxypeptidase. Xiang H, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):673–85 (82 ref.)

Lysosomal alpha-glucosidase: cell-specific processing and altered maturation in HT-29 colon cancer cells. Francí C, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):33–40

Sequence requirements for proinsulin processing at the B-chain/C-peptide junction. Kaufmann JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):869–74

Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation. Kronman C, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):959–67

The role of palmitoylation of the guanine nucleotide binding protein G11 alpha in defining interaction with the plasma membrane. McCallum JF, et al. **Biochem J** 1995 Sep 15; 310 (Pt 3):1021–7

Tyrosine phosphorylation of inducible nitric oxide synthase: implications for potential post-translational regulation. Pan J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):889–94

Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Puisieux A, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):51–5

Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding. Raftery MJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):285–93

Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Seidah NG, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):951–60

Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Vollenweider F, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):521–32

Autoprocessing: an essential step for the activation of HIV-1 protease. Wan M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):569–73

The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Willnow TE, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):71–6

Effect of diabetes and dietary ubiquinone supplementation on the post-translational modification of rat lens beta L crystallin. Jones RH, et al. **Biochem Mol Med** 1995 Aug; 55(2):96–104

Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Liu J, et al. **Biochemistry** 1995 Sep 26;34(38):12333–40

Generation of active [NiFe] hydrogenase in vitro from a nickel-free precursor form. Maier T, et al. **Biochemistry** 1996 Aug 6;35(31):10089–93

Protein splicing: evidence for an N-O acyl rearrangement as the initial step in the splicing process. Shao Y, et al. **Biochemistry** 1996 Mar 26;35(12):3810–5

Length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. Tang P, et al. **Biochemistry** 1996 Jun 25;35(25):8226–33

A precursor form of human kidney gamma-glutamyl transferase in normal and cancerous tissues, and its possible post-translational modification. Arai K, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):33–8

Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Lubec B, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):159–62

Chemical biology of protein isoprenylation/methylation. Rando RR. **Biochim Biophys Acta** 1996 Mar 29; 1300(1):5–16 (75 ref.)

Evidence for a posttranslational covalent modification of liver glyceraldehyde-3-phosphate dehydrogenase in hibernating jerboa (Jaculus orientalis). Soukri A, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):177–87

Processing and activation of recombinant mouse mastocytoma histidine decarboxylase in the particulate fraction of Sf9 cells by porcine pancreatic elastase. Tanaka S, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):9–12

Human lactase-phlorizin hydrolase is not processed by furin, PC1/PC3, PC2, PACE4 and PC5/PC6A of the family of subtilisin-like proprotein processing proteases. Wüthrich M, et al. **Biochim Biophys Acta** 1996 May 28; 1311(3):199–203

ADP-ribosylation reactions in plants. O'Farrell M. **Biochimie** 1995;77(6):486–91 (54 ref.)

Phosphatidylinositol-3-kinase activity is required for the anti-ig-mediated growth inhibition of a human B-lymphoma cell line. Beckwith M, et al. **Blood** 1996 Jan 1;87(1):202–10

Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Haimovich B, et al. **Blood** 1996 Jan 1;87(1):152–61

Protein phosphorylation in neutrophils from patients with p67-phox-deficient chronic granulomatous disease. Heyworth PG, et al. **Blood** 1996 May 15;87(10):4404–10

Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia [letter] Kanwar VS, et al. **Blood** 1996 Jun 1; 87(11):4911–2

Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Li J, et al. **Blood** 1996 Jul 15; 88(2):417–28

Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Manie SN, et al. **Blood** 1996 Mar 1;87(5):1855–61

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)

Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Nicholson SE, et al. **Blood** 1995 Nov 15;86(10):3698–704

A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met->Asp). Rees DC, et al. **Blood** 1996 Jul 1; 88(1):341–8

The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Richardson DR, et al. **Blood** 1995 Oct 15;86(8):3211–9

The molecular basis of paroxysmal nocturnal hemoglobinuria. Rosse WF, et al. **Blood** 1995 Nov 1;86(9):3277–86 (123 ref.)

Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Tauchi T, et al. **Blood** 1996 Jun 1;87(11):4495–501

Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: evidence for defective phospholipase C activation. Yang X, et al. **Blood** 1996 Sep 1;88(5):1676–83

Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Zukerberg LR, et al. **Blood** 1996 Jul 1;88(1):268–76

Expression of phosphotyrosine in squamous cell carcinoma of the oral mucosa. Preliminary study. Maiorano E, et al. **Boll Soc Ital Biol Sper** 1995 May-Jun;71(5–6):157–62

Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Jensen TJ, et al. **Cell** 1995 Oct 6;83(1):129–35

PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus. Pouyani T, et al. **Cell** 1995 Oct 20;83(2):333–43

Degradation of CFTR by the ubiquitin-proteasome pathway. Ward CL, et al. **Cell** 1995 Oct 6;83(1):121–7

Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells. Kang HS, et al. **Cell Immunol** 1996 Mar 15;168(2):174–83

Tubulin post-translational modifications in the primitive protist Trichomonas vaginalis. Delgado-Viscogliosi P, et al. **Cell Motil Cytoskeleton** 1996;33(4):288–97

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)

Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739–45 (49 ref.)

Control of SHB gene expression by protein phosphorylation. Lavergne C, et al. **Cell Signal** 1996 Jan;8(1):55–8

Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. Melillo G, et al. **Circulation** 1996 Apr 1;93(7):1447–58

Role of physiology in the determination of protein heterogeneity. Jenkins N. **Curr Opin Biotechnol** 1996 Apr; 7(2):205–9

An efficient cellular system for mutational analysis of prohormone processing. Bundgaard JR, et al. **DNA Cell Biol** 1996 Feb;15(2):147–57

Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8

Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. Moechars D, et al. **EMBO J** 1996 Mar 15; 15(6):1265–74

Yeast aminopeptidase I is post-translationally sorted from the cytosol to the vacuole by a mechanism mediated by its bipartite N-terminal extension. Seguí-Real B, et al. **EMBO J** 1995 Nov 15;14(22):5476–84

Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. Vettese-Dadey M, et al. **EMBO J** 1996 May 15; 15(10):2508–18

Differential coexpression of genes encoding prothyrotropin-releasing hormone (pro-TRH) and prohormone convertases (PC1 and PC2) in rat brain neurons: implications for differential processing of pro-TRH. Pu LP, et al. **Endocrinology** 1996 Apr; 137(4):1233–41

Impaired processing of brain proneurotensin and promelanin-concentrating hormone in obese fat/fat mice. Rovere C, et al. **Endocrinology** 1996 Jul;137(7):2954–8

Transcriptional and posttranscriptional regulation of interstitial collagenase by platelet-derived growth factor BB in bone cell cultures. Varghese S, et al. **Endocrinology** 1996 Feb;137(2):431–7

Post-translational heterocyclic backbone modifications in the 43-peptide antibiotic microcin B17. Structure elucidation and NMR study of a 13C,15N-labelled gyrase inhibitor. Bayer A, et al. **Eur J Biochem** 1995 Dec 1;234(2):414–26

The inhibition of phosphoenolpyruvate carboxykinase following in vivo chronic phenobarbital treatment in the rat is due to a post-translational event. Chauvin C, et al. **Eur J Biochem** 1996 May 15;238(1):207–13

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Gudmundsson GH, et al. **Eur J Biochem** 1996 Jun 1;238(2):325–32

Maturation of human intestinal lactase-phlorizin hydrolase: generation of the brush border form of the enzyme involves at least two proteolytic cleavage steps. Jacob R, et al. **Eur J Biochem** 1996 Mar 15;236(3):789–95

Cyclosporin A inhibits the degradation of signal sequences after processing of presecretory proteins by signal peptidase. Klappa P, et al. **Eur J Biochem** 1996 Jul 15; 239(2):509–18

Determinants in the presequence of cytochrome b2 for import into mitochondria and for proteolytic processing. Klaus C, et al. **Eur J Biochem** 1996 Mar 15;236(3):856–61

A massive new posttranslational modification occurs on axonemal tubulin at the final step of spermatogenesis in Drosophila. Bressac C, et al. **Eur J Cell Biol** 1995 Aug; 67(4):346–55

Two conserved serines in the nuclear localization signal flanking region are involved in the nuclear targeting of human lamin A. Leukel M, et al. **Eur J Cell Biol** 1995 Oct;68(2):133–42

Filensin is proteolytically processed during lens fiber cell differentiation by multiple independent pathways. Sandilands A, et al. **Eur J Cell Biol** 1995 Jul;67(3):238–53

Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Chalupny NJ, et al. **Eur J Immunol** 1995 Oct;25(10):2978–84

The role of tyrosine phosphorylation in the interaction of cellular tyrosine kinases with the T cell receptor zeta chain tyrosine-based activation motif. Osman N, et al. **Eur J Immunol** 1995 Oct;25(10):2863–9

Internalization of B cell and pre-B cell receptors is regulated by tyrosine kinase and phosphatase activities. Salamero J, et al. **Eur J Immunol** 1995 Oct;25(10):2757–64

Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models. Salmi M, et al. **Eur J Immunol** 1995 Oct;25(10):2803–12

Biosynthetic transport of a major lysosomal membrane glycoprotein, lamp-1: convergence of biosynthetic and endocytic pathways occurs at three distinctive points. Akasaki K, et al. **Exp Cell Res** 1995 Oct;220(2):464–73

Processing of 125I-insulin by polarized cultured kidney cells. Rabkin R, et al. **Exp Cell Res** 1996 Apr 10;224(1):136–42

Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Cidl K, et al. **Exp Hematol** 1996 Jun;24(7):790–4

Crithidia luciliae: effect of purine starvation on S-adenosyl-L-methionine uptake and protein methylation. Alleman MM, et al. **Exp Parasitol** 1995 Dec;81(4):519–28

Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein-1. Blackman MJ, et al. **Exp Parasitol** 1996 Jul;83(2):229–39

Identification of 3-hydroxyproline residues in several proteins of Fasciola hepatica. Bozas SE, et al. **Exp Parasitol** 1996 Jan;82(1):69–72

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570–6 (77 ref.)

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113–6 (46 ref.)

Proteolytic processing of nuclear factor kappa B by calpain in vitro. Liu ZQ, et al. **FEBS Lett** 1996 Apr 29; 385(1–2):109–13

Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: Evidence that Alzheimer mutations affect proteolytic processing. Mercken M, et al. **FEBS Lett** 1996 Jul 8;389(3):297–303

A potential site of functional modulation by protein kinase

A in the cardiac Ca2+ channel alpha 1C subunit. Perets T, et al. **FEBS Lett** 1996 Apr 15;384(2):189–92

Deoxyhypusine synthase gene is essential for cell viability in the yeast Saccharomyces cerevisiae. Sasaki K, et al. **FEBS Lett** 1996 Apr 15;384(2):151–4

Identification of POMC processing products in single melanotrope cells by matrix-assisted laser desorption/ionization mass spectrometry. van Strien FJ, et al. **FEBS Lett** 1996 Jan 29;379(2):165–70

Legumin encoding sequences from the redwood family (Taxodiaceae) reveal precursors lacking the conserved Asn–Gly processing site. Wind C, et al. **FEBS Lett** 1996 Mar 25;383(1–2):46–50

The 32 kDa tonoplast polypeptide Di associated with the V–type H+–ATPase of Mesembryanthemum crystallinum L. in the CAM state: A proteolytically processed subunit B? Zhigang A, et al. **FEBS Lett** 1996 Jul 8;389(3):314–8

Relationship of gastrin processing to colon cancer [editorial] Dickinson CJ. **Gastroenterology** 1995 Oct;109(4):1384–8

Protection from proteolysis using a T4::T7–RNAP phage expression–packaging–processing system. Hong YR, et al. **Gene** 1995 Aug 30;162(1):5–11

A removable spacer peptide in an alpha–factor–leader/insulin precursor fusion protein improves processing and concomitant yield of the insulin precursor in Saccharomyces cerevisiae. Kjeldsen T, et al. **Gene** 1996 Apr 17;170(1):107–12

Amino–acid substitutions in the cleavage site of acyl–coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum: effect on proenzyme cleavage and activity. Tobin MB, et al. **Gene** 1995 Aug 30; 162(1):29–35

STT3, a novel essential gene related to the PKC1/STT1 protein kinase pathway, is involved in protein glycosylation in yeast. Yoshida S, et al. **Gene** 1995 Oct 16;164(1):167–72

Use of gene transfer to study post–translational modifications of neuropeptides in cell lines. Tomasec P, et al. **Gene Ther** 1994;1 Suppl 1:S64

N–glycosylation/deglycosylation as a mechanism for the post–translational modification/remodification of proteins. Suzuki T, et al. **Glycoconj J** 1995 Jun;12(3):183–93 (141 ref.)

Immunocytochemical comparison of posttranslationally modified forms of tubulin in the vestibular end–organs of the gerbil: tyrosinated, acetylated and polyglutamylated tubulin. Ogata Y, et al. **Hear Res** 1995 Jun;86(1–2):125–31

Post–translational modifications of tubulin suggest that dynamic microtubules are present in sensory cells and stable microtubules are present in supporting cells of the mammalian cochlea. Slepecky NB, et al. **Hear Res** 1995 Nov;91(1–2):136–47

Cathepsin B is a prorenin processing enzyme. Neves FA, et al. **Hypertension** 1996 Mar;27(3 Pt 2):514–7

Intrinsic glycosylation potentials of insect cell cultures and insect larvae. Davis TR, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):659–63

Escherichia coli hemolysin mutants with altered target cell specificity. Pellett S, et al. **Infect Immun** 1996 Aug; 64(8):3081–7

Processing of procathepsin from Musca domestica eggs. Ribolla PE, et al. **Insect Biochem Mol Biol** 1995 Oct; 25(9):1011–7

Palmitoylation of brain capillary proteins. Poulio JF, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1133–44

Posttranslational regulation of type I collagen in corneal endothelial cells. Kay EP, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):11–9

Role of the propilin leader peptide in the maturation of F pilin. Majdalani N, et al. **J Bacteriol** 1996 Jul; 178(13):3748–54

Involvement of arginine–specific cysteine proteinase (Arg–gingipain) in fimbriation of Porphyromonas gingivalis. Nakayama K, et al. **J Bacteriol** 1996 May; 178(10):2818–24

Distinct roles of the N–terminal and C–terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. Renauld–Mongénie G, et al. **J Bacteriol** 1996 Feb;178(4):1053–60

Carboxyl–terminal processing of the cytoplasmic NAD–reducing hydrogenase of Alcaligenes eutrophus requires the hoxW gene product. Thiemermann S, et al. **J Bacteriol** 1996 Apr;178(8):2368–74

Presence of a second mechanism for the posttranslational regulation of nitrogenase activity in Azospirillum brasilense in response to ammonium. Zhang Y, et al. **J Bacteriol** 1996 May;178(10):2948–53

Effect of site–directed mutations on processing and activity of gamma–glutamyltranspeptidase of Escherichia coli K–12. Hashimoto W, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):75–80

Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase. Kamoshita K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1244–53

Proteolytic processing of human protein C in swine mammary gland. Lee TK, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):81–7

Characterization of chitin synthase 2 of Saccharomyces cerevisiae. II: Both full size and processed enzymes are active for chitin synthesis. Uchida Y, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):659–66

Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. Atkinson SJ, et al. **J Biol Chem** 1995 Dec 22;270(51):30479–85

Autocrine regulation of membrane transforming growth factor–alpha cleavage. Baselga J, et al. **J Biol Chem** 1996 Feb 9;271(6):3279–84

Cholesterol modulates alpha–secretase cleavage of amyloid precursor protein. Bodovitz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4436–40

Lysosomal protective protein/cathepsin A. Role of the "linker" domain in catalytic activation. Bonten EJ, et al. **J Biol Chem** 1995 Nov 3;270(44):26441–5

Mevalonic acid is limiting for N–linked glycosylation and translocation of the insulin–like growth factor–1 receptor to the cell surface. Evidence for a new link between 3–hydroxy–3–methylglutaryl–coenzyme a reductase and cell growth. Carlberg M, et al. **J Biol Chem** 1996 Jul 19; 271(29):17453–62

Specificity and kinetic studies on the cleavage of various prohormone mono– and paired–basic residue sites by yeast aspartic protease 3. Cawley NX, et al. **J Biol Chem** 1996 Feb 23;271(8):4168–76

Palmitoylation of Ha–Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. Dudler T, et al. **J Biol Chem** 1996 May 10;271(19):11541–7

Differential glycosylation and intracellular trafficking for the long and short isoforms of the D2 dopamine receptor. Fishburn CS, et al. **J Biol Chem** 1995 Dec 15; 270(50):29819–24

Myristoylation–facilitated binding of the G protein ARF1GDP to membrane phospholipids is required for its activation by a soluble nucleotide exchange factor. Franco M, et al. **J Biol Chem** 1996 Jan 19;271(3):1573–8

Human cathepsin G lacking functional glycosylation site is proteolytically processed and targeted for storage in granules after transfection to the rat basophilic/mast cell line RBL or the murine myeloid cell line 32D. Garwicz D, et al. **J Biol Chem** 1995 Nov 24;270(47):28413–8

Processing and activation of CMH–1 by granzyme B. Gu Y, et al. **J Biol Chem** 1996 May 3;271(18):10816–20

Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. Holthuis JCM, et al. **J Biol Chem** 1996 Jul 26;271(30):17755–60

Palmitoylation of endothelin receptor A. Differential modulation of signal transduction activity by post–translational modification. Horstmeyer A, et al. **J Biol Chem** 1996 Aug 23;271(34):20811–9

Cysteine–rich region of Raf–1 interacts with activator domain of post–translationally modified Ha–Ras. Hu CD, et al. **J Biol Chem** 1995 Dec 22;270(51):30274–7

Differential sensitivity of interleukin–1 alpha and –beta precursor proteins to cleavage by calpain, a calcium–dependent prctease. Kavita U, et al. **J Biol Chem** 1995 Nov 17;270(46):27758–65

Furin, PC1/3, and/or PC6A process rabbit, but not human, pro–lactase–phlorizin hydrolase to the 180–kDa intermediate. Keller P, et al. **J Biol Chem** 1995 Oct 27; 270(43):25722–8

Cellular mechanisms for human procollagenase–3 (MMP–13) activation. Evidence that MT1–MMP (MMP–14) and gelatinase a (MMP–2) are able to generate active enzyme. Knäuper V, et al. **J Biol Chem** 1996 Jul 19;271(29):17124–31

Proteolytic processing patterns of prosaposin in insect and mammalian cells. Leonova T, et al. **J Biol Chem** 1996 Jul 19;271(29):17312–20

Post–translational modifications of recombinant P–selectin glycoprotein ligand–1 required for binding to P– and E–selectin. Li F, et al. **J Biol Chem** 1996 Feb 9; 271(6):3255–64

Post–transcriptional stabilization by interleukin–1beta of interleukin–6 mRNA induced by c–kit ligand and interleukin–10 in mouse bone marrow–derived mast cells. Lu–Kuo JM, et al. **J Biol Chem** 1996 Sep 6; 271(36):22169–74

Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta–amyloid precursor protein. McConlogue L, et al. **J Biol Chem** 1996 Jan 19;271(3):1343–8

Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. Miyazawa K, et al. **J Biol Chem** 1996 Feb 16;271(7):3615–8

Posttranslational modification of glyceraldehyde–3–phosphate dehydrogenase by S–nitrosylation and subsequent NADH attachment. Mohr S, et al. **J Biol Chem** 1996 Feb 23;271(8):4209–14

Processive post–translational modification. Vitamin K–dependent carboxylation of a peptide substrate. Morris DP, et al. **J Biol Chem** 1995 Dec 22;270(51):30491–8

Post–translational modification of H–Ras is required for activation of, but not for association with, B–Raf. Okada T, et al. **J Biol Chem** 1996 Mar 1;271(9):4671–8

Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C–proteinase. Panchenko MV, et al. **J Biol Chem** 1996 Mar 22;271(12):7113–9

Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. Rao NV, et al. **J Biol Chem** 1996 Feb 9;271(6):2972–8

GroEL binds to and unfolds rhodanese posttranslationally. Reid BG, et al. **J Biol Chem** 1996 Mar 22;271(12):7212–7

Characterization of profilaggrin endoproteinase 1. A regulated cytoplasmic endoproteinase of epidermis. Resing KA, et al. **J Biol Chem** 1995 Nov 24;270(47):28193–8

Covalent attachment of FAD to the yeast succinate dehydrogenase flavoprotein requires import into mitochondria, presequence removal, and folding. Robinson KM, et al. **J Biol Chem** 1996 Feb 23;271(8):4055–60

A requirement for matrix processing peptidase but not for mitochondrial chaperonin in the covalent attachment of FAD to the yeast succinate dehydrogenase flavoprotein. Robinson KM, et al. **J Biol Chem** 1996 Feb 23; 271(8):4061–7

Differential processing of proglucagon by the subtilisin–like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon–like peptide. Rouillé Y, et al. **J Biol Chem** 1995 Nov 3;270(44):26488–96

Evidence that PC2 is the endogenous pro–neurotensin convertase in rMTC 6–23 cells and that PC1– and PC2–transfected PC12 cells differentially process pro–neurotensin. Rovère C, et al. **J Biol Chem** 1996 May 10;271(19):11368–75

Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta–protein. Saporito–Irwin SM, et al. **J Biol Chem** 1995 Nov 3;270(44):26265–9

Characterization of the O–glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site–directed mutagenesis and gene transfer. Sugahara T, et al. **J Biol Chem** 1996 Aug 23;271(34):20797–804

A second mutant allele of furin in the processing–incompetent cell line, LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. Takahashi S, et al. **J Biol Chem** 1995 Nov 3;270(44):26565–9

Post–translational modification of CD38 protein into a high molecular weight form alters its catalytic properties. Umar S, et al. **J Biol Chem** 1996 Jul 5;271(27):15922–7

Posttranslational folding of alpha 1–inhibitor 3. Evidence for a compaction process. Wassler M, et al. **J Biol Chem** 1995 Oct 13;270(41):24598–603

Tyrosine sulfation of P–selectin glycoprotein ligand–1 is required for high affinity binding to P–selectin. Wilkins PP, et al. **J Biol Chem** 1995 Sep 29;270(39):22677–80

A transient precursor of the HIV–1 protease. Isolation, characterization, and kinetics of maturation. Wondrak EM, et al. **J Biol Chem** 1996 Feb 23;271(8):4477–81

Pro–OmpA derivatives with a His6 tag in their N–terminal "translocation initiation domains" are arrested by Ni2+ at an early post–targeting stage of translocation. Yoshihisa T, et al. **J Biol Chem** 1996 Apr 19;271(16):9429–36

Glycosylation of CD44 is implicated in CD44–mediated cell adhesion to hyaluronan. Bartolazzi A, et al. **J Cell Biol** 1996 Mar;132(6):1199–208

Monoclonal and polyclonal antibodies detect a new type of post–translational modification of axonemal tubulin. Levilliers N, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3013–28

Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. Eskeland NL, et al. **J Clin Invest** 1996 Jul 1;98(1):148–56

An HLA–A2–restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. Skipper JC, et al. **J Exp Med** 1996 Feb 1;183(2):527–34

The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. Yang B, et al. **J Exp Med** 1996 Apr 1;183(4):1545–52

Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus–infected cells. Marshall GS, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1549–57

CD40 ligation results in protein kinase C–independent activation of ERK and JNK in resting murine splenic B cells. Li YY, et al. **J Immunol** 1996 Aug 15;157(4):1440–7

IL–1 beta activation in human epidermis. Nylander–Lundqvist E, et al. **J Immunol** 1996 Aug 15; 157(4):1699–704

Physical and functional association of Fc mu receptor on human natural killer cells with the zeta– and Fc epsilon RI gamma–chains and with src family protein tyrosine kinases. Rabinowich H, et al. **J Immunol** 1996 Aug 15; 157(4):1485–91

Lysosomal degradation and sorting of apolipoprotein E in macrophages. Deng J, et al. **J Lipid Res** 1995 Oct; 36(10):2129–40

Examination of the role of phosphorylation and phospholamban in the regulation of the cardiac sarcoplasmic reticulum Cl– channel. Decrouy A, et al. **J Membr Biol** 1995 Aug;146(3):315–26

Characteristics of the chromaffin granule aspartic proteinase involved in proenkephalin processing. Azaryan AV, et al. **J Neurochem** 1995 Oct;65(4):1771–9

Processing of the beta–amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431–44 (101 ref.)

Localization of sites in the tail domain of the middle molecular mass neurofilament subunit phosphorylated by a neurofilament–associated kinase and by casein kinase I. Hollander BA, et al. **J Neurochem** 1996 Jan;66(1):412–20

Pro–thyrotropin–releasing hormone processing by recombinant PC1. Nillni EA, et al. **J Neurochem** 1995 Dec; 65(6):2462–72

Changes in phosphorylation of tau during ischemia and reperfusion in the rabbit spinal cord. Shackelford DA, et

al. **J Neurochem** 1996 Jan;66(1):286–95
Tissue-specific processing of the neuroendocrine protein VGF. Trani E, et al. **J Neurochem** 1995 Dec;65(6):2441–9
The effects of citrullination or variable amino-terminus acylation on the encephalitogenicity of human myelin basic protein in the PL/J mouse. Zhou SR, et al. **J Neuroimmunol** 1995 Nov;62(2):147–52
Proneuropeptide Y processing in large dense-core vesicles: manipulation of prohormone convertase expression in sympathetic neurons using adenoviruses. Paquet L, et al. **J Neurosci** 1996 Feb 1;16(3):964–73
Myelin basic protein in experimental allergic encephalomyelitis is not affected at the posttranslational level: implications for demyelinating disease. Mastronardi FG, et al. **J Neurosci Res** 1996 May 15;44(4):344–9
Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. Bartenschlager R, et al. **J Virol** 1995 Dec;69(12):7519–28
Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1. Duensing TD, et al. **J Virol** 1995 Nov;69(11):7122–31
Differential processing of sindbis virus glycoprotein PE2 in cultured vertebrate and arthropod cells. Heidner HW, et al. **J Virol** 1996 Mar;70(3):2069–73
Polyprotein processing in Southampton virus: identification of 3C-like protease cleavage sites by in vitro mutagenesis. Liu B, et al. **J Virol** 1996 Apr;70(4):2605–10
Processing of rabbit hemorrhagic disease virus polyprotein. Martin Alonso JM, et al. **J Virol** 1996 Feb;70(2):1261–5
Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase. Pepinsky RB, et al. **J Virol** 1996 May;70(5):3313–8
Posttranslational signal peptidase cleavage at the flavivirus C-prM junction in vitro. Stocks CE, et al. **J Virol** 1995 Dec;69(12):8123–6
Intracellular posttranslational modifications of S1133 avian reovirus proteins. Varela R, et al. **J Virol** 1996 May; 70(5):2974–81
c-Cbl is inducibly tyrosine-phosphorylated by epidermal growth factor stimulation in fibroblasts, and constitutively tyrosine-phosphorylated and associated with v-Src in v-src-transformed fibroblasts. Odai H, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1119–26
Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease. Cover CC, et al. **Life Sci** 1996;58(8):655–64
Post-transcriptional regulation of the Na+/Ca2+ exchanger in aging rat heart. Janapati V, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):195–208
Phosphorylation of Chlamydomonas flagellar proteins. Bloodgood RA, et al. **Methods Cell Biol** 1995;47:121–7
Phosphorylation of transcription factors. Franklin CC, et al. **Methods Enzymol** 1995;254:550–64
Purification of posttranslationally modified and unmodified Rab5 protein expressed in Spodoptera frugiperda cells. Horiuchi H, et al. **Methods Enzymol** 1995;257:9–15
Proteolytic breakdown of membrane-associated polypeptides in mitochondria of Saccharomyces cerevisiae. Langer T, et al. **Methods Enzymol** 1995;260:495–503
Protein import into mammalian mitochondria. Mihara K, et al. **Methods Enzymol** 1995;260:302–10
Protein import into plant mitochondria. Winning BM, et al. **Methods Enzymol** 1995;260:293–302
De Novo synthesis and posttranslational processing of L-histidine decarboxylase in mice. Ichikawa A, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:5–9
Biosynthesis of glycoproteins in Candida albicans: activity of dolichol phosphate mannose synthase and protein mannosylation in a mixed membrane fraction. Arroyo-Flores BL, et al. **Microbiology** 1995 Sep;141 (Pt 9):2289–94
A role for second messengers in the control of activation-associated modification of the surface of Trichinella spiralis infective larvae. Modha J, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):141–8
Selection of diversity at putative glycosylation sites in the immunodominant merozoite/piroplasm surface antigen of Theileria parasites. Shiels BR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):149–62
Requirement for phosphorylation of cyclin B1 for Xenopus oocyte maturation. Li J, et al. **Mol Biol Cell** 1995 Sep; 6(9):1111–24
Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Nishiyama A, et al. **Mol Biol Cell** 1995 Dec;6(12):1819–32
The role of tau phosphorylation in transfected COS-1 cells. Medina M, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):79–88
Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. D'Oro U, et al. **Mol Cell Biol** 1996 Sep; 16(9):4996–5003
Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function. Kong G, et al. **Mol Cell Biol** 1996 Sep; 16(9):5026–35
Phosphorylation of Ga14p at a single C-terminal residue is necessary for galactose-inducible transcription. Sadowski I, et al. **Mol Cell Biol** 1996 Sep;16(9):4879–87
Csk enhances insulin-stimulated dephosphorylation of focal adhesion proteins. Tobe K, et al. **Mol Cell Biol** 1996 Sep; 16(9):4765–72
Human pro-tumor necrosis factor: molecular determinants of membrane translocation, sorting, and maturation. Utsumi T, et al. **Mol Cell Biol** 1995 Nov;15(11):6398–405
Palmitoylation of either Cys-3 or Cys-5 is required for the biological activity of the Lck tyrosine protein kinase. Yurchak LK, et al. **Mol Cell Biol** 1995 Dec;15(12):6914–22
The post-translational processing and intracellular sorting of carboxypeptidase H in the islets of Langerhans. Guest PC, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):99–108
Adenosine diphosphate ribosylation of fibroblast growth factor-2. Boulle N, et al. **Mol Endocrinol** 1995 Jun; 9(6):767–75
Evidence for redundancy in propeptide/prohormone convertase activities in processing proglucagon: an antisense study. Rothenberg ME, et al. **Mol Endocrinol** 1996 Apr;10(4):331–41
The isfA mutation inhibits mutator activity and processing of UmuD protein in Escherichia coli recA730 strains. Bebenek A, et al. **Mol Gen Genet** 1996 Apr 10; 250(6):674–80
Nuclear genes required for post-translational steps in the biogenesis of the chloroplast cytochrome b6f complex in maize. Voelker R, et al. **Mol Gen Genet** 1995 Dec 15; 249(5):507–14
An investigation into the role of N-glycosylation in the functional expression of a recombinant heteromeric NMDA receptor. Chazot PL, et al. **Mol Membr Biol** 1995 Oct-Dec; 12(4):331–7
Phenobarbital induction of hepatic CYP2B1 and CYP2B2: pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Agrawal AK, et al. **Mol Pharmacol** 1996 Mar;49(3):523–31
Evidence for proteolytic processing of tobacco mosaic virus movement protein in Arabidopsis thaliana. Hughes RK, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):658–65
Effects of different kinases and phosphatases on nuclear and cytoplasmic maturation of bovine oocytes. Lévesque JT, et al. **Mol Reprod Dev** 1995 Sep;42(1):114–21
Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease [see comments] Wang JZ, et al. **Nat Med** 1996 Aug; 2(8):871–5. Comment in: Nat Med 1996 Aug;2(8):850–2.
Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Yan SD, et al. **Nat Med** 1995 Jul;1(7):693–9
Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-I transactivator Tax and the proteasome. Rousset R, et al. **Nature** 1996 May 23; 381(6580):328–31
Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Deisseroth K, et al. **Neuron** 1996 Jan; 16(1):89–101
The post-translational incorporation of arginine into a beta-amyloid peptide increases the probability of alpha-helix formation. Bongiovanni G, et al. **Neuroreport** 1995 Dec 29;7(1):326–8
Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Johnson DG. **Oncogene** 1995 Nov 2;11(9):1685–92
Dimerization of a chimeric CD4-interferon-alpha receptor reconstitutes the signaling events preceding STAT phosphorylation. Krishnan K, et al. **Oncogene** 1996 Jul 4; 13(1):125–33
Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. Milne DM, et al. **Oncogene** 1996 Jul 4;13(1):205–11
Identification in vitro of a post-translational regulatory site in the hinge 1 region of Arabidopsis nitrate reductase. Su W, et al. **Plant Cell** 1996 Mar;8(3):519–27
O-glycosylation of a precursor to a sweet potato vacuolar protein, sporamin, expressed in tobacco cells. Matsuoka K, et al. **Plant J** 1995 Dec;8(6):877–89
Carboxyl-terminal processing protease for the D1 precursor protein: cloning and sequencing of the spinach cDNA. Inagaki N, et al. **Plant Mol Biol** 1996 Jan;30(1):39–50
A distinctly regulated protein repair L-isoaspartylmethyltransferase from Arabidopsis thaliana. Mudgett MB, et al. **Plant Mol Biol** 1996 Feb;30(4):723–37
Post-translational processing of the highly processed, secreted periplasmic carbonic anhydrase of Chlamydomonas is largely conserved in transgenic tobacco. Roberts CS, et al. **Plant Mol Biol** 1995 Oct; 29(2):303–15
Proteolytic processing of class IV chitinase in the compatible interaction of bean roots with Fusarium solani. Lange J, et al. **Plant Physiol** 1996 Aug;111(4):1135–44
Surface hydrophobic residues of multiubiquitin chains essential for proteolytic targeting. Beal R, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):861–6
Two alternative processing pathways for a preprohormone: a bioactive form of secretin. Bonetto V, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11985–9
BiP and Sec63p are required for both co- and posttranslational protein translocation into the yeast endoplasmic reticulum. Brodsky JL, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9643–6
Myristate exchange on the Trypanosoma brucei variant surface glycoprotein. Buxbaum LU, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1178–83
A defect in glycosylphosphatidylinositol (GPI) transamidase activity in mutant K cells is responsible for their inability to display GPI surface proteins. Chen R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2280–4
Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. Drews R, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10462–6
Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Fineschi B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10257–61
Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes. Gosink MM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9117–21
Posttranslational amino acid epimerization: enzyme-catalyzed isomerization of amino acid residues in peptide chains. Heck SD, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4036–9
Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Kopan R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1683–8
Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Li X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12357–61
Chromogranin B (secretogranin I) promotes sorting to the regulated secretory pathway of processing intermediates derived from a peptide hormone precursor. Natori S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4431–6
Palmitoylation of the GluR6 kainate receptor. Pickering DS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12090–4
Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Robinson LJ, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11776–80
The silver gene of Drosophila melanogaster encodes multiple carboxypeptidases similar to mammalian prohormone-processing enzymes. Settle SH Jr, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9470–4
Cytochrome c oxidase in Neurospora crassa contains myristic acid covalently linked to subunit 1. Vassilev AO, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8680–4
Regulation of phosducin phosphorylation in retinal rods by Ca2+/calmodulin-dependent adenylyl cyclase. Willardson BM, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1475–9
Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Xu H, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4081–4
The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Yang C, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9871–5
Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter. Young AT, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11613–7
Second-site suppression of regulatory phosphorylation in Escherichia coli isocitrate dehydrogenase. Chen R, et al. **Protein Sci** 1996 Feb;5(2):287–95
Posttranslational processing of recombinant human interferon-gamma in animal expression systems. James DC, et al. **Protein Sci** 1996 Feb;5(2):331–40
Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Sørensen ES, et al. **Protein Sci** 1995 Oct;4(10):2040–9
Isolation, identification and functional significance of [Hyp2]Met-callatostatin and des Gly-Pro Met-callatostatin, two further post-translational modifications of the blowfly neuropeptide Met-callatostatin. Duve H, et al. **Regul Pept** 1995 Jun 27; 57(3):237–45
Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Hupe-Sodmann K, et al. **Regul Pept** 1995 Aug 22;58(3):149–56
Proglucagon processing in islet and intestinal cell lines. Tucker JD, et al. **Regul Pept** 1996 Apr 9;62(1):29–35
When proteins receive deadly messages at birth [comment] Jentsch S. **Science** 1996 Feb 16;271(5251):955–6. Comment on: Science 1996 Feb 16;271(5251):990–3.
Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA [see comments] Keiler KC, et al. **Science** 1996 Feb 16;271(5251):990–3. Comment in: Science 1996 Feb 16;271(5251):955–6.
Protein phosphorylation and signal transduction. Barik S. **Subcell Biochem** 1996;26:115–64 (182 ref.)
Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736–42
Native and non-glycosylated recombinant single-chain

urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells. van der Kaaden ME, et al. **Thromb Haemost** 1995 Aug; 74(2):722–9

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122–6 (40 ref.)

Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active. Arad G, et al. **Virology** 1995 Dec 20;214(2):439–44

Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Gripon P, et al. **Virology** 1995 Nov 10;213(2):292–9

In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Lindhofer H, et al. **Virology** 1995 Dec 20;214(2):624–7

Intracellular synthesis, processing, and transport of proteins encoded by ORFs 5 to 7 of porcine reproductive and respiratory syndrome virus. Mardassi H, et al. **Virology** 1996 Jul 1;221(1):98–112

Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Quillent C, et al. **Virology** 1996 May 1;219(1):29–36

[Processing of hepatitis C virus envelope proteins] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:51–6 (17 ref.) **(Jpn)**

[Mechanism of hepatitis C virus protein processing] Tanji Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:25–9 (12 ref.) **(Jpn)**

[Disruption of processing of alkaline phosphatase as a result of single amino acid changes affects the composition and metabolism of phospholipids from Escherichia coli, secreting mutant proteins] Kalinin AE, et al. **Biokhimiia** 1996 Jan;61(1):100–9 (Eng. Abstr.) **(Rus)**

[Mechanisms of regulation and the biological role of carboxypeptidase H—a neuropeptide-processing enzyme] Vernigora AN, et al. **Biokhimiia** 1995 Dec;60(12):1953–63 (124 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. Jochen AL, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):65–72

Ethanol consumption alters trafficking of lysosomal enzymes and affects the processing of procathepsin L in rat liver. Kharbanda KK, et al. **Biochim Biophys Acta** 1996 Aug 29; 1291(1):45–52

Posttranslational regulation of nitrogenase activity by fixed nitrogen in Azotobacter chroococcum. Muñoz-Centeno MC, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):67–74

Myeloid differentiation and retinoblastoma phosphorylation changes in HL-60 cells induced by retinoic acid receptor- and retinoid X receptor-selective retinoic acid analogs. Brooks SC 3rd, et al. **Blood** 1996 Jan 1;87(1):227–37

Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. Carey JO, et al. **Blood** 1996 May 15;87(10):4316–24

Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. Gotoh A, et al. **Blood** 1996 Jul 1;88(1):138–45

Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells. Mu SX, et al. **Blood** 1995 Dec 15;86(12):4532–43

Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Novak U, et al. **Blood** 1995 Oct 15;86(8):2948–56

Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation. Zu YL, et al. **Blood** 1996 Jun 15;87(12):5287–96

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)

Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes. Zangar RC, et al. **Drug Metab Dispos** 1995 Jul;23(7):681–7

Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11. Fuhrer DK, et al. **Exp Hematol** 1996 Feb;24(2):195–203

Transduction signals induced in rat brain cortex astrocytes by the HIV-1 gp120 glycoprotein. Codazzi F, et al. **FEBS Lett** 1996 Apr 15;384(2):135–7

Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug. Kang MS. **Glycobiology** 1996 Mar;6(2):209–16

Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients. Beers MF. **J Biol Chem** 1996 Jun 14;271(24):14361–70

Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-beta 1 in osteoblastic MC3T3-E1 cells. Feres-Filho EJ, et al. **J Biol Chem** 1995 Dec 22;270(51):30797–803

Brefeldin A reversibly inhibits the assembly of apoB containing lipoproteins in McA-RH7777 cells. Rustaeus S, et al. **J Biol Chem** 1995 Dec 1;270(48):28879–86

Tyrphostin A9 inhibits calcium release-dependent phosphorylations and calcium entry via calcium release-activated channel in Jurkat T cells. Marhaba R, et al. **J Immunol** 1996 Aug 15;157(4):1468–73

Tenidap and other anion transport inhibitors disrupt cytolytic T lymphocyte-mediated IL-1 beta post-translational processing. Perregaux DG, et al. **J Immunol** 1996 Jul 1; 157(1):57–64

Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. Tamir A, et al. **J Immunol** 1996 Aug 15;157(4):1514–22

Glutamate induces a calcineurin-mediated dephosphorylation of Na+,K(+)-ATPase that results in its activation in cerebellar neurons in culture. Marcaida G, et al. **J Neurochem** 1996 Jan;66(1):99–104

Thymosin alpha-1 and FA-1 monoclonal antibody affect fertilizing capacity of human sperm by modulating protein phosphorylation pattern. Ahmad K, et al. **J Reprod Immunol** 1995 May;29(1):1–17

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. Turpin JA, et al. **J Virol** 1996 Sep;70(9):6180–9

Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Goishi K, et al. **Mol Biol Cell** 1995 Aug;6(8):967–80

Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Lassègue B, et al. **Mol Pharmacol** 1995 Oct; 48(4):601–9

The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells. Vaillancourt RR, et al. **Oncogene** 1996 Jul 4;13(1):151–9

GENETICS

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)

Does gene palB regulate the transcription or the post-translational modification of Pi-repressible phosphatases of Aspergillus nidulans? Maccheroni Júnior W, et al. **Braz J Med Biol Res** 1995 Jan;28(1):31–8

STT3, a highly conserved protein required for yeast oligosaccharyl transferase activity in vivo. Zufferey R, et al. **EMBO J** 1995 Oct 16;14(20):4949–60

Mutations in the processing site of the precursor of ribulose-1,5-bisphosphate carboxylase/oxygenase small subunit: effects on import, processing, assembly and stability. Levy M, et al. **Plant Mol Biol** 1995 Oct; 29(1):53–61

PHYSIOLOGY

Evidence for a link between translocation and processing during protein import into soybean mitochondria. Whelan J, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):48–54

Posttranslational mitochondrial protein import in a homologous yeast in vitro system. Hönlinger A, et al. **Biol Chem Hoppe Seyler** 1995 Aug;376(8):515–9

Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex. Whisler RL, et al. **Cell Immunol** 1996 Mar 15;168(2):201–10

Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21–6 (30 ref.)

Quantitation of procholecystokinin and its products in plasma by processing-independent analysis. Paloheimo LI, et al. **Clin Chim Acta** 1995 Jun 30;238(1):21–33

Soluble constituents of the ER lumen are required for GPI anchoring of a model protein. Vidugiriene J, et al. **EMBO J** 1995 Oct 2;14(19):4686–94

Delayed translation and posttranslational processing of cyritestin, an integral transmembrane protein of the mouse acrosome. Linder B, et al. **Exp Cell Res** 1995 Nov; 221(1):66–72

Tissue-specific posttranslational modification of the small heat shock protein HSP27 in Drosophila. Marin R, et al. **Exp Cell Res** 1996 Feb 25;223(1):1–8

A role for phosphorylation in the proteolytic processing of the human NF-kappa B1 precursor. Fujimoto K, et al. **Gene** 1995 Nov 20;165(2):183–9

Serine protease EpiP from Staphylococcus epidermidis catalyzes the processing of the epidermin precursor peptide. Geissler S, et al. **J Bacteriol** 1996 Jan;178(1):284–8

The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662–7

Cellular expression of the Drosophila melanogaster FMRFamide neuropeptide gene product DPKQDFMRFamide. Evidence for differential processing of the FMRFamide polypeptide precursor. Nichols R, et al. **J Mol Neurosci** 1995;6(1):1–10

Protein N-myristoylation as a chemotherapeutic target for cancer [editorial] Felsted RL, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1571–3

Increased N-myristoyltransferase activity observed in rat and human colonic tumors. Magnuson BA, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1630–5

Secretogranin II: regulation of synthesis and post-translational proteolysis in bovine adrenal chromaffin cells. Soszynski D, et al. **J Neuroendocrinol** 1993 Dec; 5(6):655–62

Dietary energy restriction in mice negatively regulates hepatic glucose-regulated protein 78 (GRP78) expression at the posttranscriptional level. Tillman JB, et al. **J Nutr** 1996 Feb;126(2):416–23

Ionic milieu controls the compartment-specific activation of pro-opiomelanocortin processing in AtT-20 cells. Schmidt WK, et al. **Mol Biol Cell** 1995 Oct;6(10):1271–85

PROTEIN-RESTRICTED DIET see **DIET, PROTEIN-RESTRICTED**

PROTEIN S

ANALYSIS

Adaptation of a functional assay for protein S to a Cobas Fara II centrifugal analyzer. Solomon HM, et al. **Am J Clin Pathol** 1995 Dec;104(6):655–9

Acquired free protein S deficiency in children with steroid resistant nephrosis. Hanevold CD, et al. **Ann Clin Lab Sci** 1996 May-Jun;26(3):279–82

Assay of protein S in systemic lupus erythematosus. Lawrie AS, et al. **Blood Coagul Fibrinolysis** 1995 Jun;6(4):322–4

Influence of protein C resistance (APC-R) on the determination of proteins C and S by functional clotting assays [letter] Ortega IS, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):683

Expression of S-100 protein in the human fetal inner ear. Yamashita H, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):312–5

Spatial exploration in transgenic mice expressing human beta-S100. Janus C, et al. **Neurobiol Learn Mem** 1995 Jul; 64(1):58–67

New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Aillaud MF, et al. **Thromb Haemost** 1996 Feb;75(2):283–5

Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Henkens CM, et al. **Thromb Haemost** 1995 Nov;74(5):1271–5

Parameters of haemostasis during acute venous thrombosis. Reiter W, et al. **Thromb Haemost** 1995 Aug;74(2):596–601

[May (must?) in a for recurrent thrombophlebitis [with normal AT III/ protein C+S] fully "marcumarized" patient (with [otherwise?] negative contraindications) with acute posterior wall infarct (15 min "old") a brief lysis therapy be instituted?] Seitz R. **Internist (Berl)** 1995 Dec;36(12):1202 **(Ger)**

[Protein S] Hayashi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:117–21 (18 ref.) **(Jpn)**

BIOSYNTHESIS

IL-6 upregulates protein S expression in the HepG-2 hepatoma cells. Hooper WC, et al. **Thromb Haemost** 1995 May;73(5):819–24

CEREBROSPINAL FLUID

Cerebrospinal fluid levels of S-100b protein and neuron-specific enolase in chronic inflammatory demyelinating polyneuropathy. Nagamatsu M, et al. **Acta Neurol Scand** 1995 Jun;91(6):483–7

DEFICIENCY see PROTEIN S DEFICIENCY

DRUG EFFECTS

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Gilabert J, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1849–54

GENETICS

Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Beauchamp NJ, et al. **Blood** 1996 Sep 1;88(5):1700–7

The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Duchemin J, et al. **Blood** 1995 Nov 1;86(9):3436–43

Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. Formstone CJ, et al. **Blood** 1996 May 1;87(9):3731–7

Protein S deficiency type I: identification of point mutations in 9 of 10 families. Mustafa S, et al. **Blood** 1995 Nov 1; 86(9):3444–51

Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Yamazaki T, et al. **Blood** 1996 Jun 1;87(11):4643–50

Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Holmes ZR, et al. **Br J Haematol** 1996 Mar;92(4):986–91

PROTEIN S

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81–9 (120 ref.)

Identification of eight point mutations in protein S deficiency type I—analysis of 15 pedigrees. Gómez E, et al. **Thromb Haemost** 1995 May;73(5):750–5

Protein S mRNA in patients with protein S deficiency. Sacchi E, et al. **Thromb Haemost** 1995 May;73(5):746–9

A quantitative protein S deficiency associated with a novel nonsense mutation and markedly reduced levels of mutated mRNA. Yamazaki T, et al. **Thromb Haemost** 1995 Aug; 74(2):590–5

IMMUNOLOGY

Acquired free protein S deficiency associated with multiple myeloma: a case report. Deitcher SR, et al. **Am J Hematol** 1996 Apr;51(4):319–23

METABOLISM

Molecular mechanism of the dysfunction of protein S(Tokushima) (Lys155—>Glu) for the regulation of the blood coagulation system. Hayashi T, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):159–67

Comparison of activated protein C/protein S–mediated inactivation of human factor VIII and factor V. Lu D, et al. **Blood** 1996 Jun 1;87(11):4708–17

Inflammation. They're not just for clots anymore. Esmon CT. **Curr Biol** 1995 Jul 1;5(7):743–6 (15 ref.)

The Dtk receptor tyrosine kinase, which binds protein S, is expressed during hematopoiesis. Crosier PS, et al. **Exp Hematol** 1996 Feb;24(2):318–23

The amino-terminal module of the C4b-binding protein beta-chain contains the protein S–binding site. Härdig Y, et al. **J Biol Chem** 1996 Aug 23;271(34):20861–7

Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. Rosing J, et al. **J Biol Chem** 1995 Nov 17;270(46):27852–8

Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. Tabbara IA, et al. **J Hematother** 1996 Feb;5(1):79–84

The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va. Nishioka J, et al. **Thromb Haemost** 1996 Feb;75(2):275–82

Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S. Clyne N, et al. **Thromb Res** 1995 Oct 15;80(2):161–8

[Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in TCM] Liang TJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):599–600 (Eng. Abstr.) **(Chi)**

PROTEIN S DEFICIENCY

BLOOD

Influence of protein C resistance (APC-R) on the determination of proteins C and S by functional clotting assays [letter] Ortega IS, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):683

Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Zöller B, et al. **Thromb Haemost** 1996 Feb;75(2):270–4

CHEMICALLY INDUCED

Resistance to activated protein C in healthy women taking oral contraceptives. Olivieri O, et al. **Br J Haematol** 1995 Oct;91(2):465–70

COMPLICATIONS

Short-segment jejunal stenosis complicating subacute portomesenteric venous thrombosis in a patient with protein S deficiency type II. Arentsen JC, et al. **Am J Gastroenterol** 1996 Aug;91(8):1653–4

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163–5 (11 ref.)

Cerebral and vein thrombosis, transient protein S deficiency, and anticardiolipin antibodies [letter] Ricchieri GL, et al. **Am J Hematol** 1996 May;52(1):69–70

Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Rostaing L, et al. **Am J Nephrol** 1995; 15(6):524–7

Buerger's disease and protein S deficiency: successful treatment with prostacyclin. Athanassiou P, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):371–5

Clinically silent pulmonary embolism due to transient protein S deficiency. Buffaz PD, et al. **Clin Nucl Med** 1995 Nov; 20(11):1016–7

Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Bertram B, et al. **Ger J Ophthalmol** 1995 Nov;4(6):332–5

Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis [letter] Villa P, et al. **Lancet** 1996 Feb 10;347(8998):397

Recurrent venous thrombosis in a patient with cystic fibrosis. Collinson J, et al. **Pediatr Pulmonol** 1995 Dec;20(6):410–2

Superior sagittal sinus thrombosis and acquired free protein S deficiency in the elderly [letter] D'Olhaberriague L, et al. **Stroke** 1996 Feb;27(2):338–40

New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139–48 (112 ref.)

Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Koeleman BP, et al. **Thromb Haemost** 1995 Aug;74(2):580–3

The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Sanson BJ, et al. **Thromb Haemost** 1996 Mar;75(3):387–8

Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Zöller B, et al. **Thromb Haemost** 1995 May;73(5):743–5

DIAGNOSIS

New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Aillaud MF, et al. **Thromb Haemost** 1996 Feb;75(2):283–5

EPIDEMIOLOGY

The accurate definition of protein S deficiency may avoid the misestimation of the frequency of this defect [letter; comment] Falkon L, et al. **Blood** 1996 Mar 15;87(6):2604 . Comment on: Blood 1995 May 15;85(10):2756–61.

ETIOLOGY

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Bucalossi A, et al. **Am J Hematol** 1996 May;52(1):14–20

Acquired free protein S deficiency associated with multiple myeloma: a case report. Deitcher SR, et al. **Am J Hematol** 1996 Apr;51(4):319–23

Acquired free protein S deficiency in children with steroid resistant nephrosis. Hanevold CD, et al. **Ann Clin Lab Sci** 1996 May-Jun;26(3):279–82

Protein S deficiency after varicella [letter] Pashankar D, et al. **J Pediatr** 1996 Aug;129(2):315–6

GENETICS

Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Pabinger I, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):742–8

Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Beauchamp NJ, et al. **Blood** 1996 Sep 1;88(5):1700–7

The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Duchemin J, et al. **Blood** 1995 Nov 1;86(9):3436–43

Protein S deficiency type I: identification of point mutations in 9 of 10 families. Mustafa S, et al. **Blood** 1995 Nov 1; 86(9):3444–51

Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Yamazaki T, et al. **Blood** 1996 Jun 1;87(11):4643–50

Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Holmes ZR, et al. **Br J Haematol** 1996 Mar;92(4):986–91

Hereditary deficiency of protein C, protein S and antithrombin III. Vittore CP, et al. **Can Assoc Radiol J** 1996 Aug;47(4):251–6

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81–9 (120 ref.)

Five novel mutations of the protein S active gene (PROS 1) in 8 Norman families. Duchemin J, et al. **Thromb Haemost** 1996 Mar;75(3):437–44

Identification of eight point mutations in protein S deficiency type I—analysis of 15 pedigrees. Gómez E, et al. **Thromb Haemost** 1995 May;73(5):750–5

Protein S mRNA in patients with protein S deficiency. Sacchi E, et al. **Thromb Haemost** 1995 May;73(5):746–9

A quantitative protein S deficiency associated with a novel nonsense mutation and markedly reduced levels of mutated mRNA. Yamazaki T, et al. **Thromb Haemost** 1995 Aug; 74(2):590–5

[Cerebrovascular complications and hereditary protein S deficiency: 2 cases] Pagès M, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):288–91 (Eng. Abstr.) **(Fre)**

[Thrombophilia in a family with resistance to activated protein C and protein S deficiency] Lewandowski K, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):518–24 (Eng. Abstr.) **(Pol)**

PROTEIN-SERINE-THREONINE KINASES

Expression of activin receptors type I and II only partially overlaps in the nervous system. Bengtsson H, et al. **Neuroreport** 1995 Dec 29;7(1):113–6

ANALYSIS

Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM, et al. **Am J Pathol** 1996 May;148(5):1531–41

The identification of the phosphorylated 150/160-kDa proteins of sarcoplasmic reticulum, their kinase and their association with the ryanodine receptor. Shoshan-Barmatz V, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):89–100

Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. Hoshi M, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):683–5

Analysis of the native murine bone morphogenetic protein serine threonine kinase type I receptor (ALK-3). Wu X, et al. **J Cell Physiol** 1996 Aug;168(2):453–61

Expression of myotonic dystrophy protein kinase in biopsied muscles. Tachi N, et al. **J Neurol Sci** 1995 Sep;132(1):61–4

Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Alessi DR, et al. **Methods Enzymol** 1995;255:279–90

Assay of MEK kinases. Lange-Carter CA, et al. **Methods Enzymol** 1995;255:290–301

Immune complex kinase assays for mitogen-activated protein kinase and MEK. Reuter CW, et al. **Methods Enzymol** 1995; 255:245–56

ANTAGONISTS & INHIBITORS

DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Take Y, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):207–12

OK-1035, a selective inhibitor of DNA-dependent protein kinase. Take Y, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):41–7

Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Reardon DB, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):401–4

Rapamycin-resistant human lymphoid cell lines. Kay JE, et al. **Biochem Soc Trans** 1996 Feb;24(1):89S

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA, et al. **Cancer Res** 1996 Jul 1;56(13):2973–8

The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Wang T, et al. **Cell** 1996 Aug 9;86(3):435–44

Inhibitors of serine/threonine kinases. Lee JC, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):657–61 (35 ref.)

The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Pearson RB, et al. **EMBO J** 1995 Nov 1;14(21):5279–87

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Meggio F, et al. **Eur J Biochem** 1995 Nov 15;234(1):317–22

A protein kinase-dependent block to reinitiation of DNA replication in G2 phase in mammalian cells. Coverley D, et al. **Exp Cell Res** 1996 Jun 15;225(2):294–300

Mapping the residues of protein kinase CK2 alpha subunit responsible for responsiveness to polyanionic inhibitors. Vaglio P, et al. **FEBS Lett** 1996 Feb 12;380(1-2):25–8

Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase. Korth MJ, et al. **Gene** 1996 May 8;170(2):181–8

Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. Kranenburg O, et al. **J Cell Biol** 1995 Oct;131(1):227–34

Stimulation of cell elongation in teleost rod photoreceptors by distinct protein kinase inhibitors. Pagh-Roehl K, et al. **J Neurochem** 1996 Jun;66(6):2311–9

Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. Siebert R, et al. **Leuk Res** 1996 Feb;20(2):197–200

Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Watts CK, et al. **Mol Endocrinol** 1995 Dec;9(12):1804–13

Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo [see comments] Indolfi C, et al. **Nat Med** 1995 Jun;1(6):541–5. Comment in: Nat Med 1995 Jun;1(6):513–5.

p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Fotedar R, et al. **Oncogene** 1996 May 16;12(10):2155–64

p21WAF1/CIP1 interacts with protein kinase CK2. Götz C, et al. **Oncogene** 1996 Jul 18;13(2):391–8

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2735–40

BIOSYNTHESIS

Control of renal carcinoma TC-1 growth, cyclin/kinase and nm23 expression by IFN-gamma and TGF-beta. Hall S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1755–8

Vascular smooth muscle cells express multiple type I receptors for TGF-beta, activin, and bone morphogenetic proteins. Agrotis A, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):613-8

Myotonic protein kinase expression in human and bovine lenses. Dunne PW, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):281-8

Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Konishi H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):526-34

Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog. Wu X, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):78-83

Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Borlak JT, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):517-29

Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: regulation by TGF-beta. Bloom BB, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):243-8

The Xenopus laevis homologue to the neuronal cyclin-dependent kinase (cdk5) is expressed in embryos by gastrulation. Gervasi C, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):192-200

Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Martin JH, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):47-57

Misregulated expression of the cyclin dependent kinase 2 protein in human fibroblasts is accompanied by the inability to maintain a G2 arrest following DNA damage. Walker DH, et al. **Cell Growth Differ** 1995 Sep;6(9):1053-61

Expression of raf serine/threonine protein kinases in the cell bodies of primary sensory neurons of the adult rat. Mihaly A, et al. **Cell Tissue Res** 1996 Aug;285(2):261-71

Expression of TGF-beta type I and type II receptors in rat eyes. Obata H, et al. **Curr Eye Res** 1996 Mar;15(3):335-40

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2-4):155-60 (9 ref.)

Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. Bartkova J, et al. **Int J Cancer** 1996 Jun 11;66(6):732-7

Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Landström M, et al. **Int J Cancer** 1996 Aug 7;67(4):573-9

Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos. Su JY, et al. **J Biol Chem** 1996 Jun 14;271(24):14430-7

Developmental and tissue-specific expression of mouse pelle-like protein kinase. Trofimova M, et al. **J Biol Chem** 1996 Jul 26;271(30):17609-12

Investigation of myotonic dystrophy kinase isoform translocation and membrane association. Waring JD, et al. **J Biol Chem** 1996 Jun 21;271(25):15187-93

ET-1 and PDGF BB induce MEK mRNA and protein expression in mesangial cells. Schramek H, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S95-9

CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth. Ishida T, et al. **J Immunol** 1995 Dec 15; 155(12):5527-35

A Drosophila homolog of the Rac- and Cdc42-activated serine/threonine kinase PAK is a potential focal adhesion and focal complex protein that colocalizes with dynamic actin structures. Harden N, et al. **Mol Cell Biol** 1996 May; 16(5):1896-908

Allele-specific suppression of a Saccharomyces cerevisiae prp20 mutation by overexpression of a nuclear serine/threonine protein kinase. Fleischmann M, et al. **Mol Gen Genet** 1996 Mar 20;250(5):614-25

Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice [see comments] Jansen G, et al. **Nat Genet** 1996 Jul;13(3):316-24. Comment in: Nat Genet 1996 Jul;13(3):259-60.

Raf-1 kinase and ERK2 uncoupled from mitogenic signals in rat fibroblasts. Kortenjann M, et al. **Oncogene** 1995 Nov 16;11(10):2105-12

Cold calcium signaling in Arabidopsis involves two cellular pools and a change in calcium signature after acclimation. Knight H, et al. **Plant Cell** 1996 Mar;8(3):489-503

Involvement of the double-stranded-RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity. Der SD, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8841-5

Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Oldham SM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6924-8

Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain. Xu S, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5291-5

BLOOD

A membrane-bound protein kinase from rabbit reticulocytes is an active form of multipotential S6 kinase. Bensen ES, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):249-58

CHEMISTRY

Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Konishi H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):526-34

Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. Bevilacqua PC, et al. **Biochemistry** 1996 Aug 6;35(31):9983-94

Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Geyer M, et al. **Biochemistry** 1996 Aug 13;35(32):10308-20

Arabidopsis thaliana cDNA isolated by functional complementation shows homology to serine/threonine protein kinases. Covic L, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):125-9

The protein kinase from mitotic human cells that phosphorylates Ser-209 on the casein kinase II beta-subunit is p34cdc2. Litchfield DW, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):69-78

Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Bourne Y, et al. **Cell** 1996 Mar 22;84(6):863-74

MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. Adamczewski JP, et al. **EMBO J** 1996 Apr 15; 15(8):1877-84

The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Colwill K, et al. **EMBO J** 1996 Jan 15;15(2):265-75

Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. Kohn AD, et al. **EMBO J** 1995 Sep 1;14(17):4288-95

A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. Martin GA, et al. **EMBO J** 1995 Sep 1;14(17):4385

Fission yeast pak1+ encodes a protein kinase that interacts with Cdc42p and is involved in the control of cell polarity and mating. Ottilie S, et al. **EMBO J** 1995 Dec 1; 14(23):5908-19

Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H. Higashi H, et al. **Eur J Biochem** 1996 Apr 15;237(2):460-7

Purification and characterization of a p13suc1-bound serine/threonine kinase that is expressed in mature rat brain. Tamaru T, et al. **Eur J Biochem** 1996 May 15;238(1):152-9

Immunological evidence that HMG-CoA reductase kinase-A is the cauliflower homologue of the RKIN1 subfamily of plant protein kinases. Ball KL, et al. **FEBS Lett** 1995 Dec 18;377(2):189-92

Structure of protein kinase CK2: dimerization of the human beta-subunit. Boldyreff B, et al. **FEBS Lett** 1996 Jan 29; 379(2):153-6

Mapping the residues of protein kinase CK2 alpha subunit responsible for responsiveness to polyanionic inhibitors. Vaglio P, et al. **FEBS Lett** 1996 Feb 12;380(1-2):25-8

Pk92B: a Drosophila melanogaster protein kinase that belongs to the MEKK family. Wassarman DA, et al. **Gene** 1996 Mar 9;169(2):283-4

Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. Butch ER, et al. **J Biol Chem** 1996 Feb 23;271(8):4230-5

Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. Ghosh S, et al. **J Biol Chem** 1996 Apr 5;271(14):8472-80

The physical association of casein kinase 2 with nucleolin. Li D, et al. **J Biol Chem** 1996 Jun 28;271(26):15662-8

ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). Nelson JW, et al. **J Biol Chem** 1996 Jul 19;271(29):17021-7

Dual regulation of a chimeric plant serine/threonine kinase by calcium and calcium/calmodulin. Takezawa D, et al. **J Biol Chem** 1996 Apr 5;271(14):8126-32

Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. Zhang H, et al. **J Immunol** 1996 Jan 15;156(2):564-73

Genetic dissection of intersubunit contacts within human protein kinase CK2. Kusk M, et al. **J Mol Biol** 1995 Nov 10;253(5):703-11

Identification of an autoinhibitory region in the activation loop of the Mos protein kinase. Robertson SC, et al. **Mol Cell Biol** 1996 Jul;16(7):3472-9

Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Block C, et al. **Nat Struct Biol** 1996 Mar;3(3):244-51

Picture story. Cyclin switch. Riddihough G. **Nat Struct Biol** 1995 Aug;2(8):636

Structural basis of cyclin-dependent kinase activation by phosphorylation. Russo AA, et al. **Nat Struct Biol** 1996 Aug;3(8):696-700

Under arrest at atomic resolution [news; comment] Morgan DO. **Nature** 1996 Jul 25;382(6589):295-6. Comment on: Nature 1996 Jul 25;382(6589):325-31.

Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex [see comments] Russo AA, et al. **Nature** 1996 Jul 25; 382(6589):325-31. Comment in: Nature 1996 Jul 25;382(6589):295-6.

Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. Clark GJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1577-81

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2735-40

The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Debant A, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5466-71

The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Mott HR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8312-7

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Schulze-Gahmen U, et al. **Proteins** 1995 Aug;22(4):378-91

A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Espinoza FH, et al. **Science** 1996 Sep 20;273(5282):1714-7

Structuring cell-cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131-4 (52 ref.). Comment on: Structure 1995 Nov 15;3(11):1235-47.

How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641-3 (17 ref.)

The protein kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) fused to the extracellular domain of the epidermal growth factor receptor is ligand-inducible. Smith CC, et al. **Virology** 1996 Mar 15;217(2):425-34

DEFICIENCY

p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Huang LC, et al. **Cancer Res** 1996 Jul 1;56(13):2940-4

Lack of detectable defect in DNA double-strand break repair and DNA-dependent protein kinase activity in radiosensitive human severe combined immunodeficiency fibroblasts. Nicolas N, et al. **Eur J Immunol** 1996 May; 26(5):1118-22

Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy [see comments] Reddy S, et al. **Nat Genet** 1996 Jul;13(3):325-35. Comment in: Nat Genet 1996 Jul;13(3):259-60.

DRUG EFFECTS

Effect of tumor necrosis factor-alpha on insulin-stimulated mitogen-activated protein kinase cascade in cultured rat skeletal muscle cells. Begum N, et al. **Eur J Biochem** 1996 May 15;238(1):214-20

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase [see comments] Monia BP, et al. **Nat Med** 1996 Jun;2(6):668-75 . Comment in: Nat Med 1996 Jun;2(6):634-5.

Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells. Akagi T, et al. **Oncogene** 1996 Jul 18;13(2):399-405

GENETICS

Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Liang H, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):259-65

Myotonic dystrophy: antisense oligonucleotide inhibition of DMPK gene expression in vitro. Galderisi U, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):750-4

Cloning of the gene encoding a putative serine/threonine protein kinase which enhances spermine uptake in Saccharomyces cerevisiae. Kakinuma Y, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):985-92

Molecular cloning of Xenopus activin type I receptor and the analysis of its expression during embryogenesis. Kondo M, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):549-55

Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Miwa W, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):968-74

Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. Shindoh N, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):92-9

Synergistic gene expressions of cyclin E, cdk2, cdk5 and E2F-1 during the prolactin-induced G1/S transition in rat Nb2 pre-T lymphoma cells. Hosokawa Y, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):393-9

cDNA cloning and characterization of rat Clk3, a LAMMER kinase predominately expressed in testis. Becker W, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):63-7

Arabidopsis thaliana cDNA isolated by functional complementation shows homology to serine/threonine protein kinases. Covic L, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):125-9

Genomic structure of carp mitogen-activated protein kinase

kinase 1 gene. Leu JH, et al. **Biochim Biophys Acta** 1996 May 2;1306(2–3):133–6

Ccl1, a cyclin associated with protein kinase Kin28, controls the phosphorylation of RNA polymerase II largest subunit and mRNA transcription. Valay JG, et al. **C R Acad Sci III** 1996 Mar;319(3):183–9

Molecular cloning of CDK7–associated human MAT1, a cyclin–dependent kinase–activating kinase (CAK) assembly factor. Yee A, et al. **Cancer Res** 1995 Dec 15;55(24):6058–62

LIM–kinase1 hemizygosity implicated in imparied visuospatial constructive cognition. Frangiskakis JM, et al. **Cell** 1996 Jul 12;86(1):59–69

The Cdk–activating kinase (CAK) from budding yeast. Kaldis P, et al. **Cell** 1996 Aug 23;86(4):553–64

Tomato Prf is a member of the leucine–rich repeat class of plant disease resistance genes and lies embedded within the Pto kinase gene cluster. Salmeron JM, et al. **Cell** 1996 Jul 12;86(1):123–33

Civ1 (CAK in vivo), a novel Cdk–activating kinase. Thuret JY, et al. **Cell** 1996 Aug 23;86(4):565–76

CHUK, a new member of the helix–loop–helix and leucine zipper families of interacting proteins, contains a serine–threonine kinase catalytic domain. Connelly MA, et al. **Cell Mol Biol Res** 1995;41(6):537–49

FOG1 and FOG2 genes, required for the transcriptional activation of glucose–repressible genes of Kluyveromyces lactis, are homologous to GAL83 and SNF1 of saccharomyces cerevisiae. Goffrini P, et al. **Curr Genet** 1996 Mar;29(4):316–26

PkpA, a novel Phycomyces blakesleeanus serine/threonine protein kinase. Ruiz–Pérez VL, et al. **Curr Genet** 1995 Sep; 28(4):309–16

Chromosomal mapping of the human genes CKS1 to 8q21 and CKS2 to 9q22. Demetrick DJ, et al. **Cytogenet Cell Genet** 1996;73(3):250–4

Cell–specific expression of the ZPK gene in adult mouse tissues. Blouin R, et al. **DNA Cell Biol** 1996 Aug; 15(8):631–42

Identification of a cdk–activating kinase in fission yeast. Buck V, et al. **EMBO J** 1995 Dec 15;14(24):6173–83

Schizosaccharomyces pombe Mop1–Mcs2 is related to mammalian CAK. Damagnez V, et al. **EMBO J** 1995 Dec 15;14(24):6164–72

MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H–cdk7 complexes in starfish and Xenopus CAK. Devault A, et al. **EMBO J** 1995 Oct 16; 14(20):5027–36

CPEB controls the cytoplasmic polyadenylation of cyclin, Cdk2 and c–mos mRNAs and is necessary for oocyte maturation in Xenopus. Stebbins–Boaz B, et al. **EMBO J** 1996 May 15;15(10):2582–92

Molecular cloning and characterization of a novel mammalian protein kinase harboring a homology domain that defines a subfamily of serine/threonine kinases. Becker W, et al. **Eur J Biochem** 1996 Feb 1;235(3):736–43

Escherichia coli isocitrate dehydrogenase kinase/phosphatase. Overproduction and kinetics of interaction with its substrates by using intrinsic fluorescence and fluorescent nucleotide analogues. Rittinger K, et al. **Eur J Biochem** 1996 Apr 1;237(1):247–54

Expression of the subunits of protein kinase CK2 during oogenesis in Xenopus laevis. Wilhelm V, et al. **Eur J Biochem** 1995 Sep 1;232(2):671–6

Lack of detectable defect in DNA double–strand break repair and DNA–dependent protein kinase activity in radiosensitive human severe combined immunodeficiency fibroblasts. Nicolas N, et al. **Eur J Immunol** 1996 May; 26(5):1118–22

ROCK–I and ROCK–II, two isoforms of Rho–associated coiled–coil forming protein serine/threonine kinase in mice. Nakagawa O, et al. **FEBS Lett** 1996 Aug 26;392(2):189–93

Cloning and characterization of a member of the MST subfamily of Ste20–like kinases. Creasy CL, et al. **Gene** 1995 Dec 29;167(1–2):303–6

Cloning and characterization of the Bacillus subtilis prkA gene encoding a novel serine protein kinase. Fischer C, et al. **Gene** 1996 Feb 2;168(1):55–60

Promoter region of the mouse cyclin–dependent kinase 5–encoding gene. Ishizuka T, et al. **Gene** 1995 Dec 12; 166(2):267–71

The Drosophila melanogaster homolog of the mammalian MAPK–activated protein kinase–2 (MAPKAPK–2) lacks a proline–rich N–terminus. Larochelle S, et al. **Gene** 1995 Oct 3;163(2):209–14

Identification of Schizosaccharomyces pombe gene psk1+, encoding a novel putative serine/threonine protein kinase, whose mutation conferred resistance to phenylarsine oxide. Mukai H, et al. **Gene** 1995 Dec 1;166(1):155–9

Cell–cycle–dependent expression of the STK–1 gene encoding a novel murine putative protein kinase. Niwa H, et al. **Gene** 1996 Mar 9;169(2):197–201

Pk92B: a Drosophila melanogaster protein kinase that belongs to the MEKK family. Wassarman DA, et al. **Gene** 1996 Mar 9;169(2):283–4

Mutations Modulating Raf signaling in Drosophila eye development. Dickson BJ, et al. **Genetics** 1996 Jan; 142(1):163–71

Structure of the gene encoding the murine protein kinase CK2 beta subunit. Boldyreff B, et al. **Genomics** 1995 Sep 1;29(1):253–6

Assignment of human transforming growth factor–beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33–q34 and 1p32–p33, respectively. Johnson DW, et al. **Genomics** 1995 Jul 20;28(2):356–7

Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription and processing. Krahe R, et al. **Genomics** 1995 Jul 1;28(1):1–14

CHUK, a conserved helix–loop–helix ubiquitous kinase, maps to human chromosome 10 and mouse chromosome 19. Mock BA, et al. **Genomics** 1995 May 20;27(2):348–51

Molecular cloning and chromosomal mapping of the mouse gene encoding cyclin–dependent kinase 5 regulatory subunit p35. Ohshima T, et al. **Genomics** 1996 Jul 15; 35(2):372–5

Molecular cloning and chromosomal mapping of the mouse cyclin–dependent kinase 5 gene. Ohshima T, et al. **Genomics** 1995 Aug 10;28(3):585–8

Genomic structure and chromosomal assignment of the mouse Ku70 gene. Takiguchi Y, et al. **Genomics** 1996 Jul 1;35(1):129–35

A novel homeodomain–encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat. Boucher CA, et al. **Hum Mol Genet** 1995 Oct;4(10):1919–25

RING3 is linked to the Xenopus major histocompatibility complex. Salter–Cid L, et al. **Immunogenetics** 1996; 44(5):397–9

Phylogeny and structure of the RING3 gene. Thorpe KL, et al. **Immunogenetics** 1996;44(5):391–6

Sensitivity to cis–diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c–raf–1 protein. Warenius HM, et al. **Int J Cancer** 1996 Jul 17; 67(2):224–31

A deduced Thermomonospora curvata protein containing serine/threonine protein kinase and WD–repeat domains. Janda L, et al. **J Bacteriol** 1996 Mar;178(5):1487–9

The mouse B–raf gene encodes multiple protein isoforms with tissue–specific expression. Barnier JV, et al. **J Biol Chem** 1995 Oct 6;270(40):23381–9

Overexpression of myotonic dystrophy kinase in BC3H1 cells induces the skeletal muscle phenotype. Bush EW, et al. **J Biol Chem** 1996 Jan 5;271(1):548–52

Constitutive activation of mitogen–activated protein kinase–activated protein kinase 2 by mutation of phosphorylation sites and an A–helix motif. Engel K, et al. **J Biol Chem** 1995 Nov 10;270(45):27213–21

The mitogen–activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. Gillespie–Brown J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28092–6

A cell wall–associated, receptor–like protein kinase. He ZH, et al. **J Biol Chem** 1996 Aug 16;271(33):19789–93

Prk, a cytokine–inducible human protein serine/threonine kinase whose expression appears to be down–regulated in lung carcinomas. Li B, et al. **J Biol Chem** 1996 Aug 9; 271(32):19402–8

Identification of mitogen–activated protein (MAP) kinase–activated protein kinase–3, a novel substrate of CSBP p38 MAP kinase. McLaughlin MM, et al. **J Biol Chem** 1996 Apr 5;271(14):8488–92

p53 stimulates promoter activity of the sgk. serum/glucocorticoid–inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. Maiyar AC, et al. **J Biol Chem** 1996 May 24;271(21):12414–22

Molecular cloning of a new member of the p21–Cdc42/Rac–activated kinase (PAK) family. Manser E, et al. **J Biol Chem** 1995 Oct 20;270(42):25070–8

Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho–binding domain. Reid T, et al. **J Biol Chem** 1996 Jun 7;271(23):13556–60

Characterization of the human cyclin–dependent kinase 2 gene. Promoter analysis and gene structure. Shiffman D, et al. **J Biol Chem** 1996 May 24;271(21):12199–204

Mammalian AMP–activated protein kinase subfamily. Stapleton D, et al. **J Biol Chem** 1996 Jan 12;271(2):611–4

Developmental and tissue–specific expression of mouse pelle–like protein kinase. Trofimova M, et al. **J Biol Chem** 1996 Jul 26;271(30):17609–12

Investigation of myotonic dystrophy kinase isoform translocation and membrane association. Waring JD, et al. **J Biol Chem** 1996 Jun 21;271(25):15187–93

The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. Weiss E, et al. **J Cell Biol** 1996 Jan;132(1–2):111–23

Human DNA–activated protein kinase (DNA–PK) is homologous to phosphatidylinositol kinases. Poltoratsky VP, et al. **J Immunol** 1995 Nov 15;155(10):4529–33

Report on MDA workshop on myotonic dystrophy, 10 October 1994, Montreal, Quebec, Canada. Johnson K, et al. **J Med Genet** 1995 Aug;32(8):662–5

Characterization of an Arabidopsis thaliana gene that defines a new class of putative plant receptor kinases with an extracellular lectin–like domain. Hervé C, et al. **J Mol Biol** 1996 May 24;258(5):778–88

Genetic dissection of intersubunit contacts within human protein kinase CK2. Kusk M, et al. **J Mol Biol** 1995 Nov 10;253(5):703–11

Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and human chromosome 5. Vinik BS, et al. **Mamm Genome** 1995 Nov;6(11):782–3

The murine LIM–kinase gene (limk) encodes a novel serine threonine kinase expressed predominantly in trophoblast giant cells and the developing nervous system. Cheng AK, et al. **Mech Dev** 1995 Aug;52(2–3):187–97

Raf, but not MEK or ERK, is sufficient for differentiation of hippocampal neuronal cells. Kuo WL, et al. **Mol Cell Biol** 1996 Apr;16(4):1458–70

Constitutive activation of S6 kinase by deletion of amino–terminal autoinhibitory and rapamycin sensitivity domains. Mahalingam M, et al. **Mol Cell Biol** 1996 Jan; 16(1):405–13

3pK, a new mitogen–activated protein kinase–activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Sithanandam G, et al. **Mol Cell Biol** 1996 Mar;16(3):868–76

A kinase–encoding gene from Colletotrichum trifolii complements a colonial growth mutant of Neurospora crassa. Buhr TL, et al. **Mol Gen Genet** 1996 Jul 19; 251(5):565–72

Allele–specific suppression of a Saccharomyces cerevisiae prp20 mutation by overexpression of a nuclear serine/threonine protein kinase. Fleischmann M, et al. **Mol Gen Genet** 1996 Mar 20;250(5):614–25

Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Johnson DW, et al. **Nat Genet** 1996 Jun;13(2):189–95

Molecular cloning of a novel serine/threonine kinase, MRK, possibly involved in cardiac development. Abe S, et al. **Oncogene** 1995 Dec 7;11(11):2187–95

Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Altomare DA, et al. **Oncogene** 1995 Sep 21;11(6):1055–60

Expression of the protein kinase PKR in modulated by IRF–1 and is reduced in 5q– associated leukemias. Beretta L, et al. **Oncogene** 1996 Apr 4;12(7):1593–6

Identification and functional characterization of the human and murine polo–like kinase (Plk) promoter. Bräuninger A, et al. **Oncogene** 1995 Nov 2;11(9):1793–800

Regulation of A–raf expression. Lee JE, et al. **Oncogene** 1996 Apr 18;12(8):1669–77

Limk1 is predominantly expressed in neural tissues and phosphorylates serine, threonine and tyrosine residues in vitro. Pröschel C, et al. **Oncogene** 1995 Oct 5;11(7):1271–81

DNA–dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Finnie NJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):173–9 (50 ref.)

The Arabidopsis ERECTA gene encodes a putative receptor protein kinase with extracellular leucine–rich repeats. Torii KU, et al. **Plant Cell** 1996 Apr;8(4):735–46

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Cheng JQ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3636–41

Gene for the catalytic subunit of mouse DNA–dependent protein kinase maps to the scid locus. Miller RD, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10792–5

A gene encoding a mitogen–activated protein kinase kinase kinase is induced simultaneously with genes for a mitogen–activated protein kinase and an S6 ribosomal protein kinase by touch, cold, and water stress in Arabidopsis thaliana. Mizoguchi T, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):765–9

Identification of human cyclin–dependent kinase 8, a putative protein kinase partner for cyclin C. Tassan JP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8871–5

Equine severe combined immunodeficiency: a defect in V(D)J recombination and DNA–dependent protein kinase activity. Wiler R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11485–9

A receptor kinase–like protein encoded by the rice disease resistance gene, Xa21 [see comments] Song WY, et al. **Science** 1995 Dec 15;270(5243):1804–6. Comment in: Science 1995 Dec 15;270(5243):1772–3. Comment in: Science 1995 Dec 15;270(5243):1774.

Differentiation of medullary thyroid cancer by C–Raf–1 silences expression of the neural transcription factor human achaete–scute homolog–1. Chen H, et al. **Surgery** 1996 Aug; 120(2):168–72; discussion 173

DNA double–strand break repair and V(D)J recombination: involvement of DNA–PK. Jackson SP, et al. **Trends Biochem Sci** 1995 Oct;20(10):412–5 (41 ref.)

Sequence analysis of a 30 kb DNA segment from yeast chromosome XIV carrying a ribosomal protein gene cluster, the genes encoding a plasma membrane protein and a subunit of replication factor C, and a novel putative serine/threonine protein kinase gene. Maurer KC, et al. **Yeast** 1995 Oct;11(13):1303–10

IMMUNOLOGY

Cortical and brainstem–type Lewy bodies are immunoreactive for the cyclin–dependent kinase 5. Brion JP, et al. **Am J Pathol** 1995 Nov;147(5):1465–76

Isolation and characterization of a monoclonal anti–protein kinase CK2 beta–subunit antibody of the IgG class for the direct detection of CK2 beta–subunit in tissue cultures of various mammalian species and human tumors. Nastainczyk W, et al. **Hybridoma** 1995 Aug;14(4):335–9

Autoantibodies to DNA–dependent protein kinase. Probes for the catalytic subunit. Suwa A, et al. **J Clin Invest** 1996 Mar 15;97(6):1417–21

ISOLATION & PURIFICATION

A novel tau-tubulin kinase from bovine brain. Takahashi M, et al. **FEBS Lett** 1995 Sep 18;372(1):59–64

Isolation of MEK5 and differential expression of alternatively spliced forms. English JM, et al. **J Biol Chem** 1995 Dec 1;270(48):28897–902

Demonstration of cyclin-dependent kinase inhibitory serine/threonine kinase in bovine thymus. Matsuura I, et al. **J Biol Chem** 1996 Mar 8;271(10):5443–50

Copurification of casein kinase II with transcription factor ATF/E4TF3. Wada T, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):876–84

Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2. Cano E, et al. **Oncogene** 1996 Feb 15;12(4):805–12

Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Kumagai A, et al. **Science** 1996 Sep 6;273(5280):1377–80

METABOLISM

Differential phosphorylation of ribosomal acidic proteins from yeast cell by two endogenous protein kinases: casein kinase-2 and 60S kinase. Szyszka R, et al. **Acta Biochim Pol** 1995;42(3):357–62

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)

Microfilament dynamics: regulation of actin polymerization by actin-fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199–227 (60 ref.)

Regulation of human natural killer-cell lytic activity by serine/threonine phosphatases and kinases. Bajpai A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:216–9

Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320–43 (151 ref.)

Molecular cloning and characterization of a novel casein kinase II substrate, HASPP28, from rat brain. Shen L, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):131–41

Protein kinase CK2: biphasic kinetics with peptide substrates. Tiganis T, et al. **Arch Biochem Biophys** 1996 Jan 15; 325(2):289–94

The US3 protein kinase of herpes simplex virus type 2 is associated with phosphorylation of the UL12 alkaline nuclease in vitro. Daikoku T, et al. **Arch Virol** 1995; 140(9):1637–44

Signal transduction by the IL-1 type I receptor: evidence for the involvement of a receptor-coupled protein kinase. Martin M, et al. **Behring Inst Mitt** 1995 Jun;(96):32–44

Plant calreticulin is specifically and efficiently phosphorylated by protein kinase CK2. Baldan B, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):498–502

The liver response to in vivo heat shock involves the activation of MAP kinases and RAF and the tyrosine phosphorylation of Shc proteins. Bendinelli P, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):54–61

Rat liver pp49, a protein that forms complexes with protein kinase CK2, is composed of the beta and the gamma subunits of translation initiation factor eIF-2. Gil C, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1052–7

Differences in substrate specificity between Cdk2-cyclin A and Cdk2-cyclin E in vitro. Higashi H, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):520–5

Putative nuclear cdk2 substrates in normal and transformed cells. Jaumot M, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):560–4

Interaction of the beta subunit of casein kinase II with the ribosomal protein L5. Kim JM, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):180–6

Phosphorylation by MAPKAP kinase 2 activates Mg(2+)-ATPase activity of myosin II. Komatsu S, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):741–5

The cdk2 binding domain of p27Kip correlates with the inhibition of the kinase activity of cdk2/cyclin complexes. Kwon TK, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):703–9

Phosphorylation of HIV-1 Rev protein: implication of protein kinase CK2 and pro-directed kinases. Meggio F, et al. **Biochem Biophys Res Commun** 1996 Sep 13; 226(2):547–54

K252a inhibits the phosphorylation of pRb without changing the levels of G1 cyclins and Cdk2 protein in human hepatoma cells. Nakayama T, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):180–3

Changes in the activity of nuclear protein kinase CK2 during rat liver regeneration. Pancetti F, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):35–9

Difference in the mechanism of interaction of Raf-1 and B-Raf with H-Ras. Shinkai M, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):729–34

Involvement of PIM-1 in DNA fragmentation in mouse NS-1-derived cells. Takahashi C, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):538–46

Phosphorylation of purified estradiol-liganded estrogen receptor by casein kinase II increases estrogen response element binding but does not alter ligand stability. Tzeng DZ, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):554–60

Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. Filhol O, et al. **Biochem J** 1996 May 15;316 (Pt 1):331–5

Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways. Kilgour E, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):517–22

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)

Role of p70 S6 kinase in lymphocyte activation. Frost V, et al. **Biochem Soc Trans** 1996 Feb;24(1):91S

Characterisation of a serine/threonine kinase which mediates CD28 phosphorylation following activation by B7.1. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):87S

Involvement of phosphatidylinositol 3-kinase in the activation of p70 S6 kinase by the T cell costimulatory molecule CD28. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):88S

Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. Bevilacqua PC, et al. **Biochemistry** 1996 Aug 6;35(31):9983–94

Phosphorylation of C8 and C9 subunits of the multicatalytic proteinase by casein kinase II and identification of the C8 phosphorylation sites by direct mutagenesis. Castaño JG, et al. **Biochemistry** 1996 Mar 26;35(12):3782–9

Evidence that casein kinase 2 phosphorylates hepatic microsomal calcium-binding proteins 1 and 2 but not 3. Chen NQ, et al. **Biochemistry** 1996 Jun 25;35(25):8299–306

Fragmin, a microfilament regulatory protein from Physarum polycephalum, is phosphorylated by casein kinase II-type enzymes. De Corte V, et al. **Biochemistry** 1996 Apr 30; 35(17):5472–80

Interaction sites between catalytic and regulatory subunits in human protein kinase CK2 holoenzymes as indicated by chemical cross-linking and immunological investigations. Krehan A, et al. **Biochemistry** 1996 Apr 16; 35(15):4966–75

Modulation of rabbit reticulocyte guanine nucleotide exchange factor activity by casein kinases 1 and 2 and glycogen synthase kinase 3. Singh LP, et al. **Biochemistry** 1996 Mar 12;35(10):3206–12

cDNA cloning and characterization of rat Clk3, a LAMMER kinase predominately expressed in testis. Becker W, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):63–7

Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: regulation by TGF-beta. Bloom BB, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):243–8

Expression of recombinant elongation factor 1 beta from rabbit in Escherichia coli. Phosphorylation by casein kinase II. Chen CJ, et al. **Biochim Biophys Acta** 1995 Dec 27; 1264(3):303–11

Menage à trois: double strand break repair, V(D)J recombination and DNA-PK. Jeggo PA, et al. **Bioessays** 1995 Nov;17(11):949–57 (67 ref.)

Solid phase synthesis of pp60src-related phosphopeptides via 'global' phosphorylation and their use as substrates for enzymatic phosphorylation by casein kinase-2. Perich JW, et al. **Bioorg Med Chem** 1996 Feb;4(2):143–50

Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation. Zu YL, et al. **Blood** 1996 Jun 15;87(12):5287–96

Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Fischer T, et al. **Br J Haematol** 1996 Mar;92(3):595–603

Dual specificity of casein kinase II from the yeast Yarrowia lipolytica. Chardot T, et al. **C R Acad Sci III** 1995 Sep; 318(9):937–42

Microsomal casein kinase II in endoplasmic reticulum- and Golgi apparatus-rich fractions of ROS 17/2.8 osteoblast-like cells: an enzyme that modifies osteopontin. Wu CB, et al. **Calcif Tissue Int** 1995 Oct;57(4):285–92

Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Faust RA, et al. **Cancer Lett** 1996 Mar 19; 101(1):31–5

Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Kim SH, et al. **Cancer Lett** 1996 Jan 2;98(2):199–205

Lack of correlation between DNA-dependent protein kinase activity and tumor cell radiosensitivity. Allalunis-Turner MJ, et al. **Cancer Res** 1995 Nov 15;55(22):5200–2

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, et al. **Cancer Res** 1996 Apr 15;56(8):1851–4

Activation of stress-activator protein kinase/c-Jun N-terminal kinase by the non-TPA-type tumor promoter palytoxin. Kuroki DW, et al. **Cancer Res** 1996 Feb 1; 56(3):637–44

Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Li Y, et al. **Cancer Res** 1996 Jun 15;56(12):2872–6

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Seufferlein T, et al. **Cancer Res** 1996 Sep 1; 56(17):3895–7

The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Chou MM, et al. **Cell** 1996 May 17;85(4):573–83

Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Fisher RP, et al. **Cell** 1995 Oct 6;83(1):47–57

The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Nakajima T, et al. **Cell** 1996 Aug 9; 86(3):465–74

The tomato gene Pti1 encodes a serine/threonine kinase that is phosphorylated by Pto and is involved in the hypersensitive response. Zhou J, et al. **Cell** 1995 Dec 15; 83(6):925–35

Evidence of true protein kinase CKII activity in mitochondria and its spermine-mediated translocation to inner membrane. Sarrouilhe D, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar;42(2):189–97

Porcine brain neurofilament-H tail domain kinase: its identification as cdk5/p26 complex and comparison with cdc2/cyclin B kinase. Hisanaga S, et al. **Cell Motil Cytoskeleton** 1995;31(4):283–97

Erythropoietin induces biphasic activation of p70S6k: evidence for a different regulation of early and late phase of activation. Jaster R, et al. **Cell Signal** 1995 May; 7(4):325–30

Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Sadoshima J, et al. **Circ Res** 1995 Dec;77(6):1040–52

Hypoxia and hypoxia/reoxygenation activate Raf-1, mitogen-activated protein kinase kinase, mitogen-activated protein kinases, and S6 kinase in cultured rat cardiac myocytes. Seko Y, et al. **Circ Res** 1996 Jan;78(1):82–90

Activation of p42erk2 MAPK and p90rsk by IL-2 occurs independently of protein kinase C. Franklin RA, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):116–22

Proteins of the 14-3-3 family associate with Raf and contribute to its activation. Freed E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:187–93 (45 ref.)

Protein-protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119–21 (21 ref.)

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122–5 (16 ref.)

Activation of ternary complex factor Elk-1 by stress-activated protein kinases. Gille H, et al. **Curr Biol** 1995 Oct 1;5(10):1191–200

Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. ten Dijke P, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):139–45 (58 ref.)

Activation of p90rsk during meiotic maturation and first mitosis in mouse oocytes and eggs: MAP kinase-independent and -dependent activation. Kalab P, et al. **Development** 1996 Jun;122(6):1957–64

Skeletal muscle mitogen-activated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats and reversal by vanadium. Hei YJ, et al. **Diabetes** 1995 Oct;44(10):1147–55

Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas. Eggstein S, et al. **Dig Dis Sci** 1996 Jun;41(6):1069–75

Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. Beadling C, et al. **EMBO J** 1996 Apr 15; 15(8):1902–13

Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. Ben-Levy R, et al. **EMBO J** 1995 Dec 1;14(23):5920–30

Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. Berberich I, et al. **EMBO J** 1996 Jan 2;15(1):92–101

Bcr and Raf form a complex in vivo via 14-3-3 proteins. Braselmann S, et al. **EMBO J** 1995 Oct 2;14(19):4839–48

The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Colwill K, et al. **EMBO J** 1996 Jan 15;15(2):265–75

MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. Devault A, et al. **EMBO J** 1995 Oct 16; 14(20):5027–36

The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. Ishizaki T, et al. **EMBO J** 1996 Apr 15;15(8):1885–93

Intracellular trafficking of furin is modulated by the phosphorylation state of a casein kinase II site in its cytoplasmic tail. Jones BG, et al. **EMBO J** 1995 Dec 1; 14(23):5869–83

Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. Kohn AD, et al. **EMBO J** 1995 Sep 1;14(17):4288–95

A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. Martin GA, et al. **EMBO J** 1995 Sep 1;14(17):4385

Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Matsui T, et al. **EMBO J** 1996 May 1;15(9):2208–16

Fission yeast pak1+ encodes a protein kinase that interacts with Cdc42p and is involved in the control of cell polarity and mating. Ottilie S, et al. **EMBO J** 1995 Dec 1; 14(23):5908–19

Phosphorylation of Drosophila Jun by the MAP kinase rolled regulates photoreceptor differentiation. Peverali FA, et al.

EMBO J 1996 Aug 1;15(15):3943–50

Activation of MEK–1 and SEK–1 by Tpl–2 proto–oncoprotein, a novel MAP kinase kinase kinase. Salmeron A, et al. **EMBO J** 1996 Feb 15;15(4):817–26

DNA–dependent protein kinase catalytic subunit: a target for an ICE–like protease in apoptosis. Song Q, et al. **EMBO J** 1996 Jul 1;15(13):3238–46

Rab3 reversibly recruits rabphilin to synaptic vesicles by a mechanism analogous to raf recruitment by ras. Stahl B, et al. **EMBO J** 1996 Apr 15;15(8):1799–809

Identification of a Myc–dependent step during the formation of active G1 cyclin–cdk complexes. Steiner P, et al. **EMBO J** 1995 Oct 2;14(19):4814–26

In vitro assembly of a functional human CDK7–cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. Tassan JP, et al. **EMBO J** 1995 Nov 15; 14(22):5608–17

Complementation between kinase–defective and activation–defective TGF–beta receptors reveals a novel form of receptor cooperativity essential for signaling. Weis–Garcia F, et al. **EMBO J** 1996 Jan 15;15(2):276–89

Two S–phase checkpoint systems, one involving the function of both BIME and Tyr15 phosphorylation of p34cdc2, inhibit NIMA and prevent premature mitosis. Ye XS, et al. **EMBO J** 1996 Jul 15;15(14):3599–610

Expression and localization of activin beta A–subunit and activin receptors in TM3, a mouse Leydig cell line. Ying C, et al. **Endocr Res** 1995 Nov;21(4):815–24

Effect of tumor necrosis factor–alpha on insulin–stimulated mitogen–activated protein kinase cascade in cultured rat skeletal muscle cells. Begum N, et al. **Eur J Biochem** 1996 May 15;238(1):214–20

A casein–kinase–2–related protein kinase is tightly associated with the large T antigen of simian virus 40. Götz C, et al. **Eur J Biochem** 1995 Oct 1;233(1):327–34

Cyclin–dependent kinase–2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7–cyclin–H. Higashi H, et al. **Eur J Biochem** 1996 Apr 15;237(2):460–7

Purification and characterization of a p13suc1–bound serine/threonine kinase that is expressed in mature rat brain. Tamaru T, et al. **Eur J Biochem** 1996 May 15;238(1):152–9

Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12–O–tetradecanoylphorbol–13–acetate (TPA) by modulation of CDK2 activity. Coppock DL, et al. **Exp Cell Res** 1995 Nov;221(1):92–102

Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors. De Winter JP, et al. **Exp Cell Res** 1996 May 1;224(2):323–34

Hexamethylene bisacetamide–induced differentiation of Friend virus–transformed murine erythroleukemia cells is associated with parallel changes in casein kinase II and guanine nucleotide exchange factor activities. Aroor AR, et al. **Exp Hematol** 1995 Oct;23(11):1204–11

How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein–tyrosine kinase. Taylor SS, et al. **FASEB J** 1995 Oct;9(13):1255–66 (41 ref.)

A comparison of the substrate specificity of MAPKAP kinase–2 and MAPKAP kinase–3 and their activation by cytokines and cellular stress. Clifton AD, et al. **FEBS Lett** 1996 Sep 2;392(3):209–14

A novel yeast protein showing specific association with the cyclin–dependent kinase 5. Huang QQ, et al. **FEBS Lett** 1996 Jan 2;378(1):48–50

Phosphorylation of the N–terminal domain of Xenopus TATA–box binding protein by DNA–dependent protein kinase depends on the C–terminal core domain. Labhart P. **FEBS Lett** 1996 May 20;386(2–3):110–4

Comparison of the specificities of p70 S6 kinase and MAPKAP kinase–1 identifies a relatively specific substrate for p70 S6 kinase: the N–terminal kinase domain of MAPKAP kinase–1 is essential for peptide phosphorylation. Leighton IA, et al. **FEBS Lett** 1995 Nov 20;375(3):289–93

Unfarnesylated transforming Ras mutant inhibits the Ras–signaling pathway by forming a stable Ras.Raf complex in the cytosol. Miyake M, et al. **FEBS Lett** 1996 Jan 2;378(1):15–8

DNA–binding sperm proteins with oligo–arginine clusters function as potent activators for egg CK–II. Ohtsuki K, et al. **FEBS Lett** 1996 Jan 8;378(2):115–20

Identification of a cryptic protein kinase CK2 phosphorylation site in human complement protease C1r, and its use to probe intramolecular interaction. Pelloux S, et al. **FEBS Lett** 1996 May 13;386(1):15–20

Characterization of the interaction between RhoA and the amino–terminal region of PKN. Shibata H, et al. **FEBS Lett** 1996 May 6;385(3):221–4

Physiological correlation between glycyrrhizin, glycyrrhizin–binding lipoxygenase and casein kinase II. Shimoyama Y, et al. **FEBS Lett** 1996 Aug 12;391(3):238–42

A novel tau–tubulin kinase from bovine brain. Takahashi M, et al. **FEBS Lett** 1995 Sep 18;372(1):59–64

Activation of p70 S6 protein kinase is necessary for angiotensin II–induced hypertrophy in neonatal rat cardiac myocytes. Takano H, et al. **FEBS Lett** 1996 Feb 5; 379(3):255–9

Differential regulation of Raf isozymes by growth versus differentiation inducing factors in PC12 pheochromocytoma cells. Wixler V, et al. **FEBS Lett** 1996 May 6;385(3):131–7

The aerial mycelium–defective phenotype of Streptomyces griseus resulting from A–factor deficiency is suppressed by a Ser/Thr kinase of S. coelicolor A3(2). Ueda K, et al. **Gene** 1996 Feb 22;169(1):91–5

Turnover of cyclin E by the ubiquitin–proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Clurman BE, et al. **Genes Dev** 1996 Aug 15;10(16):1979–90

A novel, mitogen–activated nuclear kinase is related to a Drosophila developmental regulator. Denis GV, et al. **Genes Dev** 1996 Feb 1;10(3):261–71

Differential effects of cdk2 and cdk3 on the control of pRb and E2F function during G1 exit. Hofmann F, et al. **Genes Dev** 1996 Apr 1;10(7):851–61

The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Nikolic M, et al. **Genes Dev** 1996 Apr 1;10(7):816–25

Genetic relationships between the G protein beta gamma complex, Ste5p, Ste20p and Cdc42p: investigation of effector roles in the yeast pheromone response pathway. Akada R, et al. **Genetics** 1996 May;143(1):103–17

Functional domains of fused, a serine–threonine kinase required for signaling in Drosophila. Thérond P, et al. **Genetics** 1996 Apr;142(4):1181–98

TNF–dependent recruitment of the protein kinase RIP to the TNF receptor–1 signaling complex. Hsu H, et al. **Immunity** 1996 Apr;4(4):387–96

Interleukin 10 induced c–fos expression in human B cells by activation of divergent protein kinases. Bönig H, et al. **Immunol Invest** 1996 Jan–Mar;25(1–2):115–28

Two phosphorylations specific to the tail region of the 204–kDa heavy chain isoform of porcine aorta smooth muscle myosin. Fukui Y, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):783–90

Purification and phosphorylation of a M(r) 25,000 protein, an effective phosphate acceptor for casein kinase II and protein kinase C, detected in the cytosolic fraction of Xenopus laevis oocytes. Hashimoto E, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):453–60

Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract. Hosoi T, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):741–9

A 96–kDa glycyrrhizin–binding protein (gp96) from soybeans acts as a substrate for casein kinase II, and is highly related to lipoxygenase 3. Ohtsuki K, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1145–50

Differential structural requirements for interaction of Ras protein with its distinct downstream effectors. Akasaka K, et al. **J Biol Chem** 1996 Mar 8;271(10):5353–60

Phosphorylation and activation of myosin by Rho–associated kinase (Rho–kinase). Amano M, et al. **J Biol Chem** 1996 Aug 23;271(34):20246–9

Identification of a mouse p21Cdc42/Rac activated kinase. Bagrodia S, et al. **J Biol Chem** 1995 Sep 29;270(39):22731–7

Cdc42 and PAK–mediated signaling leads to Jun kinase and p38 mitogen–activated protein kinase activation. Bagrodia S, et al. **J Biol Chem** 1995 Nov 24;270(47):27995–8

The mouse B–raf gene encodes multiple protein isoforms with tissue–specific expression. Barnier JV, et al. **J Biol Chem** 1995 Oct 6;270(40):23381–9

Identification of signal–induced IkappaB–alpha kinases in human endothelial cells. Bennett BL, et al. **J Biol Chem** 1996 Aug 16;271(33):19680–8

Insulin activates nuclear factor kappa B in mammalian cells through a Raf–1–mediated pathway. Bertrand F, et al. **J Biol Chem** 1995 Oct 13;270(41):24435–41

Molecular cloning of mitogen–activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen–activated protein kinase and c–Jun kinase. Blank JL, et al. **J Biol Chem** 1996 Mar 8;271(10):5361–8

Hypertrophic agonists stimulate the activities of the protein kinases c–Raf and A–Raf in cultured ventricular myocytes. Bogoyevitch MA, et al. **J Biol Chem** 1995 Nov 3; 270(44):26303–10

Phosphorylation of casein kinase II by p34cdc2. Identification of phosphorylation sites using phosphorylation site mutants in vitro. Bosc DG, et al. **J Biol Chem** 1995 Oct 27; 270(43):25872–8

A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. Burbelo PD, et al. **J Biol Chem** 1995 Dec 8;270(49):29071–4

Endogenous phosphorylation of distinct gamma–aminobutyric acid type A receptor polypeptides by Ser/Thr and Tyr kinase activities associated with the purified receptor. Bureau MH, et al. **J Biol Chem** 1995 Nov 3;270(44):26482–7

Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. Butch ER, et al. **J Biol Chem** 1996 Feb 23;271(8):4230–5

The DNA–dependent protein kinase is inactivated by autophosphorylation of the catalytic subunit. Chan DW, et al. **J Biol Chem** 1996 Apr 12;271(15):8936–41

Insulin stimulation of mitogen–activated protein kinase, p90rsk, and p70 S6 kinase in skeletal muscle of normal and insulin–resistant mice. Implications for the regulation of glycogen synthase. Chang PY, et al. **J Biol Chem** 1995 Dec 15;270(50):29928–35

Integrin–mediated activation of mitogen–activated protein (MAP) or extracellular signal–related kinase kinase (MEK) and kinase is independent of Ras. Chen Q, et al. **J Biol Chem** 1996 Jul 26;271(30):18122–7

Persistent activation of c–Jun N–terminal kinase 1 (JNK1) in gamma radiation–induced apoptosis. Chen YR, et al. **J Biol Chem** 1996 Jan 12;271(2):631–4

Interleukin–10 stimulation of phosphatidylinositol 3–kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. Crawley JB, et al. **J Biol Chem** 1996 Jul 5;271(27):16357–62

Role of cellular casein kinase II in the function of the phosphoprotein (P) subunit of RNA polymerase of vesicular stomatitis virus. Das T, et al. **J Biol Chem** 1995 Oct 13;270(41):24100–7

Inactivation of raf–1 by a protein–tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits. Dent P, et al. **J Biol Chem** 1996 Feb 9; 271(6):3119–23

Constitutive overexpression of CDK2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells. Dobashi Y, et al. **J Biol Chem** 1995 Sep 29;270(39):23031–7

Chemotactic peptide–induced activation of MEK–2, the predominant isoform in human neutrophils. Inhibition by wortmannin. Downey GP, et al. **J Biol Chem** 1996 Aug 30;271(35):21005–1011

Ras interaction with two distinct binding domains in Raf–1 may be required for Ras transformation. Drugan JK, et al. **J Biol Chem** 1996 Jan 5;271(1):233–7

Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen–activated protein kinases in Swiss mouse 3T3 fibroblasts. Edelmann HM, et al. **J Biol Chem** 1996 Jan 12;271(2):963–71

Constitutive activation of mitogen–activated protein kinase–activated protein kinase 2 by mutation of phosphorylation sites and an A–helix motif. Engel K, et al. **J Biol Chem** 1995 Nov 10;270(45):27213–21

Rac "insert region" is a novel effector region that is implicated in the activation of NADPH oxidase, but not PAK65. Freeman JL, et al. **J Biol Chem** 1996 Aug 16; 271(33):19794–801

The phosphodiesterase inhibitor SQ 20006 selectively blocks mitogen activation of p70S6k and transition to S phase of the cell division cycle without affecting the steady state phosphorylation of eIF–4E. Frost V, et al. **J Biol Chem** 1995 Nov 3;270(44):26698–706

The adaptor protein Nck links receptor tyrosine kinases with the serine–threonine kinase Pak1. Galisteo ML, et al. **J Biol Chem** 1996 Aug 30;271(35):20997–1000

The mitogen–activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. Gillespie–Brown J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28092–6

Equilibrium and kinetic measurements reveal rapidly reversible binding of Ras to Raf. Gorman C, et al. **J Biol Chem** 1996 Mar 22;271(12):6713–9

Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA–dependent protein kinase activity. Han Z, et al. **J Biol Chem** 1996 Jun 14;271(24):14098–104

Casein kinase II is required for cell cycle progression during G1 and G2/M in Saccharomyces cerevisiae. Hanna DE, et al. **J Biol Chem** 1995 Oct 27;270(43):25905–14

Differential interaction of the ras family GTP–binding proteins H–Ras, Rap1A, and R–Ras with the putative effector molecules Raf kinase and Ral–guanine nucleotide exchange factor. Herrmann C, et al. **J Biol Chem** 1996 Mar 22;271(12):6794–800

Cysteine–rich region of Raf–1 interacts with activator domain of post–translationally modified Ha–Ras. Hu CD, et al. **J Biol Chem** 1995 Dec 22;270(51):30274–7

Phosphorylation of microtubule–associated proteins MAP2 and MAP4 by the protein kinase p110mark. Phosphorylation sites and regulation of microtubule dynamics. Illenberger S, et al. **J Biol Chem** 1996 May 3; 271(18):10834–43

DNA binding specificities of YPF1, a Drosophila homolog to the DNA binding subunit of human DNA–dependent protein kinase, Ku. Jacoby DB, et al. **J Biol Chem** 1996 Jul 12;271(28):16827–32

Casein kinase II associates with Egr–1 and acts as a negative modulator of its DNA binding and transcription activities in NIH 3T3 cells. Jain N, et al. **J Biol Chem** 1996 Jun 7;271(23):13530–6

Characterization of IkappaB kinases. IkappaB–alpha is not phosphorylated by Raf–1 or protein kinase C isozymes, but is a casein kinase II substrate. Janosch P, et al. **J Biol Chem** 1996 Jun 7;271(23):13868–74

Signal transduction pathways regulated by mitogen–activated/extracellular response kinase kinase kinase induce cell death. Johnson NL, et al. **J Biol Chem** 1996 Feb 9;271(6):3229–37

S6 kinase p90rsk in granulocyte–macrophage colony–stimulating factor–stimulated proliferative and mature hematopoietic cells. Joseph DE, et al. **J Biol Chem** 1996 May 31;271(22):13088–93

Regulation of interaction of ras p21 with RalGDS and Raf–1 by cyclic AMP–dependent protein kinase. Kikuchi A, et al. **J Biol Chem** 1996 Jan 5;271(1):588–94

Role of the Raf/mitogen–activated protein kinase pathway in p21ras desensitization. Klarlund JK, et al. **J Biol Chem** 1996 Jul 12;271(28):16674–7

Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. Kohn AD, et al. **J Biol Chem** 1996 Sep 6;271(36):21920–6

The interferon-inducible protein kinase PKR modulates the transcriptional activation of immunoglobulin kappa gene. Koromilas AE, et al. **J Biol Chem** 1995 Oct 27; 270(43):25426-34

Identification of an I kappa B alpha-associated protein kinase in a human monocytic cell line and determination of its phosphorylation sites on I kappa B alpha. Kuno K, et al. **J Biol Chem** 1995 Nov 17;270(46):27914-9

Different effects of various phospholipids on Ki-Ras-, Ha-Ras-, and Rap1B-induced B-Raf activation. Kuroda S, et al. **J Biol Chem** 1996 Jun 21;271(25):14680-3

Raf-1 is activated during mitosis. Laird AD, et al. **J Biol Chem** 1995 Nov 10;270(45):26742-5

Phosphorylation of plant eukaryotic initiation factor-2 by the plant-encoded double-stranded RNA-dependent protein kinase, pPKR, and inhibition of protein synthesis in vitro. Langland JO, et al. **J Biol Chem** 1996 Feb 23; 271(8):4539-44

Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. Lee KY, et al. **J Biol Chem** 1996 Jan 19;271(3):1538-43

Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. Lenormand P, et al. **J Biol Chem** 1996 Jun 28; 271(26):15762-8

A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. Leung T, et al. **J Biol Chem** 1995 Dec 8; 270(49):29051-4

In vitro phosphorylation of the polyomavirus major capsid protein VP1 on serine 66 by casein kinase II. Li M, et al. **J Biol Chem** 1995 Oct 27;270(43):26006-11

Ku80-deficient cells exhibit excess degradation of extrachromosomal DNA. Liang F, et al. **J Biol Chem** 1996 Jun 14;271(24):14405-11

Identification of the 14.3.3 zeta domains important for self-association and Raf binding. Luo ZJ, et al. **J Biol Chem** 1995 Oct 6;270(40):23681-7

Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin. Mata M, et al. **J Biol Chem** 1996 Jul 12;271(28):16888-96

Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. Matsubara M, et al. **J Biol Chem** 1996 Aug 30;271(35):21108-13

Demonstration of cyclin-dependent kinase inhibitory serine/threonine kinase in bovine thymus. Matsuura I, et al. **J Biol Chem** 1996 Mar 8;271(10):5443-50

A casein kinase II phosphorylation site in the cytoplasmic domain of the cation-dependent mannose 6-phosphate receptor determines the high affinity interaction of the AP-1 Golgi assembly proteins with membranes. Mauxion F, et al. **J Biol Chem** 1996 Jan 26;271(4):2171-8

Isocitrate dehydrogenase kinase/phosphatase. Kinetic characteristics of the wild-type and two mutant proteins. Miller SP, et al. **J Biol Chem** 1996 Aug 9;271(32):19124-8

Phosphorylation of the MADS-Box transcription factor MEF2C enhances its DNA binding activity. Molkentin JD, et al. **J Biol Chem** 1996 Jul 19;271(29):17199-204

Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systems. Mori S, et al. **J Biol Chem** 1995 Dec 1;270(48):28834-8

A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. Moriguchi T, et al. **J Biol Chem** 1996 Jun 7;271(23):13675-9

PKN associates and phosphorylates the head-rod domain of neurofilament protein. Mukai H, et al. **J Biol Chem** 1996 Apr 19;271(16):9816-22

ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). Nelson JW, et al. **J Biol Chem** 1996 Jul 19;271(29):17021-7

A nuclear envelope-associated kinase phosphorylates arginine-serine motifs and modulates interactions between the lamin B receptor and other nuclear proteins. Nikolakaki E, et al. **J Biol Chem** 1996 Apr 5;271(14):8365-72

Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. Nishitoh H, et al. **J Biol Chem** 1996 Aug 30;271(35):21345-52

Cardiac troponin I mutants. Phosphorylation by protein kinases C and A and regulation of Ca(2+)-stimulated MgATPase of reconstituted actomyosin S-1. Noland TA Jr, et al. **J Biol Chem** 1995 Oct 27;270(43):25445-54

Activation of brain B-Raf protein kinase by Rap1B small GTP-binding protein. Ohtsuka T, et al. **J Biol Chem** 1996 Jan 19;271(3):1258-61

Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf. Okada T, et al. **J Biol Chem** 1996 Mar 1;271(9):4671-8

Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. Okadome T, et al. **J Biol Chem** 1996 Sep 6;271(36):21687-90

Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. Okano I, et al. **J Biol Chem** 1995 Dec 29; 270(52):31321-30

A role for Shc, Grb2, and Raf-1 in FcgammaRI signal relay. Park RK, et al. **J Biol Chem** 1996 Jun 7;271(23):13342-8

Activation of p70 S6 kinase and erk-encoded mitogen-activated protein kinases is resistant to high cyclic nucleotide levels in Swiss 3T3 fibroblasts. Petritsch C, et al. **J Biol Chem** 1995 Nov 3;270(44):26619-25

Activation of mitogen-activated protein kinase cascades by p21-activated protein kinases in cell-free extracts of Xenopus oocytes. Polverino A, et al. **J Biol Chem** 1995 Nov 3;270(44):26067-70

The P58 cellular inhibitor complexes with the interferon-induced, double-stranded RNA-dependent protein kinase, PKR, to regulate its autophosphorylation and activity. Polyak SJ, et al. **J Biol Chem** 1996 Jan 19; 271(3):1702-7

The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. Rana A, et al. **J Biol Chem** 1996 Aug 9;271(32):19025-8

Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. Sakata N, et al. **J Biol Chem** 1995 Dec 22;270(51):30823-8

Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. Sarno S, et al. **J Biol Chem** 1996 May 3;271(18):10595-601

Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. Schulte TW, et al. **J Biol Chem** 1995 Oct 13; 270(41):24585-8

Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. Seger R, et al. **J Biol Chem** 1995 Nov 24;270(47):28325-30

Phosphorylation of the high molecular weight neurofilament protein (NF-H) by Cdk5 and p35. Sun D, et al. **J Biol Chem** 1996 Jun 14;271(24):14245-51

An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. Tang D, et al. **J Biol Chem** 1995 Nov 10; 270(45):26897-903

Expression of the insulin receptor with a recombinant vaccinia virus. Biochemical evidence that the insulin receptor has intrinsic serine kinase activity. Tauer TJ, et al. **J Biol Chem** 1996 Jan 5;271(1):331-6

Identification and molecular cloning of a p21cdc42/rac1-activated serine/threonine kinase that is rapidly activated by thrombin in platelets. Teo M, et al. **J Biol Chem** 1995 Nov 3;270(44):26690-7

Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3. Terada K, et al. **J Biol Chem** 1995 Nov 17;270(46):27880-6

Identification and characterization of a novel protein kinase, TESK1, specifically expressed in testicular germ cells. Toshima J, et al. **J Biol Chem** 1995 Dec 29;270(52):31331-7

Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase. Tsakiridis T, et al. **J Biol Chem** 1996 Aug 16;271(33):19664-7

Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. Turchi JJ, et al. **J Biol Chem** 1996 Jun 7;271(23):13861-7

Association of a 85-kDa serine kinase with activated fibroblast growth factor receptor-4. Vainikka S, et al. **J Biol Chem** 1996 Jan 19;271(3):1270-3

Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha in yeast and mammalian cells. Ventura F, et al. **J Biol Chem** 1996 Jun 14;271(24):13931-4

Induced release of cell surface protein kinase yields CK1- and CK2-like enzymes in tandem. Walter J, et al. **J Biol Chem** 1996 Jan 5;271(1):111-9

The unfolded protein response pathway in Saccharomyces cerevisiae. Oligomerization and trans-phosphorylation of Ire1p (Ern1p) are required for kinase activation. Welihinda AA, et al. **J Biol Chem** 1996 Jul 26;271(30):18181-7

Wortmannin-sensitive activation of p70s6k by endogenous and heterologously expressed Gi-coupled receptors. Wilson M, et al. **J Biol Chem** 1996 Apr 12;271(15):8537-40

Preferential involvement of MEK1 in the tumor necrosis factor-alpha-induced activation of p42mapk/erk2 in mouse macrophages. Winston BW, et al. **J Biol Chem** 1995 Nov 17;270(46):27391-4

JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. Winston LA, et al. **J Biol Chem** 1995 Dec 29;270(52):30837-40

Involvement of p90rsk in neurite outgrowth mediated by the cell adhesion molecule L1. Wong EV, et al. **J Biol Chem** 1996 Jul 26;271(30):18217-23

Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR). Wu S, et al. **J Biol Chem** 1996 Jan 19;271(3):1756-63

Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. Wu X, et al. **J Biol Chem** 1996 Feb 9;271(6):3265-71

A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import. Xiao CY, et al. **J Biol Chem** 1996 Mar 15;271(11):6451-7

Biochemical characterization of the human cyclin-dependent protein kinase activating kinase. Identification of p35 as a novel regulatory subunit. Yee A, et al. **J Biol Chem** 1996 Jan 5;271(1):471-7

Characterization of the in vivo phosphorylation sites of the mRNA.cap-binding complex proteins eukaryotic initiation factor-4E and p20 in Saccharomyces cerevisiae. Zanchin NI, et al. **J Biol Chem** 1995 Nov 3;270(44):26505-10

Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. Zhang S, et al. **J Biol Chem** 1995 Oct 13;270(41):23934-6

Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. Fan Z, et al. **J Cell Biol** 1995 Oct;131(1):235-42

Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. Zhu X, et al. **J Cell Biol** 1996 Apr;133(2):391-403

Expression and subcellular localization of CDK2 and cdc2 kinases and their common partner cyclin A in thyroid epithelial cells: comparison of cyclic AMP-dependent and -independent cell cycles. Baptist M, et al. **J Cell Physiol** 1996 Feb;166(2):256-73

Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes. Lucas JJ, et al. **J Cell Physiol** 1995 Nov;165(2):406-16

Differential control of expression of type I and type II receptors of transforming growth factor-beta in colon carcinoma cells. Periyasamy S, et al. **J Cell Physiol** 1996 Sep;168(3):711-20

Induction of down-regulation of the kinase activities of Mek, p42Erk, p90RSK, and p63SAMK in chicken embryo fibroblast at the late stage of src-induced cellular transformation. Wang HC. **J Cell Physiol** 1996 Jul; 168(1):87-96

Protein kinases in the control of mitosis: focus on nucleocytoplasmic trafficking. Gallant P, et al. **J Cell Sci Suppl** 1995;19:21-8 (86 ref.)

1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. Zhou X, et al. **J Clin Invest** 1996 Aug 15;98(4):937-44

Membrane skeletal proteins and their integral membrane protein anchors are targets for tyrosine and threonine kinases in Euglena. Fazio MJ, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):570-80

Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death [see comments] Casciola-Rosen L, et al. **J Exp Med** 1996 May 1;183(5):1957-64. Comment in: J Exp Med 1996 May 1;183(5):1947-51.

DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. Casciola-Rosen LA, et al. **J Exp Med** 1995 Dec 1; 182(6):1625-34

Interleukin-1 beta-converting enzyme-like protease cleaves DNA-dependent protein kinase in cytotoxic T cell killing. Song Q, et al. **J Exp Med** 1996 Aug 1;184(2):619-26

Effect on substrate binding of an alteration at the conserved aspartic acid- 162 in herpes simplex virus type 1 thymidine kinase. Black ME, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1521-7

Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages. Sanghera JS, et al. **J Immunol** 1996 Jun 1;156(11):4457-65

Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. Goedert M, et al. **J Neurochem** 1995 Dec; 65(6):2804-7

Differential cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase kinase-3 and cyclin-dependent kinase-5. Guidato S, et al. **J Neurochem** 1996 Apr;66(4):1698-706

Casein kinase II phosphorylates the neural cell adhesion molecule L1. Wong EV, et al. **J Neurochem** 1996 Feb; 66(2):779-86

Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. Arnold SF, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):163-72

Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. Chirillo P, et al. **J Virol** 1996 Jan;70(1):641-6

Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. Flory E, et al. **J Virol** 1996 Apr;70(4):2260-8

The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B. Folgueira L, et al. **J Virol** 1996 Apr;70(4):2332-8

The association of Nef with a cellular serine/threonine kinase and its enhancement of infectivity are viral isolate dependent. Luo T, et al. **J Virol** 1996 Sep;70(9):6493-6

Human immunodeficiency virus type 1 Nef associates with a member of the p21-activated kinase family. Nunn MF, et al. **J Virol** 1996 Sep;70(9):6157-61

The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. Yang X, et al. **J Virol** 1996 Jul;70(7):4576-84

Casein kinase II and protein kinase C modulate hepatitis delta virus RNA replication but not empty viral particle assembly. Yeh TS, et al. **J Virol** 1996 Sep;70(9):6190-8

Ras-Raf complexes: analyses of complexes formed in vivo. Finney R, et al. **Methods Enzymol** 1995;255:310-23 (24 ref.)
Cell-free assay system for Ras-dependent MEK activation. Kuroda S, et al. **Methods Enzymol** 1995;255:257-65
Activation of Raf-1 by Ras in intact cells. Morrison DK. **Methods Enzymol** 1995;255:301-10
Ras-Raf interaction: two-hybrid analysis. Vojtek AB, et al. **Methods Enzymol** 1995;255:331-42
Ras-Raf complexes in vitro. Zhang XF, et al. **Methods Enzymol** 1995;255:323-31
Differential effects on cAMP on the MAP kinase cascade: evidence for a cAMP-insensitive step that can bypass Raf-1. Faure M, et al. **Mol Biol Cell** 1995 Aug;6(8):1025-35
Drosophila Cdk8, a kinase partner of cyclin C that interacts with the large subunit of RNA polymerase II. Leclerc V, et al. **Mol Biol Cell** 1996 Apr;7(4):505-13
Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Trinczek B, et al. **Mol Biol Cell** 1995 Dec;6(12):1887-902
Casein kinase 2 inactivation by Mg2+, Mn2+ and Co2+ ions. Jiménez JS, et al. **Mol Cell Biochem** 1995 Nov 8; 152(1):1-6
Activation of signalling by the activin receptor complex. Attisano L, et al. **Mol Cell Biol** 1996 Mar;16(3):1066-73
Single-stranded-DNA binding alters human replication protein A structure and facilitates interaction with DNA-dependent protein kinase. Blackwell LJ, et al. **Mol Cell Biol** 1996 Sep;16(9):4798-807
scid cells are deficient in Ku and replication protein A phosphorylation by the DNA-dependent protein kinase. Boubnov NV, et al. **Mol Cell Biol** 1995 Oct;15(10):5700-6
A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Catling AD, et al. **Mol Cell Biol** 1995 Oct;15(10):5214-25
Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3-kinase in activation of pp70 S6 kinase. Dahl J, et al. **Mol Cell Biol** 1996 Jun;16(6):2728-35
Evidence for two catalytically active kinase domains in pp90rsk. Fisher TL, et al. **Mol Cell Biol** 1996 Mar; 16(3):1212-9
The REG2 gene of Saccharomyces cerevisiae encodes a type 1 protein phosphatase-binding protein that functions with Reg1p and the Snf1 protein kinase to regulate growth. Frederick DL, et al. **Mol Cell Biol** 1996 Jun;16(6):2922-31
Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members. Frost JA, et al. **Mol Cell Biol** 1996 Jul; 16(7):3707-13
Interaction of the interferon-induced PKR protein kinase with inhibitory proteins P58IPK and vaccinia virus K3L is mediated by unique domains: implications for kinase regulation. Gale M Jr, et al. **Mol Cell Biol** 1996 Aug; 16(8):4172-81
Casein kinase II is required for efficient transcription by RNA polymerase III. Hockman DJ, et al. **Mol Cell Biol** 1996 Mar;16(3):892-8
Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase. Holt KH, et al. **Mol Cell Biol** 1996 Feb;16(2):577-83
Pho85p, a cyclin-dependent protein kinase, and the Snf1p protein kinase act antagonistically to control glycogen accumulation in Saccharomyces cerevisiae. Huang D, et al. **Mol Cell Biol** 1996 Aug;16(8):4357-65
Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Jelinek T, et al. **Mol Cell Biol** 1996 Mar; 16(3):1027-34
Casein kinase II increases the transcriptional activities of MRF4 and MyoD independently of their direct phosphorylation. Johnson SE, et al. **Mol Cell Biol** 1996 Apr;16(4):1604-13
Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Khosravi-Far R, et al. **Mol Cell Biol** 1996 Jul;16(7):3923-33
Yeast SNF1 protein kinase interacts with SIP4, a C6 zinc cluster transcriptional activator: a new role for SNF1 in the glucose response. Lesage P, et al. **Mol Cell Biol** 1996 May;16(5):1921-8
Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Lin R, et al. **Mol Cell Biol** 1996 Apr;16(4):1401-9
Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation. McElhinny JA, et al. **Mol Cell Biol** 1996 Mar;16(3):899-906
Regulation of Raf-1-dependent signaling during early Xenopus development. MacNicol AM, et al. **Mol Cell Biol** 1995 Dec;15(12):6686-93
Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains. Mahalingam M, et al. **Mol Cell Biol** 1996 Jan; 16(1):405-13
Casein kinase II phosphorylation site mutations in c-Myb affect DNA binding and transcriptional cooperativity with NF-M. Oelgeschläger M, et al. **Mol Cell Biol** 1995 Nov; 15(11):5966-74
Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Pritchard CA, et al. **Mol Cell Biol** 1995 Nov;15(11):6430-42
MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Raingeaud J, et al. **Mol Cell Biol** 1996 Mar;16(3):1247-55
Identification of an autoinhibitory region in the activation loop of the Mos protein kinase. Robertson SC, et al. **Mol Cell Biol** 1996 Jul;16(7):3472-9
p95vav associates with the nuclear protein Ku-70. Romero F, et al. **Mol Cell Biol** 1996 Jan;16(1):37-44
Constitutive phosphorylation of IkappaBalpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IkappaBalpha. Schwarz EM, et al. **Mol Cell Biol** 1996 Jul;16(7):3554-9
p21 Disrupts the interaction between cdk2 and the E2F-p130 complex. Shiyanov P, et al. **Mol Cell Biol** 1996 Mar; 16(3):737-44
Yeast MEK-dependent signal transduction: response thresholds and parameters affecting fidelity. Yashar B, et al. **Mol Cell Biol** 1995 Dec;15(12):6545-53
MMK2, a novel alfalfa MAP kinase, specifically complements the yeast MPK1 function. Jonak C, et al. **Mol Gen Genet** 1995 Oct 25;248(6):686-94
Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287-96
Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Gapany M, et al. **Mol Med** 1995 Sep;1(6):659-66
Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493-9 (24 ref.)
Mechanisms regulating Raf-1 activity in signal transduction pathways. Morrison DK. **Mol Reprod Dev** 1995 Dec; 42(4):507-14 (27 ref.)
Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Block C, et al. **Nat Struct Biol** 1996 Mar;3(3):244-51
Ras/Rap effector specificity determined by charge reversal [see comments] Nassar N, et al. **Nat Struct Biol** 1996 Aug; 3(8):723-9. Comment in: Nat Struct Biol 1996 Aug;3(8):653-9.
Picture story. Cyclin switch. Riddihough G. **Nat Struct Biol** 1995 Aug;2(8):636
Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Akoulitchev S, et al. **Nature** 1995 Oct 12;377(6549):557-60
Control of p70 s6 kinase by kinase activity of FRAP in vivo. Brown EJ, et al. **Nature** 1995 Oct 5;377(6548):441-6
A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor. Chen RH, et al. **Nature** 1995 Oct 12;377(6549):548-52
Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Colas P, et al. **Nature** 1996 Apr 11;380(6574):548-50
Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization [see comments] Farrar MA, et al. **Nature** 1996 Sep 12;383(6596):178-81. Comment in: Nature 1996 Sep 12;383(6596):127-8.
Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Hannigan GE, et al. **Nature** 1996 Jan 4;379(6560):91-6
Oligomerization activates c-Raf-1 through a Ras-dependent mechanism [see comments] Luo Z, et al. **Nature** 1996 Sep 12;383(6596):181-5. Comment in: Nature 1996 Sep 12;383(6596):181-5.
Cell signalling. Raf gets it together [news; comment] Marshall CJ. **Nature** 1996 Sep 12;383(6596):127-8. Comment on: Nature 1996 Sep 12;383(6596):178-81. Comment on: Nature 1996 Sep 12;383(6596):181-5.
Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Pombo CM, et al. **Nature** 1995 Oct 26;377(6551):750-4
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Verheij M, et al. **Nature** 1996 Mar 7;380(6569):75-9
Phosphorylation of Raf by ceramide-activated protein kinase. Yao B, et al. **Nature** 1995 Nov 16;378(6554):307-10
Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Maldonado R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):565-75
Structure, function, and regulation of neuronal Cdc2-like protein kinase. Lew J, et al. **Neurobiol Aging** 1995 May-Jun; 16(3):263-8; discussion 268-70
Networking with proline-directed protein kinases implicated in tau phosphorylation. Pelech SL. **Neurobiol Aging** 1995 May-Jun;16(3):247-56; discussion 257-61 (135 ref.)
Amyloid beta peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3 beta in rat hippocampal neurons. Takashima A, et al. **Neurosci Lett** 1995 Sep 29; 198(2):83-6
Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Hall SR, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1119-26
Phosphorylation of human replication protein A by the DNA-dependent protein kinase is involved in the modulation of DNA replication. Henricksen LA, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):3107-12
Dual influence of the yeast Cat1p (Snf1p) protein kinase on carbon source-dependent transcriptional activation of gluconeogenic genes by the regulatory gene CAT8. Rahner A, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2331-7
Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells. Akagi T, et al. **Oncogene** 1996 Jul 18;13(2):399-405
Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory beta-subunit of protein kinase CK2. Appel K, et al. **Oncogene** 1995 Nov 16; 11(10):1971-8
Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2. Cano E, et al. **Oncogene** 1996 Feb 15;12(4):805-12
Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Chen IT, et al. **Oncogene** 1996 Feb 1;12(3):595-607
p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Fotedar R, et al. **Oncogene** 1996 May 16;12(10):2155-64
p21WAF1/CIP1 interacts with protein kinase CK2. Götz C, et al. **Oncogene** 1996 Jul 18;13(2):391-8
Activation of the JNK pathway by distantly related protein kinases, MEKK and MUK. Hirai S, et al. **Oncogene** 1996 Feb 1;12(3):641-50
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells. Kwon TK, et al. **Oncogene** 1995 Nov 16;11(10):2077-83
Regulation of A-raf expression. Lee JE, et al. **Oncogene** 1996 Apr 18;12(8):1669-77
Activation of Mil/Raf protein kinases in mitotic cells. Lovrić J, et al. **Oncogene** 1996 Mar 7;12(5):1109-16
Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein. Lovrić J, et al. **Oncogene** 1996 Mar 7; 12(5):1145-51
HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Massimi P, et al. **Oncogene** 1996 Jun 6;12(11):2325-30
A model of the G1 phase of the cell cycle incorporating cyclin E/cdk2 complex and retinoblastoma protein. Obeyesekere MN, et al. **Oncogene** 1995 Sep 21; 11(6):1199-205
Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Papin C, et al. **Oncogene** 1996 May 16;12(10):2213-21
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Rickert P, et al. **Oncogene** 1996 Jun 20; 12(12):2631-40
Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Rommel C, et al. **Oncogene** 1996 Feb 1;12(3):609-19
Synergism between two growth regulatory pathways: cooperative transformation of NIH3T3 cells by G alpha 12 and c-raf-1. Zhang Y, et al. **Oncogene** 1996 Jun 6; 12(11):2377-83
Chloroplast ribonucleoproteins (RNPs) as phosphate acceptors for casein kinase II: purification by ssDNA-cellulose column chromatography. Kanekatsu M, et al. **Plant Cell Physiol** 1995 Dec;36(8):1649-56
Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Andjelković M, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5699-704
Activation of a serine/threonine kinase signaling pathway by transforming growth factor type beta. Atfi A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12110-4
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Benn J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11215-9
Structural and functional analysis of pp70S6k. Cheatham L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11696-700
Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Chou J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10516-20
Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo. Cosentino GP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9445-9
In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3' untranslated regions of human alpha-tropomyosin. Davis S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):508-13
The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Debant A, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5466-71
Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Hoshi M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2719-23
Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Huwiler A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6959-63
Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Jurutka PW, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;

93(8):3519–24
Inhibition of cyclin D–CDK4/CDK6 activity is associated with an E2F–mediated induction of cyclin kinase inhibitor activity. Khleif SN, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4350–4
Molecular cloning of a protein kinase whose phosphorylation is regulated by genetic adhesion during Chlamydomonas fertilization. Kurvari V, et al.
Proc Natl Acad Sci U S A 1996 Jan 9;93(1):39–43
The brain–specific activator p35 allows Cdk5 to escape inhibition by p27Kip1 in neurons. Lee MH, et al.
Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3259–63
The specificity of the transforming growth factor beta receptor kinases determined by a spatially addressable peptide library. Luo K, et al.
Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11761–5
Ras2 signals via the Cdc42/Ste20/mitogen–activated protein kinase module to induce filamentous growth in Saccharomyces cerevisiae. Mösch HU, et al.
Proc Natl Acad Sci U S A 1996 May 28;93(11):5352–6
In its active form, the GTP–binding protein rab8 interacts with a stress–activated protein kinase. Ren M, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):5151–5
Identification of human cyclin–dependent kinase 8, a putative protein kinase partner for cyclin C. Tassan JP, et al.
Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8871–5
Phosphorylation of the fused protein kinase in response to signaling from hedgehog. Thérond PP, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4224–8
4E–BP1 phosphorylation is mediated by the FRAP–p70s6k pathway and is independent of mitogen–activated protein kinase. von Manteuffel SR, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4076–80
Interactions between the double–stranded RNA binding motif and RNA: definition of the binding site for the interferon–induced protein kinase DAI (PKR) on adenovirus VA RNA. Clarke PA, et al. **RNA** 1995 Mar; 1(1):7–20
Rho returns: its targets in focal adhesions [comment] Bussey H. **Science** 1996 Jul 12;273(5272):203. Comment on: Science 1996 Jul 12;273(5272):245–8.
A cyclin–dependent kinase–activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Espinoza FH, et al. **Science** 1996 Sep 20;273(5282):1714–7
Dependence of cyclin E–CDK2 kinase activity on cell anchorage. Fang F, et al. **Science** 1996 Jan 26; 271(5248):499–502
Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption. Hardwick KG, et al. **Science** 1996 Aug 16;273(5277):953–6
Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Joneson T, et al. **Science** 1996 Feb 9;271(5250):810–2
Regulation of myosin phosphatase by Rho and Rho–associated kinase (Rho–kinase) [see comments] Kimura K, et al. **Science** 1996 Jul 12;273(5272):245–8. Comment in: Science 1996 Jul 12;273(5272):203.
Pheromone response in yeast: association of Bem1p with proteins of the MAP kinase cascade and actin. Leeuw T, et al. **Science** 1995 Nov 17;270(5239):1210–3
Myt1: a membrane–associated inhibitory kinase that phosphorylates Cdc2 on both threonine–14 and tyrosine–15. Mueller PR, et al. **Science** 1995 Oct 6; 270(5233):86–90
Dephosphorylation of Cdk2 Thr160 by the cyclin–dependent kinase–interacting phosphatase KAP in the absence of cyclin. Poon RY, et al. **Science** 1995 Oct 6;270(5233):90–3
TAB1: an activator of the TAK1 MAPKKK in TGF–beta signal transduction. Shibuya H, et al. **Science** 1996 May 24;272(5265):1179–82
The p21(RAS) farnesyltransferase alpha subunit in TGF–beta and activin signaling. Wang T, et al. **Science** 1996 Feb 23; 271(5252):1120–2
Coupling of the RAS–MAPK pathway to gene activation by RSK2, a growth factor–regulated CREB kinase. Xing J, et al. **Science** 1996 Aug 16;273(5277):959–63
Identification of a member of the MAPKKK family as a potential mediator of TGF–beta signal transduction. Yamaguchi K, et al. **Science** 1995 Dec 22;270(5244):2008–11
Requirement for BMP signaling in interdigital apoptosis and scale formation. Zou H, et al. **Science** 1996 May 3; 272(5262):738–41
Bound to activate: conformational consequences of cyclin binding to CDK2. Radzio–Andzelm E, et al. **Structure** 1995 Nov 15;3(11):1135–41
Activation of extracellular signal–regulated protein kinase (ERK/MAP kinase) following CD28 cross–linking: activation in cells lacking p56lck. August A, et al.
Tissue Antigens 1995 Sep;46(3 (Pt 1)):155–62
A target for phosphoinositide 3–kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441–2 (11 ref.)
Localization of the Us protein kinase of equine herpesvirus type 1 is affected by the cytoplasmic structures formed by the noval IR6 protein. Colle CF, et al. **Virology** 1996 Jun 15;220(2):424–35
Characterization of the heparin–mediated activation of PKR, the interferon–inducible RNA–dependent protein kinase. George CX, et al. **Virology** 1996 Jul 1;221(1):180–8
Binding of the influenza virus NS1 protein to double–stranded RNA inhibits the activation of the protein kinase that phosphorylates the eIF–2 translation initiation factor. Lu Y, et al. **Virology** 1995 Dec 1;214(1):222–8
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. McIntyre MC, et al. **Virology** 1996 Jan 1;215(1):73–82
HIV–1 Tat directly interacts with the interferon–induced, double–stranded RNA–dependent kinase, PKR. McMillan NA, et al. **Virology** 1995 Nov 10;213(2):413–24
Human PKR transfected into murine cells stimulates expression of genes under control of the HIV1 or HTLV–I LTR. Meurs EF, et al. **Virology** 1995 Dec 20;214(2):653–9
Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA–dependent protein kinase PKR from human cells. Ortega LG, et al. **Virology** 1996 Jan 1;215(1):31–9

PHARMACOLOGY

Phosphorylation of wheat germ initiation factor 2 (eIF–2) by N–ethylmaleimide–treated wheat germ lysates and by purified casein kinase II does not affect the guanine nucleotide exchange on eIF–2. Janaki N, et al.
Arch Biochem Biophys 1995 Dec 1;324(1):1–8
A eukaryotic translation initiation factor 2–associated 67 kDa glycoprotein partially reverses protein synthesis inhibition by activated double–stranded RNA–dependent protein kinase in intact cells. Wu S, et al. **Biochemistry** 1996 Jun 25;35(25):8275–80
Raf–1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor–Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215–21
Differential regulation of p34cdc2 and p33cdk2 by transforming growth factor–beta 1 in murine mammary epithelial cells. Fautsch MP, et al. **J Cell Biochem** 1995 Aug;58(4):517–26

PHYSIOLOGY

Truncated type II receptor for BMP–4 induces secondary axial structures in Xenopus embryos. Ishikawa T, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):26–33
CAK in TFIIH: crucial connection or confounding coincidence? Fisher RP, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):O7–10 (51 ref.)
Taxol induction of p21WAF1 and p53 requires c–raf–1. Blagosklonny MV, et al. **Cancer Res** 1995 Oct 15; 55(20):4623–6
Ras–interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v–Ras–induced transformation and Raf–1 activation in NIH3T3 cells. Okazaki M, et al.
Cancer Res 1996 May 15;56(10):2387–92
Integrin signaling to NF–kappa B in monocytic leukemia cells is blocked by activated oncogenes. Rosales C, et al.
Cancer Res 1996 May 15;56(10):2302–5
Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2–cyclin B kinase activity. Guadagno TM, et al. **Cell** 1996 Jan 12;84(1):73–82
The Xenopus dorsalizing factor noggin ventralizes Drosophila embryos by preventing DPP from activating its receptor. Holley SA, et al. **Cell** 1996 Aug 23; 86(4):607–17
Repair and recombination. How to make ends meet. Roth DB, et al. **Curr Biol** 1995 May 1;5(5):496–9
The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Chou MM, et al.
Curr Opin Cell Biol 1995 Dec;7(6):806–14 (72 ref.)
The effect of c–raf antisense oligonucleotides on growth factor–induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)
The activity of D–raf in torso signal transduction is altered by serine substitution, N–terminal deletion, and membrane targeting. Baek KH, et al. **Dev Biol** 1996 May 1; 175(2):191–204
The SH2–containing tyrosine phosphatase corkscrew is required during signaling by sevenless, Ras1 and Raf. Allard JD, et al. **Development** 1996 Apr;122(4):1137–46
Deficient signaling in mice devoid of double–stranded RNA–dependent protein kinase. Yang YL, et al.
EMBO J 1995 Dec 15;14(24):6095–106
Mutations in the p53 and SCID genes cooperate in tumorigenesis. Nacht M, et al. **Genes Dev** 1996 Aug 15; 10(16):2055–66
Positive regulation of the nuclear activator CREM by the mitogen–induced p70 S6 kinase. de Groot RP, et al.
Immunobiology 1995 Jul;193(2–4):155–60 (9 ref.)
MEK kinase is involved in tumor necrosis factor alpha–induced NF–kappaB activation and degradation of IkappaB–alpha. Hirano M, et al. **J Biol Chem** 1996 May 31;271(22):13234–8
Suppression of apoptosis by dominant negative mutants of cyclin–dependent protein kinases. Meikrantz W, et al.
J Biol Chem 1996 Apr 26;271(17):10205–9
Phosphorylation of actin–binding protein 280 by growth factors is mediated by p90 ribosomal protein S6 kinase. Ohta Y, et al. **J Biol Chem** 1996 May 17;271(20):11858–64
Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. Wang J, et al. **J Biol Chem** 1996 Jul 19; 271(29):17366–71
Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the raf–1/MAP kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for an obligate autocrine mechanism promoting cell proliferation induced by G–protein–coupled receptor agonist. Molloy CJ, et al.
J Clin Invest 1996 Mar 1;97(5):1173–83
Positive and negative selection invoke distinct signaling pathways. Alberola–Ila J, et al. **J Exp Med** 1996 Jul 1; 184(1):9–18
MEK1 and the extracellular signal–regulated kinases are required for the stimulation of IL–2 gene transcription in T cells. Whitehurst CE, et al. **J Immunol** 1996 Feb 1; 156(3):1020–9
pim–1 proto–oncogene expression in anti–CD3–mediated T cell activation is associated with protein kinase C activation and is independent of Raf–1. Wingett D, et al.
J Immunol 1996 Jan 15;156(2):549–57
Dmcdc2 kinase is required for both meiotic divisions during Drosophila spermatogenesis and is activated by the Twine/cdc25 phosphatase. Sigrist S, et al. **Mech Dev** 1995 Oct;53(2):247–60
Regulatory properties of neuronal cdc2–like kinase. Qi Z, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:35–9 (38 ref.)
Differential regulation of Raf–1 and B–Raf and Ras–dependent activation of mitogen–activated protein kinase by cyclic AMP in PC12 cells. Erhardt P, et al.
Mol Cell Biol 1995 Oct;15(10):5524–30
Constitutive expression of murine Sak–a suppresses cell growth and induces multinucleation. Fode C, et al.
Mol Cell Biol 1996 Sep;16(9):4665–72
Degradation of c–Fos by the 26S proteasome is accelerated by c–Jun and multiple protein kinases. Tsurumi C, et al. **Mol Cell Biol** 1995 Oct;15(10):5682–7
Yeast RLM1 encodes a serum response factor–like protein that may function downstream of the Mpk1 (Slt2) mitogen–activated protein kinase pathway. Watanabe Y, et al. **Mol Cell Biol** 1995 Oct;15(10):5740–9
Constitutively active Gq–alpha stimulates prolactin promoter activity via a pathway involving Raf activity. Tian J, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):249–56
Disruption of DNA–PK in Ku80 mutant xrs–6 and the implications in DNA double–strand break repair. Chen F, et al. **Mutat Res** 1996 Jan 2;362(1):9–19
Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Mutat Res** 1995 Dec;333(1–2):153–60 (47 ref.)
Growth factor–dependent survival of rodent fibroblasts requires phosphatidylinositol 3–kinase but is independent of pp70S6K activity. Yao R, et al. **Oncogene** 1996 Jul 18; 13(2):343–51
Synergism between two growth regulatory pathways: cooperative transformation of NIH3T3 cells by G alpha 12 and c–raf–1. Zhang Y, et al. **Oncogene** 1996 Jun 6; 12(11):2377–83
Feedback regulation of map kinase signal pathways. Errede B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):143–8; discussion 148–9 (30 ref.)
Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)
What to do at an end: DNA double–strand–break repair. Weaver DT. **Trends Genet** 1995 Oct;11(10):388–92 (51 ref.)

ULTRASTRUCTURE

p19Skp1 and p45Skp2 are essential elements of the cyclin A–CDK2 S phase kinase. Zhang H, et al. **Cell** 1995 Sep 22;82(6):915–25

PROTEIN STRUCTURE, PRIMARY see **AMINO ACID SEQUENCE**

PROTEIN STRUCTURE, QUATERNARY see **PROTEIN CONFORMATION**

PROTEIN STRUCTURE, SECONDARY

Multi–helical DNA–binding domains: their structures and modes of DNA–binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31–52 (88 ref.)
DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53–72 (47 ref.)
Fibronectin and cell adhesion: specificity of integrin–ligand interaction. Aota S, et al.
Adv Enzymol Relat Areas Mol Biol 1995;70:1–21 (81 ref.)
Structure and function of the ion channel model system annexin V. Voges D, et al.
Adv Enzymol Relat Areas Mol Biol 1995;71:209–39 (144 ref.)
Comparisons of the three–dimensional structures, specificities and glycosylation of renins, yeast proteinase A and cathepsin D. Aguilar CF, et al. **Adv Exp Med Biol** 1995; 362:155–66
Activated dynamics of flap opening in HIV–1 protease. Collins JR, et al. **Adv Exp Med Biol** 1995;362:455–60
Protein engineering of surface loops: preliminary X–ray analysis of the CHY155–165RHI mutant. Dhanaraj RR, et al. **Adv Exp Med Biol** 1995;362:95–9
Structure of human cathepsin D: comparison of inhibitor binding and subdomain displacement with other aspartic proteases. Erickson JW, et al. **Adv Exp Med Biol** 1995; 362:181–92
Breaking the shackles of the genetic code: engineering retroviral proteases through total chemical synthesis. Kent SB, et al. **Adv Exp Med Biol** 1995;362:425–38
Structure and possible function of aspartic proteinases in

barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241–54 (72 ref.)

Cathepsin D crystal structures and lysosomal sorting. Metcalf P, et al. **Adv Exp Med Biol** 1995;362:193–200

Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Sato S, et al. **Adv Exp Med Biol** 1995; 372:259–68

Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)

The G protein–coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

Conservative hydrophobic interdomain contacts of IFN–gamma remain in P17 matrix protein of HIV–1. Denesyuk AI, et al. **APMIS** 1996 Feb;104(2):141–6

Characterization of the pH titration shifts of ribonuclease A by one– and two–dimensional nuclear magnetic resonance spectroscopy. Baker WR, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):189–99

Reaction of neprilysin (neutral endopeptidase) and thermolysin with cyclic peptides. Vijayaragahaven J, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):405–9

(i, i + 4) Ion pairs stabilize helical peptides derived from smooth muscle caldesmon. Wang E, et al. **Arch Biochem Biophys** 1996 May 15;329(2):156–62

Reversible thermal denaturation of staphylococcal nuclease: a Fourier transformed infrared spectrum study. Xie L, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):122–8

Glycosylation in human thyroglobulin: location of the N–linked oligosaccharide units and comparison with bovine thyroglobulin. Yang SX, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):61–70

A highly conserved epitope on the spike protein of infectious bronchitis virus. Wang L, et al. **Arch Virol** 1995; 140(12):2201–13

Antagonistic mutant proteins of interleukin–4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87–94 (27 ref.)

A designed beta–hairpin peptide. Awasthi SK, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):375–81

Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. Chhajlani V, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):521–5

DSBC protein: a new member of the thioredoxin fold–containing family. Frishman D. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):686–9

Point mutations in the first and third intracellular loops of the glucagon–like peptide–1 receptor alter intracellular signaling. Heller RS, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):624–32

Copper binding to the N–terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Hornshaw MP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):993–9

Evidence for an alpha helical T cell epitope in the C–terminus of the main birch pollen allergen Bet V 1. Kungl AJ, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):187–92

The dimerization domain upstream binding factor contains multiple helical structures. Lai YS, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):816–23

Effect of diabetic duration on the secondary structures of the human lens capsules in diabetic cataracts. Lin SY, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):183–9

Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Pörzgen P, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):1145–50

Stabilization of helix by side–chain interactions in histatin–derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):47–53

Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Satoh T, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):438–43

Conformation of an antigenic determinant for experimental autoimmune neuritis. Shin HC, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):5–9

Total synthesis of a miniferredoxin. Sow TC, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):360–4

Comparative analysis of the regions binding beta gamma–subunits in Galpha and PH domains. Srinivasan V, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):697–702

A case of male–limited precocious puberty caused by a point mutation in the second transmembrane domain of the luteinizing hormone choriogonadotropin receptor gene. Yano K, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1036–42

Altering kinetic mechanism and enzyme stability by mutagenesis of the dimer interface of glutathione reductase. Bashir A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):527–33

Secondary structure of NADPH: protochlorophyllide oxidoreductase examined by circular dichroism and prediction methods. Birve SJ, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):549–55

Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide–RNA duplexes. Crooke ST, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):599–608

Lactoferrin–lipopolysaccharide interaction: involvement of the 28–34 loop region of human lactoferrin in the high–affinity binding to Escherichia coli 055B5 lipopolysaccharide. Elass–Rochard E, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):839–45

Location of smooth–muscle myosin and tropomyosin binding sites in the C–terminal 288 residues of human caldesmon. Huber PA, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):617–25

Identification of the ferroxidase centre of Escherichia coli bacterioferritin. Le Brun NE, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):385–92

Amino acid substitutions enhancing thermostability of Bacillus polymyxa beta–glucosidase A. Lopez–Camacho C, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):833–8

Heparin binding to platelet factor–4. An NMR and site–directed mutagenesis study: arginine residues are crucial for binding. Mayo KH, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):357–65

Rapsyn's knobs and holes: eight tetratrico peptide repeats [letter] Ponting CC, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1053–4

Structural and functional analysis of the globular domain IVa of the laminin alpha 1 chain and its impact on an adjacent RGD site. Schulze B, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):847–51

An investigation of the membrane topology of the ionotropic glutamate receptor subunit GluR1 in a cell–free system. Seal AJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):451–6

Metal content and conformation of the metalloprotease from the marine sponge Spheciospongia vesparia. Arreguín R, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):827–33

The loop region around amino acid residue 50, the N–terminal part of the alpha–helix, and the C–terminus of human retinol–binding protein are not located in or close to the transthyretin binding site. Melhus H, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1147–51

A Fourier transform infrared spectroscopic study of the secondary structure of myelin basic protein in reconstituted myelin. Stuart BH. **Biochem Mol Biol Int** 1996 Apr; 38(4):839–45

Comparative analysis of the secondary structural motifs of P450BM–3 and the regions located upstream of the calmodulin–binding domain in the nitric oxide synthases. Uvarov VYu, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):553–8

Simulation of voltage–dependent insertion of alpha–helical peptides into lipid bilayers. Biggin PC, et al. **Biochem Soc Trans** 1996 Feb;24(1):137S

Molecular modelling analyses of the C–type lectin domain in human aggrecan. Brissett NC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99S

Flavocytochrome b2: an ideal model system for studying protein–mediated electron transfer. Chapman SK, et al. **Biochem Soc Trans** 1996 Feb;24(1):73–7 (17 ref.)

Simulations on the activation of the bradykinin B2 receptor. Doughty SW, et al. **Biochem Soc Trans** 1996 Feb; 24(1):259–63

Molecular evolution and substrate specificity of acyl–CoA dehydrogenases: chimaeric 'medium/long' chain–specific enzyme from medium–chain acyl–CoA dehydrogenase. Nandy A, et al. **Biochem Soc Trans** 1996 Feb;24(1):105–10

Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)

Molecular dynamics simulations on solvated M2 helix bundles of nicotinic receptors. Sankararamakrishnan R, et al. **Biochem Soc Trans** 1996 Feb;24(1):138S

Water dynamics in model transbilayer pores. Sansom MS, et al. **Biochem Soc Trans** 1996 Feb;24(1):139S

Simulation of the packing of transmembrane alpha–helices. Son HS, et al. **Biochem Soc Trans** 1996 Feb;24(1):140S

Structure of the bradykinin B2 receptors' amino terminus. AbdAlla S, et al. **Biochemistry** 1996 Jun 11;35(23):7514–9

Determining the secondary structure and orientation of EmrE, a multi–drug transporter, indicates a transmembrane four–helix bundle. Arkin IT, et al. **Biochemistry** 1996 Jun 4;35(22):7233–8

Proton–translocating carboxyl of subunit c of F1Fo H(+)–ATP synthase: the unique environment suggested by the pKa determined by 1H NMR. Assadi–Porter FM, et al. **Biochemistry** 1995 Dec 12;34(49):16186–93

Interlobe communication in 13C–methionine–labeled human transferrin. Beatty EJ, et al. **Biochemistry** 1996 Jun 18; 35(24):7635–42

Controlling topology and native–like behavior of de novo–designed peptides: design and characterization of antiparallel four–stranded coiled coils. Betz SF, et al. **Biochemistry** 1996 May 28;35(21):6955–62

Proline pipe helix: structure of the tus proline repeat determined by 1H NMR. Butcher DJ, et al. **Biochemistry** 1996 Jan 23;35(3):698–703

Secondary structure and topology of a mitochondrial presequence peptide associated with negatively charged micelles. A 2D H–NMR study. Chupin V, et al. **Biochemistry** 1996 Mar 12;35(10):3141–6

Fatty acid interactions with a helix–less variant of intestinal fatty acid–binding protein. Cistola DP, et al. **Biochemistry** 1996 Jun 11;35(23):7559–65

Side chain packing of the N– and C–terminal helices plays a critical role in the kinetics of cytochrome c folding. Colón W, et al. **Biochemistry** 1996 Apr 30;35(17):5538–49

Structural studies of mutant glucocorticoid receptor transactivation domains establish a link between transactivation activity in vivo and alpha–helix–forming potential in vitro. Dahlman–Wright K, et al. **Biochemistry** 1996 Jan 30;35(4):1323–7

Structures of oligosaccharide–bound forms of the endoglucanase V from Humicola insolens at 1.9 A resolution. Davies GJ, et al. **Biochemistry** 1995 Dec 12; 34(49):16210–20

Identification of residues in the aromatic substrate binding site of horseradish peroxidase by 1H NMR studies on isozymes. de Ropp JS, et al. **Biochemistry** 1995 Oct 17; 34(41):13477–84

Infrared and circular dichroism spectroscopic characterization of structural differences between beta–lactoglobulin A and B. Dong A, et al. **Biochemistry** 1996 Feb 6;35(5):1450–7

Subunit III of cytochrome c oxidase influences the conformation of subunits I and II: an infrared study. Echabe I, et al. **Biochemistry** 1995 Oct 17;34(41):13565–9

Solution structure of the DNA–binding protein Sac7d from the hyperthermophile Sulfolobus acidocaldarius. Edmondson SP, et al. **Biochemistry** 1995 Oct 17; 34(41):13289–304

Ribonuclease A revisited: infrared spectroscopic evidence for lack of native–like secondary structures in the thermally denatured state. Fabian H, et al. **Biochemistry** 1995 Oct 17;34(41):13651–5

Design of heterotetrameric coiled coils: evidence for increased stabilization by Glu(–)–Lys(+) ion pair interactions. Fairman R, et al. **Biochemistry** 1996 Mar 5; 35(9):2824–9

Design challenges for hemoproteins: the solution structure of apocytochrome b5. Falzone CJ, et al. **Biochemistry** 1996 May 28;35(21):6519–26

Identification of amino acid residues in transmembrane helices VI and VII of the lutropin/choriogonadotropin receptor involved in signaling. Fernandez LM, et al. **Biochemistry** 1996 Apr 2;35(13):3986–93

Cysteine–scanning mutagenesis of helix VI and the flanking hydrophilic domains on the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Apr 23; 35(16):5333–8

Monoclonal antibody 4B1 alters the pKa of a carboxylic acid at position 325 (helix X) of the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Aug 6;35(31):10166–71

Testing the correlation between delta A and delta V of protein unfolding using m value mutants of staphylococcal nuclease. Frye KJ, et al. **Biochemistry** 1996 Aug 6; 35(31):10234–9

Prothymosin alpha: a biologically active protein with random coil conformation. Gast K, et al. **Biochemistry** 1995 Oct 10;34(40):13211–8

Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein–1 (MCP–1) dimer. Handel TM, et al. **Biochemistry** 1996 May 28;35(21):6569–84

Protein stabilization by removal of unsatisfied polar groups: computational approaches and experimental tests. Hendsch ZS, et al. **Biochemistry** 1996 Jun 18;35(24):7621–5

Three–dimensional solution structure of mu–conotoxin GIIIB, a specific blocker of skeletal muscle sodium channels. Hill JM, et al. **Biochemistry** 1996 Jul 9; 35(27):8824–35

Phospholipid binding and lecithin–cholesterol acyltransferase activation properties of apolipoprotein A–I mutants. Holvoet P, et al. **Biochemistry** 1995 Oct 17;34(41):13334–42

Lactam bridge stabilization of alpha–helices: the role of hydrophobicity in controlling dimeric versus monomeric alpha–helices. Houston ME Jr, et al. **Biochemistry** 1996 Aug 6;35(31):10041–50

Measuring the strength of side–chain hydrogen bonds in peptide helices: the Gln.Asp (i, i + 4) interaction. Huyghues–Despointes BM, et al. **Biochemistry** 1995 Oct 17;34(41):13267–71

Interaction of fusogenic synthetic peptide with phospholipid bilayers: orientation of the peptide alpha–helix and binding isotherm. Ishiguro R, et al. **Biochemistry** 1996 Apr 16; 35(15):4976–83

Residues in the fifth membrane–spanning segment of the dopamine D2 receptor exposed in the binding–site crevice. Javitch JA, et al. **Biochemistry** 1995 Dec 19;34(50):16433–9

The mechanism of binding staphylococcal protein A to immunoglobin G does not involve helix unwinding. Jendeberg L, et al. **Biochemistry** 1996 Jan 9;35(1):22–31

Structural studies of Escherichia coli UDP–N–acetylmuramate:L–alanine ligase. Jin H, et al. **Biochemistry** 1996 Feb 6;35(5):1423–31

Influence of primary sequence transpositions on the folding pathways of ribonuclease T1. Johnson JL, et al. **Biochemistry** 1996 Aug 6;35(31):10223–33

Expression, purification, and ligand–binding analysis of recombinant keratinocyte lipid–binding protein (MAL–1), an intracellular lipid–binding found overexpressed in neoplastic skin cells. Kane CD, et al. **Biochemistry** 1996 Mar 5;35(9):2894–900

Glycine–15 in the bend between two alpha–helices can explain the thermostability of DNA binding protein HU from Bacillus stearothermophilus. Kawamura S, et al. **Biochemistry** 1996 Jan 30;35(4):1195–200

Methionine–393 is an axial ligand of the heme b558 component of the cytochrome bd ubiquinol oxidase from Escherichia coli. Kaysser TM, et al. **Biochemistry** 1995 Oct

17;34(41):13491–501

Induction of nonbilayer structures in diacylphosphatidylcholine model membranes by transmembrane alpha–helical peptides: importance of hydrophobic mismatch and proposed role of tryptophans. Killian JA, et al. **Biochemistry** 1996 Jan 23;35(3):1037–45

Intestinal fatty acid–binding protein: the structure and stability of a helix–less variant. Kim K, et al. **Biochemistry** 1996 Jun 11;35(23):7553–8

A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Novel mixed mode Monte Carlo/stochastic dynamics simulations of the complex between TRH and TRH receptor. Laakkonen LJ, et al. **Biochemistry** 1996 Jun 18;35(24):7651–63

Substrate binding and catalysis by ubiquitin C–terminal hydrolases: identification of two active site residues. Larsen CN, et al. **Biochemistry** 1996 May 28;35(21):6735–44

Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide–antibody recognition. Leder L, et al. **Biochemistry** 1995 Dec 19;34(50):16509–18

pH–dependent enhancement of DNA binding by the ultrabithorax homeodomain. Li L, et al. **Biochemistry** 1996 Jul 30;35(30):9832–9

The role of Glu 57 in the mechanism of the Escherichia coli MutT enzyme by mutagenesis and heteronuclear NMR. Lin J, et al. **Biochemistry** 1996 May 28;35(21):6715–26

Solution structure and backbone dynamics of recombinant Cucurbita maxima trypsin inhibitor–V determined by NMR spectroscopy. Liu J, et al. **Biochemistry** 1996 Feb 6; 35(5):1516–24

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Loll PJ, et al. **Biochemistry** 1996 Jun 11;35(23):7330–40

Fructose–1,6–bisphosphatase: arginine–22 is involved in stabilization of the T allosteric state. Lu G, et al. **Biochemistry** 1995 Oct 17;34(41):13272–7

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL, et al. **Biochemistry** 1995 Oct 17;34(41):13527–36

Motion of spin–labeled side chains in T4 lysozyme. Correlation with protein structure and dynamics. Mchaourab HS, et al. **Biochemistry** 1996 Jun 18; 35(24):7692–704

The pKa of the general acid/base carboxyl group of a glycosidase cycles during catalysis: a 13C–NMR study of bacillus circulans xylanase. McIntosh LP, et al. **Biochemistry** 1996 Aug 6;35(31):9958–66

Structure of the R65Q mutant of yeast 3–phosphoglycerate kinase complexed with Mg–AMP–PNP and 3–phospho–D–glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

Stabilization of human triosephosphate isomerase by improvement of the stability of individual alpha–helices in dimeric as well as monomeric forms of the protein. Mainfroid V, et al. **Biochemistry** 1996 Apr 2;35(13):4110–7

Functional site in alpha–lactalbumin encompasses a region corresponding to a subsite in lysozyme and parts of two adjacent flexible substructures. Malinovskii VA, et al. **Biochemistry** 1996 Jul 30;35(30):9710–5

Iterative optimization of high–affinity proteases inhibitors using phage display. 1. Plasmin. Markland W, et al. **Biochemistry** 1996 Jun 18;35(24):8045–57

Movement of the position of the transition state in protein folding. Matouschek A, et al. **Biochemistry** 1995 Oct 17; 34(41):13656–62

Structure–function analysis of the mammalian DNA polymerase beta active site: role of aspartic acid 256, arginine 254, and arginine 258 in nucleotidyl transfer. Menge KL, et al. **Biochemistry** 1995 Dec 12; 34(49):15934–42

Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Millard CB, et al. **Biochemistry** 1995 Dec 12;34(49):15925–33

The leucine zippers of the HLH–LZ proteins Max and c–Myc preferentially form heterodimers. Muhle–Goll C, et al. **Biochemistry** 1995 Oct 17;34(41):13554–64

Analysis of i,i+5 and i,i+8 hydrophobic interactions in a helical model peptide bearing the hydrophobic staple motif. Muñoz V, et al. **Biochemistry** 1995 Nov 21;34(46):15301–6

Induction of alpha–helix in the beta–sheet protein tumor necrosis factor–alpha: thermal– and trifluoroethanol–induced denaturation at neutral pH. Narhi LO, et al. **Biochemistry** 1996 Sep 3;35(35):11447–53

Induction of alpha–helix in the beta–sheet protein tumor necrosis factor–alpha: acid–induced denaturation. Narhi LO, et al. **Biochemistry** 1996 Sep 3;35(35):11454–60

Functional and structural roles of the highly conserved Trp120 loop region of glucoamylase from Aspergillus awamori. Natarajan S, et al. **Biochemistry** 1996 Mar 5; 35(9):3050–8

Structure and stability of protein H and the M1 protein from Streptococcus pyogenes. Implications for other surface proteins of gram–positive bacteria. Nilson BH, et al. **Biochemistry** 1995 Oct 17;34(41):13688–98

Folding topologies of human interleukin–6 and its mutants as studied by NMR spectroscopy. Nishimura C, et al. **Biochemistry** 1996 Jan 9;35(1):273–81

Mechanism of laminin chain assembly into a triple–stranded coiled–coil structure. Nomizu M, et al. **Biochemistry** 1996 Mar 5;35(9):2885–93

Solution structure of an engineered insulin monomer at neutral pH. Olsen HB, et al. **Biochemistry** 1996 Jul 9; 35(27):8836–45

Three–dimensional structure analysis of mu–agatoxins: further evidence for common motifs among neurotoxins with diverse ion channel specificities. Omecinsky DO, et al. **Biochemistry** 1996 Mar 5;35(9):2836–44

Domain organization and a protease–sensitive loop in eukaryotic ornithine decarboxylase. Osterman AL, et al. **Biochemistry** 1995 Oct 17;34(41):13431–6

Influence exercised by histidine–95 on chloride transport and the photocycle in halorhodopsin. Otomo J. **Biochemistry** 1996 May 28;35(21):6684–9

beta–Site covalent reactions trigger transitions between open and closed conformations of the tryptophan synthase bienzyme complex. Pan P, et al. **Biochemistry** 1996 Apr 16;35(15):5002–13

Divalent cation selectivity in a cyclic nucleotide–gated ion channel. Park CS, et al. **Biochemistry** 1995 Oct 17; 34(41):13328–33

Structural investigation of the antibiotic and ATP–binding sites in kanamycin nucleotidyltransferase. Pedersen LC, et al. **Biochemistry** 1995 Oct 17;34(41):13305–11

A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Perlman JH, et al. **Biochemistry** 1996 Jun 18;35(24):7643–50

Membrane topology of the melibiose permease of Escherichia coli studied by melB–phoA fusion analysis. Pourcher T, et al. **Biochemistry** 1996 Apr 2;35(13):4161–8

Expression and functional characterization of isoforms 4 of the plasma membrane calcium pump. Preianò BS, et al. **Biochemistry** 1996 Jun 18;35(24):7946–53

Characterization of C415 mutants of neuronal nitric oxide synthase. Richards MK, et al. **Biochemistry** 1996 Jun 18; 35(24):7772–80

D38 is an essential part of the proton translocation pathway in bacteriorhodopsin. Riesle J, et al. **Biochemistry** 1996 May 28;35(21):6635–43

Covalent attachment of Arc repressor subunits by a peptide linker enhances affinity for operator DNA. Robinson CR, et al. **Biochemistry** 1996 Jan 9;35(1):109–16

Follitropin conformational stability mediated by loop 2 beta effects follitropin–receptor interaction. Roth KE, et al. **Biochemistry** 1996 Jun 18;35(24):7928–35

Structure effects of double D–amino acid replacements: a nuclear magnetic resonance and circular dichroism study using amphipathic model helices. Rothemund S, et al. **Biochemistry** 1995 Oct 10;34(40):12954–62

Tyrosine 147 of cytochrome b is required for efficient electron transfer at the ubihydroquinone oxidase site (Qo) of the cytochrome bc1 complex. Saribaş AS, et al. **Biochemistry** 1995 Dec 12;34(49):16004–12

Crystal structure of the complex of UMP/CMP kinase from Dictyostelium discoideum and the bisubstrate inhibitor P1–(5'–adenosyl) P5–(5'–uridyl) pentaphosphate (UP5A) and Mg2+ at 2.2 A: implications for water–mediated specificity. Scheffzek K, et al. **Biochemistry** 1996 Jul 30; 35(30):9716–27

Comparison of secondary structures in water of chondroitin–4–sulfate and dermatan sulfate: implications in the formation of tertiary structures. Scott JE, et al. **Biochemistry** 1995 Nov 28;34(47):15467–74

Escherichia coli tryptophanyl–tRNA synthetase mutants selected for tryptophan auxotrophy implicate the dimer interface in optimizing amino acid binding. Sever S, et al. **Biochemistry** 1996 Jan 9;35(1):32–40

NMR solution structure of a synthetic troponin C heterodimeric domain. Shaw GS, et al. **Biochemistry** 1996 Jun 11;35(23):7429–38

Calcium–induced interactions of calmodulin domains revealed by quantitative thrombin footprinting of Arg37 and Arg106. Shea MA, et al. **Biochemistry** 1996 Mar 5; 35(9):2943–57

A study of subunit interface residues of fructose–1,6–bisphosphatase by site–directed mutagenesis: effects on AMP and Mg2+ affinities. Shyur LF, et al. **Biochemistry** 1996 Jun 11;35(23):7492–8

Interactions contributing to the formation of a beta–hairpin–like structure in a small peptide. Sieber V, et al. **Biochemistry** 1996 Jan 9;35(1):181–8

Crystal structures of the binary and ternary complexes of 7 alpha–hydroxysteroid dehydrogenase from Escherichia coli. Tanaka N, et al. **Biochemistry** 1996 Jun 18; 35(24):7715–30

Tumor suppressor p16INK4A: structural characterization of wild–type and mutant proteins by NMR and circular dichroism. Tevelev A, et al. **Biochemistry** 1996 Jul 23; 35(29):9475–87

Importance of two buried salt bridges in the stability and folding pathway of barnase. Tissot AC, et al. **Biochemistry** 1996 May 28;35(21):6786–94

Conformation and dynamics of [3–13C]Ala– labeled bacteriorhodopsin and bacterioopsin, induced by interaction with retinal and its analogs, as studied by 13C nuclear magnetic resonance. Tuzi S, et al. **Biochemistry** 1996 Jun 11;35(23):7520–7

Membrane topology of helices VII and XI in the lactose permease of Escherichia coli studied by lacY–phoA fusion analysis and site–directed spectroscopy. Ujwal ML, et al. **Biochemistry** 1995 Nov 14;34(45):14909–17

The equilibrium folding pathway of staphylococcal nuclease: identification of the most stable chain–chain interactions by NMR and CD spectroscopy. Wang Y, et al. **Biochemistry** 1995 Dec 12;34(49):15895–905

Roles of the propeptide and metal ions in the folding and stability of the catalytic domain of stromelysin (matrix metalloproteinase 3). Wetmore DR, et al. **Biochemistry** 1996 May 28;35(21):6549–58

Involvement of the carboxyl groups of glutathione in the catalytic mechanism of human glutathione transferase A1–1. Widersten M, et al. **Biochemistry** 1996 Jun 18; 35(24):7731–42

Structure and dynamics of bacteriophage IKe major coat protein in MPG micelles by solution NMR. Williams KA, et al. **Biochemistry** 1996 Apr 23;35(16):5145–57

Fast events in protein folding: helix melting and formation in a small peptide. Williams S, et al. **Biochemistry** 1996 Jan 23;35(3):691–7

Structure of the native cysteine–sulfenic acid redox center of enterococcal NADH peroxidase refined at 2.8 A resolution. Yeh JI, et al. **Biochemistry** 1996 Aug 6; 35(31):9951–7

Backbone dynamics of the C–terminal domain of Escherichia coli topoisomerase I in the absence and presence of single–stranded DNA. Yu L, et al. **Biochemistry** 1996 Jul 30;35(30):9661–6

Topological folding and proteolysis profile of P–glycoprotein in membranes of multidrug–resistant cells: implications for the drug–transport mechanism. Zhang M, et al. **Biochemistry** 1996 Jul 30;35(30):9728–36

Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7356–61

Mechanistic implication of crystal structures of the cyclophilin–dipeptide complexes. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7362–8

Solution structure of bovine neutrophil beta–defensin–12: the peptide fold of the beta–defensins is identical to that of the classical defensins. Zimmermann GR, et al. **Biochemistry** 1995 Oct 17;34(41):13663–71

Probing the cytoplasmic LOOP1 domain of the yeast plasma membrane H(+)–ATPase by targeted factor Xa proteolysis. Bandell M, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):81–90

Conformations of synthetic beta peptides in solid state and in aqueous solution: relation to toxicity in PC12 cells. Buchet R, et al. **Biochim Biophys Acta** 1996 Jan 17; 1315(1):40–6

Fourier–transform infrared spectroscopic investigation of protein stability in the lyophilized form. Costantino HR, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):69–74

A correlation between thermal stability and structural features of staphylokinase and selected mutants: a Fourier–transform infrared study. Dornberger U, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):168–76

Circular dichroism and Fourier transform infrared spectroscopic studies on the secondary structure of Saccharomyces cerevisiae and Escherichia coli phospho enolpyruvate carboxykinases. Encinas MV, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):23–7

Band–shifting through polypeptide beta–sheet structures in the cyanine UV–Vis spectrum. Hermel H, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):79–86

FTIR studies of recombinant human granulocyte–macrophage colony–stimulating factor in aqueous solutions: secondary structure, disulfide reduction and thermal behavior. Jiang H, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):121–8

Synthesis of alpha–helix–forming peptides by gene engineering methods and their characterization by circular dichroism spectra measurements. Kojima S, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):129–37

Membrane permeabilization by alpha–helical peptides: a flow cytometry study. Midoux P, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):249–56

Modelling packing interactions in parallel helix bundles: pentameric bundles of nicotinic receptor M2 helices. Sankararamakrishnan R, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):122–32

2D–NMR studies of the effects of axial substitution on two helices in horse cytochrome c. Shao W, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):44–50

A homology model of the Id–3 helix–loop–helix domain as a basis for structure–function predictions. Wibley J, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):138–46

Effects of substrate binding and pH on the secondary structure of carnitine acetyltransferase. Yan B, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):175–80

Comparison of the immunopharmacological activities of triple and single–helical schizophyllan in mice. Ohno N, et al. **Biol Pharm Bull** 1995 Sep;18(9):1242–7

Cation effects on the conformations of muscle and non–muscle alpha–actinins. Wenegieme EF, et al. **Biometals** 1996 Jul;9(3):259–65

Molecular modeling studies of novel retro–binding tripeptide active–site inhibitors of thrombin. Lau WF, et al. **Bioorg Med Chem** 1995 Aug;3(8):1039–48

The polypeptide 3(10)–helix as a template for molecular recognition studies. Structural characterization of a side–chain functionalized octapeptide. Toniolo C, et al. **Bioorg Med Chem.** 1995 Sep;3(9):1211–21

Simulation of voltage–dependent interactions of alpha–helical peptides with lipid bilayers. Biggin PC, et al.

Biophys Chem 1996 Jun 11;60(3):99–110
The infrared dichroism of transmembrane helical polypeptides. Axelsen PH, et al. **Biophys J** 1995 Dec; 69(6):2770–81
Structures of revertant signal sequences of Escherichia coli ribose binding protein. Chi SW, et al. **Biophys J** 1995 Dec; 69(6):2703–9
Automated method for modeling seven–helix transmembrane receptors from experimental data [see comments] Herzyk P, et al. **Biophys J** 1995 Dec;69(6):2419–42. Comment in: Biophys J 1995 Dec;69(6):2183–4.
Energy transfer in spectrally inhomogeneous light–harvesting pigment–protein complexes of purple bacteria. Hess S, et al. **Biophys J** 1995 Dec;69(6):2211–25
Two classes of alamethicin transmembrane channels: molecular models from single–channel properties. Mak DO, et al. **Biophys J** 1995 Dec;69(6):2323–36
A Monte Carlo model of fd and Pf1 coat proteins in lipid membranes. Milik M, et al. **Biophys J** 1995 Oct;69(4):1382–6
New tubular single–stranded helix of poly–L–amino acids suggested by molecular mechanics calculations: I. Homopolypeptides in isolated environments. Monoi H. **Biophys J** 1995 Sep;69(3):1130–41
Membrane orientation of the N–terminal segment of alamethicin determined by solid–state 15N NMR. North CL, et al. **Biophys J** 1995 Dec;69(6):2392–7
External reflection absorption infrared spectroscopy study of lung surfactant proteins SP–B and SP–C in phospholipid monolayers at the air/water interface. Pastrana–Rios B, et al. **Biophys J** 1995 Dec;69(6):2531–40
Electron spin–lattice relaxation of the [Cu(1.5) ... Cu(1.5)] dinuclear copper center in nitrous oxide reductase. Pfenninger S, et al. **Biophys J** 1995 Dec;69(6):2761–9
Theory and application of fluorescence homotransfer to melittin oligomerization. Runnels LW, et al. **Biophys J** 1995 Oct;69(4):1569–83
Transbilayer pores formed by beta–barrels: molecular modeling of pore structures and properties. Sansom MS, et al. **Biophys J** 1995 Oct;69(4):1334–43
The radius of gyration of native and reductively methylated myosin subfragment–1 from neutron scattering. Stone DB, et al. **Biophys J** 1995 Sep;69(3):767–76
Protein structures from domain packing—a game of twenty questions? [comment] Underwood DJ. **Biophys J** 1995 Dec; 69(6):2183–4. Comment on: Biophys J 1995 Dec;69(6):2419–42.
Spectroscopic studies of a phosphoinositide–binding peptide from gelsolin: behavior in solutions of mixed solvent and anionic micelles. Xian W, et al. **Biophys J** 1995 Dec; 69(6):2695–702
Molecular dynamics study of the M412 intermediate of bacteriorhodopsin. Xu D, et al. **Biophys J** 1995 Dec; 69(6):2745–60
Structural polymorphism of the RecA protein from the thermophilic bacterium Thermus aquaticus. Yu X, et al. **Biophys J** 1995 Dec;69(6):2728–38
Influence of proline–14 substitution on the secondary structure in a synthetic analogue of alamethicin. Brachais L, et al. **Biopolymers** 1995 Oct;36(4):547–58
Exploring the peptide 3(10)–helix<—>alpha–helix equilibrium with double label electron spin resonance. Fiori WR, et al. **Biopolymers** 1995;37(6):421
Discovering protein secondary structures: classification and description of isolated alpha–turns. Pavone V, et al. **Biopolymers** 1996 Jun;38(6):705–21
A search for the ideal type I beta–turn. Perczel A, et al. **Biopolymers** 1996 Jun;38(6):723–32
Assignment of the helical structure in neuropeptide Y by HPLC studies of methionine replacement analogues and 1H–NMR spectroscopy. Rothemund S, et al. **Biopolymers** 1996 Aug;39(2):207–19
The design of enzyme sensors based on the enzyme structure. Alvarez–Icaza M, et al. **Biosens Bioelectron** 1995 Fall; 10(8):735–42
Pathways for conformational change in seryl–tRNA synthetase from Thermus thermophilus. El–Kettani MA, et al. **C R Acad Sci III** 1996 Mar;319(3):161–9
Crystal structure of the DNA–binding domain of the Epstein–Barr virus origin–binding protein, EBNA1, bound to DNA. Bochkarev A, et al. **Cell** 1996 Mar 8;84(5):791–800
Solution structure of the link module: a hyaluronan–binding domain involved in extracellular matrix stability and cell migration. Kohda D, et al. **Cell** 1996 Sep 6;86(5):767–75
Multiple elements in the 5' untranslated region down–regulate c–sis messenger RNA translation. Horvath P, et al. **Cell Growth Differ** 1995 Sep;6(9):1103–10
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Fungal metabolites. XX. Effect of proline residue on the structure of ion–channel–forming peptide, trichosporin B–VIa. Nagaoka Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1119–24
HTP: a neural network–based method for predicting the topology of helical transmembrane domains in proteins. Fariselli P, et al. **Comput Appl Biosci** 1996 Feb;12(1):41–8
alpha–Helix region prediction with stochastic rule learning. Mamitsuka H, et al. **Comput Appl Biosci** 1995 Aug; 11(4):399–411
LGANN: a parallel system combining a local genetic algorithm and neural networks for the prediction of secondary structure of proteins. Vivarelli F, et al. **Comput Appl Biosci** 1995 Jun;11(3):253–60
Structure prediction. How good are we? Russell RB, et al. **Curr Biol** 1995 May 1;5(5):488–90 (23 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)
Protein secondary structure prediction. Barton GJ. **Curr Opin Struct Biol** 1995 Jun;5(3):372–6 (39 ref.)
Native–like and structurally characterized designed alpha–helical bundles. Betz SF, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):457–63 (34 ref.)
Folding of beta–sheet proteins. Carlsson U, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):482–7 (51 ref.)
A small predicted stem–loop structure mediates oocyte localization of Drosophila K10 mRNA. Serano TL, et al. **Development** 1995 Nov;121(11):3809–18
The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57–66 (37 ref.)
Crystal structure of histidyl–tRNA synthetase from Escherichia coli complexed with histidyl–adenylate. Arnez JG, et al. **EMBO J** 1995 Sep 1;14(17):4143–55
The 3–D structure of a zinc metallo–beta–lactamase from Bacillus cereus reveals a new type of protein fold. Carfi A, et al. **EMBO J** 1995 Oct 16;14(20):4914–21
Solution structure of the single–stranded DNA binding protein of the filamentous Pseudomonas phage Pf3: similarity to other proteins binding to single–stranded nucleic acids. Folmer RH, et al. **EMBO J** 1995 Sep 1; 14(17):4132–42
Delineation of the peptide binding site of the human galanin receptor. Kask K, et al. **EMBO J** 1996 Jan 15;15(2):236–44
A left–hand beta–helix revealed by the crystal structure of a carbonic anhydrase from the archaeon Methanosarcina thermophila. Kisker C, et al. **EMBO J** 1996 May 15; 15(10):2323–30
Crystal structure of glycyl–tRNA synthetase from Thermus thermophilus. Logan DT, et al. **EMBO J** 1995 Sep 1; 14(17):4156–67
The actin binding site of thymosin beta 4 mapped by mutational analysis. Van Troys M, et al. **EMBO J** 1996 Jan 15;15(2):201–10
Complementation between kinase–defective and activation–defective TGF–beta receptors reveals a novel form of receptor cooperativity essential for signaling. Weis–Garcia F, et al. **EMBO J** 1996 Jan 15;15(2):276–89
The purification, characterization and analysis of primary and secondary–structure of prolyl oligopeptidase from human lymphocytes. Evidence that the enzyme belongs to the alpha/beta hydrolase fold family. Goossens F, et al. **Eur J Biochem** 1995 Oct 15;233(2):432–41
Pressure–tuning the conformation of bovine pancreatic trypsin inhibitor studied by Fourier–transform infrared spectroscopy. Goossens K, et al. **Eur J Biochem** 1996 Feb 15;236(1):254–62
A Fourier–transform infrared spectroscopic investigation of the hydrogen–deuterium exchange and secondary structure of the 28–kDa channel–forming integral membrane protein (CHiP28). Haris PI, et al. **Eur J Biochem** 1995 Oct 15; 233(2):659–64
1H and 15N assignments and secondary structure of the starch–binding domain of glucoamylase from Aspergillus niger. Jacks AJ, et al. **Eur J Biochem** 1995 Oct 15; 233(2):568–78
Solution structure of the DNA–binding domain of the tomato heat–stress transcription factor HSF24. Schultheiss J, et al. **Eur J Biochem** 1996 Mar 15;236(3):911–21
4–Hydroxybenzoate hydroxylase from Pseudomonas sp. CBS3. Purification, characterization, gene cloning, sequence analysis and assignment of structural features determining the coenzyme specificity. Seibold B, et al. **Eur J Biochem** 1996 Jul 15;239(2):469–78
Temperature–dependent conformational change of bacteriorhodopsin as studied by solid–state 13C NMR. Tuzi S, et al. **Eur J Biochem** 1996 Jul 15;239(2):294–301
Protein engineering studies of dichloromethane dehalogenase/glutathione S–transferase from Methylophilus sp. strain DM11. Ser12 but not Tyr6 is required for enzyme activity. Vuilleumier S, et al. **Eur J Biochem** 1996 Jul 15;239(2):410–7
Energised (entatic) states of groups and of secondary structures in proteins and metalloproteins. Williams RJ. **Eur J Biochem** 1995 Dec 1;234(2):363–81 (76 ref.)
Recombinant prespore–specific antigen from Dictyostelium discoideum is a beta–sheet glycoprotein with a spacer peptide modified by O–linked N–acetylglucosamine. Zachara NE, et al. **Eur J Biochem** 1996 Jun 1;238(2):511–8
Effect of cross–linking on the chaperone–like function of alpha crystallin. Sharma KK, et al. **Exp Eye Res** 1995 Oct; 61(4):413–21
Empirical studies of protein secondary structure by vibrational circular dichroism and related techniques. Alpha–lactalbumin and lysozyme as examples. Keiderling TA, et al. **Faraday Discuss** 1994;(99):263–85; discussion 311–26
Quantitative analysis of vibrational circular dichroism spectra of proteins. Problems and perspectives. Pancoska P, et al. **Faraday Discuss** 1994;(99):287–310
Protein fold recognition by sequence threading: tools and assessment techniques. Miller RT, et al. **FASEB J** 1996 Jan;10(1):171–8
Time–resolved surface charge change on the cytoplasmic side of bacteriorhodopsin. Alexiev U, et al. **FEBS Lett** 1995 Oct 2;373(1):81–4
Infrared evidence of a beta–hairpin peptide structure in solution. Arrondo JL, et al. **FEBS Lett** 1996 Apr 8; 384(1):35–7
Topology of the secondary structure elements of ribosomal protein L7/L12 from E. coli in solution. Bocharov EV, et al. **FEBS Lett** 1996 Feb 5;379(3):291–4
Conserved secondary structure in the actinorhodin polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2) and the fatty acid synthase acyl carrier protein from Escherichia coli. Crump MP, et al. **FEBS Lett** 1996 Aug 12;391(3):302–6
A structural tree for alpha–helical proteins containing alpha–alpha–corners and its application to protein classification. Efimov AV. **FEBS Lett** 1996 Aug 5; 391(1–2):167–70
Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the delta– and mu–opioid receptors. Fukuda K, et al. **FEBS Lett** 1995 Oct 9;373(2):177–81
Amino acid residue: is it structural or functional? Golovanov AP, et al. **FEBS Lett** 1995 Nov 13;375(1–2):162–6
Linguistic analysis of protein folding. Gross M. **FEBS Lett** 1996 Jul 29;390(3):249–52
The 21–residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane alpha–helix with a mixed nonpolar/polar surface. Gustafsson M, et al. **FEBS Lett** 1996 Apr 15; 384(2):185–8
Secondary structure of an armadillo single repeat from the APC protein. Hirschl D, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):31–6
The GA module, a mobile albumin–binding bacterial domain, adopts a three–helix–bundle structure. Johansson MU, et al. **FEBS Lett** 1995 Oct 30;374(2):257–61
NMR structures of a mitochondrial transit peptide from the green alga Chlamydomonas reinhardtii. Lancelin JM, et al. **FEBS Lett** 1996 Aug 5;391(1–2):203–8
Threading analysis suggests that the obese gene product may be a helical cytokine. Madej T, et al. **FEBS Lett** 1995 Oct 2;373(1):13–8
On the role of extracellular loops of opioid receptors in conferring ligand selectivity. Metzger TG, et al. **FEBS Lett** 1995 Nov 13;375(1–2):1–4 (21 ref.)
Conformation of surface exposed N–terminus part of bacteriorhodopsin studied by transferred NOE technique. Pashkov VS, et al. **FEBS Lett** 1996 Feb 26;381(1–2):119–22
Significance of secondary structure predictions on the reactive center loop region of serpins: a model for the folding of serpins into a metastable state. Patston PA, et al. **FEBS Lett** 1996 Mar 25;383(1–2):87–92
Predicted structure and possible ionmotive mechanism of the sodium–linked NADH–ubiquinone oxidoreductase of Vibrio alginolyticus. Rich PR, et al. **FEBS Lett** 1995 Nov 13;375(1–2):5–10 (42 ref.)
Water–mediated conformational transitions in nicotinic receptor M2 helix bundles: a molecular dynamics study. Sankararamakrishnan R, et al. **FEBS Lett** 1995 Dec 27; 377(3):377–82
Expression of porin from Rhodopseudomonas blastica in Escherichia coli inclusion bodies and folding into exact native structure. Schmid B, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):111–4
Attempts to convert chymotrypsin to trypsin. Venekei I, et al. **FEBS Lett** 1996 Jan 29;379(2):143–7
Use of immobilized synthetic peptides for the identification of contact sites between human interleukin–6 and its receptor. Weiergräber O, et al. **FEBS Lett** 1996 Jan 29; 379(2):122–6
Importance of the first external loop for substrate recognition as revealed by chimeric Chlorella monosaccharide/H+ symporters. Will A, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):127–30
A model for DNA polymerase translocation: worm–like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)
Transmembrane topology of Escherichia coli H(+)–ATPase (ATP synthase) subunit a. Yamada H, et al. **FEBS Lett** 1996 Jul 15;390(1):34–8
Canine brain glucose transporter 3: gene sequence, phylogenetic comparisons and analysis of functional sites. Borson ND, et al. **Gene** 1996 Feb 12;168(2):251–6
Nucleoside diphosphate kinase from the parasitic nematode Brugia malayi. Ghosh I, et al. **Gene** 1995 Oct 27; 164(2):261–6
Possible changes in secondary structure and composition of human lens capsules in hereditary congenital cataract. Lee SM, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 May; 234(5):342–8
Transmembrane domains participate in functions of integral membrane proteins. Ramasarma T. **Indian J Biochem Biophys** 1996 Feb;33(1):20–9 (25 ref.)
Effect of the environment and role of the pi–pi stacking interactions in the stabilization of the 3(10)–helix conformation in dehydroalanine oligopeptides. Alemán C. **Int J Pept Protein Res** 1995 Nov;46(5):408–18
Polymethylene spacer linked bis(Ala) peptides form modified beta–sheet structures. Crystal structure and self–assembly pattern of adipoyl and suberoyl analogues. Karle IL, et al. **Int J Pept Protein Res** 1995 Jul;46(1):24–9

Toward multistrategy parallel and distributed learning in sequence analysis. Chan PK, et al. **Ismb** 1993;1:65–73

Protein structure prediction: selecting salient features from large candidate pools. Cherkauer KJ, et al. **Ismb** 1993; 1:74–82

Protein topology prediction through parallel constraint logic programming. Clark DA, et al. **Ismb** 1993;1:83–91

Representation for discovery of protein motifs. Conklin D, et al. **Ismb** 1993;1:101–8

Predicting protein folding classes without overly relying on homology. Craven MW, et al. **Ismb** 1995;3:98–106

Protein secondary structure modelling with probabilistic networks. Delcher AL, et al. **Ismb** 1993;1:109–17

A modular learning environment for protein modeling. Gracy J, et al. **Ismb** 1993;1:145–53

3-D lookup: fast protein structure database searches at 90% reliability. Holm L, et al. **Ismb** 1995;3:179–87

Discovering side-chain correlation in alpha-helices. Klingler TM, et al. **Ismb** 1994;2:236–43

Protein secondary structure prediction using two-level case-based reasoning. Leng B, et al. **Ismb** 1993;1:251–9

Predicting location and structure of beta-sheet regions using stochastic tree grammars. Mamitsuka H, et al. **Ismb** 1994; 2:276–84

Softening constraints in constraint-based protein topology prediction. Parsons S. **Ismb** 1995;3:268–76

TOPITS: threading one-dimensional predictions into three-dimensional structures. Rost B. **Ismb** 1995;3:314–21

Towards an intelligent system for the automatic assignment of domains in globular proteins. Sternberg MJ, et al. **Ismb** 1995;3:376–83

Automatic derivation of substructures yields novel structural building blocks in globular proteins. Zhang X, et al. **Ismb** 1993;1:438–46

Topological analysis of the Rhodobacter capsulatus PucC protein and effects of C-terminal deletions on light-harvesting complex II. LeBlanc HN, et al. **J Bacteriol** 1996 Aug;178(16):4801–6

Actin-actin contact: chemical cross-linking between actin and the 2.6-kDa peptide from subdomain 4 of actin. Hori K, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1232–8

The role of SH and S-S groups in Bacillus cereus beta-amylase. Nomura K, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1124–30

Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25–35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1108–11

Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. Yamamoto H, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1224–31

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)

Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)

Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)

Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)

Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)

Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor. Abell A, et al. **J Biol Chem** 1996 Feb 23;271(8):4518–27

Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. abu Alla S, et al. **J Biol Chem** 1996 Jan 19;271(3):1748–55

Two residues that may ligate Ca2+ in transmembrane domain six of the plasma membrane Ca(2+)-ATPase. Adebayo AO, et al. **J Biol Chem** 1995 Nov 17; 270(46):27812–6

The structure of copper-nitrite reductase from Achromobacter cycloclastes at five pH values, with NO2- bound and with type II copper depleted. Adman ET, et al. **J Biol Chem** 1995 Nov 17;270(46):27458–74

Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. Almaula N, et al. **J Biol Chem** 1996 Jun 21;271(25):14672–5

Ligand binding characteristics of the carboxyl-terminal domain of the cytokine receptor homologous region of the granulocyte colony-stimulating factor receptor. Anaguchi H, et al. **J Biol Chem** 1995 Nov 17;270(46):27845–51

Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. Arand M, et al. **J Biol Chem** 1996 Feb 23;271(8):4223–9

Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin-releasing hormone receptor. Arora KK, et al. **J Biol Chem** 1995 Sep 29;270(39):22820–6

Schizosaccharomyces pombe proliferating cell nuclear antigen mutations affect DNA polymerase delta processivity. Arroyo MP, et al. **J Biol Chem** 1996 Jul 5; 271(27):15971–80

Immunochemical analysis of the human erythrocyte Rh polypeptides. Avent ND, et al. **J Biol Chem** 1996 Jun 14; 271(24):14233–9

Fourier transform infrared and hydrogen/deuterium exchange reveal an exchange-resistant core of alpha-helical peptide hydrogens in the nicotinic acetylcholine receptor. Baenziger JE, et al. **J Biol Chem** 1995 Dec 8;270(49):29129–37

Structure of aquaporin-2 vasopressin water channel. Bai L, et al. **J Biol Chem** 1996 Mar 1;271(9):5171–6

Characterization of the light-induced cross-linking of the alpha-subunit of cytochrome b559 and the D1 protein in isolated photosystem II reaction centers. Barbato R, et al. **J Biol Chem** 1995 Oct 13;270(41):24032–7

Dissociation of hexameric Escherichia coli inorganic pyrophosphatase into trimers on His-136-->Gln or His-140-->Gln substitution and its effect on enzyme catalytic properties. Baykov AA, et al. **J Biol Chem** 1995 Dec 22;270(51):30804–12

Apolipoprotein A-I conformation in reconstituted discoidal lipoproteins varying in phospholipid and cholesterol content. Bergeron J, et al. **J Biol Chem** 1995 Nov 17; 270(46):27429–38

Stationary phase expression of a novel Escherichia coli outer membrane lipoprotein and its relationship with mammalian apolipoprotein D. Implications for the origin of lipocalins. Bishop RE, et al. **J Biol Chem** 1995 Sep 29; 270(39):23097–103

Sequential structural changes upon zinc and calcium binding to metal-free concanavalin A. Bouckaert J, et al. **J Biol Chem** 1996 Jul 5;271(27):16144–50

Structural flexibility modulates the activity of human glutathione transferase P1-1. Influence of a poor co-substrate on dynamics and kinetics of human glutathione transferase. Caccuri AM, et al. **J Biol Chem** 1996 Jul 5;271(27):16193–8

Lock on/off disulfides identify the transmembrane signaling helix of the aspartate receptor. Chervitz SA, et al. **J Biol Chem** 1995 Oct 13;270(41):24043–53

Bovine elastin and kappa-elastin secondary structure determination by optical spectroscopies. Debelle L, et al. **J Biol Chem** 1995 Nov 3;270(44):26099–103

Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. Derossi D, et al. **J Biol Chem** 1996 Jul 26;271(30):18188–93

Mycobacterium tuberculosis chaperonin 10 forms stable tetrameric and heptameric structures. Implications for its diverse biological activities. Fossati G, et al. **J Biol Chem** 1995 Nov 3;270(44):26159–67

Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. Gillen CM, et al. **J Biol Chem** 1996 Jul 5;271(27):16237–44

The role of coiled-coil alpha-helices and disulfide bonds in the assembly and stabilization of cartilage matrix protein subunits. A mutational analysis. Haudenschild DR, et al. **J Biol Chem** 1995 Sep 29;270(39):23150–4

Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis. Hill-Eubanks D, et al. **J Biol Chem** 1996 Feb 9; 271(6):3058–65

Truncation of the C-terminal tail of the follitropin receptor does not impair the agonist- or phorbol ester-induced receptor phosphorylation and uncoupling. Hipkin RW, et al. **J Biol Chem** 1995 Nov 3;270(44):26683–9

Integral repeats and a continuous coiled coil are required for binding of striated muscle tropomyosin to the regulated actin filament. Hitchcock-DeGregori SE, et al. **J Biol Chem** 1996 Feb 16;271(7):3600–3

Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. Holtmann MH, et al. **J Biol Chem** 1996 Jun 21;271(25):14944–9

Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. Hwa J, et al. **J Biol Chem** 1995 Sep 29;270(39):23189–95

Beta-gamma subunit interaction is required for catalysis by H(+)-ATPase (ATP synthase). Beta subunit amino acid replacements suppress a gamma subunit mutation having a long unrelated carboxyl terminus. Jeanteur-De Beukelaer C, et al. **J Biol Chem** 1995 Sep 29;270(39):22850–4

Evidence that transmembrane segment 2 of the lactose permease is part of a conformationally sensitive interface between the two halves of the protein. Jessen-Marshall AE, et al. **J Biol Chem** 1996 Jan 19;271(3):1400–4

New molecular and structural determinants involved in beta 2-adrenergic receptor desensitization and sequestration. Delineation using chimeric beta 3/beta 2-adrenergic receptors. Jockers R, et al. **J Biol Chem** 1996 Apr 19; 271(16):9355–62

Refolding and oxidation of recombinant human stem cell factor produced in Escherichia coli. Jones MD, et al. **J Biol Chem** 1996 May 10;271(19):11301–8

Identification of a binding motif for ankyrin on the alpha-subunit of Na+,K(+)-ATPase. Jordan C, et al. **J Biol Chem** 1995 Dec 15;270(50):29971–5

Sialylated oligosaccharide-specific plant lectin from Japanese elderberry (Sambucus sieboldiana) bark tissue has a homologous structure to type II ribosome-inactivating proteins, ricin and abrin. cDNA cloning and molecular modeling study. Kaku H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1480–5

Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. Kast C, et al. **J Biol Chem** 1996 Apr 19;271(16):9240–8

Serine protease inhibition by insect peptides containing a cysteine knot and a triple-stranded beta-sheet. Kellenberger C, et al. **J Biol Chem** 1995 Oct 27; 270(43):25514–9

Characterization of lactogen receptor-binding site 1 of human prolactin. Kinet S, et al. **J Biol Chem** 1996 Jun 14;271(24):14353–60

Biochemical characterization of human collagenase-3. Knäuper V, et al. **J Biol Chem** 1996 Jan 19;271(3):1544–50

Mouse T cell membrane proteins Rt6-1 and Rt6-2 are arginine/protein mono(ADPribosyl)transferases and share secondary structure motifs with ADP-ribosylating bacterial toxins. Koch-Nolte F, et al. **J Biol Chem** 1996 Mar 29;271(13):7686–93

The effects of interhelical electrostatic repulsions between glutamic acid residues in controlling the dimerization and stability of two-stranded alpha-helical coiled-coils. Kohn WD, et al. **J Biol Chem** 1995 Oct 27;270(43):25495–506

The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A. Kvassman JO, et al. **J Biol Chem** 1995 Nov 17;270(46):27942–7

A pH-sensitive yeast outward rectifier K+ channel with two pore domains and novel gating properties. Lesage F, et al. **J Biol Chem** 1996 Feb 23;271(8):4183–7

Isolation and characterization of a disulfide-linked human stem cell factor dimer. Biochemical, biophysical, and biological comparison to the noncovalently held dimer. Lu HS, et al. **J Biol Chem** 1996 May 10;271(19):11309–16

Histidine patch thioredoxins. Mutant forms of thioredoxin with metal chelating affinity that provide for convenient purifications of thioredoxin fusion proteins. Lu Z, et al. **J Biol Chem** 1996 Mar 1;271(9):5059–65

Structure and topology of the influenza virus fusion peptide in lipid bilayers. Lüneberg J, et al. **J Biol Chem** 1995 Nov 17;270(46):27606–14

The ligand binding domain of the human retinoic acid receptor gamma is predominantly alpha-helical with a Trp residue in the ligand binding site. Lupisella JA, et al. **J Biol Chem** 1995 Oct 20;270(42):24884–90

A single histidine is required for activity of cytochrome c peroxidase from Paracoccus denitrificans. McGinnity DF, et al. **J Biol Chem** 1996 May 10;271(19):11126–33

Photocross-links between single-stranded DNA and Escherichia coli RecA protein map to loops L1 (amino acid residues 157–164) and L2 (amino acid residues 195–209). Malkov VA, et al. **J Biol Chem** 1995 Dec 15; 270(50):30230–3

Biochemical and biophysical comparison of native and chemically synthesized phospholamban and a monomeric phospholamban analog. Mayer EJ, et al. **J Biol Chem** 1996 Jan 19;271(3):1669–77

Modified ligands to FA and FB in photosystem I. I. Structural constraints for the formation of iron-sulfur clusters in free and rebound PsaC. Mehari T, et al. **J Biol Chem** 1995 Nov 24;270(47):28108–17

Intermediate filament protein domain interactions as revealed by two-hybrid screens. Meng JJ, et al. **J Biol Chem** 1996 Jan 19;271(3):1599–604

Enzymatic and electron transfer activities in crystalline protein complexes. Merli A, et al. **J Biol Chem** 1996 Apr 19;271(16):9177–80

A novel cytochrome b5-like domain is linked to the carboxyl terminus of the Saccharomyces cerevisiae delta-9 fatty acid desaturase. Mitchell AG, et al. **J Biol Chem** 1995 Dec 15; 270(50):29766–72

Formation of parallel and antiparallel coiled-coils controlled by the relative positions of alanine residues in the hydrophobic core. Monera OD, et al. **J Biol Chem** 1996 Feb 23;271(8):3995–4001

Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides. Monfardini C, et al. **J Biol Chem** 1996 Feb 9;271(6):2966–71

Systematic deletion analysis of ricin A-chain function. Single amino acid deletions. Munishkin A, et al. **J Biol Chem** 1995 Dec 22;270(51):30581–7

Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. Nakamura M, et al. **J Biol Chem** 1995 Dec 15; 270(50):30102–10

Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. Orimo A, et al. **J Biol Chem** 1995 Oct 13;270(41):24406–13

Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreatic acinar cell receptors. Ozcelebi F, et al. **J Biol Chem** 1996 Feb 16;271(7):3750–5

Ouabain interactions with the H5-H6 hairpin of the Na,K-ATPase reveal a possible inhibition mechanism via the cation binding domain. Palasis M, et al. **J Biol Chem** 1996 Jun 14;271(24):14176–82

Proposed ligand binding site of the transmembrane receptor for neurotensin(8–13). Pang YP, et al. **J Biol Chem** 1996

Jun 21;271(25):15060–8
Functionalized protein–like structures from conformationally defined synthetic combinatorial libraries. Pérez–Payá E, et al. **J Biol Chem** 1996 Feb 23;271(8):4120–6
Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. Peter D, et al. **J Biol Chem** 1996 Feb 9;271(6):2979–86
Amino–terminal deletions enhance aggregation of beta–amyloid peptides in vitro. Pike CJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23895–8
Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. Quilliam LA, et al. **J Biol Chem** 1996 May 10;271(19):11076–82
Cyclophilin 40 (CyP–40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP–40 for hsp90 binding. Ratajczak T, et al. **J Biol Chem** 1996 Feb 9;271(6):2961–5
The structural basis of the myosin ATPase activity [see comments] Rayment I. **J Biol Chem** 1996 Jul 5; 271(27):15850–3 (44 ref.). Comment in: J Biol Chem 1996 Jul 5;271(27):15849.
Structural flexibility modulates the activity of human glutathione transferase P1–1. Role of helix 2 flexibility in the catalytic mechanism. Ricci G, et al. **J Biol Chem** 1996 Jul 5;271(27):16187–92
Examining rhodopsin folding and assembly through expression of polypeptide fragments. Ridge KD, et al. **J Biol Chem** 1996 Mar 29;271(13):7860–7
Development of drug resistance to HIV–1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)
A helical epitope in the C4 domain of HIV glycoprotein 120. Robey FA, et al. **J Biol Chem** 1995 Oct 13; 270(41):23918–21
A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4. Robey FA, et al. **J Biol Chem** 1996 Jul 26;271(30):17990–5
Molecular determinants of high affinity binding of alpha–scorpion toxin and sea anemone toxin in the S3–S4 extracellular loop in domain IV of the Na+ channel alpha subunit. Rogers JC, et al. **J Biol Chem** 1996 Jul 5; 271(27):15950–62
Interaction of calcium with Bordetella pertussis adenylate cyclase toxin. Characterization of multiple calcium–binding sites and calcium–induced conformational changes. Rose T, et al. **J Biol Chem** 1995 Nov 3;270(44):26370–6
Exoloop 3 of the luteinizing hormone/choriogonadotropin receptor. Lys583 is essential and irreplaceable for human choriogonadotropin (hCG)–dependent receptor activation but not for high affinity hCG binding. Ryu KS, et al. **J Biol Chem** 1996 Mar 29;271(13):7301–4
Parathyroid hormone–related protein antagonizes the action of parathyroid hormone on adult cardiomyocytes. Schlüter KD, et al. **J Biol Chem** 1996 Feb 9;271(6):3074–8
Disease–associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. Seibert FS, et al. **J Biol Chem** 1996 Jun 21; 271(25):15139–45
Studies on inhibition of mu and delta opioid receptor binding by dithiothreitol and N–ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N–ethylmaleimide. Shahrestanifar M, et al. **J Biol Chem** 1996 Mar 8;271(10):5505–12
Contribution of proline residues in the membrane–spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function. Sheppard DN, et al. **J Biol Chem** 1996 Jun 21;271(25):14995–5001
Mutations leading to altered CheA binding cluster on a face of CheY. Shukla D, et al. **J Biol Chem** 1995 Oct 13; 270(41):24414–9
A segment of five amino acids in the second extracellular loop of the cholecystokinin–B receptor is essential for selectivity of the peptide agonist gastrin. Silvente–Poirot S, et al. **J Biol Chem** 1996 Jun 21;271(25):14698–706
A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled–coil pore structure. Simmerman HK, et al. **J Biol Chem** 1996 Mar 8; 271(10):5941–6
Protein loop grafting to construct a variant of tissue–type plasminogen activator that binds platelet integrin alpha IIb beta 3. Smith JW, et al. **J Biol Chem** 1995 Dec 22; 270(51):30486–90
Lysine residues at positions 234 and 236 in yeast porin are involved in its assembly into the mitochondrial outer membrane. Smith MD, et al. **J Biol Chem** 1995 Nov 24; 270(47):28331–6
A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. Songyang Z, et al. **J Biol Chem** 1995 Nov 3; 270(44):26029–32
Crystal structure of PotD, the primary receptor of the polyamine transport system in Escherichia coli. Sugiyama S, et al. **J Biol Chem** 1996 Apr 19;271(16):9519–25
Kinetics of folding and membrane insertion of a beta–barrel membrane protein. Surrey T, et al. **J Biol Chem** 1995 Nov 24;270(47):28199–203
The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane–proximal domain. Tamm A, et al. **J Biol Chem** 1996 Feb 16; 271(7):3659–66
Blocking the Ca2+–induced conformational transitions in calmodulin with disulfide bonds. Tan RY, et al. **J Biol Chem** 1996 Mar 29;271(13):7479–83
Characterization of the interface between gamma and epsilon subunits of Escherichia coli F1–ATPase. Tang C, et al. **J Biol Chem** 1996 Feb 9;271(6):3018–24
Structural analysis of the predicted coiled–coil rod domain of the cytoplasmic bullous pemphigoid antigen (BPAG1). Empirical localization of the N–terminal globular domain–rod boundary. Tang HY, et al. **J Biol Chem** 1996 Apr 19;271(16):9716–22
Site of covalent labeling by a photoreactive batrachotoxin derivative near transmembrane segment IS6 of the sodium channel alpha subunit. Trainer VL, et al. **J Biol Chem** 1996 May 10;271(19):11261–7
Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding. Unson CG, et al. **J Biol Chem** 1995 Nov 17;270(46):27720–7
Crystallographic evidence that the F2 kringle catalytic domain linker of prothrombin does not cover the fibrinogen recognition exosite. van de Locht A, et al. **J Biol Chem** 1996 Feb 16;271(7):3413–6
Localization of the putative sialic acid–binding site on the immunoglobulin superfamily cell–surface molecule CD22. van der Merwe PA, et al. **J Biol Chem** 1996 Apr 19; 271(16):9273–80
Solution structure of the sequence–specific HMG box of the lymphocyte transcriptional activator Sox–4. van Houte LP, et al. **J Biol Chem** 1995 Dec 22;270(51):30516–24
Expression and spectroscopic characterization of the hydrogenosomal [2Fe–2S] ferredoxin from the protozoan Trichomonas vaginalis. Vidakovic MS, et al. **J Biol Chem** 1996 Jun 21;271(25):14734–9
Characterization of the sialic acid–binding site in sialoadhesin by site–directed mutagenesis. Vinson M, et al. **J Biol Chem** 1996 Apr 19;271(16):9267–72
Conversion of a nonprocessed mitochondrial precursor protein into one that is processed by the mitochondrial processing peptidase. Waltner M, et al. **J Biol Chem** 1995 Nov 3;270(44):26311–7
Intracellular loop between transmembrane segments IV and V of cystic fibrosis transmembrane conductance regulator is involved in regulation of chloride channel conductance state. Xie J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28084–91
Structural and functional characteristics of partially disulfide–reduced intermediates of ovotransferrin N lobe. Cystine localization by indirect end–labeling approach and implications for the reduction pathway. Yamashita H, et al. **J Biol Chem** 1995 Dec 15;270(50):29806–12
The association of lipid activators with the amphipathic helical domain of CTP:phosphocholine cytidylyltransferase accelerates catalysis by increasing the affinity of the enzyme for CTP. Yang W, et al. **J Biol Chem** 1995 Oct 13;270(41):23951–7
On the role of helix 0 of the tryptophan synthetase alpha chain of Escherichia coli. Yee MC, et al. **J Biol Chem** 1996 Jun 21;271(25):14754–63
Requirement of cysteine residues in exons 1–6 of the extracellular domain of the luteinizing hormone receptor for gonadotropin binding. Zhang R, et al. **J Biol Chem** 1996 Mar 8;271(10):5755–60
Determinants of substrate recognition in the protein–tyrosine phosphatase, PTP1. Zhang ZY, et al. **J Biol Chem** 1996 Mar 8;271(10):5386–92
Irreversible binding of cis–(+)–3–methylfentanyl isothiocyanate to the delta opioid receptor and determination of its binding domain. Zhu J, et al. **J Biol Chem** 1996 Jan 19;271(3):1430–4
Membrane topology analysis of the sensor kinase KdpD of Escherichia coli. Zimmann P, et al. **J Biol Chem** 1995 Nov 24;270(47):28282–8
1H, 13C and 15N NMR assignments and solution secondary structure of rat Apo–S100 beta. Amburgey JC, et al. **J Biomol NMR** 1995 Sep;6(2):171–9
1H NMR investigation of the secondary structure, tertiary contacts and cluster environment of the four–iron ferredoxin from the hyperthermophilic archaeon Thermococcus litoralis. Donaire A, et al. **J Biomol NMR** 1996 Jan;7(1):35–47
Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X–ray crystallography. Gooley PR, et al. **J Biomol NMR** 1996 Jan;7(1):8–28
1H, 13C and 15N assignments and chemical shift–derived secondary structure of intestinal fatty acid–binding protein. Hodsdon ME, et al. **J Biomol NMR** 1995 Sep;6(2):198–210
1H, 15N and 13C resonance assignments and secondary structure of group II phospholipase A2 from Agkistrodon piscivorus piscivorus: presence of an amino–terminal helix in solution. Jerala R, et al. **J Biomol NMR** 1996 Mar; 7(2):107–20
1H, 15N, 13C and 13CO assignments and secondary structure determination of basic fibroblast growth factor using 3D heteronuclear NMR spectroscopy. Moy FJ, et al. **J Biomol NMR** 1995 Nov;6(3):245–54
Backbone assignment, secondary structure and protein A binding of an isolated, human antibody VH domain. Riechmann L, et al. **J Biomol NMR** 1995 Sep;6(2):141–52
Chemical shift assignments and secondary structure of the Grb2 SH2 domain by heteronuclear NMR spectroscopy. Wang YS, et al. **J Biomol NMR** 1996 Mar;7(2):89–98
Detailed description of an alpha helix–—>pi bulge transition detected by molecular dynamics simulations of the p185c–erbB2 V659G transmembrane domain. Duneau JP, et al. **J Biomol Struct Dyn** 1996 Apr;13(5):753–69
Simplified representation of proteins. Geetha V, et al. **J Biomol Struct Dyn** 1996 Apr;13(5):781–93
Role of CD3 gamma in T cell receptor assembly. Dietrich J, et al. **J Cell Biol** 1996 Feb;132(3):299–310
CD47 mediates post–adhesive events required for neutrophil migration across polarized intestinal epithelia. Parkos CA, et al. **J Cell Biol** 1996 Feb;132(3):437–50
Protein secondary structure prediction using two–level case–based reasoning. Leng B, et al. **J Comput Biol** 1994 Spring;1(1):25–38
Improving prediction of protein secondary structure using structured neural networks and multiple sequence alignments. Riis SK, et al. **J Comput Biol** 1996 Spring; 3(1):163–83
Effects of physicochemical factors on the secondary structure of beta–lactoglobulin. Boye JI, et al. **J Dairy Res** 1996 Feb; 63(1):97–109
Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):208–12 (30 ref.)
The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)
Solution structure of the N–terminal RNP domain of U1A protein: the role of C–terminal residues in structure stability and RNA binding. Avis JM, et al. **J Mol Biol** 1996 Mar 29;257(2):398–411
Predictions of secondary structure using statistical analyses of electronic and vibrational circular dichroism and Fourier transform infrared spectra of proteins in H2O. Baumruk V, et al. **J Mol Biol** 1996 Jun 21;259(4):774–91
Crystal structure of Citrobacter freundii restriction endonuclease Cfr10I at 2.15 A resolution. Bozic D, et al. **J Mol Biol** 1996 Jan 12;255(1):176–86
High–resolution structure of the catalytic domain of avian sarcoma virus integrase. Bujacz G, et al. **J Mol Biol** 1995 Oct 20;253(2):333–46
6–Pyruvoyl tetrahydropterin synthase, an enzyme with a novel type of active site involving both zinc binding and an intersubunit catalytic triad motif; site–directed mutagenesis of the proposed active center, characterization of the metal binding site and modelling of substrate binding. Bürgisser DM, et al. **J Mol Biol** 1995 Oct 20;253(2):358–69
Solution structure of the anticodon–binding domain of Escherichia coli lysyl–tRNA synthetase and studies of its interaction with tRNA(Lys). Commans S, et al. **J Mol Biol** 1995 Oct 13;253(1):100–13
Structural studies of synthetic peptides dissected from the voltage–gated sodium channel. Doak DG, et al. **J Mol Biol** 1996 May 17;258(4):672–87
Prediction of protein three–dimensional structures in insertion and deletion regions: a procedure for searching data bases of representative protein fragments using geometric scoring criteria. Fechteler T, et al. **J Mol Biol** 1995 Oct 13;253(1):114–31
Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. Gazit E, et al. **J Mol Biol** 1996 May 24;258(5):860–70
Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Gómez J, et al. **J Mol Biol** 1995 Sep 22;252(3):337–50
Search for nucleation sites in smaller fragments of chymotrypsin inhibitor 2. Itzhaki LS, et al. **J Mol Biol** 1995 Nov 24;254(2):289–304
Ionisation of cysteine residues at the termini of model alpha–helical peptides. Relevance to unusual thiol pKa values in proteins of the thioredoxin family. Kortemme T, et al. **J Mol Biol** 1995 Nov 10;253(5):799–812
A global taxonomy of loops in globular proteins. Kwasigroch JM, et al. **J Mol Biol** 1996 Jun 21;259(4):855–72
Preferential heterodimeric parallel coiled–coil formation by synthetic Max and c–Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization. Lavigne P, et al. **J Mol Biol** 1995 Dec 1;254(3):505–20
Molecular evolution of the C–terminal cytoplasmic domain of a superfamily of bacterial receptors involved in taxis. Le Moual H, et al. **J Mol Biol** 1996 Aug 30;261(4):568–85
Glycosylated threonine but not 4–hydroxyproline dominates the triple helix stabilizing positions in the sequence of a hydrothermal vent worm cuticle collagen. Mann K, et al. **J Mol Biol** 1996 Aug 16;261(2):255–66
Mutational analysis and secondary structure model of the RNP1–like sequence motif of transcription termination factor Rho. Martinez A, et al. **J Mol Biol** 1996 Apr 19; 257(5):895–908
The C–terminal portion of BM–40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. Maurer P, et al. **J Mol Biol** 1995 Oct 20;253(2):347–57
X–ray diffraction of scrapie prion rods and PrP peptides. Nguyen JT, et al. **J Mol Biol** 1995 Sep 29;252(4):412–22
The structure of the head–tail junction of the myosin molecule. Offer G, et al. **J Mol Biol** 1996 Mar 1; 256(3):407–16
NMR structure of the J–domain and the Gly/Phe–rich region of the Escherichia coli DnaJ chaperone. Pellecchia M, et

al. **J Mol Biol** 1996 Jul 12;260(2):236–50
Hyperthermostable surface layer protein tetrabrachion from the archaebacterium Staphylothermus marinus: evidence for the presence of a right-handed coiled coil derived from the primary structure. Peters J, et al. **J Mol Biol** 1996 Apr 19;257(5):1031–41
Correlation between conformational and binding properties of nebulin repeats. Pfuhl M, et al. **J Mol Biol** 1996 Mar 29;257(2):367–84
Interactions between a helical residue and tertiary structures: helix propensities in small peptides and in native proteins. Qian H, et al. **J Mol Biol** 1996 Aug 16;261(2):279–88
Prediction of alpha-helices in proteins based on thermodynamic parameters from solution chemistry. Qian H. **J Mol Biol** 1996 Mar 8;256(4):663–6
Evidence for coupling of folding and function in trp repressor: physical characterization of the superrepressor mutant AV77. Reedstrom RJ, et al. **J Mol Biol** 1995 Oct 20;253(2):266–76
Protein fold recognition by mapping predicted secondary structures. Russell RB, et al. **J Mol Biol** 1996 Jun 14; 259(3):349–65
X-ray crystal structure analysis of the catalytic domain of the oncogene product p21H-ras complexed with caged GTP and mant dGppNHp. Scheidig AJ, et al. **J Mol Biol** 1995 Oct 13;253(1):132–50
Native-like beta-structure in a trifluoroethanol-induced partially folded state of the all-beta-sheet protein tendamistat. Schönbrunner N, et al. **J Mol Biol** 1996 Jul 19;260(3):432–45
Three-dimensional structures of free form and two substrate complexes of an extradiol ring-cleavage type dioxygenase, the BphC enzyme from Pseudomonas sp. strain KKS102. Senda T, et al. **J Mol Biol** 1996 Feb 9;255(5):735–52
Analysis of main chain torsion angles in proteins: prediction of NMR coupling constants for native and random coil conformations. Smith LJ, et al. **J Mol Biol** 1996 Jan 26; 255(3):494–506
Effect of folding on the export of ribose-binding protein studied with the genetically isolated suppressors for the signal sequence mutation. Song T, et al. **J Mol Biol** 1995 Oct 20;253(2):304–12
Genetic studies of the Lac repressor. XV: 4000 single amino acid substitutions and analysis of the resulting phenotypes on the basis of the protein structure. Suckow J, et al. **J Mol Biol** 1996 Aug 30;261(4):509–23
An in-the-groove view of DNA structures in complexes with proteins. Suzuki M, et al. **J Mol Biol** 1996 Feb 9; 255(5):677–87
Conformational analysis of peptides corresponding to beta-hairpins and a beta-sheet that represent the entire sequence of the alpha-spectrin SH3 domain. Viguera AR, et al. **J Mol Biol** 1996 Jan 26;255(3):507–21
Principles of helix-helix packing in proteins: the helical lattice superposition model. Walther D, et al. **J Mol Biol** 1996 Jan 26;255(3):536–53
Crystal structure of an acidic phospholipase A2 from the venom of Agkistrodon halys pallas at 2.0 A resolution. Wang XQ, et al. **J Mol Biol** 1996 Feb 9;255(5):669–76
Automatic classification and analysis of alpha alpha-turn motifs in proteins. Wintjens RT, et al. **J Mol Biol** 1996 Jan 12;255(1):235–53
Free energy determinants of secondary structure formation: III. beta-turns and their role in protein folding. Yang AS, et al. **J Mol Biol** 1996 Jun 21;259(4):873–82
Free energy determinants of secondary structure formation: I. alpha-Helices. Yang AS, et al. **J Mol Biol** 1995 Sep 22; 252(3):351–65
Free energy determinants of secondary structure formation: II. Antiparallel beta-sheets. Yang AS, et al. **J Mol Biol** 1995 Sep 22;252(3):366–76
Ion pairs significantly stabilize coiled-coils in the absence of electrolyte. Yu Y, et al. **J Mol Biol** 1996 Jan 26; 255(3):367–72
The use of amino acid patterns of classified helices and strands in secondary structure prediction. Zhu ZY, et al. **J Mol Biol** 1996 Jul 12;260(2):261–76
Peptide and immunochemical mapping of the ectodomain of the porcine LH receptor. Couture L, et al. **J Mol Endocrinol** 1996 Feb;16(1):15–25
Nature of ligand affinity and dimerization of corticotrophin-releasing factor-binding protein may be detected by circular dichroism. Lowry PJ, et al. **J Mol Endocrinol** 1996 Feb;16(1):39–44
Feed-forward neural networks for secondary structure prediction. Barlow TW. **J Mol Graph** 1995 Jun; 13(3):175–83
ANTHEPROT 2.0: a three-dimensional module fully coupled with protein sequence analysis methods. Geourjon C, et al. **J Mol Graph** 1995 Jun;13(3):209–12, 199–200
Precipitation of proteins in supercritical carbon dioxide. Winters MA, et al. **J Pharm Sci** 1996 Jun;85(6):586–94
Critical amino acids responsible for conferring calcium channel characteristics are located on the surface and around beta-turn potentials of channel proteins. Murakami M. **J Protein Chem** 1995 Apr;14(3):111–4
An eigenvalue-eigenvector approach to predicting protein folding types. Zhang CT, et al. **J Protein Chem** 1995 Jul; 14(5):309–26
Image analysis of helical objects: the Brandeis Helical Package. Owen CH, et al. **J Struct Biol** 1996 Jan-Feb; 116(1):167–75
Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. Fruehling S, et al. **J Virol** 1996 Sep; 70(9):6216–26
What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679–83 (34 ref.)
Coxsackie B3 virus protein 2B contains cationic amphipathic helix that is required for viral RNA replication. van Kuppeveld FJ, et al. **J Virol** 1996 Jun;70(6):3876–86
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. Yao XJ, et al. **J Virol** 1995 Nov; 69(11):7032–44
Analysis of mouse hemoglobin alpha-chain locus mutation induced by N-ethyl-N-nitrosourea. Murota T. **Jpn J Genet** 1995 Aug;70(4):497–504
Implications of the sequence similarities between tau and myelin basic protein. Karthigasan J, et al. **Med Hypotheses** 1995 Sep;45(3):235–40
Three-dimensional profiles for measuring compatibility of amino acid sequence with three-dimensional structure. Bowie JU, et al. **Methods Enzymol** 1996;266:598–616
Understanding protein structure: using scop for fold interpretation. Brenner SE, et al. **Methods Enzymol** 1996; 266:635–43
GOR method for predicting protein secondary structure from amino acid sequence. Garnier J, et al. **Methods Enzymol** 1996;266:540–53
Alignment of three-dimensional protein structures: network server for database searching. Holm L, et al. **Methods Enzymol** 1996;266:653–62
X-ray crystallographic studies of cofactors in galactose oxidase. Ito N, et al. **Methods Enzymol** 1995;258:235–62
Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Johnson MS, et al. **Methods Enzymol** 1996;266:575–98
Identification of functional residues and secondary structure from protein multiple sequence alignment. Livingstone CD, et al. **Methods Enzymol** 1996;266:497–512
Prediction and analysis of coiled-coil structures. Lupas A. **Methods Enzymol** 1996;266:513–25
X-ray studies of quinoproteins. Mathews FS. **Methods Enzymol** 1995;258:191–216
Solution structure of DNA polymerases and DNA polymerase-substrate complexes. Mullen GP. **Methods Enzymol** 1995;262:147–71
SSAP: sequential structure alignment program for protein structure comparison. Orengo CA, et al. **Methods Enzymol** 1996;266:617–35
Converting sequence block alignments into structural insights. Poch O, et al. **Methods Enzymol** 1996;266:662–80
PHD: predicting one-dimensional protein structure by profile-based neural networks. Rost B. **Methods Enzymol** 1996;266:525–39
Detecting structural similarities: a user's guide. Swindells MB. **Methods Enzymol** 1996;266:643–53
Multiple protein sequence alignment: algorithms and gap insertion. Taylor WR. **Methods Enzymol** 1996;266:343–67
Molecular modeling of antibody-combining sites. Webster DM, et al. **Methods Mol Biol** 1995;51:17–49
Identification of the sequences in HMG-CoA reductase required for karmellae assembly. Parrish ML, et al. **Mol Biol Cell** 1995 Nov;6(11):1535–47
Combining protein evolution and secondary structure. Thorne JL, et al. **Mol Biol Evol** 1996 May;13(5):666–73
Identification of an autoinhibitory region in the activation loop of the Mos protein kinase. Robertson SC, et al. **Mol Cell Biol** 1996 Jul;16(7):3472–9
Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Perutz MF. **Mol Med** 1995 Nov; 1(7):718–21
Mutational analysis and molecular modelling of an amino acid sequence motif conserved in antiporters but not symporters in a transporter superfamily. Varela MF, et al. **Mol Membr Biol** 1995 Oct-Dec;12(4):313–9
Membrane topology and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD. Huang H, et al. **Mol Microbiol** 1995 Jun;16(5):931–41
Repair, refold, recycle: how bacteria can deal with spontaneous and environmental damage to proteins. Visick JE, et al. **Mol Microbiol** 1995 Jun;16(5):835–45 (124 ref.)
Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Almaula N, et al. **Mol Pharmacol** 1996 Jul;50(1):34–42
The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Befort K, et al. **Mol Pharmacol** 1996 Feb;49(2):216–23
Sand in the sheets [comment] Diehl SR. **Nat Med** 1995 Feb; 1(2):120–2. Comment on: Nat Med 1995 Feb;1(2):143–8.
Mapping the lipid-exposed surfaces of membrane proteins. Arkin IT, et al. **Nat Struct Biol** 1996 Mar;3(3):240–3
An enzyme-substrate complex involved in bacterial cell wall biosynthesis. Benson TE, et al. **Nat Struct Biol** 1995 Aug; 2(8):644–53
Resolving a resolvase [news] Craigie R. **Nat Struct Biol** 1995 Aug;2(8):607–9
Picture story. The helix from which the arch was made. Felsenfeld AL. **Nat Struct Biol** 1996 Jul;3(7):580
The hairpin stack fold, a novel protein architecture for a new family of protein growth factors [letter] Hrabal R, et al. **Nat Struct Biol** 1996 Sep;3(9):747–52
Structure of porcine aldehyde reductase holoenzyme. el-Kabbani O, et al. **Nat Struct Biol** 1995 Aug;2(8):687–92
Packing interactions in the apomyglobin folding intermediate. Kay MS, et al. **Nat Struct Biol** 1996 May;3(5):439–45
Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide [see comments] Lansbury PT Jr, et al. **Nat Struct Biol** 1995 Nov;2(11):990–8. Comment in: Nat Struct Biol 1995 Nov;2(11):926–8.
Characterization of non-inducible Tet repressor mutants suggests conformational changes necessary for induction. Müller G, et al. **Nat Struct Biol** 1995 Aug;2(8):693–703
The X-ray structures of two mutant crystallin domains shed light on the evolution of multi-domain proteins. Norledge BV, et al. **Nat Struct Biol** 1996 Mar;3(3):267–74
De novo design and structural analysis of a model beta-hairpin peptide system. Ramírez-Alvarado M, et al. **Nat Struct Biol** 1996 Jul;3(7):604–12
Picture story. Cyclin switch. Riddihough G. **Nat Struct Biol** 1995 Aug;2(8):636
Modelling membrane proteins using structural restraints. Sansom MS, et al. **Nat Struct Biol** 1995 Aug;2(8):624–31
Extremely rapid protein folding in the absence of intermediates. Schindler T, et al. **Nat Struct Biol** 1995 Aug; 2(8):663–73
Proline scanning mutagenesis of a molten globule reveals non-cooperative formation of a protein's overall topology. Schulman BA, et al. **Nat Struct Biol** 1996 Aug;3(8):682–7
A short linear peptide derived from the N-terminal sequence of ubiquitin folds into a water-stable non-native beta-hairpin. Searle MS, et al. **Nat Struct Biol** 1995 Nov; 2(11):999–1006
Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Smith SO, et al. **Nat Struct Biol** 1996 Mar;3(3):252–8
A potent new mode of beta-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex [see comments] Strynadka NC, et al. **Nat Struct Biol** 1996 Mar;3(3):290–7. Comment in: Nat Struct Biol 1996 Mar;3(3):209–10.
Crystal structure of the macrophage migration inhibitory factor from rat liver. Suzuki M, et al. **Nat Struct Biol** 1996 Mar;3(3):259–66
Residues defining V beta specificity in staphylococcal enterotoxins. Swaminathan S, et al. **Nat Struct Biol** 1995 Aug;2(8):680–6
Reading the minor groove [news] Travers AA. **Nat Struct Biol** 1995 Aug;2(8):615–8
Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone [letter] Tudor JE, et al. **Nat Struct Biol** 1996 Apr;3(4):317–20
The multisubunit active site of fumarase C from Escherichia coli. Weaver TM, et al. **Nat Struct Biol** 1995 Aug; 2(8):654–62
Structural features of the epsilon subunit of the Escherichia coli ATP synthase determined by NMR spectroscopy [see comments] Wilkens S, et al. **Nat Struct Biol** 1995 Nov; 2(11):961–7. Comment in: Nat Struct Biol 1995 Nov;2(11):915–8.
In vitro evolution of thermodynamically stable turns. Zhou HX, et al. **Nat Struct Biol** 1996 May;3(5):446–51
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Brannigan JA, et al. **Nature** 1995 Nov 23;378(6555):416–9
Context-dependent secondary structure formation of a designed protein sequence. Minor DL Jr, et al. **Nature** 1996 Apr 25;380(6576):730–4
The post-translational incorporation of arginine into a beta-amyloid peptide increases the probability of alpha-helix formation. Bongiovanni G, et al. **Neuroreport** 1995 Dec 29;7(1):326–8
Sulphated compounds attenuate beta-amyloid toxicity by inhibiting its association with cells. Sadler II, et al. **Neuroreport** 1995 Dec 29;7(1):49–53
Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Soto C, et al. **Neurosci Lett** 1995 Nov 17;200(2):105–8
Structural probing and damage selection of citrulline- and arginine-specific RNA aptamers identify base positions required for binding. Burgstaller P, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4769–76
The helix-hairpin-helix DNA-binding motif: a structural basis for non-sequence-specific recognition of DNA. Doherty AJ, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2488–97
Evidence for the late origin of introns in chloroplast genes from an evolutionary analysis of the genus Euglena. Thompson MD, et al. **Nucleic Acids Res** 1995 Dec 11; 23(23):4745–52
Domains of the qin protein required for oncogenic transformation. Chang HW, et al. **Oncogene** 1996 Jul 18; 13(2):441–4
(S)-C alpha-ethyl, C alpha-benzylglycine [(S)-(alpha Et)Phe] peptides fold in left-handed helical structures. Doi

M, et al. **Pept Res** 1995 Sep-Oct;8(5):294-7

Identification of an elicitor active site within the three-dimensional structure of the tobacco mosaic tobamovirus coat protein. Taraporewala ZF, et al. **Plant Cell** 1996 Feb;8(2):169-78

The histone fold: a ubiquitous architectural motif utilized in DNA compaction and protein dimerization. Arents G, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11170-4

Active barnase variants with completely random hydrophobic cores. Axe DD, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5590-4

Local densities orthogonal to beta-sheet amide planes: patterns of packing in globular proteins. Beardsley DS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4448-53

Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Botos I, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2749-54

Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch. Bourne Y, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10232-6

How are close residues of protein structures distributed in primary sequence? Brocchieri L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12136-40

Role of hydrophobic interactions and desolvation in determining the structural properties of a model alpha beta peptide. Butcher DJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1135-40

Nramp defines a family of membrane proteins. Cellier M, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10089-93

Three distinct structural environments of a transmembrane domain in the inwardly rectifying potassium channel ROMK1 defined by perturbation. Choe S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12046-9

The wing of the enhancer-binding domain of Mu phage transposase is flexible and is essential for efficient transposition. Clubb RT, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1146-50

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF Jr, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2735-40

Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa. Dryja TP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10177-81

Lyophilization-induced reversible changes in the secondary structure of proteins. Griebenow K, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10969-76

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Griffith DL, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):878-83

Template-nucleated alanine-lysine helices are stabilized by position-dependent interactions between the lysine side chain and the helix barrel. Groebke K, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4025-9

Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor. Hausmann H, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6907-12

Swiveling-domain mechanism for enzymatic phosphotransfer between remote reaction sites. Herzberg O, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2652-7

Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Hill CP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3099-104

Insights into antibody catalysis: structure of an oxygenation catalyst at 1.9-angstrom resolution. Hsieh-Wilson LC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5363-7

A designed beta-hairpin peptide in crystals. Karle IL, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8189-93

The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Kato Y, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):3007-10

Three-dimensional structure of human protein kinase C interacting protein 1, a member of the HIT family of proteins. Lima CD, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5357-62

A structural motif for the voltage-gated potassium channel pore. Lipkind GM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9215-9

A family of lysozyme-like virulence factors in bacterial pathogens of plants and animals. Mushegian AR, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7321-6

Active site topology and reaction mechanism of GTP cyclohydrolase I. Nar H, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12120-5

Mutation of conserved negatively charged residues in the S2 and S3 transmembrane segments of a mammalian K+ channel selectively modulates channel gating. Planells-Cases R, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9422-6

Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin. Qu A, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10277-81

DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Roca J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4057-62

Projection structure of frog rhodopsin in two crystal forms. Schertler GF, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11578-82

Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Sun HW, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5191-6

Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution. Tiedemann RE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12156-9

Nuclear magnetic dipole interactions in field-oriented proteins: information for structure determination in solution. Tolman JR, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9279-83

The neck region of the myosin motor domain acts as a lever arm to generate movement. Uyeda TQ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4459-64

The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. van Raaij MJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6913-7

A method for distance determination in proteins using a designed metal ion binding site and site-directed spin labeling: evaluation with T4 lysozyme. Voss J, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12295-9

Distance determination in proteins using designed metal ion binding sites and site-directed spin labeling: application to the lactose permease of Escherichia coli. Voss J, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12300-3

Barriers to protein folding: formation of buried polar interactions is a slow step in acquisition of structure [see comments] Waldburger CD, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2629-34. Comment in: Proc Natl Acad Sci U S A 1996 Apr 2;93(7):2627-8.

Thermodynamic parameters for the helix-coil transition of oligopeptides: molecular dynamics simulation with the peptide growth method. Wang L, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10924-8

Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Wang WW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12436-40

A cooperative model for receptor recognition and cell adhesion: evidence from the molecular packing in the 1.6-A crystal structure of the pheromone Er-1 from the ciliated protozoan Euplotes raikovi. Weiss MS, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10172-6

Crystal structure of the membrane-exposed domain from a respiratory quinol oxidase complex with an engineered dinuclear copper center [see comments] Wilmanns M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11955-9 . Comment in: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11949-51.

Conservation and diversification in homeodomain-DNA interactions: a comparative genetic analysis. Wilson DS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6886-91

Helix packing of lactose permease in Escherichia coli studied by site-directed chemical cleavage. Wu J, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9186-90

Accurate prediction of protein secondary structural class with fuzzy structural vectors. Boberg J, et al. **Protein Eng** 1995 Jun;8(6):505-12

Structural domains of P450-containing monooxygenase systems. Degtyarenko KN. **Protein Eng** 1995 Aug; 8(8):737-47 (119 ref.)

Common molecular scaffold for two unrelated RGD molecules. Ely KR, et al. **Protein Eng** 1995 Aug;8(8):823-7

Prediction of the antigenic sites of the cystic fibrosis transmembrane conductance regulator protein by molecular modelling. Gallet X, et al. **Protein Eng** 1995 Aug; 8(8):829-34

Second-generation octarellins: two new de novo (beta/alpha)8 polypeptides designed for investigating the influence of beta-residue packing on the alpha/beta-barrel structure stability. Houbrechts A, et al. **Protein Eng** 1995 Mar;8(3):249-59

Functionally essential, invariant glutamate near the C-terminus of strand beta 5 in various (alpha/beta)8-barrel enzymes as a possible indicator of their evolutionary relatedness. Janeček S, et al. **Protein Eng** 1995 Aug; 8(8):809-13

Comparison of spatial arrangements of secondary structural elements in proteins. Mizuguchi K, et al. **Protein Eng** 1995 Apr;8(4):353-62

The relative positions of alanine residues in the hydrophobic core control the formation of two-stranded or four-stranded alpha-helical coiled-coils. Monera OD, et al. **Protein Eng** 1996 Apr;9(4):353-63

The predicted secondary structure of the G-type glutamine amidotransferase is compatible with TIM-barrel topology. Niermann T, et al. **Protein Eng** 1995 Jun;8(6):535-42

The crystal structure of thermostable mutants of chimeric 3-isopropylmalate dehydrogenase, 2T2M6T. Sakurai M, et al. **Protein Eng** 1995 Aug;8(8):763-7

Redesigning the active site of Geotrichum candidum lipase. Schrag JD, et al. **Protein Eng** 1995 Aug;8(8):835-42

Secondary structure prediction of the H5 pore of potassium channels. Soman KV, et al. **Protein Eng** 1995 Apr; 8(4):397-401

A simple protein folding algorithm using a binary code and secondary structure constraints. Sun S, et al. **Protein Eng** 1995 Aug;8(8):769-78

Composition analysis of alpha-helices in thermophilic organisms. Warren GL, et al. **Protein Eng** 1995 Sep; 8(9):905-13

Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Becker JW, et al. **Protein Sci** 1995 Oct;4(10):1966-76

The importance of larger data sets for protein secondary structure prediction with neural networks. Chandonia JM, et al. **Protein Sci** 1996 Apr;5(4):768-74

De novo design of the hydrophobic cores of proteins. Desjarlais JR, et al. **Protein Sci** 1995 Oct;4(10):2006-18

Improving protein secondary structure prediction with aligned homologous sequences. Di Francesco V, et al. **Protein Sci** 1996 Jan;5(1):106-13

Prediction of polyelectrolyte polypeptide structures using Monte Carlo conformational search methods with implicit solvation modeling. Evans JS, et al. **Protein Sci** 1995 Oct; 4(10):2019-31

The Alacoil: a very tight, antiparallel coiled-coil of helices. Gernert KM, et al. **Protein Sci** 1995 Nov;4(11):2252-60

Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Helms LR, et al. **Protein Sci** 1995 Oct; 4(10):2073-81

Structural analysis of zinc substitutions in the active site of thermolysin. Holland DR, et al. **Protein Sci** 1995 Oct; 4(10):1955-65

Thrombin-binding affinities of different disulfide-bonded isomers of the fifth EGF-like domain of thrombomodulin. Hunter MJ, et al. **Protein Sci** 1995 Oct;4(10):2129-37

PROMOTIF--a program to identify and analyze structural motifs in proteins. Hutchinson EG, et al. **Protein Sci** 1996 Feb;5(2):212-20

Similarity of different beta-strands flanked in loops by glycines and prolines from distinct (alpha/beta)8-barrel enzymes: chance or a homology? Janeček S. **Protein Sci** 1995 Jun;4(6):1239-42

Alignment of 700 globin sequences: extent of amino acid substitution and its correlation with variation in volume. Kapp OH, et al. **Protein Sci** 1995 Oct;4(10):2179-90

Crystal structure of thioltransferase at 2.2 A resolution. Katti SK, et al. **Protein Sci** 1995 Oct;4(10):1998-2005

Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Kroeger Smith MB, et al. **Protein Sci** 1995 Oct;4(10):2203-22

Pseudotorsional OCCO backbone angle as a single descriptor of protein secondary structure. Laiter S, et al. **Protein Sci** 1995 Aug;4(8):1633-43

Quantitative approaches to utilizing mutational analysis and disulfide crosslinking for modeling a transmembrane domain. Lee GF, et al. **Protein Sci** 1995 Jun;4(6):1100-7

Homology modeling of an immunoglobulin-like domain in the Saccharomyces cerevisiae adhesion protein alpha-agglutinin. Lipke PN, et al. **Protein Sci** 1995 Oct; 4(10):2168-78

Molecular modeling of the GM-CSF and IL-3 receptor complexes. Lyne PD, et al. **Protein Sci** 1995 Oct; 4(10):2223-33

Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090. Malley MF, et al. **Protein Sci** 1996 Feb; 5(2):221-8

A simple and fast approach to prediction of protein secondary structure from multiply aligned sequences with accuracy above 70%. Mehta PK, et al. **Protein Sci** 1995 Dec; 4(12):2517-25

Fuzzy cluster analysis of simple physicochemical properties of amino acids for recognizing secondary structure in proteins. Mocz G. **Protein Sci** 1995 Jun;4(6):1178-87

The distribution of alpha-helix propensity along the polypeptide chain is not conserved in proteins from the same family. Muñoz V, et al. **Protein Sci** 1995 Aug; 4(8):1577-86

Structural similarity between the pleckstrin homology domain and verotoxin: the problem of measuring and evaluating structural similarity. Orengo CA, et al. **Protein Sci** 1995 Oct;4(10):1977-83

Incorporation of pairwise interactions into the Lifson-Roig model for helix prediction. Shalongo W, et al. **Protein Sci** 1995 Jun;4(6):1161-6

Thermal stability determinants of chicken egg-white lysozyme core mutants: hydrophobicity, packing volume, and conserved buried water molecules. Shih P, et al. **Protein Sci** 1995 Oct;4(10):2050-62

Design and structural analysis of an engineered thermostable chicken lysozyme. Shih P, et al. **Protein Sci** 1995 Oct; 4(10):2063-72

Addition of side chain interactions to modified Lifson-Roig helix-coil theory: application to energetics of phenylalanine-methionine interactions. Stapley BJ, et al. **Protein Sci** 1995 Nov;4(11):2383-91

Binary patterning of polar and nonpolar amino acids in the sequences and structures of native proteins. West MW, et al. **Protein Sci** 1995 Oct;4(10):2032-9

Automatic recognition of hydrophobic clusters and their correlation with protein folding units. Zehfus MH. **Protein Sci** 1995 Jun;4(6):1188-202

The phospho-beta-galactosidase and synaptotagmin predictions. Benner SA, et al. **Proteins** 1995 Nov; 23(3):446-53

Crystallographic structure of metal-free concanavalin A at 2.5 A resolution. Bouckaert J, et al. **Proteins** 1995 Dec; 23(4):510-24

Knowledge-based protein secondary structure assignment. Frishman D, et al. **Proteins** 1995 Dec;23(4):566-79

A predicted consensus structure for the protein kinase C2 homology (C2H) domain, the repeating unit of synaptotagmin. Gerloff DL, et al. **Proteins** 1995 Aug; 22(4):299–310

Solvent polarity–dependent structural refolding: a CD and NMR study of a 15 residue peptide. Graf von Stosch A, et al. **Proteins** 1995 Oct;23(2):196–203

Fold recognition and ab initio structure predictions using hidden Markov models and beta-strand pair potentials. Hubbard TJ, et al. **Proteins** 1995 Nov;23(3):398–402

Empirical correlation for the replacement of Ala by Gly: importance of amino acid secondary intrinsic propensities. López-Hernández E, et al. **Proteins** 1995 Aug;22(4):340–9

Progress of 1D protein structure prediction at last. Rost B, et al. **Proteins** 1995 Nov;23(3):295–300

Three–dimensional model of the alpha–subunit of bacterial luciferase. Sandalova T, et al. **Proteins** 1995 Oct; 23(2):241–55

Circular dichroism of the parallel beta helical proteins pectate lyase C and E. Sieber V, et al. **Proteins** 1995 Sep;23(1):32–7

Binding geometry of alpha–helices that recognize DNA. Suzuki M, et al. **Proteins** 1995 Dec;23(4):525–35

Docking of a human rhinovirus neutralizing antibody onto the viral capsid. Tormo J, et al. **Proteins** 1995 Dec; 23(4):491–501

Dynamic structure of human serum transferrin from transient electric birefringence experiments. van Haeringen B, et al. **Proteins** 1995 Oct;23(2):233–40

An analysis of side chain interactions and pair correlations within antiparallel beta–sheets: the differences between backbone hydrogen–bonded and non–hydrogen–bonded residue pairs. Wouters MA, et al. **Proteins** 1995 Jun; 22(2):119–31

Protein secondary structure prediction with partially recurrent neural networks. Reczko M. **SAR QSAR Environ Res** 1993;1(2–3):153–9

Alpha helix–RNA major groove recognition in an HIV–1 rev peptide–RRE RNA complex. Battiste JL, et al. **Science** 1996 Sep 13;273(5281):1547–51

Interhelical salt bridges, coiled–coil stability, and specificity of dimerization [letter; comment] Lavigne P, et al. **Science** 1996 Feb 23;271(5252):1136–8. Comment on: Science 1995 Apr 21;268(5209):436–9.

Organization of diphtheria toxin T domain in bilayers: a site–directed spin labeling study. Oh KJ, et al. **Science** 1996 Aug 9;273(5276):810–2

Modulation of transcription factor Ets–1 DNA binding: DNA–induced unfolding of an alpha helix. Petersen JM, et al. **Science** 1995 Sep 29;269(5232):1866–9

A left–handed parallel beta helix in the structure of UDP–N–acetylglucosamine acyltransferase. Raetz CR, et al. **Science** 1995 Nov 10;270(5238):997–1000

Between the sheets: why do proteins strands line up? [news] Service RF. **Science** 1996 Oct 4;274(5284):34–5

Guidelines for protein design: the energetics of beta sheet side chain interactions. Smith CK, et al. **Science** 1995 Nov 10;270(5238):980–2

Beta sheets and spider silk [letter] Thiel BL, et al. **Science** 1996 Sep 13;273(5281):1480–1

Crystal structure of the dual specificity protein phosphatase VHR. Yuvaniyama J, et al. **Science** 1996 May 31; 272(5266):1328–31

A role for quaternary structure in the substrate specificity of leucine dehydrogenase. Baker PJ, et al. **Structure** 1995 Jul 15;3(7):693–705

Three new crystal structures of point mutation variants of monoTIM: conformational flexibility of loop–1, loop–4 and loop–8. Borchert TV, et al. **Structure** 1995 Jul 15; 3(7):669–79

hSRY: molecular gender bender. Bramham J, et al. **Structure** 1995 Jul 15;3(7):631–3 (19 ref.)

Structural analysis of human alpha–class glutathione transferase A1–1 in the apo–form and in complexes with ethacrynic acid and its glutathione conjugate. Cameron AD, et al. **Structure** 1995 Jul 15;3(7):717–27

1.8 A crystal structure of the C–terminal domain of rabbit serum haemopexin. Faber HR, et al. **Structure** 1995 Jun 15;3(6):551–9

Structure and function of a virally encoded fungal toxin from Ustilago maydis: a fungal and mammalian Ca2+ channel inhibitor. Gu F, et al. **Structure** 1995 Aug 15;3(8):805–14

Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)

Crystal structure of Escherichia coli pyruvate kinase type I: molecular basis of the allosteric transition. Mattevi A, et al. **Structure** 1995 Jul 15;3(7):729–41

Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)

Solution structure of the cardiostimulant polypeptide anthopleurin–B and comparison with anthopleurin–A [published erratum appears in Structure 1995 Oct 15;3(10):1126] Monks SA, et al. **Structure** 1995 Aug 15; 3(8):791–803

The structure of coxsackievirus B3 at 3.5 A resolution. Muckelbauer JK, et al. **Structure** 1995 Jul 15;3(7):653–67

Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc–binding site. Papageorgiou AC, et al. **Structure** 1995 Aug 15;3(8):769–79

Structural evidence for the evolutionary divergence of mycoplasma from gram–positive bacteria: the histidine–containing phosphocarrier protein. Pieper U, et al. **Structure** 1995 Aug 15;3(8):781–90

The low ionic strength crystal structure of horse cytochrome c at 2.1 A resolution and comparison with its high ionic strength counterpart. Sanishvili R, et al. **Structure** 1995 Jul 15;3(7):707–16

The solution structure and backbone dynamics of the fibronectin type I and epidermal growth factor–like pair of modules of tissue–type plasminogen activator. Smith BO, et al. **Structure** 1995 Aug 15;3(8):823–33

The crystal structure of the catalytic domain of human urokinase–type plasminogen activator. Spraggon G, et al. **Structure** 1995 Jul 15;3(7):681–91

How Ras works: structure of a Rap–Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)

The S100 family of EF–hand calcium–binding proteins: functions and pathology. Schäfer BW, et al. **Trends Biochem Sci** 1996 Apr;21(4):134–40 (29 ref.)

[Semi–empiric method of modeling the protein spatial structure using tritium planigraphy] Bogacheva EN, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):637–46 **(Rus)**

[A theoretical analysis of the secondary structure and topology of dolichol–coupled enzymes] Shpakov AO. **Zh Evol Biokhim Fiziol** 1995 Mar–Apr;31(2):129–40 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

2,2,2–Trifluoroethanol induces helical conformation in an all beta–sheet protein. Jayaraman G, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):33–7

Effect of ethanol on the protein secondary structure of the human gastric mucosa, in vitro. Lin SY, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):255–61

RADIATION EFFECTS

Helical and reverse turn changes in the BR–>N transition of bacteriorhodopsin. Lazarova T, et al. **Biochemistry** 1996 Jun 25;35(25):8354–8

PROTEIN STRUCTURE, TERTIARY

Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Sato S, et al. **Adv Exp Med Biol** 1995; 372:259–68

Progress toward the tertiary structure of (class 3) aldehyde dehydrogenase. Sun J, et al. **Adv Exp Med Biol** 1995; 372:71–7

Mapping domains in proteins: dissection and expression of Escherichia coli adenylyl cyclase. Reddy P, et al. **Anal Biochem** 1995 Nov 1;231(2):282–6

The importance of the diversity region YYGS motif in anti–DNA antibody binding to DNA. Mahmoudi M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:424–6

Localization of protease activity in antibody subunits. Sun M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:573–5

Mechanics of motility: distinct dynein binding domains on alpha– and beta–tubulin. Goldsmith M, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):665–71

Comparative analysis of the secondary structural motifs of P450BM–3 and the regions located upstream of the calmodulin–binding domain in the nitric oxide synthases. Uvarov VYu, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):553–8

Specific recognition of coiled coils by infrared spectroscopy: analysis of the three structural domains of type III intermediate filament proteins. Heimburg T, et al. **Biochemistry** 1996 Feb 6;35(5):1375–82

Infrared amide I' band of the coiled coil. Reisdorf WC Jr, et al. **Biochemistry** 1996 Feb 6;35(5):1383–6

Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Schiffer CA, et al. **Biochemistry** 1995 Dec 19; 34(50):16279–87

Comparison of secondary structures in water of chondroitin–4–sulfate and dermatan sulfate: implications in the formation of tertiary structures. Scott JE, et al. **Biochemistry** 1995 Nov 28;34(47):15467–74

Interactions contributing to the formation of a beta–hairpin–like structure in a small peptide. Sieber V, et al. **Biochemistry** 1996 Jan 9;35(1):181–8

Modelling packing interactions in parallel helix bundles: pentameric bundles of nicotinic receptor M2 helices. Sankararamakrishnan R, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):122–32

Molecular genetic systems to study the role of poly(ADP–ribosyl)ation in the cellular response to DNA damage. Küpper JH, et al. **Biochimie** 1995;77(6):450–5

NADPH–P–450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)

The factor V B–domain provides two functions to facilitate thrombin cleavage and release of the light chain. Marquette KA, et al. **Blood** 1995 Oct 15;86(8):3026–34

Distinct regions of the granulocyte colony–stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Nicholson SE, et al. **Blood** 1995 Nov 15;86(10):3698–704

Constitutive activation of c–kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Tsujimura T, et al. **Blood** 1996 Jan 1;87(1):273–83

Factor VII G331D: a variant molecule involving replacement of a residue in the substrate–binding region of the catalytic domain. Zheng DQ, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):93–6

The identification of a functional nuclear localization signal in the Huntington disease protein. Bessert DA, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):165–73

Regulation of hemicholinium–3 sensitive choline uptake in Xenopus laevis oocytes by the second C2 domain of synaptotagmin. O'Regan S, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):135–42

Identification of two alternatively spliced transcripts of STEP: a subfamily of brain–enriched protein tyrosine phosphatases. Sharma E, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):87–93

The BTB/POZ domain: a new protein–protein interaction motif common to DNA– and actin–binding proteins. Albagli O, et al. **Cell Growth Differ** 1995 Sep;6(9):1193–8

Functional dissection of the dynein motor domain. Eshel D. **Cell Motil Cytoskeleton** 1995;32(2):133–5

Protein–protein interfaces: architectures and interactions in protein–protein interfaces and in protein cores. Their similarities and differences. Tsai CJ, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):127–52 (50 ref.)

Integrin–ligand binding. Do integrins use a 'MIDAS touch' to grasp an Asp? Bergelson JM, et al. **Curr Biol** 1995 Jun 1;5(6):615–7 (15 ref.)

Dimerization of chimeric erythropoietin/75 kDa tumour necrosis factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa–TNF receptor transmembrane domain. Declercq W, et al. **Cytokine** 1995 Oct;7(7):701–9

Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130. de Hon FD, et al. **Cytokine** 1995 Jul;7(5):398–407

Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. Schild L, et al. **EMBO J** 1996 May 15;15(10):2381–7

The IVS6 segment of the L–type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. Schuster A, et al. **EMBO J** 1996 May 15;15(10):2365–70

Internalisation of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. Vinson GP, et al. **Endocr Res** 1995 Feb–May;21(1–2):211–7

Human CD6 possesses a large, alternatively spliced cytoplasmic domain. Robinson WH, et al. **Eur J Immunol** 1995 Oct;25(10):2765–9

The structure and evolution of alpha/beta barrel proteins [letter; comment] Schwabe C. **FASEB J** 1996 Jan;10(1):184 . Comment on: FASEB J 1995 Apr;9(7):497–503.

A molecular map of titin/connectin elasticity reveals two different mechanisms acting in series. Gautel M, et al. **FEBS Lett** 1996 Apr 29;385(1–2):11–4

Does glycosylation influence the experimental antithrombotic effect of a two–domain tissue factor pathway inhibitor? Holst J, et al. **Haemostasis** 1996 Jan–Feb;26(1):23–30

Truncated erythropoietin receptor in a murine erythroleukemia cell line. Bittorf T, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):175–81

Origins of replication and the nuclear matrix: the DHFR domain as a paradigm. Dijkwel PA, et al. **Int Rev Cytol** 1995;162A:455–84 (180 ref.)

Representation for discovery of protein motifs. Conklin D, et al. **Ismb** 1993;1:101–8

Constructive induction and protein tertiary structure prediction. Ioerger TR, et al. **Ismb** 1993;1:198–206

Protein structure prediction system based on artificial neural networks. Vanhala J, et al. **Ismb** 1993;1:402–10

Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. Dubé JY, et al. **J Androl** 1995 Jul–Aug;16(4):304–11

An anti–tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free–form TFPI but not lipoprotein–associated forms in plasma. Abumiya T, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):178–82

Tertiary structure of [2Fe–2S] ferredoxin from Spirulina platensis refined at 2.5 A resolution: structural comparisons of plant–type ferredoxins and an electrostatic potential analysis. Fukuyama K, et al. **J Biochem (Tokyo)** 1995 May; 117(5):1017–23

Role of the N– and C–terminal domains of bovine beta 2–glycoprotein I in its interaction with cardiolipin. Hagihara Y, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):129–36

Structure of the gene encoding mouse reticulocalbin, a novel endoplasmic reticulum–resident Ca(2+)–binding protein with multiple EF–hand motifs. Ozawa M. **J Biochem (Tokyo)** 1995 Jul;118(1):154–60

Zn(2+)–mediated domain–domain communication in human erythrocyte band 3. Tu YP, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):161–7

Allosteric modulation by tertiary structure in mammalian hemoglobins. Introduction of the functional characteristics of bovine hemoglobin into human hemoglobin by five amino acid substitutions. Fronticelli C, et al. **J Biol Chem** 1995 Dec 22;270(51):30588–92

Refolding and oxidation of recombinant human stem cell

factor produced in Escherichia coli. Jones MD, et al. **J Biol Chem** 1996 May 10;271(19):11301–8

Isolation and characterization of a disulfide–linked human stem cell factor dimer. Biochemical, biophysical, and biological comparison to the noncovalently held dimer. Lu HS, et al. **J Biol Chem** 1996 May 10;271(19):11309–16

Histidine patch thioredoxins. Mutant forms of thioredoxin with metal chelating affinity that provide for convenient purifications of thioredoxin fusion proteins. Lu Z, et al. **J Biol Chem** 1996 Mar 1;271(9):5059–65

Structural organization of transcription termination factor Rho. Richardson JP. **J Biol Chem** 1996 Jan 19; 271(3):1251–4 (50 ref.)

Role of alpha–helical coiled–coil interactions in receptor dimerization, signaling, and adaptation during bacterial chemotaxis. Surette MG, et al. **J Biol Chem** 1996 Jul 26; 271(30):17966–73

1H NMR investigation of the secondary structure, tertiary contacts and cluster environment of the four–iron ferredoxin from the hyperthermophilic archaeon Thermococcus litoralis. Donaire A, et al. **J Biomol NMR** 1996 Jan;7(1):35–47

Selective absorption of radio frequency energy due to collective motion of charged domains: case of lysozyme crystal. Alexov E, et al. **J Biomol Struct Dyn** 1995 Oct; 13(2):219–28

The membrane skeleton of acetylcholine receptor domains in rat myotubes contains antiparallel homodimers of beta–spectrin in filaments quantitatively resembling those of erythrocytes. Pumplin DW. **J Cell Sci** 1995 Sep;108 (Pt 9):3145–54

Interphase phosphorylation of the Drosophila nuclear lamin: site–mapping using a monoclonal antibody. Stuurman N, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3137–44

Characterization of the baculovirus Choristoneura fumiferana multicapsid nuclear polyhedrosis virus p10 gene indicates that the polypeptide contains a coiled–coil domain. Wilson JA, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2923–32

Comparison of CD45 extracellular domain sequences from divergent vertebrate species suggests the conservation of three fibronectin type III domains. Okumura M, et al. **J Immunol** 1996 Aug 15;157(4):1569–75

An Alu cassette in the cytoplasmic domain of an interferon receptor subunit. Mullersman JE, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):815–7

A functional role for protein cavities in domain: domain motions. Hubbard SJ, et al. **J Mol Biol** 1996 Aug 16; 261(2):289–300

The dynamic structure of EF–G studied by fusidic acid resistance and internal revertants. Johanson U, et al. **J Mol Biol** 1996 May 10;258(3):420–32

The 2.3 A crystal structure of the catalytic domain of recombinant two–chain human tissue–type plasminogen activator. Lamba D, et al. **J Mol Biol** 1996 Apr 26; 258(1):117–35

Conservation and variability in the structures of serine proteinases of the chymotrypsin family. Lesk AM, et al. **J Mol Biol** 1996 May 10;258(3):501–37

A thermostable 35–residue subdomain within villin headpiece. McKnight CJ, et al. **J Mol Biol** 1996 Jul 12; 260(2):126–34

The C–terminal domain revealed in the structure of RNA polymerase II. Meredith GD, et al. **J Mol Biol** 1996 May 10;258(3):413–9

The structure of the head–tail junction of the myosin molecule. Offer G, et al. **J Mol Biol** 1996 Mar 1; 256(3):407–16

NMR structure of the J–domain and the Gly/Phe–rich region of the Escherichia coli DnaJ chaperone. Pellecchia M, et al. **J Mol Biol** 1996 Jul 12;260(2):236–50

Interactions between a helical residue and tertiary structures: helix propensities in small peptides and in native proteins. Qian H, et al. **J Mol Biol** 1996 Aug 16;261(2):279–88

Refined structure of lac repressor headpiece (1–56) determined by relaxation matrix calculations from 2D and 3D NOE data: change of tertiary structure upon binding to the lac operator. Slijper M, et al. **J Mol Biol** 1996 Jun 21;259(4):761–73

Vibrational Raman optical activity of alpha–lactalbumin: comparison with lysozyme, and evidence for native tertiary folds in molten globule states. Wilson G, et al. **J Mol Biol** 1995 Dec 8;254(4):747–60

The native–like tertiary fold in molten globule alpha–lactalbumin appears to be controlled by a continuous phase transition. Wilson G, et al. **J Mol Biol** 1996 Aug 23;261(3):341–7

Crystal structures of CO–, deoxy– and met–myoglobins at various pH values. Yang F, et al. **J Mol Biol** 1996 Mar 8;256(4):762–74

Identification of the border between fibronectin type III homologous repeats 2 and 3 of the neural cell adhesion molecule L1 as a neurite outgrowth promoting and signal transducing domain. Appel F, et al. **J Neurobiol** 1995 Nov; 28(3):297–312

Distinct effects of recombinant tenascin–C domains on neuronal cell adhesion, growth cone guidance, and neuronal polarity. Dörries U, et al. **J Neurosci Res** 1996 Feb 15;43(4):420–38

Membrane–protein interaction and the molten globule state: interaction of alpha–lactalbumin with membranes. Lala AK, et al. **J Protein Chem** 1995 Oct;14(7):601–9

Expression of vascular cell adhesion molecule–1 by follicular dendritic cells. Huang MJ, et al. **Leuk Lymphoma** 1995 Jul; 18(3–4):259–64

The extra sex combs product contains WD40 repeats and its time of action implies a role distinct from other Polycomb group products. Simon J, et al. **Mech Dev** 1995 Oct;53(2):197–208

The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Stassen MJ, et al. **Mech Dev** 1995 Aug; 52(2–3):209–23

Peptides derived from the lectin domain of selectin adhesion molecules inhibit leukocyte rolling in vivo. Norman KE, et al. **Microcirculation** 1996 Mar;3(1):29–38

A Plasmodium falciparum protein kinase with two unusually large kinase inserts. Kappes B, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):163–78

The cytoplasmic tail domain of the vacuolar protein sorting receptor Vps10p and a subset of VPS gene products regulate receptor stability, function, and localization. Cereghino JL, et al. **Mol Biol Cell** 1995 Sep;6(9):1089–102

The N–terminal pleckstrin, coiled–coil, and IQ domains of the exchange factor Ras–GRF act cooperatively to facilitate activation by calcium. Buchsbaum R, et al. **Mol Cell Biol** 1996 Sep;16(9):4888–96

Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Chow KN, et al. **Mol Cell Biol** 1996 Sep;16(9):4862–8

The POU domain of SCIP/Tst–1/Oct–6 is sufficient for activation of any acetylcholine receptor promoter. Fyodorov D, et al. **Mol Cell Biol** 1996 Sep;16(9):5004–14

Domain structure of the outer membrane transporter protein CyaE of Bordetella pertussis [letter] Gross R. **Mol Microbiol** 1995 Sep;17(6):1219–20

The antisense homology box: a new motif within proteins that encodes biologically active peptides [see comments] Baranyi L, et al. **Nat Med** 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Sep;1(9):876–8. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.

Structural modelling of a type I DNA methyltransferase [letter] Dryden DT, et al. **Nat Struct Biol** 1995 Aug; 2(8):632–5

Structure of porcine aldehyde reductase holoenzyme. el–Kabbani O, et al. **Nat Struct Biol** 1995 Aug;2(8):687–92

De novo design and structural analysis of a model beta–hairpin peptide system. Ramírez–Alvarado M, et al. **Nat Struct Biol** 1996 Jul;3(7):604–12

Crystal structure of the macrophage migration inhibitory factor from rat liver. Suzuki M, et al. **Nat Struct Biol** 1996 Mar;3(3):259–66

The three–dimensional structure of the first domain of neural cell adhesion molecule [letter] Thomsen NK, et al. **Nat Struct Biol** 1996 Jul;3(7):581–5

Extending molecular systematics to the third dimension. Wodak SJ. **Nat Struct Biol** 1996 Jul;3(7):575–8

A single point mutation decreases picrotoxinin sensitivity of the human GABA receptor rho 1 subunit. Enz R, et al. **Neuroreport** 1995 Jul 31;6(11):1569–72

The agonist selectivity of a class III metabotropic glutamate receptor, human mGluR4a, is determined by the N–terminal extracellular domain. Tones MA, et al. **Neuroreport** 1995 Dec 29;7(1):117–20

Dimerization of a chimeric CD4–interferon–alpha receptor reconstitutes the signaling events preceding STAT phosphorylation. Krishnan K, et al. **Oncogene** 1996 Jul 4; 13(1):125–33

Isolated growth hormone deficiency: testing the little mouse hypothesis in man and exclusion of mutations within the extracellular domain of the growth hormone–releasing hormone receptor. Cao Y, et al. **Pediatr Res** 1995 Dec; 38(6):962–6

The histone fold: a ubiquitous architectural motif utilized in DNA compaction and protein dimerization. Arents G, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11170–4

Three–dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Griffith DL, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):878–83

Characterizations of diverse residue clusters in protein three–dimensional structures. Karlin S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8344–9

Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Kopan R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1683–8

Projection structure of frog rhodopsin in two crystal forms. Schertler GF, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11578–82

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Schormann N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9490–4

Clusters of charged residues in protein three–dimensional structures. Zhu ZY, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8350–5

The relative positions of alanine residues in the hydrophobic core control the formation of two–stranded or four–stranded alpha–helical coiled–coils. Monera OD, et al. **Protein Eng** 1996 Apr;9(4):353–63

The Alacoil: a very tight, antiparallel coiled–coil of helices. Gernert KM, et al. **Protein Sci** 1995 Nov;4(11):2252–60

Two steps in the transition between the native and acid states of bovine alpha–lactalbumin detected by circular polarization of luminescence: evidence for a premolten globule state? Gussakovsky EE, et al. **Protein Sci** 1995 Nov; 4(11):2319–26

Paired natural cysteine mutation mapping: aid to constraining models of protein tertiary structure. Kreisberg R, et al. **Protein Sci** 1995 Nov;4(11):2405–10

The phospho–beta–galactosidase and synaptotagmin predictions. Benner SA, et al. **Proteins** 1995 Nov; 23(3):446–53

Interaction stabilizing tertiary structure of bacteriorhodopsin studied by denaturation experiments. Mitaku S, et al. **Proteins** 1995 Aug;22(4):350–62

A critical assessment of comparative molecular modeling of tertiary structures of proteins. Mosimann S, et al. **Proteins** 1995 Nov;23(3):301–17

Rigid domains in proteins: an algorithmic approach to their identification. Nichols WL, et al. **Proteins** 1995 Sep; 23(1):38–48

A continuum theory for the prediction of lateral and rotational positioning of alpha–helices in membrane proteins: bacteriorhodopsin. Suwa M, et al. **Proteins** 1995 Aug;22(4):363–77

Protein conformational landscapes: energy minimization and clustering of a long molecular dynamics trajectory. Troyer JM, et al. **Proteins** 1995 Sep;23(1):97–110

Dynamic structure of human serum transferrin from transient electric birefringence experiments. van Haeringen B, et al. **Proteins** 1995 Oct;23(2):233–40

Synthetic peptides corresponding to residues 551 to 555 and 650 to 653 of the rat testicular follicle–stimulating hormone (FSH) receptor are sufficient for post–receptor modulation of Sertoli cell responsiveness to FSH stimulation. Grasso P, et al. **Regul Pept** 1995 Dec 14;60(2–3):177–83

Tertiary and quaternary structural changes in Gi alpha 1 induced by GTP hydrolysis [see comments] Mixon MB, et al. **Science** 1995 Nov 10;270(5238):954–60. Comment in: Science 1995 Nov 10;270(5238):933–4.

Organization of diphtheria toxin T domain in bilayers: a site–directed spin labeling study. Oh KJ, et al. **Science** 1996 Aug 9;273(5276):810–2

Design of a monomeric 23–residue polypeptide with defined tertiary structure. Struthers MD, et al. **Science** 1996 Jan 19;271(5247):342–5

Structure of the biotinyl domain of acetyl–coenzyme A carboxylase determined by MAD phasing. Athappilly FK, et al. **Structure** 1995 Dec 15;3(12):1407–19

The three domains of a bacterial sialidase: a beta–propeller, an immunoglobulin module and a galactose–binding jelly–roll. Gaskell A, et al. **Structure** 1995 Nov 15; 3(11):1197–205

Two conformations of the integrin A–domain (I–domain): a pathway for activation? Lee JO, et al. **Structure** 1995 Dec 15;3(12):1333–40

The crystal structure of chloroperoxidase: a heme peroxidase—cytochrome P450 functional hybrid. Sundaramoorthy M, et al. **Structure** 1995 Dec 15; 3(12):1367–77

The crystal structures of the oligopeptide–binding protein OppA complexed with tripeptide and tetrapeptide ligands. Tame JR, et al. **Structure** 1995 Dec 15;3(12):1395–406

Localization of a vitronectin binding region of plasminogen activator inhibitor–1. Padmanabhan J, et al. **Thromb Haemost** 1995 May;73(5):829–34

Localization of a calcium–dependent epitope to the amino terminal region of the Gla domain of human factor IX. Cheung WF, et al. **Thromb Res** 1996 Jan 1;81(1):65–73

Human placental tissue factor: protease susceptibility of extracellular and cytoplasmic domains. Whittle SM, et al. **Thromb Res** 1995 Sep 15;79(5–6):451–9

Physico–chemical similarity of neurotransmitter receptor and transporter transmembrane domains. Batrak GN, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):65–71

[Absence of DNA polymorphisms on the region of the APOV gene coding the proposed low density lipoprotein–binding domain of the ApoB–100 protein] Shevtsov SP. **Genetika** 1996 Feb;32(2):295–7 (Eng. Abstr.) **(Rus)**

PROTEIN SYNTHESIS ANTAGONISTS see **PROTEIN SYNTHESIS INHIBITORS**

PROTEIN SYNTHESIS INHIBITORS

Clavin, a type–1 ribosome–inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant protein. Parente D, et al. **Eur J Biochem** 1996 Jul 15;239(2):272–80

ADMINISTRATION & DOSAGE

Intraventricular cycloheximide attenuates the restraint–induced long–lasting effect on plus maze exploration. Mendonca FH, et al. **Braz J Med Biol Res** 1996 Apr;29(4):501–5

ADVERSE EFFECTS

Effects of dietary n–3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin–induced nephrotoxicosis in healthy male dogs. Grauer GF, et al.

Am J Vet Res 1996 Jun;57(6):948–56

CHEMICAL SYNTHESIS

Synthesis of N-acetylglucosaminyl asparagine-substituted puromycin analogues. Kirsch P, et al. **Bioorg Med Chem** 1995 Dec;3(12):1631–6

CHEMISTRY

Generation of active immunotoxins containing recombinant restrictocin. Rathore D, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):58–63

The interaction between "R/S domain" of rat 28S ribosomal RNA and ribosome-inactivating proteins investigated by fusidic acid. Li Q, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):877–83

Spectroscopic characterization of the alkylated alpha-sarcin cytotoxin: analysis of the structural requirements for the protein–lipid bilayer hydrophobic interaction. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):43–52

Thermal unfolding of the cytotoxin alpha-sarcin: phospholipid binding induces destabilization of the protein structure. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):126–34

Primary structure of omega-hordothionin, a member of a novel family of thionins from barley endosperm, and its inhibition of protein synthesis in eukaryotic and prokaryotic cell-free systems. Méndez E, et al. **Eur J Biochem** 1996 Jul 1;239(1):67–73

Antibiotic GE37468 A: a novel inhibitor of bacterial protein synthesis. II. Structure elucidation. Ferrari P, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1304–11

IMMUNOLOGY

Production and characterization of monoclonal antibodies against the ribosome-inactivating protein PAP from Phytolacca americana. Desvoyes B, et al. **Hybridoma** 1995 Dec;14(6):571–5

ISOLATION & PURIFICATION

Isolation and characterization of a novel perchloric acid–soluble protein inhibiting cell-free protein synthesis. Oka T, et al. **J Biol Chem** 1995 Dec 15;270(50):30060–7

METABOLISM

DNA-nuclease activity of the single-chain ribosome-inactivating proteins dianthin 30, saporin 6 and gelonin. Roncuzzi L, et al. **FEBS Lett** 1996 Aug 19; 392(1):16–20

Activities associated with the presence of ribosome-inactivating proteins increase in senescent and stressed leaves. Stirpe F, et al. **FEBS Lett** 1996 Mar 18; 382(3):309–12

Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. Rosenblum MG, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):547–55

PHARMACOLOGY

Inhibition of basic fibroblast growth factor–mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Fry DW, et al. **Anticancer Drug Des** 1995 Dec; 10(8):607–22

Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Dunsaed CB, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1921–7

Effects of inhibitors of protein synthesis on lysis of Escherichia coli induced by beta-lactam antibiotics. Rodionov DG, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):899–903

Homocysteine enhances the inhibitory effect of extracellular adenosine on the synthesis of proteins in isolated rat hepatocytes. Tinton S, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):893–6

Cycloheximide induces nitric oxide synthase mRNA in vascular smooth muscle cells by prolonging mRNA lifetime. Hattori Y, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):439–45

High-ionic strength interference of ribosomal inhibition produced by aminoglycoside antibiotics. Marín I, et al. **Biochemistry** 1995 Dec 19;34(50):16519–23

A eukaryotic translation initiation factor 2-associated 67 kDa glycoprotein partially reverses protein synthesis inhibition by activated double-stranded RNA-dependent protein kinase in intact cells. Wu S, et al. **Biochemistry** 1996 Jun 25;35(25):8275–80

Modification of the alternative splicing process of testosterone-repressed prostate message-2 (TRPM-2) gene by protein synthesis inhibitors and heat shock treatment. Kimura K, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):83–8

Inhibition of doxorubicin-induced cell death in vitro and in vivo by cycloheximide. Furusawa S, et al. **Biol Pharm Bull** 1995 Oct;18(10):1367–72

Inhibition of polar body formation in mouse denuded oocytes cultured in vitro by protein synthesis inhibitors. Kanmera S, et al. **Biol Pharm Bull** 1995 Sep;18(9):1255–8

Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Puri RK, et al. **Blood** 1996 May 15;87(10):4333–9

Inhibitor of protein synthesis phase-shifts the circadian oscillator and inhibits the light induced-phase shift of the melatonin rhythm in pigeon pineal cells. Murakami N, et al. **Brain Res** 1995 Sep 25;693(1–2):1–7

Induction of apoptosis in MDA-231 cells by protein synthesis inhibitors is suppressed by multiple agents. Geier A, et al. **Cancer Invest** 1996;14(5):435–44

The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Murley JS, et al. **Carcinogenesis** 1995 Nov;16(11):2699–705

Transient inhibition of protein synthesis induces the immediate early gene VL30: alternative mechanism for thapsigargin-induced gene expression. Magun BE, et al. **Cell Growth Differ** 1995 Jul;6(7):891–7

Sensitivity of ribosomes from Agrobacterium tumefaciens to the ribosome-inactivating protein crotin 2 depending on the translocational state. Alegre C, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar;42(2):151–8

Transient inhibition of protein synthesis induces expression of proto-oncogenes and stimulates resting cells to enter the cell cycle. Rosenwald IB, et al. **Cell Prolif** 1995 Dec; 28(12):631–44

A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Yasui N, et al. **Clin Pharmacol Ther** 1996 May;59(5):514–9

Effects of the transcription inhibitor actinomycin D on postzygotic development of Tetrahymena thermophila conjugants. Ward JG, et al. **Dev Biol** 1996 Jan 10; 173(1):174–84

Contrasting effects of protein synthesis inhibition and of cyclic AMP on apoptosis in the developing retina. Rehen SK, et al. **Development** 1996 May;122(5):1439–48

Enacyloxin IIa, an inhibitor of protein biosynthesis that acts on elongation factor Tu and the ribosome. Cetin R, et al. **EMBO J** 1996 May 15;15(10):2604–11

Insulin-induced GLUT4 recycling in rat adipose cells by a pathway insensitive to brefeldin A. Kono-Sugita E, et al. **Eur J Biochem** 1996 Mar 15;236(3):1033–7

Differential up-regulation by tRNAs of ribosome-inactivating proteins. Brigotti M, et al. **FEBS Lett** 1995 Oct 9;373(2):115–8

Inhibition of aromatase expression by a psoralen-linked triplex-forming oligonucleotide targeted to a coding sequence. Macaulay VM, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):222–8

In vivo treatment of Heymann's Nephritis using a cytotoxic protein-toxin conjugate. Misquith S, et al. **FEBS Lett** 1995 Oct 9;373(2):151–4

Bolesatine induces agglutination of rat platelets and human erythrocytes and platelets in vitro. Gachet C, et al. **Hum Exp Toxicol** 1996 Jan;15(1):26–9

Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Jiang YZ, et al. **Immunology** 1996 Mar;87(3):481–6

Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes. Bansbach CC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S179–80

Inhibition of the release factor-dependent termination reaction on ribosomes by DnaJ and the N-terminal peptide of rhodanese. Kudlicki W, et al. **J Bacteriol** 1995 Oct; 177(19):5517–22

A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. Carter MS, et al. **J Biol Chem** 1995 Dec 1;270(48):28995–9003

Selective degradation of accumulated secretory proteins in the endoplasmic reticulum. A possible clearance pathway for abnormal tropoelastin. Davis EC, et al. **J Biol Chem** 1996 Feb 16;271(7):3787–94

Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. Foley BT, et al. **J Biol Chem** 1995 Sep 29;270(39):23218–25

Brefeldin A reversibly inhibits the assembly of apoB containing lipoproteins in McA-RH7777 cells. Rustaeus S, et al. **J Biol Chem** 1995 Dec 1;270(48):28879–86

Induction of P-glycoprotein mRNA by protein synthesis inhibition is not controlled by a transcriptional repressor protein in rat and human liver cells. Schuetz JD, et al. **J Cell Physiol** 1995 Nov;165(2):261–72

Evidence for a catabolic role of glucagon during an amino acid load. Charlton MR, et al. **J Clin Invest** 1996 Jul 1; 98(1):90–9

Inhibition of protein synthesis and amino acid transport by crystal violet in Trypanosoma cruzi. Hoffmann ME, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):293–7

The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. Johanson U, et al. **J Mol Biol** 1996 May 10;258(3):420–32

A sparsomycin-resistant mutant of Halobacterium salinarium lacks a modification at nucleotide U2603 in the peptidyl transferase centre of 23 S rRNA. Lázaro E, et al. **J Mol Biol** 1996 Aug 16;261(2):231–8

Mutations in the peptidyl transferase center of 23 S rRNA reveal the site of action of sparsomycin, a universal inhibitor of translation. Tan GT, et al. **J Mol Biol** 1996 Aug 16;261(2):222–30

Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line [see comments] Hochhauser D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1269–75. Comment in: J Natl Cancer Inst 1996 Sep 18;88(18):1255–6.

Mechanism of catecholamine synthesis inhibition by neuropeptide Y: role of Ca2+ channels and protein kinases. McCullough LA, et al. **J Neurochem** 1996 Sep;67(3):1090–9

Effect of cycloheximide and mRNA synthesis inhibition on death of trophically deprived ciliary ganglion neurons in culture. Brusés JL, et al. **J Neurophysiol** 1995 Dec; 74(6):2487–99

Effect of cycloheximide on eclosion hormone sensitivity and the developmental appearance of the eclosion hormone and cGMP regulated phosphoproteins in the CNS of the tobacco hornworm, Manduca sexta. Morton DB, et al. **J Recept Signal Transduct Res** 1995 Apr;15(5):773–86

Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage. Irurzun A, et al. **J Virol** 1995 Dec;69(12):7453–60

Importance of the Glu 160 and Glu 189 residues to the various biological activities of the ribosome inactivating protein trichosanthin. Ng TB, et al. **Life Sci** 1996 May 24; 58(26):2439–46

Partial inhibition of protein synthesis accelerates the synthesis of porphyrin in heme-deficient mutants of Escherichia coli. Nakayashiki T, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):139–46

Sparsomycin and its analogues: a new approach for evaluating their potency as inhibitors of peptide bond formation. Kallia-Raftopoulos S, et al. **Mol Pharmacol** 1996 Jun;49(6):1085–91

D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors. Qin ZH, et al. **Mol Pharmacol** 1995 Oct; 48(4):730–7

Drugs that show protective effects from ricin toxicity in in vitro protein synthesis assays. Thompson WL, et al. **Nat Toxins** 1995;3(5):369–77

Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: effects of vitamins E and C. Kavutcu M, et al. **Nephron** 1996; 72(2):269–74

Preincubation with protein synthesis inhibitors protects cortical neurons against oxygen-glucose deprivation-induced death. Lobner D, et al. **Neuroscience** 1996 May;72(2):335–41

Nitrogen mustard inhibits transcription and translation in a cell free system. Masta A, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3508–15

Cycloheximide inhibits context memory and long-term habituation in the crab Chasmagnathus. Pedreira ME, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):385–95

Inhibitors of protein and RNA synthesis block context memory and long-term habituation in the crab Chasmagnathus. Pedreira ME, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):611–7

Microtubule rearrangement during in vitro maturation of pig oocytes. Effect of cycloheximide. Rozinek J, et al. **Reprod Nutr Dev** 1995;35(6):685–94

TEMPOL, a superoxide dismutase mimic, ameliorates light-induced retinal degeneration. Wang M, et al. **Res Commun Mol Pathol Pharmacol** 1995 Sep; 89(3):291–305

Inhibition by erythromycin of superoxide anion production by human polymorphonuclear leukocytes through the action of cyclic AMP-dependent protein kinase. Mitsuyama T, et al. **Respiration** 1995;62(5):269–73

Application of a protein synthesis inhibitor into the ventral tegmental area, but not the nucleus accumbens, prevents behavioral sensitization to cocaine. Sorg BA, et al. **Synapse** 1995 Jul;20(3):217–24

[Protein synthesis inhibitors stimulate DNA synthesis in resting NIH 3T3 cells] Setkov NA. **Dokl Akad Nauk** 1996 Apr;347(4):552–5 **(Rus)**

[The effect of 2',5'-oligoadenylates on the expression of the cellular proto-oncogene c-myc during the development of Svec's leukemia in rats] Prima VI, et al. **Tsitol Genet** 1995 Nov-Dec;29(6):8–13 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Mycobacterium avium disease: progress at last [editorial; comment] Bates JH. **Am J Respir Crit Care Med** 1996 Jun; 153(6 Pt 1):1737–8. Comment on: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1766–72.

Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease [letter; comment] Frothingham R. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1990–1. Comment on: Am J Respir Crit Care Med 1994 May;149(5):1335–41.

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients [see comments] Wallace RJ Jr, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1766–72. Comment in: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1737–8.

Plasma cell gingivitis: treatment with 2% fusidic acid. Mahler V, et al. **J Am Acad Dermatol** 1996 Jan;34(1):145–6

Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Xu Y, et al. **Leukemia** 1996 Feb;10(2):321–6

PROTEIN SYNTHESIS INHIBITORS

TOXICITY

The binding of ricin to its receptor is not required for the expression of its toxicity. Morino H, et al. **Biol Pharm Bull** 1995 Dec;18(12):1770–2

Mechanism of the formation of megamitochondria in the mouse liver induced by chloramphenicol. Matsuhashi T, et al. **Toxicol Lett** 1996 Jul;86(1):47–54

Effects of bolesatine on a cell line from the SP2/O thymic lymphosarcoma. Basset L, et al. **Toxicology** 1995 Nov 30; 103(2):121–5

PROTEIN TP53 see PROTEIN P53

PROTEIN-TYROSINE KINASE

see related
ONCOGENE PROTEIN PP60(V-SRC)
SRC HOMOLOGY DOMAINS

The JAK-STAT pathway: summary of initial studies and recent advances. Darnell JE Jr. **Recent Prog Horm Res** 1996;51:391–403; discussion 403–4 (75 ref.)

The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)

Abl tyrosine protein kinase. Laneuville P. **Semin Immunol** 1995 Aug;7(4):255–66 (95 ref.)

The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Rawlings DJ, et al. **Semin Immunol** 1995 Aug;7(4):237–46 (81 ref.)

[Src family of protein-tyrosine kinases and their regulator tyrosine kinase, Csk] Okada M. **Seikagaku** 1996 Apr; 68(4):251–64 (94 ref.) **(Jpn)**

ANALYSIS

High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Lamant L, et al. **Blood** 1996 Jan 1; 87(1):284–91

Immunocytochemical localization of protein kinases Yes and Src in amoeboid microglia in culture: association of Yes kinase with vimentin intermediate filaments. Ciesielski-Treska J, et al. **Eur J Cell Biol** 1995 Dec; 68(4):369–76

In vivo association between p56lck and MAP kinase during IL-2-mediated lymphocyte proliferation. Taieb J, et al. **J Immunol** 1995 Dec 15;155(12):5623–30

Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions. Bolon I, et al. **Lab Invest** 1996 Jul;75(1):1–13

Immune complex kinase assays for mitogen-activated protein kinase and MEK. Reuter CW, et al. **Methods Enzymol** 1995; 255:245–56

Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases. Huff JL, et al. **Oncogene** 1996 Jan 18;12(2):299–307

Subcellular localization of the Arg protein tyrosine kinase. Wang B, et al. **Oncogene** 1996 Jul 4;13(1):193–7

ZAP-70 and p72syk are signaling response elements through MHC class II molecules. Kanner SB, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):145–54

ANTAGONISTS & INHIBITORS

Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Corbett JA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1581–7

Attenuation of endothelin-1-induced calcium response by tyrosine kinase inhibitors in vascular smooth muscle cells. Liu CY, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1825–33

Signal transduction interception as a novel approach to disease management. Levitzki A. **Ann N Y Acad Sci** 1995 Sep 7;766:363–8 (22 ref.)

Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Fry DW, et al. **Anticancer Drug Des** 1995 Dec; 10(8):607–22

Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R-associated PTK activity. Million ME, et al. **Anticancer Drug Des** 1996 Mar;11(2):129–53

TPK inhibitors differentially affect IFN-gamma activities. Aharon M, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2071–6

A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization. Ramdas L, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):237–42

The induction of cyclo-oxygenase-2 in human pulmonary epithelial cell culture (A549) activated by IL-1beta is inhibited by tyrosine kinase inhibitors. Akarasereenont P, et al. **Biochem Biophys Res Commun** 1996 Mar 7; 220(1):181–5

Protein tyrosine kinase inhibitors promote amylase secretion and inhibit ornithine decarboxylase induction in sialagogue-stimulated rat parotid explants. Kinoshita F, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):170–4

Tyrosine kinase inhibitors, genistein and herbimycin A, do not block interleukin-1 beta-induced activation of NF-kappa B in rat mesangial cells. Tetsuka T, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):808–12

Genistein, a tyrosine kinase inhibitor, reduces EGF-induced EGF receptor internalization and degradation in human hepatoma HepG2 cells. Yang EB, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):309–17

Possible involvement of a tyrosine kinase-dependent pathway in the regulation of phosphoinositide metabolism by vanadate in normal mouse islets. Jonas JC, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):49–55

Staurosporine-induced thymocyte apoptosis is inhibited by herbimycin A, a specific inhibitor of protein tyrosine kinase. Azuma Y, et al. **Biochem Mol Biol Int** 1995 Nov; 37(4):635–43

Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Mazumder A, et al. **Biochemistry** 1995 Nov 21;34(46):15111–22

Inhibition of PDGF-induced phospholipase C activation by herbimycin A. Kim BY, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):33–6

Inhibition of L-type calcium current by genistein, a tyrosine kinase inhibitor, in pregnant rat myometrial cells. Kusaka M, et al. **Biochim Biophys Acta** 1995 Dec 13; 1240(2):196–200

Genistein inhibition of fast Na+ current in uterine leiomyosarcoma cells is independent of tyrosine kinase inhibition. Kusaka M, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):1–4

Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4] oxazino-[3,4-b]quinazolin-6-one derivatives. Orfi L, et al. **Bioorg Med Chem** 1996 Apr; 4(4):547–51

Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. Carlo-Stella C, et al. **Br J Haematol** 1996 Jun 1;93(3):551–7

Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells. Wijetunge S, et al. **Br J Pharmacol** 1995 Jun;115(3):534–8

The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Stanwell C, et al. **Cancer Res** 1995 Nov 1;55(21):4950–6

Inhibitors of protein tyrosine kinases. Fry DW, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):662–7 (37 ref.)

Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro. Seckl MJ, et al. **Eur J Cancer** 1996 Feb;32A(2):342–5

Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Filipeanu CM, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):29–35

Tyrosine kinase inhibitors regulate serotonin uptake in platelets [published erratum appears in Eur J Pharmacol 1995 Nov 3;286(1):113] Helmeste DM, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R5–7

Modulation of Ca(2+)-activated K+ channel activity by tyrosine kinase inhibitors in vascular smooth muscle cell. Xiong Z, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):117–23

Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Shimokado K, et al. **Exp Cell Res** 1995 Oct;220(2):266–73

Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells. Johnson KL, et al. **FEBS Lett** 1996 Mar 25;383(1-2):1–5

Effect of genistein on amylase release and protein tyrosine phosphorylation in parotid acinar cells. Takuma T, et al. **FEBS Lett** 1996 Feb 12;380(1-2):83–6

Tyrosine kinase inhibition: an approach to drug development. Keyse SM. **Hum Exp Toxicol** 1995 Jul;14(7):618–9

Pharmacologic study of basophil histamine release induced by monocyte chemotactic protein-1 with kinase inhibitors. Suzuki M, et al. **Int Arch Allergy Immunol** 1996 Sep; 111(1):18–22

Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Clark JW, et al. **Int J Cancer** 1996 Jan 17;65(2):186–91

rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Imamura F, et al. **Int J Cancer** 1996 Mar 1;65(5):627–32

Synthetic Tyr-phospho and non-hydrolyzable phosphonopeptides as PTKs and TC-PTP inhibitors. Ruzza P, et al. **Int J Pept Protein Res** 1995 Dec; 46(6):535–46

Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. Fredenhagen A, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1355–8

Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. Azuma Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):312–8

Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex. Kwon HJ, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):221–8

Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. Mahon TM, et al. **J Biol Chem** 1995 Dec 1; 270(48):28557–64

Short circuiting stress protein expression via a tyrosine kinase inhibitor, herbimycin A. Hegde RS, et al. **J Cell Physiol** 1995 Oct;165(1):186–200

Specific induction of the 70-kD heat stress proteins by the tyrosine kinase inhibitor herbimycin-A protects rat neonatal cardiomyocytes. A new pharmacological route to stress protein expression? Morris SD, et al. **J Clin Invest** 1996 Feb 1;97(3):706–12

Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. Pazdrak K, et al. **J Immunol** 1995 Nov 1;155(9):4454–8

Differential effects of tyrosine kinase inhibitors on tumor necrosis factor and nitric oxide production by murine macrophages. Orlicek SL, et al. **J Infect Dis** 1996 Sep; 174(3):638–42

Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. Vanichkin A, et al. **J Infect Dis** 1996 Apr; 173(4):927–33

Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives. Million ME, et al. **J Med Chem** 1995 Nov 10;38(23):4693–703

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Rewcastle GW, et al. **J Med Chem** 1996 Feb 16;39(4):918–28

Inhibition of formation of filopodia after axotomy by inhibitors of protein tyrosine kinases. Goldberg DJ, et al. **J Neurobiol** 1995 Aug;27(4):553–60

The tyrosine kinase inhibitor genistein increases endogenous dopamine release from normal and weaver mutant mouse striatal slices. Bare DJ, et al. **J Neurochem** 1995 Nov; 65(5):2096–104

Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. Ho AK, et al. **J Neurochem** 1995 Oct;65(4):1597–603

Inhibition of protein tyrosine kinases impairs axon extension in the embryonic optic tract. Worley T, et al. **J Neurosci** 1996 Apr 1;16(7):2294–306

Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells. Sion-Vardy N, et al. **J Surg Res** 1995 Dec;59(6):675–80

Tyrosine kinase inhibition suppresses angiotensin contraction in hypertensive and normotensive small resistance arteries. Malloy LG, et al. **Life Sci** 1996;58(19):PL317–24

Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS. Auvinen M, et al. **Mol Cell Biol** 1995 Dec;15(12):6513–25

Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Kondapaka BS, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):53–8

Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor. Tseng CP, et al. **Mol Pharmacol** 1996 Aug; 50(2):249–57

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Druker BJ, et al. **Nat Med** 1996 May;2(5):561–6

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Meydan N, et al. **Nature** 1996 Feb 15; 379(6566):645–8

Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. Oude Weernink PA, et al. **Neurosurgery** 1996 Jan;38(1):108–13; discussion 113–4

Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells. Akagi T, et al. **Oncogene** 1996 Jul 18;13(2):399–405

Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Zhang L, et al. **Oncogene** 1996 Feb 1;12(3):571–6

Capacitative Ca2+ influx and a Ca2+-dependent nonselective cation pathway are discriminated by genistein in mouse pancreatic acinar cells. Pfeiffer F, et al. **Pflugers Arch** 1995 Oct;430(6):916–22

The effect of purified extract of Fagopyrum esculentum (buckwheat) on protein kinases involved in signal transduction pathways. Samel D, et al. **Planta Med** 1996 Apr;62(2):106–10

Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Sengupta TK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9499–504

Protein tyrosine kinase inhibitors. Groundwater PW, et al. **Prog Med Chem** 1996;33:233–329 (277 ref.)

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Xia Z, et al. **Science** 1995 Nov 24; 270(5240):1326–31

[Advances in the research on tyrosine protein kinase inhibitors] Pang SH, et al. **Yao Hsueh Hsueh Pao** 1996; 31(1):75–80 (43 ref.) **(Chi)**

[Inhibitors of protein-tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin-Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**

BIOSYNTHESIS

Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Gurniak CB, et al. **Blood** 1996 Apr 15;87(8):3151–60

Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Martin JH, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):47-57

Monoclonal antibody binding to a receptor on nonspecific cytotoxic cells (NCC) increases the expression of proto-oncogene kinases and protein kinase C. Jaso-Friedmann L, et al. **Cell Signal** 1995 Jul;7(5):463-70

Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells. Foxwell BM, et al. **Eur J Immunol** 1995 Nov;25(11):3041-6

Thyroid hormone promotes BCL-2 expression and prevents apoptosis of early differentiating cerebellar granule neurons. Muller Y, et al. **Int J Dev Neurosci** 1995 Dec; 13(8):871-85

Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells. David M, et al. **J Biol Chem** 1996 Mar 1;271(9):4585-8

Syk mutation in Jurkat E6-derived clones results in lack of p72syk expression. Fargnoli J, et al. **J Biol Chem** 1995 Nov 3;270(44):26533-7

Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. Katagiri K, et al. **J Biol Chem** 1996 May 10;271(19):11557-62

Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. Verbsky JW, et al. **J Biol Chem** 1996 Jun 14;271(24):13976-80

Interleukin-11 induces complex formation of Grb2, Fyn, and JAK2 in 3T3L1 cells. Wang XY, et al. **J Biol Chem** 1995 Nov 24;270(47):27999-8002

ET-1 and PDGF BB induce MEK mRNA and protein expression in mesangial cells. Schramek H, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S95-9

Comparison of p56lck and p59fyn protein expression in thymocyte subsets, peripheral T cells, NK cells, and lymphoid cell lines. Olszowy MW, et al. **J Immunol** 1995 Nov 1;155(9):4236-40

Regulation of JAK3 expression and activation in human B cells and B cell malignancies. Tortolani PJ, et al. **J Immunol** 1995 Dec 1;155(11):5220-6

Integrin engagement induces monocyte procoagulant activity and tumor necrosis factor production via induction of tyrosine phosphorylation. Dackiw AP, et al. **J Surg Res** 1996 Aug;64(2):210-5

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Borrello MG, et al. **Mol Cell Biol** 1996 May;16(5):2151-63

Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells. Hoehn GT, et al. **Oncogene** 1996 Feb 15;12(4):903-13

Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain. Xu S, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5291-5

BLOOD

GTPgammaS-stimulated phospholipase D activation in human neutrophils occurs by protein kinase C-dependent and -independent pathways but not tyrosine kinases. Lowe GM, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):484-90

Differential mobilization of tyrosine kinases in human platelets stimulated with thrombin or thrombin receptor agonist peptide. Satoh K, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1084-9

Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Rodríguez-Liñares B, et al. **Biochem J** 1996 May 15;316 (Pt 1):93-8

Investigation of the role of protein kinase C and tyrosine kinases during the rapid and sustained release of superoxide from adherent human neutrophils. Lindsay MA, et al. **Biochem Soc Trans** 1996 Feb;24(1):67S

Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. Brizzi MF, et al. **J Biol Chem** 1996 Feb 16; 271(7):3562-7

Endogenous reactive oxygen intermediates activate tyrosine kinases in human neutrophils. Brumell JH, et al. **J Biol Chem** 1996 Jan 19;271(3):1455-61

The FcgammaRII receptor triggers pp125FAK phosphorylation in platelets. Haimovich B, et al. **J Biol Chem** 1996 Jul 5;271(27):16332-7

Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. Ichinohe T, et al. **J Biol Chem** 1995 Nov 24;270(47):28029-36

Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia. Kohno T, et al. **Leuk Res** 1996 Mar;20(3):221-7

Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy. Sowers JR, et al. **Metabolism** 1995 Oct;44(10):1308-13

CHEMISTRY

The role of the unique motifs in the amino-terminal region of PKN on its enzymatic activity. Kitagawa M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):963-8

The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Colwill K, et al. **EMBO J** 1996 Jan 15;15(2):265-75

CD4-dependent and -independent association of protein tyrosine kinases to the T cell receptor/CD3 complex of CD4+ mouse T lymphocytes. Criado G, et al. **Eur J Immunol** 1996 Jun;26(6):1228-34

Linear and cyclic synthetic peptides related to the main autophosphorylation site of the Src tyrosine kinases as substrates and inhibitors of Lyn. Ruzza P, et al. **Int J Pept Protein Res** 1995 Jun;45(6):529-39

Detection of a physical and functional interaction between Csk and Lck which involves the SH2 domain of Csk and is mediated by autophosphorylation of Lck on tyrosine 394. Bougeret C, et al. **J Biol Chem** 1996 Mar 29; 271(13):7465-72

Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. Butch ER, et al. **J Biol Chem** 1996 Feb 23;271(8):4230-5

Sperm-egg binding protein or proto-oncogene? [letter; comment] Bork P. **Science** 1996 Mar 8;271(5254):1431-2; discussion 1434-5. Comment on: Science 1995 Jul 7;269(5220):83-6.

Sperm-egg binding protein or proto-oncogene? [letter; comment] Tsai JY, et al. **Science** 1996 Mar 8; 271(5254):1432-4; discussion 1434-5. Comment on: Science 1995 Jul 7;269(5220):83-6.

The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct. Gosser YQ, et al. **Structure** 1995 Oct 15;3(10):1075-86

Why two heads are better. Mayer BJ. **Structure** 1995 Oct 15;3(10):977-80 (27 ref.)

Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide. Narula SS, et al. **Structure** 1995 Oct 15;3(10):1061-73

DEFICIENCY

Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Lowell CA, et al. **Blood** 1996 Mar 1;87(5):1780-92

An examination of focal adhesion formation and tyrosine phosphorylation in fibroblasts isolated from src-, fyn-, and yes- mice. Bockholt SM, et al. **Cell Adhes Commun** 1995 May;3(2):91-100

Impaired expansion of mouse B cell progenitors lacking Btk. Kerner JD, et al. **Immunity** 1995 Sep;3(3):301-12

Defective B cell development and function in Btk-deficient mice. Khan WN, et al. **Immunity** 1995 Sep;3(3):283-99

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Park SY, et al. **Immunity** 1995 Dec; 3(6):771-82

Syk deficiency--a knockout for B-cell development. Harnett M. **Immunol Today** 1996 Jan;17(1):4 (6 ref.)

A mutation in zap-70 protein tyrosine kinase results in a selective immunodeficiency. Roifman CM. **J Clin Immunol** 1995 Nov;15(6 Suppl):52S-62S

In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. Candotti F, et al. **J Exp Med** 1996 Jun 1; 183(6):2687-92

Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes. Gelfand EW, et al. **J Exp Med** 1995 Oct 1;182(4):1057-65

DRUG EFFECTS

Induction of M-CSF receptor and its mRNA, and activation of tyrosine kinase in peripheral monocytes by oestradiol-17 beta and progesterone. Fujimoto J, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):399-404

In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Sawutz DG, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1631-8

Cell protein cross-linking by erbstatin and related compounds. Stanwell C, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):475-80

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Xu X, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):527-34

Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Malecka-Panas E, et al. **Carcinogenesis** 1996 Feb; 17(2):233-7

Effect of tumor necrosis factor-alpha on insulin-stimulated mitogen-activated protein kinase cascade in cultured rat skeletal muscle cells. Begum N, et al. **Eur J Biochem** 1996 May 15;238(1):214-20

Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. Mueller DL, et al. **J Immunol** 1996 Mar 1;156(5):1764-71

IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. Murata T, et al. **J Immunol** 1996 Apr 15;156(8):2972-8

Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. LeSauteur L, et al. **J Neurosci** 1996 Feb 15;16(4):1308-16

Formation of focal adhesion and spreading of polarized human colon cancer cells in association with tyrosine phosphorylation of paxillin in response to phorbol ester. Sakamoto M, et al. **Lab Invest** 1996 Jan;74(1):199-208

GENETICS

Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma. Collins KA, et al. **Am J Dermatopathol** 1995 Oct;17(5):429-38

Discordant phenotype in siblings with X-linked agammaglobulinemia. Bykowsky MJ, et al. **Am J Hum Genet** 1996 Mar;58(3):477-83

Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers. Hagemann TL, et al. **Am J Med Genet** 1995 Nov 6; 59(2):188-92

Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia. Schuster V, et al. **Am J Med Genet** 1996 May 3;63(1):318-22

Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Bolon I, et al. **Am J Pathol** 1995 Nov;147(5):1298-310

cDNA cloning and characterization of rat Clk3, a LAMMER kinase predominately expressed in testis. Becker W, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):63-7

Genomic structure of carp mitogen-activated protein kinase kinase 1 gene. Leu JH, et al. **Biochim Biophys Acta** 1996 May 2;1306(2-3):133-6

Invasive tumors induce c-ets1 transcription factor expression in adjacent stroma. Calmels TP, et al. **Biol Cell** 1995; 84(1-2):53-61

Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Elmberger PG, et al. **Blood** 1995 Nov 1; 86(9):3517-21

Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Hashimoto S, et al. **Blood** 1996 Jul 15;88(2):561-73

Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites. Himmelmann A, et al. **Blood** 1996 Feb 1;87(3):1036-44

Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Sarris AH, et al. **Blood** 1996 Sep 1;88(5):1771-9

Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene. Villa A, et al. **Blood** 1996 Aug 1;88(3):817-23

Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Wood GS, et al. **Blood** 1996 Sep 1; 88(5):1765-70

Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Yee HT, et al. **Blood** 1996 Feb 1; 87(3):1081-8

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S-16S (30 ref.)

The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Saegusa M, et al. **Cancer** 1995 Dec 1;76(11):2297-303

marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs. Hou XS, et al. **Cell** 1996 Feb 9;84(3):411-9

The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein. Lock P, et al. **Cell** 1996 Jan 12;84(1):23-4

Expression of ZAP-70 gene in the developing thymus and various nonlymphoid tissues of embryonic and adult mice. Ishijima SA, et al. **Cell Immunol** 1995 Oct 15;165(2):278-83

Mouse p87wee1 kinase is regulated by M-phase specific phosphorylation. Honda R, et al. **Chromosome Res** 1995 Aug;3(5):300-8

The spectrum of mutations in Btk that cause X-linked agammaglobulinemia. Conley ME, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S192-7 (33 ref.)

Structural basis for X-linked agammaglobulinemia (XLA): mutations at interacting Btk residues R562, W563, and A582. Maniar HS, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S198-202

Molecular and genetic insights into the role of protein tyrosine kinases in T cell receptor signaling. Weiss A. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S158-62 (30 ref.)

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Afar DE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:589-94 (49 ref.)

Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Jung M, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1245-65

The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors

in human fibroblasts. Gilles F, et al. **Exp Cell Res** 1996 Feb 1;222(2):370–8

Genomic structure and alternative splicing of the murine bhk/ctk/ntk gene. Erahler MA, et al. **FEBS Lett** 1995 Nov 13;375(1–2):50–2

Structure and developmental regulation of the murine ctk gene. Brinkley PM, et al. **Gene** 1995 Oct 3;163(2):179–84

The Drosophila melanogaster homolog of the mammalian MAPK–activated protein kinase–2 (MAPKAPK–2) lacks a proline–rich N–terminus. Larochelle S, et al. **Gene** 1995 Oct 3;163(2):209–14

Production, purification and characterization of non–myristylated human T–cell protein tyrosine kinase in a baculovirus expression system. Lehr RV, et al. **Gene** 1996 Mar 9;169(2):275–9

Molecular variant of the NPM–ALK rearrangement of Ki–1 lymphoma involving a cryptic ALK splice site. Ladanyi M, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):173–7

A search for proteins that interact genetically with histone H3 and H4 amino termini uncovers novel regulators of the Swe1 kinase in Saccharomyces cerevisiae. Ma XJ, et al. **Genes Dev** 1996 Jun 1;10(11):1327–40

Genetic interactions between the Drosophila Abelson (Abl) tyrosine kinase and failed axon connections (fax), a novel protein in axon bundles. Hill KK, et al. **Genetics** 1995 Oct; 141(2):595–606

Genomic organization of the mouse fibroblast growth factor receptor 3 (Fgfr3) gene. Perez–Castro AV, et al. **Genomics** 1995 Nov 20;30(2):157–62

Transfection of human ovarian cancer cells with the HER–2/neu receptor tyrosine kinase induces a selective increase in PTP–H1, PTP–1B, PTP–alpha expression. Wiener JR, et al. **Gynecol Oncol** 1996 May;61(2):233–40

Locoregional immuno–chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):440–7 (38 ref.)

Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization. Inazawa J, et al. **Hum Genet** 1996 Oct;98(4):508–10

Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein–tyrosine kinase gene of the EPH family. Ikegaki N, et al. **Hum Mol Genet** 1995 Nov;4(11):2033–45

Physical mapping of the Tec and Gabrb1 loci reveals that the Wsh mutation on mouse chromosome 5 is associated with an inversion. Nagle DL, et al. **Hum Mol Genet** 1995 Nov;4(11):2073–9

Improved oligonucleotide primer set for molecular diagnosis of X–linked agammaglobulinaemia: predominance of amino acid substitutions in the catalytic domain of Bruton's tyrosine kinase. Vořechovský I, et al. **Hum Mol Genet** 1995 Dec;4(12):2403–5

Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Clark DE, et al. **Hum Reprod** 1996 May;11(5):1090–8

Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Park H, et al. **Immunity** 1996 May;4(5):515–25

Induction of lytic pathways in T cell clones derived from wild–type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)

BTKbase: a database of XLA–causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)

The protein tyrosine kinase Fyn activates transcription from the HIV promoter via activation of NF kappa B–like DNA–binding proteins. Hohashi N, et al. **Int Immunol** 1995 Nov;7(11):1851–9

An activating mutation in the ATP binding site of the ABL kinase domain. Allen PB, et al. **J Biol Chem** 1996 Aug 9;271(32):19585–91

Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. Avraham S, et al. **J Biol Chem** 1995 Nov 17; 270(46):27742–51

Syk mutation in Jurkat E6–derived clones results in lack of p72syk expression. Fargnoli J, et al. **J Biol Chem** 1995 Nov 3;270(44):26533–7

The mitogen–activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. Gillespie–Brown J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28092–6

A kinase–deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. Lai KS, et al. **J Biol Chem** 1995 Oct 20;270(42):25028–36

Cloning and characterization of a functional promoter of the rat pp120 gene, encoding a substrate of the insulin receptor tyrosine kinase. Najjar SM, et al. **J Biol Chem** 1996 Apr 12;271(15):8809–17

Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho–binding domain. Reid T, et al. **J Biol Chem** 1996 Jun 7;271(23):13556–60

Tyrosine protein kinase expression in long–term quiescent WI–38 cells following growth factor simulation. Korcz A, et al. **J Cell Biochem** 1995 Sep;59(1):42–52

Multiple features of the p59fyn src homology 4 domain define a motif for immune–receptor tyrosine–based activation motif (ITAM) binding and for plasma membrane localization. Timson Gauen LK, et al. **J Cell Biol** 1996 Jun;133(5):1007–15

The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. Weiss E, et al. **J Cell Biol** 1996 Jan;132(1–2):111–23

A mutation in zap–70 protein tyrosine kinase results in a selective immunodeficiency. Roifman CM. **J Clin Immunol** 1995 Nov;15(6 Suppl):52S–62S

In vitro correction of JAK3–deficient severe combined immunodeficiency by retroviral–mediated gene transduction. Candotti F, et al. **J Exp Med** 1996 Jun 1; 183(6):2687–92

Sequential expression of Trks A, B, and C in the regenerating olfactory neuroepithelium. Roskams AJ, et al. **J Neurosci** 1996 Feb 15;16(4):1294–307

Distribution of erb–B2, erb–B3, and erb–B4 in the developing avian nervous system. Francoeur JR, et al. **J Neurosci Res** 1995 Aug 15;41(6):836–45

The murine form of TXK, a novel TEC kinase expressed in thymus maps to chromosome 5. Haire RN, et al. **Mamm Genome** 1995 Jul;6(7):476–80

Microsatellite instability in IVS3 of murine c–fes gene: tumor–associated rearrangement and mammalian divergence. Volpi L, et al. **Mamm Genome** 1996 Sep; 7(9):682–5

The myeloid–cell–specific c–fes promoter is regulated by Sp1, PU.1, and a novel transcription factor. Heydemann A, et al. **Mol Cell Biol** 1996 Apr;16(4):1676–86

Retinoic acid–mediated increase in TrkA expression is sufficient to elicit NGF–dependent survival of sympathetic neurons. von Holst A, et al. **Mol Cell Neurosci** 1995 Jun; 6(3):185–98

The glypiated neuronal cell adhesion molecule contactin/F11 complexes with src–family protein tyrosine kinase Fyn. Zisch AH, et al. **Mol Cell Neurosci** 1995 Jun;6(3):263–79

Neurotoxic injury in rat hippocampus differentially affects multiple trkB and trkC transcripts. Belluardo N, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):1–4

Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin–/CD38– stem/progenitor cells. Hoehn GT, et al. **Oncogene** 1996 Feb 15;12(4):903–13

Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Ishino M, et al. **Oncogene** 1995 Dec 7;11(11):2331–8

Human Txk: genomic organization, structure and contiguous physical linkage with the Tec gene. Ohta Y, et al. **Oncogene** 1996 Feb 15;12(4):937–42

Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP–70. Elder ME. **Pediatr Res** 1996 May; 39(5):743–8

Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Mallick–Wood CA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9704–9

Bacterial expression, purification and preliminary kinetic description of the kinase domain of v–fps. Gish G, et al. **Protein Eng** 1995 Jun;8(6):609–14

[Does the c–ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Protein tyrosine kinases in the initiation of antigen receptor signaling. Bolen JB. **Curr Opin Immunol** 1995 Jun; 7(3):306–11 (54 ref.)

Cytokine receptor signaling mechanisms. Karnitz LM, et al. **Curr Opin Immunol** 1995 Jun;7(3):320–6 (60 ref.)

Production of monoclonal antibodies to Bruton's tyrosine kinase. Stewart DM, et al. **Hybridoma** 1995 Jun;14(3):243–6

Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Liao XC, et al. **Immunity** 1995 Dec;3(6):757–69

Binding of FimD on Bordetella pertussis to very late antigen–5 on monocytes activates complement receptor type 3 via protein tyrosine kinases. Hazenbos WL, et al. **J Immunol** 1995 Oct 15;155(8):3972–8

Neurotrophin receptor proteins immunoreactivity in the rat cerebellar cortex as a function of age. Torres JM, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):1–9

ISOLATION & PURIFICATION

Isolation of MEK5 and differential expression of alternatively spliced forms. English JM, et al. **J Biol Chem** 1995 Dec 1;270(48):28897–902

Purification and characterization of human ZAP–70 protein–tyrosine kinase from a baculovirus expression system. Isakov N, et al. **J Biol Chem** 1996 Jun 28; 271(26):15753–61

Identification of a 95–kDa WEE1–like tyrosine kinase in HeLa cells. Parker LL, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9638–42

METABOLISM

JAK2 is constitutively associated with c–Kit and is phosphorylated in response to stem cell factor. Linnekin D, et al. **Acta Haematol** 1996;95(3–4):224–8

Regulation of c–myb expression in ML–1 human myeloblastic leukemia cells by c–ets–1 protein. Bloch A, et al. **Adv Enzyme Regul** 1995;35:35–41

Activation of MAP kinase and translocation with HSP27 in bombesin–induced contraction of rectosigmoid smooth muscle. Yamada H, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G683–91

Measurement of the protein tyrosine kinase activity of c–src using time–resolved fluorometry of europium chelates. Braunwalder AF, et al. **Anal Biochem** 1996 Jul 1; 238(2):159–64

A solid–phase assay for the determination of protein tyrosine kinase activity of c–src using scintillating microtitration plates. Braunwaler AF, et al. **Anal Biochem** 1996 Feb 1; 234(1):23–6

Screening of protein tyrosine kinases activated during neural induction in Xenopus. Dupont H, et al. **Anal Biochem** 1996 May 15;237(1):42–8

Oestrogen induces c–Ha–ras expression in the fibroblasts derived from human uterine endometrium. Fujimoto J, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):487–92

Interleukin–11 induces tyrosine phosphorylation, and c–jun and c–fos mRNA expression in human K562 and U937 cells. Adunyah SE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:296–9

Cytokine signal transduction through a homo– or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Molecular dissection of the growth hormone receptor. Identification of distinct cytoplasmic domains corresponding to different signaling pathways. Nielsen JH, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:481–3

Csk associates with the TCR zeta and epsilon chains through its SH2 domain. Rafnar T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:206–8

Signal transduction mediated by the T–cell antigen receptor. Samelson LE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:157–72 (68 ref.)

IL–2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL–2 receptor. Taniguchi T, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:235–44 (22 ref.)

The acute insulin–like effects of growth hormone in primary adipocyte–signaling mechanisms. Tornqvist H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:469–71

Molecular and genetic insights into T–cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149–56 (39 ref.)

Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Owens LV, et al. **Ann Surg Oncol** 1996 Jan;3(1):100–5

Transcriptional responses to polypeptide ligands: the JAK–STAT pathway. Schindler C, et al. **Annu Rev Biochem** 1995;64:621–51 (145 ref.)

A synthetic peptidic substrate of minimal size and semioptimal sequence for the protein tyrosine kinase pp60c–src. Ramdas L, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):73–8

Protein tyrosine phosphorylation induced by epidermal growth factor and insulin–like growth factor–I in a rat clonal dental pulp–cell line. Kawase T, et al. **Arch Oral Biol** 1995 Oct;40(10):921–9

In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Silvagno F, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1857–65

Role of protein phosphatase 2A in the regulation of mitogen–activated protein kinase activity in ventricular cardiomyocytes. Braconi Quintaje SB, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):539–47

Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'–triphosphate. Bronte V, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):344–51

Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin–11. Fuhrer DK, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):289–96

Analysis of CSK homologous kinase (CHK/HYL) in hematopoiesis by utilizing gene knockout mice. Hamaguchi I, et al. **Biochem Biophys Res Commun** 1996 Jul 5; 224(1):172–9

Integrin stimulation decreases tyrosine phosphorylation and activity of focal adhesion kinase in thymocytes. Kanazawa S, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):438–45

The role of the unique motifs in the amino–terminal region of PKN on its enzymatic activity. Kitagawa M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):963–8

Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3. Nagata Y, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):785–9

Shear stress activates cytosolic phospholipase A2 (cPLA2) and MAP kinase in human endothelial cells. Pearce MJ, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):500–4

Hematopoietic cell phosphatase (HCP) regulates p56LCK phosphorylation and ZAP–70 binding to T cell receptor zeta chain. Raab M, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):50–7

Phosphatidylinositol 3–kinase activity is required for the activation process of focal adhesion kinase by platelet–derived growth factor. Saito Y, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):23–6

TPO/c-mpl ligand induces tyrosine phosphorylation of multiple cellular proteins including proto-oncogene products, Vav and c-Cbl, and Ras signaling molecules. Sasaki K, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):338–47

NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Suzuki T, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):582–8

Interaction of the c-cbl proto-oncogene product with the Tyk-2 protein tyrosine kinase. Uddin S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):833–8

Phosphorylation of phosphatase-1alpha in cells expressing v-src. Villa-Moruzzi E, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):863–7

Involvement of rho p21 in cyclic strain-induced tyrosine phosphorylation of focal adhesion kinase (pp125FAK), morphological changes and migration of endothelial cells. Yano Y, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):508–15

Cyclic AMP stimulates the phosphorylation and activation of p42 and p44 mitogen-activated protein kinases in 3T3-F442A preadipocytes. Yarwood SJ, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):734–9

Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Blanco A, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):419–23

Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Bogoyevitch MA, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):115–21

Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Börsch-Haubold AG, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):207–12

Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain. Cooray P, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):41–7

A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B. Cosma MP, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):397–400

Possible involvement of a tyrosine kinase-dependent pathway in the regulation of phosphoinositide metabolism by vanadate in normal mouse islets. Jonas JC, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):49–55

Inhibition of endothelin- and phorbol ester-stimulated tyrosine kinase activity by corticotrophin in the rat adrenal zona glomerulosa. Kapas S, et al. **Biochem J** 1996 Feb 1; 313 (Pt 3):867–72

Insulin and insulin-like growth factor-1 stimulate dephosphorylation of paxillin in parallel with focal adhesion kinase. Konstantopoulos N, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):387–90

The differential regulation of cyclic AMP by sphingomyelin-derived lipids and the modulation of sphingolipid-stimulated extracellular signal regulated kinase-2 in airway smooth muscle. Pyne S, et al. **Biochem J** 1996 May 1;315 (Pt 3):917–23

Focal adhesion kinase (p125FAK) and paxillin are substrates for sphingomyelinase-induced tyrosine phosphorylation in Swiss 3T3 fibroblasts. Sasaki T, et al. **Biochem J** 1996 May 1;315 (Pt 3):1035–40

Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin. Skoudy A, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):279–84

Molecular evidence for the direct involvement of a protein kinase C in developmental and behavioural susceptibility to tumour-promoting phorbol esters in Caenorhabditis elegans. Tabuse Y, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):69–74

Protein tyrosine kinases regulate agonist-stimulated prostacyclin release but not von Willebrand factor secretion from human umbilical vein endothelial cells. Wheeler-Jones CP, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):407–16

Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor [published erratum appears in Biochem J 1996 Feb 1;313(Pt 3):1047] Yanaga F, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):471–8

Stimulation of prostacyclin release by endothelial ATP receptors requires activation of protein kinase C and tyrosine kinases. Brown CA, et al. **Biochem Soc Trans** 1996 Feb;24(1):55S

Calcium signalling in human colonic epithelial cells via tyrosine kinase and G-protein linked receptors. Wilkinson GF, et al. **Biochem Soc Trans** 1995 Aug;23(3):459S

Insight into tyrosine phosphorylation in v-Fps using proton inventory techniques. Adams JA. **Biochemistry** 1996 Aug 20;35(33):10949–56

Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated. Boerner RJ, et al. **Biochemistry** 1996 Jul 23;35(29):9519–25

Purification of bovine thymus cytosolic C-terminal Src kinase (CSK) and demonstration of differential efficiencies of phosphorylation and inactivation of p56lyn and pp60c-src by CSK. Cheng HC, et al. **Biochemistry** 1996 Sep 10;35(36):11874–87

SH2 domains mediate the sequential phosphorylation of HS1 protein by p72syk and Src-related protein tyrosine kinases. Ruzzene M, et al. **Biochemistry** 1996 Apr 23;35(16):5327–32

Replacement of the conserved tyrosine 1210 by phenylalanine in the insulin receptor affects insulin-induced dephosphorylation of focal adhesion kinase but leaves other responses intact. Van der Zon GC, et al. **Biochemistry** 1996 Aug 13;35(32):10377–82

Rate-determining steps for tyrosine phosphorylation by the kinase domain of v-fps. Wang C, et al. **Biochemistry** 1996 Feb 6;35(5):1533–9

Association of phosphatidylinositol 3-kinase, via the SH2 domains of p85, with focal adhesion kinase in polyoma middle t-transformed fibroblasts. Bachelot C, et al. **Biochim Biophys Acta** 1996 Mar 27;1311(1):45–52

cDNA cloning and characterization of rat Clk3, a LAMMER kinase predominately expressed in testis. Becker W, et al. **Biochim Biophys Acta** 1996 Jun 5;1312(1):63–7

Non-receptor cytosolic protein tyrosine kinases from various rat tissues. Elberg G, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):299–306

Cell adhesion to substratum and activation of tyrosine kinases are essentially required for G1/S phase transition in BALB/c 3T3 fibroblasts. Kuzumaki T, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):185–92

Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):73–6 (61 ref.)

Analysis of the T-cell activation signaling pathway mediated by tyrosine kinases, protein kinase C, and Ras protein, which is modulated by intracellular cyclic AMP. Ohtsuka T, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):223–32

Identification of GIYWHHY as a novel peptide substrate for human p60c-src protein tyrosine kinase. Lou Q, et al. **Bioorg Med Chem** 1996 May;4(5):677–82

Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Barge RM, et al. **Blood** 1996 Mar 15;87(6):2148–53

Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Haimovich B, et al. **Blood** 1996 Jan 1;87(1):152–61

Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia [letter] Kanwar VS, et al. **Blood** 1996 Jun 1; 87(11):4911–2

Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Li J, et al. **Blood** 1996 Jul 15; 88(2):417–28

Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Manie SN, et al. **Blood** 1996 Mar 1;87(5):1855–61

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)

Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Nicholson SE, et al. **Blood** 1995 Nov 15;86(10):3698–704

Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Novak U, et al. **Blood** 1995 Oct 15;86(8):2948–56

The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Rauprich P, et al. **Blood** 1995 Dec 15;86(12):4500–5

JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Weiler SR, et al. **Blood** 1996 May 1;87(9):3688–93

Tyrosine phosphorylation of 100–130 kDa proteins in lung cancer correlates with poor prognosis. Nishimura M, et al. **Br J Cancer** 1996 Sep;74(5):780–7

Growth factor induction of cytosolic protein tyrosine kinase activity in human haemopoietic progenitor cells isolated by flow cytometry. Harvey KA, et al. **Br J Haematol** 1996 Jun 1;93(3):515–26

Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Akarasereenont P, et al. **Br J Pharmacol** 1995 Jun;115(3):401–8

The activation and nuclear translocation of extracellular signal-regulated kinases (ERK-1 and -2) appear not to be required for elongation of neurites in PC12D cells. Sano M, et al. **Brain Res** 1995 Aug 7;688(1–2):213–8

Chromium induces a persistent activation of mitogen-activated protein kinases by a redox-sensitive mechanism in H4 rat hepatoma cells. Kim G, et al. **Cancer Res** 1996 May 1;56(9):2045–51

Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Tallett A, et al. **Cancer Res** 1996 Sep 15;56(18):4255–63

Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)

Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Lee CH, et al. **Cell** 1996 Jun 14;85(6):931–42

MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Sieweke MH, et al. **Cell** 1996 Apr 5;85(1):49–60

Differential basal protein tyrosine phosphorylation in natural killer (NK) and T cells: a biochemical correlate of lymphoid functional activity. McVicar DW, et al. **Cell Immunol** 1996 May 1;169(2):302–8

The tyrosine phosphorylation of a p72syk-like protein in activated murine resident peritoneal macrophages. Abu-Lawi KI, et al. **Cell Mol Biol Res** 1995;41(1):49–58

Multiple protein kinase activities required for activation of sperm flagellar motility. Chaudhry PS, et al. **Cell Motil Cytoskeleton** 1995;32(1):65–79

Comparative analysis of chemotaxis in Dictyostelium using a radial bioassay method: protein tyrosine kinase activity is required for chemotaxis to folate but not to cAMP. Browning DD, et al. **Cell Signal** 1995 Jul;7(5):481–9

Activation of p42erk2 MAPK and p90rsk by IL-2 occurs independently of protein kinase C. Franklin RA, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):116–22

Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727–9 (12 ref.)

Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Parsons JT. **Curr Opin Cell Biol** 1996 Apr;8(2):146–52 (47 ref.)

Nuclear tyrosine kinases: from Abl to WEE1. Pendergast AM. **Curr Opin Cell Biol** 1996 Apr;8(2):174–81 (46 ref.)

Protein tyrosine phosphatases in signaling. Streuli M. **Curr Opin Cell Biol** 1996 Apr;8(2):182–8 (81 ref.)

Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579–87 (72 ref.)

Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Kirken RA, et al. **Cytokine** 1995 Oct;7(7):689–700

Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Ockenfels HM, et al. **Dermatology** 1995;191(3):217–25

Protein tyrosine kinase activity during egg activation is important for morphogenesis at gastrulation in the sea urchin embryo. Kinsey WH. **Dev Biol** 1995 Dec; 172(2):704–7

Increased phosphorylation of focal adhesion kinase in diabetic rat kidney glomeruli. Clark S, et al. **Diabetologia** 1995 Oct;38(10):1131–7

Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Suárez A, et al. **Diabetologia** 1995 Nov;38(11):1262–70

PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation. Ali S, et al. **EMBO J** 1996 Jan 2;15(1):135–42

Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. Beadling C, et al. **EMBO J** 1996 Apr 15; 15(8):1902–13

Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. Ben-Levy R, et al. **EMBO J** 1995 Dec 1;14(23):5920–30

The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Colwill K, et al. **EMBO J** 1996 Jan 15;15(2):265–75

Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system. Huang CY, et al. **EMBO J** 1996 May 1;15(9):2169–73

A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. Lee CH, et al. **EMBO J** 1995 Oct 16; 14(20):5006–15

Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. Mainiero F, et al. **EMBO J** 1995 Sep 15;14(18):4470–81

Phosphorylation of Drosophila Jun by the MAP kinase rolled regulates photoreceptor differentiation. Peverali FA, et al. **EMBO J** 1996 Aug 1;15(15):3943–50

Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. Salmeron A, et al. **EMBO J** 1996 Feb 15;15(4):817–26

Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. Yoshimura A, et al. **EMBO J** 1996 Mar 1;15(5):1055–63

Growth regulation of the human papillary thyroid cancer cell line by protein tyrosine kinase and cAMP-dependent protein kinase. Hishinuma A, et al. **Endocr J** 1994 Aug; 41(4):399–407

Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Chow JC, et al. **Endocrinology** 1996 Jul; 137(7):2880–6

Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Dominguez LJ, et al. **Endocrinology** 1996 Jan; 137(1):113–21

Tyrosine phosphorylation of the growth hormone (GH) receptor and Janus tyrosine kinase-2 is involved in the insulin-like actions of GH in primary rat adipocytes. Eriksson H, et al. **Endocrinology** 1995 Nov; 136(11):5093–101

Regulation of mitogen-activated protein kinase in the pars tuberalis of the ovine pituitary: interactions between

melatonin, insulin-like growth factor-1, and forskolin. Hazlerigg DG, et al. **Endocrinology** 1996 Jan;137(1):210–8

Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C. Sundaresan S, et al. **Endocrinology** 1996 Jan;137(1):304–11

Neural and glial-mediated effects of growth factors acting via tyrosine kinase receptors on luteinizing hormone-releasing hormone neurons. Voigt P, et al. **Endocrinology** 1996 Jun;137(6):2593–605

Protein tyrosine phosphorylation in equine platelets: the effect of stimulation by thrombin and platelet-activating factor (PAF) [see comments] Dillon AM, et al. **Equine Vet J** 1995 Nov;27(6):448–58. Comment in: Equine Vet J 1995 Nov;27(6):407–10.

Transmembrane signalling: protein tyrosine phosphorylation and platelet activation [editorial; comment] Farndale RW, et al. **Equine Vet J** 1995 Nov;27(6):407–10. Comment on: Equine Vet J 1995 Nov;27(6):448–58.

Effect of tumor necrosis factor-alpha on insulin-stimulated mitogen-activated protein kinase cascade in cultured rat skeletal muscle cells. Begum N, et al. **Eur J Biochem** 1996 May 15;238(1):214–20

Regulation of p42 mitogen-activated-protein kinase activity by protein phosphatase 2A under conditions of growth inhibition by epidermal growth factor in A431 cells. Chajry N, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):97–102

The association of focal adhesion kinase with a 200-kDa protein that is tyrosine phosphorylated in response to platelet-derived growth factor. Chen HC, et al. **Eur J Biochem** 1996 Feb 1;235(3):495–500

Relationship between type II phosphatidylinositol 4-kinase activity and protein tyrosine phosphorylation in membranes from normal and sickle red cells. De Neef RS, et al. **Eur J Biochem** 1996 Feb 1;235(3):549–56

Cloning and expression of cystolic phospholipase A2 (cPLA2) and a naturally occurring variant. Phosphorylation of Ser505 of recombinant cPLA2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Gordon RD, et al. **Eur J Biochem** 1996 Jun 15;238(3):690–7

Sphingomyelin-derived lipids differentially regulate the extracellular signal-regulated kinase 2 (ERK-2) and c-Jun N-terminal kinase (JNK) signal cascades in airway smooth muscle. Pyne S, et al. **Eur J Biochem** 1996 May 1; 237(3):819–26

Cooperation of tyrosine kinases p72syk and p53/56lyn regulates calcium mobilization in chicken B cell oxidant stress signaling. Qin S, et al. **Eur J Biochem** 1996 Mar 1; 236(2):443–9

Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity. Radha V, et al. **Eur J Biochem** 1996 Mar 1;236(2):352–9

Phosphorylation of plant proteins and the identification of protein-tyrosine kinase activity in maize seedlings. Trojanek J, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):338–44

Phosphorylated T cell receptor zeta-chain and ZAP70 tandem SH2 domains form a 1:3 complex in vitro. Weissenhorn W, et al. **Eur J Biochem** 1996 Jun 1; 238(2):440–5

The proto-oncogene Vav product is constitutively tyrosine-phosphorylated in normal human immature T cells. Gouy H, et al. **Eur J Immunol** 1995 Nov; 25(11):3030–4

Human T lymphocyte activation induces tyrosine phosphorylation of alpha-tubulin and its association with the SH2 domain of the p59fyn protein tyrosine kinase. Marie-Cardine A, et al. **Eur J Immunol** 1995 Dec; 25(12):3290–7

Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Neumann C, et al. **Eur J Immunol** 1996 Feb;26(2):379–84

The role of tyrosine phosphorylation in the interaction of cellular tyrosine kinases with the T cell receptor zeta chain tyrosine-based activation motif. Osman N, et al. **Eur J Immunol** 1995 Oct;25(10):2863–9

The protein interactions of the immunoglobulin receptor family tyrosine-based activation motifs present in the T cell receptor zeta subunits and the CD3 gamma, delta and epsilon chains. Osman N, et al. **Eur J Immunol** 1996 May; 26(5):1063–8

CD40-mediated lymphotoxin alpha expression in human B cells is tyrosine kinase dependent. Worm M, et al. **Eur J Immunol** 1995 Sep;25(9):2438–44

p125FAK tyrosine phosphorylation and focal adhesion assembly: studies with phosphotyrosine phosphatase inhibitors. Defilippi P, et al. **Exp Cell Res** 1995 Nov; 221(1):141–52

Impairment of mobility in endodermal cells by FAK deficiency. Ilić D, et al. **Exp Cell Res** 1996 Feb 1; 222(2):298–303

Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Zhai S, et al. **Exp Cell Res** 1996 May 1;224(2):335–43

Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Gotoh A, et al. **Exp Hematol** 1995 Oct;23(11):1153–9

Entamoeba histolytica: involvement of pp125FAK in collagen-induced signal transduction. Pérez E, et al. **Exp Parasitol** 1996 Mar;82(2):164–70

Tec protein-tyrosine kinase is an effector molecule of Lyn protein-tyrosine kinase. Mano H, et al. **FASEB J** 1996 Apr; 10(5):637–42

Altered brain fyn kinase in a murine acquired immunodeficiency syndrome. Sei Y, et al. **FASEB J** 1996 Feb;10(2):339–44

Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. Deigner HP, et al. **FEBS Lett** 1996 May 6;385(3):149–53

Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. Ezumi Y, et al. **FEBS Lett** 1995 Oct 23;374(1):48–52

Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. Hane M, et al. **FEBS Lett** 1995 Oct 16; 373(3):265–8

Possible role of protein kinase C in the regulation of intracellular stability of focal adhesion kinase in mouse 3T3 cells. Mogi A, et al. **FEBS Lett** 1995 Oct 9;373(2):135–40

Herbimycin A suppresses NF-kappa B activation and tyrosine phosphorylation of JAK2 and the subsequent induction of nitric oxide synthase in C6 glioma cells. Nishiya T, et al. **FEBS Lett** 1995 Sep 11;371(3):333–6

Tyrosine phosphorylation of ACK in response to temperature shift-down, hyperosmotic shock, and epidermal growth factor stimulation. Satoh T, et al. **FEBS Lett** 1996 May 20;386(2–3):230–4

Characterization of the interaction between RhoA and the amino-terminal region of PKN. Shibata H, et al. **FEBS Lett** 1996 May 6;385(3):221–4

The catalytic activity of Src-family tyrosine kinase is required for B cell antigen receptor signaling. Takata M, et al. **FEBS Lett** 1995 Nov 6;374(3):407–11

Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI2 release but has no effect on von Willebrand factor secretion or E-selectin expression. Wheeler-Jones CP, et al. **FEBS Lett** 1996 Jun 17;388(2–3):180–4

Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. Zhang C, et al. **FEBS Lett** 1996 May 20;386(2–3):185–8

Shc is a substrate of the rat intestinal epidermal growth factor receptor tyrosine kinase. Polk DB. **Gastroenterology** 1995 Dec;109(6):1845–51

Interleukin-6 and ciliary neurotrophic factor trigger janus kinase activation and early gene response in rat hepatocytes. Wang Y, et al. **Gene** 1995 Sep 11;162(2):285–9

fyn tyrosine kinase is involved in keratinocyte differentiation control. Calautti E, et al. **Genes Dev** 1995 Sep 15; 9(18):2279–91

Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Dai Z, et al. **Genes Dev** 1995 Nov 1;9(21):2569–82

The torso response element binds GAGA and NTF-1/Elf-1, and regulates tailless by relief of repression. Liaw GJ, et al. **Genes Dev** 1995 Dec 15;9(24):3163–76

Mitogen-activated protein kinase activation in hepatocyte growth factor-stimulated rat hepatocytes: involvement of protein tyrosine kinase and protein kinase C. Adachi T, et al. **Hepatology** 1996 May;23(5):1244–53

Tyrosine kinase growth factor receptors but not seven-membrane-spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. Ginès P, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1296–303

Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Park H, et al. **Immunity** 1996 May;4(5):515–25

TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56lck. Wiest DL, et al. **Immunity** 1996 May;4(5):495–504

Interleukin 10 induced c-fos expression in human B cells by activation of divergent protein kinases. Bönig H, et al. **Immunol Invest** 1996 Jan-Mar;25(1–2):115–28

Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Nandan D, et al. **Infect Immun** 1995 Nov;63(11):4495–500

Tyrosine-phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of Syk. Wienands J, et al. **Int Immunol** 1995 Nov;7(11):1701–8

Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Andres AC, et al. **Int J Cancer** 1995 Oct 9;63(2):288–96

pp125FAK in the focal adhesion. Otey CA. **Int Rev Cytol** 1996;167:161–83 (85 ref.)

Endothelin-1 stimulates tyrosine phosphorylation of p125 focal adhesion kinase in mesangial cells. Haneda M, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1504–10

Tyrosine phosphorylation of focal adhesion kinase (p125FAK): regulation by cAMP and thrombin in mesangial cells. Troyer DA, et al. **J Am Soc Nephrol** 1996 Mar;7(3):415–23

Tyrosine phosphorylation in Myxococcus xanthus, a multicellular prokaryote. Frasch SC, et al. **J Bacteriol** 1996 Jul;178(14):4084–8

Possible involvement of protein-tyrosine kinases such as p72syk in the disc-sphere change response of porcine platelets. Maeda H, et al. **J Biochem (Tokyo)** 1995 Jun; 117(6):1201–8

Stimulation of mitogen-activated protein kinase and Na+/H+ exchanger in human platelets. Differential effect of phorbol ester and vasopressin. Aharonovitz O, et al. **J Biol Chem** 1996 Jul 12;271(28):16494–9

Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms. Bjorge JD, et al. **J Biol Chem** 1995 Oct 13; 270(41):24222–8

Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. Blank JL, et al. **J Biol Chem** 1996 Mar 8;271(10):5361–8

Detection of a physical and functional interaction between Csk and Lck which involves the SH2 domain of Csk and is mediated by autophosphorylation of Lck on tyrosine 394. Bougeret C, et al. **J Biol Chem** 1996 Mar 29; 271(13):7465–72

Endogenous phosphorylation of distinct gamma-aminobutyric acid type A receptor polypeptides by Ser/Thr and Tyr kinase activities associated with the purified receptor. Bureau MH, et al. **J Biol Chem** 1995 Nov 3;270(44):26482–7

Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. Butch ER, et al. **J Biol Chem** 1996 Feb 23;271(8):4230–5

Protein-tyrosine kinases activate while protein-tyrosine phosphatases inhibit L-type calcium channel activity in pituitary GH3 cells. Cataldi M, et al. **J Biol Chem** 1996 Apr 19;271(16):9441–6

Csk is constitutively associated with a 60-kDa tyrosine-phosphorylated protein in human T cells. Catipović B, et al. **J Biol Chem** 1996 Apr 19; 271(16):9698–703

T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation. Cenciarelli C, et al. **J Biol Chem** 1996 Apr 12;271(15):8709–13

Phosphoinositide 3-kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif. Reconstitution with synthetic phosphopeptides. Chacko GW, et al. **J Biol Chem** 1996 May 3;271(18):10775–81

Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB. Chen Y, et al. **J Biol Chem** 1996 Aug 16;271(33):19637–40

Enhanced affinities and specificities of consolidated ligands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine kinase. Cowburn D, et al. **J Biol Chem** 1995 Nov 10;270(45):26738–41

Syk tyrosine kinase is required for immunoreceptor tyrosine activation motif-dependent actin assembly. Cox D, et al. **J Biol Chem** 1996 Jul 12;271(28):16597–602

Activation-induced association of a 145-kDa tyrosine-phosphorylated protein with Shc and Syk in B lymphocytes and macrophages. Crowley MT, et al. **J Biol Chem** 1996 Jan 12;271(2):1145–52

STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. David M, et al. **J Biol Chem** 1996 Apr 19;271(16):9185–8

Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils. Inhibition by wortmannin. Downey GP, et al. **J Biol Chem** 1996 Aug 30;271(35):21005–1011

Characterization of active and inactive forms of the JAK2 protein-tyrosine kinase produced via the baculovirus expression vector system. Duhé RJ, et al. **J Biol Chem** 1995 Sep 29;270(39):23084–9

Angiotensin II activates at least two tyrosine kinases in rat liver epithelial cells. Separation of the major calcium-regulated tyrosine kinase from p125FAK. Earp HS, et al. **J Biol Chem** 1995 Nov 24;270(47):28440–7

Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. Feng GS, et al. **J Biol Chem** 1996 May 24;271(21):12129–32

Syp associates with gp130 and Janus kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes. Fuhrer DK, et al. **J Biol Chem** 1995 Oct 20;270(42):24826–30

Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. Gauzzi MC, et al. **J Biol Chem** 1996 Aug 23; 271(34):20494–500

Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. Gibbins J, et al. **J Biol Chem** 1996 Jul 26;271(30):18095–9

Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. Gibson S, et al. **J Biol Chem** 1996 Mar 22;271(12):7079–83

The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. Gillespie-Brown J, et al. **J Biol Chem** 1995 Nov 24; 270(47):28092–6

Participation of JAK and STAT proteins in growth hormone-induced signaling. Han Y, et al. **J Biol Chem** 1996 Mar 8;271(10):5947–52

p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. Harte MT, et al. **J Biol Chem** 1996 Jun 7; 271(23):13649–55

Interactions between the protein-tyrosine kinase ZAP-70, the proto-oncoprotein Vav, and tubulin in Jurkat T cells. Huby RD, et al. **J Biol Chem** 1995 Dec 22;270(51):30241-4

The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera. Jiang N, et al. **J Biol Chem** 1996 Jul 12;271(28):16472-6

Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. Jiang Y, et al. **J Biol Chem** 1996 Jan 5;271(1):160-7

Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding. Kaplan DH, et al. **J Biol Chem** 1996 Jan 5;271(1):9-12

A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase. Kawakatsu H, et al. **J Biol Chem** 1996 Mar 8;271(10):5680-5

Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells. Kontani K, et al. **J Biol Chem** 1996 Jan 19; 271(3):1534-7

Other kinases can substitute for Jak2 in signal transduction by interferon-gamma. Kotenko SV, et al. **J Biol Chem** 1996 Jul 19;271(29):17174-82

Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. Lacerda HM, et al. **J Biol Chem** 1996 Jan 5;271(1):439-45

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. Lavoie JN, et al. **J Biol Chem** 1996 Aug 23; 271(34):20608-16

Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. Lepley RA, et al. **J Biol Chem** 1996 Mar 15;271(11):6179-84

Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. Li S, et al. **J Biol Chem** 1996 Feb 16; 271(7):3863-8

Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. Luttrell LM, et al. **J Biol Chem** 1996 Aug 9;271(32):19443-50

Recruitment of activated p56lck on endosomes of CD2-triggered T cells, colocalization with ZAP-70. Marie-Cardine A, et al. **J Biol Chem** 1996 Aug 23; 271(34):20734-9

Physical and functional association of cortactin with Syk in human leukemic cell line K562. Maruyama S, et al. **J Biol Chem** 1996 Mar 22;271(12):6631-5

Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. Mimnaugh EG, et al. **J Biol Chem** 1995 Dec 1;270(48):28654-9

A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. Moriguchi T, et al. **J Biol Chem** 1996 Jun 7;271(23):13675-9

PKN associates and phosphorylates the head-rod domain of neurofilament protein. Mukai H, et al. **J Biol Chem** 1996 Apr 19;271(16):9816-22

Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. Murata T, et al. **J Biol Chem** 1995 Dec 22;270(51):30829-36

An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. Nakamura N, et al. **J Biol Chem** 1996 Aug 9; 271(32):19483-8

Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. Nunès JA, et al. **J Biol Chem** 1996 Jan 19; 271(3):1591-8

p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase. Panchamoorthy G, et al. **J Biol Chem** 1996 Feb 9; 271(6):3187-94

Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts. Patel BK, et al. **J Biol Chem** 1996 Sep 6;271(36):22175-82

Temporal activation of nontransmembrane protein-tyrosine kinases following mast cell Fc epsilon RI engagement. Penhallow RC, et al. **J Biol Chem** 1995 Oct 6; 270(40):23362-5

Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha-tubulin on tyrosine. Peters JD, et al. **J Biol Chem** 1996 Mar 1;271(9):4755-62

Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. Post GR, et al. **J Biol Chem** 1996 Apr 5;271(14):8452-7

Role of tyrosine phosphorylation in potassium channel activation. Functional association with prolactin receptor and JAK2 tyrosine kinase. Prevarskaya NB, et al. **J Biol Chem** 1995 Oct 13;270(41):24292-9

Requirement for phosphatidylinositol 3'-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin. Rankin S, et al. **J Biol Chem** 1996 Mar 29;271(13):7829-34

Reconstitution of B cell antigen receptor-induced signaling events in a nonlymphoid cell line by expressing the Syk protein-tyrosine kinase. Richards JD, et al. **J Biol Chem** 1996 Mar 15;271(11):6458-66

Autophosphorylation of the Fes tyrosine kinase. Evidence for an intermolecular mechanism involving two kinase domain tyrosine residues. Rogers JA, et al. **J Biol Chem** 1996 Jul 19;271(29):17519-25

Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. Saad MJ, et al. **J Biol Chem** 1996 Sep 6;271(36):22100-4

Possible v-Crk-induced transformation through activation of Src kinases. Sabe H, et al. **J Biol Chem** 1995 Dec 29; 270(52):31219-24

Plasmalopsychosine of human brain mimics the effect of nerve growth factor by activating its receptor kinase and mitogen-activated protein kinase in PC12 cells. Induction of neurite outgrowth and prevention of apoptosis. Sakakura C, et al. **J Biol Chem** 1996 Jan 12;271(2):946-52

Negative signaling via FcgammaRIIB1 in B cells blocks phospholipase Cgamma2 tyrosine phosphorylation but not Syk or Lyn activation. Sarkar S, et al. **J Biol Chem** 1996 Aug 16;271(33):20182-6

Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. Schwenger P, et al. **J Biol Chem** 1996 Apr 5; 271(14):8089-94

Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. Seger R, et al. **J Biol Chem** 1995 Nov 24;270(47):28325-30

Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin. Seufferlein T, et al. **J Biol Chem** 1996 Aug 30; 271(35):21471-7

Sphingosylphosphorylcholine rapidly induces tyrosine phosphorylation of p125FAK and paxillin, rearrangement of the actin cytoskeleton and focal contact assembly. Requirement of p21rho in the signaling pathway. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24343-51

Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases. Simonson MS, et al. **J Biol Chem** 1996 Jan 5;271(1):77-82

Autophosphorylation induces autoactivation and a decrease in the Src homology 2 domain accessibility of the Lyn protein kinase. Sotirellis N, et al. **J Biol Chem** 1995 Dec 15;270(50):29773-80

Interaction between G proteins and tyrosine kinases upon T cell receptor.CD3-mediated signaling. Stanners J, et al. **J Biol Chem** 1995 Dec 22;270(51):30635-42

Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. Stover DR, et al. **J Biol Chem** 1996 May 24;271(21):12481-7

The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. Sun XJ, et al. **J Biol Chem** 1996 May 3;271(18):10583-7

Exposure of B-lineage lymphoid cells to low energy electromagnetic fields stimulates Lyn kinase. Uckun FM, et al. **J Biol Chem** 1995 Nov 17;270(46):27666-70

Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. Wardenburg JB, et al. **J Biol Chem** 1996 Aug 16;271(33):19641-4

JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Watanabe S, et al. **J Biol Chem** 1996 May 24;271(21):12681-6

Preferential involvement of MEK1 in the tumor necrosis factor-alpha-induced activation of p42mapk/erk2 in mouse macrophages. Winston BW, et al. **J Biol Chem** 1995 Nov 17;270(46):27391-4

JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. Winston LA, et al. **J Biol Chem** 1995 Dec 29;270(52):30837-40

Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. Wu X, et al. **J Biol Chem** 1996 Feb 9;271(6):3265-71

Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Yoza BK, et al. **J Biol Chem** 1996 Aug 2; 271(31):18306-9

Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts. Lowe C, et al. **J Bone Miner Res** 1995 Nov;10(11):1644-50

Cell density-dependent changes in the insulin action pathway: evidence for involvement of protein-tyrosine phosphatases. Li PM, et al. **J Cell Biochem** 1996 Apr; 61(1):31-8

Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption. Tanaka S, et al. **J Cell Biochem** 1995 Aug;58(4):424-35

The tyrosine kinase substrate eps15 is constitutively associated with the plasma membrane adaptor AP-2. Benmerah A, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1831-8

Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. Lewis JM, et al. **J Cell Biol** 1996 Sep; 134(5):1323-32

Multiple features of the p59fyn src homology 4 domain define a motif for immune-receptor tyrosine-based activation motif (ITAM) binding and for plasma membrane localization. Timson Gauen LK, et al. **J Cell Biol** 1996 Jun;133(5):1007-15

Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor. Yasunaga M, et al. **J Cell Biol** 1996 Jan;132(1-2):91-9

Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures. Bhat NR, et al. **J Cell Physiol** 1995 Nov;165(2):417-24

Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). Tang DG, et al. **J Cell Physiol** 1995 Nov; 165(2):291-306

Induction of down-regulation of the kinase activities of Mek, p42Erk, p90RSK, and p63SAMK in chicken embryo fibroblast at the late stage of src-induced cellular transformation. Wang HC. **J Cell Physiol** 1996 Jul; 168(1):87-96

Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. Evans CA, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2591-8

IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. Palmer-Crocker RL, et al. **J Clin Invest** 1996 Aug 1; 98(3):604-9

1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. Zhou X, et al. **J Clin Invest** 1996 Aug 15;98(4):937-44

Insulin and IGF-I binding and tyrosine kinase activity in fish heart. Gutiérrez J, et al. **J Endocrinol** 1995 Jul; 146(1):35-44

The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1-7 (88 ref.)

Membrane skeletal proteins and their integral membrane protein anchors are targets for tyrosine and threonine kinases in Euglena. Fazio MJ, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):570-80

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. Carlesso N, et al. **J Exp Med** 1996 Mar 1;183(3):811-20

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. Chauhan D, et al. **J Exp Med** 1995 Dec 1;182(6):1801-6

Association of tyrosine protein kinase Zap-70 with the protooncogene product p120c-cbl in T lymphocytes. Fournel M, et al. **J Exp Med** 1996 Jan 1;183(1):301-6

Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. Kurosaki T, et al. **J Exp Med** 1995 Dec 1;182(6):1815-23

CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. Law CL, et al. **J Exp Med** 1996 Feb 1;183(2):547-60

T cell receptor- and beta 1 integrin-mediated signals synergize to induce tyrosine phosphorylation of focal adhesion kinase (pp125FAK) in human T cells. Maguire JE, et al. **J Exp Med** 1995 Dec 1;182(6):2079-90

Dominant-negative zeta-associated protein 70 inhibits T cell antigen receptor signaling. Qian D, et al. **J Exp Med** 1996 Feb 1;183(2):611-20

Direct association of pp125FAK with paxillin, the focal adhesion-targeting mechanism of pp125FAK. Tachibana K, et al. **J Exp Med** 1995 Oct 1;182(4):1089-99

Interaction of Ipa proteins of Shigella flexneri with alpha5beta1 integrin promotes entry of the bacteria into mammalian cells. Watarai M, et al. **J Exp Med** 1996 Mar 1;183(3):991-9

Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. Yousefi S, et al. **J Exp Med** 1996 Apr 1;183(4):1407-14

Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14-dependent manner. Role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells. Arditi M, et al. **J Immunol** 1995 Oct 15;155(8):3994-4003

IL-5 activates a 45-kilodalton mitogen-activated protein (MAP) kinase and Jak-2 tyrosine kinase in human eosinophils. Bates ME, et al. **J Immunol** 1996 Jan 15; 156(2):711-8

Cross-linking of ICAM-1 on T cells induces transient tyrosine phosphorylation and inactivation of cdc2 kinase. Chirathaworn C, et al. **J Immunol** 1995 Dec 15; 155(12):5479-82

Differential activation of phospholipase C-gamma 1 and mitogen-activated protein kinase in naive and antigen-primed CD4 T cells by the peptide/MHC ligand. Ericsson PO, et al. **J Immunol** 1996 Mar 15;156(6):2045-53

Phosphorylated immunoreceptor signaling motifs (ITAMs)

exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. Johnson SA, et al. **J Immunol** 1995 Nov 15;155(10):4596–603

Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross–linking on mast cells. Kawakami Y, et al. **J Immunol** 1995 Oct 1;155(7):3556–62

Defective TCR–mediated signaling in anergic T cells. Migita K, et al. **J Immunol** 1995 Dec 1;155(11):5083–7

CD2–induced apoptosis in activated human peripheral T cells: a Fas–independent pathway that requires early protein tyrosine phosphorylation. Mollereau B, et al. **J Immunol** 1996 May 1;156(9):3184–90

IL–13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL–4 and IL–13 signaling. Murata T, et al. **J Immunol** 1996 Apr 15;156(8):2972–8

Glycosylphosphatidylinositol toxin of Plasmodium up–regulates intercellular adhesion molecule–1, vascular cell adhesion molecule–1, and E–selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase–dependent signal transduction. Schofield L, et al. **J Immunol** 1996 Mar 1;156(5):1886–96

CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C–gamma and phosphatidylinositol 3–kinase. Silvennoinen O, et al. **J Immunol** 1996 Jan 1;156(1):100–7

CD66 family members are associated with tyrosine kinase activity in human neutrophils. Skubitz KM, et al. **J Immunol** 1995 Dec 1;155(11):5382–90

Protein tyrosine phosphatase activity associates with the high affinity IgE receptor and dephosphorylates the receptor subunits, but not Lyn or Syk. Swieter M, et al. **J Immunol** 1995 Dec 1;155(11):5330–6

Identification of IFN–gamma receptor binding sites for JAK2 and enhancement of binding by IFN–gamma and its C–terminal peptide IFN–gamma(95–133). Szente BE, et al. **J Immunol** 1995 Dec 15;155(12):5617–22

Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti–CD3. Roles of protein tyrosine kinases in the signal for IL–2 and IL–4 production. Tamura T, et al. **J Immunol** 1995 Nov 15;155(10):4692–701

CD28–mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3–kinase, and protein kinase C. Teng JM, et al. **J Immunol** 1996 May 1;156(9):3222–32

Differential utilization of Janus kinase–signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL–2, IL–12, and IFN–alpha. Yu CR, et al. **J Immunol** 1996 Jul 1; 157(1):126–37

Protein tyrosine kinases in activation signal of human basophils through the immunoglobulin E receptor type I. Benhamou M, et al. **J Leukoc Biol** 1996 Mar;59(3):461–70

Binding affinities of the SH2 domains of ZAP–70, p56lck and Shc to the zeta chain ITAMs of the T–cell receptor determined by surface plasmon resonance. Labadia ME, et al. **J Leukoc Biol** 1996 May;59(5):740–6

Tumor necrosis factor triggers redistribution to a Triton X–100–insoluble, cytoskeletal fraction of beta 2 integrins, NADPH oxidase components, tyrosine phosphorylated proteins, and the protein tyrosine kinase p58fgr in human neutrophils adherent to fibrinogen. Yan SR, et al. **J Leukoc Biol** 1995 Nov;58(5):595–606

Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c–Src and Syk as assessed by phage display. Schmitz R, et al. **J Mol Biol** 1996 Aug 2;260(5):664–77

Tyrosine kinase activity is essential for interleukin–1 beta–stimulated production of interleukin–6 in U373 human astrocytoma cells. Carlson RO, et al. **J Neurochem** 1995 Dec;65(6):2491–9

Protein tyrosine kinase–mediated potentiation of currents from cloned NMDA receptors. Chen C, et al. **J Neurochem** 1996 Jul;67(1):194–200

Shift of the cellular oxidation–reduction potential in neural cells expressing Bcl–2. Ellerby LM, et al. **J Neurochem** 1996 Sep;67(3):1259–67

Functional coupling of the delta–, mu–, and kappa–opioid receptors to mitogen–activated protein kinase and arachidonate release in Chinese hamster ovary cells. Fukuda K, et al. **J Neurochem** 1996 Sep;67(3):1309–16

SH2 and SH3 domains: potential targets for anti–cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)

Phosphorylation of caldesmon by mitogen–activated protein kinase with no effect on Ca2+ sensitivity in rabbit smooth muscle. Nixon GF, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):283–9

Thymosin alpha–1 and FA–1 monoclonal antibody affect fertilizing capacity of human sperm by modulating protein phosphorylation pattern. Ahmad K, et al. **J Reprod Immunol** 1995 May;29(1):1–17

Estrogen induces c–Ha–ras expression via activation of tyrosine kinase in uterine endometrial fibroblasts and cancer cells. Fujimoto J, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):25–33

Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma. Duncan MD, et al. **J Surg Res** 1996 Jun;63(1):359–63

Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. Watts SW, et al. **J Vasc Res** 1996 Jul–Aug;33(4):288–98

Tyrosine kinase–dependent release of an adenovirus preterminal protein complex from the nuclear matrix. Angeletti PC, et al. **J Virol** 1996 May;70(5):3060–7

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c–src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2–11

Cell–free assay system for Ras–dependent MEK activation. Kuroda S, et al. **Methods Enzymol** 1995;255:257–65

Paxillin, a tyrosine phosphorylated focal adhesion–associated protein binds to the carboxyl terminal domain of focal adhesion kinase. Hildebrand JD, et al. **Mol Biol Cell** 1995 Jun;6(6):637–47

Transformation and pp60v–src autophosphorylation correlate with SHC–GRB2 complex formation in rat and chicken cells expressing host–range and kinase–active, transformation–defective alleles of v–src. Verderame MF, et al. **Mol Biol Cell** 1995 Aug;6(8):953–66

Enhanced expression of GTP–binding proteins in differentiated U937 monocytic cells: possible involvement of tyrosine kinase and protein kinase C. Ali N, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):113–20

Regulation of Btk by Src family tyrosine kinases. Afar DE, et al. **Mol Cell Biol** 1996 Jul;16(7):3465–71

Identification of a binding site in c–Abl tyrosine kinase for the C–terminal repeated domain of RNA polymerase II. Baskaran R, et al. **Mol Cell Biol** 1996 Jul;16(7):3361–9

In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcgammaRII) phosphorylation. Bewarder N, et al. **Mol Cell Biol** 1996 Sep;16(9):4735–43

A proline–rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Catling AD, et al. **Mol Cell Biol** 1995 Oct;15(10):5214–25

Differential regulation of the alpha/beta interferon–stimulated Jak/Stat pathway by the SH2 domain–containing tyrosine phosphatase SHPTP1. David M, et al. **Mol Cell Biol** 1995 Dec;15(12):7050–8

An SH3 domain–containing GTPase–activating protein for Rho and Cdc42 associates with focal adhesion kinase. Hildebrand JD, et al. **Mol Cell Biol** 1996 Jun;16(6):3169–78

Conformational changes induced in the protein tyrosine kinase p72syk by tyrosine phosphorylation or by binding of phosphorylated immunoreceptor tyrosine–based activation motif peptides. Kimura T, et al. **Mol Cell Biol** 1996 Apr;16(4):1471–8

Phospholipase C–gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Law CL, et al. **Mol Cell Biol** 1996 Apr;16(4):1305–15

Human enhancer of filamentation 1, a novel p130cas–like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Law SF, et al. **Mol Cell Biol** 1996 Jul; 16(7):3327–37

Roles of JAKs in activation of STATs and stimulation of c–fos gene expression by epidermal growth factor. Leaman DW, et al. **Mol Cell Biol** 1996 Jan;16(1):369–75

Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mahajan S, et al. **Mol Cell Biol** 1995 Oct;15(10):5304–11

A membrane–proximal region of the interleukin–2 receptor gamma c chain sufficient for Jak kinase activation and induction of proliferation in T cells. Nelson BH, et al. **Mol Cell Biol** 1996 Jan;16(1):309–17

Characterization of the roles of SH2 domain–containing proteins in T–lymphocyte activation by using dominant negative SH2 domains. Northrop JP, et al. **Mol Cell Biol** 1996 May;16(5):2255–63

MKK3– and MKK6–regulated gene expression is mediated by the p38 mitogen–activated protein kinase signal transduction pathway. Raingeaud J, et al. **Mol Cell Biol** 1996 Mar;16(3):1247–55

Csk enhances insulin–stimulated dephosphorylation of focal adhesion proteins. Tobe K, et al. **Mol Cell Biol** 1996 Sep; 16(9):4765–72

Platelet–derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Vignais ML, et al. **Mol Cell Biol** 1996 Apr;16(4):1759–69

Abrogation of retinoblastoma protein function by c–Abl through tyrosine kinase–dependent and –independent mechanisms. Welch PJ, et al. **Mol Cell Biol** 1995 Oct; 15(10):5542–51

The proline–rich region of the GH receptor is essential for JAK2 phosphorylation, activation of cell proliferation, and gene transcription. Dinerstein H, et al. **Mol Endocrinol** 1995 Dec;9(12):1701–7

The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Smit LS, et al. **Mol Endocrinol** 1996 May; 10(5):519–33

Induction of costimulatory molecules B7–1 and B7–2 in murine B cells. the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40–mediated B7 induction. Goldstein MD, et al. **Mol Immunol** 1996 Apr;33(6):541–52

Regulation of BCR– and PKC/Ca(2+)–mediated activation of the Raf1/MEK/MAPK pathway by protein–tyrosine kinase and –tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287–96

Involvement of a tyrosine kinase pathway in the growth–promoting effects of angiotensin II on aortic smooth muscle cells. Leduc I, et al. **Mol Pharmacol** 1995 Oct;48(4):582–92

The solution structure of HIV–1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Grzesiek S, et al. **Nat Struct Biol** 1996 Apr;3(4):340–5

Myc but not Fos rescue of PDGF signalling block caused by kinase–inactive Src [see comments] Barone MV, et al. **Nature** 1995 Nov 30;378(6556):509–12. Comment in: Nature 1995 Nov 30;378(6556):438–9.

Syk tyrosine kinase required for mouse viability and B–cell development. Cheng AM, et al. **Nature** 1995 Nov 16; 378(6554):303–6

A mechanism for regulation of the adhesion–associated proteintyrosine kinase pp125FAK. Richardson A, et al. **Nature** 1996 Apr 11;380(6574):538–40

Tyrosine kinases in activation of the MAP kinase cascade by G–protein–coupled receptors. Wan Y, et al. **Nature** 1996 Apr 11;380(6574):541–4

Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Maldonado R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):565–75

Tyrosine kinase is required for long–term depression in the cerebellum. Boxall AR, et al. **Neuron** 1996 Apr; 16(4):805–13

The bombesin/GRP receptor transfected into Rat–1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125FAK and paxillin and cell proliferation. Charlesworth A, et al. **Oncogene** 1996 Mar 21;12(6):1337–45

Targeted proteolysis of the focal adhesion kinase pp125 FAK during c–MYC–induced apoptosis is suppressed by integrin signalling. Crouch DH, et al. **Oncogene** 1996 Jun 20; 12(12):2689–96

Mutagenic analysis of functional domains of the mos proto–oncogene and identification of the sites important for MAPK activation and DNA binding. Fukasawa K, et al. **Oncogene** 1995 Oct 19;11(8):1447–57

Delay in serum stimulation of Erk activity caused by oncogenic transformation. Greulich H, et al. **Oncogene** 1996 Apr 18;12(8):1689–95

A new member of the Eph family of receptors that lacks protein tyrosine kinase activity. Gurniak CB, et al. **Oncogene** 1996 Aug 15;13(4):777–86

Tyrosine phosphorylation at the membrane–microfilament interface: a p185neu–associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane– and microfilament–associated retroviral gag–like protein. Juang SH, et al. **Oncogene** 1996 Mar 7;12(5):1033–42

Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk. Koegl M, et al. **Oncogene** 1995 Dec 7;11(11):2317–29

The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP–70 and mediates TCR dependent gene activation. Milia E, et al. **Oncogene** 1996 Aug 15; 13(4):767–75

Activation of Src family kinases in Neu–induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Muthuswamy SK, et al. **Oncogene** 1995 Nov 2;11(9):1801–10

Analysis of chimeric Gag–Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C–terminal domain. Mysliwiec T, et al. **Oncogene** 1996 Feb 1; 12(3):631–40

Platelet–activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Soldi R, et al. **Oncogene** 1996 Aug 1;13(3):515–25

The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn–related tyrosine kinase. Sunitha I, et al. **Oncogene** 1996 Aug 1;13(3):547–59

Analysis of human c–Abl tyrosine kinase activity and regulation in S. pombe. Walkenhorst J, et al. **Oncogene** 1996 Apr 4;12(7):1513–20

Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS–specific Xenopus gene. Wang B, et al. **Oncogene** 1996 May 2;12(9):1921–9

Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation. Schwartz B, et al. **Oncol Res** 1995;7(6):277–87

Ornithine decarboxylase and tyrosine kinase activity in juvenile polyps of childhood. Elitsur Y, et al. **Pediatr Res** 1995 Oct;38(4):574–8

Fc epsilon RI–mediated recruitment of p53/56lyn to detergent–resistant membrane domains accompanies cellular signaling. Field KA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9201–5

Clustered syk tyrosine kinase domains trigger phagocytosis. Greenberg S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1103–7

Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Johnston JA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8705–9

Critical role of the interleukin 2 (IL–2) receptor gamma–chain–associated Jak3 in the IL–2–induced c–fos and c–myc, but not bcl–2, gene induction. Kawahara A,

et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8724–8

The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1. Kharbanda S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6898–901

CD38 ligation induces tyrosine phosphorylation of Bruton tyrosine kinase and enhanced expression of interleukin 5-receptor alpha chain: synergistic effects with interleukin 5. Kikuchi Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11814–8

Molecular cloning of a protein kinase whose phosphorylation is regulated by genetic adhesion during Chlamydomonas fertilization. Kurvari V, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):39–43

Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits. Langhans-Rajasekaran SA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8601–5

Catalytic activity of the mouse guanine nucleotide exchanger mSOS is activated by Fyn tyrosine protein kinase and the T-cell antigen receptor in T cells. Li B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1001–5

Transformation of Rat-1 fibroblasts with the v-src oncogene increases the tyrosine phosphorylation state and activity of the alpha subunit of Gq/G11. Liu WW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8258–63

Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Madrenas J, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9736–41

Staphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins). Nielsen M, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10995–9

Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Parker LL, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9638–42

Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Polte TR, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10678–82

A tyrosine kinase profile of prostate carcinoma. Robinson D, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):5958–62

Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Sengupta TK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9499–504

A JAK-STAT pathway regulates wing vein formation in Drosophila. Yan R, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5842–7

Relation of ornithine decarboxylase and tyrosine kinase activity in the jejunal mucosa in vivo. Younoszai MK, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):339–45

Cell biology. Two major signaling pathways meet at MAP-kinase [news; comment] Barinaga M. **Science** 1995 Sep 22;269(5231):1673. Comment on: Science 1995 Sep 22;269(5231):1721–3.

Jak-STAT signaling induced by the v-abl oncogene. Danial NN, et al. **Science** 1995 Sep 29;269(5232):1875–7

Regulation of a neuronal form of focal adhesion kinase by anandamide. Derkinderen P, et al. **Science** 1996 Sep 20; 273(5282):1719–22

Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption. Hardwick KG, et al. **Science** 1996 Aug 16;273(5277):953–6

Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Mueller PR, et al. **Science** 1995 Oct 6; 270(5233):86–90

Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Plas DR, et al. **Science** 1996 May 24; 272(5265):1173–6

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Rawlings DJ, et al. **Science** 1996 Feb 9;271(5250):822–5

Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Tokiwa G, et al. **Science** 1996 Aug 9; 273(5276):792–4

BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Uckun FM, et al. **Science** 1996 Aug 23;273(5278):1096–100

Tyrosine kinases in megakaryocytopoiesis. Avraham H, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):380–92 (141 ref.)

The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct. Gosser YQ, et al. **Structure** 1995 Oct 15;3(10):1075–86

Why two heads are better. Mayer BJ. **Structure** 1995 Oct 15;3(10):977–80 (27 ref.)

Activation of extracellular signal-regulated protein kinase (ERK/MAP kinase) following CD28 cross-linking: activation in cells lacking p56lck. August A, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):155–62

The actions of 2,3,7,8-tetrachlorodibenzo-p-dioxin on transforming growth factor-beta2 promoter activity are localized to the TATA box binding region and controlled through a tyrosine kinase-dependent pathway. Lee DC, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):90–9

Recognition and specificity in protein tyrosine kinase-mediated signalling. Zhou S, et al. **Trends Biochem Sci** 1995 Nov;20(11):470–5 (46 ref.)

[Tyrosine phosphorylation of focal adhesion kinase (p125FAK) and paxillin in glomeruli from diabetic rats] Shikano T, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb; 38(2):57–64 (Eng. Abstr.) **(Jpn)**

[The tyrosine kinase activity of the internalized epidermal growth factor receptor in A-431 cells] Burova EB, et al. **Tsitologiia** 1995;37(12):1230–7 (Eng. Abstr.) **(Rus)**

[Tyrosine-protein kinase activity in breast neoplasm. Comparison with activity obtained in benign diseases and in normal tissues] Pierart J, et al. **Rev Med Chil** 1995 Feb; 123(2):165–75 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Signaling pathways regulating ornithine decarboxylase activity in the embryonic chicken. Shibley IA Jr, et al. **Biol Neonate** 1995;67(6):441–9

Growth inhibition by Abl requires an interplay of its SH2 and tyrosine kinase domains. Mattioni T, et al. **FEBS Lett** 1996 Jul 22;390(2):170–4

Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. Lazarini F, et al. **J Neurochem** 1996 Feb;66(2):459–65

PHYSIOLOGY

The Janus protein tyrosine kinase family and its role in cytokine signaling. Ihle JN. **Adv Immunol** 1995;60:1–35 (230 ref.)

Tyrosine kinase-dependent modulation of calcium entry in rabbit colonic muscularis mucosae. Hatakeyama N, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1780–9

Coronary arteriolar flow-induced vasodilation signals through tyrosine kinase. Muller JM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1878–84

The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)

src-related tyrosine kinases regulate transcriptional activation of the interstitial collagenase gene, MMP-1, in interleukin-1-stimulated synovial fibroblasts. Vincenti MP, et al. **Arthritis Rheum** 1996 Apr;39(4):574–82

Tyrosine kinase is involved in angiotensin II-stimulated phospholipase D activation in aortic smooth muscle cells: function of Ca2+ influx. Suzuki A, et al. **Atherosclerosis** 1996 Mar;121(1):119–27

A combined genetic and biochemical approach to mammalian signal transduction. Della NG, et al. **Aust N Z J Med** 1995 Dec;25(6):845–51 (36 ref.)

The cbl oncogene: a novel substrate of protein tyrosine kinases. Langdon WY. **Aust N Z J Med** 1995 Dec; 25(6):859–64 (19 ref.)

Regulation of glycolipid sulfotransferase by tyrosine kinases in human renal cancer cells. Balbaa M, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):141–5

Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Kamanna VS, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):161–72

The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Anderson SM, et al. **Blood** 1996 Jan 1;87(1):238–44

Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Haskell MD, et al. **Blood** 1995 Dec 15;86(12):4627–37

p59fyn-p125FAK cooperation in development of CD4+CD8+ thymocytes. Kanazawa S, et al. **Blood** 1996 Feb 1;87(3):865–70

Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process. Rizzo MT, et al. **Blood** 1995 Oct 15;86(8):2967–75

Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation. Osorio LM, et al. **Cell Immunol** 1995 Nov;166(1):44–52

Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739–45 (49 ref.)

Role of tyrosine kinase in insulin release in an insulin secreting cell line (INS-1). Verspohl EJ, et al. **Cell Signal** 1995 Jul; 7(5):505–12

Regulation of phospholipase D by tyrosine kinases. Natarajan V, et al. **Chem Phys Lipids** 1996 May 24;80(1-2):103–16 (156 ref.)

Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. Melillo G, et al. **Circulation** 1996 Apr 1;93(7):1447–58

Role of cytokines, tyrosine kinase, and protein kinase C on production of superoxide and induction of scavenging enzymes in human leukocytes. Niwa Y, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):303–13

Nonreceptor protein tyrosine kinase involvement in signal transduction and immunodeficiency disease. Saouaf SJ, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S151–7 (65 ref.)

Molecular and genetic insights into the role of protein tyrosine kinases in T cell receptor signaling. Weiss A. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S158–62 (30 ref.)

Myogenesis in paraxial mesoderm: preferential induction by dorsal neural tube and by cells expressing Wnt-1. Stern HM, et al. **Development** 1995 Nov;121(11):3675–86

Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. Briscoe J, et al. **EMBO J** 1996 Feb 15; 15(4):799–809

Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells. Levy JB, et al. **Endocrinology** 1996 Apr; 137(4):1159–65

Fyn tyrosine kinase is required for normal amygdala kindling. Cain DP, et al. **Epilepsy Res** 1995 Oct;22(2):107–14

Involvement of Janus kinases in the insulin signaling pathway. Giorgetti-Peraldi S, et al. **Eur J Biochem** 1995 Dec 1; 234(2):656–60

The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Heim MH. **Eur J Clin Invest** 1996 Jan;26(1):1–12 (133 ref.)

Dispensability of Jak1 tyrosine kinase for interleukin-2-induced cell growth signaling in a human T cell line. Higuchi M, et al. **Eur J Immunol** 1996 Jun; 26(6):1322–7

Internalization of B cell and pre-B cell receptors is regulated by tyrosine kinase and phosphatase activities. Salamero J, et al. **Eur J Immunol** 1995 Oct;25(10):2757–64

Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Tuscano JM, et al. **Eur J Immunol** 1996 Jun;26(6):1246–52

Focal adhesion kinase in rat central nervous system. Burgaya F, et al. **Eur J Neurosci** 1995 Aug 1;7(8):1810–21

Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Lowell CA, et al. **Genes Dev** 1996 Aug 1;10(15):1845–57 (111 ref.)

Tyrosine kinase signaling pathways modulate angiotensin II-induced calcium ([Ca2+]i) transients in vascular smooth muscle cells. Touyz RM, et al. **Hypertension** 1996 May; 27(5):1097–103

Tyrosine-phosphorylated T cell receptor zeta chain associates with the actin cytoskeleton upon activation of mature T lymphocytes. Rozdzial MM, et al. **Immunity** 1995 Nov;3(5):623–33

Tyrosine phosphorylation participates in peripheral T-cell activation and programmed cell death in vivo. Migita K, et al. **Immunology** 1995 Aug;85(4):550–5

Dynamic production of tumour necrosis factor-alpha (TNF-alpha) messenger RNA, intracellular and extracellular TNF-alpha by murine macrophages and possible association with protein tyrosine phosphorylation of STAT1 alpha and ERK2 as an early signal. Zheng ZM, et al. **Immunology** 1996 Apr;87(4):544–50

Role of tyrosine kinases in lymphocyte activation: targets for drug intervention. Hanke JH, et al. **Inflamm Res** 1995 Sep;44(9):357–71 (190 ref.)

Syk and Lyn are involved in radiation-induced signaling, but inactivation of Syk or Lyn alone is not sufficient to prevent radiation-induced apoptosis. Yang C, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):33–8

The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. Hernández-Sánchez C, et al. **J Biol Chem** 1995 Dec 8;270(49):29176–81

Role of tyrosine kinases in norepinephrine-induced contraction of vascular smooth muscle. Abebe W, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):153–9

Tyrosine kinase but not phospholipid/Ca2+ signaling pathway is involved in interferon-gamma stimulation of Ia expression in macrophages. Chakrabarti R, et al. **J Cell Biochem** 1996 Feb;60(2):235–45

Control of adhesion-dependent cell survival by focal adhesion kinase. Frisch SM, et al. **J Cell Biol** 1996 Aug; 134(3):793–9

Na+/H+ exchange activity during phagocytosis in human neutrophils: role of Fcgamma receptors and tyrosine kinases. Fukushima T, et al. **J Cell Biol** 1996 Mar; 132(6):1037–52

Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. Lowell CA, et al. **J Cell Biol** 1996 May; 133(4):895–910

Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). Tang DG, et al. **J Cell Physiol** 1995 Nov; 165(2):291–306

Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription. Finidori J, et al. **J Endocrinol** 1995 Oct;147(1):11–23 (117 ref.)

Positive and negative selection invoke distinct signaling pathways. Alberola-Ila J, et al. **J Exp Med** 1996 Jul 1; 184(1):9–18

Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. Boussiotis VA, et al. **J Exp Med** 1996 Aug 1;184(2):365–76

A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. Takata M, et al. **J Exp Med** 1996 Jul 1;184(1):31–40

Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3

cells. Zhang J, et al. **J Exp Med** 1996 Jul 1;184(1):71–9
IL–4 and IFN–gamma synergistically increase total polymeric IgA receptor levels in human intestinal epithelial cells. Role of protein tyrosine kinases. Denning GM. **J Immunol** 1996 Jun 15;156(12):4807–14
Physical and functional interactions of protein tyrosine kinases, p59fyn and ZAP–70, in T cell signaling. Fusaki N, et al. **J Immunol** 1996 Feb 15;156(4):1369–77
The EMT/ITK/TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. Gibson S, et al. **J Immunol** 1996 Apr 15;156(8):2716–22
An antibody that binds domain 1 of CD4 inhibits replication of HIV–1, but not HTLV–I, in a CD4–positive/p56lck–negative HTLV–I–transformed cell line. Lemasson I, et al. **J Immunol** 1996 Jan 15; 156(2):859–65
Physical and functional association of Fc mu receptor on human natural killer cells with the zeta– and Fc epsilon RI gamma–chains and with src family protein tyrosine kinases. Rabinowich H, et al. **J Immunol** 1996 Aug 15; 157(4):1485–91
HIV glycoprotein 120 enhances intercellular adhesion molecule–1 gene expression in glial cells. Involvement of Janus kinase/signal transducer and activator of transcription and protein kinase C signaling pathways. Shrikant P, et al. **J Immunol** 1996 Feb 1;156(3):1307–14
Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase–dependent and protein kinase C–dependent signaling pathway. Tachado SD, et al. **J Immunol** 1996 Mar 1; 156(5):1897–1907
MEK1 and the extracellular signal–regulated kinases are required for the stimulation of IL–2 gene transcription in T cells. Whitehurst CE, et al. **J Immunol** 1996 Feb 1; 156(3):1020–9
Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain–derived neurotrophic factor signaling. Eide FF, et al. **J Neurosci** 1996 May 15; 16(10):3123–9
Synchronous onset of NGF and TrkA survival dependence in developing dorsal root ganglia. White FA, et al. **J Neurosci** 1996 Aug 1;16(15):4662–72
In vivo effects of angiotensin II on vascular smooth muscle contraction and blood pressure are mediated through a protein tyrosine–kinase–dependent mechanism. Sauro MD, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1744–50
Modulation of monocyte adherence to endothelial cells by endothelin–1 involvement of Src (p60src) and JAK1–like kinases. Chisholm LJ, et al. **J Vasc Surg** 1996 Feb; 23(2):288–300
Fak and focal adhesions. Martin GM. **Jpn J Cancer Res** 1996 Mar;87(3):inside front cover (34 ref.)
The function of src family tyrosine kinases in hematopoietic cells. Xu Y, et al. **Leuk Res** 1996 Mar;20(3):229–34 (60 ref.)
Tyrosine kinase inhibitors potentiate the induction of low density lipoprotein receptor gene expression by hepatocyte growth factor. Kanuck MP, et al. **Life Sci** 1995; 57(22):1981–91
Drosophila Wee1 kinase rescues fission yeast from mitotic catastrophe and phosphorylates Drosophila Cdc2 in vitro. Campbell SD, et al. **Mol Biol Cell** 1995 Oct;6(10):1333–47
The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Medico E, et al. **Mol Biol Cell** 1996 Apr;7(4):495–504
Tyrosine kinase–mediated signal transduction pathways and the actions of polypeptide growth factors and G–protein–coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug–Sep;149–150:77–85 (77 ref.)
Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)
Structural and signaling requirements for BCR–ABL–mediated transformation and inhibition of apoptosis. Cortez D, et al. **Mol Cell Biol** 1995 Oct; 15(10):5531–41
Distinct tyrosine phosphorylation sites in ZAP–70 mediate activation and negative regulation of antigen receptor function. Kong G, et al. **Mol Cell Biol** 1996 Sep; 16(9):5026–35
Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mahajan S, et al. **Mol Cell Biol** 1995 Oct;15(10):5304–11
Csk enhances insulin–stimulated dephosphorylation of focal adhesion proteins. Tobe K, et al. **Mol Cell Biol** 1996 Sep; 16(9):4765–72
Yeast RLM1 encodes a serum response factor–like protein that may function downstream of the Mpk1 (Slt2) mitogen–activated protein kinase pathway. Watanabe Y, et al. **Mol Cell Biol** 1995 Oct;15(10):5740–9
Regulation of BCR– and PKC/Ca(2+)–mediated activation of the Raf1/MEK/MAPK pathway by protein–tyrosine kinase and –tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287–96
Signal transduction. Beating a path to Myc [news; comment] Eisenman RN, et al. **Nature** 1995 Nov 30;378(6556):438–9 . Comment on: Nature 1995 Nov 30;378(6556):509–13.
Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK–deficient mice. Illé D, et al. **Nature** 1995 Oct 12;377(6549):539–44
Perinatal lethality and blocked B–cell development in mice lacking the tyrosine kinase Syk. Turner M, et al. **Nature** 1995 Nov 16;378(6554):298–302
Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Furuta Y, et al. **Oncogene** 1995 Nov 16;11(10):1989–95
Mutations in the non–catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation. Rivero–Lezcano OM, et al. **Oncogene** 1995 Dec 21;11(12):2675–9
Roles of tyrosine kinase in insulin action on cell volume of fetal rat type II pneumocyte. Marunaka Y, et al. **Pflugers Arch** 1996 Jul;432(3):571–3
JAKs, STATs and signal transduction in response to the interferons and other cytokines. Briscoe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):167–71 (12 ref.)
Janus kinases in cytokine signalling. Ihle JN. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):159–66 (120 ref.)
Molecular mechanism of T–cell activation: role of protein tyrosine kinases in antigen receptor–mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May–Jun; 146(4–5):291–307 (104 ref.)
Defective lymphoid development in mice lacking Jak3. Nosaka T, et al. **Science** 1995 Nov 3;270(5237):800–2
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Russell SM, et al. **Science** 1995 Nov 3;270(5237):797–800
Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Thomis DC, et al. **Science** 1995 Nov 3;270(5237):794–7
The Syk/ZAP–70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227–36 (71 ref.)

SECRETION

Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues. Kiefer P, et al. **Oncogene** 1996 Apr 4; 12(7):1503–11

TOXICITY

Development of cellular resistance to pp60v–src kinase–induced cell death. Wu LW, et al. **Oncogene** 1995 Oct 19;11(8):1459–68

PROTEIN–TYROSINE–PHOSPHATASE

Phosphoprotein phosphatases I: tyrosine phosphatases. Goldstein BJ. **Protein Profile** 1995;2(13):1425–1585

ANALYSIS

A solid–phase assay for the determination of protein tyrosine kinase activity of c–src using scintillating microtitration plates. Braunwaler AF, et al. **Anal Biochem** 1996 Feb 1; 234(1):23–6
Activity and molecular weight of protein tyrosine phosphatases in cell lysates determined by renaturation after gel electrophoresis. Gates RE, et al. **Anal Biochem** 1996 Jun 1;237(2):208–15
Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells. Partanen S. **Anticancer Res** 1996 Mar–Apr;16(2):943–6
Comparative localisation of CRYP alpha, a CAM–like tyrosine phosphatase, and NgCAM in the developing chick visual system. Stoker AW, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):129–40
Fluorometric and time–resolved immunofluorometric assays for protein–tyrosine phosphatase activity. Galvan B, et al. **Clin Biochem** 1996 Apr;29(2):125–31
Regulation of the src homology 2 domain–containing protein tyrosine phosphatase PTP1C by glucocorticoids in rat pancreatic AR42J cells. Cambillau C, et al. **Endocrinology** 1995 Dec;136(12):5476–84
Localization and down–regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF–stimulated cells. Cossette LJ, et al. **Exp Cell Res** 1996 Mar 15;223(2):459–66
Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. Aanstoot HJ, et al. **J Clin Invest** 1996 Jun 15;97(12):2772–83
Expression and localization of a baculovirus protein phosphatase. Li Y, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2941–8
Identification of protein tyrosine phosphatase–like IA2 (islet cell antigen 512) as the insulin–dependent diabetes–related 37/40K autoantigen and a target of islet–cell antibodies. Bonifacio E, et al. **J Immunol** 1995 Dec 1;155(11):5419–26
Protein–tyrosine phosphatases expressed in mouse epidermal keratinocytes. Hendriks W, et al. **J Invest Dermatol** 1996 May;106(5):972–6
Regional expression and subcellular localization of the tyrosine–specific phosphatase SH–PTP2 in the adult human nervous system. Reeves SA, et al. **Neuroscience** 1996 Apr; 71(4):1037–42

ANTAGONISTS & INHIBITORS

Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells. Böhmer FD, et al. **Anal Biochem** 1995 Jul 1;228(2):267–73
Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein–tyrosine phosphatases? Chen L, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):976–84
Effect of protein kinase and phosphatase inhibitors on expression of hypoxia–inducible factor 1. Wang GL, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):669–75
Thiophosphate derivatives as inhibitors of tyrosine phosphatases. Zhao Z. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):480–4
Phosphonate inhibitors of protein–tyrosine and serine/threonine phosphatases. Kole HK, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1025–31
Phenylarsine oxide and vanadate: apparent paradox of inhibition of protein phosphotyrosine phosphatases in rat adipocytes. Li J, et al. **Biochim Biophys Acta** 1996 Jul 24; 1312(3):223–30
A characterization of pervanadate, an inducer of cellular tyrosine phosphorylation and inhibitor of gap junctional intercellular communication. Mikalsen SO, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):308–18
Effects of the protein tyrosine phosphatase inhibitor phenylarsine oxide on excision–activated calcium channels in Lymnaea neurons. Pafford CM, et al. **Cell Calcium** 1995 Nov;18(5):400–10
A peroxovanadium compound induces Xenopus oocyte maturation: inhibition by a neutralizing anti–insulin receptor antibody. Cummings C, et al. **Dev Biol** 1996 May 1;175(2):338–46
Effect of orthovanadate on commitment of avian myoblasts transformed with Rous sarcoma virus to myogenic differentiation. Hase H, et al. **Eur J Cell Biol** 1995 Nov; 68(3):313–22
p125FAK tyrosine phosphorylation and focal adhesion assembly: studies with phosphotyrosine phosphatase inhibitors. Defilippi P, et al. **Exp Cell Res** 1995 Nov; 221(1):141–52
In vivo inactivation of phosphotyrosine protein phosphatases by nitric oxide. Caselli A, et al. **FEBS Lett** 1995 Oct 30; 374(2):249–52
RK–682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. Hamaguchi T, et al. **FEBS Lett** 1995 Sep 18;372(1):54–8
Synthetic Tyr–phospho and non–hydrolyzable phosphonopeptides as PTKs and TC–PTP inhibitors. Ruzza P, et al. **Int J Pept Protein Res** 1995 Dec; 46(6):535–46
Synthesis and protein tyrosine phosphatase inhibitory activity of dephostatin analogs. Watanabe T, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1460–6
A peptide–based protein–tyrosine phosphatase inhibitor specifically enhances insulin receptor function in intact cells. Kole HK, et al. **J Biol Chem** 1996 Jun 14; 271(24):14302–7
Intracluster restriction of Fc receptor gamma–chain tyrosine phosphorylation subverted by a protein–tyrosine phosphatase inhibitor. Pfefferkorn LC, et al. **J Biol Chem** 1996 May 10;271(19):11099–105
Activation of mitogen–activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases. Zhao Z, et al. **J Biol Chem** 1996 Sep 6; 271(36):22251–5
Arrest at the G2/M transition of the cell cycle by protein–tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. Faure R, et al. **J Cell Biochem** 1995 Nov;59(3):389–401
Stimulation of the T–cell antigen receptor–CD3 complex signaling pathway by the tyrosine phosphatase inhibitor pervanadate is mediated by inhibition of CD45: evidence for two interconnected Lck/Fyn– or zap–70–dependent signaling pathways. Imbert V, et al. **J Inflamm** 1996; 46(2):65–77
Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Shuai K, et al. **Mol Cell Biol** 1996 Sep;16(9):4932–41
Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate–treated mouse T–cell lines. Lee JM, et al. **Oncogene** 1996 Jan 18;12(2):253–63

BIOSYNTHESIS

Molecular cloning and developmental regulation of expression of two isoforms of the catalytic subunit of protein phosphatase 2A from Xenopus laevis. Van Hoof C, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):666–73
Preferential requirement for protein tyrosine phosphatase activity in the 12–O–tetradecanoylphorbol–13–acetate–induced differentiation of human colon cancer cells. Kuo ML, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1217–22
The protein tyrosine phosphatase DEP–1 is induced during differentiation and inhibits growth of breast cancer cells. Keane MM, et al. **Cancer Res** 1996 Sep 15;56(18):4236–43

Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST-PTP, in rat osteoblast-like cells. Mauro LJ, et al. **Endocrinology** 1996 Mar;137(3):925-33

Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu. Elson A, et al. **J Biol Chem** 1995 Nov 3; 270(44):26116-22

MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. Muda M, et al. **J Biol Chem** 1996 Feb 23; 271(8):4319-26

Polymerase chain reaction cloning of related genes. Sells MA, et al. **Methods Enzymol** 1995;254:184-95

Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Dou QP, et al.
Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9019-23

Identification of a cytoplasmic, phorbol ester-inducible isoform of protein tyrosine phosphatase epsilon. Elson A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12235-9

BLOOD

Phosphotyrosine phosphatase associated with band 3 protein in the human erythrocyte membrane. Zipser Y, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):881-7

The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Passini N, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9412-6

CHEMISTRY

Structure and catalytic properties of protein tyrosine phosphatases. Dixon JE. **Ann N Y Acad Sci** 1995 Sep 7; 766:18-22 (16 ref.)

Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. Wu LW, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):515-23

Transition-state structures for the native dual-specific phosphatase VHR and D92N and S131A mutants. Contributions to the driving force for catalysis. Hengge AC, et al. **Biochemistry** 1996 Jun 4;35(22):7084-92

Nature of the transition state of the protein-tyrosine phosphatase-catalyzed reaction. Hengge AC, et al. **Biochemistry** 1995 Oct 31;34(43):13982-7

Mammalian SH2-containing protein tyrosine phosphatases [letter] Adachi M, et al. **Cell** 1996 Apr 5;85(1):15

Molecular cloning and characterization of Byp, a murine receptor-type tyrosine phosphatase similar to human DEP-1. Kuramochi S, et al. **FEBS Lett** 1996 Jan 2; 378(1):7-14

The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications. Fauman EB, et al. **J Biol Chem** 1996 Aug 2;271(31):18780-8

Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1. Zhang ZY, et al. **J Biol Chem** 1996 Mar 8;271(10):5386-92

Polymerase chain reaction cloning of related genes. Sells MA, et al. **Methods Enzymol** 1995;254:184-95

Protein tyrosine phosphatases take off. Barford D, et al. **Nat Struct Biol** 1995 Dec;2(12):1043-53 (80 ref.)

Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Bilwes AM, et al. **Nature** 1996 Aug 8;382(6591):555-9

Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Eck MJ, et al. **Nature** 1996 Jan 18;379(6562):277-80

Purification, characterization and developmental expression of a brain-specific chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan. Maeda N, et al. **Neuroscience** 1995 Jul;67(1):23-35

Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Pei D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1141-5

A ligand-induced conformational change in the Yersinia protein tyrosine phosphatase. Schubert HL, et al. **Protein Sci** 1995 Sep;4(9):1904-13

Crystal structure of the dual specificity protein phosphatase VHR. Yuvaniyama J, et al. **Science** 1996 May 31; 272(5266):1328-31

DEFICIENCY

Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. Su X, et al. **J Immunol** 1996 Jun 1;156(11):4198-208

GENETICS

Expression of PTP35, the murine homologue of the protein tyrosine phosphatase-related sequence IA-2, is regulated during cell growth and stimulated by mitogens in 3T3 fibroblasts. Magistrelli G, et al.
Biochem Biophys Res Commun 1995 Dec 5;217(1):154-61

Molecular cloning of a novel cytoplasmic protein tyrosine phosphatase PTP epsilon. Nakamura K, et al.
Biochem Biophys Res Commun 1996 Jan 26;218(3):726-32

Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. Wu LW, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):515-23

Characterization of the receptor protein tyrosine phosphatase gene product PTP gamma: binding and activation by triphosphorylated nucleosides. Sorio C, et al.
Cancer Res 1995 Nov 1;55(21):4855-64

The transmembrane tyrosine phosphatase DLAR controls motor axon guidance in Drosophila. Krueger NX, et al. **Cell** 1996 Feb 23;84(4):611-22

Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells. Borges LG, et al. **Circ Res** 1996 Sep; 79(3):570-80

Involvement of MAP kinase in insulin signalling revealed by non-invasive imaging of luciferase gene expression in single living cells. Rutter GA, et al. **Curr Biol** 1995 Aug 1;5(8):890-9

The gene encoding protein-tyrosine phosphatase RPTP epsilon (PTPRE) is assigned to human chromosome 10q26. Melhado IG, et al. **Cytogenet Cell Genet** 1996;73(3):168-70

Assignment of the human gene for receptor-type protein tyrosine phosphatase IA-2 (PTPRN) to chromosome region 2q35 --> q36.1 and identification of an intragenic genetic marker. van den Maagdenberg AM, et al.
Cytogenet Cell Genet 1996;73(1-2):145-8

Two closely related receptor-type tyrosine phosphatases are differentially expressed during rat lung development. Katsura H, et al. **Dev Dyn** 1995 Sep;204(1):89-97

Phosphotyrosine-protein-phosphatases and human reproduction: an association between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Gloria-Bottini F, et al. **Dis Markers** 1996 Mar;12(4):261-9

Alternative splicing generates four different forms of a non-transmembrane protein tyrosine phosphatase mRNA. Reddy RS, et al. **DNA Cell Biol** 1995 Dec;14(12):1007-15

Nucleotide sequence and molecular variants of rat receptor-type protein tyrosine phosphatase-zeta/beta. Maurel P, et al. **DNA Seq** 1995;5(5):323-8

Differential expression of PTP1D, a protein tyrosine phosphatase with two SH2 domains, in a slow and fast skeletal muscle fibers. Mei L, et al. **Exp Cell Res** 1996 May 1;224(2):379-90

IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. Adachi M, et al. **FEBS Lett** 1995 Sep 18;372(1):113-8

Molecular cloning and characterization of Byp, a murine receptor-type tyrosine phosphatase similar to human DEP-1. Kuramochi S, et al. **FEBS Lett** 1996 Jan 2; 378(1):7-14

Cloning and expression of PCPTP1 encoding protein tyrosine phosphatase. Shiozuka K, et al. **Gene** 1995 Sep 11; 162(2):279-84

Gene structure, sequence, and chromosomal localization of the human red cell-type low-molecular-weight acid phosphotyrosyl phosphatase gene, ACP1. Bryson GL, et al. **Genomics** 1995 Nov 20;30(2):133-40

Structure of the murine MPTP-PEST gene: genomic organization and chromosomal mapping. Charest A, et al. **Genomics** 1995 Aug 10;28(3):501-7

Coexisting amplifications of the chromosome 1p32 genes (PTPRF and MYCL1) encoding protein tyrosine phosphatase LAR and L-myc in a small cell lung cancer line. Harder KW, et al. **Genomics** 1995 Jun 10;27(3):552-3

A 900-kb cosmid contig and 10 new transcripts within the candidate region for myotubular myopathy (MTM1). Kioschis P, et al. **Genomics** 1996 May 1;33(3):365-73

Molecular cloning of the human homolog of a striatum-enriched phosphatase (STEP) gene and chromosomal mapping of the human and murine loci. Li X, et al. **Genomics** 1995 Aug 10;28(3):442-9

Assignment of the human protein tyrosine phosphatase epsilon (PTPRE) gene to chromosome 10q26 by fluorescence in situ hybridization. van den Maagdenberg AM, et al. **Genomics** 1995 Nov 1;30(1):128-9

Chromosomal location of murine protein tyrosine phosphatase (Ptprj and Ptpre) genes. Watanabe T, et al. **Genomics** 1995 Oct 10;29(3):793-5

Genomic organization and chromosomal localization of the DUSP2 gene, encoding a MAP kinase phosphatase, to human 2p11.2-q11. Yi H, et al. **Genomics** 1995 Jul 1; 28(1):92-6

Characterization and genomic mapping of genes and pseudogenes of a new human protein tyrosine phosphatase. Zhao Z, et al. **Genomics** 1996 Jul 1;35(1):172-81

Protein-tyrosine phosphatase SH-PTP2 (PTPN11) is localized to 12q24.1-24.3. Dechert U, et al. **Hum Genet** 1995 Nov;96(5):609-15

A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Montagna M, et al. **Hum Genet** 1995 Nov;96(5):532-8

Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells. Sugimoto T, et al.
J Biol Chem 1996 Jan 5;271(1):544-7

A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. Wishart MJ, et al. **J Biol Chem** 1995 Nov 10;270(45):26782-5

Molecular cloning of a mouse epithelial protein-tyrosine phosphatase with similarities to submembranous proteins. Hendriks W, et al. **J Cell Biochem** 1995 Dec;59(4):418-30

B and T cells are not required for the viable motheaten phenotype. Yu CC, et al. **J Exp Med** 1996 Feb 1; 183(2):371-80

Expression of receptor protein tyrosine phosphatase-sigma (RPTP-sigma) in the nervous system of the developing and adult rat. Wang H, et al. **J Neurosci Res** 1995 Jun 15;41(3):297-310

Gene expressions of protein tyrosine phosphatases in regenerating rat liver and rat ascites hepatoma cells. Kitamura T, et al. **Jpn J Cancer Res** 1995 Sep;86(9):811-8

Comparative mapping on the mouse X chromosome defines a myotubular myopathy equivalent region. de Gouyon B, et al. **Mamm Genome** 1996 Aug;7(8):575-9

Genetic mapping of Ptprm on mouse chromosome 17. Mukouyama Y, et al. **Mamm Genome** 1995 Oct;6(10):757-8

Sublocalization of the rat brown gene (B=Tyrp1) by linkage mapping. Sjöling A, et al. **Mamm Genome** 1996 Sep; 7(9):710-1

Expression of protein tyrosine phosphatase genes during oogenesis in Drosophila melanogaster. Fitzpatrick KA, et al. **Mech Dev** 1995 Oct;53(2):171-83

Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Grumont RJ, et al. **Mol Cell Biol** 1996 Jun;16(6):2913-21

A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Laporte J, et al. **Nat Genet** 1996 Jun;13(2):175-82

A plant oncogene as a phosphatase [letter] Filippini F, et al. **Nature** 1996 Feb 8;379(6565):499-500

Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. Wang H, et al. **Oncogene** 1996 Jun 20;12(12):2555-62

IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Lan MS, et al.
Proc Natl Acad Sci U S A 1996 Jun 25;93(13):6367-70

Thermosensitive mutants of the MPTP and hPTP1B protein tyrosine phosphatases: isolation and structural analysis. Muise ES, et al. **Protein Sci** 1996 Apr;5(4):604-13

IMMUNOLOGY

Regulation of immune function by protein tyrosine phosphatases. Okumura M, et al. **Curr Opin Immunol** 1995 Jun;7(3):312-9 (101 ref.)

ICA512 autoantibody radioassay. Gianani R, et al.
Diabetes 1995 Nov;44(11):1340-4

Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Hawkes CJ, et al. **Diabetes** 1996 Sep;45(9):1187-92

Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Myers MA, et al. **Diabetes** 1995 Nov;44(11):1290-5

Involvement of Src-homology-2-domain-containing protein-tyrosine phosphatase 2 in T cell activation. Tailor P, et al. **Eur J Biochem** 1996 May 1;237(3):736-42

Epitope-specific engagement of the protein tyrosine phosphatase CD45 induces tumor necrosis factor-alpha gene expression via transcriptional mechanisms. Estoppey O, et al. **Eur J Immunol** 1996 Jul;26(7):1475-80

Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Burshtyn DN, et al. **Immunity** 1996 Jan; 4(1):77-85

Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. Verge CF, et al. **J Autoimmun** 1996 Jun;9(3):379-83

Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Lu J, et al.
Proc Natl Acad Sci U S A 1996 Mar 19;93(6):2307-11

The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Passini N, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9412-6

Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Sory MP, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):11998-2002

ISOLATION & PURIFICATION

Expression, purification and kinetic behaviour of fission yeast low M(r) protein-tyrosine phosphatase. Modesti A, et al. **FEBS Lett** 1995 Nov 20;375(3):235-8

Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk. King AG, et al. **Oncogene** 1995 Dec 21;11(12):2553-63

METABOLISM

Differential whole-cell extract preparation and electrophoretic mobility shift assay to evaluate the effect of tyrosine phosphatases on DNA binding activity of transcription factors. Nakshatri H, et al. **Anal Biochem** 1996 Apr 5;236(1):178-81

Regulation of human natural killer-cell lytic activity by serine/threonine phosphatases and kinases. Bajpai A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:216-9

Structure and catalytic properties of protein tyrosine phosphatases. Dixon JE. **Ann N Y Acad Sci** 1995 Sep 7; 766:18-22 (16 ref.)

Phosphotyrosyl protein phosphatase-like activity of a clonal

osteoblastic cell line (MC3T3-E1 cell). Suzuki K, et al. **Arch Oral Biol** 1995 Sep;40(9):825-30

Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. Bronte V, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):344-51

Low M(r) phosphotyrosine protein phosphatase interacts with the PDGF receptor directly via its catalytic site. Chiarugi P, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):21-5

Expression of PTP35, the murine homologue of the protein tyrosine phosphatase-related sequence IA-2, is regulated during cell growth and stimulated by mitogens in 3T3 fibroblasts. Magistrelli G, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):154-61

Evidence for a TSH-controlled ectophosphotyrosine phosphatase in pig thyroid cultured cells. Petitfrere E, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):746-53

Hematopoietic cell phosphatase (HCP) regulates p56LCK phosphorylation and ZAP-70 binding to T cell receptor zeta chain. Raab M, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):50-7

Regulation of single Cl- channel conductance by insulin and tyrosine phosphatase. Shintani Y, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):142-7

Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells. Gaits F, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):97-103

Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Reardon DB, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):401-4

Measurement of phosphotyrosine phosphatase activity using the Folin-Ciocalteu phenol reaction. Gmeiner BM, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):943-8

Increased proteolytic processing of protein tyrosine phosphatase mu in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Campan M, et al. **Biochemistry** 1996 Mar 26;35(12):3797-802

VHR and PTP1 protein phosphatases exhibit remarkably different active site specificities toward low molecular weight nonpeptidic substrates. Chen L, et al. **Biochemistry** 1996 Jul 23;35(29):9349-54

Transition-state structures for the native dual-specific phosphatase VHR and D92N and S131A mutants. Contributions to the driving force for catalysis. Hengge AC, et al. **Biochemistry** 1996 Jun 4;35(22):7084-92

Substrate specificity of IphP, a cyanobacterial dual-specificity protein phosphatase with MAP kinase phosphatase activity. Howell LD, et al. **Biochemistry** 1996 Jun 11;35(23):7566-72

Probing the function of Asp128 in the lower molecular weight protein-tyrosine phosphatase-catalyzed reaction. A pre-steady-state and steady-state kinetic investigation. Wu L, et al. **Biochemistry** 1996 Apr 30;35(17):5426-34

Catalytic function of the conserved hydroxyl group in the protein tyrosine phosphatase signature motif. Zhang ZY, et al. **Biochemistry** 1995 Dec 19;34(50):16389-96

Transition state and rate-limiting step of the reaction catalyzed by the human dual-specificity phosphatase, VHR. Zhang ZY, et al. **Biochemistry** 1995 Dec 12; 34(49):16088-96

Reactivity of alcohols toward the phosphoenzyme intermediate in the protein-tyrosine phosphatase-catalyzed reaction: probing the transition state of the dephosphorylation step. Zhao Y, et al. **Biochemistry** 1996 Sep 10;35(36):11797-804

A novel protein tyrosine phosphatase expressed in lin(lo)CD34hiSca(hi) hematopoietic progenitor cells. Cheng J, et al. **Blood** 1996 Aug 15;88(4):1156-67

Cytosolic inactivation of translocated neutrophil plasma membrane protein tyrosine phosphatase. Cui Y, et al. **Blood** 1996 Jan 1;87(1):341-9

Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Tauchi T, et al. **Blood** 1996 Jun 1;87(11):4495-501

Surgical denervation increases protein tyrosine phosphatase activity in skeletal muscle. Tanowitz M, et al. **Brain Res** 1996 Mar 18;712(2):299-306

Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Imai A, et al. **Cancer** 1996 Jan 1; 77(1):132-7

Characterization of the receptor protein tyrosine phosphatase gene product PTP gamma: binding and activation by triphosphorylated nucleosides. Sorio C, et al. **Cancer Res** 1995 Nov 1;55(21):4855-64

IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype. Xie H, et al. **Cancer Res** 1996 Jun 15;56(12):2742-4

Receptor tyrosine phosphatases are required for motor axon guidance in the Drosophila embryo. Desai CJ, et al. **Cell** 1996 Feb 23;84(4):599-609

Daughter of sevenless is a substrate of the phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling. Herbst R, et al. **Cell** 1996 Jun 14;85(6):899-909

A kinase/phosphatase system involving the protooncogene Lck is necessary for inducible modulation of Sob I during T cell activation. Benson BA, et al. **Cell Immunol** 1996 Jun 15;170(2):245-50

Phorbol ester-dependent regulation of nuclear protein tyrosine phosphatase in situ. Heimerl P, et al. **Cell Signal** 1995 May;7(4):341-50

A tyrosine phosphatase is associated with the somatostatin receptor. Delesque N, et al. **Ciba Found Symp** 1995; 190:187-96; discussion 196-203

Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells. Borges LG, et al. **Circ Res** 1996 Sep; 79(3):570-80

CD4+ lymphocytes from HIV-infected patients display impaired CD45-associated tyrosine phosphatase activity which is enhanced by anti-oxidants. Cayota A, et al. **Clin Exp Immunol** 1996 Apr;104(1):11-7

Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727-9 (12 ref.)

Decreased skeletal muscle phosphotyrosine phosphatase (PTPase) activity towards insulin receptors in insulin-resistant Zucker rats measured by delayed Europium fluorescence. Worm D, et al. **Diabetologia** 1996 Feb;39(2):142-8

Tight association of GRB2 with receptor protein-tyrosine phosphatase alpha is mediated by the SH2 and C-terminal SH3 domains. den Hertog J, et al. **EMBO J** 1996 Jun 17; 15(12):3016-27

Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. Groom LA, et al. **EMBO J** 1996 Jul 15;15(14):3621-32

Identification by mutation of the tyrosine residues in the insulin receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinase. Rocchi S, et al. **Endocrinology** 1995 Dec;136(12):5291-7

A 60-kilodalton protein in rat hepatoma cells overexpressing insulin receptor was tyrosine phosphorylated and associated with Syp, phophatidylinositol 3-kinase, and Grb2 in an insulin-dependent manner [see comments] Zhang-Sun G, et al. **Endocrinology** 1996 Jul;137(7):2649-58 . Comment in: Endocrinology 1996 Jul;137(7):2647-8.

A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn. Agostinis P, et al. **Eur J Biochem** 1996 Mar 1; 236(2):548-57

Characterization of a life-cycle-stage-regulated membrane protein tyrosine phosphatase in Trypanosoma brucei. Bakalara N, et al. **Eur J Biochem** 1995 Dec 15;234(3):871-7

A tyrosine-phosphorylated 110-120-kDa protein associates with the C-terminal SH2 domain of phosphotyrosine phosphatase-1D in T cell receptor-stimulated T cells. Frearson JA, et al. **Eur J Immunol** 1996 Jul;26(7):1539-43

Detection of restricted isoform expression and tyrosine phosphatase activity of CD45 in murine dendritic cells. Haidl ID, et al. **Eur J Immunol** 1995 Dec;25(12):3370-4

Trypanosoma brucei and Trypanosoma cruzi: life cycle-regulated protein tyrosine phosphatase activity. Bakalara N, et al. **Exp Parasitol** 1995 Nov;81(3):302-12

Activation of platelet-derived growth factor (PDGF) receptor dephosphorylation in intact Swiss 3T3 cells by elevators of intracellular Ca2+ and cAMP. Böhmer FD, et al. **FEBS Lett** 1996 Aug 5;391(1-2):219-22

PDGF receptor as a specific in vivo target for low M(r) phosphotyrosine protein phosphatase. Chiarugi P, et al. **FEBS Lett** 1995 Sep 18;372(1):49-53

Phosphatase toward MAP kinase is regulated by osmolarity in Madin-Darby canine kidney (MDCK) cells. Itoh T, et al. **FEBS Lett** 1995 Oct 9;373(2):123-6

Expression, purification and kinetic behaviour of fission yeast low M(r) protein-tyrosine phosphatase. Modesti A, et al. **FEBS Lett** 1995 Nov 20;375(3):235-8

Drosophila terminal structure development is regulated by the compensatory activities of positive and negative phosphotyrosine signaling sites on the Torso RTK. Cleghon V, et al. **Genes Dev** 1996 Mar 1;10(5):566-77

Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Wiener JR, et al. **Gynecol Oncol** 1996 May;61(2):233-40

Cloning, purification, and properties of a phosphotyrosine protein phosphatase from Streptomyces coelicolor A3(2). Li Y, et al. **J Bacteriol** 1996 Jan;178(1):136-42

Insulin signaling in mice expressing reduced levels of Syp. Arrandale JM, et al. **J Biol Chem** 1996 Aug 30; 271(35):21353-8

Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. Bokemeyer D, et al. **J Biol Chem** 1996 Jan 12; 271(2):639-42

Protein-tyrosine kinases activate while protein-tyrosine phosphatases inhibit L-type calcium channel activity in pituitary GH3 cells. Cataldi M, et al. **J Biol Chem** 1996 Apr 19;271(16):9441-6

Phosphotyrosine-independent binding of SHC to the NPLH sequence of murine protein-tyrosine phosphatase-PEST. Evidence for extended phosphotyrosine binding/phosphotyrosine interaction domain recognition specificity. Charest A, et al. **J Biol Chem** 1996 Apr 5; 271(14):8424-9

The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. Chu Y, et al. **J Biol Chem** 1996 Mar 15; 271(11):6497-591

The molecular basis of the differing kinetic behavior of the two low molecular mass phosphotyrosine protein phosphatase isoforms. Cirri P, et al. **J Biol Chem** 1996 Feb 2;271(5):2604-7

A Drosophila protein-tyrosine phosphatase associates with an adapter protein required for axonal guidance. Clemens JC, et al. **J Biol Chem** 1996 Jul 19;271(29):17002-5

The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression. David M, et al. **J Biol Chem** 1996 Jul 5; 271(27):15862-5

Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits. Dent P, et al. **J Biol Chem** 1996 Feb 9; 271(6):3119-23

The active site specificity of the Yersinia protein-tyrosine phosphatase. Dunn D, et al. **J Biol Chem** 1996 Jan 5; 271(1):168-73

Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. Florio T, et al. **J Biol Chem** 1996 Mar 15;271(11):6129-36

Association of human protein-tyrosine phosphatase kappa with members of the armadillo family. Fuchs M, et al. **J Biol Chem** 1996 Jul 12;271(28):16712-9

Syp associates with gp130 and Janus kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes. Fuhrer DK, et al. **J Biol Chem** 1995 Oct 20;270(42):24826-30

G-protein beta gamma subunits mediate specific phosphorylation of the protein-tyrosine phosphatase SH-PTP1 induced by lysophosphatidic acid. Gaits F, et al. **J Biol Chem** 1996 Aug 16;271(33):20151-5

Initiation of Xenopus oocyte maturation by activation of the mitogen-activated protein kinase cascade. Gotoh Y, et al. **J Biol Chem** 1995 Oct 27;270(43):25898-904

Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling. Haque SJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25709-14

Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. Kenner KA, et al. **J Biol Chem** 1996 Aug 16; 271(33):19810-6

The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells. Kon-Kozlowski M, et al. **J Biol Chem** 1996 Feb 16;271(7):3856-62

The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. Kulas DT, et al. **J Biol Chem** 1996 Jan 12;271(2):748-54

6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). Maeda N, et al. **J Biol Chem** 1996 Aug 30;271(35):21446-52

Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin. Milev P, et al. **J Biol Chem** 1995 Oct 20; 270(42):24650-3

Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon. Møller NP, et al. **J Biol Chem** 1995 Sep 29;270(39):23126-31

Potent low molecular weight substrates for protein-tyrosine phosphatase. Montserat J, et al. **J Biol Chem** 1996 Mar 29;271(13):7868-72

A novel cytoplasmic dual specificity protein tyrosine phosphatase implicated in muscle and neuronal differentiation. Mourey RJ, et al. **J Biol Chem** 1996 Feb 16;271(7):3795-802

MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. Muda M, et al. **J Biol Chem** 1996 Feb 23; 271(8):4319-26

Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase. Onodera H, et al. **J Biol Chem** 1996 Sep 6;271(36):22225-30

A heteromorphic protein-tyrosine phosphatase, PTP phi, is regulated by CSF-1 in macrophages. Pixley FJ, et al. **J Biol Chem** 1995 Nov 10;270(45):27339-47

pp60v-src phosphorylates and activates low molecular weight phosphotyrosine-protein phosphatase. Rigacci S, et al. **J Biol Chem** 1996 Jan 19;271(3):1278-81

Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity. Rusciano D, et al. **J Biol Chem** 1996 Aug 23;271(34):20763-9

Protein-tyrosine phosphatase-mediated decrease of epidermal growth factor and platelet-derived growth factor receptor tyrosine phosphorylation in high cell density cultures. Sörby M, et al. **J Biol Chem** 1996 May 3;271(18):10963-6

Protein-tyrosine phosphatase 1D modulates its own state of tyrosine phosphorylation. Stein-Gerlach M, et al. **J Biol Chem** 1995 Oct 20;270(42):24635-7

Positive effect of overexpressed protein-tyrosine phosphatase PTP1C on mitogen-activated signaling in 293 cells. Su L, et al. **J Biol Chem** 1996 Apr 26;271(17):10385-90

Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. Tanaka S, et al. **J Biol Chem** 1996 Jun 14;271(24):14610-6

Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'-kinase activity via modulation of phosphorylation of insulin receptor substrate-1. Ugi S, et al. **J Biol Chem** 1996 May 24;271(21):12595-602

Nerve growth factor stimulates tyrosine phosphorylation and activation of Src homology-containing protein-tyrosine phosphatase 1 in PC12 cells. Vambutas V, et al. **J Biol Chem** 1995 Oct 27;270(43):25629-33

The yeast immunophilin Fpr3 is a physiological substrate of the tyrosine-specific phosphoprotein phosphatase Ptp1. Wilson LK, et al. **J Biol Chem** 1995 Oct 20; 270(42):25185-93

A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. Wishart MJ, et al. **J Biol Chem** 1995 Nov 10;270(45):26782-5

Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2. Wong L, et al. **J Biol Chem** 1996 Aug 30;271(35):20981-4

Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1. Zhang ZY, et al. **J Biol Chem** 1996 Mar 8;271(10):5386-92

Cell density-dependent changes in the insulin action pathway: evidence for involvement of protein-tyrosine phosphatases. Li PM, et al. **J Cell Biochem** 1996 Apr; 61(1):31-8

Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of beta-catenin. Balsamo J, et al. **J Cell Biol** 1996 Aug;134(3):801-13

Role of cdc25-C phosphatase in the immediate G2 delay induced by the exogenous factors epidermal growth factor and phorbolester. Barth H, et al. **J Cell Physiol** 1996 Sep; 168(3):589-99

Activation of phosphotyrosine phosphatase activity is associated with decreased differentiation in adult bovine lens. Blanquet PR, et al. **J Cell Physiol** 1995 Nov; 165(2):358-66

XCL100, an inducible nuclear MAP kinase phosphatase from Xenopus laevis: its role in MAP kinase inactivation in differentiated cells and its expression during early development. Lewis T, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2885-96

Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. Campbell KS, et al. **J Exp Med** 1996 Jul 1;184(1):93-100

Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. Fry AM, et al. **J Exp Med** 1996 Jul 1;184(1):295-300

CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. Law CL, et al. **J Exp Med** 1996 Feb 1;183(2):547-60

Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells. Mizuno K, et al. **J Exp Med** 1996 Aug 1;184(2):457-63

Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. Olcese L, et al. **J Immunol** 1996 Jun 15;156(12):4531-4

Protein tyrosine phosphatase activity associates with the high affinity IgE receptor and dephosphorylates the receptor subunits, but not Lyn or Syk. Swieter M, et al. **J Immunol** 1995 Dec 1;155(11):5330-6

hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase. Martell KJ, et al. **J Neurochem** 1995 Oct;65(4):1823-33

The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. Liu K, et al. **J Virol** 1995 Dec;69(12):7823-34

Oxidative stress-inducible protein tyrosine phosphatase in glomerulonephritis. Feng L, et al. **Kidney Int** 1995 Dec; 48(6):1920-8

Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man. Yang DH, et al. **Lab Invest** 1996 Mar; 74(3):571-84

Rapid tyrosine phosphorylation of Grb2 and Shc in T cells exposed to anti-CD3, anti-CD4, and anti-CD45 stimuli: differential effects of aging. Ghosh J, et al. **Mech Ageing Dev** 1995 Jun 9;80(3):171-87

Dmcdc2 kinase is required for both meiotic divisions during Drosophila spermatogenesis and is activated by the Twine/cdc25 phosphatase. Sigrist S, et al. **Mech Dev** 1995 Oct;53(2):247-60

Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive. Maggard MA, et al. **Metabolism** 1996 Feb;45(2):190-5

Effect of vanadate on amylase secretion and protein tyrosine phosphatase activity in the rat parotid gland. Purushotham KR, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):87-94

Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Bennett AM, et al. **Mol Cell Biol** 1996 Mar;16(3):1189-202

Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Chen HE, et al. **Mol Cell Biol** 1996 Jul; 16(7):3685-97

Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. David M, et al. **Mol Cell Biol** 1995 Dec;15(12):7050-8

Multiple roles of the novel protein tyrosine phosphatase PTP3 during Dictyostelium growth and development. Gamper M, et al. **Mol Cell Biol** 1996 May;16(5):2431-44

Tyrosine dephosphorylation of nuclear proteins mimics transforming growth factor beta 1 stimulation of alpha 2(I) collagen gene expression. Greenwel P, et al. **Mol Cell Biol** 1995 Dec;15(12):6813-9

Inhibition of alpha interferon but not gamma interferon signal transduction by phorbol esters is mediated by a tyrosine phosphatase. Petricoin E 3rd, et al. **Mol Cell Biol** 1996 Apr;16(4):1419-24

Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Paulson RF, et al. **Nat Genet** 1996 Jul;13(3):309-15

Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: a light and electron microscopic study with a complementary DNA-generated polyclonal antibody. Oyama T, et al. **Neuroscience** 1995 Dec;69(3):869-80

Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7. Keegan K, et al. **Oncogene** 1996 Apr 4;12(7):1537-44

Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. Peng ZY, et al. **Oncogene** 1995 Nov 16;11(10):1955-62

Phorbol ester-resistant monoblastoid leukemia cells with a functional mitogen-activated protein kinase cascade but without responsive protein tyrosine phosphatases. Seimiya H, et al. **Oncogene** 1995 Nov 16;11(10):2047-54

Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. Wang H, et al. **Oncogene** 1996 Jun 20;12(12):2555-62

Somatostatin binding capacity, guanylate cyclase and tyrosine phosphatase activities during pancreatic proliferation in the rat induced by gastrectomy. Rodriguez-Martin E, et al. **Peptides** 1995;16(8):1461-7

The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation. Cabiscol E, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4170-4

The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Debant A, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5466-71

Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Denu JM, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2493-8

The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1. Kharbanda S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6898-901

Reversible phosphorylation controls the activity of cyclosome-associated cyclin-ubiquitin ligase. Lahav-Baratz S, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9303-7

Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Pei D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1141-5

The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Pulido R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11686-90

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Schmidt A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3068-73

Angiotensin II type 2 receptor mediates programmed cell death. Yamada T, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):156-60

Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Marengère LE, et al. **Science** 1996 May 24;272(5265):1170-3

Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Plas DR, et al. **Science** 1996 May 24; 272(5265):1173-6

PHARMACOLOGY

6B4 proteoglycan/phosphacan is a repulsive substratum but promotes morphological differentiation of cortical neurons. Maeda N, et al. **Development** 1996 Feb;122(2):647-58

Ca(2+)-independent reduction of N-methyl-D-aspartate channel activity by protein tyrosine phosphatase. Wang YT, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1721-5

PHYSIOLOGY

Roles of protein-tyrosine phosphatases in growth factor signalling. Matozaki T, et al. **Cell Signal** 1996 Jan;8(1):13-9 (67 ref.)

Protein tyrosine phosphatases as adhesion receptors. Brady-Kalnay SM, et al. **Curr Opin Cell Biol** 1995 Oct; 7(5):650-7 (58 ref.)

The SH2-containing tyrosine phosphatase corkscrew is required during signaling by sevenless, Ras1 and Raf. Allard JD, et al. **Development** 1996 Apr;122(4):1137-46

6B4 proteoglycan/phosphacan is a repulsive substratum but promotes morphological differentiation of cortical neurons. Maeda N, et al. **Development** 1996 Feb;122(2):647-58

Phosphotyrosine-protein-phosphatases and human reproduction: an association between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Gloria-Bottini F, et al. **Dis Markers** 1996 Mar;12(4):261-9

PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation. Ali S, et al. **EMBO J** 1996 Jan 2;15(1):135-42

An alternative role for the src-homology-domain-containing phosphotyrosine phosphatase (SH-PTP2) in regulating epidermal-growth-factor-dependent cell growth. Reeves SA, et al. **Eur J Biochem** 1995 Oct 1;233(1):55-61

Internalization of B cell and pre-B cell receptors is regulated by tyrosine kinase and phosphatase activities. Salamero J, et al. **Eur J Immunol** 1995 Oct;25(10):2757-64

Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells. Cossette LJ, et al. **Exp Cell Res** 1996 Mar 15;223(2):459-66

Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction. Kharitonenkov A, et al. **J Biol Chem** 1995 Dec 8; 270(49):29189-93

Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. McKenney DW, et al. **J Biol Chem** 1995 Oct 20;270(42):24949-54

Cell surface expression of receptor protein tyrosine phosphatase RPTP mu is regulated by cell-cell contact. Gebbink MF, et al. **J Cell Biol** 1995 Oct;131(1):251-60

COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. Lorenzen JA, et al. **J Cell Biol** 1995 Nov;131(3):631-43

The low affinity Fc gamma RIIa and Fc gamma RIIIb on polymorphonuclear neutrophils are differentially regulated by CD45 phosphatase. Hoffmeyer F, et al. **J Immunol** 1995 Oct 15;155(8):4016-23

hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase. Martell KJ, et al. **J Neurochem** 1995 Oct;65(4):1823-33

LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells. Zhai Y, et al. **Mol Carcinog** 1995 Oct; 14(2):103-10

Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287-96

Protein tyrosine phosphatases take off. Barford D, et al. **Nat Struct Biol** 1995 Dec;2(12):1043-53 (80 ref.)

PY in the fly receptor-like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065-8 (17 ref.)

GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Huang L, et al. **Oncogene** 1995 Nov 16;11(10):2097-103

Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. Lorenz U, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9624-9

Protein tyrosine phosphatases: their roles in signal transduction. Dixon JE. **Recent Prog Horm Res** 1996; 51:405-14; discussion 415 (31 ref.)

Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279-88 (85 ref.)

RADIATION EFFECTS

The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1. Kharbanda S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6898-901

SECRETION

Cell-surface-bound Yersinia translocate the protein tyrosine phosphatase YopH by a polarized mechanism into the target cell. Persson C, et al. **Mol Microbiol** 1995 Oct; 18(1):135-50

PROTEINASE INHIBITORS see **PROTEASE INHIBITORS**

PROTEINASES see **PEPTIDE PEPTIDOHYDROLASES**

PROTEINS

see related
AMINO ACID SEQUENCE
BLOOD PROTEINS
PROTEIN CONFORMATION

Nutritional value of protein hydrolysis products (oligopeptides and free amino acids) as a consequence of absorption and metabolism kinetics. Rérat A. **Arch Tierernahr** 1995;48(1-2):23-36

Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Cha MK, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):900-7

Extended length heterobifunctional coupling agents for protein conjugations. Bieniarz C, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):88-95

Immunoblotting studies on artifactual contamination of enamel homogenates by albumin and other proteins. Chen WY, et al. **Calcif Tissue Int** 1995 Aug;57(2):145-51

Leptin in humans: current progress and future directions [editorial; comment] Considine RV, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):843-4. Comment on: Clin Chem 1996 Jun;42(6 Pt 1):942-6.

Bone morphogenetic protein-2: biology and applications. Riley EH, et al. **Clin Orthop** 1996 Mar;(324):39-46 (70 ref.)

Effect of different protein supplements on motility and plasma membrane integrity of frozen-thawed stallion spermatozoa. Braun J, et al. **Cryobiology** 1995 Oct; 32(5):487-92

Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Amizuka N, et al. **Dev Biol** 1996 Apr 10;175(1):166-76

In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells which are NK1.1-. Launois P, et al. **Eur J Immunol** 1995 Dec; 25(12):3298-307

Tissue expression, structure and function of the murine Ly-6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277-96 (111 ref.)

Stochastic motif extraction using hidden Markov model. Fujiwara Y, et al. **Ismb** 1994;2:121-9

Hidden Markov models and iterative aligners: study of their equivalence and possibilities. Tanaka H, et al. **Ismb** 1993; 1:395-401

Preparation and characterization of high-surface-area polymer substrates for microcalorimetry. Lee VA, et al. **J Biomed Mater Res** 1996 May;31(1):51-62

Radiolabeling of proteins for biochemical studies. Kelman Z, et al. **Methods Enzymol** 1995;262:430-42

ATP modulation of the ligand binding and signal transduction activities of the type C natriuretic peptide receptor guanylate cyclase. Duda T, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):179-83

Bidding heats up for protein database [news] Butler D. **Nature** 1996 May 23;381(6580):266

Abnormal splicing of the leptin receptor in diabetic mice. Lee GH, et al. **Nature** 1996 Feb 15;379(6566):632-5

Government backs proteome proposal [news] Swinbanks D. **Nature** 1995 Dec 14;378(6558):653

The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247-54 (57 ref.)

[Genetically reduced effect or deficiency of the hormone leptin as the cause of obesity] Astrup AV, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4534-5 **(Dan)**

[14-3-3; a novel protein family which regulates intracellular signaling] Ichimura T, et al. **Seikagaku** 1995 Sep; 67(9):1156-62 (27 ref.) **(Jpn)**

[Measurements of density and partial specific volume] Gekko K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2461-5 (11 ref.) **(Jpn)**

[Circular dichroism of proteins: recent developments in analysis and prediction] Woody RW, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):56-69 (120 ref.) **(Jpn)**

[Heterogeneity of GTPase-activating proteins for Ras in the regulation of Ras signal transduction pathway] Hattori S, et al. **Yakugaku Zasshi** 1996 Jan;116(1):21-38 (58 ref.) (Eng. Abstr.) **(Jpn)**

[Establishment of fundamentals for protein research. Stabilization of protein] Imoto T. **Yakugaku Zasshi** 1996 Apr;116(4):259-65 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of polydioxanone and silk on normal cicatrisation of surgically injured myocardial tissue. An experimental model] Serrano-Gallardo G, et al. **Arch Inst Cardiol Mex** 1996 Jan-Feb;66(1):23-8 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):332-51 (234 ref.)

Protein release kinetics of a biodegradable implant for fracture non-unions. Agrawal CM, et al. **Biomaterials** 1995 Nov;16(16):1255-60

Invasion-inhibiting factor 2-albumin conjugate inhibits invasion and spontaneous metastasis of MKL-4 human breast cancer cells transplanted into female nude mice. Kurebayashi J, et al. **Clin Exp Metastasis** 1996 Mar; 14(2):87-94

Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635-50 (114 ref.)

Mechanisms of action of atrial natriuretic factor and C-type natriuretic peptide. Amin J, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):684-7

The introduction of proteins into mammalian cells by electroporation. Morgan WF, et al. **Methods Mol Biol** 1995; 48:63-71

A new role for a fat actor. Hamilton BS. **Nat Med** 1996 Mar;2(3):272-3

Controlled release of a therapeutic protein. Langer R. **Nat Med** 1996 Jul;2(7):742-3

Characterization of LLC-PK1 kidney epithelial cells as an in vitro model for studying renal tubular reabsorption of protein drugs. Takakura Y, et al. **Pharm Res** 1995 Dec; 12(12):1968-72

Psychosocial effects of skin treatment with Imedeen. Stronks DL, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):811-6

Role of angiotensin in the regulation of renal response to proteins. Gabbai FB, et al. **Semin Nephrol** 1995 Sep; 15(5):396-404 (56 ref.)

ADVERSE EFFECTS

Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2-3):79-83 (30 ref.)

ANALYSIS

Detection of two transforming growth factor-beta-related morphogens, bone morphogenetic proteins-4 and -5, in RNA of multiple sclerosis and Creutzfeldt-Jakob disease lesions. Deininger M, et al. **Acta Neuropathol (Berl)** 1995; 90(1):76-9

Early protein oxidation in the neonatal lung is related to development of chronic lung disease. Varsila E, et al. **Acta Paediatr** 1995 Nov;84(11):1296-9

Quantitation of major allergens in dust samples from urban populations collected in different seasons in two climatic areas of the Basque region (Spain). Echechipía S, et al. **Allergy** 1995 Jun;50(6):478-82

Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Sugi K, et al. **Am J Gastroenterol** 1996 May;91(5):927-34

Parathyroid-hormone-related peptide in hematologic malignancies. Kremer R, et al. **Am J Med** 1996 Apr; 100(4):406-11

Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acid in human amnion and chorion-decidua: implications for secretion and function. Bruns ME, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):739-46

High resolution two-dimensional electrophoresis: technique and potential applicability to the study of inner ear disease. Thalmann I, et al. **Am J Otol** 1995 Mar;16(2):153-7

Interference in protein assays of biological specimens by vanadyl compounds. Ahmed RL, et al. **Anal Biochem** 1996 May 15;237(1):76-9

A modified Coomassie blue staining of proteins in polyacrylamide gels with Bismark brown R. Choi JK, et al. **Anal Biochem** 1996 Apr 5;236(1):82-4

Rapid removal of nonspecific background in silver-stained polyacrylamide gel. Desnoyers S, et al. **Anal Biochem** 1995 Nov 20;232(1):138-40

Ultramicro-analysis by use of light-scanning photoacoustic densitometry for electrophoresed protein in human hair. Fukami T, et al. **Anal Biochem** 1996 Jun 15;238(1):60-4

Modified procedure for nonspecific protein staining on nitrocellulose paper using Coomassie brilliant blue R-250. Metkar SS, et al. **Anal Biochem** 1995 May 20;227(2):389-91

A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. Nag A, et al. **Anal Biochem** 1996 Jun 1; 237(2):224-31

Upside-down stopped-flow electrofractionation of complex protein mixtures. Naryzhny SN. **Anal Biochem** 1996 Jun 15;238(1):50-3

Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Ohno T, et al. **Anal Biochem** 1995 Oct 10;231(1):115-22

A nickel chelate microtiter plate assay for six histidine-containing proteins. Paborsky LR, et al. **Anal Biochem** 1996 Feb 1;234(1):60-5

Western blot of proteins from Coomassie-stained polyacrylamide gels. Ranganathan V, et al. **Anal Biochem** 1996 Feb 1;234(1):102-4

Detection of the amine acceptor protein substrates of transglutaminase with 5-(biotinamido) pentylamine. Singh RN, et al. **Anal Biochem** 1995 Oct 10;231(1):261-3

Application of high-performance liquid chromatography to determination of modifier activity in alpha-lactalbumin and other proteins. White FH Jr, et al. **Anal Biochem** 1995 Jul 1;228(2):202-7

Sequence-specific fragmentation of matrix-assisted laser-desorbed protein/peptide ions. Brown RS, et al. **Anal Chem** 1995 Nov 1;67(21):3990-9

Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Cohen SL, et al. **Anal Chem** 1996 Jan 1;68(1):31-7

Protein identification by capillary zone electrophoresis/microelectrospray ionization-tandem mass spectrometry at the subfemtomole level. Figeys D, et al. **Anal Chem** 1996 Jun 1;68(11):1822-8

Characterization of SDS—PAGE-separated proteins by matrix-assisted laser desorption/ionization mass spectrometry. Liang X, et al. **Anal Chem** 1996 Mar 15; 68(6):1012-8

Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Shevchenko A, et al. **Anal Chem** 1996 Mar 1;68(5):850-8

Graphite surface-assisted laser desorption/ionization time-of-flight mass spectrometry of peptides and proteins from liquid solutions. Sunner J, et al. **Anal Chem** 1995 Dec 1;67(23):4335-42

Off-line coupling of capillary electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Walker KL, et al. **Anal Chem** 1995 Nov 15;67(22):4197-204

The Protein Disease Database of human body fluids: II. Computer methods and data issues. Lemkin PF, et al. **Appl Theor Electrophor** 1995;5(2):55-72

The protein disease database of human body fluids: I. Rationale for the development of this database. Merril CR, et al. **Appl Theor Electrophor** 1995;5(2):49-54

Electron microscopic immunolocalization of caltrin proteins in guinea pig seminal vesicles. Coronel CE, et al. **Arch Androl** 1995 Nov-Dec;35(3):233-46

Identification of rat bone morphogenetic protein-3b (BMP-3b), a new member of BMP-3. Takao M, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):656-62

Electrophoretic analysis of rainbow trout (Oncorhynchus mykiss) mucus. Hutchinson AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):86S

Bioanalytical mass spectrometry: many flavors to choose [editorial] Loo JA. **Bioconjug Chem** 1995 Nov-Dec; 6(6):644-65 (262 ref.)

Antigenic proteins in latex glove extracts: sources of variability. Zehr BD, et al. **Biomed Instrum Technol** 1995 Sep-Oct;29(5):434-8

A vanadate hematoxylin stain for basic proteins. Smith AA. **Biotech Histochem** 1995 Sep;70(5):258-62

Protein immunoblotting of stained gels. Dionisi HM, et al. **Biotechniques** 1995 Sep;19(3):348-50

SDS-polyacrylamide gel electrophoretic analysis of proteins in the presence of guanidinium hydrochloride. Funderburgh JL, et al. **Biotechniques** 1996 Mar;20(3):376-8

Application of the immunoblot technique for quantitation of protein levels in cardiac homogenates. Harrer JM, et al. **Biotechniques** 1995 Jun;18(6):995-8

Quantitative dot-immunoblot assay to measure protein in multiple brain samples. Mink RB, et al. **Biotechniques** 1996 May;20(5):809-11

Environmentally benign staining procedure for electrophoresis gels using Coomassie Brilliant Blue. Nivinskas H, et al. **Biotechniques** 1996 Mar;20(3):380-2, 384-5

Rapid, simultaneous determination of protein and salt concentrations in ion-exchange fractions. Shambaugh GE 3rd, et al. **Biotechniques** 1995 Nov;19(5):725-8

DNAdraw: a program for preparing DNA and protein data for publication. Shapiro M. **Biotechniques** 1995 Jun; 18(6):1064-7

Rapid Coomassie blue staining and destaining of polyacrylamide gels. Wu W, et al. **Biotechniques** 1996 Mar; 20(3):386-8

Semi-automated protein assay using microtitre plates: some practical considerations [letter] Williams GA, et al. **Br J Biomed Sci** 1995 Sep;52(3):230-1

Differentiation-associated localization of small proline-rich protein in normal and diseased human skin. Koizumi H, et al. **Br J Dermatol** 1996 Apr;134(4):686-92

Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Johansen JS, et al. **Br J Rheumatol** 1996 Jun; 35(6):553-9

The identification of a functional nuclear localization signal in the Huntington disease protein. Bessert DA, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):165-73

Elimination of cadmium from Cd-contaminated Tilapia zilli in media containing EDTA and freshwater: changes in protein levels. Kargin F. **Bull Environ Contam Toxicol** 1996 Aug;57(2):211-6

High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Grignon DJ, et al. **Cancer Res** 1996 Apr 1;56(7):1654-9

Immunocytochemical characterization of a new marker of fibrous and reactive astrocytes. Ridet JL, et al. **Cell Tissue Res** 1996 Jan;283(1):39-49

Fourier-transform infrared spectroscopic analysis of rabbit lung surfactant: subfraction-associated phospholipid and protein profiles. Knells G, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):193-201

Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers. Lesur O, et al. **Chest** 1996 Feb;109(2):467-74

Anion gap in turpentine-induced pleural effusions. Correlation with pH and protein level. Paulson WD, et al. **Chest** 1996 Feb;109(2):504-9

Rapid differentiation of pathogenesis in patients with pulmonary edema by protein measurement with refractometer. Lien TC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):298-304

Increased Clara cell protein in serum of firefighters [letter] Bernard A, et al. **Clin Chem** 1996 Jul;42(7):1120

Radioimmunoassay of leptin in human plasma [see comments] Ma Z, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):942-6. Comment in: Clin Chem 1996 Jun;42(6 Pt 1):843-4.

Detection on immunoblot of new proteins from the soluble fraction of the cell recognized either by anti-liver-kidney microsome antibodies type 1 or by anti-liver cytosol antibodies type 1—relationship with hepatitis C virus infection. Ballot E, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):245-54

Lipids and proteins in the Rathke's gland secretions of the North American mud turtle (Kinosternon subrubrum).

Seifert WE Jr, et al.
Comp Biochem Physiol B Biochem Mol Biol 1994 Oct–Nov; 109(2–3):459–63

Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. Pellicciari C, et al. **Cytometry** 1995 Dec 1;21(4):329–37

Localization of transforming growth factor-beta 1 precursor and latent TGF-beta 1 binding protein in colorectal adenomas. Van Laethem JL, et al. **Dig Dis Sci** 1996 Sep; 41(9):1741–8

Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. Kyzer SD, et al. **Dis Colon Rectum** 1996 May;39(5):546–51

Calcitonin mRNA expression and plasma calciotropic hormones in fetal lambs. Collignon H, et al.
Domest Anim Endocrinol 1996 May;13(3):269–76

Effects of cyclosporine A on the rat liver and kidney protein pattern, and the influence of vitamin E and C coadministration. Benito B, et al. **Electrophoresis** 1995 Jul; 16(7):1273–83

Free flow-isoelectric focusing of human cellular lysates as sample preparation for protein analysis. Burggraf D, et al. **Electrophoresis** 1995 Jun;16(6):1010–5

Electrophoretic separation of biopolymers in a matrix of polyacrylamide covalently linked to agarose. Chiari M, et al. **Electrophoresis** 1996 Mar;17(3):473–8

Coelectrophoresis of cardiac tissue from human, dog, rat and mouse: towards the establishment of an integrated two-dimensional protein database. Corbett JM, et al. **Electrophoresis** 1995 Aug;16(8):1524–9

N,N,N',N'-tetramethyl-1,3-butanediamine as effective running electrolyte additive for efficient electrophoretic separation of basic proteins in bare fused-silica capillaries. Corradini D, et al. **Electrophoresis** 1995 Apr;16(4):630–5

Mineral-bound noncollagenous proteins in archaeological human skeletons. Freundorfer S, et al. **Electrophoresis** 1995 May;16(5):817–9

Analysis of proteins from human breast epithelial cells using two-dimensional gel electrophoresis. Giometti CS, et al. **Electrophoresis** 1995 Jul;16(7):1215–24

Identification of proteins by their amino acid composition: an evaluation of the method. Golaz O, et al.
Electrophoresis 1996 Mar;17(3):573–9

On the separation mechanism of capillary sodium dodecyl sulfate-gel electrophoresis of proteins. Guttman A.
Electrophoresis 1995 Apr;16(4):611–6

Electrophoretic analysis of biliary proteins: application of high resolution two-dimensional polyacrylamide gel electrophoresis with immobilized pH gradient in the first dimension. He C, et al. **Electrophoresis** 1996 Mar; 17(3):617–9

Effective blotting of ultrathin polyacrylamide gels anchored to a solid matrix. Heukeshoven J, et al. **Electrophoresis** 1995 May;16(5):748–56

Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Klose J, et al. **Electrophoresis** 1995 Jun; 16(6):1034–59

Two-dimensional electrophoretic analysis of down-regulated proteins in human fibroblasts immortalized by treatment with either 4-nitroquinoline 1-oxide or 60Co gamma rays. Kondo T, et al. **Electrophoresis** 1995 Jun;16(6):1067–73

Simple and sensitive laser-induced fluorescence detection for capillary electrophoresis and its application to protein separation. Lim HB, et al. **Electrophoresis** 1995 Apr; 16(4):674–8

Fused-silica capillaries with surface-bound dextran layer crosslinked with diepoxypolyethylene glycol for capillary electrophoresis of biological substances at reduced electroosmotic flow. Mechref Y, et al. **Electrophoresis** 1995 Apr;16(4):617–24

Mass spectrometric approaches for the identification of gel-separated proteins. Patterson SD, et al.
Electrophoresis 1995 Oct;16(10):1791–814 (202 ref.)

High-performance capillary electrophoretic separation of proteins and peptides using a bonded hydrophilic phase capillary. Piccoli G, et al. **Electrophoresis** 1995 Apr; 16(4):625–9

Protein variability in male and female Wistar rat liver proteins. Steiner S, et al. **Electrophoresis** 1995 Oct; 16(10):1969–76

Characterisation of proteins from two-dimensional electrophoresis gels by matrix-assisted laser desorption mass spectrometry and amino acid compositional analysis. Wheeler CH, et al. **Electrophoresis** 1996 Mar;17(3):580–7

Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects. McGregor GP, et al.
Endocrinology 1996 Apr;137(4):1501–4

Identification of 2 stallion sperm-specific proteins and their autoantibody response. Teuscher C, et al. **Equine Vet J** 1994 Mar;26(2):148–51

Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Johansen JS, et al. **Eur J Cancer** 1995; 31A(9):1437–42

Reference materials and reference measurement systems in laboratory medicine. Commutability and the problem of method-dependent results. Moss DW, et al.
Eur J Clin Chem Clin Biochem 1995 Dec;33(12):1003–7

Amniotic fluid and plasma levels of parathyroid hormone-related protein and hormonal modulation of its secretion by amniotic fluid cells [see comments] Dvir R, et al. **Eur J Endocrinol** 1995 Sep;133(3):277–82. Comment in: Eur J Endocrinol 1995 Sep;133(3):272–4.

Mouse gamma delta TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to alpha beta TCR+NK1.1+ thymocytes. Vicari AP, et al. **Eur J Immunol** 1996 Jul;26(7):1424–9

Automation of micro-preparation and enzymatic cleavage of gel electrophoretically separated proteins. Houthaeve T, et al. **FEBS Lett** 1995 Nov 27;376(1–2):91–4

Vigilin contains a functional nuclear localisation sequence and is present in both the cytoplasm and the nucleus. Kügler S, et al. **FEBS Lett** 1996 Mar 18;382(3):330–4

A model phage display subtraction method with potential for analysis of differential gene expression. Stausbøl-Grøn B, et al. **FEBS Lett** 1996 Aug 5;391(1–2):71–5

Acute ethanol administration induces oxidative changes in rat pancreatic tissue. Altomare E, et al. **Gut** 1996 May; 38(5):742–6

Expression of the tissue metalloproteinase inhibitors TIMP-1 and TIMP-2 in malignant fibrous histiocytomas and dermatofibromas as studied by in situ hybridization and immunohistochemistry. Hurskainen T, et al. **Hum Pathol** 1996 Jan;27(1):42–9

Sperm motility inhibitor from human seminal plasma: association with semen coagulum. Robert M, et al.
Hum Reprod 1995 Aug;10(8):2192–7

Cellular distribution of proteasome subunit Lmp7 mRNA and protein in human placentas. Roby KF, et al.
Immunology 1995 Nov;86(3):469–74

Quantitative and qualitative analysis of accessory gland secretory proteins in a few species of Drosophila immigrans group. Shivanna N, et al. **Indian J Exp Biol** 1995 Sep; 33(9):668–72

Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Onisto M, et al. **Int J Cancer** 1995 Nov 27;63(5):621–6

Sexual differentiation of reproductive tissue in bivalve molluscs: identification of male associated polypeptide in the mantle of Mytilus galloprovincialis Lmk. Mikhailov AT, et al. **Int J Dev Biol** 1995 Jun;39(3):545–8

Evaluation of serum concentration of parathyroid hormone-related protein and its implication in hypercalcemia in squamous cell carcinoma of the head and neck. Rikimaru K, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):365–8

Backscattered electron imaging of crystal matrix protein on the surface of calcium oxalate crystals using colloidal gold. Suzuki K, et al. **Int J Urol** 1995 May;2(2):87–91

Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. Kikuchi K, et al.
J Am Acad Dermatol 1995 Dec;33(6):973–8

Functional characterization of the primate sperm acrosomal antigen (PSA-63). Archibong AE, et al. **J Androl** 1995 Jul–Aug;16(4):318–26

Increased expression of a 68-kDa protein in the corpus cavernosum of some men with erectile dysfunction. van der Ven PF, et al. **J Androl** 1995 May–Jun;16(3):242–7

Effect of breed, intake, and carcass composition on the status of several macro and trace minerals of adult beef cattle. Littledike ET, et al. **J Anim Sci** 1995 Jul;73(7):2113–9

Assessing total body protein, mineral, and bone mineral content from total body water and body density. Siconolfi SF, et al. **J Appl Physiol** 1995 Nov;79(5):1837–43

Quantification of protein in dilute and complex samples: modification of the bicinchoninic acid assay. Schoel B, et al. **J Biochem Biophys Methods** 1995 Jun;30(2–3):199–206

A new luminometer for sensitive quantification by chemiluminescence of specific proteins in microtitre plates and on blot membranes. Vesterberg O.
J Biochem Biophys Methods 1995 Nov;30(4):301–14

Purification and characterization of thrombopoietin. Kato T, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):229–36

Analysis of protein carbonyls with 2,4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. Nakamura A, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):768–74

Attachment and growth of cultured fibroblast cells on silk protein matrices. Minoura N, et al.
J Biomed Mater Res 1995 Oct;29(10):1215–21

Immunoreactive endothelin in the human kidney: comparison with natriuretic peptides. Takahashi K, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 3:S510–2

Symplekin, a novel type of tight junction plaque protein. Keon BH, et al. **J Cell Biol** 1996 Aug;134(4):1003–18

Occurrence of secretogranin II in the prolactin-immunoreactive neurons of the rat lateral hypothalamus: an in situ hybridization and immunocytochemical study. Griffond B, et al.
J Chem Neuroanat 1995 Aug;9(2):113–9

Potential of on-line isotachophoresis-capillary zone electrophoresis with hydrodynamic counterflow in the analysis of various basic proteins and recombinant human interleukin-3. Bergmann J, et al. **J Chromatogr A** 1996 May 24;734(2):381–9

Analysis of protein fractions by micropreparative capillary isoelectric focusing and matrix-assisted laser desorption time-of-flight mass spectrometry. Foret F, et al.
J Chromatogr A 1995 Nov 17;716(1–2):157–66

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1–2):165–90 (72 ref.)

Gel electrophoretic analysis of cellular and secreted proteins from resting and activated rat alveolar macrophages treated with pentamidine isethionate. Selkirk JK, et al.
J Chromatogr A 1995 Sep 22;711(2):331–7

Protein analysis by isoelectric focusing in a capillary array with an absorption imaging detector. Wu J, et al.
J Chromatogr B Biomed Appl 1995 Jul 7;669(1):39–43

Paget's disease is associated with changes in the immunohistochemical distribution of noncollagenous matrix proteins in bone. Ingram RT, et al.
J Clin Endocrinol Metab 1996 May;81(5):1810–20

Presence of hypochlorite-modified proteins in human atherosclerotic lesions. Hazell LJ, et al. **J Clin Invest** 1996 Mar 15;97(6):1535–44

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. Burgmann H, et al. **J Clin Pathol** 1996 Jun;49(6):508–10

Parathyroid hormone related protein and interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients. Schweitzer DH, et al. **J Clin Pathol** 1995 Oct;48(10):896–900

Differences in protein patterns of gill epithelial cells of the fish Gillichthys mirabilis after osmotic and thermal acclimation. Kültz D, et al. **J Comp Physiol [B]** 1996; 166(2):88–100

Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma. Mori H, et al. **J Dermatol** 1996 Jul;23(7):460–2

Expression pattern of osteogenic protein-1 (bone morphogenetic protein-7) in human and mouse development. Helder MN, et al. **J Histochem Cytochem** 1995 Oct;43(10):1035–44

Efficient immunodetection of various protein antigens in glutaraldehyde-fixed brain tissue. Mrini A, et al.
J Histochem Cytochem 1995 Dec;43(12):1285–91

Determination of tissue inhibitor of metalloproteinases-2 (TIMP-2) in experimental animals using monoclonal antibodies against TIMP-2-specific oligopeptides.
Fujimoto N, et al. **J Immunol Methods** 1995 Nov 16; 187(1):33–9

Characterization and subcellular localization of human Pmel 17/silver, a 110-kDa (pre)melanosomal membrane protein associated with 5,6,-dihydroxyindole-2-carboxylic acid (DHICA) converting activity. Lee ZH, et al.
J Invest Dermatol 1996 Apr;106(4):605–10

Localization and expression of cornifin-alpha/SPRR1 in mouse epidermis, anagen hair follicles, and skin neoplasms. Owens DM, et al. **J Invest Dermatol** 1996 Apr; 106(4):647–54

Comparison of the proteins of middle ear effusion with human mast cell proteins. Rakover Y, et al.
J Laryngol Otol 1995 Dec;109(12):1146–50

Regulated expression of neurofibromin in migrating neural crest cells of avian embryos. Stocker KM, et al.
J Neurobiol 1995 Aug;27(4):535–52

Selenoprotein P concentration in plasma is an index of selenium status in selenium-deficient and selenium-supplemented Chinese subjects. Hill KE, et al.
J Nutr 1996 Jan;126(1):138–45

Effects of sex hormones on protein and collagen content of the temporomandibular joint disc of the rat. Abubaker AO, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):721–7; discussion 727–8

Histochemical and immunohistochemical studies of the effects of experimental anterior disc displacement on sulfated glycosaminoglycans, hyaluronic acid, and link protein of the rabbit craniomandibular joint. Ali AM, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):992–1003; discussion 1003–4

Protein extraction and western blotting from methacarn-fixed tissue. Lalani EN, et al. **J Pathol** 1995 Nov;177(3):323–8

Quantitation of proteins using HPLC-detector response rather than standard curve comparison. Eberlein GA.
J Pharm Biomed Anal 1995 Sep;13(10):1263–71

Analysis by two-dimensional electrophoresis of proteins secreted by sheep ovarian follicles: effects of the FecB gene, follicle size and atresia. Driancourt MA, et al.
J Reprod Fertil 1996 May;107(1):69–77

Towards a comprehensive database of proteins from the urine of patients with bladder cancer. Rasmussen HH, et al.
J Urol 1996 Jun;155(6):2113–9

Age-dependent injury in human umbilical vein endothelial cells: relationship to apoptosis and correlation with a lack of A20 expression. Varani J, et al. **Lab Invest** 1995 Dec; 73(6):851–8

Plasma concentrations of obese protein in anorexia nervosa [letter] Hebebrand J, et al. **Lancet** 1995 Dec 16; 346(8990):1624–5

Noninvasive measurement of protein concentration. Jiao X, et al. **Magn Reson Med** 1996 Feb;35(2):159–61

Expression of bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-7 (BMP-7), fibroblast growth factor-8 (FGF-8) and sonic hedgehog (SHH) during branchial arch development in the chick. Wall NA, et al.
Mech Dev 1995 Nov;53(3):383–92

Glutaredoxin. Holmgren A, et al. **Methods Enzymol** 1995; 252:283–92

Identification of GTPase-activating proteins by nitrocellulose overlay assay. Manser E, et al.
Methods Enzymol 1995;256:130–9

Comparative determinations of rat body composition by chemical, near infrared reflectance and total body electrical conductivity analyses. Guggenbuhl P.
Methods Find Exp Clin Pharmacol 1995 Nov;17(9):621–7

Multiple sites of synthesis and action of parathyroid hormone–related protein. Martin TJ, et al.
Miner Electrolyte Metab 1995;21(1–3):123–8

Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population. Chaubert P, et al. **Mod Pathol** 1996 Mar; 9(3):189–93

Ultrafast protein determinations using microwave enhancement. Akins RE, et al. **Mol Biotechnol** 1995 Aug; 4(1):17–24

Differences between atrial and ventricular protein profiling in children with congenital heart disease. Pelouch V, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):43–9

New diagnostic tests for prion diseases [editorial; comment] Collinge J. **N Engl J Med** 1996 Sep 26;335(13):963–5. Comment on: N Engl J Med 1996 Sep 26;335(13):924–30.

Fibrodysplasia ossificans progressiva — lessons from rare maladies [editorial; comment] Connor JM.
N Engl J Med 1996 Aug 22;335(8):591–3. Comment on: N Engl J Med 1996 Aug 22;335(8):555–61.

Serum immunoreactive-leptin concentrations in normal-weight and obese humans [see comments] Considine RV, et al. **N Engl J Med** 1996 Feb 1;334(5):292–5 . Comment in: N Engl J Med 1996 Feb 1;334(5):324–5. Comment in: N Engl J Med 1996 Jun 6;334(23):1544.

The 14–3–3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies [see comments] Hsich G, et al. **N Engl J Med** 1996 Sep 26; 335(13):924–30. Comment in: N Engl J Med 1996 Sep 26;335(13):963–5.

Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva [see comments] Shafritz AB, et al. **N Engl J Med** 1996 Aug 22;335(8):555–61. Comment in: N Engl J Med 1996 Aug 22;335(8):591–3.

Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Maffei M, et al. **Nat Med** 1995 Nov;1(11):1155–61

Neurofibrillary tangles of Alzheimer's disease brains contain 14–3–3 proteins. Layfield R, et al. **Neurosci Lett** 1996 May 3;209(1):57–60

Expression of immunoreactivities to 75 kDa nerve growth factor receptor, trk gene product and phosphotyrosine in granular cell tumors. Hoshi N, et al. **Pathol Int** 1995 Oct; 45(10):748–56

Parathyroid hormone–related peptide: immunolocalisation in normal salivary glands and in pleomorphic adenomas. Sunardhi–Widyaputra S, et al. **Pathol Res Pract** 1996 Jan; 192(1):15–9

Serum leptin in children with obesity: relationship to gender and development. Hassink SG, et al. **Pediatrics** 1996 Aug; 98(2 Pt 1):201–3

The characterization of proteins and peptides by automated methods. Bonner R, et al.
Rapid Commun Mass Spectrom 1995;9(11):1067–76

Curie-point pyrolysis–gas chromatography/mass spectrometry in the art field. 2—The characterization of proteinaceous binders. Carbini M, et al.
Rapid Commun Mass Spectrom 1996;10(10):1240–2

Sequencing electroblotted proteins by tandem mass spectrometry. Fabris D, et al.
Rapid Commun Mass Spectrom 1995;9(11):1051–5

Sherpa: a Macintosh–based expert system for the interpretation of electrospray ionization LC/MS and MS/MS data from protein digests. Taylor JA, et al.
Rapid Commun Mass Spectrom 1996;10(6):679–87

From genome to proteome: looking at a cell's proteins [news] Kahn P. **Science** 1995 Oct 20;270(5235):369–70

Attomole protein characterization by capillary electrophoresis–mass spectrometry. Valaskovic GA, et al. **Science** 1996 Aug 30;273(5279):1199–202

Parathyroid hormone–related protein in the colostrum of paretic post parturient dairy cows. Riond JL, et al.
Vet Rec 1996 Apr 6;138(14):333–4

[Analysis of the polypeptide profile of insulin preparations using HPLC] Středa M, et al. **Sb Lek** 1991;93(9–10):309–13 (Eng. Abstr.) **(Cze)**

[Analysis of protein nutrient reserves of the clitellum and cocoon albumin in Eisenia fetida Sav (Annelida Oligochaeta). Demonstration of a glycolipoprotein comparable to vitellogenin] Rouabah–Sadaoui L, et al.
Reprod Nutr Dev 1995;35(5):491–501 (Eng. Abstr.) **(Fre)**

[Fat/protein ratio in the milk of cattle herds in which displacement of the abomasum occurs] Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec; 102(12):469–71 (Eng. Abstr.) **(Ger)**

[Analysis of cells and proteins in bronchoalveolar lavage fluid] Hanaoka M, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Mar; 34(3):259–65 (Eng. Abstr.) **(Jpn)**

[Protein 1 (Clara cell 10 kDa protein)] Itoh Y, et al.
Nippon Rinsho 1995 Feb;53 Su Pt 1:150–3 (10 ref.) **(Jpn)**

[Parathyroid hormone–related protein (PTHrP)] Watanabe K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:397–400 (12 ref.) **(Jpn)**

[The clinical study on secretory leukoprotease inhibitor (SLPI) in sera of patients with various pulmonary diseases] Sugimoto H, et al. **Rinsho Byori** 1995 Dec;43(12):1267–72 (Eng. Abstr.) **(Jpn)**

[Alpha–1–antitrypsin, albumin and whole protein in meconium and stools during the first days of life in the neonate] Lisowska–Myjak B, et al. **Pediatr Pol** 1995 Oct; 70(10):819–26 (Eng. Abstr.) **(Pol)**

[Plasma–desorption mass spectrometry of natural compounds. 1. Basic properties of the method and its use for analyzing proteins and peptides] Reztsova NA, et al. **Bioorg Khim** 1996 Jan;22(1):3–13 (141 ref.) (Eng. Abstr.) **(Rus)**

[Identification of tissue–specific gene products in Drosophila] Erguchev DM, et al. **Dokl Akad Nauk** 1996 Mar; 347(1):136–40 **(Rus)**

[Nephelometry as optic immunochemical method in the laboratory practice] Kalinin NL, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):35–8 (Eng. Abstr.) **(Rus)**

[The value of the parathyrin–related protein (PTH–RP) in the diagnosis of cancer–associated hypercalcemia] Sagarra E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):450–4 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Antisense inhibition of parathyroid hormone–related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat. Akino K, et al.
Cancer Res 1996 Jan 1;56(1):77–86

The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Zimmerman LB, et al.
Cell 1996 Aug 23;86(4):599–606

Drosophila Notch receptor activity suppresses Hairless function during adult external sensory organ development. Lyman DF, et al. **Genetics** 1995 Dec;141(4):1491–505

Fetuin/alpha2–HS glycoprotein is a transforming growth factor–beta type II receptor mimic and cytokine antagonist. Demetriou M, et al. **J Biol Chem** 1996 May 31; 271(22):12755–61

The nuclear transport factor karyopherin beta binds stoichiometrically to Ran–GTP and inhibits the Ran GTPase activating protein. Floer M, et al. **J Biol Chem** 1996 Mar 8;271(10):5313–6

Mechanism of inhibition by arachidonic acid of the catalytic activity of Ras GTPase–activating proteins. Sermon BA, et al. **J Biol Chem** 1996 Jan 19;271(3):1566–72

Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone–related protein in the rat. Schetz JA, et al.
J Pharmacol Exp Ther 1995 Sep;274(3):1456–62

[The formation of taste aversion and preference under conditions of protein synthesis inhibition in rats] Serova ON, et al. **Zh Vysh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug;45(4):742–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Inhibition of mesothelial cell growth and protein synthesis by heparin. Manalaysay MT, et al. **Adv Perit Dial** 1995; 11:239–42

Parathyroid hormone–related protein in benign lesions [editorial; comment] Bruns DE, et al. **Am J Clin Pathol** 1996 Apr;105(4):377–9. Comment on: Am J Clin Pathol 1996 Apr;105(4):487–92.

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.). Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.

Parathyroid hormone–related protein expression in human gastric adenocarcinomas not associated with hypercalcemia. Abdeen O, et al. **Am J Gastroenterol** 1995 Oct;90(10):1864–7

Production of parathyroid hormone–related peptide in a patient with acute lymphocytic leukemia with extensive osteolytic lesions and hypercalcemia [letter] Miyamura T, et al. **Am J Hematol** 1995 Oct;50(2):150–1

Epidermal growth factor receptor (EGF–R) in human middle ear cholesteatoma: an analysis of protein production and gene expression. Bujia J, et al. **Am J Otol** 1996 Mar; 17(2):203–6

Gut mucosal protein synthesis measured using intravenous and intragastric delivery of stable tracer amino acids. Nakshabendi IM, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E996–9

A small proline–rich protein, SPRR1, is upregulated early during tobacco smoke–induced squamous metaplasia in rat nasal epithelia. Tesfaigzi J, et al.
Am J Respir Cell Mol Biol 1996 May;14(5):478–86

Complete primary sequence of equine cartilage link protein deduced from complementary DNA. Dudhia J, et al.
Am J Vet Res 1995 Jul;56(7):959–65

Effect of coculture with stallion spermatozoa on de novo protein synthesis and secretion by equine oviduct epithelial cells. Thomas PG, et al. **Am J Vet Res** 1995 Dec; 56(12):1657–62

The effect of overexpression of BMPs and GDF–5 on the development of chick limb skeletal elements. Francis–West PH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:254–5

Expression of functional link protein domains using an avian–specific retroviral vector. Hofer U, et al.
Ann N Y Acad Sci 1996 Jun 8;785:271–3

Endothelin stimulates MAP kinase activity and protein synthesis in isolated adult feline cardiac myocytes. Jones LG, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:484–6

mRNA encoding a novel growth regulatory factor is coexpressed with type II procollagen during chondrogenesis. Sandell LJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:325–7

Construction and expression of a functional recombinant gene for proteoglycan. Yang B, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:356–9

Parathyroid hormone–related protein, bone metastases and hypercalcaemia of malignancy. Bundred NJ, et al.
Ann R Coll Surg Engl 1996 Jul;78(4):354–8

Inhibition of basic fibroblast growth factor–mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2–thioindole class of tyrosine kinase inhibitors. Fry DW, et al. **Anticancer Drug Des** 1995 Dec; 10(8):607–22

Effect on cell survival and protein synthesis of benzylidene–glucose (BG) and the deuterated analogue P–1013 in cultured cells. Dunsaed CB, et al.
Anticancer Res 1995 Sep–Oct;15(5B):1921–7

Lack of suppression of tumor cell phenotype by overexpression of TIMP–3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness. Sun Y, et al.
Anticancer Res 1996 Jan–Feb;16(1):1–7

Oxidant–inducible adapt 15 RNA is associated with growth arrest– and DNA damage–inducible gadd153 and gadd45. Crawford DR, et al. **Arch Biochem Biophys** 1996 May 15; 329(2):137–44

Compression of cartilage results in differential effects on biosynthetic pathways for aggrecan, link protein, and hyaluronan. Kim YJ, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):331–40

Effect of interferon on protein translation during growth stages of 3T3 cells. Petryshyn R, et al.
Arch Biochem Biophys 1996 Feb 15;326(2):290–7

Reduced ob mRNA in hypophysectomised rats is not restored by growth hormone (GH), but further suppressed by exogenously administered insulin–like growth factor (IGF) I. Böni–Schnetzler M, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):296–301

Sequence and expression of the mouse homologue to human phospholipase C beta3 neighboring gene. Lagercrantz J, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):335–40

Structure and expression of the tenecin 3 gene in Tenebrio molitor. Lee YJ, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):6–11

The basic fibroblast growth factor (FGF–2) antisense RNA (GFG) is translated into a MutT–related protein in vivo. Li AW, et al. **Biochem Biophys Res Commun** 1996 Jun 5; 223(1):19–23

Augmented expression of the obese gene in the adipose tissue from rats fed high–fat diet. Masuzaki H, et al.
Biochem Biophys Res Commun 1995 Nov 2;216(1):355–8

cAMP, an activator of protein kinase A, suppresses the expression of sonic hedgehog. Noveen A, et al.
Biochem Biophys Res Commun 1996 Feb 6;219(1):180–5

High level expression of the IL–1 receptor related T1 receptor in insect cells. Rupp B, et al.
Biochem Biophys Res Commun 1995 Nov 13;216(2):595–601

The cytosolic chaperonin subunit TRiC–P5 begins to be expressed at the two–cell stage in mouse embryos. Sévigny G, et al. **Biochem Biophys Res Commun** 1995 Nov 2; 216(1):279–83

Rat adipose ob mRNA levels in states of altered circulating glucose and insulin. Sivitz WI, et al.
Biochem Biophys Res Commun 1996 Mar 27;220(3):520–5

C–type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Suda M, et al.
Biochem Biophys Res Commun 1996 Jun 5;223(1):1–6

Activation of two Cynops genes, fork head and sonic hedgehog, in animal cap explants. Takabatake T, et al.
Biochem Biophys Res Commun 1996 Jan 5;218(1):395–401

Age–associated changes of mitochondrial translation and respiratory function in mouse brain. Takai D, et al.
Biochem Biophys Res Commun 1995 Dec 14;217(2):668–74

Meal–feeding specifically induces obese mRNA expression. Thompson MP. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):332–7

Spatial expression of Sonic hedgehog in the lung epithelium during branching morphogenesis. Urase K, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):161–6

Genomic organization of the human bone morphogenetic protein–4 gene: molecular basis for multiple transcripts. van den Wijngaard A, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):789–94

Down–regulation of HCW9 mRNA in rat hepatocytes during chemical hypoxia involves both transcriptional and posttranscriptional mechanisms. Wang H, et al.
Biochem Biophys Res Commun 1996 Jan 5;218(1):360–4

Earthworm gene as indicator of bioefficacious cadmium. Willuhn J, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):581–5

Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases–1, –2, and –3 in rabbit aortic smooth muscle cells. Fabunmi RP, et al. **Biochem J** 1996 Apr 1; 315 (Pt 1):335–42

Oxygen and pH regulation of protein synthesis in mitochondria from Artemia franciscana embryos. Kwast KE, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):207–13

Processing of chromogranins in chromaffin cell culture: effects of reserpine and alpha–methyl–p–tyrosine.

Wolkersdorfer M, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):953–8

mRNA stabilization in continuous flow translation system. Alexandrov A, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1111–6

Retinoic acid enhances expression of bone morphogenetic protein-2 in human adenocarcinoma cell line (HSG-S8). Hatakeyama S, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1235–43

Impaired mitochondrial protein synthesis in streptozotocin diabetic rat hepatocytes. Memon RA, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):627–34

Estrogen receptor activation factor (E-RAF) of the rat uterus: hormonal control. Prem Kumar M, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1207–15

Enteral nutrition, diarrhoea and jejunal protein synthesis in vivo. Marway JS, et al. **Biochem Soc Trans** 1995 Aug; 23(3):462S

Thyroid hormone induces a 52 kDa soluble protein in goat testis Leydig cell which stimulates androgen release. Jana NR, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):209–14

Expression of genes encoding peroxisomal proteins in Saccharomyces cerevisiae is regulated by different circuits of transcriptional control. Kos W, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):79–86

Effect of the ATP level on the overall protein biosynthesis rate in a wheat germ cell-free system. Matveev SV, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):207–12

Cyclic AMP stimulates protein synthesis in L6 myoblasts and its effects are additive to those of insulin, vasopressin and 12-0-tetradecanoylphorbol-13-acetate. Possible involvement of mitogen activated protein kinase. Thompson MG, et al. **Biochim Biophys Acta** 1996 Mar 27; 1311(1):37–44

Protein synthesis in eukaryotic organisms: new insights into the function of translation initiation factor eIF-3. Hannig EM. **Bioessays** 1995 Nov;17(11):915–9 (49 ref.)

Molecular cloning and identification of a novel porcine cathelin-like antibacterial peptide precursor. Strukelj B, et al. **Biol Chem Hoppe Seyler** 1995 Aug;376(8):507–10

Effect of diabetes on protein synthesis rate and eukaryotic initiation factor activities in the liver of virgin and pregnant rats. Garcia AM, et al. **Biol Neonate** 1996;69(1):37–50

Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. van Setten PA, et al. **Blood** 1996 Jul 1;88(1):174–83

Expression of the Fanconi anemia gene FAC in human cell lines: lack of effect of oxygen tension. Joenje H, et al. **Blood Cells Mol Dis** 1995;21(3):182–91

The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone. Meikle MC, et al. **Bone** 1995 Sep;17(3):255–60

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Kossakowska AE, et al. **Br J Cancer** 1996 Jun; 73(11):1401–8

Effect of transcutaneous electrical muscle stimulation on postoperative muscle mass and protein synthesis. Vinge O, et al. **Br J Surg** 1996 Mar;83(3):360–3

MARCKS and protein F1/GAP-43 mRNA in chick brain: effects of imprinting. Meberg PJ, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):149–56

Regulation of secretogranin II mRNA in rat neuronal cultures. Scammell JG, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):326–32

Expression of parathyroid hormone-related protein in rat articular cartilage. Tsukazaki T, et al. **Calcif Tissue Int** 1995 Sep;57(3):196–200

Dissociation of thermogenic and trophic actions of norepinephrine in brown adipocytes of Richardson ground squirrels. Desautels M, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1458–65

The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Takeda N, et al. **Cancer** 1996 Mar 15;77(6):1167–79

Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53. Foley J, et al. **Cancer Res** 1996 Sep 1; 56(17):4056–62

Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Imren S, et al. **Cancer Res** 1996 Jul 1;56(13):2891–5

Elevation of interferon beta-inducible proteins in ataxia telangiectasia cells. Siddoo-Atwal C, et al. **Cancer Res** 1996 Feb 1;56(3):443–7

Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Huang MT, et al. **Carcinogenesis** 1996 Apr;17(4):761–5

Regulation of the Drosophila protein timeless suggests a mechanism for resetting the circadian clock by light. Hunter-Ensor M, et al. **Cell** 1996 Mar 8;84(5):677–85

For protein misassembly, it's the "I" decade. Wetzel R. **Cell** 1996 Sep 6;86(5):699–702 (20 ref.)

Regulation of cyclin E and p27kip during mitosis in BALB/c 3T3 cells. Agrawal D, et al. **Cell Growth Differ** 1995 Oct; 6(10):1199–205

Synthesis and secretion of proteins by the human proliferative, secretory, decidual and hyperplastic endometrium. Shivaji S, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jun;41(4):555–63

Study on the aging changes of DNA and protein synthesis of bipolar and photoreceptor cells of mouse retina by light and electron microscopic radioautography. Toriyama K. **Cell Mol Biol (Noisy-le-grand)** 1995 Jun;41(4):593–601

Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Bailey MJ, et al. **Chem Res Toxicol** 1996 Apr-May; 9(3):659–66

Differential effects of pressure and flow on DNA and protein synthesis and on fibronectin expression by arteries in a novel organ culture system. Bardy N, et al. **Circ Res** 1995 Oct;77(4):684–94

Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Komatsu Y, et al. **Circ Res** 1996 Apr; 78(4):606–14

In vitro production of parathyroid hormone-related protein by cholesteatoma and normal skin. Cheshire IM, et al. **Clin Otolaryngol** 1995 Oct;20(5):448–52

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):636–46

Protein synthesis in isolated enterocytes from septic or endotoxaemic rats: regulation by glutamine. Higashiguchi T, et al. **Clin Sci (Colch)** 1995 Sep;89(3):311–9

Biopotency of fetal bovine serum, and insulin and insulin-like growth factors I and II in enhancing whole-body protein synthesis of chicken embryos cultured in vitro. Muramatsu T, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):281–6

Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)

The role of coat proteins in the biosynthesis of secretory proteins. Salama NR, et al. **Curr Opin Cell Biol** 1995 Aug; 7(4):536–43 (54 ref.)

Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Bitgood MJ, et al. **Dev Biol** 1995 Nov;172(1):126–38

Overexpression of an Agouti cDNA in the skin of transgenic mice recapitulates dominant coat color phenotypes of spontaneous mutants. Kucera GT, et al. **Dev Biol** 1996 Jan 10;173(1):162–73

BMP-4 regulates the dorsal-ventral differences in FGF/MAPKK-mediated mesoderm induction in Xenopus. Northrop J, et al. **Dev Biol** 1995 Nov;172(1):242–52

Wingless signaling induces nautilus expression in the ventral mesoderm of the Drosophila embryo. Ranganayakulu G, et al. **Dev Biol** 1996 May 25;176(1):143–8

Digit induction by Hensen's node and notochord involves the expression of shh but not RAR-beta 2. Selleck MA, et al. **Dev Biol** 1996 Jan 10;173(1):318–26

The expression of myristoylated alanine-rich C-kinase substrate in oligodendrocytes is developmentally regulated. Bhat NR, et al. **Dev Neurosci** 1995;17(4):256–63

Expression of the genes coding for ornithine decarboxylase and its regulatory protein antizyme in the developing rat brain. Pujic Z, et al. **Dev Neurosci** 1995;17(5-6):286–91

aubergine enhances oskar translation in the Drosophila ovary. Wilson JE, et al. **Development** 1996 May;122(5):1631–9

Adipose tissue leptin production and plasma leptin kinetics in humans. Klein S, et al. **Diabetes** 1996 Jul;45(7):984–7

Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Kolaczynski JW, et al. **Diabetes** 1996 May;45(5):699–701

Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Mantzoros CS, et al. **Diabetes** 1996 Jul;45(7):909–14

Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Nolan JJ, et al. **Diabetes** 1996 Sep; 45(9):1276–8

Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue. Sainsbury A, et al. **Diabetologia** 1996 Mar; 39(3):353–6

The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. Gutjahr T, et al. **EMBO J** 1995 Sep 1;14(17):4296–306

Lack of Drosophila cytoskeletal tropomyosin affects head morphogenesis and the accumulation of oskar mRNA required for germ cell formation. Tetzlaff MT, et al. **EMBO J** 1996 Mar 15;15(6):1247–54

Molecular cloning and expression of the relaxin-like factor from the mouse testis. Pusch W, et al. **Endocrinology** 1996 Jul;137(7):3009–13

Protein synthesis in cadmium- and pentachlorophenol-tolerant Euglena gracilis. Barque JP, et al. **Environ Res** 1995 Jul;70(1):70–4

Selective up-regulation of alpha 1-chimaerin mRNA in SK-N-SH neuroblastoma cells by K+/-induced depolarisation. Dong JM, et al. **Eur J Biochem** 1996 Mar 15;236(3):820–6

Effects of graded glutamine intake on liver protein metabolism following partial hepatectomy. Skullman S, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):881–6

Transactivation of parathyroid hormone-related protein gene expression by human T-cell leukemia virus type I tax [letter] Mori N, et al. **Eur J Haematol** 1996 Jan-Feb; 56(1-2):116–7

Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U-937 cells acquiring resistance to vincristine. Pantazis P, et al. **Eur J Haematol** 1996 Jul;57(1):79–86

Dissociation of the stimuli for cell hypertrophy and cell division in the dog thyrocyte: insulin promotes protein accumulation while TSH triggers DNA synthesis. Taton M, et al. **Exp Cell Res** 1995 Dec;221(2):530–3

Messenger RNAs encoding the natriuretic peptides and their receptors are expressed in the eye. Fernandez-Durango R, et al. **Exp Eye Res** 1995 Dec;61(6):723–9

Effect of nonprotein thiols on protein synthesis in isolated rat hepatocytes. Asensi M, et al. **Experientia** 1996 Feb 15; 52(2):111–4

Modulation of obese gene expression in rat brown and white adipose tissues. Moinat M, et al. **FEBS Lett** 1995 Oct 9; 373(2):131–4

Shear stress induces expression of CNP gene in human endothelial cells. Okahara K, et al. **FEBS Lett** 1995 Oct 9;373(2):108–10

A novel murine cathelin-like protein expressed in bone marrow. Popsueva AE, et al. **FEBS Lett** 1996 Aug 5; 391(1-2):5–8

Co-expression of mRNA for type I and type II interleukin-1 receptors and the IL-1 receptor accessory protein correlates to IL-1 responsiveness. Wesche H, et al. **FEBS Lett** 1996 Aug 5;391(1-2):104–8

Induction of proteins in response to cold acclimation of rainbow trout cells. Yamashita M, et al. **FEBS Lett** 1996 Mar 18;382(3):261–4

Restoration of brain protein synthesis in mature and aged rats by a DA agonist, piribedil. Bustany P, et al. **Fundam Clin Pharmacol** 1995;9(5):458–68

Alternative splicing of the Drosophila melanogaster rotundRacGAP gene. Hoemann CD, et al. **Gene** 1996 Feb 12;168(2):135–41

Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Wu I, et al. **Gene** 1996 Feb 12;168(2):243–6

Molecular analysis of scabrous mutant alleles from Drosophila melanogaster indicates a secreted protein with two functional domains. Hu X, et al. **Genetics** 1995 Oct; 141(2):607–17

Structural organization and genetic localization of the human bone morphogenetic protein 1/mammalian tolloid gene. Takahara K, et al. **Genomics** 1995 Sep 1;29(1):9–15

Regulation of neurofibromin expression in rat sciatic nerve and cultured Schwann cells. Wrabetz L, et al. **Glia** 1995 Sep;15(1):22–32

Food restriction and lysine supplementation alter growth, RNA, DNA, and protein contents of skeletal muscle. Sika M, et al. **Growth Dev Aging** 1995 Spring-Summer; 59(1-2):15–23

De novo synthesis of glucocorticoid hormone regulated inner ear proteins in rats. Yao X, et al. **Hear Res** 1995 Jun; 86(1-2):183–8

Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia. Haber BA, et al. **Hepatology** 1996 Jul;24(1):65–71

Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Nakatsukasa H, et al. **Hepatology** 1996 Jul; 24(1):82–8

1,25 dihydroxyvitamin D and dexamethasone decrease in vivo Walker carcinoma growth, but not parathyroid hormone related protein secretion. Cohen-Solal ME, et al. **Horm Metab Res** 1995 Sep;27(9):403–7

Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. Grawunder U, et al. **Immunity** 1995 Nov; 3(5):601–8

Cholera toxin induces synthesis of phospholipase A2-activating protein. Peterson JW, et al. **Infect Immun** 1996 Jun;64(6):2137–43

Molecular cloning and characterization of rabbit TIMP2. Wertheimer SJ, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S121–2

Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Kawamata H, et al. **Int J Cancer** 1995 Nov 27;63(5):680–7

Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)

Comparison of expression of the msx-1, msx-2, BMP-2 and BMP-4 genes in the mouse upper diastemal and molar tooth primordia. Tureckova J, et al. **Int J Dev Biol** 1995 Jun; 39(3):459–68

Undifferentiated carcinoma in the cardioesophageal junction which produces parathyroid hormone related protein. Nozu T, et al. **Intern Med** 1995 Jul;34(7):695–9

Thyroid anaplastic carcinoma producing granulocyte-colony-stimulating factor and parathyroid

hormone-related protein. Yazawa S, et al. **Intern Med** 1995 Jun;34(6):584–8

Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Della NG, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1921–4

A gene expression profile of human corneal epithelium and the isolation of human keratin 12 cDNA. Nishida K, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1800–9

RNA and protein synthesis in the nonspermatozoal cells of normal human semen. Williams MA, et al. **J Anat** 1996 Feb;188 (Pt 1):137–47

In vitro ouabain-sensitive respiration and protein synthesis in rumen epithelial papillae of Hereford steers fed either timothy hay or timothy hay supplemented with cracked corn once daily. Kelly JM, et al. **J Anim Sci** 1995 Dec; 73(12):3775–84

Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. Adams JW, et al. **J Biol Chem** 1996 Jan 12;271(2):1179–86

Cloning and regulation of cornifin beta, a new member of the cornifin/spr family. Suppression by retinoic acid receptor-selective retinoids. Austin SJ, et al. **J Biol Chem** 1996 Feb 16;271(7):3737–42

Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. Bai Y, et al. **J Biol Chem** 1996 Jun 14;271(24):13939–42

Pharmacologic manipulation of ob expression in a dietary model of obesity. Collins S, et al. **J Biol Chem** 1996 Apr 19;271(16):9437–40

Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. Dietz UH, et al. **J Biol Chem** 1996 Feb 9;271(6):3311–6

A naturally occurring T14A11 tract blocks nucleosome formation over the human neurofibromatosis type 1 (NF1)-Alu element. Englander EW, et al. **J Biol Chem** 1996 Mar 8;271(10):5819–23

The mouse bone morphogenetic protein-4 gene. Analysis of promoter utilization in fetal rat calvarial osteoblasts and regulation by COUP-TFI orphan receptor. Feng JQ, et al. **J Biol Chem** 1995 Nov 24;270(47):28364–73

Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. Gaczynska M, et al. **J Biol Chem** 1996 Jul 19;271(29):17275–80

Genomic structure and promoter analysis of the human obese gene. Gong DW, et al. **J Biol Chem** 1996 Feb 23; 271(8):3971–4

Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death. Kissil JL, et al. **J Biol Chem** 1995 Nov 17;270(46):27932–6

Identification and characterization of 1,25-dihydroxyvitamin D3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene. Kremer R, et al. **J Biol Chem** 1996 Jul 5;271(27):16310–6

Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. Kuwabara K, et al. **J Biol Chem** 1996 Mar 1; 271(9):5025–32

Acute depression of mitochondrial protein synthesis during anoxia: contributions of oxygen sensing, matrix acidification, and redox state. Kwast KE, et al. **J Biol Chem** 1996 Mar 29;271(13):7313–9

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. Li M, et al. **J Biol Chem** 1996 May 10;271(19):11059–62

Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts. Miyazaki T, et al. **J Biol Chem** 1996 Jun 14;271(24):14567–71

Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. Murakami Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3340–2

IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. Parnet P, et al. **J Biol Chem** 1996 Feb 23; 271(8):3967–70

Expression of human squamous cell differentiation marker, SPR1, in tracheobronchial epithelium depends on JUN and TRE motifs. Reddy SP, et al. **J Biol Chem** 1995 Nov 3; 270(44):26451–9

Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. Slieker LJ, et al. **J Biol Chem** 1996 Mar 8;271(10):5301–4

Molecular cloning of NIPP-1, a nuclear inhibitor of protein phosphatase-1, reveals homology with polypeptides involved in RNA processing. Van Eynde A, et al. **J Biol Chem** 1995 Nov 24;270(47):28068–74

Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice' causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. Vasavada RC, et al. **J Biol Chem** 1996 Jan 12;271(2):1200–8

Interleukin-11 induces complex formation of Grb2, Fyn, and JAK2 in 3T3L1 cells. Wang XY, et al. **J Biol Chem** 1995 Nov 24;270(47):27999–8002

T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. Welsh GI, et al. **J Biol Chem** 1996 May 10;271(19):11410–3

In vivo assembly of the proteasomal complexes, implications for antigen processing. Yang Y, et al. **J Biol Chem** 1995 Nov 17;270(46):27687–94

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. Zhang B, et al. **J Biol Chem** 1996 Apr 19;271(16):9455–9

Phased protein synthesis at several circadian times does not change protein levels in Gonyaulax. Markovic P, et al. **J Biol Rhythms** 1996 Mar;11(1):57–67

Cellular responses to chemical and morphologic aspects of biomaterial surfaces. II. The biosynthetic and migratory response of bone cell populations. Chesmel KD, et al. **J Biomed Mater Res** 1995 Sep;29(9):1101–10

Regulation of protein synthesis by alpha 1-adrenergic receptor subtypes in cultured rabbit aortic vascular smooth muscle cells. Siwik DA, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):508–18

1,25(OH)2D3-dependent regulation of calbindin-D28k mRNA requires ongoing protein synthesis in chick duodenal organ culture. Meyer J, et al. **J Cell Biochem** 1995 Jul;58(3):315–27

Stimulation of protein and DNA synthesis in mouse C2C12 satellite cells: evidence for phospholipase D-dependent and -independent pathways. Morrison KS, et al. **J Cell Physiol** 1995 Nov;165(2):273–83

Expression of parathyroid hormone-related protein in cells of osteoblast lineage. Suda N, et al. **J Cell Physiol** 1996 Jan;166(1):94–104

L-fucose reduces collagen and noncollagen protein production in cultured cerebral microvessel endothelial cells. Yorek MA, et al. **J Cell Physiol** 1995 Dec; 165(3):658–66

A role for interleukin-1 in epidermal differentiation: regulation by expression of functional versus decoy receptors. Elier MS, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2741–6

Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues [see comments] Croteau W, et al. **J Clin Invest** 1996 Jul 15;98(2):405–17 . Comment in: J Clin Invest 1996 Jul 15;98(2):242–3.

Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. Dardevet D, et al. **J Clin Invest** 1995 Nov;96(5):2113–9

Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. Grunfeld C, et al. **J Clin Invest** 1996 May 1;97(9):2152–7

Early and late stimulation of ob mRNA expression in meal-fed and overfed rats. Harris RB, et al. **J Clin Invest** 1996 May 1;97(9):2020–6

The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. Hugo C, et al. **J Clin Invest** 1996 Jun 1;97(11):2499–508

Studies of the expression of the Wiskott-Aldrich syndrome protein [see comments] Stewart DM, et al. **J Clin Invest** 1996 Jun 1;97(11):2627–34. Comment in: J Clin Invest 1996 Jun 1;97(11):2407.

The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. Vidal H, et al. **J Clin Invest** 1996 Jul 15;98(2):251–5

In vitro ruminal degradation and synthesis of protein on fractions extracted from alfalfa hay and silage. Peltekova VD, et al. **J Dairy Sci** 1996 Apr;79(4):612–9

Characterization of protein production by caprine placental membranes: identification and immunolocalization of retinol-binding protein. Liu KH, et al. **J Endocrinol** 1995 Sep;146(3):527–34

Dexamethasone inhibits the release of TSH from the rat anterior pituitary gland in vitro by mechanisms dependent on de novo protein synthesis and lipocortin 1. Taylor AD, et al. **J Endocrinol** 1995 Dec;147(3):533–44

The half-life of RAG-1 protein in precursor B cells is increased in the absence of RAG-2 expression. Grawunder U, et al. **J Exp Med** 1996 Apr 1;183(4):1731–7

Stringent V beta requirement for the development of NK1.1+ T cell receptor-alpha/beta+ cells in mouse liver. Ohteki T, et al. **J Exp Med** 1996 Mar 1;183(3):1277–82

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. Wang RF, et al. **J Exp Med** 1996 Mar 1;183(3):1131–40

Parathyroid hormone-related peptide is expressed and rapidly inducible in human liver cell cultures that have a bile duct phenotype. Roskams T, et al. **J Hepatol** 1995 Aug;23(2):160–5

Expression pattern of osteogenic protein-1 (bone morphogenetic protein-7) in human and mouse development. Helder MN, et al. **J Histochem Cytochem** 1995 Oct;43(10):1035–44

Impaired hepatic protein synthesis in AIDS patients with low vitamin A levels [letter; comment] Haas DW, et al. **J Infect Dis** 1995 Oct;172(4):1167–9. Comment on: J Infect Dis 1995 May;171(5):1196–202.

Secretogranin II: regulation of synthesis and post-translational proteolysis in bovine adrenal chromaffin cells. Soszynski D, et al. **J Neuroendocrinol** 1993 Dec; 5(6):655–62

Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. Schulz JB, et al. **J Neurosci** 1996 Aug 1;16(15):4696–706

Ligands for EPH-related tyrosine kinase receptors are developmentally regulated in the CNS. Carpenter MK, et al. **J Neurosci Res** 1995 Oct 1;42(2):199–206

Lipopolysaccharide stimulates differential expression of myristoylated protein kinase C substrates in murine microglia. Rosé SD, et al. **J Neurosci Res** 1996 May 1; 44(3):235–42

Hydroxyproline and total protein levels in gingiva from patients treated with phenytoin and cyclosporine-A. Akalin FA, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):21–30

A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. Ishiwata K, et al. **J Nucl Med** 1996 Feb; 37(2):279–85

Insulin treatment affects brain protein synthesis rate in streptozotocin-induced diabetic rats. Hayase K, et al. **J Nutr** 1995 Nov;125(11):2768–72

Relationship of protein synthesis to mRNA levels in the liver of chicks under various nutritional conditions. Kita K, et al. **J Nutr** 1996 Jun;126(6):1610–7

Relationship of protein synthesis to mRNA levels in the muscle of chicks under various nutritional conditions. Kita K, et al. **J Nutr** 1996 Jul;126(7):1827–32

Dietary fiber and short-chain fatty acids affect cell proliferation and protein synthesis in isolated rat colonocytes. Marsman KE, et al. **J Nutr** 1996 May; 126(5):1429–37

Muscle and liver protein synthesis adapt efficiently to food deprivation and refeeding in 12-month-old rats. Mosoni L, et al. **J Nutr** 1996 Feb;126(2):516–22

Peptide-bound methionine can be a source of methionine for the synthesis of secreted proteins by mammary tissue explants from lactating mice. Wang S, et al. **J Nutr** 1996 Jun;126(6):1662–72

Chronic low protein intake reduces tissue protein synthesis in a pig model of protein malnutrition. Wykes LJ, et al. **J Nutr** 1996 May;126(5):1481–8

The possible involvement of LH/hCG induced mitochondrial proteins in the regulation of steroidogenesis in bovine luteal cells. Mittre H, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3–4):233–8

Effect of human growth hormone on human pancreatic carcinoma growth, protein, and cell cycle kinetics. Harrison LE, et al. **J Surg Res** 1996 Mar;61(2):317–22

Effect of glutamine supplement and hepatectomy on DNA and protein synthesis in the remnant liver. Yoshida S, et al. **J Surg Res** 1995 Oct;59(4):475–81

Inhibition of protein synthesis in a cell-free system and Vero cells by okadaic acid, a diarrhetic shellfish toxin. Matias WG, et al. **J Toxicol Environ Health** 1996 Jun 28; 48(3):309–17

Establishment of a clonal cell line producing granulocyte colony-stimulating factor and parathyroid hormone-related protein from a lung cancer patient with leukocytosis and hypercalcemia. Asahi Y, et al. **Jpn J Cancer Res** 1996 May;87(5):451–8

Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Iwata H, et al. **Jpn J Cancer Res** 1996 Jun;87(6):602–11

Expression pattern of the von Hippel-Lindau protein in human tissues. Los M, et al. **Lab Invest** 1996 Aug; 75(2):231–8

Adult, fetal, and polycystic kidney expression of polycystin, the polycystic kidney disease-1 gene product. Peters DJ, et al. **Lab Invest** 1996 Aug;75(2):221–30

Production of matrix metalloproteinases at the bone-implant interface in loose total hip replacements. Yokohama Y, et al. **Lab Invest** 1995 Dec;73(6):899–911

Characterization of a novel human dynein-related gene that is specifically expressed in testis. Milisav I, et al. **Mamm Genome** 1996 Sep;7(9):667–72

Wnt expression patterns in chick embryo nervous system. Hollyday M, et al. **Mech Dev** 1995 Jul;52(1):9–25

Induction of a secondary embryonic axis in zebrafish occurs following the overexpression of beta-catenin. Kelly GM, et al. **Mech Dev** 1995 Oct;53(2):261–73

Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R. Luo D, et al. **Melanoma Res** 1995 Oct; 5(5):303–9

Expression, purification, and functional assay of Mss4. Burton JL, et al. **Methods Enzymol** 1995;257:93–8

High expression cloning, purification, and assay of Ypt-GTPase-activating proteins. Vollmer P, et al. **Methods Enzymol** 1995;257:118–28

Programmed cell death in the tobacco hornworm, Manduca sexta: alteration in protein synthesis. Zakeri Z, et al. **Microsc Res Tech** 1996 Jun 15;34(3):192–201

A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone-related protein. Harutsumi M, et al. **Miner Electrolyte Metab** 1995; 21(1–3):171–6 (24 ref.)

Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-I-infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1–3):166–70 (36 ref.)

Parathyroid hormone-related peptide expression in endocrine tumors. Nagataki S, et al. **Miner Electrolyte Metab** 1995; 21(1–3):148–51

Expression of parathyroid hormone-related peptide and its receptor mRNAs during fetal development of rats. Segre GV, et al. **Miner Electrolyte Metab** 1995;21(1-3):129-32

MP 48 expression in red blood cells of renal transplant recipients. Mukhtar A. **Minerva Urol Nefrol** 1996 Jun; 48(2):87-8

Body temperature, rate of biosynthesis, and evolution of genome size. Xia X. **Mol Biol Evol** 1995 Sep;12(5):834-42

Biomechanical signals in the coronary artery triggering the metabolic processes during cardiac overload. Gerová M, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):69-73

Functional reconstruction of trans regulation of the Ultrabithorax promoter by the products of two antagonistic genes, trithorax and Polycomb. Chang YL, et al. **Mol Cell Biol** 1995 Dec;15(12):6601-12

C/EBPalpha regulation of the growth-arrest-associated gene gadd45. Constance CM, et al. **Mol Cell Biol** 1996 Jul; 16(7):3878-83

Transcriptional regulation of a mouse Clara cell-specific protein (mCC10) gene by the NKx transcription factor family members thyroid transciption factor 1 and cardiac muscle-specific homeobox protein (CSX). Ray MK, et al. **Mol Cell Biol** 1996 May;16(5):2056-64

Production and secretion of N-terminal secretogranin II derived peptides in GH3B6 prolactin cells. Muller L, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):101-12

The effect on methamphetamine on the mRNA level for 14.3.3 eta chain in the human cultured cells. Muratake T, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):223-30

Increased obese mRNA expression in omental fat cells from massively obese humans. Hamilton BS, et al. **Nat Med** 1995 Sep;1(9):953-6

Overexpression of the obese (ob) gene in adipose tissue of human obese subjects [see comments] Lönnqvist F, et al. **Nat Med** 1995 Sep;1(9):950-3. Comment in: Nat Med 1996 Feb;2(2):130.

The PKD1 gene produces a developmentally regulated protein in mesenchyme and vasculature [see comments] Van Adelsberg JS, et al. **Nat Med** 1995 Apr;1(4):359-64 . Comment in: Nat Med 1995 Apr;1(4):305-6. Comment in: Nat Med 1995 Jun;1(6):493.

Relationship between asymmetric nodal expression and the direction of embryonic turning [see comments] Collignon J, et al. **Nature** 1996 May 9;381(6578):155-8. Comment in: Nature 1996 May 9;381(6578):116-7.

Involvement of glutamate receptors, protein kinases, and protein synthesis in memory for visual discrimination in the young chick. Tiunova A, et al. **Neurobiol Learn Mem** 1996 May;65(3):233-4

Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. Hewett SJ, et al. **Neuroreport** 1995 Jul 31;6(11):1565-8

Decreased protein synthetic activity of the hypothalamic tuberomamillary nucleus in Alzheimer's disease as suggested by smaller Golgi apparatus. Salehi A, et al. **Neurosci Lett** 1995 Jun 23;193(1):29-32

Analysis of eukaryotic mRNA structures directing cotranslational incorporation of selenocysteine. Kollmus H, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1195-201

A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Choi SS, et al. **Oncogene** 1995 Nov 2;11(9):1693-8

Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Guha A, et al. **Oncogene** 1996 Feb 1;12(3):507-13

Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor. Smit L, et al. **Oncogene** 1996 Jul 18;13(2):381-9

Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Brinkmann U, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10427-31

Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Hwang CS, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):873-7

A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Lombard-Platet G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1265-9

Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. MacDougald OA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9034-7

The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Miller SG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5507-11

ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Schuldiner O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7143-8

Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Ward CJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1524-8

Use of stable isotopic selenium as a tracer to follow incorporation of selenium into selenoproteins. Finley JW, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):270-7

Copper deficiency increases total protein and apolipoprotein A-I synthesis in the rat small intestine. Wu JY, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):369-77

Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Fischer-Colbrie R, et al. **Prog Neurobiol** 1995 May;46(1):49-70 (209 ref.)

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625-30 (51 ref.)

Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517-35 (144 ref.)

EMF studies [letter; comment] Blank M. **Science** 1995 Nov 17;270(5239):1104-5. Comment on: Science 1995 Sep 29;269(5232):1816-7.

A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Kang H, et al. **Science** 1996 Sep 6;273(5280):1402-6

Molecular mimicry in protein synthesis? [comment] Moore PB. **Science** 1995 Dec 1;270(5241):1453-4. Comment on: Science 1995 Dec 1;270(5241):1464-72.

Fructose protects rat hepatocytes during hypoxia and improves protein synthesis recovery during reoxygenation. Lefebvre V, et al. **Transplant Proc** 1995 Oct;27(5):2823-4

Increased expression of the HDJ-2 heat shock protein in biopsies of human rejected kidney. Alevy YG, et al. **Transplantation** 1996 Mar 27;61(6):963-7

Decreased protein synthesis during dry saturation diving. Conway JM, et al. **Undersea Hyperb Med** 1995 Sep; 22(3):219-27

Interactions in glycine and methionine uptake, conversion and incorporation into proteins in the preimplantation mouse embryo. Khatchadourian C, et al. **Zygote** 1994 Nov; 2(4):301-6

[Effects of dynorphin A (1-8) on cell cycle and total cellular protein during neuronal aging in vitro] Sun XJ, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):646-50 (Eng. Abstr.) **(Chi)**

[Use of growth hormone during catabolic state in a patient in postoperative intensive care] Gjerde S, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3028-30 (Eng. Abstr.) **(Nor)**

[Lack of serum causes apoptosis of thymocytes not requiring protein synthesis and ATP generation] Gabal VL, et al. **Biokhimiia** 1995 Aug;60(8):1201-8 (Eng. Abstr.) **(Rus)**

[The intensity of protein synthesis in the cells of a diluted hepatocyte culture is higher than in a dense culture] Brodskiĭ VIa, et al. **Izv Akad Nauk Ser Biol** 1995 Sep-Oct; (5):517-20 (Eng. Abstr.) **(Rus)**

[Protein synthesis in the liver and cerebellum of rats growing at different rates of intensity] Marshak TL, et al. **Ontogenez** 1995 Nov-Dec;26(6):430-6 (Eng. Abstr.) **(Rus)**

[Effect of catechins and proanthocyanidins on the initial stage of protein biosynthesis] Arpentin GN, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):104-7 (Eng. Abstr.) **(Rus)**

BLOOD see BLOOD PROTEINS

CEREBROSPINAL FLUID see CEREBROSPINAL FLUID PROTEINS

CHEMICAL SYNTHESIS

Thiazolidine formation as a general and site-specific conjugation method for synthetic peptides and proteins. Zhang L, et al. **Anal Biochem** 1996 Jan 1;233(1):87-93

Synthesis of human C-type natriuretic peptide 22 using chlorotrityl resin and tetrafluoroboric acid deprotection. Fujiwara Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul; 44(7):1326-31

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853-8

Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403-10 (45 ref.)

Synthesis and solution structure of the antimicrobial peptide protegrin-1. Aumelas A, et al. **Eur J Biochem** 1996 May 1;237(3):575-83

Cell-free synthesis and amino acid-selective stable isotope labeling of proteins for NMR analysis. Kigawa T, et al. **J Biomol NMR** 1995 Sep;6(2):129-34

A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649-52 (18 ref.)

CHEMISTRY

Use of globic scattering factors for protein structures at low resolution. Guo DY, et al. **Acta Crystallogr A** 1995 Nov 1;51 (Pt 6):945-7

Logarithmic growth in surface adsorption. Nygren H. **Adv Colloid Interface Sci** 1995 Dec 1;62(2-3):137-59 (71 ref.)

Enthalpic contribution to protein stability: insights from atom-based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231-306 (129 ref.)

Energetics of protein structure. Makhatadze GI, et al. **Adv Protein Chem** 1995;47:307-425 (338 ref.)

Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83-229 (423 ref.)

Codon-based combinatorial alanine scanning site-directed mutagenesis: design, implementation, and polymerase chain reaction screening. Chatellier J, et al. **Anal Biochem** 1995 Aug 10;229(2):282-90

Prediction of human immunodeficiency virus protease cleavage sites in proteins. Chou KC. **Anal Biochem** 1996 Jan 1;233(1):1-14 (62 ref.)

Determination of local refractive index for protein and virus crystals in solution by Mach-Zehnder interferometry. Cole T, et al. **Anal Biochem** 1995 Oct 10;231(1):92-8

Peptide-mass profiles of polyvinylidene difluoride-bound proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the presence of nonionic detergents. Gharahdaghi F, et al. **Anal Biochem** 1996 Jan 1;233(1):94-9

Lysine-directed radioiodination of proteins with a cyanuric chloride derivative of aminofluorescein. Harapanhalli RS, et al. **Anal Biochem** 1995 Oct 10;231(1):50-6

The use of t-butyl hydroperoxide as a probe for methionine oxidation in proteins. Keck RG. **Anal Biochem** 1996 Apr 5;236(1):56-62

Stable-isotope dilution studies of an intact protein using high-performance liquid chromatography/chemical reaction interface mass spectrometry. Osborn BL, et al. **Anal Biochem** 1995 Aug 10;229(2):347-50

Precise scanning calorimeter for studying thermal properties of biological macromolecules in dilute solution. Privalov G, et al. **Anal Biochem** 1995 Nov 20;232(1):79-85

Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane. Singh R, et al. **Anal Biochem** 1996 Apr 5;236(1):114-25

5-Nitrosothio-2-nitrobenzoate: a reagent for the nitrosation of thiol groups in proteins. Studebaker MS, et al. **Anal Biochem** 1996 Jun 1;237(2):193-7

Competitive binding assay of src homology domain 3 interactions between 5-lipoxygenase and growth factor receptor binding protein 2. VanderNoot VA, et al. **Anal Biochem** 1995 Sep 1;230(1):108-14

Patterning and regeneration of surfaces with antibodies. Pritchard DJ, et al. **Anal Chem** 1995 Oct 1;67(19):3605-7

Analysis of tryptic digests using microbore HPLC with an ion trap storage/reflectron time-of-flight detector. Qian MG, et al. **Anal Chem** 1995 Sep 1;67(17):2870-7

An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. Roberts GD, et al. **Anal Chem** 1995 Oct 15; 67(20):3613-25

A self-assembled monolayer for the binding and study of histidine-tagged proteins by surface plasmon resonance. Sigal GB, et al. **Anal Chem** 1996 Feb 1;68(3):490-7

Noncovalent protein--oligonucleotide interactions monitored by matrix-assisted laser desorption/ionization mass spectrometry. Tang X, et al. **Anal Chem** 1995 Dec 15;67(24):4542-8

The multiplicity of domains in proteins. Doolittle RF. **Annu Rev Biochem** 1995;64:287-314 (237 ref.)

Isolation and identification of selenium-labeled proteins in the mouse kidney. Jamba L, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1651-7

Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress. Cohn JA, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):158-64

Proteins and their amino acid compositions: uniqueness, variability, and applications. Galat A, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):229-37

Protein inhibitor of mitochondrial ATP synthase: relationship of inhibitor structure to pH-dependent regulation. Lebowitz MS, et al. **Arch Biochem Biophys** 1996 Jun 15; 330(2):342-54

Protein crystallography in Australia. Parker MW. **Aust N Z J Med** 1995 Dec;25(6):876-82 (40 ref.)

A formal discussion of the archival journal requirements for data deposition [letter] Baker EN, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):976-7

Evidence that the PTH receptor binding site on PTHrP(1-34) can hinge at Arg19/Arg20. Barden JA, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):431-6

Introduction of carbonyl groups into proteins by the lipid peroxidation product, malondialdehyde. Burcham PC, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):996-1001

Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Cha MK, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):900-7

The porcine sperm motility inhibitor is identical to beta-microseminoprotein and is a competitive inhibitor of Na+,K(+)-ATPase. Chao CF, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):623-8

Rat liver pp49, a protein that forms complexes with protein kinase CK2, is composed of the beta and the gamma subunits of translation initiation factor eIF-2. Gil C, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1052-7

Aggregation and concentration-dependent sorting of exocrine regulated secretory proteins. Gorr SU, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):82-8

Radiolytic protein surface mapping. Greiner DP, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1006-8

Suppression of iron catalyzed free radical generation by iron tyrosinate protein models. Kitazawa M, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):36-41

Stabilization of helix by side-chain interactions in histatin-derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996

Aug 5;225(1):47–53
Rapid protein identification using N-terminal "sequence tag" and amino acid analysis. Wilkins MR, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):609–13
Nitric oxide rapidly scavenges tyrosine and tryptophan radicals. Eiserich JP, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):745–9
The lipocalin protein family: structure and function. Flower DR. **Biochem J** 1996 Aug 15;318 (Pt 1):1–14 (149 ref.)
Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Huang Y, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):925–32
Analysis of transcripts encoding novel members of the mammalian metalloprotease-like, disintegrin-like, cysteine-rich (MDC) protein family and their expression in reproductive and non-reproductive monkey tissues. Perry AC, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):239–44
Molecular heterogeneity in the Major Urinary Proteins of the house mouse Mus musculus. Robertson DH, et al. **Biochem J** 1996 May 15;316 (Pt 1):265–72
Functional domain mapping using M13 deletions. Grammatikakis N, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):771–9
Some fluorescent properties of non-enzymic transamination and measurement of the relative molecular mass of protein. He RQ, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):447–57
Diquat-dependent protein carbonyl formation. Identification of lipid-dependent and lipid-independent pathways. Blakeman DP, et al. **Biochem Pharmacol** 1995 Sep 28; 50(7):929–35
14-3-3 proteins: biological function and domain structure. Aitken A, et al. **Biochem Soc Trans** 1995 Aug;23(3):605–11 (47 ref.)
Tandem mass spectrometric characterization of modified peptides and proteins. Bolgar MS, et al. **Biochem Soc Trans** 1995 Nov;23(4):907–10
Application of SPR & FTIR spectroscopy to the study of protein-biomaterial interactions. Heaton RJ, et al. **Biochem Soc Trans** 1995 Nov;23(4):502S
Protein hydration, stability and unfolding. Knaggs M, et al. **Biochem Soc Trans** 1995 Nov;23(4):711–5
Interactions of proteins with dyes conjugated to soluble polymers. Maytum R, et al. **Biochem Soc Trans** 1996 Feb; 24(1):147S
ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Peitsch MC. **Biochem Soc Trans** 1996 Feb;24(1):274–9
Molecular recognition by proteins: protein-ligand interactions from a structural perspective. Wallace AC, et al. **Biochem Soc Trans** 1996 Feb;24(1):280–4
Probing protein structure with proteases: studies of an equilibrium intermediate in protein unfolding. Webb T, et al. **Biochem Soc Trans** 1995 Aug;23(3):477S
The determinants of pKas in proteins. Antosiewicz J, et al. **Biochemistry** 1996 Jun 18;35(24):7819–33
Domain structure and conformation of histidine-proline-rich glycoprotein. Borza DB, et al. **Biochemistry** 1996 Feb 13; 35(6):1925–34
Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ezrin-radixin-moesin association domains. Bretscher A, et al. **Biochemistry** 1995 Dec 26;34(51):16830–7
Modeling unfolded states of peptides and proteins. Creamer TP, et al. **Biochemistry** 1995 Dec 19;34(50):16245–50
Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Geyer M, et al. **Biochemistry** 1996 Aug 13;35(32):10308–20
Phosphorescence lifetime of tryptophan in proteins. Gonnelli M, et al. **Biochemistry** 1995 Oct 24;34(42):13847–57
Solution structure of bovine angiogenin by 1H nuclear magnetic resonance spectroscopy. Lequin O, et al. **Biochemistry** 1996 Jul 9;35(27):8870–80
Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Li M, et al. **Biochemistry** 1996 Jun 4;35(22):6998–7002
Cofactor A is a molecular chaperone required for beta-tubulin folding: functional and structural characterization. Melki R, et al. **Biochemistry** 1996 Aug 13;35(32):10422–35
Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Newton DL, et al. **Biochemistry** 1996 Jan 16;35(2):545–53
Formation of electrostatic interactions on the protein-folding pathway. Oliveberg M, et al. **Biochemistry** 1996 Feb 27; 35(8):2726–37
Glycerol decreases the volume and compressibility of protein interior. Priev A, et al. **Biochemistry** 1996 Feb 20; 35(7):2061–6
Membrane structure of protein kinase C and calmodulin binding domain of myristoylated alanine rich C kinase substrate determined by site-directed spin labeling. Qin Z, et al. **Biochemistry** 1996 Mar 5;35(9):2917–25
Site-directed mutagenesis of the subunit PsaC establishes a surface-exposed domain interacting with the photosystem I core binding site. Rodday SM, et al. **Biochemistry** 1996 Sep 10;35(36):11832–8
Nuclear magnetic resonance solution structure of the growth factor receptor-bound protein 2 Src homology 2 domain. Thornton KH, et al. **Biochemistry** 1996 Sep 10; 35(36):11852–64
Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Tsunemi M, et al. **Biochemistry** 1996 Sep 10;35(36):11570–6
The hydration of proteins in solutions by self-diffusion coefficients. NMR study. Baranowska HM, et al. **Biochim Biophys Acta** 1996 Apr 17;1289(3):312–4
On the interaction of alpha-crystallin with unfolded proteins. Carver JA, et al. **Biochim Biophys Acta** 1995 Oct 25; 1252(2):251–60
Understanding and increasing protein stability. Fágáin CO. **Biochim Biophys Acta** 1995 Sep 27;1252(1):1–14 (126 ref.)
Effect of chaotropic denaturant on the binding of 1-anilino-8-naphthalene sulfonic acid to proteins. Kumar TK, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):103–5
Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. Nagaraj RH, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):75–84
Histidine-49 is necessary for the pH-dependent transition between active and inactive states of the bovine F1-ATPase inhibitor protein. Schnizer R, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):241–8
Biological electron transfer: structural and mechanistic studies. Canters GW, et al. **Biochimie** 1995;77(7-8):506–15 (87 ref.)
Principles of protein-protein recognition from structure to thermodynamics. Janin J. **Biochimie** 1995;77(7-8):497–505 (43 ref.)
Rapid characterization of chemically-modified proteins by electrospray mass spectrometry. Bennett KL, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):18–22
Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Gaertner HF, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):38–44
Cement proteins of the acorn barnacle, Megabalanus rosa. Kamino K, et al. **Biol Bull** 1996 Jun;190(3):403–9
Molecular cloning and identification of a novel porcine cathelin-like antibacterial peptide precursor. Strukelj B, et al. **Biol Chem Hoppe Seyler** 1995 Aug;376(8):507–10
Capillary gas chromatographic analysis of protein amino acids as their N(O,S)-isobutoxycarbonyl methyl ester derivatives. Matsumura S, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):205–10
Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329–39 (102 ref.)
Use of fluorescence decay times of 8-ANS-protein complexes to study the conformational transitions in proteins which unfold through the molten globule state. Uversky VN, et al. **Biophys Chem** 1996 Jun 11;60(3):79–88
A comparison of the surface activity of the fungal hydrophobin SC3p with those of other proteins. van der Vegt W, et al. **Biophys Chem** 1996 Jan;57(2-3):253–60
Computation of the dipole moments of proteins. Antosiewicz J. **Biophys J** 1995 Oct;69(4):1344–54
On the pH dependence of amide proton exchange rates in proteins. Eriksson MA, et al. **Biophys J** 1995 Aug; 69(2):329–39
A Monte Carlo simulation study of protein-induced heat capacity changes and lipid-induced protein clustering. Heimburg T, et al. **Biophys J** 1996 Jan;70(1):84–96
Weighted-ensemble Brownian dynamics simulations for protein association reactions. Huber GA, et al. **Biophys J** 1996 Jan;70(1):97–110
Classes of hydration sites at protein-water interfaces: the source of contrast in magnetic resonance imaging. Koenig SH. **Biophys J** 1995 Aug;69(2):593–603
Presence of phosphorus in Nephila clavipes dragline silk. Michal CA, et al. **Biophys J** 1996 Jan;70(1):489–93
Estimating friction coefficients of mixed globular/chain molecules, such as protein/DNA complexes. Robert CH. **Biophys J** 1995 Sep;69(3):840–8
Van der Waals interactions involving proteins. Roth CM, et al. **Biophys J** 1996 Feb;70(2):977–87
Improved differentiation between luminescence decay components by use of time-resolved optical activity measurements and selective lifetime modulation. Schauerte JA, et al. **Biophys J** 1996 Apr;70(4):1996–2000
Proteins in frozen solutions: evidence of ice-induced partial unfolding. Strambini GB, et al. **Biophys J** 1996 Feb; 70(2):971–6
A genetic algorithm that seeks native states of peptides and proteins. Sun S. **Biophys J** 1995 Aug;69(2):340–55
Conformation and hydrogen ion titration of proteins: a continuum electrostatic model with conformational flexibility. You TJ, et al. **Biophys J** 1995 Nov;69(5):1721–33
Calculation of translational friction and intrinsic viscosity. II. Application to globular proteins. Zhou XZ. **Biophys J** 1995 Dec;69(6):2298–303
Low-resolution docking: prediction of complexes for underdetermined structures. Vakser IA. **Biopolymers** 1996 Sep;39(3):455–64
Characterisation of protein structure/function relationship by sequence analysis without previous alignment: distinction between sub-groups of protein kinases. Guerrucci MA, et al. **Biosci Rep** 1995 Jun;15(3):161–71
Immobilization of proteins to lipid bilayers. Ramsden JJ, et al. **Biosens Bioelectron** 1996;11(5):523–8
Ancient splice junction shadows with relation to blocks in protein structure. Strelets VB, et al. **Biosystems** 1995; 36(1):37–41
Use of polylysine in solid-phase protein sequencing. Beg OU. **Biotechniques** 1995 Dec;19(6):876–80
Molecular characterization and isolation of a 45-kilodalton imidazoline receptor protein from the rat brain. Escribá PV, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):187–96
Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Kleyn PW, et al. **Cell** 1996 Apr 19;85(2):281–90
Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Porter JA, et al. **Cell** 1996 Jul 12; 86(1):21–34
Confocal microscopy of a newly identified protein associated with heart development in the Mexican axolotl. Erginel-Unaltuna N, et al. **Cell Mol Biol Res** 1995; 41(2):117–30
The lipoic acid containing components of the 2-oxoacid dehydrogenase complexes mimic trifluoroacetylated proteins and are autoantigens associated with halothane hepatitis. Frey N, et al. **Chem Res Toxicol** 1995 Jul-Aug; 8(5):736–46
Type I benzophenone-mediated nucleophilic reaction of 5'-amino-2',5'-dideoxyguanosine. A model system for the investigation of photosensitized formation of DNA-protein cross-links. Morin B, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):792–9
Mapping functional domains of the polycomb protein of Drosophila melanogaster. Franke A, et al. **Chromosome Res** 1995 Sep;3(6):351–60
Cloning of a urochordate cDNA featuring mammalian short consensus repeats (SCR) of complement-control protein superfamily. Pancer Z, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Aug; 111(4):625–32
MitoProt, a Macintosh application for studying mitochondrial proteins. Claros MG. **Comput Appl Biosci** 1995 Aug;11(4):441–7
Alignments of DNA and protein sequences containing frameshift errors. Guan X, et al. **Comput Appl Biosci** 1996 Feb;12(1):31–40
Representing inter-residue dependencies in protein sequences with probabilistic networks. Mamitsuka H. **Comput Appl Biosci** 1995 Aug;11(4):413–22
alpha-Helix region prediction with stochastic rule learning. Mamitsuka H, et al. **Comput Appl Biosci** 1995 Aug; 11(4):399–411
Co-inertia analysis of amino-acid physico-chemical properties and protein composition with the ADE package. Thioulouse J, et al. **Comput Appl Biosci** 1995 Jun; 11(3):321–9
Algorithms for finding the axis of a helix: fast rotational and parametric least-squares methods. Christopher JA, et al. **Comput Chem** 1996 Sep;20(3):339–45
Prediction of protein structural classes. Chou KC, et al. **Crit Rev Biochem Mol Biol** 1995;30(4):275–349 (104 ref.)
Structures of protein complexes by multidimensional heteronuclear magnetic resonance spectroscopy. Gronenborn AM, et al. **Crit Rev Biochem Mol Biol** 1995; 30(5):351–85 (156 ref.)
Characterization of protein glycosylation by mass spectrometry. Burlingame AL. **Curr Opin Biotechnol** 1996 Feb;7(1):4–10 (78 ref.)
Local sequence-structure correlations in proteins. Bystroff C, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):417–21 (37 ref.)
Sequence 'minimization': exploring the sequence landscape with simplified sequences. Clarke ND. **Curr Opin Biotechnol** 1995 Aug;6(4):467–72 (19 ref.)
Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375–81 (75 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
Interfacial metal-binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
The current state of the art in protein structure prediction. Moult J. **Curr Opin Biotechnol** 1996 Aug;7(4):422–7 (36 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
Pitfalls of protein sequence analysis. Rost B, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):457–61 (12 ref.)
Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437–51 (222 ref.)
The role of protein-solvent interactions in protein unfolding. Schiffer CA, et al. **Curr Opin Biotechnol** 1996 Aug; 7(4):428–32 (58 ref.)
Protein complexes studied by NMR spectroscopy. Wand AJ, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):403–8 (100 ref.)
Sequences and topology. **Curr Opin Struct Biol** 1995 Jun; 5(3):428–40
Circular assemblies. Antson AA, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):142–50 (41 ref.)
Modeling protein-ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)
Protein secondary structure prediction. Barton GJ. **Curr Opin Struct Biol** 1995 Jun;5(3):372–6 (39 ref.)

Epitaxial growth of protein crystals from two-dimensional crystals on lipid layers. Darst SA, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):640–4 (58 ref.)

Structure-derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195–209 (92 ref.)

Potential energy functions for threading. Jones DT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):210–6 (40 ref.)

Statistical significance of sequence patterns in proteins. Karlin S. **Curr Opin Struct Biol** 1995 Jun;5(3):360–71 (47 ref.)

Field gradient techniques in NMR spectroscopy. Kay LE. **Curr Opin Struct Biol** 1995 Oct;5(5):674–81 (58 ref.)

Proteins with leucine-rich repeats. Kobe B, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):409–16 (53 ref.)

Seeking significance in three-dimensional protein structure comparisons. Mizuguchi K, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):377–82 (43 ref.)

Freeze trapping of reaction intermediates. Moffat K, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):656–63 (57 ref.)

Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227–31 (40 ref.)

Calorimetry of proteins and nucleic acids. Plum GE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):682–90 (71 ref.)

Ab initio phase determination and phase extension using non-crystallographic symmetry. Rossmann MG. **Curr Opin Struct Biol** 1995 Oct;5(5):650–5 (51 ref.)

The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Silva JL, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):166–75 (79 ref.)

Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). Stults JT. **Curr Opin Struct Biol** 1995 Oct;5(5):691–8 (120 ref.)

Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Szabo A, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):699–705 (38 ref.)

Modeling side-chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)

Automated analysis of nuclear magnetic resonance assignments for proteins. Zimmerman DE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):664–73 (65 ref.)

Partial N-terminal amino acid sequence of the anti-neoplastic urinary protein (ANUP) and the anti-tumour effect of the N-terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1–5

Expression profiles of a human gene identified as a structural homologue of meiosis-specific recA-like genes. Sato S, et al. **DNA Res** 1995 Aug 31;2(4):183–6

An updated two-dimensional gel database of rat liver proteins useful in gene regulation and drug effect studies. Anderson NL, et al. **Electrophoresis** 1995 Oct; 16(10):1977–81

Characterization of proteins by sequential isoelectric focusing on immobilized pH gradients and electrospray mass spectrometry. Breme U, et al. **Electrophoresis** 1995 Aug; 16(8):1381–4

The further construction of the two-dimensional database of common human proteins. Burggraf D, et al. **Electrophoresis** 1995 May;16(5):831–40

Amino acid compositions of proteins and their identities. Galat A, et al. **Electrophoresis** 1995 Jul;16(7):1095–103

Calculation of the isoelectric points of native proteins with spreading of pKa values. Henriksson G, et al. **Electrophoresis** 1995 Aug;16(8):1377–80

The influence of proteins on silver staining of nucleic acids following polyacrylamide gel electrophoresis. Hilbert F, et al. **Electrophoresis** 1995 Jun;16(6):903–4

A new mode of size-dependent separation of proteins by capillary electrophoresis in presence of sodium dodecyl sulfate and concentrated oligomeric dextran. Takagi T, et al. **Electrophoresis** 1995 Aug;16(8):1463–7

Micropreparative immobilized pH gradient two-dimensional electrophoresis in combination with protein microsequencing for the analysis of human liver proteins. Wirth PJ, et al. **Electrophoresis** 1995 Oct;16(10):1946–60

The CXXC motif: imperatives for the formation of native disulfide bonds in the cell. Chivers PT, et al. **EMBO J** 1996 Jun 3;15(11):2659–67

Elimination of the carboxy-terminal sequences of parathyroid hormone-related protein 1–173 increases production and secretion of the truncated forms. Ditmer LS, et al. **Endocrinology** 1996 May;137(5):1608–17

Synthesis and solution structure of the antimicrobial peptide protegrin-1. Aumelas A, et al. **Eur J Biochem** 1996 May 1;237(3):575–83

Two regions with differential growth-modulating activity in the N-terminal domain of ras GTPase-activating protein (p120GAP) src homology and Gly-Ala-Pro-rich regions. Chang JS, et al. **Eur J Biochem** 1995 Sep 15;232(3):691–9

31P solid-state NMR measurements used to detect interactions between NADPH and water and to determine the ionisation state of NADPH in a protein-ligand complex subjected to low-level hydration. Gerothanassis IP, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):262–6

The molecular biology of multidomain proteins. Selected examples. Hawkins AR, et al. **Eur J Biochem** 1995 Aug 15;232(1):7–18 (147 ref.)

Analysis of the structural organization and thermal stability of two spermadhesins. Calorimetric, circular dichroic and Fourier-transform infrared spectroscopic studies. Menéndez M, et al. **Eur J Biochem** 1995 Dec 15; 234(3):887–96

Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Ruppert R, et al. **Eur J Biochem** 1996 Apr 1;237(1):295–302

Evidence for sodium dodecyl sulfate/protein complexes adopting a necklace structure. Samsó M, et al. **Eur J Biochem** 1995 Sep 15;232(3):818–24

Regions of RAG1 protein critical for V(D)J recombination. Kirch SA, et al. **Eur J Immunol** 1996 Apr;26(4):886–91

Chemical techniques employed for the primary structural analysis of proteins and peptides. Inglis AS, et al. **EXS** 1995;73:141–71 (73 ref.)

Alcoholytic deblocking of N-terminally acetylated peptides and proteins for sequence analysis. Bergman T, et al. **FEBS Lett** 1996 Jul 22;390(2):199–202

The protein fold of the hyaluronate-binding proteoglycan tandem repeat domain of link protein, aggrecan and CD44 is similar to that of the C-type lectin superfamily. Brissett NC, et al. **FEBS Lett** 1996 Jun 17;388(2–3):211–6

N-(2-ferrocene-ethyl)maleimide: a new electroactive sulphydryl-specific reagent for cysteine-containing peptides and proteins. Di Gleria K, et al. **FEBS Lett** 1996 Jul 22;390(2):142–4

Homodimerization and intermolecular tyrosine phosphorylation of the Tyk-2 tyrosine kinase. Domanski P, et al. **FEBS Lett** 1995 Nov 6;374(3):317–22

Towards prediction of cognate complexes between the WW domain and proline-rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1–8 (53 ref.)

The structure of the O-linked carbohydrate chain of bovine seminal plasma protein PDC-109 revised by H-NMR spectroscopy A correction. Gerwig GL, et al. **FEBS Lett** 1996 May 27;387(1):99–100

Amino acid residue: is it structural or functional? Golovanov AP, et al. **FEBS Lett** 1995 Nov 13;375(1–2):162–6

Linguistic analysis of protein folding. Gross M. **FEBS Lett** 1996 Jul 29;390(3):249–52

Secondary structure of an armadillo single repeat from the APC protein. Hirschl D, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):31–6

Prediction of potential protein–protein interaction sites from amino acid sequence. Identification of a fibrin polymerization site. Kini RM, et al. **FEBS Lett** 1996 Apr 29;385(1–2):81–6

Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides. Lawyer C, et al. **FEBS Lett** 1996 Jul 15;390(1):95–8

Threading analysis suggests that the obese gene product may be a helical cytokine. Madej T, et al. **FEBS Lett** 1995 Oct 2;373(1):13–8

A novel murine cathelin-like protein expressed in bone marrow. Popsueva AE, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):5–8

Solubility of artificial proteins with random sequences. Prijambada ID, et al. **FEBS Lett** 1996 Mar 11;382(1–2):21–5

Kinetic differentiation between ligand-induced and pre-existent asymmetric models. Wang ZX, et al. **FEBS Lett** 1996 Jun 10;388(1):73–5

A novel two-site binding equation presented in terms of the total ligand concentration. Wang ZX, et al. **FEBS Lett** 1996 Sep 2;392(3):245–9

Primary structure and homology [letter] Whyte B, et al. **FEBS Lett** 1996 Feb 19;380(3):301

Structural identification of valine hydroperoxides and hydroxides on radical-damaged amino acid, peptide, and protein molecules. Fu S, et al. **Free Radic Biol Med** 1995 Sep;19(3):281–92

FliH and fliI of Borrelia burgdorferi are similar to flagellar and virulence factor export proteins of other bacteria. Ge Y, et al. **Gene** 1996 Feb 2;168(1):73–5

Interferon induction of human tryptophanyl-tRNA synthetase safeguards the synthesis of tryptophan-rich immune-system proteins: a hypothesis [letter] Xue H, et al. **Gene** 1995 Nov 20;165(2):335–9

Human endometrial proteins with cyclic changes in the expression during the normal menstrual cycle: characterization by protein sequence analysis. Byrjalsen I, et al. **Hum Reprod** 1995 Oct;10(10):2760–6

A study of aggregation of 9-(dicyano-vinyl)julolidine. Bhattacharyya A, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):442–6

Molecular cloning and characterization of rabbit TIMP2. Wertheimer SJ, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S121–2

A protein complex from Choristoneura fumiferana gut-juice involved in the precipitation of delta-endotoxin from Bacillus thuringiensis subsp. sotto. Milne RE, et al. **Insect Biochem Mol Biol** 1995 Dec;25(10):1101–14

The liquid amide transfer model and the unfolding thermodynamics of small globular proteins. Barone G, et al. **Int J Biol Macromol** 1995 Oct;17(5):251–7

Distribution of solvent and ligand molecules around aromatic side chains in proteins and its implication on carbonic anhydrase catalytic mechanism. Håkansson K. **Int J Biol Macromol** 1996 Apr;18(3):189–94

Spectroscopic studies of Manduca sexta and Sesamia nonagrioides chorion protein structure. Orfanidou CC, et al. **Int J Biol Macromol** 1995 Apr;17(2):93–8

Primary structure of a cytotoxin-like basic protein from Naja naja naja (Indian cobra) venom. Babu AS, et al. **Int J Pept Protein Res** 1995 Jul;46(1):69–72

Isolation and identification of C-terminal peptides of proteins. Gu QM, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):366–71

A new clustering system for protein sequences and its application to constraints discovery in protein evolution. Nakagawa H, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):440–51

Structural and charge requirements for antimicrobial and hemolytic activity in the peptide PKLLETFLSKWIG, corresponding to the hydrophobic region of the antimicrobial protein bovine seminalplasmin. Sitaram N, et al. **Int J Pept Protein Res** 1995 Aug;46(2):166–73

Protein docking combining symbolic descriptions of molecular surfaces and grid-based scoring functions. Ackermann F, et al. **Ismb** 1995;3:3–11

Characterizing oriented protein structural sites using biochemical properties. Bagley SC, et al. **Ismb** 1995;3:12–20

The value of prior knowledge in discovering motifs with MEME. Bailey TL, et al. **Ismb** 1995;3:21–9

Protein modeling with hybrid Hidden Markov Model/neural network architectures. Baldi P, et al. **Ismb** 1995;3:39–47

An intelligent system for comparing protein structures. Benatan E. **Ismb** 1994;2:37–43

Protein design by optimization of a sequence-structure quality function. Brenner SE, et al. **Ismb** 1994;2:44–52

A specification for defining and annotating regions of macromolecular structures. Brenner SE, et al. **Ismb** 1995; 3:66–74

Predicting free energy contributions to the conformational stability of folded proteins from the residue sequence with radial basis function networks. Casadio R, et al. **Ismb** 1995; 3:81–8

Knowledge discovery of multilevel protein motifs. Conklin D, et al. **Ismb** 1994;2:96–102

Predicting protein folding classes without overly relying on homology. Craven MW, et al. **Ismb** 1995;3:98–106

A divide and conquer approach to multiple alignment. Dress A, et al. **Ismb** 1995;3:107–13

Multiple alignment using hidden Markov models. Eddy SR. **Ismb** 1995;3:114–20

Neural net representations of empirical protein potentials. Grossman T, et al. **Ismb** 1995;3:154–61

Constituting a receptor-ligand information base from quality-enriched data. Hemm K, et al. **Ismb** 1995;3:170–8

3-D lookup: fast protein structure database searches at 90% reliability. Holm L, et al. **Ismb** 1995;3:179–87

Evaluating regularizers for estimating distributions of amino acids. Karplus K. **Ismb** 1995;3:188–96

Protein sequencing experiment planning using analogy. Kettler B, et al. **Ismb** 1993;1:216–24

An efficient method for multiple sequence alignment. Kim J, et al. **Ismb** 1994;2:212–8

Maximum entropy weighting of aligned sequences of proteins or DNA. Krogh A, et al. **Ismb** 1995;3:215–21

Segmentation and interpretation of 3D protein images. Leherte L, et al. **Ismb** 1994;2:261–8

A constraint-based assignment system for automating long side chain assignments in protein 2D NMR spectra. Leishman S, et al. **Ismb** 1995;3:231–9

Relation between protein structure, sequence homology and composition of amino acids. Mayoraz E, et al. **Ismb** 1995; 3:240–8

Sequence comparisons via algorithmic mutual information. Milosavljevic A. **Ismb** 1994;2:303–9

MMDB: an ASN.1 specification for macromolecular structure. Ohkawa H, et al. **Ismb** 1995;3:259–67

Softening constraints in constraint-based protein topology prediction. Parsons S. **Ismb** 1995;3:268–76

Time-efficient docking of flexible ligands into active sites of proteins. Rarey M, et al. **Ismb** 1995;3:300–8

TOPITS: threading one-dimensional predictions into three-dimensional structures. Rost B. **Ismb** 1995;3:314–21

A distance-based block searching algorithm. Sagot MF, et al. **Ismb** 1995;3:322–31

Automata-theoretic models of mutation and alignment. Searls DB, et al. **Ismb** 1995;3:341–9

Solvent accessible surface representation in a database system for protein docking. Seidl T, et al. **Ismb** 1995;3:350–8

BONSAI Garden: parallel knowledge discovery system for amino acid sequences. Shoudai T, et al. **Ismb** 1995;3:359–66

Towards an intelligent system for the automatic assignment of domains in globular proteins. Sternberg MJ, et al. **Ismb** 1995;3:376–83

Recursive dynamic programming for adaptive sequence and structure alignment. Thiele R, et al. **Ismb** 1995;3:384–92

Neweyes: a system for comparing biological sequences using the running Karp-Rabin Greedy String-Tiling algorithm. Wise MJ. **Ismb** 1995;3:393–401

Identification of protein motifs using conserved amino acid properties and partitioning techniques. Wu TD, et al. **Ismb** 1995;3:402–10

Exploring the nucleotide-binding site in proteins by affinity labeling and site-directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)

Variability in heat-induced fragmentation of a protein in the presence of dodecyl sulfate: the role of an intramolecular sulfhydryl/disulfide exchange. Kubo K. **J Biochem (Tokyo)** 1995 Dec;118(6):1112–7

Detection of protein 3D-1D compatibility characterized by the evaluation of side-chain packing and electrostatic interactions. Matsuo Y, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):137–48

A new family of serine protease inhibitors (Bombyx family) as established from the unique topological relation between the positions of disulphide bridges and reactive site. Pham TN, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):428–34

Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)

Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. Ahmadian MR, et al. **J Biol Chem** 1996 Jul 5;271(27):16409–15

In vivo characterization of the proteasome regulator PA28. Ahn K, et al. **J Biol Chem** 1996 Jul 26;271(30):18237–42

Glutaredoxin-3 from Escherichia coli. Amino acid sequence, 1H AND 15N NMR assignments, and structural analysis. Aslund F, et al. **J Biol Chem** 1996 Mar 22;271(12):6736–45

The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney. Bateman A, et al. **J Biol Chem** 1996 May 3;271(18):10654–9

Zipper protein, a B–G protein with the ability to regulate actin/myosin 1 interactions in the intestinal brush border. Bikle DD, et al. **J Biol Chem** 1996 Apr 12;271(15):9075–83

N-terminal sequences contained in the Src homology 2 and 3 domains of p120 GTPase-activating protein are required for full catalytic activity toward Ras. Bryant SS, et al. **J Biol Chem** 1996 Mar 1;271(9):5195–9

Identification of a binding sequence for the 14–3–3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Ib alpha. Du X, et al. **J Biol Chem** 1996 Mar 29;271(13):7362–7

ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. Duan H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1621–5

Structure-function relationships of the mouse Gap1m. Determination of the inositol 1,3,4,5-tetrakisphosphate-binding domain. Fukuda M, et al. **J Biol Chem** 1996 Aug 2;271(31):18838–42

Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH–2 receptor agonist. Gardella TJ, et al. **J Biol Chem** 1996 Aug 16;271(33):19888–93

Isoforms of selenoprotein P in rat plasma. Evidence for a full-length form and another form that terminates at the second UGA in the open reading frame. Himeno S, et al. **J Biol Chem** 1996 Jun 28;271(26):15769–75

Thermodynamic studies of SHC phosphotyrosine interaction domain recognition of the NPXpY motif. Mandiyan V, et al. **J Biol Chem** 1996 Mar 1;271(9):4770–5

Modified ligands to FA and FB in photosystem I. I. Structural constraints for the formation of iron-sulfur clusters in free and rebound PsaC. Mehari T, et al. **J Biol Chem** 1995 Nov 24;270(47):28108–17

p120 Ras GTPase-activating protein interacts with Ras-GTP through specific conserved residues. Miao W, et al. **J Biol Chem** 1996 Jun 28;271(26):15322–9

T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. Mitcham JL, et al. **J Biol Chem** 1996 Mar 8;271(10):5777–83

Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. Murakami Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3340–2

Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1-associated protein TRADD. Park A, et al. **J Biol Chem** 1996 Apr 19; 271(16):9858–62

IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. Parnet P, et al. **J Biol Chem** 1996 Feb 23; 271(8):3967–70

Functionalized protein-like structures from conformationally defined synthetic combinatorial libraries. Pérez-Payá E, et al. **J Biol Chem** 1996 Feb 23;271(8):4120–6

Molecular determinants of the myristoyl-electrostatic switch of MARCKS. Seykora JT, et al. **J Biol Chem** 1996 Aug 2;271(31):18797–802

The amino acid at the X position of an Asn-X-Ser sequon is an imprtant determinant of N-linked core-glycosylation efficiency. Shakin-Eshleman SH, et al. **J Biol Chem** 1996 Mar 15;271(11):6363–6

Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. Takeuchi M, et al. **J Biol Chem** 1996 Aug 16;271(33):19935–42

Molecular cloning of NIPP-1, a nuclear inhibitor of protein phosphatase-1, reveals homology with polypeptides involved in RNA processing. Van Eynde A, et al. **J Biol Chem** 1995 Nov 24;270(47):28068–74

Identification of residues within the SHC phosphotyrosine binding/phosphotyrosine interaction domain crucial for phosphopeptide interaction. Yajnik V, et al. **J Biol Chem** 1996 Jan 26;271(4):1813–6

Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. Yim HS, et al. **J Biol Chem** 1995 Nov 24;270(47):28228–33

Modified ligands to FA and FB in photosystem I. II. Characterization of a mixed ligand [4Fe-4S] cluster in the C51D mutant of PsaC upon rebinding to P700-Fx cores. Yu L, et al. **J Biol Chem** 1995 Nov 24;270(47):28118–25

Effects of Tween 20 on the desorption of proteins from polymer surfaces. Feng M, et al. **J Biomater Sci Polym Ed** 1995;7(5):415–24

Protein-rejecting ability of surface-bound dextran in end-on and side-on configurations: comparison to PEG. Osterberg E, et al. **J Biomed Mater Res** 1995 Jun;29(6):741–7

Fibroblast adhesion onto methyl-silica gradients with and without preadsorbed protein. Williams RL, et al. **J Biomed Mater Res** 1995 Dec;29(12):1545–55

Calibration of ring-current effects in proteins and nucleic acids. Case DA. **J Biomol NMR** 1995 Dec;6(4):341–6

Assignment of aliphatic side-chain 1HN/15N resonances in perdeuterated proteins. Farmer BT 2nd, et al. **J Biomol NMR** 1996 Jan;7(1):59–71

Spectral density function mapping using 15N relaxation data exclusively. Farrow NA, et al. **J Biomol NMR** 1995 Sep; 6(2):153–62

Validation of the use of intermolecular NOE constraints for obtaining docked structures of protein-ligand complexes. Gradwell MJ, et al. **J Biomol NMR** 1996 Jan;7(1):48–58

HeteroTOCSY-based experiments for measuring heteronuclear relaxation in nucleic acids and proteins. Schweitzer BI, et al. **J Biomol NMR** 1995 Sep;6(2):180–8

Chemical shift assignments and secondary structure of the Grb2 SH2 domain by heteronuclear NMR spectroscopy. Wang YS, et al. **J Biomol NMR** 1996 Mar;7(2):89–98

Improved 3D gd-HCACO and gd-(H)CACO-TOCSY experiments for isotopically enriched proteins dissolved in H2O. Zhang W, et al. **J Biomol NMR** 1996 May;7(3):247–50

Simplified representation of proteins. Geetha V, et al. **J Biomol Struct Dyn** 1996 Apr;13(5):781–93

The sea urchin sperm receptor for egg jelly is a modular protein with extensive homology to the human polycystic kidney disease protein, PKD1. Moy GW, et al. **J Cell Biol** 1996 May;133(4):809–17

Large-scale amino-acid analysis for proteome studies. Yan JX, et al. **J Chromatogr A** 1996 Jun 7;736(1–2):291–302

Capillary zone electrophoretic resolution of recombinant human bone morphogenetic protein 2 glycoforms. An investigation into the separation mechanisms for an exquisite separation. Yim K, et al. **J Chromatogr A** 1995 Nov 17;716(1–2):401–12

Hydration in drug design. 1. Multiple hydrogen-bonding features of water molecules in mediating protein-ligand interactions. Poornima CS, et al. **J Comput Aided Mol Des** 1995 Dec;9(6):500–12

Hydration in drug design. 2. Influence of local site surface shape on water binding. Poornima CS, et al. **J Comput Aided Mol Des** 1995 Dec;9(6):513–20

Hydration in drug design. 3. Conserved water molecules at the ligand-binding sites of homologous proteins. Poornima CS, et al. **J Comput Aided Mol Des** 1995 Dec;9(6):521–31

Placement of medium-sized molecular fragments into active sites of proteins. Rarey M, et al. **J Comput Aided Mol Des** 1996 Feb;10(1):41–54

Algorithms for protein structural motif recognition. Berger B. **J Comput Biol** 1995 Spring;2(1):125–38

Constructing lattice models of protein chains with side groups. Reva BA, et al. **J Comput Biol** 1995 Winter; 2(4):527–35

Method for calculation of probability of matching a bounded regular expression in a random data string. Sewell RF, et al. **J Comput Biol** 1995 Spring;2(1):25–31

Proteins of crustacean exoskeleton: IV. Partial amino acid sequences of exoskeletal proteins from the Bermuda land crab, Gecarcinus lateralis, and comparisons to certain insect proteins. Kumari SS, et al. **J Exp Zool** 1995 Dec 1; 273(5):389–400

Sequence and expression patterns of mouse SPR1: Correlation of expression with epithelial function. Kartasova T, et al. **J Invest Dermatol** 1996 Feb; 106(2):294–304

Molecular similarity based on DOCK-generated fingerprints. Briem H, et al. **J Med Chem** 1996 Aug 16;39(17):3401–8

The microencapsulation of protein using a novel ternary blend based on poly(epsilon-caprolactone). Huatan H, et al. **J Microencapsul** 1995 Sep-Oct;12(5):557–67

Microencapsulation of O/W emulsions by formation of a protein-surfactant insoluble complex. Magdassi S, et al. **J Microencapsul** 1995 Sep-Oct;12(5):537–45

Impact of local and non-local interactions on thermodynamics and kinetics of protein folding. Abkevich VI, et al. **J Mol Biol** 1995 Sep 29;252(4):460–71

Predictions of secondary structure using statistical analyses of electronic and vibrational circular dichroism and Fourier transform infrared spectra of proteins in H2O. Baumruk V, et al. **J Mol Biol** 1996 Jun 21;259(4):774–91

Automatic analysis of protein conformational changes by multiple linkage clustering. Boutonnet NS, et al. **J Mol Biol** 1995 Nov 3;253(4):633–47

Decomposition of interaction free energies in proteins and other complex systems. Brady GP, et al. **J Mol Biol** 1995 Nov 17;254(1):77–85

The hydration of globular proteins as derived from volume and compressibility measurements: cross correlating thermodynamic and structural data. Chalikian TV, et al. **J Mol Biol** 1996 Jul 26;260(4):588–603

Implications of N and C-terminal proximity for protein folding. Christopher JA, et al. **J Mol Biol** 1996 Mar 22; 257(1):175–87

Identifying the tertiary fold of small proteins with different topologies from sequence and secondary structure using the genetic algorithm and extended criteria specific for strand regions. Dandekar T, et al. **J Mol Biol** 1996 Mar 1;256(3):645–60

Strange bedfellows: interactions between acidic side-chains in proteins. Flocco MM, et al. **J Mol Biol** 1995 Nov 17; 254(1):96–105

An efficient mean solvation force model for use in molecular dynamics simulations of proteins in aqueous solution. Fraternali F, et al. **J Mol Biol** 1996 Mar 15;256(5):939–48

Stability changes upon mutation of solvent-accessible residues in proteins evaluated by database-derived potentials. Gilis D, et al. **J Mol Biol** 1996 Apr 19; 257(5):1112–26

Recognizing native folds by the arrangement of hydrophobic and polar residues. Huang ES, et al. **J Mol Biol** 1995 Oct 6;252(5):709–20

Using a hydrophobic contact potential to evaluate native and near-native folds generated by molecular dynamics simulations. Huang ES, et al. **J Mol Biol** 1996 Apr 5; 257(3):716–25

A functional role for protein cavities in domain: domain motions. Hubbard SJ, et al. **J Mol Biol** 1996 Aug 16; 261(2):289–300

A global taxonomy of loops in globular proteins. Kwasigroch JM, et al. **J Mol Biol** 1996 Jun 21;259(4):855–72

FASTA-SWAP and FASTA-PAT: pattern database searches using combinations of aligned amino acids, and a novel scoring theory. Ladunga I, et al. **J Mol Biol** 1996 Jun 21;259(4):840–54

X-SITE: use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. Laskowski RA, et al. **J Mol Biol** 1996 May 31;259(1):175–201

Global optimum protein threading with gapped alignment and empirical pair score functions. Lathrop RH, et al. **J Mol Biol** 1996 Feb 2;255(4):641–65

An evolutionary trace method defines binding surfaces common to protein families. Lichtarge O, et al. **J Mol Biol** 1996 Mar 29;257(2):342–58

Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data. Mikol V, et al. **J Mol Biol** 1995 Nov 17; 254(1):86–95

Residue-residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. Miyazawa S, et al. **J Mol Biol** 1996 Mar 1;256(3):623–44

Automated assignment of simulated and experimental NOESY spectra of proteins by feedback filtering and self-correcting distance geometry. Mumenthaler C, et al. **J Mol Biol** 1995 Dec 1;254(3):465–80

Complex salt bridges in proteins: statistical analysis of structure and function. Musafia B, et al. **J Mol Biol** 1995 Dec 8;254(4):761–70

Amino acid pair interchanges at spatially conserved locations. Naor D, et al. **J Mol Biol** 1996 Mar 15;256(5):924–38

Valence screening of water in protein crystals reveals potential Na+ binding sites. Nayal M, et al. **J Mol Biol** 1996 Feb 23;256(2):228–34

Helix propensities of basic amino acids increase with the length of the side-chain. Padmanabhan S, et al. **J Mol Biol** 1996 Apr 5;257(3):726–34

Energy functions that discriminate X-ray and near native folds from well-constructed decoys. Park B, et al. **J Mol Biol** 1996 May 3;258(2):367–92

The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. Peters KP, et al. **J Mol Biol** 1996 Feb 16; 256(1):201–13

Interactions between a helical residue and tertiary structures: helix propensities in small peptides and in native proteins. Qian H, et al. **J Mol Biol** 1996 Aug 16;261(2):279–88

Prediction of alpha-helices in proteins based on thermodynamic parameters from solution chemistry. Qian H. **J Mol Biol** 1996 Mar 8;256(4):663–6

A fast flexible docking method using an incremental construction algorithm. Rarey M, et al. **J Mol Biol** 1996 Aug 23;261(3):470–89

A zinc-binding domain involved in the dimerization of RAG1. Rodgers KK, et al. **J Mol Biol** 1996 Jul 5; 260(1):70–84

Local conformational signals and the statistical thermodynamics of collapsed helical proteins. Saven JG, et al. **J Mol Biol** 1996 Mar 22;257(1):199–216

Comparison between the phi distribution of the amino acids in the protein database and NMR data indicates that amino acids have various phi propensities in the random coil conformation. Serrano L. **J Mol Biol** 1995 Nov 24; 254(2):322–33

Helmholtz free energy of peptide hydrogen bonds in proteins. Sippl MJ. **J Mol Biol** 1996 Aug 2;260(5):644–8

Analysis of main chain torsion angles in proteins: prediction of NMR coupling constants for native and random coil conformations. Smith LJ, et al. **J Mol Biol** 1996 Jan 26; 255(3):494–506

Statistical potentials extracted from protein structures: how accurate are they? Thomas PD, et al. **J Mol Biol** 1996 Mar 29;257(2):457–69

A dataset of protein-protein interfaces generated with a sequence-order-independent comparison technique. Tsai CJ, et al. **J Mol Biol** 1996 Jul 26;260(4):604–20

Principles of helix-helix packing in proteins: the helical lattice

superposition model. Walther D, et al. **J Mol Biol** 1996 Jan 26;255(3):536–53
Automatic classification and analysis of alpha alpha–turn motifs in proteins. Wintjens RT, et al. **J Mol Biol** 1996 Jan 12;255(1):235–53
Free energy determinants of secondary structure formation: II. Antiparallel beta–sheets. Yang AS, et al. **J Mol Biol** 1995 Sep 22;252(3):366–76
Free energy determinants of secondary structure formation: I. alpha–Helices. Yang AS, et al. **J Mol Biol** 1995 Sep 22; 252(3):351–65
Phylogeny reconstruction for protein sequences based on amino acid properties. Schmidt W. **J Mol Evol** 1995 Oct; 41(4):522–30
Approximation and visualization of large–scale motion of protein surfaces. Duncan BS, et al. **J Mol Graph** 1995 Aug; 13(4):250–7
SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. Laskowski RA. **J Mol Graph** 1995 Oct;13(5):323–30, 307–8
The behavior of optic axons on substrate gradients of retinal basal lamina proteins and merosin. Halfter W. **J Neurosci** 1996 Jul 15;16(14):4389–401
Effect of link protein concentration on articular cartilage proteoglycan aggregation. Tang LH, et al. **J Orthop Res** 1996 Mar;14(2):334–9
Quantitation of the area of overlap between second–derivative amide I infrared spectra to determine the structural similarity of a protein in different states. Kendrick BS, et al. **J Pharm Sci** 1996 Feb;85(2):155–8
Protein location in liposomes, a drug carrier: a prediction by differential scanning calorimetry. Lo YL, et al. **J Pharm Sci** 1995 Jul;84(7):805–14
Precipitation of proteins in supercritical carbon dioxide. Winters MA, et al. **J Pharm Sci** 1996 Jun;85(6):586–94
Characterization of pyridoxal phosphate as an optical label for measuring electrostatic potentials in proteins. Kossekova G, et al. **J Photochem Photobiol B** 1996 Jan; 32(1–2):71–9
Analysis of the loop–helix interaction in bundle motif protein structures. Thompson TB, et al. **J Protein Chem** 1995 Oct; 14(7):559–66
Protein selectivity in immobilized metal affinity chromatography based on the surface accessibility of aspartic and glutamic acid residues. Zachariou M, et al. **J Protein Chem** 1995 Aug;14(6):419–30
Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor. dos Remedios CG, et al. **J Struct Biol** 1995 Sep–Oct; 115(2):175–85 (48 ref.)
Local alignment statistics. Altschul SF, et al. **Methods Enzymol** 1996;266:460–80
Superfamily classification in PIR–International Protein Sequence Database. Barker WC, et al. **Methods Enzymol** 1996;266:59–71
Three–dimensional profiles for measuring compatibility of amino acid sequence with three–dimensional structure. Bowie JU, et al. **Methods Enzymol** 1996;266:598–616
Understanding protein structure: using scop for fold interpretation. Brenner SE, et al. **Methods Enzymol** 1996; 266:635–43
Simple force field for study of peptide and protein conformational properties. Creamer TP, et al. **Methods Enzymol** 1995;259:576–89
Resonance Raman spectroscopy of quinoproteins. Dooley DM, et al. **Methods Enzymol** 1995;258:132–40
Nuclear magnetic resonance of thioredoxin and glutaredoxin. Dyson HJ. **Methods Enzymol** 1995;252:293–306
SRS: information retrieval system for molecular biology data banks. Etzold T, et al. **Methods Enzymol** 1996;266:114–28
Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods. Felsenstein J. **Methods Enzymol** 1996;266:418–27
Progressive alignment of amino acid sequences and construction of phylogenetic trees from them. Feng DF, et al. **Methods Enzymol** 1996;266:368–82
Redox–cycling detection of dialyzable pyrroloquinoline quinone and quinoproteins. Flückiger R, et al. **Methods Enzymol** 1995;258:140–9
Probing structural and physical basis of protein energetics linked to protons and salt. García–Moreno B. **Methods Enzymol** 1995;259:512–38
GOR method for predicting protein secondary structure from amino acid sequence. Garnier J, et al. **Methods Enzymol** 1996;266:540–53
PIR–International Protein Sequence Database. George DG, et al. **Methods Enzymol** 1996;266:41–59
Identification of sequence pattern with profile analysis. Gribskov M, et al. **Methods Enzymol** 1996;266:198–212
Parametric and inverse–parametric sequence alignment with XPARAL. Gusfield D, et al. **Methods Enzymol** 1996; 266:481–94
Combined DNA and protein alignment. Hein J, et al. **Methods Enzymol** 1996;266:402–18
Blocks database and its applications. Henikoff JG, et al. **Methods Enzymol** 1996;266:88–105
Using CLUSTAL for multiple sequence alignments. Higgins DG, et al. **Methods Enzymol** 1996;266:383–402
Alignment of three–dimensional protein structures: network server for database searching. Holm L, et al. **Methods Enzymol** 1996;266:653–62
Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Johnson MS, et al. **Methods Enzymol** 1996;266:575–98
Sedimentation equilibrium as thermodynamic tool. Laue TM. **Methods Enzymol** 1995;259:427–52
Analyzing solvent reorganization and hydrophobicity. Lee B. **Methods Enzymol** 1995;259:555–76
Identification of functional residues and secondary structure from protein multiple sequence alignment. Livingstone CD, et al. **Methods Enzymol** 1996;266:497–512
On the interpretation of data from isothermal processes. Lumry R. **Methods Enzymol** 1995;259:628–720
Prediction and analysis of coiled–coil structures. Lupas A. **Methods Enzymol** 1996;266:513–25
Applications of network BLAST server. Madden TL, et al. **Methods Enzymol** 1996;266:131–41
SSAP: sequential structure alignment program for protein structure comparison. Orengo CA, et al. **Methods Enzymol** 1996;266:617–35
Macromolecules and water: probing with osmotic stress. Parsegian VA, et al. **Methods Enzymol** 1995;259:43–94
Effective protein sequence comparison. Pearson WR. **Methods Enzymol** 1996;266:227–58
Converting sequence block alignments into structural insights. Poch O, et al. **Methods Enzymol** 1996;266:662–80
Studies of nucleic acids and their protein interactions by 19F NMR. Rastinejad F, et al. **Methods Enzymol** 1995; 261:560–75
Molecular volume. Rellick LM, et al. **Methods Enzymol** 1995; 259:377–95
Hydrostatic and osmotic pressure as tools to study macromolecular recognition. Robinson CR, et al. **Methods Enzymol** 1995;259:395–427
PHD: predicting one–dimensional protein structure by profile–based neural networks. Rost B. **Methods Enzymol** 1996;266:525–39
Application of pressure to biochemical equilibria: the other thermodynamic variable. Royer CA. **Methods Enzymol** 1995;259:357–77
Information services of the European Bioinformatics Institute. Shomer B, et al. **Methods Enzymol** 1996;266:3–27
Indexing and using sequence databases. Staden R. **Methods Enzymol** 1996;266:105–14
Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)
Detecting structural similarities: a user's guide. Swindells MB. **Methods Enzymol** 1996;266:643–53
Multiple protein sequence alignment: algorithms and gap insertion. Taylor WR. **Methods Enzymol** 1996;266:343–67
Analysis of compositionally biased regions in sequence databases. Wootton JC, et al. **Methods Enzymol** 1996; 266:554–71
Iterative template refinement: protein–fold prediction using iterative search and hybrid sequence/structure templates. Yi TM, et al. **Methods Enzymol** 1996;266:322–39
Structure determination using isomorphous replacement. Abdel–Meguid SS. **Methods Mol Biol** 1996;56:153–71
Preliminary characterization of crystals. Abdel–Meguid SS, et al. **Methods Mol Biol** 1996;56:55–86
Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)
Separation of peptides and protein digests by capillary electrophoresis. Herold M, et al. **Methods Mol Biol** 1996; 52:285–308
Density modification in x–ray crystallography. Podjarny AD, et al. **Methods Mol Biol** 1996;56:205–26 (88 ref.)
Crystallographic methods and protocols. Introduction. Sanderson MR. **Methods Mol Biol** 1996;56:1–21 (70 ref.)
Crystallographic and chromatographic methods for study of antibody light chains and other proteins. Schiffer M, et al. **Methods Mol Biol** 1995;51:83–98
Overexpression, isolation, and crystallization of proteins. Skelly JV, et al. **Methods Mol Biol** 1996;56:23–53 (85 ref.)
Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)
Ultrafast protein determinations using microwave enhancement. Akins RE, et al. **Mol Biotechnol** 1995 Aug; 4(1):17–24
Stimulation of ras GTPase activity by an anti–ras monoclonal antibody. Agellon S, et al. **Mol Carcinog** 1996 Jul; 16(3):132–8
The N–terminal pleckstrin, coiled–coil, and IQ domains of the exchange factor Ras–GRF act cooperatively to facilitate activation by calcium. Buchsbaum R, et al. **Mol Cell Biol** 1996 Sep;16(9):4888–96
Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)
Information please [editorial] **Nat Struct Biol** 1996 Feb; 3(2):105–6
Cooperatively folded proteins in random sequence libraries. Davidson AR, et al. **Nat Struct Biol** 1995 Oct;2(10):856–64
When one and one are not two [news] Fletterick RJ, et al. **Nat Struct Biol** 1995 Sep;2(9):721–3
Complexity in proteins [news; comment] Frauenfelder H. **Nat Struct Biol** 1995 Oct;2(10):821–3. Comment on: Nat Struct Biol 1995 Oct;2(10):848–51.
The hairpin stack fold, a novel protein architecture for a new family of protein growth factors [letter] Hrabal R, et al. **Nat Struct Biol** 1996 Sep;3(9):747–52
A disulphide–reinforced structural scaffold shared by small proteins with diverse functions [letter] Lin SL, et al. **Nat Struct Biol** 1995 Oct;2(10):835–7
Solvent isotope effect and protein stability. Makhatadze GI, et al. **Nat Struct Biol** 1995 Oct;2(10):852–5
Mechanisms of growth for protein and virus crystals. Malkin AJ, et al. **Nat Struct Biol** 1995 Nov;2(11):956–9
Not just your average structures [news] Petsko GA. **Nat Struct Biol** 1996 Jul;3(7):565–6
How molten is the molten globule?[news] Ptitsyn O. **Nat Struct Biol** 1996 Jun;3(6):488–90
Structural basis for specificity of Grb2–SH2 revealed by a novel ligand binding mode [letter] Rahuel J, et al. **Nat Struct Biol** 1996 Jul;3(7):586–9
Extending molecular systematics to the third dimension. Wodak SJ. **Nat Struct Biol** 1996 Jul;3(7):575–8
Why protein crystals favour some space–groups over others. Wukovitz SW, et al. **Nat Struct Biol** 1995 Dec;2(12):1062–7
Crystal structure of a PDZ domain. Cabral JH, et al. **Nature** 1996 Aug 15;382(6592):649–52
A potential catalytic site revealed by the 1.7–A crystal structure of the amino–terminal signalling domain of Sonic hedgehog. Hall TM, et al. **Nature** 1995 Nov 9; 378(6553):212–6
Context–dependent secondary structure formation of a designed protein sequence. Minor DL Jr, et al. **Nature** 1996 Apr 25;380(6576):730–4
Femtomole sequencing of proteins from polyacrylamide gels by nano–electrospray mass spectrometry. Wilm M, et al. **Nature** 1996 Feb 1;379(6564):466–9
Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Zhou MM, et al. **Nature** 1995 Dec 7;378(6557):584–92
Progress with the PRINTS protein fingerprint database. Attwood TK, et al. **Nucleic Acids Res** 1996 Jan 1; 24(1):182–8
The PROSITE database, its status in 1995. Bairoch A, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):189–96
The SWISS–PROT protein sequence data bank and its new supplement TREMBL. Bairoch A, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):21–5
GRBase, a database linking information on proteins involved in gene regulation. Collier B, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):219–20
The PIR–International Protein Sequence Database. George DG, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):17–20
The SBASE protein domain library, Release 4.0: a collection of annotated protein sequence segments. Murvai J, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):210–3
The Blocks database—a system for protein classification. Pietrokovski S, et al. **Nucleic Acids Res** 1996 Jan 1; 24(1):197–200
The HSSP database of protein structure–sequence alignments. Schneider R, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):201–5
Bik, a novel death–inducing protein shares a distinct sequence motif with Bcl–2 family proteins and interacts with viral and cellular survival–promoting proteins. Boyd JM, et al. **Oncogene** 1995 Nov 2;11(9):1921–8
A 15 amino acid stretch close to the Grb2–binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. Rojas JM, et al. **Oncogene** 1996 Jun 6; 12(11):2291–300
Interaction of glycyl–phenylalanine with carbohydrates as a model of N–terminal glycation of proteins. Argirov OK, et al. **Ophthalmic Res** 1996;28 Suppl 1:62–4
Degradation of macromolecules during preservation of lyophilized pathological tissues. Takahashi R, et al. **Pathol Res Pract** 1995 Jun;191(5):420–6
Amino acid sequence of a peptide with molt–inhibiting activity from the kuruma prawn Penaeus japonicus. Yang WJ, et al. **Peptides** 1996;17(2):197–202
The limb/LPM enhancer of the murine Hoxb6 gene: reporter gene analysis in transgenic embryos and studies of DNA–protein interactions. Becker D, et al. **Pharm Acta Helv** 1996 Jun;71(1):29–35
Affinity coelectrophoresis for dissecting protein–RNA domain–domain interactions in a tRNA synthetase system. Gale AJ, et al. **Pharm Acta Helv** 1996 Jun;71(1):45–50
Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. Bloemendal M, et al. **Pharm Biotechnol** 1995;7:65–100 (112 ref.)
Fourier transform infrared spectroscopy investigations of protein structure. Cooper EA, et al. **Pharm Biotechnol** 1995; 7:101–43 (114 ref.)
Application of fluorescence spectroscopy for determining the structure and function of proteins. Jiskoot W, et al. **Pharm Biotechnol** 1995;7:1–63 (185 ref.)
Thermodynamic strategies for rational protein and drug design. Murphy KP, et al. **Pharm Biotechnol** 1995;7:219–41 (57 ref.)
Mass spectrometry in protein structural analysis. Roepstorff P. **Pharm Biotechnol** 1995;7:145–77 (79 ref.)
Two–, three–, and four–dimensional nuclear magnetic resonance spectroscopy of protein pharmaceuticals. Vander Velde DG, et al. **Pharm Biotechnol** 1995;7:179–218 (186 ref.)
The origins and evolution of eukaryotic proteins. Doolittle RF. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):235–40
Conformational trapping in a membrane environment: a

regulatory mechanism for protein activity? Arumugam S, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5872–6

Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Belshaw PJ, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4604–7

Ice as a matrix for IR-matrix-assisted laser desorption/ionization: mass spectra from a protein single crystal. Berkenkamp S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7003–7

How are close residues of protein structures distributed in primary sequence? Brocchieri L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12136–40

Compressibility as a means to detect and characterize globular protein states. Chalikian TV, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1012–4

Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. Clark GJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1577–81

Protein minimization: downsizing through mutation. DeGrado WF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5680–1 (19 ref.)

The folding mechanism of larger model proteins: role of native structure. Dinner AR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8356–61

Why are some proteins structures so common? Govindarajan S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3341–5

Lyophilization-induced reversible changes in the secondary structure of proteins. Griebenow K, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10969–76

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Griffith DL, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):878–83

Global properties of the mapping between local amino acid sequence and local structure in proteins. Han KF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5814–8

How optimization of potential functions affects protein folding. Hao MH, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4984–9

Evidence for nonrandom hydrophobicity structures in protein chains. Irbäck A, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9533–8

Principles of protein-protein interactions. Jones S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):13–20 (47 ref.)

Characterizations of diverse residue clusters in protein three-dimensional structures. Karlin S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8344–9

Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide. Kidera A. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9886–9

Sequence tag identification of intact proteins by matching tanden mass spectral data against sequence data bases. Mørtz E, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8264–7

Foldons, protein structural modules, and exons. Panchenko AR, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):2008–13

The C-terminal region of human angiogenin has a dual role in enzymatic activity. Russo N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3243–7

A combined kinetic and modeling study of the catalytic center subsites of human angiogenin. Russo N, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):804–8

Lattice model for rapidly folding protein-like heteropolymers. Shrivastava I, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9206–9

Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Simon DI, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4736–41

Nuclear magnetic dipole interactions in field-oriented proteins: information for structure determination in solution. Tolman JR, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9279–83

Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites. van der Geer P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):963–8

ARD1, a 64-kDa bifunctional protein containing an 18-kDa GTP-binding ADP-ribosylation factor domain and a 46-kDa GTPase-activating domain. Vitale N, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1941–4

Mapping protein-protein interactions by affinity-directed mass spectrometry. Zhao Y, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4020–4

Clusters of charged residues in protein three-dimensional structures. Zhu ZY, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8350–5

Pulsed field gradient multi-dimensional NMR methods for the study of protein structure and dynamics in solution. Kay LE. **Prog Biophys Mol Biol** 1995;63(3):277–99 (80 ref.)

Thermal diffuse X-ray scattering and its contribution to understanding protein dynamics. Thüne T, et al. **Prog Biophys Mol Biol** 1995;63(3):251–76 (60 ref.)

Representative selection of proteins based on nuclear families [letter] Boberg J, et al. **Protein Eng** 1995 May;8(5):501–3

Prediction of the antigenic sites of the cystic fibrosis transmembrane conductance regulator protein by molecular modelling. Gallet X, et al. **Protein Eng** 1995 Aug; 8(8):829–34

In search of the ideal protein sequence. Godzik A. **Protein Eng** 1995 May;8(5):409–16

Side-chain prediction by neural networks and simulated annealing optimization. Hwang JK, et al. **Protein Eng** 1995 Apr;8(4):363–70

Identification and analysis of domains in proteins. Islam SA, et al. **Protein Eng** 1995 Jun;8(6):513–25

A simple algorithm for the calculation of multiple site titration curves. Karshikoff A. **Protein Eng** 1995 Mar; 8(3):243–8

Finding the global minimum: a fuzzy end elimination implementation. Keller DA, et al. **Protein Eng** 1995 Sep; 8(9):893–904

Hydrophobic potential by pairwise surface area sum. Kurochkina N, et al. **Protein Eng** 1995 May;8(5):437–42

Enhanced dead-end elimination in the search for the global minimum energy conformation of a collection of protein side chains. Lasters I, et al. **Protein Eng** 1995 Aug; 8(8):815–22

Improved genetic algorithm-based protein structure comparisons: pairwise and multiple superpositions. May AC, et al. **Protein Eng** 1995 Sep;8(9):873–82

Comparison of spatial arrangements of secondary structural elements in proteins. Mizuguchi K, et al. **Protein Eng** 1995 Apr;8(4):353–62

Contact pattern-induced pair potentials for protein fold recognition. Selbig J. **Protein Eng** 1995 Apr;8(4):339–51

A simple protein folding algorithm using a binary code and secondary structure constraints. Sun S, et al. **Protein Eng** 1995 Aug;8(8):769–78

Independence divergence-generated binary trees of amino acids. Tusnády GE, et al. **Protein Eng** 1995 May; 8(5):417–23

Protein docking for low-resolution structures. Vakser IA. **Protein Eng** 1995 Apr;8(4):371–7

Predicting protein structural classes from amino acid composition: application of fuzzy clustering. Zhang CT, et al. **Protein Eng** 1995 May;8(5):425–35

Domains in folding of model proteins. Abkevich VI, et al. **Protein Sci** 1995 Jun;4(6):1167–77

3D domain swapping: a mechanism for oligomer assembly. Bennett MJ, et al. **Protein Sci** 1995 Dec;4(12):2455–68 (67 ref.)

The coming of age of mass spectrometry in peptide and protein chemistry. Biemann K. **Protein Sci** 1995 Sep; 4(9):1920–7

Atomic solvation parameters in the analysis of protein-protein docking results. Cummings MD, et al. **Protein Sci** 1995 Oct;4(10):2087–99

De novo design of the hydrophobic cores of proteins. Desjarlais JR, et al. **Protein Sci** 1995 Oct;4(10):2006–18

Side-chain conformational entropy in protein folding. Doig AJ, et al. **Protein Sci** 1995 Nov;4(11):2247–51 (31 ref.)

Prediction of polyelectrolyte polypeptide structures using Monte Carlo conformational search methods with implicit solvation modeling. Evans JS, et al. **Protein Sci** 1995 Oct; 4(10):2019–31

C alpha-based torsion angles: a simple tool to analyze protein conformational changes. Flocco MM, et al. **Protein Sci** 1995 Oct;4(10):2118–22

Are proteins ideal mixtures of amino acids? Analysis of energy parameter sets. Godzik A, et al. **Protein Sci** 1995 Oct;4(10):2107–17

Structure in solution of a four-helix lipid binding protein. Heinemann B, et al. **Protein Sci** 1996 Jan;5(1):13–23

Crystallization and preliminary X-ray crystallographic studies on Type III antifreeze protein. Jia Z, et al. **Protein Sci** 1995 Jun;4(6):1236–8

Finding flexible patterns in unaligned protein sequences. Jonassen I, et al. **Protein Sci** 1995 Aug;4(8):1587–95

Comparison of atomic solvation parametric sets: applicability and limitations in protein folding and binding. Juffer AH, et al. **Protein Sci** 1995 Dec;4(12):2499–509

Multidomain organization of eukaryotic guanine nucleotide exchange translation initiation factor eIF-2B subunits revealed by analysis of conserved sequence motifs. Koonin EV. **Protein Sci** 1995 Aug;4(8):1608–17

On the role of surface tension in the stabilization of globular proteins. Lin TY, et al. **Protein Sci** 1996 Feb;5(2):372–81

Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Myers JK, et al. **Protein Sci** 1995 Oct;4(10):2138–48

A novel adenosine triphosphate analog with a heavy atom to target the nucleotide binding site of proteins. Naber N, et al. **Protein Sci** 1995 Sep;4(9):1824–31

How to measure and predict the molar absorption coefficient of a protein. Pace CN, et al. **Protein Sci** 1995 Nov; 4(11):2411–23

Extending the C2 domain family: C2s in PKCs delta, epsilon, eta, theta, phospholipases, GAPs, and perforin. Ponting CP, et al. **Protein Sci** 1996 Jan;5(1):162–6

Significance of structural changes in proteins: expected errors in refined protein structures. Stroud RM, et al. **Protein Sci** 1995 Nov;4(11):2392–404

Prediction of protein complexes using empirical free energy functions. Weng Z, et al. **Protein Sci** 1996 Apr;5(4):614–26

Binary patterning of polar and nonpolar amino acids in the sequences and structures of native proteins. West MW, et al. **Protein Sci** 1995 Oct;4(10):2032–9

Identification of a pattern in protein structure based on energetic and statistical considerations. Amadei A, et al. **Proteins** 1996 Jan;24(1):35–50

Thermally induced hydrogen exchange processes in small proteins as seen by FTIR spectroscopy. Backmann J, et al. **Proteins** 1996 Mar;24(3):379–87

Homology modeling by the ICM method. Cardozo T, et al. **Proteins** 1995 Nov;23(3):403–14

Comparing folding codes for proteins and polymers. Chan HS, et al. **Proteins** 1996 Mar;24(3):335–44

The use of position-specific rotamers in model building by homology. Chinea G, et al. **Proteins** 1995 Nov;23(3):415–21

A novel approach to predicting protein structural classes in a (20-1)-D amino acid composition space. Chou KC. **Proteins** 1995 Apr;21(4):319–44

Metal search: a computer program that helps design tetrahedral metal-binding sites. Clarke ND, et al. **Proteins** 1995 Oct;23(2):256–63

Evaluation of current techniques for ab initio protein structure prediction. Defay T, et al. **Proteins** 1995 Nov; 23(3):431–45

Structural superposition of proteins with unknown alignment and detection of topological similarity using a six-dimensional search algorithm. Diederichs K. **Proteins** 1995 Oct;23(2):187–95

Local moves: an efficient algorithm for simulation of protein folding. Elofsson A, et al. **Proteins** 1995 Sep;23(1):73–82

Progress in fold recognition. Flöckner H, et al. **Proteins** 1995 Nov;23(3):376–86

Knowledge-based protein secondary structure assignment. Frishman D, et al. **Proteins** 1995 Dec;23(4):566–79

The heat capacity of proteins. Gómez J, et al. **Proteins** 1995 Aug;22(4):404–12

Analysis of six protein structures predicted by comparative modeling techniques. Harrison RW, et al. **Proteins** 1995 Dec;23(4):463–71

Harmonicity and anharmonicity in protein dynamics: a normal mode analysis and principal component analysis. Hayward S, et al. **Proteins** 1995 Oct;23(2):177–86

Fold recognition and ab initio structure predictions using hidden Markov models and beta-strand pair potentials. Hubbard TJ, et al. **Proteins** 1995 Nov;23(3):398–402

Protein-protein interaction at crystal contacts. Janin J, et al. **Proteins** 1995 Dec;23(4):580–7

Successful protein fold recognition by optimal sequence threading validated by rigorous blind testing. Jones DT, et al. **Proteins** 1995 Nov;23(3):387–97

Atomic and residue hydrophilicity in the context of folded protein structures. Kuhn LA, et al. **Proteins** 1995 Dec; 23(4):536–47

Protein structure prediction by threading methods: evaluation of current techniques. Lemer CM, et al. **Proteins** 1995 Nov; 23(3):337–55

Threading a database of protein cores. Madej T, et al. **Proteins** 1995 Nov;23(3):356–69

Size-independent comparison of protein three-dimensional structures. Maiorov VN, et al. **Proteins** 1995 Jul; 22(3):273–83

Assessment of a protein fold recognition method that takes into account four physicochemical properties: side-chain packing, solvation, hydrogen-bonding, and local conformation. Matsuo Y, et al. **Proteins** 1995 Nov; 23(3):370–5

An automated method for dynamic ligand design. Miranker A, et al. **Proteins** 1995 Dec;23(4):472–90

A large-scale experiment to assess protein structure prediction methods. Moult J, et al. **Proteins** 1995 Nov; 23(3):ii–v

High pressure effects on protein structure and function. Mozhaev VV, et al. **Proteins** 1996 Jan;24(1):81–91 (56 ref.)

Rigid domains in proteins: an algorithmic approach to their identification. Nichols WL, et al. **Proteins** 1995 Sep; 23(1):38–48

Water transfer energetics and solid-like packing of globular proteins. Ragone R, et al. **Proteins** 1996 Mar;24(3):388–93

Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Stote RH, et al. **Proteins** 1995 Sep;23(1):12–31

Diffuse scattering in protein crystallography. Benoit JP, et al. **Q Rev Biophys** 1995 May;28(2):131–69 (92 ref.)

Comments on "A critical analysis of the use of radiation inactivation to measure the mass of protein" by Lidzey et al. (Radiat. Res. 143, 181–186, 1995) [letter; comment] Kempner ES. **Radiat Res** 1996 May;145(5):649–51. Comment on: Radiat Res 1995 Aug;143(2):181–6.

Characterization of radiation-induced thymine-tyrosine crosslinks by electrospray ionization mass spectrometry. Weir Lipton MS, et al. **Radiat Res** 1996 Jun;145(6):681–6

Preliminary investigation of glycosylated proteins by capillary electrophoresis and capillary electrophoresis/mass spectrometry using electrospray ionization and by matrix-assisted laser desorption ionization/time-to-flight mass spectrometry. Bonfichi R, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S95–106

Asparaginyl endopeptidase mapping of proteins with subsequent matrix-assisted laser desorption/ionization mass spectrometry. Kanda F, et al. **Rapid Commun Mass Spectrom** 1995;9(12):1095–100

Revisit of MALDI for small proteins. Zhu YF, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1315–20

Not the "Dark Ages" [letter; comment] Barker WC, et al. **Science** 1996 Jul 12;273(5272):165. Comment on: Science 1996 May 17;272(5264):946.

The "bio" in biochemistry: protein folding inside and outside the cell [comment] Ellis RJ. **Science** 1996 Jun 7;

272(5267):1448–9 (10 ref.). Comment on: Science 1996 Jun 7;272(5267):1497–502.
Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)
Which came first, protein sequence or structure? [comment] Karkar M. **Science** 1996 Aug 2;273(5275):610. Comment on: Science 1996 Aug 2;273(5275):666–9.
Emergence of preferred structures in a simple model of protein folding [see comments] Li H, et al. **Science** 1996 Aug 2;273(5275):666–9. Comment in: Science 1996 Aug 2;273(5275):610.
Search for better crystals explores inner, outer space [news] Normile D. **Science** 1995 Dec 22;270(5244):1921–2
Teams tackle protein prediction [news] Pennisi E. **Science** 1996 Jul 26;273(5274):426–8
Supported membranes: scientific and practical applications. Sackmann E. **Science** 1996 Jan 5;271(5245):43–8 (40 ref.)
Molecular orientation and two-component nature of the crystalline fraction of spider dragline silk [see comments] Simmons AH, et al. **Science** 1996 Jan 5;271(5245):84–7. Comment in: Science 1996 Jan 5;271(5245):39–40.
Design of a monomeric 23-residue polypeptide with defined tertiary structure. Struthers MD, et al. **Science** 1996 Jan 19;271(5247):342–5
Beta sheets and spider silk [letter] Thiel BL, et al. **Science** 1996 Sep 13;273(5281):1480–1
Putting a new spin on spider silk [comment] Tirrell DA. **Science** 1996 Jan 5;271(5245):39–40. Comment on: Science 1996 Jan 5;271(5246):84–7.
Unique protein database imperiled [news] [see comments] Williams N. **Science** 1996 May 17;272(5264):946. Comment in: Science 1996 Jul 12;273(5272):165.
Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. Kajava AV, et al. **Structure** 1995 Sep 15;3(9):867–77
Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)
The science of macromolecular crystallization. McPherson A, et al. **Structure** 1995 Aug 15;3(8):759–68 (90 ref.)
14–3–3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)
A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649–52 (18 ref.)
Weighing the evidence for structure: electrospray ionization mass spectrometry of proteins. Robinson CV, et al. **Structure** 1995 Sep 15;3(9):861–5 (19 ref.)
Direct measurement of reactivity in the protein crystal by steady-state kinetic studies. Stoddard BL, et al. **Structure** 1995 Oct 15;3(10):991–6
High-resolution macromolecular structure determination using CCD detectors and synchrotron radiation. Walter RL, et al. **Structure** 1995 Aug 15;3(8):835–44
Evidence for the presence of two amino-terminal isoforms of neurofibromin, a gene product responsible for neurofibromatosis type 1. Suzuki H, et al. **Tohoku J Exp Med** 1995 Apr;175(4):225–33
The death domain: a module shared by proteins with diverse cellular functions [letter] Feinstein E, et al. **Trends Biochem Sci** 1995 Sep;20(9):342–4
Circular permutations of protein sequence: not so rare? [letter; comment] Heinemann U, et al. **Trends Biochem Sci** 1995 Sep;20(9):349–50. Comment on: Trends Biochem Sci 1995 May;20(5):179–80.
Dali: a network tool for protein structure comparison. Holm L, et al. **Trends Biochem Sci** 1995 Nov;20(11):478–80
DNA repair in three dimensions. Pearl LH, et al. **Trends Biochem Sci** 1995 Oct;20(10):421–6 (32 ref.)
How the molten globule became. Ptitsyn OB. **Trends Biochem Sci** 1995 Sep;20(9):376–9 (43 ref.)
Porphyrin pi–cation and protein radicals in peroxidase catalysis and inhibition by anti-thyroid chemicals. Doerge DR, et al. **Xenobiotica** 1995 Jul;25(7):761–7
Reaction of 3-deoxypentosulose with N-methyl- and N,N-dimethylguanidine as model reagents for protein-bound arginine and for creatine. Sopio R, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):381–6
[Calculation of specific evolution rate of proteins based on phylogenetic] Lu B, et al. **I Chuan Hsueh Pao** 1996; 23(2):85–90 (Eng. Abstr.) **(Chi)**
[Advanced mass spectrometry in biochemical sciences] Ohashi Y. **Seikagaku** 1995 Nov;67(11):1295–301 (14 ref.) **(Jpn)**
[14–3–3 protein family: the structure and function in cell signaling pathway] Shinkai F, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):313–26 (53 ref.) **(Jpn)**
[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar–Apr;40(2):260–73 (50 ref.) (Eng. Abstr.) **(Rus)**
[An objective method for isolating globular protein domains] Berezovskii IN, et al. **Biofizika** 1995 Nov–Dec;40(6):1171–7 (Eng. Abstr.) **(Rus)**
[The role of disulfide bridges of the residual protein in chromosomal DNA organization] Struchkov VA, et al. **Biofizika** 1995 Mar–Apr;40(2):296–316 (96 ref.) (Eng. Abstr.) **(Rus)**
[Fluorometric determination of amide protein groups] Shepotinovskaia IV, et al. **Klin Lab Diagn** 1995 May–Jun; (3):18–20 (Eng. Abstr.) **(Rus)**
[Comparison of three-dimensional structures of flexible protein molecules] Andreeva NS, et al. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1102–13 (31 ref.) **(Rus)**
[A bank of protein family images Prof-Image for rapid sequences] Bachinskii AG, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):907–17 (Eng. Abstr.) **(Rus)**
[Semi-empiric method of modeling the protein spatial structure using tritium planigraphy] Bogacheva EN, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):637–46 **(Rus)**
[Dolichol-coupled biosynthesis of an oligosaccharide precursor for N-glycosylated proteins in the rough endoplasmic reticulum] Shpakov AO. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):3–17 (87 ref.) (Eng. Abstr.) **(Rus)**
[Effect of medium polarity and protein microenvironment on indo–1 fluorescence] Zyma VL, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):100–3 (Eng. Abstr.) **(Ukr)**

CLASSIFICATION

Prediction of protein structural classes. Chou KC, et al. **Crit Rev Biochem Mol Biol** 1995;30(4):275–349 (104 ref.)
A structural tree for alpha-helical proteins containing alpha–alpha–corners and its application to protein classification. Efimov AV. **FEBS Lett** 1996 Aug 5; 391(1–2):167–70
A new clustering system for protein sequences and its application to constraints discovery in protein evolution. Nakagawa H, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):440–51
Using Dirichlet mixture priors to derive hidden Markov models for protein families. Brown M, et al. **Ismb** 1993; 1:47–55
Protein classification using neural networks. Ferrán EA, et al. **Ismb** 1993;1:127–35
Evolution of a computer program for classifying protein segments as transmembrane domains using genetic programming. Koza JR. **Ismb** 1994;2:244–52
Computationally efficient cluster representation in molecular sequence megaclassification. States DJ, et al. **Ismb** 1993; 1:387–94
Neural networks for molecular sequence classification. Wu C, et al. **Ismb** 1993;1:429–37
Automatic classification and analysis of alpha alpha–turn motifs in proteins. Wintjens RT, et al. **J Mol Biol** 1996 Jan 12;255(1):235–53
Extending molecular systematics to the third dimension. Wodak SJ. **Nat Struct Biol** 1996 Jul;3(7):575–8
Classification of LIM proteins [letter] Taira M, et al. **Trends Genet** 1995 Nov;11(11):431–2

DEFICIENCY see PROTEIN DEFICIENCY

DIAGNOSTIC USE

Technetium–99m–white blood cell–specific imaging agent developed from platelet factor 4 to detect infection. Moyer BR, et al. **J Nucl Med** 1996 Apr;37(4):673–9

DRUG EFFECTS

Effect of the spin–trapping compound N–tert–butyl–alpha–phenylnitrone on protein oxidation and life span. Dubey A, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):249–54
A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'–hydroxyacetanilide. Myers TG, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):403–13
Effect of retinoic acid on p21ras and regulators of its activity in neuroblastoma. Burchill SA, et al. **Eur J Cancer** 1995; 31A(4):476–81
Inhibition of protein synthesis in a cell–free system and Vero cells by okadaic acid, a diarrhetic shellfish toxin. Matias WG, et al. **J Toxicol Environ Health** 1996 Jun 28; 48(3):309–17
Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. May RC, et al. **Kidney Int** 1996 Mar;49(3):679–83
Prolonged lead exposure modifies astrocyte cytoskeletal proteins in the rat brain. Selvín–Testa A, et al. **Neurotoxicology** 1995 Fall;16(3):389–401
Insulin–induced dissociation of Sos from Grb2 does not contribute to the down regulation of Ras activation. Corbalan–Garcia S, et al. **Oncogene** 1996 Mar 7; 12(5):1063–8
Oncogenic transformation of HPV–immortalized human oral keratinocytes is associated with the genetic instability of cells. Shin KH, et al. **Oncogene** 1996 Mar 7;12(5):1089–96
A new case of hereditary histidine–rich glycoprotein deficiency with familial thrombophilia [letter] Souto JC, et al. **Thromb Haemost** 1996 Feb;75(2):374–5

GENETICS

Rearrangement of RAG–1 recombinase gene in DNA–repair deficient/immunodeficient "wasted" mice. Woloschak GE, et al. **Adv Exp Med Biol** 1995;371B:725–8
Acute ethanol and selected growth suppressor transcripts in regenerating rat liver. Lumpkin CK Jr, et al. **Alcohol** 1995 Jul–Aug;12(4):357–62
Mutation in and lack of expression of tyrosinase–related protein–1 (TRP–1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as "OCA3". Boissy RE, et al. **Am J Hum Genet** 1996 Jun;58(6):1145–56
Quantitative variation in obesity–related traits and insulin precursors linked to the OB gene region on human chromosome 7. Duggirala R, et al. **Am J Hum Genet** 1996 Sep;59(3):694–703
Homozygosity mapping of the gene for Chediak–Higashi syndrome to chromosome 1q42–q44 in a segment of conserved synteny that includes the mouse beige locus (bg). Fukai K, et al. **Am J Hum Genet** 1996 Sep;59(3):620–4
Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene [letter] Gellera C, et al. **Am J Hum Genet** 1996 Aug;59(2):475–7
Molecular characterization of the breakpoints of a 12–kb deletion in the NF1 gene in a family showing germ–line mosaicism. Lázaro C, et al. **Am J Hum Genet** 1995 Nov; 57(5):1044–9
The oculocerebrorenal syndrome gene product is a 105–kD protein localized to the Golgi complex. Olivos–Glander IM, et al. **Am J Hum Genet** 1995 Oct;57(4):817–23
Screening the 3' region of the polycystic kidney disease 1 (PKD1) gene reveals six novel mutations. Peral B, et al. **Am J Hum Genet** 1996 Jan;58(1):86–96
Human homologue sequences to the Drosophila dishevelled segment–polarity gene are deleted in the DiGeorge syndrome. Pizzuti A, et al. **Am J Hum Genet** 1996 Apr; 58(4):722–9
Defects in the DNA repair and transcription gene ERCC2(XPD) in trichothiodystrophy. Takayama K, et al. **Am J Hum Genet** 1996 Feb;58(2):263–70
Ataxia–telangiectasia: mutations in ATM cDNA detected by protein–truncation screening. Telatar M, et al. **Am J Hum Genet** 1996 Jul;59(1):40–4
Linkage between stature and a region on chromosome 20 and analysis of a candidate gene, bone morphogenetic protein 2. Thompson DB, et al. **Am J Med Genet** 1995 Dec 4;59(4):495–500
Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Wu BL, et al. **Am J Med Genet** 1995 Dec 4;59(4):528–35
Comparison of regional variability in lung–specific gene expression using a novel method for RNA isolation from lung subcompartments of rats and mice. Royce FH, et al. **Am J Pathol** 1996 Jun;148(6):1779–86
Codon–based combinatorial alanine scanning site–directed mutagenesis: design, implementation, and polymerase chain reaction screening. Chatellier J, et al. **Anal Biochem** 1995 Aug 10;229(2):282–90
Protein production in three different expression vectors from a single polymerase chain reaction product. Winder SJ, et al. **Anal Biochem** 1995 Oct 10;231(1):271–3
A BstUI PCR/RFLP in the bovine tyrosinase–related protein–1 (TYRP1) gene. Nonneman D, et al. **Anim Genet** 1996 Jun;27(3):218–9
BMP 7 is required for nephrogenesis, eye development, and skeletal patterning. Karsenty G, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:98–107
Role of parathyroid hormone–related protein in skeletal development. Kronenberg HM, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:119–23
Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. Imam H, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2191–5
Gene expression of iron–related proteins during iron deficiency caused by scurvy in guinea pigs. Gosiewska A, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):295–303
Effect of interferon on protein translation during growth stages of 3T3 cells. Petryshyn R, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):290–7
The glucocorticoid attenuated response genes GARG–16, GARG–39, and GARG–49/IRG2 encode inducible proteins containing multiple tetratricopeptide repeat domains. Smith JB, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):290–300
The effects of ultraviolet A and reactive oxygen species on the mRNA expression of 72–kDa type IV collagenase and its tissue inhibitor in cultured human dermal fibroblasts. Kawaguchi Y, et al. **Arch Dermatol Res** 1996;288(1):39–44
Sorsby fundus dystrophy. A family with the Ser181Cys mutation of the tissue inhibitor of metalloproteinases 3. Carrero–Valenzuela RD, et al. **Arch Ophthalmol** 1996 Jun; 114(6):737–8
Bone morphogenetic protein–2 and –4 expression during murine orofacial development. Bennett JH, et al. **Arch Oral Biol** 1995 Sep;40(9):847–54
Spatial and temporal distribution of sonic hedgehog mRNA in the embryonic mouse mandible by reverse transcription/polymerase chain reaction and in situ hybridization analysis. Kronmiller JE, et al. **Arch Oral Biol** 1995 Sep;40(9):831–8
Evidence that implicates the parathyroid hormone–related peptide in vascular stenosis. Increased gene expression in the intima of injured carotid arteries and human restenotic coronary lesions. Ozeki S, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):565–75
Generation of a rat bronchiolar epithelial cell cDNA library: isolation of a proline rich protein highly enriched in bronchiolar epithelial cells. Bingle CD. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):877–82

Two nuclear proteins bind to the promoter P3 region of the human parathyroid hormone-related peptide gene. Bui TD, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):222-5

Mutation screening and identification of a sequence variation in the human ob gene coding region. Considine RV, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):735-9

Sonic hedgehog is expressed in epithelial cells during development of whisker, hair, and tooth. Iseki S, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):688-93

Cloning of the human homologue of the TGF beta-stimulated clone 22 gene. Jay P, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):821-6

Sequence and expression of the mouse homologue to human phospholipase C beta3 neighboring gene. Lagercrantz J, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):335-40

The gene of the protease inhibitor SKALP/elafin is a member of the REST gene family. Lundwall A, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):323-7

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Maeda K, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):286-9

Cloning and expression of human homolog HSMT3 to yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene. Mannen H, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):178-80

TIMP-3 is expressed in the human retinal pigment epithelium. Ruiz A, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):467-74

Molecular cloning and characterization of human bone morphogenic protein (BMP)-5 gene promoter. Sakaue M, et al. **Biochem Biophys Res Commun** 1996 Apr 25; 221(3):768-72

Molecular cloning and characterization of a novel stromal cell-derived cDNA encoding a protein that facilitates gene activation of recombination activating gene (RAG)-1 in human lymphoid progenitors. Tagoh H, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):744-9

Cloning of a novel signal-transducing adaptor molecule containing an SH3 domain and ITAM. Takeshita T, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1035-9

Genomic organization of the human bone morphogenetic protein-4 gene: molecular basis for multiple transcripts. van den Wijngaard A, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):789-94

Down-regulation of HCW9 mRNA in rat hepatocytes during chemical hypoxia involves both transcriptional and posttranscriptional mechanisms. Wang H, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):360-4

The effect of exercise on ob gene expression. Zheng D, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):747-50

Differential expression of ob mRNA in rat adipose tissues in response to insulin. Zheng D, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):434-7

Allozymic characterization and evolutionary relationships in the Brazilian Akodon cursor species group (Rodentia-Cricetidae). Rieger TT, et al. **Biochem Genet** 1995 Oct;33(9-10):283-95

Identification of a functional promoter element in the 5'-flanking region of the rat cMG1/TIS11b gene. Corps AN, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):251-8

Analysis of transcripts encoding novel members of the mammalian metalloprotease-like, disintegrin-like, cysteine-rich (MDC) protein family and their expression in reproductive and non-reproductive monkey tissues. Perry AC, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):239-44

The lung enriched transcription factor TTF-1 and the ubiquitously expressed proteins Sp1 and Sp3 interact with elements located in the minimal promoter of the rat Clara cell secretory protein gene. Toonen RF, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):467-73

Identification of two cDNA clones encoding small proline-rich proteins expressed in sheep ruminal epithelium. Wang L, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):225-33

Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Wick M, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):549-54

Wortmannin influences insulin regulation of gene 33 expression in rat hepatoma cells. Yang SH, et al. **Biochem Soc Trans** 1995 Nov;23(4):545S

Domain structure and conformation of histidine-proline-rich glycoprotein. Borza DB, et al. **Biochemistry** 1996 Feb 13; 35(6):1925-34

Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Endo S, et al. **Biochemistry** 1996 Apr 23; 35(16):5220-8

Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Newton DL, et al. **Biochemistry** 1996 Jan 16;35(2):545-53

Cloning and characterization of cDNAs encoding the epsilon-subunit of eukaryotic initiation factor-2B from rabbit and human. Asuru AI, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):309-17

Cloning a cDNA from human NK/T cells which codes for a protein with high proline content. Chen J, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):19-22

Isolation and sequence of the Drosophila virilis 60 A gene, a transforming growth factor-beta superfamily member related to vertebrate bone morphogenetic proteins. Du W, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):273-9

Cloning and characterization of complementary and genomic DNAs encoding the epsilon-subunit of rat translation initiation factor-2B. Flowers KM, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):318-24

Structure and sequence of the gene encoding the alpha-subunit of rat translation initiation factor-2B. Flowers KM, et al. **Biochim Biophys Acta** 1995 Nov 7; 1264(2):163-7

Isolation of cDNA clone encoding human homologue of senescence marker protein-30 (SMP30) and its location on the X chromosome. Fujita T, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):249-52

Cloning and characterization of cDNAs for novel proteins with glutamic acid-proline dipeptide tandem repeats. Geertman R, et al. **Biochim Biophys Acta** 1996 May 2; 1306(2-3):147-52

Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201-10 (60 ref.)

Promoter analysis of the bovine gene for seminalplasmin. Herbers J, et al. **Biochim Biophys Acta** 1995 Sep 19; 1263(3):271-4

Cloning and sequencing of human complementary DNA for the phosphoribosylpyrophosphate synthetase-associated protein 39. Ishizuka T, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):27-30

Promoter region of the rat phosphoribosylpyrophosphate synthetase-associated protein 39. Ishizuka T, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):34-7

Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17. Lea IA, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):263-6

Structure of a D-protein gene and amino-acid sequences of the highly repetitive D-proteins secreted by the accessory glands of the mealworm beetle. Paesen GC, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):171-6

Cloning and characterization of two transcripts generated from the mel-18 gene positioned adjacent to the mammalian Polycomb group-related gene mel-18. Tetsu O, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):109-12

Interspecific variations in adhesive protein sequences of Mytilus edulis, M. galloprovincialis, and M. trossulus. Inoue K, et al. **Biol Bull** 1995 Dec;189(3):370-5

Expression sites of two byssal protein genes of Mytilus galloprovincialis. Miki D, et al. **Biol Bull** 1996 Apr; 190(2):213-7

The gene for the major protein (SVSP109) of bovine semen: structure and promoter analysis. Bräuer C, et al. **Biol Chem Hoppe Seyler** 1995 Oct;376(10):631-6

Molecular cloning and characterization of the bovine and porcine outer dense fibers cDNA and organization of the bovine gene. Kim Y, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):431-5

Selenoprotein gene expression during selenium-repletion of selenium-deficient rats. Bermano G, et al. **Biol Trace Elem Res** 1996 Mar;51(3):211-23

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):85-95 (37 ref.)

A genetic algorithm that seeks native states of peptides and proteins. Sun S. **Biophys J** 1995 Aug;69(2):340-55

Ancient splice junction shadows with relation to blocks in protein structure. Strelets VB, et al. **Biosystems** 1995; 36(1):37-41

PCR screening of transgenic RAG-2 "knockout" immunodeficient mice. Horton RM, et al. **Biotechniques** 1995 Nov;19(5):690-1

CD-tagging: a new approach to gene and protein discovery and analysis. Jarvik JW, et al. **Biotechniques** 1996 May; 20(5):896-904

High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. Wengler GS, et al. **Blood** 1995 Nov 15; 86(10):3648-54

Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Whitney MA, et al. **Blood** 1996 Jul 1;88(1):49-58

Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. Yamashita T, et al. **Blood** 1996 May 15;87(10):4424-32

The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Zhu Q, et al. **Blood** 1995 Nov 15;86(10):3797-804

Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Southgate J, et al. **Br J Cancer** 1995 Nov; 72(5):1214-8

Positive diepoxybutane test in only one of two brothers found to be compound heterozygotes for Fanconi's anaemia complementation group C mutations. Dokal I, et al. **Br J Haematol** 1996 Jun 2;93(4):813-6

Induction of VGF mRNA in neurons of the rat nucleus tractus solitarius and the dorsal motor nucleus of vagus in duodenal ulceration by cysteamine. Kanemasa K, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):55-62

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cao J, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):759-63

SIL/TAL1 recombination in adult T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma [letter] Kwong YL, et al. **Cancer Genet Cytogenet** 1995 Dec;85(2):159-60

Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Chen ZP, et al. **Cancer Res** 1996 Jun 1; 56(11):2475-8

Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Imren S, et al. **Cancer Res** 1996 Jul 1;56(13):2891-5

DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Kim SK, et al. **Cancer Res** 1996 Jun 1;56(11):2519-21

The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Negrini M, et al. **Cancer Res** 1996 Jul 15;56(14):3173-9

Genomic organization of the ATM locus involved in ataxia-telangiectasia. Rasio D, et al. **Cancer Res** 1995 Dec 15;55(24):6053-7

DPC4 gene in various tumor types. Schutte M, et al. **Cancer Res** 1996 Jun 1;56(11):2527-30

Aberrant FHIT transcripts in Merkel cell carcinoma. Sozzi G, et al. **Cancer Res** 1996 Jun 1;56(11):2472-4

Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D. Takayama K, et al. **Cancer Res** 1995 Dec 1; 55(23):5656-63

Evaluation of the FHIT gene in colorectal cancers. Thiagalingam S, et al. **Cancer Res** 1996 Jul 1;56(13):2936-9

ATM mutations in cancer families. Vořechovský I, et al. **Cancer Res** 1996 Sep 15;56(18):4130-3

Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. Wysolmerski JJ, et al. **Cancer Res** 1996 Mar 1;56(5):1043-9

Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219-32 (32 ref.)

Expression of exogenous protein and analysis of morphogenesis in the developing chicken heart using an adenoviral vector. Fisher SA, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E86-95

Atm-deficient mice: a paradigm of ataxia telangiectasia. Barlow C, et al. **Cell** 1996 Jul 12;86(1):159-71

Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Kleyn PW, et al. **Cell** 1996 Apr 19;85(2):281-90

Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps. McBlane JF, et al. **Cell** 1995 Nov 3;83(3):387-95

The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Ohta M, et al. **Cell** 1996 Feb 23;84(4):587-97

Lateral and axial signals involved in avian somite patterning: a role for BMP4. Pourquié O, et al. **Cell** 1996 Feb 9; 84(3):461-71

The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157-60 (23 ref.). Comment on: Cell 1995 Oct 20;83(2):247-56.

Identification and expression cloning of a leptin receptor, OB-R. Tartaglia LA, et al. **Cell** 1995 Dec 29;83(7):1263-71

The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination. van Gent DC, et al. **Cell** 1996 Apr 5;85(1):107-13

Mutually exclusive expression of two dominant-negative helix-loop-helix (dnHLH) genes, Id4 and Id3, in the developing brain of the mouse suggests distinct regulatory roles of these dnHLH proteins during cellular proliferation and differentiation of the nervous system. Riechmann V, et al. **Cell Growth Differ** 1995 Jul;6(7):837-43

CD34 stem/progenitor cells purified from cryopreserved normal cord blood can be transduced with high efficiency by a retroviral vector and expanded ex vivo with stable integration and expression of Fanconi anemia complementation C gene. Lu L, et al. **Cell Transplant** 1995 Sep-Oct;4(5):493-503

Spatiotemporal relationships between a novel Drosophila stripe expressing gene and known segmentation genes by simultaneous visualization of transcript patterns. Hartmann C, et al. **Chromosoma** 1995 Nov;104(2):84-91

Transcriptional control and the regulation of endocrine genes. Zajac JD, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):935-43 (68 ref.)

Genetic analysis of 20 families with autosomal dominant adult polycystic kidney disease from South West Thames Region. Jeffery S, et al. **Clin Genet** 1995 Jun;47(6):290-4

RNA genetics of breast cancer: maspin as paradigm. Sager R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:537-46

Bovine chondrocyte link protein cDNA sequence: interspecies conservation of primary structure and mRNA untranslated regions. Hering TM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):197-203

Cloning of a urochordate cDNA featuring mammalian short consensus repeats (SCR) of complement-control protein superfamily. Pancer Z, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Aug;

111(4):625–32

Automat and BLAST: comparison of two protein sequence similarity search programs. Cantalloube H, et al. **Comput Appl Biosci** 1995 Jun;11(3):261–72

A rapid access motif database (RAMdb) with a search algorithm for the retrieval patterns in nucleic acids or protein databanks. Fondrat C, et al. **Comput Appl Biosci** 1995 Jun;11(3):273–9

Alignments of DNA and protein sequences containing frameshift errors. Guan X, et al. **Comput Appl Biosci** 1996 Feb;12(1):31–40

DNASTAT: a Pascal unit for the statistical analysis of DNA and protein sequences. Kleffe J, et al. **Comput Appl Biosci** 1995 Aug;11(4):449–55

PdbAlign, PdbDist and DistAlign: tools to aid in relating sequence variability to structure. Sayle R, et al. **Comput Appl Biosci** 1995 Oct;11(5):571–3

Methods for evaluating exon–protein correspondences. Stoltzfus A, et al. **Comput Appl Biosci** 1995 Oct; 11(5):509–15

Compression of protein sequence databases. Strelets VB, et al. **Comput Appl Biosci** 1995 Oct;11(5):557–61

The spatial localization of Dlx-2 during tooth development. Thomas BL, et al. **Connect Tissue Res** 1995;32(1–4):27–34

Weak evidence for allelic association in the cypriot PKD1 population. Constantinou–Deltas CD, et al. **Contrib Nephrol** 1995;115:93–6

Clinical applications of genetic linkage analysis for the molecular diagnostics of ADPKD, using DNA markers linked to the PKD1 and PKD2 genes. Turco AE, et al. **Contrib Nephrol** 1995;115:88–92

Cancer predisposition. Ataxia–telangiectasia at the crossroads. Jackson SP. **Curr Biol** 1995 Nov 1;5(11):1210–2 (13 ref.)

The orientation of gene maps by recombination of flanking markers for the am locus of Neurospora crassa. Bowring FJ, et al. **Curr Genet** 1995 Dec;29(1):27–33

Mx transgenic mice—animal models of health. Arnheiter H, et al. **Curr Top Microbiol Immunol** 1996;206:119–47 (88 ref.)

The human homologue of the murine Llglh gene (LLGL) maps within the Smith–Magenis syndrome region in 17p11.2. Koyama K, et al. **Cytogenet Cell Genet** 1996; 72(1):78–82

Determination of neuroepithelial cell fate: induction of the oligodendrocyte lineage by ventral midline cells and sonic hedgehog. Pringle NP, et al. **Dev Biol** 1996 Jul 10; 177(1):30–42

Protein characterization and targeted disruption of Grg, a mouse gene related to the groucho transcript of the Drosophila Enhancer of split complex. Mallo M, et al. **Dev Dyn** 1995 Nov;204(3):338–47

Characterization of a gene trap insertion into a novel gene, cordon–bleu, expressed in axial structures of the gastrulating mouse embryo. Gasca S, et al. **Dev Genet** 1995; 17(2):141–54

Ventral mesodermal patterning in Xenopus embryos: expression patterns and activities of BMP–2 and BMP–4. Hemmati–Brivanlou A, et al. **Dev Genet** 1995;17(1):78–89

Protein families in the metazoan genome. Chothia C. **Dev Suppl** 1994;:27–33 (41 ref.)

The hedgehog gene family in Drosophila and vertebrate development. Fietz MJ, et al. **Dev Suppl** 1994;:43–51

Establishment of Drosophila imaginal precursor cells is controlled by the Arrowhead gene. Curtiss J, et al. **Development** 1995 Nov;121(11):3819–28

groucho and hedgehog regulate engrailed expression in the anterior compartment of the Drosophila wing. de Celis JF, et al. **Development** 1995 Oct;121(10):3467–76

The pelota locus encodes a protein required for meiotic cell division: an analysis of G2/M arrest in Drosophila spermatogenesis. Eberhart CG, et al. **Development** 1995 Oct;121(10):3477–86

Variation in the number of activated torso receptors correlates with differential gene expression. Furriols M, et al. **Development** 1996 Jul;122(7):2313–7

Nodal-related signals induce axial mesoderm and dorsalize mesoderm during gastrulation. Jones CM, et al. **Development** 1995 Nov;121(11):3651–62

Dishevelled is a component of the frizzled signaling pathway in Drosophila. Krasnow RE, et al. **Development** 1995 Dec; 121(12):4095–102

A role for the Drosophila bag–of–marbles protein in the differentiation of cystoblasts from germline stem cells. McKearin D, et al. **Development** 1995 Sep;121(9):2937–47

The porcupine gene is required for wingless autoregulation in Drosophila. Manoukian AS, et al. **Development** 1995 Dec;121(12):4037–44

Translational control of oskar generates short OSK, the isoform that induces pole plasma assembly. Markussen FH, et al. **Development** 1995 Nov;121(11):3723–32

Expression and transgenic studies of the mouse agouti gene provide insight into the mechanisms by which mammalian coat color patterns are generated. Millar SE, et al. **Development** 1995 Oct;121(10):3223–32

Sonic hedgehog is an endodermal signal inducing Bmp–4 and Hox genes during induction and regionalization of the chick hindgut. Roberts DJ, et al. **Development** 1995 Oct; 121(10):3163–74

Localization of oskar RNA regulates oskar translation and requires Oskar protein. Rongo C, et al. **Development** 1995 Sep;121(9):2737–46

hedgehog, wingless and orthodenticle specify adult head development in Drosophila. Royet J, et al. **Development** 1996 Jun;122(6):1849–58

Dorsalizing and neuralizing properties of Xdsh, a maternally expressed Xenopus homolog of dishevelled. Sokol SY, et al. **Development** 1995 Oct;121(10):3487

headcase, an imaginal specific gene required for adult morphogenesis in Drosophila melanogaster. Weaver TA, et al. **Development** 1995 Dec;121(12):4149–60

Overexpression of parathyroid hormone–related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Wysolmerski JJ, et al. **Development** 1995 Nov; 121(11):3539–47

Modular cis–regulatory organization of Endo16, a gut–specific gene of the sea urchin embryo. Yuh CH, et al. **Development** 1996 Apr;122(4):1069–82

Indication for linkage of the human OB gene region with extreme obesity. Clement K, et al. **Diabetes** 1996 May; 45(5):687–90

Absence of mutations in the human OB gene in obese/diabetic subjects. Maffei M, et al. **Diabetes** 1996 May; 45(5):679–82

Human obese gene: molecular screening in Japanese and Asian Indian NIDDM patients associated with obesity. Niki T, et al. **Diabetes** 1996 May;45(5):675–8

Extreme obesity may be linked to markers flanking the human OB gene. Reed DR, et al. **Diabetes** 1996 May;45(5):691–4

Cloning, expression, and chromosomal localization of the rat mitochondrial capsule selenoprotein gene (MCS): the reading frame does not contain potential UGA selenocysteine codons. Adham IM, et al. **DNA Cell Biol** 1996 Feb;15(2):159–66

Molecular characterization of the Drosophila Mo25 gene, which is conserved among Drosophila, mouse, and yeast. Nozaki M, et al. **DNA Cell Biol** 1996 Jun;15(6):505–9

Expression profiles of a human gene identified as a structural homologue of meiosis–specific recA–like genes. Sato S, et al. **DNA Res** 1995 Aug 31;2(4):183–6

Cloning and sequence of bone morphogenetic protein 4 (BMP–4) from a human placental cDNA library. Oida S, et al. **DNA Seq** 1995;5(5):273–5

Cloning and characterization of Wnt–4 and Wnt–11 cDNAs from chick embryo. Tanda N, et al. **DNA Seq** 1995; 5(5):277–81

Ontogenies of messenger RNA encoding tissue inhibitor of metalloproteinases 1 and 2 within bovine periovulatory follicles and luteal tissue. Smith GW, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):151–60

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. Duckett CS, et al. **EMBO J** 1996 Jun 3;15(11):2685–94

mel–18, a Polycomb group–related mammalian gene, encodes a transcriptional negative regulator with tumor suppressive activity. Kanno M, et al. **EMBO J** 1995 Nov 15; 14(22):5672–8

Probes of chromatin accessibility in the Drosophila bithorax complex respond differently to Polycomb–mediated repression. McCall K, et al. **EMBO J** 1996 Feb 1; 15(3):569–80

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron–sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Reading two bases twice: mammalian antizyme frameshifting in yeast. Matsufuji S, et al. **EMBO J** 1996 Mar 15; 15(6):1360–70

The role of gsc and BMP–4 in dorsal–ventral patterning of the marginal zone in Xenopus: a loss–of–function study using antisense RNA. Steinbeisser H, et al. **EMBO J** 1995 Nov 1;14(21):5230–43

Immortalized murine osteoblasts derived from BMP 2–T–antigen expressing transgenic mice. Ghosh–Choudhury N, et al. **Endocrinology** 1996 Jan; 137(1):331–9

Induction of tissue inhibitor of metalloproteinase 3 gene expression during in vitro decidualization of human endometrial stromal cells. Higuchi T, et al. **Endocrinology** 1995 Nov;136(11):4973–81

Cell–specific and regulator–induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone–related protein. Southby J, et al. **Endocrinology** 1996 Apr;137(4):1349–57

Insulin increases the processing efficiency of messenger ribonucleic acid–S14 nuclear precursor. Walker JD, et al. **Endocrinology** 1996 Jun;137(6):2293–9

Isolation of a novel cDNA that encodes a protein localized to the pre–acrosome region of spermatids. Aoto H, et al. **Eur J Biochem** 1995 Nov 15;234(1):8–15

Identification of a functional cAMP response element in the secretogranin II gene. Cibelli G, et al. **Eur J Biochem** 1996 Feb 15;236(1):171–9

Cloning, sequencing and sites of expression of genes for the hydroxyarginine–containing adhesive–plaque protein of the mussel Mytilus galloprovincialis. Inoue K, et al. **Eur J Biochem** 1996 Jul 1;239(1):172–6

Two additional 5'exons in the human Vigilin gene distinguish it from the chicken gene and provide the structural basis for differential routes of gene expression. Kügler S, et al. **Eur J Biochem** 1996 Jun 1;238(2):410–7

The cloning of a rapidly evolving seminal–vesicle–transcribed gene encoding the major clot–forming protein of mouse semen. Lundwall A. **Eur J Biochem** 1996 Jan 15;235(1–2):424–30

Cloning and sequencing of a cDNA encoding a larval–pupal–specific cuticular protein in Tenebrio molitor (Insecta, Coleoptera). Developmental expression and effect of a juvenile hormone analogue. Rondot I, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):138–43

Patterns of DNA methylation of the parathyroid hormone–related protein gene in human lung carcinoma. Ganderton RH, et al. **Eur J Cancer** 1995 Sep; 31A(10):1697–700

Leptin secretion and action: an update. Meier CA. **Eur J Endocrinol** 1996 May;134(5):543–5

Cosmid contigs spanning 9q34 including the candidate region for TSC1. Nahmias J, et al. **Eur J Hum Genet** 1995; 3(2):65–77

Cosmid contigs from the tuberous sclerosis candidate region on chromosome 9q34. van Slegtenhorst M, et al. **Eur J Hum Genet** 1995;3(2):78–86

The 3' untranslated region of prohibitin and cellular immortalization. Jupe ER, et al. **Exp Cell Res** 1996 Apr 10;224(1):128–35

An amino acid change in novel protein D123 is responsible for temperature–sensitive G1–phase arrest in a mutant of rat fibroblast line 3Y1. Okuda A, et al. **Exp Cell Res** 1996 Mar 15;223(2):242–9

Identification and characterization of a unique chondrocyte gene involved in transition to hypertrophy. Reynolds SD, et al. **Exp Cell Res** 1996 Jul 10;226(1):197–207

The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503–10 (69 ref.)

Deleted in oral cancer–1 (doc–1), a novel oral tumor suppressor gene. Todd R, et al. **FASEB J** 1995 Oct; 9(13):1362–70

Chromosomal localization and expression pattern of the RNase L inhibitor gene. Aubry F, et al. **FEBS Lett** 1996 Feb 26;381(1–2):135–9

Diet– and diabetes–induced changes of ob gene expression in rat adipose tissue. Becker DJ, et al. **FEBS Lett** 1995 Sep 11;371(3):324–8

Molecular cloning of the cDNA encoding a novel protein disulfide isomerase–related protein (PDIR). Hayano T, et al. **FEBS Lett** 1995 Sep 25;372(2–3):210–4

Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes. Kieser A, et al. **FEBS Lett** 1995 Sep 25;372(2–3):189–93

Identification of a novel protein containing two C2 domains selectively expressed in the rat brain and kidney. Kwon OJ, et al. **FEBS Lett** 1996 Jan 8;378(2):135–9

Human testis specifically expresses a homologue of the rodent T lymphocytes RT6 mRNA. Lévy I, et al. **FEBS Lett** 1996 Mar 18;382(3):276–80

A novel gene family encoding proteins with highly differing structure because of a rapidly evolving exon. Lundwall A, et al. **FEBS Lett** 1995 Oct 23;374(1):53–6

Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide. Mahoney MM, et al. **FEBS Lett** 1995 Dec 27;377(3):519–22

Deletion of the ABL SH3 domain reactivates de–oligomerized BCR–ABL for growth factor independence. Maru Y, et al. **FEBS Lett** 1996 Feb 5; 379(3):244–6

Augmented expression of obese (ob) gene during the process of obesity in genetically obese–hyperglycemic Wistar fatty (fa/fa) rats. Masuzaki H, et al. **FEBS Lett** 1996 Jan 15; 378(3):267–71

High–level expression of fully active human glutaredoxin (thioltransferase) in E. coli and characterization of Cys7 to Ser mutant protein. Padilla CA, et al. **FEBS Lett** 1996 Jan 2;378(1):69–73

Regulation of ob gene mRNA levels in cultured adipocytes. Rentsch J, et al. **FEBS Lett** 1996 Jan 22;379(1):55–9

Molecular cloning of the defense factor in the albumen gland of the sea hare Aplysia kurodai. Takamatsu N, et al. **FEBS Lett** 1995 Dec 27;377(3):373–6

Cloning of rat GADD45 gene and induction analysis following ionizing radiation in vivo. Yoshida T, et al. **FEBS Lett** 1996 Feb 12;380(1–2):87–92

Structures of genes for two cathelin–associated antimicrobial peptides: prophenin–2 and PR–39. Zhao C, et al. **FEBS Lett** 1995 Dec 4;376(3):130–4

Cloning of the fliI gene from Rhodobacter sphaeroides WS8 by analysis of a transposon mutant with impaired motility. Goodfellow IG, et al. **FEMS Microbiol Lett** 1996 Aug 15; 142(1):111–6

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)

Flagellar genes from Rhodobacter sphaeroides are homologous to genes of the fliF operon of Salmonella typhimurium and to the type–III secretion system. Ballado T, et al. **Gene** 1996 Apr 17;170(1):69–72

Cloning and expression of the murine Elf–1 cDNA. Davis JN, et al. **Gene** 1996 Jun 1;171(2):265–9

The Drosophila melanogaster gene vha14 encoding a 14–kDa F–subunit of the vacuolar ATPase. Guo Y, et al. **Gene** 1996 Jun 26;172(2):239–43

Cloning and partial structure of the gene encoding human tissue inhibitor of metalloproteinases–3. Hammani K, et al. **Gene** 1996 May 8;170(2):287–8

Schizosaccharomyces pombe rad23 is allelic with swi10, a

mating-type switching/radioresistance gene that shares sequence homology with human and mouse ERCC1. Hang H, et al. **Gene** 1996 Apr 17;170(1):113–7

Identification of a Hydra homologue of the beta-catenin/plakoglobin/armadillo gene family. Hobmayer E, et al. **Gene** 1996 Jun 12;172(1):155–9

Alternative splicing of the Drosophila melanogaster rotundRacGAP gene. Hoemann CD, et al. **Gene** 1996 Feb 12;168(2):135–41

Isolation and characterization of a cDNA from Trichoderma harzianum P1 encoding a 14–3–3 protein homolog. Klemsdal SS, et al. **Gene** 1996 May 24;171(1):123–7

The yeast EGD2 gene encodes a homologue of the alpha NAC subunit of the human nascent-polypeptide-associated complex. Shi X, et al. **Gene** 1995 Nov 20;165(2):199–202

Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Shibahara K, et al. **Gene** 1995 Dec 12;166(2):297–301

Differential expression of CAP and CAP2 in adult rat tissues. Swiston J, et al. **Gene** 1995 Nov 20;165(2):273–7

Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Wu I, et al. **Gene** 1996 Feb 12;168(2):243–6

Cloning of the rat Gadd45 cDNA and its mRNA expression in the brain [Gene 151 (1994) 253–255] Yoshida T, et al. **Gene** 1995 Dec 12;166(2):343–4

Semliki Forest virus as a tool for protein expression in cultured rat hippocampal neurons. de Hoop MJ, et al. **Gene Ther** 1994;1 Suppl 1:S28–31

Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins. Alexandre C, et al. **Genes Dev** 1996 Aug 15;10(16):2003–13

Similarities between trunk and spätzle, putative extracellular ligands specifying body pattern in Drosophila. Casanova J, et al. **Genes Dev** 1995 Oct 15;9(20):2539–44

Cappuccino, a Drosophila maternal effect gene required for polarity of the egg and embryo, is related to the vertebrate limb deformity locus. Emmons S, et al. **Genes Dev** 1995 Oct 15;9(20):2482–94

Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. Goodrich LV, et al. **Genes Dev** 1996 Feb 1; 10(3):301–12

Analysis of the vestigial tail mutation demonstrates that Wnt-3a gene dosage regulates mouse axial development. Greco TL, et al. **Genes Dev** 1996 Feb 1;10(3):313–24

Disruption of BMP signals in embryonic Xenopus ectoderm leads to direct neural induction. Hawley SH, et al. **Genes Dev** 1995 Dec 1;9(23):2923–35

Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Mishina Y, et al. **Genes Dev** 1995 Dec 15; 9(24):3027–37

Differential splicing-in of a proline-rich exon converts alphaNAC into a muscle-specific transcription factor. Yotov WV, et al. **Genes Dev** 1996 Jul 15;10(14):1763–72

Molecular and mutational analysis of a gelsolin-family member encoded by the flightless I gene of Drosophila melanogaster. de Couet HG, et al. **Genetics** 1995 Nov; 141(3):1049–59

The tolkin gene is a tolloid/BMP-1 homologue that is essential for Drosophila development. Finelli AL, et al. **Genetics** 1995 Sep;141(1):271–81

Detecting heterogeneity of substitution along DNA and protein sequences. Gross PJ, et al. **Genetics** 1996 May; 143(1):589–602

Molecular analysis of scabrous mutant alleles from Drosophila melanogaster indicates a secreted protein with two functional domains. Hu X, et al. **Genetics** 1995 Oct; 141(2):607–17

The Drosophila meiotic recombination gene mei-9 encodes a homologue of the yeast excision repair protein Rad1. Sekelsky JJ, et al. **Genetics** 1995 Oct;141(2):619–27

Interallelic complementation at the suppressor of forked locus of Drosophila reveals complementation between suppressor of forked proteins mutated in different regions. Simonelig M, et al. **Genetics** 1996 Apr;142(4):1225–35

Elimination of introns at the Drosophila suppressor-of-forked locus by P-element-mediated gene conversion shows that an RNA lacking a stop codon is dispensable. Williams CJ, et al. **Genetics** 1996 May; 143(1):345–51

The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Green ED, et al. **Genome Res** 1995 Aug; 5(1):5–12

A gene for autosomal dominant progressive cone dystrophy (CORD5) maps to chromosome 17p12–p13. Balciuniene J, et al. **Genomics** 1995 Nov 20;30(2):281–6

The mouse angiogenin gene family: structures of an angiogenin-related protein gene and two pseudogenes. Brown WE, et al. **Genomics** 1995 Sep 1;29(1):200–6

Evaluation of gene structure prediction programs. Burset M, et al. **Genomics** 1996 Jun 15;34(3):353–67

Localization of a human homolog of the mouse Tiam-1 gene to chromosome 21q22.1. Chen H, et al. **Genomics** 1995 Nov 1;30(1):123–7

The mouse homolog of the Wiskott-Aldrich syndrome protein (WASP) gene is highly conserved and maps near the scurfy (sf) mutation on the X chromosome. Derry JM, et al. **Genomics** 1995 Sep 20;29(2):471–7

Characterization and chromosomal localization of ELANH2, the gene encoding human monocyte/neutrophil elastase inhibitor. Evans E, et al. **Genomics** 1995 Jul 20;28(2):235–40

Assignment of DAP1 and DAPK—genes that positively mediate programmed cell death triggered by IFN-gamma—to chromosome regions 5p12.2 and 9q34.1, respectively. Feinstein E, et al. **Genomics** 1995 Sep 1; 29(1):305–7

Localization of the gene encoding the putative human HLA class II associated protein (PHAPI) to chromosome 15q22.3–q23 by fluorescence in situ hybridization. Fink TM, et al. **Genomics** 1995 Sep 1;29(1):309–10

Surf5: a gene in the tightly clustered mouse surfeit locus is highly conserved and transcribed divergently from the rpL7A (Surf3) gene. Garson K, et al. **Genomics** 1995 Nov 20;30(2):163–70

Localization of the human OB gene (OBS) to chromosome 7q32 by fluorescence in situ hybridization. Geffroy S, et al. **Genomics** 1995 Aug 10;28(3):603–4

Cloning and chromosomal localization of a mouse cDNA with homology to the Saccharomyces cerevisiae gene zuotin. Hughes R, et al. **Genomics** 1995 Sep 20;29(2):546–50

Isolation, cDNA, and genomic structure of a conserved gene (NOF) at chromosome 11q13 next to FAU and oriented in the opposite transcriptional orientation. Kas K, et al. **Genomics** 1996 Jun 15;34(3):433–6

Cloning and molecular characterization of the Chinese hamster ERCC2 nucleotide excision repair gene. Kirchner JM, et al. **Genomics** 1995 May 20;27(2):387

Isolation and mapping of human homologues of an imprinted mouse gene U2af1-rs1. Kitagawa K, et al. **Genomics** 1995 Nov 20;30(2):257–63

Isolation and characterization of WNT8B, a novel human Wnt gene that maps to 10q24. Lako M, et al. **Genomics** 1996 Jul 15;35(2):386–8

Cloning the cDNA of human PWP2, which encodes a protein with WD repeats and maps to 21q22.3. Lalioti MD, et al. **Genomics** 1996 Jul 15;35(2):321–7

Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Lamerdin JE, et al. **Genomics** 1996 Jun 15;34(3):399–409

A curly-tail modifier locus, mct1, on mouse chromosome 17. Letts VA, et al. **Genomics** 1995 Oct 10;29(3):719–24

A new human gene located in the PKD1 region of chromosome 16 is a functional homologue to ERV1 of yeast. Lisowsky T, et al. **Genomics** 1995 Oct 10;29(3):690–7

Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. Mahata SK, et al. **Genomics** 1996 Apr 1;33(1):135–9

Cloning, expression, and chromosomal location of SHH and IHH: two human homologues of the Drosophila segment polarity gene hedgehog. Marigo V, et al. **Genomics** 1995 Jul 1;28(1):44–51

Chromosomal localization, embryonic expression, and imprinting tests for Bmp7 on distal mouse chromosome 2. Marker PC, et al. **Genomics** 1995 Aug 10;28(3):576–80

Genomic organization of the human PMS2 gene family. Nicolaides NC, et al. **Genomics** 1995 Nov 20;30(2):195–206

Analysis of the 5' region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. Nicolaides NC, et al. **Genomics** 1995 Sep 20;29(2):329–34

Cloning and characterization of the murine GPI anchor synthesis gene Pigf, a homologue of the human PIGF gene. Ohishi K, et al. **Genomics** 1996 Jun 15;34(3):340–6

Structure and chromosomal localization of the GPI-anchor synthesis gene PIGF and its pseudogene psi PIGF. Ohishi K, et al. **Genomics** 1995 Oct 10;29(3):804–7

Identification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene. Pecker I, et al. **Genomics** 1996 Jul 1;35(1):39–45

LIS2, gene and pseudogene, homologous to LIS1 (lissencephaly 1), located on the short and long arms of chromosome 2. Reiner O, et al. **Genomics** 1995 Nov 20; 30(2):251–6

Assignment of the human GAS6 gene to chromosome 13q34 by fluorescence in situ hybridization. Saccone S, et al. **Genomics** 1995 Nov 1;30(1):129–31

Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity. Sarfarazi M, et al. **Genomics** 1995 Nov 20; 30(2):171–7

Structure of the gene coding for the mouse TRiC-P5 subunit of the cytosolic chaperonin TRiC. Sévigny G, et al. **Genomics** 1996 Jan 1;31(1):107–10

Inactive allele-specific methylation and chromatin structure of the imprinted gene U2af1-rs1 on mouse chromosome 11. Shibata H, et al. **Genomics** 1996 Jul 1;35(1):248–52

Chromosomal structure of the human TYRP1 and TYRP2 loci and comparison of the tyrosinase-related protein gene family. Sturm RA, et al. **Genomics** 1995 Sep 1;29(1):24–34

Structural organization and genetic localization of the human bone morphogenetic protein 1/mammalian tolloid gene. Takahara K, et al. **Genomics** 1995 Sep 1;29(1):9–15

Chromosomal mapping of the gene encoding DOCK180, a major Crk-binding protein, to 10q26.13–q26.3 by fluorescence in situ hybridization. Takai S, et al. **Genomics** 1996 Jul 15;35(2):403–4

Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X. Tee MK, et al. **Genomics** 1995 Jul 20;28(2):171–8

Assignment of the human genes encoding 14,3-3 Eta (YWHAH) to 22q12, 14–3–3 zeta (YWHAZ) to 2p25.1–p25.2, and 14–3–3 beta (YWHAB) to 20q13.1 by in situ hybridization. Tommerup N, et al. **Genomics** 1996 Apr 1;33(1):149–50

Fine mapping of the human bone morphogenetic protein-4 gene (BMP4) to chromosome 14q22–q23 by in situ hybridization. van den Wijngaard A, et al. **Genomics** 1995 Jun 10;27(3):559–60

Structure and chromosomal localization of the human gene of the phosphotyrosyl phosphatase activator (PTPA) of protein phosphatase 2A. Van Hoof C, et al. **Genomics** 1995 Jul 20;28(2):261–72

Identification of a novel conserved human gene, TEGT. Walter L, et al. **Genomics** 1995 Jul 20;28(2):301–4

Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone morphogenetic protein-3. Cunningham NS, et al. **Growth Factors** 1995;12(2):99–109

Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients. Carreau M, et al. **Hum Gene Ther** 1995 Oct;6(10):1307–15

Precise chromosomal locations of the genes for dentatorubral-pallidoluysian atrophy (DRPLA), von Willebrand factor (F8vWF) and parathyroid hormone-like hormone (PTHLH) in human chromosome 12p by deletion mapping. Kuwano A, et al. **Hum Genet** 1996 Jan;97(1):95–8

Detection of a novel nonsense mutation and an intragenic polymorphism in the PKD1 gene of a Cypriot family with autosomal dominant polycystic kidney disease. Neophytou P, et al. **Hum Genet** 1996 Oct;98(4):437–42

Wiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product. Schindelhauer D, et al. **Hum Genet** 1996 Jul;98(1):68–76

Assignment of the human ST2 gene to chromosome 2 at q11.2. Tominaga S, et al. **Hum Genet** 1996 May;97(5):561–3

Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis. Ploski R, et al. **Hum Immunol** 1995 Oct;44(2):88–96

Mutations revealed by sequencing the 5' half of the gene for ataxia telangiectasia. Byrd PJ, et al. **Hum Mol Genet** 1996 Jan;5(1):145–9

A murine homologue of the human DAZ gene is autosomal and expressed only in male and female gonads. Cooke HJ, et al. **Hum Mol Genet** 1996 Apr;5(4):513–6

WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Derry JM, et al. **Hum Mol Genet** 1995 Jul;4(7):1127–35

Identification of a novel gene, ETX1 from Xp21.1, a candidate gene for X-linked retintis pigmentosa (RP3). Dry KL, et al. **Hum Mol Genet** 1995 Dec;4(12):2347–53

A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. Felbor U, et al. **Hum Mol Genet** 1995 Dec;4(12):2415–6

Predominance of null mutations in ataxia-telangiectasia. Gilad S, et al. **Hum Mol Genet** 1996 Apr;5(4):433–9

On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1. Hoffmeyer S, et al. **Hum Mol Genet** 1995 Aug;4(8):1267–72

Identification of WASP mutations in patients with Wiskott-Aldrich syndrome and isolated thrombocytopenia reveals allelic heterogeneity at the WAS locus. Kolluri R, et al. **Hum Mol Genet** 1995 Jul;4(7):1119–26

The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Savitsky K, et al. **Hum Mol Genet** 1995 Nov; 4(11):2025–32

Characterization of the 5' region of the Fanconi anaemia group C (FACC) gene. Savoia A, et al. **Hum Mol Genet** 1995 Aug;4(8):1321–6

Expression of the Huntington's disease (IT15) protein product in HD patients. Schilling G, et al. **Hum Mol Genet** 1995 Aug;4(8):1365–71

Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus. Suchy SF, et al. **Hum Mol Genet** 1995 Dec;4(12):2245–50

A novel L23-related gene 40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal and adult human tissues. Tsang P, et al. **Hum Mol Genet** 1995 Sep; 4(9):1499–507

A novel combination of mitochondrial tRNA and ND1 gene mutations in a syndrome with MELAS, cardiomyopathy, and diabetes mellitus. Jaksch M, et al. **Hum Mutat** 1996; 7(4):358–60

Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies. Yoshida K, et al. **Hybridoma** 1995 Oct;14(5):419–27

SA gene expression in the proximal tubule of normotensive and hypertensive rats. Yang T, et al. **Hypertension** 1996 Mar;27(3 Pt 2):541–51

A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Taylor GA, et al. **Immunity** 1996 May;4(5):445–54

Divergent intron arrangement in the MB1/LMP7 proteasome gene pair. Abdulla S, et al. **Immunogenetics** 1996; 44(4):254–8

The recombination activating gene 2 (RAG2) of the rainbow trout Oncorhynchus mykiss. Hansen JD, et al.

Immunogenetics 1996;44(3):203–11
Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Hanano R, et al. **Infect Immun** 1996 Aug; 64(8):3201–9
Identification of a developmentally regulated gene, esr16, in the tracheal epithelium of Manduca sexta, with homology to a protein from human epididymis. Mészáros M, et al. **Insect Biochem Mol Biol** 1996 Jan;26(1):7–11
Organization and expression of the hemolin gene, a member of the immunoglobulin superfamily in an insect, Manduca sexta. Wang Y, et al. **Insect Mol Biol** 1995 May;4(2):113–23
The ATM gene and the radiobiology of ataxia–telangiectasia. Jorgensen TJ, et al. **Int J Radiat Biol** 1996 May; 69(5):527–37 (104 ref.)
Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43–63 (23 ref.)
Identification of cDNA sequences by specific oligonucleotide sets. Computer tool and application. Kolchanov NA, et al. **Ismb** 1995;3:206–14
Automata–theoretic models of mutation and alignment. Searls DB, et al. **Ismb** 1995;3:341–9
Evolutionary recruitment of biochemically specialized subdivisions of Family I within the protein superfamily of aminotransferases. Jensen RA, et al. **J Bacteriol** 1996 Apr; 178(8):2161–71 (68 ref.)
The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. Apte SS, et al. **J Biol Chem** 1996 Feb 2;271(5):2874
Cloning and characterization of GRB14, a novel member of the GRB7 gene family. Daly RJ, et al. **J Biol Chem** 1996 May 24;271(21):12502–10
Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. Eden A, et al. **J Biol Chem** 1996 Aug 23;271(34):20242–5
A naturally occurring T14A11 tract blocks nucleosome formation over the human neurofibromatosis type 1 (NF1)–Alu element. Englander EW, et al. **J Biol Chem** 1996 Mar 8;271(10):5819–23
The mouse bone morphogenetic protein–4 gene. Analysis of promoter utilization in fetal rat calvarial osteoblasts and regulation by COUP–TFI orphan receptor. Feng JQ, et al. **J Biol Chem** 1995 Nov 24;270(47):28364–73
Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. Gächter T, et al. **J Biol Chem** 1996 Jan 5; 271(1):124–9
Genomic structure and promoter analysis of the human obese gene. Gong DW, et al. **J Biol Chem** 1996 Feb 23; 271(8):3971–4
Exons lost and found. Unusual evolution of a seminal vesicle transglutaminase substrate. Hagstrom JE, et al. **J Biol Chem** 1996 Aug 30;271(35):21114–9
A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. Hahn H, et al. **J Biol Chem** 1996 May 24;271(21):12125–8
The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer–binding protein alpha. He Y, et al. **J Biol Chem** 1995 Dec 1; 270(48):28887–91
Identification of a murine TEF-1-related gene expressed after mitogenic stimulation of quiescent fibroblasts and during myogenic differentiation. Hsu DKW, et al. **J Biol Chem** 1996 Jun 7;271(23):13786–95
Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. Hu B, et al. **J Biol Chem** 1996 Aug 9; 271(32):19415–20
AdipoQ is a novel adipose-specific gene dysregulated in obesity. Hu E, et al. **J Biol Chem** 1996 May 3; 271(18):10697–703
Structural organization and chromosomal assignment of the human obese gene. Isse N, et al. **J Biol Chem** 1995 Nov 17;270(46):27728–33
Identification of a minimum enhancer sequence for the type II collagen gene reveals several core sequence motifs in common with the link protein gene. Krebsbach PH, et al. **J Biol Chem** 1996 Feb 23;271(8):4298–303
Identification and characterization of 1,25–dihydroxyvitamin D3–responsive repressor sequences in the rat parathyroid hormone–related peptide gene. Kremer R, et al. **J Biol Chem** 1996 Jul 5;271(27):16310–6
Promoter analysis of Zfp–36, the mitogen–inducible gene encoding the zinc finger protein tristetraprolin. Lai WS, et al. **J Biol Chem** 1995 Oct 20;270(42):25266–72
ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. Lassalle P, et al. **J Biol Chem** 1996 Aug 23;271(34):20458–64
Serine phosphorylation, chromosomal localization, and transforming growth factor–beta signal transduction by human bsp–1. Lechleider RJ, et al. **J Biol Chem** 1996 Jul 26;271(30):17617–20
Expression of ob gene in adipose cells. Regulation by insulin. Leroy P, et al. **J Biol Chem** 1996 Feb 2;271(5):2365–8
Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. Milstien S, et al. **J Biol Chem** 1996 Aug 16;271(33):19743–51
Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone–related peptide gene expression and causes hypercalcemia in nude mice. Motokura T, et al. **J Biol Chem** 1995 Dec 29;270(52):30857–61
Enhancement of protein kinase C–dependent O2 production in Epstein–Barr virus–transformed B lymphocytes by p120Ras–GAP antisense oligonucleotide. Schmid E, et al. **J Biol Chem** 1996 Apr 19;271(16):9320–5
Accelerated evolution in inhibitor domains of porcine elafin family members. Tamechika I, et al. **J Biol Chem** 1996 Mar 22;271(12):7012–8
Identification and characterization of Ich–3, a member of the interleukin–1beta converting enzyme (ICE)/Ced–3 family and an upstream regulator of ICE. Wang S, et al. **J Biol Chem** 1996 Aug 23;271(34):20580–7
The cysteine–rich protein family of highly related LIM domain proteins. Weiskirchen R, et al. **J Biol Chem** 1995 Dec 1;270(48):28946–54
Expression cloning of lsc, a novel oncogene with structural similarities to the Dbl family of guanine nucleotide exchange factors. Whitehead IP, et al. **J Biol Chem** 1996 Aug 2;271(31):18643–50
Sequencing analysis of cDNA clones encoding the American cockroach Cr–PI allergens. Homology with insect hemolymph proteins. Wu CH, et al. **J Biol Chem** 1996 Jul 26;271(30):17937–43
Down–regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. Zhang B, et al. **J Biol Chem** 1996 Apr 19;271(16):9455–9
Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. Ishidou Y, et al. **J Bone Miner Res** 1995 Nov;10(11):1651–9
Tissue inhibitor of metalloproteinase–2 (TIMP–2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes. Zafarullah M, et al. **J Cell Biochem** 1996 Feb;60(2):211–7
Symplekin, a novel type of tight junction plaque protein. Keon BH, et al. **J Cell Biol** 1996 Aug;134(4):1003–18
Expression of the spr1 gene in cultured tracheal epithelial cells and its regulation by retinoids before and after confluence. Tesfaigzi J, et al. **J Cell Physiol** 1996 Mar; 166(3):480–6
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator–activated receptor gamma. De Vos P, et al. **J Clin Invest** 1996 Aug 15; 98(4):1004–9
The enigma of the Wiskott–Aldrich syndrome begins to unravel [editorial; comment] Rosen FS. **J Clin Invest** 1996 Jun 1;97(11):2407. Comment on: J Clin Invest 1996 Jun 1;97(11):2627–34.
The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. Vidal H, et al. **J Clin Invest** 1996 Jul 15;98(2):251–5
Cytoplasmic localization of FAC is essential for the correction of a prerepair defect in Fanconi anemia group C cells. Youssoufian H. **J Clin Invest** 1996 May 1; 97(9):2003–10
Locating protein coding regions in human DNA using a decision tree algorithm. Salzberg S. **J Comput Biol** 1995 Fall;2(3):473–85
gamma/delta T cell–deficient mice have impaired mucosal immunoglobulin A responses. Fujihashi K, et al. **J Exp Med** 1996 Apr 1;183(4):1929–35
Aod2, the locus controlling development of atrophy in neonatal thymectomy–induced autoimmune ovarian dysgenesis, co–localizes with Il2, Fgfb, and Idd3. Teuscher C, et al. **J Exp Med** 1996 Feb 1;183(2):631–7
B and T cells are not required for the viable motheaten phenotype. Yu CC, et al. **J Exp Med** 1996 Feb 1; 183(2):371–80
Isolation of low molecular mass polypeptide complementary DNA clones from primitive vertebrates. Implications for the origin of MHC class I–restricted antigen presentation. Kandil E, et al. **J Immunol** 1996 Jun 1;156(11):4245–53
Characterization of a rainbow trout Mx gene. Trobridge GD, et al. **J Interferon Cytokine Res** 1995 Aug;15(8):691–702
Chromosome 17 allelic loss and NF1–GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis. Gómez L, et al. **J Invest Dermatol** 1996 Mar;106(3):432–6
Agouti alleles alter cysteine and glutathione concentrations in hair follicles and serum of mice (A y/a, A wJ/A wJ, and a/a). Granholm DE, et al. **J Invest Dermatol** 1996 Mar; 106(3):559–63
Sequence and expression patterns of mouse SPR1: Correlation of expression with epithelial function. Kartasova T, et al. **J Invest Dermatol** 1996 Feb; 106(2):294–304
Genes encoding structural proteins of epidermal cornification and S100 calcium–binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. Mischke D, et al. **J Invest Dermatol** 1996 May;106(5):989–92
Differential expression of tissue inhibitor of metalloproteinases–2 by cutaneous squamous and basal cell carcinomas. Wagner SN, et al. **J Invest Dermatol** 1996 Feb; 106(2):321–6
Expression of S14 protein gene in rat liver in response to partial hepatectomy, and its regulation with T3 and sucrose. Knopp J, et al. **J Lipid Mediat Cell Signal** 1995 May; 11(3):253–60
Detection of new mutations in six out of 10 Swiss HNPCC families by genomic sequencing of the hMSH2 and hMLH1 genes. Buerstedde JM, et al. **J Med Genet** 1995 Nov; 32(11):909–12
Molecular genetic diagnosis of von Hippel–Lindau disease in familial phaeochromocytoma. Crossey PA, et al. **J Med Genet** 1995 Nov;32(11):885–6
A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases–3 (TIMP3) in Sorsby's fundus dystrophy. Felbor U, et al. **J Med Genet** 1996 Mar; 33(3):233–6
Different origins of mutations at the Machado–Joseph locus (MJD1) [letter] Iughetti P, et al. **J Med Genet** 1996 May; 33(5):439
Phenotypic expression in von Hippel–Lindau disease: correlations with germline VHL gene mutations. Maher ER, et al. **J Med Genet** 1996 Apr;33(4):328–32
Characterisation of the unstable expanded CAG repeat in the MJD1 gene in four Brazilian families of Portuguese descent with Machado–Joseph disease. Stevanin G, et al. **J Med Genet** 1995 Oct;32(10):827–30
Single nucleotide positions have proximal and distal influence on UV mutation hotspots and coldspots. Levy DD, et al. **J Mol Biol** 1996 May 3;258(2):251–60
Amino acid pair interchanges at spatially conserved locations. Naor D, et al. **J Mol Biol** 1996 Mar 15;256(5):924–38
Multiple alternative splice isoforms of parathyroid hormone–related peptide mRNA in human cell lines. Nakamura M, et al. **J Mol Endocrinol** 1995 Dec;15(3):245–9
Structure and sequence of a mouse gene encoding an androgen–regulated protein: a new member of the seminal vesicle secretory protein family. Simon AM, et al. **J Mol Endocrinol** 1995 Dec;15(3):305–16
Model of amino acid substitution in proteins encoded by mitochondrial DNA. Adachi J, et al. **J Mol Evol** 1996 Apr; 42(4):459–68
High divergence of reproductive tract proteins and their association with postzygotic reproductive isolation in Drosophila melanogaster and Drosophila virilis group species. Civetta A, et al. **J Mol Evol** 1995 Dec; 41(6):1085–95
Unbiased estimation of symmetrical directional mutation pressure from protein–coding DNA [letter] Jermiin LS, et al. **J Mol Evol** 1996 Apr;42(4):476–80
On the prevalence of certain codons ("RNY") in genes for proteins. Jukes TH. **J Mol Evol** 1996 Apr;42(4):377–81
Gene structure of chick cartilage chondroitin sulfate proteoglycan (aggrecan) core protein. Li H, et al. **J Mol Evol** 1995 Dec;41(6):878–85
The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary. Holthuis JC, et al. **J Neurochem** 1996 Jun;66(6):2248–56
Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. Liang BC, et al. **J Neurooncol** 1995 Oct;26(1):17–23
Relationship of protein synthesis to mRNA levels in the liver of chicks under various nutritional conditions. Kita K, et al. **J Nutr** 1996 Jun;126(6):1610–7
Osteoinductive ability of confluent Saos–2 cell correlates with enhanced expression of bone morphogenetic proteins. Raval P, et al. **J Orthop Res** 1996 Jul;14(4):605–10
Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA–B27 associated juvenile rheumatoid arthritis. Pryhuber KG, et al. **J Rheumatol** 1996 Apr;23(4):747–52
Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo–keto reductase superfamily: effect of steroid hormones and phorbol esters. Fabre S, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):315–25
Population evolution on a multiplicative single–peak fitness landscape. Woodcock G, et al. **J Theor Biol** 1996 Mar 7; 179(1):61–73
The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. He B, et al. **J Virol** 1996 Jan;70(1):84–90
Cloning of mouse DAN cDNA and its down–regulation in transformed cells. Ozaki T, et al. **Jpn J Cancer Res** 1996 Jan;87(1):58–61
Widespread expression of the parathyroid hormone–related peptide and PTH/PTHrP receptor genes in intestinal epithelial cells. Li H, et al. **Lab Invest** 1995 Dec; 73(6):864–70
Leptin and leptinomania [comment] Bray GA. **Lancet** 1996 Jul 20;348(9021):140–1. Comment on: Lancet 1996 Jul 20;348(9021):159–61.
A mutant form of p135tyk2, an interferon–alpha inducible tyrosine kinase, suppresses the transformed phenotype of Daudi cells. Davis E, et al. **Leukemia** 1996 Mar; 10(3):543–51
Coexpression of cell–surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG–1): two cases and derived cell lines. Nakamura F, et al. **Leukemia** 1996 Jul;10(7):1159–63
Induction of immediate-early, ornithine decarboxylase and antizyme gene expression in the rat small intestine after transient ischaemia. Pujic Z, et al. **Life Sci** 1996; 58(25):2289–96
Cbx–rs2 (M31), a mouse homolog of the Drosophila

Heterochromatin protein 1 gene, maps to distal chromosome 11 and is nonallelic to Om. Feil R, et al. **Mamm Genome** 1995 Jul;6(7):469–71

Smcx lies distal to DXHX674 and DXHX679 on the mouse X chromosome. Laval SH, et al. **Mamm Genome** 1996 Jul; 7(7):552

Chromosome mapping of the mouse and rat homologs of the human DAN gene, D1S1733E. Matsuda Y, et al. **Mamm Genome** 1996 Sep;7(9):709–10

Characterization of a novel human dynein–related gene that is specifically expressed in testis. Milisav I, et al. **Mamm Genome** 1996 Sep;7(9):667–72

The Ant1 gene maps near Klk3 on proximal mouse chromosome 8. Mills KA, et al. **Mamm Genome** 1996 Sep; 7(9):707

Molecular analysis of a recombinational hotspot adjacent to Lmp2 gene in the mouse MHC: fine location and chromatin structure. Mizuno K, et al. **Mamm Genome** 1996 Jul; 7(7):490–6

Sequence analysis of the human hTg737 gene and its polymorphic sites in patients with autosomal recessive polycystic kidney disease. Onuchic LF, et al. **Mamm Genome** 1995 Nov;6(11):805–8

Cloning and regional localization of the mouse faciogenital dysplasia (Fgd1) gene. Pasteris NG, et al. **Mamm Genome** 1995 Sep;6(9):658–61

Chromosomal localization of the bovine obesity (OBS) gene. Pfister–Genskow M, et al. **Mamm Genome** 1996 May; 7(5):398–9

Cloning and comparative mapping of a gene from the commonly deleted region of DiGeorge and Velocardiofacial syndromes conserved in C. elegans. Rizzu P, et al. **Mamm Genome** 1996 Sep;7(9):639–43

The fld mutation maps near to but distinct from the Apob locus on mouse chromosome 12. Rowe LB, et al. **Mamm Genome** 1996 Jul;7(7):555–7

The bovine homolog of the obese gene maps to chromosome 4. Stone RT, et al. **Mamm Genome** 1996 May;7(5):399–400

Human glucokinase regulatory protein (GCKR): cDNA and genomic cloning, complete primary structure, and chromosomal localization. Warner JP, et al. **Mamm Genome** 1995 Aug;6(8):532–6

Evaluation and characterization of a porcine small intestine cDNA library: analysis of 839 clones. Wintero AK, et al. **Mamm Genome** 1996 Jul;7(7):509–17

Assignment of the mouse ataxia–telangiectasia gene (Atm) to mouse chromosome 9. Xia Y, et al. **Mamm Genome** 1996 Jul;7(7):554–5

Murine Wnt–11 and Wnt–12 have temporally and spatially restricted expression patterns during embryonic development. Christiansen JH, et al. **Mech Dev** 1995 Jun; 51(2–3):341–50

Bone morphogenetic protein 2 in the early development of Xenopus laevis. Clement JH, et al. **Mech Dev** 1995 Aug; 52(2–3):357–70

The extra sex combs protein is highly conserved between Drosophila virilis and Drosophila melanogaster. Sathe SS, et al. **Mech Dev** 1995 Aug;52(2–3):225–32

The Drosophila extra sex combs protein contains WD motifs essential for its function as a repressor of homeotic genes. Sathe SS, et al. **Mech Dev** 1995 Jul;52(1):77–87

Of mice and (wo)men: the obesity (ob) gene, its product, leptin, and obesity [editorial] Zimmet PZ, et al. **Med J Aust** 1996 Apr 1;164(7):393–4

Progressive alignment of amino acid sequences and construction of phylogenetic trees from them. Feng DF, et al. **Methods Enzymol** 1996;266:368–82

Effective protein sequence comparison. Pearson WR. **Methods Enzymol** 1996;266:227–58

Iterative template refinement: protein–fold prediction using iterative search and hybrid sequence/structure templates. Yi TM, et al. **Methods Enzymol** 1996;266:322–39

Parathyroid hormone–related protein gene expression and human T cell leukemia virus–1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)

Disruption of the parathyroid hormone–related peptide gene. Kronenberg HM. **Miner Electrolyte Metab** 1995; 21(1–3):140–2

Stage–specific expression of the mRNA encoding a 14–3–3 protein during the life cycle of Schistosoma mansoni. Schechtman D, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):275–8

What does electrophoretic variation tell us about protein variation? [letter] Barbadilla A, et al. **Mol Biol Evol** 1996 Feb;13(2):427–32

Molecular population genetics of ref(2)P, a locus which confers viral resistance in Drosophila. Wayne ML, et al. **Mol Biol Evol** 1996 Jan;13(1):191–9

Distribution of the DNA adducts of 2–amino–3–methylimidazo[4,5–f] quinoline and 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine in the supF gene as determined by polymerase arrest assay. Endo H, et al. **Mol Carcinog** 1995 Nov;14(3):198–204

Differential spontaneous transformation in vitro of newly established mouse fibroblast lines carrying or lacking the viable yellow mutation (Avy) of the mouse agouti locus. Hsiao WL, et al. **Mol Carcinog** 1996 Jan;15(1):70–80

Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. Walker C, et al. **Mol Carcinog** 1996 Feb;15(2):154–61

The LIM domain–containing Dbm1 GTPase–activating protein is required for normal cellular morphogenesis in Saccharomyces cerevisiae. Chen GC, et al. **Mol Cell Biol** 1996 Apr;16(4):1376–90

The DNA rearrangement that generates the TRK–T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled–coil domain. Greco A, et al. **Mol Cell Biol** 1995 Nov;15(11):6118–27

An SH3 domain–containing GTPase–activating protein for Rho and Cdc42 associates with focal adhesion kinase. Hildebrand JD, et al. **Mol Cell Biol** 1996 Jun;16(6):3169–78

The scabrous gene encodes a secreted glycoprotein dimer and regulates proneural development in Drosophila eyes. Lee EC, et al. **Mol Cell Biol** 1996 Mar;16(3):1179–88

att, a target for regulation by tra2 in the testes of Drosophila melanogaster, encodes alternative RNAs and alternative proteins. Madigan SJ, et al. **Mol Cell Biol** 1996 Aug; 16(8):4222–30

Interaction of C/EBPbeta and v–Myb is required for synergistic activation of the mim–1 gene. Mink S, et al. **Mol Cell Biol** 1996 Apr;16(4):1316–25

The Ras–GTPase–activating protein SH3 domain is required for Cdc2 activation and mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen–activated protein kinase activation. Pomerance M, et al. **Mol Cell Biol** 1996 Jun;16(6):3179–86

Protein masking of a ribosomal RNA epitope is an early event in afferent deprivation–induced neuronal death. Garden GA, et al. **Mol Cell Neurosci** 1995 Jun;6(3):293–310

Restrictions to floor plate induction by hedgehog and winged–helix genes in the neural tube of frog embryos. Ruiz i Altaba A, et al. **Mol Cell Neurosci** 1995 Apr; 6(2):106–21

Identification by differential RT–PCR of a novel paired homeodomain protein specifically expressed in sensory neurons and a subset of their CNS targets. Saito T, et al. **Mol Cell Neurosci** 1995 Jun;6(3):280–92

Constitutive expression of the orphan receptor, Rev–erbA alpha, inhibits muscle differentiation and abrogates the expression of the myoD gene family. Downes M, et al. **Mol Endocrinol** 1995 Dec;9(12):1666–78

The C–terminal DNA–binding domain of Chironomus BR gene products shows preferential affinity for (dA.dT)–rich sequences. Botella LM, et al. **Mol Gen Genet** 1996 Jun 24; 251(4):422–7

The chloroplast chlL gene of the green alga Chlorella vulgaris C–27 contains a self–splicing group I intron. Kapoor M, et al. **Mol Gen Genet** 1996 Apr 10;250(6):655–64

Molecular cloning and functional characterization of a cDNA encoding nucleosome assembly protein 1 (NAP–1) from soybean. Yoon HW, et al. **Mol Gen Genet** 1995 Dec 15;249(5):465–73

The tissue inhibitor of metalloproteinases–3 gene in breast carcinoma: identification of multiple polyadenylation sites and a stromal pattern of expression. Byrne JA, et al. **Mol Med** 1995 May;1(4):418–27

Expression of the Von Hippel–Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Kessler PM, et al. **Mol Med** 1995 May; 1(4):457–66

In search of butterfly origins. Weller SJ, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):235–46

Five polymorphisms in the coding sequence of the xeroderma pigmentosum group D gene. Broughton BC, et al. **Mutat Res** 1996 Feb 15;362(2):209–11

Characterization of the GADD45 response to ionizing radiation in WI–L2–NS cells, a p53 mutant cell line. Carrier F, et al. **Mutat Res** 1996 Jun 10;352(1–2):79–86

Peroxynitrite–induced mutation spectra of pSP189 following replication in bacteria and in human cells. Juedes MJ, et al. **Mutat Res** 1996 Jan 17;349(1):51–61

A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets. The HYP Consortium. **Nat Genet** 1995 Oct;11(2):130–6

Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. The Treacher Collins Syndrome Collaborative Group [see comments] **Nat Genet** 1996 Feb;12(2):130–6. Comment in: Nat Genet 1996 Feb;12(2):124–9.

Complementation groups: one or more per gene? [news] Buchwald M. **Nat Genet** 1995 Nov;11(3):228–30

Gender equality in Machado–Joseph disease [letter; comment] Dürr A, et al. **Nat Genet** 1995 Oct;11(2):118–9 . Comment on: Nat Genet 1995 Apr;9(4):344–5.

Identification of the gene FMR2, associated with FRAXE mental retardation. Gecz J, et al. **Nat Genet** 1996 May; 13(1):105–8

Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. Gu Y, et al. **Nat Genet** 1996 May;13(1):109–13

Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo. Ikeda H, et al. **Nat Genet** 1996 Jun;13(2):196–202

Night blindness in Sorsby's fundus dystrophy reversed by vitamin A. Jacobson SG, et al. **Nat Genet** 1995 Sep; 11(1):27–32

Peg3 imprinted gene on proximal chromosome 7 encodes for a zinc finger protein. Kuroiwa Y, et al. **Nat Genet** 1996 Feb;12(2):186–90

Identification of the murine beige gene by YAC complementation and positional cloning. Perou CM, et al. **Nat Genet** 1996 Jul;13(3):303–8

Mad–related genes in the human. Riggins GJ, et al. **Nat Genet** 1996 Jul;13(3):347–9

Identification of NF1 mutations in both alleles of a dermal neurofibroma. Sawada S, et al. **Nat Genet** 1996 Sep; 14(1):110–2

The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Stickens D, et al. **Nat Genet** 1996 Sep;14(1):25–32

Vitamin A megatherapy for retinal abnormalities. Acott TS, et al. **Nat Med** 1995 Sep;1(9):884–5

The PKD1 gene product [letter; comment] Harris PC, et al. **Nat Med** 1995 Jun;1(6):493. Comment on: Nat Med 1995 Apr;1(4):359–64.

Tumour suppression by the human von Hippel–Lindau gene product. Iliopoulos O, et al. **Nat Med** 1995 Aug;1(8):822–6

Cerberus is a head–inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Bouwmeester T, et al. **Nature** 1996 Aug 15;382(6592):595–601

Conserved left–right asymmetry of nodal expression and alterations in murine situs inversus [see comments] Lowe LA, et al. **Nature** 1996 May 9;381(6578):158–61. Comment in: Nature 1996 May 9;381(6578):116–7.

Frameshift mutator mutations [letter] Malkhosyan S, et al. **Nature** 1996 Aug 8;382(6591):499–500

A candidate gene for the mouse mutation tubby. Noben–Trauth K, et al. **Nature** 1996 Apr 11; 380(6574):534–8

Transient increase in obese gene expression after food intake or insulin administration. Saladin R, et al. **Nature** 1995 Oct 12;377(6549):527–9

Identification of a gene for autosomal dominant polycystic kidney disease: implications for understanding the pathogenesis and treatment of the disease. Harris PC. **Nephrol Dial Transplant** 1996 Feb;11(2):258–62 (60 ref.)

Molecular cloning of linotte in Drosophila: a novel gene that functions in adults during associative learning. Bolwig GM, et al. **Neuron** 1995 Oct;15(4):829–42

period and timeless tango: a dance of two clock genes. Reppert SM, et al. **Neuron** 1995 Nov;15(5):983–6 (23 ref.)

The expression of ornithine decarboxylase antizyme mRNA and protein in rat motoneurons. Junttila T, et al. **Neurosci Lett** 1995 Sep 15;197(3):187–90

The two types of mRNAs for neurofibromin isoforms produced by von Recklinghausen neurofibromatosis (NF1) gene: analysis in human astrocytic tumors. Tokuyama T, et al. **Neurosci Lett** 1995 Aug 25;196(3):189–92

Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain. Kroesen S, et al. **Neuroscience** 1995 Dec;69(3):881–91

The SWISS–2DPAGE database of two–dimensional polyacrylamide gel electrophoresis, its status in 1995. Appel RD, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):180–1

PairWise and SearchWise: finding the optimal alignment in a simultaneous comparison of a protein profile against all DNA translation frames. Birney E, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2730–9

5' upstream sequences of MyD88, an IL–6 primary response gene in M1 cells: detection of functional IRF–1 and Stat factors binding sites. Harroch S, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3539–46

A protein binds the selenocysteine insertion element in the 3'–UTR of mammalian selenoprotein mRNAs. Hubert N, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):464–9

The neurofibromatosis type I messenger RNA undergoes base–modification RNA editing. Skuse GR, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):478–85

Expression of the receptor tyrosine kinase substrate genes eps8 and eps15 during mouse development. Avantaggiato V, et al. **Oncogene** 1995 Sep 21;11(6):1191–8

A novel Bcl–2 related gene, Bfl–1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Choi SS, et al. **Oncogene** 1995 Nov 2;11(9):1693–8

Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas. de Bruijn DR, et al. **Oncogene** 1996 Aug 1; 13(3):643–8

bcl–w, a novel member of the bcl–2 family, promotes cell survival. Gibson L, et al. **Oncogene** 1996 Aug 15; 13(4):665–75

Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T–cell receptor beta chain in an acute T–cell leukemia. Ino T, et al. **Oncogene** 1995 Dec 21; 11(12):2705–10

A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. Park SH, et al. **Oncogene** 1995 Dec 7;11(11):2349–55

A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Pelicci G, et al. **Oncogene** 1996 Aug 1; 13(3):633–41

A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine–rich protein and is mutated in renal cell carcinomas. Shridhar V, et al. **Oncogene** 1996 May 2;12(9):1931–9

The differentiation primary response gne MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21 WAF1/CIP1. Vairapandi M, et al. **Oncogene** 1996 Jun 20;12(12):2579–94

Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. van Leeuwen FN, et al. **Oncogene** 1995 Dec 7;11(11):2215–21

Incomplete expression of the tyrosinase gene family (tyrosinase, TRP–1, and TRP–2) in human malignant melanoma cells in vitro. Eberle J, et al.

Pigment Cell Res 1995 Dec;8(6):307–13

Agouti alleles influence thiol concentrations in hair follicles and extrafollicular tissues of mice (Ay/a, AwJ/AwJ, a/a). Granholm DE, et al. **Pigment Cell Res** 1995 Dec;8(6):302–6

Genomic organization and FISH mapping of human Pmel 17, the putative silver locus. Kim KK, et al. **Pigment Cell Res** 1996 Feb;9(1):42–8

Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease. Yoder BK, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):314–23

A functional Rev–erb alpha responsive element located in the human Rev–erb alpha promoter mediates a repressing activity. Adelmant G, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3553–8

Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Brinkmann U, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10427–31

Disruption of the MacMARCKS gene prevents cranial neural tube closure and results in anencephaly. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6275–9

Identification of the promoter of the mouse obese gene. de la Brousse FC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4096–101

Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Fears S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1642–7

Prevalence of germ–line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic–based population. FitzGerald MG, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8541–5

Signal transduction in T lymphocytes using a conditional allele of Sos. Holsinger LJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9810–4

Cloning and characterization of Lnk, a signal transduction protein that links T–cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3–kinase. Huang X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11618–22

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3–L1 adipocytes. Kallen CB, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5793–6

Modular cis–regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)

Selection for genes encoding secreted proteins and receptors. Klein RD, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7108–13

A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Lombard–Platet G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1265–9

The Drosophila melanogaster dodo (dod) gene, conserved in humans, is functionally interchangeable with the ESS1 cell division gene of Saccharomyces cerevisiae. Maleszka R, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):447–51

Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan. Meyer MF, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4543–7

The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Miller SG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5507–11

Protein evolution on partially correlated landscapes. Perelson AS, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9657–61

ECA39, a conserved gene regulated by c–Myc in mice, is involved in G1/S cell cycle regulation in yeast. Schuldiner O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7143–8

Homologs of the Xenopus developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod–like chitin oligosaccharides during early embryogenesis. Semino CE, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4548–53

Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor–associated factors. Uren AG, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4974–8

Rat skeletal muscle selenoprotein W: cDNA clone and mRNA modulation by dietary selenium. Vendeland SC, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8749–53

FHIT gene alterations in head and neck squamous cell carcinomas. Virgilio L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9770–5

Excessive homoplasy in an evolutionarily constrained protein. Wells RS. **Proc R Soc Lond B Biol Sci** 1996 Apr 22;263(1369):393–400

Comparison of methods for searching protein sequence databases. Pearson WR. **Protein Sci** 1995 Jun;4(6):1145–60

Sorsby's fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases–3 gene on chromosome 22. Peters AL, et al. **Retina** 1995;15(6):480–5

On the road to a DNA–protein world [letter] Bussière F, et al. **RNA** 1995 Jul;1(5):451–2

A novel RNA structural motif in the selenocysteine insertion element of eukaryotic selenoprotein mRNAs. Walczak R, et al. **RNA** 1996 Apr;2(4):367–79

Heterogeneous expression of recombination activating genes and surface CD5 in CD3low CD4+ CD8+ thymocytes. Sheard M, et al. **Scand J Immunol** 1996 Jun;43(6):619–25

Establishment and characterization of RAG–2 deficient non–obese diabetic mice. Söderstrøm I, et al. **Scand J Immunol** 1996 May;43(5):525–30

New clock gene cloned [news; comment] Barinaga M. **Science** 1995 Nov 3;270(5237):732–3. Comment on: Science 1995 Nov 3;270(5237):805–9. Comment on: Science 1995 Nov 3;270(5237):808–10. Comment on: Science 1995 Nov 3;270(5237):811–5.

Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion [see comments] Campuzano V, et al. **Science** 1996 Mar 8;271(5254):1423–7 . Comment in: Science 1996 Mar 8;271(5254):1374–5.

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. [see comments] Hahn SA, et al. **Science** 1996 Jan 19;271(5247):350–3. Comment in: Science 1996 Jan 19;271(5247):294.

Positional cloning and sequence analysis of the Drosophila clock gene, timeless [see comments] Myers MP, et al. **Science** 1995 Nov 3;270(5237):805–8. Comment in: Science 1995 Nov 3;270(5237):732–3.

New tumor suppressor found in pancreatic cancer [news; comment] O'Brien C. **Science** 1996 Jan 19;271(5247):294. Comment on: Science 1996 Jan 19;271(5247):350–3.

"Smart" genes use many cues to set cell fate [news] Roush W. **Science** 1996 May 3;272(5262):652–3

Protein builds second skeleton [news] Roush W. **Science** 1996 Aug 30;273(5279):1170

RAG mutations in human B cell–negative SCID. Schwarz K, et al. **Science** 1996 Oct 4;274(5284):97–9

Rhythmic expression of timeless: a basis for promoting circadian cycles in period gene autoregulation [see comments] Sehgal A, et al. **Science** 1995 Nov 3; 270(5237):808–10. Comment in: Science 1995 Nov 3;270(5237):732–3.

The expanding world of trinucleotide repeats [comment] Warren ST. **Science** 1996 Mar 8;271(5254):1374–5 (7 ref.) . Comment on: Science 1996 Mar 8;271(5254):1423–7.

The secreted product of Xenopus gene lunatic Fringe, a vertebrate signaling molecule. Wu JY, et al. **Science** 1996 Jul 19;273(5273):355–8

Localization of the mouse lissencephaly–1 gene to mouse chromosome 11B3, in close proximity to D11Mit65. Péterfy M, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):345–9

Restriction fragment length polymorphism of genes of the alpha 2(XI) collagen, bone morphogenetic protein–2, alkaline phosphatase, and tumor necrosis factor–alpha among patients with ossification of posterior longitudinal ligament and controls from the Japanese population. Koga H, et al. **Spine** 1996 Feb 15;21(4):469–73

Identification and genetic analysis of a common molecular variant of histidine–rich glycoprotein with a difference of 2kD in apparent molecular weight. Hennis BC, et al. **Thromb Haemost** 1995 Dec;74(6):1491–6

An amino acid polymorphism in histidine–rich glycoprotein (HRG) explains 59% of the variance in plasma HRG levels. Hennis BC, et al. **Thromb Haemost** 1995 Dec;74(6):1497–50

Protein splicing: self–splicing of genetically mobile elements at the protein level. Cooper AA, et al. **Trends Biochem Sci** 1995 Sep;20(9):351–6 (33 ref.)

Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)

The ataxia–telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375–7 (23 ref.)

Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV–1 Tat transactivator. Kamine J, et al. **Virology** 1996 Feb 15; 216(2):357–66

[Genetically reduced effect or deficiency of the hormone leptin as the cause of obesity] Astrup AV, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4534–5 **(Dan)**

[Obesity, The ob gene product and control of adipose mass] Ferré P. **Diabete Metab** 1995 Jun;21(3):217–8 **(Fre)**

[Expression of a synthetic gene for human angiogenin in a recombinant vaccinia virus] Netesova NA, et al. **Bioorg Khim** 1995 Aug;21(8):608–11 (Eng. Abstr.) **(Rus)**

[Leptin—a peptide hormone from adipocytes. Sensation of the 23rd FEBS Meeting] Pankov IuA. **Bioorg Khim** 1996 Mar;22(3):228–33 (13 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Semiconduction of proteins as an attribute of the living state: the ideas of Albert Szent–Györgyi revisited in light of the recent knowledge regarding oxygen free radicals. Nagy IZ. **Exp Gerontol** 1995 May–Aug;30(3–4):327–35

The golden years of Protein Science. Banquet address at the First European Symposium of the Protein Society, Davos, Switzerland, May 30, 1995. Neurath H. **Protein Sci** 1995 Sep;4(9):1939–43

IMMUNOLOGY

Defective natural killer cell activity in B–cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor–alpha. Katrinakis G, et al. **Acta Haematol** 1996;96(1):16–23

The fate of protein antigen in annelids—in vivo and in vitro studies. Tucková L, et al. **Adv Exp Med Biol** 1995; 371A:335–9

IgG1 and IgG4 antibody responses to the dust mite Lepidoglyphus destructor in a naturally exposed farming population. Johansson E, et al. **Allergy** 1995 Jun;50(6):473–7

Protein contact dermatitis caused by Nereis diversicolor. Purello D'Ambrosio F, et al. **Allergy** 1995 Oct;50(10):830–2

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S67–71 (56 ref.)

Antibody binding to a peptide but not the whole protein by recognition of the C–terminal carboxy group. Liang TC, et al. **Arch Biochem Biophys** 1996 May 15; 329(2):208–14

Antibody against pulmonary surfactant protein A recognizes proteins in intestine and swim bladder of the freshwater fish, carp. Rubio S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):901–6

Interaction between tissue inhibitor of metalloproteinases–2 and progelatinase A: immunoreactivity analyses. Fujimoto N, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):827–33

Predicting major histocompatibility complex–binding sequences within protein antigens. Sinigaglia F, et al. **Biochem Soc Trans** 1995 Aug;23(3):675–7 (18 ref.)

Improved technique for the preparation of water–in–oil emulsions containing protein antigens. Vulliet R. **Biotechniques** 1996 May;20(5):797–800

New methods to predict MHC–binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263–9 (60 ref.)

Identification of 2 stallion sperm–specific proteins and their autoantibody response. Teuscher C, et al. **Equine Vet J** 1994 Mar;26(2):148–51

Interleukin–4–producing CD4+ NK1.1+ TCR alpha/beta intermediate liver lymphocytes are down–regulated by Listeria monocytogenes. Emoto M, et al. **Eur J Immunol** 1995 Dec;25(12):3321–5

T lymphocytes from normal human peritoneum are phenotypically different from their counterparts in peripheral blood and CD3– lymphocyte subsets contain mRNA for the recombination activating gene RAG–1. Hartman J, et al. **Eur J Immunol** 1995 Sep;25(9):2626–31

Immunocytochemical detection of lung cancer cells with monoclonal antibodies to 14–3–3 proteins. Setoguchi Y, et al. **Hum Antibodies Hybridomas** 1995;6(4):137–44

Development and characterization of murine monoclonal antibodies to the latency–associated peptide of transforming growth factor beta 1. Hongo JA, et al. **Hybridoma** 1995 Jun;14(3):253–60

The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein. Kilpatrick KE, et al. **Hybridoma** 1995 Aug; 14(4):355–9

Studies on natural ST2 gene products in the human leukemic cell line UT–7 using monoclonal antihuman ST2 antibodies. Yoshida K, et al. **Hybridoma** 1995 Oct;14(5):419–27

Significance of rubber elongation factor as a latex allergen. Alenius H, et al. **Int Arch Allergy Immunol** 1996 Apr; 109(4):362–8

Challenge confirmation of late–onset reactions to extensively hydrolyzed formulas in infants with multiple food protein intolerance. Hill DJ, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):386–94

The use of a seminal vesicle specific protein (MHS–5 antigen) for diagnosis of agenesis of vas deferens and seminal vesicles in azoospermic men (Vol. 15, No. 6) [letter; comment] Amelar RD. **J Androl** 1995 Jul–Aug;16(4):372 . Comment on: J Androl 1994 Nov–Dec;15(6):603–7.

Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)–microglobulin–deficient BALB/c mice. Guery JC, et al. **J Exp Med** 1996 Feb 1;183(2):485–97

A novel antigen–processing–defective phenotype in major histocompatibility complex class II–positive CIITA transfectants is corrected by interferon–gamma. Siegrist CA, et al. **J Exp Med** 1995 Dec 1;182(6):1793–9

Isolation of low molecular mass polypeptide complementary DNA clones from primitive vertebrates. Implications for the origin of MHC class I–restricted antigen presentation. Kandil E, et al. **J Immunol** 1996 Jun 1;156(11):4245–53

Modulation of TCR–mediated signaling pathway by thymic shared antigen–1 (TSA–1)/stem cell antigen–2 (Sca–2). Saitoh S, et al. **J Immunol** 1995 Dec 15;155(12):5574–81

Liver NK1.1+ CD4+ alpha beta T cells activated by IL–12 as a major effector in inhibition of experimental tumor metastasis. Takeda K, et al. **J Immunol** 1996 May 1; 156(9):3366–73

Epicutaneous exposure of protein antigen induces a predominant Th2–like response with high IgE production in mice. Wang LF, et al. **J Immunol** 1996 Jun 1; 156(11):4077–82

Lesional psoriatic epidermis displays reduced neurofibromin immunoreactivity. Peltonen J, et al. **J Invest Dermatol** 1995 Nov;105(5):664–7

Neurotrophin receptor proteins immunoreactivity in the rat cerebellar cortex as a function of age. Torres JM, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):1–9

Engraftment and humoral immunity in SCID and RAG–2–deficient mice transplanted with human peripheral blood lymphocytes. Steinsvik TE, et al. **Scand J Immunol** 1995 Dec;42(6):607–16

[Immunization with neuromediators (serotonin, dopamine, noradrenaline) conjugated with a protein suppresses the

morphine abstinence syndrome] Evseev VA, et al. **Biull Eksp Biol Med** 1995 May;119(5):526–9 **(Rus)**

ISOLATION & PURIFICATION

Chromatography in the downstream processing of biotechnological products. Freitag R, et al. **Adv Biochem Eng Biotechnol** 1996;53:17–59 (383 ref.)

Ultraviolet shadowing of proteins in preparative sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Jansen S, et al. **Anal Biochem** 1995 Jun 10;228(1):177–8

Continuous beds for microchromatography: reversed–phase chromatography. Liao JL, et al. **Anal Biochem** 1996 Feb 1;234(1):27–30

Reverse isoelectric focusing procedure resolves charge variants of basic proteins. Madden MS. **Anal Biochem** 1995 Aug 10;229(2):203–6

Nonideal size–exclusion chromatography with zwitterions causes a pI–dependent elution of proteins from glycerol propylsilane–modified silica. Ovalle R. **Anal Biochem** 1995 Jul 20;229(1):1–7

No need of acetic acid for processing polyacrylamide gels. Phang T, et al. **Anal Biochem** 1996 Feb 1;234(1):96–7

Detection of fast capillary electrophoresis peptide and protein separations using electrospray ionization with a time–of–flight mass spectrometer. Banks JF Jr, et al. **Anal Chem** 1996 May 1;68(9):1480–5

Chromatography of proteins using polybutadiene–coated zirconia. Sun L, et al. **Anal Chem** 1995 Oct 15; 67(20):3717–21

Protein purification in preparative scale of mammalian cell culture–derived products. Strategies for extra high purity. Mitra G, et al. **Ann N Y Acad Sci** 1996 May 15;782:422–31

Foam fractionation of proteins: modeling of a semi–batch operation. Vázquez Lima F, et al. **Ann N Y Acad Sci** 1996 May 15;782:375–90

A computer program for predicting recovery of SDS–protein in the automated HPGE–1000 apparatus. Aldroubi A, et al. **Appl Theor Electrophor** 1995;5(1):31–4

Multiple forms of selenoprotein P in rat plasma. Chittum HS, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):124–8

Isolation and identification of a cAMP generating peptide from the flesh fly, Neobellieria bullata (Diptera: Sarcophagidae). Spittaels K, et al. **Arch Insect Biochem Physiol** 1996;31(2):135–47

A new selenoprotein found in the glandular epithelial cells of the rat prostate. Kalcklösch M, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):162–70

A novel antimicrobial peptide from Bufo bufo gargarizans. Park CB, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):408–13

Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1–latency–associated peptide. McMahon GA, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):343–51

Purification, cloning and expression of dehydroascorbic acid–reducing activity from human neutrophils: identification as glutaredoxin. Park JB, et al. **Biochem J** 1996 May 1;315 (Pt 3):931–8

Identification of two cDNA clones encoding small proline–rich proteins expressed in sheep ruminal epithelium. Wang L, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):225–33

Purification by cobalamin–Sepharose affinity chromatography and intrinsic factor–binding activity of an extramembrane proteolytic product from pig ileal mucosa. Yerima A, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):675–81

Approach to development of tentacle affinity matrices. Gyepi–Garbrah I, et al. **Biochem Soc Trans** 1996 Feb; 24(1):47S

Interactions of proteins with dyes conjugated to soluble polymers. Maytum R, et al. **Biochem Soc Trans** 1996 Feb; 24(1):147S

Isolation of the human gamma–carboxylase and a gamma–carboxylase–associated protein from factor IX–expressing mammalian cells. Lingenfelter SE, et al. **Biochemistry** 1996 Jun 25;35(25):8234–43

Application of immobilized metal ion chelate complexes as pseudocation exchange adsorbents for protein separation. Zachariou M, et al. **Biochemistry** 1996 Jan 9;35(1):202–11

Purification and identification of allergenic alpha(2u)–globulin species of rat urine. Bayard C, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):129–34

Isolation of a spermatozoa motility inhibiting factor from chicken seminal plasma with antibacterial property. Mohan J, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):407–13

Partitioning and diffusion of proteins and linear polymers in polyacrylamide gels. Tong J, et al. **Biophys J** 1996 Mar; 70(3):1505–13

Lysis buffer composition dramatically affects extraction of phosphotyrosine–containing proteins. Ignatoski KM, et al. **Biotechniques** 1996 May;20(5):794–6

Protein purification in the nineties. Scopes RK. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):197–204 (10 ref.)

Amino acid sequence determination of a protein purified from the shell of the shrimp, Pandalus borealis. Jacobsen SL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;109(2–3):209–17

Antibacterial activity in the coelomocytes of the sea urchin Paracentrotus lividus. Stabili L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):639–44

Isolation and characterization of two new morphogenetically active peptides from Hydra vulgaris. Hoffmeister SA. **Development** 1996 Jun;122(6):1941–8

Electrophoretic size separation of proteins treated with sodium dodecyl sulfate in 1% agarose gels. Acevedo F, et al. **Electrophoresis** 1995 Aug;16(8):1394–400

Single–step electrotransfer of reverse–stained proteins from sodium dodecyl sulfate–polyacrylamide gel onto reversed–phase minicartridge and subsequent desalting and elution with a conventional high–performance liquid chromatography gradient system for analysis. Fernandez–Patron C, et al. **Electrophoresis** 1995 Jun; 16(6):911–20

Sodium dodecyl sulfate–gel electrophoresis of proteins employing short capillaries. Manabe T. **Electrophoresis** 1995 Aug;16(8):1468–73

Effective ion–pairing for the separation of basic proteins in capillary electrophoresis. Okafo GN, et al. **Electrophoresis** 1995 Oct;16(10):1917–21

Matrix–assisted laser–desorption/ionization mass spectrometric approaches for the identification of gel–separated proteins in the 5–50 pmol range. Patterson SD. **Electrophoresis** 1995 Jul;16(7):1104–14

Nonreducing two–dimensional polyacrylamide gel electrophoretic analysis of human colonic proteins. Reid GE, et al. **Electrophoresis** 1995 Jul;16(7):1120–30

A new mode of size–dependent separation of proteins by capillary electrophoresis in presence of sodium dodecyl sulfate and concentrated oligomeric dextran. Takagi T, et al. **Electrophoresis** 1995 Aug;16(8):1463–7

Differential expression of the microspike–associated protein moesin in human tissues. Schwartz–Albiez R, et al. **Eur J Cell Biol** 1995 Jul;67(3):189–98

Characterization of multiple nicotinic acetylcholine receptor–binding proteins and phospholipases A2 from the venom of the coral snake Micrurus nigrocinctus. Alape–Girón A, et al. **FEBS Lett** 1996 Feb 12; 380(1–2):29–32

Expanded bed chromatography and radial flow column chromatography: the approaches for adsorption chromatography of biomolecules on industrial scale. Ambedkar SS, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):164–72 (22 ref.)

Developments and newer approaches in downstream processing of biopharmaceuticals. Chatterjee NR, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):78–97 (66 ref.)

New trends in downstream processing of biotechnological products. Patkar AY, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):141–56 (64 ref.)

Identification of gonadotrophin surge–inhibiting factor (GnSIF)/attenuin in human follicular fluid. Mroueh JM, et al. **Hum Reprod** 1996 Mar;11(3):490–6

Steady–state two–dimensional maps of very alkaline proteins in an immobilized pH 10–12 gradient, as exemplified by histone types. Righetti PG, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3–4):81–91

A novel protein phosphatase–1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. Eto M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1104–7

Purification and properties of 3–hydroxyacyl coenzyme A dehydrogenase–binding protein from rat liver mitochondria. Furuta S, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):810–8

Purification and phosphorylation of a M(r) 25,000 protein, an effective phosphate acceptor for casein kinase II and protein kinase C, detected in the cytosolic fraction of Xenopus laevis oocytes. Hashimoto E, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):453–60

Separation of protein factors that correct the defects in the seven complementation groups of xeroderma pigmentosum cells. Tateishi S, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):819–24

The isolation and characterization of a novel corticostatin/defensin–like peptide from the kidney. Bateman A, et al. **J Biol Chem** 1996 May 3;271(18):10654–9

Multiple forms of phospholipase D inhibitor from rat brain cytosol. Purification and characterization of heat–labile form. Han JS, et al. **J Biol Chem** 1996 May 10; 271(19):11163–9

Purification and characterization of a novel stress protein, the 150–kDa oxygen–regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. Kuwabara K, et al. **J Biol Chem** 1996 Mar 1; 271(9):5025–32

Isolation and characterization of a novel perchloric acid–soluble protein inhibiting cell–free protein synthesis. Oka T, et al. **J Biol Chem** 1995 Dec 15;270(50):30060–7

Purification and characterization of the XPF–ERCC1 complex of human DNA repair excision nuclease. Park CH, et al. **J Biol Chem** 1995 Sep 29;270(39):22657–60

Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori. Yoshida H, et al. **J Biol Chem** 1996 Jun 7;271(23):13854–60

Identification of major proteins associated with Dictyostelium discoideum endocytic vesicles. Adessi C, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3331–7

14th International Symposium on the Separation and Analysis of Proteins, Peptides and Polynucleotides. Heidelberg, Germany, 2–4 November 1994. **J Chromatogr A** 1995 Sep 8;711(1):1–233

Immunohistochemical localization of mouse Clara cell 10–KD protein using antibodies raised against the recombinant protein. Ray MK, et al. **J Histochem Cytochem** 1996 Aug;44(8):919–27

Biochemical characterization and microsequencing of a 205–kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. Hain NA, et al. **J Immunol** 1996 Aug 15;157(4):1773–80

Improved procedure for the purification of selenoprotein Ph from human plasma. Eberle B, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):55–7

Proteins and protein assemblies. Epstein HF, et al. **Methods Cell Biol** 1995;48:437–50 (23 ref.)

Purification of Rac–GDP dissociation inhibitor complex from phagocyte cytosol. Abo A. **Methods Enzymol** 1995; 256:33–41

Purification of recombinant Ras GTPase–activating proteins. Bollag G, et al. **Methods Enzymol** 1995;255:21–30

Expression, purification, and functional assay of Mss4. Burton JL, et al. **Methods Enzymol** 1995;257:93–8

Purification of baculovirus–expressed human Sos1 protein. Frech M, et al. **Methods Enzymol** 1995;255:125–9

Glutaredoxin. Holmgren A, et al. **Methods Enzymol** 1995; 252:283–92

Purification and GTPase–activating protein activity of baculovirus expressed p190. Settleman J, et al. **Methods Enzymol** 1995;256:105–13

Purification and properties of Rabphilin–3A. Shirataki H, et al. **Methods Enzymol** 1995;257:291–302

High expression cloning, purification, and assay of Ypt–GTPase–activating proteins. Vollmer P, et al. **Methods Enzymol** 1995;257:118–28

A Ras–GTPase–activating protein SH3–domain–binding protein. Parker F, et al. **Mol Cell Biol** 1996 Jun;16(6):2561–9

Isolation of LERK–5: a ligand of the eph–related receptor tyrosine kinases. Cerretti DP, et al. **Mol Immunol** 1995 Nov; 32(16):1197–205

Chromatographic techniques for the characterization of proteins. Holthuis JJ, et al. **Pharm Biotechnol** 1995;7:243–99 (144 ref.)

Capillary electrophoresis of proteins. van de Goor TA. **Pharm Biotechnol** 1995;7:301–27 (103 ref.)

Physicochemical characterization of protein–free low density lipoprotein models and influence of drug loading. Gerke A, et al. **Pharm Res** 1996 Jan;13(1):44–51

Two–dimensional protein crystallization via metal–ion coordination by naturally occurring surface histidines. Frey W, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4937–41

Isolation and characterization of two human transcription factor IIH (TFIIH)–related complexes: ERCC2/CAK and TFIIH. Reardon JT, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6482–7

Purification and characterization of a luminal cholecystokinin–releasing factor from rat intestinal secretion. Spannagel AW, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4415–20

A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Tamura T, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1006–11

Purification and characterization of a guanine nucleotide–exchange protein for ADP–ribosylation factor from spleen cytosol. Tsai SC, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):305–9

Identification of pigment epithelium–derived factor in the interphotoreceptor matrix of bovine eyes. Wu YQ, et al. **Protein Expr Purif** 1995 Aug;6(4):447–56

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. **Protein Sci** 1996 Feb;5(2):357–62

Combined isolation of nucleic acids and protein from small amounts of tissue. Schüssler P, et al. **Trends Genet** 1995 Oct;11(10):378–9

[Validation and characterization of chromatographic sorbent for protein purification] Santambien P, et al. **Ann Pharm Fr** 1996;54(3):119–25 (Eng. Abstr.) **(Fre)**

[An ambient and low temperature two–dimensional electrophoresis: a convenient way to detect cold–dissociable proteins] Matsuo T. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1867–70 (7 ref.) **(Jpn)**

[Determination of the level of protein contaminants in high–purity DNA preparations] Lando DIu, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):701–6 **(Rus)**

METABOLISM

Proto–oncogene products Vav and c–Cbl are involved in the signal transduction through Grb2/Ash in hematopoietic cells. Hanazono Y, et al. **Acta Haematol** 1996; 95(3–4):236–42

Role of the endothelial cytoskeleton in blood–brain–barrier permeability to protein. Nag S. **Acta Neuropathol (Berl)** 1995;90(5):454–60

Protein loss and capillary protein permeability in dependent regions upon quiet standing. Bjerkhoel P, et al. **Acta Physiol Scand** 1995 Jul;154(3):311–20

Heparan sulphate and protein recognition. Binding specificities and activation mechanisms. Gallagher JT. **Adv Exp Med Biol** 1995;376:125–34 (33 ref.)

Use of gut lavage fluid to measure intestinal humoral immunity, GI bleeding and protein losses in Sierra Leonean

children. Hodges M, et al. **Adv Exp Med Biol** 1995; 371B:813–5

Oral mercuric chloride leads to intestinal basement membrane (IBM) immune complex deposition and fecal protein loss. Knoflach P, et al. **Adv Exp Med Biol** 1995;371B:1399–401

Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Daugirdas JT. **Adv Ren Replace Ther** 1995 Oct;2(4):295–304

Whole–body protein turnover in the fed state is reduced in response to dietary protein restriction in lactating women. Motil KJ, et al. **Am J Clin Nutr** 1996 Jul;64(1):32–9

Lissencephaly gene product. Localization in the central nervous system and loss of immunoreactivity in Miller–Dieker syndrome. Mizuguchi M, et al. **Am J Pathol** 1995 Oct;147(4):1142–51

Accelerated binding of secretory leukoprotease inhibitor to human leukocyte elastase mediated by single–stranded sites in DNA from tracheobronchial mucus. Ying QL, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):703–11

Parathyroid hormone–related protein expression in the human colon: immunohistochemical evaluation. Malakouti S, et al. **Am Surg** 1996 Jul;62(7):540–4; discussion 544–5

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

A newly developed procedure for monitoring of extracellular proteins using a push–pull microdialysis. Asai S, et al. **Anal Biochem** 1996 Jun 1;237(2):182–7

Prediction of human immunodeficiency virus protease cleavage sites in proteins. Chou KC. **Anal Biochem** 1996 Jan 1;233(1):1–14 (62 ref.)

Kinetics of protein–protein interactions at the surface of an optical biosensor. Edwards PR, et al. **Anal Biochem** 1995 Oct 10;231(1):210–7

Postoperative alpha 2–adrenergic stimulation attenuates protein catabolism. Mertes N, et al. **Anesth Analg** 1996 Feb; 82(2):258–63

Changes in bone morphogenetic protein sensitivity relative to differentiation in fetal rat bone cell cultures. Centrella M, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:224–6

A 115 kDa tyrosine phosphorylated protein associates with Grb–2 in activated Jurkat cells. Meisner H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:204–5

Analysis of the interaction between two TGF–beta–binding proteins and three TGF–beta isoforms using surface plasmon resonance. O'Connor–McCourt MD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:300–2

Interaction of Shc with Grb2 regulates the Grb2 association with mSOS. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:202–3

Oxidative damage to protein in sporadic motor neuron disease spinal cord. Shaw PJ, et al. **Ann Neurol** 1995 Oct; 38(4):691–5

Effects of the beta–adrenergic agonist salbutamol and its withdrawal on protein metabolism of lambs. del Barrio AS, et al. **Ann Nutr Metab** 1995;39(5):317–24

Protein metabolism in cirrhotic rats: effect of dietary restriction. Holeček M, et al. **Ann Nutr Metab** 1995; 39(6):346–54

Carbohydrate–protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601–31 (185 ref.)

Protein–RNA recognition. Draper DE. **Annu Rev Biochem** 1995;64:593–620 (183 ref.)

Whole–body protein turnover in humans—past, present, and future. Waterlow JC. **Annu Rev Nutr** 1995;15:57–92 (171 ref.)

Roles of ubiquitinylation in proteolysis and cellular regulation. Wilkinson KD. **Annu Rev Nutr** 1995;15:161–89 (136 ref.)

Exocytosis: proteins and perturbations. Augustine GJ, et al. **Annu Rev Pharmacol Toxicol** 1996;36:659–701 (273 ref.)

Isolation and identification of selenium–labeled proteins in the mouse kidney. Jamba L, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1651–7

In vivo regulation of rat epididymal proteins by retinoids: analysis by two–dimensional electrophoresis. Astraudo C, et al. **Arch Androl** 1995 Nov–Dec;35(3):247–59

Coupling between [arginine8]–vasopressin–activated increases in protein tyrosine phosphorylation and cellular calcium in A7r5 aortic smooth muscle cells. Kaplan N, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):271–80

Proteasome activator PA28 and its interaction with 20 S proteasomes. Kuehn L, et al. **Arch Biochem Biophys** 1996 May 1;329(1):87–96

Pyrraline ether crosslinks as a basis for protein crosslinking by the advanced Maillard reaction in aging and diabetes. Nagaraj RH, et al. **Arch Biochem Biophys** 1996 Jan 15; 325(2):152–8

Binding of myristoylated alanine–rich protein kinase C substrate to phosphoinositides attenuates the phosphorylation by protein kinase C. Seki K, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):193–201

Isolation and identification of a cAMP generating peptide from the flesh fly, Neobellieria bullata (Diptera: Sarcophagidae). Spittaels K, et al. **Arch Insect Biochem Physiol** 1996;31(2):135–47

The regulation of liver protein degradation by aminoacids in vivo. Effects of glutamine and leucine. Bergamini E, et al. **Arch Physiol Biochem** 1995 Aug;103(4):512–5

Quantitative partition of protein, carbohydrate and fat pools in growing pigs. Chwalibog A, et al. **Arch Tierernahr** 1995; 48(1–2):53–61

The nutritional significance of endogenous N–losses along the gastro–intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1–2):9–22 (44 ref.)

Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Rall LC, et al. **Arthritis Rheum** 1996 Jul;39(7):1115–24

Regenerated cellulose–based hemodialyzers with immobilized proteins as potential devices for extracorporeal immunoadsorption procedures: an assessment of protein coupling capacity and in vitro dialysis performances. Vallar L, et al. **Artif Organs** 1996 Jan;20(1):8–16

Protein catabolic rate determination from a single measurement of dialyzed urea. Garred LJ, et al. **ASAIO J** 1995 Jul–Sep;41(3):M804–9

Simple equations for protein catabolic rate determination from pre dialysis and post dialysis blood urea nitrogen. Garred LJ, et al. **ASAIO J** 1995 Oct–Dec;41(4):889–95

The liver response to in vivo heat shock involves the activation of MAP kinases and RAF and the tyrosine phosphorylation of Shc proteins. Bendinelli P, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):54–61

Reduced neurofibromin content but normal GAP activity in a patient with neurofibromatosis type 1 caused by a five base pair duplication in exon 12b of the NF1 gene. Böddrich A, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):895–904

Endothelin stimulates protein phosphorylation in blood–brain barrier. Catalán RE, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):366–9

The alpha–subunit of the mammalian guanine nucleotide–exchange factor eIF–2B is essential for catalytic activity in vitro. Craddock BL, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):843–7

Association of a 14–3–3 protein with CMP–NeuAc:GM1 alpha 2,3–sialyltransferase. Gao L, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):103–7

Tyrosine phosphorylation of a 94–kDa protein associated with GRB2/ASH is implicated in the signal transduction of hematopoietic survival factors. Hanazono Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):330–7

Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Hardie LJ, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):660–5

Development of radioimmunoassay for human leptin. Hosoda K, et al. **Biochem Biophys Res Commun** 1996 Apr 16; 221(2):234–9

Identification of cellular protein that can interact specifically with the basic helix–loop–helix domain of the aromatic hydrocarbon receptor. Hossain A, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):405–11

Truncated type II receptor for BMP–4 induces secondary axial structures in Xenopus embryos. Ishikawa T, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):26–33

Leptin receptors expressed on pancreatic beta–cells. Kieffer TJ, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):522–7

DAN gene product has an affinity for Ni2+. Kondo K, et al. **Biochem Biophys Res Commun** 1995 Nov 2; 216(1):209–15

gp300sca is not a high affinity Notch ligand. Lee EC, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):720–5

Macrophage–stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Li BQ, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):110–8

Phosphorylation of the proteasome activator PA28 is required for proteasome activation. Li N, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):855–60

Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice. Lynn RB, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):884–9

The uncoupling of Shc activation from distal intracellular signalling in a cell line which expresses a truncated human epidermal growth factor receptor. McNeil A, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):740–4

The signal modulator protein 14–3–3 is a target of sphingosine– or N,N–dimethylsphingosine–dependent kinase in 3T3(A31) cells. Megidish T, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):739–47

Proadrenomedullin N–terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Nagatomo Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):539–43

Proliferation and differentiation of PC12 cells were affected by p21ras GTPase activating proteins and its deletion mutant proteins. Nakata H, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):538–43

Suc1–associated neurotrophic factor target (SNT) protein is a major FGF–stimulated tyrosine phosphorylated 90–kDa protein which binds to the SH2 domain of GRB2. Ong SH, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):1021–6

Antibody against pulmonary surfactant protein A recognizes proteins in intestine and swim bladder of the freshwater fish, carp. Rubio S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):901–6

Polyprotein processing in echovirus 22: a first assessment. Schultheiss T, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1120–7

Allosteric activation of rabbit reticulocyte guanine nucleotide exchange factor activity by sugar phosphates and inositol phosphates. Singh LP, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):616–23

The interaction of rabbit reticulocyte guanine nucleotide exchange factor eIF–2B with chain initiation factor 2: studies with N–ethylmaleimide and trypsin. Singh LP, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):604–11

Nuclear location of the regulatory protein of glucokinase in rat liver and translocation of the regulator to the cytoplasm in response to high glucose. Toyoda Y, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):467–73

Interaction of the c–cbl proto–oncogene product with the Tyk–2 protein tyrosine kinase. Uddin S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):833–8

p66Shc isoform down–regulated and not required for HER–2/neu signaling pathway in human breast cancer cell lines with HER–2/neu overexpression. Xie Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):140–5

A cytosolic sperm factor triggers calcium oscillations in rat hepatocytes. Berrie CP, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):369–72

Characterization of the endopeptidase PC2 activity towards secretogranin II in stably transfected PC12 cells. Dittié AS, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):777–87

Biological fate of amino acid, peptide and protein hydroperoxides. Fu S, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):821–7

Interaction between tissue inhibitor of metalloproteinases–2 and progelatinase A: immunoreactivity analyses. Fujimoto N, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):827–33

Effect of channelling on the concentration of bulk–phase intermediates as cytosolic proteins become more concentrated. Kholodenko BN, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):921–6

Endothelial–cell–stimulating angiogenesis factor (ESAF) activates progelatinase A (72 kDa type IV collagenase), prostromelysin 1 and procollagenase and reactivates their complexes with tissue inhibitors of metalloproteinases: a role for ESAF in non–inflammatory angiogenesis. McLaughlin B, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):739–45

Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1–latency–associated peptide. McMahon GA, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):343–51

Interaction of Ash/Grb–2 via its SH3 domains with neuron–specific p150 and p65. Miura K, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):639–45

Isolation of InsP4 and InsP6 binding proteins from human platelets: InsP4 promotes Ca2+ efflux from inside–out plasma membrane vesicles containing 104 kDa GAP1IP4BP protein. O'Rourke F, et al. **Biochem J** 1996 May 1;315 (Pt 3):1027–34

Purification, cloning and expression of dehydroascorbic acid–reducing activity from human neutrophils: identification as glutaredoxin. Park JB, et al. **Biochem J** 1996 May 1;315 (Pt 3):931–8

Early events in erythroid differentiation: accumulation of the acidic peroxidoxin (PRP/TSA/NKEF–B). Rabilloud T, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):699–705

Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Rodríguez–Liñares B, et al. **Biochem J** 1996 May 15;316 (Pt 1):93–8

Identification of 14–3–3 proteins in human platelets: effects of synthetic peptides on protein kinase C activation. Wheeler–Jones CP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):41–7

Functional domain mapping using M13 deletions. Grammatikakis N, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):771–9

Multicatalytic proteinase activity in turtle liver: responses to anoxia stress and recovery. Willmore WG, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):445–51

Effects of benzophenanthridine alkaloids on the phosphorylation of an approximately 44 kDa protein present in a mitochondrial fraction of the rat heart. Lombardini JB, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):151–7

The MARCKS family of protein kinase–C substrates. Aderem A. **Biochem Soc Trans** 1995 Aug;23(3):587–91 (31 ref.)

Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592–6 (40 ref.)

Dynamic protein acylation and the regulation of localization and function of signal–transducing proteins. Jackson CS, et al. **Biochem Soc Trans** 1995 Aug;23(3):568–71 (40 ref.)

Demyristoylation of myristoylated alanine–rich C kinase substrate. Manenti S, et al. **Biochem Soc Trans** 1995 Aug; 23(3):561–4

Chronic effects of alcohol upon protein profiling in ventricular tissue. Patel VB, et al. **Biochem Soc Trans** 1995 Aug;23(3):461S

Molecular recognition by proteins: protein–ligand interactions from a structural perspective. Wallace AC, et al. **Biochem Soc Trans** 1996 Feb;24(1):280–4

The determinants of pKas in proteins. Antosiewicz J, et al.

Biochemistry 1996 Jun 18;35(24):7819–33

A 50 KDa protein modulates guanine nucleotide binding of transglutaminase II. Baek KJ, et al. **Biochemistry** 1996 Feb 27;35(8):2651–7

Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5'''-P1,P3-triphosphate hydrolase. Barnes LD, et al. **Biochemistry** 1996 Sep 10;35(36):11529–35

Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. Brinkmann U, et al. **Biochemistry** 1996 May 28;35(21):6891–9

The designed protein M(II)–Gly–Lys–His–Fos(138–211) specifically cleaves the AP–1 binding site containing DNA. Harford C, et al. **Biochemistry** 1996 Apr 9;35(14):4271–8

Characterization of electrostatic and nonelectrostatic components of protein—membrane binding interactions. Heymann JB, et al. **Biochemistry** 1996 Feb 27;35(8):2717–25

Kinetics of inorganic phosphate release during the interaction of p21ras with the GTPase–activating proteins, p120–GAP and neurofibromin. Nixon AE, et al. **Biochemistry** 1995 Nov 28;34(47):15592–8

Properties and regulation of the catalytic domain of Ira2p, a Saccharomyces cerevisiae GTPase–activating protein of Ras2p. Parrini MC, et al. **Biochemistry** 1995 Oct 24; 34(42):13776–83

Membrane structure of protein kinase C and calmodulin binding domain of myristoylated alanine rich C kinase substrate determined by site–directed spin labeling. Qin Z, et al. **Biochemistry** 1996 Mar 5;35(9):2917–25

Differential effects of ubiquitin aldehyde on ubiquitin and ATP–dependent protein degradation. Shaeffer JR, et al. **Biochemistry** 1996 Aug 20;35(33):10886–93

Modulation of rabbit reticulocyte guanine nucleotide exchange factor activity by casein kinases 1 and 2 and glycogen synthase kinase 3. Singh LP, et al. **Biochemistry** 1996 Mar 12;35(10):3206–12

Characterization of human platelet GTPase activating protein for the Ral GTP–binding protein. Bhullar RP, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):181–8

Distribution of A–kinase anchoring proteins in parietal cells. Dransfield DT, et al. **Biochim Biophys Acta** 1995 Nov 30; 1269(3):215–20

Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Gil ML, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):140–6

The secretory pathway: mechanisms of protein sorting and transport. Harter C, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):75–93 (276 ref.)

Effect of selenium on selenoprotein P expression in cultured liver cells. Hill KE, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):29–34

Transport of proteins across membranes—a paradigm in transition. Isenman L, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):341–70 (207 ref.)

Age–related changes in mRNA, protein and catalytic activity of hepatic neutral cholesterol ester hydrolase in male rats: evidence for transcriptional regulation. Natarajan R, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):153–8

Effect of diabetes on protein synthesis rate and eukaryotic initiation factor activities in the liver of virgin and pregnant rats. Garcia AM, et al. **Biol Neonate** 1996;69(1):37–50

Ribosomal 5S RNA: tertiary structure and interactions with proteins. Barciszewska MZ, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):1–25 (135 ref.)

Conditions which promote mineralization at the bone–implant interface: a model in vitro study. Dee KC, et al. **Biomaterials** 1996 Jan;17(2):209–15

Low–temperature heat–deproteinated compact bone to heal large bone defects. Guizzardi S, et al. **Biomaterials** 1995 Aug;16(12):931–6

Poly(alpha–hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187–94 (101 ref.)

Pesticidal impact on the protein metabolism of freshwater field crab, Oziotelphusa senex senex (Fabricius). Radhakrishnaiah K, et al. **Biomed Environ Sci** 1995 Jun; 8(2):137–48

Conformational changes of small molecules binding to proteins. Nicklaus MC, et al. **Bioorg Med Chem** 1995 Apr; 3(4):411–28

Energetics of protein–DNA interactions: an exact calculation for binding of ligands to a lattice of overlapping sites. Saroff HA. **Biopolymers** 1995 Aug;36(2):121–34

Salt effects on polyelectrolyte–ligand binding: comparison of Poisson–Boltzmann, and limiting law/counterion binding models. Sharp KA, et al. **Biopolymers** 1995 Aug; 36(2):245–62

Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome–positive acute lymphoblastic leukemia [letter] Kanwar VS, et al. **Blood** 1996 Jun 1; 87(11):4911–2

CD43 regulates tyrosine phosphorylation of a 93–kD protein in T lymphocytes. Manjunath N, et al. **Blood** 1995 Dec 1;86(11):4194–8

Colony–stimulating factor 1–induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Novak U, et al. **Blood** 1995 Oct 15;86(8):2948–56

Characterization of Grb2–binding proteins in human platelets activated by Fc gamma RIIA cross–linking. Robinson A, et al. **Blood** 1996 Jul 15;88(2):522–30

Granulomonocyte–associated lysosomal protein expression during in vitro expansion and differentiation of CD34+ hematopoietic progenitor cells. Scheinecker C, et al. **Blood** 1995 Dec 1;86(11):4115–23

Glucocorticoids decrease the production of parathyroid hormone–related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model. Schilling T, et al. **Bone** 1996 Apr;18(4):315–9

Measurement of protein turnover in normal man using the end–product method with oral [15N]glycine: comparison of single–dose and intermittent–dose regimens. Grove G, et al. **Br J Nutr** 1995 Oct;74(4):491–507

Changes in protein distribution in normal and protein–deficient rats during an acute–phase 'injury' response. Jennings G, et al. **Br J Nutr** 1996 Jul;76(1):123–32

The influence of dietary fibre and environmental temperature on the development of the gastrointestinal tract, digestibility, degree of fermentation in the hind–gut and energy metabolism in pigs. Jørgensen H, et al. **Br J Nutr** 1996 Mar;75(3):365–78

Protein turnover rates of two human subjects during an unassisted crossing of Antarctica. Stroud MA, et al. **Br J Nutr** 1996 Aug;76(2):165–74

Effect of aldrin on carbohydrate, protein, and ionic metabolism of a freshwater catfish, Heteropneustes fossilis. Singh NN, et al. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):204–10

Membrane and cytosolic protein phosphorylation patterns in the early stages of DEN–induced hepatocarcinogenesis in rats fed a high or low protein diet. La Porta CA, et al. **Cancer Lett** 1995 Nov 6;97(2):217–23

Tumor target binding induces phosphorylation of two M(r) 65,000 lymphokine–activated killer proteins. Frederick MJ, et al. **Cancer Res** 1996 Jan 1;56(1):127–37

Prognostic significance of circulating matrix metalloproteinase–2 to tissue inhibitor of metalloproteinases–2 ratio in recurrence of urothelial cancer after complete resection. Gohji K, et al. **Cancer Res** 1996 Jul 15;56(14):3196–8

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase–deficient cells. Kelner MJ, et al. **Cancer Res** 1995 Nov 1;55(21):4936–40

Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Li Y, et al. **Cancer Res** 1996 Jun 15;56(12):2872–6

Grb10: A new substrate of the insulin–like growth factor I receptor. Morrione A, et al. **Cancer Res** 1996 Jul 15; 56(14):3165–7

Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Shimoyama S, et al. **Cancer Res** 1996 Jun 15;56(12):2703–6

Identification of a novel protein (VBP–1) binding to the von Hippel–Lindau (VHL) tumor suppressor gene product. Tsuchiya H, et al. **Cancer Res** 1996 Jul 1;56(13):2881–5

Pyrrolizidine alkaloid–induced DNA–protein cross–links. Kim HY, et al. **Carcinogenesis** 1995 Nov;16(11):2691–7

DNA—protein crosslinks, a biomarker of exposure to formaldehyde—in vitro and in vivo studies. Shaham J, et al. **Carcinogenesis** 1996 Jan;17(1):121–5

Angiotensin–II–induced increase in transcoronary protein clearance: role of hypertension vs. nitric oxide or cyclo–oxygenase products. Sigusch HH, et al. **Cardiovasc Res** 1995 Aug;30(2):291–8

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Chen H, et al. **Cell** 1996 Feb 9;84(3):491–5

Peptide–surface association: the case of PDZ and PTB domains. Harrison SC. **Cell** 1996 Aug 9;86(3):341–3 (17 ref.)

Protein degradation or regulation: Ub the judge. Hochstrasser M. **Cell** 1996 Mar 22;84(6):813–5 (15 ref.)

Selective protein degradation: a journey's end within the proteasome. Jentsch S, et al. **Cell** 1995 Sep 22;82(6):881–4 (22 ref.)

Mei–S332, a Drosophila protein required for sister–chromatid cohesion, can localize to meiotic centromere regions [see comments] Kerrebrock AW, et al. **Cell** 1995 Oct 20; 83(2):247–56. Comment in: Cell 1995 Oct 20;83(2):157–60.

Interaction of 14–3–3 with signaling proteins is mediated by the recognition of phosphoserine. Muslin AJ, et al. **Cell** 1996 Mar 22;84(6):889–97

Wiskott–Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Symons M, et al. **Cell** 1996 Mar 8;84(5):723–34

Osmotic effects of water compartments in protein polymers. Lew VL, et al. **Cell Biochem Funct** 1995 Sep;13(3):173–6 (15 ref.)

The PH domain of Ras–GAP is sufficient for in vitro binding to beta gamma subunits of heterotrimeric G proteins. Xu N, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):51–9

Phosphorylation of MARCKS, neuromodulin, and neurogranin by protein kinase C exhibits differential responses to diacylglycerols. Mahoney CW, et al. **Cell Signal** 1995 Sep;7(7):679–85

Characterization of the molecular and structural properties of the transformed and nuclear aryl hydrocarbon (Ah) receptor complexes by proteolytic digestion. Santostefano M, et al. **Chem Biol Interact** 1996 May 6;100(3):221–40

Bromobenzene 3,4–oxide alkylates histidine and lysine side chains of rat liver proteins in vivo. Bambal RB, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):729–35

Direct characterization of protein adducts of the lipid peroxidation product 4–hydroxy–2–nonenal using electrospray mass spectrometry. Bruenner BA, et al. **Chem Res Toxicol** 1995 Jun;8(4):552–9

Inhibition of 2,5–hexanedione–induced protein cross–linking by biological thiols: chemical mechanisms and toxicological implications. Zhu M, et al. **Chem Res Toxicol** 1995 Jul–Aug; 8(5):764–71

Plasma concentrations of atrial, brain, and C–type natriuretic peptides and endothelin–1 in patients with chronic respiratory diseases. Ando T, et al. **Chest** 1996 Aug; 110(2):462–8

Preferential depletion of selenoprotein P in hypercholesterolaemic patients treated by LDL–apheresis. Persson–Moschos M, et al. **Clin Chim Acta** 1995 Sep 15; 240(2):209–12

Plasma parathyroid hormone related–protein levels in patients with cancer, normocalcemic and hypercalcemic. Segura Domínguez A, et al. **Clin Chim Acta** 1996 Jan 31; 244(2):163–72

Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Davies SJ, et al. **Clin Nephrol** 1996 Mar;45(3):194–8

Bed rest decreases whole–body protein turnover in post–absorptive man. Bettany GE, et al. **Clin Sci (Colch)** 1996 Jan;90(1):73–5

Proteins of the 14–3–3 family associate with Raf and contribute to its activation. Freed E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:187–93 (45 ref.)

Storage proteins in ants (Hymenoptera:Formicidae). Wheeler DE, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep;112(1):15–9 (41 ref.)

Oxidative damage of glycated protein. Cheng RZ, et al. **Contrib Nephrol** 1995;112:11–7

Crosslines, fluorophores in the AGE–related cross–linked proteins. Ienaga K, et al. **Contrib Nephrol** 1995;112:42–51 (14 ref.)

Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Remuzzi G, et al. **Contrib Nephrol** 1996;118:164–72 (66 ref.)

Formation of methylglyoxal–modified proteins in vitro and in vivo and their involvement in AGE–related processes. Thornalley PJ, et al. **Contrib Nephrol** 1995;112:24–31 (31 ref.)

Inspired oxygen concentration alters the phospholipids and protein content in the bronchoalveolar lavage–accessible space. Godinez MH, et al. **Crit Care Med** 1996 May; 24(5):862–9

Protein–protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119–21 (21 ref.)

Patterning activities of vertebrate hedgehog proteins in the developing eye and brain. Ekker SC, et al. **Curr Biol** 1995 Aug 1;5(8):944–55

Molecular chaperones. Resurrection or destruction? Horwich AL. **Curr Biol** 1995 May 1;5(5):455–8 (26 ref.)

Protein translocation: nuclear export—out of the dark. Moore MS. **Curr Biol** 1996 Feb 1;6(2):137–40 (20 ref.)

Proteolysis. The proteasome: a protein–degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)

Genetic and biochemical dissection of the mitochondrial protein–import machinery. Kübrich M, et al. **Curr Genet** 1995 Apr;27(5):393–403 (110 ref.)

New protease mutants in Aspergillus niger result in strongly reduced in vitro degradation of target proteins; genetical and biochemical characterization of seven complementation groups. van den Hombergh JP, et al. **Curr Genet** 1995 Sep;28(4):299–308

Current computational tools for de novo ligand design. Böhm HJ. **Curr Opin Biotechnol** 1996 Aug;7(4):433–6 (61 ref.)

Membranes and sorting. **Curr Opin Cell Biol** 1996 Aug; 8(4):586–98

Quality control in the secretory pathway. Hammond C, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):523–9 (98 ref.)

Biogenesis of mitochondrial proteins. Lill R, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):505–12 (62 ref.)

Membranes and sorting [editorial] Mellman I. **Curr Opin Cell Biol** 1996 Aug;8(4):497–8

Approaching the mechanism of protein transport across the ER membrane. Rapoport TA, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):499–504 (53 ref.)

Convergence of model systems for peroxisome biogenesis. Subramani S. **Curr Opin Cell Biol** 1996 Aug;8(4):513–8 (52 ref.)

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)

Uremic acidosis and protein metabolism. Mitch WE. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):488–92 (41 ref.)

Stretch–induced parathyroid hormone–related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383–7 (23 ref.)

Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury [editorial] Remuzzi G. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):339–42 (20 ref.)

Proteins that interact with the pore–forming subunits of voltage–gated ion channels. Adelman JP. **Curr Opin Neurobiol** 1995 Jun;5(3):286–95 (83 ref.)

Protein–nucleic acid interactions. **Curr Opin Struct Biol** 1996 Feb;6(1):127–37

Molecular chaperones in protein folding and translocation. Clarke AR. **Curr Opin Struct Biol** 1996 Feb;6(1):43–50 (73 ref.)

Mechanisms and uses of hydrogen exchange. Englander SW, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):18–23 (92 ref.)

RNA–protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53–61 (60 ref.)

Engineering new functions and altering existing functions. Shao Z, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):513–8 (52 ref.)

Novel adapter proteins that link the human GM-CSF receptor to the phosphatidylino–sitol 3–kinase and Shc/Grb2/ras signaling pathways. Jücker M, et al. **Curr Top Microbiol Immunol** 1996;211:67–75

Hensen's node from vitamin A–deficient quail embryo induces chick limb bud duplication and retains its normal asymmetric expression of Sonic hedgehog (Shh). Chen Y, et al. **Dev Biol** 1996 Jan 10;173(1):256–64

Analysis of Wnt/Engrailed signaling in Xenopus embryos using biolistics. Koster JG, et al. **Dev Biol** 1996 Jan 10; 173(1):348–52

Ubiquitin–protein conjugates selectively distribute during early chicken embryogenesis. Wunsch AM, et al. **Dev Dyn** 1995 Oct;204(2):118–32

Ventral mesodermal patterning in Xenopus embryos: expression patterns and activities of BMP–2 and BMP–4. Hemmati–Brivanlou A, et al. **Dev Genet** 1995;17(1):78–89

BMP–like signals are required after the midblastula transition for blood cell development. Zhang C, et al. **Dev Genet** 1996;18(3):267–78

Cooperative interactions between extracellular matrix, integrins and parathyroid hormone–related peptide regulate parietal endoderm differentiation in mouse embryos. Behrendtsen O, et al. **Development** 1995 Dec; 121(12):4137–48

Evidence that Shh cooperates with a retinoic acid inducible co–factor to establish ZPA–like activity. Ogura T, et al. **Development** 1996 Feb;122(2):537–42

Plasma leptin and insulin relationships in obese and nonobese humans. Dagogo–Jack S, et al. **Diabetes** 1996 May; 45(5):695–8

Differential responsiveness of protein synthesis and degradation to amino acid availability in humans. Giordano M, et al. **Diabetes** 1996 Apr;45(4):393–9

Leptin concentrations in diabetic and nondiabetic Mexican–Americans. Haffner SM, et al. **Diabetes** 1996 Jun; 45(6):822–4

Adipose tissue leptin production and plasma leptin kinetics in humans. Klein S, et al. **Diabetes** 1996 Jul;45(7):984–7

Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Segal KR, et al. **Diabetes** 1996 Jul;45(7):988–91

Contribution of amino acids and insulin to protein anabolism during meal absorption. Volpi E, et al. **Diabetes** 1996 Sep; 45(9):1245–52

Islet transplantation reverses carcass protein loss in diabetic rats without inducing disproportionate fat accumulation. Tobin BW, et al. **Diabetologia** 1995 Aug;38(8):881–8

Lysophosphatidylcholine–stimulated protein and glycoprotein production by human gallbladder mucosal cells. Nag MK, et al. **Dig Dis Sci** 1995 Sep;40(9):1990–6

Measurement of gastric and duodenal mucosal protein turnover in humans. O'Keefe SJ. **Dig Dis Sci** 1995 Nov; 40(11):2465–8

Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase–inactive p185c–neu. Dougall WC, et al. **DNA Cell Biol** 1996 Jan;15(1):31–40

Spermatocytes and round spermatids of rat testis: protein patterns. Cossio G, et al. **Electrophoresis** 1995 Jul; 16(7):1225–30

The protein disease database. Lemkin PF, et al. **Electrophoresis** 1995 Jul;16(7):1175

The specificity of association of the IgD molecule with the accessory proteins BAP31/BAP29 lies in the IgD transmembrane sequence. Adachi T, et al. **EMBO J** 1996 Apr 1;15(7):1534–41

Bcr and Raf form a complex in vivo via 14–3–3 proteins. Braselmann S, et al. **EMBO J** 1995 Oct 2;14(19):4839–48

Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein–coupled thrombin receptor. Chen Y, et al. **EMBO J** 1996 Mar 1;15(5):1037–44

Tight association of GRB2 with receptor protein–tyrosine phosphatase alpha is mediated by the SH2 and C–terminal SH3 domains. den Hertog J, et al. **EMBO J** 1996 Jun 17; 15(12):3016–27

Rac GTPase interacts with GAPs and target proteins through multiple effector sites. Diekmann D, et al. **EMBO J** 1995 Nov 1;14(21):5297–305

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron–sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Rom1p and Rom2p are GDP/GTP exchange proteins (GEPs) for the Rho1p small GTP binding protein in Saccharomyces cerevisiae. Ozaki K, et al. **EMBO J** 1996 May 1;15(9):2196–207

Drosophila Polycomb–group regulated chromatin inhibits the accessibility of a trans–activator to its target DNA. Zink D, et al. **EMBO J** 1995 Nov 15;14(22):5660–71

ACTH–dependent proteolytic activity of a novel phosphoprotein (p43) intermediary in the activation of phospholipase A2 and steroidogenesis. Cymeryng CB, et al. **Endocr Res** 1995 Feb–May;21(1–2):281–8

Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate–1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Chow JC, et al. **Endocrinology** 1996 Jul; 137(7):2880–6

Elimination of the carboxy–terminal sequences of parathyroid hormone–related protein 1–173 increases production and secretion of the truncated forms. Ditmer LS, et al. **Endocrinology** 1996 May;137(5):1608–17

Specific binding sites for proadrenomedullin N–terminal 20 peptide (PAMP) in the rat. Iwasaki H, et al. **Endocrinology** 1996 Jul;137(7):3045–50

Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice. Malik KF, et al. **Endocrinology** 1996 Apr;137(4):1497–500

Evidence that type III iodothyronine deiodinase in rat astrocyte is a selenoprotein. Ramauge M, et al. **Endocrinology** 1996 Jul;137(7):3021–5

Estrogen regulates the stage–specific expression of kidney androgen–regulated protein in rat uterus during reproductive cycle and pregnancy. Runic R, et al. **Endocrinology** 1996 Feb;137(2):729–37

Angiotensin II–dependent down–regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Yoshimoto T, et al. **Endocrinology** 1996 Mar;137(3):1102–7

A 60–kilodalton protein in rat hepatoma cells overexpressing insulin receptor was tyrosine phosphorylated and associated with Syp, phophatidylinositol 3–kinase, and Grb2 in an insulin–dependent manner [see comments] Zhang–Sun G, et al. **Endocrinology** 1996 Jul;137(7):2649–58 . Comment in: Endocrinology 1996 Jul;137(7):2647–8.

Characterization of the first enzyme in 2,4–dichlorophenoxyacetic acid metabolism. Hausinger RP, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:37–9 (8 ref.)

Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor–2. Singh LP, et al. **Enzyme Protein** 1994–95; 48(2):61–80 (101 ref.)

Polymerization of 5,6–dihydroxyindole–2–carboxylic acid to melanin by the pmel 17/silver locus protein. Chakraborty AK, et al. **Eur J Biochem** 1996 Feb 15;236(1):180–8

Isolation from spleen of a 57–kDa protein substrate of the tyrosine kinase Lyn. Identification as a protein related to protein disulfide–isomerase and localisation of the phosphorylation sites. Donella–Deana A, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):18–25

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL–37 in granulocytes. Gudmundsson GH, et al. **Eur J Biochem** 1996 Jun 1;238(2):325–32

A receptor for the import of proteins into human mitochondria. Hanson B, et al. **Eur J Biochem** 1996 Feb 1;235(3):750–3

The molecular biology of multidomain proteins. Selected examples. Hawkins AR, et al. **Eur J Biochem** 1995 Aug 15;232(1):7–18 (147 ref.)

The myristoylated alanine–rich C–kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C. Herget T, et al. **Eur J Biochem** 1995 Oct 15; 233(2):448–57

The proteasome subunit, C2, contains an important site for binding of the PA28 (11S) activator. Kania MA, et al. **Eur J Biochem** 1996 Mar 1;236(2):510–6

Biosynthetically directed fractional 13C–labeling of proteinogenic amino acids. An efficient analytical tool to investigate intermediary metabolism. Szyperski T. **Eur J Biochem** 1995 Sep 1;232(2):433–48

In vitro activation of the NADPH oxidase by fluoride. Possible involvement of a factor activating GTP hydrolysis on Rac (Rac–GAP). Wölfl J, et al. **Eur J Biochem** 1996 Jul 15;239(2):369–75

Differential response of resident proteins and cycling proteins of the Golgi to brefeldin A. Tang BL, et al. **Eur J Cell Biol** 1995 Oct;68(2):199–205

The effect of recombinant human IGF–I on protein metabolism in post–operative patients without nutrition compared to effects in experimental animals. Sandström R, et al. **Eur J Clin Invest** 1995 Oct;25(10):784–92

Von Hippel–Lindau tumor suppressor protein and transcription elongation: new insights into regulation of gene expression. Bertherat J. **Eur J Endocrinol** 1996 Feb; 134(2):157, 159 (2 ref.)

A third interferon–gamma–induced subunit exchange in the 20S proteasome. Groettrup M, et al. **Eur J Immunol** 1996 Apr;26(4):863–9

Interleukin–6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP–1. Neumann C, et al. **Eur J Immunol** 1996 Feb;26(2):379–84

Immunoreactive parathyroid hormone–related protein: its association with preterm labor. Ramirez MM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):21–6

Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Jorens PG, et al. **Eur Respir J** 1995 Oct;8(10):1647–53

Oxidized BAL fluid proteins in patients with interstitial lung diseases. Lenz AG, et al. **Eur Respir J** 1996 Feb;9(2):307–12

Protein 1 (Clara cell protein) serum levels in lung cancer patients receiving chemotherapy. Nomori H, et al. **Eur Respir J** 1995 Oct;8(10):1654–7

Roles of XPG and XPF/ERCC1 endonucleases in UV–induced immunostaining of PCNA in fibroblasts. Miura M, et al. **Exp Cell Res** 1996 Jul 10;226(1):126–32

Synthesis, modifications, and turnover of proteins during aging. Rattan SI. **Exp Gerontol** 1996 Jan–Apr;31(1–2):33–47 (88 ref.)

DNA–protein interaction sites in differentiating cells. I. Two–dimensional mapping of modulated sites. Parkes V, et al. **Exp Hematol** 1996 Feb;24(3):466–74

Protein sorting signals: simple peptides with complex functions. von Heijne G. **EXS** 1995;73:67–76 (57 ref.)

Glucagon stimulates phosphorylation of different peptides in isolated periportal and perivenous hepatocytes. Aggarwal SR, et al. **FEBS Lett** 1995 Dec 27;377(3):439–43

Endosomal proteolysis of internalized proteins. Authier F, et al. **FEBS Lett** 1996 Jun 24;389(1):55–60 (55 ref.)

A20, an inhibitor of cell death, self–associates by its zinc finger domain. De Valck D, et al. **FEBS Lett** 1996 Apr 8;384(1):61–4

Thrombopoietin, c–Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists–induced aggregation in platelets in vitro. Ezumi Y, et al. **FEBS Lett** 1995 Oct 23;374(1):48–52

Amino acid residue: is it structural or functional? Golovanov AP, et al. **FEBS Lett** 1995 Nov 13;375(1–2):162–6

Effects of peroxynitrite–induced protein modifications on tyrosine phosphorylation and degradation. Gow AJ, et al. **FEBS Lett** 1996 Apr 29;385(1–2):63–6

Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP–dependent protein kinase. Izawa I, et al. **FEBS Lett** 1996 Mar 11;382(1–2):53–9

Antimicrobial activity of a 13 amino acid tryptophan–rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides. Lawyer C, et al. **FEBS Lett** 1996 Jul 15;390(1):95–8

A novel partner for the GTP–bound forms of rho and rac. Madaule P, et al. **FEBS Lett** 1995 Dec 18;377(2):243–8

Deletion of the ABL SH3 domain reactivates de–oligomerized BCR–ABL for growth factor independence. Maru Y, et al. **FEBS Lett** 1996 Feb 5; 379(3):244–6

Characterization of a high–affinity and specific binding site for Gas6. Nakano T, et al. **FEBS Lett** 1996 May 27; 387(1):75–7

PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and serine 163. Palmer RH, et al. **FEBS Lett** 1996 Jan 15;378(3):281–5

Protein import into the nucleus. Schlenstedt G. **FEBS Lett** 1996 Jun 24;389(1):75–9 (89 ref.)

Gastrin induces tyrosine phosphorylation of Shc proteins and their association with the Grb2/Sos complex. Seva C, et al. **FEBS Lett** 1996 Jan 2;378(1):74–8

Human lymphoblast and erythrocyte multicatalytic proteases: differential peptidase activities and responses to the 11S regulator. Ustrell V, et al. **FEBS Lett** 1995 Dec 4; 376(3):155–8

A novel two–site binding equation presented in terms of the total ligand concentration. Wang ZX, et al. **FEBS Lett** 1996 Sep 2;392(3):245–9

Formation of DNA–protein cross–links in cultured mammalian cells upon treatment with iron ions. Altman SA, et al. **Free Radic Biol Med** 1995 Dec;19(6):897–902

Endogenous ubiquinol prevents protein modification accompanying lipid peroxidation in beef heart submitochondrial particles. Forsmark–Andrée P, et al. **Free Radic Biol Med** 1995 Dec;19(6):749–57

Mitochondrial superoxide and hydrogen peroxide generation, protein oxidative damage, and longevity in different species of flies. Sohal RS, et al. **Free Radic Biol Med** 1995 Oct; 19(4):499–504

Effects of caloric restriction on age–related oxidative modifications of macromolecules and lymphocyte proliferation in rats. Tian L, et al. **Free Radic Biol Med** 1995 Dec;19(6):859–65

Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Benyon RC, et al. **Gastroenterology** 1996 Mar;110(3):821–31

Shc is a substrate of the rat intestinal epidermal growth factor receptor tyrosine kinase. Polk DB. **Gastroenterology** 1995 Dec;109(6):1845–51

Ursodeoxycholic acid reduces protein levels and nucleation–promoting activity in human gallbladder bile. Van Erpecum KJ, et al. **Gastroenterology** 1996 Apr; 110(4):1225–37

Immunochemical detection of parathyroid hormone–related protein in the saccus vasculosus of a teleost fish. Devlin AJ, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):83–90

Cloning and expression of the murine Elf–1 cDNA. Davis JN, et al. **Gene** 1996 Jun 1;171(2):265–9

A requirement for bone morphogenetic protein–7 during development of the mammalian kidney and eye. Dudley AT, et al. **Genes Dev** 1995 Nov 15;9(22):2795–807

Protein kinase A is a common negative regulator of Hedgehog signaling in the vertebrate embryo. Hammerschmidt M, et al. **Genes Dev** 1996 Mar 15; 10(6):647–58

BMP–7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Luo G, et

al. **Genes Dev** 1995 Nov 15;9(22):2808–20
The XPB and XPD DNA helicases are components of the p53–mediated apoptosis pathway. Wang XW, et al. **Genes Dev** 1996 May 15;10(10):1219–32
The HCF repeat is an unusual proteolytic cleavage signal. Wilson AC, et al. **Genes Dev** 1995 Oct 15;9(20):2445–58
The differential contribution by individual enzymes of glycolysis and protein catabolism to the relationship between heterozygosity and growth rate in the coot clam, Mulinia lateralis. Koehn RK, et al. **Genetics** 1988 Jan; 118(1):121–30
Serum levels of androgens and estrogens and 'steroid–sensitive' liver proteins in early human pregnancy: influence on the gender of the offspring. Skjöldebrand Sparre L, et al. **Gynecol Obstet Invest** 1995;40(3):145–50
Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Terada T, et al. **Hepatology** 1996 Jun;23(6):1341–4
Immunohistochemical detection of secretoneurin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues. Schmid KW, et al. **Histochem J** 1995 Jun; 27(6):473–81
Immunohistochemical detection of parathyroid hormone–related protein in a rare variant of hepatic neoplasm (sclerosing hepatic carcinoma). Albar JP, et al. **Hum Pathol** 1996 Jul;27(7):728–31
Human endometrial proteins with cyclic changes in the expression during the normal menstrual cycle: characterization by protein sequence analysis. Byrjalsen I, et al. **Hum Reprod** 1995 Oct;10(10):2760–6
TNF–dependent recruitment of the protein kinase RIP to the TNF receptor–1 signaling complex. Hsu H, et al. **Immunity** 1996 Apr;4(4):387–96
Localization, interaction, and RNA binding properties of the V(D)J recombination–activating proteins RAG1 and RAG2. Spanopoulou E, et al. **Immunity** 1995 Dec; 3(6):715–26
Histidine–rich glycoprotein binding to T–cell lines and its effect on T–cell substratum adhesion is strongly potentiated by zinc. Olsen HM, et al. **Immunology** 1996 Jun; 88(2):198–206
Increase in total protein following infection of CV–1 cells with SV40 virus as assayed by flow cytometry. Lehman JM, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):806–10
Characterization of human and rat immortalized clones parotid acinar cells with respect to specific proteins and their mRNAs, and receptor–linked adenylate cyclase. Prasad KN, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):767–72
Factors affecting nPCR in hemodialysed patients. Di Iorio B, et al. **Int J Artif Organs** 1995 Apr;18(4):181–9
Inhibition of processing of parathyroid hormone–related peptide by anti–sense furin: effect in vitro and in vivo on rat Leydig (H–500) tumor cells. Liu B, et al. **Int J Cancer** 1995 Oct 9;63(2):276–81
Inhibition of protein kinase C–dependent protein phosphorylation correlates with increased polarity and locomotion in Walker 256 carcinosarcoma cells. Niggli V, et al. **Int J Cancer** 1996 Feb 8;65(4):473–8
Does serum albumin/phospholipid index better reflect overall protein status in man? Ogunkeye OO, et al. **Int J Food Sci Nutr** 1996 May;47(3):209–11
Whole–body protein turnover in obese subjects during two very low energy diets of differing amino acid composition. Gougeon R, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19(10):739–48
ERCC1/ERCC4 5'–endonuclease activity as a determinant of hypoxic cell radiosensitivity. Murray D, et al. **Int J Radiat Biol** 1996 Mar;69(3):319–27
Proteolytic activity directed toward pigment epithelium–derived factor in vitreous of bovine eyes. Implications of proteolytic processing. Wu YQ, et al. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):1984–93
Characterizing oriented protein structural sites using biochemical properties. Bagley SC, et al. **Ismb** 1995;3:12–20
Constituting a receptor–ligand information base from quality–enriched data. Hemm K, et al. **Ismb** 1995;3:170–8
Time–efficient docking of flexible ligands into active sites of proteins. Rarey M, et al. **Ismb** 1995;3:300–8
Solvent accessible surface representation in a database system for protein docking. Seidl T, et al. **Ismb** 1995;3:350–8
Protein and lipid accretion in body components of growing gilts (20 to 45 kilograms) as affected by energy intake. Bikker P, et al. **J Anim Sci** 1995 Aug;73(8):2355–63
Performance and body composition of finishing gilts (45 to 85 kilograms) as affected by energy intake and nutrition in earlier life: II. Protein and lipid accretion in body components. Bikker P, et al. **J Anim Sci** 1996 Apr; 74(4):817–26
Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226–44 (126 ref.)
Prediction of daily protein accretion rates of pigs from estimates of fat–free lean gain between 20 and 120 kilograms live weight [published erratum appears in J Anim Sci 1996 May;74(5):1182] Schinckel AP, et al. **J Anim Sci** 1996 Mar;74(3):498–503
Effects of maturation on cell water, protein, and DNA content in ovine cerebral arteries. Elliott CF, et al. **J Appl Physiol** 1995 Sep;79(3):831–7
A method for in vivo [32P]phosphate labelling of testis proteins. Kundu TK, et al. **J Biochem Biophys Methods** 1995 Jun;30(2–3):185–9
A novel protein phosphatase–1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. Eto M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1104–7
Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)
Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)
Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha–catenin. Aberle H, et al. **J Biol Chem** 1996 Jan 19;271(3):1520–6
Structural differences in the minimal catalytic domains of the GTPase–activating proteins p120GAP and neurofibromin. Ahmadian MR, et al. **J Biol Chem** 1996 Jul 5;271(27):16409–15
In vivo characterization of the proteasome regulator PA28. Ahn K, et al. **J Biol Chem** 1996 Jul 26;271(30):18237–42
Cloning of cockroach allergen, Bla g 4, identifies ligand binding proteins (or calycins) as a cause of IgE antibody responses. Arruda LK, et al. **J Biol Chem** 1995 Dec 29; 270(52):31196–201
A mutation at tyrosine 1062 in MEN2A–Ret and MEN2B–Ret impairs their transforming activity and association with shc adaptor proteins. Asai N, et al. **J Biol Chem** 1996 Jul 26;271(30):17644–9
The role of the C–terminal domain of I kappa B alpha in protein degradation and stabilization. Beauparlant P, et al. **J Biol Chem** 1996 May 3;271(18):10690–6
The Ras–related GTPase Rac1 binds tubulin. Best A, et al. **J Biol Chem** 1996 Feb 16;271(7):3756–62
N–terminal sequences contained in the Src homology 2 and 3 domains of p120 GTPase–activating protein are required for full catalytic activity toward Ras. Bryant SS, et al. **J Biol Chem** 1996 Mar 1;271(9):5195–9
Interactions of Cbl with two adapter proteins, ?Grb2 and Crk, upon T cell activation. Buday L, et al. **J Biol Chem** 1996 Mar 15;271(11):6159–63
p190–B, a new member of the Rho GAP family, and Rho are induced to cluster after integrin cross–linking. Burbelo PD, et al. **J Biol Chem** 1995 Dec 29;270(52):30919–26
Ca2+ x calmodulin prevents myristoylated alanine–rich kinase C substrate protein phosphorylation by protein kinase Cs in C6 rat glioma cells. Chakravarthy BR, et al. **J Biol Chem** 1995 Oct 20;270(42):24911–6
Stimulus–dependent phosphorylation of MacMARCKS, a protein kinase C substrate, in nerve termini and PC12 cells. Chang S, et al. **J Biol Chem** 1996 Jan 12;271(2):1174–8
Phosphotyrosine–independent binding of SHC to the NPLH sequence of murine protein–tyrosine phosphatase–PEST. Evidence for extended phosphotyrosine binding/phosphotyrosine interaction domain recognition specificity. Charest A, et al. **J Biol Chem** 1996 Apr 5; 271(14):8424–9
A20 blocks endothelial cell activation through a NF–kappaB–dependent mechanism. Cooper JT, et al. **J Biol Chem** 1996 Jul 26;271(30):18068–73
Distal switch II region of Ras2p is required for interaction with guanine nucleotide exchange factor. Créchet JB, et al. **J Biol Chem** 1996 Jul 19;271(29):17234–40
Identification, purification, and characterization of a PA700–dependent activator of the proteasome. DeMartino GN, et al. **J Biol Chem** 1996 Feb 9;271(6):3112–8
SOS phosphorylation and disassociation of the Grb2–SOS complex by the ERK and JNK signaling pathways. Dong Chen, et al. **J Biol Chem** 1996 Mar 15;271(11):6328–32
Identification of a binding sequence for the 14–3–3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Ib alpha. Du X, et al. **J Biol Chem** 1996 Mar 29;271(13):7362–7
ICE–LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced–3 is activated during Fas– and tumor necrosis factor–induced apoptosis. Duan H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1621–5
Analysis of interleukin–2–dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin–2–dependent mitogenesis does not require Shc phosphorylation or receptor association. Evans GA, et al. **J Biol Chem** 1995 Dec 1;270(48):28858–63
Thiol–disulfide exchange of ribonuclease inhibitor bound to ribonuclease A. Evidence of active inhibitor–bound ribonuclease. Ferreras M, et al. **J Biol Chem** 1995 Dec 1; 270(48):28570–8
The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin–like activity of the bovine pituitary 20 S proteasome. Figueiredo–Pereira ME, et al. **J Biol Chem** 1996 Jul 12;271(28):16455–9
Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr–Met oncoprotein. Fixman ED, et al. **J Biol Chem** 1996 May 31;271(22):13116–22
Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase. Fournier E, et al. **J Biol Chem** 1996 May 31;271(22):12956–63
Branching tubulogenesis but not scatter of madin–darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. Fournier TM, et al. **J Biol Chem** 1996 Sep 6;271(36):22211–7
Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. Fukazawa T, et al. **J Biol Chem** 1996 Jun 14;271(24):14554–9
Structure–function relationships of the mouse Gap1m. Determination of the inositol 1,3,4,5–tetrakisphosphate–binding domain. Fukuda M, et al. **J Biol Chem** 1996 Aug 2;271(31):18838–42
Interferon–alpha–dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. Gauzzi MC, et al. **J Biol Chem** 1996 Aug 23; 271(34):20494–500
Cloning of a putative ligand for the T1/ST2 receptor. Gayle MA, et al. **J Biol Chem** 1996 Mar 8;271(10):5784–9
CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor–associated factor family of signal transducing proteins. Gedrich RW, et al. **J Biol Chem** 1996 May 31; 271(22):12852–8
Glucose stimulates the activity of the guanine nucleotide–exchange factor eIF–2B in isolated rat islets of Langerhans. Gilligan M, et al. **J Biol Chem** 1996 Jan 26; 271(4):2121–5
Differential storage of prolactin, granins (Chromogranin B and secretogranin II), and constitutive secretory markers in rat pituitary GH4C1 cells. Gorr SU. **J Biol Chem** 1996 Feb 16;271(7):3575–80
The interferon–gamma–inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. Groettrup M, et al. **J Biol Chem** 1995 Oct 6;270(40):23808–15
Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. Grune T, et al. **J Biol Chem** 1996 Jun 28;271(26):15504–9
Identification of a second functional glutaredoxin encoded by the bacteriophage T4 genome. Gvakharia BO, et al. **J Biol Chem** 1996 Jun 28;271(26):15307–10
Exons lost and found. Unusual evolution of a seminal vesicle transglutaminase substrate. Hagstrom JE, et al. **J Biol Chem** 1996 Aug 30;271(35):21114–9
Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus. Hansen H, et al. **J Biol Chem** 1996 Apr 12;271(15):8882–6
Differential interaction of the ras family GTP–binding proteins H–Ras, Rap1A, and R–Ras with the putative effector molecules Raf kinase and Ral–guanine nucleotide exchange factor. Herrmann C, et al. **J Biol Chem** 1996 Mar 22;271(12):6794–800
Epidermal growth factor receptor targeting prevents uncoupling of the Grb2–SOS complex. Holt KH, et al. **J Biol Chem** 1996 Apr 5;271(14):8300–6
Identification of the site of interaction of the 14–3–3 protein with phosphorylated tryptophan hydroxylase. Ichimura T, et al. **J Biol Chem** 1995 Dec 1;270(48):28515–8
Syk–dependent phosphorylation of Shc. A potential link between FcepsilonRI and the Ras/mitogen–activated protein kinase signaling pathway through SOS and Grb2. Jabril–Cuenod B, et al. **J Biol Chem** 1996 Jul 5; 271(27):16268–72
Proprotein–processing endoprotease furin decreases regulated secretory pathway–specific proteins in the pancreatic beta cell line MIN6. Kayo T, et al. **J Biol Chem** 1996 May 3;271(18):10731–7
Shc and a novel 89–kDa component couple to the Grb2–Sos complex in fibroblast growth factor–2–stimulated cells. Klint P, et al. **J Biol Chem** 1995 Oct 6;270(40):23337–44
Denitrification, a novel type of respiratory metabolism in fungal mitochondrion. Kobayashi M, et al. **J Biol Chem** 1996 Jul 5;271(27):16263–7
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells. Kon–Kozlowski M, et al. **J Biol Chem** 1996 Feb 16;271(7):3856–62
ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. Kumar S, et al. **J Biol Chem** 1995 Nov 17;270(46):27905–13
Identification of AF–6 and canoe as putative targets for Ras. Kuriyama M, et al. **J Biol Chem** 1996 Jan 12;271(2):607–10
Negative feedback regulation and desensitization of insulin– and epidermal growth factor–stimulated p21ras activation. Langlois WJ, et al. **J Biol Chem** 1995 Oct 27; 270(43):25320–3
Serine phosphorylation, chromosomal localization, and transforming growth factor–beta signal transduction by human bsp–1. Lechleider RJ, et al. **J Biol Chem** 1996 Jul 26;271(30):17617–20
Cloning and characterization of a novel A–kinase anchoring protein. AKAP 220, association with testicular peroxisomes. Lester LB, et al. **J Biol Chem** 1996 Apr 19; 271(16):9460–5
Specific recognition of N–acetylneuraminic acid in the GM2 epitope by human GM2 activator protein. Li SC, et al. **J Biol Chem** 1995 Oct 13;270(41):24246–51
The N terminus of antizyme promotes degradation of heterologous proteins. Li X, et al. **J Biol Chem** 1996 Feb 23;271(8):4441–6
A kinase anchor protein 75 targets regulatory (RII) subunits of cAMP–dependent protein kinase II to the cortical actin cytoskeleton in non–neuronal cells. Li Y, et al.

J Biol Chem 1996 Jul 12;271(28):16862–9
The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. Lin WJ, et al. J Biol Chem 1996 Jun 21;271(25):15034–44
Activation-modulated association of 14-3-3 proteins with Cbl in T cells. Liu YC, et al. J Biol Chem 1996 Jun 14; 271(24):14591–5
Identification of the 14.3.3 zeta domains important for self-association and Raf binding. Luo ZJ, et al. J Biol Chem 1995 Oct 6;270(40):23681–7
Thermodynamic studies of SHC phosphotyrosine interaction domain recognition of the NPXpY motif. Mandiyan V, et al. J Biol Chem 1996 Mar 1;271(9):4770–5
Oligosaccharides containing beta 1,4-linked N-acetylgalactosamine, a paradigm for protein-specific glycosylation. Manzella SM, et al. J Biol Chem 1996 May 24;271(21):12117–20 (54 ref.)
Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. Mark MR, et al. J Biol Chem 1996 Apr 19;271(16):9785–9
Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins. Matsuda M, et al. J Biol Chem 1996 Jun 14;271(24):14468–72
Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nuclease. Matsunaga T, et al. J Biol Chem 1996 May 10; 271(19):11047–50
Modified ligands to FA and FB in photosystem I. I. Structural constraints for the formation of iron-sulfur clusters in free and rebound PsaC. Mehari T, et al. J Biol Chem 1995 Nov 24;270(47):28108–17
The levels of ribonucleotide reductase, thioredoxin, glutaredoxin 1, and GSH are balanced in Escherichia coli K12. Miranda-Vizuete A, et al. J Biol Chem 1996 Aug 9;271(32):19099–103
Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets. Nakamura F, et al. J Biol Chem 1995 Dec 29;270(52):31377–85
Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties. TSA possesses thiol peroxidase activity. Netto LES, et al. J Biol Chem 1996 Jun 28;271(26):15315–21
Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. Nunès JA, et al. J Biol Chem 1996 Jan 19; 271(3):1591–8
Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC. O'Bryan JP, et al. J Biol Chem 1996 May 17;271(20):11787–91
Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. Ohashi K, et al. J Biol Chem 1995 Sep 29;270(39):22681–4
Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf. Okada T, et al. J Biol Chem 1996 Mar 1;271(9):4671–8
Exchange of beta- for alpha-tropomyosin in hearts of transgenic mice induces changes in thin filament response to Ca2+, strong cross-bridge binding, and protein phosphorylation. Palmiter KA, et al. J Biol Chem 1996 May 17;271(20):11611–4
p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase. Panchamoorthy G, et al. J Biol Chem 1996 Feb 9; 271(6):3187–94
Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. Pandey A, et al. J Biol Chem 1996 May 3;271(18):10607–10
Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1-associated protein TRADD. Park A, et al. J Biol Chem 1996 Apr 19; 271(16):9858–62
Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. Park CH, et al. J Biol Chem 1995 Sep 29;270(39):22657–60
Physical interaction between human RAD52 and RPA is required for homologous recombination in mammalian cells. Park MS, et al. J Biol Chem 1996 Aug 2; 271(31):18996–9000
A role for Shc, Grb2, and Raf-1 in FcgammaRI signal relay. Park RK, et al. J Biol Chem 1996 Jun 7;271(23):13342–8
The two mannose 6-phosphate receptors transport distinct complements of lysosomal proteins. Pohlmann R, et al. J Biol Chem 1995 Nov 10;270(45):27311–8
Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. Ponzetto C, et al. J Biol Chem 1996 Jun 14; 271(24):14119–23
Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1. Porfiri E, et al. J Biol Chem 1996 Mar 8;271(10):5871–7
Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. Quilliam LA, et al. J Biol Chem 1996 May 10;271(19):11076–82
Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis. Rajagopal I, et al. J Biol Chem 1995 Nov 17;270(46):27415–8
A proteasome activator subunit binds calcium. Realini C, et al. J Biol Chem 1995 Dec 15;270(50):29664–7
Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G. Reedquist KA, et al. J Biol Chem 1996 Apr 5;271(14):8435–42
Identification and characterization of the cytoplasmic antiproteinase (CAP) in human platelets. Evidence for the interaction of CAP with endogenous platelet proteins. Riewald M, et al. J Biol Chem 1996 Mar 22;271(12):7160–7
Functional importance of amino-terminal domain of Shc for interaction with insulin and epidermal growth factor receptors in phosphorylation-independent manner. Sasaoka T, et al. J Biol Chem 1996 Aug 16;271(33):20082–7
Enhancement of protein kinase C-dependent O2 production in Epstein-Barr virus-transformed B lymphocytes by p120Ras-GAP antisense oligonucleotide. Schmid E, et al. J Biol Chem 1996 Apr 19;271(16):9320–5
Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. Seufferlein T, et al. J Biol Chem 1995 Oct 13; 270(41):24334–42
Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-L adaptors. Smit L, et al. J Biol Chem 1996 Apr 12;271(15):8564–9
Protein kinase C-mediated phosphorylation of the myristoylated alanine-rich C-kinase substrate protects it from specific proteolytic cleavage. Spizz G, et al. J Biol Chem 1996 Jan 5;271(1):553–62
Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. Tanaka S, et al. J Biol Chem 1996 Jun 14;271(24):14610–6
In vitro interaction between human immunodeficiency virus type 1 Rev protein and splicing factor ASF/SF2-associated protein, p32. Tange TO, et al. J Biol Chem 1996 Apr 26; 271(17):10066–72
Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. Tartare-Deckert S, et al. J Biol Chem 1995 Oct 6; 270(40):23456–60
Src homologous and collagen (Shc) protein binds to F-actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells. Thomas D, et al. J Biol Chem 1995 Dec 1;270(48):28924–31
Activation of the mitogen-activated protein kinase pathway by fMet-leu-Phe in the absence of Lyn and tyrosine phosphorylation of SHC in transfected cells. Torres M, et al. J Biol Chem 1996 May 31;271(22):13244–9
Isolation of a sponge-derived extracellular matrix adhesion protein. Varner JA. J Biol Chem 1996 Jul 5; 271(27):16119–25
14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. Vincenz C, et al. J Biol Chem 1996 Aug 16; 271(33):20029–34
Systematic mapping of potential binding sites for Shc and Grb2 SH2 domains on insulin receptor substrate-1 and the receptors for insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor. Ward CW, et al. J Biol Chem 1996 Mar 8; 271(10):5603–9
Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of Ras activation. Waters SB, et al. J Biol Chem 1996 Jul 26;271(30):18224–30
Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of shc in human keratinocytes. Wery S, et al. J Biol Chem 1996 Apr 12;271(15):8529–32
Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2. Wong L, et al. J Biol Chem 1996 Aug 30;271(35):20981–4
Characterization of an alternatively spliced GM2 activator protein, GM2A protein. An activator protein which stimulates the enzymatic hydrolysis of N-acetylneuraminic acid, but not N-acetylgalactosamine, from GM2. Wu YY, et al. J Biol Chem 1996 May 3;271(18):10611–5
Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. Xie Y, et al. J Biol Chem 1995 Dec 22;270(51):30717–24
A novel GTPase-activating protein for R-Ras. Yamamoto T, et al. J Biol Chem 1995 Dec 22;270(51):30557–61
A conserved region of c-Ha-Ras is required for efficient GTPase stimulation by GTPase activating protein but not neurofibromin. Yoder-Hill J, et al. J Biol Chem 1995 Nov 17;270(46):27615–21
Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori. Yoshida H, et al. J Biol Chem 1996 Jun 7;271(23):13854–60
Modified ligands to FA and FB in photosystem I. II. Characterization of a mixed ligand [4Fe-4S] cluster in the C51D mutant of PsaC upon rebinding to P700-Fx cores. Yu L, et al. J Biol Chem 1995 Nov 24;270(47):28118–25
Two separate functions are encoded by the carboxyl-terminal domains of the yeast cyclase-associated protein and its mammalian homologs. Dimerization and actin binding. Zelicof A, et al. J Biol Chem 1996 Jul 26;271(30):18243–52
Validation of the use of intermolecular NOE constraints for obtaining docked structures of protein-ligand complexes. Gradwell MJ, et al. J Biomol NMR 1996 Jan;7(1):48–58
Biopolymer-surfactant interaction: 4. Kinetics of binding of cetyltrimethyl ammonium bromide with gelatin, hemoglobin, beta-lactoglobulin and lysozyme. Maulik S, et al. J Biomol Struct Dyn 1996 Apr;13(5):771–80
Experimental study on protein transmission through the human muscle fascia: preliminary results and application theory in lymphedema. Vettorello GF, et al. J Cardiovasc Surg (Torino) 1996 Aug;37(4):345–51
Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. Tyagi SC, et al. J Cell Biochem 1996 Apr;61(1):139–51
SPC4, SPC6, and the novel protease SPC7 are coexpressed with bone morphogenetic proteins at distinct sites during embryogenesis. Constam DB, et al. J Cell Biol 1996 Jul; 134(1):181–91
A purified Drosophila septin complex forms filaments and exhibits GTPase activity. Field CM, et al. J Cell Biol 1996 May;133(3):605–16
Roles of molecular chaperones in protein degradation. Hayes SA, et al. J Cell Biol 1996 Feb;132(3):255–8 (24 ref.)
14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor. Liao J, et al. J Cell Biol 1996 Apr; 133(2):345–57
Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit. Shattil SJ, et al. J Cell Biol 1995 Nov; 131(3):807–16
Ability of trypsin in mimicking germ cell factors that affect Sertoli cell secretory function. Aravindan GR, et al. J Cell Physiol 1996 Jul;168(1):123–33
Excess protein in nuclei isolated from heat-shocked cells results from a reduced extractability of nuclear proteins. Borrelli MJ, et al. J Cell Physiol 1996 Jun;167(3):369–79
Effect of glycosylation on the heparin-binding capability of boar and stallion seminal plasma proteins. Calvete JJ, et al. J Chromatogr A 1995 Sep 8;711(1):167–73
Effect of fasting on serum leptin in normal human subjects. Boden G, et al. J Clin Endocrinol Metab 1996 Sep; 81(9):3419–23
Elevated parathyroid hormone-related peptide levels after human gestation: relationship to changes in bone and mineral metabolism. Dobnig H, et al. J Clin Endocrinol Metab 1995 Dec;80(12):3699–707
Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. Kovacs CS, et al. J Clin Endocrinol Metab 1995 Oct;80(10):3036–42
Estrogens do not affect whole-body protein metabolism in the prepubertal female [see comments] Mauras N. J Clin Endocrinol Metab 1995 Oct;80(10):2842–5. Comment in: J Clin Endocrinol Metab 1995 Oct;80(10):2841.
Effects of estrogen therapy on whole body proteins [letter; comment] Mauras N. J Clin Endocrinol Metab 1996 Jan; 81(1):431. Comment on: J Clin Endocrinol Metab 1995 Oct;80(10):2841.
Effects of gender, body composition, and menopause on plasma concentrations of leptin. Rosenbaum M, et al. J Clin Endocrinol Metab 1996 Sep;81(9):3424–7
Evidence for a catabolic role of glucagon during an amino acid load. Charlton MR, et al. J Clin Invest 1996 Jul 1; 98(1):90–9
Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. Denne SC, et al. J Clin Invest 1996 Feb 1; 97(3):746–54
Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. Sinha MK, et al. J Clin Invest 1996 Mar 1;97(5):1344–7
Induction of Fanconi anemia cellular phenotype in human 293 cells by overexpression of a mutant FAC allele [see comments] Youssoufian H, et al. J Clin Invest 1996 Feb 15;97(4):957–62. Comment in: J Clin Invest 1996 Feb 15;97(4):897–8.
Effects of forage percentage and canola seed on ruminal protein metabolism and duodenal flows of amino acids in steers. Hussein HS, et al. J Dairy Sci 1996 Jan;79(1):98–104
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. Chauhan D, et al. J Exp Med 1995 Dec 1;182(6):1801–6
CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells. Galandrini R, et al. J Exp Med 1996 Jan 1;183(1):179–86
The half-life of RAG-1 protein in precursor B cells is increased in the absence of RAG-2 expression. Grawunder U, et al. J Exp Med 1996 Apr 1;183(4):1731–7
Implication of the GRB2-associated phosphoprotein SLP-76 in T cell receptor-mediated interleukin 2 production. Motto DG, et al. J Exp Med 1996 Apr 1;183(4):1937–43
Regulation of secretion and clearance of C-type natriuretic peptide in the interaction of vascular endothelial cells and smooth muscle cells. Komatsu Y, et al. J Hypertens 1996 May;14(5):585–92
Lipopolysaccharide-induced change of phosphorylation of two cytosolic proteins in human monocytes is prevented by inhibitors of ADP-ribosylation. Heine H, et al. J Immunol 1995 Nov 15;155(10):4899–908

Modulation of the Grb2-associated protein complex in human CD4+ T cells by receptor activation. Lahesmaa R, et al. **J Immunol** 1995 Oct 15;155(8):3815–22

Selenoprotein W of rat muscle binds glutathione and an unknown small molecular weight moiety. Beilstein MA, et al. **J Inorg Biochem** 1996 Feb;61(2):117–24

Antiprotease activity in urine of patients with inflammatory skin disorders. Streit V, et al. **J Invest Dermatol** 1995 Oct; 105(4):562–6

Beta2 integrins mediate protein tyrosine phosphorylation in human neutrophils. Walzog B, et al. **J Leukoc Biol** 1996 May;59(5):747–53

Computational methods to predict binding free energy in ligand–receptor complexes. Murcko A, et al. **J Med Chem** 1995 Dec 22;38(26):4953–67 (90 ref.)

X-SITE: use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. Laskowski RA, et al. **J Mol Biol** 1996 May 31;259(1):175–201

Hypertrophic effects of calcitonin gene–related peptide (CGRP) and amylin on adult mammalian ventricular cardiomyocytes. Bell D, et al. **J Mol Cell Cardiol** 1995 Nov;27(11):2433–43

Time–dependent increase in protein phosphorylation following one–trial enhancement in Hermissenda. Crow T, et al. **J Neurochem** 1996 Apr;66(4):1736–41

Expression of C–type natriuretic peptide in the bovine pineal gland. Middendorff R, et al. **J Neurochem** 1996 Aug; 67(2):517–24

Identification of a neuropeptide and neuropeptide–processing enzymes in aqueous humor confers neuroendocrine features to the human ocular ciliary epithelium. Ortego J, et al. **J Neurochem** 1996 Feb;66(2):787–96

Tissue–specific processing of the neuroendocrine protein VGF. Trani E, et al. **J Neurochem** 1995 Dec;65(6):2441–9

Chronic lithium–induced down–regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. Watson DG, et al. **J Neurochem** 1996 Aug;67(2):767–77

Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. Shinoura N, et al. **J Neurosurg** 1996 May;84(5):839–45; discussion 846

Maintenance requirement for valine and efficiency of its use above maintenance for accretion of whole body valine and protein in young chicks. Baker DH, et al. **J Nutr** 1996 Jul;126(7):1844–51

Methionine deficiency decreases protein accretion and synthesis but not tRNA acylation in muscles of chicks. Barnes DM, et al. **J Nutr** 1995 Oct;125(10):2623–30

Estimates of the effect of feeding on whole–body protein degradation in women vary with the amino acid used as tracer. Berthold HK, et al. **J Nutr** 1995 Oct;125(10):2516–27

Altering ruminal nitrogen metabolism to improve protein utilization. Introduction. Broderick GA. **J Nutr** 1996 Apr; 126(4 Suppl):1324S–5S

Dietary myristic acid alters acylated proteins in activated murine macrophages. Hubbard NE, et al. **J Nutr** 1996 Jun; 126(6):1563–70

Protein and lipid refeeding changes protein metabolism and colonic but not small intestinal morphology in protein–depleted rats. Qu Z, et al. **J Nutr** 1996 Apr; 126(4):906–12

Defects of copper deficiency in rats are modified by dietary treatments that affect glycation. Saari JT, et al. **J Nutr** 1995 Dec;125(12):2925–34

Nutritional state and the swelling–induced inhibition of proteolysis in perfused rat liver. Vom Dahl S, et al. **J Nutr** 1996 Feb;126(2):395–402

Lung tumours immunoreactive for parathyroid hormone related peptide: analysis of serum calcium levels and tumour type. Davidson LA, et al. **J Pathol** 1996 Apr; 178(4):398–401

Effect of parenteral amino acids on leucine and urea kinetics in preterm infants. Battista MA, et al. **J Pediatr** 1996 Jan; 128(1):130–4

A comparison of calcium binding in Callinectes sapidus premolt and postmolt cuticle homogenates: implications for regulation of biomineralization. Burgess SK, et al. **J Protein Chem** 1995 Nov;14(8):655–64

In vitro bioactivity of gonadotrophin surge attenuating factor is not affected by an antibody to human inhibin. Balen AH, et al. **J Reprod Fertil** 1995 Jul;104(2):285–9

Thymosin alpha–1 and FA–1 monoclonal antibody affect murine preimplantation embryo development by modulating protein phosphorylation. Ahmad K, et al. **J Reprod Immunol** 1995 Oct;29(3):239–63

Protein metabolism in cachectic tumor–bearing rats: effect of tumor excision. Le Bricon T, et al. **J Surg Res** 1996 Jan;60(1):207–15

Acute effects of insulin–like growth factor I on interorgan glucose and lactate flux in protein–catabolic dogs. Valentini L, et al. **J Surg Res** 1995 Nov;59(5):606–13

Protein adsorption and bacterial adhesion to biliary stent materials. Yu JL, et al. **J Surg Res** 1996 Apr;62(1):69–73

Prostate specific antigen cleaves parathyroid hormone–related protein in the PTH–like domain: inactivation of PTHrP–stimulated cAMP accumulation in mouse osteoblasts. Cramer SD, et al. **J Urol** 1996 Aug;156(2 Pt 1):526–31

Biochemical and antigenical characterization of tannin–protein complex degrading enterobacteria isolated from koalas, Phascolarctos cinereus. Nakai Y, et al. **J Vet Med Sci** 1995 Jun;57(3):559–61

Polyprotein processing in Southampton virus: identification of 3C–like protease cleavage sites by in vitro mutagenesis. Liu B, et al. **J Virol** 1996 Apr;70(4):2605–10

Substrate metabolism in humans: 1995 A.S.P.E.N. research workshop. Klein S, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):13–9

Glutamine supplementation of enteral nutrition: impact on whole body protein kinetics and glucose metabolism in critically ill patients. Long CL, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):470–6

Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure. Macias WL, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb; 20(1):56–62

Effect of glutamine supplementation on protein metabolism and glutathione in tumor–bearing rats. Yoshida S, et al. **JPEN J Parenter Enteral Nutr** 1995 Nov–Dec;19(6):492–7

Circulating parathyroid hormone–related protein (109–141) in malignancy–associated hypercalcemia. Nagasaki K, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):6–11

Correction of acidosis in CAPD decreases whole body protein degradation. Graham KA, et al. **Kidney Int** 1996 May;49(5):1396–400

Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kabanda A, et al. **Kidney Int** 1995 Dec; 48(6):1946–52

The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461–8 (78 ref.)

Decreased cerebrospinal–fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance [see comments] Caro JF, et al. **Lancet** 1996 Jul 20;348(9021):159–61. Comment in: Lancet 1996 Jul 20;348(9021):140–1.

Progressive cellular dehydration and proteolysis in critically ill patients. Finn PJ, et al. **Lancet** 1996 Mar 9; 347(9002):654–6

Induction of the PML protein by interferons in normal and APL cells. Chelbi–Alix MK, et al. **Leukemia** 1995 Dec; 9(12):2027–33

Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia. Gallagher A, et al. **Leukemia** 1995 Nov;9(11):1833–40

Preservation of intestine protein by peptide YY during total parenteral nutrition. Chance WT, et al. **Life Sci** 1996; 58(21):1785–94

Ethanol enhances the in situ phosphorylation of MARCKS and protein kinase C activity in primary cultures of astrocytes. Smith TL, et al. **Life Sci** 1996;58(10):855–60

Increased formation and degradation of malondialdehyde–modified proteins under conditions of peroxidative stress. Mahmoodi H, et al. **Lipids** 1995 Oct; 30(10):963–6

Expression of early lung cancer detection marker p31 in neoplastic and non–neoplastic respiratory epithelium. Zhou J, et al. **Lung Cancer** 1996 Feb;14(1):85–97

Rapid tyrosine phosphorylation of Grb2 and Shc in T cells exposed to anti–CD3, anti–CD4, and anti–CD45 stimuli: differential effects of aging. Ghosh J, et al. **Mech Ageing Dev** 1995 Jun 9;80(3):171–87

Dmcdc2 kinase is required for both meiotic divisions during Drosophila spermatogenesis and is activated by the Twine/cdc25 phosphatase. Sigrist S, et al. **Mech Dev** 1995 Oct;53(2):247–60

Vanadium–protein interactions. Chasteen ND. **Met Ions Biol Syst** 1995;31:231–47 (68 ref.)

Use of vanadate–induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)

Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor–bearing rats. Le Bricon T, et al. **Metabolism** 1995 Oct;44(10):1340–8

The interaction trap: in vivo analysis of protein–protein associations. Shirley BW, et al. **Methods Cell Biol** 1995; 49:401–16 (27 ref.)

GTPase–activating protein activity of n(alpha 1)–Chimaerin and effect of lipids. Ahmed S, et al. **Methods Enzymol** 1995; 256:114–25

Analyzing protein–protein interactions using two–hybrid system. Bartel PL, et al. **Methods Enzymol** 1995;254:241–63

Catalysis of guanine nucleotide exchange of Ran by RCC1 and stimulation of hydrolysis of Ran–bound GTP by Ran–GAP1. Bischoff FR, et al. **Methods Enzymol** 1995; 257:135–44

Identification of protein–protein interactions by lambda gt11 expression cloning. Blackwood EM, et al. **Methods Enzymol** 1995;254:229–40

Intrinsic and GTPase–activating protein–stimulated Ras GTPase assays. Bollag G, et al. **Methods Enzymol** 1995; 255:161–70

In vitro binding assay for interactions of Rho and Rac with GTPase–activating proteins and effectors. Diekmann D, et al. **Methods Enzymol** 1995;256:207–15

Inhibition of Rac function using antisense oligonucleotides. Dorseuil O, et al. **Methods Enzymol** 1995;256:358–66

Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry. Doyle ML, et al. **Methods Enzymol** 1995;259:183–94

Phosphorylation–dependent complexes of p120 Ras–specific GTPase–activating protein with p62 and p190. Ellis C, et al. **Methods Enzymol** 1995;255:179–92

Redox–cycling detection of dialyzable pyrroloquinoline quinone and quinoproteins. Flückiger R, et al. **Methods Enzymol** 1995;258:140–9

Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Johnson MS, et al. **Methods Enzymol** 1996;266:575–98

On the interpretation of data from isothermal processes. Lumry R. **Methods Enzymol** 1995;259:628–720

Use of yeast two–hybrid system to evaluate Ras interactions with neurofibromin–GTPase–activating protein. Poullet P, et al. **Methods Enzymol** 1995;255:488–97

Determination of Ras and GTPase–activating protein interactions by kinetic competition assay. Schaber MD, et al. **Methods Enzymol** 1995;255:171–8

Purification and properties of Rabphilin–3A. Shirataki H, et al. **Methods Enzymol** 1995;257:291–302

Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)

Linkage of protein assembly to protein–DNA binding. Wong I, et al. **Methods Enzymol** 1995;259:95–127

Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)

Muscle protein turnover in chronic renal failure patients with metabolic acidosis or normal acid–base balance. Garibotto G, et al. **Miner Electrolyte Metab** 1996;22(1–3):58–61

Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1–3):157–61 (52 ref.)

Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1–3):62–5 (20 ref.)

Protein turnover in the hypertrophying kidney. Rabkin R, et al. **Miner Electrolyte Metab** 1996;22(1–3):153–6

Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Poon RY, et al. **Mol Biol Cell** 1995 Sep; 6(9):1197–213

Transformation and pp60v–src autophosphorylation correlate with SHC–GRB2 complex formation in rat and chicken cells expressing host–range and kinase–active, transformation–defective alleles of v–src. Verderame MF, et al. **Mol Biol Cell** 1995 Aug;6(8):953–66

In vitro nucleo–cytoplasmic transport. Marshallsay C. **Mol Biol Rep** 1994–95;20(3):163–71

ras effector loop mutations that dissociate p120GAP and neurofibromin interactions. Stang S, et al. **Mol Carcinog** 1996 Jan;15(1):64–9

Post–translationally modified 14–3–3 isoforms and inhibition of protein kinase C. Aitken A, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:41–9

Functional interactions of phosphatidylinositol 3–kinase with GTPase–activating protein in 3T3–L1 adipocytes. DePaolo D, et al. **Mol Cell Biol** 1996 Apr;16(4):1450–7

Identification of Rap1 as a target for the Crk SH3 domain–binding guanine nucleotide–releasing factor C3G. Gotoh T, et al. **Mol Cell Biol** 1995 Dec;15(12):6746–53

An SH3 domain–containing GTPase–activating protein for Rho and Cdc42 associates with focal adhesion kinase. Hildebrand JD, et al. **Mol Cell Biol** 1996 Jun;16(6):3169–78

Interaction of Vav with ENX–1, a putative transcriptional regulator of homeobox gene expression. Hobert O, et al. **Mol Cell Biol** 1996 Jun;16(6):3066–73

Drosophila NAP–1 is a core histone chaperone that functions in ATP–facilitated assembly of regularly spaced nucleosomal arrays. Ito T, et al. **Mol Cell Biol** 1996 Jun; 16(6):3112–24

rag–1 and rag–2 are components of a high–molecular–weight complex, and association of rag–2 with this complex is rag–1 dependent. Leu TM, et al. **Mol Cell Biol** 1995 Oct; 15(10):5657–70

Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation. Lotti LV, et al. **Mol Cell Biol** 1996 May;16(5):1946–54

Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Morcos P, et al. **Mol Cell Biol** 1996 May;16(5):2496–503

Tyrosine phosphorylation of Grb2–associated proteins correlates with phospholipase C gamma 1 activation in T cells. Motto DG, et al. **Mol Cell Biol** 1996 Jun;16(6):2823–9

The Ras–GTPase–activating protein SH3 domain is required for Cdc2 activation and mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen–activated protein kinase activation. Pomerance M, et al. **Mol Cell Biol** 1996 Jun;16(6):3179–86

Wiskott–Aldrich syndrome protein physically associates with Nck through Src homology 3 domains. Rivero–Lezcano OM, et al. **Mol Cell Biol** 1995 Oct;15(10):5725–31

Stimulation of transcription factor binding and histone displacement by nucleosome assembly protein 1 and nucleoplasmin requires disruption of the histone octamer. Walter PP, et al. **Mol Cell Biol** 1995 Nov;15(11):6178–87

Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction. Yan H, et al. **Mol Cell Biol** 1996 May;16(5):2074–82

Mutations altering the mitochondrial–cytoplasmic distribution of Mod5p implicate the actin cytoskeleton and

mRNA 3' ends and/or protein synthesis in mitochondrial delivery. Zoladek T, et al. **Mol Cell Biol** 1995 Dec; 15(12):6884–94

Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Clark BJ, et al. **Mol Endocrinol** 1995 Oct;9(10):1346–55

Protein transport via amino–terminal targeting sequences: common themes in diverse systems. Rusch SL, et al. **Mol Membr Biol** 1995 Oct–Dec;12(4):295–307 (175 ref.)

Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Overbeck AF, et al. **Mol Reprod Dev** 1995 Dec;42(4):468–76 (32 ref.)

Antileucoprotease in the airways and emphysema. Dijkman JH. **Monaldi Arch Chest Dis** 1995 Oct;50(5):383–7

Inhibition of the phosphorylation of a myristoylated alanine–rich C kinase substrate by methyl methanesulfonate in cultured NIH 3T3 cells. Shin I, et al. **Mutat Res** 1996 Apr 13;351(2):163–71

Filling in the matrix of kidney disease [comment] Bacallao R. **Nat Med** 1995 Apr;1(4):305–6. Comment on: Nat Med 1995 Apr;1(4):359–64.

Leptin levels reflect body lipid content in mice: evidence for diet–induced resistance to leptin action. Frederich RC, et al. **Nat Med** 1995 Dec;1(12):1311–4

Release and activation of platelet latent TGF–beta in blood clots during dissolution with plasmin. Grainger DJ, et al. **Nat Med** 1995 Sep;1(9):932–7

Gender differences in plasma leptin concentrations [letter] Havel PJ, et al. **Nat Med** 1996 Sep;2(9):949–50

Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Schwartz MW, et al. **Nat Med** 1996 May;2(5):589–93

What is leptin for, and does it act on the brain? [letter] [see comments] Wurtman RJ. **Nat Med** 1996 May;2(5):492–3. Comment in: Nat Med 1996 Jul;2(7):723–4.

Complexity in proteins [news; comment] Frauenfelder H. **Nat Struct Biol** 1995 Oct;2(10):821–3. Comment on: Nat Struct Biol 1995 Oct;2(10):848–51.

A WD–domain protein that is associated with and phosphorylated by the type II TGF–beta receptor. Chen RH, et al. **Nature** 1995 Oct 12;377(6549):548–52

Initiation of V(D)J recombination in vitro obeying the 12/23 rule. Eastman QM, et al. **Nature** 1996 Mar 7;380(6569):85–8

Requirement for Drosophila cytoplasmic tropomyosin in oskar mRNA localization [see comments] Erdélyi M, et al. **Nature** 1995 Oct 12;377(6549):524–7. Comment in: Nature 1995 Oct 12;377(6549):483.

A Grb2–associated docking protein in EGF– and insulin–receptor signalling. Holgado–Madruga M, et al. **Nature** 1996 Feb 8;379(6565):560–4

A human Mad protein acting as a BMP–regulated transcriptional activator [see comments] Liu F, et al. **Nature** 1996 Jun 13;381(6583):620–3. Comment in: Nature 1996 Jun 13;381(6583):561–2.

Protein targeting. The ribosome talks back [news; comment] Powers T, et al. **Nature** 1996 May 16;381(6579):191–2. Comment on: Nature 1996 May 16;381(6579):248–51.

Developmental biology. New role for tropomyosin [news; comment] St Johnston D. **Nature** 1995 Oct 12;377(6549):483 . Comment on: Nature 1995 Oct 12;377(6549):524–7.

New chapter for the fat controller [news] Scott J. **Nature** 1996 Jan 11;379(6561):113–4

smoothened encodes a receptor–like serpentine protein required for hedgehog signalling. van den Heuvel M, et al. **Nature** 1996 Aug 8;382(6591):547–51

Leptin activation in hypothalamus [letter] Woods AJ, et al. **Nature** 1996 Jun 27;381(6585):745

The fates of proteins in cells. Bohley P. **Naturwissenschaften** 1995 Dec;82(12):544–50 (112 ref.)

Angiotensin–II–induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLC–PK1 cells. Ling H, et al. **Nephrol Dial Transplant** 1995;10(8):1305–12

Cellulose acetate and cuprophane for hemodialysis: effects on protein catabolic rate [letter] Robles NR, et al. **Nephron** 1995;70(4):508–9

Protein phosphorylation in the blood–brain barrier. Possible presence of MARCKS in brain microvessels. Edgardo Catalán R, et al. **Neurochem Int** 1996 Jan;28(1):59–65

Complementary distribution of the phosphoproteins DARPP–32 and I–1 in the cerebellar system. Alder R, et al. **Neuroreport** 1995 Nov 27;6(17):2368–72

Alteration of dynorphin and secretogranin II in the prolactin immunoreactive neurons of the rat lateral hypothalamus upon osmotic stimulation. Grillon S, et al. **Neurosci Lett** 1996 Apr 12;208(1):33–6

The expression of ornithine decarboxylase antizyme mRNA and protein in rat motoneurons. Junttila T, et al. **Neurosci Lett** 1995 Sep 15;197(3):187–90

Further observations on MxA–positive Lewy bodies in Parkinson's disease brain tissues. Yamada T. **Neurosci Lett** 1995 Jul 28;195(1):41–4

Radiolabeled metabolites of proteins play a critical role in radioactivity elimination from the liver. Arano Y, et al. **Nucl Med Biol** 1995 Jul;22(5):555–64

Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Ariza RR, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):433–40

Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P–chirality independent. Benimetskaya L, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4239–45

In vitro and in vivo evidence that protein and U1 snRNP nuclear import in somatic cells differ in their requirement for GTP–hydrolysis, Ran/TC4 and RCC1. Marshallsay C, et al. **Nucleic Acids Res** 1996 May 15;24(10):1829–36

Oligomer biology and polymer biology: primitive RNA–protein interactions. Shimizu M. **Nucleic Acids Symp Ser** 1995;(33):179–81

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul–Aug; 11(4):382–7 (66 ref.). Comment in: Nutrition 1995 Jul–Aug;11(4):398.

Influence of acidosis on protein metabolism. Ballmer PE, et al. **Nutrition** 1995 Sep–Oct;11(5):462–8; discussion 470 (66 ref.)

Understanding the pathological mechanisms underlying protein breakdown for new therapeutic strategies [editorial; comment] Cynober LA. **Nutrition** 1995 Jul–Aug;11(4):398 . Comment on: Nutrition 1995 Jul–Aug;11(4):382–7.

Differential effects of counterregulatory stress hormones on serum albumin concentrations and protein catabolism in healthy volunteers. Smeets HJ, et al. **Nutrition** 1995 Sep–Oct;11(5):423–7

The identification of p130cas–binding proteins and their role in cellular transformation. Burnham MR, et al. **Oncogene** 1996 Jun 6;12(11):2467–72

Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA. Chen IT, et al. **Oncogene** 1995 Nov 16; 11(10):1931–7

Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines. Guerrero C, et al. **Oncogene** 1996 Mar 7;12(5):1097–107

Ras–GTP levels are elevated in human NF1 peripheral nerve tumors. Guha A, et al. **Oncogene** 1996 Feb 1;12(3):507–13

Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation. Hu Y, et al. **Oncogene** 1996 May 2; 12(9):1865–72

Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Kearsey JM, et al. **Oncogene** 1995 Nov 2;11(9):1675–83

Use of the two hybrid system to detect the association of the protein–tyrosine–phosphatase, SHPTP2, with another SH2–containing protein, Grb7. Keegan K, et al. **Oncogene** 1996 Apr 4;12(7):1537–44

Networks of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins. Khwaja A, et al. **Oncogene** 1996 Jun 20;12(12):2491–8

RN–tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy–terminal truncation. Matoušková B, et al. **Oncogene** 1996 Jun 20;12(12):2679–88

The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP–70 and mediates TCR dependent gene activation. Milia E, et al. **Oncogene** 1996 Aug 15; 13(4):767–75

The proline–rich region of Vav binds to Grb2 and Grb3–3. Ramos–Morales F, et al. **Oncogene** 1995 Oct 19; 11(8):1665–9

Hydrogen peroxide induces complex formation of SHC–Grb2–SOS with receptor tyrosine kinase and activates Ras and extracellular signal–regulated protein kinases group of mitogen–activated protein kinases. Rao GN. **Oncogene** 1996 Aug 15;13(4):713–9

Analysis of protein–protein interactions involved in the activation of the Shc/Grb–2 pathway by the ErbB–2 kinase. Ricci A, et al. **Oncogene** 1995 Oct 19;11(8):1519–29

A 15 amino acid stretch close to the Grb2–binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. Rojas JM, et al. **Oncogene** 1996 Jun 6; 12(11):2291–300

Activated Ras displaces 14–3–3 protein from the amino terminus of c–Raf–1. Rommel C, et al. **Oncogene** 1996 Feb 1;12(3):609–19

MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1–Shc and mSos1–EGF receptor complexes. Rozakis–Adcock M, et al. **Oncogene** 1995 Oct 5; 11(7):1417–26

Quantitative analysis of Grb2–Sos1 interaction: the N–terminal SH3 domain of Grb2 mediates affinity. Sastry L, et al. **Oncogene** 1995 Sep 21;11(6):1107–12

Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension. Castillo L, et al. **Pediatr Res** 1995 Jul;38(1):17–24

A positive correlation of PCRN to KT/V in cross–sectional studies is not proof of a causal relationship [letter; comment] Gotch F. **Perit Dial Int** 1995 Jul–Sep;15(6):274–5 . Comment on: Perit Dial Int 1993;13(3):173–5.

Permeability of peptides and proteins in human cultured alveolar A549 cell monolayer. Kobayashi S, et al. **Pharm Res** 1995 Aug;12(8):1115–9

Age–related changes of protein turnover in specific tissues of the chick. Tesseraud S, et al. **Poult Sci** 1996 May; 75(5):627–31

Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Belshaw PJ, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4604–7

Inhibition of phosphatidylinositol 3–kinase activity by association with 14–3–3 proteins in T cells. Bonnefoy–Bérard N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10142–6

Abr and Bcr are multifunctional regulators of the Rho GTP–binding protein family. Chuang TH, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10282–6

The 145–kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5–triphosphate 5–phosphatase. Damen JE, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1689–93

OB protein binds specifically to the choroid plexus of mice and rats. Devos R, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5668–73

Mutant forms of growth factor–binding protein–2 reverse BCR–ABL–induced transformation. Gishizky ML, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10889–93

Cloning and characterization of Lnk, a signal transduction protein that links T–cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3–kinase. Huang X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11618–22

Direct interaction of the Wiskott–Aldrich syndrome protein with the GTPase Cdc42. Kolluri R, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5615–8

The intrinsic ability of ribosomes to bind to endoplasmic reticulum membranes is regulated by signal recognition particle and nascent–polypeptide–associated complex [see comments] Lauring B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9435–9. Comment in: Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9433–4.

Nuclear/cytoplasmic localization of the von Hippel–Lindau tumor suppressor gene product is determined by cell density. Lee S, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1770–5

Using ubiquitin to follow the metabolic fate of a protein. Lévy F, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4907–12

Catalytic activity of the mouse guanine nucleotide exchanger mSOS is activated by Fyn tyrosine protein kinase and the T–cell antigen receptor in T cells. Li B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1001–5

The C–proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein–1. Li SW, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5127–30

Grb–IR: a SH2–domain–containing protein that binds to the insulin receptor and inhibits its function. Liu F, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10287–91

Characterization of mouse angiogenin–related protein: implications for functional studies on angiogenin. Nobile V, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4331–5

p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3–kinase, growth factor receptor–bound protein GRB–2, and T cell–specific protein–tyrosine kinase ITK: implications for T–cell costimulation. Raab M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8891–5

Genetic evidence that the RAG1 protein directly participates in V(D)J recombination through substrate recognition. Roman CA, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2333–8

The C–terminal region of human angiogenin has a dual role in enzymatic activity. Russo N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3243–7

The human CAS protein which is homologous to the CSE1 yeast chromosome segregation gene product is associated with microtubules and mitotic spindle. Scherf U, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2670–4

Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Simon DI, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4736–41

The tumor necrosis factor–inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF–kappaB activation. Song HY, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6721–5

Cloning and characterization of the Xenopus cyclin–dependent kinase inhibitor p27XIC1. Su JY, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10187–91

A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Tamura T, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1006–11

Phosphorylation of the fused protein kinase in response to signaling from hedgehog. Thérond PP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4224–8

G protein beta gamma subunits stimulate phosphorylation of Shc adapter protein. Touhara K, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9284–7

Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor–associated factors. Uren AG, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4974–8

Identification of residues that control specific binding of the Shc phosphotyrosine–binding domain to phosphotyrosine sites. van der Geer P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):963–8

Does DG42 synthesize hyaluronan or chitin?: A controversy about oligosaccharides in vertebrate development. Varki A. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4523–5 (53 ref.)

The nascent–polypeptide–associated complex: having a "NAC" for fidelity in translocation [comment] Wickner W. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9433–4.

Comment on: Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9435–9.
Involvement of Ras/Raf/AP-1 in BMP-4 signaling during Xenopus embryonic development. Xu RH, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):834–8
A human axillary odorant is carried by apolipoprotein D. Zeng C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6626–30
Effects of exercise training in the elderly: impact of progressive- resistance training on skeletal muscle and whole-body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)
Modulation of protein tyrosine phosphorylation in human cells by LPS and enzymatically deacylated LPS. Kitchens RL, et al. **Prog Clin Biol Res** 1995;392:353–63
Protein docking for low-resolution structures. Vakser IA. **Protein Eng** 1995 Apr;8(4):371–7
Covalent attachment of functionalized lipid bilayers to planar waveguides for measuring protein binding to biomimetic membranes. Heyse S, et al. **Protein Sci** 1995 Dec; 4(12):2532–44
The protein machinery of vesicle budding and fusion. Rothman JE. **Protein Sci** 1996 Feb;5(2):185–94 (92 ref.)
Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Chou KC, et al. **Proteins** 1996 Jan;24(1):51–72
Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Stote RH, et al. **Proteins** 1995 Sep;23(1):12–31
Natriuretic peptide system in the rat submaxillary gland. Jankowski M, et al. **Regul Pept** 1996 Apr 9;62(1):53–61
Parathyroid hormone-related protein (PTHrP) concentrations in human amniotic fluid during gestation and at the time of labour. Wlodek ME, et al. **Reprod Fertil Dev** 1995;7(6):1509–13
Protein thiol modification and apoptotic cell death as cGMP-independent nitric oxide (NO) signaling pathways. Brüne B, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:1–30 (105 ref.)
Selenocysteine incorporation in eukaryotes: insights into mechanism and efficiency from sequence, structure, and spacing proximity studies of the type 1 deiodinase SECIS element. Martin GW 3rd, et al. **RNA** 1996 Feb;2(2):171–82
Cathepsin D activity and protein degradation products in organs and blood during experimental declamping shock. Głowiński S, et al. **Rocz Akad Med Bialymst** 1995; 40(1):180–6
Budding vesicles in living cells. Rothman JE, et al. **Sci Am** 1996 Mar;274(3):70–5
Interaction between Wingless and Notch signaling pathways mediated by dishevelled [see comments] Axelrod JD, et al. **Science** 1996 Mar 29;271(5257):1826–32. Comment in: Science 1996 Mar 29;271(5257):1822–3.
Researchers find the reset button for the fruit fly clock [news; comment] Barinaga M. **Science** 1996 Mar 22; 271(5256):1671–2. Comment on: Science 1996 Mar 22;271(5256):1736–40. Comment on: Science 1996 Mar 22;271(5256):1736–40. Comment on: Science 1996 Mar 22;271(5256):1740–4.
Obesity: leptin receptor weighs in [news] Barinaga M. **Science** 1996 Jan 5;271(5245):29
A receptor for the selective uptake and degradation of proteins by lysosomes. Cuervo AM, et al. **Science** 1996 Jul 26;273(5274):501–3
The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization. Cukierman E, et al. **Science** 1995 Dec 22;270(5244):1999–2002
Cation–pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163–8 (66 ref.)
Isolation of timeless by PER protein interaction: defective interaction between timeless protein and long-period mutant PERL [see comments] Gekakis N, et al. **Science** 1995 Nov 3;270(5237):811–5. Comment in: Science 1995 Nov 3;270(5237):732–3.
Nucleocytoplasmic transport. Görlich D, et al. **Science** 1996 Mar 15;271(5255):1513–8 (77 ref.)
Protein kinesis [editorial] Hurtley SM. **Science** 1996 Mar 15; 271(5255):1477
When proteins receive deadly messages at birth [comment] Jentsch S. **Science** 1996 Feb 16;271(5251):955–6. Comment on: Science 1996 Feb 16;271(5251):990–3.
Bone morphogenetic protein-1: the type I procollagen C-proteinase [see comments] Kessler E, et al. **Science** 1996 Jan 19;271(5247):360–2. Comment in: Science 1996 Jan 26;271(5248):463.
Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Klauck TM, et al. **Science** 1996 Mar 15;271(5255):1589–92
Resetting the Drosophila clock by photic regulation of PER and a PER–TIM complex [see comments] Lee C, et al. **Science** 1996 Mar 22;271(5256):1740–4. Comment in: Science 1996 Mar 22;271(5256):1671–2.
Formation of a transition-state analog of the Ras GTPase reaction by Ras-GDP, tetrafluoroaluminate, and GTPase-activating proteins. Mittal R, et al. **Science** 1996 Jul 5;273(5271):115–7
Light-induced degradation of TIMELESS and entrainment of the Drosophila circadian clock [see comments] Myers MP, et al. **Science** 1996 Mar 22;271(5256):1736–40. Comment in: Science 1996 Mar 22;271(5256):1671–2.
BMP-1: resurrection as procollagen C-proteinase [comment] Reddi AH. **Science** 1996 Jan 26;271(5248):463. Comment on: Science 1996 Jan 19;271(5247):360–2.
Protein sorting by transport vesicles. Rothman JE, et al. **Science** 1996 Apr 12;272(5259):227–34 (86 ref.)
Putting the brakes on bone growth [news; comment] Roush W. **Science** 1996 Aug 2;273(5275):579. Comment on: Science 1996 Aug 2;273(5275):613–22. Comment on: Science 1996 Aug 2;273(5275):663–6.
Common principles of protein translocation across membranes. Schatz G, et al. **Science** 1996 Mar 15; 271(5255):1519–26 (60 ref.)
Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)
Plasmodium hemozoin formation mediated by histidine-rich proteins. Sullivan DJ Jr, et al. **Science** 1996 Jan 12; 271(5246):219–22
Requirement for the adapter protein GRB2 in EGF receptor endocytosis. Wang Z, et al. **Science** 1996 Jun 28; 272(5270):1935–9
FFA-1, a protein that promotes the formation of replication centers within nuclei. Yan H, et al. **Science** 1995 Sep 29; 269(5232):1883–5
Glomerular protein trafficking and progression of renal disease to terminal uremia. Benigni A, et al. **Semin Nephrol** 1996 May;16(3):151–9 (85 ref.)
Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Niwa T. **Semin Nephrol** 1996 May;16(3):167–82 (204 ref.)
Characterization of a hepatic protein in nonhuman primates that binds mibolerone but not dihydrotestosterone or methyltrienolone. Koritnik DR, et al. **Steroids** 1995 Nov; 60(11):759–67
14-3-3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)
Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187–226 (181 ref.)
An animal model for measurement of protein metabolism in the skin. Zhang XJ, et al. **Surgery** 1996 Mar;119(3):326–32
Glycosomes—the organelles of glycogen metabolism. Rybicka KK. **Tissue Cell** 1996 Jun;28(3):253–65 (63 ref.)
The effects of peroxisome proliferators on protein abundances in mouse liver. Anderson NL, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):75–89
Monitoring of human exposure to carcinogens through DNA and protein adduct determination. Farmer PB. **Toxicol Lett** 1995 Dec;82–83:757–62 (24 ref.)
Acetaminophen-arylated proteins are detected in hepatic subcellular fractions and numerous extra-hepatic tissues in CD-1 and C57B1/6J mice. Bulera SJ, et al. **Toxicology** 1996 May 17;109(2–3):85–99
Synaptosomal binding of 125I-labelled daboiatoxin, a new PLA2 neurotoxin from the venom of Daboia russelli siamensis. Maung-Maung-Thwin, et al. **Toxicon** 1996 Feb; 34(2):183–99
Ornithine decarboxylase antizyme: a novel type of regulatory protein. Hayashi S, et al. **Trends Biochem Sci** 1996 Jan; 21(1):27–30 (47 ref.)
The use of phage display in neurobiology. Bradbury A, et al. **Trends Neurosci** 1995 Jun;18(6):243–9 (63 ref.)
Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Iwamura M, et al. **Urology** 1996 Aug;48(2):317–25
Expression of the human MxA protein is associated with hyperphosphorylation of VSV P protein in human neural Cells. Schuster A, et al. **Virology** 1996 Jun 1;220(1):241–5
[Effect of electric fields on the proteins in nerve regeneration conditioned fluid] Li Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug;75(8):470–2, 510 (Eng. Abstr.) **(Chi)**
[Diagnosis of malaria in Africa using the Parasight F test] Coue JC, et al. **Med Trop (Mars)** 1995;55(4):333–5 (Eng. Abstr.) **(Fre)**
[Empty body weight gain, protein, fat and energy deposit and utilization of metabolizable energy for energy deposit in black and white bulls. 2. Protein, fat and energy deposit] Gabel M, et al. **Arch Tierernahr** 1995;48(3):271–86 (Eng. Abstr.) **(Ger)**
[Empty body weight gain, protein, faty and energy deposit and utilization of metabolizable energy for energy deposit in black and white bulls. 2. Relationship between energy deposit and intake of metabolizable energy] Gabel M, et al. **Arch Tierernahr** 1995;48(3):287–301 (Eng. Abstr.) **(Ger)**
[Investigations of empty body weight gain, on protein, fat and energy disposition as well as on utilization of metabolizable energy for energy deposition in black and white bulls. 1. Empty body weight gain] Papstein I, et al. **Arch Tierernahr** 1995;48(1–2):201–10 (Eng. Abstr.) **(Ger)**
[Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats] Reichel K, et al. **Arch Tierernahr** 1993;45(3):211–25 (Eng. Abstr.) **(Ger)**
[Protein-carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**
[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):205–9 (22 ref.) (Eng. Abstr.) **(Ger)**
[Protein translocation machinery—how far it has been elucidated by membrane reconstitution approach] Watanabe M. **Seikagaku** 1995 Dec;67(12):1401–6 (18 ref.) **(Jpn)**
[COP-coated vesicles in intracellular protein transport] Kuge O, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(16):2427–35 (39 ref.) **(Jpn)**
[Interaction of free radicals with proteins] Skrzydlewska E, et al. **Postepy Hig Med Dosw** 1995;49(6):747–66 (92 ref.) (Eng. Abstr.) **(Pol)**
[Quantitative determination of cattle angiogenin] Rogov IA, et al. **Biokhimiia** 1995 Aug;60(8):1344–8 (Eng. Abstr.) **(Rus)**
[Endogenous phosphorylation of lysosomal proteins from rat heart and liver in the early post-resuscitation period] Ivanova TN, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):51–3 **(Rus)**
[Reconstruction of a section of the electron transfer chain, including cytochrome b561, an acidic copper-containing protein, and dopamine-beta-monooxygenase, in chromaffin granule membranes] Boiadzhian AS, et al. **Dokl Akad Nauk** 1995 Oct;344(6):827–9 **(Rus)**
[A protein product of the tobamovirus open translation frame forms a stable complex with translation elongation factor eEF-1alpha] Fedorkin ON, et al. **Dokl Akad Nauk** 1995 Aug;343(5):703–4 **(Rus)**
[Several indicators of protein and nucleic acid metabolism in lymphoid organs of rats exposed to hypokinesia and vitamin B1 deficiency] Dvorianinovich LN, et al. **Kosm Biol Aviakosm Med** 1991 Sep-Oct;25(5):41–3 (Eng. Abstr.) **(Rus)**
[Regulation by thyroxine of the functional activity of liver and brain mitochondria in developing rats and participation of cytoplasmic protein factors in this process] Turakulov IAKh, et al. **Vopr Med Khim** 1995 Sep-Oct;41(5):45–8 (Eng. Abstr.) **(Rus)**
[Epilepsy and cerebral aging. Pharmacokinetics of antiepileptic treatment in adult age] Oller Ferrer-Vidal L. **Rev Neurol** 1995 Nov-Dec;23(124):1318–9 **(Spa)**
[Leptin and obesity—an error (letter)] Lehmann A. **Lakartidningen** 1996 Feb 28;93(9):761, 763 **(Swe)**
[The hormone leptin reduces body weight. A mutant gene makes the mouse obese] Meister B, et al. **Lakartidningen** 1996 Jan 24;93(4):247–51 (18 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOKINETICS

Ileal recovery of nutrients and mucin in humans fed total enteral formulas supplemented with soy fiber. Lien KA, et al. **Am J Clin Nutr** 1996 Apr;63(4):584–95
Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Perna A, et al. **Am J Kidney Dis** 1996 Jan;27(1):34–41
Protein release kinetics of a biodegradable implant for fracture non-unions. Agrawal CM, et al. **Biomaterials** 1995 Nov;16(16):1255–60
Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins. Huatan H, et al. **Biomaterials** 1995 Nov; 16(17):1297–303
The correlation between protein catabolic rate and Kt/V in hemodialysis is not a mathematical artifact. Buur T, et al. **Int J Artif Organs** 1995 Jul;18(7):351–4
The transmucosal absorption of recombinant human interferon-alpha B/D hybrid in the rat and rabbit. Bayley D, et al. **J Pharm Pharmacol** 1995 Sep;47(9):721–4
Human leptin characterization [letter] Cohen SL, et al. **Nature** 1996 Aug 15;382(6592):589
Leptin enters the brain by a saturable system independent of insulin. Banks WA, et al. **Peptides** 1996;17(2):305–11

PHARMACOLOGY

Bone graft proteins influence osteoconduction. A titanium chamber study in rats. Aspenberg P, et al. **Acta Orthop Scand** 1996 Aug;67(4):377–82
BMP-2 for intramuscular bone induction: effect in squirrel monkeys is dependent on implantation site. Aspenberg P, et al. **Acta Orthop Scand** 1996 Feb;67(1):3–6
Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Zoja C, et al. **Am J Kidney Dis** 1995 Dec;26(6):934–41
Parathyroid hormone-related protein, an autocrine regulatory factor in alveolar epithelial cells. Hastings RH, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L353–61
Osteogenic protein-1 enhances phenotypic expression in ROS 17/2.8 cells. Kitten AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E918–26
Alginate, the slime exopolysaccharide of Pseudomonas aeruginosa, binds human leukocyte elastase, retards inhibition by alpha 1-proteinase inhibitor, and accelerates inhibition by secretory leukoprotease inhibitor. Ying QL, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):283–91
Regulation of glycosaminoglycan metabolism by bone morphogenetic protein-2 in equine cartilage explant cultures. Loredo GA, et al. **Am J Vet Res** 1996 Apr; 57(4):554–9
Changes in bone morphogenetic protein sensitivity relative to differentiation in fetal rat bone cell cultures. Centrella M, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:224–6
Role of BMP-2a in otic capsule chondrogenesis. Frenz DA,

et al. **Ann N Y Acad Sci** 1996 Jun 8;785:256–8
Identification of an AP1–like response region for osteogenic protein–1 in type X collagen promoter. Harada S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:259–60
Homeobox gene expression during bone formation induced by BMP. Iimura T, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:274–7
Protein inhibitor of mitochondrial ATP synthase: relationship of inhibitor structure to pH–dependent regulation. Lebowitz MS, et al. **Arch Biochem Biophys** 1996 Jun 15; 330(2):342–54
Differential effects of bovine PA28 on six peptidase activities of the lobster muscle proteasome (multicatalytic proteinase). Mykles DL. **Arch Biochem Biophys** 1996 Jan 1;325(1):77–81
Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. Walter M, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):81–8
Transdentinal stimulation of reparative dentine formation by osteogenic protein–1 in monkeys. Rutherford B, et al. **Arch Oral Biol** 1995 Jul;40(7):681–3
Differential activation of PKC isozymes by 14–3–3 zeta protein. Acs P, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):103–9
Bone morphogenetic protein–12 and –13 inhibit terminal differentiation of myoblasts, but do not induce their differentiation into osteoblasts. Inada M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):317–22
Stimulation by C–type natriuretic peptide of the differentiation of clonal osteoblastic MC3T3–E1 cells. Inoue A, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):703–7
Comparative study of bone marrow induced by purified BMP and recombinant human BMP–2. Kusumoto K, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):205–11
Stabilization of helix by side–chain interactions in histatin–derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):47–53
Agouti protein inhibits growth of B16 melanoma cells in vitro by acting through melanocortin receptors. Siegrist W, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):171–5
C–type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Suda M, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):1–6
Enhancement of smooth muscle contraction with protein phosphatase inhibitor 1: activation of inhibitor 1 by cGMP–dependent protein kinase. Tokui T, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):777–83
Phospholipase A2–activating peptide–induced contraction of smooth muscle is mediated by protein kinase C—MAP kinase cascade. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):203–10
Effects of BMP–2, BMP–4, and BMP–6 on osteoblastic differentiation of bone marrow–derived stromal cell lines, ST2 and MC3T3–G2/PA6. Yamaguchi A, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):366–71
Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin. Belorgey D, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):555–60
Identification of 14–3–3 proteins in human platelets: effects of synthetic peptides on protein kinase C activation. Wheeler–Jones CP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):41–7
Bone morphogenetic protein–2 is markedly synergistic with tumor necrosis factor in stimulating the production of nerve growth factor in fibroblasts. Hattori A, et al. **Biochem Mol Biol Int** 1996 May;38(6):1095–101
The myristoylated alanine–rich C–kinase substrate (MARCKS) is not required for mitogenic signalling via protein kinase C in cultured rat intestinal epithelial (RIE–1) cells. Smith RD. **Biochem Mol Biol Int** 1995 Apr; 35(5):1029–35
Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. Correia I, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):413–24
Protein and peptide inhibitors of the F1–ATPase. Harris DA. **Biochem Soc Trans** 1995 Nov;23(4):790–3
Agouti structure and function: characterization of a potent alpha–melanocyte stimulating hormone receptor antagonist. Willard DH, et al. **Biochemistry** 1995 Sep 26; 34(38):12341–6
Thyroid hormone induces a 52 kDa soluble protein in goat testis Leydig cell which stimulates androgen release. Jana NR, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):209–14
Mitogenic stimulation of human lymphocytes mediated by a cell surface elastase. Packard BZ, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):51–6
Histidine–49 is necessary for the pH–dependent transition between active and inactive states of the bovine F1–ATPase inhibitor protein. Schnizer R, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):241–8
Effectors of cyclic adenosine 5'–monophosphate up–regulating–oxytocin receptors in rabbit amnion cells: isoproterenol, parathyroid hormone–related protein, and potentiation by cortisol. Jeng YJ, et al. **Biol Reprod** 1995 Nov;53(5):1051–6
Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Molineux G, et al. **Blood** 1996 Aug 15; 88(4):1509–14
The (18–48)–fragment of human parathyroid hormone is a partial agonist for cAMP–dependent actions with retained mitogenic function. Duvos C, et al. **Bone** 1995 Oct; 17(4):403–6
Bone morphogenetic protein–2 but not bone morphogenetic protein–4 and –6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2–OS cells. LInd M, et al. **Bone** 1996 Jan;18(1):53–7
Detection of membrane–bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides. Sorci G, et al. **Brain Res** 1995 Jun 12;683(1):51–8
Phospholipase A2–mediated inflammation induces regression of malignant gliomas. Goddard DH, et al. **Cancer Lett** 1996 Apr 19;102(1–2):1–6
Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Shah NM, et al. **Cell** 1996 May 3;85(3):331–43
Vgr–1/BMP–6 induces osteoblastic differentiation of pluripotential mesenchymal cells. Gitelman SE, et al. **Cell Growth Differ** 1995 Jul;6(7):827–36
Regulation of the insect immune response: the effect of hemolin on cellular immune mechanisms. Lanz–Mendoza H, et al. **Cell Immunol** 1996 Apr 10;169(1):47–54
Rat seminal vesicle protein SV–IV and its transglutaminase–synthesized polyaminated derivative SPD2–SV–IV induce cytokine release from human resting lymphocytes and monocytes in vitro. Tufano MA, et al. **Cell Immunol** 1996 Mar 15;168(2):148–57
Bone morphogenetic protein–2 does not alter the differentiation pathway of committed progenitors of osteoblasts and chondroblasts. Komaki M, et al. **Cell Tissue Res** 1996 Apr;284(1):9–17
Synthesis of protegrin–related peptides and their antibacterial and anti–human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853–8
C–type natriuretic peptide. An endogenous inhibitor of vascular angiotensin–converting enzyme activity. Davidson NC, et al. **Circulation** 1996 Mar 15;93(6):1155–9
Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease. Matoušek J, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):235–41
Antibacterial activity in the coelomocytes of the sea urchin Paracentrotus lividus. Stabili L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):639–44
Two distinctive BMP–carriers induce zonal chondrogenesis and membranous ossification, respectively; geometrical factors of matrices for cell–differentiation. Kuboki Y, et al. **Connect Tissue Res** 1995;32(1–4):219–26
Number of adrenergic and islet–1 immunoreactive cells is increased in avian trunk neural crest cultures in the presence of human recombinant osteogenic protein–1. Varley JE, et al. **Dev Dyn** 1995 Aug;203(4):434–47
Bone morphogenetic protein–4 (BMP–4) acts during gastrula stages to cause ventralization of Xenopus embryos. Jones CM, et al. **Development** 1996 May;122(5):1545–54
Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Schwartz MW, et al. **Diabetes** 1996 Apr;45(4):531–5
Determinants of Ras proteins specifying the sensitivity to yeast Ira2p and human p120–GAP. Parrini MC, et al. **EMBO J** 1996 Mar 1;15(5):1107–11
Leptin is a metabolic signal to the reproductive system. Barash IA, et al. **Endocrinology** 1996 Jul;137(7):3144–7
The human PTH2 receptor: binding and signal transduction properties of the stably expressed recombinant receptor. Behar V, et al. **Endocrinology** 1996 Jul;137(7):2748–57
Specific binding sites for proadrenomedullin N–terminal 20 peptide (PAMP) in the rat. Iwasaki H, et al. **Endocrinology** 1996 Jul;137(7):3045–50
Effect of endogenously produced parathyroid hormone–related peptide on growth of a human hepatoma cell line (Hep G2). Li H, et al. **Endocrinology** 1996 Jun; 137(6):2367–74
Osteogenic protein–1–mediated insulin–like growth factor gene expression in primary cultures of rat osteoblastic cells. Yeh LC, et al. **Endocrinology** 1996 May;137(5):1921–31
The pentadecapeptide [Ser1]histogranin impairs passive avoidance learning in mice. Maurice T, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):251–4
Corrigendum to 'the pentadecapeptide [Ser1]histogranin impairs passive avoidance learning in mice' [Eur. J. Pharmacol. 283 (1995) 251–254]. Maurice T, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):219
Inhibition of catecholamine synthesis by proadrenomedullin N–terminal 20 peptide in cultured bovine adrenal medullary cells. Niina H, et al. **Eur J Pharmacol** 1995 Nov 3; 286(1):95–7
Human osteogenic protein–1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Asahina I, et al. **Exp Cell Res** 1996 Jan 10;222(1):38–47
TIMP–2 growth–stimulatory activity: a concentration– and cell type–specific response in the presence of insulin. Nemeth JA, et al. **Exp Cell Res** 1996 Apr 10;224(1):110–5
Recombinant human bone morphogenetic protein–2 induces a hematopoietic microenvironment in the rat that supports the growth of stem cells. An J, et al. **Exp Hematol** 1996 Jun;24(7):768–75
BMP–2 and BMP–4, but not BMP–6, increase the number of adrenergic cells which develop in quail trunk neural crest cultures. Varley JE, et al. **Exp Neurol** 1996 Jul; 140(1):84–94
The inhibitor protein of phosphorylated nitrate reductase from spinach (Spinacia oleracea) leaves is a 14–3–3 protein. Bachmann M, et al. **FEBS Lett** 1996 Jun 3;387(2–3):127–31
Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation. Mangoni ME, et al. **FEBS Lett** 1996 Mar 25;383(1–2):93–8
Combinatorial signaling by Sonic hedgehog and Wnt family members induces myogenic bHLH gene expression in the somite. Münsterberg AE, et al. **Genes Dev** 1995 Dec 1; 9(23):2911–22
Gonadotrophin surge–inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)
Natriuretic peptide receptors in human artery and vein and rabbit vein graft. Ikeda T, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):833–7
Parathyroid hormone–related protein inhibits indothelin–1 production. Jiang B, et al. **Hypertension** 1996 Mar;27(3 Pt 1):360–3
In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Miyakawa Y, et al. **Infect Immun** 1996 Mar;64(3):926–32
Inhibition of S–fimbria–mediated adhesion to human ileostomy glycoproteins by a protein isolated from bovine colostrum. Ouwehand AC, et al. **Infect Immun** 1995 Dec; 63(12):4917–20
Susceptibility of Neisseria gonorrhoeae to protegrins. Qu XD, et al. **Infect Immun** 1996 Apr;64(4):1240–5
Susceptibility of Chlamydia trachomatis to protegrins and defensins. Yasin B, et al. **Infect Immun** 1996 Mar; 64(3):709–13
Presence of functional type B natriuretic peptide receptor in human ocular cells. Pang IH, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1724–31
Secretory leukoprotease inhibitor attenuates lung injury induced by continuous air embolization into sheep. Gossage JR, et al. **J Appl Physiol** 1995 Oct;79(4):1163–72
Parathyroid hormone and parathyroid hormone–related peptide activate the Na+/H+ exchanger NHE–1 isoform in osteoblastic cells (UMR–106) via a cAMP–dependent pathway. Azarani A, et al. **J Biol Chem** 1995 Sep 29; 270(39):23166–72
Structurally diverse N–terminal peptides of parathyroid hormone (PTH) and PTH–related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. Azarani A, et al. **J Biol Chem** 1996 Jun 21;271(25):14931–6
Pigment epithelium–derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. Becerra SP, et al. **J Biol Chem** 1995 Oct 27;270(43):25992–9
Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. Franzke CW, et al. **J Biol Chem** 1996 Sep 6;271(36):21886–90
Characterization of the bone morphogenetic protein–2 as a neurotrophic factor. Induction of neuronal differentiation of PC12 cells in the absence of mitogen–activated protein kinase activation. Iwasaki S, et al. **J Biol Chem** 1996 Jul 19;271(29):17360–5
The myeloid leukemia–associated protein SET is a potent inhibitor of protein phosphatase 2A. Li M, et al. **J Biol Chem** 1996 May 10;271(19):11059–62
Human cytoplasmic antiproteinase neutralizes rapidly and efficiently chymotrypsin and trypsin–like proteases utilizing distinct reactive site residues. Riewald M, et al. **J Biol Chem** 1996 Jun 14;271(24):14526–32
Parathyroid hormone–related protein antagonizes the action of parathyroid hormone on adult cardiomyocytes. Schlüter KD, et al. **J Biol Chem** 1996 Feb 9;271(6):3074–8
Variabilin, a novel RGD–containing antagonist of glycoprotein IIb–IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Wang X, et al. **J Biol Chem** 1996 Jul 26;271(30):17785–90
The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP–2 and TIMP–3. Will H, et al. **J Biol Chem** 1996 Jul 19;271(29):17119–23
Parathyroid hormone–related protein is an autocrine modulator of rabbit proximal tubule cell growth. García–Ocaña A, et al. **J Bone Miner Res** 1995 Dec; 10(12):1875–84
A comparison of the effects of parathyroid hormone and parathyroid hormone–related protein on osteocalcin in the rat. Gundberg CM, et al. **J Bone Miner Res** 1995 Jun; 10(6):903–9
Stimulatory effect of bone morphogenetic protein–2 on osteoclast–like cell formation and bone–resorbing activity. Kanatani M, et al. **J Bone Miner Res** 1995 Nov; 10(11):1681–90
Bone morphogenetic proteins inhibit adipocyte differentiation

by bone marrow stromal cells. Gimble JM, et al. **J Cell Biochem** 1995 Jul;58(3):393–402

Transforming growth factor–beta, osteogenin, and bone morphogenetic protein–2 inhibit intercellular communication and alter cell proliferation in MC3T3–E1 cells. Rudkin GH, et al. **J Cell Physiol** 1996 Aug; 168(2):433–41

Parathyroid hormone (PTH)–related protein(1–36) is equipotent to PTH(1–34) in humans. Everhart–Caye M, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):199–208

Elafin, a serine elastase inhibitor, attenuates post–cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. Cowan B, et al. **J Clin Invest** 1996 Jun 1;97(11):2452–68

Proadrenomedullin NH2–terminal 20 peptide inhibits the voltage–gated Ca2+ channel current through a pertussis toxin–sensitive G protein in rat pheochromocytoma–derived PC 12 cells. Takano K, et al. **J Clin Invest** 1996 Jul 1;98(1):14–7

Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. Weigle DS, et al. **J Clin Invest** 1995 Oct;96(4):2065–70

Agouti protein can act independently of melanocyte–stimulating hormone to inhibit melanogenesis. Hunt G, et al. **J Endocrinol** 1995 Nov;147(2):R1–4

A20 zinc finger protein inhibits TNF and IL–1 signaling. Jäättelä M, et al. **J Immunol** 1996 Feb 1;156(3):1166–73

Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein. van den Berg RH, et al. **J Immunol** 1996 Jun 1; 156(11):4466–73

Identification of Gas6 as a growth factor for human Schwann cells. Li R, et al. **J Neurosci** 1996 Mar 15;16(6):2012–9

Human cementum protein extract promotes chondrogenesis and mineralization in mesenchymal cells. Arzate H, et al. **J Periodontal Res** 1996 Feb;31(2):144–8

Commercially–prepared allograft material has biological activity in vitro. Shigeyama Y, et al. **J Periodontol** 1995 Jun;66(6):478–87

Acceleration of puberty onset in female mice by male urinary proteins. Mucignat–Caretta C, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):517–22

HL–60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase–9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. Ries C, et al. **Leukemia** 1996 Sep; 10(9):1520–6

Comparison of bronchodilator responses to adrenomedullin and proadrenomedullin N–terminal 20 peptide. Kanazawa H, et al. **Life Sci** 1995;57(16):PL241–5

Histogranin, a modified histone H4 fragment endowed with N–methyl–D–aspartate antagonist and immunostimulatory activities. Lemaire S, et al. **Life Sci** 1995 Mar 3; 56(15):1233–41 (34 ref.)

Induction in the mouse of gene expression of immunomodulating cytokines by mushroom polysaccharide–protein complexes. Liu F, et al. **Life Sci** 1996;58(21):1795–803

Role of parathyroid hormone–related protein in the proliferation of vascular smooth muscle cells. Jiang B, et al. **Miner Electrolyte Metab** 1995;21(1–3):157–60

Effects of C–terminal parathyroid hormone–related peptide on osteoblasts. Seitz PK, et al. **Miner Electrolyte Metab** 1995;21(1–3):180–3

Signal transduction mechanisms of parathyroid hormone– and parathyroid hormone–related–peptide–stimulated osteoclast–like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)

DOCK180, a major CRK–binding protein, alters cell morphology upon translocation to the cell membrane. Hasegawa H, et al. **Mol Cell Biol** 1996 Apr;16(4):1770–6

Parathyroid hormone–related peptide and 8701–BC breast cancer cell growth and invasion in vitro: evidence for growth–inhibiting and invasion–promoting effects. Luparello C, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):225–32

Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus. Glaum SR, et al. **Mol Pharmacol** 1996 Aug;50(2):230–5

Effect of cyclic GMP–increasing agents nitric oxide and C–type natriuretic peptide on bovine chromaffin cell function: inhibitory role mediated by cyclic GMP–dependent protein kinase. Rodriguez–Pascual F, et al. **Mol Pharmacol** 1996 Jun;49(6):1058–70

Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y [see comments] Erickson JC, et al. **Nature** 1996 May 30;381(6581):415–21. Comment in: Nature 1996 May 30;381(6581):377–8.

Parathyroid–hormone–related protein: a previously unrecognized renal vasodilator [editorial] Massfelder T, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):1984–6

Osteogenic protein–1 induces dendritic growth in rat sympathetic neurons. Lein P, et al. **Neuron** 1995 Sep; 15(3):597–605

C–type natriuretic peptide can modify the acute and chronic effects of morphine. Babarczy E, et al. **Neuropeptides** 1995 Sep;29(3):145–9

Repair of calvarial defects with flap tissue: role of bone morphogenetic proteins and competent responding tissues. Khouri RK, et al. **Plast Reconstr Surg** 1996 Jul;98(1):103–9

The recombinant proregion of transforming growth factor beta1 (latency–associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Böttinger EP, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5877–82

Signaling by N– and C–terminal sequences of parathyroid hormone–related protein in hippocampal neurons. Fukayama S, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10182–6

Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Levin N, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1726–30

Purification and characterization of a luminal cholecystokinin–releasing factor from rat intestinal secretion. Spannagel AW, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4415–20

Recombinant human bone morphogenetic protein (rhBMP) induced heterotopic bone development in vivo and in vitro. Volek–Smith H, et al. **Proc Soc Exp Biol Med** 1996 Mar; 211(3):265–72

Histamine release induced by human natriuretic peptide from rat peritoneal mast cells. Yoshida H, et al. **Regul Pept** 1996 Jan 16;61(1):45–9

Does the p53 up–regulated Gadd45 protein have a role in excision repair? [letter; comment] Kazantsev A, et al. **Science** 1995 Nov 10;270(5238):1003–4; discussion 1005–6 . Comment on: Science 1994 Nov 25;266(5189):1376–80.

Does the p53 up–regulated Gadd45 protein have a role in excision repair? [letter; comment] Kearsey JM, et al. **Science** 1995 Nov 10;270(5238):1004–5; discussion 1005–6 . Comment on: Science 1994 Nov 25;266(5189):1376–80.

Evaluation of rhBMP–2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Sandhu HS, et al. **Spine** 1995 Dec 15;20(24):2669–82

A comparison of the effect of decorsin and two disintegrins, albolabrin and eristostatin, on platelet function. McLane MA, et al. **Thromb Haemost** 1995 Nov;74(5):1316–22

Interaction of echicetin with a high affinity thrombin binding site on platelet glycoprotein GPIb. Peng M, et al. **Thromb Haemost** 1995 Sep;74(3):954–7

Antimicrobial activity of chicken and turkey heterophil peptides CHP1, CHP2, THP1, and THP3. Evans EW, et al. **Vet Microbiol** 1995 Dec;47(3–4):295–303

Inhibition of human parainfluenza virus–3 replication by interferon and human MxA. Zhao H, et al. **Virology** 1996 Jun 15;220(2):330–8

[Characteristics and osteoinductive activity of bone morphogenetic protein (BMP) encapsulated with poly (DL–lactide–co–glycolide)] Isobe M. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):506–12 (Eng. Abstr.) **(Jpn)**

[Effect of protein inhibitors of mitochondrial ATPase in intact rat thymocytes and Ehrlich ascites carcinoma cells] Dedov VN, et al. **Biokhimiia** 1995 Jul;60(7):1138–45 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cartilage–derived morphogenetic proteins. Key regulators in chondrocyte differentiation? Luyten FP. **Acta Orthop Scand Suppl** 1995 Oct;266:51–4 (22 ref.)

Comparative bioactivity of atrial, brain, and C–type natriuretic peptides in conscious sheep. Charles CJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1324–31

Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone–induced acute inflammation. Nadziejko C, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1592–8

Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half–length secretory leukoprotease inhibitor. Suzuki T, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1405–11

BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80–97 (68 ref.)

BMP 7 is required for nephrogenesis, eye development, and skeletal patterning. Karsenty G, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:98–107

The role of BMPs and GDFs in development of region–specific skeletal structures. King JA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:70–9 (56 ref.)

Role of parathyroid hormone–related protein in skeletal development. Kronenberg HM, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:119–23

Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)

Lack of suppression of tumor cell phenotype by overexpression of TIMP–3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness. Sun Y, et al. **Anticancer Res** 1996 Jan–Feb;16(1):1–7

Electrophoretic modification of sperm plasma membrane by ventral prostate secretion in golden hamsters. Cheng LY, et al. **Arch Androl** 1995 Jul–Aug;35(1):13–20

Overexpression of MP41 gene in a transformed endothelial cell line correlates with the increased fibronectin expression and a decreased incidence of tumorigenicity. Kondo M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):398–404

Osteogenic protein–1 is required for mammalian eye development. Solursh M, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):438–43

The myristoylated alanine–rich C–kinase substrate (MARCKS) is not required for mitogenic signalling via protein kinase C in cultured rat intestinal epithelial (RIE–1) cells. Smith RD. **Biochem Mol Biol Int** 1995 Apr; 35(5):1029–35

14–3–3 proteins: biological function and domain structure. Aitken A, et al. **Biochem Soc Trans** 1995 Aug;23(3):605–11 (47 ref.)

Liposome fusion induced by a M(r) 18,000 protein localized to the acrosomal region of acrosome–reacted abalone spermatozoa. Swanson WJ, et al. **Biochemistry** 1995 Oct 31;34(43):14202–8

BMP–1 and the astacin family of metalloproteinases: a potential link between the extracellular matrix, growth factors and pattern formation. Sarras MP Jr. **Bioessays** 1996 Jun;18(6):439–42 (26 ref.)

Characterisation of protein structure/function relationship by sequence analysis without previous alignment: distinction between sub–groups of protein kinases. Guerrucci MA, et al. **Biosci Rep** 1995 Jun;15(3):161–71

Specific involvement of tyrosine 764 of human granulocyte colony–stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. de Koning JP, et al. **Blood** 1996 Jan 1;87(1):132–40

Fanconi anemia genes act to suppress a cross–linker–inducible p53–independent apoptosis pathway in lymphoblastoid cell lines. Kruyt FA, et al. **Blood** 1996 Feb 1;87(3):938–48

The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. Kupfer GM, et al. **Blood** 1996 Aug 1;88(3):1019–25

The role of BMP–4 and GATA–2 in the induction and differentiation of hematopoietic mesoderm in Xenopus laevis. Maeno M, et al. **Blood** 1996 Sep 15;88(6):1965–72

The Fanconi anemia complementation group C protein corrects DNA interstrand cross–link–specific apoptosis in HSC536N cells. Marathi UK, et al. **Blood** 1996 Sep 15; 88(6):2298–305

Proceedings of the XII International Conference on Calcium Regulating Hormones. Melbourne, Australia, February 14–19, 1995. **Bone** 1995 Aug;17(2 Suppl):1S–111S

bfl–1, a bcl–2 homologue, suppresses p53–induced apoptosis and exhibits potent cooperative transforming activity. D'Sa–Eipper C, et al. **Cancer Res** 1996 Sep 1; 56(17):3879–82

An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone–related protein in bone metastasis. Iguchi H, et al. **Cancer Res** 1996 Sep 1;56(17):4040–3

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel–Lindau tumor suppressor protein. Siemeister G, et al. **Cancer Res** 1996 May 15;56(10):2299–301

MARCKS functions as a novel growth suppressor in cells of melanocyte origin. Brooks G, et al. **Carcinogenesis** 1996 Apr;17(4):683–9

The Drosophila smoothened gene encodes a seven–pass membrane protein, a putative receptor for the hedgehog signal. Alcedo J, et al. **Cell** 1996 Jul 26;86(2):221–32

Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Dick TP, et al. **Cell** 1996 Jul 26;86(2):253–62

The Xenopus dorsalizing factor noggin ventralizes Drosophila embryos by preventing DPP from activating its receptor. Holley SA, et al. **Cell** 1996 Aug 23; 86(4):607–17

MADR1, a MAD–related protein that functions in BMP2 signaling pathways. Hoodless PA, et al. **Cell** 1996 May 17;85(4):489–500

Hedgehog, transmitted along retinal axons, triggers neurogenesis in the developing visual centers of the Drosophila brain. Huang Z, et al. **Cell** 1996 Aug 9; 86(3):411–22

Dorsal differentiation of neural plate cells induced by BMP–mediated signals from epidermal ectoderm. Liem KF Jr, et al. **Cell** 1995 Sep 22;82(6):969–79

Topographically specific effects of ELF–1 on retinal axon guidance in vitro and retinal axon mapping in vivo. Nakamoto M, et al. **Cell** 1996 Sep 6;86(5):755–66

Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)

Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP–4. Piccolo S, et al. **Cell** 1996 Aug 23;86(4):589–98

Lateral and axial signals involved in avian somite patterning: a role for BMP4. Pourquié O, et al. **Cell** 1996 Feb 9; 84(3):461–71

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Quelle DE, et al. **Cell** 1995 Dec 15; 83(6):993–1000

Induction of the LIM homeobox gene Lmx1 by WNT7a establishes dorsoventral pattern in the vertebrate limb. Riddle RD, et al. **Cell** 1995 Nov 17;83(4):631–40

The TNFR2–TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Rothe M, et al. **Cell** 1995 Dec 29;83(7):1243–52

The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Zimmerman LB, et al. **Cell** 1996 Aug 23;86(4):599–606

A progesterone–induced protein increases the synthesis of asymmetric antibodies. Kelemen K, et al. **Cell Immunol** 1996 Jan 10;167(1):129–34

Osteogenic protein-1: biology and applications. Cook SD, et al. **Clin Orthop** 1996 Mar;(324):29–38 (45 ref.)
Bone morphogenetic protein–induced heterotopic bone in osteopetrosis. Miyazawa K, et al. **Clin Orthop** 1996 Mar; (324):259–68
Regulation of bone formation by bone morphogenetic proteins and other growth factors. Mundy GR. **Clin Orthop** 1996 Mar;(324):24–8 (25 ref.)
Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Zhang LM, et al. **Crit Care Med** 1996 Feb;24(2):306–10
Parathyroid hormone–related protein. Moseley JM, et al. **Crit Rev Clin Lab Sci** 1995;32(3):299–343 (295 ref.)
Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612–4 (13 ref.)
Secretion of the amino–terminal fragment of the hedgehog protein is necessary and sufficient for hedgehog signalling in Drosophila. Fietz MJ, et al. **Curr Biol** 1995 Jun 1; 5(6):643–50
Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)
Limb–patterning activity and restricted posterior localization of the amino–terminal product of Sonic hedgehog cleavage. López-Martínez A, et al. **Curr Biol** 1995 Jul 1;5(7):791–6
Induction of motor neurons by Sonic hedgehog is independent of floor plate differentiation. Tanabe Y, et al. **Curr Biol** 1995 Jun 1;5(6):651–8
Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW. **Curr Opin Genet Dev** 1995 Aug;5(4):492–8 (67 ref.)
Natriuretic peptides and hypertension. Prins BA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):170–3 (29 ref.)
Maspin: a tumor suppressing serpin. Sager R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):51–64 (14 ref.)
Hairless promotes stable commitment to the sensory organ precursor cell fate by negatively regulating the activity of the Notch signaling pathway. Bang AG, et al. **Dev Biol** 1995 Dec;172(2):479–94
Bone morphogenetic protein–2 (BMP–2) inhibits muscle development and promotes cartilage formation in chick limb bud cultures. Duprez DM, et al. **Dev Biol** 1996 Mar 15;174(2):448–52
Specification of the anteroposterior neural axis through synergistic interaction of the Wnt signaling cascade with noggin and follistatin. McGrew LL, et al. **Dev Biol** 1995 Nov;172(1):337–42
Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp–4) plays a role in mouse embryonic lung morphogenesis. Bellusci S, et al. **Development** 1996 Jun;122(6):1693–702
The roles of hedgehog, wingless and lines in patterning the dorsal epidermis in Drosophila. Bokor P, et al. **Development** 1996 Apr;122(4):1083–92
Activation of Fgf-4 and HoxD gene expression by BMP-2 expressing cells in the developing chick limb. Duprez DM, et al. **Development** 1996 Jun;122(6):1821–8
hedgehog is required for the proliferation and specification of ovarian somatic cells prior to egg chamber formation in Drosophila. Forbes AJ, et al. **Development** 1996 Apr; 122(4):1125–35
Role of TGF beta s and BMPs as signals controlling the position of the digits and the areas of interdigital cell death in the developing chick limb autopod. Ganan Y, et al. **Development** 1996 Aug;122(8):2349–57
Complex expression of the zp–50 pou gene in the embryonic zebrafish brain is altered by overexpression of sonic hedgehog. Hauptmann G, et al. **Development** 1996 Jun; 122(6):1769–80
Xom: a Xenopus homeobox gene that mediates the early effects of BMP–4. Ladher R, et al. **Development** 1996 Aug; 122(8):2385–94
Fibroblast growth factor is a direct neural inducer, which combined with noggin generates anterior–posterior neural pattern. Lamb TM, et al. **Development** 1995 Nov; 121(11):3627–36
Function of the Polycomb protein is conserved in mice and flies. Müller J, et al. **Development** 1995 Sep;121(9):2847–52
Involvement of bone morphogenetic protein–4 and bone morphogenetic protein–7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons. Reissmann E, et al. **Development** 1996 Jul;122(7):2079–88
Neurofibromin–deficient fibroblasts fail to form perineurium in vitro. Rosenbaum T, et al. **Development** 1995 Nov; 121(11):3583–92
The functional conservation of proteins in evolutionary alleles and the dominant role of enhancers in evolution. Xue L, et al. **EMBO J** 1996 Jul 15;15(14):3722–31
The nature and function of putative gonadotropin surge–attenuating/inhibiting factor (GnSAF/IF). Fowler PA, et al. **Endocr Rev** 1996 Apr;17(2):103–20 (240 ref.)
C-type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa. Kawai M, et al. **Endocrinology** 1996 Jan;137(1):42–6
Activation of the JAK–STAT signal transduction pathway by oncostatin–M cultured human and mouse osteoblastic cells. Levy JB, et al. **Endocrinology** 1996 Apr; 137(4):1159–65
Carbohydrate and protein determinants are involved in thyroglobulin recognition by FRTL 5 cells. Mziaut H, et al. **Endocrinology** 1996 Apr;137(4):1370–7
Regulation in vivo of the growth of Leydig cell tumors by antisense ribonucleic acid for parathyroid hormone–related peptide. Rabbani SA, et al. **Endocrinology** 1995 Dec; 136(12):5416–22
Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661–71 (81 ref.)
Thyroid hormone induces the generation of a novel putative protein in piscine ovarian follicle that stimulates the conversion of pregnenolone to progesterone. Bhattacharya S, et al. **Eur J Endocrinol** 1996 Jan;134(1):128–35
Advances in the understanding of the molecular basis of obesity. Meier CA. **Eur J Endocrinol** 1995 Dec; 133(6):761–3
Parathyroid hormone–related protein: a polyhormone involved in growth, development and gestation [comment] Rizzoli R, et al. **Eur J Endocrinol** 1995 Sep;133(3):272–4 (35 ref.). Comment on: Eur J Endocrinol 1995 Sep;133(3):278–83.
Prohibitin and the senescent phenotype. Dell'Orco RT, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):245–52 (46 ref.)
Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):99–124 (90 ref.)
The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503–10 (69 ref.)
Prevention of growth arrest–induced cell death of vascular smooth muscle cells by a product of growth arrest–specific gene, gas6. Nakano T, et al. **FEBS Lett** 1996 May 27; 387(1):78–80
Stimulation of catecholamine secretion from adrenal chromaffin cells by 14–3–3 proteins is due to reorganisation of the cortical actin network. Roth D, et al. **FEBS Lett** 1995 Oct 23;374(1):77–81
20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferences. Stohwasser R, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):109–13
Genomes with distinct function composition. Tamames J, et al. **FEBS Lett** 1996 Jun 24;389(1):96–101 (13 ref.)
Four Arabidopsis thaliana 14–3–3 protein isoforms can complement the lethal yeast bmh1 bmh2 double disruption. van Heusden GP, et al. **FEBS Lett** 1996 Aug 12; 391(3):252–6
TANK, a co–inducer with TRAF2 of TNF– and CD 40L–mediated NF–kappaB activation. Cheng G, et al. **Genes Dev** 1996 Apr 15;10(8):963–73
Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL. **Genes Dev** 1996 Jul 1;10(13):1580–94 (160 ref.)
Lef1 expression is activated by BMP–4 and regulates inductive tissue interactions in tooth and hair development. Kratochwil K, et al. **Genes Dev** 1996 Jun 1;10(11):1382–94
The gene encoding bone morphogenetic protein 8B is required for the initiation and maintenance of spermatogenesis in the mouse. Zhao GQ, et al. **Genes Dev** 1996 Jul 1;10(13):1657–69
IL–4 producing CD4+ TCR alpha beta int liver lymphocytes: influence of thymus, beta 2–microglobulin and NK1.1 expression. Emoto M, et al. **Int Immunol** 1995 Nov;7(11):1729–39
Generation of normal lymphocytes derived from N–myc–deficient embryonic stem cells. Malynn BA, et al. **Int Immunol** 1995 Oct;7(10):1637–47
Time–dependent expression of bone sialoprotein fragments in osteogenesis induced by bone morphogenetic protein. Kobayashi D, et al. **J Biochem (Tokyo)** 1996 Mar; 119(3):475–81
Role of MacMARCKS in integrin–dependent macrophage spreading and tyrosine phosphorylation of paxillin. Li J, et al. **J Biol Chem** 1996 May 31;271(22):12985–90
MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. Matsumine A, et al. **J Biol Chem** 1996 Apr 26;271(17):10341–6
T1/ST2 signaling establishes it as a member of an expanding interleukin–1 receptor family. Mitcham JL, et al. **J Biol Chem** 1996 Mar 8;271(10):5777–83
Inhibition of Ras/Raf interaction by anti–oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell–free systems. Mori S, et al. **J Biol Chem** 1995 Dec 1;270(48):28834–8
Armadillo is required for adherens junction assembly, cell polarity, and morphogenesis during Drosophila embryogenesis. Cox RT, et al. **J Cell Biol** 1996 Jul; 134(1):133–48
Mutations in the Drosophila hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. Krämer H, et al. **J Cell Biol** 1996 Jun;133(6):1205–15
armadillo, bazooka, and stardust are critical for early stages in formation of the zonula adherens and maintenance of the polarized blastoderm epithelium in Drosophila. Müller HA, et al. **J Cell Biol** 1996 Jul;134(1):149–63
An in vivo structure–function study of armadillo, the beta–catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling. Orsulic S, et al. **J Cell Biol** 1996 Sep;134(5):1283–300
Isolation and characterization of a Drosophila gene essential for early embryonic development and formation of cortical cleavage furrows. Zhang CX, et al. **J Cell Biol** 1996 Aug; 134(4):923–34
C–terminal fragment of parathyroid hormone–related protein, PTHrP–(107–111), stimulates membrane–associated protein kinase C activity and modulates the proliferation of human and murine skin keratinocytes. Whitfield JF, et al. **J Cell Physiol** 1996 Jan; 166(1):1–11
Stratifin, a keratinocyte specific 14–3–3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. Dellambra E, et al. **J Cell Sci** 1995 Nov; 108 (Pt 11):3569–79
Phorbol esters induce death in MCF–7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53–independent induction of gadd–45 in initiating death. de Vente JE, et al. **J Clin Invest** 1995 Oct; 96(4):1874–86
The cell–coded polypeptide U90 increased by herpes simplex virus type 2 infection induces Fos and DNA synthesis. Macnab JC, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3131–6
Retroviral infection with human tyrosinase–related protein–1 (TRP–1) cDNA upregulates tyrosinase activity and melanin synthesis in a TRP–1–deficient melanoma cell line. Zhao H, et al. **J Invest Dermatol** 1996 Apr;106(4):744–52
Overexpression of MARCKS, but not protein kinase C–alpha, increases phorbol ester–stimulated synthesis of phosphatidylcholine in human SK–N–MC neuroblastoma cells. Rose SD, et al. **J Neurochem** 1996 Apr;66(4):1766–9
Increased zona–binding ability after incubation of spermatozoa with proteins extracted from spermatozoa of fertile semen. Jean M, et al. **J Reprod Fertil** 1995 Sep; 105(1):43–8
Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein. Frese M, et al. **J Virol** 1996 Feb; 70(2):915–23
Elevated parathyroid hormone–related peptide associated with lactation and bone density loss. Sowers MF, et al. **JAMA** 1996 Aug 21;276(7):549–54
The Drosophila cubitus interruptus protein and its role in the wingless and hedgehog signal transduction pathways. Motzny CK, et al. **Mech Dev** 1995 Jul;52(1):137–50
Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1–12 (133 ref.)
Parathyroid hormone–related peptide and models of vascular disease: its expression and action in vascular smooth muscle cells. Nishizawa Y, et al. **Miner Electrolyte Metab** 1995; 21(1–3):152–6 (36 ref.)
Localization and possible functions of Drosophila septins. Fares H, et al. **Mol Biol Cell** 1995 Dec;6(12):1843–59
The rho–GAP encoded by BEM2 regulates cytoskeletal structure in budding yeast. Wang T, et al. **Mol Biol Cell** 1995 Aug;6(8):1011–24
Protective effect of seminal plasma proteins on the degradation of ascorbic acid. Liu L, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):59–66
Genetic enhancement of RNA–processing defects by a dominant mutation in B52, the Drosophila gene for an SR protein splicing factor. Peng X, et al. **Mol Cell Biol** 1995 Nov;15(11):6273–82
Actions of parathyroid hormone–related peptide and its receptors [editorial; comment] Martin TJ. **N Engl J Med** 1996 Sep 5;335(10):736–8. Comment on: N Engl J Med 1996 Sep 5;335(10):708–14.
Serum leptin in normal–weight and obese humans [letter; comment] Pijl H, et al. **N Engl J Med** 1996 Jun 6; 334(23):1544. Comment on: N Engl J Med 1996 Feb 1;334(5):292–5.
Obesity, leptin, and the brain [editorial; comment] Rohner–Jeanrenaud F, et al. **N Engl J Med** 1996 Feb 1; 334(5):324–5. Comment on: N Engl J Med 1996 Feb 1;334(5):292–5.
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Bollag G, et al. **Nat Genet** 1996 Feb;12(2):144–8
Leptin activation of Stat3 in the hypothalamus of wild–type and ob/ob mice but not db/db mice. Vaisse C, et al. **Nat Genet** 1996 Sep;14(1):95–7
A broader role for leptin [letter; comment] Chehab FF. **Nat Med** 1996 Jul;2(7):723–4. Comment on: Nat Med 1996 May;2(5):492–3.
Leptin and nerve growth factor regulate adipose tissue [letter; comment] Nisoli E, et al. **Nat Med** 1996 Feb;2(2):130. Comment on: Nat Med 1995 Sep;1(9):950–3.
Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Wang MZ, et al. **Nat Med** 1995 Nov;1(11):1184–8
Access of ligands to cavities within the core of a protein is rapid. Feher VA, et al. **Nat Struct Biol** 1996 Jun; 3(6):516–21
Role of leptin in fat regulation [letter] Collins S, et al. **Nature** 1996 Apr 25;380(6576):677
A role for the proteasome regulator PA28alpha in antigen presentation. Groettrup M, et al. **Nature** 1996 May 9; 381(6578):166–8
Vascular system defects and neuronal apoptosis in mice lacking ras GTPase–activating protein. Henkemeyer M, et al. **Nature** 1995 Oct 26;377(6551):695–701
Fat regulation. Prime time for neuropeptide Y [news; comment] Howlett R. **Nature** 1996 Jul 11;382(6587):113. Comment on: Nature 1996 Jul 11;382(6587):168–71.
Function of 14–3–3 proteins [letter] Jin DY, et al. **Nature** 1996 Jul 25;382(6589):308
BMP–4–responsive regulation of dorsal–ventral patterning

by the homeobox protein Mix.1. Mead PE, et al. **Nature** 1996 Jul 25;382(6589):357–60

Calcium oscillations in mammalian eggs triggered by a soluble sperm protein. Parrington J, et al. **Nature** 1996 Jan 25;379(6563):364–8

The role of neuropeptide Y in the antiobesity action of the obese gene product. Stephens TW, et al. **Nature** 1995 Oct 12;377(6549):530–2

A light–entrainment mechanism for the Drosophila circadian clock. Zeng H, et al. **Nature** 1996 Mar 14;380(6570):129–35

Symposium on RNA biology. I. RNA–Protein Interactions. Research Triangle Park, North Carolina, October 13–15, 1995. **Nucleic Acids Symp Ser** 1995;(33):1–259

The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)– and GADD45–mediated response to DNA damage produced by ionising radiation. Artuso M, et al. **Oncogene** 1995 Oct 19;11(8):1427–35

The role of Grb2 in the growth and transformation of mouse embryo cells. D'Ambrosio C, et al. **Oncogene** 1996 Jan 18; 12(2):371–8

Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Goruppi S, et al. **Oncogene** 1996 Feb 1; 12(3):471–80

The SH2 domain of Shc suppresses EGF–induced mitogenesis in a dominant negative manner. Gotoh N, et al. **Oncogene** 1995 Dec 21;11(12):2525–33

GRB2 and SH–PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Huang L, et al. **Oncogene** 1995 Nov 16;11(10):2097–103

Analysis of protein–protein interactions involved in the activation of the Shc/Grb–2 pathway by the ErbB–2 kinase. Ricci A, et al. **Oncogene** 1995 Oct 19;11(8):1519–29

A cellular protein activates the sequence–specific DNA–binding of p53 by interacting with the central conserved region. Srinivasan R, et al. **Oncogene** 1996 Jan 4;12(1):193–200

Regulation of the Ras signaling pathway by GTPase–activating protein in PC12 cells. Yao R, et al. **Oncogene** 1995 Oct 19;11(8):1607–14

Application of fluorescence spectroscopy for determining the structure and function of proteins. Jiskoot W, et al. **Pharm Biotechnol** 1995;7:1–63 (185 ref.)

Defining the roles of parathyroid hormone–related protein in normal physiology. Philbrick WM, et al. **Physiol Rev** 1996 Jan;76(1):127–73 (293 ref.)

How optimization of potential functions affects protein folding. Hao MH, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4984–9

Regulation of patched by sonic hedgehog in the developing neural tube. Marigo V, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9346–51

Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. Re'em–Kalma Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12141–5

I–TRAF is a novel TRAF–interacting protein that regulates TRAF–mediated signal transduction. Rothe M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8241–6

Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor–associated factors. Uren AG, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4974–8

Neural tube defects and abnormal brain development in F52–deficient mice. Wu M, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2110–5

Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Fischer–Colbrie R, et al. **Prog Neurobiol** 1995 May;46(1):49–70 (209 ref.)

Parathyroid hormone–related protein. An analog of parathyroid hormone involved in regulation of growth, development, and gestation [editorial] Rizzoli R. **Rev Rhum Engl Ed** 1996 Feb;63(2):79–82 (40 ref.)

Receptors find work as guides [news] Barinaga M. **Science** 1995 Sep 22;269(5231):1668–70

Sending and receiving the hedgehog signal: control by the Drosophila Gli protein Cubitus interruptus [see comments] Dominguez M, et al. **Science** 1996 Jun 14;272(5268):1621–5 . Comment in: Science 1996 Jun 14;272(5268):1583–4.

Regulating G protein signaling [news]. Roush W. **Science** 1996 Feb 23;271(5252):1056–8

Putting the brakes on bone growth [news; comment] Roush W. **Science** 1996 Aug 2;273(5275):579. Comment on: Science 1996 Aug 2;273(5275):613–22. Comment on: Science 1996 Aug 2;273(5275):663–6.

Regulation of rate of cartilage differentiation by Indian hedgehog and PTH–related protein [see comments] Vortkamp A, et al. **Science** 1996 Aug 2;273(5275):613–22 . Comment in: Science 1996 Aug 2;273(5275):579.

The secreted product of Xenopus gene lunatic Fringe, a vertebrate signaling molecule. Wu JY, et al. **Science** 1996 Jul 19;273(5273):355–8

Requirement for BMP signaling in interdigital apoptosis and scale formation. Zou H, et al. **Science** 1996 May 3; 272(5262):738–41

Relationship of the ataxia–telangiectasia protein ATM to phosphoinositide 3–kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382–3 (22 ref.)

[Leptin—a new way to diet?] Holst JJ. **Ugeskr Laeger** 1996 Aug 5;158(32):4505–8 (25 ref.) (Eng. Abstr.) **(Dan)**

[Parathyroid hormone related peptide (PTHrP) and bone metabolism] Rouffet J, et al. **Arch Physiol Biochem** 1995 Apr;103(1):3–13 (76 ref.) (Eng. Abstr.) **(Fre)**

[Actions and physiological BMP—toward its clinical application] Komaki M, et al. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):430 **(Jpn)**

[Induction of an additional limb by FGF and duplication of digits by Sonic hedgehog] Ohuchi H, et al. **Seikagaku** 1995 Oct;67(10):1232–6 (16 ref.) **(Jpn)**

[14–3–3 protein family: the structure and function in cell signaling pathway] Shinkai F, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):313–26 (53 ref.) **(Jpn)**

[Leptin—satiety hormone? (editorial)] Chudek J, et al. **Pol Arch Med Wewn** 1996 May;95(5):397–401 **(Pol)**

[Interactions of proteins with damaged DNA] Widlak P. **Postepy Biochem** 1995;41(3):195–200 (71 ref.) **(Pol)**

RADIATION EFFECTS

Radiolytic protein surface mapping. Greiner DP, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1006–8

Molecular cloning of the human gene SUVCC3 associated with the formation of DNA–protein crosslinks following exposure to solar UV radiation. Rosenstein BS, et al. **Somat Cell Mol Genet** 1995 Jul;21(4):255–63

[Native protein activated by low doses of gamma radiation as a source of secondary biogenic radiation] Kuzin AM, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):284–90 (Eng. Abstr.) **(Rus)**

SECRETION

Lipoproteins regulate C–type natriuretic peptide secretion from cultured vascular endothelial cells. Sugiyama S, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1968–74

Structure of a D–protein gene and amino–acid sequences of the highly repetitive D–proteins secreted by the accessory glands of the mealworm beetle. Paesen GC, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):171–6

A new human breast cancer cell line, KPL–3C, secretes parathyroid hormone–related protein and produces tumours associated with microcalcifications in nude mice. Kurebayashi J, et al. **Br J Cancer** 1996 Jul;74(2):200–7

Membrane–type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Imai K, et al. **Cancer Res** 1996 Jun 15;56(12):2707–10

Insulin suppresses endothelial secretion of C–type natriuretic peptide, a novel endothelium–derived relaxing peptide. Igaki T, et al. **Diabetes** 1996 Jul;45 Suppl 3:S62–4

Amniotic fluid and plasma levels of parathyroid hormone–related protein and hormonal modulation of its secretion by amniotic fluid cells [see comments] Dvir R, et al. **Eur J Endocrinol** 1995 Sep;133(3):277–82. Comment in: Eur J Endocrinol 1995 Sep;133(3):272–4.

The secretion of parathyroid hormone–related protein in the saliva of sheep and its effects on the salivary clearance of phosphate, calcium, magnesium, potassium and sodium ions. Dua K, et al. **Exp Physiol** 1995 Jul;80(4):589–95

Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p–glycoprotein gene. Groen AK, et al. **Gastroenterology** 1995 Dec;109(6):1997–2006

Vascular endothelial growth factor suppresses C–type natriuretic peptide secretion. Doi K, et al. **Hypertension** 1996 Mar;27(3 Pt 2):811–5

Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. Holthuis JCM, et al. **J Biol Chem** 1996 Jul 26;271(30):17755–60

Neither type of mannose 6–phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. Kasper D, et al. **J Cell Biol** 1996 Aug;134(3):615–23

Peptide–bound methionine can be a source of methionine for the synthesis of secreted proteins by mammary tissue explants from lactating mice. Wang S, et al. **J Nutr** 1996 Jun;126(6):1662–72

Establishment and characterization of a novel cell line, TK–6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone–related protein. Watanabe T, et al. **Leukemia** 1995 Nov;9(11):1926–34

Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1–12 (133 ref.)

Modulation by melatonin of protein secretion from melanoma cells: is cAMP involved? Bubis M, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):169–75

Production and secretion of N–terminal secretogranin II derived peptides in GH3B6 prolactin cells. Muller L, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):101–12

Gastric acid–independent enhancement of exocrine pancreatic secretion by dietary protein in chronic bile–pancreatic juice diverted rats. Hara H, et al. **Pancreas** 1995 Aug;11(2):173–8

Nonclathrin coat protein gamma, a subunit of coatomer, binds to the cytoplasmic dilysine motif of membrane proteins of the early secretory pathway. Harter C, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1902–6

Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia. Kuznetsov G, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8584–9

The intrinsic ability of ribosomes to bind to endoplasmic reticulum membranes is regulated by signal recognition particle and nascent–polypeptide–associated complex [see comments] Lauring B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9435–9. Comment in: Proc Natl Acad Sci U S A 1995 Oct 10;92(21):9433–4.

Parathyroid hormone—related protein (PTHrP) is an epidermal growth factor–regulated secretory product of human prostatic epithelial cells. Cramer SD, et al. **Prostate** 1996 Jul;29(1):20–9

Characterization of natural killer cytotoxic factor (NKCF) from canine NK cells. Nakada Y, et al. **Vet Immunol Immunopathol** 1996 Jan;49(4):283–93

STANDARDS

[1995: a decisive progress for the interlaboratory transferability of results by using enzyme and protein reference materials (editorial)] Férard G, et al. **Ann Biol Clin (Paris)** 1995;53(9):469–71 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Administration of truncated secretory leukoprotease inhibitor ameliorates bleomycin–induced pulmonary fibrosis in hamsters. Mitsuhashi H, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):369–74

What's in the pipeline? Manuel SM. **Am Pharm** 1995 Sep; NS35(9):8–9

Extended lung preservation with the use of hibernation trigger factors. Oeltgen PR, et al. **Ann Thorac Surg** 1996 May;61(5):1488–93

Use of bone morphogenetic protein–2 in the rabbit ulnar nonunion model. Bostrom M, et al. **Clin Orthop** 1996 Jun; (327):272–82

Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Sikirić P, et al. **Dig Dis Sci** 1996 Aug;41(8):1604–14

Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Sikirić P, et al. **Dig Dis Sci** 1996 Jul; 41(7):1518–26

Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661–71 (81 ref.)

Efficacy of bone morphogenetic protein (BMP) with osteopromotive membranes—an experimental study in rat mandibular defects. Hedner E, et al. **Eur J Oral Sci** 1995 Aug;103(4):236–41

Dental benefit found during orthopedic study [news] **J Am Dent Assoc** 1996 Jul;127(7):854

Normalization of mineral homeostasis after reversal of osteopetrosis. Nesbitt T, et al. **J Bone Miner Res** 1995 Jul; 10(7):1116–21

Periodontal regenerative potential of space–providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511–21 (37 ref.)

The potential role of bone morphogenetic proteins in periodontal reconstruction. Wozney JM. **J Periodontol** 1995 Jun;66(6):506–10 (34 ref.)

Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Chehab FF, et al. **Nat Genet** 1996 Mar;12(3):318–20

Maxillary alveolar cleft repair in dogs using recombinant human bone morphogenetic protein–2 and a polymer carrier. Mayer M, et al. **Plast Reconstr Surg** 1996 Aug; 98(2):247–59

Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker–Head CA. **Vet Surg** 1995 Sep–Oct;24(5):408–19 (80 ref.)

[The use of bone morphogenetic proteins in delayed fracture healing, pseudoarthrosis and in ulna osteotomy carried out because of elbow joint diseases] Paatsama S, et al. **Tierarztl Prax** 1996 Apr;24(2):164–8 (Eng. Abstr.) **(Ger)**

TOXICITY

Partial N–terminal amino acid sequence of the anti–neoplastic urinary protein (ANUP) and the anti–tumour effect of the N–terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1–5

Special considerations for conducting genotoxicity tests with protein materials. Kirkland DJ, et al. **Mutagenesis** 1995 Sep; 10(5):393–8

ULTRASTRUCTURE

Direct structure determination by electron crystallography: protein data sets. Dorset DL. **Micron** 1995;26(6):511–20

Why protein crystals favour some space–groups over others. Wukovitz SW, et al. **Nat Struct Biol** 1995 Dec;2(12):1062–7

URINE see PROTEINURIA

PROTEINS, ACUTE–PHASE see **ACUTE–PHASE PROTEINS**

PROTEINS, IMMEDIATE–EARLY see

IMMEDIATE-EARLY PROTEINS

PROTEINS, RIBOSOMAL see RIBOSOMAL PROTEINS

PROTEINURIA

Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Kabanda A, et al. **Am J Kidney Dis** 1996 Jun;27(6):803–8

Urinary indices in llamas fed different diets. Lackey MN, et al. **Am J Vet Res** 1995 Jul;56(7):859–65

Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Wang SL, et al. **Diabetes Care** 1996 Apr; 19(4):305–12

24-h ambulatory blood pressure, daytime and nighttime urinary albumin and retinol-binding protein excretion in type I diabetic patients. Pontuch P, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):234–6

Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria. Wanner C, et al. **Miner Electrolyte Metab** 1996;22(1-3):26–30

Quantitative determination of urine proteins: a rapid, noninvasive, sensitive, and inexpensive method to monitor renal grafts. Hoyer J, et al. **Transplant Proc** 1995 Oct; 27(5):2571–2

Correlation between proteinuria and prognosis of transplant IgA nephropathy. Kimata N, et al. **Transplant Proc** 1996 Jun;28(3):1537–9

The mismatch of donor/recipient size influences development of proteinuria in allograft kidney transplants. Lee SW, et al. **Transplant Proc** 1996 Jun;28(3):1480–1

Urinary protein/creatinine ratio in the evaluation of renal failure in canine leishmaniasis. Palacio J, et al. **Vet Rec** 1995 Nov 25;137(22):567–8

[Anti-proteinuria effects of nonsteroidal anti-inflammatory drugs in patients with nephrotic syndrome: an illusion or a read improvement?] Stošić Z, et al. **Med Pregl** 1995; 48(5-6):155–8 (Eng. Abstr.) **(Scr)**

BLOOD

Low molecular weight proteinuria in Chinese herbs nephropathy. Kabanda A, et al. **Kidney Int** 1995 Nov; 48(5):1571–6

The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. Dullaart RP, et al. **Metabolism** 1996 Jun;45(6):723–30

CHEMICALLY INDUCED

Absence of tubular proteinuria following environmental exposure to chromium. Wedeen RP, et al. **Arch Environ Health** 1996 Jul-Aug;51(4):321–3

Thrombolytic treatment and proteinuria. Lynch M, et al. **Br Heart J** 1995 Oct;74(4):354–7

Should tests for proteinuria be included in the monitoring schedule of sulphasalazine? Helliwell PS. **Br J Rheumatol** 1995 Aug;34(8):790–1

Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Heeringa P, et al. **Clin Exp Immunol** 1996 Aug;105(2):321–9

Urinary protein excretion of semidomesticated mink in a chronic methylmercury study. Chamberland G, et al. **J Toxicol Environ Health** 1996 Feb 23;47(3):285–97

S-(1,2-dichlorovinyl)-L-cysteine-induced nephrotoxicity in the New Zealand white rabbit: characterization of proteinuria and examination of the potential role of oxidative injury. Davis JW, et al. **Toxicol Pathol** 1995 Jul-Aug;23(4):487–97

COMPLICATIONS

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Peterson JC, et al. **Ann Intern Med** 1995 Nov 15; 123(10):754–62

Proteinuria: a mediator of interstitial fibrosis? Harris KP, et al. **Contrib Nephrol** 1996;118:173–9 (28 ref.)

Poststreptococcal glomerulonephritis with the nephrotic range of proteinuria. Washio M, et al. **Int Urol Nephrol** 1995;27(4):457–64

Antineutrophil cytoplasmic antibodies are present in long standing type 1 diabetics but do not correlate with selective proteinuria. Pietravalle P, et al. **J Autoimmun** 1996 Feb; 9(1):113–7

Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I. Hirschberg R. **J Clin Invest** 1996 Jul 1;98(1):116–24

Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. Sawicki PT, et al. **J Intern Med** 1996 Apr;239(4):345–52

Polymyositis, arthritis, and proteinuria in a patient with adult celiac disease. Evron E, et al. **J Rheumatol** 1996 Apr; 23(4):782–3

Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Jungers P, et al. **Nephrol Dial Transplant** 1995; 10(8):1353–60

Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Locatelli F, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):461–7

[A case of hemolytic uremic syndrome accompanied by massive proteinuria and ascites] Ookawara S, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb;38(2):98–102 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

A comparison between two screening methods for detection of microproteinuria. Higby K, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1111–4

Development and evaluation of a urine protein expert system. Ivandić M, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1214–22

A mathematical equation to differentiate overload proteinuria from tubulo-interstitial involvement in glomerular diseases. Hofmann W, et al. **Clin Nephrol** 1995 Jul;44(1):28–31

Validity in nulliparas of increased beta-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation. Vaillant P, et al. **Nephron** 1996;72(4):557–63

Renal tubular dysfunction after urinary diversion. Kristjansson A, et al. **Scand J Urol Nephrol** 1995 Dec; 29(4):407–12

DIET THERAPY

Effect of mild dietary protein restriction on urinary protein excretion in patients with renal transplant fibrosis. Biesenbach G, et al. **Wien Med Wochenschr** 1996; 146(4):75–8

DRUG THERAPY

Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. Grekas D, et al. **Clin Nephrol** 1995 Nov; 44(5):299–302

Isosorbide 5 mononitrate administration increases nitric oxide blood levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urinary endothelin/cyclic GMP ratio. Roccatello D, et al. **Clin Nephrol** 1995 Sep;44(3):163–9

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Wapstra FH, et al. **Clin Sci (Colch)** 1996 May;90(5):393–401

Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. Zietse R, et al. **Contrib Nephrol** 1995;114:6–18

Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. Ambalavanan S, et al. **J Am Soc Nephrol** 1996 Feb;7(2):290–8

ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Ruiz-Ortega M, et al. **Kidney Int** 1995 Dec;48(6):1778–91

Low-dose captopril and proteinuria [letter; comment] Boulton-Jones JM. **Nephrol Dial Transplant** 1995 Nov; 10(11):2157–8. Comment on: Nephrol Dial Transplant 1995;10(1):25–9.

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Gansevoort RT, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):1963–74

The effect of rhubarb extract on experimental renal fibrosis. Zhang G, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):186–90

Is there any reason to lower proteinuria in a child with nephrotic-range proteinuria who is not clinically edematous? Kees-Folts D. **Pediatr Nephrol** 1996 Apr; 10(2):180 (17 ref.)

Nifedipine reduces postexercise proteinuria in young volunteers. Cosenzi A, et al. **Ren Physiol Biochem** 1995 Nov-Dec;18(6):306–10

EPIDEMIOLOGY

The racial prevalence of glomerular lesions in nephrotic adults. Korbet SM, et al. **Am J Kidney Dis** 1996 May; 27(5):647–51

Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro- or macroproteinuria. Sawicki PT, et al. **Diabet Med** 1995 Oct;12(10):893–8

Prevalence and associated features of albuminuria in Koreans with NIDDM. Lee KU, et al. **Diabetes Care** 1995 Jun; 18(6):793–9

Proteinuria in NIDDM in south India: analysis of predictive factors. Viswanathan VV, et al. **Diabetes Res Clin Pract** 1995 Apr;28(1):41–6

ETIOLOGY

Proteinuria in recipients of liver transplants. Jindal RM, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):39–44

Proteinuria as a marker for organ damage [letter; comment] Guthrie RM, et al. **J Fam Pract** 1996 Jan;42(1):85. Comment on: J Fam Pract 1993 Sep;37(3):253–6.

Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Ehrenstein MR, et al. **Kidney Int** 1995 Sep;48(3):705–11

High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. Joles JA, et al. **Lab Invest** 1995 Dec;73(6):912–21

Bence Jones proteinuria and myeloma kidney [editorial] Chauveau D, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):413–5 (7 ref.)

Amyloid—the great pretender. Korzets Z, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1938–9

Acute brucellosis associated with massive proteinuria. Odeh M, et al. **Nephron** 1996;72(4):688–9

Elevation of plasma thrombomodulin level in primary glomerulonephritis with heavy proteinuria. Ohsawa I, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul;38(7):300–4

GENETICS

Parental hypertension and proteinuria in Pima Indians with NIDDM. Nelson RG, et al. **Diabetologia** 1996 Apr; 39(4):433–8

METABOLISM

Increased glomerular and interstitial LFA-1 expression in proteinuric immunoglobulin A nephropathy. Alexopoulos E, et al. **Am J Kidney Dis** 1996 Mar;27(3):327–33

Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Ittel TH, et al. **Clin Nephrol** 1995 Sep; 44(3):156–62

Species comparison of the content and composition of urinary proteins. Hard GC. **Food Chem Toxicol** 1995 Sep; 33(9):731–46 (173 ref.)

Inhibition of puromycin-induced renal injury by a superoxide dismutase derivative with prolonged in vivo half-life. Nishimura Y, et al. **Nephron** 1995;70(4):460–5

Time course analysis of serum and urinary proteins by SDS-PAGE in experimental nephrotic syndrome. Pedraza-Chaverrí J, et al. **Ren Fail** 1996 Mar;18(2):181–94

PATHOLOGY

An ultrastructural study of glomerular basement membrane in rheumatoid arthritis patients with urinary abnormalities. Saito T, et al. **Clin Nephrol** 1995 Jun;43(6):360–7

PHYSIOPATHOLOGY

The role of proteinuria in the progression of chronic renal failure. Burton C, et al. **Am J Kidney Dis** 1996 Jun; 27(6):765–75 (94 ref.)

Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. Zietse R, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2057–66

Impaired endothelial function in patients with nephrotic range proteinuria. Stroes ES, et al. **Kidney Int** 1995 Aug; 48(2):544–50

[Microproteinuria and circadian rhythm of blood pressure in patients with arterial hypertension] Marczewski K, et al. **Pol Arch Med Wewn** 1996 Jan;95(1):29–34 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Smith MC, et al. **Am J Med** 1996 Jul;101(1):41–8

Effects of delapril on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Inada Y, et al. **Drugs Exp Clin Res** 1995;21(2):41–9

Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Remuzzi A, et al. **Exp Nephrol** 1996 Jan-Feb;4(1):19–25

Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. Jyothirmayi GN, et al. **Hypertension** 1996 May;27(5):1108–14

Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. Dworkin LD, et al. **J Am Soc Nephrol** 1996 Mar;7(3):437–42

The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. Hutchison FN, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1216–22

Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. Chandrasekar B, et al. **J Autoimmun** 1995 Jun;8(3):381–93

Purified omega-3 fatty acids retard the development of proteinuria in salt-loaded hypertensive rats. Rayner TE, et al. **J Hypertens** 1995 Jul;13(7):771–80

Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease [editorial] Gambaro G, et al. **Nephrol Dial Transplant** 1996 May; 11(5):762–4 (17 ref.)

Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. Garini G, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):628–34

Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis. Hruby Z, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):32–9

[Are ACE inhibitors nephroprotective? (letter)] Hörl WH. **Wien Klin Wochenschr** 1996;108(12):373–7 **(Ger)**

PROTEINURIA

THERAPY

Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Kamper AL, et al. **Nephrol Dial Transplant** 1995;10(7):1182–8

Massive proteinuria after renal transplantation treated with LDL-apheresis. Yanagisawa T, et al. **Transplant Proc** 1996 Jun;28(3):1482–3

[Excellent antiproteinuric effect by LDL apheresis in a case with severe renal dysfunction due to focal segmental glomerulosclerosis] Iwahori T, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb;38(2):91–7 (Eng. Abstr.) **(Jpn)**

URINE

The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Rodby RA, et al. **Am J Kidney Dis** 1995 Dec;26(6):904–9

Simple gold overstaining enhances sensitivity of automated electrophoresis of unconcentrated urine. Cesati R. **Clin Chem** 1996 Aug;42(8 Pt 1):1293–4

Screening urine protein abnormalities by a novel test paper. Shiba K, et al. **Clin Chim Acta** 1995 Aug 31;240(1):83–8

Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria. Honkanen E, et al. **Clin Nephrol** 1995 Jul; 44(1):22–7

Semiautomated quantitation of urinary protein and creatinine. Steinert BW, et al. **Comput Biomed Res** 1995 Jun; 28(3):211–20

Urinary excretion of proteins among metal welders. Bonde JP, et al. **Hum Exp Toxicol** 1996 Jan;15(1):1–4

Effects of benidipine, a calcium antagonist, on urinary kallikrein excretion and renal impairment in experimental diabetes. Yoshida K, et al. **J Hypertens** 1996 Feb; 14(2):215–22

Direct quantitative determination of optically active absorbing drugs in human urine by circular dichroism. Simultaneous direct determination of beta-lactam antibiotics and proteins. Gortázar P, et al. **J Pharm Sci** 1995 Nov;84(11):1316–21

Age-dependent enzymuria, proteinuria and changes in renal blood flow and glomerular filtration rate in rats. Casadevall G, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):51–60

Dipstick proteinuria? [letter] Macdonald A. **N Z Med J** 1996 Feb 23;109(1016):62

Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis [letter] Ogawa M, et al. **Nephron** 1995;70(3):376–7

Quantitation of proteinuria in patients with IgA nephropathy and membranous nephropathy in early morning and spot urine specimens [letter] Wan LL, et al. **Nephron** 1996; 72(2):369–70

[Urinary proteins during pregnancy in women with and without pregnancy induced hypertension] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):395–7 (Eng. Abstr.) **(Chi)**

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265–71 (53 ref.) (Eng. Abstr.) **(Ger)**

[A new protein titrator tape for self-assessment by outpatients with proteinuria] Yasuda G, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):511–7 (Eng. Abstr.) **(Jpn)**

[Urine protein and its fractionation] Ohno I, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:125–8 (6 ref.) **(Jpn)**

[Urinary proteins (focusing on alkaline phosphatases)] Sato T, et al. **Rinsho Byori** 1996 Jul;44(7):622–6 (Eng. Abstr.) **(Jpn)**

[Sports and measurement of components in urine—responses of renal blood flow, electrolytes and hormones and of excretion of proteins into urine to exercise] Suzuki M, et al. **Rinsho Byori** 1996 Jul;44(7):627–32 (Eng. Abstr.) **(Jpn)**

[The immunochemical study of urinary proteins in immunoglobulinopathies] Kotova TS, et al. **Klin Lab Diagn** 1995 Nov–Dec;(6):113–4 **(Rus)**

PROTEINURIA–EDEMA–HYPERTENSION GESTOSIS see **GESTOSIS, EPH**

PROTEOCHONDROITIN SULFATES

ANALYSIS

High levels of aggrecan aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis. Ratcliffe A, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:111–5

2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Isogai Z, et al. **Cancer Res** 1996 Sep 1;56(17):3902–8

Relationship between chondroitin sulfate proteoglycan and coronary atherosclerosis in the youth. Yang F, et al. **Chin Med J (Engl)** 1996 Feb;109(2):162–7

The biochemically and immunologically distinct CSPG of notochord is a product of the aggrecan gene. Domowicz M, et al. **Dev Biol** 1995 Oct;171(2):655–64

Chondroitin sulfate proteoglycan staining in astrocyte-Schwann cell co-cultures. Ghirnikar RS, et al. **Glia** 1995 Jun;14(2):145–52

Perlecan and basement membrane-chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix. Couchman JR, et al. **J Biol Chem** 1996 Apr 19;271(16):9595–602

BIOSYNTHESIS

Distinct rat aortic smooth muscle cells differ in versican/PG-M expression. Lemire JM, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):821–9

Proteoglycans in polarized epithelial Madin-Darby canine kidney cells. Svennevig K, et al. **Biochem J** 1995 Nov 1; 311 (Pt 3):881–8

The sulfation degree of membrane-associated proteoglycan from a hemopoietic cell line is determined by changes in the growth state of the cell. Rodríguez JP, et al. **Eur J Cell Biol** 1995 Jul;67(3):261–6

Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13. Naso MF, et al. **Genomics** 1995 Sep 1;29(1):297–300

Differential expression of versican isoforms in brain tumors. Paulus W, et al. **J Neuropathol Exp Neurol** 1996 May; 55(5):528–33

BLOOD

Molecular cloning and tissue distribution of keratocan. Bovine corneal keratan sulfate proteoglycan 37A. Corpuz LM, et al. **J Biol Chem** 1996 Apr 19;271(16):9759–63

CHEMISTRY

A small RNA is associated with dermatan sulfate proteoglycan. Umbreit JN. **Anticancer Res** 1996 Jul-Aug; 16(4A):1899–914

Characterization of a large chondroitin sulfate proteoglycan present in bovine collateral ligament. Campbell MA, et al. **Arch Biochem Biophys** 1996 May 15;329(2):181–90

cDNA cloning and the identification of an aggrecanase-like cleavage site in rat brevican. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):957–63

Conformation, stability and interactions of corneal keratan sulfate proteoglycan. Uma L, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):8–14

Sequence, molecular properties, and chromosomal mapping of mouse lumican. Funderburgh JL, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2296–303

Structural and electron microscopic analysis of neurocan and recombinant neurocan fragments. Retzler C, et al. **J Biol Chem** 1996 Jul 19;271(29):17107–13

Effect of link protein concentration on articular cartilage proteoglycan aggregation. Tang LH, et al. **J Orthop Res** 1996 Mar;14(2):334–9

Purification, characterization and developmental expression of a brain-specific chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan. Maeda N, et al. **Neuroscience** 1995 Jul;67(1):23–35

GENETICS

cDNA cloning and the identification of an aggrecanase-like cleavage site in rat brevican. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):957–63

Nucleotide sequence and molecular variants of rat receptor-type protein tyrosine phosphatase-zeta/beta. Maurel P, et al. **DNA Seq** 1995;5(5):323–8

Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3–q22. Chakravarti S, et al. **Genomics** 1995 Jun 10;27(3):481–8

Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13. Naso MF, et al. **Genomics** 1995 Sep 1;29(1):297–300

Structure and chromosomal localization of the mouse neurocan gene. Rauch U, et al. **Genomics** 1995 Aug 10; 28(3):405–10

Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Pluschke G, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9710–5

IMMUNOLOGY

Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Liu L, et al. **J Hematother** 1995 Oct;4(5):477–83

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2—a preliminary report. Bigner DD, et al. **J Neurooncol** 1995;24(1):109–22

METABOLISM

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92–7 (31 ref.)

Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring. Sandy JD, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:26–32

Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican? Perides G, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):377–84

Conformation, stability and interactions of corneal keratan sulfate proteoglycan. Uma L, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):8–14

Purification of a meningeal cell-derived chondroitin sulphate proteoglycan with neurotrophic activity for brain neurons and its identification as biglycan. Junghans U, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2341–50

Fibrillin: evidence that chondroitin sulphate proteoglycans are components of microfibrils and associate with newly synthesised monomers. Kielty CM, et al. **FEBS Lett** 1996 May 20;386(2–3):169–73

6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). Maeda N, et al. **J Biol Chem** 1996 Aug 30;271(35):21446–52

Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin. Milev P, et al. **J Biol Chem** 1995 Oct 20; 270(42):24650–3

TAG-1/axonin-1 is a high-affinity ligand of neurocan, phosphacan/protein-tyrosine phosphatase-zeta/beta, and N-CAM. Milev P, et al. **J Biol Chem** 1996 Jun 28; 271(26):15716–23

Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. Seidenbecher CI, et al. **J Biol Chem** 1995 Nov 10; 270(45):27206–12

Neuroglycan C, a novel membrane-spanning chondroitin sulfate proteoglycan that is restricted to the brain. Watanabe E, et al. **J Biol Chem** 1995 Nov 10; 270(45):26876–82

Chondroitin sulfate proteoglycan modulates the permeability of hyaluronan-containing coats around normal human mesothelial cells. Heldin P, et al. **J Cell Physiol** 1995 Oct; 165(1):54–61

Distribution of the large aggregating proteoglycan versican in adult human tissues. Bode-Lesniewska B, et al. **J Histochem Cytochem** 1996 Apr;44(4):303–12

Chondroitin sulfate and chondroitin/keratan sulfate proteoglycans of nervous tissue: developmental changes of neurocan and phosphacan. Meyer-Puttlitz B, et al. **J Neurochem** 1995 Nov;65(5):2327–37

Characterization of cell surface-expressed proteochondroitin sulfate of pre-B Nalm-6 cells and its possible role in laminin adhesion. Blase L, et al. **Leukemia** 1996 Jun;10(6):1000–11

A keratan sulfate proteoglycan marks the boundaries in the cortical barrel fields of the adult rat. Seo H, et al. **Neurosci Lett** 1995 Sep 1;197(1):13–6

The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Aspberg A, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10590–4

Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Halpert I, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9748–53

Chondroitin-4-sulphate (proteoglycan), a receptor for Plasmodium falciparum-infected erythrocyte adherence on brain microvascular endothelial cells. Robert C, et al. **Res Immunol** 1995 Jul-Aug;146(6):383–93

PHARMACOKINETICS

Kinetics of release of aggrecan from explant cultures of bovine cartilage from different sources and from animals of different ages. Ilic MZ, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:33–7

PHARMACOLOGY

Facilitation of learning following injection of the chondroitin sulfate proteoglycan biglycan into the vicinity of the nucleus basalis magnocellularis. Hasenöhrl RU, et al. **Behav Brain Res** 1995 Sep;70(1):59–67

Nitric oxide-mediated death of cultured neonatal retinal ganglion cells: neuroprotective properties of glutamate and chondroitin sulfate proteoglycan. Nichol KA, et al. **Brain Res** 1995 Oct 30;697(1–2):1–16

6B4 proteoglycan/phosphacan is a repulsive substratum but promotes morphological differentiation of cortical neurons. Maeda N, et al. **Development** 1996 Feb;122(2):647–58

Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Rada JA, et al. **Exp Eye Res** 1993 Jun;56(6):635–48

Inhibitory effects of PG-H/aggrecan and PG-M/versican on avian neural crest cell migration. Perris R, et al. **FASEB J** 1996 Feb;10(2):293–301

PHYSIOLOGY

6B4 proteoglycan/phosphacan is a repulsive substratum but promotes morphological differentiation of cortical neurons. Maeda N, et al. **Development** 1996 Feb;122(2):647–58

Age-dependent inhibition of neural crest migration by the notochord correlates with alterations in the S103L chondroitin sulfate proteoglycan. Pettway Z, et al. **Exp Cell Res** 1996 May 25;225(1):195–206

CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. Henke CA, et al. **J Clin Invest** 1996 Jun

1;97(11):2541–52

SECRETION

Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. Le Doux JM, et al. **J Virol** 1996 Sep; 70(9):6468–73

ULTRASTRUCTURE

The proteins of proteodermatan and proteokeratan sulphates (decoron and fibromodulon/lumicon) are horseshoe shaped, resembling ribonuclease inhibitor. Scott JE, et al. **Biochem Soc Trans** 1995 Nov;23(4):515S

Structural and electron microscopic analysis of neurocan and recombinant neurocan fragments. Retzler C, et al. **J Biol Chem** 1996 Jul 19;271(29):17107–13

PROTEOGLYCANS

Tumor necrosis factor alpha and lymphotoxin stimulate human myeloblastic leukemia cell (ML–1) invasion through a reconstituted basement membrane (Matrigel) with concomitant induction of 92 kDa gelatinase secretion. Kubota S, et al. **Cancer Lett** 1996 Jan 2;98(2):233–40

Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. Iozzo RV, et al. **FASEB J** 1996 Apr;10(5):598–614 (92 ref.)

Growth rate, labeling index, and radiation survival of cells grown in the Matrigel thread in vitro tumor model. Casciari JJ, et al. **In Vitro Cell Dev Biol Anim** 1995 Sep;31(8):582–9

Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288–11 and normal human megakaryocytes. Schick BP, et al. **J Cell Physiol** 1995 Oct; 165(1):96–106

[Structure and function of extracellular matrix with special references to proteoglycan] Takeuchi J. **Rinsho Byori** 1995 Oct;43(10):979–87 (32 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Concentrations of proteoglycan fragments in relation to maturation, sex and time of day: physiologic variations in knee joint fluid of rabbits. Wei X, et al. **Acta Orthop Scand** 1996 Apr;67(2):185–8

High levels of aggrecan aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis. Ratcliffe A, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:111–5

Expression of extracellular matrix proteoglycans perlecan and decorin in carbon–tetrachloride–injured rat liver and in isolated liver cells. Gallai M, et al. **Am J Pathol** 1996 May;148(5):1463–71

Site-specific proteoglycan characteristics of third carpal articular cartilage in exercised and nonexercised horses. Palmer JL, et al. **Am J Vet Res** 1995 Dec;56(12):1570–6

Hyaluronate and large molecular weight proteoglycans in synovial fluid from horses with various arthritides. Tulamo RM, et al. **Am J Vet Res** 1996 Jun;57(6):932–7

Use of rhodamine B isothiocyanate to detect proteoglycan core proteins in polyacrylamide gels. Fernàndez–Busquets X, et al. **Anal Biochem** 1995 May 20;227(2):394–6

Proteoglycans in articular cartilage revealed with a quick freezing and deep etching method. Toriumi H, et al. **Ann Rheum Dis** 1996 Jul;55(7):466–74

Proteoglycan depletion and size reduction in lesions of early grade chondromalacia of the patella. Väätäinen U, et al. **Ann Rheum Dis** 1995 Oct;54(10):831–5

Perineuronal sulfated proteoglycans and dark neurons in the brain and spinal cord: a histochemical and electron microscopic study of newborn and adult mice. Murakami T, et al. **Arch Histol Cytol** 1995 Dec;58(5):557–65

Immunolocalization of the small proteoglycan decorin in human teeth. Yoshiba N, et al. **Arch Oral Biol** 1996 Apr; 41(4):351–7

Identification of a new membrane–bound heparan sulphate proteoglycan. Filmus J, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):561–5

Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide– and proteoglycan–rich sources. Chomczynski P, et al. **Biotechniques** 1995 Dec;19(6):942–5

Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Behm FG, et al. **Blood** 1996 Feb 1; 87(3):1134–9

Proteoglycan alterations in skin fibroblast cultures from patients affected with pseudoxanthoma elasticum. Passi A, et al. **Cell Biochem Funct** 1996 Jun;14(2):111–20

Immunohistochemical mapping of perineuronal nets containing chondroitin unsulfated proteoglycan in the rat central nervous system. Bertolotto A, et al. **Cell Tissue Res** 1996 Feb;283(2):283–95

Chemical characterization and quantification of proteoglycans in human post–burn hypertrophic and mature scars. Scott PG, et al. **Clin Sci (Colch)** 1996 May; 90(5):417–25

Expression of syndecan–1 changes during the differentiation of visceral and parietal endoderm from murine F9 teratocarcinoma cells. Jiang R, et al. **Differentiation** 1995 Nov;59(4):225–33

Purification of a meningeal cell–derived chondroitin sulphate proteoglycan with neurotrophic activity for brain neurons and its identification as biglycan. Junghans U, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2341–50

Proteoglycan alterations in the aortic intima–media of alloxan–diabetic rabbits: an ultrastructural and biochemical study. Richardson M, et al. **Exp Mol Pathol** 1995 Jun; 62(3):145–59

On the resorcin–fuchsin stainings. III. Demonstration of sulfated glycoproteins and proteoglycans. Krutsay M. **Gen Diagn Pathol** 1996 Mar;141(3–4):193–5

Proteoglycans associated with the ciliary zonule of the rat eye: a histochemical and immunocytochemical study. Chan FL, et al. **Histochem Cell Biol** 1995 Nov;104(5):369–81

An histochemical approach to characterization of anionic constituents in mast cell secretory granules. Skutelsky E, et al. **Histochem Cell Biol** 1995 Dec;104(6):453–8

Family study of atypical nevi with investigation of heparin sulfate proteoglycan. Bjarnason B, et al. **Int J Dermatol** 1995 Sep;34(9):630–3

Structure and cellular distribution of mouse brain testican. Association with the postsynaptic area of hippocampus pyramidal cells. Bonnet F, et al. **J Biol Chem** 1996 Feb 23;271(8):4373–80

Perlecan and basement membrane–chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth–Holm–Swarm tumor matrix. Couchman JR, et al. **J Biol Chem** 1996 Apr 19;271(16):9595–602

Visualization of proteoglycans and link protein in embryonic chick limb cartilage via cryofixation, freeze–substitution and immunochemical techniques. Allenspach AL, et al. **J Microsc** 1996 May;182 (Pt 2):84–94

Histochemical and immunohistochemical studies of the effects of experimental anterior disc displacement on sulfated glycosaminoglycans, hyaluronic acid, and link protein of the rabbit craniomandibular joint. Ali AM, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):992–1003; discussion 1003–4

Proteoglycans of human rotator cuff tendons. Berenson MC, et al. **J Orthop Res** 1996 Jul;14(4):518–25

Synovial reaction and concentrations of proteoglycan fragments in joint fluid after intraarticular knee injuries. Messner K, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):101–4

Proteoglycans in haemodialysis–related amyloidosis. Ohashi K, et al. **Virchows Arch** 1995;427(1):49–59

BIOSYNTHESIS

Regulation of chondrocyte differentiation by transforming growth factors beta 1, beta 2, beta 3, and beta 5. Chimal–Monroy J, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:241–4

Studies on the G3 domain of aggrecan from human cartilage. Dudhia J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:245–7

Construction and expression of a functional recombinant gene for proteoglycan. Yang B, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:356–9

Compression of cartilage results in differential effects on biosynthetic pathways for aggrecan, link protein, and hyaluronan. Kim YJ, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):331–40

Heparin–induced overexpression of basic fibroblast growth factor, basic fibroblast growth factor receptor, and cell–associated proteoheparan sulfate in cultured coronary smooth muscle cells. Skaletz–Rorowski A, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1063–9

Heparin proteoglycans synthesized by mouse mastocytoma contain chondroitin sulphate. Lidholt K, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):233–8

Proteoglycan synthesis in human and murine haematopoietic progenitor cell lines: isolation and characterization of a heparan sulphate proteoglycan as a major proteoglycan from the human haematopoietic cell line TF–1. Stöcker G, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):203–12

Proteoglycans in polarized epithelial Madin–Darby canine kidney cells. Svennevig K, et al. **Biochem J** 1995 Nov 1; 311 (Pt 3):881–8

Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Silbert JE, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):371–84 (163 ref.)

The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor–prognosis patients with abnormalities of chromosome band 11q23. Smith FO, et al. **Blood** 1996 Feb 1;87(3):1123–33

Syndecan–1 alterations during the tumorigenic progression of human colonic Caco–2 cells induced by human Ha–ras or polyoma middle T oncogenes. Levy P, et al. **Br J Cancer** 1996 Aug;74(3):423–31

Production of binding proteins and role of the insulin–like growth factor I binding protein 3 in human articular cartilage explants. Chevalier X, et al. **Br J Rheumatol** 1996 Jun;35(6):515–22

Cyclosporin A (CsA) modulates the glomerular production of inflammatory mediators and proteoglycans in experimental nephrosis. Bustos C, et al. **Clin Exp Immunol** 1995 Dec;102(3):608–13

Localization and possible gene expression of proteoglycan decorin in the trabecular meshwork. Tanihara H, et al. **Curr Eye Res** 1995 Aug;14(8):727–30

Cell autonomous expression of perlecan and plasticity of cell shape in embryonic muscle of Caenorhabditis elegans. Moerman DG, et al. **Dev Biol** 1996 Jan 10;173(1):228–42

Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Lowe GN, et al. **Endocrinology** 1996 Jun;137(6):2208–16

Effect of insulin and growth hormone on the synthesis of radiolabelled proteoglycans from cultured human arterial smooth–muscle cells. Thøgersen VB, et al. **Eur J Endocrinol** 1996 Mar;134(3):326–30

Characterization of proteoglycans produced by rat pleural mesothelial cells in vitro. Milligan SA, et al. **Exp Lung Res** 1995 Jul–Aug;21(4):559–75

Injury–induced proteoglycans inhibit the potential for laminin–mediated axon growth on astrocytic scars. McKeon RJ, et al. **Exp Neurol** 1995 Nov;136(1):32–43

Amino–terminal deletions in the decorin core protein leads to the biosynthesis of proteoglycans with shorter glycosaminoglycan chains. Oldberg A, et al. **FEBS Lett** 1996 May 13;386(1):29–32

Expression of c–fos gene inhibits proteoglycan synthesis in transfected chondrocyte. Tsuji M, et al. **FEBS Lett** 1996 Mar 4;381(3):222–6

Developmental expression of proteoglycans in the tectorial and basilar membrane of the gerbil cochlea. Munyer PD, et al. **Hear Res** 1995 May;85(1–2):85–94

Divergent regulation of proteoglycan and glycosaminoglycan free chain expression in human keratinocytes and melanocytes. Piepkorn M, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul–Aug;31(7):536–41

Modulation of chondrocyte proteoglycan synthesis by endogeneously produced nitric oxide. Stefanovic–Racic M, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S216–7

Mechanical loading affects the synthesis of decorin and biglycan in intact immature articular cartilage in vitro. Visser Na, et al. **Int J Tissue React** 1994;16(5–6):195–203

Proteoglycan synthesis by chicken corneal explants. Nakazawa K, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):697–706

Proteoglycan synthesis by corneal explants from developing embryonic chicken. Nakazawa K, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):707–18

Structure and cellular distribution of mouse brain testican. Association with the postsynaptic area of hippocampus pyramidal cells. Bonnet F, et al. **J Biol Chem** 1996 Feb 23;271(8):4373–80

Fetal lung fibroblasts selectively down–regulate proteoglycan synthesis in response to elevated oxygen. Caniggia I, et al. **J Biol Chem** 1996 Mar 22;271(12):6625–30

Molecular cloning and tissue distribution of keratocan. Bovine corneal keratan sulfate proteoglycan 37A. Corpuz LM, et al. **J Biol Chem** 1996 Apr 19;271(16):9759–63

Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells. Hosseini G, et al. **J Biol Chem** 1996 Sep 6;271(36):22090–9

Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. Rossi A, et al. **J Biol Chem** 1996 Aug 2;271(31):18456–64

Transport of UDP–galactose into the Golgi lumen regulates the biosynthesis of proteoglycans. Toma L, et al. **J Biol Chem** 1996 Feb 16;271(7):3897–901

Changes in proteoglycan synthesis of chondrocytes in articular cartilage are associated with the time–dependent changes in their mechanical environment. Bachrach NM, et al. **J Biomech** 1995 Dec;28(12):1561–9

Heparan sulfate expression in polarized epithelial cells: the apical sorting of glypican (GPI–anchored proteoglycan) is inversely related to its heparan sulfate content. Mertens G, et al. **J Cell Biol** 1996 Feb;132(3):487–97

Regulation of basement membrane heparan sulfate proteoglycan, perlecan, gene expression in glomerular epithelial cells by high glucose medium. Kasinath BS, et al. **J Cell Physiol** 1996 Apr;167(1):131–6

Proteoglycan synthesis by bovine myocardial endothelial cells is increased by long–term exposure to high concentrations of glucose. Klein DJ, et al. **J Cell Physiol** 1995 Dec;165(3):493–502

A method of quantitative autoradiography for the spatial localization of proteoglycan synthesis rates in cartilage. Buschmann MD, et al. **J Histochem Cytochem** 1996 May; 44(5):423–31

The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. Stefanovic–Racic M, et al. **J Immunol** 1996 Feb 1;156(3):1213–20

TGF–beta modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. Heimer R, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2191–8

Co–localization of NG2 proteoglycan and PDGF alpha–receptor on O2A progenitor cells in the developing rat brain. Nishiyama A, et al. **J Neurosci Res** 1996 Feb 1;43(3):299–314

Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. DesRosiers EA, et al. **J Orthop Res** 1996 Mar; 14(2):200–8

Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an

experimental study in sheep. Little CB, et al. **J Orthop Res** 1996 May;14(3):433–44

Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin–1. Fukuda K, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1672–5

Interleukin–1 reversibly inhibits the synthesis of biglycan and decorin in intact articular cartilage in culture. von den Hoff H, et al. **J Rheumatol** 1995 Aug;22(8):1520–6

Bovine herpesvirus 1 U(s) open reading frame 4 encodes a glycoproteoglycan. Keil GM, et al. **J Virol** 1996 May; 70(5):3032–8

Rat mesangial cells in vitro synthesize a spectrum of proteoglycan species including those of the basement membrane and interstitium. Thomas GJ, et al. **Kidney Int** 1995 Oct;48(4):1278–89

Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. van Det NF, et al. **Kidney Int** 1996 Apr;49(4):1079–89

Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. Dodge GR, et al. **Lab Invest** 1995 Nov;73(5):649–57

Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Nishiyama A, et al. **Mol Biol Cell** 1995 Dec;6(12):1819–32

Effects of transforming growth factor beta on proteoglycan synthesis by cell and explant cultures derived from the knee joint meniscus. Collier S, et al. **Osteoarthritis Cartilage** 1995 Jun;3(2):127–38

Pulsed electromagnetic fields influence hyaline cartilage extracellular matrix composition without affecting molecular structure. Liu H, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):63–76

Phenotypic modulation of newly synthesized proteoglycans in human cartilage and chondrocytes. Malemud CJ, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):227–38

Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Iida J, et al. **Semin Cancer Biol** 1996 Jun;7(3):155–62 (64 ref.)

BLOOD

Serglycin–binding proteins in activated macrophages and platelets. Kolset SO, et al. **J Leukoc Biol** 1996 Apr; 59(4):545–54

Isolation and electrophoretic analysis of human serum proteoglycans and their reaction with nickel in vitro. Savolainen H. **Res Commun Mol Pathol Pharmacol** 1995 Jun;88(3):359–62

Circulating dermatan sulfate and heparan sulfate/heparin proteoglycans in children undergoing liver transplantation. Mitchell L, et al. **Thromb Haemost** 1995 Sep;74(3):859–63

[Proteoglycans] Murata K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:575–8 (18 ref.) **(Jpn)**

CHEMISTRY

Studies on the G3 domain of aggrecan from human cartilage. Dudhia J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:245–7

Proteoglycans and proteins in the extracellular matrix of mouse cumulus cell–oocyte complexes. Camaioni A, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):190–8

Use of an antibody against the matrix metalloproteinase–generated aggrecan neoepitope FVDIPEN–COOH to assess the effects of stromelysin in a rabbit model of cartilage degradation. Bayne EK, et al. **Arthritis Rheum** 1995 Oct;38(10):1400–9

cDNA cloning and the identification of an aggrecanase–like cleavage site in rat brevican. Yamada H, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):957–63

Modulation of collagen gel contraction by decorin. Bittner K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):159–66

Effects of aging on the synthesis of antithrombin–binding sites on heparin chains and heparan sulphate chains in the rat. Horner AA. **Biochem J** 1995 Nov 15;312 (Pt 1):245–9

Phosphorylation of a membrane–intercalated proteoglycan, syndecan–2, expressed in a stroma–inducing clone from a mouse Lewis lung carcinoma. Itano N, et al. **Biochem J** 1996 May 1;315 (Pt 3):925–30

Protein kinase C phosphorylates two of the four known syndecan cytoplasmic domains in vitro. Prasthofer T, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):793–802

Molecular modelling analyses of the C–type lectin domain in human aggrecan. Brissett NC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99S

A stereocontrolled synthetic approach to glycopeptides corresponding to the carbohydrate–protein linkage region of cell–surface proteoglycans. Neumann KW, et al. **Bioorg Med Chem** 1995 Dec;3(12):1637–50

Proteoglycans contain a 4.6 A repeat in muscular dystrophy corneas: x–ray diffraction evidence. Quantock AJ, et al. **Biophys J** 1996 Apr;70(4):1966–72

Anionic biopolymers as blood flow sensors. Siegel G, et al. **Biosens Bioelectron** 1996;11(3):281–94

Synthesis and glycosaminoglycan priming activity of three disaccharides related to the linkage region tetrasaccharide of proteoglycans. Sarkar AK, et al. **Carbohydr Res** 1995 Dec 27;279:161–71

The macrophage cell surface glycoprotein F4/80 is a highly glycosylated proteoglycan. Haidl ID, et al. **Eur J Immunol** 1996 May;26(5):1139–46

The protein fold of the hyaluronate–binding proteoglycan tandem repeat domain of link protein, aggrecan and CD44 is similar to that of the C–type lectin superfamily. Brissett NC, et al. **FEBS Lett** 1996 Jun 17;388(2–3):211–6

Amino–terminal deletions in the decorin core protein leads to the biosynthesis of proteoglycans with shorter glycosaminoglycan chains. Oldberg A, et al. **FEBS Lett** 1996 May 13;386(1):29–32

Identification of transferrin and inhibin–like proteins in matrigel [letter] Dirami G, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):404–11

Self–association of N–syndecan (syndecan–3) core protein is mediated by a novel structural motif in the transmembrane domain and ectodomain flanking region. Asundi VK, et al. **J Biol Chem** 1995 Nov 3; 270(44):26404–10

Recombinant decorin glycoforms. Purification and structure. Ramamurthy P, et al. **J Biol Chem** 1996 Aug 9; 271(32):19578–84

Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. Rossi A, et al. **J Biol Chem** 1996 Aug 2;271(31):18456–64

Repetitive Ser–Gly sequences enhance heparan sulfate assembly in proteoglycans. Zhang L, et al. **J Biol Chem** 1995 Nov 10;270(45):27127–35

Proteoglycan form of colony–stimulating factor–1 (proteoglycan–100). Stimulation of activity by glycosaminoglycan removal and proteolytic processing. Partenheimer A, et al. **J Immunol** 1995 Dec 15; 155(12):5557–65

Endoglin is a component of the transforming growth factor (TGF)–beta receptor complex of human pre–B leukemic cells. Zhang H, et al. **J Immunol** 1996 Jan 15;156(2):564–73

Effect of link protein concentration on articular cartilage proteoglycan aggregation. Tang LH, et al. **J Orthop Res** 1996 Mar;14(2):334–9

DRUG EFFECTS

Effect of growth hormone on the distribution of decorin and biglycan during odontogenesis in the rat incisor. Zhang CZ, et al. **J Dent Res** 1995 Oct;74(10):1636–43

The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. Stefanovic–Racic M, et al. **J Immunol** 1996 Feb 1;156(3):1213–20

Interleukin–4, an inhibitor of cartilage breakdown in bovine articular cartilage explants. Yeh LA, et al. **J Rheumatol** 1995 Sep;22(9):1740–6

The effect of substance P on proliferation and proteoglycan deposition of cells derived from rabbit intervertebral disc. Ashton IK, et al. **Spine** 1996 Feb 15;21(4):421–6

GENETICS

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161–6 (34 ref.)

Primary structure of bovine aorta biglycan core protein deduced from cloned CDNA. Xu JH, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):263–72

Gene expression of syndecans and betaglycan in isolated rat liver cells. Weiner OH, et al. **Cell Tissue Res** 1996 Jul; 285(1):11–6

The biochemically and immunologically distinct CSPG of notochord is a product of the aggrecan gene. Domowicz M, et al. **Dev Biol** 1995 Oct;171(2):655–64

The mec–8 gene of C. elegans encodes a protein with two RNA recognition motifs and regulates alternative splicing of unc–52 transcripts. Lundquist EA, et al. **Development** 1996 May;122(5):1601–10

The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. Nakato H, et al. **Development** 1995 Nov;121(11):3687–702

Assignment of human transforming growth factor–beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33–q34 and 1p32–p33, respectively. Johnson DW, et al. **Genomics** 1995 Jul 20;28(2):356–7

The murine biglycan: complete cDNA cloning, genomic organization, promoter function, and expression. Wegrowski Y, et al. **Genomics** 1995 Nov 1;30(1):8–17

Aberrant expressions of decorin and biglycan genes in the carbohydrate–deficient glycoprotein syndrome. Gu J, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1276–9

Eukaryotic expression of recombinant biglycan. Post–translational processing and the importance of secondary structure for biological activity. Hocking AM, et al. **J Biol Chem** 1996 Aug 9;271(32):19571–7

Suppression of syndecan–1 expression in endothelial cells by tumor necrosis factor–alpha. Kainulainen V, et al. **J Biol Chem** 1996 Aug 2;271(31):18759–66

Transcriptional regulation of the human biglycan gene. Ungefroren H, et al. **J Biol Chem** 1996 Jun 28; 271(26):15787–95

Functional characterization of mouse syndecan–1 promoter. Vihinen T, et al. **J Biol Chem** 1996 May 24; 271(21):12532–41

Gene structure of chick cartilage chondroitin sulfate proteoglycan (aggrecan) core protein. Li H, et al. **J Mol Evol** 1995 Dec;41(6):878–85

Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription–polymerase chain reaction. Maresh GA, et al. **J Neurochem** 1996 Sep; 67(3):1132–44

Expression of syndecan–3 and tenascin–C: possible involvement in periosteum development. Koyama E, et al. **J Orthop Res** 1996 May;14(3):403–12

Posttranscriptional effects of glucose on proteoglycan expression in mesangial cells. Templeton DM, et al. **Metabolism** 1996 Sep;45(9):1136–46

Mutations in GPC3, a glypican gene, cause the Simpson–Golabi–Behmel overgrowth syndrome [see comments] Pilia G, et al. **Nat Genet** 1996 Mar;12(3):241–7 . Comment in: Nat Genet 1996 Mar;12(3):225–7.

Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Isaka Y, et al. **Nat Med** 1996 Apr;2(4):418–23

Investigation of co–amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan–1 and a DEAD box gene, DDX1, with N–myc in neuroblastoma. United Kingdom Children's Cancer Study Group. George RE, et al. **Oncogene** 1996 Apr 4; 12(7):1583–7

IMMUNOLOGY

Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non–arthritic controls. Goodstone NJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):40–6

A plasmocyte selective monoclonal antibody (B–B4) recognizes syndecan–1. Wijdenes J, et al. **Br J Haematol** 1996 Aug;94(2):318–23

Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. Leroux JY, et al. **J Clin Invest** 1996 Feb 1;97(3):621–32

Gliding bacterial adjuvant stimulates feline cytokines in vitro and antigen–specific IgG in vivo. Zeidner NS, et al. **Vaccine** 1995 Oct;13(14):1294–9

ISOLATION & PURIFICATION

Inseparable iduronic acid–containing proteoglycan PG(IdoA) preparations of human skin and post–burn scar tissues: evidence for elevated levels of PG(IdoA)–I in hypertrophic scar by N–terminal sequencing. Garg HG, et al. **Carbohydr Res** 1996 Apr 30;284(2):223–8

Purification and structural characterization of a filamentous, mucin–like proteophosphoglycan secreted by Leishmania parasites. Ilg T, et al. **J Biol Chem** 1996 Aug 30; 271(35):21583–96

Recombinant decorin glycoforms. Purification and structure. Ramamurthy P, et al. **J Biol Chem** 1996 Aug 9; 271(32):19578–84

Isolation of a sponge–derived extracellular matrix adhesion protein. Varner JA. **J Biol Chem** 1996 Jul 5; 271(27):16119–25

Comparison of separation modes of high–performance liquid chromatography for the analysis of glycoprotein– and proteoglycan–derived oligosaccharides. Davies MJ, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):227–33

Affinity purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer's disease. Williamson TG, et al. **J Neurochem** 1995 Nov;65(5):2201–8

Characterization of a cancer cachectic factor. Todorov P, et al. **Nature** 1996 Feb 22;379(6567):739–42

METABOLISM

Articular chondrocytes interact with basement membrane Matrigel through laminin active binding sites. Bulić K. **Acta Med Croatica** 1996;50(2):69–74

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:121–4 (32 ref.)

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92–7 (31 ref.)

Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring. Sandy JD, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:26–32

Sorting and budding of constitutive secretory vesicles in hepatocytes and hepatoma cells. Barthel A, et al. **Adv Enzyme Regul** 1995;35:283–92

Albumin reduces basement membrane hydraulic conductance in part due to arginyl side groups. Katz MA, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1514–21

Hyperoxia alone causes changes in lung proteoglycans and hyaluronan in neonatal rat pups. Juul SE, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):629–38

Effects of stromelysin activity on proteoglycan degradation of canine articular cartilage explants. Todhunter RJ, et al. **Am J Vet Res** 1995 Sep;56(9):1241–7

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti–Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195–201 (26 ref.)

Immunocytochemical study of proteoglycans in vocal folds. Pawlak AS, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):6–11

Mesenchymal commitment to digital joint formation.

Ginsburg GT, et al. **Ann Plast Surg** 1995 Jul;35(1):95–104

Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage. Lundberg C, et al. **Ann Rheum Dis** 1996 Aug;55(8):525–34

Catabolism and loss of proteoglycans from cultures of bovine collateral ligament. Campbell MA, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):64–72

Alterations of heparan sulfate moieties in cultured endothelial cells exposed to endotoxin. Colburn P, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):129–38

Catabolism of aggrecan by explant cultures of human articular cartilage in the presence of retinoic acid. Ilic MZ, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):22–30

Neurons with perineuronal sulfated proteoglycans in the human visual cortex, with special reference to their reactions to lectins. Murakami T, et al. **Arch Histol Cytol** 1995 Aug;58(3):357–64

Oxidized lipid-mediated alterations in proteoglycan metabolism in cultured pulmonary endothelial cells. Ramasamy S, et al. **Atherosclerosis** 1996 Feb; 120(1–2):199–208

Degradation of aggrecan precursors within a specialized subcompartment of the chicken chondrocyte endoplasmic reticulum. Alonso M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):487–95

Transforming growth factor-beta 1 increases internalization of basic fibroblast growth factor by smooth muscle cells: implication of cell-surface heparan sulphate proteoglycan endocytosis. Berrou E, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):393–9

Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Dudhia J, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):933–40

Phosphorylation of a membrane-intercalated proteoglycan, syndecan-2, expressed in a stroma-inducing clone from a mouse Lewis lung carcinoma. Itano N, et al. **Biochem J** 1996 May 1;315 (Pt 3):925–30

Betaglycan has multiple binding sites for transforming growth factor-beta 1. Kaname S, et al. **Biochem J** 1996 May 1;315 (Pt 3):815–20

Marked alteration of proteoglycan metabolism in cholesterol-enriched human arterial smooth muscle cells. Vijayagopal P, et al. **Biochem J** 1996 May 1;315 (Pt 3):995–1000

Recognition of lactoferrin and aminopeptidase M-modified lactoferrin by the liver: involvement of proteoglycans and the remnant receptor. Ziere GJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):289–95

Protein kinase C phosphorylates two of the four known syndecan cytoplasmic domains in vitro. Prasthofer T, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):793–802

Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats. Hadad SJ, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):18–28

Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Silbert JE, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):371–84 (163 ref.)

Human leukemia cell lines bind basic fibroblast growth factor (FGF) on FGF receptors and heparan sulfates: downmodulation of FGF receptors by phorbol ester. Liuzzo JP, et al. **Blood** 1996 Jan 1;87(1):245–55

Proteoglycan-degrading activity associated with the 40 kDa collagen-binding fragment of fibronectin. Chevalier X, et al. **Br J Rheumatol** 1996 Jun;35(6):506–14

Signal transduction mechanisms subserving activity-dependent release of neuronal proteoglycans. Dow KE, et al. **Brain Res Dev Brain Res** 1995 Nov 21; 89(2):320–4

Dual incorporation of (35S)sulfate into dentin proteoglycans acting as mineralization promotors in rat molars and predentin proteoglycans. Lormée P, et al. **Calcif Tissue Int** 1996 May;58(5):368–75

Immunohistochemical identification of proteoglycan form of macrophage colony-stimulating factor on bone surface. Ohtsuki T, et al. **Calcif Tissue Int** 1995 Sep;57(3):213–7

An ultrastructural and immunogold localization study of proteoglycans associated with the osteocytes of fetal bone in osteogenesis imperfecta. Sarathchandra P, et al. **Calcif Tissue Int** 1996 Jun;58(6):435–42

Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. Numa F, et al. **Cancer Res** 1995 Oct 15;55(20):4676–80

Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Heeringa P, et al. **Clin Exp Immunol** 1996 Aug;105(2):321–9

Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Vleming LJ, et al. **Clin Nephrol** 1995 Oct;44(4):211–9

Effect of cross-linking on matrix permeability. A model for AGE-modified basement membranes. Boyd-White J, et al. **Diabetes** 1996 Mar;45(3):348–53

An investigation of the proteoglycan metabolism of mature equine articular cartilage and its regulation by interleukin-1. Platt D, et al. **Equine Vet J** 1994 Jul; 26(4):297–303

Identification of basal lamina acidic glycoconjugates, particularly heparan sulphate proteoglycans, using a poly-L-lysine-gold probe in induced oral carcinomas. Jiang DJ, et al. **Eur J Cancer B Oral Oncol** 1996 Jan; 32B(1):8–13

The macrophage cell surface glycoprotein F4/80 is a highly glycosylated proteoglycan. Haidl ID, et al. **Eur J Immunol** 1996 May;26(5):1139–46

Purification of a meningeal cell-derived chondroitin sulphate proteoglycan with neurotrophic activity for brain neurons and its identification as biglycan. Junghans U, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2341–50

Heterophilic NCAM-mediated cell adhesion to proteoglycans from chick embryonic brain membranes. Storms SD, et al. **Exp Cell Res** 1996 Mar 15;223(2):385–94

H2O2 renders cells accessible to lysis by exogenous phospholipase A2: a novel mechanism for cell damage in inflammatory processes. Dan P, et al. **FEBS Lett** 1996 Mar 25;383(1–2):75–8

Degradation of cartilage aggrecan by collagenase-3 (MMP-13). Fosang AJ, et al. **FEBS Lett** 1996 Feb 12; 380(1–2):17–20

Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-beta receptor type III extracellular domain. Pepin MC, et al. **FEBS Lett** 1995 Dec 27; 377(3):368–72

Recycling of a glycosylphosphatidylinositol-anchored heparan sulphate proteoglycan (glypican) in skin fibroblasts. Fransson LA, et al. **Glycobiology** 1995 Jun; 5(4):407–15

Interactions between the Flk-1 receptor, vascular endothelial growth factor, and cell surface proteoglycan identified with a soluble receptor reagent. Chiang MK, et al. **Growth Factors** 1995;12(1):1–10

Distribution of hyaluronan in articular cartilage as probed by a biotinylated binding region of aggrecan. Parkkinen JJ, et al. **Histochem Cell Biol** 1996 Mar;105(3):187–94

Degradation of bovine cartilage proteoglycan in vitro is enhanced by inhibition of nitric oxide synthase. Hanglow AC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S151–2

Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. O'Byrne EM, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S117–8

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414–29 (72 ref.)

Extracellular matrix, supramolecular organisation and shape. Scott JE. **J Anat** 1995 Oct;187 (Pt 2):259–69 (21 ref.)

Self-association of N-syndecan (syndecan-3) core protein is mediated by a novel structural motif in the transmembrane domain and ectodomain flanking region. Asundi VK, et al. **J Biol Chem** 1995 Nov 3; 270(44):26404–10

Regulation of constitutive exocytic transport by membrane receptors. A biochemical and morphometric study. Buccione R, et al. **J Biol Chem** 1996 Feb 16;271(7):3523–33

The cytoplasmic domain of syndecan-1 is required for cytoskeleton association but not detergent insolubility. Identification of essential cytoplasmic domain residues. Carey DJ, et al. **J Biol Chem** 1996 Jun 21;271(25):15253–60

Schwann cells secrete a novel collagen-like adhesive protein that binds N-syndecan. Chernousov MA, et al. **J Biol Chem** 1996 Jun 7;271(23):13844–53

Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. Fannon M, et al. **J Biol Chem** 1996 Jul 26;271(30):17949–56

Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface. Kinnunen T, et al. **J Biol Chem** 1996 Jan 26;271(4):2243–8

Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. Kojima T, et al. **J Biol Chem** 1996 Mar 8; 271(10):5914–20

Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. Lucas M, et al. **J Biol Chem** 1996 Jun 7;271(23):13454–60

Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. Richard C, et al. **J Biol Chem** 1995 Oct 13;270(41):24188–96

Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. Sivaram P, et al. **J Biol Chem** 1995 Dec 15;270(50):29760–5

Isolation of a sponge-derived extracellular matrix adhesion protein. Varner JA. **J Biol Chem** 1996 Jul 5; 271(27):16119–25

The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. Whitelock JM, et al. **J Biol Chem** 1996 Apr 26; 271(17):10079–86

In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity. Guillonneau X, et al. **J Cell Physiol** 1996 Jan;166(1):170–87

Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. Ihrcke NS, et al. **J Cell Physiol** 1996 Sep; 168(3):625–37

Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288-11 and normal human megakaryocytes. Schick BP, et al. **J Cell Physiol** 1995 Oct; 165(1):96–106

Cell adhesion in sponges: potentiation by a cell surface 68 kDa proteoglycan-binding protein. Varner JA. **J Cell Sci** 1995 Sep;108 (Pt 9):3119–26

Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. McCaffrey TA, et al. **J Clin Invest** 1995 Dec; 96(6):2667–75

Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. Carroll GJ, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):567–73

Basement membrane proteoglycans are of epithelial origin in rodent skin. Yamane Y, et al. **J Invest Dermatol** 1996 Mar;106(3):531–7

IL-1 beta and TGF-beta 1 modulate the sulphation grade of chondro-disaccharides in porcine articular cartilage: a capillary electrophoresis study. Zanni M, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):29–44

Chondroitin sulfate and chondroitin/keratan sulfate proteoglycans of nervous tissue: developmental changes of neurocan and phosphacan. Meyer-Puttlitz B, et al. **J Neurochem** 1995 Nov;65(5):2327–37

Affinity purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer's disease. Williamson TG, et al. **J Neurochem** 1995 Nov;65(5):2201–8

A distinct subset of tenascin/CS-6-PG-rich astrocytes restricts neuronal growth in vitro. Meiners S, et al. **J Neurosci** 1995 Dec;15(12):8096–108

Effect of link protein concentration on articular cartilage proteoglycan aggregation. Tang LH, et al. **J Orthop Res** 1996 Mar;14(2):334–9

Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. Arner EC, et al. **J Rheumatol** 1995 Jul;22(7):1338–46

Requirement for heparan sulphate proteoglycans to mediate basic fibroblast growth factor (FGF-2)-induced stimulation of Leydig cell steroidogenesis. Laslett AL, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5–6):245–50

Expression of collagens and decorin during aortic arch artery development: implications for matrix pattern formation. Thieszen SL, et al. **Matrix Biol** 1995 Jul;14(7):573–82

Protein kinase C regulates the recruitment of syndecan-4 into focal contacts. Baciu PC, et al. **Mol Biol Cell** 1995 Nov; 6(11):1503–13

FORSE-1, an antibody that labels regionally restricted subpopulations of progenitor cells in the embryonic central nervous system, recognizes the Le(x) carbohydrate on a proteoglycan and two glycolipid antigens. Allendoerfer KL, et al. **Mol Cell Neurosci** 1995 Aug;6(4):381–95

Glypicans: a growing trend [news; comment] Weksberg R, et al. **Nat Genet** 1996 Mar;12(3):225–7. Comment on: Nat Genet 1996 Mar;12(3):241–7.

Is microalbuminuria in diabetes due to changes in glomerular heparan sulphate? [editorial] van den Born J, et al. **Nephrol Dial Transplant** 1995;10(8):1277–9

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

Detection of proteoglycans in human posterior capsule opacification. Ishibashi T, et al. **Ophthalmic Res** 1995; 27(4):208–13

Characterization of proteoglycan accumulation during formation of cartilagenous tissue in vitro. Boyle J, et al. **Osteoarthritis Cartilage** 1995 Jun;3(2):117–25

Articular cartilage proteoglycans in osteoarthritic STR/Ort mice. Gaffen JD, et al. **Osteoarthritis Cartilage** 1995 Jun; 3(2):95–104

The interactions of 'non-aggregating' proteoglycans. Roughley PJ, et al. **Osteoarthritis Cartilage** 1995 Dec; 3(4):239–48

Lipopolysaccharide alters aggrecan metabolism in the growth plate. Chong LJ, et al. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):378–84

Effects of X irradiation on metabolism of proteoglycans. Jikko A, et al. **Radiat Res** 1996 Jul;146(1):93–9

The effect of substance P on proliferation and proteoglycan deposition of cells derived from rabbit intervertebral disc. Ashton IK, et al. **Spine** 1996 Feb 15;21(4):421–6

Intra-articular morphine and saline injections induce release of large molecular weight proteoglycans into equine synovial fluid. Tulamo RM, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):147–53

[Changes of proteoglycans in lumbar intervertebral disc of bipedal rats with aging] Dong F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):352–4, 383 (Eng. Abstr.) **(Chi)**

[Glycosaminoglycans in subepithelial opacity after excimer laser keratectomy] Nakayasu K, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):350–7 (Eng. Abstr.) **(Jpn)**

[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. **Nippon Rinsho** 1995 Dec;53(12):2904–10 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Kinetics of release of aggrecan from explant cultures of

bovine cartilage from different sources and from animals of different ages. Ilic MZ, et al.
Acta Orthop Scand Suppl 1995 Oct;266:33–7

PHARMACOLOGY

Effects of ganoderma lucidum and krestin on subset T-cell in spleen of gamma-irradiated mice. Chen WC, et al.
Am J Chin Med 1995;23(3–4):289–98

In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer. Sugimachi K, et al.
Anticancer Res 1995 Sep–Oct;15(5B):2175–9

The effect of cornea proteoglycans on liposome peroxidation. Albertini R, et al. **Arch Biochem Biophys** 1996 Mar 15; 327(2):209–14

Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Vijayagopal P, et al.
Arterioscler Thromb Vasc Biol 1996 Sep;16(9):1112–21

Modulation of collagen gel contraction by decorin. Bittner K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):159–66

Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice. Mehta RR, et al.
Br J Cancer 1995 Nov;72(5):1160–4

Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line. Asai K, et al.
Cancer Immunol Immunother 1996 Jun;42(5):275–9

The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. Nakato H, et al.
Development 1995 Nov;121(11):3687–702

Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan. Pejler G, et al. **Eur J Biochem** 1995 Oct 1;233(1):192–9

Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Rada JA, et al. **Exp Eye Res** 1993 Jun;56(6):635–48

Inhibitory effects of PG-H/aggrecan and PG-M/versican on avian neural crest cell migration. Perris R, et al.
FASEB J 1996 Feb;10(2):293–301

A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo. Ito Y, et al.
Int J Cancer 1996 Jul 3;67(1):148–52

Effect of exogenous decorin on cell morphology and attachment of decorin-deficient fibroblasts. Gu J, et al.
J Biochem (Tokyo) 1996 Apr;119(4):743–8

Reconstituted basement membrane (matrigel) enhances the growth of human glioma cell lines in nude mice. Akbasak A, et al. **J Neurooncol** 1996 Jan;27(1):23–30

[Involvement of sulfated proteoglycans in the control of proliferation of MCF-7 breast cancer cells] Delehedde M, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):129–34 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The role of proteoglycans in bladder structure and function. Levy BJ, et al. **Adv Exp Med Biol** 1995;385:191–205; discussion 223–8 (66 ref.)

Pulmonary interstitial pressure and proteoglycans during development of pulmonary edema. Negrini D, et al.
Am J Physiol 1996 Jun;270(6 Pt 2):H2000–7

The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Small DH, et al.
Ann N Y Acad Sci 1996 Jan 17;777:316–21 (18 ref.)

The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Muir H. **Bioessays** 1995 Dec; 17(12):1039–48 (79 ref.)

Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Schlessinger J, et al. **Cell** 1995 Nov 3;83(3):357–60 (20 ref.)

Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation. Schuger L, et al. **Development** 1996 Jun; 122(6):1759–67

Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Grako KA, et al. **Exp Cell Res** 1995 Nov;221(1):231–40

Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines. Bruno E, et al. **Exp Hematol** 1995 Oct;23(11):1212–7

Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules. Salmivirta M, et al. **Experientia** 1995 Sep 29;51(9–10):863–72 (118 ref.)

The role of proteoglycans in maintaining collagen fibril morphology. Dell'Orbo C, et al. **Histol Histopathol** 1995 Jul;10(3):583–8

Tendon response to tensile stress: an ultrastructural investigation of collagen:proteoglycan interactions in stressed tendon. Cribb AM, et al. **J Anat** 1995 Oct;187 (Pt 2):423–8

Heparan sulfate proteoglycans are primarily responsible for the maintenance of enzyme activity, binding, and degradation of lipoprotein lipase in Chinese hamster ovary cells. Berryman DE, et al. **J Biol Chem** 1995 Oct 13; 270(41):24525–31

Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. De Luca A, et al. **J Biol Chem** 1996 Aug 2; 271(31):18961–5

Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. Narita M, et al. **J Biol Chem** 1995 Oct 20;270(42):24800–4

Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells. Lebakken CS, et al.
J Cell Biol 1996 Mar;132(6):1209–21

Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. Steinfeld R, et al. **J Cell Biol** 1996 Apr; 133(2):405–16

Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. SundarRaj N, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2663–72

GM-CSF and IL-3 activities in schistosomal liver granulomas are controlled by stroma-associated heparan sulfate proteoglycans. Alvarez-Silva M, et al.
J Leukoc Biol 1996 Mar;59(3):435–41

Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889–99 (140 ref.)

Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. Nishiyama A, et al.
J Neurosci Res 1996 Feb 1;43(3):315–30

Calories lost--another mediator of cancer cachexia? Nabel GJ, et al. **Nat Med** 1996 Apr;2(4):397–8 (16 ref.)

Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Hennig B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):315–24 (114 ref.)

Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Vlodavsky I, et al.
Thromb Haemost 1995 Jul;74(1):534–40 (33 ref.)

SECRETION

Divergent secretory behavior of the opposite ends of aggrecan. Luo W, et al. **J Biol Chem** 1996 Jul 12; 271(28):16447–50

Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. Le Doux JM, et al. **J Virol** 1996 Sep; 70(9):6468–73

THERAPEUTIC USE

Effect of polysaccharide-peptide (PSP), an extract from yun-zhi, on chemotherapy-induced cytopenias. Zhou LQ, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):143–6

Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Iino Y, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2907–11

An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter. Sugita M, et al.
Cancer Immunol Immunother 1995 Oct;41(4):251–6

Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Yefenof E, et al. **Cancer Immunol Immunother** 1995 Dec; 41(6):389–96

Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Morimoto T, et al.
Eur J Cancer 1996 Feb;32A(2):235–42

ULTRASTRUCTURE

The proteins of proteodermatan and proteokeratan sulphates (decoron and fibromodulon/lumicon) are horseshoe shaped, resembling ribonuclease inhibitor. Scott JE, et al.
Biochem Soc Trans 1995 Nov;23(4):515S

Proteodermatan and proteokeratan sulfate (decorin, lumican/fibromodulin) proteins are horseshoe shaped. Implications for their interactions with collagen. Scott JE.
Biochemistry 1996 Jul 9;35(27):8795–9

Ultrastructure of proteoglycans in the specific granules of guinea-pig basophilic leukocytes as demonstrated by cuprolinic blue staining. Landemore G, et al.
Histochem Cell Biol 1995 Mar;103(3):205–11

URINE

Urinary heparan sulphate proteoglycan excretion is abnormal in insulin dependent diabetes. Shield JP, et al.
Ann Clin Biochem 1995 Nov;32 (Pt 6):557–60

PROTEOLIPID PROTEIN, MYELIN see **MYELIN PROTEOLIPID PROTEIN**

PROTEOLIPIDS

see related

LIPOPROTEINS

Translocation of ricin A-chain into proteoliposomes reconstituted from Golgi and endoplasmic reticulum. Bilge A, et al. **J Biol Chem** 1995 Oct 6;270(40):23720–5

Electrical currents generated by a partially purified Na/Ca exchanger from lobster muscle reconstituted into liposomes and adsorbed on black lipid membranes: activation by photolysis of Ca2+. Eisenrauch A, et al.
J Membr Biol 1995 May;145(2):151–64

Neonatal respiratory disease due to surfactant protein B deficiency. Ballard PL. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S28–34 (42 ref.)

Partial deficiency of surfactant protein B in an infant with chronic lung disease. Ballard PL, et al. **Pediatrics** 1995 Dec; 96(6):1046–52

ANALYSIS

Fetal lung maturation in congenital diaphragmatic hernia. Moya FR, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1401–5

ELISA technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid. Krämer HJ, et al.
Am J Respir Crit Care Med 1995 Nov;152(5 Pt 1):1540–4

Quantitative analysis of pulmonary surfactant proteins B and C. van Eijk M, et al. **Anal Biochem** 1995 Dec 10; 232(2):231–7

Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Honda Y, et al. **Chest** 1996 Apr; 109(4):1006–9

Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers. Lesur O, et al.
Chest 1996 Feb;109(2):467–74

Surfactant associated protein A determination using a chemiluminescence system--application to tracheal aspirates from newborns. Taïeb J, et al. **Clin Chim Acta** 1995 Mar 31;235(2):229–34

Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat. Phelps DS, et al.
Eur Respir J 1996 Mar;9(3):565–70

Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al.
Eur Respir J 1996 Feb;9(2):328–33 (34 ref.)

ANTAGONISTS & INHIBITORS

Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Strayer DS, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1116–22

Quinine specifically inhibits the proteolipid subunit of the F0F1 H+ -ATPase of Streptococcus pneumoniae. Muñoz R, et al. **J Bacteriol** 1996 Apr;178(8):2455–8

BIOSYNTHESIS

Expression and distribution of surfactant proteins and lysozyme after prolonged hyperpnea. Yogalingam G, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L320–30

Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Ohta T, et al.
Br J Cancer 1996 Jun;73(12):1511–7

Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients. Beers MF.
J Biol Chem 1996 Jun 14;271(24):14361–70

BLOOD

Pulmonary surfactant protein A: a serum marker of pulmonary fibrosis in patients with collagen vascular diseases [letter] Takahashi H, et al. **Clin Chim Acta** 1995 Aug 14;239(2):213–5

[Clinical significance of levels of lung surfactant protein A in serum, in various lung diseases] Abe S, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Nov; 33(11):1219–25 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The first putative transmembrane helix of the 16 kDa proteolipid lines a pore in the Vo sector of the vacuolar H(+)-ATPase. Jones PC, et al. **Biochem J** 1995 Dec 15; 312 (Pt 3):739–47

Surfactant-associated protein A is important for maintaining surfactant large-aggregate forms during surface-area cycling. Veldhuizen RA, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):835–40

Functional properties of the purified Na(+)-dependent citrate carrier of Klebsiella pneumoniae: evidence for asymmetric orientation of the carrier protein in proteoliposomes. Pos KM, et al. **Biochemistry** 1996 Jan 23; 35(3):1018–26

External reflection absorption infrared spectroscopy study of lung surfactant proteins SP-B and SP-C in phospholipid monolayers at the air/water interface. Pastrana-Rios B, et al. **Biophys J** 1995 Dec;69(6):2531–40

Ancient weapons: NK-lysin, is a mammalian homolog to pore-forming peptides of a protozoan parasite [letter] Leippe M. **Cell** 1995 Oct 6;83(1):17–8

NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity. Andersson M, et al. **J Biol Chem** 1996 Apr 26;271(17):10116–20

Acylation of pulmonary surfactant protein-C is required for its optimal surface active interactions with phospholipids. Wang Z, et al. **J Biol Chem** 1996 Aug 9;271(32):19104–9

Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide. Lipp MM, et al. **Science** 1996 Aug 30;273(5279):1196–9

DRUG EFFECTS

Interaction of dibutyltin-3-hydroxyflavone bromide with the 16 kDa proteolipid indicates the disposition of proton translocation sites of the vacuolar ATPase. Hughes G, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):425-31

GENETICS

Sequence of rat surfactant protein A gene and functional mapping of its upstream region. Smith CI, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L603-12

Keratinocyte growth factor increases mRNAs for SP-A and SP-B in adult rat alveolar type II cells in culture. Sugahara K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L344-50

Transcriptional regulation of human pulmonary surfactant proteins SP-B and SP-C by glucocorticoids. Ballard PL, et al. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):599-607

The mitochondrial atpA/atp9 co-transcript in wheat and triticale: RNA processing depends on the nuclear genotype. Laser B, et al. **Curr Genet** 1995 Dec;29(1):50-7

Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-beta 1 chimeric gene. Zhou L, et al. **Dev Biol** 1996 May 1;175(2):227-38

A downstream AP-1 element regulates in vitro lung transcription from the human pulmonary surfactant protein B promoter. McWhinney CD. **DNA Cell Biol** 1996 Jul; 15(7):519-29

Full-lenth cloning, expression and cellular localization of rat plasmolipin mRNA, a proteolipid of PNS and CNS. Gillen C, et al. **Eur J Neurosci** 1996 Feb;8(2):405-14

VIP17/MAL, a proteolipid in apical transport vesicles. Zacchetti D, et al. **FEBS Lett** 1995 Dec 27;377(3):465-9

The upstream region of the SP-B gene: intrinsic promoter activity and glucocorticoid responsiveness related to a new DNA-binding protein. Luzi P, et al. **Gene** 1995 Nov 20; 165(2):285-90

Physical and genetic mapping of the CMT4A locus and exclusion of PMP-2 as the defect in CMT4A. Othmane KB, et al. **Genomics** 1995 Jul 20;28(2):286-90

Transcription of the lung-specific surfactant protein C gene is mediated by thyroid transcription factor 1. Kelly SE, et al. **J Biol Chem** 1996 Mar 22;271(12):6881-8

Upstream enhancer activity in the human surfactant protein B gene is mediated by thyroid transcription factor 1. Yan C, et al. **J Biol Chem** 1995 Oct 20;270(42):24852-7

Oligodendrocyte development in PLP "pt" mutant rabbits: glycolipid antigens and PLP gene expression. Sypecka J, et al. **Metab Brain Dis** 1995 Dec;10(4):321-33

Parallel evolution and coexpression of the proteolipid proteins and protein zero in vertebrate myelin. Yoshida M, et al. **Neuron** 1996 Jun;16(6):1115-26

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

The Tokumasu radish mitochondrial genome contains two complete atp9 reading frames. Albaum M, et al. **Plant Mol Biol** 1995 Oct;29(1):179-85

Several distinct genes encode nearly identical to 16 kDa proteolipids of the vacuolar H(+)-ATPase from Arabidopsis thaliana. Perera IY, et al. **Plant Mol Biol** 1995 Oct;29(2):227-44

Molecular and cellular pathobiology of pulmonary surfactant protein B deficiency. Colten HR. **Proc Assoc Am Physicians** 1995 Oct;107(3):334-9 (60 ref.)

Glucocorticoid responsiveness conferred by a cloned DNA binding protein. Luzi P, et al. **Receptor** 1995 Summer; 5(2):93-103

IMMUNOLOGY

Antibody against pulmonary surfactant protein A recognizes proteins in intestine and swim bladder of the freshwater fish, carp. Rubio S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):901-6

Human autoantibodies against Clq: lack of cross reactivity with the collectins mannan-binding protein, lung surfactant protein A and bovine conglutinin. Mårtensson U, et al. **Scand J Immunol** 1996 Mar;43(3):314-20

ISOLATION & PURIFICATION

Single-step purification/solubilization of recombinant proteins: application to surfactant protein B. Holzinger A, et al. **Biotechniques** 1996 May;20(5):804-6, 808

METABOLISM

Synthesis and processing of hydrophobic surfactant protein C by isolated rat type II cells. Beers MF, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L744-53

Posttranslational processing of surfactant protein C in rat type II cells. Vorbroker DK, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L727-33

Surfactant protein A accumulating in the alveoli of patients with pulmonary alveolar proteinosis: oligomeric structure and interaction with lipids. Hattori A, et al. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):608-19

Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Williams MD, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):232-8

Surfactant protein A predicts survival in idiopathic pulmonary fibrosis [letter] McFadden RG. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):825-6

Calcium dependent association of surfactant protein A with pulmonary surfactant: application to simple surfactant protein A purification. Suwabe A, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):285-91

Fatal familial surfactant protein B deficiency [letter] Ball R, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F53

Antibody against pulmonary surfactant protein A recognizes proteins in intestine and swim bladder of the freshwater fish, carp. Rubio S, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):901-6

Methodology for assaying iodide conductance in proteoliposomes: specific induction by thyroid membrane protein. Golstein PE, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):543-8

Human surfactant protein A with two distinct oligomeric structures which exhibit different capacities to interact with alveolar type II cells. Hattori A, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):939-44

Ca(2+)-dependent binding of annexin IV to surfactant protein A and lamellar bodies in alveolar type II cells. Sohma H, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):175-81

Electrogenic K+ transport by the Kdp-ATPase of Escherichia coli. Fendler K, et al. **Biochemistry** 1996 Jun 18;35(24):8009-17

Surfactant protein B metabolism in newborn rabbits. Henry M, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):97-102

Structural requirements for intracellular transport of pulmonary surfactant protein B (SP-B). Lin S, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):177-85

Altered regulation of surfactant phospholipid and protein A during acute pulmonary inflammation. Viviano CJ, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):235-44

Effect of starvation on the activity of the mitochondrial tricarboxylate carrier. Zara V, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):33-8

Receptor-mediated regulation of pulmonary surfactant secretion. Strayer DS, et al. **Exp Cell Res** 1996 Jul 10; 226(1):90-7

Purification of a cell-surface receptor for surfactant protein A. Chroneos ZC, et al. **J Biol Chem** 1996 Jul 5; 271(27):16375-83

Structural requirements for targeting of surfactant protein B (SP-B) to secretory granules in vitro and in vivo. Lin S, et al. **J Biol Chem** 1996 Aug 16;271(33):19689-95

Autocatalytic gene expression occurs via transertion and membrane domain formation and underlies differentiation in bacteria: a model. Norris V, et al. **J Mol Biol** 1995 Nov 10;253(5):739-48

Differential targeting to the plasma membrane of the Torpedo 15-kDa proteolipid expressed in oocytes. Leroy C, et al. **J Neurochem** 1995 Oct;65(4):1789-97

Surfactant protein B in human fetal lung: developmental and glucocorticoid regulation. Beers MF, et al. **Pediatr Res** 1995 Nov;38(5):668-75

[Neonatal pulmonary alveolar proteinosis and SP-B deficiency: pulmonary surfactant at the time of molecular pathology (editorial)] Lacaze-Masmonteil T, et al. **Arch Pediatr** 1996 Apr;3(4):309-12 (33 ref.) **(Fre)**

PHARMACOKINETICS

Alveolar-to-vascular leakage of surfactant protein A in ventilated immature newborn rabbits. Robertson B, et al. **Biol Neonate** 1995;68(3):185-90

PHARMACOLOGY

Surfactant associated protein-A inhibits human lymphocyte proliferation and IL-2 production. Borron P, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):115-21

Interaction of phospholipid liposomes with plasma membrane isolated from alveolar type II cells: effect of pulmonary surfactant protein A. Kuroki Y, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):53-9

Kinetics of phospholipid membrane fusion induced by surfactant apoproteins A and B. Poulain FR, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):169-75

Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. Chao W, et al. **J Clin Invest** 1995 Dec;96(6):2654-60

Role of surfactant protein A in the pathogenesis of tuberculosis in subjects with human immunodeficiency virus infection. Martin WJ 2nd, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):340-5

PHYSIOLOGY

Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. Gaynor CD, et al. **J Immunol** 1995 Dec 1;155(11):5343-51

Monitoring of the membrane potential in proteoliposomes with incorporated cytochrome-c oxidase using the fluorescent dye indocyanine. Ivashchuk-Kienbaum YA. **J Membr Biol** 1996 Jun;151(3):247-59

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

Altered surfactant function and structure in SP-A gene targeted mice. Korfhagen TR, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9594-9

SECRETION

Bronchoalveolar lavage fluid composition in alveolar proteinosis. Early changes after therapeutic lavage. Alberti A, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):817-20

THERAPEUTIC USE

Lung function in premature rabbits treated with recombinant human surfactant protein-C. Hawgood S, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):484-90

PROTEOLYTIC ENZYMES see **PEPTIDE HYDROLASES**

PROTESTANTISM see **CHRISTIANITY**

PROTEUS

CHEMISTRY

Structural and immunochemical studies on O-specific polysaccharide of Proteus penneri strain 14. Sidorczyk Z, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):209-15

The structure of the O-specific polysaccharide chain of Proteus penneri strain 42 lipopolysaccharide. Knirel YA, et al. **Carbohydr Res** 1995 Sep 15;275(1):201-6

DRUG EFFECTS

[Sensitivity of bacteria of the genus Proteus to antibiotics] Vereshchagin IA, et al. **Antibiot Khimioter** 1995 Sep; 40(9):35-7 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[The immune reactivity of patients with chronic bronchitis on vaccinal therapy] Sukhovskaia OA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):68-71 (Eng. Abstr.) **(Rus)**

PROTEUS INFECTIONS

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Metastatic choroidal abscess in the acquired immunodeficiency syndrome [letter] Walton RC, et al. **Arch Ophthalmol** 1996 Jul;114(7):880-1

Adult-onset Langerhans cell histiocytosis associated with severe abscesses. Watson LC, et al. **Clin Exp Dermatol** 1995 Sep;20(5):415-8

DIAGNOSIS

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956-9 (8 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Typing of proteus from patients with bacteriuria. Clarke SC, et al. **J R Soc Health** 1996 Feb;116(1):27-9

Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Mobley HL, et al. **Trends Microbiol** 1995 Jul;3(7):280-4 (36 ref.)

SURGERY

[Nonparasitic liver abscesses] Stoianov G, et al. **Khirurgiia (Sofiia)** 1994;47(6):11-3 (Eng. Abstr.) **(Bul)**

TRANSMISSION

Retrograde transmission of Proteus mirabilis during platelet transfusion and the use of arbitrarily primed polymerase chain reaction for bacteria typing in suspected cases of transfusion transmission of infection. Engstrand M, et al. **Transfusion** 1995 Oct;35(10):871-3

VETERINARY

Traumatic ear canal separations and para-aural abscessation in three dogs. McCarthy PE, et al. **J Am Anim Hosp Assoc** 1995 Sep-Oct;31(5):419-24

Isolation and characterisation of dog uropathogenic Proteus mirabilis strains. Gaastra W, et al. **Vet Microbiol** 1996 Jan; 48(1-2):57-71

PROTEUS MIRABILIS

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956-9 (8 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Methanol extracts LPS from deep rough bacteria. Nurminen M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):441-4

The structure and serological specificity of Proteus mirabilis O43 O antigen. Cedzyński M, et al. **Eur J Biochem** 1995 Sep 1;232(2):558-62

PROTEUS MIRABILIS

Structures of new acidic O-specific polysaccharides of the bacterium Proteus mirabilis serogroups O26 and O30. Shashkov AS, et al. **FEBS Lett** 1996 May 20; 386(2-3):247-51

Study of a melanic pigment of Proteus mirabilis. Agodi A, et al. **Res Microbiol** 1996 Mar-Apr;147(3):167-74

Isolation and characterisation of dog uropathogenic Proteus mirabilis strains. Gaastra W, et al. **Vet Microbiol** 1996 Jan; 48(1-2):57-71

[Structure of a new lysine-containing O-specific polysaccharide from Proteus mirabilis O26] Shashkov AS, et al. **Biokhimiia** 1996 Jan;61(1):24-33 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Typing of proteus from patients with bacteriuria. Clarke SC, et al. **J R Soc Health** 1996 Feb;116(1):27-9

DRUG EFFECTS

Heavy metal effects on Proteus mirabilis superoxide dismutase production. Eickhoff J, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):271-6

Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. Neuwirth C, et al. **J Antimicrob Chemother** 1995 Aug; 36(2):335-42

ENZYMOLOGY

Cleavage of IgG and IgA in vitro and in vivo by the urinary tract pathogen Proteus mirabilis. Kerr MA, et al. **Adv Exp Med Biol** 1995;371A:609-11

Purification and characterization of a heterodimeric 23/20-kDa proteolytic fragment of bacterial glutathione transferase B1-1. Aceto A, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):302-8

Molecular cloning and overexpression of a glutathione transferase gene from Proteus mirabilis. Perito B, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):157-62

Simulations of electron transfer in the NADPH-bound catalase from Proteus mirabilis PR. Bicout DJ, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):172-6

Analysis by limited proteolysis of domain organization and GSH-site arrangement of bacterial glutathione transferase B1-1. Aceto A, et al. **Int J Biochem Cell Biol** 1995 Oct; 27(10):1033-41

Potential contribution of optional urease-positive bacteria to idiopathic urinary calcium stone formation. II. Microlith formation kinetics in a fermenter model of the urinary tract infected by optional urease-positive microorganisms. Leusmann DB, et al. **Urol Res** 1996;24(2):73-8

GENETICS

Proteus mirabilis urease: operon fusion and linker insertion analysis of ure gene organization, regulation, and function. Island MD, et al. **J Bacteriol** 1995 Oct;177(19):5653-60

Proteus mirabilis amino acid deaminase: cloning, nucleotide sequence, and characterization of aad. Massad G, et al. **J Bacteriol** 1995 Oct;177(20):5878-83

Molecular analysis of a metalloprotease from Proteus mirabilis. Wassif C, et al. **J Bacteriol** 1995 Oct; 177(20):5790-8

Synthesis and secretion of recombinant penicillin G acylase in bacterial L-forms. Gumpert J, et al. **J Basic Microbiol** 1996;36(2):89-98

Retrograde transmission of Proteus mirabilis during platelet transfusion and the use of arbitrarily primed polymerase chain reaction for bacteria typing in suspected cases of transfusion transmission of infection. Engstrand M, et al. **Transfusion** 1995 Oct;35(10):871-3

GROWTH & DEVELOPMENT

Inhibition of growth of Proteus mirabilis and Escherichia coli in urine in response to fasting and vegetarian diet. Kjeldsen-Kragh J, et al. **APMIS** 1995 Nov;103(11):818-22

An improved model for bacterial encrustation studies. Sarangapani S, et al. **J Biomed Mater Res** 1995 Oct; 29(10):1185-91

IMMUNOLOGY

The structure and serological specificity of Proteus mirabilis O43 O antigen. Cedzyński M, et al. **Eur J Biochem** 1995 Sep 1;232(2):558-62

The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Fielder M, et al. **Rheumatol Int** 1995;15(2):79-82

ISOLATION & PURIFICATION

[Phenotypes of resistance to antibiotics of the most frequently isolated strains in five specialized hospital centers. Multicenter study] Gabastou JM, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):320-3 (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Mobley HL, et al. **Trends Microbiol** 1995 Jul;3(7):280-4 (36 ref.)

PHYSIOLOGY

A cell-surface polysaccharide that facilitates rapid population migration by differentiated swarm cells of Proteus mirabilis. Gygi D, et al. **Mol Microbiol** 1995 Sep;17(6):1167-75

PROTEUS SYNDROME

PATHOLOGY

Hemifacial hyperplasia with meningeal involvement: a variant of proteus syndrome? Haramoto U, et al. **Am J Med Genet** 1995 Nov 6;59(2):164-7

Proteus syndrome: association with gingival hyperplasia. Arendorf TM, et al. **J Oral Pathol Med** 1995 Sep; 24(8):383-4

Regional Proteus syndrome: report of an autopsy case. Horie Y, et al. **Pathol Int** 1995 Jul;45(7):530-5

[Bifocal lesion of striated muscle (hamartoma or focal myositis) in the course of Proteus syndrome] Nodari F, et al. **Ann Pathol** 1996;16(1):53-5 (Eng. Abstr.) **(Fre)**

PROTEUS VULGARIS

[Nonparasitic liver abscesses] Stoianov G, et al. **Khirurgiia (Sofiia)** 1994;47(6):11-3 (Eng. Abstr.) **(Bul)**

CLASSIFICATION

Replacement of NCTC 4175, the current type strain of Proteus vulgaris, with ATCC 29905. Request for an opinion. Brenner DJ, et al. **Int J Syst Bacteriol** 1995 Oct; 45(4):870-1

DRUG EFFECTS

Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants). Higashitani F, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1027-33

ENZYMOLOGY

Characterization of an alkaline lipase from Proteus vulgaris K80 and the DNA sequence of the encoding gene. Kim HK, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):117-21

PHYSIOLOGY

Examination of biofilm formation and risk of infection associated with the use of urinary catheters with leg bags. Rogers J, et al. **J Hosp Infect** 1996 Feb;32(2):105-15

PROTHROMBIN

see related
COAGULANTS

ANALOGS & DERIVATIVES

Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Nomura F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1380-3

Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma. Nakao A, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):160-3

ANALYSIS

Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman. Ciepluch R, et al. **Acta Haematol Pol** 1996; 27(1):21-5

Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Scharfstein JS, et al. **Am J Cardiol** 1996 Sep 1;78(5):503-10

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293-7

Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Smith CJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1221-5

Thrombin-antithrombin III and prothrombin fragment 1.2 levels in early respiratory distress syndrome [letter] Yurdakök M, et al. **Am J Hematol** 1996 Mar;51(3):247-8

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Merlini PA, et al. **Blood** 1995 Nov 1;86(9):3327-32

Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Simioni P, et al. **Br J Haematol** 1996 Feb;92(2):435-41

Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Aoyagi Y, et al. **Cancer** 1996 May 1; 77(9):1781-6

Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction. Carville DG, et al. **Clin Chem** 1996 Sep;42(9):1537-41

Increased prothrombin fragment 1.2 concentrations in hemodialysis patients [letter] Erdem Y, et al. **Clin Nephrol** 1996 Jan;45(1):69

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Ceriello A, et al. **Diabetologia** 1996 Apr; 39(4):469-73

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107-8

Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gadducci A, et al. **Gynecol Oncol** 1996 May;61(2):215-7

Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Izuno K, et al. **Hepatogastroenterology** 1995 Jul-Aug; 42(4):387-93

Effect of oral water soluble vitamin K on PIVKA-II levels in newborns. Sharma RK, et al. **Indian Pediatr** 1995 Aug; 32(8):863-7

Liver cell adenoma in a young man with elevated serum PIVKA-II level. Uto H, et al. **J Gastroenterol** 1996 Jun; 31(3):441-5

First clinical application of the Medos-HIA ventricular support system: monitoring of the thrombotic risk by means of the biomarker prothrombin fragment F1 + 2 and scanning electron microscopy evaluation. Guldner NW, et al. **J Heart Lung Transplant** 1996 Mar;15(3):291-6

Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. Grosley BM, et al. **J Lab Clin Med** 1996 Jun;127(6):553-64

Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Stapleton AM, et al. **Kidney Int** 1996 Mar;49(3):880-8

Normotest and abnormal prothrombin in liver transplantation. Nakao A, et al. **Liver** 1995 Oct;15(5):260-4

Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. Davi G, et al. **Thromb Haemost** 1995 Aug;74(2):631-4

Prothrombin fragment F 1+2 levels are high in NIDDM patients independently of the Hb A1 c [letter; comment] Marongiu F, et al. **Thromb Haemost** 1995 Aug;74(2):805-6 . Comment on: Thromb Haemost 1994 Jun;71(6):692-7.

Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Zöller B, et al. **Thromb Haemost** 1996 Feb;75(2):270-4

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003-7 (5 ref.) **(Jpn)**

[Effects of the administration of vitamin K on the activity of Factor II, VII and X in healthy newborns] Arteaga-Vizcaíno M, et al. **Invest Clin** 1995 Jun;36(2):83-93 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Evidence for competition between vitamin K-dependent clotting factors for intracellular processing by the vitamin K-dependent gamma-carboxylase. Stanton C, et al. **Thromb Res** 1995 Oct 1;80(1):63-73

CHEMISTRY

Crystallographic evidence that the F2 kringle catalytic domain linker of prothrombin does not cover the fibrinogen recognition exosite. van de Locht A, et al. **J Biol Chem** 1996 Feb 16;271(7):3413-6

Intramolecular domain-domain interactions and intermolecular self-association in bovine prothrombin. A potentiometric and laser light-scattering study. Koehler KA, et al. **J Protein Chem** 1995 Oct;14(7):537-48

Homology modeling and molecular dynamics simulation of human prothrombin fragment 1. Li L, et al. **Protein Sci** 1995 Nov;4(11):2341-8

DEFICIENCY see HYPOPROTHROMBINEMIAS

DRUG EFFECTS

Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Nowak G, et al. **Thromb Res** 1995 Nov 15;80(4):317-25

[The effect of the quaternary ammonium salt of conidine oligomer-25 (QAS CO-25) on the activity of prothrombin complex factors] Efimov VS, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):34-6 (Eng. Abstr.) **(Rus)**

GENETICS

Prothrombin Molise I: documentation of a second incidence of replacement of a critical Arg near the active site. James HL, et al. **Thromb Res** 1995 Nov 15;80(4):363-6

IMMUNOLOGY

Transient hemorrhagic diathesis associated with an inhibitor

of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307–14 (46 ref.)

Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. Matsuda J, et al. **Br J Rheumatol** 1996 Jun;35(6):589–91

Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Arvieux J, et al. **Thromb Haemost** 1995 Oct;74(4):1120–5

Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Vaarala O, et al. **Thromb Haemost** 1996 Mar;75(3):456–9

[Transitions of each inhibitor in a patient with lupus anticoagulant and anti-prothrombin antibody] Murakami F, et al. **Rinsho Byori** 1996 Jul;44(7):692–6 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus. Jantsch-Plunger V, et al. **Vox Sang** 1995;69(4):352–4

METABOLISM

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Hatton MW, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1147–55

Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Billy D, et al. **Biochemistry** 1995 Oct 17; 34(41):13699–704

Importance of cis-proline 22 in the membrane-binding conformation of bovine prothrombin. Evans TC Jr, et al. **Biochemistry** 1996 Jun 25;35(25):8210–5

Soluble phospholipids enhance factor Xa-catalyzed prothrombin activation in solution. Koppaka V, et al. **Biochemistry** 1996 Jun 11;35(23):7482–91

Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: implications for protein--membrane contact. Lu Y, et al. **Biochemistry** 1996 Jun 25;35(25):8193–200

A binding site expressed on the surface of activated human platelets is shared by factor X and prothrombin. Scandura JM, et al. **Biochemistry** 1996 Jul 9;35(27):8890–902

Biospecific interactions of Vitamin K-dependent factors with phospholipid-like polystyrene derivatives. Part I: Factor II. Migonney V, et al. **Biomaterials** 1996 Apr;17(8):823–9

Is Ca(II) ion binding to prothrombin fragment 1 intrinsically cooperative, or is the cooperative binding accounted for by self-association? Cabaniss S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):464–73

Suppression of F1+2 (thrombin) generation in patients with DVT requires increased doses of heparin [letter] Korte W, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):684–6

Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases. Mohamedein A, et al. **East Afr Med J** 1995 Sep;72(9):584–7

Inhibition of factor Xa-mediated procoagulant activity of human lung fibroblasts and pleural mesothelial cells. Kumar A, et al. **Eur Respir J** 1995 Dec;8(12):2038–45

Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. Billy D, et al. **J Biol Chem** 1995 Nov 10;270(45):26883–9

Crystallographic evidence that the F2 kringle catalytic domain linker of prothrombin does not cover the fibrinogen recognition exosite. van de Locht A, et al. **J Biol Chem** 1996 Feb 16;271(7):3413–6

Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. Yamada D, et al. **J Biol Chem** 1996 Mar 1;271(9):5200–7

Prothrombin cleavage by human vascular smooth muscle cells: a potential alternative pathway to the coagulation cascade. Benzakour O, et al. **J Cell Biochem** 1995 Dec; 59(4):514–28

The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation. Bruhn HD, et al. **J Heart Valve Dis** 1995 Mar;4(2):138–40

Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo. Hatton MW, et al. **J Lab Clin Med** 1995 Dec;126(6):521–9

Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Rao LV, et al. **Thromb Haemost** 1995 Apr;73(4):668–74

Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Xu N, et al. **Thromb Res** 1995 Oct 1; 80(1):35–46

Activation of human prothrombin by porcine endothelium. Jurd KM, et al. **Transplant Proc** 1996 Apr;28(2):610

[Determination of PIVKA-II levels in patients with small hepatocellular carcinoma--comparison of new sensitive methods] Ishijima M, et al. **Rinsho Byori** 1996 Jul; 44(7):635–9 (Eng. Abstr.) **(Jpn)**

[Determination of the general prothrombin level and detection of its functionally inactive forms using the enzyme ecamulin purified from Echis multisquamatus venom] Platonova TN, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):75–80 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Billy D, et al. **Biochemistry** 1995 Oct 17; 34(41):13699–704

The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Ryall RL, et al. **Clin Sci (Colch)** 1995 Nov;89(5):533–41

THERAPEUTIC USE

Prothrombin complex concentrate contains protein Z and prevents bleeding in a patient with protein Z deficiency [letter] Greten J, et al. **Thromb Haemost** 1995 Sep; 74(3):992–3

PROTHROMBIN TIME

Heparin-induced increase in the International Normalized Ratio [letter; comment] Carroll JJ. **Am J Clin Pathol** 1996 Feb;105(2):253–4. Comment on: Am J Clin Pathol 1995 Jun;103(6):735–9.

Low interinstrument variability of the international normalized ratio with the coagamate X2/Simplastin excel system. Cunningham MT, et al. **Am J Clin Pathol** 1996 Mar;105(3):301–4

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293–7

Prothrombin time: one tube or two. Yawn BP, et al. **Am J Clin Pathol** 1996 Jun;105(6):794–7

A simple method for the derivation of the international normalized ratio for the reporting of prothrombin time results. Habibzadeh F, et al. **Am J Hematol** 1995 Dec; 50(4):283–7

Discrepancy between thromboelastography and prothrombin time [letter] Pivalizza EG, et al. **Anesthesiology** 1996 May; 84(5):1262

Membrane-based, dry-reagent prothrombin time tests. Zweig SE, et al. **Biomed Instrum Technol** 1996 May-Jun; 30(3):245–56

Changes in plasma warfarin levels and variations in steady-state prothrombin times. White RH, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):588–93

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Black DJ, et al. **Drug Metab Dispos** 1996 Apr;24(4):422–8

Reference materials and reference measurement systems in laboratory medicine. Prothrombin time standardization: the problem of the control plasma. D'Angelo A. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):1019–22

Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen. Hara A, et al. **Glycoconj J** 1996 Apr;13(2):187–94

Study of some biochemical changes among workers occupationally exposed to phenol, alone or in combination with other organic solvents. Shamy MY, et al. **Ind Health** 1994;32(4):207–14

What is the INR? Troulis MJ, et al. **J Can Dent Assoc** 1996 May;62(5):428–30

Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass [see comments] Nuttall GA, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):355–61. Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):353–4.

An easier alternative to orthogonal regression for calculation of International Sensitivity Indexes. Taberner DA, et al. **J Clin Pathol** 1995 Oct;48(10):901–3

Multicentre evaluation of the Thrombotest International Sensitivity Index used with a steel ball coagulometer. van den Besselaar AM, et al. **J Clin Pathol** 1996 May; 49(5):414–7

Has the prothrombin time stood the test of time? [letter; comment] Spillert CR, et al. **Mayo Clin Proc** 1996 Jul; 71(7):721. Comment on: Mayo Clin Proc 1995 Aug;70(8):806–8.

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

Use of INR to assess degree of anticoagulation in patients who have dental procedures. Steinberg MJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):175–7

INR and PTR anticoagulation values [letter] Wahl MJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):377–8

Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients. Bleske BE, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):709–12

Calibration of thromboplastins. Finney DJ. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):71–5 (18 ref.)

Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter] Malacarne P, et al. **Recenti Prog Med** 1996 Mar;87(3):135

Rapid fibrinogen determination with the prothrombin time using a potentiophotometer. Carroll WE, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):67–76

Is it time to change the prothrombin time? [editorial] Lazaro EJ, et al. **Surgery** 1995 Nov;118(5):912–3

Quality control and oral anticoagulation. Preston FE. **Thromb Haemost** 1995 Jul;74(1):515–20

A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Tripodi A, et al. **Thromb Haemost** 1996 Feb; 75(2):309–12

A proposed scheme for calibration of international reference preparations of thromboplastin for the prothrombin time. On behalf of the Subcommittee on Control of Anticoagulation. Tripodi A, et al. **Thromb Haemost** 1995 Nov;74(5):1368–9

[Prothrombin time (PT)] Fukutake K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:10–3 (4 ref.) **(Jpn)**

[Thrombotest (TBT), hepaplastin test (HPT)] Ueda M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:14–7 (5 ref.) **(Jpn)**

VETERINARY

Influence of sample predilution on the sensitivity of prothrombin time in feline plasma. Mischke R, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):155–62

PROTIRELIN

see related
RECEPTORS, THYROTROPIN-RELEASING HORMONE

ADMINISTRATION & DOSAGE

Thyrotropin-releasing hormone: does two hundred micrograms provide effective stimulation to the preterm fetal pituitary gland compared with four hundred micrograms? Crowther C, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):719–23

Effects of thyrotropin-releasing hormone administration on the electroconvulsive therapy induced prolactin responses and seizure time. Papakostas Y, et al. **Biol Psychiatry** 1996 Mar 15;39(6):444–7

Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Van den Berghe G, et al. **Crit Care Med** 1996 Apr;24(4):590–5

Assessment of a combined anterior pituitary function test in beagle dogs: rapid sequential intravenous administration of four hypothalamic releasing hormones. Meij BP, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):161–70

Effect of continuous infusion of thyrotrophin-releasing hormone on plasma prolactin and on ovarian activity in melatonin-treated ewes. Robinson JJ, et al. **J Reprod Fertil** 1996 May;107(1):17–22

Euprolactinemic Galactorrhea. Response of bioassayable prolactin to thyrotropin-releasing hormone. Ataya KM, et al. **J Reprod Med** 1996 Mar;41(3):156–60

Application of a spray drying technique in the production of TRH-containing injectable sustained-release microparticles of biodegradable polymers. Takada S, et al. **PDA J Pharm Sci Technol** 1995 Jul-Aug;49(4):180–4

Effect of lithium and oral thyrotrophin-releasing hormone (TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma. Ang ES, et al. **Singapore Med J** 1995 Dec; 36(6):606–8

ANALOGS & DERIVATIVES

A thyrotropin-releasing hormone analogue: pGlu-Phe-D-Pro-psi [CN4]-NMe at 293 and 107 K. Howell PL, et al. **Acta Crystallogr C** 1995 Dec 15;51 (Pt 12):2575–9

Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Parnetti L, et al. **Acta Neurol Scand** 1995 Aug;92(2):135–40

Low doses of TRH analogue act in the dorsal motor nucleus to induce gastric protection in rats. Kato K, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1301–7

Microinjection of TRH analogue into the dorsal vagal complex stimulates pancreatic secretion in rats. Okumura T, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G328–34

Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Sasaki I, et al. **Biol Pharm Bull** 1995 Jul; 18(7):976–9

The cardiovascular and subjective effects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethyl proline-TRH, in healthy volunteers. Coupland NJ, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):223–9

Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area. Kinoshita K, et al. **Br J Pharmacol** 1995 Dec;116(8):3274–8

A novel analog of TRH, YM14673, causes a decrease in brain TRH receptors in vitro. Monden T, et al. **Endocr Res** 1995

Nov;21(4):803–14
Long–term antiepileptic effects of chronic intake of CNK–602A, a thyrotropin–releasing hormone analogue, on spontaneously epileptic rats. Momiyama T, et al. **Epilepsia** 1996 Apr;37(4):328–31
The TRH–like peptides in rabbit testis are different from the TRH–like peptide in the prostate. Linden H, et al. **FEBS Lett** 1996 Jan 22;379(1):11–4
Fertilization–promoting peptide: a novel peptide, structurally similar to TRH, with potent physiological activity. Cockle SM. **J Endocrinol** 1995 Jul;146(1):3–8
Further studies on the regulation, localization and function of the TRH–like peptide pyroglutamyl–glutamyl–prolineamide in the rat anterior pituitary gland. Rondeel JM, et al. **J Endocrinol** 1995 Aug; 146(2):293–300
Conformationally restricted TRH analogs: a probe for the pyroglutamate region. Rutledge LD, et al. **J Med Chem** 1996 Apr 12;39(8):1571–4
Permeability of NS–3, a thyrotropin–releasing hormone analogue, into the brain after its systemic administration in rats: a microdialysis study. Itoh Y, et al. **J Pharm Pharmacol** 1995 Oct;47(10):833–6
Effects of RGH 2202 on cognitive and motor behavior of the rat. Drago F, et al. **Neurobiol Aging** 1996 Jan–Feb; 17(1):67–71
Effects of RGH–2202 on behavioral deficits after focal cerebral ischemia in rats. Noda Y, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):695–9
[Effect of (–)–N–[(S)–hexahydro–1–methyl–2, 6–dioxo–4–pyrimidinylcarbonyl]–L–histidyl–L–prolinamide (TA–0910), a new TRH analog, on plasma levels of TSH and thyroid hormones in rats] Moriyasu M, et al. **Nippon Yakurigaku Zasshi** 1996 Jun;107(6):285–97 (Eng. Abstr.) **(Jpn)**
[Montirelin hydrate (NS–3), a TRH analog, improved the disturbance of consciousness caused by head concussion and pentobarbital in mice] Mushiroi T, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):237–45 (Eng. Abstr.) **(Jpn)**
[Montirelin hydrate (NS–3), a TRH analog, improved disturbance of consciousness in cats: electroencephalographical studies] Ukai Y, et al. **Nippon Yakurigaku Zasshi** 1996 Jun;107(6):273–84 (Eng. Abstr.) **(Jpn)**
[Electrophysiological evaluation of the demented state and the nootropic effect of TA–0910 by "automated fluctuation analysis" of the high–frequency EEG—relation between neuropsychological test results and Lorentzian parameters] Nakata M. **No To Shinkei** 1996 Jun;48(6):551–8 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Thyrotropin–releasing hormone–immunoreactive varicosities synapse on rat phrenic motoneurons. Murphy SM, et al. **J Comp Neurol** 1995 Aug 21;359(2):310–22
Thyrotropin–releasing hormone inputs are preferentially directed towards respiratory motoneurons in rat nucleus ambiguus. Sun QJ, et al. **J Comp Neurol** 1995 Nov 20; 362(3):320–30

ANTAGONISTS & INHIBITORS

A constitutively active mutant thyrotropin–releasing hormone receptor is chronically down–regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Heinflink M, et al. **Mol Endocrinol** 1995 Nov;9(11):1455–60

BIOSYNTHESIS

Homologous conditioned medium enhances expression of TRH in hypothalamic neurons in primary culture. Charli JL, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):155–60

BLOOD

[Thyrotropin releasing hormone (TRH)] Oshima I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:300–3 (11 ref.) **(Jpn)**

CHEMISTRY

Nuclear magnetic resonance studies of thyrotropin–releasing hormone (TRH) and analogues incorporating D–histidine and 4–hydroxy–L–proline. Aksnes DW, et al. **Acta Chem Scand** 1996 May;50(5):411–6
A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Novel mixed mode Monte Carlo/stochastic dynamics simulations of the complex between TRH and TRH receptor. Laakkonen LJ, et al. **Biochemistry** 1996 Jun 18;35(24):7651–63
A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Perlman JH, et al. **Biochemistry** 1996 Jun 18;35(24):7643–50
Enhancement of intestinal transport of thyrotropin–releasing hormone via a carrier–mediated transport system by chemical modification with lauric acid. Tanaka K, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):119–26
Restricted analogues provide evidence of a biologically active conformation of thyrotropin–releasing hormone. Laakkonen L, et al. **Mol Pharmacol** 1996 Jun;49(6):1092–6
The electrophoretic mobility of tripeptides as a function of pH and ionic strength: comparison with iontophoretic flux data. VanOrman Huff B, et al. **Pharm Res** 1995 May; 12(5):751–5

DIAGNOSTIC USE

The thyrotropin releasing hormone stimulation test in alcoholism. Pienaar WP, et al. **Alcohol Alcohol** 1995 Sep; 30(5):661–7
Thyrotropin and prolactin responses to thyrotropin–releasing hormone in young men at high or low risk for alcoholism. Garbutt JC, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1133–40
Thyrotropin–releasing hormone: does two hundred micrograms provide effective stimulation to the preterm fetal pituitary gland compared with four hundred micrograms? Crowther C, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):719–23
Thyrotropin–releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment] Coupland N, et al. **Biol Psychiatry** 1996 Mar 15;39(6):465–6. Comment on: Biol Psychiatry 1994 Jul 15;36(2):73–83.
Correlation between vasopressin baseline and TSH–blunting in depressives. Lenzinger E, et al. **Biol Psychiatry** 1996 Mar 1;39(5):341–5
Effect of haemoglobin and endogenous erythropoietin on hypothalamic–pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. Ramirez G, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):167–74
Combined pyridostigmine–thyrotrophin–releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. Yang I, et al. **Eur J Endocrinol** 1995 Oct;133(4):457–62
Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients. De Marinis L, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):67–71
Prolactin response to metoclopramide and thyrotropin–releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity. Bussen S, et al. **Gynecol Endocrinol** 1996 Apr; 10(2):83–90
Thyroid–stimulating hormone and prolactin responses to thyrotropin–releasing hormone in juvenile obesity before and after hypocaloric diet. Guzzaloni G, et al. **J Endocrinol Invest** 1995 Sep;18(8):621–9
Low serum TSH levels and negative TRH test in dialysis patients [letter] Evers J, et al. **Nephron** 1995;71(3):357–8
Effect of parathyroidectomy on thyrotropic and lactotropic function in patients with renal osteopathy. Zofková I, et al. **Nephron** 1995;71(3):284–90
Sensitive assay of thyroid stimulating hormone in depressed patients. Poirier MF, et al. **Psychiatry Res** 1995 Jun 29; 57(1):41–8

DRUG EFFECTS

Effect of a novel prolyl endopeptidase inhibitor, JTP–4819, on thyrotropin–releasing hormone–like immunoreactivity in the cerebral cortex and hippocampus of aged rats. Shinoda M, et al. **Jpn J Pharmacol** 1995 Nov;69(3):273–6

GENETICS

Activation of thyrotropin–releasing hormone gene expression in cultured fetal diencephalic neurons by differentiating agents. Bruhn TO, et al. **Endocrinology** 1996 Feb; 137(2):572–9
Pituitary adenylate cyclase–activating polypeptide regulates prolactin promoter activity via a protein kinase A–mediated pathway that is independent of the transcriptional pathway employed by thyrotropin–releasing hormone. Coleman DT, et al. **Endocrinology** 1996 Apr;137(4):1276–85
Glucocorticoids stimulate thyrotropin–releasing hormone gene expression in cultured hypothalamic neurons. Luo LG, et al. **Endocrinology** 1995 Nov;136(11):4945–50
Differential coexpression of genes encoding prothyrotropin–releasing hormone (pro–TRH) and prohormone convertases (PC1 and PC2) in rat brain neurons: implications for differential processing of pro–TRH. Pu LP, et al. **Endocrinology** 1996 Apr; 137(4):1233–41
Pups removal enhances thyrotropin–releasing hormone mRNA in the hypothalamic paraventricular nucleus. Uribe RM, et al. **Eur J Endocrinol** 1995 Sep;133(3):354–60
The human thyrotropin–releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Hollenberg AN, et al. **Mol Endocrinol** 1995 May;9(5):540–50
Differential regulation of basal and kindling–induced TRH mRNA expression by thyroid hormone in the hypothalamic and limbic structures. Kim SY, et al. **Neuroendocrinology** 1996 Mar;63(3):297–304
Phorbol ester or cAMP enhance thyrotropin–releasing hormone mRNA in primary cultures of hypothalamic cells. Uribe RM, et al. **Neurosci Lett** 1995 Dec 1;201(1):41–4

IMMUNOLOGY

Production and characterization of monoclonal and polyclonal antibodies against thyrotropin–releasing hormone. Klootwijk W, et al. **Hybridoma** 1995 Jun; 14(3):285–90

METABOLISM

Case report: thyrotropin–releasing hormone–induced myoclonus and tremor in a patient with Hashimoto's encephalopathy. Ishii K, et al. **Am J Med Sci** 1995 Nov; 310(5):202–5
Identification of Asn289 as a ligand binding site in the rat thyrotropin–releasing hormone (THR) receptor as determined by complementary modifications in the ligand and receptor: a new model for THR binding. Han B, et al. **Biochemistry** 1995 Oct 17;34(41):13412–22
A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Novel mixed mode Monte Carlo/stochastic dynamics simulations of the complex between TRH and TRH receptor. Laakkonen LJ, et al. **Biochemistry** 1996 Jun 18;35(24):7651–63
A refined model of the thyrotropin–releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Perlman JH, et al. **Biochemistry** 1996 Jun 18;35(24):7643–50
Enhancement of intestinal transport of thyrotropin–releasing hormone via a carrier–mediated transport system by chemical modification with lauric acid. Tanaka K, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):119–26
Identification and cellular localization of thyrotropin–releasing hormone–related peptides in rat testis. Montagne JJ, et al. **Endocrinology** 1996 Jan; 137(1):185–91
Changes of thyrotropin–releasing hormone concentration in the brain and levels of prolactin and thyroxin in the serum during spawning migration of the chum salmon Oncorhynchus keta. Hamano K, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):275–81
A study of a synaptosomal thyrotropin releasing hormone–inactivating pyroglutamate aminopeptidase from bovine brain. O'Leary RM, et al. **Int J Biochem Cell Biol** 1995 Sep;27(9):881–90
Further studies on the regulation, localization and function of the TRH–like peptide pyroglutamyl–glutamyl–prolineamide in the rat anterior pituitary gland. Rondeel JM, et al. **J Endocrinol** 1995 Aug; 146(2):293–300
Pro–thyrotropin–releasing hormone processing by recombinant PC1. Nillni EA, et al. **J Neurochem** 1995 Dec; 65(6):2462–72
The human thyrotropin–releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Hollenberg AN, et al. **Mol Endocrinol** 1995 May;9(5):540–50
The effects of repeated amphetamine administration on the thyrotropin–releasing hormone level. Its release and receptors in the rat brain. Jaworska–Feil L, et al. **Neuropeptides** 1995 Sep;29(3):171–6
Activation of the thyrotropin–releasing hormone (TRH) receptor by a direct precursor of TRH, TRH–Gly. Yamada M, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):109–12
Response surface method: a novel strategy to optimize iontophoretic transdermal delivery of thyrotropin–releasing hormone. Huang YY, et al. **Pharm Res** 1996 Apr; 13(4):547–52

PHARMACOLOGY

Thyrotropin–releasing hormone (TRH) inhibits vasopressin and oxytocin release from rat hypothalamo–neurohypophysial explants in vitro. Ciosek J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):35–40
Effects of maternal administration of dexamethasone and thyrotropin–releasing hormone on fetal rat pulmonary surfactant synthesis. Yokoyama N, et al. **Biol Neonate** 1995; 68(1):39–46
The cardiovascular and subjective effects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethyl proline–TRH, in healthy volunteers. Coupland NJ, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):223–9
Anti–ataxic effects of TRH and its analogue, TA–0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area. Kinoshita K, et al. **Br J Pharmacol** 1995 Dec;116(8):3274–8
TRH in the dorsal motor nucleus of vagus is involved in gastric erosion induced by excitation of raphe pallidus in rats. Kaneko H, et al. **Brain Res** 1995 Nov 13;699(1):97–102
Circadian rhythms of dopamine and cholecystokinin in nucleus accumbens and striatum of rats—influence on dopaminergic stimulation. Schade R, et al. **Chronobiol Int** 1995 Apr;12(2):87–99
Direct inhibitory effect of thyrotropin–releasing hormone on isolated cecal circular smooth muscle cells of guinea pig. Harada N, et al. **Digestion** 1996;57(2):79–82
Autocrine and/or paracrine action of vasoactive intestinal peptide on thyrotropin–releasing hormone induced prolactin release. Balsa JA, et al. **Endocrinology** 1996 Jan; 137(1):144–50
Pyroglutamyl–phenylalanyl–proline amide attenuates thyrotropin–releasing hormone–stimulated insulin secretion in perifused rat islets and insulin–secreting clonal beta–cell lines. Kulkarni RN, et al. **Endocrinology** 1995 Nov; 136(11):5155–64
Preprothyrotropin–releasing hormone–(178–199) does not

inhibit corticotropin release. Nicholson WE, et al. **Endocrinology** 1996 May;137(5):2171–4

Prolyl–leucyl–glycinamide, thyrotropin–releasing hormone and beta–endorphin–(10–16), like antidepressants, antagonize melatonin–induced behavioural changes in rats. Hatta K, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):327–30

Effects of intravenous thyrotropin–releasing hormone on urethral closure pressure in females with voiding dysfunction. Rosario DJ, et al. **Eur Urol** 1995;28(1):64–7

Inhibitory effect of thyrotropin–releasing hormone on enzyme secretion from isolated rat pancreatic acinar cells. Kemmer TP, et al. **Horm Metab Res** 1995 Aug;27(8):367–71

Thyrotropin–releasing hormone (TRH) and CNS regulation of anorectal motility in the rat. Holmes GM, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):8–14

The role of the calpain–calpastatin system in thyrotropin–releasing hormone–induced selective down–regulation of a protein kinase C isozyme, nPKC epsilon, in rat pituitary GH4C1 cells. Eto A, et al. **J Biol Chem** 1995 Oct 20;270(42):25115–20

TRH receptor on immune cells: in vitro and in vivo stimulation of human lymphocyte and rat splenocyte DNA synthesis by TRH. Raiden S, et al. **J Clin Immunol** 1995 Sep;15(5):242–9

Functional and morphological changes of the thyroid gland following 5 days of pulsatile TRH stimulation in male rats. Hoang–Vu C, et al. **J Endocrinol** 1995 Aug;146(2):339–48

Role of guanine nucleotide–binding proteins, Gi alpha 3 and Gs alpha, in dopamine and thyrotropin–releasing hormone signal transduction: evidence for competition and commonality. Kineman RD, et al. **J Endocrinol** 1996 Mar; 148(3):447–55

Cyclosporine effects on in vitro responsiveness of anterior pituitary hormone release to dopamine and thyrotropin–releasing hormone in young female rats. Moreno ML, et al. **J Neuroendocrinol** 1995 Oct; 7(10):765–74

Actions of norepinephrine on rat hypoglossal motoneurons. Parkis MA, et al. **J Neurophysiol** 1995 Nov;74(5):1911–9

Thyrotropin–releasing hormone (TRH) depolarizes a subset of inspiratory neurons in the newborn mouse brain stem in vitro. Rekling JC, et al. **J Neurophysiol** 1996 Feb; 75(2):811–9

Control of Ca2+ entry into rat lactotrophs by thyrotrophin–releasing hormone. Carew MA, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):349–60

Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH–secreting adenomatous cells (GH1) in culture. Giustina A, et al. **Life Sci** 1996;58(1):83–90

Thyrotropin–releasing hormone–induced subcellular redistribution and down–regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants. Svoboda P, et al. **Mol Pharmacol** 1996 Apr; 49(4):646–55

Semicircadian rhythm of dopamine release in the mediobasal hypothalamus in awake rats during pseudopregnancy: evidence that a thyrotropin–releasing hormone analogue stimulates dopamine release and thereby inhibits prolactin secretion. Timmerman W, et al. **Neuroendocrinology** 1995 Nov;62(5):434–43

Effect of thyrotropin–releasing hormone on Na(+)–K(+)–Adenosine triphosphatase activity following experimental spinal cord trauma. Baykal S, et al. **Neurol Med Chir (Tokyo)** 1996 May;36(5):296–9

Effect of thyrotropin–releasing hormone on microtubules in GH3 cells. Ravindra R, et al. **Neuroreport** 1995 Jul 10; 6(10):1405–8

Activation of the thyrotropin–releasing hormone (TRH) receptor by a direct precursor of TRH, TRH–Gly. Yamada M, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):109–12

Gastric emptying and gastric–intestinal transit in rats with varying ovarian hormone status. Bond EF, et al. **Nurs Res** 1996 Jul–Aug;45(4):218–24

Effects of TRH and atropine on induction and duration of anesthesia with propofol in rats. Larsson JE, et al. **Peptides** 1996;17(2):293–7

Capacitative Ca2+ entry contributes to the Ca2+ influx induced by thyrotropin–releasing hormone (TRH) in GH3 pituitary cells. Villalobos C, et al. **Pflugers Arch** 1995 Oct; 430(6):923–35

Dopaminergic neuronal systems modulate the central cardiovascular effects of TRH in rats. Jędrusiak J, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):43–52

Analeptic effect of TRH in rats selectively bred for differential CNS sensitivity to ethanol. French TA, et al. **Proc West Pharmacol Soc** 1995;38:5–7

Cholinergic modulation of growth hormone, prolactin and thyroid stimulating hormone responses to thyrotropin–releasing hormone in normal aging. Giusti M, et al. **Recenti Prog Med** 1995 Sep;86(9):341–4

Influence of thyrotropin–releasing hormone on experimental pancreatitis in rats. Alhan E, et al. **Res Exp Med (Berl)** 1995;195(4):243–8

Effects of thyrotropin releasing hormone on cardiac and extracardiac flows of appropriately grown and growth–retarded fetuses. Rizzo G, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):8–14

[Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine] Eulry F, et al. **Ann Med Interne (Paris)** 1996;147(1):15–9 (Eng. Abstr.) **(Fre)**

[The genetic characteristics of the analgesic action of substance P, bradykinin and thyroliberin in the rats of 2 inbred strains] Sudakov SK, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):13–5 (Eng. Abstr.) **(Rus)**

[The modulating effect of the thyrotropin–releasing hormone on genetically induced mechanisms of morphine sensitivity] Borisova EV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1174–81 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Thyrotropin releasing hormone. Occurrence and role outside the central nervous system. Iversen E. **Dan Med Bull** 1995 Jun;42(3):257–68 (216 ref.)

Cold–restraint– and TRH–induced ulcer models demonstrate different biochemical and morphological manifestations in gastric and hepatic tissues in rats. Role of calcitonin. Erin N, et al. **Dig Dis Sci** 1996 Jan;41(1):55–64

Thyrotropin–releasing hormone hyperactivity in the preoptic area of spontaneously hypertensive rats. Garcia SI, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1105–10

Studies on the role of TRH and corticosterone in the regulation of prolactin and thyrotrophin secretion during lactation. van Haasteren GA, et al. **J Endocrinol** 1996 Feb; 148(2):325–36

Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH. Wolff G, et al. **Nat Genet** 1996 Mar;12(3):274–9

Thyrotrophin–releasing hormone (TRH) and lung maturation. Liggins GC. **Reprod Fertil Dev** 1995; 7(3):443–50 (54 ref.)

THERAPEUTIC USE

Antenatal lung maturation—should we all be using thyrotropin–releasing hormone? Fisk NM, et al. **Eur J Pediatr** 1995;154(8 Suppl 3):S7–9

Treatment with thyrotropin–releasing hormone (TRH) in patients with traumatic spinal cord injuries. Pitts LH, et al. **J Neurotrauma** 1995 Jun;12(3):235–43

[The efficacy of protirelin in subjects with stabilized outcomes of stroke] Ciffo F, et al. **Clin Ter** 1996 Mar; 147(3):123–9 (Eng. Abstr.) **(Ita)**

PROTIRELIN RECEPTORS see RECEPTORS, THYROTROPIN–RELEASING HORMONE

PROTO–ONCOGENE PROTEIN FMS see RECEPTORS, MACROPHAGE COLONY–STIMULATING FACTOR

PROTO–ONCOGENE PROTEIN P21(RAS)

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)

ANALYSIS

Analysis of p53, K–ras–2, and C–raf–1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM, et al. **Am J Pathol** 1996 May;148(5):1531–41

Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well–differentiated epithelial carcinomas of the human ovary. Kuwashima Y, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2847–50

ANTAGONISTS & INHIBITORS

Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo [see comments] Indolfi C, et al. **Nat Med** 1995 Jun;1(6):541–5. Comment in: Nat Med 1995 Jun;1(6):513–5.

Peptides containing a consensus Ras binding sequence from Raf–1 and theGTPase activating protein NF1 inhibit Ras function. Clark GJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1577–81

BIOSYNTHESIS

Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras–p21 and p53 by sulindac during azoxymethane–induced colon carcinogenesis. Singh J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:205–9

Activated c–Ha–ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. Miller FR, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):1765–9

Overexpression of C–myc, Ras and C–erbB–2 oncoproteins in carcinoma of unknown primary origin. Pavlidis N, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2563–7

Expression of ras p21, p53 and c–erbB–2 in advanced breast cancer and response to first line hormonal therapy. Archer SG, et al. **Br J Cancer** 1995 Nov;72(5):1259–66

EJ–Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet–derived growth factor–BB via phosphatidylinositol 3–kinase. Heldman AW, et al. **Circ Res** 1996 Feb;78(2):312–21

Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E–cadherin expression and correlated with reduced Ha–ras oncogene products. Caulín C, et al. **Mol Carcinog** 1996 Feb;15(2):104–14

Induced mitotic death of HeLa cells by abnormal expression of c–H–ras. Miranda EI, et al. **Mutat Res** 1996 Feb 1; 349(2):173–82

[Expression of ras and erbB2 in benign and malignant lesions of the stomach] Zhao A, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):336–9 (Eng. Abstr.) **(Chi)**

[Quantitation of Ras p21 oncogene and DNA content of gastrointestinal smooth muscle tumors and prognostic significance] Cai J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):225–8 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Conformational transitions in p21ras and in its complexes with the effector protein Raf–RBD and the GTPase activating protein GAP. Geyer M, et al. **Biochemistry** 1996 Aug 13;35(32):10308–20

Differential structural requirements for interaction of Ras protein with its distinct downstream effectors. Akasaka K, et al. **J Biol Chem** 1996 Mar 8;271(10):5353–60

The differential effects of the Gly–60 to Ala mutation on the interaction of H–Ras p21 with different downstream targets. Hwang MC, et al. **J Biol Chem** 1996 Apr 5; 271(14):8196–202

p120 Ras GTPase–activating protein interacts with Ras–GTP through specific conserved residues. Miao W, et al. **J Biol Chem** 1996 Jun 28;271(26):15322–9

Comparison of the computed three–dimensional structures of oncogenic forms (bound to GDP) of the ras–gene–encoded p21 protein with the structure of the normal (non–transforming) wild–type protein. Monaco R, et al. **J Protein Chem** 1995 Aug;14(6):457–66

Structural effects of the binding of GTP to the wild–type and oncogenic forms of the ras–gene–encoded p21 proteins. Monaco R, et al. **J Protein Chem** 1995 Nov;14(8):721–9

Refolding and purification of Ras proteins. Campbell–Burk SL, et al. **Methods Enzymol** 1995;255:3–13

Ras–catalyzed hydrolysis of GTP: a new perspective from model studies. Maegley KA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8160–6 (93 ref.)

DRUG EFFECTS

Effect of retinoic acid on p21ras and regulators of its activity in neuroblastoma. Burchill SA, et al. **Eur J Cancer** 1995; 31A(4):476–81

GENETICS

Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Konishi N, et al. **Am J Pathol** 1995 Oct; 147(4):1112–22

Synchronous colon carcinomas: molecular–genetic evidence for multicentricity. Koness RJ, et al. **Ann Surg Oncol** 1996 Mar;3(2):136–43

Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c–Ki–ras promoter. Vigneswaran N, et al. **Biochemistry** 1996 Jan 30;35(4):1106–14

Cloning of a ras–related gene from Hydra which responds to head–specific signals. Bosch TC, et al. **Gene** 1995 Dec 29;167(1–2):191–5

Morphology of ras–transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras–GTP complex. Kwon HJ, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):221–8

Transforming p21ras mutants and c–Ets–2 activate the cyclin D1 promoter through distinguishable regions. Albanese C, et al. **J Biol Chem** 1995 Oct 6;270(40):23589–97

Massive programmed cell death in intestinal epithelial cells induced by three–dimensional growth conditions: suppression by mutant c–H–ras oncogene expression. Rak J, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1587–98

Detection of c–ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis. Tsuda T, et al. **J Gastroenterol** 1995 Nov; 30 Suppl 8:30–2

Estrogen induces c–Ha–ras expression via activation of tyrosine kinase in uterine endometrial fibroblasts and cancer cells. Fujimoto J, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):25–33

Inducible expression of Ras N17 dominant inhibitory protein. Cai H, et al. **Methods Enzymol** 1995;255:230–7

Vaccinia virus expression of p21 rasAsn–17. de Vries–Smits AM, et al. **Methods Enzymol** 1995;255:221–9

Frequency of Ki–ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester. Jackson PE, et al. **Mol Carcinog** 1996 May;16(1):12–9

Frequent mutations of Ki–ras but no mutations of Ha–ras and p53 in lung lesions induced by N–nitrosobis(2–hydroxypropyl)amine in rats. Kitaʳ.. H, et al. **Mol Carcinog** 1996 Apr;15(4):276–83

Simple and sensitive detection of mutations in the ras proto–oncogenes using PNA–mediated PCR clamping. Thiede C, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):983–4

Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Ieda S, et al. **Surg Today** 1996;26(4):230–5

[Prognostic value of K–ras gene mutation in colorectal cancer] Cerottini JP, et al. **Swiss Surg** 1995;(6):304–6 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules. Murakami S, et al. **Immunol Lett** 1996 Mar;49(3):149-53

Specific detection of the precursor of ras p21 with a mouse monoclonal anti-C-terminal peptide antibody, SARA-K1. Ishihara H, et al. **J Immunol Methods** 1995 Sep 25; 185(2):217-23

Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli [see comments] Fenton RG, et al. **J Natl Cancer Inst** 1995 Dec 20;87(24):1853-61. Comment in: J Natl Cancer Inst 1995 Dec 20;87(24):1820-2.

Stimulation of ras GTPase activity by an anti-ras monoclonal antibody. Agellon S, et al. **Mol Carcinog** 1996 Jul; 16(3):132-8

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118-34 (79 ref.)

ISOLATION & PURIFICATION

Refolding and purification of Ras proteins. Campbell-Burk SL, et al. **Methods Enzymol** 1995;255:3-13

[Ras-oncogene detection in feces of patients with colorectal tumors (letter)] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):510-1 **(Dut)**

METABOLISM

Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Ratnam S, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):313-22

Molecular analysis of Ras activation by tyrosine phosphorylated Vav. Gulbins E, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):876-85

Inhibitors of farnesyltransferase and Ras processing peptidase. Hall CC, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):728-32

Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Singh SV, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):660-5

The novel cyclic dinucleotide 3'-5' cyclic diguanylic acid binds to p21ras and enhances DNA synthesis but not cell replication in the Molt 4 cell line. Amikam D, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):921-7

Early response gene expression in Ras oncoprotein signalling. Travers H, et al. **Biochem Soc Trans** 1996 Feb;24(1):4S

Characterization of mammalian C-CDC25Mm exchange factor and kinetic properties of the exchange reaction intermediate p21.C-CDC25Mm. Jacquet E, et al. **Biochemistry** 1995 Sep 26;34(38):12347-54

Kinetics of inorganic phosphate release during the interaction of p21ras with the GTPase-activating proteins, p120-GAP and neurofibromin. Nixon AE, et al. **Biochemistry** 1995 Nov 28;34(47):15592-8

Analysis of the T-cell activation signaling pathway mediated by tyrosine kinases, protein kinase C, and Ras protein, which is modulated by intracellular cyclic AMP. Ohtsuka T, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):223-32

Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Barge RM, et al. **Blood** 1996 Mar 15;87(6):2148-53

Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening. Kusafuka T, et al. **Cancer** 1995 Aug 15;76(4):695-9

Cellular Ras partly mediates gap junction closure by the polyoma virus middle tumor antigen. Brownell HL, et al. **Cancer Lett** 1996 May 15;103(1):99-106

Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Li Y, et al. **Cancer Res** 1996 Jun 15;56(12):2872-6

Hepatocyte expression of tumor associated aldehyde dehydrogenase (ALDH-3) and p21 Ras following diethylnitrosamine (DEN) initiation and chronic exposure to di(2-ethylhexyl)phthalate (DHEP). Richmond RE, et al. **Carcinogenesis** 1996 Aug;17(8):1647-55

Activation of Ca2+ influx by transforming Ha-ras. Maly K, et al. **Cell Calcium** 1995 Aug;18(2):120-34

Rapid activation of mitogen-activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells. Rao YP, et al. **Cell Growth Differ** 1995 Oct;6(10):1235-44

Expression of a dominant-negative Ras mutant does not affect stimulation of glucose uptake and glycogen synthesis by insulin. Dorrestijn J, et al. **Diabetologia** 1996 May; 39(5):558-63

Multiple p21ras effector pathways regulate nuclear factor of activated T cells. Genot E, et al. **EMBO J** 1996 Aug 1;15(15):3923-33

Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. Rodriguez-Viciana P, et al. **EMBO J** 1996 May 15;15(10):2442-51

Entamoeba histolytica: isoprenylation of p21ras and p21rap in vitro. Shen PS, et al. **Exp Parasitol** 1996 Jan;82(1):65-8

rap1 p21 regulates the interaction of ras p21 with RGL, a new effector protein of ras p21. Ikeda M, et al. **FEBS Lett** 1995 Nov 13;375(1-2):37-40

Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Clark JW, et al. **Int J Cancer** 1996 Jan 17;65(2):186-91

Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Shack S, et al. **Int J Cancer** 1995 Sep 27;63(1):124-9

Differential structural requirements for interaction of Ras protein with its distinct downstream effectors. Akasaka K, et al. **J Biol Chem** 1996 Mar 8;271(10):5353-60

Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq-mediated p21ras activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase. Eguchi S, et al. **J Biol Chem** 1996 Jun 14;271(24):14169-75

Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator. Hinoi T, et al. **J Biol Chem** 1996 Aug 16;271(33):19710-6

Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras. Hu CD, et al. **J Biol Chem** 1995 Dec 22;270(51):30274-7

Syk-dependent phosphorylation of Shc. A potential link between FcepsilonRI and the Ras/mitogen-activated protein kinase signaling pathway through SOS and Grb2. Jabril-Cuenod B, et al. **J Biol Chem** 1996 Jul 5; 271(27):16268-72

Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation. Just I, et al. **J Biol Chem** 1996 Apr 26;271(17):10149-53

Role of the Raf/mitogen-activated protein kinase pathway in p21ras desensitization. Klarlund JK, et al. **J Biol Chem** 1996 Jul 12;271(28):16674-7

Divergent mechanisms for homologous desensitization of p21ras by insulin and growth factors. Klarlund JK, et al. **J Biol Chem** 1995 Oct 6;270(40):23421-8

Different effects of various phospholipids on Ki-Ras-, Ha-Ras-, and Rap1B-induced B-Raf activation. Kuroda S, et al. **J Biol Chem** 1996 Jun 21;271(25):14680-3

Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation. Langlois WJ, et al. **J Biol Chem** 1995 Oct 27; 270(43):25320-3

Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf. Okada T, et al. **J Biol Chem** 1996 Mar 1;271(9):4671-8

Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation. Popoff MR, et al. **J Biol Chem** 1996 Apr 26;271(17):10217-24

Angiotensin II controls p21ras activity via pp60c-src. Schieffer B, et al. **J Biol Chem** 1996 Apr 26; 271(17):10329-33

Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase. Tsakiridis T, et al. **J Biol Chem** 1996 Aug 16;271(33):19664-7

A conserved region of c-Ha-Ras is required for efficient GTPase stimulation by GTPase activating protein but not neurofibromin. Yoder-Hill J, et al. **J Biol Chem** 1995 Nov 17;270(46):27615-21

CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells. Galandrini R, et al. **J Exp Med** 1996 Jan 1;183(1):179-86

p21ras links Fc epsilon RI to NF-AT family member in mast cells. The AP3-like factor in this cell type is an NF-AT family member. Prieschl EE, et al. **J Immunol** 1995 Nov 15;155(10):4963-70

Activation of p21ras by nerve growth factor in neuroblastoma cells. Burchill SA, et al. **J Neurol Sci** 1995 Nov;133(1-2):3-10

Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein. Monaco R, et al. **J Protein Chem** 1995 Aug;14(6):457-66

The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B. Folgueira L, et al. **J Virol** 1996 Apr;70(4):2332-8

Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia. Gallagher A, et al. **Leukemia** 1995 Nov;9(11):1833-40

Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements. Lenzen C, et al. **Methods Enzymol** 1995;255:95-109

Mitogen-activated protein kinase activation by scrape loading of p21ras. Marshall CJ, et al. **Methods Enzymol** 1995;255:273-9

ras effector loop mutations that dissociate p120GAP and neurofibromin interactions. Stang S, et al. **Mol Carcinog** 1996 Jan;15(1):64-9

Functional interactions of phosphatidylinositol 3-kinase with GTPase-activating protein in 3T3-L1 adipocytes. DePaolo D, et al. **Mol Cell Biol** 1996 Apr;16(4):1450-7

Stepwise transformation of rat embryo fibroblasts: c-Jun, JunB, or JunD can cooperate with Ras for focus formation, but a c-Jun-containing heterodimer is required for immortalization. Vandel L, et al. **Mol Cell Biol** 1996 May; 16(5):1881-8

Redox regulation of cell signalling [letter] Lander HM, et al. **Nature** 1996 May 30;381(6581):380-1

Biochemical and biological consequences of changing the specificity of p21ras from guanosine to xanthosine nucleotides. Schmidt G, et al. **Oncogene** 1996 Jan 4; 12(1):87-96

Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Gishizky ML, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10889-93

Antibody-induced engagement of beta 2 integrins on adherent human neutrophils triggers activation of p21ras through tyrosine phosphorylation of the protooncogene product Vav. Zheng L, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8431-6

Blocked Ras activation in anergic CD4+ T cells [see comments] Fields PE, et al. **Science** 1996 Mar 1; 271(5253):1276-8. Comment in: Science 1996 Mar 1;271(5253):1234.

T cell inactivation linked to Ras block [news; comment] Williams N. **Science** 1996 Mar 1;271(5253):1234. Comment on: Science 1996 Mar 1;271(5253):1272-6. Comment on: Science 1996 Mar 1;271(5253):1276-8.

PHYSIOLOGY

Intestinal cell cycle regulations. Interactions of cyclin D1, Cdk4, and p21Cip1. Beauchamp RD, et al. **Ann Surg** 1996 May;223(5):620-7; discussion 627-8

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Rak J, et al. **Cancer Res** 1995 Oct 15; 55(20):4575-80

Integrin signaling to NF-kappa B in monocytic leukemia cells is blocked by activated oncogenes. Rosales C, et al. **Cancer Res** 1996 May 15;56(10):2302-5

Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells. Zhao J, et al. **Cancer Res** 1995 Dec 15;55(24):6181-8

Ras is involved in gap junction closure in proliferating fibroblasts or preadipocytes but not in differentiated adipocytes. Brownell HL, et al. **DNA Cell Biol** 1996 Jun; 15(6):443-51

The heterotrimeric G q protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. Sadoshima J, et al. **EMBO J** 1996 Feb 15;15(4):775-87

Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. Urano T, et al. **EMBO J** 1996 Feb 15;15(4):810-6

Ras target proteins in eukaryotic cells. Marshall MS. **FASEB J** 1995 Oct;9(13):1311-8 (78 ref.)

Mechanisms of unusually high antioxidant activity of RSV-SR-transformed cells and of its suppression by activated p21ras. Deichman GI, et al. **Int J Cancer** 1996 Jun 11;66(6):747-52

Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. Hunter JJ, et al. **J Biol Chem** 1995 Sep 29;270(39):23173-8

p21ras signaling is necessary but not sufficient to mediate neurotrophin induction of calcium channels in PC12 cells. Pollock JD, et al. **J Biol Chem** 1996 Apr 5;271(14):8008-14

Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3. Terada K, et al. **J Biol Chem** 1995 Nov 17;270(46):27880-6

Positive and negative selection invoke distinct signaling pathways. Alberola-Ila J, et al. **J Exp Med** 1996 Jul 1; 184(1):9-18

Mutant Ras proteins and peptides: bad news for tumors [editorial; comment] Stauss HJ. **J Natl Cancer Inst** 1995 Dec 20;87(24):1820-2 (18 ref.). Comment on: J Natl Cancer Inst 1995 Dec 20;87(24):1853-61.

Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. Ray RB, et al. **J Virol** 1996 Jul;70(7):4438-43

Activation of codependent transcription factors is required for transcriptional induction of the vgf gene by nerve growth factor and Ras. D'Arcangelo G, et al. **Mol Cell Biol** 1996 Sep;16(9):4621-31

Cellular transformation and malignancy induced by ras require c-jun. Johnson R, et al. **Mol Cell Biol** 1996 Aug; 16(8):4504-11

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Khosravi-Far R, et al. **Mol Cell Biol** 1995 Nov;15(11):6443-53

Evidence for different signalling pathways of PKC zeta and ras-p21 in Xenopus oocytes. Carnero A, et al. **Oncogene** 1995 Oct 19;11(8):1541-7

Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Chen CY, et al. **Oncogene** 1995 Oct 19;11(8):1487-98

Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Gutmann DH, et al. **Oncogene** 1996 May 16;12(10):2121-7

Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines. Lee JM, et al. **Oncogene** 1996 Jan 18;12(2):253-63

Regulation of the Ras signaling pathway by GTPase-activating protein in PC12 cells. Yao R, et al. **Oncogene** 1995 Oct 19;11(8):1607-14

A role for activated p21 ras in inhibition/regulation of platelet-derived growth factor (PDGF) type-beta receptor activation. Zubiaur M, et al. **Oncogene** 1996 Mar 21; 12(6):1213-22

Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Kauffmann RC, et al.

Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10919-23

PROTO-ONCOGENE PROTEIN P185(NEU) see PROTO-ONCOGENE PROTEINS C-ERBB-2

PROTO-ONCOGENE PROTEIN PP60(C-SRC)

The Src and Csk families of tyrosine protein kinases in hemopoietic cells. Chow LM, et al. **Semin Immunol** 1995 Aug;7(4):207-26 (222 ref.)

ANALYSIS

Monoclonal antibodies to oncoproteins. Chang JH, et al. **Methods Enzymol** 1995;254:430-45

ANTAGONISTS & INHIBITORS

SRC as a target for anti-cancer drugs. Levitzki A. **Anticancer Drug Des** 1996 Apr;11(3):175-82 (45 ref.)

A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization. Ramdas L, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):237-42

BIOSYNTHESIS

Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms. Bjorge JD, et al. **J Biol Chem** 1995 Oct 13; 270(41):24222-8

[A study of c-src gene express product pp60c-src in esophageal carcinoma] Wang X, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):197-201 (Eng. Abstr.) **(Chi)**

BLOOD

Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. Ichinohe T, et al. **J Biol Chem** 1995 Nov 24;270(47):28029-36

CHEMISTRY

Novel phosphorylation at a mitotic site, serine 75, in human pp60c-src from unsynchronized human tumor cells having a spherical morphology. Kato G, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):619-29

Catalytic activity of the SH2 domain of human pp60c-src; evidence from NMR, mass spectrometry, site-directed mutagenesis and kinetic studies for an inherent phosphatase activity. Boerner RJ, et al. **Biochemistry** 1995 Nov 21; 34(46):15351-8

Linear and cyclic synthetic peptides related to the main autophosphorylation site of the Src tyrosine kinases as substrates and inhibitors of Lyn. Ruzza P, et al. **Int J Pept Protein Res** 1995 Jun;45(6):529-39

DEFICIENCY

Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Lowell CA, et al. **Blood** 1996 Mar 1;87(5):1780-92

An examination of focal adhesion formation and tyrosine phosphorylation in fibroblasts isolated from src-, fyn-, and yes- mice. Bockholt SM, et al. **Cell Adhes Commun** 1995 May;3(2):91-100

GENETICS

Solid phase synthesis of pp60src-related phosphopeptides via 'global' phosphorylation and their use as substrates for enzymatic phosphorylation by casein kinase-2. Perich JW, et al. **Bioorg Med Chem** 1996 Feb;4(2):143-50

Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes. Levy P, et al. **Br J Cancer** 1996 Aug;74(3):423-31

Modulation of prostaglandin G/H synthase expression in mesangial cells transfected by pp60c-src proto-oncogene. Reiser CO, et al. **Exp Cell Res** 1996 Feb 1;222(2):304-11

Regulation of cell-cell contacts in developing Drosophila eyes by Dsrc41, a new, close relative of vertebrate c-src. Takahashi F, et al. **Genes Dev** 1996 Jul 1;10(13):1645-56

Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Lam KS, et al. **Int J Pept Protein Res** 1995 Jun; 45(6):587-92

Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms. Bjorge JD, et al. **J Biol Chem** 1995 Oct 13; 270(41):24222-8

Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Visser CJ, et al. **Lab Invest** 1996 Jan;74(1):2-11

Conserved intron elements repress splicing of a neuron-specific c-src exon in vitro. Chan RC, et al. **Mol Cell Biol** 1995 Nov;15(11):6377-85

Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Chackalaparampil I, et al. **Oncogene** 1996 Apr 4;12(7):1457-67

Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk. Koegl M, et al. **Oncogene** 1995 Dec 7;11(11):2317-29

Endogenous c-src as a determinant of the tumorigenicity of src oncogenes. Halpern MS, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):824-7

IMMUNOLOGY

A 56,000 Mr phosphoseryl protein in PC12 cell lysates strongly associates with protein-A sepharose beads and was observed in immune complex kinase assays for PP60c-src. Buensuceso C, et al. **Cell Signal** 1995 Nov;7(8):765-71

METABOLISM

A synthetic peptidic substrate of minimal size and semioptimal sequence for the protein tyrosine kinase pp60c-src. Ramdas L, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):73-8

Src kinase plays an essential role in integrin-mediated tyrosine phosphorylation of Crk-associated substrate p130Cas. Hamasaki K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):338-43

Novel phosphorylation at a mitotic site, serine 75, in human pp60c-src from unsynchronized human tumor cells having a spherical morphology. Kato G, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):619-29

c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Sato K, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1078-87

Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Barker SC, et al. **Biochemistry** 1995 Nov 14;34(45):14843-51

Examination of the dephosphorylation reactions catalyzed by pp60c-src tyrosine kinase explores the roles of autophosphorylation and SH2 ligand binding. Boerner RJ, et al. **Biochemistry** 1995 Nov 14;34(45):14852-60

Catalytic activity of the SH2 domain of human pp60c-src; evidence from NMR, mass spectrometry, site-directed mutagenesis and kinetic studies for an inherent phosphatase activity. Boerner RJ, et al. **Biochemistry** 1995 Nov 21; 34(46):15351-8

Kinetic mechanisms of the forward and reverse pp60c-src tyrosine kinase reactions. Boerner RJ, et al. **Biochemistry** 1995 Dec 19;34(50):16419-23

Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated. Boerner RJ, et al. **Biochemistry** 1996 Jul 23;35(29):9519-25

Purification of bovine thymus cytosolic C-terminal Src kinase (CSK) and demonstration of differential efficiencies of phosphorylation and inactivation of p56lyn and pp60c-src by CSK. Cheng HC, et al. **Biochemistry** 1996 Sep 10;35(36):11874-87

In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites. Lombardo CR, et al. **Biochemistry** 1995 Dec 19;34(50):16456-66

Identification of sites on epidermal growth factor receptors which are phosphorylated by pp60src in vitro. Wright JD, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):85-93

Identification of GIYWHHY as a novel peptide substrate for human p60c-src protein tyrosine kinase. Lou Q, et al. **Bioorg Med Chem** 1996 May;4(5):677-82

Angiotensin II activates pp60c-src in vascular smooth muscle cells. Ishida M, et al. **Circ Res** 1995 Dec;77(6):1053-9

Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Chellaiah M, et al. **Endocrinology** 1996 Jun; 137(6):2432-40

Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome. Hedborg F, et al. **Eur J Cancer** 1995; 31A(4):435-43

Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11. Fuhrer DK, et al. **Exp Hematol** 1996 Feb;24(2):195-203

The catalytic activity of Src-family tyrosine kinase is required for B cell antigen receptor signaling. Takata M, et al. **FEBS Lett** 1995 Nov 6;374(3):407-11

Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin. Alexandropoulos K, et al. **Genes Dev** 1996 Jun 1; 10(11):1341-55

Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. Broome MA, et al. **J Biol Chem** 1996 Jul 12;271(28):16798-806

Exploration of the sequence specificity of pp60c-src tyrosine kinase. Minimal peptide sequence required for maximal activity. Edison AM, et al. **J Biol Chem** 1995 Nov 10; 270(45):27112-5

The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor. Erpel T, et al. **J Biol Chem** 1996 Jul 12; 271(28):16807-12

Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains. He W, et al. **J Biol Chem** 1995 Oct 6;270(40):23258-62

Mechanical strain induces pp60src activation and translocation to cytoskeleton in fetal rat lung cells. Liu M, et al. **J Biol Chem** 1996 Mar 22;271(12):7066-71

Autophosphorylation of purified c-Src at its primary negative regulation site. Osusky M, et al. **J Biol Chem** 1995 Oct 27;270(43):25729-32

Angiotensin II controls p21ras activity via pp60c-src. Schieffer B, et al. **J Biol Chem** 1996 Apr 26; 271(17):10329-33

Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases. Simonson MS, et al. **J Biol Chem** 1996 Jan 5;271(1):77-82

Identification of efficient pentapeptide substrates for the tyrosine kinase pp60c-src. Nair SA, et al. **J Med Chem** 1995 Oct 13;38(21):4276-83

Reduction of oncoprotein transformation in vitro by albumin [letter] **Raju PV, et al. J Natl Cancer Inst** 1996 Apr 17; 88(8):556-7

Regulation of Btk by Src family tyrosine kinases. Afar DE, et al. **Mol Cell Biol** 1996 Jul;16(7):3465-71

Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Weng Z, et al. **Mol Cell Biol** 1995 Oct;15(10):5627-34

Prolactin receptor is associated with c-src kinase in rat liver. Berlanga JJ, et al. **Mol Endocrinol** 1995 Nov;9(11):1461-7

Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. Brümmer J, et al. **Oncogene** 1995 Oct 19;11(8):1649-55

Identification of D-peptide ligands through mirror-image phage display. Schumacher TN, et al. **Science** 1996 Mar 29;271(5257):1854-7

PHARMACOLOGY

Regulation of single Cl- channel conductance by insulin and tyrosine phosphatase. Shintani Y, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):142-7

PHYSIOLOGY

pp60c-src increases voltage-operated calcium channel currents in vascular smooth muscle cells. Wijetunge S, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1039-44

Src and the control of cell division. Taylor SJ, et al. **Bioessays** 1996 Jan;18(1):9-11 (40 ref.)

pp60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. Rodier JM, et al. **J Cell Biol** 1995 Nov;131(3):761-73

Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mahajan S, et al. **Mol Cell Biol** 1995 Oct;15(10):5304-11

PROTO-ONCOGENE PROTEINS

Variation in the expression of p53, c-myc, and bcl-2 oncoproteins in individual patient cultures of normal urothelium exposed to cobalt 60 gamma-rays and N-nitrosodiethanolamine. Harney JV, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):617-25

Relationship of EBV and bcl-2 in Hodgkin's disease [letter] Chetty R, et al. **Histopathology** 1995 Oct;27(4):392-3

[Mechanism of DNA recognition by a protooncogene product, Myb] Ogata K, et al. **Seikagaku** 1996 Feb; 68(2):111-28 (24 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. Farese AM, et al. **J Clin Invest** 1996 May 1;97(9):2145-51

ANALYSIS

Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. Hamazaki K, et al. **Acta Med Okayama** 1995 Aug;49(4):227-30

Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. Nguyen PL, et al. **Am J Clin Pathol** 1996 May;105(5):538-43

Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Alpers CE, et al. **Am J Pathol** 1996 Feb;148(2):439-51

Prognostic significance of Bcl-2 in clinically localized prostate cancer. Bubendorf L, et al. **Am J Pathol** 1996 May; 148(5):1557-65

Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Flenghi L, et al. **Am J Pathol** 1996 May; 148(5):1543-55

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Krajewska M, et al. **Am J Pathol** 1996 May;148(5):1567-76

Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Morris CB, et al. **Am J Pathol** 1996 Apr;148(4):1055-63

Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological

subtype and clinical outcome. Przygodzki RM, et al. **Am J Pathol** 1996 May;148(5):1531–41

Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Shibayama E, et al. **Am J Pathol** 1996 Jun;148(6):1807–18

Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Tuck AB, et al. **Am J Pathol** 1996 Jan;148(1):225–32

Massive apoptosis detected by in situ DNA nick end labeling in neuroblastoma. Ikeda H, et al. **Am J Surg Pathol** 1996 Jun;20(6):649–55

Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Binder C, et al. **Ann Oncol** 1996 Feb;7(2):129–33

Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Binder C, et al. **Ann Oncol** 1995 Dec; 6(10):1005–10

Bcl-2 expression in neuroblastoma is differentially regulated by differentiation inducers. Kim CJ, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1997–2000

Differential expression of cerbB3 in naevi and malignant melanomas. Korabiowska M, et al. **Anticancer Res** 1996 Jan–Feb;16(1):471–4

Topographical immunohistochemical expression of bcl-2 protein in human liver lesions. Skopelitou A, et al. **Anticancer Res** 1996 Mar–Apr;16(2):975–8

Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Wilson GD, et al. **Anticancer Res** 1996 Jul–Aug; 16(4C):2403–8

Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value. Wang T, et al. **APMIS** 1995 Sep; 103(9):655–62

Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Ofner D, et al. **Br J Cancer** 1995 Oct; 72(4):981–5

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Travis A, et al. **Br J Cancer** 1996 Jul;74(2):229–33

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. van Slooten HJ, et al. **Br J Cancer** 1996 Jul;74(1):78–85

Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Watson AJ, et al. **Br J Cancer** 1996 Apr;73(8):889–95

Expression of Bcl-2 and Bax in the frontoparietal cortex of the rat following cardiac arrest. Jaw SP, et al. **Brain Res Bull** 1995;38(6):577–80

bcl-2 expression in the spectrum of preinvasive breast lesions. Sziopikou KP, et al. **Cancer** 1996 Feb 1;77(3):499–506

A flow cytometric study of c-erbB-3 expression in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):280–6

Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Ravi D, et al. **Cancer Lett** 1996 Aug 2;105(2):139–46

Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Adam L, et al. **Cancer Res** 1995 Nov 15;55(22):5156–60

Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Han Z, et al. **Cancer Res** 1996 Apr 1;56(7):1621–8

Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Haugen DR, et al. **Cancer Res** 1996 Mar 15;56(6):1184–8

Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Katabuchi H, et al. **Cancer Res** 1995 Dec 1; 55(23):5556–60

Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Leach FS, et al. **Cancer Res** 1996 Jan 15;56(2):235–40

Expression of apoptosis-preventing Bcl-2 protein and -inducing Fas antigen in glomeruli of IgA nephropathy. Yoshimura A, et al. **Contrib Nephrol** 1996;118:48–53

Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Uyttendaele H, et al. **Development** 1996 Jul;122(7):2251–9

Immunohistochemical detection of high-affinity nerve growth factor receptor in neuroblastoma. Dominici C, et al. **Eur J Cancer** 1995;31A(4):444–6

Expression of the proto-oncogene bcl-2 in uterine cervical squamous cell carcinoma: its relationship to clinical outcome. Uehara T, et al. **Eur J Gynaecol Oncol** 1995; 16(6):453–60

Localization of the Bcl-2 protein to the outer mitochondrial membrane by electron microscopy. Riparbelli MG, et al. **Exp Cell Res** 1995 Dec;221(2):363–9

Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. Jennings T, et al. **Exp Mol Pathol** 1995 Jun;62(3):199–206

Analysis of SRF, SAP-1 and ELK-1 transcripts and proteins in human cell lines. Magnaghi-Jaulin L, et al. **FEBS Lett** 1996 Aug 12;391(3):247–51

Immunohistochemical detection of bcl-2 protein in thymoma. Brocheriou I, et al. **Histopathology** 1995 Sep;27(3):251–5

p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Pacinda SJ, et al. **Hum Pathol** 1996 Jun;27(6):542–6

Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Ritter JH, et al. **Hum Pathol** 1995 Nov; 26(11):1227–32

Immunolocalization of bcl-2 protein in human endometrium in the menstrual cycle and simulated early pregnancy. Koh EA, et al. **Hum Reprod** 1995 Jun;10(6):1557–62

Immunolocalization of bcl-2 in the human corpus luteum. Rodger FE, et al. **Hum Reprod** 1995 Jun;10(6):1566–70

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. Kramer MH, et al. **J Clin Oncol** 1996 Jul;14(7):2131–8

p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. Kurvinen K, et al. **J Clin Oncol** 1996 Jul;14(7):2120–30

Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias [letter; comment] Cerroni L, et al. **J Cutan Pathol** 1995 Oct;22(5):476–8. Comment on: J Cutan Pathol 1995 Feb;22(1):2–10.

Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. Schiffer D, et al. **J Neurooncol** 1996 Feb;27(2):101–9

Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. Li GL, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):280–9

An immunohistochemical study of TAL-1 protein expression in leukaemias and lymphomas with a novel monoclonal antibody, 2TL 242. Chetty R, et al. **J Pathol** 1996 Mar; 178(3):311–5

Differential expression of the protooncogene bcl-2 in normal and osteoarthritic human articular cartilage. Erlacher L, et al. **J Rheumatol** 1995 May;22(5):926–31

Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions. Bolon I, et al. **Lab Invest** 1996 Jul;75(1):1–13

Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Stacchini A, et al. **Leukemia** 1996 Oct; 10(10):1584–91

Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines. Tani A, et al. **Leukemia** 1996 Oct;10(10):1592–603

Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Alessi DR, et al. **Methods Enzymol** 1995;255:279–90

Expression of the protooncogene bcl-2 in Alzheimer's disease brain. O'Barr S, et al. **Neurobiol Aging** 1996 Jan–Feb; 17(1):131–6

Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases. Huff JL, et al. **Oncogene** 1996 Jan 18;12(2):299–307

Cell death in colorectal polyps as evaluated by in situ 3'-tailing reaction and its relationship to BCL-2 expression. Nakamura T, et al. **Pathol Int** 1995 Oct;45(10):721–8

Ret-oncogene expression correlates with neuronal differentiation of neuroblastic tumors. Ikuno N, et al. **Pathol Res Pract** 1995 Mar;191(2):92–9

Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Luna-Moré S, et al. **Pathol Res Pract** 1996 Jan;192(1):27–32

The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers. Rodriguez-Villanueva J, et al. **Pathol Res Pract** 1995 Jun; 191(5):391–8

Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Cohen RJ, et al. **Pathology** 1995 Jul; 27(3):229–32

Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Kindblom LG, et al. **Virchows Arch** 1995;427(1):19–26

Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Koizumi H, et al. **Virchows Arch** 1995;427(2):167–73

Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Segers K, et al. **Virchows Arch** 1995;427(4):431–6

[Bcl-2 proto-oncogene expression in neoplastic and non neoplastic thyroid tissue] Branet F, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):213–7 (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Reardon DB, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):401–4

Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. Jacobsen SE, et al. **Blood** 1996 Jun 15;87(12):5016–26

Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? [editorial] de Fabritiis P, et al. **Haematologica** 1995 Jul–Aug; 80(4):295–9

TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Arsura M, et al. **Immunity** 1996 Jul;5(1):31–40

Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. Torres MA, et al. **J Cell Biol** 1996 Jun;133(5):1123–37

Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo [see comments] Indolfi C, et al. **Nat Med** 1995 Jun;1(6):541–5. Comment in: Nat Med 1995 Jun;1(6):513–5.

Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Shimizu S, et al. **Oncogene** 1996 May 16; 12(10):2045–50

BIOSYNTHESIS

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Diebold J, et al. **Am J Clin Pathol** 1996 Mar; 105(3):341–9

In vitro culture with prednisolone increases BCL-2 protein expression in adult acute lymphoblastic leukemia cells. Tosi P, et al. **Am J Hematol** 1996 Apr;51(4):261–4

Kaposi's sarcoma tumor cells preferentially express Bcl-xL. Foreman KE, et al. **Am J Pathol** 1996 Sep;149(3):795–803

Expression of Trk receptors during cartilage differentiation. Mitsiadis TA, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:298–300

Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Shintani S, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2623–6

Down-regulation of bcl-xs gene expression in rat thymocytes by dexamethasone. Sakamoto T, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):511–6

Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression. Bardot O, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1001–6

Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Borlak JT, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):517–29

BCL-6 expression during B-cell activation. Allman D, et al. **Blood** 1996 Jun 15;87(12):5257–68

Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Benito A, et al. **Blood** 1996 May 1;87(9):3837–43

Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Carow CE, et al. **Blood** 1996 Feb 1;87(3):1089–96

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Chen GQ, et al. **Blood** 1996 Aug 1;88(3):1052–61

bcl-2, Epstein-Barr virus-latent membrane protein, EBNA-1, and EBNA-2 staining in posttransplantation lymphoproliferative disorders [letter; comment] Chetty R, et al. **Blood** 1996 Jun 15;87(12):5395. Comment on: Blood 1996 Jan 15;87(2):706–11.

Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Cocault L, et al. **Blood** 1996 Sep 1;88(5):1656–65

Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Coustan-Smith E, et al. **Blood** 1996 Feb 1;87(3):1140–6

Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Falini B, et al. **Blood** 1996 Jan 15;87(2):465–71

Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. Golay J, et al. **Blood** 1996 Mar 1;87(5):1900–11

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Hermine O, et al. **Blood** 1996 Jan 1;87(1):265–72

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Hill ME, et al. **Blood** 1996 Aug 1; 88(3):1046–51

BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders [see comments] Murray PG, et al. **Blood** 1996 Jan 15;87(2):706–11. Comment in: Blood 1996 Jun 15;87(12):5395.

Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Rigal-Huguet F, et al. **Blood** 1996 Mar 15;87(6):2470–5

Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Tu Y, et al. **Blood** 1996 Sep 1; 88(5):1805–12

The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines

and primary peripheral blood mononuclear cells. Zauli G, et al. **Blood** 1995 Nov 15;86(10):3823–34

Expression and prognostic significance of Bcl–2 in ovarian tumours. Henriksen R, et al. **Br J Cancer** 1995 Nov; 72(5):1324–9

bcl–2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Pollina L, et al. **Br J Cancer** 1996 Jan; 73(2):139–43

RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase–n–polymerase chain reaction approach on archival–nested material. Williams GH, et al. **Br J Cancer** 1996 Aug;74(4):585–9

Immunochemical and immunohistochemical localization of Bcl–x protein in the rat central nervous system. Mizuguchi M, et al. **Brain Res** 1996 Mar 18;712(2):281–6

Combination of a potent 20–epi–vitamin D3 analogue (KH 1060) with 9–cis–retinoic acid irreversibly inhibits clonal growth, decreases bcl–2 expression, and induces apoptosis in HL–60 leukemic cells. Elstner E, et al. **Cancer Res** 1996 Aug 1;56(15):3570–6

erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Ethier SP, et al. **Cancer Res** 1996 Feb 15;56(4):899–907

Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Gallahan D, et al. **Cancer Res** 1996 Apr 15;56(8):1775–85

The prognostic significance of Bcl–2 and p53 expression in ovarian carcinoma. Herod JJ, et al. **Cancer Res** 1996 May 1;56(9):2178–84

Elevated expression of Bcl–X and reduced Bak in primary colorectal adenocarcinomas. Krajewska M, et al. **Cancer Res** 1996 May 15;56(10):2422–7

Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl–2 and Bcl–XL. Shimizu S, et al. **Cancer Res** 1996 May 1;56(9):2161–6

Positive selection by thymic nurse cells requires IL–1 beta and is associated with an increased Bcl–2 expression. Pezzano M, et al. **Cell Immunol** 1996 May 1;169(2):174–84

Monoclonal antibody binding to a receptor on nonspecific cytotoxic cells (NCC) increases the expression of proto–oncogene kinases and protein kinase C. Jaso–Friedmann L, et al. **Cell Signal** 1995 Jul;7(5):463–70

Expression of raf serine/threonine protein kinases in the cell bodies of primary sensory neurons of the adult rat. Mihaly A, et al. **Cell Tissue Res** 1996 Aug;285(2):261–71

Microvessel density, expression of proto–oncogenes, resistance–related proteins and incidence of metastases in primary ovarian carcinomas. Volm M, et al. **Clin Exp Metastasis** 1996 May;14(3):209–14

bcl–2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report. Troncone G, et al. **Cytopathology** 1995 Aug;6(4):219–25

Synapse–associated expression of an acetylcholine receptor–inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Moscoso LM, et al. **Dev Biol** 1995 Nov; 172(1):158–69

Low bcl–2 expression and increased spontaneous apoptosis in T–lymphocytes from newly–diagnosed IDDM patients. Giordano C, et al. **Diabetologia** 1995 Aug;38(8):953–8

Cytokine–induced apoptotic cell death in a mouse pancreatic beta–cell line: inhibition by Bcl–2. Iwahashi H, et al. **Diabetologia** 1996 May;39(5):530–6

Effect of decidualization on the expression of bax and bcl–2 in the rat uterine endometrium. Akcali KC, et al. **Endocrinology** 1996 Jul;137(7):3123–31

Expression of blc–x during mouse B cell differentiation and following activation by various stimuli. Choi MS, et al. **Eur J Immunol** 1996 Mar;26(3):676–82

Bcl–2 expression in malignant melanoma and its prognostic significance. Grover R, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):347–9

Merkel cells and Merkel cell carcinoma express the BCL–2 proto–oncogene. Plettenberg A, et al. **Exp Dermatol** 1996 Apr;5(2):102–7

Suppression of bcl–2 gene expression by sphingosine in the apoptosis of human leukemic HL–60 cells during phorbol ester–induced terminal differentiation. Sakakura C, et al. **FEBS Lett** 1996 Jan 29;379(2):177–80

Overexpression of p53 and MDM2 proteins in cervical neoplasia. Lukáš Z, et al. **Folia Biol (Praha)** 1995; 41(3–4):197–9

Expression of bcl–2 inhibits cellular radical generation. Wiedau–Pazos M, et al. **Free Radic Res** 1996 Mar; 24(3):205–12

The zebrafish Fgf–3 gene: cDNA sequence, transcript structure and genomic organization. Kiefer P, et al. **Gene** 1996 Feb 12;168(2):211–5

The organization and expression of the mdm2 gene. de Oca Luna RM, et al. **Genomics** 1996 May 1;33(3):352–7

The MAS proto–oncogene is not imprinted in humans. Riesewijk AM, et al. **Genomics** 1996 Jul 15;35(2):380–2

Differential expression of the bcl–2 oncogene in human basal cell carcinoma. Crowson AN, et al. **Hum Pathol** 1996 Apr; 27(4):355–9

Epstein–Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl–2 expression and p53 accumulation. Gulley ML, et al. **Hum Pathol** 1996 Jan; 27(1):20–7

Inverse correlation between the expression of bcl–2 and p53 proteins in primary gastric lymphoma. Nakamura S, et al. **Hum Pathol** 1996 Mar;27(3):225–33

Tumor necrosis factor–alpha up–regulates Bcl–2 expression and decreases calcium–dependent apoptosis in human B cell lines. Genestier L, et al. **Int Immunol** 1995 Apr; 7(4):533–40

Frequent expression of Bcl–2 in renal–cell carcinomas carrying wild–type p53. Tomita Y, et al. **Int J Cancer** 1996 May 3;66(3):322–5

Thyroid hormone promotes BCL–2 expression and prevents apoptosis of early differentiating cerebellar granule neurons. Muller Y, et al. **Int J Dev Neurosci** 1995 Dec; 13(8):871–85

bcl–2 expression on prostate cancer and its relationship to cell cycle and prognosis. Matsushima H, et al. **Int J Urol** 1996 Mar;3(2):113–7

The Fas–Fas ligand system and other modulators of apoptosis in the cornea. Wilson SE, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1582–92

Granulocyte–macrophage colony–stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. Brizzi MF, et al. **J Biol Chem** 1996 Feb 16; 271(7):3562–7

Lyn and Fgr protein–tyrosine kinases prevent apoptosis during retinoic acid–induced granulocytic differentiation of HL–60 cells. Katagiri K, et al. **J Biol Chem** 1996 May 10;271(19):11557–62

Events in apoptosis. Acidification is downstream of protease activation and BCL–2 protection. Meisenholder GW, et al. **J Biol Chem** 1996 Jul 5;271(27):16260–2

Overexpression of the Bcl–2 protein increases the half–life of p21Bax. Miyashita T, et al. **J Biol Chem** 1995 Nov 3; 270(44):26049–52

A novel promoter for vascular endothelial growth factor receptor (flt–1) that confers endothelial–specific gene expression. Morishita K, et al. **J Biol Chem** 1995 Nov 17; 270(46):27948–53

c–sis/PDGF–B promoter transactivation by the Yax protein of human T–cell leukemia virus type 1. Trejo SR, et al. **J Biol Chem** 1996 Jun 14;271(24):14584–90

Interleukin–11 induces complex formation of Grb2, Fyn, and JAK2 in 3T3L1 cells. Wang XY, et al. **J Biol Chem** 1995 Nov 24;270(47):27999–8002

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. Zhang K, et al. **J Biol Chem** 1996 Feb 16;271(7):3884–90

Expression of apoptosis–related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. Efferth T, et al. **J Cancer Res Clin Oncol** 1995;121(11):648–56

Bcl–2 expression and allelic loss of the p53 gene in gastric carcinomas. Saegusa M, et al. **J Cancer Res Clin Oncol** 1996;122(7):427–32

Overexpression of the death–promoting gene bax–alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice [see comments] Bargou RC, et al. **J Clin Invest** 1996 Jun 1;97(11):2651–9. Comment in: J Clin Invest 1996 Jun 1;97(11):2403–4.

BCL–2 expression or antioxidants prevent hyperglycemia–induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. Giardino I, et al. **J Clin Invest** 1996 Mar 15;97(6):1422–8

Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c–myb expression. Lee KS, et al. **J Clin Invest** 1995 Nov; 96(5):2461–8

Balancing cell life and death: bax, apoptosis, and breast cancer [editorial; comment] Reed JC. **J Clin Invest** 1996 Jun 1;97(11):2403–4. Comment on: J Clin Invest 1996 Jun 1;97(11):2651–9.

bcl–x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. Grillot DA, et al. **J Exp Med** 1996 Feb 1;183(2):381–91

Constitutive expression of bcl–2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H–2b alloantigens. López–Hoyos M, et al. **J Exp Med** 1996 Jun 1;183(6):2523–31

Human germinal center B cells express the apoptosis–inducing genes Fas, c–myc, P53, and Bax but not the survival gene bcl–2. Martinez–Valdez H, et al. **J Exp Med** 1996 Mar 1;183(3):971–7

Regulation of cell division cycle progression by bcl–2 expression: a potential mechanism for inhibition of programmed cell death. Mazel S, et al. **J Exp Med** 1996 May 1;183(5):2219–26

A bcl–2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti–Fas antibody injection. Rodriguez I, et al. **J Exp Med** 1996 Mar 1;183(3):1031–6

Apoptosis associated with ex vivo down–regulation of Bcl–2 and up–regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. Boudet F, et al. **J Immunol** 1996 Mar 15;156(6):2282–93

CD40 signaling–mediated induction of Bcl–XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth. Ishida T, et al. **J Immunol** 1995 Dec 15; 155(12):5527–35

Bcl–2 blocks glucocorticoid– but not Fas– or activation–induced apoptosis in a T cell hybridoma. Memon SA, et al. **J Immunol** 1995 Nov 15;155(10):4644–52

Comparison of p56lck and p59fyn protein expression in thymocyte subsets, peripheral T cells, NK cells, and lymphoid cell lines. Olszowy MW, et al. **J Immunol** 1995 Nov 1;155(9):4236–40

pim–1 proto–oncogene expression in anti–CD3–mediated T cell activation is associated with protein kinase C activation and is independent of Raf–1. Wingett D, et al. **J Immunol** 1996 Jan 15;156(2):549–57

Prognostic value of Bcl–2 and p53 expression in urinary tract transitional cell cancer [letter] Bilim V, et al. **J Natl Cancer Inst** 1996 May 15;88(10):686–8

Apoptosis in ALS is not restricted to motoneurons: Bcl–2 expression is increased in post–central cortex, adjacent to the affected motor cortex. Troost D, et al. **J Neurol Sci** 1995 May;129 Suppl:79–80

Incidence of apoptosis, cell proliferation and bcl–2 expression in transitional cell carcinoma of the bladder: association with tumor progression [see comments] King ED, et al. **J Urol** 1996 Jan;155(1):316–20. Comment in: J Urol 1996 Jan;155(1):2.

Effects of anti–E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl–2. Després P, et al. **J Virol** 1995 Nov;69(11):7006–14

A novel non–mouse mammary tumor virus activation of the Int–3 gene in a spontaneous mouse mammary tumor. Kordon EC, et al. **J Virol** 1995 Dec;69(12):8066–9

Heterogeneity of B lineage acute lymphoblastic leukemias (B–ALL) with regard to their in vitro spontaneous proliferation, growth factor response and BCL–2 expression. Pontvert–Delucq S, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):267–80

A multivariate study of non Hodgkin's lymphoma involving proliferation, apoptosis, bcl–2 and the microenvironment. Shetty V, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):273–9

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588–99 (118 ref.)

The B cell transcriptional coactivator BOB1/OBF1 gene fuses to the LAZ3/BCL6 gene by t(3;11)(q27;q23.1) chromosomal translocation in a B cell leukemia line (Karpas 231). Galiéque Zouitina S, et al. **Leukemia** 1996 Apr;10(4):579–87

Association of bcl–2, bax, bcl–xL and interleukin–1 beta–converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Stoetzer OJ, et al. **Leukemia** 1996 Jul;10 Suppl 3:S18–S22

Wnt expression patterns in chick embryo nervous system. Hollyday M, et al. **Mech Dev** 1995 Jul;52(1):9–25

Pax–2 expression in the murine neural plate precedes and encompasses the expression domains of Wnt–1 and En–1. Rowitch DH, et al. **Mech Dev** 1995 Jul;52(1):3–8

Microinjection of antibodies. Kovary K. **Methods Enzymol** 1995;254:445–58

Epitope tagging. Shiio Y, et al. **Methods Enzymol** 1995; 254:497–502

Regulatable chimeric oncogenes. Walker AK, et al. **Methods Enzymol** 1995;254:469–80

Identification of an inducible regulator of c–myb expression during T–cell activation. Phan SC, et al. **Mol Cell Biol** 1996 May;16(5):2387–93

Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration. Venero JL, et al. **Mol Pharmacol** 1996 Feb;49(2):303–10

Bcl–2 protects from lethal hepatic apoptosis induced by an anti–Fas antibody in mice. Lacronique V, et al. **Nat Med** 1996 Jan;2(1):80–6

Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl–2 expression is increased in unaffected post–central gyrus. Troost D, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):498–504

Induction of p21ras in Alzheimer pathology. Gärtner U, et al. **Neuroreport** 1995 Jul 10;6(10):1441–4

Neurotrophin receptor expression during development of the chick spinal sensory ganglion. Williams R, et al. **Neuroreport** 1995 Nov 27;6(17):2277–82

trkA, CGRP and IB4 expression in retrogradely labelled cutaneous and visceral primary sensory neurones in the rat. Bennett DL, et al. **Neurosci Lett** 1996 Mar 8;206(1):33–6

Overexpression of Bcl–2 in a murine dopaminergic neuronal cell line leads to neurite outgrowth. Oh YJ, et al. **Neurosci Lett** 1996 Jan 5;202(3):161–4

Highly–expressed p100/p52 (NFKB2) sequesters other NF–kappa B–related proteins in the cytoplasm of human breast cancer cells. Dejardin E, et al. **Oncogene** 1995 Nov 2;11(9):1835–41

Differential regulation of p53, c–Myc, Bcl–2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Jiang MC, et al. **Oncogene** 1996 Aug 1;13(3):609–16

Raf–1 kinase and ERK2 uncoupled from mitogenic signals in rat fibroblasts. Kortenjann M, et al. **Oncogene** 1995 Nov 16;11(10):2105–12

Overexpression of the AML1 proto–oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA–binding and transactivational potencies. Kurokawa M, et al. **Oncogene** 1996 Feb 15;12(4):883–92

Novel members of the eph receptor tyrosine kinase subfamily expressed during Xenopus development. Scales JB, et al. **Oncogene** 1995 Nov 2;11(9):1745–52

Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu–bcl–2 transgenic mice. Shinto

Y, et al. **Oncogene** 1995 Nov 2;11(9):1729-36
Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor. Smit L, et al. **Oncogene** 1996 Jul 18;13(2):381-9
Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Suzuki A, et al. **Oncogene** 1996 Jul 4;13(1):31-7
The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression. Zheng S, et al. **Oncogene** 1996 Feb 1;12(3):555-62
p53 and MDM2 expression in oral squamous cell carcinoma. Matsumura T, et al. **Oncology** 1996 Jul-Aug;53(4):308-12
Lack of c-mpl proto-oncogene transcripts and growth-stimulatory effects of thrombopoietin on human small cell lung cancer cell lines. Shinohara A, et al. **Oncology** 1996 Sep-Oct;53(5):426-34
Isolation of two novel myb-like genes from Arabidopsis and studies on the DNA-binding properties of their products. Li SF, et al. **Plant J** 1995 Dec;8(6):963-72
Axotomized neonatal motoneurons overexpressing the bcl2 proto-oncogene retain functional electrophysiological properties. Alberi S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3978-83
bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7042-7
Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. Kawahara A, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8724-8
Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Oldham SM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6924-8
Bcl-2 interrupts the ceramide-mediated pathway of cell death. Zhang J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5325-8
Correlation between proto-oncogene, fibroblast growth factor and adaptive response in brain infarct. Liu HM. **Prog Brain Res** 1995;105:239-44 (44 ref.)
Gene targeting in mouse embryonic stem cells with an adenoviral vector. Mitani K, et al. **Somat Cell Mol Genet** 1995 Jul;21(4):221-31
Expression of BCL-2 gene product in embryonal tumors of the central nervous system. Oka H, et al. **Surg Neurol** 1996 Mar;45(3):230-5
Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Moul JW, et al. **Surgery** 1996 Aug;120(2):159-66; discussion 166-7
[Modulation of bcl-2 antisense RNA on programmed cell death of leukemic cell line] Chen X, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):112-5 (Eng. Abstr.) **(Chi)**

BLOOD

Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Ichikawa Y, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):307-13
Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Ohta K, et al. **Int Immunol** 1995 Nov;7(11):1817-25
Thrombin receptor activation and integrin engagement stimulate tyrosine phosphorylation of the proto-oncogene product, p95vav, in platelets. Cichowski K, et al. **J Biol Chem** 1996 Mar 29;271(13):7544-50
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia. Kohno T, et al. **Leuk Res** 1996 Mar;20(3):221-7

CHEMISTRY

Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Kendall RL, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):324-8
Detection of ret homodimers in MEN 2A-associated pheochromocytomas. Wada M, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):606-9
Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Geyer M, et al. **Biochemistry** 1996 Aug 13;35(32):10308-20
Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation. Kamikura DM, et al. **Biochemistry** 1996 Jan 23;35(3):1010-7
The solution structure of the human ETS1-DNA complex reveals a novel mode of binding and true side chain intercalation. Werner MH, et al. **Cell** 1995 Dec 1; 83(5):761-71
Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. Donaldson LW, et al. **EMBO J** 1996 Jan 2;15(1):125-34
Solution studies of the SH2 domain from the fyn tyrosine kinase: secondary structure, backbone dynamics and protein association. Pintar A, et al. **Eur Biophys J** 1996; 24(6):371-80
Conformational changes upon binding of a receptor loop to lipid structures: possible role in signal transduction. Pertinhez TA, et al. **FEBS Lett** 1995 Nov 20;375(3):239-42
Isolation and characterization of a monoclonal antibody binding to the extracellular domain of the flk-2 tyrosine kinase receptor. Rose C, et al. **Hybridoma** 1995 Oct; 14(5):453-9
Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Ohta K, et al. **Int Immunol** 1995 Nov;7(11):1817-25
Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. Durick K, et al. **J Biol Chem** 1995 Oct 20;270(42):24642-5
Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. Ghosh S, et al. **J Biol Chem** 1996 Apr 5;271(14):8472-80
Extensive sequencing of tryptic peptides of a rabbit reticulocyte 66-kDa protein that promotes recycling of Hsp 70. Homology To stress-related proteins. Gross M, et al. **J Biol Chem** 1996 Jul 12;271(28):16842-9
Nerve growth factor binding site on TrkA mapped to a single 24-amino acid leucine-rich motif. Windisch JM, et al. **J Biol Chem** 1995 Nov 24;270(47):28133-8
Product of the oncogene-activating gene Tpr is a phosphorylated protein of the nuclear pore complex. Bangs PL, et al. **J Cell Biochem** 1996 Apr;61(1):48-60
An African swine fever virus Bcl-2 homolog, 5-HL, suppresses apoptotic cell death. Afonso CL, et al. **J Virol** 1996 Jul;70(7):4858-63
bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Goldblum JR, et al. **Mod Pathol** 1995 Oct;8(8):866-9
Determinants of DNA-binding specificity of ETS-domain transcription factors. Shore P, et al. **Mol Cell Biol** 1996 Jul;16(7):3338-49
Role of the N terminus in DNA recognition by the v-erb A protein, an oncogenic derivative of a thyroid hormone receptor. Wong CW, et al. **Mol Endocrinol** 1995 May; 9(5):551-62
Inhibition of NF-kappaB activation by a dominant-negative mutant of IkappaBalpha. Chen CG, et al. **Mol Immunol** 1996 Jan;33(1):57-61
Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Block C, et al. **Nat Struct Biol** 1996 Mar;3(3):244-51
The cavity in the hydrophobic core of Myb DNA-binding domain is reserved for DNA recognition and trans-activation. Ogata K, et al. **Nat Struct Biol** 1996 Feb; 3(2):178-87
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Muchmore SW, et al. **Nature** 1996 May 23;381(6580):335-41
Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Boyd JM, et al. **Oncogene** 1995 Nov 2;11(9):1921-8
Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. Clark GJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1577-81
Selective repression of transcriptional activators by Pbx1 does not require the homeodomain. Lu Q, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):470-4
The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Mott HR, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8312-7
Structural coupling of the inhibitory regions flanking the ETS domain of murine Ets-1. Skalicky JJ, et al. **Protein Sci** 1996 Feb;5(2):296-309
Sequence of the canine c-yes proto-oncogene. Zhao DM, et al. **Res Vet Sci** 1995 Nov;59(3):230-3
Sperm-egg binding protein or proto-oncogene? [letter; comment] Bork P. **Science** 1996 Mar 8;271(5254):1431-2; discussion 1434-5. Comment on: Science 1995 Jul 7;269(5220):83-6.
Sperm-egg binding protein or proto-oncogene? [letter; comment] Tsai JY, et al. **Science** 1996 Mar 8; 271(5254):1432-4; discussion 1434-5. Comment on: Science 1995 Jul 7;269(5220):83-6.
How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641-3 (17 ref.)

DEFICIENCY

Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice. Nagata M, et al. **Am J Pathol** 1996 May;148(5):1601-11
Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Sorenson CM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F184-93
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Alexander WS, et al. **Blood** 1996 Mar 15;87(6):2162-70
Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Carver-Moore K, et al. **Blood** 1996 Aug 1;88(3):803-8
Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Lowell CA, et al. **Blood** 1996 Mar 1;87(5):1780-92
MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Reitmair AH, et al. **Cancer Res** 1996 Jul 1;56(13):2922-6
Accelerated disappearance of melanocytes in bcl-2-deficient mice. Yamamura K, et al. **Cancer Res** 1996 Aug 1; 56(15):3546-50
An examination of focal adhesion formation and tyrosine phosphorylation in fibroblasts isolated from src-, fyn-, and yes- mice. Bockholt SM, et al. **Cell Adhes Commun** 1995 May;3(2):91-100
T-B cell interaction inhibits spontaneous apoptosis of mature lymphocytes in Bcl-2-deficient mice. Nakayama K, et al. **J Exp Med** 1995 Oct 1;182(4):1101-9
Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Gerondakis S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3405-9
Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Knudson CM, et al. **Science** 1995 Oct 6; 270(5233):96-9

DRUG EFFECTS

BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells. Neumann M, et al. **Anticancer Res** 1996 May-Jun;16(3A):1075-83
Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Chen J, et al. **Blood** 1995 Dec 1; 86(11):4054-62
Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Kawamoto K, et al. **Blood** 1995 Dec 15;86(12):4638-44
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Ku H, et al. **Blood** 1996 Jun 1; 87(11):4544-51
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439-46 (36 ref.)
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253-5
The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. Piacibello W, et al. **Exp Hematol** 1996 Feb;24(2):340-6
Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines. Lucarelli E, et al. **J Biol Chem** 1995 Oct 20; 270(42):24725-31
Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway. Pica F, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1793-800
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase [see comments] Monia BP, et al. **Nat Med** 1996 Jun;2(6):668-75 . Comment in: Nat Med 1996 Jun;2(6):634-5.

GENETICS

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Picksley SM, et al. **Acta Oncol** 1996;35(4):429-34
Regulation of c-myb expression in ML-1 human myeloblastic leukemia cells by c-ets-1 protein. Bloch A, et al. **Adv Enzyme Regul** 1995;35:35-41
Apoptosis and bcl-2 protein expression in experimental alcoholic liver disease in the rat. Yacoub LK, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):854-9
Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma. Collins KA, et al. **Am J Dermatopathol** 1995 Oct;17(5):429-38
Rearrangement of the bcl-6 gene in Hodgkin's disease, lymphocyte predominant type [letter] Liang R, et al. **Am J Hematol** 1996 May;52(1):63-4
Nonsyndromic cleft lip with or without cleft palate: new BCL3 information [letter] Amos C, et al. **Am J Hum Genet** 1996 Sep;59(3):743-4
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Bolon I, et al. **Am J Pathol** 1995 Nov;147(5):1298-310
The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Keleti J, et al. **Am J Pathol** 1996 Jul;149(1):143-51
RET proto-oncogene mutations and rearrangements in endocrine diseases [comment] Lloyd RV. **Am J Pathol** 1995 Dec;147(6):1539-44. Comment on: Am J Pathol 1995 Dec;147(6):1600-7.
Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland [see comments] Padberg BC, et al. **Am J Pathol** 1995 Dec; 147(6):1600-7. Comment in: Am J Pathol 1995 Dec;147(6):1539-44.
In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Ueda M, et al. **Am J Pathol** 1996 Sep;149(3):831-43
Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Sorenson CM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F184-93

Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. Kitagawa Y, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):45-54

Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids. Azzoni C, et al. **Am J Surg Pathol** 1996 Apr;20(4):433-41

Investigation of the possible role of WNT genes in human breast cancer. Bergstein I, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:257

p53, myc, APC, hMSH2, ras, etc. in colorectal cancer - a never ending story! [editorial] Fey MF. **Ann Oncol** 1995 Dec;6(10):961-2

Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Dooley S, et al. **Ann Rheum Dis** 1996 May;55(5):298-304

Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ikeda Y, et al. **Ann Thorac Surg** 1996 Sep;62(3):835-8

Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line. Morelli S, et al. **Anticancer Drug Des** 1996 Jan;11(1):1-14

Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Liang H, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):259-65

Expression and function of a recombinant PDGF B gene in porcine arteries. Pompili VJ, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2254-64

The cbl oncogene: a novel substrate of protein tyrosine kinases. Langdon WY. **Aust N Z J Med** 1995 Dec; 25(6):859-64 (19 ref.)

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609-30 (64 ref.)

Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. Mochida S, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):176-9

Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/apopain. Monney L, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):340-5

Early gene signalling-dependent and -independent induction of apoptosis in Ramos human B cells can be inhibited by over-expression of Bcl-2. Ning ZQ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):23-9

A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Urano F, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):608-12

A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B. Cosma MP, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):397-400

Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo. Liu XM, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1545-51

Transcriptional regulation of c-Fes in myeloid leukemia cells. He Y, et al. **Biochim Biophys Acta** 1996 May 2; 1306(2-3):179-86

Naturally occurring splicing variants of the hMSH2 gene containing nonsense codons identify possible mRNA instability motifs within the gene coding region. Marshall B, et al. **Biochim Biophys Acta** 1996 Jul 31;1308(1):88-92

Invasive tumors induce c-ets1 transcription factor expression in adjacent stroma. Calmels TP, et al. **Biol Cell** 1995; 84(1-2):53-61

Expression of vav proto-oncogene by nonhematopoietic trophoblast cells at the human uteroplacental interface. Higuchi T, et al. **Biol Reprod** 1995 Oct;53(4):840-6

Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization. Coignet LJ, et al. **Blood** 1996 Feb 15;87(4):1512-9

Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Deveaux S, et al. **Blood** 1996 Jun 1;87(11):4678-85

REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Houldsworth J, et al. **Blood** 1996 Jan 1;87(1):25-9

Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Joos S, et al. **Blood** 1996 Feb 15;87(4):1571-8

Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Karsan A, et al. **Blood** 1996 Apr 15;87(8):3089-96

A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Luger SM, et al. **Blood** 1996 Feb 15;87(4):1326-34

Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Macintyre EA, et al. **Blood** 1995 Dec 15;86(12):4691-8

DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. Monni O, et al. **Blood** 1996 Jun 15;87(12):5269-78

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S-16S (30 ref.)

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Del Bufalo D, et al. **Br J Cancer** 1996 Aug;74(3):387-93

Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Eng C, et al. **Br J Cancer** 1996 Aug;74(3):339-41

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Foulkes WD, et al. **Br J Cancer** 1995 Oct;72(4):883-8

Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Reeve JG, et al. **Br J Cancer** 1996 May;73(10):1193-200

Bcl6/Laz3 rearrangements in post-transplant lymphoproliferative disorders. Delecluse HJ, et al. **Br J Haematol** 1995 Sep;91(1):101-3

Molecular alterations of IL-6R, lck and c-myc genes in transforming monoclonal gammopathies of undetermined significance. Gernone A, et al. **Br J Haematol** 1996 Jun 1;93(3):623-31

Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Li Y, et al. **Br J Haematol** 1996 Jan;92(1):60-6

Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome. Marks DI, et al. **Br J Haematol** 1996 Mar;92(4):890-9

New type of t(14;18) in a non-Hodgkin's lymphoma provides insight in molecular events in early B-cell differentiation. Meijerink JP, et al. **Br J Haematol** 1995 Nov;91(3):630-9

Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. Merup M, et al. **Br J Haematol** 1996 Mar; 92(3):647-52

Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement. Muramatsu M, et al. **Br J Haematol** 1996 Jun 2;93(4):911-20

Leukaemic CD5+ B-cell apoptosis: co-incidence of cell death and DNA fragmentation with reduced bcl-2 expression. Tangye SG, et al. **Br J Haematol** 1996 Mar; 92(4):950-3

TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina. Ugolini G, et al. **Brain Res** 1995 Dec 15;704(1):121-4

Transient expression of FGF receptor-4 mRNA in the rat cerebellum during postnatal development. Miyake A, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):95-100

Expression of platelet-derived growth factor B-chain in the mature rat brain and pituitary gland. Sasahara M, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):63-74

INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes. Pauley RJ, et al. **Breast Cancer Res Treat** 1996;37(1):65-76

p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Ikenberg H, et al. **Cancer** 1995 Jul 1;76(1):57-66

Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P, et al. **Cancer** 1995 Aug 1; 76(3):479-89

The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Saegusa M, et al. **Cancer** 1995 Dec 1;76(11):2297-303

The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. Zou M, et al. **Cancer** 1995 Jul 15;76(2):314-8

Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Smith MR, et al. **Cancer Gene Ther** 1995 Sep;2(3):207-12

Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia. Brunel V, et al. **Cancer Genet Cytogenet** 1995 Nov;85(1):82-4

Proto-RET is rearranged in the new human papillary thyroid cancer cell line PTC-1113A. Herrmann ME. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):14-20

The BCL-1, BCL-2, and BCL-3 oncogenes are involved in chronic lymphocytic leukemia. Detection by fluorescence in situ hybridization. Lishner M, et al. **Cancer Genet Cytogenet** 1995 Dec;85(2):118-23

No evidence for the amplifications of MDM2 and C-myc genes involved in the genetic susceptibility to esophageal cancer in a high-risk area of north China [letter] Zhu D, et al. **Cancer Genet Cytogenet** 1996 Jul 15;89(2):184-5

Expression of the c-jun, jun-B, ets-2 and liver regeneration factor-1 (LRF-1) genes during promotion and progression of rat liver carcinogenesis in the resistant hepatocyte model. Liao DZ, et al. **Cancer Lett** 1996 Feb 27;100(1-2):215-21

bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Ealovega MW, et al. **Cancer Res** 1996 May 1;56(9):1965-9

Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Eng C, et al. **Cancer Res** 1996 May 1;56(9):2167-70

Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Fugazzola L, et al. **Cancer Res** 1995 Dec 1;55(23):5617-20

Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Hewitt SM, et al. **Cancer Res** 1995 Nov 15;55(22):5386-9

Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Nagatake M, et al. **Cancer Res** 1996 Apr 15;56(8):1886-91

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P, et al. **Cancer Res** 1996 Feb 1; 56(3):556-62

Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Risinger JI, et al. **Cancer Res** 1995 Dec 1;55(23):5664-9

Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Uhlmann EJ, et al. **Cancer Res** 1996 Jun 1;56(11):2506-9

Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat. Wada H, et al. **Cancer Res** 1995 Nov 1;55(21):4780-3

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195-205 (31 ref.)

The effect of afterload and angiotensin II on proto-oncogene mRNA levels in the isolated working rat heart. Roffe C, et al. **Cardiovasc Res** 1996 Jun;31(6):907-16

The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Ho IC, et al. **Cell** 1996 Jun 28;85(7):973-83

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Jing S, et al. **Cell** 1996 Jun 28;85(7):1113-24

Control of SHB gene expression by protein phosphorylation. Lavergne C, et al. **Cell Signal** 1996 Jan;8(1):55-8

Spatiotemporal relationships between a novel Drosophila stripe expressing gene and known segmentation genes by simultaneous visualization of transcript patterns. Hartmann C, et al. **Chromosoma** 1995 Nov;104(2):84-91

Denaturing gradient gel electrophoresis to diagnose multiple endocrine neoplasia type 2. Blank RD, et al. **Clin Chem** 1996 Apr;42(4):598-603

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Marsh DJ, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):249-57

No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B. Toogood AA, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):759-62

BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117-23 (49 ref.)

Autocrine mechanism for met proto-oncogene tumorigenicity. Rong S, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:629-36

Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35-46 (96 ref.)

The Dbl family of oncogenes. Cerione RA, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):216-22 (46 ref.)

Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228-34 (97 ref.)

The c-myb negative regulatory domain. Gonda TJ, et al. **Curr Top Microbiol Immunol** 1996;211:99-109 (43 ref.)

MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Meddeb M, et al. **Cytogenet Cell Genet** 1996;73(4):325-30

Suppression of Lck protooncogene expression in murine somatic cell hybrids between T lymphoma cells and fibroblasts. Oikawa T, et al. **Cytogenet Cell Genet** 1996; 72(1):12-9

NGF receptor expression in sensory neurons develops normally in embryos lacking NGF. Davies AM, et al. **Dev Biol** 1995 Oct;171(2):434-8

decapentaplegic overexpression affects Drosophila wing and leg imaginal disc development and wingless expression. Morimura S, et al. **Dev Biol** 1996 Jul 10;177(1):136-51

The wingless signaling pathway is directly involved in Drosophila heart development. Park M, et al. **Dev Biol** 1996 Jul 10;177(1):104-16

Selective expression of a ski transgene affects IIb fast muscles and skeletal structure. Lana DP, et al. **Dev Dyn** 1996 Jan; 205(1):13-23

Enhanced expression of mouse c-ski accompanies terminal skeletal muscle differentiation in vivo and in vitro. Namciu S, et al. **Dev Dyn** 1995 Nov;204(3):291-300

wingless is required for the formation of a subset of muscle founder cells during Drosophila embryogenesis. Baylies MK, et al. **Development** 1995 Nov;121(11):3829-37

Formin isoforms are differentially expressed in the mouse embryo and are required for normal expression of fgf-4 and shh in the limb bud. Chan DC, et al. **Development** 1995 Oct;121(10):3151-62

Serrate signals through Notch to establish a Wingless-dependent organizer at the dorsal/ventral compartment boundary of the Drosophila wing. Diaz-Benjumea FJ, et al. **Development** 1995 Dec; 121(12):4215-25

Activation of Fgf-4 and HoxD gene expression by BMP-2 expressing cells in the developing chick limb. Duprez DM, et al. **Development** 1996 Jun;122(6):1821-8

Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Durbec PL,

et al. **Development** 1996 Jan;122(1):349–58
The porcupine gene is required for wingless autoregulation in Drosophila. Manoukian AS, et al. **Development** 1995 Dec;121(12):4037–44
hedgehog, wingless and orthodenticle specify adult head development in Drosophila. Royet J, et al. **Development** 1996 Jun;122(6):1849–58
Notch regulates wingless expression and is not required for reception of the paracrine wingless signal during wing margin neurogenesis in Drosophila. Rulifson EJ, et al. **Development** 1995 Sep;121(9):2813–24
wingless inhibits morphogenetic furrow movement in the Drosophila eye disc. Treisman JE, et al. **Development** 1995 Nov;121(11):3519–27
Cloning and characterization of Wnt-4 and Wnt-11 cDNAs from chick embryo. Tanda N, et al. **DNA Seq** 1995; 5(5):277–81
T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. gene product in. Brady HJ, et al. **EMBO J** 1996 Mar 15; 15(6):1221–30
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. Carlomagno F, et al. **EMBO J** 1996 Jun 3;15(11):2717–25
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. Haupt Y, et al. **EMBO J** 1996 Apr 1;15(7):1596–606
ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. Sgouras DN, et al. **EMBO J** 1995 Oct 2;14(19):4781–93
Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. Strasser A, et al. **EMBO J** 1996 Aug 1;15(15):3823–34
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. Ye BH, et al. **EMBO J** 1995 Dec 15;14(24):6209–17
Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells. Buckley AR, et al. **Endocrinology** 1995 Dec;136(12):5252–9
ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation [editorial; comment] Gagel RF. **Endocrinology** 1996 May; 137(5):1509–11. Comment on: Endocrinology 1996 May;137(5):1512–9.
Prolactin, proliferation, and protooncogenes [editorial] Horseman ND. **Endocrinology** 1995 Dec;136(12):5249–51
Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Jhiang SM, et al. **Endocrinology** 1996 Jan;137(1):375–8
Susceptibility of avian ovarian granulosa cells to apoptosis is dependent upon stage of follicle development and is related to endogenous levels of bcl-xlong gene expression. Johnson AL, et al. **Endocrinology** 1996 May;137(5):2059–66
Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes [see comments] Xing S, et al. **Endocrinology** 1996 May;137(5):1512–9. Comment in: Endocrinology 1996 May;137(5):1509–11.
Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Corvi R, et al. **Eur J Cancer** 1995;31A(4):520–3
MSH2 sequence variations and inherited colorectal cancer susceptibility [letter; comment] Froggatt NJ, et al. **Eur J Cancer** 1996 Jan;32A(1):178. Comment on: Eur J Cancer 1994;30A(10):1550–2.
Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. Qian W, et al. **Eur J Cancer B Oral Oncol** 1995 Sep; 31B(5):328–32
Monoclonal lymphocyte proliferation and bcl-2 rearrangement in essential mixed cryoglobulinaemia. Ellis M, et al. **Eur J Clin Invest** 1995 Nov;25(11):833–7
Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors [see comments] Kimura T, et al. **Eur J Endocrinol** 1996 Mar;134(3):314–9. Comment in: Eur J Endocrinol 1996 Mar;134(3):263–6.
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513–22 (114 ref.)
Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Akbar AN, et al. **Eur J Immunol** 1996 Feb;26(2):294–9
Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Schröter M, et al. **Eur J Immunol** 1995 Dec;25(12):3509–13
Evidence for the promotion of positive selection of thymocytes by Ah receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin. Kremer J, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):413–27
The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors in human fibroblasts. Gilles F, et al. **Exp Cell Res** 1996 Feb 1;222(2):370–8
BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Reynolds JE, et al. **Exp Cell Res** 1996 Jun 15;225(2):430–6
Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):253–65 (43 ref.)
Transfection of cells with basic fibroblast growth factor and Kaposi fibroblast growth factor genes induce resistance to and receptor modulation of tumor necrosis factor. Aggarwal BB, et al. **FEBS Lett** 1995 Sep 18;372(1):44–8
The mouse Wnt-10B gene isolated from helper T cells is widely expressed and a possible oncogene in BR6 mouse mammary tumorigenesis. Hardiman G, et al. **Gene** 1996 Jun 26;172(2):199–205
Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein. Hellyer NJ, et al. **Gene** 1995 Nov 20;165(2):279–84
The Drosophila melanogaster gene lethal(3)73Ah encodes a ring finger protein homologous to the oncoproteins MEL-18 and BMI-1. Irminger-Finger I, et al. **Gene** 1995 Oct 3;163(2):203–8
The zebrafish Fgf-3 gene: cDNA sequence, transcript structure and genomic organization. Kiefer P, et al. **Gene** 1996 Feb 12;168(2):211–5
Structure and regulation of the gene encoding avian inhibitor of nuclear factor kappa B-alpha. Krishnan VA, et al. **Gene** 1995 Dec 12;166(2):261–6
Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia. Nicolson NL, et al. **Gene** 1996 Mar 9;169(2):173–8
Cloning and expression of a murine cDNA homologous to the human RCK/P54, a lymphoma-linked chromosomal translocation junction gene on 11q23. Seto M, et al. **Gene** 1995 Dec 12;166(2):293–6
Cloning and transcription factor-binding sites of the human c-rel proto-oncogene promoter. Viswanathan M, et al. **Gene** 1996 May 8;170(2):271–6
Isolation and characterization of xnov, a Xenopus laevis ortholog of the chicken nov gene. Ying Z, et al. **Gene** 1996 Jun 1;171(2):243–8
An unexpected transforming gene in calf-thymus carrier DNA: bovine hst. Yu JC, et al. **Gene** 1995 Sep 11; 162(2):333–4
Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Ohnishi H, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):187–90
Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin's lymphomas with BCL6/LAZ3 rearrangement. Wlodarska I, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):1–7
The Caenorhabditis elegans gene lin-1 encodes an ETS-domain protein and defines a branch of the vulval induction pathway. Beitel GJ, et al. **Genes Dev** 1995 Dec 15;9(24):3149–62
The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. Dash AB, et al. **Genes Dev** 1996 Aug 1;10(15):1858–69
Life, death, and the pursuit of apoptosis. White E. **Genes Dev** 1996 Jan 1;10(1):1–15 (191 ref.)
Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Yuan H, et al. **Genes Dev** 1995 Nov 1;9(21):2635–45
Mutations Modulating Raf signaling in Drosophila eye development. Dickson BJ, et al. **Genetics** 1996 Jan; 142(1):163–71
Sternopleural is a regulatory mutation of wingless with both dominant and recessive effects on larval development of Drosophila melanogaster. Neumann CJ, et al. **Genetics** 1996 Apr;142(4):1147–55
A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Butti MG, et al. **Genomics** 1995 Jul 1;28(1):15–24
The organization and expression of the mdm2 gene. de Oca Luna RM, et al. **Genomics** 1996 May 1;33(3):352–7
Locations of the ets subfamily members net, elk1, and sap1 (ELK3, ELK1, and ELK4) on three homologous regions of the mouse and human genomes. Giovane A, et al. **Genomics** 1995 Oct 10;29(3):769–72
Assignment of the ets-related transcription factor E1A-F gene (ETV4) to human chromosome region 17q21. Isobe M, et al. **Genomics** 1995 Jul 20;28(2):357–9
Paralogy mapping: identification of a region in the human MHC triplicated onto human chromosomes 1 and 9 allows the prediction and isolation of novel PBX and NOTCH loci. Katsanis N, et al. **Genomics** 1996 Jul 1;35(1):101–8
Genomic organization of the mouse fibroblast growth factor receptor 3 (Fgfr3) gene. Perez-Castro AV, et al. **Genomics** 1995 Nov 20;30(2):157–62
The MAS proto-oncogene is not imprinted in humans. Riesewijk AM, et al. **Genomics** 1996 Jul 15;35(2):380–2
DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Medl M, et al. **Gynecol Oncol** 1995 Dec;59(3):321–6
Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):440–7 (38 ref.)
No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma. Hofstra RM, et al. **Hum Genet** 1996 Mar;97(3):362–4
Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM, et al. **Hum Genet** 1996 Jan;97(1):11–4
CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC mutations. Maliaka YK, et al. **Hum Genet** 1996 Feb;97(2):251–5
Interleukin-7 rescues human activated T lymphocytes from apoptosis induced by glucocorticoesteroids and regulates bcl-2 and CD25 expression. Hernández-Caselles T, et al. **Hum Immunol** 1995 Jul;43(3):181–9
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Attié T, et al. **Hum Mol Genet** 1995 Aug;4(8):1381–6
Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Kitamura Y, et al. **Hum Mol Genet** 1995 Oct;4(10):1987–8
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Smanik PA, et al. **Hum Mol Genet** 1995 Dec;4(12):2313–8
Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Jeon HM, et al. **Hum Mutat** 1996;7(4):327–33
Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis. Peacock ML, et al. **Hum Mutat** 1996;7(2):100–4
bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Arsura M, et al. **Immunity** 1996 Jul;5(1):31–40
Induction of lytic pathways in T cell clones derived from wild-type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)
The protein tyrosine kinase Fyn activates transcription from the HIV promoter via activation of NF kappa B-like DNA-binding proteins. Hohashi N, et al. **Int Immunol** 1995 Nov;7(11):1851–9
Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Agular-Santelises M, et al. **Int J Cancer** 1996 Apr 22;69(2):114–9
Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Fink M, et al. **Int J Cancer** 1996 Aug 22;69(4):312–6
Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Fujita M, et al. **Int J Cancer** 1995 Dec 20;64(6):361–6
Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Gazzaniga P, et al. **Int J Cancer** 1996 Apr 22;69(2):100–4
Fibroblast growth factor 3 is tumorigenic for mouse mammary cells orthotopically implanted in nude mice. Hajitou A, et al. **Int J Cancer** 1995 Nov 27;63(5):702–9
Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Liu AY, et al. **Int J Cancer** 1996 Jan 3;65(1):85–9
C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Lönn U, et al. **Int J Cancer** 1996 Aug 22;69(4):273–7
MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Nakayama T, et al. **Int J Cancer** 1995 Oct 20;64(5):342–6
Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Ogretmen B, et al. **Int J Cancer** 1996 Sep 4;67(5):608–14
bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Sarbia M, et al. **Int J Cancer** 1996 Aug 22;69(4):324–8
Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Wagener C, et al. **Int J Cancer** 1996 Jul 3;67(1):138–41
Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Warenius HM, et al. **Int J Cancer** 1996 Jul 17; 67(2):224–31
Validation of the STR system FES/FPS for forensic purposes in an Austrian population sample. Klintschar M. **Int J Legal Med** 1995;108(3):162–4
HumFES/FPS and HumF13B: population genetic data from north Italy. Piccinini A, et al. **Int J Legal Med** 1996; 108(5):283–4
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. Albanese C, et al. **J Biol Chem** 1995 Oct 6;270(40):23589–97
A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. Asai N, et al. **J Biol Chem** 1996 Jul 26;271(30):17644–9
The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. Barnier JV, et al. **J Biol Chem** 1995 Oct 6;270(40):23381–9
Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. Chen H, et al. **J Biol Chem** 1996 Jun 28;271(26):15743–52
Molecular ordering of the cell death pathway. Bcl-2 and

Bcl-xL function upstream of the CED-3-like apoptotic proteases. Chinnaiyan AM, et al. **J Biol Chem** 1996 Mar 1;271(9):4573-6

Urea inducibility of egr-1 in murine inner medullary collecting duct cells is mediated by the serum response element and adjacent Ets motifs. Cohen DM, et al. **J Biol Chem** 1996 May 31;271(22):12903-8

Characterization of the complete genomic structure of the human WNT-5A gene, functional analysis of its promoter, chromosomal mapping, and expression in early human embryogenesis. Danielson KG, et al. **J Biol Chem** 1995 Dec 29;270(52):31225-34

Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors. Liang Y, et al. **J Biol Chem** 1996 May 17; 271(20):11792-7

Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. Logan SK, et al. **J Biol Chem** 1996 Jan 12;271(2):774-82

The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor. Pandit SD, et al. **J Biol Chem** 1996 Mar 8;271(10):5850-8

Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. Pinkas-Kramarski R, et al. **J Biol Chem** 1996 Aug 9;271(32):19029-32

Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter. Scarpati EM, et al. **J Biol Chem** 1996 Feb 9;271(6):3025-32

Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Miller CW, et al. **J Cancer Res Clin Oncol** 1996; 122(9):559-65

Multiple features of the p59fyn src homology 4 domain define a motif for immune-receptor tyrosine-based activation motif (ITAM) binding and for plasma membrane localization. Timson Gauen LK, et al. **J Cell Biol** 1996 Jun;133(5):1007-15

RET mutation screening in sporadic pheochromocytoma [letter; comment] Arnold A. **J Clin Endocrinol Metab** 1996 Jan;81(1):430. Comment on: J Clin Endocrinol Metab 1995 Jul;80(7):2063-8.

Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. Bongarzone I, et al. **J Clin Endocrinol Metab** 1996 May;81(5):2006-9

Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. Branet F, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2726-30

C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Caron P, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2731-3

Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. Frank-Raue K, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1780-3

Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. Pausova Z, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2711-8

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Romei C, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1619-22

A primary, lateral-cervical medullary thyroid carcinoma: a case report. Santini L, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1784-6

ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? Sugg SL, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3360-5

Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. Zedenius J, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3088-90

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon I, et al. **J Clin Invest** 1996 Jan 1; 97(1):187-95

Regulation of T cell receptor delta gene rearrangement by c-Myb. Hernández-Munain C, et al. **J Exp Med** 1996 Jan 1;183(1):289-93

B cell lymphoma-2 transfected P815 cells resist reactive nitrogen intermediate-mediated macrophage-dependent cytotoxicity. Albina JE, et al. **J Immunol** 1996 Jul 1; 157(1):279-83

Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. Mueller DL, et al. **J Immunol** 1996 Mar 1;156(5):1764-71

bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. Reap EA, et al. **J Immunol** 1995 Dec 1;155(11):5455-62

Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. Wang Z, et al. **J Immunol** 1995 Oct 15;155(8):3722-5

Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays. Boise LH, et al. **J Immunol Methods** 1996 May 27;191(2):143-8

BAX gene expression in melanoma metastases [letter] Grandilone A, et al. **J Invest Dermatol** 1996 Feb;106(2):382

Differentiation-associated expression of the proto-oncogene pim-1 in cultured human keratinocytes. Stewart BE, et al. **J Invest Dermatol** 1995 Nov;105(5):699-703

Detection of new mutations in six out of 10 Swiss HNPCC families by genomic sequencing of the hMSH2 and hMLH1 genes. Buerstedde JM, et al. **J Med Genet** 1995 Nov; 32(11):909-12

Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. Crossey PA, et al. **J Med Genet** 1995 Nov;32(11):885-6

Molecular evolution and secondary structural conservation in the B-cell lymphoma leukemia 2 (bcl-2) family of proto-oncogene products. Evans DL, et al. **J Mol Evol** 1995 Dec;41(6):775-83

Expression of the apoptosis-effector gene, Bax, is up-regulated in vulnerable hippocampal CA1 neurons following global ischemia. Chen J, et al. **J Neurochem** 1996 Jul;67(1):64-71

Regulation of Bcl-2 protein expression in human neuroblastoma SH-SY5Y cells: positive and negative effects of protein kinases C and A, respectively. Itano Y, et al. **J Neurochem** 1996 Jul;67(1):131-7

Cytokine-regulated expression of platelet-derived growth factor gene and protein in cultured human astrocytes. Silberstein FC, et al. **J Neurochem** 1996 Apr;66(4):1409-17

Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. Lawrence MS, et al. **J Neurosci** 1996 Jan 15; 16(2):486-96

Differential regulation of bcl-2, bax, c-fos, junB, and krox-24 expression in the cerebellum of Purkinje cell degeneration mutant mice. Gillardon F, et al. **J Neurosci Res** 1995 Aug 1;41(5):708-15

Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. Krishna M, et al. **J Neurosurg** 1995 Dec;83(6):1017-22

bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. Ott MM, et al. **J Pathol** 1996 Jul; 179(3):238-42

Analysis of the BCL-6 gene configuration in diffuse B-cell non-Hodgkin's lymphomas and Hodgkin's disease. Pescarmona E, et al. **J Pathol** 1995 Sep;177(1):21-5

Ret protein in the human fetal rectum. Tam PK, et al. **J Pediatr Surg** 1996 Apr;31(4):568-71

The Rep68 protein of adeno-associated virus type 2 stimulates expression of the platelet-derived growth factor B c-sis proto-oncogene. Wonderling RS, et al. **J Virol** 1996 Jul;70(7):4783-6

Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II [see comments] Neumann HP, et al. **JAMA** 1995 Oct 11;274(14):1149-51. Comment in: JAMA 1996 Mar 20;275(11):839-40.

A novel somatic point mutation of the RET Proto-oncogene in tumor tissues of small cell lung cancer patients. Futami H, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1127-30

Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Kobayashi K, et al. **Jpn J Cancer Res** 1996 Feb;87(2):141-5

Loss or somatic mutations of hMSH2 occur in hereditary nonpolyposis colorectal cancers with hMSH2 germline mutations. Lu SL, et al. **Jpn J Cancer Res** 1996 Mar; 87(3):279-87

Intratumoral heterogeneity of hst-1 gene amplification in esophageal carcinoma with reference to DNA stem line heterogeneity. Chikuba K, et al. **Jpn J Clin Oncol** 1995 Dec;25(6):229-33

Cloning of mouse c-ros renal cDNA, its role in development and relationship to extracellular matrix glycoproteins. Kanwar YS, et al. **Kidney Int** 1995 Nov;48(5):1646-59

Enhanced expression of bcl-2 inhibits apoptosis in cultured human keratinocytes. Maeyama Y. **Kurume Med J** 1995; 42(4):291-7

Hodgkin cells accumulate mRNA for bcl-2. Hell K, et al. **Lab Invest** 1995 Oct;73(4):492-6

RET oncogene puzzle in Chernobyl thyroid tumours [news] Bonn D. **Lancet** 1996 Apr 27;347(9009):1176

BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Offit K, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):85-9

bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Blagosklonny MV, et al. **Leuk Res** 1996 Feb;20(2):101-7

c-myb intron I protein binding and association with transcriptional activity in leukemic cells. Dooley S, et al. **Leuk Res** 1996 May;20(5):429-39

Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Campos L, et al. **Leukemia** 1996 Mar;10(3):434-8

Preservation of functional and regulatory domains of expressed bcl-2 genes in non-Hodgkin's lymphoma. Dirks W, et al. **Leukemia** 1996 Jan;10(1):150-8

Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Dyer MJ, et al. **Leukemia** 1996 Jul;10(7):1198-208

Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Hu ZB, et al. **Leukemia** 1996 Mar;10(3):410-6

Coexpression of thrombopoietin and c-mpl genes in human acute myeloblastic leukemia cells. Matsumura I, et al. **Leukemia** 1996 Jan;10(1):91-4

Bax mutations in cell lines derived from hematological malignancies. Meijerink JP, et al. **Leukemia** 1995 Nov; 9(11):1828-32

Internal DNA deletion within the BCL-6 gene on untranslocated chromosome in non-Hodgkin's lymphoma with 3q27 abnormality. Nakamura Y, et al. **Leukemia** 1996 Apr;10(4):658-61

Elevated pim-1 and c-myc proto-oncogene induction in B lymphocytes from BLV-infected cows with persistent B lymphocytosis. Stone DM, et al. **Leukemia** 1996 Oct; 10(10):1629-38

Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases. Yabumoto K, et al. **Leukemia** 1996 Jun;10(6):970-7

Mapping of the mouse Bcl6 gene to chromosome 16. Liao X, et al. **Mamm Genome** 1996 Aug;7(8):621-2

The ets-related mouse Pea3 gene maps to distal chromosome 11. Noben-Trauth K, et al. **Mamm Genome** 1996 Jul; 7(7):551

Somatic cell mapping of the SKI proto-oncogene to bovine syntenic group U25 (BTA 27). Ryan AM, et al. **Mamm Genome** 1995 Aug;6(8):560-1

Syntenic assignment of human serotonin receptor subtype 2 (HTR2), esterase D (ESD), and fms-related tyrosine kinase (FLT) homologs to bovine chromosome 12. Sun HS, et al. **Mamm Genome** 1996 Jul;7(7):518-9

Microsatellite instability in IVS3 of murine c-fes gene: tumor-associated rearrangement and mammalian divergence. Volpi L, et al. **Mamm Genome** 1996 Sep; 7(9):682-5

Localization of Pbx1 transcripts in developing rat embryos. Roberts VJ, et al. **Mech Dev** 1995 Jun;51(2-3):193-8

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Borrello MG, et al. **Mol Cell Biol** 1996 May;16(5):2151-63

Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Broccoli D, et al. **Mol Cell Biol** 1996 Jul;16(7):3765-72

Pbx modulation of Hox homeodomain amino-terminal arms establishes different DNA-binding specificities across the Hox locus. Chang CP, et al. **Mol Cell Biol** 1996 Apr; 16(4):1734-45

The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Greco A, et al. **Mol Cell Biol** 1995 Nov;15(11):6118-27

The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor. Heydemann A, et al. **Mol Cell Biol** 1996 Apr;16(4):1676-86

Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis. Hunter JJ, et al. **Mol Cell Biol** 1996 Mar;16(3):877-83

Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Moskow JJ, et al. **Mol Cell Biol** 1995 Oct;15(10):5434-43

Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Perrotti D, et al. **Mol Cell Biol** 1995 Nov;15(11):6075-87

The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Ribon V, et al. **Mol Cell Biol** 1996 Jan;16(1):45-52

Transcriptional down regulation of the nov proto-oncogene in fibroblasts transformed by p60v-src. Scholz G, et al. **Mol Cell Biol** 1996 Feb;16(2):481-6

Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth. Xiong Q, et al. **Mol Cell Biol** 1996 Apr;16(4):1509-18

Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Chen J, et al. **Mol Med** 1995 Jan;1(2):142-52

Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis [see comments] Indo Y, et al. **Nat Genet** 1996 Aug;13(4):485-8 . Comment in: Nat Genet 1996 Aug;13(4):382-3.

Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias [see comments] Nakamura T, et al. **Nat Genet** 1996 Feb;12(2):149-53. Comment in: Nat Genet 1996 Feb;12(2):113-4.

No pain, some gain [news; comment] Wood JN. **Nat Genet** 1996 Aug;13(4):382-3. Comment on: Nat Genet 1996 Aug;13(4):485-8.

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Sigalas I, et al. **Nat Med** 1996 Aug;2(8):912-7

Functional receptor for GDNF encoded by the c-ret proto-oncogene [see comments] Trupp M, et al. **Nature** 1996 Jun 27;381(6585):785-8. Comment in: Nature 1996 Jul 4;382(6586):29-30.

Visual projection map specified by topographic expression of transcription factors in the retina. Yuasa J, et al. **Nature** 1996 Aug 15;382(6592):632-5

Olfactory experience modulates Bcl-2 expression in the developing olfactory bulb [see comments] Najbauer J, et al. **Neuroreport** 1995 Dec 29;7(1):197-200. Comment in: Neuroreport 1995 Dec 29;7(1):9.

Time course of axotomy-induced apoptotic cell death in facial motoneurons of neonatal wild type and bcl-2 transgenic mice. de Bilbao F, et al. **Neuroscience** 1996 Apr; 71(4):1111-9

Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. Gryaznov S, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1508-14

Binding of DNA oligonucleotides to sequences in the promoter of the human bcl-2 gene. Olivas WM, et al. **Nucleic Acids Res** 1996 May 1;24(9):1758-64

Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 proto-oncogene promotor. Svinarchuk F, et al. **Nucleic Acids Res** 1996 Jan 15; 24(2):295-302

The Gag-Myb-Ets fusion oncogene alters the apoptotic response and growth factor dependence of interleukin-3 dependent murine cells. Athanasiou M, et al. **Oncogene** 1996 Jan 18;12(2):337-44

RET activation by germline MEN2A and MEN2B mutations. Borrello MG, et al. **Oncogene** 1995 Dec 7; 11(11):2419-27

Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Bubb VJ, et al. **Oncogene** 1996 Jun 20; 12(12):2641-9

A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines. Capaccioli S, et al. **Oncogene** 1996 Jul 4;13(1):105-15

Domains of the qin protein required for oncogenic transformation. Chang HW, et al. **Oncogene** 1996 Jul 18; 13(2):441-4

A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Choi SS, et al. **Oncogene** 1995 Nov 2;11(9):1693-8

MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Dubs-Poterszman MC, et al. **Oncogene** 1995 Dec 7;11(11):2445-9

The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Eliopoulos AG, et al. **Oncogene** 1995 Oct 5;11(7):1217-28

The murine BCL6 gene is induced in activated lymphocytes as an immediate early gene. Fukuda T, et al. **Oncogene** 1995 Oct 19;11(8):1657-63

Back-mutation of the V-Ets to the C-Ets carboxy-terminal amino acids in the P135gag-myb-ets results in chicken neuroretina cells transformation and loss of basic fibroblast growth factor responsiveness. Garrido C, et al. **Oncogene** 1996 Apr 4;12(7):1449-56

bcl-w, a novel member of the bcl-2 family, promotes cell survival. Gibson L, et al. **Oncogene** 1996 Aug 15; 13(4):665-75

Induction of expression of growth-related genes by FGF-4 in mouse fibroblasts. Guthridge MA, et al. **Oncogene** 1996 Mar 21;12(6):1267-78

A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Harigai M, et al. **Oncogene** 1996 Mar 21;12(6):1369-74

Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T, et al. **Oncogene** 1996 Feb 1;12(3):481-7

Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Katzav S, et al. **Oncogene** 1995 Sep 21;11(6):1079-88

High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Klugbauer S, et al. **Oncogene** 1995 Dec 21; 11(12):2459-67

Regulation of A-raf expression. Lee JE, et al. **Oncogene** 1996 Apr 18;12(8):1669-77

Functional analysis of the SIS proximal element and its activating factors: regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells. Liang Y, et al. **Oncogene** 1996 Aug 15;13(4):863-71

Regulation of nov by WT1: a potential role for nov in nephrogenesis. Martinerie C, et al. **Oncogene** 1996 Apr 4; 12(7):1479-92

Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Myers SM, et al. **Oncogene** 1995 Nov 16;11(10):2039-45

The physical map of the human RET proto-oncogene. Pasini B, et al. **Oncogene** 1995 Nov 2;11(9):1737-43

Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Santoro M, et al. **Oncogene** 1996 Apr 18; 12(8):1821-6

Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins. Subramanian T, et al. **Oncogene** 1995 Dec 7; 11(11):2403-9

Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Vider BZ, et al. **Oncogene** 1996 Jan 4; 12(1):153-8

RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Viglietto G, et al. **Oncogene** 1995 Sep 21; 11(6):1207-10

Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Zörnig M, et al. **Oncogene** 1995 Nov 16;11(10):2165-74

Int-2 influences the development of the nodose ganglion. Qin F, et al. **Pediatr Res** 1995 Oct;38(4):485-92

Alleles of the maize P gene with distinct tissue specificities encode Myb-homologous proteins with C-terminal replacements. Chopra S, et al. **Plant Cell** 1996 Jul; 8(7):1149-58

Isolation of two novel myb-like genes from Arabidopsis and studies on the DNA-binding properties of their products. Li SF, et al. **Plant J** 1995 Dec;8(6):963-72

Environmental factors may regulate BCL2 associated lymphomagenesis: a very low incidence of BCL2-MBR translocation in Poland. Lubiński J, et al. **Pol J Pathol** 1995; 46(4):219-24

The BCL2 major breakpoint region is a sequence- and cell-cycle-specific binding site of the Ku antigen. DiCroce PA, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10137-41

Bc1-2 protects mice against fatal alphavirus encephalitis. Levine B, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4810-5

Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Migliazza A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12520-4

Inhibition of apoptosis by overexpressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Yin DX, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3394-8

Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257-60 (67 ref.)

Sequence of the canine c-yes proto-oncogene. Zhao DM, et al. **Res Vet Sci** 1995 Nov;59(3):230-3

Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. Jarvis TC, et al. **RNA** 1996 May;2(5):419-28

Antagonistic interactions between wingless and decapentaplegic responsible for dorsal-ventral pattern in the Drosophila Leg. Brook WJ, et al. **Science** 1996 Sep 6;273(5280):1373-7

Control of the gene optomotor-blind in Drosophila wing development by decapentaplegic and wingless. Grimm S, et al. **Science** 1996 Mar 15;271(5255):1601-4

Pharmacia Biotech & Science prize. Grand prize winner. Life and death decisions: ced-9 and programmed cell death in Caenorhabditis elegans. Hengartner MO. **Science** 1995 Nov 10;270(5238):930-1

The bcl-2 gene family. Craig RW. **Semin Cancer Biol** 1995 Feb;6(1):35-43 (71 ref.)

Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Chen H, et al. **Surgery** 1996 Aug; 120(2):168-72; discussion 173

Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Frilling A, et al. **Surgery** 1995 Dec; 118(6):1099-103; discussion 1103-4

Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Pacini F, et al. **Surgery** 1995 Dec;118(6):1031-5

c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526-8 (15 ref.)

Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May-Jun;82(3):205-9 (57 ref.)

Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. **Verh Dtsch Ges Pathol** 1995;79:L-LV

Clonal variations among multiple primary mammary tumors and within a tumor of individual mice: insertion mutations of int oncogenes. Sarkar NH. **Virology** 1995 Oct 1; 212(2):490-9

Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. Lindner V. **Z Kardiol** 1995;84 Suppl 4:137-44

[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):493-509 (56 ref.) (Eng. Abstr.) **(Fre)**

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35-36):503-6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Prognostic factors for esophageal cancer--from the viewpoint of molecular biology] Shimada Y, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):972-81 (98 ref.) (Eng. Abstr.) **(Jpn)**

[Endocrine surgery. Series 6: Alteration of RET proto-oncogene and clinical implication in medullary thyroid carcinoma. Genetic screening of family members at risk for inherited medullary thyroid carcinoma] Kitamura Y, et al. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):228-32 **(Jpn)**

[Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis] Irie K, et al. **Rinsho Byori** 1996 Jan;44(1):32-41 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications] Bugalho MJ, et al. **Acta Med Port** 1995 Jul-Aug;8(7-8):419-24 (66 ref.) (Eng. Abstr.) **(Por)**

[Expression of MIB-1/KI-67 and bcl-2 in gastric carcinoma. Relationship with clinico-pathological factors] Sundblad AS, et al. **Acta Gastroenterol Latinoam** 1995;25(2):67-72 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunohistochemical detection of Bax and Bcl-2 proteins in gerbil hippocampus following transient forebrain ischemia. Hara A, et al. **Brain Res** 1996 Mar 4; 711(1-2):249-53

Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Selter H, et al. **Cancer Lett** 1995 Sep 4;96(1):111-5

Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat. Wada H, et al. **Cancer Res** 1995 Nov 1;55(21):4780-3

Isolation and characterization of a monoclonal antibody binding to the extracellular domain of the flk-2 tyrosine kinase receptor. Rose C, et al. **Hybridoma** 1995 Oct; 14(5):453-9

Immunity to oncogenic proteins. Cheever MA, et al. **Immunol Rev** 1995 Jun;145:33-59 (81 ref.)

A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. Dahl AM, et al. **J Immunol** 1996 Jul 1;157(1):239-46

ISOLATION & PURIFICATION

Electrophoretic mobility shift assay. Kerr LD. **Methods Enzymol** 1995;254:619-32

[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)] Komminoth P, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31-32):1329-38 (57 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Proto-oncogene products Vav and c-Cbl are involved in the signal transduction through Grb2/Ash in hematopoietic cells. Hanazono Y, et al. **Acta Haematol** 1996; 95(3-4):236-42

Expression and signal transduction of the FLT3 tyrosine kinase receptor. Rosnet O, et al. **Acta Haematol** 1996; 95(3-4):218-23

Axonal accumulation of p75NTR and TrkA in the septum following lesion of septo-hippocampal pathways. Skup M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):515-25

Regulation of c-myb expression in ML-1 human myeloblastic leukemia cells by c-ets-1 protein. Bloch A, et al. **Adv Enzyme Regul** 1995;35:35-41

Mass spectrometric characterization of sequence-specific complexes of DNA and transcription factor PU.1 DNA binding domain. Cheng X, et al. **Anal Biochem** 1996 Jul 15;239(1):35-40

Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. Collecchi P, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:419-26

Relationships between proliferative activity and oncogene expression in human breast cancer. Geuna M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:555-63

Mechanisms of enhanced nuclear translocation of the transcription factors c-Rel and NF-kappa B by CD28 costimulation in human T lymphocytes. Lai JH, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:220-3

Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression. Albagli O, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):911-5

The liver response to in vivo heat shock involves the activation of MAP kinases and RAF and the tyrosine phosphorylation of Shc proteins. Bendinelli P, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):54-61

Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Dipietrantonio A, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):837-42

Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Fuhrer DK, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):289-96

Molecular analysis of Ras activation by tyrosine phosphorylated Vav. Gulbins E, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):876-85

A RING finger motif regulates transforming activity of the rfp/ret fusion gene. Hasegawa N, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):627-31

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Kita Y, et al. **Biochem Biophys Res Commun** 1996 Sep 4;

226(1):59-69
An upstream positive regulatory element in human GM-CSF promoter is recognized by NF-kappa B/Rel family members. Musso M, et al.
Biochem Biophys Res Commun 1996 Jun 5;223(1):64-72
Difference in the mechanism of interaction of Raf-1 and B-Raf with H-Ras. Shinkai M, et al.
Biochem Biophys Res Commun 1996 Jun 25;223(3):729-34
Differences in binding of PI 3-kinase to the src-homology domains 2 and 3 of p56 lck and p59 fyn tyrosine kinases. Suša M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):729-34
NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Suzuki T, et al.
Biochem Biophys Res Commun 1995 Nov 13;216(2):582-8
Involvement of PIM-1 in DNA fragmentation in mouse NS-1-derived cells. Takahashi C, et al.
Biochem Biophys Res Commun 1995 Oct 13;215(2):538-46
Interaction of the c-cbl proto-oncogene product with the Tyk-2 protein tyrosine kinase. Uddin S, et al.
Biochem Biophys Res Commun 1996 Aug 23;225(3):833-8
A carboxy terminal domain of the hMSH-2 gene product is sufficient for binding specific mismatched oligonucleotides. Whitehouse A, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):289-95
Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Zarn JA, et al.
Biochem Biophys Res Commun 1996 Aug 14;225(2):384-91
Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. James SR, et al. **Biochem J** 1996 May 1;315 (Pt 3):709-13
Streptozotocin-induced diabetes elicits the phosphorylation of hepatocyte Gi2 alpha at the protein kinase C site but not at the protein kinase A-controlled site. Morris NJ, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):417-20
A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K(+)-ATPase inhibition in the early changes in proto-oncogene expression. Numazawa S, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):321-9
Inhibition of NF kappa B activity by oxidative processes in intact cells mechanism of action of pyrolidine dithiocarbamate and diamide. Brennan P, et al.
Biochem Soc Trans 1996 Feb;24(1):3S
Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: implications for regulation of tyrosine kinase activity. Ladbury JE, et al. **Biochemistry** 1996 Aug 27;35(34):11062-9
Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Bárcena A, et al. **Blood** 1996 Sep 15;88(6):2013-25
An Ets/Sp1 interaction in the 5'-flanking region of the megakaryocyte-specific alpha IIb gene appears to stabilize Sp1 binding and is essential for expression of this TATA-less gene. Block KL, et al. **Blood** 1996 Sep 15; 88(6):2071-80
Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. Carey JO, et al. **Blood** 1996 May 15;87(10):4316-24
Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Fielder PJ, et al. **Blood** 1996 Mar 15; 87(6):2154-61
CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-oncogene. Kitanaka A, et al. **Blood** 1996 Jul 15;88(2):590-8
Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Bradbury DA, et al.
Br J Haematol 1995 Oct;91(2):374-9
Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Xerri L, et al.
Br J Haematol 1996 Mar;92(4):900-6
Overexpression of proto-oncogene bcl-2 in rheumatoid synovium [letter] Liang HY, et al. **Br J Rheumatol** 1996 Aug;35(8):803-4
Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer. Taniguchi J, et al. **Br J Urol** 1996 May;77(5):719-23
Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Satou T, et al. **Brain Res** 1995 Oct 30;697(1-2):35-43
Abnormal expression of MDM-2 in breast carcinomas. Bueso-Ramos CE, et al. **Breast Cancer Res Treat** 1996; 37(2):179-88
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Baretton GB, et al. **Cancer** 1996 Jan 15;77(2):255-64
trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Tanaka T, et al. **Cancer** 1995 Sep 15;76(6):1086-95
Oncogene expression in carotid body tumors. Wang DG, et al. **Cancer** 1996 Jun 15;77(12):2581-7
Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Kim SH, et al. **Cancer Lett** 1996 Jan 2;98(2):199-205
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, et al.
Cancer Res 1996 Apr 15;56(8):1851-4
Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Chresta CM, et al.
Cancer Res 1996 Apr 15;56(8):1834-41
Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2. Cortazzo M, et al. **Cancer Res** 1996 Mar 15;56(6):1199-203
Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Gauthier ER, et al. **Cancer Res** 1996 Mar 15;56(6):1451-6
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253-5
Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Lasorella A, et al. **Cancer Res** 1995 Oct 15;55(20):4711-6
Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Li Y, et al. **Cancer Res** 1996 Jun 15;56(12):2872-6
Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. Zhuang SM, et al. **Carcinogenesis** 1995 Dec;16(12):2939-44
Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Lee CH, et al. **Cell** 1996 Jun 14;85(6):931-42
MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Sieweke MH, et al.
Cell 1996 Apr 5;85(1):49-60
A kinase/phosphatase system involving the protooncogene Lck is necessary for inducible modulation of Sob 1 during T cell activation. Benson BA, et al. **Cell Immunol** 1996 Jun 15;170(2):245-50
Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Hultgårdh-Nilsson A, et al. **Circ Res** 1996 Apr;78(4):589-95
Hypoxia and hypoxia/reoxygenation activate Raf-1, mitogen-activated protein kinase kinase, mitogen-activated protein kinases, and S6 kinase in cultured rat cardiac myocytes. Seko Y, et al. **Circ Res** 1996 Jan;78(1):82-90
High levels of bcl-2 protein in the T lymphocytes of patients with Behçet's disease [letter] Hamzaoui A, et al.
Clin Exp Rheumatol 1996 Jan-Feb;14(1):106-7
Induction and regulation of NFkappaB during aging: role of protein kinases. Trebilcock GU, et al.
Clin Immunol Immunopathol 1996 Apr;79(1):87-91
Proteins of the 14-3-3 family associate with Raf and contribute to its activation. Freed E, et al.
Cold Spring Harb Symp Quant Biol 1994;59:187-93 (45 ref.)
The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crepieux P, et al. **Crit Rev Oncog** 1994;5(6):615-38 (192 ref.)
Protein-protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119-21 (21 ref.)
Activation of ternary complex factor Elk-1 by stress-activated protein kinases. Gille H, et al.
Curr Biol 1995 Oct 1;5(10):1191-200
Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579-87 (72 ref.)
Biphasic activation of Fyn kinase upon fertilization of the sea urchin egg. Kinsey WH. **Dev Biol** 1996 Mar 15; 174(2):281-7
Wingless signaling induces nautilus expression in the ventral mesoderm of the Drosophila embryo. Ranganayakulu G, et al. **Dev Biol** 1996 May 25;176(1):143-8
Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Takagi H, et al. **Diabetes** 1996 Aug;45(8):1016-23
Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas. Eggstein S, et al.
Dig Dis Sci 1996 Jun;41(6):1069-75
Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. Alexander WS, et al. **EMBO J** 1995 Nov 15;14(22):5569-78
ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. Altiok N, et al.
EMBO J 1995 Sep 1;14(17):4258-66
Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. Beadling C, et al. **EMBO J** 1996 Apr 15; 15(8):1902-13
Bcr and Raf form a complex in vivo via 14-3-3 proteins. Braselmann S, et al. **EMBO J** 1995 Oct 2;14(19):4839-48
Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. Cavigelli M, et al.
EMBO J 1995 Dec 1;14(23):5957-64
A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. Chittenden T, et al. **EMBO J** 1995 Nov 15;14(22):5589-96
Developmental changes in NT3 signalling via TrkA and TrkB in embryonic neurons. Davies AM, et al.
EMBO J 1995 Sep 15;14(18):4482-9
Two different thresholds of wingless signalling with distinct developmental consequences in the Drosophila midgut. Hoppler S, et al. **EMBO J** 1995 Oct 16;14(20):5016-26
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Karunagaran D, et al. **EMBO J** 1996 Jan 15;15(2):254-64
A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. Lee CH, et al. **EMBO J** 1995 Oct 16; 14(20):5006-15
Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. Oelgeschläger M, et al.
EMBO J 1996 Jun 3;15(11):2771-80
Engrailed and Hox homeodomain proteins contain a related Pbx interaction motif that recognizes a common structure present in Pbx. Peltenburg LT, et al. **EMBO J** 1996 Jul 1;15(13):3385-93
ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. Sgouras DN, et al. **EMBO J** 1995 Oct 2;14(19):4781-93
Rab3 reversibly recruits rabphilin to synaptic vesicles by a mechanism analogous to raf recruitment by ras. Stahl B, et al. **EMBO J** 1996 Apr 15;15(8):1799-809
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Wallasch C, et al. **EMBO J** 1995 Sep 1;14(17):4267-75
Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. Zhu X, et al. **EMBO J** 1995 Dec 1;14(23):5842-8
Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells. Baxter RM, et al. **Eur J Biochem** 1995 Nov 15;234(1):84-91
Bacterial expression, characterization and DNA binding studies on Drosophila melanogaster c-Myb DNA-binding protein. Madan A, et al. **Eur J Biochem** 1995 Aug 15; 232(1):150-8
Detection of BCL-2 RNA in low grade tumours of the urinary bladder [letter] Gazzaniga P, et al.
Eur J Cancer 1995 Nov;31A(12):2119-20
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Riva C, et al.
Eur J Cancer B Oral Oncol 1995 Nov;31B(6):384-91
Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors [see comments] Kimura T, et al.
Eur J Endocrinol 1996 Mar;134(3):314-9. Comment in: Eur J Endocrinol 1996 Mar;134(3):263-6.
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Petersen AJ, et al. **Eur J Haematol** 1996 Apr;56(4):213-20
Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Chalupny NJ, et al.
Eur J Immunol 1995 Oct;25(10):2978-84
Human T lymphocyte activation induces tyrosine phosphorylation of alpha-tubulin and its association with the SH2 domain of the p59fyn protein tyrosine kinase. Marie-Cardine A, et al. **Eur J Immunol** 1995 Dec; 25(12):3290-7
The role of tyrosine phosphorylation in the interaction of cellular tyrosine kinases with the T cell receptor zeta chain tyrosine-based activation motif. Osman N, et al.
Eur J Immunol 1995 Oct;25(10):2863-9
Interleukin-7 activates p56lck and p59fyn, two tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T cells. Page TH, et al.
Eur J Immunol 1995 Oct;25(10):2956-60
Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Averill S, et al. **Eur J Neurosci** 1995 Jul 1; 7(7):1484-94
Biochemical analysis of murine Wnt proteins reveals both shared and distinct properties. Burrus LW, et al.
Exp Cell Res 1995 Oct;220(2):363-73
Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Zhai S, et al. **Exp Cell Res** 1996 May 1;224(2):335-43
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. Bonati A, et al.
Exp Hematol 1996 Feb;24(3):459-65
Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11. Fuhrer DK, et al.
Exp Hematol 1996 Feb;24(2):195-203
Stromal cells regulate bcl-2 and bax expression in pro-B cells. Gibson LF, et al. **Exp Hematol** 1996 Apr;24(5):628-37
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Salgia R, et al. **Exp Hematol** 1996 Feb; 24(2):310-3
Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product. Uddin S, et al. **Exp Hematol** 1996 Apr;24(5):622-7
Altered brain fyn kinase in a murine acquired immunodeficiency syndrome. Sei Y, et al. **FASEB J** 1996 Feb;10(2):339-44
Does Vav bind to F-actin through a CH domain? Castresana J, et al. **FEBS Lett** 1995 Oct 30;374(2):149-51
Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. Hane M, et al. **FEBS Lett** 1995 Oct 16;

373(3):265–8
Specific association of phosphatidylinositol 3–kinase with the protooncogene product Cbl in Fc gamma receptor signaling. Matsuo T, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):11–4
Unfarnesylated transforming Ras mutant inhibits the Ras–signaling pathway by forming a stable Ras.Raf complex in the cytosol. Miyake M, et al. **FEBS Lett** 1996 Jan 2;378(1):15–8
Conformational changes upon binding of a receptor loop to lipid structures: possible role in signal transduction. Pertinhez TA, et al. **FEBS Lett** 1995 Nov 20;375(3):239–42
Specific neurotrophin binding to leucine–rich motif peptides of TrkA and TrkB. Windisch JM, et al. **FEBS Lett** 1995 Oct 23;374(1):125–9
Differential regulation of Raf isozymes by growth versus differentiation inducing factors in PC12 pheochromocytoma cells. Wixler V, et al. **FEBS Lett** 1996 May 6;385(3):131–7
Activation of SRC family kinases in human neutrophils. Evidence that p58C–FGR and p53/56LYN redistributed to a Triton X–100–insoluble cytoskeletal fraction, also enriched in the caveolar protein caveolin, display an enhanced kinase activity. Yan SR, et al. **FEBS Lett** 1996 Feb 12;380(1–2):198–203
Analysis of the hepatocyte growth factor receptor in regeneration and oncogenesis of the liver. Annen K, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):179–86
Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein. Hellyer NJ, et al. **Gene** 1995 Nov 20;165(2):279–84
Coordinate activation of c–Src by SH3– and SH2–binding sites on a novel p130Cas–related protein, Sin. Alexandropoulos K, et al. **Genes Dev** 1996 Jun 1; 10(11):1341–55
fyn tyrosine kinase is involved in keratinocyte differentiation control. Calautti E, et al. **Genes Dev** 1995 Sep 15; 9(18):2279–91
CBP as a transcriptional coactivator of c–Myb. Dai P, et al. **Genes Dev** 1996 Mar 1;10(5):528–40
The EVES motif mediates both intermolecular and intramolecular regulation of c–Myb. Dash AB, et al. **Genes Dev** 1996 Aug 1;10(15):1858–69
The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53–inducible and death–promoting Bax protein. Han J, et al. **Genes Dev** 1996 Feb 15;10(4):461–77
p150Ship, a signal transduction molecule with inositol polyphosphate–5–phosphatase activity. Lioubin MN, et al. **Genes Dev** 1996 May 1;10(9):1084–95
Rel/NF–kappa B/I kappa B family: intimate tales of association and dissociation. Verma IM, et al. **Genes Dev** 1995 Nov 15;9(22):2723–35 (114 ref.)
Colocalisation of vascular endothelial growth factor and its Flt–1 receptor in human placenta. Ahmed A, et al. **Growth Factors** 1995;12(3):235–43
Mitotic count, nuclear atypia, and immunohistochemical determination of Ki–67, c–myc, p21–ras, c–erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki–67 are indicators of poor prognosis. King LA, et al. **Gynecol Oncol** 1996 May;61(2):227–32
p53 overexpression and bcl–2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes [see comments] Zheng W, et al. **Gynecol Oncol** 1996 May;61(2):167–74. Comment in: Gynecol Oncol 1996 May;61(2):163–5.
Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Tanizawa S, et al. **Heart** 1996 Jun;75(6):549–56
PU. 1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Olson MC, et al. **Immunity** 1995 Dec;3(6):703–14
A novel anti–Thy–1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T–lymphoma cells in spite of inducing bcl–2 expression. Fujita N, et al. **Int J Cancer** 1996 May 16;66(4):544–50
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl–2 oncoprotein. Sangfelt O, et al. **Int J Cancer** 1995 Oct 9; 63(2):190–2
Differential structural requirements for interaction of Ras protein with its distinct downstream effectors. Akasaka K, et al. **J Biol Chem** 1996 Mar 8;271(10):5353–60
Fas–induced activation of the cell death–related protease CPP32 Is inhibited by Bcl–2 and by ICE family protease inhibitors. Armstrong RC, et al. **J Biol Chem** 1996 Jul 12; 271(28):16850–5
Critical role for lysines 21 and 22 in signal–induced, ubiquitin–mediated proteolysis of I kappa B–alpha. Baldi L, et al. **J Biol Chem** 1996 Jan 5;271(1):376–9
The mouse B–raf gene encodes multiple protein isoforms with tissue–specific expression. Barnier JV, et al. **J Biol Chem** 1995 Oct 6;270(40):23381–9
The proto–oncogene product c–Crk associates with insulin receptor substrate–1 and 4PS. Modulation by insulin growth factor–I (IGF) and enhanced IGF–I signaling Beitner–Johnson D, et al. **J Biol Chem** 1996 Apr 19; 271(16):9287–90
Identification of signal–induced IkappaB–alpha kinases in human endothelial cells. Bennett BL, et al. **J Biol Chem** 1996 Aug 16;271(33):19680–8
Insulin activates nuclear factor kappa B in mammalian cells through a Raf–1–mediated pathway. Bertrand F, et al. **J Biol Chem** 1995 Oct 13;270(41):24435–41
Evidence that the pertussis toxin–sensitive trimeric GTP–binding protein Gi2 is required for agonist– and store–activated Ca2+ inflow in hepatocytes. Berven LA, et al. **J Biol Chem** 1995 Oct 27;270(43):25893–7
Phosphatidylinositol–3'kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase. Beslu N, et al. **J Biol Chem** 1996 Aug 16;271(33):20075–81
Hypertrophic agonists stimulate the activities of the protein kinases c–Raf and A–Raf in cultured ventricular myocytes. Bogoyevitch MA, et al. **J Biol Chem** 1995 Nov 3; 270(44):26303–10
Interactions of Cbl with two adapter proteins, ?Grb2 and Crk, upon T cell activation. Buday L, et al. **J Biol Chem** 1996 Mar 15;271(11):6159–63
Transphosphorylation of the neurotrophin Trk receptors. Canossa M, et al. **J Biol Chem** 1996 Mar 8;271(10):5812–8
Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes. Carver RS, et al. **J Biol Chem** 1996 Jun 7;271(23):13491–6
Activity of the distal positive element of the peripherin gene is dependent on proteins binding to an Ets–like recognition site and a novel inverted repeat site. Chang L, et al. **J Biol Chem** 1996 Mar 15;271(11):6467–75
Phosphorylation of Bcl–2 protein and association with p21Ras in Ras–induced apoptosis. Chen CY, et al. **J Biol Chem** 1996 Feb 2;271(5):2376–9
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB–3 and ErbB–4. Chen X, et al. **J Biol Chem** 1996 Mar 29; 271(13):7620–9
The vascular endothelial growth factor receptor Flt–1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. Clauss M, et al. **J Biol Chem** 1996 Jul 26; 271(30):17629–34
TrkA mediates the nerve growth factor–induced intracellular calcium accumulation. De Bernardi MA, et al. **J Biol Chem** 1996 Mar 15;271(11):6092–8
Nerve growth factor–induced growth arrest and induction of p21Cip1/WAF1 in NIH–3T3 cells expressing TrkA. Decker SJ. **J Biol Chem** 1995 Dec 29;270(52):30841–4
Inactivation of raf–1 by a protein–tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits. Dent P, et al. **J Biol Chem** 1996 Feb 9; 271(6):3119–23
Ras interaction with two distinct binding domains in Raf–1 may be required for Ras transformation. Drugan JK, et al. **J Biol Chem** 1996 Jan 5;271(1):233–7
Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl–xL. Erhardt P, et al. **J Biol Chem** 1996 Jul 26;271(30):17601–4
Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. Fukazawa T, et al. **J Biol Chem** 1996 Jun 14;271(24):14554–9
Equilibrium and kinetic measurements reveal rapidly reversible binding of Ras to Raf. Gorman C, et al. **J Biol Chem** 1996 Mar 22;271(12):6713–9
Interleukin–1beta and glutamate activate the NF–kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. Grilli M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15002–7
Lipopolysaccharide induction of THP–1 cells activates binding of c–Jun, Ets, and Egr–1 to the tissue factor promoter. Groupp ER, et al. **J Biol Chem** 1996 May 24; 271(21):12423–30
Formation of c–Cbl.phosphatidylinositol 3–kinase complexes on lymphocyte membranes by a p56lck–independent mechanism. Hartley D, et al. **J Biol Chem** 1996 Sep 6; 271(36):21939–43
Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. Hashimoto Y, et al. **J Biol Chem** 1995 Oct 13; 270(41):24532–9
Differential interaction of the ras family GTP–binding proteins H–Ras, Rap1A, and R–Ras with the putative effector molecules Raf kinase and Ral–guanine nucleotide exchange factor. Herrmann C, et al. **J Biol Chem** 1996 Mar 22;271(12):6794–800
Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. Horan T, et al. **J Biol Chem** 1995 Oct 13;270(41):24604–8
Cysteine–rich region of Raf–1 interacts with activator domain of post–translationally modified Ha–Ras. Hu CD, et al. **J Biol Chem** 1995 Dec 22;270(51):30274–7
Interactions between the protein–tyrosine kinase ZAP–70, the proto–oncoprotein Vav, and tubulin in Jurkat T cells. Huby RD, et al. **J Biol Chem** 1995 Dec 22;270(51):30241–4
Characterization of IkappaB kinases. IkappaB–alpha is not phosphorylated by Raf–1 or protein kinase C isozymes, but is a casein kinase II substrate. Janosch P, et al. **J Biol Chem** 1996 Jun 7;271(23):13868–74
Identification of vascular endothelial growth factor determinants for binding KDR and FLT–1 receptors. Generation of receptor–selective VEGF variants by site–directed mutagenesis. Keyt BA, et al. **J Biol Chem** 1996 Mar 8;271(10):5638–46
Regulation of interaction of ras p21 with RalGDS and Raf–1 by cyclic AMP–dependent protein kinase. Kikuchi A, et al. **J Biol Chem** 1996 Jan 5;271(1):588–94
Association of activated phosphatidylinositol 3–kinase with p120cbl in antigen receptor–ligated B cells. Kim TJ, et al. **J Biol Chem** 1995 Nov 17;270(46):27504–9
Role of the Raf/mitogen–activated protein kinase pathway in p21ras desensitization. Klarlund JK, et al. **J Biol Chem** 1996 Jul 12;271(28):16674–7
Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. Kohn AD, et al. **J Biol Chem** 1996 Sep 6;271(36):21920–6
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells. Kon–Kozlowski M, et al. **J Biol Chem** 1996 Feb 16;271(7):3856–62
Tyrosine phosphorylation of the c–cbl proto–oncogene product mediated by cell surface antigen CD38 in HL–60 cells. Kontani K, et al. **J Biol Chem** 1996 Jan 19; 271(3):1534–7
Different effects of various phospholipids on Ki–Ras–, Ha–Ras–, and Rap1B–induced B–Raf activation. Kuroda S, et al. **J Biol Chem** 1996 Jun 21;271(25):14680–3
Raf–1 is activated during mitosis. Laird AD, et al. **J Biol Chem** 1995 Nov 10;270(45):26742–5
Oncogenic Raf–1 activates p70 S6 kinase via a mitogen–activated protein kinase–independent pathway. Lenormand P, et al. **J Biol Chem** 1996 Jun 28; 271(26):15762–8
Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. Liu X, et al. **J Biol Chem** 1996 Mar 8; 271(10):5309–12
Activation–modulated association of 14–3–3 proteins with Cbl in T cells. Liu YC, et al. **J Biol Chem** 1996 Jun 14; 271(24):14591–5
Identification of the 14.3.3 zeta domains important for self–association and Raf binding. Luo ZJ, et al. **J Biol Chem** 1995 Oct 6;270(40):23681–7
Receptor binding and mitogenic properties of mouse fibroblast growth factor 3. Modulation of response by heparin. Mathieu M, et al. **J Biol Chem** 1995 Oct 13; 270(41):24197–203
Interaction between the amino–terminal SH3 domain of CRK and its natural target proteins. Matsuda M, et al. **J Biol Chem** 1996 Jun 14;271(24):14468–72
Coupling of the proto–oncogene product c–Cbl to the epidermal growth factor receptor. Meisner H, et al. **J Biol Chem** 1995 Oct 27;270(43):25332–5
Interaction between c–Rel and the mitogen–activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation. Meyer CF, et al. **J Biol Chem** 1996 Apr 12;271(15):8971–6
Overexpression of the Bcl–2 protein increases the half–life of p21Bax. Miyashita T, et al. **J Biol Chem** 1995 Nov 3; 270(44):26049–52
Inhibition of Ras/Raf interaction by anti–oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell–free systems. Mori S, et al. **J Biol Chem** 1995 Dec 1;270(48):28834–8
Activation of brain B–Raf protein kinase by Rap1B small GTP–binding protein. Ohtsuka T, et al. **J Biol Chem** 1996 Jan 19;271(3):1258–61
Post–translational modification of H–Ras is required for activation of, but not for association with, B–Raf. Okada T, et al. **J Biol Chem** 1996 Mar 1;271(9):4671–8
Regulation of the human P–selectin promoter by Bcl–3 and specific homodimeric members of the NF–kappa B/Rel family. Pan J, et al. **J Biol Chem** 1995 Sep 29; 270(39):23077–83
Direct association between the Ret receptor tyrosine kinase and the Src homology 2–containing adapter protein Grb7. Pandey A, et al. **J Biol Chem** 1996 May 3;271(18):10607–10
A role for Shc, Grb2, and Raf–1 in FcgammaRI signal relay. Park RK, et al. **J Biol Chem** 1996 Jun 7;271(23):13342–8
Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G. Reedquist KA, et al. **J Biol Chem** 1996 Apr 5;271(14):8435–42
The epidermal growth factor receptor couples transforming growth factor–alpha, heparin–binding epidermal growth factor–like factor, and amphiregulin to Neu, ErbB–3, and ErbB–4. Riese DJ, et al. **J Biol Chem** 1996 Aug 16; 271(33):20047–52
Autophosphorylation of the Fes tyrosine kinase. Evidence for an intermolecular mechanism involving two kinase domain tyrosine residues. Rogers JA, et al. **J Biol Chem** 1996 Jul 19;271(29):17519–25
Binding of neurotrophin–3 to p75LNGFR, TrkA, and TrkB mediated by a single functional epitope distinct from that recognized by trkC. Rydén M, et al. **J Biol Chem** 1996 Mar 8;271(10):5623–7
Selective activation of c–Jun kinase mitogen–activated protein kinase by CD40 on human B cells. Sakata N, et al. **J Biol Chem** 1995 Dec 22;270(51):30823–8
Disruption of the Raf–1–Hsp90 molecular complex results in destabilization of Raf–1 and loss of Raf–1–Ras association. Schulte TW, et al. **J Biol Chem** 1995 Oct 13; 270(41):24585–8
Differential utilization of Trk autophosphorylation sites. Segal RA, et al. **J Biol Chem** 1996 Aug 16;271(33):20175–81
Cardiac myotrophin exhibits rel/NF–kappa B interacting activity in vitro. Sivasubramanian N, et al. **J Biol Chem** 1996 Feb 2;271(5):2812–6

Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-L adaptors. Smit L, et al. **J Biol Chem** 1996 Apr 12;271(15):8564-9

p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. Soltoff SP, et al. **J Biol Chem** 1996 Jan 5;271(1):563-7

The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. Sun XJ, et al. **J Biol Chem** 1996 May 3;271(18):10583-7

Heterodimeric neurotrophins induce phosphorylation of Trk receptors and promote neuronal differentiation in PC12 cells. Treanor JJ, et al. **J Biol Chem** 1995 Sep 29; 270(39):23104-10

c-Cbl is transiently tyrosine-phosphorylated, ubiquitinated, and membrane-targeted following CSF-1 stimulation of macrophages. Wang Y, et al. **J Biol Chem** 1996 Jan 5; 271(1):17-20

Nerve growth factor binding site on TrkA mapped to a single 24-amino acid leucine-rich motif. Windisch JM, et al. **J Biol Chem** 1995 Nov 24;270(47):28133-8

JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. Winston LA, et al. **J Biol Chem** 1995 Dec 29;270(52):30837-40

Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. Wu X, et al. **J Biol Chem** 1996 Feb 9;271(6):3265-71

Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. Zha H, et al. **J Biol Chem** 1996 Mar 29;271(13):7440-4

Determination of the NMR solution structure of a specific DNA complex of the Myb DNA-binding domain. Morikawa S, et al. **J Biomol NMR** 1995 Nov;6(3):294-305

TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. Cabrera N, et al. **J Cell Biol** 1996 Feb;132(3):427-36

Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. Grimm S, et al. **J Cell Biol** 1996 Jul;134(1):13-23

Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. Lin KI, et al. **J Cell Biol** 1995 Dec;131(5):1149-61

Bcl-2 inhibits retinoic acid-induced apoptosis during the neural differentiation of embryonal stem cells. Okazawa H, et al. **J Cell Biol** 1996 Mar;132(5):955-68

An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling. Orsulic S, et al. **J Cell Biol** 1996 Sep;134(5):1283-300

The neurotrophin receptor, gp75, forms a complex with the receptor tyrosine kinase TrkA. Ross AH, et al. **J Cell Biol** 1996 Mar;132(5):945-53

Multiple features of the p59fyn src homology 4 domain define a motif for immune-receptor tyrosine-based activation motif (ITAM) binding and for plasma membrane localization. Timson Gauen LK, et al. **J Cell Biol** 1996 Jun;133(5):1007-15

Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor. Yasunaga M, et al. **J Cell Biol** 1996 Jan;132(1-2):91-9

1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. Zhou X, et al. **J Clin Invest** 1996 Aug 15;98(4):937-44

Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. Puglisi F, et al. **J Clin Pathol** 1996 Jun;49(6):456-9

Mdm-2 is not induced by p53 in human keratinocytes in vivo. Burden AD, et al. **J Cutan Pathol** 1996 Feb;23(1):25-9

Association of tyrosine protein kinase Zap-70 with the protooncogene product p120c-cbl in T lymphocytes. Fournel M, et al. **J Exp Med** 1996 Jan 1;183(1):301-6

Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. Grillot DA, et al. **J Exp Med** 1995 Dec 1;182(6):1973-83

T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. Guan E, et al. **J Exp Med** 1996 May 1;183(5):2025-32

Physical and functional association of the cbl protooncogen product with an src-family protein tyrosine kinase, p53/56lyn, in the B cell antigen receptor-mediated signaling. Tezuka T, et al. **J Exp Med** 1996 Feb 1; 183(2):675-80

Anti-immunoglobulin M activates nuclear calcium/calmodulin-dependent protein kinase II in human B lymphocytes. Valentine MA, et al. **J Exp Med** 1995 Dec 1;182(6):1943-9

Tyrosine-phosphorylated Cbl binds to Crk after T cell activation. Sawasdikosol S, et al. **J Immunol** 1996 Jul 1; 157(1):110-6

Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. Roles of protein tyrosine kinases in the signal for IL-2 and IL-4 production. Tamura T, et al. **J Immunol** 1995 Nov 15;155(10):4692-701

Differential regulation of c-Rel translocation in activated B and T cells. Venkataraman L, et al. **J Immunol** 1996 Aug 1;157(3):1149-55

IL-4-dependent proliferation of BA/F3 cells expressing a growth-negative mutant of the human IL-4 receptor is restored by enforced expression of Bcl-2. Chung J, et al. **J Leukoc Biol** 1996 Apr;59(4):586-90

Tumor necrosis factor triggers redistribution to a Triton X-100-insoluble, cytoskeletal fraction of beta 2 integrins, NADPH oxidase components, tyrosine phosphorylated proteins, and the protein tyrosine kinase p58fgr in human neutrophils adherent to fibrinogen. Yan SR, et al. **J Leukoc Biol** 1995 Nov;58(5):595-606

Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. Ellerby LM, et al. **J Neurochem** 1996 Sep;67(3):1259-67

The F3 neuronal glycosylphosphatidylinositol-linked molecule is localized to glycolipid-enriched membrane subdomains and interacts with L1 and fyn kinase in cerebellum. Olive S, et al. **J Neurochem** 1995 Nov; 65(5):2307-17

Upregulation of bax protein levels in neurons following cerebral ischemia. Krajewski S, et al. **J Neurosci** 1995 Oct; 15(10):6364-76

Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. Sagot Y, et al. **J Neurosci** 1995 Nov;15(11):7727-33

Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. Chan WK, et al. **J Pathol** 1995 Nov;177(3):241-6

Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. Flohil CC, et al. **J Pathol** 1996 Apr;178(4):393-7

Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. Furihata M, et al. **J Pathol** 1996 Feb;178(2):133-9

Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. Jiang SX, et al. **J Pathol** 1995 Oct; 177(2):135-8

Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. Kaklamanis L, et al. **J Pathol** 1996 May;179(1):10-4

Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. Lipponen P, et al. **J Pathol** 1995 Sep; 177(1):49-55

MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. Martinez JC, et al. **J Pathol** 1995 Sep; 177(1):27-34

Expression of bcl-2 oncoprotein in renal cell tumours. Paraf F, et al. **J Pathol** 1995 Nov;177(3):247-52

BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. Pittaluga S, et al. **J Pathol** 1996 Jun;179(2):145-50

BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. Ter Harmsel B, et al. **J Pathol** 1996 May; 179(1):26-30

Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. Glick SH, et al. **J Urol** 1996 May;155(5):1754-7

Regulation of avian leukosis virus long terminal repeat-enhanced transcription by C/EBP-Rel interactions. Bowers WJ, et al. **J Virol** 1996 May;70(5):3051-9

Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. Chirillo P, et al. **J Virol** 1996 Jan;70(1):641-6

Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. Flory E, et al. **J Virol** 1996 Apr;70(4):2260-8

The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B. Folgueira L, et al. **J Virol** 1996 Apr;70(4):2332-8

ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. Fuks F, et al. **J Virol** 1996 Mar;70(3):1331-9

Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of I kappa B beta. Good L, et al. **J Virol** 1996 May;70(5):2730-5

bcl-2 alters influenza virus yield, spread, and hemagglutinin glycosylation. Olsen CW, et al. **J Virol** 1996 Jan;70(1):663-6

PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms. Rottjakob EM, et al. **J Virol** 1996 May; 70(5):3176-88

Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. Su F, et al. **J Virol** 1996 Jul; 70(7):4558-66

c-Cbl is inducibly tyrosine-phosphorylated by epidermal growth factor stimulation in fibroblasts, and constitutively tyrosine-phosphorylated and associated with v-Src in v-src-transformed fibroblasts. Odai H, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1119-26

Expression of Fas antigen and Bcl-2 in human glomerulonephritis. Takemura T, et al. **Kidney Int** 1995 Dec;48(6):1886-92

c-myb intron I protein binding and association with transcriptional activity in leukemic cells. Dooley S, et al. **Leuk Res** 1996 May;20(5):429-39

Retinoid-regulated expression of BCL-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells. Nagy L, et al. **Leuk Res** 1996 Jun;20(6):499-505

A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation? Reed JC. **Leuk Res** 1996 Feb;20(2):109-11

DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells. Britos-Bray M, et al. **Leukemia** 1996 Jun; 10(6):984-90

Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. Quentmeier H, et al. **Leukemia** 1996 Feb;10(2):297-310

The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation. Rasko JE, et al. **Leukemia** 1995 Dec;9(12):2058-66

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Robertson LE, et al. **Leukemia** 1996 Mar; 10(3):456-9

Expression of bcl-2 mRNA and protein in leukemia-lymphoma cell lines. Steube KG, et al. **Leukemia** 1995 Nov;9(11):1841-6

c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. Wisniewski D, et al. **Leukemia** 1996 Sep;10(9):1436-42

Hox gene products modulate the DNA binding activity of Pbx1 and Pbx2. van Dijk MA, et al. **Mech Dev** 1995 Jul; 52(1):99-108

Ras-Raf complexes: analyses of complexes formed in vivo. Finney R, et al. **Methods Enzymol** 1995;255:310-23 (24 ref.)

Interaction of ect2 and Dbl with Rho-related GTPases. Miki T. **Methods Enzymol** 1995;256:90-8

Activation of Raf-1 by Ras in intact cells. Morrison DK. **Methods Enzymol** 1995;255:301-10

Ras-Raf interaction: two-hybrid analysis. Vojtek AB, et al. **Methods Enzymol** 1995;255:331-42

Ras-Raf complexes in vitro. Zhang XF, et al. **Methods Enzymol** 1995;255:323-31

Differential effects on cAMP on the MAP kinase cascade: evidence for a cAMP-insensitive step that can bypass Raf-1. Faure M, et al. **Mol Biol Cell** 1995 Aug;6(8):1025-35

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Beerli RR, et al. **Mol Cell Biol** 1995 Dec; 15(12):6496-505

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Borrello MG, et al. **Mol Cell Biol** 1996 May;16(5):2151-63

Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Caamaño JH, et al. **Mol Cell Biol** 1996 Apr;16(4):1342-8

A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Catling AD, et al. **Mol Cell Biol** 1995 Oct;15(10):5214-25

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Chen J, et al. **Mol Cell Biol** 1996 May;16(5):2445-52

A central role for a single c-Myb binding site in a thymic locus control region. Ess KC, et al. **Mol Cell Biol** 1995 Oct;15(10):5707-15

Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Gille H, et al. **Mol Cell Biol** 1996 Mar;16(3):1094-102

Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Hobert O, et al. **Mol Cell Biol** 1996 Jun;16(6):3066-73

Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Jelinek T, et al. **Mol Cell Biol** 1996 Mar; 16(3):1027-34

Characterization of the cooperative function of inhibitory sequences in Ets-1. Jonsen MD, et al. **Mol Cell Biol** 1996 May;16(5):2065-73

The pentapeptide motif of Hox proteins is required for cooperative DNA binding with Pbx1, physically contacts Pbx1, and enhances DNA binding by Pbx1. Knoepfler PS, et al. **Mol Cell Biol** 1995 Oct;15(10):5811-9

Structural determinants within Pbx1 that mediate cooperative DNA binding with pentapeptide-containing Hox proteins: proposal for a model of a Pbx1-Hox-DNA complex. Lu Q, et al. **Mol Cell Biol** 1996 Apr;16(4):1632-40

Regulation of Raf-1-dependent signaling during early Xenopus development. MacNicol AM, et al. **Mol Cell Biol** 1995 Dec;15(12):6686-93

Precise alignment of sites required for mu enhancer activation in B cells. Nikolajczyk BS, et al. **Mol Cell Biol** 1996 Aug; 16(8):4544-54

Casein kinase II phosphorylation site mutations in c-Myb affect DNA binding and transcriptional cooperativity with NF-M. Oelgeschläger M, et al. **Mol Cell Biol** 1995 Nov; 15(11):5966-74

Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Papkoff J, et al. **Mol Cell Biol** 1996 May;16(5):2128-34

The pancreatic islet factor STF-1 binds cooperatively with Pbx to a regulatory element in the somatostatin promoter:

importance of the FPWMK motif and of the homeodomain. Peers B, et al. **Mol Cell Biol** 1995 Dec;15(12):7091-7

Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Pritchard CA, et al. **Mol Cell Biol** 1995 Nov;15(11):6430-42

The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Ribon V, et al. **Mol Cell Biol** 1996 Jan;16(1):45-52

p95vav associates with the nuclear protein Ku-70. Romero F, et al. **Mol Cell Biol** 1996 Jan;16(1):37-44

Determinants of DNA-binding specificity of ETS-domain transcription factors. Shore P, et al. **Mol Cell Biol** 1996 Jul;16(7):3338-49

Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Yang BS, et al. **Mol Cell Biol** 1996 Feb; 16(2):538-47

Pheromone signalling in Saccharomyces cerevisiae requires the small GTP-binding protein Cdc42p and its activator CDC24. Zhao ZS, et al. **Mol Cell Biol** 1995 Oct; 15(10):5246-57

Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities. Kawauchi K, et al. **Mol Immunol** 1996 Feb;33(3):287-96

Regulation of the leukocyte integrin gene CD11c is mediated by AP1 and Ets transcription factors. Noti JD, et al. **Mol Immunol** 1996 Feb;33(2):115-27

Increase in the specific activity of p50csk in proliferating T cells correlates with decreased specific activity of p56lck and p59fyn and reduced phosphorylation of CD3 subunits. Orchansky PL, et al. **Mol Immunol** 1996 Apr;33(6):531-40

Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493-9 (24 ref.)

Mechanisms regulating Raf-1 activity in signal transduction pathways. Morrison DK. **Mol Reprod Dev** 1995 Dec; 42(4):507-14 (27 ref.)

Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Block C, et al. **Nat Struct Biol** 1996 Mar;3(3):244-51

The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Grzesiek S, et al. **Nat Struct Biol** 1996 Apr;3(4):340-5

Ras/Rap effector specificity determined by charge reversal [see comments] Nassar N, et al. **Nat Struct Biol** 1996 Aug; 3(8):723-9. Comment in: Nat Struct Biol 1996 Aug;3(8):653-9.

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Cross DA, et al. **Nature** 1995 Dec 21-28;378(6559):785-9

Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development. Danielian PS, et al. **Nature** 1996 Sep 26;383(6598):332-4

GDNF signalling through the Ret receptor tyrosine kinase [see comments] Durbec P, et al. **Nature** 1996 Jun 27; 381(6585):789-93. Comment in: Nature 1996 Jul 4;382(6586):29-30.

Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization [see comments] Farrar MA, et al. **Nature** 1996 Sep 12;383(6596):178-81. Comment in: Nature 1996 Sep 12;383(6596):127-8.

Oligomerization activates c-Raf-1 through a Ras-dependent mechanism [see comments] Luo Z, et al. **Nature** 1996 Sep 12;383(6596):181-5. Comment in: Nature 1996 Sep 12;383(6596):181-5.

Cell signalling. Raf gets it together [news; comment] Marshall CJ. **Nature** 1996 Sep 12;383(6596):127-8. Comment on: Nature 1996 Sep 12;383(6596):178-81. Comment on: Nature 1996 Sep 12;383(6596):181-5.

Neurotrophic factors. Crossing receptor boundaries [news; comment] Massagué J. **Nature** 1996 Jul 4;382(6586):29-30 . Comment on: Nature 1996 Jun 27;381(6585):785-8. Comment on: Nature 1996 Jun 27;381(6585):789-93. Comment on: Nature 1996 Jul 4;382(6586):80-3.

Characterization of a multicomponent receptor for GDNF [see comments] Treanor JJ, et al. **Nature** 1996 Jul 4; 382(6586):80-3. Comment in: Nature 1996 Jul 4;382(6585):29-30.

Phosphorylation of Raf by ceramide-activated protein kinase. Yao B, et al. **Nature** 1995 Nov 16;378(6554):307-10

Binding site analysis of c-Myb: screening of potential binding sites by using the mutation matrix derived from systematic binding affinity measurements. Deng QL, et al. **Nucleic Acids Res** 1996 Feb 15;24(4):766-74

Pbx-1 Hox heterodimers bind DNA on inseparable half-sites that permit intrinsic DNA binding specificity of the Hox partner at nucleotides 3' to a TAAT motif. Knoepfler PS, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2288-94

Elk-1 can recruit SRF to form a ternary complex upon the serum response element. Latinkić BV, et al. **Nucleic Acids Res** 1996 Apr 1;24(7):1345-51

Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Shen WF, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):898-906

The ETS-domain transcription factors Elk-1 and SAP-1 exhibit differential DNA binding specificities. Shore P, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4698-706

The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Andoniou CE, et al. **Oncogene** 1996 May 2;12(9):1981-9

Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Boulakia CA, et al. **Oncogene** 1996 Feb 1;12(3):529-35

The protein product of the c-cbl oncogene rapidly complexes with the EGF receptor and is tyrosine phosphorylated following EGF stimulation. Bowtell DD, et al. **Oncogene** 1995 Oct 19;11(8):1561-7

A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Ellis C, et al. **Oncogene** 1996 Apr 18;12(8):1727-36

30 KDa phosphorylated form of Bcl-2 protein in human colon. Guan RJ, et al. **Oncogene** 1996 Jun 20;12(12):2605-9

SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. Hobert O, et al. **Oncogene** 1996 Apr 4;12(7):1577-81

Interaction of ETS-1 and ERGB/FLI-1 proteins with DNA is modulated by spacing between multiple binding sites as well as phosphorylation. Hodge DR, et al. **Oncogene** 1996 Jan 4;12(1):11-8

Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Ishino M, et al. **Oncogene** 1995 Dec 7;11(11):2331-8

Regulation of A-raf expression. Lee JE, et al. **Oncogene** 1996 Apr 18;12(8):1669-77

Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Levkowitz G, et al. **Oncogene** 1996 Mar 7;12(5):1117-25

Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells. Li W, et al. **Oncogene** 1996 Aug 15;13(4):731-7

Activation of Mil/Raf protein kinases in mitotic cells. Lovrić J, et al. **Oncogene** 1996 Mar 7;12(5):1109-16

Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein. Lovrić J, et al. **Oncogene** 1996 Mar 7; 12(5):1145-51

Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Momand J, et al. **Oncogene** 1996 Jun 6;12(11):2279-89

Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Papin C, et al. **Oncogene** 1996 May 16;12(10):2213-21

Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis. Rabault B, et al. **Oncogene** 1996 Aug 15;13(4):877-81

The proline-rich region of Vav binds to Grb2 and Grb3-3. Ramos-Morales F, et al. **Oncogene** 1995 Oct 19; 11(8):1665-9

Regulation of c-Myb through protein phosphorylation and leucine zipper interactions. Ramsay RG, et al. **Oncogene** 1995 Nov 16;11(10):2113-20

Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Rommel C, et al. **Oncogene** 1996 Feb 1;12(3):609-19

Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Sastry KJ, et al. **Oncogene** 1996 Aug 1;13(3):487-93

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Sattler M, et al. **Oncogene** 1996 Feb 15; 12(4):839-46

Properties of Wnt-1 protein that enable cell surface association. Schryver B, et al. **Oncogene** 1996 Jul 18; 13(2):333-42

The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase. Sunitha I, et al. **Oncogene** 1996 Aug 1;13(3):547-59

Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Thomas A, et al. **Oncogene** 1996 Mar 7;12(5):1055-62

Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes. Tobin D, et al. **Oncogene** 1996 Feb 15;12(4):785-93

Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC-gamma 1 but excludes P130CAS. Torres M, et al. **Oncogene** 1996 Jan 4;12(1):77-86

ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction. Venanzoni MC, et al. **Oncogene** 1996 Mar 21; 12(6):1199-1204

Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Viglietto G, et al. **Oncogene** 1995 Oct 19; 11(8):1569-79

The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression. Zheng S, et al. **Oncogene** 1996 Feb 1;12(3):555-62

Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Yan JJ, et al. **Oncology** 1996 Jan-Feb; 53(1):6-11

Correlation between the number of apoptotic cells and expression of the apoptosis-related antigens Fas, Le(y) and bcl-2 protein in non-Hodgkin's lymphomas. Aftabuddin M, et al. **Pathol Int** 1995 Jun;45(6):422-9

Expression of bcl-2 oncogene product in primary non-Hodgkin's malignant lymphoma of the oral cavity. Takahashi H, et al. **Pathol Res Pract** 1996 Jan;192(1):44-53

BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Chang CC, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6947-52

Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia. Granelli-Piperno A, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10944-8

Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Huwiler A, et al. **Proc Natl Acad Sci U S A** 1996 Jul. 9;93(14):6959-63

Catalytic activity of the mouse guanine nucleotide exchanger mSOS is activated by Fyn tyrosine protein kinase and the T-cell antigen receptor in T cells. Li B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1001-5

Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Linette GP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9545-52

The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis. Melotti P, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5313-8

The hexapeptide LFPWMR in Hoxb-8 is required for cooperative DNA binding with Pbx1 and Pbx2 proteins. Neuteboom ST, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9166-70

Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Scherer DC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11259-63

Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Strack PR, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9571-6

Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Wang HG, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7063-8

Involvement of Ras/Raf/AP-1 in BMP-4 signaling during Xenopus embryonic development. Xu RH, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):834-8

Activation of the protein kinase A increases the DNA-binding and transcriptional activity of c-Rel in T cells. Lahdenpohja N, et al. **Scand J Immunol** 1996 Jun; 43(6):640-5

Interaction between Wingless and Notch signaling pathways mediated by dishevelled [see comments] Axelrod JD, et al. **Science** 1996 Mar 29;271(5257):1826-32. Comment in: Science 1996 Mar 29;271(5257):1822-3.

Notch and Wingless signals collide [see comments] Blair SS. **Science** 1996 Mar 29;271(5257):1822-3 (16 ref.). Comment in: Science 1996 Mar 29;271(5257):1826-32.

Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Desbois C, et al. **Science** 1996 Aug 16;273(5277):951-3

Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Joneson T, et al. **Science** 1996 Feb 9;271(5250):810-2

Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix. Petersen JM, et al. **Science** 1995 Sep 29;269(5232):1866-9

Developmental biology. Receptor for vital protein finally found [news] Roush W. **Science** 1996 Jul 19;273(5273):309

A target for phosphoinositide 3-kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441-2 (11 ref.)

p75 and Trk: a two-receptor system. Chao MV, et al. **Trends Neurosci** 1995 Jul;18(7):321-6 (61 ref.)

Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR. Harhaj E, et al. **Virology** 1996 Feb 1;216(1):284-7

[Analysis of Fas and bcl-2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451-5 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Sjögren's syndrome as a lymphoaggressive disorder; bcl-2 expression in lymphocytes infiltrated in salivary glands] Takeshita S, et al. **Nippon Rinsho** 1995 Oct;53(10):2440-5 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Montrucchio G, et al. **Blood** 1996 Apr 1;87(7):2762-8

Effects of fibroblast growth factor-4 (k-FGF) on long-term cultures of human bone marrow cells. Quito FL, et al. **Blood** 1996 Feb 15;87(4):1282-91

Recombinant human c-Mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. Ito T, et al. **Br J Haematol** 1996 Aug;94(2):387-90

Activity of the ligand for c-mpl, thrombopoietin, in early haemopoiesis. Itoh R, et al. **Br J Haematol** 1996 Aug; 94(2):228-35

A diphtheria toxin/fibroblast growth factor 6 mitotoxin selectively kills fibroblast growth factor receptor-expressing cell lines. Batoz M, et al. **Cell Growth Differ** 1995 Sep;6(9):1143-9

Apoptosis in the developing tooth: association with an

embryonic signaling center and suppression by EGF and FGF-4. Vaahtokari A, et al. **Development** 1996 Jan; 122(1):121-9

Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Ray RJ, et al. **Eur J Immunol** 1996 Jul; 26(7):1504-10

Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor-Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215-21

Induction of p53-independent apoptosis by hygromycin B: suppression by Bcl-2 and adenovirus E1B 19-kDa protein. Chen G, et al. **Exp Cell Res** 1995 Nov;221(1):55-9

FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells. Pizette S, et al. **Exp Cell Res** 1996 Apr 10;224(1):143-51

Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2. Messmer UK, et al. **FEBS Lett** 1996 Apr 15;384(2):162-6

FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Jouanneau J, et al. **Growth Factors** 1995; 12(1):37-47

Receptor binding and mitogenic properties of mouse fibroblast growth factor 3. Modulation of response by heparin. Mathieu M, et al. **J Biol Chem** 1995 Oct 13; 270(41):24197-203

Fibroblast growth factor receptors 1 and 2 are differentially regulated in murine embryonal carcinoma cells and in response to fibroblast growth factor-4. Ali J, et al. **J Cell Physiol** 1995 Nov;165(2):438-48

Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. Hsu S, et al. **J Cell Physiol** 1995 Nov;165(2):239-45

Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. Myers KM, et al. **J Neurochem** 1995 Dec;65(6):2432-40

In vivo effects of kFGF on embryonic nigral grafts in a rat model of Parkinson's disease. Haque NS, et al. **Neuroreport** 1995 Nov 13;6(16):2177-81

Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. Wang H, et al. **Oncogene** 1996 Jul 18;13(2):373-9

Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Murphy AN, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9893-8

PHYSIOLOGY

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281-316 (141 ref.)

Mechanisms of NK recognition and activation based on lectin-saccharide interactions. Pospisil M, et al. **Adv Exp Med Biol** 1995;371A:307-11

Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice. Nagata M, et al. **Am J Pathol** 1996 May;148(5):1601-11

Upregulation of Bcl-2 protein in the myasthenic thymus. Onodera J, et al. **Ann Neurol** 1996 Apr;39(4):521-8

BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells. Neumann M, et al. **Anticancer Res** 1996 May-Jun;16(3A):1075-83

An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. George SJ, et al. **Atherosclerosis** 1996 Feb;120(1-2):227-40

Transcriptional activation of the chicken lysozyme gene by NF-kappa Bp65 (RelA) and c-Rel, but not by NF-kappa Bp50. Phi van L. **Biochem J** 1996 Jan 1;313 (Pt 1):39-44

prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Smyth MJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):25-8

Rel signalling pathway and the melanotic tumour phenotype of Drosophila. Govind S. **Biochem Soc Trans** 1996 Feb; 24(1):39-44 (44 ref.)

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Barleon B, et al. **Blood** 1996 Apr 15;87(8):3336-43

Hematologic effects of flt3 ligand in vivo in mice. Brasel K, et al. **Blood** 1996 Sep 15;88(6):2004-12

Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Broudy VC, et al. **Blood** 1996 Sep 15;88(6):2026-32

Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Deveaux S, et al. **Blood** 1996 Jun 1;87(11):4678-85

p59fyn-p125FAK cooperation in development of CD4+CD8+ thymocytes. Kanazawa S, et al. **Blood** 1996 Feb 1;87(3):865-70

Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. Melotti P, et al. **Blood** 1996 Mar 15; 87(6):2221-34

p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Oda A, et al. **Blood** 1996 Aug 15;88(4):1330-8

Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Onishi M, et al. **Blood** 1996 Aug 15;88(4):1399-406

Suppression of apoptosis during cytokine deprivation of 32D cells is not sufficient to induce complete granulocytic differentiation. Rodel JE, et al. **Blood** 1996 Feb 1; 87(3):858-64

Inhibition of erythro-myeloid differentiation by constitutive expression of a DNA binding-deficient c-myb mutant: implication for c-myb function. Sala A, et al. **Blood** 1995 Nov 1;86(9):3404-12

Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Silva M, et al. **Blood** 1996 Sep 1;88(5):1576-82

Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Tuscano JM, et al. **Blood** 1996 Aug 15;88(4):1359-64

Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Veiby OP, et al. **Blood** 1996 Aug 15;88(4):1256-65

Molecular thanatopsis: a discourse on the BCL2 family and cell death. Yang E, et al. **Blood** 1996 Jul 15;88(2):386-401 (150 ref.)

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437-45 (131 ref.)

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. McLeskey SW, et al. **Br J Cancer** 1996 May; 73(9):1053-62

Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential. Papayannopoulou T. **Cancer Chemother Pharmacol** 1996;38 Suppl:S69-73 (32 ref.)

Taxol induction of p21WAF1 and p53 requires c-raf-1. Blagosklonny MV, et al. **Cancer Res** 1995 Oct 15; 55(20):4623-6

bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. D'Sa-Eipper C, et al. **Cancer Res** 1996 Sep 1; 56(17):3879-82

The oncogene qin codes for a transcriptional repressor. Li J, et al. **Cancer Res** 1995 Dec 1;55(23):5540-4

Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Lock RB, et al. **Cancer Res** 1996 Sep 1;56(17):4006-12

Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Løvmo J, et al. **Cancer Res** 1996 Jan 1;56(1):40-3

Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells. Okazaki M, et al. **Cancer Res** 1996 May 15;56(10):2387-92

Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Potapova O, et al. **Cancer Res** 1996 Jan 15;56(2):280-6

Integrin signaling to NF-kappa B in monocytic leukemia cells is blocked by activated oncogenes. Rosales C, et al. **Cancer Res** 1996 May 15;56(10):2302-5

bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Upadhyay S, et al. **Cancer Res** 1995 Oct 15;55(20):4520-4

BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Yin DX, et al. **Cancer Res** 1995 Nov 1; 55(21):4922-8

Complementary and mutually exclusive activities of decapentaplegic and wingless organize axial patterning during Drosophila leg development. Jiang J, et al. **Cell** 1996 Aug 9;86(3):401-9

Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513-6 (19 ref.)

JUN cooperates with the ETS domain protein pointed to induce photoreceptor R7 fate in the Drosophila eye. Treier M, et al. **Cell** 1995 Dec 1;83(5):753-60

Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. D'Alessio A, et al. **Cell Growth Differ** 1995 Nov;6(11):1387-94

Bcl-2 and thermotolerance cooperate in cell survival. Strasser A, et al. **Cell Growth Differ** 1995 Jul;6(7):799-805

Inhibition of apoptosis and augmentation of lymphoproliferation in bcl-2 transgenic Fas/Fas ligand-defective mice. Tamura A, et al. **Cell Immunol** 1996 Mar 15;168(2):220-8

Control of p53-dependent apoptosis by E1B, Bcl-2, and Ha-ras proteins. White E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:395-402

Apoptosis. A sticky business. Häcker G, et al. **Curr Biol** 1995 Jun 1;5(6):622-4 (26 ref.)

Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541-6 (57 ref.)

Structure and function of the proteins encoded by the myb gene family. Kanei-Ishii C, et al. **Curr Top Microbiol Immunol** 1996;211:89-98 (51 ref.)

The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43-53 (25 ref.)

Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Subramanian T, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):153-61 (52 ref.)

The activity of D-raf in torso signal transduction is altered by serine substitution, N-terminal deletion, and membrane targeting. Baek KH, et al. **Dev Biol** 1996 May 1; 175(2):191-204

beta-Catenin has Wnt-like activity and mimics the Nieuwkoop signaling center in Xenopus dorsal-ventral patterning. Guger KA, et al. **Dev Biol** 1995 Nov; 172(1):115-25

The role of FGF-3 in early inner ear development: an analysis in normal and kreisler mutant mice. McKay IJ, et al. **Dev Biol** 1996 Mar 15;174(2):370-8

Cell fates in the adult abdomen of Drosophila are determined by wingless during pupal development. Shirras AD, et al. **Dev Biol** 1996 Apr 10;175(1):24-36

Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Breier G, et al. **Dev Dyn** 1995 Nov;204(3):228-39

Involvement of wnt1 and pax2 in the formation of the midbrain-hindbrain boundary in the zebrafish gastrula. Kelly GM, et al. **Dev Genet** 1995;17(2):129-40

The SH2-containing tyrosine phosphatase corkscrew is required during signaling by sevenless, Ras1 and Raf. Allard JD, et al. **Development** 1996 Apr;122(4):1137-46

The roles of hedgehog, wingless and lines in patterning the dorsal epidermis in Drosophila. Bokor P, et al. **Development** 1996 Apr;122(4):1083-92

Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl-2 in spermatogonia. Furuchi T, et al. **Development** 1996 Jun;122(6):1703-9

Alterations in somite patterning of Myf-5-deficient mice: a possible role for FGF-4 and FGF-6. Grass S, et al. **Development** 1996 Jan;122(1):141-50

Bax promotes neuronal survival and antagonises the survival effects of neurotrophic factors. Middleton G, et al. **Development** 1996 Feb;122(2):695-701

Distinct mitogenic and cell fate specification functions of wingless in different regions of the wing. Neumann CJ, et al. **Development** 1996 Jun;122(6):1781-9

Renal agenesis and hypodysplasia in ret-k- mutant mice result from defects in ureteric bud development. Schuchardt A, et al. **Development** 1996 Jun;122(6):1919-29

Myogenesis in paraxial mesoderm: preferential induction by dorsal neural tube and by cells expressing Wnt-1. Stern HM, et al. **Development** 1995 Nov;121(11):3675-86

decapentaplegic, a target gene of the wingless signalling pathway in the Drosophila midgut. Yu X, et al. **Development** 1996 Mar;122(3):849-58

Conditional inhibition of erythroid differentiation by c-Myb/oestrogen receptor fusion proteins. Lyon JJ, et al. **Differentiation** 1995 Oct;59(3):171-8

ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. Altiok N, et al. **EMBO J** 1995 Sep 1;14(17):4258-66

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Pinkas-Kramarski R, et al. **EMBO J** 1996 May 15;15(10):2452-67

Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. Strasser A, et al. **EMBO J** 1995 Dec 15;14(24):6136-47

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Wallasch C, et al. **EMBO J** 1995 Sep 1;14(17):4267-75

A role for trkA nerve growth factor receptors in mammalian ovulation. Dissen GA, et al. **Endocrinology** 1996 Jan; 137(1):198-209

Bcl-2 delays macrophage engulfment of human B cells induced to undergo apoptosis. Flora PK, et al. **Eur J Immunol** 1996 Sep;26(9):2243-7

Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140trk. Melamed I, et al. **Eur J Immunol** 1996 Sep;26(9):1985-92

Role of Bcl-2 in the brain-derived neurotrophic factor survival response. Allsopp TE, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1266-72

TrkA tyrosine residues involved in NGF-induced neurite outgrowth of PC12 cells. Inagaki N, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1125-33

The neurotrophin receptors TrkA and TrkB are inhibitory for neurite outgrowth. Tannahill L, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1424-8

Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Hjertson M, et al. **Exp Hematol** 1996 May;24(6):748-54

Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae. Greenhalf W, et al. **FEBS Lett** 1996 Feb 12;380(1-2):169-75

Activin A-induced apoptosis is suppressed by BCL-2. Koseki T, et al. **FEBS Lett** 1995 Dec 4;376(3):247-50

TrkA mediates an NGF survival response in NGF-independent sensory neurons but not in parasympathetic neurons. Allsopp TE, et al. **Gene Ther** 1994;1 Suppl 1:S59

The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis.

Sonnenberg-Riethmacher E, et al. **Genes Dev** 1996 May 15;10(10):1184-93

bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102-10 (85 ref.)

Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2-4):356-62 (15 ref.)

Pleiotropic effects of Bcl-2 on transcription factors in T cells: potential role of NF-kappa B p50-p50 for the anti-apoptotic function of Bcl-2. Ivanov VN, et al. **Int Immunol** 1995 Nov;7(11):1709-20

Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Potapova O, et al. **Int J Cancer** 1996 May 29;66(5):669-77

Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Sakakura C, et al. **Int J Cancer** 1996 Jul 3;67(1):101-5

Control of axis formation in Xenopus by the NF-kappa B-I kappa B system. Tannahill D, et al. **Int J Dev Biol** 1995 Aug;39(4):549-58

Biology of flt3 ligand and receptor. Lyman SD. **Int J Hematol** 1995 Aug;62(2):63-73 (42 ref.)

Effects of human immunodeficiency virus type 1 infection on programmed cell death in the presence or absence of Bcl-2. Park IW, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):321-8

A physical interaction between the cell death protein Fas and the tyrosine kinase p59fynT. Atkinson EA, et al. **J Biol Chem** 1996 Mar 15;271(11):5968-71

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. Baulida J, et al. **J Biol Chem** 1996 Mar 1;271(9):5251-7

Diminished cell proliferation associated with the death-protective activity of Bcl-2. Borner C. **J Biol Chem** 1996 May 31;271(22):12695-8

Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. Galang CK, et al. **J Biol Chem** 1996 Apr 5;271(14):7992-8

A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis. Hunter JJ, et al. **J Biol Chem** 1996 Apr 12;271(15):8521-4

Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. McKenney DW, et al. **J Biol Chem** 1995 Oct 20;270(42):24949-54

Bcl-2 protects macrophages from nitric oxide-induced apoptosis. Messmer UK, et al. **J Biol Chem** 1996 Aug 16; 271(33):20192-7

Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). Minn AJ, et al. **J Biol Chem** 1996 Mar 15;271(11):6306-12

An additional form of rat Bcl-x, Bcl-xbeta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells. Shiraiwa N, et al. **J Biol Chem** 1996 May 31; 271(22):13258-65

Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. Lowell CA, et al. **J Cell Biol** 1996 May; 133(4):895-910

Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. Torres MA, et al. **J Cell Biol** 1996 Jun;133(5):1123-37

Association of BCL-2 with membrane hyperpolarization and radioresistance. Gilbert MS, et al. **J Cell Physiol** 1996 Jul; 168(1):114-22

Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the raf-1/MAP kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for an obligate autocrine mechanism promoting cell proliferation induced by G-protein-coupled receptor agonist. Molloy CJ, et al. **J Clin Invest** 1996 Mar 1;97(5):1173-83

The transcription factor PU.1 is involved in macrophage proliferation. Celada A, et al. **J Exp Med** 1996 Jul 1; 184(1):61-9

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545-56

Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas. Brown DM, et al. **J Immunol** 1996 Aug 15;157(4):1359-70

Physical and functional interactions of protein tyrosine kinases, p59fyn and ZAP-70, in T cell signaling. Fusaki N, et al. **J Immunol** 1996 Feb 15;156(4):1369-77

flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. Hunte BE, et al. **J Immunol** 1996 Jan 15;156(2):489-96

bcl-2 alters the antigen-driven selection of B cells in mukappa but not in mu-only Xid transgenic mice. Kenny JJ, et al. **J Immunol** 1996 Aug 1;157(3):1054-61

Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. Merino R, et al. **J Immunol** 1995 Oct 15;155(8):3830-8

pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1. Wingett D, et al. **J Immunol** 1996 Jan 15;156(2):549-57

Synchronous onset of NGF and TrkA survival dependence in developing dorsal root ganglia. White FA, et al. **J Neurosci** 1996 Aug 1;16(15):4662-72

Regulation of apoptosis by Bcl-2 and its related proteins: immunochemical challenges and therapeutic implications [editorial] Kernohan NM, et al. **J Pathol** 1996 May; 179(1):1-3

bcl-2 expression facilitates human immunodeficiency virus type-1 mediated cytopathic effects during acute spreading infections. Sandstrom PA, et al. **J Virol** 1996 Jul; 70(7):4617-22

VEGF-FLT1 receptor system: a new ligand-receptor system involved in normal and tumor angiogenesis. Birnbaum D. **Jpn J Cancer Res** 1995 Jul;86(7):inside cover

Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Mainou-Fowler T, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):301-8

Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Drexler HG, et al. **Leukemia** 1996 Sep;10(9):1405-21 (136 ref.)

Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Hedley DW, et al. **Leukemia** 1996 Jul;10(7):1143-9

Involvement of Wnt-1 in the formation of the mes/metencephalic boundary. Bally-Cuif L, et al. **Mech Dev** 1995 Sep;53(1):23-34

The Drosophila cubitus interruptus protein and its role in the wingless and hedgehog signal transduction pathways. Motzny CK, et al. **Mech Dev** 1995 Jul;52(1):137-50

Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. Erhardt P, et al. **Mol Cell Biol** 1995 Oct;15(10):5524-30

Amplification of MDM2 inhibits MyoD-mediated myogenesis. Fiddler TA, et al. **Mol Cell Biol** 1996 Sep; 16(9):5048-57

Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Han Z, et al. **Mol Cell Biol** 1995 Nov;15(11):5849-57

Activation of NF-kappaB/Rel by CD40 engagement induces the mouse germ line immunoglobulin Cgamma1 promoter. Lin SC, et al. **Mol Cell Biol** 1996 Sep;16(9):4591-603

C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Oelgeschläger M, et al. **Mol Cell Biol** 1996 Sep;16(9):4717-25

Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin. Porteu F, et al. **Mol Cell Biol** 1996 May; 16(5):2473-82

Constitutively active Gq-alpha stimulates prolactin promoter activity via a pathway involving Raf activity. Tian J, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):249-56

An Ets site in the whey acidic protein gene promoter mediates transcriptional activation in the mammary gland of pregnant mice but is dispensable during lactation. McKnight RA, et al. **Mol Endocrinol** 1995 Jun;9(6):717-24

The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule [see comments] McMahon SB, et al. **Nat Med** 1995 Aug;1(8):774-80. Comment in: Nat Med 1995 Aug;1(8):740-1.

Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Bories JC, et al. **Nature** 1995 Oct 19;377(6550):635-8

Bax-independent inhibition of apoptosis by Bcl-XL. Cheng EH, et al. **Nature** 1996 Feb 8;379(6565):554-6

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Jones SN, et al. **Nature** 1995 Nov 9; 378(6553):206-8

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Montes de Oca Luna R, et al. **Nature** 1995 Nov 9;378(6553):203-6

Defective activation and survival of T cells lacking the Ets-1 transcription factor. Muthusamy N, et al. **Nature** 1995 Oct 19;377(6550):639-42

Specification of the wing by localized expression of wingless protein. Ng M, et al. **Nature** 1996 May 23;381(6580):316-8

Decapentaplegic restricts the domain of wingless during Drosophila limb patterning. Penton A, et al. **Nature** 1996 Jul 11;382(6587):162-4

Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Sumarsono SH, et al. **Nature** 1996 Feb 8;379(6565):534-7

Role of BCL-2 in the survival and function of developing and mature sympathetic neurons. Greenlund LJ, et al. **Neuron** 1995 Sep;15(3):649-61

Postmigratory neural crest cells expressing c-RET display restricted developmental and proliferative capacities. Lo L, et al. **Neuron** 1995 Sep;15(3):527-39

Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Chen CY, et al. **Oncogene** 1995 Oct 19;11(8):1487-98

Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Crespo P, et al. **Oncogene** 1996 Aug 1; 13(3):455-60

The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo. Dhordain P, et al. **Oncogene** 1995 Dec 21;11(12):2689-97

Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion. Distelhorst CW, et al. **Oncogene** 1996 May 16; 12(10):2051-5

Enforced expression of full length c-Myb leads to density-dependent transformation of murine haemopoietic cells. Ferrao P, et al. **Oncogene** 1995 Oct 19;11(8):1631-8

Requirement of the ETS domain transcription factor D-ELG for egg chamber patterning and development during Drosophila oogenesis. Gajewski KM, et al. **Oncogene** 1995 Sep 21;11(6):1033-40

DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation. Kamps MP, et al. **Oncogene** 1996 Jan 4; 12(1):19-30

Impaired development of CD4+ CD8+ thymoyctes by csk-'knock-in' into fyn locus. Kanazawa S, et al. **Oncogene** 1996 Jul 4;13(1):199-204

A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Kaya M, et al. **Oncogene** 1996 Jan 18;12(2):221-7

HST-1/FGF-4 stimulates proliferation of megakaryocyte progenitors synergistically and promotes megakaryocyte maturation. Konishi H, et al. **Oncogene** 1996 Jul 4; 13(1):9-19

Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Marin MC, et al. **Oncogene** 1996 Jun 6;12(11):2259-66

The Wnt-1 proto-oncogene regulates MAP kinase activation by multiple growth factors in PC12 cells. Pan MG, et al. **Oncogene** 1995 Nov 16;11(10):2005-12

Mutations in the non-catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation. Rivero-Lezcano OM, et al. **Oncogene** 1995 Dec 21;11(12):2675-9

Bcl-XL protects cancer cells from p53-mediated apoptosis. Schott AF, et al. **Oncogene** 1995 Oct 5;11(7):1389-94

Transcriptional repression by the proto-oncogene BCL-6. Seyfert VL, et al. **Oncogene** 1996 Jun 6;12(11):2331-42

Activation of the retinoblastoma gene expression by Bcl-3: implication for muscle cell differentiation. Shiio Y, et al. **Oncogene** 1996 May 2;12(9):1837-45

Bcl-2 expression prevents activation of the ICE protease cascade. Shimizu S, et al. **Oncogene** 1996 Jun 6; 12(11):2251-7

Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Shimizu S, et al. **Oncogene** 1996 May 16; 12(10):2045-50

Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Shimizu S, et al. **Oncogene** 1996 Jul 4;13(1):21-9

Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. van Weering DH, et al. **Oncogene** 1995 Dec 7;11(11):2207-14

Synergism between two growth regulatory pathways: cooperative transformation of NIH3T3 cells by G alpha 12 and c-raf-1. Zhang Y, et al. **Oncogene** 1996 Jun 6; 12(11):2377-83

Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2. Zörnig M, et al. **Oncogene** 1996 Apr 18; 12(8):1789-801

A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Clarke MF, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11024-8

Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Ray SK, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2019-24

BCL2 regulates neural differentiation. Zhang KZ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4504-8

Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135-45 (143 ref.)

Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281-4 (30 ref.)

Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521-5 (43 ref.)

c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526-8 (15 ref.)

Bcl-2 family proteins: regulators of chemoresistance in cancer. Reed JC. **Toxicol Lett** 1995 Dec;82-83:155-8 (21 ref.)

The Bcl-2 family of proteins, and the regulation of neuronal survival. Davies AM. **Trends Neurosci** 1995 Aug; 18(8):355-8 (49 ref.)

[Bcl-2 with anti-apoptotic activity] Katsumata M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2062-73 (64 ref.) **(Jpn)**

[Regulation of apoptosis by products of the bcl-2 gene family] Miyawaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):127-35 (44 ref.) **(Jpn)**

RADIATION EFFECTS

Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Kitada S, et al. **Oncogene** 1996 Jan 4;12(1):187-92

SECRETION

Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues. Kiefer P, et al. **Oncogene** 1996 Apr 4; 12(7):1503–11

THERAPEUTIC USE

Effects of oxygen on wound responses to growth factors: Kaposi's FGF, but not basic FGF stimulates repair in ischemic wounds. Wu L, et al. **Growth Factors** 1995; 12(1):29–35

PROTO-ONCOGENE PROTEINS C-ABL

see related
FUSION PROTEINS, BCR-ABL

Abl tyrosine protein kinase. Laneuville P. **Semin Immunol** 1995 Aug;7(4):255–66 (95 ref.)

ANALYSIS

A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients. Testoni N, et al. **Blood** 1996 May 1;87(9):3822–7

ANTAGONISTS & INHIBITORS

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Druker BJ, et al. **Nat Med** 1996 May;2(5):561–6

GENETICS

Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression. Albrecht T, et al. **Ann Hematol** 1996 Feb;72(2):73–9

An activating mutation in the ATP binding site of the ABL kinase domain. Allen PB, et al. **J Biol Chem** 1996 Aug 9;271(32):19585–91

Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice. Hardin JD, et al. **Oncogene** 1996 Jun 20;12(12):2669–77

IMMUNOLOGY

Specific human cellular immunity to bcr-abl oncogene-derived peptides. Bocchia M, et al. **Blood** 1996 May 1;87(9):3587–92

METABOLISM

Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. Pisabarro MT, et al. **Biochemistry** 1996 Aug 20;35(33):10634–40

Nuclear tyrosine kinases: from Abl to WEE1. Pendergast AM. **Curr Opin Cell Biol** 1996 Apr;8(2):174–81 (46 ref.)

Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Dai Z, et al. **Genes Dev** 1995 Nov 1;9(21):2569–82

c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. Kharbanda S, et al. **J Biol Chem** 1995 Dec 22; 270(51):30278–81

Identification of a binding site in c-Abl tyrosine kinase for the C-terminal repeated domain of RNA polymerase II. Baskaran R, et al. **Mol Cell Biol** 1996 Jul;16(7):3361–9

Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Golub TR, et al. **Mol Cell Biol** 1996 Aug;16(8):4107–16

Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms. Welch PJ, et al. **Mol Cell Biol** 1995 Oct; 15(10):5542–51

Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Mysliwiec T, et al. **Oncogene** 1996 Feb 1; 12(3):631–40

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Sattler M, et al. **Oncogene** 1996 Feb 15; 12(4):839–46

Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe. Walkenhorst J, et al. **Oncogene** 1996 Apr 4;12(7):1513–20

p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues. Dikstein R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2387–91

The stress response to ionizing radiation involoves c-Abl-dependent phosphorylation of SHPTP1. Kharbanda S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):6898–901

PHARMACOLOGY

Growth inhibition by Abl requires an interplay of its SH2 and tyrosine kinase domains. Mattioni T, et al. **FEBS Lett** 1996 Jul 22;390(2):170–4

PHYSIOLOGY

Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Rosti V, et al. **Blood** 1995 Nov 1;86(9):3387–93

The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. Wen ST, et al. **EMBO J** 1996 Apr 1;15(7):1583–95

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545–56

PROTO-ONCOGENE PROTEINS C-ERBA see **RECEPTORS, THYROID HORMONE**

PROTO-ONCOGENE PROTEINS C-ERBB-1 see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

PROTO-ONCOGENE PROTEINS C-ERBB-2

HER-2/neu gene bumped into the limelight [news] Holzman D. **J Natl Cancer Inst** 1996 Feb 21;88(3-4):147–8

ANALYSIS

Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. Terrier P, et al. **Acta Oncol** 1996; 35(1):23–30

c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Costa MJ, et al. **Am J Clin Pathol** 1995 Dec;104(6):634–42

Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Nazeer T, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1829–34

Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. Sun XF, et al. **Anal Cell Pathol** 1995 Apr; 8(3):203–11

Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma. Weinstein GS, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):275–9

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Albanell J, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):1027–32

C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Giatromanolaki A, et al. **Anticancer Res** 1996 Mar-Apr;16(2):987–93

Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions. Goussia A, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2313–8

C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases. Kalogeraki A, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):765–71

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Molina R, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2295–300

Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Suo Z, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2797–8

c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Haapasalo H, et al. **Br J Cancer** 1996 Mar;73(5):620–3

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Pfeiffer P, et al. **Br J Cancer** 1996 Jul;74(1):86–91

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Soubeyran I, et al. **Br J Cancer** 1996 Mar; 73(6):735–43

The expression of c-erbB-2 protein in the keratinocytes of oral mucosal lichen planus. Kilpi A, et al. **Br J Dermatol** 1995 Dec;133(6):847–52

Identification of a 140 kDa protein of rat presynaptic terminal membranes encompassing the active zones. Stieber A, et al. **Brain Res** 1995 Nov 27;700(1-2):261–70

Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Iglehart JD, et al. **Breast Cancer Res Treat** 1995 Jun; 34(3):253–63

The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Quénel N, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):283–91

Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases. Costa MJ, et al. **Cancer** 1996 Feb 1; 77(3):533–42

Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Kristensen GB, et al. **Cancer** 1996 Aug 1;78(3):433–40

Application of quantitative analysis to biologic profile evaluation in breast cancer. Querzoli P, et al. **Cancer** 1995 Dec 15;76(12):2510–7

New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Roychowdhury DF, et al. **Cancer** 1996 Apr 15;77(8):1419–26

Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri. Sanfilippo JS, et al. **Cancer** 1996 Feb 15;77(4):710–6

The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):137–45

Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Kohlberger P, et al. **Cancer Lett** 1996 Jan 2;98(2):151–5

Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Robertson KW, et al. **Cancer Res** 1996 Aug 15;56(16):3823–30

ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Szöllösi J, et al. **Cancer Res** 1995 Nov 15; 55(22):5400–7

Quantitative measurement of c-erbB-2 p185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay. Mabrouk GM, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):981–2

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Stål O, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2185–90

Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Day JD, et al. **Hum Pathol** 1996 Feb; 27(2):119–24

Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Sun XF, et al. **Int J Cancer** 1996 Feb 20;69(1):5–8

Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Valerón PF, et al. **Int J Cancer** 1996 Jan 17;65(2):129–33

Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Haffty BG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):751–7

The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. Vogel W, et al. **J Cancer Res Clin Oncol** 1996;122(2):118–21

Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. Pupa SM, et al. **J Clin Oncol** 1996 Jan;14(1):85–94

Apocrine adenosis: a precursor of aggressive breast cancer? Wells CA, et al. **J Clin Pathol** 1995 Aug;48(8):737–42

Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. Chozick BS, et al. **J Neurooncol** 1996 Feb;27(2):117–26

EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. Meden H, et al. **J Obstet Gynaecol** 1995 Apr;21(2):167–78

Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Dabbs DJ. **Mod Pathol** 1995 Aug;8(6):637–42

Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Gorgoulis VG, et al. **Mod Pathol** 1995 Sep;8(7):758–64

Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Lee HR, et al. **Oncology** 1996 May-Jun;53(3):192–7

Combined analysis of expression of c-erbB-2, Ki-67 antigen, and tenascin provides a better prognostic indicator of carcinoma of the papilla of Vater. Vaidya P, et al. **Pancreas** 1996 Mar;12(2):196–201

Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Luna-Moré S, et al. **Pathol Res Pract** 1996 Jan;192(1):27–32

[Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies] Edorh A, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):584–9 (Eng. Abstr.) **(Fre)**

[C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer] Schönborn I, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):566–71 (Eng. Abstr.) **(Ger)**

[Study of the expression of proliferating cell nuclear antigen and p185 in non-small cell lung carcinoma] Alemany Monraval P, et al. **Arch Bronconeumol** 1996 Apr; 32(4):165–9 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.

Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113-28 (47 ref.)

Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Deshane J, et al. **Gene Ther** 1994 Sep;1(5):332-7

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. Schnur RC, et al. **J Med Chem** 1995 Sep 15; 38(19):3806-12

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. Schnur RC, et al. **J Med Chem** 1995 Sep 15; 38(19):3813-20

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor [see comments] Katsumata M, et al. **Nat Med** 1995 Jul;1(7):644-8. Comment in: Nat Med 1995 Jul;1(7):631-2.

BIOSYNTHESIS

Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. Tannapfel A, et al. **Anal Cell Pathol** 1996 Mar;10(2):149-60

NDF/heregulins stimulate expression of the erbB-2 tyrosine kinase growth factor receptor gene in human breast cancer cells. Maggiora P, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:443-7

Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Pavlidis N, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2563-7

nm23 expression in advanced and borderline ovarian carcinoma. Schneider J, et al. **Anticancer Res** 1996 May-Jun;16(3A):1197-202

Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Shintani S, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2623-6

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. DiGiovanna MP, et al. **Br J Cancer** 1996 Sep;74(5):802-6

Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice. Mehta RR, et al. **Br J Cancer** 1995 Nov;72(5):1160-4

Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Gu K, et al. **Cancer Lett** 1996 Feb 6; 99(2):185-9

Effects of sodium saccharin and linoleic acid on mRNA levels of Her2/neu and p53 in a human breast epithelial cell line. Ogretmen B, et al. **Cancer Lett** 1996 Apr 19;102(1-2):91-9

erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Ethier SP, et al. **Cancer Res** 1996 Feb 15;56(4):899-907

Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Tsai CM, et al. **Cancer Res** 1996 Mar 1;56(5):1068-74

Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Moscoso LM, et al. **Dev Biol** 1995 Nov; 172(1):158-69

Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina. Bermingham-McDonogh O, et al. **Development** 1996 May;122(5):1427-38

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Karunagaran D, et al. **EMBO J** 1996 Jan 15;15(2):254-64

Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Giunciuglio D, et al. **Int J Cancer** 1995 Dec 11;63(6):815-22

c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Wiechen K, et al. **Int J Cancer** 1995 Nov 15;63(4):604-8

p185neu is expressed in yolk sac during rat postimplantation development. Knezevic V, et al. **J Anat** 1994 Aug;185 (Pt 1):181-7

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. Zhang K, et al. **J Biol Chem** 1996 Feb 16;271(7):3884-90

Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas. Naundorf H, et al. **J Cancer Res Clin Oncol** 1996;122(1):14-20

Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Zhang L, et al. **Oncogene** 1996 Feb 1;12(3):571-6

An improved method for semiquantification of gene amplification from archival material. Underwood MA, et al. **PCR Methods Appl** 1994 Dec;4(3):178-84

[Expression of ras and erbB2 in benign and malignant lesions of the stomach] Zhao A, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):336-9 (Eng. Abstr.) **(Chi)**

BLOOD

Serial serum c-erbB-2 levels in patients with breast carcinoma. Volas GH, et al. **Cancer** 1996 Jul 15; 78(2):267-72

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Revillion F, et al. **Eur J Cancer** 1996 Feb;32A(2):231-4

The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. Vogel W, et al. **J Cancer Res Clin Oncol** 1996;122(2):118-21

The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Brandt-Rauf PW. **Mutat Res** 1995 Dec;333(1-2):203-8 (25 ref.)

[Increased serum level of c-erbB-2-coded protein p105 in patients with pre-eclampsia] Meden H, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:157-60 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Detailed description of an alpha helix-->pi bulge transition detected by molecular dynamics simulations of the p185c-erbB2 V659G transmembrane domain. Duneau JP, et al. **J Biomol Struct Dyn** 1996 Apr;13(5):753-69

Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Smith SO, et al. **Nat Struct Biol** 1996 Mar;3(3):252-8

DRUG EFFECTS

Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. Wärri AM, et al. **Eur J Cancer** 1996 Jan; 32A(1):134-40

The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. King CR, et al. **Semin Cancer Biol** 1996 Apr;7(2):79-86 (48 ref.)

GENETICS

Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. Terrier P, et al. **Acta Oncol** 1996; 35(1):23-30

Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Ahern TE, et al. **Am J Vet Res** 1996 May;57(5):693-6

NDF/heregulins stimulate expression of the erbB-2 tyrosine kinase growth factor receptor gene in human breast cancer cells. Maggiora P, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:443-7

p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. Xie Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):140-5

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Archer SG, et al. **Br J Cancer** 1995 Nov;72(5):1259-66

Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. Porumb H, et al. **Cancer Res** 1996 Feb 1;56(3):515-22

Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Tsai CM, et al. **Cancer Res** 1996 Jan 1;56(1):206-9

Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Sauter G, et al. **Cytometry** 1995 Sep 1;21(1):40-6

Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Wong YF, et al. **Gynecol Obstet Invest** 1995;40(3):209-12

Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Tanner B, et al. **Gynecol Oncol** 1996 Aug; 62(2):268-77

Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Wiener JR, et al. **Gynecol Oncol** 1996 May;61(2):233-40

c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Wiechen K, et al. **Int J Cancer** 1995 Nov 15;63(4):604-8

No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas [letter] Ménard S, et al. **J Natl Cancer Inst** 1996 Jul 17; 88(14):1002-3

HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. Wong YF, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):171-5

Gene therapy for HER-2-related cancer [news] Holzmann D. **Mol Med Today** 1996 Apr;2(4):138-9

Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Muthuswamy SK, et al. **Oncogene** 1995 Nov 2;11(9):1801-10

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Pauletti G, et al. **Oncogene** 1996 Jul 4;13(1):63-72

Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Yu D, et al. **Oncogene** 1995 Oct 5; 11(7):1383-8

[C-erbB-2, PCNA and histomorphologic factors in breast carcinoma after oral contraceptive use] Schönborn I, et al. **Pathologe** 1996 May;17(3):202-7 (Eng. Abstr.) **(Ger)**

[Amplification of protooncogenes and expression of the HER2/neu oncogene in invasive breast cancer] Ben-Aharon U, et al. **Harefuah** 1996 Jan 1;130(1):4-8, 72 (Eng. Abstr.) **(Heb)**

IMMUNOLOGY

neu/HER-2 cDNA vaccination and pregnancy loss. Venanzi FM, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:274-7

Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Kopreski MS, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):433-6

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Kita Y, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):59-69

Immunoselective cell growth inhibition by antibody-adriamycin conjugates targeting c-erbB-2 product on human cancer cells. Suzuki S, et al. **Biol Pharm Bull** 1995 Sep;18(9):1279-82

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202-10

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Tokuda Y, et al. **Br J Cancer** 1996 Jun;73(11):1362-5

Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Deshane J, et al. **Cancer Gene Ther** 1996 Mar-Apr;3(2):89-98

Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Taylor P, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):179-84

Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Tai MS, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5983s-5989s

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **Cancer Res** 1995 Oct 15;55(20):4586-93

Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Schier R, et al. **Gene** 1996 Mar 9;169(2):147-55

Targeted tumor killing via an intracellular antibody against erbB-2. Deshane J, et al. **J Clin Invest** 1995 Dec; 96(6):2980-9

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see comments] Baselga J, et al. **J Clin Oncol** 1996 Mar; 14(3):737-44. Comment in: J Clin Oncol 1996 Mar;14(3):697-9.

Should we treat HER, too? [editorial; comment] Hayes DF. **J Clin Oncol** 1996 Mar;14(3):697-9. Comment on: J Clin Oncol 1996 Mar;14(3):737-44.

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415-21 (26 ref.)

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. Valone FH, et al. **J Hematother** 1995 Oct; 4(5):471-5

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **J Hematother** 1995 Oct;4(5):453-6

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. Disis ML, et al. **J Immunol** 1996 May 1;156(9):3151-8

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. Schier R, et al. **J Mol Biol** 1996 Jan 12;255(1):28-43

Active tumor-specific immunization of the bone marrow (progenitor stem cell) donor [letter] Sinkovics JG. **J Natl Cancer Inst** 1995 Dec 6;87(23):1804

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides. McCartney JE, et al. **Protein Eng** 1995 Mar;8(3):301-14

ISOLATION & PURIFICATION

ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Onda M, et al. **Cancer** 1996 Jan 1;77(1):71-8

METABOLISM

Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Bacus SS, et al. **Am J Pathol** 1996 Feb;148(2):549-58

Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma. Midulla C, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):157-62

DNA ploidy, cell kinetics, and epidermal growth factor receptor and HER2/neu oncoprotein expression in primary operable breast cancer. d'Agnano I, et al.

Ann N Y Acad Sci 1996 Apr 30;784:472–81

Competitive reverse transcriptase–PCR: an improved method for determination of c-erbB–2 gene expression. Schneeberger C, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):849–52

Differential distribution of ErbB–2 and pS2 proteins in ductal carcinoma in situ of the breast. Inaji H, et al. **Breast Cancer Res Treat** 1996;37(1):89–92

Adenovirus E1a–mediated tumor suppression by a c–erbB–2/neu–independent mechanism. Frisch SM, et al. **Cancer Res** 1995 Dec 1;55(23):5551–5

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Lewis GD, et al. **Cancer Res** 1996 Mar 15;56(6):1457–65

Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy. Nakano T, et al. **Cancer Res** 1996 Jun 15;56(12):2771–5

Amplification and overexpression of HER–2/neu (c–erbB2) in endometrial cancers: correlation with overall survival. Saffari B, et al. **Cancer Res** 1995 Dec 1;55(23):5693–8

Cytotoxic effects of gemcitabine–containing regimens against human non–small cell lung cancer cell lines which express different levels of p185neu. Tsai CM, et al. **Cancer Res** 1996 Feb 15;56(4):794–801

Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase–inactive p185c–neu. Dougall WC, et al. **DNA Cell Biol** 1996 Jan;15(1):31–40

ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. Altiok N, et al. **EMBO J** 1995 Sep 1;14(17):4258–66

Heregulin–dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Wallasch C, et al. **EMBO J** 1995 Sep 1;14(17):4267–75

Interleukin–6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP–1. Neumann C, et al. **Eur J Immunol** 1996 Feb;26(2):379–84

Expression of retinoblastoma tumor suppressor gene protein, epidermal growth factor receptor, and c–erbB–2 oncoprotein in primary vaginal carcinomas. Skomedal H, et al. **Gynecol Oncol** 1995 Dec;59(3):379–83

Prognostic significance of p53 and c–erbB–2 immunohistochemical evaluation in colorectal adenocarcinoma. Lazaris AC, et al. **Histol Histopathol** 1995 Jul;10(3):661–8

p53 in breast cancer. Its relation to histological grade, lymph–node status, hormone receptors, cell–proliferation fraction (ki–67) and c–erbB–2. Immunohistochemical study of 153 cases. Sirvent JJ, et al. **Histol Histopathol** 1995 Jul; 10(3):531–9

Bidirectional interactions between the estrogen receptor and the cerbB–2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Grunt TW, et al. **Int J Cancer** 1995 Nov 15;63(4):560–7

Endometrial adenocarcinoma of endometrioid subtype with squamous differentiation: an immunohistochemical study of MIB–1 (ki–67 paraffin), cathepsin D, and C–erbB–2 protein (p185). Nielsen AL, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):230–4

Epidermal growth factor–related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. Beerli RR, et al. **J Biol Chem** 1996 Mar 15; 271(11):6071–6

p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. Chavany C, et al. **J Biol Chem** 1996 Mar 1;271(9):4974–7

Activated neu induces rapid tumor progression. Guy CT, et al. **J Biol Chem** 1996 Mar 29;271(13):7673–8

Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. Horan T, et al. **J Biol Chem** 1995 Oct 13;270(41):24604–8

Human cancer cells exhibit protein kinase C–dependent c–erbB–2 transmodulation that correlates with phosphatase sensitivity and kinase activity. Ouyang X, et al. **J Biol Chem** 1996 Sep 6;271(36):21786–92

The epidermal growth factor receptor couples transforming growth factor–alpha, heparin–binding epidermal growth factor–like factor, and amphiregulin to Neu, ErbB–3, and ErbB–4. Riese DJ, et al. **J Biol Chem** 1996 Aug 16; 271(33):20047–52

Dominant–negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation–activated rat HER–2/Neu. Xie Y, et al. **J Biol Chem** 1995 Dec 22;270(51):30717–24

Relationship of histologic grade, c–erbB–2 expression, and inflammatory infiltrate to prognosis in carcinoma of the breast [letter] Lee AH, et al. **J Clin Oncol** 1996 Aug; 14(8):2406–7

Overexpression of c–erbB–2 and p21 oncoproteins in human radiation–induced skin ulcers. Zhao P, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):21–3

Schwannoma–derived growth factor interacts with the epidermal growth factor receptor. Maher PA, et al. **J Neurochem** 1995 Oct;65(4):1895–8

Prognostic significance of the co–expression of p53 and c–erbB–2 proteins in breast cancer. Nakopoulou LL, et al. **J Pathol** 1996 May;179(1):31–8

Prognosis of breast cancer: evidence for interaction between c–erbB–2 overexpression and number of involved axillary lymph nodes. Mittra I, et al. **J Surg Oncol** 1995 Oct; 60(2):106–11

Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. Tetu B, et al. **J Urol** 1996 May;155(5):1784–8

Insulin–like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c–erbB–2 gene amplification and progressively elevated levels of tyrosine–phosphorylated p185erbB–2. Ram TG, et al. **Mol Carcinog** 1996 Mar;15(3):227–38

Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer. Lehrer S, et al. **Mt Sinai J Med** 1995 Nov;62(6):415–8

Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB–2 receptor. Smith SO, et al. **Nat Struct Biol** 1996 Mar;3(3):252–8

HER–2/c–erbB2 is phosphorylation by calmodulin–dependent protein kinaseII on a single site in the cytoplasmic tail at threonine–1172. Feinmesser RL, et al. **Oncogene** 1996 Jun 20;12(12):2725–30

Tyrosine phosphorylation at the membrane–microfilament interface: a p185neu–associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane– and microfilament–associated retroviral gag–like protein. Juang SH, et al. **Oncogene** 1996 Mar 7;12(5):1033–42

Tob, a novel protein that interacts with p185erbB2, is associated with anti–proliferative activity. Matsuda S, et al. **Oncogene** 1996 Feb 15;12(4):705–13

Activation of Src family kinases in Neu–induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Muthuswamy SK, et al. **Oncogene** 1995 Nov 2;11(9):1801–10

Structural analysis of p185c–neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Murali R, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6252–7

p53, erbB–2 and K–ras gene alterations are rare in spontaneous and plutonium–239–induced canine lung neoplasia. Tierney LA, et al. **Radiat Res** 1996 Feb; 145(2):181–7

Relationship between ERBB2 and E–cadherin expression in human breast cancer. Palacios J, et al. **Virchows Arch** 1995; 427(3):259–63

PHARMACOLOGY

Humoral and cellular responses raised against the human HER2 oncoprotein are cross–reactive with the homologous product of the new proto–oncogene, but do not protect rats against B104 tumors expressing mutated neu. Taylor P, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):179–84

Changes in an HER–2 peptide upregulating HLA–A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor–specific CTL induction. Fisk B, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):197–209

PHYSIOLOGY

Involvement of heregulin–beta2 in the acquisition of the hormone–independent phenotype of breast cancer cells. Tang CK, et al. **Cancer Res** 1996 Jul 15;56(14):3350–8

Unexpected transcriptional signals in normal and mitotically defective cells mediated through cytokine and growth factor receptors. Samanta A, et al. **DNA Cell Biol** 1995 Nov;14(11):921–30

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. Baulida J, et al. **J Biol Chem** 1996 Mar 1;271(9):5251–7

Oncogenic Neu/ErbB–2 increases ets, AP–1, and NF–kappaB–dependent gene expression, and inhibiting ets activation blocks Neu–mediated cellular transformation. Galang CK, et al. **J Biol Chem** 1996 Apr 5;271(14):7992–8

Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C–terminal autophosphorylation sites. Sasaoka T, et al. **J Biol Chem** 1996 Apr 5; 271(14):8338–44

Requirement for neuregulin receptor erbB2 in neural and cardiac development [see comments] Lee KF, et al. **Nature** 1995 Nov 23;378(6555):394–8. Comment in: Nature 1995 Nov 23;378(6555):334–5.

Analysis of protein–protein interactions involved in the activation of the Shc/Grb–2 pathway by the ErbB–2 kinase. Ricci A, et al. **Oncogene** 1995 Oct 19;11(8):1519–29

PROTO-ONCOGENE PROTEINS C-FOS

see related

TRANSCRIPTION FACTOR AP–1

ANALYSIS

Cellular colocalization of Fos and neuropeptide Y in the intergeniculate leaflet after nonphotic phase–shifting events. Janik D, et al. **Brain Res** 1995 Nov 6; 698(1–2):137–45

The hypothalamic paraventricular nucleus in two types of Wistar rats with different stress responses. II. Differential Fos–expression. Mulders WH, et al. **Brain Res** 1995 Aug 14;689(1):61–70

Differences in Fos expression in the rat brains between cold and warm ambient exposures. Kiyohara T, et al. **Brain Res Bull** 1995;38(2):193–201

Developmental changes in the inducibility of fos–like immunoreactivity in primary embryonic spinal cord cultures. von Agoston D, et al. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):173–86

A method to study changes in eye–related columns in the visual cortex of kittens during and following early periods of monocular deprivation. Mitchell DE, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1352–63

Overexpressions of c–fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Morishita S, et al. **Cancer Lett** 1995 Nov 6; 97(2):225–31

Cyclophosphamide cystitis as a model of visceral pain in rats. A survey of hindbrain structures involved in visceroception and nociception using the expression of c–Fos and Krox–24 proteins. Bon K, et al. **Exp Brain Res** 1996 Mar; 108(3):404–16

Altered c–fos in rostral medulla and spinal cord of spontaneously hypertensive rats. Minson J, et al. **Hypertension** 1996 Mar;27(3 Pt 1):433–41

Medial preoptic area afferents to periaqueductal gray medullo–output neurons: a combined Fos and tract tracing study. Rizvi TA, et al. **J Neurosci** 1996 Jan;16(1):333–44

Functional classification of antidepressants based on antagonism of swim stress–induced fos–like immunoreactivity. Duncan GE, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1076–89

Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: an analysis of formalin–evoked C–fos expression. Gogas KR, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):801–9

Early hypothalamic activation of combined Fos and CRH41 immunoreactivity and of CRH41 release in push–pull cannulated rats after systemic endotoxin challenge. Givalois L, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):171–86

Deafness–induced plasticity in the mature central auditory system. Bledsoe SC Jr, et al. **Neuroreport** 1995 Dec 29; 7(1):225–9

c–fos Expression in the rat brain after unilateral labyrinthectomy and its relation to the uncompensated and compensated stages. Cirelli C, et al. **Neuroscience** 1996 Jan; 70(2):515–46

Differential expression of the fos and jun family members c–fos, fosB, Fra–1, Fra–2, c–jun, junB and junD during human epidermal keratinocyte differentiation. Welter JF, et al. **Oncogene** 1995 Dec 21;11(12):2681–7

BIOSYNTHESIS

c–Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

Interleukin–11 induces tyrosine phosphorylation, and c–jun and c–fos mRNA expression in human K562 and U937 cells. Adunyah SE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:296–9

Differences between rapid and longer–term actions of angiotensin II in isolated rat hepatocytes. Effects on phosphorylase a activity and c–fos expression. García–Sáinz JA, et al. **Arch Med Res** 1995;26 Spec No:S189–93

Nuclear matrix condensation and c–myc and c–fos expression are specifically altered in culture rat hepatocytes after exposure to cyproterone acetate and phenobarbital. Duivenvoorden WC, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):598–605

Sustained c–fos expression is associated with excitotoxicity during the development of neuronal cells in vitro. Meredith C, et al. **Biochem Soc Trans** 1996 Feb;24(1):6S

Cellular pattern of c–fos induction by estradiol in the immature rat uterus. Boettger–Tong HL, et al. **Biol Reprod** 1995 Dec;53(6):1398–406

c–fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May–Jun; 4(3):117–23 (25 ref.)

Canine bone marrow cell cultures infected with canine distemper virus: an in vitro model of Paget's disease. Mee AP, et al. **Bone** 1995 Oct;17(4 Suppl):461S–466S

Remembrance of times past: the significance of c–fos in pain [editorial; comment] Munglani R, et al. **Br J Anaesth** 1996 Jan;76(1):1–4. Comment on: Br J Anaesth 1996 Jan;76(1):99–105.

Nitrous oxide or halothane, or both, fail to suppress c–fos expression in rat spinal cord dorsal horn neurones after subcutaneous formalin [see comments] Sun WZ, et al. **Br J Anaesth** 1996 Jan;76(1):99–105. Comment in: Br J Anaesth 1996 Jan;76(1):1–4.

The contribution of NMDA receptor activation to spinal c–Fos expression in a model of inflammatory pain. Chapman V, et al. **Br J Pharmacol** 1995 Sep;116(1):1628–34

Attenuation by valproate of c–fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Cutrer FM, et al. **Br J Pharmacol** 1995 Dec; 116(8):3199–204

Substance P receptor regulates the photic induction of

Fos-like protein in the suprachiasmatic nucleus of Syrian hamsters. Abe H, et al. **Brain Res** 1996 Feb 5; 708(1-2):135-42

c-fos expression in specific rat brain nuclei after intestinal anaphylaxis: involvement of 5-HT3 receptors and vagal afferent fibers. Castex N, et al. **Brain Res** 1995 Aug 7; 688(1-2):149-60

7-Nitro-indazole, a selective inhibitor of neuronal nitric oxide synthase, reduces formalin evoked c-Fos expression in dorsal horn neurons of the rat spinal cord. Chapman V, et al. **Brain Res** 1995 Oct 30;697(1-2):258-61

Non-photic manipulations induce expression of Fos protein in the suprachiasmatic nucleus and intergeniculate leaflet in the rat. Edelstein K, et al. **Brain Res** 1995 Sep 4; 690(2):254-8

Dissociation of Fos-like immunoreactivity in lamina terminalis and magnocellular hypothalamic nuclei induced by hypernatremia. Han L, et al. **Brain Res** 1996 Feb 5; 708(1-2):45-9

A learned odor evokes an enhanced Fos-like glomerular response in the olfactory bulb of young rats. Johnson BA, et al. **Brain Res** 1995 Nov 20;699(2):192-200

Effects of MK801 on Fos expression in the rat brainstem after unilateral labyrinthectomy. Kitahara T, et al. **Brain Res** 1995 Nov 27;700(1-2):182-90

Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors. Liste I, et al. **Brain Res** 1995 Nov 27;700(1-2):1-12

Expression of c-fos and c-jun in rat retina following protracted illumination. Mallo G, et al. **Brain Res** 1995 Sep 25;693(1-2):196-200

Induction of c-fos protein by patterned visual stimulation in central visual pathways of the rat. Montero VM, et al. **Brain Res** 1995 Sep 4;690(2):189-99

Hypovolaemic and osmotic stimuli induce distinct patterns of c-Fos expression in the rat subfornical organ. Smith DW, et al. **Brain Res** 1995 Nov 6;698(1-2):232-6

Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Tassorelli C, et al. **Brain Res** 1995 Jun 5;682(1-2):167-81

C-Fos-like immunoreactivity in the cat brainstem evoked by sneeze-inducing air puff stimulation of the nasal mucosa. Wallois F, et al. **Brain Res** 1995 Jul 31;687(1-2):143-54

Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Wan W, et al. **Brain Res** 1995 Aug 7; 688(1-2):95-104

Nitric oxide synthase inhibitor blocks light-induced phase shifts of the circadian activity rhythm, but not c-fos expression in the suprachiasmatic nucleus of the Syrian hamster. Weber ET, et al. **Brain Res** 1995 Sep 18; 692(1-2):137-42

Distribution of Fos-positive neurons in cortical and subcortical structures after picrotoxin-induced convulsions varies with seizure type. Willoughby JO, et al. **Brain Res** 1995 Jun 12;683(1):73-87

Induction of Fos protein in a model of closed head injury in rats. Woodside B, et al. **Brain Res** 1995 Aug 28; 690(1):48-54

Neuropeptide Y injection into the fourth cerebroventricle stimulates c-Fos expression in the paraventricular nucleus and other nuclei in the forebrain: effect of food consumption. Xu B, et al. **Brain Res** 1995 Nov 6; 698(1-2):227-31

Roles of dopamine D1 receptors in striatal fos protein induction associated with methamphetamine behavioral sensitization in rats. Yoshida H, et al. **Brain Res Bull** 1995; 38(4):393-7

Induction of PGH synthase and c-fos mRNA during early reperfusion of ischemic rat brain. Holtz ML, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):339-43

Müller and retinal pigment epithelial (RPE) cell expression of NGFI-A and c-fos mRNA in response to medium conditioned by the RPE. Jaynes CD, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):329-37

Expression of c-fos and hsp70 mRNA after traumatic brain injury in transgenic mice overexpressing CuZn-superoxide dismutase. Mikawa S, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):288-94

Central glucoprivation evoked by administration of 2-deoxy-D-glucose induces expression of the c-fos gene in a subpopulation of neuropeptide Y neurons in the rat hypothalamus. Minami S, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):305-10

Caffeine-induced expression of c-fos mRNA and NGFI-A mRNA in caudate putamen and in nucleus accumbens are differentially affected by the N-methyl-D-aspartate receptor antagonist MK-801. Svenningsson P, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):183-9

Altered expression of cyclins and c-fos in R6 cells that overproduce PKC epsilon. Han EK, et al. **Carcinogenesis** 1995 Oct;16(10):2423-8

c-fos mRNA is present in axons of the hypothalamo-neurohypophysial system of the rat. Skutella T, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Sep; 41(6):793-8

Effects of various types of extracellular matrices on adhesion, proliferation, differentiation, and c-fos protein expression of porcine thyroid follicle cells. Toda S, et al. **Cell Struct Funct** 1995 Oct;20(5):345-54

Connectivity between brainstem autonomic structures and expression of c-fos following electrical stimulation of the central nucleus of the amygdala in rat. Petrov T, et al. **Cell Tissue Res** 1996 Mar;283(3):367-74

Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Merchant KM, et al. **Cereb Cortex** 1996 Jul-Aug; 6(4):561-70

Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists. Tomitaka S, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):207-11

Peripheral injection of arginine8-vasopressin increases Fos in specific brain areas. Wu PH, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):263-9

Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins. Lantéri-Minet M, et al. **Exp Brain Res** 1995;105(2):220-32

Expression of c-fos and c-jun proteins and AP-1 binding activity during cell cycle progression of HL60 cells and phytohemagglutinin-stimulated lymphocytes. Tay DL, et al. **Exp Hematol** 1996 Feb;24(2):277-84

c-JUN, KROX-24, and c-FOS expression in hippocampal grafts placed in excitotoxic hippocampal lesions of the rat. Aznar S, et al. **Exp Neurol** 1995 Dec;136(2):205-11

Expression of c-fos gene inhibits proteoglycan synthesis in transfected chondrocyte. Tsuji M, et al. **FEBS Lett** 1996 Mar 4;381(3):222-6

Interleukin 10 induced c-fos expression in human B cells by activation of divergent protein kinases. Bönig H, et al. **Immunol Invest** 1996 Jan-Mar;25(1-2):115-28

Co-localization of c-fos protein and protein kinase C gamma in the rat brain following anodal polarization. Islam N, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):209-15

Cone-associated c-fos gene expression in the light-damaged rat retina. Harada T, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1250-5

Differential distribution of CaM kinases and induction of c-fos expression by flashing and sustained light in rat retinal cells. Yoshida K, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):174-9

The N-methyl-D-aspartate receptor pathway is involved in hypoxia-induced c-Fos protein expression in the rat nucleus of the solitary tract. Haxhiu MA, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1-2):65-8

Granulocyte-macrophage colony-stimulating factor provokes RAS activation and transcription of c-fos through different modes of signaling. Itoh T, et al. **J Biol Chem** 1996 Mar 29;271(13):7587-92

Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells. Miralem T, et al. **J Biol Chem** 1996 Jul 19;271(29):17100-6

Unexpected c-fos gene expression in the suprachiasmatic nucleus of mice entrained to a skeleton photoperiod. Schwartz WJ, et al. **J Biol Rhythms** 1996 Mar;11(1):35-44

Fos expression in forebrain afferents to the hypothalamic paraventricular nucleus following swim stress. Cullinan WE, et al. **J Comp Neurol** 1996 Apr 22;368(1):88-99

The circadian system of c-fos deficient mice. Honrado GI, et al. **J Comp Physiol [A]** 1996 Apr;178(4):563-70

The cell-coded polypeptide U90 increased by herpes simplex virus type 2 infection induces Fos and DNA synthesis. Macnab JC, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3131-6

Intranigral injections of glutamate antagonists modulate dopamine D1-mediated turning behavior and striatal c-fos expression. Fenu S, et al. **J Neural Transm Suppl** 1995; 45:75-81

Mating-induced FOS-like immunoreactivity in the rat forebrain: a sex comparison and a dimorphic effect of pelvic nerve transection. Wersinger SR, et al. **J Neuroendocrinol** 1993 Oct;5(5):557-68

To what extent do spinal interactions between an alpha-2 adrenoceptor agonist and a mu opioid agonist influence noxiously evoked c-Fos expression in the rat? A pharmacological study. Honoré P, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):393-403

Pharmacological studies of the regulation of chronic FOS-related antigen induction by cocaine in the striatum and nucleus accumbens. Nye HE, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1671-80

Studies of qingyangshen (I): Differential expression of hippocampal c-fos proto-oncogene during kainic acid induced acute and chronic seizures. Guo Q, et al. **J Tradit Chin Med** 1995 Dec;15(4):292-6

PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Draoui M, et al. **Life Sci** 1996;59(4):307-13

Microinjection of antibodies. Kovary K. **Methods Enzymol** 1995;254:445-58

Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: a model for intercellular communication in bone. Lee K, et al. **Miner Electrolyte Metab** 1995; 21(1-3):120-2

Dependence of stimulus-transcription coupling on phospholipase D in agonist-stimulated pituitary cells. Cesnjaj M, et al. **Mol Biol Cell** 1995 Aug;6(8):1037-47

Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. Nye HE, et al. **Mol Pharmacol** 1996 Apr;49(4):636-45

Patterns of induction of the immediate-early genes c-fos and egr-1 in the female rat brain following differential amounts of mating stimulation. Polston EK, et al. **Neuroendocrinology** 1995 Oct;62(4):370-84

Hypotension induces Fos immunoreactivity in NADPH-diaphorase positive neurons in the paraventricular and supraoptic hypothalamic nuclei of the rat. Petrov T, et al. **Neuropharmacology** 1995 May; 34(5):509-14

Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. Buritova J, et al. **Neuroreport** 1995 Jul 10;6(10):1385-8

Sound induced expression of c-Fos in GABA positive neurones of the gerbil cochlear nucleus. Gleich O, et al. **Neuroreport** 1995 Dec 29;7(1):29-32

Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice. Kano T, et al. **Neuroreport** 1995 Nov 13;6(16):2197-200

Hypertension inhibits noxious-evoked c-fos expression in the rat spinal cord. Tavares I, et al. **Neuroreport** 1995 Aug 21;6(12):1664-8

Effects of local anaesthesia on formalin-induced Fos expression in the rat dorsal horn. Tokunaga A, et al. **Neuroreport** 1995 Nov 27;6(17):2301-4

Fenfluramine-induced c-fos in the striatum and hypothalamus: a tract-tracing study. Torres G. **Neuroreport** 1995 Aug 21;6(12):1679-83

Effect of TENS-like stimulation on C afferent-induced c-fos expression in the rat spinal cord. Wei F, et al. **Neuroreport** 1995 Aug 21;6(12):1659-63

Seizure-induced c-fos expression in rat medulla oblongata is not dependent on associated elevation of blood pressure. Kanter RK, et al. **Neurosci Lett** 1995 Jul 21;194(3):201-4

Expression of c-fos protein in substance P receptor-like immunoreactive neurons in response to noxious stimuli on the urinary bladder: an observation in the lumbosacral cord segments of the rat. Lü Y, et al. **Neurosci Lett** 1995 Sep 29;198(2):139-42

Prostaglandin-dependent c-Fos expression in the median preoptic nucleus of pigs subjected to restraint: correlation with hyperthermia. Vellucci SV, et al. **Neurosci Lett** 1995 Sep 22;198(1):49-51

Fos expression in the hypothalamic magnocellular neurons of rats during pregnancy, parturition and lactation. Lin SH, et al. **Neurosci Res** 1995 Aug;23(1):29-34

Burst stimulation of the medial forebrain bundle selectively increase Fos-like immunoreactivity in the limbic forebrain of the rat. Chergui K, et al. **Neuroscience** 1996 May; 72(1):141-56

Effect of administration of high dose intrathecal clonidine or morphine prior to sciatic nerve section on c-Fos expression in rat lumbar spinal cord. Luo L, et al. **Neuroscience** 1995 Oct;68(4):1219-27

Induction of c-fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine levels. Moorman JM, et al. **Neuroscience** 1995 Oct;68(4):1089-96

P-chloroamphetamine induces c-fos in rat brain: a study of serotonin2A/2C receptor function. Moorman JM, et al. **Neuroscience** 1996 May;72(1):129-39

Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity expression increases in subpopulations of spinal cord neurons during withdrawal. Rohde DS, et al. **Neuroscience** 1996 May;72(1):233-42

Differential expression of c-fos messenger RNA in the rat spinal cord after mucosal and serosal irritation of the stomach. Schuligoi R, et al. **Neuroscience** 1996 May; 72(2):535-44

Behavioural, autonomic and endocrine responses associated with C-fos expression in the forebrain and brainstem after intracerebroventricular infusions of endothelins. Zhu B, et al. **Neuroscience** 1996 Apr;71(4):1049-62

c-fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation. Veyrune JL, et al. **Oncogene** 1995 Nov 16;11(10):2127-34

Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Honoré P, et al. **Pain** 1995 Dec;63(3):365-75

Expression of Fos protein in various rat brain areas following acute nicotine and diazepam. Salminen O, et al. **Pharmacol Biochem Behav** 1996 May;54(1):241-8

Audiogenic seizure induces c-fos mRNA expression in the inferior colliculus and not in the hippocampus. Ishida N, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S280-2

Induction of c-fos and reduction of dynorphin in dentate granule cells of a rat model of epilepsy produced by systemic administration of kainic acid: an immunohistochemical study. Kitamura Y, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S213-6

Ontogeny of Fos protein-like immunoreactivity in the suprachiasmatic nucleus. Joyce MP, et al. **Synapse** 1995 Sep;21(1):54-9

Differential induction of fos and jun family genes by thyrotropin in rat thyroid FRTL-5 cells. Kambe F, et al. **Thyroid** 1996 Apr;6(2):123-8

Expression of c-fos oncogenes in adrenal cortex of the rat with renal hypertension. Gao JY, et al. **Tissue Cell** 1995 Oct;27(5):499-503

Implications of prolonged expression of Fos-related antigens. Pennypacker KR, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):317-21 (44 ref.)

c-fos gene expression in postnatal rat retinas with light/dark cycle. Ohki K, et al. **Vision Res** 1996 Jul;36(13):1883-6

CHEMISTRY

Mammalian Sug1 and c-Fos in the nuclear 26S proteasome. Wang W, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;

93(16):8236–40

DRUG EFFECTS

Effect of different xanthines and phosphodiesterase inhibitors on c–fos expression in rat striatum. Svenningsson P, et al. **Acta Physiol Scand** 1995 May;154(1):17–24

NADPH–diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Tassorelli C, et al. **Brain Res** 1995 Oct 9;695(1):37–44

Inhibitions of protein kinase C and proto–oncogene expressions in NIH 3T3 cells by apigenin. Huang YT, et al. **Eur J Cancer** 1996 Jan;32A(1):146–51

Glutamate induces c–fos proto–oncogene expression and inhibits proliferation in oligodendrocyte progenitors: receptor characterization. Liu HN, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2355–63

Peripheral injection of arginine8–vasopressin increases Fos in specific brain areas. Wu PH, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):263–9

Intrastriatal DNQX induces rotation and pallidal Fos in the 6–OHDA model of Parkinson's disease. Schuller JJ, et al. **Neuroreport** 1995 Dec 15;6(18):2594–8

Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Deutch AY, et al. **Neuroscience** 1995 May; 66(2):337–46

The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Deutch AY, et al. **Neuroscience** 1996 Jan;70(2):377–89

The effects of the kappa agonist U–50,488 on cocaine–induced conditioned and unconditioned behaviors and Fos immunoreactivity. Crawford CA, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):392–9

GENETICS

Frontal cingulotomy reconsidered from a WGA–HRP and c–Fos study in cat. Kuroda R, et al. **Acta Neurochir Suppl (Wien)** 1995;64:69–73

Changes in Fos and Jun expression in the rat brainstem in the process of vestibular compensation. Kitahara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:401–4

Role of endogenous renin–angiotensin system in c–fos activation and PKC–epsilon translocation in adult rat hearts. Kang PM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2177–83

Osteocytic expression of mRNA for c–fos and IGF–I: an immediate early gene response to an osteogenic stimulus. Lean JM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E937–45

PACAP stimulates transcription of c–Fos and c–Jun and activates the AP–1 transcription factor in rat pancreatic carcinoma cells. Schäfer H, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):111–6

Hormonal modulation of c–fos expression in isolated hepatocytes. Effects of angiotensin II and phorbol myristate acetate on transcription and mRNA degradation. González–Espinosa C, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):217–22

The effect of adrenalectomy on stress–induced c–fos mRNA expression in the rat brain. Helmreich DL, et al. **Brain Res** 1996 Jan 8;706(1):137–44

NADPH–diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Tassorelli C, et al. **Brain Res** 1995 Oct 9;695(1):37–44

Differential time courses of c–fos mRNA expression in hippocampal subfields following acquisition and recall testing in mice. Bertaina V, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):269–75

A defect in nurturing in mice lacking the immediate early gene fosB. Brown JR, et al. **Cell** 1996 Jul 26;86(2):297–309

Expression and characterization of mouse cFos protein using the baculovirus expression system: ability to form functional AP–1 complex with coexpressed cJun protein. Corvello CM, et al. **Cell Mol Biol Res** 1995;41(6):527–35

Differential activation of c–fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. Hill CS, et al. **EMBO J** 1995 Oct 16;14(20):5037–47

In vivo effects of adrenocorticotropin on c–jun, jun–B, c–fos and fos–B in rat adrenal. LeHoux JG, et al. **Endocr Res** 1995 Feb–May;21(1–2):267–74

Biphasic expression of the fos and jun families of transcription factors following transient forebrain ischaemia in the rat. Effect of hypothermia. Kamme F, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2007–16

Decrease of zif–268 and c–fos and increase of c–jun mRNA in the cat areas 17, 18 and 19 following complete visual deafferentation. Zhang F, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1292–6

Regulation of the c–fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2–4):137–42 (14 ref.)

Fos leucine zipper variants with increased association capacity. Porte D, et al. **J Biol Chem** 1995 Sep 29; 270(39):22721–30

Differential effects of n–6 and n–3 polyunsaturated fatty acids on cell growth and early gene expression in Swiss 3T3 fibroblasts. Danesch U, et al. **J Cell Physiol** 1996 Sep; 168(3):618–24

D1 dopamine receptor–mediated induction of zif268 and c–fos in the dopamine–depleted striatum: differential regulation and independence from NMDA receptors. Keefe KA, et al. **J Comp Neurol** 1996 Apr 1;367(2):165–76

Fos expression induced by changes in arterial pressure is localized in distinct, longitudinally organized columns of neurons in the rat midbrain periaqueductal gray. Murphy AZ, et al. **J Comp Neurol** 1995 Sep 18;360(2):286–300

The circadian system of c–fos deficient mice. Honrado GI, et al. **J Comp Physiol [A]** 1996 Apr;178(4):563–70

GH–deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH–releasing peptide–6. Dickson SL, et al. **J Endocrinol** 1995 Sep;146(3):519–26

Effect of growth factors on the expression of proto–oncogenes c–fos and c–myc in FRTL–5 cell line. Yoo HY, et al. **J Korean Med Sci** 1995 Jun;10(3):155–63

Bacterial lipopolysaccharide–induced changes in FOS protein expression in the rat brain: correlation with thermoregulatory changes and plasma corticosterone. Hare AS, et al. **J Neuroendocrinol** 1995 Oct;7(10):791–9

Spinal cord NMDA receptors modulate peripheral immune responses and spinal cord c–fos expression after immune challenge in rats subjected to unilateral mononeuropathy. Herzberg U, et al. **J Neurosci** 1996 Jan 15;16(2):730–43

Regional patterns of c–fos mRNA expression in rat hippocampus following exploration of a novel environment versus performance of a well–learned discrimination. Hess US, et al. **J Neurosci** 1995 Dec;15(12):7796–809

Null mutation of c–fos impairs structural and functional plasticities in the kindling model of epilepsy. Watanabe Y, et al. **J Neurosci** 1996 Jun 15;16(12):3827–36

Regional and temporal profiles of c–fos and nerve growth factor mRNA expression in rat brain after lateral cortical impact injury. Yang K, et al. **J Neurosci Res** 1995 Nov 1;42(4):571–8

Suppression of protooncogene c–fos expression by antioxidant dihydrolipoic acid. Mizuno M, et al. **Methods Enzymol** 1995;252:180–6

Regulation of c–fos mRNA expression in Sertoli cells by cyclic AMP, calcium, and protein kinase C mediated pathways. Jia MC, et al. **Mol Cell Biochem** 1996 Mar 9; 156(1):43–9

A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF–1 family of transcription factors mediates the vitamin D responsiveness of the c–fos promoter. Candeliere GA, et al. **Mol Cell Biol** 1996 Feb;16(2):584–92

mRNA decay mediated by two distinct AU–rich elements from c–fos and granulocyte–macrophage colony–stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Chen CY, et al. **Mol Cell Biol** 1995 Oct;15(10):5777–88

YY1 facilitates the association of serum response factor with the c–fos serum response element. Natesan S, et al. **Mol Cell Biol** 1995 Nov;15(11):5975–82

Regulation of delta FosB and FosB–like proteins by electroconvulsive seizure and cocaine treatments. Chen J, et al. **Mol Pharmacol** 1995 Nov;48(5):880–9

Induction of Fos protein in the rat hypothalamus elicited by insulin–induced hypoglycemia. Niimi M, et al. **Neurosci Res** 1995 Nov;23(4):361–4

c–fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation. Veyrune JL, et al. **Oncogene** 1995 Nov 16;11(10):2127–34

Dextromethorphan suppresses both formalin–induced nociceptive behavior and the formalin–induced increase in spinal cord c–fos mRNA. Elliott KJ, et al. **Pain** 1995 Jun; 61(3):401–9

Does nature drive nurture? [news] Cohen J. **Science** 1996 Aug 2;273(5275):577–8

Induction of fos–like immunoreactivity by electrocutaneous stimulation of the rat hindpaw. Willcockson HH, et al. **Somatosens Mot Res** 1995;12(2):151–61

[Expression of c–fos mRNA induced by pressure overload in the left ventricle] Tan DD, et al. **Sheng Li Hsueh Pao** 1996 Feb;48(1):65–9 (Eng. Abstr.) (Chi)

IMMUNOLOGY

Topographic organization of Fos–like immunoreactivity in the rostral nucleus of the solitary tract evoked by gustatory stimulation with sucrose and quinine. Harrer MI, et al. **Brain Res** 1996 Mar 4;711(1–2):125–37

Cholecystokinin octapeptide and the D2 antagonist raclopride induce Fos–like immunoreactivity in the shell part of the rat nucleus accumbens via different mechanisms. Li X, et al. **Brain Res** 1995 Jul 3;684(2):225–9

Distribution of Fos–like immunoreactivity in the caudal medullary reticular formation following noxious facial stimulation in the rat. Mineta Y, et al. **Exp Brain Res** 1995; 107(1):34–8

Elevated striatal Fos immunoreactivity following 6–hydroxydopamine lesioning of the rat is mediated by excitatory amino acid transmission. Cooper AJ, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):73–6

The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha 1–adrenergic or 5HT2 receptor blockade to haloperidol. Fink–Jensen A, et al. **Neurosci Lett** 1995 Jul 14; 194(1–2):77–80

Sodium depletion and Fos–immunoreactivity in lamina terminalis. Han L, et al. **Neurosci Lett** 1995 Jul 7; 193(3):173–6

Sex comparison of neuronal Fos immunoreactivity in the rat vomeronasal projection circuit after chemosensory stimulation. Bressler SC, et al. **Neuroscience** 1996 Apr; 71(4):1063–72

The effects of the kappa agonist U–50,488 on cocaine–induced conditioned and unconditioned behaviors and Fos immunoreactivity. Crawford CA, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):392–9

Ontogeny of Fos protein–like immunoreactivity in the suprachiasmatic nucleus. Joyce MP, et al. **Synapse** 1995 Sep;21(1):54–9

METABOLISM

C–fos expression in spinal cord and brainstem following noxious stimulation and electroacupuncture plus noxious stimulation. Wang H, et al. **Acupunct Electrother Res** 1995 Aug–Dec;20(3–4):163–72

Effect of vagal and splanchnic nerve section on Fos expression in ferret brain stem after emetic stimuli. Boissonade FM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R228–36

Spinal anesthesia by local anesthetics stimulates the enzyme protein kinase C and induces the expression of an immediate early oncogene, c–Fos. Nivarthi RN, et al. **Anesth Analg** 1996 Sep;83(3):542–7

Neuronal organization of stress response. Pain–induced c–fos expression in brain stem catecholaminergic cell groups. Palkovits M, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:313–26

The effects of olfactory and somatosensory desensitization on Fos–like immunoreactivity in the brains of pup–exposed postpartum rats. Walsh CJ, et al. **Behav Neurosci** 1996 Feb; 110(1):134–53

C–Fos is not essential for apoptosis. Gajate C, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):267–72

PEST motifs are not required for rapid calpain–mediated proteolysis of c–fos protein. Carillo S, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):245–51

Tissue factor gene transcription in serum–stimulated fibroblasts is mediated by recruitment of c–Fos into specific AP–1 DNA–binding complexes. Felts SJ, et al. **Biochemistry** 1995 Sep 26;34(38):12355–62

Molecular biology of pain. Munglani R, et al. **Br J Anaesth** 1995 Aug;75(2):186–92 (84 ref.)

Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c–Fos and electrophysiological study. Hoskin KL, et al. **Brain** 1996 Feb;119 (Pt 1):249–56

The exogenous control of transfected c–fos gene expression and angiogenesis in cells implanted into the rat brain. Asakuno K, et al. **Brain Res** 1995 Dec 8;702(1–2):23–31

Glucoprivic treatments that induce anestrus, but do not affect food intake, increase FOS–like immunoreactivity in the area postrema and nucleus of the solitary tract in Syrian hamsters. Schneider JE, et al. **Brain Res** 1995 Nov 6; 698(1–2):107–13

Fos–like immunoreactivity in the mamillary body and thalamus following injections of muscimol into the ventral tegmental nucleus of Gudden in the rat. Shim I, et al. **Brain Res** 1996 Mar 18;712(2):173–8

Water deprivation induces regional expression of c–fos protein in the brain of inbred polydipsic mice. Ueta Y, et al. **Brain Res** 1995 Apr 24;677(2):221–8

Electrically induced fos–like immunoreactivity in the auditory pathway of the rat: effects of survival time, duration, and intensity of stimulation. Zhang JS, et al. **Brain Res Bull** 1996;39(2):75–82

Transient functional connections between the developing corticospinal tract and cervical spinal interneurons as demonstrated by c–fos immunohistochemistry. Curfs MH, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):214–9

A labile hyperphosphorylated c–Fos protein is induced in mouse fibroblast cells treated with a combination of phorbol ester and anti–tumor promoter curcumin. Huang TS, et al. **Cancer Lett** 1995 Sep 4;96(1):1–7

Increased c–fos mRNA and binding to the AP–1 recognition sequence accompanies the proliferative response to deoxycholate of HT29 cells. Matheson H, et al. **Carcinogenesis** 1996 Mar;17(3):421–6

A regulatory role of c–Fos in the development of precursor B lymphocytes mediated by interleukin–7. Imoto S, et al. **Cell Immunol** 1996 Apr 10;169(1):67–74

The c Fos immunoreactivities in the developing and adult rat cerebella. Ruan Y, et al. **Cell Mol Biol Res** 1995; 41(2):111–5

CBP–induced stimulation of c–Fos activity is abrogated by E1A. Bannister AJ, et al. **EMBO J** 1995 Oct 2; 14(19):4758–62

The Mos/MAP kinase pathway stabilizes c–Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. Okazaki K, et al. **EMBO J** 1995 Oct 16; 14(20):5048–59

Interleukin 1–induced Fos and Jun do not regulate inducible nitric oxide synthase in rat islets of Langerhans and RINm5F cells. Kwon G, et al. **Endocrinology** 1996 Mar; 137(3):825–30

Nicotine–induced cFos expression in the hypothalamic paraventricular nucleus is dependent on brainstem effects: correlations with cFos in catecholaminergic and noncatecholaminergic neurons in the nucleus tractus solitarius. Valentine JD, et al. **Endocrinology** 1996 Feb; 137(2):622–30

Estrogen and progesterone receptors, cell proliferation, and

c-fos expression in the ovine uterus during early pregnancy. Zheng J, et al. **Endocrinology** 1996 Jan;137(1):340–8

Comparison of frequency-specific c-Fos expression and fluoro-2-deoxyglucose uptake in auditory cortex of gerbils (Meriones unguiculatus). Zuschratter W, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1614–26

Intercellular heterogeneity of early mitogenic events: cAMP generalizes the EGF effect on c-Fos protein appearance but not on MAP kinase phosphorylation and nuclear translocation in dog thyroid epithelial cells. Baptist M, et al. **Exp Cell Res** 1995 Nov;221(1):160–71

Cyclo-oxygenase mediation of endotoxin-induced fever, anterior and posterior pituitary hormone release, and hypothalamic c-Fos expression in the prepubertal pig. Parrott RF, et al. **Exp Physiol** 1995 Jul;80(4):663–74

Selective uptake and degradation of c-Fos and v-Fos by rat liver lysosomes. Aniento F, et al. **FEBS Lett** 1996 Jul 15;390(1):47–52

Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Ramael M, et al. **Histol Histopathol** 1995 Jul; 10(3):639–43

Entamoeba histolytica stimulates the unstable transcription of c-fos and tumour necrosis factor-alpha mRNA by protein kinase C signal transduction in macrophages. Seguin R, et al. **Immunology** 1995 Sep;86(1):49–57

Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes. Hermida-Matsumoto ML, et al. **J Biol Chem** 1996 Mar 1;271(9):4930–6

Hypoglycemia-elicited immediate early gene expression in neurons and glia of the hippocampus: novel patterns of FOS, JUN, and KROX expression following excitotoxic injury. Gass P, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):989–1001

Heat-shock protein and C-fos expression in focal microvascular brain damage. Lindsberg PJ, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):82–91

Sound stimulation induces Fos-related antigens in cells with common morphological properties throughout the auditory brainstem. Adams JC. **J Comp Neurol** 1995 Oct 30; 361(4):645–68

Subnuclear localization of FOS-like immunoreactivity in the rat parabrachial nucleus after nociceptive stimulation. Hermanson O, et al. **J Comp Neurol** 1996 Apr 22; 368(1):45–56

Preparation of a bispecific F(ab')2 targeted to the human IL-2 receptor. Tso JY, et al. **J Hematother** 1995 Oct; 4(5):389–94

Convulsant agents activate c-fos induction in both a calmodulin-dependent and calmodulin-independent manner. Barrón S, et al. **J Neurochem** 1995 Oct; 65(4):1731–9

Synaptogenesis and Fos expression in the motor cortex of the adult rat after motor skill learning. Kleim JA, et al. **J Neurosci** 1996 Jul 15;16(14):4529–35

Convergent influence of the central nucleus of the amygdala and the paraventricular hypothalamic nucleus upon brainstem autonomic neurons as revealed by c-fos expression and anatomical tracing. Petrov T, et al. **J Neurosci Res** 1995 Dec 15;42(6):835–45

The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. Barke RA, et al. **J Surg Res** 1996 Jan;60(1):101–6

Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. Kolman JL, et al. **J Virol** 1996 Mar;70(3):1493–504

Effects of high glucose concentration on c-fos: role of protein kinase C. Cosio FG, et al. **Kidney Int Suppl** 1995 Sep; 51:S12–7

Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. White LA, et al. **Matrix Biol** 1995 Dec;14(9):715–25

Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Gille H, et al. **Mol Cell Biol** 1996 Mar;16(3):1094–102

Fos-Jun dimerization promotes interaction of the basic region with TFIIE-34 and TFIIF. Martin ML, et al. **Mol Cell Biol** 1996 May;16(5):2110–8

Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Stancovski I, et al. **Mol Cell Biol** 1995 Dec; 15(12):7106–16

Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Tsurumi C, et al. **Mol Cell Biol** 1995 Oct;15(10):5682–7

Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src [see comments] Barone MV, et al. **Nature** 1995 Nov 30;378(6556):509–12. Comment in: Nature 1995 Nov 30;378(6556):438–9.

Seizure induced C-Fos mRNA in the rat brain: comparison between young and aging animals. Retchkiman I, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):41–4

Odors increase Fos in olfactory bulb neurons including dopaminergic cells. Guthrie KM, et al. **Neuroreport** 1995 Nov 13;6(16):2145–9; discussion 2103

Induction of c-fos mRNA in the arcuate nucleus of normal and mutant growth hormone-deficient mice by a synthetic non-peptidyl growth hormone secretagogue. Sirinathsinghji DJ, et al. **Neuroreport** 1995 Oct 23; 6(15):1989–92

Fos immuno-positive neurons in the subthalamic nucleus following reversal of parkinsonian symptoms by antagonism of excitatory amino acid transmission in the entopeduncular nucleus of the monoamine depleted rat. Cooper AJ, et al. **Neurosci Lett** 1995 Dec 15;201(3):251–4

Fos-like immunoreactivity increases in the lumbar spinal cord following a chronic constriction injury to the sciatic nerve of rat. Kajander KC, et al. **Neurosci Lett** 1996 Mar 8;206(1):9–12

Central mechanism of neural activation with cold acclimation of rats using Fos immunohistochemistry. Miyata S, et al. **Neurosci Res** 1995 May;22(2):209–18

Distribution of NADPH-diaphorase staining and light-induced Fos expression in the rat suprachiasmatic nucleus region supports a role for nitric oxide in the circadian system. Amir S, et al. **Neuroscience** 1995 Nov; 69(2):545–55

Brainstem neurons expressing c-Fos immunoreactivity following irritant chemical stimulation of the rat's tongue. Carstens E, et al. **Neuroscience** 1995 Dec;69(3):939–53

Hemodynamic regulation of tyrosine hydroxylase messenger RNA in medullary catecholamine neurons: a c-fos-guided hybridization histochemical study. Chan RK, et al. **Neuroscience** 1995 May;66(2):377–90

Expression of c-fos protein in the nucleus tractus solitarius in response to physiological activation of carotid baroreceptors. Dean C, et al. **Neuroscience** 1995 Nov; 69(1):249–57

Clonidine and rilmenidine suppress hypotension-induced Fos expression in the lower brainstem of the conscious rabbit. Li YW, et al. **Neuroscience** 1995 May;66(2):391–402

The association of thirst, sodium appetite and vasopressin release with c-fos expression in the forebrain of the rat after intracerebroventricular injection of angiotensin II, angiotensin-(1–7) or carbachol. Mahon JM, et al. **Neuroscience** 1995 Nov;69(1):199–208

Differential distribution of Fos-like immunoreactivity in the spinal trigeminal nucleus after noxious and innocuous thermal and chemical stimulation of rat cornea. Meng ID, et al. **Neuroscience** 1996 May;72(1):243–54

Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and Fos-related antigen immunoreactivity in rat striatum. Simpson JN, et al. **Neuroscience** 1995 Nov;69(2):441–57

Fos and serotonin immunoreactivity in the raphe nuclei of the cat during carbachol-induced active sleep: a double-labeling study. Yamuy J, et al. **Neuroscience** 1995 Jul;67(1):211–23

Effects of aging on light-induced phase-shifting of circadian behavioral rhythms, fos expression and CREB phosphorylation in the hamster suprachiasmatic nucleus. Zhang Y, et al. **Neuroscience** 1996 Feb;70(4):951–61

2-Deoxy-D-glucose but not 2-mercaptoacetate increases Fos-like immunoreactivity in adrenal medulla and sympathetic preganglionic neurons. Ritter S, et al. **Obes Res** 1995 Dec;3 Suppl 5:729S–734S

17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. Bonapace IM, et al. **Oncogene** 1996 Feb 15; 12(4):753–63

Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Chen RH, et al. **Oncogene** 1996 Apr 4;12(7):1493–502

Fos-like immunoreactivity in vagal and hypoglossal nuclei in different feeding states: a quantitative study. Emond MH, et al. **Physiol Behav** 1995 Sep;58(3):459–65

Fos and Jun do not bend the AP-1 recognition site. Sitlani A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16; 93(8):3248–52

The ratio of retinoblastoma (RB) to fos and RB to myc expression during the cell cycle. Yen A, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):205–12

Chronic dietary lithium inhibits basal c-fos mRNA expression in rat brain. Mathé AA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Nov; 19(7):1177–87

Day-night changes in c-fos expression in the fetal sheep suprachiasmatic nucleus at late gestation. Constandil L, et al. **Reprod Fertil Dev** 1995;7(3):411–3

Time-dependent changes in dopamine agonist-induced striatal Fos immunoreactivity are related to sensory neglect and its recovery after unilateral prefrontal cortex injury. Vargo JM, et al. **Synapse** 1995 Aug;20(4):305–15

[Changes of proto-oncogene expression and cytosolic free calcium in activited T-lymphocytes of aged mice] Ran Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug;75(8):466–9, 509–510 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Deregulated c-Fos/AP-1 accelerates cell cycle progression of B lymphocytes stimulated with lipopolysaccharide. Phuchareon J, et al. **Immunobiology** 1995 Aug;193(5):391–9

Induction of apoptosis by c-Fos protein. Preston GA, et al. **Mol Cell Biol** 1996 Jan;16(1):211–8

PHYSIOLOGY

c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Wang ZQ, et al. **Cancer Res** 1995 Dec 15;55(24):6244–51

Dissociation of c-fos induction and mitogen-activated-protein kinase activation from the hepatocyte-growth-factor-induced motility response in human gastric carcinoma cells. Nagamine K, et al. **Eur J Biochem** 1996 Mar 1;236(2):476–81

A polyclonal antibody against mammalian FOS can be used as a cytoplasmic neuronal activity marker in a teleost fish. Bosch TJ, et al. **J Neurosci Methods** 1995 May; 58(1–2):173–9

Induction of apoptosis by c-Fos protein. Preston GA, et al. **Mol Cell Biol** 1996 Jan;16(1):211–8

Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Boutillier AL, et al. **Mol Endocrinol** 1995 Jun; 9(6):745–55

Endogenous acetylcholine-induced Fos expression in magnocellular neurosecretory neurons in the supraoptic nucleus of the rat hypothalamus. Shen E, et al. **Neurosci Lett** 1995 Aug 11;195(3):191–4

Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins. Kataoka K, et al. **Oncogene** 1996 Jan 4;12(1):53–62

Fos and bone cell development: lessons from a nuclear oncogene. Grigoriadis AE, et al. **Trends Genet** 1995 Nov; 11(11):436–41 (57 ref.)

PROTO-ONCOGENE PROTEINS C-JUN

see related
TRANSCRIPTION FACTOR AP-1

ANALYSIS

Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Morishita S, et al. **Cancer Lett** 1995 Nov 6; 97(2):225–31

Differential expression of the fos and jun family members c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD during human epidermal keratinocyte differentiation. Welter JF, et al. **Oncogene** 1995 Dec 21;11(12):2681–7

BIOSYNTHESIS

Interleukin-11 induces tyrosine phosphorylation, and c-jun and c-fos mRNA expression in human K562 and U937 cells. Adunyah SE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:296–9

Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down- and up-regulation. Barrett TJ, et al. **Biochemistry** 1996 Jul 30;35(30):9746–53

Expression of c-fos and c-jun in rat retina following protracted illumination. Mallo G, et al. **Brain Res** 1995 Sep 25;693(1-2):196–200

Differential and antagonistic effects of v-Jun and c-Jun. Gao M, et al. **Cancer Res** 1996 Sep 15;56(18):4229–35

jun-B gene expression in rat retinal cells following focal retinal injury. Ohki K, et al. **Curr Eye Res** 1995 Nov; 14(11):1021–4

Expression of c-fos and c-jun proteins and AP-1 binding activity during cell cycle progression of HL60 cells and phytohemagglutinin-stimulated lymphocytes. Tay DL, et al. **Exp Hematol** 1996 Feb;24(2):277–84

c-JUN, KROX-24, and c-FOS expression in hippocampal grafts placed in excitotoxic hippocampal lesions of the rat. Aznar S, et al. **Exp Neurol** 1995 Dec;136(2):205–11

Coincidental expression of E5a and c-jun in human papillomavirus type 6/11-infected condylomata. Chen SL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1145–9

Calcium signals and protein tyrosine kinases are required for the induction of c-jun in Jurkat cells stimulated by the T cell-receptor complex and oxidative signals. Liu B, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):77–90

Microinjection of antibodies. Kovary K. **Methods Enzymol** 1995;254:445–58

DNA fragmentation and activation of c-Jun in the cerebellum of mutant mice (weaver, Purkinje cell degeneration). Gillardon F, et al. **Neuroreport** 1995 Sep 11;6(13):1766–8

Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Neyns B, et al. **Oncogene** 1996 Mar 21;12(6):1247–57

Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. Sonoda H, et al. **Oncogene** 1996 Jul 4;13(1):143–9

Differential induction of fos and jun family genes by thyrotropin in rat thyroid FRTL-5 cells. Kambe F, et al. **Thyroid** 1996 Apr;6(2):123–8

CHEMISTRY

Backbone dynamics of the c-Jun leucine zipper: 15N NMR relaxation studies. MacKay JP, et al. **Biochemistry** 1996 Apr 16;35(15):4867–77

Dissection of the basic subdomain of the c-Jun oncoprotein: a structural analysis of two peptide fragments by CD, Fourier-transform infrared and NMR. Krebs D, et al. **Eur J Biochem** 1996 Feb 1;235(3):699–712

High resolution NMR solution structure of the leucine zipper domain of the c-Jun homodimer. Junius FK, et al. **J Biol Chem** 1996 Jun 7;271(23):13663-7

DRUG EFFECTS

Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin. Huang YT, et al. **Eur J Cancer** 1996 Jan;32A(1):146-51

GENETICS

Changes in Fos and Jun expression in the rat brainstem in the process of vestibular compensation. Kitahara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:401-4

Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Zhao R, et al. **Anticancer Drugs** 1995 Oct;6(5):657-68

PACAP stimulates transcription of c-Fos and c-Jun and activates the AP-1 transcription factor in rat pancreatic carcinoma cells. Schäfer H, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):111-6

Changes in expression of NR-1 and c-jun mRNA in rat lumbar spinal cord after neonatal common peroneal nerve crush. Hay C, et al. **Brain Res** 1995 Dec 15;704(1):145-50

Expression and characterization of mouse cFos protein using the baculovirus expression system: ability to form functional AP-1 complex with coexpressed cJun protein. Corvello CM, et al. **Cell Mol Biol Res** 1995;41(6):527-35

jun-B gene expression in rat retinal cells following focal retinal injury. Ohki K, et al. **Curr Eye Res** 1995 Nov; 14(11):1021-4

In vivo effects of adrenocorticotropin on c-jun, jun-B, c-fos and fos-B in rat adrenal. LeHoux JG, et al. **Endocr Res** 1995 Feb-May;21(1-2):267-74

Biphasic expression of the fos and jun families of transcription factors following transient forebrain ischaemia in the rat. Effect of hypothermia. Kamme F, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2007-16

Decrease of zif-268 and c-fos and increase of c-jun mRNA in the cat areas 17, 18 and 19 following complete visual deafferentation. Zhang F, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1292-6

Complex genetic organization of junB: multiple blocks of flanking evolutionarily conserved sequence at the murine and human junB loci. Phinney DG, et al. **Genomics** 1995 Jul 20;28(2):228-34

The kinetics of induction of Hox1.6 and C-jun mRNA during three different ways of inducing differentiation in teratocarcinoma F9 cells. Iwai SA, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):462-6

Transcriptional regulation of the junB promoter in mature B lymphocytes. Activation through a cyclic adenosine 3',5'-monophosphate-like binding site. Amato SF, et al. **J Immunol** 1996 Jul 1;157(1):146-55

Induction of c-myc and c-jun proto-oncogene expression in rat L6 myoblasts by cadmium is inhibited by zinc preinduction of the metallothionein gene. Abshire MK, et al. **J Toxicol Environ Health** 1996 Jul;48(4):359-77

Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis. Kuwakado K, et al. **Leuk Res** 1995 Sep;19(9):645-50

Adenovirus E1A downregulates cJun- and JunB-mediated transcription by targeting their coactivator p300. Lee JS, et al. **Mol Cell Biol** 1996 Aug;16(8):4312-26

Functional characterization of a non-AUUUA AU-rich element from the c-jun proto-oncogene mRNA: evidence for a novel class of AU-rich elements. Peng SS, et al. **Mol Cell Biol** 1996 Apr;16(4):1490-9

METABOLISM

The primary structure of rat ribosomal protein L10: relationship to a Jun-binding protein and to a putative Wilms' tumor suppressor. Chan YL, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):952-6

The transformation of c-jun-overexpressing cells is correlated with IGFS-induced c-jun phosphorylation. Lagarrigue S, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):501-8

Phosphorylation of c-Jun stimulated in primary cultured rat liver parenchymal cells by a coplanar polychlorinated biphenyl. Tanno K, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):863-6

Phosphorylation of Drosophila Jun by the MAP kinase rolled regulates photoreceptor differentiation. Peverali FA, et al. **EMBO J** 1996 Aug 1;15(15):3943-50

Interleukin 1-induced Fos and Jun do not regulate inducible nitric oxide synthase in rat islets of Langerhans and RINm5F cells. Kwon G, et al. **Endocrinology** 1996 Mar; 137(3):825-30

Expression of c-Jun, Jun B, Jun D and cAMP response element binding protein by Schwann cells and their precursors in vivo and in vitro. Stewart HJ. **Eur J Neurosci** 1995 Jun 1;7(6):1366-75

The c-Jun delta-domain inhibits neuroendocrine promoter activity in a DNA sequence- and pituitary-specific manner. Farrow KN, et al. **J Biol Chem** 1996 Jul 19; 271(29):17139-46

Lipopolysaccharide induction of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the tissue factor promoter. Groupp ER, et al. **J Biol Chem** 1996 May 24; 271(21):12423-30

Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes. Hermida-Matsumoto ML, et al. **J Biol Chem** 1996 Mar 1;271(9):4930-6

Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. Lo YYC, et al. **J Biol Chem** 1996 Jun 28;271(26):15703-7

Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. Morooka H, et al. **J Biol Chem** 1995 Dec 15;270(50):30084-92

ERM, a PEA3 subfamily of Ets transcription factors, can cooperate with c-Jun. Nakae K, et al. **J Biol Chem** 1995 Oct 6;270(40):23795-800

Cyclic AMP inhibition of thrombin-induced growth in vascular smooth muscle cells correlates with decreased JNK1 activity and c-Jun expression. Rao GN, et al. **J Biol Chem** 1996 Aug 23;271(34):20805-10

Expression of human squamous cell differentiation marker, SPR1, in tracheobronchial epithelium depends on JUN and TRE motifs. Reddy SP, et al. **J Biol Chem** 1995 Nov 3; 270(44):26451-9

c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells. Reyes JG, et al. **J Biol Chem** 1996 Aug 30;271(35):21375-80

v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. Xie W, et al. **J Biol Chem** 1995 Nov 17;270(46):27622-8

Hypoglycemia-elicited immediate early gene expression in neurons and glia of the hippocampus: novel patterns of FOS, JUN, and KROX expression following excitotoxic injury. Gass P, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):989-1001

Preparation of a bispecific F(ab')2 targeted to the human IL-2 receptor. Tso JY, et al. **J Hematother** 1995 Oct; 4(5):389-94

Overexpression of the proto-oncogene c-jun in association with low-risk type specific human papillomavirus infection in condyloma acuminata. Yang YF, et al. **J Med Virol** 1996 Apr;48(4):302-7

Patch clamp detection of transcription factor translocation along the nuclear pore complex channel. Bustamante JO, et al. **J Membr Biol** 1995 Aug;146(3):253-61

Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): association of c-Jun with A beta-induced apoptosis. Anderson AJ, et al. **J Neurochem** 1995 Oct;65(4):1487-98

Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. Shinoda H, et al. **Laryngoscope** 1995 Nov;105(11):1232-7

Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. White LA, et al. **Matrix Biol** 1995 Dec;14(9):715-25

Phosphorylation of transcription factors. Franklin CC, et al. **Methods Enzymol** 1995;254:550-64

Methods for analyzing c-Jun kinase. Westwick JK, et al. **Methods Enzymol** 1995;255:342-59

Fos-Jun dimerization promotes interaction of the basic region with TFIIE-34 and TFIIF. Martin ML, et al. **Mol Cell Biol** 1996 May;16(5):2110-8

Stepwise transformation of rat embryo fibroblasts: c-Jun, JunB, or JunD can cooperate with Ras for focus formation, but a c-Jun-containing heterodimer is required for immortalization. Vandel L, et al. **Mol Cell Biol** 1996 May; 16(5):1881-8

Angiotensin II stimulates calcium-dependent activation of c-Jun N-terminal kinase. Zohn IE, et al. **Mol Cell Biol** 1995 Nov;15(11):6160-8

Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Bannister AJ, et al. **Oncogene** 1995 Dec 21;11(12):2509-14

Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Franklin CC, et al. **Oncogene** 1995 Dec 7;11(11):2365-74

Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to EIA-dependent induction of ATF3. Hagmeyer BM, et al. **Oncogene** 1996 Mar 7;12(5):1025-32

The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction. Kilbey A, et al. **Oncogene** 1996 Jun 6; 12(11):2409-18

Cyclic AMP stimulates a JunD/Fra-2 AP-1 complex and inhibits the proliferation of interleukin-6-dependent cell lines. Rezzonico R, et al. **Oncogene** 1995 Sep 21; 11(6):1069-78

Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Adler V, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10585-9

The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Raitano AB, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11746-50

Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Schaefer TS, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9097-101

Fos and Jun do not bend the AP-1 recognition site. Sitlani A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16; 93(8):3248-52

PHARMACOLOGY

The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Kim S, et al. **Oncogene** 1996 Mar 7;12(5):1043-53

PHYSIOLOGY

Role of c-jun in the inhibition of erythropoietin receptor-mediated apoptosis. Shimizu R, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):1-6

Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. Sakai M, et al. **Cancer Res** 1995 Nov 15;55(22):5370-6

JUN cooperates with the ETS domain protein pointed to induce photoreceptor R7 fate in the Drosophila eye. Treier M, et al. **Cell** 1995 Dec 1;83(5):753-60

The NF-jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2-4):149-54 (16 ref.)

The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions. Fialka I, et al. **J Cell Biol** 1996 Mar;132(6):1115-32

Cellular transformation and malignancy induced by ras require c-jun. Johnson R, et al. **Mol Cell Biol** 1996 Aug; 16(8):4504-11

Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Tsurumi C, et al. **Mol Cell Biol** 1995 Oct;15(10):5682-7

Synergistic activation of neurotensin/neuromedin N gene expression by c-Jun and glucocorticoids: novel effects of Fos family proteins. Harrison RJ, et al. **Mol Endocrinol** 1995 Aug;9(8):981-93

Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Freemerman AJ, et al. **Mol Pharmacol** 1996 May; 49(5):788-95

Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins. Kataoka K, et al. **Oncogene** 1996 Jan 4;12(1):53-62

RADIATION EFFECTS

Both ATF-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2-4):143-8 (22 ref.)

Ionizing radiation-induced apoptosis is associated with c-Jun expression and c-Jun/AP-1 activation in the developing cerebellum of the rat. Ferrer I, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):105-8

ULTRASTRUCTURE

DNA loops induced by cooperative binding of transcriptional activator proteins and preinitiation complexes. Becker JC, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9727-31

PROTO-ONCOGENE PROTEINS C-KIT

ANALYSIS

Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Manz CY, et al. **Am J Hematol** 1996 Aug; 52(4):264-74

The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitiligo. Norris A, et al. **Br J Dermatol** 1996 Feb;134(2):299-306

In vitro progenitor analysis in a Diamond Blackfan anaemia patient who responded once but not twice to interleukin-3 therapy, using short-term and long-term cultures and c-kit analysis. McGuckin CP, et al. **Br J Haematol** 1996 May; 93(2):319-25

Distinct stages of melanocyte differentiation revealed by anlaysis of nonuniform pigmentation patterns. Yoshida H, et al. **Development** 1996 Apr;122(4):1207-14

Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. Bokemeyer C, et al. **J Cancer Res Clin Oncol** 1996;122(5):301-6

CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. Werfel T, et al. **J Immunol** 1996 Aug 15;157(4):1729-35

KIT expression reveals a population of precursor melanocytes in human skin. Grichnik JM, et al. **J Invest Dermatol** 1996 May;106(5):967-71

Lack of intestinal pacemaker (C-KIT-positive) cells in infantile hypertrophic pyloric stenosis. Yamataka A, et al. **J Pediatr Surg** 1996 Jan;31(1):96-8; discussion 98-9

Localization of intestinal pacemaker cells and synapses in the muscle layers of a patient with colonic hypoganglionosis. Yamataka A, et al. **J Pediatr Surg** 1996 Apr;31(4):584-7

Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid

leukemia blasts. Stacchini A, et al. **Leukemia** 1996 Oct; 10(10):1584–91

c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Ohashi A, et al. **Melanoma Res** 1996 Feb;6(1):25–30

Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours. Takahashi H, et al. **Virchows Arch** 1995;427(3):283–8

BIOSYNTHESIS

CD117/CD34 expression in leukemic blasts. Wells SJ, et al. **Am J Clin Pathol** 1996 Aug;106(2):192–5

C-kit receptor (CD117) expression in acute leukemia. Valverde LR, et al. **Ann Hematol** 1996 Jan;72(1):11–5

Expression of multiple c-kit receptor messenger ribonucleic acid transcripts during postnatal development of the rat testis. Ali S, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):104–12

Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors. Beck D, et al. **Blood** 1995 Oct 15;86(8):3132–8

Changes in c-Kit expression and effects of SCF during differentiation of human erythroid progenitor cells. Uoshima N, et al. **Br J Haematol** 1995 Sep;91(1):30–6

Ectopic c-kit expression affects the fate of melanocyte precursors in Patch mutant embryos. Wehrle-Haller B, et al. **Dev Biol** 1996 Aug 1;177(2):463–74

Coexpression of stem cell factor and c-kit in embryonic and adult liver. Fujio K, et al. **Exp Cell Res** 1996 May 1; 224(2):243–50

Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R. Luo D, et al. **Melanoma Res** 1995 Oct; 5(5):303–9

BLOOD

c-kit-positive cells and CD34-positive cells in cryopreserved peripheral blood stem cell samples. Yamane T, et al. **Acta Haematol** 1995;94(2):112–3

Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders. Kawakita M, et al. **Br J Haematol** 1995 Sep;91(1):23–9

CHEMISTRY

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)

Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Tsujimura T, et al. **Blood** 1996 Jan 1;87(1):273–83

Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit. Philo JS, et al. **J Biol Chem** 1996 Mar 22;271(12):6895–902

DRUG EFFECTS

Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of Steel factor receptor: biologic similarity with membrane-bound form of Steel factor rather than its soluble form. Kurosawa K, et al. **Blood** 1996 Mar 15;87(6):2235–43

Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Miller CL, et al. **Exp Hematol** 1996 Feb;24(2):185–94

GENETICS

Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Hashimoto K, et al. **Am J Pathol** 1996 Jan;148(1):189–200

Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Kitayama H, et al. **Blood** 1996 Aug 1; 88(3):995–1004

Xenogeneic expression of human stem cell factor in transgenic mice mimics codominant c-kit mutations. Majumdar MK, et al. **Blood** 1996 Apr 15;87(8):3203–11

A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Piao X, et al. **Blood** 1996 Apr 15;87(8):3117–23

Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Tsujimura T, et al. **Blood** 1996 Aug 15;88(4):1225–33

c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Nakata Y, et al. **Br J Haematol** 1995 Nov;91(3):661–3

A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation. Albanesi C, et al. **Development** 1996 Apr;122(4):1291–302

Origin of the c-kit-positive interstitial cells in the avian bowel. Lecoin L, et al. **Development** 1996 Mar; 122(3):725–33

Characterization of c-kit expression by primitive hematopoietic progenitors in umbilical cord blood. Laver JH, et al. **Exp Hematol** 1995 Dec;23(14):1515–9

Down-modulation of c-kit mRNA and protein expression by erythroid differentiation factor/activin A. Hino M, et al. **FEBS Lett** 1995 Oct 23;374(1):69–71

A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian kindred with piebaldism. Riva P, et al. **Hum Mutat** 1995;6(4):343–5

Localization of mRNA encoding c-kit during the initiation of folliculogenesis in ovine fetal ovaries. Clark DE, et al. **J Reprod Fertil** 1996 Mar;106(2):329–35

Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts. Yamanishi Y, et al. **Jpn J Cancer Res** 1996 May; 87(5):534–42

Assignment of c-KIT gene to swine chromosome 8p12–p21 by fluorescence in situ hybridization. Sakurai M, et al. **Mamm Genome** 1996 May;7(5):397

Phenotypic reversions at the W/Kit locus mediated by mitotic recombination in mice. De Sepulveda P, et al. **Mol Cell Biol** 1995 Nov;15(11):5898–905

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Longley BJ, et al. **Nat Genet** 1996 Mar;12(3):312–4

Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Paulson RF, et al. **Nat Genet** 1996 Jul;13(3):309–15

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Nagata H, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10560–4

IMMUNOLOGY

Role of IL-7 and KL in activating molecules controlling the G1/S transition of B precursor cells. Itoh N, et al. **Int Immunol** 1996 Mar;8(3):317–23

A role for stem cell factor (SCF): c-kit interaction(s) in the intestinal tract response to Salmonella typhimurium infection. Klimpel GR, et al. **J Exp Med** 1996 Jul 1; 184(1):271–6

Differential responsiveness of purified mouse c-kit+ mast cells and their progenitors to IL-3 and stem cell factor. Lantz CS, et al. **J Immunol** 1995 Oct 15;155(8):4024–9

Isolation and characterization of two monoclonal antibodies that recognize different epitopes of the human c-kit receptor. Morita S, et al. **Tohoku J Exp Med** 1996 Feb; 178(2):187–98

METABOLISM

JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor. Linnekin D, et al. **Acta Haematol** 1996;95(3–4):224–8

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)

Separation of myeloid and erythroid progenitors based on expression of CD34 and c-kit. De Jong MO, et al. **Blood** 1995 Dec 1;86(11):4076–85

Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor. Schwarzenberger P, et al. **Blood** 1996 Jan 15;87(2):472–8

Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Tsujimura T, et al. **Blood** 1996 Jan 1;87(1):273–83

JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Weiler SR, et al. **Blood** 1996 May 1;87(9):3688–93

Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Chui X, et al. **Br J Cancer** 1996 May;73(10):1233–6

Stem cell factor receptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid mallignancies but is also a characteristic of a subset of acute promyelocytic leukaemia. Di Noto R, et al. **Br J Haematol** 1996 Mar;92(3):562–4

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Hallek M, et al. **Br J Haematol** 1996 Jul;94(1):5–16

c-Kit proto-oncogene is more likely to lose expression in differentiated thyroid carcinoma than three thyroid-specific genes: thyroid peroxidase, thyroglobulin, and thyroid stimulating hormone receptor. Tanaka T, et al. **Endocr J** 1995 Oct;42(5):723–8

The use of recombinant SCF protein for rapid determination of c-kit expression in normal and abnormal erythropoiesis. McGuckin CP, et al. **Eur J Haematol** 1996 Jul;57(1):72–8

Stem cell factor induces phosphorylation of a 200 kDa protein which associates with c-kit. Linnekin D, et al. **Growth Factors** 1995;12(1):57–67

Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. Moriyama Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3347–50

Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells: new protein and RNA synthesis are required for reappearance of Kit. Shimizu Y, et al. **J Immunol** 1996 May 1;156(9):3443–9

Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia. Fukuda T, et al. **J Pathol** 1995 Oct;177(2):139–46

Differential expression of the c-kit proto-oncogene in germ cell tumours. Izquierdo MA, et al. **J Pathol** 1995 Nov; 177(3):253–8

Prolonged expression of the c-kit receptor in germ cells of intersex fetal testes. Meyts ER, et al. **J Pathol** 1996 Feb; 178(2):166–9

Characterization of chicken kit tyrosine kinase receptor in Cos cell transfectants and in chicken brain. Sasaki E, et al. **J Vet Med Sci** 1995 Apr;57(2):231–6

Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia. Lauria F, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):451–5

Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Backx B, et al. **Leukemia** 1996 Mar;10(3):466–72

Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. Cole SR, et al. **Leukemia** 1996 Feb;10(2):288–96

Primary acute myeloid leukemia cells negative for c-kit receptor protein expression do not proliferate in vitro in response to colony-stimulating factors. Hirakawa K, et al. **Leukemia** 1996 Feb;10(2):279–87

Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture. Morita S, et al. **Leukemia** 1996 Jan; 10(1):102–5

Specificity of CD117 expression in the diagnosis of acute myeloid leukemia. Muroi K, et al. **Leukemia** 1996 Jun; 10(6):1048

Activation of Stat 5b in erythroid progenitors correlates with the ability of ErbB to induce sustained cell proliferation. Mellitzer G, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9600–5

PHYSIOLOGY

Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Hashimoto K, et al. **Am J Pathol** 1996 Jan;148(1):189–200

Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen. Broudy VC, et al. **Blood** 1996 Jul 1; 88(1):75–81

CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Kawashima I, et al. **Blood** 1996 May 15; 87(10):4136–42

The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Lukacs NW, et al. **Blood** 1996 Mar 15;87(6):2262–8

Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Olweus J, et al. **Blood** 1996 Sep 1;88(5):1594–607

Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Krystal GW, et al. **Cancer Res** 1996 Jan 15;56(2):370–6

Engraftment of W/c-kit mutant mice is determined by stem cell competition, not by increased marrow 'space'. Fleishman RA. **Exp Hematol** 1996 Feb;24(2):209–13

A role for stem cell factor and c-kit in the murine intestinal tract secretory response to cholera toxin. Klimpel GR, et al. **J Exp Med** 1995 Dec 1;182(6):1931–42

Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells. Sui X, et al. **J Exp Med** 1996 Mar 1;183(3):837–45

c-kit+ stem cells and thymocyte precursors in the livers of adult mice. Watanabe H, et al. **J Exp Med** 1996 Aug 1;184(2):687–93

Kit ligand mediates survival of type A spermatogonia and dividing spermatocytes in postnatal mouse testes. Packer AI, et al. **Mol Reprod Dev** 1995 Nov;42(3):303–10

Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M. Sudo T, et al. **Oncogene** 1995 Dec 21;11(12):2469–76

PROTO-ONCOGENE PROTEINS C-MOS

see related
PROTEIN-SERINE-THREONINE KINASES

ANALYSIS

Primate reproductive organs reveal a novel pattern of proto-oncogene c-mos and transcription factor Oct-3 mRNA expression. Heikinheimo O, et al. **Mol Reprod Dev** 1995 Dec;42(4):397–406

CHEMISTRY

Identification of an autoinhibitory region in the activation loop of the Mos protein kinase. Robertson SC, et al. **Mol Cell Biol** 1996 Jul;16(7):3472–9

GENETICS

CPEB controls the cytoplasmic polyadenylation of cyclin, Cdk2 and c-mos mRNAs and is necessary for oocyte maturation in Xenopus. Stebbins-Boaz B, et al.

EMBO J 1996 May 15;15(10):2582-92
Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Fukasawa K, et al. **Oncogene** 1995 Oct 19;11(8):1447-57
Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells. Gao C, et al. **Oncogene** 1996 Apr 4;12(7):1571-6

METABOLISM

Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system. Huang CY, et al. **EMBO J** 1996 May 1;15(9):2169-73
The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. Okazaki K, et al. **EMBO J** 1995 Oct 16; 14(20):5048-59
Identification of an autoinhibitory region in the activation loop of the Mos protein kinase. Robertson SC, et al. **Mol Cell Biol** 1996 Jul;16(7):3472-9
The Mos/mitogen-activated protein kinase (MAPK) pathway regulates the size and degradation of the first polar body in maturing mouse oocytes. Choi T, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7032-5
Calcium-dependent development of secondary cytostatic factor (2 degrees CSF) from Xenopus laevis oocytes and zygotes. Zhang J, et al. **Zygote** 1996 Feb;4(1):11-9

PHARMACOLOGY

Identification of a complex between centrin and heat shock proteins in CSF-arrested Xenopus oocytes and dissociation of the complex following oocyte activation. Uzawa M, et al. **Dev Biol** 1995 Sep;171(1):51-9

PHYSIOLOGY

Mos is required for MAP kinase activation and is involved in microtubule organization during meiotic maturation in the mouse. Verlhac MH, et al. **Development** 1996 Mar; 122(3):815-22

PROTO-ONCOGENE PROTEINS C-MYC

Variation in the expression of p53, c-myc, and bcl-2 oncoproteins in individual patient cultures of normal urothelium exposed to cobalt 60 gamma-rays and N-nitrosodiethanolamine. Harney JV, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):617-25

ANALYSIS

Flow cytometric analysis of c-myc oncoprotein in non-small-cell lung carcinoma: comparison with immunohistochemical results. De Santis L, et al. **Anal Cell Pathol** 1995 Apr;8(3):247-57
Prognostic relevance of Ki-67 antigen and c-myc oncoprotein in malignant fibrous histocytoma. Brinck U, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1915-9
The expression of myc and ras oncogene protein in childhood lymphomas. Sakalidou A, et al. **Anticancer Res** 1996 Jan-Feb;16(1):487-91
Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma. Holly A, et al. **Eur Arch Otorhinolaryngol** 1995;252(6):366-9
Activation-induced apoptosis in Jurkat cells through a myc-independent mechanism. Ruiz-Ruiz MC, et al. **Mol Immunol** 1995 Sep;32(13):947-55
Infrequent alteration of the c-myc gene in human glial tumours associated with increased numbers of c-myc positive cells. Chattopadhyay P, et al. **Oncogene** 1995 Dec 21;11(12):2711-4

ANTAGONISTS & INHIBITORS

Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Bergan R, et al. **Blood** 1996 Jul 15;88(2):731-41
Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin. Lymboussaki A, et al. **Br J Cancer** 1996 Jun;73(11):1347-55
Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Chen J, et al. **Nat Med** 1995 Jul;1(7):638-43

BIOSYNTHESIS

Alcohol inhibits neurite extension and increases N-myc and c-myc proteins. Saunders DE, et al. **Alcohol** 1995 Sep-Oct; 12(5):475-83
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Santoni-Rugiu E, et al. **Am J Pathol** 1996 Aug;149(2):407-28
N-myc protein expression in human breast carcinoma: prognostic implications. Mizukami Y, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2899-905
Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Pavlidis N, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2563-7
Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Van Waardenburg RC, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1963-70
Nuclear matrix condensation and c-myc and c-fos expression are specifically altered in culture rat hepatocytes after exposure to cyproterone acetate and phenobarbital. Duivenvoorden WC, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):598-605
Cloning and expression of a myc family member from the pituitary gland of the Rainbow trout, Oncorhynchus mykiss. Panno JP, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):7-11
Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643. Miller RT, et al. **Carcinogenesis** 1996 Jun; 17(6):1337-41
Characterization of c-myc-transformed rat fibroblasts resistant to apoptosis induced ny growth factor deprivation. Dhanaraj, SN, et al. **Exp Cell Res** 1996 Apr 10;224(1):52-62
Prothymosin alpha mRNA levels vary with c-myc expression during tissue proliferation, viral infection and heat shock. Vareli K, et al. **FEBS Lett** 1995 Sep 11;371(3):337-40
Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Manohar CF, et al. **Genes Chromosomes Cancer** 1995 Nov;14(3):196-203
Genomic structure and precise mapping of a thymic regulatory region on mouse chromosome 17 revealed by a c-myc transgene insertion. Lavenu A, et al. **Genomics** 1996 Jun 15;34(3):381-8
Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. Martinez-Valdez H, et al. **J Exp Med** 1996 Mar 1;183(3):971-7
c-MYC oncoprotein production in experimental vein graft intimal hyperplasia. Ramirez JA, et al. **J Surg Res** 1996 Mar;61(2):323-9
Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. Yang D, et al. **J Virol** 1996 Sep;70(9):6260-8
Establishment of the novel B acute lymphoblastic leukemia (FAB L3) cell line KHM-10B with a 13q34 abnormality and constitutive expression of c-myc and max during cell cycle. Sonoki T, et al. **Leukemia** 1995 Dec;9(12):2093-9
v-Abl activates c-myc transcription through the E2F site. Wong KK, et al. **Mol Cell Biol** 1995 Dec;15(12):6535-44
Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Wu M, et al. **Mol Cell Biol** 1996 Sep; 16(9):5015-25
Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Jiang MC, et al. **Oncogene** 1996 Aug 1;13(3):609-16
c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Mai S, et al. **Oncogene** 1996 Jan 18;12(2):277-88
Aberrant translational control of the c-myc gene in multiple myeloma. Paulin FE, et al. **Oncogene** 1996 Aug 1; 13(3):505-13
Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype. Xu L, et al. **Oncogene** 1995 Nov 2;11(9):1865-72

CHEMISTRY

Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. McEwan IJ, et al. **Biochemistry** 1996 Jul 23;35(29):9584-93
The leucine zippers of the HLH-LZ proteins Max and c-Myc preferentially form heterodimers. Muhle-Goll C, et al. **Biochemistry** 1995 Oct 17;34(41):13554-64
A novel DNA binding protein that recognizes the methylated c-Myc binding motif. Suetake I, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):244-9
Preferential heterodimeric parallel coiled-coil formation by synthetic Max and c-Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization. Lavigne P, et al. **J Mol Biol** 1995 Dec 1;254(3):505-20

DRUG EFFECTS

[The effect of 2',5'-oligoadenylates on the expression of the cellular proto-oncogene c-myc during the development of Svec's leukemia in rats] Prima VI, et al. **Tsitol Genet** 1995 Nov-Dec;29(6):8-13 (Eng. Abstr.) **(Rus)**

GENETICS

Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Skorski T, et al. **Blood** 1996 Aug 1;88(3):1005-12
Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191-9 (33 ref.)
pRb is necessary for inhibition of N-myc expression by TGF-beta 1 in embryonic lung organ cultures. Serra R, et al. **Development** 1995 Sep;121(9):3057-66
Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. Hurlin PJ, et al. **EMBO J** 1995 Nov 15; 14(22):5646-59
The mycN/max protein complex in neuroblastoma. Short review. Wenzel A, et al. **Eur J Cancer** 1995;31A(4):516-9 (40 ref.)
c-Myc and Max interactions in quiescent and mitogen-stimulated primary hepatocytes. Skouteris GG, et al. **Exp Cell Res** 1996 Jun 15;225(2):237-44
Mapping of a human LIM protein (CLP) to human chromosome 11p15.1 by fluorescence in situ hybridization. Fung YW, et al. **Genomics** 1995 Aug 10;28(3):602-3
Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts. Kohlhuber F, et al. **J Biol Chem** 1995 Dec 1; 270(48):28797-805
The cysteine-rich protein family of highly related LIM domain proteins. Weiskirchen R, et al. **J Biol Chem** 1995 Dec 1;270(48):28946-54
Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. Schauer SL, et al. **J Immunol** 1996 Jul 1;157(1):81-6
Effect of growth factors on the expression of proto-oncogenes c-fos and c-myc in FRTL-5 cell line. Yoo HY, et al. **J Korean Med Sci** 1995 Jun;10(3):155-63
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice [see comments] Leonetti C, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):419-29. Comment in: J Natl Cancer Inst 1996 Apr 3;88(7):391-3.
c-myc mRNA is stabilized by deprivation of amino acids in primary cultured rat hepatocytes. Yokota T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):455-63
Induction of c-myc and c-jun proto-oncogene expression in rat L6 myoblasts by cadmium is inhibited by zinc preinduction of the metallothionein gene. Abshire MK, et al. **J Toxicol Environ Health** 1996 Jul;48(4):359-77
Activation of MYCN in a case of non-Hodgkin's lymphoma. Finnegan MC, et al. **Leuk Lymphoma** 1995 Aug; 18(5-6):511-4
Exon 2-mediated c-myc mRNA decay in vivo is independent of its translation. Pistoi S, et al. **Mol Cell Biol** 1996 Sep; 16(9):5107-16
Signal transduction. Beating a path to Myc [news; comment] Eisenman RN, et al. **Nature** 1995 Nov 30;378(6556):438-9 . Comment on: Nature 1995 Nov 30;378(6556):509-13.
Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. Gryaznov S, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1508-14
Mouse and rat B-myc share amino acid sequence homology with the c-myc transcriptional activator domain and contain a B-myc specific carboxy terminal region. Asker CE, et al. **Oncogene** 1995 Nov 16;11(10):1963-9
Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Lutz W, et al. **Oncogene** 1996 Aug 15;13(4):803-12
A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Lotem J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9672-6
Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II. Ueda K, et al. **Virology** 1996 Mar 1;217(1):413-7
[Analysis of rearrangements in the first exon of c-myc oncogene in squamous cell carcinoma of the head and neck] Rodrigo Tapia JP, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):287-92 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Yamamoto A, et al. **Int J Cancer** 1996 Aug 22;69(4):283-9

METABOLISM

Expression of activation markers of the rheumatoid arthritis synovial membrane: comment on the article by Qu et al [letter; comment] Kinne RW, et al. **Arthritis Rheum** 1995 Sep;38(9):1346-8. Comment on: Arthritis Rheum 1994 Feb;37(2):212-20.
Transcriptional repression activity of N-MYC protein requires phosphorylation by MAP kinase. Manabe A, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):813-23
C-myc is required for the G0/G1-S transition of primary hepatocytes stimulated with a deleted form of hepatocyte growth factor. Skouteris GG, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):879-86
Deregulated c-myc expression is insufficient for emergence of the tumorigenic phenotype in malignancy-suppressed intratypic T-cell lymphoma hybrids: an in vitro model for multistep lymphomagenesis. Kubota K, et al. **Cancer Lett** 1996 Mar 29;101(2):199-203
Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859-61 (13 ref.)
Structural constraints for DNA recognition by Myc and other b-HLH-ZIP proteins: design of oncoprotein analogues. Takemoto C, et al. **Gene Expr** 1995;4(6):311-7
Specificity of single LIM motifs in targeting and LIM/LIM

interactions in situ. Arber S, et al. **Genes Dev** 1996 Feb 1;10(3):289–300

Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Ramael M, et al. **Histol Histopathol** 1995 Jul; 10(3):639–43

Oncogene expression in patients with familial polyposis coli/Gardner's syndrome. Yuwono M, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):89–95

Human T-cell leukemia virus type I tax masks c-Myc function through a cAMP-dependent pathway. Semmes OJ, et al. **J Biol Chem** 1996 Apr 19;271(16):9730–8

Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. Smith-Sørensen B, et al. **J Biol Chem** 1996 Mar 8;271(10):5513–8

Dominant negative mutants of Myc inhibit cooperation of both Myc and adenovirus serotype-5 E1a with Ras. MacGregor D, et al. **J Cell Physiol** 1996 Apr;167(1):95–105

Induced luteal regression in the primate: evidence for apoptosis and changes in c-myc protein. Fraser HM, et al. **J Endocrinol** 1995 Oct;147(1):131–7

Expression of the c-myc gene in human adrenals: regulation by adrenocorticotropin in primary cultures. Liu J, et al. **J Endocrinol** 1996 Mar;148(3):523–9

Neonatal deprivation of maternal touch may suppress ornithine decarboxylase via downregulation of the proto-oncogenes c-myc and max. Wang S, et al. **J Neurosci** 1996 Jan 15;16(2):836–42

Expression of c-myc oncoprotein in chronic T cell leukemias. Maljaie SH, et al. **Leukemia** 1995 Oct;9(10):1694–9

Variant Max protein, derived by alternative splicing, associates with c-Myc in vivo and inhibits transactivation. Arsura M, et al. **Mol Cell Biol** 1995 Dec;15(12):6702–9

Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Mol PC, et al. **Mol Cell Biol** 1995 Dec;15(12):6999–7009

Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src [see comments] Barone MV, et al. **Nature** 1995 Nov 30;378(6556):509–12. Comment in: Nature 1995 Nov 30;378(6556):438–9.

Cdc25 cell-cycle phosphatase as a target of c-myc. Galaktionov K, et al. **Nature** 1996 Aug 8;382(6591):511–7

Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Amundadottir LT, et al. **Oncogene** 1996 Aug 15;13(4):757–65

Isolation and characterization of Nmi, a novel partner of Myc proteins. Bao J, et al. **Oncogene** 1996 May 16;12(10):2171–6

Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Hurlin PJ, et al. **Oncogene** 1995 Dec 21;11(12):2487–501

Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. Li W, et al. **Oncogene** 1996 Jun 6;12(11):2473–7

Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1. Rao G, et al. **Oncogene** 1996 Mar 7;12(5):1165–72

Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Solomon DL, et al. **Oncogene** 1995 Nov 2;11(9):1893–7

c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs. Tobias KE, et al. **Oncogene** 1995 Nov 2;11(9):1721–7

Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Wu S, et al. **Oncogene** 1996 Feb 1;12(3):621–9

ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Schuldiner O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7143–8

The ratio of retinoblastoma (RB) to fos and RB to myc expression during the cell cycle. Yen A, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):205–12

PHYSIOLOGY

Proteins of the Myc network: essential regulators of cell growth and differentiation. Henriksson M, et al. **Adv Cancer Res** 1996;68:109–82 (267 ref.)

The proto-oncogene c-myc blocks myeloid differentiation independently of its target gene ornithine decarboxylase. Selvakumaran M, et al. **Blood** 1996 Aug 15;88(4):1248–55

Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Hoffman B, et al. **Curr Top Microbiol Immunol** 1996;211:17–27 (51 ref.)

Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. Steiner P, et al. **EMBO J** 1995 Oct 2;14(19):4814–26

Generation of normal lymphocytes derived from N-myc-deficient embryonic stem cells. Malynn BA, et al. **Int Immunol** 1995 Oct;7(10):1637–47

Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. Eden A, et al. **J Biol Chem** 1996 Aug 23;271(34):20242–5

Regulation of cell proliferation and differentiation by Myc. Hopewell R, et al. **J Cell Sci Suppl** 1995;19:85–9

Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells [see comments] Kang Y, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):279–84 . Comment in: J Natl Cancer Inst 1996 Mar 6;88(5):224–6.

An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Jones RM, et al. **Mol Cell Biol** 1996 Sep;16(9):4754–64

The transactivation potential of a c-Myc N-terminal region (residues 92–143) is regulated by growth factor/Ras signaling. Colman MS, et al. **Nucleic Acids Res** 1996 May 15;24(10):1971–8

Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Hermeking H, et al. **Oncogene** 1995 Oct 5;11(7):1409–15

Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation. Marhin WW, et al. **Oncogene** 1996 Jan 4;12(1):43–52

c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Packham G, et al. **Oncogene** 1996 Aug 1;13(3):461–9

c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Sakamuro D, et al. **Oncogene** 1995 Dec 7;11(11):2411–8

Sin3 corepressor function in Myc-induced transcription and transformation. Harper SE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8536–40

RADIATION EFFECTS

Effects of 50 Hz magnetic fields on C-myc transcript levels in nonsynchronized and synchronized human cells. Desjobert H, et al. **Bioelectromagnetics** 1995;16(5):277–83

PROTO-ONCOGENE PROTEINS HER-2 see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENES

Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1–23 (144 ref.)

bcl-1 gene rearrangements in paraffin-embedded tissues [letter] Hammer RD, et al. **Am J Clin Pathol** 1996 Jun; 105(6):806–7

bcl-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Kumar S, et al. **Am J Clin Pathol** 1996 Jun;105(6):737–43

Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Pinyol M, et al. **Am J Clin Pathol** 1996 May; 105(5):532–7

Investigation of the possible role of WNT genes in human breast cancer. Bergstein I, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:257

Role of reactive oxygen species (ROS) in neuronal degeneration. Modulation by protooncogene expression. Verity MA, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:340

Molecular genetics of malignant insulinoma. Pavelic K, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1707–17

Expression of bcl-2 in uveal malignant melanoma. Jay V, et al. **Arch Pathol Lab Med** 1996 May;120(5):497–8

Instability at the H-ras minisatellite is associated with the spontaneous abortion of the embryo. Kiaris H, et al **Biochem Biophys Res Commun** 1995 Sep 25;214(3):788–92

Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Borlak JT, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):517–29

BCL-6 expression during B-cell activation. Allman D, et al. **Blood** 1996 Jun 15;87(12):5257–68

REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Houldsworth J, et al. **Blood** 1996 Jan 1;87(1):25–9

The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties. Hunger SP, et al. **Blood** 1996 Jun 1;87(11):4607–17

Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Kitayama H, et al. **Blood** 1996 Aug 1; 88(3):995–1004

A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Luger SM, et al. **Blood** 1996 Feb 15;87(4):1326–34

Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Eng C, et al. **Br J Cancer** 1996 Aug;74(3):339–41

RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Williams GH, et al. **Br J Cancer** 1996 Aug;74(4):585–9

Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study. Kato S, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1654–61

Proto-RET is rearranged in the new human papillary thyroid cancer cell line PTC-1113A. Herrmann ME. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):14–20

Translocation (3;14)(q27;q11): a new variant translocation in a patient with non-Hodgkin's lymphoma of B-cell type with BCL6 rearrangement. Takahashi N, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):49–53

Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Hewitt SM, et al. **Cancer Res** 1995 Nov 15;55(22):5386–9

Seventh annual Pezcoller Symposium: cancer genes--functional aspects. Mihich E, et al. **Cancer Res** 1996 Sep 15;56(18):4282–7

Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Nagatake M, et al. **Cancer Res** 1996 Apr 15;56(8):1886–91

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195–205 (31 ref.)

Analysis of EGFR, TGF-alpha, neu and c-myc in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary tumors using RT-PCR. Davis CD, et al. **Carcinogenesis** 1995 Dec;16(12):3087–92

Interleukin 4 down-regulates expression of c-kit and autocrine stem cell factor in human colorectal carcinoma cells. Lahm H, et al. **Cell Growth Differ** 1995 Sep; 6(9):1111–8

bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. Wang Y, et al. **Cell Growth Differ** 1995 Sep;6(9):1071–5

Transient inhibition of protein synthesis induces expression of proto-oncogenes and stimulates resting cells to enter the cell cycle. Rosenwald IB, et al. **Cell Prolif** 1995 Dec; 28(12):631–44

Proto-oncogenes and plasticity in cell signaling. Bishop JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:165–71 (25 ref.)

BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117–23 (49 ref.)

Autocrine mechanism for met proto-oncogene tumorigenicity. Rong S, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:629–36

Molecular genetics of proto-oncogenes and candidate tumor suppressors in Caenorhabditis elegans. Sternberg PW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:155–63 (49 ref.)

Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35–46 (96 ref.)

Suppression of Lck protooncogene expression in murine somatic cell hybrids between T lymphoma cells and fibroblasts. Oikawa T, et al. **Cytogenet Cell Genet** 1996; 72(1):12–9

Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Durbec PL, et al. **Development** 1996 Jan;122(1):349–58

Cytokine-induced apoptotic cell death in a mouse pancreatic beta-cell line: inhibition by Bcl-2. Iwahashi H, et al. **Diabetologia** 1996 May;39(5):530–6

mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Marchetti A, et al. **Diagn Mol Pathol** 1995 Jun;4(2):93–7

Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Alexander RJ, et al. **Dig Dis Sci** 1996 Apr;41(4):660–9

The role of scatter factor and the c-met proto-oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)

The discovery of proto-oncogenes. Bishop JM. **FASEB J** 1996 Feb;10(2):362–4

Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. Sakakura C, et al. **FEBS Lett** 1996 Jan 29;379(2):177–80

Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Ohnishi H, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):187–90

Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Feinstein PG, et al. **Genetics** 1995 Jun; 140(2):573–86

High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Reiter JL, et al. **Genomics** 1996 Feb 15;32(1):97–103

The MAS proto-oncogene is not imprinted in humans. Riesewijk AM, et al. **Genomics** 1996 Jul 15;35(2):380–2

Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Gaidano G, et al. **Haematologica** 1995 Sep-Oct;80(5):454–72 (151 ref.)

Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM, et al. **Hum Genet** 1996 Jan;97(1):11–4

Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Attié T, et al. **Hum Mol Genet** 1995 Aug;4(8):1381–6

Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Kitamura Y, et al. **Hum Mol Genet** 1995 Oct;4(10):1987–8

Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Tomita Y, et al. **Int J Cancer** 1996 May 3;66(3):322–5

Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Wagener C, et al. **Int J Cancer** 1996 Jul 3;67(1):138–41

Expression of c-Mpl and c-Mpl ligand gene in hematopoietic cells of individuals with and without myeloproliferative disorders and leukemia cell lines. Sasaki A, et al. **Int J Hematol** 1995 Dec;62(4):217–23

Age-related differences in TGF-alpha and proto-oncogenes

expression in rat liver after a low dose of carbon tetrachloride. Dalu A, et al. **J Biochem Toxicol** 1995 Oct; 10(5):259–264

The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. Barnier JV, et al. **J Biol Chem** 1995 Oct 6;270(40):23381–9

Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. Brizzi MF, et al. **J Biol Chem** 1996 Feb 16; 271(7):3562–7

LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i-2 protooncogene transcription. Kinane TB, et al. **J Biol Chem** 1995 Dec 22;270(51):30760–4

c-sis/PDGF-B promoter transactivation by the Yax protein of human T-cell leukemia virus type 1. Trejo SR, et al. **J Biol Chem** 1996 Jun 14;271(24):14584–90

Progress against cancer. Broder S, et al. **J Cancer Res Clin Oncol** 1995;121(11):633–47 (134 ref.)

RET mutation screening in sporadic pheochromocytoma [letter; comment] Arnold A. **J Clin Endocrinol Metab** 1996 Jan;81(1):430. Comment on: J Clin Endocrinol Metab 1995 Jul;80(7):2063–8.

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Romei C, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1619–22

Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. Zedenius J, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3088–90

Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age. Chin JH, et al. **J Clin Invest** 1996 May 15; 97(10):2316–23

Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. Liang TJ, et al. **J Clin Invest** 1996 Jun 15;97(12):2872–7

Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. Schunkert H, et al. **J Clin Invest** 1995 Dec;96(6):2768–74

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon I, et al. **J Clin Invest** 1996 Jan 1; 97(1):187–95

Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H-2b alloantigens. López-Hoyos M, et al. **J Exp Med** 1996 Jun 1;183(6):2523–31

pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1. Wingett D, et al. **J Immunol** 1996 Jan 15;156(2):549–57

Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays. Boise LH, et al. **J Immunol Methods** 1996 May 27;191(2):143–8

RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis. Schuchardt A, et al. **J Intern Med** 1995 Oct;238(4):327–32

Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. Crossey PA, et al. **J Med Genet** 1995 Nov;32(11):885–6

Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. Sbih-Lammali F, et al. **J Med Virol** 1996 May; 49(1):7–14

Molecular biology of testicular germ cell tumors: current status. Schmidt B, et al. **J Mol Med** 1995 Jul;73(7):355–67 (189 ref.)

Proto-oncogene expression in human glomerular diseases. Takemura T, et al. **J Pathol** 1996 Mar;178(3):343–51

Effects of anti-E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl-2. Després P, et al. **J Virol** 1995 Nov;69(11):7006–14

A novel non-mouse mammary tumor virus activation of the Int-3 gene in a spontaneous mouse mammary tumor. Kordon EC, et al. **J Virol** 1995 Dec;69(12):8066–9

Intratumoral heterogenеity of hst-1 gene amplification in esophageal carcinoma with reference to DNA stem line heterogeneity. Chikuba K, et al. **Jpn J Clin Oncol** 1995 Dec;25(6):229–33

Enhanced expression of bcl-2 inhibits apoptosis in cultured human keratinocytes. Maeyama Y. **Kurume Med J** 1995; 42(4):291–7

p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Chang H, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):165–71

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3-4):231–6 (32 ref.)

BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Offit K, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):85–9

Preservation of functional and regulatory domains of expressed bcl-2 genes in non-Hodgkin's lymphoma. Dirks W, et al. **Leukemia** 1996 Jan;10(1):150–8

Bax mutations in cell lines derived from hematological malignancies. Meijerink JP, et al. **Leukemia** 1995 Nov; 9(11):1828–32

Internal DNA deletion within the BCL-6 gene on untranslocated chromosome in non-Hodgkin's lymphoma with 3q27 abnormality. Nakamura Y, et al. **Leukemia** 1996 Apr;10(4):658–61

Expression of bcl-2 mRNA and protein in leukemia-lymphoma cell lines. Steube KG, et al. **Leukemia** 1995 Nov;9(11):1841–6

Elevated pim-1 and c-myc proto-oncogene induction in B lymphocytes from BLV-infected cows with persistent B lymphocytosis. Stone DM, et al. **Leukemia** 1996 Oct; 10(10):1629–38

Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)

Microsatellite instability in IVS3 of murine c-fes gene: tumor-associated rearrangement and mammalian divergence. Volpi L, et al. **Mamm Genome** 1996 Sep; 7(9):682–5

Polycomb and bmi-1 homologs are expressed in overlapping patterns in Xenopus embryos and are able to interact with each other. Reijnen MJ, et al. **Mech Dev** 1995 Sep; 53(1):35–46

Fingerprinting of DNA and RNA by arbitrarily primed polymerase chain reaction: applications in cancer research. Perucho M, et al. **Methods Enzymol** 1995;254:275–90

Replication-competent and -defective retrovirus vectors for oncogenic studies. Samarut J, et al. **Methods Enzymol** 1995; 254:206–28

Superfamilies of protooncogenes: homology cloning and characterization of related members. Yamamoto T, et al. **Methods Enzymol** 1995;254:169–83

Cell transformation by dbl oncogene. Zangrilli D, et al. **Methods Enzymol** 1995;256:347–58

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Borrello MG, et al. **Mol Cell Biol** 1996 May;16(5):2151–63

Phenotypic reversions at the W/Kit locus mediated by mitotic recombination in mice. De Sepulveda P, et al. **Mol Cell Biol** 1995 Nov;15(11):5898–905

The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor. Heydemann A, et al. **Mol Cell Biol** 1996 Apr;16(4):1676–86

Identification of an inducible regulator of c-myb expression during T-cell activation. Phan SC, et al. **Mol Cell Biol** 1996 May;16(5):2387–93

The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Ribon V, et al. **Mol Cell Biol** 1996 Jan;16(1):45–52

Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Lacronique V, et al. **Nat Med** 1996 Jan;2(1):80–6

A matter of life or death: is the Bcl-2 anti-apoptosis gene involved in neural plasticity in the olfactory system? [comment] Getchell TV. **Neuroreport** 1995 Dec 29;7(1):9 . Comment on: Neuroreport 1995 Dec 29;7(1):197–200.

A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Choi SS, et al. **Oncogene** 1995 Nov 2;11(9):1693–8

An Inr-containing sequence flanking the TATA box of the human c-sis (PDGF-B) proto-oncogene promoter functions in cis as a co-activator for its intronic enhancer. Franklin GC, et al. **Oncogene** 1995 Nov 2;11(9):1873–84

Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T, et al. **Oncogene** 1996 Feb 1;12(3):481–7

High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Klugbauer S, et al. **Oncogene** 1995 Dec 21; 11(12):2459–67

Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Kurokawa M, et al. **Oncogene** 1996 Feb 15;12(4):883–92

The Wnt-1 proto-oncogene regulates MAP kinase activation by multiple growth factors in PC12 cells. Pan MG, et al. **Oncogene** 1995 Nov 16;11(10):2005–12

The physical map of the human RET proto-oncogene. Pasini B, et al. **Oncogene** 1995 Nov 2;11(9):1737–43

Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Vider BZ, et al. **Oncogene** 1996 Jan 4; 12(1):153–8

RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Viglietto G, et al. **Oncogene** 1995 Sep 21; 11(6):1207–10

The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression. Zheng S, et al. **Oncogene** 1996 Feb 1;12(3):555–62

Int-2 influences the development of the nodose ganglion. Qin F, et al. **Pediatr Res** 1995 Oct;38(4):485–92

Axotomized neonatal motoneurons overexpressing the bcl2 proto-oncogene retain functional electrophysiological properties. Alberi S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3978–83

Myc and Max: molecular evolution of a family of proto-oncogene products and their dimerization partner. Atchley WR, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10217–21

bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7042–7

The BCL2 major breakpoint region is a sequence- and cell-cycle-specific binding site of the Ku antigen. DiCroce PA, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10137–41

Pax3 modulates expression of the c-Met receptor during limb muscle development. Epstein JA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4213–8

Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Fears S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1642–7

Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Migliazza A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12520–4

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Nagata H, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10560–4

Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Wang Q, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3444–9

Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Munglani R, et al. **Prog Brain Res** 1995;104:283–98 (114 ref.)

Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. **Verh Dtsch Ges Pathol** 1995;79:L-LV

[Correlation of c-met activation with human carcinogenesis] Gao CF, et al. **Sheng Li Ke Hsueh Chin Chan** 1995 Jul; 26(3):243–5 (8 ref.) **(Chi)**

[Endocrine surgery. Series 6: Alteration of RET proto-oncogene and clinical implication in medullary thyroid carcinoma. Genetic screening of family members at risk for inherited medullary thyroid carcinoma] Kitamura Y, et al. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):228–32 **(Jpn)**

[Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266–70 (42 ref.) (Eng. Abstr.) **(Nor)**

DRUG EFFECTS

Differential EGF action on nuclear protooncogenes in human endometrial carcinoma RL95-2 cells. Sallot M, et al. **Anticancer Res** 1996 Jan-Feb;16(1):401–6

Bradykinin upregulates immediate-early gene mRNA in human keratinocytes. Coutant KD, et al. **Arch Dermatol Res** 1996;288(1):2–6

Down-regulation of bcl-xs gene expression in rat thymocytes by dexamethasone. Sakamoto T, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):511–6

Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells. Buckley AR, et al. **Endocrinology** 1995 Dec;136(12):5252–9

Prolactin, proliferation, and protooncogenes [editorial] Horseman ND. **Endocrinology** 1995 Dec;136(12):5249–51

Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium. Nephew KP, et al. **Endocrinology** 1996 Jan;137(1):219–24

Expression of estrogen receptor and proto-oncogene messenger ribonucleic acids in reproductive tracts of neonatally diethylstilbestrol-exposed female mice with or without post-puberal estrogen administration. Kamiya K, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):111–22

Repression of the c-myb gene by WT1 protein in T and B cell lines. McCann S, et al. **J Biol Chem** 1995 Oct 6; 270(40):23785–9

GENETICS

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Picksley SM, et al. **Acta Oncol** 1996;35(4):429–34

Regulation of c-myb expression in ML-1 human myeloblastic leukemia cells by c-ets-1 protein. Bloch A, et al. **Adv Enzyme Regul** 1995;35:35–41

RET proto-oncogene mutations and rearrangements in endocrine diseases [comment] Lloyd RV. **Am J Pathol** 1995 Dec;147(6):1539–44. Comment on: Am J Pathol 1995 Dec;147(6):1600–7.

Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland [see comments] Padberg BC, et al. **Am J Pathol** 1995 Dec; 147(6):1600–7. Comment in: Am J Pathol 1995 Dec;147(6):1539–44.

Differential effect of interleukin-4 and transforming growth factor beta 1 on expression of proto-oncogenes and autocrine insulin-like growth factor II in colorectal carcinoma cells. Lahm H, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):334–40

Embryo infiltration by maternal macrophages is associated with selective expression of proto-oncogenes in a murine model of spontaneous abortion. Duclos AJ, et al. **Biol Reprod** 1996 May;54(5):1088–95

The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Saegusa M, et al. **Cancer** 1995 Dec 1;76(11):2297–303

The BAX gene maps to the glioma candidate region at

19q13.3, but is not altered in human gliomas. Chou D, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):136–40

Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Fugazzola L, et al. **Cancer Res** 1995 Dec 1;55(23):5617–20

Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Katabuchi H, et al. **Cancer Res** 1995 Dec 1; 55(23):5556–60

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Marsh DJ, et al. **Cancer Res** 1996 Mar 15;56(6):1241–3

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Marsh DJ, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):249–57

No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B. Toogood AA, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):759–62

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905–13 (100 ref.)

Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma. Kimura T, et al. **Endocr J** 1995 Aug;42(4):517–25

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S, et al. **Endocr J** 1995 Aug;42(4):527–36

Monoclonal lymphocyte proliferation and bcl-2 rearrangement in essential mixed cryoglobulinaemia. Ellis M, et al. **Eur J Clin Invest** 1995 Nov;25(11):833–7

Cell cycle progression proteins (cyclins), oncogene expression, and signal transduction during the proliferative response of human hepatocytes to hepatocyte growth factor. Gómez-Lechón MJ, et al. **Hepatology** 1996 May; 23(5):1012–9

PAX genes: what's new in developmental biology and cancer? Stuart ET, et al. **Hum Mol Genet** 1995;4 Spec No:1717–20 (52 ref.)

Differential expression of the bcl-2 oncogene in human basal cell carcinoma. Crowson AN, et al. **Hum Pathol** 1996 Apr; 27(4):355–9

The RET proto-oncogene and cancer. Donis-Keller H. **J Intern Med** 1995 Oct;238(4):319–25

Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. Gagel RF, et al. **J Intern Med** 1995 Oct;238(4):333–41

From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. Lips CJ, et al. **J Intern Med** 1995 Oct;238(4):347–56

Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Mulligan LM, et al. **J Intern Med** 1995 Oct; 238(4):343–6

RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)

Effects of dietary protein on the induction of DNA synthesis and expression of growth-related genes in liver and kidney of growing rats. Yokota T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):227–39

Differential expression of the protooncogene bcl-2 in normal and osteoarthritic human articular cartilage. Erlacher L, et al. **J Rheumatol** 1995 May;22(5):926–31

Expression of growth factors, proto-oncogenes, and p53 in nasopharyngeal angiofibromas. Nagai MA, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):190–5

Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Campos L, et al. **Leukemia** 1996 Mar;10(3):434–8

Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Dyer MJ, et al. **Leukemia** 1996 Jul;10(7):1198–208

Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C. **N Engl J Med** 1996 Sep 26;335(13):943–51 (89 ref.)

Tissue-specific expression, evolutionary conservation and localization of the cph proto-oncogene on Syrian hamster chromosome X. Velasco JA, et al. **Oncogene** 1996 Jun 20; 12(12):2713–7

Sequence of the canine c-yes proto-oncogene. Zhao DM, et al. **Res Vet Sci** 1995 Nov;59(3):230–3

RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Jhiang SM, et al. **Thyroid** 1996 Apr;6(2):115–21

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?—An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65–74 (78 ref.)

Clonal variations among multiple primary mammary tumors and within a tumor of individual mice: insertion mutations of int oncogenes. Sarkar NH. **Virology** 1995 Oct 1; 212(2):490–9

[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):131–41 (37 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Schröter M, et al. **Eur J Immunol** 1995 Dec;25(12):3509–13

Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Fang W, et al. **Immunity** 1996 Mar;4(3):291–9

Regulation of B cell survival in xid mice by the proto-oncogene bcl-2. Woodland RT, et al. **J Immunol** 1996 Mar 15;156(6):2143–54

PHYSIOLOGY

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Del Bufalo D, et al. **Br J Cancer** 1996 Aug;74(3):387–93

Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Gauthier ER, et al. **Cancer Res** 1996 Mar 15;56(6):1451–6

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)

Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Schröter M, et al. **Eur J Immunol** 1995 Dec;25(12):3509–13

Bcl-2 expression in malignant melanoma and its prognostic significance. Grover R, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):347–9

Changes in proto-oncogene activity in the testis of the frog, Rana esculenta, during the annual reproductive cycle. Chieffi P, et al. **Gen Comp Endocrinol** 1995 Aug; 99(2):127–36

Lack of intestinal pacemaker (C-KIT-positive) cells in infantile hypertrophic pyloric stenosis. Yamataka A, et al. **J Pediatr Surg** 1996 Jan;31(1):96–8; discussion 98–9

The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Gaudino G, et al. **Oncogene** 1995 Dec 21;11(12):2627–37

Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Katzav S, et al. **Oncogene** 1995 Sep 21;11(6):1079–88

Transcriptional repression by the proto-oncogene BCL-6. Seyfert VL, et al. **Oncogene** 1996 Jun 6;12(11):2331–42

v-rel and c-rel induce a membrane protein, p75, on avian hematopoietic cells. Zhang G, et al. **Oncogene** 1996 Mar 7;12(5):1153–7

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. Hallahan DE, et al. **J Biol Chem** 1995 Dec 22; 270(51):30303–9

Sequential alteration of proto-oncogene expression in liver, spleen, kidney and brain of mice subjected to whole body irradiation. Ogawa Y, et al. **Oncology** 1996 Sep-Oct; 53(5):412–6

PROTOCHLOROPHYLLIDE

CHEMISTRY

Protochlorophyllide reductase. III: Synthesis of a protochlorophyllide-dihydroflavin complex. Nayar P, et al. **Photochem Photobiol** 1996 Jan;63(1):100–5

METABOLISM

Protochlorophyllide reduction: a key step in the greening of plants. Fujita Y. **Plant Cell Physiol** 1996 Jun;37(4):411–21

PROTOCHLOROPHYLLIDE A see **PROTOCHLOROPHYLLIDE**

PROTOCOL-DIRECTED THERAPY, COMPUTER-ASSISTED see **THERAPY, COMPUTER-ASSISTED**

PROTOCOL DRUG THERAPY, COMPUTER-ASSISTED see **DRUG THERAPY, COMPUTER-ASSISTED**

PROTOCOLLAGEN see **PROCOLLAGEN**

PROTOCOLLAGEN LYSYL HYDROXYLASE see **PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE**

PROTOCOLLAGEN PROLYL HYDROXYLASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

PROTOHEME see **HEME**

PROTON-INDUCED X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

PROTON-MOTIVE FORCE

see related
PROTON PUMP

Membrane insertion of the F-pilin subunit is Sec independent but requires leader peptidase B and the proton motive force. Majdalani N, et al. **J Bacteriol** 1996 Jul;178(13):3742–7

The proton motive force generated in Leuconostoc oenos by L-malate fermentation. Salema M, et al. **J Bacteriol** 1996 Jun;178(11):3127–32

The proton/electron ration of the menaquinone-dependent electron transport from dihydrogen to tetrachloroethene in "Dehalobacter restrictus". Schumacher W, et al. **J Bacteriol** 1996 Apr;178(8):2328–33

DRUG EFFECTS

Ammonium/urea-dependent generation of a proton electrochemical potential and synthesis of ATP in Bacillus pasteurii. Jahns T. **J Bacteriol** 1996 Jan;178(2):403–9

PHYSIOLOGY

Membrane potential-generating transport of citrate and malate catalyzed by CitP of Leuconostoc mesenteroides. Marty-Teysset C, et al. **J Biol Chem** 1995 Oct 27; 270(43):25370–6

PROTON PUMP

see related
H(+)-TRANSPORTING ATP SYNTHASE

Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)

ANALYSIS

The pegs on the decorated tubules of the contractile vacuole complex of Paramecium are proton pumps. Fok AK, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3163–70

ANTAGONISTS & INHIBITORS

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

Drugs for pH control in upper gastrointestinal bleeding. Brunner G, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 1:47–50 (26 ref.)

Omeprazole may delay gastric emptying? DeVault KR. **Am J Gastroenterol** 1996 Sep;91(9):1869–70

Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Orlando RC. **Am J Gastroenterol** 1996 Sep;91(9):1692–6 (22 ref.)

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Robinson M, et al. **Ann Intern Med** 1996 May 15;124(10):859–67

Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum. Nagata K, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2187–92

Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Ochiai H, et al. **Antiviral Res** 1995 Aug;27(4):425–30

Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Tsuchiya M, et al. **Biol Pharm Bull** 1995 Aug;18(8):1053–6

A comparison of intravenous ranitidine and omeprazole on gastric volume and pH in women undergoing emergency caesarean section. Tripathi A, et al. **Can J Anaesth** 1995 Sep;42(9):797–800

Omeprazole causes delay in gastric emptying of digestible meals. Benini L, et al. **Dig Dis Sci** 1996 Mar;41(3):469–74

Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter. Aoyama N, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S86–9

Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. Asaki S, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S56–8

Clinical study on the pathophysiology and treatment of PPI-resistant ulcers. Ashida K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S67–71

Quality of peptic ulcer healing induced by lansoprazole and roxatidine. Fujino MA, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S44–6

Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa. Fukuda T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S5–7

Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. Fukuda Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S132–5

Effects of lansoprazole with or without amoxicillin on ulcer

healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107–11

Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration? Hoshino E, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S72–4

Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring. Inoue M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S17–21

Factors affecting quality of ulcer healing after lansoprazole treatment. Ito G, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S62–6

Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. Katoh M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S112–4

Effects of lansoprazole on gastric ulcer healing and mucin content. Komuro Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S47–51

The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. Mine T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S75–8

Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. Murakami M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S79–82

Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth. Nakajima N, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S90–2

Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings. Obara K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S36–9

Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. Ogoshi K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S97–9

Effect of lansoprazole on peptic ulcers. Ohashi T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S83–5

Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress. Otani Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S22–6

Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. Sakaguchi M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S27–31

Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S100–3

Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. Shimoyama T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S125–7

Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. Shirai T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S128–31

Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring. Sugiyama M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S14–6

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. Sugiyama T, et al. **J Clin Gastroenterol** 1995; 20 Suppl 2:S104–6

Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. Suzuki M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S93–6

Efficacy of lansoprazole in eradication of Helicobacter pylori. Takimoto T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S121–4

Endosonographic evaluation of the quality of ulcer healing induced by proton pump inhibitors. Tsukamoto Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S40–3

Lansoprazole--a new proton pump inhibitor [letter] Ahmed W, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):144–5

Anti-helicobacter regimens [letter; comment] Harris A, et al. **Lancet** 1996 Apr 27;347(9009):1193–4. Comment on: Lancet 1996 Mar 16;347(9003):763.

Anti-helicobacter regimens [letter; comment] Savarino V, et al. **Lancet** 1996 Apr 27;347(9009):1194. Comment on: Lancet 1996 Mar 16;347(9003):763.

[Proton pump blockers and their significance in gastroenterology] Dítě P, et al. **Vnitr Lek** 1995 Aug; 41(8):549–54 (23 ref.) (Eng. Abstr.) **(Cze)**

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

[Gastroesophageal reflux: current status of therapy] Seifert E. **Leber Magen Darm** 1995 Jul;25(4):156–60, 163 (55 ref.) (Eng. Abstr.) **(Ger)**

[Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons] Holtmann G, et al. **Z Gastroenterol** 1996 May; 34(5):267–72 (Eng. Abstr.) **(Ger)**

[Treatment of H2-blocker-resistant reflux esophagitis in severely handicapped children with omeprazole] Maeoka Y, et al. **No To Hattatsu** 1996 Jan;28(1):74–7 **(Jpn)**

DRUG EFFECTS

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Proton pump inhibitors: new drugs and indications. Mears JM, et al. **Am Fam Physician** 1996 Jan;53(1):285–92 (38 ref.)

Effect of current direction and K+ on polarization of the frog gastric mucosa proton pump. Carrasquer G, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):41–7

Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Katashima M, et al. **Drug Metab Dispos** 1995 Jul; 23(7):718–23

Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat. Morini G, et al. **Gen Pharmacol** 1995 Sep;26(5):1021–5

A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. Hirai M, et al. **J Gastroenterol** 1995 Aug;30(4):461–4

Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradication--a meta-analysis [letter] [see comments] Holtmann G, et al. **Lancet** 1996 Mar 16; 347(9003):763. Comment in: Lancet 1996 Apr 27;347(9009):1193–4. Comment in: Lancet 1996 Apr 27;347(9009):1194.

GENETICS

Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Li YP, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):813–21

Functional expression of bacteriorhodopsin in oocytes allows direct measurement of voltage dependence of light induced H+ pumping. Nagel G, et al. **FEBS Lett** 1995 Dec 18; 377(2):263–6

METABOLISM

A ligand-exchange mechanism of proton pumping involving tyrosine-422 of subunit I of cytochrome oxidase is ruled out. Mitchell DM, et al. **Biochemistry** 1996 Jan 23; 35(3):824–8

Control of the integral membrane proton pump, bacteriorhodopsin, by purple membrane lipids of Halobacterium halobium. Mukhopadhyay AK, et al. **Biochemistry** 1996 Jul 16;35(28):9245–52

Effects of hydrostatic pressure on the kinetics reveal a volume increase during the bacteriorhodopsin photocycle. Váró G, et al. **Biochemistry** 1995 Sep 26;34(38):12161–9

The vacuolar ATPase proton pump is required for the cytotoxicity of Bacillus anthracis lethal toxin. Ménard A, et al. **FEBS Lett** 1996 May 20;386(2–3):161–4

ATP-dependent H+ -pump activity in inverted vesicles of Methanosarcina mazei Gö1 and characterization of membrane ATPase. Inatomi KI. **J Bacteriol** 1996 Apr; 178(8):2424–6

Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. Moriyama Y. **J Exp Biol** 1996 Jul;199 (Pt 7):1447–54 (70 ref.)

[Membrane fusion between Ehrlich ascites of mastocarcinoma cells and liposome induced by proton translocation of transplasma membrane NADH-ferricyanide redox enzymes] Liu SS, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Jun;28(2):137–45 (Eng. Abstr.) **(Chi)**

[Character of K+ absorption and its interaction with membrane protein pumps in Escherichia coli, grown under anaerobic conditions in the presence of nitrate] Bagramian KA, et al. **Biofizika** 1996 Mar-Apr;41(2):377–83 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Chemoattractant-induced activation of vacuolar H+ pumps and of an H(+)-selective conductance in neutrophils. Nanda A, et al. **J Cell Physiol** 1995 Dec;165(3):588–99

The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. Papini E, et al. **J Med Microbiol** 1996 Aug;45(2):84–9

Acidification of the male reproductive tract by a proton pumping (H+)-ATPase. Breton S, et al. **Nat Med** 1996 Apr;2(4):470–2

PROTON-TRANSLOCATING ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

PROTONS

Dietary protein regimens and chronic ethanol administration effects on sodium- and proton-dependent solute uptake in rat intestine. Kaur J, et al. **Alcohol** 1995 Sep-Oct; 12(5):459–62

Angiotensin II stimulates sodium-dependent proton extrusion in perfused ferret heart. Grace AA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1687–94

Spectrophotometric assay for processes involving changes in hydrogen ion concentration in aqueous solution. Penketh PG, et al. **Anal Biochem** 1996 Jun 15;238(1):46–9

Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Simkhovich BZ, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):397–403

Small pH gradients inhibit cytochrome c oxidase: implications for H+ entry to the binuclear center. Sharpe MA, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):931–8

Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-cholorophenyl) urea (LY181984). Sun E, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1461–8

An active site phenylalanine of 3-oxo-delta 5-steroid isomerase is catalytically important for proton transfer. Brothers PN, et al. **Biochemistry** 1995 Nov 28; 34(47):15453–8

Solvent-derived protons in catalysis by brewers' yeast pyruvate decarboxylase. Harris TK, et al. **Biochemistry** 1995 Oct 31;34(43):14001–11

Distribution of the thiamin diphosphate C(2)-proton during catalysis of acetaldehyde formation by brewers' yeast pyruvate decarboxylase. Harris TK, et al. **Biochemistry** 1995 Oct 31;34(43):13994–4000

Structure-based design of an intramolecular proton transfer site in murine carbonic anhydrase V. Heck RW, et al. **Biochemistry** 1996 Sep 10;35(36):11605–11

Estimation of the H+/H- ratio of the reaction catalysed by the nicotinamide nucleotide transhydrogenase in chromatophores from over-expressing strains of Rhodospirillum rubrum and in liposomes inlaid with the purified bovine enzyme. Bizouarn T, et al. **Biochim Biophys Acta** 1996 Jan 11;1273(1):4–12

Effect of pH buffers on proton secretion from gastric oxyntic cells measured with vibrating ion-selective microelectrodes. Demarest JR, et al. **Biol Bull** 1995 Oct-Nov;189(2):219–20

Pattern of potassium ion and proton currents in the ovariole of the cockroach, Periplaneta americana, indicates future embryonic polarity. Kunkel JG, et al. **Biol Bull** 1995 Oct-Nov;189(2):197–8

Proton and potassium transport by H+/K(+)-ATPases. van Driel IR, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):952–60 (91 ref.)

Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Harguindey S, et al. **Crit Rev Oncog** 1995;6(1):1–33 (303 ref.)

Intrinsic hydrogen ion buffering in rat CNS neurones maintained in culture. Amos BJ, et al. **Exp Physiol** 1996 Mar;81(2):261–71

Regulation of the H+/e- stoichiometry of cytochrome c oxidase from bovine heart by intramitochondrial ATP/ADP ratios. Frank V, et al. **FEBS Lett** 1996 Mar 11;382(1–2):121–4

Dose equivalent measurements at a 2.7 GeV proton accelerator and comparison with the Moyer model. Bourgois L, et al. **Health Phys** 1996 Jan;70(1):36–40

Dose equivalent near the bone-soft tissue interface from nuclear fragments produced by high-energy protons. Shavers MR, et al. **Health Phys** 1996 Apr;70(4):473–83

On the mechanism of fatty acid-induced proton transport by mitochondrial uncoupling protein. Garlid KD, et al. **J Biol Chem** 1996 Feb 2;271(5):2615–20

Imino proton exchange provides an 1H-NMR footprint of protein-DNA interactions: general strategy and application to the SRY HMG box. Weiss MA, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):261–8

The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons. Lande MB, et al. **J Gen Physiol** 1995 Jul;106(1):67–84

A voltage-dependent and pH-sensitive proton current in Rana esculenta oocytes. Humez S, et al. **J Membr Biol** 1995 Sep;147(2):207–15

Effects of H+ liberated from hydrolytic cleavage of polyester microcapsules on their permeability and degradability. Sah H, et al. **J Pharm Sci** 1995 Nov; 84(11):1353–9

Lactate and H+ uptake in inactive muscles during intense exercise in man. Bangsbo J, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):219–29

Voltage-activated proton currents in membrane patches of rat alveolar epithelial cells. DeCoursey TE, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):299–307

Modification by protons of frog skeletal muscle KATP channels: effects on ion conduction and nucleotide inhibition. Vivaudou M, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):629–45

Proton activation analysis of stable isotopes for a molybdenum biokinetics study in humans. Cantone MC, et al. **Med Phys** 1995 Aug;22(8):1293–8

Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry. Doyle ML, et al. **Methods Enzymol** 1995;259:183–94

Transcriptional regulation of the proton translocating NADH dehydrogenase genes (nuoA-N) of Escherichia coli by electron acceptors, electron donors and gene regulators. Bongaerts J, et al. **Mol Microbiol** 1995 May;16(3):521–34

Lateral proton diffusion [letter; comment] Teissié J. **Nature** 1996 Jan 25;379(6563):305–6. Comment on: Nature 1995 Mar 16;374(6519):222.

Proton modulation of outward K+ currents in interferon-gamma-activated microglia. Eder C, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):101–4

PROTONS

Intracellular free calcium responses to protons and capsaicin in cultured trigeminal neurons. García-Hirschfeld J, et al. **Neuroscience** 1995 Jul;67(1):235–43

Base-boronated dinucleotides: synthesis and effect of N7-cyanoborane substitution on the base protons. Hasan A, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2150–7

pH regulation and proton signalling by glial cells. Deitmer JW, et al. **Prog Neurobiol** 1996 Feb;48(2):73–103 (265 ref.)

The quality of DNA double-strand breaks: a Monte Carlo simulation of the end-structure of strand breaks produced by protons and alpha particles. Ottolenghi A, et al. **Radiat Environ Biophys** 1995 Nov;34(4):239–44

Measurements of radiobiological effectiveness in the 85 MeV proton beam produced at the cyclotron CYCLONE of Louvain-la-Neuve, Belgium. Gueulette J, et al. **Radiat Res** 1996 Jan;145(1):70–4

Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. Wouters BG, et al. **Radiat Res** 1996 Aug;146(2):159–70

Inflammation reduces mucosal secretion of hydrogen ions and impairs concentrating function and luminal acidification in feline gallbladder. Nilsson B, et al. **Scand J Gastroenterol** 1995 Oct;30(10):1021–6

Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB. Zahn R, et al. **Science** 1996 Feb 2;271(5249):642–5

Nuclear spin-lattice relaxation mechanisms in kaolinite confirmed by magic-angle spinning. Hayashi S, et al. **Solid State Nucl Magn Reson** 1995 Aug;4(6):331–40

Separating subspectra from cross-polarization magic-angle spinning nuclear magnetic resonance spectra by proton spin relaxation editing. Newman RH, et al. **Solid State Nucl Magn Reson** 1995 Jul;4(5):259–66

Measurement of Hartmann-Hahn cross-polarization dynamics with quenching of proton T1 rho relaxation dependence. Tekely P, et al. **Solid State Nucl Magn Reson** 1995 Aug;4(6):361–7

Proton production and consumption pathways in yeast metabolism. A chemostat culture analysis. Castrillo JI, et al. **Yeast** 1995 Nov;11(14):1353–65

[Which equipment for proton therapy of the future?] Schwartz LH, et al. **Bull Cancer Radiother** 1995;82(4):365–9 (Eng. Abstr.) **(Fre)**

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Effects of proton irradiation on radiolabeled monoclonal antibody uptake in human colon tumor xenografts. Gridley DS, et al. **J Immunother Emphasis Tumor Immunol** 1995 May;17(4):229–37

A review of proton beam radiation therapy. Miller DW. **Med Phys** 1995 Nov;22(11 Pt 2):1943–54 (84 ref.)

Faraday cup dosimetry in a proton therapy beam without collimation. Grusell E, et al. **Phys Med Biol** 1995 Nov; 40(11):1831–40

Deduction of the air w value in a therapeutic proton beam. Siebers JV, et al. **Phys Med Biol** 1995 Aug;40(8):1339–56

Applications of proton beam therapy. Nicholson J, et al. **Radiol Technol** 1996 May-Jun;67(5):439–41 (9 ref.)

[Application of protons in the treatment of malignant tumors] Barendsen GW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2407–9 **(Dut)**

[Proton therapy in Japan] Schwartz LH, et al. **Bull Cancer Radiother** 1995;82(3):279–82 (Eng. Abstr.) **(Fre)**

PROTOPLASMIC STREAMING see **CYTOPLASMIC STREAMING**

PROTOPLASTS

Generation of giant protoplasts of Escherichia coli and an inner-membrane anion selective conductance. Kubalski A. **Biochim Biophys Acta** 1995 Sep 13;1238(2):177–82

Expression of the tomato ringsport nepovirus movement and coat proteins in protoplasts. Sanfaçon H, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2299–303

Agrobacterium-mediated transformation of protoplasts from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:71–8

CHEMISTRY

Ultrahigh-resolution low-voltage SEM reveals ultrastructure of the glucan network formation from fission yeast protoplast. Osumi M, et al. **J Electron Microsc (Tokyo)** 1995 Aug;44(4):198–206

CYTOLOGY

Enhanced protoplast growth at the interface between oxygenated fluorocarbon liquid and aqueous culture medium supplemented with pluronic F-68. Lowe KC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):417–22

Protoplast culture and plant regeneration from the suspension cells of Gynostemma pentaphyllum (Thumb) Mak. Zhang H, et al. **Chin J Biotechnol** 1995;11(3):207–11

[Interspecific protoplast fusion between Bacillus thuringensis Bt-3701 and Bacillus megaterium Bm-107] Mu G, et al. **Wei Sheng Wu Hsueh Pao** 1995 Oct;35(5):322–6 (Eng. Abstr.) **(Chi)**

METABOLISM

Ionic transport in the plasma membrane of carrot protoplasts from embryogenic cell-suspension cultures. Bregante M, et al. **FEBS Lett** 1996 Feb 12;380(1–2):97–102

The use of protoplasts to study protein synthesis and transport by the plant endomembrane system. Denecke J, et al. **Methods Cell Biol** 1995;50:335–48

Phytotoxic effect of deoxynivalenol and gibberella ear rot resistance of corn. Cossette F, et al. **Nat Toxins** 1995; 3(5):383–8

PHYSIOLOGY

Response of yeast protoplasts to their mating partners. Pokorná I, et al. **Folia Microbiol (Praha)** 1995;40(6):583–7

Kinetic analysis of two simultaneously activated K+ currents in root cell protoplasts of Plantago media L. Vogelzang SA, et al. **J Membr Biol** 1995 Jul;146(1):59–71

Protoplast electrofusion and regeneration in potato. Cheng J, et al. **Methods Mol Biol** 1995;55:181–8

Electrofusion of plant protoplasts. Selection and screening for somatic hybrids of Nicotiana. Trick HN, et al. **Methods Mol Biol** 1995;55:165–79

Electrofusion of yeast protoplasts. Weber H, et al. **Methods Mol Biol** 1995;47:93–104

Polymer-supported electrofusion of protoplasts. A novel method and a synergistic effect. Zhang L. **Methods Mol Biol** 1995;55:189–202

Fusiogenic activity of natural amphiphiles, 5-n-alkylresorcinols in a yeast protoplast system. Kozubek A, et al. **Z Naturforsch [C]** 1995 Sep-Oct;50(9–10):656–9

ULTRASTRUCTURE

Ultrahigh-resolution low-voltage SEM reveals ultrastructure of the glucan network formation from fission yeast protoplast. Osumi M, et al. **J Electron Microsc (Tokyo)** 1995 Aug;44(4):198–206

Tobacco protoplast transformation and use for functional analysis of newly isolated genes and gene constructs. Fischer R, et al. **Methods Cell Biol** 1995;50:401–10

Preparation and transformation of monocot protoplasts. Maas C, et al. **Methods Cell Biol** 1995;50:383–99

VIROLOGY

Inhibition of brome mosaic virus (BMV) amplification in protoplasts from transgenic tobacco plants expressing replicable BMV RNAs. Kaido M, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2827–33

PROTOPORPHYRIA, ERYTHROPOIETIC see **PORPHYRIA, ERYTHROHEPATIC**

PROTOPORPHYRINS

Intramolecular electronic energy transfer in peptides carrying naphthalene and protoporphyrin molecules: a spectroscopic and conformational statistics investigation. Pispisa B, et al. **Biopolymers** 1995 Oct;36(4):497–510

On the role of protoporphyrin IX photoproducts in photodynamic therapy [news] Gudgin Dickson EF, et al. **J Photochem Photobiol B** 1995 Jul;29(1):91–3

ANALYSIS

Protoporphyric disorder in livers of broiler chickens. Shiozawa M, et al. **J Vet Med Sci** 1995 Jun;57(3):549–51

Fourier transform multipixel spectroscopy and spectral imaging of protoporphyrin in single melanoma cells. Malik Z, et al. **Photochem Photobiol** 1996 May;63(5):608–14

BIOSYNTHESIS

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Orenstein A, et al. **Br J Cancer** 1996 Apr; 73(8):937–44

Anaerobic protoporphyrin biosynthesis does not require incorporation of methyl groups from methionine. Bollivar DW, et al. **J Bacteriol** 1995 Oct;177(20):5778–83

HepG2 human hepatocarcinoma cells: an experimental model for photosensitization by endogenous porphyrins. Vonarx-Coinsman V, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):201–8

Subcellular damage kinetics within co-cultivated WI38 and VA13-transformed WI38 human fibroblasts following 5-aminolevulinic acid-induced protoporphyrin IX formation. Uberriegler KP, et al. **Photochem Photobiol** 1995 Dec;62(6):1052–7

BLOOD

Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Schwartz BS, et al. **Am J Epidemiol** 1995 Oct 1; 142(7):738–45

Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Fromm D, et al. **Arch Surg** 1996 Jun;131(6):667–9

Blood lead dynamics of lead-exposed pregnant women and its effects on fetus development. Wan BJ, et al. **Biomed Environ Sci** 1996 Mar;9(1):41–5

Erythropoietic protoporphyria: two populations of reticulocytes, with and without protoporphyrin. Brun A, et al. **Eur J Clin Invest** 1996 Apr;26(4):270–8

Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Baldus M, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):486–91

Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Braun J, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):492–7

Usefulness of red cell zinc protoporphyrin concentration in the investigation of microcytosis in children. Hinchliffe RF, et al. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):455–62

CHEMISTRY

Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 2. The partition of hematoporphyrin and protoporphyrin in mitochondria. Ricchelli F, et al. **Eur J Biochem** 1995 Oct 1;233(1):165–70

Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 1. The partition of hematoporphyrin and protoporphyrin in liposomes. Ricchelli F, et al. **Eur J Biochem** 1995 Oct 1;233(1):159–64

Oxygen equilibrium and electron paramagnetic resonance studies on copper(II)-iron(II) hybrid hemoglobins at room temperature. Shibayama N, et al. **FEBS Lett** 1995 Sep 18; 372(1):126–30

Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Bezdetnaya L, et al. **Photochem Photobiol** 1996 Aug;64(2):382–6

Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Steinbach P, et al. **Photochem Photobiol** 1995 Nov; 62(5):887–95

METABOLISM

Photosensitization of the endometrium with topical 5-aminolevulinic acid. Gannon MJ, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1826–8

Cloning, sequence, and expression of mouse protoporphyrinogen oxidase. Dailey TA, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):379–84

Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Martin A, et al. **Arch Dermatol Res** 1995; 287(7):665–74

Accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in normal and neoplastic human endometrial epithelial cells. Wyss-Desserich MT, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):819–24

The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Berg K, et al. **Br J Cancer** 1996 Sep;74(5):688–97

Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice. van der Veen N, et al. **Br J Cancer** 1996 Apr;73(7):925–30

Formation of water-soluble porphyrins and protoporphyrin IX in 5-aminolevulinic-acid-incubated carcinoma cells. Dietel W, et al. **J Photochem Photobiol B** 1996 May; 33(3):225–31

Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX [see comments] Barr H, et al. **Lancet** 1996 Aug 31;348(9027):584–5. Comment in: Lancet 1996 Aug 31;348(9027):561–2.

Accumulation of protoporphyrin isomers I and III, and multiple decarboxylation products of uroporphyrin in a case of porphyria in a slaughtered pig. Roels S, et al. **Zentralbl Veterinarmed A** 1995 Apr;42(2):145–51

PHARMACOKINETICS

Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. Chang SC, et al. **J Urol** 1996 May;155(5):1744–8

PHARMACOLOGY

The influence of merocyanine 540 and protoporphyrin on physicochemical properties of the erythrocyte membrane. Lagerberg JW, et al. **Biochim Biophys Acta** 1996 Jan 31; 1278(2):247–53

Resistance of hepatic lysosomes, mitochondria and microsomes of protoporphyrin-administered rats to peroxidative damage. Imai K, et al. **Biol Pharm Bull** 1995 Jun;18(6):913–6

Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription. Reddy SV, et al. **Blood** 1996 Sep 15;88(6):2288–97

Photodynamic therapy on the normal rabbit larynx with phthalocyanine and 5-aminolaevulinic acid induced protoporphyrin IX photosensitisation. Kleemann D, et al. **Br J Cancer** 1996 Jul;74(1):49–58

The effect of aminolaevulinic acid-induced, protoporphyrin IX-mediated photodynamic therapy on the cremaster muscle microcirculation in vivo. Leveckis J, et al. **Br J Cancer** 1995 Nov;72(5):1113-9

Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22-9

Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers. Kimmett SM, et al. **Mol Pharmacol** 1996 Apr;49(4):676-82

Modulation of carbon monoxide production and enhanced spatial learning by tin protoporphyrin. Bing O, et al. **Neuroreport** 1995 Jul 10;6(10):1369-72

Carbon monoxide as a putative messenger molecule in the feline lower oesophageal sphincter of the cat. Ny L, et al. **Neuroreport** 1995 Jul 10;6(10):1389-93

Depletion of cytochrome P-450 by thyroid hormone and cobalt-protoporphyrin IX in rat liver: evidence that susceptibility varies among forms of the heme protein. Rosenberg DW, et al. **Pharmacology** 1995 Oct;51(4):254-62

Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Bezdetnaya L, et al. **Photochem Photobiol** 1996 Aug;64(2):382-6

RADIATION EFFECTS

Burst-forming units-erythroid from erythropoietic protoporphyria patients fluoresce under 405 nm light [letter] Mathews-Roth MM, et al. **Blood** 1996 May 15; 87(10):4480-1

SECRETION

Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. Beukeveld GJ, et al. **J Hepatol** 1996 Mar;24(3):343-52

PROTOTHECA

Human cutaneous protothecosis. Mendez CM, et al. **Int J Dermatol** 1995 Aug;34(8):554-5

Cutaneous protothecosis. Monopoli A, et al. **Int J Dermatol** 1995 Nov;34(11):766-7

First report of Prototheca wickerhami algaemia in an adult leukemic patient [letter] Kunovà A, et al. **J Chemother** 1996 Apr;8(2):166-7

CLASSIFICATION

Simple new test for rapid differentiation of Prototheca stagnora from P. wickerhamii and P. zopfii. Casal MJ, et al. **Mycopathologia** 1995 May;130(2):93-4

GENETICS

Transcript mapping and processing of mitochondrial RNA in the chlorophyte alga Prototheca wickerhamii. Wolff G, et al. **Plant Mol Biol** 1996 Feb;30(3):577-95

ISOLATION & PURIFICATION

Cutaneous protothecosis: report of a case in Hong Kong. Tang WY, et al. **Br J Dermatol** 1995 Sep;133(3):479-82

Olecranon bursitis due to Prototheca wickerhamii, an algal opportunistic pathogen [letter] de Montclos M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):561-2

An increased incidence of mastitis caused by Prototheca species and Nocardia species on a farm in São Paulo, Brazil. Da Costa EO, et al. **Vet Res Commun** 1996;20(3):237-41

PATHOGENICITY

Epithelioid cell granulomas experimentally induced by prototheca in the skin of mice: a light microscopic study. Horiuchi Y, et al. **Hiroshima J Med Sci** 1995 Jun;44(2):21-7

Bovine mastitis due to algae of the genus Prototheca. Costa EO, et al. **Mycopathologia** 1996;133(2):85-8

PROTOZOA

see related
ANTIPROTOZOAL AGENTS

CHEMISTRY

Influence of sampling time and diet on amino acid composition of protozoal and bacterial fractions from bovine ruminal contents. Martin C, et al. **J Anim Sci** 1996 May;74(5):1157-63

CLASSIFICATION

Current status of the plasmodiophorids. Braselton JP. **Crit Rev Microbiol** 1995;21(4):263-75 (50 ref.)

Myxosporeans infecting the gills of bigmouth buffalo (Ictiobus bubalus) in Illinois, USA. Lom J, et al. **Folia Parasitol (Praha)** 1996;43(1):37-42

Henneguya adherens n. sp. (Myxozoa, Myxosporea), parasite of the Amazonian fish, Acestrorhynchus falcatus. Azevedo C, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):515-8

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

Myxobolus cognati n. sp. (Myxosporea) from the opercular integument of Cottus cognatus (Cottidae) in Lake Michigan. Cone DK, et al. **J Parasitol** 1996 Feb;82(1):137-9

Phylogeny of the Haplosporidia (Eukaryota: Alveolata) based on small subunit ribosomal RNA gene sequence. Flores BS, et al. **J Parasitol** 1996 Aug;82(4):616-23

The demise of a phylum of protists: phylogeny of Myxozoa and other parasitic cnidaria. Siddall ME, et al. **J Parasitol** 1995 Dec;81(6):961-7

Phylogeny of the Chlamydomonadales (Chlorophyceae): a comparison of ribosomal RNA gene sequences from the nucleus and the chloroplast. Buchheim MA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):391-402

Henneguya malabarica sp. nov. (Myxozoa, Myxobolidae) in the Amazonian fish Hoplias malabaricus. Azevedo C, et al. **Parasitol Res** 1996;82(3):222-4

A nuclear gene of eubacterial origin in Euglena gracilis reflects cryptic endosymbioses during protist evolution. Henze K, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9122-6

CYTOLOGY

Light microscopic description of Eimeria sparis sp. nov. and Goussia sparis sp. nov. (Protozoa:Apicomplexa) from Sparus aurata L. (Pisces: Teleostei). Sitjà-Bobadilla A, et al. **Parasitol Res** 1996;82(4):323-32

DRUG EFFECTS

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427-60 (196 ref.)

Anti-Mastigina activities of eight contact lens solutions. Niszl IA, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2364-6

The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768-76 (40 ref.)

ENZYMOLOGY

High-resolution negative staining of the isolated dynein ATPase. Marchese-Ragona SP. **Methods Cell Biol** 1995; 47:177-82

GENETICS

Population genetics of parasitic protozoa and other microorganisms. Tibayrenc M. **Adv Parasitol** 1995; 36:47-115 (164 ref.)

The chlorarachniophyte: a cell with two different nuclei and two different telomeres. Gilson P, et al. **Chromosoma** 1995 May;103(9):635-41

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

Early origin of foraminifera suggested by SSU rRNA gene sequences. Pawlowski J, et al. **Mol Biol Evol** 1996 Mar; 13(3):445-50

Phylogeny of the Chlamydomonadales (Chlorophyceae): a comparison of ribosomal RNA gene sequences from the nucleus and the chloroplast. Buchheim MA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):391-402

Phylogenetic analysis of beta-tubulin sequences from amitochondrial protozoa. Edlind TD, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):359-67

A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675-9 (33 ref.)

A nuclear gene of eubacterial origin in Euglena gracilis reflects cryptic endosymbioses during protist evolution. Henze K, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9122-6

Multiple origins of anaerobic ciliates with hydrogenosomes within the radiation of aerobic ciliates. Embley TM, et al. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):87-93

GROWTH & DEVELOPMENT

Effect of fetal bovine serum glycoproteins on the in vitro proliferation of the oyster parasite Perkinsus marinus: development of a fully defined medium. Gauthier JD, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):307-13

IMMUNOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239-76 (187 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387-91 (36 ref.)

ISOLATION & PURIFICATION

Comparison of fresh versus sodium acetate acetic acid formalin preserved stool specimens for diagnosis of intestinal protozoal infections. Mank TG, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1076-81

Aspects of the ecology of metazoan ectoparasites of marine fishes. Rohde K, et al. **Int J Parasitol** 1995 Aug; 25(8):945-70

Kudoa miniauriculata n. sp. (Myxozoa, Myxosporea) from the musculature of bocaccio (Sebastes paucispinis) from California. Whitaker DJ, et al. **J Parasitol** 1996 Apr; 82(2):312-5

A new species of Chloromyxum (Myxozoa: Chloromyxidae) from the gall bladder of Eurycea spp. (Caudata: Plethodontidae) in North America. Upton SJ, et al. **J Wildl Dis** 1995 Jul;31(3):394-6

[Intestinal parasite contamination of vegetables sold at supermarkets in the city of Rio de Janeiro] da Silva JP, et al. **Rev Soc Bras Med Trop** 1995 Jul-Sep;28(3):237-41 (Eng. Abstr.) **(Por)**

METABOLISM

Simulation of the effects of diet on the contribution of rumen protozoa to degradation of fibre in the rumen. Dijkstra J, et al. **Br J Nutr** 1995 Nov;74(5):617-34

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622-35 (74 ref.)

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76-85 (60 ref.)

Studies on the dissociation of cryptomonad biliproteins. MacColl R, et al. **J Biol Chem** 1995 Nov 17; 270(46):27555-61

Effect of rumen protozoa on nitrogen utilization by ruminants. Jouany JP. **J Nutr** 1996 Apr;126(4 Suppl):1335S-46S (127 ref.)

Conservation and diversification in homeodomain-DNA interactions: a comparative genetic analysis. Wilson DS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6886-91

MICROBIOLOGY

The design and application of ribosomal RNA-targeted, fluorescent oligonucleotide probes for the identification of endosymbionts in protozoa. Springer N, et al. **Methods Mol Biol** 1996;50:133-44

[Protozoa as reservoirs for human bacterial pathogens] Kołodyński J. **Wiad Parazytol** 1996;42(1):37-43 (34 ref.) (Eng. Abstr.) **(Pol)**

PARASITOLOGY

Use of a single slide trichrome-stained concentrate for the detection of intestinal parasites. Stained concentration procedure for ova and parasites. Hale DC, et al. **Am J Clin Pathol** 1996 Aug;106(2):175-9

PHYSIOLOGY

Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Goodgame RW. **Ann Intern Med** 1996 Feb 15; 124(4):429-41 (170 ref.)

Symposium introductory remarks: "protistan molecular ecology and systematics". Caron DA. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):87-8 (22 ref.)

Evolution of cell adhesion systems: evidence for Arg-Gly-Asp-mediated adhesion in the protozoan Neoparamoeba aestuarina. Custodio MR, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):721-4

The effect of Saccharomyces cerevisiae and Aspergillus oryzae on fermentations in the rumen of faunated and defaunated sheep; protozoal and probiotic interactions. Mathieu F, et al. **Reprod Nutr Dev** 1996;36(3):271-87

ULTRASTRUCTURE

Platelets mimicking microorganisms in cytology preparations [letter] Abramczuk JW, et al. **Cytopathology** 1995 Dec; 6(6):422-5

Ceratomyxa drepanopsettae in the gallbladder of Atlantic halibut, Hippoglossus hippoglossus, from the northwest Atlantic Ocean. Morrison CM, et al. **Folia Parasitol (Praha)** 1996;43(1):20-36

Light and electron microscopic study of a myxosporean, Tetrauronema desaequalis n. sp. (fam. Tetrauronematidae), from an Amazonian fish. Azevedo C, et al. **J Parasitol** 1996 Apr;82(2):288-91

Structural organization of the cell surface of pathogenic protozoa. De Souza W. **Micron** 1995;26(5):405-30 (156 ref.)

VIROLOGY

Virus-like particles in Polysporoplasma mugilis (Protozoa:Myxosporea), parasitic in a marine fish (Liza aurata L.). Sitjà-Bobadilla A, et al. **Int J Parasitol** 1996 Apr;26(4):457-9

[Viruses of parasitic protozoa] Kasprzak W, et al. **Wiad Parazytol** 1995;41(2):131-7 (Eng. Abstr.) **(Pol)**

PROTOZOAN ANTIBODIES see **ANTIBODIES, PROTOZOAN**

PROTOZOAN ANTIGENS see **ANTIGENS, PROTOZOAN**

PROTOZOAN DNA see **DNA, PROTOZOAN**

PROTOZOAN GENES see **GENES, PROTOZOAN**

PROTOZOAN GENOME see **GENOME, PROTOZOAN**

PROTOZOAN INFECTIONS

see related

ANTIPROTOZOAL AGENTS

Management of protozoan infections in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):237–40 (7 ref.)

Protozoan infections in the male genital tract. Martínez-García F, et al. **J Urol** 1996 Aug;156(2 Pt 1):340–9 (171 ref.)

XXII Annual meeting on Basic Research in Chagas Disease and XI meeting of the Brazilian Society of Protozoology. Caxumbu, MG, Brazil, November 6–10, 1995. Abstracts. **Mem Inst Oswaldo Cruz** 1995;90 Suppl:1–312

[Infectious diseases of the liver due to protozoa] Kume H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):82–6 (8 ref.) **(Jpn)**

BLOOD

Infectious hazards associated with blood transfusion. Hurley DR. **Adverse Drug React Toxicol Rev** 1995 Autumn; 14(3):157–74 (69 ref.)

COMPLICATIONS

Pathology of microsporidiosis: emerging parasitic infections in patients with acquired immunodeficiency syndrome. Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):173–88 (72 ref.)

Clinical and microscopical features of small-intestinal microsporidiosis in patients with AIDS. Caramello P, et al. **Infection** 1995 Nov–Dec;23(6):362–8

[Viruses of parasitic protozoa] Kasprzak W, et al. **Wiad Parazytol** 1995;41(2):131–7 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Laboratory diagnosis and autofluorescence of Cyclospora [letter] Clarke SC. **Br J Biomed Sci** 1995 Sep;52(3):231–2

[The current problems of the laboratory diagnosis of AIDS-related infections and infestations] Lysenko AIa. **Klin Lab Diagn** 1995 Nov–Dec;(6):110–3 **(Rus)**

DRUG THERAPY

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)

Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Gillis JC, et al. **Drugs** 1996 Apr;51(4):621–38 (56 ref.)

Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178–84 (100 ref.)

EPIDEMIOLOGY

Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study. Smart FW, et al. **J Heart Lung Transplant** 1996 Apr;15(4):329–41

Prevalence of intestinal parasitic infection in five farms in Holambra, São Paulo, Brazil. Kobayashi J, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):13–8

[3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections] van Gool T, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20; 140(3):155–60 (31 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Pneumocystis carinii and parasitic infections in transplantation. Fishman JA. **Infect Dis Clin North Am** 1995 Dec;9(4):1005–44 (128 ref.)

Opportunistic intestinal protozoa in chronic diarrhoeic immunosuppressed patients. Hammouda NA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):143–53

IMMUNOLOGY

Serologic responses of cattle and other animals infected with Neospora caninum. Dubey JP, et al. **Am J Vet Res** 1996 Mar;57(3):329–36

[Intestinal immunology in digestive parasitoses] Gottstein B, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B85–90 **(Fre)**

PARASITOLOGY

The incidence of Cyclospora cayetanensis in stool samples submitted to a district general hospital. Clarke SC, et al. **Epidemiol Infect** 1996 Aug;117(1):189–93

Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus–infected patients by PCR. Franzen C, et al. **J Clin Microbiol** 1995 Sep;33(9):2294–6

[3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections] van Gool T, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20; 140(3):155–60 (31 ref.) (Eng. Abstr.) **(Dut)**

PREVENTION & CONTROL

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S32–43

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Kaplan JE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S1–11

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Kaplan JE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S12–31

TRANSMISSION

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Klossiella equi infection in horses; sporocyst stage identified in urine. Reppas GP, et al. **Aust Vet J** 1995 Aug;72(8):316–8

Runting of ducklings associated with Cochlosoma anatis infection. Bollinger TK, et al. **Avian Dis** 1996 Jan–Mar; 40(1):181–5

Myxosporeans infecting the gills of bigmouth buffalo (Ictiobus bubalus) in Illinois, USA. Lom J, et al. **Folia Parasitol (Praha)** 1996;43(1):37–42

Ceratomyxa drepanopsettae in the gallbladder of Atlantic halibut, Hippoglossus hippoglossus, from the northwest Atlantic Ocean. Morrison CM, et al. **Folia Parasitol (Praha)** 1996;43(1):20–36

Aspects of the ecology of metazoan ectoparasites of marine fishes. Rohde K, et al. **Int J Parasitol** 1995 Aug; 25(8):945–70

Light and electron microscopic study of a myxosporean, Tetrauronema desaequalis n. sp. (fam. Tetrauronematidae), from an Amazonian fish. Azevedo C, et al. **J Parasitol** 1996 Apr;82(2):288–91

Myxobolus cognati n. sp. (Myxosporea) from the opercular integument of Cottus cognatus (Cottidae) in Lake Michigan. Cone DK, et al. **J Parasitol** 1996 Feb;82(1):137–9

Kudoa miniauriculata n. sp. (Myxozoa, Myxosporea) from the musculature of bocaccio (Sebastes paucispinis) from California. Whitaker DJ, et al. **J Parasitol** 1996 Apr; 82(2):312–5

Zoonotic intestinal parasites of hamadryas baboons Papio hamadryas in the western and northern regions of Saudi Arabia. Ghandour AM, et al. **J Trop Med Hyg** 1995 Dec; 98(6):431–9

Hemosporid (Apicomplexa, Hematozoea, Hemosporida) community structure off pattern in wintering wild turkeys. Fedynich AM, et al. **J Wildl Dis** 1995 Jul;31(3):404–9

Survey for blood parasites in redheads (Aythya americana) wintering at the Chandeleur Islands, Louisiana. Michot TC, et al. **J Wildl Dis** 1995 Jan;31(1):90–2

Hemograms and hematozoa of sharp-shinned (Accipiter striatus) and Cooper's hawks (Accipiter cooperii) captured during spring migration in northern New York. Phalen DN, et al. **J Wildl Dis** 1995 Apr;31(2):216–22

A new species of Chloromyxum (Myxozoa: Chloromyxidae) from the gall bladder of Eurycea spp. (Caudata: Plethodontidae) in North America. Upton SJ, et al. **J Wildl Dis** 1995 Jul;31(3):394–6

Histopathologic features of naturally occurring hepatozoonosis in wild martens (Martes melampus) in Japan. Yanai T, et al. **J Wildl Dis** 1995 Apr;31(2):233–7

The prevalence of neosporosis in aborted bovine foetuses submitted to the Allerton Regional Veterinary Laboratory. Jardine JE, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):207–9

Effects of an asymmetric triazine derivative, HOE 092 V, on Glugea anomala, Moniez, 1887 (Microsporidia) parasitic in the three-spined stickleback Gasterosteus aculeatus. Schmahl G, et al. **Parasitol Res** 1996;82(3):225–9

Intestinal parasite burden in five troops of olive baboons (Papio cynocephalus anubis) in Gombe Stream National Park, Tanzania. Müller-Graf CD, et al. **Parasitology** 1996 May;112 (Pt 5):489–97

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parasitologia** 1995 Apr;37(1):63–7 (40 ref.)

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235–8 (10 ref.)

Nervous mortality syndrome in farmed Atlantic salmon. Rodger HD, et al. **Vet Rec** 1995 Dec 9;137(24):616–7

PROTOZOAN PROTEINS

Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Hui GS, et al. **Infect Immun** 1996 May;64(5):1502–9

ADMINISTRATION & DOSAGE

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Burghaus PA, et al. **Infect Immun** 1996 Sep;64(9):3614–9

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group [see comments] Nosten F, et al. **Lancet** 1996 Sep 14;348(9029):701–7. Comment in: Lancet 1996 Sep 14;348(9029):695.

Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Alonzo PL, et al. **Med Trop (Mars)** 1995;55(4 Suppl):41–6 (6 ref.)

ADVERSE EFFECTS

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Gordon DM, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):63–8

ANALYSIS

Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Rattanarithikul R, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):114–21

High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Nascimento AE, et al. **Biol Cell** 1996;86(1):53–8

Characterization and immunoprotective properties of a monoclonal antibody against the major oocyst wall protein of Eimeria tenella. Karim MJ, et al. **Infect Immun** 1996 Apr;64(4):1227–32

Citrate synthase purified from Tetrahymena mitochondria is identical with Tetrahymena 14-nm filament protein. Kojima H, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):189–95

Identification of a novel Giardia lamblia cyst wall protein with leucine-rich repeats. Implications for secretory granule formation and protein assembly into the cyst wall. Luján HD, et al. **J Biol Chem** 1995 Dec 8;270(49):29307–13

The gene B protein localises to the surface of Leishmania major parasites in the absence of metacyclic stage lipophosphoglycan. Rangarajan D, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3359–66

Evidence for heterotrimeric GTP-binding proteins in Toxoplasma gondii. Halonen SK, et al. **J Eukaryot Microbiol** 1996 May–Jun;43(3):187–93

Molecular comparison of the mitochondrial and cytoplasmic hsp70 of Trypanosoma cruzi, Trypanosoma brucei and Leishmania major. Klein KG, et al. **J Eukaryot Microbiol** 1995 Sep–Oct;42(5):473–6

Plasmodium falciparum rhoptry proteins of 140/130/110 kd (Rhop-H) are located in an electron lucent compartment in the neck of the rhoptries. Sam-Yellowe TY, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):224–31

Nonradioactive methods for labeling and identifying membrane surface proteins. Dentler WL. **Methods Cell Biol** 1995;47:407–11

Nonradioactive method for ATPase assays. Kagami O, et al. **Methods Cell Biol** 1995;47:147–50

Measurement of ATPase activity using [gamma-32P]ATP. King SM. **Methods Cell Biol** 1995;47:141–5

Analysis of flagellar calcium-binding proteins. Otter T. **Methods Cell Biol** 1995;47:113–9

Detection of flagellar protein kinases on polyvinylidene difluoride membranes following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. San Agustin JT, et al. **Methods Cell Biol** 1995;47:135–40

Flagellar adenylyl cyclases in Chlamydomonas. Zhang Y, et al. **Methods Cell Biol** 1995;47:459–65

Analysis for adhesins and specific cytoadhesion of Trichomonas vaginalis. Alderete JF, et al. **Methods Enzymol** 1995;253:407–14

Free radical detoxification in Giardia duodenalis. Brown DM, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):47–56

The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. de Sousa CB, et al. **Rev Soc Bras Med Trop** 1996 Mar–Apr; 29(2):153–63

ANTAGONISTS & INHIBITORS

Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Gamboa de Domínguez ND, et al. **Blood** 1996 May 15;87(10):4448–54

BIOSYNTHESIS

Production of a malaria transmission-blocking protein from recombinant yeast. Wang MY, et al. **Ann N Y Acad Sci** 1996 May 15;782:123–32

A megadalton protein (Pc2500) is present during the intraerythrocytic development of P. chabaudi. Garcia CR, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):983–9

The release of the variant surface protein of Giardia to its soluble isoform is mediated by the selective cleavage of the conserved carboxy-terminal domain. Papanastasiou P, et al. **Biochemistry** 1996 Aug 6;35(31):10143–8

Plasmodium yoelii: expression of circumsporozoite protein

and sporozoite surface protein 2 by sporozoites in culture. Siu NF, et al. **Exp Parasitol** 1995 Dec;81(4):600–3

Expression of a 32 kilodalton Theileria sergenti piroplasm surface protein by recombinant baculoviruses. Matsuba T, et al. **Int J Parasitol** 1995 Aug;25(8):939–43

N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum. Kimura EA, et al. **J Biol Chem** 1996 Jun 14;271(24):14452–61

Giardia gene predicts a 183 kDa nucleotide-binding head-stalk protein. Marshall J, et al. **J Cell Sci** 1995 Jul; 108 (Pt 7):2683–92

Comparison of the 24 kDa flagellar calcium-binding protein cDNA of two strains of Trypanosoma cruzi. Godsel LM, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):320–2

Inhibition of protein synthesis and amino acid transport by crystal violet in Trypanosoma cruzi. Hoffmann ME, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):293–7

Effects of temperature on promastigotes of several species of Leishmania. Leon LL, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):219–23

Sexual-stage-specific RNA expression of a new Plasmodium falciparum gene detected by in situ hybridisation. Baker DA, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):193–201

Functional expression of a myo-inositol/H+ symporter from Leishmania donovani. Drew ME, et al. **Mol Cell Biol** 1995 Oct;15(10):5508–15

Heat shock proteins of Toxoplasma gondii. Lyons RE, et al. **Parasite Immunol** 1995 Jul;17(7):353–9

BLOOD

Asymptomatic malaria parasitaemia and seroreactivities to Plasmodium falciparum antigens in blood donors from Ibadan, south-western Nigeria. Achidi EA, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):601–10

Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis. Letillois MF, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):899–903

[Diagnosis of malaria in Africa using the Parasight F test] Coue JC, et al. **Med Trop (Mars)** 1995;55(4):333–5 (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17–18):1301–9

CHEMISTRY

Leishmania mexicana p12cks1, a homologue of fission yeast p13suc1, associates with a stage-regulated histone H1 kinase. Mottram JC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):833–9

Ancient weapons: NK-lysin, is a mammalian homolog to pore-forming peptides of a protozoan parasite [letter] Leippe M. **Cell** 1995 Oct 6;83(1):17–8

Comparison of axonemal proteins from two kinds of Tetrahymena. I. Different characteristics of dyneins in heat stability. Takaya C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):727–32

Characterization of centrin genes in Paramecium. Madeddu L, et al. **Eur J Biochem** 1996 May 15;238(1):121–8

Trypanosoma cruzi: the Tc-85 surface glycoprotein shed by trypomastigotes bears a modified glycosylphosphatidylinositol anchor. Abuin G, et al. **Exp Parasitol** 1996 Apr;82(3):290–7

A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Chatterjee S, et al. **Infect Immun** 1995 Nov; 63(11):4375–81

A major tyrosine-phosphorylated protein of Trypanosoma brucei is a nucleolar RNA-binding protein. Das A, et al. **J Biol Chem** 1996 Jun 28;271(26):15675–81

Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. Guichard G, et al. **J Biol Chem** 1995 Nov 3;270(44):26057–9

Reconstitution of dynein arms in vitro. Smith EF. **Methods Cell Biol** 1995;47:491–6

Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Carter R, et al. **Mol Biochem Parasitol** 1995 May;71(2):203–10

A Plasmodium falciparum protein kinase with two unusually large kinase inserts. Kappes B, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):163–78

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Roggero MA, et al. **Mol Immunol** 1995 Dec; 32(17–18):1301–9

Picture story. Jellyroll boat. Riddihough G. **Nat Struct Biol** 1996 Aug;3(8):675

A cooperative model for receptor recognition and cell adhesion: evidence from the molecular packing in the 1.6-A crystal structure of the pheromone Er-1 from the ciliated protozoan Euplotes raikovi. Weiss MS, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10172–6

Active site properties of monomeric triosephosphate isomerase (monoTIM) as deduced from mutational and structural studies. Schliebs W, et al. **Protein Sci** 1996 Feb; 5(2):229–39

Structural basis of light harvesting by carotenoids: peridinin-chlorophyll-protein from Amphidinium carterae [see comments] Hofmann E, et al. **Science** 1996 Jun 21; 272(5269):1788–91. Comment in: Science 1996 Jun 21;272(5269):1743–4.

Form follows function when plants harvest light [news; comment] Moffat AS. **Science** 1996 Jun 21; 272(5269):1743–4. Comment on: Science 1996 Jun 21;272(5269):1788–91.

DIAGNOSTIC USE

Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. Singh S, et al. **J Parasitol** 1995 Dec;81(6):1000–3

GENETICS

Characterization of cDNAs encoding adhesin proteins involved in trichomonas vaginalis cytoadherence. Arroyo R, et al. **Arch Med Res** 1995 Winter;26(4):361–9

Functional expression and characterization of the Trypanosoma brucei procyclic glucose transporter, THT2. Barrett MP, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):687–91

Identification and sequence analysis of a rap gene from the true slime mold Physarum polycephalum. Kozlowski P, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):29–33

Cloning and expression of an Entamoeba histolytica NAPD+(-)dependent alcohol dehydrogenase gene. Rodríguez MA, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):23–6

Extracellular cAMP depletion triggers stalk gene expression in Dictyostelium: disparities in developmental timing and dose dependency indicate that prespore induction and stalk repression by cAMP are mediated by separate signaling pathways. Soede RDM, et al. **Dev Biol** 1996 Jul 10; 177(1):152–9

Differential amplification of pheromone genes of the ciliate Euplotes raikovi. La Terza A, et al. **Dev Genet** 1995; 17(3):272–9

Progressive maturation of chromatin structure regulates HSP70.1 gene expression in the preimplantation mouse embryo. Thompson EM, et al. **Development** 1995 Oct; 121(10):3425–37

The var genes of Plasmodium falciparum are located in the subtelomeric region of most chromosomes. Rubio JP, et al. **EMBO J** 1996 Aug 1;15(15):4069–77

Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from Plasmodium falciparum. Färber PM, et al. **Eur J Biochem** 1996 Aug 1;239(3):655–61

Characterization of centrin genes in Paramecium. Madeddu L, et al. **Eur J Biochem** 1996 May 15;238(1):121–8

Trypanosoma brucei: molecular cloning of homologues of small GTP-binding proteins involved in vesicle trafficking. Field MC, et al. **Exp Parasitol** 1995 Nov;81(3):313–20

The genomic organization of the HSP83 gene locus is conserved in three Leishmania species. Hübel A, et al. **Exp Parasitol** 1996 Mar;82(2):225–8

Plasmodium vivax: favored gene frequencies of the merozoite surface protein-1 and the multiplicity of infection in a malaria endemic region. Kolakovich KA, et al. **Exp Parasitol** 1996 Jun;83(1):11–9

Trypanosoma cruzi: interruption of both alleles of a gene encoding a protein containing 14-amino-acid repeats by targeted insertion of NEOr and HYGr. Otsu K, et al. **Exp Parasitol** 1995 Dec;81(4):529–35

Dictyostelium discoideum contains a family of calmodulin-related EF-hand proteins that are developmentally regulated. André B, et al. **FEBS Lett** 1996 Mar 11;382(1–2):198–202

Allelic forms of the knob associated histidine-rich protein gene of Plasmodium falciparum. Kant R, et al. **FEBS Lett** 1996 Feb 12;380(1–2):147–51

A new cysteine-rich protein-encoding gene family in Giardia duodenalis. Chen N, et al. **Gene** 1996 Feb 22;169(1):33–8

The s29x gene of symbiotic bacteria in Amoeba proteus with a novel promoter. Pak JW, et al. **Gene** 1996 May 24; 171(1):89–93

Developmental changes in the expression of Leishmania chagasi gp63 and heat shock protein in a human macrophage cell line. Streit JA, et al. **Infect Immun** 1996 May;64(5):1810–8

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584–91

Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine-rich Entamoeba histolytica protein induces an antiamebic immune response and protects gerbils from amebic liver abscess. Zhang T, et al. **Infect Immun** 1996 May; 64(5):1526–31

The deletion of petG in Chlamydomonas reinhardtii disrupts the cytochrome bf complex. Berthold DA, et al. **J Biol Chem** 1995 Dec 8;270(49):29293–8

The protozoan Trypanosoma cruzi has a family of genes resembling the mucin genes of mammalian cells. Di Noia JM, et al. **J Biol Chem** 1995 Oct 13;270(41):24146–9

Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. Doolan DL, et al. **J Biol Chem** 1996 Jul 26;271(30):17861–8

Cloning and sequence analysis of genes coding for paramecium secretory granule (trichocyst) proteins. A unique protein fold for a family of polypeptides with different primary structures. Gautier MC, et al. **J Biol Chem** 1996 Apr 26;271(17):10247–55

Identification of two novel Dictyostelium discoideum cysteine proteinases that carry N-acetylglucosamine-1-P-modification. Souza GM, et al. **J Biol Chem** 1995 Dec 1;270(48):28938–45

The plastid-encoded ccsA gene is required for heme attachment to chloroplast c-type cytochromes. Xie Z, et al. **J Biol Chem** 1996 Mar 1;271(9):4632–9

Giardia gene predicts a 183 kDa nucleotide-binding head-stalk protein. Marshall J, et al. **J Cell Sci** 1995 Jul; 108 (Pt 7):2683–92

Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. Campos-Neto A, et al. **J Exp Med** 1995 Nov 1;182(5):1423–33

Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. Craig AA, et al. **J Infect Dis** 1996 Aug;174(2):373–9

Primary structure and eubacterial relationships of the pyruvate:ferredoxin oxidoreductase of the amitochondriate eukaryote Trichomonas vaginalis. Hrdý I, et al. **J Mol Evol** 1995 Sep;41(3):388–96

Enrichment of mRNA encoding flagellar proteins. Keller LR. **Methods Cell Biol** 1995;47:551–7

Molecular mapping of genes for flagellar proteins in Chlamydomonas. Silflow CD, et al. **Methods Cell Biol** 1995;47:525–30

COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Alano P, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):143–56

Merozoite surface antigen 2 (MSA-2) gene of Plasmodium falciparum strains from India. Bhattacharya P, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):125–7

Molecular characterization of the mitochondrial heat shock protein 60 gene from Trypanosoma brucei. Bringaud F, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):119–23

Analysis of the 170-kDa lectin gene promoter of Entamoeba histolytica. Buss H, et al. **Mol Biochem Parasitol** 1995 Jun; 72(1–2):1–10

Sequence analysis of apical membrane antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):267–70

Extensive polymorphism at the Gp63 locus in field isolates of Leishmania peruviana. Espinoza JR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):203–13

Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme. Gamarro F, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):11–22

Absence of the glutamic acid/alanine-rich protein (GARP) genes in the Nannomonas species Trypanosoma simiae and T. godfreyi. Garside LH, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):211–5

Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Kang Y, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):103–10

A Plasmodium falciparum gene encoding a high mobility group protein box. Kun JF, et al. **Mol Biochem Parasitol** 1995 May;71(2):249–53

The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species. Longacre S. **Mol Biochem Parasitol** 1995 Oct;74(1):105–11

The putative promoter for a metacyclic VSG gene in African trypanosomes. Nagoshi YL, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):33–45

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):241–4

Phenotype and genotype diversity in the circumsporozoite proteins of Plasmodium vivax in Thailand. Rongnoparut P, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):201–10

Complementation of a Toxoplasma gondii ROP1 knock-out mutant using phleomycin selection. Soldati D, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):87–97

Structure and sequence variation of the genes encoding the polymorphic, immunodominant molecule (PIM), an antigen of Theileria parva recognized by inhibitory monoclonal antibodies. Toye P, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):165–77

Molecular cloning of a gene from Plasmodium falciparum that codes for a protein sharing motifs found in adhesive molecules from mammals and plasmodia. Trottein F, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):129–41

Molecular phylogeny of annexins and identification of a primitive homologue in Giardia lamblia. Morgan RO, et al. **Mol Biol Evol** 1995 Nov;12(6):967–79

Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Eldin de Pecoulas P, et al. **Mol Cell Probes** 1995 Dec;9(6):391–7

Cloning and molecular characterization of two genes encoding adhesion proteins involved in Trichomonas vaginalis cytoadherence. Alderete JF, et al. **Mol Microbiol** 1995 Jul;17(1):69–83

The analysis of protein coding genes suggests monophyly of Trypanosoma. Alvarez F, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):333–43

Phylogenetic analysis of beta-tubulin sequences from amitochondrial protozoa. Edlind TD, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):359–67

A promotor directing alpha-amanitin-sensitive transcription of GARP, the major surface antigen of insect stage Trypanosoma congolense. Graham SV, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):272–81

Plasticity of gp63 gene organization in Leishmania (Viannia) braziliensis and Leishmania (Viannia) peruviana. Victoir K, et al. **Parasitology** 1995 Sep;111 (Pt 3):265–73

The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Ruetz S, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9942–7

Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Volkman SK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8921–5

HISTORY

Creation of first malaria vaccine raises troubling questions about "intellectual racism" [interview by Kirsteen MacLeod] Patarroyo M. **Can Med Assoc J** 1995 Nov 1; 153(9):1319–21

IMMUNOLOGY

Recognition of acidic proteins of Giardia muris by anti-trophozoite antibodies. Heyworth MF, et al. **Adv Exp Med Biol** 1995;371B:939–43

Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population. Beck HP, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):284–8

Malaria and pregnancy in Cameroonian primigravidae: humoral and cellular immune responses to Plasmodium falciparum blood-stage antigens. Fievet N, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):612–7

Parasitized erythrocyte membrane antigens of Plasmodium brasilianum: relationships with the ring-infected erythrocyte surface antigen of Plasmodium falciparum. Sulzer AJ, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):618–23

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. al-Yaman F, et al. **Am J Trop Med Hyg** 1996 May;54(5):443–8

Characterization of helper T cell responses against rhoptry-associated protein 1 (RAP-1) of babesial parasites. Brown WC, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:128–35

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Detection of anti-Plasmodium falciparum antibodies directed against a repetitive peptide of the gametocyte antigen Pfs2400 in malaria patients in Brazil. Marrelli MT, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):593–99

Prevalence of antibodies to the repeat epitope of the circumsporozoite protein of Plasmodium vivax in San Luis Potosi, Mexico. Mota J, et al. **Arch Med Res** 1996 Summer; 27(2):233–6

Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Lalvani A, et al. **Eur J Immunol** 1996 Apr;26(4):773–9

Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Ahlborg N, et al. **Exp Parasitol** 1996 Mar; 82(2):155–63

Conservation of neutralizing determinants between the sporozoite surface antigens of Theileria annulata and Theileria parva. Knight P, et al. **Exp Parasitol** 1996 Apr; 82(3):229–41

Plasmodium falciparum: characterization of toxin-associated proteins and identification of a hemoglobin containing parasite cytokine stimulator. Kristensen G, et al. **Exp Parasitol** 1996 Mar;82(2):147–54

Babesia bigemina: identification of B cell epitopes associated with parasitized erythrocytes. Vidotto O, et al. **Exp Parasitol** 1995 Dec;81(4):491–500

CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Renggli J, et al. **Immunol Lett** 1995 May;46(1-2):199–205

Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Soto M, et al. **Immunol Lett** 1995 Nov;48(1):23–8

Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Beving DE, et al. **Infect Immun** 1996 Apr;64(4):1473–6

Babesia bovis rhoptry-associated protein 1 is immunodominant for T helper cells of immune cattle and contains T-cell epitopes conserved among geographically distant B. bovis strains. Brown WC, et al. **Infect Immun** 1996 Aug;64(8):3341–50

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Daly TM, et al. **Infect Immun** 1996 Jul;64(7):2602–8

Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Debard N, et al. **Infect Immun** 1996 Jun;64(6):2158–66

Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. De Souza JB, et al. **Infect Immun** 1996 Sep;64(9):3532–6

Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Lal AA, et al. **Infect Immun** 1996 Mar;64(3):1054–9

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Lanar DE, et al. **Infect Immun** 1996 May;64(5):1666–71

CD4+ T-helper lymphocyte responses against Babesia bigemina rhoptry-associated protein I. Rodríguez SD, et al. **Infect Immun** 1996 Jun;64(6):2079–87

Epitopes recognized by human T lymphocytes in the ROP2 protein antigen of Toxoplasma gondii. Saavedra R, et al. **Infect Immun** 1996 Sep;64(9):3858–62

Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro. Sharma P, et al. **Infect Immun** 1996 Jun;64(6):2172–9

Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Shi YP, et al. **Infect Immun** 1996 Jul; 64(7):2716–23

Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Skeiky YA, et al. **Infect Immun** 1995 Oct;63(10):4105–14

Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. Su S, et al. **Infect Immun** 1996 Jan;64(1):326–31

Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum. Suffia I, et al. **Infect Immun** 1995 Oct;63(10):3765–71

T-cell suppression and selective in vivo activation of TH2 subpopulation by the Entamoeba histolytica 220-kilodalton lectin. Talamás-Rohana P, et al. **Infect Immun** 1995 Oct; 63(10):3953–8

Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Taylor RR, et al. **Infect Immun** 1995 Nov;63(11):4382–8

Identification of neutralization and diagnostic epitopes on PIM, the polymorphic immunodominant molecule of Theileria parva. Toye P, et al. **Infect Immun** 1996 May; 64(5):1832–8

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584–91

Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine-rich Entamoeba histolytica protein induces an antiamebic immune response and protects gerbils from amebic liver abscess. Zhang T, et al. **Infect Immun** 1996 May; 64(5):1526–31

Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection. Godsel LM, et al. **J Clin Microbiol** 1995 Aug;33(8):2082–5

Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. Krautz GM, et al. **J Clin Microbiol** 1995 Aug;33(8):2086–90

Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. Ramirez AD, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):705–8

Identification of immunogenic epitopes of the 170-kDa subunit adhesin of Entamoeba histolytica in patients with invasive amebiasis. Velazquez C, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):636–41

Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. Wizel B, et al. **J Exp Med** 1995 Nov 1; 182(5):1435–45

Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. Prina E, et al. **J Immunol** 1996 Jun 1;156(11):4318–27

Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. Tian JH, et al. **J Immunol** 1996 Aug 1; 157(3):1176–83

rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. Badaró R, et al. **J Infect Dis** 1996 Mar;173(3):758–61

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765–9

Identification of Leishmania chagasi antigens recognized by human lymphocytes. Jeronimo SM, et al. **J Infect Dis** 1995 Oct;172(4):1055–60

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Terrientes ZI, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:55–61

Aspects of immunity for the AMA-1 family of molecules in humans and non-human primates malarias. Thomas AW, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:67–70

Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50

COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Alano P, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):143–56

Sequence analysis of apical membrane antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):267–70

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):241–4

Structure and sequence variation of the genes encoding the polymorphic, immunodominant molecule (PIM), an antigen of Theileria parva recognized by inhibitory monoclonal antibodies. Toye P, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1-2):165–77

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Kumar S, et al. **Mol Med** 1995 Mar; 1(3):325–32

Detection and characterization by immunoblot analysis of potentially diagnostic Leishmania infantum polypeptides in human visceral leishmaniasis. Cardeñosa N, et al. **Parasite Immunol** 1995 Oct;17(10):509–16

The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite. Ling IT, et al. **Parasite Immunol** 1995 Aug;17(8):425–33

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. al-Yaman F, et al. **Parasite Immunol** 1995 Sep;17(9):493–501

Immunity to Plasmodium berghei exoerythrocytic forms derived from irradiated sporozoites. Chatterjee S, et al. **Parasitol Res** 1996;82(4):297–303

Improved specificity of Trypanosoma cruzi identification by polymerase chain reaction using an oligonucleotide derived from the amino-terminal sequence of a Tc24 protein. Taibi A, et al. **Parasitology** 1995 Dec;111 (Pt 5):581–90

Identification of the galactose-adherence lectin epitopes of Entamoeba histolytica that stimulate tumor necrosis factor-alpha production by macrophages. Séguin R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12175–9

SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach. Urdaneta M, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):259–69

Serious setback for Patarroyo vaccine [news] Marshall E. **Science** 1996 Sep 20;273(5282):1652

Humoral immune responses to the Plasmodium falciparum antigen Pf155 RESA in adults with differential clinical conditions from an Indian zone where malaria is endemic. Biswas S, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):219–27

Evaluation of circumsporozoite antibody testing as a sero-epidemiological tool for the detection of Plasmodium falciparum infection in non-immune travelers. Jelinek T, et al. **Trop Med Parasitol** 1995 Sep;46(3):154–7

Relationship of antibodies to soluble Plasmodium falciparum antigen (Pf70) and protection against malaria in a human population living under intense transmission in Kinshasa, Zaire. Tshefu K, et al. **Trop Med Parasitol** 1995 Jun; 46(2):72–6

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Hioe CE, et al. **Vaccine** 1996 Apr;14(5):412–8

Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey. Stanley SL Jr, et al. **Vaccine** 1995 Jul;13(10):947–51

[The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?] Robert F, et al. **Sante** 1996 Jan-Feb;6(1):56–7 (11 ref.) **(Fre)**

ISOLATION & PURIFICATION

Trypanosoma cruzi: a 52-kDa protein sharing sequence homology with glutathione S-transferase is localized in parasite organelles morphologically resembling reservosomes. Ouaissi MA, et al. **Exp Parasitol** 1995 Dec; 81(4):453–61

Identification of a 148-kDa surface lectin from Giardia lamblia with specificity for alpha-methyl-D-mannoside. Sreenivas K, et al. **FEMS Microbiol Lett** 1995 Dec 1; 134(1):33–7

Identification of a microsporidian polar tube protein reactive

monoclonal antibody. Keohane EM, et al. **J Eukaryot Microbiol** 1996 Jan-Feb;43(1):26-31

Immunolocalization of protein phosphatase type 1 in Paramecium cells using antibodies against recombinant protein and peptides. Momayezi M, et al. **J Histochem Cytochem** 1996 Aug;44(8):891-905

A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Oeuvray C, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:77-80

Isolation of inner- and outer-arm dyneins. Howard DR, et al. **Methods Cell Biol** 1995;47:481-6

Separation of dynein species by high-pressure liquid chromatography. Kagami O, et al. **Methods Cell Biol** 1995; 47:487-9

Isolation of flagellar paraxonemal rod proteins. Ngô HM, et al. **Methods Cell Biol** 1995;47:355-60

Electrophoretic separation of dynein heavy chains. Piperno G. **Methods Cell Biol** 1995;47:101-5

Two-dimensional separation of axonemal proteins. Piperno G. **Methods Cell Biol** 1995;47:107-12

Isolation and fractionation of the Tetrahymena cytoskeleton and oral apparatus. Williams NE, et al. **Methods Cell Biol** 1995;47:301-6

Partial purification and characterization of a soluble protein phosphatase from Leishmania donovani promastigotes. Nandi S, et al. **Mol Cell Biochem** 1995 Jul 19;148(2):191-8

Nucleus-encoded histone H1-like proteins are associated with kinetoplast DNA in the trypanosomatid Crithidia fasciculata. Xu CW, et al. **Mol Cell Biol** 1996 Feb; 16(2):564-76

The development of malaria vaccines: SPf66--what next? Tanner M, et al. **Schweiz Med Wochenschr** 1996 Jul 9; 126(27-28):1210-5

METABOLISM

Src kinase plays an essential role in integrin-mediated tyrosine phosphorylation of Crk-associated substrate p130Cas. Hamasaki K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):338-43

Leishmania mexicana p12cks1, a homologue of fission yeast p13suc1, associates with a stage-regulated histone H1 kinase. Mottram JC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):833-9

An uncleaved glycosylphosphatidylinositol signal mediates Ca(2+)-sensitive protein degradation. Pauly PC, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):533-40

Hexose uptake in Trypanosoma cruzi: structure-activity relationship between substrate and transporter. Tetaud E, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):353-9

Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii. Naguib FN, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1685-93

Analysis of the active site and activation mechanism of the Leishmania surface metalloproteinase GP63. Macdonald MH, et al. **Biochim Biophys Acta** 1995 Dec 6; 1253(2):199-207

Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein Tag. Maniak M, et al. **Cell** 1995 Dec 15;83(6):915-24

Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein-1. Blackman MJ, et al. **Exp Parasitol** 1996 Jul;83(2):229-39

Plasmodium falciparum: effects of membrane modulating agents on direct binding of rhoptry proteins to human erythrocytes. Ndengele MM, et al. **Exp Parasitol** 1995 Sep; 81(2):191-201

A Babesia bovis 225-kilodalton spherical-body protein: localization to the cytoplasmic face of infected erythrocytes after merozoite invasion. Dowling SC, et al. **Infect Immun** 1996 Jul;64(7):2618-26

The major surface glycoprotein of Trypanosoma cruzi amastigotes are ligands of the human serum mannose-binding protein. Kahn SJ, et al. **Infect Immun** 1996 Jul;64(7):2649-56

Contact-dependent transfer of the galactose-specific lectin of Entamoeba histolytica to the lateral surface of enterocytes in culture. Leroy A, et al. **Infect Immun** 1995 Nov;63(11):4253-60

Partial purification and characterization of ornithine decarboxylase from Entamoeba histolytica. Arteaga-Nieto P, et al. **Int J Parasitol** 1996 Mar;26(3):253-60

Polymerization of highly purified Tetrahymena 14-nm filament protein/citrate synthase into filaments and its possible role in regulation of enzymatic activity. Takeda T, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):869-74

Interactions of Cbl with two adapter proteins, ?Grb2 and Crk, upon T cell activation. Buday L, et al. **J Biol Chem** 1996 Mar 15;271(11):6159-63

Identification of Acan125 as a myosin-I-binding protein present with myosin-I on cellular organelles of Acanthamoeba. Xu P, et al. **J Biol Chem** 1995 Oct 27; 270(43):25316-9

Biochemical kinetic characterization of the Acanthamoeba myosin-I ATPase. Ostap EM, et al. **J Cell Biol** 1996 Mar; 132(6):1053-60

Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei. Steverding D, et al. **J Cell Biol** 1995 Dec;131(5):1173-82

Membrane skeletal proteins and their integral membrane protein anchors are targets for tyrosine and threonine kinases in Euglena. Fazio MJ, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):570-80

Deciliation induces phosphorylation of a 90-kDa cortical protein in Tetrahymena thermophila. Gitz DL, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):742-8

Proteolysis of a 34 kDa phosphoprotein coincident with a decrease in protein kinase activity during the erythrocytic schizont stage of the malaria parasite. Wiser MF. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):659-64

Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor. Kahn S, et al. **J Exp Med** 1995 Nov 1;182(5):1243-58

Phosphorylation of Chlamydomonas flagellar proteins. Bloodgood RA, et al. **Methods Cell Biol** 1995;47:121-7

Reactivation of Chlamydomonas cell models. Horst CJ, et al. **Methods Cell Biol** 1995;47:207-10

Protein trafficking in kinetoplastid protozoa. Clayton C, et al. **Microbiol Rev** 1995 Sep;59(3):325-44 (250 ref.)

L-arginine transport and metabolism in Giardia intestinalis support its position as a transition between the prokaryotic and eukaryotic kingdoms. Knodler LA, et al. **Microbiology** 1995 Sep;141 (Pt 9):2063-70

RNA-protein interactions in the ribonucleoprotein T-complexes in a mitochondrial extract from Leishmania tarentolae. Byrne E, et al. **Mol Biochem Parasitol** 1995 Jun; 72(1-2):65-76

The secretary pathway of plasmodium falciparum regulates transport of p82/RAP1 to the rhoptries. Howard RF, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):43-54

Processing and transport of a lysosomal membrane glycoprotein is developmentally regulated in African trypanosomes. Kelley RJ, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):167-78

Isoprenylation of proteins in the protozoan Giardia lamblia. Luján HD, et al. **Mol Biochem Parasitol** 1995 Jun; 72(1-2):121-7

Processing of the Plasmodium chabaudi chabaudi AS merozoite surface protein 1 in vivo and in vitro. O'Dea KP, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):111-9

Cell adhesion-dependent inactivation of a soluble protein kinase during fertilization in Chlamydomonas. Zhang Y, et al. **Mol Biol Cell** 1996 Apr;7(4):515-27

Multiple roles of the novel protein tyrosine phosphatase PTP3 during Dictyostelium growth and development. Gamper M, et al. **Mol Cell Biol** 1996 May;16(5):2431-44

Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Gotoh T, et al. **Mol Cell Biol** 1995 Dec;15(12):6746-53

Acanthamoeba castellanii contains a ribosomal RNA enhancer binding protein which stimulates TIF-IB binding and transcription under stringent conditions. Yang Q, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4345-52

Toxoplasma gondii: redistribution of tachyzoite surface protein during host cell invasion and intracellular development. Grimwood J, et al. **Parasitol Res** 1995; 81(8):657-61

Identification of the polyamine N8-acetyltransferase involved in the pathway of 1,3-diaminopropane production in Acanthamoeba culbertsoni. Shukla OP, et al. **Parasitol Res** 1996;82(3):270-2

Identification of a 44 kDa protein localized within the endoplasmic reticulum of Trypanosoma brucei brucei. Nandan D, et al. **Parasitology** 1995 Sep;111 (Pt 3):313-23

Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Baruch DI, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3497-502

Plasmodium hemozoin formation mediated by histidine-rich proteins. Sullivan DJ Jr, et al. **Science** 1996 Jan 12; 271(5246):219-22

PHARMACOKINETICS

Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Ansorge I, et al. **Biochem J** 1996 Apr 1; 315 (Pt 1):307-14

PHARMACOLOGY

Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Ansorge I, et al. **Biochem J** 1996 Apr 1; 315 (Pt 1):307-14

Nitric oxide-mediated suppression of T cell responses during Trypanosoma brucei infection: soluble trypanosome products and interferon-gamma are synergistic inducers of nitric oxide synthase. Sternberg MJ, et al. **Eur J Immunol** 1996 Mar;26(3):539-43

Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity. Andrä J, et al. **FEBS Lett** 1996 Apr 29;385(1-2):96-100

PHYSIOLOGY

Characterization of cDNAs encoding adhesin proteins involved in trichomonas vaginalis cytoadherence. Arroyo R, et al. **Arch Med Res** 1995 Winter;26(4):361-9

Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Magowan C, et al. **Blood** 1995 Oct 15;86(8):3196-204

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125-8 (27 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106-9 (23 ref.)

Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121-4 (27 ref.)

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98-102 (34 ref.)

Regulation of dynein activity within Chlamydomonas flagella. Piperno G. **Cell Motil Cytoskeleton** 1995; 32(2):103-5

Loss of spatial control of the mitotic spindle apparatus in a Chlamydomonas reinhardtii mutant strain lacking basal bodies. Ehler LL, et al. **Genetics** 1995 Nov;141(3):945-60

Toxoplasma gondii: the role of parasite surface and secreted proteins in host cell invasion. Grimwood J, et al. **Int J Parasitol** 1996 Feb;26(2):169-73

A protein secreted by Trypanosoma cruzi capable of inducing the entry of inert particles into HeLa cells. Osuna A, et al. **Int J Parasitol** 1995 Oct;25(10):1213-25

Multifunctional proteins in Tetrahymena: 14-nm filament protein/citrate synthase and translation elongation factor-1 alpha. Numata O. **Int Rev Cytol** 1996;164:1-35 (126 ref.)

Activated platelets signal chemokine synthesis by human monocytes. Weyrich AS, et al. **J Clin Invest** 1996 Mar 15; 97(6):1525-34

Kinetics of entry of virulent and avirulent strains of Leishmania donovani into macrophages: a possible role of virulence molecules (gp63 and LPG). Chakrabarty R, et al. **J Parasitol** 1996 Aug;82(4):632-5

A specialized pathway affecting virulence glycoconjugates of Leishmania. Descoteaux A, et al. **Science** 1995 Sep 29; 269(5232):1869-72

SECRETION

A soluble secretory reporter system in Trypanosoma brucei. Studies on endoplasmic reticulum targeting. Bangs JD, et al. **J Biol Chem** 1996 Aug 2;271(31):18387-93

Entamoeba histolytica: proteinase secretion induced by collagen type I is dependent on cytoskeleton integrity. Serrano JJ, et al. **Parasitol Res** 1996;82(3):200-5

Spontaneous release of cysteine proteinases but not of pore-forming peptides by viable Entamoeba histolytica. Leippe M, et al. **Parasitology** 1995 Dec;111 (Pt 5):569-74

THERAPEUTIC USE

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Chang SP, et al. **Infect Immun** 1996 Jan;64(1):253-61

Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Crewther PE, et al. **Infect Immun** 1996 Aug;64(8):3310-7

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. Alonso PL, et al. **J Infect Dis** 1996 Aug;174(2):367-72

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. Heppner DG, et al. **J Infect Dis** 1996 Aug;174(2):361-6

TOXICITY

Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity. Andrä J, et al. **FEBS Lett** 1996 Apr 29;385(1-2):96-100

ULTRASTRUCTURE

High-resolution negative staining of the isolated dynein ATPase. Marchese-Ragona SP. **Methods Cell Biol** 1995; 47:177-82

Scanning transmission electron microscopic analysis of the isolated dynein ATPase. Marchese-Ragona SP, et al. **Methods Cell Biol** 1995;47:171-5

PROTOZOAN RNA see **RNA, PROTOZOAN**

PROTOZOAN STRUCTURAL GENES see **GENES, STRUCTURAL, PROTOZOAN**

PROTOZOAN VACCINES

Eimeria tenella and E. acervulina: differences in ability to elicit cross-species protection as compared with the turkey coccidium, E. adenoeides. Augustine PC, et al. **Avian Dis** 1995 Oct-Dec;39(4):709-17

Cryopreservation of an attenuated vaccine strain of the protozoan parasite Toxoplasma gondii. Booth KS, et al. **Cryobiology** 1996 Jun;33(3):330-7

Schistosoma mansoni induces in the Kenyan baboon a novel intestinal pathology that is manifestly modulated by an irradiated cercarial vaccine. Farah IO, et al. **J Parasitol** 1996 Aug;82(4):601-7

Vaccination of patas monkeys experimentally infected with

Schistosoma haematobium using a recombinant glutathione S-transferase cloned from S. mansoni. Boulanger D, et al. **Parasite Immunol** 1995 Jul;17(7):361–9

Immunity to Plasmodium berghei exoerythrocytic forms derived from irradiated sporozoites. Chatterjee S, et al. **Parasitol Res** 1996;82(4):297–303

Efficacy of a live Cryptobia salmositica vaccine, and the mechanism of protection in vaccinated rainbow trout, Oncorhynchus mykiss, against cryptobiosis. Li S, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):343–53

Viability after thawing and dilution of simultaneously cryopreserved vaccinal Babesia bovis and Babesia bigemina strains cultured in vitro. Mangold AJ, et al. **Vet Parasitol** 1996 Feb;61(3–4):345–8

A mild Theileria parva parasite with potential for immunisation against East Coast fever. Mbogo SK, et al. **Vet Parasitol** 1996 Jan;61(1–2):41–7

Identification of an immunodominant 40 kDa merozoite antigen common to the Australian T and Dixie vaccine strains of Babesia bovis and the development of diagnostic tests specific for these strains. Molloy JB, et al. **Vet Parasitol** 1995 Dec;60(3–4):229–40

Exoantigens of an attenuated strain of Babesia bovis used as a vaccine against bovine babesiosis. Patarroyo JH, et al. **Vet Parasitol** 1995 Oct;59(3–4):189–99

Effect of silica treatment on resistance to Babesia rodhaini infection in immunized mice. Saeki H, et al. **Vet Parasitol** 1996 Feb;61(3–4):201–10

ADMINISTRATION & DOSAGE

Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine-rich Entamoeba histolytica protein induces an antiamebic immune response and protects gerbils from amebic liver abscess. Zhang T, et al. **Infect Immun** 1996 May; 64(5):1526–31

A live attenuated vaccine for the control of avian coccidiosis: trials in broiler breeders and replacement layer flocks in the United Kingdom. Shirley MW, et al. **Vet Rec** 1995 Oct 28;137(18):453–7

BIOSYNTHESIS

Production of a malaria transmission-blocking protein from recombinant yeast. Wang MY, et al. **Ann N Y Acad Sci** 1996 May 15;782:123–32

IMMUNOLOGY

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Sturchler D, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):423–31

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Handman E, et al. **Infect Immun** 1995 Nov;63(11):4261–7

Conservation of the sporozoite p67 vaccine antigen in cattle-derived Theileria parva stocks with different cross-immunity profiles. Nene V, et al. **Infect Immun** 1996 Jun;64(6):2056–61

Intact immune defenses are required for mice to resist the ts-4 vaccine strain of Toxoplasma gondii. Sayles PC, et al. **Infect Immun** 1996 Aug;64(8):3088–92

Immune responses to South African Babesia canis and the development of a preliminary vaccine. Lewis BD, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):61–5

Anti-fecundity immunity induced in pigs vaccinated with recombinant Schistosoma japonicum 26kDa glutathione-S-transferase. Liu SX, et al. **Parasite Immunol** 1995 Jul;17(7):355–40

Development of a safe live Leishmania vaccine line by gene replacement. Titus RG, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10267–71

Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey. Stanley SL Jr, et al. **Vaccine** 1995 Jul;13(10):947–51

Attempts to protect severe combined immunodeficient (scid) mice with antibody enriched for reactivity to Cryptosporidium parvum surface antigen-1. Tatalick LM, et al. **Vet Parasitol** 1995 Jul;58(4):281–90

[Antigenic variation and the problem of vaccines against African trypanosomes] Pays E. **Bull Mem Acad R Med Belg** 1995;150(1–2):123–31; discussion 131–5 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Lanar DE, et al. **Infect Immun** 1996 May;64(5):1666–71

STANDARDS

Studies on failure of T strain live Babesia bovis vaccine. Bock RE, et al. **Aust Vet J** 1995 Aug;72(8):296–300

THERAPEUTIC USE

Responses to vaccination in strains of mice that differ in susceptibility to coccidiosis. Rose ME, et al. **Infect Immun** 1996 Jan;64(1):246–52

Elevated innate peripheral blood eosinophilia fails to augment irradiated cercarial vaccine-induced resistance to Schistosoma mansoni in IL-5 transgenic mice. Freeman GL Jr, et al. **J Parasitol** 1995 Dec;81(6):1010–1

PROVENTRICULUS

EMBRYOLOGY

Histochemical characterization of the mucins of the epithelial cells in the chick embryo proventriculus. Sgambati E, et al. **Ital J Anat Embryol** 1995 Apr–Jun;100(2):83–97

INNERVATION

Vagal preganglionic neurons innervating the different gastric regions in the Japanese quail (Coturnix japonica). Iizuka Y, et al. **Okajimas Folia Anat Jpn** 1995 Aug;72(2–3):149–62

PARASITOLOGY

Esophageal and proventricular cryptosporidiosis in a chicken. Goodwin MA. **Avian Dis** 1995 Jul–Sep;39(3):643–5

PATHOLOGY

Experimental reproduction of proventriculitis using homogenates of proventricular tissue. Bayyari GR, et al. **Poult Sci** 1995 Nov;74(11):1799–809

PROVERBS see APHORISMS AND PROVERBS

PROVIDENCIA

Bacteremia due to Providencia stuartii: review of 49 episodes. Woods TD, et al. **South Med J** 1996 Feb;89(2):221–4

DRUG EFFECTS

Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections. Cornaglia G, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2819–21

GENETICS

aarD, a Providencia stuartii homologue of cydD: role in 2'-N-acetyltransferase expression, cell morphology and growth in the presence of an extracellular factor. Macinga DR, et al. **Mol Microbiol** 1996 Feb;19(3):511–20

PROVIRUS INTEGRATION see VIRUS INTEGRATION

PROVIRUSES

see related
MUTAGENESIS, INSERTIONAL

In situ polymerase chain reaction detection of HTLV-I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T cell leukemia. Higuchi I, et al. **Acta Neuropathol (Berl)** 1995;90(3):323–7

A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. Ariyoshi K, et al. **J Infect Dis** 1996 Jan;173(1):245–8

GENETICS

The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. Kaye S, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1221–5

Sequence analysis of HTLV-1 provirus associated with adult T-cell leukemia/lymphoma in Hong Kong [letter] Chan WP, et al. **Am J Hematol** 1996 Jan;51(1):94–5

Flow cytometric immunodetection of human immunodeficiency virus type 1 proviral DNA by heminested PCR and digoxigenin-labeled probes. Yang G, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):26–31

Simplified plasmid rescue of host sequences adjacent to integrated proviruses. Kurdi-Haidar B, et al. **Gene** 1996 Feb 12;168(2):199–203

Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Ashe MP, et al. **Genes Dev** 1995 Dec 1;9(23):3008–25

Sequence heterogeneity of murine acquired immunodeficiency syndrome virus: the role of endogenous virus. Gayama S, et al. **Int Immunol** 1995 May;7(5):861–8

Human T-cell-leukemia virus type I in post-transfusional spastic paraparesis: complete proviral sequence from uncultured blood cells. Bazarbachi A, et al. **Int J Cancer** 1995 Nov 15;63(4):494–9

Quantification of HTLV-II proviral copies by competitive polymerase chain reaction in peripheral blood mononuclear cells of Italian injecting drug users, central Africans, and Amerindians. Cimarelli A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):198–204

Potential applications of proviral load measurement in clinical retrovirology. Conway B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S45–50

Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S51–6 (24 ref.)

HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. Kaplan EH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):175–6

Characterization of the primary immunity region of the Escherichia coli linear plasmid prophage N15. Lobocka MB, et al. **J Bacteriol** 1996 May;178(10):2902–10

Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. Lin HJ, et al. **J Clin Microbiol** 1996 Feb;34(2):329–33

Detection of human immunodeficiency virus type 1 proviral DNA by PCR using an electrochemiluminescence-tagged probe. Schutzbank TE, et al. **J Clin Microbiol** 1995 Aug; 33(8):2036–41

til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. Stewart M, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):443–6

Assessing genetic-based therapies for AIDS using the simian immunodeficiency virus. Endres CL, et al. **J Med Primatol** 1995 May;24(3):141–4

Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. Cho BC, et al. **J Virol** 1995 Nov; 69(11):7138–46

A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. Federico M, et al. **J Virol** 1995 Nov;69(11):6618–26

Genetics of intracisternal-A-particle-related envelope-encoding proviral elements in mice. Reuss FU, et al. **J Virol** 1996 Sep;70(9):6450–4

Localization of the mouse mammary tumor provirus, Mtv44, on chromosome 11. Fairchild SP, et al. **Mamm Genome** 1995 Jul;6(7):472–3

Characterization of cryptic prophages (monocins) in Listeria and sequence analysis of a holin/endolysin gene. Zink R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2577–84

Tissue- and stage-specific activation of an endogenous provirus after transcription through its integration site in the opposite orientation. Moser T, et al. **Mol Cell Biol** 1996 Jan;16(1):384–9

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Chun TW, et al. **Nat Med** 1995 Dec;1(12):1284–90

Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion. Chen J, et al. **Oncogene** 1996 Mar 7;12(5):979–88

Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Salminen MO, et al. **Virology** 1995 Oct 20; 213(1):80–6

Use of the polymerase chain reaction for the detection of reticuloendotheliosis virus in Marek's disease vaccines and chicken tissues. Reimann I, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):75–84

[Generation of a trans-complementable defective recombinant provirus and loading a transgene] Noguiez-Hellin P, et al. **C R Acad Sci III** 1996 Jan; 319(1):45–50 (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Henderson AJ, et al. **Immunity** 1996 Jul;5(1):91–101

Characterization of Mu prophage lacking the central strong gyrase binding site: localization of the block in replication. Pato ML, et al. **J Bacteriol** 1995 Oct;177(20):5937–42

Tissue- and stage-specific activation of an endogenous provirus after transcription through its integration site in the opposite orientation. Moser T, et al. **Mol Cell Biol** 1996 Jan;16(1):384–9

IMMUNOLOGY

Spontaneous lymphocyte proliferation in human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infection: T-cell subset responses and their relationships to the presence of provirus and viral antigen production. Prince HE, et al. **Clin Diagn Lab Immunol** 1994 May; 1(3):273–82

ISOLATION & PURIFICATION

Investigation of proviral load in individuals infected with human T-lymphotropic virus type II. Woods TC, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1235–9

Failure to detect HTLV-I proviral DNA in the liver of a patient with primary biliary cirrhosis and HTLV-I-associated myelopathy [letter] Ijichi T, et al. **Am J Gastroenterol** 1996 Apr;91(4):827–8

Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers. Achiron A, et al. **Arch Virol** 1996; 141(1):147–53

No detection of HTLV-1 proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)

Proviral HTLV-I and HTLV-II in the Efe pygmies of

northeastern Zaire [letter] Goubau P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):208–9

Detection of human immunodeficiency virus type 1 proviral DNA by PCR using an electrochemiluminescence-tagged probe. Schutzbank TE, et al. **J Clin Microbiol** 1995 Aug; 33(8):2036–41

Localization of human T-cell lymphotropic virus-1 tax proviral sequences in skin biopsies of patients with mycosis fungoides by in situ polymerase chain reaction. Khan ZM, et al. **J Invest Dermatol** 1996 Apr;106(4):667–72

Short-term stability of HIV provirus levels in the peripheral blood of HIV-infected individuals. Paul DB, et al. **J Med Virol** 1995 Nov;47(3):292–7

Quantification of feline immunodeficiency virus (FIV) proviral DNA in peripheral blood mononuclear cells of cats infected with Japanese strains of FIV. Inoshima Y, et al. **J Vet Med Sci** 1995 Jun;57(3):487–92

The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection. Mirsky ML, et al. **J Virol** 1996 Apr; 70(4):2178–83

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

Use of a rapid and simple method to extract proviral DNA in the identification of HIV-1 by PCR. Tagliaferro L, et al. **New Microbiol** 1995 Jul;18(3):303–6

PHYSIOLOGY

In vivo proviral burden and viral RNA expression in T cell subsets of patients with human T lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis. Cho I, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):412–8

The packaging phenotype of the SE21Q1b provirus is related to high proviral expression and not trans-acting factors. Anderson DJ, et al. **J Virol** 1995 Nov;69(11):7319–23

Expression of ecotropic murine leukemia virus in the brains of C58/M, DBA2/J, and in utero-infected CE/J mice. Anderson GW, et al. **J Virol** 1995 Dec;69(12):8089–95

Generation and role of defective proviruses in cytopathic feline leukemia virus (FeLV-FAIDS) infections. de Noronha CM, et al. **J Virol** 1996 Jan;70(1):359–67

The zinc finger of nucleocapsid protein of Friend murine leukemia virus is critical for proviral DNA synthesis in vivo. Yu Q, et al. **J Virol** 1996 Sep;70(9):5791–8

PROVOCATION TESTS, BRONCHIAL see **BRONCHIAL PROVOCATION TESTS**

PROVOCATION TESTS, NASAL see **NASAL PROVOCATION TESTS**

PROXIMAL RENAL TUBULAR DYSFUNCTION see **FANCONI SYNDROME**

PROZAMINE see **PROMETHAZINE**

PRP 27-30 PROTEIN

BLOOD

PrP27-30 is a normal soluble prion protein fragment released by human platelets. Perini F, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):572–7

CHEMISTRY

X-ray diffraction of scrapie prion rods and PrP peptides. Nguyen JT, et al. **J Mol Biol** 1995 Sep 29;252(4):412–22

GENETICS

High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Mehlhorn I, et al. **Biochemistry** 1996 Apr 30;35(17):5528–37

METABOLISM

Recombinant prion protein rPrP27-30 from Syrian golden hamster reveals proteinase K sensitivity. Weiss S, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):173–9

ULTRASTRUCTURE

Separation of scrapie prion infectivity from PrP amyloid polymers. Wille H, et al. **J Mol Biol** 1996 Jun 21; 259(4):608–21

Comparative study of electron microscopical techniques for the detection of scrapie-associated fibrils. Stack MJ, et al. **Res Vet Sci** 1995 Nov;59(3):247–54

PRP PROTEINS see **PRIONS**

PRPC PROTEINS

ANALYSIS

A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. Horiuchi M, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2583–7

BIOSYNTHESIS

Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35. Hope J, et al. **Neurodegeneration** 1996 Mar;5(1):1–11

CHEMISTRY

Putting prions to the test [news] Mestel R. **Science** 1996 Jul 12;273(5272):184–9

GENETICS

High-frequency cell surface expression of a foreign protein in murine hematopoietic stem cells using a new retroviral vector. Tumas DB, et al. **Blood** 1996 Jan 15;87(2):509–17

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

METABOLISM

Prion diseases and the 'protein only' hypothesis: a theoretical dynamic study. Laurent M. **Biochem J** 1996 Aug 15;318 (Pt 1):35–9

Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Telling GC, et al. **Cell** 1995 Oct 6; 83(1):79–90

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. Shyng SL, et al. **J Biol Chem** 1995 Dec 15;270(50):30221–9

Prion protein PrPc interacts with molecular chaperones of the Hsp60 family. Edenhofer F, et al. **J Virol** 1996 Jul; 70(7):4724–8

Normal host prion protein necessary for scrapie-induced neurotoxicity. Brandner S, et al. **Nature** 1996 Jan 25; 379(6563):339–43

PHARMACOLOGY

Regulation of intracellular free calcium levels by the cellular prion protein. Whatley SA, et al. **Neuroreport** 1995 Nov 27;6(17):2333–7

ULTRASTRUCTURE

Separation of scrapie prion infectivity from PrP amyloid polymers. Wille H, et al. **J Mol Biol** 1996 Jun 21; 259(4):608–21

PRPP SYNTHETASE see **RIBOSE-PHOSPHATE PYROPHOSPHOKINASE**

PRPSC PROTEINS

ANALYSIS

Preclinical test for prion diseases [letter] Schreuder BE, et al. **Nature** 1996 Jun 13;381(6583):563

DRUG EFFECTS

Exposure to autoclaving or sodium hydroxide extends the dose-response curve of the 263K strain of scrapie agent in hamsters. Taylor DM, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):811–3

GENETICS

Natural scrapie in a closed flock of Cheviot sheep occurs only in specific PrP genotypes. Hunter N, et al. **Arch Virol** 1996;141(5):809–24

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

Thermodynamic prediction of conserved secondary structure: application to the RRE element of HIV, the tRNA-like element of CMV and the mRNA of prion protein. Lück R, et al. **J Mol Biol** 1996 May 24; 258(5):813–26

The nature of the scrapie agent: the virus theory. Narang H. **Proc Soc Exp Biol Med** 1996 Jul;212(3):208–24 (139 ref.)

IMMUNOLOGY

Scrapie infection can be established readily through skin scarification in immunocompetent but not immunodeficient mice. Taylor DM, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1595–9

Immune system-dependent and -independent replication of the scrapie agent. Lasmézas CI, et al. **J Virol** 1996 Feb; 70(2):1292–5

METABOLISM

Prion diseases and the 'protein only' hypothesis: a theoretical dynamic study. Laurent M. **Biochem J** 1996 Aug 15;318 (Pt 1):35–9

Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Telling GC, et al. **Cell** 1995 Oct 6; 83(1):79–90

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. van Keulen LJ, et al. **J Clin Microbiol** 1996 May;34(5):1228–31

Protease-resistant PrP deposition in brain and non-central nervous system tissues of a murine model of bovine spongiform encephalopathy. Farquhar CF, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1941–6

PATHOGENICITY

Strain specific and common pathogenic events in murine models of scrapie and bovine spongiform encephalopathy. Lasmézas CI, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1601–9

Keeping an open mind about prions [news] Finkel E. **Lancet** 1996 Aug 3;348(9023):326

Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. Taylor DM, et al. **Vet Rec** 1995 Dec 9;137(24):605–10

TOXICITY

Normal host prion protein necessary for scrapie-induced neurotoxicity. Brandner S, et al. **Nature** 1996 Jan 25; 379(6563):339–43

PRUNE BELLY SYNDROME

The prune-belly syndrome: current insights. Sutherland RS, et al. **Pediatr Nephrol** 1995 Dec;9(6):770–8 (72 ref.)

DIAGNOSIS

Association of prune belly with cleft lip. Matsuzaki K, et al. **Am J Med Genet** 1996 Jan 2;61(1):79–80

A child with recurrent urine infections and undescended testes. Woodhouse CR, et al. **Nephrol Dial Transplant** 1995; 10(5):711–3

ETIOLOGY

Prune-belly syndrome in a female, complicated by intestinal malrotation after successful antenatal treatment of hydrops fetalis. Hirose R, et al. **J Pediatr Surg** 1995 Sep;30(9):1373–5

GENETICS

Early urethral obstruction sequence and trisomy of the long arm of chromosome 1. van Buggenhout G, et al. **Ann Genet** 1995;38(2):106–7

PHYSIOPATHOLOGY

The effect of the absence of abdominal muscles on pulmonary function and exercise. Ewig JM, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1314–21

RADIOGRAPHY

Unilateral abdominal wall hypoplasia: radiographic findings in two infant girls. Donnelly LF, et al. **Pediatr Radiol** 1995; 25(4):278–81

SURGERY

Fetal therapy for obstructive uropathy: specific outcomes diagnosis. Freedman AL, et al. **J Urol** 1996 Aug;156(2 Pt 2):720–3; discussion 723–4

ULTRASONOGRAPHY

The origin of ascites in prune belly syndrome--early sonographic evidence [letter] Fried S, et al. **Prenat Diagn** 1995 Sep;15(9):876–7

[A case of Prune Belly Syndrome. Prenatal diagnosis] Montoya S, et al. **Ginecol Obstet Mex** 1995 Sep;63:382–4 (Eng. Abstr.) **(Spa)**

PRURIGO

COMPLICATIONS

Cutaneous Horn in a lesion of prurigo nodularis [letter] Khaitan BK, et al. **Acta Derm Venereol** 1996 Jan;76(1):85–6

DRUG THERAPY

Nodular prurigo responsive to azathioprine [letter] Lear JT, et al. **Br J Dermatol** 1996 Jun;134(6):1151

Prurigo pigmentosa treated with minocycline [letter] Schepis C, et al. **Br J Dermatol** 1996 Jul;135(1):158–9

Treatment of actinic prurigo in Chimila Indians. Durán MM, et al. **Int J Dermatol** 1996 Jun;35(6):413–6

Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. Berger TG, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):837–8

ETIOLOGY

Prurigo pigmentosa associated with ketosis [letter] Murao K, et al. **Br J Dermatol** 1996 Feb;134(2):379–81

Ketosis is involved in the origin of prurigo pigmentosa. Teraki Y, et al. **J Am Acad Dermatol** 1996 Mar;34(3):509–11

[Bullous pemphigoid simulation subacute simple prurigo] Wever S, et al. **Hautarzt** 1995 Nov;46(11):789–95 (Eng. Abstr.) **(Ger)**

PRURIGO

GENETICS

Hereditary polymorphic light eruption of American Indians: occurrence in non-Indians with polymorphic light eruption. Fusaro RM, et al. **J Am Acad Dermatol** 1996 Apr; 34(4):612-7

IMMUNOLOGY

HLA-DR4 may determine expression of actinic prurigo in British patients. Menagé H duP, et al. **J Invest Dermatol** 1996 Feb;106(2):362-7

MICROBIOLOGY

Mycobacteria in prurigo nodularis: the cause or a consequence? Mattila JO, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):224-8

PATHOLOGY

Follicular cheilitis. A distinctive histopathologic finding in actinic prurigo. Herrera-Geopfert R, et al. **Am J Dermatopathol** 1995 Aug;17(4):357-61

Prurigo papules with blisters. Kossard S. **Australas J Dermatol** 1996 May;37(2):104-5

Prurigo pigmentosa in a white woman. Yanguas I, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):473-5

PRURITUS

see related
ANTIPRURITICS

BLOOD

Uraemic pruritus is not related to plasma histamine concentrations. De Filippi C, et al. **Clin Exp Dermatol** 1995 Jul;20(4):294-6

Increased met-enkephalin plasma levels in hemodialysis patients with or without pruritus. Danno K, et al. **J Dermatol Sci** 1995 Nov;10(3):238-40

CHEMICALLY INDUCED

Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Heyer G, et al. **Acta Derm Venereol** 1995 Sep;75(5):348-52

Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Wahlgren CF, et al. **Arch Dermatol Res** 1995; 287(6):572-80

Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethylstarch plasma expander. Cox NH, et al. **Br J Dermatol** 1996 Feb; 134(2):353-7

Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. Thomas DA, et al. **Brain Res** 1995 Oct 16; 695(2):267-70

Chloroquine pruritus: a possible fixed cutaneous reaction. George AO. **Int J Dermatol** 1996 May;35(5):323-4

COMPLICATIONS

B-cell chronic lymphocytic leukemia associated with high serum IGE levels and pruriginous skin lesions: successful therapy with IFN-alpha 2b after failure on IFN-gamma. Neuber K, et al. **Dermatology** 1996;192(2):110-5

DIAGNOSIS

Pruritus circumscriptus sine materia: a sequel of postzosteric neuralgia. Evaluation by quantitative psychophysical examination and laser-evoked potentials. Darsow U, et al. **Acta Derm Venereol** 1996 Jan;76(1):45-7

Two-point discrimination of itch in patients with atopic dermatitis and healthy subjects. Wahlgren CF, et al. **Acta Derm Venereol** 1996 Jan;76(1):48-51

A young woman with a photosensitive pruritic rash on her face and upper trunk. Zuber M, et al. **Arthritis Rheum** 1996 Aug;39(8):1419-22

Pruritic eruption on the ankle. What is the most likely cause of this recurrent reaction pattern? LEVINE N. **Geriatrics** 1996 Mar;51(3):20

The itchy scalp and other pruritic curiosities. Bernhard JD. **Semin Dermatol** 1995 Dec;14(4):326-9 (27 ref.)

Investigation of the pruritic patient in daily practice. Kantor GR, et al. **Semin Dermatol** 1995 Dec;14(4):290-6 (32 ref.)

The measurement of scratching. Savin J. **Semin Dermatol** 1995 Dec;14(4):285-9 (33 ref.)

Measurement of itch. Wahlgren CF. **Semin Dermatol** 1995 Dec;14(4):277-84 (53 ref.)

[The approach to generalized pruritus in primary care] Sarrasqueta Sáenz P, et al. **Aten Primaria** 1996 May 31; 17(9):590-4 **(Spa)**

DIET THERAPY

Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Peck LW, et al. **Am J Clin Nutr** 1996 Aug; 64(2):210-4

DRUG THERAPY

The antipruritic effects of chlorpheniramine, cyproheptadine and sulphapyridine monitored with limb activity meters on chloroquine induced pruritus among patients with malaria. Osifo NG. **Afr J Med Med Sci** 1995 Mar; 24(1):67-73

Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Carson KL, et al. **Am J Gastroenterol** 1996 May;91(5):1022-3

Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases. Kolodny L, et al. **Am J Hematol** 1996 Feb;51(2):112-6

Ondansetron for the treatment of pruritus after spinal opioids [letter] Crighton IM, et al. **Anaesthesia** 1996 Feb; 51(2):199-200

Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Jeanmougin M, et al. **Ann Hematol** 1996 Aug;73(2):91-3

B-cell chronic lymphocytic leukemia associated with high serum IGE levels and pruriginous skin lesions: successful therapy with IFN-alpha 2b after failure on IFN-gamma. Neuber K, et al. **Dermatology** 1996;192(2):110-5

Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Davies MH, et al. **Gut** 1995 Oct;37(4):580-4

The pruritus of cholestasis is relieved by an opiate antagonist: is this pruritus a centrally mediated phenomenon? Heathcote J. **Hepatology** 1996 May;23(5):1280-2

Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch. Foster AP, et al. **Inflamm Res** 1995 Oct;44(10):412-7

Solar (brachioradial) pruritus--response to capsaicin cream [letter; comment] Teixeira F, et al. **Int J Dermatol** 1995 Aug;34(8):594-5. Comment on: Int J Dermatol 1994 Mar;33(3):206-9.

Treatment of cholestatic itching in primary biliary cirrhosis with ondansetron [letter] Di Martino M, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):455

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801-5 (32 ref.)

Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. Tsutsui K, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):313-5

Oral activated charcoal in patients with uremic pruritus. Giovannetti S, et al. **Nephron** 1995;70(2):193-6

Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Tarng DC, et al. **Nephron** 1996;72(4):617-22

Treating pruritus. What's new in safe relief of symptoms? Millikan LE. **Postgrad Med** 1996 Jan;99(1):173-6, 179-84 (17 ref.)

Pruritus of chronic cholestasis. Raiford DS. **QJM** 1995 Sep; 88(9):603-7 (34 ref.)

Treatment of itch. Hägermark O, et al. **Semin Dermatol** 1995 Dec;14(4):320-5 (62 ref.)

[Acute pseudo-angiocholitic hepatitis caused by oxatomide (letter)] Mohib S, et al. **Gastroenterol Clin Biol** 1996 Feb; 20(1):122-3 **(Fre)**

ETIOLOGY

Solar pruritus. Bech-Thomsen N, et al. **Acta Derm Venereol** 1995 Nov;75(6):488-9

Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic eczema. Cremer B, et al. **Acta Derm Venereol** 1995 Nov;75(6):426-8

Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Carson KL, et al. **Am J Gastroenterol** 1996 May;91(5):1022-3

The seven year itch [letter] Spittal MJ, et al. **Anaesthesia** 1995 Oct;50(10):913-4

Sensitivity to sternotomy wires may cause postoperative pruritus. Gordon PM, et al. **Ann Thorac Surg** 1996 May; 61(5):1514-6

Generalized pruritus in anorexia nervosa. Taniguchi S, et al. **Br J Dermatol** 1996 Mar;134(3):510-1

Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Yosipovitch G, et al. **Br J Dermatol** 1995 Oct;133(4):561-4

'Winter itch': what's causing this rash? Levine N. **Geriatrics** 1996 Jan;51(1):20

Which came first: the itch or the rash? Patient's scratching may be unrelated to a primary skin disease. Levine N. **Geriatrics** 1996 Jul;51(7):24

Why do cholestatic patients itch? Jones EA, et al. **Gut** 1996 May;38(5):644-5

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801-5 (32 ref.)

Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Tarng DC, et al. **Nephron** 1996;72(4):617-22

An outbreak of pruritic skin lesions in a group of laboratory workers--a case report. Sim MR, et al. **Occup Med (Oxf)** 1996 Jun;46(3):235-8

Masked Hodgkin's disease: the pruriginous disguise [letter] Stefanato CM, et al. **Pediatr Hematol Oncol** 1996 May-Jun; 13(3):293-4

Pruritus of chronic cholestasis. Raiford DS. **QJM** 1995 Sep; 88(9):603-7 (34 ref.)

The pruritus of cholestasis. Bergasa NV. **Semin Dermatol** 1995 Dec;14(4):302-12 (86 ref.)

Aquagenic pruritus. du Peloux Menagé H, et al. **Semin Dermatol** 1995 Dec;14(4):313-6 (40 ref.)

Uremic pruritus. Ståhle-Bäckdahl M. **Semin Dermatol** 1995 Dec;14(4):297-301 (43 ref.)

[Question of the month: should direct immunofluorescence be performed in every case of papulous or pruriginous gestational dermatosis?] **Ann Dermatol Venereol** 1996; 123(1):60-2 **(Fre)**

[Facial involvement in papulous, prurient and urticarial skin disease in pregnancy] Estève E, et al. **Ann Dermatol Venereol** 1996;123(2):122-3 **(Fre)**

[Etiology of isolated pruritus in dermatology consultations at Lome (Togo)] Pitche P, et al. **Sante** 1996 Jan-Feb; 6(1):17-9 (Eng. Abstr.) **(Fre)**

[Uremic pruritus. Pathophysiologic and therapeutic concepts] Mettang T, et al. **Dtsch Med Wochenschr** 1996 Aug 16; 121(33):1025-31 (66 ref.) **(Ger)**

[Pruritus] Reinauer S, et al. **Hautarzt** 1996 Mar;47(3):229-42 (11 ref.) **(Ger)**

[Pruritus. Physiology, pathophysiology, clinical aspects and therapy] Heyer G. **Med Monatsschr Pharm** 1995 Nov; 18(11):320-9 (77 ref.) **(Ger)**

[Pruritus--also a challenge in internal medicine] Brunner W. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2244-50 (Eng. Abstr.) **(Ger)**

[Pruritus due to obstructive jaundice, with delusions of parasitosis] Nevo A, et al. **Harefuah** 1996 Jan 15; 130(2):93-4, 143 (Eng. Abstr.) **(Heb)**

PATHOLOGY

Pruritic urticarial papules and plaques of pregnancy (polymorphic eruption of pregnancy): two unusual cases. Vaughan Jones SA, et al. **Br J Dermatol** 1996 Jul; 135(1):102-5

Pruritus and mast cell proliferation in the skin of haemodialysis patients. Szepietowski J, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S84-5

Pruritus in the elderly. Gilchrest BA. **Semin Dermatol** 1995 Dec;14(4):317-9 (22 ref.)

PHYSIOPATHOLOGY

Itch and pain. Teofoli P, et al. **Int J Dermatol** 1996 Mar; 35(3):159-66 (98 ref.)

Some neurophysiological aspects of itch. Ekblom A. **Semin Dermatol** 1995 Dec;14(4):262-70 (60 ref.)

Itch mediators. Hägermark O. **Semin Dermatol** 1995 Dec; 14(4):271-6 (76 ref.)

PREVENTION & CONTROL

Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Kendrick WD, et al. **Anesth Analg** 1996 Mar;82(3):641-7

High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. Yosipovitch G, et al. **J Am Acad Dermatol** 1996 Jul;35(1):118-20

The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. Woodward DF, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):339-47

[Infusion therapy in sudden deafness. Reducing the risk of pruritus after hydroxyethyl starch and maintaining therapeutic success--a prospective randomized study] Desloovere C, et al. **Laryngorhinootologie** 1995 Aug; 74(8):468-72 (Eng. Abstr.) **(Ger)**

THERAPY

Pruritus associated with cholestatic liver disease [letter] Horsmans Y, et al. **Ann Intern Med** 1996 Oct 15;125(8):701

Medical therapy of pruritus of cholestasis. Luketic VA, et al. **Gastroenterologist** 1995 Sep;3(3):257-60 (11 ref.)

Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin. Kikuchi-Numagami K, et al. **J Dermatol** 1996 May; 23(5):340-3

VETERINARY

Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch. Foster AP, et al. **Inflamm Res** 1995 Oct;44(10):412-7

Severe pruritus associated with lymphoma in a dog. Anderson RK, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):455-6

Responses of dogs with food allergies to single-ingredient dietary provocation. Jeffers JG, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):608-11

Factors associated with elevated cutaneous Malassezia pachydermatis populations in dogs with pruritic skin disease. Bond R, et al. **J Small Anim Pract** 1996 Mar; 37(3):103-7

PRURITUS VULVAE

ETIOLOGY

[Pruritus of the artificial vagina of a transsexual patient caused by gonococcal infection] Haustein UF. **Hautarzt** 1995 Dec;46(12):858-9 (Eng. Abstr.) **(Ger)**

PSAMMOMYS see **GERBILLINAE**

PSEUDALLESCHERIA

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

Arthritis without grains caused by Pseudallescheria boydii. Ginter G, et al. **Mycoses** 1995 Sep–Oct;38(9–10):369–71

Cerebral Pseudallescheria mycosis after near–drowning. Rüchel R, et al. **Mycoses** 1995 Nov–Dec;38(11–12):473–5

DRUG EFFECTS

Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Walsh TJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1361–4

Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia. Cunningham R, et al. **J Clin Pathol** 1996 Jan;49(1):93–4

ENZYMOLOGY

A 33 kDa serine proteinase from Scedosporium apiospermum. Larcher G, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):119–26

ISOLATION & PURIFICATION

Scedosporium apiospermum infection imitating lymphocutaneous sporotrichosis in a patient with myeloblastic–monocytic leukaemia. Török L, et al. **Br J Dermatol** 1995 Nov;133(5):805–9

PSEUDARTHROSIS

COMPLICATIONS

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)

Ulna non–union leading to Monteggia fracture deformity. Two cases of slowly developing radial head luxation. Kramhøft M. **Ital J Orthop Traumatol** 1993;19(1):95–7

Pseudoarthrosis between a patellar tendon ossicle and the tibial tuberosity in Osgood–Schlatter's disease. Robertsen K, et al. **Scand J Med Sci Sports** 1996 Feb;6(1):57–9

Cervical myelopathy caused by pseudoarthrosis between the atlas and axis associated with diffuse idiopathic skeletal hyperostosis. Goto S, et al. **Spine** 1995 Dec 1;20(23):2572–5

CONGENITAL

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)

Congenital pseudarthrosis of the tibia in children [editorial] Shevstov VI. **Chir Organi Mov** 1995 Apr–Jun; 80(2):IX–XXII **(Eng, Ita)**

Congenital annular constricting band: a case report with pseudarthrosis and review of the literature. Martinot–Duquennoy V, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):380–4 (23 ref.)

[Contribution of Ilizarov's equipment in the treatment of congenital pseudarthrosis of the lower limb] Damsin JP, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(1):34–41 (Eng. Abstr.) **(Fre)**

[Congenital pseudarthrosis of the tibia treated with permanent electromagnetic fields (letter)] Traina GC. **Chir Organi Mov** 1995 Oct–Dec;80(4):457 **(Ita)**

DIAGNOSIS

A 68–year–old man with gradual onset of low–back pain. Peh WC, et al. **Am J Orthop** 1996 Jan;25(1):55–8

A 9–year–old girl with a bowed right forearm 6 months after a fracture. Yin Y, et al. **Am J Orthop** 1995 Sep;24(9):717, 720–2

ETIOLOGY

[Femoral loosening of total hip prosthesis caused by pseudarthrosis resulting from trochanterotomy] Langlais F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(2):95–105 (Eng. Abstr.) **(Fre)**

[Pseudarthrosis and delayed union of the distal phalanx of the long fingers. Apropos of 13 cases] Voche P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):485–90 (Eng. Abstr.) **(Fre)**

[Two cases of congenital defects within the transverse processes of the lumbar spine] Malawski S, et al. **Chir Narzadow Ruchu Ortop Pol** 1993;58(6):445–8 (Eng. Abstr.) **(Pol)**

GENETICS

Familial congenital pseudarthrosis of the ulna. Craigen MA, et al. **J Hand Surg [Br]** 1995 Jun;20(3):331–2

RADIOGRAPHY

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452–3 (11 ref.) **(Ger)**

[The mobile segment above fusion] Schulitz KP, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr;134(2):171–6 (Eng. Abstr.) **(Ger)**

[Pedicular–process and laminar–process pseudoarthroses in computed tomography and ther clinical significance] Królewski J, et al. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(2):111–4 (Eng. Abstr.) **(Pol)**

SURGERY

Simultaneous anterior and posterior approaches for correction of late deformity due to thoracolumbar fractures. Acaroglu ER, et al. **Eur Spine J** 1996;5(1):56–62

Repair of a pseudarthrosis of the lumbar spine. A functional outcome study. Carpenter CT, et al. **J Bone Joint Surg Am** 1996 May;78(5):712–20

Treatment of pseudarthrosis of the distal phalanx with a compression screw. Botelheiro JC. **J Hand Surg [Br]** 1995 Oct;20(5):618–9

Treatment of congenital pseudarthrosis of tibia with the circular frame technique. Grill F. **J Pediatr Orthop B** 1996 Winter;5(1):6–16

Congenital tibial pseudoarthrosis treated with vascularised bone allograft [letter] Doi K, et al. **Lancet** 1996 Apr 6; 347(9006):970–1

Surgical revision for failed anterior cervical fusions. Articular pillar plating or anterior revision? Lowery GL, et al. **Spine** 1995 Nov 15;20(22):2436–41

[Results 37 years after insertion of an acrylic implant for scaphoid pseudoarthrosis] Orsi R, et al. **Ann Chir Main Memb Super** 1995;14(4–5):214–7 (Eng. Abstr.) **(Fre)**

[Treatment of pseudarthrosis of the clavicle by bone plate with screw fixation and autologous spongiosa graft] Nikiforidis P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):125–9 (Eng. Abstr.) **(Fre)**

[Role of intramedullary nailing in pseudarthrosis and malalignment] Weise K, et al. **Orthopade** 1996 Jun; 25(3):247–58 (Eng. Abstr.) **(Ger)**

[Post–traumatic os odontoideum] Schwarz N, et al. **Unfallchirurg** 1995 Sep;98(9):483–6 (Eng. Abstr.) **(Ger)**

[Surgical and conservative therapy of scaphoid pseudarthrosis] Martini AK. **Zentralbl Chir** 1995; 120(12):940–4 (Eng. Abstr.) **(Ger)**

[Transoral approach to the anterior aspect of C1–C3 cervical vertebrae] Doniec J, et al. **Chir Narzadow Ruchu Ortop Pol** 1993;58(6):433–6 (Eng. Abstr.) **(Pol)**

THERAPY

Percutaneous autogenous bone–marrow grafting in congenital tibial pseudarthrosis [see comments] Garg NK, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):830–1. Comment in: J Bone Joint Surg Br 1996 Jul;78(4):683–4.

[Tibial pseudoarthrosis. Treatment using the Ilizarov technique] Andersen LR, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2237–40 (Eng. Abstr.) **(Dan)**

[Congenital pseudarthrosis of the tibia treated with permanent electromagnetic fields (letter)] Traina GC. **Chir Organi Mov** 1995 Oct–Dec;80(4):457 **(Ita)**

ULTRASONOGRAPHY

[Possible applications of ultrasound in corticotomy–callus distraction] Gruber G, et al. **Aktuelle Radiol** 1995 Jul; 5(4):268–73 (Eng. Abstr.) **(Ger)**

VETERINARY

[The use of bone morphogenetic proteins in delayed fracture healing, pseudoarthrosis and in ulna osteotomy carried out because of elbow joint diseases] Paatsama S, et al. **Tierarztl Prax** 1996 Apr;24(2):164–8 (Eng. Abstr.) **(Ger)**

PSEUDO–HURLER POLYDYSTROPHY see **MUCOLIPIDOSIS**

PSEUDO–OBSTRUCTION, COLONIC see **COLONIC PSEUDO–OBSTRUCTION**

PSEUDO–OBSTRUCTION, INTESTINAL see **INTESTINAL PSEUDO–OBSTRUCTION**

PSEUDOBULBAR PARALYSIS see **PARALYSIS**

PSEUDOCHOLINESTERASE

ANTAGONISTS & INHIBITORS see CHOLINESTERASE INHIBITORS

BLOOD

Does age or pseudocholinesterase activity predict mivacurium infusion rate in children? Markakis DA, et al. **Anesth Analg** 1996 Jan;82(1):39–43

Serum cholinesterase in obsessive–compulsive disorder. Erzegovesi S, et al. **Psychiatry Res** 1995 Oct 16;58(3):265–8

DEFICIENCY

[Prolonged curarization with mivacurium and suxamethonium: will molecular biology allow a diagnostic and therapeutic approach? (editorial)] Duvaldestin P. **Ann Fr Anesth Reanim** 1995;14(6):465–6 **(Fre)**

[Prolonged curarization with suxamethonium caused by pseudocholinesterase plasma deficiency during the immediate postpartum period (letter)] Elhairy A, et al. **Ann Fr Anesth Reanim** 1995;14(6):533 **(Fre)**

[Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency] Kaiser E, et al. **Ann Fr Anesth Reanim** 1995; 14(6):505–7 (Eng. Abstr.) **(Fre)**

[Prolonged neuromuscular block after mivacurium injection] Viggiano M, et al. **Ann Fr Anesth Reanim** 1995;14(6):502–4 (Eng. Abstr.) **(Fre)**

METABOLISM

Course of pseudocholinesterase isozymes during an acute phase in Crohn's disease. Novacek G, et al. **Digestion** 1996; 57(2):90–4

PHYSIOLOGY

Pseudocholinesterase–mediated hydrolysis is superior to neostigmine for reversal of mivacurium–induced paralysis in vitro. Yang HS, et al. **Anesthesiology** 1996 Apr; 84(4):936–44

From pseudocholinesterase to human immunodeficiency virus. Madhavankutty K, et al. **Med Hypotheses** 1995 Sep; 45(3):225–6

PSEUDOCYESIS see **PSEUDOPREGNANCY**

PSEUDODEMENTIA see **FACTITIOUS DISORDERS**

PSEUDOEPHEDRINE see **EPHEDRINE**

PSEUDOEXFOLIATION SYNDROME see **EXFOLIATION SYNDROME**

PSEUDOGENES

Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromosome 13 [letter] Doll JA, et al. **Am J Hum Genet** 1996 Feb;58(2):425–8

Processed pseudogenes interfere with reverse transcriptase–polymerase chain reaction controls. Garbay B, et al. **Anal Biochem** 1996 May 15;237(1):157–9

Pseudogenes for the human uracil–DNA glycosylase on chromosomes 14 and 16. Lund H, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):265–70

Molecular cloning of human mitochondrial glycerophosphate dehydrogenase gene: genomic structure, chromosomal localization, and existence of a pseudogene. Matsutani A, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):481–6

Identification of a brain–specific protein kinase C zeta pseudogene (psi PKC zeta) transcript. Andrea JE, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):835–43

Seventeen copies of the human 37 kDa laminin receptor precursor/p40 ribosome–associated protein gene are processed pseudogenes arisen from retropositional events. Jackers P, et al. **Biochim Biophys Acta** 1996 Feb 7; 1305(1–2):98–104

Multi–copy nuclear pseudogenes of mitochondrial DNA reveal recent acute genetic changes in the human genome. Hu G, et al. **Curr Genet** 1995 Oct;28(5):410–4

Structure and chromosomal assignment of the murine sterol carrier protein 2 gene (Scp2) and two related pseudogenes by in situ hybridization. Raabe M, et al. **Cytogenet Cell Genet** 1996;73(4):279–81

Localization by fluorescence in situ hybridization of the human functional beta–glucuronidase gene (GUSB) to 7q11.21 —> q11.22 and two pseudogenes to 5p13 and 5q13. Speleman F, et al. **Cytogenet Cell Genet** 1996; 72(1):53–5

Structures and chromosome locations of the human MEF2A gene and a pseudogene MEF2AP. Suzuki E, et al. **Cytogenet Cell Genet** 1996;73(3):244–9

Cloning and chromosomal localization of a pseudogene corresponding to a mRNA for a soluble IL–6 receptor. Snyers L, et al. **DNA Seq** 1995;5(5):311–4

mRNA retroposition in human cells: processed pseudogene formation. Maestre J, et al. **EMBO J** 1995 Dec 15; 14(24):6333–8

Characterization of the functional gene encoding mouse class III alcohol dehydrogenase (glutathione–dependent formaldehyde dehydrogenase) and an unexpressed processed pseudogene with an intact open reading frame. Foglio MH, et al. **Eur J Biochem** 1996 Apr 15; 237(2):496–504

Pseudogenes in ribonuclease evolution: a source of new biomacromolecular function? Trabesinger–Ruef N, et al. **FEBS Lett** 1996 Mar 18;382(3):319–22

Isolation, characterization and chromosomal localization of a human pseudogene for hexokinase II. Ardehali H, et al. **Gene** 1995 Oct 27;164(2):357–61

Structural organization and mapping of the human mitochondrial glycerol phosphate dehydrogenase–encoding gene and pseudogene. Brown LJ, et al. **Gene** 1996 Jun 26;172(2):309–12

Structural characterization and chromosomal location of the

mouse macrophage migration inhibitory factor gene and pseudogenes. Bozza M, et al. **Genomics** 1995 Jun 10; 27(3):412–9

The mouse angiogenin gene family: structures of an angiogenin-related protein gene and two pseudogenes. Brown WE, et al. **Genomics** 1995 Sep 1;29(1):200–6

The mouse glutathione peroxidase Gpx2 gene maps to chromosome 12; its pseudogene Gpx2–ps maps to chromosome 7. Chu FF, et al. **Genomics** 1996 May 1; 33(3):516–8

The structure of the prostaglandin EP4 receptor gene and related pseudogenes. Foord SM, et al. **Genomics** 1996 Jul 1;35(1):182–8

Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. Jacobson MA, et al. **Genomics** 1995 May 20;27(2):374–6

Tandem repeats 3' of the IGHA genes in the human immunoglobulin heavy chain gene cluster. Kang HK, et al. **Genomics** 1996 Jul 1;35(1):189–95

The IL-9 receptor gene (IL9R): genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter. Kermouni A, et al. **Genomics** 1995 Sep 20;29(2):371–82

Genomic cloning of mouse MIF (macrophage inhibitory factor) and genetic mapping of the human and mouse expressed gene and nine mouse pseudogenes. Kozak CA, et al. **Genomics** 1995 Jun 10;27(3):405–11

The Pem homeobox gene: rapid evolution of the homeodomain, X chromosomal localization, and expression in reproductive tissue. Maiti S, et al. **Genomics** 1996 Jun 15;34(3):304–16

The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. Miyazaki S, et al. **Genomics** 1995 Jun 10;27(3):420–4

Structure and chromosomal localization of the GPI-anchor synthesis gene PIGF and its pseudogene psi PIGF. Ohishi K, et al. **Genomics** 1995 Oct 10;29(3):804–7

LIS2, gene and pseudogene, homologous to LIS1 (lissencephaly 1), located on the short and long arms of chromosome 2. Reiner O, et al. **Genomics** 1995 Nov 20; 30(2):251–6

Characterization and genomic mapping of genes and pseudogenes of a new human protein tyrosine phosphatase. Zhao Z, et al. **Genomics** 1996 Jul 1;35(1):172–81

Organization of a human UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase gene and a related processed pseudogene. Meurer JA, et al. **Glycobiology** 1996 Mar;6(2):231–41

Identification and characterization of NF1-related loci on human chromosomes 22, 14 and 2. Hulsebos TJ, et al. **Hum Genet** 1996 Jul;98(1):7–11

Structural repertoire in human VL pseudogenes of immunoglobulins: comparison with functional germline genes and amino acid sequences. Almagro JC, et al. **Immunogenetics** 1996;43(1-2):92–6

Genomic organization and expression of mouse thymic shared antigen-1 (TSA-1): evidence for a processed pseudogene. Classon BJ, et al. **Immunogenetics** 1996; 44(3):222–6

A new human IghV4.21-related pseudogene capable of V D J rearrangement. Dunn-Walters DK, et al. **Immunogenetics** 1996;43(5):321–2

Generation and reactivation of T-cell receptor A joining region pseudogenes in primates. Thiel C, et al. **Immunogenetics** 1996;43(1-2):57–62

The human T-cell receptor gamma variable pseudogene V10 is a distinctive marker of human speciation. Zhang XM, et al. **Immunogenetics** 1996;43(4):196–203

Short stature in a girl with partial monosomy of the pseudoautosomal region distal to DXYS15: further evidence for the assignment of the critical region for a pseudoautosomal growth gene(s). Ogata T, et al. **J Med Genet** 1995 Oct;32(10):831–4

Activation of a yeast pseudo DNA methyltransferase by deletion of a single amino acid. Pinarbasi E, et al. **J Mol Biol** 1996 Apr 12;257(4):804–13

Genetic mapping of the bovine cytochrome c oxidase subunit IV pseudogene. Dolf G, et al. **Mamm Genome** 1996 Sep; 7(9):711–2

Characterization of the mouse Tdgf1 gene and Tdgf pseudogenes. Liguori G, et al. **Mamm Genome** 1996 May; 7(5):344–8

Characterization and mapping of a highly conserved processed pseudogene and an intron-carrying gene of the heat shock cognate protein 70 (Hsc70) gene family in the rat. Rothermel E, et al. **Mamm Genome** 1995 Sep;6(9):602–6

Identification of an S19 pseudogene lying close to the Xist sequence in the mouse. Rougeulle C, et al. **Mamm Genome** 1996 Aug;7(8):606–7

A nascent micronuclear pseudogene in the ciliate Euplotes crassus. Florian V, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3195–200

Improved cloning of antibody variable regions from hybridomas by an antisense-directed RNase H digestion of the P3-X63-Ag8.653 derived pseudogene mRNA. Ostermeier C, et al. **Nucleic Acids Res** 1996 May 15; 24(10):1979–80

PCR analysis of the H ferritin multigene family reveals the existence of two classes of processed pseudogenes. Quaresima B, et al. **PCR Methods Appl** 1994 Oct;4(2):85–8

Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Tusié-Luna MT, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10796–800

Human beta-actin retropseudogenes interfere with RT-PCR. Dirnhofer S, et al. **Trends Genet** 1995 Oct;11(10):380–1

GENETICS

Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease [letter] Tayebi N, et al. **Am J Hum Genet** 1996 Sep;59(3):740–1

Identification of CYP2B14P and CYP2B16P, two apparent pseudogenes in the rat cytochrome P450 2B (CYP2B) subfamily. Trottier E, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):963–5

Molecular anatomy of human chromosome 9: comparative mapping of the immunoglobulin processed pseudogene C epsilon 3 (IGHEP2) in primates. Tanabe H, et al. **Cytogenet Cell Genet** 1996;73(1-2):92–6

A phospholipase A2-like pseudogene retaining the highly conserved introns of Mojave toxin and other snake venom group II PLA2s, but having different exons. John TR, et al. **DNA Cell Biol** 1996 Aug;15(8):661–8

Characterisation of a second, apparently inactive, copy of the bovine beta-lactoglobulin gene. Passey RJ, et al. **Eur J Biochem** 1995 Nov 1;233(3):736–43

Identification of a human RAD52 pseudogene located on chromosome 2. Johnson BL, et al. **Gene** 1996 Mar 9; 169(2):229–32

A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Montagna M, et al. **Hum Genet** 1995 Nov;96(5):532–8

Characterization of a partial pseudogene homologous to the adrenoleukodystrophy gene and application to mutation detection. Braun A, et al. **Hum Mutat** 1996;7(2):105–8

Mouse HLA-DPA homologue H2-Pa: a pseudogene that maps between H2-Pb and H2-Oa. Arimura Y, et al. **Immunogenetics** 1996;43(3):152–5

A sequence analysis of von Willebrand factor mRNA, gene, and pseudogene in two patients with von Willebrand disease type 2B, and an investigation of gene conversion in its gene. Kanaji T, et al. **Int J Hematol** 1996 Jul; 64(1):53–9

Comparison of a mitochondrial gene and a corresponding nuclear pseudogene. Arctander P. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):13–9

IMMUNOLOGY

A DNA binding protein in human thymocytes recognizes the T cell receptor-delta-deleting element psi J alpha. Verschuren MC, et al. **J Immunol** 1996 May 15; 156(10):3806–14

PHYSIOLOGY

Constitutive human steroid 21-hydroxylase promoter gene and pseudogene activity in steroidogenic and nonsteroidogenic cells with the luciferase gene as a reporter. Kyllo JH, et al. **Endocr Res** 1995 Nov; 21(4):777–91

PSEUDOGLOBULINS see SERUM GLOBULINS

PSEUDOGOUT see CHONDROCALCINOSIS

PSEUDOHERMAPHRODITISM

Persistent müllerian duct syndrome. Köksal S, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):276–7

Persistent müllerian duct syndrome and transverse testicular ectopia [letter; comment] Abu Zidan FM, et al. **Eur J Surg** 1995 Aug;161(8):615. Comment on: Eur J Surg 1994 Feb;160(2):125–6. Comment on: Eur J Surg 1994 Apr;160(4):249–50.

[17 beta-hydroxysteroid dehydrogenase defect: female phenotype with 46,XY karyotype] Sólyom J, et al. **Orv Hetil** 1996 Apr 14;137(15):807–10 (Eng. Abstr.) **(Hun)**

CLASSIFICATION

Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Sinnecker GH, et al. **Am J Med Genet** 1996 May 3;63(1):223–30

COMPLICATIONS

Denys-Drash syndrome. Suri M, et al. **Indian Pediatr** 1995 Dec;32(12):1310–3

Persistent müllerian duct syndrome: report of a case with bilateral cryptorchidism. Sarica K, et al. **Int Urol Nephrol** 1995;27(4):431–8

Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Ravichandran R, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1776–9

[Seminoma in a male pseudohermaphrodite. Apropos of a case] Mansouri A, et al. **Ann Urol (Paris)** 1995;29(5):306–7 **(Fre)**

DIAGNOSIS

Macronodular congenital adrenal hyperplasia in an adult with female pseudohermaphroditism. Norris AM, et al. **Eur Radiol** 1996;6(4):470–2

Male pseudohermaphroditism with 5-alpha-reductase deficiency: report of two new familial cases. The importance of early diagnosis. Aguilar-Diosdado M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar;8(1):67–71

[Male pseudohermaphroditism due to 17-alpha-hydroxylase deficiency] Bartolucci L, et al. **Minerva Endocrinol** 1995 Dec;20(4):237–41 (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Mendonca BB, et al. **Medicine (Baltimore)** 1996 Mar;75(2):64–76

5-Alpha-reductase deficiency in a Saudi "girl" [letter] Punnose J, et al. **Postgrad Med J** 1995 Nov;71(841):701

[Male pseudohermaphroditism due to 17-alpha-hydroxylase deficiency] Bartolucci L, et al. **Minerva Endocrinol** 1995 Dec;20(4):237–41 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Case report: 17 alpha-hydroxylase/17,20-lyase deficiency: a rare cause of endocrine hypertension. Hermans C, et al. **Am J Med Sci** 1996 Sep;312(3):126–9

GENETICS

A newly identified exonic mutation of the WT1 gene in a patient with Denys-Drash syndrome. Tsuda M, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):265–6

Schizophrenia and the androgen receptor gene: report of a sibship showing co-segregation with Reifenstein syndrome but no evidence for linkage in 23 multiply affected families. Arranz M, et al. **Am J Med Genet** 1995 Oct 9;60(5):377–81

Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Sinnecker GH, et al. **Am J Med Genet** 1996 May 3;63(1):223–30

Steroid 5 alpha-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Forti G, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):477–82

A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Laue L, et al. **Hum Mol Genet** 1995 Aug;4(8):1429–33

A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females. Rösler A, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1827–31

Male pseudohermaphroditism with 5-alpha-reductase deficiency: report of two new familial cases. The importance of early diagnosis. Aguilar-Diosdado M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar;8(1):67–71

Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. Latronico AC, et al. **N Engl J Med** 1996 Feb 22;334(8):507–12

Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Imbeaud S, et al. **Nat Genet** 1995 Dec;11(4):382–8

Monosomy 7 syndrome associated with congenital adrenal hypoplasia and male pseudohermaphroditism. Le SQ, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):854–6

[Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism] Sultan C, et al. **C R Seances Soc Biol Fil** 1995;189(5):713–40 (83 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly. On the familiar occurrence of intersexuality and adrenal gland hyperplasia. 1941. (classical article)] Werthemann A. **Schweiz Med Wochenschr** 1995 Sep 9; 125(36):1697–701 **(Ger)**

METABOLISM

A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Laue L, et al. **Hum Mol Genet** 1995 Aug;4(8):1429–33

[Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism] Sultan C, et al. **C R Seances Soc Biol Fil** 1995;189(5):713–40 (83 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Corpus albicans-like structures in the gonads in androgen insensitivity syndrome. Siegler RW, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):177–80

Hypoplastic left heart syndrome with male pseudohermaphroditism and bicornuate uterus bicollis. Calaluce RD, et al. **Pediatr Cardiol** 1995 Sep-Oct; 16(5):239–41

PHYSIOPATHOLOGY

[Effect of prepuberal gonadectomy in partial androgen resistance syndrome] Garcia Morales MA, et al.

Ginecol Obstet Mex 1996 Mar;64:120–1 (Eng. Abstr.) (Spa)

SURGERY

Transsphincterican orectal reconstruction of ambiguous genitalia: an innovative approach to neovaginoplasty, pioneer in Brazil. Braz A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1022–32 (25 ref.)

PSEUDOHYPOALDOSTERONISM

COMPLICATIONS

Disordered meibomian gland function in pseudohypoaldosteronism [letter] Ainsworth JR, et al. **Arch Ophthalmol** 1996 Aug;114(8):1018–9

DIAGNOSIS

Pseudohypoaldosteronism: report of a case presenting as failure to thrive. Buzi F, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):61–5

ETIOLOGY

Bartter's syndrome associated with severe retinopathy and presenting as pseudohypoaldosteronism in a newborn. Eckhardt S, et al. **J R Soc Med** 1995 Dec;88(12):712p–3p

GENETICS

Pseudohypoaldosteronism in a family with variable presentation. Bala K. **Indian Pediatr** 1995 Jul;32(7):810–1

Exclusion of the locus for autosomal recessive pseudohypoaldosteronism type 1 from the mineralocorticoid receptor gene region on human chromosome 4q by linkage analysis. Chung E, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3341–5

Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Chang SS, et al. **Nat Genet** 1996 Mar;12(3):248–53

A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Strautnieks SS, et al. **Nat Genet** 1996 Jun;13(2):248–50

PSEUDOHYPOPARATHYROIDISM

COMPLICATIONS

Radiological case of the month. Ectopic ossification and calcification in pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Zung A, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):643–4

Therapy-resistant seizures in pseudohypoparathyroidism. A case report. Pollak L, et al. **J Pediatr Endocrinol Metab** 1995 Jul–Sep;8(3):209–11

GENETICS

Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. Shapira H, et al. **Hum Genet** 1996 Jan;97(1):73–5

Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. Fukumoto S, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2554–8

HISTORY

Albright's hereditary osteodystrophy. Kruse K. **Eur J Pediatr** 1996 May;155(5):349–50

METABOLISM

Real-time monitoring of reduced beta-adrenergic response in fibroblasts from patients with pseudohypoparathyroidism. Ong OC, et al. **Anal Biochem** 1996 Jun 15;238(1):76–81

PHYSIOPATHOLOGY

Pseudohypoparathyroidism, a novel mutation in the betagamma-contact region of Gsalpha impairs receptor stimulation. Farfel Z, et al. **J Biol Chem** 1996 Aug 16; 271(33):19653–5

Pseudohypoparathyroidism type Ia and growth hormone deficiency in two siblings. Scott DC, et al. **J Pediatr Endocrinol Metab** 1995 Jul–Sep;8(3):205–7

[Pseudohypoparathyroidism] Robertson LM, et al. **Medicina (B Aires)** 1995;55(2):140–4 (Eng. Abstr.) (Spa)

PSEUDOMONADACEAE

ENZYMOLOGY

Measurements of oxidoreductase-like activity of intact bacterial cells by an amperometric method using a membrane-coated electrode. Ikeda T, et al. **Anal Chem** 1996 Jan 1;68(1):192–8

PSEUDOMONAS

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

Characterization of lipopolysaccharides from Pseudomonas syringae (serogroup II). Iakovleva LM, et al. **Mikrobiol Z** 1995 Sep–Oct;57(5):26–9

Sump bay fever: inhalational fever associated with a biologically contaminated water aerosol. Anderson K, et al. **Occup Environ Med** 1996 Feb;53(2):106–11

CHEMISTRY

Characterization of a lipopolysaccharide O antigen containing two different trisaccharide repeating units from Burkholderia cepacia serotype E (O2). Beynon LM, et al. **Carbohydr Res** 1995 Aug 11;272(2):231–9

The structure of the acidic exopolysaccharide produced by Pseudomonas "gingeri" strain Pf9. Cescutti P, et al. **Carbohydr Res** 1995 Oct 2;275(2):371–9

Solution conformation of the Pseudomonas syringae pv. syringae phytotoxic lipodepsipeptide syringopeptin 25-A. Two-dimensional NMR, distance geometry and molecular dynamics. Ballio A, et al. **Eur J Biochem** 1995 Dec 15; 234(3):747–58

Structure and activity of persicomycins, toxins produced by a Pseudomonas syringae pv. persicae/Prunus persica isolate. Barzic MR, et al. **Eur J Biochem** 1996 Aug 1; 239(3):702–9

Protective effect of cell-permeable ceramide analogs against modeccin, ricin, Pseudomonas toxin, and diphtheria toxin. Oda T, et al. **Exp Cell Res** 1995 Nov;221(1):1–10

Alkylresorcinols are abundant lipid components in different strains of Azotobacter chroococcum and Pseudomonas spp. Kozubek A, et al. **J Bacteriol** 1996 Jul;178(14):4027–30

Chemistry and antimicrobial activity of caryoynencins analogs. Yamaguchi M, et al. **J Med Chem** 1995 Dec 22; 38(26):5015–22

[The characteristics of the lipid A of the lipopolysaccharides in Pseudomonas syringae strains] Zdorovenko GM, et al. **Mikrobiol Z** 1995 Sep–Oct;57(5):30–9 (Eng. Abstr.) (Rus)

CLASSIFICATION

Distribution of Pseudomonas syringae pathovars into twenty-three O serogroups. Saunier M, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2360–74

16S rRNA gene sequence analysis relative to genomovars of Pseudomonas stutzeri and proposal of Pseudomonas balearica sp. nov. Bennasar A, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):200–5

Isolation and identification of poly(3-hydroxyvalerate)-degrading strains of Pseudomonas lemoignei. Mergaert J, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):769–73

Transfer of "Pseudomonas riboflavina" (Foster 1944), a gram-negative, motile rod with long-chain 3-hydroxy fatty acids, to Devosia riboflavina gen. nov., sp. nov., nom. rev. Nakagawa Y, et al. **Int J Syst Bacteriol** 1996 Jan; 46(1):16–22

Analysis of the phylogenetic relationships of strains of Burkholderia solanacearum, Pseudomonas syzygii, and the blood disease bacterium of banana based on 16S rRNA gene sequences. Taghavi M, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):10–5

Phylogenetic evidence for the transfer of Pseudomonas cocovenenans (van Damme et al. 1960) to the genus Burkholderia as Burkholderia cocovenenans (van Damme et al. 1960) comb. nov. Zhao N, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):600–3

Epidemiological typing of Flavimonas oryzihabitans by PCR and pulsed-field gel electrophoresis. Liu PY, et al. **J Clin Microbiol** 1996 Jan;34(1):68–70

DRUG EFFECTS

Metal sensitivity of some symbiotic N2-fixing bacteria and Pseudomonas strains. Biró B, et al. **Acta Biol Hung** 1995; 46(1):9–16

Chromosome-encoded inducible copper resistance in Pseudomonas strains. Vargas E, et al. **Antonie Van Leeuwenhoek** 1995 Oct;68(3):225–9

Induction of toluene oxidation activity in Pseudomonas mendocina KR1 and Pseudomonas sp. strain ENVPC5 by chlorinated solvents and alkanes. McClay K, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3479–81

Toxicity of phenol and monochlorophenols to growth and metabolic activities of Pseudomonas. Huang DS, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):69–76

Antibacterial polyphenols from olive oil mill waste waters. Capasso R, et al. **J Appl Bacteriol** 1995 Oct;79(4):393–8

[Must pefloxacin and norfloxacin be studied separately against bacteria isolated from urinary tract infections by the API-ATB method?] Soussy CJ, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):294–9 (Eng. Abstr.) (Fre)

[Resistance of Pseudomonas mallei to tetracyclines: assessment of the feasibility of chemotherapy] Manzeniuk IN, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):40–4 (Eng. Abstr.) (Rus)

ENZYMOLOGY

Pepstatin-insensitive carboxyl proteinases. Oda K, et al. **Adv Exp Med Biol** 1995;362:529–42

Preparative synthesis of beta-L-malyl-coenzyme A assisted by malyl-coenzyme A synthetase from Pseudomonas AM1. Willibald B, et al. **Anal Biochem** 1995 May 20;227(2):363–7

Protein engineering of a cephalosporin C acylase from Pseudomonas strain N176. Saito Y, et al. **Ann N Y Acad Sci** 1996 May 15;782:226–40

Nucleotide sequence analysis of genes encoding a toluene/benzene-2-monooxygenase from Pseudomonas sp. strain JS150. Johnson GR, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3336–46

Catechol 2,3-dioxygenases functional in oxygen-limited (hypoxic) environments. Kukor JJ, et al. **Appl Environ Microbiol** 1996 May;62(5):1728–40

Toluene and ethylbenzene oxidation by purified naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816-4. Lee K, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3101–6

Oxidative modification of a cephalosporin C acylase from Pseudomonas strain N176 and site-directed mutagenesis of the gene. Saito Y, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2919–25

Characterization of active recombinant 2,3-dihydro-2,3-dihydroxybiphenyl dehydrogenase from Comamonas testosteroni B-356 and sequence of the encoding gene (bphB). Sylvestre M, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2710–5

Evidence of histidine coordination to the catalytic ferrous ion in the ring-cleaving 2,2',3-trihydroxybiphenyl dioxygenase from the dibenzofuran-degrading bacterium Sphingomonas sp. strain RW1. Bertini I, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):855–60

Dietary estrogenic isoflavones are potent inhibitors of beta-hydroxysteroid dehydrogenase of P. testosteronii. Keung WM. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):1137–44

Enhancement of thermostability and catalytic efficiency of AprP, an alkaline protease from Pseudomonas sp., by the introduction of a disulfide bond. Ko JH, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):631–5

Physical structure and expression of alkBA encoding alkane hydroxylase and rubredoxin reductase from Pseudomonas maltophilia. Lee NR, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):17–21

An active site phenylalanine of 3-oxo-delta 5-steroid isomerase is catalytically important for proton transfer. Brothers PN, et al. **Biochemistry** 1995 Nov 28; 34(47):15453–8

Insights into the catalytic mechanism and active-site environment of Comamonas testosteroni delta 5-3-ketosteroid isomerase as revealed by site-directed mutagenesis of the catalytic base aspartate-38. Holman CM, et al. **Biochemistry** 1995 Oct 31;34(43):14245–53

Metal-substrate interactions facilitate the catalytic activity of the bacterial phosphotriesterase. Hong SB, et al. **Biochemistry** 1996 Aug 20;35(33):10904–12

Recombinant toluene-4-monooxygenase: catalytic and Mössbauer studies of the purified diiron and rieske components of a four-protein complex. Pikus JD, et al. **Biochemistry** 1996 Jul 16;35(28):9106–19

Evidence for electrophilic catalysis in the 4-chlorobenzoyl-CoA dehalogenase reaction: UV, Raman, and 13C-NMR spectral studies of dehalogenase complexes of benzoyl-CoA adducts. Taylor KL, et al. **Biochemistry** 1995 Oct 24;34(42):13881–8

Purification and characterization of a prokaryotic xanthine dehydrogenase from Comamonas acidovorans. Xiang Q, et al. **Biochemistry** 1996 Apr 30;35(17):5441–50

Multiple nosZ promoters and anaerobic expression of nos genes necessary for Pseudomonas stutzeri nitrous oxide reductase and assembly of its copper centers. Cuypers H, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):183–90

Preparative-scale kinetic resolutions catalysed by microbial lipases immobilised in AOT-stabilised microemulsion-based organogels: cryoenzymology as a tool for improving enantioselectivity. Rees GD, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):73–81

Biochemical properties of cloned lipases from the Pseudomonas family. Svendsen A, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):9–17

Mediated amperometric determination of ammonia with a methanol dehydrogenase from Pseudomonas sp. AM-1 immobilized carbon paste electrode. Suye S, et al. **Biosens Bioelectron** 1996;11(5):529–34

Enzymes from Pseudomonas sp. strain NCIB 11097 participating in biotransformation of acetaldehyde and glycine to threonine isomers. Diaz-Diaz M, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):438–43

Mutation of the conserved Cys165 outside of the CuA domain destabilizes nitrous oxide reductase but maintains its catalytic activity. Evidence for disulfide bridges and a putative protein disulfide isomerase gene. Dreusch A, et al. **Eur J Biochem** 1996 Apr 15;237(2):447–53

Resolution of the nirD locus for heme d1 synthesis of cytochrome cd1 (respiratory nitrite reductase) from Pseudomonas stutzeri. Palmedo G, et al. **Eur J Biochem** 1995 Sep 15;232(3):737–46

A high-potential soluble cytochrome c-551 from the purple phototrophic bacterium Chromatium vinosum is homologous to cytochrome c8 from denitrifying pseudomonads. Samyn B, et al. **Eur J Biochem** 1996 Mar 1;236(2):689–96

Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline

5,6-dioxygenase from Comamonas testosteroni 63. The first two enzymes in quinoline and 3-methylquinoline degradation. Schach S, et al. **Eur J Biochem** 1995 Sep 1; 232(2):536-44

4-Hydroxybenzoate hydroxylase from Pseudomonas sp. CBS3. Purification, characterization, gene cloning, sequence analysis and assignment of structural features determining the coenzyme specificity. Seibold B, et al. **Eur J Biochem** 1996 Jul 15;239(2):469-78

Site-directed mutagenesis of the formate dehydrogenase active centre: role of the His332-Gln313 pair in enzyme catalysis. Tishkov VI, et al. **FEBS Lett** 1996 Jul 15; 390(1):104-8

High-molecular-mass, iron-repressed cytoplasmic proteins in fluorescent Pseudomonas: potential peptide-synthetases for pyoverdine biosynthesis. Georges C, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):9-15

Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors [letter] Pradhananga SL, et al. **J Antimicrob Chemother** 1996 Feb;37(2):394-6

Atrazine chlorohydrolase from Pseudomonas sp. strain ADP: gene sequence, enzyme purification, and protein characterization. de Souza ML, et al. **J Bacteriol** 1996 Aug; 178(16):4894-900

Comamonas testosteroni 3-ketosteroid-delta 4(5 alpha)-dehydrogenase: gene and protein characterization. Florin C, et al. **J Bacteriol** 1996 Jun;178(11):3322-30

Purification and characterization of the oxygenase component of biphenyl 2,3-dioxygenase from Pseudomonas sp. strain LB400. Haddock JD, et al. **J Bacteriol** 1995 Oct; 177(20):5834-9

Mutational analysis of the active site of Pseudomonas fluorescens pyrrolidone carboxyl peptidase. Le Saux O, et al. **J Bacteriol** 1996 Jun;178(11):3308-13

Stereospecific dihydroxylation of the styrene vinyl group by purified naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816-4. Lee K, et al. **J Bacteriol** 1996 Jun; 178(11):3353-6

A novel dipeptidyl aminopeptidase from Pseudomonas sp. strain WO24. Ogasawara W, et al. **J Bacteriol** 1996 Mar; 178(5):1283-8

The primary structure of pepstatin-insensitive carboxyl proteinase produced by Pseudomonas sp. No. 101. Hayashi K, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):738-44

A novel phenylserine dehydratase from Pseudomonas pickettii PS22: purification, characterization, and sequence of its phosphopyridoxyl peptide. Okuda H, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):690-6

Crystal structure of L-2-haloacid dehalogenase from Pseudomonas sp. YL. An alpha/beta hydrolase structure that is different from the alpha/beta hydrolase fold. Hisano T, et al. **J Biol Chem** 1996 Aug 23;271(34):20322-30

A novel enzyme that cleaves the N-acyl linkage of ceramides in various glycosphingolipids as well as sphingomyelin to produce their lyso forms. Ito M, et al. **J Biol Chem** 1995 Oct 13;270(41):24370-4

The broad substrate chlorobenzene dioxygenase and cis-chlorobenzene dihydrodiol dehydrogenase of Pseudomonas sp. strain P51 are linked evolutionarily to the enzymes for benzene and toluene degradation. Werlen C, et al. **J Biol Chem** 1996 Feb 23;271(8):4009-16

Three-dimensional structures of free form and two substrate complexes of an extradiol ring-cleavage type dioxygenase, the BphC enzyme from Pseudomonas sp. strain KKS102. Senda T, et al. **J Mol Biol** 1996 Feb 9;255(5):735-52

Cloning, sequencing and expression of Pseudomonas testosteroni gene encoding 3 alpha-hydroxysteroid dehydrogenase. Abalain JH, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):233-8

Crystallization and preliminary crystallographic analysis of a 2,3-dihydroxybiphenyl dioxygenase from Pseudomonas sp. strain KKS102 having polychlorinated biphenyl (PCB)-degrading activity. Sugiyama K, et al. **Proteins** 1995 Jul;22(3):284-6

Crystal structure of the biphenyl-cleaving extradiol dioxygenase from a PCB-degrading pseudomonad. Han S, et al. **Science** 1995 Nov 10;270(5238):976-80

[Cloning of genes coding for 3-alpha-hydroxysteroid dehydrogenase and for (3-17)-beta-hydroxysteroid dehydrogenase from Pseudomonas testosteroni] Floch HH, et al. **C R Seances Soc Biol Fil** 1995;189(5):705-12 (Eng. Abstr.) **(Fre)**

GENETICS

Development of a gene reporter system in moderately halophilic bacteria by employing the ice nucleation gene of Pseudomonas syringae. Arvanitis N, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3821-5

Cloning, characterization, and expression of a gene region from Pseudomonas sp. strain ADP involved in the dechlorination of atrazine. de Souza ML, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3373-8

Nucleotide sequence analysis of genes encoding a toluene/benzene-2-monooxygenase from Pseudomonas sp. strain JS150. Johnson GR, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3336-46

Conservation of the 2,4-diacetylphloroglucinol biosynthesis locus among fluorescent Pseudomonas strains from diverse geographic locations. Keel C, et al. **Appl Environ Microbiol** 1996 Feb;62(2):552-63

Genetic structures of the genes encoding 2,3-dihydroxybiphenyl 1,2-dioxygenase and 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid hydrolase from biphenyl- and 4-chlorobiphenyl-degrading Pseudomonas sp. strain DJ-12. Kim E, et al. **Appl Environ Microbiol** 1996 Jan;62(1):262-5

Characterization and transcriptional analysis of the gene cluster for coronafacic acid, the polyketide component of the phytotoxin coronatine. Liyanage H, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3843-8

Increased mutagenesis mediated by cloned plasmid CAM-OCT genes: potential for expanding substrate ranges of Pseudomonas spp. McBeth DL, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3538-40

Genetic diversity of Burkholderia solanacearum (synonym Pseudomonas solanacearum) race 3 in Kenya. Smith JJ, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4263-8

Expression of the strA-strB streptomycin resistance genes in Pseudomonas syringae and Xanthomonas campestris and characterization of IS6100 in X. campestris. Sundin GW, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2891-7

Cloning and characterization of the genes for p-nitrobenzoate degradation from Pseudomonas pickettii YH105. Yabannavar AV, et al. **Appl Environ Microbiol** 1995 Dec; 61(12):4284-90

Structure of the pcbC gene encoding 2,3-dihydroxybiphenyl dioxygenase of Pseudomonas sp. P20. Kim CK, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):15-20

Physical structure and expression of alkBA encoding alkane hydroxylase and rubredoxin reductase from Pseudomonas maltophilia. Lee NR, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):17-21

Multiple nosZ promoters and anaerobic expression of nos genes necessary for Pseudomonas stutzeri nitrous oxide reductase and assembly of its copper centers. Cuypers H, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):183-90

The repB gene required for production of extracellular enzymes and fluorescent siderophores in Pseudomonas viridiflava is an analog of the gacA gene of Pseudomonas syringae. Liao CH, et al. **Can J Microbiol** 1996 Feb; 42(2):177-82

Biochemistry and genetics of PCB metabolism. Furukawa K, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:21-3

Mutation of the conserved Cys165 outside of the CuA domain destabilizes nitrous oxide reductase but maintains its catalytic activity. Evidence for disulfide bridges and a putative protein disulfide isomerase gene. Dreusch A, et al. **Eur J Biochem** 1996 Apr 15;237(2):447-53

Resolution of the nirD locus for heme d1 synthesis of cytochrome cd1 (respiratory nitrite reductase) from Pseudomonas stutzeri. Palmedo G, et al. **Eur J Biochem** 1995 Sep 15;232(3):737-46

4-Hydroxybenzoate hydroxylase from Pseudomonas sp. CBS3. Purification, characterization, gene cloning, sequence analysis and assignment of structural features determining the coenzyme specificity. Seibold B, et al. **Eur J Biochem** 1996 Jul 15;239(2):469-78

Molecular analysis of genes encoding phenazine biosynthesis in the biological control bacterium. Pseudomonas aureofaciens 30-84. Pierson LS 3rd, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):299-307

Characterisation of carbon dioxide-inducible genes of the marine bacterium, Pseudomonas sp. S91. Stretton S, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):37-42

An open reading frame in the approximately 28-kb tox-argk gene cluster encodes a polypeptide with homology to fatty acid desaturases. Hatziloukas E, et al. **Gene** 1995 Dec 1; 166(1):83-7

Sequence of a gene encoding periplasmic Pseudomonas syringae ankyrin. Klotz MG, et al. **Gene** 1995 Oct 16; 164(1):187-8

Cloning and sequencing of the membrane-bound hydrogenase-encoding genes (hupS and hupL) from Pseudomonas hydrogenovora. Ohtsuki T, et al. **Gene** 1995 Dec 1;166(1):89-93

Cloning and comparison of mercury- and organomercurial-resistance determinants from a Pseudomonas stutzeri plasmid. Reniero D, et al. **Gene** 1995 Dec 1;166(1):77-82

Atrazine chlorohydrolase from Pseudomonas sp. strain ADP: gene sequence, enzyme purification, and protein characterization. de Souza ML, et al. **J Bacteriol** 1996 Aug; 178(16):4894-900

Suppression of a sensor kinase-dependent phenotype in Pseudomonas syringae by ribosomal proteins L35 and L20. Kitten T, et al. **J Bacteriol** 1996 Mar;178(6):1548-55

Characterization of genes required for pilus expression in Pseudomonas syringae pathovar phaseolicola. Roine E, et al. **J Bacteriol** 1996 Jan;178(2):410-7

Engineering hybrid pseudomonads capable of utilizing a wide range of aromatic hydrocarbons and of efficient degradation of trichloroethylene. Suyama A, et al. **J Bacteriol** 1996 Jul;178(14):4039-46

Growth phase-dependent transcription of the sigma(54)-dependent Po promoter controlling the Pseudomonas-derived (methyl)phenol dmp operon of pVI150. Sze CC, et al. **J Bacteriol** 1996 Jul;178(13):3727-35

A modified two-component regulatory system is involved in temperature-dependent biosynthesis of the Pseudomonas syringae phytotoxin coronatine. Ullrich M, et al. **J Bacteriol** 1995 Nov;177(21):6160-9

The broad substrate chlorobenzene dioxygenase and cis-chlorobenzene dihydrodiol dehydrogenase of Pseudomonas sp. strain P51 are linked evolutionarily to the enzymes for benzene and toluene degradation. Werlen C, et al. **J Biol Chem** 1996 Feb 23;271(8):4009-16

Epidemiological typing of Flavimonas oryzihabitans by PCR and pulsed-field gel electrophoresis. Liu PY, et al. **J Clin Microbiol** 1996 Jan;34(1):68-70

Cloning, sequencing and expression of Pseudomonas testosteroni gene encoding 3 alpha-hydroxysteroid dehydrogenase. Abalain JH, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):233-8

Electrotransformation of Pseudomonas. Dennis JJ, et al. **Methods Mol Biol** 1995;47:125-33

High frequency of conjugation versus plasmid segregation of RP1 in epiphytic Pseudomonas syringae populations. Björklöf K, et al. **Microbiology** 1995 Oct;141 (Pt 10):2719-27

The 4-hydroxy-2-oxovalerate aldolase and acetaldehyde dehydrogenase (acylating) encoded by the nahM and nahO genes of the naphthalene catabolic plasmid pWW60-22 provide further evidence of conservation of meta-cleavage pathway gene sequences. Platt A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2223-33

Gene transfer from a bacterium injected into an aquifer to an indigenous bacterium. Zhou JZ, et al. **Mol Ecol** 1995 Oct;4(5):613-8

Regulatory noise in prokaryotic promoters: how bacteria learn to respond to novel environmental signals. de Lorenzo V, et al. **Mol Microbiol** 1996 Mar;19(6):1177-84 (37 ref.)

Molecular characterization of the eps gene cluster of Pseudomonas solanacearum and its transcriptional regulation at a single promoter. Huang J, et al. **Mol Microbiol** 1995 Jun;16(5):977-89

Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor. Venturi V, et al. **Mol Microbiol** 1995 Aug;17(4):603-10 (40 ref.)

Molecular characterization of the Pseudomonas syringae pv. pisi plasmid-borne avirulence gene avrPpiB which matches the R3 resistance locus in pea. Cournoyer B, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):700-8

Cloning and characterization of tek, the gene encoding the major extracellular protein of Pseudomonas solanacearum. Denny TP, et al. **Mol Plant Microbe Interact** 1996 May; 9(4):272-81

Identification of a new Arabidopsis disease resistance locus, RPs4, and cloning of the corresponding avirulence gene, avrRps4, from Pseudomonas syringae pv. pisi. Hinsch M, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):55-61

The complete hrp gene cluster of Pseudomonas syringae pv. syringae 61 includes two blocks of genes required for harpinPss secretion that are arranged colinearly with Yersinia ysc homologs. Huang HC, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):733-46

Complementation analyses of Pseudomonas solanacearum extracellular polysaccharide mutants and identification of genes responsive to EpsR. McWilliams R, et al. **Mol Plant Microbe Interact** 1995 Nov-Dec;8(6):837-44

Phenotypic expression of Pseudomonas syringae avr genes in E. coli is linked to the activities of the hrp-encoded secretion system. Pirhonen MU, et al. **Mol Plant Microbe Interact** 1996 May;9(4):252-60

The HrpZ proteins of Pseudomonas syringae pvs. syringae, glycinea, and tomato are encoded by an operon containing Yersinia ysc homologs and elicit the hypersensitive response in tomato but not soybean. Preston G, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):717-32

A disease resistance gene in Arabidopsis with specificity for the avrPph3 gene of Pseudomonas syringae pv. phaseolicola. Simonich MT, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):637-40

Expression of the Pseudomonas syringae avirulence protein AvrB in plant cells alleviates its dependence on the hypersensitive response and pathogenicity (Hrp) secretion system in eliciting genotype-specific hypersensitive cell death [see comments] Gopalan S, et al. **Plant Cell** 1996 Jul;8(7):1095-105. Comment in: Plant Cell 1996 Jul;8(7):1091-3.

Molecular analysis of closely related copper- and streptomycin-resistance plasmids in Pseudomonas syringae pv. syringae. Sundin GW, et al. **Plasmid** 1996 Mar; 35(2):98-107

[Study on Pseudomonas transposons and molecular genetic analysis of Pseudomonas by use of transposons] Tsuda M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):947-59 (58 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Evidence for two domains of growth temperature for the psychrotrophic bacterium Pseudomonas fluorescens MF0. Guillou C, et al. **Appl Environ Microbiol** 1996 Sep; 62(9):3319-24

Competition between Salmonella and Pseudomonas species growing in and on agar, as affected by pH, sodium chloride concentration and temperature. Thomas LV, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):361-70

The assimilation of sulfur from multiple sources and its correlation with expression of the sulfate-starvation-induced stimulon in Pseudomonas putida S-313. Beil S, et al. **Microbiology** 1996 Aug;142 (Pt 8):1989-95

IMMUNOLOGY

Structure of the O6 antigen of Stenotrophomonas (Xanthomonas or Pseudomonas) maltophilia. Winn AM, et al. **Carbohydr Res** 1995 Aug 11;272(2):225–30

Structure of the O3 antigen of Stenotrophomonas (Xanthomonas or Pseudomonas) maltophilia. Winn AM, et al. **Carbohydr Res** 1996 Feb 28;282(1):149–56

[Results of phase III clinical trial of Pseudomonas jinanensis vaccine injection (PVI) in the treatment of malignant pleural effusion] Wang J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):458–60 (Eng. Abstr.) **(Chi)**

[Monoclonal antibodies in the differentiation of Pseudomonas mallei and Pseudomonas pseudomallei] Iakovleva IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):14–5 **(Rus)**

ISOLATION & PURIFICATION

Use of a pentachlorophenol degrading bacterium to bioremediate highly contaminated soil. Colores GM, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):271–5

A simple method for quantifying activity and survival of microorganisms involved in bioremediation processes. Schmidt SK, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep; 54(1–3):259–70

Comparison of chemical dehydration and critical point drying for the stabilization and visualization of aging biofilm present on interior surfaces of PVC distribution pipe. Carr JH, et al. **J Appl Bacteriol** 1996 Feb;80(2):225–32

Tracheal colonization with Sphingomonas paucimobilis in mechanically ventilated neonates due to contaminated ventilator temperature probes. Lemaitre D, et al. **J Hosp Infect** 1996 Mar;32(3):199–206

Pseudomonas spp. associated vegetative endocarditis in two horses. Travers CW, et al. **J S Afr Vet Assoc** 1995 Sep; 66(3):172–6

Burkholderia pseudomallei and Indian plague–like illness [letter; comment] [see comments] Dance DA, et al. **Lancet** 1995 Sep 30;346(8979):904–5. Comment on: Lancet 1994 Dec 3;344(8936):1574. Comment in: Lancet 1995 Oct 7;346(8980):975.

Extraction and purification of microbial DNA from petroleum–contaminated soils and detection of low numbers of toluene, octane and pesticide degraders by multiplex polymerase chain reaction and Southern analysis. Knaebel DB, et al. **Mol Ecol** 1995 Oct;4(5):579–91

Evaluation of recovery filters for use in bacterial retention testing of sterilizing–grade filters. Carter J. **PDA J Pharm Sci Technol** 1996 May–Jun;50(3):147–53

[Isolation and identification of a pathogen of grasshoppers] Liu S, et al. **Wei Sheng Wu Hsueh Pao** 1995 Apr;35(2):86–90 (Eng. Abstr.) **(Chi)**

[The outlook for improving the immunoglobulin preparations for the detection and identification of the causative agents of glanders and melioidosis] Khrapova NP, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):49–53 (Eng. Abstr.) **(Rus)**

METABOLISM

Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. García P, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1569–73

Cloning, characterization, and expression of a gene region from Pseudomonas sp. strain ADP involved in the dechlorination of atrazine. de Souza ML, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3373–8

Identification of exopolysaccharides produced by fluorescent pseudomonads associated with commercial mushroom (Agaricus bisporus) production. Fett WF, et al. **Appl Environ Microbiol** 1995 Feb;61(2):513–7

Actions of a versatile fluorene–degrading bacterial isolate on polycyclic aromatic compounds. Grifoll M, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3711–23

Quantifying the biodegradation of phenanthrene by Pseudomonas stutzeri P16 in the presence of a nonionic surfactant. Grimberg SJ, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2387–92

Conservation of the 2,4–diacetylphloroglucinol biosynthesis locus among fluorescent Pseudomonas strains from diverse geographic locations. Keel C, et al. **Appl Environ Microbiol** 1996 Feb;62(2):552–63

Characterization and transcriptional analysis of the gene cluster for coronafacic acid, the polyketide component of the phytotoxin coronatine. Liyanage H, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3843–8

Chloroform mineralization by toluene–oxidizing bacteria. McClay K, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2716–22

Induction of toluene oxidation activity in Pseudomonas mendocina KR1 and Pseudomonas sp. strain ENVPC5 by chlorinated solvents and alkanes. McClay K, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3479–81

Bacterial degradation of m–nitrobenzoic acid. Nadeau LJ, et al. **Appl Environ Microbiol** 1995 Feb;61(2):840–3

Oxidation of nitric oxide by a new heterotrophic Pseudomonas sp. Koschorreck M, et al. **Arch Microbiol** 1996 Jul;166(1):23–31

Identification of activities that catalyze the cis–trans isomerization of the double bond of a mono–unsaturated fatty acid in Pseudomonas sp. strain E–3. Okuyama H, et al. **Arch Microbiol** 1996 Jun;165(6):415–7

Influence of chlorobenzoates on the utilisation of chlorobiphenyls and chlorobenzoate mixtures by chlorobiphenyl/chlorobenzoate–mineralising hybrid bacterial strains. Stratford J, et al. **Arch Microbiol** 1996 Mar;165(3):213–8

Adaptation of Pseudomonas sp. GJ1 to 2–bromoethanol caused by overexpression of an NAD–dependent aldehyde dehydrogenase with low affinity for halogenated aldehydes. Van der Ploeg JR, et al. **Arch Microbiol** 1996 Apr;165(4):258–64

Novel polypeptides induced by the insecticide lindane (gamma–hexachlorocyclohexane) are required for its biodegradation by a Sphingomonas paucimobilis strain. Adhya TK, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):755–61

Assessment of biodegradability of organic acids by a defined microbial mixture. Sharma A, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):34–40

Viability and respiratory activity of Pseudomonas syringae cells starved in buffer. Cabral JP. **Can J Microbiol** 1995 Apr–May;41(4–5):372–7

Halopicolinic acids, novel products arising through the degradation of chloro– and bromo–biphenyl by Sphingomonas paucimobilis BPSI–3. Davison AD, et al. **Can J Microbiol** 1996 Jan;42(1):66–71

The repB gene required for production of extracellular enzymes and fluorescent siderophores in Pseudomonas viridiflava is an analog of the gacA gene of Pseudomonas syringae. Liao CH, et al. **Can J Microbiol** 1996 Feb; 42(2):177–82

Production and rheological properties of a succinoglycan from Pseudomonas sp. 31260 grown on wood hydrolysates. Meade MJ, et al. **Can J Microbiol** 1995 Dec;41(12):1147–52

Isolation and description of carbazole–degrading bacteria. Shotbolt–Brown J, et al. **Can J Microbiol** 1996 Jan; 42(1):79–82

Microbial degradation of resins fractionated from Arabian light crude oil. Venkateswaran K, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):418–24

The presence of glass beads or Triton X–100 in the medium enhances the aerobic dechlorination of Aroclor 1221 in Pseudomonas sp. CPE1 culture. Fava F. **Chemosphere** 1996 Apr;32(8):1469–75

Aroclor 1221 aerobic dechlorination by a bacterial co–culture: role of chlorobenzoic acid degrading bacteria in the process. Fava F. **Chemosphere** 1996 Apr; 32(8):1477–83

Synthesis of phytohormones by plant–associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

Biochemistry and genetics of PCB metabolism. Furukawa K, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:21–3

Structure of fuscopeptins, phytotoxic metabolites of Pseudomonas fuscovaginae. Ballio A, et al. **FEBS Lett** 1996 Mar 4;381(3):213–6

Direct involvement of hydrogen peroxide in bacterial alpha–hydroxylation of fatty acid. Matsunaga I, et al. **FEBS Lett** 1996 May 20;386(2–3):252–4

Saprophytic Pseudomonas syringae strain M1 of wheat produces cyclic lipodepsipeptides. Adetuyi FC, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):63–7

Cadmium binding by bacteria: screening and characterization of new isolates and mutants. Minz D, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):191–4

Molecular analysis of genes encoding phenazine biosynthesis in the biological control bacterium. Pseudomonas aureofaciens 30–84. Pierson LS 3rd, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):299–307

Degradation of chlorobiphenyls catalyzed by the bph–encoded biphenyl–2,3–dioxygenase and biphenyl–2,3–dihydrodiol–2,3–dehydrogenase of Pseudomonas sp. LB400. Seeger M, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):259–64

Metabolism of 2–chlorobenzoic acid in Pseudomonas stutzeri. Kozlovsky SA, et al. **Folia Microbiol (Praha)** 1995; 40(5):454–6

The phzI gene of Pseudomonas aureofaciens 30–84 is responsible for the production of a diffusible signal required for phenazine antibiotic production. Wood DW, et al. **Gene** 1996 Feb 2;168(1):49–53

Degradation of naphthalene by a Pseudomonas strain NGK1. Manohar S, et al. **Indian J Exp Biol** 1995 May;33(5):353–6

A novel chitinase inhibitor from a marine bacterium, Pseudomonas sp. Izumida H, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):76–80

Growth on octane alters the membrane lipid fatty acids of Pseudomonas oleovorans due to the induction of alkB and synthesis of octanol. Chen Q, et al. **J Bacteriol** 1995 Dec; 177(23):6894–901

Desaturation and oxygenation of 1,2–dihydronaphthalene by toluene and naphthalene dioxygenase. Torok DS, et al. **J Bacteriol** 1995 Oct;177(20):5799–805

Stimulation of phagocytosis and phagosome–lysosome fusion by glycosphingolipids from Sphingomonas paucimobilis. Miyazaki Y, et al. **J Biochem (Tokyo)** 1995 Aug; 118(2):271–7

Complex formation with methylamine dehydrogenase affects the pathway of electron transfer from amicyanin to cytochrome c–551i. Davidson VL, et al. **J Biol Chem** 1995 Oct 13;270(41):23941–3

Acquisition of iron by the non–siderophore–producing Pseudomonas fragi. Champomier–Vergès MC, et al. **Microbiology** 1996 May;142 (Pt 5):1191–9

Ether–bond scission in the biodegradation of alcohol ethoxylate nonionic surfactants by Pseudomonas sp. strain SC25A. Tidswell EC, et al. **Microbiology** 1996 May;142 (Pt 5):1123–31

Molecular characterization of the eps gene cluster of Pseudomonas solanacearum and its transcriptional regulation at a single promoter. Huang J, et al. **Mol Microbiol** 1995 Jun;16(5):977–89

Role of biosurfactant and ion channel–forming activities of syringomycin in transmembrane ion flux: a model for the mechanism of action in the plant–pathogen interaction. Hutchison ML, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug;8(4):610–20

[Studies on bacterial metabolism pathway of 2–naphthoic acid] Sun G, et al. **Wei Sheng Wu Hsueh Pao** 1995 Dec; 35(6):421–6 (Eng. Abstr.) **(Chi)**

PATHOGENICITY

Distribution of Pseudomonas syringae pathovars into twenty–three O serogroups. Saunier M, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2360–74

Cholera toxin elevates pathogen resistance and induces pathogenesis–related gene expression in tobacco. Beffa R, et al. **EMBO J** 1995 Dec 1;14(23):5753–61

Soybean resistance genes specific for different Pseudomonas syringae avirulence genes are allelic, or closely linked, at the RPG1 locus. Ashfield T, et al. **Genetics** 1995 Dec; 141(4):1597–604

Role of biosurfactant and ion channel–forming activities of syringomycin in transmembrane ion flux: a model for the mechanism of action in the plant–pathogen interaction. Hutchison ML, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug;8(4):610–20

Expression of the Pseudomonas syringae avirulence protein AvrB in plant cells alleviates its dependence on the hypersensitive response and pathogenicity (Hrp) secretion system in eliciting genotype–specific hypersensitive cell death [see comments] Gopalan S, et al. **Plant Cell** 1996 Jul;8(7):1095–105. Comment in: Plant Cell 1996 Jul;8(7):1091–3.

Isolation of Arabidopsis genes that differentiate between resistance responses mediated by the RPS2 and RPM1 disease resistance genes. Reuber TL, et al. **Plant Cell** 1996 Feb;8(2):241–9

Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091–3 (22 ref.). Comment on: Plant Cell 1996 Jul;8(7):1095–105.

[Pseudomonas pseudomallei and Pseudomonas mallei—capsule–forming bacteria] Popov SF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):32–6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Comamonas testosteroni colony phenotype influences exopolysaccharide production and coaggregation with yeast cells. Bossier P, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2687–91

Development of a microbial community of bacterial and yeast antagonists to control wound–invading postharvest pathogens of fruits. Janisiewicz WJ, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3261–7

Nucleotide sequences of four pathogen–induced alfalfa peroxidase–encoding cDNAs. el–Turk J, et al. **Gene** 1996 May 8;170(2):213–6

Interaction between fish spoilage bacteria Pseudomonas sp. and Shewanella putrefaciens in fish extracts and on fish tissue. Gram L, et al. **J Appl Bacteriol** 1996 Jun; 80(6):589–95

Some factors affecting the airborne survival of bacteria outdoors. Handley BA, et al. **J Appl Bacteriol** 1995 Oct; 79(4):368–78

Characterization of Pseudomonas paucimobilis FP2001 which forms flagella depending upon the presence of rhamnose in liquid medium. Miake F, et al. **Microbiol Immunol** 1995;39(7):437–42

PSEUDOMONAS AERUGINOSA

Role of CD 11/CD 18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa–induced pneumonia in rabbits. Kumasaka T, et al. **Am J Pathol** 1996 Apr;148(4):1297–305

Neutrophil–induced lung protection and injury are dependent on the amount of Pseudomonas aeruginosa administered via airways in guinea pigs. Terashima T, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2150–6

Local Pseudomonas instillation induces contralateral lung injury and plasma cytokines. Terashima T, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1600–5

Ventilator–associated pneumonia due to Pseudomonas aeruginosa. Crouch Brewer S, et al. **Chest** 1996 Apr; 109(4):1019–29

Bactericidal activity against Pseudomonas aeruginosa is acquired by cultured human monocyte–derived macrophages after uptake of myeloperoxidase. Mathy–Hartert M, et al. **Experientia** 1996 Feb 15; 52(2):167–74

Treatment of experimental rabbit infective endocarditis due to a multidrug–resistant Pseudomonas aeruginosa with

high-dose ceftazidime alone and combined with amikacin or sulbactam or both. Xiong YQ, et al. **J Antimicrob Chemother** 1995 May;35(5):697-706

Effect of aerobic bacteriology on the clinical presentation and treatment results of chronic suppurative otitis media. Vartiainen E, et al. **J Laryngol Otol** 1996 Apr;110(4):315-8

Pseudomonas peritonitis treated with simultaneous catheter replacement and removal [letter] Mayo RR, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):389-90

The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin. Li M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9308-12

New approaches to Pseudomonas aeruginosa lower respiratory tract infections. Matsumoto K. **Verh K Acad Geneeskd Belg** 1995;57(2):109-22

[Preliminary studies on microbe-mediated N-nitrosamide synthesis] Pan K, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):222-4 (Eng. Abstr.) **(Chi)**

[Cloning and sequencing of the gene PE40, coding for a portion of Pseudomonas exotoxin A] Zhang M, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):161-6 (Eng. Abstr.) **(Chi)**

[Pseudomonas aeruginosa folliculitis after depilation] De La Cuadra J, et al. **Ann Dermatol Venereol** 1996;123(4):268-70 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Alginate, the slime exopolysaccharide of Pseudomonas aeruginosa, binds human leukocyte elastase, retards inhibition by alpha 1-proteinase inhibitor, and accelerates inhibition by secretory leukoprotease inhibitor. Ying QL, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):283-91

Biochemical characterization and posttranslational modification of AlgU, a regulator of stress response in Pseudomonas aeruginosa. Schurr MJ, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):874-80

Environment of copper in Pseudomonas aeruginosa azurin probed by binding of exogenous ligands to Met121X (X = Gly, Ala, Val, Leu, or Asp) mutants. Bonander N, et al. **Biochemistry** 1996 Feb 20;35(7):2429-36

Comparison of NMR solution structures of the receptor binding domains of Pseudomonas aeruginosa pili strains PAO, KB7, and PAK: implications for receptor binding and synthetic vaccine design. Campbell AP, et al. **Biochemistry** 1995 Dec 19;34(50):16255-68

Spectroscopic and mechanistic studies of type-1 and type-2 copper sites in Pseudomonas aeruginosa azurin as obtained by addition of external ligands to mutant His46Gly. van Pouderoyen G, et al. **Biochemistry** 1996 Feb 6; 35(5):1397-407

Structure-function analysis of the adherence-binding domain on the pilin of Pseudomonas aeruginosa strains PAK and KB7. Wong WY, et al. **Biochemistry** 1995 Oct 10; 34(40):12963-72

Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients. Gimeno C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):82-5

Pseudomonas aeruginosa A-band and B-band lipopolysaccharides [letter; comment] Pier GB, et al. **Infect Immun** 1995 Dec;63(12):4964-5. Comment on: Infect Immun 1995 May;63(5):1674-80.

The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa. Huang H, et al. **J Bacteriol** 1996 Jun;178(11):3085-90

Construction and characterization of pyocin-colicin chimeric proteins. Kageyama M, et al. **J Bacteriol** 1996 Jan; 178(1):103-10

Structural elucidation of the lipopolysaccharide core region of the O-chain-deficient mutant strain A28 from Pseudomonas aeruginosa serotype 06 (International Antigenic Typing Scheme). Masoud H, et al. **J Bacteriol** 1995 Dec;177(23):6718-26

Membrane topology of the outer membrane protein OprH from Pseudomonas aeruginosa: PCR-mediated site-directed insertion and deletion mutagenesis. Rehm BH, et al. **J Bacteriol** 1996 Jun;178(11):3346-9

A simple gel electrophoretic method for analyzing the muropeptide composition of bacterial peptidoglycan. Young KD. **J Bacteriol** 1996 Jul;178(13):3962-6

X-ray crystal structure of the two site-specific mutants Ile7Ser and Phe110Ser of azurin from Pseudomonas aeruginosa. Hammann C, et al. **J Mol Biol** 1996 Jan 26; 255(3):362-6

[A semi-quantitative measurement of glycocalyx and an ATP bioluminescent assay for the analysis of Pseudomonas aeruginosa biofilm] Ono N. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1440-9 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Epidemiological characterization of human and environmental Pseudomonas aeruginosa strains: use of plasmid pattern analysis in addition to other typing methods. Orsi N, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):653-64

Pseudomonas aeruginosa in otitis externa. A particular variety of the bacteria? Sundström J, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):833-6

Studies on multiple Pseudomonas aeruginosa isolates from individual burn patients by RFLP, O antigen serotyping and antibiogram analysis. Holder IA, et al. **Burns** 1995 Sep; 21(6):441-4

Epidemiological characteristics of Pseudomonas aeruginosa strains causing infection in an Italian general hospital. A one-year surveillance. Grigis A, et al. **Eur J Epidemiol** 1995 Jun;11(3):339-44

Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Bennekov T, et al. **J Clin Microbiol** 1996 Jan; 34(1):202-4

Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients. Kersulyte D, et al. **J Clin Microbiol** 1995 Aug;33(8):2216-9

Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. Mahenthiralingam E, et al. **J Clin Microbiol** 1996 May;34(5):1129-35

DNA fingerprinting of Pseudomonas aeruginosa serotype O11 by enterobacterial repetitive intergenic consensus-polymerase chain reaction and pulsed-field gel electrophoresis. Lau YJ, et al. **J Hosp Infect** 1995 Sep; 31(1):61-6

Discriminatory power and usefulness of pulsed-field gel electrophoresis in epidemiological studies of Pseudomonas aeruginosa. Talon D, et al. **J Hosp Infect** 1996 Feb; 32(2):135-45

Flagellin gene and protein variation amongst clinical isolates of Pseudomonas aeruginosa. Winstanley C, et al. **Microbiology** 1996 Aug;142 (Pt 8):2145-51

[Evaluation of multiple Pseudomonas aeruginosa strains with different characteristics in clinical specimens; combined results from serotyping, drug susceptibility and enzyme production] Nakasone I, et al. **Rinsho Byori** 1995 Nov; 43(11):1135-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

A model for testing drug susceptibility of Pseudomonas aeruginosa and Staphylococcus aureus grown in biofilms on medical devices [see comments] Kétyi I. **Acta Microbiol Immunol Hung** 1995;42(2):215-9. Comment in: Acta Microbiol Immunol Hung 1995;42(2):221.

Application of exponential smoothing for nosocomial infection surveillance. Ngo L, et al. **Am J Epidemiol** 1996 Mar 15;143(6):637-47

Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Fekete T, et al. **Am J Med** 1996 Jun 24;100(6A):20S-25S

Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Cambau E, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2248-52

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Klepser ME, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2503-10

Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Masuda N, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):909-13

Effects of ciprofloxacin and protamine sulfate combinations against catheter-associated Pseudomonas aeruginosa biofilms. Soboh F, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1281-6

Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I. Trafny EA, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2645-9

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Weiss K, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2411-4

Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. White R, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):904-8

Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Yassien M, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2262-8

Effects of Chinese medicinal herbs on a rat model of chronic Pseudomonas aeruginosa lung infection. Song Z, et al. **APMIS** 1996 May;104(5):350-4

Magnetic field enhancement of antibiotic activity in biofilm forming Pseudomonas aeruginosa. Benson DE, et al. **ASAIO J** 1994 Jul-Sep;40(3):M371-6

Binding of myeloperoxidase to bacteria: effect on hydroxyl radical formation and susceptibility to oxidant-mediated killing. Britigan BE, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):231-40

Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Cohn RC, et al. **Chemotherapy** 1995 Sep-Oct;41(5):330-3

Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents. Dan M, et al. **Chemotherapy** 1995 Sep-Oct;41(5):323-9

Comparison of imipenem and five other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Sep-Oct;41(5):334-6

Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Nov-Dec;41(6):433-6

Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria. Scaglione F, et al. **Chemotherapy** 1995 Jul-Aug;41(4):239-46

Meropenem resistance in Pseudomonas aeruginosa. Sumita Y, et al. **Chemotherapy** 1996 Jan-Feb;42(1):47-56

Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Hurley JC, et al. **Diagn Microbiol Infect Dis** 1995 Aug; 22(4):331-6

Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients. Corti G, et al. **Drugs** 1995; 49 Suppl 2:175-6

Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Giamarellos-Bourboulis EJ, et al. **Drugs** 1995;49 Suppl 2:203-4

Susceptibility to new quinolones of Pseudomonas aeruginosa isolated from a patient with chronic respiratory tract infection. Goto H, et al. **Drugs** 1995;49 Suppl 2:177-8

Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems. Cipriani P, et al. **Drugs Exp Clin Res** 1995;21(4):139-44

Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008 [letter] Babálová M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):925-7

Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa [letter] Başustaoğlu AC, et al. **Eur J Clin Microbiol Infect Dis** 1995 May; 14(5):469-70

Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain. Colom K, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):964-71

Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa. Dib C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):979-86

Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem [letter] Miró E, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):731-2

In vitro activity of commercially manufactured disinfectants against Pseudomonas aeruginosa. Orsi GB, et al. **Eur J Epidemiol** 1995 Aug;11(4):453-7

Induction of phenazine biosynthesis in cultures of Pseudomonas aeruginosa by L-N-(3-oxohexanoyl)homoserine lactone. Stead P, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):15-22

Association of metal tolerance with multiple antibiotic resistance of enteropathogenic organisms isolated from coastal region of deltaic Sunderbans. Choudhury P, et al. **Indian J Med Res** 1996 Jul;104:148-51

Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States [letter; comment] Blumberg HM, et al. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):620-1. Comment on: Infect Control Hosp Epidemiol 1995 Feb;16(2):71-5.

Incidence and mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa serotype O11 isolates. Kettner M, et al. **Infection** 1995 Nov-Dec;23(6):380-3

Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa. Hazumi N, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1364-7

Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. Hikida M, et al. **J Antibiot (Tokyo)** 1995 Aug; 48(8):891-2

Comparative distribution of resistance patterns and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards. Bert F, et al. **J Antimicrob Chemother** 1996 Apr;37(4):809-13

In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA, et al. **J Antimicrob Chemother** 1995 Oct;36(4):707-11

A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. Madaras-Kelly KJ, et al. **J Antimicrob Chemother** 1996 Apr;37(4):703-10

Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. Omri A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):631-9

Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pseudomonas aeruginosa in vitro [letter] Takahashi A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):743-5

Newer antipseudomonal cephalosporins. Watanabe NA. **J Chemother** 1996 Feb;8 Suppl 2:48-56

Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. Marley EF, et al. **J Clin Microbiol** 1995 Dec;33(12):3191-3

Disinfectant testing on surfaces. van Klingeren B. **J Hosp Infect** 1995 Jun;30 Suppl:397–408

Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. Chen HY, et al. **J Med Microbiol** 1995 Oct; 43(4):300–9

Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both gram-negative and gram-positive bacteria. Minnock A, et al. **J Photochem Photobiol B** 1996 Feb;32(3):159–64

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Cheng K, et al. **Lancet** 1996 Sep 7;348(9028):639–42

Effect of quaternary ammonium salts and amine oxides on Pseudomonas aeruginosa. Majtán V, et al. **Microbios** 1995; 84(338):41–51

Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. Antos M, et al. **Pharmacol Res** 1995 Jul-Aug;32(1-2):85–7

Mode of antibacterial action of totarol, a diterpene from Podocarpus nagi. Haraguchi H, et al. **Planta Med** 1996 Apr; 62(2):122–5

Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance. Jackson JJ, et al. **Prog Clin Biol Res** 1995; 392:235–51

In vivo and in vitro study of several pharmacodynamic effects of meropenem. Fuentes F, et al. **Scand J Infect Dis** 1995;27(5):469–74

[Comparison of the activity of beta-lactams against Pseudomonas aeruginosa according to phenotypes of resistance] Bert F, et al. **Pathol Biol (Paris)** 1996 May; 44(5):329–32 (Eng. Abstr.) **(Fre)**

[Comparison of four methods for the determination of the susceptibility of 47 strains of Pseudomonas aeruginosa to ceftazidime and cefepime: influence of the choice of interpretative criteria] Boucaud-Maître Y, et al. **Pathol Biol (Paris)** 1996 May;44(5):363–6 (Eng. Abstr.) **(Fre)**

[In vitro study of the bacteriostatic and bactericidal activity of meropenem against strains of Pseudomonas aeruginosa multiresistant to antibiotics] Delisle F, et al. **Pathol Biol (Paris)** 1996 May;44(5):337–40 (Eng. Abstr.) **(Fre)**

[In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients] Maugein J, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):253–7 (Eng. Abstr.) **(Fre)**

[Effects of azithromycin on the virulence of Pseudomonas aeruginosa] Reinert P. **Pathol Biol (Paris)** 1995 Jun; 43(6):551–3 (Eng. Abstr.) **(Fre)**

[In vitro antibacterial activity of a new fluoroquinolone, enoxacin against hospital bacteria and regression curve] Soussy CJ, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):274–80 (Eng. Abstr.) **(Fre)**

[In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta-lactams] Vachée A, et al. **Pathol Biol (Paris)** 1996 Feb;44(2):132–7 (Eng. Abstr.) **(Fre)**

[Antibacterial activities of combination uses of isepamicin and beta-lactams in vitro against clinically isolated strains. Part 3. The results against Pseudomonas aeruginosa] Deguchi K, et al. **Jpn J Antibiot** 1996 May;49(5):509–16 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activities of clavulanic acid/ticarcillin against clinical isolates] Koguchi M, et al. **Jpn J Antibiot** 1995 Dec;48(12):1899–905 (Eng. Abstr.) **(Jpn)**

[In vitro antibacterial activities of carbapenems and other antibiotics against Pseudomonas aeruginosa determined using low-amino-acid agar] Kouda M, et al. **Jpn J Antibiot** 1995 Oct;48(10):1590–6 (Eng. Abstr.) **(Jpn)**

[Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa] Murase M, et al. **Jpn J Antibiot** 1995 Oct;48(10):1581–9 (Eng. Abstr.) **(Jpn)**

[Heterogeneity of lipopolysaccharide chain size of Pseudomonas aeruginosa isolated from different clinical sources—with reference to gentamicin-susceptibility and serotype] Hasegawa M, et al. **Kansenshogaku Zasshi** 1995 Jul;69(7):811–7 (Eng. Abstr.) **(Jpn)**

[Drug-resistance patterns of clinical isolates of Pseudomonas aeruginosa in regard to their lipopolysaccharide-chain sizes] Hasegawa M, et al. **Kansenshogaku Zasshi** 1996 Jun; 70(6):605–12 (Eng. Abstr.) **(Jpn)**

[Comparative susceptibility of 10 antimicrobials against Pseudomonas aeruginosa isolated from complicated urinary tract infection on 1992 & 1993 vs. 1994 & 1995] Ishikawa K, et al. **Kansenshogaku Zasshi** 1996 Jun;70(6):584–90 (Eng. Abstr.) **(Jpn)**

[Mechanisms of the combined effect of SHF electromagnetic radiation and hydrogen peroxide on the viability of microorganisms] Kuchma TN, et al. **Biofizika** 1996 Mar-Apr;41(2):433–9 (Eng. Abstr.) **(Rus)**

[Determinant of plasmid pBS221 resistance to potassium tellurite] Anisimova LA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):36–40 (Eng. Abstr.) **(Rus)**

[Postantibiotic effects and postantibiotic effects of subinhibitory levels of quinolines on Pseudomonas aeruginosa] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):56–8 (Eng. Abstr.) **(Slo)**

ENZYMOLOGY

Synthetic peptide substrates for a conductimetric assay of Pseudomonas aeruginosa elastase. Besson C, et al. **Anal Biochem** 1996 Jun 1;237(2):216–23

OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Danel F, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1881–4

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Kitamura A, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1467–71

Cloning and characterization of a 3-N-aminoglycoside acetyltransferase gene, aac(3)-Ib, from Pseudomonas aeruginosa. Schwocho LR, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1790–6

DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Yonezawa M, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1970–2

Identification of a multienzyme complex of the tricarboxylic acid cycle enzymes containing citrate synthase isoenzymes from Pseudomonas aeruginosa. Mitchell CG. **Biochem J** 1996 Feb 1;313 (Pt 3):769–74

Amino acid sequence alignment of a "small' citrate synthase from Pseudomonas aeruginosa PAC 514, with other citrate synthase sequences. Mitchell CG, et al. **Biochem Soc Trans** 1996 Feb;24(1):46S

In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide. Beattie BK, et al. **Biochemistry** 1996 Jul 16; 35(28):9042–51

Identification of glutamic acid 381 as a candidate active site residue of Pseudomonas aeruginosa exoenzyme S. Liu S, et al. **Biochemistry** 1996 Feb 27;35(8):2754–8

Effects of metals on elastase from Pseudomonas aeruginosa SES-938-1. Kocabiyik S, et al. **Biol Trace Elem Res** 1995 Oct;50(1):25–31

Catabolic ornithine carbamoyltransferase of Pseudomonas aeruginosa. Importance of the N-terminal region for dodecameric structure and homotropic carbamoylphosphate cooperativity. Nguyen VT, et al. **Eur J Biochem** 1996 Feb 15;236(1):283–93

A reinvestigation of the covalent structure of Pseudomonas aeruginosa cytochrome c peroxidase. Samyn B, et al. **FEBS Lett** 1995 Dec 18;377(2):145–9

Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa. Goranson J, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):149–55 (39 ref.)

A mutant of Pseudomonas aeruginosa that lacks c-type cytochromes has a functional cyanide-insensitive oxidase. Ray A, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):123–9

Characterization of elastase-deficient clinical isolates of Pseudomonas aeruginosa. Hamood AN, et al. **Infect Immun** 1996 Aug;64(8):3154–60

Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes. König B, et al. **Infect Immun** 1996 Aug;64(8):3252–8

Protease cleavage of iron-transferrin augments pyocyanin-mediated endothelial cell injury via promotion of hydroxyl radical formation. Miller RA, et al. **Infect Immun** 1996 Jan;64(1):182–8

Role of manganese superoxide dismutase in a mucoid isolate of Pseudomonas aeruginosa: adaptation to oxidative stress. Polack B, et al. **Infect Immun** 1996 Jun;64(6):2216–9

Cloning and characterization of the katB gene of Pseudomonas aeruginosa encoding a hydrogen peroxide-inducible catalase: purification of KatB, cellular localization, and demonstration that it is essential for optimal resistance to hydrogen peroxide. Brown SM, et al. **J Bacteriol** 1995 Nov;177(22):6536–44

Pseudomonas aeruginosa sodA and sodB mutants defective in manganese- and iron-cofactored superoxide dismutase activity demonstrate the importance of the iron-cofactored form in aerobic metabolism. Hassett DJ, et al. **J Bacteriol** 1995 Nov;177(22):6330–7

A major autolysin of Pseudomonas aeruginosa: subcellular distribution, potential role in cell growth and division and secretion in surface membrane vesicles. Li Z, et al. **J Bacteriol** 1996 May;178(9):2479–88

Maleylacetate reductases in chloroaromatic-degrading bacteria using the modified ortho pathway: comparison of catalytic properties. Müller D, et al. **J Bacteriol** 1996 Jan; 178(1):298–300

Two forms of the nucleoside diphosphate kinase of Pseudomonas aeruginosa 8830: altered specificity of nucleoside triphosphate synthesis by the cell membrane-associated form of the truncated enzyme. Shankar S, et al. **J Bacteriol** 1996 Apr;178(7):1777–81

Crystal structure of the unliganded alkaline protease from Pseudomonas aeruginosa IFO3080 and its conformational changes on ligand binding. Miyatake H, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):474–9

Characterization of a phosphoprotein phosphatase for the phosphorylated form of nucleoside-diphosphate kinase from Pseudomonas aeruginosa. Shankar S, et al. **J Biol Chem** 1995 Nov 24;270(47):28246–50

Isolation and characterization of the d1 domain of Pseudomonas aeruginosa nitrite reductase. Silvestrini MC, et al. **J Inorg Biochem** 1996 May 1;62(2):77–87

The influence of exo-enzyme S and proteases on endogenous Pseudomonas aeruginosa bacteraemia in mice. Hirakata Y, et al. **J Med Microbiol** 1995 Oct;43(4):258–61

Use of a designed fusion protein dissociates allosteric properties from the dodecameric state of Pseudomonas aeruginosa catabolic ornithine carbamoyltransferase. Mouz N, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9414–9

Crystal structure of Pseudomonas aeruginosa catabolic ornithine transcarbamoylase at 3.0-A resolution: a different oligomeric organization in the transcarbamoylase family. Villeret V, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10762–6

Crystal structure of the di-haem cytochrome c peroxidase from Pseudomonas aeruginosa. Fülöp V, et al. **Structure** 1995 Nov 15;3(11):1225–33

GENETICS

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89–118 (70 ref.)

The outer membrane protein OprM of Pseudomonas aeruginosa is encoded by oprK of the mexA-mexB-oprK multidrug resistance operon. Gotoh N, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2567–9

OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa. Hamzehpour MM, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2392–6

Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Li XZ, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1948–53

Cloning and characterization of the Pseudomonas aeruginosa pbpB gene encoding penicillin-binding protein 3. Liao X, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1871–4

DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Yonezawa M, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1970–2

Anaerobically controlled expression system derived from the arcDABC operon of Pseudomonas aeruginosa: application to lipase production. Winteler HV, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3391–8

The Pseudomonas aeruginosa fumc and soda genes belong to an iron-responsive operon. Polack B, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):555–60

Characterization of the Pseudomonas aeruginosa transposable bacteriophage D3112 A and B genes. Ulycznyj PI, et al. **Biochim Biophys Acta** 1995 Dec 27;1264(3):249–53

DNA hybridization analysis of the Pseudomonas aeruginosa elastase gene (lasB) from different clinical isolates. Hamood AN, et al. **Can J Microbiol** 1995 Oct;41(10):910–7

Prevalence of gca, a gene involved in synthesis of A-band common antigen polysaccharide in Pseudomonas aeruginosa. Currie HL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):554–62

Oligonucleotide primers designed to differentiate pathogenic pseudomonads on the basis of the sequencing of genes coding for 16S-23S rRNA internal transcribed spacers. Tyler SD, et al. **Clin Diagn Lab Immunol** 1995 Jul; 2(4):448–53

A leucine zipper motif determines different functions in a DNA replication protein. Garcia de Viedma D, et al. **EMBO J** 1996 Feb 15;15(4):925–34

Isolation and structure of a new integron that includes a streptomycin resistance gene from the R plasmid of Pseudomonas aeruginosa. Kazama H, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):137–41

Cloning and characterization of the gene (rfc) encoding O-antigen polymerase of Pseudomonas aeruginosa PAO1. Coyne MJ Jr, et al. **Gene** 1995 Dec 29;167(1-2):81–6

Sequencing and characterization of the downstream region of the genes encoding nitrite reductase and cytochrome c-551 (nirSM) from Pseudomonas aeruginosa: identification of the gene necessary for biosynthesis of heme d1. Kawasaki S, et al. **Gene** 1995 Dec 29;167(1-2):87–91

Cloning of the Pseudomonas aeruginosa gene encoding CDP-diglyceride synthetase. Taguchi K, et al. **Gene** 1996 Jun 12;172(1):165–6

Construction of improved vectors for protein production in Pseudomonas aeruginosa. Watson AA, et al. **Gene** 1996 Jun 12;172(1):163–4

Cloning and characterization of Pseudomonas aeruginosa fliF, necessary for flagellar assembly and bacterial adherence to mucin. Arora SK, et al. **Infect Immun** 1996 Jun;64(6):2130–6

Cloning and phenotypic characterization of fleS and fleR, new response regulators of Pseudomonas aeruginosa which regulate motility and adhesion to mucin. Ritchings BW, et al. **Infect Immun** 1995 Dec;63(12):4868–76

Identification of a novel gene, pilZ, essential for type 4 fimbrial biogenesis in Pseudomonas aeruginosa. Alm RA, et al. **J Bacteriol** 1996 Jan;178(1):46–53

Identification of two genes with prepilin-like leader sequences involved in type 4 fimbrial biogenesis in Pseudomonas aeruginosa. Alm RA, et al. **J Bacteriol** 1996 Jul;178(13):3809–17

Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA. Boucher JC, et al. **J Bacteriol** 1996 Jan;178(2):511–23

Dual function of PilS during transcriptional activation of the Pseudomonas aeruginosa pilin subunit gene. Boyd JM, et al. **J Bacteriol** 1996 Feb;178(3):831–9

Identification of algI and algJ in the Pseudomonas aeruginosa alginate biosynthetic gene cluster which are required for alginate O acetylation. Franklin MJ, et al. **J Bacteriol** 1996 Apr;178(8):2186–95

PchR, a regulator of ferripyochelin receptor gene (fptA) expression in Pseudomonas aeruginosa, functions both as an activator and as a repressor. Heinrichs DE, et al. **J Bacteriol** 1996 May;178(9):2586–92

Molecular cloning and characterization of a chemotactic transducer gene in Pseudomonas aeruginosa. Kuroda A, et al. **J Bacteriol** 1995 Dec;177(24):7019–25

Iron-regulated transcription of the pvdA gene in Pseudomonas aeruginosa: effect of Fur and PvdS on promoter activity. Leoni L, et al. **J Bacteriol** 1996 Apr; 178(8):2299–313

Analysis of the Pseudomonas aeruginosa elastase (lasB) regulatory region. Rust L, et al. **J Bacteriol** 1996 Feb; 178(4):1134–40

Comparative genome mapping of Pseudomonas aeruginosa PAO with P. aeruginosa C, which belongs to a major clone in cystic fibrosis patients and aquatic habitats. Schmidt KD, et al. **J Bacteriol** 1996 Jan;178(1):85–93

Control of AlgU, a member of the sigma E-like family of stress sigma factors, by the negative regulators MucA and MucB and Pseudomonas aeruginosa conversion to mucoidy in cystic fibrosis. Schurr MJ, et al. **J Bacteriol** 1996 Aug; 178(16):4997–5004

Multiple promoters and induction by heat shock of the gene encoding the alternative sigma factor AlgU (sigma E) which controls mucoidy in cystic fibrosis isolates of Pseudomonas aeruginosa. Schurr MJ, et al. **J Bacteriol** 1995 Oct;177(19):5670–9

Purification and characterization of the Pseudomonas aeruginosa NfxB protein, the negative regulator of the nfxB gene. Shiba T, et al. **J Bacteriol** 1995 Oct;177(20):5872–7

Mechanism of retrotransfer in conjugation: prior transfer of the conjugative plasmid is required. Sia EA, et al. **J Bacteriol** 1996 Mar;178(5):1457–64

Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa. Yahr TL, et al. **J Bacteriol** 1996 Mar;178(5):1412–9

Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Bennekov T, et al. **J Clin Microbiol** 1996 Jan; 34(1):202–4

Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients. Kersulyte D, et al. **J Clin Microbiol** 1995 Aug;33(8):2216–9

Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. Mahenthiralingam E, et al. **J Clin Microbiol** 1996 May;34(5):1129–35

DNA fingerprinting of Pseudomonas aeruginosa serotype O11 by enterobacterial repetitive intergenic consensus-polymerase chain reaction and pulsed-field gel electrophoresis. Lau YJ, et al. **J Hosp Infect** 1995 Sep; 31(1):61–6

Physical mapping of 32 genetic markers on the Pseudomonas aeruginosa PAO1 chromosome. Liao X, et al. **Microbiology** 1996 Jan;142 (Pt 1):79–86

The Pseudomonas aeruginosa tonB gene encodes a novel TonB protein. Poole K, et al. **Microbiology** 1996 Jun;142 (Pt 6):1449–58

Novel pyoverdine biosynthesis gene(s) of Pseudomonas aeruginosa PAO. Stintzi A, et al. **Microbiology** 1996 May; 142 (Pt 5):1181–90

Flagellin gene and protein variation amongst clinical isolates of Pseudomonas aeruginosa. Winstanley C, et al. **Microbiology** 1996 Aug;142 (Pt 8):2145–51

Cloning, mapping and characterization of the Pseudomonas aeruginosa hemL gene. Hungerer C, et al. **Mol Gen Genet** 1995 Aug 21;248(3):375–80

Molecular analysis of the phosphate-specific transport (pst) operon of Pseudomonas aeruginosa. Nikata T, et al. **Mol Gen Genet** 1996 Apr 10;250(6):692–8

Structural genes for salicylate biosynthesis from chorismate in Pseudomonas aeruginosa. Serino L, et al. **Mol Gen Genet** 1995 Nov 15;249(2):217–28

Identification of a gene, pilV, required for type 4 fimbrial biogenesis in Pseudomonas aeruginosa, whose product possesses a pre-pilin-like leader sequence. Alm RA, et al. **Mol Microbiol** 1995 May;16(3):485–96

Molecular cloning and characterization of the rfc gene of Pseudomonas aeruginosa (serotype O5). de Kievit TR, et al. **Mol Microbiol** 1995 May;16(3):565–74

Multiple homologues of LuxR and LuxI control expression of virulence determinants and secondary metabolites through quorum sensing in Pseudomonas aeruginosa PAO1. Latifi A, et al. **Mol Microbiol** 1995 Jul;17(2):333–43

Importance of lipooligosaccharide structure in determining gonococcal resistance to hydrophobic antimicrobial agents resulting from the mtr efflux system. Lucas CE, et al. **Mol Microbiol** 1995 Jun;16(5):1001–9

Characterization of a five-gene cluster required for the biogenesis of type 4 fimbriae in Pseudomonas aeruginosa. Martin PR, et al. **Mol Microbiol** 1995 May;16(3):497–508

Gradient of genomic diversity in the Pseudomonas aeruginosa chromosome. Römling U, et al. **Mol Microbiol** 1995 Jul;17(2):323–32

The Escherichia coli genes sspA and rnk can functionally replace the Pseudomonas aeruginosa alginate regulatory gene algR2. Schlictman D, et al. **Mol Microbiol** 1995 Apr; 16(2):309–20

Gene repression by the ferric uptake regulator in Pseudomonas aeruginosa: cycle selection of iron-regulated genes. Ochsner UA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4409–14

[Preliminary study on multi-resistant gene location of 20 strains of Pseudomonas aeruginosa] Jia C, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):330–1 (Eng. Abstr.) **(Chi)**

[Origin and properties of Pseudomonas aeruginosa PAO1 clones surviving after induction of prophages-transposons] Krylov VN, et al. **Genetika** 1995 Aug;31(8):1065–72 (Eng. Abstr.) **(Rus)**

[Mucoid clones of Pseudomonas aeruginosa PAO1, surviving after induction of prophage transposons] Krylov VN, et al. **Genetika** 1995 Oct;31(10):1375–9 (Eng. Abstr.) **(Rus)**

[Recombination properties of the modified Pseudomonas aeruginosa RecA protein] Namsaraev EA, et al. **Mol Biol (Mosk)** 1995 Jul-Aug;29(4):801–12 (Eng. Abstr.) **(Rus)**

[Mobilization of genetic determinants of antibiotic resistance in strains of Pseudomonas aeruginosa] Babálová M, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):161–4 (Eng. Abstr.) **(Slo)**

GROWTH & DEVELOPMENT

Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Crowther J, et al. **Anesth Analg** 1996 Mar;82(3):475–8

Filamentous growth in activated sludge. Chua H, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:851–6

Inhibition of bacterial growth in vitro by human ejaculate seminal plasma fraction 1 and its possible practical use in male infertility phenomenon. Marcus ZH, et al. **J Assist Reprod Genet** 1995 Aug;12(7):443–6

The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. Barth AL, et al. **J Med Microbiol** 1996 Aug; 45(2):110–9

IMMUNOLOGY

The protective role of pulmonary neutrophils in rats intestinally immunized with Pseudomonas aeruginosa. Buret A, et al. **Adv Exp Med Biol** 1995;371B:765–9

Immunity to Pseudomonas aeruginosa induced by OprF following intestinal immunization. Cripps AW, et al. **Adv Exp Med Biol** 1995;371B:761–3

Immunity to respiratory Pseudomonas aeruginosa infection: P. aeruginosa-specific T cells arising after intestinal immunization. Dunkley ML, et al. **Adv Exp Med Biol** 1995; 371B:755–9

Immunity to respiratory Pseudomonas aeruginosa infection: the role of gut-derived T helper cells and immune serum. Dunkley ML, et al. **Adv Exp Med Biol** 1995;371B:771–5

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Johansen HK, et al. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 1):1337–46

Appropriate coating methods and other conditions for enzyme-linked immunosorbent assay of smooth, rough, and neutral lipopolysaccharides of Pseudomonas aeruginosa. Bantroch S, et al. **Clin Diagn Lab Immunol** 1994 Jan; 1(1):55–62

Serum antibody responses of divers to waterborne pathogens. Losonsky GA, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):182–5

Identification of outer membrane proteins as target antigens of Pseudomonas aeruginosa Homma serotype M. Yokota S. **Clin Diagn Lab Immunol** 1995 Nov;2(6):747–52

Secretory monoclonal IgA class-switch variants against bacterial enteric pathogens in bile and intestinal secretions. Steinmetz I, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):329–36

The effect of the length of a malarial epitope on its antigenicity and immunogenicity in an epitope presentation system using the Pseudomonas aeruginosa outer membrane protein OprF as the carrier. Wong RS, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2-3):209–14

Production of ScFv antibody fragments following immunization with a phage-displayed fusion protein and analysis of reactivity to surface-exposed epitopes of the protein F of Pseudomonas aeruginosa by cytofluorometry. Kermani P, et al. **Hybridoma** 1995 Aug;14(4):323–8

Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Mahenthiralingam E, et al. **Infect Immun** 1995 Nov;63(11):4519–23

Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Pollack M, et al. **Infect Immun** 1995 Nov;63(11):4481–8

Immunoglobulin A antibodies against Pseudomonas aeruginosa in the tear fluid of contact lens wearers. Cheng KH, et al. **Invest Ophthalmol Vis Sci** 1996 Sep; 37(10):2081–8

Diverse VH and V kappa genes encode antibodies to Pseudomonas aeruginosa LPS. Emara MG, et al. **J Immunol** 1995 Oct 15;155(8):3912–21

Escherichia coli and Pseudomonas aeruginosa induce expansion of V delta 2 cells in adult peripheral blood, but of V delta 1 cells in cord blood. Kersten CM, et al. **J Immunol** 1996 Aug 15;157(4):1613–9

Analysis of naturally occurring antibodies to mucoid Pseudomonas aeruginosa in cystic fibrosis patients [letter; comment] Pier GB. **J Infect Dis** 1996 Feb;173(2):513–5. Comment on: J Infect Dis 1995 Aug;172(2):453–61.

In vitro culture of murine peritoneal and alveolar macrophages modulates phagocytosis of Pseudomonas aeruginosa and glucose transport. Everett KD, et al. **J Leukoc Biol** 1996 Apr;59(4):539–44

IgG subclass responses to Pseudomonas aeruginosa a- and b-type flagellins in patients with cystic fibrosis: a prospective study. Lagacé J, et al. **J Med Microbiol** 1995 Oct;43(4):270–6

Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB, et al. **J Pediatr** 1995 Nov; 127(5):711–7

Pseudomonas aeruginosa exotoxin A antibodies in rapidly deteriorating chronic leg ulcers [letter] Danielsen L, et al. **Lancet** 1996 Jan 27;347(8996):265

High levels of complement-activation capacity in sera from patients with cystic fibrosis correlate with high levels of IgG3 antibodies to Pseudomonas aeruginosa antigens and poor lung function. Pressler T, et al. **Pediatr Pulmonol** 1995 Aug;20(2):71–7

Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Hughes EE, et al. **Vaccine** 1995 Dec; 13(18):1750–3

[Immunomodulation in Pseudomonas urinary infection] Urban M, et al. **Rozhl Chir** 1995 Nov;74(7):319–21 (Eng. Abstr.) **(Cze)**

[Structure and properties of the common polysaccharide antigen of Pseudomonas aeruginosa bacteria (review)] Knirel' IuA, et al. **Biokhimiia** 1995 Dec;60(12):1964–76 (53 ref.) (Eng. Abstr.) **(Rus)**

[An immunological study of the cell wall proteins of Pseudomonas aeruginosa] Makarenko TA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr;(2):7–9 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Application of exponential smoothing for nosocomial infection surveillance. Ngo L, et al. **Am J Epidemiol** 1996 Mar 15;143(6):637–47

In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Dohar JE, et al. **Am J Otol** 1996 Mar;17(2):207–9

Microbiology of tracheal granulation tissue associated with silicone airway prostheses. Brown MT, et al. **Ann Otol Rhinol Laryngol** 1996 Aug;105(8):624–7

Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. Porco FV, et al. **Ann Pharmacother** 1995 Nov;29(11):1122–3

Bacterial growth in saline implants: in vitro and in vivo studies. Chen NT, et al. **Ann Plast Surg** 1996 Apr; 36(4):337–41

The clinical significance of Pseudomonas aeruginosa isolation from stool of neonates. Somekh E, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):108–9

Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. van Asperen IA, et al. **BMJ** 1995 Nov 25;311(7017):1407–10

Levels and identities of nonrhizobial microorganisms found in commercial legume inoculant made with nonsterile peat carrier. Olsen PE, et al. **Can J Microbiol** 1996 Jan; 42(1):72–5

Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Maniatis AN, et al. **Clin Infect Dis** 1995 Aug;21(2):437–9

Fluorescence-based DNA fingerprinting elucidates nosocomial transmission of phenotypically variable Pseudomonas aeruginosa in intensive care units. Grundmann H, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1057–62

Pollution of modern metalworking fluids containing biocides by pathogenic bacteria in France. Reexamination of chemical treatments accuracy. Chazal PM. **Eur J Epidemiol** 1995 Feb;11(1):1–7

The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance. Aebi C, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S69–73

Survey of Pseudomonas aeruginosa contamination in human beings and laboratory animals. Urano T, et al. **Exp Anim** 1995 Jul;44(3):233–9

Quality improvement in gastrointestinal endoscopy: microbiologic surveillance of disinfection [see comments] Merighi A, et al. **Gastrointest Endosc** 1996 May; 43(5):457–62. Comment in: Gastrointest Endosc 1996 May;43(5):522–4.

Use of pulsed-field gel electrophoresis as an epidemiologic tool during an outbreak of Pseudomonas aeruginosa lung infections in an intensive care unit. Talon D, et al. **Intensive Care Med** 1995 Dec;21(12):996–1002

An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. Spencer RC. **J Antimicrob Chemother** 1996 Feb;

37(2):295–301
Note: development of an external quality assurance scheme for the detection and enumeration of Pseudomonas aeruginosa from water and comparison of results using modified King's A broth and a commercial agar. Place BM, et al. **J Appl Bacteriol** 1996 Jun;80(6):682–6
Safety of expressed breast milk [letter] Garg AK, et al. **J Infect** 1995 Nov;31(3):247–8
Parapharyngeal abscess from Pseudomonas aeruginosa infection in an HIV positive patient [letter] Sanderson RJ, et al. **J Infect** 1995 Sep;31(2):174
Resistance of microorganisms to disinfection in dental and medical devices [see comments] Lewis DL, et al. **Nat Med** 1995 Sep;1(9):956–8. Comment in: Nat Med 1995 Dec;1(12):1223–5.
Usefulness of a computerized expert system associated with systematic O-serotyping for the early detection of outbreaks of hospital acquired infections and for the presumptive antibiotic therapy of Pseudomonas aeruginosa infections. Watine J, et al. **Pathol Biol (Paris)** 1996 Feb; 44(2):125–31
Detection of Pseudomonas aeruginosa from ovine fleece washings by PCR amplification of 16S ribosomal RNA. Kingsford NM, et al. **Vet Microbiol** 1995 Nov; 47(1–2):61–70
[Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis] Canis F, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):343–51 (Eng. Abstr.) **(Fre)**
[Characterization of Pseudomonas aeruginosa strains isolated at therapeutic institutions of Moscow] Grinenko GI, et al. **Klin Lab Diagn** 1995 May–Jun;(3):11–4 (Eng. Abstr.) **(Rus)**
[The epidemiological markers of Pseudomonas aeruginosa strains circulating in different types of hospitals] Makarova NV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):13–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Microbial oxidation of unsaturated fatty acids. Hou CT. **Adv Appl Microbiol** 1995;41:1–23 (37 ref.)
Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)
Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Hosaka M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1731–5
Role of mexA–mexB–oprM in antibiotic efflux in Pseudomonas aeruginosa. Li XZ, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1948–53
Scavenging of neutrophil-derived superoxide anion by 1-hydroxyphenazine, a phenazine derivative associated with chronic Pseudomonas aeruginosa infection: relevance to cystic fibrosis. Muller M. **Biochim Biophys Acta** 1995 Dec 12;1272(3):185–9
Pseudomonas aeruginosa strain MA01 aerobically metabolizes the aminodinitrotoluenes produced by 2,4,6-trinitrotoluene nitro group reduction. Alvarez MA, et al. **Can J Microbiol** 1995 Nov;41(11):984–91
Some P. aeruginosa pilus-binding proteins of human corneal epithelium are cytokeratins. Wu X, et al. **Curr Eye Res** 1996 Jul;15(7):782–91
Characterization of P. aeruginosa pili binding human corneal epithelial proteins. Wu X, et al. **Curr Eye Res** 1995 Oct; 14(10):969–77
A specific targeting domain in mature exotoxin A is required for its extracellular secretion from Pseudomonas aeruginosa. Lu HM, et al. **EMBO J** 1996 Jan 15; 15(2):429–36
The role of His117 in the redox reactions of azurin from Pseudomonas aeruginosa. Gorren AC, et al. **FEBS Lett** 1996 Feb 26;381(1–2):140–2
Induction of phenazine biosynthesis in cultures of Pseudomonas aeruginosa by L-N-(3-oxohexanoyl)homoserine lactone. Stead P, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):15–22
The effect of concurrent Pseudomonas or Xanthomonas exposure on adherence of Acanthamoeba castellanii to soft contact lenses. Kelly LD, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 May;234(5):311–4
Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. Dupont MJ, et al. **J Antimicrob Chemother** 1995 Jul;36(1):231–6
Inhibition of Helicobacter pylori growth by 4-hydroxy-2-alkyl-quinolines produced by Pseudomonas aeruginosa. Lacey SL, et al. **J Antimicrob Chemother** 1995 Nov;36(5):827–31
Use of ultrasound to facilitate antibiotic diffusion through Pseudomonas aeruginosa alginate. Williams KA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):463–73
Synthesis of multiple exoproducts in Pseudomonas aeruginosa is under the control of RhlR-RhlI, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family. Brint JM, et al. **J Bacteriol** 1995 Dec;177(24):7155–63
Pseudomonas aeruginosa PAO1 ceases to express serotype-specific lipopolysaccharide at 45 degrees C. Makin SA, et al. **J Bacteriol** 1996 Jun;178(11):3350–2
Alginate synthesis in Pseudomonas aeruginosa: the role of AlgL (alginate lyase) and AlgX. Monday SR, et al. **J Bacteriol** 1996 Feb;178(3):625–32
Role of the ferric uptake regulator of Pseudomonas aeruginosa in the regulation of siderophores and exotoxin A expression: purification and activity on iron-regulated promoters. Ochsner UA, et al. **J Bacteriol** 1995 Dec; 177(24):7194–201
The role of specific lysine residues in the passage of anions through the Pseudomonas aeruginosa porin OprP. Sukhan A, et al. **J Biol Chem** 1996 Aug 30;271(35):21239–42
Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. DiMango E, et al. **J Clin Invest** 1995 Nov;96(5):2204–10
Inhibitory action of metabolites of Pseudomonas aeruginosa against gram-negative bacteria. Li Z, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):924–7
Protein C (OprC) of the outer membrane of Pseudomonas aeruginosa is a copper-regulated channel protein. Yoneyama H, et al. **Microbiology** 1996 Aug;142 (Pt 8):2137–44
Toxin A secretion in Pseudomonas aeruginosa: the role of the first 30 amino acids of the mature toxin. McVay CS, et al. **Mol Gen Genet** 1995 Dec 15;249(5):515–25
Structural genes for salicylate biosynthesis from chorismate in Pseudomonas aeruginosa. Serino L, et al. **Mol Gen Genet** 1995 Nov 15;249(2):217–28
Rhamnolipid biosurfactant enhancement of hexadecane biodegradation by Pseudomonas aeruginosa. Shreve GS, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):331–7
Membrane topology and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD. Huang H, et al. **Mol Microbiol** 1995 Jun;16(5):931–41
Purification and characterization of LasD: a second staphylolytic proteinase produced by Pseudomonas aeruginosa. Park S, et al. **Mol Microbiol** 1995 Apr; 16(2):263–70
Use of synthetic peptides to confirm that the Pseudomonas aeruginosa PAK pilus adhesin and the Candida albicans fimbrial adhesin possess a homologous receptor-binding domain. Yu L, et al. **Mol Microbiol** 1996 Mar;19(5):1107–16
Gene repression by the ferric uptake regulator in Pseudomonas aeruginosa: cycle selection of iron-regulated genes. Ochsner UA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4409–14
Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Winson MK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9427–31
Production, purification and characterization of two proteinaceous hen-egg-white lysozyme inhibitors from Pseudomonas aeruginosa M-1001. Wang SL, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):166–75
Caco-2 and IEC-18 intestinal epithelial cells exert bactericidal activity through an oxidant-dependent pathway. Deitch EA, et al. **Shock** 1995 Nov;4(5):345–50
Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409–10; discussion 411–3 (49 ref.)
[The effect of subinhibitory concentrations of quinolone and macrolide antibiotics on production of thermolabile hemolysins in Pseudomonas aeruginosa] Hybenová D, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):169–70 (Eng. Abstr.) **(Cze)**
[Alginates of Pseudomonas aeruginosa: a complex regulation of the pathway of biosynthesis] Schmitt-Andrieu L, et al. **C R Acad Sci III** 1996 Mar;319(3):153–60 (62 ref.) (Eng. Abstr.) **(Fre)**
[Active transport of fosfomycin into cells of Escherichia coli, multidrug-resistant Pseudomonas aeruginosa and Staphylococcus aureus] Tsuruoka T, et al. **Jpn J Antibiot** 1995 Dec;48(12):1935–8 (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Azghani AO. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):132–40
Role of recruited neutrophils in interleukin-8 production in dog trachea after stimulation with Pseudomonas in vivo. Inoue H, et al. **Am J Respir Cell Mol Biol** 1995 Nov; 13(5):570–7
Purified Pseudomonas aeruginosa PA-I lectin induces gut growth when orally ingested by rats. Grant G, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):191–5
Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. de Bentzmann S, et al. **Infect Immun** 1996 May;64(5):1582–8
Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Fleiszig SM, et al. **Infect Immun** 1996 Jun;64(6):2288–94
Avirulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection. Goldberg JB, et al. **Infect Immun** 1995 Oct;63(10):4166–9
Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells. Gu M, et al. **Infect Immun** 1996 Feb;64(2):524–7
Pyocyanin from Pseudomonas aeruginosa inhibits prostacyclin release from endothelial cells. Kamath JM, et al. **Infect Immun** 1995 Dec;63(12):4921–3
Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Meyer JM, et al. **Infect Immun** 1996 Feb; 64(2):518–23
Pathogenesis of corneal infection: binding of Pseudomonas aeruginosa to specific phospholipids. Panjwani N, et al. **Infect Immun** 1996 May;64(5):1819–25
Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Tang HB, et al. **Infect Immun** 1996 Jan;64(1):37–43
Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE). Yu H, et al. **Infect Immun** 1996 Jul;64(7):2774–81
Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. O'Callaghan RJ, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):534–43
Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections. Hamood AN, et al. **J Surg Res** 1996 Mar;61(2):425–32
Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Winson MK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9427–31
Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance. Jackson JJ, et al. **Prog Clin Biol Res** 1995; 392:235–51
[The effect of subinhibitory concentrations of norfloxacin, erythromycin and roxithromycin on Pseudomonas aeruginosa virulence factors] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1995 Sep;44(3):115–7 (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

Biofilms produced by Pseudomonas aeruginosa and by Staphylococcus aureus on model medical devices [comment] Kétyi I. **Acta Microbiol Immunol Hung** 1995; 42(2):221–7. Comment on: Acta Microbiol Immunol Hung 1995;42(2):215–9.
Effect of adhered bacteria on the binding of Acanthamoeba to hydrogel lenses. Gorlin AI, et al. **Arch Ophthalmol** 1996 May;114(5):576–80
Assessment of molecular sieving across bacterial outer membrane of Pseudomonas. Kulkarni SB, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):189–204
Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro. Fleiszig SM, et al. **Infect Immun** 1995 Oct;63(10):4072–7
Pathogenesis of corneal infection: binding of Pseudomonas aeruginosa to specific phospholipids. Panjwani N, et al. **Infect Immun** 1996 May;64(5):1819–25
Pseudomonas aeruginosa strains possess specific adhesins for laminin. Plotkowski MC, et al. **Infect Immun** 1996 Feb; 64(2):600–5
Blood group phenotype determines lectin-mediated adhesion of Pseudomonas aeruginosa to human outer ear canal epithelium. Steuer MK, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):287–95
Lipopolysaccharide outer core is a ligand for corneal cell binding and ingestion of Pseudomonas aeruginosa. Zaidi TS, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):976–86
The effects of short-term contact lens wear on adherence of Pseudomonas aeruginosa to human corneal cells. Harding AS, et al. **J Am Optom Assoc** 1995 Dec; 66(12):775–9
Ferric uptake regulator (Fur) mutants of Pseudomonas aeruginosa demonstrate defective siderophore-mediated iron uptake, altered aerobic growth, and decreased superoxide dismutase and catalase activities. Hassett DJ, et al. **J Bacteriol** 1996 Jul;178(14):3996–4003
Bacteriolytic effect of membrane vesicles from Pseudomonas aeruginosa on other bacteria including pathogens: conceptually new antibiotics. Kadurugamuwa JL, et al. **J Bacteriol** 1996 May;178(10):2767–74
Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia: evidence of interspecies communication. McKenney D, et al. **J Bacteriol** 1995 Dec;177(23):6989–92
Sigma factor-anti-sigma factor interaction in alginate synthesis: inhibition of AlgT by MucA. Xie ZD, et al. **J Bacteriol** 1996 Aug;178(16):4990–6
The measurement of swimming velocity of Vibrio cholerae and Pseudomonas aeruginosa using the video tracking methods. Shigematsu M, et al. **Microbiol Immunol** 1995; 39(10):741–4
The alginate regulator AlgR and an associated sensor FimS are required for twitching motility in Pseudomonas aeruginosa. Whitchurch CB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9839–43
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Pier GB, et al. **Science** 1996 Jan 5;271(5245):64–7
Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)
[Formation of experimental rat bladder calculus and adherence of Pseudomonas aeruginosa to the calculus] Takahata M, et al. **Kansenshogaku Zasshi** 1995 Aug;

PSEUDOMONAS AERUGINOSA

69(8):913–8 (Eng. Abstr.) **(Jpn)**
[Direct suppression of bacteria viability in vitro by antibodies] Pal'tsyn AA, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):662–4 **(Rus)**

RADIATION EFFECTS

Lethal effect induced in Pseudomonas aeruginosa Exposed to Ultraviolet–A radiation. Fernández RO, et al. **Photochem Photobiol** 1996 Aug;64(2):334–9
[Mechanisms of the combined effect of SHF electromagnetic radiation and hydrogen peroxide on the viability of microorganisms] Kuchma TN, et al. **Biofizika** 1996 Mar–Apr;41(2):433–9 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Membrane topology of three Xcp proteins involved in exoprotein transport by Pseudomonas aeruginosa. Bleves S, et al. **J Bacteriol** 1996 Jul;178(14):4297–300

VIROLOGY

Plasmids containing cos ends inhibit the replication of phage phi CTX in Pseudomonas aeruginosa. Xiong G, et al. **Virus Res** 1996 Mar;41(1):77–87
[Cryptic transposable phages of Pseudomonas aeruginosa] Krylov VN, et al. **Genetika** 1995 Nov;31(11):1507–11 (Eng. Abstr.) **(Rus)**
[Introduction of mutator phage D3112 of Pseudomonas aeruginosa into Alcaligenes eutrophus var. metallotollerans (Strain CH34)] Krylov VN. **Genetika** 1996 Jan;32(1):146–9 (Eng. Abstr.) **(Rus)**

PSEUDOMONAS CEPACIA see **BURKHOLDERIA CEPACIA**

PSEUDOMONAS FLUORESCENS

CHEMISTRY

Pseudomonas fluorescens adhesion and transport through porous media are affected by lipopolysaccharide composition. Williams V, et al. **Appl Environ Microbiol** 1996 Jan;62(1):100–4
Structures of decasaccharide and tridecasaccharide tetraphosphates isolated by strong alkaline degradation of O–deacylated lipopolysaccharide of Pseudomonas fluorescens strain ATCC 49271. Knirel YA, et al. **Carbohydr Res** 1995 Dec 27;279:215–26

DRUG EFFECTS

Cesium stress and adaptation in Pseudomonas fluorescens. Appanna VD, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):833–8

ENZYMOLOGY

Measurements of oxidoreductase–like activity of intact bacterial cells by an amperometric method using a membrane–coated electrode. Ikeda T, et al. **Anal Chem** 1996 Jan 1;68(1):192–8
Novel cellulose–binding domains, NodB homologues and conserved modular architecture in xylanases from the aerobic soil bacteria Pseudomonas fluorescens subsp. cellulosa and Cellvibrio mixtus. Millward–Sadler SJ, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):39–48
The purification and properties of phosphonoacetate hydrolase, a novel carbon–phosphorus bond–cleavage enzyme from Pseudomonas fluorescens 23F. McGrath JW, et al. **Eur J Biochem** 1995 Nov 15;234(1):225–30
Cross–reactivity of antibodies raised to Pseudomonas fluorescens protease with extracellular proteins produced by meat–spoiling pseudomonads. Lundy FT, et al. **J Appl Bacteriol** 1996 Jul;81(1):1–6
Purification and characterization of a dipeptidase from Pseudomonas fluorescens ATCC 948. Gobbetti M, et al. **J Dairy Sci** 1996 Mar;79(3):357–65
Chemical modification of bacterial 4–aminobutyrate aminotransferase by phenylglyoxal. Tunnicliff G. **J Enzym Inhib** 1995;9(4):309–16
The non–haem chloroperoxidase from Pseudomonas fluorescens and its relationship to pyrrolnitrin biosynthesis. Kirner S, et al. **Microbiology** 1996 Aug;142 (Pt 8):2129–35
Characterisation of a phospholipase C produced by Pseudomonas fluorescens. Ivanov A, et al. **New Microbiol** 1996 Apr;19(2):113–21

GENETICS

Influence of earthworm activity on gene transfer from Pseudomonas fluorescens to indigenous soil bacteria. Daane LL, et al. **Appl Environ Microbiol** 1996 Feb;62(2):515–21
Cloning and characterization of styrene catabolism genes from Pseudomonas fluorescens ST. Marconi AM, et al. **Appl Environ Microbiol** 1996 Jan;62(1):121–7
Tn5–directed cloning of pqq genes from Pseudomonas fluorescens CHA0: mutational inactivation of the genes results in overproduction of the antibiotic pyoluteorin. Schnider U, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):3856–64
Construction of a modified mini–Tn5 lacZY non–antibiotic marker cassette: ecological evaluation of a lacZY marked Pseudomonas strain in the sugarbeet rhizosphere. Fedi S, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):251–7
A global regulator of secondary metabolite production in Pseudomonas fluorescens Pf–5. Corbell N, et al. **J Bacteriol** 1995 Nov;177(21):6230–6
Site directed chromosomal marking of a fluorescent pseudomonad isolated from the phytosphere of sugar beet; stability and potential for marker gene transfer. Bailey MJ, et al. **Mol Ecol** 1995 Dec;4(6):755–63
The phylogenetic distribution of a transposable dioxygenase from the Niagara River watershed. Nakatsu CH, et al. **Mol Ecol** 1995 Oct;4(5):593–603
Transcriptional regulation of the iron–responsive sigma factor gene pbrA. Sexton R, et al. **Mol Gen Genet** 1996 Jan 15;250(1):50–8
Physical and genetic map of the Pseudomonas fluorescens SBW25 chromosome. Rainey PB, et al. **Mol Microbiol** 1996 Feb;19(3):521–33
A chromosomal locus required for copper resistance, competitive fitness, and cytochrome c biogenesis in Pseudomonas fluorescens. Yang CH, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7315–20

GROWTH & DEVELOPMENT

Rate of growth of Pseudomonas fluorescens in donated blood. Gibb AP, et al. **J Clin Pathol** 1995 Aug;48(8):717–8

ISOLATION & PURIFICATION

Site directed chromosomal marking of a fluorescent pseudomonad isolated from the phytosphere of sugar beet; stability and potential for marker gene transfer. Bailey MJ, et al. **Mol Ecol** 1995 Dec;4(6):755–63

METABOLISM

Bioconversion of 2,4–diamino–6–nitrotoluene to a novel metabolite under anoxic and aerobic conditions. Gilcrease PC, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4209–14
Degradation of cocaine by a mixed culture of Pseudomonas fluorescens MBER and Comamonas acidovorans MBLF. Lister DL, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):94–9
Tn5–directed cloning of pqq genes from Pseudomonas fluorescens CHA0: mutational inactivation of the genes results in overproduction of the antibiotic pyoluteorin. Schnider U, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):3856–64
Aluminum tolerance of Pseudomonas fluorescens in a phosphate–deficient medium. Appanna VD, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):404–11
The sigma factor sigma s affects antibiotic production and biological control activity of Pseudomonas fluorescens Pf–5. Sarniguet A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12255–9

PHYSIOLOGY

Survival of, and induced stress resistance in, carbon–starved Pseudomonas fluorescens cells residing in soil. van Overbeek LS, et al. **Appl Environ Microbiol** 1995 Dec; 61(12):4202–8
Pseudomonas fluorescens adhesion and transport through porous media are affected by lipopolysaccharide composition. Williams V, et al. **Appl Environ Microbiol** 1996 Jan;62(1):100–4
Some factors affecting the airborne survival of bacteria outdoors. Handley BA, et al. **J Appl Bacteriol** 1995 Oct; 79(4):368–78
Evaluation of cytogenetic effects of a naturally occurring non–ice–nucleation Pseudomonas fluorescens strain in Chinese hamster ovary (CHO) cells. Caruso P, et al. **Teratog Carcinog Mutagen** 1995;15(3):103–8

PSEUDOMONAS INFECTIONS

Infectious complications after epidural anesthesia [letter] Kindler CH, et al. **Anesthesiology** 1996 Aug;85(2):444–5
Pseudomonas keratitis associated with biofilm formation on a disposable soft contact lens [letter] Stapleton F, et al. **Br J Ophthalmol** 1995 Sep;79(9):864–5
Bacterial keratitis in trichothiodystrophy. O'Brien TP, et al. **Can J Ophthalmol** 1995 Aug;30(5):270–1
Pseudomonas aeruginosa pneumonia/sepsis as an initial opportunistic infection in an HIV patient. Amundson DE, et al. **Mil Med** 1996 Mar;161(3):179
Ecthyma gangrenosum. Palmer A, et al. **Trop Doct** 1996 Apr; 26(2):80
[Nosocomial bacterial infection in comprehensive intensive care unit] Du B, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):262–6 (Eng. Abstr.) **(Chi)**
[Combination therapy with arbekacin and fosfomycin against postoperative severe mixed–pneumonia of MRSA in primary lung cancer patients] Harada R, et al. **Kyobu Geka** 1995 Sep;48(10):836–40 (Eng. Abstr.) **(Jpn)**
[Endophthalmitis caused by Fusarium moniliforme and Pseudomonas species] Cvetković L, et al. **Vojnosanit Pregl** 1994 Sep–Oct;51(5):429–34 **(Scr)**

BLOOD

Blood group phenotype determines lectin–mediated adhesion of Pseudomonas aeruginosa to human outer ear canal epithelium. Steuer MK, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):287–95
Role of LPS length in clearance rate of bacteria from the bloodstream in mice. Ohno A, et al. **Microbiology** 1995 Oct;141 (Pt 10):2749–56

COMPLICATIONS

Potentially lethal bacterial infection associated with varicella zoster virus. Pollard AJ, et al. **BMJ** 1996 Aug 3; 313(7052):283–5
Cystic fibrosis and the pseudomonads. Wright KC. **Br J Biomed Sci** 1996 Jun;53(2):140–5 (51 ref.)
Chorioamnionitis due to pseudomonas aeruginosa: a complication of prolonged antibiotic therapy for premature rupture of membranes. Kyle P, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):181–3
Pseudomonas aeruginosa infections and HIV [letter; comment] Moore D, et al. **Genitourin Med** 1995 Oct; 71(5):336. Comment on: Genitourin Med 1995 Apr;71(2):73–7.
Successful prevention of recurrent pneumonia caused by Pseudomonas aeruginosa in a patient with AIDS [letter] Ainsworth J. **Int J STD AIDS** 1995 Nov–Dec;6(6):454–5
Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Byrne S, et al. **J Antimicrob Chemother** 1995 Jul; 36 Suppl A:135–43
Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Bennekov T, et al. **J Clin Microbiol** 1996 Jan; 34(1):202–4
Evaluation of E–Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. Marley EF, et al. **J Clin Microbiol** 1995 Dec;33(12):3191–3
Ecthyma gangrenosum associated with aplastic anemia. Chun WH, et al. **J Korean Med Sci** 1996 Feb;11(1):64–7
Effect of aerobic bacteriology on the clinical presentation and treatment results of chronic suppurative otitis media. Vartiainen E, et al. **J Laryngol Otol** 1996 Apr;110(4):315–8
Images in clinical medicine. Cauliflower ear. Khalak R, et al. **N Engl J Med** 1996 Aug 8;335(6):399
Identifying the killer in cystic fibrosis [comment] Hearst JE, et al. **Nat Med** 1995 Jul;1(7):626–7. Comment on: Nat Med 1995 Jul;1(7):661–6.
Breast abscess with lethal septicemia due to Pseudomonas aeruginosa in a patient with AIDS. Roca B, et al. **Presse Med** 1996 May 18;25(17):803–4
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta–analysis of benefits and risks. Mukhopadhyay S, et al. **Thorax** 1996 Apr;51(4):364–8
[Influence of bacterial infection and formalin vapors on the course of ovalbumin induced experimental bronchospastic reaction in guinea pigs] Pindel B, et al. **Pneumonol Alergol Pol** 1995;63(5–6):253–8 (Eng. Abstr.) **(Pol)**
[Histology of the respiratory system after exposure to bacterial infection and formalin vapors used to induce experimental bronchospasm] Sachs K, et al. **Pneumonol Alergol Pol** 1995;63(5–6):259–63 (Eng. Abstr.) **(Pol)**
[Spontaneous bilateral pneumothorax (letter)] Alemany Francés ML, et al. **Arch Bronconeumol** 1996 Apr; 32(4):211–2 **(Spa)**
[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Skin rash from a tropical island. Golledge CL. **Aust Fam Physician** 1996 Jul;25(7):1167
Fluorescence–based DNA fingerprinting elucidates nosocomial transmission of phenotypically variable Pseudomonas aeruginosa in intensive care units. Grundmann H, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1057–62
Case of the month: a 20–month–old boy with fever, respiratory distress and necrotizing skin lesions. Alsaeid K, et al. **Eur J Pediatr** 1996 Apr;155(4):341–2
Pseudomonas spp. associated vegetative endocarditis in two horses. Travers CW, et al. **J S Afr Vet Assoc** 1995 Sep; 66(3):172–6
Idiopathic chronic hypertrophic craniocervical pachymeningitis: case report [letter; comment] Uemura K, et al. **Neurosurgery** 1995 Aug;37(2):358. Comment on: Neurosurgery 1994 Dec;35(6):1144–9.
Complicated multiorganism peritonitis [clinical conference] Piraino B, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):394–400
Severity and predicted outcome of postoperative Pseudomonas aeruginosa infections. Kodama T, et al. **Surg Today** 1995;25(8):672–8

DRUG THERAPY

In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Dohar JE, et al. **Am J Otol** 1996 Mar;17(2):207–9
Effect of sodium nitroprusside and diethylcarbamazine on hypoxic pulmonary vasoconstriction and regional distribution of pulmonary blood flow in experimental pneumonia. Light RB. **Am J Respir Crit Care Med** 1996 Jan;153(1):325–30

Aminoglycoside toxicity after sternal wound irrigations [letter] Hernandez JE, et al. **Ann Thorac Surg** 1996 Feb; 61(2):772

Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Brouqui P, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2423-5

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Cappelletty DM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1797-801

Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis. Opal SM, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2813-5

Critical influence of timing of administration of granulocyte colony-stimulating factor on antibacterial effect in experimental endocarditis due to Pseudomonas aeruginosa. Vignes S, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2702-7

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Weiss K, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2411-4

Effects of Chinese medicinal herbs on a rat model of chronic Pseudomonas aeruginosa lung infection. Song Z, et al. **APMIS** 1996 May;104(5):350-4

Pseudomonas ear infections [letter] Pien FD. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):898-9

Changes of nitric oxide and protective effects of nitric oxide inhibitors in newborn rats with sepsis. Shi Y, et al. **Chin Med Sci J** 1995 Sep;10(3):174-7

Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. Raz R, et al. **Clin Infect Dis** 1995 Jul;21(1):194-5

Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa. Sato A, et al. **Drugs** 1995;49 Suppl 2:253-5

Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem [letter] Miró E, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):731-2

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Byrne S, et al. **J Antimicrob Chemother** 1995 Jul; 36 Suppl A:135-43

Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. Xiong YQ, et al. **J Antimicrob Chemother** 1995 May;35(5):697-706

Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model. Owusu-Ababio G, et al. **J Med Microbiol** 1995 Nov;43(5):368-76

Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. Kim IT, et al. **Korean J Ophthalmol** 1996 Jun;10(1):8-17

Aminoglycoside dosing: one, two or three times a day? [see comments] McLean AJ, et al. **Med J Aust** 1996 Jan 1; 164(1):39-42 (54 ref.). Comment in: Med J Aust 1996 May 20;164(10):636-7.

The effects of experimental splenic autotransplantation and imipenem-cilastatin treatment in postsplenectomy Pseudomonas aeruginosa sepsis. Eskitürk A, et al. **Res Exp Med (Berl)** 1995;195(3):163-9

Effect of recombinant human granulocyte colony-stimulating factor on hemodynamic and cytokine response in a porcine model of Pseudomonas sepsis. Haberstroh J, et al. **Shock** 1995 Sep;4(3):216-24

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Fujii T, et al. **Thorax** 1995 Dec;50(12):1246-52

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Mukhopadhyay S, et al. **Thorax** 1996 Apr;51(4):364-8

[The effect of different topical agents on pseudomonas infection of burn wound] Guo Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Nov;11(6):421-4 (Eng. Abstr.) **(Chi)**

[Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis] Canis F, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):343-51 (Eng. Abstr.) **(Fre)**

[Effects of azithromycin on the virulence of Pseudomonas aeruginosa] Reinert P. **Pathol Biol (Paris)** 1995 Jun; 43(6):551-3 (Eng. Abstr.) **(Fre)**

[Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer] Gagnadoux F, et al. **Rev Mal Respir** 1996; 13(1):55-60 (Eng. Abstr.) **(Fre)**

[Resistance of Pseudomonas mallei to tetracyclines: assessment of the feasibility of chemotherapy] Manzeniuk IN, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11-12):40-4 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Application of exponential smoothing for nosocomial infection surveillance. Ngo L, et al. **Am J Epidemiol** 1996 Mar 15;143(6):637-47

Epidemiological characteristics of Pseudomonas aeruginosa strains causing infection in an Italian general hospital. A one-year surveillance. Grigis A, et al. **Eur J Epidemiol** 1995 Jun;11(3):339-44

An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. Spencer RC. **J Antimicrob Chemother** 1996 Feb; 37(2):295-301

Usefulness of a computerized expert system associated with systematic O-serotyping for the early detection of outbreaks of hospital acquired infections and for the presumptive antibiotic therapy of Pseudomonas aeruginosa infections. Watine J, et al. **Pathol Biol (Paris)** 1996 Feb; 44(2):125-31

Pseudomonas aeruginosa bacteraemia in Enugu, Nigeria. A review of 24 cases. Ozumba UC. **Trop Geogr Med** 1995; 47(5):193-6

ETIOLOGY

Late bacterial scleritis following beta irradiation presenting as orbital cellulitis. Furness GA, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):153-5

Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. van Asperen IA, et al. **BMJ** 1995 Nov 25;311(7017):1407-10

Subretinal Pseudomonas abscess after lung transplantation [letter] Webber SK, et al. **Br J Ophthalmol** 1995 Sep; 79(9):861-6

Catheter-related bacteremia due to Pseudomonas paucimobilis in neutropenic cancer patients: report of two cases [letter] Salazar R, et al. **Clin Infect Dis** 1995 Jun; 20(6):1573-4

Pathogenesis of corneal infection: binding of Pseudomonas aeruginosa to specific phospholipids. Panjwani N, et al. **Infect Immun** 1996 May;64(5):1819-25

Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Tang HB, et al. **Infect Immun** 1996 Jan;64(1):37-43

Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. O'Callaghan RJ, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):534-43

The neonatal laryngoscope as a potential source of cross-infection [letter; comment] Neal TJ, et al. **J Hosp Infect** 1995 Aug;30(4):315-7. Comment on: J Hosp Infect 1995 Apr;29(4):315-6.

Incarcerated paraumbilical incisional hernia and abscess--complications of a spilled gallstone. Freedman AN, et al. **J Laparoendosc Surg** 1995 Jun;5(3):189-91

Ecthyma gangrenosum occurring at sites of iatrogenic trauma in pediatric oncology patients. Murphy O, et al. **Med Pediatr Oncol** 1996 Jul;27(1):62-3

Outbreaks of postoperative bacterial endophthalmitis caused by intrinsically contaminated ophthalmic solutions--Thailand, 1992, and Canada, 1993. **MMWR Morb Mortal Wkly Rep** 1996 Jun 14;45(23):491-4

Fatal pneumonia complicating hypothermia for the treatment of postoperative junctional ectopic tachycardia. Matthys D, et al. **Pediatr Cardiol** 1995 Nov-Dec;16(6):294-6

Ruptured hepatic hydatid cyst and an unusual case of pseudomonas septicaemia. Fulton JO. **S Afr J Surg** 1995 Sep;33(3):128-30

Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Pier GB, et al. **Science** 1996 Jan 5;271(5245):64-7

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16-23;24(39):1882-7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Pseudomonas aeruginosa mediastinitis after transesophageal echocardiography (letter)] Lalanne B, et al. **Presse Med** 1996 Jun 8;25(20):952 **(Fre)**

[Pseudomonas aeruginosa and mucoviscidosis] Lenoir G. **Rev Pneumol Clin** 1995;51(3):151-9 (Eng. Abstr.) **(Fre)**

[Protozoan infection (Blastocystis hominis) concomitant with Pseudomonas sp. peritonitis in continuous ambulatory peritoneal dialysis (CAPD)] Boccardo G, et al. **Minerva Urol Nefrol** 1996 Mar;48(1):55-8 (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Immunity to respiratory Pseudomonas aeruginosa infection: the role of gut-derived T helper cells and immune serum. Dunkley ML, et al. **Adv Exp Med Biol** 1995;371B:771-5

Immunity to respiratory Pseudomonas aeruginosa infection: P. aeruginosa-specific T cells arising after intestinal immunization. Dunkley ML, et al. **Adv Exp Med Biol** 1995; 371B:755-9

Local Pseudomonas instillation induces contralateral lung injury and plasma cytokines. Terashima T, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1600-5

Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor. Vogels MT, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1744-7

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418-24 (84 ref.)

Immunoprophyiaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. Donta ST, et al. **J Infect Dis** 1996 Sep;174(3):537-43

Analysis of naturally occurring antibodies to mucoid Pseudomonas aeruginosa in cystic fibrosis patients [letter; comment] Pier GB. **J Infect Dis** 1996 Feb;173(2):513-5. Comment on: J Infect Dis 1995 Aug;172(2):453-61.

IgG subclass responses to Pseudomonas aeruginosa a- and b-type flagellins in patients with cystic fibrosis: a prospective study. Lagacé J, et al. **J Med Microbiol** 1995 Oct;43(4):270-6

A complement to host defence [news; comment] Henson P. **Nature** 1996 Sep 5;383(6595):25-6. Comment on: Nature 1996 Sep 5;383(6595):86-9.

The C5a chemoattractant receptor mediates mucosal defence to infection [see comments] Höpken UE, et al. **Nature** 1996 Sep 5;383(6595):86-9. Comment in: Nature 1996 Sep 5;383(6595):25-6.

METABOLISM

Scavenging of neutrophil-derived superoxide anion by 1-hydroxyphenazine, a phenazine derivative associated with chronic Pseudomonas aeruginosa infection: relevance to cystic fibrosis. Muller M. **Biochim Biophys Acta** 1995 Dec 12;1272(3):185-9

MICROBIOLOGY

Epidemiological characterization of human and environmental Pseudomonas aeruginosa strains: use of plasmid pattern analysis in addition to other typing methods. Orsi N, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):653-64

Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. Porco FV, et al. **Ann Pharmacother** 1995 Nov;29(11):1122-3

Pseudomonas aeruginosa in otitis externa. A particular variety of the bacteria? Sundström J, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):833-6

The clinical significance of Pseudomonas aeruginosa isolation from stool of neonates. Somekh E, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):108-9

Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Maniatis AN, et al. **Clin Infect Dis** 1995 Aug;21(2):437-9

Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Giamarellos-Bourboulis EJ, et al. **Drugs** 1995;49 Suppl 2:203-4

Use of pulsed-field gel electrophoresis as an epidemiologic tool during an outbreak of Pseudomonas aeruginosa lung infections in an intensive care unit. Talon D, et al. **Intensive Care Med** 1995 Dec;21(12):996-1002

Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Bennekov T, et al. **J Clin Microbiol** 1996 Jan; 34(1):202-4

Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. Marley EF, et al. **J Clin Microbiol** 1995 Dec;33(12):3191-3

Parapharyngeal abscess from Pseudomonas aeruginosa infection in an HIV positive patient [letter] Sanderson RJ, et al. **J Infect** 1995 Sep;31(2):174

Pseudomonas pickettii pneumonia in a diabetic patient. Ahkee S, et al. **J Ky Med Assoc** 1995 Nov;93(11):511-3

The influence of exo-enzyme S and proteases on endogenous Pseudomonas aeruginosa bacteraemia in mice. Hirakata Y, et al. **J Med Microbiol** 1995 Oct;43(4):258-61

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Cheng K, et al. **Lancet** 1996 Sep 7;348(9028):639-42

Pseudomonas aeruginosa exotoxin A antibodies in rapidly deteriorating chronic leg ulcers [letter] Danielsen L, et al. **Lancet** 1996 Jan 27;347(8996):265

Pseudomonas (Burkholderia) cepacia in children with cystic fibrosis: epidemiological investigation by analysis or restriction fragment length polymorphism. Valcin M, et al. **Pathol Biol (Paris)** 1996 May;44(5):442-6

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351-6 (59 ref.)

New approaches to Pseudomonas aeruginosa lower respiratory tract infections. Matsumoto K. **Verh K Acad Geneeskd Belg** 1995;57(2):109-22

[Molecular typing by pulsed field gel electrophoresis of Stenotrophomonas maltophilia isolated in a department of hematology] Fabe C, et al. **Pathol Biol (Paris)** 1996 May; 44(5):435-41 (Eng. Abstr.) **(Fre)**

[Molecular typing by pulsed field gel electrophoresis of Pseudomonas (Burkholderia) cepacia isolated from a nosocomial infection] Rodriguez P, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):352-7 (Eng. Abstr.) **(Fre)**

[Drug-resistance patterns of clinical isolates of Pseudomonas aeruginosa in regard to their lipopolysaccharide-chain sizes] Hasegawa M, et al. **Kansenshogaku Zasshi** 1996 Jun; 70(6):605-12 (Eng. Abstr.) **(Jpn)**

[Bacteriopyncnosis--morphological expression of bacterial death in an animal] Pal'tsyn AA, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):665-8 **(Rus)**

[The epidemiological markers of Pseudomonas aeruginosa

strains circulating in different types of hospitals] Makarova NV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep-Oct;(5):13-5 (Eng. Abstr.) **(Rus)**

MORTALITY

Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crouch Brewer S, et al. **Chest** 1996 Apr; 109(4):1019-29

[Pseudomonas aeruginosa septicemia. Host-related risk factors in 82 episodes] Roche O, et al. **Presse Med** 1995 Sep 2-9;24(25):1164-6 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Effect of vitamin A deficiency on the early response to experimental Pseudomonas keratitis. Twining SS, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):511-22

Susceptibility to local and systemic bacterial infections in intercellular adhesion molecule 1-deficient transgenic mice. Sarman G, et al. **J Infect Dis** 1995 Oct;172(4):1001-6

Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Potts SB, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct;15(5):707-21

PHYSIOPATHOLOGY

Pulmonary artery endothelial cell function in swine pseudomonas sepsis. Kadletz M, et al. **J Surg Res** 1996 Jan;60(1):186-92

PREVENTION & CONTROL

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Johansen HK, et al. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 1):1337-46

Tumor necrosis factor alpha plus interleukin 1 beta treatment protects granulocytopenic mice from Pseudomonas aeruginosa lung infection: role of an unusual inflammatory response. Amura CR, et al. **APMIS** 1995 Jun;103(6):447-59

Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594-604 (65 ref.)

Histopathology of the lung following intratracheal challenge with live Pseudomonas aeruginosa in intestinally immunized rats. Wilson NR, et al. **Immunol Cell Biol** 1995 Oct;73(5):440-5

Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Barletta JP, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):20-8

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. Donta ST, et al. **J Infect Dis** 1996 Sep;174(3):537-43

Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB, et al. **J Pediatr** 1995 Nov; 127(5):711-7

Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Hughes EE, et al. **Vaccine** 1995 Dec; 13(18):1750-3

[Assessment of effectiveness of AgSD-ZnSD-Azone cream, negative ion irradiation and "moisture burn ointment" in prevention of burn wound infection as judged by changes in LPS, TNF and ET levels] Sun S, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):332-4 (Eng. Abstr.) **(Chi)**

[Immunomodulation in Pseudomonas urinary infection] Urban M, et al. **Rozhl Chir** 1995 Nov;74(7):319-21 (Eng. Abstr.) **(Cze)**

RADIOGRAPHY

Pneumonia with an enlarged cardiac silhouette. Tirdel GB, et al. **Chest** 1996 May;109(5):1380-2

SURGERY

[Abscess of the skull base—therapy and reconstruction after zygoma resection] Prochno T, et al. **Zentralbl Neurochir** 1996;57(2):97-102 (Eng. Abstr.) **(Ger)**

THERAPY

Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Johansen HK, et al. **Clin Exp Immunol** 1996 Feb;103(2):212-8

Efficacy of topical gentamicin treatment after 193-nm photorefractive keratectomy in an experimental Pseudomonas keratitis model. Frucht-Pery J, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug;233(8):532-4

Potential hazards of combination immunotherapy in the treatment of experimental septic shock. Opal SM, et al. **J Infect Dis** 1996 Jun;173(6):1415-21

Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin. Ishibashi K, et al. **J Urol** 1996 Jun;155(6):2094-7

Use of the rotating hinge for salvage of the infected total knee arthroplasty. Berman AT, et al. **Orthopedics** 1996 Jan; 19(1):73-6

Pseudomonas peritonitis treated with simultaneous catheter replacement and removal [letter] Mayo RR, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):389-90

TRANSMISSION

Survey of Pseudomonas aeruginosa contamination in human beings and laboratory animals. Urano T, et al. **Exp Anim** 1995 Jul;44(3):233-9

VETERINARY

Complications of indwelling, silastic central venous access catheters in dogs and cats. Blaiset MA, et al. **J Am Anim Hosp Assoc** 1995 Sep-Oct;31(5):379-84

Granulomatous lesions caused by Pseudomonas aeruginosa in the ostrich (Struthio camelus). Momotani E, et al. **J Comp Pathol** 1995 Apr;112(3):273-82

What is your diagnosis?. Infected fracture with secondary osteomyelitis. Ferguson JF. **J Small Anim Pract** 1995 Aug; 36(8):348, 373-4

Detection of Pseudomonas aeruginosa from ovine fleece washings by PCR amplification of 16S ribosomal RNA. Kingsford NM, et al. **Vet Microbiol** 1995 Nov; 47(1-2):61-70

PSEUDOMONAS PHAGE PHI 6 see BACTERIOPHAGE PHI 6

PSEUDOMONAS PHAGES

[The efficacy of bacteriophage preparations in treating inflammatory urologic diseases] Perepanova TS, et al. **Urol Nefrol (Mosk)** 1995 Sep-Oct;(5):14-7 (Eng. Abstr.) **(Rus)**

GENETICS

Construction and analysis of a bacteriophage phi 6 gene 14 nonsense mutant. Casini G, et al. **Virology** 1996 Feb 15; 216(2):455-8

[Cryptic transposable phages of Pseudomonas aeruginosa] Krylov VN, et al. **Genetika** 1995 Nov;31(11):1507-11 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Introduction of Pseudomonas aeruginosa mutator phage D3112 into Alcaligenes eutrophus strain CH34. Krylov V, et al. **Res Microbiol** 1995 Mar-Apr;146(3):245-50

METABOLISM

Solution structure of the single-stranded DNA binding protein of the filamentous Pseudomonas phage Pf3: similarity to other proteins binding to single-stranded nucleic acids. Folmer RH, et al. **EMBO J** 1995 Sep 1; 14(17):4132-42

PHYSIOLOGY

Plasmids containing cos ends inhibit the replication of phage phi CTX in Pseudomonas aeruginosa. Xiong G, et al. **Virus Res** 1996 Mar;41(1):77-87

[Origin and properties of Pseudomonas aeruginosa PAO1 clones surviving after induction of prophages-transposons] Krylov VN, et al. **Genetika** 1995 Aug;31(8):1065-72 (Eng. Abstr.) **(Rus)**

PSEUDOMONAS PSEUDOMALLEI see BURKHOLDERIA PSEUDOMALLEI

PSEUDOMONAS PUTIDA

CHEMISTRY

ATP binding to the sigma 54-dependent activator XylR triggers a protein multimerization cycle catalyzed by UAS DNA. Pérez-Martín J, et al. **Cell** 1996 Jul 26;86(2):331-9

A novel cell surface polysaccharide in Pseudomonas putida WCS358, which shares characteristics with Escherichia coli K antigens, is not involved in root colonization. de Weger LA, et al. **J Bacteriol** 1996 Apr;178(7):1955-61

ENZYMOLOGY

Purification of 2,3-dihydroxybiphenyl 1,2-dioxygenase from Pseudomonas putida OU83 and characterization of the gene (bphC). Khan AA, et al. **Appl Environ Microbiol** 1996 May; 62(5):1825-30

Purification and characterization of dihydroorotase from Pseudomonas putida. Ogawa J, et al. **Arch Microbiol** 1995 Nov;164(5):353-7

Bacterial morphinone reductase is related to Old Yellow Enzyme. French CE, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):671-8

The purification and crystallisation of 2,5-diketocamphane 1,2-monooxygenase and 3,6-diketocamphane 1,6-monooxygenase from Pseudomonas putida NCIMB 10007. McGhie EJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):29S

Coordination of the Rieske-type [2Fe-2S] cluster of the terminal iron-sulfur protein of Pseudomonas putida benzene 1,2-dioxygenase, studied by one- and two-dimensional electron spin-echo envelope modulation spectroscopy. Shergill JK, et al. **Biochemistry** 1995 Dec 26;34(51):16533-42

The 2Fe2S centres of the 2-oxo-1,2-dihydroquinoline 8-monooxygenase from Pseudomonas putida 86 studied by EPR spectroscopy. Rosche B, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):177-9

Gene cloning and characterization of Pseudomonas putida L-methionine-alpha-deamino-gamma-mercaptomethane-lyase. Hori H, et al. **Cancer Res** 1996 May 1;56(9):2116-22

Purification of active E1 alpha 2 beta 2 of Pseudomonas putida branched-chain-oxoacid dehydrogenase. Hester K, et al. **Eur J Biochem** 1995 Nov 1;233(3):828-36

Structural analysis of the L-methionine gamma-lyase gene from Pseudomonas putida. Inoue H, et al. **J Biochem (Tokyo)** 1995 May;117(5):1120-5

Uncoupling oxygen transfer and electron transfer in the oxygenation of camphor analogues by cytochrome P450-CAM. Direct observation of an intermolecular isotope effect for substrate C-H activation. Kadkhodayan S, et al. **J Biol Chem** 1995 Nov 24;270(47):28042-8

The refined X-ray structure of muconate lactonizing enzyme from Pseudomonas putida PRS2000 at 1.85 A resolution. Helin S, et al. **J Mol Biol** 1995 Dec 15;254(5):918-41

[Modification of the ortho-route in Pseudomonas putida strain 87: purification and properties of dienlactone hydrolase] Solianikova IP, et al. **Biokhimiia** 1995 Aug; 60(8):1251-60 (Eng. Abstr.) **(Rus)**

GENETICS

Nondisruptive detection of activity of catabolic promoters of Pseudomonas putida with an antigenic surface reporter system. Cebolla A, et al. **Appl Environ Microbiol** 1996 Jan; 62(1):214-20

Application of reverse transcriptase PCR for monitoring expression of the catabolic dmpN gene in a phenol-degrading sequencing batch reactor. Selvaratnam S, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3981-5

Structure of catechol 2,3-dioxygenase gene encoded in chromosomal DNA of Pseudomonas putida KF715. Lee J, et al. **Biochem Biophys Res Commun** 1996 Jul 25; 224(3):831-6

Nucleotide sequence of salicylate hydroxylase gene and its 5'-flanking region of Pseudomonas putida KF715. Lee J, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):544-8

Structure of chromosomal DNA coding for Pseudomonas putida S-1 salicylate hydroxylase. Suzuki K, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):154-6

Bacterial plasmid conjugation on semi-solid surfaces monitored with the green fluorescent protein (GFP) from Aequorea victoria as a marker. Christensen BB, et al. **Gene** 1996;173(1 Spec No):59-65

Analysis of the rpoD gene encoding the principal sigma factor of Pseudomonas putida. Fujita M, et al. **Gene** 1995 Dec 29;167(1-2):93-8

VTR expression cassettes for engineering conditional phenotypes in Pseudomonas: activity of the Pu promoter of the TOL plasmid under limiting concentrations of the XylR activator protein. Pérez-Martín J, et al. **Gene** 1996 Jun 12;172(1):81-6

Polymerase chain reaction for verification of fluorescent colonies of Erwinia chrysanthemi and Pscudomonas putida WCS358 in immunofluorescence colony staining. van der Wolf JM, et al. **J Appl Bacteriol** 1995 Nov;79(5):569-77

Formation of indigo and related compounds from indolecarboxylic acids by aromatic acid-degrading bacteria: chromogenic reactions for cloning genes encoding dioxygenases that act on aromatic acids. Eaton RW, et al. **J Bacteriol** 1995 Dec;177(23):6983-8

p-Cumate catabolic pathway in Pseudomonas putida Fl: cloning and characterization of DNA carrying the cmt operon. Eaton RW. **J Bacteriol** 1996 Mar;178(5):1351-62

Expression of the TOL plasmid xylS gene in Pseudomonas putida occurs from a alpha 70-dependent promoter or from alpha 70- and alpha 54-dependent tandem promoters according to the compound used for growth. Gallegos MT, et al. **J Bacteriol** 1996 Apr;178(8):2356-61

The Pseudomonas putida peptidoglycan-associated outer membrane lipoprotein is involved in maintenance of the integrity of the cell cell envelope. Rodríguez-Herva JJ, et al. **J Bacteriol** 1996 Mar;178(6):1699-706

Identification of the repressor subdomain within the signal reception module of the prokaryotic enhancer-binding protein XylR of Pseudomonas putida. Pérez-Martín J, et al. **J Biol Chem** 1996 Apr 5;271(14):7899-902

Physical and functional analysis of the prokaryotic enhancer of the sigma 54-promoters of the TOL plasmid of Pseudomonas putida. Pérez-Martín J, et al. **J Mol Biol** 1996 May 17;258(4):562-74

In vitro activities of an N-terminal truncated form of XylR, a sigma 54-dependent transcriptional activator of Pseudomonas putida. Pérez-Martín J, et al. **J Mol Biol** 1996 May 17;258(4):575-87

Sequence motifs in a flagellin of Pseudomonas putida [letter; comment] Jank B, et al. **Microbiology** 1995 Jul;141 (Pt 7):1491-2. Comment on: Microbiology 1994 Aug;140 (Pt 8):2019-31.

The use of two-dimensional gradient plates to investigate the range of conditions under which conjugal plasmid transfer occurs. Venables WA, et al. **Microbiology** 1995 Oct;141 (Pt 10):2713-8

Characterization of type II protein secretion (xcp) genes in

the plant growth-stimulating Pseudomonas putida, strain WCS358. de Groot A, et al. **Mol Gen Genet** 1996 Mar 7;250(4):491-504

Multiple outer membrane receptors for uptake of ferric pseudobactins in Pseudomonas putida WCS358. Koster M, et al. **Mol Gen Genet** 1995 Oct 25;248(6):735-43

Activation of the transcriptional regulator XylR of Pseudomonas putida by release of repression between functional domains. Fernández S, et al. **Mol Microbiol** 1995 Apr;16(2):205-13

sigma54-dependent transcription of the Pseudomonas putida xylS operon is influenced by the IIANtr protein of the phosphotransferase system in Escherichia coli. Du Y, et al. **Res Microbiol** 1996 Mar-Apr;147(3):129-32

[Selection and properties of totally phage-resistant mutant Pseudomonas putida PpG1] Krylov VN, et al. **Genetika** 1996 Mar;32(3):348-53 (Eng. Abstr.) **(Rus)**

METABOLISM

Catabolite repression of the toluene degradation pathway in Pseudomonas putida harboring pWW0 under various conditions of nutrient limitation in chemostat culture. Duetz WA, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):601-6

Maintenance and induction of naphthalene degradation activity in Pseudomonas putida and an Alcaligenes sp. under different culture conditions. Guerin WF, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4061-8

Transformations of morphine alkaloids by Pseudomonas putida M10. Long MT, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3645-9

Possible regulatory role for nonaromatic carbon sources in styrene degradation by Pseudomonas putida CA-3. O'Connor K, et al. **Appl Environ Microbiol** 1995 Feb; 61(2):544-8

Application of reverse transcriptase PCR for monitoring expression of the catabolic dmpN gene in a phenol-degrading sequencing batch reactor. Selvaratnam S, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3981-5

Stoichiometry of BkdR to substrate DNA in Pseudomonas putida. Huang N, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):315-9

Carbon catabolite repression of phenol degradation in Pseudomonas putida is mediated by the inhibition of the activator protein PhlR. Müller C, et al. **J Bacteriol** 1996 Apr;178(7):2030-6

Repression of 4-hydroxybenzoate transport and degradation by benzoate: a new layer of regulatory control in the Pseudomonas putida beta-ketoadipate pathway. Nichols NN, et al. **J Bacteriol** 1995 Dec;177(24):7033-40

Genetic evidence for interdomain regulation of the phenol-responsive final sigma54-dependent activator DmpR. Ng LC, et al. **J Biol Chem** 1996 Jul 19; 271(29):17281-6

Direct regulation of the ATPase activity of the transcriptional activator DmpR by aromatic compounds. Shingler V, et al. **Mol Microbiol** 1995 Aug;17(3):505-13

Structure and characterization of isopyoverdin from Pseudomonas putida BTP1 and its relation to the biogenetic pathway leading to pyoverdins. Jacques P, et al. **Z Naturforsch [C]** 1995 Sep-Oct;50(9-10):622-9

PHYSIOLOGY

Low temperature growth, freezing survival, and production of antifreeze protein by the plant growth promoting rhizobacterium Pseudomonas putida GR12-2. Sun X, et al. **Can J Microbiol** 1995 Sep;41(9):776-84

A transposon for green fluorescent protein transcriptional fusions: application for bacterial transport experiments. Burlage RS, et al. **Gene** 1996;173(1 Spec No):53-8

PSEUDOMONIC ACID see MUPIROCIN

PSEUDOMYXOMA PERITONEI

[Pseudomyxoma peritonei] Andreassen G. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2783 (Eng. Abstr.) **(Nor)**

[Peritoneal pseudomyxoma] Sánchez Muñoz LA, et al. **Rev Clin Esp** 1995 Nov;195(11):781-6 (20 ref.) **(Spa)**

[Peritoneal pseudomyxoma and liver metastasis (letter)] Serrano Lira F, et al. **Rev Esp Enferm Dig** 1995 Sep; 87(9):684-5 **(Spa)**

DIAGNOSIS

Pseudomyxoma peritonei. Walensky RP, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):471-4

Case report: pseudomyxoma extraperitonei: an unusual presentation mimicking a hugh hydronephrotic kidney. Mor Y, et al. **Clin Radiol** 1996 Mar;51(3):221-2

A case of retroperitoneal pseudomyxoma. Baba Y, et al. **Radiat Med** 1995 Sep-Oct;13(5):247-9

DRUG THERAPY

Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. Niwa K, et al. **Gynecol Oncol** 1995 Dec;59(3):398-400

ETIOLOGY

Pseudomyxoma peritonei. Fox H. **Br J Obstet Gynaecol** 1996 Mar;103(3):197-8

PATHOLOGY

Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Cuatrecasas M, et al. **Am J Surg Pathol** 1996 Jun;20(6):739-46

Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Ronnett BM, et al. **Am J Surg Pathol** 1995 Dec;19(12):1390-408

Epithelial noncarcinoid tumors and tumor-like lesions of the appendix [letter] Carr NJ, et al. **Cancer** 1995 Dec 1; 76(11):2383-4

Cytology of pseudomyxoma peritonei. Pfitzer P, et al. **Cytopathology** 1995 Oct;6(5):304-15

Appendiceal mucinous cystadenoma associated with pseudomyxoma peritonei and multicystic peritoneal mesothelioma: report of a case. Kusuyama T, et al. **Surg Today** 1995;25(8):745-9

[An analysis of pathologic features and prognostic factors of 10 cases with pseudomyxoma peritonei] Zhou X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):543-6 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Computed tomographic and ultrasonographic findings of pseudomyxoma peritonei. Ozcan O, et al. **Australas Radiol** 1996 May;40(2):169-71

ULTRASONOGRAPHY

Computed tomographic and ultrasonographic findings of pseudomyxoma peritonei. Ozcan O, et al. **Australas Radiol** 1996 May;40(2):169-71

PSEUDONEUROTIC SCHIZOPHRENIA see SCHIZOTYPAL PERSONALITY DISORDER

PSEUDOPELADE see ALOPECIA

PSEUDOPLEURONECTES see FLOUNDER

PSEUDOPODIA

DRUG EFFECTS

Sphingosine-1-phosphate inhibits actin nucleation and pseudopodium formation to control cell motility of mouse melanoma cells. Yamamura S, et al. **FEBS Lett** 1996 Mar 11;382(1-2):193-7

Inhibition of formation of filopodia after axotomy by inhibitors of protein tyrosine kinases. Goldberg DJ, et al. **J Neurobiol** 1995 Aug;27(4):553-60

PATHOLOGY

HIV-induced syncytia in peripheral blood cell cultures crawl by extending giant pseudopods. Shutt DC, et al. **Cell Immunol** 1995 Dec;166(2):261-74

PHYSIOLOGY

In Ascaris sperm pseudopods, MSP fibers move proximally at a constant rate regardless of the forward rate of cellular translocation. Royal D, et al. **Cell Motil Cytoskeleton** 1995; 31(3):241-53

Ponticulin plays a role in the positional stabilization of pseudopods. Shutt DC, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1495-506

Talin and vinculin play distinct roles in filopodial motility in the neuronal growth cone. Sydor AM, et al. **J Cell Biol** 1996 Sep;134(5):1197-207

Function of myosin-V in filopodial extension of neuronal growth cones. Wang FS, et al. **Science** 1996 Aug 2; 273(5275):660-3

ULTRASTRUCTURE

The GTPase-activating protein n-chimaerin cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia. Kozma R, et al. **Mol Cell Biol** 1996 Sep; 16(9):5069-80

PSEUDOPOLYARTHRITIS, RHIZOMELIC see POLYMYALGIA RHEUMATICA

PSEUDOPREGNANCY

Inhibin is present in the corpus luteum of pseudopregnant rats and can interact with progesterone to inhibit resumption of estrous cycles. Foreman D, et al. **Endocr Res** 1995 Aug;21(3):595-614

A study of the luteolytic mechanism of the antiprogesterone RU486 during the late-luteal phase in pseudopregnant rats. Nakamura Y, et al. **J Endocrinol** 1996 Jul;150(1):93-8

Uterine receptivity to the artificial deciduogenic agent, concanavalin A, in pseudopregnant QS mice. Sakoff JA, et al. **Reprod Fertil Dev** 1995;7(5):1095-100

CHEMICALLY INDUCED

Immunolocalization of bcl-2 protein in human endometrium in the menstrual cycle and simulated early pregnancy. Koh EA, et al. **Hum Reprod** 1995 Jun;10(6):1557-62

ENZYMOLOGY

Expression and activity of ovarian tissue inhibitors of metalloproteinases during pseudopregnancy in the rat. Nothnick WB, et al. **Biol Reprod** 1995 Sep;53(3):684-91

Prostaglandin-E2 9-reductase from corpus luteum of pseudopregnant rabbit is a member of the aldo-keto reductase superfamily featuring 20 alpha-hydroxysteroid dehydrogenase activity. Wintergalen N, et al. **Eur J Biochem** 1995 Nov 15;234(1):264-70

METABOLISM

Pseudopregnancy induces the expression of hepatocyte nuclear factor-1 beta and its target gene aminopeptidase N in rabbit endometrium via the epithelial promoter. Olsen J, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):31-7

Regulation and localization of cellular retinol-binding protein, retinol-binding protein, cellular retinoic acid-binding protein (CRABP), and CRABP II in the uterus of the pseudopregnant rat. Bucco RA, et al. **Endocrinology** 1996 Jul;137(7):3111-22

Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Liu K, et al. **Endocrinology** 1996 May; 137(5):2126-32

Progesterone inhibits superoxide radical production by mononuclear phagocytes in pseudopregnant rats. Sugino N, et al. **Endocrinology** 1996 Feb;137(2):749-54

Role of gonadotrophin releasing hormone baseline concentrations in the control of pituitary gonadotrophin and ovarian steroid secretion in the pseudopregnant rat. Schuiling GA, et al. **Hum Reprod** 1996 Jan;11(1):13-8

Progesterone and oestrogen receptors in the decidualized mouse uterus and effects of different types of anti-progesterone treatment. Parandoosh Z, et al. **J Reprod Fertil** 1995 Nov;105(2):215-20

Changes in lipid peroxide and antioxidant enzyme activities in corpora lutea during pseudopregnancy in rats. Shimamura K, et al. **J Reprod Fertil** 1995 Nov;105(2):253-7

Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat. Shetty G, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3-4):347-53

Influence of progesterone levels on prostaglandin concentrations in isolated uterine tissue and incubation medium from pseudopregnant rats. Motta A, et al. **Prostaglandins** 1995 Oct;50(4):213-23

Effect of an oxytocin receptor antagonist on ovarian and uterine synthesis and release of prostaglandin F2 alpha in pseudopregnant rats. Motta AB, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):95-100

PHYSIOPATHOLOGY

Effect of deprivation of serotonin by p-chlorophenylalanine on induction and maintenance of pseudopregnancy in female rats. Maekawa F, et al. **Brain Res Bull** 1996; 39(5):317-21

Effects of splenectomy on luteolysis in pseudopregnant rabbits. Nariai K, et al. **J Vet Med Sci** 1995 Jun;57(3):503-5

Semicircadian rhythm of dopamine release in the mediobasal hypothalamus in awake rats during pseudopregnancy: evidence that a thyrotropin-releasing hormone analogue stimulates dopamine release and thereby inhibits prolactin secretion. Timmerman W, et al. **Neuroendocrinology** 1995 Nov;62(5):434-43

Sleep patterns in cyclic and pseudopregnant rats. Zhang SQ, et al. **Neurosci Lett** 1995 Jun 30;193(2):125-8

VETERINARY

Serum prolactin concentration in pseudopregnant and normally reproducing goats. Hesselink JW, et al. **Vet Rec** 1995 Aug 12;137(7):166-8

[Study of pregnancy and pseudopregnancy in goats] Hesselink JW. **Tijdschr Diergeneeskd** 1996 Jan 15; 121(2):51-2 **(Dut)**

[The treatment of pseudopregnancy in the bitch with prolactin inhibitors metergoline and bromocriptine] Grünau B, et al. **Tierarztl Prax** 1996 Apr;24(2):149-55 (Eng. Abstr.) **(Ger)**

PSEUDOPROMOTER (GENETICS) see PROMOTER REGIONS (GENETICS)

PSEUDOPSEUDOHYPOPARATHYROIDISM

COMPLICATIONS

Radiological case of the month. Ectopic ossification and calcification in pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Zung A, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):643-4

PSEUDOPSEUDOHYPOPARATHYROIDISM

GENETICS

Albright hereditary osteodystrophy and del(2) (q37.3) in four unrelated individuals. Phelan MC, et al. **Am J Med Genet** 1995 Jul 31;58(1):1-7

Hemifacial spasm in Albright's hereditary osteodystrophy with pseudopseudohypoparathyroidism and nephrogenic diabetes insipidus--case report. Oyama H, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):380-4

PSEUDOPSYCHOPATHIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPSYCHOSIS see **FACTITIOUS DISORDERS**

PSEUDORABIES

DIAGNOSIS

Comparison of the abilities of serologic tests to detect pseudorabies-infected pigs during the latent phase of infection. White AK, et al. **Am J Vet Res** 1996 May; 57(5):608-11

EPIDEMIOLOGY

Estimating sample sizes for a two-stage sampling survey of seroprevalence of pseudorabies virus (PRV)-infected swine at a regional level in The Netherlands. Elbers AR, et al. **Vet Q** 1995 Sep;17(3):92-5

IMMUNOLOGY

Study of immune function in inbred miniature pigs vaccinated and challenged with suid herpesvirus 1. Williams PP. **Can J Vet Res** 1995 Oct;59(4):285-93

Development and antigen specificity of the lymphoproliferation responses of pigs to pseudorabies virus: dichotomy between secondary B- and T-cell responses. Kimman TG, et al. **Immunology** 1995 Nov;86(3):372-8

METABOLISM

Transneuronal labeling of CNS neuropeptide and monoamine neurons after pseudorabies virus injections into the stellate ganglion. Jansen AS, et al. **Brain Res** 1995 Jun 12; 683(1):1-24

Pseudorabies virus mutants as transneuronal markers. Sams JM, et al. **Brain Res** 1995 Jul 31;687(1-2):182-90

PATHOLOGY

Specific infection of rat neuronal circuits by pseudorabies virus. Enquist LW, et al. **Gene Ther** 1994;1 Suppl 1:S10

Central nervous system neurons infected by pseudorabies virus injected into the rat urinary bladder following unilateral transection of the pelvic nerve. Nadelhaft I, et al. **J Comp Neurol** 1995 Aug 28;359(3):443-56

Gastrointestinal and skin lesions in piglets naturally infected with pseudorabies virus. Ezura K, et al. **J Vet Diagn Invest** 1995 Oct;7(4):451-5

PHYSIOPATHOLOGY

Study of transneuronal passage of pseudorabies virus in rat central nervous system by use of immunohistochemistry and in situ hybridization. Sur JH, et al. **Am J Vet Res** 1995 Sep;56(9):1195-200

Acetylcholine activates latent pseudorabies virus in pigs. Tanaka S, et al. **Arch Virol** 1996;141(1):161-6

PREVENTION & CONTROL

Field trial to evaluate immunogenicity of a glycoprotein I (gE)-deleted pseudorabies virus vaccine after its administration in the presence of maternal antibodies. Weigel RM, et al. **Am J Vet Res** 1995 Sep;56(9):1155-62

Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Takada A, et al. **Arch Virol** 1995; 140(9):1629-35

Benefit-cost analysis of the national pseudorabies virus eradication program. Miller GY, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):208-13

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. **Vet Q** 1995 Dec;17(4):150-6 (85 ref.)

[Results of Aujeszky disease control using marker vaccines] Stegeman JA. **Tijdschr Diergeneeskd** 1995 Sep 1; 120(17):502-4 **(Dut)**

[Way, aim, state and perspective of the Aujeszky's disease (AD) eradication program in North Rhine Westphalia] Jaeger F. **Tierarztl Prax** 1995 Dec;23(6):575-9 (Eng. Abstr.) **(Ger)**

[Progress in the development of vaccines against Aujeszky's disease] Mettenleiter TC. **Tierarztl Prax** 1995 Dec; 23(6):570-4 (22 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Experimental quantification of transmission of genetically engineered pseudorabies virus. Mulder WA, et al. **Vaccine** 1995 Dec;13(18):1763-9

VIROLOGY

Glycoprotein D-negative pseudorabies virus can spread transneuronally via direct neuron-to-neuron transmission in its natural host, the pig, but not after additional inactivation of gE or gI. Mulder W, et al. **J Virol** 1996 Apr;70(4):2191-200

Deletion of glycoprotein gE reduces the propagation of pseudorabies virus in the nervous system of mice after intranasal inoculation. Babic N, et al. **Virology** 1996 May 1;219(1):279-84

A study of two mutant strains of pseudorabies virus (PRV) unable to express thymidine kinase (TK) function. Ferrari M, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):1-11

PSEUDORABIES VIRUS see **HERPESVIRUS 1, SUID**

PSEUDOSCLEROSIS see **HEPATOLENTICULAR DEGENERATION**

PSEUDOTUBERCULOSIS, PASTEURELLA see **YERSINIA PSEUDOTUBERCULOSIS INFECTIONS**

PSEUDOTUMOR CEREBRI

CHEMICALLY INDUCED

Bulging fontanelle after supplementation with 25,000 IU of vitamin A in infancy using immunization contacts. Baqui AH, et al. **Acta Paediatr** 1995 Aug;84(8):863-6

Successful allogeneic bone marrow transplantation in a patient with ATRA-induced pseudotumor cerebri [letter] Varadi G, et al. **Am J Hematol** 1995 Oct;50(2):147-8

Pseudotumor cerebri associated with cyclosporine use. Cruz OA, et al. **Am J Ophthalmol** 1996 Sep;122(3):436-7

Pseudotumor cerebri and hypercalcemia resulting from vitamin A toxicity. Sharieff GQ, et al. **Ann Emerg Med** 1996 Apr;27(4):518-21

All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Selleri C, et al. **Br J Haematol** 1996 Mar;92(4):937-40

Amiodarone and reversible benign intracranial hypertension [letter] Ahmad S. **Cardiology** 1996 Jan-Feb;87(1):90

Pseudotumor cerebri (toxic effect of the "magic bullet"). Alemayehu W. **Ethiop Med J** 1995 Oct;33(4):265-70

Vitamin A and vaccines, the importance of side-effects [letter; comment] de Francisco A, et al. **Eur J Clin Nutr** 1996 Feb;50(2):122. Comment on: Eur J Clin Nutr 1995 Jan;49(1):73-4.

All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Visani G, et al. **Haematologica** 1996 Mar-Apr; 81(2):152-4 (12 ref.)

Acute glaucoma and intracranial hypertension in a child on long-term peritoneal dialysis treated with growth hormone. Wingenfeld P, et al. **Pediatr Nephrol** 1995 Dec;9(6):742-5

Symptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis. Nasr SZ, et al. **Pediatr Pulmonol** 1995 Jun;19(6):396-7

COMPLICATIONS

Severe sudden visual loss caused by pseudotumor cerebri and lumboperitoneal shunt failure. Liu GT, et al. **Am J Ophthalmol** 1996 Jul;122(1):129-31

Tolosa-Hunt syndrome with pseudotumor cerebri. Report of an unusual case. Nezu A, et al. **Brain Dev** 1995 May-Jun; 17(3):216-8

Pseudotumour cerebri in SLE. Horoshovski D, et al. **Clin Rheumatol** 1995 Nov;14(6):708-10

Pseudotumor cerebri in systemic lupus erythematosus. Green L, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):103-8 (14 ref.)

[Incidence of ophthalmologic complications in acute intracranial hypertension] Mueller AJ, et al. **Ophthalmologe** 1995 Oct;92(5):708-13 (Eng. Abstr.) **(Ger)**

[Increasing vision disorder (clinical conference)] Kolakovic P, et al. **Schweiz Rundsch Med Prax** 1996 Feb 27; 85(9):283-6 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Measurement of blood flow in the superior sagittal sinus in healthy volunteers, and in patients with normal pressure hydrocephalus and idiopathic intracranial hypertension with phase-contrast cine MR imaging. Gideon P, et al. **Acta Radiol** 1996 Mar;37(2):171-6

MR of optic papilla protrusion in patients with high intracranial pressure. Jinkins JR, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):665-8

Blind drive [letter; comment] Lee AG. **Arch Neurol** 1996 May;53(5):401; discussion 401-2. Comment on: Arch Neurol 1995 Sep;52(9):880-5.

Benign intracranial hypertension in infants with cystic fibrosis. Bikangaga P, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):551-2

Monitoring and management of raised intracranial pressure (ICP) in the intensive care unit with an analysis of one year of intracranial pressure monitoring. Kapadia F, et al. **J Assoc Physicians India** 1995 Nov;43(11):783-90 (16 ref.)

Lhermitte's sign in pseudotumour cerebri [letter] Comabella M, et al. **J Neurol** 1995 Sep;242(9):610-1

Magnetic resonance visualization of the swollen optic disc in papilledema. Brodsky MC, et al. **J Neuroophthalmol** 1995 Jun;15(2):122-4

Intracranial hypertension and the syndrome of acquired hyperopia with choroidal folds. Jacobson DM. **J Neuroophthalmol** 1995 Sep;15(3):178-85

Bilateral disc edema in an adolescent girl. Kosmorsky GS, et al. **J Neuroophthalmol** 1995 Sep;15(3):176-7

Scanning laser tomography in benign intracranial hypertension [letter] Hudson C, et al. **Lancet** 1995 Nov 25;346(8987):1435

The diagnostic value of optic disc evaluation in acute elevated intracranial pressure. Steffen H, et al. **Ophthalmology** 1996 Aug;103(8):1229-32

How to handle the pressure or too much of a good thing. Sedwick L. **Surv Ophthalmol** 1996 Jan-Feb;40(4):307-11

[Intracranial hypertension cannot be excluded with computerized tomography (letter)] Mustonen E. **Duodecim** 1994;110(18):1736-7 **(Fin)**

[Benign intracranial hypertension and continuous CSF pressure monitoring: case report] Tokuno T, et al. **No Shinkei Geka** 1996 Jan;24(1):93-8 (Eng. Abstr.) **(Jpn)**

[The syndrome of benign intracranial hypertension] Deev AS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):70-2 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Gangrene and renal failure caused by dihydroergotamine used to treat raised intracranial pressure following head trauma. Gupta VL, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):389-91

MMC in ONS decompression [letter] Kersten RC, et al. **Ophthalmology** 1996 Jun;103(6):864-5

ETIOLOGY

Recurrent pseudotumor cerebri in an HIV-positive patient [letter] Javeed N, et al. **AIDS** 1995 Jul;9(7):817-9

Cardiocirculatory effects of acutely increased intracranial pressure and subsequent brain death. Sebening C, et al. **Eur J Cardiothorac Surg** 1995;9(7):360-72

Obesity and intracranial hypertension [letter; comment] Sugerman HJ. **Int J Obes Relat Metab Disord** 1995 Oct; 19(10):762-3. Comment on: Int J Obes Relat Metab Disord 1995 Apr;19(4):240-4.

Pseudotumor cerebri as presenting syndrome of Addisonian crisis. Leggio MG, et al. **Ital J Neurol Sci** 1995 Sep; 16(6):387-9

Swelling at the site of a skull defect during migraine headache [letter] Lance JW. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):641

Pseudotumour cerebri from intranasal oxytocin and excessive fluid intake [letter] Mayer-Hubner B. **Lancet** 1996 Mar 2; 347(9001):623

Benign intracranial hypertension: a non-thrombotic complication of the primary antiphospholipid syndrome? Orefice G, et al. **Lupus** 1995 Aug;4(4):324-6

Idiopathic intracranial hypertension: orbital MRI. Manfré L, et al. **Neuroradiology** 1995 Aug;37(6):459-61

Pseudotumour cerebri in an Italian girl with a kidney transplant [letter; comment] Giordano M, et al. **Pediatr Nephrol** 1995 Oct;9(5):672. Comment on: Pediatr Nephrol 1994 Feb;8(1):91-3.

Index of suspicion. Case 3. Hypertensive encephalopathy. **Pediatr Rev** 1996 Jan;17(1):32, 34-5

IMMUNOLOGY

Intrathecal synthesis of IgG in benign intracranial hypertension: a re-examination. Inshasi JS, et al. **J Neurol** 1995 Sep;242(9):593-5

MICROBIOLOGY

[Pseudotumor cerebri in children. Neuroborreliosis may be the cause] Jonsell G. **Lakartidningen** 1996 Apr 17; 93(16):1557-8 **(Swe)**

PHYSIOPATHOLOGY

Cardiocirculatory effects of acutely increased intracranial pressure and subsequent brain death. Sebening C, et al. **Eur J Cardiothorac Surg** 1995;9(7):360-72

Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. McArthur CJ, et al. **Intensive Care Med** 1995 Jul;21(7):573-6

Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. Karahalios DG, et al. **Neurology** 1996 Jan;46(1):198-202

Cerebral venography and manometry in idiopathic intracranial hypertension. King JO, et al. **Neurology** 1995 Dec;45(12):2224-8

Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Mathew NT, et al. **Neurology** 1996 May;46(5):1226-30

[Optic nerve sheath enlargement and reversal of optic nerve head in pseudotumor cerebri] Kesler A, et al. **Harefuah** 1996 Apr 1;130(7):457-9, 503 (Eng. Abstr.) **(Heb)**

[Relevance of ventilatory optimization in acute intracranial hypertension. A clinical, physiological, and therapeutic approach] Cruz J. **Arq Neuropsiquiatr** 1995 Mar; 53(1):131-40 (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Cases of intracranial pressure [letter] Kalangu KK.

Neurosurgery 1995 Sep;37(3):553–4
[Optic nerve sheath enlargement and reversal of optic nerve head in pseudotumor cerebri] Kesler A, et al. **Harefuah** 1996 Apr 1;130(7):457–9, 503 (Eng. Abstr.) **(Heb)**

SURGERY

Subtenon's local anesthesia for optic nerve sheath fenestration. Rizzuto PR, et al. **Am J Ophthalmol** 1996 Mar; 121(3):326–7
Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Eggenberger ER, et al. **Neurology** 1996 Jun; 46(6):1524–30 (49 ref.)
Surgical management of pseudotumor cerebri in pregnancy: case report. Shapiro S, et al. **Neurosurgery** 1995 Oct; 37(4):829–31

THERAPY

Monitoring and management of raised intracranial pressure (ICP) in the intensive care unit with an analysis of one year of intracranial pressure monitoring. Kapadia F, et al. **J Assoc Physicians India** 1995 Nov;43(11):783–90 (16 ref.)
Intracranial hypertension and adult respiratory distress syndrome: usefulness of tracheal gas insufflation. Levy B, et al. **J Trauma** 1995 Oct;39(4):799–801
Reduction of post-traumatic intracranial hypertension by hypertonic/hyperoncotic saline/dextran and hypertonic mannitol. Berger S, et al. **Neurosurgery** 1995 Jul; 37(1):98–107; discussion 107–8

ULTRASONOGRAPHY

Optic nerve diameters and perimetric thresholds in idiopathic intracranial hypertension. Salgarello T, et al. **Br J Ophthalmol** 1996 Jun;80(6):509–14

PSEUDOTUMOR, INFLAMMATORY see **GRANULOMA, PLASMA CELL**

PSEUDOTUMOR, INFLAMMATORY, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PSEUDOTUMOR, INFLAMMATORY, PULMONARY see **GRANULOMA, PLASMA CELL, PULMONARY**

PSEUDOURIDINE

Stabilization of RNA stacking by pseudouridine. Davis DR. **Nucleic Acids Res** 1995 Dec 25;23(24):5020–6

ANALOGS & DERIVATIVES

Structural characterization of U*-1915 in domain IV from Escherichia coli 23S ribosomal RNA as 3-methylpseudouridine. Kowalak JA, et al. **Nucleic Acids Res** 1996 Feb 15;24(4):688–93

BIOSYNTHESIS

Purification, cloning, and properties of the tRNA psi 55 synthase from Escherichia coli. Nurse K, et al. **RNA** 1995 Mar;1(1):102–12
A dual-specificity pseudouridine synthase: an Escherichia coli synthase purified and cloned on the basis of its specificity for psi 746 in 23S RNA is also specific for psi 32 in tRNA(phe). Wrzesinski J, et al. **RNA** 1995 Jun; 1(4):437–48

BLOOD

Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression. Intrieri M, et al. **J Infect Dis** 1996 Jul;174(1):199–203
[Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice] Ishiwata S, et al. **Yakugaku Zasshi** 1995 Jul;115(7):523–7 (Eng. Abstr.) **(Jpn)**

METABOLISM

Pseudouridine synthases: four families of enzymes containing a putative uridine-binding motif also conserved in dUTPases and dCTP deaminases. Koonin EV. **Nucleic Acids Res** 1996 Jun 15;24(12):2411–5

URINE

The effect of human growth hormone therapy on L-(methyl-2H3)-leucine turnover and urinary pseudouridine concentration in patients with Ullrich-Turner syndrome. Böhles H, et al. **Eur J Pediatr** 1996 Apr;155(4):275–80

PSEUDOXANTHOMA ELASTICUM

COMPLICATIONS

Pseudoxanthoma elasticum: a rare cause of gastrointestinal bleeding. Spinzi G, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1631–4
Deterioration of pseudoxanthoma elasticum in a patient with active Crohn's disease [letter] Jones AR, et al. **Aust N Z J Med** 1995 Dec;25(6):739
Pseudoxanthoma elasticum and its complications: two case reports. Weenink AC, et al. **Neth J Med** 1996 Jul;49(1):24–9
[Pseudoxanthoma elasticum with pulmonary calcification] Yamamoto N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):716–20 (Eng. Abstr.) **(Jpn)**
[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

DIAGNOSIS

An unusual cutaneous manifestation of pseudoxanthoma elasticum mimicking reticulate pigmentary disorders [letter] Li TH, et al. **Br J Dermatol** 1996 Jun;134(6):1157–9
Hematemesis in a woman with skin, eye, and heart abnormalities. Fred HL, et al. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):28R, 28U
[Pseudoxanthoma elasticum; etiology, diagnosis and therapy (letter)] Swart J, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):954 **(Dut)**
[Pseudoxanthoma elasticum--a rare hereditary connective tissue disease] Lommi J, et al. **Duodecim** 1995;111(3):253–6 **(Fin)**
[White papulosis of the neck. Clinical aspects of pseudoxanthoma elasticum] Perrin C, et al. **Ann Dermatol Venereol** 1996;123(2):114–7 (Eng. Abstr.) **(Fre)**

METABOLISM

Matrix proteins with high affinity for calcium ions are associated with mineralization within the elastic fibers of pseudoxanthoma elasticum dermis. Contri MB, et al. **Am J Pathol** 1996 Feb;148(2):569–77
Proteoglycan alterations in skin fibroblast cultures from patients affected with pseudoxanthoma elasticum. Passi A, et al. **Cell Biochem Funct** 1996 Jun;14(2):111–20
Hyaluronic acid and dermatan sulfate in non-lesional pseudoxanthoma elasticum skin. Lebwohl M, et al. **Clin Chim Acta** 1995 Jun 30;238(1):101–7

PATHOLOGY

A yellow plaque with keratotic papules on the abdomen. Perforating calcific elastosis (periumbilical perforating pseudoxanthoma elasticum [PXE], localized acquired cutaneous PXE). Karp DL, et al. **Arch Dermatol** 1996 Feb; 132(2):224–5, 227–8
Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma-elasticum-like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19–24 (32 ref.)
[Pseudoxanthoma elasticum; etiology, diagnosis and therapy] Vegter F, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10; 140(6):300–3 **(Dut)**

PHYSIOPATHOLOGY

Calcification of elastic fibers in pseudoxanthoma elasticum. Truter S, et al. **Mt Sinai J Med** 1996 May-Sep; 63(3-4):210–5 (53 ref.)

PSILOCYBINE

ADVERSE EFFECTS

Serotonin, psilocybin, and body dysmorphic disorder: a case report [letter] Hanes KR. **J Clin Psychopharmacol** 1996 Apr;16(2):188–9

POISONING

[A caution for psilocybine in wild mushrooms. A young addict acquired acute delirium] Bergman B, et al. **Lakartidningen** 1995 Oct 11;92(41):3779–80 **(Swe)**

PSITTACINES

Chlamydia psittaci infections: a review with emphasis on avian chlamydiosis. Vanrompay D, et al. **Vet Microbiol** 1995 Jul;45(2-3):93–119 (237 ref.)
Diseases of the respiratory tract in psittacine birds. Zwart P. **Vet Q** 1995 Apr;17 Suppl 1:S52–3 (3 ref.)

PHYSIOLOGY

Effects of mydriatic agents in cockatoos, African gray parrots, and Blue-fronted Amazon parrots. Ramer JC, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):227–30

PSITTACOSIS see **ORNITHOSIS**

PSITTACOSIS-LYMPHOGRANULOMA GROUP see **CHLAMYDIA**

PSOAS ABSCESS

Iliopsoas abscess: etiology, diagnosis, and treatment. Desandre AR, et al. **Am Surg** 1995 Dec;61(12):1087–91 (22 ref.)
Primary vs secondary iliopsoas abscess. Presentation, microbiology, and treatment. Santaella RO, et al. **Arch Surg** 1995 Dec;130(12):1309–13
Tuberculous psoas abscess. Harrigan RA, et al. **J Emerg Med** 1995 Jul-Aug;13(4):493–8 (32 ref.)

DIAGNOSIS

Retroperitoneal abscess after normal delivery. A report of two cases. Segal S, et al. **J Reprod Med** 1996 Apr; 41(4):276–8
Re: Psoas abscess: case report and review of the literature [letter] González Martín TJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):480
Pediatric spinal blastomycosis: case report. Hardjasudarma M, et al. **Neurosurgery** 1995 Sep;37(3):534–6
[Psoas abscess] Lipsky H, et al. **Wien Klin Wochenschr** 1996; 108(8):248–52 (Eng. Abstr.) **(Ger)**
[The diagnosis and treatment of suppurative iliopsoitis] Briukhanov VP, et al. **Vestn Khir Im I I Grek** 1992 Feb; 148(2):180–2 **(Rus)**

DRUG THERAPY

[Comments on the treatment of Salmonella infections (letter)] López Jiménez L. **An Med Interna** 1996 May;13(5):254–5 **(Spa)**

ETIOLOGY

Psoas abscess secondary to metastases from transitional cell carcinoma of the bladder. Masters JG, et al. **Br J Urol** 1996 Jan;77(1):155–6
Xanthogranulomatous pyelonephritis presenting as a psoas abscess in a child. N'Dow J, et al. **Br J Urol** 1996 Feb; 77(2):326–7
Latent solitary tuberculous psoas abscess 52 years after healed thoracolumbar tuberculous spondylitis. Korovessis P, et al. **Spine** 1995 Aug 1;20(15):1709–12
Psoas abscess complicating Crohn's disease: report of two cases. Funayama Y, et al. **Surg Today** 1996;26(5):345–8
[A rare etiology of an abscess of the psoas: brucellosis. Apropos of 2 cases (letter)] el Alami el Faricha EH, et al. **J Chir (Paris)** 1995 Oct;132(10):414–5 **(Fre)**
[Psoas abscess as initial manifestation of appendiceal tumor (letter)] Tabet J, et al. **Med Clin (Barc)** 1996 Apr 13; 106(14):556–7 **(Spa)**
[Psoas abscess secondary to colonic neoplasm (letter)] Insua Vilariño SA, et al. **Rev Esp Enferm Dig** 1995 Nov; 87(11):830–1 **(Spa)**

MICROBIOLOGY

Pneumococcal pyomyositis. Case report, review of the literature, and comparison with classic pyomyositis caused by other bacteria. Collazos J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1470–4 (40 ref.)
Pelvic abscess induced by a methicillin-resistant Staphylococcus aureus from haematogenous spread via the CVP line in a burn patient. Lin TW, et al. **Burns** 1995 Aug;21(5):387–8
Psoas pyomyositis as a late complication of typhoid fever. Lortholary O, et al. **Clin Infect Dis** 1995 Oct;21(4):1049–50
Haemophilus parainfluenzae: an unusual case of psoas abscess. Laing RB, et al. **Infection** 1995 Nov-Dec;23(6):391–2
Retrofascial nontuberculous psoas abscess. Sadat-Ali M, et al. **Int Orthop** 1995;19(5):323–6
[Calcified tuberculous abscess of the psoas muscle. Apropos of a case (letter)] Gazzaz M, et al. **Acta Neurol Belg** 1995 Dec;95(4):247–8 **(Fre)**
[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Percutaneous catheter drainage of an unusually extensive tuberculous hypostatic abscess] Freund M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):96–8 (11 ref.) **(Ger)**

ULTRASONOGRAPHY

[Diagnosis of a retroperitoneal BCG abscess in an infant. Case report and review of the literature] Stegmann J. **Ultraschall Med** 1996 Feb;17(1):27–30 (21 ref.) (Eng. Abstr.) **(Ger)**

PSOAS MUSCLES

Psoas abscess secondary to metastases from transitional cell carcinoma of the bladder. Masters JG, et al. **Br J Urol** 1996 Jan;77(1):155–6
Psoas pyomyositis as a late complication of typhoid fever. Lortholary O, et al. **Clin Infect Dis** 1995 Oct;21(4):1049–50
A rare site and appearance for lymphomatous recurrence. Lam WM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):332–3
Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. Fernandez-Palazzi F, et al. **Clin Orthop** 1996 Jul; (328):19–24
Case report: ossifying metastases from carcinoma of the large bowel demonstrated by bone scintigraphy. Stabler J. **Clin Radiol** 1995 Oct;50(10):730–1
Juvenile xanthogranuloma of the pelvic origin: a case report. Yamanaka K, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):246–7
Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. Linn JF, et al. **J Urol** 1996 Jul;156(1):173 (2 ref.)
[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994;

ISBN 0-16-048940-7

